
TTD - Therapeutic Targets Database Full Data Download File
Title - TTD targets information in raw format
Version 10.1.01 (2024.01.10)
Provided by IDRB   Lab of Innovative Drug Reasearch and Bioinformatics
                   College of Pharmaceutical Sciences
                   Zhejiang University
                   https://idrblab.org/
Provided by BIDD   BioInformatic and Drug Design Group
                   Department of Pharmacy
                   National Unviersity of Singapore
                   https://bidd.group/
Any question about data provided here, please contact with:
Dr. Zhou (zhou_ying@zju.edu.cn) and Dr. Zhang (zhangyintao@zju.edu.cn)

--------------------------------------------------------------------------------------------------------
Abbreviations:
TARGETID	TTD Target ID
FORMERID	TTD Former Target ID
UNIPROID	Uniprot ID
TARGNAME	Target Name
GENENAME	Target Gene Name
TARGTYPE	Target Type
SYNONYMS	Synonyms
FUNCTION	Function
PDBSTRUC	PDB Structure
BIOCLASS	BioChemical Class
ECNUMBER	EC Number
SEQUENCE	Sequence
DRUGINFO	TTD Drug ID	Drug Name	Highest Clinical Status
--------------------------------------------------------------------------------------------------------

T47101	TARGETID	T47101
T47101	FORMERID	TTDC00024
T47101	UNIPROID	FGFR1_HUMAN
T47101	TARGNAME	Fibroblast growth factor receptor 1 (FGFR1)
T47101	GENENAME	FGFR1
T47101	TARGTYPE	Successful
T47101	SYNONYMS	c-fgr; bFGF-R-1; bFGF-R; N-sam; HBGFR; Fms-like tyrosine kinase 2; FLT2; FLT-2; FLG; FGFR-1; FGFBR; CEK; CD331 antigen; CD331; Basic fibroblast growth factor receptor 1; BFGFR
T47101	FUNCTION	Required for normal mesoderm patterning and correct axial organization during embryonic development, normal skeletogenesis and normal development of the gonadotropin-releasing hormone (GnRH) neuronal system. Phosphorylates PLCG1, FRS2, GAB1 and SHB. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes phosphorylation of SHC1, STAT1 and PTPN11/SHP2. In the nucleus, enhances RPS6KA1 and CREB1 activity and contributes to the regulation of transcription. FGFR1 signaling is down-regulated by IL17RD/SEF, and by FGFR1 ubiquitination, internalization and degradation. Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of embryonic development, cell proliferation, differentiation and migration.
T47101	PDBSTRUC	6MZW; 6MZQ; 6C1O; 6C1C; 6C1B
T47101	BIOCLASS	Kinase
T47101	ECNUMBER	EC 2.7.10.1
T47101	SEQUENCE	MWSWKCLLFWAVLVTATLCTARPSPTLPEQAQPWGAPVEVESFLVHPGDLLQLRCRLRDDVQSINWLRDGVQLAESNRTRITGEEVEVQDSVPADSGLYACVTSSPSGSDTTYFSVNVSDALPSSEDDDDDDDSSSEEKETDNTKPNRMPVAPYWTSPEKMEKKLHAVPAAKTVKFKCPSSGTPNPTLRWLKNGKEFKPDHRIGGYKVRYATWSIIMDSVVPSDKGNYTCIVENEYGSINHTYQLDVVERSPHRPILQAGLPANKTVALGSNVEFMCKVYSDPQPHIQWLKHIEVNGSKIGPDNLPYVQILKTAGVNTTDKEMEVLHLRNVSFEDAGEYTCLAGNSIGLSHHSAWLTVLEALEERPAVMTSPLYLEIIIYCTGAFLISCMVGSVIVYKMKSGTKKSDFHSQMAVHKLAKSIPLRRQVTVSADSSASMNSGVLLVRPSRLSSSGTPMLAGVSEYELPEDPRWELPRDRLVLGKPLGEGCFGQVVLAEAIGLDKDKPNRVTKVAVKMLKSDATEKDLSDLISEMEMMKMIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLQARRPPGLEYCYNPSHNPEEQLSSKDLVSCAYQVARGMEYLASKKCIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTNGRLPVKWMAPEALFDRIYTHQSDVWSFGVLLWEIFTLGGSPYPGVPVEELFKLLKEGHRMDKPSNCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRIVALTSNQEYLDLSMPLDQYSPSFPDTRSSTCSSGEDSVFSHEPLPEEPCLPRHPAQLANGGLKRR
T47101	DRUGINFO	D0O6UY	Pemigatinib	Approved
T47101	DRUGINFO	D09HNV	Intedanib	Approved
T47101	DRUGINFO	D01PZD	Romiplostim	Approved
T47101	DRUGINFO	D07PQJ	ARQ-087	Phase 3
T47101	DRUGINFO	D05PWX	Sulfatinib	Phase 3
T47101	DRUGINFO	D0A1AQ	Rosiglitazone + metformin	Phase 3
T47101	DRUGINFO	D02WVT	E-3810	Phase 3
T47101	DRUGINFO	D0NU0U	AZD4547	Phase 2/3
T47101	DRUGINFO	D08DFF	AM-001	Phase 2
T47101	DRUGINFO	D08ZHL	FGF-1	Phase 2
T47101	DRUGINFO	D0U2DO	FP-1039	Phase 2
T47101	DRUGINFO	DR8CM0	MK-3655	Phase 2
T47101	DRUGINFO	D0XT0W	Debio 1347	Phase 2
T47101	DRUGINFO	D00DRL	MK-2461	Phase 1/2
T47101	DRUGINFO	D0DJ0S	NGM313	Phase 1
T47101	DRUGINFO	D00ABO	KW-2449	Phase 1
T47101	DRUGINFO	D0LF0O	BMS-695735	Preclinical
T47101	DRUGINFO	D0Z0KD	PD-0183812	Terminated
T47101	DRUGINFO	D00JZS	Anti-FGFR1 mab program	Investigative
T47101	DRUGINFO	D01AVF	SAR-106881	Investigative
T47101	DRUGINFO	D04FNY	NP-506	Investigative
T47101	DRUGINFO	D06FFZ	PMID26080733C7r	Investigative
T47101	DRUGINFO	D06QUJ	3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine	Investigative
T47101	DRUGINFO	D07QMC	3-Benzimidazol-2-ylhydroquinolin-2-one	Investigative
T47101	DRUGINFO	D0EE6A	AAL-993	Investigative
T47101	DRUGINFO	D0OH3J	PD-0179483	Investigative
T47101	DRUGINFO	D0R6OM	ACTB-1003	Investigative
T47101	DRUGINFO	D0S1KJ	PD-0173952	Investigative
T47101	DRUGINFO	D0XC6G	2-(1H-indazol-3-yl)-1H-benzo[d]imidazole	Investigative
T47101	DRUGINFO	D0Z7GH	PD-0173958	Investigative
T47101	DRUGINFO	D03NPX	PD-0173955	Investigative
T47101	DRUGINFO	D0D5EW	HKI-9924129	Investigative
T47101	DRUGINFO	D0GW4Q	PD-0173956	Investigative
T47101	DRUGINFO	D0P3JW	PD-0166326	Investigative
T47101	DRUGINFO	D0E7VO	PMID24900538C2c	Investigative
T47101	DRUGINFO	D0C2GE	PMID22765894C8h	Investigative
T47101	DRUGINFO	D09XIL	Ro-4396686	Investigative

T59328	TARGETID	T59328
T59328	FORMERID	TTDS00355
T59328	UNIPROID	EGFR_HUMAN
T59328	TARGNAME	Epidermal growth factor receptor (EGFR)
T59328	GENENAME	EGFR
T59328	TARGTYPE	Successful
T59328	SYNONYMS	Receptor tyrosine-protein kinase erbB-1; Proto-oncogene c-ErbB-1; HER1; ERBB1; ERBB
T59328	FUNCTION	Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin. Plays a role in enhancing learning and memory performance (By similarity).
T59328	PDBSTRUC	6D8E; 6B3S; 6ARU; 5ZWJ; 5YU9
T59328	BIOCLASS	Kinase
T59328	ECNUMBER	EC 2.7.10.1
T59328	SEQUENCE	MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALAVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDFQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRVAPQSSEFIGA
T59328	DRUGINFO	D03WPP	Necitumumab	Approved
T59328	DRUGINFO	D05GGP	HEGF	Approved
T59328	DRUGINFO	D07POC	Erlotinib	Approved
T59328	DRUGINFO	D09XZB	Gefitinib	Approved
T59328	DRUGINFO	D0HU9H	Panitumumab	Approved
T59328	DRUGINFO	D0N5OV	Cetuximab	Approved
T59328	DRUGINFO	D05UFG	BIBW 2992	Approved
T59328	DRUGINFO	D07YDE	Nitroglycerin	Approved
T59328	DRUGINFO	D08TPS	Epidermal growth factor	Approved
T59328	DRUGINFO	D0O8GK	Osimertinib	Approved
T59328	DRUGINFO	D0U1ZV	NERATINIB MALEATE	Approved
T59328	DRUGINFO	DQ5X1Z	Amivantamab	Approved
T59328	DRUGINFO	D03MNN	SKI-758	Approved
T59328	DRUGINFO	D06XXH	Dacomitinib	Approved
T59328	DRUGINFO	D08CDI	Lapatinib	Approved
T59328	DRUGINFO	D0F0ZE	Merimepodib	Approved
T59328	DRUGINFO	D0G6QF	Vandetanib	Approved
T59328	DRUGINFO	D0W5HK	Sorafenib	Approved
T59328	DRUGINFO	D06WRJ	Icotinib hydrochloride	Registered
T59328	DRUGINFO	D05FRP	Rindopepimut	Phase 3
T59328	DRUGINFO	D0CR8H	SYM-004	Phase 3
T59328	DRUGINFO	D0FJ1W	DE-766	Phase 3
T59328	DRUGINFO	D0K7FY	EGF816	Phase 3
T59328	DRUGINFO	D0M4AV	CO-1686	Phase 3
T59328	DRUGINFO	D0R4PW	Zalutumumab	Phase 3
T59328	DRUGINFO	DDH8L6	Almonertinib	Phase 3
T59328	DRUGINFO	DWK96T	ASP1929	Phase 3
T59328	DRUGINFO	DXZ31K	A140	Phase 3
T59328	DRUGINFO	D09BKY	Bevacizumab + Erlotinib	Phase 3
T59328	DRUGINFO	D0Q9CY	HKI-272	Phase 3
T59328	DRUGINFO	D0F3KC	Indium-111	Phase 2/3
T59328	DRUGINFO	D00NYJ	Varlitinib	Phase 2/3
T59328	DRUGINFO	D02BYZ	ASP8273	Phase 2
T59328	DRUGINFO	D06XIT	ABT-414	Phase 2
T59328	DRUGINFO	D0A6CC	Depatuxizumab	Phase 2
T59328	DRUGINFO	D0BZ7V	Matuzumab	Phase 2
T59328	DRUGINFO	D0C3LL	HER1-VSSP vaccine	Phase 2
T59328	DRUGINFO	D0FN4T	RM-1929	Phase 2
T59328	DRUGINFO	D0K9MC	CetuGEX	Phase 2
T59328	DRUGINFO	D0P9RG	ABX-EGF	Phase 2
T59328	DRUGINFO	D0S3PO	Pelitinib	Phase 2
T59328	DRUGINFO	D00YER	HM-78136B	Phase 2
T59328	DRUGINFO	D03UKJ	Pazopanib + Tyverb/Tykerb	Phase 2
T59328	DRUGINFO	D09BZJ	MEHD-7945A	Phase 2
T59328	DRUGINFO	D0T5JS	TT-100	Phase 2
T59328	DRUGINFO	D0U4FF	BMS-599626	Phase 2
T59328	DRUGINFO	DUW81M	Tarloxotinib	Phase 2
T59328	DRUGINFO	D0P6DJ	VATALANIB	Phase 2
T59328	DRUGINFO	D0R6UV	BMS-690514	Phase 2
T59328	DRUGINFO	D0YB3W	CI-1033	Phase 2
T59328	DRUGINFO	D04DHZ	CART-EGFR	Phase 1/2
T59328	DRUGINFO	D05ETC	SN-32793	Phase 1/2
T59328	DRUGINFO	D0G1ZU	EGFR CART	Phase 1/2
T59328	DRUGINFO	D0S8BG	EMD 55900	Phase 1/2
T59328	DRUGINFO	DC1GH7	TAK-186	Phase 1/2
T59328	DRUGINFO	DF0PR6	ZN-e4	Phase 1/2
T59328	DRUGINFO	DWQ6J1	EMB-01	Phase 1/2
T59328	DRUGINFO	D0B4OK	Sym015	Phase 1/2
T59328	DRUGINFO	D9FJ5V	BDTX-189	Phase 1/2
T59328	DRUGINFO	DK8QG3	AFM24	Phase 1/2
T59328	DRUGINFO	D0FF2G	Sym013	Phase 1/2
T59328	DRUGINFO	D0V4XY	S-222611	Phase 1b
T59328	DRUGINFO	D00KML	SYN004	Phase 1
T59328	DRUGINFO	D00RMC	BIBX-1382	Phase 1
T59328	DRUGINFO	D04HSH	IMGN289	Phase 1
T59328	DRUGINFO	D04OLK	AST-1306	Phase 1
T59328	DRUGINFO	D05LMC	AMG 595	Phase 1
T59328	DRUGINFO	D0E7RC	HER-2/HER-1 vaccine	Phase 1
T59328	DRUGINFO	D0I7ZH	EGFR806-specific CAR T cell	Phase 1
T59328	DRUGINFO	D0JS0W	PF-05230907	Phase 1
T59328	DRUGINFO	D0N3PC	MR1-1	Phase 1
T59328	DRUGINFO	D0T0SE	Anti-EGFR CAR T	Phase 1
T59328	DRUGINFO	D0X7BN	AP32788	Phase 1
T59328	DRUGINFO	D68RMI	CLN-081	Phase 1
T59328	DRUGINFO	D01IJM	LY3164530	Phase 1
T59328	DRUGINFO	D01NAP	MM-151	Phase 1
T59328	DRUGINFO	D08JAN	Cipatinib	Phase 1
T59328	DRUGINFO	D0JW2O	Anti-HER3/EGFR DAF	Phase 1
T59328	DRUGINFO	D0U7XJ	BCA101	Phase 1
T59328	DRUGINFO	D0Z4RC	CUDC-101	Phase 1
T59328	DRUGINFO	D6JM8Z	SI-B001	Phase 1
T59328	DRUGINFO	D73FNL	CX-904	Phase 1
T59328	DRUGINFO	DN47VK	AZD9592	Phase 1
T59328	DRUGINFO	DR4ND6	D2C7	Phase 1
T59328	DRUGINFO	DV8I4Q	MCLA-158	Phase 1
T59328	DRUGINFO	D0U3XL	JNJ-26483327	Phase 1
T59328	DRUGINFO	D0Z2PC	Pyrrolo[2,3-d]pyrimidine derivative 24	Patented
T59328	DRUGINFO	D07GFF	PKI166	Discontinued in Phase 2
T59328	DRUGINFO	D0E2CQ	RG7160	Discontinued in Phase 2
T59328	DRUGINFO	D0Q7HO	PD-153035	Discontinued in Phase 1
T59328	DRUGINFO	D02RZL	AZD4769	Discontinued in Phase 1
T59328	DRUGINFO	D0A9OV	TAK165	Discontinued in Phase 1
T59328	DRUGINFO	D0V2FZ	111In-hEGF	Preclinical
T59328	DRUGINFO	D0TI4U	EGFR/IGFR tandem adnectin	Preclinical
T59328	DRUGINFO	D02GFZ	Heparin-EGF-like factor	Terminated
T59328	DRUGINFO	D03QTP	CGP-52411	Terminated
T59328	DRUGINFO	D0HO1S	CGP-53353	Terminated
T59328	DRUGINFO	D0Y1YX	AZD-9935	Terminated
T59328	DRUGINFO	D00TJF	N4-(3-chlorophenyl)quinazoline-4,6-diamine	Investigative
T59328	DRUGINFO	D00VZA	2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile	Investigative
T59328	DRUGINFO	D00WZG	6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline	Investigative
T59328	DRUGINFO	D01NTW	2-cyano-3-(3,4-dihydroxyphenyl)acrylamide	Investigative
T59328	DRUGINFO	D01SQP	HM-61713B	Investigative
T59328	DRUGINFO	D01WDI	Benzyl-quinazolin-4-yl-amine	Investigative
T59328	DRUGINFO	D01WXV	6,7-diethoxy-4-styrylquinazoline	Investigative
T59328	DRUGINFO	D02FGG	AFM-21	Investigative
T59328	DRUGINFO	D02GCE	PD182905	Investigative
T59328	DRUGINFO	D02KVB	AG 112	Investigative
T59328	DRUGINFO	D02RIG	2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile	Investigative
T59328	DRUGINFO	D02ZRO	(3-Bromo-phenyl)-quinazolin-4-yl-amine	Investigative
T59328	DRUGINFO	D03ATU	PD-158780	Investigative
T59328	DRUGINFO	D03BJB	EGFR inhibitor	Investigative
T59328	DRUGINFO	D03CVQ	6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline	Investigative
T59328	DRUGINFO	D03MTY	LA22-radioimmunoconjugates	Investigative
T59328	DRUGINFO	D03WEN	5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	Investigative
T59328	DRUGINFO	D03ZIW	ICR 62	Investigative
T59328	DRUGINFO	D04GCH	Bmab-200	Investigative
T59328	DRUGINFO	D04HGN	HTS-00213	Investigative
T59328	DRUGINFO	D04LXG	6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline	Investigative
T59328	DRUGINFO	D05ARF	N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine	Investigative
T59328	DRUGINFO	D05MEY	Epitinib	Investigative
T59328	DRUGINFO	D06QEQ	OSI-75	Investigative
T59328	DRUGINFO	D06UEK	(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin	Investigative
T59328	DRUGINFO	D07CZM	HTS-02876	Investigative
T59328	DRUGINFO	D07IHD	2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile	Investigative
T59328	DRUGINFO	D07UYV	PMID8568816C56	Investigative
T59328	DRUGINFO	D08RXW	MT-062	Investigative
T59328	DRUGINFO	D09RXX	Anti-EGFR mab	Investigative
T59328	DRUGINFO	D0A0JL	RG-50810	Investigative
T59328	DRUGINFO	D0AC7C	IPS-01003	Investigative
T59328	DRUGINFO	D0AH2V	RM-6427	Investigative
T59328	DRUGINFO	D0B4PH	N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine	Investigative
T59328	DRUGINFO	D0B8DE	3-Pyridin-4-yl-quinoline-6,7-diol	Investigative
T59328	DRUGINFO	D0C5WE	AGT-2000	Investigative
T59328	DRUGINFO	D0C9KC	3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one	Investigative
T59328	DRUGINFO	D0CY9O	ON-128	Investigative
T59328	DRUGINFO	D0D0GS	FHT-2107	Investigative
T59328	DRUGINFO	D0D0YK	GI-3000	Investigative
T59328	DRUGINFO	D0DF3Z	6,7-dimethoxy-N-m-tolylquinazolin-4-amine	Investigative
T59328	DRUGINFO	D0EH6L	5,6-Bis-p-tolylamino-isoindole-1,3-dione	Investigative
T59328	DRUGINFO	D0EP1G	HTS-05058	Investigative
T59328	DRUGINFO	D0F6FZ	N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide	Investigative
T59328	DRUGINFO	D0G4HR	4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid	Investigative
T59328	DRUGINFO	D0G9KD	Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine	Investigative
T59328	DRUGINFO	D0GB7F	ARX-AHD	Investigative
T59328	DRUGINFO	D0H3FX	TGF alpha	Investigative
T59328	DRUGINFO	D0H3UI	AG 9	Investigative
T59328	DRUGINFO	D0HM5W	N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine	Investigative
T59328	DRUGINFO	D0I7RA	4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline	Investigative
T59328	DRUGINFO	D0J3EA	Theliatinib	Investigative
T59328	DRUGINFO	D0J9WO	4-(3-Bromo-phenylamino)-quinazoline-6,7-diol	Investigative
T59328	DRUGINFO	D0K2VO	6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline	Investigative
T59328	DRUGINFO	D0K2YY	4-(2-nitroprop-1-enyl)benzene-1,2-diol	Investigative
T59328	DRUGINFO	D0K3FG	EDP-13	Investigative
T59328	DRUGINFO	D0K7GD	N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine	Investigative
T59328	DRUGINFO	D0KN1L	(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate	Investigative
T59328	DRUGINFO	D0L3SN	4-(2-nitrovinyl)benzene-1,2-diol	Investigative
T59328	DRUGINFO	D0NH7M	AG-538	Investigative
T59328	DRUGINFO	D0NJ3Q	WZ-3146	Investigative
T59328	DRUGINFO	D0O9UR	2-methoxy-4-(2-nitrovinyl)phenol	Investigative
T59328	DRUGINFO	D0P0JW	MG-111	Investigative
T59328	DRUGINFO	D0P2GE	6,7-dimethoxy-4-(2-phenylethynyl)quinazoline	Investigative
T59328	DRUGINFO	D0R2RV	Anti-EGFR humanized mabs	Investigative
T59328	DRUGINFO	D0S9QP	4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline	Investigative
T59328	DRUGINFO	D0T7OS	AL-6802	Investigative
T59328	DRUGINFO	D0U6WB	BPIQ-I	Investigative
T59328	DRUGINFO	D0V0JV	mabionHER2	Investigative
T59328	DRUGINFO	D0W1BE	4-(2-nitrovinyl)phenol	Investigative
T59328	DRUGINFO	D0W2PQ	4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	Investigative
T59328	DRUGINFO	D0WD8R	MDP-01	Investigative
T59328	DRUGINFO	D0X4UE	N4-(3-methylphenyl)-4,6-quinazolinediamine	Investigative
T59328	DRUGINFO	D0Y1LD	RX-1792	Investigative
T59328	DRUGINFO	D0Y2AM	(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine	Investigative
T59328	DRUGINFO	D0Y6MD	NRC-2694	Investigative
T59328	DRUGINFO	D0ZT9D	Cochliobolic acid	Investigative
T59328	DRUGINFO	D01VFR	PD-168393	Investigative
T59328	DRUGINFO	D01WYI	N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide	Investigative
T59328	DRUGINFO	D03HLH	4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline	Investigative
T59328	DRUGINFO	D05QMN	4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline	Investigative
T59328	DRUGINFO	D0AM9O	YH013	Investigative
T59328	DRUGINFO	D0D9TU	LAVENDUSTIN A	Investigative
T59328	DRUGINFO	D0J2CP	PF 5208766	Investigative
T59328	DRUGINFO	D0J5SK	6-chloro-N-(3-chlorophenyl)quinazolin-4-amine	Investigative
T59328	DRUGINFO	D0N8TQ	N-(4-(phenylamino)quinazolin-6-yl)acrylamide	Investigative
T59328	DRUGINFO	D0Q3GG	AG-213	Investigative
T59328	DRUGINFO	D0Q8GX	SYM-011	Investigative
T59328	DRUGINFO	D0W6CE	10-hydroxy-18-methoxybetaenone	Investigative
T59328	DRUGINFO	D0X4OU	4557W	Investigative
T59328	DRUGINFO	D0ZH1U	Tyrphostin ag-1478	Investigative
T59328	DRUGINFO	D00TZD	CL-387785	Investigative
T59328	DRUGINFO	D05FFT	HDS-029	Investigative
T59328	DRUGINFO	D0E5IP	WHI-P154	Investigative
T59328	DRUGINFO	D06BJG	PMID24915291C38	Investigative
T59328	DRUGINFO	D0D5EW	HKI-9924129	Investigative
T59328	DRUGINFO	D0GW4Q	PD-0173956	Investigative
T59328	DRUGINFO	D0P3JW	PD-0166326	Investigative
T59328	DRUGINFO	D03EHM	PP121	Investigative
T59328	DRUGINFO	D06AOY	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	Investigative
T59328	DRUGINFO	D09XIL	Ro-4396686	Investigative
T59328	DRUGINFO	D00NYT	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	Investigative
T59328	DRUGINFO	D0C3WY	3,4-diphenyl-1H-pyrrole-2,5-dione	Investigative
T59328	DRUGINFO	D0EK0G	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	Investigative

T89515	TARGETID	T89515
T89515	FORMERID	TTDS00208
T89515	UNIPROID	DEFM_HUMAN
T89515	TARGNAME	Polypeptide deformylase (PDF)
T89515	GENENAME	PDF
T89515	TARGTYPE	Successful
T89515	SYNONYMS	PDF
T89515	FUNCTION	Bifunctional enzyme. Involved in de novo dTMP biosynthesis. Key enzyme in folate metabolism. Catalyzes an essential reaction for de novo glycine and purine synthesis, DNA precursor synthesis, and for the conversion of dUMP to dTMP.
T89515	PDBSTRUC	3G5P; 3G5K
T89515	BIOCLASS	CH-NH donor oxidoreductase
T89515	ECNUMBER	EC 3.5.1.88
T89515	SEQUENCE	MARLWGALSLWPLWAAVPWGGAAAVGVRACSSTAAPDGVEGPALRRSYWRHLRRLVLGPPEPPFSHVCQVGDPVLRGVAAPVERAQLGGPELQRLTQRLVQVMRRRRCVGLSAPQLGVPRQVLALELPEALCRECPPRQRALRQMEPFPLRVFVNPSLRVLDSRLVTFPEGCESVAGFLACVPRFQAVQISGLDPNGEQVVWQASGWAARIIQHEMDHLQGCLFIDKMDSRTFTNVYWMKVND
T89515	DRUGINFO	D02LWU	Pralatrexate	Approved
T89515	DRUGINFO	D0E3SF	MCB-3837	Approved
T89515	DRUGINFO	D0P8RS	Proguanil	Approved
T89515	DRUGINFO	D0Y2DI	Chlorproguanil	Approved
T89515	DRUGINFO	D0Y7TS	Trimetrexate	Approved
T89515	DRUGINFO	D0A2UV	Ustekinumab	Approved
T89515	DRUGINFO	D0Y4AW	Meprobamate	Approved
T89515	DRUGINFO	D02AIM	Metoprine	Phase 2
T89515	DRUGINFO	D0W3LI	LY333531	Phase 2
T89515	DRUGINFO	D0D2RN	Aminopterin	Withdrawn from market
T89515	DRUGINFO	D01ILN	6,7-Diphenyl-pteridine-2,4-diamine	Investigative
T89515	DRUGINFO	D01UOO	3-Benzyl-2-ethylthio-6-nitro-quinazolin-4(3H)-one	Investigative
T89515	DRUGINFO	D02ZCP	5-Phenylsulfanyl-2,4-Quinazolinediamine	Investigative
T89515	DRUGINFO	D02ZPZ	5-((E)-Styryl)-quinazoline-2,4-diamine	Investigative
T89515	DRUGINFO	D03DRF	2-Allylthio-3-benzyl-6-nitro-quinazolin-4(3H)-one	Investigative
T89515	DRUGINFO	D03POU	8-(3,4-dimethoxyphenyl)-9H-purine-2,6-diamine	Investigative
T89515	DRUGINFO	D04MOZ	NB3178	Investigative
T89515	DRUGINFO	D04UBQ	8-(3,4-dichlorophenyl)-9H-purine-2,6-diamine	Investigative
T89515	DRUGINFO	D05KJX	8-(2,4,6-trimethoxyphenyl)-9H-purine-2,6-diamine	Investigative
T89515	DRUGINFO	D05TPU	8-(2,4,5-trimethoxyphenyl)-9H-purine-2,6-diamine	Investigative
T89515	DRUGINFO	D05WHM	Edatrexate	Investigative
T89515	DRUGINFO	D06DIH	Furo[2,3d]Pyrimidine Antifolate	Investigative
T89515	DRUGINFO	D06QEN	7-Methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine	Investigative
T89515	DRUGINFO	D06UPT	Sri-9439	Investigative
T89515	DRUGINFO	D07BKE	8-(3,4,5-trimethoxyphenyl)-9H-purine-2,6-diamine	Investigative
T89515	DRUGINFO	D07XLJ	N*6*-Benzyl-quinazoline-2,4,6-triamine	Investigative
T89515	DRUGINFO	D08CMW	6-Phenylaminomethyl-quinazoline-2,4-diamine	Investigative
T89515	DRUGINFO	D08GPU	5-Phenethyl-quinazoline-2,4-diamine	Investigative
T89515	DRUGINFO	D09YVN	Dihydrofolic Acid	Investigative
T89515	DRUGINFO	D0A5GM	8-(2,5-dimethoxyphenyl)-9H-purine-2,6-diamine	Investigative
T89515	DRUGINFO	D0A6CS	Bromo-WR99210	Investigative
T89515	DRUGINFO	D0A8HX	6-m-Tolyl-pteridine-2,4,7-triamine	Investigative
T89515	DRUGINFO	D0A9WT	5-Formyl-6-Hydrofolic Acid	Investigative
T89515	DRUGINFO	D0AT2Z	3-Phenylsulfanylmethyl-quinoxaline-5,7-diamine	Investigative
T89515	DRUGINFO	D0B9MY	8-Pyridin-4-yl-9H-purine-2,6-diamine	Investigative
T89515	DRUGINFO	D0C1EF	5-(4-Methoxyphenoxy)-2,4-Quinazolinediamine	Investigative
T89515	DRUGINFO	D0C1UM	Tylophorinidine	Investigative
T89515	DRUGINFO	D0C9NE	Biopterin	Investigative
T89515	DRUGINFO	D0CH7U	2'-Monophosphoadenosine-5'-Diphosphate	Investigative
T89515	DRUGINFO	D0D1ON	Sri-9662	Investigative
T89515	DRUGINFO	D0DT4R	Brodimoprim-4,6-Dicarboxylate	Investigative
T89515	DRUGINFO	D0H2VY	8-benzyl-9H-purine-2,6-diamine	Investigative
T89515	DRUGINFO	D0H4NN	NB3322	Investigative
T89515	DRUGINFO	D0H8AW	GNF-PF-607	Investigative
T89515	DRUGINFO	D0J4KJ	5-p-Tolylsulfanyl-quinazoline-2,4-diamine	Investigative
T89515	DRUGINFO	D0KY9B	5-Chloryl-2,4,6-Quinazolinetriamine	Investigative
T89515	DRUGINFO	D0LH5P	GNF-PF-173	Investigative
T89515	DRUGINFO	D0ME8Z	5-(2-fluorobenzyloxy)quinazoline-2,4-diamine	Investigative
T89515	DRUGINFO	D0O9YG	Cycloguanil	Investigative
T89515	DRUGINFO	D0S1VJ	8-(3,5-dimethoxyphenyl)-9H-purine-2,6-diamine	Investigative
T89515	DRUGINFO	D0S4ZT	2-Allylthio-6-amino-3-benzyl-quinazolin-4(3H)-one	Investigative
T89515	DRUGINFO	D0SB0W	8-(2,4-dimethoxyphenyl)-9H-purine-2,6-diamine	Investigative
T89515	DRUGINFO	D0U0KY	8-(2,6-Dichloro-phenyl)-9H-purine-2,6-diamine	Investigative
T89515	DRUGINFO	D0U7CJ	4-(2,6-diamino-9H-purin-8-yl)-2,6-dimethoxyphenol	Investigative
T89515	DRUGINFO	D0UR9D	3-benzyl-2-mercapto-6-nitroquinazolin-4(3H)-one	Investigative
T89515	DRUGINFO	D0V1UL	6-(2-Phenylsulfanyl-ethyl)-pteridine-2,4-diamine	Investigative
T89515	DRUGINFO	D0V9US	6-Phenylsulfanylmethyl-pteridine-2,4-diamine	Investigative
T89515	DRUGINFO	D0Y3TU	7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine	Investigative
T89515	DRUGINFO	D0Y5JB	8-(2,3,4-trimethoxyphenyl)-9H-purine-2,6-diamine	Investigative
T89515	DRUGINFO	D06YIB	DDATHF	Investigative
T89515	DRUGINFO	D0B1PE	Ro 5-4864	Investigative
T89515	DRUGINFO	D0T1XE	Pergularinine	Investigative
T89515	DRUGINFO	D0UZ9U	PREMETREXED	Investigative
T89515	DRUGINFO	D07KZA	2-(N-Morpholino)-Ethanesulfonic Acid	Investigative
T89515	DRUGINFO	D0J2FY	2'-Monophosphoadenosine 5'-Diphosphoribose	Investigative
T89515	DRUGINFO	D0Q5FV	2-Sulfhydryl-Ethanol	Investigative

T08391	TARGETID	T08391
T08391	FORMERID	TTDC00187
T08391	UNIPROID	JAK2_HUMAN
T08391	TARGNAME	Janus kinase 2 (JAK-2)
T08391	GENENAME	JAK2
T08391	TARGTYPE	Successful
T08391	SYNONYMS	Tyrosine-protein kinase JAK2
T08391	FUNCTION	Mediates essential signaling events in both innate and adaptive immunity. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin (THPO); or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. Following ligand-binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, cell stimulation with erythropoietin (EPO) during erythropoiesis leads to JAK2 autophosphorylation, activation, and its association with erythropoietin receptor (EPOR) that becomes phosphorylated in its cytoplasmic domain. Then, STAT5 (STAT5A or STAT5B) is recruited, phosphorylated and activated by JAK2. Once activated, dimerized STAT5 translocates into the nucleus and promotes the transcription of several essential genes involved in the modulation of erythropoiesis. Part of a signaling cascade that is activated by increased cellular retinol and that leads to the activation of STAT5 (STAT5A or STAT5B). In addition, JAK2 mediates angiotensin-2-induced ARHGEF1 phosphorylation. Plays a role in cell cycle by phosphorylating CDKN1B. Cooperates with TEC through reciprocal phosphorylation to mediate cytokine-driven activation of FOS transcription. In the nucleus, plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin. Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications.
T08391	PDBSTRUC	6M9H; 6E2Q; 6E2P; 6DRW; 6BSS
T08391	BIOCLASS	Kinase
T08391	ECNUMBER	EC 2.7.10.2
T08391	SEQUENCE	MGMACLTMTEMEGTSTSSIYQNGDISGNANSMKQIDPVLQVYLYHSLGKSEADYLTFPSGEYVAEEICIAASKACGITPVYHNMFALMSETERIWYPPNHVFHIDESTRHNVLYRIRFYFPRWYCSGSNRAYRHGISRGAEAPLLDDFVMSYLFAQWRHDFVHGWIKVPVTHETQEECLGMAVLDMMRIAKENDQTPLAIYNSISYKTFLPKCIRAKIQDYHILTRKRIRYRFRRFIQQFSQCKATARNLKLKYLINLETLQSAFYTEKFEVKEPGSGPSGEEIFATIIITGNGGIQWSRGKHKESETLTEQDLQLYCDFPNIIDVSIKQANQEGSNESRVVTIHKQDGKNLEIELSSLREALSFVSLIDGYYRLTADAHHYLCKEVAPPAVLENIQSNCHGPISMDFAISKLKKAGNQTGLYVLRCSPKDFNKYFLTFAVERENVIEYKHCLITKNENEEYNLSGTKKNFSSLKDLLNCYQMETVRSDNIIFQFTKCCPPKPKDKSNLLVFRTNGVSDVPTSPTLQRPTHMNQMVFHKIRNEDLIFNESLGQGTFTKIFKGVRREVGDYGQLHETEVLLKVLDKAHRNYSESFFEAASMMSKLSHKHLVLNYGVCVCGDENILVQEFVKFGSLDTYLKKNKNCINILWKLEVAKQLAWAMHFLEENTLIHGNVCAKNILLIREEDRKTGNPPFIKLSDPGISITVLPKDILQERIPWVPPECIENPKNLNLATDKWSFGTTLWEICSGGDKPLSALDSQRKLQFYEDRHQLPAPKWAELANLINNCMDYEPDFRPSFRAIIRDLNSLFTPDYELLTENDMLPNMRIGALGFSGAFEDRDPTQFEERHLKFLQQLGKGNFGSVEMCRYDPLQDNTGEVVAVKKLQHSTEEHLRDFEREIEILKSLQHDNIVKYKGVCYSAGRRNLKLIMEYLPYGSLRDYLQKHKERIDHIKLLQYTSQICKGMEYLGTKRYIHRDLATRNILVENENRVKIGDFGLTKVLPQDKEYYKVKEPGESPIFWYAPESLTESKFSVASDVWSFGVVLYELFTYIEKSKSPPAEFMRMIGNDKQGQMIVFHLIELLKNNGRLPRPDGCPDEIYMIMTECWNNNVNQRPSFRDLALRVDQIRDNMAG
T08391	DRUGINFO	D0G8BM	Fedratinib	Approved
T08391	DRUGINFO	D0D5ZJ	Momelotinib	Approved
T08391	DRUGINFO	D04LKS	Ruxolitinib	Approved
T08391	DRUGINFO	D05PCM	Abrocitinib	Approved
T08391	DRUGINFO	D0Y7IC	Baricitinib	Approved
T08391	DRUGINFO	D05AJT	XL019	Phase 3
T08391	DRUGINFO	D0GH3Q	ITF2357	Phase 3
T08391	DRUGINFO	D05TSJ	LY2784544	Phase 2
T08391	DRUGINFO	D0DK8X	BMS-911543	Phase 2
T08391	DRUGINFO	D0MP0X	AZD1480	Phase 2
T08391	DRUGINFO	D01UAU	CTP-543	Phase 2
T08391	DRUGINFO	D09AFI	INCB039110	Phase 2
T08391	DRUGINFO	DH0A6O	A223	Phase 2
T08391	DRUGINFO	DU10JI	CTP-543	Phase 2
T08391	DRUGINFO	D2KTG5	TD-8236	Phase 2
T08391	DRUGINFO	D0BI3N	Cerdulatinib	Phase 2
T08391	DRUGINFO	D00MYW	NS-018	Phase 1/2
T08391	DRUGINFO	D2JZ3U	ALXN2075	Phase 1/2
T08391	DRUGINFO	D00RYA	SB-1578	Phase 1
T08391	DRUGINFO	D08CNP	AC430	Phase 1
T08391	DRUGINFO	D0S0NX	Peginterferon beta	Phase 1
T08391	DRUGINFO	DI19BZ	KN-002	Phase 1
T08391	DRUGINFO	DX72LV	AZD4604	Phase 1
T08391	DRUGINFO	DXVA93	PF-07295324	Phase 1
T08391	DRUGINFO	DZ2RH6	GDC-0214	Phase 1
T08391	DRUGINFO	D0HS2J	PMID27774824-Compound-Figure8Example99	Patented
T08391	DRUGINFO	D0KF8H	PMID27774824-Compound-Figure8Example22	Patented
T08391	DRUGINFO	D00JUI	Triazolo-pyridine derivative 1	Patented
T08391	DRUGINFO	D02VGC	Pyrazolopyridine derivative 6	Patented
T08391	DRUGINFO	D03PBI	Pyrrolo-pyridone derivative 2	Patented
T08391	DRUGINFO	D03TEE	Tricyclic heterocycle derivative 2	Patented
T08391	DRUGINFO	D04OCD	PMID27774822-Compound-Figure7Example63	Patented
T08391	DRUGINFO	D05GEL	Cyclic cyanoethypypazole derivative 1	Patented
T08391	DRUGINFO	D06MQB	Pyrrolo-pyridone derivative 1	Patented
T08391	DRUGINFO	D09RTW	Aromatic bicyclic compound 6	Patented
T08391	DRUGINFO	D0A8BV	PMID27774822-Compound-Figure10Compound12	Patented
T08391	DRUGINFO	D0AE0M	PMID27774822-Compound-Figure10Compound4	Patented
T08391	DRUGINFO	D0B9TH	PMID27774822-Compound-Figure8Example5	Patented
T08391	DRUGINFO	D0CD6Y	Pyrimidopyridazinone derivative 1	Patented
T08391	DRUGINFO	D0D1QH	Pyrazolopyridine derivative 7	Patented
T08391	DRUGINFO	D0E2WK	PMID27774822-Compound-Figure2Example1-1left	Patented
T08391	DRUGINFO	D0F3BK	PMID27774824-Compound-Figure6Example6	Patented
T08391	DRUGINFO	D0H6XN	Geminally-substituted cyanoethylpypazolo pyridone derivative 1	Patented
T08391	DRUGINFO	D0IC8O	Curcumin analog 2	Patented
T08391	DRUGINFO	D0IQ6G	PMID27774822-Compound-Figure2Example1-1right	Patented
T08391	DRUGINFO	D0JZ2B	Alkynyl-substituted pyrimidinyl-pyrrole derivative 1	Patented
T08391	DRUGINFO	D0K2RW	Cyanomethyl pypazole carboxamide derivative 1	Patented
T08391	DRUGINFO	D0KI5F	Geminally-substituted cyanoethylpypazolo pyridone derivative 2	Patented
T08391	DRUGINFO	D0M2OK	Bis-aminopyrimidine derivative 5	Patented
T08391	DRUGINFO	D0M5AG	Aromatic bicyclic compound 3	Patented
T08391	DRUGINFO	D0M9YZ	Aromatic bicyclic compound 4	Patented
T08391	DRUGINFO	D0NP2W	1,2,4-triazolo[1,5a]pyridine derivative 2	Patented
T08391	DRUGINFO	D0NY6M	PMID27774822-Compound-Figure3CompoundI-165	Patented
T08391	DRUGINFO	D0PB5X	Cycloalkyl nitrile pyrazolo pyridone derivative 1	Patented
T08391	DRUGINFO	D0PM8K	PMID27774824-Compound-Figure7Example10	Patented
T08391	DRUGINFO	D0Q5JV	Aromatic bicyclic compound 5	Patented
T08391	DRUGINFO	D0QD5Y	Aromatic bicyclic compound 1	Patented
T08391	DRUGINFO	D0S4TH	Cycloalkyl nitrile pyrazolo pyridone derivative 2	Patented
T08391	DRUGINFO	D0V0KI	Cycloalkyl nitrile pyrazole carboxamide derivative 1	Patented
T08391	DRUGINFO	D0VI7E	Aromatic bicyclic compound 2	Patented
T08391	DRUGINFO	D0VQ7P	Pyrrolo[2,3-d]pyrimidine derivative 11	Patented
T08391	DRUGINFO	D0W8DN	PMID27774822-Compound-Figure10Example19	Patented
T08391	DRUGINFO	D0WD1Z	Curcumin analog 1	Patented
T08391	DRUGINFO	D01EYJ	Ruxolitinib derivative 2	Patented
T08391	DRUGINFO	D07XYI	1,2,4-triazolo[1,5a]pyridine derivative 1	Patented
T08391	DRUGINFO	D08WPB	Five-and-six-membered heterocyclic compound 1	Patented
T08391	DRUGINFO	D09RUN	Pyrazolopyridine derivative 4	Patented
T08391	DRUGINFO	D09UBE	Pyrrole six-membered heteroaryl ring derivative 1	Patented
T08391	DRUGINFO	D0A6RG	PMID27774824-Compound-Figure2Example4	Patented
T08391	DRUGINFO	D0G0FK	Tricyclic compound 1	Patented
T08391	DRUGINFO	D0G9MM	Isoxazole derivative 1	Patented
T08391	DRUGINFO	D0GH8D	PMID27774822-Compound-Figure10Example1	Patented
T08391	DRUGINFO	D0M3CB	PMID27774822-Compound-Figure1Example20	Patented
T08391	DRUGINFO	D0TX2G	Isoxazole derivative 2	Patented
T08391	DRUGINFO	D0VR6E	Pyrrolo-pyridine derivative 3	Patented
T08391	DRUGINFO	D0Y2IM	N-(cyanomethyl)-4-(2-(phenylamino)pyrimidin-4-yl)benzamide derivative 1	Patented
T08391	DRUGINFO	D0YJ4D	Pyrrole derivative 7	Patented
T08391	DRUGINFO	D01CRX	Benzimidazole derivative 7	Patented
T08391	DRUGINFO	D01FVC	Bis-aminopyrimidine derivative 1	Patented
T08391	DRUGINFO	D03QAY	Pyrazolopyridine derivative 3	Patented
T08391	DRUGINFO	D04BOW	Tricyclic pyrrolopyridine compound 1	Patented
T08391	DRUGINFO	D05AXE	Aminooxazole carboxamide derivative 1	Patented
T08391	DRUGINFO	D0FQ4Z	Pyrrolo[2,3-d]pyrimidine derivative 6	Patented
T08391	DRUGINFO	D0GB7G	PMID27774824-Compound-Figure6Example12	Patented
T08391	DRUGINFO	D0KL3B	Pyrrolo[2,3-d]pyrimidine derivative 8	Patented
T08391	DRUGINFO	D0LR6J	Bis-aminopyrimidine derivative 2	Patented
T08391	DRUGINFO	D0LS1O	Tricyclic compound 11	Patented
T08391	DRUGINFO	D0M2WA	Tricyclic heterocycle derivative 5	Patented
T08391	DRUGINFO	D0RJ3W	PMID27774822-Compound-Figure11Example5	Patented
T08391	DRUGINFO	D0S6XT	Bis-aminopyrimidine derivative 3	Patented
T08391	DRUGINFO	D0SJ1Q	Bis-aminopyrimidine derivative 4	Patented
T08391	DRUGINFO	D0U1HA	PMID27774824-Compound-Figure3Example18	Patented
T08391	DRUGINFO	D0U5FZ	Pyrrolo[2,3-d]pyrimidine derivative 7	Patented
T08391	DRUGINFO	D0WA1V	Pyrimidopyridazinone derivative 2	Patented
T08391	DRUGINFO	D0X1FD	Tricyclic heterocycle derivative 1	Patented
T08391	DRUGINFO	D0WZ8N	PMID27774824-Compound-Figure9Example2up	Patented
T08391	DRUGINFO	D01DBB	PMID27774824-Compound-Figure9Example2down	Patented
T08391	DRUGINFO	D09ALF	Aminotriazolopyridine derivative 1	Patented
T08391	DRUGINFO	D0VJ1R	Imidazo[4,5-c]pyridine derivative 2	Patented
T08391	DRUGINFO	D0YR8S	PMID27774824-Compound-Figure11Example1up	Patented
T08391	DRUGINFO	D09PIS	Pyrazolo[4,3-c]pyridine derivative 2	Patented
T08391	DRUGINFO	D0GZ7B	AG490	Terminated
T08391	DRUGINFO	D00MAM	AMG-JAK2-01	Investigative
T08391	DRUGINFO	D02UVS	NSC-1771	Investigative
T08391	DRUGINFO	D09VZR	SGI-1252	Investigative
T08391	DRUGINFO	D0I3EY	5-phenyl-1H-indazol-3-amine	Investigative
T08391	DRUGINFO	D0I6QN	K-454	Investigative
T08391	DRUGINFO	D0N8CN	BVB-808	Investigative
T08391	DRUGINFO	D0OP3D	AZ960	Investigative
T08391	DRUGINFO	DLW69V	1,2,3,4,5,6-hexabromocyclohexane	Investigative
T08391	DRUGINFO	D05MHL	Atropisomer 1	Investigative
T08391	DRUGINFO	D0A7XQ	ON-044580	Investigative
T08391	DRUGINFO	D0IR6U	CMP-6	Investigative
T08391	DRUGINFO	D0US9O	PMID24359159C19a	Investigative
T08391	DRUGINFO	D0E5IP	WHI-P154	Investigative
T08391	DRUGINFO	D02NNT	PMID21493067C1d	Investigative

T07663	TARGETID	T07663
T07663	FORMERID	TTDS00296
T07663	UNIPROID	PDE5A_HUMAN
T07663	TARGNAME	Phosphodiesterase 5A (PDE5A)
T07663	GENENAME	PDE5A
T07663	TARGTYPE	Successful
T07663	SYNONYMS	cGMP-specific 3',5'-cyclic phosphodiesterase; PDE5A; CGMP-binding cGMP-specific phosphodiesterase; CGB-PDE
T07663	FUNCTION	Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'-GMP. Specifically regulates nitric-oxide-generated cGMP.
T07663	PDBSTRUC	6ACB; 5ZZ2; 5JO3; 4OEX; 4OEW
T07663	BIOCLASS	Phosphoric diester hydrolase
T07663	ECNUMBER	EC 3.1.4.35
T07663	SEQUENCE	MERAGPSFGQQRQQQQPQQQKQQQRDQDSVEAWLDDHWDFTFSYFVRKATREMVNAWFAERVHTIPVCKEGIRGHTESCSCPLQQSPRADNSAPGTPTRKISASEFDRPLRPIVVKDSEGTVSFLSDSEKKEQMPLTPPRFDHDEGDQCSRLLELVKDISSHLDVTALCHKIFLHIHGLISADRYSLFLVCEDSSNDKFLISRLFDVAEGSTLEEVSNNCIRLEWNKGIVGHVAALGEPLNIKDAYEDPRFNAEVDQITGYKTQSILCMPIKNHREEVVGVAQAINKKSGNGGTFTEKDEKDFAAYLAFCGIVLHNAQLYETSLLENKRNQVLLDLASLIFEEQQSLEVILKKIAATIISFMQVQKCTIFIVDEDCSDSFSSVFHMECEELEKSSDTLTREHDANKINYMYAQYVKNTMEPLNIPDVSKDKRFPWTTENTGNVNQQCIRSLLCTPIKNGKKNKVIGVCQLVNKMEENTGKVKPFNRNDEQFLEAFVIFCGLGIQNTQMYEAVERAMAKQMVTLEVLSYHASAAEEETRELQSLAAAVVPSAQTLKITDFSFSDFELSDLETALCTIRMFTDLNLVQNFQMKHEVLCRWILSVKKNYRKNVAYHNWRHAFNTAQCMFAALKAGKIQNKLTDLEILALLIAALSHDLDHRGVNNSYIQRSEHPLAQLYCHSIMEHHHFDQCLMILNSPGNQILSGLSIEEYKTTLKIIKQAILATDLALYIKRRGEFFELIRKNQFNLEDPHQKELFLAMLMTACDLSAITKPWPIQQRIAELVATEFFDQGDRERKELNIEPTDLMNREKKNKIPSMQVGFIDAICLQLYEALTHVSEDCFPLLDGCRKNRQKWQALAEQQEKMLINGESGQAKRN
T07663	DRUGINFO	D01GUS	Udenafil	Approved
T07663	DRUGINFO	D05MQK	Tadalafil	Approved
T07663	DRUGINFO	D0C9SY	Vardenafil	Approved
T07663	DRUGINFO	D0F9GE	Dipyridamole	Approved
T07663	DRUGINFO	D0Y5JC	Avanafil	Approved
T07663	DRUGINFO	D0NJ3V	Papaverine	Approved
T07663	DRUGINFO	D0Z7ZM	Rhucin	Approved
T07663	DRUGINFO	D05OQG	ICARIIN	Phase 3
T07663	DRUGINFO	D0M9VE	EXISULIND	Phase 3
T07663	DRUGINFO	D0M9FQ	PF-489791	Phase 2
T07663	DRUGINFO	D09OCK	UK-371800	Phase 1
T07663	DRUGINFO	D00SPK	E-4021	Discontinued in Phase 2
T07663	DRUGINFO	D04NPP	SLX-2101	Discontinued in Phase 2
T07663	DRUGINFO	D0D7XW	SINITRODIL	Discontinued in Phase 2
T07663	DRUGINFO	D0K2QG	DASANTAFIL	Discontinued in Phase 2
T07663	DRUGINFO	D0X1LO	EMR-62203	Discontinued in Phase 2
T07663	DRUGINFO	D0K2BQ	BRL-61063	Discontinued in Phase 2
T07663	DRUGINFO	D0N5SC	UK-369003	Discontinued in Phase 1/2
T07663	DRUGINFO	D01FRF	Trequinsin	Terminated
T07663	DRUGINFO	D0W8OH	SKF-96231	Terminated
T07663	DRUGINFO	D0W8QG	FR-229934	Terminated
T07663	DRUGINFO	D00YPW	ZAPRINAST	Terminated
T07663	DRUGINFO	D09UMA	IMAZODAN	Terminated
T07663	DRUGINFO	D03BWH	7-(2-Hydroxyethyl)-3-O-rhamnosylicariin	Investigative
T07663	DRUGINFO	D06TLQ	Icariside II	Investigative
T07663	DRUGINFO	D06URK	CKD-533	Investigative
T07663	DRUGINFO	D08VGM	Gamma-Glutamyl[S-(2-Iodobenzyl)Cysteinyl]Glycine	Investigative
T07663	DRUGINFO	D09WUP	3,7-Bis(2-hydroxyethyl)icaritin	Investigative
T07663	DRUGINFO	D0H6ZC	RWJ-387273	Investigative
T07663	DRUGINFO	D0KD6S	SCH-57726	Investigative
T07663	DRUGINFO	D0LZ5R	T0156	Investigative
T07663	DRUGINFO	D0O3QI	Benzo[1,3]dioxol-5-ylmethyl-quinazolin-4-yl-amine	Investigative
T07663	DRUGINFO	D0V1CL	Cartazolate	Investigative
T07663	DRUGINFO	D0V3BI	Aom-0890	Investigative
T07663	DRUGINFO	D0W2BI	8-prenylquercetin	Investigative
T07663	DRUGINFO	D0X7SR	8-prenylapigenin	Investigative
T07663	DRUGINFO	D0XQ8A	TPN-729	Investigative
T07663	DRUGINFO	D0YZ0L	LORNEIC ACID A	Investigative
T07663	DRUGINFO	D0S8AV	SOPHORAFLAVANONE B	Investigative
T07663	DRUGINFO	D00QCL	SOPHOFLAVESCENOL	Investigative
T07663	DRUGINFO	D0T5PO	ROLIPRAM	Investigative
T07663	DRUGINFO	D0W4ZU	KURARINOL	Investigative
T07663	DRUGINFO	D04AWP	Guanosine-5'-Monophosphate	Investigative
T07663	DRUGINFO	D02VHD	SCH51866	Investigative
T07663	DRUGINFO	D06GUJ	KURAIDIN	Investigative
T07663	DRUGINFO	D0R6MT	isobutylmethylxanthine	Investigative

T63505	TARGETID	T63505
T63505	FORMERID	TTDNS00592
T63505	UNIPROID	ABL1_HUMAN
T63505	TARGNAME	Tyrosine-protein kinase ABL1 (ABL)
T63505	GENENAME	ABL1
T63505	TARGTYPE	Successful
T63505	SYNONYMS	p150; Proto-oncogene tyrosine-protein kinase ABL1; Proto-oncogene c-Abl; JTK7; C-ABL; Abl; Abelson tyrosine-protein kinase 1; Abelson murine leukemia viral oncogene homolog 1
T63505	FUNCTION	Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 (involved in branch formation); ANXA1 (involved in membrane anchoring); DBN1, DBNL, CTTN, RAPH1 and ENAH (involved in signaling); or MAPT and PXN (microtubule-binding proteins). Phosphorylation of WASF3 is critical for the stimulation of lamellipodia formation and cell migration. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as BCAR1, CRK, CRKL, DOK1, EFS or NEDD9. Phosphorylates multiple receptor tyrosine kinases and more particularly promotes endocytosis of EGFR, facilitates the formation of neuromuscular synapses through MUSK, inhibits PDGFRB-mediated chemotaxis and modulates the endocytosis of activated B-cell receptor complexes. Other substrates which are involved in endocytosis regulation are the caveolin (CAV1) and RIN1. Moreover, ABL1 regulates the CBL family of ubiquitin ligases that drive receptor down-regulation and actin remodeling. Phosphorylation of CBL leads to increased EGFR stability. Involved in late-stage autophagy by regulating positively the trafficking and function of lysosomal components. ABL1 targets to mitochondria in response to oxidative stress and thereby mediates mitochondrial dysfunction and cell death. In response to oxidative stress, phosphorylates serine/threonine kinase PRKD2 at 'Tyr-717'. ABL1 is also translocated in the nucleus where it has DNA-binding activity and is involved in DNA-damage response and apoptosis. Many substrates are known mediators of DNA repair: DDB1, DDB2, ERCC3, ERCC6, RAD9A, RAD51, RAD52 or WRN. Activates the proapoptotic pathway when the DNA damage is too severe to be repaired. Phosphorylates TP73, a primary regulator for this type of damage-induced apoptosis. Phosphorylates the caspase CASP9 on 'Tyr-153' and regulates its processing in the apoptotic response to DNA damage. Phosphorylates PSMA7 that leads to an inhibition of proteasomal activity and cell cycle transition blocks. ABL1 acts also as a regulator of multiple pathological signaling cascades during infection. Several known tyrosine-phosphorylated microbial proteins have been identified as ABL1 substrates. This is the case of A36R of Vaccinia virus, Tir (translocated intimin receptor) of pathogenic E. coli and possibly Citrobacter, CagA (cytotoxin-associated gene A) of H. pylori, or AnkA (ankyrin repeat-containing protein A) of A. phagocytophilum. Pathogens can highjack ABL1 kinase signaling to reorganize the host actin cytoskeleton for multiple purposes, like facilitating intracellular movement and host cell exit. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1. Regulates T-cell differentiation in a TBX21-dependent manner. Phosphorylates TBX21 on tyrosine residues leading to an enhancement of its transcriptional activator activity. Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis.
T63505	PDBSTRUC	6NPV; 6NPU; 6NPE; 6BL8; 6AMW
T63505	BIOCLASS	Kinase
T63505	ECNUMBER	EC 2.7.10.2
T63505	SEQUENCE	MLEICLKLVGCKSKKGLSSSSSCYLEEALQRPVASDFEPQGLSEAARWNSKENLLAGPSENDPNLFVALYDFVASGDNTLSITKGEKLRVLGYNHNGEWCEAQTKNGQGWVPSNYITPVNSLEKHSWYHGPVSRNAAEYLLSSGINGSFLVRESESSPGQRSISLRYEGRVYHYRINTASDGKLYVSSESRFNTLAELVHHHSTVADGLITTLHYPAPKRNKPTVYGVSPNYDKWEMERTDITMKHKLGGGQYGEVYEGVWKKYSLTVAVKTLKEDTMEVEEFLKEAAVMKEIKHPNLVQLLGVCTREPPFYIITEFMTYGNLLDYLRECNRQEVNAVVLLYMATQISSAMEYLEKKNFIHRDLAARNCLVGENHLVKVADFGLSRLMTGDTYTAHAGAKFPIKWTAPESLAYNKFSIKSDVWAFGVLLWEIATYGMSPYPGIDLSQVYELLEKDYRMERPEGCPEKVYELMRACWQWNPSDRPSFAEIHQAFETMFQESSISDEVEKELGKQGVRGAVSTLLQAPELPTKTRTSRRAAEHRDTTDVPEMPHSKGQGESDPLDHEPAVSPLLPRKERGPPEGGLNEDERLLPKDKKTNLFSALIKKKKKTAPTPPKRSSSFREMDGQPERRGAGEEEGRDISNGALAFTPLDTADPAKSPKPSNGAGVPNGALRESGGSGFRSPHLWKKSSTLTSSRLATGEEEGGGSSSKRFLRSCSASCVPHGAKDTEWRSVTLPRDLQSTGRQFDSSTFGGHKSEKPALPRKRAGENRSDQVTRGTVTPPPRLVKKNEEAADEVFKDIMESSPGSSPPNLTPKPLRRQVTVAPASGLPHKEEAGKGSALGTPAAAEPVTPTSKAGSGAPGGTSKGPAEESRVRRHKHSSESPGRDKGKLSRLKPAPPPPPAASAGKAGGKPSQSPSQEAAGEAVLGAKTKATSLVDAVNSDAAKPSQPGEGLKKPVLPATPKPQSAKPSGTPISPAPVPSTLPSASSALAGDQPSSTAFIPLISTRVSLRKTRQPPERIASGAITKGVVLDSTEALCLAISRNSEQMASHSAVLEAGKNLYTFCVSYVDSIQQMRNKFAFREAINKLENNLRELQICPATAGSGPAATQDFSKLLSSVKEISDIVQR
T63505	DRUGINFO	D01BYB	Adenosine triphosphate	Approved
T63505	DRUGINFO	D0OB0F	Bosutinib	Approved
T63505	DRUGINFO	D03MNN	SKI-758	Approved
T63505	DRUGINFO	D0H0EQ	Ponatinib	Approved
T63505	DRUGINFO	D06JHV	Flumatinib	Phase 2
T63505	DRUGINFO	D0M0XB	Saracatinib	Phase 2
T63505	DRUGINFO	D0E0NM	DCC-2036	Phase 1/2
T63505	DRUGINFO	DC7P4Z	IkT-148009	Phase 1
T63505	DRUGINFO	D00ABO	KW-2449	Phase 1
T63505	DRUGINFO	D06CIJ	ISIS-CRP	Phase 1
T63505	DRUGINFO	D03JXD	PMID25656651-Compound-34c	Patented
T63505	DRUGINFO	D05TYI	Azaindole derivative 2	Patented
T63505	DRUGINFO	D06LHV	PMID25656651-Compound-34a	Patented
T63505	DRUGINFO	D0F4AW	Indol-5-ol derivative 1	Patented
T63505	DRUGINFO	D0JD9Z	PMID25656651-Compound-33b	Patented
T63505	DRUGINFO	D0KM7V	PMID25656651-Compound-34b	Patented
T63505	DRUGINFO	D0O0RB	6,6-fused nitrogenous heterocyclic compound 1	Patented
T63505	DRUGINFO	D0QD6T	6,6-fused nitrogenous heterocyclic compound 2	Patented
T63505	DRUGINFO	D0RT8M	PMID25656651-Compound-28b	Patented
T63505	DRUGINFO	D0TX1S	PMID25656651-Compound-33a	Patented
T63505	DRUGINFO	D0X0VH	PMID25656651-Compound-28a	Patented
T63505	DRUGINFO	D0X9VH	Azaindole derivative 1	Patented
T63505	DRUGINFO	D0XL1M	6,6-fused nitrogenous heterocyclic compound 3	Patented
T63505	DRUGINFO	D0Y0PE	PMID25656651-Compound-46	Patented
T63505	DRUGINFO	D0ZH4I	PMID25656651-Compound-42	Patented
T63505	DRUGINFO	D0WZ8N	PMID27774824-Compound-Figure9Example2up	Patented
T63505	DRUGINFO	D01DBB	PMID27774824-Compound-Figure9Example2down	Patented
T63505	DRUGINFO	D04GFO	MC-2001	Preclinical
T63505	DRUGINFO	D0H3RD	BAS-0338876	Investigative
T63505	DRUGINFO	D01GNF	BAS-00387328	Investigative
T63505	DRUGINFO	D03GQI	BAS-00387347	Investigative
T63505	DRUGINFO	D03PLP	[1,1':2',1'']-terphenyl-4,3'',5''-triol	Investigative
T63505	DRUGINFO	D04QUI	BAS-00387275	Investigative
T63505	DRUGINFO	D07LYJ	BAS-00672722	Investigative
T63505	DRUGINFO	D09QKH	BAS-0338872	Investigative
T63505	DRUGINFO	D0A5MG	BAS-09534324	Investigative
T63505	DRUGINFO	D0D8OY	AP-24226	Investigative
T63505	DRUGINFO	D0D8ZN	BAS-01373578	Investigative
T63505	DRUGINFO	D0O9NE	TRISMETHOXYRESVERATROL	Investigative
T63505	DRUGINFO	D0I3XZ	Bis-(5-hydroxy-1H-indol-2-yl)-methanone	Investigative
T63505	DRUGINFO	D0YZ7H	JNJ-10198409	Investigative
T63505	DRUGINFO	D0GW4Q	PD-0173956	Investigative
T63505	DRUGINFO	D0H1OK	TG-100435	Investigative
T63505	DRUGINFO	D0P3JW	PD-0166326	Investigative
T63505	DRUGINFO	D08OBF	MYRISTIC ACID	Investigative
T63505	DRUGINFO	D0A5RM	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	Investigative

T13201	TARGETID	T13201
T13201	FORMERID	TTDR01224
T13201	UNIPROID	CAH1_HUMAN
T13201	TARGNAME	Carbonic anhydrase I (CA-I)
T13201	GENENAME	CA1
T13201	TARGTYPE	Successful
T13201	SYNONYMS	Carbonic anhydrase B; Carbonic anhydrase 1; Carbonate dehydratase I; CAB
T13201	FUNCTION	Can hydrates cyanamide to urea. Reversible hydration of carbon dioxide.
T13201	PDBSTRUC	6HWZ; 6G3V; 6FAG; 6FAF; 6F3B
T13201	BIOCLASS	Alpha-carbonic anhydrase
T13201	ECNUMBER	EC 4.2.1.1
T13201	SEQUENCE	MASPDWGYDDKNGPEQWSKLYPIANGNNQSPVDIKTSETKHDTSLKPISVSYNPATAKEIINVGHSFHVNFEDNDNRSVLKGGPFSDSYRLFQFHFHWGSTNEHGSEHTVDGVKYSAELHVAHWNSAKYSSLAEAASKADGLAVIGVLMKVGEANPKLQKVLDALQAIKTKGKRAPFTNFDPSTLLPSSLDFWTYPGSLTHPPLYESVTWIICKESISVSSEQLAQFRSLLSNVEGDNAVPMQHNNRPTQPLKGRTVRASF
T13201	DRUGINFO	D0C2II	Methazolamide	Approved
T13201	DRUGINFO	D0E1SW	Acetazolamide	Approved
T13201	DRUGINFO	D07INV	Ethoxzolamide	Approved
T13201	DRUGINFO	D0J4GO	Dichlorphenamide	Approved
T13201	DRUGINFO	D07HBX	Salicyclic acid	Approved
T13201	DRUGINFO	D0W2CX	CG-100649	Phase 3
T13201	DRUGINFO	D0A8JP	PARABEN	Phase 3
T13201	DRUGINFO	D07SDQ	Curcumin	Phase 3
T13201	DRUGINFO	D0L6HN	PHENOL	Phase 2/3
T13201	DRUGINFO	D0Y6OA	Coumate	Phase 2
T13201	DRUGINFO	D0V0UK	SULFAMIDE	Phase 1
T13201	DRUGINFO	D03SLR	FERULIC ACID	Patented
T13201	DRUGINFO	D03LWY	SULFATE	Investigative
T13201	DRUGINFO	D04FXD	CYANATE	Investigative
T13201	DRUGINFO	D05EPY	L-693612	Investigative
T13201	DRUGINFO	D09QHC	BENZENESULFONAMIDE	Investigative
T13201	DRUGINFO	D0CM3O	[Au(CN)2]-	Investigative
T13201	DRUGINFO	D0D1HC	5-oxo-1-tosyl-2,5-dihydro-1Hpyrrol-2-yl acetate	Investigative
T13201	DRUGINFO	D0F7QZ	Styrylboronic acid	Investigative
T13201	DRUGINFO	D0T6VB	Cynooxide anion	Investigative
T13201	DRUGINFO	D0X0RE	4-methylstyrylboronic acid	Investigative
T13201	DRUGINFO	D00RJT	NITRATE	Investigative
T13201	DRUGINFO	D00ZUQ	ETHYL 3-[4-(AMINOSULFONYL)PHENYL]PROPANOATE	Investigative
T13201	DRUGINFO	D01GNQ	Phenoxyarsonous acid	Investigative
T13201	DRUGINFO	D04RCR	3-phenylprop-1-enylboronic acid	Investigative
T13201	DRUGINFO	D05FMD	5-Chlorosalicylic Acid	Investigative
T13201	DRUGINFO	D05WQF	2-Hydroxycinnamic acid	Investigative
T13201	DRUGINFO	D06SME	5-hydroxy-1-tosyl-1H-pyrrol-2(5H)-one	Investigative
T13201	DRUGINFO	D07OMY	3-phenyl-5-sulfamoyl-1H-indole-2-carboxamide	Investigative
T13201	DRUGINFO	D08RKK	IODIDE	Investigative
T13201	DRUGINFO	D08TBP	2-Acetylamino-indan-5-sulfonic acid hydrate	Investigative
T13201	DRUGINFO	D0A8HW	4-Chloro-N-(5-sulfamoyl-indan-2-yl)-benzamide	Investigative
T13201	DRUGINFO	D0BR1D	4,6-Dinitro salicylic acid	Investigative
T13201	DRUGINFO	D0FD8G	2-(biphenyl-4-yl)vinylboronic acid	Investigative
T13201	DRUGINFO	D0K5NQ	N-[4-(trifluoromethyl)phenyl]sulfamide	Investigative
T13201	DRUGINFO	D0L2GD	[Cu(CN)2]-	Investigative
T13201	DRUGINFO	D0M7QA	N-{2-[4-(AMINOSULFONYL)PHENYL]ETHYL}ACETAMIDE	Investigative
T13201	DRUGINFO	D0O1QT	6-Amino-benzothiazole-2-sulfonic acid amide	Investigative
T13201	DRUGINFO	D0S6CO	2,4-dichloro-5-sulfamoylbenzoic acid	Investigative
T13201	DRUGINFO	D0U1AN	4-isothiocyanatobenzenesulfonamide	Investigative
T13201	DRUGINFO	D0Y6EL	Carbamoyl phosphate disodium	Investigative
T13201	DRUGINFO	D00BMI	N-1,3,4-thiadiazol-2-ylsulfamide	Investigative
T13201	DRUGINFO	D00FGB	2-acetamido-5-sulfonamidoindane	Investigative
T13201	DRUGINFO	D00GVA	4-(2-Pyridin-4-ylacetamido)benzenesulfonamide	Investigative
T13201	DRUGINFO	D00XIB	1-acetamido-5-sulfonamidoindane	Investigative
T13201	DRUGINFO	D01EEM	2-Mercapto-N-(4-sulfamoyl-phenyl)-benzamide	Investigative
T13201	DRUGINFO	D01ISX	4-[2-(2-Thienyl)acetamidoethyl]benzenesulfonamide	Investigative
T13201	DRUGINFO	D01UDU	3-Chloro-4-hydrazino-benzenesulfonamide	Investigative
T13201	DRUGINFO	D01YHK	3-Fluoro-4-hydrazino-benzenesulfonamide	Investigative
T13201	DRUGINFO	D03EAQ	N-hydroxysulfonamides	Investigative
T13201	DRUGINFO	D04BKU	Sulfamic acid 4-sulfamoyloxy-butyl ester	Investigative
T13201	DRUGINFO	D05BMD	2-(4-chlorobenzyloxyamino)-N-hydroxyacetamide	Investigative
T13201	DRUGINFO	D05FNN	Sulfamic acid 7-sulfamoyloxy-heptyl ester	Investigative
T13201	DRUGINFO	D05NFU	4-butylphenylboronic acid	Investigative
T13201	DRUGINFO	D05QEK	Aminobenzolamide derivative	Investigative
T13201	DRUGINFO	D06NDR	2-(4-chlorobenzyloxyamino)-N-hydroxyhexanamide	Investigative
T13201	DRUGINFO	D06ORV	Phenethylboronic acid	Investigative
T13201	DRUGINFO	D06XNT	4-(2-Phenylacetamidomethyl)benzenesulfonamide	Investigative
T13201	DRUGINFO	D07CBA	Sulfamic acid 16-sulfamoyloxy-hexadecyl ester	Investigative
T13201	DRUGINFO	D07IHP	Sulfamic acid 3-sulfamoyloxy-phenyl ester	Investigative
T13201	DRUGINFO	D07LYW	2-valproylamido-5-sulfonamidoindane	Investigative
T13201	DRUGINFO	D07PNA	2-nonylamido-5-sulfonamidoindane	Investigative
T13201	DRUGINFO	D07YSQ	N-(4-sulfamoylphenylethyl)-4-sulfamoylbenzamide	Investigative
T13201	DRUGINFO	D07ZXR	Sulfamic acid 12-sulfamoyloxy-dodecyl ester	Investigative
T13201	DRUGINFO	D08AOA	2-ethylamido-5-sulfonamidoindane	Investigative
T13201	DRUGINFO	D09CSP	3-(4-sulfamoylphenyl)propanoic acid	Investigative
T13201	DRUGINFO	D09JHA	Azide	Investigative
T13201	DRUGINFO	D09LWR	4-(2-Phenylacetamidoethyl)benzenesulfonamide	Investigative
T13201	DRUGINFO	D0A3JR	4-(2-Phenylacetamido)-3-chlorobenzenesulfonamide	Investigative
T13201	DRUGINFO	D0B4IN	NSC-654077	Investigative
T13201	DRUGINFO	D0C8ZY	Beta-naphthylboronic acid	Investigative
T13201	DRUGINFO	D0D0BO	2-Morpholin-4-yl-N-(4-sulfamoyl-phenyl)-acetamide	Investigative
T13201	DRUGINFO	D0D2JA	4-phenoxyphenylboronic acid	Investigative
T13201	DRUGINFO	D0D5XC	Sodium trithiocarbonate	Investigative
T13201	DRUGINFO	D0DY9U	3-mercapto-N-(4-sulfamoyl-phenyl)-propionamide	Investigative
T13201	DRUGINFO	D0G0OP	2-(4-chlorobenzyloxyamino)-N-hydroxypropanamide	Investigative
T13201	DRUGINFO	D0G9NE	1-cyclohexylamido-5-sulfonamidoindane	Investigative
T13201	DRUGINFO	D0HN0R	2-cyclohexylamido-5-sulfonamidoindane	Investigative
T13201	DRUGINFO	D0I0RT	Thioureido sulfonamide	Investigative
T13201	DRUGINFO	D0J1PZ	N-(5-Mercapto-[1,3,4]thiadiazol-2-yl)-acetamide	Investigative
T13201	DRUGINFO	D0J3SP	2-pentafluorophenylamido-5-sulfonamidoindane	Investigative
T13201	DRUGINFO	D0KZ2D	1-valproylamido-5-sulfonamidoindane	Investigative
T13201	DRUGINFO	D0L4FM	PHENYLSULFAMATE	Investigative
T13201	DRUGINFO	D0LJ5P	4-ethynyl benzene sulfonamide	Investigative
T13201	DRUGINFO	D0N7WP	4-(2-Pyridin-2-ylacetamido)benzenesulfonamide	Investigative
T13201	DRUGINFO	D0O0UE	4-(2-Phenylacetamido)benzenesulfonamide	Investigative
T13201	DRUGINFO	D0O4KL	1-pentafluorophenylamido-5-sulfonamidoindane	Investigative
T13201	DRUGINFO	D0O8WV	2-propylamido-5-sulfonamidoindane	Investigative
T13201	DRUGINFO	D0O9VU	4-(2-Phenylacetamido)-3-fluorobenzenesulfonamide	Investigative
T13201	DRUGINFO	D0Q0EK	4-Hydrazinocarbonyl-benzenesulfonamide	Investigative
T13201	DRUGINFO	D0SF3B	2-butylamido-5-sulfonamidoindane	Investigative
T13201	DRUGINFO	D0T0YI	4-nitrophenyl phosphate	Investigative
T13201	DRUGINFO	D0T6ZX	HYDROSULFIDE	Investigative
T13201	DRUGINFO	D0W9VC	4-[2-(2-Thienyl)acetamido]benzenesulfonamide	Investigative
T13201	DRUGINFO	D0X0PO	Sulfamic acid 6-sulfamoyloxy-hexyl ester	Investigative
T13201	DRUGINFO	D0X1MY	5-Amino-[1,3,4]thiadiazole-2-thiol	Investigative
T13201	DRUGINFO	D0X9LJ	4-fluoro-N-(4-sulfamoylbenzyl)benzenesulfonamide	Investigative
T13201	DRUGINFO	D0XL5K	Benzothiazole-2-sulfonic acid amide	Investigative
T13201	DRUGINFO	D0Z1CL	4-bromophenylboronic acid	Investigative
T13201	DRUGINFO	D0Z5GE	4-(2-Phenylacetamido)-3-bromobenzenesulfonamide	Investigative
T13201	DRUGINFO	D00IKQ	4-Methoxy-3-pyridinesulfonamide	Investigative
T13201	DRUGINFO	D00NUK	4-Methanesulfonylamino-benzenesulfonamide	Investigative
T13201	DRUGINFO	D01JTI	3-bromophenyl-difluoromethanesulfonamide	Investigative
T13201	DRUGINFO	D02NQK	4-(N-Oxide-2-pyridylthio)pyridine-3-sulfonamide	Investigative
T13201	DRUGINFO	D04JIN	(2-bromophenyl)difluoromethanesulfonamide	Investigative
T13201	DRUGINFO	D04PSK	N-[5-(methylthio)-1,3,4-thiadiazol-2-yl]sulfamide	Investigative
T13201	DRUGINFO	D04SNH	1-Benzyl-1,4-dihydro-4-oxo-3-pyridinesulfonamide	Investigative
T13201	DRUGINFO	D05EBZ	4-(4-Cyanophenoxy)-3-pyridinesulfonamide	Investigative
T13201	DRUGINFO	D05RAB	1,4-Dihydro-1-methyl-4-oxo-3-pyridinesulfonamide	Investigative
T13201	DRUGINFO	D06GPL	4-methylphenyl-difluoromethanesulfonamide	Investigative
T13201	DRUGINFO	D06JVR	N-(5-phenyl-1,3,4-thiadiazol-2-yl)sulfamide	Investigative
T13201	DRUGINFO	D06ZMH	3-(3-Phenyl-ureido)-benzenesulfonamide	Investigative
T13201	DRUGINFO	D07SIA	PHENYLMETHANESULFONAMIDE	Investigative
T13201	DRUGINFO	D08JCC	4-(4-Fluorophenoxy)-3-pyridinesulfonamide	Investigative
T13201	DRUGINFO	D09CXX	N-hydroxysulfamide	Investigative
T13201	DRUGINFO	D09LUD	4-[2-(3-Phenyl-ureido)-ethyl]-benzenesulfonamide	Investigative
T13201	DRUGINFO	D09OSN	Biphenyl-4-ylboronic acid	Investigative
T13201	DRUGINFO	D0A4HS	4-methoxyphenylboronic acid	Investigative
T13201	DRUGINFO	D0E3VJ	N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]sulfamide	Investigative
T13201	DRUGINFO	D0I5YQ	4-nitrophenyl-difluoromethanesulfonamide	Investigative
T13201	DRUGINFO	D0IU3X	(4-bromophenyl)difluoromethanesulfonamide	Investigative
T13201	DRUGINFO	D0K3LN	N-(4-Sulfamoyl-phenyl)-butyramide	Investigative
T13201	DRUGINFO	D0KB6T	N-(4-Sulfamoyl-phenyl)-benzamide	Investigative
T13201	DRUGINFO	D0M4EV	N-(4-cyanophenyl)sulfamide	Investigative
T13201	DRUGINFO	D0N8LR	N-(4-Sulfamoyl-phenyl)-propionamide	Investigative
T13201	DRUGINFO	D0PA5L	N-(pentafluorophenyl)sulfamide	Investigative
T13201	DRUGINFO	D0Q0XO	Pentanoic acid (4-sulfamoyl-phenyl)-amide	Investigative
T13201	DRUGINFO	D0RK7J	2,2,2-Trifluoro-N-(4-sulfamoyl-phenyl)-acetamide	Investigative
T13201	DRUGINFO	D0S4NO	N-(5-ethyl-1,3,4-thiadiazol-2-yl)sulfamide	Investigative
T13201	DRUGINFO	D0S8RD	Trecadrine	Investigative
T13201	DRUGINFO	D0T2VH	N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)sulfamide	Investigative
T13201	DRUGINFO	D0UN0E	PHENYLDIFLUOROMETHANESULFONAMIDE	Investigative
T13201	DRUGINFO	D0YD9F	4-Benzenesulfonylamino-benzenesulfonamide	Investigative
T13201	DRUGINFO	D0Z6TM	4-azidobenzenesulfonamide	Investigative
T13201	DRUGINFO	D00IAE	Prop-2-ynyl 4-sulfamoylbenzoate	Investigative
T13201	DRUGINFO	D01OTW	4-(Cyanomethylthio)pyridine-3-sulfonamide	Investigative
T13201	DRUGINFO	D01XFH	N-propynyl amidebenzenesulphonide	Investigative
T13201	DRUGINFO	D02BMV	4-(2-Propynylthio)pyridine-3-sulfonamide	Investigative
T13201	DRUGINFO	D03KRB	4,4'-thiodipyridine-3-sulfonamide	Investigative
T13201	DRUGINFO	D03VDJ	SULFAMATE	Investigative
T13201	DRUGINFO	D04VSP	4-Ethoxy-3-pyridinesulfonamide	Investigative
T13201	DRUGINFO	D05ETN	4-(2-Methyl-8-quinolinoxy)-3-pyridinesulfonamide	Investigative
T13201	DRUGINFO	D05JAJ	4-(Quinolinoxy)-3-pyridinesulfonamide	Investigative
T13201	DRUGINFO	D06DYP	8-methoxy-2-oxo-2H-chromene-3-carboxylic acid	Investigative
T13201	DRUGINFO	D06IOI	4-Benzythiopyridine-3-sulfonamide	Investigative
T13201	DRUGINFO	D09TKG	4-(Allylamino)-3-pyridinesulfonamide	Investigative
T13201	DRUGINFO	D0A0YX	SACCHARIN	Investigative
T13201	DRUGINFO	D0C4QB	2-Amino-indan-5-sulfonic acid	Investigative
T13201	DRUGINFO	D0J7GU	4-Methylthiopyridine-3-sulfonamide	Investigative
T13201	DRUGINFO	D0LC0F	2,3-dihydro-1H-indene-5-sulfonamide	Investigative
T13201	DRUGINFO	D0Q5VB	4-(Methylhydrazino)-3-pyridinesulfonamide	Investigative
T13201	DRUGINFO	D0R4KQ	4-(5-Methyl-2-pirazolino)-3-pyridinesulfonamide	Investigative
T13201	DRUGINFO	D0RB0D	7-methoxy-2-oxo-2H-chromene-4-carboxylic acid	Investigative
T13201	DRUGINFO	D0TY8X	4-(2-aminopyrimidin-4-ylamino)benzenesulfonamide	Investigative
T13201	DRUGINFO	D0UM1I	4-Hydrazino-3-pyridinesulfonamide	Investigative
T13201	DRUGINFO	D0V5OW	4-(Carbamolymethylthio)pyridine-3-sulfonamide	Investigative
T13201	DRUGINFO	D0X6IE	4-amino-N-(4-sulfamoylbenzyl)benzenesulfonamide	Investigative
T13201	DRUGINFO	D0Z1HY	4-amino-6-chlorobenzene-1,3-disulfonamide	Investigative
T13201	DRUGINFO	D00XJA	6-methoxy-2-oxo-2H-chromene-3-carboxylic acid	Investigative
T13201	DRUGINFO	D08XQI	PARAOXON	Investigative
T13201	DRUGINFO	D0D6UR	2-oxo-2H-thiochromene-3-carboxylic acid	Investigative
T13201	DRUGINFO	D0EJ9B	Phenyl Boronic acid	Investigative
T13201	DRUGINFO	D0H3NS	2-oxo-2H-chromene-3-carboxylic acid	Investigative
T13201	DRUGINFO	D04NSN	4-(2-AMINOETHYL)BENZENESULFONAMIDE	Investigative
T13201	DRUGINFO	D05XZM	4-(hydroxymethyl)benzenesulfonamide	Investigative
T13201	DRUGINFO	D09JPC	Hexane-1,6-diamine	Investigative
T13201	DRUGINFO	D09PWX	Carzenide	Investigative
T13201	DRUGINFO	D0G3BI	6-methyl-2-oxo-2H-chromene-3-carboxylic acid	Investigative
T13201	DRUGINFO	D0Q2LL	6-Hydroxy-benzothiazole-2-sulfonic acid amide	Investigative
T13201	DRUGINFO	D0U4BB	HERNIARIN	Investigative
T13201	DRUGINFO	D00YEF	Decane-1,10-diyl disulfamate	Investigative
T13201	DRUGINFO	D01STY	4-Amino-3-iodo-benzenesulfonamide	Investigative
T13201	DRUGINFO	D02QGI	Pentane-1,5-diamine	Investigative
T13201	DRUGINFO	D03ZMQ	COUMARIN	Investigative
T13201	DRUGINFO	D04CVC	4-Amino-3-fluoro-benzenesulfonamide	Investigative
T13201	DRUGINFO	D05TLB	Octyl sulfamate	Investigative
T13201	DRUGINFO	D09WSJ	Decyl sulfamate	Investigative
T13201	DRUGINFO	D0AU0M	P-Coumaric Acid	Investigative
T13201	DRUGINFO	D0D4OV	Octane-1,8-diyl disulfamate	Investigative
T13201	DRUGINFO	D0E8CC	BENZOLAMIDE	Investigative
T13201	DRUGINFO	D0M3PO	2,4-Disulfamyltrifluoromethylaniline	Investigative
T13201	DRUGINFO	D0N1AW	6-(aminomethyl)-2H-chromen-2-one	Investigative
T13201	DRUGINFO	D0NN3Q	4-Hydrazino-benzenesulfonamide	Investigative
T13201	DRUGINFO	D0P6AM	4-Amino-3-bromo-benzenesulfonamide	Investigative
T13201	DRUGINFO	D0Q7DJ	Syringic Acid	Investigative
T13201	DRUGINFO	D0VD7H	CL-5343	Investigative
T13201	DRUGINFO	D0YU8J	4-Amino-3-chloro-benzenesulfonamide	Investigative
T13201	DRUGINFO	D0V7AA	CATECHIN	Investigative
T13201	DRUGINFO	D0Y3TZ	GALLICACID	Investigative
T13201	DRUGINFO	D0A1CM	ELLAGIC ACID	Investigative

T20401	TARGETID	T20401
T20401	FORMERID	TTDS00306
T20401	UNIPROID	CAH2_HUMAN
T20401	TARGNAME	Carbonic anhydrase II (CA-II)
T20401	GENENAME	CA2
T20401	TARGTYPE	Successful
T20401	SYNONYMS	Carbonic anhydrase C; Carbonic anhydrase 2; Carbonate dehydratase II; CAC
T20401	FUNCTION	Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate exchange activity of SLC26A6. Essential for bone resorption and osteoclast differentiation.
T20401	PDBSTRUC	9CA2; 8CA2; 7CA2; 6QEB; 6MBY
T20401	BIOCLASS	Alpha-carbonic anhydrase
T20401	ECNUMBER	EC 4.2.1.1
T20401	SEQUENCE	MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK
T20401	DRUGINFO	D03CNS	Cyclothiazide	Approved
T20401	DRUGINFO	D05UYW	Dorzolamide	Approved
T20401	DRUGINFO	D0CK3G	Ethinamate	Approved
T20401	DRUGINFO	D0L2MX	Benzthiazide	Approved
T20401	DRUGINFO	D0M9WM	Chlorothiazide	Approved
T20401	DRUGINFO	D07INV	Ethoxzolamide	Approved
T20401	DRUGINFO	D0J4GO	Dichlorphenamide	Approved
T20401	DRUGINFO	D0K1QD	Sulfamylon	Approved
T20401	DRUGINFO	D07HBX	Salicyclic acid	Approved
T20401	DRUGINFO	D02JUW	GUAIACOL	Phase 3
T20401	DRUGINFO	D06PII	SULTHIAME	Phase 3
T20401	DRUGINFO	D0W2CX	CG-100649	Phase 3
T20401	DRUGINFO	D0A8JP	PARABEN	Phase 3
T20401	DRUGINFO	D07SDQ	Curcumin	Phase 3
T20401	DRUGINFO	D0L6HN	PHENOL	Phase 2/3
T20401	DRUGINFO	D07ZNI	STX-140	Phase 2
T20401	DRUGINFO	D0Y6OA	Coumate	Phase 2
T20401	DRUGINFO	D0W1SL	BUTYLATEDHYDROXYTOLUENE	Phase 1
T20401	DRUGINFO	D0V0UK	SULFAMIDE	Phase 1
T20401	DRUGINFO	D03SLR	FERULIC ACID	Patented
T20401	DRUGINFO	D00SJT	4-Flourobenzenesulfonamide	Investigative
T20401	DRUGINFO	D01KOO	(2,2-dimethyl-1,3-dioxolan-4-yl)methyl sulfamate	Investigative
T20401	DRUGINFO	D02DCD	4-(4-tert-butylbenzylideneamino)benzoic acid	Investigative
T20401	DRUGINFO	D04GDW	2-methoxyestradiol-17-O-sulfamate	Investigative
T20401	DRUGINFO	D04LNI	Di(2,6-dimethylphenol)	Investigative
T20401	DRUGINFO	D04MAM	Sulfamic acid chroman-2-ylmethyl ester	Investigative
T20401	DRUGINFO	D04XMZ	Al7089a	Investigative
T20401	DRUGINFO	D05DFJ	2,6-Difluorobenzenesulfonamide	Investigative
T20401	DRUGINFO	D05DIH	Methyl 4-(4-tert-butylbenzylideneamino)benzoate	Investigative
T20401	DRUGINFO	D05NAR	Allyl 4-(aminosulfonyl)benzoate	Investigative
T20401	DRUGINFO	D06CGS	Mercuribenzoic Acid	Investigative
T20401	DRUGINFO	D06IYU	PHENYLSULFAMIDE	Investigative
T20401	DRUGINFO	D06MZK	2,6-di-t-butylphenol	Investigative
T20401	DRUGINFO	D06OVA	1-pentenyl-4-(aminosulfonyl)benzoate	Investigative
T20401	DRUGINFO	D07AUN	Methyl 4-(4-hydroxybenzylideneamino)benzoate	Investigative
T20401	DRUGINFO	D07JYF	6-Nitro-benzothiazole-2-sulfonic acid amide	Investigative
T20401	DRUGINFO	D07QHM	4-(Hydroxymercury)Benzoic Acid	Investigative
T20401	DRUGINFO	D07RZN	N-Benzyl-4-Sulfamoyl-Benzamide	Investigative
T20401	DRUGINFO	D08CNG	AL5300	Investigative
T20401	DRUGINFO	D08ORD	2-(4-tert-butylbenzylideneamino)ethanesulfonamide	Investigative
T20401	DRUGINFO	D09HNP	AL4623	Investigative
T20401	DRUGINFO	D09LMH	AL6528	Investigative
T20401	DRUGINFO	D09PUF	2-methoxyestrrone-3-O-sulfamate	Investigative
T20401	DRUGINFO	D09SFY	2-(4-hydroxybenzylideneamino)ethanesulfonamide	Investigative
T20401	DRUGINFO	D09ZUN	2,6-di-tert-butyl-4-methoxyphenol	Investigative
T20401	DRUGINFO	D0A0RT	Di(2,6-diisopropylphenol)	Investigative
T20401	DRUGINFO	D0A2PD	3-Mercuri-4-Aminobenzenesulfonamide	Investigative
T20401	DRUGINFO	D0A5XB	Sulfamic acid benzo[1,3]dioxol-2-ylmethyl ester	Investigative
T20401	DRUGINFO	D0A7ZH	N-(2,3-DIFLUORO-BENZYL)-4-SULFAMOYL-BENZAMIDE	Investigative
T20401	DRUGINFO	D0B8CU	AL7182	Investigative
T20401	DRUGINFO	D0C3SL	Di(2,6-di-t-butylphenol)	Investigative
T20401	DRUGINFO	D0C9ZY	3-hydroxy-2-methoxybenzaldehyde	Investigative
T20401	DRUGINFO	D0D6UL	AL5424	Investigative
T20401	DRUGINFO	D0F4ZW	SODIUM PERFLUOROHEXANESULFONAMIDE	Investigative
T20401	DRUGINFO	D0G6OW	Sodium 2,3,5,6-tetrafluorobenzoate	Investigative
T20401	DRUGINFO	D0GI2R	N-[(5-chloro-1-benzothien-3-yl)methyl]sulfamide	Investigative
T20401	DRUGINFO	D0I1XT	4-((benzylideneamino)methyl)benzenesulfonamide	Investigative
T20401	DRUGINFO	D0I8DW	4-nitrophenylsulfamide	Investigative
T20401	DRUGINFO	D0K4IH	4-(benzylideneamino)benzoic acid	Investigative
T20401	DRUGINFO	D0KK4F	4-Methylimidazole	Investigative
T20401	DRUGINFO	D0L4KE	N-(2-Thienylmethyl)-2,5-Thiophenedisulfonamide	Investigative
T20401	DRUGINFO	D0LM8L	N-[(4-bromo-1-benzothien-3-yl)methyl]sulfamide	Investigative
T20401	DRUGINFO	D0M7DE	N-(1-benzofuran-3-ylmethyl)sulfamide	Investigative
T20401	DRUGINFO	D0M8HC	AL5927	Investigative
T20401	DRUGINFO	D0M8UY	6-hydroxybenzo[d][1,3]oxathiol-2-one	Investigative
T20401	DRUGINFO	D0N8RD	N-[2-(1h-Indol-5-Yl)-Butyl]-4-Sulfamoyl-Benzamide	Investigative
T20401	DRUGINFO	D0O0HT	4-Sulfonamide-[1-(4-Aminobutane)]Benzamide	Investigative
T20401	DRUGINFO	D0OT2H	1,2,4-Triazole	Investigative
T20401	DRUGINFO	D0R6JK	4-(4-hydroxybenzylideneamino)benzoic acid	Investigative
T20401	DRUGINFO	D0S5LS	N-(2,6-Diflouro-Benzyl)-4-Sulfamoyl-Benzamide	Investigative
T20401	DRUGINFO	D0S6GK	3,5-Difluorobenzenesulfonamide	Investigative
T20401	DRUGINFO	D0S7NH	Dansylamide	Investigative
T20401	DRUGINFO	D0T8SN	4-methoxyphenylsulfamide	Investigative
T20401	DRUGINFO	D0U0QW	2-(benzylideneamino)ethanesulfonamide	Investigative
T20401	DRUGINFO	D0U7GL	N-(2-Flouro-Benzyl)-4-Sulfamoyl-Benzamide	Investigative
T20401	DRUGINFO	D0XX9C	AL7099A	Investigative
T20401	DRUGINFO	D00CIW	Phenyl-phosphonic acid	Investigative
T20401	DRUGINFO	D00RJT	NITRATE	Investigative
T20401	DRUGINFO	D00ZUQ	ETHYL 3-[4-(AMINOSULFONYL)PHENYL]PROPANOATE	Investigative
T20401	DRUGINFO	D01GNQ	Phenoxyarsonous acid	Investigative
T20401	DRUGINFO	D02KDH	2-(N''-Acetyl-hydrazino)-benzenesulfonamide	Investigative
T20401	DRUGINFO	D03VUQ	4-(4-hydroxy-benzylideneamino)-benzenesulfonamide	Investigative
T20401	DRUGINFO	D04RCR	3-phenylprop-1-enylboronic acid	Investigative
T20401	DRUGINFO	D05FMD	5-Chlorosalicylic Acid	Investigative
T20401	DRUGINFO	D05PRS	4-Thiocyanato-benzenesulfonamide	Investigative
T20401	DRUGINFO	D05WQF	2-Hydroxycinnamic acid	Investigative
T20401	DRUGINFO	D06KTD	2-Hydrazinocarbonyl-benzenesulfonamide	Investigative
T20401	DRUGINFO	D06LVE	4-Nitro-benzenesulfonamide	Investigative
T20401	DRUGINFO	D06SME	5-hydroxy-1-tosyl-1H-pyrrol-2(5H)-one	Investigative
T20401	DRUGINFO	D07AGM	4-Methylamino-benzenesulfonamide	Investigative
T20401	DRUGINFO	D07CQI	2-Sulfamoyl-benzoic acid methyl ester	Investigative
T20401	DRUGINFO	D07OMY	3-phenyl-5-sulfamoyl-1H-indole-2-carboxamide	Investigative
T20401	DRUGINFO	D07ZHE	3-Nitro-benzenesulfonamide	Investigative
T20401	DRUGINFO	D08RKK	IODIDE	Investigative
T20401	DRUGINFO	D08TBP	2-Acetylamino-indan-5-sulfonic acid hydrate	Investigative
T20401	DRUGINFO	D09CZV	Methyl Mercury Ion	Investigative
T20401	DRUGINFO	D0A6HS	6-HYDROXY-1,3-BENZOTHIAZOLE-2-SULFONAMIDE	Investigative
T20401	DRUGINFO	D0A8HW	4-Chloro-N-(5-sulfamoyl-indan-2-yl)-benzamide	Investigative
T20401	DRUGINFO	D0BR1D	4,6-Dinitro salicylic acid	Investigative
T20401	DRUGINFO	D0C6ED	1,4-phenylene disulfamate	Investigative
T20401	DRUGINFO	D0F7SO	Quinoline-8-sulfonamide	Investigative
T20401	DRUGINFO	D0K5NQ	N-[4-(trifluoromethyl)phenyl]sulfamide	Investigative
T20401	DRUGINFO	D0L8ZG	P-tolylboronic acid	Investigative
T20401	DRUGINFO	D0M7QA	N-{2-[4-(AMINOSULFONYL)PHENYL]ETHYL}ACETAMIDE	Investigative
T20401	DRUGINFO	D0M7VN	4-(N-Methyl-hydrazino)-benzenesulfonamide	Investigative
T20401	DRUGINFO	D0N5KX	Sulfamic acid 4-sulfamoyloxymethyl-benzyl ester	Investigative
T20401	DRUGINFO	D0O1QT	6-Amino-benzothiazole-2-sulfonic acid amide	Investigative
T20401	DRUGINFO	D0R7QY	EMATE	Investigative
T20401	DRUGINFO	D0S2II	4-(benzylideneamino)benzenesulfonamide	Investigative
T20401	DRUGINFO	D0S6CO	2,4-dichloro-5-sulfamoylbenzoic acid	Investigative
T20401	DRUGINFO	D0SV6C	PRONTOCIL	Investigative
T20401	DRUGINFO	D0U1AN	4-isothiocyanatobenzenesulfonamide	Investigative
T20401	DRUGINFO	D0Y1XM	2-(benzyloxyamino)-N-hydroxyhexanamide	Investigative
T20401	DRUGINFO	D00BMI	N-1,3,4-thiadiazol-2-ylsulfamide	Investigative
T20401	DRUGINFO	D00FGB	2-acetamido-5-sulfonamidoindane	Investigative
T20401	DRUGINFO	D00GVA	4-(2-Pyridin-4-ylacetamido)benzenesulfonamide	Investigative
T20401	DRUGINFO	D00XIB	1-acetamido-5-sulfonamidoindane	Investigative
T20401	DRUGINFO	D01EEM	2-Mercapto-N-(4-sulfamoyl-phenyl)-benzamide	Investigative
T20401	DRUGINFO	D01ISX	4-[2-(2-Thienyl)acetamidoethyl]benzenesulfonamide	Investigative
T20401	DRUGINFO	D01UDU	3-Chloro-4-hydrazino-benzenesulfonamide	Investigative
T20401	DRUGINFO	D01YHK	3-Fluoro-4-hydrazino-benzenesulfonamide	Investigative
T20401	DRUGINFO	D03DAM	2,2-Dimethyl-N-(4-sulfamoyl-phenyl)-propionamide	Investigative
T20401	DRUGINFO	D03EAQ	N-hydroxysulfonamides	Investigative
T20401	DRUGINFO	D04BKU	Sulfamic acid 4-sulfamoyloxy-butyl ester	Investigative
T20401	DRUGINFO	D04HRS	4-((4-hydroxyphenyl)diazenyl)benzenesulfonamide	Investigative
T20401	DRUGINFO	D04POB	ACETYLSULFANILAMIDE	Investigative
T20401	DRUGINFO	D05BMD	2-(4-chlorobenzyloxyamino)-N-hydroxyacetamide	Investigative
T20401	DRUGINFO	D05FNN	Sulfamic acid 7-sulfamoyloxy-heptyl ester	Investigative
T20401	DRUGINFO	D05NFU	4-butylphenylboronic acid	Investigative
T20401	DRUGINFO	D05QEK	Aminobenzolamide derivative	Investigative
T20401	DRUGINFO	D06NDR	2-(4-chlorobenzyloxyamino)-N-hydroxyhexanamide	Investigative
T20401	DRUGINFO	D06ORV	Phenethylboronic acid	Investigative
T20401	DRUGINFO	D06XNT	4-(2-Phenylacetamidomethyl)benzenesulfonamide	Investigative
T20401	DRUGINFO	D07CBA	Sulfamic acid 16-sulfamoyloxy-hexadecyl ester	Investigative
T20401	DRUGINFO	D07IHP	Sulfamic acid 3-sulfamoyloxy-phenyl ester	Investigative
T20401	DRUGINFO	D07LYW	2-valproylamido-5-sulfonamidoindane	Investigative
T20401	DRUGINFO	D07PNA	2-nonylamido-5-sulfonamidoindane	Investigative
T20401	DRUGINFO	D07YSQ	N-(4-sulfamoylphenylethyl)-4-sulfamoylbenzamide	Investigative
T20401	DRUGINFO	D07ZXR	Sulfamic acid 12-sulfamoyloxy-dodecyl ester	Investigative
T20401	DRUGINFO	D08AOA	2-ethylamido-5-sulfonamidoindane	Investigative
T20401	DRUGINFO	D09CSP	3-(4-sulfamoylphenyl)propanoic acid	Investigative
T20401	DRUGINFO	D09JHA	Azide	Investigative
T20401	DRUGINFO	D09LWR	4-(2-Phenylacetamidoethyl)benzenesulfonamide	Investigative
T20401	DRUGINFO	D0A3JR	4-(2-Phenylacetamido)-3-chlorobenzenesulfonamide	Investigative
T20401	DRUGINFO	D0B4IN	NSC-654077	Investigative
T20401	DRUGINFO	D0BD0K	3-(4'-Hydroxyphenyl)diazenylbenzenesulfonamide	Investigative
T20401	DRUGINFO	D0C7WG	3-((4-hydroxyphenyl)diazenyl)benzenesulfonamide	Investigative
T20401	DRUGINFO	D0C8ZY	Beta-naphthylboronic acid	Investigative
T20401	DRUGINFO	D0D0BO	2-Morpholin-4-yl-N-(4-sulfamoyl-phenyl)-acetamide	Investigative
T20401	DRUGINFO	D0D2JA	4-phenoxyphenylboronic acid	Investigative
T20401	DRUGINFO	D0D5XC	Sodium trithiocarbonate	Investigative
T20401	DRUGINFO	D0DY9U	3-mercapto-N-(4-sulfamoyl-phenyl)-propionamide	Investigative
T20401	DRUGINFO	D0G0OP	2-(4-chlorobenzyloxyamino)-N-hydroxypropanamide	Investigative
T20401	DRUGINFO	D0G9NE	1-cyclohexylamido-5-sulfonamidoindane	Investigative
T20401	DRUGINFO	D0H4CF	3-((4-aminophenyl)diazenyl)benzenesulfonamide	Investigative
T20401	DRUGINFO	D0HN0R	2-cyclohexylamido-5-sulfonamidoindane	Investigative
T20401	DRUGINFO	D0I0RT	Thioureido sulfonamide	Investigative
T20401	DRUGINFO	D0J1PZ	N-(5-Mercapto-[1,3,4]thiadiazol-2-yl)-acetamide	Investigative
T20401	DRUGINFO	D0J3SP	2-pentafluorophenylamido-5-sulfonamidoindane	Investigative
T20401	DRUGINFO	D0KZ2D	1-valproylamido-5-sulfonamidoindane	Investigative
T20401	DRUGINFO	D0L4FM	PHENYLSULFAMATE	Investigative
T20401	DRUGINFO	D0LJ5P	4-ethynyl benzene sulfonamide	Investigative
T20401	DRUGINFO	D0N7WP	4-(2-Pyridin-2-ylacetamido)benzenesulfonamide	Investigative
T20401	DRUGINFO	D0O0UE	4-(2-Phenylacetamido)benzenesulfonamide	Investigative
T20401	DRUGINFO	D0O4KL	1-pentafluorophenylamido-5-sulfonamidoindane	Investigative
T20401	DRUGINFO	D0O8WV	2-propylamido-5-sulfonamidoindane	Investigative
T20401	DRUGINFO	D0O9VU	4-(2-Phenylacetamido)-3-fluorobenzenesulfonamide	Investigative
T20401	DRUGINFO	D0Q0EK	4-Hydrazinocarbonyl-benzenesulfonamide	Investigative
T20401	DRUGINFO	D0SF3B	2-butylamido-5-sulfonamidoindane	Investigative
T20401	DRUGINFO	D0T0YI	4-nitrophenyl phosphate	Investigative
T20401	DRUGINFO	D0T2YZ	N-(4-Sulfamoyl-phenyl)-isobutyramide	Investigative
T20401	DRUGINFO	D0T6ZX	HYDROSULFIDE	Investigative
T20401	DRUGINFO	D0W9VC	4-[2-(2-Thienyl)acetamido]benzenesulfonamide	Investigative
T20401	DRUGINFO	D0X0PO	Sulfamic acid 6-sulfamoyloxy-hexyl ester	Investigative
T20401	DRUGINFO	D0X1MY	5-Amino-[1,3,4]thiadiazole-2-thiol	Investigative
T20401	DRUGINFO	D0X9LJ	4-fluoro-N-(4-sulfamoylbenzyl)benzenesulfonamide	Investigative
T20401	DRUGINFO	D0XL5K	Benzothiazole-2-sulfonic acid amide	Investigative
T20401	DRUGINFO	D0Z1CL	4-bromophenylboronic acid	Investigative
T20401	DRUGINFO	D0Z5GE	4-(2-Phenylacetamido)-3-bromobenzenesulfonamide	Investigative
T20401	DRUGINFO	D00IKQ	4-Methoxy-3-pyridinesulfonamide	Investigative
T20401	DRUGINFO	D00IUB	4-CYANOPHENOL	Investigative
T20401	DRUGINFO	D00NUK	4-Methanesulfonylamino-benzenesulfonamide	Investigative
T20401	DRUGINFO	D01JTI	3-bromophenyl-difluoromethanesulfonamide	Investigative
T20401	DRUGINFO	D02NQK	4-(N-Oxide-2-pyridylthio)pyridine-3-sulfonamide	Investigative
T20401	DRUGINFO	D04JIN	(2-bromophenyl)difluoromethanesulfonamide	Investigative
T20401	DRUGINFO	D04PSK	N-[5-(methylthio)-1,3,4-thiadiazol-2-yl]sulfamide	Investigative
T20401	DRUGINFO	D04SNH	1-Benzyl-1,4-dihydro-4-oxo-3-pyridinesulfonamide	Investigative
T20401	DRUGINFO	D05EBZ	4-(4-Cyanophenoxy)-3-pyridinesulfonamide	Investigative
T20401	DRUGINFO	D05RAB	1,4-Dihydro-1-methyl-4-oxo-3-pyridinesulfonamide	Investigative
T20401	DRUGINFO	D06GPL	4-methylphenyl-difluoromethanesulfonamide	Investigative
T20401	DRUGINFO	D06JVR	N-(5-phenyl-1,3,4-thiadiazol-2-yl)sulfamide	Investigative
T20401	DRUGINFO	D06ZMH	3-(3-Phenyl-ureido)-benzenesulfonamide	Investigative
T20401	DRUGINFO	D07QJJ	CATECHOL	Investigative
T20401	DRUGINFO	D07SIA	PHENYLMETHANESULFONAMIDE	Investigative
T20401	DRUGINFO	D08JCC	4-(4-Fluorophenoxy)-3-pyridinesulfonamide	Investigative
T20401	DRUGINFO	D09CXX	N-hydroxysulfamide	Investigative
T20401	DRUGINFO	D09LUD	4-[2-(3-Phenyl-ureido)-ethyl]-benzenesulfonamide	Investigative
T20401	DRUGINFO	D09OSN	Biphenyl-4-ylboronic acid	Investigative
T20401	DRUGINFO	D09UQM	1-(3,4-dichlorophenyl)-3-hydroxyurea	Investigative
T20401	DRUGINFO	D0A4HS	4-methoxyphenylboronic acid	Investigative
T20401	DRUGINFO	D0E3VJ	N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]sulfamide	Investigative
T20401	DRUGINFO	D0I5YQ	4-nitrophenyl-difluoromethanesulfonamide	Investigative
T20401	DRUGINFO	D0IU3X	(4-bromophenyl)difluoromethanesulfonamide	Investigative
T20401	DRUGINFO	D0K3LN	N-(4-Sulfamoyl-phenyl)-butyramide	Investigative
T20401	DRUGINFO	D0KB6T	N-(4-Sulfamoyl-phenyl)-benzamide	Investigative
T20401	DRUGINFO	D0L6CN	N-(phosphonacetyl)-L-aspartate	Investigative
T20401	DRUGINFO	D0M4EV	N-(4-cyanophenyl)sulfamide	Investigative
T20401	DRUGINFO	D0N8LR	N-(4-Sulfamoyl-phenyl)-propionamide	Investigative
T20401	DRUGINFO	D0PA5L	N-(pentafluorophenyl)sulfamide	Investigative
T20401	DRUGINFO	D0Q0XO	Pentanoic acid (4-sulfamoyl-phenyl)-amide	Investigative
T20401	DRUGINFO	D0RK7J	2,2,2-Trifluoro-N-(4-sulfamoyl-phenyl)-acetamide	Investigative
T20401	DRUGINFO	D0S4NO	N-(5-ethyl-1,3,4-thiadiazol-2-yl)sulfamide	Investigative
T20401	DRUGINFO	D0S8RD	Trecadrine	Investigative
T20401	DRUGINFO	D0T2VH	N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)sulfamide	Investigative
T20401	DRUGINFO	D0UN0E	PHENYLDIFLUOROMETHANESULFONAMIDE	Investigative
T20401	DRUGINFO	D0YD9F	4-Benzenesulfonylamino-benzenesulfonamide	Investigative
T20401	DRUGINFO	D0Z6TM	4-azidobenzenesulfonamide	Investigative
T20401	DRUGINFO	D00IAE	Prop-2-ynyl 4-sulfamoylbenzoate	Investigative
T20401	DRUGINFO	D01OTW	4-(Cyanomethylthio)pyridine-3-sulfonamide	Investigative
T20401	DRUGINFO	D01XFH	N-propynyl amidebenzenesulphonide	Investigative
T20401	DRUGINFO	D02BMV	4-(2-Propynylthio)pyridine-3-sulfonamide	Investigative
T20401	DRUGINFO	D02DBP	RESORCINOL	Investigative
T20401	DRUGINFO	D03KRB	4,4'-thiodipyridine-3-sulfonamide	Investigative
T20401	DRUGINFO	D03VDJ	SULFAMATE	Investigative
T20401	DRUGINFO	D04VSP	4-Ethoxy-3-pyridinesulfonamide	Investigative
T20401	DRUGINFO	D05ETN	4-(2-Methyl-8-quinolinoxy)-3-pyridinesulfonamide	Investigative
T20401	DRUGINFO	D05JAJ	4-(Quinolinoxy)-3-pyridinesulfonamide	Investigative
T20401	DRUGINFO	D06IOI	4-Benzythiopyridine-3-sulfonamide	Investigative
T20401	DRUGINFO	D09TKG	4-(Allylamino)-3-pyridinesulfonamide	Investigative
T20401	DRUGINFO	D0A0YX	SACCHARIN	Investigative
T20401	DRUGINFO	D0C4QB	2-Amino-indan-5-sulfonic acid	Investigative
T20401	DRUGINFO	D0G0FJ	2-hydrazinylbenzenesulfonamide	Investigative
T20401	DRUGINFO	D0J7GU	4-Methylthiopyridine-3-sulfonamide	Investigative
T20401	DRUGINFO	D0LC0F	2,3-dihydro-1H-indene-5-sulfonamide	Investigative
T20401	DRUGINFO	D0Q5VB	4-(Methylhydrazino)-3-pyridinesulfonamide	Investigative
T20401	DRUGINFO	D0R4KQ	4-(5-Methyl-2-pirazolino)-3-pyridinesulfonamide	Investigative
T20401	DRUGINFO	D0TY8X	4-(2-aminopyrimidin-4-ylamino)benzenesulfonamide	Investigative
T20401	DRUGINFO	D0UM1I	4-Hydrazino-3-pyridinesulfonamide	Investigative
T20401	DRUGINFO	D0V5OW	4-(Carbamolymethylthio)pyridine-3-sulfonamide	Investigative
T20401	DRUGINFO	D0X6IE	4-amino-N-(4-sulfamoylbenzyl)benzenesulfonamide	Investigative
T20401	DRUGINFO	D0Z1HY	4-amino-6-chlorobenzene-1,3-disulfonamide	Investigative
T20401	DRUGINFO	D0ZC3W	P-toluenesulfonamide	Investigative
T20401	DRUGINFO	D00XJA	6-methoxy-2-oxo-2H-chromene-3-carboxylic acid	Investigative
T20401	DRUGINFO	D04VLI	4-(2-Hydroxy-ethyl)-benzenesulfonamide	Investigative
T20401	DRUGINFO	D08XQI	PARAOXON	Investigative
T20401	DRUGINFO	D0D6UR	2-oxo-2H-thiochromene-3-carboxylic acid	Investigative
T20401	DRUGINFO	D0EJ9B	Phenyl Boronic acid	Investigative
T20401	DRUGINFO	D0J2AE	3-Amino-benzenesulfonamide	Investigative
T20401	DRUGINFO	D0OI1H	2-Amino-benzenesulfonamide	Investigative
T20401	DRUGINFO	D04NSN	4-(2-AMINOETHYL)BENZENESULFONAMIDE	Investigative
T20401	DRUGINFO	D05XZM	4-(hydroxymethyl)benzenesulfonamide	Investigative
T20401	DRUGINFO	D09PWX	Carzenide	Investigative
T20401	DRUGINFO	D0G3BI	6-methyl-2-oxo-2H-chromene-3-carboxylic acid	Investigative
T20401	DRUGINFO	D0L5TZ	6-(hydroxymethyl)-2H-chromen-2-one	Investigative
T20401	DRUGINFO	D0Q2LL	6-Hydroxy-benzothiazole-2-sulfonic acid amide	Investigative
T20401	DRUGINFO	D00YEF	Decane-1,10-diyl disulfamate	Investigative
T20401	DRUGINFO	D01STY	4-Amino-3-iodo-benzenesulfonamide	Investigative
T20401	DRUGINFO	D02QGI	Pentane-1,5-diamine	Investigative
T20401	DRUGINFO	D03ZMQ	COUMARIN	Investigative
T20401	DRUGINFO	D04CVC	4-Amino-3-fluoro-benzenesulfonamide	Investigative
T20401	DRUGINFO	D05TLB	Octyl sulfamate	Investigative
T20401	DRUGINFO	D09WSJ	Decyl sulfamate	Investigative
T20401	DRUGINFO	D0AU0M	P-Coumaric Acid	Investigative
T20401	DRUGINFO	D0D4OV	Octane-1,8-diyl disulfamate	Investigative
T20401	DRUGINFO	D0E8CC	BENZOLAMIDE	Investigative
T20401	DRUGINFO	D0M3PO	2,4-Disulfamyltrifluoromethylaniline	Investigative
T20401	DRUGINFO	D0N1AW	6-(aminomethyl)-2H-chromen-2-one	Investigative
T20401	DRUGINFO	D0NN3Q	4-Hydrazino-benzenesulfonamide	Investigative
T20401	DRUGINFO	D0P6AM	4-Amino-3-bromo-benzenesulfonamide	Investigative
T20401	DRUGINFO	D0Q7DJ	Syringic Acid	Investigative
T20401	DRUGINFO	D0VD7H	CL-5343	Investigative
T20401	DRUGINFO	D0YU8J	4-Amino-3-chloro-benzenesulfonamide	Investigative
T20401	DRUGINFO	D0V7AA	CATECHIN	Investigative
T20401	DRUGINFO	D0Y3TZ	GALLICACID	Investigative
T20401	DRUGINFO	D06EWG	Formic Acid	Investigative
T20401	DRUGINFO	D0A4TC	MMI270	Investigative
T20401	DRUGINFO	D0Q5FV	2-Sulfhydryl-Ethanol	Investigative
T20401	DRUGINFO	D0A1CM	ELLAGIC ACID	Investigative
T20401	DRUGINFO	D0F2ME	Acetate Ion	Investigative

T89534	TARGETID	T89534
T89534	FORMERID	TTDS00242
T89534	UNIPROID	ESR1_HUMAN
T89534	TARGNAME	Estrogen receptor (ESR)
T89534	GENENAME	ESR1
T89534	TARGTYPE	Successful
T89534	SYNONYMS	Nuclear receptor subfamily 3 group A member 1; NR3A1; Estradiol receptor; ESR; ER-alpha; ER
T89534	FUNCTION	Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full-length receptor. Essential for MTA1-mediated transcriptional regulation of BRCA1 and BCAS3. Isoform 3 can bind to ERE and inhibit isoform 1.
T89534	PDBSTRUC	6IAR; 6HMU; 6HKF; 6HKB; 6HHP
T89534	BIOCLASS	Nuclear hormone receptor
T89534	SEQUENCE	MTMTLHTKASGMALLHQIQGNELEPLNRPQLKIPLERPLGEVYLDSSKPAVYNYPEGAAYEFNAAAAANAQVYGQTGLPYGPGSEAAAFGSNGLGGFPPLNSVSPSPLMLLHPPPQLSPFLQPHGQQVPYYLENEPSGYTVREAGPPAFYRPNSDNRRQGGRERLASTNDKGSMAMESAKETRYCAVCNDYASGYHYGVWSCEGCKAFFKRSIQGHNDYMCPATNQCTIDKNRRKSCQACRLRKCYEVGMMKGGIRKDRRGGRMLKHKRQRDDGEGRGEVGSAGDMRAANLWPSPLMIKRSKKNSLALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWAKRVPGFVDLTLHDQVHLLECAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKCVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLDKITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPLYDLLLEMLDAHRLHAPTSRGGASVEETDQSHLATAGSTSSHSLQKYYITGEAEGFPATV
T89534	DRUGINFO	D00ZFP	Estrone	Approved
T89534	DRUGINFO	D01ICU	Conjugated estrogens b	Approved
T89534	DRUGINFO	D01XBA	Raloxifene	Approved
T89534	DRUGINFO	D02CTS	Ospemifene	Approved
T89534	DRUGINFO	D03IUY	Estropipate	Approved
T89534	DRUGINFO	D04UZT	Quinestrol	Approved
T89534	DRUGINFO	D04VFJ	Toremifene	Approved
T89534	DRUGINFO	D06NXY	Ethinyl Estradiol	Approved
T89534	DRUGINFO	D07KSG	Tamoxifen	Approved
T89534	DRUGINFO	D07KUN	Elacestrant	Approved
T89534	DRUGINFO	D07VBA	Estradiol Valerate	Approved
T89534	DRUGINFO	D08QMX	Estradiol	Approved
T89534	DRUGINFO	D09IPV	Danazol	Approved
T89534	DRUGINFO	D09ZQN	Dienestrol	Approved
T89534	DRUGINFO	D0A2RG	Conjugated estrogens a	Approved
T89534	DRUGINFO	D0C4NY	Promestriene	Approved
T89534	DRUGINFO	D0CT9Y	Clomifene	Approved
T89534	DRUGINFO	D0I5WB	Clomiphene Citrate	Approved
T89534	DRUGINFO	D0J1ML	Mestranol	Approved
T89534	DRUGINFO	D0JO7Y	Fulvestrant	Approved
T89534	DRUGINFO	D0JO8Z	Fosfestrol	Approved
T89534	DRUGINFO	D0JY8T	Bazedoxifene	Approved
T89534	DRUGINFO	D0M5RF	Gestrinone	Approved
T89534	DRUGINFO	D0N6YV	Cenestin	Approved
T89534	DRUGINFO	D0R6RE	Esterified estrogens	Approved
T89534	DRUGINFO	D0S1UW	Premarin/Trimegestone	Approved
T89534	DRUGINFO	D0T7ZQ	Estradiol Acetate	Approved
T89534	DRUGINFO	D0U0XD	Estradiol Cypionate	Approved
T89534	DRUGINFO	D0V2JK	Nomegestrol acetate	Approved
T89534	DRUGINFO	D0W9GA	Levormeloxifene	Approved
T89534	DRUGINFO	D0X1EZ	Cyclofenil	Approved
T89534	DRUGINFO	D0Y2NE	Diethylstilbestrol	Approved
T89534	DRUGINFO	D0Z1FX	Estriol	Approved
T89534	DRUGINFO	D0Z5OE	Mitotane	Approved
T89534	DRUGINFO	D06LOQ	ARZOXIFENE	Approved
T89534	DRUGINFO	D09NMD	Lasofoxifene	Approved
T89534	DRUGINFO	D0M8PD	Estrogen	Approved
T89534	DRUGINFO	D02BAE	Synthetic conjugated estrogen	Phase 3
T89534	DRUGINFO	D0C6XR	Trimegestone/ethinyl estradiol	Phase 3
T89534	DRUGINFO	D0IC7A	TZTX-001	Phase 3
T89534	DRUGINFO	D0XB0T	Acolbifene	Phase 3
T89534	DRUGINFO	D9I6QG	NE3107	Phase 3
T89534	DRUGINFO	DGW9U7	Giredestrant	Phase 3
T89534	DRUGINFO	DON71B	Imlunestrant	Phase 3
T89534	DRUGINFO	D0VF3C	NPC-01	Phase 3
T89534	DRUGINFO	D0G7IV	Premarin/Pravachol	Phase 3
T89534	DRUGINFO	D00JFE	ARN-810	Phase 2
T89534	DRUGINFO	D02PYN	SR 16234	Phase 2
T89534	DRUGINFO	D09NST	Afimoxifene	Phase 2
T89534	DRUGINFO	D0E7FM	GTx-758	Phase 2
T89534	DRUGINFO	D0L0BX	ICARITIN	Phase 2
T89534	DRUGINFO	D0L3TR	Estetrol	Phase 2
T89534	DRUGINFO	D0W4EB	Endoxifen	Phase 2
T89534	DRUGINFO	DATO92	AZD9833	Phase 2
T89534	DRUGINFO	D0Z5VW	H3B-6545	Phase 1/2
T89534	DRUGINFO	DJ1W5R	ZN-c5	Phase 1/2
T89534	DRUGINFO	DZ91HE	OP-1250	Phase 1/2
T89534	DRUGINFO	D03YGP	CC-8490	Phase 1
T89534	DRUGINFO	D08OUV	CHF-4227	Phase 1
T89534	DRUGINFO	D09BQO	ATD transdermal gel	Phase 1
T89534	DRUGINFO	D09OJI	D-0502	Phase 1
T89534	DRUGINFO	D0NZ3C	TTC-352	Phase 1
T89534	DRUGINFO	D0X1OW	AZD9496	Phase 1
T89534	DRUGINFO	DG38QS	G1T-48	Phase 1
T89534	DRUGINFO	DH4Y3O	LY3484356	Phase 1
T89534	DRUGINFO	DI9GC3	AC0682	Phase 1
T89534	DRUGINFO	DNTW18	SCO-120	Phase 1
T89534	DRUGINFO	DT4WU3	TTC-352	Phase 1
T89534	DRUGINFO	D0X0KJ	Chlorotrianisene	Withdrawn from market
T89534	DRUGINFO	D0C4FT	HEXESTROL	Withdrawn from market
T89534	DRUGINFO	D0QQ1J	BITHIONOL	Withdrawn from market
T89534	DRUGINFO	D01OML	IoGen	Discontinued in Phase 3
T89534	DRUGINFO	D02VFB	Miproxifene	Discontinued in Phase 3
T89534	DRUGINFO	D0GR2J	Idoxifene	Discontinued in Phase 3
T89534	DRUGINFO	D0MU0S	EM-800	Discontinued in Phase 3
T89534	DRUGINFO	D01AXT	NP-50301	Discontinued in Phase 2
T89534	DRUGINFO	D04BIG	SR-90067	Discontinued in Phase 2
T89534	DRUGINFO	D04HVB	Panomifene	Discontinued in Phase 2
T89534	DRUGINFO	D04MNL	SERM-3339	Discontinued in Phase 2
T89534	DRUGINFO	D0R2JS	Droloxifene	Discontinued in Phase 2
T89534	DRUGINFO	D0R8TB	ERA-923	Discontinued in Phase 2
T89534	DRUGINFO	D0B6HS	HRT	Discontinued in Phase 1
T89534	DRUGINFO	D05BCA	MX-4509	Discontinued in Phase 1
T89534	DRUGINFO	D08DZZ	HE2100	Discontinued in Phase 1
T89534	DRUGINFO	D01EXY	BN-AO-014	Preclinical
T89534	DRUGINFO	D06YGP	BN-OD-026	Preclinical
T89534	DRUGINFO	D0N6YN	BN-DF-037	Preclinical
T89534	DRUGINFO	D0P5NU	BN-AA-003-NY	Preclinical
T89534	DRUGINFO	D0QI9N	BN-CB-045	Preclinical
T89534	DRUGINFO	D0QX9U	BN-GU-005-DHP	Preclinical
T89534	DRUGINFO	D0J4ZH	Tamoxifen methyl iodide	Terminated
T89534	DRUGINFO	D0TR4Z	Zindoxifene	Terminated
T89534	DRUGINFO	D09AAM	ICI-164384	Terminated
T89534	DRUGINFO	D0H5CV	ZK-119010	Terminated
T89534	DRUGINFO	D0SM0J	LY-117018	Terminated
T89534	DRUGINFO	D00DJX	JNJ-17148066	Investigative
T89534	DRUGINFO	D00XLU	N-benzyl-4-hydroxy-N-phenylbenzenesulfonamide	Investigative
T89534	DRUGINFO	D00ZAJ	2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE	Investigative
T89534	DRUGINFO	D01NDN	SNG-8006	Investigative
T89534	DRUGINFO	D01XCA	N-cyclohexyl-4-hydroxy-N-phenylbenzenesulfonamide	Investigative
T89534	DRUGINFO	D01ZRX	3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL	Investigative
T89534	DRUGINFO	D02GLM	2,4-diisobutylamino-6-isopentylpyrimidine	Investigative
T89534	DRUGINFO	D02TPO	JNJ-26529152	Investigative
T89534	DRUGINFO	D03AVA	SNG-8033	Investigative
T89534	DRUGINFO	D03BOO	2,4-Dibenzylamino-6-isopentylpyrimidine	Investigative
T89534	DRUGINFO	D03NWC	SNG-8023	Investigative
T89534	DRUGINFO	D04PEM	LTERHKILHRLLQEGSPSD	Investigative
T89534	DRUGINFO	D04SAO	GW7604	Investigative
T89534	DRUGINFO	D04TPC	4-benzyl-2,6-diisobutylamino-pyrimidine	Investigative
T89534	DRUGINFO	D05QTG	7-Cyclopentyloxy-3-(4-hydroxyphenyl)chromen-4-one	Investigative
T89534	DRUGINFO	D07HBQ	N,N,N-Triisobutyl-pyrimidine-2,4,6-triamine	Investigative
T89534	DRUGINFO	D07KXE	Carboron Cluster with phenol	Investigative
T89534	DRUGINFO	D07TGS	4-[1-(4-hydroxyphenyl)-2-phenylvinyl]phenol	Investigative
T89534	DRUGINFO	D07TGW	MPrP	Investigative
T89534	DRUGINFO	D08GWS	Tamoxifen isopropyl bromide	Investigative
T89534	DRUGINFO	D08JCJ	17-METHYL-17-ALPHA-DIHYDROEQUILENIN	Investigative
T89534	DRUGINFO	D08LVT	4-hydroxy-N-neopentyl-N-phenylbenzenesulfonamide	Investigative
T89534	DRUGINFO	D09BDK	SNG-163	Investigative
T89534	DRUGINFO	D09NFD	GSK-5182	Investigative
T89534	DRUGINFO	D09ULU	N-ethyl-4-hydroxy-N-phenylbenzenesulfonamide	Investigative
T89534	DRUGINFO	D09UQU	JNJ-19398990	Investigative
T89534	DRUGINFO	D09WEK	4-(1-benzyl-7-chloro-1H-indazol-3-yl)phenol	Investigative
T89534	DRUGINFO	D0A8CS	3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL	Investigative
T89534	DRUGINFO	D0AD8G	N-allyl-4-hydroxy-N-phenylbenzenesulfonamide	Investigative
T89534	DRUGINFO	D0C4VX	4-(7-chloro-1-propyl-1H-indazol-3-yl)phenol	Investigative
T89534	DRUGINFO	D0C6UR	Tamoxifen ethyl bromide	Investigative
T89534	DRUGINFO	D0C9XW	6-butyl-2,4-dipropylaminopyrimidine	Investigative
T89534	DRUGINFO	D0E3UW	RG6046	Investigative
T89534	DRUGINFO	D0E6AP	STX	Investigative
T89534	DRUGINFO	D0F8LS	4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenol	Investigative
T89534	DRUGINFO	D0GH1I	3-(4-Hydroxyphenyl)-7-isobutoxychromen-4-one	Investigative
T89534	DRUGINFO	D0GY3R	SERMs	Investigative
T89534	DRUGINFO	D0H6MZ	6-ethyl-2,4-diisobutylaminopyrimidine	Investigative
T89534	DRUGINFO	D0H8ZT	4-(7-chloro-1-cyclohexyl-1H-indazol-3-yl)phenol	Investigative
T89534	DRUGINFO	D0I6QZ	Org-37663	Investigative
T89534	DRUGINFO	D0J3PM	4-hydroxy-N-isopropyl-N-phenylbenzenesulfonamide	Investigative
T89534	DRUGINFO	D0J6KN	4-(7-methyl-1-propyl-1H-indazol-3-yl)phenol	Investigative
T89534	DRUGINFO	D0K5LX	4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL	Investigative
T89534	DRUGINFO	D0K8QD	4-[1-(4-hydroxyphenyl)-2-phenylbut-1-enyl]phenol	Investigative
T89534	DRUGINFO	D0L0RK	4-hydroxy-N-phenyl-N-propylbenzenesulfonamide	Investigative
T89534	DRUGINFO	D0M4LQ	N-butyl-4-hydroxy-N-phenylbenzenesulfonamide	Investigative
T89534	DRUGINFO	D0O9UY	3-(4-Hydroxyphenyl)-7-isopropoxychromen-4-one	Investigative
T89534	DRUGINFO	D0OV3S	4-[1-(4-hydroxyphenyl)-2-phenylpent-1-enyl]phenol	Investigative
T89534	DRUGINFO	D0Q4VG	4-(1-butyl-7-chloro-1H-indazol-3-yl)phenol	Investigative
T89534	DRUGINFO	D0Q6MS	4-[1-(4-hydroxyphenyl)-2-phenylprop-1-enyl]phenol	Investigative
T89534	DRUGINFO	D0S5RI	Tamoxifen butyl bromide	Investigative
T89534	DRUGINFO	D0V4DH	Estriol E3	Investigative
T89534	DRUGINFO	D0V7OK	4-(1,2-Diphenyl-but-1-enyl)-phenol	Investigative
T89534	DRUGINFO	D0V7ZI	4-(7-chloro-1-cyclopentyl-1H-indazol-3-yl)phenol	Investigative
T89534	DRUGINFO	D0W1YZ	TSERaM	Investigative
T89534	DRUGINFO	D0X0RJ	JNJ-26529126	Investigative
T89534	DRUGINFO	D0X6LK	5-hydroxy-2-phenylisoindoline-1,3-dione	Investigative
T89534	DRUGINFO	D0XC3V	4-[1-(4-hydroxyphenyl)-2-phenylhex-1-enyl]phenol	Investigative
T89534	DRUGINFO	D0XF9F	methyl-piperidino-pyrazole	Investigative
T89534	DRUGINFO	D0Y8UF	propylpyrazoletriol	Investigative
T89534	DRUGINFO	D0Z9ZY	4-hydroxy-N,N-diphenylbenzenesulfonamide	Investigative
T89534	DRUGINFO	D00AAU	3-[1-ethyl-2-(3-hydroxyphenyl)butyl]phenol	Investigative
T89534	DRUGINFO	D00CWN	2-(4-Hydroxy-phenyl)-quinolin-6-ol	Investigative
T89534	DRUGINFO	D00FUO	Nafoxidine	Investigative
T89534	DRUGINFO	D00HUB	[1,1':2',1'']Terphenyl-4'-carbaldehyde oxime	Investigative
T89534	DRUGINFO	D00HZT	2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-6-ol	Investigative
T89534	DRUGINFO	D00IXB	6-ethyl-4,7-dimethyl-6H-benzo[c]chromene-3,8-diol	Investigative
T89534	DRUGINFO	D00NEK	4-(3-phenyl-1H-indol-2-yl)phenol	Investigative
T89534	DRUGINFO	D00OLH	4-[1,2-bis(4-hydroxyphenyl)vinyl]phenol	Investigative
T89534	DRUGINFO	D00URP	4,10-dimethyl-6H-benzo[c]chromene-3,8-diol	Investigative
T89534	DRUGINFO	D00ZBL	7-Allyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol	Investigative
T89534	DRUGINFO	D01GPY	6-(4-Hydroxy-2-methyl-phenyl)-naphthalen-2-ol	Investigative
T89534	DRUGINFO	D01KJU	1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL	Investigative
T89534	DRUGINFO	D01KSR	5-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-6-ol	Investigative
T89534	DRUGINFO	D01QXL	2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-5-ol	Investigative
T89534	DRUGINFO	D01SWO	2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol	Investigative
T89534	DRUGINFO	D01UAO	3-chloro-4-(4-hydroxyphenyl)salicylaldoxime	Investigative
T89534	DRUGINFO	D01WCA	2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL	Investigative
T89534	DRUGINFO	D02DML	COUMESTROL	Investigative
T89534	DRUGINFO	D02DVT	4-[1,2-bis(4-hydroxyphenyl)pent-1-enyl]phenol	Investigative
T89534	DRUGINFO	D02EJM	2-(4-Hydroxy-phenyl)-7-propenyl-benzooxazol-5-ol	Investigative
T89534	DRUGINFO	D02HGS	5-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol	Investigative
T89534	DRUGINFO	D02JJU	2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-5-ol	Investigative
T89534	DRUGINFO	D02LCC	2-(4-Hydroxy-phenyl)-7-isopropyl-benzooxazol-5-ol	Investigative
T89534	DRUGINFO	D02OKF	6-(2-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol	Investigative
T89534	DRUGINFO	D02VIW	DIHYDRORALOXIFENE	Investigative
T89534	DRUGINFO	D03DVM	2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-6-ol	Investigative
T89534	DRUGINFO	D03EOD	4-[2,2-bis(4-hydroxyphenyl)-1-methylvinyl]phenol	Investigative
T89534	DRUGINFO	D03GYS	7-Butyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol	Investigative
T89534	DRUGINFO	D03QHG	8-(2,2-dimethylpropyl)naringenin	Investigative
T89534	DRUGINFO	D03RYU	4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol	Investigative
T89534	DRUGINFO	D03XEU	2-(4-Hydroxy-phenyl)-7-methoxy-benzofuran-5-ol	Investigative
T89534	DRUGINFO	D04EAY	3-(2-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol	Investigative
T89534	DRUGINFO	D04SEX	R,R-THC	Investigative
T89534	DRUGINFO	D04WHH	2-(4-Hydroxy-phenyl)-7-propyl-benzooxazol-5-ol	Investigative
T89534	DRUGINFO	D05FUY	1,8-Dichloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol	Investigative
T89534	DRUGINFO	D05JKC	6-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-5-ol	Investigative
T89534	DRUGINFO	D05JPW	2-(4-Hydroxy-phenyl)-7-methoxy-benzooxazol-5-ol	Investigative
T89534	DRUGINFO	D05KXP	8-n-undecylnaringenin	Investigative
T89534	DRUGINFO	D05YIU	7-Chloro-2-(4-hydroxy-phenyl)-benzofuran-5-ol	Investigative
T89534	DRUGINFO	D06DDT	BROUSSONIN A	Investigative
T89534	DRUGINFO	D06DNN	4-[1,2-bis(4-hydroxyphenyl)hex-1-enyl]phenol	Investigative
T89534	DRUGINFO	D06OAL	7-Ethyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol	Investigative
T89534	DRUGINFO	D06SCS	WAY200070	Investigative
T89534	DRUGINFO	D07LUI	6-(4-Hydroxy-phenyl)-naphthalen-2-ol	Investigative
T89534	DRUGINFO	D07VPM	2-(4-Hydroxy-phenyl)-7-phenyl-benzooxazol-5-ol	Investigative
T89534	DRUGINFO	D07XBD	6-(4-Hydroxy-phenyl)-1-methyl-naphthalen-2-ol	Investigative
T89534	DRUGINFO	D07XUY	8-methylnaringenin	Investigative
T89534	DRUGINFO	D08FLV	3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-5-ol	Investigative
T89534	DRUGINFO	D08HCF	2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-6-ol	Investigative
T89534	DRUGINFO	D08VDX	8-Chloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol	Investigative
T89534	DRUGINFO	D08WDN	4-Benzo[d]isoxazol-3-yl-benzene-1,3-diol	Investigative
T89534	DRUGINFO	D09CQC	2-(4-Hydroxy-phenyl)-benzooxazol-6-ol	Investigative
T89534	DRUGINFO	D09DEK	7-(4-Hydroxy-phenyl)-naphthalen-2-ol	Investigative
T89534	DRUGINFO	D09NOH	8-(3-methylbutyl)naringenin	Investigative
T89534	DRUGINFO	D09PXU	4,7-dimethyl-6H-benzo[c]chromene-3,8-diol	Investigative
T89534	DRUGINFO	D09TQE	2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-5-ol	Investigative
T89534	DRUGINFO	D0A1JP	3'-Methoxy-4'Hydroxyclomiphene	Investigative
T89534	DRUGINFO	D0AD3U	2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-6-ol	Investigative
T89534	DRUGINFO	D0B1HP	3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol	Investigative
T89534	DRUGINFO	D0B4VV	Trans-hydroxytamoxifen	Investigative
T89534	DRUGINFO	D0C5FY	3,8-dihydroxy-4-methyl-6H-benzo[c]chromen-6-one	Investigative
T89534	DRUGINFO	D0C6AP	2-(4-Hydroxy-phenyl)-7-methyl-benzofuran-5-ol	Investigative
T89534	DRUGINFO	D0C9XK	4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol	Investigative
T89534	DRUGINFO	D0CC6R	6-(2-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol	Investigative
T89534	DRUGINFO	D0D1LB	8-benzylnaringenin	Investigative
T89534	DRUGINFO	D0DK9S	2-(3-Butoxy-4-hydroxy-phenyl)-benzooxazol-6-ol	Investigative
T89534	DRUGINFO	D0FD6Z	8-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol	Investigative
T89534	DRUGINFO	D0H1CO	2-Naphthalen-1-yl-benzooxazol-6-ol	Investigative
T89534	DRUGINFO	D0H2FI	6-(4-Hydroxy-phenyl)-1-nitro-naphthalen-2-ol	Investigative
T89534	DRUGINFO	D0H5HI	4,6,6,7-tetramethyl-6H-benzo[c]chromene-3,8-diol	Investigative
T89534	DRUGINFO	D0HM8Y	3,8-dihydroxy-7-methyl-6H-benzo[c]chromen-6-one	Investigative
T89534	DRUGINFO	D0HR8L	6-(3-Hydroxy-phenyl)-naphthalen-1-ol	Investigative
T89534	DRUGINFO	D0I1NX	4-[1,2-bis(4-hydroxyphenyl)but-1-enyl]phenol	Investigative
T89534	DRUGINFO	D0I5HZ	4-(2-phenyl-1H-benzo[d]imidazol-1-yl)phenol	Investigative
T89534	DRUGINFO	D0J0AG	5-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol	Investigative
T89534	DRUGINFO	D0J2NG	8-n-heptylnaringenin	Investigative
T89534	DRUGINFO	D0K0IC	4-(2-phenyl-1H-indol-3-yl)phenol	Investigative
T89534	DRUGINFO	D0K1TW	2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol	Investigative
T89534	DRUGINFO	D0K6TE	6-(3-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol	Investigative
T89534	DRUGINFO	D0L2MU	7-Bromo-2-(4-hydroxy-phenyl)-benzofuran-5-ol	Investigative
T89534	DRUGINFO	D0L3AX	4-Naphthalen-2-yl-phenol	Investigative
T89534	DRUGINFO	D0L6IQ	2-(4-Hydroxy-phenyl)-4-methoxy-quinolin-6-ol	Investigative
T89534	DRUGINFO	D0LI0M	8-n-pentylnaringenin	Investigative
T89534	DRUGINFO	D0M0XL	6-(4-Hydroxy-phenyl)-1-methoxy-naphthalen-2-ol	Investigative
T89534	DRUGINFO	D0MY8V	6-(3,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol	Investigative
T89534	DRUGINFO	D0N0OY	2-(4-Hydroxy-phenyl)-benzooxazol-5-ol	Investigative
T89534	DRUGINFO	D0NN0V	4',5,7-trihydroxy-6,8-dimethylisoflavone	Investigative
T89534	DRUGINFO	D0O2KP	2-phenyl-1,2'-spirobi[1H-indene]-5'-ol	Investigative
T89534	DRUGINFO	D0O5KR	4,6,7-trimethyl-6H-benzo[c]chromene-3,8-diol	Investigative
T89534	DRUGINFO	D0O6FX	4,6,7,10-tetramethyl-6H-benzo[c]chromene-3,8-diol	Investigative
T89534	DRUGINFO	D0P0FN	ZK-164015	Investigative
T89534	DRUGINFO	D0P6FN	6-(4-Hydroxy-2-methoxy-phenyl)-naphthalen-2-ol	Investigative
T89534	DRUGINFO	D0P7PK	2,3-diphenyl-1H-indole	Investigative
T89534	DRUGINFO	D0R7AG	4-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol	Investigative
T89534	DRUGINFO	D0RI6O	Doxorubicin-Formaldehyde Conjugate	Investigative
T89534	DRUGINFO	D0S0SZ	7-Ethynyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol	Investigative
T89534	DRUGINFO	D0S2ZJ	3-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol	Investigative
T89534	DRUGINFO	D0S6NV	1-Bromo-6-(4-hydroxy-phenyl)-naphthalen-2-ol	Investigative
T89534	DRUGINFO	D0S8EB	4,6,10-trimethyl-6H-benzo[c]chromene-3,8-diol	Investigative
T89534	DRUGINFO	D0SR8Q	7-Phenyl-naphthalen-2-ol	Investigative
T89534	DRUGINFO	D0U0ZE	3-hydroxy-8,10-dimethyl-6H-benzo[c]chromen-6-one	Investigative
T89534	DRUGINFO	D0U2VA	2-(5-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol	Investigative
T89534	DRUGINFO	D0U7KV	4-(3-(4-hydroxyphenyl)-1H-indol-2-yl)phenol	Investigative
T89534	DRUGINFO	D0UV9G	6-Phenyl-naphthalen-2-ol	Investigative
T89534	DRUGINFO	D0V6KJ	6-(2,6-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol	Investigative
T89534	DRUGINFO	D0V7QZ	2-(2-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol	Investigative
T89534	DRUGINFO	D0VN2R	6-(4-Hydroxy-phenyl)-1-phenyl-naphthalen-2-ol	Investigative
T89534	DRUGINFO	D0W0LG	8-n-propylnaringenin	Investigative
T89534	DRUGINFO	D0W2YR	3-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol	Investigative
T89534	DRUGINFO	D0W3FF	2-(4-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol	Investigative
T89534	DRUGINFO	D0W4WF	EFFUSOL	Investigative
T89534	DRUGINFO	D0W5HT	8-n-nonylnaringenin	Investigative
T89534	DRUGINFO	D0X2VK	2-(4-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol	Investigative
T89534	DRUGINFO	D0X4VN	6-(3-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol	Investigative
T89534	DRUGINFO	D0X7DJ	6-(2,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol	Investigative
T89534	DRUGINFO	D0Y2LJ	8-(2-methylpropyl)naringenin	Investigative
T89534	DRUGINFO	D0Y9BO	WAY-169916	Investigative
T89534	DRUGINFO	D0YH4T	2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol	Investigative
T89534	DRUGINFO	D0YW4C	2-(4-Hydroxy-phenyl)-7-vinyl-benzooxazol-5-ol	Investigative
T89534	DRUGINFO	D0Z0UC	1,2-Bis-(4-hydroxy-phenyl)-3H-inden-5-ol	Investigative
T89534	DRUGINFO	D0ZT4U	1-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol	Investigative
T89534	DRUGINFO	D01IAT	7-(3-Hydroxy-phenyl)-naphthalen-2-ol	Investigative
T89534	DRUGINFO	D01TUB	4-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol	Investigative
T89534	DRUGINFO	D03CBX	4-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol	Investigative
T89534	DRUGINFO	D08SJL	4-Ethynyl-2-(4-hydroxy-phenyl)-quinolin-6-ol	Investigative
T89534	DRUGINFO	D09FWS	4-Ethyl-2-(4-hydroxy-phenyl)-quinolin-6-ol	Investigative
T89534	DRUGINFO	D0H8PI	6-(4-Hydroxy-phenyl)-naphthalen-1-ol	Investigative
T89534	DRUGINFO	D0K7HR	2-(4-Hydroxy-phenyl)-4-vinyl-quinolin-6-ol	Investigative
T89534	DRUGINFO	D0S8AV	SOPHORAFLAVANONE B	Investigative
T89534	DRUGINFO	D0H6OS	Geldanamycin-estradiol hybrid	Investigative
T89534	DRUGINFO	D0J7XZ	CP-409069	Investigative
T89534	DRUGINFO	D0L5IC	CP-394531	Investigative
T89534	DRUGINFO	D0P8PK	6-(3-Hydroxy-phenyl)-naphthalen-2-ol	Investigative
T89534	DRUGINFO	D0SY2M	daidzein	Investigative

T52450	TARGETID	T52450
T52450	FORMERID	TTDC00147
T52450	UNIPROID	MMP1_HUMAN
T52450	TARGNAME	Matrix metalloproteinase-1 (MMP-1)
T52450	GENENAME	MMP1
T52450	TARGTYPE	Successful
T52450	SYNONYMS	Interstitial collagenase; Fibroblast collagenase; CLG
T52450	FUNCTION	Cleaves collagens of types VII and X. In case of HIV infection, interacts and cleaves the secreted viral Tat protein, leading to a decrease in neuronal Tat's mediated neurotoxicity. Cleaves collagens of types I, II, and III at one site in the helical domain.
T52450	PDBSTRUC	966C; 4AYK; 4AUO; 3SHI; 3AYK
T52450	BIOCLASS	Peptidase
T52450	ECNUMBER	EC 3.4.24.7
T52450	SEQUENCE	MHSFPPLLLLLFWGVVSHSFPATLETQEQDVDLVQKYLEKYYNLKNDGRQVEKRRNSGPVVEKLKQMQEFFGLKVTGKPDAETLKVMKQPRCGVPDVAQFVLTEGNPRWEQTHLTYRIENYTPDLPRADVDHAIEKAFQLWSNVTPLTFTKVSEGQADIMISFVRGDHRDNSPFDGPGGNLAHAFQPGPGIGGDAHFDEDERWTNNFREYNLHRVAAHELGHSLGLSHSTDIGALMYPSYTFSGDVQLAQDDIDGIQAIYGRSQNPVQPIGPQTPKACDSKLTFDAITTIRGEVMFFKDRFYMRTNPFYPEVELNFISVFWPQLPNGLEAAYEFADRDEVRFFKGNKYWAVQGQNVLHGYPKDIYSSFGFPRTVKHIDAALSEENTGKTYFFVANKYWRYDEYKRSMDPGYPKMIAHDFPGIGHKVDAVFMKDGFFYFFHGTRQYKFDPKTKRILTLQKANSWFNCRKN
T52450	DRUGINFO	D00MDP	Prinomastat	Approved
T52450	DRUGINFO	D0MW3H	CIPEMASTAT	Phase 3
T52450	DRUGINFO	D05VZE	Marimastat	Phase 3
T52450	DRUGINFO	D0HG5M	Apratastat	Phase 2
T52450	DRUGINFO	D05GAP	PMID29130358-Compound-Figure10(2a)	Patented
T52450	DRUGINFO	D0X6GG	PMID29130358-Compound-Figure18(14a)	Patented
T52450	DRUGINFO	D01EUF	BMS 275291	Discontinued in Phase 3
T52450	DRUGINFO	D0G4OT	XL784	Discontinued in Phase 2
T52450	DRUGINFO	D03BOZ	RS-130830	Discontinued in Phase 2
T52450	DRUGINFO	D0T9HG	GM6001	Discontinued in Phase 2
T52450	DRUGINFO	D0EF7V	Ro-31-4724	Terminated
T52450	DRUGINFO	D08CEE	L-696418	Terminated
T52450	DRUGINFO	D08WBF	BB-3644	Terminated
T52450	DRUGINFO	D0E5GY	RO-319790	Terminated
T52450	DRUGINFO	D05VNG	BB-1101	Terminated
T52450	DRUGINFO	D0Y1XT	SC-44463	Terminated
T52450	DRUGINFO	D01QOB	4-Butoxy-N-hydroxycarbamoylmethyl-benzamide	Investigative
T52450	DRUGINFO	D02BTV	3-Benzenesulfinyl-heptanoic acid hydroxyamide	Investigative
T52450	DRUGINFO	D06BYR	N-Hydroxy-4-oxo-4-(4-phenoxy-phenyl)-butyramide	Investigative
T52450	DRUGINFO	D08ZDD	N-Hydroxy-4-(4-methoxy-phenyl)-4-oxo-butyramide	Investigative
T52450	DRUGINFO	D09SYW	N-Hydroxycarbamoylmethyl-4-phenoxy-benzamide	Investigative
T52450	DRUGINFO	D0L7AY	N-(Ethylphosphoryl)-L-isoleucyl-L-Trp-NHCH3	Investigative
T52450	DRUGINFO	D0P2OA	N-Hydroxycarbamoylmethyl-4-methoxy-benzamide	Investigative
T52450	DRUGINFO	D0T4AN	4-(4-Butoxy-phenyl)-N-hydroxy-4-oxo-butyramide	Investigative
T52450	DRUGINFO	D01OCR	3-(4-Methoxy-benzenesulfonyl)-pentane-1-thiol	Investigative
T52450	DRUGINFO	D09XUQ	3-(4-Methoxy-benzenesulfonyl)-hexane-1-thiol	Investigative
T52450	DRUGINFO	D0R2BO	METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID	Investigative
T52450	DRUGINFO	D0XE4B	4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol	Investigative
T52450	DRUGINFO	D0BI8T	RS-39066	Investigative
T52450	DRUGINFO	D0D7UA	3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol	Investigative
T52450	DRUGINFO	D0K3RC	3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol	Investigative
T52450	DRUGINFO	D0N0FX	3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol	Investigative
T52450	DRUGINFO	D08ELY	3-Benzenesulfonyl-heptanoic acid hydroxyamide	Investigative
T52450	DRUGINFO	D0N6CD	3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide	Investigative
T52450	DRUGINFO	D0H2PA	PKF-242-484	Investigative
T52450	DRUGINFO	D0XL8K	Ro-37-9790	Investigative
T52450	DRUGINFO	D03AMR	SR-973	Investigative
T52450	DRUGINFO	D0A4TC	MMI270	Investigative

T53585	TARGETID	T53585
T53585	FORMERID	TTDS00195
T53585	UNIPROID	HMDH_HUMAN
T53585	TARGNAME	HMG-CoA reductase (HMGCR)
T53585	GENENAME	HMGCR
T53585	TARGTYPE	Successful
T53585	SYNONYMS	3-hydroxy-3-methylglutaryl-coenzyme A reductase
T53585	FUNCTION	Transmembrane glycoprotein that is the rate-limiting enzyme in cholesterol biosynthesis as well as in the biosynthesis of nonsterol isoprenoids that are essential for normal cell function including ubiquinone and geranylgeranyl proteins.
T53585	PDBSTRUC	3CDB; 3CDA; 3CD7; 3CD5; 3CD0
T53585	BIOCLASS	CH-OH donor oxidoreductase
T53585	ECNUMBER	EC 1.1.1.34
T53585	SEQUENCE	MLSRLFRMHGLFVASHPWEVIVGTVTLTICMMSMNMFTGNNKICGWNYECPKFEEDVLSSDIIILTITRCIAILYIYFQFQNLRQLGSKYILGIAGLFTIFSSFVFSTVVIHFLDKELTGLNEALPFFLLLIDLSRASTLAKFALSSNSQDEVRENIARGMAILGPTFTLDALVECLVIGVGTMSGVRQLEIMCCFGCMSVLANYFVFMTFFPACVSLVLELSRESREGRPIWQLSHFARVLEEEENKPNPVTQRVKMIMSLGLVLVHAHSRWIADPSPQNSTADTSKVSLGLDENVSKRIEPSVSLWQFYLSKMISMDIEQVITLSLALLLAVKYIFFEQTETESTLSLKNPITSPVVTQKKVPDNCCRREPMLVRNNQKCDSVEEETGINRERKVEVIKPLVAETDTPNRATFVVGNSSLLDTSSVLVTQEPEIELPREPRPNEECLQILGNAEKGAKFLSDAEIIQLVNAKHIPAYKLETLMETHERGVSIRRQLLSKKLSEPSSLQYLPYRDYNYSLVMGACCENVIGYMPIPVGVAGPLCLDEKEFQVPMATTEGCLVASTNRGCRAIGLGGGASSRVLADGMTRGPVVRLPRACDSAEVKAWLETSEGFAVIKEAFDSTSRFARLQKLHTSIAGRNLYIRFQSRSGDAMGMNMISKGTEKALSKLHEYFPEMQILAVSGNYCTDKKPAAINWIEGRGKSVVCEAVIPAKVVREVLKTTTEAMIEVNINKNLVGSAMAGSIGGYNAHAANIVTAIYIACGQDAAQNVGSSNCITLMEASGPTNEDLYISCTMPSIEIGTVGGGTNLLPQQACLQMLGVQGACKDNPGENARQLARIVCGTVMAGELSLMAALAAGHLVKSHMIHNRSKINLQDLQGACTKKTA
T53585	DRUGINFO	D01QIN	Atorvastatin	Approved
T53585	DRUGINFO	D02RQU	Pravastatin	Approved
T53585	DRUGINFO	D03KIA	Cerivastatin	Approved
T53585	DRUGINFO	D03VFL	TOCOTRIENOL	Approved
T53585	DRUGINFO	D04XGU	Crestor/TriLipix	Approved
T53585	DRUGINFO	D06WTZ	Lovastatin	Approved
T53585	DRUGINFO	D08GHB	Fluvastatin	Approved
T53585	DRUGINFO	D0G1WL	PITAVASTATIN CALCIUM	Approved
T53585	DRUGINFO	D0H0ND	Simvastatin	Approved
T53585	DRUGINFO	D0JE2E	Rosuvastatin	Approved
T53585	DRUGINFO	D0GY5Z	Aspirin	Approved
T53585	DRUGINFO	D07QFP	Teriflunomide	Approved
T53585	DRUGINFO	D0WL5V	LAROPIPRANT	Phase 4
T53585	DRUGINFO	D0G7IV	Premarin/Pravachol	Phase 3
T53585	DRUGINFO	D06BBV	XZK-monascus	Phase 2
T53585	DRUGINFO	D0CC8L	CRILVASTATIN	Phase 2
T53585	DRUGINFO	D0H0FX	NCX-6560	Phase 1
T53585	DRUGINFO	D00YVL	PMID27537201-Compound-Figure15a	Patented
T53585	DRUGINFO	D03HKN	PMID27537201-Compound-Figure13b	Patented
T53585	DRUGINFO	D04MFJ	Quinoline derivative 17	Patented
T53585	DRUGINFO	D05SOY	Hexahydro naphthalene derivative 3	Patented
T53585	DRUGINFO	D08FMC	Sterol derivative 1	Patented
T53585	DRUGINFO	D09ZXW	Atorvastatin lactole derivative 1	Patented
T53585	DRUGINFO	D0AP6V	Poly-substituted azoles statin lactone derivative 2	Patented
T53585	DRUGINFO	D0AY4N	Lactol derivative 1	Patented
T53585	DRUGINFO	D0CM4R	Lactol derivative 2	Patented
T53585	DRUGINFO	D0CW2F	Poly-substituted miazine derivative 1	Patented
T53585	DRUGINFO	D0EF9J	PMID27537201-Compound-Figure13c	Patented
T53585	DRUGINFO	D0G8JX	Pitavastatin derivative 1	Patented
T53585	DRUGINFO	D0KU2T	Pravastatin derivative 1	Patented
T53585	DRUGINFO	D0L3BE	Hexahydro naphthalene derivative 1	Patented
T53585	DRUGINFO	D0LJ0M	2-cyclopropyl-4-substituted-phenoxy-quinoline derivative 1	Patented
T53585	DRUGINFO	D0M9ZW	Hexahydro naphthalene derivative 2	Patented
T53585	DRUGINFO	D0O0OD	Sterol derivative 3	Patented
T53585	DRUGINFO	D0QW7F	Quinoline derivative 16	Patented
T53585	DRUGINFO	D0RW8J	Poly-substituted azoles statin lactone derivative 1	Patented
T53585	DRUGINFO	D0S3BE	PMID27537201-Compound-Figure17	Patented
T53585	DRUGINFO	D0SH0L	PMID27537201-Compound-Figure15b	Patented
T53585	DRUGINFO	D0U2CK	Quinoline derivative 1	Patented
T53585	DRUGINFO	D0YX0O	PMID27537201-Compound-Figure11	Patented
T53585	DRUGINFO	D0YZ3U	Sterol derivative 2	Patented
T53585	DRUGINFO	D0Y9XD	Dalvastatin	Discontinued in Phase 3
T53585	DRUGINFO	D02GSA	RBx10558	Discontinued in Phase 2
T53585	DRUGINFO	D04NCJ	BMY-21950	Discontinued in Phase 2
T53585	DRUGINFO	D0L1LJ	Bervastatin	Discontinued in Phase 2
T53585	DRUGINFO	D0U5NU	GLENVASTATIN	Discontinued in Phase 2
T53585	DRUGINFO	D0MF7U	PF-3052334	Discontinued in Phase 1
T53585	DRUGINFO	D07QSA	CP-83101	Terminated
T53585	DRUGINFO	D0C7RV	SR12813	Terminated
T53585	DRUGINFO	D0E2CO	BMY-22089	Terminated
T53585	DRUGINFO	D0J9GD	Mevastatin	Terminated
T53585	DRUGINFO	D0Y3OR	SQ-33600	Terminated
T53585	DRUGINFO	D0YQ9G	GT-16-239	Terminated
T53585	DRUGINFO	D00RHH	PMID17574411C41	Investigative
T53585	DRUGINFO	D00TBG	PMID8246233C5ab	Investigative
T53585	DRUGINFO	D00TIO	PMID1656041C4ff	Investigative
T53585	DRUGINFO	D00UOI	PMID17574412C33	Investigative
T53585	DRUGINFO	D00VMO	PMID1992149C13	Investigative
T53585	DRUGINFO	D00ZJG	PMID2231594C3k	Investigative
T53585	DRUGINFO	D01WQF	FPYVAE peptide	Investigative
T53585	DRUGINFO	D01XMY	PMID1895299C1	Investigative
T53585	DRUGINFO	D01YQX	6-hydroxy-7,9-octadecadiynoic acid	Investigative
T53585	DRUGINFO	D01ZAL	PMID2296036C4i	Investigative
T53585	DRUGINFO	D02EQL	PMID2231594C3u	Investigative
T53585	DRUGINFO	D02ITS	PMID1992149C9	Investigative
T53585	DRUGINFO	D02MEX	PMID2153213C2c	Investigative
T53585	DRUGINFO	D02OET	PMID1895299C4p	Investigative
T53585	DRUGINFO	D02SRB	BPL-001	Investigative
T53585	DRUGINFO	D02TIT	PMID18412317C13b	Investigative
T53585	DRUGINFO	D03CYY	GFPDGG	Investigative
T53585	DRUGINFO	D03EAN	PMID2153213C1e	Investigative
T53585	DRUGINFO	D03GRA	(R)-Mevalonate	Investigative
T53585	DRUGINFO	D03TKT	o-hydroxyatorvastatin	Investigative
T53585	DRUGINFO	D03ZIK	MT-001	Investigative
T53585	DRUGINFO	D04XQG	NCX-1067	Investigative
T53585	DRUGINFO	D05GWF	PMID2153213C2d	Investigative
T53585	DRUGINFO	D05UQC	PMID2296036C2t	Investigative
T53585	DRUGINFO	D05YUT	PMID8426367C18	Investigative
T53585	DRUGINFO	D06BIF	PMID2153213C13b	Investigative
T53585	DRUGINFO	D06FRE	PMID1656041C11dd	Investigative
T53585	DRUGINFO	D06HNA	PMID1875346C18	Investigative
T53585	DRUGINFO	D07QAX	PMID15686906C17	Investigative
T53585	DRUGINFO	D07VEB	PMID8246234C3h	Investigative
T53585	DRUGINFO	D08SKU	3-(1,3 dodecadiynyl)-6-oxiranebutanoic acid	Investigative
T53585	DRUGINFO	D09CSQ	DFGYVAE	Investigative
T53585	DRUGINFO	D09EBV	7,9-tetradecadiynoic acid	Investigative
T53585	DRUGINFO	D09QIA	9-octadecynoic acid	Investigative
T53585	DRUGINFO	D09TKN	PMID2153213C13g	Investigative
T53585	DRUGINFO	D0A6FX	(E)-octadecan-9-ynoic acid	Investigative
T53585	DRUGINFO	D0B2FM	GLPTGG	Investigative
T53585	DRUGINFO	D0C1RY	GFPEGG	Investigative
T53585	DRUGINFO	D0C5LO	7,9-octadecadiynoic acid	Investigative
T53585	DRUGINFO	D0C8HK	(E)-5-octadecen-7,9-diynoic acid	Investigative
T53585	DRUGINFO	D0CU3I	(Z)-7-octedecan-9-ynoic acid	Investigative
T53585	DRUGINFO	D0FD8Q	PMID8246237C18t	Investigative
T53585	DRUGINFO	D0G2QW	PMID1992138C8b	Investigative
T53585	DRUGINFO	D0G4ZG	PMID2153213C2f	Investigative
T53585	DRUGINFO	D0G6PS	PMID17574411C42	Investigative
T53585	DRUGINFO	D0I0IM	5-ketodihydromevinolin	Investigative
T53585	DRUGINFO	D0I9TR	PMID2296036C4d	Investigative
T53585	DRUGINFO	D0IJ7H	3-Hydroxy-3-Methyl-Glutaric Acid	Investigative
T53585	DRUGINFO	D0J8BD	PMID2909732C7	Investigative
T53585	DRUGINFO	D0J9DY	PMID2296027C25	Investigative
T53585	DRUGINFO	D0K1MB	PMID7932551C9	Investigative
T53585	DRUGINFO	D0L6HX	PMID18072721C50	Investigative
T53585	DRUGINFO	D0M4YT	PMID1895299C6v	Investigative
T53585	DRUGINFO	D0M9BZ	PMID1656041C11nn	Investigative
T53585	DRUGINFO	D0MU7C	PMID2231594C3j	Investigative
T53585	DRUGINFO	D0N7RK	PMID19502059C25d	Investigative
T53585	DRUGINFO	D0NJ5U	PMID8246233C35	Investigative
T53585	DRUGINFO	D0NU6K	(Z)-5-octadecen-7,9-diynoic acid	Investigative
T53585	DRUGINFO	D0O1OC	PMID2296036C2g	Investigative
T53585	DRUGINFO	D0O2FD	PMID1656041C11ff	Investigative
T53585	DRUGINFO	D0O7AS	PMID18155906C16f	Investigative
T53585	DRUGINFO	D0O8XW	PMID17560788C29f	Investigative
T53585	DRUGINFO	D0Q2EH	Brutieridin	Investigative
T53585	DRUGINFO	D0Q6WP	PMID15686906C29	Investigative
T53585	DRUGINFO	D0R1FP	PMID2153213C1a	Investigative
T53585	DRUGINFO	D0R8YV	PMID1656041C74	Investigative
T53585	DRUGINFO	D0RA8F	PMID2153213C1f	Investigative
T53585	DRUGINFO	D0S1ER	PMID8246233C28	Investigative
T53585	DRUGINFO	D0S1LA	GFPTGG	Investigative
T53585	DRUGINFO	D0T4PL	PMID1656041C11jj	Investigative
T53585	DRUGINFO	D0UQ6A	PMID2231594C3q	Investigative
T53585	DRUGINFO	D0W5FM	PMID1527791C29	Investigative
T53585	DRUGINFO	D0W7VX	Statin	Investigative
T53585	DRUGINFO	D0X0GG	PMID1656041C4rr	Investigative
T53585	DRUGINFO	D0X0GV	GLPDGG peptide	Investigative
T53585	DRUGINFO	D0X1VL	F(4-Fluoro)VAE	Investigative
T53585	DRUGINFO	D0Y6DJ	rawsonol	Investigative
T53585	DRUGINFO	D0ZQ3B	PMID2296027C29	Investigative
T53585	DRUGINFO	D01GMJ	1,4-Dithiothreitol	Investigative
T53585	DRUGINFO	D0W3NA	Coenzyme A	Investigative
T53585	DRUGINFO	D0J2FY	2'-Monophosphoadenosine 5'-Diphosphoribose	Investigative
T53585	DRUGINFO	D0R6JE	Nicotinamide-Adenine-Dinucleotide	Investigative

T14597	TARGETID	T14597
T14597	FORMERID	TTDS00249
T14597	UNIPROID	ERBB2_HUMAN
T14597	TARGNAME	Erbb2 tyrosine kinase receptor (HER2)
T14597	GENENAME	ERBB2
T14597	TARGTYPE	Successful
T14597	SYNONYMS	p185erbB2; Tyrosine kinase-type cell surface receptor HER2; Receptor tyrosine-protein kinase erbB-2; Proto-oncogene c-ErbB-2; Proto-oncogene Neu; NGL; NEU; Metastatic lymph node gene 19 protein; MLN19; MLN 19; HER2; CD340
T14597	FUNCTION	Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.
T14597	PDBSTRUC	6OGE; 6J71; 6BGT; 6ATT; 5TQS
T14597	BIOCLASS	Kinase
T14597	ECNUMBER	EC 2.7.10.1
T14597	SEQUENCE	MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNLELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNGDPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLALTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQCAAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACPYNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSANIQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLPDLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTVPWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQECVEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARCPSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVGILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETELRKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFTHQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDAEEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEGAGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYVNQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQGGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV
T14597	DRUGINFO	D01YYP	Margetuximab	Approved
T14597	DRUGINFO	D04WFL	Trastuzumab	Approved
T14597	DRUGINFO	D09GRX	Tucatinib	Approved
T14597	DRUGINFO	D0CI4E	Pertuzumab	Approved
T14597	DRUGINFO	D0U3YB	Masoprocol	Approved
T14597	DRUGINFO	D05UFG	BIBW 2992	Approved
T14597	DRUGINFO	D0U1ZV	NERATINIB MALEATE	Approved
T14597	DRUGINFO	D06XXH	Dacomitinib	Approved
T14597	DRUGINFO	D08CDI	Lapatinib	Approved
T14597	DRUGINFO	D0F0ZE	Merimepodib	Approved
T14597	DRUGINFO	D04VRB	NeuVax	Phase 3
T14597	DRUGINFO	D0F8UV	Nelipepimut S	Phase 3
T14597	DRUGINFO	D0HR7Z	PF-05280014	Phase 3
T14597	DRUGINFO	D0P4TH	Trastuzumab-DM1	Phase 3
T14597	DRUGINFO	DI0ED3	SYD985	Phase 3
T14597	DRUGINFO	D04SLF	Bevacizumab + Trastuzumab	Phase 3
T14597	DRUGINFO	D0J6PY	Taxol/Paraplatin/Herceptin	Phase 3
T14597	DRUGINFO	D0Q9CY	HKI-272	Phase 3
T14597	DRUGINFO	D00NYJ	Varlitinib	Phase 2/3
T14597	DRUGINFO	D06KOM	DN24-02	Phase 2
T14597	DRUGINFO	D09XHU	HER-2 Protein AutoVac	Phase 2
T14597	DRUGINFO	D0B1TL	Her2-targeted autologous T-cell therapy	Phase 2
T14597	DRUGINFO	D0BM7M	AZD8931	Phase 2
T14597	DRUGINFO	D0CN9Q	CP-724714	Phase 2
T14597	DRUGINFO	D0G5GB	MGAH22	Phase 2
T14597	DRUGINFO	D0P1DI	MCLA-128	Phase 2
T14597	DRUGINFO	D0P7KI	Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells	Phase 2
T14597	DRUGINFO	D0Q2KM	MM-111	Phase 2
T14597	DRUGINFO	D0QF7Z	HER2/neu peptide vaccine	Phase 2
T14597	DRUGINFO	DM7WY2	MRG002	Phase 2
T14597	DRUGINFO	DV2N5P	KN026	Phase 2
T14597	DRUGINFO	D00YER	HM-78136B	Phase 2
T14597	DRUGINFO	D03UKJ	Pazopanib + Tyverb/Tykerb	Phase 2
T14597	DRUGINFO	D0U4FF	BMS-599626	Phase 2
T14597	DRUGINFO	D1J4CI	Zenocutuzumab	Phase 2
T14597	DRUGINFO	DUW81M	Tarloxotinib	Phase 2
T14597	DRUGINFO	D0O2JI	Ertumaxomab	Phase 2
T14597	DRUGINFO	D0YB3W	CI-1033	Phase 2
T14597	DRUGINFO	D03TQB	AU105	Phase 1/2
T14597	DRUGINFO	D06KQG	HER-2-targeting CAR T Cells	Phase 1/2
T14597	DRUGINFO	D08KCJ	ABY-025	Phase 1/2
T14597	DRUGINFO	D08QZH	Anti-HER2 CAR-T	Phase 1/2
T14597	DRUGINFO	D0F3MT	AVX901	Phase 1/2
T14597	DRUGINFO	D0G4AJ	AGN-208397	Phase 1/2
T14597	DRUGINFO	D0NN7P	CART-HER-2	Phase 1/2
T14597	DRUGINFO	DD94ZN	A166	Phase 1/2
T14597	DRUGINFO	DY13WU	TAS-0728	Phase 1/2
T14597	DRUGINFO	D6SL3N	Zenocutuzomab	Phase 1/2
T14597	DRUGINFO	D9FJ5V	BDTX-189	Phase 1/2
T14597	DRUGINFO	DNC79U	ISB 1302	Phase 1/2
T14597	DRUGINFO	D0FF2G	Sym013	Phase 1/2
T14597	DRUGINFO	D0V4XY	S-222611	Phase 1b
T14597	DRUGINFO	D02UFQ	TAK-285	Phase 1
T14597	DRUGINFO	D05ATQ	MVA HER-2 AutoVac	Phase 1
T14597	DRUGINFO	D06RCE	HER2-specific T cells	Phase 1
T14597	DRUGINFO	D06XWD	CAR-T Cells targeting HER2	Phase 1
T14597	DRUGINFO	D07USV	MM-302	Phase 1
T14597	DRUGINFO	D08UDG	MEDI4276	Phase 1
T14597	DRUGINFO	D09UGG	Zemab	Phase 1
T14597	DRUGINFO	D0H7ZN	VM-206	Phase 1
T14597	DRUGINFO	D0JI4M	CAR-T cells targeting HER2	Phase 1
T14597	DRUGINFO	D0M8AI	ARRY-380	Phase 1
T14597	DRUGINFO	D0O9HF	TrasGEX	Phase 1
T14597	DRUGINFO	D0TN5W	HER2-CAR T Cells	Phase 1
T14597	DRUGINFO	D0U2PS	HER2p63-71 peptide vaccine	Phase 1
T14597	DRUGINFO	D0YF6K	HER2-specific CAR T cell	Phase 1
T14597	DRUGINFO	D1C0WB	DZD1516	Phase 1
T14597	DRUGINFO	D56ECJ	BB-1701	Phase 1
T14597	DRUGINFO	D6IOB5	BAY 2701439	Phase 1
T14597	DRUGINFO	DEI07S	AIP-303	Phase 1
T14597	DRUGINFO	DEX8D5	NJH395	Phase 1
T14597	DRUGINFO	DH09QZ	ZW49	Phase 1
T14597	DRUGINFO	DQ04FJ	MBS301	Phase 1
T14597	DRUGINFO	DQ1RZ8	ACE1702	Phase 1
T14597	DRUGINFO	DS60CK	MT-5111	Phase 1
T14597	DRUGINFO	DSOE74	GQ1001	Phase 1
T14597	DRUGINFO	DU54BA	MB-103	Phase 1
T14597	DRUGINFO	DWS76U	TT16	Phase 1
T14597	DRUGINFO	D08JAN	Cipatinib	Phase 1
T14597	DRUGINFO	D0DBS7	GBR1302	Phase 1
T14597	DRUGINFO	D0UL7L	Recombinant human Erbb3 fragment therapeutic tumor vaccine	Phase 1
T14597	DRUGINFO	D0Z4RC	CUDC-101	Phase 1
T14597	DRUGINFO	D3FYE1	M802	Phase 1
T14597	DRUGINFO	DUA7P2	SBT6050	Phase 1
T14597	DRUGINFO	DL6F3E	SAR443216	Phase 1
T14597	DRUGINFO	DCUQ32	Runimotamab	Phase 1
T14597	DRUGINFO	DCUQ32	Runimotamab	Phase 1
T14597	DRUGINFO	D0U3XL	JNJ-26483327	Phase 1
T14597	DRUGINFO	D05YLO	Her-2-Bi-armed ATC	Discontinued in Phase 2
T14597	DRUGINFO	D0A9OV	TAK165	Discontinued in Phase 1
T14597	DRUGINFO	DO6UE8	227Th-labelled HER2-TTC	Preclinical
T14597	DRUGINFO	D02YAQ	GW-974	Terminated
T14597	DRUGINFO	D0NX2G	(1-Benzyl-1H-indazol-5-yl)-quinazolin-4-yl-amine	Investigative
T14597	DRUGINFO	D0O5CR	TA1-RTA	Investigative
T14597	DRUGINFO	D02ARA	(1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine	Investigative
T14597	DRUGINFO	D0B1SW	Redoxal	Investigative
T14597	DRUGINFO	D0J2CP	PF 5208766	Investigative
T14597	DRUGINFO	DKHL40	YH012	Investigative

T07173	TARGETID	T07173
T07173	FORMERID	TTDC00318
T07173	UNIPROID	NTRK1_HUMAN
T07173	TARGNAME	Tropomyosin-related kinase A (TrkA)
T07173	GENENAME	NTRK1
T07173	TARGTYPE	Successful
T07173	SYNONYMS	gp140trk; Tyrosine kinase receptor A; Tyrosine kinase receptor; Trk-A; TRKA; TRK1-transforming tyrosine kinase protein; TRK1 transforming tyrosinekinase protein; TRK; P140-TrkA; Neurotrophic tyrosine kinase receptor type 1; NGF-trk receptor type A; MTC; High affinity nerve growth factor receptor
T07173	FUNCTION	High affinity receptor for NGF which is its primary ligand. Can also bind and be activated by NTF3/neurotrophin-3. However, NTF3 only supports axonal extension through NTRK1 but has no effect on neuron survival. Upon dimeric NGF ligand-binding, undergoes homodimerization, autophosphorylation and activation. Recruits, phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades driving cell survival and differentiation. Through SHC1 and FRS2 activates a GRB2-Ras-MAPK cascade that regulates cell differentiation and survival. Through PLCG1 controls NF-Kappa-B activation and the transcription of genes involved in cell survival. Through SHC1 and SH2B1 controls a Ras-PI3 kinase-AKT1 signaling cascade that is also regulating survival. In absence of ligand and activation, may promote cell death, making the survival of neurons dependent on trophic factors. Receptor tyrosine kinase involved in the development and the maturation of the central and peripheral nervous systems through regulation of proliferation, differentiation and survival of sympathetic and nervous neurons.
T07173	PDBSTRUC	6NSS; 6NSP; 6NPT; 6DKW; 6DKI
T07173	BIOCLASS	Kinase
T07173	ECNUMBER	EC 2.7.10.1
T07173	SEQUENCE	MLRGGRRGQLGWHSWAAGPGSLLAWLILASAGAAPCPDACCPHGSSGLRCTRDGALDSLHHLPGAENLTELYIENQQHLQHLELRDLRGLGELRNLTIVKSGLRFVAPDAFHFTPRLSRLNLSFNALESLSWKTVQGLSLQELVLSGNPLHCSCALRWLQRWEEEGLGGVPEQKLQCHGQGPLAHMPNASCGVPTLKVQVPNASVDVGDDVLLRCQVEGRGLEQAGWILTELEQSATVMKSGGLPSLGLTLANVTSDLNRKNVTCWAENDVGRAEVSVQVNVSFPASVQLHTAVEMHHWCIPFSVDGQPAPSLRWLFNGSVLNETSFIFTEFLEPAANETVRHGCLRLNQPTHVNNGNYTLLAANPFGQASASIMAAFMDNPFEFNPEDPIPVSFSPVDTNSTSGDPVEKKDETPFGVSVAVGLAVFACLFLSTLLLVLNKCGRRNKFGINRPAVLAPEDGLAMSLHFMTLGGSSLSPTEGKGSGLQGHIIENPQYFSDACVHHIKRRDIVLKWELGEGAFGKVFLAECHNLLPEQDKMLVAVKALKEASESARQDFQREAELLTMLQHQHIVRFFGVCTEGRPLLMVFEYMRHGDLNRFLRSHGPDAKLLAGGEDVAPGPLGLGQLLAVASQVAAGMVYLAGLHFVHRDLATRNCLVGQGLVVKIGDFGMSRDIYSTDYYRVGGRTMLPIRWMPPESILYRKFTTESDVWSFGVVLWEIFTYGKQPWYQLSNTEAIDCITQGRELERPRACPPEVYAIMRGCWQREPQQRHSIKDVHARLQALAQAPPVYLDVLG
T07173	DRUGINFO	D05NFR	Repotrectinib	Approved
T07173	DRUGINFO	D07TOK	Larotrectinib	Approved
T07173	DRUGINFO	D0O0LS	Entrectinib	Approved
T07173	DRUGINFO	D0C2OR	MIM-D3	Phase 3
T07173	DRUGINFO	D04QYS	SNA-120	Phase 2
T07173	DRUGINFO	D0B7OY	CT 327	Phase 2
T07173	DRUGINFO	D0QP8X	ONO-7579	Phase 1/2
T07173	DRUGINFO	D03UDF	LOXO-195	Phase 1
T07173	DRUGINFO	D1ZD0N	VMD-928	Phase 1
T07173	DRUGINFO	D0N0DU	DS-6051	Phase 1
T07173	DRUGINFO	D07PSL	PLX7486	Phase 1
T07173	DRUGINFO	D0FA6S	Altiratinib	Phase 1
T07173	DRUGINFO	D00DIZ	Pyrazolo[1,5-a]pyrimidine derivative 17	Patented
T07173	DRUGINFO	D00EUL	PMID28270021-Compound-WO2016054807Example82	Patented
T07173	DRUGINFO	D00FJH	N-acylpiperidine ether derivative 4	Patented
T07173	DRUGINFO	D00ICS	Pyrrolidinyl urea derivative 11	Patented
T07173	DRUGINFO	D00XXZ	N-acylpiperidine ether derivative 1	Patented
T07173	DRUGINFO	D02ETU	PMID28270021-Compound-WO2014152663 701	Patented
T07173	DRUGINFO	D02IBX	Pyrrolo[2,3-b]pyridine derivative 3	Patented
T07173	DRUGINFO	D02OLJ	N-acylpiperidine ether derivative 7	Patented
T07173	DRUGINFO	D02QWP	N-arylmethyl-N-phenyl cyclic urea derivative 2	Patented
T07173	DRUGINFO	D02ZQN	PMID28270021-Compound-WO2013009582Example16	Patented
T07173	DRUGINFO	D03BAY	N-acylpiperidine ether derivative 5	Patented
T07173	DRUGINFO	D03USW	Pyrazolo[1,5-a]pyrimidine derivative 25	Patented
T07173	DRUGINFO	D04BRW	Five membered heterocyclic benzamide derivative 2	Patented
T07173	DRUGINFO	D04GCC	N-acylpiperidine ether derivative 6	Patented
T07173	DRUGINFO	D04JCD	Six-membered heterocyclic benzamide derivative 6	Patented
T07173	DRUGINFO	D04KQB	Pyrazolo[1,5-a]pyrimidine derivative 24	Patented
T07173	DRUGINFO	D04QHI	Imidazo[1,2-b]pyridazine derivative 7	Patented
T07173	DRUGINFO	D04RXX	N-acylpiperidine ether derivative 2	Patented
T07173	DRUGINFO	D05AQT	PMID28270021-Compound-WO2014078408Example1	Patented
T07173	DRUGINFO	D05KHT	Pyrazolo[1,5-a]pyrimidine derivative 19	Patented
T07173	DRUGINFO	D05MRY	Six-membered heterocyclic benzamide derivative 7	Patented
T07173	DRUGINFO	D05NBR	PMID28270010-Compound-Figure16-a	Patented
T07173	DRUGINFO	D05RKT	Pyrazolo[1,5-a]pyrimidine derivative 18	Patented
T07173	DRUGINFO	D06GOT	Pyrrolo[2,3-b]pyridine derivative 2	Patented
T07173	DRUGINFO	D06NPZ	Pyrazolo[1,5-a]pyrimidine derivative 23	Patented
T07173	DRUGINFO	D06STX	Thiadiazolyl carboxamide derivative 1	Patented
T07173	DRUGINFO	D06YON	Pyrrolidinyl urea derivative 9	Patented
T07173	DRUGINFO	D07AJO	Bicyclic heteroaryl benzamide derivative 9	Patented
T07173	DRUGINFO	D07CPL	Bicyclic heteroaryl benzamide derivative 6	Patented
T07173	DRUGINFO	D07KVL	PMID28270021-Compound-WO2010077680 811	Patented
T07173	DRUGINFO	D07VFQ	Six-membered heterocyclic benzamide derivative 3	Patented
T07173	DRUGINFO	D08BIH	N-acylpyrrolidine ether derivative 2	Patented
T07173	DRUGINFO	D08CZY	PMID28270021-Compound-WO2016054807Example71	Patented
T07173	DRUGINFO	D08IWT	Pyrazolo[1,5-a]pyrimidine derivative 27	Patented
T07173	DRUGINFO	D08SDJ	Ureido-phenyl-substituted triazine derivative 1	Patented
T07173	DRUGINFO	D09SYD	Pyrazolo[1,5-a]pyrimidine derivative 26	Patented
T07173	DRUGINFO	D0A4YR	Pyrrolidinyl urea derivative 8	Patented
T07173	DRUGINFO	D0BI5I	Pyrazolo[1,5-a]pyrimidine derivative 15	Patented
T07173	DRUGINFO	D0BO1H	PMID28270021-Compound-WO2016054807Example80	Patented
T07173	DRUGINFO	D0BP9B	N,N-bis(5-pyrazoyl)urea derivative 1	Patented
T07173	DRUGINFO	D0BZ0T	Pyrazolo[1,5-a]pyrimidine derivative 16	Patented
T07173	DRUGINFO	D0C3RK	N-(phenylpyrazolyl)benzamide derivative 1	Patented
T07173	DRUGINFO	D0CG8N	Tri-substituted urea derivative 2	Patented
T07173	DRUGINFO	D0CY3U	Five membered heterocyclic benzamide derivative 3	Patented
T07173	DRUGINFO	D0D6UF	Pyrazolo[1,5-a]pyrimidine derivative 21	Patented
T07173	DRUGINFO	D0D7EG	PMID28270010-Compound-Figure17-3	Patented
T07173	DRUGINFO	D0DN3Q	Pyrazolo[1,5-a]pyridine derivative 1	Patented
T07173	DRUGINFO	D0DO4I	Imidazo[1,2-b]pyridazine derivative 5	Patented
T07173	DRUGINFO	D0DQ5G	Pyrrolo[3,2-c]pyridine derivative 1	Patented
T07173	DRUGINFO	D0DY5R	Bicyclic heteroaryl benzamide derivative 8	Patented
T07173	DRUGINFO	D0EC4Z	Six-membered heterocyclic benzamide derivative 4	Patented
T07173	DRUGINFO	D0F2BF	PMID28270021-Compound-WO2010077680 803	Patented
T07173	DRUGINFO	D0F8BF	Bicyclic heteroaryl benzamide derivative 2	Patented
T07173	DRUGINFO	D0FL8A	PMID28270021-Compound-WO2010077680 481	Patented
T07173	DRUGINFO	D0FS4S	Imidazo[1,2-b]pyridazine derivative 4	Patented
T07173	DRUGINFO	D0H3ZG	Six-membered heterocyclic benzamide derivative 2	Patented
T07173	DRUGINFO	D0H8XH	Pyrazolo[1,5-a]pyrimidine derivative 14	Patented
T07173	DRUGINFO	D0HF1A	Bicyclic heteroaryl benzamide derivative 1	Patented
T07173	DRUGINFO	D0I2OO	PMID28270021-Compound-WO2013161919Example85-117	Patented
T07173	DRUGINFO	D0I5DM	N-arylmethyl-N-phenyl cyclic urea derivative 1	Patented
T07173	DRUGINFO	D0I8AY	Pyrrolidinyl urea derivative 10	Patented
T07173	DRUGINFO	D0I9FU	Bicyclic heteroaryl benzamide derivative 4	Patented
T07173	DRUGINFO	D0J4CA	PMID28270021-Compound-WO2010077680 103	Patented
T07173	DRUGINFO	D0J5OO	Pyrrolidinyl urea derivative 6	Patented
T07173	DRUGINFO	D0JJ0T	Pyrrolidinyl urea derivative 2	Patented
T07173	DRUGINFO	D0JU4R	Thiazole derivative 4	Patented
T07173	DRUGINFO	D0K2GH	Pyrrolidinyl urea derivative 12	Patented
T07173	DRUGINFO	D0K3QT	Pyrrolidinyl urea derivative 4	Patented
T07173	DRUGINFO	D0K6IM	PMID28270021-Compound-WO2010077680 495	Patented
T07173	DRUGINFO	D0KC8X	Bicyclic heteroaryl benzamide derivative 5	Patented
T07173	DRUGINFO	D0LB7Z	Pyrrolidinyl urea derivative 3	Patented
T07173	DRUGINFO	D0LK8E	PMID28270021-Compound-WO2016054807Example112	Patented
T07173	DRUGINFO	D0ME5D	Pyrrolidinyl urea derivative 5	Patented
T07173	DRUGINFO	D0MZ7K	Triazolo[4,3-b]pyridazine derivative 2	Patented
T07173	DRUGINFO	D0N6NG	Bicyclic heteroaryl benzamide derivative 7	Patented
T07173	DRUGINFO	D0O0GZ	Bicyclic heteroaryl benzamide derivative 3	Patented
T07173	DRUGINFO	D0O8SX	Pyrazolo[4,3-h]quinazoline-3-carboxamide derivative 1	Patented
T07173	DRUGINFO	D0P3VK	PMID28270010-Compound-Figure17-1	Patented
T07173	DRUGINFO	D0P8SR	Pyrrolo[2,3-b]pyridine derivative 1	Patented
T07173	DRUGINFO	D0PY0G	PMID28270021-Compound-WO2010077680 201	Patented
T07173	DRUGINFO	D0QT8L	PMID28270021-Compound-WO2014129431Example8-1	Patented
T07173	DRUGINFO	D0RK6W	Pyrazolo[4,3-c]pyridine derivative 1	Patented
T07173	DRUGINFO	D0RR8O	Pyrido[3,2-d]pyrimidine derivative 2	Patented
T07173	DRUGINFO	D0S0II	Pyrrolo[2,3-d]pyrimidine derivative 3	Patented
T07173	DRUGINFO	D0T0HM	PMID28270021-Compound-WO2010077680 109	Patented
T07173	DRUGINFO	D0T4CF	Five membered heterocyclic benzamide derivative 1	Patented
T07173	DRUGINFO	D0T5OF	PMID28270010-Compound-Figure17-2	Patented
T07173	DRUGINFO	D0U2GJ	Pyrazolo[1,5-a]pyrimidine derivative 22	Patented
T07173	DRUGINFO	D0U3RD	Pyrido[3,2-d]pyrimidine derivative 3	Patented
T07173	DRUGINFO	D0U5XI	PMID28270021-Compound-WO2015042088Example11	Patented
T07173	DRUGINFO	D0UN4M	Six-membered heterocyclic benzamide derivative 5	Patented
T07173	DRUGINFO	D0UQ2G	Tri-substituted urea derivative 1	Patented
T07173	DRUGINFO	D0V7QU	Ureido-phenyl-substituted triazine derivative 2	Patented
T07173	DRUGINFO	D0V9ZJ	Pyrazolo[1,5-a]pyridine derivative 2	Patented
T07173	DRUGINFO	D0VD5J	PMID28270021-Compound-WO2015042088Example12	Patented
T07173	DRUGINFO	D0W0UF	Imidazo[1,2-b]pyridazine derivative 6	Patented
T07173	DRUGINFO	D0W9RH	PMID28270010-Compound-Figure16-b-1	Patented
T07173	DRUGINFO	D0WI7N	Imidazo pyridine derivative 1	Patented
T07173	DRUGINFO	D0X0YJ	Pyrrolidinyl urea derivative 7	Patented
T07173	DRUGINFO	D0X1LP	N-acylpiperidine ether derivative 3	Patented
T07173	DRUGINFO	D0X4LA	N-acylpyrrolidine ether derivative 1	Patented
T07173	DRUGINFO	D0Y0XJ	PMID28270021-Compound-WO2013009582Example76	Patented
T07173	DRUGINFO	D0YM2S	PMID28270010-Compound-Figure16-b-2	Patented
T07173	DRUGINFO	D0YN0I	PMID28270021-Compound-WO2014078408Example26	Patented
T07173	DRUGINFO	D0Z5PA	Pyrazolo[1,5-a]pyrimidine derivative 20	Patented
T07173	DRUGINFO	D0Z6LB	Pyrrolidinyl urea derivative 13	Patented
T07173	DRUGINFO	D0ZE6H	Six-membered heterocyclic benzamide derivative 1	Patented
T07173	DRUGINFO	D0M8UO	Imidazo[1,2-b]pyridazine derivative 2	Patented
T07173	DRUGINFO	D0N1CF	Imidazo[1,2-b]pyridazine derivative 3	Patented
T07173	DRUGINFO	D0T3TZ	Benzimidazole derivative 6	Patented
T07173	DRUGINFO	D0T8XD	Imidazo[1,2-b]pyridazine derivative 1	Patented
T07173	DRUGINFO	D0X9VS	PMID28270010-Compound-Figure24-a	Patented
T07173	DRUGINFO	D00MGO	PMID28270021-Compound-WO2016054807Example1	Patented
T07173	DRUGINFO	D07RLB	PMID28270010-Compound-Figure24-b	Patented
T07173	DRUGINFO	D0AG2A	Pyrrolo[2,3-d]pyrimidine derivative 4	Patented
T07173	DRUGINFO	D0AU4G	3-amino-5-benzyl-substituted indazole derivative 1	Patented
T07173	DRUGINFO	D0J9ZG	PMID28270010-Compound-Figure5-1	Patented
T07173	DRUGINFO	D0M8VS	PMID28270021-Compound-WO2015042088Example4	Patented
T07173	DRUGINFO	D0T2OX	PMID28270010-Compound-Figure5-2	Patented
T07173	DRUGINFO	D0V5AG	PMID28270010-Compound-Figure5-3	Patented
T07173	DRUGINFO	D0Y1NH	Azaindazole amide derivative 1	Patented
T07173	DRUGINFO	D0LX8D	AZD6918	Discontinued in Phase 1
T07173	DRUGINFO	D07SYN	FX-007	Preclinical
T07173	DRUGINFO	D02RWK	K-252a analogue	Investigative
T07173	DRUGINFO	D0Z5TQ	GW-5074	Investigative
T07173	DRUGINFO	D07IHM	CEP-6331	Investigative
T07173	DRUGINFO	D09QBA	CEP-5104	Investigative

T85435	TARGETID	T85435
T85435	FORMERID	TTDS00292
T85435	UNIPROID	INSR_HUMAN
T85435	TARGNAME	Insulin receptor (INSR)
T85435	GENENAME	INSR
T85435	TARGTYPE	Successful
T85435	SYNONYMS	IR; CD220 antigen; CD220
T85435	FUNCTION	Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosine residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin. Receptor tyrosine kinase which mediates the pleiotropic actions of insulin.
T85435	PDBSTRUC	6HN5; 6HN4; 5U1M; 5KQV; 5J3H
T85435	BIOCLASS	Kinase
T85435	ECNUMBER	EC 2.7.10.1
T85435	SEQUENCE	MATGGRRGAAAAPLLVAVAALLLGAAGHLYPGEVCPGMDIRNNLTRLHELENCSVIEGHLQILLMFKTRPEDFRDLSFPKLIMITDYLLLFRVYGLESLKDLFPNLTVIRGSRLFFNYALVIFEMVHLKELGLYNLMNITRGSVRIEKNNELCYLATIDWSRILDSVEDNYIVLNKDDNEECGDICPGTAKGKTNCPATVINGQFVERCWTHSHCQKVCPTICKSHGCTAEGLCCHSECLGNCSQPDDPTKCVACRNFYLDGRCVETCPPPYYHFQDWRCVNFSFCQDLHHKCKNSRRQGCHQYVIHNNKCIPECPSGYTMNSSNLLCTPCLGPCPKVCHLLEGEKTIDSVTSAQELRGCTVINGSLIINIRGGNNLAAELEANLGLIEEISGYLKIRRSYALVSLSFFRKLRLIRGETLEIGNYSFYALDNQNLRQLWDWSKHNLTITQGKLFFHYNPKLCLSEIHKMEEVSGTKGRQERNDIALKTNGDQASCENELLKFSYIRTSFDKILLRWEPYWPPDFRDLLGFMLFYKEAPYQNVTEFDGQDACGSNSWTVVDIDPPLRSNDPKSQNHPGWLMRGLKPWTQYAIFVKTLVTFSDERRTYGAKSDIIYVQTDATNPSVPLDPISVSNSSSQIILKWKPPSDPNGNITHYLVFWERQAEDSELFELDYCLKGLKLPSRTWSPPFESEDSQKHNQSEYEDSAGECCSCPKTDSQILKELEESSFRKTFEDYLHNVVFVPRKTSSGTGAEDPRPSRKRRSLGDVGNVTVAVPTVAAFPNTSSTSVPTSPEEHRPFEKVVNKESLVISGLRHFTGYRIELQACNQDTPEERCSVAAYVSARTMPEAKADDIVGPVTHEIFENNVVHLMWQEPKEPNGLIVLYEVSYRRYGDEELHLCVSRKHFALERGCRLRGLSPGNYSVRIRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIIIGPLIFVFLFSVVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFPCSVYVPDEWEVSREKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKGFTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMAAEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDNCPERVTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFHSEENKAPESEELEMEFEDMENVPLDRSSHCQREEAGGRDGGSSLGFKRSYEEHIPYTHMNGGKKNGRILTLPRSNPS
T85435	DRUGINFO	D02EHV	Human neutral insulin	Approved
T85435	DRUGINFO	D03VXG	Insulin Lyspro recombinant	Approved
T85435	DRUGINFO	D05ELO	Insulin, porcine	Approved
T85435	DRUGINFO	D06SVW	Insulin recombinant	Approved
T85435	DRUGINFO	D09PPG	Metformin arginine-hemisuccinimide	Approved
T85435	DRUGINFO	D0L6JE	Insulin-lispro	Approved
T85435	DRUGINFO	D0M2XE	Insulin-glulisine	Approved
T85435	DRUGINFO	D0Y3VQ	Ryzodeq	Approved
T85435	DRUGINFO	D07MEH	Meglitinides	Approved
T85435	DRUGINFO	D0U8YK	NN5401	Phase 3
T85435	DRUGINFO	D0U3LK	Metformin glycinate	Phase 2/3
T85435	DRUGINFO	D00AUX	MSDC-0602	Phase 2
T85435	DRUGINFO	D02SXZ	S-707106	Phase 2
T85435	DRUGINFO	D03VCJ	NP-01	Phase 2
T85435	DRUGINFO	D06MOY	DM-99	Phase 2
T85435	DRUGINFO	D07NKZ	VVP-808	Phase 2
T85435	DRUGINFO	D0A6OS	TAK-379	Phase 2
T85435	DRUGINFO	D0D4ZW	EGS-21	Phase 2
T85435	DRUGINFO	D0T5YX	DM-71	Phase 2
T85435	DRUGINFO	D0ZK7B	Tesofensine	Phase 2
T85435	DRUGINFO	DJM3W0	RZ358	Phase 2
T85435	DRUGINFO	D00SWQ	Mitoglitazone	Phase 2
T85435	DRUGINFO	D06HPP	AGT-182	Phase 1
T85435	DRUGINFO	D07DLA	ISF-402	Phase 1
T85435	DRUGINFO	D08TGG	Insulin transdermal	Phase 1
T85435	DRUGINFO	D08XFJ	NN-1218	Phase 1
T85435	DRUGINFO	D0D5EJ	Insulin oral sublingual	Phase 1
T85435	DRUGINFO	D07HPJ	AEW-541	Phase 1
T85435	DRUGINFO	D05LSY	AKP-020	Discontinued in Phase 2
T85435	DRUGINFO	D0F1MU	EML-336	Discontinued in Phase 2
T85435	DRUGINFO	D0Z8UQ	DM-83	Discontinued in Phase 2
T85435	DRUGINFO	D0M3OR	KW-2450	Discontinued in Phase 1/2
T85435	DRUGINFO	D02IJP	CLX-0900	Terminated
T85435	DRUGINFO	D03CMR	TER-16998	Terminated
T85435	DRUGINFO	D02QOL	XMetD	Investigative
T85435	DRUGINFO	D03BCE	FPT-038	Investigative
T85435	DRUGINFO	D08ZLL	Quick-acting insulin	Investigative
T85435	DRUGINFO	D0C7QW	XMetS	Investigative
T85435	DRUGINFO	D0I4LQ	RHIIP	Investigative
T85435	DRUGINFO	D0KC9V	AD10-1025	Investigative
T85435	DRUGINFO	D0R2WK	NVP-TAE684	Investigative
T85435	DRUGINFO	D0XQ0V	DC-9703	Investigative
T85435	DRUGINFO	D0YN9H	VVP-100X	Investigative
T85435	DRUGINFO	D0L7MM	4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol	Investigative
T85435	DRUGINFO	D0W9KO	4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol	Investigative
T85435	DRUGINFO	D0G4CS	PMID24900237C15	Investigative
T85435	DRUGINFO	D0UG4S	L-betagamma-meATP	Investigative
T85435	DRUGINFO	D06PJW	GSK-1838705A	Investigative

T12499	TARGETID	T12499
T12499	FORMERID	TTDS00407
T12499	UNIPROID	LCK_HUMAN
T12499	TARGNAME	LCK tyrosine protein kinase (LCK)
T12499	GENENAME	LCK
T12499	TARGTYPE	Successful
T12499	SYNONYMS	p56-LCK; Tyrosine-protein kinase Lck; T cell-specific protein-tyrosine kinase; Proto-oncogene tyrosine-protein kinase LCK; Proto-oncogene Lck; Protein YT16; Lymphocyte cell-specific protein-tyrosine kinase; Leukocyte C-terminal Src kinase; LSK; LCK p59-Fyn; LCK Protooncogene Syn
T12499	FUNCTION	Plays a key role in T-cell antigen receptor (TCR)-linked signal transduction pathways. Constitutively associated with the cytoplasmic portions of the CD4 and CD8 surface receptors. Association of the TCR with a peptide antigen-bound MHC complex facilitates the interaction of CD4 and CD8 with MHC class II and class I molecules, respectively, thereby recruiting the associated LCK protein to the vicinity of the TCR/CD3 complex. LCK then phosphorylates tyrosine residues within the immunoreceptor tyrosine-based activation motifs (ITAM) of the cytoplasmic tails of the TCR-gamma chains and CD3 subunits, initiating the TCR/CD3 signaling pathway. Once stimulated, the TCR recruits the tyrosine kinase ZAP70, that becomes phosphorylated and activated by LCK. Following this, a large number of signaling molecules are recruited, ultimately leading to lymphokine production. LCK also contributes to signaling by other receptor molecules. Associates directly with the cytoplasmic tail of CD2, which leads to hyperphosphorylation and activation of LCK. Also plays a role in the IL2 receptor-linked signaling pathway that controls the T-cell proliferative response. Binding of IL2 to its receptor results in increased activity of LCK. Is expressed at all stages of thymocyte development and is required for the regulation of maturation events that are governed by both pre-TCR and mature alpha beta TCR. Phosphorylates other substrates including RUNX3, PTK2B/PYK2, the microtubule-associated protein MAPT, RHOH or TYROBP. Interacts with FYB2. Non-receptor tyrosine-protein kinase that plays an essential role in the selection and maturation of developing T-cells in the thymus and in the function of mature T-cells.
T12499	PDBSTRUC	6H6A; 5MTN; 5MTM; 4D8K; 4C3F
T12499	BIOCLASS	Kinase
T12499	ECNUMBER	EC 2.7.10.2
T12499	SEQUENCE	MGCGCSSHPEDDWMENIDVCENCHYPIVPLDGKGTLLIRNGSEVRDPLVTYEGSNPPASPLQDNLVIALHSYEPSHDGDLGFEKGEQLRILEQSGEWWKAQSLTTGQEGFIPFNFVAKANSLEPEPWFFKNLSRKDAERQLLAPGNTHGSFLIRESESTAGSFSLSVRDFDQNQGEVVKHYKIRNLDNGGFYISPRITFPGLHELVRHYTNASDGLCTRLSRPCQTQKPQKPWWEDEWEVPRETLKLVERLGAGQFGEVWMGYYNGHTKVAVKSLKQGSMSPDAFLAEANLMKQLQHQRLVRLYAVVTQEPIYIITEYMENGSLVDFLKTPSGIKLTINKLLDMAAQIAEGMAFIEERNYIHRDLRAANILVSDTLSCKIADFGLARLIEDNEYTAREGAKFPIKWTAPEAINYGTFTIKSDVWSFGILLTEIVTHGRIPYPGMTNPEVIQNLERGYRMVRPDNCPEELYQLMRLCWKERPEDRPTFDYLRSVLEDFFTATEGQYQPQP
T12499	DRUGINFO	D0E6XR	Dasatinib	Approved
T12499	DRUGINFO	D02XNW	VX-680	Phase 2
T12499	DRUGINFO	D06CIJ	ISIS-CRP	Phase 1
T12499	DRUGINFO	D0U3XL	JNJ-26483327	Phase 1
T12499	DRUGINFO	D02BUW	2-(3,4,5-Trihydroxy-benzylidene)-malononitrile	Investigative
T12499	DRUGINFO	D03AER	A-641359	Investigative
T12499	DRUGINFO	D08DVL	3-(4-(o-toluidino)pyrimidin-2-ylamino)benzamide	Investigative
T12499	DRUGINFO	D08WOG	4-(3-Chloro-phenoxy)-6,7-dimethoxy-quinazoline	Investigative
T12499	DRUGINFO	D0L4HJ	RPR-108518A	Investigative
T12499	DRUGINFO	D0OZ2S	Lck inhibitor	Investigative
T12499	DRUGINFO	D06WGX	A-770041	Investigative
T12499	DRUGINFO	D07ERV	Y-c[D-Pen-(3,5-diI)Tyr-GSFC]KR-NH2	Investigative
T12499	DRUGINFO	D0A2LX	Y-c[D-Pen-(3-I)Tyr-GSFC]KR-NH2	Investigative
T12499	DRUGINFO	D0D5KZ	PMID17280833C30	Investigative
T12499	DRUGINFO	D0D9TU	LAVENDUSTIN A	Investigative
T12499	DRUGINFO	D0IZ8M	PMID21855335C19a	Investigative
T12499	DRUGINFO	D0M3CT	4-Phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine	Investigative
T12499	DRUGINFO	D0Y1SR	WH-4-023	Investigative
T12499	DRUGINFO	D07AIB	(4-Phenoxy-phenyl)-quinazolin-4-yl-amine	Investigative
T12499	DRUGINFO	D0A7FQ	CGP-57380	Investigative
T12499	DRUGINFO	D0BS6R	A-420983	Investigative
T12499	DRUGINFO	D0C3AD	GW-788388	Investigative
T12499	DRUGINFO	D00NWF	ZM-336372	Investigative
T12499	DRUGINFO	D04TLI	PMID17600705C23	Investigative
T12499	DRUGINFO	D09HXU	6-o-tolylquinazolin-2-amine	Investigative
T12499	DRUGINFO	D06WJA	L-779450	Investigative
T12499	DRUGINFO	D0CE3R	SU 6656	Investigative
T12499	DRUGINFO	D0GT8N	NM-PP1	Investigative
T12499	DRUGINFO	D0OH3J	PD-0179483	Investigative
T12499	DRUGINFO	D0S1KJ	PD-0173952	Investigative
T12499	DRUGINFO	D0Y4BL	JNJ-28312141	Investigative
T12499	DRUGINFO	D0Z7GH	PD-0173958	Investigative
T12499	DRUGINFO	D03NPX	PD-0173955	Investigative
T12499	DRUGINFO	D0YZ7H	JNJ-10198409	Investigative
T12499	DRUGINFO	D08RZB	PMID15546730C2	Investigative
T12499	DRUGINFO	D09QBA	CEP-5104	Investigative
T12499	DRUGINFO	D0D5EW	HKI-9924129	Investigative
T12499	DRUGINFO	D0GW4Q	PD-0173956	Investigative
T12499	DRUGINFO	D0H1OK	TG-100435	Investigative
T12499	DRUGINFO	D0P3JW	PD-0166326	Investigative
T12499	DRUGINFO	D0GB4V	STAUROSPORINONE	Investigative
T12499	DRUGINFO	D0M5FF	Ro31-8220	Investigative
T12499	DRUGINFO	D00ICA	AMP-PNP	Investigative
T12499	DRUGINFO	D0M4SY	BMS-536924	Investigative
T12499	DRUGINFO	D0N6ES	KN-62	Investigative
T12499	DRUGINFO	D0B9BU	CI-1040	Investigative
T12499	DRUGINFO	D0O1YH	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	Investigative
T12499	DRUGINFO	D0TO6S	Bisindolylmaleimide-I	Investigative
T12499	DRUGINFO	D0L8HO	RO-316233	Investigative

T60631	TARGETID	T60631
T60631	FORMERID	TTDS00348
T60631	UNIPROID	RET_HUMAN
T60631	TARGNAME	Proto-oncogene c-Ret (RET)
T60631	GENENAME	RET
T60631	TARGTYPE	Successful
T60631	SYNONYMS	RET51; RET receptor tyrosine kinase; RET mutant Y791F; RET mutant V804M; RET mutant V804L; RET mutant S891A; RET mutant M918T; RET mutant G691S; Proto-oncogene tyrosine-protein kinase receptor Ret; PTC; Cadherin family member 12; CDHR16; CDHF12; C-ret
T60631	FUNCTION	Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut-associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e. g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration. Mediates, through interaction with GDF15-receptor GFRAL, GDF15-induced cell-signaling in the brainstem which induces inhibition of food-intake. Activates MAPK- and AKT-signaling pathways. Isoform 1 in complex with GFRAL induces higher activation of MAPK-signaling pathway than isoform 2 in complex with GFRAL. Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands.
T60631	PDBSTRUC	6FEK; 5FM3; 5FM2; 5AMN; 4UX8
T60631	BIOCLASS	Kinase
T60631	ECNUMBER	EC 2.7.10.1
T60631	SEQUENCE	MAKATSGAAGLRLLLLLLLPLLGKVALGLYFSRDAYWEKLYVDQAAGTPLLYVHALRDAPEEVPSFRLGQHLYGTYRTRLHENNWICIQEDTGLLYLNRSLDHSSWEKLSVRNRGFPLLTVYLKVFLSPTSLREGECQWPGCARVYFSFFNTSFPACSSLKPRELCFPETRPSFRIRENRPPGTFHQFRLLPVQFLCPNISVAYRLLEGEGLPFRCAPDSLEVSTRWALDREQREKYELVAVCTVHAGAREEVVMVPFPVTVYDEDDSAPTFPAGVDTASAVVEFKRKEDTVVATLRVFDADVVPASGELVRRYTSTLLPGDTWAQQTFRVEHWPNETSVQANGSFVRATVHDYRLVLNRNLSISENRTMQLAVLVNDSDFQGPGAGVLLLHFNVSVLPVSLHLPSTYSLSVSRRARRFAQIGKVCVENCQAFSGINVQYKLHSSGANCSTLGVVTSAEDTSGILFVNDTKALRRPKCAELHYMVVATDQQTSRQAQAQLLVTVEGSYVAEEAGCPLSCAVSKRRLECEECGGLGSPTGRCEWRQGDGKGITRNFSTCSPSTKTCPDGHCDVVETQDINICPQDCLRGSIVGGHEPGEPRGIKAGYGTCNCFPEEEKCFCEPEDIQDPLCDELCRTVIAAAVLFSFIVSVLLSAFCIHCYHKFAHKPPISSAEMTFRRPAQAFPVSYSSSGARRPSLDSMENQVSVDAFKILEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRAGYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDHPDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAASTPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMDTFDS
T60631	DRUGINFO	D01KOA	Selpercatinib	Approved
T60631	DRUGINFO	D0OD2I	Pralsetinib	Approved
T60631	DRUGINFO	D09GDD	Regorafenib	Approved
T60631	DRUGINFO	D0G6QF	Vandetanib	Approved
T60631	DRUGINFO	D0H0EQ	Ponatinib	Approved
T60631	DRUGINFO	D01PZD	Romiplostim	Approved
T60631	DRUGINFO	D05BLN	MGCD516	Phase 2/3
T60631	DRUGINFO	D05BLN	MGCD516	Phase 2/3
T60631	DRUGINFO	D04MXN	CEP-32496	Phase 1/2
T60631	DRUGINFO	DS7CY4	TPX-0046	Phase 1/2
T60631	DRUGINFO	D0AX4H	GSK3179106	Phase 1
T60631	DRUGINFO	D1BG7C	BOS172738	Phase 1
T60631	DRUGINFO	DJVC36	A400	Phase 1
T60631	DRUGINFO	D0S6TK	tamatinib	Clinical trial
T60631	DRUGINFO	D01BMX	Pyrazolo[3,4-d]pyrimidine derivative 8	Patented
T60631	DRUGINFO	D03JZP	Dihydropyridine compound 4	Patented
T60631	DRUGINFO	D03MMZ	Pyrazolo[3,4-d]pyrimidine derivative 6	Patented
T60631	DRUGINFO	D03ORX	Dihydropyridine compound 6	Patented
T60631	DRUGINFO	D05HYJ	Pyrazolo[3,4-d]pyrimidine derivative 7	Patented
T60631	DRUGINFO	D05NBB	Pyrrolo-pyridinone derivative 3	Patented
T60631	DRUGINFO	D06BNK	Pyrazolo[3,4-d]pyrimidine derivative 5	Patented
T60631	DRUGINFO	D07OLQ	Pyrrolo-pyrimidine derivative 6	Patented
T60631	DRUGINFO	D07QKP	Pyrrolo-pyridinone derivative 4	Patented
T60631	DRUGINFO	D08LCQ	Benzo(b)carbazol-11-one compound 1	Patented
T60631	DRUGINFO	D09FBJ	Pyrrolo-pyrimidine derivative 2	Patented
T60631	DRUGINFO	D0A6RR	Dihydropyridine compound 1	Patented
T60631	DRUGINFO	D0B3GX	Quinazoline derivative 14	Patented
T60631	DRUGINFO	D0FU0I	Pyrrolo-pyrimidine derivative 3	Patented
T60631	DRUGINFO	D0JY9S	Dihydropyridine compound 2	Patented
T60631	DRUGINFO	D0NH2H	Pyrrolo-pyrimidine derivative 5	Patented
T60631	DRUGINFO	D0P1AH	Pyrrolo-pyrimidine derivative 4	Patented
T60631	DRUGINFO	D0QY6M	Pyrrolo-pyridinone derivative 2	Patented
T60631	DRUGINFO	D0X7IS	Dihydropyridine compound 5	Patented
T60631	DRUGINFO	D0XR9O	Pyrrolo-pyridinone derivative 1	Patented
T60631	DRUGINFO	D0YC7C	Dihydropyridine compound 3	Patented
T60631	DRUGINFO	D05PRG	Quinazoline derivative 15	Patented
T60631	DRUGINFO	D0DV4X	Quinazoline derivative 16	Patented
T60631	DRUGINFO	D0MX7B	Carboxamide derivative 4	Patented
T60631	DRUGINFO	D0NB1V	Pyridine derivative 20	Patented
T60631	DRUGINFO	D0O0AW	Pyridine derivative 21	Patented
T60631	DRUGINFO	D0O4TA	Pyridine derivative 22	Patented
T60631	DRUGINFO	D0T7BE	Pyridine derivative 19	Patented
T60631	DRUGINFO	D0O9JD	Benzo(b)carbazol-11-one compound 2	Patented
T60631	DRUGINFO	D0AK1F	Pyridine derivative 18	Patented
T60631	DRUGINFO	D0J5TN	CEP-751	Terminated
T60631	DRUGINFO	D02CFR	GW-559768X	Investigative
T60631	DRUGINFO	D0N5TB	ITRI-305	Investigative
T60631	DRUGINFO	D0W4UQ	(Z)-5-Amino-3-(4-methoxybenzylidene)indolin-2-one	Investigative
T60631	DRUGINFO	D0Y1UL	(E)-3-(4-hydroxybenzylidene)indolin-2-one	Investigative
T60631	DRUGINFO	D00ATA	(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one	Investigative
T60631	DRUGINFO	D0N7AJ	AST-487	Investigative
T60631	DRUGINFO	D02NNT	PMID21493067C1d	Investigative
T60631	DRUGINFO	D02BXJ	PMID21561767C8h	Investigative
T60631	DRUGINFO	D0H1OK	TG-100435	Investigative

T68251	TARGETID	T68251
T68251	FORMERID	TTDC00104
T68251	UNIPROID	MMP2_HUMAN
T68251	TARGNAME	Matrix metalloproteinase-2 (MMP-2)
T68251	GENENAME	MMP2
T68251	TARGTYPE	Successful
T68251	SYNONYMS	TBE-1; Matrix metalloproteinase 2; CLG4A; 72 kDa type IV collagenase; 72 kDa gelatinase
T68251	FUNCTION	As well as degrading extracellular matrix proteins, can also act on several nonmatrix proteins such as big endothelial 1 and beta-type CGRP promoting vasoconstriction. Also cleaves KISS at a Gly-|-Leu bond. Appears to have a role in myocardial cell death pathways. Contributes to myocardial oxidative stress by regulating the activity of GSK3beta. Cleaves GSK3beta in vitro. Involved in the formation of the fibrovascular tissues in association with MMP14. Ubiquitinous metalloproteinase that is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture.
T68251	PDBSTRUC	3AYU; 1RTG; 1QIB; 1KS0; 1J7M
T68251	BIOCLASS	Peptidase
T68251	ECNUMBER	EC 3.4.24.24
T68251	SEQUENCE	MEALMARGALTGPLRALCLLGCLLSHAAAAPSPIIKFPGDVAPKTDKELAVQYLNTFYGCPKESCNLFVLKDTLKKMQKFFGLPQTGDLDQNTIETMRKPRCGNPDVANYNFFPRKPKWDKNQITYRIIGYTPDLDPETVDDAFARAFQVWSDVTPLRFSRIHDGEADIMINFGRWEHGDGYPFDGKDGLLAHAFAPGTGVGGDSHFDDDELWTLGEGQVVRVKYGNADGEYCKFPFLFNGKEYNSCTDTGRSDGFLWCSTTYNFEKDGKYGFCPHEALFTMGGNAEGQPCKFPFRFQGTSYDSCTTEGRTDGYRWCGTTEDYDRDKKYGFCPETAMSTVGGNSEGAPCVFPFTFLGNKYESCTSAGRSDGKMWCATTANYDDDRKWGFCPDQGYSLFLVAAHEFGHAMGLEHSQDPGALMAPIYTYTKNFRLSQDDIKGIQELYGASPDIDLGTGPTPTLGPVTPEICKQDIVFDGIAQIRGEIFFFKDRFIWRTVTPRDKPMGPLLVATFWPELPEKIDAVYEAPQEEKAVFFAGNEYWIYSASTLERGYPKPLTSLGLPPDVQRVDAAFNWSKNKKTYIFAGDKFWRYNEVKKKMDPGFPKLIADAWNAIPDNLDAVVDLQGGGHSYFFKGAYYLKLENQSLKSVKFGSIKSDWLGC
T68251	DRUGINFO	D00MDP	Prinomastat	Approved
T68251	DRUGINFO	D05VZE	Marimastat	Phase 3
T68251	DRUGINFO	D0U2BH	Epigallocatechin gallate	Phase 3
T68251	DRUGINFO	D0IJ7O	Metastat	Phase 1
T68251	DRUGINFO	D0T4BL	Neovastat	Phase 1
T68251	DRUGINFO	D0A9ZW	PMID29130358-Compound-Figure16(9b)	Patented
T68251	DRUGINFO	D0DB0Z	PMID29130358-Compound-SB-3CT	Patented
T68251	DRUGINFO	D0LS4Y	PMID29130358-Compound-Figure16(9a)	Patented
T68251	DRUGINFO	D0O8RQ	PMID29130358-Compound-Figure18(14)	Patented
T68251	DRUGINFO	D0Q4QB	PMID29130358-Compound-Figure13(4)	Patented
T68251	DRUGINFO	D0S3PN	PMID29130358-Compound-Figure16(9c)	Patented
T68251	DRUGINFO	D0W7HO	PMID29130358-Compound-LonimacranthoideVII	Patented
T68251	DRUGINFO	D0Y1LO	PMID29130358-Compound-Figure11(3)	Patented
T68251	DRUGINFO	D05GAP	PMID29130358-Compound-Figure10(2a)	Patented
T68251	DRUGINFO	D0X6GG	PMID29130358-Compound-Figure18(14a)	Patented
T68251	DRUGINFO	D0Q1CD	Tanomastat	Discontinued in Phase 3
T68251	DRUGINFO	D01EUF	BMS 275291	Discontinued in Phase 3
T68251	DRUGINFO	D05WTZ	Galarubicin	Discontinued in Phase 2
T68251	DRUGINFO	D03BOZ	RS-130830	Discontinued in Phase 2
T68251	DRUGINFO	D0T9HG	GM6001	Discontinued in Phase 2
T68251	DRUGINFO	D0C0ME	RO-26-2853	Preclinical
T68251	DRUGINFO	D02GYD	CDP-845	Terminated
T68251	DRUGINFO	D08CEE	L-696418	Terminated
T68251	DRUGINFO	D08WBF	BB-3644	Terminated
T68251	DRUGINFO	D05VNG	BB-1101	Terminated
T68251	DRUGINFO	D0Y1XT	SC-44463	Terminated
T68251	DRUGINFO	D06ALC	Lithospermic acid	Investigative
T68251	DRUGINFO	D08NSS	SC-74020	Investigative
T68251	DRUGINFO	D0H9BL	Clinopodic acid C	Investigative
T68251	DRUGINFO	D0T1FR	Cis-2-aminocyclohexylcarbamoylphosphonic acid	Investigative
T68251	DRUGINFO	D01HKU	Methotrexate gamma-L-proline-hydroxamic acid	Investigative
T68251	DRUGINFO	D02EFQ	PD-169469	Investigative
T68251	DRUGINFO	D05JPV	4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid	Investigative
T68251	DRUGINFO	D07LTB	5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione	Investigative
T68251	DRUGINFO	D0B0UI	Methotrexate gamma-hydroxamic acid	Investigative
T68251	DRUGINFO	D0E5MB	2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid	Investigative
T68251	DRUGINFO	D0F7BE	PNU-107859	Investigative
T68251	DRUGINFO	D0K4TI	5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione	Investigative
T68251	DRUGINFO	D0Q9LC	5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione	Investigative
T68251	DRUGINFO	D0U7CD	Roche 28-2653	Investigative
T68251	DRUGINFO	D0ZB6O	Folate gamma-L-proline-hydroxamic acid	Investigative
T68251	DRUGINFO	D00RNA	N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide	Investigative
T68251	DRUGINFO	D08ICI	N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)	Investigative
T68251	DRUGINFO	D0A5MV	3-(4-Phenylethynylbenzoyl)nonanoic acid	Investigative
T68251	DRUGINFO	D0P8EY	Folate gamma-hydroxamic acid	Investigative
T68251	DRUGINFO	D0Y7NV	5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione	Investigative
T68251	DRUGINFO	D0G3YZ	(+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid	Investigative
T68251	DRUGINFO	D0L4EO	3-(4-(2-phenylethynyl)benzoyl)pentanoic acid	Investigative
T68251	DRUGINFO	D0NP8A	UK-356618	Investigative
T68251	DRUGINFO	D0XL8K	Ro-37-9790	Investigative
T68251	DRUGINFO	D05THD	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	Investigative
T68251	DRUGINFO	D07MJD	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	Investigative
T68251	DRUGINFO	D0S9OL	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	Investigative
T68251	DRUGINFO	D03AMR	SR-973	Investigative
T68251	DRUGINFO	D0W2UK	IK-862	Investigative
T68251	DRUGINFO	D0A4TC	MMI270	Investigative

T00140	TARGETID	T00140
T00140	FORMERID	TTDS00112
T00140	UNIPROID	LOX5_HUMAN
T00140	TARGNAME	Arachidonate 5-lipoxygenase (5-LOX)
T00140	GENENAME	ALOX5
T00140	TARGTYPE	Successful
T00140	SYNONYMS	LOG5; 5-lipoxygenase; 5-LO
T00140	FUNCTION	Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
T00140	PDBSTRUC	3V99; 3V98; 3V92; 3O8Y; 2ABV
T00140	BIOCLASS	Oxygenase
T00140	ECNUMBER	EC 1.13.11.34
T00140	SEQUENCE	MPSYTVTVATGSQWFAGTDDYIYLSLVGSAGCSEKHLLDKPFYNDFERGAVDSYDVTVDEELGEIQLVRIEKRKYWLNDDWYLKYITLKTPHGDYIEFPCYRWITGDVEVVLRDGRAKLARDDQIHILKQHRRKELETRQKQYRWMEWNPGFPLSIDAKCHKDLPRDIQFDSEKGVDFVLNYSKAMENLFINRFMHMFQSSWNDFADFEKIFVKISNTISERVMNHWQEDLMFGYQFLNGCNPVLIRRCTELPEKLPVTTEMVECSLERQLSLEQEVQQGNIFIVDFELLDGIDANKTDPCTLQFLAAPICLLYKNLANKIVPIAIQLNQIPGDENPIFLPSDAKYDWLLAKIWVRSSDFHVHQTITHLLRTHLVSEVFGIAMYRQLPAVHPIFKLLVAHVRFTIAINTKAREQLICECGLFDKANATGGGGHVQMVQRAMKDLTYASLCFPEAIKARGMESKEDIPYYFYRDDGLLVWEAIRTFTAEVVDIYYEGDQVVEEDPELQDFVNDVYVYGMRGRKSSGFPKSVKSREQLSEYLTVVIFTASAQHAAVNFGQYDWCSWIPNAPPTMRAPPPTAKGVVTIEQIVDTLPDRGRSCWHLGAVWALSQFQENELFLGMYPEEHFIEKPVKEAMARFRKNLEAIVSVIAERNKKKQLPYYYLSPDRIPNSVAI
T00140	DRUGINFO	D06RCB	Diethylcarbamazine	Approved
T00140	DRUGINFO	D09JUG	Zileuton	Approved
T00140	DRUGINFO	D0AZ8C	Silymarin	Phase 4
T00140	DRUGINFO	D0V9EN	3,4-Dihydroxycinnamic Acid	Phase 4
T00140	DRUGINFO	D02RQT	Tenidap	Phase 3
T00140	DRUGINFO	D02YEY	FPL-62064	Phase 3
T00140	DRUGINFO	D08PXR	ABT-761	Phase 3
T00140	DRUGINFO	D0X8VV	Flobufen	Phase 3
T00140	DRUGINFO	D0C0NH	Avastin+/-Tarceva	Phase 3
T00140	DRUGINFO	D0AL8T	Darbufelone	Phase 2/3
T00140	DRUGINFO	D00RJB	Rilopirox	Phase 2
T00140	DRUGINFO	D0A7JH	WY-50295-tromethamine	Phase 2
T00140	DRUGINFO	D0L4SL	TA-270	Phase 2
T00140	DRUGINFO	D0L5XG	PF-4191834	Phase 2
T00140	DRUGINFO	D0S2PY	MK-866	Phase 2
T00140	DRUGINFO	DES36M	Q301	Phase 2
T00140	DRUGINFO	D04FNQ	BIM23A760	Phase 2
T00140	DRUGINFO	D04JIM	UCB-35440	Phase 2
T00140	DRUGINFO	D04WMR	Tepoxalin	Phase 2
T00140	DRUGINFO	D05VVX	PTC299	Phase 2
T00140	DRUGINFO	D0D5ZV	CMI-392	Phase 2
T00140	DRUGINFO	D0K9UK	E-6700	Phase 2
T00140	DRUGINFO	D0Q7UG	Tipelukast	Phase 2
T00140	DRUGINFO	D00YEV	BAICALEIN	Phase 2
T00140	DRUGINFO	D0L6VH	BF-389	Phase 1
T00140	DRUGINFO	D0Y4OI	SKF-105809	Phase 1
T00140	DRUGINFO	D0U2CB	Ibuproxam	Withdrawn from market
T00140	DRUGINFO	D00HFD	E-6080	Discontinued in Phase 2
T00140	DRUGINFO	D01DAD	CJ-13610	Discontinued in Phase 2
T00140	DRUGINFO	D04QVN	FPL-64170	Discontinued in Phase 2
T00140	DRUGINFO	D06UVO	DuP-654	Discontinued in Phase 2
T00140	DRUGINFO	D0H7GH	ETH615	Discontinued in Phase 2
T00140	DRUGINFO	D0JY4Y	E-3040	Discontinued in Phase 2
T00140	DRUGINFO	D0K2ER	MK-886	Discontinued in Phase 2
T00140	DRUGINFO	D0M0QX	MK-591	Discontinued in Phase 2
T00140	DRUGINFO	D0P1TZ	MLN-977	Discontinued in Phase 2
T00140	DRUGINFO	D0U5EU	SC-45662	Discontinued in Phase 2
T00140	DRUGINFO	D0V3HG	CV-6504	Discontinued in Phase 2
T00140	DRUGINFO	D0E8UV	Linetastine	Discontinued in Phase 2
T00140	DRUGINFO	D0G5GJ	R-68151	Discontinued in Phase 2
T00140	DRUGINFO	D08ORO	OPC-21268	Discontinued in Phase 2
T00140	DRUGINFO	D0P3KA	TEBUFELONE	Discontinued in Phase 2
T00140	DRUGINFO	D0F5NB	CD-581	Discontinued in Phase 1
T00140	DRUGINFO	D0N1SU	Licofelone	Discontinued in Phase 1
T00140	DRUGINFO	D0P3CF	AZD-4407	Discontinued in Phase 1
T00140	DRUGINFO	D01QAR	LY-221068	Terminated
T00140	DRUGINFO	D02QGM	CGS-26529	Terminated
T00140	DRUGINFO	D06MPF	Sch-40120	Terminated
T00140	DRUGINFO	D06XRQ	AA-861	Terminated
T00140	DRUGINFO	D06YOD	ZD-7717	Terminated
T00140	DRUGINFO	D09JYF	Epocarbazolin-A	Terminated
T00140	DRUGINFO	D09SCI	SKF-104351	Terminated
T00140	DRUGINFO	D0C5HV	R zileuton	Terminated
T00140	DRUGINFO	D0C9RZ	BU-4601A	Terminated
T00140	DRUGINFO	D0D8MD	ZM-230487	Terminated
T00140	DRUGINFO	D0DP8P	BW755C	Terminated
T00140	DRUGINFO	D0H2RB	NAFAZATROM	Terminated
T00140	DRUGINFO	D0HJ1Y	BW B70C	Terminated
T00140	DRUGINFO	D0J8RS	PD-146176	Terminated
T00140	DRUGINFO	D0L1IH	A-79175	Terminated
T00140	DRUGINFO	D0L8RG	CI-986	Terminated
T00140	DRUGINFO	D0O8ZE	REV-5901	Terminated
T00140	DRUGINFO	D0QI8I	CGS 8515	Terminated
T00140	DRUGINFO	D0S5DY	R-85355	Terminated
T00140	DRUGINFO	D0SZ3B	ER-34122	Terminated
T00140	DRUGINFO	D0T4EL	A-80263	Terminated
T00140	DRUGINFO	D0U6AL	BI-L-357	Terminated
T00140	DRUGINFO	D0X9KE	A-78773	Terminated
T00140	DRUGINFO	D01LXG	KC-11425	Terminated
T00140	DRUGINFO	D04APY	KC-11404	Terminated
T00140	DRUGINFO	D05WPQ	BW A4C	Terminated
T00140	DRUGINFO	D08JKK	RWJ-63556	Terminated
T00140	DRUGINFO	D0H0IA	WY-28342	Terminated
T00140	DRUGINFO	D0V4GT	CMI-206	Terminated
T00140	DRUGINFO	D00BSX	1,3,8-Trihydroxy-6-methyl-10H-anthracen-9-one	Investigative
T00140	DRUGINFO	D00ENR	1,8-Dihydroxy-2-propionyl-10H-anthracen-9-one	Investigative
T00140	DRUGINFO	D00JPV	N-Phenylbenzo[d]oxazol-2-amine	Investigative
T00140	DRUGINFO	D00MIM	FR-122788	Investigative
T00140	DRUGINFO	D00OWE	L-652,343	Investigative
T00140	DRUGINFO	D00XKA	SC-41661A	Investigative
T00140	DRUGINFO	D01QDG	4-Hydroxy-5-methoxy-10H-anthracen-9-one	Investigative
T00140	DRUGINFO	D01SQY	TZI-41127	Investigative
T00140	DRUGINFO	D01VLQ	15-hydroxyeicosatetraenoic acid	Investigative
T00140	DRUGINFO	D02HQK	2-Biphenyl-4-yl-N-hydroxy-N-methyl-acetamide	Investigative
T00140	DRUGINFO	D02RBU	4-Butoxy-N-hydroxy-N-methyl-benzamide	Investigative
T00140	DRUGINFO	D02TLZ	3-Biphenyl-4-yl-N-hydroxy-N-methyl-acrylamide	Investigative
T00140	DRUGINFO	D02YPE	1,2-Dihydroxy-10H-anthracen-9-one	Investigative
T00140	DRUGINFO	D03QNE	BW A360C	Investigative
T00140	DRUGINFO	D04IFV	5-Methyl-2-p-tolyl-thiazol-4-ol	Investigative
T00140	DRUGINFO	D04MBD	1,8-Dichloro-10H-anthracen-9-one	Investigative
T00140	DRUGINFO	D04RQG	1-Benzyl-1,2-dihydro-indazol-3-one	Investigative
T00140	DRUGINFO	D04UJI	Naphthalene-2-carboxylic acid hydroxyamide	Investigative
T00140	DRUGINFO	D04XPJ	Biphenyl-4-carboxylic acid hydroxyamide	Investigative
T00140	DRUGINFO	D04ZGR	Phenanthrene-3-carboxylic acid hydroxyamide	Investigative
T00140	DRUGINFO	D05GZI	N-(4-Ethylphenyl)benzo[d]oxazol-2-amine	Investigative
T00140	DRUGINFO	D05KCN	2-Pyridin-2-ylmethyl-1,2-dihydro-indazol-3-one	Investigative
T00140	DRUGINFO	D05PHI	2-(4-Methoxy-phenyl)-5-phenyl-thiazol-4-ol	Investigative
T00140	DRUGINFO	D05QBX	Biphenyl-3-carboxylic acid hydroxyamide	Investigative
T00140	DRUGINFO	D05RIE	3-Benzoyl-N-hydroxy-benzamide	Investigative
T00140	DRUGINFO	D06AFD	N-Hydroxy-3-naphthalen-2-yl-N-p-tolyl-acrylamide	Investigative
T00140	DRUGINFO	D06CWX	1-Hydroxy-8-methoxy-10H-anthracen-9-one	Investigative
T00140	DRUGINFO	D06GRW	N-Hydroxy-N-methyl-2,3,3-triphenyl-acrylamide	Investigative
T00140	DRUGINFO	D06KQD	N-Hydroxy-N-methyl-3-naphthalen-2-yl-propionamide	Investigative
T00140	DRUGINFO	D06MUA	N-Hydroxy-4-iodo-benzamide	Investigative
T00140	DRUGINFO	D06TPF	PYROGALLOL	Investigative
T00140	DRUGINFO	D06XYZ	10-Benzoyl-1,8-dihydroxy-10H-anthracen-9-one	Investigative
T00140	DRUGINFO	D07LMV	SK&F 107649	Investigative
T00140	DRUGINFO	D07MYE	N-Hydroxy-3-phenyl-acrylamide	Investigative
T00140	DRUGINFO	D07OKS	1,8,9-Trimethoxy-9,10-dihydro-anthracene	Investigative
T00140	DRUGINFO	D07PCS	N-Hydroxy-N-methyl-2-naphthalen-2-yl-propionamide	Investigative
T00140	DRUGINFO	D07XMM	N-(4-Ethylphenyl)-5-methylbenzo[d]oxazol-2-amine	Investigative
T00140	DRUGINFO	D08BNV	4,5-Dimethoxy-10H-anthracen-9-one	Investigative
T00140	DRUGINFO	D08FPY	10-Acetyl-1,8-dihydroxy-10H-anthracen-9-one	Investigative
T00140	DRUGINFO	D08HFK	5-Chloro-N-phenylbenzo[d]oxazol-2-amine	Investigative
T00140	DRUGINFO	D08MCE	2-(4-Phenyl-butyl)-1,2-dihydro-indazol-3-one	Investigative
T00140	DRUGINFO	D08NDV	4-(1H-indol-3-yl)-1-morpholinobutan-1-one	Investigative
T00140	DRUGINFO	D08UXT	3-(4-Butoxy-phenyl)-N-hydroxy-N-methyl-acrylamide	Investigative
T00140	DRUGINFO	D09PDD	N-Hydroxy-3-naphthalen-2-yl-acrylamide	Investigative
T00140	DRUGINFO	D09WYM	3-Biphenyl-3-yl-N-hydroxy-N-methyl-acrylamide	Investigative
T00140	DRUGINFO	D0A2QP	N-Hydroxy-N-methyl-benzamide	Investigative
T00140	DRUGINFO	D0A9HL	1-Methyl-1,2-dihydro-indazol-3-one	Investigative
T00140	DRUGINFO	D0B0XK	1-furan-2-yl-3-pyridin-2-yl-propenone (FPP-3)	Investigative
T00140	DRUGINFO	D0C1XI	Acetic acid 2-phenyl-5-propyl-thiazol-4-yl ester	Investigative
T00140	DRUGINFO	D0C4KD	N-(3-Bromophenyl)-5-methoxybenzo[d]oxazol-2-amine	Investigative
T00140	DRUGINFO	D0C6BU	ANTHRONE	Investigative
T00140	DRUGINFO	D0C7GT	N-Hydroxy-N-methyl-3-phenanthren-2-yl-acrylamide	Investigative
T00140	DRUGINFO	D0CT9V	Anthracene-2-carboxylic acid hydroxyamide	Investigative
T00140	DRUGINFO	D0DP9F	Phenanthrene-2-carboxylic acid hydroxyamide	Investigative
T00140	DRUGINFO	D0E1NK	N-Hydroxy-N-methyl-3-phenanthren-3-yl-acrylamide	Investigative
T00140	DRUGINFO	D0E3CO	N-(2-Ethylphenyl)-5-methylbenzo[d]oxazol-2-amine	Investigative
T00140	DRUGINFO	D0E4JU	N-Hydroxy-N-methyl-3-naphthalen-2-yl-acrylamide	Investigative
T00140	DRUGINFO	D0F1ZE	2-Naphthalen-1-ylmethyl-1,2-dihydro-indazol-3-one	Investigative
T00140	DRUGINFO	D0F4HT	ICI-211965	Investigative
T00140	DRUGINFO	D0G3VE	Acetic acid 5-butyl-2-phenyl-thiazol-4-yl ester	Investigative
T00140	DRUGINFO	D0H4MV	5-Methyl-N-phenylbenzo[d]oxazol-2-amine	Investigative
T00140	DRUGINFO	D0H6JC	1,2-Dihydro-indazol-3-one	Investigative
T00140	DRUGINFO	D0H7UQ	N-Hydroxy-3-naphthalen-2-yl-propionamide	Investigative
T00140	DRUGINFO	D0HZ9X	2-Pyridin-3-ylmethyl-1,2-dihydro-indazol-3-one	Investigative
T00140	DRUGINFO	D0I9RY	N-Hydroxy-2-methyl-3-naphthalen-2-yl-acrylamide	Investigative
T00140	DRUGINFO	D0IF2H	2-(4-Butoxy-phenyl)-N-hydroxy-N-methyl-acetamide	Investigative
T00140	DRUGINFO	D0J5OV	Chebulagic acid	Investigative
T00140	DRUGINFO	D0J7AM	4-Bromo-N-hydroxy-benzamide	Investigative
T00140	DRUGINFO	D0K3AO	CYLINDOL A	Investigative
T00140	DRUGINFO	D0K7XU	N-Hydroxy-4-naphthalen-2-yl-benzamide	Investigative
T00140	DRUGINFO	D0KB6Q	N-Hydroxy-2-naphthalen-2-yl-acetamide	Investigative
T00140	DRUGINFO	D0L3BQ	N-Hydroxy-4-isobutyl-benzamide	Investigative
T00140	DRUGINFO	D0M6UM	BW-A137C	Investigative
T00140	DRUGINFO	D0N6CN	2-(4-Butoxy-phenoxy)-N-hydroxy-propionamide	Investigative
T00140	DRUGINFO	D0O6OJ	N-Hydroxy-N-methyl-3-phenanthren-9-yl-acrylamide	Investigative
T00140	DRUGINFO	D0O7SM	BUDDLEDIN A	Investigative
T00140	DRUGINFO	D0P8IX	1-Hydroxy-10H-anthracen-9-one	Investigative
T00140	DRUGINFO	D0PD7X	2'-Nitro-biphenyl-4-carboxylic acid hydroxyamide	Investigative
T00140	DRUGINFO	D0PU1J	BW B218C	Investigative
T00140	DRUGINFO	D0R1ER	2-(1H-Indol-3-ylmethyl)-1,2-dihydro-indazol-3-one	Investigative
T00140	DRUGINFO	D0R2MQ	BW-858C	Investigative
T00140	DRUGINFO	D0R2XE	4-Pentadeca-1,3,6-trienylsulfanyl-butyric acid	Investigative
T00140	DRUGINFO	D0S6XY	4,5-Dihydroxy-10H-anthracen-9-one	Investigative
T00140	DRUGINFO	D0S8UP	3,4-Dihydroxy-10H-anthracen-9-one	Investigative
T00140	DRUGINFO	D0T0CY	2-(4-Butoxy-phenoxy)-N-hydroxy-N-methyl-acetamide	Investigative
T00140	DRUGINFO	D0T1HY	N-Hydroxy-3-naphthalen-2-yl-N-phenyl-acrylamide	Investigative
T00140	DRUGINFO	D0T8TS	Hexanoic acid 2,5-diphenyl-thiazol-4-yl ester	Investigative
T00140	DRUGINFO	D0U2YL	CGS-23885	Investigative
T00140	DRUGINFO	D0U9UL	5-Chloro-N-(4-ethylphenyl)benzo[d]oxazol-2-amine	Investigative
T00140	DRUGINFO	D0V8UV	N-Hydroxy-N-methyl-3-naphthalen-1-yl-acrylamide	Investigative
T00140	DRUGINFO	D0WW1K	2-(4-hydroxylphenyl)-3-(3,5-dihydroxylphenyl) propenoic acid (NNU-hdpa)	Investigative
T00140	DRUGINFO	D0X8BS	2-(4-Butoxy-phenoxy)-N-hydroxy-acetamide	Investigative
T00140	DRUGINFO	D0X9RM	2-Thiophen-2-ylmethyl-1,2-dihydro-indazol-3-one	Investigative
T00140	DRUGINFO	D0XL5D	5-Methoxy-N-phenylbenzo[d]oxazol-2-amine	Investigative
T00140	DRUGINFO	D0XQ8P	2-Thiazol-5-ylmethyl-1,2-dihydro-indazol-3-one	Investigative
T00140	DRUGINFO	D0Y0KF	1,5-Dihydroxy-10H-anthracen-9-one	Investigative
T00140	DRUGINFO	D0Z0ZM	SB-202235	Investigative
T00140	DRUGINFO	D0Z5XD	2-Pyridin-4-ylmethyl-1,2-dihydro-indazol-3-one	Investigative
T00140	DRUGINFO	D03HNC	N-hydroxy-4-(naphthalen-1-yl)benzamide	Investigative
T00140	DRUGINFO	D09CXQ	Acanthus ilicifolius Linn	Investigative
T00140	DRUGINFO	D0AS0V	5,8-Dihydroxy-1,4-naphthoquinone	Investigative
T00140	DRUGINFO	D0K7XQ	N-hydroxy-N-[1-(4-isobutylphenyl)ethyl]urea	Investigative
T00140	DRUGINFO	D02COM	7-tert-butyl-2, 3-dihydro-3, 3-dimethyl substituted dihydrofuran 30 (DHDMBF30)	Investigative
T00140	DRUGINFO	D06HUQ	2-Phenethyl-1,2-dihydro-indazol-3-one	Investigative
T00140	DRUGINFO	D07CJR	5S-HETE	Investigative
T00140	DRUGINFO	D09VTJ	Hyperforin	Investigative
T00140	DRUGINFO	D0J7YU	2-Benzyl-1,2-dihydro-indazol-3-one	Investigative
T00140	DRUGINFO	D0L4TM	2-(3-Phenyl-propyl)-1,2-dihydro-indazol-3-one	Investigative
T00140	DRUGINFO	D0NS1S	ACACETIN	Investigative
T00140	DRUGINFO	D0P1LP	PHENIDONE	Investigative
T00140	DRUGINFO	D0S0PB	2-Phenyl-1,2-dihydro-indazol-3-one	Investigative
T00140	DRUGINFO	D0SJ3W	2-Furan-2-ylmethyl-1,2-dihydro-indazol-3-one	Investigative
T00140	DRUGINFO	D0U8CM	2-Methyl-1,2-dihydro-indazol-3-one	Investigative
T00140	DRUGINFO	D0X6SA	2-Naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one	Investigative
T00140	DRUGINFO	D0UU1I	Heme	Investigative

T57700	TARGETID	T57700
T57700	FORMERID	TTDS00270
T57700	UNIPROID	KIT_HUMAN
T57700	TARGNAME	Tyrosine-protein kinase Kit (KIT)
T57700	GENENAME	KIT
T57700	TARGTYPE	Successful
T57700	SYNONYMS	v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; p145 c-kit; Proto-oncogene tyrosine-protein kinase Kit; Proto-oncogene c-Kit; Piebald trait protein; PBT; Mast/stem cell growth factor receptor Kit; CD117 antigen; CD117; C-kit
T57700	FUNCTION	In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1, SH2B2/APS and CBL. Activates the AKT1 signaling pathway by phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Activated KIT also transmits signals via GRB2 and activation of RAS, RAF1 and the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3, STAT5A and STAT5B. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. KIT signaling is modulated by protein phosphatases, and by rapid internalization and degradation of the receptor. Activated KIT promotes phosphorylation of the protein phosphatases PTPN6/SHP-1 and PTPRU, and of the transcription factors STAT1, STAT3, STAT5A and STAT5B. Promotes phosphorylation of PIK3R1, CBL, CRK (isoform Crk-II), LYN, MAPK1/ERK2 and/or MAPK3/ERK1, PLCG1, SRC and SHC1. Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis.
T57700	PDBSTRUC	6GQM; 6GQL; 6GQK; 6GQJ; 4U0I
T57700	BIOCLASS	Kinase
T57700	ECNUMBER	EC 2.7.10.1
T57700	SEQUENCE	MRGARGAWDFLCVLLLLLRVQTGSSQPSVSPGEPSPPSIHPGKSDLIVRVGDEIRLLCTDPGFVKWTFEILDETNENKQNEWITEKAEATNTGKYTCTNKHGLSNSIYVFVRDPAKLFLVDRSLYGKEDNDTLVRCPLTDPEVTNYSLKGCQGKPLPKDLRFIPDPKAGIMIKSVKRAYHRLCLHCSVDQEGKSVLSEKFILKVRPAFKAVPVVSVSKASYLLREGEEFTVTCTIKDVSSSVYSTWKRENSQTKLQEKYNSWHHGDFNYERQATLTISSARVNDSGVFMCYANNTFGSANVTTTLEVVDKGFINIFPMINTTVFVNDGENVDLIVEYEAFPKPEHQQWIYMNRTFTDKWEDYPKSENESNIRYVSELHLTRLKGTEGGTYTFLVSNSDVNAAIAFNVYVNTKPEILTYDRLVNGMLQCVAAGFPEPTIDWYFCPGTEQRCSASVLPVDVQTLNSSGPPFGKLVVQSSIDSSAFKHNGTVECKAYNDVGKTSAYFNFAFKGNNKEQIHPHTLFTPLLIGFVIVAGMMCIIVMILTYKYLQKPMYEVQWKVVEEINGNNYVYIDPTQLPYDHKWEFPRNRLSFGKTLGAGAFGKVVEATAYGLIKSDAAMTVAVKMLKPSAHLTEREALMSELKVLSYLGNHMNIVNLLGACTIGGPTLVITEYCCYGDLLNFLRRKRDSFICSKQEDHAEAALYKNLLHSKESSCSDSTNEYMDMKPGVSYVVPTKADKRRSVRIGSYIERDVTPAIMEDDELALDLEDLLSFSYQVAKGMAFLASKNCIHRDLAARNILLTHGRITKICDFGLARDIKNDSNYVVKGNARLPVKWMAPESIFNCVYTFESDVWSYGIFLWELFSLGSSPYPGMPVDSKFYKMIKEGFRMLSPEHAPAEMYDIMKTCWDADPLKRPTFKQIVQLIEKQISESTNHIYSNLANCSPNRQKPVVDHSVRINSVGSTASSSQPLLVHDDV
T57700	DRUGINFO	D09AAK	Ripretinib	Approved
T57700	DRUGINFO	D09GDD	Regorafenib	Approved
T57700	DRUGINFO	D09TAB	Pexidartinib	Approved
T57700	DRUGINFO	D0F0ZY	Pazopanib HCl	Approved
T57700	DRUGINFO	D0AZ3C	Imatinib	Approved
T57700	DRUGINFO	D0H0EQ	Ponatinib	Approved
T57700	DRUGINFO	D0W5HK	Sorafenib	Approved
T57700	DRUGINFO	D01PZD	Romiplostim	Approved
T57700	DRUGINFO	D0T1GF	MP470	Phase 2
T57700	DRUGINFO	D00NSD	XL-820	Phase 2
T57700	DRUGINFO	D0Z6MT	Famitinib	Phase 2
T57700	DRUGINFO	D03MDY	PLX9486	Phase 1/2
T57700	DRUGINFO	DB8G4D	JSP191	Phase 1/2
T57700	DRUGINFO	D05CFQ	AMG-191	Phase 1
T57700	DRUGINFO	D0E0SH	CART-117 cells	Phase 1
T57700	DRUGINFO	D0N8RV	OSI-930	Phase 1
T57700	DRUGINFO	D0D3FB	PMID25656651-Compound-21a	Patented
T57700	DRUGINFO	D0XQ5F	PMID25656651-Compound-21b	Patented
T57700	DRUGINFO	D0NB1V	Pyridine derivative 20	Patented
T57700	DRUGINFO	D0O0AW	Pyridine derivative 21	Patented
T57700	DRUGINFO	D0O4TA	Pyridine derivative 22	Patented
T57700	DRUGINFO	D0T7BE	Pyridine derivative 19	Patented
T57700	DRUGINFO	D0AK1F	Pyridine derivative 18	Patented
T57700	DRUGINFO	D00DQX	Motesanib	Discontinued in Phase 3
T57700	DRUGINFO	D0TS2B	CAR-T cells targeting CD117	Preclinical
T57700	DRUGINFO	D03SGF	WBZ-7	Investigative
T57700	DRUGINFO	D08ZWJ	9-Bromo-5,11-dimethyl-6H-pyrido[4,3-b]carbazole	Investigative
T57700	DRUGINFO	D0T2UB	APCK-110	Investigative
T57700	DRUGINFO	D0T4SL	9-Methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazole	Investigative
T57700	DRUGINFO	D0BL0O	PMID23521020C7k	Investigative
T57700	DRUGINFO	D0T5OS	Phosphonotyrosine	Investigative
T57700	DRUGINFO	D05FFB	5,11-Dimethyl-6H-pyrido[4,3-b]carbazol-9-ol	Investigative
T57700	DRUGINFO	D05QBZ	CP-673451	Investigative
T57700	DRUGINFO	D0Y9GK	4-(4-aminophenyl)-1H-indazol-3yl-amine	Investigative
T57700	DRUGINFO	D08BJR	Ki-20227	Investigative
T57700	DRUGINFO	D0N7AJ	AST-487	Investigative
T57700	DRUGINFO	D0UN9O	GTP-14564	Investigative
T57700	DRUGINFO	D0I3XZ	Bis-(5-hydroxy-1H-indol-2-yl)-methanone	Investigative
T57700	DRUGINFO	D0Y4BL	JNJ-28312141	Investigative
T57700	DRUGINFO	D0GW4Q	PD-0173956	Investigative
T57700	DRUGINFO	D0P3JW	PD-0166326	Investigative
T57700	DRUGINFO	D0C2GE	PMID22765894C8h	Investigative

T85943	TARGETID	T85943
T85943	FORMERID	TTDS00247
T85943	UNIPROID	SRC_HUMAN
T85943	TARGNAME	Proto-oncogene c-Src (SRC)
T85943	GENENAME	SRC
T85943	TARGTYPE	Successful
T85943	SYNONYMS	pp60c-src; Tyrosine kinase (pp60(src)); Src tyrosine kinase; SRC1; Proto-oncogene tyrosine-protein kinase Src; Pp60(src); P60-Src; C-src TK; C-Src
T85943	FUNCTION	Participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription, immune response, cell adhesion, cell cycle progression, apoptosis, migration, and transformation. Due to functional redundancy between members of the SRC kinase family, identification of the specific role of each SRC kinase is very difficult. SRC appears to be one of the primary kinases activated following engagement of receptors and plays a role in the activation of other protein tyrosine kinase (PTK) families. Receptor clustering or dimerization leads to recruitment of SRC to the receptor complexes where it phosphorylates the tyrosine residues within the receptor cytoplasmic domains. Plays an important role in the regulation of cytoskeletal organization through phosphorylation of specific substrates such as AFAP1. Phosphorylation of AFAP1 allows the SRC SH2 domain to bind AFAP1 and to localize to actin filaments. Cytoskeletal reorganization is also controlled through the phosphorylation of cortactin (CTTN). When cells adhere via focal adhesions to the extracellular matrix, signals are transmitted by integrins into the cell resulting in tyrosine phosphorylation of a number of focal adhesion proteins, including PTK2/FAK1 and paxillin (PXN). In addition to phosphorylating focal adhesion proteins, SRC is also active at the sites of cell-cell contact adherens junctions and phosphorylates substrates such as beta-catenin (CTNNB1), delta-catenin (CTNND1), and plakoglobin (JUP). Another type of cell-cell junction, the gap junction, is also a target for SRC, which phosphorylates connexin-43 (GJA1). SRC is implicated in regulation of pre-mRNA-processing and phosphorylates RNA-binding proteins such as KHDRBS1. Also plays a role in PDGF-mediated tyrosine phosphorylation of both STAT1 and STAT3, leading to increased DNA binding activity of these transcription factors. Involved in the RAS pathway through phosphorylation of RASA1 and RASGRF1. Plays a role in EGF-mediated calcium-activated chloride channel activation. Required for epidermal growth factor receptor (EGFR) internalization through phosphorylation of clathrin heavy chain (CLTC and CLTCL1) at 'Tyr-1477'. Involved in beta-arrestin (ARRB1 and ARRB2) desensitization through phosphorylation and activation of GRK2, leading to beta-arrestin phosphorylation and internalization. Has a critical role in the stimulation of the CDK20/MAPK3 mitogen-activated protein kinase cascade by epidermal growth factor. Might be involved not only in mediating the transduction of mitogenic signals at the level of the plasma membrane but also in controlling progression through the cell cycle via interaction with regulatory proteins in the nucleus. Plays an important role in osteoclastic bone resorption in conjunction with PTK2B/PYK2. Both the formation of a SRC-PTK2B/PYK2 complex and SRC kinase activity are necessary for this function. Recruited to activated integrins by PTK2B/PYK2, thereby phosphorylating CBL, which in turn induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function. Promotes energy production in osteoclasts by activating mitochondrial cytochrome C oxidase. Phosphorylates DDR2 on tyrosine residues, thereby promoting its subsequent autophosphorylation. Phosphorylates RUNX3 and COX2 on tyrosine residues, TNK2 on 'Tyr-284' and CBL on 'Tyr-731'. Enhances DDX58/RIG-I-elicited antiviral signaling. Phosphorylates PDPK1 at 'Tyr-9', 'Tyr-373' and 'Tyr-376'. Phosphorylates BCAR1 at 'Tyr-128'. Phosphorylates CBLC at multiple tyrosine residues, phosphorylation at 'Tyr-341' activates CBLC E3 activity. Involved in anchorage-independent cell growth. Required for podosome formation. Non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion receptors, receptor protein tyrosine kinases, G protein-coupled receptors as well as cytokine receptors.
T85943	PDBSTRUC	6EHJ; 6C4S; 6ATE; 4MXZ; 4MXY
T85943	BIOCLASS	Kinase
T85943	ECNUMBER	EC 2.7.10.2
T85943	SEQUENCE	MGSNKSKPKDASQRRRSLEPAENVHGAGGGAFPASQTPSKPASADGHRGPSAAFAPAAAEPKLFGGFNSSDTVTSPQRAGPLAGGVTTFVALYDYESRTETDLSFKKGERLQIVNNTEGDWWLAHSLSTGQTGYIPSNYVAPSDSIQAEEWYFGKITRRESERLLLNAENPRGTFLVRESETTKGAYCLSVSDFDNAKGLNVKHYKIRKLDSGGFYITSRTQFNSLQQLVAYYSKHADGLCHRLTTVCPTSKPQTQGLAKDAWEIPRESLRLEVKLGQGCFGEVWMGTWNGTTRVAIKTLKPGTMSPEAFLQEAQVMKKLRHEKLVQLYAVVSEEPIYIVTEYMSKGSLLDFLKGETGKYLRLPQLVDMAAQIASGMAYVERMNYVHRDLRAANILVGENLVCKVADFGLARLIEDNEYTARQGAKFPIKWTAPEAALYGRFTIKSDVWSFGILLTELTTKGRVPYPGMVNREVLDQVERGYRMPCPPECPESLHDLMCQCWRKEPEERPTFEYLQAFLEDYFTSTEPQYQPGENL
T85943	DRUGINFO	D07DIM	Herbimycin A	Approved
T85943	DRUGINFO	D0OB0F	Bosutinib	Approved
T85943	DRUGINFO	D03MNN	SKI-758	Approved
T85943	DRUGINFO	D0E6XR	Dasatinib	Approved
T85943	DRUGINFO	D0G2CG	AL3818	Phase 3
T85943	DRUGINFO	D0TY3L	KX-01	Phase 3
T85943	DRUGINFO	D0J1GR	CP-868596	Phase 3
T85943	DRUGINFO	D0MW0N	Masitinib	Phase 3
T85943	DRUGINFO	D0M0XB	Saracatinib	Phase 2
T85943	DRUGINFO	DS7CY4	TPX-0046	Phase 1/2
T85943	DRUGINFO	D05YEI	SUN-K0706	Phase 1
T85943	DRUGINFO	D0RE4L	KX2-361	Phase 1
T85943	DRUGINFO	D7M8LI	TPX-0022	Phase 1
T85943	DRUGINFO	DG2EK3	PUR1800	Phase 1
T85943	DRUGINFO	D06CIJ	ISIS-CRP	Phase 1
T85943	DRUGINFO	D02VDD	Deuterated 3-cyanoquinoline derivative 1	Patented
T85943	DRUGINFO	D07QBF	PMID28460551-Compound-6	Patented
T85943	DRUGINFO	D09RTW	Aromatic bicyclic compound 6	Patented
T85943	DRUGINFO	D0M5AG	Aromatic bicyclic compound 3	Patented
T85943	DRUGINFO	D0M9YZ	Aromatic bicyclic compound 4	Patented
T85943	DRUGINFO	D0Q5JV	Aromatic bicyclic compound 5	Patented
T85943	DRUGINFO	D0QD5Y	Aromatic bicyclic compound 1	Patented
T85943	DRUGINFO	D0VI7E	Aromatic bicyclic compound 2	Patented
T85943	DRUGINFO	D0AK1F	Pyridine derivative 18	Patented
T85943	DRUGINFO	D09WPN	AP22408	Terminated
T85943	DRUGINFO	D0H8KG	PD166285	Terminated
T85943	DRUGINFO	D00JID	Ac-Cys-Ile-Tyr-Lys-Phe(4-Cl)-Tyr	Investigative
T85943	DRUGINFO	D00TVY	Glu-Pro-Gln-F2Pmp-Glu-Glu-Ile-Pro-Ile-Tyr-Leu	Investigative
T85943	DRUGINFO	D01IDD	BAS-4844343	Investigative
T85943	DRUGINFO	D01IZN	Y-c[D-Pen-(2')Nal-GSFC]KR-NH2	Investigative
T85943	DRUGINFO	D01JJR	RU90395	Investigative
T85943	DRUGINFO	D02HOG	RU78300	Investigative
T85943	DRUGINFO	D02IYN	RU82129	Investigative
T85943	DRUGINFO	D02SRA	Y-c[D-Pen-D-(2')Nal-GSFC]KR-NH2	Investigative
T85943	DRUGINFO	D02TIO	RU85053	Investigative
T85943	DRUGINFO	D03DEX	N6-Benzyl Adenosine-5'-Diphosphate	Investigative
T85943	DRUGINFO	D03NCK	RU82197	Investigative
T85943	DRUGINFO	D03OKV	BMS-279700	Investigative
T85943	DRUGINFO	D03XDN	PD-174265	Investigative
T85943	DRUGINFO	D04QEW	Ac-Cys-Ile-Tyr-Lys-Phe(4-I)-Tyr	Investigative
T85943	DRUGINFO	D05GYO	RU85493	Investigative
T85943	DRUGINFO	D05YQC	ISO24	Investigative
T85943	DRUGINFO	D06CYG	Glu-Pro-Gln-pTyr-Glu-Glu-Ile-Pro-Ile-Tyr-Leu	Investigative
T85943	DRUGINFO	D06MYD	Ac-Cys-Ile-Tyr-Lys-Phe(4-NO2)-Phe(4-NO2)	Investigative
T85943	DRUGINFO	D06QUQ	CGP 77675	Investigative
T85943	DRUGINFO	D07HBR	PAS219	Investigative
T85943	DRUGINFO	D07RQB	7-(naphthalen-2-yl)benzo[e][1,2,4]triazin-3-amine	Investigative
T85943	DRUGINFO	D08AWZ	Ac-Cys-Ile-Phe(4-NO2)-Lys-Phe(4-NO2)-Tyr	Investigative
T85943	DRUGINFO	D08WEV	BAS-0338868	Investigative
T85943	DRUGINFO	D08YUQ	Ac-Cys-Ile-Tyr-Lys-Phe(4-N3)-Tyr	Investigative
T85943	DRUGINFO	D09DVB	Y-c[D-Pen-(2R,3R)-2-Me-(2')Nal-GSFC]KR-NH2	Investigative
T85943	DRUGINFO	D09NGN	RU79256	Investigative
T85943	DRUGINFO	D09WNM	PASBN	Investigative
T85943	DRUGINFO	D0A5IW	Ac-Cys-Ile-Phe(4-NO2)-Lys-Tyr-Tyr	Investigative
T85943	DRUGINFO	D0AJ4T	RU78262	Investigative
T85943	DRUGINFO	D0B4PI	Y-c[D-Pen-(2R,3S)-2-Me-(2')Nal-GSFC]KR-NH2	Investigative
T85943	DRUGINFO	D0BU6T	CGP-62464	Investigative
T85943	DRUGINFO	D0D1FK	RU78299	Investigative
T85943	DRUGINFO	D0D9PD	SKS-927	Investigative
T85943	DRUGINFO	D0GN1A	Ac-Cys-Ile-Tyr-Lys-Phe(4-NO2)-Tyr-Phe	Investigative
T85943	DRUGINFO	D0H3XF	5,7-Diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ol	Investigative
T85943	DRUGINFO	D0J4RY	BAS-450225	Investigative
T85943	DRUGINFO	D0K9TT	Ac-Cys-Ile-cyclo[Phe-Lys]-Tyr-Tyr	Investigative
T85943	DRUGINFO	D0KS2T	RU81843	Investigative
T85943	DRUGINFO	D0L4NP	RU84687	Investigative
T85943	DRUGINFO	D0LK4J	Ac-Cys-Ile-Tyr-Lys-Tyr-Phe(4-NO2)	Investigative
T85943	DRUGINFO	D0LP2M	BAS-01047655	Investigative
T85943	DRUGINFO	D0M5RA	RU78783	Investigative
T85943	DRUGINFO	D0M9QM	CGP-191	Investigative
T85943	DRUGINFO	D0MI2W	Cyclo[Ac-Cys-Ile-Tyr-Lys-Tyr-Tyr]	Investigative
T85943	DRUGINFO	D0N4FS	DPI59	Investigative
T85943	DRUGINFO	D0O8BX	Ac-Cys-Ile-Tyr-Lys-Phe(4-CN)-Tyr	Investigative
T85943	DRUGINFO	D0OB0M	Cyclo[Ac-Cys-Ile-Tyr-Lys-Tyr-Phe]	Investigative
T85943	DRUGINFO	D0OG1Q	4-Chloro-5,7-diphenyl-7H-pyrrolo[2,3-d]pyrimidine	Investigative
T85943	DRUGINFO	D0P2QG	BAS-01047341	Investigative
T85943	DRUGINFO	D0P5ST	3-(3-aminobenzo[e][1,2,4]triazin-7-yl)phenol	Investigative
T85943	DRUGINFO	D0Q2UZ	Y-c[D-Pen-(2S,3R)-2-Me-(2')Nal-GSFC]KR-NH2	Investigative
T85943	DRUGINFO	D0R1PD	RU83876	Investigative
T85943	DRUGINFO	D0R2AT	2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE	Investigative
T85943	DRUGINFO	D0R7BX	RU78191	Investigative
T85943	DRUGINFO	D0S3FW	N-Phenyl-5-phenylimidazo[1,5-a]pyrazin-8-amine	Investigative
T85943	DRUGINFO	D0S9LT	Phenylphosphate	Investigative
T85943	DRUGINFO	D0TC1E	RU82209	Investigative
T85943	DRUGINFO	D0U1BA	Ac-Cys-Ile-Phe(4-NO2)-Lys-Tyr-Phe(4-NO2)	Investigative
T85943	DRUGINFO	D0U5KF	RU79073	Investigative
T85943	DRUGINFO	D0U7BY	Oxalic Acid	Investigative
T85943	DRUGINFO	D0U8UH	RU79072	Investigative
T85943	DRUGINFO	D0W6WU	Cyclo[Ac-Cys-Ile-Phe]-Lys-Tyr-Tyr	Investigative
T85943	DRUGINFO	D0W7LW	Y-c[D-Pen-(2S,3S)-2-Me-(2')Nal-GSFC]KR-NH2	Investigative
T85943	DRUGINFO	D01GNF	BAS-00387328	Investigative
T85943	DRUGINFO	D03GQI	BAS-00387347	Investigative
T85943	DRUGINFO	D03YUW	SBB007833	Investigative
T85943	DRUGINFO	D04QUI	BAS-00387275	Investigative
T85943	DRUGINFO	D06WGX	A-770041	Investigative
T85943	DRUGINFO	D07ERV	Y-c[D-Pen-(3,5-diI)Tyr-GSFC]KR-NH2	Investigative
T85943	DRUGINFO	D07LYJ	BAS-00672722	Investigative
T85943	DRUGINFO	D09QKH	BAS-0338872	Investigative
T85943	DRUGINFO	D0A2LX	Y-c[D-Pen-(3-I)Tyr-GSFC]KR-NH2	Investigative
T85943	DRUGINFO	D0A5MG	BAS-09534324	Investigative
T85943	DRUGINFO	D0D3RL	AP-24163	Investigative
T85943	DRUGINFO	D0D8OY	AP-24226	Investigative
T85943	DRUGINFO	D0D8ZN	BAS-01373578	Investigative
T85943	DRUGINFO	D0N8TQ	N-(4-(phenylamino)quinazolin-6-yl)acrylamide	Investigative
T85943	DRUGINFO	D0T5OS	Phosphonotyrosine	Investigative
T85943	DRUGINFO	D0Y1SR	WH-4-023	Investigative
T85943	DRUGINFO	D0BS6R	A-420983	Investigative
T85943	DRUGINFO	D0Q7TO	K00244	Investigative
T85943	DRUGINFO	D0VF6E	PD173074	Investigative
T85943	DRUGINFO	D0V6UC	Cysteine Sulfenic Acid	Investigative
T85943	DRUGINFO	D0CE3R	SU 6656	Investigative
T85943	DRUGINFO	D0GT8N	NM-PP1	Investigative
T85943	DRUGINFO	D0OH3J	PD-0179483	Investigative
T85943	DRUGINFO	D0S1KJ	PD-0173952	Investigative
T85943	DRUGINFO	D0X7IC	NG-25	Investigative
T85943	DRUGINFO	D0Z7GH	PD-0173958	Investigative
T85943	DRUGINFO	D03NPX	PD-0173955	Investigative
T85943	DRUGINFO	D0YZ7H	JNJ-10198409	Investigative
T85943	DRUGINFO	D08RZB	PMID15546730C2	Investigative
T85943	DRUGINFO	D0D5EW	HKI-9924129	Investigative
T85943	DRUGINFO	D0GW4Q	PD-0173956	Investigative
T85943	DRUGINFO	D0H1OK	TG-100435	Investigative
T85943	DRUGINFO	D0P3JW	PD-0166326	Investigative
T85943	DRUGINFO	D03EHM	PP121	Investigative
T85943	DRUGINFO	D0C2GE	PMID22765894C8h	Investigative

T51408	TARGETID	T51408
T51408	FORMERID	TTDC00184
T51408	UNIPROID	ADRB3_HUMAN
T51408	TARGNAME	Adrenergic receptor beta-3 (ADRB3)
T51408	GENENAME	ADRB3
T51408	TARGTYPE	Successful
T51408	SYNONYMS	Beta3AR; Beta3-AR; Beta-3 adrenoreceptor; Beta-3 adrenoceptor; Beta-3 adrenergic receptor; B3AR; ADRB3R
T51408	FUNCTION	Beta-3 is involved in the regulation of lipolysis and thermogenesis. Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins.
T51408	PDBSTRUC	2CDW
T51408	BIOCLASS	GPCR rhodopsin
T51408	SEQUENCE	MAPWPHENSSLAPWPDLPTLAPNTANTSGLPGVPWEAALAGALLALAVLATVGGNLLVIVAIAWTPRLQTMTNVFVTSLAAADLVMGLLVVPPAATLALTGHWPLGATGCELWTSVDVLCVTASIETLCALAVDRYLAVTNPLRYGALVTKRCARTAVVLVWVVSAAVSFAPIMSQWWRVGADAEAQRCHSNPRCCAFASNMPYVLLSSSVSFYLPLLVMLFVYARVFVVATRQLRLLRGELGRFPPEESPPAPSRSLAPAPVGTCAPPEGVPACGRRPARLLPLREHRALCTLGLIMGTFTLCWLPFFLANVLRALGGPSLVPGPAFLALNWLGYANSAFNPLIYCRSPDFRSAFRRLLCRCGRRLPPEPCAAARPALFPSGVPAARSSPAQPRLCQRLDGASWGVS
T51408	DRUGINFO	D03NOS	Rimiterol	Approved
T51408	DRUGINFO	D06RUL	Bitolterol	Approved
T51408	DRUGINFO	D09SSC	Nipradilol	Approved
T51408	DRUGINFO	D0DH5X	Vibegron	Approved
T51408	DRUGINFO	D0H5MB	Bopindolol	Approved
T51408	DRUGINFO	D0O5YZ	Mepindolol	Approved
T51408	DRUGINFO	D0X5UN	Mirabegron	Approved
T51408	DRUGINFO	D09GFL	Trihexyphenidyl	Approved
T51408	DRUGINFO	D0D0YM	Amosulalol	Approved
T51408	DRUGINFO	D00GZW	ONO-2506	Phase 2/3
T51408	DRUGINFO	D00NNI	ASP-3652	Phase 2
T51408	DRUGINFO	D01VAP	YM-430	Phase 2
T51408	DRUGINFO	D03FLT	CP-331684	Phase 2
T51408	DRUGINFO	D06UKG	LY-377604	Phase 2
T51408	DRUGINFO	D09PYV	AZ-40140	Phase 2
T51408	DRUGINFO	D0A5EF	GW-427353	Phase 2
T51408	DRUGINFO	D0D1FC	LY-362884	Phase 2
T51408	DRUGINFO	D0U7HL	N-5984	Phase 2
T51408	DRUGINFO	D0V9IE	ZD2079	Phase 2
T51408	DRUGINFO	DFS18G	APD418	Phase 2
T51408	DRUGINFO	D07WHS	CL-316,243	Phase 2
T51408	DRUGINFO	D0W3UH	QLT-091568	Phase 1/2
T51408	DRUGINFO	D03INQ	Laevo-Bambuterol	Phase 1
T51408	DRUGINFO	D03QKW	KUC-7483	Phase 1
T51408	DRUGINFO	D05EPU	ZD7114	Phase 1
T51408	DRUGINFO	D07NFW	BMS-196085	Phase 1
T51408	DRUGINFO	D04UNO	KUL-7211	Phase 1
T51408	DRUGINFO	D01KKB	PW-2101	Discontinued in Preregistration
T51408	DRUGINFO	D0Y0GG	Epanolol	Discontinued in Preregistration
T51408	DRUGINFO	D0E8CZ	Amibegron	Discontinued in Phase 3
T51408	DRUGINFO	D01SWK	Rafabegron	Discontinued in Phase 2
T51408	DRUGINFO	D02RHV	PROXODOLOL	Discontinued in Phase 2
T51408	DRUGINFO	D02ZEM	OBERADILOL MONOETHYL MALEATE	Discontinued in Phase 2
T51408	DRUGINFO	D06TVC	Tienoxolol	Discontinued in Phase 2
T51408	DRUGINFO	D0D5DE	ALPRENOXIME HYDROCHLORIDE	Discontinued in Phase 2
T51408	DRUGINFO	D0PU5L	Adaprolol maleate-SME	Discontinued in Phase 2
T51408	DRUGINFO	D0X5ES	NCX 950	Discontinued in Phase 1/2
T51408	DRUGINFO	D00BKV	SB 418790	Discontinued in Phase 1
T51408	DRUGINFO	D03ISE	PAFENOLOL	Discontinued in Phase 1
T51408	DRUGINFO	D04NXR	RO-16-8714	Discontinued in Phase 1
T51408	DRUGINFO	D0GT0Y	MN-246	Discontinued in Phase 1
T51408	DRUGINFO	D00MIX	CP-114271	Preclinical
T51408	DRUGINFO	D03VGW	GCR-1087	Preclinical
T51408	DRUGINFO	D08SIR	CL-314698	Preclinical
T51408	DRUGINFO	D0MT5C	L-742791	Preclinical
T51408	DRUGINFO	D0WS1V	L-751250	Preclinical
T51408	DRUGINFO	D00TVI	SR-58894A	Terminated
T51408	DRUGINFO	D03GLM	BMS-210285	Terminated
T51408	DRUGINFO	D04DZE	BRL 26830A	Terminated
T51408	DRUGINFO	D06XAK	H-216/44	Terminated
T51408	DRUGINFO	D0I9QH	SR-58878	Terminated
T51408	DRUGINFO	D0V4FK	SM 11044	Terminated
T51408	DRUGINFO	D0Y1PG	BRL 37344	Terminated
T51408	DRUGINFO	D00PLX	MystiLol	Investigative
T51408	DRUGINFO	D01OIK	xamoterol	Investigative
T51408	DRUGINFO	D01OIV	T-0509	Investigative
T51408	DRUGINFO	D02DKX	LK 204-545	Investigative
T51408	DRUGINFO	D02VPW	[3H](-)CGP 12177	Investigative
T51408	DRUGINFO	D03VHK	L-748337	Investigative
T51408	DRUGINFO	D04UNE	NIHP	Investigative
T51408	DRUGINFO	D07HTM	(-)-Ro 363	Investigative
T51408	DRUGINFO	D07KMN	Trimetoquinol	Investigative
T51408	DRUGINFO	D07ZZG	cicloprolol	Investigative
T51408	DRUGINFO	D0A0KP	zinterol	Investigative
T51408	DRUGINFO	D0C4NF	FMP-825	Investigative
T51408	DRUGINFO	D0G6RK	ER-23006	Investigative
T51408	DRUGINFO	D0JK0I	prenalterol	Investigative
T51408	DRUGINFO	D0K6MI	[125I]ICYP	Investigative
T51408	DRUGINFO	D0R2JT	iodocyanopindolol	Investigative
T51408	DRUGINFO	D0U5HS	L748328	Investigative
T51408	DRUGINFO	D0V5OS	H87/07	Investigative
T51408	DRUGINFO	D0XR9Z	SB251023	Investigative
T51408	DRUGINFO	D0A9ED	Carazolol	Investigative
T51408	DRUGINFO	D0F7BV	1-(1H-Indol-4-yloxy)-3-phenethylamino-propan-2-ol	Investigative
T51408	DRUGINFO	D03BZW	[3H]CGP12177	Investigative
T51408	DRUGINFO	D04HXF	1-(2-isopropylphenoxy)-3-morpholinopropan-2-ol	Investigative
T51408	DRUGINFO	D0A4FU	1-(2-allylphenoxy)-3-morpholinopropan-2-ol	Investigative
T51408	DRUGINFO	D0S8RD	Trecadrine	Investigative

T99089	TARGETID	T99089
T99089	FORMERID	TTDS00346
T99089	UNIPROID	BRAF_HUMAN
T99089	TARGNAME	Serine/threonine-protein kinase B-raf (BRAF)
T99089	GENENAME	BRAF
T99089	TARGTYPE	Successful
T99089	SYNONYMS	V-Raf murine sarcoma viral oncogene homolog B1; RAFB1; Proto-oncogene B-Raf; P94; BRAF1; BRAF(V599E); BRAF serine/threonine kinase; B-raf protein; B-Raf
T99089	FUNCTION	May play a role in the postsynaptic responses of hippocampal neuron. Phosphorylates MAP2K1, and thereby contributes to the MAP kinase signal transduction pathway. Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus.
T99089	PDBSTRUC	6CAD; 6B8U; 5VYK; 5VR3; 5VAM
T99089	BIOCLASS	Kinase
T99089	ECNUMBER	EC 2.7.11.1
T99089	SEQUENCE	MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH
T99089	DRUGINFO	D05ROI	Dabrafenib	Approved
T99089	DRUGINFO	D0TK7R	LGX818	Approved
T99089	DRUGINFO	D0Y9EW	Vemurafenib	Approved
T99089	DRUGINFO	D05HTS	PLX8394	Phase 2
T99089	DRUGINFO	D0M5XN	BGB-283	Phase 1/2
T99089	DRUGINFO	D04MXN	CEP-32496	Phase 1/2
T99089	DRUGINFO	D04AZM	ARQ 736	Phase 1
T99089	DRUGINFO	D0G0PU	RO-5212054	Phase 1
T99089	DRUGINFO	D0XL8W	ASN003	Phase 1
T99089	DRUGINFO	D0Z2FD	BMS-908662	Phase 1
T99089	DRUGINFO	D6E1GI	PF-07799933	Phase 1
T99089	DRUGINFO	DIS4N5	ABM-1310	Phase 1
T99089	DRUGINFO	DJ8QW7	PF-07284890	Phase 1
T99089	DRUGINFO	D0RV7J	RG-7256	Discontinued in Phase 1
T99089	DRUGINFO	D03TTT	AR-00341677	Investigative
T99089	DRUGINFO	D0C0ZC	AZ-628	Investigative

T26623	TARGETID	T26623
T26623	FORMERID	TTDS00115
T26623	UNIPROID	ALDR_HUMAN
T26623	TARGNAME	Aldose reductase (AKR1B1)
T26623	GENENAME	AKR1B1
T26623	TARGTYPE	Successful
T26623	SYNONYMS	Aldehyde reductase; AKR1B1
T26623	FUNCTION	Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols with a broad range of catalytic efficiencies.
T26623	PDBSTRUC	6F8O; 6F84; 6F82; 6F81; 6F7R
T26623	BIOCLASS	Short-chain dehydrogenases reductase
T26623	ECNUMBER	EC 1.1.1.300
T26623	SEQUENCE	MASRLLLNNGAKMPILGLGTWKSPPGQVTEAVKVAIDVGYRHIDCAHVYQNENEVGVAIQEKLREQVVKREELFIVSKLWCTYHEKGLVKGACQKTLSDLKLDYLDLYLIHWPTGFKPGKEFFPLDESGNVVPSDTNILDTWAAMEELVDEGLVKAIGISNFNHLQVEMILNKPGLKYKPAVNQIECHPYLTQEKLIQYCQSKGIVVTAYSPLGSPDRPWAKPEDPSLLEDPRIKAIAAKHNKTTAQVLIRFPMQRNLVVIPKSVTPERIAENFKVFDFELSSQDMTTLLSYNRNWRVCALLSCTSHKDYPFHEEF
T26623	DRUGINFO	D0Z5IU	Sulindac	Approved
T26623	DRUGINFO	D03KOZ	Epalrestat	Approved
T26623	DRUGINFO	D00EWR	Fidarestat	Phase 3
T26623	DRUGINFO	D0K8TI	Ranirestat	Phase 3
T26623	DRUGINFO	D4PL6G	BNV-222	Phase 2/3
T26623	DRUGINFO	D04PBH	CONTIGOSIDE B	Phase 2/3
T26623	DRUGINFO	D04BFU	LIDORESTAT	Phase 2
T26623	DRUGINFO	D0B4XX	QR-333	Phase 2
T26623	DRUGINFO	D0P7SO	ADMVA	Phase 2
T26623	DRUGINFO	D0V4UO	M-16209	Phase 2
T26623	DRUGINFO	D00QKL	T2c-003	Phase 1/2
T26623	DRUGINFO	D07DIX	ALO-1567	Phase 1
T26623	DRUGINFO	D0Q7QY	SSR-125047	Phase 1
T26623	DRUGINFO	D0J6JZ	MINALRESTAT	Discontinued in Phase 3
T26623	DRUGINFO	D0Q7AW	IMIRESTAT	Discontinued in Phase 3
T26623	DRUGINFO	D0U9TM	Ponalrestat	Discontinued in Phase 3
T26623	DRUGINFO	D03PIB	Alrestatin	Discontinued in Phase 2
T26623	DRUGINFO	D06EDT	ZOPOLRESTAT	Discontinued in Phase 2
T26623	DRUGINFO	D08VMO	JTT-811	Discontinued in Phase 2
T26623	DRUGINFO	D0E0FY	CTL-102-GDEPT	Discontinued in Phase 2
T26623	DRUGINFO	D0O2ET	AD-5467	Discontinued in Phase 2
T26623	DRUGINFO	D0M9RE	ARI-809	Preclinical
T26623	DRUGINFO	D02CGC	Sorbinil	Terminated
T26623	DRUGINFO	D09BHF	WF-2421	Terminated
T26623	DRUGINFO	D0B0GC	E-0722	Terminated
T26623	DRUGINFO	D0C7KK	Zenarestat	Terminated
T26623	DRUGINFO	D0E6LC	SPR-210	Terminated
T26623	DRUGINFO	D0RZ0N	FR-62765	Terminated
T26623	DRUGINFO	D00EPD	6-(2-Chloro-benzenesulfonyl)-2H-pyridazin-3-one	Investigative
T26623	DRUGINFO	D00KCB	Fidarestat(Stereoisomer)	Investigative
T26623	DRUGINFO	D00VHG	Inhibitor Idd 384	Investigative
T26623	DRUGINFO	D00WFB	7-Hydroxy-2-(4-hydroxy-benzyl)-chromen-4-one	Investigative
T26623	DRUGINFO	D01KAM	O7-Nitrooxyethyl chrysin	Investigative
T26623	DRUGINFO	D01LWJ	Apigenin-7-O-beta-D-glucuronide	Investigative
T26623	DRUGINFO	D01UNC	2-(4-aminophenylsulfonamido)acetic acid	Investigative
T26623	DRUGINFO	D02AAH	6-(4-Chloro-benzenesulfonyl)-2H-pyridazin-3-one	Investigative
T26623	DRUGINFO	D02DYB	TRIPTOCALLINE A	Investigative
T26623	DRUGINFO	D02WZA	6-(Benzothiazole-2-sulfonyl)-2H-pyridazin-3-one	Investigative
T26623	DRUGINFO	D03DEO	PALBINONE	Investigative
T26623	DRUGINFO	D03LRQ	2-(3-benzoyl-1H-pyrrol-1-yl)acetic acid	Investigative
T26623	DRUGINFO	D03NEF	6-methoxykaempferol 3-O-beta-D-robinobioside	Investigative
T26623	DRUGINFO	D03YBR	6-Phenylmethanesulfonyl-2H-pyridazin-3-one	Investigative
T26623	DRUGINFO	D04GYD	2-Benzhydryl-7-hydroxy-chromen-4-one	Investigative
T26623	DRUGINFO	D04YIV	2-(Phenylsulfonamido)acetic Acid	Investigative
T26623	DRUGINFO	D05HBF	6,7-Dihydroxy-2-phenyl-chromen-4-one	Investigative
T26623	DRUGINFO	D05SLZ	7-Hydroxy-2-(4-methoxy-benzyl)-chromen-4-one	Investigative
T26623	DRUGINFO	D06YQS	6-(2-Fluoro-benzenesulfonyl)-2H-pyridazin-3-one	Investigative
T26623	DRUGINFO	D07DJS	QUERCITRIN	Investigative
T26623	DRUGINFO	D07GTX	(8-Hydroxy-2-oxo-2H-quinolin-1-yl)-acetic acid	Investigative
T26623	DRUGINFO	D07JEY	IDD552	Investigative
T26623	DRUGINFO	D07XXK	6-(Biphenyl-2-sulfonyl)-2H-pyridazin-3-one	Investigative
T26623	DRUGINFO	D08DRD	Patuletin 3-O-beta-D-robinobioside	Investigative
T26623	DRUGINFO	D08JEI	6-(Naphthalene-2-sulfonyl)-2H-pyridazin-3-one	Investigative
T26623	DRUGINFO	D08MHU	6-Hydroxy-2-(4-hydroxy-benzyl)-chromen-4-one	Investigative
T26623	DRUGINFO	D08NKL	Isorhamnetin 3,7-disulfate	Investigative
T26623	DRUGINFO	D08OYH	O5-Acetyl-O7-nitrooxyethyl chrysin	Investigative
T26623	DRUGINFO	D08ZZX	4-(3-Methoxy-phenyl)-isoxazolidine-3,5-dione	Investigative
T26623	DRUGINFO	D09MYF	N-Acetylalanine	Investigative
T26623	DRUGINFO	D09PNQ	2,3-dihydroxypropanal	Investigative
T26623	DRUGINFO	D0A2FM	6-(1H-Indole-2-sulfonyl)-2H-pyridazin-3-one	Investigative
T26623	DRUGINFO	D0A4LM	EPALRESTATE	Investigative
T26623	DRUGINFO	D0A9NE	2-(3,4-Dihydroxy-benzyl)-7-hydroxy-chromen-4-one	Investigative
T26623	DRUGINFO	D0BH6B	Apigenin-7-O-beta-D-glucuronide methyl ester	Investigative
T26623	DRUGINFO	D0BU5K	TINGENIN B	Investigative
T26623	DRUGINFO	D0CX4E	3-(3-Benzoyl-1H-pyrrol-1-yl)propanoic acid	Investigative
T26623	DRUGINFO	D0F6AI	TINGENONE	Investigative
T26623	DRUGINFO	D0F6TM	(6-Hydroxy-2-oxo-2H-quinolin-1-yl)-acetic acid	Investigative
T26623	DRUGINFO	D0FJ7G	IDD594	Investigative
T26623	DRUGINFO	D0G1OW	Quercetin 3-O-neohesperidoside	Investigative
T26623	DRUGINFO	D0G4CJ	4-(3-Benzoyl-1H-pyrrol-1-yl)butanoic acid	Investigative
T26623	DRUGINFO	D0IB8C	6-(Toluene-4-sulfonyl)-2H-pyridazin-3-one	Investigative
T26623	DRUGINFO	D0IF8Z	(4-Methyl-2-oxo-2H-quinolin-1-yl)-acetic acid	Investigative
T26623	DRUGINFO	D0J7MD	(6-Methoxy-2-oxo-2H-quinolin-1-yl)-acetic acid	Investigative
T26623	DRUGINFO	D0J7VA	Isorhamnetin 3-O-rhamnoside	Investigative
T26623	DRUGINFO	D0K8NO	AK198	Investigative
T26623	DRUGINFO	D0L7MI	7-Hydroxy-6-nitro-2-phenyl-chromen-4-one	Investigative
T26623	DRUGINFO	D0O9KV	6-(2-Bromo-benzenesulfonyl)-2H-pyridazin-3-one	Investigative
T26623	DRUGINFO	D0OC4B	7-Hydroxy-4-phenylcoumarin	Investigative
T26623	DRUGINFO	D0OZ4C	6-Benzenesulfonyl-2H-pyridazin-3-one	Investigative
T26623	DRUGINFO	D0P1ZM	6-(Naphthalene-1-sulfonyl)-2H-pyridazin-3-one	Investigative
T26623	DRUGINFO	D0P3AU	6-(4-Methoxy-benzenesulfonyl)-2H-pyridazin-3-one	Investigative
T26623	DRUGINFO	D0QP9D	2-Benzyl-7-hydroxy-chromen-4-one	Investigative
T26623	DRUGINFO	D0R3MB	6-(Benzofuran-2-sulfonyl)-2H-pyridazin-3-one	Investigative
T26623	DRUGINFO	D0R3OQ	BNV-222	Investigative
T26623	DRUGINFO	D0R7IJ	6-(3-Chloro-benzenesulfonyl)-2H-pyridazin-3-one	Investigative
T26623	DRUGINFO	D0T2TW	3-[5-(3-nitrophenyl)thiophen-2-yl]propanoic acid	Investigative
T26623	DRUGINFO	D0U8GZ	Tamarixetin 3-glucoside-7-sulfate	Investigative
T26623	DRUGINFO	D0XD1Q	6-(4-Fluoro-benzenesulfonyl)-2H-pyridazin-3-one	Investigative
T26623	DRUGINFO	D0Y7PW	6-(4-Bromo-benzenesulfonyl)-2H-pyridazin-3-one	Investigative
T26623	DRUGINFO	D0YJ3Q	2-(3,4-Dihydroxy-phenyl)-7-hydroxy-chromen-4-one	Investigative
T26623	DRUGINFO	D0Z3FX	Patuletin 3-O-beta-D-galactoside	Investigative
T26623	DRUGINFO	D04UYB	MANGIFERIN	Investigative
T26623	DRUGINFO	D06SPO	3,5-dichlorosalicylic acid	Investigative
T26623	DRUGINFO	D06YEV	Hydroxydimethylarsine Oxide	Investigative
T26623	DRUGINFO	D08BFU	ASTRAGALIN	Investigative
T26623	DRUGINFO	D01KKU	NSC-94258	Investigative
T26623	DRUGINFO	D01AWD	Alpha-D-Glucose-6-Phosphate	Investigative
T26623	DRUGINFO	D01UYI	Chrysin	Investigative
T26623	DRUGINFO	D0SY2M	daidzein	Investigative
T26623	DRUGINFO	D00RIX	APIGENIN	Investigative
T26623	DRUGINFO	D0G3TK	KAEMPFEROL	Investigative
T26623	DRUGINFO	D0J2FY	2'-Monophosphoadenosine 5'-Diphosphoribose	Investigative

T53524	TARGETID	T53524
T53524	FORMERID	TTDC00311
T53524	UNIPROID	PGFRA_HUMAN
T53524	TARGNAME	Platelet-derived growth factor receptor alpha (PDGFRA)
T53524	GENENAME	PDGFRA
T53524	TARGTYPE	Successful
T53524	SYNONYMS	RHEPDGFRA; Platelet-derived growth factor receptor 2; Platelet-derived growth factor alpha receptor; PDGFR2; PDGFR-alpha; PDGFR-2; PDGF-R-alpha; CD140a antigen; CD140a; CD140 antigen-like family member A; Alpha-type platelet-derived growth factor receptor; Alpha platelet-derived growth factor receptor
T53524	FUNCTION	Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for normal skeleton development and cephalic closure during embryonic development. Required for normal development of the mucosa lining the gastrointestinal tract, and for recruitment of mesenchymal cells and normal development of intestinal villi. Plays a role in cell migration and chemotaxis in wound healing. Plays a role in platelet activation, secretion of agonists from platelet granules, and in thrombin-induced platelet aggregation. Binding of its cognate ligands - homodimeric PDGFA, homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFC -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PIK3R1, PLCG1, and PTPN11. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylates PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and thereby mediates activation of the AKT1 signaling pathway. Mediates activation of HRAS and of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3 and STAT5A and/or STAT5B. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor. Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis.
T53524	PDBSTRUC	5K5X; 5GRN; 1GQ5
T53524	BIOCLASS	Kinase
T53524	ECNUMBER	EC 2.7.10.1
T53524	SEQUENCE	MGTSHPAFLVLGCLLTGLSLILCQLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPCRTTDPETPVTLHNSEGVVPASYDSRQGFNGTFTVGPYICEATVKGKKFQTIPFNVYALKATSELDLEMEALKTVYKSGETIVVTCAVFNNEVVDLQWTYPGEVKGKGITMLEEIKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVKEMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENLTEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDLVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRDRSTVEGRVTFAKVEETIAVRCLAKNLLGAENRELKLVAPTLRSELTVAAAVLVLLVIVIISLIVLVVIWKQKPRYEIRWRVIESISPDGHEYIYVDPMQLPYDSRWEFPRDGLVLGRVLGSGAFGKVVEGTAYGLSRSQPVMKVAVKMLKPTARSSEKQALMSELKIMTHLGPHLNIVNLLGACTKSGPIYIITEYCFYGDLVNYLHKNRDSFLSHHPEKPKKELDIFGLNPADESTRSYVILSFENNGDYMDMKQADTTQYVPMLERKEVSKYSDIQRSLYDRPASYKKKSMLDSEVKNLLSDDNSEGLTLLDLLSFTYQVARGMEFLASKNCVHRDLAARNVLLAQGKIVKICDFGLARDIMHDSNYVSKGSTFLPVKWMAPESIFDNLYTTLSDVWSYGILLWEIFSLGGTPYPGMMVDSTFYNKIKSGYRMAKPDHATSEVYEIMVKCWNSEPEKRPSFYHLSEIVENLLPGQYKKSYEKIHLDFLKSDHPAVARMRVDSDNAYIGVTYKNEEDKLKDWEGGLDEQRLSADSGYIIPLPDIDPVPEEEDLGKRNRHSSQTSEESAIETGSSSSTFIKREDETIEDIDMMDDIGIDSSDLVEDSFL
T53524	DRUGINFO	D09QZS	Olaratumab	Approved
T53524	DRUGINFO	D0UO2P	Avapritinib	Approved
T53524	DRUGINFO	D09AAK	Ripretinib	Approved
T53524	DRUGINFO	D01PZD	Romiplostim	Approved
T53524	DRUGINFO	D0J1GR	CP-868596	Phase 3
T53524	DRUGINFO	D02WVT	E-3810	Phase 3
T53524	DRUGINFO	D0AG7N	MEDI-575	Phase 2
T53524	DRUGINFO	D0T1GF	MP470	Phase 2
T53524	DRUGINFO	D00NSD	XL-820	Phase 2
T53524	DRUGINFO	D0Z6MT	Famitinib	Phase 2
T53524	DRUGINFO	D0IH3I	PMID28460551-Compound-1	Patented
T53524	DRUGINFO	D0NB1V	Pyridine derivative 20	Patented
T53524	DRUGINFO	D0O0AW	Pyridine derivative 21	Patented
T53524	DRUGINFO	D0O4TA	Pyridine derivative 22	Patented
T53524	DRUGINFO	D0T7BE	Pyridine derivative 19	Patented
T53524	DRUGINFO	D0AK1F	Pyridine derivative 18	Patented
T53524	DRUGINFO	D00QCB	SRI-62-834	Discontinued in Phase 2
T53524	DRUGINFO	D0KX1E	CEP-2563	Discontinued in Phase 1
T53524	DRUGINFO	D03WTT	RG-13022	Terminated
T53524	DRUGINFO	D06GBK	AG1295	Terminated
T53524	DRUGINFO	D03DJR	D-65476	Investigative
T53524	DRUGINFO	D05EDW	6,7-Dimethoxy-3-(2-methoxy-phenyl)-quinoline	Investigative
T53524	DRUGINFO	D0N4VR	5-Fluoro-3-thiophen-3-yl-quinoline	Investigative
T53524	DRUGINFO	D00LRC	3-Cyclopentyl-6,7-dimethoxy-quinoline	Investigative
T53524	DRUGINFO	D00RBV	6,7-Dimethoxy-3-pyridin-3-yl-quinoline	Investigative
T53524	DRUGINFO	D00YCU	1-Phenyl-1H-benzoimidazol-5-ol	Investigative
T53524	DRUGINFO	D01FWD	1-Phenyl-1H-benzoimidazole	Investigative
T53524	DRUGINFO	D01MUN	4-Benzoimidazol-1-yl-phenylamine	Investigative
T53524	DRUGINFO	D01UYS	5-(6,7-Dimethoxy-quinolin-3-yl)-1H-pyridin-2-one	Investigative
T53524	DRUGINFO	D02CUF	Benzyl-(6,7-dimethoxy-quinolin-3-yl)-amine	Investigative
T53524	DRUGINFO	D02PZZ	7-Methoxy-3-pyridin-4-yl-quinoline	Investigative
T53524	DRUGINFO	D02XKJ	5-Methoxy-1-phenyl-1H-benzoimidazole	Investigative
T53524	DRUGINFO	D03MQI	4-(6,7-Dimethoxy-quinolin-3-yl)-benzoic acid	Investigative
T53524	DRUGINFO	D04PQX	6-Methoxy-3-pyridin-4-yl-quinoline	Investigative
T53524	DRUGINFO	D05GBY	3-Thiophen-3-yl-quinoline	Investigative
T53524	DRUGINFO	D05SNG	7-Fluoro-3-thiophen-3-yl-quinoline	Investigative
T53524	DRUGINFO	D06LLF	6,7-Dimethoxy-3-((E)-styryl)-quinoline	Investigative
T53524	DRUGINFO	D06MCJ	3-(1H-Indol-3-yl)-6,7-dimethoxy-quinoline	Investigative
T53524	DRUGINFO	D06VNR	3-Benzyloxy-6,7-dimethoxy-quinoline	Investigative
T53524	DRUGINFO	D07CFT	6,7-Dimethoxy-3-(3-methoxy-phenyl)-quinoline	Investigative
T53524	DRUGINFO	D07JDY	3-((E)-Styryl)-quinoline	Investigative
T53524	DRUGINFO	D07ZWN	5,7-Dimethyl-3-thiophen-3-yl-quinoline	Investigative
T53524	DRUGINFO	D08JGS	6,7-Dimethoxy-3-(4-nitro-phenyl)-quinoline	Investigative
T53524	DRUGINFO	D08KWL	3-Cyclohexylethynyl-6,7-dimethoxy-quinoline	Investigative
T53524	DRUGINFO	D08SUH	3-(3,4-Dimethoxy-phenyl)-6,7-dimethoxy-quinoline	Investigative
T53524	DRUGINFO	D0A6AA	7-Thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline	Investigative
T53524	DRUGINFO	D0A6YP	3-(3-Fluoro-phenyl)-6,7-dimethoxy-quinoline	Investigative
T53524	DRUGINFO	D0AO6T	3-(3,4-Difluoro-phenyl)-6,7-dimethoxy-quinoline	Investigative
T53524	DRUGINFO	D0C1BE	6,7-Dimethoxy-3-p-tolyl-quinoline	Investigative
T53524	DRUGINFO	D0CF9B	6,7-Dichloro-3-thiophen-3-yl-quinoline	Investigative
T53524	DRUGINFO	D0FH3M	RPR-108514A	Investigative
T53524	DRUGINFO	D0G0KN	6,7-Dimethoxy-3-(4-methoxy-phenyl)-quinoline	Investigative
T53524	DRUGINFO	D0G0ZQ	6,7-Dimethoxy-3-thiophen-2-yl-quinoline	Investigative
T53524	DRUGINFO	D0G6SA	6,7-Dimethoxy-3-phenyl-quinoline	Investigative
T53524	DRUGINFO	D0GN3E	3-(1H-Indol-3-yl)-quinoline	Investigative
T53524	DRUGINFO	D0H4JB	4-(6,7-Dimethoxy-quinolin-3-yl)-phenol	Investigative
T53524	DRUGINFO	D0H9TO	3-Pyridin-4-yl-quinolin-7-ol	Investigative
T53524	DRUGINFO	D0I0GL	3-(4-Fluoro-phenyl)-6,7-dimethoxy-quinoline	Investigative
T53524	DRUGINFO	D0IR5I	3-Pyridin-3-yl-quinoline-6,7-diol	Investigative
T53524	DRUGINFO	D0K2YG	4-(5-Methoxy-benzoimidazol-1-yl)-phenylamine	Investigative
T53524	DRUGINFO	D0K9ON	3-(2-Cyclohexyl-ethyl)-6,7-dimethoxy-quinoline	Investigative
T53524	DRUGINFO	D0K9VE	3-Pyridin-4-yl-quinoline-5,7-diol	Investigative
T53524	DRUGINFO	D0KF3N	3-Cyclopent-1-enyl-6,7-dimethoxy-quinoline	Investigative
T53524	DRUGINFO	D0P0RD	3-(3,4-Dichloro-phenyl)-6,7-dimethoxy-quinoline	Investigative
T53524	DRUGINFO	D0P0WT	5,7-Dimethoxy-3-pyridin-4-yl-quinoline	Investigative
T53524	DRUGINFO	D0Q3DS	3-Pyridin-4-yl-quinoline	Investigative
T53524	DRUGINFO	D0QT4X	6,7-Difluoro-3-thiophen-3-yl-quinoline	Investigative
T53524	DRUGINFO	D0RD5S	5,7-Dimethoxy-3-thiophen-3-yl-quinoline	Investigative
T53524	DRUGINFO	D0SG0G	5,6,7-Trimethoxy-3-pyridin-4-yl-quinoline	Investigative
T53524	DRUGINFO	D0T9FQ	6,7-Dimethoxy-3-pyridin-4-yl-quinoline	Investigative
T53524	DRUGINFO	D0V8QI	7-Methoxy-3-thiophen-3-yl-quinoline	Investigative
T53524	DRUGINFO	D0W7IN	6-Methoxy-3-thiophen-3-yl-quinoline	Investigative
T53524	DRUGINFO	D0W9BF	RPR-101511	Investigative
T53524	DRUGINFO	D0WW8M	6,7-Dimethoxy-3-phenylethynyl-quinoline	Investigative
T53524	DRUGINFO	D0YE1X	4-(3,4-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline	Investigative
T53524	DRUGINFO	D0Z4HV	7-Chloro-3-pyridin-4-yl-quinoline	Investigative
T53524	DRUGINFO	D05FFB	5,11-Dimethyl-6H-pyrido[4,3-b]carbazol-9-ol	Investigative
T53524	DRUGINFO	D05QBZ	CP-673451	Investigative
T53524	DRUGINFO	D09OLH	(1H-indol-2-yl)(5-methoxy-1H-indol-2-yl)methanone	Investigative
T53524	DRUGINFO	D0D7ZL	(1H-indol-2-yl)(6-methoxy-1H-indol-2-yl)methanone	Investigative
T53524	DRUGINFO	D0G0KQ	(1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone	Investigative
T53524	DRUGINFO	D0G5YI	Di(1H-indol-2-yl)methanone	Investigative
T53524	DRUGINFO	D0H7MF	(5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone	Investigative
T53524	DRUGINFO	D0XS9E	(5-hydroxy-1H-indol-2-yl)(1H-indol-2-yl)methanone	Investigative
T53524	DRUGINFO	D09LPL	SU-11652	Investigative
T53524	DRUGINFO	D0I3XZ	Bis-(5-hydroxy-1H-indol-2-yl)-methanone	Investigative
T53524	DRUGINFO	D0OH3J	PD-0179483	Investigative
T53524	DRUGINFO	D0S1KJ	PD-0173952	Investigative
T53524	DRUGINFO	D0Z7GH	PD-0173958	Investigative
T53524	DRUGINFO	D03NPX	PD-0173955	Investigative
T53524	DRUGINFO	D0YZ7H	JNJ-10198409	Investigative
T53524	DRUGINFO	D02BXJ	PMID21561767C8h	Investigative
T53524	DRUGINFO	D0D5EW	HKI-9924129	Investigative
T53524	DRUGINFO	D0GW4Q	PD-0173956	Investigative
T53524	DRUGINFO	D0P3JW	PD-0166326	Investigative
T53524	DRUGINFO	D03EHM	PP121	Investigative
T53524	DRUGINFO	D0C2GE	PMID22765894C8h	Investigative
T53524	DRUGINFO	D09XIL	Ro-4396686	Investigative
T53524	DRUGINFO	D0M4SY	BMS-536924	Investigative

T83875	TARGETID	T83875
T83875	FORMERID	TTDS00289
T83875	UNIPROID	AOFA_HUMAN
T83875	TARGNAME	Monoamine oxidase type A (MAO-A)
T83875	GENENAME	MAOA
T83875	TARGTYPE	Successful
T83875	SYNONYMS	Monoamine oxidase A; Amine oxidase [flavin-containing] A
T83875	FUNCTION	MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine. Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues.
T83875	PDBSTRUC	2Z5Y; 2Z5X; 2BXS; 2BXR; 1H8Q
T83875	BIOCLASS	CH-NH(2) donor oxidoreductase
T83875	ECNUMBER	EC 1.4.3.4
T83875	SEQUENCE	MENQEKASIAGHMFDVVVIGGGISGLSAAKLLTEYGVSVLVLEARDRVGGRTYTIRNEHVDYVDVGGAYVGPTQNRILRLSKELGIETYKVNVSERLVQYVKGKTYPFRGAFPPVWNPIAYLDYNNLWRTIDNMGKEIPTDAPWEAQHADKWDKMTMKELIDKICWTKTARRFAYLFVNINVTSEPHEVSALWFLWYVKQCGGTTRIFSVTNGGQERKFVGGSGQVSERIMDLLGDQVKLNHPVTHVDQSSDNIIIETLNHEHYECKYVINAIPPTLTAKIHFRPELPAERNQLIQRLPMGAVIKCMMYYKEAFWKKKDYCGCMIIEDEDAPISITLDDTKPDGSLPAIMGFILARKADRLAKLHKEIRKKKICELYAKVLGSQEALHPVHYEEKNWCEEQYSGGCYTAYFPPGIMTQYGRVIRQPVGRIFFAGTETATKWSGYMEGAVEAGERAAREVLNGLGKVTEKDIWVQEPESKDVPAVEITHTFWERNLPSVSGLLKIIGFSTSVTALGFVLYKYKLLPRS
T83875	DRUGINFO	D0I2VK	Isocarboxazid	Approved
T83875	DRUGINFO	D01ZSO	Moclobemide	Approved
T83875	DRUGINFO	D09QDP	Clorgyline	Approved
T83875	DRUGINFO	D0H0HJ	Tranylcypromine	Approved
T83875	DRUGINFO	D00VUI	Psoralen	Phase 3
T83875	DRUGINFO	D08CJK	TRYPTAMINE	Phase 3
T83875	DRUGINFO	D00RWQ	CX157	Phase 2
T83875	DRUGINFO	D04RCT	CHF-3381	Phase 2
T83875	DRUGINFO	D0C3UC	Ladostigil	Phase 2
T83875	DRUGINFO	D0H7PW	PIPERINE	Phase 1/2
T83875	DRUGINFO	D0T5AW	Desoxypeganine	Phase 1
T83875	DRUGINFO	D01OGR	Secondary and tertiary (hetero)arylamide derivative 2	Patented
T83875	DRUGINFO	D03EHC	PMID25399762-Compound-Table 5-8	Patented
T83875	DRUGINFO	D03QMA	PMID25399762-Compound-Figure2-Artoxanthochromane	Patented
T83875	DRUGINFO	D03VGN	PMID25399762-Compound-Table 5-O-methyl-M30	Patented
T83875	DRUGINFO	D03YOU	GypensapogeninA	Patented
T83875	DRUGINFO	D05GWJ	PMID25399762-Compound-Figure1-Sarcaboside A	Patented
T83875	DRUGINFO	D05MYL	PMID25399762-Compound-Figure1-Sarcaboside B	Patented
T83875	DRUGINFO	D07MEE	PhyllanthoidA	Patented
T83875	DRUGINFO	D08HOV	PMID25399762-Compound-Figure3-Aspeverin	Patented
T83875	DRUGINFO	D0AH9P	PMID29324067-Compound-25	Patented
T83875	DRUGINFO	D0E7OQ	PMID25399762-Compound-Figure3-Lycojaponicumin B	Patented
T83875	DRUGINFO	D0G3TH	KadcoccitoneA	Patented
T83875	DRUGINFO	D0H7HH	PMID25399762-Compound-Figure3-Lycojaponicumin C	Patented
T83875	DRUGINFO	D0I5DV	PMID25399762-Compound-Figure2-Spirooliganone B	Patented
T83875	DRUGINFO	D0I9CK	MyriberineA	Patented
T83875	DRUGINFO	D0K3UV	PMID25399762-Compound-Figure1-Chukrasone A	Patented
T83875	DRUGINFO	D0KW7O	PMID25399762-Compound-Figure3-Fluevirosine A	Patented
T83875	DRUGINFO	D0LZ2M	IncarviatoneA	Patented
T83875	DRUGINFO	D0M0EP	PMID25399762-Compound-Figure3-Lycojaponicumin A	Patented
T83875	DRUGINFO	D0N1CG	PMID25399762-Compound-Figure1-Eryngiolide A	Patented
T83875	DRUGINFO	D0P1PC	HouttuynoidA	Patented
T83875	DRUGINFO	D0R2YC	GypensapogeninB	Patented
T83875	DRUGINFO	D0TX9E	PMID25399762-Compound-Figure1-Aphanamixoid A	Patented
T83875	DRUGINFO	D0V6TF	PMID25399762-Compound-Figure1-Neonectrolide A	Patented
T83875	DRUGINFO	D0XY6I	AphanamgrandiolA	Patented
T83875	DRUGINFO	D0Y9VB	PMID25399762-Compound-Figure1-Chukrasone B	Patented
T83875	DRUGINFO	D05RJG	Schiff base compound 1	Patented
T83875	DRUGINFO	D0T9JB	Tacrine-coumarin hybrid derivative 1	Patented
T83875	DRUGINFO	D04OEV	Cyclic peptide derivative 1	Patented
T83875	DRUGINFO	D07NTA	Heteroaryl-cyclopropylamine derivative 1	Patented
T83875	DRUGINFO	D08IOP	N-(2-phenylcyclopropyl) amino acid derivative 3	Patented
T83875	DRUGINFO	D0AA7U	PMID29757691-Compound-4	Patented
T83875	DRUGINFO	D00OWF	Harmine	Patented
T83875	DRUGINFO	D02EME	Tetra-hydro-isoquinoline derivative 3	Patented
T83875	DRUGINFO	D04AXC	Tetra-hydro-isoquinoline derivative 1	Patented
T83875	DRUGINFO	D04OHC	Tarnylcypromine derivative 2	Patented
T83875	DRUGINFO	D0NB7Z	Tetra-hydro-isoquinoline derivative 2	Patented
T83875	DRUGINFO	D0O7IH	Tarnylcypromine derivative 3	Patented
T83875	DRUGINFO	D0R6RT	Tetra-hydro-isoquinoline derivative 4	Patented
T83875	DRUGINFO	D05WEP	Befloxatone	Discontinued in Phase 3
T83875	DRUGINFO	D06QOJ	RS-8359	Discontinued in Phase 2
T83875	DRUGINFO	D0H9DE	CS-722	Discontinued in Phase 2
T83875	DRUGINFO	D0IZ1D	Brofaromine	Discontinued in Phase 2
T83875	DRUGINFO	D0ZM5W	Esuprone	Discontinued in Phase 2
T83875	DRUGINFO	D0E8UJ	BW-1370U87	Discontinued in Phase 1
T83875	DRUGINFO	D01OLO	AS602868	Discontinued in Phase 1
T83875	DRUGINFO	D02CGY	Bifemelane	Terminated
T83875	DRUGINFO	D0G9AP	E-2011	Terminated
T83875	DRUGINFO	D00JUD	4-methyl-2H-benzofuro[3,2-g]chromen-2-one	Investigative
T83875	DRUGINFO	D00KQB	1-(4-butoxyphenyl)propan-2-amine	Investigative
T83875	DRUGINFO	D00YVE	1-(2-Naphthyl)-2-aminopropane	Investigative
T83875	DRUGINFO	D01UPT	FA-70	Investigative
T83875	DRUGINFO	D02AQG	N-Benzyl-(6-butoxy-2-naphthyl)-2-aminopropane	Investigative
T83875	DRUGINFO	D02PSR	N'-(2-phenylallyl)hydrazine hydrochloride	Investigative
T83875	DRUGINFO	D02ZZA	(S)-2-amino-1-(4-ethylthiophenyl)-propane	Investigative
T83875	DRUGINFO	D04EDK	6-Fluoro-N-(2-morpholinoethyl)nicotinamide	Investigative
T83875	DRUGINFO	D04SJC	6-Chloro-N-(3-morpholinopropyl)nicotinamide	Investigative
T83875	DRUGINFO	D04UYZ	(R,S)-N-(R-phenylethyl)-1H-pyrrole-2-carboxamide	Investigative
T83875	DRUGINFO	D05GGH	6-Chloro-N-(2-morpholinoethyl)nicotinamide	Investigative
T83875	DRUGINFO	D05HJT	Ethyl 4-(2-oxo-2H-chromene-3-carboxamido)benzoate	Investigative
T83875	DRUGINFO	D05OXR	N-Phenyl-1-methyl-1H-indole-2-carboxamide	Investigative
T83875	DRUGINFO	D06FXI	5-Methoxymethyl-3-pyrrol-1-yl-oxazolidin-2-one	Investigative
T83875	DRUGINFO	D06IAE	4-Chloro-N-(3-morpholinopropyl)nicotinamide	Investigative
T83875	DRUGINFO	D07LCW	5-Azidomethyl-3-pyrrol-1-yl-oxazolidin-2-one	Investigative
T83875	DRUGINFO	D07ULQ	N-methyl-N-(prop-2-ynyl)-1H-pyrrole-2-carboxamide	Investigative
T83875	DRUGINFO	D07WFU	Trans-(+/-)-2-Fluoro-1,2-diphenylcyclopropylamine	Investigative
T83875	DRUGINFO	D08PEW	N-(1H-Indol-2-ylmethyl)-N-(4-phenylbutyl)amine	Investigative
T83875	DRUGINFO	D08QZP	N-((1H-indol-2-yl)methyl)(phenyl)methanamine	Investigative
T83875	DRUGINFO	D0A4FA	N-benzyl-1H-pyrrole-2-carboxamide	Investigative
T83875	DRUGINFO	D0B0JK	DECYL(DIMETHYL)PHOSPHINE OXIDE	Investigative
T83875	DRUGINFO	D0B5CR	1-(3-(4-chlorobenzyl)quinoxalin-2-yl)hydrazine	Investigative
T83875	DRUGINFO	D0BE0S	1-(1-Naphthyl)-2-aminopropane	Investigative
T83875	DRUGINFO	D0C0MP	2-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-imidazole	Investigative
T83875	DRUGINFO	D0C8RD	N-benzyl,N-methyl-1H-pyrrole-2-carboxamide	Investigative
T83875	DRUGINFO	D0C9RO	N-(2-benzyl),N-(1-methylpyrrol-2-ylmethyl)amine	Investigative
T83875	DRUGINFO	D0D0SC	6-Hydroxy-N-(2-morpholinoethyl)nicotinamide	Investigative
T83875	DRUGINFO	D0E5VT	6,11-dihydro-5H-benzo[a]carbazole	Investigative
T83875	DRUGINFO	D0H1GQ	2-(3-benzylquinoxalin-2-ylamino)ethanol	Investigative
T83875	DRUGINFO	D0H1VT	Cis-(+/-)-2-Fluoro-1,2-diphenylcyclopropylamine	Investigative
T83875	DRUGINFO	D0H5MV	N-propargyl-1H-pyrrole-2-carboxamide	Investigative
T83875	DRUGINFO	D0H6UA	1-(4-propoxyphenyl)propan-2-amine	Investigative
T83875	DRUGINFO	D0J3IA	5,6-Dichloro-N-(2-morpholinoethyl)nicotinamide	Investigative
T83875	DRUGINFO	D0K8SK	2-(4-methoxyphenyl)-4,5-dihydro-1H-imidazole	Investigative
T83875	DRUGINFO	D0KB2R	N-(1-Methyl-1H-indol-2-ylmethyl)-N-phenylamine	Investigative
T83875	DRUGINFO	D0KU2D	N-phenyl-1H-pyrrole-2-carboxamide	Investigative
T83875	DRUGINFO	D0KW6V	3-benzyl-N-(2-morpholinoethyl)quinoxalin-2-amine	Investigative
T83875	DRUGINFO	D0M0HM	N-Benzyl-(6-methoxy-2-naphthyl)-2-aminopropane	Investigative
T83875	DRUGINFO	D0O0QN	3-aminoacetamido-4'-methylfuro[3,2-g]coumarin	Investigative
T83875	DRUGINFO	D0O4XF	1-(3-benzylquinoxalin-2-yl)hydrazine	Investigative
T83875	DRUGINFO	D0P0XO	3-methyl-2(1H)-thioxo-4(3H)-quinazolinone	Investigative
T83875	DRUGINFO	D0P3DV	N-(4-phenylbutyl)-1H-pyrrole-2-carboxamide	Investigative
T83875	DRUGINFO	D0Q2QA	(S)-2-amino-1-(4-methylthiophenyl)-propane	Investigative
T83875	DRUGINFO	D0R4PR	7-acetonyloxy-3-acetylamino-8-methoxycoumarin	Investigative
T83875	DRUGINFO	D0R4TI	(6-methylthio-2-naphthyl)isopropylamine	Investigative
T83875	DRUGINFO	D0S9JC	4-Chloro-N-(2-morpholinoethyl)nicotinamide	Investigative
T83875	DRUGINFO	D0SN3L	N-2-phenylethyl-1H-pyrrole-2-carboxamide	Investigative
T83875	DRUGINFO	D0U9VX	9-(3-aminopropoxy)-7H-furo[3,2-g]chromen-7-one	Investigative
T83875	DRUGINFO	D0V7RM	(6-Butoxy-2-naphthyl)-2-aminopropane	Investigative
T83875	DRUGINFO	D0W3BX	2-phenyl-5H-indeno[1,2-d]pyrimidine	Investigative
T83875	DRUGINFO	D0WI3V	1-(3-benzyl-6,7-dichloroquinoxalin-2-yl)hydrazine	Investigative
T83875	DRUGINFO	D0X0PA	1-(4-ethoxyphenyl)propan-2-amine	Investigative
T83875	DRUGINFO	D0Y0LQ	N-((1H-indol-2-yl)methyl)-2-phenylethanamine	Investigative
T83875	DRUGINFO	D0Y1XS	3,4-Benzo-7-acetonyloxy-8-methylcoumarin	Investigative
T83875	DRUGINFO	D0Y4JQ	N-(3-phenylpropyl)-1H-pyrrole-2-carboxamide	Investigative
T83875	DRUGINFO	D0ZA4J	5,6-Dichloro-N-(3-morpholinopropyl)nicotinamide	Investigative
T83875	DRUGINFO	D00KDZ	N-(1H-Indol-2-ylmethyl)-N-methyl-N-phenylamine	Investigative
T83875	DRUGINFO	D00OLX	8-(3-Methylbenzyloxy)caffeine	Investigative
T83875	DRUGINFO	D00OQL	7-Acetonyloxy-3,4-cyclopentene-8-methylcoumarin	Investigative
T83875	DRUGINFO	D00WSM	2-oxo-N-m-tolyl-2H-chromene-3-carboxamide	Investigative
T83875	DRUGINFO	D00WVG	2-(2-cyclopentylidenehydrazinyl)-4-phenylthiazole	Investigative
T83875	DRUGINFO	D01LUB	4,8-Dimethyl-7-(2'-oxocyclohexyloxy)coumarin	Investigative
T83875	DRUGINFO	D01PES	N-(1H-Indol-2-ylmethyl)-N-phenylamine	Investigative
T83875	DRUGINFO	D01SBZ	1-(4-(benzyloxy)phenyl)propan-2-amine	Investigative
T83875	DRUGINFO	D02BBT	2-Bromo-N-(2-morpholinoethyl)nicotinamide	Investigative
T83875	DRUGINFO	D02FJX	8-[(3-Trifluoromethyl)benzyloxy]caffeine	Investigative
T83875	DRUGINFO	D02IDM	(6-Methoxy-2-naphthyl)-2-aminopropane	Investigative
T83875	DRUGINFO	D02QBV	N2-{4-[(3-fluorobenzyl)oxy]benzyl}glycinamide	Investigative
T83875	DRUGINFO	D02TFD	(7-Benzyloxy-2-oxo-2H-chromen-4-yl)acetonitrile	Investigative
T83875	DRUGINFO	D02UVG	7-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline	Investigative
T83875	DRUGINFO	D03HXD	(6-Benzyloxy-2-naphthyl)-2-aminopropane	Investigative
T83875	DRUGINFO	D03KDD	N-methyl,N-(propargyl),N-(pyrrol-2-ylmethyl)amine	Investigative
T83875	DRUGINFO	D03LGV	Trans-2-(4-chlorophenyl)-2-fluorocyclopropanamine	Investigative
T83875	DRUGINFO	D03PXS	2-oxo-N-phenyl-2H-chromene-3-carboxamide	Investigative
T83875	DRUGINFO	D03XKJ	N2-{4-[(4-chlorobenzyl)oxy]benzyl}glycinamide	Investigative
T83875	DRUGINFO	D04FLL	(+/-)-2-Phenylthiomorpholin-5-one	Investigative
T83875	DRUGINFO	D04GVX	6-Bromo-4,9-dihydro-3H-beta-carboline	Investigative
T83875	DRUGINFO	D04LPY	8-(3-Fluorobenzyloxy)caffeine	Investigative
T83875	DRUGINFO	D04QRS	PNU-22394	Investigative
T83875	DRUGINFO	D04ZPU	2-(naphthalen-2-yl)-4,5-dihydro-1H-imidazole	Investigative
T83875	DRUGINFO	D05ANK	N-Benzyl-N-(1H-indol-2-ylmethyl)-N-methylamine	Investigative
T83875	DRUGINFO	D05FMZ	C-(1H-Indol-3-yl)-methylamine	Investigative
T83875	DRUGINFO	D05FQN	7-Methoxy-9H-beta-carboline	Investigative
T83875	DRUGINFO	D05GQQ	6-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline	Investigative
T83875	DRUGINFO	D05WQN	N-(2-Methyl-1H-indol-5-yl)cyclohexanecarboxamide	Investigative
T83875	DRUGINFO	D06AJP	(E)-5-(3-Chlorostyryl)isatin	Investigative
T83875	DRUGINFO	D07LCU	N-(3-Phenylpropyl)-1H-indole-2-carboxamide	Investigative
T83875	DRUGINFO	D07NBB	8-(3-Bromobenzyloxy)caffeine	Investigative
T83875	DRUGINFO	D08CNS	IPRONIAZIDE	Investigative
T83875	DRUGINFO	D08FFH	7-Acetonyloxy-3,4-cyclohexene-8-methylcoumarin	Investigative
T83875	DRUGINFO	D08FXH	(+/-)-2-(4'-Propoxyphenyl)thiomorpholine	Investigative
T83875	DRUGINFO	D08HAM	5-Bromo-4,9-dihydro-3H-beta-carboline	Investigative
T83875	DRUGINFO	D08HNJ	N-(4-Phenylbutyl)-1H-indole-2-carboxamide	Investigative
T83875	DRUGINFO	D08PHY	Trans-2-fluoro-2-(4-fluorophenyl)cyclopropanamine	Investigative
T83875	DRUGINFO	D08QVY	5-Hydroxymethyl-3-pyrrol-1-yl-oxazolidin-2-one	Investigative
T83875	DRUGINFO	D08SRB	Phenyl 4-(4,5-dihydro-1H-imidazol-2-yl)benzoate	Investigative
T83875	DRUGINFO	D08SSS	(S)-2-amino-1-(4-propylthiophenyl)-propane	Investigative
T83875	DRUGINFO	D08TFN	(+/-)-2-(4'-Methoxyphenyl)thiomorpholine	Investigative
T83875	DRUGINFO	D08YCE	8-(3-Chlorobenzyloxy)caffeine	Investigative
T83875	DRUGINFO	D09HBX	Trans-2-fluoro-2-phenylcyclopropylamin	Investigative
T83875	DRUGINFO	D09NNZ	3,4-Dichloro-N-(2-methyl-1H-indol-5-yl)benzamide	Investigative
T83875	DRUGINFO	D09XSB	(E)-5-Styrylisatin	Investigative
T83875	DRUGINFO	D09ZDQ	2-Furan-2-yl-4,5-dihydro-1H-imidazole	Investigative
T83875	DRUGINFO	D0A1RE	4-methyl-7-(2-oxocyclopentyloxy)-2H-chromen-2-one	Investigative
T83875	DRUGINFO	D0A4AB	2-(4,5-dihydro-1H-imidazol-2-yl)quinoline	Investigative
T83875	DRUGINFO	D0A4IY	HYDRAZINECARBOXAMIDE	Investigative
T83875	DRUGINFO	D0B1WD	N-(4-Ethylphenyl)-2-oxo-2H-chromene-3-carboxamide	Investigative
T83875	DRUGINFO	D0B4CA	NSC-656158	Investigative
T83875	DRUGINFO	D0B6MV	8-(3-Methoxybenzyloxy)caffeine	Investigative
T83875	DRUGINFO	D0C7PD	6-Methoxy-4,9-dihydro-3H-beta-carboline	Investigative
T83875	DRUGINFO	D0C9WW	7-(3-chlorobenzyloxy)-4-carboxaldehyde-coumarin	Investigative
T83875	DRUGINFO	D0D1PE	CGS-19281A	Investigative
T83875	DRUGINFO	D0D2YR	9-Methyl-2,3,4,9-tetrahydro-1H-beta-carboline	Investigative
T83875	DRUGINFO	D0D5KD	(+/-)-2-(4'-Ethoxyphenyl)thiomorpholin-5-one	Investigative
T83875	DRUGINFO	D0D6OR	(+/-)-2-(4'-Benzyloxyphenyl)thiomorpholine	Investigative
T83875	DRUGINFO	D0D6QI	3-Chloro-N-(2-methyl-1H-indol-5-yl)benzamide	Investigative
T83875	DRUGINFO	D0E8IE	4-(2-oxo-2H-chromene-3-carboxamido)benzoic acid	Investigative
T83875	DRUGINFO	D0F2DC	Trans-2-fluoro-2-p-tolylcyclopropanamine	Investigative
T83875	DRUGINFO	D0F7JK	N-Methyl,N-phenyl-1H-indole-2-carboxamide	Investigative
T83875	DRUGINFO	D0G4BG	N-(propargyl),N-(pyrrol-2-ylmethyl)amine	Investigative
T83875	DRUGINFO	D0G8BT	4,9-Dihydro-3H-beta-carboline	Investigative
T83875	DRUGINFO	D0H0GZ	2-oxo-N-p-tolyl-2H-chromene-3-carboxamide	Investigative
T83875	DRUGINFO	D0HU4J	(+/-)-2-Phenylthiomorpholine	Investigative
T83875	DRUGINFO	D0ID3Y	(+/-)-2-(4'-Methoxyphenyl)thiomorpholin-5-one	Investigative
T83875	DRUGINFO	D0IP7L	(6-Propoxy-2-naphthyl)-2-aminopropane	Investigative
T83875	DRUGINFO	D0J0QW	(+/-)-2-(4'-Ethoxyphenyl)thiomorpholine	Investigative
T83875	DRUGINFO	D0JN9R	8-Benzyloxycaffeine	Investigative
T83875	DRUGINFO	D0K9UN	N-Phenyl-1H-indole-2-carboxamide	Investigative
T83875	DRUGINFO	D0L5EW	(6-Ethoxy-2-naphthyl)-2-aminopropane	Investigative
T83875	DRUGINFO	D0M0XR	(R/R)BEFLOXATONE	Investigative
T83875	DRUGINFO	D0M4GR	(+/-)-2-(4'-Butoxyphenyl)thiomorpholin-5-one	Investigative
T83875	DRUGINFO	D0M7WE	2,3,4,5-Tetrahydro-1H-pyrido[4,3-b]indole	Investigative
T83875	DRUGINFO	D0MO1O	N-methyl,N-(benzyl),N-(pyrrol-2-ylmethyl)amine	Investigative
T83875	DRUGINFO	D0N8UE	N-(2-phenylethyl),N-(pyrrol-2-ylmethyl)amine	Investigative
T83875	DRUGINFO	D0N9FH	2-Phenoxymethyl-4,5-dihydro-1H-imidazole	Investigative
T83875	DRUGINFO	D0NS9X	2-Chloro-N-(3-morpholinopropyl)nicotinamide	Investigative
T83875	DRUGINFO	D0O2UK	N-(benzyl),N-(pyrrol-2-ylmethyl)amine	Investigative
T83875	DRUGINFO	D0P1UC	2-(5-phenyl-furan-2-yl)-4,5-dihydro-1H-imidazole	Investigative
T83875	DRUGINFO	D0P4GF	3,4-Benzo-7-(beta-bromoallyloxy)-8-methylcoumarin	Investigative
T83875	DRUGINFO	D0Q1IP	2-(2-cycloheptylidenehydrazinyl)-4-phenylthiazole	Investigative
T83875	DRUGINFO	D0Q9NC	2-phenyl-9H-indeno[2,1-d]pyrimidine	Investigative
T83875	DRUGINFO	D0R5EW	2-Chloro-N-(2-morpholinoethyl)nicotinamide	Investigative
T83875	DRUGINFO	D0S0JH	6-amino-9-methoxy-7H-furo[3,2-g]chromen-7-one	Investigative
T83875	DRUGINFO	D0S3QN	2-[7-(Benzyloxy)-2-oxo-2H-chromen-4-yl]acetamide	Investigative
T83875	DRUGINFO	D0S7FP	(R)-Indan-1-yl-methyl-prop-2-ynyl-amine	Investigative
T83875	DRUGINFO	D0T1FJ	4-(Aminomethyl)-7-(benzyloxy)-2H-chromen-2-one	Investigative
T83875	DRUGINFO	D0T3XC	(+/-)-2-(4'-Butoxyphenyl)thiomorpholine	Investigative
T83875	DRUGINFO	D0T6XC	N2-[4-(benzyloxy)benzyl]glycinamide	Investigative
T83875	DRUGINFO	D0TL3S	3,4-Benzo-7-acetonyloxy-8-methoxycoumarin	Investigative
T83875	DRUGINFO	D0V0TN	N-Benzyl,N-methyl-1H-indole-2-carboxamide	Investigative
T83875	DRUGINFO	D0V3NT	TOLOXATONE	Investigative
T83875	DRUGINFO	D0W4TW	7-Bromo-4,9-dihydro-3H-beta-carboline	Investigative
T83875	DRUGINFO	D0X8HH	(E)-5-(3-Fluorostyryl)isatin	Investigative
T83875	DRUGINFO	D0X8RN	Cis-2-phenylcyclopropylamine	Investigative
T83875	DRUGINFO	D0YO7C	N-(2-Phenylethyl)-1H-indole-2-carboxamide	Investigative
T83875	DRUGINFO	D0Z0ZU	(S)-2-amino-1-(4-butylthiophenyl)-propane	Investigative
T83875	DRUGINFO	D0Z5BU	(+/-)-2-(4'-Propoxyphenyl)thiomorpholin-5-one	Investigative
T83875	DRUGINFO	D0Z5YO	N-Benzyl-1H-indole-2-carboxamide	Investigative
T83875	DRUGINFO	D0Z7NC	2-Phenethyl-4,5-dihydro-1H-imidazole	Investigative
T83875	DRUGINFO	D00NSA	5-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline	Investigative
T83875	DRUGINFO	D06BAC	8-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline	Investigative
T83875	DRUGINFO	D0G2EF	8-Bromo-4,9-dihydro-3H-beta-carboline	Investigative
T83875	DRUGINFO	D0J3SN	6-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline	Investigative
T83875	DRUGINFO	D0L8ND	5-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline	Investigative
T83875	DRUGINFO	D0Q3VI	8-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline	Investigative
T83875	DRUGINFO	D0V6XA	5-Methoxy-4,9-dihydro-3H-beta-carboline	Investigative
T83875	DRUGINFO	D0Y1GL	8-Methoxy-4,9-dihydro-3H-beta-carboline	Investigative
T83875	DRUGINFO	D08SCH	2-Amino-1-(4-methylthiophenyl)propane	Investigative
T83875	DRUGINFO	D09BIV	TRACIZOLINE	Investigative
T83875	DRUGINFO	D0LI3J	2-BFi	Investigative
T83875	DRUGINFO	D03LPH	TRYPTOLINE	Investigative
T83875	DRUGINFO	D05GDP	7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline	Investigative
T83875	DRUGINFO	D0C1SE	1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole	Investigative
T83875	DRUGINFO	D0I4ME	MMDA	Investigative
T83875	DRUGINFO	D0R7ZC	Beta-methoxyamphetamine	Investigative
T83875	DRUGINFO	D00IMW	Flavin-Adenine Dinucleotide	Investigative

T58454	TARGETID	T58454
T58454	FORMERID	TTDS00171
T58454	UNIPROID	FGFR2_HUMAN
T58454	TARGNAME	Fibroblast growth factor receptor 2 (FGFR2)
T58454	GENENAME	FGFR2
T58454	TARGTYPE	Successful
T58454	SYNONYMS	Keratinocyte growth factor receptor 2; Keratinocyte growth factor receptor; KSAM; KGFR; K-sam; FGFR-2; FGF-2 receptor; CD332; BEK
T58454	FUNCTION	Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1. Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development.
T58454	PDBSTRUC	5UI0; 5UHN; 5UGX; 5UGL; 5EG3
T58454	BIOCLASS	Kinase
T58454	ECNUMBER	EC 2.7.10.1
T58454	SEQUENCE	MVSWGRFICLVVVTMATLSLARPSFSLVEDTTLEPEEPPTKYQISQPEVYVAAPGESLEVRCLLKDAAVISWTKDGVHLGPNNRTVLIGEYLQIKGATPRDSGLYACTASRTVDSETWYFMVNVTDAISSGDDEDDTDGAEDFVSENSNNKRAPYWTNTEKMEKRLHAVPAANTVKFRCPAGGNPMPTMRWLKNGKEFKQEHRIGGYKVRNQHWSLIMESVVPSDKGNYTCVVENEYGSINHTYHLDVVERSPHRPILQAGLPANASTVVGGDVEFVCKVYSDAQPHIQWIKHVEKNGSKYGPDGLPYLKVLKAAGVNTTDKEIEVLYIRNVTFEDAGEYTCLAGNSIGISFHSAWLTVLPAPGREKEITASPDYLEIAIYCIGVFLIACMVVTVILCRMKNTTKKPDFSSQPAVHKLTKRIPLRRQVTVSAESSSSMNSNTPLVRITTRLSSTADTPMLAGVSEYELPEDPKWEFPRDKLTLGKPLGEGCFGQVVMAEAVGIDKDKPKEAVTVAVKMLKDDATEKDLSDLVSEMEMMKMIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLRARRPPGMEYSYDINRVPEEQMTFKDLVSCTYQLARGMEYLASQKCIHRDLAARNVLVTENNVMKIADFGLARDINNIDYYKKTTNGRLPVKWMAPEALFDRVYTHQSDVWSFGVLMWEIFTLGGSPYPGIPVEELFKLLKEGHRMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEEYLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHINGSVKT
T58454	DRUGINFO	D09PMV	Interferon Alfa-2a, Recombinant	Approved
T58454	DRUGINFO	D0O7GU	Palifermin	Approved
T58454	DRUGINFO	D0O6UY	Pemigatinib	Approved
T58454	DRUGINFO	D0KV1Q	Trafermin	Phase 3
T58454	DRUGINFO	D02WVT	E-3810	Phase 3
T58454	DRUGINFO	D0D4VV	LY2874455	Phase 2
T58454	DRUGINFO	D0XT0W	Debio 1347	Phase 2
T58454	DRUGINFO	D0G2QH	AEE-788	Phase 1/2
T58454	DRUGINFO	D00DRL	MK-2461	Phase 1/2
T58454	DRUGINFO	D0L6RF	BAY1179470	Phase 1
T58454	DRUGINFO	D47MOS	Alofanib	Phase 1
T58454	DRUGINFO	DU1DL0	RLY-4008	Phase 1
T58454	DRUGINFO	D0Z0KD	PD-0183812	Terminated
T58454	DRUGINFO	D02VPS	Anti-FGFR2 humanized mab	Investigative
T58454	DRUGINFO	D0IE6Z	Platelet factor 4 (PF-4)	Investigative
T58454	DRUGINFO	D0VN4K	PK 11195	Investigative
T58454	DRUGINFO	D0R6OM	ACTB-1003	Investigative
T58454	DRUGINFO	D0H1OK	TG-100435	Investigative
T58454	DRUGINFO	D09XIL	Ro-4396686	Investigative

T30082	TARGETID	T30082
T30082	FORMERID	TTDS00140
T30082	UNIPROID	ACES_HUMAN
T30082	TARGNAME	Acetylcholinesterase (AChE)
T30082	GENENAME	ACHE
T30082	TARGTYPE	Successful
T30082	SYNONYMS	YT; N-ACHE; ARACHE
T30082	FUNCTION	Role in neuronal apoptosis. Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft.
T30082	PDBSTRUC	6O69; 6F25; 6CQZ; 6CQY; 6CQX
T30082	BIOCLASS	Carboxylic ester hydrolase
T30082	ECNUMBER	EC 3.1.1.7
T30082	SEQUENCE	MRPPQCLLHTPSLASPLLLLLLWLLGGGVGAEGREDAELLVTVRGGRLRGIRLKTPGGPVSAFLGIPFAEPPMGPRRFLPPEPKQPWSGVVDATTFQSVCYQYVDTLYPGFEGTEMWNPNRELSEDCLYLNVWTPYPRPTSPTPVLVWIYGGGFYSGASSLDVYDGRFLVQAERTVLVSMNYRVGAFGFLALPGSREAPGNVGLLDQRLALQWVQENVAAFGGDPTSVTLFGESAGAASVGMHLLSPPSRGLFHRAVLQSGAPNGPWATVGMGEARRRATQLAHLVGCPPGGTGGNDTELVACLRTRPAQVLVNHEWHVLPQESVFRFSFVPVVDGDFLSDTPEALINAGDFHGLQVLVGVVKDEGSYFLVYGAPGFSKDNESLISRAEFLAGVRVGVPQVSDLAAEAVVLHYTDWLHPEDPARLREALSDVVGDHNVVCPVAQLAGRLAAQGARVYAYVFEHRASTLSWPLWMGVPHGYEIEFIFGIPLDPSRNYTAEEKIFAQRLMRYWANFARTGDPNEPRDPKAPQWPPYTAGAQQYVSLDLRPLEVRRGLRAQACAFWNRFLPKLLSATDTLDEAERQWKAEFHRWSSYMVHWKNQFDHYSKQDRCSDL
T30082	DRUGINFO	D00WVW	YM443	Approved
T30082	DRUGINFO	D06IAQ	Ambenonium	Approved
T30082	DRUGINFO	D06IDT	Demecarium bromide	Approved
T30082	DRUGINFO	D08USJ	Neostigmine	Approved
T30082	DRUGINFO	D0B2OT	Isoflurophate	Approved
T30082	DRUGINFO	D0E6YQ	Tacrine	Approved
T30082	DRUGINFO	D0K3LW	Malathion	Approved
T30082	DRUGINFO	D0NS6H	Donepezil	Approved
T30082	DRUGINFO	D0O2WB	Pyridostigmine	Approved
T30082	DRUGINFO	D0R9VR	Galantamine	Approved
T30082	DRUGINFO	D0S5LH	Edrophonium	Approved
T30082	DRUGINFO	D0U8AT	Echothiophate Iodide	Approved
T30082	DRUGINFO	D0WY5Q	Rivastigmine	Approved
T30082	DRUGINFO	D0X7NU	Pralidoxime Chloride	Approved
T30082	DRUGINFO	D06XWB	Huperzine A	Approved
T30082	DRUGINFO	D05UXU	INM-176	Phase 3
T30082	DRUGINFO	D0SH2X	Amocarzine	Phase 3
T30082	DRUGINFO	D01LYX	Eptastigmine	Phase 3
T30082	DRUGINFO	D07CIN	(-)-Phenserine	Phase 3
T30082	DRUGINFO	D0MZ9A	Suronacrine maleate	Phase 3
T30082	DRUGINFO	D0O5GK	R-phenserine	Phase 2
T30082	DRUGINFO	D0PC1V	T-82	Phase 2
T30082	DRUGINFO	D0W3BA	Methanesulfonyl fluoride	Phase 2
T30082	DRUGINFO	D67DST	AD-35	Phase 2
T30082	DRUGINFO	D0C3UC	Ladostigil	Phase 2
T30082	DRUGINFO	D01KDM	GTP-004	Phase 1
T30082	DRUGINFO	D05REB	ZT-1	Phase 1
T30082	DRUGINFO	D08ZRR	KW-5092	Phase 1
T30082	DRUGINFO	D0JA7V	PRX-105	Phase 1
T30082	DRUGINFO	D0WI9W	CPC-250	Phase 1
T30082	DRUGINFO	D0X1XK	CPC-212	Phase 1
T30082	DRUGINFO	D0T5AW	Desoxypeganine	Phase 1
T30082	DRUGINFO	D00AQW	PMID27967267-Compound-36	Patented
T30082	DRUGINFO	D01EGC	PMID27967267-Compound-47	Patented
T30082	DRUGINFO	D01FRI	PMID27967267-Compound-15	Patented
T30082	DRUGINFO	D01RZG	Amidine oxime derivative 1	Patented
T30082	DRUGINFO	D02GCZ	PMID27967267-Compound-stenine	Patented
T30082	DRUGINFO	D02SQQ	PMID27967267-Compound-13	Patented
T30082	DRUGINFO	D03VUN	Lycorine dimer salt derivative 1	Patented
T30082	DRUGINFO	D03WGA	PMID27967267-Compound-neostenine	Patented
T30082	DRUGINFO	D04TGJ	PMID27967267-Compound-3	Patented
T30082	DRUGINFO	D04XHE	PMID27967267-Compound-39	Patented
T30082	DRUGINFO	D05QVX	Tacrine-indole hybrid derivative 3	Patented
T30082	DRUGINFO	D05WPG	Tacrine-caffeic acid hybrid derivative 1	Patented
T30082	DRUGINFO	D06GSR	PMID27967267-Compound-52	Patented
T30082	DRUGINFO	D07HNU	PMID27967267-Compound-42	Patented
T30082	DRUGINFO	D0AH3R	Fluorinated donepezil derivative 2	Patented
T30082	DRUGINFO	D0C0LQ	2-PAM derivative 1	Patented
T30082	DRUGINFO	D0C1UA	Tacrine-dihydropyridine hybrid derivative 1	Patented
T30082	DRUGINFO	D0G4YS	4-PAM derivative 1	Patented
T30082	DRUGINFO	D0G9HY	Tacrine-indole hybrid derivative 1	Patented
T30082	DRUGINFO	D0HI1R	PMID27967267-Compound-48	Patented
T30082	DRUGINFO	D0I2FM	Tacrine-phenothiazine hybrid derivative 1	Patented
T30082	DRUGINFO	D0I6UA	PMID27967267-Compound-27	Patented
T30082	DRUGINFO	D0I7KU	Tacrine-indole hybrid derivative 2	Patented
T30082	DRUGINFO	D0OG8Z	PMID27967267-Compound-49	Patented
T30082	DRUGINFO	D0QJ5H	PMID27967267-Compound-12	Patented
T30082	DRUGINFO	D0SW0V	Tacrine-caffeic acid hybrid derivative 2	Patented
T30082	DRUGINFO	D0T0CB	PMID27967267-Compound-7	Patented
T30082	DRUGINFO	D0UX5I	PMID27967267-Compound-14	Patented
T30082	DRUGINFO	D0V2JR	PMID27967267-Compound-neotuberostemonine	Patented
T30082	DRUGINFO	D0W9ZU	Galantamine analog 1	Patented
T30082	DRUGINFO	D0X5KA	PMID27967267-Compound-51	Patented
T30082	DRUGINFO	D0XS3N	Fluorinated donepezil derivative 1	Patented
T30082	DRUGINFO	D0YF7A	PMID27967267-Compound-43	Patented
T30082	DRUGINFO	D0ZX8C	PMID27967267-Compound-28	Patented
T30082	DRUGINFO	D01SQO	Quinazoline alkaloid derivative 1	Patented
T30082	DRUGINFO	D03DIQ	Egonol compound 1	Patented
T30082	DRUGINFO	D04FAS	PMID29757691-Compound-8b	Patented
T30082	DRUGINFO	D0B9TI	PMID29757691-Compound-8d	Patented
T30082	DRUGINFO	D0CB1C	Tacrine heterodimer derivative 1	Patented
T30082	DRUGINFO	D0H3YG	PMID29757691-Compound-2a	Patented
T30082	DRUGINFO	D0J3OD	Indoline derivative 1	Patented
T30082	DRUGINFO	D0K3EB	Di-substituted piperidine derivative 2	Patented
T30082	DRUGINFO	D0OE6G	Isochroman-4-ketone derivative 1	Patented
T30082	DRUGINFO	D0RS6O	PMID29757691-Compound-8a	Patented
T30082	DRUGINFO	D0VQ2N	PMID29757691-Compound-8c	Patented
T30082	DRUGINFO	D0W9OC	PMID29757691-Compound-7	Patented
T30082	DRUGINFO	D0WD0M	PMID29757691-Compound-2a-i	Patented
T30082	DRUGINFO	D0X9CR	PMID29757691-Compound-10	Patented
T30082	DRUGINFO	D0Y4CG	Decyle nelycorine dibromo salt derivative 1	Patented
T30082	DRUGINFO	D0AA7U	PMID29757691-Compound-4	Patented
T30082	DRUGINFO	D02EME	Tetra-hydro-isoquinoline derivative 3	Patented
T30082	DRUGINFO	D04AXC	Tetra-hydro-isoquinoline derivative 1	Patented
T30082	DRUGINFO	D0NB7Z	Tetra-hydro-isoquinoline derivative 2	Patented
T30082	DRUGINFO	D0R6RT	Tetra-hydro-isoquinoline derivative 4	Patented
T30082	DRUGINFO	D0AM8W	Zanapezil	Discontinued in Phase 3
T30082	DRUGINFO	D0L8QQ	VELNACRINE	Discontinued in Phase 3
T30082	DRUGINFO	D03GAX	TAK-802	Discontinued in Phase 2
T30082	DRUGINFO	D05UHJ	SM-10888	Discontinued in Phase 2
T30082	DRUGINFO	D09JVV	Physostigmine	Discontinued in Phase 2
T30082	DRUGINFO	D09PTA	HP-290	Discontinued in Phase 2
T30082	DRUGINFO	D0B2BQ	Icopezil maleate	Discontinued in Phase 2
T30082	DRUGINFO	D0F1VQ	ZIFROSILONE	Discontinued in Phase 2
T30082	DRUGINFO	D0F3FB	S-9977	Discontinued in Phase 2
T30082	DRUGINFO	D0R5UZ	Caracemide	Discontinued in Phase 2
T30082	DRUGINFO	D04UKJ	NP-61	Discontinued in Phase 1
T30082	DRUGINFO	D0SR4T	PHENSERINE TARTRATE	Preclinical
T30082	DRUGINFO	D0V7FG	SPH-1285	Preclinical
T30082	DRUGINFO	D02UQU	ABS-301	Terminated
T30082	DRUGINFO	D03DFY	NP-7557	Terminated
T30082	DRUGINFO	D06ZAM	MF268	Terminated
T30082	DRUGINFO	D09IUG	F-3796	Terminated
T30082	DRUGINFO	D0J4GQ	FR-152558	Terminated
T30082	DRUGINFO	D0K0XG	MF-8615	Terminated
T30082	DRUGINFO	D0M2GI	CI-1002	Terminated
T30082	DRUGINFO	D0S1VV	7-methoxytacrine	Terminated
T30082	DRUGINFO	D0TK0W	Ro-46-5934	Terminated
T30082	DRUGINFO	D00AJB	Voacangine	Investigative
T30082	DRUGINFO	D00FEH	Mesuagenin D	Investigative
T30082	DRUGINFO	D00RLO	(3-Bromo-propyl)-trimethyl-ammonium	Investigative
T30082	DRUGINFO	D00YHI	N-(14-methylallyl)norgalanthamine	Investigative
T30082	DRUGINFO	D01MVX	TACRINE(8)-4-AMINOQUINOLINE	Investigative
T30082	DRUGINFO	D01RUH	LYSICAMINE	Investigative
T30082	DRUGINFO	D01XRG	CRYPTADINE B	Investigative
T30082	DRUGINFO	D01ZHK	N-isopropylnorlitebamine	Investigative
T30082	DRUGINFO	D02DUJ	GENESERINE	Investigative
T30082	DRUGINFO	D02ELG	4-formylphenyl-O-beta-Dglucopyranoside	Investigative
T30082	DRUGINFO	D02VFM	DECIDIUM	Investigative
T30082	DRUGINFO	D03EPB	BIS(18)-HUPERZINE B	Investigative
T30082	DRUGINFO	D03FHV	MESUAGENIN A	Investigative
T30082	DRUGINFO	D03FZK	(4-Bromo-butyl)-trimethyl-ammonium	Investigative
T30082	DRUGINFO	D03JRX	N-n-dodecyl-7-methoxytacrine hydrochloride	Investigative
T30082	DRUGINFO	D03KMG	1-benzene sulfonyl-cis-2,6-dimethyl piperidine	Investigative
T30082	DRUGINFO	D03PQH	3-hydroxy-N,N,N-trimethylbenzenaminium iodide	Investigative
T30082	DRUGINFO	D03WOS	5-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamine	Investigative
T30082	DRUGINFO	D03XXV	6-Methyl-4-(4-phenylpiperazin-1-yl)coumarin	Investigative
T30082	DRUGINFO	D04JAX	6-Methyl-4-(4-o-tolylpiperazin-1-yl)coumarin	Investigative
T30082	DRUGINFO	D04KWA	Bis(14)-Huperzine B	Investigative
T30082	DRUGINFO	D04LMJ	MMB-4	Investigative
T30082	DRUGINFO	D04OUJ	1-Deoxy-1-Thio-Heptaethylene Glycol	Investigative
T30082	DRUGINFO	D04XXE	CORONARIDINE	Investigative
T30082	DRUGINFO	D04ZJK	BIS(20)-HUPERZINE B	Investigative
T30082	DRUGINFO	D04ZJO	(-)-huperzine B	Investigative
T30082	DRUGINFO	D04ZQL	But-3-enyl-trimethyl-ammonium bromide	Investigative
T30082	DRUGINFO	D05CCT	3,7-BIS(DIMETHYLAMINO)PHENOTHIAZIN-5-IUM	Investigative
T30082	DRUGINFO	D05EPI	Isosorbide-di-(4-nitrophenyl carbamate)	Investigative
T30082	DRUGINFO	D05KZH	(5-Bromo-pentyl)-trimethyl-ammonium	Investigative
T30082	DRUGINFO	D05QXU	1,3-Bis-(3-imidazolidin-2-yl-phenyl)-urea	Investigative
T30082	DRUGINFO	D06ACI	BZYX	Investigative
T30082	DRUGINFO	D06EJS	BIS(12)-HUPERZINE B	Investigative
T30082	DRUGINFO	D06LRC	Isosorbide-di-phenylcarbamate	Investigative
T30082	DRUGINFO	D07EMX	(1R)-1,2,2-TRIMETHYLPROPYL (S)-METHYLPHOSPHINATE	Investigative
T30082	DRUGINFO	D07FFB	Carinatumins B (2)	Investigative
T30082	DRUGINFO	D07YQY	N-benzylnorlitebamine	Investigative
T30082	DRUGINFO	D08JOR	(3-Hydroxy-2-methyl-phenyl)-trimethyl-ammonium	Investigative
T30082	DRUGINFO	D08LBC	N-butylnorlitebamine	Investigative
T30082	DRUGINFO	D08PWL	N-n-propyl-7-methoxytacrine hydrochloride	Investigative
T30082	DRUGINFO	D08QQR	Beta-L-fucose	Investigative
T30082	DRUGINFO	D08TRN	(2-Ethoxy-ethyl)-trimethyl-ammonium iodide	Investigative
T30082	DRUGINFO	D08UET	Propidium	Investigative
T30082	DRUGINFO	D08WRG	3-(4-o-Tolylpiperazine-1-carbonyl)coumarin	Investigative
T30082	DRUGINFO	D08XPP	9-hydrazino-1,2,3,4-tetrahydroacridine	Investigative
T30082	DRUGINFO	D09DJX	(S,S)-(-)-bis(12)-hupyridone	Investigative
T30082	DRUGINFO	D09JAB	3-(2,5-Dioxo-pyrrolidin-1-yl)-benzoic acid	Investigative
T30082	DRUGINFO	D09JZY	Cis-2,6-dimethyl-1-methyl sulfonyl piperidine	Investigative
T30082	DRUGINFO	D09NEH	6-Methyl-4-(4-benzoylpiperazin-1-yl)coumarin	Investigative
T30082	DRUGINFO	D09ZGN	2-Hex-5-enyl-5-non-8-enyl-3,4-dihydro-2H-pyrrole	Investigative
T30082	DRUGINFO	D0A0FK	Huprine Y	Investigative
T30082	DRUGINFO	D0A6MF	MESUAGENIN B	Investigative
T30082	DRUGINFO	D0A9IM	(R)-tacrine(10)-hupyridone	Investigative
T30082	DRUGINFO	D0B2JV	N-propylnorlitebamine	Investigative
T30082	DRUGINFO	D0C0NS	4ALPHA-(HYDROXYMETHYL)-4ALPHA-DEMETHYLTERRITREM B	Investigative
T30082	DRUGINFO	D0C6QF	2-Hex-5-enyl-5-non-8-enyl-pyrrolidine	Investigative
T30082	DRUGINFO	D0D3TB	N-ALLYLNORGALANTHAMINE	Investigative
T30082	DRUGINFO	D0D3TG	5-Hex-5-enyl-2-nonyl-3,4-dihydro-2H-pyrrole	Investigative
T30082	DRUGINFO	D0D4SK	6,8-Dichloro-1,2,3,4-tetrahydro-acridin-9-ylamine	Investigative
T30082	DRUGINFO	D0D5QT	1-(3-Bromomethyl-phenyl)-2,2,2-trifluoro-ethanone	Investigative
T30082	DRUGINFO	D0D9PI	Tetraethylene Glycol	Investigative
T30082	DRUGINFO	D0DV9Z	6-methoxy-2,9-dimethyl-9H-beta-carbolin-2-ium	Investigative
T30082	DRUGINFO	D0E0ZV	3-(2-N-Piperidyl-acetamino)-rutaecarpine	Investigative
T30082	DRUGINFO	D0E2LR	3-[2-(1-Benzyl-piperidin-4-yl)-ethyl]-1H-indazole	Investigative
T30082	DRUGINFO	D0E3OZ	OBIDOXIME	Investigative
T30082	DRUGINFO	D0ER5C	6-hydroxy-2,9-dimethyl-9H-beta-carbolin-2-ium	Investigative
T30082	DRUGINFO	D0FI9G	10-Hydroxy-infractopicrin	Investigative
T30082	DRUGINFO	D0FS3L	4-formylphenyl-O-beta-D-ribopyranoside	Investigative
T30082	DRUGINFO	D0FY2N	NPRx-30	Investigative
T30082	DRUGINFO	D0G2WI	CP-126998	Investigative
T30082	DRUGINFO	D0G5QX	TRIMEDOXIME	Investigative
T30082	DRUGINFO	D0GT6I	(2-Mercapto-ethyl)-trimethyl-ammonium iodide	Investigative
T30082	DRUGINFO	D0H4DW	9-Ethyl-beta-carboline	Investigative
T30082	DRUGINFO	D0H5XD	3-(3-Carboxy-propionylamino)-benzoic acid	Investigative
T30082	DRUGINFO	D0H7OP	N-allylnorlitebamine	Investigative
T30082	DRUGINFO	D0I0EN	TURBINATINE	Investigative
T30082	DRUGINFO	D0J3EU	(2-Chloro-ethyl)-trimethyl-ammonium chloride	Investigative
T30082	DRUGINFO	D0J9FT	3-[(1s)-1-(Dimethylamino)Ethyl]Phenol	Investigative
T30082	DRUGINFO	D0K8AU	2-morpholino-N-phenethylpyrimidin-4-amine	Investigative
T30082	DRUGINFO	D0L0ZH	TASPINE	Investigative
T30082	DRUGINFO	D0L4OW	GANSTIGMINE	Investigative
T30082	DRUGINFO	D0L8UL	Pseudopalmatine trifluoroacetate	Investigative
T30082	DRUGINFO	D0M1CG	Allyl-trimethyl-ammonium	Investigative
T30082	DRUGINFO	D0M5ES	CHLORPYRIFOS	Investigative
T30082	DRUGINFO	D0M8SQ	Trimethyl-(3-nitro-phenyl)-ammonium iodide	Investigative
T30082	DRUGINFO	D0M9JF	Petrosamine	Investigative
T30082	DRUGINFO	D0MB3S	7-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamine	Investigative
T30082	DRUGINFO	D0N8EC	BIS(8)-HUPERZINE B	Investigative
T30082	DRUGINFO	D0N9DB	9-amino-7H-dibenzo[de,h]quinolin-7-one	Investigative
T30082	DRUGINFO	D0O1JC	2-Hex-5-enyl-5-nonyl-pyrrolidine	Investigative
T30082	DRUGINFO	D0O1QB	BW284C51	Investigative
T30082	DRUGINFO	D0O6AH	Trimethyl-(4-oxo-pentyl)-ammonium iodide	Investigative
T30082	DRUGINFO	D0O9OW	N-isobutylnorlitebamine	Investigative
T30082	DRUGINFO	D0P5CV	BIS(16)-HUPERZINE B	Investigative
T30082	DRUGINFO	D0P5YS	TERRITREM B	Investigative
T30082	DRUGINFO	D0P8KQ	(4-Iodo-butyl)-trimethyl-ammonium iodide	Investigative
T30082	DRUGINFO	D0PF3Z	N-isopropylnorlitebamineN-methoiodide	Investigative
T30082	DRUGINFO	D0Q2DE	CHOLINE IODIDE	Investigative
T30082	DRUGINFO	D0R1FR	(3R)-9-amino-3-methyl-1,2,3,4-tetrahydroacridine	Investigative
T30082	DRUGINFO	D0R2QC	4-[4-(benzhydryloxy)piperidino]butyl benzoate	Investigative
T30082	DRUGINFO	D0RA5T	Pseudocolumbamine trifluoroacetate	Investigative
T30082	DRUGINFO	D0S2DW	AP-2238	Investigative
T30082	DRUGINFO	D0S7HC	3-(4-Phenylpiperazin-1-carbonyl)coumarin	Investigative
T30082	DRUGINFO	D0SE8T	(2-Butyryloxy-ethyl)-trimethyl-ammonium iodide	Investigative
T30082	DRUGINFO	D0ST5U	Galanthamine derivative	Investigative
T30082	DRUGINFO	D0T4UO	(S)-tacrine(10)-hupyridone	Investigative
T30082	DRUGINFO	D0T7ZN	Dimethyl-pent-4-enyl-ammonium bromide	Investigative
T30082	DRUGINFO	D0U1SE	Hexyl-trimethyl-ammonium	Investigative
T30082	DRUGINFO	D0UF9K	BIS(9)-HUPERZINE B	Investigative
T30082	DRUGINFO	D0V0PS	9-Amino-1,2,3,4-tetrahydro-acridine-1,7-diol	Investigative
T30082	DRUGINFO	D0V7EA	3-(4-Benzoylpiperazine-1-carbonyl)coumarin	Investigative
T30082	DRUGINFO	D0VI6N	Isosorbide-2-benzylcarbamate-5-tosylate	Investigative
T30082	DRUGINFO	D0W8RP	Monoisopropylphosphorylserine	Investigative
T30082	DRUGINFO	D0X4EV	8-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamine	Investigative
T30082	DRUGINFO	D0XL1R	ETHYLPHENSERINE	Investigative
T30082	DRUGINFO	D0XN8A	Infractopicrin	Investigative
T30082	DRUGINFO	D0Y3LO	(S,S)-(-)-bis(10)-hupyridone	Investigative
T30082	DRUGINFO	D0Z4OS	N-benzyl-2-morpholinopyrimidin-4-amine	Investigative
T30082	DRUGINFO	D0Z6GG	N-benzyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine	Investigative
T30082	DRUGINFO	D00FPI	1,4-Di(berberine-9-O-yl)ethane dibromide	Investigative
T30082	DRUGINFO	D00MFR	6-methoxy-1,2-dimethyl-9H-beta-carbolin-2-ium	Investigative
T30082	DRUGINFO	D00NIX	9-O-[3-(Phenylamino)propyl]-berberine bromide	Investigative
T30082	DRUGINFO	D01AJQ	Isosorbide-di-(benzylcarbamate)	Investigative
T30082	DRUGINFO	D01DHW	9-O-[2-(Phenylol-1-yloxy)ethyl]berberine bromide	Investigative
T30082	DRUGINFO	D01EZC	3-[4-(benzylmethylamino)butoxy]xanthen-9-one	Investigative
T30082	DRUGINFO	D01GWN	(24S)-ethylcholesta-7,9(11),22(E)-triene-3b-ol	Investigative
T30082	DRUGINFO	D01KVT	MEMOQUIN	Investigative
T30082	DRUGINFO	D01OND	3-(dimethylamino)phenyl phenylcarbamate	Investigative
T30082	DRUGINFO	D01QRR	Isosorbide-2-benzylcarbamate-5-cyclopentanoate	Investigative
T30082	DRUGINFO	D01TLN	9-O-[4-(Phenylol-1-yloxy)butyl]berberine bromide	Investigative
T30082	DRUGINFO	D02AFZ	2-Propyl-beta-carboline-2-ium iodide	Investigative
T30082	DRUGINFO	D02DWE	3,6,9,12,15-Pentaoxaheptadecane	Investigative
T30082	DRUGINFO	D02JXK	N,N'-(1',11'-undecydene)-bis-(-)-nor-MEP	Investigative
T30082	DRUGINFO	D02LWX	6-hydroxy-2-methyl-9H-beta-carbolin-2-ium	Investigative
T30082	DRUGINFO	D02QMU	9-O-[3-(2-Pyridinoxyl)butyl]-berberine bromide	Investigative
T30082	DRUGINFO	D02WKB	9-O-[2-(Phenylol-1-yloxy)hexyl]berberine bromide	Investigative
T30082	DRUGINFO	D03DIP	3-(2-Diethylamino-propionamino)-rutaecarpine	Investigative
T30082	DRUGINFO	D04FHZ	(-)-Tolserine	Investigative
T30082	DRUGINFO	D04GTP	CHF-2819	Investigative
T30082	DRUGINFO	D04SYM	Isosorbide-2-(methylcarbamate)-5-mononitrate	Investigative
T30082	DRUGINFO	D05QNR	N,N'-(1',9'-nonylene)-bis-(-)-nor-MEP	Investigative
T30082	DRUGINFO	D05UJV	N-n-pentyl-7-methoxytacrine hydrochloride	Investigative
T30082	DRUGINFO	D07VIO	3-(2-Diethylamino-acetamino)-rutaecarpine	Investigative
T30082	DRUGINFO	D07YJG	1,11-bis(pyridinium)-undecane dibromide	Investigative
T30082	DRUGINFO	D09CGV	6-hydroxy-1,2-dimethyl-9H-beta-carbolin-2-ium	Investigative
T30082	DRUGINFO	D09FAU	(RS)-tacrine(10)-hupyridone	Investigative
T30082	DRUGINFO	D09GXM	3-[7-(benzylmethylamino)-heptyloxy]xanthen-9-one	Investigative
T30082	DRUGINFO	D09JCF	Huprine-Tacrine Heterodimer	Investigative
T30082	DRUGINFO	D09MCN	Haloxysterol D	Investigative
T30082	DRUGINFO	D09QDC	Iso-OMPA	Investigative
T30082	DRUGINFO	D09RJH	Huprine X	Investigative
T30082	DRUGINFO	D09XSI	9-O-[5-(Phenylol-1-yloxy)pentyl]berberine bromide	Investigative
T30082	DRUGINFO	D0A2BE	CLEBOPRIDE	Investigative
T30082	DRUGINFO	D0A8OX	N,N'-(1',5'-pentylene)-bis-(-)-nor-MEP	Investigative
T30082	DRUGINFO	D0B4DT	3-[8-(benzylmethylamino)octyloxy]xanthen-9-one	Investigative
T30082	DRUGINFO	D0C0XU	N-n-heptyl-7-methoxytacrine hydrochloride	Investigative
T30082	DRUGINFO	D0C3IS	3-(2-N-Piperidyl-propionamino)-rutaecarpine	Investigative
T30082	DRUGINFO	D0E0LL	Haloxysterol C	Investigative
T30082	DRUGINFO	D0E4BT	N-benzyl-2-thiomorpholinopyrimidin-4-amine	Investigative
T30082	DRUGINFO	D0EX1R	N,N'-(1',7'-heptylene)-bis-(-)-nor-MEP	Investigative
T30082	DRUGINFO	D0F0PY	N,N'-(1',12'-dodecydene)-bis-(-)-nor-MEP	Investigative
T30082	DRUGINFO	D0F5EJ	LIPOCRINE	Investigative
T30082	DRUGINFO	D0F6VM	3-(2-N-Pyrrolyl-propionamino)-rutaecarpine	Investigative
T30082	DRUGINFO	D0G0GZ	N-Methyl-1'H-phenothiazine-1'-carboxamide	Investigative
T30082	DRUGINFO	D0G5SM	HALOXYSTEROL A	Investigative
T30082	DRUGINFO	D0G5TL	6-hydroxy-1,2,9-trimethyl-9H-beta-carbolin-2-ium	Investigative
T30082	DRUGINFO	D0H2UG	N-n-nonyl-7-methoxytacrine hydrochloride	Investigative
T30082	DRUGINFO	D0H3BC	3-[5-(benzylmethylamino)pentyloxy]xanthen-9-one	Investigative
T30082	DRUGINFO	D0I3UA	7-Oxo-7H-dibenzo[de,g]quinoline	Investigative
T30082	DRUGINFO	D0J4LR	24-ethyl-cholest-7-ene-3,5,6-triol	Investigative
T30082	DRUGINFO	D0J4QH	Methyl Phosphinic Acid	Investigative
T30082	DRUGINFO	D0K2FQ	1,2-Di(berberine-9-O-yl)ethane dibromide	Investigative
T30082	DRUGINFO	D0K6GY	Ethyl octylfluorophosphonate	Investigative
T30082	DRUGINFO	D0K8BT	Isosorbide-2-(methylcarbamate)-5-benzoate	Investigative
T30082	DRUGINFO	D0L3IS	1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE	Investigative
T30082	DRUGINFO	D0L5QJ	1,9-bis(pyridinium)-nonane dibromide	Investigative
T30082	DRUGINFO	D0L9YJ	3-[3-(benzylmethylamino)propoxy]xanthen-9-one	Investigative
T30082	DRUGINFO	D0LT0T	3-(2-N-Pyrrolyl-acetamino)-rutaecarpine	Investigative
T30082	DRUGINFO	D0M0BM	6-chlorotacrine hydrochloride	Investigative
T30082	DRUGINFO	D0M2EM	BENZOQUINONE	Investigative
T30082	DRUGINFO	D0MC3U	N,N'-(1',10'-decylene)-bis-(-)-nor-MEP	Investigative
T30082	DRUGINFO	D0MV0T	2,3-dihydropyrrolo[2,1-b]quinazolin-9(1H)-imine	Investigative
T30082	DRUGINFO	D0NJ5W	CAPROCTAMINE	Investigative
T30082	DRUGINFO	D0O2OH	4-ISOPROPYLPHENSERINE	Investigative
T30082	DRUGINFO	D0O8AQ	Isosorbide-di-(ethylcarbamate)	Investigative
T30082	DRUGINFO	D0O8DZ	3-[6-(benzylmethylamino)hexyloxy]xanthen-9-one	Investigative
T30082	DRUGINFO	D0O9YQ	N-n-hexyl-7-methoxytacrine hydrochloride	Investigative
T30082	DRUGINFO	D0P2VL	9-O-[3-(4-Nitro-phenoxyl)butyl]-berberine bromide	Investigative
T30082	DRUGINFO	D0P5BT	1,3-Di(berberine-9-O-yl)ethane dibromide	Investigative
T30082	DRUGINFO	D0P6PQ	THIOCTIC ACID	Investigative
T30082	DRUGINFO	D0PF7F	TOLSERINE	Investigative
T30082	DRUGINFO	D0Q3EV	N-n-octyl-7-methoxytacrine hydrochloride	Investigative
T30082	DRUGINFO	D0S1MC	AP-2243	Investigative
T30082	DRUGINFO	D0T5MD	Isosorbide-2-benzylcarbamate-5-cyclopropanoate	Investigative
T30082	DRUGINFO	D0V3LC	24-ethylcholest-6-ene-3,5-diol	Investigative
T30082	DRUGINFO	D0W7XL	9-O-[3-(Phenylol-1-yloxy)propyl]berberine bromide	Investigative
T30082	DRUGINFO	D0W8NK	9-Ethyl-2-methyl-beta-carboline-2-ium iodide	Investigative
T30082	DRUGINFO	D0X3FF	HALOXYSTEROL B	Investigative
T30082	DRUGINFO	D0X4HG	XANTHOSTIGMINE	Investigative
T30082	DRUGINFO	D0XI4U	6-methoxy-2-methyl-9H-beta-carbolin-2-ium	Investigative
T30082	DRUGINFO	D0Y0VQ	N,N'-(1',8'-octylene)-bis-(-)-nor-MEP	Investigative
T30082	DRUGINFO	D0Y7UG	N,N'-(1',6-hexylene)-bis-(-)-nor-MEP	Investigative
T30082	DRUGINFO	D0Z6RT	LAWSARITOL	Investigative
T30082	DRUGINFO	D0Z6WU	1,10-bis(pyridinium)-decane dibromide	Investigative
T30082	DRUGINFO	D0ZI7F	6-methoxy-1,9-dimethyl-9H-pyrido[3,4-b]indole	Investigative
T30082	DRUGINFO	D0ZL9I	9-O-[3-(4-Bromo-phenoxyl)butyl]-berberine bromide	Investigative
T30082	DRUGINFO	D0ZY4C	N-phenethyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine	Investigative
T30082	DRUGINFO	D06IEN	2-(Acetylamino)-2-Deoxy-a-D-Glucopyranose	Investigative
T30082	DRUGINFO	D0D0BI	CHLORANIL	Investigative
T30082	DRUGINFO	D0F5VY	NSC-23180	Investigative
T30082	DRUGINFO	D0HQ4M	Isopropyl dodecylfluorophosphonate	Investigative
T30082	DRUGINFO	D0M4IE	Bis-7-tacrine	Investigative
T30082	DRUGINFO	D0N0HK	3,4,5,6-Tetrachloro-[1,2]benzoquinone	Investigative
T30082	DRUGINFO	D0W6PT	Chlorphrifos oxon	Investigative
T30082	DRUGINFO	D0WX6R	5,6-dinitroacenaphthoquinone	Investigative
T30082	DRUGINFO	D0W9VA	1,2-NAPHTHOQUINONE	Investigative
T30082	DRUGINFO	D08XQI	PARAOXON	Investigative
T30082	DRUGINFO	D07KZA	2-(N-Morpholino)-Ethanesulfonic Acid	Investigative
T30082	DRUGINFO	D0G6XS	Fucose	Investigative
T30082	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T53378	TARGETID	T53378
T53378	FORMERID	TTDR00209
T53378	UNIPROID	CAH4_HUMAN
T53378	TARGNAME	Carbonic anhydrase IV (CA-IV)
T53378	GENENAME	CA4
T53378	TARGTYPE	Successful
T53378	SYNONYMS	Carbonic anhydrase 4; Carbonate dehydratase IV; CAIV
T53378	FUNCTION	May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina and retina epithelium, and acid release in the choriocapillaris in the choroid. Reversible hydration of carbon dioxide.
T53378	PDBSTRUC	5KU6; 5JNC; 5JNA; 5JN9; 5JN8
T53378	BIOCLASS	Alpha-carbonic anhydrase
T53378	ECNUMBER	EC 4.2.1.1
T53378	SEQUENCE	MRMLLALLALSAARPSASAESHWCYEVQAESSNYPCLVPVKWGGNCQKDRQSPINIVTTKAKVDKKLGRFFFSGYDKKQTWTVQNNGHSVMMLLENKASISGGGLPAPYQAKQLHLHWSDLPYKGSEHSLDGEHFAMEMHIVHEKEKGTSRNVKEAQDPEDEIAVLAFLVEAGTQVNEGFQPLVEALSNIPKPEMSTTMAESSLLDLLPKEEKLRHYFRYLGSLTTPTCDEKVVWTVFREPIQLHREQILAFSQKLYYDKEQTVSMKDNVRPLQQLGQRTVIKSGAPGRPLPWALPALLGPMLACLLAGFLR
T53378	DRUGINFO	D01MUR	Brinzolamide	Approved
T53378	DRUGINFO	D0K1QD	Sulfamylon	Approved
T53378	DRUGINFO	D07HBX	Salicyclic acid	Approved
T53378	DRUGINFO	D0A8JP	PARABEN	Phase 3
T53378	DRUGINFO	D07SDQ	Curcumin	Phase 3
T53378	DRUGINFO	D0L6HN	PHENOL	Phase 2/3
T53378	DRUGINFO	D0Y6OA	Coumate	Phase 2
T53378	DRUGINFO	D02ECG	Sodium pyruvate	Phase 1/2
T53378	DRUGINFO	D0V0UK	SULFAMIDE	Phase 1
T53378	DRUGINFO	D03SLR	FERULIC ACID	Patented
T53378	DRUGINFO	D0LD9S	SPERMINE	Terminated
T53378	DRUGINFO	D01DOW	Trisodium phosphate	Investigative
T53378	DRUGINFO	D01ENA	[Fe(CN)6]4-	Investigative
T53378	DRUGINFO	D03MXZ	Malonate sodium	Investigative
T53378	DRUGINFO	D04HQK	N-(5-Sulfamoyl-[1,3,4]thiadiazol-2-yl)-benzamide	Investigative
T53378	DRUGINFO	D05KTE	SODIUM CITRATE	Investigative
T53378	DRUGINFO	D0EX9Q	2-Propyl-pentanoic acid 4-sulfamoyl-benzyl ester	Investigative
T53378	DRUGINFO	D0GQ9A	Sodium phenylarsonate	Investigative
T53378	DRUGINFO	D0H0PQ	Aminocarbonyl dihydrogen phosphate	Investigative
T53378	DRUGINFO	D0H7JJ	Sodium sulfamate	Investigative
T53378	DRUGINFO	D0Q4VO	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS	Investigative
T53378	DRUGINFO	D0R3DQ	SYL-040003	Investigative
T53378	DRUGINFO	D0S1OY	2-Propyl-pentanoic acid 4-sulfamoyl-benzylamide	Investigative
T53378	DRUGINFO	D00CIW	Phenyl-phosphonic acid	Investigative
T53378	DRUGINFO	D0L2GD	[Cu(CN)2]-	Investigative
T53378	DRUGINFO	D0M6RM	Phenylarsonic acid	Investigative
T53378	DRUGINFO	D0Y6EL	Carbamoyl phosphate disodium	Investigative
T53378	DRUGINFO	D00BMI	N-1,3,4-thiadiazol-2-ylsulfamide	Investigative
T53378	DRUGINFO	D03EAQ	N-hydroxysulfonamides	Investigative
T53378	DRUGINFO	D0D5XC	Sodium trithiocarbonate	Investigative
T53378	DRUGINFO	D04PSK	N-[5-(methylthio)-1,3,4-thiadiazol-2-yl]sulfamide	Investigative
T53378	DRUGINFO	D06JVR	N-(5-phenyl-1,3,4-thiadiazol-2-yl)sulfamide	Investigative
T53378	DRUGINFO	D07QJJ	CATECHOL	Investigative
T53378	DRUGINFO	D09UQM	1-(3,4-dichlorophenyl)-3-hydroxyurea	Investigative
T53378	DRUGINFO	D0E3VJ	N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]sulfamide	Investigative
T53378	DRUGINFO	D0L6CN	N-(phosphonacetyl)-L-aspartate	Investigative
T53378	DRUGINFO	D0S4NO	N-(5-ethyl-1,3,4-thiadiazol-2-yl)sulfamide	Investigative
T53378	DRUGINFO	D0S8RD	Trecadrine	Investigative
T53378	DRUGINFO	D0T2VH	N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)sulfamide	Investigative
T53378	DRUGINFO	D00RNZ	7-(benzyloxy)-2H-chromen-2-one	Investigative
T53378	DRUGINFO	D03VDJ	SULFAMATE	Investigative
T53378	DRUGINFO	D07TAJ	Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate	Investigative
T53378	DRUGINFO	D0EJ9B	Phenyl Boronic acid	Investigative
T53378	DRUGINFO	D0H3NS	2-oxo-2H-chromene-3-carboxylic acid	Investigative
T53378	DRUGINFO	D0J2AE	3-Amino-benzenesulfonamide	Investigative
T53378	DRUGINFO	D0X5HL	N1-(naphthalen-1-yl)ethane-1,2-diamine	Investigative
T53378	DRUGINFO	D04NSN	4-(2-AMINOETHYL)BENZENESULFONAMIDE	Investigative
T53378	DRUGINFO	D09JPC	Hexane-1,6-diamine	Investigative
T53378	DRUGINFO	D0G3BI	6-methyl-2-oxo-2H-chromene-3-carboxylic acid	Investigative
T53378	DRUGINFO	D0L5TZ	6-(hydroxymethyl)-2H-chromen-2-one	Investigative
T53378	DRUGINFO	D0U4BB	HERNIARIN	Investigative
T53378	DRUGINFO	D00YEF	Decane-1,10-diyl disulfamate	Investigative
T53378	DRUGINFO	D01STY	4-Amino-3-iodo-benzenesulfonamide	Investigative
T53378	DRUGINFO	D02QGI	Pentane-1,5-diamine	Investigative
T53378	DRUGINFO	D03ZMQ	COUMARIN	Investigative
T53378	DRUGINFO	D04CVC	4-Amino-3-fluoro-benzenesulfonamide	Investigative
T53378	DRUGINFO	D05TLB	Octyl sulfamate	Investigative
T53378	DRUGINFO	D09WSJ	Decyl sulfamate	Investigative
T53378	DRUGINFO	D0AU0M	P-Coumaric Acid	Investigative
T53378	DRUGINFO	D0D4OV	Octane-1,8-diyl disulfamate	Investigative
T53378	DRUGINFO	D0E8CC	BENZOLAMIDE	Investigative
T53378	DRUGINFO	D0M3PO	2,4-Disulfamyltrifluoromethylaniline	Investigative
T53378	DRUGINFO	D0N1AW	6-(aminomethyl)-2H-chromen-2-one	Investigative
T53378	DRUGINFO	D0NN3Q	4-Hydrazino-benzenesulfonamide	Investigative
T53378	DRUGINFO	D0P6AM	4-Amino-3-bromo-benzenesulfonamide	Investigative
T53378	DRUGINFO	D0Q7DJ	Syringic Acid	Investigative
T53378	DRUGINFO	D0VD7H	CL-5343	Investigative
T53378	DRUGINFO	D0YU8J	4-Amino-3-chloro-benzenesulfonamide	Investigative
T53378	DRUGINFO	D0V7AA	CATECHIN	Investigative
T53378	DRUGINFO	D0Y3TZ	GALLICACID	Investigative
T53378	DRUGINFO	D0A1CM	ELLAGIC ACID	Investigative

T80975	TARGETID	T80975
T80975	FORMERID	TTDS00008
T80975	UNIPROID	VGFR2_HUMAN
T80975	TARGNAME	Vascular endothelial growth factor receptor 2 (KDR)
T80975	GENENAME	KDR
T80975	TARGTYPE	Successful
T80975	SYNONYMS	VEGFR2; VEGFR-2; VEGF-2 receptor; Protein-tyrosine kinase receptor flk-1; Kinase insert domain receptor; Fetal liver kinase 1; FLK1; FLK-1; CD309
T80975	FUNCTION	Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC. Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD.
T80975	PDBSTRUC	6GQQ; 6GQP; 6GQO; 5OYJ; 5EW3
T80975	BIOCLASS	Kinase
T80975	ECNUMBER	EC 2.7.10.1
T80975	SEQUENCE	MQSKVLLAVALWLCVETRAASVGLPSVSLDLPRLSIQKDILTIKANTTLQITCRGQRDLDWLWPNNQSGSEQRVEVTECSDGLFCKTLTIPKVIGNDTGAYKCFYRETDLASVIYVYVQDYRSPFIASVSDQHGVVYITENKNKTVVIPCLGSISNLNVSLCARYPEKRFVPDGNRISWDSKKGFTIPSYMISYAGMVFCEAKINDESYQSIMYIVVVVGYRIYDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKPFVAFGSGMESLVEATVGERVRIPAKYLGYPPPEIKWYKNGIPLESNHTIKAGHVLTIMEVSERDTGNYTVILTNPISKEKQSHVVSLVVYVPPQIGEKSLISPVDSYQYGTTQTLTCTVYAIPPPHHIHWYWQLEEECANEPSQAVSVTNPYPCEEWRSVEDFQGGNKIEVNKNQFALIEGKNKTVSTLVIQAANVSALYKCEAVNKVGRGERVISFHVTRGPEITLQPDMQPTEQESVSLWCTADRSTFENLTWYKLGPQPLPIHVGELPTPVCKNLDTLWKLNATMFSNSTNDILIMELKNASLQDQGDYVCLAQDRKTKKRHCVVRQLTVLERVAPTITGNLENQTTSIGESIEVSCTASGNPPPQIMWFKDNETLVEDSGIVLKDGNRNLTIRRVRKEDEGLYTCQACSVLGCAKVEAFFIIEGAQEKTNLEIIILVGTAVIAMFFWLLLVIILRTVKRANGGELKTGYLSIVMDPDELPLDEHCERLPYDASKWEFPRDRLKLGKPLGRGAFGQVIEADAFGIDKTATCRTVAVKMLKEGATHSEHRALMSELKILIHIGHHLNVVNLLGACTKPGGPLMVIVEFCKFGNLSTYLRSKRNEFVPYKTKGARFRQGKDYVGAIPVDLKRRLDSITSSQSSASSGFVEEKSLSDVEEEEAPEDLYKDFLTLEHLICYSFQVAKGMEFLASRKCIHRDLAARNILLSEKNVVKICDFGLARDIYKDPDYVRKGDARLPLKWMAPETIFDRVYTIQSDVWSFGVLLWEIFSLGASPYPGVKIDEEFCRRLKEGTRMRAPDYTTPEMYQTMLDCWHGEPSQRPTFSELVEHLGNLLQANAQQDGKDYIVLPISETLSMEEDSGLSLPTSPVSCMEEEEVCDPKFHYDNTAGISQYLQNSKRKSRPVSVKTFEDIPLEEPEVKVIPDDNQTDSGMVLASEELKTLEDRTKLSPSFGGMVPSKSRESVASEGSNQTSGYQSGYHSDDTDTTVYSSEEAELLKLIEIGVQTGSTAQILQPDSGTTLSSPPV
T80975	DRUGINFO	D01ZRI	Axitinib	Approved
T80975	DRUGINFO	D09HVD	Ramucirumab	Approved
T80975	DRUGINFO	D0R0FO	Lenvatinib	Approved
T80975	DRUGINFO	D0R0MW	Sunitinib	Approved
T80975	DRUGINFO	D0SZ6E	YN-968D1	Approved
T80975	DRUGINFO	D0IQ6P	Cabozantinib	Approved
T80975	DRUGINFO	D09GDD	Regorafenib	Approved
T80975	DRUGINFO	D0F0ZY	Pazopanib HCl	Approved
T80975	DRUGINFO	D0G6QF	Vandetanib	Approved
T80975	DRUGINFO	D0W7JZ	Tivozanib	Approved
T80975	DRUGINFO	D0W5HK	Sorafenib	Approved
T80975	DRUGINFO	D01PZD	Romiplostim	Approved
T80975	DRUGINFO	D09VMI	Cediranib	Phase 3
T80975	DRUGINFO	D0D7BX	Rivoceranib	Phase 3
T80975	DRUGINFO	D0HS5V	Brivanib	Phase 3
T80975	DRUGINFO	D0Q9CY	HKI-272	Phase 3
T80975	DRUGINFO	D05PWX	Sulfatinib	Phase 3
T80975	DRUGINFO	D0A1AQ	Rosiglitazone + metformin	Phase 3
T80975	DRUGINFO	D02WVT	E-3810	Phase 3
T80975	DRUGINFO	D05BLN	MGCD516	Phase 2/3
T80975	DRUGINFO	D00YPR	CP-547632	Phase 2
T80975	DRUGINFO	D03AND	RAF265	Phase 2
T80975	DRUGINFO	D09LOZ	TTAC-0001	Phase 2
T80975	DRUGINFO	D0HN7I	Alacizumab pegol	Phase 2
T80975	DRUGINFO	D0ZN1R	Delphinidin	Phase 2
T80975	DRUGINFO	DN3Z5D	L-DOS47	Phase 2
T80975	DRUGINFO	D0D1GF	XL880	Phase 2
T80975	DRUGINFO	D07NOI	BAY-57-9352	Phase 2
T80975	DRUGINFO	D0P6DJ	VATALANIB	Phase 2
T80975	DRUGINFO	D0R6UV	BMS-690514	Phase 2
T80975	DRUGINFO	D0Z6MT	Famitinib	Phase 2
T80975	DRUGINFO	D0Q0HZ	Elpamotide	Phase 1/2
T80975	DRUGINFO	D04NOE	OTSGC-A24	Phase 1/2
T80975	DRUGINFO	D0U6BQ	Anti-VEGFR2 CD8 cell therapy	Phase 1/2
T80975	DRUGINFO	D00DRL	MK-2461	Phase 1/2
T80975	DRUGINFO	D07HRU	KRN633	Phase 1
T80975	DRUGINFO	D07PNT	XL999	Phase 1
T80975	DRUGINFO	D0GM6E	Pegdinetanib	Phase 1
T80975	DRUGINFO	D0L9PU	A168	Phase 1
T80975	DRUGINFO	D0ZI5A	PF-00337210	Phase 1
T80975	DRUGINFO	D09ETH	E-7050	Phase 1
T80975	DRUGINFO	D0F5JZ	PLX-4720	Phase 1
T80975	DRUGINFO	D0N8RV	OSI-930	Phase 1
T80975	DRUGINFO	D0T2ER	TAK-593	Phase 1
T80975	DRUGINFO	D0CY1B	CYC116	Phase 1
T80975	DRUGINFO	D0FD6D	CEP-11981	Phase 1
T80975	DRUGINFO	D0FA6S	Altiratinib	Phase 1
T80975	DRUGINFO	D01AXK	Antibodie derivative 10	Patented
T80975	DRUGINFO	D06BTN	Pyrimidine derivative 14	Patented
T80975	DRUGINFO	D06HEO	Pyrimidine derivative 4	Patented
T80975	DRUGINFO	D08OXH	Quinoline and quinazoline derivative 1	Patented
T80975	DRUGINFO	D08XAY	Antibodie derivative 6	Patented
T80975	DRUGINFO	D0G1YI	Pyrimidine derivative 13	Patented
T80975	DRUGINFO	D0JU8E	Pyrimidine derivative 12	Patented
T80975	DRUGINFO	D05PRG	Quinazoline derivative 15	Patented
T80975	DRUGINFO	D0DV4X	Quinazoline derivative 16	Patented
T80975	DRUGINFO	D0AK1F	Pyridine derivative 18	Patented
T80975	DRUGINFO	D00DQX	Motesanib	Discontinued in Phase 3
T80975	DRUGINFO	D09DJU	SU-14813	Discontinued in Phase 2
T80975	DRUGINFO	D0E8VF	IMC-1C11	Discontinued in Phase 1
T80975	DRUGINFO	D0H4GI	CEP-5214	Terminated
T80975	DRUGINFO	D06GBK	AG1295	Terminated
T80975	DRUGINFO	D00GVV	Indolin-2-one deriv. 4b	Investigative
T80975	DRUGINFO	D00MCJ	6-(1H-Benzoimidazol-2-yl)-benzocyclohepten-7-one	Investigative
T80975	DRUGINFO	D00YWZ	3-(4-aminophenyl)thieno[3,2-c]pyridin-4-amine	Investigative
T80975	DRUGINFO	D01LEV	3-((3-bromothiophen-2-yl)methylene)indolin-2-one	Investigative
T80975	DRUGINFO	D02AOT	Isoindolinone Urea derivative	Investigative
T80975	DRUGINFO	D04RQU	8-methyl-4H,7H-indolo[6,5,4-cd]indol-5-one	Investigative
T80975	DRUGINFO	D05GMB	BIBF-1202	Investigative
T80975	DRUGINFO	D07OIZ	R-84	Investigative
T80975	DRUGINFO	D07OSK	VEGF receptor 2 kinase inhibitor I	Investigative
T80975	DRUGINFO	D07SRX	AG-E-85378	Investigative
T80975	DRUGINFO	D08JSJ	4-(4-p-Tolylamino-phthalazin-1-yl)-benzamide	Investigative
T80975	DRUGINFO	D09AKX	4-(4-m-Tolylamino-phthalazin-1-yl)-benzamide	Investigative
T80975	DRUGINFO	D09LKM	Pyrazolo[1,5-a]pyrimidine 3G	Investigative
T80975	DRUGINFO	D09TQP	3-phenyl-1,4-dihydroindeno[1,2-c]pyrazole	Investigative
T80975	DRUGINFO	D0A9ZQ	(3-Phenoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine	Investigative
T80975	DRUGINFO	D0AK4H	AMG-429	Investigative
T80975	DRUGINFO	D0E3HC	L000021649	Investigative
T80975	DRUGINFO	D0F0AU	3-methyl-1H-thieno[2,3-c]pyrazole-5-carboxamide	Investigative
T80975	DRUGINFO	D0J3OZ	2-(pyrimidin-4-ylamino)thiazole-5-carbonitrile	Investigative
T80975	DRUGINFO	D0Q4EQ	JNJ-38158471	Investigative
T80975	DRUGINFO	D0R3IK	EPI-0030	Investigative
T80975	DRUGINFO	D0ST4P	IM-023911	Investigative
T80975	DRUGINFO	D0U3ZP	5-(4-Methoxy-phenyl)-1-phenyl-1H-benzoimidazole	Investigative
T80975	DRUGINFO	D0UX3T	3-(5-Thiophen-3-yl-pyridin-3-yl)-1H-indole	Investigative
T80975	DRUGINFO	D02RWK	K-252a analogue	Investigative
T80975	DRUGINFO	D03HTT	4-(isoquinolin-5-yl)-N-o-tolylphthalazin-1-amine	Investigative
T80975	DRUGINFO	D06BVH	4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile	Investigative
T80975	DRUGINFO	D0A9ZP	IM-094882	Investigative
T80975	DRUGINFO	D0D3QA	4-(isoquinolin-5-yl)-N-m-tolylphthalazin-1-amine	Investigative
T80975	DRUGINFO	D0E9DI	2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile	Investigative
T80975	DRUGINFO	D0KH5T	4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline	Investigative
T80975	DRUGINFO	D0M9OF	3-(1H-Indol-2-yl)-1H-quinolin-2-one	Investigative
T80975	DRUGINFO	D0Z7TM	BMS-645737	Investigative
T80975	DRUGINFO	D0Z8TR	IM-094261	Investigative
T80975	DRUGINFO	D03HQK	2-(5-Phenyl-oxazol-2-ylamino)-benzonitrile	Investigative
T80975	DRUGINFO	D05THI	4-Chloro-N-(3-chloro-benzoyl)-benzenesulfonamide	Investigative
T80975	DRUGINFO	D06GJO	(2-Methoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine	Investigative
T80975	DRUGINFO	D07AIB	(4-Phenoxy-phenyl)-quinazolin-4-yl-amine	Investigative
T80975	DRUGINFO	D07QMC	3-Benzimidazol-2-ylhydroquinolin-2-one	Investigative
T80975	DRUGINFO	D07XBW	N-(2,4-Dichloro-benzoyl)-benzenesulfonamide	Investigative
T80975	DRUGINFO	D09LEK	4-(5-Phenyl-oxazol-2-ylamino)-benzenesulfonamide	Investigative
T80975	DRUGINFO	D09MSA	4-Chloro-N-(4-chloro-benzoyl)-benzenesulfonamide	Investigative
T80975	DRUGINFO	D0BM4F	Phenyl-(5-phenyl-oxazol-2-yl)-amine	Investigative
T80975	DRUGINFO	D0C6KI	CB-676475	Investigative
T80975	DRUGINFO	D0C6OD	4-Chloro-N-(4-nitro-benzoyl)-benzenesulfonamide	Investigative
T80975	DRUGINFO	D0D3YL	(5-Phenyl-oxazol-2-yl)-m-tolyl-amine	Investigative
T80975	DRUGINFO	D0J2XD	3-(5-Phenyl-oxazol-2-ylamino)-benzonitrile	Investigative
T80975	DRUGINFO	D0M2QA	N-(3-Bromo-benzoyl)-4-chloro-benzenesulfonamide	Investigative
T80975	DRUGINFO	D0UZ5W	4-Chloro-N-(2-chloro-benzoyl)-benzenesulfonamide	Investigative
T80975	DRUGINFO	D0V4BR	4-Chloro-N-(2-methyl-benzoyl)-benzenesulfonamide	Investigative
T80975	DRUGINFO	D0V9DQ	[3-(5-Phenyl-oxazol-2-ylamino)-phenyl]-methanol	Investigative
T80975	DRUGINFO	D0Y9GK	4-(4-aminophenyl)-1H-indazol-3yl-amine	Investigative
T80975	DRUGINFO	D0YN1E	3,6-Di-pyridin-4-yl-pyrazolo[1,5-a]pyrimidine	Investigative
T80975	DRUGINFO	D08BJR	Ki-20227	Investigative
T80975	DRUGINFO	D09HXU	6-o-tolylquinazolin-2-amine	Investigative
T80975	DRUGINFO	D09LPL	SU-11652	Investigative
T80975	DRUGINFO	D0EE6A	AAL-993	Investigative
T80975	DRUGINFO	D0N7AJ	AST-487	Investigative
T80975	DRUGINFO	D0XC6G	2-(1H-indazol-3-yl)-1H-benzo[d]imidazole	Investigative
T80975	DRUGINFO	D0IX7Y	BX-912	Investigative
T80975	DRUGINFO	D0PP6Y	PMID23639540C13a	Investigative
T80975	DRUGINFO	D0RG0Z	BX-795	Investigative
T80975	DRUGINFO	D09QBA	CEP-5104	Investigative
T80975	DRUGINFO	D0H1OK	TG-100435	Investigative
T80975	DRUGINFO	D03EHM	PP121	Investigative
T80975	DRUGINFO	D0C2GE	PMID22765894C8h	Investigative
T80975	DRUGINFO	D09XIL	Ro-4396686	Investigative
T80975	DRUGINFO	D0M4SY	BMS-536924	Investigative
T80975	DRUGINFO	D00NYT	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	Investigative
T80975	DRUGINFO	D0C3WY	3,4-diphenyl-1H-pyrrole-2,5-dione	Investigative
T80975	DRUGINFO	D0EK0G	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	Investigative

T74312	TARGETID	T74312
T74312	FORMERID	TTDS00090
T74312	UNIPROID	FLT3_HUMAN
T74312	TARGNAME	Fms-like tyrosine kinase 3 (FLT-3)
T74312	GENENAME	FLT3
T74312	TARGTYPE	Successful
T74312	SYNONYMS	Stem cell tyrosine kinase 1; STK1; STK-1; Receptor-type tyrosine-protein kinase FLT3; Fetal liver kinase-2; FLT-3; FLK2; FLK-2; FL cytokine receptor; CD135
T74312	FUNCTION	Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways.
T74312	PDBSTRUC	6IL3; 5X02; 4XUF; 4RT7; 3QS9
T74312	BIOCLASS	Kinase
T74312	ECNUMBER	EC 2.7.10.1
T74312	SEQUENCE	MPALARDGGQLPLLVVFSAMIFGTITNQDLPVIKCVLINHKNNDSSVGKSSSYPMVSESPEDLGCALRPQSSGTVYEAAAVEVDVSASITLQVLVDAPGNISCLWVFKHSSLNCQPHFDLQNRGVVSMVILKMTETQAGEYLLFIQSEATNYTILFTVSIRNTLLYTLRRPYFRKMENQDALVCISESVPEPIVEWVLCDSQGESCKEESPAVVKKEEKVLHELFGTDIRCCARNELGRECTRLFTIDLNQTPQTTLPQLFLKVGEPLWIRCKAVHVNHGFGLTWELENKALEEGNYFEMSTYSTNRTMIRILFAFVSSVARNDTGYYTCSSSKHPSQSALVTIVEKGFINATNSSEDYEIDQYEEFCFSVRFKAYPQIRCTWTFSRKSFPCEQKGLDNGYSISKFCNHKHQPGEYIFHAENDDAQFTKMFTLNIRRKPQVLAEASASQASCFSDGYPLPSWTWKKCSDKSPNCTEEITEGVWNRKANRKVFGQWVSSSTLNMSEAIKGFLVKCCAYNSLGTSCETILLNSPGPFPFIQDNISFYATIGVCLLFIVVLTLLICHKYKKQFRYESQLQMVQVTGSSDNEYFYVDFREYEYDLKWEFPRENLEFGKVLGSGAFGKVMNATAYGISKTGVSIQVAVKMLKEKADSSEREALMSELKMMTQLGSHENIVNLLGACTLSGPIYLIFEYCCYGDLLNYLRSKREKFHRTWTEIFKEHNFSFYPTFQSHPNSSMPGSREVQIHPDSDQISGLHGNSFHSEDEIEYENQKRLEEEEDLNVLTFEDLLCFAYQVAKGMEFLEFKSCVHRDLAARNVLVTHGKVVKICDFGLARDIMSDSNYVVRGNARLPVKWMAPESLFEGIYTIKSDVWSYGILLWEIFSLGVNPYPGIPVDANFYKLIQNGFKMDQPFYATEEIYIIMQSCWAFDSRKRPSFPNLTSFLGCQLADAEEAMYQNVDGRVSECPHTYQNRRPFSREMDLGLLSPQAQVEDS
T74312	DRUGINFO	D07KYT	Quizartinib	Approved
T74312	DRUGINFO	D0V9WF	Lestaurtinib	Approved (orphan drug)
T74312	DRUGINFO	D01XYJ	Zidovudine	Approved
T74312	DRUGINFO	D04KZY	Gilteritinib	Approved
T74312	DRUGINFO	D07NVU	Midostaurin	Approved
T74312	DRUGINFO	D0PN8H	Pacritinib	Approved
T74312	DRUGINFO	D09TAB	Pexidartinib	Approved
T74312	DRUGINFO	D09HNV	Intedanib	Approved
T74312	DRUGINFO	D0H0EQ	Ponatinib	Approved
T74312	DRUGINFO	D0Q8CV	CDX-301	Phase 2
T74312	DRUGINFO	D06KTJ	TAK-659	Phase 2
T74312	DRUGINFO	D0R6UV	BMS-690514	Phase 2
T74312	DRUGINFO	D0Z6MT	Famitinib	Phase 2
T74312	DRUGINFO	D28HJI	FF-10101	Phase 1/2
T74312	DRUGINFO	D0V2ZC	SEL24	Phase 1/2
T74312	DRUGINFO	D0X8ID	SEL-24	Phase 1/2
T74312	DRUGINFO	DI1VM3	HM43239	Phase 1/2
T74312	DRUGINFO	D00DRL	MK-2461	Phase 1/2
T74312	DRUGINFO	D07UUB	4SC-203	Phase 1
T74312	DRUGINFO	D07ZNF	IMC-EB10	Phase 1
T74312	DRUGINFO	D0D1HS	Ki23819	Phase 1
T74312	DRUGINFO	D0YQ9I	FF-10101-01	Phase 1
T74312	DRUGINFO	DIA08F	SKI-G-801	Phase 1
T74312	DRUGINFO	D10LNV	MRX-2843	Phase 1
T74312	DRUGINFO	D91CMX	AMG 427	Phase 1
T74312	DRUGINFO	D00ABO	KW-2449	Phase 1
T74312	DRUGINFO	DKCU40	FN-1501	Phase 1
T74312	DRUGINFO	D0MX7B	Carboxamide derivative 4	Patented
T74312	DRUGINFO	D0AK1F	Pyridine derivative 18	Patented
T74312	DRUGINFO	D0IT6Q	Tandutinib	Discontinued in Phase 2
T74312	DRUGINFO	D04GFO	MC-2001	Preclinical
T74312	DRUGINFO	D01MIP	SU5614	Terminated
T74312	DRUGINFO	D06GBK	AG1295	Terminated
T74312	DRUGINFO	D0D0TQ	AKN-028	Investigative
T74312	DRUGINFO	D0X1JO	IN1479	Investigative
T74312	DRUGINFO	D0X6KS	N-[4-(3-amino-1H-indazol-4-yl)phenyl]benzamide	Investigative
T74312	DRUGINFO	D0X7JK	TCS-359	Investigative
T74312	DRUGINFO	D0ZO8Z	2-(3,4-dimethoxybenzamido)thiophene-3-carboxamide	Investigative
T74312	DRUGINFO	D02OBA	Bis(5-hydroxybenzo[b]furan-2-yl)methanone	Investigative
T74312	DRUGINFO	D03VAA	Bis(6-hydroxybenzo[b]furan-2-yl)methanone	Investigative
T74312	DRUGINFO	D07AXL	Bis(5-aminobenzo[b]furan-2-yl)methanone	Investigative
T74312	DRUGINFO	D0I7QX	(benzo[b]furan-2-yl)-(1H-indol-2-yl)methanone	Investigative
T74312	DRUGINFO	D0L0MZ	Bis(5-acetoxybenzo[b]furan-2-yl)methanone	Investigative
T74312	DRUGINFO	D0N3XP	G749	Investigative
T74312	DRUGINFO	D0Z3DW	Bis(benzo[b]furan-2-yl)methanone	Investigative
T74312	DRUGINFO	D09OLH	(1H-indol-2-yl)(5-methoxy-1H-indol-2-yl)methanone	Investigative
T74312	DRUGINFO	D0D7ZL	(1H-indol-2-yl)(6-methoxy-1H-indol-2-yl)methanone	Investigative
T74312	DRUGINFO	D0G0KQ	(1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone	Investigative
T74312	DRUGINFO	D0G5YI	Di(1H-indol-2-yl)methanone	Investigative
T74312	DRUGINFO	D0H7MF	(5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone	Investigative
T74312	DRUGINFO	D0XS9E	(5-hydroxy-1H-indol-2-yl)(1H-indol-2-yl)methanone	Investigative
T74312	DRUGINFO	D0Y9GK	4-(4-aminophenyl)-1H-indazol-3yl-amine	Investigative
T74312	DRUGINFO	D0N7AJ	AST-487	Investigative
T74312	DRUGINFO	D0UN9O	GTP-14564	Investigative
T74312	DRUGINFO	D06UKS	PMID21982499C14k	Investigative
T74312	DRUGINFO	D0I3XZ	Bis-(5-hydroxy-1H-indol-2-yl)-methanone	Investigative
T74312	DRUGINFO	D0Y4BL	JNJ-28312141	Investigative
T74312	DRUGINFO	D07ADX	URMC-099	Investigative
T74312	DRUGINFO	D0E7VO	PMID24900538C2c	Investigative
T74312	DRUGINFO	D0C2GE	PMID22765894C8h	Investigative

T75243	TARGETID	T75243
T75243	FORMERID	TTDS00265
T75243	UNIPROID	MTOR_HUMAN
T75243	TARGNAME	Serine/threonine-protein kinase mTOR (mTOR)
T75243	GENENAME	MTOR
T75243	TARGTYPE	Successful
T75243	SYNONYMS	Target of rapamycin; TOR kinase; Rapamycin target protein 1; Rapamycin target protein; Rapamycin and FKBP12 target 1; RAPT1; RAFT1; Mechanistic target of rapamycin; Mammalian target of rapamycin; FRAP2; FRAP1; FRAP; FKBP12-rapamycin complex-associated protein; FKBP-rapamycin associated protein; FK506-binding protein 12-rapamycin complex-associated protein 1
T75243	FUNCTION	MTOR directly or indirectly regulates the phosphorylation of at least 800 proteins. Functions as part of 2 structurally and functionally distinct signaling complexes mTORC1 and mTORC2 (mTOR complex 1 and 2). Activated mTORC1 up-regulates protein synthesis by phosphorylating key regulators of mRNA translation and ribosome synthesis. This includes phosphorylation of EIF4EBP1 and release of its inhibition toward the elongation initiation factor 4E (eiF4E). Moreover, phosphorylates and activates RPS6KB1 and RPS6KB2 that promote protein synthesis by modulating the activity of their downstream targets including ribosomal protein S6, eukaryotic translation initiation factor EIF4B, and the inhibitor of translation initiation PDCD4. Stimulates the pyrimidine biosynthesis pathway, both by acute regulation through RPS6KB1-mediated phosphorylation of the biosynthetic enzyme CAD, and delayed regulation, through transcriptional enhancement of the pentose phosphate pathway which produces 5-phosphoribosyl-1-pyrophosphate (PRPP), an allosteric activator of CAD at a later step in synthesis, this function is dependent on the mTORC1 complex. Regulates ribosome synthesis by activating RNA polymerase III-dependent transcription through phosphorylation and inhibition of MAF1 an RNA polymerase III-repressor. In parallel to protein synthesis, also regulates lipid synthesis through SREBF1/SREBP1 and LPIN1. To maintain energy homeostasis mTORC1 may also regulate mitochondrial biogenesis through regulation of PPARGC1A. mTORC1 also negatively regulates autophagy through phosphorylation of ULK1. Under nutrient sufficiency, phosphorylates ULK1 at 'Ser-758', disrupting the interaction with AMPK and preventing activation of ULK1. Also prevents autophagy through phosphorylation of the autophagy inhibitor DAP. Also prevents autophagy by phosphorylating RUBCNL/Pacer under nutrient-rich conditions. mTORC1 exerts a feedback control on upstream growth factor signaling that includes phosphorylation and activation of GRB10 a INSR-dependent signaling suppressor. Among other potential targets mTORC1 may phosphorylate CLIP1 and regulate microtubules. As part of the mTORC2 complex MTOR may regulate other cellular processes including survival and organization of the cytoskeleton. Plays a critical role in the phosphorylation at 'Ser-473' of AKT1, a pro-survival effector of phosphoinositide 3-kinase, facilitating its activation by PDK1. mTORC2 may regulate the actin cytoskeleton, through phosphorylation of PRKCA, PXN and activation of the Rho-type guanine nucleotide exchange factors RHOA and RAC1A or RAC1B. mTORC2 also regulates the phosphorylation of SGK1 at 'Ser-422'. Regulates osteoclastogenesis by adjusting the expression of CEBPB isoforms. Plays an important regulatory role in the circadian clock function; regulates period length and rhythm amplitude of the suprachiasmatic nucleus (SCN) and liver clocks. Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals.
T75243	PDBSTRUC	6BCX; 6BCU; 5ZCS; 5WBY; 5WBU
T75243	BIOCLASS	Kinase
T75243	ECNUMBER	EC 2.7.11.1
T75243	SEQUENCE	MLGTGPAAATTAATTSSNVSVLQQFASGLKSRNEETRAKAAKELQHYVTMELREMSQEESTRFYDQLNHHIFELVSSSDANERKGGILAIASLIGVEGGNATRIGRFANYLRNLLPSNDPVVMEMASKAIGRLAMAGDTFTAEYVEFEVKRALEWLGADRNEGRRHAAVLVLRELAISVPTFFFQQVQPFFDNIFVAVWDPKQAIREGAVAALRACLILTTQREPKEMQKPQWYRHTFEEAEKGFDETLAKEKGMNRDDRIHGALLILNELVRISSMEGERLREEMEEITQQQLVHDKYCKDLMGFGTKPRHITPFTSFQAVQPQQSNALVGLLGYSSHQGLMGFGTSPSPAKSTLVESRCCRDLMEEKFDQVCQWVLKCRNSKNSLIQMTILNLLPRLAAFRPSAFTDTQYLQDTMNHVLSCVKKEKERTAAFQALGLLSVAVRSEFKVYLPRVLDIIRAALPPKDFAHKRQKAMQVDATVFTCISMLARAMGPGIQQDIKELLEPMLAVGLSPALTAVLYDLSRQIPQLKKDIQDGLLKMLSLVLMHKPLRHPGMPKGLAHQLASPGLTTLPEASDVGSITLALRTLGSFEFEGHSLTQFVRHCADHFLNSEHKEIRMEAARTCSRLLTPSIHLISGHAHVVSQTAVQVVADVLSKLLVVGITDPDPDIRYCVLASLDERFDAHLAQAENLQALFVALNDQVFEIRELAICTVGRLSSMNPAFVMPFLRKMLIQILTELEHSGIGRIKEQSARMLGHLVSNAPRLIRPYMEPILKALILKLKDPDPDPNPGVINNVLATIGELAQVSGLEMRKWVDELFIIIMDMLQDSSLLAKRQVALWTLGQLVASTGYVVEPYRKYPTLLEVLLNFLKTEQNQGTRREAIRVLGLLGALDPYKHKVNIGMIDQSRDASAVSLSESKSSQDSSDYSTSEMLVNMGNLPLDEFYPAVSMVALMRIFRDQSLSHHHTMVVQAITFIFKSLGLKCVQFLPQVMPTFLNVIRVCDGAIREFLFQQLGMLVSFVKSHIRPYMDEIVTLMREFWVMNTSIQSTIILLIEQIVVALGGEFKLYLPQLIPHMLRVFMHDNSPGRIVSIKLLAAIQLFGANLDDYLHLLLPPIVKLFDAPEAPLPSRKAALETVDRLTESLDFTDYASRIIHPIVRTLDQSPELRSTAMDTLSSLVFQLGKKYQIFIPMVNKVLVRHRINHQRYDVLICRIVKGYTLADEEEDPLIYQHRMLRSGQGDALASGPVETGPMKKLHVSTINLQKAWGAARRVSKDDWLEWLRRLSLELLKDSSSPSLRSCWALAQAYNPMARDLFNAAFVSCWSELNEDQQDELIRSIELALTSQDIAEVTQTLLNLAEFMEHSDKGPLPLRDDNGIVLLGERAAKCRAYAKALHYKELEFQKGPTPAILESLISINNKLQQPEAAAGVLEYAMKHFGELEIQATWYEKLHEWEDALVAYDKKMDTNKDDPELMLGRMRCLEALGEWGQLHQQCCEKWTLVNDETQAKMARMAAAAAWGLGQWDSMEEYTCMIPRDTHDGAFYRAVLALHQDLFSLAQQCIDKARDLLDAELTAMAGESYSRAYGAMVSCHMLSELEEVIQYKLVPERREIIRQIWWERLQGCQRIVEDWQKILMVRSLVVSPHEDMRTWLKYASLCGKSGRLALAHKTLVLLLGVDPSRQLDHPLPTVHPQVTYAYMKNMWKSARKIDAFQHMQHFVQTMQQQAQHAIATEDQQHKQELHKLMARCFLKLGEWQLNLQGINESTIPKVLQYYSAATEHDRSWYKAWHAWAVMNFEAVLHYKHQNQARDEKKKLRHASGANITNATTAATTAATATTTASTEGSNSESEAESTENSPTPSPLQKKVTEDLSKTLLMYTVPAVQGFFRSISLSRGNNLQDTLRVLTLWFDYGHWPDVNEALVEGVKAIQIDTWLQVIPQLIARIDTPRPLVGRLIHQLLTDIGRYHPQALIYPLTVASKSTTTARHNAANKILKNMCEHSNTLVQQAMMVSEELIRVAILWHEMWHEGLEEASRLYFGERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFRRISKQLPQLTSLELQYVSPKLLMCRDLELAVPGTYDPNQPIIRIQSIAPSLQVITSKQRPRKLTLMGSNGHEFVFLLKGHEDLRQDERVMQLFGLVNTLLANDPTSLRKNLSIQRYAVIPLSTNSGLIGWVPHCDTLHALIRDYREKKKILLNIEHRIMLRMAPDYDHLTLMQKVEVFEHAVNNTAGDDLAKLLWLKSPSSEVWFDRRTNYTRSLAVMSMVGYILGLGDRHPSNLMLDRLSGKILHIDFGDCFEVAMTREKFPEKIPFRLTRMLTNAMEVTGLDGNYRITCHTVMEVLREHKDSVMAVLEAFVYDPLLNWRLMDTNTKGNKRSRTRTDSYSAGQSVEILDGVELGEPAHKKTGTTVPESIHSFIGDGLVKPEALNKKAIQIINRVRDKLTGRDFSHDDTLDVPTQVELLIKQATSHENLCQCYIGWCPFW
T75243	DRUGINFO	D03FCF	Novolimus	Approved
T75243	DRUGINFO	D0ES1Q	Temsirolimus	Approved
T75243	DRUGINFO	D0K3QS	Everolimus	Approved
T75243	DRUGINFO	D0V7WS	Zotarolimus	Approved
T75243	DRUGINFO	D03LJR	Sirolimus	Approved
T75243	DRUGINFO	D0S5LO	PF-04449913	Approved
T75243	DRUGINFO	D0O3CV	Ridaforolimus	Phase 3
T75243	DRUGINFO	D03DPZ	INK128	Phase 2
T75243	DRUGINFO	D0H7XL	OSI-027	Phase 2
T75243	DRUGINFO	D0W3UV	ABI-009	Phase 2
T75243	DRUGINFO	D00KTV	Salirasib	Phase 2
T75243	DRUGINFO	D01PGR	SAR245409	Phase 2
T75243	DRUGINFO	D03NJY	SF1126	Phase 2
T75243	DRUGINFO	D0D8JB	PF-05212384	Phase 2
T75243	DRUGINFO	D0H1WC	LY3023414	Phase 2
T75243	DRUGINFO	D0N5JZ	PF-04691502	Phase 2
T75243	DRUGINFO	D0O6VZ	GDC-0980/RG7422	Phase 2
T75243	DRUGINFO	D0VG0D	BEZ235	Phase 2
T75243	DRUGINFO	D00BUO	MM-141	Phase 2
T75243	DRUGINFO	D0TU7B	PQR309	Phase 2
T75243	DRUGINFO	D0Z2UQ	AZD2014	Phase 2
T75243	DRUGINFO	D05EXN	CC-223	Phase 1/2
T75243	DRUGINFO	D0X7IN	BGT226	Phase 1/2
T75243	DRUGINFO	D03IXK	ME-344	Phase 1/2
T75243	DRUGINFO	D08PSC	BI 860585	Phase 1
T75243	DRUGINFO	D0QN5M	LAM-001	Phase 1
T75243	DRUGINFO	D0R9VX	DS-3078	Phase 1
T75243	DRUGINFO	D0U8QH	GDC-0349	Phase 1
T75243	DRUGINFO	D1RLY2	CERC 006	Phase 1
T75243	DRUGINFO	D0X4RT	DS-7423	Phase 1
T75243	DRUGINFO	D0Y0FE	PWT-33597	Phase 1
T75243	DRUGINFO	D0U3DP	VS-5584	Phase 1
T75243	DRUGINFO	D07TVO	PMID25726713-Compound-49	Patented
T75243	DRUGINFO	D0KH7Q	PMID25726713-Compound-51	Patented
T75243	DRUGINFO	D0WJ3W	PMID25726713-Compound-48	Patented
T75243	DRUGINFO	D0X5VI	PMID25726713-Compound-47	Patented
T75243	DRUGINFO	D0Y8JF	PMID25726713-Compound-50	Patented
T75243	DRUGINFO	D0K1VK	AZD8055	Discontinued in Phase 1/2
T75243	DRUGINFO	D0H5MX	TAFA-93	Discontinued in Phase 1
T75243	DRUGINFO	D05SXC	SCR-44001	Terminated
T75243	DRUGINFO	D00GQM	(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol	Investigative
T75243	DRUGINFO	D01AQN	Rapamycin complexed with immunophilin FKBP12	Investigative
T75243	DRUGINFO	D02TCF	C-16-(S)-3-methylindolerapamycin	Investigative
T75243	DRUGINFO	D03XRZ	PF-05094037	Investigative
T75243	DRUGINFO	D05SOW	SX-MTR1	Investigative
T75243	DRUGINFO	D07JKB	2-(6-morpholino-9H-purin-2-yl)phenol	Investigative
T75243	DRUGINFO	D07NFT	P-2281	Investigative
T75243	DRUGINFO	D08BTX	X-387	Investigative
T75243	DRUGINFO	D09FBN	4-(6-morpholino-9H-purin-2-yl)phenol	Investigative
T75243	DRUGINFO	D09VHS	EM-101	Investigative
T75243	DRUGINFO	D0A8ES	EC-0845	Investigative
T75243	DRUGINFO	D0AH8Q	4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine	Investigative
T75243	DRUGINFO	D0E1YN	SB-2280	Investigative
T75243	DRUGINFO	D0F1SI	4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine	Investigative
T75243	DRUGINFO	D0H0HR	torin 1	Investigative
T75243	DRUGINFO	D0H4KF	EC-0565	Investigative
T75243	DRUGINFO	D0J9PK	OXA-01	Investigative
T75243	DRUGINFO	D0N9TK	AR-mTOR-26	Investigative
T75243	DRUGINFO	D0P0UV	2-chloro-N-(6-cyanopyridin-3-yl)propanamide	Investigative
T75243	DRUGINFO	D0TC5H	3-(6-morpholino-9H-purin-2-yl)phenol	Investigative
T75243	DRUGINFO	D0U8GR	AP-21967	Investigative
T75243	DRUGINFO	D0Y1DR	4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine	Investigative
T75243	DRUGINFO	D2B7WM	Torin2	Investigative
T75243	DRUGINFO	D02ELN	HM-5016699	Investigative
T75243	DRUGINFO	D05RSS	PF-03772304	Investigative
T75243	DRUGINFO	D0H2CM	PP-242	Investigative
T75243	DRUGINFO	D0JD4S	CU-906	Investigative
T75243	DRUGINFO	D0QE9F	P-6915	Investigative
T75243	DRUGINFO	D0T0BY	2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one	Investigative
T75243	DRUGINFO	D0X7TB	2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one	Investigative
T75243	DRUGINFO	D0W1ST	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	Investigative
T75243	DRUGINFO	D03EHM	PP121	Investigative

T25005	TARGETID	T25005
T25005	FORMERID	TTDR00233
T25005	UNIPROID	BTK_HUMAN
T25005	TARGNAME	Tyrosine-protein kinase BTK (ATK)
T25005	GENENAME	BTK
T25005	TARGTYPE	Successful
T25005	SYNONYMS	Bruton's tyrosine kinase; Bruton tyrosine kinase; BPK; B-cell progenitor kinase; B cell progenitor kinase; Agammaglobulinemia tyrosine kinase; Agammaglobulinaemia tyrosine kinase; AGMX1
T25005	FUNCTION	Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation. After BCR engagement and activation at the plasma membrane, phosphorylates PLCG2 at several sites, igniting the downstream signaling pathway through calcium mobilization, followed by activation of the protein kinase C (PKC) family members. PLCG2 phosphorylation is performed in close cooperation with the adapter protein B-cell linker protein BLNK. BTK acts as a platform to bring together a diverse array of signaling proteins and is implicated in cytokine receptor signaling pathways. Plays an important role in the function of immune cells of innate as well as adaptive immunity, as a component of the Toll-like receptors (TLR) pathway. The TLR pathway acts as a primary surveillance system for the detection of pathogens and are crucial to the activation of host defense. Especially, is a critical molecule in regulating TLR9 activation in splenic B-cells. Within the TLR pathway, induces tyrosine phosphorylation of TIRAP which leads to TIRAP degradation. BTK plays also a critical role in transcription regulation. Induces the activity of NF-kappa-B, which is involved in regulating the expression of hundreds of genes. BTK is involved on the signaling pathway linking TLR8 and TLR9 to NF-kappa-B. Transiently phosphorylates transcription factor GTF2I on tyrosine residues in response to BCR. GTF2I then translocates to the nucleus to bind regulatory enhancer elements to modulate gene expression. ARID3A and NFAT are other transcriptional target of BTK. BTK is required for the formation of functional ARID3A DNA-binding complexes. There is however no evidence that BTK itself binds directly to DNA. BTK has a dual role in the regulation of apoptosis. Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling.
T25005	PDBSTRUC	6O8I; 6NFI; 6NFH; 6N9P; 6HRT
T25005	BIOCLASS	Kinase
T25005	ECNUMBER	EC 2.7.10.2
T25005	SEQUENCE	MAAVILESIFLKRSQQKKKTSPLNFKKRLFLLTVHKLSYYEYDFERGRRGSKKGSIDVEKITCVETVVPEKNPPPERQIPRRGEESSEMEQISIIERFPYPFQVVYDEGPLYVFSPTEELRKRWIHQLKNVIRYNSDLVQKYHPCFWIDGQYLCCSQTAKNAMGCQILENRNGSLKPGSSHRKTKKPLPPTPEEDQILKKPLPPEPAAAPVSTSELKKVVALYDYMPMNANDLQLRKGDEYFILEESNLPWWRARDKNGQEGYIPSNYVTEAEDSIEMYEWYSKHMTRSQAEQLLKQEGKEGGFIVRDSSKAGKYTVSVFAKSTGDPQGVIRHYVVCSTPQSQYYLAEKHLFSTIPELINYHQHNSAGLISRLKYPVSQQNKNAPSTAGLGYGSWEIDPKDLTFLKELGTGQFGVVKYGKWRGQYDVAIKMIKEGSMSEDEFIEEAKVMMNLSHEKLVQLYGVCTKQRPIFIITEYMANGCLLNYLREMRHRFQTQQLLEMCKDVCEAMEYLESKQFLHRDLAARNCLVNDQGVVKVSDFGLSRYVLDDEYTSSVGSKFPVRWSPPEVLMYSKFSSKSDIWAFGVLMWEIYSLGKMPYERFTNSETAEHIAQGLRLYRPHLASEKVYTIMYSCWHEKADERPTFKILLSNILDVMDEES
T25005	DRUGINFO	D09KTS	Ibrutinib	Approved
T25005	DRUGINFO	D09PQZ	Acalabrutinib	Approved
T25005	DRUGINFO	D0UT4W	Zanubrutinib	Approved
T25005	DRUGINFO	DXP04H	Pirtobrutinib	Approved
T25005	DRUGINFO	D0A9PN	GDC-0853	Phase 3
T25005	DRUGINFO	D7OZC3	Tolebrutinib	Phase 3
T25005	DRUGINFO	DUTJ12	ICP-022	Phase 3
T25005	DRUGINFO	D04BFC	CC-292	Phase 2
T25005	DRUGINFO	D08AOZ	BMS-986142	Phase 2
T25005	DRUGINFO	D0C0OB	LOU064	Phase 2
T25005	DRUGINFO	D0E8PG	BGB-3112	Phase 2
T25005	DRUGINFO	D0GH7L	PRN1008	Phase 2
T25005	DRUGINFO	D0H0KH	GS-4059	Phase 2
T25005	DRUGINFO	D0KQ7M	ARQ 531	Phase 2
T25005	DRUGINFO	D0QX8X	M2951	Phase 2
T25005	DRUGINFO	DE3VU1	Branebrutinib	Phase 2
T25005	DRUGINFO	DS6V8H	SAR 444727	Phase 2
T25005	DRUGINFO	DVS81T	DTRM-555	Phase 2
T25005	DRUGINFO	D0UF0N	ACP-319	Phase 1/2
T25005	DRUGINFO	D0YI4F	Vecabrutinib	Phase 1/2
T25005	DRUGINFO	DT3BA1	CG-806	Phase 1/2
T25005	DRUGINFO	D02MRX	ONO-4059	Phase 1
T25005	DRUGINFO	D05SGI	BGB-3113	Phase 1
T25005	DRUGINFO	D08SGE	M7583	Phase 1
T25005	DRUGINFO	D09NVR	PRN2246	Phase 1
T25005	DRUGINFO	D0KT8D	AC0058TA	Phase 1
T25005	DRUGINFO	D0VS3U	TAK-020	Phase 1
T25005	DRUGINFO	D0WP9A	BIIB068	Phase 1
T25005	DRUGINFO	D3Q4SZ	DTRMWXHS-12	Phase 1
T25005	DRUGINFO	D7GTX4	BIIB091	Phase 1
T25005	DRUGINFO	DB2Q4X	HMPL-760	Phase 1
T25005	DRUGINFO	DBO39X	JNJ-64264681	Phase 1
T25005	DRUGINFO	DDEI09	TT-01488	Phase 1
T25005	DRUGINFO	DELW64	NX-5948	Phase 1
T25005	DRUGINFO	DJ6ZB0	BGB-16673	Phase 1
T25005	DRUGINFO	DQ21NM	TG-1701	Phase 1
T25005	DRUGINFO	DTF20P	HM71224	Phase 1
T25005	DRUGINFO	D7YN4H	NX-2127	Phase 1
T25005	DRUGINFO	D00KEX	Pyrrolo[2,3-d]pyrimidine derivative 14	Patented
T25005	DRUGINFO	D00KPQ	Pyrrolo[2,3-d]pyrimidine derivative 19	Patented
T25005	DRUGINFO	D03ULH	Pyrrolo[2,3-d]pyrimidine derivative 13	Patented
T25005	DRUGINFO	D05UXK	Pyrrolo[2,3-d]pyrimidine derivative 29	Patented
T25005	DRUGINFO	D05YNZ	Pyrrolo[2,3-d]pyrimidine derivative 30	Patented
T25005	DRUGINFO	D06ZNU	Pyrrolo[2,3-d]pyrimidine derivative 16	Patented
T25005	DRUGINFO	D09IOW	Pyrrolo[2,3-d]pyrimidine derivative 23	Patented
T25005	DRUGINFO	D09TKO	Pyrrolo[2,3-d]pyrimidine derivative 15	Patented
T25005	DRUGINFO	D0CG3V	Pyrrolo[2,3-d]pyrimidine derivative 25	Patented
T25005	DRUGINFO	D0IX7O	Pyrrolo[2,3-d]pyrimidine derivative 27	Patented
T25005	DRUGINFO	D0J8UO	Pyrrolo[2,3-d]pyrimidine derivative 33	Patented
T25005	DRUGINFO	D0Q1BE	Pyrrolo[2,3-d]pyrimidine derivative 20	Patented
T25005	DRUGINFO	D0Q8LH	Pyrrolo[2,3-d]pyrimidine derivative 32	Patented
T25005	DRUGINFO	D0QW4H	Pyrrolo[2,3-d]pyrimidine derivative 12	Patented
T25005	DRUGINFO	D0R9HP	Pyrrolo[2,3-d]pyrimidine derivative 26	Patented
T25005	DRUGINFO	D0SR0U	Pyrrolo[2,3-d]pyrimidine derivative 22	Patented
T25005	DRUGINFO	D0TI0R	Pyrrolo[2,3-d]pyrimidine derivative 21	Patented
T25005	DRUGINFO	D0V8JZ	Pyrrolo[2,3-d]pyrimidine derivative 17	Patented
T25005	DRUGINFO	D0W3BE	Pyrrolo[2,3-d]pyrimidine derivative 31	Patented
T25005	DRUGINFO	D0WN2X	Pyrrolo[2,3-d]pyrimidine derivative 18	Patented
T25005	DRUGINFO	D00BYK	PMID27774824-Compound-Figure12Example61	Patented
T25005	DRUGINFO	D00GTY	Pyrrolo[2,3-d]pyrimidine derivative 28	Patented
T25005	DRUGINFO	D0NK1R	PMID27774824-Compound-Figure12Example1	Patented
T25005	DRUGINFO	D0P3UH	Imidazopyridine derivative 4	Patented
T25005	DRUGINFO	D0UH8J	PMID27774824-Compound-Figure12Example10	Patented
T25005	DRUGINFO	D09PIS	Pyrazolo[4,3-c]pyridine derivative 2	Patented
T25005	DRUGINFO	D0D4AQ	PCI-45292	Preclinical
T25005	DRUGINFO	D03FUO	GDC-0834	Terminated
T25005	DRUGINFO	D08NTB	LFM-A13	Investigative
T25005	DRUGINFO	D0H3JH	CGI-1316	Investigative
T25005	DRUGINFO	D0MH9X	Inositol 1,3,4,5-Tetrakisphosphate	Investigative
T25005	DRUGINFO	D0N0LN	RN486	Investigative
T25005	DRUGINFO	D01RHR	PMID24915291C31	Investigative
T25005	DRUGINFO	D06BJG	PMID24915291C38	Investigative
T25005	DRUGINFO	D0E7VO	PMID24900538C2c	Investigative

T01318	TARGETID	T01318
T01318	FORMERID	TTDS00059
T01318	UNIPROID	PYRD_PLAF7
T01318	TARGNAME	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
T01318	GENENAME	Malaria DHOdehase
T01318	TARGTYPE	Successful
T01318	SYNONYMS	PFF0160c; Mitochondrially bound dihydroorotate-ubiqui oxidoreductase; Dihydroorotate oxidase of Plasmodium falciparum; Dihydroorotate dehydrogenase of Plasmodium falciparum; DHOdehase of Plasmodium falciparum; DHODase; DHODH of Plasmodium falciparum; DHOD
T01318	FUNCTION	Catalyzes the conversion of dihydroorotate to orotate with quinone as electron acceptor.
T01318	PDBSTRUC	6GJG; 6E0B; 5TBO; 5FI8; 5DEL
T01318	BIOCLASS	CH-CH donor oxidoreductase
T01318	ECNUMBER	EC 1.3.5.2
T01318	SEQUENCE	MISKLKPQFMFLPKKHILSYCRKDVLNLFEQKFYYTSKRKESNNMKNESLLRLINYNRYYNKIDSNNYYNGGKILSNDRQYIYSPLCEYKKKINDISSYVSVPFKINIRNLGTSNFVNNKKDVLDNDYIYENIKKEKSKHKKIIFLLFVSLFGLYGFFESYNPEFFLYDIFLKFCLKYIDGEICHDLFLLLGKYNILPYDTSNDSIYACTNIKHLDFINPFGVAAGFDKNGVCIDSILKLGFSFIEIGTITPRGQTGNAKPRIFRDVESRSIINSCGFNNMGCDKVTENLILFRKRQEEDKLLSKHIVGVSIGKNKDTVNIVDDLKYCINKIGRYADYIAINVSSPNTPGLRDNQEAGKLKNIILSVKEEIDNLEKNNIMNDESTYNEDNKIVEKKNNFNKNNSHMMKDAKDNFLWFNTTKKKPLVFVKLAPDLNQEQKKEIADVLLETNIDGMIISNTTTQINDIKSFENKKGGVSGAKLKDISTKFICEMYNYTNKQIPIIASGGIFSGLDALEKIEAGASVCQLYSCLVFNGMKSAVQIKRELNHLLYQRGYYNLKEAIGRKHSKS
T01318	DRUGINFO	D06ZEE	Atovaquone	Approved
T01318	DRUGINFO	D08ROP	Leflunomide	Approved
T01318	DRUGINFO	D0S3WH	Artemisinin	Approved
T01318	DRUGINFO	D07QFP	Teriflunomide	Approved
T01318	DRUGINFO	D0C0NH	Avastin+/-Tarceva	Phase 3
T01318	DRUGINFO	D00CQT	Dichloroallyl lawsone	Investigative
T01318	DRUGINFO	D00LCE	Antiproliferative Agent A771726	Investigative
T01318	DRUGINFO	D00YPH	3-hydroxy-2-phenylquinoline-4-carboxylic acid	Investigative
T01318	DRUGINFO	D01NWQ	N-(4-bromo-2-methylphenyl)-2-naphthamide	Investigative
T01318	DRUGINFO	D02TJY	Triazine	Investigative
T01318	DRUGINFO	D02YDM	Dichloroally-lawsone	Investigative
T01318	DRUGINFO	D03QKF	2-(3-(3,5-dichlorophenyl)ureido)benzoic acid	Investigative
T01318	DRUGINFO	D04FYN	Diethyl 2-((biphenyl-3-ylamino)methylene)malonate	Investigative
T01318	DRUGINFO	D04HZA	2-(2-bromo-2-naphthamido)benzoic acid	Investigative
T01318	DRUGINFO	D04LBT	Antimycin A	Investigative
T01318	DRUGINFO	D05SXU	2-(2-naphthamido)benzoic acid	Investigative
T01318	DRUGINFO	D05YJP	Ethyl 3-(biphenyl-3-ylamino)-2-cyanoacrylate	Investigative
T01318	DRUGINFO	D06IPT	N-(Biphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide	Investigative
T01318	DRUGINFO	D07NYQ	Cinchoninic acid	Investigative
T01318	DRUGINFO	D07PUS	DSM1	Investigative
T01318	DRUGINFO	D07TKG	NSC 665564	Investigative
T01318	DRUGINFO	D08LMT	3,6,9,12,15-PENTAOXATRICOSAN-1-OL	Investigative
T01318	DRUGINFO	D09EAO	LY214352	Investigative
T01318	DRUGINFO	D09WBQ	DSM2	Investigative
T01318	DRUGINFO	D0C1LW	5,8-hydroxy-naphthoquinone	Investigative
T01318	DRUGINFO	D0C1NU	N-(3,5-dichlorophenyl)-2-methyl-3-nitrobenzamide	Investigative
T01318	DRUGINFO	D0H6QL	Salicylhydroxamic acid	Investigative
T01318	DRUGINFO	D0HQ1I	GNF-PF-85	Investigative
T01318	DRUGINFO	D0P0IE	Plumbagin	Investigative
T01318	DRUGINFO	D0R1GF	2-[(biphenyl-4-carbonyl)-amino]-benzoic acid	Investigative
T01318	DRUGINFO	D0S7BK	Orotic acid	Investigative
T01318	DRUGINFO	D0S8AC	1-hydroxy-2-dodecyl-4(1H)quinolone	Investigative
T01318	DRUGINFO	D0S8YD	Decylamine-N,N-Dimethyl-N-Oxide	Investigative
T01318	DRUGINFO	D0V8EH	Isoxazol	Investigative
T01318	DRUGINFO	D0WV5R	Cyanide	Investigative
T01318	DRUGINFO	D0X4NX	Polyporic acid	Investigative
T01318	DRUGINFO	D0YQ2A	Undecylamine-n,n-dimethyl-n-oxide	Investigative
T01318	DRUGINFO	D0AZ4T	Dihydroorotate	Investigative
T01318	DRUGINFO	D0B1SW	Redoxal	Investigative
T01318	DRUGINFO	D0B1TS	Orotate	Investigative
T01318	DRUGINFO	D0DQ6Z	1,4-Naphthoquinone	Investigative
T01318	DRUGINFO	D0E2WX	5-Fluoro orotate	Investigative
T01318	DRUGINFO	D0YN5P	8-aminoquinolines	Investigative
T01318	DRUGINFO	D0C7PY	Lauryl Dimethylamine-N-Oxide	Investigative
T01318	DRUGINFO	D02UVH	B-Octylglucoside	Investigative
T01318	DRUGINFO	D0F2ME	Acetate Ion	Investigative

T68547	TARGETID	T68547
T68547	FORMERID	TTDS00095
T68547	UNIPROID	HDAC1_HUMAN
T68547	TARGNAME	Histone deacetylase 1 (HDAC1)
T68547	GENENAME	HDAC1
T68547	TARGTYPE	Successful
T68547	SYNONYMS	RPD3L1; HD1
T68547	FUNCTION	Gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Deacetylates SP proteins, SP1 and SP3, and regulates their function. Component of the BRG1-RB1-HDAC1 complex, which negatively regulates the CREST-mediated transcription in resting neurons. Upon calcium stimulation, HDAC1 is released from the complex and CREBBP is recruited, which facilitates transcriptional activation. Deacetylates TSHZ3 and regulates its transcriptional repressor activity. Deacetylates 'Lys-310' in RELA and thereby inhibits the transcriptional activity of NF-kappa-B. Deacetylates NR1D2 and abrogates the effect of KAT5-mediated relieving of NR1D2 transcription repression activity. Component of a RCOR/GFI/KDM1A/HDAC complex that suppresses, via histone deacetylase (HDAC) recruitment, a number of genes implicated in multilineage blood cell development. Involved in CIART-mediated transcriptional repression of the circadian transcriptional activator: CLOCK-ARNTL/BMAL1 heterodimer. Required for the transcriptional repression of circadian target genes, such as PER1, mediated by the large PER complex or CRY1 through histone deacetylation. Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4).
T68547	PDBSTRUC	5ICN; 4BKX; 1TYI
T68547	BIOCLASS	Carbon-nitrogen hydrolase
T68547	ECNUMBER	EC 3.5.1.98
T68547	SEQUENCE	MAQTQGTRRKVCYYYDGDVGNYYYGQGHPMKPHRIRMTHNLLLNYGLYRKMEIYRPHKANAEEMTKYHSDDYIKFLRSIRPDNMSEYSKQMQRFNVGEDCPVFDGLFEFCQLSTGGSVASAVKLNKQQTDIAVNWAGGLHHAKKSEASGFCYVNDIVLAILELLKYHQRVLYIDIDIHHGDGVEEAFYTTDRVMTVSFHKYGEYFPGTGDLRDIGAGKGKYYAVNYPLRDGIDDESYEAIFKPVMSKVMEMFQPSAVVLQCGSDSLSGDRLGCFNLTIKGHAKCVEFVKSFNLPMLMLGGGGYTIRNVARCWTYETAVALDTEIPNELPYNDYFEYFGPDFKLHISPSNMTNQNTNEYLEKIKQRLFENLRMLPHAPGVQMQAIPEDAIPEESGDEDEDDPDKRISICSSDKRIACEEEFSDSEEEGEGGRKNSSNFKKAKRVKTEDEKEKDPEEKKEVTEEEKTKEEKPEAKGVKEEVKLA
T68547	DRUGINFO	D0E3SH	Panobinostat	Approved
T68547	DRUGINFO	D0E7PQ	Vorinostat	Approved
T68547	DRUGINFO	D0L7LC	Romidepsin	Approved
T68547	DRUGINFO	D00SQN	HBI-8000	Registered
T68547	DRUGINFO	D0B3FV	NVP-LAQ824	Phase 3
T68547	DRUGINFO	D0M8FD	SNDX-275	Phase 3
T68547	DRUGINFO	D0GH3Q	ITF2357	Phase 3
T68547	DRUGINFO	D01UXJ	Resminostat	Phase 2
T68547	DRUGINFO	D0I7IB	Sodium butyrate	Phase 2
T68547	DRUGINFO	D0VE1W	SB-623	Phase 2
T68547	DRUGINFO	D00FHR	MGCD-0103	Phase 2
T68547	DRUGINFO	D0B7CH	Phenylbutyrate	Phase 2
T68547	DRUGINFO	D06TKI	CHR-3996	Phase 1/2
T68547	DRUGINFO	D07FPY	SB-639	Phase 1
T68547	DRUGINFO	D0GE5B	RG-2833	Phase 1
T68547	DRUGINFO	D00SSZ	OBP-801	Phase 1
T68547	DRUGINFO	D0YT8O	PMID29671355-Compound-42	Patented
T68547	DRUGINFO	D00ACL	PMID28092474-Compound-33d	Patented
T68547	DRUGINFO	D00GLJ	PMID28092474-Compound-32u	Patented
T68547	DRUGINFO	D00LLN	PMID28092474-Compound-33a	Patented
T68547	DRUGINFO	D00XWZ	PMID28092474-Compound-32a	Patented
T68547	DRUGINFO	D01LCZ	PMID28092474-Compound-32j	Patented
T68547	DRUGINFO	D02YDG	PMID28092474-Compound-32z	Patented
T68547	DRUGINFO	D03EUD	PMID28092474-Compound-32g	Patented
T68547	DRUGINFO	D04AMI	PMID28092474-Compound-34c	Patented
T68547	DRUGINFO	D04KQU	PMID28092474-Compound-32x	Patented
T68547	DRUGINFO	D04MVN	PMID28092474-Compound-33b	Patented
T68547	DRUGINFO	D04VQE	PMID28092474-Compound-32b	Patented
T68547	DRUGINFO	D06IIL	PMID28092474-Compound-32o	Patented
T68547	DRUGINFO	D08GBR	PMID28092474-Compound-33g	Patented
T68547	DRUGINFO	D08GQL	PMID28092474-Compound-33j	Patented
T68547	DRUGINFO	D08SNJ	PMID28092474-Compound-33p	Patented
T68547	DRUGINFO	D08XLK	PMID28092474-Compound-33m	Patented
T68547	DRUGINFO	D08ZJZ	PMID28092474-Compound-32v	Patented
T68547	DRUGINFO	D09PVH	PMID29671355-Compound-24	Patented
T68547	DRUGINFO	D0BY1R	PMID28092474-Compound-34b	Patented
T68547	DRUGINFO	D0CH4M	PMID28092474-Compound-33e	Patented
T68547	DRUGINFO	D0CX1Y	PMID28092474-Compound-32t	Patented
T68547	DRUGINFO	D0DH7R	PMID28092474-Compound-32c	Patented
T68547	DRUGINFO	D0E5CO	PMID28092474-Compound-33i	Patented
T68547	DRUGINFO	D0ET4U	PMID28092474-Compound-32r	Patented
T68547	DRUGINFO	D0EU5A	PMID28092474-Compound-32h	Patented
T68547	DRUGINFO	D0F3TB	PMID29671355-Compound-65a	Patented
T68547	DRUGINFO	D0HM6Y	PMID28092474-Compound-32y	Patented
T68547	DRUGINFO	D0JN0A	PMID28092474-Compound-33h	Patented
T68547	DRUGINFO	D0JR9L	PMID29671355-Compound-38a	Patented
T68547	DRUGINFO	D0K2UF	PMID28092474-Compound-33f	Patented
T68547	DRUGINFO	D0KA3X	Diaryl amine derivative 3	Patented
T68547	DRUGINFO	D0L3CU	PMID28092474-Compound-33c	Patented
T68547	DRUGINFO	D0L7HG	PMID29671355-Compound-39	Patented
T68547	DRUGINFO	D0LV6K	PMID29671355-Compound-19	Patented
T68547	DRUGINFO	D0M7XL	PMID28092474-Compound-32e	Patented
T68547	DRUGINFO	D0MQ2D	PMID28092474-Compound-32m	Patented
T68547	DRUGINFO	D0MR7U	PMID28092474-Compound-32p	Patented
T68547	DRUGINFO	D0N1RX	PMID28092474-Compound-32d	Patented
T68547	DRUGINFO	D0O6SJ	PMID28092474-Compound-32n	Patented
T68547	DRUGINFO	D0Q9XK	PMID28092474-Compound-33k	Patented
T68547	DRUGINFO	D0QF0Y	PMID28092474-Compound-32k	Patented
T68547	DRUGINFO	D0QN8W	PMID28092474-Compound-34a	Patented
T68547	DRUGINFO	D0QR1Z	Isosteric imidazolyl pyrimidine derivative 1	Patented
T68547	DRUGINFO	D0QX3G	PMID29671355-Compound-22	Patented
T68547	DRUGINFO	D0R3RJ	PMID29671355-Compound-26	Patented
T68547	DRUGINFO	D0RD7T	PMID28092474-Compound-33o	Patented
T68547	DRUGINFO	D0S3ZB	PMID28092474-Compound-32f	Patented
T68547	DRUGINFO	D0S7NE	Diaryl amine derivative 2	Patented
T68547	DRUGINFO	D0SF8N	PMID28092474-Compound-33l	Patented
T68547	DRUGINFO	D0SK9K	PMID28092474-Compound-32i	Patented
T68547	DRUGINFO	D0TH3L	PMID28092474-Compound-32q	Patented
T68547	DRUGINFO	D0TN6E	PMID29671355-Compound-18	Patented
T68547	DRUGINFO	D0UD9R	PMID29671355-Compound-57	Patented
T68547	DRUGINFO	D0V5IQ	PMID29671355-Compound-27	Patented
T68547	DRUGINFO	D0W1AX	PMID28092474-Compound-32l	Patented
T68547	DRUGINFO	D0YC2M	PMID28092474-Compound-32s	Patented
T68547	DRUGINFO	D0YD7B	PMID29671355-Compound-38b	Patented
T68547	DRUGINFO	D0Z7QI	PMID29671355-Compound-28	Patented
T68547	DRUGINFO	D0C9NX	PMID29671355-Compound-59	Patented
T68547	DRUGINFO	D0OU0J	PMID29671355-Compound-55	Patented
T68547	DRUGINFO	D0T7OQ	PMID29671355-Compound-73	Patented
T68547	DRUGINFO	D0ZG5X	PMID29671355-Compound-13	Patented
T68547	DRUGINFO	D0EH2K	PMID29671355-Compound-11	Patented
T68547	DRUGINFO	D0Q1QY	PMID29671355-Compound-9	Patented
T68547	DRUGINFO	D0LN1T	PMID29671355-Compound-8	Patented
T68547	DRUGINFO	D0JB4S	PMID29671355-Compound-61	Patented
T68547	DRUGINFO	D00HXJ	PMID29671355-Compound-23	Patented
T68547	DRUGINFO	D0N2DK	PMID29671355-Compound-44	Patented
T68547	DRUGINFO	D0CH8Q	PMID29671355-Compound-56	Patented
T68547	DRUGINFO	D0M0RE	PMID29671355-Compound-67	Patented
T68547	DRUGINFO	D0DI9S	PMID29671355-Compound-31	Patented
T68547	DRUGINFO	D0LP1K	PMID29671355-Compound-21	Patented
T68547	DRUGINFO	D07WAT	PMID29671355-Compound-62	Patented
T68547	DRUGINFO	D0BP8I	PMID29671355-Compound-43	Patented
T68547	DRUGINFO	D0RA0D	PMID29671355-Compound-25	Patented
T68547	DRUGINFO	D0MP2U	AN-9	Discontinued in Phase 2
T68547	DRUGINFO	D0W9NH	Tacedinaline	Discontinued in Phase 2
T68547	DRUGINFO	D0N3SH	Pyroxamide	Discontinued in Phase 1
T68547	DRUGINFO	D03SZR	M-carboxycinnamic acid bishydroxamide	Preclinical
T68547	DRUGINFO	D06RQU	HC-Toxin	Preclinical
T68547	DRUGINFO	D0DO5U	SK-7068	Preclinical
T68547	DRUGINFO	D0J8OC	Scriptaid	Preclinical
T68547	DRUGINFO	D0L5DZ	4SC-202	Preclinical
T68547	DRUGINFO	D0UC6H	Chlamydocin	Preclinical
T68547	DRUGINFO	D0UL5X	SK-7041	Preclinical
T68547	DRUGINFO	D0W8JE	Depudecin	Preclinical
T68547	DRUGINFO	D03YVR	Oxamflatin	Terminated
T68547	DRUGINFO	D00GBB	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide	Investigative
T68547	DRUGINFO	D00LSZ	N,8-dihydroxy-8-(naphthalen-2-yl)octanamide	Investigative
T68547	DRUGINFO	D00PLM	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide	Investigative
T68547	DRUGINFO	D00RGD	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide	Investigative
T68547	DRUGINFO	D01EDB	NSC-746457	Investigative
T68547	DRUGINFO	D02VVU	4-Benzenesulfonylamino-N-hydroxy-benzamide	Investigative
T68547	DRUGINFO	D03FFI	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide	Investigative
T68547	DRUGINFO	D03FOD	4-tert-butyl-N-hydroxybenzamide	Investigative
T68547	DRUGINFO	D03OYL	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide	Investigative
T68547	DRUGINFO	D03ZUZ	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide	Investigative
T68547	DRUGINFO	D04XPZ	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide	Investigative
T68547	DRUGINFO	D05PYF	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide	Investigative
T68547	DRUGINFO	D06NVX	N-hydroxy-5-phenylthiophene-2-carboxamide	Investigative
T68547	DRUGINFO	D06ONC	Azithromycin-N-benzyltriazolyldecahydroxamic Acid	Investigative
T68547	DRUGINFO	D07HUH	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide	Investigative
T68547	DRUGINFO	D0A6CB	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide	Investigative
T68547	DRUGINFO	D0A7IF	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide	Investigative
T68547	DRUGINFO	D0B1YM	Gymnochrome E	Investigative
T68547	DRUGINFO	D0CJ7L	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide	Investigative
T68547	DRUGINFO	D0D3XC	N-hydroxybenzo[b]thiophene-2-carboxamide	Investigative
T68547	DRUGINFO	D0G0OF	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide	Investigative
T68547	DRUGINFO	D0GJ1E	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide	Investigative
T68547	DRUGINFO	D0K8MF	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide	Investigative
T68547	DRUGINFO	D0KM7H	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide	Investigative
T68547	DRUGINFO	D0L4ML	N-hydroxy-6-oxo-6-phenylhexanamide	Investigative
T68547	DRUGINFO	D0L5WI	N-hydroxy-8-(naphthalen-2-yl)octanamide	Investigative
T68547	DRUGINFO	D0M0QJ	ADS-102550	Investigative
T68547	DRUGINFO	D0O7UF	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide	Investigative
T68547	DRUGINFO	D0P1RQ	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide	Investigative
T68547	DRUGINFO	D0PP3Q	N-hydroxy-2,2'-bithiophene-5-carboxamide	Investigative
T68547	DRUGINFO	D0Q8QA	ADS-100380	Investigative
T68547	DRUGINFO	D0QX6R	N-hydroxy-7-oxo-7-phenylheptanamide	Investigative
T68547	DRUGINFO	D0T0BE	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide	Investigative
T68547	DRUGINFO	D0U3MB	SK-683	Investigative
T68547	DRUGINFO	D0Z2VP	N-hydroxy-9-oxo-9-phenylnonanamide	Investigative
T68547	DRUGINFO	D00HFS	N-Hydroxy-N'-(4-methylphenyl)octanediamide	Investigative
T68547	DRUGINFO	D01AMS	N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide	Investigative
T68547	DRUGINFO	D01FYB	N-(2-aminophenyl)quinoxaline-6-carboxamide	Investigative
T68547	DRUGINFO	D01RJY	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	Investigative
T68547	DRUGINFO	D01ZMJ	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	Investigative
T68547	DRUGINFO	D03XXI	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	Investigative
T68547	DRUGINFO	D04ETX	1,1,1-Trifluoro-8-phenoxy-octan-2-one	Investigative
T68547	DRUGINFO	D04LLD	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	Investigative
T68547	DRUGINFO	D05GRZ	N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide	Investigative
T68547	DRUGINFO	D05ZGM	7-Phenoxy-heptanoic acid hydroxyamide	Investigative
T68547	DRUGINFO	D06BKA	1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one	Investigative
T68547	DRUGINFO	D06FAK	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	Investigative
T68547	DRUGINFO	D06THS	Desclasinose Azithromycinarylalkyl Hydroxamate	Investigative
T68547	DRUGINFO	D08ICY	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	Investigative
T68547	DRUGINFO	D08TIJ	N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide	Investigative
T68547	DRUGINFO	D08XMS	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	Investigative
T68547	DRUGINFO	D0B8RC	N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide	Investigative
T68547	DRUGINFO	D0D7KH	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	Investigative
T68547	DRUGINFO	D0E0TA	N-(4-hydroxybiphenyl-3-yl)benzamide	Investigative
T68547	DRUGINFO	D0E9DD	AZUMAMIDE E	Investigative
T68547	DRUGINFO	D0H3RO	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	Investigative
T68547	DRUGINFO	D0H7QA	N-Hydroxy-N'-(3-methylphenyl)octanediamide	Investigative
T68547	DRUGINFO	D0H9DS	8-Phenyl-octanoic acid hydroxyamide	Investigative
T68547	DRUGINFO	D0I5XM	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	Investigative
T68547	DRUGINFO	D0J3CY	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	Investigative
T68547	DRUGINFO	D0L5KP	N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide	Investigative
T68547	DRUGINFO	D0L6YF	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	Investigative
T68547	DRUGINFO	D0M1ZI	AZUMAMIDE B	Investigative
T68547	DRUGINFO	D0NL6C	8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one	Investigative
T68547	DRUGINFO	D0P9CQ	Azithromycinarylalkylhydroxamic Acid	Investigative
T68547	DRUGINFO	D0Q2CC	N-Hydroxy-N'-(2-methylphenyl)octanediamide	Investigative
T68547	DRUGINFO	D0Q5DI	nexturastat A	Investigative
T68547	DRUGINFO	D0Q9PO	AZUMAMIDE C	Investigative
T68547	DRUGINFO	D0SQ1F	N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide	Investigative
T68547	DRUGINFO	D0YP4F	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	Investigative
T68547	DRUGINFO	D0Z8PX	LARGAZOLE	Investigative
T68547	DRUGINFO	D00XTC	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	Investigative
T68547	DRUGINFO	D02HVH	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	Investigative
T68547	DRUGINFO	D02NAF	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	Investigative
T68547	DRUGINFO	D02NVY	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	Investigative
T68547	DRUGINFO	D03PRG	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	Investigative
T68547	DRUGINFO	D04CDZ	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	Investigative
T68547	DRUGINFO	D04DOL	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	Investigative
T68547	DRUGINFO	D04UVL	N-(2-aminophenyl)nicotinamide	Investigative
T68547	DRUGINFO	D0E8UH	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	Investigative
T68547	DRUGINFO	D0G1EX	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	Investigative
T68547	DRUGINFO	D0M9LJ	N-(4-aminobiphenyl-3-yl)nicotinamide	Investigative
T68547	DRUGINFO	D0N5RV	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	Investigative
T68547	DRUGINFO	D0Q2GM	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	Investigative
T68547	DRUGINFO	D0R3XO	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	Investigative
T68547	DRUGINFO	D0U0EZ	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	Investigative
T68547	DRUGINFO	D0X4QC	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	Investigative
T68547	DRUGINFO	D0YO6M	N-(2-aminophenyl)-4-methoxybenzamide	Investigative
T68547	DRUGINFO	D0Z6HR	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	Investigative
T68547	DRUGINFO	D0Z6MI	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	Investigative
T68547	DRUGINFO	D02NWS	4-Phenylbutyrohydroxamic acid	Investigative
T68547	DRUGINFO	D0S0WK	8-Oxo-8-phenyl-octanoic acid hydroxyamide	Investigative
T68547	DRUGINFO	D01YBR	ST-3050	Investigative
T68547	DRUGINFO	D07YZZ	Octanedioic acid bis-hydroxyamide	Investigative
T68547	DRUGINFO	D0N9AK	ST-2986	Investigative
T68547	DRUGINFO	D00KFF	9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide	Investigative
T68547	DRUGINFO	D00SEE	7-Mercapto-heptanoic acid phenylamide	Investigative
T68547	DRUGINFO	D00ZSD	6-benzenesulfinylhexanoic acid hydroxamide	Investigative
T68547	DRUGINFO	D01MFV	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	Investigative
T68547	DRUGINFO	D01XWZ	7-Mercapto-heptanoic acid biphenyl-4-ylamide	Investigative
T68547	DRUGINFO	D01XXN	N-Hydroxy-4-phenylacetylamino-benzamide	Investigative
T68547	DRUGINFO	D02MQM	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	Investigative
T68547	DRUGINFO	D02UTC	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	Investigative
T68547	DRUGINFO	D02WZK	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	Investigative
T68547	DRUGINFO	D04GGW	Octanedioic acid hydroxyamide pyridin-4-ylamide	Investigative
T68547	DRUGINFO	D04HSS	N-(6-Mercapto-hexyl)-benzamide	Investigative
T68547	DRUGINFO	D04NSP	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	Investigative
T68547	DRUGINFO	D04ZDI	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	Investigative
T68547	DRUGINFO	D05AHZ	6-benzenesulfonylhexanoic acid hydroxamide	Investigative
T68547	DRUGINFO	D05FEJ	9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one	Investigative
T68547	DRUGINFO	D05GVY	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	Investigative
T68547	DRUGINFO	D05LLX	4-Butyrylamino-N-hydroxy-benzamide	Investigative
T68547	DRUGINFO	D05VFP	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	Investigative
T68547	DRUGINFO	D05XAN	7-Mercapto-heptanoic acid biphenyl-3-ylamide	Investigative
T68547	DRUGINFO	D06IQB	5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione	Investigative
T68547	DRUGINFO	D06VBN	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	Investigative
T68547	DRUGINFO	D06XNP	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	Investigative
T68547	DRUGINFO	D07FJU	7-Mercapto-heptanoic acid pyridin-3-ylamide	Investigative
T68547	DRUGINFO	D09YBN	6-Phenoxy-hexane-1-thiol	Investigative
T68547	DRUGINFO	D09ZNU	4-Benzoylamino-N-hydroxy-benzamide	Investigative
T68547	DRUGINFO	D0A5LS	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	Investigative
T68547	DRUGINFO	D0AX7B	8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one	Investigative
T68547	DRUGINFO	D0B2ZJ	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	Investigative
T68547	DRUGINFO	D0B3ZM	6-Mercapto-hexanoic acid phenylamide	Investigative
T68547	DRUGINFO	D0C0VP	Cyclostellettamine derivative	Investigative
T68547	DRUGINFO	D0C2KD	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	Investigative
T68547	DRUGINFO	D0D2KE	5-Mercapto-pentanoic acid phenylamide	Investigative
T68547	DRUGINFO	D0E8KR	Octanedioic acid hydroxyamide pyridin-2-ylamide	Investigative
T68547	DRUGINFO	D0F0KS	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	Investigative
T68547	DRUGINFO	D0H1FZ	2-(methylsulfonylthio)ethyl 2-propylpentanoate	Investigative
T68547	DRUGINFO	D0KE3I	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	Investigative
T68547	DRUGINFO	D0QO0L	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	Investigative
T68547	DRUGINFO	D0R4BS	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	Investigative
T68547	DRUGINFO	D0R5VG	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	Investigative
T68547	DRUGINFO	D0RU1X	8-Oxo-8-phenyl-octanoic acid	Investigative
T68547	DRUGINFO	D0S7WQ	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	Investigative
T68547	DRUGINFO	D0S9JF	6-phenylsulfanylhexanoic acid hydroxamide	Investigative
T68547	DRUGINFO	D0T0SK	ST-2987	Investigative
T68547	DRUGINFO	D0T4IY	7-Mercapto-heptanoic acid quinolin-3-ylamide	Investigative
T68547	DRUGINFO	D0V2ZO	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	Investigative
T68547	DRUGINFO	D0XZ9Q	8-Mercapto-octanoic acid phenylamide	Investigative
T68547	DRUGINFO	D0YY9M	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	Investigative
T68547	DRUGINFO	D0Z3BM	7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one	Investigative
T68547	DRUGINFO	D0Z5KX	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	Investigative
T68547	DRUGINFO	D0Z7YS	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	Investigative
T68547	DRUGINFO	D0N0TS	PSAMMAPLIN A	Investigative

T93344	TARGETID	T93344
T93344	FORMERID	TTDS00302
T93344	UNIPROID	ERG1_HUMAN
T93344	TARGNAME	Squalene monooxygenase (SQLE)
T93344	GENENAME	SQLE
T93344	TARGTYPE	Successful
T93344	SYNONYMS	Squalene epoxidase; SQLE; SE; Oxidosqaulene cyclase
T93344	FUNCTION	Catalyzes the first oxygenation step in sterol biosynthesis and is suggested to be one of the rate-limiting enzymes in this pathway.
T93344	PDBSTRUC	6C6R; 6C6P; 6C6N
T93344	BIOCLASS	Paired donor oxygen oxidoreductase
T93344	ECNUMBER	EC 1.14.14.17
T93344	SEQUENCE	MWTFLGIATFTYFYKKFGDFITLANREVLLCVLVFLSLGLVLSYRCRHRNGGLLGRQQSGSQFALFSDILSGLPFIGFFWAKSPPESENKEQLEARRRRKGTNISETSLIGTAACTSTSSQNDPEVIIVGAGVLGSALAAVLSRDGRKVTVIERDLKEPDRIVGEFLQPGGYHVLKDLGLGDTVEGLDAQVVNGYMIHDQESKSEVQIPYPLSENNQVQSGRAFHHGRFIMSLRKAAMAEPNAKFIEGVVLQLLEEDDVVMGVQYKDKETGDIKELHAPLTVVADGLFSKFRKSLVSNKVSVSSHFVGFLMKNAPQFKANHAELILANPSPVLIYQISSSETRVLVDIRGEMPRNLREYMVEKIYPQIPDHLKEPFLEATDNSHLRSMPASFLPPSSVKKRGVLLLGDAYNMRHPLTGGGMTVAFKDIKLWRKLLKGIPDLYDDAAIFEAKKSFYWARKTSHSFVVNILAQALYELFSATDDSLHQLRKACFLYFKLGGECVAGPVGLLSVLSPNPLVLIGHFFAVAIYAVYFCFKSEPWITKPRALLSSGAVLYKACSVIFPLIYSEMKYMVH
T93344	DRUGINFO	D00HPK	Naftifine	Approved
T93344	DRUGINFO	D02NTO	Tolnaftate	Approved
T93344	DRUGINFO	D0U2BH	Epigallocatechin gallate	Phase 3
T93344	DRUGINFO	D04DMO	FR-194738	Terminated
T93344	DRUGINFO	D06MUZ	SDZ-87-469	Terminated
T93344	DRUGINFO	D0I3XW	NB-598	Terminated
T93344	DRUGINFO	D01VEP	N-cetylgallate	Investigative
T93344	DRUGINFO	D02ZSX	OCTYL_GALLATE	Investigative
T93344	DRUGINFO	D03RKP	Trisnorsqualene difluoromethylidene	Investigative
T93344	DRUGINFO	D05UWZ	Mallotinic acid	Investigative
T93344	DRUGINFO	D06CPD	ETHYLGALLATE	Investigative
T93344	DRUGINFO	D06YCQ	Procyanidin B-2 3,3'-di-O-gallate	Investigative
T93344	DRUGINFO	D07WLU	1,2,6-tri-O-galloyl-beta-D-glucose	Investigative
T93344	DRUGINFO	D0A1QJ	Tellurium	Investigative
T93344	DRUGINFO	D0C6QS	GERANIIN	Investigative
T93344	DRUGINFO	D0F3KP	Thiocarbamate	Investigative
T93344	DRUGINFO	D0F9KV	1(beta)-O-galloylpedunculagin	Investigative
T93344	DRUGINFO	D0F9RE	Allylamines	Investigative
T93344	DRUGINFO	D0G3SL	FUROSIN	Investigative
T93344	DRUGINFO	D0J1DW	Trisnorsqualene cyclopropylamine	Investigative
T93344	DRUGINFO	D0J1QQ	Sanguiin H-6	Investigative
T93344	DRUGINFO	D0K2XJ	EUGENIIN	Investigative
T93344	DRUGINFO	D0QN6H	Mallotusinic acid	Investigative
T93344	DRUGINFO	D0T0XY	THEASINENSIN A	Investigative
T93344	DRUGINFO	D0VS1V	N-dodecylgallate	Investigative
T93344	DRUGINFO	D0Z9PB	Trisnorsqualene alcohol	Investigative
T93344	DRUGINFO	D0Z9YK	Chebulinic acid	Investigative
T93344	DRUGINFO	D03SPJ	CORILAGIN	Investigative
T93344	DRUGINFO	D0L1XR	Green tea	Investigative
T93344	DRUGINFO	D0Z2TG	Pedunculagin	Investigative
T93344	DRUGINFO	D00QDR	1,2,3,4,6-penta-O-galloyl-beta-D-glucose	Investigative
T93344	DRUGINFO	D0A1CM	ELLAGIC ACID	Investigative

T92057	TARGETID	T92057
T92057	FORMERID	TTDC00114
T92057	UNIPROID	ERBB4_HUMAN
T92057	TARGNAME	Erbb4 tyrosine kinase receptor (Erbb-4)
T92057	GENENAME	ERBB4
T92057	TARGTYPE	Successful
T92057	SYNONYMS	Tyrosine kinase-type cell surface receptor HER4; Receptor tyrosine-protein kinase erbB-4; Proto-oncogene-like protein c-ErbB-4; P180erbB4; HER4
T92057	FUNCTION	Required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyocyte proliferation. Required for normal development of the embryonic central nervous system, especially for normal neural crest cell migration and normal axon guidance. Required for mammary gland differentiation, induction of milk proteins and lactation. Acts as cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and the EGF family members BTC, EREG and HBEGF. Ligand binding triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Ligand specificity and signaling is modulated by alternative splicing, proteolytic processing, and by the formation of heterodimers with other ERBB family members, thereby creating multiple combinations of intracellular phosphotyrosines that trigger ligand- and context-specific cellular responses. Mediates phosphorylation of SHC1 and activation of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Isoform JM-A CYT-1 and isoform JM-B CYT-1 phosphorylate PIK3R1, leading to the activation of phosphatidylinositol 3-kinase and AKT1 and protect cells against apoptosis. Isoform JM-A CYT-1 and isoform JM-B CYT-1 mediate reorganization of the actin cytoskeleton and promote cell migration in response to NRG1. Isoform JM-A CYT-2 and isoform JM-B CYT-2 lack the phosphotyrosine that mediates interaction with PIK3R1, and hence do not phosphorylate PIK3R1, do not protect cells against apoptosis, and do not promote reorganization of the actin cytoskeleton and cell migration. Proteolytic processing of isoform JM-A CYT-1 and isoform JM-A CYT-2 gives rise to the corresponding soluble intracellular domains (4ICD) that translocate to the nucleus, promote nuclear import of STAT5A, activation of STAT5A, mammary epithelium differentiation, cell proliferation and activation of gene expression. The ERBB4 soluble intracellular domains (4ICD) colocalize with STAT5A at the CSN2 promoter to regulate transcription of milk proteins during lactation. The ERBB4 soluble intracellular domains can also translocate to mitochondria and promote apoptosis. Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis.
T92057	PDBSTRUC	3U9U; 3U7U; 3U2P; 3BCE; 3BBW
T92057	BIOCLASS	Kinase
T92057	ECNUMBER	EC 2.7.10.1
T92057	SEQUENCE	MKPATGLWVWVSLLVAAGTVQPSDSQSVCAGTENKLSSLSDLEQQYRALRKYYENCEVVMGNLEITSIEHNRDLSFLRSVREVTGYVLVALNQFRYLPLENLRIIRGTKLYEDRYALAIFLNYRKDGNFGLQELGLKNLTEILNGGVYVDQNKFLCYADTIHWQDIVRNPWPSNLTLVSTNGSSGCGRCHKSCTGRCWGPTENHCQTLTRTVCAEQCDGRCYGPYVSDCCHRECAGGCSGPKDTDCFACMNFNDSGACVTQCPQTFVYNPTTFQLEHNFNAKYTYGAFCVKKCPHNFVVDSSSCVRACPSSKMEVEENGIKMCKPCTDICPKACDGIGTGSLMSAQTVDSSNIDKFINCTKINGNLIFLVTGIHGDPYNAIEAIDPEKLNVFRTVREITGFLNIQSWPPNMTDFSVFSNLVTIGGRVLYSGLSLLILKQQGITSLQFQSLKEISAGNIYITDNSNLCYYHTINWTTLFSTINQRIVIRDNRKAENCTAEGMVCNHLCSSDGCWGPGPDQCLSCRRFSRGRICIESCNLYDGEFREFENGSICVECDPQCEKMEDGLLTCHGPGPDNCTKCSHFKDGPNCVEKCPDGLQGANSFIFKYADPDRECHPCHPNCTQGCNGPTSHDCIYYPWTGHSTLPQHARTPLIAAGVIGGLFILVIVGLTFAVYVRRKSIKKKRALRRFLETELVEPLTPSGTAPNQAQLRILKETELKRVKVLGSGAFGTVYKGIWVPEGETVKIPVAIKILNETTGPKANVEFMDEALIMASMDHPHLVRLLGVCLSPTIQLVTQLMPHGCLLEYVHEHKDNIGSQLLLNWCVQIAKGMMYLEERRLVHRDLAARNVLVKSPNHVKITDFGLARLLEGDEKEYNADGGKMPIKWMALECIHYRKFTHQSDVWSYGVTIWELMTFGGKPYDGIPTREIPDLLEKGERLPQPPICTIDVYMVMVKCWMIDADSRPKFKELAAEFSRMARDPQRYLVIQGDDRMKLPSPNDSKFFQNLLDEEDLEDMMDAEEYLVPQAFNIPPPIYTSRARIDSNRSEIGHSPPPAYTPMSGNQFVYRDGGFAAEQGVSVPYRAPTSTIPEAPVAQGATAEIFDDSCCNGTLRKPVAPHVQEDSSTQRYSADPTVFAPERSPRGELDEEGYMTPMRDKPKQEYLNPVEENPFVSRRKNGDLQALDNPEYHNASNGPPKAEDEYVNEPLYLNTFANTLGKAEYLKNNILSMPEKAKKAFDNPDYWNHSLPPRSTLQHPDYLQEYSTKYFYKQNGRIRPIVAENPEYLSEFSLKPGTVLPPPPYRHRNTVV
T92057	DRUGINFO	D06XXH	Dacomitinib	Approved
T92057	DRUGINFO	D0OC4O	RG7388	Phase 3
T92057	DRUGINFO	D0Z7IW	JI-101	Phase 2
T92057	DRUGINFO	D0YB3W	CI-1033	Phase 2
T92057	DRUGINFO	D0U3XL	JNJ-26483327	Phase 1
T92057	DRUGINFO	D05FFT	HDS-029	Investigative
T92057	DRUGINFO	D06BJG	PMID24915291C38	Investigative

T67849	TARGETID	T67849
T67849	FORMERID	TTDR00930
T67849	UNIPROID	PK3CD_HUMAN
T67849	TARGNAME	PI3-kinase delta (PIK3CD)
T67849	GENENAME	PIK3CD
T67849	TARGTYPE	Successful
T67849	SYNONYMS	PtdIns-3-kinase subunit p110-delta; PtdIns-3-kinase subunit delta; Phosphoinositide 3-kinase delta; Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, delta isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit delta; PI3Kdelta; PI3K-delta; PI3-kinase subunit delta; PI3-kinase p110 subunit delta; P110delta
T67849	FUNCTION	Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Mediates immune responses. Plays a role in B-cell development, proliferation, migration, and function. Required for B-cell receptor (BCR) signaling. Mediates B-cell proliferation response to anti-IgM, anti-CD40 and IL4 stimulation. Promotes cytokine production in response to TLR4 and TLR9. Required for antibody class switch mediated by TLR9. Involved in the antigen presentation function of B-cells. Involved in B-cell chemotaxis in response to CXCL13 and sphingosine 1-phosphate (S1P). Required for proliferation, signaling and cytokine production of naive, effector and memory T-cells. Required for T-cell receptor (TCR) signaling. Mediates TCR signaling events at the immune synapse. Activation by TCR leads to antigen-dependent memory T-cell migration and retention to antigenic tissues. Together with PIK3CG participates in T-cell development. Contributes to T-helper cell expansion and differentiation. Required for T-cell migration mediated by homing receptors SELL/CD62L, CCR7 and S1PR1 and antigen dependent recruitment of T-cells. Together with PIK3CG is involved in natural killer (NK) cell development and migration towards the sites of inflammation. Participates in NK cell receptor activation. Have a role in NK cell maturation and cytokine production. Together with PIK3CG is involved in neutrophil chemotaxis and extravasation. Together with PIK3CG participates in neutrophil respiratory burst. Have important roles in mast-cell development and mast cell mediated allergic response. Involved in stem cell factor (SCF)-mediated proliferation, adhesion and migration. Required for allergen-IgE-induced degranulation and cytokine release. The lipid kinase activity is required for its biological function. Isoform 2 may be involved in stabilizing total RAS levels, resulting in increased ERK phosphorylation and increased PI3K activity.
T67849	PDBSTRUC	6G6W; 5VLR; 5UBT; 5T8F; 5M6U
T67849	BIOCLASS	Kinase
T67849	ECNUMBER	EC 2.7.1.153
T67849	SEQUENCE	MPPGVDCPMEFWTKEENQSVVVDFLLPTGVYLNFPVSRNANLSTIKQLLWHRAQYEPLFHMLSGPEAYVFTCINQTAEQQELEDEQRRLCDVQPFLPVLRLVAREGDRVKKLINSQISLLIGKGLHEFDSLCDPEVNDFRAKMCQFCEEAAARRQQLGWEAWLQYSFPLQLEPSAQTWGPGTLRLPNRALLVNVKFEGSEESFTFQVSTKDVPLALMACALRKKATVFRQPLVEQPEDYTLQVNGRHEYLYGSYPLCQFQYICSCLHSGLTPHLTMVHSSSILAMRDEQSNPAPQVQKPRAKPPPIPAKKPSSVSLWSLEQPFRIELIQGSKVNADERMKLVVQAGLFHGNEMLCKTVSSSEVSVCSEPVWKQRLEFDINICDLPRMARLCFALYAVIEKAKKARSTKKKSKKADCPIAWANLMLFDYKDQLKTGERCLYMWPSVPDEKGELLNPTGTVRSNPNTDSAAALLICLPEVAPHPVYYPALEKILELGRHSECVHVTEEEQLQLREILERRGSGELYEHEKDLVWKLRHEVQEHFPEALARLLLVTKWNKHEDVAQMLYLLCSWPELPVLSALELLDFSFPDCHVGSFAIKSLRKLTDDELFQYLLQLVQVLKYESYLDCELTKFLLDRALANRKIGHFLFWHLRSEMHVPSVALRFGLILEAYCRGSTHHMKVLMKQGEALSKLKALNDFVKLSSQKTPKPQTKELMHLCMRQEAYLEALSHLQSPLDPSTLLAEVCVEQCTFMDSKMKPLWIMYSNEEAGSGGSVGIIFKNGDDLRQDMLTLQMIQLMDVLWKQEGLDLRMTPYGCLPTGDRTGLIEVVLRSDTIANIQLNKSNMAATAAFNKDALLNWLKSKNPGEALDRAIEEFTLSCAGYCVATYVLGIGDRHSDNIMIRESGQLFHIDFGHFLGNFKTKFGINRERVPFILTYDFVHVIQQGKTNNSEKFERFRGYCERAYTILRRHGLLFLHLFALMRAAGLPELSCSKDIQYLKDSLALGKTEEEALKHFRVKFNEALRESWKTKVNWLAHNVSKDNRQ
T67849	DRUGINFO	D0J5VR	Idelalisib	Approved
T67849	DRUGINFO	DGO2C1	Leniolisib	Approved
T67849	DRUGINFO	D0O8SJ	Umbralisib	Approved
T67849	DRUGINFO	D0RU0O	IPI-145	Approved
T67849	DRUGINFO	D0S5LD	BAY 80-6946	Approved
T67849	DRUGINFO	D01QSO	Buparlisib	Phase 3
T67849	DRUGINFO	D07RHP	INCB50465	Phase 2
T67849	DRUGINFO	D0LG7X	RP6530	Phase 2
T67849	DRUGINFO	DP1SE6	Parsaclisib	Phase 2
T67849	DRUGINFO	DQ62LM	AZD8154	Phase 2
T67849	DRUGINFO	D07CWH	INCB40093	Phase 1/2
T67849	DRUGINFO	DHX7S8	ZX-101A	Phase 1/2
T67849	DRUGINFO	D05CBJ	PA-799	Phase 1/2
T67849	DRUGINFO	D03FOP	AMG 319	Phase 1
T67849	DRUGINFO	D03IJO	GS-9820	Phase 1
T67849	DRUGINFO	D08WLY	ME-401	Phase 1
T67849	DRUGINFO	D0U5PT	GS-9901	Phase 1
T67849	DRUGINFO	DA02DE	BGB-10188	Phase 1
T67849	DRUGINFO	DDE3Z4	HMPL-689	Phase 1
T67849	DRUGINFO	DDE6F1	GSK2292767	Phase 1
T67849	DRUGINFO	D00GTY	Pyrrolo[2,3-d]pyrimidine derivative 28	Patented
T67849	DRUGINFO	D08TAB	XL-499	Preclinical
T67849	DRUGINFO	D0P1JI	Wortmannin	Terminated
T67849	DRUGINFO	D00ZIK	IC87114	Investigative
T67849	DRUGINFO	D0O2HL	IC980033	Investigative
T67849	DRUGINFO	DOR1I0	ETP-46321	Investigative
T67849	DRUGINFO	D07APP	LY-292223	Investigative
T67849	DRUGINFO	D0W1ST	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	Investigative

T10897	TARGETID	T10897
T10897	FORMERID	TTDS00516
T10897	UNIPROID	ACOD_HUMAN
T10897	TARGNAME	Acyl-CoA desaturase (SCD)
T10897	GENENAME	SCD
T10897	TARGTYPE	Successful
T10897	SYNONYMS	hSCD1; Stearoyl-coenzyme A (Delta9) desaturase; Stearoyl-CoA desaturase; Membrane-bound 9 desaturase; Fatty acid desaturase; DesA3; Des A3; Delta-9-stearoyl desaturase; Delta-9 desaturase; Delta(9)-desaturase; 9 stearoyl-desaturase
T10897	FUNCTION	Catalyzes the insertion of a cis double bond at the delta-9 position into fatty acyl-CoA substrates including palmitoyl-CoA and stearoyl-CoA. Gives rise to a mixture of 16:1 and 18:1 unsaturated fatty acids. Plays an important role in lipid biosynthesis. Plays an important role in regulating the expression of genes that are involved in lipogenesis and in regulating mitochondrial fatty acid oxidation. Plays an important role in body energy homeostasis. Contributes to the biosynthesis of membrane phospholipids, cholesterol esters and triglycerides. Stearyl-CoA desaturase that utilizes O(2) and electrons from reduced cytochrome b5 to introduce the first double bond into saturated fatty acyl-CoA substrates.
T10897	PDBSTRUC	4ZYO
T10897	BIOCLASS	Paired donor oxygen oxidoreductase
T10897	ECNUMBER	EC 1.14.19.1
T10897	SEQUENCE	MPAHLLQDDISSSYTTTTTITAPPSRVLQNGGDKLETMPLYLEDDIRPDIKDDIYDPTYKDKEGPSPKVEYVWRNIILMSLLHLGALYGITLIPTCKFYTWLWGVFYYFVSALGITAGAHRLWSHRSYKARLPLRLFLIIANTMAFQNDVYEWARDHRAHHKFSETHADPHNSRRGFFFSHVGWLLVRKHPAVKEKGSTLDLSDLEAEKLVMFQRRYYKPGLLMMCFILPTLVPWYFWGETFQNSVFVATFLRYAVVLNATWLVNSAAHLFGYRPYDKNISPRENILVSLGAVGEGFHNYHHSFPYDYSASEYRWHINFTTFFIDCMAALGLAYDRKKVSKAAILARIKRTGDGNYKSG
T10897	DRUGINFO	D0I8CA	Isoxyl	Approved
T10897	DRUGINFO	D09PVO	Aramchol	Phase 2/3
T10897	DRUGINFO	D0S0RS	MK-8245	Phase 2
T10897	DRUGINFO	D00GQC	Sterculic acid	Investigative
T10897	DRUGINFO	D0D9QN	ISIS 147919	Investigative
T10897	DRUGINFO	D0N1QW	2-(4-benzoylpiperazin-1-yl)thiazole-5-carboxamide	Investigative
T10897	DRUGINFO	D0O3TT	MF-152	Investigative
T10897	DRUGINFO	D0O7DP	CVT-12012	Investigative

T16987	TARGETID	T16987
T16987	FORMERID	TTDR00212
T16987	UNIPROID	CAH12_HUMAN
T16987	TARGNAME	Carbonic anhydrase XII (CA-XII)
T16987	GENENAME	CA12
T16987	TARGTYPE	Successful
T16987	SYNONYMS	Tumor antigen HOM-RCC-3.1.3; Carbonic anhydrase 12; Carbonate dehydratase XII
T16987	FUNCTION	Reversible hydration of carbon dioxide.
T16987	PDBSTRUC	6G7A; 6G5L; 5MSB; 5MSA; 5LLP
T16987	BIOCLASS	Alpha-carbonic anhydrase
T16987	ECNUMBER	EC 4.2.1.1
T16987	SEQUENCE	MPRRSLHAAAVLLLVILKEQPSSPAPVNGSKWTYFGPDGENSWSKKYPSCGGLLQSPIDLHSDILQYDASLTPLEFQGYNLSANKQFLLTNNGHSVKLNLPSDMHIQGLQSRYSATQLHLHWGNPNDPHGSEHTVSGQHFAAELHIVHYNSDLYPDASTASNKSEGLAVLAVLIEMGSFNPSYDKIFSHLQHVKYKGQEAFVPGFNIEELLPERTAEYYRYRGSLTTPPCNPTVLWTVFRNPVQISQEQLLALETALYCTHMDDPSPREMINNFRQVQKFDERLVYTSFSQVQVCTAAGLSLGIILSLALAGILGICIVVVVSIWLFRRKSIKKGDNKGVIYKPATKMETEAHA
T16987	DRUGINFO	D0K1QD	Sulfamylon	Approved
T16987	DRUGINFO	D07HBX	Salicyclic acid	Approved
T16987	DRUGINFO	D0A8JP	PARABEN	Phase 3
T16987	DRUGINFO	D07SDQ	Curcumin	Phase 3
T16987	DRUGINFO	D0L6HN	PHENOL	Phase 2/3
T16987	DRUGINFO	D0Y6OA	Coumate	Phase 2
T16987	DRUGINFO	D03SLR	FERULIC ACID	Patented
T16987	DRUGINFO	D00RDE	4-(4'-N-Methylphenyl)diazenylbenzenesulfonamide	Investigative
T16987	DRUGINFO	D07AGM	4-Methylamino-benzenesulfonamide	Investigative
T16987	DRUGINFO	D07UCQ	Sodium phenylaminomethanesulfonate	Investigative
T16987	DRUGINFO	D0M7VN	4-(N-Methyl-hydrazino)-benzenesulfonamide	Investigative
T16987	DRUGINFO	D0M9IQ	Sodium N-methylphenylaminomethanesulfonate	Investigative
T16987	DRUGINFO	D03DAM	2,2-Dimethyl-N-(4-sulfamoyl-phenyl)-propionamide	Investigative
T16987	DRUGINFO	D04HRS	4-((4-hydroxyphenyl)diazenyl)benzenesulfonamide	Investigative
T16987	DRUGINFO	D04POB	ACETYLSULFANILAMIDE	Investigative
T16987	DRUGINFO	D07CYN	2-amino-2,3-dihydro-1H-indene-5-sulfonamide	Investigative
T16987	DRUGINFO	D09TES	2-acetamido-2,3-dihydro-1H-indene-5-sulfonic acid	Investigative
T16987	DRUGINFO	D0BD0K	3-(4'-Hydroxyphenyl)diazenylbenzenesulfonamide	Investigative
T16987	DRUGINFO	D0C7WG	3-((4-hydroxyphenyl)diazenyl)benzenesulfonamide	Investigative
T16987	DRUGINFO	D0H4CF	3-((4-aminophenyl)diazenyl)benzenesulfonamide	Investigative
T16987	DRUGINFO	D0I0RT	Thioureido sulfonamide	Investigative
T16987	DRUGINFO	D0T2YZ	N-(4-Sulfamoyl-phenyl)-isobutyramide	Investigative
T16987	DRUGINFO	D00IKQ	4-Methoxy-3-pyridinesulfonamide	Investigative
T16987	DRUGINFO	D00IUB	4-CYANOPHENOL	Investigative
T16987	DRUGINFO	D00NUK	4-Methanesulfonylamino-benzenesulfonamide	Investigative
T16987	DRUGINFO	D02NQK	4-(N-Oxide-2-pyridylthio)pyridine-3-sulfonamide	Investigative
T16987	DRUGINFO	D04SNH	1-Benzyl-1,4-dihydro-4-oxo-3-pyridinesulfonamide	Investigative
T16987	DRUGINFO	D05EBZ	4-(4-Cyanophenoxy)-3-pyridinesulfonamide	Investigative
T16987	DRUGINFO	D05QUG	7-phenethoxy-2H-chromen-2-one	Investigative
T16987	DRUGINFO	D05RAB	1,4-Dihydro-1-methyl-4-oxo-3-pyridinesulfonamide	Investigative
T16987	DRUGINFO	D05VSK	ETHOXYCOUMARIN	Investigative
T16987	DRUGINFO	D06ZMH	3-(3-Phenyl-ureido)-benzenesulfonamide	Investigative
T16987	DRUGINFO	D07QJJ	CATECHOL	Investigative
T16987	DRUGINFO	D08JCC	4-(4-Fluorophenoxy)-3-pyridinesulfonamide	Investigative
T16987	DRUGINFO	D09CXX	N-hydroxysulfamide	Investigative
T16987	DRUGINFO	D09LUD	4-[2-(3-Phenyl-ureido)-ethyl]-benzenesulfonamide	Investigative
T16987	DRUGINFO	D0K3LN	N-(4-Sulfamoyl-phenyl)-butyramide	Investigative
T16987	DRUGINFO	D0KB6T	N-(4-Sulfamoyl-phenyl)-benzamide	Investigative
T16987	DRUGINFO	D0M4EV	N-(4-cyanophenyl)sulfamide	Investigative
T16987	DRUGINFO	D0N8LR	N-(4-Sulfamoyl-phenyl)-propionamide	Investigative
T16987	DRUGINFO	D0PA5L	N-(pentafluorophenyl)sulfamide	Investigative
T16987	DRUGINFO	D0Q0XO	Pentanoic acid (4-sulfamoyl-phenyl)-amide	Investigative
T16987	DRUGINFO	D0RK7J	2,2,2-Trifluoro-N-(4-sulfamoyl-phenyl)-acetamide	Investigative
T16987	DRUGINFO	D0YD9F	4-Benzenesulfonylamino-benzenesulfonamide	Investigative
T16987	DRUGINFO	D00IAE	Prop-2-ynyl 4-sulfamoylbenzoate	Investigative
T16987	DRUGINFO	D00RNZ	7-(benzyloxy)-2H-chromen-2-one	Investigative
T16987	DRUGINFO	D01OTW	4-(Cyanomethylthio)pyridine-3-sulfonamide	Investigative
T16987	DRUGINFO	D01XFH	N-propynyl amidebenzenesulphonide	Investigative
T16987	DRUGINFO	D02BMV	4-(2-Propynylthio)pyridine-3-sulfonamide	Investigative
T16987	DRUGINFO	D02DBP	RESORCINOL	Investigative
T16987	DRUGINFO	D03KRB	4,4'-thiodipyridine-3-sulfonamide	Investigative
T16987	DRUGINFO	D04VSP	4-Ethoxy-3-pyridinesulfonamide	Investigative
T16987	DRUGINFO	D05ETN	4-(2-Methyl-8-quinolinoxy)-3-pyridinesulfonamide	Investigative
T16987	DRUGINFO	D05JAJ	4-(Quinolinoxy)-3-pyridinesulfonamide	Investigative
T16987	DRUGINFO	D06DYP	8-methoxy-2-oxo-2H-chromene-3-carboxylic acid	Investigative
T16987	DRUGINFO	D06IOI	4-Benzythiopyridine-3-sulfonamide	Investigative
T16987	DRUGINFO	D09TKG	4-(Allylamino)-3-pyridinesulfonamide	Investigative
T16987	DRUGINFO	D09WVV	N1-(2-aminoethyl)ethane-1,2-diamine	Investigative
T16987	DRUGINFO	D0A0YX	SACCHARIN	Investigative
T16987	DRUGINFO	D0C4QB	2-Amino-indan-5-sulfonic acid	Investigative
T16987	DRUGINFO	D0G0FJ	2-hydrazinylbenzenesulfonamide	Investigative
T16987	DRUGINFO	D0J7GU	4-Methylthiopyridine-3-sulfonamide	Investigative
T16987	DRUGINFO	D0LC0F	2,3-dihydro-1H-indene-5-sulfonamide	Investigative
T16987	DRUGINFO	D0LU4S	7-butoxy-2H-chromen-2-one	Investigative
T16987	DRUGINFO	D0OT5L	7-propoxy-2H-chromen-2-one	Investigative
T16987	DRUGINFO	D0Q5VB	4-(Methylhydrazino)-3-pyridinesulfonamide	Investigative
T16987	DRUGINFO	D0R4KQ	4-(5-Methyl-2-pirazolino)-3-pyridinesulfonamide	Investigative
T16987	DRUGINFO	D0RB0D	7-methoxy-2-oxo-2H-chromene-4-carboxylic acid	Investigative
T16987	DRUGINFO	D0UM1I	4-Hydrazino-3-pyridinesulfonamide	Investigative
T16987	DRUGINFO	D0V5OW	4-(Carbamolymethylthio)pyridine-3-sulfonamide	Investigative
T16987	DRUGINFO	D0ZC3W	P-toluenesulfonamide	Investigative
T16987	DRUGINFO	D00XJA	6-methoxy-2-oxo-2H-chromene-3-carboxylic acid	Investigative
T16987	DRUGINFO	D04VLI	4-(2-Hydroxy-ethyl)-benzenesulfonamide	Investigative
T16987	DRUGINFO	D07TAJ	Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate	Investigative
T16987	DRUGINFO	D0D6UR	2-oxo-2H-thiochromene-3-carboxylic acid	Investigative
T16987	DRUGINFO	D0H3NS	2-oxo-2H-chromene-3-carboxylic acid	Investigative
T16987	DRUGINFO	D0J2AE	3-Amino-benzenesulfonamide	Investigative
T16987	DRUGINFO	D0OI1H	2-Amino-benzenesulfonamide	Investigative
T16987	DRUGINFO	D0X5HL	N1-(naphthalen-1-yl)ethane-1,2-diamine	Investigative
T16987	DRUGINFO	D04NSN	4-(2-AMINOETHYL)BENZENESULFONAMIDE	Investigative
T16987	DRUGINFO	D05XZM	4-(hydroxymethyl)benzenesulfonamide	Investigative
T16987	DRUGINFO	D09JPC	Hexane-1,6-diamine	Investigative
T16987	DRUGINFO	D09PWX	Carzenide	Investigative
T16987	DRUGINFO	D0G3BI	6-methyl-2-oxo-2H-chromene-3-carboxylic acid	Investigative
T16987	DRUGINFO	D0L5TZ	6-(hydroxymethyl)-2H-chromen-2-one	Investigative
T16987	DRUGINFO	D0Q2LL	6-Hydroxy-benzothiazole-2-sulfonic acid amide	Investigative
T16987	DRUGINFO	D0U4BB	HERNIARIN	Investigative
T16987	DRUGINFO	D00YEF	Decane-1,10-diyl disulfamate	Investigative
T16987	DRUGINFO	D01STY	4-Amino-3-iodo-benzenesulfonamide	Investigative
T16987	DRUGINFO	D02QGI	Pentane-1,5-diamine	Investigative
T16987	DRUGINFO	D03ZMQ	COUMARIN	Investigative
T16987	DRUGINFO	D04CVC	4-Amino-3-fluoro-benzenesulfonamide	Investigative
T16987	DRUGINFO	D05TLB	Octyl sulfamate	Investigative
T16987	DRUGINFO	D09WSJ	Decyl sulfamate	Investigative
T16987	DRUGINFO	D0AU0M	P-Coumaric Acid	Investigative
T16987	DRUGINFO	D0D4OV	Octane-1,8-diyl disulfamate	Investigative
T16987	DRUGINFO	D0E8CC	BENZOLAMIDE	Investigative
T16987	DRUGINFO	D0M3PO	2,4-Disulfamyltrifluoromethylaniline	Investigative
T16987	DRUGINFO	D0N1AW	6-(aminomethyl)-2H-chromen-2-one	Investigative
T16987	DRUGINFO	D0NN3Q	4-Hydrazino-benzenesulfonamide	Investigative
T16987	DRUGINFO	D0P6AM	4-Amino-3-bromo-benzenesulfonamide	Investigative
T16987	DRUGINFO	D0Q7DJ	Syringic Acid	Investigative
T16987	DRUGINFO	D0VD7H	CL-5343	Investigative
T16987	DRUGINFO	D0YU8J	4-Amino-3-chloro-benzenesulfonamide	Investigative
T16987	DRUGINFO	D0V7AA	CATECHIN	Investigative
T16987	DRUGINFO	D0Y3TZ	GALLICACID	Investigative
T16987	DRUGINFO	D0A1CM	ELLAGIC ACID	Investigative

T19433	TARGETID	T19433
T19433	FORMERID	TTDS00192
T19433	UNIPROID	HPGDS_HUMAN
T19433	TARGNAME	Glutathione-dependent PGD synthase (HPGDS)
T19433	GENENAME	HPGDS
T19433	TARGTYPE	Successful
T19433	SYNONYMS	HPGDS; Glutathione-S-transferase; GST class-alpha
T19433	FUNCTION	Bifunctional enzyme which catalyzes both the conversion of PGH2 to PGD2, a prostaglandin involved in smooth muscle contraction/relaxation and a potent inhibitor of platelet aggregation, and the conjugation of glutathione with a widerange of aryl halides and organic isothiocyanates. Also exhibits low glutathione-peroxidase activity towards cumene hydroperoxide.
T19433	PDBSTRUC	6N4E; 5YX1; 5YWX; 5YWE; 5AIX
T19433	BIOCLASS	Intramolecular oxidoreductases
T19433	ECNUMBER	EC 5.3.99.2
T19433	SEQUENCE	MPNYKLTYFNMRGRAEIIRYIFAYLDIQYEDHRIEQADWPEIKSTLPFGKIPILEVDGLTLHQSLAIARYLTKNTDLAGNTEMEQCHVDAIVDTLDDFMSCFPWAEKKQDVKEQMFNELLTYNAPHLMQDLDTYLGGREWLIGNSVTWADFYWEICSTTLLVFKPDLLDNHPRLVTLRKKVQAIPAVANWIKRRPQTKL
T19433	DRUGINFO	D0L9ZR	Praziquantel	Approved
T19433	DRUGINFO	D02AOD	HF-0220	Phase 2
T19433	DRUGINFO	D06GJP	Cibacron blue	Investigative
T19433	DRUGINFO	D08IXW	S-hexylglutathione	Investigative
T19433	DRUGINFO	D0AF3A	Protoporphyrin IX	Investigative
T19433	DRUGINFO	D0PI1C	HQL-79	Investigative
T19433	DRUGINFO	D06EWG	Formic Acid	Investigative

T94033	TARGETID	T94033
T94033	FORMERID	TTDS00202
T94033	UNIPROID	THRB_HUMAN
T94033	TARGNAME	Coagulation factor IIa (F2)
T94033	GENENAME	F2
T94033	TARGTYPE	Successful
T94033	SYNONYMS	Prothrombin; Coagulation factor II
T94033	FUNCTION	Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.
T94033	PDBSTRUC	8KME; 7KME; 6EO9; 6EO8; 6EO7
T94033	BIOCLASS	Peptidase
T94033	ECNUMBER	EC 3.4.21.5
T94033	SEQUENCE	MAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLERECVEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHVNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQECSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASAQAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETGDGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYIDGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTENDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHPVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDSTRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKYGFYTHVFRLKKWIQKVIDQFGE
T94033	DRUGINFO	D03LWO	Desirudin Recombinant	Approved
T94033	DRUGINFO	D07KFG	Human prothrombin complex concentrate	Approved
T94033	DRUGINFO	D07UWV	Argatroban	Approved
T94033	DRUGINFO	D09LPN	Lepirudin	Approved
T94033	DRUGINFO	D09WKB	Anisindione	Approved
T94033	DRUGINFO	D0AW9T	ATryn antithrombin	Approved
T94033	DRUGINFO	D0M7JT	Dabigatran	Approved
T94033	DRUGINFO	D06JGH	Pyridoxal Phosphate	Approved
T94033	DRUGINFO	D09HVL	Bivalirudin	Approved
T94033	DRUGINFO	D0B5LF	Ximelegatran	Approved
T94033	DRUGINFO	D0F3SZ	Hirudin	Phase 4
T94033	DRUGINFO	D01MUU	MELAGATRAN	Phase 3
T94033	DRUGINFO	D0VL4V	SR-123781A	Phase 2/3
T94033	DRUGINFO	D09DFB	EFEGATRAN SULFATE HYDRATE	Phase 2
T94033	DRUGINFO	D0GG5I	Recombinant RGD-hirudin	Phase 2
T94033	DRUGINFO	D0H9RN	NU-172	Phase 2
T94033	DRUGINFO	D0I7MX	LB-30870	Phase 2
T94033	DRUGINFO	D0K8FI	Pegmusirudin	Phase 2
T94033	DRUGINFO	D0N6EA	Odiparcil	Phase 2
T94033	DRUGINFO	D0PX0N	TF0023	Phase 2
T94033	DRUGINFO	D0UK1L	EP-217609	Phase 2
T94033	DRUGINFO	D00LOB	RWJ-671818	Phase 1
T94033	DRUGINFO	D05HAD	DP-4088	Phase 1
T94033	DRUGINFO	D0K4FP	AZD-8165	Phase 1
T94033	DRUGINFO	D0L2XU	Solulin	Phase 1
T94033	DRUGINFO	D02UIC	SSR-128428	Phase 1
T94033	DRUGINFO	D0G6UQ	EP-42675	Phase 1
T94033	DRUGINFO	D0JQ7Y	Ximelagatran	Withdrawn from market
T94033	DRUGINFO	D06DUO	SSR-182289	Discontinued in Phase 2
T94033	DRUGINFO	D07MZC	Vasoflux	Discontinued in Phase 2
T94033	DRUGINFO	D0B1KK	AZD0837	Discontinued in Phase 2
T94033	DRUGINFO	D0H4UJ	INOGATRAN	Discontinued in Phase 2
T94033	DRUGINFO	D0Q3WN	Napsagatran	Discontinued in Phase 2
T94033	DRUGINFO	D0B9EH	Dermolastin	Discontinued in Phase 2
T94033	DRUGINFO	D01IBO	BCX-1470	Discontinued in Phase 1
T94033	DRUGINFO	D02MHE	CVS-1123	Discontinued in Phase 1
T94033	DRUGINFO	D05KTK	CJC-1004	Discontinued in Phase 1
T94033	DRUGINFO	D05MXK	GW-473178	Discontinued in Phase 1
T94033	DRUGINFO	D09CKF	Licostinel	Discontinued in Phase 1
T94033	DRUGINFO	D0G0XN	UK-156406	Discontinued in Phase 1
T94033	DRUGINFO	D0H2ZQ	S-18326	Discontinued in Phase 1
T94033	DRUGINFO	D0UF5I	MPC-0920	Discontinued in Phase 1
T94033	DRUGINFO	D0W5XT	ARC-183	Discontinued in Phase 1
T94033	DRUGINFO	D02QTV	Efegatran	Terminated
T94033	DRUGINFO	D02ZWG	SR-80027A	Terminated
T94033	DRUGINFO	D05WYW	L-373890	Terminated
T94033	DRUGINFO	D06ALB	BCH-2763	Terminated
T94033	DRUGINFO	D0G7YZ	BMS-189664	Terminated
T94033	DRUGINFO	D0J6VU	CVS-995	Terminated
T94033	DRUGINFO	D0L6UZ	L-374,087	Terminated
T94033	DRUGINFO	D0RP8F	PPACK	Terminated
T94033	DRUGINFO	D0S2JG	LB30057	Terminated
T94033	DRUGINFO	D0S6XJ	GS-522	Terminated
T94033	DRUGINFO	D0SF5F	Org-34092	Terminated
T94033	DRUGINFO	D0WL1C	Hementin	Terminated
T94033	DRUGINFO	D0Y5EX	DuP 714	Terminated
T94033	DRUGINFO	D01ARY	Bbs-Arg-(D-Pip)-Gly-S-(GS)3-Gly-Hir	Investigative
T94033	DRUGINFO	D01NEZ	CHLORODYSINOSIN A	Investigative
T94033	DRUGINFO	D01RTU	METHYL-PHE-PRO-AMINO-CYCLOHEXYLGLYCINE	Investigative
T94033	DRUGINFO	D01WDB	S-2238	Investigative
T94033	DRUGINFO	D02KKL	Hemi-Babim	Investigative
T94033	DRUGINFO	D03KFJ	TB-102	Investigative
T94033	DRUGINFO	D03LGM	Beta-phenyl-D-phenylalanyl-N-propyl-L-prolinamide	Investigative
T94033	DRUGINFO	D03MYL	Lysophosphotidylserine	Investigative
T94033	DRUGINFO	D04CQG	Heparin-Cantithrombin III	Investigative
T94033	DRUGINFO	D04PPE	VE-04051645	Investigative
T94033	DRUGINFO	D04VYT	Bbs-Arg-(D-Pip)-Gly-S-(GS)7-Gly-Hir	Investigative
T94033	DRUGINFO	D05BMA	D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide	Investigative
T94033	DRUGINFO	D05NRZ	N4-(N,N-diphenylcarbamoyl)-aminoguanidine	Investigative
T94033	DRUGINFO	D05RFC	Tumor vascular thrombogen	Investigative
T94033	DRUGINFO	D06KCW	6-(2-HYDROXY-CYCLOPENTYL)-7-OXO-HEPTANAMIDINE	Investigative
T94033	DRUGINFO	D06YJX	Enoxaprin	Investigative
T94033	DRUGINFO	D07BJZ	Bbs-Arg-(D-Pip)-Gly-S-(GS)11-Gly-Hir	Investigative
T94033	DRUGINFO	D07BMA	Bbs-Arg-(D-Pip)-Gly-S-(GS)5-Gly-Hir	Investigative
T94033	DRUGINFO	D07NYX	BENZOTHIAZOLE	Investigative
T94033	DRUGINFO	D07QPA	Vitamin K	Investigative
T94033	DRUGINFO	D07YNF	D-phenylalanyl-N-(3-fluorobenzyl)-L-prolinamide	Investigative
T94033	DRUGINFO	D08EUH	D-phenylalanyl-N-benzyl-L-prolinamide	Investigative
T94033	DRUGINFO	D08MEC	Melogatran	Investigative
T94033	DRUGINFO	D08YGD	Haempatch	Investigative
T94033	DRUGINFO	D09CVG	4-[3-(4-CHLOROPHENYL)-1H-PYRAZOL-5-YL]PIPERIDINE	Investigative
T94033	DRUGINFO	D09HFC	Bbs-Arg-(D-Pip)-Gly-S-(GS)13-Gly-Hir	Investigative
T94033	DRUGINFO	D09QZJ	AC-(D)PHE-PRO-BOROHOMOLYS-OH	Investigative
T94033	DRUGINFO	D0CF3B	Cyclotheonamide E5	Investigative
T94033	DRUGINFO	D0CV4F	Bbs-Arg-(D-Pip)-Gly-S-(GS)1-Gly-Hir	Investigative
T94033	DRUGINFO	D0D8AK	Cyclotheonamide E	Investigative
T94033	DRUGINFO	D0D9NT	4-TERT-BUTYLBENZENESULFONIC ACID	Investigative
T94033	DRUGINFO	D0E1NH	1-(HYDROXYMETHYLENEAMINO)-8-HYDROXY-OCTANE	Investigative
T94033	DRUGINFO	D0E9ON	AC-(D)PHE-PRO-BOROHOMOORNITHINE-OH	Investigative
T94033	DRUGINFO	D0F4VK	TB-101	Investigative
T94033	DRUGINFO	D0H5WV	OSCILLARIN	Investigative
T94033	DRUGINFO	D0H8OB	Desirudine	Investigative
T94033	DRUGINFO	D0I0NY	L-370,518	Investigative
T94033	DRUGINFO	D0I6DO	bufrudin	Investigative
T94033	DRUGINFO	D0I8WD	Methyl L-phenylalaninate	Investigative
T94033	DRUGINFO	D0K3JC	D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide	Investigative
T94033	DRUGINFO	D0KQ1K	Bbs-Arg-(D-Pip)-Gly-(SPH(pY)EKVS)-Gly-Hir	Investigative
T94033	DRUGINFO	D0M1AC	Cyclotheonamide E4	Investigative
T94033	DRUGINFO	D0N0PI	2-NAPHTHALENESULFONIC ACID	Investigative
T94033	DRUGINFO	D0N1HV	4-(2,5-DIAMINO-5-HYDROXY-PENTYL)-PHENOL	Investigative
T94033	DRUGINFO	D0O1DU	D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide	Investigative
T94033	DRUGINFO	D0P0LG	Bbs-Arg-(D-Pip)-Gly-(SPHYEKVS)-Gly-Hir	Investigative
T94033	DRUGINFO	D0P1JQ	D-leucyl-N-(3-chlorobenzyl)-L-prolinamide	Investigative
T94033	DRUGINFO	D0QQ4Z	LB30812	Investigative
T94033	DRUGINFO	D0R4AV	AC-(D)PHE-PRO-BOROLYS-OH	Investigative
T94033	DRUGINFO	D0T5WR	Bbs-Arg-(D-Pip)-Gly-(EQKLISEEDL)-Gly-Hir	Investigative
T94033	DRUGINFO	D0U4HG	COCHINCHINENIN B	Investigative
T94033	DRUGINFO	D0V7RD	DYSINOSIN A	Investigative
T94033	DRUGINFO	D0W5AW	SC-79407	Investigative
T94033	DRUGINFO	D0WF2C	Bbs-Arg-(D-Pip)-Gly-S-(GS)9-Gly-Hir	Investigative
T94033	DRUGINFO	D0X0IF	COCHINCHINENENE B	Investigative
T94033	DRUGINFO	D0Y8QU	CVS-1578	Investigative
T94033	DRUGINFO	D02NHS	L-375378	Investigative
T94033	DRUGINFO	D07HWB	5-desgalloylstachyurin	Investigative
T94033	DRUGINFO	D07IBU	GR-133686	Investigative
T94033	DRUGINFO	D09OBJ	RWJ-50353	Investigative
T94033	DRUGINFO	D0E6SO	Tellimagrandin II	Investigative
T94033	DRUGINFO	D0G6RI	4-hydroxyphenylpyruvic acid	Investigative
T94033	DRUGINFO	D0I1UF	CASUARIIN	Investigative
T94033	DRUGINFO	D0JU9N	BMS-740808	Investigative
T94033	DRUGINFO	D0K7YL	CRA_8696	Investigative
T94033	DRUGINFO	D0N0YX	Beta-(2-Naphthyl)-Alanine	Investigative
T94033	DRUGINFO	D0P3OH	3-chlorophenyl 2-oxo-2H-chromene-3-carboxylate	Investigative
T94033	DRUGINFO	D0RQ2T	Macrocyclic tripeptide motif	Investigative
T94033	DRUGINFO	D00WFQ	(4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone	Investigative
T94033	DRUGINFO	D05MJU	4-iodobenzo[b]thiophene 2-carboxamidine	Investigative
T94033	DRUGINFO	D06LPR	(4-nitro-1H-pyrazol-1-yl)(phenyl)methanone	Investigative
T94033	DRUGINFO	D06UUK	Gamma-Carboxy-Glutamic Acid	Investigative
T94033	DRUGINFO	D08WQJ	(3-nitro-1H-pyrazol-1-yl)(phenyl)methanone	Investigative
T94033	DRUGINFO	D0CT8A	4-(3,4-Diethoxy-benzylamino)-benzamidine	Investigative
T94033	DRUGINFO	D0J1QT	BMS-344577	Investigative
T94033	DRUGINFO	D0SP2I	2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine	Investigative
T94033	DRUGINFO	D0Z2TG	Pedunculagin	Investigative
T94033	DRUGINFO	D00QDR	1,2,3,4,6-penta-O-galloyl-beta-D-glucose	Investigative
T94033	DRUGINFO	D02XPB	4-(4-Benzyloxy-3-methoxy-benzylamino)-benzamidine	Investigative
T94033	DRUGINFO	D05ZIP	(4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone	Investigative
T94033	DRUGINFO	D08OCS	(3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone	Investigative
T94033	DRUGINFO	D0IU5E	1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide	Investigative
T94033	DRUGINFO	D0M4VZ	D-Pro-Phe-Arg chloromethyl ketone	Investigative
T94033	DRUGINFO	D0ON2Z	RAZAXABAN	Investigative
T94033	DRUGINFO	D0X1OY	(3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone	Investigative
T94033	DRUGINFO	D08OLP	2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine	Investigative

T83369	TARGETID	T83369
T83369	FORMERID	TTDC00078
T83369	UNIPROID	FA9_HUMAN
T83369	TARGNAME	Coagulation factor IX (F9)
T83369	GENENAME	F9
T83369	TARGTYPE	Successful
T83369	SYNONYMS	Plasma thromboplastin component; PTC protein; Factor IX; Christmas factor
T83369	FUNCTION	Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca(2+) ions, phospholipids, and factor VIIIa.
T83369	PDBSTRUC	6MV4; 5VYG; 5TNT; 5TNO; 5JBC
T83369	BIOCLASS	Peptidase
T83369	ECNUMBER	EC 3.4.21.22
T83369	SEQUENCE	MQRVNMIMAESPGLITICLLGYLLSAECTVFLDHENANKILNRPKRYNSGKLEEFVQGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCPFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTRAETVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT
T83369	DRUGINFO	D0P8QN	Recombinant Factor IX	Approved
T83369	DRUGINFO	D09XTN	Emicizumab	Approved
T83369	DRUGINFO	D04AYZ	CSL-654	Phase 3
T83369	DRUGINFO	D08YTF	RG6013	Phase 3
T83369	DRUGINFO	DBHO19	AMT-061	Phase 3
T83369	DRUGINFO	DN87BL	Fidanacogene elaparvovec	Phase 3
T83369	DRUGINFO	D2AK6X	Mim8	Phase 3
T83369	DRUGINFO	D0VT1S	TTP889	Phase 2
T83369	DRUGINFO	D0A9PW	AMT-060	Phase 1/2
T83369	DRUGINFO	DH40QT	SB-FIX	Phase 1/2
T83369	DRUGINFO	D00TXL	AAV2-hFIX16	Phase 1
T83369	DRUGINFO	D05RBH	N9-GP	Phase 1
T83369	DRUGINFO	DA5J0E	RG6512	Phase 1
T83369	DRUGINFO	D03MCV	RB-006	Discontinued in Phase 3
T83369	DRUGINFO	D03PJP	Trenonacog alfa	Discontinued in Phase 3
T83369	DRUGINFO	D07JQO	SB 249417	Discontinued in Phase 1
T83369	DRUGINFO	D0K9KS	Draculin	Terminated
T83369	DRUGINFO	D06IGE	Factor IX-XTEN	Investigative
T83369	DRUGINFO	D09PDK	F-9TG	Investigative
T83369	DRUGINFO	D0EK9T	4-Phenyl-benzo[b]thiophene-2-carboxamidine	Investigative
T83369	DRUGINFO	D0G4LX	PMID20121197C57	Investigative
T83369	DRUGINFO	D0LX0D	6-Benzyloxybenzo[b]thiophene-2-carboxamidine	Investigative
T83369	DRUGINFO	D0Q4XG	MOD-3012	Investigative
T83369	DRUGINFO	D0Y4KJ	5-Benzyloxy-benzo[b]thiophene-2-carboxamidine	Investigative
T83369	DRUGINFO	D0YX8X	MG-1104	Investigative
T83369	DRUGINFO	D0Z2PJ	4-Benzyloxybenzo[b]thiophene-2-carboxamidine	Investigative
T83369	DRUGINFO	D0Z2UT	BNP-FIX	Investigative
T83369	DRUGINFO	D05MJU	4-iodobenzo[b]thiophene 2-carboxamidine	Investigative
T83369	DRUGINFO	D06UUK	Gamma-Carboxy-Glutamic Acid	Investigative
T83369	DRUGINFO	D0ON2Z	RAZAXABAN	Investigative

T84631	TARGETID	T84631
T84631	FORMERID	TTDS00203
T84631	UNIPROID	FA10_HUMAN
T84631	TARGNAME	Coagulation factor Xa (F10)
T84631	GENENAME	F10
T84631	TARGTYPE	Successful
T84631	SYNONYMS	Fxa; Factor Xa; F10; Activated coagulation factor X
T84631	FUNCTION	Factor Xa is avitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
T84631	PDBSTRUC	6RK9; 5VOF; 5VOE; 5K0H; 5JZU
T84631	BIOCLASS	Peptidase
T84631	ECNUMBER	EC 3.4.21.6
T84631	SEQUENCE	MGRPLHLVLLSASLAGLLLLGESLFIRREQANNILARVTRANSFLEEMKKGHLERECMEETCSYEEAREVFEDSDKTNEFWNKYKDGDQCETSPCQNQGKCKDGLGEYTCTCLEGFEGKNCELFTRKLCSLDNGDCDQFCHEEQNSVVCSCARGYTLADNGKACIPTGPYPCGKQTLERRKRSVAQATSSSGEAPDSITWKPYDAADLDPTENPFDLLDFNQTQPERGDNNLTRIVGGQECKDGECPWQALLINEENEGFCGGTILSEFYILTAAHCLYQAKRFKVRVGDRNTEQEEGGEAVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPACLPERDWAESTLMTQKTGIVSGFGRTHEKGRQSTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDSGGPHVTRFKDTYFVTGIVSWGEGCARKGKYGIYTKVTAFLKWIDRSMKTRGLPKAKSHAPEVITSSPLK
T84631	DRUGINFO	D08PSU	Lmw heparin	Approved
T84631	DRUGINFO	D0C3BS	DU-176b	Approved
T84631	DRUGINFO	D0I5HF	Apixaban	Approved
T84631	DRUGINFO	D0J0BU	BETRIXABAN	Approved
T84631	DRUGINFO	D0KG3R	Rivaroxaban	Approved
T84631	DRUGINFO	D0N2BX	Nadroparin calcium	Approved
T84631	DRUGINFO	D0NE9T	Fondaparinux sodium	Approved
T84631	DRUGINFO	D0P3SY	Danaparoid	Approved
T84631	DRUGINFO	D0Q5KL	Coagulation Factor IX	Approved
T84631	DRUGINFO	D0U7HJ	Certoparin sodium	Approved
T84631	DRUGINFO	D09XTN	Emicizumab	Approved
T84631	DRUGINFO	D07JEW	Human coagulation factor X	BLA submitted
T84631	DRUGINFO	D00ITC	PRT4445	Phase 3
T84631	DRUGINFO	D0P2RO	SSR-126517E	Phase 3
T84631	DRUGINFO	D2AK6X	Mim8	Phase 3
T84631	DRUGINFO	D01MUU	MELAGATRAN	Phase 3
T84631	DRUGINFO	D0VL4V	SR-123781A	Phase 2/3
T84631	DRUGINFO	D01FFG	Antistasin	Phase 2
T84631	DRUGINFO	D07BRZ	LY-517717	Phase 2
T84631	DRUGINFO	D0ID3W	GW-813893	Phase 2
T84631	DRUGINFO	D0UK1L	EP-217609	Phase 2
T84631	DRUGINFO	D00RGF	GCC-4401	Phase 1
T84631	DRUGINFO	D00ZPT	BI-11634	Phase 1
T84631	DRUGINFO	D08UUD	R-1663	Phase 1
T84631	DRUGINFO	D0X2NN	BIBT986	Phase 1
T84631	DRUGINFO	D02UIC	SSR-128428	Phase 1
T84631	DRUGINFO	D0G6UQ	EP-42675	Phase 1
T84631	DRUGINFO	DA5J0E	RG6512	Phase 1
T84631	DRUGINFO	D07OGZ	Darexaban maleate	Discontinued in Phase 3
T84631	DRUGINFO	D0CY3A	Idraparinux	Discontinued in Phase 3
T84631	DRUGINFO	D0E2MJ	Otamixaban	Discontinued in Phase 3
T84631	DRUGINFO	D09TGX	Valspodar	Discontinued in Phase 3
T84631	DRUGINFO	D0L9YS	Octopamine	Discontinued in Phase 2a
T84631	DRUGINFO	D0D5RH	TAK-442	Discontinued in Phase 2
T84631	DRUGINFO	D0JH6W	DX-9065a	Discontinued in Phase 2
T84631	DRUGINFO	D0T4UL	PD-348292	Discontinued in Phase 2
T84631	DRUGINFO	D0V2OS	DX-9065	Discontinued in Phase 2
T84631	DRUGINFO	D0G5GJ	R-68151	Discontinued in Phase 2
T84631	DRUGINFO	D00CIF	EMD-503982	Discontinued in Phase 1
T84631	DRUGINFO	D03QJN	DPC 423	Discontinued in Phase 1
T84631	DRUGINFO	D0G6UP	YM-75466	Discontinued in Phase 1
T84631	DRUGINFO	D0L4PM	AVE-3247	Discontinued in Phase 1
T84631	DRUGINFO	D0N8JP	JTV-803	Discontinued in Phase 1
T84631	DRUGINFO	D0PG5J	ZD-4927	Discontinued in Phase 1
T84631	DRUGINFO	D0K5WM	CS-3030	Preclinical
T84631	DRUGINFO	D0X1ZV	Trimidox	Preclinical
T84631	DRUGINFO	D0J9UI	YM60828	Terminated
T84631	DRUGINFO	D0Q1JW	Hirufaxin	Terminated
T84631	DRUGINFO	D0K9KS	Draculin	Terminated
T84631	DRUGINFO	D01AUI	SF303	Investigative
T84631	DRUGINFO	D02AVL	ZK-813039	Investigative
T84631	DRUGINFO	D03QAQ	SN429	Investigative
T84631	DRUGINFO	D04QZF	SK554	Investigative
T84631	DRUGINFO	D06BPU	SC-83157	Investigative
T84631	DRUGINFO	D06HOI	BMS-269223	Investigative
T84631	DRUGINFO	D07NYR	YM-96765	Investigative
T84631	DRUGINFO	D08CEU	Recombinant Factor X	Investigative
T84631	DRUGINFO	D09KKU	Lefaxin	Investigative
T84631	DRUGINFO	D09TXU	DT-831j	Investigative
T84631	DRUGINFO	D0ES5A	Molecule 11	Investigative
T84631	DRUGINFO	D0FV9Y	PhSO2-Gly-(Me-Gly)-Arg-(2-thiazole)	Investigative
T84631	DRUGINFO	D0I8WY	M55113	Investigative
T84631	DRUGINFO	D0K7NJ	Recombinant coagulation factors	Investigative
T84631	DRUGINFO	D0Q2VA	EP-37	Investigative
T84631	DRUGINFO	D0QR3J	GC-2107	Investigative
T84631	DRUGINFO	D0R5KV	CI-1031	Investigative
T84631	DRUGINFO	D0SP5Q	PRT-064445	Investigative
T84631	DRUGINFO	D0Z8VP	Beta-Hydroxy Aspartic Acid	Investigative
T84631	DRUGINFO	D0Z9TY	SK549	Investigative
T84631	DRUGINFO	D00MZS	SK509	Investigative
T84631	DRUGINFO	D07HWB	5-desgalloylstachyurin	Investigative
T84631	DRUGINFO	D0E6SO	Tellimagrandin II	Investigative
T84631	DRUGINFO	D0I1UF	CASUARIIN	Investigative
T84631	DRUGINFO	D0JU9N	BMS-740808	Investigative
T84631	DRUGINFO	D0P3OH	3-chlorophenyl 2-oxo-2H-chromene-3-carboxylate	Investigative
T84631	DRUGINFO	D0R9CH	ZK-810388	Investigative
T84631	DRUGINFO	D02PAU	ZK-814048	Investigative
T84631	DRUGINFO	D06UUK	Gamma-Carboxy-Glutamic Acid	Investigative
T84631	DRUGINFO	D0J1QT	BMS-344577	Investigative
T84631	DRUGINFO	D0Z2TG	Pedunculagin	Investigative
T84631	DRUGINFO	D00QDR	1,2,3,4,6-penta-O-galloyl-beta-D-glucose	Investigative
T84631	DRUGINFO	D02XPB	4-(4-Benzyloxy-3-methoxy-benzylamino)-benzamidine	Investigative
T84631	DRUGINFO	D0M4VZ	D-Pro-Phe-Arg chloromethyl ketone	Investigative
T84631	DRUGINFO	D0ON2Z	RAZAXABAN	Investigative

T89034	TARGETID	T89034
T89034	FORMERID	TTDS00392
T89034	UNIPROID	PLMN_HUMAN
T89034	TARGNAME	Plasminogen (PLG)
T89034	GENENAME	PLG
T89034	TARGTYPE	Successful
T89034	SYNONYMS	Plasmin
T89034	FUNCTION	In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells. Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation.
T89034	PDBSTRUC	6D40; 6D3Z; 6D3Y; 6D3X; 5UGG
T89034	BIOCLASS	Peptidase
T89034	ECNUMBER	EC 3.4.21.7
T89034	SEQUENCE	MEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFTCRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKNGITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILECEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRELRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWSAQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTEQLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAGLTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEEDCMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGGPWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRTRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLEPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYVRVSRFVTWIEGVMRNN
T89034	DRUGINFO	D03HYQ	Ranolazine	Approved
T89034	DRUGINFO	D04URO	Streptokinase	Approved
T89034	DRUGINFO	D05HXX	Tranexamic Acid	Approved
T89034	DRUGINFO	D07BQE	Alteplase	Approved
T89034	DRUGINFO	D0FX8A	Tenecteplase	Approved
T89034	DRUGINFO	D0K4DI	Anistreplase	Approved
T89034	DRUGINFO	D0T1UJ	Reteplase	Approved
T89034	DRUGINFO	D0FD0H	Aminocaproic Acid	Approved
T89034	DRUGINFO	D0TC4R	Desmoteplase	Phase 3
T89034	DRUGINFO	D01MUU	MELAGATRAN	Phase 3
T89034	DRUGINFO	D0S4YT	Plasminogen	Phase 2/3
T89034	DRUGINFO	D09IOF	Troplasminogen alfa	Phase 2
T89034	DRUGINFO	DEV2G0	BIIB131	Phase 2
T89034	DRUGINFO	D0RD0Y	RetinoStat	Phase 2
T89034	DRUGINFO	D0PK7J	bis-triazole derivative 10	Clinical trial
T89034	DRUGINFO	D04DYA	SMTP-0	Investigative
T89034	DRUGINFO	D0A9HM	1-(2-Oxo-2-p-tolyl-ethyl)-1H-indole-2,3-dione	Investigative
T89034	DRUGINFO	D0LJ7R	M5	Investigative
T89034	DRUGINFO	D0M9XH	XP-21510	Investigative
T89034	DRUGINFO	D0ND8N	Textilinin	Investigative
T89034	DRUGINFO	D0V2MR	Bicine	Investigative
T89034	DRUGINFO	D01JUI	N-(4-Chloro-7-p-tolyl-isoquinolin-1-yl)-guanidine	Investigative
T89034	DRUGINFO	D0K4PK	1-guanidino-7-isoquinolinesulphonamide	Investigative
T89034	DRUGINFO	D0VP6M	1-(3,3-Dimethyl-2-oxo-butyl)-1H-indole-2,3-dione	Investigative
T89034	DRUGINFO	D00PEJ	1-guanidino-N-phenyl-7-isoquinolinesulphonamide	Investigative
T89034	DRUGINFO	D08OLP	2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine	Investigative
T89034	DRUGINFO	D0Y5IQ	Grassystatin a	Investigative

T17758	TARGETID	T17758
T17758	FORMERID	TTDC00312
T17758	UNIPROID	UROK_HUMAN
T17758	TARGNAME	Urokinase-type plasminogen activator (PLAU)
T17758	GENENAME	PLAU
T17758	TARGTYPE	Successful
T17758	SYNONYMS	UPA; U-plasminogen activator
T17758	FUNCTION	Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.
T17758	PDBSTRUC	6NMB; 5ZC5; 5ZAJ; 5ZAH; 5ZAG
T17758	BIOCLASS	Peptidase
T17758	ECNUMBER	EC 3.4.21.73
T17758	SEQUENCE	MRALLARLLLCVLVVSDSKGSNELHQVPSNCDCLNGGTCVSNKYFSNIHWCNCPKKFGGQHCEIDKSKTCYEGNGHFYRGKASTDTMGRPCLPWNSATVLQQTYHAHRSDALQLGLGKHNYCRNPDNRRRPWCYVQVGLKPLVQECMVHDCADGKKPSSPPEELKFQCGQKTLRPRFKIIGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLISPCWVISATHCFIDYPKKEDYIVYLGRSRLNSNTQGEMKFEVENLILHKDYSADTLAHHNDIALLKIRSKEGRCAQPSRTIQTICLPSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMTVVKLISHRECQQPHYYGSEVTTKMLCAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVSWGRGCALKDKPGVYTRVSHFLPWIRSHTKEENGLAL
T17758	DRUGINFO	D03VNX	Pro-urokinase	Approved
T17758	DRUGINFO	D0E8UO	Urokinase	Approved
T17758	DRUGINFO	D03ZJE	PAI-1	Phase 4
T17758	DRUGINFO	D0G6ZG	Amediplase	Phase 3
T17758	DRUGINFO	D03KGH	Upamostat	Phase 2
T17758	DRUGINFO	D0G5UW	Saruplase	Phase 2
T17758	DRUGINFO	D01HHJ	HTU-PA	Phase 1/2
T17758	DRUGINFO	D00EPS	PMID18163548C4	Clinical trial
T17758	DRUGINFO	D0G0YZ	UK-356202	Clinical trial
T17758	DRUGINFO	D0D3VA	PAI-2	Discontinued in Phase 2
T17758	DRUGINFO	D08INO	WX-UK1	Discontinued in Phase 1/2
T17758	DRUGINFO	D0K1PR	B-428	Terminated
T17758	DRUGINFO	D00LDI	UPA-targeted oncolytic Sendai virus	Investigative
T17758	DRUGINFO	D01LCS	CRA_10655	Investigative
T17758	DRUGINFO	D02XJW	5-Methylsulfanyl-thiophene-2-carboxamidine	Investigative
T17758	DRUGINFO	D03BWQ	ATN-658	Investigative
T17758	DRUGINFO	D03NLL	(2R)-1-(2,6-dimethylphenoxy)propan-2-amine	Investigative
T17758	DRUGINFO	D05DNW	B-623	Investigative
T17758	DRUGINFO	D06CJP	4-chloro-1-guanidino-7-isoquinolinesulphonamide	Investigative
T17758	DRUGINFO	D09KKF	2-Amino-5-Hydroxy-Benzimidazole	Investigative
T17758	DRUGINFO	D0A8WP	6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine	Investigative
T17758	DRUGINFO	D0B1AK	Thieno[2,3-B]Pyridine-2-Carboxamidine	Investigative
T17758	DRUGINFO	D0D1TX	Recombinant human pro-urokinase	Investigative
T17758	DRUGINFO	D0EV6B	N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea	Investigative
T17758	DRUGINFO	D0F6EZ	(4-guanidino-benzyl)-carbamic acid benzyl ester	Investigative
T17758	DRUGINFO	D0ZM9M	1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine	Investigative
T17758	DRUGINFO	D02AKP	4-methoxy-N'-(2-phenylacetyl)benzohydrazide	Investigative
T17758	DRUGINFO	D05ABK	ATF-HI-8	Investigative
T17758	DRUGINFO	D0K4PK	1-guanidino-7-isoquinolinesulphonamide	Investigative
T17758	DRUGINFO	D0K7YL	CRA_8696	Investigative
T17758	DRUGINFO	D00PEJ	1-guanidino-N-phenyl-7-isoquinolinesulphonamide	Investigative
T17758	DRUGINFO	D00WFQ	(4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone	Investigative
T17758	DRUGINFO	D05MJU	4-iodobenzo[b]thiophene 2-carboxamidine	Investigative
T17758	DRUGINFO	D06LPR	(4-nitro-1H-pyrazol-1-yl)(phenyl)methanone	Investigative
T17758	DRUGINFO	D0SP2I	2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine	Investigative
T17758	DRUGINFO	D05ZIP	(4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone	Investigative
T17758	DRUGINFO	D07SFI	Benzamidine	Investigative
T17758	DRUGINFO	D08OCS	(3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone	Investigative
T17758	DRUGINFO	D0IU5E	1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide	Investigative
T17758	DRUGINFO	D0X1OY	(3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone	Investigative
T17758	DRUGINFO	D08OLP	2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine	Investigative
T17758	DRUGINFO	D0G6XS	Fucose	Investigative

T61622	TARGETID	T61622
T61622	FORMERID	TTDS00451
T61622	UNIPROID	RENI_HUMAN
T61622	TARGNAME	Angiotensinogenase renin (REN)
T61622	GENENAME	REN
T61622	TARGTYPE	Successful
T61622	SYNONYMS	Renin; Angiotensinogenase
T61622	FUNCTION	Renin is a highly specific endopeptidase, whose only knownfunction is to generate angiotensin I from angiotensinogen in the plasma, initiating a cascade of reactions that produce an elevation of blood pressure and increased sodium retention by the kidney.
T61622	PDBSTRUC	6I3F; 5VRP; 5VPM; 5V8V; 5TMK
T61622	BIOCLASS	Peptidase
T61622	ECNUMBER	EC 3.4.23.15
T61622	SEQUENCE	MDGWRRMPRWGLLLLLWGSCTFGLPTDTTTFKRIFLKRMPSIRESLKERGVDMARLGPEWSQPMKRLTLGNTTSSVILTNYMDTQYYGEIGIGTPPQTFKVVFDTGSSNVWVPSSKCSRLYTACVYHKLFDASDSSSYKHNGTELTLRYSTGTVSGFLSQDIITVGGITVTQMFGEVTEMPALPFMLAEFDGVVGMGFIEQAIGRVTPIFDNIISQGVLKEDVFSFYYNRDSENSQSLGGQIVLGGSDPQHYEGNFHYINLIKTGVWQIQMKGVSVGSSTLLCEDGCLALVDTGASYISGSTSSIEKLMEALGAKKRLFDYVVKCNEGPTLPDISFHLGGKEYTLTSADYVFQESYSSKKLCTLAIHAMDIPPPTGPTWALGATFIRKFYTEFDRRNNRIGFALAR
T61622	DRUGINFO	D03SVX	Aliskiren	Approved
T61622	DRUGINFO	D0C2EP	Remikiren	Approved
T61622	DRUGINFO	D07JXN	SPP-600	Phase 2
T61622	DRUGINFO	D0A5SA	TAK-272	Phase 2
T61622	DRUGINFO	D0H8WZ	SR-43845	Phase 2
T61622	DRUGINFO	D0V3UN	CP-80794	Phase 2
T61622	DRUGINFO	DN9DB6	SPH3127	Phase 2
T61622	DRUGINFO	D01QSG	VTP-27999	Phase 1
T61622	DRUGINFO	D03XHS	ACT-178882	Phase 1
T61622	DRUGINFO	D0U7OS	CARD-024	Phase 1
T61622	DRUGINFO	D01SGM	FK-906	Discontinued in Phase 2
T61622	DRUGINFO	D09ELW	Enalkiren	Discontinued in Phase 2
T61622	DRUGINFO	D0J5GT	ZANKIREN	Discontinued in Phase 2
T61622	DRUGINFO	D02KEY	SPP-676	Discontinued in Phase 1
T61622	DRUGINFO	D0L4VZ	SPP-1148	Discontinued in Phase 1
T61622	DRUGINFO	D0V4LG	RS-8891	Discontinued in Phase 1
T61622	DRUGINFO	D00MIF	JTP-4761	Terminated
T61622	DRUGINFO	D01EZY	JTP-2724	Terminated
T61622	DRUGINFO	D02KBO	Ciprokiren	Terminated
T61622	DRUGINFO	D05FTY	ES-1005	Terminated
T61622	DRUGINFO	D06ZKG	SC-56525	Terminated
T61622	DRUGINFO	D08IDQ	BILA-2157BS	Terminated
T61622	DRUGINFO	D0K1AF	A-74273	Terminated
T61622	DRUGINFO	D0M7HO	SQ-33800	Terminated
T61622	DRUGINFO	D0V5XL	KRI-1314	Terminated
T61622	DRUGINFO	D00FHV	Iva-His-Pro-Phe-His-ACHPA-Leu-Phe-NH2	Investigative
T61622	DRUGINFO	D01FJQ	Pro-His-Pro-His-Phe-Phe-Val-Tyr	Investigative
T61622	DRUGINFO	D02MBW	2-Methyl-3-(2-Aminothiazolo)Propanal	Investigative
T61622	DRUGINFO	D02MME	N-Methyl-N-(Methylbenzyl)Formamide	Investigative
T61622	DRUGINFO	D04DZP	(H-261)Boc-His-Pro-Phe-His-Leu(OH)-Val-Ile-His-OH	Investigative
T61622	DRUGINFO	D04GXL	Sul-Pro-Phe-N-MeHis-LVA-Ile-Amp-(O)	Investigative
T61622	DRUGINFO	D04QIA	Ro-66-1168	Investigative
T61622	DRUGINFO	D06JQM	SPP-800	Investigative
T61622	DRUGINFO	D06OBP	1-Hydroxy-2-Amino-3-Cyclohexylpropane	Investigative
T61622	DRUGINFO	D08BRJ	Pro-His-Pro-His-Leu-Phe-Val-Tyr	Investigative
T61622	DRUGINFO	D09PZT	Iva-His-Pro-Phe-His-Sta-Leu-Phe-NH2	Investigative
T61622	DRUGINFO	D09QXR	3-Phenyl-1,2-Propandiol	Investigative
T61622	DRUGINFO	D09RQD	2-Cyclopropylmethylenepropanal	Investigative
T61622	DRUGINFO	D0A3LJ	Sul-Pro-Phe-N-MeHis-LVA-Ile-Amp	Investigative
T61622	DRUGINFO	D0A9BK	1-Methyl-2-Oxy-5,5-Dimethyl Pyrrolidine	Investigative
T61622	DRUGINFO	D0E5QB	Ro-65-7219	Investigative
T61622	DRUGINFO	D0G9DJ	Iva-His-Pro-Phe-His-AHPPA-Leu-Phe-NH2	Investigative
T61622	DRUGINFO	D0J6QC	PP1-Pro-Phe-N-MeHis-LVA-Ile-Amp-(O)	Investigative
T61622	DRUGINFO	D0K0OY	Glu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro	Investigative
T61622	DRUGINFO	D0KH9Z	Pro-His-Pro-Phe-His-Leu(CH2NH)Val-Ile-His-Lys	Investigative
T61622	DRUGINFO	D0P7NP	CP-305202	Investigative
T61622	DRUGINFO	D0Q3IE	Pro-His-Pro-His-Phe-Phe-Val-Tyr-Lys	Investigative
T61622	DRUGINFO	D0Q8VT	JT-2724	Investigative
T61622	DRUGINFO	D0TD2F	ES-6864	Investigative
T61622	DRUGINFO	D0V4EK	1-Hydroxy-3-Methylbutane	Investigative
T61622	DRUGINFO	D0VI7P	PP2-Pro-Phe-N-MeHis-LVA-Ile-Amp-(O)	Investigative
T61622	DRUGINFO	D0E1KX	Dimethylformamide	Investigative

T56915	TARGETID	T56915
T56915	FORMERID	TTDS00320
T56915	UNIPROID	POL_HV1B1
T56915	TARGNAME	Human immunodeficiency virus Protease (HIV PR)
T56915	GENENAME	HIV PR
T56915	TARGTYPE	Successful
T56915	SYNONYMS	HIV Retropepsin; HIV PR
T56915	FUNCTION	Gag-Pol polyprotein: Mediates, with Gag polyprotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi). Gag-Pol polyprotein may regulate its own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, the polyprotein would promote translation, whereas at high concentration, the polyprotein would encapsidate genomic RNA and then shut off translation.
T56915	PDBSTRUC	6OE3; 6HAK; 6ELI; 6DUH; 6DUG
T56915	BIOCLASS	Peptidase
T56915	ECNUMBER	EC 3.4.23.16
T56915	SEQUENCE	PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVRQYDQILIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF
T56915	DRUGINFO	D03IGH	Darunavir	Approved
T56915	DRUGINFO	D07IQS	Atazanavir	Approved
T56915	DRUGINFO	D0A0OO	Amprenavir	Approved
T56915	DRUGINFO	D0EV6T	Tipranavir	Approved
T56915	DRUGINFO	D0F5MT	Fosamprenavir	Approved
T56915	DRUGINFO	D0V7CF	Indinavir	Approved
T56915	DRUGINFO	D0WI3T	Saquinavir	Approved
T56915	DRUGINFO	D0ZU9R	Ritonavir	Approved
T56915	DRUGINFO	D06KJQ	BI 201335	Phase 3
T56915	DRUGINFO	D01RXW	Vaniprevir	Phase 2
T56915	DRUGINFO	D01ZNQ	TMC-310911	Phase 2
T56915	DRUGINFO	D04MCY	BMS 650032	Phase 2
T56915	DRUGINFO	D05TKB	GS-9256	Phase 2
T56915	DRUGINFO	D07OHT	ABT-450	Phase 2
T56915	DRUGINFO	D07SMH	MK-5172	Phase 2
T56915	DRUGINFO	D07ZAH	ACH-1625	Phase 2
T56915	DRUGINFO	D0R9MN	Danoprevir	Phase 2
T56915	DRUGINFO	D0W9JM	KNI-272	Phase 2
T56915	DRUGINFO	D0Y3JI	DG-17	Phase 2
T56915	DRUGINFO	D02MMP	VX-500	Phase 1
T56915	DRUGINFO	D04CJN	CTP-298	Phase 1
T56915	DRUGINFO	D08FYH	PF-04776548	Phase 1
T56915	DRUGINFO	D09QKI	PPL-100	Phase 1
T56915	DRUGINFO	D0W6LW	BIT225	Phase 1
T56915	DRUGINFO	D04GWY	Telinavir	Discontinued in Phase 2
T56915	DRUGINFO	D05UMD	R-87366	Discontinued in Phase 2
T56915	DRUGINFO	D07FJM	BRECANAVIR	Discontinued in Phase 2
T56915	DRUGINFO	D07MPJ	A-75925	Discontinued in Phase 2
T56915	DRUGINFO	D0E4FG	Mozenavir	Discontinued in Phase 2
T56915	DRUGINFO	D0J9AK	MK-944a	Discontinued in Phase 2
T56915	DRUGINFO	D09HEV	GS-9005	Discontinued in Phase 1/2
T56915	DRUGINFO	D01KIS	CGP-53437	Discontinued in Phase 1
T56915	DRUGINFO	D03MIP	SPI-256	Discontinued in Phase 1
T56915	DRUGINFO	D06KPW	U-103017	Discontinued in Phase 1
T56915	DRUGINFO	D07JJC	DPC-684	Discontinued in Phase 1
T56915	DRUGINFO	D08JTU	R-944	Discontinued in Phase 1
T56915	DRUGINFO	D09CAC	U-96988	Discontinued in Phase 1
T56915	DRUGINFO	D0N3ZY	DPC-681	Discontinued in Phase 1
T56915	DRUGINFO	D0PB4P	XM-323	Discontinued in Phase 1
T56915	DRUGINFO	D0R5AU	LASINAVIR	Discontinued in Phase 1
T56915	DRUGINFO	D0U7WN	A-80987	Discontinued in Phase 1
T56915	DRUGINFO	D0U8AR	DMP-851	Discontinued in Phase 1
T56915	DRUGINFO	D0X8AU	KNI-764	Discontinued in Phase 1
T56915	DRUGINFO	D00XRK	BMS-182193	Terminated
T56915	DRUGINFO	D01RCC	BMS-186318	Terminated
T56915	DRUGINFO	D02TGW	GE-20372A	Terminated
T56915	DRUGINFO	D05GQL	KNI-102	Terminated
T56915	DRUGINFO	D05UMO	BAY-793	Terminated
T56915	DRUGINFO	D06FMY	CGP-70726	Terminated
T56915	DRUGINFO	D07PIA	AG-1350	Terminated
T56915	DRUGINFO	D07PSP	U-75875	Terminated
T56915	DRUGINFO	D0GM4S	AG-1284	Terminated
T56915	DRUGINFO	D0P6DF	PD-153103	Terminated
T56915	DRUGINFO	D0QH0R	SB-206343	Terminated
T56915	DRUGINFO	D0R3JE	GS-2992	Terminated
T56915	DRUGINFO	D0T4OE	Palinavir	Terminated
T56915	DRUGINFO	D0V8PN	Droxinavir hydrochloride	Terminated
T56915	DRUGINFO	D0B0XX	KH-164	Investigative
T56915	DRUGINFO	D0G6HC	JG-365	Investigative

T31595	TARGETID	T31595
T31595	FORMERID	TTDS00174
T31595	UNIPROID	NRAM_I33A0
T31595	TARGNAME	Influenza Neuraminidase (Influ NA)
T31595	GENENAME	Influ NA
T31595	TARGTYPE	Successful
T31595	SYNONYMS	STNA; NEU1; NANase; N-acylneuraminate glycohydrolase; Influ Sialidase
T31595	FUNCTION	Unlike other strains, A/WSN/33 neuraminidase binds and activates plasminogen into plasmin in the vicinity of HA so that activated plasmin cleaves HA rendering the virus infectious.
T31595	BIOCLASS	Glycosylase
T31595	ECNUMBER	EC 3.2.1.18
T31595	SEQUENCE	MNPNQKIITIGSICMVVGIISLILQIGNIISIWISHSIQTGNQNHTGICNQGIITYNVVAGQDSTSVILTGNSSLCPIRGWAIHSKDNGIRIGSKGDVFVIREPFISCSHLECRTFFLTQGALLNDKHSNGTVKDRSPYRALMSCPVGEAPSPYNSRFESVAWSASACHDGMGWLTIGISGPDNGAVAVLKYNGIITETIKSWRKKILRTQESECTCVNGSCFTIMTDGPSNGLASYKIFKIEKGKVTKSIELNAPNSHYEECSCYPDTGKVMCVCRDNWHGSNRPWVSFDQNLDYQIGYICSGVFGDNPRPKDGPGSCGPVSADGANGVKGFSYRYGNGVWIGRTKSDSSRHGFEMIWDPNGWTETDSRFSVRQDVVAMTDRSGYSGSFVQHPELTGLDCMRPCFWVELIRGRPEEETIWTSGSIISFCGVNSDTVDWSWPDGAELPFTIDK
T31595	DRUGINFO	D00NPP	Zanamivir	Approved
T31595	DRUGINFO	D0O5NK	Oseltamivir	Approved
T31595	DRUGINFO	D0P2IW	Peramivir	Approved
T31595	DRUGINFO	D04VSM	CS-8958	Phase 3
T31595	DRUGINFO	D03ZKM	UX-001	Phase 3
T31595	DRUGINFO	D0YO7Y	DAS-181	Phase 2
T31595	DRUGINFO	D0Q3ZN	GS-3435	Terminated
T31595	DRUGINFO	D0XJ0P	BCX-140	Terminated
T31595	DRUGINFO	D00LEQ	FANA	Investigative
T31595	DRUGINFO	D00PAS	Cristacarpin	Investigative
T31595	DRUGINFO	D00PZM	Erythribyssin D	Investigative
T31595	DRUGINFO	D01FEA	8-DEOXYGARTANIN	Investigative
T31595	DRUGINFO	D01FQZ	Erythribyssin O	Investigative
T31595	DRUGINFO	D01WTQ	MANGOSTANIN	Investigative
T31595	DRUGINFO	D02HYW	CUDRATRICUSXANTHONE	Investigative
T31595	DRUGINFO	D02NRI	Eryvarin D	Investigative
T31595	DRUGINFO	D02QCC	Erythribyssin M	Investigative
T31595	DRUGINFO	D03XVT	(S)-1,7-Diphenyl-6(E)-hepten-3-ol	Investigative
T31595	DRUGINFO	D05BUX	Cyclopentane amide derivatives 1	Investigative
T31595	DRUGINFO	D05FLL	CALOPOCARPIN	Investigative
T31595	DRUGINFO	D05GSS	ISONEORAUTENOL	Investigative
T31595	DRUGINFO	D05KWF	Cudraxanthone M	Investigative
T31595	DRUGINFO	D06BSN	2-Deoxy-2,3-Dehydro-N-Acetyl-Neuraminic Acid	Investigative
T31595	DRUGINFO	D06IDO	GS4071	Investigative
T31595	DRUGINFO	D06LUX	A-315675	Investigative
T31595	DRUGINFO	D07TDM	PHASEOLIN	Investigative
T31595	DRUGINFO	D08UEU	4-(ACETYLAMINO)-5-AMINO-3-HYDROXYBENZOIC ACID	Investigative
T31595	DRUGINFO	D09YOY	Cyclopentane amide derivatives 2	Investigative
T31595	DRUGINFO	D09YVT	HERBACETIN	Investigative
T31595	DRUGINFO	D0A2OH	Cudraxanthone L	Investigative
T31595	DRUGINFO	D0A9CZ	PHASEOLLIDIN	Investigative
T31595	DRUGINFO	D0B1NY	Cyclopentane amide derivatives 3	Investigative
T31595	DRUGINFO	D0C4GE	4-Amino-2-Deoxy-2,3-Dehydro-N-Neuraminic Acid	Investigative
T31595	DRUGINFO	D0D8WQ	2,4-Deoxy-4-Guanidino-5-N-Acetyl-Neuraminic Acid	Investigative
T31595	DRUGINFO	D0D9NX	(E,E)-5-Hydroxy-1,7-diphenyl-4,6-heptadien-3-one	Investigative
T31595	DRUGINFO	D0E8VD	Erythribyssin L	Investigative
T31595	DRUGINFO	D0F8CH	4-(Acetylamino)-3-Amino Benzoic Acid	Investigative
T31595	DRUGINFO	D0G5MS	MANGOSTANOL	Investigative
T31595	DRUGINFO	D0G5PT	DEMETHYLMEDICARPIN	Investigative
T31595	DRUGINFO	D0I0WF	RHODIOLININ	Investigative
T31595	DRUGINFO	D0I1BA	BCX-1898	Investigative
T31595	DRUGINFO	D0I6EH	Cudraxanthone D	Investigative
T31595	DRUGINFO	D0IH6W	(E,E)-1,7-Diphenyl-4,6-heptadien-3-one	Investigative
T31595	DRUGINFO	D0J7YV	MANGOSTENONE F	Investigative
T31595	DRUGINFO	D0K6FM	SMEATHXANTHONE A	Investigative
T31595	DRUGINFO	D0K8XC	Lactose	Investigative
T31595	DRUGINFO	D0MA3M	MANGOSTENONE G	Investigative
T31595	DRUGINFO	D0O8EB	GARTANIN	Investigative
T31595	DRUGINFO	D0P3BL	A-192558	Investigative
T31595	DRUGINFO	D0P5MJ	ERYSTAGALLIN A	Investigative
T31595	DRUGINFO	D0PE5T	BCX-1827	Investigative
T31595	DRUGINFO	D0Q8HV	4-(ACETYLAMINO)-3-HYDROXY-5-NITROBENZOIC ACID	Investigative
T31595	DRUGINFO	D0R6YP	BCX-1923	Investigative
T31595	DRUGINFO	D0U8AU	MACLURAXANTHONE	Investigative
T31595	DRUGINFO	D0UD1U	Erysubin D	Investigative
T31595	DRUGINFO	D0UK4O	KATSUMADAIN A	Investigative
T31595	DRUGINFO	D0UR7U	Cudratricusxanthone F	Investigative
T31595	DRUGINFO	D0W0BO	Cyclopentane amide derivatives 4	Investigative
T31595	DRUGINFO	D01EJH	NEORAUTENOL	Investigative
T31595	DRUGINFO	D04UYB	MANGIFERIN	Investigative
T31595	DRUGINFO	D05IWY	Gamma-mangostin	Investigative
T31595	DRUGINFO	D05YJR	GARCINONE D	Investigative
T31595	DRUGINFO	D0M7ZZ	Erysubin E	Investigative
T31595	DRUGINFO	D0Z7EL	GOSSYPETIN	Investigative
T31595	DRUGINFO	D06PRC	MANGOSTIN	Investigative
T31595	DRUGINFO	D08WQM	O-Sialic Acid	Investigative
T31595	DRUGINFO	D0SD9H	Beta-D-Mannose	Investigative
T31595	DRUGINFO	D00RIX	APIGENIN	Investigative
T31595	DRUGINFO	D0G3TK	KAEMPFEROL	Investigative
T31595	DRUGINFO	D0G6XS	Fucose	Investigative
T31595	DRUGINFO	D07LUR	Alpha-D-Mannose	Investigative

T31479	TARGETID	T31479
T31479	FORMERID	TTDS00065
T31479	UNIPROID	PA21B_HUMAN
T31479	TARGNAME	Phospholipase A2 (PLA2G1B)
T31479	GENENAME	PLA2G1B
T31479	TARGTYPE	Successful
T31479	SYNONYMS	Secreted phospholipase A(2); Phosphatidylcholine 2-acylhydrolase 1B; PLA2G1B; Group IB phospholipase A2
T31479	FUNCTION	PA2 catalyzes the calcium-dependent hydrolysis of the 2- acyl groups in 3-sn-phosphoglycerides, this releases glycerophospholipids and arachidonic acid that serve as the precursors of signal molecules.
T31479	PDBSTRUC	3ELO; 1YSK
T31479	BIOCLASS	Carboxylic ester hydrolase
T31479	ECNUMBER	EC 3.1.1.4
T31479	SEQUENCE	MKLLVLAVLLTVAAADSGISPRAVWQFRKMIKCVIPGSDPFLEYNNYGCYCGLGGSGTPVDELDKCCQTHDNCYDQAKKLDSCKFLLDNPYTHTYSYSCSGSAITCSSKNKECEAFICNCDRNAAICFSKAPYNKAHKNLDTKKYCQS
T31479	DRUGINFO	D00FGR	Miltefosine	Approved
T31479	DRUGINFO	D00GOS	Clocortolone	Approved
T31479	DRUGINFO	D0FL5V	Clobetasol	Approved
T31479	DRUGINFO	D0G7KJ	Diflorasone	Approved
T31479	DRUGINFO	D0OR2L	Cholic Acid	Approved
T31479	DRUGINFO	D0C0KP	AllerB	Phase 2b
T31479	DRUGINFO	D00XQO	MANOALIDE	Phase 2
T31479	DRUGINFO	D03VYZ	MRX-4	Phase 2
T31479	DRUGINFO	D07RKO	MRX-6	Phase 2
T31479	DRUGINFO	D74PRE	Varespladib	Phase 2
T31479	DRUGINFO	D07LUJ	URSOLIC ACID	Phase 2
T31479	DRUGINFO	D05GZD	Rilapladib	Phase 1
T31479	DRUGINFO	D0L5UO	Darapladib	Discontinued in Phase 3
T31479	DRUGINFO	D03RNX	EPC-K1	Discontinued in Phase 2
T31479	DRUGINFO	D08VGT	BMY-30129	Discontinued in Phase 2
T31479	DRUGINFO	D0D3KY	SC-106	Discontinued in Phase 2
T31479	DRUGINFO	D0MF3C	WAY-123641	Discontinued in Phase 2
T31479	DRUGINFO	D08YFD	PF-05212372	Discontinued in Phase 1
T31479	DRUGINFO	D09NBM	SB-435495	Discontinued in Phase 1
T31479	DRUGINFO	D07OGR	YM-26734	Terminated
T31479	DRUGINFO	D00XNF	LY256548	Investigative
T31479	DRUGINFO	D02COQ	Petrosaspongiolide P	Investigative
T31479	DRUGINFO	D02FVV	HELENAQUINONE	Investigative
T31479	DRUGINFO	D03IDX	WA-8242-A1	Investigative
T31479	DRUGINFO	D05DUX	Petrosaspongiolide M	Investigative
T31479	DRUGINFO	D05SQA	4'-hydroxy-6,3',5'-triprenylisoflavonone	Investigative
T31479	DRUGINFO	D06PLG	SB-203347	Investigative
T31479	DRUGINFO	D07IRQ	P-Anisic Acid	Investigative
T31479	DRUGINFO	D0H1JX	3,9-dihydroxy-2,10-diprenylpterocap-6a-ene	Investigative
T31479	DRUGINFO	D0H2RZ	Heptanoic Acid	Investigative
T31479	DRUGINFO	D0HZ3Q	AGN-190383	Investigative
T31479	DRUGINFO	D0L3IQ	ABYSSINONE V	Investigative
T31479	DRUGINFO	D0O2DQ	Mepacrine	Investigative
T31479	DRUGINFO	D0P0DA	BM-162115	Investigative
T31479	DRUGINFO	D0SS5D	Lpc-Ether	Investigative
T31479	DRUGINFO	D0TN4X	LY178002	Investigative
T31479	DRUGINFO	D0V4NV	folipastatin	Investigative
T31479	DRUGINFO	D0YD6H	Hyrtiosulawesine	Investigative
T31479	DRUGINFO	D02IVU	CACOSPONGIONOLIDE	Investigative
T31479	DRUGINFO	D03BAB	Cacospongionolide E	Investigative
T31479	DRUGINFO	D06YGT	N-Tridecanoic Acid	Investigative
T31479	DRUGINFO	D0B9VV	CACOSPONGIONOLIDE B	Investigative
T31479	DRUGINFO	D0G4CI	methylglyoxal	Investigative
T31479	DRUGINFO	D0O0ZU	Hexane-1,6-Diol	Investigative
T31479	DRUGINFO	D0T3CM	BOLINAQUINONE	Investigative
T31479	DRUGINFO	D06GOK	2-Methyl-2,4-Pentanediol	Investigative
T31479	DRUGINFO	D0F2ME	Acetate Ion	Investigative
T31479	DRUGINFO	D07LUR	Alpha-D-Mannose	Investigative

T40016	TARGETID	T40016
T40016	FORMERID	TTDS00283
T40016	UNIPROID	GCR_HUMAN
T40016	TARGNAME	Glucocorticoid receptor (NR3C1)
T40016	GENENAME	NR3C1
T40016	TARGTYPE	Successful
T40016	SYNONYMS	Nuclear receptor subfamily 3 group C member 1; GRL; GR
T40016	FUNCTION	Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Involved in chromatin remodeling. Plays a role in rapid mRNA degradation by binding to the 5' UTR of target mRNAs and interacting with PNRC2 in a ligand-dependent manner which recruits the RNA helicase UPF1 and the mRNA-decapping enzyme DCP1A, leading to RNA decay. Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth (By similarity).
T40016	PDBSTRUC	6EL9; 6EL7; 6EL6; 6DXK; 6CFN
T40016	BIOCLASS	Nuclear hormone receptor
T40016	SEQUENCE	MDSKESLTPGREENPSSVLAQERGDVMDFYKTLRGGATVKVSASSPSLAVASQSDSKQRRLLVDFPKGSVSNAQQPDLSKAVSLSMGLYMGETETKVMGNDLGFPQQGQISLSSGETDLKLLEESIANLNRSTSVPENPKSSASTAVSAAPTEKEFPKTHSDVSSEQQHLKGQTGTNGGNVKLYTTDQSTFDILQDLEFSSGSPGKETNESPWRSDLLIDENCLLSPLAGEDDSFLLEGNSNEDCKPLILPDTKPKIKDNGDLVLSSPSNVTLPQVKTEKEDFIELCTPGVIKQEKLGTVYCQASFPGANIIGNKMSAISVHGVSTSGGQMYHYDMNTASLSQQQDQKPIFNVIPPIPVGSENWNRCQGSGDDNLTSLGTLNFPGRTVFSNGYSSPSMRPDVSSPPSSSSTATTGPPPKLCLVCSDEASGCHYGVLTCGSCKVFFKRAVEGQHNYLCAGRNDCIIDKIRRKNCPACRYRKCLQAGMNLEARKTKKKIKGIQQATTGVSQETSENPGNKTIVPATLPQLTPTLVSLLEVIEPEVLYAGYDSSVPDSTWRIMTTLNMLGGRQVIAAVKWAKAIPGFRNLHLDDQMTLLQYSWMFLMAFALGWRSYRQSSANLLCFAPDLIINEQRMTLPCMYDQCKHMLYVSSELHRLQVSYEEYLCMKTLLLLSSVPKDGLKSQELFDEIRMTYIKELGKAIVKREGNSSQNWQRFYQLTKLLDSMHEVVENLLNYCFQTFLDKTMSIEFPEMLAEIITNQIPKYSNGNIKKLLFHQK
T40016	DRUGINFO	D02QJH	Fluocinolone Acetonide	Approved
T40016	DRUGINFO	D03BLF	Triamcinolone	Approved
T40016	DRUGINFO	D03HYX	Mometasone	Approved
T40016	DRUGINFO	D03SXE	Betamethasone Valerate	Approved
T40016	DRUGINFO	D05RXI	Hydrocortamate	Approved
T40016	DRUGINFO	D06CWH	Betamethasone Benzoate	Approved
T40016	DRUGINFO	D08PIQ	Methylprednisolone	Approved
T40016	DRUGINFO	D09WYX	Deflazacort	Approved
T40016	DRUGINFO	D0CW1P	Betamethasone	Approved
T40016	DRUGINFO	D0D1SG	Prednisolone	Approved
T40016	DRUGINFO	D0FM2P	Flunisolide	Approved
T40016	DRUGINFO	D0I5DS	Meprednisone	Approved
T40016	DRUGINFO	D0IL7L	Prednisone	Approved
T40016	DRUGINFO	D0IT2G	Dexamethasone	Approved
T40016	DRUGINFO	D0KR5B	Hydrocortisone	Approved
T40016	DRUGINFO	D0LC6K	Fluticasone	Approved
T40016	DRUGINFO	D0NA8U	Dexamethasone sodium phosphate	Approved
T40016	DRUGINFO	D0P0HT	Fluorometholone	Approved
T40016	DRUGINFO	D0Y7IU	Budesonide	Approved
T40016	DRUGINFO	D0Y7JU	GW685698X	Approved
T40016	DRUGINFO	D0Z4EI	Mifepristone	Approved
T40016	DRUGINFO	D00TPW	FST-201	Phase 3
T40016	DRUGINFO	D01IUS	Mapracorat	Phase 3
T40016	DRUGINFO	D03WNG	CORT-125134	Phase 3
T40016	DRUGINFO	D4R1JE	TLC599	Phase 3
T40016	DRUGINFO	D01HYQ	IONIS-GCCRRX	Phase 2
T40016	DRUGINFO	D05MDJ	ORG-34517	Phase 2
T40016	DRUGINFO	D05RXW	LAS-41002	Phase 2
T40016	DRUGINFO	D06XSB	GW-870086-X	Phase 2
T40016	DRUGINFO	D0I1DZ	DE-110	Phase 2
T40016	DRUGINFO	D0M8VL	GW-870086-X	Phase 2
T40016	DRUGINFO	D0OR8W	ETIPREDNOL DICLOACETATE	Phase 2
T40016	DRUGINFO	D0T5TU	TPI-1020	Phase 2
T40016	DRUGINFO	DWSG41	CORT113176	Phase 2
T40016	DRUGINFO	D0E2WF	ORG 34517/34850	Phase 2
T40016	DRUGINFO	D0L3HU	BAY 86-5044	Phase 2
T40016	DRUGINFO	D0J6UV	IBI-20089	Phase 1
T40016	DRUGINFO	D0OS8C	NCX-1015	Phase 1
T40016	DRUGINFO	D9HQE2	PT-150	Phase 1
T40016	DRUGINFO	D01NUG	GSK870086	Discontinued in Phase 2
T40016	DRUGINFO	D03RCP	NM-135	Discontinued in Phase 2
T40016	DRUGINFO	D09UFV	AZD-5423	Discontinued in Phase 2
T40016	DRUGINFO	D0G2CQ	WC-3027	Discontinued in Phase 2
T40016	DRUGINFO	D03CHE	PF-251802	Discontinued in Phase 1
T40016	DRUGINFO	D0I7EX	Org-34116	Terminated
T40016	DRUGINFO	D0O0ZU	Hexane-1,6-Diol	Investigative
T40016	DRUGINFO	D02UVH	B-Octylglucoside	Investigative

T30081	TARGETID	T30081
T30081	FORMERID	TTDR00500
T30081	UNIPROID	KITH_HUMAN
T30081	TARGNAME	Thymidine kinase 1 (TK1)
T30081	GENENAME	TK1
T30081	TARGTYPE	Successful
T30081	SYNONYMS	Thymidine kinase, cytosolic
T30081	FUNCTION	cytosol, identical protein binding, thymidine kinase activity, zinc ion binding, DNA metabolic process, nucleobase-containing compound metabolic process, protein homotetramerization, pyrimidine nucleoside salvage, thymidine metabolic process
T30081	PDBSTRUC	2WVJ; 2ORV; 1XBT; 1W4R
T30081	BIOCLASS	Kinase
T30081	ECNUMBER	EC 2.7.1.21
T30081	SEQUENCE	MSCINLPTVLPGSPSKTRGQIQVILGPMFSGKSTELMRRVRRFQIAQYKCLVIKYAKDTRYSSSFCTHDRNTMEALPACLLRDVAQEALGVAVIGIDEGQFFPDIVEFCEAMANAGKTVIVAALDGTFQRKPFGAILNLVPLAESVVKLTAVCMECFREAAYTKRLGTEKEVEVIGGADKYHSVCRLCYFKKASGQPAGPDNKENCPVPGKPGEAVAARKLFAPQQILQCSPAN
T30081	DRUGINFO	D0RX7Z	DEOXYCYTIDINE	Approved
T30081	DRUGINFO	D07BYK	Penciclovir	Approved
T30081	DRUGINFO	D08AMJ	TK-DLI	Preregistration
T30081	DRUGINFO	D04QPD	FV-100	Phase 3
T30081	DRUGINFO	D0X4NF	Radiosensitizer gene therapy	Phase 3
T30081	DRUGINFO	D0Z9LP	RP101	Phase 2/3
T30081	DRUGINFO	D05RRA	HQK-1004	Phase 2
T30081	DRUGINFO	D02KBE	Ad-OC-hsvTK/valacyclovir	Phase 1
T30081	DRUGINFO	D0FY1W	Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy	Phase 1
T30081	DRUGINFO	D05GZD	Rilapladib	Phase 1
T30081	DRUGINFO	D0W8RX	Sitimagene ceradenovec	Discontinued in Phase 3
T30081	DRUGINFO	D00CEO	6-Hydroxypropylthymine	Investigative
T30081	DRUGINFO	D01CUJ	3-(2-propyn-1-yl)thymidine	Investigative
T30081	DRUGINFO	D01VKE	ITdU	Investigative
T30081	DRUGINFO	D04GXW	5-Iodo-2'-Deoxyuridine-5'-Monophosphate	Investigative
T30081	DRUGINFO	D07GKK	1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine	Investigative
T30081	DRUGINFO	D07OOW	(South)-Methanocarba-Thymidine	Investigative
T30081	DRUGINFO	D08AOD	6-(Dihydroxy-Isobutyl)-Thymine	Investigative
T30081	DRUGINFO	D0C7YS	5-propyl-2'-deoxyuridine	Investigative
T30081	DRUGINFO	D0D7FB	L-5-(bromovinyl)deoxyuridine	Investigative
T30081	DRUGINFO	D0G5VO	9-(4-Hydroxybutyl)-N2-Phenylguanine	Investigative
T30081	DRUGINFO	D0HO0W	L-5-iodo-2'-deoxyuridine	Investigative
T30081	DRUGINFO	D0O7GD	3'-(1,2,3-Triazol-1-yl)-3'-deoxy-beta-D-thymidine	Investigative
T30081	DRUGINFO	D0PC2Y	BVDU-MP	Investigative
T30081	DRUGINFO	D0R0EI	9-Hydroxypropyladenine, S-Isomer	Investigative
T30081	DRUGINFO	D0S4SQ	2-phenylamino-9-(4-hydroxy-butyl)-6-oxopurine	Investigative
T30081	DRUGINFO	D0ST5A	5-Bromothienyldeoxyuridine	Investigative
T30081	DRUGINFO	D0W8AD	1-[7-(triphenylmethoxy)heptyl]thymine	Investigative
T30081	DRUGINFO	D0X1HX	9-Hydroxypropyladenine, R-Isomer	Investigative
T30081	DRUGINFO	D0Y4MD	Edoxudine	Investigative
T30081	DRUGINFO	D0YJ5W	N2-(3-trifluoromethylphenyl)guanine	Investigative
T30081	DRUGINFO	D00CVB	2'-Deoxyuridine	Investigative
T30081	DRUGINFO	D00KWL	1-[5-(triphenylmethoxy)pentyl]thymine	Investigative
T30081	DRUGINFO	D01GLG	Deoxythymidine	Investigative
T30081	DRUGINFO	D02CCD	1-[6-(triphenylmethoxy)hexyl]thymine	Investigative
T30081	DRUGINFO	D04BBF	P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate	Investigative
T30081	DRUGINFO	D0I6UV	1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine	Investigative
T30081	DRUGINFO	D0ZH0I	Thymidine-5'-Phosphate	Investigative
T30081	DRUGINFO	D09WYY	2'-deoxythymidine triphosphate	Investigative

T89041	TARGETID	T89041
T89041	FORMERID	TTDS00241
T89041	UNIPROID	CP17A_HUMAN
T89041	TARGNAME	Steroid 17-alpha-monooxygenase (S17AH)
T89041	GENENAME	CYP17A1
T89041	TARGTYPE	Successful
T89041	SYNONYMS	Steroid 17-alpha-hydroxylase/17,20 lyase; P450c17; P450-C17; P450 17; CYPXVII; CYP17A1; CYP 17; 17 alpha-Hydroxylase/C17-20-lyase
T89041	FUNCTION	Conversion of pregnenolone and progesterone to their 17- alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation and the 17,20-lyase reaction. Involved in sexual development during fetal life and at puberty.
T89041	PDBSTRUC	6CIZ; 6CIR; 6CHI; 5UYS; 5IRV
T89041	BIOCLASS	Paired donor oxygen oxidoreductase
T89041	ECNUMBER	EC 1.14.14.19
T89041	SEQUENCE	MWELVALLLLTLAYLFWPKRRCPGAKYPKSLLSLPLVGSLPFLPRHGHMHNNFFKLQKKYGPIYSVRMGTKTTVIVGHHQLAKEVLIKKGKDFSGRPQMATLDIASNNRKGIAFADSGAHWQLHRRLAMATFALFKDGDQKLEKIICQEISTLCDMLATHNGQSIDISFPVFVAVTNVISLICFNTSYKNGDPELNVIQNYNEGIIDNLSKDSLVDLVPWLKIFPNKTLEKLKSHVKIRNDLLNKILENYKEKFRSDSITNMLDTLMQAKMNSDNGNAGPDQDSELLSDNHILTTIGDIFGAGVETTTSVVKWTLAFLLHNPQVKKKLYEEIDQNVGFSRTPTISDRNRLLLLEATIREVLRLRPVAPMLIPHKANVDSSIGEFAVDKGTEVIINLWALHHNEKEWHQPDQFMPERFLNPAGTQLISPSVSYLPFGAGPRSCIGEILARQELFLIMAWLLQRFDLEVPDDGQLPSLEGIPKVVFLIDSFKVKIKVRQAWREAQAEGST
T89041	DRUGINFO	D02STN	ABIRATERONE	Approved
T89041	DRUGINFO	D06CNP	Abiraterone acetate	Approved
T89041	DRUGINFO	D0X3OI	TAK-700	Phase 3
T89041	DRUGINFO	D78CME	TAVT-45	Phase 3
T89041	DRUGINFO	D0Q9KR	Seviteronel	Phase 2
T89041	DRUGINFO	D05RVA	CFG920	Phase 1/2
T89041	DRUGINFO	D01ARU	DST-2970	Phase 1
T89041	DRUGINFO	D00GIK	1-(3-(4-chlorophenyl)propyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D00GIW	1-(3,5-dibromobenzyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D00IUN	1-(1-(4-thiophen-3-ylphenyl)ethyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D00YHD	4'-(2-methyl-1-(pyridin-4-yl)propyl)biphenyl-3-ol	Investigative
T89041	DRUGINFO	D00ZME	1-((9H-Fluoren-2-yl)ethyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D01JZO	1-(4-chlorobenzyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D02HTG	1-(3,5-difluorobenzyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D02ZQK	N-3-(4-bromophenyl)propyl imidazole	Investigative
T89041	DRUGINFO	D03EDD	VN/107-1	Investigative
T89041	DRUGINFO	D04SHY	Rac-4'-(1-Imidazol-1-yl-propyl)-biphenyl-3,5-diol	Investigative
T89041	DRUGINFO	D05LXA	1-(1-Biphenyl-4-yl-2-methyl-propyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D05PKT	4-[4-(6-methoxynaphthalen-2-yl)benzyl]pyridine	Investigative
T89041	DRUGINFO	D05VLU	2,3,4,5-Tetrafluoro-6-pentafluorophenylazo-phenol	Investigative
T89041	DRUGINFO	D06AKB	3-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine	Investigative
T89041	DRUGINFO	D07ORY	1-(3,5-dichlorobenzyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D08OHU	1-(3,5-bis(trifluoromethyl)benzyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D08YCD	1-(1-Biphenyl-4-yl-ethyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D09GEH	1-(1-Biphenyl-4-yl-propyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D09TTR	1-(3-phenylpropyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D0AL3G	1-(3,4-dichlorobenzyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D0B9XL	1-(1-(4-thiophen-3-yl-phenyl)propyl)-1Himidazole	Investigative
T89041	DRUGINFO	D0GJ7J	ISOCONAZOLE	Investigative
T89041	DRUGINFO	D0J4VA	3-fluoro-4'-(1-(pyridin-4-yl)propyl)biphenyl-4-ol	Investigative
T89041	DRUGINFO	D0L6HY	1-(Bis-biphenyl-4-yl-methyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D0LC7Z	6-(3-(pyridin-4-yl)phenyl)naphthalen-2-ol	Investigative
T89041	DRUGINFO	D0M1YW	ANG-3407	Investigative
T89041	DRUGINFO	D0M8JE	1-(1-Biphenyl-4-yl-2-phenyl-ethyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D0MM7G	1-((9H-Fluoren-2-yl)methyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D0N5GZ	1-(4-methyl-benzyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D0N7CQ	Rac-4'-(1-Imidazol-1-yl-propyl)-biphenyl-3,4-diol	Investigative
T89041	DRUGINFO	D0P5CT	4'-(Pyridin-4-ylmethyl)biphenyl-4-carboxamide	Investigative
T89041	DRUGINFO	D0P8PG	1-(4-bromophenethyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D0Q1FX	Rac-4'-(1-Imidazol-1-yl-propyl)-biphenyl-3-ol	Investigative
T89041	DRUGINFO	D0Q1LG	1-(1-Biphenyl-4-yl-pentyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D0QW7W	4-((1H-imidazol-1-yl)methyl)phenol	Investigative
T89041	DRUGINFO	D0RD3C	1-(1-Biphenyl-4-yl-3-methyl-butyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D0RI7T	1-(1-(Biphenyl-4-yl)allyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D0S0EP	1-(4-nitrobenzyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D0SM4F	Rac-4'-(1-Imidazol-1-yl-propyl)-biphenyl-4-ol	Investigative
T89041	DRUGINFO	D0SU0Y	1-(1-Biphenyl-4-yl-butyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D0T1CH	4-[1-(4'-Methoxybiphenyl-4-yl)propyl]pyridine	Investigative
T89041	DRUGINFO	D0T3BL	1-(4-chlorophenethyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D0U5GF	2-(1-Imidazol-1-yl-ethyl)-9H-carbazole	Investigative
T89041	DRUGINFO	D0U6JI	4'-(1-(pyridin-4-yl)propyl)biphenyl-3-ol	Investigative
T89041	DRUGINFO	D0U6QM	1-(4-iodobenzyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D0X1DV	1-(1-(4'-Ethylbiphenyl-4-yl)propyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D0X4XX	1-(3,4-difluorobenzyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D00DSE	4-(4'-Fluoro-biphenyl-4-ylmethyl)pyridine	Investigative
T89041	DRUGINFO	D01SZX	1-Imidazol-1-ylmethylxanthen-9-one	Investigative
T89041	DRUGINFO	D02ALK	6-Pyridin-3-yl-naphthalen-2-ol	Investigative
T89041	DRUGINFO	D02BXS	4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diamine	Investigative
T89041	DRUGINFO	D03VRC	1-(4-Bromobenzyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D04CFP	5-[4-(Pyridin-4-ylmethyl)phenyl]-1H-indole	Investigative
T89041	DRUGINFO	D04ISG	3-(1-Chloro-7-methoxy-naphthalen-2-yl)-pyridine	Investigative
T89041	DRUGINFO	D05QPR	1-(4-fluorobenzyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D06FHE	1-Ethyl-5-(imidazol-1-yl-phenyl-methyl)-1H-indole	Investigative
T89041	DRUGINFO	D07CTI	1-Imidazol-1-ylmethyl-4-nitro-xanthen-9-one	Investigative
T89041	DRUGINFO	D07IQG	4-Bromo-1-imidazol-1-ylmethyl-xanthen-9-one	Investigative
T89041	DRUGINFO	D07VGT	6-[4-(Pyridin-4-ylmethyl)phenyl]naphthalen-2-ol	Investigative
T89041	DRUGINFO	D09GJI	7-(1-(1H-imidazol-1-yl)ethyl)-9H-fluoren-2-ol	Investigative
T89041	DRUGINFO	D09VPA	4-[5-Bromo-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T89041	DRUGINFO	D09VQZ	4-((3',4'-Difluorobiphenyl-4-yl)methyl)pyridine	Investigative
T89041	DRUGINFO	D0D0DR	1-(3-(4-fluorophenyl)propyl)-1H-imidazole	Investigative
T89041	DRUGINFO	D0E0ZS	N-(4'-Isonicotinoylbiphenyl-3-yl)acetamide	Investigative
T89041	DRUGINFO	D0E8DX	6-Pyridin-3-yl-3,4-dihydroquinoline-2(1H)-thione	Investigative
T89041	DRUGINFO	D0L1JF	3-[4-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T89041	DRUGINFO	D0LJ9D	4-(4-(thiophen-2-yl)benzyl)pyridine	Investigative
T89041	DRUGINFO	D0N1GH	6-(pyridin-3-yl)-2-naphthonitrile	Investigative
T89041	DRUGINFO	D0Y5KX	4'-(Pyridin-4-ylmethyl)biphenyl-4-amine	Investigative
T89041	DRUGINFO	D0Z3GX	4-(4-(thiophen-3-yl)benzyl)pyridine	Investigative
T89041	DRUGINFO	D01REI	4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diol	Investigative
T89041	DRUGINFO	D02CSU	4-Indan-(1Z)-ylidenemethyl-pyridine	Investigative
T89041	DRUGINFO	D03EXD	4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine	Investigative
T89041	DRUGINFO	D03MKT	4-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T89041	DRUGINFO	D06HFV	5-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyrimidine	Investigative
T89041	DRUGINFO	D07ZNR	2,3,5,6-Tetrafluoro-4-pentafluorophenylazo-phenol	Investigative
T89041	DRUGINFO	D09HEA	4-((1H-imidazol-1-yl)methyl)benzonitrile	Investigative
T89041	DRUGINFO	D09HOE	4-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T89041	DRUGINFO	D0D9FR	4-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T89041	DRUGINFO	D0F5YU	4-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T89041	DRUGINFO	D0I1YH	4-[(3'-Hydroxybiphenyl-4-yl)methyl]pyridine	Investigative
T89041	DRUGINFO	D0K5KG	3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine	Investigative
T89041	DRUGINFO	D0MA9G	3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine	Investigative
T89041	DRUGINFO	D0N1PQ	3-(6-methoxynaphthalen-2-yl)pyridine	Investigative
T89041	DRUGINFO	D0NX0M	3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine	Investigative
T89041	DRUGINFO	D0Q0BK	3-Fluoro-4'-(pyridin-4-ylmethyl)biphenyl-4-ol	Investigative
T89041	DRUGINFO	D0R0TE	3-(6-Ethoxy-naphthalen-2-yl)-pyridine	Investigative
T89041	DRUGINFO	D0WN9P	4'-(Pyridin-4-ylmethyl)biphenyl-3-amine	Investigative
T89041	DRUGINFO	D0YD9J	4-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine	Investigative

T47107	TARGETID	T47107
T47107	FORMERID	TTDC00015
T47107	UNIPROID	KPCG_HUMAN
T47107	TARGNAME	Protein kinase C gamma (PRKCG)
T47107	GENENAME	PRKCG
T47107	TARGTYPE	Successful
T47107	SYNONYMS	PRKCG; PKCG; PKC-gamma
T47107	FUNCTION	Calcium-activated, phospholipid-and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays diverse roles in neuronal cells and eye tissues, such as regulation of the neuronal receptors GRIA4/GLUR4 and GRIN1/NMDAR1, modulation of receptors and neuronal functions related to sensitivity to opiates, pain and alcohol, mediation of synaptic function and cell survival after ischemia, and inhibition of gap junction activity after oxidative stress. Binds and phosphorylates GRIA4/GLUR4 glutamate receptor and regulates its function by increasing plasma membrane-associated GRIA4 expression. In primary cerebellar neurons treated with the agonist 3,5-dihyidroxyphenylglycine, functions downstream of the metabotropic glutamate receptor GRM5/MGLUR5 and phosphorylates GRIN1/NMDAR1 receptor which plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. May be involved in the regulation of hippocampal long-term potentiation (LTP), but may be not necessary for the process of synaptic plasticity. May be involved in desensitization of mu-type opioid receptor-mediated G-protein activation in the spinal cord, and may be critical for the development and/or maintenance ofmorphine-induced reinforcing effects in the limbic forebrain. May modulate the functionality of mu-type-opioid receptors by participating in a signaling pathway which leads to the phosphorylation anddegradation of opioid receptors. May also contributes to chronic morphine-induced changes in nociceptive processing. Plays a role in neuropathic pain mechanisms and contributes to the maintenance of the allodynia pain produced by peripheral inflammation. Plays an important role in initial sensitivity and tolerance to ethanol, by mediating the behavioral effects of ethanol as well as the effects of this drug on the GABA(A) receptors. During and after cerebral ischemia modulate neurotransmission and cell survival in synaptic membranes, and is involved in insulin-induced inhibition of necrosis, an important mechanism for minimizing ischemic injury. Required for the elimination of multiple climbing fibers during innervation of Purkinje cells in developing cerebellum. Is activated in lens epithelial cells upon hydrogen peroxide treatment, and phosphorylates connexin-43 (GJA1/CX43), resulting in disassembly of GJA1 gap junction plaques and inhibition of gap junction activity which could provide a protective effect against oxidative stress. Phosphorylates p53/TP53 and promotes p53/TP53-dependent apoptosis in response to DNA damage. Involved in the phase resetting of the cerebral cortex circadian clock during temporally restricted feeding. Stabilizes the core clock component ARNTL/BMAL1 by interfering with its ubiquitination, thus suppressing its degradation, resultingin phase resetting of the cerebral cortex clock.
T47107	PDBSTRUC	2UZP; 2.00E+73
T47107	BIOCLASS	Kinase
T47107	ECNUMBER	EC 2.7.11.13
T47107	SEQUENCE	MAGLGPGVGDSEGGPRPLFCRKGALRQKVVHEVKSHKFTARFFKQPTFCSHCTDFIWGIGKQGLQCQVCSFVVHRRCHEFVTFECPGAGKGPQTDDPRNKHKFRLHSYSSPTFCDHCGSLLYGLVHQGMKCSCCEMNVHRRCVRSVPSLCGVDHTERRGRLQLEIRAPTADEIHVTVGEARNLIPMDPNGLSDPYVKLKLIPDPRNLTKQKTRTVKATLNPVWNETFVFNLKPGDVERRLSVEVWDWDRTSRNDFMGAMSFGVSELLKAPVDGWYKLLNQEEGEYYNVPVADADNCSLLQKFEACNYPLELYERVRMGPSSSPIPSPSPSPTDPKRCFFGASPGRLHISDFSFLMVLGKGSFGKVMLAERRGSDELYAIKILKKDVIVQDDDVDCTLVEKRVLALGGRGPGGRPHFLTQLHSTFQTPDRLYFVMEYVTGGDLMYHIQQLGKFKEPHAAFYAAEIAIGLFFLHNQGIIYRDLKLDNVMLDAEGHIKITDFGMCKENVFPGTTTRTFCGTPDYIAPEIIAYQPYGKSVDWWSFGVLLYEMLAGQPPFDGEDEEELFQAIMEQTVTYPKSLSREAVAICKGFLTKHPGKRLGSGPDGEPTIRAHGFFRWIDWERLERLEIPPPFRPRPCGRSGENFDKFFTRAAPALTPPDRLVLASIDQADFQGFTYVNPDFVHPDARSPTSPVPVPVM
T47107	DRUGINFO	D07NVU	Midostaurin	Approved
T47107	DRUGINFO	D0X0HN	LY-317644	Terminated
T47107	DRUGINFO	D0R5ZR	RO-320432	Terminated
T47107	DRUGINFO	D0R2TM	BALANOL	Terminated
T47107	DRUGINFO	D08GFG	Monoctanoin component C	Investigative
T47107	DRUGINFO	D04OHM	4-cyclopentyliden(4-hydroxyphenyl)methylphenol	Investigative
T47107	DRUGINFO	D0L1YA	(-)-Cercosporamide	Investigative
T47107	DRUGINFO	D04AXH	8-Octyl-benzolactam-V9	Investigative
T47107	DRUGINFO	D06TLL	Go 6983	Investigative
T47107	DRUGINFO	D00TWA	[2,2':5',2'']Terthiophen-4-yl-methanol	Investigative
T47107	DRUGINFO	D02PUV	4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol	Investigative
T47107	DRUGINFO	D02QME	2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile	Investigative
T47107	DRUGINFO	D05LRV	[2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde	Investigative
T47107	DRUGINFO	D09TSC	Ro-32-0557	Investigative
T47107	DRUGINFO	D09XIE	3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile	Investigative
T47107	DRUGINFO	D0A8MN	3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile	Investigative
T47107	DRUGINFO	D0D3MR	[2,2':5',2'']Terthiophene-4-carbaldehyde	Investigative
T47107	DRUGINFO	D0Q3GQ	4-cycloheptyliden(4-hydroxyphenyl)methylphenol	Investigative
T47107	DRUGINFO	D0S9UK	2,3,3-Triphenyl-acrylonitrile	Investigative
T47107	DRUGINFO	D0T0UH	3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile	Investigative
T47107	DRUGINFO	D0V9SW	4-cyclohexyliden(4-hydroxyphenyl)methylphenol	Investigative
T47107	DRUGINFO	D04JNZ	PROSTRATIN	Investigative
T47107	DRUGINFO	D06ZCX	LY-326449	Investigative
T47107	DRUGINFO	D06AOY	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	Investigative
T47107	DRUGINFO	D00NYT	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	Investigative
T47107	DRUGINFO	D0C3WY	3,4-diphenyl-1H-pyrrole-2,5-dione	Investigative
T47107	DRUGINFO	D0EK0G	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	Investigative
T47107	DRUGINFO	D0TO6S	Bisindolylmaleimide-I	Investigative
T47107	DRUGINFO	D0L8HO	RO-316233	Investigative

T17980	TARGETID	T17980
T17980	FORMERID	TTDS00406
T17980	UNIPROID	FYN_HUMAN
T17980	TARGNAME	Fyn tyrosine protein kinase (FYN)
T17980	GENENAME	FYN
T17980	TARGTYPE	Successful
T17980	SYNONYMS	Tyrosine-protein kinase Fyn; Src-like kinase; SLK; Proto-oncogene tyrosine-protein kinase Fyn; Proto-oncogene c-Fyn; Proto-oncogene Syn; Fyn p59-Fyn; Fyn Protooncogene Syn
T17980	FUNCTION	Inactive FYN is phosphorylated on its C-terminal tail within the catalytic domain. Following activation by PKA, the protein subsequently associates with PTK2/FAK1, allowing PTK2/FAK1 phosphorylation, activation and targeting to focal adhesions. Involved in the regulation of cell adhesion and motility through phosphorylation of CTNNB1 (beta-catenin) and CTNND1 (delta-catenin). Regulates cytoskeletal remodeling by phosphorylating several proteins including the actin regulator WAS and the microtubule-associated proteins MAP2 and MAPT. Promotes cell survival by phosphorylating AGAP2/PIKE-A and preventing its apoptotic cleavage. Participates in signal transduction pathways that regulate the integrity of the glomerular slit diaphragm (an essential part of the glomerular filter of the kidney) by phosphorylating several slit diaphragm components including NPHS1, KIRREL1 and TRPC6. Plays a role in neural processes by phosphorylating DPYSL2, a multifunctional adapter protein within the central nervous system, ARHGAP32, a regulator for Rho family GTPases implicated in various neural functions, and SNCA, a small pre-synaptic protein. Participates in the downstream signaling pathways that lead to T-cell differentiation and proliferation following T-cell receptor (TCR) stimulation. Phosphorylates PTK2B/PYK2 in response to T-cell receptor activation. Also participates in negative feedback regulation of TCR signaling through phosphorylation of PAG1, thereby promoting interaction between PAG1 and CSK and recruitment of CSK to lipid rafts. CSK maintains LCK and FYN in an inactive form. Promotes CD28-induced phosphorylation of VAV1. Non-receptor tyrosine-protein kinase that plays a role in many biological processes including regulation of cell growth and survival, cell adhesion, integrin-mediated signaling, cytoskeletal remodeling, cell motility, immune response and axon guidance.
T17980	PDBSTRUC	6IPZ; 6IPY; 6EDF; 4ZNX; 4U1P
T17980	BIOCLASS	Kinase
T17980	ECNUMBER	EC 2.7.10.2
T17980	SEQUENCE	MGCVQCKDKEATKLTEERDGSLNQSSGYRYGTDPTPQHYPSFGVTSIPNYNNFHAAGGQGLTVFGGVNSSSHTGTLRTRGGTGVTLFVALYDYEARTEDDLSFHKGEKFQILNSSEGDWWEARSLTTGETGYIPSNYVAPVDSIQAEEWYFGKLGRKDAERQLLSFGNPRGTFLIRESETTKGAYSLSIRDWDDMKGDHVKHYKIRKLDNGGYYITTRAQFETLQQLVQHYSERAAGLCCRLVVPCHKGMPRLTDLSVKTKDVWEIPRESLQLIKRLGNGQFGEVWMGTWNGNTKVAIKTLKPGTMSPESFLEEAQIMKKLKHDKLVQLYAVVSEEPIYIVTEYMNKGSLLDFLKDGEGRALKLPNLVDMAAQVAAGMAYIERMNYIHRDLRSANILVGNGLICKIADFGLARLIEDNEYTARQGAKFPIKWTAPEAALYGRFTIKSDVWSFGILLTELVTKGRVPYPGMNNREVLEQVERGYRMPCPQDCPISLHELMIHCWKKDPEERPTFEYLQSFLEDYFTATEPQYQPGENL
T17980	DRUGINFO	D0E6XR	Dasatinib	Approved
T17980	DRUGINFO	D0U3XL	JNJ-26483327	Phase 1
T17980	DRUGINFO	D0OD8N	1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane	Investigative
T17980	DRUGINFO	D07IHM	CEP-6331	Investigative
T17980	DRUGINFO	D0YZ7H	JNJ-10198409	Investigative
T17980	DRUGINFO	D08RZB	PMID15546730C2	Investigative
T17980	DRUGINFO	D09QBA	CEP-5104	Investigative
T17980	DRUGINFO	D09XIL	Ro-4396686	Investigative

T27602	TARGETID	T27602
T27602	FORMERID	TTDS00282
T27602	UNIPROID	TRY1_HUMAN
T27602	TARGNAME	Cationic trypsinogen (PRSS1)
T27602	GENENAME	PRSS1
T27602	TARGTYPE	Successful
T27602	SYNONYMS	Trypsin-1; Trypsin I; TRYP1; TRY1; TRP1; Serine protease 1; Beta-trypsin
T27602	FUNCTION	Has activity against the synthetic substrates Boc-Phe-Ser-Arg-Mec, Boc-Leu-Thr-Arg-Mec, Boc-Gln-Ala-Arg-Mec and Boc-Val-Pro-Arg-Mec. The single-chain form is more active than the two-chain form against all of these substrates.
T27602	PDBSTRUC	4WXV; 4WWY; 2RA3; 1TRN; 1FXY
T27602	BIOCLASS	Peptidase
T27602	ECNUMBER	EC 3.4.21.4
T27602	SEQUENCE	MNPLLILTFVAAALAAPFDDDDKIVGGYNCEENSVPYQVSLNSGYHFCGGSLINEQWVVSAGHCYKSRIQVRLGEHNIEVLEGNEQFINAAKIIRHPQYDRKTLNNDIMLIKLSSRAVINARVSTISLPTAPPATGTKCLISGWGNTASSGADYPDELQCLDAPVLSQAKCEASYPGKITSNMFCVGFLEGGKDSCQGDSGGPVVCNGQLQGVVSWGDGCAQKNKPGVYTKVYNYVKWIKNTIAANS
T27602	DRUGINFO	D0SH3I	Bortezomib	Approved
T27602	DRUGINFO	D0DF1R	Ulinastatin	Phase 3
T27602	DRUGINFO	D01MUU	MELAGATRAN	Phase 3
T27602	DRUGINFO	D04TEF	Alpha-1 antitrypsin	Phase 2
T27602	DRUGINFO	D0B9EH	Dermolastin	Discontinued in Phase 2
T27602	DRUGINFO	D05QMJ	RWJ-56423	Discontinued in Phase 1
T27602	DRUGINFO	D0CV7T	Patamostat	Terminated
T27602	DRUGINFO	D0GR2H	BMY-44621	Terminated
T27602	DRUGINFO	D00POF	6-Styryl-naphthalene-2-carboxamidine	Investigative
T27602	DRUGINFO	D03ZUM	Tert-butyloxy carbonyl-D-Phe-pro-Arg-H	Investigative
T27602	DRUGINFO	D05ICF	1,3-Di-p-tolyl-[1,3]diazetidine-2,4-dione	Investigative
T27602	DRUGINFO	D08OCL	4-(5-Nitro-indol-1-ylmethyl)-benzamidine	Investigative
T27602	DRUGINFO	D08SKX	recAAT, PPL Therapeutics/Bayer	Investigative
T27602	DRUGINFO	D09TNA	1-(3-Amino-benzyl)-1H-indole-5-carboxamidine	Investigative
T27602	DRUGINFO	D0C1TS	CVS-2359	Investigative
T27602	DRUGINFO	D0EH1F	1-(3-Nitro-benzyl)-1H-indole-5-carboxamidine	Investigative
T27602	DRUGINFO	D0J2SM	2-(2-Iodo-phenyl)-benzo[d][1,3]oxazin-4-one	Investigative
T27602	DRUGINFO	D0K0GU	8-Furan-3-yl-6-styryl-naphthalene-2-carboxamidine	Investigative
T27602	DRUGINFO	D0M1LO	Piperidine-1-carboxamidine	Investigative
T27602	DRUGINFO	D0M2PE	1-Benzyl-1H-indole-5-carboxamidine	Investigative
T27602	DRUGINFO	D0N1PW	4-Indol-1-ylmethyl-benzamidine	Investigative
T27602	DRUGINFO	D0O0GT	CVS-2139	Investigative
T27602	DRUGINFO	D0S4MQ	8-Bromo-6-styryl-naphthalene-2-carboxamidine	Investigative
T27602	DRUGINFO	D0Z7YI	2-Propionyl-1H-indole-6-carboxamidine	Investigative
T27602	DRUGINFO	D02NHS	L-375378	Investigative
T27602	DRUGINFO	D05ABK	ATF-HI-8	Investigative
T27602	DRUGINFO	D07IBU	GR-133686	Investigative
T27602	DRUGINFO	D09OBJ	RWJ-50353	Investigative
T27602	DRUGINFO	D0F2YC	1,3-Dibenzyl-[1,3]diazetidine-2,4-dione	Investigative
T27602	DRUGINFO	D0F9YV	PMID3514912C9	Investigative
T27602	DRUGINFO	D0RQ2T	Macrocyclic tripeptide motif	Investigative
T27602	DRUGINFO	D08SMN	POP-1	Investigative
T27602	DRUGINFO	D0CT8A	4-(3,4-Diethoxy-benzylamino)-benzamidine	Investigative
T27602	DRUGINFO	D0JR9V	JBP-1	Investigative
T27602	DRUGINFO	D02XPB	4-(4-Benzyloxy-3-methoxy-benzylamino)-benzamidine	Investigative
T27602	DRUGINFO	D07SFI	Benzamidine	Investigative
T27602	DRUGINFO	D08OLP	2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine	Investigative
T27602	DRUGINFO	D0Y5IQ	Grassystatin a	Investigative

T18477	TARGETID	T18477
T18477	FORMERID	TTDC00018
T18477	UNIPROID	HS90A_HUMAN
T18477	TARGNAME	Heat shock protein 90 alpha (HSP90A)
T18477	GENENAME	HSP90AA1
T18477	TARGTYPE	Successful
T18477	SYNONYMS	Renal carcinoma antigen NY-REN-38; Lipopolysaccharide-associated protein 2; LPS-associated protein 2; LAP-2; Heat shock protein HSP 90-alpha; Heat shock 86 kDa; HSPCA; HSPC1; HSP90A; HSP86; HSP 86
T18477	FUNCTION	Undergoes a functional cycle that is linked to its ATPase activity which is essential for its chaperone activity. This cycle probably induces conformational changes in the client proteins, thereby causing their activation. Interacts dynamically with various co-chaperones that modulate its substrate recognition, ATPase cycle and chaperone function. Engages with a range of client protein classes via its interaction with various co-chaperone proteins or complexes, that act as adapters, simultaneously able to interact with the specific client and the central chaperone itself. Recruitment of ATP and co-chaperone followed by client protein forms a functional chaperone. After the completion of the chaperoning process, properly folded client protein and co-chaperone leave HSP90 in an ADP-bound partially open conformation and finally, ADP is released from HSP90 which acquires an open conformation for the next cycle. Apart from its chaperone activity, it also plays a role in the regulation of the transcription machinery. HSP90 and its co-chaperones modulate transcription at least at three different levels. In the first place, they alter the steady-state levels of certain transcription factors in response to various physiological cues(). Second, they modulate the activity of certain epigenetic modifiers, such as histone deacetylases or DNA methyl transferases, and thereby respond to the change in the environment. Third, they participate in the eviction of histones from the promoter region of certain genes and thereby turn on gene expression. Binds bacterial lipopolysaccharide (LPS) and mediates LPS-induced inflammatory response, including TNF secretion by monocytes. Antagonizes STUB1-mediated inhibition of TGF-beta signaling via inhibition of STUB1-mediated SMAD3 ubiquitination and degradation. Molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved for instance in cell cycle control and signal transduction.
T18477	PDBSTRUC	6GR5; 6GR4; 6GR3; 6GR1; 6GQU
T18477	BIOCLASS	Heat shock protein
T18477	SEQUENCE	MPEETQTQDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAEEKEDKEEEKEKEEKESEDKPEIEDVGSDEEEEKKDGDKKKKKKIKEKYIDQEELNKTKPIWTRNPDDITNEEYGEFYKSLTNDWEDHLAVKHFSVEGQLEFRALLFVPRRAPFDLFENRKKKNNIKLYVRRVFIMDNCEELIPEYLNFIRGVVDSEDLPLNISREMLQQSKILKVIRKNLVKKCLELFTELAEDKENYKKFYEQFSKNIKLGIHEDSQNRKKLSELLRYYTSASGDEMVSLKDYCTRMKENQKHIYYITGETKDQVANSAFVERLRKHGLEVIYMIEPIDEYCVQQLKEFEGKTLVSVTKEGLELPEDEEEKKKQEEKKTKFENLCKIMKDILEKKVEKVVVSNRLVTSPCCIVTSTYGWTANMERIMKAQALRDNSTMGYMAAKKHLEINPDHSIIETLRQKAEADKNDKSVKDLVILLYETALLSSGFSLEDPQTHANRIYRMIKLGLGIDEDDPTADDTSAAVTEEMPPLEGDDDTSRMEEVD
T18477	DRUGINFO	D06NSS	Cromoglicate	Approved
T18477	DRUGINFO	D0G5UB	Amlexanox	Approved
T18477	DRUGINFO	D05BYA	NVP-AUY922	Phase 2
T18477	DRUGINFO	D05HWN	BIIB-021	Phase 2
T18477	DRUGINFO	D08PYO	KW-2478	Phase 2
T18477	DRUGINFO	D09XGB	VER 50589	Phase 2
T18477	DRUGINFO	D0SC2J	Tanespimycin	Phase 2
T18477	DRUGINFO	D0Y9PZ	Efungumab	Phase 2
T18477	DRUGINFO	D07MPL	SNX-5422	Phase 1/2
T18477	DRUGINFO	D02PGP	PU3	Phase 1
T18477	DRUGINFO	D02TTL	Debio 0932	Phase 1
T18477	DRUGINFO	D03LRU	Alvespimycin hydrochloride	Phase 1
T18477	DRUGINFO	D06YSP	AT13387	Phase 1
T18477	DRUGINFO	D0H3VK	BIIB 028	Phase 1
T18477	DRUGINFO	D0ME2T	RTA-901	Phase 1
T18477	DRUGINFO	D0V9MT	PU-AD	Phase 1
T18477	DRUGINFO	D03IKZ	HBP-347	Discontinued in Phase 3
T18477	DRUGINFO	D03PKI	Geldanamycin	Discontinued in Phase 2
T18477	DRUGINFO	D0BM6S	IPI-493	Discontinued in Phase 1
T18477	DRUGINFO	D00OCB	CCT-018159	Preclinical
T18477	DRUGINFO	D0X5YU	KOS-2484	Preclinical
T18477	DRUGINFO	D0KC7K	EC-154	Terminated
T18477	DRUGINFO	D00PMS	8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-	Investigative
T18477	DRUGINFO	D01GGU	9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine	Investigative
T18477	DRUGINFO	D02IIL	KOSN1559	Investigative
T18477	DRUGINFO	D05GKC	ZEARALANONE	Investigative
T18477	DRUGINFO	D05RTH	17-desmethoxy-17-aminogeldanamycin	Investigative
T18477	DRUGINFO	D05UTX	9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine	Investigative
T18477	DRUGINFO	D07WDQ	GNF-PF-67	Investigative
T18477	DRUGINFO	D08CZD	4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine	Investigative
T18477	DRUGINFO	D0D3BP	6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE	Investigative
T18477	DRUGINFO	D0D5KQ	PU24S	Investigative
T18477	DRUGINFO	D0H0KA	Macbecin	Investigative
T18477	DRUGINFO	D0K0TJ	SNX-2112	Investigative
T18477	DRUGINFO	D0K4RN	2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol	Investigative
T18477	DRUGINFO	D0M2TY	RHEIN	Investigative
T18477	DRUGINFO	D0T4MS	VER-49009	Investigative
T18477	DRUGINFO	D0ZA6G	Radicicol	Investigative
T18477	DRUGINFO	D0H6OS	Geldanamycin-estradiol hybrid	Investigative
T18477	DRUGINFO	D06GOK	2-Methyl-2,4-Pentanediol	Investigative

T48069	TARGETID	T48069
T48069	FORMERID	TTDS00269
T48069	UNIPROID	IGF1R_HUMAN
T48069	TARGNAME	Insulin-like growth factor I receptor (IGF1R)
T48069	GENENAME	IGF1R
T48069	TARGTYPE	Successful
T48069	SYNONYMS	Type 1 insulin-like growth factor receptor; Insulin-like growth factor 1 receptor; IGF-IR; IGF-I receptor; IGF-1R; IGF-1 receptor; CD221 antigen; CD221
T48069	FUNCTION	Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R. Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1).
T48069	PDBSTRUC	5U8R; 5U8Q; 5HZN; 5FXS; 5FXR
T48069	BIOCLASS	Kinase
T48069	ECNUMBER	EC 2.7.10.1
T48069	SEQUENCE	MKSGSGGGSPTSLWGLLFLSAALSLWPTSGEICGPGIDIRNDYQQLKRLENCTVIEGYLHILLISKAEDYRSYRFPKLTVITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIFEMTNLKDIGLYNLRNITRGAIRIEKNADLCYLSTVDWSLILDAVSNNYIVGNKPPKECGDLCPGTMEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSTCGKRACTENNECCHPECLGSCSAPDNDTACVACRHYYYAGVCVPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHDGECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEEKKTKTIDSVTSAQMLQGCTIFKGNLLINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSFYVLDNQNLQQLWDWDHRNLTIKAGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTRNNGERASCESDVLHFTSTTTSKNRIIITWHRYRPPDYRDLISFTVYYKEAPFKNVTEYDGQDACGSNSWNMVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAVTLTMVENDHIRGAKSEILYIRTNASVPSIPLDVLSASNSSSQLIVKWNPPSLPNGNLSYYIVRWQRQPQDGYLYRHNYCSKDKIPIRKYADGTIDIEEVTENPKTEVCGGEKGPCCACPKTEAEKQAEKEEAEYRKVFENFLHNSIFVPRPERKRRDVMQVANTTMSSRSRNTTAADTYNITDPEELETEYPFFESRVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEGADDIPGPVTWEPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECVSRQEYRKYGGAKLNRLNPGNYTARIQATSLSGNGSWTDPVFFYVQAKTGYENFIHLIIALPVAVLLIVGGLVIMLYVFHRKRNNSRLGNGVLYASVNPEYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKGVVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIMELMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARNCMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGVVLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFLEIISSIKEEMEPGFREVSFYYSEENKLPEPEELDLEPENMESVPLDPSASSSSLPLPDRHSGHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALPLPQSSTC
T48069	DRUGINFO	D0EN0W	Teprotumumab	Approved
T48069	DRUGINFO	D0F3JT	Mecasermin	Approved
T48069	DRUGINFO	D0N3NZ	Somatomedin-1	Approved
T48069	DRUGINFO	D01GFX	OSI-906	Phase 3
T48069	DRUGINFO	D06APK	Rinfabate	Phase 2/3
T48069	DRUGINFO	D00AKR	AMG 479	Phase 2
T48069	DRUGINFO	D00VKK	VPI-2690B	Phase 2
T48069	DRUGINFO	D01SJS	AXL-1717	Phase 2
T48069	DRUGINFO	D03BHM	R1507	Phase 2
T48069	DRUGINFO	D0E5DP	Cixutumumab	Phase 2
T48069	DRUGINFO	D0T5JS	TT-100	Phase 2
T48069	DRUGINFO	D00BUO	MM-141	Phase 2
T48069	DRUGINFO	D01OYS	Cyclolignan picropodophyllin	Phase 1
T48069	DRUGINFO	D03WNN	RG-7010	Phase 1
T48069	DRUGINFO	D0L1ZM	HF-0299	Phase 1
T48069	DRUGINFO	D0O7QQ	BIIB 022	Phase 1
T48069	DRUGINFO	D4JYH3	FPI-1434	Phase 1
T48069	DRUGINFO	D07HPJ	AEW-541	Phase 1
T48069	DRUGINFO	D10KTZ	SAR446159	Phase 1
T48069	DRUGINFO	D00BPE	AVE-1642	Discontinued in Phase 2
T48069	DRUGINFO	D0M3OR	KW-2450	Discontinued in Phase 1/2
T48069	DRUGINFO	D0U6KH	Figitumumab	Discontinued in Phase 1
T48069	DRUGINFO	D0LF0O	BMS-695735	Preclinical
T48069	DRUGINFO	D0TI4U	EGFR/IGFR tandem adnectin	Preclinical
T48069	DRUGINFO	D06NMZ	NVP-ADW742	Investigative
T48069	DRUGINFO	D0O0RY	JB-1	Investigative
T48069	DRUGINFO	D0L7MM	4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol	Investigative
T48069	DRUGINFO	D0W9KO	4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol	Investigative
T48069	DRUGINFO	D00ICA	AMP-PNP	Investigative
T48069	DRUGINFO	D0M4SY	BMS-536924	Investigative
T48069	DRUGINFO	D0G6XS	Fucose	Investigative
T48069	DRUGINFO	D07LUR	Alpha-D-Mannose	Investigative

T40474	TARGETID	T40474
T40474	FORMERID	TTDC00110
T40474	UNIPROID	MET_HUMAN
T40474	TARGNAME	Proto-oncogene c-Met (MET)
T40474	GENENAME	MET
T40474	TARGTYPE	Successful
T40474	SYNONYMS	Tyrosine-protein kinase Met; Scatter factor receptor; SF receptor; Met proto-oncogene tyrosine kinase; Hepatocyte growth factor receptor; HGF/SF receptor; HGF-SF receptor; HGF receptor; C-met; C-Met receptor tyrosine kinase
T40474	FUNCTION	Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells. May regulate cortical bone osteogenesis. Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand.
T40474	PDBSTRUC	6I04; 6GCU; 5YA5; 5UAF; 5UAD
T40474	BIOCLASS	Kinase
T40474	ECNUMBER	EC 2.7.10.1
T40474	SEQUENCE	MKAPAVLAPGILVLLFTLVQRSNGECKEALAKSEMNVNMKYQLPNFTAETPIQNVILHEHHIFLGATNYIYVLNEEDLQKVAEYKTGPVLEHPDCFPCQDCSSKANLSGGVWKDNINMALVVDTYYDDQLISCGSVNRGTCQRHVFPHNHTADIQSEVHCIFSPQIEEPSQCPDCVVSALGAKVLSSVKDRFINFFVGNTINSSYFPDHPLHSISVRRLKETKDGFMFLTDQSYIDVLPEFRDSYPIKYVHAFESNNFIYFLTVQRETLDAQTFHTRIIRFCSINSGLHSYMEMPLECILTEKRKKRSTKKEVFNILQAAYVSKPGAQLARQIGASLNDDILFGVFAQSKPDSAEPMDRSAMCAFPIKYVNDFFNKIVNKNNVRCLQHFYGPNHEHCFNRTLLRNSSGCEARRDEYRTEFTTALQRVDLFMGQFSEVLLTSISTFIKGDLTIANLGTSEGRFMQVVVSRSGPSTPHVNFLLDSHPVSPEVIVEHTLNQNGYTLVITGKKITKIPLNGLGCRHFQSCSQCLSAPPFVQCGWCHDKCVRSEECLSGTWTQQICLPAIYKVFPNSAPLEGGTRLTICGWDFGFRRNNKFDLKKTRVLLGNESCTLTLSESTMNTLKCTVGPAMNKHFNMSIIISNGHGTTQYSTFSYVDPVITSISPKYGPMAGGTLLTLTGNYLNSGNSRHISIGGKTCTLKSVSNSILECYTPAQTISTEFAVKLKIDLANRETSIFSYREDPIVYEIHPTKSFISGGSTITGVGKNLNSVSVPRMVINVHEAGRNFTVACQHRSNSEIICCTTPSLQQLNLQLPLKTKAFFMLDGILSKYFDLIYVHNPVFKPFEKPVMISMGNENVLEIKGNDIDPEAVKGEVLKVGNKSCENIHLHSEAVLCTVPNDLLKLNSELNIEWKQAISSTVLGKVIVQPDQNFTGLIAGVVSISTALLLLLGFFLWLKKRKQIKDLGSELVRYDARVHTPHLDRLVSARSVSPTTEMVSNESVDYRATFPEDQFPNSSQNGSCRQVQYPLTDMSPILTSGDSDISSPLLQNTVHIDLSALNPELVQAVQHVVIGPSSLIVHFNEVIGRGHFGCVYHGTLLDNDGKKIHCAVKSLNRITDIGEVSQFLTEGIIMKDFSHPNVLSLLGICLRSEGSPLVVLPYMKHGDLRNFIRNETHNPTVKDLIGFGLQVAKGMKYLASKKFVHRDLAARNCMLDEKFTVKVADFGLARDMYDKEYYSVHNKTGAKLPVKWMALESLQTQKFTTKSDVWSFGVLLWELMTRGAPPYPDVNTFDITVYLLQGRRLLQPEYCPDPLYEVMLKCWHPKAEMRPSFSELVSRISAIFSTFIGEHYVHVNATYVNVKCVAPYPSLLSSEDNADDEVDTRPASFWETS
T40474	DRUGINFO	D07OJZ	Capmatinib	Approved
T40474	DRUGINFO	D0R8QG	Tepotinib	Approved
T40474	DRUGINFO	D0IQ6P	Cabozantinib	Approved
T40474	DRUGINFO	DQ5X1Z	Amivantamab	Approved
T40474	DRUGINFO	D03ZBT	Crizotinib	Approved
T40474	DRUGINFO	D0H9PT	RG3638	Phase 3
T40474	DRUGINFO	D0LW0T	Savolitinib	Phase 3
T40474	DRUGINFO	D0N1YF	Beperminogene perplasmid	Phase 3
T40474	DRUGINFO	D0ZI1F	Tivantinib	Phase 3
T40474	DRUGINFO	D05BLN	MGCD516	Phase 2/3
T40474	DRUGINFO	D05BLN	MGCD516	Phase 2/3
T40474	DRUGINFO	D03SXS	LY-2875358	Phase 2
T40474	DRUGINFO	D07ARN	SAR-125844	Phase 2
T40474	DRUGINFO	D0FE7D	Emibetuzumab	Phase 2
T40474	DRUGINFO	D0G0BL	AMG 337	Phase 2
T40474	DRUGINFO	D0OK2N	AMG 208	Phase 2
T40474	DRUGINFO	D0R0YW	HM-5016504	Phase 2
T40474	DRUGINFO	D42TUS	Telisotuzumab vedotin	Phase 2
T40474	DRUGINFO	DV3Y7F	APL-101	Phase 2
T40474	DRUGINFO	D01TBJ	CMX-2043	Phase 2
T40474	DRUGINFO	D06EGV	LY2801653	Phase 2
T40474	DRUGINFO	D0D1GF	XL880	Phase 2
T40474	DRUGINFO	D09ZNL	ChronSeal	Phase 1/2
T40474	DRUGINFO	D0A3OE	Anti-C-met CAR-T cells	Phase 1/2
T40474	DRUGINFO	D0O6WV	BMS-777607	Phase 1/2
T40474	DRUGINFO	D0B4OK	Sym015	Phase 1/2
T40474	DRUGINFO	D00DRL	MK-2461	Phase 1/2
T40474	DRUGINFO	D01FSX	REGN5093	Phase 1
T40474	DRUGINFO	D01LCC	PF-4217903	Phase 1
T40474	DRUGINFO	D02EOR	ABBV-399	Phase 1
T40474	DRUGINFO	D04XUJ	CBT-101	Phase 1
T40474	DRUGINFO	D05OMT	MK-8033	Phase 1
T40474	DRUGINFO	D0D1HI	Autologous T Cells Expressing MET scFv CAR	Phase 1
T40474	DRUGINFO	D0I2IY	ABT-700	Phase 1
T40474	DRUGINFO	D0N6VK	Hepapoietin	Phase 1
T40474	DRUGINFO	D0Y8UV	EMD-1204831	Phase 1
T40474	DRUGINFO	D0YT8P	JNJ-38877605	Phase 1
T40474	DRUGINFO	D0ZU5F	SGX523	Phase 1
T40474	DRUGINFO	DU6H8Z	TR1801-ADC	Phase 1
T40474	DRUGINFO	D01IJM	LY3164530	Phase 1
T40474	DRUGINFO	D03GTO	C-Met/PD-L1 CAR-T Cell	Phase 1
T40474	DRUGINFO	D09ETH	E-7050	Phase 1
T40474	DRUGINFO	D1TNJ2	XL092	Phase 1
T40474	DRUGINFO	D95YSW	BPI-9016 M	Phase 1
T40474	DRUGINFO	DN47VK	AZD9592	Phase 1
T40474	DRUGINFO	D7M8LI	TPX-0022	Phase 1
T40474	DRUGINFO	D7HZ3T	RXDX-106	Phase 1
T40474	DRUGINFO	D0FA6S	Altiratinib	Phase 1
T40474	DRUGINFO	D0NO6E	Mteron-F1	Preclinical
T40474	DRUGINFO	D1AD6L	NPS-1034	Preclinical
T40474	DRUGINFO	D00FZA	ALD-805	Investigative
T40474	DRUGINFO	D00TBD	PHA-665752	Investigative
T40474	DRUGINFO	D03LZK	APS-3010	Investigative
T40474	DRUGINFO	D05GSI	LA-480	Investigative
T40474	DRUGINFO	D07CFW	Anti-cMET mab	Investigative
T40474	DRUGINFO	D07OXC	AM7	Investigative
T40474	DRUGINFO	D0AD6Z	mab 224G11	Investigative
T40474	DRUGINFO	D0BS6B	TP-801	Investigative
T40474	DRUGINFO	D0E1QI	SU11274	Investigative
T40474	DRUGINFO	D0G3ZN	PF-00614435	Investigative
T40474	DRUGINFO	D0I2PS	CMET Avimer polypeptides	Investigative
T40474	DRUGINFO	D0M0SV	PRS-110	Investigative
T40474	DRUGINFO	D0N5XG	1-benzyl-1H-pyrrolo[3,2-b]pyridine	Investigative
T40474	DRUGINFO	D0N6QO	RP-1040	Investigative
T40474	DRUGINFO	D0NX6F	BAY-85-3474	Investigative
T40474	DRUGINFO	D0PS7U	GE-137	Investigative
T40474	DRUGINFO	D0S0GT	3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine	Investigative
T40474	DRUGINFO	D0S1II	1-(2-nitrophenethyl)-1H-pyrrolo[3,2-b]pyridine	Investigative
T40474	DRUGINFO	D0T1YH	ALD-806	Investigative
T40474	DRUGINFO	D0U4JW	1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine	Investigative
T40474	DRUGINFO	D0W8GP	DP-3590	Investigative
T40474	DRUGINFO	D0Z4RX	HuMax-cMet	Investigative
T40474	DRUGINFO	D0AM9O	YH013	Investigative
T40474	DRUGINFO	D04CUA	PMID24210504C1o	Investigative
T40474	DRUGINFO	D0RO9R	PMID21123062C27	Investigative
T40474	DRUGINFO	D00EMH	PMID21967808CR-16	Investigative
T40474	DRUGINFO	D0M4SY	BMS-536924	Investigative

T43332	TARGETID	T43332
T43332	FORMERID	TTDR00947
T43332	UNIPROID	FA7_HUMAN
T43332	TARGNAME	Coagulation factor VII (F7)
T43332	GENENAME	F7
T43332	TARGTYPE	Successful
T43332	SYNONYMS	Serum prothrombin conversion accelerator; SPCA; Proconvertin; Eptacog alfa
T43332	FUNCTION	Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. In the presence of tissue factor and calcium ions, factor VIIa then converts factor X to factor Xa by limited proteolysis. Factor VIIa will also convert factor IX to factor IXa in the presence of tissue factor and calcium.
T43332	PDBSTRUC	5U6J; 5TQG; 5TQF; 5TQE; 5PB6
T43332	BIOCLASS	Peptidase
T43332	ECNUMBER	EC 3.4.21.21
T43332	SEQUENCE	MVSQALRLLCLLLGLQGCLAAGGVAKASGGETRDMPWKPGPHRVFVTQEEAHGVLHRRRRANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQCASSPCQNGGSCKDQLQSYICFCLPAFEGRNCETHKDDQLICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGRIVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP
T43332	DRUGINFO	D0C9IW	Factor viia	Approved
T43332	DRUGINFO	D00VMA	Vatreptacog alfa (activated)	Phase 3
T43332	DRUGINFO	D09SHH	BAX-817	Phase 3
T43332	DRUGINFO	D0C0CE	Activated recombinant FVII-albumin fusion protein	Phase 2/3
T43332	DRUGINFO	D0HZ2A	Recombinant factor VIIa PEGylated liposomal	Phase 1/2
T43332	DRUGINFO	D00EYC	F-7TG	Phase 1
T43332	DRUGINFO	D05GPB	Eptacog alfa	Phase 1
T43332	DRUGINFO	D0R4YQ	CB-813	Phase 1
T43332	DRUGINFO	D0J3YX	BAY 86-6150	Discontinued in Phase 2/3
T43332	DRUGINFO	D0K3LX	RNAPc2	Discontinued in Phase 2
T43332	DRUGINFO	D01NCC	Factor-VIIa-XTEN	Investigative
T43332	DRUGINFO	D02PKV	Human recombinant factor VIIa	Investigative
T43332	DRUGINFO	D0O9RV	MOD-5023	Investigative
T43332	DRUGINFO	D0R9UQ	Long-acting Factor VII conjugate	Investigative
T43332	DRUGINFO	D0CT8A	4-(3,4-Diethoxy-benzylamino)-benzamidine	Investigative
T43332	DRUGINFO	D02XPB	4-(4-Benzyloxy-3-methoxy-benzylamino)-benzamidine	Investigative
T43332	DRUGINFO	D0G6XS	Fucose	Investigative

T33489	TARGETID	T33489
T33489	FORMERID	TTDC00149
T33489	UNIPROID	STS_HUMAN
T33489	TARGNAME	Steryl-sulfatase (STS)
T33489	GENENAME	STS
T33489	TARGTYPE	Successful
T33489	SYNONYMS	Steryl-sulfate sulfohydrolase; Steroid sulfatase; STS; Estrone sulfatase; Arylsulfatase C; ASC
T33489	FUNCTION	Conversion of sulfated steroid precursors to estrogens during pregnancy.
T33489	PDBSTRUC	1P49
T33489	BIOCLASS	Sulfuric ester hydrolase
T33489	ECNUMBER	EC 3.1.6.2
T33489	SEQUENCE	MPLRKMKIPFLLLFFLWEAESHAASRPNIILVMADDLGIGDPGCYGNKTIRTPNIDRLASGGVKLTQHLAASPLCTPSRAAFMTGRYPVRSGMASWSRTGVFLFTASSGGLPTDEITFAKLLKDQGYSTALIGKWHLGMSCHSKTDFCHHPLHHGFNYFYGISLTNLRDCKPGEGSVFTTGFKRLVFLPLQIVGVTLLTLAALNCLGLLHVPLGVFFSLLFLAALILTLFLGFLHYFRPLNCFMMRNYEIIQQPMSYDNLTQRLTVEAAQFIQRNTETPFLLVLSYLHVHTALFSSKDFAGKSQHGVYGDAVEEMDWSVGQILNLLDELRLANDTLIYFTSDQGAHVEEVSSKGEIHGGSNGIYKGGKANNWEGGIRVPGILRWPRVIQAGQKIDEPTSNMDIFPTVAKLAGAPLPEDRIIDGRDLMPLLEGKSQRSDHEFLFHYCNAYLNAVRWHPQNSTSIWKAFFFTPNFNPVGSNGCFATHVCFCFGSYVTHHDPPLLFDISKDPRERNPLTPASEPRFYEILKVMQEAADRHTQTLPEVPDQFSWNNFLWKPWLQLCCPSTGLSCQCDREKQDKRLSR
T33489	DRUGINFO	D0E6OC	Tranilast	Approved
T33489	DRUGINFO	D04ZND	PGL-2001	Phase 2
T33489	DRUGINFO	D0I3RN	PGL-2	Phase 2
T33489	DRUGINFO	D07ZNI	STX-140	Phase 2
T33489	DRUGINFO	D0Y6OA	Coumate	Phase 2
T33489	DRUGINFO	D05NJI	STX 64	Phase 1
T33489	DRUGINFO	D00AON	Sulfamic acid 2-nonyl-4-oxo-4H-chromen-6-yl ester	Investigative
T33489	DRUGINFO	D00LFX	Estradiol 17-O-sulfamate	Investigative
T33489	DRUGINFO	D00OZS	4-Sulfamoyloxy-benzoic acid pentyl ester	Investigative
T33489	DRUGINFO	D01ACT	4-Sulfamoyloxy-benzoic acid propyl ester	Investigative
T33489	DRUGINFO	D02RJA	Sulfamic acid 3-(3-methoxy-benzoyl)-phenyl ester	Investigative
T33489	DRUGINFO	D03NUT	4-Sulfamoyloxy-benzoic acid octyl ester	Investigative
T33489	DRUGINFO	D03XJE	2-Adamantan-2-ylidenemethyl-benzooxazol-6-ol	Investigative
T33489	DRUGINFO	D04HNO	3-{3-[(aminosulfonyl)oxy]benzoyl}phenyl sulfamate	Investigative
T33489	DRUGINFO	D04YVS	3-{4-[(aminosulfonyl)oxy]benzoyl}phenyl sulfamate	Investigative
T33489	DRUGINFO	D05KKB	Sulfamic acid 3-(4-methoxy-benzoyl)-phenyl ester	Investigative
T33489	DRUGINFO	D05TRN	4-Sulfamoyloxy-benzoic acid cycloheptyl ester	Investigative
T33489	DRUGINFO	D06ADL	Sulfamic acid 4-(3-methoxy-benzoyl)-phenyl ester	Investigative
T33489	DRUGINFO	D06DVJ	Sulfamic acid 3-(3-hydroxy-benzoyl)-phenyl ester	Investigative
T33489	DRUGINFO	D06IMK	3-(4-cyclohexylthiosemicarbazono)methyl-phenol	Investigative
T33489	DRUGINFO	D06SMY	4-Sulfamoyloxy-benzoic acid nonyl ester	Investigative
T33489	DRUGINFO	D06YDQ	4-Sulfamoyloxy-benzoic acid heptyl ester	Investigative
T33489	DRUGINFO	D07GRM	2-Amino-3-Oxo-4-Sulfo-Butyric Acid	Investigative
T33489	DRUGINFO	D08BTV	2-(4-cyclohexylthiosemicarbazono)methyl-phenol	Investigative
T33489	DRUGINFO	D09BUM	4-(4-cyclohexylthiosemicarbazono)methyl-phenol	Investigative
T33489	DRUGINFO	D09ROV	Nortropinyl-arylsulfonylurea 3	Investigative
T33489	DRUGINFO	D0AL2D	4-{4-[(aminosulfonyl)oxy]benzoyl}phenyl sulfamate	Investigative
T33489	DRUGINFO	D0B1JM	Sulfamic acid 4-(2-methoxy-benzoyl)-phenyl ester	Investigative
T33489	DRUGINFO	D0B2XN	Sulfamic acid 4-benzoyl-phenyl ester	Investigative
T33489	DRUGINFO	D0D1CV	4-Sulfamoyloxy-benzoic acid hexyl ester	Investigative
T33489	DRUGINFO	D0FH1V	2-methylsulfanylestradiol 3,17-O,O-bis-sulfamate	Investigative
T33489	DRUGINFO	D0G1XC	MHL cyclohexylthiosemicarbazone	Investigative
T33489	DRUGINFO	D0G8HD	Sulfamic acid 3-benzoyl-phenyl ester	Investigative
T33489	DRUGINFO	D0I4LL	2',4'-dicyanobiphenyl-4-yl sulfamate	Investigative
T33489	DRUGINFO	D0M2WG	Sulfamic acid 4-(2-hydroxy-benzoyl)-phenyl ester	Investigative
T33489	DRUGINFO	D0N8VZ	2-ethylestradiol 3,17-O,O-bis-sulfamate	Investigative
T33489	DRUGINFO	D0P6IO	4-Sulfamoyloxy-benzoic acid butyl ester	Investigative
T33489	DRUGINFO	D0P9ZV	4-Sulfamoyloxy-benzoic acid cyclohexyl ester	Investigative
T33489	DRUGINFO	D0S3RZ	Estradiol 3,17-O,O-bis-sulfamate	Investigative
T33489	DRUGINFO	D0S5BA	Sulfamic acid 3-(4-hydroxy-benzoyl)-phenyl ester	Investigative
T33489	DRUGINFO	D0T5OD	4-Sulfamoyloxy-benzoic acid cyclooctyl ester	Investigative
T33489	DRUGINFO	D0U7PV	4-Sulfamoyloxy-benzoic acid cyclopentyl ester	Investigative
T33489	DRUGINFO	D0W6GB	Benzomate	Investigative
T33489	DRUGINFO	D0Y9SI	3-(4-hexylthiosemicarbazono)methyl-benzoic acid	Investigative
T33489	DRUGINFO	D0R7QY	EMATE	Investigative
T33489	DRUGINFO	D02UVH	B-Octylglucoside	Investigative

T69128	TARGETID	T69128
T69128	FORMERID	TTDNS00597
T69128	UNIPROID	ROS1_HUMAN
T69128	TARGNAME	Proto-oncogene c-Ros (ROS1)
T69128	GENENAME	ROS1
T69128	TARGTYPE	Successful
T69128	SYNONYMS	c-Ros receptor tyrosine kinase; Receptor tyrosine kinase c-ros oncogene 1; ROS; Proto-oncogene tyrosine-protein kinase ROS; Proto-oncogene c-Ros-1; MCF3
T69128	FUNCTION	Orphan receptor tyrosine kinase (RTK) that plays a role in epithelial cell differentiation and regionalization of the proximal epididymal epithelium. May activate several downstream signaling pathways related to cell differentiation, proliferation, growth and survival including the PI3 kinase-mTOR signaling pathway. Mediates the phosphorylation of PTPN11, an activator of this pathway. May also phosphorylate and activate the transcription factor STAT3 to control anchorage-independent cell growth. Mediates the phosphorylation and the activation of VAV3, a guanine nucleotide exchange factor regulating cell morphology. May activate other downstream signaling proteins including AKT1, MAPK1, MAPK3, IRS1 and PLCG2.
T69128	PDBSTRUC	4UXL; 3ZBF
T69128	BIOCLASS	Kinase
T69128	ECNUMBER	EC 2.7.10.1
T69128	SEQUENCE	MKNIYCLIPKLVNFATLGCLWISVVQCTVLNSCLKSCVTNLGQQLDLGTPHNLSEPCIQGCHFWNSVDQKNCALKCRESCEVGCSSAEGAYEEEVLENADLPTAPFASSIGSHNMTLRWKSANFSGVKYIIQWKYAQLLGSWTYTKTVSRPSYVVKPLHPFTEYIFRVVWIFTAQLQLYSPPSPSYRTHPHGVPETAPLIRNIESSSPDTVEVSWDPPQFPGGPILGYNLRLISKNQKLDAGTQRTSFQFYSTLPNTIYRFSIAAVNEVGEGPEAESSITTSSSAVQQEEQWLFLSRKTSLRKRSLKHLVDEAHCLRLDAIYHNITGISVDVHQQIVYFSEGTLIWAKKAANMSDVSDLRIFYRGSGLISSISIDWLYQRMYFIMDELVCVCDLENCSNIEEITPPSISAPQKIVADSYNGYVFYLLRDGIYRADLPVPSGRCAEAVRIVESCTLKDFAIKPQAKRIIYFNDTAQVFMSTFLDGSASHLILPRIPFADVKSFACENNDFLVTDGKVIFQQDALSFNEFIVGCDLSHIEEFGFGNLVIFGSSSQLHPLPGRPQELSVLFGSHQALVQWKPPALAIGANVILISDIIELFELGPSAWQNWTYEVKVSTQDPPEVTHIFLNISGTMLNVPELQSAMKYKVSVRASSPKRPGPWSEPSVGTTLVPASEPPFIMAVKEDGLWSKPLNSFGPGEFLSSDIGNVSDMDWYNNSLYYSDTKGDVFVWLLNGTDISENYHLPSIAGAGALAFEWLGHFLYWAGKTYVIQRQSVLTGHTDIVTHVKLLVNDMVVDSVGGYLYWTTLYSVESTRLNGESSLVLQTQPWFSGKKVIALTLDLSDGLLYWLVQDSQCIHLYTAVLRGQSTGDTTITEFAAWSTSEISQNALMYYSGRLFWINGFRIITTQEIGQKTSVSVLEPARFNQFTIIQTSLKPLPGNFSFTPKVIPDSVQESSFRIEGNASSFQILWNGPPAVDWGVVFYSVEFSAHSKFLASEQHSLPVFTVEGLEPYALFNLSVTPYTYWGKGPKTSLSLRAPETVPSAPENPRIFILPSGKCCNKNEVVVEFRWNKPKHENGVLTKFEIFYNISNQSITNKTCEDWIAVNVTPSVMSFQLEGMSPRCFIAFQVRAFTSKGPGPYADVVKSTTSEINPFPHLITLLGNKIVFLDMDQNQVVWTFSAERVISAVCYTADNEMGYYAEGDSLFLLHLHNRSSSELFQDSLVFDITVITIDWISRHLYFALKESQNGMQVFDVDLEHKVKYPREVKIHNRNSTIISFSVYPLLSRLYWTEVSNFGYQMFYYSIISHTLHRILQPTATNQQNKRNQCSCNVTEFELSGAMAIDTSNLEKPLIYFAKAQEIWAMDLEGCQCWRVITVPAMLAGKTLVSLTVDGDLIYWIITAKDSTQIYQAKKGNGAIVSQVKALRSRHILAYSSVMQPFPDKAFLSLASDTVEPTILNATNTSLTIRLPLAKTNLTWYGITSPTPTYLVYYAEVNDRKNSSDLKYRILEFQDSIALIEDLQPFSTYMIQIAVKNYYSDPLEHLPPGKEIWGKTKNGVPEAVQLINTTVRSDTSLIISWRESHKPNGPKESVRYQLAISHLALIPETPLRQSEFPNGRLTLLVTRLSGGNIYVLKVLACHSEEMWCTESHPVTVEMFNTPEKPYSLVPENTSLQFNWKAPLNVNLIRFWVELQKWKYNEFYHVKTSCSQGPAYVCNITNLQPYTSYNVRVVVVYKTGENSTSLPESFKTKAGVPNKPGIPKLLEGSKNSIQWEKAEDNGCRITYYILEIRKSTSNNLQNQNLRWKMTFNGSCSSVCTWKSKNLKGIFQFRVVAANNLGFGEYSGISENIILVGDDFWIPETSFILTIIVGIFLVVTIPLTFVWHRRLKNQKSAKEGVTVLINEDKELAELRGLAAGVGLANACYAIHTLPTQEEIENLPAFPREKLTLRLLLGSGAFGEVYEGTAVDILGVGSGEIKVAVKTLKKGSTDQEKIEFLKEAHLMSKFNHPNILKQLGVCLLNEPQYIILELMEGGDLLTYLRKARMATFYGPLLTLVDLVDLCVDISKGCVYLERMHFIHRDLAARNCLVSVKDYTSPRIVKIGDFGLARDIYKNDYYRKRGEGLLPVRWMAPESLMDGIFTTQSDVWSFGILIWEILTLGHQPYPAHSNLDVLNYVQTGGRLEPPRNCPDDLWNLMTQCWAQEPDQRPTFHRIQDQLQLFRNFFLNSIYKSRDEANNSGVINESFEGEDGDVICLNSDDIMPVALMETKNREGLNYMVLATECGQGEEKSEGPLGSQESESCGLRKEEKEPHADKDFCQEKQVAYCPSGKPEGLNYACLTHSGYGDGSD
T69128	DRUGINFO	D05NFR	Repotrectinib	Approved
T69128	DRUGINFO	D0AF6O	Lorlatinib	Approved
T69128	DRUGINFO	D03ZBT	Crizotinib	Approved
T69128	DRUGINFO	D0O0LS	Entrectinib	Approved
T69128	DRUGINFO	D2KV8B	AB-106	Phase 2
T69128	DRUGINFO	D0N0DU	DS-6051	Phase 1
T69128	DRUGINFO	D0M8UO	Imidazo[1,2-b]pyridazine derivative 2	Patented
T69128	DRUGINFO	D0N1CF	Imidazo[1,2-b]pyridazine derivative 3	Patented
T69128	DRUGINFO	D0N8YJ	PMID28270010-Compound-Figure21-b	Patented
T69128	DRUGINFO	D0T8XD	Imidazo[1,2-b]pyridazine derivative 1	Patented
T69128	DRUGINFO	D0MX7B	Carboxamide derivative 4	Patented
T69128	DRUGINFO	D0K5UF	PMID24432909C8e	Investigative

T73475	TARGETID	T73475
T73475	FORMERID	TTDR00029
T73475	UNIPROID	MMP7_HUMAN
T73475	TARGNAME	Matrix metalloproteinase-7 (MMP-7)
T73475	GENENAME	MMP7
T73475	TARGTYPE	Successful
T73475	SYNONYMS	Uterine metalloproteinase; Pump-1 protease; PUMP1; Matrin; Matrilysin; MPSL1
T73475	FUNCTION	Activates procollagenase. Degrades casein, gelatins of types I, III, IV, and V, and fibronectin.
T73475	PDBSTRUC	5UE5; 5UE2; 2Y6D; 2Y6C; 2MZI
T73475	BIOCLASS	Peptidase
T73475	ECNUMBER	EC 3.4.24.23
T73475	SEQUENCE	MRLTVLCAVCLLPGSLALPLPQEAGGMSELQWEQAQDYLKRFYLYDSETKNANSLEAKLKEMQKFFGLPITGMLNSRVIEIMQKPRCGVPDVAEYSLFPNSPKWTSKVVTYRIVSYTRDLPHITVDRLVSKALNMWGKEIPLHFRKVVWGTADIMIGFARGAHGDSYPFDGPGNTLAHAFAPGTGLGGDAHFDEDERWTDGSSLGINFLYAATHELGHSLGMGHSSDPNAVMYPTYGNGDPQNFKLSQDDIKGIQKLYGKRSNSRKK
T73475	DRUGINFO	D00MDP	Prinomastat	Approved
T73475	DRUGINFO	D05VZE	Marimastat	Phase 3
T73475	DRUGINFO	D01EUF	BMS 275291	Discontinued in Phase 3
T73475	DRUGINFO	D08WBF	BB-3644	Terminated
T73475	DRUGINFO	D0Y1XT	SC-44463	Terminated
T73475	DRUGINFO	D06HSC	Folate gamma-L-phenylalaninehydroxamic acid	Investigative
T73475	DRUGINFO	D0ZB6O	Folate gamma-L-proline-hydroxamic acid	Investigative
T73475	DRUGINFO	D07SPC	N-hydroxy-2,3-bis(phenylsulfonamido)propanamide	Investigative
T73475	DRUGINFO	D0BI8T	RS-39066	Investigative
T73475	DRUGINFO	D0P8EY	Folate gamma-hydroxamic acid	Investigative
T73475	DRUGINFO	D08ELY	3-Benzenesulfonyl-heptanoic acid hydroxyamide	Investigative
T73475	DRUGINFO	D0N6CD	3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide	Investigative
T73475	DRUGINFO	D07GEL	SL422	Investigative
T73475	DRUGINFO	D03AMR	SR-973	Investigative
T73475	DRUGINFO	D0W2UK	IK-862	Investigative
T73475	DRUGINFO	D0A4TC	MMI270	Investigative

T59102	TARGETID	T59102
T59102	FORMERID	TTDR01217
T59102	UNIPROID	PGFRB_HUMAN
T59102	TARGNAME	Platelet-derived growth factor receptor beta (PDGFRB)
T59102	GENENAME	PDGFRB
T59102	TARGTYPE	Successful
T59102	SYNONYMS	Platelet-derived growth factor receptor 1; PDGFR1; PDGFR-beta; PDGFR-1; PDGFR; PDGF-R-beta; CD140b antigen; CD140b; CD140 antigen-like family member B; Beta-type platelet-derived growth factor receptor; Beta-PDGFR; Beta platelet-derived growth factor receptor
T59102	FUNCTION	Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of pericytes and smooth muscle cells to endothelial cells. Plays a role in the migration of vascular smooth muscle cells and the formation of neointima at vascular injury sites. Required for normal development of the cardiovascular system. Required for normal recruitment of pericytes (mesangial cells) in the kidney glomerulus, and for normal formation of a branched network of capillaries in kidney glomeruli. Promotes rearrangement of the actin cytoskeleton and the formation of membrane ruffles. Binding of its cognate ligands - homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFD -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PLCG1, PIK3R1, PTPN11, RASA1/GAP, CBL, SHC1 and NCK1. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leads to the activation of the AKT1 signaling pathway. Phosphorylation of SHC1, or of the C-terminus of PTPN11, creates a binding site for GRB2, resulting in the activation of HRAS, RAF1 and down-stream MAP kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation and activation of SRC family kinases. Promotes phosphorylation of PDCD6IP/ALIX and STAM. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor. Tyrosine-protein kinase that acts as cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration.
T59102	PDBSTRUC	3MJG; 2PLE; 2PLD; 2L6W; 2IUI
T59102	BIOCLASS	Kinase
T59102	ECNUMBER	EC 2.7.10.1
T59102	SEQUENCE	MRLPGAMPALALKGELLLLSLLLLLEPQISQGLVVTPPGPELVLNVSSTFVLTCSGSAPVVWERMSQEPPQEMAKAQDGTFSSVLTLTNLTGLDTGEYFCTHNDSRGLETDERKRLYIFVPDPTVGFLPNDAEELFIFLTEITEITIPCRVTDPQLVVTLHEKKGDVALPVPYDHQRGFSGIFEDRSYICKTTIGDREVDSDAYYVYRLQVSSINVSVNAVQTVVRQGENITLMCIVIGNEVVNFEWTYPRKESGRLVEPVTDFLLDMPYHIRSILHIPSAELEDSGTYTCNVTESVNDHQDEKAINITVVESGYVRLLGEVGTLQFAELHRSRTLQVVFEAYPPPTVLWFKDNRTLGDSSAGEIALSTRNVSETRYVSELTLVRVKVAEAGHYTMRAFHEDAEVQLSFQLQINVPVRVLELSESHPDSGEQTVRCRGRGMPQPNIIWSACRDLKRCPRELPPTLLGNSSEEESQLETNVTYWEEEQEFEVVSTLRLQHVDRPLSVRCTLRNAVGQDTQEVIVVPHSLPFKVVVISAILALVVLTIISLIILIMLWQKKPRYEIRWKVIESVSSDGHEYIYVDPMQLPYDSTWELPRDQLVLGRTLGSGAFGQVVEATAHGLSHSQATMKVAVKMLKSTARSSEKQALMSELKIMSHLGPHLNVVNLLGACTKGGPIYIITEYCRYGDLVDYLHRNKHTFLQHHSDKRRPPSAELYSNALPVGLPLPSHVSLTGESDGGYMDMSKDESVDYVPMLDMKGDVKYADIESSNYMAPYDNYVPSAPERTCRATLINESPVLSYMDLVGFSYQVANGMEFLASKNCVHRDLAARNVLICEGKLVKICDFGLARDIMRDSNYISKGSTFLPLKWMAPESIFNSLYTTLSDVWSFGILLWEIFTLGGTPYPELPMNEQFYNAIKRGYRMAQPAHASDEIYEIMQKCWEEKFEIRPPFSQLVLLLERLLGEGYKKKYQQVDEEFLRSDHPAILRSQARLPGFHGLRSPLDTSSVLYTAVQPNEGDNDYIIPLPDPKPEVADEGPLEGSPSLASSTLNEVNTSSTISCDSPLEPQDEPEPEPQLELQVEPEPELEQLPDSGCPAPRAEAEDSFL
T59102	DRUGINFO	D0T5QT	Becaplermin	Approved
T59102	DRUGINFO	D0W5HK	Sorafenib	Approved
T59102	DRUGINFO	D01PZD	Romiplostim	Approved
T59102	DRUGINFO	D02WVT	E-3810	Phase 3
T59102	DRUGINFO	D00NSD	XL-820	Phase 2
T59102	DRUGINFO	D0Z6MT	Famitinib	Phase 2
T59102	DRUGINFO	D0GB2L	SNN-0031	Phase 1/2
T59102	DRUGINFO	D00DRL	MK-2461	Phase 1/2
T59102	DRUGINFO	D0T2ER	TAK-593	Phase 1
T59102	DRUGINFO	D0YX2B	PMID28460551-Compound-2	Patented
T59102	DRUGINFO	D0D3FB	PMID25656651-Compound-21a	Patented
T59102	DRUGINFO	D0XQ5F	PMID25656651-Compound-21b	Patented
T59102	DRUGINFO	D0AK1F	Pyridine derivative 18	Patented
T59102	DRUGINFO	D08PAV	CDP-860	Discontinued in Phase 2
T59102	DRUGINFO	D00QCB	SRI-62-834	Discontinued in Phase 2
T59102	DRUGINFO	D0KX1E	CEP-2563	Discontinued in Phase 1
T59102	DRUGINFO	D03WTT	RG-13022	Terminated
T59102	DRUGINFO	D06GBK	AG1295	Terminated
T59102	DRUGINFO	D00QPG	3-(4-dimethylamino-benzylidenyl)-2-indolinone	Investigative
T59102	DRUGINFO	D00YNJ	XB-387	Investigative
T59102	DRUGINFO	D01XDV	6,7-Dimethoxy-4-(2-methoxy-phenoxy)-quinoline	Investigative
T59102	DRUGINFO	D02QBH	3-(6,7-Dimethoxy-quinolin-4-yloxy)-phenylamine	Investigative
T59102	DRUGINFO	D03FCU	4-(3-Ethyl-phenoxy)-6,7-dimethoxy-quinoline	Investigative
T59102	DRUGINFO	D03IPZ	4-(3-Fluoro-phenoxy)-6,7-dimethoxy-quinoline	Investigative
T59102	DRUGINFO	D05WTI	(2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamine	Investigative
T59102	DRUGINFO	D06ZUA	Ki-11502	Investigative
T59102	DRUGINFO	D09PUW	Bis(5-methoxybenzo[b]furan-2-yl)methanone	Investigative
T59102	DRUGINFO	D09QTC	6,7-Dimethoxy-4-(3-methoxy-phenoxy)-quinoline	Investigative
T59102	DRUGINFO	D0BW4G	PDGF receptor tyrosine kinase inhibitor III	Investigative
T59102	DRUGINFO	D0C2KK	4-(3,5-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline	Investigative
T59102	DRUGINFO	D0CW1Q	6,7-Dimethoxy-4-phenoxy-quinoline	Investigative
T59102	DRUGINFO	D0F1RU	4-(2,3-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline	Investigative
T59102	DRUGINFO	D0K3CJ	3-(6,7-Dimethoxy-quinolin-4-yloxy)-phenol	Investigative
T59102	DRUGINFO	D0R8BC	6,7-Dimethoxy-4-(4-methoxy-phenoxy)-quinoline	Investigative
T59102	DRUGINFO	D0U3WQ	AGL 2043	Investigative
T59102	DRUGINFO	D0VJ5W	6,7-Dimethoxy-4-m-tolyloxy-quinoline	Investigative
T59102	DRUGINFO	D0Y1CJ	4-(3-Ethoxy-phenoxy)-6,7-dimethoxy-quinoline	Investigative
T59102	DRUGINFO	D0ZS3F	6,7-Dimethoxy-4-(3-nitro-phenoxy)-quinoline	Investigative
T59102	DRUGINFO	D00LRC	3-Cyclopentyl-6,7-dimethoxy-quinoline	Investigative
T59102	DRUGINFO	D00RBV	6,7-Dimethoxy-3-pyridin-3-yl-quinoline	Investigative
T59102	DRUGINFO	D00YCU	1-Phenyl-1H-benzoimidazol-5-ol	Investigative
T59102	DRUGINFO	D01FWD	1-Phenyl-1H-benzoimidazole	Investigative
T59102	DRUGINFO	D01MUN	4-Benzoimidazol-1-yl-phenylamine	Investigative
T59102	DRUGINFO	D01UYS	5-(6,7-Dimethoxy-quinolin-3-yl)-1H-pyridin-2-one	Investigative
T59102	DRUGINFO	D02CUF	Benzyl-(6,7-dimethoxy-quinolin-3-yl)-amine	Investigative
T59102	DRUGINFO	D02OBA	Bis(5-hydroxybenzo[b]furan-2-yl)methanone	Investigative
T59102	DRUGINFO	D02PZZ	7-Methoxy-3-pyridin-4-yl-quinoline	Investigative
T59102	DRUGINFO	D02XKJ	5-Methoxy-1-phenyl-1H-benzoimidazole	Investigative
T59102	DRUGINFO	D03HLH	4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline	Investigative
T59102	DRUGINFO	D03MQI	4-(6,7-Dimethoxy-quinolin-3-yl)-benzoic acid	Investigative
T59102	DRUGINFO	D03VAA	Bis(6-hydroxybenzo[b]furan-2-yl)methanone	Investigative
T59102	DRUGINFO	D04PQX	6-Methoxy-3-pyridin-4-yl-quinoline	Investigative
T59102	DRUGINFO	D05GBY	3-Thiophen-3-yl-quinoline	Investigative
T59102	DRUGINFO	D05QMN	4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline	Investigative
T59102	DRUGINFO	D05SNG	7-Fluoro-3-thiophen-3-yl-quinoline	Investigative
T59102	DRUGINFO	D06LLF	6,7-Dimethoxy-3-((E)-styryl)-quinoline	Investigative
T59102	DRUGINFO	D06MCJ	3-(1H-Indol-3-yl)-6,7-dimethoxy-quinoline	Investigative
T59102	DRUGINFO	D06VNR	3-Benzyloxy-6,7-dimethoxy-quinoline	Investigative
T59102	DRUGINFO	D07AXL	Bis(5-aminobenzo[b]furan-2-yl)methanone	Investigative
T59102	DRUGINFO	D07CFT	6,7-Dimethoxy-3-(3-methoxy-phenyl)-quinoline	Investigative
T59102	DRUGINFO	D07JDY	3-((E)-Styryl)-quinoline	Investigative
T59102	DRUGINFO	D07ZWN	5,7-Dimethyl-3-thiophen-3-yl-quinoline	Investigative
T59102	DRUGINFO	D08JGS	6,7-Dimethoxy-3-(4-nitro-phenyl)-quinoline	Investigative
T59102	DRUGINFO	D08KWL	3-Cyclohexylethynyl-6,7-dimethoxy-quinoline	Investigative
T59102	DRUGINFO	D08SUH	3-(3,4-Dimethoxy-phenyl)-6,7-dimethoxy-quinoline	Investigative
T59102	DRUGINFO	D0A6AA	7-Thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline	Investigative
T59102	DRUGINFO	D0A6YP	3-(3-Fluoro-phenyl)-6,7-dimethoxy-quinoline	Investigative
T59102	DRUGINFO	D0AO6T	3-(3,4-Difluoro-phenyl)-6,7-dimethoxy-quinoline	Investigative
T59102	DRUGINFO	D0C1BE	6,7-Dimethoxy-3-p-tolyl-quinoline	Investigative
T59102	DRUGINFO	D0CF9B	6,7-Dichloro-3-thiophen-3-yl-quinoline	Investigative
T59102	DRUGINFO	D0FH3M	RPR-108514A	Investigative
T59102	DRUGINFO	D0G0KN	6,7-Dimethoxy-3-(4-methoxy-phenyl)-quinoline	Investigative
T59102	DRUGINFO	D0G0ZQ	6,7-Dimethoxy-3-thiophen-2-yl-quinoline	Investigative
T59102	DRUGINFO	D0G6SA	6,7-Dimethoxy-3-phenyl-quinoline	Investigative
T59102	DRUGINFO	D0GN3E	3-(1H-Indol-3-yl)-quinoline	Investigative
T59102	DRUGINFO	D0H4JB	4-(6,7-Dimethoxy-quinolin-3-yl)-phenol	Investigative
T59102	DRUGINFO	D0H9TO	3-Pyridin-4-yl-quinolin-7-ol	Investigative
T59102	DRUGINFO	D0I0GL	3-(4-Fluoro-phenyl)-6,7-dimethoxy-quinoline	Investigative
T59102	DRUGINFO	D0I7QX	(benzo[b]furan-2-yl)-(1H-indol-2-yl)methanone	Investigative
T59102	DRUGINFO	D0IR5I	3-Pyridin-3-yl-quinoline-6,7-diol	Investigative
T59102	DRUGINFO	D0K2YG	4-(5-Methoxy-benzoimidazol-1-yl)-phenylamine	Investigative
T59102	DRUGINFO	D0K9ON	3-(2-Cyclohexyl-ethyl)-6,7-dimethoxy-quinoline	Investigative
T59102	DRUGINFO	D0K9VE	3-Pyridin-4-yl-quinoline-5,7-diol	Investigative
T59102	DRUGINFO	D0KF3N	3-Cyclopent-1-enyl-6,7-dimethoxy-quinoline	Investigative
T59102	DRUGINFO	D0L0MZ	Bis(5-acetoxybenzo[b]furan-2-yl)methanone	Investigative
T59102	DRUGINFO	D0P0RD	3-(3,4-Dichloro-phenyl)-6,7-dimethoxy-quinoline	Investigative
T59102	DRUGINFO	D0P0WT	5,7-Dimethoxy-3-pyridin-4-yl-quinoline	Investigative
T59102	DRUGINFO	D0Q3DS	3-Pyridin-4-yl-quinoline	Investigative
T59102	DRUGINFO	D0QT4X	6,7-Difluoro-3-thiophen-3-yl-quinoline	Investigative
T59102	DRUGINFO	D0RD5S	5,7-Dimethoxy-3-thiophen-3-yl-quinoline	Investigative
T59102	DRUGINFO	D0SG0G	5,6,7-Trimethoxy-3-pyridin-4-yl-quinoline	Investigative
T59102	DRUGINFO	D0T9FQ	6,7-Dimethoxy-3-pyridin-4-yl-quinoline	Investigative
T59102	DRUGINFO	D0V8QI	7-Methoxy-3-thiophen-3-yl-quinoline	Investigative
T59102	DRUGINFO	D0W7IN	6-Methoxy-3-thiophen-3-yl-quinoline	Investigative
T59102	DRUGINFO	D0W9BF	RPR-101511	Investigative
T59102	DRUGINFO	D0WW8M	6,7-Dimethoxy-3-phenylethynyl-quinoline	Investigative
T59102	DRUGINFO	D0YE1X	4-(3,4-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline	Investigative
T59102	DRUGINFO	D0Z3DW	Bis(benzo[b]furan-2-yl)methanone	Investigative
T59102	DRUGINFO	D0Z4HV	7-Chloro-3-pyridin-4-yl-quinoline	Investigative
T59102	DRUGINFO	D05QBZ	CP-673451	Investigative
T59102	DRUGINFO	D07QMC	3-Benzimidazol-2-ylhydroquinolin-2-one	Investigative
T59102	DRUGINFO	D09OLH	(1H-indol-2-yl)(5-methoxy-1H-indol-2-yl)methanone	Investigative
T59102	DRUGINFO	D0D7ZL	(1H-indol-2-yl)(6-methoxy-1H-indol-2-yl)methanone	Investigative
T59102	DRUGINFO	D0G0KQ	(1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone	Investigative
T59102	DRUGINFO	D0G5YI	Di(1H-indol-2-yl)methanone	Investigative
T59102	DRUGINFO	D0H7MF	(5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone	Investigative
T59102	DRUGINFO	D0XS9E	(5-hydroxy-1H-indol-2-yl)(1H-indol-2-yl)methanone	Investigative
T59102	DRUGINFO	D08BJR	Ki-20227	Investigative
T59102	DRUGINFO	D09LPL	SU-11652	Investigative
T59102	DRUGINFO	D0UN9O	GTP-14564	Investigative
T59102	DRUGINFO	D0I3XZ	Bis-(5-hydroxy-1H-indol-2-yl)-methanone	Investigative
T59102	DRUGINFO	D0OH3J	PD-0179483	Investigative
T59102	DRUGINFO	D0S1KJ	PD-0173952	Investigative
T59102	DRUGINFO	D0XC6G	2-(1H-indazol-3-yl)-1H-benzo[d]imidazole	Investigative
T59102	DRUGINFO	D0Z7GH	PD-0173958	Investigative
T59102	DRUGINFO	D03NPX	PD-0173955	Investigative
T59102	DRUGINFO	D0YZ7H	JNJ-10198409	Investigative
T59102	DRUGINFO	D0D5EW	HKI-9924129	Investigative
T59102	DRUGINFO	D0GW4Q	PD-0173956	Investigative
T59102	DRUGINFO	D0H1OK	TG-100435	Investigative
T59102	DRUGINFO	D0P3JW	PD-0166326	Investigative
T59102	DRUGINFO	D0C2GE	PMID22765894C8h	Investigative
T59102	DRUGINFO	D09XIL	Ro-4396686	Investigative
T59102	DRUGINFO	D0M4SY	BMS-536924	Investigative

T76024	TARGETID	T76024
T76024	FORMERID	TTDC00085
T76024	UNIPROID	C1S_HUMAN
T76024	TARGNAME	Complement C1s component (C1S)
T76024	GENENAME	C1S
T76024	TARGTYPE	Successful
T76024	SYNONYMS	Complement component 1 subcomponent s; Complement C1s subcomponent; C1-esterase; C1 esterase
T76024	FUNCTION	C1r activates C1s so that it can, in turn, activate C2 and C4. C1s B chain is a serine protease that combines with C1q and C1r to form C1, the first component of the classical pathway of the complement system.
T76024	PDBSTRUC	6F1H; 6F1C; 4LOT; 4LOS; 4LOR
T76024	BIOCLASS	Peptidase
T76024	ECNUMBER	EC 3.4.21.42
T76024	SEQUENCE	MWCIVLFSLLAWVYAEPTMYGEILSPNYPQAYPSEVEKSWDIEVPEGYGIHLYFTHLDIELSENCAYDSVQIISGDTEEGRLCGQRSSNNPHSPIVEEFQVPYNKLQVIFKSDFSNEERFTGFAAYYVATDINECTDFVDVPCSHFCNNFIGGYFCSCPPEYFLHDDMKNCGVNCSGDVFTALIGEIASPNYPKPYPENSRCEYQIRLEKGFQVVVTLRREDFDVEAADSAGNCLDSLVFVAGDRQFGPYCGHGFPGPLNIETKSNALDIIFQTDLTGQKKGWKLRYHGDPMPCPKEDTPNSVWEPAKAKYVFRDVVQITCLDGFEVVEGRVGATSFYSTCQSNGKWSNSKLKCQPVDCGIPESIENGKVEDPESTLFGSVIRYTCEEPYYYMENGGGGEYHCAGNGSWVNEVLGPELPKCVPVCGVPREPFEEKQRIIGGSDADIKNFPWQVFFDNPWAGGALINEYWVLTAAHVVEGNREPTMYVGSTSVQTSRLAKSKMLTPEHVFIHPGWKLLEVPEGRTNFDNDIALVRLKDPVKMGPTVSPICLPGTSSDYNLMDGDLGLISGWGRTEKRDRAVRLKAARLPVAPLRKCKEVKVEKPTADAEAYVFTPNMICAGGEKGMDSCKGDSGGAFAVQDPNDKTKFYAAGLVSWGPQCGTYGLYTRVKNYVDWIMKTMQENSTPRED
T76024	DRUGINFO	DJ0L4K	Sutimlimab	Approved
T76024	DRUGINFO	D0BK4X	Cinryze	Approved
T76024	DRUGINFO	DHQI14	SAR445088	Phase 2
T76024	DRUGINFO	D05TDJ	TS01	Phase 1
T76024	DRUGINFO	D06SHZ	SHP616	Phase 1
T76024	DRUGINFO	D0OC5T	ANX005	Phase 1
T76024	DRUGINFO	D0X1EV	TNT009	Phase 1
T76024	DRUGINFO	D0J1CC	PMID16460935C28	Investigative
T76024	DRUGINFO	D0G6XS	Fucose	Investigative

T06273	TARGETID	T06273
T06273	FORMERID	TTDS00191
T06273	UNIPROID	PARP1_HUMAN
T06273	TARGNAME	Poly [ADP-ribose] polymerase 1 (PARP1)
T06273	GENENAME	PARP1
T06273	TARGTYPE	Successful
T06273	SYNONYMS	Protein poly-ADP-ribosyltransferase PARP1; Poly[ADP-ribose] synthetase-1; Poly[ADP-ribose] synthase 1; Poly(ADP-ribose)polymerase-1; PPOL; PARP-1; NAD(+)Poly [ADP-ribose] polymerase-1 ADP-ribosyltransferase-1; NAD(+) ADP-ribosyltransferase-1; NAD(+) ADP-ribosyltransferase 1; DNA ADP-ribosyltransferase PARP1; ARTD1; ADPRT 1; ADPRT; ADP-ribosyltransferase diphtheria toxin-like 1
T06273	FUNCTION	Mainly mediates glutamate and aspartate ADP-ribosylation of target proteins: the ADP-D-ribosyl group of NAD(+) is transferred to the acceptor carboxyl group of glutamate and aspartate residues and further ADP-ribosyl groups are transferred to the 2'-position of the terminal adenosine moiety, building up a polymer with an average chain length of 20-30 units. Mediates the poly(ADP-ribosyl)ation of a number of proteins, including itself, APLF and CHFR. Also mediates serine ADP-ribosylation of target proteins following interaction with HPF1; HPF1 conferring serine specificity. Probably also catalyzes tyrosine ADP-ribosylation of target proteins following interaction with HPF1. Catalyzes the poly-ADP-ribosylation of histones in a HPF1-dependent manner. Involved in the base excision repair (BER) pathway by catalyzing the poly-ADP-ribosylation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. ADP-ribosylation follows DNA damage and appears as an obligatory step in a detection/signaling pathway leading to the reparation of DNA strand breaks. In addition to base excision repair (BER) pathway, also involved in double-strand breaks (DSBs) repair: together with TIMELESS, accumulates at DNA damage sites and promotes homologous recombination repair by mediating poly-ADP-ribosylation. In addition to proteins, also able to ADP-ribosylate DNA: catalyzes ADP-ribosylation of DNA strand break termini containing terminal phosphates and a 2'-OH group in single- and double-stranded DNA, respectively. Required for PARP9 and DTX3L recruitment to DNA damage sites. PARP1-dependent PARP9-DTX3L-mediated ubiquitination promotes the rapid and specific recruitment of 53BP1/TP53BP1, UIMC1/RAP80, and BRCA1 to DNA damage sites. Acts as a regulator of transcription: positively regulates the transcription of MTUS1 and negatively regulates the transcription of MTUS2/TIP150. With EEF1A1 and TXK, forms a complex that acts as a T-helper 1 (Th1) cell-specific transcription factor and binds the promoter of IFN-gamma to directly regulate its transcription, and is thus involved importantly in Th1 cytokine production. Involved in the synthesis of ATP in the nucleus, together with NMNAT1, PARG and NUDT5. Nuclear ATP generation is required for extensive chromatin remodeling events that are energy-consuming. Poly-ADP-ribosyltransferase that mediates poly-ADP-ribosylation of proteins and plays a key role in DNA repair.
T06273	PDBSTRUC	6GHK; 6BHV; 5XSU; 5XST; 5XSR
T06273	BIOCLASS	Glycosyltransferases
T06273	ECNUMBER	EC 2.4.2.30
T06273	SEQUENCE	MAESSDKLYRVEYAKSGRASCKKCSESIPKDSLRMAIMVQSPMFDGKVPHWYHFSCFWKVGHSIRHPDVEVDGFSELRWDDQQKVKKTAEAGGVTGKGQDGIGSKAEKTLGDFAAEYAKSNRSTCKGCMEKIEKGQVRLSKKMVDPEKPQLGMIDRWYHPGCFVKNREELGFRPEYSASQLKGFSLLATEDKEALKKQLPGVKSEGKRKGDEVDGVDEVAKKKSKKEKDKDSKLEKALKAQNDLIWNIKDELKKVCSTNDLKELLIFNKQQVPSGESAILDRVADGMVFGALLPCEECSGQLVFKSDAYYCTGDVTAWTKCMVKTQTPNRKEWVTPKEFREISYLKKLKVKKQDRIFPPETSASVAATPPPSTASAPAAVNSSASADKPLSNMKILTLGKLSRNKDEVKAMIEKLGGKLTGTANKASLCISTKKEVEKMNKKMEEVKEANIRVVSEDFLQDVSASTKSLQELFLAHILSPWGAEVKAEPVEVVAPRGKSGAALSKKSKGQVKEEGINKSEKRMKLTLKGGAAVDPDSGLEHSAHVLEKGGKVFSATLGLVDIVKGTNSYYKLQLLEDDKENRYWIFRSWGRVGTVIGSNKLEQMPSKEDAIEHFMKLYEEKTGNAWHSKNFTKYPKKFYPLEIDYGQDEEAVKKLTVNPGTKSKLPKPVQDLIKMIFDVESMKKAMVEYEIDLQKMPLGKLSKRQIQAAYSILSEVQQAVSQGSSDSQILDLSNRFYTLIPHDFGMKKPPLLNNADSVQAKVEMLDNLLDIEVAYSLLRGGSDDSSKDPIDVNYEKLKTDIKVVDRDSEEAEIIRKYVKNTHATTHNAYDLEVIDIFKIEREGECQRYKPFKQLHNRRLLWHGSRTTNFAGILSQGLRIAPPEAPVTGYMFGKGIYFADMVSKSANYCHTSQGDPIGLILLGEVALGNMYELKHASHISKLPKGKHSVKGLGKTTPDPSANISLDGVDVPLGTGISSGVNDTSLLYNEYIVYDIAQVNLKYLLKLKFNFKTSLW
T06273	DRUGINFO	D06NVJ	Nicotinamide	Approved
T06273	DRUGINFO	D09LSX	KU-0058948	Approved
T06273	DRUGINFO	D0DN0W	Niraparib Tosylate	Approved
T06273	DRUGINFO	D0Z2UW	Nicaraven	Phase 3
T06273	DRUGINFO	D09NTC	CC-486	Phase 3
T06273	DRUGINFO	D06KZL	AG140699	Phase 2
T06273	DRUGINFO	D0YTM9	AZD5305	Phase 2
T06273	DRUGINFO	D0F5TD	PMID27841036-Compound-37	Phase 2
T06273	DRUGINFO	DP48WE	Stenoparib	Phase 2
T06273	DRUGINFO	D8TE4F	AMXI 5001	Phase 1/2
T06273	DRUGINFO	DO0LP3	NMS-03305293	Phase 1
T06273	DRUGINFO	D01KFW	3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 1	Patented
T06273	DRUGINFO	D01PYO	Benzimidazole carboxamide derivative 1	Patented
T06273	DRUGINFO	D02KMI	PMID27841036-Compound-33	Patented
T06273	DRUGINFO	D02QFM	3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 4	Patented
T06273	DRUGINFO	D05ZBB	Phthalazine ketone derivative 1	Patented
T06273	DRUGINFO	D08KAH	Quinazolinedione derivative 3	Patented
T06273	DRUGINFO	D08YPU	4-Carboxamido-isoindolinone derivative 2	Patented
T06273	DRUGINFO	D09HUV	3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 3	Patented
T06273	DRUGINFO	D09WUA	7-azaindole derivative 8	Patented
T06273	DRUGINFO	D09ZIM	3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 5	Patented
T06273	DRUGINFO	D0AN7Z	Phthalazine ketone derivative 3	Patented
T06273	DRUGINFO	D0B3QI	Dihydropyrido phthalazinone derivative 1	Patented
T06273	DRUGINFO	D0B4FV	Phthalazine ketone derivative 2	Patented
T06273	DRUGINFO	D0E9JI	Tricyclic indole compound 13	Patented
T06273	DRUGINFO	D0G8HX	3-phenyl isoquinolin-1(2H) derivative 2	Patented
T06273	DRUGINFO	D0GH4V	4-Carboxamido-isoindolinone derivative 5	Patented
T06273	DRUGINFO	D0IX2C	Quinazolinedione derivative 2	Patented
T06273	DRUGINFO	D0J2SR	Quinazolinedione derivative 1	Patented
T06273	DRUGINFO	D0J4GY	Dihydropyrido phthalazinone derivative 2	Patented
T06273	DRUGINFO	D0M0WS	3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 2	Patented
T06273	DRUGINFO	D0M9TG	Phthalazine derivative 3	Patented
T06273	DRUGINFO	D0MP4W	Tetra-hydro-quinoline derivative 1	Patented
T06273	DRUGINFO	D0O9FC	4-Carboxamido-isoindolinone derivative 1	Patented
T06273	DRUGINFO	D0R0PO	4-Carboxamido-isoindolinone derivative 3	Patented
T06273	DRUGINFO	D0Z5DI	4-Carboxamido-isoindolinone derivative 4	Patented
T06273	DRUGINFO	D0P3YA	Dihydrodiazepinocarbazolone derivative 1	Patented
T06273	DRUGINFO	D0Z8IR	Tetra-cyclic pyridophthalazinone derivative 1	Patented
T06273	DRUGINFO	D0TD8R	3-phenyl isoquinolin-1(2H) derivative 1	Patented
T06273	DRUGINFO	D04ABS	CPH-102	Preclinical
T06273	DRUGINFO	D04WDX	PJ34	Preclinical
T06273	DRUGINFO	D0O3FX	NU1025	Terminated
T06273	DRUGINFO	D00OZA	3-Ethynylquinoline-8-carboxamide	Investigative
T06273	DRUGINFO	D00TUB	2-(4-Amino-phenyl)-8-hydroxy-3H-quinazolin-4-one	Investigative
T06273	DRUGINFO	D00WMC	N-(4-Phenylthiazol-2-yl)isonicotinamide	Investigative
T06273	DRUGINFO	D01EVX	5-Chloro-2-methyl-3H-quinazolin-4-one	Investigative
T06273	DRUGINFO	D01RXM	BZ3	Investigative
T06273	DRUGINFO	D01YIR	2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide	Investigative
T06273	DRUGINFO	D02GPJ	CEP-6800	Investigative
T06273	DRUGINFO	D02JHW	ANG-2864	Investigative
T06273	DRUGINFO	D02MPP	3-Methoxybenzamide	Investigative
T06273	DRUGINFO	D02QZF	2-Benzyl-2H-indazole-7-carboxamide	Investigative
T06273	DRUGINFO	D02XLC	5-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione	Investigative
T06273	DRUGINFO	D03JTS	4-amino-1,8-naphthalimide	Investigative
T06273	DRUGINFO	D03VNZ	Pyrrolo[3,4-e]indole-1,3(2H,6H)-dione	Investigative
T06273	DRUGINFO	D04ATU	8-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one	Investigative
T06273	DRUGINFO	D04AYN	EB-47	Investigative
T06273	DRUGINFO	D04LDH	BZ6	Investigative
T06273	DRUGINFO	D04TDX	2-(4-methoxyphenyl)quinoline-8-carboxamide	Investigative
T06273	DRUGINFO	D04UPQ	9-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one	Investigative
T06273	DRUGINFO	D04ZQJ	(E)-N-(4-Phenylthiazol-2-yl) cinnamamide	Investigative
T06273	DRUGINFO	D05APM	ANG-2684	Investigative
T06273	DRUGINFO	D05GMW	4-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione	Investigative
T06273	DRUGINFO	D05HJG	2,3-dihydro-1H-benzo[de]isoquinolin-1-one	Investigative
T06273	DRUGINFO	D05RXG	5-amino-3,4-dihydroisoquinolin-1(2H)-one	Investigative
T06273	DRUGINFO	D05SYO	KR-33889	Investigative
T06273	DRUGINFO	D05WYN	4-(5-Morpholin-4-yl-pentyl)-2H-phthalazin-1-one	Investigative
T06273	DRUGINFO	D05XMG	AG-014376	Investigative
T06273	DRUGINFO	D05ZTI	3-Hydroxy-benzamide	Investigative
T06273	DRUGINFO	D06NKJ	8-Methoxy-2-phenyl-3H-quinazolin-4-one	Investigative
T06273	DRUGINFO	D07AGU	Quinoline-8-carboxamide	Investigative
T06273	DRUGINFO	D07BBR	9-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one	Investigative
T06273	DRUGINFO	D07BPT	8-Methyl-2-(4-nitro-phenyl)-3H-quinazolin-4-one	Investigative
T06273	DRUGINFO	D07CRG	2H-Isoquinolin-1-one	Investigative
T06273	DRUGINFO	D07QPV	KU-58684	Investigative
T06273	DRUGINFO	D07SRJ	2,8-Dimethyl-3H-quinazolin-4-one	Investigative
T06273	DRUGINFO	D07WPL	5-aminoisoquinolin-1(2H)-one	Investigative
T06273	DRUGINFO	D08AOV	INO-1002	Investigative
T06273	DRUGINFO	D08GMO	3-(4-aminophenyl)quinoxaline-5-carboxamide	Investigative
T06273	DRUGINFO	D08OUR	2-phenylpyrazolo-[1,5-a]pyridine-7-carboxamide	Investigative
T06273	DRUGINFO	D08QWR	4-benzylphthalazin-1(2H)-one	Investigative
T06273	DRUGINFO	D08XPZ	3-Methylquinoline-8-carboxamide	Investigative
T06273	DRUGINFO	D08ZVM	2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide	Investigative
T06273	DRUGINFO	D0B2WX	2-(4-Methoxy-phenyl)-8-methyl-3H-quinazolin-4-one	Investigative
T06273	DRUGINFO	D0CA2S	HYDAMTIQ	Investigative
T06273	DRUGINFO	D0E0QT	8-Nitro-6H,11H-indeno[1,2-c]isoquinolin-5-one	Investigative
T06273	DRUGINFO	D0E2VC	PD-128763	Investigative
T06273	DRUGINFO	D0E5EW	8-Methyl-2-phenyl-3H-quinazolin-4-one	Investigative
T06273	DRUGINFO	D0E7UW	TI3	Investigative
T06273	DRUGINFO	D0EI6X	3-aminobenzo[c][1,5]naphthyridin-6(5H)-one	Investigative
T06273	DRUGINFO	D0EQ1J	S-111	Investigative
T06273	DRUGINFO	D0EW8Y	Thieno-phenanthridin-6-one	Investigative
T06273	DRUGINFO	D0F8ZI	3-Morpholin-4-ylmethyl-5H-phenanthridin-6-one	Investigative
T06273	DRUGINFO	D0FF4M	1,2,3,4,4a,5-hexahydrophenanthridin-6(10bH)-one	Investigative
T06273	DRUGINFO	D0G5VD	8-Hydroxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one	Investigative
T06273	DRUGINFO	D0GA0Y	2-(4-Amino-phenyl)-8-methyl-3H-quinazolin-4-one	Investigative
T06273	DRUGINFO	D0GJ8U	4-(4-Morpholin-4-yl-butyl)-2H-phthalazin-1-one	Investigative
T06273	DRUGINFO	D0I2AF	2-phenyl-2H-benzo[d][1,2,3]triazole-4-carboxamide	Investigative
T06273	DRUGINFO	D0IX3I	2-phenyl-2H-indazole-7-carboxamide	Investigative
T06273	DRUGINFO	D0JD1O	Carba-Nicotinamide-Adenine-Dinucleotide	Investigative
T06273	DRUGINFO	D0K2PD	3-aminobenzamide	Investigative
T06273	DRUGINFO	D0K7JT	3-Ethenylquinoline-8-carboxamide	Investigative
T06273	DRUGINFO	D0L1NQ	3-Phenylquinoline-8-carboxamide	Investigative
T06273	DRUGINFO	D0L1RZ	3-(4-methoxyphenyl)quinoxaline-5-carboxamide	Investigative
T06273	DRUGINFO	D0L6LO	TI4	Investigative
T06273	DRUGINFO	D0M6WJ	Benzo[c][1,5]naphthyridin-6(5H)-one	Investigative
T06273	DRUGINFO	D0M9TW	3-(4-cyanophenyl)quinoxaline-5-carboxamide	Investigative
T06273	DRUGINFO	D0NU5Z	1,7,8,9-tetrahydro-1,5-diaza-trindene-4,6-dione	Investigative
T06273	DRUGINFO	D0O0GA	8-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one	Investigative
T06273	DRUGINFO	D0O6WW	8-Hydroxy-2-phenyl-3H-quinazolin-4-one	Investigative
T06273	DRUGINFO	D0OF1I	8-Methoxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one	Investigative
T06273	DRUGINFO	D0PT1K	2-(4-Chlorophenyl)-2H-indazole-7-carboxamide	Investigative
T06273	DRUGINFO	D0R7FS	BPI-704001	Investigative
T06273	DRUGINFO	D0R7HU	Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione	Investigative
T06273	DRUGINFO	D0S8HZ	2-Methylquinoline-8-carboxamide	Investigative
T06273	DRUGINFO	D0T3SY	8-Methoxy-2-methyl-3H-quinazolin-4-one	Investigative
T06273	DRUGINFO	D0T5TT	3-Prop-1-ynylquinoline-8-carboxamide	Investigative
T06273	DRUGINFO	D0TH7S	2-(2-Chlorophenyl)-2H-indazole-7-carboxamide	Investigative
T06273	DRUGINFO	D0U5WY	2-(3-Piperidin-1-yl-propyl)-3H-quinazolin-4-one	Investigative
T06273	DRUGINFO	D0UF0U	3-Ethylquinoline-8-carboxamide	Investigative
T06273	DRUGINFO	D0VY5O	A-620223	Investigative
T06273	DRUGINFO	D0W7XH	DR2313	Investigative
T06273	DRUGINFO	D0WO3P	2-(4-Azido-phenyl)-8-methoxy-3H-quinazolin-4-one	Investigative
T06273	DRUGINFO	D0XZ5D	2-(3-Chlorophenyl)-2H-indazole-7-carboxamide	Investigative
T06273	DRUGINFO	D0Y1MH	2-(4-Hydroxy-phenyl)-8-methyl-3H-quinazolin-4-one	Investigative
T06273	DRUGINFO	D0Z3PB	2-ethylquinoline-8-carboxamide	Investigative
T06273	DRUGINFO	D0Z9DY	2-phenylquinoline-8-carboxamide	Investigative
T06273	DRUGINFO	D0ZK3L	BZ5	Investigative
T06273	DRUGINFO	D04QRM	ME0328	Investigative
T06273	DRUGINFO	D09SZG	[2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala	Investigative
T06273	DRUGINFO	D0P4DG	S-070	Investigative

T03691	TARGETID	T03691
T03691	FORMERID	TTDC00130
T03691	UNIPROID	LKHA4_HUMAN
T03691	TARGNAME	Leukotriene A-4 hydrolase (LTA4H)
T03691	GENENAME	LTA4H
T03691	TARGTYPE	Successful
T03691	SYNONYMS	Leukotriene A4 hydrolase; Leukotriene A(4)Leukotriene A-4 hydrolase hydrolase; Leukotriene A(4) hydrolase; LTA4; LTA-H; LTA-4hydrolase; LTA-4 hydrolase
T03691	FUNCTION	Has also aminopeptidase activity. Epoxide hydrolase that catalyzes the final step in the biosynthesis of the proinflammatory mediator leukotriene B4.
T03691	PDBSTRUC	6END; 6ENC; 6ENB; 5NIE; 5NID
T03691	BIOCLASS	Ether bond hydrolase
T03691	ECNUMBER	EC 3.3.2.6
T03691	SEQUENCE	MPEIVDTCSLASPASVCRTKHLHLRCSVDFTRRTLTGTAALTVQSQEDNLRSLVLDTKDLTIEKVVINGQEVKYALGERQSYKGSPMEISLPIALSKNQEIVIEISFETSPKSSALQWLTPEQTSGKEHPYLFSQCQAIHCRAILPCQDTPSVKLTYTAEVSVPKELVALMSAIRDGETPDPEDPSRKIYKFIQKVPIPCYLIALVVGALESRQIGPRTLVWSEKEQVEKSAYEFSETESMLKIAEDLGGPYVWGQYDLLVLPPSFPYGGMENPCLTFVTPTLLAGDKSLSNVIAHEISHSWTGNLVTNKTWDHFWLNEGHTVYLERHICGRLFGEKFRHFNALGGWGELQNSVKTFGETHPFTKLVVDLTDIDPDVAYSSVPYEKGFALLFYLEQLLGGPEIFLGFLKAYVEKFSYKSITTDDWKDFLYSYFKDKVDVLNQVDWNAWLYSPGLPPIKPNYDMTLTNACIALSQRWITAKEDDLNSFNATDLKDLSSHQLNEFLAQTLQRAPLPLGHIKRMQEVYNFNAINNSEIRFRWLRLCIQSKWEDAIPLALKMATEQGRMKFTRPLFKDLAAFDKSHDQAVRTYQEHKASMHPVTAMLVGKDLKVD
T03691	DRUGINFO	D0RA5Q	Bestatin	Approved
T03691	DRUGINFO	DI2KZ7	LYS006	Phase 2
T03691	DRUGINFO	D07VNH	Acebilustat	Phase 1
T03691	DRUGINFO	D06XEL	DG051	Discontinued in Phase 2
T03691	DRUGINFO	D00FCJ	N5-[4-(3-methylphenoxy)phenyl]-L-glutamamide	Investigative
T03691	DRUGINFO	D00FDS	(R)-2-((4-phenoxyphenoxy)methyl)piperidine	Investigative
T03691	DRUGINFO	D00TNN	(R/S)-2-((4-phenoxyphenoxy)methyl)piperidine	Investigative
T03691	DRUGINFO	D00TWK	5-[2-(4-hydroxyphenyl)ethyl]benzene-1,3-diol	Investigative
T03691	DRUGINFO	D00YCG	5-[2-(1H-pyrrol-1-yl)ethoxy]-1H-indole	Investigative
T03691	DRUGINFO	D01QWO	4-(4-butoxyphenoxy)phenol	Investigative
T03691	DRUGINFO	D01RVF	(R)-N-benzyl-4-(pyrrolidin-2-ylmethoxy)aniline	Investigative
T03691	DRUGINFO	D01YJJ	N5-[4-(3-Phenylpropoxy)phenyl]-L-glutamine	Investigative
T03691	DRUGINFO	D02TMR	N5-[(4-Phenoxy)-3-pyridyl]-L-glutamamide	Investigative
T03691	DRUGINFO	D03GON	2-[4-(2-Azepan-1-ylethoxy)phenoxy]benzooxazole	Investigative
T03691	DRUGINFO	D03UIF	SA-6541	Investigative
T03691	DRUGINFO	D04CZF	N5-[4-(Phenylmethoxy)phenyl]-L-glutamamide	Investigative
T03691	DRUGINFO	D04DRM	N1-[4-(Phenylmethoxy)phenyl]-D-glutamine	Investigative
T03691	DRUGINFO	D04ZLZ	N4-[4-(Phenylmethoxy)phenyl]-L-aspartamine	Investigative
T03691	DRUGINFO	D05NXQ	(S)-2-((4-phenoxyphenoxy)methyl)piperidine	Investigative
T03691	DRUGINFO	D06RWH	2-Amino-N-[4-(phenylmethoxy)phenyl]-acetamide	Investigative
T03691	DRUGINFO	D06SMN	(R)-2-(4-Benzylphenoxymethyl)pyrrolidine	Investigative
T03691	DRUGINFO	D07KBF	N5-[4-(2-methylphenoxy)phenyl]-L-glutamamide	Investigative
T03691	DRUGINFO	D07LTR	1-(pentyloxy)-4-phenoxybenzene	Investigative
T03691	DRUGINFO	D07TVA	1-butoxy-4-phenoxybenzene	Investigative
T03691	DRUGINFO	D07ZJS	(R/S)-2-((4-benzylphenoxy)methyl)piperidine	Investigative
T03691	DRUGINFO	D08TNQ	N5-[4-(Phenylmethoxy)phenyl]-L-glutamine	Investigative
T03691	DRUGINFO	D08UIO	2-[4-(2-Azepan-1-ylethoxy)phenoxy]benzothiazole	Investigative
T03691	DRUGINFO	D08WZB	N5-[4-(1H-pyrrol-1-yl)phenyl]-L-glutamamide	Investigative
T03691	DRUGINFO	D09BWE	1-[4-(Benzothiazol-2-yloxy)benzyl]piperidin-4-ol	Investigative
T03691	DRUGINFO	D09MDO	4-amino-N-[4-(benzyloxy)phenyl]butanamide	Investigative
T03691	DRUGINFO	D09OWF	N5-(4-Phenoxyphenyl)-L-glutamine	Investigative
T03691	DRUGINFO	D09PGC	2-[4-(2-Morpholin-4-ylethoxy)phenoxy]benzooxazole	Investigative
T03691	DRUGINFO	D0A2YG	N-methyl-1-(2-thiophen-2-ylphenyl)methanamine	Investigative
T03691	DRUGINFO	D0B0DP	N6-[4-(4-methylphenoxy)phenyl]-L-homoglutamine	Investigative
T03691	DRUGINFO	D0B9UW	N5-[4-(4-(3-Furyl)phenoxy)phenyl]-L-glutamamide	Investigative
T03691	DRUGINFO	D0C1XE	(R)-2-((4-benzylphenoxy)methyl)piperidine	Investigative
T03691	DRUGINFO	D0DI4I	N5-[4-(2-Oxo-3-phenylpropoxy)phenyl]-L-glutamine	Investigative
T03691	DRUGINFO	D0G0JC	N-(pyridin-3-ylmethyl)aniline	Investigative
T03691	DRUGINFO	D0G8SW	N5-[4-(4-methylphenoxy)phenyl]-L-glutamamide	Investigative
T03691	DRUGINFO	D0H9NZ	(R/S)-2-((4-benzylphenoxy)methyl)piperazine	Investigative
T03691	DRUGINFO	D0HA1K	N1-[4-(Phenylmethoxy)phenyl]-L-glutamine	Investigative
T03691	DRUGINFO	D0I4OV	(4-(thiophen-2-yl)phenyl)methanamine	Investigative
T03691	DRUGINFO	D0I7MC	4-(4-(pentyloxy)phenoxy)phenol	Investigative
T03691	DRUGINFO	D0J0WO	(4-fluorophenyl)(pyridin-4-yl)methanone	Investigative
T03691	DRUGINFO	D0LZ3O	N1-[4-(Phenylmethoxy)phenyl]-L-aspartamine	Investigative
T03691	DRUGINFO	D0M2CY	4S-4,5-Diamino-N-(4-phenoxyphenyl)pentanamide	Investigative
T03691	DRUGINFO	D0N6TC	N5-[4-(2-phenylethoxy)phenyl]-L-glutamine	Investigative
T03691	DRUGINFO	D0P7DF	1-[4-(4-Iodophenoxy)phenyl]piperazine	Investigative
T03691	DRUGINFO	D0PF9Q	2-(4-Piperidin-1-ylmethylphenoxy)benzothiazole	Investigative
T03691	DRUGINFO	D0R7BT	1-(2,2'-bithiophen-5-yl)methanamine	Investigative
T03691	DRUGINFO	D0SZ9E	8(S)-amino-2(R)-methyl-7-oxononanoic acid	Investigative
T03691	DRUGINFO	D0U1EV	N5-[4-(Phenylmethoxy)phenyl]-D-glutamine	Investigative
T03691	DRUGINFO	D0U1UV	N1-[4-(Phenylmethoxy)phenyl]-D-aspartamine	Investigative
T03691	DRUGINFO	D0U2AM	N5-[4-Benzylphenyl]-L-glutamamide	Investigative
T03691	DRUGINFO	D0V0MH	1-(4-Phenoxyphenyl)piperazine	Investigative
T03691	DRUGINFO	D0VN8V	4-[2-(4-Benzylphenoxy)ethyl]pyridine	Investigative
T03691	DRUGINFO	D0W2OP	2-(4-benzylphenoxy)ethanamine	Investigative
T03691	DRUGINFO	D0Y6IV	4-(4-propoxyphenoxy)phenol	Investigative
T03691	DRUGINFO	D0Z6DL	N5-[4-(N-Phenylamino)phenyl]-L-glutamine	Investigative
T03691	DRUGINFO	D01KOI	4-(2-amino-1,3-thiazol-4-yl)phenol	Investigative
T03691	DRUGINFO	D02AYI	2-(4-phenoxyphenoxy)ethanamine	Investigative
T03691	DRUGINFO	D09DRF	3-(Benzyloxy)Pyridin-2-Amine	Investigative
T03691	DRUGINFO	D0C8MT	2-(7-(benzyloxy)-1H-indol-3-yl)ethanamine	Investigative
T03691	DRUGINFO	D0Q8LS	2-[4-(2-Piperidin-1-ylethyl)phenoxy]benzothiazole	Investigative
T03691	DRUGINFO	D00UIN	JNJ-10392980	Investigative
T03691	DRUGINFO	D0F2ME	Acetate Ion	Investigative

T11211	TARGETID	T11211
T11211	FORMERID	TTDS00367
T11211	UNIPROID	ANDR_HUMAN
T11211	TARGNAME	Androgen receptor (AR)
T11211	GENENAME	AR
T11211	TARGTYPE	Successful
T11211	SYNONYMS	Testosterone receptor; Nuclear receptor subfamily 3 group C member 4; NR3C4; Dihydrotestosterone receptor; DHTR
T11211	FUNCTION	Transcription factor activity is modulated by bound coactivator and corepressor proteins like ZBTB7A that recruits NCOR1 and NCOR2 to the androgen response elements/ARE on target genes, negatively regulating androgen receptor signaling and androgen-induced cell proliferation. Transcription activation is also down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3. Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues.
T11211	PDBSTRUC	5VO4; 5V8Q; 5T8J; 5T8E; 5JJM
T11211	BIOCLASS	Nuclear hormone receptor
T11211	SEQUENCE	MEVQLGLGRVYPRPPSKTYRGAFQNLFQSVREVIQNPGPRHPEAASAAPPGASLLLLQQQQQQQQQQQQQQQQQQQQQQQETSPRQQQQQQGEDGSPQAHRRGPTGYLVLDEEQQPSQPQSALECHPERGCVPEPGAAVAASKGLPQQLPAPPDEDDSAAPSTLSLLGPTFPGLSSCSADLKDILSEASTMQLLQQQQQEAVSEGSSSGRAREASGAPTSSKDNYLGGTSTISDNAKELCKAVSVSMGLGVEALEHLSPGEQLRGDCMYAPLLGVPPAVRPTPCAPLAECKGSLLDDSAGKSTEDTAEYSPFKGGYTKGLEGESLGCSGSAAAGSSGTLELPSTLSLYKSGALDEAAAYQSRDYYNFPLALAGPPPPPPPPHPHARIKLENPLDYGSAWAAAAAQCRYGDLASLHGAGAAGPGSGSPSAAASSSWHTLFTAEEGQLYGPCGGGGGGGGGGGGGGGGGGGGGGGEAGAVAPYGYTRPPQGLAGQESDFTAPDVWYPGGMVSRVPYPSPTCVKSEMGPWMDSYSGPYGDMRLETARDHVLPIDYYFPPQKTCLICGDEASGCHYGALTCGSCKVFFKRAAEGKQKYLCASRNDCTIDKFRRKNCPSCRLRKCYEAGMTLGARKLKKLGNLKLQEEGEASSTTSPTEETTQKLTVSHIEGYECQPIFLNVLEAIEPGVVCAGHDNNQPDSFAALLSSLNELGERQLVHVVKWAKALPGFRNLHVDDQMAVIQYSWMGLMVFAMGWRSFTNVNSRMLYFAPDLVFNEYRMHKSRMYSQCVRMRHLSQEFGWLQITPQEFLCMKALLLFSIIPVDGLKNQKFFDELRMNYIKELDRIIACKRKNPTSCSRRFYQLTKLLDSVQPIARELHQFTFDLLIKSHMVSVDFPEMMAEIISVQVPKILSGKVKPIYFHTQ
T11211	DRUGINFO	D00YWP	Nandrolone	Approved
T11211	DRUGINFO	D06AEO	Cyproterone	Approved
T11211	DRUGINFO	D06XMU	Testosterone	Approved
T11211	DRUGINFO	D08TEJ	Clascoterone	Approved
T11211	DRUGINFO	D09NNA	Dromostanolone	Approved
T11211	DRUGINFO	D0BC2E	Hydroxyflutamide	Approved
T11211	DRUGINFO	D0DV6D	Darolutamide	Approved
T11211	DRUGINFO	D0L2LS	Fluoxymesterone	Approved
T11211	DRUGINFO	D0QK5X	Enzalutamide	Approved
T11211	DRUGINFO	D0S7LG	ARN-509	Approved
T11211	DRUGINFO	D0SC8F	Ethylestrenol	Approved
T11211	DRUGINFO	D0SN9T	Nilutamide	Approved
T11211	DRUGINFO	D0U3GL	Oxandrolone	Approved
T11211	DRUGINFO	D0V9BD	Bicalutamide	Approved
T11211	DRUGINFO	D0Y0SW	Flutamide	Approved
T11211	DRUGINFO	D0K0EK	Prasterone	Approved
T11211	DRUGINFO	D0R7JT	Fludrocortisone	Approved
T11211	DRUGINFO	D0B2WJ	Flufenamic Acid	Approved
T11211	DRUGINFO	D04DJN	Dihydrotestosterone	Phase 4
T11211	DRUGINFO	D04NNJ	ZANOTERONE	Phase 3
T11211	DRUGINFO	DE4AO8	HC-1119	Phase 3
T11211	DRUGINFO	D04KYB	ASCJ-9	Phase 2
T11211	DRUGINFO	D0C9EN	AZD5312	Phase 2
T11211	DRUGINFO	D0G1IV	Testogen TDS	Phase 2
T11211	DRUGINFO	D0RV6F	MK-0773	Phase 2
T11211	DRUGINFO	D0U0BU	TOK-001	Phase 2
T11211	DRUGINFO	DZTX12	ASC-J9	Phase 2
T11211	DRUGINFO	D03CVT	ONC1-13B	Phase 1/2
T11211	DRUGINFO	D0N7DQ	APC-100	Phase 1/2
T11211	DRUGINFO	D3XE7Y	ARV-766	Phase 1/2
T11211	DRUGINFO	D3ZY1K	ARV-110	Phase 1/2
T11211	DRUGINFO	DS41PJ	ARV-471	Phase 1/2
T11211	DRUGINFO	D04XWX	PS-178990	Phase 1
T11211	DRUGINFO	D05VNP	TESTOSTERONE BUCICLATE	Phase 1
T11211	DRUGINFO	D08AAV	AZD-3514	Phase 1
T11211	DRUGINFO	D09ZLZ	RAD-140	Phase 1
T11211	DRUGINFO	D0C4FS	DT-200	Phase 1
T11211	DRUGINFO	D0D3FP	Drug 2881078	Phase 1
T11211	DRUGINFO	D0N5NC	TAS3681	Phase 1
T11211	DRUGINFO	D8C1OA	AC0176	Phase 1
T11211	DRUGINFO	DNY63Z	CC-94676	Phase 1
T11211	DRUGINFO	DY7Q1O	EPI-7386	Phase 1
T11211	DRUGINFO	D08NNR	Testosterone glucoside	Discontinued in Phase 2
T11211	DRUGINFO	D09IZX	GW-275919	Discontinued in Phase 2
T11211	DRUGINFO	D0E3EK	NP-619	Discontinued in Phase 2
T11211	DRUGINFO	D0F7WQ	HE-2000	Discontinued in Phase 2
T11211	DRUGINFO	D00ABW	Opterone	Discontinued in Phase 1
T11211	DRUGINFO	D03KTE	LGD2941	Discontinued in Phase 1
T11211	DRUGINFO	D03SHP	GSK2849466	Discontinued in Phase 1
T11211	DRUGINFO	D0S7UU	PF-06260414	Discontinued in Phase 1
T11211	DRUGINFO	D05BCA	MX-4509	Discontinued in Phase 1
T11211	DRUGINFO	D0BJ7W	GLPG-0492	Preclinical
T11211	DRUGINFO	D07VUD	ZD-3980	Terminated
T11211	DRUGINFO	D0G6PL	LG-2293	Terminated
T11211	DRUGINFO	D00QVP	6,11-dihydrothiochromeno[4,3-b]indol-8-ol	Investigative
T11211	DRUGINFO	D02RZC	ASC-JMX2	Investigative
T11211	DRUGINFO	D03KYW	Calusterone	Investigative
T11211	DRUGINFO	D04MFW	DL-3	Investigative
T11211	DRUGINFO	D04QFY	GTx-027	Investigative
T11211	DRUGINFO	D07KOY	RU-59063	Investigative
T11211	DRUGINFO	D07TLT	11-methyl-6,11-dihydro-5H-benzo[a]carbazol-9-ol	Investigative
T11211	DRUGINFO	D09HQH	Boldenone	Investigative
T11211	DRUGINFO	D09XGK	Testetrol	Investigative
T11211	DRUGINFO	D0A7YH	Palodesangren C	Investigative
T11211	DRUGINFO	D0C1UP	SX-ARPC	Investigative
T11211	DRUGINFO	D0D8QN	ARN34	Investigative
T11211	DRUGINFO	D0I3LL	Palodesangren D	Investigative
T11211	DRUGINFO	D0JC4J	SARMs	Investigative
T11211	DRUGINFO	D0JI4G	Palodesangren E	Investigative
T11211	DRUGINFO	D0MM9P	OXENDLONE	Investigative
T11211	DRUGINFO	D0NH0U	HYG-440	Investigative
T11211	DRUGINFO	D0O0II	ASC-JMZ1	Investigative
T11211	DRUGINFO	D0T1DZ	EPI-001	Investigative
T11211	DRUGINFO	D0W5IF	CH-4933468	Investigative
T11211	DRUGINFO	D0W8AI	Andromustine	Investigative
T11211	DRUGINFO	D0Z3WA	Delta1-dihydrotestosterone	Investigative
T11211	DRUGINFO	D06BLF	1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane	Investigative
T11211	DRUGINFO	D06VZE	[3H]mibolerone	Investigative
T11211	DRUGINFO	D01ETZ	[3H]methyltrienolone	Investigative

T63484	TARGETID	T63484
T63484	FORMERID	TTDR00008
T63484	UNIPROID	G6PD_HUMAN
T63484	TARGNAME	Glucose-6-phosphate dehydrogenase (G6PD)
T63484	GENENAME	G6PD
T63484	TARGTYPE	Successful
T63484	SYNONYMS	Glucose-6-phosphate 1-dehydrogenase
T63484	FUNCTION	The main function of this enzyme is to provide reducing power (NADPH) and pentose phosphates for fatty acid and nucleic acid synthesis. Catalyzes the rate-limiting step of the oxidative pentose-phosphate pathway, which represents a route for the dissimilation of carbohydrates besides glycolysis.
T63484	PDBSTRUC	6.00E+08; 6.00E+07; 5UKW; 2BHL; 2BH9
T63484	BIOCLASS	CH-OH donor oxidoreductase
T63484	ECNUMBER	EC 1.1.1.49
T63484	SEQUENCE	MAEQVALSRTQVCGILREELFQGDAFHQSDTHIFIIMGASGDLAKKKIYPTIWWLFRDGLLPENTFIVGYARSRLTVADIRKQSEPFFKATPEEKLKLEDFFARNSYVAGQYDDAASYQRLNSHMNALHLGSQANRLFYLALPPTVYEAVTKNIHESCMSQIGWNRIIVEKPFGRDLQSSDRLSNHISSLFREDQIYRIDHYLGKEMVQNLMVLRFANRIFGPIWNRDNIACVILTFKEPFGTEGRGGYFDEFGIIRDVMQNHLLQMLCLVAMEKPASTNSDDVRDEKVKVLKCISEVQANNVVLGQYVGNPDGEGEATKGYLDDPTVPRGSTTATFAAVVLYVENERWDGVPFILRCGKALNERKAEVRLQFHDVAGDIFHQQCKRNELVIRVQPNEAVYTKMMTKKPGMFFNPEESELDLTYGNRYKNVKLPDAYERLILDVFCGSQMHFVRSDELREAWRIFTPLLHQIELEKPKPIPYIYGSRGPTEADELMKRVGFQYEGTYKWVNPHKL
T63484	DRUGINFO	D0K0EK	Prasterone	Approved
T63484	DRUGINFO	D0O8FW	EPIANDROSTERONE	Phase 3
T63484	DRUGINFO	D05JCG	CBF-BS2	Discontinued in Phase 2
T63484	DRUGINFO	D01HNP	Hydroxyacetic Acid	Investigative
T63484	DRUGINFO	D0FF3D	Metazamide	Investigative
T63484	DRUGINFO	D0J2FY	2'-Monophosphoadenosine 5'-Diphosphoribose	Investigative

T34234	TARGETID	T34234
T34234	FORMERID	TTDS00251
T34234	UNIPROID	VDR_HUMAN
T34234	TARGNAME	Vitamin D3 receptor (VDR)
T34234	GENENAME	VDR
T34234	TARGTYPE	Successful
T34234	SYNONYMS	Vitamin D(3) receptor; Nuclear vitamin D receptor; Nuclear receptor subfamily 1 group I member 1; NR1I1; 1,25-dihydroxyvitamin D3 receptor
T34234	FUNCTION	Enters the nucleus upon vitamin D3 binding where it forms heterodimers with the retinoid X receptor/RXR. The VDR-RXR heterodimers bind to specific response elements on DNA and activate the transcription of vitamin D3-responsive target genes. Plays a central role in calcium homeostasis. Nuclear receptor for calcitriol, the active form of vitamin D3 which mediates the action of this vitamin on cells.
T34234	PDBSTRUC	5YT2; 5YSY; 5V39; 5GT4; 4ITF
T34234	BIOCLASS	Nuclear hormone receptor
T34234	SEQUENCE	MEAMAASTSLPDPGDFDRNVPRICGVCGDRATGFHFNAMTCEGCKGFFRRSMKRKALFTCPFNGDCRITKDNRRHCQACRLKRCVDIGMMKEFILTDEEVQRKREMILKRKEEEALKDSLRPKLSEEQQRIIAILLDAHHKTYDPTYSDFCQFRPPVRVNDGGGSHPSRPNSRHTPSFSGDSSSSCSDHCITSSDMMDSSSFSNLDLSEEDSDDPSVTLELSQLSMLPHLADLVSYSIQKVIGFAKMIPGFRDLTSEDQIVLLKSSAIEVIMLRSNESFTMDDMSWTCGNQDYKYRVSDVTKAGHSLELIEPLIKFQVGLKKLNLHEEEHVLLMAICIVSPDRPGVQDAALIEAIQDRLSNTLQTYIRCRHPPPGSHLLYAKMIQKLADLRSLNEEHSKQYRCLSFQPECSMKLTPLVLEVFGNEIS
T34234	DRUGINFO	D01QUS	Calcipotriol	Approved
T34234	DRUGINFO	D01UFN	Falecalcitrol	Approved
T34234	DRUGINFO	D02VPX	Calcidiol	Approved
T34234	DRUGINFO	D06JPB	Ergocalciferol	Approved
T34234	DRUGINFO	D0G5CF	Doxercalciferol	Approved
T34234	DRUGINFO	D0G8OC	Dihydrotachysterol	Approved
T34234	DRUGINFO	D0K5WS	Cholecalciferol	Approved
T34234	DRUGINFO	D0N1TP	Paricalcitol	Approved
T34234	DRUGINFO	D0T2PL	Calcitriol	Approved
T34234	DRUGINFO	D09ZJQ	Seocalcitol	Phase 3
T34234	DRUGINFO	D0U8CR	S-06911	Phase 3
T34234	DRUGINFO	D0R8IE	Inecalcitol oral	Phase 2
T34234	DRUGINFO	D00CGH	RO-23-7553	Phase 1
T34234	DRUGINFO	D05SOH	CTAP-201	Phase 1
T34234	DRUGINFO	D00SZR	PMID27454349-Compound-98	Patented
T34234	DRUGINFO	D03ZXP	PMID27454349-Compound-97	Patented
T34234	DRUGINFO	D09KWM	PMID27454349-Compound-93	Patented
T34234	DRUGINFO	D0JC8M	PMID27454349-Compound-95	Patented
T34234	DRUGINFO	D0O2HK	PMID27454349-Compound-102	Patented
T34234	DRUGINFO	D0P1KV	PMID27454349-Compound-100	Patented
T34234	DRUGINFO	D0P8CM	PMID27454349-Compound-92	Patented
T34234	DRUGINFO	D0PJ2C	PMID27454349-Compound-99	Patented
T34234	DRUGINFO	D0UK7K	PMID27454349-Compound-91	Patented
T34234	DRUGINFO	D0UY3J	PMID27454349-Compound-96	Patented
T34234	DRUGINFO	D0WT4I	PMID27454349-Compound-101	Patented
T34234	DRUGINFO	D0WV1W	PMID27454349-Compound-94	Patented
T34234	DRUGINFO	D06SBK	Atocalcitol	Discontinued in Phase 2
T34234	DRUGINFO	D07BDY	Tisocalcitate	Discontinued in Phase 2
T34234	DRUGINFO	D0I4GI	RO-26-9228	Discontinued in Phase 2
T34234	DRUGINFO	D0RF9T	Lexacalcitol	Discontinued in Phase 2
T34234	DRUGINFO	D08KZR	BXL-746	Discontinued in Phase 1
T34234	DRUGINFO	D0KK4U	CB-1267	Terminated
T34234	DRUGINFO	D0O6WJ	Ecalcidene	Terminated
T34234	DRUGINFO	D0T9SJ	CEP-4186	Terminated
T34234	DRUGINFO	D02EHY	2MD	Investigative
T34234	DRUGINFO	D06DEL	calcitriol-26,23-lactone	Investigative
T34234	DRUGINFO	D07AHG	LG190178	Investigative
T34234	DRUGINFO	D0C7NV	MC-1301	Investigative
T34234	DRUGINFO	D0D6XV	TEI-9647	Investigative
T34234	DRUGINFO	D0K8VA	gemini	Investigative
T34234	DRUGINFO	D0X0AM	ZK159222	Investigative
T34234	DRUGINFO	D0X3DK	KSP-BCS-1-alpha-CHF2-1624F2-2	Investigative
T34234	DRUGINFO	D0XZ2P	KSP-BCS-1-alpha-CHF2-20-epi-22-oxabishomo-26-OH	Investigative
T34234	DRUGINFO	D06RBG	3-keto-lithocholic acid	Investigative

T13260	TARGETID	T13260
T13260	FORMERID	TTDS00252
T13260	UNIPROID	CP19A_HUMAN
T13260	TARGNAME	Aromatase (CYP19A1)
T13260	GENENAME	CYP19A1
T13260	TARGTYPE	Successful
T13260	SYNONYMS	P-450AROM; Estrogen synthetase; Estrogen synthase; Cytochrome P450 19A1; Cytochrome P-450AROM; CYPXIX; CYP19; CYAR; ARO1
T13260	FUNCTION	Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
T13260	PDBSTRUC	5JL9; 5JL7; 5JL6; 5JKW; 5JKV
T13260	BIOCLASS	Paired donor oxygen oxidoreductase
T13260	ECNUMBER	EC 1.14.14.14
T13260	SEQUENCE	MVLEMLNPIHYNITSIVPEAMPAATMPVLLLTGLFLLVWNYEGTSSIPGPGYCMGIGPLISHGRFLWMGIGSACNYYNRVYGEFMRVWISGEETLIISKSSSMFHIMKHNHYSSRFGSKLGLQCIGMHEKGIIFNNNPELWKTTRPFFMKALSGPGLVRMVTVCAESLKTHLDRLEEVTNESGYVDVLTLLRRVMLDTSNTLFLRIPLDESAIVVKIQGYFDAWQALLIKPDIFFKISWLYKKYEKSVKDLKDAIEVLIAEKRRRISTEEKLEECMDFATELILAEKRGDLTRENVNQCILEMLIAAPDTMSVSLFFMLFLIAKHPNVEEAIIKEIQTVIGERDIKIDDIQKLKVMENFIYESMRYQPVVDLVMRKALEDDVIDGYPVKKGTNIILNIGRMHRLEFFPKPNEFTLENFAKNVPYRYFQPFGFGPRGCAGKYIAMVMMKAILVTLLRRFHVKTLQGQCVESIQKIHDLSLHPDETKNMLEMIFTPRNSDRCLEH
T13260	DRUGINFO	D0C1WH	Letrozole	Approved
T13260	DRUGINFO	D0C7JF	Testolactone	Approved
T13260	DRUGINFO	D0D2VS	Exemestane	Approved
T13260	DRUGINFO	D0W0BF	Anastrozole	Approved
T13260	DRUGINFO	D0M6DO	Aminoglutethimide	Approved
T13260	DRUGINFO	D0ZX1P	FADROZOLE	Approved
T13260	DRUGINFO	D0B4ES	Atamestane + Toremifene	Phase 3
T13260	DRUGINFO	D08UGX	LIAROZOLE	Phase 2/3
T13260	DRUGINFO	D02XMD	BGS-649	Phase 2
T13260	DRUGINFO	D0J8RR	Dextromethorphan+quinidine	Phase 2
T13260	DRUGINFO	D0Y6OA	Coumate	Phase 2
T13260	DRUGINFO	D02ABO	NARINGENIN	Phase 1
T13260	DRUGINFO	D0B6PZ	FORMESTANE	Withdrawn from market
T13260	DRUGINFO	D04PSL	FINROZOLE	Discontinued in Phase 2
T13260	DRUGINFO	D0D3PF	VOROZOLE	Discontinued in Phase 2
T13260	DRUGINFO	D0U9LL	NKS-01	Discontinued in Phase 2
T13260	DRUGINFO	D0Y2OG	YM-511	Discontinued in Phase 2
T13260	DRUGINFO	D06JUR	Rogletimide	Terminated
T13260	DRUGINFO	D0FS9K	MINAMESTANE	Terminated
T13260	DRUGINFO	D00AVS	MR-20814	Investigative
T13260	DRUGINFO	D00BVP	3-(imidazolylmethyl)-4'-methoxyflavone	Investigative
T13260	DRUGINFO	D00GCK	3-Fluoren-9-ylidenemethyl-pyridine	Investigative
T13260	DRUGINFO	D00VUO	3-[6-Methoxy-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D00ZPJ	NSC-12999	Investigative
T13260	DRUGINFO	D01IJX	1-(2-(benzo[b]thiophen-4-yl)ethyl)-1H-imidazole	Investigative
T13260	DRUGINFO	D01LOU	4-Imidazol-1-ylmethyl-1-nitro-xanthen-9-one	Investigative
T13260	DRUGINFO	D01MPK	3-(4-Amino-phenyl)-1-methyl-pyrrolidine-2,5-dione	Investigative
T13260	DRUGINFO	D01OQW	ALBANOL A	Investigative
T13260	DRUGINFO	D02BWQ	3-[3-Methyl-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D02LTV	MR-20494	Investigative
T13260	DRUGINFO	D02QSH	NSC-368280	Investigative
T13260	DRUGINFO	D02SIT	1-(9-Phenyl-9H-fluoren-9-yl)1H-imidazole	Investigative
T13260	DRUGINFO	D02XTS	3-(2,2-Diphenyl-vinyl)-pyridine	Investigative
T13260	DRUGINFO	D03FBI	3,5-Diamino-4'-amino-trans-stilbene	Investigative
T13260	DRUGINFO	D04DZZ	N-(2-nonyloxy-4-nitrophenyl)methanesulfonamide	Investigative
T13260	DRUGINFO	D04HVL	4-(3,4,5-Trimethoxyphenethyl)aniline	Investigative
T13260	DRUGINFO	D04IJE	4-Fluoren-9-ylidenemethyl-pyridine	Investigative
T13260	DRUGINFO	D04REX	5-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyrimidine	Investigative
T13260	DRUGINFO	D04TBB	11BETA,13-DIHYDRO-10-EPI-8-DEOXYCUMAM-BRIN B	Investigative
T13260	DRUGINFO	D04VRY	3-(imidazolylmethyl)-7-methoxy-4'-nitroflavone	Investigative
T13260	DRUGINFO	D04WJN	3-((1H-imidazol-1-yl)methyl)-9H-xanthen-9-one	Investigative
T13260	DRUGINFO	D05HRP	3-(4-Amino-phenyl)-3-methyl-pyrrolidine-2,5-dione	Investigative
T13260	DRUGINFO	D05PXK	4'-cyano-3-(imidazolylmethyl)-7-methoxyflavone	Investigative
T13260	DRUGINFO	D05YNW	4-Indan-(1E)-ylidenemethyl-pyridine	Investigative
T13260	DRUGINFO	D05ZPO	7-hydroxy-2-phenylchroman-4-one	Investigative
T13260	DRUGINFO	D06AZC	NSC-131736	Investigative
T13260	DRUGINFO	D06GIV	NSC-356483	Investigative
T13260	DRUGINFO	D06HJB	LUDARTIN	Investigative
T13260	DRUGINFO	D06WPP	4'-bromo-3-(imidazolylmethyl)-7-methoxyflavone	Investigative
T13260	DRUGINFO	D07FGX	2-Phenyl-3-pyridin-4-ylmethylene-chroman-4-one	Investigative
T13260	DRUGINFO	D07JKK	3,4-bis(3,4-dimethoxyphenyl)furan-2(5H)-one	Investigative
T13260	DRUGINFO	D07PHT	NSC-289311	Investigative
T13260	DRUGINFO	D07PHV	1-Bromo-4-imidazol-1-ylmethyl-xanthen-9-one	Investigative
T13260	DRUGINFO	D07SOM	3-(imidazolylmethyl)flavone	Investigative
T13260	DRUGINFO	D07TIJ	1-(9H-fluoren-9-yl)-1H-imidazole	Investigative
T13260	DRUGINFO	D07TUX	7-(2-(1H-imidazol-1-yl)ethoxy)-2H-chromen-2-one	Investigative
T13260	DRUGINFO	D07UVN	3-Methoxyl-4'-amino-trans-stilbene	Investigative
T13260	DRUGINFO	D07ZCD	4-[6-Methyl-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D07ZYL	4-[5-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D08AAP	NSC-75308	Investigative
T13260	DRUGINFO	D08ARY	NSC-368272	Investigative
T13260	DRUGINFO	D08EZA	3-(imidazolylmethyl)-4'-nitroflavone	Investigative
T13260	DRUGINFO	D08FOJ	2-phenyl-2,3-dihydrobenzo[h]chromen-4-one	Investigative
T13260	DRUGINFO	D08IIW	MR-16089	Investigative
T13260	DRUGINFO	D08KLN	3,4'-(Ethane-1,2-diyl)dibenzenamine	Investigative
T13260	DRUGINFO	D08TKB	1-(2-phenoxybenzyl)-1H-imidazole	Investigative
T13260	DRUGINFO	D08UQH	2-(1H-Imidazol-1-yl)-1-(4-nitrophenyl)ethanone	Investigative
T13260	DRUGINFO	D09HGK	4-[5-Methoxy-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D09MYQ	NSC-93358	Investigative
T13260	DRUGINFO	D09OPA	(2S)-euchrenone a7	Investigative
T13260	DRUGINFO	D09XKH	(2S)-5,7,2',4'-tetrahydroxyflavanone	Investigative
T13260	DRUGINFO	D09ZHX	4'-bromo-3-(imidazolylmethyl)flavone	Investigative
T13260	DRUGINFO	D09ZIW	Isogemichalcone C	Investigative
T13260	DRUGINFO	D0A7PA	2,4-Dimethoxy-3'-amino-trans-stilbene	Investigative
T13260	DRUGINFO	D0AH1B	3-[4-Methyl-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D0AM2Z	3-(4-Amino-phenyl)-3-propyl-piperidine-2,6-dione	Investigative
T13260	DRUGINFO	D0AW7Q	2-Imidazol-1-ylmethylxanthen-9-one	Investigative
T13260	DRUGINFO	D0AY4E	3-[6-Methyl-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D0B8PE	2-(3-hydroxyphenyl)-7-methoxychroman-4-one	Investigative
T13260	DRUGINFO	D0C3XU	10-EPI-8-DEOXY-CUMAMBRIN B	Investigative
T13260	DRUGINFO	D0C5ZP	N-(2-benzyloxy-4-nitrophenyl)methanesulfonamide	Investigative
T13260	DRUGINFO	D0C8EO	5-[5-Methoxy-indan-(1E)-ylidenemethyl]-thiazole	Investigative
T13260	DRUGINFO	D0CR6B	4'-cyano-3-(imidazolylmethyl)flavone	Investigative
T13260	DRUGINFO	D0D7GG	1-(1-Benzyl-2-biphenyl-4-yl-ethyl)-1H-imidazole	Investigative
T13260	DRUGINFO	D0D8GU	4-[6-Methyl-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D0DJ3R	7-((1H-imidazol-1-yl)methyl)-4H-chromen-4-one	Investigative
T13260	DRUGINFO	D0DO1T	MR-20492	Investigative
T13260	DRUGINFO	D0E2RV	3-(4-Amino-phenyl)-3-heptyl-piperidine-2,6-dione	Investigative
T13260	DRUGINFO	D0E3IK	N-(2-Propyloxy-4-nitrophenyl)methanesulfonamide	Investigative
T13260	DRUGINFO	D0E5FV	ISOLICOFLAVONOL	Investigative
T13260	DRUGINFO	D0F4MF	2,3-Dimethoxy-4'-amino-trans-stilbene	Investigative
T13260	DRUGINFO	D0F4WQ	1-(4-Nitro-2-phenylsulfanylbenzyl)-1H-imidazole	Investigative
T13260	DRUGINFO	D0F5AC	4-Imidazol-1-ylmethylxanthen-9-one	Investigative
T13260	DRUGINFO	D0F8IB	MONODICTYOCHROMONE B	Investigative
T13260	DRUGINFO	D0F9MQ	N-(2-hexyloxy-4-nitrophenyl)methanesulfonamide	Investigative
T13260	DRUGINFO	D0G2JV	2,3,5-Trimethoxy-4'-amino-trans-stilbene	Investigative
T13260	DRUGINFO	D0GL0L	1-(9-phenyl-9H-fluoren-9-yl)-1H-1,2,4-triazole	Investigative
T13260	DRUGINFO	D0H1LK	3-(4-Amino-phenyl)-pyrrolidine-2,5-dione	Investigative
T13260	DRUGINFO	D0HC9U	4-Imidazol-1-ylmethyl-2-nitroxanthen-9-one	Investigative
T13260	DRUGINFO	D0HR9S	NSC-683634	Investigative
T13260	DRUGINFO	D0I1SI	2,4-Dimethoxy-4'-amino-trans-stilbene	Investigative
T13260	DRUGINFO	D0I2UE	4-Imidazol-1-ylmethylthioxanthen-9-one	Investigative
T13260	DRUGINFO	D0I5PY	1-(biphenyl-3-ylmethyl)-1H-1,2,4-triazole	Investigative
T13260	DRUGINFO	D0J2WW	4-[6-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D0J3PK	4-Imidazol-1-yl-2-phenyl-chroman-7-ol	Investigative
T13260	DRUGINFO	D0J4VR	3,5-Dihydroxyl-4'-amino-trans-stilbene	Investigative
T13260	DRUGINFO	D0J8FS	3-Nitro-4'-nitro-trans-stilbene	Investigative
T13260	DRUGINFO	D0K3CE	4-[6-Methoxy-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D0K5GG	2,3,4-Trimethoxy-4'-amino-trans-stilbene	Investigative
T13260	DRUGINFO	D0K5JU	4-Imidazol-1-ylmethyl-3-nitroxanthen-9-one	Investigative
T13260	DRUGINFO	D0L9BT	7-[1,2,4]Triazol-4-ylmethyl-chromen-4-one	Investigative
T13260	DRUGINFO	D0M0FE	N-[2-(4'-Nitrophenyl)ethyl]-imidazole	Investigative
T13260	DRUGINFO	D0M2IB	MDL-18962	Investigative
T13260	DRUGINFO	D0M4CX	NSC-613604	Investigative
T13260	DRUGINFO	D0M5EW	4-((1H-imidazol-1-yl)methyl)-2H-chromen-2-one	Investigative
T13260	DRUGINFO	D0N7QV	4-(1-Imidazol-1-yl-vinyl)-benzonitrile	Investigative
T13260	DRUGINFO	D0NB8V	3,4,5-Trimethoxy-3'-amino-trans-stilbene	Investigative
T13260	DRUGINFO	D0NH6T	(2S)-abyssinone II	Investigative
T13260	DRUGINFO	D0O0BL	2-Phenyl-4-[1,2,4]triazol-1-yl-chroman-7-ol	Investigative
T13260	DRUGINFO	D0O1ZM	3-(4-Amino-phenyl)-3-hexyl-piperidine-2,6-dione	Investigative
T13260	DRUGINFO	D0O6ZM	4-(3,4-Dimethoxyphenethyl)aniline	Investigative
T13260	DRUGINFO	D0OY1J	7-((1H-imidazol-1-yl)methyl)-2H-chromen-2-one	Investigative
T13260	DRUGINFO	D0P3ND	1-[(7-Fluoronaphth-2-yl)methyl]-1H-imidazole	Investigative
T13260	DRUGINFO	D0P5ZV	NSC-94891	Investigative
T13260	DRUGINFO	D0PU5V	7-((1H-imidazol-1-yl)methyl)isoquinoline	Investigative
T13260	DRUGINFO	D0Q6XB	3-Amino-4'-amino-trans-stilbene	Investigative
T13260	DRUGINFO	D0QL1V	Benzyl-biphenyl-4-ylmethyl-imidazol-1-yl-amine	Investigative
T13260	DRUGINFO	D0R2YN	NSC-122427	Investigative
T13260	DRUGINFO	D0R4WW	MR-20496	Investigative
T13260	DRUGINFO	D0S0OV	1-(7-Methoxy-2-phenyl-chroman-4-yl)-1H-imidazole	Investigative
T13260	DRUGINFO	D0S7VY	3,5-Diacetoxy-4'-amino-trans-stilbene	Investigative
T13260	DRUGINFO	D0S8MJ	NSC-356781	Investigative
T13260	DRUGINFO	D0SY6C	7,4'-Dihydroxyflavone	Investigative
T13260	DRUGINFO	D0T0CK	3,4-Dimethoxy-4'-amino-trans-stilbene	Investigative
T13260	DRUGINFO	D0T2IX	6-((1H-imidazol-1-yl)methyl)-2H-chromene-2-thione	Investigative
T13260	DRUGINFO	D0T3ED	NSC-666292	Investigative
T13260	DRUGINFO	D0TM4K	3-[3-Methyl-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D0U6IT	5-[5-Methoxy-indan-(1Z)-ylidenemethyl]-thiazole	Investigative
T13260	DRUGINFO	D0U6NJ	4-(2-(1H-imidazol-1-yl)ethoxy)-2H-chromen-2-one	Investigative
T13260	DRUGINFO	D0U8JC	MORACHALCONE A	Investigative
T13260	DRUGINFO	D0U9QB	DEHYDROLEUCODIN	Investigative
T13260	DRUGINFO	D0UI8Q	5-Bromo-8-imidazol-1-ylmethyl-chromen-4-one	Investigative
T13260	DRUGINFO	D0V0DB	9-Hydroxy-7,8-benzoflavone	Investigative
T13260	DRUGINFO	D0V1UY	CGS-18320B	Investigative
T13260	DRUGINFO	D0V3MV	1-(4-nitro-2-phenoxybenzyl)-1H-imidazole	Investigative
T13260	DRUGINFO	D0V8SM	8-Imidazol-1-ylmethyl-5-nitro-chromen-4-one	Investigative
T13260	DRUGINFO	D0W3LG	Broussoflavonol F	Investigative
T13260	DRUGINFO	D0W3LM	2-(4-hydroxyphenyl)-7-methoxychroman-4-one	Investigative
T13260	DRUGINFO	D0W4IB	2-Imidazol-1-yl-7-methoxy-3-phenyl-chromen-4-one	Investigative
T13260	DRUGINFO	D0W7GU	2,5-Dimethoxy-4'-amino-trans-stilbene	Investigative
T13260	DRUGINFO	D0W9PF	ANDROSTENEDONE	Investigative
T13260	DRUGINFO	D0W9ZC	4-Imidazol-1-ylmethyl-1-nitrothioxanthen-9-one	Investigative
T13260	DRUGINFO	D0WK9Q	4-(3,5-Dimethoxyphenethyl)benzenamine	Investigative
T13260	DRUGINFO	D0X8UK	5-(2-(1H-imidazol-1-yl)ethyl)quinoline	Investigative
T13260	DRUGINFO	D0XS6T	1-(4-Aminophenyl)-2-(1H-imidazol-1-yl)ethanone	Investigative
T13260	DRUGINFO	D0Y0CT	3-[3-Phenyl-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D0Y0EK	7-hydroxy-2-(3-hydroxyphenyl)chroman-4-one	Investigative
T13260	DRUGINFO	D0Y0QI	5-((1H-imidazol-1-yl)methyl)-7,8-dihydroquinoline	Investigative
T13260	DRUGINFO	D0Y1EX	Org-33201	Investigative
T13260	DRUGINFO	D0Y4TE	NSC-369087	Investigative
T13260	DRUGINFO	D0Y7RB	3-[6-Methyl-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D0Y8XJ	Docosapentaenoic acid	Investigative
T13260	DRUGINFO	D0Y9HD	NSC-625409	Investigative
T13260	DRUGINFO	D0Z1OI	3-(4-Amino-phenyl)-3-ethyl-pyrrolidine-2,5-dione	Investigative
T13260	DRUGINFO	D0Z4GR	4-(2,2-Diphenyl-vinyl)-pyridine	Investigative
T13260	DRUGINFO	D00HVZ	(+/-)-7-methoxy-2-(4-methoxyphenyl)chroman-4-one	Investigative
T13260	DRUGINFO	D01SUE	3-Indan-(1E)-ylidenemethyl-pyridine	Investigative
T13260	DRUGINFO	D01SZX	1-Imidazol-1-ylmethylxanthen-9-one	Investigative
T13260	DRUGINFO	D02NAG	3-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D02XHH	5-[5-Bromo-indan-(1Z)-ylidenemethyl]-1H-imidazole	Investigative
T13260	DRUGINFO	D03KLN	1-(3-Methoxy-naphthalen-2-yl)-1H-imidazole	Investigative
T13260	DRUGINFO	D03TRM	5-Indan-(1E)-ylidenemethyl-1H-imidazole	Investigative
T13260	DRUGINFO	D04CLL	3-[4-Methyl-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D04ELJ	3-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D04IBH	3-(5-Bromo-6-methoxy-naphthalen-2-yl)-pyridine	Investigative
T13260	DRUGINFO	D04QPK	3-[4-Fluoro-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D05FFY	1-(4-Cyanobenzyl)-5-methyl-1H-imidazole	Investigative
T13260	DRUGINFO	D05IWY	Gamma-mangostin	Investigative
T13260	DRUGINFO	D05MQE	3-[4-Chloro-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D05YJR	GARCINONE D	Investigative
T13260	DRUGINFO	D06FHE	1-Ethyl-5-(imidazol-1-yl-phenyl-methyl)-1H-indole	Investigative
T13260	DRUGINFO	D07CTI	1-Imidazol-1-ylmethyl-4-nitro-xanthen-9-one	Investigative
T13260	DRUGINFO	D07IQG	4-Bromo-1-imidazol-1-ylmethyl-xanthen-9-one	Investigative
T13260	DRUGINFO	D07PYC	3-Indan-(1Z)-ylidenemethyl-pyridine	Investigative
T13260	DRUGINFO	D08AZK	3-[5-Bromo-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D08FAB	3-(naphthalen-2-yl)pyridine	Investigative
T13260	DRUGINFO	D08HPU	3-(3-methyl-3,4-dihydronaphthalen-2-yl)pyridine	Investigative
T13260	DRUGINFO	D08PKR	6-Imidazol-1-yl-isoquinoline	Investigative
T13260	DRUGINFO	D08PNF	3-[5-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D08ZTZ	3-(5-Chloro-6-methoxy-naphthalen-2-yl)-pyridine	Investigative
T13260	DRUGINFO	D09MQF	3,4,5-Trimethoxy-4'-amino-trans-stilbene	Investigative
T13260	DRUGINFO	D09QDY	5-Indan-(1Z)-ylidenemethyl-1H-imidazole	Investigative
T13260	DRUGINFO	D09YXV	3-[5-Methoxy-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D0A2FO	(+/-)-7-methoxy-2-phenylchroman-4-one	Investigative
T13260	DRUGINFO	D0A2GB	3-(4-Amino-phenyl)-3-pentyl-piperidine-2,6-dione	Investigative
T13260	DRUGINFO	D0B5MZ	3-(4-Amino-phenyl)-3-butyl-piperidine-2,6-dione	Investigative
T13260	DRUGINFO	D0D0DR	1-(3-(4-fluorophenyl)propyl)-1H-imidazole	Investigative
T13260	DRUGINFO	D0E9WX	5-[5-Bromo-indan-(1E)-ylidenemethyl]-1H-imidazole	Investigative
T13260	DRUGINFO	D0G6QL	1-Naphthalen-2-yl-1H-imidazole	Investigative
T13260	DRUGINFO	D0G9WP	5-Pyridin-3-yl-2,3-dihydro-1H-inden-1-one	Investigative
T13260	DRUGINFO	D0I5NW	3-(3,4-dihydronaphthalen-2-yl)pyridine	Investigative
T13260	DRUGINFO	D0I7GE	ALPHA-NAPHTHOFLAVONE	Investigative
T13260	DRUGINFO	D0K2DR	5-Pyridin-3-yl-1,3-dihydro-2H-indol-2-one	Investigative
T13260	DRUGINFO	D0K4PY	LIQUIRTIGENIN	Investigative
T13260	DRUGINFO	D0L1JF	3-[4-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D0M7FS	3-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D0N9PY	3-[5-Ethoxy-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D0Q3JZ	3-[5-Ethoxy-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D0Q8UZ	3,5-Dimethoxy-4'-amino-trans-stilbene	Investigative
T13260	DRUGINFO	D0U7RR	3-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D0V3YH	3-[4-Chloro-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D0V8CR	3-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D0X1QS	3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine	Investigative
T13260	DRUGINFO	D0YS2F	3-[7-Methoxy-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D0Z7EL	GOSSYPETIN	Investigative
T13260	DRUGINFO	D01KKU	NSC-94258	Investigative
T13260	DRUGINFO	D01REI	4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diol	Investigative
T13260	DRUGINFO	D02CSU	4-Indan-(1Z)-ylidenemethyl-pyridine	Investigative
T13260	DRUGINFO	D03EXD	4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine	Investigative
T13260	DRUGINFO	D03MKT	4-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D06HFV	5-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyrimidine	Investigative
T13260	DRUGINFO	D09HEA	4-((1H-imidazol-1-yl)methyl)benzonitrile	Investigative
T13260	DRUGINFO	D09HOE	4-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D0D9FR	4-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D0F5YU	4-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D0I1YH	4-[(3'-Hydroxybiphenyl-4-yl)methyl]pyridine	Investigative
T13260	DRUGINFO	D0K5KG	3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine	Investigative
T13260	DRUGINFO	D0MA9G	3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine	Investigative
T13260	DRUGINFO	D0N1PQ	3-(6-methoxynaphthalen-2-yl)pyridine	Investigative
T13260	DRUGINFO	D0NX0M	3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine	Investigative
T13260	DRUGINFO	D0Q0BK	3-Fluoro-4'-(pyridin-4-ylmethyl)biphenyl-4-ol	Investigative
T13260	DRUGINFO	D0R0TE	3-(6-Ethoxy-naphthalen-2-yl)-pyridine	Investigative
T13260	DRUGINFO	D0WN9P	4'-(Pyridin-4-ylmethyl)biphenyl-3-amine	Investigative
T13260	DRUGINFO	D0YD9J	4-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T13260	DRUGINFO	D0M8RO	4-ANDROSTENE-3-17-DIONE	Investigative
T13260	DRUGINFO	D01UYI	Chrysin	Investigative
T13260	DRUGINFO	D0S9YX	biochanin A	Investigative
T13260	DRUGINFO	D0S0RK	flavone	Investigative
T13260	DRUGINFO	D00RIX	APIGENIN	Investigative

T85799	TARGETID	T85799
T85799	FORMERID	TTDC00165
T85799	UNIPROID	CDK4_HUMAN
T85799	TARGNAME	Cyclin-dependent kinase 4 (CDK4)
T85799	GENENAME	CDK4
T85799	TARGTYPE	Successful
T85799	SYNONYMS	PSK-J3; Cell division protein kinase 4
T85799	FUNCTION	Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complexes and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also phosphorylates SMAD3 in a cell-cycle-dependent manner and represses its transcriptional activity. Component of the ternary complex, cyclin D/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex. Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G(1)/S transition.
T85799	PDBSTRUC	5FWP; 5FWM; 5FWL; 5FWK; 3G33
T85799	BIOCLASS	Kinase
T85799	ECNUMBER	EC 2.7.11.22
T85799	SEQUENCE	MATSRYEPVAEIGVGAYGTVYKARDPHSGHFVALKSVRVPNGGGGGGGLPISTVREVALLRRLEAFEHPNVVRLMDVCATSRTDREIKVTLVFEHVDQDLRTYLDKAPPPGLPAETIKDLMRQFLRGLDFLHANCIVHRDLKPENILVTSGGTVKLADFGLARIYSYQMALTPVVVTLWYRAPEVLLQSTYATPVDMWSVGCIFAEMFRRKPLFCGNSEADQLGKIFDLIGLPPEDDWPRDVSLPRGAFPPRGPRPVQSVVPEMEESGAQLLLEMLTFNPHKRISAFRALQHSYLHKDEGNPE
T85799	DRUGINFO	D00UZR	Palbociclib	Approved
T85799	DRUGINFO	D01HVT	Ribociclib Succinate	Approved
T85799	DRUGINFO	D05SBO	LY2835219	Approved
T85799	DRUGINFO	D0AP9E	Trilaciclib	Approved
T85799	DRUGINFO	D07ESC	Apremilast	Approved
T85799	DRUGINFO	D08MXP	LEE011	Phase 3
T85799	DRUGINFO	D0W8IY	P-276	Phase 2
T85799	DRUGINFO	D0WU1O	G1T38	Phase 2
T85799	DRUGINFO	D01UMT	Ro 31-7453	Phase 2
T85799	DRUGINFO	D05IRT	P276-00	Phase 2
T85799	DRUGINFO	D4IS0G	GLR2007	Phase 1/2
T85799	DRUGINFO	D8ZV2Q	FCN-437	Phase 1/2
T85799	DRUGINFO	D70HZT	NUV-422	Phase 1/2
T85799	DRUGINFO	D0DX4J	P1446A-05	Phase 1
T85799	DRUGINFO	DZJ3D5	PF-07220060	Phase 1
T85799	DRUGINFO	D01XZG	G1T28-1	Phase 1
T85799	DRUGINFO	D0IX4B	AG-024322	Phase 1
T85799	DRUGINFO	D0P1CV	PHA-793887	Phase 1
T85799	DRUGINFO	DYH94Z	RGT-419B	Phase 1
T85799	DRUGINFO	DKCU40	FN-1501	Phase 1
T85799	DRUGINFO	D03DKV	RGB-286638	Phase 1
T85799	DRUGINFO	D0WT7D	Imidazo pyridine derivative 3	Patented
T85799	DRUGINFO	D03HED	Palbociclib/ribociclib analog 1	Patented
T85799	DRUGINFO	D04AKA	Pyrrolo[2,3-d]pyrimidine derivative 10	Patented
T85799	DRUGINFO	D0FQ6V	PMID26161698-Compound-17	Patented
T85799	DRUGINFO	D08KKC	Pyrrolo[2,3-d]pyrimidine derivative 9	Patented
T85799	DRUGINFO	D07TVO	PMID25726713-Compound-49	Patented
T85799	DRUGINFO	D0KH7Q	PMID25726713-Compound-51	Patented
T85799	DRUGINFO	D0LX6X	Indole-based analog 13	Patented
T85799	DRUGINFO	D0W4MN	Isoquinoline 1,3-dione derivative 1	Patented
T85799	DRUGINFO	D0WJ3W	PMID25726713-Compound-48	Patented
T85799	DRUGINFO	D0X5VI	PMID25726713-Compound-47	Patented
T85799	DRUGINFO	D0Y8JF	PMID25726713-Compound-50	Patented
T85799	DRUGINFO	D0H4HD	PMID25991433-Compound-A1	Patented
T85799	DRUGINFO	D0M5DX	Oxazolyl methylthiothiazole derivative 1	Patented
T85799	DRUGINFO	D0NV9O	BAY 10-00394	Discontinued in Phase 2
T85799	DRUGINFO	D04FHB	R547	Discontinued in Phase 1
T85799	DRUGINFO	D00VBT	ZK 304709	Discontinued in Phase 1
T85799	DRUGINFO	D07ZJC	INOC-005	Preclinical
T85799	DRUGINFO	D0Y6HA	CYC-103	Terminated
T85799	DRUGINFO	D0Z0KD	PD-0183812	Terminated
T85799	DRUGINFO	D03VDM	N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide	Investigative
T85799	DRUGINFO	D0G4JS	1-(1H-Indazol-6-yl)-3-pyridin-2-yl-urea	Investigative
T85799	DRUGINFO	D0M8CO	1-(7-Hydroxy-naphthalen-1-yl)-3-pyridin-2-yl-urea	Investigative
T85799	DRUGINFO	D0T2VG	1-Pyridin-2-yl-3-quinolin-5-yl-urea	Investigative
T85799	DRUGINFO	D0X1NW	1-(9-Oxo-9H-fluoren-4-yl)-3-pyridin-2-yl-urea	Investigative
T85799	DRUGINFO	D07HPE	Cdk4 inhibitor III	Investigative
T85799	DRUGINFO	D09OAH	Fascaplysin	Investigative
T85799	DRUGINFO	D09RYV	Ro-0505124	Investigative
T85799	DRUGINFO	D0VD8B	NSC-625987	Investigative
T85799	DRUGINFO	D0W6CE	10-hydroxy-18-methoxybetaenone	Investigative
T85799	DRUGINFO	D02DLC	PYRAZOLOPYRIDAZINE 1	Investigative
T85799	DRUGINFO	D0D5HQ	K00024	Investigative
T85799	DRUGINFO	D0O0VP	PYRAZOLOPYRIDAZINE 2	Investigative
T85799	DRUGINFO	D0P6JS	PMID18986805C9b	Investigative
T85799	DRUGINFO	D0Y5RO	NU-6102	Investigative
T85799	DRUGINFO	D04WFN	NU6140	Investigative
T85799	DRUGINFO	D06AOY	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	Investigative
T85799	DRUGINFO	D00NYT	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	Investigative
T85799	DRUGINFO	D0C3WY	3,4-diphenyl-1H-pyrrole-2,5-dione	Investigative
T85799	DRUGINFO	D0EK0G	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	Investigative
T85799	DRUGINFO	D0A5RM	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	Investigative

T60366	TARGETID	T60366
T60366	FORMERID	TTDS00313
T60366	UNIPROID	DCOR_HUMAN
T60366	TARGNAME	Ornithine decarboxylase (ODC1)
T60366	GENENAME	ODC1
T60366	TARGTYPE	Successful
T60366	SYNONYMS	ODC
T60366	FUNCTION	Polyamines are essential for cell proliferation and are implicated in cellular processes, ranging from DNA replication to apoptosis. Catalyzes the first and rate-limiting step of polyamine biosynthesis that converts ornithine into putrescine, which is the precursor for the polyamines, spermidine and spermine.
T60366	PDBSTRUC	5BWA; 4ZGY; 2OO0; 2ON3; 1D7K
T60366	BIOCLASS	Carbon-carbon lyase
T60366	ECNUMBER	EC 4.1.1.17
T60366	SEQUENCE	MNNFGNEEFDCHFLDEGFTAKDILDQKINEVSSSDDKDAFYVADLGDILKKHLRWLKALPRVTPFYAVKCNDSKAIVKTLAATGTGFDCASKTEIQLVQSLGVPPERIIYANPCKQVSQIKYAANNGVQMMTFDSEVELMKVARAHPKAKLVLRIATDDSKAVCRLSVKFGATLRTSRLLLERAKELNIDVVGVSFHVGSGCTDPETFVQAISDARCVFDMGAEVGFSMYLLDIGGGFPGSEDVKLKFEEITGVINPALDKYFPSDSGVRIIAEPGRYYVASAFTLAVNIIAKKIVLKEQTGSDDEDESSEQTFMYYVNDGVYGSFNCILYDHAHVKPLLQKRPKPDEKYYSSSIWGPTCDGLDRIVERCDLPEMHVGDWMLFENMGAYTVAAASTFNGFQRPTIYYVMSGPAWQLMQQFQNPDFPPEVEEQDASTLPVSCAWESGMKRHRAACASASINV
T60366	DRUGINFO	D0X7JR	Eflornithine	Approved
T60366	DRUGINFO	D00FMV	Putrescine	Discontinued in Phase 2
T60366	DRUGINFO	D01IGU	APA	Investigative
T60366	DRUGINFO	D01OHD	AMXT-1501	Investigative
T60366	DRUGINFO	D02XYV	(2R,5R)-delta-methyl-alpha-acetylenic putrescine	Investigative
T60366	DRUGINFO	D04FIN	ZAPOTIN	Investigative
T60366	DRUGINFO	D04ZDD	LONCHOCARPUSONE	Investigative
T60366	DRUGINFO	D08CKE	Alpha-monofluoromethyl-3,4-dehydroornithine methyl ester	Investigative
T60366	DRUGINFO	D08TLJ	Alpha-monofluoromethyl-3,4-dehydroornithine	Investigative
T60366	DRUGINFO	D09AHL	N-Pyridoxyl-Glycine-5-Monophosphate	Investigative
T60366	DRUGINFO	D0F3QP	4-hydroxylonchocarpin	Investigative
T60366	DRUGINFO	D0H2OA	Alpha-monofluoromethyl-3,4-dehydroornithine ethyl ester	Investigative
T60366	DRUGINFO	D0K6WI	3-(Aminooxy)propan-1-amine hydrochloride	Investigative
T60366	DRUGINFO	D0N4YR	3-methoxy-4-hydroxylonchocarpin	Investigative
T60366	DRUGINFO	D0XR2J	1-Amino-3-(aminoxy)-2-propanol Dihydrochloride	Investigative
T60366	DRUGINFO	D03LMM	G418	Investigative
T60366	DRUGINFO	D0B8JD	Pyridoxine-5'-Phosphate	Investigative
T60366	DRUGINFO	D0I5PZ	N'-Pyridoxyl-Lysine-5'-Monophosphate	Investigative

T52227	TARGETID	T52227
T52227	FORMERID	TTDS00301
T52227	UNIPROID	TYSY_CANAL
T52227	TARGNAME	Candida Thymidylate synthase (Candi TMP1)
T52227	GENENAME	Candi TMP1
T52227	TARGTYPE	Successful
T52227	SYNONYMS	Tsase of Candida albicans; TS of Candida albicans; TMP1; Human recombinant thymidylate synthase; HrTS
T52227	FUNCTION	Contributes to thede novo mitochondrial thymidylate biosynthesis pathway.
T52227	BIOCLASS	Methyltransferase
T52227	ECNUMBER	EC 2.1.1.45
T52227	SEQUENCE	MTVSPNTAEQAYLDLCKRIIDEGEHRPDRTGTGTKSLFAPPQLRFDLSNDTFPLLTTKKVFSKGIIHELLWFVAGSTDAKILSEKGVKIWEGNGSREFLDKLGLTHRREGDLGPVYGFQWRHFGAEYKDCDSDYTGQGFDQLQDVIKKLKTNPYDRRIIMSAWNPPDFAKMALPPCHVFCQFYVNFPTSSPDPNNPKQAKTAKPKLSCLLYQRSCDMGLGVPFNIASYALLTKMIAHVVDMDCGEFIHTLGDAHVYLDHIDALKEQFERIPKQFPKLVIKEERKNEIKSIDDFKFEDFEIVGYEPYPPIKMKMSV
T52227	DRUGINFO	D00HCQ	Capecitabine	Approved
T52227	DRUGINFO	D01KKQ	Raltitrexed	Approved
T52227	DRUGINFO	D05RHI	Trifluridine	Approved
T52227	DRUGINFO	D0M3MN	Leucovorin/5-fluorouracil	Approved
T52227	DRUGINFO	D0S5WG	Flucytosine	Approved
T52227	DRUGINFO	D0TS1Z	Floxuridine	Approved
T52227	DRUGINFO	D0Y4GO	Pemetrexed	Approved
T52227	DRUGINFO	D05LEO	Fluorouracil	Approved
T52227	DRUGINFO	D0O1WX	Ciprofloxacin XR	Approved
T52227	DRUGINFO	D06WQT	Nolatrexed	Phase 3
T52227	DRUGINFO	D0I9GR	Plevitrexed	Phase 2
T52227	DRUGINFO	D0Q0UA	UFT/leucovorin calcium	Phase 2
T52227	DRUGINFO	D04FYZ	Plevitrexed (R)-isomer	Phase 2
T52227	DRUGINFO	D05CQS	NB1011	Phase 1/2
T52227	DRUGINFO	D0S9MD	DFP-11207	Phase 1
T52227	DRUGINFO	D0U2CT	EMITEFUR	Discontinued in Preregistration
T52227	DRUGINFO	D0Y4AZ	Galocitabine	Discontinued in Phase 3
T52227	DRUGINFO	D0B6GJ	TT-62	Discontinued in Phase 2
T52227	DRUGINFO	D0E8JO	FO-152	Discontinued in Phase 2
T52227	DRUGINFO	D0C4YA	AG-331	Discontinued in Phase 1
T52227	DRUGINFO	D03BTP	Fosfluridine tidoxil	Terminated
T52227	DRUGINFO	D0L0AU	DMPDDF	Terminated
T52227	DRUGINFO	D00BNE	(6s)-5,6,7,8-Tetrahydrofolate	Investigative
T52227	DRUGINFO	D01FCH	Sp-722	Investigative
T52227	DRUGINFO	D01OVV	OVI-117	Investigative
T52227	DRUGINFO	D02MUO	4-CHLORO-3',3''-DIBROMOPHENOL-1,8-NAPHTHALEIN	Investigative
T52227	DRUGINFO	D04IRR	Ly231514 Tetra Glu	Investigative
T52227	DRUGINFO	D05HOO	2-bromophenol	Investigative
T52227	DRUGINFO	D06FMH	2'-Deoxycytidine-5'-Monophosphate	Investigative
T52227	DRUGINFO	D07LML	Tosyl-D-Proline	Investigative
T52227	DRUGINFO	D08STR	2'-5'dideoxyuridine	Investigative
T52227	DRUGINFO	D09QPT	3-Methyl-2H-benzo[f]quinazolin-1-one	Investigative
T52227	DRUGINFO	D0A6BH	5,10-Methylene-6-Hydrofolic Acid	Investigative
T52227	DRUGINFO	D0F1LA	N,O-Didansyl-L-Tyrosine	Investigative
T52227	DRUGINFO	D0F2VL	3-Amino-5,6-dihydro-2H-benzo[f]quinazolin-1-one	Investigative
T52227	DRUGINFO	D0G6CU	1,3-propanediphosphonic acid	Investigative
T52227	DRUGINFO	D0G9XX	2'-Deoxyguanosine-5'-Monophosphate	Investigative
T52227	DRUGINFO	D0I0OH	5-Fluoro-2'-Deoxyuridine-5'-Monophosphate	Investigative
T52227	DRUGINFO	D0JY6J	6-ETHYL-5-PHENYLPYRIMIDINE-2,4-DIAMINE	Investigative
T52227	DRUGINFO	D0K7CR	Sp-876	Investigative
T52227	DRUGINFO	D0U0VO	N-[Tosyl-D-Prolinyl]Amino-Ethanethiol	Investigative
T52227	DRUGINFO	D0UL7N	3-DIPHENOL-6-NITRO-3H-BENZO[DE]ISOCHROMEN-1-ONE	Investigative
T52227	DRUGINFO	D0VZ0I	ZD1604	Investigative
T52227	DRUGINFO	D0X9QV	LY341770	Investigative
T52227	DRUGINFO	D0YX9D	N-Carboxymethionine	Investigative
T52227	DRUGINFO	D00CVB	2'-Deoxyuridine	Investigative
T52227	DRUGINFO	D0CZ3C	2'-deoxyuridylic acid	Investigative
T52227	DRUGINFO	D0H9DJ	Uridine-5'-Monophosphate	Investigative
T52227	DRUGINFO	D0PG5D	10-Propargyl-5,8-Dideazafolic Acid	Investigative
T52227	DRUGINFO	D0XV3B	Methionine Sulfoxide	Investigative
T52227	DRUGINFO	D01GMJ	1,4-Dithiothreitol	Investigative
T52227	DRUGINFO	D0UZ9U	PREMETREXED	Investigative
T52227	DRUGINFO	D0ZH0I	Thymidine-5'-Phosphate	Investigative
T52227	DRUGINFO	D0P7JE	S,S-(2-Hydroxyethyl)Thiocysteine	Investigative
T52227	DRUGINFO	D0Q5FV	2-Sulfhydryl-Ethanol	Investigative

T82577	TARGETID	T82577
T82577	FORMERID	TTDS00181
T82577	UNIPROID	ACE_HUMAN
T82577	TARGNAME	Angiotensin-converting enzyme (ACE)
T82577	GENENAME	SLC33A1
T82577	TARGTYPE	Successful
T82577	SYNONYMS	Kininase II; Dipeptidyl carboxypeptidase I; DCP1; DCP; CD143 antigen; CD143; ACE
T82577	FUNCTION	Able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin.
T82577	PDBSTRUC	6QS1; 6H5X; 6H5W; 6F9V; 6F9U
T82577	BIOCLASS	Glycosylase
T82577	ECNUMBER	EC 3.2.1.-
T82577	SEQUENCE	MGAASGRRGPGLLLPLPLLLLLPPQPALALDPGLQPGNFSADEAGAQLFAQSYNSSAEQVLFQSVAASWAHDTNITAENARRQEEAALLSQEFAEAWGQKAKELYEPIWQNFTDPQLRRIIGAVRTLGSANLPLAKRQQYNALLSNMSRIYSTAKVCLPNKTATCWSLDPDLTNILASSRSYAMLLFAWEGWHNAAGIPLKPLYEDFTALSNEAYKQDGFTDTGAYWRSWYNSPTFEDDLEHLYQQLEPLYLNLHAFVRRALHRRYGDRYINLRGPIPAHLLGDMWAQSWENIYDMVVPFPDKPNLDVTSTMLQQGWNATHMFRVAEEFFTSLELSPMPPEFWEGSMLEKPADGREVVCHASAWDFYNRKDFRIKQCTRVTMDQLSTVHHEMGHIQYYLQYKDLPVSLRRGANPGFHEAIGDVLALSVSTPEHLHKIGLLDRVTNDTESDINYLLKMALEKIAFLPFGYLVDQWRWGVFSGRTPPSRYNFDWWYLRTKYQGICPPVTRNETHFDAGAKFHVPNVTPYIRYFVSFVLQFQFHEALCKEAGYEGPLHQCDIYRSTKAGAKLRKVLQAGSSRPWQEVLKDMVGLDALDAQPLLKYFQPVTQWLQEQNQQNGEVLGWPEYQWHPPLPDNYPEGIDLVTDEAEASKFVEEYDRTSQVVWNEYAEANWNYNTNITTETSKILLQKNMQIANHTLKYGTQARKFDVNQLQNTTIKRIIKKVQDLERAALPAQELEEYNKILLDMETTYSVATVCHPNGSCLQLEPDLTNVMATSRKYEDLLWAWEGWRDKAGRAILQFYPKYVELINQAARLNGYVDAGDSWRSMYETPSLEQDLERLFQELQPLYLNLHAYVRRALHRHYGAQHINLEGPIPAHLLGNMWAQTWSNIYDLVVPFPSAPSMDTTEAMLKQGWTPRRMFKEADDFFTSLGLLPVPPEFWNKSMLEKPTDGREVVCHASAWDFYNGKDFRIKQCTTVNLEDLVVAHHEMGHIQYFMQYKDLPVALREGANPGFHEAIGDVLALSVSTPKHLHSLNLLSSEGGSDEHDINFLMKMALDKIAFIPFSYLVDQWRWRVFDGSITKENYNQEWWSLRLKYQGLCPPVPRTQGDFDPGAKFHIPSSVPYIRYFVSFIIQFQFHEALCQAAGHTGPLHKCDIYQSKEAGQRLATAMKLGFSRPWPEAMQLITGQPNMSASAMLSYFKPLLDWLRTENELHGEKLGWPQYNWTPNSARSEGPLPDSGRVSFLGLDLDAQQARVGQWLLLFLGIALLVATLGLSQRLFSIRHRSLHRHSHGPQFGSEVELRHS
T82577	DRUGINFO	D00HDU	Moexipril	Approved
T82577	DRUGINFO	D00SEB	Enalapril	Approved
T82577	DRUGINFO	D01STB	Ramipril	Approved
T82577	DRUGINFO	D02DSZ	Temocapril hydrochloride	Approved
T82577	DRUGINFO	D03KYG	Perindopril	Approved
T82577	DRUGINFO	D04GKO	Cilazapril	Approved
T82577	DRUGINFO	D05MFG	Spirapril	Approved
T82577	DRUGINFO	D07HGR	Lisinopril	Approved
T82577	DRUGINFO	D09HDR	Deserpidine	Approved
T82577	DRUGINFO	D0G8NJ	Rescinnamine	Approved
T82577	DRUGINFO	D0G8QW	Delapril	Approved
T82577	DRUGINFO	D0I0EG	Captopril	Approved
T82577	DRUGINFO	D0I7SZ	Quinapril	Approved
T82577	DRUGINFO	D0M5OC	Trandolapril	Approved
T82577	DRUGINFO	D0N5HJ	Enalaprilat	Approved
T82577	DRUGINFO	D0S0ES	Imidapril	Approved
T82577	DRUGINFO	D0U3EC	Benazepril	Approved
T82577	DRUGINFO	D0U4UQ	Hydrochlorothiazide	Approved
T82577	DRUGINFO	D0X5SJ	Alacepril	Approved
T82577	DRUGINFO	D0X8KY	Fosinopril	Approved
T82577	DRUGINFO	D04PBH	CONTIGOSIDE B	Phase 2/3
T82577	DRUGINFO	D00ERV	Gallopamil	Phase 2
T82577	DRUGINFO	D0C1AY	GW-796406	Phase 1
T82577	DRUGINFO	D0K6SM	Ilepatril	Discontinued in Phase 2/3
T82577	DRUGINFO	D00FHI	Zabiciprilat	Discontinued in Phase 2
T82577	DRUGINFO	D02JUM	METIAPRIL	Discontinued in Phase 2
T82577	DRUGINFO	D03DRW	UTIBAPRIL	Discontinued in Phase 2
T82577	DRUGINFO	D05NRI	Ceronapril	Discontinued in Phase 2
T82577	DRUGINFO	D08DWH	Idrapril	Discontinued in Phase 2
T82577	DRUGINFO	D0N5HN	M-100240	Discontinued in Phase 2
T82577	DRUGINFO	D05COG	DU-1777	Terminated
T82577	DRUGINFO	D04MBS	BMS-182657	Terminated
T82577	DRUGINFO	D05UQD	Omapatrilat	Terminated
T82577	DRUGINFO	D0F9BX	GW-660511	Terminated
T82577	DRUGINFO	D0I5QZ	SQ-26332	Terminated
T82577	DRUGINFO	D0KR3X	CGS-30440	Terminated
T82577	DRUGINFO	D0K9YR	SCH-54470	Terminated
T82577	DRUGINFO	D02FMN	RXP-407	Investigative
T82577	DRUGINFO	D07BNP	BRL-36378	Investigative
T82577	DRUGINFO	D0A1RG	RIP	Investigative
T82577	DRUGINFO	D0B8WQ	lisinopril-tryptophan	Investigative
T82577	DRUGINFO	D0HC9P	Kaempferol-3-O-(2''-O-galloyl)-glucoside	Investigative
T82577	DRUGINFO	D0K8ED	N-Carboxymethyl-N-cyclopentyl-phthalamic acid	Investigative
T82577	DRUGINFO	D0OZ3S	RJM-0035-K002	Investigative
T82577	DRUGINFO	D0R6KV	moexiprilat	Investigative
T82577	DRUGINFO	D0U7TM	[Cyclopentyl-(2-nitro-benzoyl)-amino]-acetic acid	Investigative
T82577	DRUGINFO	D04DHD	fasidotrilat	Investigative
T82577	DRUGINFO	D08BFU	ASTRAGALIN	Investigative
T82577	DRUGINFO	D09GXF	RB-105	Investigative
T82577	DRUGINFO	D0EW3L	BUTEIN	Investigative
T82577	DRUGINFO	D06IEN	2-(Acetylamino)-2-Deoxy-a-D-Glucopyranose	Investigative
T82577	DRUGINFO	D07APP	LY-292223	Investigative
T82577	DRUGINFO	D0F2ME	Acetate Ion	Investigative

T97587	TARGETID	T97587
T97587	FORMERID	TTDS00445
T97587	UNIPROID	ITA4_HUMAN
T97587	TARGNAME	Integrin alpha-4 (ITGA4)
T97587	GENENAME	ITGA4
T97587	TARGTYPE	Successful
T97587	SYNONYMS	Very late antigen 4; VLA4 subunit alpha; VLA-4 subunit alpha; VLA-4; Integrin alphaIV; Integrin alpha4; Integrin alpha-IV; CD49d; CD49 antigenlike family member D; CD49 antigen-like family member D
T97587	FUNCTION	Integrins alpha-4/beta-1 (VLA-4) and alpha-4/beta-7 are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1. Integrin alpha-4/beta-1 recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha-4/beta-7 is also a receptor for MADCAM1. It recognizes the sequence L-D-T in MADCAM1. On activated endothelial cells integrin VLA-4 triggers homotypic aggregation for most VLA-4-positive leukocyte cell lines. It may also participate in cytolytic T-cell interactions with target cells. ITGA4:ITGB1 binds to fractalkine (CX3CL1) and may act as its coreceptor in CX3CR1-dependent fractalkine signaling. ITGA4:ITGB1 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1.
T97587	PDBSTRUC	5FPI; 5C7Z; 4HKC; 3V4V; 3V4P
T97587	BIOCLASS	Integrin
T97587	SEQUENCE	MAWEARREPGPRRAAVRETVMLLLCLGVPTGRPYNVDTESALLYQGPHNTLFGYSVVLHSHGANRWLLVGAPTANWLANASVINPGAIYRCRIGKNPGQTCEQLQLGSPNGEPCGKTCLEERDNQWLGVTLSRQPGENGSIVTCGHRWKNIFYIKNENKLPTGGCYGVPPDLRTELSKRIAPCYQDYVKKFGENFASCQAGISSFYTKDLIVMGAPGSSYWTGSLFVYNITTNKYKAFLDKQNQVKFGSYLGYSVGAGHFRSQHTTEVVGGAPQHEQIGKAYIFSIDEKELNILHEMKGKKLGSYFGASVCAVDLNADGFSDLLVGAPMQSTIREEGRVFVYINSGSGAVMNAMETNLVGSDKYAARFGESIVNLGDIDNDGFEDVAIGAPQEDDLQGAIYIYNGRADGISSTFSQRIEGLQISKSLSMFGQSISGQIDADNNGYVDVAVGAFRSDSAVLLRTRPVVIVDASLSHPESVNRTKFDCVENGWPSVCIDLTLCFSYKGKEVPGYIVLFYNMSLDVNRKAESPPRFYFSSNGTSDVITGSIQVSSREANCRTHQAFMRKDVRDILTPIQIEAAYHLGPHVISKRSTEEFPPLQPILQQKKEKDIMKKTINFARFCAHENCSADLQVSAKIGFLKPHENKTYLAVGSMKTLMLNVSLFNAGDDAYETTLHVKLPVGLYFIKILELEEKQINCEVTDNSGVVQLDCSIGYIYVDHLSRIDISFLLDVSSLSRAEEDLSITVHATCENEEEMDNLKHSRVTVAIPLKYEVKLTVHGFVNPTSFVYGSNDENEPETCMVEKMNLTFHVINTGNSMAPNVSVEIMVPNSFSPQTDKLFNILDVQTTTGECHFENYQRVCALEQQKSAMQTLKGIVRFLSKTDKRLLYCIKADPHCLNFLCNFGKMESGKEASVHIQLEGRPSILEMDETSALKFEIRATGFPEPNPRVIELNKDENVAHVLLEGLHHQRPKRYFTIVIISSSLLLGLIVLLLISYVMWKAGFFKRQYKSILQEENRRDSWSYINSKSNDD
T97587	DRUGINFO	D09EBL	Antegren	Approved
T97587	DRUGINFO	D3LWJ7	Natalizumab	Approved
T97587	DRUGINFO	D0N5ZS	Vedolizmab	Approved
T97587	DRUGINFO	DWKI46	PB006	Phase 3
T97587	DRUGINFO	D0Q5LF	BIO-1211	Phase 2
T97587	DRUGINFO	D04WQJ	AMG-181	Phase 2
T97587	DRUGINFO	D05ZWG	Senktide	Phase 2
T97587	DRUGINFO	D0C9XA	GSK683699	Phase 2
T97587	DRUGINFO	D01CYT	ELND-002	Phase 1
T97587	DRUGINFO	D05JPJ	ELND-004	Phase 1
T97587	DRUGINFO	D0FU1J	PTG-100	Phase 1
T97587	DRUGINFO	D00GWR	CT301	Investigative
T97587	DRUGINFO	D05SHQ	ASP-2002	Investigative

T84621	TARGETID	T84621
T84621	FORMERID	TTDS00420
T84621	UNIPROID	C11B1_HUMAN
T84621	TARGNAME	Steroid 11-beta-hydroxylase (CYP11B1)
T84621	GENENAME	CYP11B1
T84621	TARGTYPE	Successful
T84621	SYNONYMS	S11BH; P450C11; P-450c11; CYPXIB1; CYP11B1
T84621	FUNCTION	Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochrome P450 XIB.
T84621	PDBSTRUC	6M7X
T84621	BIOCLASS	Paired donor oxygen oxidoreductase
T84621	ECNUMBER	EC 1.14.15.4
T84621	SEQUENCE	MALRAKAEVCMAVPWLSLQRAQALGTRAARVPRTVLPFEAMPRRPGNRWLRLLQIWREQGYEDLHLEVHQTFQELGPIFRYDLGGAGMVCVMLPEDVEKLQQVDSLHPHRMSLEPWVAYRQHRGHKCGVFLLNGPEWRFNRLRLNPEVLSPNAVQRFLPMVDAVARDFSQALKKKVLQNARGSLTLDVQPSIFHYTIEASNLALFGERLGLVGHSPSSASLNFLHALEVMFKSTVQLMFMPRSLSRWTSPKVWKEHFEAWDCIFQYGDNCIQKIYQELAFSRPQQYTSIVAELLLNAELSPDAIKANSMELTAGSVDTTVFPLLMTLFELARNPNVQQALRQESLAAAASISEHPQKATTELPLLRAALKETLRLYPVGLFLERVASSDLVLQNYHIPAGTLVRVFLYSLGRNPALFPRPERYNPQRWLDIRGSGRNFYHVPFGFGMRQCLGRRLAEAEMLLLLHHVLKHLQVETLTQEDIKMVYSFILRPSMFPLLTFRAIN
T84621	DRUGINFO	D03AJU	Osilodrostat	Approved
T84621	DRUGINFO	D0Q9JT	Metyrapone	Approved
T84621	DRUGINFO	D0ZX1P	FADROZOLE	Approved
T84621	DRUGINFO	D00DUJ	3-Phenanthren-9-yl-pyridine	Investigative
T84621	DRUGINFO	D00PXF	1-(4-Cyanobenzyl)-5-(3-fluorophenyl)-1H-imidazole	Investigative
T84621	DRUGINFO	D00RRV	3-Imidazol-1-ylmethyl-1H-indole	Investigative
T84621	DRUGINFO	D01CGR	3-Imidazol-1-ylmethyl-2-isopropyl-1H-indole	Investigative
T84621	DRUGINFO	D02FRA	3-(2-Chloro-1,1-dimethyl-2-phenyl-ethyl)-pyridine	Investigative
T84621	DRUGINFO	D02JUJ	5-(6-Methoxynaphthalen-2-yl)pyridin-3-ol	Investigative
T84621	DRUGINFO	D02LWB	3-(1H-inden-2-yl)pyridine	Investigative
T84621	DRUGINFO	D02PSL	1-(4-Cyanobenzyl)-5-(3-methylphenyl)-1H-imidazole	Investigative
T84621	DRUGINFO	D02UZI	3-[(Z)-2-phenylvinyl]pyridine	Investigative
T84621	DRUGINFO	D02ZQM	6-Pyridin-3-yl-1,2,3,4-tetrahydronaphthalen-2-ol	Investigative
T84621	DRUGINFO	D03CWL	Methyl 3-(1-Benzyl-1H-imidazol-5-yl)-propanoate	Investigative
T84621	DRUGINFO	D03YHZ	6-Isoquinolin-4-yl-3,4-dihydroquinolin-2(1H)-one	Investigative
T84621	DRUGINFO	D04MEE	2-Methyl-1,2-di-pyridin-3-yl-propyliodide	Investigative
T84621	DRUGINFO	D04PKP	3-(1,2-dihydroacenaphthylen-5-yl)pyridine	Investigative
T84621	DRUGINFO	D04QWX	2-Methyl-1,2-di-pyridin-3-yl-propylchloride	Investigative
T84621	DRUGINFO	D05IXU	3-(3-Benzylnaphthalen-2-yl)pyridine	Investigative
T84621	DRUGINFO	D05VAN	1-Ethyl-3-imidazol-1-ylmethyl-1H-indole	Investigative
T84621	DRUGINFO	D06NFC	1-(4-Fluorobenzyl)-5-phenyl-1H-imidazole	Investigative
T84621	DRUGINFO	D06RSD	1-(4-Cyanobenzyl)-5-(4-pyridyl)-1H-imidazole	Investigative
T84621	DRUGINFO	D07DQJ	1-(4-Bromobenzyl)-5-phenyl-1H-imidazole	Investigative
T84621	DRUGINFO	D07EJK	1-(4-Cyanobenzyl)-5-formyl-1H-imidazole	Investigative
T84621	DRUGINFO	D07JCO	3-Imidazol-1-yl-quinoline	Investigative
T84621	DRUGINFO	D07JMO	1-(3-Bromobenzyl)-1H-imidazole	Investigative
T84621	DRUGINFO	D07NAH	5-Naphthalen-2-yl-1H-imidazole	Investigative
T84621	DRUGINFO	D07SAF	2-Methyl-1-phenyl-2-pyridin-3-yl-propan-1-ol	Investigative
T84621	DRUGINFO	D08HHA	1-(3-Fluorobenzyl)-1H-imidazole	Investigative
T84621	DRUGINFO	D08ORG	1-(4-Cyanobenzyl)-5-hydroxymethyl-1H-imidazole	Investigative
T84621	DRUGINFO	D08UWI	2-Methyl-1-phenyl-2-pyridin-3-yl-propan-1-one	Investigative
T84621	DRUGINFO	D08WHC	(3-((1H-imidazol-1-yl)methyl)phenyl)methanol	Investigative
T84621	DRUGINFO	D08YGW	1-Benzyl-5-phenyl-1H-imidazole	Investigative
T84621	DRUGINFO	D0AK9S	3-[1-(4-Bromobenzyl)-1H-imidazol-5-yl]-1-propanol	Investigative
T84621	DRUGINFO	D0B2UM	3-(6-Methoxynaphthalen-2-yl)-4-methylpyridine	Investigative
T84621	DRUGINFO	D0C6US	4-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine	Investigative
T84621	DRUGINFO	D0C7YL	3-((1H-imidazol-1-yl)methyl)aniline	Investigative
T84621	DRUGINFO	D0D7YL	3-(1,2-dihydroacenaphthylen-3-yl)pyridine	Investigative
T84621	DRUGINFO	D0D8KN	3-(1-Benzyl-1H-imidazol-5-yl)-1-propanol	Investigative
T84621	DRUGINFO	D0D8YE	3-(5-methoxy-1H-inden-2-yl)pyridine	Investigative
T84621	DRUGINFO	D0G3RD	2-Methyl-1,2-di-pyridin-3-yl-propane	Investigative
T84621	DRUGINFO	D0HL9S	1-(4-Aminobenzyl)-1H-imidazole	Investigative
T84621	DRUGINFO	D0HV5D	2-Methyl-1,2-di-pyridin-3-yl-propan-1-one oxime	Investigative
T84621	DRUGINFO	D0I0NP	SL125	Investigative
T84621	DRUGINFO	D0I2UH	1-(4-Cyanobenzyl)-5-(2-methylphenyl)-1H-imidazole	Investigative
T84621	DRUGINFO	D0I9PA	3-(2,3-Dihydro-1,4-benzodioxin-6-yl)pyridine	Investigative
T84621	DRUGINFO	D0JE1I	R-fadrozole	Investigative
T84621	DRUGINFO	D0L2QD	1-(4-Cyanobenzyl)-5-bromo-1H-imidazole	Investigative
T84621	DRUGINFO	D0L4NG	3-(4-ethyl-3,4-dihydronaphthalen-2-yl)pyridine	Investigative
T84621	DRUGINFO	D0L8KL	5-Naphthalen-2-yl-oxazole	Investigative
T84621	DRUGINFO	D0M9VK	1-(6-Methoxy-naphthalen-2-yl)-1H-imidazole	Investigative
T84621	DRUGINFO	D0N4VI	1-(3,4-dihydronaphthalen-2-yl)-1H-imidazole	Investigative
T84621	DRUGINFO	D0N8QD	(4-((1H-imidazol-1-yl)methyl)phenyl)methanol	Investigative
T84621	DRUGINFO	D0NV7W	1-(4-Cyanobenzyl)-5-(2-fluorophenyl)-1H-imidazole	Investigative
T84621	DRUGINFO	D0O7TC	7-Pyridin-3-yl-2H-1,4-benzothiazin-3(4H)-one	Investigative
T84621	DRUGINFO	D0P1UO	1-(4-Cyanobenzyl)-5-(4-fluorophenyl)-1H-imidazole	Investigative
T84621	DRUGINFO	D0P9JF	2-Methyl-1,2-di-pyridin-3-yl-1-methoxypropane	Investigative
T84621	DRUGINFO	D0PH1G	3-[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]-1-propanol	Investigative
T84621	DRUGINFO	D0Q3CX	6-(4-Methylpyridin-3-yl)-2-naphthonitrile	Investigative
T84621	DRUGINFO	D0Q5ZZ	3-(3-Benzyl-6-methoxynaphthalen-2-yl)pyridine	Investigative
T84621	DRUGINFO	D0Q6BJ	3-(6-Methoxynaphthalen-2-yl)-5-phenylpyridine	Investigative
T84621	DRUGINFO	D0Q8KM	1-(4-Cyanobenzyl)-5-phenyl-1H-imidazole	Investigative
T84621	DRUGINFO	D0R8NE	1-(2-Phenoxy-ethyl)-1H-imidazole	Investigative
T84621	DRUGINFO	D0RJ6S	3-(6-Bromo-naphthalen-2-yl)-pyridine	Investigative
T84621	DRUGINFO	D0S4KP	4-(6-Methoxy-3-methylnaphthalen-2-yl)isoquinoline	Investigative
T84621	DRUGINFO	D0S4WQ	1-(3-Chlorobenzyl)-1H-imidazole	Investigative
T84621	DRUGINFO	D0S8FV	3-(6-Methoxy-3-methylnaphthalen-2-yl)pyridine	Investigative
T84621	DRUGINFO	D0T8JU	1-(4-Methoxybenzyl)-5-phenyl-1H-imidazole	Investigative
T84621	DRUGINFO	D0V6QN	1-(4-Cyanobenzyl)-5-(4-methylphenyl)-1H-imidazole	Investigative
T84621	DRUGINFO	D0V9JS	3-(1,1-Dimethyl-2-phenyl-ethyl)-pyridine	Investigative
T84621	DRUGINFO	D0VL3R	3-(5,6,7,8-Tetrahydronaphthalen-2-yl)pyridine	Investigative
T84621	DRUGINFO	D0W8IZ	1-(4-Chlorobenzyl)-5-phenyl-1H-imidazole	Investigative
T84621	DRUGINFO	D0WW4F	METYRAPOL	Investigative
T84621	DRUGINFO	D0X0IH	BENZYLIMIDAZOLE	Investigative
T84621	DRUGINFO	D0X4LQ	3-MeSO2-DDE	Investigative
T84621	DRUGINFO	D0Y1YZ	4-(2-Imidazol-1-yl-ethoxy)-benzamide	Investigative
T84621	DRUGINFO	D0Y2AK	1-Phenyl-2-pyridin-3-yl-propan-1-one	Investigative
T84621	DRUGINFO	D0Y3AV	3-Ethoxy-5-(6-methoxynaphthalen-2-yl)pyridine	Investigative
T84621	DRUGINFO	D00DSE	4-(4'-Fluoro-biphenyl-4-ylmethyl)pyridine	Investigative
T84621	DRUGINFO	D01SUE	3-Indan-(1E)-ylidenemethyl-pyridine	Investigative
T84621	DRUGINFO	D02ALK	6-Pyridin-3-yl-naphthalen-2-ol	Investigative
T84621	DRUGINFO	D02BXS	4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diamine	Investigative
T84621	DRUGINFO	D02GFK	3-(6-Methoxynaphthalen-2-yl)pyridin-4-amine	Investigative
T84621	DRUGINFO	D02NAG	3-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T84621	DRUGINFO	D02XHH	5-[5-Bromo-indan-(1Z)-ylidenemethyl]-1H-imidazole	Investigative
T84621	DRUGINFO	D03KLN	1-(3-Methoxy-naphthalen-2-yl)-1H-imidazole	Investigative
T84621	DRUGINFO	D03TRM	5-Indan-(1E)-ylidenemethyl-1H-imidazole	Investigative
T84621	DRUGINFO	D03VRC	1-(4-Bromobenzyl)-1H-imidazole	Investigative
T84621	DRUGINFO	D04CFP	5-[4-(Pyridin-4-ylmethyl)phenyl]-1H-indole	Investigative
T84621	DRUGINFO	D04CLL	3-[4-Methyl-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T84621	DRUGINFO	D04ELJ	3-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T84621	DRUGINFO	D04IBH	3-(5-Bromo-6-methoxy-naphthalen-2-yl)-pyridine	Investigative
T84621	DRUGINFO	D04ISG	3-(1-Chloro-7-methoxy-naphthalen-2-yl)-pyridine	Investigative
T84621	DRUGINFO	D04QPK	3-[4-Fluoro-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T84621	DRUGINFO	D05FFY	1-(4-Cyanobenzyl)-5-methyl-1H-imidazole	Investigative
T84621	DRUGINFO	D05MQE	3-[4-Chloro-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T84621	DRUGINFO	D05QPR	1-(4-fluorobenzyl)-1H-imidazole	Investigative
T84621	DRUGINFO	D06CWR	4-(6-Methoxynaphthalen-2-yl)isoquinoline	Investigative
T84621	DRUGINFO	D06JYY	3-[3-(4-Methoxybenzyl)naphthalen-2-yl]pyridine	Investigative
T84621	DRUGINFO	D07PYC	3-Indan-(1Z)-ylidenemethyl-pyridine	Investigative
T84621	DRUGINFO	D07VGT	6-[4-(Pyridin-4-ylmethyl)phenyl]naphthalen-2-ol	Investigative
T84621	DRUGINFO	D07WLT	6-Pyridin-3-yl-3,4-dihydronaphthalen-2(1H)-one	Investigative
T84621	DRUGINFO	D08AZK	3-[5-Bromo-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T84621	DRUGINFO	D08FAB	3-(naphthalen-2-yl)pyridine	Investigative
T84621	DRUGINFO	D08HPU	3-(3-methyl-3,4-dihydronaphthalen-2-yl)pyridine	Investigative
T84621	DRUGINFO	D08IDC	3-methoxy-5-(6-methoxynaphthalen-2-yl)pyridine	Investigative
T84621	DRUGINFO	D08PNF	3-[5-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T84621	DRUGINFO	D08ZTZ	3-(5-Chloro-6-methoxy-naphthalen-2-yl)-pyridine	Investigative
T84621	DRUGINFO	D09CPC	6-Pyridin-3-yl-3,4-dihydro-1H-quinolin-2-one	Investigative
T84621	DRUGINFO	D09GJI	7-(1-(1H-imidazol-1-yl)ethyl)-9H-fluoren-2-ol	Investigative
T84621	DRUGINFO	D09QDY	5-Indan-(1Z)-ylidenemethyl-1H-imidazole	Investigative
T84621	DRUGINFO	D09VPA	4-[5-Bromo-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T84621	DRUGINFO	D09VQZ	4-((3',4'-Difluorobiphenyl-4-yl)methyl)pyridine	Investigative
T84621	DRUGINFO	D09YXV	3-[5-Methoxy-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T84621	DRUGINFO	D0E0ZS	N-(4'-Isonicotinoylbiphenyl-3-yl)acetamide	Investigative
T84621	DRUGINFO	D0E8DX	6-Pyridin-3-yl-3,4-dihydroquinoline-2(1H)-thione	Investigative
T84621	DRUGINFO	D0E9WX	5-[5-Bromo-indan-(1E)-ylidenemethyl]-1H-imidazole	Investigative
T84621	DRUGINFO	D0G6QL	1-Naphthalen-2-yl-1H-imidazole	Investigative
T84621	DRUGINFO	D0G9WP	5-Pyridin-3-yl-2,3-dihydro-1H-inden-1-one	Investigative
T84621	DRUGINFO	D0I5NW	3-(3,4-dihydronaphthalen-2-yl)pyridine	Investigative
T84621	DRUGINFO	D0K2DR	5-Pyridin-3-yl-1,3-dihydro-2H-indol-2-one	Investigative
T84621	DRUGINFO	D0LJ9D	4-(4-(thiophen-2-yl)benzyl)pyridine	Investigative
T84621	DRUGINFO	D0M7FS	3-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T84621	DRUGINFO	D0N1GH	6-(pyridin-3-yl)-2-naphthonitrile	Investigative
T84621	DRUGINFO	D0N9PY	3-[5-Ethoxy-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T84621	DRUGINFO	D0Q3JZ	3-[5-Ethoxy-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T84621	DRUGINFO	D0U7RR	3-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T84621	DRUGINFO	D0V3YH	3-[4-Chloro-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T84621	DRUGINFO	D0V8CR	3-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T84621	DRUGINFO	D0X1QS	3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine	Investigative
T84621	DRUGINFO	D0Y5KX	4'-(Pyridin-4-ylmethyl)biphenyl-4-amine	Investigative
T84621	DRUGINFO	D0YS2F	3-[7-Methoxy-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T84621	DRUGINFO	D0Z3GX	4-(4-(thiophen-3-yl)benzyl)pyridine	Investigative
T84621	DRUGINFO	D01REI	4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diol	Investigative
T84621	DRUGINFO	D02CSU	4-Indan-(1Z)-ylidenemethyl-pyridine	Investigative
T84621	DRUGINFO	D03EXD	4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine	Investigative
T84621	DRUGINFO	D03MKT	4-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine	Investigative
T84621	DRUGINFO	D06HFV	5-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyrimidine	Investigative
T84621	DRUGINFO	D09HEA	4-((1H-imidazol-1-yl)methyl)benzonitrile	Investigative
T84621	DRUGINFO	D09HOE	4-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T84621	DRUGINFO	D0D9FR	4-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T84621	DRUGINFO	D0F5YU	4-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine	Investigative
T84621	DRUGINFO	D0I1YH	4-[(3'-Hydroxybiphenyl-4-yl)methyl]pyridine	Investigative
T84621	DRUGINFO	D0K5KG	3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine	Investigative
T84621	DRUGINFO	D0MA9G	3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine	Investigative
T84621	DRUGINFO	D0N1PQ	3-(6-methoxynaphthalen-2-yl)pyridine	Investigative
T84621	DRUGINFO	D0NX0M	3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine	Investigative
T84621	DRUGINFO	D0Q0BK	3-Fluoro-4'-(pyridin-4-ylmethyl)biphenyl-4-ol	Investigative
T84621	DRUGINFO	D0R0TE	3-(6-Ethoxy-naphthalen-2-yl)-pyridine	Investigative
T84621	DRUGINFO	D0WN9P	4'-(Pyridin-4-ylmethyl)biphenyl-3-amine	Investigative
T84621	DRUGINFO	D0YD9J	4-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine	Investigative

T55922	TARGETID	T55922
T55922	FORMERID	TTDR00414
T55922	UNIPROID	DCAM_HUMAN
T55922	TARGNAME	S-adenosylmethionine decarboxylase proenzyme (AMD1)
T55922	GENENAME	AMD1
T55922	TARGTYPE	Successful
T55922	SYNONYMS	SamDC; S-adenosylmethioninedecarboxylase; AdoMetDC; AMD
T55922	FUNCTION	Promotes maintenance and self-renewal of embryonic stem cells, by maintaining spermine levels. Essential for biosynthesis of the polyamines spermidine and spermine.
T55922	PDBSTRUC	3H0W; 3H0V; 3EPB; 3EPA; 3EP9
T55922	BIOCLASS	Carbon-carbon lyase
T55922	ECNUMBER	EC 4.1.1.50
T55922	SEQUENCE	MEAAHFFEGTEKLLEVWFSRQQPDANQGSGDLRTIPRSEWDILLKDVQCSIISVTKTDKQEAYVLSESSMFVSKRRFILKTCGTTLLLKALVPLLKLARDYSGFDSIQSFFYSRKNFMKPSHQGYPHRNFQEEIEFLNAIFPNGAAYCMGRMNSDCWYLYTLDFPESRVISQPDQTLEILMSELDPAVMDQFYMKDGVTAKDVTRESGIRDLIPGSVIDATMFNPCGYSMNGMKSDGTYWTIHITPEPEFSYVSFETNLSQTSYDDLIRKVVEVFKPGKFVTTLFVNQSSKCRTVLASPQKIEGFKRLDCQSAMFNDYNFVFTSFAKKQQQQQS
T55922	DRUGINFO	D03ZFN	Tromethamine	Approved
T55922	DRUGINFO	D0E2WF	ORG 34517/34850	Phase 2
T55922	DRUGINFO	D00FMV	Putrescine	Discontinued in Phase 2
T55922	DRUGINFO	D05FFR	MGBG	Terminated
T55922	DRUGINFO	D0S6VX	CGP-40215A	Terminated
T55922	DRUGINFO	D03OLX	5'-Deoxy-5'-(N,N-dimethylamino)adenosine	Investigative
T55922	DRUGINFO	D0BI4H	Hydroxyalanine	Investigative
T55922	DRUGINFO	D0I7IA	5'-Deoxy-5'-dimethylsulfonioadenosine chloride	Investigative
T55922	DRUGINFO	D0P5YR	[(2-aminooxyethyl)methylamino]-5'-deoxyadenosine	Investigative
T55922	DRUGINFO	D0Y7YL	5'-([(Z)-4-amino-2-butenyl]methylamino)-5'-deoxyadenosine	Investigative
T55922	DRUGINFO	D0YM6B	5'-Deoxy-5'-(N,N-dimethylamino)-8-methyladenosine	Investigative
T55922	DRUGINFO	D0V2QF	5'-deoxy-5'-[(3-hydrazinopropyl)methylamino]adenosine	Investigative

T59929	TARGETID	T59929
T59929	FORMERID	TTDR00251
T59929	UNIPROID	TYPH_HUMAN
T59929	TARGNAME	Thymidine phosphorylase (TYMP)
T59929	GENENAME	TYMP
T59929	TARGTYPE	Successful
T59929	SYNONYMS	TdRPase; TYMP; TP; Platelet-derived endothelial cell growth factor; PDECGF; PD-ECGF; Gliostatin
T59929	FUNCTION	Catalyzes the reversible phosphorolysis of thymidine. The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis.
T59929	PDBSTRUC	2WK6; 2WK5; 2J0F; 1UOU
T59929	BIOCLASS	Pentosyltransferase
T59929	ECNUMBER	EC 2.4.2.4
T59929	SEQUENCE	MAALMTPGTGAPPAPGDFSGEGSQGLPDPSPEPKQLPELIRMKRDGGRLSEADIRGFVAAVVNGSAQGAQIGAMLMAIRLRGMDLEETSVLTQALAQSGQQLEWPEAWRQQLVDKHSTGGVGDKVSLVLAPALAACGCKVPMISGRGLGHTGGTLDKLESIPGFNVIQSPEQMQVLLDQAGCCIVGQSEQLVPADGILYAARDVTATVDSLPLITASILSKKLVEGLSALVVDVKFGGAAVFPNQEQARELAKTLVGVGASLGLRVAAALTAMDKPLGRCVGHALEVEEALLCMDGAGPPDLRDLVTTLGGALLWLSGHAGTQAQGAARVAAALDDGSALGRFERMLAAQGVDPGLARALCSGSPAERRQLLPRAREQEELLAPADGTVELVRALPLALVLHELGAGRSRAGEPLRLGVGAELLVDVGQRLRRGTPWLRVHRDGPALSGPQSRALQEALVLSDRAPFAAPSPFAELVLPPQQ
T59929	DRUGINFO	D0Y7DP	Uridine	Approved
T59929	DRUGINFO	D00PMF	5-bromo-6-hydrazinouracil hydrochloride	Investigative
T59929	DRUGINFO	D01DAQ	5-fluoro-6-[(2-aminoimidazol-1-yl)methyl]uracil	Investigative
T59929	DRUGINFO	D01IGW	6-chloro-5-phenylpyrimidine-2,4(1H,3H)-dione	Investigative
T59929	DRUGINFO	D03IMY	6-chloro-5-heptylpyrimidine-2,4(1H,3H)-dione	Investigative
T59929	DRUGINFO	D03ITH	1-(cyclohexyl)methyl-5'-O-tritylinosine	Investigative
T59929	DRUGINFO	D04OWX	1-(cyclopropyl)methyl-5'-O-tritylinosine	Investigative
T59929	DRUGINFO	D05OUP	1-propyl-5'-O-tritylinosine	Investigative
T59929	DRUGINFO	D06BMN	1-allyl-5'-O-tritylinosine	Investigative
T59929	DRUGINFO	D09TBA	5-benzyl-6-chloropyrimidine-2,4(1H,3H)-dione	Investigative
T59929	DRUGINFO	D0C0HN	6-chloro-5-(2-thienyl)pyrimidine-2,4(1H,3H)-dione	Investigative
T59929	DRUGINFO	D0CO5S	6-chloro-5-hexylpyrimidine-2,4(1H,3H)-dione	Investigative
T59929	DRUGINFO	D0CQ1J	2'-aminoimidazolylmethyluracils	Investigative
T59929	DRUGINFO	D0DX8A	6-chloro-5-propylpyrimidine-2,4(1H,3H)-dione	Investigative
T59929	DRUGINFO	D0E7SH	6-chloro-5-pentylpyrimidine-2,4(1H,3H)-dione	Investigative
T59929	DRUGINFO	D0E9PL	6-fluoro-5-phenylpyrimidine-2,4(1H,3H)-dione	Investigative
T59929	DRUGINFO	D0F4KL	Thymine	Investigative
T59929	DRUGINFO	D0G1DS	5-chloro-6-hydrazinouracil hydrochloride	Investigative
T59929	DRUGINFO	D0I7IF	6-bromo-5-phenylpyrimidine-2,4(1H,3H)-dione	Investigative
T59929	DRUGINFO	D0RE9X	5-butyl-6-chloropyrimidine-2,4(1H,3H)-dione	Investigative
T59929	DRUGINFO	D0VW6H	6-amino-5-chlorouracil hydrochloride	Investigative
T59929	DRUGINFO	D0W6LJ	1-benzyl-5'-O-tritylinosine	Investigative
T59929	DRUGINFO	D0X5RA	6-amino-5-bromouracil	Investigative
T59929	DRUGINFO	D0Y5UF	5-bromo-6-(cyclopropylamino)uracil hydrochloride	Investigative

T67684	TARGETID	T67684
T67684	FORMERID	TTDS00004
T67684	UNIPROID	ACM3_HUMAN
T67684	TARGNAME	Muscarinic acetylcholine receptor M3 (CHRM3)
T67684	GENENAME	CHRM3
T67684	TARGTYPE	Successful
T67684	SYNONYMS	M3 receptor; CHRM3
T67684	FUNCTION	The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
T67684	PDBSTRUC	2CSA
T67684	BIOCLASS	GPCR rhodopsin
T67684	SEQUENCE	MTLHNNSTTSPLFPNISSSWIHSPSDAGLPPGTVTHFGSYNVSRAAGNFSSPDGTTDDPLGGHTVWQVVFIAFLTGILALVTIIGNILVIVSFKVNKQLKTVNNYFLLSLACADLIIGVISMNLFTTYIIMNRWALGNLACDLWLAIDYVASNASVMNLLVISFDRYFSITRPLTYRAKRTTKRAGVMIGLAWVISFVLWAPAILFWQYFVGKRTVPPGECFIQFLSEPTITFGTAIAAFYMPVTIMTILYWRIYKETEKRTKELAGLQASGTEAETENFVHPTGSSRSCSSYELQQQSMKRSNRRKYGRCHFWFTTKSWKPSSEQMDQDHSSSDSWNNNDAAASLENSASSDEEDIGSETRAIYSIVLKLPGHSTILNSTKLPSSDNLQVPEEELGMVDLERKADKLQAQKSVDDGGSFPKSFSKLPIQLESAVDTAKTSDVNSSVGKSTATLPLSFKEATLAKRFALKTRSQITKRKRMSLVKEKKAAQTLSAILLAFIITWTPYNIMVLVNTFCDSCIPKTFWNLGYWLCYINSTVNPVCYALCNKTFRTTFKMLLLCQCDKKKRRKQQYQQRQSVIFHKRAPEQAL
T67684	DRUGINFO	D04LHJ	Methscopolamine Bromide	Approved
T67684	DRUGINFO	D07KHH	LAS-34273	Approved
T67684	DRUGINFO	D0BZ7W	Tolterodine	Approved
T67684	DRUGINFO	D0L4YD	Solifenacin	Approved
T67684	DRUGINFO	D0Q4CS	Cevimeline	Approved
T67684	DRUGINFO	D0Q7ZQ	Succinylcholine	Approved
T67684	DRUGINFO	D0S0AS	Ipratropium	Approved
T67684	DRUGINFO	D0P1WA	Tiotropium	Approved
T67684	DRUGINFO	D0Y5AM	Darifenacin	Approved
T67684	DRUGINFO	D04MWJ	Methacholine Chloride	Approved
T67684	DRUGINFO	D05KZK	SMT-D002	Approved
T67684	DRUGINFO	D0M6VK	Methylscopolamine	Approved
T67684	DRUGINFO	D0R7WU	ACECLIDINE	Approved
T67684	DRUGINFO	D02TXV	TRN-157	Phase 2
T67684	DRUGINFO	D04YEW	Tarafenacin	Phase 2
T67684	DRUGINFO	D0V0JQ	CHF 5407	Phase 1
T67684	DRUGINFO	D04SBH	Zamifenacin	Discontinued in Phase 3
T67684	DRUGINFO	D06GCP	PSD-506	Discontinued in Phase 2
T67684	DRUGINFO	D09LMX	Revatropate	Discontinued in Phase 1
T67684	DRUGINFO	D0X8MZ	Alvameline	Terminated
T67684	DRUGINFO	D05YBO	Nocardimicin C	Investigative
T67684	DRUGINFO	D06UOE	3-(1-carbamoyl-1,1-diphenylmethyl)-1-(4-methoxyphenylethyl)pyrrolidine (APP)	Investigative
T67684	DRUGINFO	D07QGQ	Noccardimicin E	Investigative
T67684	DRUGINFO	D07TDE	Olterodine	Investigative
T67684	DRUGINFO	D09YBC	NOCARDIMICIN A	Investigative
T67684	DRUGINFO	D0A2KT	4-DAMP	Investigative
T67684	DRUGINFO	D0BP7C	J-104135	Investigative
T67684	DRUGINFO	D0F5LH	Oxybutynine	Investigative
T67684	DRUGINFO	D0I2XG	Nocardimicin D	Investigative
T67684	DRUGINFO	D0IM7C	AE-9C90CB	Investigative
T67684	DRUGINFO	D0J4DJ	Nocardimicin F	Investigative
T67684	DRUGINFO	D00NRJ	silahexocyclium	Investigative
T67684	DRUGINFO	D00WNA	ML381	Investigative
T67684	DRUGINFO	D02BOW	McN-A-343	Investigative
T67684	DRUGINFO	D02IIN	WIN 62,577	Investigative
T67684	DRUGINFO	D02MJE	NNC 11-1314	Investigative
T67684	DRUGINFO	D02UNX	VU0255035	Investigative
T67684	DRUGINFO	D02VGM	[3H]QNB	Investigative
T67684	DRUGINFO	D03DMR	lithocholylcholine	Investigative
T67684	DRUGINFO	D03LSH	UH-AH 37	Investigative
T67684	DRUGINFO	D05EEV	DAU-5750	Investigative
T67684	DRUGINFO	D05PSD	WIN 51,708	Investigative
T67684	DRUGINFO	D05WXF	thiochrome	Investigative
T67684	DRUGINFO	D07CAB	NNC 11-1585	Investigative
T67684	DRUGINFO	D07GPQ	tripitramine	Investigative
T67684	DRUGINFO	D07LDP	hexahydrosiladifenidol	Investigative
T67684	DRUGINFO	D07OAK	Go7874	Investigative
T67684	DRUGINFO	D08BGK	N-chloromethyl-brucine	Investigative
T67684	DRUGINFO	D08KNP	N-benzyl brucine	Investigative
T67684	DRUGINFO	D08XBQ	NNC 11-1607	Investigative
T67684	DRUGINFO	D0G4CG	[3H]oxotremorine-M	Investigative
T67684	DRUGINFO	D0H2UT	brucine	Investigative
T67684	DRUGINFO	D0I9AL	guanylpirenzepine	Investigative
T67684	DRUGINFO	D0I9LU	arecaidine propargyl ester	Investigative
T67684	DRUGINFO	D0K3VR	p-F-HHSiD	Investigative
T67684	DRUGINFO	D0PL0Y	furtrethonium	Investigative
T67684	DRUGINFO	D0R8AZ	DAU-5884	Investigative
T67684	DRUGINFO	D0S4DT	vinburnine	Investigative
T67684	DRUGINFO	D0T6ID	pentylthio-TZTP	Investigative
T67684	DRUGINFO	D0W8XI	hexahydrodifenidol	Investigative
T67684	DRUGINFO	D0WO3A	methylfurmethide	Investigative
T67684	DRUGINFO	D00JTE	1,1-diphenyl-2-(3-tropanyl)ethanol	Investigative
T67684	DRUGINFO	D09AAZ	PTAC	Investigative
T67684	DRUGINFO	D02ZPV	UCB-101333-3	Investigative
T67684	DRUGINFO	D04XNH	Propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester	Investigative
T67684	DRUGINFO	D0Z5RQ	Cremastrine	Investigative
T67684	DRUGINFO	D01UDC	Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester	Investigative
T67684	DRUGINFO	D02EXX	GNF-PF-5618	Investigative
T67684	DRUGINFO	D02PFJ	1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea	Investigative
T67684	DRUGINFO	D05EML	1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione	Investigative
T67684	DRUGINFO	D05MDY	2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one	Investigative
T67684	DRUGINFO	D06IUC	FM1-10	Investigative
T67684	DRUGINFO	D06VST	3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one	Investigative
T67684	DRUGINFO	D07DEY	3-(3-benzylamino)-piperidin-2-one	Investigative
T67684	DRUGINFO	D07VZG	BRL-55473	Investigative
T67684	DRUGINFO	D08ZTA	6-Dimethylamino-2-methyl-hex-4-ynal oxime	Investigative
T67684	DRUGINFO	D0AR0H	FM1-43	Investigative
T67684	DRUGINFO	D0B8AQ	7-Pyrrolidin-1-yl-hept-5-yn-2-one	Investigative
T67684	DRUGINFO	D0C9VH	N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide	Investigative
T67684	DRUGINFO	D0C9ZE	Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester	Investigative
T67684	DRUGINFO	D0O1BN	SULFOARECOLINE	Investigative
T67684	DRUGINFO	D0OE0K	3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane	Investigative
T67684	DRUGINFO	D0QL1X	7-Dimethylamino-3-methyl-hept-5-yn-2-one	Investigative
T67684	DRUGINFO	D0R2JE	N-methoxyquinuclidine-3-carboximidoyl chloride	Investigative
T67684	DRUGINFO	D0R8FS	7-Dimethylamino-hept-5-yn-2-one	Investigative
T67684	DRUGINFO	D0U2IL	2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime	Investigative
T67684	DRUGINFO	D0X2JU	N-methoxyquinuclidine-3-carboximidoyl fluoride	Investigative
T67684	DRUGINFO	D0HV3A	FLUMEZAPINE	Investigative
T67684	DRUGINFO	D0Q2GP	ISOLOXAPINE	Investigative
T67684	DRUGINFO	D0F9QT	A-987306	Investigative
T67684	DRUGINFO	D0P0IX	ISOCLOZAPINE	Investigative
T67684	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T62193	TARGETID	T62193
T62193	FORMERID	TTDS00361
T62193	UNIPROID	DDC_HUMAN
T62193	TARGNAME	Aromatic-L-amino-acid decarboxylase (DDC)
T62193	GENENAME	DDC
T62193	TARGTYPE	Successful
T62193	SYNONYMS	DOPA decarboxylase; AADC
T62193	FUNCTION	Catalyzes the decarboxylation of L-3,4-dihydroxyphenylalanine (DOPA) to dopamine, L-5-hydroxytryptophan to serotonin and L-tryptophan to tryptamine.
T62193	PDBSTRUC	3RCH; 3RBL; 3RBF
T62193	BIOCLASS	Carbon-carbon lyase
T62193	ECNUMBER	EC 4.1.1.28
T62193	SEQUENCE	MNASEFRRRGKEMVDYMANYMEGIEGRQVYPDVEPGYLRPLIPAAAPQEPDTFEDIINDVEKIIMPGVTHWHSPYFFAYFPTASSYPAMLADMLCGAIGCIGFSWAASPACTELETVMMDWLGKMLELPKAFLNEKAGEGGGVIQGSASEATLVALLAARTKVIHRLQAASPELTQAAIMEKLVAYSSDQAHSSVERAGLIGGVKLKAIPSDGNFAMRASALQEALERDKAAGLIPFFMVATLGTTTCCSFDNLLEVGPICNKEDIWLHVDAAYAGSAFICPEFRHLLNGVEFADSFNFNPHKWLLVNFDCSAMWVKKRTDLTGAFRLDPTYLKHSHQDSGLITDYRHWQIPLGRRFRSLKMWFVFRMYGVKGLQAYIRKHVQLSHEFESLVRQDPRFEICVEVILGLVCFRLKGSNKVNEALLQRINSAKKIHLVPCHLRDKFVLRFAICSRTVESAHVQRAWEHIKELAADVLRAERE
T62193	DRUGINFO	D07MUN	Vitamin B6	Approved
T62193	DRUGINFO	D0P7JZ	Carbidopa	Approved
T62193	DRUGINFO	D03QFN	Patrome	Phase 3
T62193	DRUGINFO	D0X8ED	Benserazide	Phase 3
T62193	DRUGINFO	D02ITL	AV-201	Phase 2
T62193	DRUGINFO	D4X6SZ	PTC-AADC	Phase 2
T62193	DRUGINFO	DH1W0G	VY-AADC	Phase 2
T62193	DRUGINFO	DX9KC2	GT-AADC	Phase 2
T62193	DRUGINFO	D05ICS	ProSavin	Phase 1/2
T62193	DRUGINFO	D72UDH	OXB-102	Phase 1/2
T62193	DRUGINFO	DZ4LX5	VY-AADC01	Phase 1
T62193	DRUGINFO	D0IB8N	Noradrenalone (arterenone)	Investigative
T62193	DRUGINFO	D0P9BM	3-hydroxybenzylhydrazine	Investigative

T13852	TARGETID	T13852
T13852	FORMERID	TTDC00258
T13852	UNIPROID	S1PR1_HUMAN
T13852	TARGNAME	Sphingosine-1-phosphate receptor 1 (S1PR1)
T13852	GENENAME	S1PR1
T13852	TARGTYPE	Successful
T13852	SYNONYMS	Sphingosine 1-phosphate receptor Edg-1; S1P1; S1P receptor Edg-1; S1P receptor 1; Endothelial differentiation G-protein coupled receptor 1; CHEDG1; CD363
T13852	FUNCTION	Signaling leads to the activation of RAC1, SRC, PTK2/FAK1 and MAP kinases. Plays an important role in cell migration, probably via its role in the reorganization of the actin cytoskeleton and the formation of lamellipodia in response to stimuli that increase the activity of the sphingosine kinase SPHK1. Required for normal chemotaxis toward sphingosine 1-phosphate. Required for normal embryonic heart development and normal cardiac morphogenesis. Plays an important role in the regulation of sprouting angiogenesis and vascular maturation. Inhibits sprouting angiogenesis to prevent excessive sprouting during blood vessel development. Required for normal egress of mature T-cells from the thymus into the blood stream and into peripheral lymphoid organs. Plays a role in the migration of osteoclast precursor cells, the regulation of bone mineralization and bone homeostasis. Plays a role in responses to oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine by pulmonary endothelial cells and in the protection against ventilator-induced lung injury. G-protein coupled receptor for the bioactive lysosphingolipid sphingosine 1-phosphate (S1P) that seems to be coupled to the G(i) subclass of heteromeric G proteins.
T13852	PDBSTRUC	3V2Y; 3V2W
T13852	BIOCLASS	GPCR rhodopsin
T13852	SEQUENCE	MGPTSVPLVKAHRSSVSDYVNYDIIVRHYNYTGKLNISADKENSIKLTSVVFILICCFIILENIFVLLTIWKTKKFHRPMYYFIGNLALSDLLAGVAYTANLLLSGATTYKLTPAQWFLREGSMFVALSASVFSLLAIAIERYITMLKMKLHNGSNNFRLFLLISACWVISLILGGLPIMGWNCISALSSCSTVLPLYHKHYILFCTTVFTLLLLSIVILYCRIYSLVRTRSRRLTFRKNISKASRSSEKSLALLKTVIIVLSVFIACWAPLFILLLLDVGCKVKTCDILFRAEYFLVLAVLNSGTNPIIYTLTNKEMRRAFIRIMSCCKCPSGDSAGKFKRPIIAGMEFSRSKSDNSSHPQKDEGDNPETIMSSGNVNSSS
T13852	DRUGINFO	D07EDB	Ozanimod	Approved
T13852	DRUGINFO	D07UHS	Fingolimod	Approved
T13852	DRUGINFO	D0L9KH	Etrasimod	Approved
T13852	DRUGINFO	D0Y4SI	Ponesimod	Approved
T13852	DRUGINFO	D07FKQ	Siponimod	Approved
T13852	DRUGINFO	D00ISN	MT-1303	Phase 2
T13852	DRUGINFO	D0I2RB	ONO-4641	Phase 2
T13852	DRUGINFO	D0Y5ZT	KRP-203	Phase 2
T13852	DRUGINFO	D6C7FG	VTX-002	Phase 2
T13852	DRUGINFO	DLK93N	CBP-307	Phase 2
T13852	DRUGINFO	D07UGA	Sphingosine-1-phosphate	Phase 1
T13852	DRUGINFO	D0B4CD	GSK-2018682	Phase 1
T13852	DRUGINFO	D0GG7L	BMS-986104	Phase 1
T13852	DRUGINFO	D0KV2E	Sonepcizumab	Phase 1
T13852	DRUGINFO	D0X8XT	CS-0777	Phase 1
T13852	DRUGINFO	D0XE5M	SAR247799	Phase 1
T13852	DRUGINFO	D0Q0JI	ASP-4058	Phase 1
T13852	DRUGINFO	D0N8AB	PF-4629991	Discontinued in Phase 1
T13852	DRUGINFO	D0Y0BC	XL-541	Terminated
T13852	DRUGINFO	D00VHN	3-(N-alkylamino) propylphosphonic acid derivative	Investigative
T13852	DRUGINFO	D00ZXX	CYM5442	Investigative
T13852	DRUGINFO	D02LTS	NIBR-0213	Investigative
T13852	DRUGINFO	D02OCD	NIBR-785	Investigative
T13852	DRUGINFO	D03AAC	W146	Investigative
T13852	DRUGINFO	D04XCB	3-amino-5-(4-octylphenyl)pentanoic acid	Investigative
T13852	DRUGINFO	D05SYL	CYM5181	Investigative
T13852	DRUGINFO	D06XMB	(3-Tetradecylamino-cyclohexyl)-phosphonic acid	Investigative
T13852	DRUGINFO	D07EAB	1-(4-nonylbenzyl)pyrrolidine-3-carboxylic acid	Investigative
T13852	DRUGINFO	D08VLT	4-amino-6-(4-octylphenyl)hexanoic acid	Investigative
T13852	DRUGINFO	D09NWW	AMG-247	Investigative
T13852	DRUGINFO	D0D5QS	[3-(4-Nonyl-benzylamino)-propyl]-phosphonic acid	Investigative
T13852	DRUGINFO	D0G6KH	NOX-S91	Investigative
T13852	DRUGINFO	D0IL7V	KRP-107	Investigative
T13852	DRUGINFO	D0LO4T	1-(4-nonylbenzyl)pyrrolidin-3-ylphosphonic acid	Investigative
T13852	DRUGINFO	D0N0BN	(3-Tetradecylamino-cyclopentyl)-phosphonic acid	Investigative
T13852	DRUGINFO	D0O4JU	(S)-FTY720P	Investigative
T13852	DRUGINFO	D0P1TY	3-(tetradecylamino)propylphosphonic acid	Investigative
T13852	DRUGINFO	D0P2AZ	1-(4-nonylbenzyl)azetidine-3-carboxylic acid	Investigative
T13852	DRUGINFO	D0T4LT	GSK-1842799C	Investigative
T13852	DRUGINFO	D0YC1R	BMS-520	Investigative
T13852	DRUGINFO	D0ZU0O	SEW2871	Investigative
T13852	DRUGINFO	D05EDD	VPC23019	Investigative
T13852	DRUGINFO	D09ESF	GNF-PF-78	Investigative
T13852	DRUGINFO	D0R2ZN	GNF-PF-826	Investigative
T13852	DRUGINFO	D0U7YK	KRP 203-phosphate	Investigative
T13852	DRUGINFO	D06GFH	VPC44116	Investigative
T13852	DRUGINFO	D05KEE	AFD(R)	Investigative
T13852	DRUGINFO	D06DYN	FTY720-phosphate	Investigative
T13852	DRUGINFO	D0W1ZW	VPC03090-P	Investigative
T13852	DRUGINFO	D03BRM	AUY954	Investigative
T13852	DRUGINFO	D0X0UR	LPA	Investigative

T76904	TARGETID	T76904
T76904	FORMERID	TTDS00362
T76904	UNIPROID	COMT_HUMAN
T76904	TARGNAME	Catechol-O-methyl-transferase (COMT)
T76904	GENENAME	COMT
T76904	TARGTYPE	Successful
T76904	SYNONYMS	S-COMT; MB-COMT; Catechol-O-methyltransferase; COMT
T76904	FUNCTION	Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOPA, alpha-methyl DOPA and isoproterenol.
T76904	PDBSTRUC	5LSA; 4XUE; 4XUD; 4XUC; 4PYK
T76904	BIOCLASS	Methyltransferase
T76904	ECNUMBER	EC 2.1.1.6
T76904	SEQUENCE	MPEAPPLLLAAVLLGLVLLVVLLLLLRHWGWGLCLIGWNEFILQPIHNLLMGDTKEQRILNHVLQHAEPGNAQSVLEAIDTYCEQKEWAMNVGDKKGKIVDAVIQEHQPSVLLELGAYCGYSAVRMARLLSPGARLITIEINPDCAAITQRMVDFAGVKDKVTLVVGASQDIIPQLKKKYDVDTLDMVFLDHWKDRYLPDTLLLEECGLLRKGTVLLADNVICPGAPDFLAHVRGSSCFECTHYQSFLEYREVVDGLEKAIYKGPGSEAGP
T76904	DRUGINFO	D01SGK	Opicapone	Approved
T76904	DRUGINFO	D0J1VY	Entacapone	Approved
T76904	DRUGINFO	D0Y7PG	Tolcapone	Approved
T76904	DRUGINFO	D0R2NE	Entacapone+levodopa+carbidopa	Phase 3
T76904	DRUGINFO	D0G4DE	BIA 3-202	Phase 2
T76904	DRUGINFO	D0P5TR	CGP-28014	Phase 2
T76904	DRUGINFO	D08LVF	Nitecapone	Discontinued in Phase 2
T76904	DRUGINFO	D0U1CL	PGX-200097	Preclinical
T76904	DRUGINFO	D01AFH	1-(3,4-dihydroxy-5-nitrophenyl)-2-phenoxyethanone	Investigative
T76904	DRUGINFO	D06LED	7,8-dihydroxy-4-phenyl-2H-chromen-2-one	Investigative
T76904	DRUGINFO	D09AYR	3,5-Dinitrocatechol	Investigative
T76904	DRUGINFO	D0C0OT	1-(3,4-dihydroxy-2-nitrophenyl)-2-phenylethanone	Investigative
T76904	DRUGINFO	D0HW3Y	5,6-dihydroxy-7-nitro-2,3-dihydroinden-1-one	Investigative
T76904	DRUGINFO	D0M3PG	6,7-dihydroxy-8-nitro-1-tetralone	Investigative
T76904	DRUGINFO	D0OE1R	(3,4-DIHYDROXY-2-NITROPHENYL)(PHENYL)METHANONE	Investigative
T76904	DRUGINFO	D0XT0I	BIA	Investigative

T76369	TARGETID	T76369
T76369	FORMERID	TTDR00274
T76369	UNIPROID	EST1_HUMAN
T76369	TARGNAME	Liver carboxylesterase (CES1)
T76369	GENENAME	CES1
T76369	TARGTYPE	Successful
T76369	SYNONYMS	Serine esterase 1; Monocyte/macrophage serine esterase; Human carboxylesterase 1; HMSE; HCE1; CES1; Brain carboxylesterase hBr1; Acyl coenzyme A:cholesterol acyltransferase
T76369	FUNCTION	Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acyl coa ester.
T76369	PDBSTRUC	5A7H; 5A7G; 5A7F; 4AB1; 3K9B
T76369	BIOCLASS	Carboxylic ester hydrolase
T76369	ECNUMBER	EC 3.1.1.1
T76369	SEQUENCE	MWLRAFILATLSASAAWGHPSSPPVVDTVHGKVLGKFVSLEGFAQPVAIFLGIPFAKPPLGPLRFTPPQPAEPWSFVKNATSYPPMCTQDPKAGQLLSELFTNRKENIPLKLSEDCLYLNIYTPADLTKKNRLPVMVWIHGGGLMVGAASTYDGLALAAHENVVVVTIQYRLGIWGFFSTGDEHSRGNWGHLDQVAALRWVQDNIASFGGNPGSVTIFGESAGGESVSVLVLSPLAKNLFHRAISESGVALTSVLVKKGDVKPLAEQIAITAGCKTTTSAVMVHCLRQKTEEELLETTLKMKFLSLDLQGDPRESQPLLGTVIDGMLLLKTPEELQAERNFHTVPYMVGINKQEFGWLIPMQLMSYPLSEGQLDQKTAMSLLWKSYPLVCIAKELIPEATEKYLGGTDDTVKKKDLFLDLIADVMFGVPSVIVARNHRDAGAPTYMYEFQYRPSFSSDMKPKTVIGDHGDELFSVFGAPFLKEGASEEEIRLSKMVMKFWANFARNGNPNGEGLPHWPEYNQKEGYLQIGANTQAAQKLKDKEVAFWTNLFAKKAVEKPPQTEHIEL
T76369	DRUGINFO	D0OR2L	Cholic Acid	Approved
T76369	DRUGINFO	D02GWF	PACTIMIBE	Phase 2/3
T76369	DRUGINFO	D03PYD	K-604	Phase 2
T76369	DRUGINFO	D0YB4D	Eldacimibe	Phase 2
T76369	DRUGINFO	D05EMV	GR148672X	Clinical trial
T76369	DRUGINFO	D0O1KX	Avasimibe	Discontinued in Phase 3
T76369	DRUGINFO	D01IDE	E-5324	Discontinued in Phase 2
T76369	DRUGINFO	D07DBS	RP-64477	Discontinued in Phase 2
T76369	DRUGINFO	D0D1XG	CI-976	Discontinued in Phase 2
T76369	DRUGINFO	D0E1UZ	CL-283796	Discontinued in Phase 2
T76369	DRUGINFO	D0W0ED	Eflucimibe	Discontinued in Phase 2
T76369	DRUGINFO	D03QZB	F-1394	Discontinued in Phase 1
T76369	DRUGINFO	D04ODQ	447C88	Discontinued in Phase 1
T76369	DRUGINFO	D06FCR	CL-277082	Discontinued in Phase 1
T76369	DRUGINFO	D0D9AD	YM-750	Discontinued in Phase 1
T76369	DRUGINFO	D0IZ7T	YM-17E	Discontinued in Phase 1
T76369	DRUGINFO	D09MJO	HL-004	Preclinical
T76369	DRUGINFO	D00KQT	FR-129169	Terminated
T76369	DRUGINFO	D03EHR	Lecimibide	Terminated
T76369	DRUGINFO	D03JRJ	NTE-122	Terminated
T76369	DRUGINFO	D03YPL	RP-70676	Terminated
T76369	DRUGINFO	D06KFR	RP-73163	Terminated
T76369	DRUGINFO	D0J8TH	CEB-925	Terminated
T76369	DRUGINFO	D0K8KJ	DuP-129	Terminated
T76369	DRUGINFO	D0O2AC	FR-145237	Terminated
T76369	DRUGINFO	D0OK8M	TEI-6522	Terminated
T76369	DRUGINFO	D0PG0S	CI-999	Terminated
T76369	DRUGINFO	D00PLH	1,2-bis(2,5-difluorophenyl)-2-hydroxyethanone	Investigative
T76369	DRUGINFO	D01GSO	Diethyl 2,2,2-trifluoro-1-phenylethyl phosphate	Investigative
T76369	DRUGINFO	D01HRG	1-phenyl-1H-indole-2,3-dione	Investigative
T76369	DRUGINFO	D01HZN	1,2-bis(3,4,5-trifluorophenyl)-2-hydroxyethanone	Investigative
T76369	DRUGINFO	D01VAU	1,2-Bis-(3-methoxy-phenyl)-ethane-1,2-dione	Investigative
T76369	DRUGINFO	D01VCS	1,2-bis(2,6-difluorophenyl)ethane-1,2-dione	Investigative
T76369	DRUGINFO	D02EZF	SMP-797	Investigative
T76369	DRUGINFO	D02GJG	1,2-bis(2-fluorophenyl)ethane-1,2-dione	Investigative
T76369	DRUGINFO	D02HQS	1,2-bis(2,4-difluorophenyl)ethane-1,2-dione	Investigative
T76369	DRUGINFO	D02TLP	1-Phenyl-propane-1,2-dione	Investigative
T76369	DRUGINFO	D02VYI	Dibutyl 2,2,2-trifluoro-1-phenylethyl phosphate	Investigative
T76369	DRUGINFO	D03HZT	1,2-Bis-(2-chloro-phenyl)-ethane-1,2-dione	Investigative
T76369	DRUGINFO	D03TPH	5-chloro-1H-indole-2,3-dione	Investigative
T76369	DRUGINFO	D03WOU	1,2-Di-naphthalen-2-yl-ethane-1,2-dione	Investigative
T76369	DRUGINFO	D04AXR	4-chloro-1H-indole-2,3-dione	Investigative
T76369	DRUGINFO	D04CDV	1,2-bis(2,6-difluorophenyl)-2-hydroxyethanone	Investigative
T76369	DRUGINFO	D04EXR	4,6-dichloro-1H-indole-2,3-dione	Investigative
T76369	DRUGINFO	D04JVA	1,1,1-trifluoro-3-(hexylsulfonyl)propan-2-one	Investigative
T76369	DRUGINFO	D05AVX	Heptane-2,3-dione	Investigative
T76369	DRUGINFO	D05EMT	1,2-bis(2,5-difluorophenyl)ethane-1,2-dione	Investigative
T76369	DRUGINFO	D05EYA	1,2-Bis-(4-chloro-phenyl)-ethane-1,2-dione	Investigative
T76369	DRUGINFO	D05PNO	1-(2-iodoethyl)-1H-indole-2,3-dione	Investigative
T76369	DRUGINFO	D05VUC	1,2-bis(2-fluorophenyl)-2-hydroxyethanone	Investigative
T76369	DRUGINFO	D05XRY	11,12-dihydro-dibenzo[a,e]cyclooctene-5,6-dione	Investigative
T76369	DRUGINFO	D05ZCX	Thieno[3,2-e][1]benzothiophene-4,5-dione	Investigative
T76369	DRUGINFO	D06FFD	1,2-Bis-(4-bromo-phenyl)-ethane-1,2-dione	Investigative
T76369	DRUGINFO	D06GYH	1,2-bis(2,3,4-trifluorophenyl)-2-hydroxyethanone	Investigative
T76369	DRUGINFO	D06ZPI	N-Methylnaloxonium	Investigative
T76369	DRUGINFO	D07CFJ	1-propionyl-1H-indole-2,3-dione	Investigative
T76369	DRUGINFO	D07WHV	4-Piperidino-Piperidine	Investigative
T76369	DRUGINFO	D08AOG	2,2-Dimethoxy-1,2-diphenyl-ethanone	Investigative
T76369	DRUGINFO	D08UOB	1,2-bis(2,3,5-trifluorophenyl)ethane-1,2-dione	Investigative
T76369	DRUGINFO	D09LSR	1,2-bis(3,5-difluorophenyl)ethane-1,2-dione	Investigative
T76369	DRUGINFO	D0AW4P	1,2-bis(3-fluorophenyl)-2-hydroxyethanon	Investigative
T76369	DRUGINFO	D0B1TQ	4-chloro-7-methyl-1H-indole-2,3-dione	Investigative
T76369	DRUGINFO	D0B8YX	1-Phenyl-2-p-tolyl-ethane-1,2-dione	Investigative
T76369	DRUGINFO	D0BB2U	4-(2-Oxo-2-phenyl-acetyl)-benzoic acid	Investigative
T76369	DRUGINFO	D0C9AD	1-(4-chlorobenzyl)-1H-indole-2,3-dione	Investigative
T76369	DRUGINFO	D0CN8Z	1,2-bis(3,4,5-trifluorophenyl)ethane-1,2-dione	Investigative
T76369	DRUGINFO	D0D2HH	1,2-bis(2,3,5-trifluorophenyl)-2-hydroxyethanone	Investigative
T76369	DRUGINFO	D0D7FN	1-(4-Nitro-phenyl)-2-phenyl-ethane-1,2-dione	Investigative
T76369	DRUGINFO	D0DW9J	1,2-bis(4-fluorophenyl)ethane-1,2-dione	Investigative
T76369	DRUGINFO	D0E2IG	1,2-bis(2,3,6-trifluorophenyl)ethane-1,2-dione	Investigative
T76369	DRUGINFO	D0E5ZP	7-(trifluoromethyl)-1H-indole-2,3-dione	Investigative
T76369	DRUGINFO	D0EK7H	4,7-dichloro-1H-indole-2,3-dione	Investigative
T76369	DRUGINFO	D0F0JI	(E)-Octadec-9-enoic acid phenylamide	Investigative
T76369	DRUGINFO	D0F3RN	1-(4-Chloro-phenyl)-2-phenyl-ethane-1,2-dione	Investigative
T76369	DRUGINFO	D0F4QX	Thenoyltrifluoroacetone	Investigative
T76369	DRUGINFO	D0F7NU	1,1,1-trifluoro-3-(hexylsulfinyl)propan-2-one	Investigative
T76369	DRUGINFO	D0FO4J	3-(butylthio)-1,1,1-trifluoropropan-2-one	Investigative
T76369	DRUGINFO	D0H5II	2-methoxy-3,4-methylenedioxybenzophenone	Investigative
T76369	DRUGINFO	D0JH7C	1,10-phenanthroline-5,6-dione	Investigative
T76369	DRUGINFO	D0JI0H	1-(2-bromoethyl)-1H-indole-2,3-dione	Investigative
T76369	DRUGINFO	D0K6OM	1,2-bis(3,4-difluorophenyl)ethane-1,2-dione	Investigative
T76369	DRUGINFO	D0K6PO	Acenanthrene-9,10-dione	Investigative
T76369	DRUGINFO	D0L1ST	1-(4-Chloro-phenyl)-2-p-tolyl-ethane-1,2-dione	Investigative
T76369	DRUGINFO	D0L4MF	1,2-bis(3,5-difluorophenyl)-2-hydroxyethanone	Investigative
T76369	DRUGINFO	D0LJ2F	1,2-dicyclohexylethane-1,2-dione	Investigative
T76369	DRUGINFO	D0M2ZD	1,2-bis(2,3-difluorophenyl)-2-hydroxyethanone	Investigative
T76369	DRUGINFO	D0M5NR	1-butyryl-1H-indole-2,3-dione	Investigative
T76369	DRUGINFO	D0N8YZ	1-(3,4-Dimethyl-phenyl)-2-phenyl-ethane-1,2-dione	Investigative
T76369	DRUGINFO	D0N9ZR	6-bromo-5-methyl-1H-indole-2,3-dione	Investigative
T76369	DRUGINFO	D0NJ4G	5,7-dichloro-1H-indole-2,3-dione	Investigative
T76369	DRUGINFO	D0O0LU	1-benzyl-1H-indole-2,3-dione	Investigative
T76369	DRUGINFO	D0O9EB	3-(butylsulfinyl)-1,1,1-trifluoropropan-2-one	Investigative
T76369	DRUGINFO	D0OH1O	VULM-1457	Investigative
T76369	DRUGINFO	D0P1IK	1,2-bis(2,3,4-trifluorophenyl)ethane-1,2-dione	Investigative
T76369	DRUGINFO	D0T5XC	1-(4-Methoxy-phenyl)-2-phenyl-ethane-1,2-dione	Investigative
T76369	DRUGINFO	D0U0BV	1,2-bis(3,4-difluorophenyl)-2-hydroxyethanone	Investigative
T76369	DRUGINFO	D0U3JD	1-methyl-1H-indole-2,3-dione	Investigative
T76369	DRUGINFO	D0UK5A	1,2-Di-p-tolyl-ethane-1,2-dione	Investigative
T76369	DRUGINFO	D0UT1X	1,2-Bis-(3-nitro-phenyl)-ethane-1,2-dione	Investigative
T76369	DRUGINFO	D0UZ8R	1,2-Bis-(4-methoxy-phenyl)-ethane-1,2-dione	Investigative
T76369	DRUGINFO	D0V9MG	KY-382	Investigative
T76369	DRUGINFO	D0W0PH	SCH-48375	Investigative
T76369	DRUGINFO	D0X0ER	7-chloro-1H-indole-2,3-dione	Investigative
T76369	DRUGINFO	D0XP0J	Dimethyl 2,2,2-trifluoro-1-phenylethyl phosphate	Investigative
T76369	DRUGINFO	D0Y6RZ	1,2-bis(3-fluorophenyl)ethane-1,2-dione	Investigative
T76369	DRUGINFO	D0Y7FX	BENZIL	Investigative
T76369	DRUGINFO	D0Z1WQ	3,5-Di-tert-butyl-[1,2]benzoquinone	Investigative
T76369	DRUGINFO	D0Z5KQ	Benzoin	Investigative
T76369	DRUGINFO	D0Z6CZ	4,5-dichloro-1H-indole-2,3-dione	Investigative
T76369	DRUGINFO	D0Z8HX	6,7-dichloro-1H-indole-2,3-dione	Investigative
T76369	DRUGINFO	D0ZL6B	1-hexadecyl-1H-indole-2,3-dione	Investigative
T76369	DRUGINFO	D0ZR2T	5-(trifluoromethoxy)-1H-indole-2,3-dione	Investigative
T76369	DRUGINFO	D0ZT5C	1,2-bis(2,4-difluorophenyl)-2-hydroxyethanone	Investigative
T76369	DRUGINFO	D00ANJ	1-dodecyl-1H-indole-2,3-dione	Investigative
T76369	DRUGINFO	D00IAK	1,1,1-trifluoro-3-(octylsulfonyl)propan-2-one	Investigative
T76369	DRUGINFO	D00VKB	3-(decylsulfinyl)-1,1,1-trifluoropropan-2-one	Investigative
T76369	DRUGINFO	D01NDE	2,2-dimethyl-3-methyleneheptadecane	Investigative
T76369	DRUGINFO	D01XGP	1,2-indanedione	Investigative
T76369	DRUGINFO	D02SDT	3-(dodecylsulfonyl)-1,1,1-trifluoropropan-2-one	Investigative
T76369	DRUGINFO	D04UEN	1,1,1-trifluoro-3-(octylsulfinyl)propan-2-one	Investigative
T76369	DRUGINFO	D05LTW	1,2-bis(2,3-fluorophenyl)ethane-1,2-dione	Investigative
T76369	DRUGINFO	D06VGD	ACENAPHTHOQUINONE	Investigative
T76369	DRUGINFO	D07EDG	1-(3,4-dichlorobenzyl)-1H-indole-2,3-dione	Investigative
T76369	DRUGINFO	D0A2NK	PYRIPYROPENE A	Investigative
T76369	DRUGINFO	D0B4GJ	3-(dodecylsulfinyl)-1,1,1-trifluoropropan-2-one	Investigative
T76369	DRUGINFO	D0E5CF	3-(decylthio)-1,1,1-trifluoropropan-2-one	Investigative
T76369	DRUGINFO	D0I7FF	1,1,1-trifluorododecan-2-one	Investigative
T76369	DRUGINFO	D0Q2YJ	Phenanthrene-9,10-dione	Investigative
T76369	DRUGINFO	D0Q3GH	1,1,1-trifluoro-3-(octylthio)propan-2-one	Investigative
T76369	DRUGINFO	D0T7YM	Oleic acid anilide	Investigative
T76369	DRUGINFO	D0Y0FN	3-(decylsulfonyl)-1,1,1-trifluoropropan-2-one	Investigative
T76369	DRUGINFO	D0Y8RM	(1r)-1,2,2-trimethylpropyl (r)-methylphosphinate	Investigative
T76369	DRUGINFO	D0Z7WK	1,1,1-trifluoro-3-(hexylthio)propan-2-one	Investigative
T76369	DRUGINFO	D0D0BI	CHLORANIL	Investigative
T76369	DRUGINFO	D0F5VY	NSC-23180	Investigative
T76369	DRUGINFO	D0N0HK	3,4,5,6-Tetrachloro-[1,2]benzoquinone	Investigative
T76369	DRUGINFO	D0WX6R	5,6-dinitroacenaphthoquinone	Investigative
T76369	DRUGINFO	D08WQM	O-Sialic Acid	Investigative
T76369	DRUGINFO	D0W9VA	1,2-NAPHTHOQUINONE	Investigative
T76369	DRUGINFO	D07LUR	Alpha-D-Mannose	Investigative

T60529	TARGETID	T60529
T60529	FORMERID	TTDS00040
T60529	UNIPROID	PGH1_HUMAN
T60529	TARGNAME	Prostaglandin G/H synthase 1 (COX-1)
T60529	GENENAME	PTGS1
T60529	TARGTYPE	Successful
T60529	SYNONYMS	Prostaglandin-endoperoxide synthase 1; Prostaglandin H2 synthase 1; PHS 1; PGHS-1; PGH synthase 1; Cyclooxygenase-1; COX1; COX-1
T60529	FUNCTION	Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the generation of thromboxane A2 (TXA2), which promotes platelet activation and aggregation, vasoconstriction and proliferation of vascular smooth muscle cells.
T60529	BIOCLASS	Paired donor oxygen oxidoreductase
T60529	ECNUMBER	EC 1.14.99.1
T60529	SEQUENCE	MSRSLLLWFLLFLLLLPPLPVLLADPGAPTPVNPCCYYPCQHQGICVRFGLDRYQCDCTRTGYSGPNCTIPGLWTWLRNSLRPSPSFTHFLLTHGRWFWEFVNATFIREMLMRLVLTVRSNLIPSPPTYNSAHDYISWESFSNVSYYTRILPSVPKDCPTPMGTKGKKQLPDAQLLARRFLLRRKFIPDPQGTNLMFAFFAQHFTHQFFKTSGKMGPGFTKALGHGVDLGHIYGDNLERQYQLRLFKDGKLKYQVLDGEMYPPSVEEAPVLMHYPRGIPPQSQMAVGQEVFGLLPGLMLYATLWLREHNRVCDLLKAEHPTWGDEQLFQTTRLILIGETIKIVIEEYVQQLSGYFLQLKFDPELLFGVQFQYRNRIAMEFNHLYHWHPLMPDSFKVGSQEYSYEQFLFNTSMLVDYGVEALVDAFSRQIAGRIGGGRNMDHHILHVAVDVIRESREMRLQPFNEYRKRFGMKPYTSFQELVGEKEMAAELEELYGDIDALEFYPGLLLEKCHPNSIFGESMIEIGAPFSLKGLLGNPICSPEYWKPSTFGGEVGFNIVKTATLKKLVCLNTKTCPYVSFRVPDASQDDGPAVERPSTEL
T60529	DRUGINFO	D00IBN	Piroxicam	Approved
T60529	DRUGINFO	D07BPS	Suprofen	Approved
T60529	DRUGINFO	D0A6KR	Balsalazide	Approved
T60529	DRUGINFO	D0C4YC	Mesalazine	Approved
T60529	DRUGINFO	D0O1TC	Gamma-Homolinolenic acid	Approved
T60529	DRUGINFO	D0U1OM	Bromfenac	Approved
T60529	DRUGINFO	D0Y0JH	Salsalate	Approved
T60529	DRUGINFO	D06LHG	FENBUFEN	Approved
T60529	DRUGINFO	D0DJ1B	Naproxen	Approved
T60529	DRUGINFO	D0MN9K	Meclofenamate Sodium	Approved
T60529	DRUGINFO	D0Q5XX	Eicosapentaenoic acid/docosa-hexaenoic acid	Approved
T60529	DRUGINFO	D01WJL	Aminosalicylic Acid	Approved
T60529	DRUGINFO	D0B2WJ	Flufenamic Acid	Approved
T60529	DRUGINFO	D07HBX	Salicyclic acid	Approved
T60529	DRUGINFO	D0AL8M	IMRECOXIB	Phase 4
T60529	DRUGINFO	D0G2IC	(S)-FLURBIPROFEN	Preregistration
T60529	DRUGINFO	D0C4DZ	ThermoProfen	Phase 3
T60529	DRUGINFO	D0U3EP	Resveratrol	Phase 3
T60529	DRUGINFO	D07SDQ	Curcumin	Phase 3
T60529	DRUGINFO	D0F5BL	EXO-230	Phase 1/2
T60529	DRUGINFO	D05TPI	EPICATECHIN	Phase 1/2
T60529	DRUGINFO	D0S8TB	Carbamate derivative 2	Patented
T60529	DRUGINFO	D06JRD	Metamizole	Withdrawn from market
T60529	DRUGINFO	D0O2IE	Phenacetin	Withdrawn from market
T60529	DRUGINFO	D0Q5PL	INDOPROFEN	Withdrawn from market
T60529	DRUGINFO	D0BZ1Q	CRx-401	Discontinued in Phase 2
T60529	DRUGINFO	D0P3KA	TEBUFELONE	Discontinued in Phase 2
T60529	DRUGINFO	D0ZL4F	R-ketoprofen	Discontinued in Phase 2
T60529	DRUGINFO	D03AKL	ATLIPROFEN METHYL ESTER	Terminated
T60529	DRUGINFO	D0O9JX	SC-58451	Terminated
T60529	DRUGINFO	D00RCV	Acetic acid 2-hex-2-ynylsulfanyl-phenyl ester	Investigative
T60529	DRUGINFO	D00VHS	4-(5-(4-Hydroxyphenyl)isothiazol-4-yl)phenol	Investigative
T60529	DRUGINFO	D00XIX	5-(4-Chlorophenyl)-4-p-tolyl-3H-1,2-dithiol-3-one	Investigative
T60529	DRUGINFO	D01EWD	Acetic acid 2-heptylselanyl-phenyl ester	Investigative
T60529	DRUGINFO	D01HXN	TRL-382	Investigative
T60529	DRUGINFO	D02GZX	2-(3'-Ethylsulfanyl-biphenyl-4-yl)-propionic acid	Investigative
T60529	DRUGINFO	D02HSZ	IODOINDOMETHACIN	Investigative
T60529	DRUGINFO	D02HVL	(3-Chloro-4-Propoxy-Phenyl)-Acetic Acid	Investigative
T60529	DRUGINFO	D02PLG	4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiole-3-thione	Investigative
T60529	DRUGINFO	D02VLR	Acetic acid 2-hept-2-ynylsulfanyl-phenyl ester	Investigative
T60529	DRUGINFO	D03EDF	DEMETHOXYCURCUMIN	Investigative
T60529	DRUGINFO	D03IRR	Phenazone	Investigative
T60529	DRUGINFO	D03TLR	5-(4-Chlorophenyl)-4-p-tolylisothiazole	Investigative
T60529	DRUGINFO	D04KAM	Acetic acid 2-hexylsulfanyl-phenyl ester	Investigative
T60529	DRUGINFO	D04ORY	4-amino-N-p-tolylbenzenesulfonamide	Investigative
T60529	DRUGINFO	D05DOM	2-Bromoacetyl Group	Investigative
T60529	DRUGINFO	D05KYE	2'-epi-guianin	Investigative
T60529	DRUGINFO	D06FTI	2-(1,1'-Biphenyl-4-Yl)Propanoic Acid	Investigative
T60529	DRUGINFO	D06GSY	P-(2'-Iodo-5'-Thenoyl)Hydrotropic Acid	Investigative
T60529	DRUGINFO	D07OAV	5-(2-1H-indenyl)-1,3-benzodioxole	Investigative
T60529	DRUGINFO	D07SAI	Protoporphyrin Ix Containing Co	Investigative
T60529	DRUGINFO	D08BPE	(-)-3-O-acetylspectaline	Investigative
T60529	DRUGINFO	D08QAH	2-(3'-Ethyl-biphenyl-4-yl)-propionic acid	Investigative
T60529	DRUGINFO	D08RCQ	5-(4-Methoxyphenyl)-4-p-tolylisothiazole	Investigative
T60529	DRUGINFO	D09CMJ	FR122047	Investigative
T60529	DRUGINFO	D09XYZ	Acetic Acid Salicyloyl-Amino-Ester	Investigative
T60529	DRUGINFO	D0G7RA	4-(4-Chlorophenyl)-5-p-tolyl-3H-1,2-dithiol-3-one	Investigative
T60529	DRUGINFO	D0HD9P	Arachidonic Acid	Investigative
T60529	DRUGINFO	D0IB5L	O-Acetylserine	Investigative
T60529	DRUGINFO	D0J6TU	5-(4-Chlorophenyl)-4-(4-methoxyphenyl)isothiazole	Investigative
T60529	DRUGINFO	D0JQ1T	2-[4-(1H-Indol-5-yl)-phenyl]-propionic acid	Investigative
T60529	DRUGINFO	D0L6TP	N-(3-phenoxy-4-pyridinyl)propanesulfonamide	Investigative
T60529	DRUGINFO	D0M5MI	SC-560	Investigative
T60529	DRUGINFO	D0M7EI	Acetic acid 2-pentylsulfanyl-phenyl ester	Investigative
T60529	DRUGINFO	D0M9RL	2-(3'-Allyl-biphenyl-4-yl)-propionic acid	Investigative
T60529	DRUGINFO	D0N7OP	2-(2-methoxyphenyl)-1H-indene	Investigative
T60529	DRUGINFO	D0O8XG	Acetic acid 2-hept-3-ynylsulfanyl-phenyl ester	Investigative
T60529	DRUGINFO	D0OW4W	4-(4-Chlorophenyl)-5-p-tolylisothiazole	Investigative
T60529	DRUGINFO	D0PQ3Q	4-(4-Chlorophenyl)-5-(4-methoxyphenyl)isothiazole	Investigative
T60529	DRUGINFO	D0Q8TK	1-(4-aminosulfonylphenyl)-2-(4-pyridyl)acetylene	Investigative
T60529	DRUGINFO	D0R1UO	2-(2-Methylpropanoyl)-1,3,5-benzenetriol	Investigative
T60529	DRUGINFO	D0T5DO	IODOSUPROFEN	Investigative
T60529	DRUGINFO	D0VF6F	N-(3-phenoxypyridin-4-yl)methanesulfonamide	Investigative
T60529	DRUGINFO	D0X9VY	Acetic acid 2-heptylsulfanyl-phenyl ester	Investigative
T60529	DRUGINFO	D0Y7ND	4-amino-N-(2-chlorophenyl)benzenesulfonamide	Investigative
T60529	DRUGINFO	D0YI3V	2-(3'-Vinyl-biphenyl-4-yl)-propionic acid	Investigative
T60529	DRUGINFO	D00GBX	Prifelone	Investigative
T60529	DRUGINFO	D00VBX	2-(p-Methylsulfonylbenzoyl)furan	Investigative
T60529	DRUGINFO	D01VRB	4,5-Bis(4-chlorophenyl)isothiazole	Investigative
T60529	DRUGINFO	D01WLL	N-(3-(phenylthio)pyridin-4-yl)methanesulfonamide	Investigative
T60529	DRUGINFO	D02CCB	2-(2,3,4-trimethoxyphenyl)-1H-indene	Investigative
T60529	DRUGINFO	D02DYG	4-amino-N-(4-chlorophenyl)benzenesulfonamide	Investigative
T60529	DRUGINFO	D02FGY	2-(N-(2-Ffuorophenyl)pyrrol-3-yl) acetic acid	Investigative
T60529	DRUGINFO	D04TNI	Nitroflurbiprofen	Investigative
T60529	DRUGINFO	D04YPP	5-Methyl-3,4-diphenyl-isoxazole	Investigative
T60529	DRUGINFO	D06DRL	N-(3-phenylamino-4-pyridinyl)methanesulfonamide	Investigative
T60529	DRUGINFO	D06WML	5-Ethyl-3,4-diphenyl-isoxazole	Investigative
T60529	DRUGINFO	D07ARK	5-Phenyl-pentanoic acid benzyl-hydroxy-amide	Investigative
T60529	DRUGINFO	D07RTV	5-(4-Methoxyphenyl)-4-p-tolyl-1,2-selenazole	Investigative
T60529	DRUGINFO	D07STC	2-(N-(2-fluorophenyl)pyrrol-2-yl) acetic acid	Investigative
T60529	DRUGINFO	D08RYB	5-(4-Chlorophenyl)-4-p-tolyl-1,2-selenazole	Investigative
T60529	DRUGINFO	D09HWQ	3-(4-Methanesulfonyl-phenyl)-1-phenyl-propynone	Investigative
T60529	DRUGINFO	D09MDB	4-(4-Chlorophenyl)-5-p-tolyl-1,2-selenazole	Investigative
T60529	DRUGINFO	D0A4LW	(R)-2-(4-Isobutyl-phenyl)-N-phenyl-propionamide	Investigative
T60529	DRUGINFO	D0BO9W	N-(3-phenoxy-4-pyridinyl)ethanesulfonamide	Investigative
T60529	DRUGINFO	D0CW3A	Resveratrol Potassium3-Sulfate	Investigative
T60529	DRUGINFO	D0D0JE	4,5-Bis(4-methoxyphenyl)-1,2-selenazole	Investigative
T60529	DRUGINFO	D0D6UC	(Z)-2'-des-methyl sulindac sulfide	Investigative
T60529	DRUGINFO	D0E5MK	4,5-Bis(4-chlorophenyl)-1,2-selenazole	Investigative
T60529	DRUGINFO	D0F0JU	4,5-Bis(4-methoxyphenyl)isothiazole	Investigative
T60529	DRUGINFO	D0GF9J	(11H-Dibenzo[b,e][1,4]dioxepin-8-yl)-acetic acid	Investigative
T60529	DRUGINFO	D0J7YE	N-(1H-indazol-5-yl)acetamide	Investigative
T60529	DRUGINFO	D0LL9E	1-(4-(methylsulfonyl)phenyl)-3-phenylurea	Investigative
T60529	DRUGINFO	D0N0YS	(11H-Dibenzo[b,e][1,4]dioxepin-2-yl)-acetic acid	Investigative
T60529	DRUGINFO	D0OX0B	1,2-dihydro-3-(2,3,4-trimethoxyphenyl)naphthalene	Investigative
T60529	DRUGINFO	D0S7ZQ	4'-Methoxy-5,3'-dipropyl-biphenyl-2ol	Investigative
T60529	DRUGINFO	D0T4VL	Primary alcohol metabolite of celecoxib	Investigative
T60529	DRUGINFO	D0T7BP	1-(4-(methylsulfonyl)phenyl)-3-p-tolylurea	Investigative
T60529	DRUGINFO	D0T9QW	Oxametacin	Investigative
T60529	DRUGINFO	D0U0YE	2-(2-(2,6-dimethylphenylamino)phenyl)acetic acid	Investigative
T60529	DRUGINFO	D0V9AU	1-(4-aminosulfonylphenyl)-2-(2-pyridyl)acetylene	Investigative
T60529	DRUGINFO	D0X4LI	4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiol-3-one	Investigative
T60529	DRUGINFO	D0X5RR	(11H-Dibenzo[b,e][1,4]dioxepin-7-yl)-acetic acid	Investigative
T60529	DRUGINFO	D0ZI8Y	3 beta-O-acetyloleanolic acid	Investigative
T60529	DRUGINFO	D01JYF	2,4'-Dimethoxy-5,3'-di-(2-propenyl)-biphenyl	Investigative
T60529	DRUGINFO	D01OFH	METHYLHONOKIOL	Investigative
T60529	DRUGINFO	D04DQJ	HONOKIOL	Investigative
T60529	DRUGINFO	D04JZY	Resveratrol Potassium4,-Sulfate	Investigative
T60529	DRUGINFO	D04ZGF	5-(2-Imidazol-1-yl-ethyl)-7,8-dihydro-quinoline	Investigative
T60529	DRUGINFO	D06HUQ	2-Phenethyl-1,2-dihydro-indazol-3-one	Investigative
T60529	DRUGINFO	D09VTJ	Hyperforin	Investigative
T60529	DRUGINFO	D0J7YU	2-Benzyl-1,2-dihydro-indazol-3-one	Investigative
T60529	DRUGINFO	D0L4TM	2-(3-Phenyl-propyl)-1,2-dihydro-indazol-3-one	Investigative
T60529	DRUGINFO	D0P1LP	PHENIDONE	Investigative
T60529	DRUGINFO	D0R6ZC	5,3'-Dipropyl-biphenyl-2,4'-diol	Investigative
T60529	DRUGINFO	D0S0PB	2-Phenyl-1,2-dihydro-indazol-3-one	Investigative
T60529	DRUGINFO	D0SJ3W	2-Furan-2-ylmethyl-1,2-dihydro-indazol-3-one	Investigative
T60529	DRUGINFO	D0U8CM	2-Methyl-1,2-dihydro-indazol-3-one	Investigative
T60529	DRUGINFO	D0X6SA	2-Naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one	Investigative
T60529	DRUGINFO	D02DBP	RESORCINOL	Investigative
T60529	DRUGINFO	D0SD9H	Beta-D-Mannose	Investigative
T60529	DRUGINFO	D07ONX	Beta-D-Glucose	Investigative
T60529	DRUGINFO	D0V7AA	CATECHIN	Investigative
T60529	DRUGINFO	D0UU1I	Heme	Investigative
T60529	DRUGINFO	D02UVH	B-Octylglucoside	Investigative
T60529	DRUGINFO	D07LUR	Alpha-D-Mannose	Investigative

T06569	TARGETID	T06569
T06569	FORMERID	TTDR00210
T06569	UNIPROID	CAH6_HUMAN
T06569	TARGNAME	Carbonic anhydrase VI (CA-VI)
T06569	GENENAME	CA6
T06569	TARGTYPE	Successful
T06569	SYNONYMS	Secreted carbonic anhydrase; Salivary carbonic anhydrase; Carbonic anhydrase 6; Carbonate dehydratase VI
T06569	FUNCTION	Its role in saliva is unknown. Reversible hydration of carbon dioxide.
T06569	PDBSTRUC	3FE4
T06569	BIOCLASS	Alpha-carbonic anhydrase
T06569	ECNUMBER	EC 4.2.1.1
T06569	SEQUENCE	MRALVLLLSLFLLGGQAQHVSDWTYSEGALDEAHWPQHYPACGGQRQSPINLQRTKVRYNPSLKGLNMTGYETQAGEFPMVNNGHTVQISLPSTMRMTVADGTVYIAQQMHFHWGGASSEISGSEHTVDGIRHVIEIHIVHYNSKYKSYDIAQDAPDGLAVLAAFVEVKNYPENTYYSNFISHLANIKYPGQRTTLTGLDVQDMLPRNLQHYYTYHGSLTTPPCTENVHWFVLADFVKLSRTQVWKLENSLLDHRNKTIHNDYRRTQPLNHRVVESNFPNQEYTLGSEFQFYLHKIEEILDYLRRALN
T06569	DRUGINFO	D0K1QD	Sulfamylon	Approved
T06569	DRUGINFO	D07HBX	Salicyclic acid	Approved
T06569	DRUGINFO	D0A8JP	PARABEN	Phase 3
T06569	DRUGINFO	D07SDQ	Curcumin	Phase 3
T06569	DRUGINFO	D43GZX	SAR566658	Phase 2
T06569	DRUGINFO	D0Y6OA	Coumate	Phase 2
T06569	DRUGINFO	D03SLR	FERULIC ACID	Patented
T06569	DRUGINFO	D0LD9S	SPERMINE	Terminated
T06569	DRUGINFO	D00IUB	4-CYANOPHENOL	Investigative
T06569	DRUGINFO	D09WVV	N1-(2-aminoethyl)ethane-1,2-diamine	Investigative
T06569	DRUGINFO	D0G0FJ	2-hydrazinylbenzenesulfonamide	Investigative
T06569	DRUGINFO	D0LU4S	7-butoxy-2H-chromen-2-one	Investigative
T06569	DRUGINFO	D0OT5L	7-propoxy-2H-chromen-2-one	Investigative
T06569	DRUGINFO	D0TY8X	4-(2-aminopyrimidin-4-ylamino)benzenesulfonamide	Investigative
T06569	DRUGINFO	D0X6IE	4-amino-N-(4-sulfamoylbenzyl)benzenesulfonamide	Investigative
T06569	DRUGINFO	D0Z1HY	4-amino-6-chlorobenzene-1,3-disulfonamide	Investigative
T06569	DRUGINFO	D0ZC3W	P-toluenesulfonamide	Investigative
T06569	DRUGINFO	D04VLI	4-(2-Hydroxy-ethyl)-benzenesulfonamide	Investigative
T06569	DRUGINFO	D07TAJ	Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate	Investigative
T06569	DRUGINFO	D0OI1H	2-Amino-benzenesulfonamide	Investigative
T06569	DRUGINFO	D0X5HL	N1-(naphthalen-1-yl)ethane-1,2-diamine	Investigative
T06569	DRUGINFO	D05XZM	4-(hydroxymethyl)benzenesulfonamide	Investigative
T06569	DRUGINFO	D09JPC	Hexane-1,6-diamine	Investigative
T06569	DRUGINFO	D09PWX	Carzenide	Investigative
T06569	DRUGINFO	D0L5TZ	6-(hydroxymethyl)-2H-chromen-2-one	Investigative
T06569	DRUGINFO	D0Q2LL	6-Hydroxy-benzothiazole-2-sulfonic acid amide	Investigative
T06569	DRUGINFO	D0U4BB	HERNIARIN	Investigative
T06569	DRUGINFO	D00YEF	Decane-1,10-diyl disulfamate	Investigative
T06569	DRUGINFO	D01STY	4-Amino-3-iodo-benzenesulfonamide	Investigative
T06569	DRUGINFO	D02QGI	Pentane-1,5-diamine	Investigative
T06569	DRUGINFO	D03ZMQ	COUMARIN	Investigative
T06569	DRUGINFO	D04CVC	4-Amino-3-fluoro-benzenesulfonamide	Investigative
T06569	DRUGINFO	D05TLB	Octyl sulfamate	Investigative
T06569	DRUGINFO	D09WSJ	Decyl sulfamate	Investigative
T06569	DRUGINFO	D0AU0M	P-Coumaric Acid	Investigative
T06569	DRUGINFO	D0D4OV	Octane-1,8-diyl disulfamate	Investigative
T06569	DRUGINFO	D0E8CC	BENZOLAMIDE	Investigative
T06569	DRUGINFO	D0M3PO	2,4-Disulfamyltrifluoromethylaniline	Investigative
T06569	DRUGINFO	D0N1AW	6-(aminomethyl)-2H-chromen-2-one	Investigative
T06569	DRUGINFO	D0NN3Q	4-Hydrazino-benzenesulfonamide	Investigative
T06569	DRUGINFO	D0P6AM	4-Amino-3-bromo-benzenesulfonamide	Investigative
T06569	DRUGINFO	D0Q7DJ	Syringic Acid	Investigative
T06569	DRUGINFO	D0VD7H	CL-5343	Investigative
T06569	DRUGINFO	D0YU8J	4-Amino-3-chloro-benzenesulfonamide	Investigative
T06569	DRUGINFO	D0V7AA	CATECHIN	Investigative
T06569	DRUGINFO	D0Y3TZ	GALLICACID	Investigative
T06569	DRUGINFO	D0A1CM	ELLAGIC ACID	Investigative

T68334	TARGETID	T68334
T68334	FORMERID	TTDS00438
T68334	UNIPROID	FSHR_HUMAN
T68334	TARGNAME	Follicle-stimulating hormone receptor (FSHR)
T68334	GENENAME	FSHR
T68334	TARGTYPE	Successful
T68334	SYNONYMS	LGR1; Follitropin receptor; FSH-R
T68334	FUNCTION	G protein-coupled receptor for follitropin, the follicle-stimulating hormone. Through cAMP production activates the downstream PI3K-AKT and ERK1/ERK2 signaling pathways.
T68334	PDBSTRUC	4MQW; 4AY9; 1XWD; 1XUN
T68334	BIOCLASS	GPCR rhodopsin
T68334	SEQUENCE	MALLLVSLLAFLSLGSGCHHRICHCSNRVFLCQESKVTEIPSDLPRNAIELRFVLTKLRVIQKGAFSGFGDLEKIEISQNDVLEVIEADVFSNLPKLHEIRIEKANNLLYINPEAFQNLPNLQYLLISNTGIKHLPDVHKIHSLQKVLLDIQDNINIHTIERNSFVGLSFESVILWLNKNGIQEIHNCAFNGTQLDELNLSDNNNLEELPNDVFHGASGPVILDISRTRIHSLPSYGLENLKKLRARSTYNLKKLPTLEKLVALMEASLTYPSHCCAFANWRRQISELHPICNKSILRQEVDYMTQARGQRSSLAEDNESSYSRGFDMTYTEFDYDLCNEVVDVTCSPKPDAFNPCEDIMGYNILRVLIWFISILAITGNIIVLVILTTSQYKLTVPRFLMCNLAFADLCIGIYLLLIASVDIHTKSQYHNYAIDWQTGAGCDAAGFFTVFASELSVYTLTAITLERWHTITHAMQLDCKVQLRHAASVMVMGWIFAFAAALFPIFGISSYMKVSICLPMDIDSPLSQLYVMSLLVLNVLAFVVICGCYIHIYLTVRNPNIVSSSSDTRIAKRMAMLIFTDFLCMAPISFFAISASLKVPLITVSKAKILLVLFHPINSCANPFLYAIFTKNFRRDFFILLSKCGCYEMQAQIYRTETSSTVHNTHPRNGHCSSAPRVTNGSTYILVPLSHLAQN
T68334	DRUGINFO	D02SBQ	Urofollitropin	Approved
T68334	DRUGINFO	D04WBY	Menotropins	Approved
T68334	DRUGINFO	D0OM3A	Follitropin beta	Approved
T68334	DRUGINFO	D0H2UB	Suramin	Phase 1
T68334	DRUGINFO	D02FTU	Recombinant follicle stimulating hormone	Investigative
T68334	DRUGINFO	D08MVV	PRX-111	Investigative
T68334	DRUGINFO	D09HCE	Long-acting FSH conjugate	Investigative
T68334	DRUGINFO	D0W3SX	FSHR NAM	Investigative

T83011	TARGETID	T83011
T83011	FORMERID	TTDS00341
T83011	UNIPROID	AOFB_HUMAN
T83011	TARGNAME	Monoamine oxidase type B (MAO-B)
T83011	GENENAME	MAOB
T83011	TARGTYPE	Successful
T83011	SYNONYMS	MAO-B; Amine oxidase [flavin-containing] B
T83011	FUNCTION	Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
T83011	PDBSTRUC	6FWC; 6FW0; 6FVZ; 5MRL; 4CRT
T83011	BIOCLASS	CH-NH(2) donor oxidoreductase
T83011	ECNUMBER	EC 1.4.3.4
T83011	SEQUENCE	MSNKCDVVVVGGGISGMAAAKLLHDSGLNVVVLEARDRVGGRTYTLRNQKVKYVDLGGSYVGPTQNRILRLAKELGLETYKVNEVERLIHHVKGKSYPFRGPFPPVWNPITYLDHNNFWRTMDDMGREIPSDAPWKAPLAEEWDNMTMKELLDKLCWTESAKQLATLFVNLCVTAETHEVSALWFLWYVKQCGGTTRIISTTNGGQERKFVGGSGQVSERIMDLLGDRVKLERPVIYIDQTRENVLVETLNHEMYEAKYVISAIPPTLGMKIHFNPPLPMMRNQMITRVPLGSVIKCIVYYKEPFWRKKDYCGTMIIDGEEAPVAYTLDDTKPEGNYAAIMGFILAHKARKLARLTKEERLKKLCELYAKVLGSLEALEPVHYEEKNWCEEQYSGGCYTTYFPPGILTQYGRVLRQPVDRIYFAGTETATHWSGYMEGAVEAGERAAREILHAMGKIPEDEIWQSEPESVDVPAQPITTTFLERHLPSVPGLLRLIGLTTIFSATALGFLAHKRGLLVRV
T83011	DRUGINFO	D06OMW	Rasagiline	Approved
T83011	DRUGINFO	D07TGY	Indeloxazine	Approved
T83011	DRUGINFO	D0J2MJ	Selegiline Hydrochloride	Approved
T83011	DRUGINFO	D0RM9Q	Budipine	Approved
T83011	DRUGINFO	D0TV6I	Safinamide	Approved
T83011	DRUGINFO	D0XM1A	Safinamide mesylate	Approved
T83011	DRUGINFO	D07PAO	Sulphadoxine	Approved
T83011	DRUGINFO	D0P9AC	Phenelzine	Approved
T83011	DRUGINFO	D0R0UJ	Pargyline	Approved
T83011	DRUGINFO	D0H0HJ	Tranylcypromine	Approved
T83011	DRUGINFO	D0S2UG	Selegiline	Approved
T83011	DRUGINFO	D00VUI	Psoralen	Phase 3
T83011	DRUGINFO	D01NKW	P2B-001	Phase 3
T83011	DRUGINFO	D08CJK	TRYPTAMINE	Phase 3
T83011	DRUGINFO	D02PSS	RG1577	Phase 2
T83011	DRUGINFO	D06PHS	EVT302	Phase 2
T83011	DRUGINFO	DL50ZE	ORY-2001	Phase 2
T83011	DRUGINFO	D04RCT	CHF-3381	Phase 2
T83011	DRUGINFO	D0C3UC	Ladostigil	Phase 2
T83011	DRUGINFO	D0D1UQ	Neu-120	Phase 1/2
T83011	DRUGINFO	D0H7PW	PIPERINE	Phase 1/2
T83011	DRUGINFO	D0W7LO	PF9601N	Phase 1
T83011	DRUGINFO	D00KTI	PMID25399762-Compound-Table1-C17	Patented
T83011	DRUGINFO	D00NDF	3-Hydroxy-2-butanone	Patented
T83011	DRUGINFO	D00VSX	PMID25399762-Compound-Table1-C10	Patented
T83011	DRUGINFO	D00YBT	PMID25399762-Compound-Table1-C3	Patented
T83011	DRUGINFO	D01JDK	PMID25399762-Compound-Table1-C13	Patented
T83011	DRUGINFO	D01PCI	PMID25399762-Compound-Table1-C19	Patented
T83011	DRUGINFO	D02FRR	PMID25399762-Compound-Table1-C18	Patented
T83011	DRUGINFO	D03VOJ	3,4-Dihydroxybenzaldehyde	Patented
T83011	DRUGINFO	D03ZOH	4-Hydroxy-2,5-dimethyl-3(2H)-furanone	Patented
T83011	DRUGINFO	D04FJY	PMID25399762-Compound-Table1-C24	Patented
T83011	DRUGINFO	D04OXC	PMID29324067-Compound-38	Patented
T83011	DRUGINFO	D05UNM	PMID25399762-Compound-Table1-C12	Patented
T83011	DRUGINFO	D06BFA	PMID25399762-Compound-Table1-C5	Patented
T83011	DRUGINFO	D06EIP	PMID25399762-Compound-Table1-C9	Patented
T83011	DRUGINFO	D07GZU	PMID25399762-Compound-Table1-C22	Patented
T83011	DRUGINFO	D07UZL	PMID29324067-Compound-40	Patented
T83011	DRUGINFO	D08YYW	PMID25399762-Compound-Table1-C15	Patented
T83011	DRUGINFO	D09SWE	4-Methoxybenzaldehyde	Patented
T83011	DRUGINFO	D0AF7J	PMID25399762-Compound-Table1-C16	Patented
T83011	DRUGINFO	D0B2YJ	PMID25399762-Compound-Table1-C11	Patented
T83011	DRUGINFO	D0BT3Y	Coumaricacid	Patented
T83011	DRUGINFO	D0C2EW	PMID25399762-Compound-Table1-C7	Patented
T83011	DRUGINFO	D0C7LB	Lazabemide analog 1	Patented
T83011	DRUGINFO	D0DM9L	PMID25399762-Compound-Table1-C6	Patented
T83011	DRUGINFO	D0DW5P	Schiff base compound 2	Patented
T83011	DRUGINFO	D0GY4F	PMID25399762-Compound-Table1-C8	Patented
T83011	DRUGINFO	D0HR6P	PMID25399762-Compound-Table1-C23	Patented
T83011	DRUGINFO	D0J3JY	PMID25399762-Compound-Table1-C25	Patented
T83011	DRUGINFO	D0J7HR	Secondary and tertiary (hetero)arylamide derivative 1	Patented
T83011	DRUGINFO	D0K2LB	PMID25399762-Compound-Table1-C2	Patented
T83011	DRUGINFO	D0L9FL	Coumarin/resveratrol hybrid derivative 1	Patented
T83011	DRUGINFO	D0ME4N	PMID25399762-Compound-Table 7-Vanillyl alcohol	Patented
T83011	DRUGINFO	D0N3SU	Piperonal	Patented
T83011	DRUGINFO	D0N9JJ	Ethylvanillin	Patented
T83011	DRUGINFO	D0NH9P	4-Hydroxybenzoicacid	Patented
T83011	DRUGINFO	D0Q1MN	PMID25399762-Compound-Table1-C4	Patented
T83011	DRUGINFO	D0S2LV	PMID25399762-Compound-Table1-C21	Patented
T83011	DRUGINFO	D0TR7N	PMID25399762-Compound-Table 7-Veratraldehyde	Patented
T83011	DRUGINFO	D0UA3V	PMID25399762-Compound-Table 7-Vanillic acid	Patented
T83011	DRUGINFO	D0UL2R	PMID25399762-Compound-Table1-C20	Patented
T83011	DRUGINFO	D0V2NC	PMID25399762-Compound-Table1-C14	Patented
T83011	DRUGINFO	D0X7BT	4-Hydroxybenzylalcohol	Patented
T83011	DRUGINFO	D0XV2A	Benzylcinnamate	Patented
T83011	DRUGINFO	D0Z5VD	Coumarin/resveratrol hybrid derivative 2	Patented
T83011	DRUGINFO	D0Z6ZH	PMID25399762-Compound-Table1-C1	Patented
T83011	DRUGINFO	D00BRD	4-hydroxybenzaldehyde	Patented
T83011	DRUGINFO	D02WXS	PMID25399762-Compound-Table 6-11	Patented
T83011	DRUGINFO	D05RJG	Schiff base compound 1	Patented
T83011	DRUGINFO	D06KBT	PMID25399762-Compound-Table 6-13	Patented
T83011	DRUGINFO	D06QRW	Lazabemide	Patented
T83011	DRUGINFO	D06VMN	Heteroaryl-cyclopropylamine derivative 3	Patented
T83011	DRUGINFO	D0AI6J	PMID25399762-Compound-Table 6-10	Patented
T83011	DRUGINFO	D0DL1O	Tetra-hydro-oxazolopyridine derivative 2	Patented
T83011	DRUGINFO	D0E7SF	PMID25399762-Compound-Table 6-12	Patented
T83011	DRUGINFO	D0GQ2Z	Tetra-hydro-oxazolopyridine derivative 1	Patented
T83011	DRUGINFO	D0IO2A	PMID25399762-Compound-Table 6-9	Patented
T83011	DRUGINFO	D0O4QB	EUGENOL	Patented
T83011	DRUGINFO	D0PM2S	PMID25399762-Compound-Table 6-14	Patented
T83011	DRUGINFO	D0Q1EG	PMID25399762-Compound-Table 6-15	Patented
T83011	DRUGINFO	D0T9JB	Tacrine-coumarin hybrid derivative 1	Patented
T83011	DRUGINFO	D04OEV	Cyclic peptide derivative 1	Patented
T83011	DRUGINFO	D07NTA	Heteroaryl-cyclopropylamine derivative 1	Patented
T83011	DRUGINFO	D08IOP	N-(2-phenylcyclopropyl) amino acid derivative 3	Patented
T83011	DRUGINFO	D0AA7U	PMID29757691-Compound-4	Patented
T83011	DRUGINFO	D0B5YS	T83193	Patented
T83011	DRUGINFO	D0UL9U	N-(2-phenylcyclopropyl) amino acid derivative 1	Patented
T83011	DRUGINFO	D02EME	Tetra-hydro-isoquinoline derivative 3	Patented
T83011	DRUGINFO	D04AXC	Tetra-hydro-isoquinoline derivative 1	Patented
T83011	DRUGINFO	D04OHC	Tarnylcypromine derivative 2	Patented
T83011	DRUGINFO	D0NB7Z	Tetra-hydro-isoquinoline derivative 2	Patented
T83011	DRUGINFO	D0O7IH	Tarnylcypromine derivative 3	Patented
T83011	DRUGINFO	D0R6RT	Tetra-hydro-isoquinoline derivative 4	Patented
T83011	DRUGINFO	D03SLR	FERULIC ACID	Patented
T83011	DRUGINFO	D01LAC	MOFEGILINE	Discontinued in Phase 3
T83011	DRUGINFO	D0E3JL	SL-25.1188	Discontinued in Phase 1
T83011	DRUGINFO	D0O5QL	HT-1067	Discontinued in Phase 1
T83011	DRUGINFO	D0P1WB	EVT-301	Discontinued in Phase 1
T83011	DRUGINFO	D01OLO	AS602868	Discontinued in Phase 1
T83011	DRUGINFO	D0I9LO	RWJ-416457	Preclinical
T83011	DRUGINFO	D07OLO	Milacemide	Terminated
T83011	DRUGINFO	D00AHV	SKL-PD	Investigative
T83011	DRUGINFO	D00PJT	(S)(+)-7-fluoro-2-p-tolylchroman-4-one	Investigative
T83011	DRUGINFO	D01DEU	2-p-tolyl-4,5-dihydro-1H-imidazole	Investigative
T83011	DRUGINFO	D01FTB	2-(4-chlorophenyl)-4,5-dihydro-1H-imidazole	Investigative
T83011	DRUGINFO	D01GAX	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	Investigative
T83011	DRUGINFO	D01HQV	3-(4-hydroxyphenyl)-6-methyl-2H-chromen-2-one	Investigative
T83011	DRUGINFO	D01JMW	2-Bromo-N-(3-morpholinopropyl)nicotinamide	Investigative
T83011	DRUGINFO	D01KZF	(S)(+)-2-(4-fluorophenyl)-7-methoxychroman-4-one	Investigative
T83011	DRUGINFO	D01UFM	N-cyclohexyl-2-oxo-2H-chromene-3-carboxamide	Investigative
T83011	DRUGINFO	D01VPZ	2-p-tolyl-4H-chromene-4-thione	Investigative
T83011	DRUGINFO	D02AQM	VAR-10300	Investigative
T83011	DRUGINFO	D02KGZ	N-(2-aminoethyl)-2-oxo-2H-chromene-3-carboxamide	Investigative
T83011	DRUGINFO	D02KXU	(+/-)-7-methoxy-2-p-tolylchroman-4-one	Investigative
T83011	DRUGINFO	D02VIV	2-Hydrazino-3-methyl-4(3H)-quinazolinone	Investigative
T83011	DRUGINFO	D02WOQ	(R)(+)-7-fluoro-2-p-tolylchroman-4-one	Investigative
T83011	DRUGINFO	D03BQJ	2-p-tolyl-4H-chromen-4-one	Investigative
T83011	DRUGINFO	D03KYZ	(S)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}alaninamide	Investigative
T83011	DRUGINFO	D03XQB	(+/-)-7-fluoro-2-(4-methoxyphenyl)chroman-4-one	Investigative
T83011	DRUGINFO	D04DCW	(+/-)-2-(4-fluorophenyl)-7-methylchroman-4-one	Investigative
T83011	DRUGINFO	D04TGN	4-oxo-4H-chromene-3-carboxylic acid	Investigative
T83011	DRUGINFO	D04TZI	Cis-2-fluoro-2-phenylcyclopropanamine	Investigative
T83011	DRUGINFO	D05HVV	(R)-N2-{4-[(3-fluorobenzyl)oxy]benzyl}alaninamide	Investigative
T83011	DRUGINFO	D05ILO	(R)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}serinamide	Investigative
T83011	DRUGINFO	D05LMT	2-Phenyl-cyclopropylamine hydrochloride	Investigative
T83011	DRUGINFO	D05OTR	(S)-N2-[4-(benzyloxy)benzyl]alaninamide	Investigative
T83011	DRUGINFO	D06AAA	Cis-2-(4-chlorophenyl)-2-fluorocyclopropanamine	Investigative
T83011	DRUGINFO	D06ERH	CHALCONE	Investigative
T83011	DRUGINFO	D06ETG	4-HYDROXY-N-PROPARGYL-1(R)-AMINOINDAN	Investigative
T83011	DRUGINFO	D06QNN	N-benzyl-2-oxo-2H-chromene-3-carboxamide	Investigative
T83011	DRUGINFO	D07AAZ	4-phenyl-1,2,3,6-tetrahydropyridine	Investigative
T83011	DRUGINFO	D07BAO	(R)-3-Prop-2-ynylamino-indan-5-ol	Investigative
T83011	DRUGINFO	D07GUX	(E)-6-Styrylisatin	Investigative
T83011	DRUGINFO	D07HFF	7-methoxy-2-p-tolyl-4H-chromene-4-thione	Investigative
T83011	DRUGINFO	D07KCC	Butyl-methyl-prop-2-ynyl-amine hydrochloride	Investigative
T83011	DRUGINFO	D07KIB	4-fluoroselegiline	Investigative
T83011	DRUGINFO	D07WIJ	(R)(+)-7-fluoro-2-(4-fluorophenyl)chroman-4-one	Investigative
T83011	DRUGINFO	D07YZD	2-(3-nitrophenyl)-4,5-dihydro-1H-imidazole	Investigative
T83011	DRUGINFO	D08BUB	N2-{4-[(4-nitrobenzyl)oxy]benzyl}glycinamide	Investigative
T83011	DRUGINFO	D08HKC	7-methyl-2-p-tolyl-4H-chromene-4-thione	Investigative
T83011	DRUGINFO	D08IDJ	3-phenyl-9H-indeno[1,2-e][1,2,4]triazin-9-one	Investigative
T83011	DRUGINFO	D08ILX	N-(2-Methyl-1H-indol-5-yl)benzamide	Investigative
T83011	DRUGINFO	D09FAD	N-isobutyl-2-oxo-2H-chromene-3-carboxamide	Investigative
T83011	DRUGINFO	D09GCE	(S)-N2-{4-[(4-nitrobenzyl)oxy]benzyl}serinamide	Investigative
T83011	DRUGINFO	D09GQS	JD-0100	Investigative
T83011	DRUGINFO	D09PBW	(R)(+)-7-fluoro-2-phenylchroman-4-one	Investigative
T83011	DRUGINFO	D0A2AF	N-Methyl-N-Propargyl-1(R)-Aminoindan	Investigative
T83011	DRUGINFO	D0B1XZ	(+/-)-2-(4-fluorophenyl)-7-methoxychroman-4-one	Investigative
T83011	DRUGINFO	D0B2TV	Cis-2-Fluoro-2-(4-methoxyphenyl)cyclopropylamine	Investigative
T83011	DRUGINFO	D0B3QN	(R)(+)-7-methyl-2-phenylchroman-4-one	Investigative
T83011	DRUGINFO	D0BV8Y	LU-53439	Investigative
T83011	DRUGINFO	D0C9GI	7-fluoro-2-p-tolyl-4H-chromen-4-one	Investigative
T83011	DRUGINFO	D0D2JH	(+/-)-7-fluoro-2-(4-fluorophenyl)chroman-4-one	Investigative
T83011	DRUGINFO	D0E4HB	2-(2-cyclohexylidenehydrazinyl)-4-phenylthiazole	Investigative
T83011	DRUGINFO	D0EX4L	Methyl piperate	Investigative
T83011	DRUGINFO	D0F2SM	(R)(+)-2-(4-fluorophenyl)-7-methoxychroman-4-one	Investigative
T83011	DRUGINFO	D0F7KG	L-136662	Investigative
T83011	DRUGINFO	D0FH5A	2-methyl-9H-indeno[2,1-d]pyrimidin-9-one	Investigative
T83011	DRUGINFO	D0FR3X	(S)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}serinamide	Investigative
T83011	DRUGINFO	D0G2LF	[(1e)-4-Phenylbut-1-Enyl]Benzene	Investigative
T83011	DRUGINFO	D0G5YA	(S)-N2-{4-[(4-chlorobenzyl)oxy]benzyl}alaninamide	Investigative
T83011	DRUGINFO	D0G6MA	2-(4-fluorophenyl)-7-methoxy-4H-chromen-4-one	Investigative
T83011	DRUGINFO	D0H3RQ	8-Bromo-6-methyl-3-(4'-methoxyphenyl)coumarin	Investigative
T83011	DRUGINFO	D0I2GP	2-(2-cyclohexylidenehydrazinyl)-4-p-tolylthiazole	Investigative
T83011	DRUGINFO	D0I5CZ	(S)(+)-7-fluoro-2-phenylchroman-4-one	Investigative
T83011	DRUGINFO	D0I6GH	3-(phenoxymethyl)-5H-indeno[1,2-c]pyridazin-5-one	Investigative
T83011	DRUGINFO	D0I9AA	7-fluoro-2-p-tolyl-4H-chromene-4-thione	Investigative
T83011	DRUGINFO	D0IK2S	(+/-)-7-fluoro-2-phenylchroman-4-one	Investigative
T83011	DRUGINFO	D0IN0X	(S)-N2-{4-[(3-fluorobenzyl)oxy]benzyl}serinamide	Investigative
T83011	DRUGINFO	D0J0MX	1,4-diphenyl-(1E,3E)-1,3-butadiene	Investigative
T83011	DRUGINFO	D0JY9B	(R)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}alaninamide	Investigative
T83011	DRUGINFO	D0K0SA	N-(2-aminoethyl)-p-chlorobenzamide	Investigative
T83011	DRUGINFO	D0K1FE	8-Bromo-6-methyl-3-phenylcoumarin	Investigative
T83011	DRUGINFO	D0K4GD	RS-1636	Investigative
T83011	DRUGINFO	D0K5LJ	N-Propargyl-1(S)-Aminoindan	Investigative
T83011	DRUGINFO	D0K8EE	NSC-93405	Investigative
T83011	DRUGINFO	D0L6HE	(S)(+)-7-fluoro-2-(4-fluorophenyl)chroman-4-one	Investigative
T83011	DRUGINFO	D0M0CF	Farnesol	Investigative
T83011	DRUGINFO	D0MX1T	Methyl-(1,2,3,4-tetrahydro-naphthalen-1-yl)-amine	Investigative
T83011	DRUGINFO	D0N4DR	(S)(+)-7-methyl-2-phenylchroman-4-one	Investigative
T83011	DRUGINFO	D0N6JE	Methyl-pentyl-prop-2-ynyl-amine oxalic acid	Investigative
T83011	DRUGINFO	D0O0MY	(+/-)-2-(4-methoxyphenyl)-7-methylchroman-4-one	Investigative
T83011	DRUGINFO	D0O1GE	3-(3-methoxyphenyl)-6-methyl-2H-chromen-2-one	Investigative
T83011	DRUGINFO	D0OW5Y	NW-1772	Investigative
T83011	DRUGINFO	D0P1YC	(R)(+)-7-methyl-2-p-tolylchroman-4-one	Investigative
T83011	DRUGINFO	D0P7SY	2-(4-methoxyphenyl)-4H-chromene-4-thione	Investigative
T83011	DRUGINFO	D0Q3VS	2-(2,4-dichlorophenyl)-4,5-dihydro-1H-imidazole	Investigative
T83011	DRUGINFO	D0R3LP	(+/-)-2-p-tolylchroman-4-one	Investigative
T83011	DRUGINFO	D0R7UO	5-Aminomethyl-3-pyrrol-1-yl-oxazolidin-2-one	Investigative
T83011	DRUGINFO	D0R9TX	3-(4-methoxyphenyl)-6-methyl-2H-chromen-2-one	Investigative
T83011	DRUGINFO	D0SP2O	1H-Indole-2,3-dione	Investigative
T83011	DRUGINFO	D0T1GP	(+/-)-7-methyl-2-phenylchroman-4-one	Investigative
T83011	DRUGINFO	D0T3ZS	(+/-)-2-(4'-Benzyloxyphenyl)thiomorpholin-5-one	Investigative
T83011	DRUGINFO	D0T7EJ	N2-{4-[(3-chlorobenzyl)oxy]benzyl}glycinamide	Investigative
T83011	DRUGINFO	D0T7VA	NSC-50187	Investigative
T83011	DRUGINFO	D0T8AD	(S)-N2-{4-[(4-chlorobenzyl)oxy]benzyl}serinamide	Investigative
T83011	DRUGINFO	D0TB1E	(S)(+)-7-methyl-2-p-tolylchroman-4-one	Investigative
T83011	DRUGINFO	D0U4JD	(S)-N2-[4-(benzyloxy)benzyl]serinamide	Investigative
T83011	DRUGINFO	D0U8ET	3-(2-Bromophenyl)-6-methylcoumarin	Investigative
T83011	DRUGINFO	D0UF1R	1,2,3,4-Tetrahydro-naphthalen-1-ylamine	Investigative
T83011	DRUGINFO	D0UL6Y	Cis-2-(para-fluorophenyl)cyclopropylamine	Investigative
T83011	DRUGINFO	D0US0J	CORDOIN	Investigative
T83011	DRUGINFO	D0V4KL	VAR-10200	Investigative
T83011	DRUGINFO	D0W1WE	N-Methyl-N-phenyl-2-oxo-2H-chromene-3-carboxamide	Investigative
T83011	DRUGINFO	D0W7XK	7-fluoro-2-(4-methoxyphenyl)-4H-chromen-4-one	Investigative
T83011	DRUGINFO	D0X3SE	Isopropyl-methyl-prop-2-ynyl-amine hydrochloride	Investigative
T83011	DRUGINFO	D0Y0JM	Benzyl-methyl-[1-(1H-pyrrol-2-yl)-vinyl]-amine	Investigative
T83011	DRUGINFO	D0Y0KU	(+/-)-7-fluoro-2-p-tolylchroman-4-one	Investigative
T83011	DRUGINFO	D0Y5OB	7-fluoro-2-(4-fluorophenyl)-4H-chromene-4-thione	Investigative
T83011	DRUGINFO	D0Y8AN	Deprenyl	Investigative
T83011	DRUGINFO	D0Z2NN	Heptyl-methyl-prop-2-ynyl-amine hydrochloride	Investigative
T83011	DRUGINFO	D0Z2XR	(+/-)-7-methyl-2-p-tolylchroman-4-one	Investigative
T83011	DRUGINFO	D0ZH0T	(+/-)-2-(4-fluorophenyl)chroman-4-one	Investigative
T83011	DRUGINFO	D0ZI0S	7-methoxy-2-p-tolyl-4H-chromen-4-one	Investigative
T83011	DRUGINFO	D00HVZ	(+/-)-7-methoxy-2-(4-methoxyphenyl)chroman-4-one	Investigative
T83011	DRUGINFO	D00KDZ	N-(1H-Indol-2-ylmethyl)-N-methyl-N-phenylamine	Investigative
T83011	DRUGINFO	D00OLX	8-(3-Methylbenzyloxy)caffeine	Investigative
T83011	DRUGINFO	D00OQL	7-Acetonyloxy-3,4-cyclopentene-8-methylcoumarin	Investigative
T83011	DRUGINFO	D00WSM	2-oxo-N-m-tolyl-2H-chromene-3-carboxamide	Investigative
T83011	DRUGINFO	D00WVG	2-(2-cyclopentylidenehydrazinyl)-4-phenylthiazole	Investigative
T83011	DRUGINFO	D01LUB	4,8-Dimethyl-7-(2'-oxocyclohexyloxy)coumarin	Investigative
T83011	DRUGINFO	D01PES	N-(1H-Indol-2-ylmethyl)-N-phenylamine	Investigative
T83011	DRUGINFO	D01SBZ	1-(4-(benzyloxy)phenyl)propan-2-amine	Investigative
T83011	DRUGINFO	D02BBT	2-Bromo-N-(2-morpholinoethyl)nicotinamide	Investigative
T83011	DRUGINFO	D02FJX	8-[(3-Trifluoromethyl)benzyloxy]caffeine	Investigative
T83011	DRUGINFO	D02IDM	(6-Methoxy-2-naphthyl)-2-aminopropane	Investigative
T83011	DRUGINFO	D02QBV	N2-{4-[(3-fluorobenzyl)oxy]benzyl}glycinamide	Investigative
T83011	DRUGINFO	D02TFD	(7-Benzyloxy-2-oxo-2H-chromen-4-yl)acetonitrile	Investigative
T83011	DRUGINFO	D02UVG	7-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline	Investigative
T83011	DRUGINFO	D03HXD	(6-Benzyloxy-2-naphthyl)-2-aminopropane	Investigative
T83011	DRUGINFO	D03KDD	N-methyl,N-(propargyl),N-(pyrrol-2-ylmethyl)amine	Investigative
T83011	DRUGINFO	D03LGV	Trans-2-(4-chlorophenyl)-2-fluorocyclopropanamine	Investigative
T83011	DRUGINFO	D03PXS	2-oxo-N-phenyl-2H-chromene-3-carboxamide	Investigative
T83011	DRUGINFO	D03XKJ	N2-{4-[(4-chlorobenzyl)oxy]benzyl}glycinamide	Investigative
T83011	DRUGINFO	D04FLL	(+/-)-2-Phenylthiomorpholin-5-one	Investigative
T83011	DRUGINFO	D04GVX	6-Bromo-4,9-dihydro-3H-beta-carboline	Investigative
T83011	DRUGINFO	D04LPY	8-(3-Fluorobenzyloxy)caffeine	Investigative
T83011	DRUGINFO	D04QRS	PNU-22394	Investigative
T83011	DRUGINFO	D04ZPU	2-(naphthalen-2-yl)-4,5-dihydro-1H-imidazole	Investigative
T83011	DRUGINFO	D05ANK	N-Benzyl-N-(1H-indol-2-ylmethyl)-N-methylamine	Investigative
T83011	DRUGINFO	D05FMZ	C-(1H-Indol-3-yl)-methylamine	Investigative
T83011	DRUGINFO	D05FQN	7-Methoxy-9H-beta-carboline	Investigative
T83011	DRUGINFO	D05GQQ	6-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline	Investigative
T83011	DRUGINFO	D05WQN	N-(2-Methyl-1H-indol-5-yl)cyclohexanecarboxamide	Investigative
T83011	DRUGINFO	D06AJP	(E)-5-(3-Chlorostyryl)isatin	Investigative
T83011	DRUGINFO	D07LCU	N-(3-Phenylpropyl)-1H-indole-2-carboxamide	Investigative
T83011	DRUGINFO	D07NBB	8-(3-Bromobenzyloxy)caffeine	Investigative
T83011	DRUGINFO	D08CNS	IPRONIAZIDE	Investigative
T83011	DRUGINFO	D08FFH	7-Acetonyloxy-3,4-cyclohexene-8-methylcoumarin	Investigative
T83011	DRUGINFO	D08FXH	(+/-)-2-(4'-Propoxyphenyl)thiomorpholine	Investigative
T83011	DRUGINFO	D08HAM	5-Bromo-4,9-dihydro-3H-beta-carboline	Investigative
T83011	DRUGINFO	D08HNJ	N-(4-Phenylbutyl)-1H-indole-2-carboxamide	Investigative
T83011	DRUGINFO	D08NQM	5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE	Investigative
T83011	DRUGINFO	D08PHY	Trans-2-fluoro-2-(4-fluorophenyl)cyclopropanamine	Investigative
T83011	DRUGINFO	D08QVY	5-Hydroxymethyl-3-pyrrol-1-yl-oxazolidin-2-one	Investigative
T83011	DRUGINFO	D08SRB	Phenyl 4-(4,5-dihydro-1H-imidazol-2-yl)benzoate	Investigative
T83011	DRUGINFO	D08SSS	(S)-2-amino-1-(4-propylthiophenyl)-propane	Investigative
T83011	DRUGINFO	D08TFN	(+/-)-2-(4'-Methoxyphenyl)thiomorpholine	Investigative
T83011	DRUGINFO	D08YCE	8-(3-Chlorobenzyloxy)caffeine	Investigative
T83011	DRUGINFO	D09HBX	Trans-2-fluoro-2-phenylcyclopropylamin	Investigative
T83011	DRUGINFO	D09NNZ	3,4-Dichloro-N-(2-methyl-1H-indol-5-yl)benzamide	Investigative
T83011	DRUGINFO	D09XSB	(E)-5-Styrylisatin	Investigative
T83011	DRUGINFO	D09ZDQ	2-Furan-2-yl-4,5-dihydro-1H-imidazole	Investigative
T83011	DRUGINFO	D0A1RE	4-methyl-7-(2-oxocyclopentyloxy)-2H-chromen-2-one	Investigative
T83011	DRUGINFO	D0A2FO	(+/-)-7-methoxy-2-phenylchroman-4-one	Investigative
T83011	DRUGINFO	D0A4AB	2-(4,5-dihydro-1H-imidazol-2-yl)quinoline	Investigative
T83011	DRUGINFO	D0A4IY	HYDRAZINECARBOXAMIDE	Investigative
T83011	DRUGINFO	D0B1WD	N-(4-Ethylphenyl)-2-oxo-2H-chromene-3-carboxamide	Investigative
T83011	DRUGINFO	D0B4VE	Flavanone	Investigative
T83011	DRUGINFO	D0B6MV	8-(3-Methoxybenzyloxy)caffeine	Investigative
T83011	DRUGINFO	D0C7PD	6-Methoxy-4,9-dihydro-3H-beta-carboline	Investigative
T83011	DRUGINFO	D0C9WW	7-(3-chlorobenzyloxy)-4-carboxaldehyde-coumarin	Investigative
T83011	DRUGINFO	D0D1PE	CGS-19281A	Investigative
T83011	DRUGINFO	D0D2YR	9-Methyl-2,3,4,9-tetrahydro-1H-beta-carboline	Investigative
T83011	DRUGINFO	D0D5KD	(+/-)-2-(4'-Ethoxyphenyl)thiomorpholin-5-one	Investigative
T83011	DRUGINFO	D0D6OR	(+/-)-2-(4'-Benzyloxyphenyl)thiomorpholine	Investigative
T83011	DRUGINFO	D0D6QI	3-Chloro-N-(2-methyl-1H-indol-5-yl)benzamide	Investigative
T83011	DRUGINFO	D0E8IE	4-(2-oxo-2H-chromene-3-carboxamido)benzoic acid	Investigative
T83011	DRUGINFO	D0F2DC	Trans-2-fluoro-2-p-tolylcyclopropanamine	Investigative
T83011	DRUGINFO	D0F7JK	N-Methyl,N-phenyl-1H-indole-2-carboxamide	Investigative
T83011	DRUGINFO	D0G4BG	N-(propargyl),N-(pyrrol-2-ylmethyl)amine	Investigative
T83011	DRUGINFO	D0G8BT	4,9-Dihydro-3H-beta-carboline	Investigative
T83011	DRUGINFO	D0H0GZ	2-oxo-N-p-tolyl-2H-chromene-3-carboxamide	Investigative
T83011	DRUGINFO	D0HU4J	(+/-)-2-Phenylthiomorpholine	Investigative
T83011	DRUGINFO	D0ID3Y	(+/-)-2-(4'-Methoxyphenyl)thiomorpholin-5-one	Investigative
T83011	DRUGINFO	D0IP7L	(6-Propoxy-2-naphthyl)-2-aminopropane	Investigative
T83011	DRUGINFO	D0J0QW	(+/-)-2-(4'-Ethoxyphenyl)thiomorpholine	Investigative
T83011	DRUGINFO	D0JN9R	8-Benzyloxycaffeine	Investigative
T83011	DRUGINFO	D0K9UN	N-Phenyl-1H-indole-2-carboxamide	Investigative
T83011	DRUGINFO	D0L5EW	(6-Ethoxy-2-naphthyl)-2-aminopropane	Investigative
T83011	DRUGINFO	D0M0XR	(R/R)BEFLOXATONE	Investigative
T83011	DRUGINFO	D0M4GR	(+/-)-2-(4'-Butoxyphenyl)thiomorpholin-5-one	Investigative
T83011	DRUGINFO	D0M7WE	2,3,4,5-Tetrahydro-1H-pyrido[4,3-b]indole	Investigative
T83011	DRUGINFO	D0MO1O	N-methyl,N-(benzyl),N-(pyrrol-2-ylmethyl)amine	Investigative
T83011	DRUGINFO	D0N8UE	N-(2-phenylethyl),N-(pyrrol-2-ylmethyl)amine	Investigative
T83011	DRUGINFO	D0N9FH	2-Phenoxymethyl-4,5-dihydro-1H-imidazole	Investigative
T83011	DRUGINFO	D0NS9X	2-Chloro-N-(3-morpholinopropyl)nicotinamide	Investigative
T83011	DRUGINFO	D0O2UK	N-(benzyl),N-(pyrrol-2-ylmethyl)amine	Investigative
T83011	DRUGINFO	D0P1UC	2-(5-phenyl-furan-2-yl)-4,5-dihydro-1H-imidazole	Investigative
T83011	DRUGINFO	D0P4GF	3,4-Benzo-7-(beta-bromoallyloxy)-8-methylcoumarin	Investigative
T83011	DRUGINFO	D0Q1IP	2-(2-cycloheptylidenehydrazinyl)-4-phenylthiazole	Investigative
T83011	DRUGINFO	D0Q9NC	2-phenyl-9H-indeno[2,1-d]pyrimidine	Investigative
T83011	DRUGINFO	D0R5EW	2-Chloro-N-(2-morpholinoethyl)nicotinamide	Investigative
T83011	DRUGINFO	D0S0JH	6-amino-9-methoxy-7H-furo[3,2-g]chromen-7-one	Investigative
T83011	DRUGINFO	D0S3QN	2-[7-(Benzyloxy)-2-oxo-2H-chromen-4-yl]acetamide	Investigative
T83011	DRUGINFO	D0S7FP	(R)-Indan-1-yl-methyl-prop-2-ynyl-amine	Investigative
T83011	DRUGINFO	D0T1FJ	4-(Aminomethyl)-7-(benzyloxy)-2H-chromen-2-one	Investigative
T83011	DRUGINFO	D0T3XC	(+/-)-2-(4'-Butoxyphenyl)thiomorpholine	Investigative
T83011	DRUGINFO	D0T6XC	N2-[4-(benzyloxy)benzyl]glycinamide	Investigative
T83011	DRUGINFO	D0TL3S	3,4-Benzo-7-acetonyloxy-8-methoxycoumarin	Investigative
T83011	DRUGINFO	D0V0TN	N-Benzyl,N-methyl-1H-indole-2-carboxamide	Investigative
T83011	DRUGINFO	D0V3NT	TOLOXATONE	Investigative
T83011	DRUGINFO	D0W4TW	7-Bromo-4,9-dihydro-3H-beta-carboline	Investigative
T83011	DRUGINFO	D0X8HH	(E)-5-(3-Fluorostyryl)isatin	Investigative
T83011	DRUGINFO	D0X8RN	Cis-2-phenylcyclopropylamine	Investigative
T83011	DRUGINFO	D0YO7C	N-(2-Phenylethyl)-1H-indole-2-carboxamide	Investigative
T83011	DRUGINFO	D0Z0ZU	(S)-2-amino-1-(4-butylthiophenyl)-propane	Investigative
T83011	DRUGINFO	D0Z5BU	(+/-)-2-(4'-Propoxyphenyl)thiomorpholin-5-one	Investigative
T83011	DRUGINFO	D0Z5YO	N-Benzyl-1H-indole-2-carboxamide	Investigative
T83011	DRUGINFO	D0Z7NC	2-Phenethyl-4,5-dihydro-1H-imidazole	Investigative
T83011	DRUGINFO	D00NSA	5-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline	Investigative
T83011	DRUGINFO	D06BAC	8-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline	Investigative
T83011	DRUGINFO	D0C7PY	Lauryl Dimethylamine-N-Oxide	Investigative
T83011	DRUGINFO	D0G2EF	8-Bromo-4,9-dihydro-3H-beta-carboline	Investigative
T83011	DRUGINFO	D0J3SN	6-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline	Investigative
T83011	DRUGINFO	D0L8ND	5-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline	Investigative
T83011	DRUGINFO	D0Q3VI	8-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline	Investigative
T83011	DRUGINFO	D0V6XA	5-Methoxy-4,9-dihydro-3H-beta-carboline	Investigative
T83011	DRUGINFO	D0Y1GL	8-Methoxy-4,9-dihydro-3H-beta-carboline	Investigative
T83011	DRUGINFO	D0TU7I	(E)-8-(3-chlorostyryl)-caffeine	Investigative
T83011	DRUGINFO	D09BIV	TRACIZOLINE	Investigative
T83011	DRUGINFO	D0LI3J	2-BFi	Investigative
T83011	DRUGINFO	D03LPH	TRYPTOLINE	Investigative
T83011	DRUGINFO	D05GDP	7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline	Investigative
T83011	DRUGINFO	D0C1SE	1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole	Investigative
T83011	DRUGINFO	D0I4ME	MMDA	Investigative
T83011	DRUGINFO	D0R7ZC	Beta-methoxyamphetamine	Investigative
T83011	DRUGINFO	D00IMW	Flavin-Adenine Dinucleotide	Investigative

T31391	TARGETID	T31391
T31391	FORMERID	TTDS00093
T31391	UNIPROID	DPP4_HUMAN
T31391	TARGNAME	Dipeptidyl peptidase 4 (DPP-4)
T31391	GENENAME	DPP4
T31391	TARGTYPE	Successful
T31391	SYNONYMS	Tcell activation antigen CD26; TP103; T-cell activation antigen CD26; Dipeptidyl peptidase IV; Dipeptidyl peptidase 4 soluble form; DPP-IV; DPP IV; DPP 4; CD26; Adenosine deaminase complexing protein-2; Adenosine deaminase complexing protein 2; ADCP2; ADCP-2; ADABP
T31391	FUNCTION	Acts as a positive regulator of T-cell coactivation, by binding at least ADA, CAV1, IGF2R, and PTPRC. Its binding to CAV1 and CARD11 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Its interaction with ADA also regulates lymphocyte-epithelial cell adhesion. In association with FAP is involved in the pericellular proteolysis of the extracellular matrix (ECM), the migration and invasion of endothelial cells into the ECM. May be involved in the promotion of lymphatic endothelial cells adhesion, migration and tube formation. When overexpressed, enhanced cell proliferation, a process inhibited by GPC3. Acts also as a serine exopeptidase with a dipeptidyl peptidase activity that regulates various physiological processes by cleaving peptides in the circulation, including many chemokines, mitogenic growth factors, neuropeptides and peptide hormones. Removes N-terminal dipeptides sequentially from polypeptides having unsubstituted N-termini provided that the penultimate residue is proline. Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation.
T31391	PDBSTRUC	6B1O; 6B1E; 5ZID; 5Y7K; 5Y7J
T31391	BIOCLASS	Peptidase
T31391	ECNUMBER	EC 3.4.14.5
T31391	SEQUENCE	MKTPWKVLLGLLGAAALVTIITVPVVLLNKGTDDATADSRKTYTLTDYLKNTYRLKLYSLRWISDHEYLYKQENNILVFNAEYGNSSVFLENSTFDEFGHSINDYSISPDGQFILLEYNYVKQWRHSYTASYDIYDLNKRQLITEERIPNNTQWVTWSPVGHKLAYVWNNDIYVKIEPNLPSYRITWTGKEDIIYNGITDWVYEEEVFSAYSALWWSPNGTFLAYAQFNDTEVPLIEYSFYSDESLQYPKTVRVPYPKAGAVNPTVKFFVVNTDSLSSVTNATSIQITAPASMLIGDHYLCDVTWATQERISLQWLRRIQNYSVMDICDYDESSGRWNCLVARQHIEMSTTGWVGRFRPSEPHFTLDGNSFYKIISNEEGYRHICYFQIDKKDCTFITKGTWEVIGIEALTSDYLYYISNEYKGMPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYSVSFSKEAKYYQLRCSGPGLPLYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPSKKLDFIILNETKFWYQMILPPHFDKSKKYPLLLDVYAGPCSQKADTVFRLNWATYLASTENIIVASFDGRGSGYQGDKIMHAINRRLGTFEVEDQIEAARQFSKMGFVDNKRIAIWGWSYGGYVTSMVLGSGSGVFKCGIAVAPVSRWEYYDSVYTERYMGLPTPEDNLDHYRNSTVMSRAENFKQVEYLLIHGTADDNVHFQQSAQISKALVDVGVDFQAMWYTDEDHGIASSTAHQHIYTHMSHFIKQCFSLP
T31391	DRUGINFO	D02EYG	Linagliptin	Approved
T31391	DRUGINFO	D05IPF	Kombiglyze XR/Komboglyze FDC	Approved
T31391	DRUGINFO	D0K9MY	Saxagliptin	Approved
T31391	DRUGINFO	D0L3DK	Vildagliptin	Approved
T31391	DRUGINFO	D0NJ5H	Alogliptin	Approved
T31391	DRUGINFO	D0T8XB	Anagliptin	Approved
T31391	DRUGINFO	D0U2JP	Sitagliptin	Approved
T31391	DRUGINFO	D0Y6QC	Dapagliflozin Propanediol; Saxagliptin Hydrochloride	Approved
T31391	DRUGINFO	D02ZBW	LC-150444	Phase 3
T31391	DRUGINFO	D04XIO	Dutogliptin	Phase 3
T31391	DRUGINFO	D0M3XR	MK-3102	Phase 3
T31391	DRUGINFO	D0N6SO	SYR-472	Phase 3
T31391	DRUGINFO	D0N7JZ	SAND-26	Phase 3
T31391	DRUGINFO	D0V0KJ	IDDBCP161883	Phase 3
T31391	DRUGINFO	D0ZD3C	Gemigliptin	Phase 3
T31391	DRUGINFO	D09XMX	SaxaDapa FDC	Phase 3
T31391	DRUGINFO	D06VCN	Denagliptin	Phase 2/3
T31391	DRUGINFO	D03SKC	KRP-104	Phase 2
T31391	DRUGINFO	D06VMJ	Melogliptin	Phase 2
T31391	DRUGINFO	D07HZG	PF-00734200	Phase 2
T31391	DRUGINFO	D0H2IO	P32/98	Phase 2
T31391	DRUGINFO	D0E3HY	IP10 C8	Phase 2
T31391	DRUGINFO	D05VXF	YSCMA	Phase 1/2
T31391	DRUGINFO	D03JWU	REC-01	Phase 1
T31391	DRUGINFO	D05LPW	DA-1229	Phase 1
T31391	DRUGINFO	D07EPV	Teneligliptin	Phase 1
T31391	DRUGINFO	D0BA5E	ZYDPLA 1	Phase 1
T31391	DRUGINFO	D0Z1OS	ARI-2243	Phase 1
T31391	DRUGINFO	D00GNP	Triazole piperazine derivative 1	Patented
T31391	DRUGINFO	D01MMT	PMID25482888-Compound-13	Patented
T31391	DRUGINFO	D02LNB	PMID25482888-Compound-15	Patented
T31391	DRUGINFO	D02SUS	Imidazo cyclohexylamine derivative 1	Patented
T31391	DRUGINFO	D02UOW	Beta-phe compound 2	Patented
T31391	DRUGINFO	D04MAZ	Pyrimidine derivative 33	Patented
T31391	DRUGINFO	D04UXC	Imidazo cyclohexylamine derivative 3	Patented
T31391	DRUGINFO	D04XXF	Peptide analog 49	Patented
T31391	DRUGINFO	D05GEY	PMID25482888-Compound-21	Patented
T31391	DRUGINFO	D05HLQ	Quinazoline derivative 1	Patented
T31391	DRUGINFO	D05LJQ	Peptide analog 48	Patented
T31391	DRUGINFO	D06GQG	PMID25482888-Compound-16	Patented
T31391	DRUGINFO	D06PDK	PMID25482888-Compound-52	Patented
T31391	DRUGINFO	D06PIP	Aminopiperidine derivative 2	Patented
T31391	DRUGINFO	D07JJT	Pyrimidine derivative 31	Patented
T31391	DRUGINFO	D0A5QV	PMID25482888-Compound-34	Patented
T31391	DRUGINFO	D0A6LI	Aminopiperidine derivative 1	Patented
T31391	DRUGINFO	D0B4CH	Peptide analog 45	Patented
T31391	DRUGINFO	D0BJ2X	PMID25482888-Compound-37	Patented
T31391	DRUGINFO	D0BY2H	Peptide analog 50	Patented
T31391	DRUGINFO	D0CW9H	Pyrimidine derivative 32	Patented
T31391	DRUGINFO	D0E8AS	Tricyclic heterocycle derivative 6	Patented
T31391	DRUGINFO	D0E8WW	Peptide analog 46	Patented
T31391	DRUGINFO	D0E9MO	PMID25482888-Compound-14	Patented
T31391	DRUGINFO	D0EL5B	Pyrrolo[1,2-f]triazine derivative 2	Patented
T31391	DRUGINFO	D0G1CF	PMID25482888-Compound-71	Patented
T31391	DRUGINFO	D0G3IL	PMID25482888-Compound-17	Patented
T31391	DRUGINFO	D0IO0M	Beta-phe compound 3	Patented
T31391	DRUGINFO	D0J0UN	PMID25482888-Compound-69	Patented
T31391	DRUGINFO	D0J4KQ	Peptide analog 51	Patented
T31391	DRUGINFO	D0J5EW	Pyrimidinedione derivative 1	Patented
T31391	DRUGINFO	D0JP6A	PMID25482888-Compound-6	Patented
T31391	DRUGINFO	D0K2ZQ	Xanthine/amino piperidine compound 1	Patented
T31391	DRUGINFO	D0K5YJ	PMID25482888-Compound-50	Patented
T31391	DRUGINFO	D0KR7R	PMID25482888-Compound-18	Patented
T31391	DRUGINFO	D0KS8Y	Imidazo cyclohexylamine derivative 2	Patented
T31391	DRUGINFO	D0LG1I	PMID25482888-Compound-12	Patented
T31391	DRUGINFO	D0N9CV	PMID25482888-Compound-11	Patented
T31391	DRUGINFO	D0ND5K	Xanthine derivative 1	Patented
T31391	DRUGINFO	D0O6SK	Triazolo-pyrimidinedione derivative 2	Patented
T31391	DRUGINFO	D0P3DS	Pyrrolo[1,2-f]triazine derivative 1	Patented
T31391	DRUGINFO	D0PF2W	PMID25482888-Compound-72	Patented
T31391	DRUGINFO	D0PM4N	Triazolo-pyrimidinedione derivative 1	Patented
T31391	DRUGINFO	D0QE8Z	Peptide analog 44	Patented
T31391	DRUGINFO	D0RT1R	Pyrimidine derivative 30	Patented
T31391	DRUGINFO	D0T1WB	PMID25482888-Compound-70	Patented
T31391	DRUGINFO	D0T6SD	PMID25482888-Compound-56	Patented
T31391	DRUGINFO	D0UV3I	Imidazo pyridine derivative 2	Patented
T31391	DRUGINFO	D0W6HL	Beta-phe compound 1	Patented
T31391	DRUGINFO	D0WE8K	Peptide analog 47	Patented
T31391	DRUGINFO	D0XB0Q	Dihydropyrrolopyrazole derivative 1	Patented
T31391	DRUGINFO	D0XN3O	PMID25482888-Compound-38	Patented
T31391	DRUGINFO	D06HJX	Thiomorpholine derivative 1	Patented
T31391	DRUGINFO	D0D4BP	Thiomorpholine derivative 2	Patented
T31391	DRUGINFO	D00FYF	NVP-DPP728	Discontinued in Phase 2
T31391	DRUGINFO	D0E4EZ	R-1438	Discontinued in Phase 2
T31391	DRUGINFO	D0FD0B	PSN-9301	Discontinued in Phase 2
T31391	DRUGINFO	D0H2KV	ALS 2-0426	Discontinued in Phase 2
T31391	DRUGINFO	D0JA1Z	TA-6666	Discontinued in Phase 2
T31391	DRUGINFO	D0A1NU	ABT-279	Discontinued in Phase 1
T31391	DRUGINFO	D0Q4YP	TAK-100	Discontinued in Phase 1
T31391	DRUGINFO	D0X5ZO	SSR-162369	Discontinued in Phase 1
T31391	DRUGINFO	D0O6DC	LY-2463665	Preclinical
T31391	DRUGINFO	D0Q6ED	ASP8497	Preclinical
T31391	DRUGINFO	D0XL4I	ER-319711-15	Preclinical
T31391	DRUGINFO	D7K0GP	PT630	Preclinical
T31391	DRUGINFO	D0F3TI	PT-630	Terminated
T31391	DRUGINFO	D0M9SL	DSP-7238	Terminated
T31391	DRUGINFO	D00HSG	(2-(2-chlorophenyl)pyridin-3-yl)methanamine	Investigative
T31391	DRUGINFO	D00KMP	3-butyl-1-(naphthalen-1-yl)piperidin-4-amine	Investigative
T31391	DRUGINFO	D01KRQ	EMC-0901	Investigative
T31391	DRUGINFO	D01OUJ	D-Val-L-boroPro	Investigative
T31391	DRUGINFO	D01ZWF	BPI-711001	Investigative
T31391	DRUGINFO	D02RIE	4-(2,4-dichlorophenyl)-1-tosylpyrrolidin-3-amine	Investigative
T31391	DRUGINFO	D02WBC	2-(2-chlorophenyl)-2-morpholinoethanamine	Investigative
T31391	DRUGINFO	D03FDC	Diisopropylphosphono Group	Investigative
T31391	DRUGINFO	D04CAR	(R)-1-(2-aminoacetyl)pyrrolidin-2-ylboronic acid	Investigative
T31391	DRUGINFO	D04QDB	ABT-341	Investigative
T31391	DRUGINFO	D05LYC	KR-62436	Investigative
T31391	DRUGINFO	D05TKO	Retagliptin	Investigative
T31391	DRUGINFO	D05UUA	(+/-)-6-(2-chlorophenyl)cyclohex-3-enamine	Investigative
T31391	DRUGINFO	D05WKT	PK-44	Investigative
T31391	DRUGINFO	D05XWX	FE 999011	Investigative
T31391	DRUGINFO	D06AUB	1-benzyl-4-(2,4-dichlorophenyl)pyrrolidin-3-amine	Investigative
T31391	DRUGINFO	D06NRU	C-(2'-Chloro-biphenyl-2-yl)-methylamine	Investigative
T31391	DRUGINFO	D06UKY	4-(2,4-dichlorophenyl)-1-phenylpyrrolidin-3-amine	Investigative
T31391	DRUGINFO	D07HWI	(1R,2S)-1,2-diphenylethane-1,2-diamine	Investigative
T31391	DRUGINFO	D07IJU	(S)-pyrrolidin-1-yl(pyrrolidin-2-yl)methanone	Investigative
T31391	DRUGINFO	D07VDJ	(2s)-Pyrrolidin-2-Ylmethylamine	Investigative
T31391	DRUGINFO	D09BYA	(3S,4R)-3-butyl-1-phenylpiperidin-4-amine	Investigative
T31391	DRUGINFO	D09MVE	1-biphenyl-2-ylmethanamine	Investigative
T31391	DRUGINFO	D0C2NQ	L-Val-L-boroPro	Investigative
T31391	DRUGINFO	D0D9ON	Iodo-Phenylalanine	Investigative
T31391	DRUGINFO	D0FH8R	DB-160	Investigative
T31391	DRUGINFO	D0IQ4S	L-Ala-L-boroPro	Investigative
T31391	DRUGINFO	D0JI3S	1-benzhydryl-3-butylpiperidin-4-amine	Investigative
T31391	DRUGINFO	D0L1NF	D-420720	Investigative
T31391	DRUGINFO	D0L5RI	(S)-2-Amino-1-thiazolidin-3-yl-propane-1-thione	Investigative
T31391	DRUGINFO	D0L9XR	2-Amino-3-Methyl-1-Pyrrolidin-1-Yl-Butan-1-One	Investigative
T31391	DRUGINFO	D0N1FU	N-isoleucylthiazolidine	Investigative
T31391	DRUGINFO	D0N1QQ	DIPROTIN A	Investigative
T31391	DRUGINFO	D0N3YL	ASC-201	Investigative
T31391	DRUGINFO	D0N5CI	(5-phenyl-3H-benzo[d]imidazol-4-yl)methanamine	Investigative
T31391	DRUGINFO	D0O9RD	(S)-2-Amino-1-azetidin-1-yl-2-cyclohexyl-ethanone	Investigative
T31391	DRUGINFO	D0P5OE	(1R,2R)-1,2-diphenylethane-1,2-diamine	Investigative
T31391	DRUGINFO	D0PB2M	4-iodophenyl-alaninyl-(S)-2-cyano-pyrrolidine	Investigative
T31391	DRUGINFO	D0R5OE	(S)-pyrrolidin-2-yl(thiazolidin-3-yl)methanone	Investigative
T31391	DRUGINFO	D0T2EW	Cyclohexylglycine-(2S)-cyanopyrrolidine	Investigative
T31391	DRUGINFO	D0T8UH	E-3024	Investigative
T31391	DRUGINFO	D0W4GM	(1-phenylcyclopentyl)methanamine	Investigative
T31391	DRUGINFO	D0X2JG	(2-chloro-6-phenoxyphenyl)methanamine	Investigative
T31391	DRUGINFO	D07ALM	N4-(4-chlorobenzyl)-2,4-diaminobutanoylpiperidine	Investigative
T31391	DRUGINFO	D08NMS	PMID20684603C24dd	Investigative
T31391	DRUGINFO	D0G6XS	Fucose	Investigative
T31391	DRUGINFO	D07LUR	Alpha-D-Mannose	Investigative

T61744	TARGETID	T61744
T61744	FORMERID	TTDS00280
T61744	UNIPROID	PDE4A_HUMAN
T61744	TARGNAME	Phosphodiesterase 4A (PDE4A)
T61744	GENENAME	PDE4A
T61744	TARGTYPE	Successful
T61744	SYNONYMS	cAMP-specific 3',5'-cyclic phosphodiesterase 4A; Type 4A cAMP phosphodiesterase; PDE46; DPDE2
T61744	FUNCTION	Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
T61744	PDBSTRUC	3TVX; 3I8V; 2QYK
T61744	BIOCLASS	Phosphoric diester hydrolase
T61744	ECNUMBER	EC 3.1.4.53
T61744	SEQUENCE	MEPPTVPSERSLSLSLPGPREGQATLKPPPQHLWRQPRTPIRIQQRGYSDSAERAERERQPHRPIERADAMDTSDRPGLRTTRMSWPSSFHGTGTGSGGAGGGSSRRFEAENGPTPSPGRSPLDSQASPGLVLHAGAATSQRRESFLYRSDSDYDMSPKTMSRNSSVTSEAHAEDLIVTPFAQVLASLRSVRSNFSLLTNVPVPSNKRSPLGGPTPVCKATLSEETCQQLARETLEELDWCLEQLETMQTYRSVSEMASHKFKRMLNRELTHLSEMSRSGNQVSEYISTTFLDKQNEVEIPSPTMKEREKQQAPRPRPSQPPPPPVPHLQPMSQITGLKKLMHSNSLNNSNIPRFGVKTDQEELLAQELENLNKWGLNIFCVSDYAGGRSLTCIMYMIFQERDLLKKFRIPVDTMVTYMLTLEDHYHADVAYHNSLHAADVLQSTHVLLATPALDAVFTDLEILAALFAAAIHDVDHPGVSNQFLINTNSELALMYNDESVLENHHLAVGFKLLQEDNCDIFQNLSKRQRQSLRKMVIDMVLATDMSKHMTLLADLKTMVETKKVTSSGVLLLDNYSDRIQVLRNMVHCADLSNPTKPLELYRQWTDRIMAEFFQQGDRERERGMEISPMCDKHTASVEKSQVGFIDYIVHPLWETWADLVHPDAQEILDTLEDNRDWYYSAIRQSPSPPPEEESRGPGHPPLPDKFQFELTLEEEEEEEISMAQIPCTAQEALTAQGLSGVEEALDATIAWEASPAQESLEVMAQEASLEAELEAVYLTQQAQSTGSAPVAPDEFSSREEFVVAVSHSSPSALALQSPLLPAWRTLSVSEHAPGLPGLPSTAAEVEAQREHQAAKRACSACAGTFGEDTSALPAPGGGGSGGDPT
T61744	DRUGINFO	D02PWM	Dyphylline	Approved
T61744	DRUGINFO	D09AMZ	Enprofylline	Approved
T61744	DRUGINFO	D01XHG	DENBUFYLLINE	Phase 3
T61744	DRUGINFO	D06VFP	SOTB07	Phase 3
T61744	DRUGINFO	D00JED	AN-2898	Phase 2
T61744	DRUGINFO	D01XFZ	GPD-1116	Phase 2
T61744	DRUGINFO	D02POH	TA-7906	Phase 2
T61744	DRUGINFO	D07OCV	HT-0712	Phase 2
T61744	DRUGINFO	D09TFB	TOFIMILAST	Phase 2
T61744	DRUGINFO	D0F4TV	AWD-12-281	Phase 2
T61744	DRUGINFO	D0F5IY	LIRIMILAST	Phase 2
T61744	DRUGINFO	D0L8KJ	Oglemilast	Phase 2
T61744	DRUGINFO	D0M7CB	MK-0873	Phase 2
T61744	DRUGINFO	D0RJ1W	OX-914	Phase 2
T61744	DRUGINFO	D0U2DH	CC-1088	Phase 2
T61744	DRUGINFO	D0X0PW	Revamilast	Phase 2
T61744	DRUGINFO	D0Z2FB	Piclamilast	Phase 2
T61744	DRUGINFO	DB82TO	Tofisopam	Phase 2
T61744	DRUGINFO	D01WZL	AVE-8112	Phase 1
T61744	DRUGINFO	D03CWX	MEM-1414	Phase 1
T61744	DRUGINFO	D0K9DI	GSK-356278	Phase 1
T61744	DRUGINFO	D0O8JW	Ronomilast	Phase 1
T61744	DRUGINFO	D02EMR	Cilomilast	Discontinued in Phase 3
T61744	DRUGINFO	D0U7PS	GSK256066	Discontinued in Phase 2
T61744	DRUGINFO	D00DBE	CI-1018	Discontinued in Phase 2
T61744	DRUGINFO	D03ZVD	KW-4490	Discontinued in Phase 2
T61744	DRUGINFO	D08SNX	V-11294A	Discontinued in Phase 2
T61744	DRUGINFO	D0I0GM	Daxalipram	Discontinued in Phase 2
T61744	DRUGINFO	D0UG4T	CDP840	Discontinued in Phase 2
T61744	DRUGINFO	D0V2CN	LAS-37779	Discontinued in Phase 2
T61744	DRUGINFO	D01FXD	SCH-351591	Discontinued in Phase 1
T61744	DRUGINFO	D0C7JT	YM-976	Discontinued in Phase 1
T61744	DRUGINFO	D0K1OA	D-4418	Discontinued in Phase 1
T61744	DRUGINFO	D01OUA	TJN-598	Terminated
T61744	DRUGINFO	D01QUF	GW-3600	Terminated
T61744	DRUGINFO	D07UHY	NIK-616	Terminated
T61744	DRUGINFO	D0F7TV	Torbafylline	Terminated
T61744	DRUGINFO	D0R1QJ	D-22888	Terminated
T61744	DRUGINFO	D01CAY	2,5-Bis-(3,4-dimethoxy-phenyl)-furan	Investigative
T61744	DRUGINFO	D04XRV	6-Azido-8-(3-iodo-phenyl)-quinoline	Investigative
T61744	DRUGINFO	D0J4AT	4-(2,5-Diphenyl-furan-3-yl)-morpholine	Investigative
T61744	DRUGINFO	D0K4HG	8-(3-Nitro-phenyl)-6-pyridin-4-ylmethyl-quinoline	Investigative
T61744	DRUGINFO	D0L0NY	6-Imidazol-1-ylmethyl-8-phenyl-quinoline	Investigative
T61744	DRUGINFO	D0N2KP	2,5-Bis-(3-cyclopentyloxy-4-methoxy-phenyl)-furan	Investigative
T61744	DRUGINFO	D0V1IM	L-791943	Investigative
T61744	DRUGINFO	D0V8DB	8-(3-Azido-phenyl)-6-iodo-quinoline	Investigative
T61744	DRUGINFO	D0W7BI	(2,5-Diphenyl-furan-3-yl)-phenyl-methanone	Investigative
T61744	DRUGINFO	D0Y3PP	NIS-62949	Investigative
T61744	DRUGINFO	D0Z5SB	8-(3-Azido-phenyl)-6-pyridin-4-ylmethyl-quinoline	Investigative
T61744	DRUGINFO	D00JBC	1-Butyl-3-methyl-3,7-dihydro-purine-2,6-dione	Investigative
T61744	DRUGINFO	D00TQR	1-Methyl-3-propyl-3,7-dihydro-purine-2,6-dione	Investigative
T61744	DRUGINFO	D02NKD	8-(3-Nitro-phenyl)-6-phenyl-[1,7]naphthyridine	Investigative
T61744	DRUGINFO	D02NWF	Benzyl-(2-thiophen-2-yl-quinazolin-4-yl)-amine	Investigative
T61744	DRUGINFO	D09AUL	Benzyl-(2-imidazol-1-yl-quinazolin-4-yl)-amine	Investigative
T61744	DRUGINFO	D0DL6J	CI-1044	Investigative
T61744	DRUGINFO	D0O3BL	RS-14491	Investigative
T61744	DRUGINFO	D0V5BX	NITRAQUAZONE	Investigative
T61744	DRUGINFO	D01RUN	(R)-Rolipram	Investigative
T61744	DRUGINFO	D01TOR	Benzyl-(2-pyridin-3-yl-quinazolin-4-yl)-amine	Investigative
T61744	DRUGINFO	D02FZD	(S)-Rolipram	Investigative
T61744	DRUGINFO	D04BMR	AL-59640	Investigative
T61744	DRUGINFO	D04JNC	ZL-N-91	Investigative
T61744	DRUGINFO	D05YEL	CH-3697	Investigative
T61744	DRUGINFO	D0E5VP	KF-66490	Investigative
T61744	DRUGINFO	D0J7GF	Benzyl-(2-phenyl-quinazolin-4-yl)-amine	Investigative
T61744	DRUGINFO	D0JD4C	L-454560	Investigative
T61744	DRUGINFO	D0K9PS	CHF-5480	Investigative
T61744	DRUGINFO	D0N7HS	ASP-3258	Investigative
T61744	DRUGINFO	D0S1HX	TAS-203	Investigative
T61744	DRUGINFO	D0S6MA	OCID-2987	Investigative
T61744	DRUGINFO	D0U4SS	CD-160130	Investigative
T61744	DRUGINFO	D0U8YQ	Benzyl-(2-pyridin-4-yl-quinazolin-4-yl)-amine	Investigative
T61744	DRUGINFO	D0W7WV	L-869298	Investigative
T61744	DRUGINFO	D00QCL	SOPHOFLAVESCENOL	Investigative
T61744	DRUGINFO	D02ZPV	UCB-101333-3	Investigative
T61744	DRUGINFO	D0P2HX	RS-25344	Investigative
T61744	DRUGINFO	D0T5PO	ROLIPRAM	Investigative
T61744	DRUGINFO	D0W4ZU	KURARINOL	Investigative
T61744	DRUGINFO	D06GUJ	KURAIDIN	Investigative
T61744	DRUGINFO	D0R6MT	isobutylmethylxanthine	Investigative

T92072	TARGETID	T92072
T92072	FORMERID	TTDS00186
T92072	UNIPROID	AA1R_HUMAN
T92072	TARGNAME	Adenosine A1 receptor (ADORA1)
T92072	GENENAME	ADORA1
T92072	TARGTYPE	Successful
T92072	SYNONYMS	Adenosine receptor A1; A(1) adenosine receptor
T92072	FUNCTION	The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. Receptor for adenosine.
T92072	PDBSTRUC	6D9H; 5UEN; 5N2S
T92072	BIOCLASS	GPCR rhodopsin
T92072	SEQUENCE	MPPSISAFQAAYIGIEVLIALVSVPGNVLVIWAVKVNQALRDATFCFIVSLAVADVAVGALVIPLAILINIGPQTYFHTCLMVACPVLILTQSSILALLAIAVDRYLRVKIPLRYKMVVTPRRAAVAIAGCWILSFVVGLTPMFGWNNLSAVERAWAANGSMGEPVIKCEFEKVISMEYMVYFNFFVWVLPPLLLMVLIYLEVFYLIRKQLNKKVSASSGDPQKYYGKELKIAKSLALILFLFALSWLPLHILNCITLFCPSCHKPSILTYIAIFLTHGNSAMNPIVYAFRIQKFRVTFLKIWNDHFRCQPAPPIDEDLPEERPDD
T92072	DRUGINFO	D0B3HD	Caffeine	Approved
T92072	DRUGINFO	D0X0IY	Rolofylline	Phase 3
T92072	DRUGINFO	D04YAJ	SELODENOSON	Phase 2
T92072	DRUGINFO	D0BA5K	Apaxifylline	Phase 2
T92072	DRUGINFO	D0F5UN	SLV320	Phase 2
T92072	DRUGINFO	D0I1EX	DTI-0009	Phase 2
T92072	DRUGINFO	D0I3YX	Capadenoson	Phase 2
T92072	DRUGINFO	D0M7BL	BAY 1067197	Phase 2
T92072	DRUGINFO	D0QH7H	AMP-579	Phase 2
T92072	DRUGINFO	D00SUK	Tonapofylline	Phase 2
T92072	DRUGINFO	D05KBP	INO-8875	Phase 1/2
T92072	DRUGINFO	D0Z9RJ	GS 9667	Phase 1
T92072	DRUGINFO	D7FJX0	AST-004	Phase 1
T92072	DRUGINFO	D02YQO	SCH-442416	Phase 1
T92072	DRUGINFO	D0L5VS	KF-17837	Phase 1
T92072	DRUGINFO	D0T0YA	PMID27387065-Compound-6	Patented
T92072	DRUGINFO	D07VZV	N-0861	Discontinued in Phase 3
T92072	DRUGINFO	D09GGJ	CVT-124	Discontinued in Phase 3
T92072	DRUGINFO	D00YSJ	Tecadenoson	Discontinued in Phase 3
T92072	DRUGINFO	D01VPK	FK-453	Discontinued in Phase 2
T92072	DRUGINFO	D03JHJ	FK-352	Discontinued in Phase 2
T92072	DRUGINFO	D0EK6D	FK-838	Discontinued in Phase 2
T92072	DRUGINFO	D0UH4T	GW-493838	Discontinued in Phase 2
T92072	DRUGINFO	D0K2BQ	BRL-61063	Discontinued in Phase 2
T92072	DRUGINFO	D08ZBT	SDZ-WAG-994	Discontinued in Phase 1
T92072	DRUGINFO	D0V5DX	GR-79236	Discontinued in Phase 1
T92072	DRUGINFO	D0HE1P	BAY 60-6583	Preclinical
T92072	DRUGINFO	D0I7BL	ARISTEROMYCIN	Terminated
T92072	DRUGINFO	D0NQ5I	METRIFUDIL	Terminated
T92072	DRUGINFO	D0Y6GJ	ZM-241385	Terminated
T92072	DRUGINFO	D0E4WF	METHYLTHIOADENOSINE	Terminated
T92072	DRUGINFO	D00JXL	N-(4-Phenyl-thiazol-2-yl)-benzamide	Investigative
T92072	DRUGINFO	D00UFJ	4-Chloro-N-(4-phenyl-thiazol-2-yl)-benzamide	Investigative
T92072	DRUGINFO	D00WFU	LUF-5737	Investigative
T92072	DRUGINFO	D01EHP	Cyclopentyl-(9-methyl-9H-purin-6-yl)-amine	Investigative
T92072	DRUGINFO	D01GUK	Cyclopentyl-(9-phenyl-9H-purin-6-yl)-amine	Investigative
T92072	DRUGINFO	D01MOQ	7-Methyl-2-propyl-[1,8]naphthyridin-4-ol	Investigative
T92072	DRUGINFO	D03KLO	2,6-dimethyl-8-ethyl-1-deazapurine	Investigative
T92072	DRUGINFO	D04LPX	4-Bromo-N-(4-phenyl-thiazol-2-yl)-benzamide	Investigative
T92072	DRUGINFO	D04QAD	4-tert-Butyl-N-(4-phenyl-thiazol-2-yl)-benzamide	Investigative
T92072	DRUGINFO	D05MCK	7-Chloro-2-phenyl-[1,8]naphthyridin-4-ol	Investigative
T92072	DRUGINFO	D05SYY	7-Bromo-2-phenyl-[1,8]naphthyridin-4-ol	Investigative
T92072	DRUGINFO	D05ZYN	Cyclopentyl-(9-ethyl-9H-purin-6-yl)-amine	Investigative
T92072	DRUGINFO	D06QRI	7-Dimethylamino-2-phenyl-[1,8]naphthyridin-4-ol	Investigative
T92072	DRUGINFO	D06TSQ	LUF5831	Investigative
T92072	DRUGINFO	D06ZWQ	2-phenyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one	Investigative
T92072	DRUGINFO	D07DGH	Pentanoic acid (4,6-diphenylpyrimidin-2-yl)amide	Investigative
T92072	DRUGINFO	D07DTC	L-97-1 intravenous	Investigative
T92072	DRUGINFO	D07HXL	PD-81723	Investigative
T92072	DRUGINFO	D08VXF	Cyclohexyl-(9-methyl-9H-purin-6-yl)-amine	Investigative
T92072	DRUGINFO	D09ETC	Cyclohexyl-(9-ethyl-9H-purin-6-yl)-amine	Investigative
T92072	DRUGINFO	D09FUO	(1-Phenyl-propyl)-(9-phenyl-9H-purin-6-yl)-amine	Investigative
T92072	DRUGINFO	D09KUY	4-Chloro-7-methyl-2-phenyl-[1,8]naphthyridine	Investigative
T92072	DRUGINFO	D0BZ3S	Phenyl-(9-phenyl-9H-purin-6-yl)-amine	Investigative
T92072	DRUGINFO	D0C3ID	N-(4,6-diphenylpyrimidin-2-yl)benzamide	Investigative
T92072	DRUGINFO	D0D8WN	(9-Methyl-9H-purin-6-yl)-phenyl-amine	Investigative
T92072	DRUGINFO	D0G6SL	MRS1062	Investigative
T92072	DRUGINFO	D0G8GA	9-Phenyl-9H-purin-6-ylamine	Investigative
T92072	DRUGINFO	D0G8XJ	5-Cl-5-deoxy-(+/-)-ENBA	Investigative
T92072	DRUGINFO	D0H2VA	LUF-5853	Investigative
T92072	DRUGINFO	D0H3QX	4-Nitro-N-(4-phenyl-thiazol-2-yl)-benzamide	Investigative
T92072	DRUGINFO	D0J3TY	2-m-tolyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one	Investigative
T92072	DRUGINFO	D0J4SW	2-p-tolyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one	Investigative
T92072	DRUGINFO	D0K2QF	3,4-Dichloro-N-(4-phenyl-thiazol-2-yl)-benzamide	Investigative
T92072	DRUGINFO	D0L4TY	N-(4,6-diphenylpyrimidin-2-yl)-3-methylbutyramide	Investigative
T92072	DRUGINFO	D0L5JL	8-cyclopentyltheophylline	Investigative
T92072	DRUGINFO	D0L7DL	8-cyclohexyl-6-(4-tolyl)-2-phenyl-9H-purine	Investigative
T92072	DRUGINFO	D0L8DZ	8-Phenyl-3,7-dihydro-purine-2,6-dione	Investigative
T92072	DRUGINFO	D0L8SN	P-IODOAMPHETAMINE	Investigative
T92072	DRUGINFO	D0N0OE	7-(3,6,9,12-tetraoxatricos-22-enyl)theophylline	Investigative
T92072	DRUGINFO	D0N1PS	Cyclopentyl-(9-cyclopentyl-9H-purin-6-yl)-amine	Investigative
T92072	DRUGINFO	D0N9WG	N-(4,6-diphenylpyrimidin-2-yl)-3-chlorobenzamide	Investigative
T92072	DRUGINFO	D0NH5X	2-(6-Cyclopentylamino-purin-9-yl)-ethanol	Investigative
T92072	DRUGINFO	D0PD0F	Paeoniflorin	Investigative
T92072	DRUGINFO	D0S2MO	FR194921	Investigative
T92072	DRUGINFO	D0T5FY	2,4-Dichloro-N-(4-phenyl-thiazol-2-yl)-benzamide	Investigative
T92072	DRUGINFO	D0U8KW	LUF-6258	Investigative
T92072	DRUGINFO	D0UM4R	(2-Chloro-9-methyl-9H-purin-6-yl)-phenyl-amine	Investigative
T92072	DRUGINFO	D0W0QF	4-Methyl-N-(4-phenyl-thiazol-2-yl)-benzamide	Investigative
T92072	DRUGINFO	D0WN3O	N-(4,6-diphenylpyrimidin-2-yl)-2-ethylbutyramide	Investigative
T92072	DRUGINFO	D0XE8T	Anthoptilide C	Investigative
T92072	DRUGINFO	D0YB3X	3-Chloro-N-(4-phenyl-thiazol-2-yl)-benzamide	Investigative
T92072	DRUGINFO	D0YV1R	WRC-0571	Investigative
T92072	DRUGINFO	D0Z3BT	LUF-5764	Investigative
T92072	DRUGINFO	D0Z3YY	LUF-5735	Investigative
T92072	DRUGINFO	D0Z7BC	VCP-28	Investigative
T92072	DRUGINFO	D0ZO1R	Cirsimarin	Investigative
T92072	DRUGINFO	D00CJJ	8-Bromo-9-phenylethyl-9H-adenine	Investigative
T92072	DRUGINFO	D00HYS	2-Amino-4,6-diphenyl-pyrimidin-5-carbonitrile	Investigative
T92072	DRUGINFO	D00MPA	6-(furan-2-yl)-9H-purin-2-amine	Investigative
T92072	DRUGINFO	D00NYG	4-Amino-2,6-diphenyl-pyrimidine-5-carbonitrile	Investigative
T92072	DRUGINFO	D00OFN	4-(ethylthio)-6-phenyl-1,3,5-triazin-2-amine	Investigative
T92072	DRUGINFO	D00YOM	3-Benzyl-7-methyl-[1,8]naphthyridin-4-ol	Investigative
T92072	DRUGINFO	D01WXR	N-(4,5-diphenylpyrimidin-2-yl)acetamide	Investigative
T92072	DRUGINFO	D02BGA	9-Methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine	Investigative
T92072	DRUGINFO	D02HHW	CP608,039	Investigative
T92072	DRUGINFO	D02HZJ	N-(2,6-diphenylpyrimidin-4-yl)benzamide	Investigative
T92072	DRUGINFO	D02NBB	9-(3-nitrobenzyl)-6-(furan-2-yl)-9H-purin-2-amine	Investigative
T92072	DRUGINFO	D02RBK	9-Benzyl-8-bromo-9H-adenine	Investigative
T92072	DRUGINFO	D02TEW	2-p-tolyl-2H-pyrazolo[3,4-c]quinolin-4-amine	Investigative
T92072	DRUGINFO	D02WTN	Hexanoic Acid (2,6-diphenylpyrimidin-4-yl)amide	Investigative
T92072	DRUGINFO	D03JFX	9-Ethyl-9H-adenine	Investigative
T92072	DRUGINFO	D04AGC	Phenyl(2-(trifluoromethyl)quinolin-4-yl)methanol	Investigative
T92072	DRUGINFO	D04GFX	MRS1132	Investigative
T92072	DRUGINFO	D04JIR	9-Methyl-9H-adenine	Investigative
T92072	DRUGINFO	D04MMG	N6-[(4-Nitro)-phenyl]-9-benzyl-2-phenyladenine	Investigative
T92072	DRUGINFO	D04PJO	2-m-tolyl-2H-pyrazolo[3,4-c]quinolin-4-amine	Investigative
T92072	DRUGINFO	D04PLH	VUF-8507	Investigative
T92072	DRUGINFO	D04RHI	MRS1086	Investigative
T92072	DRUGINFO	D04XLX	2-amino-N-benzyl-6-phenyl-9H-purine-9-carboxamide	Investigative
T92072	DRUGINFO	D04ZTH	2-Amino-4,6-di-thiophen-2-yl-nicotinonitrile	Investigative
T92072	DRUGINFO	D05TFM	2-ethyl-4-(furan-2-yl)thieno[3,2-d]pyrimidine	Investigative
T92072	DRUGINFO	D05ZRR	9-(3-aminobenzyl)-6-(furan-2-yl)-9H-purin-2-amine	Investigative
T92072	DRUGINFO	D06NQD	2-amino-6-phenyl-4-p-tolylnicotinonitrile	Investigative
T92072	DRUGINFO	D07DOE	2'-Me-tecadenoson	Investigative
T92072	DRUGINFO	D07FGB	2,6-bis(4-tolyl)-9H-purine	Investigative
T92072	DRUGINFO	D07FZA	AS99	Investigative
T92072	DRUGINFO	D07HKU	DEPX	Investigative
T92072	DRUGINFO	D07RSH	MRS923	Investigative
T92072	DRUGINFO	D07YKU	2-ethyl-4-(thiophen-2-yl)thieno[3,2-d]pyrimidine	Investigative
T92072	DRUGINFO	D08AJS	3-(3-chloro-1H-pyrazol-5-yl)quinoxalin-2(1H)-one	Investigative
T92072	DRUGINFO	D08AXT	9-(4-nitrobenzyl)-6-(furan-2-yl)-9H-purin-2-amine	Investigative
T92072	DRUGINFO	D08CIY	2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-amine	Investigative
T92072	DRUGINFO	D08FOT	PSB-1115	Investigative
T92072	DRUGINFO	D08INY	2,6-Diphenyl-pyrimidin-4-ylamine	Investigative
T92072	DRUGINFO	D08RGW	3-Benzyl-7-methyl-[1,8]naphthyridine-4-thiol	Investigative
T92072	DRUGINFO	D08RSU	[3H]DPCPX	Investigative
T92072	DRUGINFO	D09HAM	2-phenyl-2H-pyrazolo[3,4-c]quinolin-4-amine	Investigative
T92072	DRUGINFO	D09TBE	MRS1065	Investigative
T92072	DRUGINFO	D09UDF	2-chloro-4-(thiophen-2-yl)thieno[3,2-d]pyrimidine	Investigative
T92072	DRUGINFO	D0A4MK	AS100	Investigative
T92072	DRUGINFO	D0A5KG	2-azido-N6-methyl-9-(beta-D-ribofuranosyl)adenine	Investigative
T92072	DRUGINFO	D0BA7Q	1-Methyl-8-phenyl-3,7-dihydro-purine-2,6-dione	Investigative
T92072	DRUGINFO	D0BC7P	2-Amino-6-phenyl-4-thiophen-2-yl-nicotinonitrile	Investigative
T92072	DRUGINFO	D0CB9B	4-(thiazol-2-yl)thieno[3,2-d]pyrimidin-2-amine	Investigative
T92072	DRUGINFO	D0D3WR	9-benzyl-6-(furan-2-yl)-9H-purin-2-amine	Investigative
T92072	DRUGINFO	D0F9JF	FR-166124	Investigative
T92072	DRUGINFO	D0G2JG	CPFPX	Investigative
T92072	DRUGINFO	D0HK5B	SCH-63390	Investigative
T92072	DRUGINFO	D0I6MT	N6-[(4-Amino)-phenyl]-9-benzyl-2-phenyladenine	Investigative
T92072	DRUGINFO	D0J6ME	2-ethyl-4-(pyridin-2-yl)thieno[3,2-d]pyrimidine	Investigative
T92072	DRUGINFO	D0KM0Y	2-Amino-4-phenyl-6-thiophen-2-yl-nicotinonitrile	Investigative
T92072	DRUGINFO	D0L3BI	MRS1084	Investigative
T92072	DRUGINFO	D0M8NW	Kuanoniamine D	Investigative
T92072	DRUGINFO	D0N1PT	2-(4-chloro-1H-benzo[d]imidazol-2-yl)quinoxaline	Investigative
T92072	DRUGINFO	D0N2DP	N*6*-Cyclooctyl-N*2*-phenyl-9H-purine-2,6-diamine	Investigative
T92072	DRUGINFO	D0N2VO	2-Amino-4,6-diphenyl-nicotinonitrile	Investigative
T92072	DRUGINFO	D0O8QS	4-Methoxy-N-(3-phenyl-isoquinolin-1-yl)-benzamide	Investigative
T92072	DRUGINFO	D0P1JJ	6-ethylamino-2-(3''-indolyl)ethyloxy)adenosine	Investigative
T92072	DRUGINFO	D0Q5HW	N6-methoxy-2-[(4-methylphenyl)ethynyl]adenosine	Investigative
T92072	DRUGINFO	D0Q9GL	AS70	Investigative
T92072	DRUGINFO	D0QD3O	2-Amino-4,6-diphenyl-pyrimidine	Investigative
T92072	DRUGINFO	D0QN5I	4-(furan-2-yl)thieno[3,2-d]pyrimidin-2-amine	Investigative
T92072	DRUGINFO	D0R4LZ	2-(4-methoxyphenyl)-6-phenyl-9H-purine	Investigative
T92072	DRUGINFO	D0T6XM	1,3-Diisobutyl-3,7-dihydro-purine-2,6-dione	Investigative
T92072	DRUGINFO	D0UM6O	2-chloro-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine	Investigative
T92072	DRUGINFO	D0W5CZ	4-(furan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine	Investigative
T92072	DRUGINFO	D0W8RB	8-Bromo-9-(but-3-enyl)-9H-adenine	Investigative
T92072	DRUGINFO	D0Y7AV	2-ethyl-4-(furan-3-yl)thieno[3,2-d]pyrimidine	Investigative
T92072	DRUGINFO	D0Y8SB	L-249313	Investigative
T92072	DRUGINFO	D0Z3IZ	N*6*-Cyclohexyl-N*2*-ethyl-9H-purine-2,6-diamine	Investigative
T92072	DRUGINFO	D0ZV1T	N-(2,6-diphenylpyrimidin-4-yl)-2-ethylbutyramide	Investigative
T92072	DRUGINFO	D00ASZ	2-(3''-pyrrolylethyloxy)adenosine	Investigative
T92072	DRUGINFO	D00GQI	N-(2,6-diphenylpyrimidin-4-yl)isobutyramide	Investigative
T92072	DRUGINFO	D00IOF	PSB36	Investigative
T92072	DRUGINFO	D00NFW	2,6-diphenyl-8-ethyl-1-deazapurine	Investigative
T92072	DRUGINFO	D01AAI	VUF5574	Investigative
T92072	DRUGINFO	D01NHH	2,6-diphenyl-8-tButyl-1-deazapurine	Investigative
T92072	DRUGINFO	D01PGY	2-(hex-1-ynyl)-N6-methoxyadenosine	Investigative
T92072	DRUGINFO	D01QBK	8-Bromo-9-cyclohexyl-9H-adenine	Investigative
T92072	DRUGINFO	D01VEU	9-Ethyl-8-phenylethynyl-9H-purin-6-ylamine	Investigative
T92072	DRUGINFO	D01VXC	N-(4,6-diphenylpyrimidin-2-yl)propionamide	Investigative
T92072	DRUGINFO	D01VXP	2-ethynyl-N6-methoxyadenosine	Investigative
T92072	DRUGINFO	D01WNA	8-Bromo-9-ethyl-9H-adenine	Investigative
T92072	DRUGINFO	D02EAO	N*6*-Cyclohexyl-N*2*-phenyl-9H-purine-2,6-diamine	Investigative
T92072	DRUGINFO	D02FLH	2,6-dphenyl-8-propyl-1-deazapurine	Investigative
T92072	DRUGINFO	D02HOL	8-Bromo-9-propyl-9H-adenine	Investigative
T92072	DRUGINFO	D02HYT	N-(2,6-diphenylpyrimidin-4-yl)propionamide	Investigative
T92072	DRUGINFO	D02JCM	N(6)-cyclohexyladenosine	Investigative
T92072	DRUGINFO	D02JMR	2-(3''-(6''-chloro-indolyl)ethyloxy)adenosine	Investigative
T92072	DRUGINFO	D02RMR	1,3-Diethyl-3,7-dihydro-purine-2,6-dione	Investigative
T92072	DRUGINFO	D02SKN	MRS1041	Investigative
T92072	DRUGINFO	D02VQK	LUF-5433	Investigative
T92072	DRUGINFO	D03FVK	N6-methoxy-2-[(4-pyridinyl)ethynyl]adenosine	Investigative
T92072	DRUGINFO	D03HBG	2-(3''-(4''-bromo-indolyl)ethyloxy)adenosine	Investigative
T92072	DRUGINFO	D03KKK	1,3-Dipropyl-3,7-dihydro-purine-2,6-dione	Investigative
T92072	DRUGINFO	D03POP	N6-methoxy-2-phenylethynyladenosine	Investigative
T92072	DRUGINFO	D04TTP	5,7-dibromo-9H-pyrido[3,4-b]indol-6-ol	Investigative
T92072	DRUGINFO	D04WHE	9-Propyl-9H-adenine	Investigative
T92072	DRUGINFO	D05QNV	ATL802	Investigative
T92072	DRUGINFO	D05XGF	PSB-0788	Investigative
T92072	DRUGINFO	D06KMJ	MRS5151	Investigative
T92072	DRUGINFO	D06RCT	2-(3''-indolylethyloxy)adenosine	Investigative
T92072	DRUGINFO	D07DNX	PD-115199	Investigative
T92072	DRUGINFO	D07HNM	1,3-Diallyl-3,7-dihydro-purine-2,6-dione	Investigative
T92072	DRUGINFO	D07IPZ	2-(4-hydroxypent-1-yl)-N6-methoxyadenosine	Investigative
T92072	DRUGINFO	D07PPM	PSB-10	Investigative
T92072	DRUGINFO	D07VCN	4-Ethoxy-7-((E)-styryl)-furo[3,2-g]chromen-5-one	Investigative
T92072	DRUGINFO	D08BCH	TCPA	Investigative
T92072	DRUGINFO	D08EBT	[3H]HEMADO	Investigative
T92072	DRUGINFO	D08EZI	N-(2,6-diphenylpyrimidin-4-yl)-3-methylbutyramide	Investigative
T92072	DRUGINFO	D08HBH	N-(2,6-diphenylpyrimidin-4-yl)butyramide	Investigative
T92072	DRUGINFO	D08JUQ	2-tolyl-6-phenyl-9H-purine	Investigative
T92072	DRUGINFO	D08JYX	2-[(4-acetylphenyl)ethynyl]-N6-methoxyadenosine	Investigative
T92072	DRUGINFO	D08LZN	Cyclohexyl-(2-phenylsulfanyl-9H-purin-6-yl)-amine	Investigative
T92072	DRUGINFO	D08MRB	1H-Imidazo[4,5-c]quinolin-4-ylamine HCl	Investigative
T92072	DRUGINFO	D09IRV	LUF-5957	Investigative
T92072	DRUGINFO	D09RKX	PSB-11	Investigative
T92072	DRUGINFO	D09VOP	2-(3''-(5''-methoxy-indolyl)ethyloxy)adenosine	Investigative
T92072	DRUGINFO	D09VRX	2-(4-methyl-1H-benzo[d]imidazol-2-yl)quinoxaline	Investigative
T92072	DRUGINFO	D0A6IO	MRE 3008F20	Investigative
T92072	DRUGINFO	D0A6JX	9-Cyclobutyl-9H-adenine	Investigative
T92072	DRUGINFO	D0A9BZ	PSB-601	Investigative
T92072	DRUGINFO	D0B0QW	N6-methoxy-2-[(4-pentylphenyl)ethynyl]adenosine	Investigative
T92072	DRUGINFO	D0B1RV	2-Cyclopentyl-1H-imidazo[4,5-c]quinolin-4-ylamine	Investigative
T92072	DRUGINFO	D0B1YW	8-Phenyl-1-propyl-3,7-dihydro-purine-2,6-dione	Investigative
T92072	DRUGINFO	D0B3NZ	N-(5-Benzoyl-4-phenylthiazol-2-yl)benzamide	Investigative
T92072	DRUGINFO	D0B3UE	9-Cyclopentyl-9H-adenine	Investigative
T92072	DRUGINFO	D0B7OW	sakuranetin	Investigative
T92072	DRUGINFO	D0B8DR	MRS1093	Investigative
T92072	DRUGINFO	D0B8RQ	LUF-5767	Investigative
T92072	DRUGINFO	D0C2UJ	2-chloroadenosine	Investigative
T92072	DRUGINFO	D0DB7A	9-Isopropyl-9H-adenine	Investigative
T92072	DRUGINFO	D0E4LB	2-(5-cyano-1-pent-1-ynyl)-N6-methoxyadenosine	Investigative
T92072	DRUGINFO	D0E7YE	2,6,8-triphenyl-9H-purine	Investigative
T92072	DRUGINFO	D0E8RA	8-Bromo-9-(2,3-dihydroxypropyl)-9H-adenine	Investigative
T92072	DRUGINFO	D0E9QX	(S)-PIA	Investigative
T92072	DRUGINFO	D0F1AS	1-METHYLXANTHINE	Investigative
T92072	DRUGINFO	D0F4XB	2-Amino-4,6-di-furan-2-yl-nicotinonitrile	Investigative
T92072	DRUGINFO	D0G5ZF	N6-methoxy-2-[(2-pyridinyl)ethynyl]adenosine	Investigative
T92072	DRUGINFO	D0G6BI	2-(3''-(6''-bromo-indolyl)ethyloxy)adenosine	Investigative
T92072	DRUGINFO	D0G6VT	2-(3''-(5''-iodo-indolyl)ethyloxy)adenosine	Investigative
T92072	DRUGINFO	D0H9BP	xanthine amine congener	Investigative
T92072	DRUGINFO	D0I1EP	MRS928	Investigative
T92072	DRUGINFO	D0I1IW	2-(3''-(5''-fluoro-indolyl)ethyloxy)adenosine	Investigative
T92072	DRUGINFO	D0I2EQ	2,6-diphenyl-8-methyl-1-deazapurine	Investigative
T92072	DRUGINFO	D0I3HE	KF26777	Investigative
T92072	DRUGINFO	D0I7HL	2-phenylpropoxyadenosine	Investigative
T92072	DRUGINFO	D0J1BA	MRS1191	Investigative
T92072	DRUGINFO	D0KJ3H	2-(2''-indolylethyloxy)adenosine	Investigative
T92072	DRUGINFO	D0KT3L	2-[(4-fluorophenyl)ethynyl]-N6-methoxyadenosine	Investigative
T92072	DRUGINFO	D0L0VU	MRE 2029F20	Investigative
T92072	DRUGINFO	D0L2MN	2-(4-chlorophenyl)-6-phenyl-9H-purine	Investigative
T92072	DRUGINFO	D0L6YI	2-(3''-(5''-bromo-indolyl)ethyloxy)adenosine	Investigative
T92072	DRUGINFO	D0LD0X	1-Propyl-3,7-dihydro-purine-2,6-dione	Investigative
T92072	DRUGINFO	D0LP5G	2-Phenyl-1H-imidazo[4,5-c]quinolin-4-ylamine	Investigative
T92072	DRUGINFO	D0LP5V	LUF-5956	Investigative
T92072	DRUGINFO	D0N1QO	N6-methoxy-2-[(4-methoxyphenyl)ethynyl]adenosine	Investigative
T92072	DRUGINFO	D0N1QP	2,6-diphenyl-1-deazapurine	Investigative
T92072	DRUGINFO	D0O0FP	ST-1535	Investigative
T92072	DRUGINFO	D0O1CW	GNF-PF-2700	Investigative
T92072	DRUGINFO	D0OX0V	2-(4-ethylthiobenzimidazol-2-yl)quinoxaline	Investigative
T92072	DRUGINFO	D0P0BV	2-(3''-(5''-hydroxyindolyl)ethyloxy)adenosine	Investigative
T92072	DRUGINFO	D0P7CS	LUF-5417	Investigative
T92072	DRUGINFO	D0P7FK	2-Amino-4-furan-2-yl-6-phenyl-nicotinonitrile	Investigative
T92072	DRUGINFO	D0P8MK	2-(6-amino-8-bromo-9H-purin-9-yl)ethanol	Investigative
T92072	DRUGINFO	D0PU6F	2-(1H-benzo[d]imidazol-2-yl)quinoxaline	Investigative
T92072	DRUGINFO	D0Q1RD	2-(3''(5''-chloro-indolyl)ethyloxy)adenosine	Investigative
T92072	DRUGINFO	D0Q3LM	N6-methoxy-2-[2-(trimethylsilyl)ethynyl]adenosine	Investigative
T92072	DRUGINFO	D0Q5CS	6-guanidino-2-(3''-indolylethyloxy)adenosine	Investigative
T92072	DRUGINFO	D0QN4U	2-(3''(7''-bromo-indolyl)ethyloxy)adenosine	Investigative
T92072	DRUGINFO	D0R8OK	8-Bromo-9-methyl-9H-adenine	Investigative
T92072	DRUGINFO	D0RZ2M	2,6-diphenyl-9H-purine	Investigative
T92072	DRUGINFO	D0S5XP	9-Allyl-8-bromo-9H-adenine	Investigative
T92072	DRUGINFO	D0S6QA	8-Bromo-9-(2-butyl)-9H-adenine	Investigative
T92072	DRUGINFO	D0T7GG	LUF-5816	Investigative
T92072	DRUGINFO	D0TC7N	PENECA	Investigative
T92072	DRUGINFO	D0U8DW	1-Butyl-8-phenyl-3,7-dihydro-purine-2,6-dione	Investigative
T92072	DRUGINFO	D0V9EE	2-Amino-6-furan-2-yl-4-phenyl-nicotinonitrile	Investigative
T92072	DRUGINFO	D0V9OO	(R,S)-PHPNECA	Investigative
T92072	DRUGINFO	D0VB6X	(1H-Imidazo[4,5-c]quinolin-4-yl)-phenyl-amine HCl	Investigative
T92072	DRUGINFO	D0W3MT	8-propyl-2,6-diphenyl-9H-purine	Investigative
T92072	DRUGINFO	D0W6FC	8-Bromo-9-(2-hydroxypropyl)-9H-adenine	Investigative
T92072	DRUGINFO	D0WI4D	LUF-5962	Investigative
T92072	DRUGINFO	D0XC9U	MRS1042	Investigative
T92072	DRUGINFO	D0Y2RM	Isoguanosine	Investigative
T92072	DRUGINFO	D0Y5WQ	PSB603	Investigative
T92072	DRUGINFO	D0Y6HQ	N6-methoxy-2-[(3-pyridinyl)ethynyl]-adenosine	Investigative
T92072	DRUGINFO	D0Z1WY	2-chloro-2'-C-methyl-tecadenoson	Investigative
T92072	DRUGINFO	D0Z3XC	N-(2,6-diphenylpyrimidin-4-yl)acetamide	Investigative
T92072	DRUGINFO	D0ZL2A	MRS1523	Investigative
T92072	DRUGINFO	D0ZW9L	5,7-diphenyl-3H-imidazo[4,5-b]pyridin-2-ol	Investigative
T92072	DRUGINFO	D00GNW	2,6-diphenyl-8-(1-ethylpropyl)-1-deazapurine	Investigative
T92072	DRUGINFO	D00JWA	N-(2-(furan-2-yl)-3,4'-bipyridin-6-yl)acetamide	Investigative
T92072	DRUGINFO	D02PBY	3-noradamantyl-1,3-dipropylxanthine	Investigative
T92072	DRUGINFO	D04LZN	8-Bromo-9-cyclobutyl-9H-adenine	Investigative
T92072	DRUGINFO	D05KEF	LUF-5978	Investigative
T92072	DRUGINFO	D06KYP	8-Bromo-9-isopropyl-9H-adenine	Investigative
T92072	DRUGINFO	D0AI8F	8-Bromo-9-cyclopentyl-9H-adenine	Investigative
T92072	DRUGINFO	D0B0TX	8-bromo-9-isobutyl-9H-purin-6-amine	Investigative
T92072	DRUGINFO	D0CX7N	8-Bromo-9-(3-hydroxypropyl)-9H-adenine	Investigative
T92072	DRUGINFO	D0IG5E	2,5'-dichloro-5'-deoxy-N6-cyclopentyladenosine	Investigative
T92072	DRUGINFO	D0JJ6T	N6-((+/-)-endo-norborn-2-yl)adenosine	Investigative
T92072	DRUGINFO	D0K6ZA	[3H]OSIP339391	Investigative
T92072	DRUGINFO	D0K8ZZ	[3H]NECA	Investigative
T92072	DRUGINFO	D0M3CG	R-N6-(phenylisopropyl)adenosine	Investigative
T92072	DRUGINFO	D0NO5E	Ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate	Investigative
T92072	DRUGINFO	D0O4KI	2-ethyl-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine	Investigative
T92072	DRUGINFO	D0R1XY	[3H]CCPA	Investigative
T92072	DRUGINFO	D0TU7I	(E)-8-(3-chlorostyryl)-caffeine	Investigative
T92072	DRUGINFO	D0V8MD	8-PHENYL THEOPHYLLINE	Investigative
T92072	DRUGINFO	D0W1PF	LUF-5980	Investigative
T92072	DRUGINFO	D0Y9WZ	SB-298	Investigative
T92072	DRUGINFO	D0Z8NC	LUF-5981	Investigative
T92072	DRUGINFO	D0Z8VU	8-Bromo-9-(sec-butyl)-9H-adenine	Investigative
T92072	DRUGINFO	D0K0OT	GNF-PF-2224	Investigative
T92072	DRUGINFO	D03RFA	N6-CYCLOPENTYLADENOSINE	Investigative
T92072	DRUGINFO	D0S0RK	flavone	Investigative
T92072	DRUGINFO	D0R6MT	isobutylmethylxanthine	Investigative
T92072	DRUGINFO	D0F9QT	A-987306	Investigative
T92072	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T74456	TARGETID	T74456
T74456	FORMERID	TTDS00267
T74456	UNIPROID	AGTR1_HUMAN
T74456	TARGNAME	Angiotensin II receptor type-1 (AGTR1)
T74456	GENENAME	AGTR1
T74456	TARGTYPE	Successful
T74456	SYNONYMS	Type-1 angiotensin II receptor; Angiotensin II type-1 receptor; Angiotensin II receptor 1; Angiotensin 1 receptor; AT2R1B; AT2R1; AT1BR; AT1AR; AT1; AGTR1B; AGTR1A
T74456	FUNCTION	Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Receptor for angiotensin II.
T74456	PDBSTRUC	6DO1; 4ZUD; 4YAY; 1ZV0
T74456	BIOCLASS	GPCR rhodopsin
T74456	SEQUENCE	MILNSSTEDGIKRIQDDCPKAGRHNYIFVMIPTLYSIIFVVGIFGNSLVVIVIYFYMKLKTVASVFLLNLALADLCFLLTLPLWAVYTAMEYRWPFGNYLCKIASASVSFNLYASVFLLTCLSIDRYLAIVHPMKSRLRRTMLVAKVTCIIIWLLAGLASLPAIIHRNVFFIENTNITVCAFHYESQNSTLPIGLGLTKNILGFLFPFLIILTSYTLIWKALKKAYEIQKNKPRNDDIFKIIMAIVLFFFFSWIPHQIFTFLDVLIQLGIIRDCRIADIVDTAMPITICIAYFNNCLNPLFYGFLGKKFKRYFLQLLKYIPPKAKSHSNLSTKMSTLSYRPSDNVSSSTKKPAPCFEVE
T74456	DRUGINFO	D00JAU	Irbesartan	Approved
T74456	DRUGINFO	D00NVX	Forasartan	Approved
T74456	DRUGINFO	D00VFE	Saralasin Acetate	Approved
T74456	DRUGINFO	D05FGG	Azilsartan	Approved
T74456	DRUGINFO	D06UDG	Valsartan	Approved
T74456	DRUGINFO	D07UBG	Olmesartan medoxomil	Approved
T74456	DRUGINFO	D0B9AO	Saprisartan	Approved
T74456	DRUGINFO	D0D5SQ	Candesartan	Approved
T74456	DRUGINFO	D0DD0K	Losartan	Approved
T74456	DRUGINFO	D0I7PO	Micardis telmisartan	Approved
T74456	DRUGINFO	D0M7TO	Tasosartan	Approved
T74456	DRUGINFO	D0N6RF	Telmisartan	Approved
T74456	DRUGINFO	D0T7US	Eprosartan	Approved
T74456	DRUGINFO	D0G6SE	ANGIOTENSIN II	Approved
T74456	DRUGINFO	D0K0AT	SARALASIN	Approved
T74456	DRUGINFO	D0YS1U	Sparsentan	Approved
T74456	DRUGINFO	D05FUU	Pratosartan	Phase 3
T74456	DRUGINFO	D0A2RA	TAK-491	Phase 3
T74456	DRUGINFO	D0H9QC	S-474474	Phase 3
T74456	DRUGINFO	D02BBC	CL-329167	Phase 2
T74456	DRUGINFO	D06LRG	TRV027	Phase 2
T74456	DRUGINFO	D0C3BA	YM-358	Phase 2
T74456	DRUGINFO	D06TZT	RIPISARTAN	Discontinued in Phase 2
T74456	DRUGINFO	D0DL2S	MILFASARTAN	Discontinued in Phase 2
T74456	DRUGINFO	D0E3XG	Zolasartan	Discontinued in Phase 2
T74456	DRUGINFO	D0J2NB	KRH-594	Discontinued in Phase 2
T74456	DRUGINFO	D00XZP	UR-7198	Discontinued in Phase 1
T74456	DRUGINFO	D0A8EG	TAK-591	Discontinued in Phase 1
T74456	DRUGINFO	D00XTS	CR-3834	Terminated
T74456	DRUGINFO	D06EQN	XR-510	Terminated
T74456	DRUGINFO	D0N0JE	UP-275-22	Terminated
T74456	DRUGINFO	D0Q7SO	RS-66252	Terminated
T74456	DRUGINFO	D00UBK	L-159689	Terminated
T74456	DRUGINFO	D06MUI	A-81988	Terminated
T74456	DRUGINFO	D0GS7N	L-158809	Terminated
T74456	DRUGINFO	D0Q6YP	HELENALIN	Terminated
T74456	DRUGINFO	D00DIJ	CGP-49870	Investigative
T74456	DRUGINFO	D00LWG	[Sar1,Tdf8]AngII	Investigative
T74456	DRUGINFO	D00TWV	[125I]EXP985	Investigative
T74456	DRUGINFO	D01YPD	GNF-PF-3832	Investigative
T74456	DRUGINFO	D04FQA	4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone	Investigative
T74456	DRUGINFO	D05EQC	LY301875	Investigative
T74456	DRUGINFO	D06DRC	[Sar1,Tdf3]AngII	Investigative
T74456	DRUGINFO	D06PJZ	[Sar1,Bpa2]AngII	Investigative
T74456	DRUGINFO	D07EWK	[Sar1,Bpa3]AngII	Investigative
T74456	DRUGINFO	D0AD7P	LY303336	Investigative
T74456	DRUGINFO	D0D1FT	EXP3174	Investigative
T74456	DRUGINFO	D0F3VE	GNF-PF-2812	Investigative
T74456	DRUGINFO	D0I6HJ	INC-106	Investigative
T74456	DRUGINFO	D0I9IB	5-butyl-methyl immidazole carboxylate 30	Investigative
T74456	DRUGINFO	D0K0TY	N,N`-bis-alkyl butylimmidazole 12b	Investigative
T74456	DRUGINFO	D0L2HK	5-oxo-1-2-4-oxadiazol biphenyl	Investigative
T74456	DRUGINFO	D0N2WA	[Bpa1]AngII	Investigative
T74456	DRUGINFO	D0N7HN	(E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)n	Investigative
T74456	DRUGINFO	D0O1YO	[Sar1,Tdf2]AngII	Investigative
T74456	DRUGINFO	D0OO4P	CV-11194	Investigative
T74456	DRUGINFO	D0T1YO	GNF-PF-2307	Investigative
T74456	DRUGINFO	D0T6WV	4-(2-Butyl-benzoimidazol-1-ylmethyl)-phenol	Investigative
T74456	DRUGINFO	D0U3WW	L-163,101	Investigative
T74456	DRUGINFO	D0U7QE	[Tdf1]AngII	Investigative
T74456	DRUGINFO	D0XO1T	[Sar1,Bpa8]AngII	Investigative
T74456	DRUGINFO	D0Z7AF	L-162782	Investigative
T74456	DRUGINFO	D04SVT	L-159093	Investigative
T74456	DRUGINFO	D07OOI	[3H]GBR12935	Investigative
T74456	DRUGINFO	D0A4NO	L-162313	Investigative
T74456	DRUGINFO	D0D9AS	angiotensin III	Investigative
T74456	DRUGINFO	D0RE7T	4-[(diphenylmethyl)amino]-2-phenylquinazoline	Investigative

T38301	TARGETID	T38301
T38301	FORMERID	TTDS00421
T38301	UNIPROID	RIR2_HUMAN
T38301	TARGNAME	Ribonucleoside-diphosphate reductase M2 (RRM2)
T38301	GENENAME	RRM2
T38301	TARGTYPE	Successful
T38301	SYNONYMS	Ribonucleotide reductase small subunit; Ribonucleotide reductase small chain; Ribonucleoside-diphosphate reductase subunit M2; RR2
T38301	FUNCTION	Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides. Inhibits Wnt signaling. Provides the precursors necessary for DNA synthesis.
T38301	PDBSTRUC	3VPO; 3VPN; 3VPM; 3OLJ; 2UW2
T38301	BIOCLASS	CH/CH(2) oxidoreductase
T38301	ECNUMBER	EC 1.17.4.1
T38301	SEQUENCE	MLSLRVPLAPITDPQQLQLSPLKGLSLVDKENTPPALSGTRVLASKTARRIFQEPTEPKTKAAAPGVEDEPLLRENPRRFVIFPIEYHDIWQMYKKAEASFWTAEEVDLSKDIQHWESLKPEERYFISHVLAFFAASDGIVNENLVERFSQEVQITEARCFYGFQIAMENIHSEMYSLLIDTYIKDPKEREFLFNAIETMPCVKKKADWALRWIGDKEATYGERVVAFAAVEGIFFSGSFASIFWLKKRGLMPGLTFSNELISRDEGLHCDFACLMFKHLVHKPSEERVREIIINAVRIEQEFLTEALPVKLIGMNCTLMKQYIEFVADRLMLELGFSKVFRVENPFDFMENISLEGKTNFFEKRVGEYQRMGVMSSPTENSFTLDADF
T38301	DRUGINFO	D03UVS	Gemcitabine	Approved
T38301	DRUGINFO	D07CWD	Hydroxyurea	Approved
T38301	DRUGINFO	D0DT1R	Triapine	Phase 2
T38301	DRUGINFO	D0V0CJ	CO-101	Phase 2
T38301	DRUGINFO	D0A1GR	CALAA-01	Phase 1
T38301	DRUGINFO	D0F2JY	LY-2334737	Phase 1
T38301	DRUGINFO	D05ACQ	Gallium maltolate	Discontinued in Phase 2
T38301	DRUGINFO	D05HZI	MDL 101,731	Discontinued in Phase 2
T38301	DRUGINFO	D0V2RK	NKP-46	Preclinical

T05849	TARGETID	T05849
T05849	FORMERID	TTDS00043
T05849	UNIPROID	GASR_HUMAN
T05849	TARGNAME	Gastrin/cholecystokinin type B receptor (CCKBR)
T05849	GENENAME	CCKBR
T05849	TARGTYPE	Successful
T05849	SYNONYMS	Cholecystokinin-2 receptor; CCKRB; CCK2-R; CCK-BR; CCK-B receptor
T05849	FUNCTION	The CCK-B receptors occur throughout the central nervous system where they modulate anxiety, analgesia, arousal, and neuroleptic activity. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Receptor for gastrin and cholecystokinin.
T05849	PDBSTRUC	1L4T
T05849	BIOCLASS	GPCR rhodopsin
T05849	SEQUENCE	MELLKLNRSVQGTGPGPGASLCRPGAPLLNSSSVGNLSCEPPRIRGAGTRELELAIRITLYAVIFLMSVGGNMLIIVVLGLSRRLRTVTNAFLLSLAVSDLLLAVACMPFTLLPNLMGTFIFGTVICKAVSYLMGVSVSVSTLSLVAIALERYSAICRPLQARVWQTRSHAARVIVATWLLSGLLMVPYPVYTVVQPVGPRVLQCVHRWPSARVRQTWSVLLLLLLFFIPGVVMAVAYGLISRELYLGLRFDGDSDSDSQSRVRNQGGLPGAVHQNGRCRPETGAVGEDSDGCYVQLPRSRPALELTALTAPGPGSGSRPTQAKLLAKKRVVRMLLVIVVLFFLCWLPVYSANTWRAFDGPGAHRALSGAPISFIHLLSYASACVNPLVYCFMHRRFRQACLETCARCCPRPPRARPRALPDEDPPTPSIASLSRLSYTTISTLGPG
T05849	DRUGINFO	D0O5TQ	Pentagastrin	Approved
T05849	DRUGINFO	D0Y9TS	Ceruletide	Approved
T05849	DRUGINFO	D09XUH	GASTRAZOLE	Phase 3
T05849	DRUGINFO	D02FYE	TT-223	Phase 2
T05849	DRUGINFO	D02RPK	Z 360	Phase 2
T05849	DRUGINFO	D0H5WM	S-0509	Phase 2
T05849	DRUGINFO	D0H7FW	YF-476	Phase 2
T05849	DRUGINFO	D0K2RY	Itriglumide	Phase 2
T05849	DRUGINFO	D0TL7L	Dexloxiglumide	Phase 2
T05849	DRUGINFO	D04KHY	Spiroglumide	Phase 2
T05849	DRUGINFO	D0QJ6L	Demogastrin	Phase 1
T05849	DRUGINFO	D0X4AV	GV-150013	Discontinued in Phase 2
T05849	DRUGINFO	D0XJ0S	PD-134308	Discontinued in Phase 2
T05849	DRUGINFO	D0Z1RQ	L-365260	Discontinued in Phase 2
T05849	DRUGINFO	D07YHY	CR-2093	Discontinued in Phase 1
T05849	DRUGINFO	D0E8QK	JNJ-26070109	Preclinical
T05849	DRUGINFO	D06DPS	PD-170292	Preclinical
T05849	DRUGINFO	D0W4OZ	GG-8573	Preclinical
T05849	DRUGINFO	D00COB	PD136450	Terminated
T05849	DRUGINFO	D00UEG	LY288513	Terminated
T05849	DRUGINFO	D05HYL	YM-022	Terminated
T05849	DRUGINFO	D07SXO	AG-041R	Terminated
T05849	DRUGINFO	D0EG1F	GR-199114X	Terminated
T05849	DRUGINFO	D01ZDR	FR-208419	Terminated
T05849	DRUGINFO	D05HGU	IQM-95333	Terminated
T05849	DRUGINFO	D0I3BT	PD-135666	Terminated
T05849	DRUGINFO	D0W8TS	SNF-9007	Terminated
T05849	DRUGINFO	D00UPU	RPR-107836	Investigative
T05849	DRUGINFO	D02VGS	desulfated cholecystokinin-8	Investigative
T05849	DRUGINFO	D02ZWC	[125I]PD142308	Investigative
T05849	DRUGINFO	D06WOQ	RP-72540	Investigative
T05849	DRUGINFO	D08VRJ	PD-149164	Investigative
T05849	DRUGINFO	D09TNC	RB-400	Investigative
T05849	DRUGINFO	D0A7RT	Cholecystokinin-9	Investigative
T05849	DRUGINFO	D0A9EA	PD-138917	Investigative
T05849	DRUGINFO	D0F5WV	[3H]JB-93182	Investigative
T05849	DRUGINFO	D0IU6I	[3H]PD140376	Investigative
T05849	DRUGINFO	D0J0NS	[3H]PBC-264	Investigative
T05849	DRUGINFO	D0L9RP	PBC-264	Investigative
T05849	DRUGINFO	D0O0AR	RP-71483	Investigative
T05849	DRUGINFO	D0R4TA	tetronothiodin	Investigative
T05849	DRUGINFO	D0U5NA	RP-69758	Investigative
T05849	DRUGINFO	D0Y8KY	RP73870	Investigative
T05849	DRUGINFO	D0Z4HK	BC-264	Investigative
T05849	DRUGINFO	D0Z4SS	[125I]-BDZ2	Investigative
T05849	DRUGINFO	D00FLQ	PD-140547	Investigative
T05849	DRUGINFO	D02MIN	PD-138915	Investigative
T05849	DRUGINFO	D02ZML	GW-5823	Investigative
T05849	DRUGINFO	D04VOM	PD-136621	Investigative
T05849	DRUGINFO	D05OUQ	CCK-33	Investigative
T05849	DRUGINFO	D05XXE	Tetragastrin	Investigative
T05849	DRUGINFO	D06NIP	Tyr-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2	Investigative
T05849	DRUGINFO	D08EYZ	PD-140548	Investigative
T05849	DRUGINFO	D0C2KS	CI-1015	Investigative
T05849	DRUGINFO	D0CE9U	Asp-Tyr(OSO3H)-Met-Gly-Trp-Met-Asp-Phe	Investigative
T05849	DRUGINFO	D0D2ZM	PD-135158	Investigative
T05849	DRUGINFO	D0E4JX	PD-137337	Investigative
T05849	DRUGINFO	D0ES2U	TP-680	Investigative
T05849	DRUGINFO	D0G1CK	PD-140723	Investigative
T05849	DRUGINFO	D0G7RE	PD-137342	Investigative
T05849	DRUGINFO	D0I8AF	CCK-8	Investigative
T05849	DRUGINFO	D0L9OU	PD-138916	Investigative
T05849	DRUGINFO	D0M6ZF	Boc-Asp-Tyr(So3-)-Nle-Gly-Trp-Asp-Phe-NH2	Investigative
T05849	DRUGINFO	D0O0IZ	PD-135118	Investigative
T05849	DRUGINFO	D01ADK	Tyr-D-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2	Investigative
T05849	DRUGINFO	D03WGS	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Ac	Investigative
T05849	DRUGINFO	D08QKT	Tyr-D-Nle-Gly-Trp-NMeNle-Asp-Phe-NH2	Investigative
T05849	DRUGINFO	D0S7SO	H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-Bo	Investigative
T05849	DRUGINFO	D0V0RB	Tyr-D-Nle-Gly-D-Trp-Nle-Asp-Phe-NH2	Investigative
T05849	DRUGINFO	D0X7LC	Tyr-Gly-Gly-Trp-NMeNle-Asp-Phe-NH2	Investigative
T05849	DRUGINFO	D01AQC	Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2	Investigative
T05849	DRUGINFO	D03EPA	Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2	Investigative
T05849	DRUGINFO	D06BRA	Tyr-D-Ala-Gly-D-Trp-Nle-Asp-Phe-NH2	Investigative
T05849	DRUGINFO	D07ICW	Tyr-D-Ala-Gly-D-Trp-NMeNle-Asp-Phe-NH2	Investigative
T05849	DRUGINFO	D07LQQ	Tyr-D-Nle-Gly-Trp-Nle-Asp-Phe-NH2	Investigative
T05849	DRUGINFO	D09EMR	Tyr-D-Phe-Gly-D-Trp-Nle-Asp-Phe-NH2	Investigative
T05849	DRUGINFO	D0E2OG	Tyr-D-Nle-Gly-D-Trp-NMeNle-Asp-Phe-NH2	Investigative
T05849	DRUGINFO	D0J7GJ	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-H	Investigative
T05849	DRUGINFO	D0N6DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Boc	Investigative
T05849	DRUGINFO	D0QP2S	Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-NMeNle-D-Trp-Boc	Investigative
T05849	DRUGINFO	D0R4GI	Tyr-D-Ala-Gly-Trp-NMeNle-Asp-Phe-NH2	Investigative
T05849	DRUGINFO	D0TR0U	Tyr-D-Phe-Gly-D-Trp-NMeNle-Asp-Phe-NH2	Investigative
T05849	DRUGINFO	D0U6OA	Tyr-D-Ala-Gly-Trp-Nle-Asp-Phe-NH2	Investigative
T05849	DRUGINFO	D0V9DY	H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-H	Investigative
T05849	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T72458	TARGETID	T72458
T72458	FORMERID	TTDC00072
T72458	UNIPROID	MC4R_HUMAN
T72458	TARGNAME	Melanocortin receptor 4 (MC4R)
T72458	GENENAME	MC4R
T72458	TARGTYPE	Successful
T72458	SYNONYMS	MC4-R
T72458	FUNCTION	Plays a central role in energy homeostasis and somatic growth. This receptor is mediated by G proteins that stimulate adenylate cyclase (cAMP). Receptor specific to the heptapeptide core common to adrenocorticotropic hormone and alpha-, beta-, and gamma-MSH.
T72458	PDBSTRUC	2IQW; 2IQV; 2IQU; 2IQS; 2IQR
T72458	BIOCLASS	GPCR rhodopsin
T72458	SEQUENCE	MVNSTHRGMHTSLHLWNRSSYRLHSNASESLGKGYSDGGCYEQLFVSPEVFVTLGVISLLENILVIVAIAKNKNLHSPMYFFICSLAVADMLVSVSNGSETIVITLLNSTDTDAQSFTVNIDNVIDSVICSSLLASICSLLSIAVDRYFTIFYALQYHNIMTVKRVGIIISCIWAACTVSGILFIIYSDSSAVIICLITMFFTMLALMASLYVHMFLMARLHIKRIAVLPGTGAIRQGANMKGAITLTILIGVFVVCWAPFFLHLIFYISCPQNPYCVCFMSHFNLYLILIMCNSIIDPLIYALRSQELRKTFKEIICCYPLGGLCDLSSRY
T72458	DRUGINFO	D0YP7B	Setmelanotide	Approved
T72458	DRUGINFO	D03YVO	Methylnaltrexone bromide	Approved
T72458	DRUGINFO	D0X9PF	Bremelanotide	Approved
T72458	DRUGINFO	D0PI8W	Amylin	Phase 4
T72458	DRUGINFO	D0K8NR	AMG 386	Phase 3
T72458	DRUGINFO	D04QUX	PF-446687	Phase 2
T72458	DRUGINFO	D0G2XE	PMX-53	Phase 2
T72458	DRUGINFO	D0H3HV	AP-1030	Phase 1/2
T72458	DRUGINFO	D39UDP	PF-07258669	Phase 1
T72458	DRUGINFO	D09XVQ	PT-14	Discontinued in Phase 2
T72458	DRUGINFO	D0J9CF	IDDBCP-150101	Preclinical
T72458	DRUGINFO	D0N0IQ	Ro-27-3225	Preclinical
T72458	DRUGINFO	D06SDP	Melanotetan II	Preclinical
T72458	DRUGINFO	D00GCC	MCL0129	Investigative
T72458	DRUGINFO	D00XMP	1-Methyl-4-(1-phenyl-ethyl)-piperazine	Investigative
T72458	DRUGINFO	D02TOS	AMSH	Investigative
T72458	DRUGINFO	D04BOG	C[Nle-Asp-D-Phe-Arg-Trp-Glu]-NH2	Investigative
T72458	DRUGINFO	D07IBF	Ac-YR[CE(1-Me-H)dFRWC]-NH2	Investigative
T72458	DRUGINFO	D07RRN	C[Thr-Tyr-Thr-His-DNaf-Arg-Trp-Thr-Ile-Pro]	Investigative
T72458	DRUGINFO	D07SRW	His-DPhe-Arg-Trp	Investigative
T72458	DRUGINFO	D08EBV	C[Ser-Tyr-Thr-His-Dphe-Arg-Trp-Thr-Ile-Pro]	Investigative
T72458	DRUGINFO	D08QRO	BL-6020	Investigative
T72458	DRUGINFO	D09HHW	ML-253764	Investigative
T72458	DRUGINFO	D09LHF	C(his-D-phe-arg-trp-Aoc)	Investigative
T72458	DRUGINFO	D0D1BC	Melanocortin-4 Receptor antagonist	Investigative
T72458	DRUGINFO	D0D7ZA	Ser-Tyr-Ser-Nle-Glu-His-Dphe-Arg	Investigative
T72458	DRUGINFO	D0D8YP	1-Benzyl-4-methyl-piperazine	Investigative
T72458	DRUGINFO	D0GH5N	NDP-alpha-MSH	Investigative
T72458	DRUGINFO	D0J0ZG	HS014	Investigative
T72458	DRUGINFO	D0M2QK	C(his-D-phe-arg-trp-Ahp)	Investigative
T72458	DRUGINFO	D0N6AS	AC-Nle-c[Asp-His-DPhe-Pro-Trp-Lys]-NH2	Investigative
T72458	DRUGINFO	D0N6KO	THIQ	Investigative
T72458	DRUGINFO	D0QW4A	C[CO-o-C6H4-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2	Investigative
T72458	DRUGINFO	D0R5KO	C(his-D-phe-arg-trp-Ahx)	Investigative
T72458	DRUGINFO	D0U1UZ	C(his-D-phe-arg-trp-Abu)	Investigative
T72458	DRUGINFO	D0V5YV	C(his-L-phe-arg-trp-Aoc)	Investigative
T72458	DRUGINFO	D0Z1QU	MCL-129	Investigative
T72458	DRUGINFO	D09XCH	Ac-YR[CEHFRWC]-NH2	Investigative
T72458	DRUGINFO	D0R3GC	D-Phe-Arg-2-Nal-NHCH3	Investigative
T72458	DRUGINFO	D0U5KM	Ac-His-DPhe-Arg-Trp-NH2	Investigative
T72458	DRUGINFO	D0U6XP	Ac-Nle-c[Asp-His-DNaI(2')-Pro-Trp-Lys]-NH2	Investigative
T72458	DRUGINFO	D00HAJ	Hoo-Phe-Orn-Pro-hle-Pff-Phe-NH2	Investigative
T72458	DRUGINFO	D00NOG	MK-11	Investigative
T72458	DRUGINFO	D00TSX	C[Nle-His-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T72458	DRUGINFO	D00VYC	Ac-YR[CEHdFRWC]-NH2	Investigative
T72458	DRUGINFO	D01HTX	C[Nle-Nle-D-Phe-Arg-Trp-Glu]-NH2	Investigative
T72458	DRUGINFO	D02MPZ	C[Nle-His-D-Phe-Arg-Trp-Glu]-NH2	Investigative
T72458	DRUGINFO	D04YZZ	C[CO-(CH2)3-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2	Investigative
T72458	DRUGINFO	D05WNC	C[Nle-Glu-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T72458	DRUGINFO	D05XRI	Ac-R[CEHdFRWC]-NH2	Investigative
T72458	DRUGINFO	D06PNU	Tic-D-Phe-Arg-2-Nal-NHCH3	Investigative
T72458	DRUGINFO	D07DWH	Ac-dR[CEHdFRWC]-NH2	Investigative
T72458	DRUGINFO	D07UXW	C[Nle-Asp-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T72458	DRUGINFO	D08DND	C[CO-(CH2)2-CO-Nle-D-Phe-Arg-Trp-Lys]-NH2	Investigative
T72458	DRUGINFO	D09OMI	Ac-YK[CEHdFRWC]-NH2	Investigative
T72458	DRUGINFO	D09UUC	MK-10	Investigative
T72458	DRUGINFO	D0A8ME	Ac-[CEHdFRWC]-NH2	Investigative
T72458	DRUGINFO	D0B8GR	Ac-His-D-Phe-Arg-2-Nal-NHCH3	Investigative
T72458	DRUGINFO	D0C7VI	Ac-YR[CEHdFRWC]SPPKD-NH2	Investigative
T72458	DRUGINFO	D0F6GX	Ac-Tyr-D-Phe-Arg-2-Nal-NHCH3	Investigative
T72458	DRUGINFO	D0M4EF	C[Nle-Val-D-Phe-Arg-Trp-Glu]-NH2	Investigative
T72458	DRUGINFO	D0P4GI	C[Nle-Pro-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T72458	DRUGINFO	D0VD7R	C[Nle-Pro-D-Phe-Arg-Trp-Glu]-NH2	Investigative
T72458	DRUGINFO	D0ZD3M	Ac-YCit[CEHdFRWC]-NH2	Investigative
T72458	DRUGINFO	D02JVA	C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T72458	DRUGINFO	D03AZC	Ac-YRMEHdFRWG-NH2	Investigative
T72458	DRUGINFO	D05LLI	C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T72458	DRUGINFO	D06RTP	C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T72458	DRUGINFO	D07SFD	C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2	Investigative
T72458	DRUGINFO	D07TBR	Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2	Investigative
T72458	DRUGINFO	D09PDT	C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2	Investigative
T72458	DRUGINFO	D0AU4C	AEKKDEGPYRMEHFRWGSPPKD	Investigative
T72458	DRUGINFO	D0B4OL	Ac-YRMEHdFRWGSPPKD-NH2	Investigative
T72458	DRUGINFO	D0CK0K	Ac-Nle-c[Asp-His-DNal(2')-Pro-Trp-Lys]-NH2	Investigative
T72458	DRUGINFO	D0I8SJ	NDP-SYSMEHFRWGKPVG	Investigative
T72458	DRUGINFO	D0ID5M	GPYRMEHFRWGSPPKD-NH2	Investigative
T72458	DRUGINFO	D0L1MJ	C[Nle-Nle-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T72458	DRUGINFO	D0R0BY	Ac-YR[CEH(pCl-dF)RWC]-NH2	Investigative
T72458	DRUGINFO	D0WG8P	Ac-YR[CEH(pF-dF)RWC]-NH2	Investigative
T72458	DRUGINFO	D0WI8M	C[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2	Investigative
T72458	DRUGINFO	D0X1YL	Ac-YRC(Me)*EHdFRWC(Me)NH2	Investigative
T72458	DRUGINFO	D0YB7F	MT-II	Investigative
T72458	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T11288	TARGETID	T11288
T11288	FORMERID	TTDS00288
T11288	UNIPROID	MRP1_HUMAN
T11288	TARGNAME	Multidrug resistance-associated protein 1 (ABCC1)
T11288	GENENAME	ABCC1
T11288	TARGTYPE	Successful
T11288	SYNONYMS	MRP1; MRP; Leukotriene C(4) transporter; LTC4 transporter; ATP-binding cassette sub-family C member 1
T11288	FUNCTION	Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency. Mediates export of organic anions and drugs from the cytoplasm.
T11288	PDBSTRUC	4C3Z; 2CBZ
T11288	BIOCLASS	ABC transporter
T11288	ECNUMBER	EC 7.6.2.2
T11288	SEQUENCE	MALRGFCSADGSDPLWDWNVTWNTSNPDFTKCFQNTVLVWVPCFYLWACFPFYFLYLSRHDRGYIQMTPLNKTKTALGFLLWIVCWADLFYSFWERSRGIFLAPVFLVSPTLLGITMLLATFLIQLERRKGVQSSGIMLTFWLVALVCALAILRSKIMTALKEDAQVDLFRDITFYVYFSLLLIQLVLSCFSDRSPLFSETIHDPNPCPESSASFLSRITFWWITGLIVRGYRQPLEGSDLWSLNKEDTSEQVVPVLVKNWKKECAKTRKQPVKVVYSSKDPAQPKESSKVDANEEVEALIVKSPQKEWNPSLFKVLYKTFGPYFLMSFFFKAIHDLMMFSGPQILKLLIKFVNDTKAPDWQGYFYTVLLFVTACLQTLVLHQYFHICFVSGMRIKTAVIGAVYRKALVITNSARKSSTVGEIVNLMSVDAQRFMDLATYINMIWSAPLQVILALYLLWLNLGPSVLAGVAVMVLMVPVNAVMAMKTKTYQVAHMKSKDNRIKLMNEILNGIKVLKLYAWELAFKDKVLAIRQEELKVLKKSAYLSAVGTFTWVCTPFLVALCTFAVYVTIDENNILDAQTAFVSLALFNILRFPLNILPMVISSIVQASVSLKRLRIFLSHEELEPDSIERRPVKDGGGTNSITVRNATFTWARSDPPTLNGITFSIPEGALVAVVGQVGCGKSSLLSALLAEMDKVEGHVAIKGSVAYVPQQAWIQNDSLRENILFGCQLEEPYYRSVIQACALLPDLEILPSGDRTEIGEKGVNLSGGQKQRVSLARAVYSNADIYLFDDPLSAVDAHVGKHIFENVIGPKGMLKNKTRILVTHSMSYLPQVDVIIVMSGGKISEMGSYQELLARDGAFAEFLRTYASTEQEQDAEENGVTGVSGPGKEAKQMENGMLVTDSAGKQLQRQLSSSSSYSGDISRHHNSTAELQKAEAKKEETWKLMEADKAQTGQVKLSVYWDYMKAIGLFISFLSIFLFMCNHVSALASNYWLSLWTDDPIVNGTQEHTKVRLSVYGALGISQGIAVFGYSMAVSIGGILASRCLHVDLLHSILRSPMSFFERTPSGNLVNRFSKELDTVDSMIPEVIKMFMGSLFNVIGACIVILLATPIAAIIIPPLGLIYFFVQRFYVASSRQLKRLESVSRSPVYSHFNETLLGVSVIRAFEEQERFIHQSDLKVDENQKAYYPSIVANRWLAVRLECVGNCIVLFAALFAVISRHSLSAGLVGLSVSYSLQVTTYLNWLVRMSSEMETNIVAVERLKEYSETEKEAPWQIQETAPPSSWPQVGRVEFRNYCLRYREDLDFVLRHINVTINGGEKVGIVGRTGAGKSSLTLGLFRINESAEGEIIIDGINIAKIGLHDLRFKITIIPQDPVLFSGSLRMNLDPFSQYSDEEVWTSLELAHLKDFVSALPDKLDHECAEGGENLSVGQRQLVCLARALLRKTKILVLDEATAAVDLETDDLIQSTIRTQFEDCTVLTIAHRLNTIMDYTRVIVLDKGEIQEYGAPSDLLQQRGLFYSMAKDAGLV
T11288	DRUGINFO	D03DEI	Sulfinpyrazone	Approved
T11288	DRUGINFO	D0Z3DY	Benzbromarone	Approved
T11288	DRUGINFO	D0KX3H	Pyrrolopyrimidine	Investigative
T11288	DRUGINFO	D04GYT	XR-9456	Investigative
T11288	DRUGINFO	D09HIM	XR-9504	Investigative
T11288	DRUGINFO	D0A4TF	XR-9544	Investigative
T11288	DRUGINFO	D0S8CE	XR-9577	Investigative

T37693	TARGETID	T37693
T37693	FORMERID	TTDC00314
T37693	UNIPROID	CNR2_HUMAN
T37693	TARGNAME	Cannabinoid receptor 2 (CB2)
T37693	GENENAME	CNR2
T37693	TARGTYPE	Successful
T37693	SYNONYMS	hCB2; Cannabinoid CB2 receptor; CX5; CB2B; CB2A; CB-2
T37693	FUNCTION	May function in inflammatory response, nociceptive transmission and bone homeostasis. Heterotrimeric G protein-coupled receptor for endocannabinoid 2-arachidonoylglycerol mediating inhibition of adenylate cyclase.
T37693	PDBSTRUC	5ZTY; 2KI9
T37693	BIOCLASS	GPCR rhodopsin
T37693	SEQUENCE	MEECWVTEIANGSKDGLDSNPMKDYMILSGPQKTAVAVLCTLLGLLSALENVAVLYLILSSHQLRRKPSYLFIGSLAGADFLASVVFACSFVNFHVFHGVDSKAVFLLKIGSVTMTFTASVGSLLLTAIDRYLCLRYPPSYKALLTRGRALVTLGIMWVLSALVSYLPLMGWTCCPRPCSELFPLIPNDYLLSWLLFIAFLFSGIIYTYGHVLWKAHQHVASLSGHQDRQVPGMARMRLDVRLAKTLGLVLAVLLICWFPVLALMAHSLATTLSDQVKKAFAFCSMLCLINSMVNPVIYALRSGEIRSSAHHCLAHWKKCVRGLGSEAKEEAPRSSVTETEADGKITPWPDSRDLDLSDC
T37693	DRUGINFO	D0L7AS	NABILONE	Approved
T37693	DRUGINFO	D07ILQ	Guanfacine extended release	Approved
T37693	DRUGINFO	D00FBC	KHK-6188	Phase 2
T37693	DRUGINFO	D06UIS	LY-2828360	Phase 2
T37693	DRUGINFO	D0I4PW	APD371	Phase 2
T37693	DRUGINFO	D0J6KZ	S-777469	Phase 2
T37693	DRUGINFO	D0Q7NB	842166X	Phase 2
T37693	DRUGINFO	D53QMP	Beta-caryophyllene	Phase 2
T37693	DRUGINFO	DMJ2N9	Vicasinabin	Phase 2
T37693	DRUGINFO	D05BMC	GW-42004	Phase 2
T37693	DRUGINFO	D0Q8WG	Tedalinab	Phase 1
T37693	DRUGINFO	DK3WQ5	NTRX-07	Phase 1
T37693	DRUGINFO	D00TIB	PMID27215781-Compound-34	Patented
T37693	DRUGINFO	D01PUS	PMID27215781-Compound-32	Patented
T37693	DRUGINFO	D03YAA	PMID27215781-Compound-28	Patented
T37693	DRUGINFO	D03YWY	PMID27215781-Compound-30	Patented
T37693	DRUGINFO	D07IHT	N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 1	Patented
T37693	DRUGINFO	D07ULI	PMID27215781-Compound-25	Patented
T37693	DRUGINFO	D08XES	PMID27215781-Compound-4	Patented
T37693	DRUGINFO	D0CR0Y	PMID27215781-Compound-31	Patented
T37693	DRUGINFO	D0D1TS	Isoquinoline derivative 2	Patented
T37693	DRUGINFO	D0E6YT	PMID27215781-Compound-27	Patented
T37693	DRUGINFO	D0EX1T	PMID27215781-Compound-11	Patented
T37693	DRUGINFO	D0HG0F	1,3,5-triazine derivative 1	Patented
T37693	DRUGINFO	D0O2TY	PMID27215781-Compound-13	Patented
T37693	DRUGINFO	D0OE0D	PMID27215781-Compound-33	Patented
T37693	DRUGINFO	D0Q9TO	PMID27215781-Compound-12	Patented
T37693	DRUGINFO	D0SR5L	PMID27215781-Compound-19	Patented
T37693	DRUGINFO	D0T9OL	Adamantyl derivative 1	Patented
T37693	DRUGINFO	D0TC7X	Isoquinoline derivative 1	Patented
T37693	DRUGINFO	D0XG7K	PMID27215781-Compound-29	Patented
T37693	DRUGINFO	D0YZ8I	JWH-015	Patented
T37693	DRUGINFO	D0ZM1H	Isoquinoline derivative 3	Patented
T37693	DRUGINFO	D02TOI	Tricyclic phytocannabinoid derivative 2	Patented
T37693	DRUGINFO	D05CEL	2-cycloalkyl resorcinol cannabinoid ligand derivative 1	Patented
T37693	DRUGINFO	D07BFP	PMID27215781-Compound-37	Patented
T37693	DRUGINFO	D09GJQ	Tricyclic phytocannabinoid derivative 1	Patented
T37693	DRUGINFO	D09WPA	Phytocannabinoid/aminoalkylindole derivative 2	Patented
T37693	DRUGINFO	D0FA2L	N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 3	Patented
T37693	DRUGINFO	D0GQ8W	Carbazole-3-carboxamide analog 1	Patented
T37693	DRUGINFO	D0H0XC	2-cycloalkyl resorcinol cannabinoid ligand derivative 2	Patented
T37693	DRUGINFO	D0LN9D	Cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 1	Patented
T37693	DRUGINFO	D0RZ4M	Phytocannabinoid/aminoalkylindole derivative 1	Patented
T37693	DRUGINFO	D0W9PY	PMID27215781-Compound-2	Patented
T37693	DRUGINFO	D0WJ3F	N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 2	Patented
T37693	DRUGINFO	D0X5ZS	Cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 2	Patented
T37693	DRUGINFO	D03ACT	PRS-211375 iv	Discontinued in Phase 2
T37693	DRUGINFO	D0LF5B	KN-38-7271	Discontinued in Phase 2
T37693	DRUGINFO	D03KTK	TAK-937	Discontinued in Phase 1
T37693	DRUGINFO	D01DTQ	PXS-2076	Terminated
T37693	DRUGINFO	D07XGT	AM-577	Terminated
T37693	DRUGINFO	D0A4XN	PRS-639058	Terminated
T37693	DRUGINFO	D0J7RW	WIN-55212-2	Terminated
T37693	DRUGINFO	D00ECV	SCH-225336	Investigative
T37693	DRUGINFO	D00TPO	JWH-201	Investigative
T37693	DRUGINFO	D01IUI	JWH-253	Investigative
T37693	DRUGINFO	D01JTY	JWH-313	Investigative
T37693	DRUGINFO	D02GTT	AR-XYZ	Investigative
T37693	DRUGINFO	D02INF	L-759,656	Investigative
T37693	DRUGINFO	D02UEJ	JWH-311	Investigative
T37693	DRUGINFO	D03DDL	JWH-303	Investigative
T37693	DRUGINFO	D03SCD	5-Biphenyl-4-ylmethyl-1-isobutyl-1H-tetrazole	Investigative
T37693	DRUGINFO	D04EOZ	JWH-294	Investigative
T37693	DRUGINFO	D04XGX	2-(2-Methoxybenzyl)-3H-benzo[f]chromen-3-one	Investigative
T37693	DRUGINFO	D05DXW	JWH-251	Investigative
T37693	DRUGINFO	D05EWD	JWH-167	Investigative
T37693	DRUGINFO	D05RKV	Sch-036	Investigative
T37693	DRUGINFO	D05TQX	O-oleoyl-N-(2-hydroxyethyl)hydroxylamine	Investigative
T37693	DRUGINFO	D06GAF	N1-(4-bromophenyl)-N2,N2-dipentylphthalamide	Investigative
T37693	DRUGINFO	D06JFN	N-benzyl-4-bromo-3-(morpholinosulfonyl)benzamide	Investigative
T37693	DRUGINFO	D06SRX	MDA-19	Investigative
T37693	DRUGINFO	D08BGZ	JWH-315	Investigative
T37693	DRUGINFO	D08JCV	JWH-204	Investigative
T37693	DRUGINFO	D08JFL	3-benzoyl-1-pentyl-1,4-dihydroquinolin-4-one	Investigative
T37693	DRUGINFO	D08RYN	RQ-00202730	Investigative
T37693	DRUGINFO	D09DSK	JWH-051	Investigative
T37693	DRUGINFO	D0BS7G	L-759,633	Investigative
T37693	DRUGINFO	D0D4HH	JWH-250	Investigative
T37693	DRUGINFO	D0EC6B	Dodeca-2E,4E-dienoic acid isobutylamide	Investigative
T37693	DRUGINFO	D0F3CH	JWH-151	Investigative
T37693	DRUGINFO	D0G9EU	JWH-295	Investigative
T37693	DRUGINFO	D0GD9G	JWH-207	Investigative
T37693	DRUGINFO	D0I9XR	JWH-302	Investigative
T37693	DRUGINFO	D0IW4Q	JWH-305	Investigative
T37693	DRUGINFO	D0J8KW	SR144528	Investigative
T37693	DRUGINFO	D0L5IM	JWH-306	Investigative
T37693	DRUGINFO	D0M1MQ	JWH-203	Investigative
T37693	DRUGINFO	D0M1ZC	JWH-343	Investigative
T37693	DRUGINFO	D0P6NA	JWH-202	Investigative
T37693	DRUGINFO	D0P9KU	JWH-252	Investigative
T37693	DRUGINFO	D0PC1Z	JWH-323	Investigative
T37693	DRUGINFO	D0Q4IM	JWH-237	Investigative
T37693	DRUGINFO	D0Q4YR	JWH-296	Investigative
T37693	DRUGINFO	D0Q6FF	JWH-249	Investigative
T37693	DRUGINFO	D0Q8QH	N-oleoyl-N-(2-hydroxyethyl)hydroxylamine	Investigative
T37693	DRUGINFO	D0Q8SO	JWH-208	Investigative
T37693	DRUGINFO	D0R1UA	GNF-PF-5188	Investigative
T37693	DRUGINFO	D0RI8G	JWH-312	Investigative
T37693	DRUGINFO	D0T3CP	N-oleoyl-O-(2-hydroxyethyl)hydroxylamine	Investigative
T37693	DRUGINFO	D0U3ME	4'-(1,1-dimethyl-heptyl)-3,5-dimethyl-biphenyl	Investigative
T37693	DRUGINFO	D0UX4A	HU-433	Investigative
T37693	DRUGINFO	D0W9BD	JWH-314	Investigative
T37693	DRUGINFO	D0WD1F	JWH-205	Investigative
T37693	DRUGINFO	D0X0FB	JWH-206	Investigative
T37693	DRUGINFO	D0X1EC	JWH-248	Investigative
T37693	DRUGINFO	D0X1FX	JWH-441	Investigative
T37693	DRUGINFO	D0YM8O	JWH-209	Investigative
T37693	DRUGINFO	D00DNT	JWH-406	Investigative
T37693	DRUGINFO	D00LZJ	JWH-405	Investigative
T37693	DRUGINFO	D00TRZ	JWH-407	Investigative
T37693	DRUGINFO	D01JHA	2'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol	Investigative
T37693	DRUGINFO	D01JQX	JWH-342	Investigative
T37693	DRUGINFO	D01MJF	JWH-404	Investigative
T37693	DRUGINFO	D01PEC	(2R)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)	Investigative
T37693	DRUGINFO	D01RWS	3-Benzyl-5-isopropyl-8-methylchromen-2-one	Investigative
T37693	DRUGINFO	D01VIA	(4-benzhydrylpiperazin-1-yl)(cyclohexyl)methanone	Investigative
T37693	DRUGINFO	D02NAW	N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXY-2-METHYLPROPANAMIDE (ENANTIOMERIC MIX)	Investigative
T37693	DRUGINFO	D02POA	5-(1,1-dimethyl-heptyl)-2-pyridin-3-yl-phenol	Investigative
T37693	DRUGINFO	D02QTB	JWH-307	Investigative
T37693	DRUGINFO	D02VSL	JWH-133	Investigative
T37693	DRUGINFO	D03AWH	AM-4768	Investigative
T37693	DRUGINFO	D03GDP	AM-1715	Investigative
T37693	DRUGINFO	D03HFM	(1R,2R)-N-Arachidonoylcyclopropanolamide	Investigative
T37693	DRUGINFO	D03REA	5-Methoxy-3-(2-methoxybenzyl)-2H-chromen-2-one	Investigative
T37693	DRUGINFO	D03RGV	JWH-156	Investigative
T37693	DRUGINFO	D03SRV	JWH-292	Investigative
T37693	DRUGINFO	D04AMC	N-arachidonoyl-N-(2-hydroxyethyl)hydroxylamine	Investigative
T37693	DRUGINFO	D04AUM	AM-1710	Investigative
T37693	DRUGINFO	D04ECZ	Rac-trans-N-oleoylcyclopropanolamide	Investigative
T37693	DRUGINFO	D04GDY	DELTA 8-TETRAHYDROCANNOBINOL	Investigative
T37693	DRUGINFO	D04ICJ	4-benzhydryl-N-cyclohexylpiperazine-1-carboxamide	Investigative
T37693	DRUGINFO	D04LZA	JWH-370	Investigative
T37693	DRUGINFO	D04TSL	JWH-392	Investigative
T37693	DRUGINFO	D06BXT	[3H]WIN55212-2	Investigative
T37693	DRUGINFO	D06DTC	(2S)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)	Investigative
T37693	DRUGINFO	D06EHU	JWH-268	Investigative
T37693	DRUGINFO	D06SKK	JWH-440	Investigative
T37693	DRUGINFO	D07KZW	JWH-364	Investigative
T37693	DRUGINFO	D07QUV	JWH-345	Investigative
T37693	DRUGINFO	D08BNY	(E)-N-(4-methoxyphenyl)undec-2-enamide	Investigative
T37693	DRUGINFO	D08GLU	4'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol	Investigative
T37693	DRUGINFO	D08OAQ	4-(1,1-dimethyl-heptyl)-3'-methoxy-biphenyl-2-ol	Investigative
T37693	DRUGINFO	D08TXL	A-796260	Investigative
T37693	DRUGINFO	D08VLG	4-(1,1-dimethyl-heptyl)-2'-methoxy-biphenyl-2-ol	Investigative
T37693	DRUGINFO	D09BYO	N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX)	Investigative
T37693	DRUGINFO	D09CKZ	AM-411	Investigative
T37693	DRUGINFO	D09FMK	AM-630	Investigative
T37693	DRUGINFO	D09JER	JWH-344	Investigative
T37693	DRUGINFO	D09KFJ	JWH-229	Investigative
T37693	DRUGINFO	D09PIQ	JWH-367	Investigative
T37693	DRUGINFO	D0A2BC	JWH-385	Investigative
T37693	DRUGINFO	D0B8AN	JWH-347	Investigative
T37693	DRUGINFO	D0C4CG	N-(2-chloroethyl)icosa-5,8,11,14-tetraenamide	Investigative
T37693	DRUGINFO	D0CO6T	NAPHTHYRIDINONE	Investigative
T37693	DRUGINFO	D0D7OR	KM-233-M	Investigative
T37693	DRUGINFO	D0DE9L	JWH-368	Investigative
T37693	DRUGINFO	D0DQ3F	JWH-365	Investigative
T37693	DRUGINFO	D0E0AA	N-(7-(2-CHLOROPHENYL)-6-(4-CHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX)	Investigative
T37693	DRUGINFO	D0E0JU	JWH-401	Investigative
T37693	DRUGINFO	D0E3ET	AM-1714	Investigative
T37693	DRUGINFO	D0E3OY	JWH-372	Investigative
T37693	DRUGINFO	D0E4OT	JWH-325	Investigative
T37693	DRUGINFO	D0EE0Q	JWH-366	Investigative
T37693	DRUGINFO	D0EX7J	JWH-442	Investigative
T37693	DRUGINFO	D0F3XG	JWH-346	Investigative
T37693	DRUGINFO	D0F4BE	O-arachidonoyl-N-(2-hydroxyethyl)hydroxylamine	Investigative
T37693	DRUGINFO	D0G2EQ	(1S,2S)-N-Arachidonoylcyclopropanolamide	Investigative
T37693	DRUGINFO	D0G4VV	SCH-356036	Investigative
T37693	DRUGINFO	D0G7GF	3'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol	Investigative
T37693	DRUGINFO	D0GG4T	JWH-150	Investigative
T37693	DRUGINFO	D0I4AF	N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXY-2,2-DIMETHYLPROPANAMIDE (ENANTIOMERIC MIX)	Investigative
T37693	DRUGINFO	D0I7MW	JWH-244	Investigative
T37693	DRUGINFO	D0J3XJ	N-(3-Phenyl)propyl-2-(4-bromophenylacetamide)	Investigative
T37693	DRUGINFO	D0J7CR	Rac-cis-N-arachidonoylcyclopropanolamide	Investigative
T37693	DRUGINFO	D0K4PV	6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-((R)-1-HYDROXYETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)	Investigative
T37693	DRUGINFO	D0K7QP	(1S,2S)-N-Oleoylcyclopropanolamide	Investigative
T37693	DRUGINFO	D0K8MN	5-Biphenyl-4-ylmethyl-2-isobutyl-2H-tetrazole	Investigative
T37693	DRUGINFO	D0K8VR	[3H]HU-243	Investigative
T37693	DRUGINFO	D0L6RT	PRAVADOLINE	Investigative
T37693	DRUGINFO	D0N0ME	4-benzhydryl-N-butylpiperazine-1-carboxamide	Investigative
T37693	DRUGINFO	D0N5VO	JWH-403	Investigative
T37693	DRUGINFO	D0O3NY	AM-1241	Investigative
T37693	DRUGINFO	D0O7ZJ	JWH-120	Investigative
T37693	DRUGINFO	D0O8IC	JWH-309	Investigative
T37693	DRUGINFO	D0P5VJ	KM-233	Investigative
T37693	DRUGINFO	D0PE8U	N-(1H-indazol-5-yl)icosa-5,8,11,14-tetraenamide	Investigative
T37693	DRUGINFO	D0Q0XV	(1R,2S)-N-Oleoylcyclopropanolamide	Investigative
T37693	DRUGINFO	D0Q9FB	JWH-308	Investigative
T37693	DRUGINFO	D0R1NR	JWH-371	Investigative
T37693	DRUGINFO	D0R3GN	JWH-373	Investigative
T37693	DRUGINFO	D0R6MB	6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)	Investigative
T37693	DRUGINFO	D0R7QF	(1R,2S)-N-Arachidonoylcyclopropanolamide	Investigative
T37693	DRUGINFO	D0R9VY	6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(1-HYDROXY-2-METHYLPROPAN-2-YL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)	Investigative
T37693	DRUGINFO	D0S2ZR	JWH-147	Investigative
T37693	DRUGINFO	D0S3UA	JWH-145	Investigative
T37693	DRUGINFO	D0T4SE	(E)-N-(4-methoxyphenethyl)undec-2-enamide	Investigative
T37693	DRUGINFO	D0T5WY	JWH-293	Investigative
T37693	DRUGINFO	D0TN1L	JWH-146	Investigative
T37693	DRUGINFO	D0TS5I	JWH-245	Investigative
T37693	DRUGINFO	D0U4JI	JWH-337	Investigative
T37693	DRUGINFO	D0UD9H	AM-281	Investigative
T37693	DRUGINFO	D0V3TO	JWH-348	Investigative
T37693	DRUGINFO	D0V3YB	3,4-diarylpyrazoline derivative	Investigative
T37693	DRUGINFO	D0V7QA	1,4-dihydroindeno[1,2-c]-pyrazole	Investigative
T37693	DRUGINFO	D0Y0MY	JWH-402	Investigative
T37693	DRUGINFO	D0Y1MM	N-arachidonoyl-O-(2-hydroxyethyl)hydroxylamine	Investigative
T37693	DRUGINFO	D0Y6MS	JWH-297	Investigative
T37693	DRUGINFO	D0Y9HT	JWH-363	Investigative
T37693	DRUGINFO	D0Z1NH	Cis-N-oleoylcyclopropanolamide	Investigative
T37693	DRUGINFO	D0Z1XE	JWH-324	Investigative
T37693	DRUGINFO	D0Z5CX	N-(3,3-Diphenyl)propyl-2,2-diphenylacetamide	Investigative
T37693	DRUGINFO	D0Z6BY	JWH-243	Investigative
T37693	DRUGINFO	D0Z7FF	JWH-246	Investigative
T37693	DRUGINFO	D0Z7OB	(E)-N-(3,5-dimethoxyphenethyl)undec-2-enamide	Investigative
T37693	DRUGINFO	D0ZL2P	JWH-369	Investigative
T37693	DRUGINFO	D0ZM1T	VER-156085	Investigative
T37693	DRUGINFO	D01MCD	(2R)-N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)	Investigative
T37693	DRUGINFO	D02GOH	AM-404	Investigative
T37693	DRUGINFO	D06NXC	N-[6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-YL]-4,4,4-TRIFLUORO-3-HYDROXYBUTANAMIDE (DIASTEREOMERIC MIX)	Investigative
T37693	DRUGINFO	D0D6OH	[3H]CP55940	Investigative
T37693	DRUGINFO	D0FJ1I	N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)	Investigative
T37693	DRUGINFO	D0L1UA	N-(4-hydroxybenzyl)icosa-5,8,11,14-tetraenamide	Investigative
T37693	DRUGINFO	D0OQ5H	6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)	Investigative
T37693	DRUGINFO	D0PC5A	VER-156084	Investigative

T77913	TARGETID	T77913
T77913	FORMERID	TTDS00086
T77913	UNIPROID	HRH1_HUMAN
T77913	TARGNAME	Histamine H1 receptor (H1R)
T77913	GENENAME	HRH1
T77913	TARGTYPE	Successful
T77913	SYNONYMS	HH1R; H1R
T77913	FUNCTION	In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
T77913	PDBSTRUC	3RZE
T77913	BIOCLASS	GPCR rhodopsin
T77913	SEQUENCE	MSLPNSSCLLEDKMCEGNKTTMASPQLMPLVVVLSTICLVTVGLNLLVLYAVRSERKLHTVGNLYIVSLSVADLIVGAVVMPMNILYLLMSKWSLGRPLCLFWLSMDYVASTASIFSVFILCIDRYRSVQQPLRYLKYRTKTRASATILGAWFLSFLWVIPILGWNHFMQQTSVRREDKCETDFYDVTWFKVMTAIINFYLPTLLMLWFYAKIYKAVRQHCQHRELINRSLPSFSEIKLRPENPKGDAKKPGKESPWEVLKRKPKDAGGGSVLKSPSQTPKEMKSPVVFSQEDDREVDKLYCFPLDIVHMQAAAEGSSRDYVAVNRSHGQLKTDEQGLNTHGASEISEDQMLGDSQSFSRTDSDTTTETAPGKGKLRSGSNTGLDYIKFTWKRLRSHSRQYVSGLHMNRERKAAKQLGFIMAAFILCWIPYFIFFMVIAFCKNCCNEHLHMFTIWLGYINSTLNPLIYPLCNENFKKTFKRILHIRS
T77913	DRUGINFO	D00FGV	Carbinoxamine	Approved
T77913	DRUGINFO	D00JVR	Azelastine	Approved
T77913	DRUGINFO	D00TLN	Cyproheptadine	Approved
T77913	DRUGINFO	D01GBY	Desloratadine	Approved
T77913	DRUGINFO	D01KPV	Fexofenadine	Approved
T77913	DRUGINFO	D01NJI	Mepyramine maleate	Approved
T77913	DRUGINFO	D02WIW	Dexbrompheniramine	Approved
T77913	DRUGINFO	D02XJI	Emedastine	Approved
T77913	DRUGINFO	D03XSJ	Buclizine	Approved
T77913	DRUGINFO	D04OBB	Pheniramine	Approved
T77913	DRUGINFO	D04USC	Ergotidine	Approved
T77913	DRUGINFO	D05GPO	Olopatadine	Approved
T77913	DRUGINFO	D05ZGQ	Dexchlorpheniramine Maleate	Approved
T77913	DRUGINFO	D06ABF	Loratadine	Approved
T77913	DRUGINFO	D06EQP	Aceprometazine	Approved
T77913	DRUGINFO	D06FES	Doxepin	Approved
T77913	DRUGINFO	D06FZX	Antazoline	Approved
T77913	DRUGINFO	D06MAJ	Mizolastine	Approved
T77913	DRUGINFO	D06UDO	Phenindamine	Approved
T77913	DRUGINFO	D08CTT	Dimethindene	Approved
T77913	DRUGINFO	D08HRJ	Cyclizine	Approved
T77913	DRUGINFO	D08HZL	Trimeprazine	Approved
T77913	DRUGINFO	D08JZS	Mepyramine	Approved
T77913	DRUGINFO	D08SEI	Levocabastine	Approved
T77913	DRUGINFO	D08VXO	Brompheniramine	Approved
T77913	DRUGINFO	D09IMS	Mequitazine	Approved
T77913	DRUGINFO	D0AJ5L	Oxatomide	Approved
T77913	DRUGINFO	D0B4JQ	Tripelennamine	Approved
T77913	DRUGINFO	D0B7NG	Chlorpheniramine	Approved
T77913	DRUGINFO	D0C5XC	Clemastine	Approved
T77913	DRUGINFO	D0DK8V	Cetirizine	Approved
T77913	DRUGINFO	D0DV3O	Epinastine	Approved
T77913	DRUGINFO	D0E8CI	Triprolidine	Approved
T77913	DRUGINFO	D0EC6Q	Chlophedianol	Approved
T77913	DRUGINFO	D0K5LQ	Pemirolast	Approved
T77913	DRUGINFO	D0LR0R	Methdilazine	Approved
T77913	DRUGINFO	D0M8PW	Levocetirizine dihydrochloride	Approved
T77913	DRUGINFO	D0N7AD	Azatadine	Approved
T77913	DRUGINFO	D0O4EU	Acrivastine	Approved
T77913	DRUGINFO	D0O6SX	Hydroxyzine	Approved
T77913	DRUGINFO	D0O7JW	Alcaftadine	Approved
T77913	DRUGINFO	D0Q0RC	Ethopropazine	Approved
T77913	DRUGINFO	D0Q3YO	Cinnarizine	Approved
T77913	DRUGINFO	D0R9ZB	Propiomazine	Approved
T77913	DRUGINFO	D0T2XU	Promethazine	Approved
T77913	DRUGINFO	D0U5VZ	Bepotastine	Approved
T77913	DRUGINFO	D0U8UV	Dimenhydrinate	Approved
T77913	DRUGINFO	D0W6DY	Diphenylpyraline	Approved
T77913	DRUGINFO	D0Y2LR	Doxylamine	Approved
T77913	DRUGINFO	D0Y5GK	Bromodiphenhydramine	Approved
T77913	DRUGINFO	D0YG7M	Ketotifen	Approved
T77913	DRUGINFO	D0ZJ1C	(S)-(+)-Dimethindene maleate	Approved
T77913	DRUGINFO	D01FGR	Diphenhydramine	Approved
T77913	DRUGINFO	D0E6OC	Tranilast	Approved
T77913	DRUGINFO	D0S1CQ	RUPATADINE	Phase 4
T77913	DRUGINFO	D01JFM	AC-170	Phase 3
T77913	DRUGINFO	D0LK4X	Carebastine	Phase 3
T77913	DRUGINFO	D03DRR	Noberastine	Phase 2
T77913	DRUGINFO	D04HAF	LY-2624803	Phase 2
T77913	DRUGINFO	D08TLI	E-4716	Phase 2
T77913	DRUGINFO	D08WOJ	OBE-101	Phase 2
T77913	DRUGINFO	D0E8ZY	Vapitadine	Phase 2
T77913	DRUGINFO	D04JIM	UCB-35440	Phase 2
T77913	DRUGINFO	D05XEA	RP5063	Phase 2
T77913	DRUGINFO	D0R6LF	Citalopram derivative 1	Patented
T77913	DRUGINFO	D0FA3G	PMID29334795-Compound-61	Patented
T77913	DRUGINFO	D0VX6P	Piperidine derivative 1	Patented
T77913	DRUGINFO	D08SOF	Terfenadine	Withdrawn from market
T77913	DRUGINFO	D0Y2HR	Astemizole	Withdrawn from market
T77913	DRUGINFO	D0I5UU	Norastemizole	Discontinued in Preregistration
T77913	DRUGINFO	D00WJE	SUN-1334H	Discontinued in Phase 2
T77913	DRUGINFO	D02YBP	Mequitamium iodide	Discontinued in Phase 2
T77913	DRUGINFO	D08RZV	HSR-609	Discontinued in Phase 2
T77913	DRUGINFO	D09TEI	ReN-1869	Discontinued in Phase 2
T77913	DRUGINFO	D04IFU	GSK835726	Discontinued in Phase 2
T77913	DRUGINFO	D09UXP	AZD-1744	Discontinued in Phase 1
T77913	DRUGINFO	D0B4TT	GSK1004723	Discontinued in Phase 1
T77913	DRUGINFO	D0FQ4M	Selenotifen	Terminated
T77913	DRUGINFO	D0VZ8S	KA-398	Terminated
T77913	DRUGINFO	D01HUN	UR-PG131A	Investigative
T77913	DRUGINFO	D01XZI	(-)-trans-H2-PAT	Investigative
T77913	DRUGINFO	D05IHR	9-Phenyl-2,3-dihydro-1H-indeno[2,1-c]pyridine	Investigative
T77913	DRUGINFO	D06QQS	Hydroxyclemastine	Investigative
T77913	DRUGINFO	D08NXC	1-[(Furan-2(5H)-one)-4-methyl]-desloratadine	Investigative
T77913	DRUGINFO	D08TBU	Diphenyl(piperidin-4-yl)methanol	Investigative
T77913	DRUGINFO	D0A6IQ	2-(3-iodophenyl)histamine	Investigative
T77913	DRUGINFO	D0B0PP	3,3-diphenylpropan-1-amine	Investigative
T77913	DRUGINFO	D0B9TV	(+/-)-cis-H2-PAT	Investigative
T77913	DRUGINFO	D0BT1A	2-pyridylethylamine	Investigative
T77913	DRUGINFO	D0G3OY	methylhistaprodifen	Investigative
T77913	DRUGINFO	D0K9KJ	BU-E 47	Investigative
T77913	DRUGINFO	D0PB6B	dimethylhistaprodifen	Investigative
T77913	DRUGINFO	D0PC7A	(+)-trans-H2-PAT	Investigative
T77913	DRUGINFO	D0QW5N	(+)-cis-H2-PAT	Investigative
T77913	DRUGINFO	D0RG8O	histaprodifen	Investigative
T77913	DRUGINFO	D0T7AR	2-(3-chlorophenyl)histamine	Investigative
T77913	DRUGINFO	D0UG1U	UR-PG55B	Investigative
T77913	DRUGINFO	D0XY3G	2-(2-thiazolyl)ethanamine	Investigative
T77913	DRUGINFO	D0Y5QR	8R-Lisuride	Investigative
T77913	DRUGINFO	D0Y9IB	UR-PG153	Investigative
T77913	DRUGINFO	D0Z1WW	(S)-cetirizine	Investigative
T77913	DRUGINFO	D01CXD	9-(Aminomethyl)-9,10-dihydroanthracene	Investigative
T77913	DRUGINFO	D01HJZ	N,N-dimethyl-2,2-diphenylethanamine	Investigative
T77913	DRUGINFO	D02GNN	N-methyl-3,3-diphenylpropan-1-amine	Investigative
T77913	DRUGINFO	D02SDX	N,N-Dimethyl-3,3-diphenylpropan-1-amine	Investigative
T77913	DRUGINFO	D02YSX	DIMEBOLIN	Investigative
T77913	DRUGINFO	D03SNI	VUF-10148	Investigative
T77913	DRUGINFO	D03VUU	2-(9,10-dihydroanthracen-9-yl)-N-methylethanamine	Investigative
T77913	DRUGINFO	D04SCQ	4,4-Diphenylbutan-1-amine	Investigative
T77913	DRUGINFO	D04WXI	oxo-arpromidine	Investigative
T77913	DRUGINFO	D05RKS	N-methyl-4,4-diphenylbutan-1-amine	Investigative
T77913	DRUGINFO	D05YFZ	9-(2-aminoethyl)-9,10-dihydroanthracene	Investigative
T77913	DRUGINFO	D08RCH	KF-A6	Investigative
T77913	DRUGINFO	D08SLS	arpromidine	Investigative
T77913	DRUGINFO	D0A1DE	MDL-28163	Investigative
T77913	DRUGINFO	D0AU0F	UR-PG146	Investigative
T77913	DRUGINFO	D0G6AQ	2-(3-bromophenyl)histamine	Investigative
T77913	DRUGINFO	D0I0UW	1-(4-p-Tolyl-butyl)-piperidine	Investigative
T77913	DRUGINFO	D0S0WX	9-(2-aminopropyl)-9,10-dihydroanthracene	Investigative
T77913	DRUGINFO	D0S3WR	N,N-dimethyl-4,4-diphenylbutan-1-amine	Investigative
T77913	DRUGINFO	D0H8XV	R-dimethindene	Investigative
T77913	DRUGINFO	D0B4SF	impromidine	Investigative
T77913	DRUGINFO	D0Y4MC	9-OH-risperidone	Investigative
T77913	DRUGINFO	D0D3YN	OCTOCLOTHEPIN	Investigative
T77913	DRUGINFO	D0PN9R	R-226161	Investigative
T77913	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T58921	TARGETID	T58921
T58921	FORMERID	TTDS00338
T58921	UNIPROID	PPARG_HUMAN
T58921	TARGNAME	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
T58921	GENENAME	PPARG
T58921	TARGTYPE	Successful
T58921	SYNONYMS	PPAR-gamma; Nuclear receptor subfamily 1 group C member 3; NR1C3
T58921	FUNCTION	Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses. Plays a role in the regulation of cardiovascular circadian rhythms by regulating the transcription of ARNTL/BMAL1 in the blood vessels (By similarity).
T58921	PDBSTRUC	6MD4; 6MD2; 6MD1; 6MD0; 6MCZ
T58921	BIOCLASS	Nuclear hormone receptor
T58921	SEQUENCE	MGETLGDSPIDPESDSFTDTLSANISQEMTMVDTEMPFWPTNFGISSVDLSVMEDHSHSFDIKPFTTVDFSSISTPHYEDIPFTRTDPVVADYKYDLKLQEYQSAIKVEPASPPYYSEKTQLYNKPHEEPSNSLMAIECRVCGDKASGFHYGVHACEGCKGFFRRTIRLKLIYDRCDLNCRIHKKSRNKCQYCRFQKCLAVGMSHNAIRFGRMPQAEKEKLLAEISSDIDQLNPESADLRALAKHLYDSYIKSFPLTKAKARAILTGKTTDKSPFVIYDMNSLMMGEDKIKFKHITPLQEQSKEVAIRIFQGCQFRSVEAVQEITEYAKSIPGFVNLDLNDQVTLLKYGVHEIIYTMLASLMNKDGVLISEGQGFMTREFLKSLRKPFGDFMEPKFEFAVKFNALELDDSDLAIFIAVIILSGDRPGLLNVKPIEDIQDNLLQALELQLKLNHPESSQLFAKLLQKMTDLRQIVTEHVQLLQVIKKTETDMSLHPLLQEIYKDLY
T58921	DRUGINFO	D03OFF	Pioglitazone	Approved
T58921	DRUGINFO	D06XZW	Troglitazone	Approved
T58921	DRUGINFO	D0K5ER	Rosiglitazone XR	Approved
T58921	DRUGINFO	D0K8IX	Thiazolidinedione	Approved
T58921	DRUGINFO	D04BCB	Lobeglitazone	Approved
T58921	DRUGINFO	D0S2BV	Glitazone	Phase 4
T58921	DRUGINFO	D08PFA	Rivoglitazone	Phase 3
T58921	DRUGINFO	D0F3NH	Balaglitazone	Phase 3
T58921	DRUGINFO	D0M0SS	FARGLITAZAR	Phase 3
T58921	DRUGINFO	D0Q6IW	Rosiglitazone + simvastatin	Phase 3
T58921	DRUGINFO	DCA13V	Leriglitazone	Phase 3
T58921	DRUGINFO	D02NHD	Ragaglitazar	Phase 3
T58921	DRUGINFO	D0F5JH	CS-038	Phase 3
T58921	DRUGINFO	D0H1NL	TESAGLITAZAR	Phase 3
T58921	DRUGINFO	D0M3UT	MURAGLITAZAR	Phase 3
T58921	DRUGINFO	D0T7MN	ZYH-1	Phase 3
T58921	DRUGINFO	D0VU5M	Imiglitazar	Phase 3
T58921	DRUGINFO	D0A1AQ	Rosiglitazone + metformin	Phase 3
T58921	DRUGINFO	D0X7VB	MBX-102	Phase 2/3
T58921	DRUGINFO	D00PJJ	FK-614	Phase 2
T58921	DRUGINFO	D02TGD	Netoglitazone	Phase 2
T58921	DRUGINFO	D08NPG	MBX-2044	Phase 2
T58921	DRUGINFO	D0E6ME	GED-0507-34-Levo	Phase 2
T58921	DRUGINFO	D0P5SU	CHS-131	Phase 2
T58921	DRUGINFO	D0W0JP	OMS405	Phase 2
T58921	DRUGINFO	D04BPS	Naveglitazar	Phase 2
T58921	DRUGINFO	D0PP8G	ONO-5129	Phase 2
T58921	DRUGINFO	D53BEH	T3D‐959	Phase 2
T58921	DRUGINFO	D0ZT8A	T3D-959	Phase 1/2
T58921	DRUGINFO	D06TWE	CLX-0921	Phase 1
T58921	DRUGINFO	D07IGC	DSP-8658	Phase 1
T58921	DRUGINFO	D08EEU	Englitazone sodium	Phase 1
T58921	DRUGINFO	D03RJZ	Oxeglitazar	Phase 1
T58921	DRUGINFO	D0AX9S	GW-409544	Phase 1
T58921	DRUGINFO	D03GFB	Spirolaxine derivative 1	Patented
T58921	DRUGINFO	D09OXG	Phenylpropionic acid derivative 1	Patented
T58921	DRUGINFO	D0E9GF	A-substituted phenylpropionic acid derivative 1	Patented
T58921	DRUGINFO	D0G3KY	PMID25416646-Compound-Figure2-K	Patented
T58921	DRUGINFO	D0GG5K	PMID25416646-Compound-Figure2-N	Patented
T58921	DRUGINFO	D0H5FI	MRL24	Patented
T58921	DRUGINFO	D0HT9C	Sulfonamide derivative 18	Patented
T58921	DRUGINFO	D0M4RD	Crystalline anhydrous toluene derivative 1	Patented
T58921	DRUGINFO	D0M5YQ	A-substituted phenylpropionic acid derivative 2	Patented
T58921	DRUGINFO	D0O8PR	Biaromatic compound 1	Patented
T58921	DRUGINFO	D0PO7F	MRL20	Patented
T58921	DRUGINFO	D0SL0K	Fused ring compound 1	Patented
T58921	DRUGINFO	D0SV6U	3-phenyl acrylic acid derivative 1	Patented
T58921	DRUGINFO	D0TF0T	Thiazolidine dione crystalline derivative 1	Patented
T58921	DRUGINFO	D0UG1W	Fused aromatic compound 1	Patented
T58921	DRUGINFO	D0UH5B	PMID25416646-Compound-Figure2-J	Patented
T58921	DRUGINFO	D0ZO0D	Cannabinoid quinone derivative 1	Patented
T58921	DRUGINFO	D05AUY	PMID25416646-Compound-Figure5-H	Patented
T58921	DRUGINFO	D0HW6Y	Flavonoid derivative 8	Patented
T58921	DRUGINFO	D0LA6O	PMID25416646-Compound-Figure5-E	Patented
T58921	DRUGINFO	D0NF8V	Phenylpyridine derivative 3	Patented
T58921	DRUGINFO	D0O5IN	PMID25416646-Compound-Figure5-A	Patented
T58921	DRUGINFO	D0U6AW	1-(biphenyl-4-yl-methyl)-1H-imidazole derivative 1	Patented
T58921	DRUGINFO	D0V0JN	PMID25416646-Compound-Figure5-C	Patented
T58921	DRUGINFO	D0KL3K	YM-440	Discontinued in Phase 2
T58921	DRUGINFO	D02RAU	KRP-297	Discontinued in Phase 2
T58921	DRUGINFO	D02ZKL	Reglixane	Discontinued in Phase 2
T58921	DRUGINFO	D0W2IU	AVE-0847	Discontinued in Phase 2
T58921	DRUGINFO	D01JGG	Sodelglitazar	Discontinued in Phase 2
T58921	DRUGINFO	D09OHP	Indeglitazar	Discontinued in Phase 2
T58921	DRUGINFO	D0S6KX	GSK-677954	Discontinued in Phase 2
T58921	DRUGINFO	D0Z6OI	DS-6930	Discontinued in Phase 1
T58921	DRUGINFO	D06PHO	E-3030	Discontinued in Phase 1
T58921	DRUGINFO	D0B0EB	LY-929	Discontinued in Phase 1
T58921	DRUGINFO	D03GWY	Ciglitazone	Preclinical
T58921	DRUGINFO	D08WOE	MC-3002	Preclinical
T58921	DRUGINFO	D00YGA	SB-219994	Terminated
T58921	DRUGINFO	D04JVX	AKP-320	Terminated
T58921	DRUGINFO	D08VKZ	Edaglitazone	Terminated
T58921	DRUGINFO	D0N1EF	DARGLITAZONE	Terminated
T58921	DRUGINFO	D0I0RF	BVT-142	Terminated
T58921	DRUGINFO	D0LB4T	AD-5075	Terminated
T58921	DRUGINFO	D0OW6Z	Sipoglitazar	Terminated
T58921	DRUGINFO	D0V0TT	CS-204	Terminated
T58921	DRUGINFO	D01PGU	15-deoxy-Delta(12, 14)-prostaglandin J(2)	Investigative
T58921	DRUGINFO	D06MDX	(2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid	Investigative
T58921	DRUGINFO	D0E5HC	3-(5-methoxy-1H-indol-3-yl)propanoic acid	Investigative
T58921	DRUGINFO	D0H4US	(2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid	Investigative
T58921	DRUGINFO	D0J3UU	(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid	Investigative
T58921	DRUGINFO	D0O2US	GW7845	Investigative
T58921	DRUGINFO	D0Z5TV	(9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid	Investigative
T58921	DRUGINFO	D01POG	GW-2331	Investigative
T58921	DRUGINFO	D0SZ4T	9-hydroxyoctadecadienoic acid	Investigative
T58921	DRUGINFO	D0Z4MH	ZY H2	Investigative
T58921	DRUGINFO	D00ACX	2-chloro-5-nitro-N-phenylbenzamide	Investigative
T58921	DRUGINFO	D01ARG	DB-900	Investigative

T60857	TARGETID	T60857
T60857	FORMERID	TTDR00033
T60857	UNIPROID	AK1C3_HUMAN
T60857	TARGNAME	Dihydrodiol dehydrogenase type I (AKR1C3)
T60857	GENENAME	AKR1C3
T60857	TARGTYPE	Successful
T60857	SYNONYMS	Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase; Testosterone 17-beta-dehydrogenase 5; Prostaglandin F synthase; PGFS; KIAA0119; Indanol dehydrogenase; HSD17B5; HA1753; Dihydrodiol dehydrogenase 3; DDH1; DD3; DD-3; Chlordecone reductase homolog HAKRb; Aldo-keto reductase family 1 member C3; 3-alpha-hydroxysteroid dehydrogenase type 2; 3-alpha-HSD type II, brain; 3-alpha-HSD type 2; 17-beta-hydroxysteroid dehydrogenase type 5; 17-beta-HSD 5
T60857	FUNCTION	Catalyzes the conversion of aldehydes and ketones to alcohols. Catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta-PGF2 to PGD2. Functions as a bi-directional 3-alpha-, 17-beta- and 20-alpha HSD. Can interconvert active androgens, estrogens and progestins with their cognate inactive metabolites. Preferentially transforms androstenedione (4-dione) to testosterone.
T60857	PDBSTRUC	6GXK; 6F78; 6F2U; 5JM5; 5HNU
T60857	BIOCLASS	Short-chain dehydrogenases reductase
T60857	ECNUMBER	EC 1.-.-.-
T60857	SEQUENCE	MDSKHQCVKLNDGHFMPVLGFGTYAPPEVPRSKALEVTKLAIEAGFRHIDSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWSTFHRPELVRPALENSLKKAQLDYVDLYLIHSPMSLKPGEELSPTDENGKVIFDIVDLCTTWEAMEKCKDAGLAKSIGVSNFNRRQLEMILNKPGLKYKPVCNQVECHPYFNRSKLLDFCKSKDIVLVAYSALGSQRDKRWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTAEDMKAIDGLDRNLHYFNSDSFASHPNYPYSDEY
T60857	DRUGINFO	D0B2WJ	Flufenamic Acid	Approved
T60857	DRUGINFO	D0H7XJ	ASP-9521	Phase 1/2
T60857	DRUGINFO	D02JPV	N-(benzimidazole/indole) benzoic acid derivative 2	Patented
T60857	DRUGINFO	D05GKS	N-(phenylamino)-benzoate derivative 1	Patented
T60857	DRUGINFO	D0E2TY	Indomethacin analog 3	Patented
T60857	DRUGINFO	D0F0PK	Indomethacin analog 2	Patented
T60857	DRUGINFO	D0G8VB	Beta-naphthylacetic acids derivative 1	Patented
T60857	DRUGINFO	D0GY2Z	Indomethacin analog 1	Patented
T60857	DRUGINFO	D0M6LX	N-(naphthylamino)-benzoate derivative 1	Patented
T60857	DRUGINFO	D0N3XY	N-(benzimidazolylcarbonyl)-piperidine derivative 1	Patented
T60857	DRUGINFO	D0PI1W	Nitrogen/sulfur-substituted estrene derivative 1	Patented
T60857	DRUGINFO	D0Q8RC	N-(indolylcarbonyl)-piperidine derivative 1	Patented
T60857	DRUGINFO	D0S6TL	N-(benzimidazole/indole) benzoic acid derivative 1	Patented
T60857	DRUGINFO	D0SM2O	N-(pyridinepyrroylylcarbonyl)-piperidine derivative 1	Patented
T60857	DRUGINFO	D0Y7XJ	Isoquinolone derivative 1	Patented
T60857	DRUGINFO	D00DDO	3-Bromo-5-phenylsalicylc acid	Investigative
T60857	DRUGINFO	D00XMO	2-(4-chlorobenzylidene)cyclopentyl ethyl ether	Investigative
T60857	DRUGINFO	D03POE	2-[(2,2-diphenylacetyl)amino]benzoic acid	Investigative
T60857	DRUGINFO	D09ALJ	Rutin	Investigative
T60857	DRUGINFO	D0DF1Z	M-Phenoxybenzoic Acid For Cis-Isomer	Investigative
T60857	DRUGINFO	D0K9YS	EM1396	Investigative
T60857	DRUGINFO	D0MC5H	2-(4-Chlorobenzylidene)cyclopentanone	Investigative
T60857	DRUGINFO	D0Q9RA	2-(4-chlorobenzylidene)cyclopentylmethyl ether	Investigative
T60857	DRUGINFO	D0V5AQ	2,2-Dibenzylcyclopentanol	Investigative
T60857	DRUGINFO	D0Z0IR	3-Phenylcyclopentanecarboxylic acid	Investigative
T60857	DRUGINFO	D0ZR1V	EM-1424	Investigative
T60857	DRUGINFO	D0M8RO	4-ANDROSTENE-3-17-DIONE	Investigative
T60857	DRUGINFO	D0J2FY	2'-Monophosphoadenosine 5'-Diphosphoribose	Investigative
T60857	DRUGINFO	D06GOK	2-Methyl-2,4-Pentanediol	Investigative
T60857	DRUGINFO	D0F2ME	Acetate Ion	Investigative

T80276	TARGETID	T80276
T80276	FORMERID	TTDNC00388
T80276	UNIPROID	PK3CA_HUMAN
T80276	TARGNAME	PI3-kinase alpha (PIK3CA)
T80276	GENENAME	PIK3CA
T80276	TARGTYPE	Successful
T80276	SYNONYMS	p110alpha; Serine/threonine protein kinase PIK3CA; PtdIns3kinase subunit p110alpha; PtdIns3kinase subunit alpha; PtdIns-3-kinase subunit p110-alpha; PtdIns-3-kinase subunit alpha; Phosphoinositide3kinase catalytic alpha polypeptide; Phosphoinositide-3-kinase catalytic alpha polypeptide; Phosphatidylinositol 4,5bisphosphate 3kinase catalytic subunit alpha isoform; Phosphatidylinositol 4,5bisphosphate 3kinase 110 kDa catalytic subunit alpha; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha; PI3kinase subunit alpha; PI3Kalpha; PI3K-alpha; PI3-kinase subunit alpha
T80276	FUNCTION	Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns (Phosphatidylinositol), PtdIns4P (Phosphatidylinositol 4-phosphate) and PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Participates in cellular signaling in response to various growth factors. Involved in the activation of AKT1 upon stimulation by receptor tyrosine kinases ligands such as EGF, insulin, IGF1, VEGFA and PDGF. Involved in signaling via insulin-receptor substrate (IRS) proteins. Essential in endothelial cell migration during vascular development through VEGFA signaling, possibly by regulating RhoA activity. Required for lymphatic vasculature development, possibly by binding to RAS and by activation by EGF and FGF2, but not by PDGF. Regulates invadopodia formation through the PDPK1-AKT1 pathway. Participates in cardiomyogenesis in embryonic stem cells through a AKT1 pathway. Participates in vasculogenesis in embryonic stem cells through PDK1 and protein kinase C pathway. Also has serine-protein kinase activity: phosphorylates PIK3R1 (p85alpha regulatory subunit), EIF4EBP1 and HRAS. Plays a role in the positive regulation of phagocytosis and pinocytosis.
T80276	PDBSTRUC	6NCT; 5XGJ; 5XGI; 5XGH; 5UL1
T80276	BIOCLASS	Kinase
T80276	ECNUMBER	EC 2.7.1.153
T80276	SEQUENCE	MPPRPSSGELWGIHLMPPRILVECLLPNGMIVTLECLREATLITIKHELFKEARKYPLHQLLQDESSYIFVSVTQEAEREEFFDETRRLCDLRLFQPFLKVIEPVGNREEKILNREIGFAIGMPVCEFDMVKDPEVQDFRRNILNVCKEAVDLRDLNSPHSRAMYVYPPNVESSPELPKHIYNKLDKGQIIVVIWVIVSPNNDKQKYTLKINHDCVPEQVIAEAIRKKTRSMLLSSEQLKLCVLEYQGKYILKVCGCDEYFLEKYPLSQYKYIRSCIMLGRMPNLMLMAKESLYSQLPMDCFTMPSYSRRISTATPYMNGETSTKSLWVINSALRIKILCATYVNVNIRDIDKIYVRTGIYHGGEPLCDNVNTQRVPCSNPRWNEWLNYDIYIPDLPRAARLCLSICSVKGRKGAKEEHCPLAWGNINLFDYTDTLVSGKMALNLWPVPHGLEDLLNPIGVTGSNPNKETPCLELEFDWFSSVVKFPDMSVIEEHANWSVSREAGFSYSHAGLSNRLARDNELRENDKEQLKAISTRDPLSEITEQEKDFLWSHRHYCVTIPEILPKLLLSVKWNSRDEVAQMYCLVKDWPPIKPEQAMELLDCNYPDPMVRGFAVRCLEKYLTDDKLSQYLIQLVQVLKYEQYLDNLLVRFLLKKALTNQRIGHFFFWHLKSEMHNKTVSQRFGLLLESYCRACGMYLKHLNRQVEAMEKLINLTDILKQEKKDETQKVQMKFLVEQMRRPDFMDALQGFLSPLNPAHQLGNLRLEECRIMSSAKRPLWLNWENPDIMSELLFQNNEIIFKNGDDLRQDMLTLQIIRIMENIWQNQGLDLRMLPYGCLSIGDCVGLIEVVRNSHTIMQIQCKGGLKGALQFNSHTLHQWLKDKNKGEIYDAAIDLFTRSCAGYCVATFILGIGDRHNSNIMVKDDGQLFHIDFGHFLDHKKKKFGYKRERVPFVLTQDFLIVISKGAQECTKTREFERFQEMCYKAYLAIRQHANLFINLFSMMLGSGMPELQSFDDIAYIRKTLALDKTEQEALEYFMKQMNDAHHGGWTTKMDWIFHTIKQHALN
T80276	DRUGINFO	D0W7HE	Alpelisib	Approved
T80276	DRUGINFO	D0S5LD	BAY 80-6946	Approved
T80276	DRUGINFO	D0UP1Z	GDC-0032	Phase 3
T80276	DRUGINFO	D01QSO	Buparlisib	Phase 3
T80276	DRUGINFO	D0H1WC	LY3023414	Phase 2
T80276	DRUGINFO	D0Y2NS	MLN1117	Phase 1/2
T80276	DRUGINFO	D05CBJ	PA-799	Phase 1/2
T80276	DRUGINFO	D01LMM	BLY719	Phase 1
T80276	DRUGINFO	D8IJR1	LY3849524	Phase 1
T80276	DRUGINFO	DYF2N4	HHCYH33	Phase 1
T80276	DRUGINFO	D0Y0FE	PWT-33597	Phase 1
T80276	DRUGINFO	DOR1I0	ETP-46321	Investigative

T62431	TARGETID	T62431
T62431	FORMERID	TTDC00156
T62431	UNIPROID	KSYK_HUMAN
T62431	TARGNAME	Tyrosine-protein kinase SYK (SYK)
T62431	GENENAME	SYK
T62431	TARGTYPE	Successful
T62431	SYNONYMS	p72-Syk; Spleen tyrosine kinase
T62431	FUNCTION	Regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. Assembles into signaling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosine-phosphorylated ITAM domains. The association with the receptor can also be indirect and mediated by adapter proteins containing ITAM or partial hemITAM domains. The phosphorylation of the ITAM domains is generally mediated by SRC subfamily kinases upon engagement of the receptor. More rarely signal transduction via SYK could be ITAM-independent. Direct downstream effectors phosphorylated by SYK include VAV1, PLCG1, PI-3-kinase, LCP2 and BLNK. Initially identified as essential in B-cell receptor (BCR) signaling, it is necessary for the maturation of B-cells most probably at the pro-B to pre-B transition. Activated upon BCR engagement, it phosphorylates and activates BLNK an adapter linking the activated BCR to downstream signaling adapters and effectors. It also phosphorylates and activates PLCG1 and the PKC signaling pathway. It also phosphorylates BTK and regulates its activity in B-cell antigen receptor (BCR)-coupled signaling. In addition to its function downstream of BCR plays also a role in T-cell receptor signaling. Plays also a crucial role in the innate immune response to fungal, bacterial and viral pathogens. It is for instance activated by the membrane lectin CLEC7A. Upon stimulation by fungal proteins, CLEC7A together with SYK activates immune cells inducing the production of ROS. Also activates the inflammasome and NF-kappa-B-mediated transcription of chemokines and cytokines in presence of pathogens. Regulates neutrophil degranulation and phagocytosis through activation of the MAPK signaling cascade. Required for the stimulation of neutrophil phagocytosis by IL15. Also mediates the activation of dendritic cells by cell necrosis stimuli. Also involved in mast cells activation. Involved in interleukin-3/IL3-mediated signaling pathway in basophils. Also functions downstream of receptors mediating cell adhesion. Relays for instance, integrin-mediated neutrophils and macrophages activation and P-selectin receptor/SELPG-mediated recruitment of leukocytes to inflammatory loci. Plays also a role in non-immune processes. It is for instance involved in vascular development where it may regulate blood and lymphatic vascular separation. It is also required for osteoclast development and function. Functions in the activation of platelets by collagen, mediating PLCG2 phosphorylation and activation. May be coupled to the collagen receptor by the ITAM domain-containing FCER1G. Also activated by the membrane lectin CLEC1B that is required for activation of platelets by PDPN/podoplanin. Involved in platelet adhesion being activated by ITGB3 engaged by fibrinogen. Together with CEACAM20, enhances production of the cytokine CXCL8/IL-8 via the NFKB pathway and may thus have a role in the intestinal immune response. Non-receptor tyrosine kinase which mediates signal transduction downstream of a variety of transmembrane receptors including classical immunoreceptors like the B-cell receptor (BCR).
T62431	PDBSTRUC	6HM7; 6HM6; 5Y5U; 5Y5T; 5TT7
T62431	BIOCLASS	Kinase
T62431	ECNUMBER	EC 2.7.10.2
T62431	SEQUENCE	MASSGMADSANHLPFFFGNITREEAEDYLVQGGMSDGLYLLRQSRNYLGGFALSVAHGRKAHHYTIERELNGTYAIAGGRTHASPADLCHYHSQESDGLVCLLKKPFNRPQGVQPKTGPFEDLKENLIREYVKQTWNLQGQALEQAIISQKPQLEKLIATTAHEKMPWFHGKISREESEQIVLIGSKTNGKFLIRARDNNGSYALCLLHEGKVLHYRIDKDKTGKLSIPEGKKFDTLWQLVEHYSYKADGLLRVLTVPCQKIGTQGNVNFGGRPQLPGSHPATWSAGGIISRIKSYSFPKPGHRKSSPAQGNRQESTVSFNPYEPELAPWAADKGPQREALPMDTEVYESPYADPEEIRPKEVYLDRKLLTLEDKELGSGNFGTVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAEANVMQQLDNPYIVRMIGICEAESWMLVMEMAELGPLNKYLQQNRHVKDKNIIELVHQVSMGMKYLEESNFVHRDLAARNVLLVTQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYAPECINYYKFSSKSDVWSFGVLMWEAFSYGQKPYRGMKGSEVTAMLEKGERMGCPAGCPREMYDLMNLCWTYDVENRPGFAAVELRLRNYYYDVVN
T62431	DRUGINFO	D0V8HJ	Fostamatinib	Approved
T62431	DRUGINFO	D00OPX	Fostamatinib disodium	Phase 3
T62431	DRUGINFO	D0BW6F	GS-9876	Phase 2
T62431	DRUGINFO	D0G9AW	GS-9973	Phase 2
T62431	DRUGINFO	DY57LN	Cevidoplenib	Phase 2
T62431	DRUGINFO	D06KTJ	TAK-659	Phase 2
T62431	DRUGINFO	D0BI3N	Cerdulatinib	Phase 2
T62431	DRUGINFO	DI1VM3	HM43239	Phase 1/2
T62431	DRUGINFO	D2JZ3U	ALXN2075	Phase 1/2
T62431	DRUGINFO	D01IDW	SKI-O-703	Phase 1
T62431	DRUGINFO	D0C0SZ	PRT6207	Phase 1
T62431	DRUGINFO	D0H2HZ	GSK2646264	Phase 1
T62431	DRUGINFO	D0R9IU	PRT-062607	Phase 1
T62431	DRUGINFO	D7CI9P	BI 894416	Phase 1
T62431	DRUGINFO	DODG42	HMPL-523	Phase 1
T62431	DRUGINFO	DG2EK3	PUR1800	Phase 1
T62431	DRUGINFO	D0S6TK	tamatinib	Clinical trial
T62431	DRUGINFO	D0CD6Y	Pyrimidopyridazinone derivative 1	Patented
T62431	DRUGINFO	D0JU1R	Pyrrolo-pyrazine derivative 3	Patented
T62431	DRUGINFO	D0Y6ON	Pyrrolo-pyrazine derivative 4	Patented
T62431	DRUGINFO	D0WA1V	Pyrimidopyridazinone derivative 2	Patented
T62431	DRUGINFO	D08DBE	R-343	Discontinued in Phase 2
T62431	DRUGINFO	D0Y2XQ	PF-3526299	Discontinued in Phase 1
T62431	DRUGINFO	D00EIL	CG-103065	Investigative
T62431	DRUGINFO	D04LGK	VRT-750018	Investigative
T62431	DRUGINFO	D09KEB	PRT-060318	Investigative
T62431	DRUGINFO	D0C7AS	N-Benzyl-4-(2,5-dihydroxy-benzylamino)-benzamide	Investigative
T62431	DRUGINFO	D0J3FK	DNX-2000	Investigative
T62431	DRUGINFO	D03YUW	SBB007833	Investigative
T62431	DRUGINFO	D0O6OH	PMID23312943C21	Investigative
T62431	DRUGINFO	D0T4MJ	K00592a	Investigative
T62431	DRUGINFO	D04TLI	PMID17600705C23	Investigative
T62431	DRUGINFO	D0A1CM	ELLAGIC ACID	Investigative

T97613	TARGETID	T97613
T97613	FORMERID	TTDI01766
T97613	UNIPROID	MTR1A_HUMAN
T97613	TARGNAME	Melatonin receptor type 1A (MTNR1A)
T97613	GENENAME	MTNR1A
T97613	TARGTYPE	Successful
T97613	SYNONYMS	Mel1a receptor; Mel1AR; Mel-1A-R
T97613	FUNCTION	Likely to mediate the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that inhibit adenylate cyclase activity. High affinity receptor for melatonin.
T97613	PDBSTRUC	6ME5; 6ME4; 6ME3; 6ME2
T97613	BIOCLASS	GPCR rhodopsin
T97613	SEQUENCE	MQGNGSALPNASQPVLRGDGARPSWLASALACVLIFTIVVDILGNLLVILSVYRNKKLRNAGNIFVVSLAVADLVVAIYPYPLVLMSIFNNGWNLGYLHCQVSGFLMGLSVIGSIFNITGIAINRYCYICHSLKYDKLYSSKNSLCYVLLIWLLTLAAVLPNLRAGTLQYDPRIYSCTFAQSVSSAYTIAVVVFHFLVPMIIVIFCYLRIWILVLQVRQRVKPDRKPKLKPQDFRNFVTMFVVFVLFAICWAPLNFIGLAVASDPASMVPRIPEWLFVASYYMAYFNSCLNAIIYGLLNQNFRKEYRRIIVSLCTARVFFVDSSNDVADRVKWKPSPLMTNNNVVKVDSV
T97613	DRUGINFO	D0AN7B	Melatonin	Approved
T97613	DRUGINFO	D0Q5MQ	Tasimelteon	Approved
T97613	DRUGINFO	D0U0KW	Ramelteon	Approved
T97613	DRUGINFO	D0D8FN	LY-156735	Phase 2
T97613	DRUGINFO	D00CVJ	Neu-P11	Phase 2
T97613	DRUGINFO	D0Y8UB	Agomelatine	Withdrawn from market
T97613	DRUGINFO	D01ESJ	Luzindole	Terminated
T97613	DRUGINFO	D05GOM	S-20928	Terminated
T97613	DRUGINFO	D0B1VQ	GR-133347	Terminated
T97613	DRUGINFO	D0B2CQ	GR-131663	Terminated
T97613	DRUGINFO	D0T4XV	SL-18.1616	Terminated
T97613	DRUGINFO	D01SNS	IIK7	Investigative
T97613	DRUGINFO	D01YDR	[125I]SD6	Investigative
T97613	DRUGINFO	D02VIZ	GR 196429	Investigative
T97613	DRUGINFO	D03OGA	2-methoxy-alpha,beta-didehydro-agomelatine	Investigative
T97613	DRUGINFO	D04BLO	difluoroagomelatine	Investigative
T97613	DRUGINFO	D04VGL	4P-PDOT	Investigative
T97613	DRUGINFO	D04YWX	S22153	Investigative
T97613	DRUGINFO	D06AUM	S26284	Investigative
T97613	DRUGINFO	D07BKH	(hydroxymethylphenyl)agomelatine	Investigative
T97613	DRUGINFO	D07EOD	S24773	Investigative
T97613	DRUGINFO	D07FDL	N-(2,3-Dihydro-1H-phenalen-2-yl)-acetamide	Investigative
T97613	DRUGINFO	D07MFG	CBOBNEA	Investigative
T97613	DRUGINFO	D07YFL	EFPPEA	Investigative
T97613	DRUGINFO	D08SGV	5-HEAT	Investigative
T97613	DRUGINFO	D08TBF	BOMPPA	Investigative
T97613	DRUGINFO	D08WOV	2-[125I]melatonin	Investigative
T97613	DRUGINFO	D08ZJM	isoamyl-agomelatine	Investigative
T97613	DRUGINFO	D09HWZ	[125I]S70254	Investigative
T97613	DRUGINFO	D09LPG	GR 128107	Investigative
T97613	DRUGINFO	D0B8PD	6-Cl-MLT	Investigative
T97613	DRUGINFO	D0F9ZW	N-acetylserotonin	Investigative
T97613	DRUGINFO	D0I4DJ	AAE-M-PBP-amine	Investigative
T97613	DRUGINFO	D0K1HD	UCM 793	Investigative
T97613	DRUGINFO	D0OY8Y	UCM 549	Investigative
T97613	DRUGINFO	D0Q0LH	S24014	Investigative
T97613	DRUGINFO	D0Q3WV	[125I]DIV880	Investigative
T97613	DRUGINFO	D0R5JD	S26131	Investigative
T97613	DRUGINFO	D0RF4L	5-methoxy-luzindole	Investigative
T97613	DRUGINFO	D0S3NS	2-(indolin-1yl)-melatonin	Investigative
T97613	DRUGINFO	D0S6SN	6-hydroxymelatonin	Investigative
T97613	DRUGINFO	D0TM0N	UCM 765	Investigative
T97613	DRUGINFO	D0WE4C	K185	Investigative
T97613	DRUGINFO	D0XX9Y	DH97	Investigative
T97613	DRUGINFO	D0Y2JY	CIFEA	Investigative
T97613	DRUGINFO	D0YN8Q	UCM 724	Investigative
T97613	DRUGINFO	D01FVY	N-(2,3,4,9-Tetrahydro-1H-carbazol-3-yl)-acetamide	Investigative
T97613	DRUGINFO	D01LAU	5-methoxycarbonylamino-N-acetyltryptamine	Investigative
T97613	DRUGINFO	D01UIY	N-(3-(2-ethoxy-5-methoxyphenyl)propyl)acetamide	Investigative
T97613	DRUGINFO	D05EDR	Beta-methylmelatonin	Investigative
T97613	DRUGINFO	D05WKI	UCM-454	Investigative
T97613	DRUGINFO	D07ZQU	N-(3-(4-hydroxy-3-methoxyphenyl)propyl)acetamide	Investigative
T97613	DRUGINFO	D09ETU	N-(3-(5-methoxy-2-propoxyphenyl)propyl)acetamide	Investigative
T97613	DRUGINFO	D0D6IK	N-(3-(3-methoxyphenyl)propyl)propionamide	Investigative
T97613	DRUGINFO	D0F6VI	N-(3-(2-hydroxy-5-methoxyphenyl)propyl)acetamide	Investigative
T97613	DRUGINFO	D0O2GK	N-(2-(5-methoxybenzofuran-3-yl)ethyl)acetamide	Investigative
T97613	DRUGINFO	D0Q6HT	Beta,beta-dimethylmelatonin	Investigative
T97613	DRUGINFO	D0U8OS	N-(3-(3-methoxyphenyl)propyl)acetamide	Investigative
T97613	DRUGINFO	D0V7VF	N-(3-(3-methoxyphenyl)-3-phenylallyl)acetamide	Investigative
T97613	DRUGINFO	D0W7ZB	N-(3-(2,5-dimethoxyphenyl)propyl)acetamide	Investigative
T97613	DRUGINFO	D0H6YF	2-iodo-melatonin	Investigative
T97613	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T95913	TARGETID	T95913
T95913	FORMERID	TTDR00356
T95913	UNIPROID	PK3CG_HUMAN
T95913	TARGNAME	PI3-kinase gamma (PIK3CG)
T95913	GENENAME	PIK3CG
T95913	TARGTYPE	Successful
T95913	SYNONYMS	p120-PI3K; p110gamma; Serine/threonine protein kinase PIK3CG; PtdIns-3-kinase subunit p110-gamma; PtdIns-3-kinase subunit gamma; PtdIns-3-kinase p110; Phosphoinositol-3 kinase; Phosphoinositide-3-kinase catalytic gamma polypeptide; Phosphoinositide 3-Kinase gamma; Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit gamma; PI3Kgamma; PI3K-gamma; PI3K; PI3-kinase subunit gamma; PI3-kinase p110 subunit gamma
T95913	FUNCTION	Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Links G-protein coupled receptor activation to PIP3 production. Involved in immune, inflammatory and allergic responses. Modulates leukocyte chemotaxis to inflammatory sites and in response to chemoattractant agents. May control leukocyte polarization and migration by regulating the spatial accumulation of PIP3 and by regulating the organization of F-actin formation and integrin-based adhesion at the leading edge. Controls motility of dendritic cells. Together with PIK3CD is involved in natural killer (NK) cell development and migration towards the sites of inflammation. Participates in T-lymphocyte migration. Regulates T-lymphocyte proliferation and cytokine production. Together with PIK3CD participates in T-lymphocyte development. Required for B-lymphocyte development and signaling. Together with PIK3CD participates in neutrophil respiratory burst. Together with PIK3CD is involved in neutrophil chemotaxis and extravasation. Together with PIK3CB promotes platelet aggregation and thrombosis. Regulates alpha-IIb/beta-3 integrins (ITGA2B/ ITGB3) adhesive function in platelets downstream of P2Y12 through a lipid kinase activity-independent mechanism. May have also a lipid kinase activity-dependent function in platelet aggregation. Involved in endothelial progenitor cell migration. Negative regulator of cardiac contractility. Modulates cardiac contractility by anchoring protein kinase A (PKA) and PDE3B activation, reducing cAMP levels. Regulates cardiac contractility also by promoting beta-adrenergic receptor internalization by binding to GRK2 and by non-muscle tropomyosin phosphorylation. Also has serine/threonine protein kinase activity: both lipid and protein kinase activities are required for beta-adrenergic receptor endocytosis. May also have a scaffolding role in modulating cardiac contractility. Contributes to cardiac hypertrophy under pathological stress. Through simultaneous binding of PDE3B to RAPGEF3 and PIK3R6 is assembled in a signaling complex in which the PI3K gamma complex is activated by RAPGEF3 and which is involved in angiogenesis.
T95913	PDBSTRUC	6GQ7; 6FH5; 6C1S; 6AUD; 5T23
T95913	BIOCLASS	Kinase
T95913	ECNUMBER	EC 2.7.1.153
T95913	SEQUENCE	MELENYKQPVVLREDNCRRRRRMKPRSAAASLSSMELIPIEFVLPTSQRKCKSPETALLHVAGHGNVEQMKAQVWLRALETSVAADFYHRLGPHHFLLLYQKKGQWYEIYDKYQVVQTLDCLRYWKATHRSPGQIHLVQRHPPSEESQAFQRQLTALIGYDVTDVSNVHDDELEFTRRGLVTPRMAEVASRDPKLYAMHPWVTSKPLPEYLWKKIANNCIFIVIHRSTTSQTIKVSPDDTPGAILQSFFTKMAKKKSLMDIPESQSEQDFVLRVCGRDEYLVGETPIKNFQWVRHCLKNGEEIHVVLDTPPDPALDEVRKEEWPLVDDCTGVTGYHEQLTIHGKDHESVFTVSLWDCDRKFRVKIRGIDIPVLPRNTDLTVFVEANIQHGQQVLCQRRTSPKPFTEEVLWNVWLEFSIKIKDLPKGALLNLQIYCGKAPALSSKASAESPSSESKGKVQLLYYVNLLLIDHRFLLRRGEYVLHMWQISGKGEDQGSFNADKLTSATNPDKENSMSISILLDNYCHPIALPKHQPTPDPEGDRVRAEMPNQLRKQLEAIIATDPLNPLTAEDKELLWHFRYESLKHPKAYPKLFSSVKWGQQEIVAKTYQLLARREVWDQSALDVGLTMQLLDCNFSDENVRAIAVQKLESLEDDDVLHYLLQLVQAVKFEPYHDSALARFLLKRGLRNKRIGHFLFWFLRSEIAQSRHYQQRFAVILEAYLRGCGTAMLHDFTQQVQVIEMLQKVTLDIKSLSAEKYDVSSQVISQLKQKLENLQNSQLPESFRVPYDPGLKAGALAIEKCKVMASKKKPLWLEFKCADPTALSNETIGIIFKHGDDLRQDMLILQILRIMESIWETESLDLCLLPYGCISTGDKIGMIEIVKDATTIAKIQQSTVGNTGAFKDEVLNHWLKEKSPTEEKFQAAVERFVYSCAGYCVATFVLGIGDRHNDNIMITETGNLFHIDFGHILGNYKSFLGINKERVPFVLTPDFLFVMGTSGKKTSPHFQKFQDICVKAYLALRHHTNLLIILFSMMLMTGMPQLTSKEDIEYIRDALTVGKNEEDAKKYFLDQIEVCRDKGWTVQFNWFLHLVLGIKQGEKHSA
T95913	DRUGINFO	D0RU0O	IPI-145	Approved
T95913	DRUGINFO	D0S5LD	BAY 80-6946	Approved
T95913	DRUGINFO	D0KF9Q	Rigosertib	Phase 3
T95913	DRUGINFO	D0UP1Z	GDC-0032	Phase 3
T95913	DRUGINFO	D0I6VU	Enzastaurin	Phase 3
T95913	DRUGINFO	D01QSO	Buparlisib	Phase 3
T95913	DRUGINFO	D03KAC	XL147	Phase 2
T95913	DRUGINFO	D03KHN	CLR-1404	Phase 2
T95913	DRUGINFO	D07BGC	GDC-0084	Phase 2
T95913	DRUGINFO	D08QGT	GDC0941	Phase 2
T95913	DRUGINFO	D0AW5T	PX-866	Phase 2
T95913	DRUGINFO	D0GW8X	GDC-0077	Phase 2
T95913	DRUGINFO	D0I3LO	IPI-549	Phase 2
T95913	DRUGINFO	D01PGR	SAR245409	Phase 2
T95913	DRUGINFO	D03NJY	SF1126	Phase 2
T95913	DRUGINFO	D0D8JB	PF-05212384	Phase 2
T95913	DRUGINFO	D0N5JZ	PF-04691502	Phase 2
T95913	DRUGINFO	D0O6VZ	GDC-0980/RG7422	Phase 2
T95913	DRUGINFO	D0VG0D	BEZ235	Phase 2
T95913	DRUGINFO	DQ62LM	AZD8154	Phase 2
T95913	DRUGINFO	D0TU7B	PQR309	Phase 2
T95913	DRUGINFO	D07ACZ	CLR457	Phase 1/2
T95913	DRUGINFO	D07MEX	CLR-1401	Phase 1/2
T95913	DRUGINFO	D0C3ZR	TG100-115	Phase 1/2
T95913	DRUGINFO	D0E6UZ	CUDC-907	Phase 1/2
T95913	DRUGINFO	D0X7IN	BGT226	Phase 1/2
T95913	DRUGINFO	DHX7S8	ZX-101A	Phase 1/2
T95913	DRUGINFO	D05CBJ	PA-799	Phase 1/2
T95913	DRUGINFO	D03EZE	GSK2126458	Phase 1
T95913	DRUGINFO	D09SFV	LY294002	Phase 1
T95913	DRUGINFO	D0J8MA	KA2237	Phase 1
T95913	DRUGINFO	D0O1LD	ZSTK474	Phase 1
T95913	DRUGINFO	D0R1VU	Perifosine	Phase 1
T95913	DRUGINFO	D0R8ID	P-7170	Phase 1
T95913	DRUGINFO	D03BHZ	AZD8186	Phase 1
T95913	DRUGINFO	D0X4RT	DS-7423	Phase 1
T95913	DRUGINFO	D0U3DP	VS-5584	Phase 1
T95913	DRUGINFO	D02CQL	Adyvia	Discontinued in Phase 2
T95913	DRUGINFO	D0L0ZC	GSK1059615	Discontinued in Phase 1
T95913	DRUGINFO	D0T5IN	PX-867	Terminated
T95913	DRUGINFO	D05SXC	SCR-44001	Terminated
T95913	DRUGINFO	D0P1JI	Wortmannin	Terminated
T95913	DRUGINFO	D00JIV	PF-4989216	Investigative
T95913	DRUGINFO	D00LZO	CZC-19091	Investigative
T95913	DRUGINFO	D02WGD	LOR-220	Investigative
T95913	DRUGINFO	D03DRM	AS-604850	Investigative
T95913	DRUGINFO	D03FIE	AEZS-126	Investigative
T95913	DRUGINFO	D04DBA	BAG956	Investigative
T95913	DRUGINFO	D06PWI	CZC 24832	Investigative
T95913	DRUGINFO	D07PMP	PKI-402	Investigative
T95913	DRUGINFO	D08RBS	WX-037	Investigative
T95913	DRUGINFO	D0J1CF	Her2- and PSA-targeted TGX-D1	Investigative
T95913	DRUGINFO	D0O6JE	Multiform PI3K inhibitors	Investigative
T95913	DRUGINFO	D0R2UG	HS-173	Investigative
T95913	DRUGINFO	D0T3PW	Myricetin	Investigative
T95913	DRUGINFO	D0W8XH	PI-103	Investigative
T95913	DRUGINFO	D01SSI	PI-3065	Investigative
T95913	DRUGINFO	D02ELN	HM-5016699	Investigative
T95913	DRUGINFO	D05BPX	3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol	Investigative
T95913	DRUGINFO	D05RSS	PF-03772304	Investigative
T95913	DRUGINFO	D06DNH	TGX-221	Investigative
T95913	DRUGINFO	D08NQM	5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE	Investigative
T95913	DRUGINFO	D0JD4S	CU-906	Investigative
T95913	DRUGINFO	D0QE9F	P-6915	Investigative
T95913	DRUGINFO	D00HSJ	PIK-75	Investigative
T95913	DRUGINFO	D0R0TW	KU-0060648	Investigative
T95913	DRUGINFO	D07APP	LY-292223	Investigative
T95913	DRUGINFO	D0W1ST	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	Investigative
T95913	DRUGINFO	D03EHM	PP121	Investigative

T48268	TARGETID	T48268
T48268	FORMERID	TTDS00422
T48268	UNIPROID	MTR1B_HUMAN
T48268	TARGNAME	Melatonin receptor type 1B (MTNR1B)
T48268	GENENAME	MTNR1B
T48268	TARGTYPE	Successful
T48268	SYNONYMS	Mel1b receptor; Mel1b melatonin receptor; Mel-1B-R
T48268	FUNCTION	Likely to mediate the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that inhibit adenylate cyclase activity. High affinity receptor for melatonin.
T48268	PDBSTRUC	6ME9; 6ME8; 6ME7; 6ME6
T48268	BIOCLASS	GPCR rhodopsin
T48268	SEQUENCE	MSENGSFANCCEAGGWAVRPGWSGAGSARPSRTPRPPWVAPALSAVLIVTTAVDVVGNLLVILSVLRNRKLRNAGNLFLVSLALADLVVAFYPYPLILVAIFYDGWALGEEHCKASAFVMGLSVIGSVFNITAIAINRYCYICHSMAYHRIYRRWHTPLHICLIWLLTVVALLPNFFVGSLEYDPRIYSCTFIQTASTQYTAAVVVIHFLLPIAVVSFCYLRIWVLVLQARRKAKPESRLCLKPSDLRSFLTMFVVFVIFAICWAPLNCIGLAVAINPQEMAPQIPEGLFVTSYLLAYFNSCLNAIVYGLLNQNFRREYKRILLALWNPRHCIQDASKGSHAEGLQSPAPPIIGVQHQADAL
T48268	DRUGINFO	D0Q5MQ	Tasimelteon	Approved
T48268	DRUGINFO	D0U0KW	Ramelteon	Approved
T48268	DRUGINFO	D0RL5B	VLB-01	Phase 3
T48268	DRUGINFO	D03AJW	N-(3-Benzooxazol-7-yl-propyl)-butyramide	Investigative
T48268	DRUGINFO	D03NND	N-(3-Benzooxazol-7-yl-propyl)-propionamide	Investigative
T48268	DRUGINFO	D05TRX	N-[3-(2-Ethyl-benzooxazol-7-yl)-propyl]-acetamide	Investigative
T48268	DRUGINFO	D0L9YA	N-(3-Benzooxazol-7-yl-propyl)-acetamide	Investigative
T48268	DRUGINFO	D01FVY	N-(2,3,4,9-Tetrahydro-1H-carbazol-3-yl)-acetamide	Investigative
T48268	DRUGINFO	D01LAU	5-methoxycarbonylamino-N-acetyltryptamine	Investigative
T48268	DRUGINFO	D01UIY	N-(3-(2-ethoxy-5-methoxyphenyl)propyl)acetamide	Investigative
T48268	DRUGINFO	D05EDR	Beta-methylmelatonin	Investigative
T48268	DRUGINFO	D05WKI	UCM-454	Investigative
T48268	DRUGINFO	D07ZQU	N-(3-(4-hydroxy-3-methoxyphenyl)propyl)acetamide	Investigative
T48268	DRUGINFO	D09ETU	N-(3-(5-methoxy-2-propoxyphenyl)propyl)acetamide	Investigative
T48268	DRUGINFO	D0D6IK	N-(3-(3-methoxyphenyl)propyl)propionamide	Investigative
T48268	DRUGINFO	D0F6VI	N-(3-(2-hydroxy-5-methoxyphenyl)propyl)acetamide	Investigative
T48268	DRUGINFO	D0O2GK	N-(2-(5-methoxybenzofuran-3-yl)ethyl)acetamide	Investigative
T48268	DRUGINFO	D0Q6HT	Beta,beta-dimethylmelatonin	Investigative
T48268	DRUGINFO	D0U8OS	N-(3-(3-methoxyphenyl)propyl)acetamide	Investigative
T48268	DRUGINFO	D0V7VF	N-(3-(3-methoxyphenyl)-3-phenylallyl)acetamide	Investigative
T48268	DRUGINFO	D0W7ZB	N-(3-(2,5-dimethoxyphenyl)propyl)acetamide	Investigative
T48268	DRUGINFO	D0H6YF	2-iodo-melatonin	Investigative

T76910	TARGETID	T76910
T76910	FORMERID	TTDS00136
T76910	UNIPROID	GSK3A_HUMAN
T76910	TARGNAME	Glycogen synthase kinase-3 alpha (GSK-3A)
T76910	GENENAME	GSK3A
T76910	TARGTYPE	Successful
T76910	SYNONYMS	Serine/threonineprotein kinase GSK3A; Serine/threonine-protein kinase GSK3A; Glycogen synthase kinase3 alpha; Glycogen synthase kinase 3; GSK3 alpha; GSK-3 alpha; GSK-3
T76910	FUNCTION	Requires primed phosphorylation of the majority of its substrates. Contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glycogen synthesis. Regulates glycogen metabolism in liver, but not in muscle. May also mediate the development of insulin resistance by regulating activation of transcription factors. In Wnt signaling, regulates the level and transcriptional activity of nuclear CTNNB1/beta-catenin. Facilitates amyloid precursor protein (APP) processing and the generation of APP-derived amyloid plaques found in Alzheimer disease. May be involved in the regulation of replication in pancreatic beta-cells. Is necessary for the establishment of neuronal polarity and axon outgrowth. Through phosphorylation of the anti-apoptotic protein MCL1, may control cell apoptosis in response to growth factors deprivation. Acts as a regulator of autophagy by mediating phosphorylation of KAT5/TIP60 under starvation conditions, leading to activate KAT5/TIP60 acetyltransferase activity and promote acetylation of key autophagy regulators, such as ULK1 and RUBCNL/Pacer. Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), CTNNB1/beta-catenin, APC and AXIN1.
T76910	PDBSTRUC	2DFM
T76910	BIOCLASS	Kinase
T76910	ECNUMBER	EC 2.7.11.26
T76910	SEQUENCE	MSGGGPSGGGPGGSGRARTSSFAEPGGGGGGGGGGPGGSASGPGGTGGGKASVGAMGGGVGASSSGGGPGGSGGGGSGGPGAGTSFPPPGVKLGRDSGKVTTVVATLGQGPERSQEVAYTDIKVIGNGSFGVVYQARLAETRELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFYSSGEKKDELYLNLVLEYVPETVYRVARHFTKAKLTIPILYVKVYMYQLFRSLAYIHSQGVCHRDIKPQNLLVDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSSIDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIKAHPWTKVFKSRTPPEAIALCSSLLEYTPSSRLSPLEACAHSFFDELRCLGTQLPNNRPLPPLFNFSAGELSIQPSLNAILIPPHLRSPAGTTTLTPSSQALTETPTSSDWQSTDATPTLTNSS
T76910	DRUGINFO	D0Y3KG	Valproate	Approved
T76910	DRUGINFO	D0Z1DH	LY2090314	Phase 2
T76910	DRUGINFO	D5MF8Y	Lithium	Phase 2
T76910	DRUGINFO	D01WAJ	PMID27828716-Compound-21	Patented
T76910	DRUGINFO	D02OGA	Thiadiazolidindione derivative 2	Patented
T76910	DRUGINFO	D03ETN	PMID27828716-Compound-18	Patented
T76910	DRUGINFO	D03SNE	PMID27828716-Compound-BIO-acetoxime	Patented
T76910	DRUGINFO	D04RDR	Quinoline derivative 15	Patented
T76910	DRUGINFO	D06ZRL	Quinolinyl pyrazinyl urea derivative 1	Patented
T76910	DRUGINFO	D08CWE	PMID27828716-Compound-19	Patented
T76910	DRUGINFO	D09PGW	Spiroquinolone derivative 1	Patented
T76910	DRUGINFO	D0A4QD	Quinoline derivative 14	Patented
T76910	DRUGINFO	D0CR2E	Thiadiazolidindione derivative 3	Patented
T76910	DRUGINFO	D0FV9Z	Pyrazolodihydropyridine derivative 1	Patented
T76910	DRUGINFO	D0I2RF	Indirubin derivative 2	Patented
T76910	DRUGINFO	D0J6UW	Maleimides derivative 3	Patented
T76910	DRUGINFO	D0J9YX	PMID27828716-Compound-17	Patented
T76910	DRUGINFO	D0M9JE	Pyrazole and benzimidazole derivative 1	Patented
T76910	DRUGINFO	D0NG2F	Maleimides derivative 1	Patented
T76910	DRUGINFO	D0NO7V	PMID27828716-Compound-20	Patented
T76910	DRUGINFO	D0P8RK	PMID27828716-Compound-16	Patented
T76910	DRUGINFO	D0QE2H	Thiadiazolidindione derivative 1	Patented
T76910	DRUGINFO	D0QW6B	Maleimides derivative 2	Patented
T76910	DRUGINFO	D0RD9V	Quinolinyl pyrazinyl urea derivative 2	Patented
T76910	DRUGINFO	D0UL2V	PMID27828716-Compound-15	Patented
T76910	DRUGINFO	D0UZ7I	N-naphtyl-N-benzylurea derivative 1	Patented
T76910	DRUGINFO	D0WX0K	Indazole derivative 6	Patented
T76910	DRUGINFO	D0XR7S	Tricyclic 5-quinolone derivative 1	Patented
T76910	DRUGINFO	D06KNK	TDZD-8	Patented
T76910	DRUGINFO	D0A3MV	AR-A014418	Patented
T76910	DRUGINFO	D0YK9D	CHIR-99021	Patented
T76910	DRUGINFO	D00PWQ	KENPAULLONE	Patented
T76910	DRUGINFO	D02BIK	AR-534	Investigative
T76910	DRUGINFO	D07WXT	Lithium chloride	Investigative
T76910	DRUGINFO	D0A1YQ	SB216763	Investigative
T76910	DRUGINFO	D0S7ZZ	Benzofuran-3-yl-(indol-3-yl)maleimides	Investigative
T76910	DRUGINFO	D06OAH	6-bromoindirubin-3-oxime	Investigative

T09960	TARGETID	T09960
T09960	FORMERID	TTDS00326
T09960	UNIPROID	CCR5_HUMAN
T09960	TARGNAME	C-C chemokine receptor type 5 (CCR5)
T09960	GENENAME	CCR5
T09960	TARGTYPE	Successful
T09960	SYNONYMS	HIV-1 fusion coreceptor; HIV-1 fusion co-receptor; Chemokine receptor CCR5; CMKBR5; CHEMR13; CD195 antigen; CD195; CCR-5; CC-CKR-5; C-C CKR-5
T09960	FUNCTION	May play a role in the control of granulocytic lineage proliferation or differentiation. Receptor for a number of inflammatory CC-chemokines including CCL3/MIP-1-alpha, CCL4/MIP-1-beta and RANTES and subsequently transduces a signal by increasing the intracellular calcium ion level.
T09960	PDBSTRUC	6MET; 6MEO; 6FGP; 5YY4; 5YD5
T09960	BIOCLASS	GPCR rhodopsin
T09960	SEQUENCE	MDYQVSSPIYDINYYTSEPCQKINVKQIAARLLPPLYSLVFIFGFVGNMLVILILINCKRLKSMTDIYLLNLAISDLFFLLTVPFWAHYAAAQWDFGNTMCQLLTGLYFIGFFSGIFFIILLTIDRYLAVVHAVFALKARTVTFGVVTSVITWVVAVFASLPGIIFTRSQKEGLHYTCSSHFPYSQYQFWKNFQTLKIVILGLVLPLLVMVICYSGILKTLLRCRNEKKRHRAVRLIFTIMIVYFLFWAPYNIVLLLNTFQEFFGLNNCSSSNRLDQAMQVTETLGMTHCCINPIIYAFVGEKFRNYLLVFFQKHIAKRFCKCCSIFQQEAPERASSVYTRSTGEQEISVGL
T09960	DRUGINFO	D0NR6S	Maraviroc	Approved
T09960	DRUGINFO	D09JLI	Vicriviroc	Phase 3
T09960	DRUGINFO	D0CG0N	PRO-140	Phase 3
T09960	DRUGINFO	D0J7QU	E-913	Phase 3
T09960	DRUGINFO	D1M8GC	PRO 140	Phase 2/3
T09960	DRUGINFO	D0Y7NA	INCB9471	Phase 2a
T09960	DRUGINFO	D06FIT	SB-728-T	Phase 2
T09960	DRUGINFO	D0F7PZ	PF-232798	Phase 2
T09960	DRUGINFO	D0UV4H	GSK-706769	Phase 2
T09960	DRUGINFO	D0B1SG	BMS-813160	Phase 2
T09960	DRUGINFO	D0YQ7U	Cenicriviroc	Phase 2
T09960	DRUGINFO	D0A0BK	Cal-1	Phase 1/2
T09960	DRUGINFO	D06KNE	INCB15050	Phase 1
T09960	DRUGINFO	D09XXH	VCH-286	Phase 1
T09960	DRUGINFO	D0K1OK	CCR5 mab	Phase 1
T09960	DRUGINFO	D0O9UC	Tak-220	Phase 1
T09960	DRUGINFO	D0G6SZ	GW873140	Discontinued in Phase 3
T09960	DRUGINFO	D06EMW	AZD8566	Discontinued in Phase 1
T09960	DRUGINFO	D0G6JE	SCH-C	Discontinued in Phase 1
T09960	DRUGINFO	D07GIB	AZD5672	Terminated
T09960	DRUGINFO	D0O9AZ	CCR5Qb	Terminated
T09960	DRUGINFO	D0W0LS	TAK-779	Terminated
T09960	DRUGINFO	D01LRC	ANIBAMINE	Investigative
T09960	DRUGINFO	D01TYO	SCH-210971	Investigative
T09960	DRUGINFO	D06TQD	CMPD-167	Investigative
T09960	DRUGINFO	D06XIC	VARIECOLIN	Investigative
T09960	DRUGINFO	D06XRS	N-(2-(4-chlorobenzyloxy)-5-bromobenzyl)ethanamine	Investigative
T09960	DRUGINFO	D0BD3G	4-(2-(4-chlorobenzyloxy)-5-bromobenzyl)morpholine	Investigative
T09960	DRUGINFO	D0BD6A	GT-1282	Investigative
T09960	DRUGINFO	D0I3IZ	(2-(4-chlorobenzyloxy)-5-bromophenyl)methanamine	Investigative
T09960	DRUGINFO	D0J3BT	NIFEVIROC	Investigative

T23172	TARGETID	T23172
T23172	FORMERID	TTDC00084
T23172	UNIPROID	JAK3_HUMAN
T23172	TARGNAME	Janus kinase 3 (JAK-3)
T23172	GENENAME	JAK3
T23172	TARGTYPE	Successful
T23172	SYNONYMS	Tyrosine-protein kinase JAK3; Leukocyte janus kinase; L-JAK
T23172	FUNCTION	Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, upon IL2R activation by IL2, JAK1 and JAK3 molecules bind to IL2R beta (IL2RB) and gamma chain (IL2RG) subunits inducing the tyrosine phosphorylation of both receptor subunits on their cytoplasmic domain. Then, STAT5A AND STAT5B are recruited, phosphorylated and activated by JAK1 and JAK3. Once activated, dimerized STAT5 translocates to the nucleus and promotes the transcription of specific target genes in a cytokine-specific fashion. Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation.
T23172	PDBSTRUC	6NY4; 6GLB; 6GLA; 6GL9; 6DUD
T23172	BIOCLASS	Kinase
T23172	ECNUMBER	EC 2.7.10.2
T23172	SEQUENCE	MAPPSEETPLIPQRSCSLLSTEAGALHVLLPARGPGPPQRLSFSFGDHLAEDLCVQAAKASGILPVYHSLFALATEDLSCWFPPSHIFSVEDASTQVLLYRIRFYFPNWFGLEKCHRFGLRKDLASAILDLPVLEHLFAQHRSDLVSGRLPVGLSLKEQGECLSLAVLDLARMAREQAQRPGELLKTVSYKACLPPSLRDLIQGLSFVTRRRIRRTVRRALRRVAACQADRHSLMAKYIMDLERLDPAGAAETFHVGLPGALGGHDGLGLLRVAGDGGIAWTQGEQEVLQPFCDFPEIVDISIKQAPRVGPAGEHRLVTVTRTDNQILEAEFPGLPEALSFVALVDGYFRLTTDSQHFFCKEVAPPRLLEEVAEQCHGPITLDFAINKLKTGGSRPGSYVLRRSPQDFDSFLLTVCVQNPLGPDYKGCLIRRSPTGTFLLVGLSRPHSSLRELLATCWDGGLHVDGVAVTLTSCCIPRPKEKSNLIVVQRGHSPPTSSLVQPQSQYQLSQMTFHKIPADSLEWHENLGHGSFTKIYRGCRHEVVDGEARKTEVLLKVMDAKHKNCMESFLEAASLMSQVSYRHLVLLHGVCMAGDSTMVQEFVHLGAIDMYLRKRGHLVPASWKLQVVKQLAYALNYLEDKGLPHGNVSARKVLLAREGADGSPPFIKLSDPGVSPAVLSLEMLTDRIPWVAPECLREAQTLSLEADKWGFGATVWEVFSGVTMPISALDPAKKLQFYEDRQQLPAPKWTELALLIQQCMAYEPVQRPSFRAVIRDLNSLISSDYELLSDPTPGALAPRDGLWNGAQLYACQDPTIFEERHLKYISQLGKGNFGSVELCRYDPLGDNTGALVAVKQLQHSGPDQQRDFQREIQILKALHSDFIVKYRGVSYGPGRQSLRLVMEYLPSGCLRDFLQRHRARLDASRLLLYSSQICKGMEYLGSRRCVHRDLAARNILVESEAHVKIADFGLAKLLPLDKDYYVVREPGQSPIFWYAPESLSDNIFSRQSDVWSFGVVLYELFTYCDKSCSPSAEFLRMMGCERDVPALCRLLELLEEGQRLPAPPACPAEVHELMKLCWAPSPQDRPSFSALGPQLDMLWSGSRGCETHAFTAHPEGKHHSLSFS
T23172	DRUGINFO	D02TUL	Ritlecitinib	Approved
T23172	DRUGINFO	D0EG1I	Tofacitinib	Approved
T23172	DRUGINFO	D0PN8H	Pacritinib	Approved
T23172	DRUGINFO	D05PCM	Abrocitinib	Approved
T23172	DRUGINFO	D06EIC	ASP-015K	Phase 3
T23172	DRUGINFO	D04QWQ	VX-509	Phase 2/3
T23172	DRUGINFO	D6INZ9	ATI-501	Phase 2
T23172	DRUGINFO	D6N5UC	ATI-502	Phase 2
T23172	DRUGINFO	D2KTG5	TD-8236	Phase 2
T23172	DRUGINFO	D0BI3N	Cerdulatinib	Phase 2
T23172	DRUGINFO	D2JZ3U	ALXN2075	Phase 1/2
T23172	DRUGINFO	D0Q0IM	SNA-125	Phase 1
T23172	DRUGINFO	DI19BZ	KN-002	Phase 1
T23172	DRUGINFO	DX72LV	AZD4604	Phase 1
T23172	DRUGINFO	DXVA93	PF-07295324	Phase 1
T23172	DRUGINFO	DZ2RH6	GDC-0214	Phase 1
T23172	DRUGINFO	D00ZVY	Pyrazolopyridine derivative 2	Patented
T23172	DRUGINFO	D09JLL	PMID27774822-Compound-Figure6Example3	Patented
T23172	DRUGINFO	D0EX5C	Pyrrolo-pyrazine derivative 1	Patented
T23172	DRUGINFO	D0HL5C	Pyrrolo-pyrazine derivative 2	Patented
T23172	DRUGINFO	D0QL7J	Tricyclic compound 2	Patented
T23172	DRUGINFO	D0SX1B	Benzimidazole derivative 5	Patented
T23172	DRUGINFO	D0T5AF	PMID27774824-Compound-Figure5Example13	Patented
T23172	DRUGINFO	D0VJ5M	Pyrazolopyridine derivative 1	Patented
T23172	DRUGINFO	D0WB5U	PMID27774822-Compound-Figure2Example4-3	Patented
T23172	DRUGINFO	D0X6DL	PMID27774822-Compound-Figure6Example2	Patented
T23172	DRUGINFO	D00BYK	PMID27774824-Compound-Figure12Example61	Patented
T23172	DRUGINFO	D00PTE	Imidazopyridazine derivative 2	Patented
T23172	DRUGINFO	D02IET	PMID27774824-Compound-Figure3Example7	Patented
T23172	DRUGINFO	D02VGC	Pyrazolopyridine derivative 6	Patented
T23172	DRUGINFO	D03TEE	Tricyclic heterocycle derivative 2	Patented
T23172	DRUGINFO	D07BND	Imidazopyridazine derivative 1	Patented
T23172	DRUGINFO	D0B9TH	PMID27774822-Compound-Figure8Example5	Patented
T23172	DRUGINFO	D0D1QH	Pyrazolopyridine derivative 7	Patented
T23172	DRUGINFO	D0E2WK	PMID27774822-Compound-Figure2Example1-1left	Patented
T23172	DRUGINFO	D0IQ6G	PMID27774822-Compound-Figure2Example1-1right	Patented
T23172	DRUGINFO	D0JU1R	Pyrrolo-pyrazine derivative 3	Patented
T23172	DRUGINFO	D0NK1R	PMID27774824-Compound-Figure12Example1	Patented
T23172	DRUGINFO	D0P3UH	Imidazopyridine derivative 4	Patented
T23172	DRUGINFO	D0UH8J	PMID27774824-Compound-Figure12Example10	Patented
T23172	DRUGINFO	D0W8DN	PMID27774822-Compound-Figure10Example19	Patented
T23172	DRUGINFO	D0Y6ON	Pyrrolo-pyrazine derivative 4	Patented
T23172	DRUGINFO	D01EYJ	Ruxolitinib derivative 2	Patented
T23172	DRUGINFO	D07XYI	1,2,4-triazolo[1,5a]pyridine derivative 1	Patented
T23172	DRUGINFO	D08WPB	Five-and-six-membered heterocyclic compound 1	Patented
T23172	DRUGINFO	D09RUN	Pyrazolopyridine derivative 4	Patented
T23172	DRUGINFO	D09UBE	Pyrrole six-membered heteroaryl ring derivative 1	Patented
T23172	DRUGINFO	D0A6RG	PMID27774824-Compound-Figure2Example4	Patented
T23172	DRUGINFO	D0G0FK	Tricyclic compound 1	Patented
T23172	DRUGINFO	D0G9MM	Isoxazole derivative 1	Patented
T23172	DRUGINFO	D0GH8D	PMID27774822-Compound-Figure10Example1	Patented
T23172	DRUGINFO	D0M3CB	PMID27774822-Compound-Figure1Example20	Patented
T23172	DRUGINFO	D0TX2G	Isoxazole derivative 2	Patented
T23172	DRUGINFO	D0VR6E	Pyrrolo-pyridine derivative 3	Patented
T23172	DRUGINFO	D0XH7H	N-methylmethanesulfonamide derivative 1	Patented
T23172	DRUGINFO	D0Y2IM	N-(cyanomethyl)-4-(2-(phenylamino)pyrimidin-4-yl)benzamide derivative 1	Patented
T23172	DRUGINFO	D01CRX	Benzimidazole derivative 7	Patented
T23172	DRUGINFO	D01FVC	Bis-aminopyrimidine derivative 1	Patented
T23172	DRUGINFO	D03QAY	Pyrazolopyridine derivative 3	Patented
T23172	DRUGINFO	D04BOW	Tricyclic pyrrolopyridine compound 1	Patented
T23172	DRUGINFO	D05AXE	Aminooxazole carboxamide derivative 1	Patented
T23172	DRUGINFO	D0FQ4Z	Pyrrolo[2,3-d]pyrimidine derivative 6	Patented
T23172	DRUGINFO	D0GB7G	PMID27774824-Compound-Figure6Example12	Patented
T23172	DRUGINFO	D0KL3B	Pyrrolo[2,3-d]pyrimidine derivative 8	Patented
T23172	DRUGINFO	D0LR6J	Bis-aminopyrimidine derivative 2	Patented
T23172	DRUGINFO	D0LS1O	Tricyclic compound 11	Patented
T23172	DRUGINFO	D0M2WA	Tricyclic heterocycle derivative 5	Patented
T23172	DRUGINFO	D0RJ3W	PMID27774822-Compound-Figure11Example5	Patented
T23172	DRUGINFO	D0S6XT	Bis-aminopyrimidine derivative 3	Patented
T23172	DRUGINFO	D0SJ1Q	Bis-aminopyrimidine derivative 4	Patented
T23172	DRUGINFO	D0U1HA	PMID27774824-Compound-Figure3Example18	Patented
T23172	DRUGINFO	D0U5FZ	Pyrrolo[2,3-d]pyrimidine derivative 7	Patented
T23172	DRUGINFO	D0WA1V	Pyrimidopyridazinone derivative 2	Patented
T23172	DRUGINFO	D0X1FD	Tricyclic heterocycle derivative 1	Patented
T23172	DRUGINFO	D07PTU	Imidazo[4,5-c]pyridine derivative 1	Patented
T23172	DRUGINFO	D0WZ8N	PMID27774824-Compound-Figure9Example2up	Patented
T23172	DRUGINFO	D01DBB	PMID27774824-Compound-Figure9Example2down	Patented
T23172	DRUGINFO	D09ALF	Aminotriazolopyridine derivative 1	Patented
T23172	DRUGINFO	D0VJ1R	Imidazo[4,5-c]pyridine derivative 2	Patented
T23172	DRUGINFO	D0YR8S	PMID27774824-Compound-Figure11Example1up	Patented
T23172	DRUGINFO	D09PIS	Pyrazolo[4,3-c]pyridine derivative 2	Patented
T23172	DRUGINFO	D01XEQ	R348	Terminated
T23172	DRUGINFO	D0Z1HQ	PNU156804	Terminated
T23172	DRUGINFO	D0GZ7B	AG490	Terminated
T23172	DRUGINFO	D0G7YF	VX-467	Investigative
T23172	DRUGINFO	D0M2AN	AD-412	Investigative
T23172	DRUGINFO	D0P1BK	NC1153	Investigative
T23172	DRUGINFO	D0V6VQ	PF-956980	Investigative
T23172	DRUGINFO	D05MHL	Atropisomer 1	Investigative
T23172	DRUGINFO	D0YX5U	ZM-39923	Investigative
T23172	DRUGINFO	D0IR6U	CMP-6	Investigative
T23172	DRUGINFO	D0US9O	PMID24359159C19a	Investigative
T23172	DRUGINFO	D09HXU	6-o-tolylquinazolin-2-amine	Investigative
T23172	DRUGINFO	D0E5IP	WHI-P154	Investigative
T23172	DRUGINFO	D02NNT	PMID21493067C1d	Investigative
T23172	DRUGINFO	D08RZB	PMID15546730C2	Investigative

T89361	TARGETID	T89361
T89361	FORMERID	TTDC00169
T89361	UNIPROID	CDK6_HUMAN
T89361	TARGNAME	Cyclin-dependent kinase 6 (CDK6)
T89361	GENENAME	CDK6
T89361	TARGTYPE	Successful
T89361	SYNONYMS	Serine/threonine-protein kinase PLSTIRE; Serine/threonine protein kinase PLSTIRE; Cell division protein kinase 6; CDKN6
T89361	FUNCTION	Phosphorylates pRB/RB1 and NPM1. Interacts with D-type G1 cyclins during interphase at G1 to form a pRB/RB1 kinase and controls the entrance into the cell cycle. Involved in initiation and maintenance of cell cycle exit during cell differentiation; prevents cell proliferation and regulates negatively cell differentiation, but is required for the proliferation of specific cell types (e. g. erythroid and hematopoietic cells). Essential for cell proliferation within the dentate gyrus of the hippocampus and the subventricular zone of the lateral ventricles. Required during thymocyte development. Promotes the production of newborn neurons, probably by modulating G1 length. Promotes, at least in astrocytes, changes in patterns of gene expression, changes in the actin cytoskeleton including loss of stress fibers, and enhanced motility during cell differentiation. Prevents myeloid differentiation by interfering with RUNX1 and reducing its transcription transactivation activity, but promotes proliferation of normal myeloid progenitors. Delays senescence. Promotes the proliferation of beta-cells in pancreatic islets of Langerhans. May play a role in the centrosome organization during the cell cycle phases. Serine/threonine-protein kinase involved in the control of the cell cycle and differentiation; promotes G1/S transition.
T89361	PDBSTRUC	5L2T; 5L2S; 5L2I; 4TTH; 4EZ5
T89361	BIOCLASS	Kinase
T89361	ECNUMBER	EC 2.7.11.22
T89361	SEQUENCE	MEKDGLCRADQQYECVAEIGEGAYGKVFKARDLKNGGRFVALKRVRVQTGEEGMPLSTIREVAVLRHLETFEHPNVVRLFDVCTVSRTDRETKLTLVFEHVDQDLTTYLDKVPEPGVPTETIKDMMFQLLRGLDFLHSHRVVHRDLKPQNILVTSSGQIKLADFGLARIYSFQMALTSVVVTLWYRAPEVLLQSSYATPVDLWSVGCIFAEMFRRKPLFRGSSDVDQLGKILDVIGLPGEEDWPRDVALPRQAFHSKSAQPIEKFVTDIDELGKDLLLKCLTFNPAKRISAYSALSHPYFQDLERCKENLDSHLPPSQNTSELNTA
T89361	DRUGINFO	D00UZR	Palbociclib	Approved
T89361	DRUGINFO	D01HVT	Ribociclib Succinate	Approved
T89361	DRUGINFO	D05SBO	LY2835219	Approved
T89361	DRUGINFO	D0AP9E	Trilaciclib	Approved
T89361	DRUGINFO	D07ESC	Apremilast	Approved
T89361	DRUGINFO	D08MXP	LEE011	Phase 3
T89361	DRUGINFO	D0WU1O	G1T38	Phase 2
T89361	DRUGINFO	D4IS0G	GLR2007	Phase 1/2
T89361	DRUGINFO	D8ZV2Q	FCN-437	Phase 1/2
T89361	DRUGINFO	D70HZT	NUV-422	Phase 1/2
T89361	DRUGINFO	D01XZG	G1T28-1	Phase 1
T89361	DRUGINFO	DYH94Z	RGT-419B	Phase 1
T89361	DRUGINFO	DKCU40	FN-1501	Phase 1
T89361	DRUGINFO	D07TVO	PMID25726713-Compound-49	Patented
T89361	DRUGINFO	D0KH7Q	PMID25726713-Compound-51	Patented
T89361	DRUGINFO	D0W4MN	Isoquinoline 1,3-dione derivative 1	Patented
T89361	DRUGINFO	D0WJ3W	PMID25726713-Compound-48	Patented
T89361	DRUGINFO	D0X5VI	PMID25726713-Compound-47	Patented
T89361	DRUGINFO	D0Y8JF	PMID25726713-Compound-50	Patented
T89361	DRUGINFO	D0M5DX	Oxazolyl methylthiothiazole derivative 1	Patented
T89361	DRUGINFO	D07ZJC	INOC-005	Preclinical
T89361	DRUGINFO	D0Y6HA	CYC-103	Terminated
T89361	DRUGINFO	D0Z0KD	PD-0183812	Terminated
T89361	DRUGINFO	D09OAH	Fascaplysin	Investigative
T89361	DRUGINFO	D0CI3C	Deschloroflavopiridol	Investigative
T89361	DRUGINFO	D0J4ON	RGB-286147	Investigative
T89361	DRUGINFO	D01UYI	Chrysin	Investigative
T89361	DRUGINFO	D0MF5Y	3,7,3',4'-TETRAHYDROXYFLAVONE	Investigative
T89361	DRUGINFO	D00RIX	APIGENIN	Investigative
T89361	DRUGINFO	D00NYT	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	Investigative
T89361	DRUGINFO	D0C3WY	3,4-diphenyl-1H-pyrrole-2,5-dione	Investigative
T89361	DRUGINFO	D0EK0G	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	Investigative

T38338	TARGETID	T38338
T38338	FORMERID	TTDS00529
T38338	UNIPROID	CAC1B_HUMAN
T38338	TARGNAME	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
T38338	GENENAME	CACNA1B
T38338	TARGTYPE	Successful
T38338	SYNONYMS	Voltage-gated calcium channel alpha subunit Cav2.2; Voltage-dependent N-type calcium channel alpha-1B subunit; N-type Ca2+ channel; Calcium channel, L type, alpha-1 polypeptide isoform 5; CACNA1B; Brain calcium channel III; BIII
T38338	FUNCTION	Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1B gives rise to N-type calcium currents. N-type calcium channels belong to the 'high-voltage activated' (HVA) group and are blocked by omega-conotoxin-GVIA (omega-CTx-GVIA) and by omega-agatoxin- IIIA (omega-Aga-IIIA). They are however insensitive to dihydropyridines (DHP), and omega-agatoxin-IVA (omega-Aga-IVA). Calcium channels containing alpha-1B subunit may play a role in directed migration of immature neurons.
T38338	PDBSTRUC	2LCM
T38338	BIOCLASS	Voltage-gated ion channel
T38338	SEQUENCE	MVRFGDELGGRYGGPGGGERARGGGAGGAGGPGPGGLQPGQRVLYKQSIAQRARTMALYNPIPVKQNCFTVNRSLFVFSEDNVVRKYAKRITEWPPFEYMILATIIANCIVLALEQHLPDGDKTPMSERLDDTEPYFIGIFCFEAGIKIIALGFVFHKGSYLRNGWNVMDFVVVLTGILATAGTDFDLRTLRAVRVLRPLKLVSGIPSLQVVLKSIMKAMVPLLQIGLLLFFAILMFAIIGLEFYMGKFHKACFPNSTDAEPVGDFPCGKEAPARLCEGDTECREYWPGPNFGITNFDNILFAILTVFQCITMEGWTDILYNTNDAAGNTWNWLYFIPLIIIGSFFMLNLVLGVLSGEFAKERERVENRRAFLKLRRQQQIERELNGYLEWIFKAEEVMLAEEDRNAEEKSPLDVLKRAATKKSRNDLIHAEEGEDRFADLCAVGSPFARASLKSGKTESSSYFRRKEKMFRFFIRRMVKAQSFYWVVLCVVALNTLCVAMVHYNQPRRLTTTLYFAEFVFLGLFLTEMSLKMYGLGPRSYFRSSFNCFDFGVIVGSVFEVVWAAIKPGSSFGISVLRALRLLRIFKVTKYWSSLRNLVVSLLNSMKSIISLLFLLFLFIVVFALLGMQLFGGQFNFQDETPTTNFDTFPAAILTVFQILTGEDWNAVMYHGIESQGGVSKGMFSSFYFIVLTLFGNYTLLNVFLAIAVDNLANAQELTKDEEEMEEAANQKLALQKAKEVAEVSPMSAANISIAARQQNSAKARSVWEQRASQLRLQNLRASCEALYSEMDPEERLRFATTRHLRPDMKTHLDRPLVVELGRDGARGPVGGKARPEAAEAPEGVDPPRRHHRHRDKDKTPAAGDQDRAEAPKAESGEPGAREERPRPHRSHSKEAAGPPEARSERGRGPGPEGGRRHHRRGSPEEAAEREPRRHRAHRHQDPSKECAGAKGERRARHRGGPRAGPREAESGEEPARRHRARHKAQPAHEAVEKETTEKEATEKEAEIVEADKEKELRNHQPREPHCDLETSGTVTVGPMHTLPSTCLQKVEEQPEDADNQRNVTRMGSQPPDPNTIVHIPVMLTGPLGEATVVPSGNVDLESQAEGKKEVEADDVMRSGPRPIVPYSSMFCLSPTNLLRRFCHYIVTMRYFEVVILVVIALSSIALAAEDPVRTDSPRNNALKYLDYIFTGVFTFEMVIKMIDLGLLLHPGAYFRDLWNILDFIVVSGALVAFAFSGSKGKDINTIKSLRVLRVLRPLKTIKRLPKLKAVFDCVVNSLKNVLNILIVYMLFMFIFAVIAVQLFKGKFFYCTDESKELERDCRGQYLDYEKEEVEAQPRQWKKYDFHYDNVLWALLTLFTVSTGEGWPMVLKHSVDATYEEQGPSPGYRMELSIFYVVYFVVFPFFFVNIFVALIIITFQEQGDKVMSECSLEKNERACIDFAISAKPLTRYMPQNRQSFQYKTWTFVVSPPFEYFIMAMIALNTVVLMMKFYDAPYEYELMLKCLNIVFTSMFSMECVLKIIAFGVLNYFRDAWNVFDFVTVLGSITDILVTEIAETNNFINLSFLRLFRAARLIKLLRQGYTIRILLWTFVQSFKALPYVCLLIAMLFFIYAIIGMQVFGNIALDDDTSINRHNNFRTFLQALMLLFRSATGEAWHEIMLSCLSNQACDEQANATECGSDFAYFYFVSFIFLCSFLMLNLFVAVIMDNFEYLTRDSSILGPHHLDEFIRVWAEYDPAACGRISYNDMFEMLKHMSPPLGLGKKCPARVAYKRLVRMNMPISNEDMTVHFTSTLMALIRTALEIKLAPAGTKQHQCDAELRKEISVVWANLPQKTLDLLVPPHKPDEMTVGKVYAALMIFDFYKQNKTTRDQMQQAPGGLSQMGPVSLFHPLKATLEQTQPAVLRGARVFLRQKSSTSLSNGGAIQNQESGIKESVSWGTQRTQDAPHEARPPLERGHSTEIPVGRSGALAVDVQMQSITRRGPDGEPQPGLESQGRAASMPRLAAETQPVTDASPMKRSISTLAQRPRGTHLCSTTPDRPPPSQASSHHHHHRCHRRRDRKQRSLEKGPSLSADMDGAPSSAVGPGLPPGEGPTGCRRERERRQERGRSQERRQPSSSSSEKQRFYSCDRFGGREPPKPKPSLSSHPTSPTAGQEPGPHPQGSGSVNGSPLLSTSGASTPGRGGRRQLPQTPLTPRPSITYKTANSSPIHFAGAQTSLPAFSPGRLSRGLSEHNALLQRDPLSQPLAPGSRIGSDPYLGQRLDSEASVHALPEDTLTFEEAVATNSGRSSRTSYVSSLTSQSHPLRRVPNGYHCTLGLSSGGRARHSYHHPDQDHWC
T38338	DRUGINFO	D01NLB	Ziconotide	Approved
T38338	DRUGINFO	D0I9HF	Hesperidin	Approved
T38338	DRUGINFO	D0N3ZJ	LOMERIZINE	Approved
T38338	DRUGINFO	D00GEG	Ralfinamide	Phase 3
T38338	DRUGINFO	D0N3SR	Cilnidipine	Phase 3
T38338	DRUGINFO	D01UDS	CNV-2197944	Phase 2
T38338	DRUGINFO	D0K8NW	Ritanserin	Discontinued in Phase 3
T38338	DRUGINFO	D0T4YZ	CNSB-004	Preclinical
T38338	DRUGINFO	D03QMS	PD-157667	Terminated
T38338	DRUGINFO	D04BSZ	PD-0204318	Terminated
T38338	DRUGINFO	D0G6HZ	PD-29361	Terminated
T38338	DRUGINFO	D0QQ7N	TH-9229	Terminated
T38338	DRUGINFO	D06NHS	TROX-1	Investigative
T38338	DRUGINFO	D07BDQ	PD-151307	Investigative
T38338	DRUGINFO	D0C3VI	PD-167341	Investigative
T38338	DRUGINFO	D0GX2A	NSC-87509	Investigative
T38338	DRUGINFO	D0K4ZX	Conotoxin	Investigative
T38338	DRUGINFO	D00PVO	GNF-PF-3464	Investigative
T38338	DRUGINFO	D09LRA	omega-conotoxin GVIA	Investigative
T38338	DRUGINFO	D0WN7V	NSC-180246	Investigative
T38338	DRUGINFO	D0X7VM	KYS-05090	Investigative
T38338	DRUGINFO	D09YTH	CPU-228	Investigative
T38338	DRUGINFO	D08RJC	PD-32577	Investigative

T00895	TARGETID	T00895
T00895	FORMERID	TTDC00066
T00895	UNIPROID	KPCE_HUMAN
T00895	TARGNAME	Protein kinase C epsilon (PRKCE)
T00895	GENENAME	PRKCE
T00895	TARGTYPE	Successful
T00895	SYNONYMS	Protein kinase C epsilon type; PKCE; PKC epsilon; NPKC-epsilon
T00895	FUNCTION	Mediates cell adhesion to the extracellular matrix via integrin-dependent signaling, by mediating angiotensin-2-induced activation of integrin beta-1 (ITGB1) in cardiac fibroblasts. Phosphorylates MARCKS, which phosphorylates and activates PTK2/FAK, leading to the spread of cardiomyocytes. Involved in the control of the directional transport of ITGB1 in mesenchymal cells by phosphorylating vimentin (VIM), an intermediate filament (IF) protein. In epithelial cells, associates with and phosphorylates keratin-8 (KRT8), which induces targeting of desmoplakin at desmosomes and regulates cell-cell contact. Phosphorylates IQGAP1, which binds to CDC42, mediating epithelial cell-cell detachment prior to migration. In HeLa cells, contributes to hepatocyte growth factor (HGF)-induced cell migration, and in human corneal epithelial cells, plays a critical role in wound healing after activation by HGF. During cytokinesis, forms a complex with YWHAB, which is crucial for daughter cell separation, and facilitates abscission by a mechanism which may implicate the regulation of RHOA. In cardiac myocytes, regulates myofilament function and excitation coupling at the Z-lines, where it is indirectly associated with F-actin via interaction with COPB1. During endothelin-induced cardiomyocyte hypertrophy, mediates activation of PTK2/FAK, which is critical for cardiomyocyte survival and regulation of sarcomere length. Plays a role in the pathogenesis of dilated cardiomyopathy via persistent phosphorylation of troponin I (TNNI3). Involved in nerve growth factor (NFG)-induced neurite outgrowth and neuron morphological change independently of its kinase activity, by inhibition of RHOA pathway, activation of CDC42 and cytoskeletal rearrangement. May be involved in presynaptic facilitation by mediating phorbol ester-induced synaptic potentiation. Phosphorylates gamma-aminobutyric acid receptor subunit gamma-2 (GABRG2), which reduces the response of GABA receptors to ethanol and benzodiazepines and may mediate acute tolerance to the intoxicating effects of ethanol. Upon PMA treatment, phosphorylates the capsaicin- and heat-activated cation channel TRPV1, which is required for bradykinin-induced sensitization of the heat response in nociceptive neurons. Is able to form a complex with PDLIM5 and N-type calcium channel, and may enhance channel activities and potentiates fast synaptic transmission by phosphorylating the pore-forming alpha subunit CACNA1B (CaV2. 2). In prostate cancer cells, interacts with and phosphorylates STAT3, which increases DNA-binding and transcriptional activity of STAT3 and seems to be essential for prostate cancer cell invasion. Downstream of TLR4, plays an important role in the lipopolysaccharide (LPS)-induced immune response by phosphorylating and activating TICAM2/TRAM, which in turn activates the transcription factor IRF3 and subsequent cytokines production. In differentiating erythroid progenitors, is regulated by EPO and controls the protection against the TNFSF10/TRAIL-mediated apoptosis, via BCL2. May be involved in the regulation of the insulin-induced phosphorylation and activation of AKT1. Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays essential roles in the regulation of multiple cellular processes linked to cytoskeletal proteins, such as cell adhesion, motility, migration and cell cycle, functions in neuron growth and ion channel regulation, and is involved in immune response, cancer cell invasion and regulation of apoptosis.
T00895	PDBSTRUC	5LIH; 2WH0
T00895	BIOCLASS	Kinase
T00895	ECNUMBER	EC 2.7.11.13
T00895	SEQUENCE	MVVFNGLLKIKICEAVSLKPTAWSLRHAVGPRPQTFLLDPYIALNVDDSRIGQTATKQKTNSPAWHDEFVTDVCNGRKIELAVFHDAPIGYDDFVANCTIQFEELLQNGSRHFEDWIDLEPEGRVYVIIDLSGSSGEAPKDNEERVFRERMRPRKRQGAVRRRVHQVNGHKFMATYLRQPTYCSHCRDFIWGVIGKQGYQCQVCTCVVHKRCHELIITKCAGLKKQETPDQVGSQRFSVNMPHKFGIHNYKVPTFCDHCGSLLWGLLRQGLQCKVCKMNVHRRCETNVAPNCGVDARGIAKVLADLGVTPDKITNSGQRRKKLIAGAESPQPASGSSPSEEDRSKSAPTSPCDQEIKELENNIRKALSFDNRGEEHRAASSPDGQLMSPGENGEVRQGQAKRLGLDEFNFIKVLGKGSFGKVMLAELKGKDEVYAVKVLKKDVILQDDDVDCTMTEKRILALARKHPYLTQLYCCFQTKDRLFFVMEYVNGGDLMFQIQRSRKFDEPRSRFYAAEVTSALMFLHQHGVIYRDLKLDNILLDAEGHCKLADFGMCKEGILNGVTTTTFCGTPDYIAPEILQELEYGPSVDWWALGVLMYEMMAGQPPFEADNEDDLFESILHDDVLYPVWLSKEAVSILKAFMTKNPHKRLGCVASQNGEDAIKQHPFFKEIDWVLLEQKKIKPPFKPRIKTKRDVNNFDQDFTREEPVLTLVDEAIVKQINQEEFKGFSYFGEDLMP
T00895	DRUGINFO	D0Y4AW	Meprobamate	Approved
T00895	DRUGINFO	D0E6AH	Bryostatin-1	Phase 2
T00895	DRUGINFO	D0J7CE	CDE-6960	Terminated
T00895	DRUGINFO	D0X0HN	LY-317644	Terminated
T00895	DRUGINFO	D0R5ZR	RO-320432	Terminated
T00895	DRUGINFO	D0D4ZL	Phorbol 12-myristate	Investigative
T00895	DRUGINFO	D00TWA	[2,2':5',2'']Terthiophen-4-yl-methanol	Investigative
T00895	DRUGINFO	D02PUV	4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol	Investigative
T00895	DRUGINFO	D02QME	2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile	Investigative
T00895	DRUGINFO	D05LRV	[2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde	Investigative
T00895	DRUGINFO	D09TSC	Ro-32-0557	Investigative
T00895	DRUGINFO	D09XIE	3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile	Investigative
T00895	DRUGINFO	D0A8MN	3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile	Investigative
T00895	DRUGINFO	D0D3MR	[2,2':5',2'']Terthiophene-4-carbaldehyde	Investigative
T00895	DRUGINFO	D0Q3GQ	4-cycloheptyliden(4-hydroxyphenyl)methylphenol	Investigative
T00895	DRUGINFO	D0S9UK	2,3,3-Triphenyl-acrylonitrile	Investigative
T00895	DRUGINFO	D0T0UH	3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile	Investigative
T00895	DRUGINFO	D0V9SW	4-cyclohexyliden(4-hydroxyphenyl)methylphenol	Investigative
T00895	DRUGINFO	D06ZCX	LY-326449	Investigative
T00895	DRUGINFO	D06AOY	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	Investigative
T00895	DRUGINFO	D00NYT	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	Investigative
T00895	DRUGINFO	D0C3WY	3,4-diphenyl-1H-pyrrole-2,5-dione	Investigative
T00895	DRUGINFO	D0EK0G	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	Investigative
T00895	DRUGINFO	D0L8HO	RO-316233	Investigative

T97071	TARGETID	T97071
T97071	FORMERID	TTDS00441
T97071	UNIPROID	FOLH1_HUMAN
T97071	TARGNAME	Glutamate carboxypeptidase II (GCPII)
T97071	GENENAME	FOLH1
T97071	TARGTYPE	Successful
T97071	SYNONYMS	Pteroylpoly-gamma-glutamate carboxypeptidase; Prostate-specific membrane antigen; PSMA; PSM; NAALADase I; NAALAD1; N-acetylated-alpha-linked acidic dipeptidase I; Membrane glutamate carboxypeptidase; MGCP; Glutamate carboxypeptidase 2; GIG27; Folylpoly-gamma-glutamate carboxypeptidase; Folate hydrolase 1; FOLH; FGCP; Cell growth-inhibiting gene 27 protein
T97071	FUNCTION	Has a preference for tri-alpha-glutamate peptides. In the intestine, required for the uptake of folate. In the brain, modulates excitatory neurotransmission through the hydrolysis of the neuropeptide, N-aceylaspartylglutamate (NAAG), thereby releasing glutamate. Involved in prostate tumor progression. Has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity.
T97071	PDBSTRUC	6HKZ; 6HKJ; 6H7Z; 6H7Y; 6FE5
T97071	BIOCLASS	Peptidase
T97071	ECNUMBER	EC 3.4.17.21
T97071	SEQUENCE	MWNLLHETDSAVATARRPRWLCAGALVLAGGFFLLGFLFGWFIKSSNEATNITPKHNMKAFLDELKAENIKKFLYNFTQIPHLAGTEQNFQLAKQIQSQWKEFGLDSVELAHYDVLLSYPNKTHPNYISIINEDGNEIFNTSLFEPPPPGYENVSDIVPPFSAFSPQGMPEGDLVYVNYARTEDFFKLERDMKINCSGKIVIARYGKVFRGNKVKNAQLAGAKGVILYSDPADYFAPGVKSYPDGWNLPGGGVQRGNILNLNGAGDPLTPGYPANEYAYRRGIAEAVGLPSIPVHPIGYYDAQKLLEKMGGSAPPDSSWRGSLKVPYNVGPGFTGNFSTQKVKMHIHSTNEVTRIYNVIGTLRGAVEPDRYVILGGHRDSWVFGGIDPQSGAAVVHEIVRSFGTLKKEGWRPRRTILFASWDAEEFGLLGSTEWAEENSRLLQERGVAYINADSSIEGNYTLRVDCTPLMYSLVHNLTKELKSPDEGFEGKSLYESWTKKSPSPEFSGMPRISKLGSGNDFEVFFQRLGIASGRARYTKNWETNKFSGYPLYHSVYETYELVEKFYDPMFKYHLTVAQVRGGMVFELANSIVLPFDCRDYAVVLRKYADKIYSISMKHPQEMKTYSVSFDSLFSAVKNFTEIASKFSERLQDFDKSNPIVLRMMNDQLMFLERAFIDPLGLPDRPFYRHVIYAPSSHNKYAGESFPGIYDALFDIESKVDPSKAWGEVKRQIYVAAFTVQAAAETLSEVA
T97071	DRUGINFO	D09PGL	Capromab	Approved
T97071	DRUGINFO	DBG46D	PSMA-11 Ga-68	Approved
T97071	DRUGINFO	DGQW52	Lutetium Lu-177 vipivotide tetraxetan	Approved
T97071	DRUGINFO	DENO78	BAY 2315497	Phase 3
T97071	DRUGINFO	DSM5X9	177-Lu-PSMA-617	Phase 3
T97071	DRUGINFO	D02EEK	J 591 Lu-177	Phase 2
T97071	DRUGINFO	D05MOZ	G-202	Phase 2
T97071	DRUGINFO	D06URI	ATL101	Phase 2
T97071	DRUGINFO	D08FTP	99mTc-MIP-1404	Phase 2
T97071	DRUGINFO	D0H5ER	MLN-591RL	Phase 2
T97071	DRUGINFO	D0RO2L	CAR-T cells targeting PSMA	Phase 1/2
T97071	DRUGINFO	D0VI8T	4SCAR-PSMA	Phase 1/2
T97071	DRUGINFO	D0W7FC	MLN-2704	Phase 1/2
T97071	DRUGINFO	D1CZ8K	177-Lu-PSMA-R2	Phase 1/2
T97071	DRUGINFO	D4GH1L	67Cu-SAR-bisPSMA	Phase 1/2
T97071	DRUGINFO	DBHQ20	64Cu-SAR-bisPSMA	Phase 1/2
T97071	DRUGINFO	DP6J5K	177Lu-labelled PSMA-R2	Phase 1/2
T97071	DRUGINFO	DR8JH4	LAVA-1207	Phase 1/2
T97071	DRUGINFO	D5MV0R	Acapatamab	Phase 1/2
T97071	DRUGINFO	D6L5YT	REGN4336	Phase 1/2
T97071	DRUGINFO	D8UZM7	REGN5678	Phase 1/2
T97071	DRUGINFO	D03JTL	APVO414	Phase 1
T97071	DRUGINFO	D04KRV	Iofolastat I-124	Phase 1
T97071	DRUGINFO	D07KHR	PSMA-VRP	Phase 1
T97071	DRUGINFO	D08JYV	PSMA subunit vaccine	Phase 1
T97071	DRUGINFO	D0F5KN	99mTc-MIP-1405	Phase 1
T97071	DRUGINFO	D0H4IU	GPI-16072	Phase 1
T97071	DRUGINFO	D0N6QB	MT-112	Phase 1
T97071	DRUGINFO	D0O0JB	PSMA-targeted tubulysin B conjugates	Phase 1
T97071	DRUGINFO	D0TN7S	BAY-1075553	Phase 1
T97071	DRUGINFO	D2Y9IG	JNJ-63898081	Phase 1
T97071	DRUGINFO	D48MDS	HPN424	Phase 1
T97071	DRUGINFO	DA03JS	MIP-1095	Phase 1
T97071	DRUGINFO	DAS4D6	PSMA CAR-T cell therapy	Phase 1
T97071	DRUGINFO	DH5S6Z	CTT1403	Phase 1
T97071	DRUGINFO	DJME35	225Ac-PSMA-617	Phase 1
T97071	DRUGINFO	DM6CE2	177Lu-labelled CTT-1403	Phase 1
T97071	DRUGINFO	DXOR23	225Ac-J591	Phase 1
T97071	DRUGINFO	DXV67Q	227Th-labelled PSMA-TTC	Phase 1
T97071	DRUGINFO	DKX1U6	AMG 340	Phase 1
T97071	DRUGINFO	DOY4E6	AMG 160	Phase 1
T97071	DRUGINFO	DY4X5W	CCW702	Phase 1
T97071	DRUGINFO	D04UWG	Autologous T-cell therapy	Phase 1
T97071	DRUGINFO	D03ZHE	MDX-070	Discontinued in Phase 2
T97071	DRUGINFO	D0M8PM	IRX-4	Preclinical
T97071	DRUGINFO	D02CYQ	2-Hydroxycarbamoyl-pentanedioic acid	Investigative
T97071	DRUGINFO	D03JFL	2-(2-carboxy-7-mercaptoheptyl)benzoic acid	Investigative
T97071	DRUGINFO	D03RMT	3-(2-carboxy-6-mercaptohexyl)benzoic acid	Investigative
T97071	DRUGINFO	D04SZR	4-(2-carboxy-5-mercaptopentyl)benzoic acid	Investigative
T97071	DRUGINFO	D04VFS	3-(2-carboxy-4-mercaptobutyl)benzoic acid	Investigative
T97071	DRUGINFO	D05SNS	2-(2-Hydroxycarbamoyl-ethyl)-pentanedioic acid	Investigative
T97071	DRUGINFO	D05UAO	J591-Ac-225	Investigative
T97071	DRUGINFO	D05VWZ	2-(3-carboxybenzyl)succinic acid	Investigative
T97071	DRUGINFO	D06JOJ	PMID15027864C8d	Investigative
T97071	DRUGINFO	D06LAX	PGI-02749	Investigative
T97071	DRUGINFO	D08CYU	2-Mercapto-pentanedioic acid	Investigative
T97071	DRUGINFO	D08TDE	2-(4-Mercapto-butyl)-pentanedioic acid	Investigative
T97071	DRUGINFO	D0A1FL	2-Phosphonooxy-pentanedioic acid	Investigative
T97071	DRUGINFO	D0B9YO	2-benzyl-5-mercaptopentanoic acid	Investigative
T97071	DRUGINFO	D0C2FS	2-(2-Mercapto-ethyl)-pentanedioic acid	Investigative
T97071	DRUGINFO	D0C5JP	3-(2-carboxy-3-phosphonopropyl)benzoic acid	Investigative
T97071	DRUGINFO	D0D8NM	2-(3-carbamoylbenzyl)-5-mercaptopentanoic acid	Investigative
T97071	DRUGINFO	D0E0HK	2-Mercaptomethyl-pentanedioic acid	Investigative
T97071	DRUGINFO	D0E3OH	2-(3-cyanobenzyl)-5-mercaptopentanoic acid	Investigative
T97071	DRUGINFO	D0F8TZ	3-(2-carboxy-5-mercaptopentyl)benzoic acid	Investigative
T97071	DRUGINFO	D0FU7Y	2-Hydroxycarbamoylmethyl-pentanedioic acid	Investigative
T97071	DRUGINFO	D0IW9Q	MDX-1147	Investigative
T97071	DRUGINFO	D0JX2S	3-(2-carbamoyl-5-mercaptopentyl)benzoic acid	Investigative
T97071	DRUGINFO	D0K3GB	99mTc-MIP-1340	Investigative
T97071	DRUGINFO	D0M1NS	CTT-54	Investigative
T97071	DRUGINFO	D0ND1C	3-(1-carboxy-4-mercaptobutoxy)benzoic acid	Investigative
T97071	DRUGINFO	D0Q2OH	2-(3-Methylsulfanyl-propyl)-pentanedioic acid	Investigative
T97071	DRUGINFO	D0Q3KD	2-(5-Mercapto-pentyl)-pentanedioic acid	Investigative
T97071	DRUGINFO	D0QA5U	2-(2-carboxy-5-mercaptopentyl)benzoic acid	Investigative
T97071	DRUGINFO	D0T8ZL	3-(2-carboxy-3-mercaptopropyl)benzoic acid	Investigative
T97071	DRUGINFO	D0X1DO	3-[(1-carboxy-4-mercaptobutyl)thio]benzoic acid	Investigative
T97071	DRUGINFO	D0Y6UB	2-PMPA	Investigative
T97071	DRUGINFO	D0Y7AN	2-(3-Mercapto-propyl)-pentanedioic acid	Investigative
T97071	DRUGINFO	D0Z0UQ	5-Mercapto-pentanoic acid	Investigative
T97071	DRUGINFO	D0Z5UD	MIP-1375	Investigative
T97071	DRUGINFO	D0Z5VI	2-(2-Phosphonooxy-ethyl)-pentanedioic acid	Investigative
T97071	DRUGINFO	D0Z9BU	99mTc-EC-0652	Investigative
T97071	DRUGINFO	D0ZJ9S	2-(3-Hydroxycarbamoyl-propyl)-pentanedioic acid	Investigative
T97071	DRUGINFO	D06DUE	[3H]quisqualate	Investigative

T86591	TARGETID	T86591
T86591	FORMERID	TTDS00340
T86591	UNIPROID	PPARA_HUMAN
T86591	TARGNAME	Peroxisome proliferator-activated receptor alpha (PPARA)
T86591	GENENAME	PPARA
T86591	TARGTYPE	Successful
T86591	SYNONYMS	Peroxisome proliferater-activated receptor alpha; PPARalpha; PPAR-alpha; PPAR; Nuclear receptor subfamily 1 group C member 1; NR1C1
T86591	FUNCTION	Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleylethanolamide, a naturally occurring lipid that regulates satiety. Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as transcription activator for the ACOX1 and P450 genes. Transactivation activity requires heterodimerization with RXRA and is antagonized by NR2C2. May be required for the propagation of clock information to metabolic pathways regulated by PER2. Ligand-activated transcription factor.
T86591	PDBSTRUC	5HYK; 5AZT; 4CI4; 4BCR; 3VI8
T86591	BIOCLASS	Nuclear hormone receptor
T86591	SEQUENCE	MVDTESPLCPLSPLEAGDLESPLSEEFLQEMGNIQEISQSIGEDSSGSFGFTEYQYLGSCPGSDGSVITDTLSPASSPSSVTYPVVPGSVDESPSGALNIECRICGDKASGYHYGVHACEGCKGFFRRTIRLKLVYDKCDRSCKIQKKNRNKCQYCRFHKCLSVGMSHNAIRFGRMPRSEKAKLKAEILTCEHDIEDSETADLKSLAKRIYEAYLKNFNMNKVKARVILSGKASNNPPFVIHDMETLCMAEKTLVAKLVANGIQNKEAEVRIFHCCQCTSVETVTELTEFAKAIPGFANLDLNDQVTLLKYGVYEAIFAMLSSVMNKDGMLVAYGNGFITREFLKSLRKPFCDIMEPKFDFAMKFNALELDDSDISLFVAAIICCGDRPGLLNVGHIEKMQEGIVHVLRLHLQSNHPDDIFLFPKLLQKMADLRQLVTEHAQLVQIIKKTESDAALHPLLQEIYRDMY
T86591	DRUGINFO	D00WCX	Bezafibrate	Approved
T86591	DRUGINFO	D04QIE	Pemafibrate	Approved
T86591	DRUGINFO	D07XGR	Fenofibrate	Approved
T86591	DRUGINFO	D0EJ6O	Ciprofibrate	Approved
T86591	DRUGINFO	D04BCB	Lobeglitazone	Approved
T86591	DRUGINFO	D02NHD	Ragaglitazar	Phase 3
T86591	DRUGINFO	D0F5JH	CS-038	Phase 3
T86591	DRUGINFO	D0H1NL	TESAGLITAZAR	Phase 3
T86591	DRUGINFO	D0LW1Y	GFT-505	Phase 3
T86591	DRUGINFO	D0M3UT	MURAGLITAZAR	Phase 3
T86591	DRUGINFO	D0T7MN	ZYH-1	Phase 3
T86591	DRUGINFO	D0VU5M	Imiglitazar	Phase 3
T86591	DRUGINFO	D0I5IM	LY-518674	Phase 2
T86591	DRUGINFO	D0RJ0V	GFT14	Phase 2
T86591	DRUGINFO	DE6GF4	ZYH7	Phase 2
T86591	DRUGINFO	D04BPS	Naveglitazar	Phase 2
T86591	DRUGINFO	D0PP8G	ONO-5129	Phase 2
T86591	DRUGINFO	D00HYD	CDT-fenofibrate	Phase 1
T86591	DRUGINFO	D01UJK	AVE0897	Phase 1
T86591	DRUGINFO	DF8M1T	TPST-1120	Phase 1
T86591	DRUGINFO	D03RJZ	Oxeglitazar	Phase 1
T86591	DRUGINFO	D0AX9S	GW-409544	Phase 1
T86591	DRUGINFO	D05AUY	PMID25416646-Compound-Figure5-H	Patented
T86591	DRUGINFO	D0HW6Y	Flavonoid derivative 8	Patented
T86591	DRUGINFO	D0O5IN	PMID25416646-Compound-Figure5-A	Patented
T86591	DRUGINFO	D0B9EN	Aleglitazar	Discontinued in Phase 3
T86591	DRUGINFO	D08LZI	NS-220	Discontinued in Phase 2
T86591	DRUGINFO	D0B8JQ	KRP-101	Discontinued in Phase 2
T86591	DRUGINFO	D0Q8UU	BM-17.0744	Discontinued in Phase 2
T86591	DRUGINFO	D0R5QQ	AVE-8134	Discontinued in Phase 2
T86591	DRUGINFO	D02RAU	KRP-297	Discontinued in Phase 2
T86591	DRUGINFO	D02ZKL	Reglixane	Discontinued in Phase 2
T86591	DRUGINFO	D0W2IU	AVE-0847	Discontinued in Phase 2
T86591	DRUGINFO	D01JGG	Sodelglitazar	Discontinued in Phase 2
T86591	DRUGINFO	D09OHP	Indeglitazar	Discontinued in Phase 2
T86591	DRUGINFO	D0S6KX	GSK-677954	Discontinued in Phase 2
T86591	DRUGINFO	D04FTB	AR-H049020	Discontinued in Phase 1
T86591	DRUGINFO	D09SLU	LG-101280	Discontinued in Phase 1
T86591	DRUGINFO	D0W3YW	DRF 10945	Discontinued in Phase 1
T86591	DRUGINFO	D0Z3XO	MP-136	Discontinued in Phase 1
T86591	DRUGINFO	D06PHO	E-3030	Discontinued in Phase 1
T86591	DRUGINFO	D0B0EB	LY-929	Discontinued in Phase 1
T86591	DRUGINFO	D04PBS	MC-3001	Preclinical
T86591	DRUGINFO	D09XCX	PIRINIXIC ACID	Preclinical
T86591	DRUGINFO	D0U2FN	Romazarit	Preclinical
T86591	DRUGINFO	D08WOE	MC-3002	Preclinical
T86591	DRUGINFO	D03CUS	CS-207	Terminated
T86591	DRUGINFO	D0BB1X	KRP-105	Terminated
T86591	DRUGINFO	D0I0RF	BVT-142	Terminated
T86591	DRUGINFO	D0OW6Z	Sipoglitazar	Terminated
T86591	DRUGINFO	D0V0TT	CS-204	Terminated
T86591	DRUGINFO	D00TFA	GW7647	Investigative
T86591	DRUGINFO	D01KPN	CP-775146	Investigative
T86591	DRUGINFO	D05CLM	GSK-9578	Investigative
T86591	DRUGINFO	D06RRD	Fibrates	Investigative
T86591	DRUGINFO	D08UWZ	BMS-687453	Investigative
T86591	DRUGINFO	D0EN7T	pristanic acid	Investigative
T86591	DRUGINFO	D0G9IP	eicosatetranoic acid	Investigative
T86591	DRUGINFO	D0K6TI	8S-HETE	Investigative
T86591	DRUGINFO	D0K8HA	LL-6531	Investigative
T86591	DRUGINFO	D0S4GK	Deoxy-Bigchap	Investigative
T86591	DRUGINFO	D00AII	(E)-4-(3,5-dimethoxystyryl)phenol	Investigative
T86591	DRUGINFO	D00EOP	AD-5061	Investigative
T86591	DRUGINFO	D01POG	GW-2331	Investigative
T86591	DRUGINFO	D04JOG	TZD18	Investigative
T86591	DRUGINFO	D06GYO	(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid	Investigative
T86591	DRUGINFO	D08XGH	reglitazar	Investigative
T86591	DRUGINFO	D0M8VN	DRF 2519	Investigative
T86591	DRUGINFO	D0M9LL	(E)-12-Nitrooctadec-12-enoic Acid	Investigative
T86591	DRUGINFO	D0P5QM	(E)-13-Nitrooctadec-12-enoic Acid	Investigative
T86591	DRUGINFO	D0Z4MH	ZY H2	Investigative
T86591	DRUGINFO	D0Z7OX	LY-465608	Investigative
T86591	DRUGINFO	D01ARG	DB-900	Investigative
T86591	DRUGINFO	D09JII	L-796449	Investigative
T86591	DRUGINFO	D0F0MP	L-165461	Investigative
T86591	DRUGINFO	D07MBC	N-oleoylethanolamide	Investigative

T25464	TARGETID	T25464
T25464	FORMERID	TTDS00363
T25464	UNIPROID	PP2BA_HUMAN
T25464	TARGNAME	Calcineurin (PPP3CA)
T25464	GENENAME	PPP3CA
T25464	TARGTYPE	Successful
T25464	SYNONYMS	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform; Calmodulin-dependent calcineurin A subunit alpha isoform; CNA; CAM-PRP catalytic subunit; CALNA
T25464	FUNCTION	Many of the substrates contain a PxIxIT motif and/or a LxVP motif. In response to increased Ca(2+) levels, dephosphorylates and activates phosphatase SSH1 which results in cofilin dephosphorylation. In response to increased Ca(2+) levels following mitochondrial depolarization, dephosphorylates DNM1L inducing DNM1L translocation to the mitochondrion. Dephosphorylates heat shock protein HSPB1. Dephosphorylates and activates transcription factor NFATC1. In response to increased Ca(2+) levels, regulates NFAT-mediated transcription probably by dephosphorylating NFAT and promoting its nuclear translocation. Dephosphorylates and inactivates transcription factor ELK1. Dephosphorylates DARPP32. May dephosphorylate CRTC2 at 'Ser-171' resulting in CRTC2 dissociation from 14-3-3 proteins. Calcium-dependent, calmodulin-stimulated protein phosphatase which plays an essential role in the transduction of intracellular Ca(2+)-mediated signals.
T25464	PDBSTRUC	5SVE; 5C1V; 4Q5U; 4F0Z; 3LL8
T25464	BIOCLASS	Phosphoric monoester hydrolase
T25464	ECNUMBER	EC 3.1.3.16
T25464	SEQUENCE	MSEPKAIDPKLSTTDRVVKAVPFPPSHRLTAKEVFDNDGKPRVDILKAHLMKEGRLEESVALRIITEGASILRQEKNLLDIDAPVTVCGDIHGQFFDLMKLFEVGGSPANTRYLFLGDYVDRGYFSIECVLYLWALKILYPKTLFLLRGNHECRHLTEYFTFKQECKIKYSERVYDACMDAFDCLPLAALMNQQFLCVHGGLSPEINTLDDIRKLDRFKEPPAYGPMCDILWSDPLEDFGNEKTQEHFTHNTVRGCSYFYSYPAVCEFLQHNNLLSILRAHEAQDAGYRMYRKSQTTGFPSLITIFSAPNYLDVYNNKAAVLKYENNVMNIRQFNCSPHPYWLPNFMDVFTWSLPFVGEKVTEMLVNVLNICSDDELGSEEDGFDGATAAARKEVIRNKIRAIGKMARVFSVLREESESVLTLKGLTPTGMLPSGVLSGGKQTLQSATVEAIEADEAIKGFSPQHKITSFEEAKGLDRINERMPPRRDAMPSDANLNSINKALTSETNGTDSNGSNSSNIQ
T25464	DRUGINFO	D06OMK	Tacrolimus	Approved
T25464	DRUGINFO	D0L9HX	Voclosporin	Approved
T25464	DRUGINFO	D0O3YF	Ciclosporin	Approved
T25464	DRUGINFO	D0Z4UN	Pimecrolimus	Approved
T25464	DRUGINFO	D08IGF	L-685,818	Investigative

T88975	TARGETID	T88975
T88975	FORMERID	TTDS00390
T88975	UNIPROID	PDE3A_HUMAN
T88975	TARGNAME	Phosphodiesterase 3A (PDE3A)
T88975	GENENAME	PDE3A
T88975	TARGTYPE	Successful
T88975	SYNONYMS	cGMP-inhibited 3',5'-cyclic phosphodiesterase A; Phosphodiesterase  3A; Cyclic GMP-inhibited phosphodiesterase A; Cyclic GMP inhibited phosphodiesterase A; CGI-PDE A
T88975	FUNCTION	Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes.
T88975	PDBSTRUC	1LRC
T88975	BIOCLASS	Phosphoric diester hydrolase
T88975	ECNUMBER	EC 3.1.4.17
T88975	SEQUENCE	MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRKLSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAPGGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGVGEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYLAYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEMSGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDLLADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLAIPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWNNPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVSKISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADEPLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYAPETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFEDMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVINDHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDHPGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFLVIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKELHLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAGLMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLLQNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPDQ
T88975	DRUGINFO	D03TYI	Aminophylline	Approved
T88975	DRUGINFO	D0D1HW	Anagrelide	Approved
T88975	DRUGINFO	D03VPC	Cilostazol	Approved
T88975	DRUGINFO	D0E0SW	Enoximone	Approved
T88975	DRUGINFO	D0L0ZF	VESNARINONE	Approved
T88975	DRUGINFO	D08HKT	BEMORADAN	Phase 2
T88975	DRUGINFO	D0BK6B	CI-930	Discontinued in Phase 2
T88975	DRUGINFO	D0Y6HV	EMD-53998	Discontinued in Phase 1
T88975	DRUGINFO	D01OFY	LAS-31180	Terminated
T88975	DRUGINFO	D08NXX	BMY-20844	Terminated
T88975	DRUGINFO	D09UMA	IMAZODAN	Terminated
T88975	DRUGINFO	D00YPO	TETRAHYDROBENXIMIDAZOLE	Investigative
T88975	DRUGINFO	D03GAQ	8-Methyl-1,3-dihydro-imidazo[4,5-b]quinolin-2-one	Investigative
T88975	DRUGINFO	D04BXL	2-morpholino-7-(2-phenylethynyl)-4H-chromen-4-one	Investigative
T88975	DRUGINFO	D04KDB	6-Imidazol-1-yl-3,4-dihydro-1H-quinolin-2-one	Investigative
T88975	DRUGINFO	D05HFD	7-Methyl-1,3-dihydro-imidazo[4,5-b]quinolin-2-one	Investigative
T88975	DRUGINFO	D06XVV	BENZOYLENUREA	Investigative
T88975	DRUGINFO	D07BFF	8-methyl-2-morpholino-7-phenyl-4H-chromen-4-one	Investigative
T88975	DRUGINFO	D07LCE	1,3,9,9a-Tetrahydro-imidazo[4,5-b]quinolin-2-one	Investigative
T88975	DRUGINFO	D08WIJ	8-methyl-2-morpholino-7-phenoxy-4H-chromen-4-one	Investigative
T88975	DRUGINFO	D08XKO	8-Chloro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one	Investigative
T88975	DRUGINFO	D09GTN	7-Fluoro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one	Investigative
T88975	DRUGINFO	D0DX3V	7-Ethoxy-1,3-dihydro-imidazo[4,5-b]quinolin-2-one	Investigative
T88975	DRUGINFO	D0E3ID	7-Iodo-1,5-dihydro-imidazo[2,1-b]quinazolin-2-one	Investigative
T88975	DRUGINFO	D0J7NR	5-Methyl-1,3-dihydro-imidazo[4,5-b]quinolin-2-one	Investigative
T88975	DRUGINFO	D0MJ1L	2-morpholino-7-phenyl-4H-chromen-4-one	Investigative
T88975	DRUGINFO	D0N6MR	1,3-Dihydro-imidazo[4,5-b]quinolin-2-one	Investigative
T88975	DRUGINFO	D0NI4Z	7-Chloro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one	Investigative
T88975	DRUGINFO	D0T3UP	1,3-Dihydro-naphtho[2,3-d]imidazol-2-one	Investigative
T88975	DRUGINFO	D0TE6A	1,5-Dihydro-imidazo[2,1-b]quinazolin-2-one	Investigative
T88975	DRUGINFO	D0TZ8C	6-(2-Imidazol-1-yl-vinyl)-1H-quinolin-2-one	Investigative
T88975	DRUGINFO	D09CPC	6-Pyridin-3-yl-3,4-dihydro-1H-quinolin-2-one	Investigative
T88975	DRUGINFO	D0W3RR	2-Morpholin-4-yl-8-phenylethynyl-chromen-4-one	Investigative
T88975	DRUGINFO	D00QCL	SOPHOFLAVESCENOL	Investigative
T88975	DRUGINFO	D0W4ZU	KURARINOL	Investigative
T88975	DRUGINFO	D06GUJ	KURAIDIN	Investigative
T88975	DRUGINFO	D0R6MT	isobutylmethylxanthine	Investigative

T14558	TARGETID	T14558
T14558	FORMERID	TTDS00130
T14558	UNIPROID	TRYB1_HUMAN
T14558	TARGNAME	Tryptase alpha/beta-1 (Tryptase)
T14558	GENENAME	TPSAB1
T14558	TARGTYPE	Successful
T14558	SYNONYMS	Tryptase-1; Tryptase alpha-1; Tryptase I; TPSB1; TPS2; TPS1
T14558	FUNCTION	May play a role in innate immunity. Isoform 2 cleaves large substrates, such as fibronectin, more efficiently than isoform 1, but seems less efficient toward small substrates. Tryptase is the major neutral protease present in mast cells and is secreted upon the coupled activation-degranulation response of this cell type.
T14558	PDBSTRUC	5WI6; 5F03; 4MQA; 4MPX; 4MPW
T14558	BIOCLASS	Peptidase
T14558	ECNUMBER	EC 3.4.21.59
T14558	SEQUENCE	MLNLLLLALPVLASRAYAAPAPGQALQRVGIVGGQEAPRSKWPWQVSLRVHGPYWMHFCGGSLIHPQWVLTAAHCVGPDVKDLAALRVQLREQHLYYQDQLLPVSRIIVHPQFYTAQIGADIALLELEEPVNVSSHVHTVTLPPASETFPPGMPCWVTGWGDVDNDERLPPPFPLKQVKVPIMENHICDAKYHLGAYTGDDVRIVRDDMLCAGNTRRDSCQGDSGGPLVCKVNGTWLQAGVVSWGEGCAQPNRPGIYTRVTYYLDWIHHYVPKKP
T14558	DRUGINFO	D05EAM	Pentamidine	Approved
T14558	DRUGINFO	D0O5WD	Lactoferrin	Approved
T14558	DRUGINFO	D08RMH	APC-2059	Discontinued in Phase 2
T14558	DRUGINFO	D0N9WB	APC-366	Discontinued in Phase 2
T14558	DRUGINFO	D02INZ	BABIM	Terminated
T14558	DRUGINFO	D0L7ZX	BAY-17-1998	Terminated
T14558	DRUGINFO	D0W7DD	BAY-44-3428	Terminated
T14558	DRUGINFO	D07IZR	AMG-126737	Investigative
T14558	DRUGINFO	D0NZ3Q	Lactoferrin	Investigative
T14558	DRUGINFO	D0Q4PB	MOL 6131	Investigative
T14558	DRUGINFO	D09YQM	BMS-262084	Investigative
T14558	DRUGINFO	D0Y5IQ	Grassystatin a	Investigative

T51076	TARGETID	T51076
T51076	FORMERID	TTDI01807
T51076	UNIPROID	NTRK3_HUMAN
T51076	TARGNAME	NT-3 growth factor receptor (TrkC)
T51076	GENENAME	NTRK3
T51076	TARGTYPE	Successful
T51076	SYNONYMS	TrkC tyrosine kinase; Trk-C; TRKC; Neurotrophic tyrosine kinase receptor type 3; NT3 growth factor receptor; GP145TrkC; GP145-TrkC
T51076	FUNCTION	Upon binding of its ligand NTF3/neurotrophin-3, NTRK3 autophosphorylates and activates different signaling pathways, including the phosphatidylinositol 3-kinase/AKT and the MAPK pathways, that control cell survival and differentiation. Receptor tyrosine kinase involved in nervous system and probably heart development.
T51076	PDBSTRUC	4YMJ; 3V5Q; 1WWC
T51076	BIOCLASS	Kinase
T51076	ECNUMBER	EC 2.7.10.1
T51076	SEQUENCE	MDVSLCPAKCSFWRIFLLGSVWLDYVGSVLACPANCVCSKTEINCRRPDDGNLFPLLEGQDSGNSNGNASINITDISRNITSIHIENWRSLHTLNAVDMELYTGLQKLTIKNSGLRSIQPRAFAKNPHLRYINLSSNRLTTLSWQLFQTLSLRELQLEQNFFNCSCDIRWMQLWQEQGEAKLNSQNLYCINADGSQLPLFRMNISQCDLPEISVSHVNLTVREGDNAVITCNGSGSPLPDVDWIVTGLQSINTHQTNLNWTNVHAINLTLVNVTSEDNGFTLTCIAENVVGMSNASVALTVYYPPRVVSLEEPELRLEHCIEFVVRGNPPPTLHWLHNGQPLRESKIIHVEYYQEGEISEGCLLFNKPTHYNNGNYTLIAKNPLGTANQTINGHFLKEPFPESTDNFILFDEVSPTPPITVTHKPEEDTFGVSIAVGLAAFACVLLVVLFVMINKYGRRSKFGMKGPVAVISGEEDSASPLHHINHGITTPSSLDAGPDTVVIGMTRIPVIENPQYFRQGHNCHKPDTYVQHIKRRDIVLKRELGEGAFGKVFLAECYNLSPTKDKMLVAVKALKDPTLAARKDFQREAELLTNLQHEHIVKFYGVCGDGDPLIMVFEYMKHGDLNKFLRAHGPDAMILVDGQPRQAKGELGLSQMLHIASQIASGMVYLASQHFVHRDLATRNCLVGANLLVKIGDFGMSRDVYSTDYYRLFNPSGNDFCIWCEVGGHTMLPIRWMPPESIMYRKFTTESDVWSFGVILWEIFTYGKQPWFQLSNTEVIECITQGRVLERPRVCPKEVYDVMLGCWQREPQQRLNIKEIYKILHALGKATPIYLDILG
T51076	DRUGINFO	D07TOK	Larotrectinib	Approved
T51076	DRUGINFO	D0O0LS	Entrectinib	Approved
T51076	DRUGINFO	D00DRL	MK-2461	Phase 1/2
T51076	DRUGINFO	D0FA6S	Altiratinib	Phase 1
T51076	DRUGINFO	D0NS6S	Cyclopenta[d]pyrimidine derivative 1	Patented
T51076	DRUGINFO	D00MGO	PMID28270021-Compound-WO2016054807Example1	Patented
T51076	DRUGINFO	D07RLB	PMID28270010-Compound-Figure24-b	Patented
T51076	DRUGINFO	D0AG2A	Pyrrolo[2,3-d]pyrimidine derivative 4	Patented
T51076	DRUGINFO	D0AU4G	3-amino-5-benzyl-substituted indazole derivative 1	Patented
T51076	DRUGINFO	D0J9ZG	PMID28270010-Compound-Figure5-1	Patented
T51076	DRUGINFO	D0M8VS	PMID28270021-Compound-WO2015042088Example4	Patented
T51076	DRUGINFO	D0T2OX	PMID28270010-Compound-Figure5-2	Patented
T51076	DRUGINFO	D0V5AG	PMID28270010-Compound-Figure5-3	Patented
T51076	DRUGINFO	D0Y1NH	Azaindazole amide derivative 1	Patented
T51076	DRUGINFO	D0KX1E	CEP-2563	Discontinued in Phase 1
T51076	DRUGINFO	D02RWC	GNF-5837	Investigative
T51076	DRUGINFO	D0MH1X	AZD1332	Investigative
T51076	DRUGINFO	D0Y4BL	JNJ-28312141	Investigative
T51076	DRUGINFO	D02NNT	PMID21493067C1d	Investigative
T51076	DRUGINFO	D0E7VO	PMID24900538C2c	Investigative

T80896	TARGETID	T80896
T80896	FORMERID	TTDS00250
T80896	UNIPROID	ESR2_HUMAN
T80896	TARGNAME	Estrogen receptor beta (ESR2)
T80896	GENENAME	ESR2
T80896	TARGTYPE	Successful
T80896	SYNONYMS	Oestrogen receptor beta; Nuclear receptor subfamily 3 group A member 2; NR3A2; Erbeta; ESTRB; ER-beta; Beta-1
T80896	FUNCTION	Binds estrogens with an affinity similar to that of ESR1, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent manner. Isoform beta-cx lacks ligand binding ability and has no or only very low ere binding activity resulting in the loss of ligand-dependent transactivation ability. DNA-binding by ESR1 and ESR2 is rapidly lost at 37 degrees Celsius in the absence of ligand while in the presence of 17 beta-estradiol and 4-hydroxy-tamoxifen loss in DNA-binding at elevated temperature is more gradual. Nuclear hormone receptor.
T80896	PDBSTRUC	5TOA; 4ZI1; 4J26; 4J24; 3OMQ
T80896	BIOCLASS	Nuclear hormone receptor
T80896	SEQUENCE	MDIKNSPSSLNSPSSYNCSQSILPLEHGSIYIPSSYVDSHHEYPAMTFYSPAVMNYSIPSNVTNLEGGPGRQTTSPNVLWPTPGHLSPLVVHRQLSHLYAEPQKSPWCEARSLEHTLPVNRETLKRKVSGNRCASPVTGPGSKRDAHFCAVCSDYASGYHYGVWSCEGCKAFFKRSIQGHNDYICPATNQCTIDKNRRKSCQACRLRKCYEVGMVKCGSRRERCGYRLVRRQRSADEQLHCAGKAKRSGGHAPRVRELLLDALSPEQLVLTLLEAEPPHVLISRPSAPFTEASMMMSLTKLADKELVHMISWAKKIPGFVELSLFDQVRLLESCWMEVLMMGLMWRSIDHPGKLIFAPDLVLDRDEGKCVEGILEIFDMLLATTSRFRELKLQHKEYLCVKAMILLNSSMYPLVTATQDADSSRKLAHLLNAVTDALVWVIAKSGISSQQQSMRLANLLMLLSHVRHASNKGMEHLLNMKCKNVVPVYDLLLEMLNAHVLRGCKSSITGSECSPAEDSKSKEGSQNPQSQ
T80896	DRUGINFO	D03XOC	Trilostane	Approved
T80896	DRUGINFO	D0T0LU	Conjugated Estrogens	Approved
T80896	DRUGINFO	D06LOQ	ARZOXIFENE	Approved
T80896	DRUGINFO	D0M8PD	Estrogen	Approved
T80896	DRUGINFO	D02GLD	MF-101	Phase 3
T80896	DRUGINFO	D0G7IV	Premarin/Pravachol	Phase 3
T80896	DRUGINFO	D0L4FS	Genistein	Phase 2/3
T80896	DRUGINFO	D01HXA	AUS-131	Phase 2
T80896	DRUGINFO	D07LZH	ERB-041	Phase 2
T80896	DRUGINFO	D0R2SK	Erteberel	Phase 2
T80896	DRUGINFO	D01PTS	VG-101	Phase 1/2
T80896	DRUGINFO	D05KUP	ERB-257	Phase 1
T80896	DRUGINFO	D02ABO	NARINGENIN	Phase 1
T80896	DRUGINFO	D0C4FT	HEXESTROL	Withdrawn from market
T80896	DRUGINFO	D0QQ1J	BITHIONOL	Withdrawn from market
T80896	DRUGINFO	D0MU0S	EM-800	Discontinued in Phase 3
T80896	DRUGINFO	D0R8TB	ERA-923	Discontinued in Phase 2
T80896	DRUGINFO	D08HIH	ERB-196	Discontinued in Phase 1
T80896	DRUGINFO	D08DZZ	HE2100	Discontinued in Phase 1
T80896	DRUGINFO	D09AAM	ICI-164384	Terminated
T80896	DRUGINFO	D0H5CV	ZK-119010	Terminated
T80896	DRUGINFO	D0SM0J	LY-117018	Terminated
T80896	DRUGINFO	D00FPJ	3,4,6-Trihydroxy-2-(4-hydroxy-phenyl)-inden-1-one	Investigative
T80896	DRUGINFO	D01AHL	7-hydroxy-1,2,9,9a-tetrahydrofluoren-3-one	Investigative
T80896	DRUGINFO	D01CYI	7-hydroxy-3-(4-hydroxyphenyl)-3H-quinazolin-4-one	Investigative
T80896	DRUGINFO	D01IRO	4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME	Investigative
T80896	DRUGINFO	D01MWF	GTx-878	Investigative
T80896	DRUGINFO	D02EIK	Para-Mercury-Benzenesulfonic Acid	Investigative
T80896	DRUGINFO	D02WRU	PHTPP	Investigative
T80896	DRUGINFO	D02WSA	5,7-dihydroxy-3-phenyl-3H-quinazolin-4-one	Investigative
T80896	DRUGINFO	D02XVV	3-hydroxy-4,7-dimethyl-6H-benzo[c]chromen-6-one	Investigative
T80896	DRUGINFO	D05EOW	diarylpropionitril	Investigative
T80896	DRUGINFO	D05LQD	3-hydroxy-4,10-dimethyl-6H-benzo[c]chromen-6-one	Investigative
T80896	DRUGINFO	D05PNP	TUPICHINOL C	Investigative
T80896	DRUGINFO	D05QIZ	GTx-822	Investigative
T80896	DRUGINFO	D09FWP	6-(2-Hydroxy-phenyl)-naphthalen-2-ol	Investigative
T80896	DRUGINFO	D0H4RV	NDC-1022	Investigative
T80896	DRUGINFO	D0I5VJ	THIOGENISTEIN	Investigative
T80896	DRUGINFO	D0K0TR	3-(4-Hydroxy-phenyl)-4H-chromen-7-ol	Investigative
T80896	DRUGINFO	D0OX6I	KB-9520	Investigative
T80896	DRUGINFO	D0P4SR	2-(4-Hydroxy-phenyl)-1-p-tolyl-3H-inden-5-ol	Investigative
T80896	DRUGINFO	D0V3OR	3,6-Dihydroxy-2-(4-hydroxy-phenyl)-inden-1-one	Investigative
T80896	DRUGINFO	D0WP6A	3-hydroxy-4-methyl-6H-benzo[c]chromen-6-one	Investigative
T80896	DRUGINFO	D0XD4N	ERB-002	Investigative
T80896	DRUGINFO	D0Z3NC	HPTE	Investigative
T80896	DRUGINFO	D00AAU	3-[1-ethyl-2-(3-hydroxyphenyl)butyl]phenol	Investigative
T80896	DRUGINFO	D00CWN	2-(4-Hydroxy-phenyl)-quinolin-6-ol	Investigative
T80896	DRUGINFO	D00FUO	Nafoxidine	Investigative
T80896	DRUGINFO	D00HUB	[1,1':2',1'']Terphenyl-4'-carbaldehyde oxime	Investigative
T80896	DRUGINFO	D00HZT	2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-6-ol	Investigative
T80896	DRUGINFO	D00IXB	6-ethyl-4,7-dimethyl-6H-benzo[c]chromene-3,8-diol	Investigative
T80896	DRUGINFO	D00NEK	4-(3-phenyl-1H-indol-2-yl)phenol	Investigative
T80896	DRUGINFO	D00OLH	4-[1,2-bis(4-hydroxyphenyl)vinyl]phenol	Investigative
T80896	DRUGINFO	D00URP	4,10-dimethyl-6H-benzo[c]chromene-3,8-diol	Investigative
T80896	DRUGINFO	D00ZBL	7-Allyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol	Investigative
T80896	DRUGINFO	D01GPY	6-(4-Hydroxy-2-methyl-phenyl)-naphthalen-2-ol	Investigative
T80896	DRUGINFO	D01KJU	1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL	Investigative
T80896	DRUGINFO	D01KSR	5-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-6-ol	Investigative
T80896	DRUGINFO	D01QXL	2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-5-ol	Investigative
T80896	DRUGINFO	D01SWO	2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol	Investigative
T80896	DRUGINFO	D01UAO	3-chloro-4-(4-hydroxyphenyl)salicylaldoxime	Investigative
T80896	DRUGINFO	D01WCA	2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL	Investigative
T80896	DRUGINFO	D02DML	COUMESTROL	Investigative
T80896	DRUGINFO	D02DVT	4-[1,2-bis(4-hydroxyphenyl)pent-1-enyl]phenol	Investigative
T80896	DRUGINFO	D02EJM	2-(4-Hydroxy-phenyl)-7-propenyl-benzooxazol-5-ol	Investigative
T80896	DRUGINFO	D02HGS	5-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol	Investigative
T80896	DRUGINFO	D02JJU	2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-5-ol	Investigative
T80896	DRUGINFO	D02LCC	2-(4-Hydroxy-phenyl)-7-isopropyl-benzooxazol-5-ol	Investigative
T80896	DRUGINFO	D02OKF	6-(2-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol	Investigative
T80896	DRUGINFO	D02RQP	bisphenol A	Investigative
T80896	DRUGINFO	D02VIW	DIHYDRORALOXIFENE	Investigative
T80896	DRUGINFO	D03DVM	2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-6-ol	Investigative
T80896	DRUGINFO	D03EOD	4-[2,2-bis(4-hydroxyphenyl)-1-methylvinyl]phenol	Investigative
T80896	DRUGINFO	D03GYS	7-Butyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol	Investigative
T80896	DRUGINFO	D03QHG	8-(2,2-dimethylpropyl)naringenin	Investigative
T80896	DRUGINFO	D03RYU	4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol	Investigative
T80896	DRUGINFO	D03XEU	2-(4-Hydroxy-phenyl)-7-methoxy-benzofuran-5-ol	Investigative
T80896	DRUGINFO	D04EAY	3-(2-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol	Investigative
T80896	DRUGINFO	D04SEX	R,R-THC	Investigative
T80896	DRUGINFO	D04WHH	2-(4-Hydroxy-phenyl)-7-propyl-benzooxazol-5-ol	Investigative
T80896	DRUGINFO	D05FUY	1,8-Dichloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol	Investigative
T80896	DRUGINFO	D05JKC	6-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-5-ol	Investigative
T80896	DRUGINFO	D05JPW	2-(4-Hydroxy-phenyl)-7-methoxy-benzooxazol-5-ol	Investigative
T80896	DRUGINFO	D05KXP	8-n-undecylnaringenin	Investigative
T80896	DRUGINFO	D05YIU	7-Chloro-2-(4-hydroxy-phenyl)-benzofuran-5-ol	Investigative
T80896	DRUGINFO	D06DDT	BROUSSONIN A	Investigative
T80896	DRUGINFO	D06DNN	4-[1,2-bis(4-hydroxyphenyl)hex-1-enyl]phenol	Investigative
T80896	DRUGINFO	D06OAL	7-Ethyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol	Investigative
T80896	DRUGINFO	D06SCS	WAY200070	Investigative
T80896	DRUGINFO	D07LUI	6-(4-Hydroxy-phenyl)-naphthalen-2-ol	Investigative
T80896	DRUGINFO	D07VPM	2-(4-Hydroxy-phenyl)-7-phenyl-benzooxazol-5-ol	Investigative
T80896	DRUGINFO	D07XBD	6-(4-Hydroxy-phenyl)-1-methyl-naphthalen-2-ol	Investigative
T80896	DRUGINFO	D07XUY	8-methylnaringenin	Investigative
T80896	DRUGINFO	D08FLV	3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-5-ol	Investigative
T80896	DRUGINFO	D08HCF	2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-6-ol	Investigative
T80896	DRUGINFO	D08VDX	8-Chloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol	Investigative
T80896	DRUGINFO	D08WDN	4-Benzo[d]isoxazol-3-yl-benzene-1,3-diol	Investigative
T80896	DRUGINFO	D09CQC	2-(4-Hydroxy-phenyl)-benzooxazol-6-ol	Investigative
T80896	DRUGINFO	D09DEK	7-(4-Hydroxy-phenyl)-naphthalen-2-ol	Investigative
T80896	DRUGINFO	D09NOH	8-(3-methylbutyl)naringenin	Investigative
T80896	DRUGINFO	D09PXU	4,7-dimethyl-6H-benzo[c]chromene-3,8-diol	Investigative
T80896	DRUGINFO	D09TQE	2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-5-ol	Investigative
T80896	DRUGINFO	D0A1JP	3'-Methoxy-4'Hydroxyclomiphene	Investigative
T80896	DRUGINFO	D0AD3U	2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-6-ol	Investigative
T80896	DRUGINFO	D0B1HP	3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol	Investigative
T80896	DRUGINFO	D0B4VV	Trans-hydroxytamoxifen	Investigative
T80896	DRUGINFO	D0C5FY	3,8-dihydroxy-4-methyl-6H-benzo[c]chromen-6-one	Investigative
T80896	DRUGINFO	D0C6AP	2-(4-Hydroxy-phenyl)-7-methyl-benzofuran-5-ol	Investigative
T80896	DRUGINFO	D0C9XK	4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol	Investigative
T80896	DRUGINFO	D0CC6R	6-(2-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol	Investigative
T80896	DRUGINFO	D0D1LB	8-benzylnaringenin	Investigative
T80896	DRUGINFO	D0DK9S	2-(3-Butoxy-4-hydroxy-phenyl)-benzooxazol-6-ol	Investigative
T80896	DRUGINFO	D0FD6Z	8-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol	Investigative
T80896	DRUGINFO	D0H1CO	2-Naphthalen-1-yl-benzooxazol-6-ol	Investigative
T80896	DRUGINFO	D0H2FI	6-(4-Hydroxy-phenyl)-1-nitro-naphthalen-2-ol	Investigative
T80896	DRUGINFO	D0H5HI	4,6,6,7-tetramethyl-6H-benzo[c]chromene-3,8-diol	Investigative
T80896	DRUGINFO	D0HM8Y	3,8-dihydroxy-7-methyl-6H-benzo[c]chromen-6-one	Investigative
T80896	DRUGINFO	D0HR8L	6-(3-Hydroxy-phenyl)-naphthalen-1-ol	Investigative
T80896	DRUGINFO	D0I1NX	4-[1,2-bis(4-hydroxyphenyl)but-1-enyl]phenol	Investigative
T80896	DRUGINFO	D0I5HZ	4-(2-phenyl-1H-benzo[d]imidazol-1-yl)phenol	Investigative
T80896	DRUGINFO	D0J0AG	5-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol	Investigative
T80896	DRUGINFO	D0J2NG	8-n-heptylnaringenin	Investigative
T80896	DRUGINFO	D0K0IC	4-(2-phenyl-1H-indol-3-yl)phenol	Investigative
T80896	DRUGINFO	D0K1TW	2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol	Investigative
T80896	DRUGINFO	D0K6TE	6-(3-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol	Investigative
T80896	DRUGINFO	D0L2MU	7-Bromo-2-(4-hydroxy-phenyl)-benzofuran-5-ol	Investigative
T80896	DRUGINFO	D0L3AX	4-Naphthalen-2-yl-phenol	Investigative
T80896	DRUGINFO	D0L6IQ	2-(4-Hydroxy-phenyl)-4-methoxy-quinolin-6-ol	Investigative
T80896	DRUGINFO	D0LI0M	8-n-pentylnaringenin	Investigative
T80896	DRUGINFO	D0M0XL	6-(4-Hydroxy-phenyl)-1-methoxy-naphthalen-2-ol	Investigative
T80896	DRUGINFO	D0MY8V	6-(3,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol	Investigative
T80896	DRUGINFO	D0N0OY	2-(4-Hydroxy-phenyl)-benzooxazol-5-ol	Investigative
T80896	DRUGINFO	D0NN0V	4',5,7-trihydroxy-6,8-dimethylisoflavone	Investigative
T80896	DRUGINFO	D0O2KP	2-phenyl-1,2'-spirobi[1H-indene]-5'-ol	Investigative
T80896	DRUGINFO	D0O5KR	4,6,7-trimethyl-6H-benzo[c]chromene-3,8-diol	Investigative
T80896	DRUGINFO	D0O6FX	4,6,7,10-tetramethyl-6H-benzo[c]chromene-3,8-diol	Investigative
T80896	DRUGINFO	D0P0FN	ZK-164015	Investigative
T80896	DRUGINFO	D0P6FN	6-(4-Hydroxy-2-methoxy-phenyl)-naphthalen-2-ol	Investigative
T80896	DRUGINFO	D0P7PK	2,3-diphenyl-1H-indole	Investigative
T80896	DRUGINFO	D0P8XE	GNF-PF-3037	Investigative
T80896	DRUGINFO	D0R7AG	4-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol	Investigative
T80896	DRUGINFO	D0RI6O	Doxorubicin-Formaldehyde Conjugate	Investigative
T80896	DRUGINFO	D0S0SZ	7-Ethynyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol	Investigative
T80896	DRUGINFO	D0S2ZJ	3-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol	Investigative
T80896	DRUGINFO	D0S6NV	1-Bromo-6-(4-hydroxy-phenyl)-naphthalen-2-ol	Investigative
T80896	DRUGINFO	D0S8EB	4,6,10-trimethyl-6H-benzo[c]chromene-3,8-diol	Investigative
T80896	DRUGINFO	D0SR8Q	7-Phenyl-naphthalen-2-ol	Investigative
T80896	DRUGINFO	D0U0ZE	3-hydroxy-8,10-dimethyl-6H-benzo[c]chromen-6-one	Investigative
T80896	DRUGINFO	D0U2VA	2-(5-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol	Investigative
T80896	DRUGINFO	D0U7KV	4-(3-(4-hydroxyphenyl)-1H-indol-2-yl)phenol	Investigative
T80896	DRUGINFO	D0UV9G	6-Phenyl-naphthalen-2-ol	Investigative
T80896	DRUGINFO	D0V6KJ	6-(2,6-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol	Investigative
T80896	DRUGINFO	D0V7QZ	2-(2-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol	Investigative
T80896	DRUGINFO	D0VN2R	6-(4-Hydroxy-phenyl)-1-phenyl-naphthalen-2-ol	Investigative
T80896	DRUGINFO	D0W0LG	8-n-propylnaringenin	Investigative
T80896	DRUGINFO	D0W2YR	3-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol	Investigative
T80896	DRUGINFO	D0W3FF	2-(4-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol	Investigative
T80896	DRUGINFO	D0W4WF	EFFUSOL	Investigative
T80896	DRUGINFO	D0W5HT	8-n-nonylnaringenin	Investigative
T80896	DRUGINFO	D0X2VK	2-(4-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol	Investigative
T80896	DRUGINFO	D0X4VN	6-(3-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol	Investigative
T80896	DRUGINFO	D0X7DJ	6-(2,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol	Investigative
T80896	DRUGINFO	D0Y2LJ	8-(2-methylpropyl)naringenin	Investigative
T80896	DRUGINFO	D0Y9BO	WAY-169916	Investigative
T80896	DRUGINFO	D0YH4T	2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol	Investigative
T80896	DRUGINFO	D0YW4C	2-(4-Hydroxy-phenyl)-7-vinyl-benzooxazol-5-ol	Investigative
T80896	DRUGINFO	D0Z0UC	1,2-Bis-(4-hydroxy-phenyl)-3H-inden-5-ol	Investigative
T80896	DRUGINFO	D0ZT4U	1-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol	Investigative
T80896	DRUGINFO	D01IAT	7-(3-Hydroxy-phenyl)-naphthalen-2-ol	Investigative
T80896	DRUGINFO	D01TUB	4-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol	Investigative
T80896	DRUGINFO	D03CBX	4-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol	Investigative
T80896	DRUGINFO	D08SJL	4-Ethynyl-2-(4-hydroxy-phenyl)-quinolin-6-ol	Investigative
T80896	DRUGINFO	D09FWS	4-Ethyl-2-(4-hydroxy-phenyl)-quinolin-6-ol	Investigative
T80896	DRUGINFO	D0H8PI	6-(4-Hydroxy-phenyl)-naphthalen-1-ol	Investigative
T80896	DRUGINFO	D0K7HR	2-(4-Hydroxy-phenyl)-4-vinyl-quinolin-6-ol	Investigative
T80896	DRUGINFO	D0S8AV	SOPHORAFLAVANONE B	Investigative
T80896	DRUGINFO	D0H6OS	Geldanamycin-estradiol hybrid	Investigative
T80896	DRUGINFO	D0J7XZ	CP-409069	Investigative
T80896	DRUGINFO	D0L5IC	CP-394531	Investigative
T80896	DRUGINFO	D0P8PK	6-(3-Hydroxy-phenyl)-naphthalen-2-ol	Investigative
T80896	DRUGINFO	D0NJ4H	MORIN	Investigative
T80896	DRUGINFO	D0SY2M	daidzein	Investigative
T80896	DRUGINFO	D0F2ME	Acetate Ion	Investigative

T46360	TARGETID	T46360
T46360	FORMERID	TTDS00129
T46360	UNIPROID	SGMR1_HUMAN
T46360	TARGNAME	Opioid receptor sigma 1 (OPRS1)
T46360	GENENAME	SIGMAR1
T46360	TARGTYPE	Successful
T46360	SYNONYMS	hSigmaR1; Sigma1R; Sigma1-receptor; Sigma non-opioid intracellular receptor 1; Sigma 1-type opioid receptor; SRBP; SR31747-binding protein; SR31747 binding protein 1; SR-BP; SIG-1R; Opioid receptor, sigma 1, isoform 1; OPRS1 protein; Aging-associated gene 8 protein; AAG8
T46360	FUNCTION	Involved in the regulation of different receptors it plays a role in BDNF signaling and EGF signaling. Also regulates ion channels like the potassium channel and could modulate neurotransmitter release. Plays a role in calcium signaling through modulation together with ANK2 of the ITP3R-dependent calcium efflux at the endoplasmic reticulum. Plays a role in several other cell functions including proliferation, survival and death. Originally identified for its ability to bind various psychoactive drugs it is involved in learning processes, memory and mood alteration. Necessary for proper mitochondrial axonal transport in motor neurons, in particular the retrograde movement of mitochondria. Plays a role in protecting cells against oxidative stress-induced cell death via its interaction with RNF112. Functions in lipid transport from the endoplasmic reticulum and is involved in a wide array of cellular functions probably through regulation of the biogenesis of lipid microdomains at the plasma membrane.
T46360	PDBSTRUC	6DK1; 6DK0; 6DJZ; 5HK2; 5HK1
T46360	BIOCLASS	GPCR rhodopsin
T46360	SEQUENCE	MQWAVGRRWAWAALLLAVAAVLTQVVWLWLGTQSFVFQREEIAQLARQYAGLDHELAFSRLIVELRRLHPGHVLPDEELQWVFVNAGGWMGAMCLLHASLSEYVLLFGTALGSRGHSGRYWAEISDTIISGTFHQWREGTTKSEVFYPGETVVHGPGEATAVEWGPNTWMVEYGRGVIPSTLAFALADTVFSTQDFLTLFYTLRSYARGLRLELTTYLFGQDP
T46360	DRUGINFO	D09OBB	Dextromethorphan	Approved
T46360	DRUGINFO	D00KFB	Dextromethorphan Polistirex	Approved
T46360	DRUGINFO	D0GW6K	ADX N05	Phase 3
T46360	DRUGINFO	D0Z6IB	AVP-786	Phase 3
T46360	DRUGINFO	D0X6XH	CM-2395	Phase 3
T46360	DRUGINFO	D0N5LJ	Igmesine	Phase 2
T46360	DRUGINFO	D0R8GR	OPC-14523	Phase 2
T46360	DRUGINFO	D0G9SH	SA-5845	Phase 1
T46360	DRUGINFO	D0T6ES	SSR-125329A	Phase 1
T46360	DRUGINFO	D09AOO	ANAVEX 2-73	Phase 1
T46360	DRUGINFO	D0Q7QY	SSR-125047	Phase 1
T46360	DRUGINFO	DZ02CQ	ANAVEX 3-71	Phase 1
T46360	DRUGINFO	D04PCA	Pyrazole derivative 86	Patented
T46360	DRUGINFO	D07XVQ	Aryl alkanolamine derivative 2	Patented
T46360	DRUGINFO	D08RUG	1,2,4-triazole derivative 4	Patented
T46360	DRUGINFO	D0A0DV	Phenylpropylamine derivative 4	Patented
T46360	DRUGINFO	D0C1YW	Phenylpropylamine derivative 3	Patented
T46360	DRUGINFO	D0E9CK	Aryl alkanolamine derivative 1	Patented
T46360	DRUGINFO	D0G4GT	Phenylpropylamine derivative 1	Patented
T46360	DRUGINFO	D0G7GN	Phenylpropylamine derivative 5	Patented
T46360	DRUGINFO	D0L0CD	Phenylpropylamine derivative 2	Patented
T46360	DRUGINFO	D0MD6P	1,2,4-triazole derivative 3	Patented
T46360	DRUGINFO	D0X5FS	Piperidine derivative 4	Patented
T46360	DRUGINFO	D03MKY	Benzamide derivative 9	Patented
T46360	DRUGINFO	D05YFF	Benzamide derivative 10	Patented
T46360	DRUGINFO	D0DW1D	PMID30185082-Compound-57	Patented
T46360	DRUGINFO	D0EO9Z	PMID28051882-Compound-XIV	Patented
T46360	DRUGINFO	D0H2SE	Benzamide derivative 8	Patented
T46360	DRUGINFO	D0J9SL	Piperazine derivative 7	Patented
T46360	DRUGINFO	D0RS2J	Benzamide derivative 7	Patented
T46360	DRUGINFO	D0SG9W	PMID30185082-Compound-64	Patented
T46360	DRUGINFO	D0T5SO	Piperidine derivative 6	Patented
T46360	DRUGINFO	D0W3TS	Benzamide derivative 11	Patented
T46360	DRUGINFO	D0X9RA	Piperidine derivative 5	Patented
T46360	DRUGINFO	D02NPB	Isoindoline derivative 5	Patented
T46360	DRUGINFO	D06FNA	Isoindoline derivative 3	Patented
T46360	DRUGINFO	D0EK3Z	Isoindoline derivative 4	Patented
T46360	DRUGINFO	D0F8XU	Isoindoline derivative 2	Patented
T46360	DRUGINFO	D0S3ON	Isoindoline derivative 1	Patented
T46360	DRUGINFO	D01YOC	BMS-181100	Discontinued in Phase 3
T46360	DRUGINFO	D00EZE	Panamesine	Discontinued in Phase 2
T46360	DRUGINFO	D0L4PY	KB-5492	Discontinued in Phase 2
T46360	DRUGINFO	D02JNX	OxycoDex	Discontinued in Phase 2
T46360	DRUGINFO	D0L7BV	Gevotroline	Discontinued in Phase 1
T46360	DRUGINFO	D0Z4QV	DUP-734	Discontinued in Phase 1
T46360	DRUGINFO	D00KVE	Cutamesine	Preclinical
T46360	DRUGINFO	D0T0UC	ANAVEX 1-41	Preclinical
T46360	DRUGINFO	D0M6OW	ANAVEX 1007	Preclinical
T46360	DRUGINFO	D00IRU	E-5842	Terminated
T46360	DRUGINFO	D01KIU	PRE-084	Terminated
T46360	DRUGINFO	D09DRG	NE-100	Terminated
T46360	DRUGINFO	D09OTG	MS-377	Terminated
T46360	DRUGINFO	D0B1PD	NPC-16377	Terminated
T46360	DRUGINFO	D0B7BX	E-6276	Terminated
T46360	DRUGINFO	D0L1YS	NE-033	Terminated
T46360	DRUGINFO	D0M9GE	Rimcazole	Terminated
T46360	DRUGINFO	D0MK2C	SR-31742A	Terminated
T46360	DRUGINFO	D0T8BP	AH-9700	Terminated
T46360	DRUGINFO	D0T8HU	LU-29252	Terminated
T46360	DRUGINFO	D0U7VO	CNS-1307	Terminated
T46360	DRUGINFO	D0Z5HB	FH-510	Terminated
T46360	DRUGINFO	D0Q7OA	HydrocoDex	Terminated
T46360	DRUGINFO	D05BLG	MC-116	Investigative
T46360	DRUGINFO	D07LVT	(RS)-PPCC	Investigative
T46360	DRUGINFO	D09AUU	Dimemorfan	Investigative
T46360	DRUGINFO	D09CGH	BD-1047	Investigative
T46360	DRUGINFO	D0A3XA	CNS-1169	Investigative
T46360	DRUGINFO	D0F1WD	C-10068	Investigative
T46360	DRUGINFO	D0G4KB	[3H]pentazocine	Investigative
T46360	DRUGINFO	D0G5RT	MC-113	Investigative
T46360	DRUGINFO	D0IZ1X	(+)-SK&F10047	Investigative
T46360	DRUGINFO	D0J9VK	CM-156	Investigative
T46360	DRUGINFO	D03DLZ	2-(1H-indol-3-yl)-N,N-dimethylethanamine	Investigative
T46360	DRUGINFO	D02WJT	1,3-ditolylguanidine	Investigative

T66505	TARGETID	T66505
T66505	FORMERID	TTDNS00536
T66505	UNIPROID	SMO_HUMAN
T66505	TARGNAME	Smoothened homolog (SMO)
T66505	GENENAME	SMO
T66505	TARGTYPE	Successful
T66505	SYNONYMS	Smo-D473H; SMOH; Protein Gx
T66505	FUNCTION	Binding of sonic hedgehog (SHH) to its receptor patched is thought to prevent normal inhibition by patched of smoothened (SMO). Required for the accumulation of KIF7, GLI2 and GLI3 in the cilia. Interacts with DLG5 at the ciliary base to induce the accumulation of KIF7 and GLI2 at the ciliary tip for GLI2 activation. G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog's proteins signal.
T66505	PDBSTRUC	5V57; 5V56; 5L7I; 5L7D; 4QIN
T66505	BIOCLASS	GPCR frizzled
T66505	SEQUENCE	MAAARPARGPELPLLGLLLLLLLGDPGRGAASSGNATGPGPRSAGGSARRSAAVTGPPPPLSHCGRAAPCEPLRYNVCLGSVLPYGATSTLLAGDSDSQEEAHGKLVLWSGLRNAPRCWAVIQPLLCAVYMPKCENDRVELPSRTLCQATRGPCAIVERERGWPDFLRCTPDRFPEGCTNEVQNIKFNSSGQCEVPLVRTDNPKSWYEDVEGCGIQCQNPLFTEAEHQDMHSYIAAFGAVTGLCTLFTLATFVADWRNSNRYPAVILFYVNACFFVGSIGWLAQFMDGARREIVCRADGTMRLGEPTSNETLSCVIIFVIVYYALMAGVVWFVVLTYAWHTSFKALGTTYQPLSGKTSYFHLLTWSLPFVLTVAILAVAQVDGDSVSGICFVGYKNYRYRAGFVLAPIGLVLIVGGYFLIRGVMTLFSIKSNHPGLLSEKAASKINETMLRLGIFGFLAFGFVLITFSCHFYDFFNQAEWERSFRDYVLCQANVTIGLPTKQPIPDCEIKNRPSLLVEKINLFAMFGTGIAMSTWVWTKATLLIWRRTWCRLTGQSDDEPKRIKKSKMIAKAFSKRHELLQNPGQELSFSMHTVSHDGPVAGLAFDLNEPSADVSSAWAQHVTKMVARRGAILPQDISVTPVATPVPPEEQANLWLVEAEISPELQKRLGRKKKRRKRKKEVCPLAPPPELHPPAPAPSTIPRLPQLPRQKCLVAAGAWGAGDSCRQGAWTLVSNPFCPEPSPPQDPFLPSAPAPVAWAHGRRQGLGPIHSRTNLMDTELMDADSDF
T66505	DRUGINFO	D03EDQ	Vismodegib	Approved
T66505	DRUGINFO	D0S5LO	PF-04449913	Approved
T66505	DRUGINFO	D09BNZ	LDE225	Phase 2
T66505	DRUGINFO	D0W0SL	LY2940680	Phase 1/2
T66505	DRUGINFO	D03DUY	BMS-833923	Phase 1b
T66505	DRUGINFO	D09UMN	LEQ-506	Phase 1
T66505	DRUGINFO	D0Q4JM	TAK-441	Phase 1
T66505	DRUGINFO	D00GMI	PMID25726713-Compound-36	Patented
T66505	DRUGINFO	D00ITT	PMID25726713-Compound-43	Patented
T66505	DRUGINFO	D01AJO	Imidazo bicyclic iminium derivative 9	Patented
T66505	DRUGINFO	D01AWH	PMID25726713-Compound-45	Patented
T66505	DRUGINFO	D02JSW	PMID25726713-Compound-58	Patented
T66505	DRUGINFO	D03HMW	Pyrimidine derivative 20	Patented
T66505	DRUGINFO	D03QAU	PMID25726713-Compound-42	Patented
T66505	DRUGINFO	D03SCM	PMID25726713-Compound-62	Patented
T66505	DRUGINFO	D05CWM	PMID25726713-Compound-12	Patented
T66505	DRUGINFO	D05MIG	PMID25726713-Compound-31	Patented
T66505	DRUGINFO	D05QCM	PMID25726713-Compound-60	Patented
T66505	DRUGINFO	D05QYN	PMID25726713-Compound-15	Patented
T66505	DRUGINFO	D06ELK	PMID25726713-Compound-32	Patented
T66505	DRUGINFO	D06MXI	PMID25726713-Compound-63	Patented
T66505	DRUGINFO	D06NBL	PMID25726713-Compound-23	Patented
T66505	DRUGINFO	D07ZUO	PMID25726713-Compound-28	Patented
T66505	DRUGINFO	D08LBZ	PMID25726713-Compound-56	Patented
T66505	DRUGINFO	D0AB3D	Imidazo bicyclic iminium derivative 5	Patented
T66505	DRUGINFO	D0B3FN	PMID25726713-Compound-35	Patented
T66505	DRUGINFO	D0B3XW	Cyclic sulfonamide derivative 2	Patented
T66505	DRUGINFO	D0B6GA	PMID25726713-Compound-37	Patented
T66505	DRUGINFO	D0B9ML	PMID25726713-Compound-24	Patented
T66505	DRUGINFO	D0C4PD	PMID25726713-Compound-38	Patented
T66505	DRUGINFO	D0C4VR	PMID25726713-Compound-16	Patented
T66505	DRUGINFO	D0CD8G	PMID25726713-Compound-19	Patented
T66505	DRUGINFO	D0DH0O	PMID25726713-Compound-30	Patented
T66505	DRUGINFO	D0E4TO	PMID25726713-Compound-13	Patented
T66505	DRUGINFO	D0FS1J	Imidazo bicyclic iminium derivative 4	Patented
T66505	DRUGINFO	D0FT1X	PMID25726713-Compound-59	Patented
T66505	DRUGINFO	D0I8RK	Bicyclic hexapeptide derivative 2	Patented
T66505	DRUGINFO	D0IS8B	PMID25726713-Compound-33	Patented
T66505	DRUGINFO	D0IW7A	Cyclic sulfonamide derivative 1	Patented
T66505	DRUGINFO	D0J0AT	PMID25726713-Compound-25	Patented
T66505	DRUGINFO	D0J9JS	Pyrimidine derivative 22	Patented
T66505	DRUGINFO	D0K0IO	Pyrimidine derivative 21	Patented
T66505	DRUGINFO	D0K2FK	Cyclic sulfonamide derivative 3	Patented
T66505	DRUGINFO	D0K6XL	PMID25726713-Compound-29	Patented
T66505	DRUGINFO	D0K8HU	PMID25726713-Compound-39	Patented
T66505	DRUGINFO	D0KC6Y	PMID25726713-Compound-21	Patented
T66505	DRUGINFO	D0KS3J	PMID25726713-Compound-64	Patented
T66505	DRUGINFO	D0KX5G	Imidazo bicyclic iminium derivative 8	Patented
T66505	DRUGINFO	D0LH6R	Imidazo bicyclic iminium derivative 6	Patented
T66505	DRUGINFO	D0O7BH	PMID25726713-Compound-46	Patented
T66505	DRUGINFO	D0P8IR	Bicyclic hexapeptide derivative 1	Patented
T66505	DRUGINFO	D0PG1G	PMID25726713-Compound-57	Patented
T66505	DRUGINFO	D0QA9Q	PMID25726713-Compound-14	Patented
T66505	DRUGINFO	D0QO1Y	PMID25726713-Compound-22	Patented
T66505	DRUGINFO	D0R3UI	PMID25726713-Compound-61	Patented
T66505	DRUGINFO	D0R8UO	PMID25726713-Compound-26	Patented
T66505	DRUGINFO	D0RH3O	PMID25726713-Compound-27	Patented
T66505	DRUGINFO	D0RV9D	PMID25726713-Compound-20	Patented
T66505	DRUGINFO	D0SO6T	PMID25726713-Compound-44	Patented
T66505	DRUGINFO	D0TK2O	PMID25726713-Compound-10	Patented
T66505	DRUGINFO	D0V9AB	Cyclic sulfonamide derivative 4	Patented
T66505	DRUGINFO	D0VR8N	Imidazo bicyclic iminium derivative 3	Patented
T66505	DRUGINFO	D0WB2S	Pyrimidine derivative 19	Patented
T66505	DRUGINFO	D0XH5O	Imidazo bicyclic iminium derivative 7	Patented
T66505	DRUGINFO	D0Y6EY	PMID25726713-Compound-18	Patented
T66505	DRUGINFO	D0Y8SC	PMID25726713-Compound-34	Patented
T66505	DRUGINFO	D0ZF1N	PMID25726713-Compound-11	Patented
T66505	DRUGINFO	D00RRB	Isoflavone derivative 1	Patented
T66505	DRUGINFO	D01BGG	Isoflavone derivative 5	Patented
T66505	DRUGINFO	D04IFL	Isoflavone derivative 7	Patented
T66505	DRUGINFO	D05NRG	Isoflavone derivative 8	Patented
T66505	DRUGINFO	D07BIQ	PMID25726713-Compound-17	Patented
T66505	DRUGINFO	D09VIE	Isoflavone derivative 9	Patented
T66505	DRUGINFO	D0J1RB	Isoflavone derivative 6	Patented
T66505	DRUGINFO	D0TP0S	Isoflavone derivative 3	Patented
T66505	DRUGINFO	D0WI1G	Isoflavone derivative 2	Patented
T66505	DRUGINFO	D0Z6IS	Isoflavone derivative 4	Patented
T66505	DRUGINFO	D07TVO	PMID25726713-Compound-49	Patented
T66505	DRUGINFO	D0KH7Q	PMID25726713-Compound-51	Patented
T66505	DRUGINFO	D0WJ3W	PMID25726713-Compound-48	Patented
T66505	DRUGINFO	D0X5VI	PMID25726713-Compound-47	Patented
T66505	DRUGINFO	D0Y8JF	PMID25726713-Compound-50	Patented
T66505	DRUGINFO	D05UKJ	CYCLOPAMINE	Investigative
T66505	DRUGINFO	D06MUB	SMOi2-17	Investigative
T66505	DRUGINFO	D0R8DO	1-Benzyl-4-(4-phenylpiperazin-1-yl)phthalazine	Investigative
T66505	DRUGINFO	D0V8GX	AZD8542	Investigative

T31992	TARGETID	T31992
T31992	FORMERID	TTDR00213
T31992	UNIPROID	CAH14_HUMAN
T31992	TARGNAME	Carbonic anhydrase XIV (CA-XIV)
T31992	GENENAME	CA14
T31992	TARGTYPE	Successful
T31992	SYNONYMS	UNQ690/PRO1335; Carbonic anhydrase 14; Carbonate dehydratase XIV
T31992	FUNCTION	Reversible hydration of carbon dioxide.
T31992	PDBSTRUC	5CJF; 4LU3
T31992	BIOCLASS	Alpha-carbonic anhydrase
T31992	ECNUMBER	EC 4.2.1.1
T31992	SEQUENCE	MLFSALLLEVIWILAADGGQHWTYEGPHGQDHWPASYPECGNNAQSPIDIQTDSVTFDPDLPALQPHGYDQPGTEPLDLHNNGHTVQLSLPSTLYLGGLPRKYVAAQLHLHWGQKGSPGGSEHQINSEATFAELHIVHYDSDSYDSLSEAAERPQGLAVLGILIEVGETKNIAYEHILSHLHEVRHKDQKTSVPPFNLRELLPKQLGQYFRYNGSLTTPPCYQSVLWTVFYRRSQISMEQLEKLQGTLFSTEEEPSKLLVQNYRALQPLNQRMVFASFIQAGSSYTTGEMLSLGVGILVGCLCLLLAVYFIARKIRKKRLENRKSVVFTSAQATTEA
T31992	DRUGINFO	D09VAZ	TRIENTINE	Approved
T31992	DRUGINFO	D0K1QD	Sulfamylon	Approved
T31992	DRUGINFO	D0A8JP	PARABEN	Phase 3
T31992	DRUGINFO	D07SDQ	Curcumin	Phase 3
T31992	DRUGINFO	D0L6HN	PHENOL	Phase 2/3
T31992	DRUGINFO	D0Y6OA	Coumate	Phase 2
T31992	DRUGINFO	D03SLR	FERULIC ACID	Patented
T31992	DRUGINFO	D0LD9S	SPERMINE	Terminated
T31992	DRUGINFO	D07MTM	4-AMINOPHENOL	Investigative
T31992	DRUGINFO	D07CYN	2-amino-2,3-dihydro-1H-indene-5-sulfonamide	Investigative
T31992	DRUGINFO	D09TES	2-acetamido-2,3-dihydro-1H-indene-5-sulfonic acid	Investigative
T31992	DRUGINFO	D05QUG	7-phenethoxy-2H-chromen-2-one	Investigative
T31992	DRUGINFO	D05VSK	ETHOXYCOUMARIN	Investigative
T31992	DRUGINFO	D00IAE	Prop-2-ynyl 4-sulfamoylbenzoate	Investigative
T31992	DRUGINFO	D00RNZ	7-(benzyloxy)-2H-chromen-2-one	Investigative
T31992	DRUGINFO	D01OTW	4-(Cyanomethylthio)pyridine-3-sulfonamide	Investigative
T31992	DRUGINFO	D01XFH	N-propynyl amidebenzenesulphonide	Investigative
T31992	DRUGINFO	D02BMV	4-(2-Propynylthio)pyridine-3-sulfonamide	Investigative
T31992	DRUGINFO	D02DBP	RESORCINOL	Investigative
T31992	DRUGINFO	D03KRB	4,4'-thiodipyridine-3-sulfonamide	Investigative
T31992	DRUGINFO	D04VSP	4-Ethoxy-3-pyridinesulfonamide	Investigative
T31992	DRUGINFO	D05ETN	4-(2-Methyl-8-quinolinoxy)-3-pyridinesulfonamide	Investigative
T31992	DRUGINFO	D05JAJ	4-(Quinolinoxy)-3-pyridinesulfonamide	Investigative
T31992	DRUGINFO	D06DYP	8-methoxy-2-oxo-2H-chromene-3-carboxylic acid	Investigative
T31992	DRUGINFO	D06IOI	4-Benzythiopyridine-3-sulfonamide	Investigative
T31992	DRUGINFO	D09TKG	4-(Allylamino)-3-pyridinesulfonamide	Investigative
T31992	DRUGINFO	D09WVV	N1-(2-aminoethyl)ethane-1,2-diamine	Investigative
T31992	DRUGINFO	D0C4QB	2-Amino-indan-5-sulfonic acid	Investigative
T31992	DRUGINFO	D0J7GU	4-Methylthiopyridine-3-sulfonamide	Investigative
T31992	DRUGINFO	D0LC0F	2,3-dihydro-1H-indene-5-sulfonamide	Investigative
T31992	DRUGINFO	D0LU4S	7-butoxy-2H-chromen-2-one	Investigative
T31992	DRUGINFO	D0OT5L	7-propoxy-2H-chromen-2-one	Investigative
T31992	DRUGINFO	D0Q5VB	4-(Methylhydrazino)-3-pyridinesulfonamide	Investigative
T31992	DRUGINFO	D0R4KQ	4-(5-Methyl-2-pirazolino)-3-pyridinesulfonamide	Investigative
T31992	DRUGINFO	D0RB0D	7-methoxy-2-oxo-2H-chromene-4-carboxylic acid	Investigative
T31992	DRUGINFO	D0SD9H	Beta-D-Mannose	Investigative
T31992	DRUGINFO	D0UM1I	4-Hydrazino-3-pyridinesulfonamide	Investigative
T31992	DRUGINFO	D0V5OW	4-(Carbamolymethylthio)pyridine-3-sulfonamide	Investigative
T31992	DRUGINFO	D00XJA	6-methoxy-2-oxo-2H-chromene-3-carboxylic acid	Investigative
T31992	DRUGINFO	D04VLI	4-(2-Hydroxy-ethyl)-benzenesulfonamide	Investigative
T31992	DRUGINFO	D07TAJ	Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate	Investigative
T31992	DRUGINFO	D0D6UR	2-oxo-2H-thiochromene-3-carboxylic acid	Investigative
T31992	DRUGINFO	D0H3NS	2-oxo-2H-chromene-3-carboxylic acid	Investigative
T31992	DRUGINFO	D0J2AE	3-Amino-benzenesulfonamide	Investigative
T31992	DRUGINFO	D0OI1H	2-Amino-benzenesulfonamide	Investigative
T31992	DRUGINFO	D0X5HL	N1-(naphthalen-1-yl)ethane-1,2-diamine	Investigative
T31992	DRUGINFO	D04NSN	4-(2-AMINOETHYL)BENZENESULFONAMIDE	Investigative
T31992	DRUGINFO	D05XZM	4-(hydroxymethyl)benzenesulfonamide	Investigative
T31992	DRUGINFO	D09JPC	Hexane-1,6-diamine	Investigative
T31992	DRUGINFO	D09PWX	Carzenide	Investigative
T31992	DRUGINFO	D0G3BI	6-methyl-2-oxo-2H-chromene-3-carboxylic acid	Investigative
T31992	DRUGINFO	D0L5TZ	6-(hydroxymethyl)-2H-chromen-2-one	Investigative
T31992	DRUGINFO	D0Q2LL	6-Hydroxy-benzothiazole-2-sulfonic acid amide	Investigative
T31992	DRUGINFO	D0U4BB	HERNIARIN	Investigative
T31992	DRUGINFO	D00YEF	Decane-1,10-diyl disulfamate	Investigative
T31992	DRUGINFO	D01STY	4-Amino-3-iodo-benzenesulfonamide	Investigative
T31992	DRUGINFO	D02QGI	Pentane-1,5-diamine	Investigative
T31992	DRUGINFO	D03ZMQ	COUMARIN	Investigative
T31992	DRUGINFO	D04CVC	4-Amino-3-fluoro-benzenesulfonamide	Investigative
T31992	DRUGINFO	D05TLB	Octyl sulfamate	Investigative
T31992	DRUGINFO	D09WSJ	Decyl sulfamate	Investigative
T31992	DRUGINFO	D0AU0M	P-Coumaric Acid	Investigative
T31992	DRUGINFO	D0D4OV	Octane-1,8-diyl disulfamate	Investigative
T31992	DRUGINFO	D0E8CC	BENZOLAMIDE	Investigative
T31992	DRUGINFO	D0M3PO	2,4-Disulfamyltrifluoromethylaniline	Investigative
T31992	DRUGINFO	D0N1AW	6-(aminomethyl)-2H-chromen-2-one	Investigative
T31992	DRUGINFO	D0NN3Q	4-Hydrazino-benzenesulfonamide	Investigative
T31992	DRUGINFO	D0P6AM	4-Amino-3-bromo-benzenesulfonamide	Investigative
T31992	DRUGINFO	D0Q7DJ	Syringic Acid	Investigative
T31992	DRUGINFO	D0VD7H	CL-5343	Investigative
T31992	DRUGINFO	D0YU8J	4-Amino-3-chloro-benzenesulfonamide	Investigative
T31992	DRUGINFO	D0V7AA	CATECHIN	Investigative
T31992	DRUGINFO	D0Y3TZ	GALLICACID	Investigative
T31992	DRUGINFO	D0A1CM	ELLAGIC ACID	Investigative

T56418	TARGETID	T56418
T56418	FORMERID	TTDI02271
T56418	UNIPROID	ALK_HUMAN
T56418	TARGNAME	ALK tyrosine kinase receptor (ALK)
T56418	GENENAME	ALK
T56418	TARGTYPE	Successful
T56418	SYNONYMS	CD246; Anaplastic lymphoma kinase
T56418	FUNCTION	Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK. Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system.
T56418	PDBSTRUC	6MX8; 6EDL; 6EBW; 6E0R; 6CDT
T56418	BIOCLASS	Kinase
T56418	ECNUMBER	EC 2.7.10.1
T56418	SEQUENCE	MGAIGLLWLLPLLLSTAAVGSGMGTGQRAGSPAAGPPLQPREPLSYSRLQRKSLAVDFVVPSLFRVYARDLLLPPSSSELKAGRPEARGSLALDCAPLLRLLGPAPGVSWTAGSPAPAEARTLSRVLKGGSVRKLRRAKQLVLELGEEAILEGCVGPPGEAAVGLLQFNLSELFSWWIRQGEGRLRIRLMPEKKASEVGREGRLSAAIRASQPRLLFQIFGTGHSSLESPTNMPSPSPDYFTWNLTWIMKDSFPFLSHRSRYGLECSFDFPCELEYSPPLHDLRNQSWSWRRIPSEEASQMDLLDGPGAERSKEMPRGSFLLLNTSADSKHTILSPWMRSSSEHCTLAVSVHRHLQPSGRYIAQLLPHNEAAREILLMPTPGKHGWTVLQGRIGRPDNPFRVALEYISSGNRSLSAVDFFALKNCSEGTSPGSKMALQSSFTCWNGTVLQLGQACDFHQDCAQGEDESQMCRKLPVGFYCNFEDGFCGWTQGTLSPHTPQWQVRTLKDARFQDHQDHALLLSTTDVPASESATVTSATFPAPIKSSPCELRMSWLIRGVLRGNVSLVLVENKTGKEQGRMVWHVAAYEGLSLWQWMVLPLLDVSDRFWLQMVAWWGQGSRAIVAFDNISISLDCYLTISGEDKILQNTAPKSRNLFERNPNKELKPGENSPRQTPIFDPTVHWLFTTCGASGPHGPTQAQCNNAYQNSNLSVEVGSEGPLKGIQIWKVPATDTYSISGYGAAGGKGGKNTMMRSHGVSVLGIFNLEKDDMLYILVGQQGEDACPSTNQLIQKVCIGENNVIEEEIRVNRSVHEWAGGGGGGGGATYVFKMKDGVPVPLIIAAGGGGRAYGAKTDTFHPERLENNSSVLGLNGNSGAAGGGGGWNDNTSLLWAGKSLQEGATGGHSCPQAMKKWGWETRGGFGGGGGGCSSGGGGGGYIGGNAASNNDPEMDGEDGVSFISPLGILYTPALKVMEGHGEVNIKHYLNCSHCEVDECHMDPESHKVICFCDHGTVLAEDGVSCIVSPTPEPHLPLSLILSVVTSALVAALVLAFSGIMIVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEPSSLTANMKEVPLFRLRHFPCGNVNYGYQQQGLPLEAATAPGAGHYEDTILKSKNSMNQPGP
T56418	DRUGINFO	D04LVK	Ceritinib	Approved
T56418	DRUGINFO	D08PIE	Brigatinib	Approved
T56418	DRUGINFO	D0U3SY	Alectinib	Approved
T56418	DRUGINFO	D0AF6O	Lorlatinib	Approved
T56418	DRUGINFO	D03ZBT	Crizotinib	Approved
T56418	DRUGINFO	D0O0LS	Entrectinib	Approved
T56418	DRUGINFO	D0KX7I	Ensartinib	Phase 3
T56418	DRUGINFO	D04DYC	PF-06463922	Phase 2
T56418	DRUGINFO	D0O9PQ	AP26113	Phase 2
T56418	DRUGINFO	D01HKZ	TSR-011	Phase 1/2
T56418	DRUGINFO	D0L9PA	X-396	Phase 1/2
T56418	DRUGINFO	D09GEK	ASP3026	Phase 1
T56418	DRUGINFO	D0N8YJ	PMID28270010-Compound-Figure21-b	Patented
T56418	DRUGINFO	D0NP2W	1,2,4-triazolo[1,5a]pyridine derivative 2	Patented
T56418	DRUGINFO	D0T3TZ	Benzimidazole derivative 6	Patented
T56418	DRUGINFO	D0MX7B	Carboxamide derivative 4	Patented
T56418	DRUGINFO	D03IDK	CEP-18050	Investigative
T56418	DRUGINFO	D09PTP	CEP-28122	Investigative
T56418	DRUGINFO	D0D2SU	DLX-521	Investigative
T56418	DRUGINFO	D0I3TD	CRL-37212	Investigative
T56418	DRUGINFO	D02NZE	PMID20483621C5m	Investigative
T56418	DRUGINFO	D0H0LP	PMID20483621C5g	Investigative
T56418	DRUGINFO	D0O7LU	AZD3463	Investigative
T56418	DRUGINFO	D08TVU	PMID20483621C5n	Investigative
T56418	DRUGINFO	D0G4CS	PMID24900237C15	Investigative
T56418	DRUGINFO	D06PJW	GSK-1838705A	Investigative
T56418	DRUGINFO	D0K5UF	PMID24432909C8e	Investigative
T56418	DRUGINFO	D09AID	PMID22564207C25b	Investigative

T47623	TARGETID	T47623
T47623	FORMERID	TTDC00060
T47623	UNIPROID	HPSE_HUMAN
T47623	TARGNAME	Heparanase (HPSE)
T47623	GENENAME	HPSE
T47623	TARGTYPE	Successful
T47623	SYNONYMS	Hpa1; Heparanase-1; Heparanase 8 kDa subunit; Heparanase 50 kDa subunit; HSE1; HPSE1; HPR1; HPA; HEP protein; Endo-glucoronidase
T47623	FUNCTION	Participates in extracellular matrix (ECM) degradation and remodeling. Selectively cleaves the linkage between a glucuronic acid unit and an N-sulfo glucosamine unit carrying either a 3-O-sulfo or a 6-O-sulfo group. Can also cleave the linkage between a glucuronic acid unit and an N-sulfo glucosamine unit carrying a 2-O-sulfo group, but not linkages between a glucuronic acid unit and a 2-O-sulfated iduronic acid moiety. It is essentially inactive at neutral pH but becomes active under acidic conditions such as during tumor invasion and in inflammatory processes. Facilitates cell migration associated with metastasis, wound healing and inflammation. Enhances shedding of syndecans, and increases endothelial invasion and angiogenesis in myelomas. Acts as procoagulant by increasing the generation of activation factor X in the presence of tissue factor and activation factor VII. Increases cell adhesion to the extracellular matrix (ECM), independent of its enzymatic activity. Induces AKT1/PKB phosphorylation via lipid rafts increasing cell mobility and invasion. Heparin increases this AKT1/PKB activation. Regulates osteogenesis. Enhances angiogenesis through up-regulation of SRC-mediated activation of VEGF. Implicated in hair follicle inner root sheath differentiation and hair homeostasis. Endoglycosidase that cleaves heparan sulfate proteoglycans (HSPGs) into heparan sulfate side chains and core proteoglycans.
T47623	PDBSTRUC	5LA7; 5LA4; 5L9Z; 5L9Y; 5E9C
T47623	BIOCLASS	Glycosylase
T47623	ECNUMBER	EC 3.2.1.166
T47623	SEQUENCE	MLLRSKPALPPPLMLLLLGPLGPLSPGALPRPAQAQDVVDLDFFTQEPLHLVSPSFLSVTIDANLATDPRFLILLGSPKLRTLARGLSPAYLRFGGTKTDFLIFDPKKESTFEERSYWQSQVNQDICKYGSIPPDVEEKLRLEWPYQEQLLLREHYQKKFKNSTYSRSSVDVLYTFANCSGLDLIFGLNALLRTADLQWNSSNAQLLLDYCSSKGYNISWELGNEPNSFLKKADIFINGSQLGEDFIQLHKLLRKSTFKNAKLYGPDVGQPRRKTAKMLKSFLKAGGEVIDSVTWHHYYLNGRTATKEDFLNPDVLDIFISSVQKVFQVVESTRPGKKVWLGETSSAYGGGAPLLSDTFAAGFMWLDKLGLSARMGIEVVMRQVFFGAGNYHLVDENFDPLPDYWLSLLFKKLVGTKVLMASVQGSKRRKLRVYLHCTNTDNPRYKEGDLTLYAINLHNVTKYLRLPYPFSNKQVDKYLLRPLGPHGLLSKSVQLNGLTLKMVDDQTLPPLMEKPLRPGSSLGLPAFSYSFFVIRNAKVAACI
T47623	DRUGINFO	D04KNL	PG-545	Phase 1
T47623	DRUGINFO	D0H2UB	Suramin	Phase 1
T47623	DRUGINFO	D0G9LP	Neutralase	Discontinued in Phase 3

T80782	TARGETID	T80782
T80782	FORMERID	TTDC00334
T80782	UNIPROID	VGFR1_HUMAN
T80782	TARGNAME	VEGFR1 messenger RNA (VEGFR1 mRNA)
T80782	GENENAME	FLT1
T80782	TARGTYPE	Successful
T80782	SYNONYMS	Vascular permeability factor receptor (mRNA); VEGFR1 (mRNA); VEGFR-1 (mRNA); VEGF-1 receptor (mRNA); Tyrosine-protein kinase receptor FLT (mRNA); Tyrosine-protein kinase FRT (mRNA); Fms-like tyrosine kinase 1 (mRNA); FRT (mRNA); FLT (mRNA)
T80782	FUNCTION	May play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. Can promote endothelial cell proliferation, survival and angiogenesis in adulthood. Its function in promoting cell proliferation seems to be cell-type specific. Promotes PGF-mediated proliferation of endothelial cells, proliferation of some types of cancer cells, but does not promote proliferation of normal fibroblasts (in vitro). Has very high affinity for VEGFA and relatively low protein kinase activity; may function as a negative regulator of VEGFA signaling by limiting the amount of free VEGFA and preventing its binding to KDR. Likewise, isoforms lacking a transmembrane domain, such as isoform 2, isoform 3 and isoform 4, may function as decoy receptors for VEGFA. Modulates KDR signaling by forming heterodimers with KDR. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leading to activation of phosphatidylinositol kinase and the downstream signaling pathway. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Phosphorylates SRC and YES1, and may also phosphorylate CBL. Isoform 1 phosphorylates PLCG. Promotes phosphorylation of AKT1 at 'Ser-473'. Promotes phosphorylation of PTK2/FAK1. Isoform 7 has a truncated kinase domain; it increases phosphorylation of SRC at 'Tyr-418' by unknown means and promotes tumor cell invasion. Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion.
T80782	PDBSTRUC	5T89; 5EX3; 5ABD; 4CL7; 4CKV
T80782	BIOCLASS	mRNA target
T80782	ECNUMBER	EC 2.7.10.1
T80782	SEQUENCE	MVSYWDTGVLLCALLSCLLLTGSSSGSKLKDPELSLKGTQHIMQAGQTLHLQCRGEAAHKWSLPEMVSKESERLSITKSACGRNGKQFCSTLTLNTAQANHTGFYSCKYLAVPTSKKKETESAIYIFISDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVQISTPRPVKLLRGHTLVLNCTATTPLNTRVQMTWSYPDEKNKRASVRRRIDQSNSHANIFYSVLTIDKMQNKDKGLYTCRVRSGPSFKSVNTSVHIYDKAFITVKHRKQQVLETVAGKRSYRLSMKVKAFPSPEVVWLKDGLPATEKSARYLTRGYSLIIKDVTEEDAGNYTILLSIKQSNVFKNLTATLIVNVKPQIYEKAVSSFPDPALYPLGSRQILTCTAYGIPQPTIKWFWHPCNHNHSEARCDFCSNNEESFILDADSNMGNRIESITQRMAIIEGKNKMASTLVVADSRISGIYICIASNKVGTVGRNISFYITDVPNGFHVNLEKMPTEGEDLKLSCTVNKFLYRDVTWILLRTVNNRTMHYSISKQKMAITKEHSITLNLTIMNVSLQDSGTYACRARNVYTGEEILQKKEITIRDQEAPYLLRNLSDHTVAISSSTTLDCHANGVPEPQITWFKNNHKIQQEPGIILGPGSSTLFIERVTEEDEGVYHCKATNQKGSVESSAYLTVQGTSDKSNLELITLTCTCVAATLFWLLLTLFIRKMKRSSSEIKTDYLSIIMDPDEVPLDEQCERLPYDASKWEFARERLKLGKSLGRGAFGKVVQASAFGIKKSPTCRTVAVKMLKEGATASEYKALMTELKILTHIGHHLNVVNLLGACTKQGGPLMVIVEYCKYGNLSNYLKSKRDLFFLNKDAALHMEPKKEKMEPGLEQGKKPRLDSVTSSESFASSGFQEDKSLSDVEEEEDSDGFYKEPITMEDLISYSFQVARGMEFLSSRKCIHRDLAARNILLSENNVVKICDFGLARDIYKNPDYVRKGDTRLPLKWMAPESIFDKIYSTKSDVWSYGVLLWEIFSLGGSPYPGVQMDEDFCSRLREGMRMRAPEYSTPEIYQIMLDCWHRDPKERPRFAELVEKLGDLLQANVQQDGKDYIPINAILTGNSGFTYSTPAFSEDFFKESISAPKFNSGSSDDVRYVNAFKFMSLERIKTFEELLPNATSMFDDYQGDSSTLLASPMLKRFTWTDSKPKASLKIDLRVTSKSKESGLSDVSRPSFCHSSCGHVSEGKRRFTYDHAELERKIACCSPPPDYNSVVLYSTPPI
T80782	DRUGINFO	D01PZD	Romiplostim	Approved
T80782	DRUGINFO	D0P6DJ	VATALANIB	Phase 2
T80782	DRUGINFO	D04WIE	Sirna-027	Phase 1/2
T80782	DRUGINFO	D00DRL	MK-2461	Phase 1/2
T80782	DRUGINFO	D02MFX	C[homoPhe-Hca-Glu-Gly-Leu-Glu-Glu]-NH2	Investigative
T80782	DRUGINFO	D02NZG	C[YYDEKLEE]-NH2	Investigative
T80782	DRUGINFO	D03ZHK	LYCOGARUBIN B	Investigative
T80782	DRUGINFO	D04NYQ	N3-GHQMFYYPra-NH2	Investigative
T80782	DRUGINFO	D0K7FA	C[YYAEGLEE]-NH2	Investigative
T80782	DRUGINFO	D0R0XY	C[YYDEGLEE]-NH2	Investigative
T80782	DRUGINFO	D03HTT	4-(isoquinolin-5-yl)-N-o-tolylphthalazin-1-amine	Investigative
T80782	DRUGINFO	D0A9ZP	IM-094882	Investigative
T80782	DRUGINFO	D0D3QA	4-(isoquinolin-5-yl)-N-m-tolylphthalazin-1-amine	Investigative
T80782	DRUGINFO	D0Z8TR	IM-094261	Investigative
T80782	DRUGINFO	D00ERW	PMID17935989C25	Investigative
T80782	DRUGINFO	D03HQK	2-(5-Phenyl-oxazol-2-ylamino)-benzonitrile	Investigative
T80782	DRUGINFO	D05THI	4-Chloro-N-(3-chloro-benzoyl)-benzenesulfonamide	Investigative
T80782	DRUGINFO	D06GJO	(2-Methoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine	Investigative
T80782	DRUGINFO	D07OCA	Cdk1/2 inhibitor III	Investigative
T80782	DRUGINFO	D07XBW	N-(2,4-Dichloro-benzoyl)-benzenesulfonamide	Investigative
T80782	DRUGINFO	D09LEK	4-(5-Phenyl-oxazol-2-ylamino)-benzenesulfonamide	Investigative
T80782	DRUGINFO	D09MSA	4-Chloro-N-(4-chloro-benzoyl)-benzenesulfonamide	Investigative
T80782	DRUGINFO	D0BM4F	Phenyl-(5-phenyl-oxazol-2-yl)-amine	Investigative
T80782	DRUGINFO	D0C6KI	CB-676475	Investigative
T80782	DRUGINFO	D0C6OD	4-Chloro-N-(4-nitro-benzoyl)-benzenesulfonamide	Investigative
T80782	DRUGINFO	D0D3YL	(5-Phenyl-oxazol-2-yl)-m-tolyl-amine	Investigative
T80782	DRUGINFO	D0J2XD	3-(5-Phenyl-oxazol-2-ylamino)-benzonitrile	Investigative
T80782	DRUGINFO	D0M2QA	N-(3-Bromo-benzoyl)-4-chloro-benzenesulfonamide	Investigative
T80782	DRUGINFO	D0UZ5W	4-Chloro-N-(2-chloro-benzoyl)-benzenesulfonamide	Investigative
T80782	DRUGINFO	D0V4BR	4-Chloro-N-(2-methyl-benzoyl)-benzenesulfonamide	Investigative
T80782	DRUGINFO	D0V9DQ	[3-(5-Phenyl-oxazol-2-ylamino)-phenyl]-methanol	Investigative
T80782	DRUGINFO	D0YN1E	3,6-Di-pyridin-4-yl-pyrazolo[1,5-a]pyrimidine	Investigative
T80782	DRUGINFO	D0EE6A	AAL-993	Investigative
T80782	DRUGINFO	D0XC6G	2-(1H-indazol-3-yl)-1H-benzo[d]imidazole	Investigative
T80782	DRUGINFO	D0C2GE	PMID22765894C8h	Investigative

T89529	TARGETID	T89529
T89529	FORMERID	TTDR01437
T89529	UNIPROID	PTN1_HUMAN
T89529	TARGNAME	PTPN1 messenger RNA (PTPN1 mRNA)
T89529	GENENAME	PTPN1
T89529	TARGTYPE	Successful
T89529	SYNONYMS	Tyrosine-protein phosphatase non-receptor type 1 (mRNA); PTP-1B (mRNA)
T89529	FUNCTION	Mediates dephosphorylation of EIF2AK3/PERK; inactivating the protein kinase activity of EIF2AK3/PERK. May play an important role in CKII- and p60c-src-induced signal transduction cascades. May regulate the EFNA5-EPHA3 signaling pathway which modulates cell reorganization and cell-cell repulsion. May also regulate the hepatocyte growth factor receptor signaling pathway through dephosphorylation of MET. Tyrosine-protein phosphatase which acts as a regulator of endoplasmic reticulum unfolded protein response.
T89529	PDBSTRUC	6CWV; 6CWU; 6BAI; 6B95; 6B90
T89529	BIOCLASS	mRNA target
T89529	ECNUMBER	EC 3.1.3.48
T89529	SEQUENCE	MEMEKEFEQIDKSGSWAAIYQDIRHEASDFPCRVAKLPKNKNRNRYRDVSPFDHSRIKLHQEDNDYINASLIKMEEAQRSYILTQGPLPNTCGHFWEMVWEQKSRGVVMLNRVMEKGSLKCAQYWPQKEEKEMIFEDTNLKLTLISEDIKSYYTVRQLELENLTTQETREILHFHYTTWPDFGVPESPASFLNFLFKVRESGSLSPEHGPVVVHCSAGIGRSGTFCLADTCLLLMDKRKDPSSVDIKKVLLEMRKFRMGLIQTADQLRFSYLAVIEGAKFIMGDSSVQDQWKELSHEDLEPPPEHIPPPPRPPKRILEPHNGKCREFFPNHQWVKEETQEDKDCPIKEEKGSPLNAAPYGIESMSQDTEVRSRVVGGSLRGAQAASPAKGEPSLPEKDEDHALSYWKPFLVNMCVATVLTAGAYLCYRFLFNSNT
T89529	DRUGINFO	D03IDU	Hydrogen peroxide	Approved
T89529	DRUGINFO	D03TTQ	TRYPAN BLUE	Approved
T89529	DRUGINFO	D0J1WO	ISIS 113715	Phase 2
T89529	DRUGINFO	D0SM6N	ISIS-PTP1Brx	Phase 2
T89529	DRUGINFO	D07LUJ	URSOLIC ACID	Phase 2
T89529	DRUGINFO	D06WBE	ERTIPROTAFIB	Terminated
T89529	DRUGINFO	D00BLD	1,2,3,4,6-penta-O-galloyl-D-glucopyranose	Investigative
T89529	DRUGINFO	D00KZO	Erybreadin C	Investigative
T89529	DRUGINFO	D00MNE	Abyssinone-IV	Investigative
T89529	DRUGINFO	D00RZN	Abyssinin II	Investigative
T89529	DRUGINFO	D00VNC	3beta-hydroxyolean-12-en-27-oic acid	Investigative
T89529	DRUGINFO	D01BZE	MASLINIC ACID	Investigative
T89529	DRUGINFO	D01NUT	Mulberrofuran D	Investigative
T89529	DRUGINFO	D01TNT	Sanggenon G	Investigative
T89529	DRUGINFO	D03BHQ	FORMYLCHROMONE	Investigative
T89529	DRUGINFO	D03CBD	Isoxazolecarboxylic acid	Investigative
T89529	DRUGINFO	D03EGZ	OHIOENSIN A	Investigative
T89529	DRUGINFO	D03KGX	Rotungenic acid	Investigative
T89529	DRUGINFO	D03KJL	1-Iodyl-4-nitro-benzene	Investigative
T89529	DRUGINFO	D03NTG	Sp7343-Sp7964	Investigative
T89529	DRUGINFO	D03ZIH	Oxalylaminobenzoic acid	Investigative
T89529	DRUGINFO	D04TTB	3alpha,24-dihydroxyolean-12-en-27-oic acid	Investigative
T89529	DRUGINFO	D05AOH	1-Iodyl-3-nitro-benzene	Investigative
T89529	DRUGINFO	D05SEV	3-(4,5-Bis-biphenyl-4-yl-1H-imidazol-2-yl)-phenol	Investigative
T89529	DRUGINFO	D05WJI	ISIS 107792	Investigative
T89529	DRUGINFO	D05YZE	Abyssinoflavanone VI	Investigative
T89529	DRUGINFO	D06AWX	CAULERPIN	Investigative
T89529	DRUGINFO	D06BFB	3beta,6beta-dihydroxyolean-12-en-27-oic acid	Investigative
T89529	DRUGINFO	D06LNL	Iodyl-benzene	Investigative
T89529	DRUGINFO	D06NGA	1,2,5-THIADIAZOLIDIN-3-ONE-1,1-DIOXIDE	Investigative
T89529	DRUGINFO	D07DNK	3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid	Investigative
T89529	DRUGINFO	D07VEP	USIMINE A	Investigative
T89529	DRUGINFO	D08ABU	18alpha-Glycyrrhetic acid	Investigative
T89529	DRUGINFO	D08AHA	PARA-(BENZOYL)-PHENYLALANINE	Investigative
T89529	DRUGINFO	D08BSQ	RK-682	Investigative
T89529	DRUGINFO	D08GDJ	ISOTHIAZOLIDINONE ANALOG	Investigative
T89529	DRUGINFO	D08GEN	LICOAGROCHACONE A	Investigative
T89529	DRUGINFO	D08NUF	3-oxoolean-12-en-27-oic acid	Investigative
T89529	DRUGINFO	D08SAG	Ohioensin F	Investigative
T89529	DRUGINFO	D08VRV	Kuwanon V	Investigative
T89529	DRUGINFO	D09GPV	Spathodic acid	Investigative
T89529	DRUGINFO	D09HAX	SIGMOIDIN B	Investigative
T89529	DRUGINFO	D09JSD	USNIC ACID	Investigative
T89529	DRUGINFO	D09OWE	UVAOL	Investigative
T89529	DRUGINFO	D09TUB	LICOAGROCHALCONE A	Investigative
T89529	DRUGINFO	D09WED	Kuwanon R	Investigative
T89529	DRUGINFO	D09YKH	BURTTINONE	Investigative
T89529	DRUGINFO	D0A1QK	Isochroman mono-carboxylic acid	Investigative
T89529	DRUGINFO	D0A4ML	4'-(2-butylbenzofuran-3-yl)biphenyl-4-ol	Investigative
T89529	DRUGINFO	D0A8WJ	Kuwanon L	Investigative
T89529	DRUGINFO	D0AL8P	ISIS 107772	Investigative
T89529	DRUGINFO	D0D4SI	24-hydroxyursolic acid	Investigative
T89529	DRUGINFO	D0D8QO	Kuwanon J	Investigative
T89529	DRUGINFO	D0DU3J	5-deoxyabyssinin II	Investigative
T89529	DRUGINFO	D0E0BU	6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid	Investigative
T89529	DRUGINFO	D0E1UG	Methyl3beta-hydroxyolean-12-en-27-oate	Investigative
T89529	DRUGINFO	D0E1ZS	ALBAFURAN A	Investigative
T89529	DRUGINFO	D0G7HN	4-Iodyl-benzoic acid	Investigative
T89529	DRUGINFO	D0H1WV	Mulberrofuran W	Investigative
T89529	DRUGINFO	D0J1GM	3beta-hydroxyurs-12-en-27-oic acid	Investigative
T89529	DRUGINFO	D0J5KG	Methyl 3beta-hydroxyolean-12-en-28-oate	Investigative
T89529	DRUGINFO	D0J7EN	KR61639	Investigative
T89529	DRUGINFO	D0JB4G	CHROMOTROPATE	Investigative
T89529	DRUGINFO	D0JL8I	ERYTHRIBYSSIN A	Investigative
T89529	DRUGINFO	D0K0PR	19alpha,24-dihydroxyurs-12-en-3-on-28-oic acid	Investigative
T89529	DRUGINFO	D0K3TS	SIGMOIDIN A	Investigative
T89529	DRUGINFO	D0L1ZD	ISIS 107791	Investigative
T89529	DRUGINFO	D0M0XS	3beta-acetoxyolean-12-en-27-oic acid	Investigative
T89529	DRUGINFO	D0M6KC	Abyssinin I	Investigative
T89529	DRUGINFO	D0M7IA	Sanggenon C	Investigative
T89529	DRUGINFO	D0MG9O	PHELLIGRIDIN I	Investigative
T89529	DRUGINFO	D0N8OO	Sigmoidin F	Investigative
T89529	DRUGINFO	D0O7ZL	Augustic acid	Investigative
T89529	DRUGINFO	D0O8PQ	[[4-(Aminomethyl)Phenyl]Amino]Oxo-Acetic Acid,	Investigative
T89529	DRUGINFO	D0OJ1V	16-alphaH,17-isovaleryloxy-ent-kauran-19-oic acid	Investigative
T89529	DRUGINFO	D0OK8N	1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID	Investigative
T89529	DRUGINFO	D0OY2V	3,9-Dihydroxy-4-prenyl-[6aR,11aR]pterocarpan	Investigative
T89529	DRUGINFO	D0P2TB	ISIS 107773	Investigative
T89529	DRUGINFO	D0P9SW	Erybreadin D	Investigative
T89529	DRUGINFO	D0Q0XJ	ISIS 107774	Investigative
T89529	DRUGINFO	D0Q3KF	4'-((2-butylbenzofuran-3-yl)methyl)biphenyl-4-ol	Investigative
T89529	DRUGINFO	D0Q5PQ	FOLITENOL	Investigative
T89529	DRUGINFO	D0Q8AT	3-epi-masilinic acid	Investigative
T89529	DRUGINFO	D0QQ7A	Abyssinone-VI-4-O-methyl ether	Investigative
T89529	DRUGINFO	D0QV8M	ISIS 107776	Investigative
T89529	DRUGINFO	D0S0XV	ISIS 107775	Investigative
T89529	DRUGINFO	D0S9GU	Abyssinoflavanone VII	Investigative
T89529	DRUGINFO	D0U2WU	3-Iodyl-benzoic acid	Investigative
T89529	DRUGINFO	D0V0LU	Ohioensin C	Investigative
T89529	DRUGINFO	D0VA9F	Mulberrofuran C	Investigative
T89529	DRUGINFO	D0X2OD	18beta-Glycyrrhetic acid	Investigative
T89529	DRUGINFO	D0XB7H	PNU177836	Investigative
T89529	DRUGINFO	D0Y1RO	Novo Nordisk a/S Compound	Investigative
T89529	DRUGINFO	D0Y5SB	2-(Oxalyl-Amino)-Benzoic Acid	Investigative
T89529	DRUGINFO	D0Z1HV	Pomolic acid	Investigative
T89529	DRUGINFO	D0ZE8C	Ohioensin G	Investigative
T89529	DRUGINFO	D0ZS7M	Erybreadin b	Investigative
T89529	DRUGINFO	D01EJH	NEORAUTENOL	Investigative
T89529	DRUGINFO	D02KKU	Oleanonic acid	Investigative
T89529	DRUGINFO	D0M7ZZ	Erysubin E	Investigative
T89529	DRUGINFO	D0U9HN	DYSIDINE	Investigative
T89529	DRUGINFO	D08GWQ	3-isopropyl-4-(phenylthio)naphthalene-1,2-dione	Investigative
T89529	DRUGINFO	D0N7YT	4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione	Investigative
T89529	DRUGINFO	D0SJ2Q	OLEANOLIC_ACID	Investigative
T89529	DRUGINFO	D05AMX	Cysteinesulfonic Acid	Investigative
T89529	DRUGINFO	D0V6UC	Cysteine Sulfenic Acid	Investigative
T89529	DRUGINFO	D0W9VA	1,2-NAPHTHOQUINONE	Investigative
T89529	DRUGINFO	D0H1GU	Double Oxidized Cysteine	Investigative
T89529	DRUGINFO	D06GOK	2-Methyl-2,4-Pentanediol	Investigative
T89529	DRUGINFO	D02UVH	B-Octylglucoside	Investigative
T89529	DRUGINFO	D0F2ME	Acetate Ion	Investigative

T08922	TARGETID	T08922
T08922	FORMERID	TTDS00357
T08922	UNIPROID	ACACB_HUMAN
T08922	TARGNAME	Acetyl-CoA carboxylase 2 (ACACB)
T08922	GENENAME	ACACB
T08922	TARGTYPE	Successful
T08922	SYNONYMS	Acetyl-Coenzyme A carboxylase beta; Acetyl CoA carboxylase beta; ACCbeta; ACC2; ACC-beta; ACACB
T08922	FUNCTION	Catalyzes the ATP-dependent carboxylation of acetyl-CoA to malonyl-CoA. Carries out three functions: biotin carboxyl carrier protein, biotin carboxylase and carboxyltransferase. Involved in inhibition of fatty acid and glucose oxidation and enhancement of fat storage. May play a role in regulation of mitochondrial fatty acid oxidation through malonyl- CoA-dependent inhibition of carnitine palmitoyltransferase 1.
T08922	PDBSTRUC	5KKN; 4HQ6; 3TDC; 3JRX; 3JRW
T08922	BIOCLASS	Carbon-carbon ligase
T08922	ECNUMBER	EC 6.4.1.2
T08922	SEQUENCE	MVLLLCLSCLIFSCLTFSWLKIWGKMTDSKPITKSKSEANLIPSQEPFPASDNSGETPQRNGEGHTLPKTPSQAEPASHKGPKDAGRRRNSLPPSHQKPPRNPLSSSDAAPSPELQANGTGTQGLEATDTNGLSSSARPQGQQAGSPSKEDKKQANIKRQLMTNFILGSFDDYSSDEDSVAGSSRESTRKGSRASLGALSLEAYLTTGEAETRVPTMRPSMSGLHLVKRGREHKKLDLHRDFTVASPAEFVTRFGGDRVIEKVLIANNGIAAVKCMRSIRRWAYEMFRNERAIRFVVMVTPEDLKANAEYIKMADHYVPVPGGPNNNNYANVELIVDIAKRIPVQAVWAGWGHASENPKLPELLCKNGVAFLGPPSEAMWALGDKIASTVVAQTLQVPTLPWSGSGLTVEWTEDDLQQGKRISVPEDVYDKGCVKDVDEGLEAAERIGFPLMIKASEGGGGKGIRKAESAEDFPILFRQVQSEIPGSPIFLMKLAQHARHLEVQILADQYGNAVSLFGRDCSIQRRHQKIVEEAPATIAPLAIFEFMEQCAIRLAKTVGYVSAGTVEYLYSQDGSFHFLELNPRLQVEHPCTEMIADVNLPAAQLQIAMGVPLHRLKDIRLLYGESPWGVTPISFETPSNPPLARGHVIAARITSENPDEGFKPSSGTVQELNFRSSKNVWGYFSVAATGGLHEFADSQFGHCFSWGENREEAISNMVVALKELSIRGDFRTTVEYLINLLETESFQNNDIDTGWLDYLIAEKVQAEKPDIMLGVVCGALNVADAMFRTCMTDFLHSLERGQVLPADSLLNLVDVELIYGGVKYILKVARQSLTMFVLIMNGCHIEIDAHRLNDGGLLLSYNGNSYTTYMKEEVDSYRITIGNKTCVFEKENDPTVLRSPSAGKLTQYTVEDGGHVEAGSSYAEMEVMKMIMTLNVQERGRVKYIKRPGAVLEAGCVVARLELDDPSKVHPAEPFTGELPAQQTLPILGEKLHQVFHSVLENLTNVMSGFCLPEPVFSIKLKEWVQKLMMTLRHPSLPLLELQEIMTSVAGRIPAPVEKSVRRVMAQYASNITSVLCQFPSQQIATILDCHAATLQRKADREVFFINTQSIVQLVQRYRSGIRGYMKTVVLDLLRRYLRVEHHFQQAHYDKCVINLREQFKPDMSQVLDCIFSHAQVAKKNQLVIMLIDELCGPDPSLSDELISILNELTQLSKSEHCKVALRARQILIASHLPSYELRHNQVESIFLSAIDMYGHQFCPENLKKLILSETTIFDVLPTFFYHANKVVCMASLEVYVRRGYIAYELNSLQHRQLPDGTCVVEFQFMLPSSHPNRMTVPISITNPDLLRHSTELFMDSGFSPLCQRMGAMVAFRRFEDFTRNFDEVISCFANVPKDTPLFSEARTSLYSEDDCKSLREEPIHILNVSIQCADHLEDEALVPILRTFVQSKKNILVDYGLRRITFLIAQEKEFPKFFTFRARDEFAEDRIYRHLEPALAFQLELNRMRNFDLTAVPCANHKMHLYLGAAKVKEGVEVTDHRFFIRAIIRHSDLITKEASFEYLQNEGERLLLEAMDELEVAFNNTSVRTDCNHIFLNFVPTVIMDPFKIEESVRYMVMRYGSRLWKLRVLQAEVKINIRQTTTGSAVPIRLFITNESGYYLDISLYKEVTDSRSGNIMFHSFGNKQGPQHGMLINTPYVTKDLLQAKRFQAQTLGTTYIYDFPEMFRQALFKLWGSPDKYPKDILTYTELVLDSQGQLVEMNRLPGGNEVGMVAFKMRFKTQEYPEGRDVIVIGNDITFRIGSFGPGEDLLYLRASEMARAEGIPKIYVAANSGARIGMAEEIKHMFHVAWVDPEDPHKGFKYLYLTPQDYTRISSLNSVHCKHIEEGGESRYMITDIIGKDDGLGVENLRGSGMIAGESSLAYEEIVTISLVTCRAIGIGAYLVRLGQRVIQVENSHIILTGASALNKVLGREVYTSNNQLGGVQIMHYNGVSHITVPDDFEGVYTILEWLSYMPKDNHSPVPIITPTDPIDREIEFLPSRAPYDPRWMLAGRPHPTLKGTWQSGFFDHGSFKEIMAPWAQTVVTGRARLGGIPVGVIAVETRTVEVAVPADPANLDSEAKIIQQAGQVWFPDSAYKTAQAVKDFNREKLPLMIFANWRGFSGGMKDMYDQVLKFGAYIVDGLRQYKQPILIYIPPYAELRGGSWVVIDATINPLCIEMYADKESRGGVLEPEGTVEIKFRKKDLIKSMRRIDPAYKKLMEQLGEPDLSDKDRKDLEGRLKAREDLLLPIYHQVAVQFADFHDTPGRMLEKGVISDILEWKTARTFLYWRLRRLLLEDQVKQEILQASGELSHVHIQSMLRRWFVETEGAVKAYLWDNNQVVVQWLEQHWQAGDGPRSTIRENITYLKHDSVLKTIRGLVEENPEVAVDCVIYLSQHISPAERAQVVHLLSTMDSPAST
T08922	DRUGINFO	D0D7LA	Metformin	Approved
T08922	DRUGINFO	D03KHO	PF-05175157	Phase 2
T08922	DRUGINFO	D01OKS	Axokine	Discontinued in Phase 3
T08922	DRUGINFO	D08FSR	QLT-091382	Investigative
T08922	DRUGINFO	D0K4WI	2-[4-(2,4-Dichlorophenoxy)Phenoxy]Propanoic Acid	Investigative
T08922	DRUGINFO	D0WD1E	Soraphen A	Investigative
T08922	DRUGINFO	D07WIC	CP-640186	Investigative
T08922	DRUGINFO	D0IY5Y	A-80040	Investigative
T08922	DRUGINFO	D0P7HI	AC-8632	Investigative

T21334	TARGETID	T21334
T21334	FORMERID	TTDC00224
T21334	UNIPROID	TNF11_HUMAN
T21334	TARGNAME	Osteoclast differentiation factor (ODF)
T21334	GENENAME	TNFSF11
T21334	TARGTYPE	Successful
T21334	SYNONYMS	Tumor necrosis factor ligand superfamily member 11; TRANCE; TNF-related activation-induced cytokine; Receptor activatorof nuclear factor kappa B ligand; Receptor activator of nuclear factor kappa-B ligand; RANKL; Osteoprotegerin ligand; OPGL; CD254
T21334	FUNCTION	Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy. Induces osteoclastogenesis by activating multiple signaling pathways in osteoclast precursor cells, chief among which is induction of long lasting oscillations in the intracellular concentration of Ca (2+) resulting in the activation of NFATC1, which translocates to the nucleus and induces osteoclast-specific gene transcription to allow differentiation of osteoclasts. During osteoclast differentiation, in a TMEM64 and ATP2A2-dependent manner induces activation of CREB1 and mitochondrial ROS generation necessary for proper osteoclast generation. Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK.
T21334	PDBSTRUC	5BNQ; 3URF
T21334	BIOCLASS	Cytokine: tumor necrosis factor
T21334	SEQUENCE	MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPPAPHQPPAASRSMFVALLGLGLGQVVCSVALFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIKQAFQGAVQKELQHIVGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAHLTINATDIPSGSHKVSLSSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMVYVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLDPDQDATYFGAFKVRDID
T21334	DRUGINFO	D08WSY	Denosumab	Approved
T21334	DRUGINFO	D09QWD	CEP-37251	Phase 1
T21334	DRUGINFO	D0MG2R	ALX-0141	Phase 1

T92777	TARGETID	T92777
T92777	FORMERID	TTDS00291
T92777	UNIPROID	MGA_HUMAN
T92777	TARGNAME	Intestinal maltase-glucoamylase (MGAM)
T92777	GENENAME	MGAM
T92777	TARGTYPE	Successful
T92777	SYNONYMS	MGAM
T92777	FUNCTION	May serve as an alternate pathway for starch digestion when luminal alpha-amylase activity is reduced because of immaturity or malnutrition. May play a unique role in the digestion of malted dietary oligosaccharides used in food manufacturing.
T92777	PDBSTRUC	3TOP; 3TON; 3L4Z; 3L4Y; 3L4X
T92777	BIOCLASS	Glycosylase
T92777	SEQUENCE	MARKKLKKFTTLEIVLSVLLLVLFIISIVLIVLLAKESLKSTAPDPGTTGTPDPGTTGTPDPGTTGTTHARTTGPPDPGTTGTTPVSAECPVVNELERINCIPDQPPTKATCDQRGCCWNPQGAVSVPWCYYSKNHSYHVEGNLVNTNAGFTARLKNLPSSPVFGSNVDNVLLTAEYQTSNRFHFKLTDQTNNRFEVPHEHVQSFSGNAAASLTYQVEISRQPFSIKVTRRSNNRVLFDSSIGPLLFADQFLQLSTRLPSTNVYGLGEHVHQQYRHDMNWKTWPIFNRDTTPNGNGTNLYGAQTFFLCLEDASGLSFGVFLMNSNAMEVVLQPAPAITYRTIGGILDFYVFLGNTPEQVVQEYLELIGRPALPSYWALGFHLSRYEYGTLDNMREVVERNRAAQLPYDVQHADIDYMDERRDFTYDSVDFKGFPEFVNELHNNGQKLVIIVDPAISNNSSSSKPYGPYDRGSDMKIWVNSSDGVTPLIGEVWPGQTVFPDYTNPNCAVWWTKEFELFHNQVEFDGIWIDMNEVSNFVDGSVSGCSTNNLNNPPFTPRILDGYLFCKTLCMDAVQHWGKQYDIHNLYGYSMAVATAEAAKTVFPNKRSFILTRSTFAGSGKFAAHWLGDNTATWDDLRWSIPGVLEFNLFGIPMVGPDICGFALDTPEELCRRWMQLGAFYPFSRNHNGQGYKDQDPASFGADSLLLNSSRHYLNIRYTLLPYLYTLFFRAHSRGDTVARPLLHEFYEDNSTWDVHQQFLWGPGLLITPVLDEGAEKVMAYVPDAVWYDYETGSQVRWRKQKVEMELPGDKIGLHLRGGYIFPTQQPNTTTLASRKNPLGLIIALDENKEAKGELFWDNGETKDTVANKVYLLCEFSVTQNRLEVNISQSTYKDPNNLAFNEIKILGTEEPSNVTVKHNGVPSQTSPTVTYDSNLKVAIITDIDLLLGEAYTVEWSIKIRDEEKIDCYPDENGASAENCTARGCIWEASNSSGVPFCYFVNDLYSVSDVQYNSHGATADISLKSSVYANAFPSTPVNPLRLDVTYHKNEMLQFKIYDPNKNRYEVPVPLNIPSMPSSTPEGQLYDVLIKKNPFGIEIRRKSTGTIIWDSQLLGFTFSDMFIRISTRLPSKYLYGFGETEHRSYRRDLEWHTWGMFSRDQPPGYKKNSYGVHPYYMGLEEDGSAHGVLLLNSNAMDVTFQPLPALTYRTTGGVLDFYVFLGPTPELVTQQYTELIGRPVMVPYWSLGFQLCRYGYQNDSEIASLYDEMVAAQIPYDVQYSDIDYMERQLDFTLSPKFAGFPALINRMKADGMRVILILDPAISGNETQPYPAFTRGVEDDVFIKYPNDGDIVWGKVWPDFPDVVVNGSLDWDSQVELYRAYVAFPDFFRNSTAKWWKREIEELYNNPQNPERSLKFDGMWIDMNEPSSFVNGAVSPGCRDASLNHPPYMPHLESRDRGLSSKTLCMESQQILPDGSLVQHYNVHNLYGWSQTRPTYEAVQEVTGQRGVVITRSTFPSSGRWAGHWLGDNTAAWDQLKKSIIGMMEFSLFGISYTGADICGFFQDAEYEMCVRWMQLGAFYPFSRNHNTIGTRRQDPVSWDVAFVNISRTVLQTRYTLLPYLYTLMHKAHTEGVTVVRPLLHEFVSDQVTWDIDSQFLLGPAFLVSPVLERNARNVTAYFPRARWYDYYTGVDINARGEWKTLPAPLDHINLHVRGGYILPWQEPALNTHLSRQKFMGFKIALDDEGTAGGWLFWDDGQSIDTYGKGLYYLASFSASQNTMQSHIIFNNYITGTNPLKLGYIEIWGVGSVPVTSVSISVSGMVITPSFNNDPTTQVLSIDVTDRNISLHNFTSLTWISTL
T92777	DRUGINFO	D04ZTY	Voglibose	Approved
T92777	DRUGINFO	D0AD5C	Acarbose	Approved
T92777	DRUGINFO	D0D0ZD	Miglitol	Approved
T92777	DRUGINFO	D0M1CZ	Rh-alphaglucosidase	Approved
T92777	DRUGINFO	D0Y2SE	Alpha-glucosidase	Phase 3
T92777	DRUGINFO	D0S5LT	Deoxynojirimycin	Phase 3
T92777	DRUGINFO	D0H9WY	PAZ-320	Phase 2
T92777	DRUGINFO	D0O1HL	SC-49483	Phase 2
T92777	DRUGINFO	D08CDE	Celgosivir	Phase 1/2
T92777	DRUGINFO	D04RYY	Maltose	Phase 1/2
T92777	DRUGINFO	D07TSW	SALACINOL	Phase 1/2
T92777	DRUGINFO	D0H9SF	A-76202M	Terminated
T92777	DRUGINFO	D05GYF	PONKORANOL	Investigative
T92777	DRUGINFO	D0F9YZ	KOTALANOL	Investigative
T92777	DRUGINFO	D0GS0O	1,4-dideoxy-1,4-imino-D-arabinito	Investigative
T92777	DRUGINFO	D0O6OI	4'-(p-toluenesulfonamide)-3,4-dihydroxy chalcone	Investigative
T92777	DRUGINFO	D0R5HV	2,5-Dideoxy-2,5-imino-D-mannitol	Investigative
T92777	DRUGINFO	D0T0EJ	2-Cyclopentylaminomethyl-pyrrolidine-3,4-diol	Investigative
T92777	DRUGINFO	D0T9YU	Imino sugars	Investigative
T92777	DRUGINFO	D0U8XY	3-(4-(4-hydroxyphenyl)phthalazin-1-ylamino)phenol	Investigative
T92777	DRUGINFO	D0V3WN	BMN-103	Investigative
T92777	DRUGINFO	D0W8GU	De-O-sulfonated kotalanol	Investigative
T92777	DRUGINFO	D0Z2RR	2-Aminomethyl-pyrrolidine-3,4-diol	Investigative
T92777	DRUGINFO	D0Z7LK	GSC-1	Investigative
T92777	DRUGINFO	D0H1GU	Double Oxidized Cysteine	Investigative
T92777	DRUGINFO	D0R6JE	Nicotinamide-Adenine-Dinucleotide	Investigative

T00494	TARGETID	T00494
T00494	FORMERID	TTDR00288
T00494	UNIPROID	ABCA1_HUMAN
T00494	TARGNAME	ATP-binding cassette transporter A1 (ABCA1)
T00494	GENENAME	ABCA1
T00494	TARGTYPE	Successful
T00494	SYNONYMS	Cholesterol mobilizing transporter ABCA1; Cholesterol efflux regulatory protein; CERP; ATP-binding cassette transporter (ABCA1) transmembrane protein; ATP-binding cassette sub-family A member 1; ATP-binding cassette 1; ABC1; ABC-1
T00494	FUNCTION	Involved in the efflux of intracellular cholesterol and phospholipids and their transfer to apoliproteins to form nascent high density lipoproteins/HDLs. cAMP-dependent and sulfonylurea-sensitive anion transporter.
T00494	PDBSTRUC	5XJY
T00494	BIOCLASS	ABC transporter
T00494	ECNUMBER	EC 7.6.2.1
T00494	SEQUENCE	MACWPQLRLLLWKNLTFRRRQTCQLLLEVAWPLFIFLILISVRLSYPPYEQHECHFPNKAMPSAGTLPWVQGIICNANNPCFRYPTPGEAPGVVGNFNKSIVARLFSDARRLLLYSQKDTSMKDMRKVLRTLQQIKKSSSNLKLQDFLVDNETFSGFLYHNLSLPKSTVDKMLRADVILHKVFLQGYQLHLTSLCNGSKSEEMIQLGDQEVSELCGLPREKLAAAERVLRSNMDILKPILRTLNSTSPFPSKELAEATKTLLHSLGTLAQELFSMRSWSDMRQEVMFLTNVNSSSSSTQIYQAVSRIVCGHPEGGGLKIKSLNWYEDNNYKALFGGNGTEEDAETFYDNSTTPYCNDLMKNLESSPLSRIIWKALKPLLVGKILYTPDTPATRQVMAEVNKTFQELAVFHDLEGMWEELSPKIWTFMENSQEMDLVRMLLDSRDNDHFWEQQLDGLDWTAQDIVAFLAKHPEDVQSSNGSVYTWREAFNETNQAIRTISRFMECVNLNKLEPIATEVWLINKSMELLDERKFWAGIVFTGITPGSIELPHHVKYKIRMDIDNVERTNKIKDGYWDPGPRADPFEDMRYVWGGFAYLQDVVEQAIIRVLTGTEKKTGVYMQQMPYPCYVDDIFLRVMSRSMPLFMTLAWIYSVAVIIKGIVYEKEARLKETMRIMGLDNSILWFSWFISSLIPLLVSAGLLVVILKLGNLLPYSDPSVVFVFLSVFAVVTILQCFLISTLFSRANLAAACGGIIYFTLYLPYVLCVAWQDYVGFTLKIFASLLSPVAFGFGCEYFALFEEQGIGVQWDNLFESPVEEDGFNLTTSVSMMLFDTFLYGVMTWYIEAVFPGQYGIPRPWYFPCTKSYWFGEESDEKSHPGSNQKRISEICMEEEPTHLKLGVSIQNLVKVYRDGMKVAVDGLALNFYEGQITSFLGHNGAGKTTTMSILTGLFPPTSGTAYILGKDIRSEMSTIRQNLGVCPQHNVLFDMLTVEEHIWFYARLKGLSEKHVKAEMEQMALDVGLPSSKLKSKTSQLSGGMQRKLSVALAFVGGSKVVILDEPTAGVDPYSRRGIWELLLKYRQGRTIILSTHHMDEADVLGDRIAIISHGKLCCVGSSLFLKNQLGTGYYLTLVKKDVESSLSSCRNSSSTVSYLKKEDSVSQSSSDAGLGSDHESDTLTIDVSAISNLIRKHVSEARLVEDIGHELTYVLPYEAAKEGAFVELFHEIDDRLSDLGISSYGISETTLEEIFLKVAEESGVDAETSDGTLPARRNRRAFGDKQSCLRPFTEDDAADPNDSDIDPESRETDLLSGMDGKGSYQVKGWKLTQQQFVALLWKRLLIARRSRKGFFAQIVLPAVFVCIALVFSLIVPPFGKYPSLELQPWMYNEQYTFVSNDAPEDTGTLELLNALTKDPGFGTRCMEGNPIPDTPCQAGEEEWTTAPVPQTIMDLFQNGNWTMQNPSPACQCSSDKIKKMLPVCPPGAGGLPPPQRKQNTADILQDLTGRNISDYLVKTYVQIIAKSLKNKIWVNEFRYGGFSLGVSNTQALPPSQEVNDAIKQMKKHLKLAKDSSADRFLNSLGRFMTGLDTKNNVKVWFNNKGWHAISSFLNVINNAILRANLQKGENPSHYGITAFNHPLNLTKQQLSEVALMTTSVDVLVSICVIFAMSFVPASFVVFLIQERVSKAKHLQFISGVKPVIYWLSNFVWDMCNYVVPATLVIIIFICFQQKSYVSSTNLPVLALLLLLYGWSITPLMYPASFVFKIPSTAYVVLTSVNLFIGINGSVATFVLELFTDNKLNNINDILKSVFLIFPHFCLGRGLIDMVKNQAMADALERFGENRFVSPLSWDLVGRNLFAMAVEGVVFFLITVLIQYRFFIRPRPVNAKLSPLNDEDEDVRRERQRILDGGGQNDILEIKELTKIYRRKRKPAVDRICVGIPPGECFGLLGVNGAGKSSTFKMLTGDTTVTRGDAFLNKNSILSNIHEVHQNMGYCPQFDAITELLTGREHVEFFALLRGVPEKEVGKVGEWAIRKLGLVKYGEKYAGNYSGGNKRKLSTAMALIGGPPVVFLDEPTTGMDPKARRFLWNCALSVVKEGRSVVLTSHSMEECEALCTRMAIMVNGRFRCLGSVQHLKNRFGDGYTIVVRIAGSNPDLKPVQDFFGLAFPGSVLKEKHRNMLQYQLPSSLSSLARIFSILSQSKKRLHIEDYSVSQTTLDQVFVNFAKDQSDDDHLKDLSLHKNQTVVDVAVLTSFLQDEKVKESYV
T00494	DRUGINFO	D0H2DQ	Probucol	Approved
T00494	DRUGINFO	D03JQR	RG-7273	Discontinued in Phase 1
T00494	DRUGINFO	D01WMW	RG7232	Investigative

T17345	TARGETID	T17345
T17345	FORMERID	TTDI00931
T17345	UNIPROID	DYR_HUMAN
T17345	TARGNAME	Dihydrofolate reductase (DHFR)
T17345	GENENAME	DHFR
T17345	TARGTYPE	Successful
T17345	SYNONYMS	DYR; DHFRP1
T17345	FUNCTION	Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis. Binds its own mRNA and that of DHFR2. Key enzyme in folate metabolism.
T17345	PDBSTRUC	6DE4; 6DAV; 6A7E; 6A7C; 5HVE
T17345	BIOCLASS	CH-NH donor oxidoreductase
T17345	ECNUMBER	EC 1.5.1.3
T17345	SEQUENCE	MVGSLNCIVAVSQNMGIGKNGDLPWPPLRNEFRYFQRMTTTSSVEGKQNLVIMGKKTWFSIPEKNRPLKGRINLVLSRELKEPPQGAHFLSRSLDDALKLTEQPELANKVDMVWIVGGSSVYKEAMNHPGHLKLFVTRIMQDFESDTFFPEIDLEKYKLLPEYPGVLSDVQEEKGIKYKFEVYEKND
T17345	DRUGINFO	D0AO5H	Trimethoprim	Approved
T17345	DRUGINFO	D0B6TW	Leucovorin Calcium	Approved
T17345	DRUGINFO	D0D3DU	Methotrexate Sodium	Approved
T17345	DRUGINFO	D01WJL	Aminosalicylic Acid	Approved
T17345	DRUGINFO	D04LBC	Iclaprim	Phase 3
T17345	DRUGINFO	D02OTK	CH-4051	Phase 2
T17345	DRUGINFO	D09AYQ	PIRITREXIM	Phase 2
T17345	DRUGINFO	D0DO5J	MDAM (y-methylene-10-deazaaminopterin)	Phase 1
T17345	DRUGINFO	D0S9OH	L-MDAM	Phase 1
T17345	DRUGINFO	D9ZQ7T	VYR 006	Phase 1
T17345	DRUGINFO	D00CQW	TNP-351	Discontinued in Phase 2
T17345	DRUGINFO	D05HCO	1954U89	Preclinical

T45299	TARGETID	T45299
T45299	FORMERID	TTDR01233
T45299	UNIPROID	TPA_HUMAN
T45299	TARGNAME	Tissue-type plasminogen activator (PLAT)
T45299	GENENAME	PLAT
T45299	TARGTYPE	Successful
T45299	SYNONYMS	TPA; T-plasminogen activator; T-PA; Reteplase; Alteplase
T45299	FUNCTION	By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. Plays a direct role in facilitating neuronal migration. Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen.
T45299	PDBSTRUC	5ZLZ; 5BRR; 1TPN; 1TPM; 1TPK
T45299	BIOCLASS	Peptidase
T45299	ECNUMBER	EC 3.4.21.68
T45299	SEQUENCE	MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP
T45299	DRUGINFO	D0FD0H	Aminocaproic Acid	Approved
T45299	DRUGINFO	D03CKG	5-(DIMETHYLAMINO)-2-NAPHTHALENESULFONIC ACID	Investigative
T45299	DRUGINFO	D07PSW	N-(4-Phenyl-pyridin-2-yl)-guanidine	Investigative
T45299	DRUGINFO	D09YLF	N-(7-Benzyloxy-isoquinolin-1-yl)-guanidine	Investigative
T45299	DRUGINFO	D0C3QE	N-(5-Benzyloxy-isoquinolin-1-yl)-guanidine	Investigative
T45299	DRUGINFO	D01JUI	N-(4-Chloro-7-p-tolyl-isoquinolin-1-yl)-guanidine	Investigative
T45299	DRUGINFO	D00PEJ	1-guanidino-N-phenyl-7-isoquinolinesulphonamide	Investigative
T45299	DRUGINFO	D0J1QT	BMS-344577	Investigative
T45299	DRUGINFO	D08OLP	2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine	Investigative

T03661	TARGETID	T03661
T03661	FORMERID	TTDS00092
T03661	UNIPROID	ADA_HUMAN
T03661	TARGNAME	Adenosine deaminase (ADA)
T03661	GENENAME	ADA
T03661	TARGTYPE	Successful
T03661	SYNONYMS	Adenosine aminohydrolase; ADA1
T03661	FUNCTION	Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, and so contributes indirectly to cellular signaling events. Acts as a positive regulator of T-cell coactivation, by binding DPP4. Its interaction with DPP4 regulates lymphocyte-epithelial cell adhesion. Enhances dendritic cell immunogenicity by affecting dendritic cell costimulatory molecule expression and cytokines and chemokines secretion. Enhances CD4+ T-cell differentiation and proliferation. Acts as a positive modulator of adenosine receptors ADORA1 and ADORA2A, by enhancing their ligand affinity via conformational change. Stimulates plasminogen activation. Plays a role in male fertility. Plays a protective role in early postimplantation embryonic development. Catalyzes the hydrolytic deamination of adenosine and 2-deoxyadenosine.
T03661	PDBSTRUC	3IAR; 1M7M
T03661	BIOCLASS	Carbon-nitrogen hydrolase
T03661	ECNUMBER	EC 3.5.4.4
T03661	SEQUENCE	MAQTPAFDKPKVELHVHLDGSIKPETILYYGRRRGIALPANTAEGLLNVIGMDKPLTLPDFLAKFDYYMPAIAGCREAIKRIAYEFVEMKAKEGVVYVEVRYSPHLLANSKVEPIPWNQAEGDLTPDEVVALVGQGLQEGERDFGVKARSILCCMRHQPNWSPKVVELCKKYQQQTVVAIDLAGDETIPGSSLLPGHVQAYQEAVKSGIHRTVHAGEVGSAEVVKEAVDILKTERLGHGYHTLEDQALYNRLRQENMHFEICPWSSYLTGAWKPDTEHAVIRLKNDQANYSLNTDDPLIFKSTLDTDYQMTKRDMGFTEEEFKRLNINAAKSSFLPEDEKRELLDLLYKAYGMPPSASAGQNL
T03661	DRUGINFO	D01VEJ	Elapegademase	Approved
T03661	DRUGINFO	D05GJW	Cladribine	Approved
T03661	DRUGINFO	D0F2XQ	Fludarabine	Approved
T03661	DRUGINFO	D0T3AD	Pentostatin	Approved
T03661	DRUGINFO	D0F4QV	GSK2696273	Preregistration
T03661	DRUGINFO	D47RIS	OTL-101	Phase 3
T03661	DRUGINFO	D05YUI	Ex vivo adenosine deaminase-transduced hematopoietic stem cell therapy	Phase 1/2
T03661	DRUGINFO	D00FIT	3-(6-Amino-purin-9-yl)-6-phenyl-hexan-2-ol	Investigative
T03661	DRUGINFO	D01XFT	3-(6-Amino-purin-9-yl)-8-phenyl-octan-2-ol	Investigative
T03661	DRUGINFO	D03PLV	1-Deaza-Adenosine	Investigative
T03661	DRUGINFO	D04GWR	FR117016	Investigative
T03661	DRUGINFO	D05RDO	3-(6-Amino-purin-9-yl)-4-butoxy-butan-2-ol	Investigative
T03661	DRUGINFO	D06EHE	6-Hydroxy-1,6-Dihydro Purine Nucleoside	Investigative
T03661	DRUGINFO	D06QTC	FR230513	Investigative
T03661	DRUGINFO	D08FWE	3-(6-Amino-purin-9-yl)-non-5-en-2-ol	Investigative
T03661	DRUGINFO	D08ZMX	FR239087	Investigative
T03661	DRUGINFO	D09JNN	3-(6-Amino-purin-9-yl)-7-phenyl-heptan-2-ol	Investigative
T03661	DRUGINFO	D0D2OM	3-(6-Amino-purin-9-yl)-4-p-tolyl-butan-2-ol	Investigative
T03661	DRUGINFO	D0D7CM	FR233623	Investigative
T03661	DRUGINFO	D0D8YG	3-(6-Amino-purin-9-yl)-4-phenethyloxy-butan-2-ol	Investigative
T03661	DRUGINFO	D0E6ON	3-(6-Amino-purin-9-yl)-5-m-tolyl-pentan-2-ol	Investigative
T03661	DRUGINFO	D0G0TP	3-(6-Amino-purin-9-yl)-non-5-yn-2-ol	Investigative
T03661	DRUGINFO	D0KC9E	3-(6-Amino-purin-9-yl)-6-o-tolyl-hexan-2-ol	Investigative
T03661	DRUGINFO	D0L5XY	FR221647	Investigative
T03661	DRUGINFO	D0R7RB	Purine Riboside	Investigative
T03661	DRUGINFO	D0V4UU	6-Hydroxy-7,8-Dihydro Purine Nucleoside	Investigative
T03661	DRUGINFO	D0V4WB	(2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol	Investigative
T03661	DRUGINFO	D0V6TX	FR236913	Investigative
T03661	DRUGINFO	D05ZHQ	EHNA	Investigative

T20178	TARGETID	T20178
T20178	FORMERID	TTDS00131
T20178	UNIPROID	TNFA_HUMAN
T20178	TARGNAME	Tumor necrosis factor (TNF)
T20178	GENENAME	TNF
T20178	TARGTYPE	Successful
T20178	SYNONYMS	Tumour necrosis factor alpha; Tumour necrosis factor; Tumor necrosis factor ligand superfamily member 2; TNFalpha; TNFSF2; TNFA; TNF-alpha; TNF-a; TNF alpha; Cachectin
T20178	FUNCTION	It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Upregulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective. Key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO/SMAC mimetic in the RT4v6 bladder cancer cell line. Induces insulin resistance in adipocytes via inhibition of insulin-induced IRS1 tyrosine phosphorylation and insulin-induced glucose uptake. Induces GKAP42 protein degradation in adipocytes which is partially responsible for TNF-induced insulin resistance. Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR.
T20178	PDBSTRUC	5YOY; 5WUX; 5UUI; 5TSW; 5MU8
T20178	BIOCLASS	Cytokine: tumor necrosis factor
T20178	SEQUENCE	MSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLFCLLHFGVIGPQREEFPRDLSLISPLAQAVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELRDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL
T20178	DRUGINFO	D05LTY	Enbrel	Approved
T20178	DRUGINFO	D09FSG	Golimumab	Approved
T20178	DRUGINFO	D09QEI	Pentoxifylline	Approved
T20178	DRUGINFO	D0CA0P	Certolizumab	Approved
T20178	DRUGINFO	D0I5QX	Etanercept	Approved
T20178	DRUGINFO	D0K5KS	Adalimumab	Approved
T20178	DRUGINFO	D0PG5G	Infliximab	Approved
T20178	DRUGINFO	D0Q5NX	Lenalidomide	Approved
T20178	DRUGINFO	D0U7GK	Thalidomide	Approved
T20178	DRUGINFO	D07XHO	Nafamostat	Approved
T20178	DRUGINFO	D03QBT	Golnerminogene pradenovac	Phase 3
T20178	DRUGINFO	D06FMO	ABP 501	Phase 3
T20178	DRUGINFO	D08DGC	CPL-7075	Phase 3
T20178	DRUGINFO	D0D9HZ	PF-06438179	Phase 3
T20178	DRUGINFO	D0Y8TZ	PF-06410293	Phase 3
T20178	DRUGINFO	DI0CX8	AVT02	Phase 3
T20178	DRUGINFO	D03VPJ	AN0128	Phase 2
T20178	DRUGINFO	D04GTA	Pegsunercept	Phase 2
T20178	DRUGINFO	D04ZHJ	TNF alpha kinoid	Phase 2
T20178	DRUGINFO	D05CJU	DLX-105	Phase 2
T20178	DRUGINFO	D0A8JM	RDP58	Phase 2
T20178	DRUGINFO	D0G9ZU	ESBA-105	Phase 2
T20178	DRUGINFO	D0Q5CH	AP-301-IH	Phase 2
T20178	DRUGINFO	D2AQW7	ABBV-154	Phase 2
T20178	DRUGINFO	D0OX5H	ABT-122	Phase 2
T20178	DRUGINFO	D0YX7E	Ortataxel	Phase 2
T20178	DRUGINFO	D00YEV	BAICALEIN	Phase 2
T20178	DRUGINFO	D00BPH	COVA322	Phase 1/2a
T20178	DRUGINFO	D08KCK	ART621	Phase 1/2
T20178	DRUGINFO	DU7G5P	XTMAB-16	Phase 1/2
T20178	DRUGINFO	D02PTI	AST-005	Phase 1
T20178	DRUGINFO	D04DUH	PMI-005	Phase 1
T20178	DRUGINFO	D0DC8J	CYT-609	Phase 1
T20178	DRUGINFO	D0Y0FZ	PF-05230905	Phase 1
T20178	DRUGINFO	D1ROU2	IA-14069	Phase 1
T20178	DRUGINFO	DQA23T	SAR441566	Phase 1
T20178	DRUGINFO	DR5LW8	INB03	Phase 1
T20178	DRUGINFO	D03HIG	AVX-470	Phase 1
T20178	DRUGINFO	D04DQO	ABBV-257	Phase 1
T20178	DRUGINFO	D31CPE	SAR442970	Phase 1
T20178	DRUGINFO	DKX8W5	SAR444419	Phase 1
T20178	DRUGINFO	D07AWM	Segard	Discontinued in Phase 3
T20178	DRUGINFO	D0S2GT	CDP571	Discontinued in Phase 3
T20178	DRUGINFO	D0Q9ZD	Camobucol	Discontinued in Phase 2
T20178	DRUGINFO	D0VA2I	CRx-191	Discontinued in Phase 2
T20178	DRUGINFO	D04VGY	CYT-007-TNFQb	Discontinued in Phase 1/2
T20178	DRUGINFO	D05RTF	AME-527	Discontinued in Phase 1/2
T20178	DRUGINFO	D05NUT	ALS-00T2-0501	Discontinued in Phase 1
T20178	DRUGINFO	D0D1RF	ABX-0401	Preclinical
T20178	DRUGINFO	D0I9XH	Celastrol	Preclinical
T20178	DRUGINFO	D01ZEY	MDL-201112	Terminated
T20178	DRUGINFO	D06MJP	TNFQb therapeutic vaccines	Terminated
T20178	DRUGINFO	D04SVB	FR-133605	Terminated
T20178	DRUGINFO	D06VXD	DOM-0215	Investigative
T20178	DRUGINFO	D06YWZ	Y-39041	Investigative
T20178	DRUGINFO	D02UYR	PKF-241-466	Investigative
T20178	DRUGINFO	D0H2PA	PKF-242-484	Investigative
T20178	DRUGINFO	D0W7LK	2-Propanol, Isopropanol	Investigative
T20178	DRUGINFO	D0W2UK	IK-862	Investigative

T77664	TARGETID	T77664
T77664	FORMERID	TTDC00096
T77664	UNIPROID	IFNG_HUMAN
T77664	TARGNAME	Interferon-gamma (IFNG)
T77664	GENENAME	IFNG
T77664	TARGTYPE	Successful
T77664	SYNONYMS	Interferon gamma; Immune interferon; IFN-gamma
T77664	FUNCTION	Produced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons.
T77664	PDBSTRUC	6E3L; 6E3K; 3BES; 1HIG; 1FYH
T77664	BIOCLASS	Cytokine: interferon
T77664	SEQUENCE	MKYTSYILAFQLCIVLGSLGCYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVMAELSPAAKTGKRKRSQMLFRGRRASQ
T77664	DRUGINFO	D0UI7K	Emapalumab	Approved
T77664	DRUGINFO	D03GOO	Fumaric acid	Phase 3
T77664	DRUGINFO	D0I5QV	VIR-201	Phase 1/2
T77664	DRUGINFO	D06FLP	AMG 811	Phase 1
T77664	DRUGINFO	D06NDP	CIGB-128	Phase 1
T77664	DRUGINFO	D0H6PX	TAK-603	Discontinued in Phase 2
T77664	DRUGINFO	D0N4ND	Fontolizumab	Discontinued in Phase 2
T77664	DRUGINFO	D0Z9MR	TG-1042	Discontinued in Phase 2
T77664	DRUGINFO	D0VA2I	CRx-191	Discontinued in Phase 2
T77664	DRUGINFO	D0WD6K	VPM-4-001	Preclinical

T42000	TARGETID	T42000
T42000	FORMERID	TTDS00447
T42000	UNIPROID	IL1B_HUMAN
T42000	TARGNAME	Interleukin-1 beta (IL1B)
T42000	GENENAME	IL1B
T42000	TARGTYPE	Successful
T42000	SYNONYMS	IL1F2; IL-1beta; IL-1 beta; Catabolin
T42000	FUNCTION	Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production. Promotes Th17 differentiation of T-cells. Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells. Potent proinflammatory cytokine.
T42000	PDBSTRUC	9ILB; 7I1B; 6I1B; 5MVZ; 5I1B
T42000	BIOCLASS	Cytokine: interleukin
T42000	SEQUENCE	MAEVPELASEMMAYYSGNEDDLFFEADGPKQMKCSFQDLDLCPLDGGIQLRISDHHYSKGFRQAASVVVAMDKLRKMLVPCPQTFQENDLSTFFPFIFEEEPIFFDTWDNEAYVHDAPVRSLNCTLRDSQQKSLVMSGPYELKALHLQGQDMEQQVVFSMSFVQGEESNDKIPVALGLKEKNLYLSCVLKDDKPTLQLESVDPKNYPKKKMEKRFVFNKIEINNKLEFESAQFPNWYISTSQAENMPVFLGGTKGGQDITDFTMQFVSS
T42000	DRUGINFO	D07NSU	Glucosamine	Approved
T42000	DRUGINFO	D09DBY	Rilonacept	Approved
T42000	DRUGINFO	D0R4ZT	Gallium nitrate	Approved
T42000	DRUGINFO	D0TD2G	Canakinumab	Approved
T42000	DRUGINFO	D0N1FS	Diacerein	Phase 4
T42000	DRUGINFO	D0C4KT	XOMA 052	Phase 3
T42000	DRUGINFO	D02DJG	LY-2189102	Phase 2
T42000	DRUGINFO	D01WQQ	ABT-981	Phase 2
T42000	DRUGINFO	D0WP2R	AC-201	Phase 2
T42000	DRUGINFO	D00EHX	TT-301	Phase 1
T42000	DRUGINFO	D09YAS	CYT-013-IL1bQb	Phase 1
T42000	DRUGINFO	D05FVX	CDP-484	Discontinued in Phase 1/2
T42000	DRUGINFO	D0I9XH	Celastrol	Preclinical
T42000	DRUGINFO	D0K8YK	DVD-Ig	Investigative

T03313	TARGETID	T03313
T03313	FORMERID	TTDR01101
T03313	UNIPROID	IL2RA_HUMAN
T03313	TARGNAME	Interleukin 2 receptor alpha (IL2RA)
T03313	GENENAME	IL2RA
T03313	TARGTYPE	Successful
T03313	SYNONYMS	TAC antigen; Interleukin-2 receptor subunit alpha; IL2-RA; IL-2R subunit alpha; IL-2-RA; IL-2 receptor subunit alpha; IL-2 receptor alpha subunit; CD25 antigen; CD25
T03313	FUNCTION	The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T-cells. Receptor for interleukin-2.
T03313	PDBSTRUC	3NFP; 3IU3; 2ERJ; 2B5I; 1Z92
T03313	BIOCLASS	Cytokine receptor
T03313	SEQUENCE	MDSYLLMWGLLTFIMVPGCQAELCDDDPPEIPHATFKAMAYKEGTMLNCECKRGFRRIKSGSLYMLCTGNSSHSSWDNQCQCTSSATRNTTKQVTPQPEEQKERKTTEMQSPMQPVDQASLPGHCREPPPWENEATERIYHFVVGQMVYYQCVQGYRALHRGPAESVCKMTHGKTRWTQPQLICTGEMETSQFPGEEKPQASPEGRPESETSCLVTTTDFQIQTEMAATMETSIFTTEYQVAVAGCVFLLISVLLLSGLTWQRRQRKSRRTI
T03313	DRUGINFO	D06SBB	Basiliximab	Approved
T03313	DRUGINFO	D0OX9W	Inolimomab	Phase 3
T03313	DRUGINFO	D06EIJ	RFT-5.dgA	Phase 2
T03313	DRUGINFO	D0X0IU	LMB-2	Phase 2
T03313	DRUGINFO	D0U3UJ	CHT-25	Phase 1
T03313	DRUGINFO	DK52QX	RG6292	Phase 1
T03313	DRUGINFO	D0Q4DT	HuMax-TAC	Terminated

T10191	TARGETID	T10191
T10191	FORMERID	TTDC00265
T10191	UNIPROID	CD4_HUMAN
T10191	TARGNAME	T-cell surface glycoprotein CD4 (CD4)
T10191	GENENAME	CD4
T10191	TARGTYPE	Successful
T10191	SYNONYMS	T-cell surface antigen T4/Leu-3
T10191	FUNCTION	In T-cells, functions primarily as a coreceptor for MHC class II molecule:peptide complex. The antigens presented by class II peptides are derived from extracellular proteins while class I peptides are derived from cytosolic proteins. Interacts simultaneously with the T-cell receptor (TCR) and the MHC class II presented by antigen presenting cells (APCs). In turn, recruits the Src kinase LCK to the vicinity of the TCR-CD3 complex. LCK then initiates different intracellular signaling pathways by phosphorylating various substrates ultimately leading to lymphokine production, motility, adhesion and activation of T-helper cells. In other cells such as macrophages or NK cells, plays a role in differentiation/activation, cytokine expression and cell migration in a TCR/LCK-independent pathway. Participates in the development of T-helper cells in the thymus and triggers the differentiation of monocytes into functional mature macrophages. Integral membrane glycoprotein that plays an essential role in the immune response and serves multiple functions in responses against both external and internal offenses.
T10191	PDBSTRUC	6MET; 6MEO; 6EDU; 6CM3; 5VN3
T10191	BIOCLASS	Immunoglobulin
T10191	SEQUENCE	MNRGVPFRHLLLVLQLALLPAATQGKKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICEVEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPSVQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKKVEFKIDIVVLAFQKASSIVYKKEGEQVEFSFPLAFTVEKLTGSGELWWQAERASSSKSWITFDLKNKEVSVKRVTQDPKLQMGKKLPLHLTLPQALPQYAGSGNLTLALEAKTGKLHQEVNLVVMRATQLQKNLTCEVWGPTSPKLMLSLKLENKEAKVSKREKAVWVLNPEAGMWQCLLSDSGQVLLESNIKVLPTWSTPVQPMALIVLGGVAGLLLFIGLGIFFCVRCRHRRRQAERMSQIKRLLSEKKTCQCPHRFQKTCSPI
T10191	DRUGINFO	D0E7AD	Ibalizumab 	Approved
T10191	DRUGINFO	D00UBX	TNX-355	Phase 3
T10191	DRUGINFO	D0Z8KS	Zanolimumab	Phase 3
T10191	DRUGINFO	DN5CM6	Magrolimab	Phase 3
T10191	DRUGINFO	D0NQ0V	BT-061	Phase 2
T10191	DRUGINFO	D0C8AL	Fluoropeptide vaccine	Phase 2
T10191	DRUGINFO	DFQ17Y	TMB-365	Phase 1
T10191	DRUGINFO	DO7MC9	CD4CAR	Phase 1
T10191	DRUGINFO	DRGC82	VRC07-523LS	Phase 1
T10191	DRUGINFO	D0T7LV	LIPO-4	Phase 1
T10191	DRUGINFO	DO61WZ	Combinectin	Phase 1
T10191	DRUGINFO	D04ZLG	IDEC-151	Discontinued in Phase 2
T10191	DRUGINFO	D0F3VI	CEL-1000	Investigative

T39087	TARGETID	T39087
T39087	FORMERID	TTDC00211
T39087	UNIPROID	POL_HV1B1
T39087	TARGNAME	Human immunodeficiency virus Integrase (HIV IN)
T39087	GENENAME	HIV IN
T39087	TARGTYPE	Successful
T39087	SYNONYMS	HIV IN
T39087	FUNCTION	Gag-Pol polyprotein: Mediates, with Gag polyprotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi). Gag-Pol polyprotein may regulate its own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, the polyprotein would promote translation, whereas at high concentration, the polyprotein would encapsidate genomic RNA and then shut off translation.
T39087	PDBSTRUC	6OE3; 6HAK; 6ELI; 6DUH; 6DUG
T39087	BIOCLASS	Integrase
T39087	ECNUMBER	EC 2.7.7.-
T39087	SEQUENCE	FLDGIDKAQDEHEKYHSNWRAMASDFNLPPVVAKEIVASCDKCQLKGEAMHGQVDCSPGIWQLDCTHLEGKVILVAVHVASGYIEAEVIPAETGQETAYFLLKLAGRWPVKTIHTDNGSNFTSATVKAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIHNFKRKGGIGGYSAGERIVDIIATDIQTKELQKQITKIQNFRVYYRDSRNPLWKGPAKLLWKGEGAVVIQDNSDIKVVPRRKAKIIRDYGKQMAGDDCVASRQDED
T39087	DRUGINFO	D00YZD	Dolutegravir	Approved
T39087	DRUGINFO	D0I1FQ	Raltegravir	Approved
T39087	DRUGINFO	D0QD1G	Elvitegravir	Approved
T39087	DRUGINFO	D01IRG	Bictegravir, emtricitabine and tenofovir alafenamide	Approved
T39087	DRUGINFO	D08LDB	GSK1265744	Phase 3
T39087	DRUGINFO	D02DMW	S-1360	Phase 2
T39087	DRUGINFO	D09HOW	S-364735	Phase 2
T39087	DRUGINFO	D0C1WL	C-2507	Phase 1
T39087	DRUGINFO	D0N3NL	Acriflavine	Phase 1
T39087	DRUGINFO	D0P0PC	S-265744 LAP	Phase 1
T39087	DRUGINFO	D7PY9O	VH4524184	Phase 1
T39087	DRUGINFO	D0F0OJ	JTK-656	Discontinued in Phase 1
T39087	DRUGINFO	D06SIG	AR177	Terminated
T39087	DRUGINFO	D0V8HF	GS-9160	Terminated
T39087	DRUGINFO	D01HGV	L-708,906	Investigative
T39087	DRUGINFO	D05KKV	Dicaffeoylquinic acids	Investigative
T39087	DRUGINFO	D05PMU	Dicaffeoyltartaric acids	Investigative
T39087	DRUGINFO	D07ECH	V-165	Investigative
T39087	DRUGINFO	D08FSC	L-731,988	Investigative
T39087	DRUGINFO	D09OSF	L17	Investigative
T39087	DRUGINFO	D0XJ7I	Purpurin	Investigative

T77195	TARGETID	T77195
T77195	FORMERID	TTDS00469
T77195	UNIPROID	NU3M_HUMAN
T77195	TARGNAME	NADH dehydrogenase (MT-ND3)
T77195	GENENAME	MT-ND3
T77195	TARGTYPE	Successful
T77195	SYNONYMS	ND; NADH-ubiquinone oxidoreductase; NADH; MTND; MT-ND3; MT-ND
T77195	FUNCTION	Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in thetransfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.
T77195	PDBSTRUC	5XTD; 5XTC
T77195	BIOCLASS	NADH/NADPH oxidoreductase
T77195	ECNUMBER	EC 7.1.1.2
T77195	SEQUENCE	MNFALILMINTLLALLLMIITFWLPQLNGYMEKSTPYECGFDPMSPARVPFSMKFFLVAITFLLFDLEIALLLPLPWALQTTNLPLMVMSSLLLIIILALSLAYEWLQKGLDWTE
T77195	DRUGINFO	D0B8SV	NADH	Approved
T77195	DRUGINFO	D07FRX	6-Thiophen-3-yl-imidazo[2,1-b]thiazole	Investigative
T77195	DRUGINFO	D0J3TS	6-Thiophen-2-yl-imidazo[2,1-b]thiazole	Investigative
T77195	DRUGINFO	D0GV9Q	N-Formylmethionine	Investigative

T82739	TARGETID	T82739
T82739	FORMERID	TTDC00013
T82739	UNIPROID	KLKB1_HUMAN
T82739	TARGNAME	Plasma kallikrein (KLKB1)
T82739	GENENAME	KLKB1
T82739	TARGTYPE	Successful
T82739	SYNONYMS	Plasma prekallikrein; Plasma kallikrein light chain; Plasma kallikrein heavy chain; PKK; Kininogenin; KLK3; Fletcher factor
T82739	FUNCTION	It activates, in a reciprocal reaction, factor XII after its binding to a negatively charged surface. It also releases bradykinin from HMW kininogen and may also play a role in the renin-angiotensin system by converting prorenin into renin. The enzyme cleaves Lys-Arg and Arg-Ser bonds.
T82739	PDBSTRUC	6O1S; 6O1G; 6I44; 5TJX; 5F8Z
T82739	BIOCLASS	Peptidase
T82739	ECNUMBER	EC 3.4.21.34
T82739	SEQUENCE	MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA
T82739	DRUGINFO	D08LEY	Lanadelumab	Approved
T82739	DRUGINFO	DQ1S0B	Berotralstat	Approved
T82739	DRUGINFO	D0P5AE	Ecallantide	Approved
T82739	DRUGINFO	D03GSN	KVD001	Phase 2
T82739	DRUGINFO	D9SMF2	KVD824	Phase 2
T82739	DRUGINFO	DA8W3Q	THR-149	Phase 2
T82739	DRUGINFO	D0R9CH	ZK-810388	Investigative
T82739	DRUGINFO	D02PAU	ZK-814048	Investigative
T82739	DRUGINFO	D08WQJ	(3-nitro-1H-pyrazol-1-yl)(phenyl)methanone	Investigative
T82739	DRUGINFO	D05ZIP	(4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone	Investigative
T82739	DRUGINFO	D08OCS	(3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone	Investigative
T82739	DRUGINFO	D0IU5E	1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide	Investigative
T82739	DRUGINFO	D0M4VZ	D-Pro-Phe-Arg chloromethyl ketone	Investigative
T82739	DRUGINFO	D0X1OY	(3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone	Investigative

T84173	TARGETID	T84173
T84173	FORMERID	TTDC00014
T84173	UNIPROID	GLCM_HUMAN
T84173	TARGNAME	Glucosylceramidase (GBA)
T84173	GENENAME	GBA
T84173	TARGTYPE	Successful
T84173	SYNONYMS	SGTase; Lysosomal acid glucosylceramidase; Lysosomal acid GCase; Imiglucerase; GLUC; GC; D-glucosyl-N-acylsphingosine glucohydrolase; Cholesteryl-beta-glucosidase; Cholesterol glucosyltransferase; Beta-glucocerebrosidase; Beta-GC; Alglucerase; Acid beta-glucosidase
T84173	FUNCTION	Glucosylceramidase that catalyzes, within the lysosomal compartment, the hydrolysis of glucosylceramide/GlcCer into free ceramide and glucose. Thereby, plays a central role in the degradation of complex lipids and the turnover of cellular membranes. Through the production of ceramides, participates to the PKC-activated salvage pathway of ceramide formation. Also plays a role in cholesterol metabolism. May either catalyze the glucosylation of cholesterol, through a transglucosylation reaction that transfers glucose from glucosylceramide to cholesterol. The short chain saturated C8:0-GlcCer and the mono-unsaturated C18:0-GlcCer being the most effective glucose donors for that transglucosylation reaction. Under specific conditions, may alternatively catalyze the reverse reaction, transferring glucose from cholesteryl-beta-D-glucoside to ceramide. Finally, may also hydrolyze cholesteryl-beta-D-glucoside to produce D-glucose and cholesterol.
T84173	PDBSTRUC	6Q6N; 6Q6L; 6Q6K; 5LVX; 3RIL
T84173	BIOCLASS	Glycosylase
T84173	ECNUMBER	EC 3.2.1.45
T84173	SEQUENCE	MEFSSPSREECPKPLSRVSIMAGSLTGLLLLQAVSWASGARPCIPKSFGYSSVVCVCNATYCDSFDPPTFPALGTFSRYESTRSGRRMELSMGPIQANHTGTGLLLTLQPEQKFQKVKGFGGAMTDAAALNILALSPPAQNLLLKSYFSEEGIGYNIIRVPMASCDFSIRTYTYADTPDDFQLHNFSLPEEDTKLKIPLIHRALQLAQRPVSLLASPWTSPTWLKTNGAVNGKGSLKGQPGDIYHQTWARYFVKFLDAYAEHKLQFWAVTAENEPSAGLLSGYPFQCLGFTPEHQRDFIARDLGPTLANSTHHNVRLLMLDDQRLLLPHWAKVVLTDPEAAKYVHGIAVHWYLDFLAPAKATLGETHRLFPNTMLFASEACVGSKFWEQSVRLGSWDRGMQYSHSIITNLLYHVVGWTDWNLALNPEGGPNWVRNFVDSPIIVDITKDTFYKQPMFYHLGHFSKFIPEGSQRVGLVASQKNDLDAVALMHPDGSAVVVVLNRSSKDVPLTIKDPAVGFLETISPGYSIHTYLWRRQ
T84173	DRUGINFO	D0G5ET	Velaglucerase alfa	Approved
T84173	DRUGINFO	D0G6HA	Taliglucerase alfa	Approved
T84173	DRUGINFO	D04BQV	Isofagomine tartrate	Phase 2
T84173	DRUGINFO	D1SWN3	Afegostat	Discontinued in Phase 2
T84173	DRUGINFO	DJK0W9	NCGC607	Preclinical
T84173	DRUGINFO	DPUF69	N-Octyl-beta-valienamine	Preclinical
T84173	DRUGINFO	D00MFZ	L-Isofagomine	Investigative
T84173	DRUGINFO	D06YQR	(2R,3S,4S,5R)-2-propylpiperidine-3,4,5-triol	Investigative
T84173	DRUGINFO	D09IWI	N-(Propylamide-acetophenone)-1-deoxynojirimycin	Investigative
T84173	DRUGINFO	D0B1WB	(2R,3S,4S,5R)-2-nonylpiperidine-3,4,5-triol	Investigative
T84173	DRUGINFO	D0Q7SF	N-(Propylamide-benzophenone)-1-deoxynojirimycin	Investigative
T84173	DRUGINFO	D0R4JZ	(2R,3S,4S,5R)-2-hexylpiperidine-3,4,5-triol	Investigative
T84173	DRUGINFO	D0R8TR	1,5-Dideoxy-1,5-imino-D-xylitol	Investigative
T84173	DRUGINFO	D06IEN	2-(Acetylamino)-2-Deoxy-a-D-Glucopyranose	Investigative

T24836	TARGETID	T24836
T24836	FORMERID	TTDS00470
T24836	UNIPROID	PROC_HUMAN
T24836	TARGNAME	Vitamin K-dependent protein C (PROC)
T24836	GENENAME	PROC
T24836	TARGTYPE	Successful
T24836	SYNONYMS	Vitamin K-dependent protein C light chain; Vitamin K-dependent protein C heavy chain; PROC; Blood coagulation factor XIV; Autoprothrombin IIA; Anticoagulant protein C; Activation peptide
T24836	FUNCTION	Protein C is avitamin K-dependent serine protease that regulates blood coagulation by inactivating factors Va and VIIIa in the presence of calcium ions and phospholipids.
T24836	PDBSTRUC	4DT7; 3JTC; 3F6U; 2PCT; 1PCU
T24836	BIOCLASS	Peptidase
T24836	ECNUMBER	EC 3.4.21.69
T24836	SEQUENCE	MWQLTSLLLFVATWGISGTPAPLDSVFSSSERAHQVLRIRKRANSFLEELRHSSLERECIEEICDFEEAKEIFQNVDDTLAFWSKHVDGDQCLVLPLEHPCASLCCGHGTCIDGIGSFSCDCRSGWEGRFCQREVSFLNCSLDNGGCTHYCLEEVGWRRCSCAPGYKLGDDLLQCHPAVKFPCGRPWKRMEKKRSHLKRDTEDQEDQVDPRLIDGKMTRRGDSPWQVVLLDSKKKLACGAVLIHPSWVLTAAHCMDESKKLLVRLGEYDLRRWEKWELDLDIKEVFVHPNYSKSTTDNDIALLHLAQPATLSQTIVPICLPDSGLAERELNQAGQETLVTGWGYHSSREKEAKRNRTFVLNFIKIPVVPHNECSEVMSNMVSENMLCAGILGDRQDACEGDSGGPMVASFHGTWFLVGLVSWGEGCGLLHNYGVYTKVSRYLDWIHGHIRDKEAPQKSWAP
T24836	DRUGINFO	D0Z5SM	Sodium Tetradecyl Sulfate	Approved
T24836	DRUGINFO	D05BII	Ancrod	Phase 3
T24836	DRUGINFO	D0UT7F	3K3A-APC	Phase 2
T24836	DRUGINFO	D0F8RK	GED-aPC	Discontinued in Phase 1
T24836	DRUGINFO	D00KJP	RPR-120844	Investigative
T24836	DRUGINFO	D0MQ6K	RPR-118071	Investigative
T24836	DRUGINFO	D0V7TH	PMID24418773C37	Investigative

T40800	TARGETID	T40800
T40800	FORMERID	TTDS00045
T40800	UNIPROID	AT1A1_HUMAN
T40800	TARGNAME	Sodium pump subunit alpha-1 (ATP1A1)
T40800	GENENAME	ATP1A1
T40800	TARGTYPE	Successful
T40800	SYNONYMS	Sodium/potassium-transporting ATPase alpha1; Sodium pump 1; Na+/K+ ATPase 1; ATP1A1
T40800	FUNCTION	This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of atp coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions.
T40800	BIOCLASS	Acid anhydrides hydrolase
T40800	ECNUMBER	EC 7.2.2.13
T40800	SEQUENCE	MGKGVGRDKYEPAAVSEQGDKKGKKGKKDRDMDELKKEVSMDDHKLSLDELHRKYGTDLSRGLTSARAAEILARDGPNALTPPPTTPEWIKFCRQLFGGFSMLLWIGAILCFLAYSIQAATEEEPQNDNLYLGVVLSAVVIITGCFSYYQEAKSSKIMESFKNMVPQQALVIRNGEKMSINAEEVVVGDLVEVKGGDRIPADLRIISANGCKVDNSSLTGESEPQTRSPDFTNENPLETRNIAFFSTNCVEGTARGIVVYTGDRTVMGRIATLASGLEGGQTPIAAEIEHFIHIITGVAVFLGVSFFILSLILEYTWLEAVIFLIGIIVANVPEGLLATVTVCLTLTAKRMARKNCLVKNLEAVETLGSTSTICSDKTGTLTQNRMTVAHMWFDNQIHEADTTENQSGVSFDKTSATWLALSRIAGLCNRAVFQANQENLPILKRAVAGDASESALLKCIELCCGSVKEMRERYAKIVEIPFNSTNKYQLSIHKNPNTSEPQHLLVMKGAPERILDRCSSILLHGKEQPLDEELKDAFQNAYLELGGLGERVLGFCHLFLPDEQFPEGFQFDTDDVNFPIDNLCFVGLISMIDPPRAAVPDAVGKCRSAGIKVIMVTGDHPITAKAIAKGVGIISEGNETVEDIAARLNIPVSQVNPRDAKACVVHGSDLKDMTSEQLDDILKYHTEIVFARTSPQQKLIIVEGCQRQGAIVAVTGDGVNDSPALKKADIGVAMGIAGSDVSKQAADMILLDDNFASIVTGVEEGRLIFDNLKKSIAYTLTSNIPEITPFLIFIIANIPLPLGTVTILCIDLGTDMVPAISLAYEQAESDIMKRQPRNPKTDKLVNERLISMAYGQIGMIQALGGFFTYFVILAENGFLPIHLLGLRVDWDDRWINDVEDSYGQQWTYEQRKIVEFTCHTAFFVSIVVVQWADLVICKTRRNSVFQQGMKNKILIFGLFEETALAAFLSYCPGMGVALRMYPLKPTWWFCAFPYSLLIFVYDEVRKLIIRRRPGGWVEKETYY
T40800	DRUGINFO	D06MQM	Lumefantrine	Approved
T40800	DRUGINFO	D07NAJ	Chloroprocaine	Approved
T40800	DRUGINFO	D07TGN	Deslanoside	Approved
T40800	DRUGINFO	D0AR3J	Acocantherin	Approved
T40800	DRUGINFO	D0D9NA	Almitrine	Approved
T40800	DRUGINFO	D0M9BW	Artemether	Approved
T40800	DRUGINFO	D0V3GA	Acetyldigitoxin	Approved
T40800	DRUGINFO	D0V8TQ	Aluminium	Approved
T40800	DRUGINFO	D04TSO	UNBS-1450	Phase 1
T40800	DRUGINFO	D08ZNS	DIGITOXIGENIN	Investigative

T87024	TARGETID	T87024
T87024	FORMERID	TTDC00180
T87024	UNIPROID	A4_HUMAN
T87024	TARGNAME	Amyloid beta A4 protein (APP)
T87024	GENENAME	APP
T87024	TARGTYPE	Successful
T87024	SYNONYMS	Protease nexin-II; PreA4; PN-II; Cerebral vascular amyloid peptide; CVAP; Amyloid-beta precursor protein; Amyloid-beta A4 protein; Alzheimer disease amyloid protein; APPI; APP; AD1; ABPP; A4
T87024	FUNCTION	Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(O) and JIP. Inhibits G(o) alpha ATPase activity (By similarity). Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1. Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Provides Cu(2+) ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1.
T87024	PDBSTRUC	6IYC; 6GFI; 6CO3; 5W3P; 5VZY
T87024	BIOCLASS	Amyloid beta-protein peptide
T87024	SEQUENCE	MLPGLALLLLAAWTARALEVPTDGNAGLLAEPQIAMFCGRLNMHMNVQNGKWDSDPSGTKTCIDTKEGILQYCQEVYPELQITNVVEANQPVTIQNWCKRGRKQCKTHPHFVIPYRCLVGEFVSDALLVPDKCKFLHQERMDVCETHLHWHTVAKETCSEKSTNLHDYGMLLPCGIDKFRGVEFVCCPLAEESDNVDSADAEEDDSDVWWGGADTDYADGSEDKVVEVAEEEEVAEVEEEEADDDEDDEDGDEVEEEAEEPYEEATERTTSIATTTTTTTESVEEVVREVCSEQAETGPCRAMISRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAMSQSLLKTTQEPLARDPVKLPTTAASTPDAVDKYLETPGDENEHAHFQKAKERLEAKHRERMSQVMREWEEAERQAKNLPKADKKAVIQHFQEKVESLEQEAANERQQLVETHMARVEAMLNDRRRLALENYITALQAVPPRPRHVFNMLKKYVRAEQKDRQHTLKHFEHVRMVDPKKAAQIRSQVMTHLRVIYERMNQSLSLLYNVPAVAEEIQDEVDELLQKEQNYSDDVLANMISEPRISYGNDALMPSLTETKTTVELLPVNGEFSLDDLQPWHSFGADSVPANTENEVEPVDARPAADRGLTTRPGSGLTNIKTEEISEVKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVITLVMLKKKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN
T87024	DRUGINFO	D00RRU	Aducanumab	Approved
T87024	DRUGINFO	D06XVR	Lecanemab	Approved
T87024	DRUGINFO	D09CGE	Florbetapir F-18	Approved
T87024	DRUGINFO	D00CZT	Solanezumab	Phase 3
T87024	DRUGINFO	D09DLP	Tramiprosate	Phase 3
T87024	DRUGINFO	D0A1MX	Bapineuzumab	Phase 3
T87024	DRUGINFO	D0CH6B	ALZT-OP1	Phase 3
T87024	DRUGINFO	D0Q7YZ	Gantenerumab	Phase 3
T87024	DRUGINFO	D0R7EQ	Crenezumab	Phase 3
T87024	DRUGINFO	D0Z2GF	NI-101	Phase 3
T87024	DRUGINFO	D1KR3N	GV-971	Phase 3
T87024	DRUGINFO	D2ZP0A	Donanemab	Phase 3
T87024	DRUGINFO	D2ZP0A	Donanemab	Phase 3
T87024	DRUGINFO	D07SDQ	Curcumin	Phase 3
T87024	DRUGINFO	D0I3VT	CAD-106	Phase 2/3
T87024	DRUGINFO	D02XKK	FRM-0962	Phase 2
T87024	DRUGINFO	D07VAI	ALZ-801	Phase 2
T87024	DRUGINFO	D0B5EB	Ponezumab	Phase 2
T87024	DRUGINFO	D0NR6T	UB-311	Phase 2
T87024	DRUGINFO	D0T6KV	GSK933776A	Phase 2
T87024	DRUGINFO	D0W0NU	NIC5-15	Phase 2
T87024	DRUGINFO	D0X4ZL	AN-1792	Phase 2
T87024	DRUGINFO	D3XP8N	Trontinemab	Phase 2
T87024	DRUGINFO	DY6DS3	ABBV-916	Phase 2
T87024	DRUGINFO	D03SHD	Myo-inositol	Phase 2
T87024	DRUGINFO	D0E8HA	T-817MA	Phase 2
T87024	DRUGINFO	D67DST	AD-35	Phase 2
T87024	DRUGINFO	D0R6UR	ACI-24	Phase 1/2
T87024	DRUGINFO	D0TU1E	EB-101	Phase 1/2
T87024	DRUGINFO	D01ZSP	AAB-003/PF-05236812	Phase 1
T87024	DRUGINFO	D05ORO	Anti-N3pG-Abeta antibody	Phase 1
T87024	DRUGINFO	D06KWU	DWP-09031	Phase 1
T87024	DRUGINFO	D08QDF	Systebryl	Phase 1
T87024	DRUGINFO	D0HRC9	ANVS301	Phase 1
T87024	DRUGINFO	D0N9JB	SAR228810	Phase 1
T87024	DRUGINFO	D0V0VI	11C-AZD-2184	Phase 1
T87024	DRUGINFO	D0X2UK	Affitope AD-01	Phase 1
T87024	DRUGINFO	D0ZX2D	11C-6-Me-BTA-1	Phase 1
T87024	DRUGINFO	D4YD7V	LY3372993	Phase 1
T87024	DRUGINFO	DCP0I8	ACU193	Phase 1
T87024	DRUGINFO	DFM7X6	BEY2153	Phase 1
T87024	DRUGINFO	D06BVT	Affitope AD-02	Discontinued in Phase 2
T87024	DRUGINFO	D0Z1VS	RN6G	Discontinued in Phase 2
T87024	DRUGINFO	D0K3SV	PF-05236812	Discontinued in Phase 1
T87024	DRUGINFO	D01QLM	AAB-002	Phase 0
T87024	DRUGINFO	D09OUT	NN-818	Preclinical
T87024	DRUGINFO	D0G7LP	Pepticlere	Preclinical
T87024	DRUGINFO	D00BTZ	CT-003230	Investigative
T87024	DRUGINFO	D01BJK	Mimovax	Investigative
T87024	DRUGINFO	D01GAZ	123I-DRM-106	Investigative
T87024	DRUGINFO	D01HHL	Gelsolin	Investigative
T87024	DRUGINFO	D01MMU	5-methoxy-2-(4-methylaminophenyl)benzofuran	Investigative
T87024	DRUGINFO	D02BBJ	5-hydroxy-2-(4-methylaminophenyl)benzofuran	Investigative
T87024	DRUGINFO	D02DFT	4-(5-(4-(methylamino)phenyl)thiophen-2-yl)phenol	Investigative
T87024	DRUGINFO	D02FZQ	2,5-bis(4-methoxyphenyl)thiophene	Investigative
T87024	DRUGINFO	D03RJH	2,5-bis(2-methoxyphenyl)thiophene	Investigative
T87024	DRUGINFO	D03THP	4-(5-(4-methoxyphenyl)thiophen-2-yl)benzenamine	Investigative
T87024	DRUGINFO	D03TOK	1,6-Bis(4'-hydroxyphenyl)-hexa-1,3,5-triene	Investigative
T87024	DRUGINFO	D04LBV	AZ4800	Investigative
T87024	DRUGINFO	D04QXW	ARC-069	Investigative
T87024	DRUGINFO	D04TPS	A-887755	Investigative
T87024	DRUGINFO	D04ZTA	ANA-5	Investigative
T87024	DRUGINFO	D05GRI	DEHYDROZINGERONE	Investigative
T87024	DRUGINFO	D06CTD	IN-N01	Investigative
T87024	DRUGINFO	D06DRD	Chrysamine -G	Investigative
T87024	DRUGINFO	D06LRQ	TKP-1001	Investigative
T87024	DRUGINFO	D06MBR	ACI-636	Investigative
T87024	DRUGINFO	D07DNV	ARN-2966	Investigative
T87024	DRUGINFO	D07JKA	SEN-1500	Investigative
T87024	DRUGINFO	D07LFZ	4-(5-(4-aminophenyl)thiophen-2-yl)benzenamine	Investigative
T87024	DRUGINFO	D07SNW	1,6-bis(4'-dimethylaminophenyl)-hexa-1,3,5-triene	Investigative
T87024	DRUGINFO	D07YAC	Anticalin	Investigative
T87024	DRUGINFO	D07ZDG	EDN-OL1	Investigative
T87024	DRUGINFO	D08GHI	18F-AV-45 dimer	Investigative
T87024	DRUGINFO	D08GKL	6-iodo-4'-methylaminoflavone	Investigative
T87024	DRUGINFO	D08TME	2,5-bis(4-nitrophenyl)thiophene	Investigative
T87024	DRUGINFO	D09MQZ	4-(5-(4-methoxyphenyl)thiophen-2-yl)phenol	Investigative
T87024	DRUGINFO	D09MRY	ACU-0101979	Investigative
T87024	DRUGINFO	D09RAM	4-(5-(4-aminophenyl)thiophen-2-yl)phenol	Investigative
T87024	DRUGINFO	D09UWI	2,5-bis(4-Hydroxyphenyl)thiophene	Investigative
T87024	DRUGINFO	D0B1CL	5-methoxy-2-(4-aminophenyl)benzofuran	Investigative
T87024	DRUGINFO	D0B4AH	RECALL-VAX	Investigative
T87024	DRUGINFO	D0C1AU	1,6-bis(4'-nitrophenyl)-hexa-1,3,5-triene	Investigative
T87024	DRUGINFO	D0C4WY	SP-08	Investigative
T87024	DRUGINFO	D0C9QW	5-hydroxy-2-(4-dimethylaminophenyl)benzofuran	Investigative
T87024	DRUGINFO	D0E5CX	Abloid	Investigative
T87024	DRUGINFO	D0F5UO	KMS-88009	Investigative
T87024	DRUGINFO	D0G4AE	KNX-Monoclonal204	Investigative
T87024	DRUGINFO	D0H0AT	2-(4-nitrophenyl)-5-(4-methoxyphenyl)thiophene	Investigative
T87024	DRUGINFO	D0HK7G	DBT-1339	Investigative
T87024	DRUGINFO	D0I8XD	SB-13	Investigative
T87024	DRUGINFO	D0I9NH	5-hydroxy-2-(4-aminophenyl)benzofuran	Investigative
T87024	DRUGINFO	D0J5SD	Gamma-secretase modulators	Investigative
T87024	DRUGINFO	D0K4WW	11A1	Investigative
T87024	DRUGINFO	D0K9ZU	CD45RB	Investigative
T87024	DRUGINFO	D0L7MD	6-iodo-4'-methoxyflavone	Investigative
T87024	DRUGINFO	D0O5FK	2-(4-(methylamino)phenyl)benzo[d]thiazol-6-ol	Investigative
T87024	DRUGINFO	D0O7XG	SEM-606	Investigative
T87024	DRUGINFO	D0P0CB	6-iodo-4'-dimethyaminoflavone	Investigative
T87024	DRUGINFO	D0Q2XN	Turmeric extracts	Investigative
T87024	DRUGINFO	D0Q5VC	BAN-2203	Investigative
T87024	DRUGINFO	D0Q6ZQ	ELND-007	Investigative
T87024	DRUGINFO	D0R0LQ	5-methoxy-2-(4-dimethylaminophenyl)benzofuran	Investigative
T87024	DRUGINFO	D0S7CP	VK-12	Investigative
T87024	DRUGINFO	D0U6KE	1,6-bis(4'-aminophenyl)-hexa-1,3,5-triene	Investigative
T87024	DRUGINFO	D0V5PR	AS-602704	Investigative
T87024	DRUGINFO	D0W0WL	1,6-bis(4'-methylaminophenyl)-hexa-1,3,5-triene	Investigative
T87024	DRUGINFO	D0W8VC	PA-1637	Investigative
T87024	DRUGINFO	D0X1EY	6-iodo-4'-hydroxyflavone	Investigative
T87024	DRUGINFO	D0Y4TQ	VK-11	Investigative
T87024	DRUGINFO	D0Y9ES	AD-0802	Investigative
T87024	DRUGINFO	D0XV3B	Methionine Sulfoxide	Investigative
T87024	DRUGINFO	D03AMR	SR-973	Investigative

T23145	TARGETID	T23145
T23145	FORMERID	TTDS00419
T23145	UNIPROID	CP11A_HUMAN
T23145	TARGNAME	Cholesterol desmolase (CYP11A1)
T23145	GENENAME	CYP11A1
T23145	TARGTYPE	Successful
T23145	SYNONYMS	P450(scc); Cytochrome P450(scc); Cytochrome P450 11A1; Cholesterol side-chain cleavage enzyme, mitochondrial; CYPXIA1; CYP11A
T23145	FUNCTION	Catalyzes the side-chain cleavage reaction of cholesterol to pregnenolone, the precursor of most steroid hormones.
T23145	PDBSTRUC	3NA1; 3NA0; 3N9Z; 3N9Y
T23145	BIOCLASS	Paired donor oxygen oxidoreductase
T23145	ECNUMBER	EC 1.14.15.6
T23145	SEQUENCE	MLAKGLPPRSVLVKGCQTFLSAPREGLGRLRVPTGEGAGISTRSPRPFNEIPSPGDNGWLNLYHFWRETGTHKVHLHHVQNFQKYGPIYREKLGNVESVYVIDPEDVALLFKSEGPNPERFLIPPWVAYHQYYQRPIGVLLKKSAAWKKDRVALNQEVMAPEATKNFLPLLDAVSRDFVSVLHRRIKKAGSGNYSGDISDDLFRFAFESITNVIFGERQGMLEEVVNPEAQRFIDAIYQMFHTSVPMLNLPPDLFRLFRTKTWKDHVAAWDVIFSKADIYTQNFYWELRQKGSVHHDYRGILYRLLGDSKMSFEDIKANVTEMLAGGVDTTSMTLQWHLYEMARNLKVQDMLRAEVLAARHQAQGDMATMLQLVPLLKASIKETLRLHPISVTLQRYLVNDLVLRDYMIPAKTLVQVAIYALGREPTFFFDPENFDPTRWLSKDKNITYFRNLGFGWGVRQCLGRRIAELEMTIFLINMLENFRVEIQHLSDVGTTFNLILMPEKPISFTFWPFNQEATQQ
T23145	DRUGINFO	D0M6DO	Aminoglutethimide	Approved
T23145	DRUGINFO	DL73JW	MK-5684	Phase 1/2
T23145	DRUGINFO	D0A2GB	3-(4-Amino-phenyl)-3-pentyl-piperidine-2,6-dione	Investigative
T23145	DRUGINFO	D0B5MZ	3-(4-Amino-phenyl)-3-butyl-piperidine-2,6-dione	Investigative

T78585	TARGETID	T78585
T78585	FORMERID	TTDR00088
T78585	UNIPROID	IL5_HUMAN
T78585	TARGNAME	Interleukin-5 (IL5)
T78585	GENENAME	IL5
T78585	TARGTYPE	Successful
T78585	SYNONYMS	TRF protein; T-cell replacing factor; IL-5; Eosinophil differentiation factor; B-cell differentiation factor I; B cell differentiation factor I
T78585	FUNCTION	Factor that induces terminal differentiation of late-developing B-cells to immunoglobulin secreting cells.
T78585	PDBSTRUC	3VA2; 3QT2; 1HUL
T78585	BIOCLASS	Cytokine: interleukin
T78585	SEQUENCE	MRMLLHLSLLALGAAYVYAIPTEIPTSALVKETLALLSTHRTLLIANETLRIPVPVHKNHQLCTEEIFQGIGTLESQTVQGGTVERLFKNLSLIKKYIDGQKKKCGEERRRVNQFLDYLQEFLGVMNTEWIIES
T78585	DRUGINFO	D03MTN	Mepolizumab	Approved
T78585	DRUGINFO	D0O8KX	Reslizumab	Approved
T78585	DRUGINFO	D02PIO	Benralizumab	Approved
T78585	DRUGINFO	DP8AS7	GSK3511294	Phase 3
T78585	DRUGINFO	DS9J7L	Depemokimab	Phase 3
T78585	DRUGINFO	D07CEU	SOPHORICOSIDE	Investigative

T09538	TARGETID	T09538
T09538	FORMERID	TTDS00256
T09538	UNIPROID	PPBT_HUMAN
T09538	TARGNAME	Alkaline phosphatase tissue-nonspecific (ALPL)
T09538	GENENAME	ALPL
T09538	TARGTYPE	Successful
T09538	SYNONYMS	TNSALP; Liver/bone/kidney isozyme; Alkaline phosphatase, tissue-nonspecific isozyme; Alkaline phosphatase liver/bone/kidney isozyme; AP-TNAP
T09538	FUNCTION	This isozyme plays a key role in skeletal mineralization by regulating levels of diphosphate (PPi).
T09538	BIOCLASS	Phosphoric monoester hydrolase
T09538	ECNUMBER	EC 3.1.3.1
T09538	SEQUENCE	MISPFLVLAIGTCLTNSLVPEKEKDPKYWRDQAQETLKYALELQKLNTNVAKNVIMFLGDGMGVSTVTAARILKGQLHHNPGEETRLEMDKFPFVALSKTYNTNAQVPDSAGTATAYLCGVKANEGTVGVSAATERSRCNTTQGNEVTSILRWAKDAGKSVGIVTTTRVNHATPSAAYAHSADRDWYSDNEMPPEALSQGCKDIAYQLMHNIRDIDVIMGGGRKYMYPKNKTDVEYESDEKARGTRLDGLDLVDTWKSFKPRYKHSHFIWNRTELLTLDPHNVDYLLGLFEPGDMQYELNRNNVTDPSLSEMVVVAIQILRKNPKGFFLLVEGGRIDHGHHEGKAKQALHEAVEMDRAIGQAGSLTSSEDTLTVVTADHSHVFTFGGYTPRGNSIFGLAPMLSDTDKKPFTAILYGNGPGYKVVGGERENVSMVDYAHNNYQAQSAVPLRHETHGGEDVAVFSKGPMAHLLHGVHEQNYVPHVMAYAACIGANLGHCAPASSAGSLAAGPLLLALALYPLSVLF
T09538	DRUGINFO	D05XSJ	Asfotase alfa	Approved
T09538	DRUGINFO	D0CF2Q	Levamisole	Approved
T09538	DRUGINFO	D29GPF	DS-1211	Phase 2
T09538	DRUGINFO	D2DX6Z	ALXN1910	Phase 1
T09538	DRUGINFO	DNW79M	ALXN1850	Phase 1

T32578	TARGETID	T32578
T32578	FORMERID	TTDC00080
T32578	UNIPROID	IL6_HUMAN
T32578	TARGNAME	Interleukin-6 (IL6)
T32578	GENENAME	IL6
T32578	TARGTYPE	Successful
T32578	SYNONYMS	Interferon beta-2; IL-6; IFNB2; IFN-beta-2; Hybridoma growth factor; CTL differentiation factor; CDF; BSF-2; B-cell stimulatory factor 2
T32578	FUNCTION	It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. Acts on B-cells, T-cells, hepatocytes, hematopoietic progenitor cells and cells of the CNS. Required for the generation of T(H)17 cells. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation. Cytokine with a wide variety of biological functions.
T32578	PDBSTRUC	5FUC; 4ZS7; 4O9H; 4NI9; 4NI7
T32578	BIOCLASS	Cytokine: interleukin
T32578	SEQUENCE	MNSFSTSAFGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSSERIDKQIRYILDGISALRKETCNKSNMCESSKEALAENNLNLPKMAEKDGCFQSGFNEETCLVKIITGLLEFEVYLEYLQNRFESSEEQARAVQMSTKVLIQFLQKKAKNLDAITTPDPTTNASLLTKLQAQNQWLQDMTTHLILRSFKEFLQSSLRALRQM
T32578	DRUGINFO	D07NJN	Siltuximab	Approved
T32578	DRUGINFO	D00NUG	Olokizumab	Phase 3
T32578	DRUGINFO	DF86OC	Ziltivekimab	Phase 3
T32578	DRUGINFO	DWJM12	RG6179	Phase 3
T32578	DRUGINFO	D01XVF	Sirukumab	Phase 3
T32578	DRUGINFO	D04RMM	Clazakizumab	Phase 2
T32578	DRUGINFO	D07TCS	CDP-6038	Phase 2
T32578	DRUGINFO	D0N0BW	ALD-518	Phase 2
T32578	DRUGINFO	D0VS2W	YSIL6	Phase 2
T32578	DRUGINFO	D06NXG	PF-04236921	Phase 2
T32578	DRUGINFO	D07IVS	Gerilimzumab	Phase 1
T32578	DRUGINFO	D0DT8Y	MEDI5117	Phase 1
T32578	DRUGINFO	D0GJ1U	C326	Phase 1
T32578	DRUGINFO	D0OK5R	OP-R003	Phase 1
T32578	DRUGINFO	DKX8W5	SAR444419	Phase 1

T99799	TARGETID	T99799
T99799	FORMERID	TTDS00143
T99799	UNIPROID	CHLE_HUMAN
T99799	TARGNAME	Cholinesterase (BCHE)
T99799	GENENAME	BCHE
T99799	TARGTYPE	Successful
T99799	SYNONYMS	Pseudocholinesterase; Choline esterase II; CHE1; Butyrylcholine esterase; Acylcholine acylhydrolase
T99799	FUNCTION	Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
T99799	PDBSTRUC	6QAE; 6QAD; 6QAC; 6QAB; 6QAA
T99799	BIOCLASS	Type-B carboxylesterase/lipase
T99799	ECNUMBER	EC 3.1.1.8
T99799	SEQUENCE	MHSKVTIICIRFLFWFLLLCMLIGKSHTEDDIIIATKNGKVRGMNLTVFGGTVTAFLGIPYAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDCLYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALGFLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPGSHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEILLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVYGAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDVVGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLERRDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMTKLRAQQCRFWTSFFPKVLEMTGNIDEAEWEWKAGFHRWNNYMMDWKNQFNDYTSKKESCVGL
T99799	DRUGINFO	D0Q2MH	Hexafluronium bromide	Approved
T99799	DRUGINFO	D0S5YC	MEPTAZINOL	Approved
T99799	DRUGINFO	D01LYX	Eptastigmine	Phase 3
T99799	DRUGINFO	D07CIN	(-)-Phenserine	Phase 3
T99799	DRUGINFO	D04JMI	Plasma derived human butyrylcholinesterase	Phase 1
T99799	DRUGINFO	D06FGJ	Protexia	Phase 1
T99799	DRUGINFO	D09MEV	JES-9501	Phase 1
T99799	DRUGINFO	D0S1KR	RVT-103+RVT-104	Phase 1
T99799	DRUGINFO	D00GSF	Di-substituted piperidine derivative 3	Patented
T99799	DRUGINFO	D0BS8I	Di-substituted piperidine derivative 1	Patented
T99799	DRUGINFO	D0WR9T	Oxime derivative 1	Patented
T99799	DRUGINFO	D01SQO	Quinazoline alkaloid derivative 1	Patented
T99799	DRUGINFO	D03DIQ	Egonol compound 1	Patented
T99799	DRUGINFO	D04FAS	PMID29757691-Compound-8b	Patented
T99799	DRUGINFO	D0B9TI	PMID29757691-Compound-8d	Patented
T99799	DRUGINFO	D0CB1C	Tacrine heterodimer derivative 1	Patented
T99799	DRUGINFO	D0H3YG	PMID29757691-Compound-2a	Patented
T99799	DRUGINFO	D0J3OD	Indoline derivative 1	Patented
T99799	DRUGINFO	D0K3EB	Di-substituted piperidine derivative 2	Patented
T99799	DRUGINFO	D0OE6G	Isochroman-4-ketone derivative 1	Patented
T99799	DRUGINFO	D0RS6O	PMID29757691-Compound-8a	Patented
T99799	DRUGINFO	D0VQ2N	PMID29757691-Compound-8c	Patented
T99799	DRUGINFO	D0W9OC	PMID29757691-Compound-7	Patented
T99799	DRUGINFO	D0WD0M	PMID29757691-Compound-2a-i	Patented
T99799	DRUGINFO	D0X9CR	PMID29757691-Compound-10	Patented
T99799	DRUGINFO	D0Y4CG	Decyle nelycorine dibromo salt derivative 1	Patented
T99799	DRUGINFO	D02EME	Tetra-hydro-isoquinoline derivative 3	Patented
T99799	DRUGINFO	D04AXC	Tetra-hydro-isoquinoline derivative 1	Patented
T99799	DRUGINFO	D0NB7Z	Tetra-hydro-isoquinoline derivative 2	Patented
T99799	DRUGINFO	D0R6RT	Tetra-hydro-isoquinoline derivative 4	Patented
T99799	DRUGINFO	D00AHD	Anthracen-10-yl(10H-phenothiazin-10-yl)methanone	Investigative
T99799	DRUGINFO	D00KTT	Isopropyl 10H-phenothiazine-10-carboxylate	Investigative
T99799	DRUGINFO	D00QLR	(-)-DEBROMOFLUSTRAMINE B	Investigative
T99799	DRUGINFO	D00VXE	N-(Adamant-1-yl)-1'H-phenothiazine-1'-carboxamide	Investigative
T99799	DRUGINFO	D00XHC	N,N-Diisopropyl-1'H-phenothiazine-1'-carboxamide	Investigative
T99799	DRUGINFO	D01FNH	4-methoxyphenyl 10H-phenothiazine-10-carboxylate	Investigative
T99799	DRUGINFO	D01LVY	(10H-phenothiazin-10-yl)(p-tolyl)methanone	Investigative
T99799	DRUGINFO	D01MAC	Isosorbide-2-(butylcarbamate)-5-mononitrate	Investigative
T99799	DRUGINFO	D01XKY	(4-bromophenyl)(10H-phenothiazin-10-yl)methanone	Investigative
T99799	DRUGINFO	D02XHM	3-[10-(benzylmethylamino)decyloxy]xanthen-9-one	Investigative
T99799	DRUGINFO	D03NTO	Isosorbide-2-benzylcarbamate-5-nicotinate	Investigative
T99799	DRUGINFO	D03OGO	Cyclosal-d4TMP	Investigative
T99799	DRUGINFO	D03UCC	ETHYL HYDROGEN DIETHYLAMIDOPHOSPHATE	Investigative
T99799	DRUGINFO	D04AWS	N-Cyclopentyl-1'H-phenothiazine-1'-carboxamide	Investigative
T99799	DRUGINFO	D04CTO	2-biphenyl-4-yl-1-phenothiazin-10-yl-ethanone	Investigative
T99799	DRUGINFO	D04IXN	4-chlorophenyl 10H-phenothiazine-10-carboxylate	Investigative
T99799	DRUGINFO	D04JCW	Isosorbide-2-benzylcarbamate-5-pentanoate	Investigative
T99799	DRUGINFO	D04PKD	Isosorbide-2-benzylcarbamate-5-propionate	Investigative
T99799	DRUGINFO	D04ZWS	DEMETHYLDEBROMOFLUSTRAMINE B	Investigative
T99799	DRUGINFO	D04ZZU	3-chlorophenyl 10H-phenothiazine-10-carboxylate	Investigative
T99799	DRUGINFO	D05DIN	2-methoxyphenyl 10H-phenothiazine-10-carboxylate	Investigative
T99799	DRUGINFO	D05GPI	3-[11-(benzylmethylamino)undecyloxy]xanthen-9-one	Investigative
T99799	DRUGINFO	D05QFR	Isosorbide-2-(cyclohexylcarbamate)-5-mononitrate	Investigative
T99799	DRUGINFO	D05VLV	(10H-phenothiazin-10-yl)(m-tolyl)methanone	Investigative
T99799	DRUGINFO	D05XPL	2-Methyl-beta-carboline-2-ium iodide	Investigative
T99799	DRUGINFO	D05XPW	Isosorbide-di-(butylcarbamate)	Investigative
T99799	DRUGINFO	D06BDB	Isosorbide-2-benzylcarbamate-5-acetate	Investigative
T99799	DRUGINFO	D06HUH	Recombinant human butyrylcholinesterase	Investigative
T99799	DRUGINFO	D06KQH	4-[4-(benzyloxy)piperidino]butyl-3-fluorobenzoate	Investigative
T99799	DRUGINFO	D06RTA	N,N'-(1',4'-butylene)-bis-(-)-nor-MEP	Investigative
T99799	DRUGINFO	D06SWV	Diethylphosphono Group	Investigative
T99799	DRUGINFO	D06YEB	1-(10H-phenothiazin-10-yl)-3-phenylbutan-1-one	Investigative
T99799	DRUGINFO	D07AYF	Methyl 10H-phenothiazine-10-carboxylate	Investigative
T99799	DRUGINFO	D07MNG	Ethyl Dihydrogen Phosphate	Investigative
T99799	DRUGINFO	D07YXP	9-[5-(beta-Carboline-9-yl)pentyl]-beta-carboline	Investigative
T99799	DRUGINFO	D08BKE	Isosorbide-2-benzylcarbamate-5-triflate	Investigative
T99799	DRUGINFO	D08FQW	M-tolyl 10H-phenothiazine-10-carboxylate	Investigative
T99799	DRUGINFO	D08LNT	Butyrylthiocholine	Investigative
T99799	DRUGINFO	D08NNF	N-Cyclobutyl-1'H-phenothiazine-1'-carboxamide	Investigative
T99799	DRUGINFO	D08TBI	Cyclopentyl 10H-phenothiazine-10-carboxylate	Investigative
T99799	DRUGINFO	D08ZLS	N-Benzyl-1'H-phenothiazine-1'-carboxamide	Investigative
T99799	DRUGINFO	D09DQV	(1S)-MENTHYL HEXYL PHOSPHONATE GROUP	Investigative
T99799	DRUGINFO	D09DWA	(10H-phenothiazin-10-yl)(o-tolyl)methanone	Investigative
T99799	DRUGINFO	D09GKY	N-Cyclohexyl-1'H-phenothiazine-1'-carboxamide	Investigative
T99799	DRUGINFO	D09HZE	Morpholino(1'H-phenothiazin-1'-yl)methanone	Investigative
T99799	DRUGINFO	D09OPL	(1'H-Phenothiazin-1'-yl)(piperidin-1-yl)methanone	Investigative
T99799	DRUGINFO	D09YLY	Isosorbide-2-benzylcarbamate-5-isonicotinate	Investigative
T99799	DRUGINFO	D0A5FO	1,2-di(10H-phenothiazin-10-yl)ethane-1,2-dione	Investigative
T99799	DRUGINFO	D0AQ3K	3-[9-(benzylmethylamino)nonyloxy]xanthen-9-one	Investigative
T99799	DRUGINFO	D0B0ZM	N,N-Dipropyl-1'H-phenothiazine-1'-carboxamide	Investigative
T99799	DRUGINFO	D0B6IQ	N,N-Dimethyl-1'H-phenothiazine-1'-carboxamide	Investigative
T99799	DRUGINFO	D0D7MN	Naphthalen-1-yl(10H-phenothiazin-10-yl)methanone	Investigative
T99799	DRUGINFO	D0D8IH	N-Phenyl-1'H-phenothiazine-1'-carboxamide	Investigative
T99799	DRUGINFO	D0DB9T	N-tert-Butyl-1'H-phenothiazine-1'-carboxamide	Investigative
T99799	DRUGINFO	D0DR7A	N-p-Tolyl-1'H-phenothiazine-1'-carboxamide	Investigative
T99799	DRUGINFO	D0E4GM	3-isopr-sal-cyclosal-d4TMP	Investigative
T99799	DRUGINFO	D0EI5V	Bis-cyclosal-d4TMP	Investigative
T99799	DRUGINFO	D0EQ1Z	Isosorbide-2-benzylcarbamate-5-(o-toluate)	Investigative
T99799	DRUGINFO	D0FP5F	Isosorbide-di-(propylcarbamate)	Investigative
T99799	DRUGINFO	D0G0ED	3-sal-cyclosal-d4TMP	Investigative
T99799	DRUGINFO	D0G6WQ	(1R)-MENTHYL HEXYL PHOSPHONATE GROUP	Investigative
T99799	DRUGINFO	D0H1NU	4-[4-(benzyloxy)piperidino]butyl-4-chlorobenzoate	Investigative
T99799	DRUGINFO	D0H3WJ	1-(10H-phenothiazin-10-yl)-2-phenylpropan-1-one	Investigative
T99799	DRUGINFO	D0I4LX	AS-1397	Investigative
T99799	DRUGINFO	D0I5LV	3-methoxyphenyl 10H-phenothiazine-10-carboxylate	Investigative
T99799	DRUGINFO	D0I7BX	Naphthalen-1-yl 10H-phenothiazine-10-carboxylate	Investigative
T99799	DRUGINFO	D0IC5U	Isosorbide-2-(benzylcarbamate)-5-mononitrate	Investigative
T99799	DRUGINFO	D0J1IX	1-(10H-phenothiazin-10-yl)-2-phenylethanone	Investigative
T99799	DRUGINFO	D0J5AU	Isosorbide-2-(ethylcarbamate)-5-mononitrate	Investigative
T99799	DRUGINFO	D0J8LQ	(3-bromophenyl)(10H-phenothiazin-10-yl)methanone	Investigative
T99799	DRUGINFO	D0K3YM	N-Isopropyl-1'H-phenothiazine-1'-carboxamide	Investigative
T99799	DRUGINFO	D0K7EC	N,N-Diethyl-1'H-phenothiazine-1'-carboxamide	Investigative
T99799	DRUGINFO	D0L0SD	N,N'-(1',3'-propylene)-bis-(-)-nor-MEP	Investigative
T99799	DRUGINFO	D0L1EI	4-[4-(benzyloxy)piperidino]butyl benzoate	Investigative
T99799	DRUGINFO	D0L3EE	(10H-phenothiazin-10-yl)(phenyl)methanone	Investigative
T99799	DRUGINFO	D0LL8H	Isosorbide-2-(benzylcarbamate)-5-benzoate	Investigative
T99799	DRUGINFO	D0M2EH	Non-PEGylated butyrylcholinesterase	Investigative
T99799	DRUGINFO	D0M6IJ	Naphthalen-2-yl(10H-phenothiazin-10-yl)methanone	Investigative
T99799	DRUGINFO	D0M7SD	MF-8623	Investigative
T99799	DRUGINFO	D0N4QQ	VAGANINE D	Investigative
T99799	DRUGINFO	D0N6XS	1-(10H-phenothiazin-10-yl)-2-phenylbutan-1-one	Investigative
T99799	DRUGINFO	D0NU3J	NOSTOCARBOLINE	Investigative
T99799	DRUGINFO	D0O8LK	3-[12-(benzylmethylamino)dodecyloxy]xanthen-9-one	Investigative
T99799	DRUGINFO	D0OJ9P	1-methyl-3-(phenylcarbamoyloxy)pyridinium bromide	Investigative
T99799	DRUGINFO	D0P3VH	1-(10H-phenothiazin-10-yl)-3-phenylpropan-1-one	Investigative
T99799	DRUGINFO	D0P7TN	5-methyl-cyclosal-d4TMP	Investigative
T99799	DRUGINFO	D0PQ5R	P-tolyl 10H-phenothiazine-10-carboxylate	Investigative
T99799	DRUGINFO	D0Q0BV	Naphthalen-2-yl 10H-phenothiazine-10-carboxylate	Investigative
T99799	DRUGINFO	D0R2GR	N-Neopentyl-1'H-phenothiazine-1'-carboxamide	Investigative
T99799	DRUGINFO	D0RO8V	9-(3-IODOBENZYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE	Investigative
T99799	DRUGINFO	D0RW1Y	9-N-Phenylmethylamino-Tacrine	Investigative
T99799	DRUGINFO	D0S3WF	4-[4-(benzyloxy)piperidino]butyl-3-chlorobenzoate	Investigative
T99799	DRUGINFO	D0S8AS	Tert-butyl 10H-phenothiazine-10-carboxylate	Investigative
T99799	DRUGINFO	D0T4JQ	Butanoic Acid	Investigative
T99799	DRUGINFO	D0U7BQ	O-tolyl 10H-phenothiazine-10-carboxylate	Investigative
T99799	DRUGINFO	D0U9AU	(-)-Phenethylcymserine	Investigative
T99799	DRUGINFO	D0V4RD	(4-nitrophenyl)(10H-phenothiazin-10-yl)methanone	Investigative
T99799	DRUGINFO	D0V7EK	Phenyl 10H-phenothiazine-10-carboxylate	Investigative
T99799	DRUGINFO	D0V8PE	Butyl 10H-phenothiazine-10-carboxylate	Investigative
T99799	DRUGINFO	D0W2SX	NP-0336	Investigative
T99799	DRUGINFO	D0W4WB	Isosorbide-2-benzyl carbamate	Investigative
T99799	DRUGINFO	D0WB1D	4-[4-(benzyloxy)piperidino]butyl-4-fluorobenzoate	Investigative
T99799	DRUGINFO	D0WH4J	Isosorbide-2-(propylcarbamate)-5-mononitrate	Investigative
T99799	DRUGINFO	D0X7CW	3-phenyl-cyclosal-d4TMP	Investigative
T99799	DRUGINFO	D0X9TF	N,N'-(1',2'-ethylene)-bis-(-)-nor-MEP	Investigative
T99799	DRUGINFO	D0Y0UV	N-o-Tolyl-1'H-phenothiazine-1'-carboxamide	Investigative
T99799	DRUGINFO	D0Y2TE	4-[4-(benzyloxy)piperidino]butyl-4-nitrobenzoate	Investigative
T99799	DRUGINFO	D0Y4SO	9-[9-(beta-Carboline-9-yl)nonyl]-beta-carboline	Investigative
T99799	DRUGINFO	D0Y5KN	Isosorbide-2-(butylcarbamate)-5-benzoate	Investigative
T99799	DRUGINFO	D0Y7WJ	Dodecanesulfonate ion	Investigative
T99799	DRUGINFO	D0YZ3E	1-(10H-phenothiazin-10-yl)-4-phenylbutan-1-one	Investigative
T99799	DRUGINFO	D00FPI	1,4-Di(berberine-9-O-yl)ethane dibromide	Investigative
T99799	DRUGINFO	D00MFR	6-methoxy-1,2-dimethyl-9H-beta-carbolin-2-ium	Investigative
T99799	DRUGINFO	D00NIX	9-O-[3-(Phenylamino)propyl]-berberine bromide	Investigative
T99799	DRUGINFO	D01AJQ	Isosorbide-di-(benzylcarbamate)	Investigative
T99799	DRUGINFO	D01DHW	9-O-[2-(Phenylol-1-yloxy)ethyl]berberine bromide	Investigative
T99799	DRUGINFO	D01EZC	3-[4-(benzylmethylamino)butoxy]xanthen-9-one	Investigative
T99799	DRUGINFO	D01GWN	(24S)-ethylcholesta-7,9(11),22(E)-triene-3b-ol	Investigative
T99799	DRUGINFO	D01KVT	MEMOQUIN	Investigative
T99799	DRUGINFO	D01OND	3-(dimethylamino)phenyl phenylcarbamate	Investigative
T99799	DRUGINFO	D01QRR	Isosorbide-2-benzylcarbamate-5-cyclopentanoate	Investigative
T99799	DRUGINFO	D01TLN	9-O-[4-(Phenylol-1-yloxy)butyl]berberine bromide	Investigative
T99799	DRUGINFO	D01XGP	1,2-indanedione	Investigative
T99799	DRUGINFO	D02AFZ	2-Propyl-beta-carboline-2-ium iodide	Investigative
T99799	DRUGINFO	D02JXK	N,N'-(1',11'-undecydene)-bis-(-)-nor-MEP	Investigative
T99799	DRUGINFO	D02LWX	6-hydroxy-2-methyl-9H-beta-carbolin-2-ium	Investigative
T99799	DRUGINFO	D02QMU	9-O-[3-(2-Pyridinoxyl)butyl]-berberine bromide	Investigative
T99799	DRUGINFO	D02WKB	9-O-[2-(Phenylol-1-yloxy)hexyl]berberine bromide	Investigative
T99799	DRUGINFO	D03DIP	3-(2-Diethylamino-propionamino)-rutaecarpine	Investigative
T99799	DRUGINFO	D04FHZ	(-)-Tolserine	Investigative
T99799	DRUGINFO	D04GTP	CHF-2819	Investigative
T99799	DRUGINFO	D04SYM	Isosorbide-2-(methylcarbamate)-5-mononitrate	Investigative
T99799	DRUGINFO	D05LTW	1,2-bis(2,3-fluorophenyl)ethane-1,2-dione	Investigative
T99799	DRUGINFO	D05QNR	N,N'-(1',9'-nonylene)-bis-(-)-nor-MEP	Investigative
T99799	DRUGINFO	D05UJV	N-n-pentyl-7-methoxytacrine hydrochloride	Investigative
T99799	DRUGINFO	D06VGD	ACENAPHTHOQUINONE	Investigative
T99799	DRUGINFO	D07EDG	1-(3,4-dichlorobenzyl)-1H-indole-2,3-dione	Investigative
T99799	DRUGINFO	D07VIO	3-(2-Diethylamino-acetamino)-rutaecarpine	Investigative
T99799	DRUGINFO	D07YJG	1,11-bis(pyridinium)-undecane dibromide	Investigative
T99799	DRUGINFO	D09CGV	6-hydroxy-1,2-dimethyl-9H-beta-carbolin-2-ium	Investigative
T99799	DRUGINFO	D09FAU	(RS)-tacrine(10)-hupyridone	Investigative
T99799	DRUGINFO	D09GXM	3-[7-(benzylmethylamino)-heptyloxy]xanthen-9-one	Investigative
T99799	DRUGINFO	D09JCF	Huprine-Tacrine Heterodimer	Investigative
T99799	DRUGINFO	D09MCN	Haloxysterol D	Investigative
T99799	DRUGINFO	D09QDC	Iso-OMPA	Investigative
T99799	DRUGINFO	D09RJH	Huprine X	Investigative
T99799	DRUGINFO	D09XSI	9-O-[5-(Phenylol-1-yloxy)pentyl]berberine bromide	Investigative
T99799	DRUGINFO	D0A8OX	N,N'-(1',5'-pentylene)-bis-(-)-nor-MEP	Investigative
T99799	DRUGINFO	D0B4DT	3-[8-(benzylmethylamino)octyloxy]xanthen-9-one	Investigative
T99799	DRUGINFO	D0C0XU	N-n-heptyl-7-methoxytacrine hydrochloride	Investigative
T99799	DRUGINFO	D0C3IS	3-(2-N-Piperidyl-propionamino)-rutaecarpine	Investigative
T99799	DRUGINFO	D0E0LL	Haloxysterol C	Investigative
T99799	DRUGINFO	D0E4BT	N-benzyl-2-thiomorpholinopyrimidin-4-amine	Investigative
T99799	DRUGINFO	D0EX1R	N,N'-(1',7'-heptylene)-bis-(-)-nor-MEP	Investigative
T99799	DRUGINFO	D0F0PY	N,N'-(1',12'-dodecydene)-bis-(-)-nor-MEP	Investigative
T99799	DRUGINFO	D0F5EJ	LIPOCRINE	Investigative
T99799	DRUGINFO	D0F6VM	3-(2-N-Pyrrolyl-propionamino)-rutaecarpine	Investigative
T99799	DRUGINFO	D0G0GZ	N-Methyl-1'H-phenothiazine-1'-carboxamide	Investigative
T99799	DRUGINFO	D0G5SM	HALOXYSTEROL A	Investigative
T99799	DRUGINFO	D0G5TL	6-hydroxy-1,2,9-trimethyl-9H-beta-carbolin-2-ium	Investigative
T99799	DRUGINFO	D0H2UG	N-n-nonyl-7-methoxytacrine hydrochloride	Investigative
T99799	DRUGINFO	D0H3BC	3-[5-(benzylmethylamino)pentyloxy]xanthen-9-one	Investigative
T99799	DRUGINFO	D0I3UA	7-Oxo-7H-dibenzo[de,g]quinoline	Investigative
T99799	DRUGINFO	D0J4LR	24-ethyl-cholest-7-ene-3,5,6-triol	Investigative
T99799	DRUGINFO	D0J4QH	Methyl Phosphinic Acid	Investigative
T99799	DRUGINFO	D0K2FQ	1,2-Di(berberine-9-O-yl)ethane dibromide	Investigative
T99799	DRUGINFO	D0K8BT	Isosorbide-2-(methylcarbamate)-5-benzoate	Investigative
T99799	DRUGINFO	D0L5QJ	1,9-bis(pyridinium)-nonane dibromide	Investigative
T99799	DRUGINFO	D0L9YJ	3-[3-(benzylmethylamino)propoxy]xanthen-9-one	Investigative
T99799	DRUGINFO	D0LT0T	3-(2-N-Pyrrolyl-acetamino)-rutaecarpine	Investigative
T99799	DRUGINFO	D0M0BM	6-chlorotacrine hydrochloride	Investigative
T99799	DRUGINFO	D0M2EM	BENZOQUINONE	Investigative
T99799	DRUGINFO	D0MC3U	N,N'-(1',10'-decylene)-bis-(-)-nor-MEP	Investigative
T99799	DRUGINFO	D0MV0T	2,3-dihydropyrrolo[2,1-b]quinazolin-9(1H)-imine	Investigative
T99799	DRUGINFO	D0NJ5W	CAPROCTAMINE	Investigative
T99799	DRUGINFO	D0NL4Z	Monoisopropyl Ester Phosphonic Acid Group	Investigative
T99799	DRUGINFO	D0O2OH	4-ISOPROPYLPHENSERINE	Investigative
T99799	DRUGINFO	D0O8AQ	Isosorbide-di-(ethylcarbamate)	Investigative
T99799	DRUGINFO	D0O8DZ	3-[6-(benzylmethylamino)hexyloxy]xanthen-9-one	Investigative
T99799	DRUGINFO	D0O9YQ	N-n-hexyl-7-methoxytacrine hydrochloride	Investigative
T99799	DRUGINFO	D0P2VL	9-O-[3-(4-Nitro-phenoxyl)butyl]-berberine bromide	Investigative
T99799	DRUGINFO	D0P5BT	1,3-Di(berberine-9-O-yl)ethane dibromide	Investigative
T99799	DRUGINFO	D0PF7F	TOLSERINE	Investigative
T99799	DRUGINFO	D0Q2YJ	Phenanthrene-9,10-dione	Investigative
T99799	DRUGINFO	D0Q3EV	N-n-octyl-7-methoxytacrine hydrochloride	Investigative
T99799	DRUGINFO	D0T5MD	Isosorbide-2-benzylcarbamate-5-cyclopropanoate	Investigative
T99799	DRUGINFO	D0V3LC	24-ethylcholest-6-ene-3,5-diol	Investigative
T99799	DRUGINFO	D0W7XL	9-O-[3-(Phenylol-1-yloxy)propyl]berberine bromide	Investigative
T99799	DRUGINFO	D0W8NK	9-Ethyl-2-methyl-beta-carboline-2-ium iodide	Investigative
T99799	DRUGINFO	D0X3FF	HALOXYSTEROL B	Investigative
T99799	DRUGINFO	D0X4HG	XANTHOSTIGMINE	Investigative
T99799	DRUGINFO	D0XI4U	6-methoxy-2-methyl-9H-beta-carbolin-2-ium	Investigative
T99799	DRUGINFO	D0Y0VQ	N,N'-(1',8'-octylene)-bis-(-)-nor-MEP	Investigative
T99799	DRUGINFO	D0Y7UG	N,N'-(1',6-hexylene)-bis-(-)-nor-MEP	Investigative
T99799	DRUGINFO	D0Z6RT	LAWSARITOL	Investigative
T99799	DRUGINFO	D0Z6WU	1,10-bis(pyridinium)-decane dibromide	Investigative
T99799	DRUGINFO	D0ZI7F	6-methoxy-1,9-dimethyl-9H-pyrido[3,4-b]indole	Investigative
T99799	DRUGINFO	D0ZL9I	9-O-[3-(4-Bromo-phenoxyl)butyl]-berberine bromide	Investigative
T99799	DRUGINFO	D0ZY4C	N-phenethyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine	Investigative
T99799	DRUGINFO	D0D0BI	CHLORANIL	Investigative
T99799	DRUGINFO	D0F5VY	NSC-23180	Investigative
T99799	DRUGINFO	D0M4IE	Bis-7-tacrine	Investigative
T99799	DRUGINFO	D0N0HK	3,4,5,6-Tetrachloro-[1,2]benzoquinone	Investigative
T99799	DRUGINFO	D0WX6R	5,6-dinitroacenaphthoquinone	Investigative
T99799	DRUGINFO	D0SD9H	Beta-D-Mannose	Investigative
T99799	DRUGINFO	D0W9VA	1,2-NAPHTHOQUINONE	Investigative
T99799	DRUGINFO	D07KZA	2-(N-Morpholino)-Ethanesulfonic Acid	Investigative
T99799	DRUGINFO	D0G6XS	Fucose	Investigative
T99799	DRUGINFO	D07LUR	Alpha-D-Mannose	Investigative

T21678	TARGETID	T21678
T21678	FORMERID	TTDC00016
T21678	UNIPROID	AGAL_HUMAN
T21678	TARGNAME	Alpha-galactosidase A (GLA)
T21678	GENENAME	GLA
T21678	TARGTYPE	Successful
T21678	SYNONYMS	Melibiase; INN=Agalsidase; Alpha-D-galactoside galactohydrolase; Alpha-D-galactosidase A
T21678	FUNCTION	A homodimeric glycoprotein that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins. Predominantly hydrolyzes ceramide trihexoside, and  can catalyze the hydrolysis of melibiose into galactose and glucose.
T21678	PDBSTRUC	4NXS; 3TV8; 3S5Z; 3S5Y; 3LXC
T21678	BIOCLASS	Glycosylase
T21678	ECNUMBER	EC 3.2.1.22
T21678	SEQUENCE	MQLRNPELHLGCALALRFLALVSWDIPGARALDNGLARTPTMGWLHWERFMCNLDCQEEPDSCISEKLFMEMAELMVSEGWKDAGYEYLCIDDCWMAPQRDSEGRLQADPQRFPHGIRQLANYVHSKGLKLGIYADVGNKTCAGFPGSFGYYDIDAQTFADWGVDLLKFDGCYCDSLENLADGYKHMSLALNRTGRSIVYSCEWPLYMWPFQKPNYTEIRQYCNHWRNFADIDDSWKSIKSILDWTSFNQERIVDVAGPGGWNDPDMLVIGNFGLSWNQQVTQMALWAIMAAPLFMSNDLRHISPQAKALLQDKDVIAINQDPLGKQGYQLRQGDNFEVWERPLSGLAWAVAMINRQEIGGPRSYTIAVASLGKGVACNPACFITQLLPVKRKLGFYEWTSRLRSHINPTGTVLLQLENTMQMSLKDLL
T21678	DRUGINFO	D07URD	Pegunigalsidase alfa	Approved
T21678	DRUGINFO	D0MU9L	Migalastat	Approved
T21678	DRUGINFO	DE3M8U	ST-920	Phase 1/2
T21678	DRUGINFO	DT28NV	AVR-RD-01	Phase 1/2
T21678	DRUGINFO	DX5HW2	isaralgagene civaparvovec	Phase 1/2
T21678	DRUGINFO	DZ97RW	4D-310	Phase 1/2
T21678	DRUGINFO	D07RRH	Beta-1-C-Butyl-1-deoxygalactonojirimycin	Investigative
T21678	DRUGINFO	D0RU5N	Beta-1-C-butenyl-1-deoxygalactonojirimycin	Investigative
T21678	DRUGINFO	D0S4DV	CALYSTEGINE B2	Investigative
T21678	DRUGINFO	D0V0WB	(+)-5-deoxyadeenophorine	Investigative
T21678	DRUGINFO	D0SQ1T	2,5-dideoxy-2,5-imino-D-altritol	Investigative
T21678	DRUGINFO	D0G6XS	Fucose	Investigative
T21678	DRUGINFO	D07LUR	Alpha-D-Mannose	Investigative

T22939	TARGETID	T22939
T22939	FORMERID	TTDS00245
T22939	UNIPROID	PRGR_HUMAN
T22939	TARGNAME	Progesterone receptor (PGR)
T22939	GENENAME	PGR
T22939	TARGTYPE	Successful
T22939	SYNONYMS	PR; Nuclear receptor subfamily 3 group C member 3; NR3C3
T22939	FUNCTION	Depending on the isoform, progesterone receptor functions as transcriptional activator or repressor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues.
T22939	PDBSTRUC	5CC0; 4OAR; 4APU; 4A2J; 3ZRB
T22939	BIOCLASS	Nuclear hormone receptor
T22939	SEQUENCE	MTELKAKGPRAPHVAGGPPSPEVGSPLLCRPAAGPFPGSQTSDTLPEVSAIPISLDGLLFPRPCQGQDPSDEKTQDQQSLSDVEGAYSRAEATRGAGGSSSSPPEKDSGLLDSVLDTLLAPSGPGQSQPSPPACEVTSSWCLFGPELPEDPPAAPATQRVLSPLMSRSGCKVGDSSGTAAAHKVLPRGLSPARQLLLPASESPHWSGAPVKPSPQAAAVEVEEEDGSESEESAGPLLKGKPRALGGAAAGGGAAAVPPGAAAGGVALVPKEDSRFSAPRVALVEQDAPMAPGRSPLATTVMDFIHVPILPLNHALLAARTRQLLEDESYDGGAGAASAFAPPRSSPCASSTPVAVGDFPDCAYPPDAEPKDDAYPLYSDFQPPALKIKEEEEGAEASARSPRSYLVAGANPAAFPDFPLGPPPPLPPRATPSRPGEAAVTAAPASASVSSASSSGSTLECILYKAEGAPPQQGPFAPPPCKAPGASGCLLPRDGLPSTSASAAAAGAAPALYPALGLNGLPQLGYQAAVLKEGLPQVYPPYLNYLRPDSEASQSPQYSFESLPQKICLICGDEASGCHYGVLTCGSCKVFFKRAMEGQHNYLCAGRNDCIVDKIRRKNCPACRLRKCCQAGMVLGGRKFKKFNKVRVVRALDAVALPQPVGVPNESQALSQRFTFSPGQDIQLIPPLINLLMSIEPDVIYAGHDNTKPDTSSSLLTSLNQLGERQLLSVVKWSKSLPGFRNLHIDDQITLIQYSWMSLMVFGLGWRSYKHVSGQMLYFAPDLILNEQRMKESSFYSLCLTMWQIPQEFVKLQVSQEEFLCMKVLLLLNTIPLEGLRSQTQFEEMRSSYIRELIKAIGLRQKGVVSSSQRFYQLTKLLDNLHDLVKQLHLYCLNTFIQSRALSVEFPEMMSEVIAAQLPKILAGMVKPLLFHKK
T22939	DRUGINFO	D02KIU	Etonogestrel	Approved
T22939	DRUGINFO	D04GJN	Megestrol	Approved
T22939	DRUGINFO	D06CGB	Desogestrel	Approved
T22939	DRUGINFO	D06RFG	Estradiol valerate/dienogest	Approved
T22939	DRUGINFO	D07BSQ	Progesterone	Approved
T22939	DRUGINFO	D09QZI	Norgestimate	Approved
T22939	DRUGINFO	D0BA9U	Levonorgestrel	Approved
T22939	DRUGINFO	D0F1UL	Dydrogesterone	Approved
T22939	DRUGINFO	D0GL7U	Norethindrone	Approved
T22939	DRUGINFO	D0I2SD	Medroxyprogesterone	Approved
T22939	DRUGINFO	D0R2KY	Ethynodiol Diacetate	Approved
T22939	DRUGINFO	D0V4WD	Ulipristal	Approved
T22939	DRUGINFO	D06LDT	Segesterone acetate; ethinyl estradiol	Approved
T22939	DRUGINFO	D02HUB	Nestorone	Phase 3
T22939	DRUGINFO	D0VF3C	NPC-01	Phase 3
T22939	DRUGINFO	D01KMY	MK-8342	Phase 2
T22939	DRUGINFO	D07MON	ONAPRISTONE	Phase 2
T22939	DRUGINFO	D07YGK	Vilaprisan	Phase 2
T22939	DRUGINFO	D0H5BC	Tosagestin	Phase 2
T22939	DRUGINFO	D0J0EM	Virexxa	Phase 2
T22939	DRUGINFO	D0S1YX	S-PRAnt	Phase 2
T22939	DRUGINFO	D0U8AS	Telapristone	Phase 2
T22939	DRUGINFO	D0L3HU	BAY 86-5044	Phase 2
T22939	DRUGINFO	D0K2HA	PF-2413873	Phase 1
T22939	DRUGINFO	D0W5RL	Asoprisnil	Discontinued in Phase 3
T22939	DRUGINFO	D03AZU	Org-31710	Discontinued in Phase 1
T22939	DRUGINFO	D0N4PC	RU-46556	Terminated
T22939	DRUGINFO	D0O1PU	BAY-39-9624	Terminated
T22939	DRUGINFO	D00ZGW	GSK-325971A	Investigative
T22939	DRUGINFO	D01NVD	GSK-1564023A	Investigative
T22939	DRUGINFO	D01OYG	ZK-136798	Investigative
T22939	DRUGINFO	D01UFF	ORG2058	Investigative
T22939	DRUGINFO	D02WQR	GSK-008A	Investigative
T22939	DRUGINFO	D05CND	6-(3-Nitro-phenyl)-3H-benzothiazol-2-one	Investigative
T22939	DRUGINFO	D06DSF	5-(2-oxoindolin-5-yl)-1H-pyrrole-2-carbonitrile	Investigative
T22939	DRUGINFO	D07XCB	1-Benzyl-3-phenylquinazoline-2,4(1H,3H)-dione	Investigative
T22939	DRUGINFO	D09GQF	5,N-Dihydroxythalidomide	Investigative
T22939	DRUGINFO	D09VWK	3,3-dimethyl-5-m-tolyl-2,3-dihydro-1H-inden-1-one	Investigative
T22939	DRUGINFO	D09XAM	GTPL8662	Investigative
T22939	DRUGINFO	D0D6HI	4-(2,4-diethyl-1H-pyrrol-3-yloxy)benzonitrile	Investigative
T22939	DRUGINFO	D0E9CG	3-Phenyl-1-propylquinazoline-2,4(1H,3H)-dione	Investigative
T22939	DRUGINFO	D0F1SS	Lecanindole D	Investigative
T22939	DRUGINFO	D0H2MF	PF-02367982	Investigative
T22939	DRUGINFO	D0KX6D	ZK-112993	Investigative
T22939	DRUGINFO	D0N1RQ	2-(4-Amino-3'-chloro-biphenyl-3-yl)-propan-2-ol	Investigative
T22939	DRUGINFO	D0V4PL	3-(3,3-dimethyl-2-oxoindolin-5-yl)benzonitrile	Investigative
T22939	DRUGINFO	D0V9NE	Tanaproget	Investigative
T22939	DRUGINFO	D0VJ7A	ZK-114043	Investigative
T22939	DRUGINFO	D0ZM6R	2,2,4-Trimethyl-6-phenyl-1,2-dihydro-quinoline	Investigative
T22939	DRUGINFO	D01ETZ	[3H]methyltrienolone	Investigative
T22939	DRUGINFO	D0G5OV	WAY-255348	Investigative
T22939	DRUGINFO	D08KQM	LGD-5552	Investigative
T22939	DRUGINFO	D0GR5L	AL-43	Investigative

T95678	TARGETID	T95678
T95678	FORMERID	TTDS00175
T95678	UNIPROID	M2_I34A1
T95678	TARGNAME	Influenza M2 protein (Influ M)
T95678	GENENAME	Influ M
T95678	TARGTYPE	Successful
T95678	SYNONYMS	Matrix protein M2; M2 proton channel; M
T95678	FUNCTION	Forms a proton-selective ion channel that is necessary for the efficient release of the viral genome during virus entry. After attaching to the cell surface, the virion enters the cell by endocytosis. Acidification of the endosome triggers M2 ion channel activity. The influx of protons into virion interior is believed to disrupt interactions between the viral ribonucleoprotein (RNP), matrix protein 1 (M1), and lipid bilayers, thereby freeing the viral genome from interaction with viral proteins and enabling RNA segments to migrate to the host cell nucleus, where influenza virus RNA transcription and replication occur. Also plays a role in viral proteins secretory pathway. Elevates the intravesicular pH of normally acidic compartments, such as trans-Golgi network, preventing newly formed hemagglutinin from premature switching to the fusion-active conformation.
T95678	PDBSTRUC	5DLM
T95678	BIOCLASS	Influenza viruses matrix protein
T95678	SEQUENCE	MSLLTEVETPIRNEWGCRCNGSSDPLAIAANIIGILHLILWILDRLFFKCIYRRFKYGLKGGPSTEGVPKSMREEYRKEQQSAVDADDGHFVSIELE
T95678	DRUGINFO	D02KRS	Amantadine	Approved
T95678	DRUGINFO	D0TQ1G	Rimantadine	Approved
T95678	DRUGINFO	D0L1HK	TCN-032	Phase 2
T95678	DRUGINFO	D00SOM	Spiro[piperidine-2,2-adamantane]	Investigative
T95678	DRUGINFO	D03FAX	2-(1-adamantyl) piperidine	Investigative
T95678	DRUGINFO	D04LRA	Rimantadine isomer 2	Investigative
T95678	DRUGINFO	D04WWM	2-(1-adamantyl) pyrrolidine	Investigative
T95678	DRUGINFO	D06IGJ	3-(2-adamantyl) pyrrolidine	Investigative
T95678	DRUGINFO	D07FOH	Spiro[pyrrolidine-2,2-adamantane]	Investigative
T95678	DRUGINFO	D07IGD	2-(1-adamantyl)-2-methyl-pyrrolidine	Investigative
T95678	DRUGINFO	D0B0PI	2-(2-adamantyl) piperidine	Investigative
T95678	DRUGINFO	D0O6GL	Spiro[cyclopropane-1,2-adamantan]-2-amine	Investigative
T95678	DRUGINFO	D0P2NN	Rimantadine isomer 1	Investigative
T95678	DRUGINFO	D02UVH	B-Octylglucoside	Investigative

T28692	TARGETID	T28692
T28692	FORMERID	TTDS00066
T28692	UNIPROID	LIPL_HUMAN
T28692	TARGNAME	Lipoprotein lipase (LPL)
T28692	GENENAME	LPL
T28692	TARGTYPE	Successful
T28692	SYNONYMS	LIPD
T28692	FUNCTION	Catalyzes the hydrolysis of triglycerides from circulating chylomicrons and very low density lipoproteins (VLDL), and thereby plays an important role in lipid clearance from the blood stream, lipid utilization and storage. Mediates margination of triglyceride-rich lipoprotein particles in capillaries. Recruited to its site of action on the luminal surface of vascular endothelium by binding to GPIHBP1 and cell surface heparan sulfate proteoglycans. Key enzyme in triglyceride metabolism.
T28692	PDBSTRUC	6OB0; 6OAZ; 6OAU; 6E7K
T28692	BIOCLASS	Carboxylic ester hydrolase
T28692	ECNUMBER	EC 3.1.1.34
T28692	SEQUENCE	MESKALLVLTLAVWLQSLTASRGGVAAADQRRDFIDIESKFALRTPEDTAEDTCHLIPGVAESVATCHFNHSSKTFMVIHGWTVTGMYESWVPKLVAALYKREPDSNVIVVDWLSRAQEHYPVSAGYTKLVGQDVARFINWMEEEFNYPLDNVHLLGYSLGAHAAGIAGSLTNKKVNRITGLDPAGPNFEYAEAPSRLSPDDADFVDVLHTFTRGSPGRSIGIQKPVGHVDIYPNGGTFQPGCNIGEAIRVIAERGLGDVDQLVKCSHERSIHLFIDSLLNEENPSKAYRCSSKEAFEKGLCLSCRKNRCNNLGYEINKVRAKRSSKMYLKTRSQMPYKVFHYQVKIHFSGTESETHTNQAFEISLYGTVAESENIPFTLPEVSTNKTYSFLIYTEVDIGELLMLKLKWKSDSYFSWSDWWSSPGFAIQKIRVKAGETQKKVIFCSREKVSHLQKGKAPAVFVKCHDKSLNKKSG
T28692	DRUGINFO	D05VIX	Gemfibrozil	Approved
T28692	DRUGINFO	D0J5DC	Clofibrate	Approved
T28692	DRUGINFO	D01RNV	AMT-011	Phase 3
T28692	DRUGINFO	D0SA3J	Ibrolipim	Phase 2
T28692	DRUGINFO	D0OH9B	WS-070117	Investigative

T62390	TARGETID	T62390
T62390	FORMERID	TTDS00365
T62390	UNIPROID	TY3H_HUMAN
T62390	TARGNAME	Tyrosine 3-monooxygenase (TH)
T62390	GENENAME	TH
T62390	TARGTYPE	Successful
T62390	SYNONYMS	Tyrosine 3-hydroxylase; TH
T62390	FUNCTION	Plays an important role in the physiology of adrenergic neurones.
T62390	PDBSTRUC	4J6S; 2XSN
T62390	BIOCLASS	Paired donor oxygen oxidoreductase
T62390	ECNUMBER	EC 1.14.16.2
T62390	SEQUENCE	MPTPDATTPQAKGFRRAVSELDAKQAEAIMVRGQGAPGPSLTGSPWPGTAAPAASYTPTPRSPRFIGRRQSLIEDARKEREAAVAAAAAAVPSEPGDPLEAVAFEEKEGKAVLNLLFSPRATKPSALSRAVKVFETFEAKIHHLETRPAQRPRAGGPHLEYFVRLEVRRGDLAALLSGVRQVSEDVRSPAGPKVPWFPRKVSELDKCHHLVTKFDPDLDLDHPGFSDQVYRQRRKLIAEIAFQYRHGDPIPRVEYTAEEIATWKEVYTTLKGLYATHACGEHLEAFALLERFSGYREDNIPQLEDVSRFLKERTGFQLRPVAGLLSARDFLASLAFRVFQCTQYIRHASSPMHSPEPDCCHELLGHVPMLADRTFAQFSQDIGLASLGASDEEIEKLSTLYWFTVEFGLCKQNGEVKAYGAGLLSSYGELLHCLSEEPEIRAFDPEAAAVQPYQDQTYQSVYFVSESFSDAKDKLRSYASRIQRPFSVKFDPYTLAIDVLDSPQAVRRSLEGVQDELDTLAHALSAIG
T62390	DRUGINFO	D01CRB	L-Tyrosine	Approved
T62390	DRUGINFO	D0B3QM	Metyrosine	Approved
T62390	DRUGINFO	D0Q9YT	Tetrahydrobiopterin	Approved
T62390	DRUGINFO	D0R1CR	L-Phenylalanine	Approved
T62390	DRUGINFO	DI7SP5	L1-79	Phase 2
T62390	DRUGINFO	D05ICS	ProSavin	Phase 1/2
T62390	DRUGINFO	D72UDH	OXB-102	Phase 1/2
T62390	DRUGINFO	D05XGI	Meta-Tyrosine	Investigative
T62390	DRUGINFO	D0CI3A	3-iodotyrosine	Investigative
T62390	DRUGINFO	D0X6LZ	3-chlorotyrosine	Investigative
T62390	DRUGINFO	D0F3XT	7,8-dihydrobiopterin	Investigative
T62390	DRUGINFO	D0IT5D	alpha-propyldopacetamide	Investigative

T51120	TARGETID	T51120
T51120	FORMERID	TTDS00380
T51120	UNIPROID	PERT_HUMAN
T51120	TARGNAME	Thyroid peroxidase (TPO)
T51120	GENENAME	TPO
T51120	TARGTYPE	Successful
T51120	SYNONYMS	Thyroperoxidase; TPO
T51120	FUNCTION	Iodination and coupling of the hormonogenic tyrosines in thyroglobulin to yield the thyroid hormones T(3) and T(4).
T51120	BIOCLASS	Peroxidases
T51120	ECNUMBER	EC 1.11.1.8
T51120	SEQUENCE	MRALAVLSVTLVMACTEAFFPFISRGKELLWGKPEESRVSSVLEESKRLVDTAMYATMQRNLKKRGILSPAQLLSFSKLPEPTSGVIARAAEIMETSIQAMKRKVNLKTQQSQHPTDALSEDLLSIIANMSGCLPYMLPPKCPNTCLANKYRPITGACNNRDHPRWGASNTALARWLPPVYEDGFSQPRGWNPGFLYNGFPLPPVREVTRHVIQVSNEVVTDDDRYSDLLMAWGQYIDHDIAFTPQSTSKAAFGGGADCQMTCENQNPCFPIQLPEEARPAAGTACLPFYRSSAACGTGDQGALFGNLSTANPRQQMNGLTSFLDASTVYGSSPALERQLRNWTSAEGLLRVHARLRDSGRAYLPFVPPRAPAACAPEPGIPGETRGPCFLAGDGRASEVPSLTALHTLWLREHNRLAAALKALNAHWSADAVYQEARKVVGALHQIITLRDYIPRILGPEAFQQYVGPYEGYDSTANPTVSNVFSTAAFRFGHATIHPLVRRLDASFQEHPDLPGLWLHQAFFSPWTLLRGGGLDPLIRGLLARPAKLQVQDQLMNEELTERLFVLSNSSTLDLASINLQRGRDHGLPGYNEWREFCGLPRLETPADLSTAIASRSVADKILDLYKHPDNIDVWLGGLAENFLPRARTGPLFACLIGKQMKALRDGDWFWWENSHVFTDAQRRELEKHSLSRVICDNTGLTRVPMDAFQVGKFPEDFESCDSITGMNLEAWRETFPQDDKCGFPESVENGDFVHCEESGRRVLVYSCRHGYELQGREQLTCTQEGWDFQPPLCKDVNECADGAHPPCHASARCRNTKGGFQCLCADPYELGDDGRTCVDSGRLPRVTWISMSLAALLIGGFAGLTSTVICRWTRTGTKSTLPISETGGGTPELRCGKHQAVGTSPQRAAAQDSEQESAGMEGRDTHRLPRAL
T51120	DRUGINFO	D02CKX	Carbimazole	Approved
T51120	DRUGINFO	D0S4BR	Methimazole	Approved
T51120	DRUGINFO	D00MIN	Propylthiouracil	Approved
T51120	DRUGINFO	D0M9ZL	TPO gene plasmid	Investigative

T52522	TARGETID	T52522
T52522	FORMERID	TTDS00037
T52522	UNIPROID	ADRB2_HUMAN
T52522	TARGNAME	Adrenergic receptor beta-2 (ADRB2)
T52522	GENENAME	ADRB2
T52522	TARGTYPE	Successful
T52522	SYNONYMS	Beta-2 adrenoreceptor; Beta-2 adrenoceptor; Beta-2 adrenergic receptor; B2AR; ADRB2R
T52522	FUNCTION	The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine. Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins.
T52522	PDBSTRUC	6MXT; 5X7D; 5JQH; 5D6L; 5D5B
T52522	BIOCLASS	GPCR rhodopsin
T52522	SEQUENCE	MGQPGNGSAFLLAPNGSHAPDHDVTQERDEVWVVGMGIVMSLIVLAIVFGNVLVITAIAKFERLQTVTNYFITSLACADLVMGLAVVPFGAAHILMKMWTFGNFWCEFWTSIDVLCVTASIETLCVIAVDRYFAITSPFKYQSLLTKNKARVIILMVWIVSGLTSFLPIQMHWYRATHQEAINCYANETCCDFFTNQAYAIASSIVSFYVPLVIMVFVYSRVFQEAKRQLQKIDKSEGRFHVQNLSQVEQDGRTGHGLRRSSKFCLKEHKALKTLGIIMGTFTLCWLPFFIVNIVHVIQDNLIRKEVYILLNWIGYVNSGFNPLIYCRSPDFRIAFQELLCLRRSSLKAYGNGYSSNGNTGEQSGYHVEQEKENKLLCEDLPGTEDFVGHQGTVPSDNIDSQGRNCSTNDSLL
T52522	DRUGINFO	D00LFB	Ritodrine	Approved
T52522	DRUGINFO	D02UFG	Metaproterenol Sulfate	Approved
T52522	DRUGINFO	D02ZJI	Levalbuterol	Approved
T52522	DRUGINFO	D03DJL	Indacaterol	Approved
T52522	DRUGINFO	D04KJO	Formoterol	Approved
T52522	DRUGINFO	D04UTT	Olodaterol	Approved
T52522	DRUGINFO	D04XEG	Fenoterol	Approved
T52522	DRUGINFO	D07XYV	Bambuterol	Approved
T52522	DRUGINFO	D08HUC	Isoetharine	Approved
T52522	DRUGINFO	D0D1DI	Arformoterol	Approved
T52522	DRUGINFO	D0FG6M	GW642444	Approved
T52522	DRUGINFO	D0K5CB	Salbutamol	Approved
T52522	DRUGINFO	D0L0GM	Vilanterol	Approved
T52522	DRUGINFO	D0L5YV	Salmeterol	Approved
T52522	DRUGINFO	D0M8RC	Terbutaline	Approved
T52522	DRUGINFO	D0SS4P	Pirbuterol	Approved
T52522	DRUGINFO	D0X5NX	Clenbuterol	Approved
T52522	DRUGINFO	D0Z1WA	Procaterol	Approved
T52522	DRUGINFO	D0I8FI	Isoproterenol	Approved
T52522	DRUGINFO	D04DJS	ICI 118,551	Phase 3
T52522	DRUGINFO	D0Q5AT	QVA-149	Phase 3
T52522	DRUGINFO	D0T6TW	GSK642444	Phase 3
T52522	DRUGINFO	D0YS2W	PT005	Phase 3
T52522	DRUGINFO	D03MZJ	BUCINDOLOL	Phase 2/3
T52522	DRUGINFO	D03LQC	APD-209	Phase 2
T52522	DRUGINFO	D04GRB	THRX-198321	Phase 2
T52522	DRUGINFO	D09CMK	R-salbutamol sulphate	Phase 2
T52522	DRUGINFO	D0G0RT	Carmoterol	Phase 2
T52522	DRUGINFO	D0GP8P	GSK961081	Phase 2
T52522	DRUGINFO	D0J1AV	LAS 100977	Phase 2
T52522	DRUGINFO	D0L6LD	AZD-3199	Phase 2
T52522	DRUGINFO	D0VU2M	TA-2005	Phase 2
T52522	DRUGINFO	D0YF4I	MN-221	Phase 2
T52522	DRUGINFO	D0L9CD	AZD-2115	Phase 2
T52522	DRUGINFO	D04UNO	KUL-7211	Phase 1
T52522	DRUGINFO	D0I2XM	L-796568	Phase 1
T52522	DRUGINFO	D0P0TR	Meluadrine	Discontinued in Preregistration
T52522	DRUGINFO	D0OR2S	Broxaterol	Discontinued in Phase 3
T52522	DRUGINFO	D0C5PA	Sibenadet	Discontinued in Phase 3
T52522	DRUGINFO	D02KMG	Milveterol	Discontinued in Phase 2
T52522	DRUGINFO	D04MOF	Milveterol+Fluticasone	Discontinued in Phase 2
T52522	DRUGINFO	D0AQ3H	PF-610355	Discontinued in Phase 2
T52522	DRUGINFO	D0GP4R	Picumeterol	Discontinued in Phase 2
T52522	DRUGINFO	D0YL3E	GSK159802	Discontinued in Phase 2
T52522	DRUGINFO	D0N8MQ	GSK-159797	Discontinued in Phase 2
T52522	DRUGINFO	D08HDD	RP-58802B	Terminated
T52522	DRUGINFO	D0F6AB	AR-C-89855	Terminated
T52522	DRUGINFO	D05ZGW	DPI-201-106	Terminated
T52522	DRUGINFO	D04YJU	L-755507	Terminated
T52522	DRUGINFO	D04UOP	Butoxamine	Investigative
T52522	DRUGINFO	D05RWZ	2-fluoronorepinehprine	Investigative
T52522	DRUGINFO	D08JOS	D 2343	Investigative
T52522	DRUGINFO	D0C6CZ	GNF-PF-1694	Investigative
T52522	DRUGINFO	D0OL3X	(S,R)-(+)-fenoterol	Investigative
T52522	DRUGINFO	D02QPP	(R,S)-(-)-fenoterol	Investigative
T52522	DRUGINFO	D04JGC	(R,R)-(-)-fenoterol	Investigative
T52522	DRUGINFO	D0XX5S	Dichloroisoproterenol	Investigative
T52522	DRUGINFO	D03BZW	[3H]CGP12177	Investigative
T52522	DRUGINFO	D04HXF	1-(2-isopropylphenoxy)-3-morpholinopropan-2-ol	Investigative
T52522	DRUGINFO	D0A4FU	1-(2-allylphenoxy)-3-morpholinopropan-2-ol	Investigative

T50942	TARGETID	T50942
T50942	FORMERID	TTDC00189
T50942	UNIPROID	TNR16_HUMAN
T50942	TARGNAME	Low-affinity nerve growth factor receptor (NGFR)
T50942	GENENAME	NGFR
T50942	TARGTYPE	Successful
T50942	SYNONYMS	p75 ICD; Tumor necrosis factor receptor superfamily member 16; TNFRSF16; P75neurotrophin receptor (p75(NTR)); P75NTR; P75ICD; NGFreceptor; NGF-P75 receptor; NGF receptor; Lowaffinity neurotrophin receptor p75NTR; Low affinity neurotrophin receptor p75NTR; Gp80-LNGFR; CD271; 75kD-neurotrophin receptor
T50942	FUNCTION	Low affinity receptor which can bind to NGF, BDNF, NT-3, and NT-4. Can mediate cell survival as well as cell death of neural cells. Necessary for the circadian oscillation of the clock genes ARNTL/BMAL1, PER1, PER2 and NR1D1 in the suprachiasmatic nucleus (SCN) of the brain and in liver and of the genes involved in glucose and lipid metabolism in the liver. Plays a role in the regulation of the translocation of GLUT4 to the cell surface in adipocytes and skeletal muscle cells in response to insulin, probably by regulating RAB31 activity, and thereby contributes to the regulation of insulin-dependent glucose uptake.
T50942	PDBSTRUC	5ZGG; 3EWV; 2N97; 2N83; 2N80
T50942	BIOCLASS	Cytokine receptor
T50942	SEQUENCE	MGAGATGRAMDGPRLLLLLLLGVSLGGAKEACPTGLYTHSGECCKACNLGEGVAQPCGANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSMSAPCVEADDAVCRCAYGYYQDETTGRCEACRVCEAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPCTVCEDTERQLRECTRWADAECEEIPGRWITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTVMGSSQPVVTRGTTDNLIPVYCSILAAVVVGLVAYIAFKRWNSCKQNKQGANSRPVNQTPPPEGEKLHSDSGISVDSQSLHDQQPHTQTASGQALKGDGGLYSSLPPAKREEVEKLLNGSAGDTWRHLAGELGYQPEHIDSFTHEACPVRALLASWATQDSATLDALLAALRRIQRADLVESLCSESTATSPV
T50942	DRUGINFO	D02KUO	Cenegermin	Approved
T50942	DRUGINFO	D0O1GS	Fulranumab	Phase 3
T50942	DRUGINFO	D0XR0B	SPI-205	Phase 2
T50942	DRUGINFO	D02XJJ	LM11A-31	Phase 1/2
T50942	DRUGINFO	D82DMK	LM11A-31	Phase 1/2
T50942	DRUGINFO	D00KEF	Org-2766	Discontinued in Phase 3
T50942	DRUGINFO	D0L8TN	BU-4514N	Terminated
T50942	DRUGINFO	D0M9FF	ReN-1820	Terminated
T50942	DRUGINFO	D0O7DN	CEP-427	Terminated
T50942	DRUGINFO	D04LRQ	TDI-0059	Investigative
T50942	DRUGINFO	D07UZX	Nerve growth factor conjugated RAP peptide	Investigative
T50942	DRUGINFO	D0A0ZY	ALD-901	Investigative
T50942	DRUGINFO	D0F2QP	CRB-0022	Investigative
T50942	DRUGINFO	D0Q8ZP	TDI-0033	Investigative
T50942	DRUGINFO	D0V1QX	Axogenesis Factor-1	Investigative

T46185	TARGETID	T46185
T46185	FORMERID	TTDS00003
T46185	UNIPROID	ACM2_HUMAN
T46185	TARGNAME	Muscarinic acetylcholine receptor M2 (CHRM2)
T46185	GENENAME	CHRM2
T46185	TARGTYPE	Successful
T46185	SYNONYMS	M2 receptor; CHRM2
T46185	FUNCTION	The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then triggers calcium ion release into the cytosol.
T46185	PDBSTRUC	6OIK; 5ZKC; 5ZKB; 5ZK8; 5ZK3
T46185	BIOCLASS	GPCR rhodopsin
T46185	SEQUENCE	MNNSTNSSNNSLALTSPYKTFEVVFIVLVAGSLSLVTIIGNILVMVSIKVNRHLQTVNNYFLFSLACADLIIGVFSMNLYTLYTVIGYWPLGPVVCDLWLALDYVVSNASVMNLLIISFDRYFCVTKPLTYPVKRTTKMAGMMIAAAWVLSFILWAPAILFWQFIVGVRTVEDGECYIQFFSNAAVTFGTAIAAFYLPVIIMTVLYWHISRASKSRIKKDKKEPVANQDPVSPSLVQGRIVKPNNNNMPSSDDGLEHNKIQNGKAPRDPVTENCVQGEEKESSNDSTSVSAVASNMRDDEITQDENTVSTSLGHSKDENSKQTCIRIGTKTPKSDSCTPTNTTVEVVGSSGQNGDEKQNIVARKIVKMTKQPAKKKPPPSREKKVTRTILAILLAFIITWAPYNVMVLINTFCAPCIPNTVWTIGYWLCYINSTINPACYALCNATFKKTFKHLLMCHYKNIGATR
T46185	DRUGINFO	D05SJW	Gallamine Triethiodide	Approved
T46185	DRUGINFO	D04MWJ	Methacholine Chloride	Approved
T46185	DRUGINFO	D05KZK	SMT-D002	Approved
T46185	DRUGINFO	D0M6VK	Methylscopolamine	Approved
T46185	DRUGINFO	D0R7WU	ACECLIDINE	Approved
T46185	DRUGINFO	D02MMF	FP-1097	Phase 2
T46185	DRUGINFO	D0A2OW	Otenzepad	Discontinued in Phase 2
T46185	DRUGINFO	D06GCP	PSD-506	Discontinued in Phase 2
T46185	DRUGINFO	D08YVT	SCH-211803	Discontinued in Phase 1
T46185	DRUGINFO	D02JNY	BIBN-140	Terminated
T46185	DRUGINFO	D07IZF	Sch-57790	Terminated
T46185	DRUGINFO	D0R1VL	BIBN-99	Terminated
T46185	DRUGINFO	D0VZ3D	AQ-RA-741	Terminated
T46185	DRUGINFO	D06ACX	HIMBACINE	Terminated
T46185	DRUGINFO	D0X8MZ	Alvameline	Terminated
T46185	DRUGINFO	D0W3KR	(R)-4-[2-[3-(4-methoxy-benzoylamino)-benzyl]-piperidin-1-ylmethyl]piperidine-1-carboxylic acid amide (Ro-320-6206)	Investigative
T46185	DRUGINFO	D04AAV	2-(4-Diethylamino-but-2-ynyl)-isoindole-1,3-dione	Investigative
T46185	DRUGINFO	D06UXW	METHOCTRAMINE	Investigative
T46185	DRUGINFO	D08CTL	CMI-936	Investigative
T46185	DRUGINFO	D09TDI	CARAMIPEN	Investigative
T46185	DRUGINFO	D0L1XR	Green tea	Investigative
T46185	DRUGINFO	D0MW7H	CMI-1145	Investigative
T46185	DRUGINFO	D00JTE	1,1-diphenyl-2-(3-tropanyl)ethanol	Investigative
T46185	DRUGINFO	D09AAZ	PTAC	Investigative
T46185	DRUGINFO	D0HP1O	AF-DX-384	Investigative
T46185	DRUGINFO	D04XNH	Propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester	Investigative
T46185	DRUGINFO	D01UDC	Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester	Investigative
T46185	DRUGINFO	D02EXX	GNF-PF-5618	Investigative
T46185	DRUGINFO	D02PFJ	1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea	Investigative
T46185	DRUGINFO	D05EML	1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione	Investigative
T46185	DRUGINFO	D05MDY	2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one	Investigative
T46185	DRUGINFO	D06IUC	FM1-10	Investigative
T46185	DRUGINFO	D06VST	3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one	Investigative
T46185	DRUGINFO	D07DEY	3-(3-benzylamino)-piperidin-2-one	Investigative
T46185	DRUGINFO	D07VZG	BRL-55473	Investigative
T46185	DRUGINFO	D08ZTA	6-Dimethylamino-2-methyl-hex-4-ynal oxime	Investigative
T46185	DRUGINFO	D0AR0H	FM1-43	Investigative
T46185	DRUGINFO	D0B8AQ	7-Pyrrolidin-1-yl-hept-5-yn-2-one	Investigative
T46185	DRUGINFO	D0C9VH	N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide	Investigative
T46185	DRUGINFO	D0C9ZE	Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester	Investigative
T46185	DRUGINFO	D0O1BN	SULFOARECOLINE	Investigative
T46185	DRUGINFO	D0OE0K	3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane	Investigative
T46185	DRUGINFO	D0QL1X	7-Dimethylamino-3-methyl-hept-5-yn-2-one	Investigative
T46185	DRUGINFO	D0R2JE	N-methoxyquinuclidine-3-carboximidoyl chloride	Investigative
T46185	DRUGINFO	D0R8FS	7-Dimethylamino-hept-5-yn-2-one	Investigative
T46185	DRUGINFO	D0U2IL	2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime	Investigative
T46185	DRUGINFO	D0X2JU	N-methoxyquinuclidine-3-carboximidoyl fluoride	Investigative
T46185	DRUGINFO	D0HV3A	FLUMEZAPINE	Investigative
T46185	DRUGINFO	D0Q2GP	ISOLOXAPINE	Investigative
T46185	DRUGINFO	D0F9QT	A-987306	Investigative
T46185	DRUGINFO	D0P0IX	ISOCLOZAPINE	Investigative
T46185	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T20709	TARGETID	T20709
T20709	FORMERID	TTDS00005
T20709	UNIPROID	ACM4_HUMAN
T20709	TARGNAME	Muscarinic acetylcholine receptor M4 (CHRM4)
T20709	GENENAME	CHRM4
T20709	TARGTYPE	Successful
T20709	SYNONYMS	M4 receptor; CHRM4
T20709	FUNCTION	The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
T20709	PDBSTRUC	6D9H; 5DSG
T20709	BIOCLASS	GPCR rhodopsin
T20709	SEQUENCE	MANFTPVNGSSGNQSVRLVTSSSHNRYETVEMVFIATVTGSLSLVTVVGNILVMLSIKVNRQLQTVNNYFLFSLACADLIIGAFSMNLYTVYIIKGYWPLGAVVCDLWLALDYVVSNASVMNLLIISFDRYFCVTKPLTYPARRTTKMAGLMIAAAWVLSFVLWAPAILFWQFVVGKRTVPDNQCFIQFLSNPAVTFGTAIAAFYLPVVIMTVLYIHISLASRSRVHKHRPEGPKEKKAKTLAFLKSPLMKQSVKKPPPGEAAREELRNGKLEEAPPPALPPPPRPVADKDTSNESSSGSATQNTKERPATELSTTEATTPAMPAPPLQPRALNPASRWSKIQIVTKQTGNECVTAIEIVPATPAGMRPAANVARKFASIARNQVRKKRQMAARERKVTRTIFAILLAFILTWTPYNVMVLVNTFCQSCIPDTVWSIGYWLCYVNSTINPACYALCNATFKKTFRHLLLCQYRNIGTAR
T20709	DRUGINFO	D09PNY	Tropicamide	Approved
T20709	DRUGINFO	D0W9VB	Diphenidol	Approved
T20709	DRUGINFO	D04MWJ	Methacholine Chloride	Approved
T20709	DRUGINFO	D0R7WU	ACECLIDINE	Approved
T20709	DRUGINFO	D04BBK	VU10007	Investigative
T20709	DRUGINFO	D0N2VN	VU10010	Investigative
T20709	DRUGINFO	D08CTL	CMI-936	Investigative
T20709	DRUGINFO	D0MW7H	CMI-1145	Investigative
T20709	DRUGINFO	D09AAZ	PTAC	Investigative
T20709	DRUGINFO	D0HP1O	AF-DX-384	Investigative
T20709	DRUGINFO	D04XNH	Propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester	Investigative
T20709	DRUGINFO	D0Z5RQ	Cremastrine	Investigative
T20709	DRUGINFO	D01UDC	Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester	Investigative
T20709	DRUGINFO	D02EXX	GNF-PF-5618	Investigative
T20709	DRUGINFO	D02PFJ	1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea	Investigative
T20709	DRUGINFO	D05EML	1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione	Investigative
T20709	DRUGINFO	D05MDY	2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one	Investigative
T20709	DRUGINFO	D06IUC	FM1-10	Investigative
T20709	DRUGINFO	D06VST	3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one	Investigative
T20709	DRUGINFO	D07DEY	3-(3-benzylamino)-piperidin-2-one	Investigative
T20709	DRUGINFO	D07VZG	BRL-55473	Investigative
T20709	DRUGINFO	D08ZTA	6-Dimethylamino-2-methyl-hex-4-ynal oxime	Investigative
T20709	DRUGINFO	D0AR0H	FM1-43	Investigative
T20709	DRUGINFO	D0B8AQ	7-Pyrrolidin-1-yl-hept-5-yn-2-one	Investigative
T20709	DRUGINFO	D0C9VH	N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide	Investigative
T20709	DRUGINFO	D0C9ZE	Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester	Investigative
T20709	DRUGINFO	D0N2KU	PF-3409409	Investigative
T20709	DRUGINFO	D0O1BN	SULFOARECOLINE	Investigative
T20709	DRUGINFO	D0OE0K	3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane	Investigative
T20709	DRUGINFO	D0QL1X	7-Dimethylamino-3-methyl-hept-5-yn-2-one	Investigative
T20709	DRUGINFO	D0R2JE	N-methoxyquinuclidine-3-carboximidoyl chloride	Investigative
T20709	DRUGINFO	D0R8FS	7-Dimethylamino-hept-5-yn-2-one	Investigative
T20709	DRUGINFO	D0U2IL	2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime	Investigative
T20709	DRUGINFO	D0X2JU	N-methoxyquinuclidine-3-carboximidoyl fluoride	Investigative
T20709	DRUGINFO	D0HV3A	FLUMEZAPINE	Investigative
T20709	DRUGINFO	D0Q2GP	ISOLOXAPINE	Investigative
T20709	DRUGINFO	D0F9QT	A-987306	Investigative
T20709	DRUGINFO	D0P0IX	ISOCLOZAPINE	Investigative
T20709	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T72168	TARGETID	T72168
T72168	FORMERID	TTDS00206
T72168	UNIPROID	MCR_HUMAN
T72168	TARGNAME	Mineralocorticoid receptor  (MR)
T72168	GENENAME	NR3C2
T72168	TARGTYPE	Successful
T72168	SYNONYMS	Nuclear receptor subfamily 3 group C member 2; Mineralocorticoid receptor; MLR; MCR; Inner ear mineralocorticoid receptor; Delta
T72168	FUNCTION	Binds to mineralocorticoid response elements (MRE) and transactivates target genes. The effect of MC is to increase ion and water transport and thus raise extracellular fluid volume and blood pressure and lower potassium levels. Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol.
T72168	PDBSTRUC	6GGG; 6GG8; 6GEV; 5MWY; 5MWP
T72168	BIOCLASS	Nuclear hormone receptor
T72168	SEQUENCE	METKGYHSLPEGLDMERRWGQVSQAVERSSLGPTERTDENNYMEIVNVSCVSGAIPNNSTQGSSKEKQELLPCLQQDNNRPGILTSDIKTELESKELSATVAESMGLYMDSVRDADYSYEQQNQQGSMSPAKIYQNVEQLVKFYKGNGHRPSTLSCVNTPLRSFMSDSGSSVNGGVMRAVVKSPIMCHEKSPSVCSPLNMTSSVCSPAGINSVSSTTASFGSFPVHSPITQGTPLTCSPNVENRGSRSHSPAHASNVGSPLSSPLSSMKSSISSPPSHCSVKSPVSSPNNVTLRSSVSSPANINNSRCSVSSPSNTNNRSTLSSPAASTVGSICSPVNNAFSYTASGTSAGSSTLRDVVPSPDTQEKGAQEVPFPKTEEVESAISNGVTGQLNIVQYIKPEPDGAFSSSCLGGNSKINSDSSFSVPIKQESTKHSCSGTSFKGNPTVNPFPFMDGSYFSFMDDKDYYSLSGILGPPVPGFDGNCEGSGFPVGIKQEPDDGSYYPEASIPSSAIVGVNSGGQSFHYRIGAQGTISLSRSARDQSFQHLSSFPPVNTLVESWKSHGDLSSRRSDGYPVLEYIPENVSSSTLRSVSTGSSRPSKICLVCGDEASGCHYGVVTCGSCKVFFKRAVEGQHNYLCAGRNDCIIDKIRRKNCPACRLQKCLQAGMNLGARKSKKLGKLKGIHEEQPQQQQPPPPPPPPQSPEEGTTYIAPAKEPSVNTALVPQLSTISRALTPSPVMVLENIEPEIVYAGYDSSKPDTAENLLSTLNRLAGKQMIQVVKWAKVLPGFKNLPLEDQITLIQYSWMCLSSFALSWRSYKHTNSQFLYFAPDLVFNEEKMHQSAMYELCQGMHQISLQFVRLQLTFEEYTIMKVLLLLSTIPKDGLKSQAAFEEMRTNYIKELRKMVTKCPNNSGQSWQRFYQLTKLLDSMHDLVSDLLEFCFYTFRESHALKVEFPAMLVEIISDQLPKVESGNAKPLYFHRK
T72168	DRUGINFO	D02CJX	Desoxycorticosterone Acetate	Approved
T72168	DRUGINFO	D0EP0C	Spironolactone	Approved
T72168	DRUGINFO	D0NV5O	Finerenone	Approved
T72168	DRUGINFO	D0Q4SD	Eplerenone	Approved
T72168	DRUGINFO	D0W5LS	Desoxycorticosterone Pivalate	Approved
T72168	DRUGINFO	D0Z4ZT	Drospirenone	Approved
T72168	DRUGINFO	D0I1LH	Aldosterone	Approved
T72168	DRUGINFO	D0R7JT	Fludrocortisone	Approved
T72168	DRUGINFO	D01JIO	ZK-91587	Phase 2
T72168	DRUGINFO	D03MSF	Nerenone	Phase 2
T72168	DRUGINFO	D05RZE	LY-2623091	Phase 2
T72168	DRUGINFO	D0G4YR	MT-3995	Phase 2
T72168	DRUGINFO	D0OH2H	BR-4628	Phase 2
T72168	DRUGINFO	DP6AO8	AZD9977	Phase 2
T72168	DRUGINFO	D00DFP	KBP-5074	Phase 1/2
T72168	DRUGINFO	D09UKH	XL550	Phase 1
T72168	DRUGINFO	DS4A5E	SP 20202	Clinical trial
T72168	DRUGINFO	D01VJR	PMID27551786-Compound-138	Patented
T72168	DRUGINFO	D02LAD	PMID27551786-Compound-IV	Patented
T72168	DRUGINFO	D08NNH	PMID27551786-Compound-106	Patented
T72168	DRUGINFO	D0LZ4V	PMID27551786-Compound-II	Patented
T72168	DRUGINFO	D0NC3Q	PMID27551786-Compound-III	Patented
T72168	DRUGINFO	D0W5ZQ	PMID27551786-Compound-I	Patented
T72168	DRUGINFO	D02KAU	PF-03882845	Terminated
T72168	DRUGINFO	D02SLV	CB-1922	Investigative
T72168	DRUGINFO	D09WWY	RU28318	Investigative
T72168	DRUGINFO	D04SQY	deoxycorticosterone	Investigative
T72168	DRUGINFO	D03TNT	(11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE	Investigative
T72168	DRUGINFO	D09OKK	LG-120838	Investigative
T72168	DRUGINFO	D0G5OV	WAY-255348	Investigative
T72168	DRUGINFO	D0XS0R	Epierenone	Investigative
T72168	DRUGINFO	D08KQM	LGD-5552	Investigative
T72168	DRUGINFO	D0GR5L	AL-43	Investigative
T72168	DRUGINFO	D02UVH	B-Octylglucoside	Investigative

T78709	TARGETID	T78709
T78709	FORMERID	TTDS00098
T78709	UNIPROID	5HT1A_HUMAN
T78709	TARGNAME	5-HT 1A receptor (HTR1A)
T78709	GENENAME	HTR1A
T78709	TARGTYPE	Successful
T78709	SYNONYMS	Serotonin receptor 1A; G-21; ADRBRL1; ADRB2RL1; 5-hydroxytryptamine receptor 1A; 5-HT1A receptor; 5-HT1A; 5-HT-1A
T78709	FUNCTION	Functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling inhibits adenylate cyclase activity and activates a phosphatidylinositol-calcium second messenger system that regulates the release of Ca(2+) ions from intracellular stores. Plays a role in the regulation of 5-hydroxytryptamine release and in the regulation of dopamine and 5-hydroxytryptamine metabolism. Plays a role in the regulation of dopamine and 5-hydroxytryptamine levels in the brain, and thereby affects neural activity, mood and behavior. Plays a role in the response to anxiogenic stimuli. G-protein coupled receptor for 5-hydroxytryptamine (serotonin).
T78709	BIOCLASS	GPCR rhodopsin
T78709	SEQUENCE	MDVLSPGQGNNTTSPPAPFETGGNTTGISDVTVSYQVITSLLLGTLIFCAVLGNACVVAAIALERSLQNVANYLIGSLAVTDLMVSVLVLPMAALYQVLNKWTLGQVTCDLFIALDVLCCTSSILHLCAIALDRYWAITDPIDYVNKRTPRRAAALISLTWLIGFLISIPPMLGWRTPEDRSDPDACTISKDHGYTIYSTFGAFYIPLLLMLVLYGRIFRAARFRIRKTVKKVEKTGADTRHGASPAPQPKKSVNGESGSRNWRLGVESKAGGALCANGAVRQGDDGAALEVIEVHRVGNSKEHLPLPSEAGPTPCAPASFERKNERNAEAKRKMALARERKTVKTLGIIMGTFILCWLPFFIVALVLPFCESSCHMPTLLGAIINWLGYSNSLLNPVIYAYFNKDFQNAFKKIIKCKFCRQ
T78709	DRUGINFO	D03SFU	TERTATOLOL	Approved
T78709	DRUGINFO	D07NJI	Treximet	Approved
T78709	DRUGINFO	D0R5GS	Gepirone	Approved
T78709	DRUGINFO	D0U2OO	Buspirone	Approved
T78709	DRUGINFO	D00USF	Trazodone	Approved
T78709	DRUGINFO	D0K0VO	Urapidil	Approved
T78709	DRUGINFO	D0P0OU	OPC-34712	Approved
T78709	DRUGINFO	D0S9CB	Flibanserin	Approved
T78709	DRUGINFO	D0X6BV	Vilazodone	Approved
T78709	DRUGINFO	D02OJC	Xaliproden	Phase 3
T78709	DRUGINFO	D04ZKY	SEP-363856	Phase 3
T78709	DRUGINFO	D06FKC	Eltoprazine	Phase 3
T78709	DRUGINFO	D0X6XH	CM-2395	Phase 3
T78709	DRUGINFO	D0E2IN	LECOZOTAN HYDROCHLORIDE	Phase 2/3
T78709	DRUGINFO	D0W5EH	Sarizotan	Phase 2/3
T78709	DRUGINFO	D00CQQ	TGFK09SD	Phase 2
T78709	DRUGINFO	D00KIE	Ensaculin hydrochloride	Phase 2
T78709	DRUGINFO	D00QOF	ORG-13011	Phase 2
T78709	DRUGINFO	D09OOQ	TGFK08AA	Phase 2
T78709	DRUGINFO	D09UMP	MN-305	Phase 2
T78709	DRUGINFO	D0F6TD	SUN N4057	Phase 2
T78709	DRUGINFO	D0OP8W	Zalospirone	Phase 2
T78709	DRUGINFO	D0P2QO	S-15535	Phase 2
T78709	DRUGINFO	D0T6BA	S-16924	Phase 2
T78709	DRUGINFO	D04FVD	TGBA01AD	Phase 2
T78709	DRUGINFO	D04JZP	Mazapertine succinate	Phase 2
T78709	DRUGINFO	D08FKX	SDZ-MAR-327	Phase 2
T78709	DRUGINFO	D0R8GR	OPC-14523	Phase 2
T78709	DRUGINFO	D0S8DU	TGWOOAA	Phase 2
T78709	DRUGINFO	D0SQ6A	FKW00GA	Phase 2
T78709	DRUGINFO	D00CVJ	Neu-P11	Phase 2
T78709	DRUGINFO	D0MT8G	FKB01MD	Phase 2
T78709	DRUGINFO	D0Z4FE	MIN-117	Phase 2
T78709	DRUGINFO	D05XEA	RP5063	Phase 2
T78709	DRUGINFO	D09CEY	SKL-PSY	Phase 1
T78709	DRUGINFO	D0EH0C	AV-965	Phase 1
T78709	DRUGINFO	D0F2NF	GSK-958108	Phase 1
T78709	DRUGINFO	D0F8HS	NLX-101	Phase 1
T78709	DRUGINFO	D0Y2GJ	DSP-1053	Phase 1
T78709	DRUGINFO	D00ZEG	Umespirone	Phase 1
T78709	DRUGINFO	D0K0GF	SSR-181507	Phase 1
T78709	DRUGINFO	D0C7WO	1192U90	Phase 1
T78709	DRUGINFO	D0F9TY	Aryl piperazine derivative 16	Patented
T78709	DRUGINFO	D0M9LM	Aryl piperazine derivative 14	Patented
T78709	DRUGINFO	D0T7HK	Aryl piperazine derivative 15	Patented
T78709	DRUGINFO	D0E7FT	PMID30124346-Compound-60TABLE5	Patented
T78709	DRUGINFO	D0SG8X	PMID30124346-Compound-LDT66	Patented
T78709	DRUGINFO	D0EO8F	PMID30124346-Compound-LDT8	Patented
T78709	DRUGINFO	D0M1UF	Aryl piperazine derivative 1	Patented
T78709	DRUGINFO	D0Z9WY	Aryl piperazine derivative 6	Patented
T78709	DRUGINFO	D09BCJ	PMID30124346-Compound-34TABLE4	Patented
T78709	DRUGINFO	D0F4NB	PMID30124346-Compound-13TABLE4	Patented
T78709	DRUGINFO	D0M7LV	LYSERGIC ACID DIETHYLAMIDE	Withdrawn from market
T78709	DRUGINFO	D02VZP	Flesinoxan	Discontinued in Phase 3
T78709	DRUGINFO	D01DAW	Bifeprunox	Discontinued in Phase 3
T78709	DRUGINFO	D01YOC	BMS-181100	Discontinued in Phase 3
T78709	DRUGINFO	D03ITI	Sunepitron	Discontinued in Phase 3
T78709	DRUGINFO	D01RCS	TIOSPIRONE	Discontinued in Phase 3
T78709	DRUGINFO	D01QKR	ALNESPIRONE	Discontinued in Phase 2
T78709	DRUGINFO	D01XAR	AP-521	Discontinued in Phase 2
T78709	DRUGINFO	D04HXS	REC-15/3079	Discontinued in Phase 2
T78709	DRUGINFO	D08AWI	PRX-00023	Discontinued in Phase 2
T78709	DRUGINFO	D08JAP	Robalzotan	Discontinued in Phase 2
T78709	DRUGINFO	D0B7SP	GSK163090	Discontinued in Phase 2
T78709	DRUGINFO	D0G5TU	LESOPITRON DIHYDROCHLORIDE	Discontinued in Phase 2
T78709	DRUGINFO	D0U4FW	DU 125530	Discontinued in Phase 2
T78709	DRUGINFO	D0X2TO	Adatanserin	Discontinued in Phase 2
T78709	DRUGINFO	D01WJZ	MAZAPERTINE	Discontinued in Phase 2
T78709	DRUGINFO	D01DOY	GR-127607	Discontinued in Phase 1
T78709	DRUGINFO	D05AAM	BINOSPIRONE MESYLATE	Discontinued in Phase 1
T78709	DRUGINFO	D05DSK	E2101	Discontinued in Phase 1
T78709	DRUGINFO	D0BN4Y	Ebalzotan	Discontinued in Phase 1
T78709	DRUGINFO	D0G5ZL	U-93385	Discontinued in Phase 1
T78709	DRUGINFO	D0O9EM	Eptapirone	Discontinued in Phase 1
T78709	DRUGINFO	D0S2WC	Nerisopam	Discontinued in Phase 1
T78709	DRUGINFO	D0T8KF	SUN-8399	Discontinued in Phase 1
T78709	DRUGINFO	D03ZZH	SLV-313	Discontinued in Phase 1
T78709	DRUGINFO	D09WHM	DU-29894	Discontinued in Phase 1
T78709	DRUGINFO	D02CJA	CM-2236	Preclinical
T78709	DRUGINFO	D04UXX	PD-158771	Preclinical
T78709	DRUGINFO	D02FNU	Ipsapirone	Terminated
T78709	DRUGINFO	D02OKK	SDZ 216-525	Terminated
T78709	DRUGINFO	D07BCO	WAY-100635	Terminated
T78709	DRUGINFO	D07RPB	HT-90B	Terminated
T78709	DRUGINFO	D0A6PL	S-14506	Terminated
T78709	DRUGINFO	D0L9SN	NAN-190	Terminated
T78709	DRUGINFO	D0Q2PF	LY-293284	Terminated
T78709	DRUGINFO	D0R1DP	A-74283	Terminated
T78709	DRUGINFO	D0RJ6R	Du-123015	Terminated
T78709	DRUGINFO	D0T0BS	CGS-18102A	Terminated
T78709	DRUGINFO	D0Z7AW	CP-293019	Terminated
T78709	DRUGINFO	D02ZPM	Anpirtoline	Terminated
T78709	DRUGINFO	D05IPO	BTS-79018	Terminated
T78709	DRUGINFO	D0R9PL	RWJ-25730	Terminated
T78709	DRUGINFO	D0U4WG	SLV-307	Terminated
T78709	DRUGINFO	D00KZF	BMY-7378	Terminated
T78709	DRUGINFO	D03QMR	WB-4101	Terminated
T78709	DRUGINFO	D0K9JP	A-80426	Terminated
T78709	DRUGINFO	D00FHZ	CP 93129	Investigative
T78709	DRUGINFO	D00XVV	[11C]WAY100635	Investigative
T78709	DRUGINFO	D01WWC	N-methyllaurotetanine	Investigative
T78709	DRUGINFO	D02CTZ	LY433221	Investigative
T78709	DRUGINFO	D02MVR	3-(1,2,3,6-Tetrahydro-pyridin-4-yl)-1H-indole	Investigative
T78709	DRUGINFO	D03DKG	EMD 56551	Investigative
T78709	DRUGINFO	D03ESA	P-MPPI	Investigative
T78709	DRUGINFO	D03FKF	repinotan	Investigative
T78709	DRUGINFO	D03ICS	NPT-500	Investigative
T78709	DRUGINFO	D03LDH	1-Benzyl-4-chroman-2-ylmethyl-piperazine	Investigative
T78709	DRUGINFO	D04JZJ	3-(4-Benzyl-piperidin-1-ylmethyl)-chromen-4-one	Investigative
T78709	DRUGINFO	D04YJO	CGS-19480A	Investigative
T78709	DRUGINFO	D05CGI	2-(4-Benzyl-piperidin-1-ylmethyl)-chroman-4-one	Investigative
T78709	DRUGINFO	D06BYY	S-14671	Investigative
T78709	DRUGINFO	D06DSX	ESCHOLTZINE	Investigative
T78709	DRUGINFO	D06FWM	N-(3-(1H-indol-4-yloxy)propyl)cyclohexanamine	Investigative
T78709	DRUGINFO	D06JVZ	SR-59026	Investigative
T78709	DRUGINFO	D07ROK	N-(3-(1H-indol-4-yloxy)propyl)cyclopentanamine	Investigative
T78709	DRUGINFO	D07XUM	FG-5893	Investigative
T78709	DRUGINFO	D08VUQ	1-(2-methoxyphenyl)-4-pentylpiperazine	Investigative
T78709	DRUGINFO	D09BJW	9-Methoxy-1,2,3,4-tetrahydro-anthracen-2-ylamine	Investigative
T78709	DRUGINFO	D09BYW	N-[4-(4-Phenyl-piperazin-1-yl)-butyl]-benzamide	Investigative
T78709	DRUGINFO	D0B5ST	2-(3-Bromophenylthio)-N,N-dimethylethanamine	Investigative
T78709	DRUGINFO	D0C9TZ	3-(3-Methanesulfonyl-phenyl)-1-propyl-pyrrolidine	Investigative
T78709	DRUGINFO	D0E1PL	[3H]NLX-112	Investigative
T78709	DRUGINFO	D0H3YR	[3H]robalzotan	Investigative
T78709	DRUGINFO	D0K6XD	4-(1H-indol-4-yloxy)-1-(isopropylamino)butan-2-ol	Investigative
T78709	DRUGINFO	D0KJ4Q	p-[18F]MPPF	Investigative
T78709	DRUGINFO	D0KL1P	PB-28	Investigative
T78709	DRUGINFO	D0L5YC	8-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-ylamine	Investigative
T78709	DRUGINFO	D0MA8C	GR 125,743	Investigative
T78709	DRUGINFO	D0MS3V	2-(Biphenyl-3-ylthio)-N,N-dimethylethanamine	Investigative
T78709	DRUGINFO	D0Q1HK	2-Dipropylamino-1,2,3,4-tetrahydro-anthracen-9-ol	Investigative
T78709	DRUGINFO	D0U0VH	U92016A	Investigative
T78709	DRUGINFO	D0XK0T	WAY 100135	Investigative
T78709	DRUGINFO	D0Z1LY	[3H]p-MPPF	Investigative
T78709	DRUGINFO	D0Z7KW	RS-30199	Investigative
T78709	DRUGINFO	D00JJO	1-[(3-methoxybenzyl)oxy]-2-(2-phenylethyl)benzene	Investigative
T78709	DRUGINFO	D00VHW	4-Benzyl-1-chroman-3-ylmethyl-piperidine	Investigative
T78709	DRUGINFO	D01YBD	2-(4-Methyl-piperazin-1-yl)-4-phenyl-pyrimidine	Investigative
T78709	DRUGINFO	D02AVN	(3-Chloro-phenyl)-piperazin-1-yl-methanone	Investigative
T78709	DRUGINFO	D02PLD	1-(2-Butoxy-phenyl)-piperazine	Investigative
T78709	DRUGINFO	D02XXA	3-Phenyl-1-propyl-pyrrolidine	Investigative
T78709	DRUGINFO	D02YCY	(R)-11-Amino-2-methoxyaporphine	Investigative
T78709	DRUGINFO	D02YFZ	2-Piperazin-1-yl-benzonitrile	Investigative
T78709	DRUGINFO	D03CEZ	AGROCLAVINE	Investigative
T78709	DRUGINFO	D03NWV	1-(2-Ethoxy-phenyl)-piperazine	Investigative
T78709	DRUGINFO	D03PAH	1-(2-Methoxy-phenyl)-4-propyl-piperazine	Investigative
T78709	DRUGINFO	D03XYG	1-Methyl-1,3-dihydro-indol-2-one	Investigative
T78709	DRUGINFO	D04TQF	1-(benzyloxy)-2-[2-(3-methoxyphenyl)ethyl]benzene	Investigative
T78709	DRUGINFO	D04ZMS	3-(4-Benzyl-piperidin-1-ylmethyl)-chroman-4-one	Investigative
T78709	DRUGINFO	D07IWZ	(R)-2,11-Diaminoaporphine	Investigative
T78709	DRUGINFO	D07LSC	1-(3-Fluoro-phenyl)-piperazine	Investigative
T78709	DRUGINFO	D08YJP	1-(2-Fluoro-phenyl)-piperazine	Investigative
T78709	DRUGINFO	D09MGF	1-(benzyloxy)-2-(2-phenylethyl)benzene	Investigative
T78709	DRUGINFO	D09WIL	SB-656104	Investigative
T78709	DRUGINFO	D0A7AK	3-{[2-(2-phenylethyl)phenoxy]methyl}pyridine	Investigative
T78709	DRUGINFO	D0CA9H	N-Benzyl-4-(2-diphenyl)-1-piperazinehexanamide	Investigative
T78709	DRUGINFO	D0E2FY	1-(2-Isopropoxy-phenyl)-piperazine	Investigative
T78709	DRUGINFO	D0I0ML	2-(2'-methyl-biphenyl-3-yl)-ethylamine	Investigative
T78709	DRUGINFO	D0J3ZK	(R)-flurocarazolol	Investigative
T78709	DRUGINFO	D0ND2Y	1-(3-Nitro-phenyl)-piperazine	Investigative
T78709	DRUGINFO	D0O8QJ	(S)-flurocarazolol	Investigative
T78709	DRUGINFO	D0P6LN	3-Butyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-ol	Investigative
T78709	DRUGINFO	D0PC2C	3-Ethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-ol	Investigative
T78709	DRUGINFO	D0R5QM	1-Butyl-4-(2-methoxy-phenyl)-piperazine	Investigative
T78709	DRUGINFO	D0R5WX	4-Benzyl-1-chroman-2-ylmethyl-piperidine	Investigative
T78709	DRUGINFO	D0RQ8R	2-{[2-(2-phenylethyl)phenoxy]methyl}pyridine	Investigative
T78709	DRUGINFO	D0T4PS	LY 165,163	Investigative
T78709	DRUGINFO	D0U1MN	1-Ethyl-4-(2-methoxy-phenyl)-piperazine	Investigative
T78709	DRUGINFO	D0Z5GR	1-(2-(2-chlorophenoxy)pyridin-3-yl)piperazine	Investigative
T78709	DRUGINFO	D00CGJ	2-(4-Bromo-2-methoxy-phenyl)-1-methyl-ethylamine	Investigative
T78709	DRUGINFO	D00FMX	3-(piperidin-4-yl)-2-(o-tolyloxy)pyridine	Investigative
T78709	DRUGINFO	D00FUS	2-(2-Methoxy-phenyl)-1-methyl-ethylamine	Investigative
T78709	DRUGINFO	D00GSD	LP-211	Investigative
T78709	DRUGINFO	D00QSV	2-(3-Methoxy-phenyl)-1-methyl-ethylamine	Investigative
T78709	DRUGINFO	D00UIN	JNJ-10392980	Investigative
T78709	DRUGINFO	D00WEQ	Brolamfetamine	Investigative
T78709	DRUGINFO	D01HRV	L-772,405	Investigative
T78709	DRUGINFO	D02OZB	2-Piperazin-1-yl-phenol	Investigative
T78709	DRUGINFO	D02SAF	1-(2,5-Dimethoxy-phenyl)-piperazine	Investigative
T78709	DRUGINFO	D03DET	SB 714786	Investigative
T78709	DRUGINFO	D04CTN	3-(1-Propyl-pyrrolidin-3-yl)-phenol	Investigative
T78709	DRUGINFO	D04MVL	(R)-(-)-10-methyl-11-hydroxyaporphine	Investigative
T78709	DRUGINFO	D06OJI	2-(2-Amino-propyl)-5-bromo-4-methoxy-phenol	Investigative
T78709	DRUGINFO	D06PKJ	1-(2,5-dimethoxyphenyl)propan-2-amine	Investigative
T78709	DRUGINFO	D07DWS	1-(2-(2-fluorobenzyloxy)phenyl)piperazine	Investigative
T78709	DRUGINFO	D08HOJ	1,2,3,4-Tetrahydro-naphthalen-2-ylamine	Investigative
T78709	DRUGINFO	D09JOE	1-(2,5-Dimethoxy-4-methyl-phenyl)-piperazine	Investigative
T78709	DRUGINFO	D09YVA	8-Methoxy-2-(4-methyl-piperazin-1-yl)-quinoline	Investigative
T78709	DRUGINFO	D0B2GS	3-Amino-1-(2-amino-5-methoxy-phenyl)-propan-1-one	Investigative
T78709	DRUGINFO	D0D2PL	8-Methoxy-quinolin-2-ylamine	Investigative
T78709	DRUGINFO	D0D3OF	1-(4-Bromo-2,5-dimethoxy-phenyl)-piperazine	Investigative
T78709	DRUGINFO	D0I9FI	2-(4-Bromo-phenyl)-1-methyl-ethylamine	Investigative
T78709	DRUGINFO	D0K0FI	7-methoxy-1-naphthylpiperazine	Investigative
T78709	DRUGINFO	D0K6ZT	2-(2-fluorophenoxy)-3-(piperidin-4-yl)pyridine	Investigative
T78709	DRUGINFO	D0KX3X	MCL-516	Investigative
T78709	DRUGINFO	D0N0LZ	3-Naphthalen-1-yl-pyrrolidine	Investigative
T78709	DRUGINFO	D0N2RJ	1-(2-(3-fluorophenoxy)phenyl)piperazine	Investigative
T78709	DRUGINFO	D0O3GF	[3H]8-OH-DPAT	Investigative
T78709	DRUGINFO	D0O9HS	1-(2-Chloro-phenyl)-piperazine	Investigative
T78709	DRUGINFO	D0PN8D	1-(7-Methoxy-naphthalen-2-yl)-piperazine	Investigative
T78709	DRUGINFO	D0QM3E	SB 272183	Investigative
T78709	DRUGINFO	D0R3GW	SB 649915	Investigative
T78709	DRUGINFO	D0R3XC	1,6-bis(4-(pyridin-2-yl)piperazin-1-yl)hexane	Investigative
T78709	DRUGINFO	D0S5ZY	3-Naphthalen-1-yl-1-propyl-pyrrolidine	Investigative
T78709	DRUGINFO	D0TH8D	8-Methoxy-2-piperazin-1-yl-quinoline	Investigative
T78709	DRUGINFO	D0X4RC	PHENYLPIPERAZINE	Investigative
T78709	DRUGINFO	D0Y5CG	1-(2-((3-fluorophenoxy)methyl)phenyl)piperazine	Investigative
T78709	DRUGINFO	D0YG1E	Etisulergine	Investigative
T78709	DRUGINFO	D0ZU5W	1-(2-(benzyloxy)phenyl)piperazine	Investigative
T78709	DRUGINFO	D00CCV	1,6-bis(4-m-tolylpiperazin-1-yl)hexane	Investigative
T78709	DRUGINFO	D00DEH	4-(2-(3-chlorophenoxy)phenyl)piperidine	Investigative
T78709	DRUGINFO	D00HCC	1-(2-phenoxyphenyl)piperazine	Investigative
T78709	DRUGINFO	D00KRQ	4-(2-phenoxyphenyl)piperidine	Investigative
T78709	DRUGINFO	D01MBF	4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine	Investigative
T78709	DRUGINFO	D01YNZ	4-(2-(benzyloxy)phenyl)piperidine	Investigative
T78709	DRUGINFO	D02NNS	SNAP-8719	Investigative
T78709	DRUGINFO	D03DQQ	4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine	Investigative
T78709	DRUGINFO	D03PIP	1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane	Investigative
T78709	DRUGINFO	D03XKL	1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane	Investigative
T78709	DRUGINFO	D03ZHB	5-chloro-4-ethyl-3,4-dihydroquinazolin-2-amine	Investigative
T78709	DRUGINFO	D04NDO	4-(2-(2-fluorobenzyloxy)phenyl)piperidine	Investigative
T78709	DRUGINFO	D04NKQ	4-(2-(4-fluorophenoxy)phenyl)piperidine	Investigative
T78709	DRUGINFO	D04ZPF	4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine	Investigative
T78709	DRUGINFO	D05LJC	4-(2-(benzyloxy)-3-fluorophenyl)piperidine	Investigative
T78709	DRUGINFO	D08EFH	2-(5-Methoxy-1H-indol-3-yl)-1-methyl-ethylamine	Investigative
T78709	DRUGINFO	D08JLB	4-(2-(benzyloxy)-6-fluorophenyl)piperidine	Investigative
T78709	DRUGINFO	D09IIH	4-(3-fluoro-2-phenoxyphenyl)piperidine	Investigative
T78709	DRUGINFO	D0C6BP	1,6-bis(4-phenylpiperazin-1-yl)hexane	Investigative
T78709	DRUGINFO	D0CG2Y	2-phenoxy-3-(piperidin-4-yl)pyridine	Investigative
T78709	DRUGINFO	D0E6PQ	4-(2-fluoro-6-phenoxyphenyl)piperidine	Investigative
T78709	DRUGINFO	D0F6GB	2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine	Investigative
T78709	DRUGINFO	D0G7NW	cyamemazine	Investigative
T78709	DRUGINFO	D0I4VT	1-Propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine	Investigative
T78709	DRUGINFO	D0IC4J	4-(2-(3-fluorophenoxy)phenyl)piperidine	Investigative
T78709	DRUGINFO	D0KT2M	2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine	Investigative
T78709	DRUGINFO	D0M2ZE	UH-232	Investigative
T78709	DRUGINFO	D0M3TK	1-(2-(4-fluorophenoxy)phenyl)piperazine	Investigative
T78709	DRUGINFO	D0O4BC	3-(2-Benzylamino-ethoxy)-phenol	Investigative
T78709	DRUGINFO	D0R3TA	4-(2-(4-fluorobenzyloxy)phenyl)piperidine	Investigative
T78709	DRUGINFO	D0S4JT	1-(2-(phenoxymethyl)phenyl)piperazine	Investigative
T78709	DRUGINFO	D0S8KA	3-(2-Amino-propyl)-1H-indol-5-ol	Investigative
T78709	DRUGINFO	D0W1HM	nafadotride	Investigative
T78709	DRUGINFO	D0W2YN	1-Naphthalen-2-yl-piperazine	Investigative
T78709	DRUGINFO	D0W8YO	4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine	Investigative
T78709	DRUGINFO	D0X4PH	LP-44	Investigative
T78709	DRUGINFO	D0Z1OF	LP-12	Investigative
T78709	DRUGINFO	D04TPO	5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine	Investigative
T78709	DRUGINFO	D06ROA	UH-301	Investigative
T78709	DRUGINFO	D0MU4A	spiroxatrine	Investigative
T78709	DRUGINFO	D0P1XQ	SEL-73	Investigative
T78709	DRUGINFO	D0XX2U	8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine	Investigative
T78709	DRUGINFO	D07GQP	PG-01037	Investigative
T78709	DRUGINFO	D07GXY	piribedil	Investigative
T78709	DRUGINFO	D0CK9K	EDMT	Investigative
T78709	DRUGINFO	D0D9YW	SB 216641	Investigative
T78709	DRUGINFO	D0V3XU	CHLOROPHENYLPIPERAZINE	Investigative
T78709	DRUGINFO	D0Y4MC	9-OH-risperidone	Investigative
T78709	DRUGINFO	D06VPR	WAY-466	Investigative
T78709	DRUGINFO	D08BCF	QUIPAZINE	Investigative
T78709	DRUGINFO	D0C5GF	MPDT	Investigative
T78709	DRUGINFO	D0LG8A	1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine	Investigative
T78709	DRUGINFO	D0V4RP	1-(2-Methoxy-phenyl)-piperazine	Investigative
T78709	DRUGINFO	D0Y9TL	5-chloro-3,4-dihydroquinazolin-2-amine	Investigative
T78709	DRUGINFO	D01KAX	1-((S)-2-aminopropyl)-1H-indazol-6-ol	Investigative
T78709	DRUGINFO	D05EQG	[3H]spiperone	Investigative
T78709	DRUGINFO	D08VGJ	5,6-dichloro-3,4-dihydroquinazolin-2-amine	Investigative
T78709	DRUGINFO	D03TDN	1-naphthylpiperazine	Investigative
T78709	DRUGINFO	D04TVG	BRL-15572	Investigative
T78709	DRUGINFO	D07LRJ	SB-271046	Investigative
T78709	DRUGINFO	D02UWB	5-CT	Investigative
T78709	DRUGINFO	D0V5HV	TFMPP	Investigative
T78709	DRUGINFO	D0F6CD	SEROTONIN	Investigative
T78709	DRUGINFO	D0F9QT	A-987306	Investigative
T78709	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T88240	TARGETID	T88240
T88240	FORMERID	TTDS00237
T88240	UNIPROID	DHPS_ECOLI
T88240	TARGNAME	Bacterial Dihydropteroate synthetase (Bact folP)
T88240	GENENAME	Bact folP
T88240	TARGTYPE	Successful
T88240	SYNONYMS	folP; H2Pte synthase; Dihydropteroate synthase; Dihydropteroate pyrophosphorylase; DHPS
T88240	FUNCTION	Dhps catalyzes the formation of the immediate precursor of folic acid. It is implicated in resistance to sulfonamide.
T88240	PDBSTRUC	1AJZ; 1AJ2; 1AJ0
T88240	BIOCLASS	Alkyl aryl transferase
T88240	ECNUMBER	EC 2.5.1.15
T88240	SEQUENCE	MKLFAQGTSLDLSHPHVMGILNVTPDSFSDGGTHNSLIDAVKHANLMINAGATIIDVGGESTRPGAAEVSVEEELQRVIPVVEAIAQRFEVWISVDTSKPEVIRESAKVGAHIINDIRSLSEPGALEAAAETGLPVCLMHMQGNPKTMQEAPKYDDVFAEVNRYFIEQIARCEQAGIAKEKLLLDPGFGFGKNLSHNYSLLARLAEFHHFNLPLLVGMSRKSMIGQLLNVGPSERLSGSLACAVIAAMQGAHIIRVHDVKETVEAMRVVEATLSAKENKRYE
T88240	DRUGINFO	D02IBU	Oritavancin	Approved
T88240	DRUGINFO	D02IIW	Faropenem	Approved
T88240	DRUGINFO	D03QWT	Doripenem	Approved
T88240	DRUGINFO	D05HPI	Daptomycin	Approved
T88240	DRUGINFO	D05LKP	Sulfadiazine	Approved
T88240	DRUGINFO	D07JJS	Sulfamethizole	Approved
T88240	DRUGINFO	D08JCA	Silver sulfadiazine	Approved
T88240	DRUGINFO	D09OOV	Polymyxin B Sulfate	Approved
T88240	DRUGINFO	D09TBD	Sulfisoxazole	Approved
T88240	DRUGINFO	D0B5FZ	Cefozopran	Approved
T88240	DRUGINFO	D0D4CY	Sulfapyridine	Approved
T88240	DRUGINFO	D0H1GJ	Sulfamerazine	Approved
T88240	DRUGINFO	D0J7XL	Gramicidin D	Approved
T88240	DRUGINFO	D0K7NQ	Colistin	Approved
T88240	DRUGINFO	D0L4JT	Sulfanilamide	Approved
T88240	DRUGINFO	D0Q3BV	Colistimethate	Approved
T88240	DRUGINFO	D0R9OH	Sulfamethoxazole	Approved
T88240	DRUGINFO	D0T1EO	Sulfonamides	Approved
T88240	DRUGINFO	D0T1GT	Sulfacytine	Approved
T88240	DRUGINFO	D0V4GY	Chlorhexidine	Approved
T88240	DRUGINFO	D0V9YR	Sulfamethazine	Approved
T88240	DRUGINFO	D07PAO	Sulphadoxine	Approved
T88240	DRUGINFO	D0F0OK	Sulfametopyrazine	Withdrawn from market
T88240	DRUGINFO	D00DBR	6-Methylamino-5-Nitroisocytosine	Investigative
T88240	DRUGINFO	D01LEP	2-amino-8-methyl-7,8-dihydropteridin-4(3H)-one	Investigative
T88240	DRUGINFO	D03GJB	Pteroic Acid	Investigative
T88240	DRUGINFO	D04TLB	2,6-diamino-5-nitrosopyrimidin-4(3H)-one	Investigative
T88240	DRUGINFO	D0E4UI	2,6-diamino-5-nitropyrimidin-4(3H)-one	Investigative
T88240	DRUGINFO	D0WT6A	Ethylene diamine	Investigative
T88240	DRUGINFO	D0YX4U	Pterin-6-Yl-Methyl-Monophosphate	Investigative
T88240	DRUGINFO	D03BIT	[Pterin-6-Yl Methanyl]-Phosphonophosphate	Investigative
T88240	DRUGINFO	D0D5EW	HKI-9924129	Investigative

T22658	TARGETID	T22658
T22658	FORMERID	TTDR00205
T22658	UNIPROID	IL8_HUMAN
T22658	TARGNAME	Interleukin-8 (IL8)
T22658	GENENAME	CXCL8
T22658	TARGTYPE	Successful
T22658	SYNONYMS	T-cell chemotactic factor; Protein 3-10C; Neutrophil-activating protein 1; NAP-1; Monocyte-derived neutrophil-activating peptide; Monocyte-derived neutrophil chemotactic factor; MONAP; MDNCF; IL8; IL-8; Granulocyte chemotactic protein 1; GCP-1; Emoctakin; Chemokine (C-X-C motif) ligand 8; C-X-C motif chemokine 8
T22658	FUNCTION	IL-8 is a chemotactic factor that attracts neutrophils, basophils, and T-cells, but not monocytes. It is also involved in neutrophil activation. It is released from several cell types in response to an inflammatory stimulus. IL-8(6-77) has a 5-10-fold higher activity on neutrophil activation, IL-8(5-77) has increased activity on neutrophil activation and IL-8(7-77) has a higher affinity to receptors CXCR1 and CXCR2 as compared to IL-8(1-77), respectively.
T22658	PDBSTRUC	5WDZ; 5D14; 4XDX; 3IL8; 2IL8
T22658	BIOCLASS	Cytokine: interleukin
T22658	SEQUENCE	MTSKLAVALLAAFLISAALCEGAVLPRSAKELRCQCIKTYSKPFHPKFIKELRVIESGPHCANTEIIVKLSDGRELCLDPKENWVQRVVEKFLKRAENS
T22658	DRUGINFO	D0R1QE	Ibuprofen	Approved
T22658	DRUGINFO	D0BF9K	ABX-IL8	Phase 2
T22658	DRUGINFO	DJ2N3L	BMS-986253	Phase 2
T22658	DRUGINFO	D0W4HA	MDX-018	Phase 1
T22658	DRUGINFO	D0ZL4F	R-ketoprofen	Discontinued in Phase 2
T22658	DRUGINFO	D05EMX	2-(2-(2,5-dichlorophenylamino)phenyl)acetic acid	Investigative
T22658	DRUGINFO	D08GOT	2-(2-(2-chlorophenylamino)phenyl)acetic acid	Investigative
T22658	DRUGINFO	D0I8YN	2-(2-(2-fluorophenylamino)phenyl)acetic acid	Investigative
T22658	DRUGINFO	D0Q8ZV	2-(2-(2-chlorophenoxy)phenyl)acetic acid	Investigative
T22658	DRUGINFO	D0T8RL	2-(2-(2-fluorophenoxy)phenyl)acetic acid	Investigative

T31309	TARGETID	T31309
T31309	FORMERID	TTDC00319
T31309	UNIPROID	BCL2_HUMAN
T31309	TARGNAME	Apoptosis regulator Bcl-2 (BCL-2)
T31309	GENENAME	BCL2
T31309	TARGTYPE	Successful
T31309	SYNONYMS	Bcl-2
T31309	FUNCTION	Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1). May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release. Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells.
T31309	PDBSTRUC	6GL8; 5VAY; 5VAX; 5VAU; 5JSN
T31309	BIOCLASS	B-cell lymphoma Bcl-2
T31309	SEQUENCE	MAHAGRTGYDNREIVMKYIHYKLSQRGYEWDAGDVGAAPPGAAPAPGIFSSQPGHTPHPAASRDPVARTSPLQTPAAPGAAAGPALSPVPPVVHLTLRQAGDDFSRRYRRDFAEMSSQLHLTPFTARGRFATVVEELFRDGVNWGRIVAFFEFGGVMCVESVNREMSPLVDNIALWMTEYLNRHLHTWIQDNGGWDAFVELYGPSMRPLFDFSWLSLKTLLSLALVGACITLGAYLGHK
T31309	DRUGINFO	D00PBX	GDC-0199	Approved
T31309	DRUGINFO	D06DLI	MCI-186	Approved
T31309	DRUGINFO	D0C4RB	Taxol	Approved
T31309	DRUGINFO	D05RJP	Oblimersen	Phase 3
T31309	DRUGINFO	D0I6OI	RG7601	Phase 3
T31309	DRUGINFO	D0J6PY	Taxol/Paraplatin/Herceptin	Phase 3
T31309	DRUGINFO	D06ETI	ABT-263	Phase 3
T31309	DRUGINFO	DY4OZ6	Thymoquinone	Phase 2/3
T31309	DRUGINFO	D0Z0HH	Gossypol	Phase 2
T31309	DRUGINFO	D0K8LB	PI-88/Taxotere	Phase 2
T31309	DRUGINFO	D02OZK	Obatoclax	Phase 2
T31309	DRUGINFO	D2Y7ZG	APG-2575	Phase 1/2
T31309	DRUGINFO	D4WN2M	APG-1252	Phase 1/2
T31309	DRUGINFO	DQ1P6X	AZD0466	Phase 1/2
T31309	DRUGINFO	D0C6YQ	BCL201	Phase 1
T31309	DRUGINFO	D0L2YF	Pc4	Phase 1
T31309	DRUGINFO	D74BRK	BGB-11417	Phase 1
T31309	DRUGINFO	DBY42T	LP-108	Phase 1
T31309	DRUGINFO	DJLX87	LOXO-338	Phase 1
T31309	DRUGINFO	DP63FS	VOB560	Phase 1
T31309	DRUGINFO	D03UDW	AI-850	Phase 1
T31309	DRUGINFO	D05CHN	Irofulven/Taxotere	Phase 1
T31309	DRUGINFO	D0C2DV	Indole-based analog 2	Patented
T31309	DRUGINFO	D0IS8R	PMID27744724-Compound-10	Patented
T31309	DRUGINFO	D0J9FN	PMID27744724-Compound-21	Patented
T31309	DRUGINFO	D0MZ7I	Indole-based analog 3	Patented
T31309	DRUGINFO	D0TU3N	PMID27744724-Compound-18	Patented
T31309	DRUGINFO	D0L8WH	ABT-737	Terminated
T31309	DRUGINFO	D04HAA	WL-276	Investigative
T31309	DRUGINFO	D04RTY	N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide	Investigative
T31309	DRUGINFO	D06AQG	5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine	Investigative
T31309	DRUGINFO	D0S0YV	modified HA14-1 compounds (cancer)	Investigative
T31309	DRUGINFO	D0V7PX	Apogossypol	Investigative
T31309	DRUGINFO	D0X0CS	2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide	Investigative
T31309	DRUGINFO	D0D6BH	4,5-dibenzylbenzene-1,2-diol	Investigative
T31309	DRUGINFO	D00LHS	TW-37	Investigative
T31309	DRUGINFO	D0S6IW	QEDIIRNIARHLAQVGDSMDR	Investigative

T57392	TARGETID	T57392
T57392	FORMERID	TTDS00475
T57392	UNIPROID	CP2D6_HUMAN
T57392	TARGNAME	Debrisoquine 4-hydroxylase (CYP2D6)
T57392	GENENAME	CYP2D6
T57392	TARGTYPE	Successful
T57392	SYNONYMS	P450-DB1; Cytochrome P450-DB1; Cytochrome P450 2D6; CYPIID6; CYP2DL1
T57392	FUNCTION	It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants. Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes.
T57392	PDBSTRUC	6CSD; 6CSB; 5TFU; 5TFT; 4XRZ
T57392	BIOCLASS	Paired donor oxygen oxidoreductase
T57392	ECNUMBER	EC 1.14.14.-
T57392	SEQUENCE	MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQLRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVFLARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDKAVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKVLRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVADLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVIHEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHFLDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGVFAFLVSPSPYELCAVPR
T57392	DRUGINFO	D0Z9NZ	Glutethimide	Approved
T57392	DRUGINFO	D03GNI	ISOQUINE	Phase 1
T57392	DRUGINFO	D00AEX	2-Hexyloxy-5-imidazol-1-yl-pyridine	Investigative
T57392	DRUGINFO	D00XOQ	SB-210313	Investigative
T57392	DRUGINFO	D01DAU	4-(3-Pent-1-ynyl-benzyl)-1H-imidazole	Investigative
T57392	DRUGINFO	D05ROV	GNF-PF-5411	Investigative
T57392	DRUGINFO	D06QFO	(5-(pyridin-3-yl)furan-2-yl)methanamine	Investigative
T57392	DRUGINFO	D0C7PK	(2-hydroxy-3-phenoxypropyl)(propan-2-yl)amine	Investigative
T57392	DRUGINFO	D0FF0Z	4-(3-Phenylethynyl-benzyl)-1H-imidazole	Investigative
T57392	DRUGINFO	D0FQ1Z	GNF-PF-4292	Investigative
T57392	DRUGINFO	D0G8KT	GBR-12289	Investigative
T57392	DRUGINFO	D0IM5E	Desethyl isoquine	Investigative
T57392	DRUGINFO	D0IO0I	Go-Y022	Investigative
T57392	DRUGINFO	D0J6RQ	1,5-bis(4-hydroxyphenyl)penta-1,4-dien-3-one	Investigative
T57392	DRUGINFO	D0J9SO	BS 7840	Investigative
T57392	DRUGINFO	D0M0IQ	Bis-(5-pyridin-3-yl-thiophen-2-ylmethyl)-amine	Investigative
T57392	DRUGINFO	D0P2DU	Prodipine	Investigative
T57392	DRUGINFO	D0QH6F	4-methylaminomethyl-7-methoxycoumarin	Investigative
T57392	DRUGINFO	D0S6NP	Kaempferol-3-O-methyl ether	Investigative
T57392	DRUGINFO	D0SE3C	BS 7581	Investigative
T57392	DRUGINFO	D0X4DE	GBR 12530	Investigative
T57392	DRUGINFO	D0YQ8U	(5-phenylfuran-2-yl)methanamine	Investigative
T57392	DRUGINFO	D0ZY7X	GNF-PF-2094	Investigative
T57392	DRUGINFO	D0ZZ2L	BS 9106	Investigative
T57392	DRUGINFO	D00PYW	4-[2-(4-Imidazol-1-yl-phenoxy)-ethyl]-morpholine	Investigative
T57392	DRUGINFO	D00TOF	DIHYDROCUBEBIN	Investigative
T57392	DRUGINFO	D01ARE	Methyl-(5-pyridin-3-yl-thiophen-2-yl)-amine	Investigative
T57392	DRUGINFO	D02DTR	3-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine	Investigative
T57392	DRUGINFO	D02GFK	3-(6-Methoxynaphthalen-2-yl)pyridin-4-amine	Investigative
T57392	DRUGINFO	D03KXT	4-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine	Investigative
T57392	DRUGINFO	D05MSG	BMS-694153	Investigative
T57392	DRUGINFO	D07ANY	1H-1,2,3-benzotriazol-1-amine	Investigative
T57392	DRUGINFO	D07VHB	1-(4-Butoxy-phenyl)-1H-imidazole	Investigative
T57392	DRUGINFO	D0B0LC	2-(4-Imidazol-1-yl-phenoxymethyl)-pyridine	Investigative
T57392	DRUGINFO	D0C4XQ	GB-12819	Investigative
T57392	DRUGINFO	D0G6BJ	1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)	Investigative
T57392	DRUGINFO	D0J4CB	1-(METHOXYMETHYL)-6-(NAPHTHALEN-2-YL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)	Investigative
T57392	DRUGINFO	D0K3EW	6-(3,4-DICHLOROPHENYL)-1-[1-(METHYLOXY)-3-BUTEN-1-YL]-3-AZABICYCLO[4.1.0]HEPTANE (DIASTEREOMERIC MIX)	Investigative
T57392	DRUGINFO	D0U7BJ	2-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine	Investigative
T57392	DRUGINFO	D0YP4A	(5-pyridin-3-yl-furan-2-yl)methanethiol	Investigative
T57392	DRUGINFO	D01RZP	4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol	Investigative
T57392	DRUGINFO	D0M0KX	2-Fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol	Investigative
T57392	DRUGINFO	D0Y2RL	4-[5-(3-Hydroxyphenyl)-2-thienyl)-2-methyl]phenol	Investigative
T57392	DRUGINFO	D01JXM	2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole	Investigative
T57392	DRUGINFO	D03SAV	ICI-199441	Investigative
T57392	DRUGINFO	D08DSJ	ML-3163	Investigative
T57392	DRUGINFO	D0L9YP	4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide	Investigative

T28893	TARGETID	T28893
T28893	FORMERID	TTDS00002
T28893	UNIPROID	ACM1_HUMAN
T28893	TARGNAME	Muscarinic acetylcholine receptor M1 (CHRM1)
T28893	GENENAME	CHRM1
T28893	TARGTYPE	Successful
T28893	SYNONYMS	M1 receptor
T28893	FUNCTION	Primary transducing effect is Pi turnover. The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins.
T28893	PDBSTRUC	6OIJ; 5CXV
T28893	BIOCLASS	GPCR rhodopsin
T28893	SEQUENCE	MNTSAPPAVSPNITVLAPGKGPWQVAFIGITTGLLSLATVTGNLLVLISFKVNTELKTVNNYFLLSLACADLIIGTFSMNLYTTYLLMGHWALGTLACDLWLALDYVASNASVMNLLLISFDRYFSVTRPLSYRAKRTPRRAALMIGLAWLVSFVLWAPAILFWQYLVGERTVLAGQCYIQFLSQPIITFGTAMAAFYLPVTVMCTLYWRIYRETENRARELAALQGSETPGKGGGSSSSSERSQPGAEGSPETPPGRCCRCCRAPRLLQAYSWKEEEEEDEGSMESLTSSEGEEPGSEVVIKMPMVDPEAQAPTKQPPRSSPNTVKRPTKKGRDRAGKGQKPRGKEQLAKRKTFSLVKEKKAARTLSAILLAFILTWTPYNIMVLVSTFCKDCVPETLWELGYWLCYVNSTINPMCYALCNKAFRDTFRLLLLCRWDKRRWRKIPKRPGSVHRTPSRQC
T28893	DRUGINFO	D00BLL	Fesoterodine fumarate	Approved
T28893	DRUGINFO	D02LRQ	Cycrimine	Approved
T28893	DRUGINFO	D07XJM	Dicyclomine	Approved
T28893	DRUGINFO	D0B4TN	Biperiden	Approved
T28893	DRUGINFO	D0D1MA	Oxyphenonium	Approved
T28893	DRUGINFO	D0HQ6N	Benztropine	Approved
T28893	DRUGINFO	D0M0AM	Glycopyrrolate	Approved
T28893	DRUGINFO	D0NF0W	Metixene	Approved
T28893	DRUGINFO	D0OK5Q	Diphemanil Methylsulfate	Approved
T28893	DRUGINFO	D0T0LM	Pirenzepine	Approved
T28893	DRUGINFO	D0V5ZZ	Propantheline	Approved
T28893	DRUGINFO	D09GFL	Trihexyphenidyl	Approved
T28893	DRUGINFO	D0Q1BT	Clidinium	Approved
T28893	DRUGINFO	D05KZK	SMT-D002	Approved
T28893	DRUGINFO	D0R7WU	ACECLIDINE	Approved
T28893	DRUGINFO	D0DY7W	Nebracetam	Phase 3
T28893	DRUGINFO	D0H0UB	Darotropium + 642444	Phase 3
T28893	DRUGINFO	D07QAK	Xanomeline tartrate	Phase 2
T28893	DRUGINFO	D0E0AS	(S)-oxybutynin	Phase 2
T28893	DRUGINFO	D0K4HW	N-DESMETHYLCLOZAPINE	Phase 2
T28893	DRUGINFO	D0L5WA	SR-46559A	Phase 2
T28893	DRUGINFO	D0R1YL	NGX-267	Phase 2
T28893	DRUGINFO	D02MMF	FP-1097	Phase 2
T28893	DRUGINFO	D03TDW	Thiopilocarpine	Phase 1
T28893	DRUGINFO	D04GGJ	WST-057	Phase 1
T28893	DRUGINFO	D04SIU	MCD-386	Phase 1
T28893	DRUGINFO	D07EFM	Arecoline	Phase 1
T28893	DRUGINFO	D09BBA	TAK-071	Phase 1
T28893	DRUGINFO	D0FP0D	AZD-6088	Phase 1
T28893	DRUGINFO	D0RO8H	AC-262271	Phase 1
T28893	DRUGINFO	D01QXY	B7-2/GM-CSF	Phase 1
T28893	DRUGINFO	D09AOO	ANAVEX 2-73	Phase 1
T28893	DRUGINFO	DZ02CQ	ANAVEX 3-71	Phase 1
T28893	DRUGINFO	D0FX4J	Telenzepine	Discontinued in Preregistration
T28893	DRUGINFO	D03STA	Darotropium	Discontinued in Phase 2
T28893	DRUGINFO	D06ODM	Talsaclidine fumarate	Discontinued in Phase 2
T28893	DRUGINFO	D0F8BS	YM-796	Discontinued in Phase 2
T28893	DRUGINFO	D0XE5L	Rispenzepine	Discontinued in Phase 2
T28893	DRUGINFO	D09EEV	Declopramide	Discontinued in Phase 2
T28893	DRUGINFO	D07MVE	PD-151832	Discontinued in Phase 1/2
T28893	DRUGINFO	D09FYQ	Sabcomeline	Discontinued in Phase 1
T28893	DRUGINFO	D0D1VJ	SDZ-210-086	Discontinued in Phase 1
T28893	DRUGINFO	D0IE4H	TAZOMELINE	Discontinued in Phase 1
T28893	DRUGINFO	D0JN3M	ITAMELINE	Discontinued in Phase 1
T28893	DRUGINFO	D0J8UV	AC-260584	Terminated
T28893	DRUGINFO	D0PZ9R	WAY-132983	Terminated
T28893	DRUGINFO	D06ACX	HIMBACINE	Terminated
T28893	DRUGINFO	D0X8MZ	Alvameline	Terminated
T28893	DRUGINFO	D03FZG	LY-593039	Investigative
T28893	DRUGINFO	D06BSD	Bo(15)PZ	Investigative
T28893	DRUGINFO	D08TRD	hexocyclium	Investigative
T28893	DRUGINFO	D09HXG	RR(17)PZ	Investigative
T28893	DRUGINFO	D0M2LD	BQCA	Investigative
T28893	DRUGINFO	D0Q6BG	DAU-6202	Investigative
T28893	DRUGINFO	D0ZZ9M	AF150(S)	Investigative
T28893	DRUGINFO	D03WGD	AMINOBENZTROPINE	Investigative
T28893	DRUGINFO	D04AAV	2-(4-Diethylamino-but-2-ynyl)-isoindole-1,3-dione	Investigative
T28893	DRUGINFO	D05EEV	DAU-5750	Investigative
T28893	DRUGINFO	D09TDI	CARAMIPEN	Investigative
T28893	DRUGINFO	D0R8AZ	DAU-5884	Investigative
T28893	DRUGINFO	D00JTE	1,1-diphenyl-2-(3-tropanyl)ethanol	Investigative
T28893	DRUGINFO	D0H8XV	R-dimethindene	Investigative
T28893	DRUGINFO	D04XNH	Propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester	Investigative
T28893	DRUGINFO	D0F0BS	3alpha-(bis-chloro-phenylmethoxy)tropane	Investigative
T28893	DRUGINFO	D0Y8UC	Difluorobenztropine	Investigative
T28893	DRUGINFO	D0Z5RQ	Cremastrine	Investigative
T28893	DRUGINFO	D01UDC	Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester	Investigative
T28893	DRUGINFO	D02EXX	GNF-PF-5618	Investigative
T28893	DRUGINFO	D02PFJ	1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea	Investigative
T28893	DRUGINFO	D05EML	1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione	Investigative
T28893	DRUGINFO	D05MDY	2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one	Investigative
T28893	DRUGINFO	D06IUC	FM1-10	Investigative
T28893	DRUGINFO	D06VST	3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one	Investigative
T28893	DRUGINFO	D07DEY	3-(3-benzylamino)-piperidin-2-one	Investigative
T28893	DRUGINFO	D07VZG	BRL-55473	Investigative
T28893	DRUGINFO	D08ZTA	6-Dimethylamino-2-methyl-hex-4-ynal oxime	Investigative
T28893	DRUGINFO	D0AR0H	FM1-43	Investigative
T28893	DRUGINFO	D0B8AQ	7-Pyrrolidin-1-yl-hept-5-yn-2-one	Investigative
T28893	DRUGINFO	D0C9VH	N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide	Investigative
T28893	DRUGINFO	D0C9ZE	Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester	Investigative
T28893	DRUGINFO	D0O1BN	SULFOARECOLINE	Investigative
T28893	DRUGINFO	D0OE0K	3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane	Investigative
T28893	DRUGINFO	D0QL1X	7-Dimethylamino-3-methyl-hept-5-yn-2-one	Investigative
T28893	DRUGINFO	D0R2JE	N-methoxyquinuclidine-3-carboximidoyl chloride	Investigative
T28893	DRUGINFO	D0R8FS	7-Dimethylamino-hept-5-yn-2-one	Investigative
T28893	DRUGINFO	D0U2IL	2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime	Investigative
T28893	DRUGINFO	D0X2JU	N-methoxyquinuclidine-3-carboximidoyl fluoride	Investigative
T28893	DRUGINFO	D0HV3A	FLUMEZAPINE	Investigative
T28893	DRUGINFO	D0Q2GP	ISOLOXAPINE	Investigative
T28893	DRUGINFO	D0F9QT	A-987306	Investigative
T28893	DRUGINFO	D0P0IX	ISOCLOZAPINE	Investigative
T28893	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T09826	TARGETID	T09826
T09826	FORMERID	TTDNC00422
T09826	UNIPROID	TOP1_HUMAN
T09826	TARGNAME	DNA topoisomerase I (TOP1)
T09826	GENENAME	TOP1
T09826	TARGTYPE	Successful
T09826	SYNONYMS	DNA topoisomerase I
T09826	FUNCTION	Introduces a single-strand break via transesterification at a target site in duplex DNA. The scissile phosphodiester is attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-(3'-phosphotyrosyl)-enzyme intermediate and the expulsion of a 5'-OH DNA strand. The free DNA strand then rotates around the intact phosphodiester bond on the opposing strand, thus removing DNA supercoils. Finally, in the religation step, the DNA 5'-OH attacks the covalent intermediate to expel the active-site tyrosine and restore the DNA phosphodiester backbone. Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells. Involved in the circadian transcription of the core circadian clock component ARNTL/BMAL1 by altering the chromatin structure around the ROR response elements (ROREs) on the ARNTL/BMAL1 promoter. Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex.
T09826	PDBSTRUC	1TL8; 1T8I; 1SEU; 1SC7; 1RRJ
T09826	BIOCLASS	Topoisomerase
T09826	ECNUMBER	EC 5.6.2.2
T09826	SEQUENCE	MSGDHLHNDSQIEADFRLNDSHKHKDKHKDREHRHKEHKKEKDREKSKHSNSEHKDSEKKHKEKEKTKHKDGSSEKHKDKHKDRDKEKRKEEKVRASGDAKIKKEKENGFSSPPQIKDEPEDDGYFVPPKEDIKPLKRPRDEDDADYKPKKIKTEDTKKEKKRKLEEEEDGKLKKPKNKDKDKKVPEPDNKKKKPKKEEEQKWKWWEEERYPEGIKWKFLEHKGPVFAPPYEPLPENVKFYYDGKVMKLSPKAEEVATFFAKMLDHEYTTKEIFRKNFFKDWRKEMTNEEKNIITNLSKCDFTQMSQYFKAQTEARKQMSKEEKLKIKEENEKLLKEYGFCIMDNHKERIANFKIEPPGLFRGRGNHPKMGMLKRRIMPEDIIINCSKDAKVPSPPPGHKWKEVRHDNKVTWLVSWTENIQGSIKYIMLNPSSRIKGEKDWQKYETARRLKKCVDKIRNQYREDWKSKEMKVRQRAVALYFIDKLALRAGNEKEEGETADTVGCCSLRVEHINLHPELDGQEYVVEFDFLGKDSIRYYNKVPVEKRVFKNLQLFMENKQPEDDLFDRLNTGILNKHLQDLMEGLTAKVFRTYNASITLQQQLKELTAPDENIPAKILSYNRANRAVAILCNHQRAPPKTFEKSMMNLQTKIDAKKEQLADARRDLKSAKADAKVMKDAKTKKVVESKKKAVQRLEEQLMKLEVQATDREENKQIALGTSKLNYLDPRITVAWCKKWGVPIEKIYNKTQREKFAWAIDMADEDYEF
T09826	DRUGINFO	D02PMO	Topotecan	Approved
T09826	DRUGINFO	D06VYE	Belotecan hydrocholoride	Approved
T09826	DRUGINFO	D07HOB	Irinotecan	Approved
T09826	DRUGINFO	D0Z4XW	Topetecan	Approved
T09826	DRUGINFO	D04AIT	B-Lactams	Approved
T09826	DRUGINFO	D01FUC	Exatecan	Phase 3
T09826	DRUGINFO	D09YDM	Camptothecin	Phase 3
T09826	DRUGINFO	D0H5IZ	Etirinotecan pegol	Phase 3
T09826	DRUGINFO	D0I1DW	Edotecarin	Phase 3
T09826	DRUGINFO	D0Y1FO	Rubitecan	Phase 3
T09826	DRUGINFO	DP41HV	Datopotamab deruxtecan	Phase 3
T09826	DRUGINFO	D02CZK	Karenitecin	Phase 3
T09826	DRUGINFO	D00BZS	Gimatecan	Phase 2
T09826	DRUGINFO	D00XCX	DIFLOMOTECAN	Phase 2
T09826	DRUGINFO	D02PAW	TLC-388	Phase 2
T09826	DRUGINFO	D05UFP	PEG-SN38	Phase 2
T09826	DRUGINFO	D06XCF	EQ-917	Phase 2
T09826	DRUGINFO	D07UHX	9-AMINOCAMPTOTHECIN	Phase 2
T09826	DRUGINFO	D0B6YB	LE-SN38	Phase 2
T09826	DRUGINFO	D0D4CX	Pegamotecan	Phase 2
T09826	DRUGINFO	D0K0IS	Polyglutamate camptothecin	Phase 2
T09826	DRUGINFO	D0M6BA	AR-67	Phase 2
T09826	DRUGINFO	D0ND9T	CRLX101	Phase 2
T09826	DRUGINFO	D0U6ML	CKD602	Phase 2
T09826	DRUGINFO	D0W0VD	Beta-Lapachone	Phase 2
T09826	DRUGINFO	DX5A8D	Patritumab deruxtecan	Phase 2
T09826	DRUGINFO	D08EES	XR-5000	Phase 2
T09826	DRUGINFO	D0RS4X	PEN-866	Phase 1/2
T09826	DRUGINFO	DT8R1L	DS-7300	Phase 1/2
T09826	DRUGINFO	D04TIJ	Namitecan	Phase 1
T09826	DRUGINFO	D05GUK	INTOPLICINE	Phase 1
T09826	DRUGINFO	D07PMG	Afeletecan	Phase 1
T09826	DRUGINFO	D09CZS	DRF-1042	Phase 1
T09826	DRUGINFO	D0A1LS	Genz-644282	Phase 1
T09826	DRUGINFO	D0BW2N	GZ402674	Phase 1
T09826	DRUGINFO	D0E1VV	ELOMOTECAN HYDROCHLORIDE	Phase 1
T09826	DRUGINFO	D0K6QU	IT-141	Phase 1
T09826	DRUGINFO	D0U0BP	DFP 13318	Phase 1
T09826	DRUGINFO	D0Z5VG	CZ-48	Phase 1
T09826	DRUGINFO	D0Z7FK	XMT-1001	Phase 1
T09826	DRUGINFO	DD90AS	DAN-222	Phase 1
T09826	DRUGINFO	DDXH71	LMP744	Phase 1
T09826	DRUGINFO	DV3WF1	LMP400	Phase 1
T09826	DRUGINFO	D07BXE	Daniquidone	Phase 1
T09826	DRUGINFO	D07DAU	Tafluposide	Phase 1
T09826	DRUGINFO	D0Y1GJ	MLN-576	Phase 1
T09826	DRUGINFO	DJ4X7D	DS-6157	Phase 1
T09826	DRUGINFO	D0P4KU	ABI-011	Phase 1
T09826	DRUGINFO	D0M8KY	(S)-DRF-1042	Clinical trial
T09826	DRUGINFO	D0N1FR	BECATECARIN	Discontinued in Phase 3
T09826	DRUGINFO	D05ZQV	NK-611	Discontinued in Phase 2
T09826	DRUGINFO	D07YCR	S-16020-2	Discontinued in Phase 2
T09826	DRUGINFO	D08ODH	Atiratecan	Discontinued in Phase 2
T09826	DRUGINFO	D0Q7FC	Lurtotecan	Discontinued in Phase 2
T09826	DRUGINFO	D0H2DN	DE-310	Discontinued in Phase 1
T09826	DRUGINFO	D06UFH	CZ-112	Terminated
T09826	DRUGINFO	D0B3CT	BE-13793C	Terminated
T09826	DRUGINFO	D0G9RW	TAN-1496	Terminated
T09826	DRUGINFO	D0J7AI	BN-80245	Terminated
T09826	DRUGINFO	D0OH5V	PIROXANTRONE	Terminated
T09826	DRUGINFO	D0T6VU	ED-110	Terminated
T09826	DRUGINFO	D0T7WQ	Datelliptium chloride	Terminated
T09826	DRUGINFO	D00QTU	TH-1320	Investigative
T09826	DRUGINFO	D00SSW	7-amino-4-hydroxy-2-naphthalenesulfonic acid	Investigative
T09826	DRUGINFO	D01EGN	4-(4,6-diphenylpyridin-2-yl)phenol	Investigative
T09826	DRUGINFO	D01ILT	CRISNATOL MESILATE	Investigative
T09826	DRUGINFO	D01JEX	ROSETTACIN	Investigative
T09826	DRUGINFO	D01QKX	(5Z,9Z)-5,9-heptacosadienoic acid	Investigative
T09826	DRUGINFO	D02MMY	2,3-Dimethoxybenzo[i]phenanthridines	Investigative
T09826	DRUGINFO	D02VPC	5-hydroxy-1H-indole-3-acetic acid	Investigative
T09826	DRUGINFO	D03QAS	E-758	Investigative
T09826	DRUGINFO	D03RLA	Nogalamycin	Investigative
T09826	DRUGINFO	D04DJM	4-hydroxysaprothoquinone	Investigative
T09826	DRUGINFO	D04VPP	ATI-1150	Investigative
T09826	DRUGINFO	D06VGG	KT6528	Investigative
T09826	DRUGINFO	D07ILP	10-hydroxycamptothecin	Investigative
T09826	DRUGINFO	D07VJK	IDN-6384	Investigative
T09826	DRUGINFO	D08VGL	KT6006	Investigative
T09826	DRUGINFO	D0A6NP	A35566-A	Investigative
T09826	DRUGINFO	D0C0AA	DTS-108	Investigative
T09826	DRUGINFO	D0DW4J	Dibenzo-p-dioxin-2-carboxylic acid	Investigative
T09826	DRUGINFO	D0E6QI	MEN-14295	Investigative
T09826	DRUGINFO	D0G8ZX	Homocamptothecins (hCPTs)	Investigative
T09826	DRUGINFO	D0I6EJ	3-(4-phenyl-2,4'-bipyridin-6-yl)phenol	Investigative
T09826	DRUGINFO	D0K0WK	NSC-341622	Investigative
T09826	DRUGINFO	D0M0WX	3-(6-phenyl-2,4'-bipyridin-4-yl)phenol	Investigative
T09826	DRUGINFO	D0N0VW	IDN-5174	Investigative
T09826	DRUGINFO	D0RL8X	CHO793076	Investigative
T09826	DRUGINFO	D0TH1I	4-(6-phenyl-2,4'-bipyridin-4-yl)phenol	Investigative
T09826	DRUGINFO	D0Y6OK	Quinizarin	Investigative
T09826	DRUGINFO	D0Z1VE	SER-203	Investigative
T09826	DRUGINFO	D00WYS	3-(4-phenyl-6-(thiophen-2-yl)pyridin-2-yl)-phenol	Investigative
T09826	DRUGINFO	D03JZQ	3-(4-phenyl-6-(thiophen-3-yl)pyridin-2-yl)-phenol	Investigative
T09826	DRUGINFO	D0MI5C	3,3'-(4-phenylpyridine-2,6-diyl)diphenol	Investigative
T09826	DRUGINFO	D0L8BN	TOPOSTATIN	Investigative

T72841	TARGETID	T72841
T72841	FORMERID	TTDR00270
T72841	UNIPROID	ERR1_HUMAN
T72841	TARGNAME	Estrogen-related receptor-alpha (ESRRA)
T72841	GENENAME	ESRRA
T72841	TARGTYPE	Successful
T72841	SYNONYMS	Nuclear receptor subfamily 3 group B member 1; NR3B1; Estrogen-relatedreceptor, alpha; Estrogen-relatedreceptor alpha; Estrogen-related receptor alpha; Estrogen receptor-like 1; ESRL1; ERRalpha; ERR1; ERR-alpha
T72841	FUNCTION	Can bind to the medium-chain acyl coenzyme A dehydrogenase (MCAD) response element NRRE-1 and may act as an important regulator of MCAD promoter. Binds to the C1 region of the lactoferrin gene promoter. Requires dimerization and the coactivator, PGC-1A, for full activity. The ERRalpha/PGC1alpha complex is a regulator of energy metabolism. Induces the expression of PERM1 in the skeletal muscle. Binds to an ERR-alpha response element (ERRE) containing a single consensus half-site, 5'-TNAAGGTCA-3'.
T72841	PDBSTRUC	3K6P; 3D24; 2PJL; 1XB7
T72841	BIOCLASS	Nuclear hormone receptor
T72841	SEQUENCE	MSSQVVGIEPLYIKAEPASPDSPKGSSETETEPPVALAPGPAPTRCLPGHKEEEDGEGAGPGEQGGGKLVLSSLPKRLCLVCGDVASGYHYGVASCEACKAFFKRTIQGSIEYSCPASNECEITKRRRKACQACRFTKCLRVGMLKEGVRLDRVRGGRQKYKRRPEVDPLPFPGPFPAGPLAVAGGPRKTAAPVNALVSHLLVVEPEKLYAMPDPAGPDGHLPAVATLCDLFDREIVVTISWAKSIPGFSSLSLSDQMSVLQSVWMEVLVLGVAQRSLPLQDELAFAEDLVLDEEGARAAGLGELGAALLQLVRRLQALRLEREEYVLLKALALANSDSVHIEDAEAVEQLREALHEALLEYEAGRAGPGGGAERRRAGRLLLTLPLLRQTAGKVLAHFYGVKLEGKVPMHKLFLEMLEAMMD
T72841	DRUGINFO	D0D2TN	Rimexolone	Approved
T72841	DRUGINFO	D0B4RU	Pregnenolone	Phase 4
T72841	DRUGINFO	D0W8CW	D-5519	Phase 3
T72841	DRUGINFO	D07MME	Dexamethasone palmitate	Phase 1/2
T72841	DRUGINFO	D09UGP	RPR-106541	Discontinued in Phase 2
T72841	DRUGINFO	D0G9FP	Rofleponide	Discontinued in Phase 2
T72841	DRUGINFO	D06YFO	AD-121	Discontinued in Phase 1/2
T72841	DRUGINFO	D01EDO	GW-250495	Discontinued in Phase 1
T72841	DRUGINFO	D02WUW	PLD-177	Terminated
T72841	DRUGINFO	D03RZM	Steroid hormone conjugates	Terminated
T72841	DRUGINFO	D00QDE	7-bromo-6H-chromeno[4,3-b]quinoline-3,9-diol	Investigative
T72841	DRUGINFO	D01MFT	chlordane	Investigative
T72841	DRUGINFO	D06PFK	TDT-044	Investigative
T72841	DRUGINFO	D07XJC	7-ethyl-6H-chromeno[4,3-b]quinoline-3,9-diol	Investigative
T72841	DRUGINFO	D0E7RI	PMID17556356C1a	Investigative
T72841	DRUGINFO	D0I1AF	7-vinyl-6H-chromeno[4,3-b]quinoline-3,9-diol	Investigative
T72841	DRUGINFO	D0LV7F	NCX-1047	Investigative
T72841	DRUGINFO	D0RD6G	7-ethynyl-6H-chromeno[4,3-b]quinoline-3,9-diol	Investigative
T72841	DRUGINFO	D0W1YT	7-chloro-6H-chromeno[4,3-b]quinoline-3,9-diol	Investigative
T72841	DRUGINFO	D0X6OV	toxaphene	Investigative
T72841	DRUGINFO	D0ZB7Z	XCT790	Investigative
T72841	DRUGINFO	D01TUB	4-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol	Investigative
T72841	DRUGINFO	D03CBX	4-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol	Investigative
T72841	DRUGINFO	D08SJL	4-Ethynyl-2-(4-hydroxy-phenyl)-quinolin-6-ol	Investigative
T72841	DRUGINFO	D09FWS	4-Ethyl-2-(4-hydroxy-phenyl)-quinolin-6-ol	Investigative
T72841	DRUGINFO	D0K7HR	2-(4-Hydroxy-phenyl)-4-vinyl-quinolin-6-ol	Investigative
T72841	DRUGINFO	D0S9YX	biochanin A	Investigative
T72841	DRUGINFO	D0SY2M	daidzein	Investigative

T73215	TARGETID	T73215
T73215	FORMERID	TTDS00268
T73215	UNIPROID	CD20_HUMAN
T73215	TARGNAME	Leukocyte surface antigen Leu-16 (CD20)
T73215	GENENAME	MS4A1
T73215	TARGTYPE	Successful
T73215	SYNONYMS	Membrane-spanning 4-domains subfamily A member 1; Leu-16; Bp35; B-lymphocyte surface antigen B1; B-lymphocyte antigen CD20
T73215	FUNCTION	Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR. B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes.
T73215	PDBSTRUC	3PP4; 3BKY; 2OSL; 1S8B
T73215	BIOCLASS	CD20 calcium channel
T73215	SEQUENCE	MTTPRNSVNGTFPAEPMKGPIAMQSGPKPLFRRMSSLVGPTQSFFMRESKTLGAVQIMNGLFHIALGGLLMIPAGIYAPICVTVWYPLWGGIMYIISGSLLAATEKNSRKCLVKGKMIMNSLSLFAAISGMILSIMDILNIKISHFLKMESLNFIRAHTPYINIYNCEPANPSEKNSPSTQYCYSIQSLFLGILSVMLIFAFFQELVIAGIVENEWKRTCSRPKSNIVLLSAEEKKEQTIEIKEEVVGLTETSSQPKNEEDIEIIPIQEEEEEETETNFPEPPQDQESSPIENDSSP
T73215	DRUGINFO	D01TVQ	Ibritumomab	Approved
T73215	DRUGINFO	D09EXD	Rituximab	Approved
T73215	DRUGINFO	D0A8GM	Ublituximab	Approved
T73215	DRUGINFO	D0I2AV	Tositumomab	Approved
T73215	DRUGINFO	D0S8WA	Obinutuzumab	Approved
T73215	DRUGINFO	D0Y8ZN	Ofatumumab	Approved
T73215	DRUGINFO	D0YM7U	Rituximab	Approved
T73215	DRUGINFO	D0YV4F	Ocrelizumab	Approved
T73215	DRUGINFO	D0IM6T	Tisagenlecleucel	Approved
T73215	DRUGINFO	D2HDB8	Mosunetuzumab	Approved
T73215	DRUGINFO	DB4M9J	Epcoritamab	Approved
T73215	DRUGINFO	DKF7G0	Glofitamab	Approved
T73215	DRUGINFO	D07PML	Ublituximab + umbralisib	Phase 3
T73215	DRUGINFO	D0GP8N	MK-8808	Phase 3
T73215	DRUGINFO	D0O9DK	PF-05280586	Phase 3
T73215	DRUGINFO	DJ5E7O	SAIT101	Phase 3
T73215	DRUGINFO	D08CGU	Bevacizumab + Rituximab	Phase 3
T73215	DRUGINFO	D03RRJ	Iodine-131-tositumomab	Phase 2
T73215	DRUGINFO	D07NBA	Veltuzumab	Phase 2
T73215	DRUGINFO	D0A6DY	ATM AVI	Phase 2
T73215	DRUGINFO	D0AU2T	REGN1979	Phase 2
T73215	DRUGINFO	D0KA9L	AME-133v	Phase 2
T73215	DRUGINFO	D0KX6E	DI-Leu16-IL2	Phase 2
T73215	DRUGINFO	D0M6GC	TRU-015	Phase 2
T73215	DRUGINFO	D0OR6L	CAR-T cells targeting CD20	Phase 2
T73215	DRUGINFO	D0W9QG	SBI-087	Phase 2
T73215	DRUGINFO	D0Y3HP	CD20 CAR T cells	Phase 2
T73215	DRUGINFO	DZNH43	MT-3724	Phase 2
T73215	DRUGINFO	DDIO36	Odronextamab	Phase 2
T73215	DRUGINFO	DLM8G6	Plamotamab	Phase 2
T73215	DRUGINFO	D00FIO	Anti-CD20-CAR-transduced T cells	Phase 1/2
T73215	DRUGINFO	D05PZI	MB-CART20.1	Phase 1/2
T73215	DRUGINFO	D09GSV	FBT-A05	Phase 1/2
T73215	DRUGINFO	D0E0RP	CART20	Phase 1/2
T73215	DRUGINFO	D0Q0RX	CD20-Specific CAR T Cells	Phase 1/2
T73215	DRUGINFO	D0V6VD	Anti-CD20-CAR vector-transduced autologous T cells	Phase 1/2
T73215	DRUGINFO	DT6EN8	PBCAR20A	Phase 1/2
T73215	DRUGINFO	D03ZCH	4SCAR19 and 4SCAR20	Phase 1/2
T73215	DRUGINFO	D04GIO	Anti-CD19 and Anti-CD20 CAR-T Cells	Phase 1/2
T73215	DRUGINFO	D0MA4O	Anti-CD20 CAR-T cells	Phase 1/2
T73215	DRUGINFO	D0QB1O	CD19 and CD20 CAR-T Cells	Phase 1/2
T73215	DRUGINFO	D9OMQ3	GEN3013	Phase 1/2
T73215	DRUGINFO	D01SXH	CD20-CAR-T Cells	Phase 1
T73215	DRUGINFO	D05YQL	BM-ca	Phase 1
T73215	DRUGINFO	D0A0UU	RG7828	Phase 1
T73215	DRUGINFO	D0E8ZL	CD20-CART	Phase 1
T73215	DRUGINFO	D0FL5S	CART-20 cells	Phase 1
T73215	DRUGINFO	D0L2JE	XmAb13676	Phase 1
T73215	DRUGINFO	D7X8CB	RG6035	Phase 1
T73215	DRUGINFO	D07TCV	Anti-CD19 anti-CD20 Bispecific CAR-T	Phase 1
T73215	DRUGINFO	D0NU9L	CAR-20/19-T Cells	Phase 1
T73215	DRUGINFO	D0TW3L	CD20Bi aATC	Phase 1
T73215	DRUGINFO	D51HBQ	CD20-CD19 cCAR	Phase 1
T73215	DRUGINFO	DI6BK9	KITE-363	Phase 1
T73215	DRUGINFO	DN91RC	IGM-2323	Phase 1
T73215	DRUGINFO	D0J2VB	Iboctadekin + rituximab	Phase 1
T73215	DRUGINFO	D0NL9N	Anti-CD19/20-CAR vector-transduced T cells	Clinical trial
T73215	DRUGINFO	DY2EJ1	ATA2431	Preclinical
T73215	DRUGINFO	D00GLQ	2LM20-4	Investigative
T73215	DRUGINFO	D00RTU	227Th-rituximab	Investigative
T73215	DRUGINFO	D05QGH	DXL-625	Investigative
T73215	DRUGINFO	D08CWX	BVX-20-CD20	Investigative
T73215	DRUGINFO	D08KAL	MEDI-552	Investigative
T73215	DRUGINFO	D0K9HF	BLX-301	Investigative
T73215	DRUGINFO	D0S4OH	Anti-CD20 engineered toxin bodies	Investigative
T73215	DRUGINFO	D0SN8K	Anti-CD-20 mab	Investigative

T89360	TARGETID	T89360
T89360	FORMERID	TTDS00063
T89360	UNIPROID	IMDH2_HUMAN
T89360	TARGNAME	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
T89360	GENENAME	IMPDH2
T89360	TARGTYPE	Successful
T89360	SYNONYMS	IMPDH-II; IMPDH 2; IMPD2; IMPD 2; IMP dehydrogenase 2
T89360	FUNCTION	Could also have a single-stranded nucleic acid-binding activity and could play a role in RNA and/or DNA metabolism. It may also have a role in the development of malignancy and the growth progression of some tumors. Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth.
T89360	PDBSTRUC	6I0O; 6I0M; 1NFB; 1NF7; 1B3O
T89360	BIOCLASS	CH-OH donor oxidoreductase
T89360	ECNUMBER	EC 1.1.1.205
T89360	SEQUENCE	MADYLISGGTSYVPDDGLTAQQLFNCGDGLTYNDFLILPGYIDFTADQVDLTSALTKKITLKTPLVSSPMDTVTEAGMAIAMALTGGIGFIHHNCTPEFQANEVRKVKKYEQGFITDPVVLSPKDRVRDVFEAKARHGFCGIPITDTGRMGSRLVGIISSRDIDFLKEEEHDCFLEEIMTKREDLVVAPAGITLKEANEILQRSKKGKLPIVNEDDELVAIIARTDLKKNRDYPLASKDAKKQLLCGAAIGTHEDDKYRLDLLAQAGVDVVVLDSSQGNSIFQINMIKYIKDKYPNLQVIGGNVVTAAQAKNLIDAGVDALRVGMGSGSICITQEVLACGRPQATAVYKVSEYARRFGVPVIADGGIQNVGHIAKALALGASTVMMGSLLAATTEAPGEYFFSDGIRLKKYRGMGSLDAMDKHLSSQNRYFSEADKIKVAQGVSGAVQDKGSIHKFVPYLIAGIQHSCQDIGAKSLTQVRAMMYSGELKFEKRTSSAQVEGGVHSLHSYEKRLF
T89360	DRUGINFO	D04FBR	Mycophenolate mofetil	Approved
T89360	DRUGINFO	D09HTY	Urea and carbamate bioisostere derivative 1	Patented
T89360	DRUGINFO	D00FPG	1-methyl-1H-indole-3-carboxamide	Investigative
T89360	DRUGINFO	D02YMQ	6-phenyl-3-(pyridin-4-yl)-1H-indole	Investigative
T89360	DRUGINFO	D03HDS	C4-MAD	Investigative
T89360	DRUGINFO	D04LRN	2-Benzyl-6-methoxy-5-oxazol-5-yl-1H-indole	Investigative
T89360	DRUGINFO	D05AJZ	6-bromo-1-methyl-3-(pyridin-4-yl)-1H-indole	Investigative
T89360	DRUGINFO	D05SKE	6-bromo-3-(pyridin-4-yl)-1H-indole	Investigative
T89360	DRUGINFO	D06FSR	1-methyl-1H-indole-3-carbonitrile	Investigative
T89360	DRUGINFO	D06RQV	2-methyl-3-(pyridin-4-yl)-1H-indol-6-amine	Investigative
T89360	DRUGINFO	D07HZQ	Selenazole-4-Carboxyamide-Adenine Dinucleotide	Investigative
T89360	DRUGINFO	D08OSM	3-(furan-3-yl)-1H-indole	Investigative
T89360	DRUGINFO	D0A0UW	6-Methoxy-5-oxazol-5-yl-2-phenyl-1H-indole	Investigative
T89360	DRUGINFO	D0A4AL	C2-MAD	Investigative
T89360	DRUGINFO	D0AL2E	3-(pyridin-4-yl)-1H-indol-7-amine	Investigative
T89360	DRUGINFO	D0D1KZ	1-methyl-1H-indole-3-carbaldehyde	Investigative
T89360	DRUGINFO	D0D2ST	2-methyl-3-(pyridin-4-yl)-1H-indole	Investigative
T89360	DRUGINFO	D0G3BY	3-(3-cyano-1H-indol-6-yl)-1-methyl-1-phenylurea	Investigative
T89360	DRUGINFO	D0H1II	1-(3-cyano-1-methyl-1H-indol-6-yl)-3-phenylurea	Investigative
T89360	DRUGINFO	D0J9OS	3-(furan-3-yl)-1-methyl-1H-indole	Investigative
T89360	DRUGINFO	D0K4EM	3-(pyridin-4-yl)-1H-indol-6-amine	Investigative
T89360	DRUGINFO	D0L0MJ	Rockout	Investigative
T89360	DRUGINFO	D0L0ZP	3-methoxy-4-(oxazol-5-yl)aniline	Investigative
T89360	DRUGINFO	D0Q3WC	1-methoxy-3-(3-(pyridin-4-yl)-1H-indol-6-yl)urea	Investigative
T89360	DRUGINFO	D0V0YP	3-(thiophen-3-yl)-1H-indol-6-amine	Investigative
T89360	DRUGINFO	D0Z0YB	N-benzyl-9-oxo-9,10-dihydroacridine-3-carboxamide	Investigative
T89360	DRUGINFO	D0ZG3O	Ethyl 3-(pyridin-4-yl)-1H-indole-6-carboxylate	Investigative
T89360	DRUGINFO	D01LDQ	Mycophenolic hydroxamic acid	Investigative
T89360	DRUGINFO	D0S4BK	Tiazofurin adenine dinucleotide	Investigative
T89360	DRUGINFO	D0T4UE	Mycophenolic bis(sulfonamide)	Investigative
T89360	DRUGINFO	D0VD5N	6-Chloropurine Riboside, 5'-Monophosphate	Investigative
T89360	DRUGINFO	D0H2YT	Inosinic Acid	Investigative
T89360	DRUGINFO	D0R6JE	Nicotinamide-Adenine-Dinucleotide	Investigative

T82146	TARGETID	T82146
T82146	FORMERID	TTDS00075
T82146	UNIPROID	RARG_HUMAN
T82146	TARGNAME	Retinoic acid receptor gamma (RARG)
T82146	GENENAME	RARG
T82146	TARGTYPE	Successful
T82146	SYNONYMS	RAR-gamma; Nuclear receptor subfamily 1 group B member 3; NR1B3
T82146	FUNCTION	Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence of ligand, acts mainly as an activator of gene expression due to weak binding to corepressors. Required for limb bud development. In concert with RARA or RARB, required for skeletal growth, matrix homeostasis and growth plate function (By similarity).
T82146	PDBSTRUC	6FX0; 5M24; 4LBD; 3LBD; 2LBD
T82146	BIOCLASS	Nuclear hormone receptor
T82146	SEQUENCE	MATNKERLFAAGALGPGSGYPGAGFPFAFPGALRGSPPFEMLSPSFRGLGQPDLPKEMASLSVETQSTSSEEMVPSSPSPPPPPRVYKPCFVCNDKSSGYHYGVSSCEGCKGFFRRSIQKNMVYTCHRDKNCIINKVTRNRCQYCRLQKCFEVGMSKEAVRNDRNKKKKEVKEEGSPDSYELSPQLEELITKVSKAHQETFPSLCQLGKYTTNSSADHRVQLDLGLWDKFSELATKCIIKIVEFAKRLPGFTGLSIADQITLLKAACLDILMLRICTRYTPEQDTMTFSDGLTLNRTQMHNAGFGPLTDLVFAFAGQLLPLEMDDTETGLLSAICLICGDRMDLEEPEKVDKLQEPLLEALRLYARRRRPSQPYMFPRMLMKITDLRGISTKGAERAITLKMEIPGPMPPLIREMLENPEMFEDDSSQPGPHPNASSEDEVPGGQGKGGLKSPA
T82146	DRUGINFO	D06FOU	Trifarotene	Approved
T82146	DRUGINFO	D0BM5G	Tazarotene	Approved
T82146	DRUGINFO	D0H8OH	Palovarotene	Approved
T82146	DRUGINFO	D02DGU	Tretinoin	Approved
T82146	DRUGINFO	D0G3PI	Alitretinoin	Approved
T82146	DRUGINFO	D01OYE	PMID27336223-Compound-13	Patented
T82146	DRUGINFO	D09YFJ	PMID27336223-Compound-12	Patented
T82146	DRUGINFO	D0MC3J	PMID27336223-Compound-14	Patented
T82146	DRUGINFO	D0W8JK	PMID27336223-Compound-11	Patented
T82146	DRUGINFO	D0YP0T	PMID27336223-Compound-15	Patented
T82146	DRUGINFO	D0ZQ0X	PMID27336223-Compound-9	Patented
T82146	DRUGINFO	D05DWG	Dodecyl-Alpha-D-Maltoside	Investigative
T82146	DRUGINFO	D06RAM	MM 11253	Investigative
T82146	DRUGINFO	D0A6NQ	AHPN	Investigative
T82146	DRUGINFO	D0E3SB	SR11254	Investigative
T82146	DRUGINFO	D0M3LK	BMS270394	Investigative
T82146	DRUGINFO	D0O6QU	CD564	Investigative
T82146	DRUGINFO	D0OM2S	BMS184394	Investigative
T82146	DRUGINFO	D0Y6WJ	CD2665	Investigative
T82146	DRUGINFO	D0F8CC	CD666	Investigative
T82146	DRUGINFO	D0Q0IR	AGN193109	Investigative

T67162	TARGETID	T67162
T67162	FORMERID	TTDS00012
T67162	UNIPROID	DRD2_HUMAN
T67162	TARGNAME	Dopamine D2 receptor (D2R)
T67162	GENENAME	DRD2
T67162	TARGTYPE	Successful
T67162	SYNONYMS	Dopamine receptor 2; D(2) dopamine receptor
T67162	FUNCTION	Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
T67162	PDBSTRUC	6CM4; 5AER; 1I15
T67162	BIOCLASS	GPCR rhodopsin
T67162	SEQUENCE	MDPLNLSWYDDDLERQNWSRPFNGSDGKADRPHYNYYATLLTLLIAVIVFGNVLVCMAVSREKALQTTTNYLIVSLAVADLLVATLVMPWVVYLEVVGEWKFSRIHCDIFVTLDVMMCTASILNLCAISIDRYTAVAMPMLYNTRYSSKRRVTVMISIVWVLSFTISCPLLFGLNNADQNECIIANPAFVVYSSIVSFYVPFIVTLLVYIKIYIVLRRRRKRVNTKRSSRAFRAHLRAPLKGNCTHPEDMKLCTVIMKSNGSFPVNRRRVEAARRAQELEMEMLSSTSPPERTRYSPIPPSHHQLTLPDPSHHGLHSTPDSPAKPEKNGHAKDHPKIAKIFEIQTMPNGKTRTSLKTMSRRKLSQQKEKKATQMLAIVLGVFIICWLPFFITHILNIHCDCNIPPVLYSAFTWLGYVNSAVNPIIYTTFNIEFRKAFLKILHC
T67162	DRUGINFO	D00HHS	Pseudoephedrine	Approved
T67162	DRUGINFO	D00KHM	Pimozide	Approved
T67162	DRUGINFO	D01AZG	Risperidone	Approved
T67162	DRUGINFO	D01JUF	Phentolamine	Approved
T67162	DRUGINFO	D01QML	Carphenazine	Approved
T67162	DRUGINFO	D01SAT	Bevantolol	Approved
T67162	DRUGINFO	D01ZII	Chlorpromazine	Approved
T67162	DRUGINFO	D02HED	Perphenazine	Approved
T67162	DRUGINFO	D03CJL	Droperidol	Approved
T67162	DRUGINFO	D03ELL	Amisulpride	Approved
T67162	DRUGINFO	D03QGM	Sulpiride	Approved
T67162	DRUGINFO	D03RZV	Tolazoline	Approved
T67162	DRUGINFO	D04AAN	Mesoridazine	Approved
T67162	DRUGINFO	D04EGX	Cabergoline	Approved
T67162	DRUGINFO	D04EYC	Metaraminol	Approved
T67162	DRUGINFO	D06YFA	Bromocriptine	Approved
T67162	DRUGINFO	D07JWT	Perazine	Approved
T67162	DRUGINFO	D08HVR	Levodopa	Approved
T67162	DRUGINFO	D08VYV	Metoclopramide	Approved
T67162	DRUGINFO	D09LZT	Levomepromazine	Approved
T67162	DRUGINFO	D09OQV	N-0923	Approved
T67162	DRUGINFO	D09TPF	Molindone	Approved
T67162	DRUGINFO	D0AO6B	Piperacetazine	Approved
T67162	DRUGINFO	D0AV3G	Domperidone	Approved
T67162	DRUGINFO	D0B0CP	Chlorprothixene	Approved
T67162	DRUGINFO	D0B2UZ	Prochlorperazine	Approved
T67162	DRUGINFO	D0BA6T	Methyldopa	Approved
T67162	DRUGINFO	D0C1IW	Ergonovine	Approved
T67162	DRUGINFO	D0D1AL	Haloperidol	Approved
T67162	DRUGINFO	D0E0LQ	Thiothixene	Approved
T67162	DRUGINFO	D0G1OZ	Mephentermine	Approved
T67162	DRUGINFO	D0H3HM	Aripiprazole	Approved
T67162	DRUGINFO	D0H6QU	Apomorphine	Approved
T67162	DRUGINFO	D0H7KF	Quetiapine	Approved
T67162	DRUGINFO	D0I8LU	Zuclopenthixol	Approved
T67162	DRUGINFO	D0IN7I	Nemonapride	Approved
T67162	DRUGINFO	D0K2TB	Docarpamine	Approved
T67162	DRUGINFO	D0L0MB	Acetophenazine	Approved
T67162	DRUGINFO	D0LG8E	Ephedrine	Approved
T67162	DRUGINFO	D0O6IU	Phenylephrine	Approved
T67162	DRUGINFO	D0O6IZ	Naphazoline	Approved
T67162	DRUGINFO	D0Q9ON	Denopamine	Approved
T67162	DRUGINFO	D0T2IA	Dapiprazole	Approved
T67162	DRUGINFO	D0T7OW	Dopamine	Approved
T67162	DRUGINFO	D0U1OE	Thioridazine	Approved
T67162	DRUGINFO	D0U5FS	Fluspirilene	Approved
T67162	DRUGINFO	D0U5OE	Loxapine	Approved
T67162	DRUGINFO	D0U9QU	Ibopamine hci	Approved
T67162	DRUGINFO	D0V3ZA	Dihydroergotamine	Approved
T67162	DRUGINFO	D0V4QS	Olanzapine	Approved
T67162	DRUGINFO	D0V7XF	Dopexamine	Approved
T67162	DRUGINFO	D0W9ZF	Quinagolide	Approved
T67162	DRUGINFO	D0X2DK	Phenoxybenzamine	Approved
T67162	DRUGINFO	D0X7KB	Lisuride	Approved
T67162	DRUGINFO	D0Y0ER	Thiethylperazine	Approved
T67162	DRUGINFO	D01QGX	Lurasidone hydrochloride	Approved
T67162	DRUGINFO	D02DPU	Aniracetam	Approved
T67162	DRUGINFO	D02LCR	Tiapride	Approved
T67162	DRUGINFO	D04JCN	Pergolide	Approved
T67162	DRUGINFO	D05XGO	Cariprazine	Approved
T67162	DRUGINFO	D07MEH	Meglitinides	Approved
T67162	DRUGINFO	D0G8NN	Pramipexole	Approved
T67162	DRUGINFO	D0M8VE	Iloperidone	Approved
T67162	DRUGINFO	D0P0OU	OPC-34712	Approved
T67162	DRUGINFO	D0P6UB	Methamphetamine	Approved
T67162	DRUGINFO	D0R1JV	Ziprasidone	Approved
T67162	DRUGINFO	D0R9EQ	Ropinirole	Approved
T67162	DRUGINFO	D0SP3D	Dihydroergotoxine	Approved
T67162	DRUGINFO	D1CWL0	lumateperone tosylate	Approved
T67162	DRUGINFO	D0KS6W	Phenyltoloxamine	Approved
T67162	DRUGINFO	D0Y7XC	Talipexole	Phase 4
T67162	DRUGINFO	D04NPR	Lu AF35700	Phase 3
T67162	DRUGINFO	D07GJZ	CQA 206-291	Phase 3
T67162	DRUGINFO	D07YVK	Sumanirole	Phase 3
T67162	DRUGINFO	D0F4SY	Pridopidine	Phase 3
T67162	DRUGINFO	D0O5TR	RBP-7000	Phase 3
T67162	DRUGINFO	DB6IM8	esamisulpride	Phase 3
T67162	DRUGINFO	D05UAV	Bis(olanzapine) pamoate monohydrate	Phase 3
T67162	DRUGINFO	D08GJH	Blonanserin	Phase 3
T67162	DRUGINFO	D0R2NE	Entacapone+levodopa+carbidopa	Phase 3
T67162	DRUGINFO	D01NKW	P2B-001	Phase 3
T67162	DRUGINFO	D02YVM	Zicronapine	Phase 3
T67162	DRUGINFO	D0W5EH	Sarizotan	Phase 2/3
T67162	DRUGINFO	D01GEB	ROXINDOLE	Phase 2
T67162	DRUGINFO	D02UJD	PD-143188	Phase 2
T67162	DRUGINFO	D06MNF	Pardoprunox	Phase 2
T67162	DRUGINFO	D09QAD	CGS-15873A	Phase 2
T67162	DRUGINFO	D0C8PE	JNJ-37822681	Phase 2
T67162	DRUGINFO	D0P3SJ	XP-21279	Phase 2
T67162	DRUGINFO	D0T1HE	APD-403	Phase 2
T67162	DRUGINFO	D0XE0X	Aplindore fumarate	Phase 2
T67162	DRUGINFO	D04FNQ	BIM23A760	Phase 2
T67162	DRUGINFO	D04JZP	Mazapertine succinate	Phase 2
T67162	DRUGINFO	D04VHK	CLR-3001	Phase 2
T67162	DRUGINFO	D08FKX	SDZ-MAR-327	Phase 2
T67162	DRUGINFO	D0L6OA	BL-1020	Phase 2
T67162	DRUGINFO	D2L8NT	TBR-760	Phase 2
T67162	DRUGINFO	DD5VO3	TAK-906	Phase 2
T67162	DRUGINFO	DS31JZ	SEP--4199	Phase 2
T67162	DRUGINFO	D01FQR	Ocaperidone	Phase 2
T67162	DRUGINFO	D07XQS	ONC201	Phase 2
T67162	DRUGINFO	D05XEA	RP5063	Phase 2
T67162	DRUGINFO	D0B9DI	Lu-AE04621	Phase 1
T67162	DRUGINFO	D0CH4T	Lu-02-750	Phase 1
T67162	DRUGINFO	D0J0WX	(-)-3PPP, Maryland	Phase 1
T67162	DRUGINFO	D0K2PS	Carmoxirole	Phase 1
T67162	DRUGINFO	D6P9OU	ONC206	Phase 1
T67162	DRUGINFO	D00ZEG	Umespirone	Phase 1
T67162	DRUGINFO	D02JGD	SKL-10406	Phase 1
T67162	DRUGINFO	D0A7KI	Abaperidone	Phase 1
T67162	DRUGINFO	D0K0GF	SSR-181507	Phase 1
T67162	DRUGINFO	D0N4NJ	YKP-1358	Phase 1
T67162	DRUGINFO	DJ2OV7	Lu AF28996	Phase 1
T67162	DRUGINFO	D06NOF	ATI-9242	Phase 1
T67162	DRUGINFO	D0AI8V	DSP-1200	Phase 1
T67162	DRUGINFO	D0C7WO	1192U90	Phase 1
T67162	DRUGINFO	D05KKZ	PMID29334795-Compound-67	Patented
T67162	DRUGINFO	D0BZ0N	Benzo[d]oxazol-2(3H)-one derivative 2	Patented
T67162	DRUGINFO	D0D5AH	PMID29334795-Compound-62	Patented
T67162	DRUGINFO	D0N8CU	Benzo[d]oxazol-2(3H)-one derivative 3	Patented
T67162	DRUGINFO	D0RP1J	PMID29334795-Compound-66	Patented
T67162	DRUGINFO	D0SO4O	Benzo[d]oxazol-2(3H)-one derivative 1	Patented
T67162	DRUGINFO	D0E7FT	PMID30124346-Compound-60TABLE5	Patented
T67162	DRUGINFO	D0J4AZ	L-piperazino-3-phenyl-indane derivative 1	Patented
T67162	DRUGINFO	D0M1UF	Aryl piperazine derivative 1	Patented
T67162	DRUGINFO	D0Z9WY	Aryl piperazine derivative 6	Patented
T67162	DRUGINFO	D09BCJ	PMID30124346-Compound-34TABLE4	Patented
T67162	DRUGINFO	D0F4NB	PMID30124346-Compound-13TABLE4	Patented
T67162	DRUGINFO	D01PIL	Remoxipride	Withdrawn from market
T67162	DRUGINFO	D06BPG	Nomifensine	Withdrawn from market
T67162	DRUGINFO	D0OC3J	Flupenthixol	Withdrawn from market
T67162	DRUGINFO	D0OS6O	Sertindole	Withdrawn from market
T67162	DRUGINFO	D0P3DM	Fencamfamine	Withdrawn from market
T67162	DRUGINFO	D0QU8H	(S)-amisulpride	Discontinued in Phase 4
T67162	DRUGINFO	D0Q6SD	Lamectacin	Discontinued in Phase 3
T67162	DRUGINFO	D01DAW	Bifeprunox	Discontinued in Phase 3
T67162	DRUGINFO	D02ALD	NOLOMIROLE HYDROCHLORIDE	Discontinued in Phase 3
T67162	DRUGINFO	D0C5PA	Sibenadet	Discontinued in Phase 3
T67162	DRUGINFO	D01RCS	TIOSPIRONE	Discontinued in Phase 3
T67162	DRUGINFO	D02JMI	SLV-310	Discontinued in Phase 2
T67162	DRUGINFO	D02VUX	PF-217830	Discontinued in Phase 2
T67162	DRUGINFO	D0K1DC	Romergoline	Discontinued in Phase 2
T67162	DRUGINFO	D0N8NC	SAVOXEPIN MESYLATE	Discontinued in Phase 2
T67162	DRUGINFO	D0TH1Z	Naxagolide	Discontinued in Phase 2
T67162	DRUGINFO	D0X8QP	FOSOPAMINE	Discontinued in Phase 2
T67162	DRUGINFO	D02KKQ	BAM-1110	Discontinued in Phase 2
T67162	DRUGINFO	D09EEV	Declopramide	Discontinued in Phase 2
T67162	DRUGINFO	D01WJZ	MAZAPERTINE	Discontinued in Phase 2
T67162	DRUGINFO	D0A8FD	S-18327	Discontinued in Phase 1
T67162	DRUGINFO	D0OZ4F	Ordopidine	Discontinued in Phase 1
T67162	DRUGINFO	D03ZZH	SLV-313	Discontinued in Phase 1
T67162	DRUGINFO	D09WHM	DU-29894	Discontinued in Phase 1
T67162	DRUGINFO	D0LE7P	SDZ-GLC-756	Discontinued in Phase 1
T67162	DRUGINFO	D0A8IE	AM-831	Discontinued in Phase 1
T67162	DRUGINFO	D0Q3GV	S32504	Preclinical
T67162	DRUGINFO	D0R1PZ	F-15063	Preclinical
T67162	DRUGINFO	D0U1CL	PGX-200097	Preclinical
T67162	DRUGINFO	D04UXX	PD-158771	Preclinical
T67162	DRUGINFO	D0N5NM	Org-23366	Preclinical
T67162	DRUGINFO	D0F6WV	PD-157695	Preclinical
T67162	DRUGINFO	D01TSN	PD-128483	Terminated
T67162	DRUGINFO	D02ONK	Y-20024	Terminated
T67162	DRUGINFO	D04LFG	CGP-25454A	Terminated
T67162	DRUGINFO	D05KTV	NGD-93-1	Terminated
T67162	DRUGINFO	D07VMC	LY-243062	Terminated
T67162	DRUGINFO	D0A7PW	CP-903397	Terminated
T67162	DRUGINFO	D0CQ8D	AMR-103	Terminated
T67162	DRUGINFO	D0LS4U	Etrabamine	Terminated
T67162	DRUGINFO	D0Q0HR	Y-931	Terminated
T67162	DRUGINFO	D03NPZ	NNC-22-0031	Terminated
T67162	DRUGINFO	D08IRR	Org-10490	Terminated
T67162	DRUGINFO	D0G3MH	PNU-96391A	Terminated
T67162	DRUGINFO	D0N1WM	A-68930	Terminated
T67162	DRUGINFO	D0R9PL	RWJ-25730	Terminated
T67162	DRUGINFO	D0U4WG	SLV-307	Terminated
T67162	DRUGINFO	D05RMW	ZD-3638	Terminated
T67162	DRUGINFO	D0A3OF	GMC-283	Terminated
T67162	DRUGINFO	D0EH2O	BIMG80	Terminated
T67162	DRUGINFO	D0P3IZ	E-2040	Terminated
T67162	DRUGINFO	D0N5UA	Dianicline+rimonabant	Terminated
T67162	DRUGINFO	D0K9JP	A-80426	Terminated
T67162	DRUGINFO	D00CPI	1-(3-Hydroxyphenyl)-4-propylpiperazine	Investigative
T67162	DRUGINFO	D00DHM	SDZ-208911	Investigative
T67162	DRUGINFO	D00HHK	PD-135478	Investigative
T67162	DRUGINFO	D01ADA	N-Propyl-2-methylnorapomorphine hydrochloride	Investigative
T67162	DRUGINFO	D01HZE	BRL-25594	Investigative
T67162	DRUGINFO	D01KLI	1-Propyl-3-m-tolyl-piperidine hydrochloride	Investigative
T67162	DRUGINFO	D01KWU	Uinagolide	Investigative
T67162	DRUGINFO	D01YNL	PD-137789	Investigative
T67162	DRUGINFO	D02OEI	3-(2,3-Dimethyl-phenyl)-piperidine	Investigative
T67162	DRUGINFO	D02RMS	Ethyl-(4,5,6,7-tetrahydro-2H-indazol-5-yl)-amine	Investigative
T67162	DRUGINFO	D03KUH	ETICLOPRIDE	Investigative
T67162	DRUGINFO	D03TYT	PF-03800130	Investigative
T67162	DRUGINFO	D04AAI	1-Benzyl-4-[3-(methylsulfonyl)phenyl]piperazine	Investigative
T67162	DRUGINFO	D04HPX	MCL-515	Investigative
T67162	DRUGINFO	D04JUJ	1-Methyl-1,2,3,4-tetrahydro-isoquinoline-6,7-diol	Investigative
T67162	DRUGINFO	D04LWD	4-Benzyl-1-indan-2-ylmethyl-piperidine	Investigative
T67162	DRUGINFO	D04PBD	MLS1547	Investigative
T67162	DRUGINFO	D04ZYA	3-(Octahydro-indolizin-8-yl)-phenol	Investigative
T67162	DRUGINFO	D05AIN	1-Benzyl-4-(3-hydroxyphenyl)piperidine	Investigative
T67162	DRUGINFO	D05ARI	Propyl-(4,5,6,7-tetrahydro-2H-indazol-5-yl)-amine	Investigative
T67162	DRUGINFO	D05DTJ	3-Phenyl-1-propyl-piperidine hydrochloride	Investigative
T67162	DRUGINFO	D05EHE	(S,R)-pseudoxandrine hydrochloride	Investigative
T67162	DRUGINFO	D05GBE	3-(Octahydro-quinolizin-3-yl)-phenol	Investigative
T67162	DRUGINFO	D05NET	PD-137821	Investigative
T67162	DRUGINFO	D05NZI	BRL-26175	Investigative
T67162	DRUGINFO	D05TZE	SKF-89124A	Investigative
T67162	DRUGINFO	D05XNR	2,3-Dihydro-1H-indol-5-ol	Investigative
T67162	DRUGINFO	D06CXG	PD-135540	Investigative
T67162	DRUGINFO	D06FUV	Preclamol	Investigative
T67162	DRUGINFO	D06GGB	N-Ethyl-2-phenylnorapomorphine hydrochloride	Investigative
T67162	DRUGINFO	D06XKX	N-Propyl-2-phenylnorapomorphine hydrochloride	Investigative
T67162	DRUGINFO	D06YYJ	Bis-{[R-(-)-apomorphine-2-oxy]ethyl} ether	Investigative
T67162	DRUGINFO	D08OUX	IODOPRIDE	Investigative
T67162	DRUGINFO	D09CFW	ML321	Investigative
T67162	DRUGINFO	D0A3XB	PD-135188	Investigative
T67162	DRUGINFO	D0B1FV	(S,R)-isotetrandrine hydrochloride	Investigative
T67162	DRUGINFO	D0BN9C	(S)-secoantioquine hydrochloride	Investigative
T67162	DRUGINFO	D0C6KQ	IODOSULPIRIDE	Investigative
T67162	DRUGINFO	D0C8WL	EPIDEPRIDE	Investigative
T67162	DRUGINFO	D0E3AL	UNC0006	Investigative
T67162	DRUGINFO	D0E4JL	Rotigitine	Investigative
T67162	DRUGINFO	D0G2HT	1-Benzyl-4-[3-(methylsulfonyl)phenyl]piperidine	Investigative
T67162	DRUGINFO	D0G5PK	3-Cyclohexyl-1-propyl-piperidine hydrochloride	Investigative
T67162	DRUGINFO	D0G8CV	SLV-314	Investigative
T67162	DRUGINFO	D0G8VU	PD-168077	Investigative
T67162	DRUGINFO	D0GI7S	3-Phenyl-pyrrolidine	Investigative
T67162	DRUGINFO	D0H2GH	3-(3,4-Dimethyl-phenyl)-1-propyl-piperidine	Investigative
T67162	DRUGINFO	D0H2IT	PD-172939	Investigative
T67162	DRUGINFO	D0H7RN	PD-135146	Investigative
T67162	DRUGINFO	D0H9GP	PD-135111	Investigative
T67162	DRUGINFO	D0J2NS	Anti-D	Investigative
T67162	DRUGINFO	D0J8RP	3-(2,3-Dimethyl-phenyl)-1-propyl-piperidine	Investigative
T67162	DRUGINFO	D0K6QX	3-(2,6-Dimethyl-phenyl)-1-propyl-piperidine	Investigative
T67162	DRUGINFO	D0L1IS	NOR-ROEFRACTINE	Investigative
T67162	DRUGINFO	D0L4FJ	PD-135385	Investigative
T67162	DRUGINFO	D0L7ZD	UNC9975	Investigative
T67162	DRUGINFO	D0L8NG	(5-Methoxy-chroman-3-yl)-dipropyl-amine	Investigative
T67162	DRUGINFO	D0M9TM	3-(3,5-Dimethyl-phenyl)-1-propyl-piperidine	Investigative
T67162	DRUGINFO	D0MT1N	N-Ethyl-2-methylnorapomorphine hydrochloride	Investigative
T67162	DRUGINFO	D0N6FZ	WS-50030	Investigative
T67162	DRUGINFO	D0N7WB	CLR-151	Investigative
T67162	DRUGINFO	D0P7OB	PD-172938	Investigative
T67162	DRUGINFO	D0Q0KD	1-Propyl-3-o-tolyl-piperidine hydrochloride	Investigative
T67162	DRUGINFO	D0Q2MX	UNC9994	Investigative
T67162	DRUGINFO	D0Q4BK	PD-135222	Investigative
T67162	DRUGINFO	D0R5ZL	S-(-)-sulpiride	Investigative
T67162	DRUGINFO	D0R6LU	1-Propyl-3-p-tolyl-piperidine hydrochloride	Investigative
T67162	DRUGINFO	D0R9KV	3-(2,5-Dimethyl-phenyl)-1-propyl-piperidine	Investigative
T67162	DRUGINFO	D0S1GB	3-(3,4-Dimethyl-phenyl)-piperidine	Investigative
T67162	DRUGINFO	D0U6BT	Rolicyclidine	Investigative
T67162	DRUGINFO	D0UL6I	3-(Octahydro-quinolizin-1-yl)-phenol	Investigative
T67162	DRUGINFO	D0V3WS	(S,R)-antioquine hydrochloride	Investigative
T67162	DRUGINFO	D0VE4Z	7-(2-Dipropylamino-ethyl)-3H-benzothiazol-2-one	Investigative
T67162	DRUGINFO	D0X3JB	1-[3-(Methylsulfonyl)phenyl]-4-propylpiperazine	Investigative
T67162	DRUGINFO	D0X5LJ	3-(N-propylpiperidin-4-yl)phenol	Investigative
T67162	DRUGINFO	D0Y2BL	7-(2-Amino-ethyl)-4-hydroxy-3H-benzothiazol-2-one	Investigative
T67162	DRUGINFO	D0Y3UL	3-(3,5-Dimethyl-phenyl)-piperidine	Investigative
T67162	DRUGINFO	D0Z4VD	3-(2,4-Dimethyl-phenyl)-1-propyl-piperidine	Investigative
T67162	DRUGINFO	D00CDM	PD 128907	Investigative
T67162	DRUGINFO	D00JJO	1-[(3-methoxybenzyl)oxy]-2-(2-phenylethyl)benzene	Investigative
T67162	DRUGINFO	D00QMQ	D-220	Investigative
T67162	DRUGINFO	D00SDJ	A-706149	Investigative
T67162	DRUGINFO	D00VHW	4-Benzyl-1-chroman-3-ylmethyl-piperidine	Investigative
T67162	DRUGINFO	D02RAY	GLAUCINE	Investigative
T67162	DRUGINFO	D02XXA	3-Phenyl-1-propyl-pyrrolidine	Investigative
T67162	DRUGINFO	D03EDW	D-193	Investigative
T67162	DRUGINFO	D03PYX	[3H]7-OH-DPAT	Investigative
T67162	DRUGINFO	D03RMB	2-{[R-(-)-Apomorphine-2'-oxy]ethoxy}-ethanol	Investigative
T67162	DRUGINFO	D03YXB	(+)-(1R,1'S)-berbamunine hydrochloride	Investigative
T67162	DRUGINFO	D03ZOJ	D-189	Investigative
T67162	DRUGINFO	D04GRS	(S)-BULBOCAPNINE	Investigative
T67162	DRUGINFO	D04IIK	(R)-(-)-N-ethyl-2-methoxy-11-hydroxynoraporphine	Investigative
T67162	DRUGINFO	D04PBA	3-(4-Benzyl-piperazin-1-yl)-phenol	Investigative
T67162	DRUGINFO	D04RBU	D-366	Investigative
T67162	DRUGINFO	D04TQF	1-(benzyloxy)-2-[2-(3-methoxyphenyl)ethyl]benzene	Investigative
T67162	DRUGINFO	D04TTN	(+)-(1R,1'S)-thaligrisine hydrochloride	Investigative
T67162	DRUGINFO	D04ZMS	3-(4-Benzyl-piperidin-1-ylmethyl)-chroman-4-one	Investigative
T67162	DRUGINFO	D05HMW	2-(4-Dipropylamino-cyclohexylidene)-malononitrile	Investigative
T67162	DRUGINFO	D05HWC	PUKATEINE	Investigative
T67162	DRUGINFO	D05NBK	1-Aminomethyl-3-cyclohexyl-isochroman-5,6-diol	Investigative
T67162	DRUGINFO	D05NED	D-190	Investigative
T67162	DRUGINFO	D05OHF	(R)-(+)-coclaurine	Investigative
T67162	DRUGINFO	D06AIQ	IBZM	Investigative
T67162	DRUGINFO	D06HTJ	D-264	Investigative
T67162	DRUGINFO	D07ISL	D-210	Investigative
T67162	DRUGINFO	D08DLP	3-Chloroboldine	Investigative
T67162	DRUGINFO	D08EMG	(S)APOMORPHINE	Investigative
T67162	DRUGINFO	D08HTJ	2-methoxyapomorphine	Investigative
T67162	DRUGINFO	D08UQU	(R)-(-)-2-methoxy-11-hydroxyaporphine	Investigative
T67162	DRUGINFO	D09AQJ	D-203	Investigative
T67162	DRUGINFO	D09MGF	1-(benzyloxy)-2-(2-phenylethyl)benzene	Investigative
T67162	DRUGINFO	D09PJF	D-315	Investigative
T67162	DRUGINFO	D09QRL	2-Methyl-8-phenyl-1,2,3,4-tetrahydro-isoquinoline	Investigative
T67162	DRUGINFO	D0A2BE	CLEBOPRIDE	Investigative
T67162	DRUGINFO	D0A4GE	1,2,3,7,12,12a-hexahydro-1-aza-pleiadene-5,6-diol	Investigative
T67162	DRUGINFO	D0A7AK	3-{[2-(2-phenylethyl)phenoxy]methyl}pyridine	Investigative
T67162	DRUGINFO	D0B4SL	D-218	Investigative
T67162	DRUGINFO	D0C7SE	SNAP-94847	Investigative
T67162	DRUGINFO	D0CA9H	N-Benzyl-4-(2-diphenyl)-1-piperazinehexanamide	Investigative
T67162	DRUGINFO	D0D1PR	(R)-(-)-2-methoxy-N-npropylnorapomorphine	Investigative
T67162	DRUGINFO	D0D2CU	(R)-(-)-2-Methyl-apomorphine hydrochloride	Investigative
T67162	DRUGINFO	D0FU2V	D-237	Investigative
T67162	DRUGINFO	D0G3MD	(4-Quinolin-2-ylpiperazin-1-yl)acetic Acid	Investigative
T67162	DRUGINFO	D0H9QG	SB-258719	Investigative
T67162	DRUGINFO	D0HG4U	(R)-(-)-2-Phenyl-apomorphine hydrochloride	Investigative
T67162	DRUGINFO	D0HO7I	ANONAINE	Investigative
T67162	DRUGINFO	D0I7CE	SK&F-89626	Investigative
T67162	DRUGINFO	D0M1OE	ANOLOBINE	Investigative
T67162	DRUGINFO	D0M5XV	D-219	Investigative
T67162	DRUGINFO	D0M7SY	SB269652	Investigative
T67162	DRUGINFO	D0M8LN	A-690344	Investigative
T67162	DRUGINFO	D0N9DY	3-Iodoboldine	Investigative
T67162	DRUGINFO	D0NA2T	(R)-(-)-N-propyl-2-methoxy-11-hydroxynoraporphine	Investigative
T67162	DRUGINFO	D0ND8J	(-)-(1S,1'R)-O,O-dimethylgrisbine hydrochloride	Investigative
T67162	DRUGINFO	D0P4BY	SCH-24518	Investigative
T67162	DRUGINFO	D0P6LN	3-Butyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-ol	Investigative
T67162	DRUGINFO	D0P8AW	Ro-21-7767	Investigative
T67162	DRUGINFO	D0PC2C	3-Ethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-ol	Investigative
T67162	DRUGINFO	D0PV6G	(+)-S-14297	Investigative
T67162	DRUGINFO	D0Q7FM	Azaperone	Investigative
T67162	DRUGINFO	D0R5WX	4-Benzyl-1-chroman-2-ylmethyl-piperidine	Investigative
T67162	DRUGINFO	D0RQ8R	2-{[2-(2-phenylethyl)phenoxy]methyl}pyridine	Investigative
T67162	DRUGINFO	D0S5ZE	D-192	Investigative
T67162	DRUGINFO	D0S7WZ	(-)-3-(1-Propyl-piperidin-3-yl)-benzonitrile	Investigative
T67162	DRUGINFO	D0TA8F	(S,S)-oxandrine hydrochloride	Investigative
T67162	DRUGINFO	D0U6IL	1-Aminomethyl-isochroman-5,6-diol	Investigative
T67162	DRUGINFO	D0V3DO	1,2-Bis-[R-(-)-apomorphine-2'-oxy]ethane	Investigative
T67162	DRUGINFO	D0YB0K	7-trans-OH-PIPAT	Investigative
T67162	DRUGINFO	D0Z9JY	[R-(-)-Apomorphine-2-yl]-(2'-hydroxy-ethyl)ether	Investigative
T67162	DRUGINFO	D00GSD	LP-211	Investigative
T67162	DRUGINFO	D00HUV	[2-(1H-Benzoimidazol-4-yloxy)-ethyl]-benzyl-amine	Investigative
T67162	DRUGINFO	D01KIH	4-(4-Benzyl-piperazin-1-yl)-1H-benzoimidazole	Investigative
T67162	DRUGINFO	D03GES	1-Benzyl-4-(3-oxazol-5-yl-pyrrol-1-yl)-piperidine	Investigative
T67162	DRUGINFO	D03JOS	3-(4-Phenyl-piperazin-1-ylmethyl)-1H-indole	Investigative
T67162	DRUGINFO	D04CTN	3-(1-Propyl-pyrrolidin-3-yl)-phenol	Investigative
T67162	DRUGINFO	D04KGP	(R)-(-)-11-hydroxy-N-n-propylnoraporphine	Investigative
T67162	DRUGINFO	D04MVL	(R)-(-)-10-methyl-11-hydroxyaporphine	Investigative
T67162	DRUGINFO	D05BCJ	1-Benzyl-4-pyrrol-1-yl-piperidine	Investigative
T67162	DRUGINFO	D05QJK	Benzyl-[2-(1H-indazol-4-yloxy)-ethyl]-amine	Investigative
T67162	DRUGINFO	D06FLU	3,8-dibromoboldine	Investigative
T67162	DRUGINFO	D06NTB	3-(4-Methyl-piperidin-1-ylmethyl)-1H-indole	Investigative
T67162	DRUGINFO	D06WLB	Benzyl-[2-(1H-indol-4-yloxy)-ethyl]-amine	Investigative
T67162	DRUGINFO	D09BSE	3-bromoboldine	Investigative
T67162	DRUGINFO	D0H3KU	5-OH-DPAT	Investigative
T67162	DRUGINFO	D0IU8V	4-(2-Benzylamino-ethoxy)-1,3-dihydro-indol-2-one	Investigative
T67162	DRUGINFO	D0KX3X	MCL-516	Investigative
T67162	DRUGINFO	D0LV7U	1-(4-(4-phenyl-1-piperazinyl)butyl)indolin-2-one	Investigative
T67162	DRUGINFO	D0M3PV	L-741626	Investigative
T67162	DRUGINFO	D0N0LZ	3-Naphthalen-1-yl-pyrrolidine	Investigative
T67162	DRUGINFO	D0O1PM	(4-Ethynyl-cyclohex-3-enyl)-dipropyl-amine	Investigative
T67162	DRUGINFO	D0O9BZ	4-(4-Benzyl-piperazin-1-yl)-1H-indole	Investigative
T67162	DRUGINFO	D0Q5IP	3-(4-Phenyl-piperidin-1-ylmethyl)-1H-indole	Investigative
T67162	DRUGINFO	D0R3XC	1,6-bis(4-(pyridin-2-yl)piperazin-1-yl)hexane	Investigative
T67162	DRUGINFO	D0S1XN	4-(4-Benzyl-piperazin-1-yl)-7-bromo-1H-indole	Investigative
T67162	DRUGINFO	D0S5ZY	3-Naphthalen-1-yl-1-propyl-pyrrolidine	Investigative
T67162	DRUGINFO	D0T1TU	Etoloxamine	Investigative
T67162	DRUGINFO	D0T3IH	[3H]N-methylspiperone	Investigative
T67162	DRUGINFO	D0TU5W	4-(4-Benzyl-piperazin-1-yl)-5-chloro-1H-indole	Investigative
T67162	DRUGINFO	D00CCV	1,6-bis(4-m-tolylpiperazin-1-yl)hexane	Investigative
T67162	DRUGINFO	D03PIP	1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane	Investigative
T67162	DRUGINFO	D03XKL	1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane	Investigative
T67162	DRUGINFO	D06LQH	N-propylnorapomorphine	Investigative
T67162	DRUGINFO	D07UUQ	1-Benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine	Investigative
T67162	DRUGINFO	D0B9DR	1-Benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine	Investigative
T67162	DRUGINFO	D0C6BP	1,6-bis(4-phenylpiperazin-1-yl)hexane	Investigative
T67162	DRUGINFO	D0H2WQ	QUINPIROLE	Investigative
T67162	DRUGINFO	D0I4VT	1-Propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine	Investigative
T67162	DRUGINFO	D0LH4L	BOLDINE	Investigative
T67162	DRUGINFO	D0M2BB	1-(4-(1H-pyrazol-1-yl)benzyl)-4-phenylpiperazine	Investigative
T67162	DRUGINFO	D0M2ZE	UH-232	Investigative
T67162	DRUGINFO	D0O4BC	3-(2-Benzylamino-ethoxy)-phenol	Investigative
T67162	DRUGINFO	D0O7DA	(+)-BUTACLAMOL	Investigative
T67162	DRUGINFO	D0V4NW	N-(4-Dipropylaminobutyl)-4-biphenylcarboxamide	Investigative
T67162	DRUGINFO	D0W1HM	nafadotride	Investigative
T67162	DRUGINFO	D0WD6J	1-Benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine	Investigative
T67162	DRUGINFO	D0X4PH	LP-44	Investigative
T67162	DRUGINFO	D0Z1OF	LP-12	Investigative
T67162	DRUGINFO	D01TOU	FLUANISONE	Investigative
T67162	DRUGINFO	D05UUW	1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine	Investigative
T67162	DRUGINFO	D06ROA	UH-301	Investigative
T67162	DRUGINFO	D0E1RX	1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine	Investigative
T67162	DRUGINFO	D0L7OM	STEPHOLIDINE	Investigative
T67162	DRUGINFO	D0MC2R	FLUTROLINE	Investigative
T67162	DRUGINFO	D0OG0R	WAY-208466	Investigative
T67162	DRUGINFO	D0P1XQ	SEL-73	Investigative
T67162	DRUGINFO	D0R8UU	1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine	Investigative
T67162	DRUGINFO	D07GQP	PG-01037	Investigative
T67162	DRUGINFO	D07GXY	piribedil	Investigative
T67162	DRUGINFO	D0D3YN	OCTOCLOTHEPIN	Investigative
T67162	DRUGINFO	D05EQG	[3H]spiperone	Investigative
T67162	DRUGINFO	D07LRJ	SB-271046	Investigative
T67162	DRUGINFO	D0HV3A	FLUMEZAPINE	Investigative
T67162	DRUGINFO	D0Q2GP	ISOLOXAPINE	Investigative
T67162	DRUGINFO	D0P0IX	ISOCLOZAPINE	Investigative
T67162	DRUGINFO	D0L5MW	(+/-)-nantenine	Investigative
T67162	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T97035	TARGETID	T97035
T97035	FORMERID	TTDS00373
T97035	UNIPROID	TYRO_HUMAN
T97035	TARGNAME	Tyrosinase (TYR)
T97035	GENENAME	TYR
T97035	TARGTYPE	Successful
T97035	SYNONYMS	Tumor rejection antigen AB; SK29-AB; Monophenol monooxygenase; LB24-AB
T97035	FUNCTION	Catalyzes the initial and rate limiting step in the cascade of reactions leading to melanin production from tyrosine. In addition to hydroxylating tyrosine to DOPA (3,4-dihydroxyphenylalanine), also catalyzes the oxidation of DOPA to DOPA-quinone, and possibly the oxidation of DHI (5,6-dihydroxyindole) to indole-5,6 quinone. This is a copper-containing oxidase that functions in the formation of pigments such as melanins and other polyphenolic compounds.
T97035	BIOCLASS	Paired donor oxygen oxidoreductase
T97035	ECNUMBER	EC 1.14.18.1
T97035	SEQUENCE	MLLAVLYCLLWSFQTSAGHFPRACVSSKNLMEKECCPPWSGDRSPCGQLSGRGSCQNILLSNAPLGPQFPFTGVDDRESWPSVFYNRTCQCSGNFMGFNCGNCKFGFWGPNCTERRLLVRRNIFDLSAPEKDKFFAYLTLAKHTISSDYVIPIGTYGQMKNGSTPMFNDINIYDLFVWMHYYVSMDALLGGSEIWRDIDFAHEAPAFLPWHRLFLLRWEQEIQKLTGDENFTIPYWDWRDAEKCDICTDEYMGGQHPTNPNLLSPASFFSSWQIVCSRLEEYNSHQSLCNGTPEGPLRRNPGNHDKSRTPRLPSSADVEFCLSLTQYESGSMDKAANFSFRNTLEGFASPLTGIADASQSSMHNALHIYMNGTMSQVQGSANDPIFLLHHAFVDSIFEQWLRRHRPLQEVYPEANAPIGHNRESYMVPFIPLYRNGDFFISSKDLGYDYSYLQDSDPDSFQDYIKSYLEQASRIWSWLLGAAMVGAVLTALLAGLVSLLCRHKRKQLPEEKQPLLMEKEDYHSLYQSHL
T97035	DRUGINFO	D0H6TP	Monobenzone	Approved
T97035	DRUGINFO	D03UOT	Hydroquinone	Approved
T97035	DRUGINFO	D0P5TG	Multi-epitope peptide melanoma vaccine	Phase 3
T97035	DRUGINFO	D0U9MJ	Melanoma vaccine	Phase 3
T97035	DRUGINFO	D0J7MQ	MKC-1106-MT	Phase 2
T97035	DRUGINFO	D0N7FD	Multi-epitope tyrosinase/gp100 vaccine	Phase 2
T97035	DRUGINFO	D00DSV	Polynoma-1	Phase 2
T97035	DRUGINFO	D00DYI	Benzothiazole analog 1	Patented
T97035	DRUGINFO	D00EGV	Monoamine derivative 2	Patented
T97035	DRUGINFO	D00JQA	Benzimidazole derivative 3	Patented
T97035	DRUGINFO	D00LSQ	PMID26815044-Compound-126	Patented
T97035	DRUGINFO	D00QVY	Resorcinol compound 23	Patented
T97035	DRUGINFO	D00YRS	PMID26815044-Compound-H	Patented
T97035	DRUGINFO	D01CFL	Benzothiazoline derivative 1	Patented
T97035	DRUGINFO	D01EVP	Resorcinol compound 17	Patented
T97035	DRUGINFO	D01NJW	PMID26815044-Compound-31	Patented
T97035	DRUGINFO	D01QYA	Diamine derivative 1	Patented
T97035	DRUGINFO	D01RTO	Polyhydroxy benzamide derivative 4	Patented
T97035	DRUGINFO	D01VTT	P-coumaric acid derivative 6	Patented
T97035	DRUGINFO	D01ZCC	PMID26815044-Compound-118	Patented
T97035	DRUGINFO	D02CXZ	PMID26815044-Compound-123	Patented
T97035	DRUGINFO	D02EGY	Aromatic hydrazine carboxyimidoamide derivative 6	Patented
T97035	DRUGINFO	D02JVX	Resorcinol compound 7	Patented
T97035	DRUGINFO	D02SGL	PMID26815044-Compound-49	Patented
T97035	DRUGINFO	D02TIY	Monoamine derivative 1	Patented
T97035	DRUGINFO	D02WJB	PMID26815044-Compound-124	Patented
T97035	DRUGINFO	D03BRP	Aromatic hydrazine carboxyimidoamide derivative 5	Patented
T97035	DRUGINFO	D03FQY	PMID26815044-Compound-121	Patented
T97035	DRUGINFO	D03KNZ	Monoamine derivative 3	Patented
T97035	DRUGINFO	D03MKE	Resorcinol compound 15	Patented
T97035	DRUGINFO	D03NCL	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 3	Patented
T97035	DRUGINFO	D03PLQ	Benzothiazole analog 3	Patented
T97035	DRUGINFO	D03PYA	Cyclohexyl carbamate derivative 3	Patented
T97035	DRUGINFO	D03PZZ	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 7	Patented
T97035	DRUGINFO	D04HEW	PMID26815044-Compound-32	Patented
T97035	DRUGINFO	D04ZZM	Resorcinol compound 21	Patented
T97035	DRUGINFO	D05NHA	Resorcinol compound 20	Patented
T97035	DRUGINFO	D05XAH	Aromatic hydrazine carboxyimidoamide derivative 4	Patented
T97035	DRUGINFO	D06FUM	PMID26815044-Compound-114	Patented
T97035	DRUGINFO	D06KKO	PMID26815044-Compound-50	Patented
T97035	DRUGINFO	D06LIQ	Cyclohexyl carbamate derivative 8	Patented
T97035	DRUGINFO	D06LMS	P-coumaric acid derivative 4	Patented
T97035	DRUGINFO	D06WGO	Resorcinol compound 8	Patented
T97035	DRUGINFO	D06YKN	Resorcinol compound 22	Patented
T97035	DRUGINFO	D07DFC	Aromatic hydrazine carboxyimidoamide derivative 1	Patented
T97035	DRUGINFO	D07PNX	PMID26815044-Compound-115	Patented
T97035	DRUGINFO	D07PSJ	Resorcinol compound 24	Patented
T97035	DRUGINFO	D07RJD	Resorcinol compound 2	Patented
T97035	DRUGINFO	D07RUH	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 14	Patented
T97035	DRUGINFO	D07UBZ	Thiazoline derivative 2	Patented
T97035	DRUGINFO	D08OJB	Benzoic acid linked peptide analog 4	Patented
T97035	DRUGINFO	D09EFW	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 13	Patented
T97035	DRUGINFO	D09JLP	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 10	Patented
T97035	DRUGINFO	D09MHU	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 6	Patented
T97035	DRUGINFO	D09QZB	Resorcinol compound 32	Patented
T97035	DRUGINFO	D09VRO	Cyclohexyl carbamate derivative 6	Patented
T97035	DRUGINFO	D09YKI	Polyhydroxy benzamide derivative 1	Patented
T97035	DRUGINFO	D0A0RM	PMID26815044-Compound-51	Patented
T97035	DRUGINFO	D0A2RI	PMID26815044-Compound-127	Patented
T97035	DRUGINFO	D0A8UJ	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 9	Patented
T97035	DRUGINFO	D0AE8D	Benzothiazole analog 4	Patented
T97035	DRUGINFO	D0AG7M	Benzoic acid linked peptide analog 6	Patented
T97035	DRUGINFO	D0CH3F	Resorcinol compound 16	Patented
T97035	DRUGINFO	D0CI2U	Benzoic acid linked peptide analog 3	Patented
T97035	DRUGINFO	D0CP6B	3-(phenoxymethyl) benzylamine derivative 5	Patented
T97035	DRUGINFO	D0D2JW	Polyhydroxy benzamide derivative 3	Patented
T97035	DRUGINFO	D0DW3Z	PMID26815044-Compound-93	Patented
T97035	DRUGINFO	D0E6LU	Resorcinol compound 10	Patented
T97035	DRUGINFO	D0EH4P	PMID26815044-Compound-117	Patented
T97035	DRUGINFO	D0EQ3V	Resorcinol compound 4	Patented
T97035	DRUGINFO	D0F0VF	Benzoic acid linked peptide analog 2	Patented
T97035	DRUGINFO	D0F3HA	Cyclohexyl carbamate derivative 2	Patented
T97035	DRUGINFO	D0FL1E	Resorcinol compound 33	Patented
T97035	DRUGINFO	D0FQ3D	Nicotinyl hydroxamic acid derivative 1	Patented
T97035	DRUGINFO	D0G5CV	Resorcinol compound 1	Patented
T97035	DRUGINFO	D0G7XW	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 2	Patented
T97035	DRUGINFO	D0GW5H	Polyhydroxy benzamide derivative 5	Patented
T97035	DRUGINFO	D0H0UC	Resorcinol compound 12	Patented
T97035	DRUGINFO	D0H4LK	Thiazoline derivative 1	Patented
T97035	DRUGINFO	D0HH4L	Thiazolidine derivative 1	Patented
T97035	DRUGINFO	D0HO0I	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 12	Patented
T97035	DRUGINFO	D0I3KT	PMID26815044-Compound-64	Patented
T97035	DRUGINFO	D0IB3Z	Thiazolidine derivative 3	Patented
T97035	DRUGINFO	D0IH6G	Resorcinol compound 26	Patented
T97035	DRUGINFO	D0J0BB	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 11	Patented
T97035	DRUGINFO	D0J2HH	Cyclohexyl carbamate derivative 1	Patented
T97035	DRUGINFO	D0J4YH	P-coumaric acid derivative 3	Patented
T97035	DRUGINFO	D0J6DS	Thiazolidine derivative 2	Patented
T97035	DRUGINFO	D0JC3U	Resorcinol compound 11	Patented
T97035	DRUGINFO	D0JR0P	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 4	Patented
T97035	DRUGINFO	D0K1UO	Resorcinol compound 30	Patented
T97035	DRUGINFO	D0K2XK	PMID26815044-Compound-I	Patented
T97035	DRUGINFO	D0K5JG	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 5	Patented
T97035	DRUGINFO	D0K6TN	Resorcinol compound 25	Patented
T97035	DRUGINFO	D0K7LI	Resorcinol compound 31	Patented
T97035	DRUGINFO	D0KR9E	PMID26815044-Compound-122	Patented
T97035	DRUGINFO	D0KU5J	Resorcinol compound 5	Patented
T97035	DRUGINFO	D0L0CV	Diamine derivative 2	Patented
T97035	DRUGINFO	D0L1SV	Cyclohexyl carbamate derivative 4	Patented
T97035	DRUGINFO	D0LA2R	Dihydroxyfumaric acid derivative 1	Patented
T97035	DRUGINFO	D0LC2G	Cyclohexyl carbamate derivative 7	Patented
T97035	DRUGINFO	D0M4EQ	PMID26815044-Compound-48	Patented
T97035	DRUGINFO	D0MA7A	3-(phenoxymethyl) benzylamine derivative 4	Patented
T97035	DRUGINFO	D0MM1Y	Polyhydroxy benzamide derivative 2	Patented
T97035	DRUGINFO	D0MT3J	Benzimidazole derivative 4	Patented
T97035	DRUGINFO	D0N7BW	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 1	Patented
T97035	DRUGINFO	D0NR2A	Resorcinol compound 6	Patented
T97035	DRUGINFO	D0O3JR	P-coumaric acid derivative 1	Patented
T97035	DRUGINFO	D0P0PT	Aromatic hydrazine carboxyimidoamide derivative 3	Patented
T97035	DRUGINFO	D0P6ZB	Resorcinol compound 14	Patented
T97035	DRUGINFO	D0PI1Z	Resorcinol compound 13	Patented
T97035	DRUGINFO	D0PN6U	PMID26815044-Compound-52	Patented
T97035	DRUGINFO	D0Q1HU	Resorcinol compound 28	Patented
T97035	DRUGINFO	D0Q1NF	3-(phenoxymethyl) benzylamine derivative 6	Patented
T97035	DRUGINFO	D0QC9I	Benzoic acid linked peptide analog 1	Patented
T97035	DRUGINFO	D0QR0E	Resorcinol compound 27	Patented
T97035	DRUGINFO	D0QU3G	Diamine derivative 3	Patented
T97035	DRUGINFO	D0RC7R	Resorcinol compound 9	Patented
T97035	DRUGINFO	D0SD9L	Monoamine derivative 5	Patented
T97035	DRUGINFO	D0SF6C	P-coumaric acid derivative 2	Patented
T97035	DRUGINFO	D0SJ1U	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 8	Patented
T97035	DRUGINFO	D0SJ4S	P-coumaric acid derivative 5	Patented
T97035	DRUGINFO	D0T7BH	Resorcinol compound 34	Patented
T97035	DRUGINFO	D0TL2C	Resorcinol compound 18	Patented
T97035	DRUGINFO	D0U5GU	PMID26815044-Compound-125	Patented
T97035	DRUGINFO	D0UT0X	Aromatic hydrazine carboxyimidoamide derivative 2	Patented
T97035	DRUGINFO	D0UT9H	Cyclohexyl carbamate derivative 5	Patented
T97035	DRUGINFO	D0VY9O	3-(phenoxymethyl) benzylamine derivative 2	Patented
T97035	DRUGINFO	D0W6ZO	PMID26815044-Compound-30	Patented
T97035	DRUGINFO	D0W8RV	PMID26815044-Compound-116	Patented
T97035	DRUGINFO	D0WT1C	Benzothiazole analog 2	Patented
T97035	DRUGINFO	D0X0RV	PMID26815044-Compound-47	Patented
T97035	DRUGINFO	D0X4EC	Benzoic acid linked peptide analog 5	Patented
T97035	DRUGINFO	D0X5VH	Monoamine derivative 4	Patented
T97035	DRUGINFO	D0X7EQ	Resorcinol compound 19	Patented
T97035	DRUGINFO	D0XO4I	3-(phenoxymethyl) benzylamine derivative 3	Patented
T97035	DRUGINFO	D0YX1C	Thiazole derivative 1	Patented
T97035	DRUGINFO	D0Z0DX	Benzothiazole analog 5	Patented
T97035	DRUGINFO	D0Z1LJ	3-(phenoxymethyl) benzylamine derivative 1	Patented
T97035	DRUGINFO	D0ZJ4M	Resorcinol compound 3	Patented
T97035	DRUGINFO	D0ZT3U	Resorcinol compound 29	Patented
T97035	DRUGINFO	D0Y1LO	PMID29130358-Compound-Figure11(3)	Patented
T97035	DRUGINFO	D00GRN	5-hydroxy-2-(pentylthiomethyl)-4H-pyran-4-one	Investigative
T97035	DRUGINFO	D00LMT	1'-(4-Methyl-benzyl)-[1,4']bipiperidinyl	Investigative
T97035	DRUGINFO	D00MPM	Broussonin C	Investigative
T97035	DRUGINFO	D00OUF	1-(3-phenoxypropyl)-4-(piperidin-1-yl)piperidine	Investigative
T97035	DRUGINFO	D00VQZ	1-hydroxy-3-(4-nitrophenyl)urea	Investigative
T97035	DRUGINFO	D01IFR	5-benzhydryl-1,3,4-oxadiazole-2(3H)-thione	Investigative
T97035	DRUGINFO	D01SLA	ETHISTERONE	Investigative
T97035	DRUGINFO	D01VOU	2,2',4,4',6'-pentahydroxychalcone	Investigative
T97035	DRUGINFO	D02CFH	PHENYLTHIOUREA	Investigative
T97035	DRUGINFO	D02IJM	DAEDALIN A	Investigative
T97035	DRUGINFO	D02JWY	SRI-224	Investigative
T97035	DRUGINFO	D02LHQ	3-(2,4-dihydroxyphenyl)propionic acid	Investigative
T97035	DRUGINFO	D02PWZ	N-(2,4-dihydroxybenzyl)-3,5-dihydroxybenzamide	Investigative
T97035	DRUGINFO	D02UKE	5-(pyridin-4-yl)-1,3,4-thiadiazole-2(3H)-thione	Investigative
T97035	DRUGINFO	D02UUK	KAZINOL S	Investigative
T97035	DRUGINFO	D02VKX	4-adamantyl resorcinol	Investigative
T97035	DRUGINFO	D03ESC	5-{8(Z),11(Z),14-pentadecatrienyl}resorcinol	Investigative
T97035	DRUGINFO	D03TYV	5,5'-methylenebis(1,3,4-thiadiazole-2(3H)-thione)	Investigative
T97035	DRUGINFO	D04KCX	5-(4-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione	Investigative
T97035	DRUGINFO	D04QFU	2-(cyclohexylthiomethyl)-5-hydroxy-4H-pyran-4-one	Investigative
T97035	DRUGINFO	D04QYN	5-(pyridin-4-yl)-1,3,4-oxadiazole-2(3H)-thione	Investigative
T97035	DRUGINFO	D04WLH	5-{8(Z),11(Z)-pentadecadienyl}resorcinol	Investigative
T97035	DRUGINFO	D04XED	Crocusatin-K	Investigative
T97035	DRUGINFO	D04ZQC	3-hydroxyphenethyl 3,4,5-trihydroxybenzoate	Investigative
T97035	DRUGINFO	D05OML	5-(3-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione	Investigative
T97035	DRUGINFO	D06MNV	1-(1-phenylethylidene)thiosemicarbazide	Investigative
T97035	DRUGINFO	D06ZRX	OXYRESVERATROL	Investigative
T97035	DRUGINFO	D07DAP	4,4'-(ethane-1,2-diyl)dibenzene-1,3-diol	Investigative
T97035	DRUGINFO	D07EFI	1-(4-Methylpent-3-en-2-ylidene)thiosemicarbazide	Investigative
T97035	DRUGINFO	D07EGB	4-hexyl resorcinol	Investigative
T97035	DRUGINFO	D07FKO	N-(2,4-dihydroxybenzyl)-3,4,5-trihydroxybenzamide	Investigative
T97035	DRUGINFO	D07HYL	2,4,3',5'-tetrahydroxybibenzyl	Investigative
T97035	DRUGINFO	D07KXZ	5-phenyl-1,3,4-oxadiazole-2(3H)-thione	Investigative
T97035	DRUGINFO	D07RGP	ASKENDOSIDE B	Investigative
T97035	DRUGINFO	D07ZAV	2-(butylthiomethyl)-5-hydroxy-4H-pyran-4-one	Investigative
T97035	DRUGINFO	D07ZVP	1-(2,5-Dimethyl-1H-pyrrol-1-yl)thiourea	Investigative
T97035	DRUGINFO	D08EJQ	1-hydroxy-3-(4-(trifluoromethyl)phenyl)urea	Investigative
T97035	DRUGINFO	D08OFD	1-(1-p-tolylethylidene)thiosemicarbazide	Investigative
T97035	DRUGINFO	D08UHS	1-(1,4-diacetylphenyl)dithiosemicarbazide	Investigative
T97035	DRUGINFO	D08UML	1-(Butan-2-ylidene)thiosemicarbazide	Investigative
T97035	DRUGINFO	D09FDZ	7,8,4'-trihydroxyisoflavone	Investigative
T97035	DRUGINFO	D09OGW	4'-(4-Nitrobenzensulfonamide)-4-hydroxychalcone	Investigative
T97035	DRUGINFO	D09SIW	2-(hexylthiomethyl)-5-hydroxy-4H-pyran-4-one	Investigative
T97035	DRUGINFO	D09YGD	4'-(4-Aminobenzensulfonamide)-4-hydroxychalcone	Investigative
T97035	DRUGINFO	D09YJS	2-hydroxyphenethyl 3,4,5-trihydroxybenzoate	Investigative
T97035	DRUGINFO	D0A3QM	1-(1-(pyridin-3-yl)ethylidene)thiosemicarbazide	Investigative
T97035	DRUGINFO	D0A6ZK	2-hydroxy-3-isopropyl-2,4,6-cycloheptatrien-1-one	Investigative
T97035	DRUGINFO	D0A7WB	7-(3,5-dihydroxyphenyl)naphthalene-1,3-diol	Investigative
T97035	DRUGINFO	D0AZ0Y	5-(6-hydroxynaphthalen-2-yl)benzene-1,3-diol	Investigative
T97035	DRUGINFO	D0B9IX	1-(3-Phenylallylidene)thiosemicarbazide	Investigative
T97035	DRUGINFO	D0BH2T	2,2',4,4'-tetrahydroxychalcone	Investigative
T97035	DRUGINFO	D0BR1V	4'-(Benzensulfonamide)-4-hydroxychalcone	Investigative
T97035	DRUGINFO	D0D5OG	Kazinol C	Investigative
T97035	DRUGINFO	D0D7ES	1-(4-(benzyloxy)phenyl)-3-hydroxyurea	Investigative
T97035	DRUGINFO	D0D7GL	TROPOLONE	Investigative
T97035	DRUGINFO	D0D7KE	4'-(4-Fluorobenzensulfonamide)-4-hydroxychalcone	Investigative
T97035	DRUGINFO	D0DU4B	1-Propylidenethiosemicarbazide	Investigative
T97035	DRUGINFO	D0E7TO	1-(1-(4-bromophenyl)ethylidene)thiosemicarbazide	Investigative
T97035	DRUGINFO	D0EB9U	1-Cyclohexylidenethiosemicarbazide	Investigative
T97035	DRUGINFO	D0EN7L	1-(But-2-enylidene)thiosemicarbazide	Investigative
T97035	DRUGINFO	D0F1XE	1-(3-Methylbutylidene)thiosemicarbazide	Investigative
T97035	DRUGINFO	D0F3CO	KOJIC ACID	Investigative
T97035	DRUGINFO	D0F6RH	2-(heptylthiomethyl)-5-hydroxy-4H-pyran-4-one	Investigative
T97035	DRUGINFO	D0G6IO	1-(4-bromophenyl)-3-hydroxyurea	Investigative
T97035	DRUGINFO	D0G9WX	5-benzhydryl-1,3,4-thiadiazole-2(3H)-thione	Investigative
T97035	DRUGINFO	D0H4YW	HINOKITIOL	Investigative
T97035	DRUGINFO	D0H5WY	5,5'-methylenebis(1,3,4-oxadiazole-2(3H)-thione)	Investigative
T97035	DRUGINFO	D0H5XP	2-(ethylthiomethyl)-5-hydroxy-4H-pyran-4-one	Investigative
T97035	DRUGINFO	D0HS3M	1-(1-(pyrazin-2-yl)ethylidene)thiosemicarbazide	Investigative
T97035	DRUGINFO	D0J5DN	7,3',4'-trihydroxyisoflavone	Investigative
T97035	DRUGINFO	D0L3KR	2,2',4,4'-tetrahydroxy-6'-methoxychalcone	Investigative
T97035	DRUGINFO	D0M2EN	N-butylresorcinol	Investigative
T97035	DRUGINFO	D0M4XH	1-Ethylidenethiosemicarbazide	Investigative
T97035	DRUGINFO	D0M7LC	4-(6-hydroxynaphthalen-2-yl)benzene-1,3-diol	Investigative
T97035	DRUGINFO	D0N3DW	5-phenyl-1,3,4-thiadiazole-2(3H)-thione	Investigative
T97035	DRUGINFO	D0O7CX	4'-Amino-4-hydroxychalcone	Investigative
T97035	DRUGINFO	D0O9BS	S-2-(o-toluidino)-2-oxoethyl carbamothioate	Investigative
T97035	DRUGINFO	D0OE5N	5-{8(Z),-pentadecenyl}resorcinol	Investigative
T97035	DRUGINFO	D0OG4X	1-(1-(4-fluorophenyl)ethylidene)thiosemicarbazide	Investigative
T97035	DRUGINFO	D0PG8M	4',4-Dihydroxychalcone	Investigative
T97035	DRUGINFO	D0Q5RG	1-(1-(thiophen-2-yl)ethylidene)thiosemicarbazide	Investigative
T97035	DRUGINFO	D0Q6UT	5-cyclohexyl-1,3,4-oxadiazole-2(3H)-thione	Investigative
T97035	DRUGINFO	D0QS2N	3hydroxy-1-methyl-1-phenylurea	Investigative
T97035	DRUGINFO	D0S5OR	(+/-)-Daedalin A	Investigative
T97035	DRUGINFO	D0S7TM	2,2'-bi(1,3,4-thiadiazole)-5,5'(4H,4'H)-dithione	Investigative
T97035	DRUGINFO	D0SE1R	4'-(p-Toluenesulfonamide)-4-hydroxychalcone	Investigative
T97035	DRUGINFO	D0T2WM	N-(2,4-dihydroxybenzyl)-3,4-dihydroxybenzamide	Investigative
T97035	DRUGINFO	D0T4WL	1-hydroxy-3-phenylurea	Investigative
T97035	DRUGINFO	D0T7DV	SODIUM ZINC DIHYDROLIPOYLHISTIDINATE	Investigative
T97035	DRUGINFO	D0TS8S	1-Cyclopentylidenethiosemicarbazide	Investigative
T97035	DRUGINFO	D0U1MF	3,4-dihydroxybenzaldehyde-O-ethyloxime	Investigative
T97035	DRUGINFO	D0UN0R	Kazinol F	Investigative
T97035	DRUGINFO	D0X3SO	1-(Propan-2-ylidene)thiosemicarbazide	Investigative
T97035	DRUGINFO	D0X6PH	5-(6-hydroxy-2-naphthyl)-1,2,3-benzenetriol	Investigative
T97035	DRUGINFO	D0X9DP	5-hydroxy-2-(propylthiomethyl)-4H-pyran-4-one	Investigative
T97035	DRUGINFO	D0Z1XR	2-hydroxy-5-isopropyl-2,4,6-cycloheptatrien-1-one	Investigative
T97035	DRUGINFO	D0Z8MX	5-benzyl-1,3,4-oxadiazole-2(3H)-thione	Investigative
T97035	DRUGINFO	D0Z9JS	1-(3-Oxocyclohexylidene)thiosemicarbazide	Investigative
T97035	DRUGINFO	D0ZK2F	Kojic acid-phenylalanine amide	Investigative
T97035	DRUGINFO	D0ZR4M	4-hydroxyphenethyl 3,4,5-trihydroxybenzoate	Investigative
T97035	DRUGINFO	D05PTT	ROSMARINIC ACID	Investigative
T97035	DRUGINFO	D0P8PK	6-(3-Hydroxy-phenyl)-naphthalen-2-ol	Investigative

T81900	TARGETID	T81900
T81900	FORMERID	TTDS00134
T81900	UNIPROID	IDE_HUMAN
T81900	TARGNAME	Insulin-degrading enzyme (IDE)
T81900	GENENAME	IDE
T81900	TARGTYPE	Successful
T81900	SYNONYMS	Insulysin; Insulinase; Insulin protease; Abeta-degrading protease
T81900	FUNCTION	Substrate binding induces important conformation changes, making it possible to bind and degrade larger substrates, such as insulin. Contributes to the regulation of peptide hormone signaling cascades and regulation of blood glucose homeostasis via its role in the degradation of insulin, glucagon and IAPP. Plays a role in the degradation and clearance of APP-derived amyloidogenic peptides that are secreted by neurons and microglia. Involved in antigen processing. Produces both the N terminus and the C terminus of MAGEA3-derived antigenic peptide (EVDPIGHLY) that is presented to cytotoxic T lymphocytes by MHC class I. Plays a role in the cellular breakdown of insulin, APP peptides, IAPP peptides, glucagon, bradykinin, kallidin and other peptides, and thereby plays a role in intercellular peptide signaling.
T81900	PDBSTRUC	6MQ3; 6EDS; 6BYZ; 6BFC; 6BF9
T81900	BIOCLASS	Peptidase
T81900	ECNUMBER	EC 3.4.24.56
T81900	SEQUENCE	MRYRLAWLLHPALPSTFRSVLGARLPPPERLCGFQKKTYSKMNNPAIKRIGNHITKSPEDKREYRGLELANGIKVLLISDPTTDKSSAALDVHIGSLSDPPNIAGLSHFCEHMLFLGTKKYPKENEYSQFLSEHAGSSNAFTSGEHTNYYFDVSHEHLEGALDRFAQFFLCPLFDESCKDREVNAVDSEHEKNVMNDAWRLFQLEKATGNPKHPFSKFGTGNKYTLETRPNQEGIDVRQELLKFHSAYYSSNLMAVCVLGRESLDDLTNLVVKLFSEVENKNVPLPEFPEHPFQEEHLKQLYKIVPIKDIRNLYVTFPIPDLQKYYKSNPGHYLGHLIGHEGPGSLLSELKSKGWVNTLVGGQKEGARGFMFFIINVDLTEEGLLHVEDIILHMFQYIQKLRAEGPQEWVFQECKDLNAVAFRFKDKERPRGYTSKIAGILHYYPLEEVLTAEYLLEEFRPDLIEMVLDKLRPENVRVAIVSKSFEGKTDRTEEWYGTQYKQEAIPDEVIKKWQNADLNGKFKLPTKNEFIPTNFEILPLEKEATPYPALIKDTAMSKLWFKQDDKFFLPKACLNFEFFSPFAYVDPLHCNMAYLYLELLKDSLNEYAYAAELAGLSYDLQNTIYGMYLSVKGYNDKQPILLKKIIEKMATFEIDEKRFEIIKEAYMRSLNNFRAEQPHQHAMYYLRLLMTEVAWTKDELKEALDDVTLPRLKAFIPQLLSRLHIEALLHGNITKQAALGIMQMVEDTLIEHAHTKPLLPSQLVRYREVQLPDRGWFVYQQRNEVHNNCGIEIYYQTDMQSTSENMFLELFCQIISEPCFNTLRTKEQLGYIVFSGPRRANGIQGLRFIIQSEKPPHYLESRVEAFLITMEKSIEDMTEEAFQKHIQALAIRRLDKPKKLSAECAKYWGEIISQQYNFDRDNTEVAYLKTLTKEDIIKFYKEMLAVDAPRRHKVSVHVLAREMDSCPVVGEFPCQNDINLSQAPALPQPEVIQNMTEFKRGLPLFPLVKPHINFMAAKL
T81900	DRUGINFO	D0M1IO	Bacitracin	Approved
T81900	DRUGINFO	D0K6HE	PRO-001	Phase 2
T81900	DRUGINFO	D0E9JD	quinoline 2	Investigative
T81900	DRUGINFO	D0N0ED	NTE-2	Investigative
T81900	DRUGINFO	D0N9YP	NTE-1	Investigative
T81900	DRUGINFO	D06DKB	GNF-PF-4478	Investigative

T72515	TARGETID	T72515
T72515	FORMERID	TTDS00138
T72515	UNIPROID	IL1R1_HUMAN
T72515	TARGNAME	Interleukin 1 receptor type 1 (IL1R1)
T72515	GENENAME	IL1R1
T72515	TARGTYPE	Successful
T72515	SYNONYMS	p80; Interleukin-1 receptor type I; Interleukin-1 receptor type 1; Interleukin-1 receptor alpha; IL1RT1; IL1RA; IL1R; IL-1RT1; IL-1RT-1; IL-1R-alpha; IL-1R-1; CD121a; CD121 antigen-like family member A
T72515	FUNCTION	Receptor for IL1A, IL1B and IL1RN. After binding to interleukin-1 associates with the coreceptor IL1RAP to form the high affinity interleukin-1 receptor complex which mediates interleukin-1-dependent activation of NF-kappa-B, MAPK and other pathways. Signaling involves the recruitment of adapter molecules such as TOLLIP, MYD88, and IRAK1 or IRAK2 via the respective TIR domains of the receptor/coreceptor subunits. Binds ligands with comparable affinity and binding of antagonist IL1RN prevents association with IL1RAP to form a signaling complex. Involved in IL1B-mediated costimulation of IFNG production from T-helper 1 (Th1) cells.
T72515	PDBSTRUC	4GAF; 4DEP; 1ITB; 1IRA; 1G0Y
T72515	BIOCLASS	Cytokine receptor
T72515	SEQUENCE	MKVLLRLICFIALLISSLEADKCKEREEKIILVSSANEIDVRPCPLNPNEHKGTITWYKDDSKTPVSTEQASRIHQHKEKLWFVPAKVEDSGHYYCVVRNSSYCLRIKISAKFVENEPNLCYNAQAIFKQKLPVAGDGGLVCPYMEFFKNENNELPKLQWYKDCKPLLLDNIHFSGVKDRLIVMNVAEKHRGNYTCHASYTYLGKQYPITRVIEFITLEENKPTRPVIVSPANETMEVDLGSQIQLICNVTGQLSDIAYWKWNGSVIDEDDPVLGEDYYSVENPANKRRSTLITVLNISEIESRFYKHPFTCFAKNTHGIDAAYIQLIYPVTNFQKHMIGICVTLTVIIVCSVFIYKIFKIDIVLWYRDSCYDFLPIKASDGKTYDAYILYPKTVGEGSTSDCDIFVFKVLPEVLEKQCGYKLFIYGRDDYVGEDIVEVINENVKKSRRLIIILVRETSGFSWLGGSSEEQIAMYNALVQDGIKVVLLELEKIQDYEKMPESIKFIKQKHGAIRWSGDFTQGPQSAKTRFWKNVRYHMPVQRRSPSSKHQLLSPATKEKLQREAHVPLG
T72515	DRUGINFO	D02DES	Anakinra	Approved
T72515	DRUGINFO	D0F8DL	SB 203580	Terminated

T51487	TARGETID	T51487
T51487	FORMERID	TTDS00403
T51487	UNIPROID	GBRA1_HUMAN
T51487	TARGNAME	GABA(A) receptor alpha-1 (GABRA1)
T51487	GENENAME	GABRA1
T51487	TARGTYPE	Successful
T51487	SYNONYMS	Gamma-aminobutyric acid receptor subunit alpha-1; GABA(A) receptor subunit alpha-1
T51487	FUNCTION	Ligand-gated chloride channel which is a component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the brain. Plays an important role in the formation of functional inhibitory GABAergic synapses in addition to mediating synaptic inhibition as a GABA-gated ion channel. The gamma2 subunit is necessary but not sufficient for a rapid formation of active synaptic contacts and the synaptogenic effect of this subunit is influenced by the type of alpha and beta subunits present in the receptor pentamer (By similarity). The alpha1/beta2/gamma2 receptor and the alpha1/beta3/gamma2 receptor exhibit synaptogenic activity. GABRA1-mediated plasticity in the orbitofrontal cortex regulates context-dependent action selection (By similarity). Functions also as histamine receptor and mediates cellular responses to histamine (By similarity).
T51487	PDBSTRUC	6I53; 6D6U; 6D6T; 6D1S; 6CDU
T51487	BIOCLASS	Ligand-gated ion channel
T51487	SEQUENCE	MRKSPGLSDCLWAWILLLSTLTGRSYGQPSLQDELKDNTTVFTRILDRLLDGYDNRLRPGLGERVTEVKTDIFVTSFGPVSDHDMEYTIDVFFRQSWKDERLKFKGPMTVLRLNNLMASKIWTPDTFFHNGKKSVAHNMTMPNKLLRITEDGTLLYTMRLTVRAECPMHLEDFPMDAHACPLKFGSYAYTRAEVVYEWTREPARSVVVAEDGSRLNQYDLLGQTVDSGIVQSSTGEYVVMTTHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISARNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGYAWDGKSVVPEKPKKVKDPLIKKNNTYAPTATSYTPNLARGDPGLATIAKSATIEPKEVKPETKPPEPKKTFNSVSKIDRLSRIAFPLLFGIFNLVYWATYLNREPQLKAPTPHQ
T51487	DRUGINFO	D00AMQ	Ethanol	Approved
T51487	DRUGINFO	D00ETS	Hexobarbital	Approved
T51487	DRUGINFO	D00SJE	Secobarbital	Approved
T51487	DRUGINFO	D05BQK	Butalbital	Approved
T51487	DRUGINFO	D05OQJ	Methyprylon	Approved
T51487	DRUGINFO	D07SOO	Methoxyflurane	Approved
T51487	DRUGINFO	D08UMH	Methylphenobarbital	Approved
T51487	DRUGINFO	D09DWL	Zaleplon	Approved
T51487	DRUGINFO	D0A4JK	Butabarbital	Approved
T51487	DRUGINFO	D0E0WQ	Barbital	Approved
T51487	DRUGINFO	D0F0YZ	Pentobarbital	Approved
T51487	DRUGINFO	D0GA5T	Indiplon	Approved
T51487	DRUGINFO	D0KR9U	Picrotoxin	Approved
T51487	DRUGINFO	D0O3AB	Butethal	Approved
T51487	DRUGINFO	D0R6BR	Amobarbital	Approved
T51487	DRUGINFO	D0S8TD	Methohexital	Approved
T51487	DRUGINFO	D0T5WK	Nitrazepam	Approved
T51487	DRUGINFO	D0U5RT	Primidone	Approved
T51487	DRUGINFO	D03VZH	Ethchlorvynol	Approved
T51487	DRUGINFO	D0S9MC	Clobazam - Lundbeck	Approved
T51487	DRUGINFO	D0T1WN	Zolpidem	Approved
T51487	DRUGINFO	D0WB9V	Barbiturate	Approved
T51487	DRUGINFO	D0Y4AW	Meprobamate	Approved
T51487	DRUGINFO	D00VZZ	Allopregnanolone	approved
T51487	DRUGINFO	D0IG4I	THIOCOLCHICOSIDE	Approved
T51487	DRUGINFO	D07ZCK	ZK-93423	Phase 3
T51487	DRUGINFO	D00OVC	EVT-201	Phase 2
T51487	DRUGINFO	D0C9XA	GSK683699	Phase 2
T51487	DRUGINFO	D0B8YZ	ELTANOLONE	Discontinued in Phase 3
T51487	DRUGINFO	D05EVI	U-78875	Discontinued in Phase 1
T51487	DRUGINFO	D01BCQ	Divaplon	Terminated
T51487	DRUGINFO	D0V4GI	CGS-9896	Terminated
T51487	DRUGINFO	D00ASA	2-(3-Chloro-phenyl)-chromen-4-one	Investigative
T51487	DRUGINFO	D02ANG	(2-Amino-4,5-dihydro-thiazol-4-yl)-acetic acid	Investigative
T51487	DRUGINFO	D02CHG	6-Chloro-2-phenyl-chromen-4-one	Investigative
T51487	DRUGINFO	D02HEK	1-(9H-beta-Carbolin-3-yl)-ethanone	Investigative
T51487	DRUGINFO	D02HRB	RWJ-16979	Investigative
T51487	DRUGINFO	D02LLU	2-Phenyl-6H-pyrazolo[1,5-c]quinazolin-5-one	Investigative
T51487	DRUGINFO	D02ONZ	6-Bromo-2-(4-nitro-phenyl)-chromen-4-one	Investigative
T51487	DRUGINFO	D03EQH	RIPAZEPAM	Investigative
T51487	DRUGINFO	D03NWH	2-(3-Bromo-phenyl)-chromen-4-one	Investigative
T51487	DRUGINFO	D04JTK	(6-Benzylamino-9H-beta-carbolin-3-yl)-methanol	Investigative
T51487	DRUGINFO	D04JUH	NSC-73613	Investigative
T51487	DRUGINFO	D04UUT	2-Furan-2-yl-6H-pyrazolo[1,5-c]quinazolin-5-one	Investigative
T51487	DRUGINFO	D04WIA	2-Pyridin-2-yl-6H-pyrazolo[1,5-c]quinazolin-5-one	Investigative
T51487	DRUGINFO	D04YHZ	3-Methoxycarbonyl-2-methyl-9H-beta-carbolin-2-ium	Investigative
T51487	DRUGINFO	D05AEG	N-(9H-beta-Carbolin-3-yl)-acetamide	Investigative
T51487	DRUGINFO	D05LXP	7,12-Dihydro-7,12-diaza-indeno[1,2-a]fluorene	Investigative
T51487	DRUGINFO	D05YQE	3-(2,2-Dimethyl-propoxy)-9H-beta-carboline	Investigative
T51487	DRUGINFO	D06BNI	(9H-beta-Carbolin-3-yl)-methanol	Investigative
T51487	DRUGINFO	D06DTT	RO-054520	Investigative
T51487	DRUGINFO	D06JBP	Benzyl-(9H-beta-carbolin-6-yl)-amine	Investigative
T51487	DRUGINFO	D07CUW	6-Bromo-2-(3-nitro-phenyl)-chromen-4-one	Investigative
T51487	DRUGINFO	D07LCC	4-Methoxymethyl-3,6-dipropoxy-9H-beta-carboline	Investigative
T51487	DRUGINFO	D07MRF	3-Nitro-9H-beta-carboline	Investigative
T51487	DRUGINFO	D08LJJ	6-Bromo-2-(2-nitro-phenyl)-chromen-4-one	Investigative
T51487	DRUGINFO	D09NNI	3-Methoxy-9H-beta-carboline	Investigative
T51487	DRUGINFO	D09PKJ	2-Isoxazol-3-yl-3H-imidazo[4,5-c]quinoline	Investigative
T51487	DRUGINFO	D0A4UQ	6-Bromo-2-(3-bromo-phenyl)-chromen-4-one	Investigative
T51487	DRUGINFO	D0A6AX	(9H-beta-Carbolin-3-yl)-carbamic acid ethyl ester	Investigative
T51487	DRUGINFO	D0AU7Y	2-p-Tolyl-6H-pyrazolo[1,5-c]quinazolin-5-one	Investigative
T51487	DRUGINFO	D0C5XB	NSC-93394	Investigative
T51487	DRUGINFO	D0C8CR	9H-beta-Carbolin-6-ylamine	Investigative
T51487	DRUGINFO	D0D2NV	Pyrrolidin-3-yl-acetic acid	Investigative
T51487	DRUGINFO	D0F8AP	9H-beta-Carbolin-3-ol	Investigative
T51487	DRUGINFO	D0K6WD	(9H-beta-Carbolin-3-yl)-ethyl-amine	Investigative
T51487	DRUGINFO	D0N9DG	3-Isopropoxy-9H-beta-carboline	Investigative
T51487	DRUGINFO	D0O4MK	3-Chloro-9H-beta-carboline	Investigative
T51487	DRUGINFO	D0P2DB	7,12-Dihydro-5,7,12-triaza-indeno[1,2-a]fluorene	Investigative
T51487	DRUGINFO	D0Q6CJ	2-(3-Bromo-phenyl)-6-nitro-chromen-4-one	Investigative
T51487	DRUGINFO	D0R2ES	2-Phenyl-5,6-dihydro-pyrazolo[1,5-c]quinazoline	Investigative
T51487	DRUGINFO	D0R2HJ	Isoquinoline-3-carboxylic acid methyl ester	Investigative
T51487	DRUGINFO	D0R6FJ	NORHARMANE	Investigative
T51487	DRUGINFO	D0S4RQ	3-sec-Butoxy-9H-beta-carboline	Investigative
T51487	DRUGINFO	D0S6GS	6-Bromo-2-phenyl-chromen-4-one	Investigative
T51487	DRUGINFO	D0T4ZI	6-Chloro-2-(3-nitro-phenyl)-chromen-4-one	Investigative
T51487	DRUGINFO	D0V4AR	2-(4-Chloro-phenyl)-3H-imidazo[4,5-c]quinoline	Investigative
T51487	DRUGINFO	D0W3FQ	6-Nitro-2-phenyl-chromen-4-one	Investigative
T51487	DRUGINFO	D0W7ND	2-Phenyl-3H-imidazo[4,5-c]quinoline	Investigative
T51487	DRUGINFO	D0W9WW	6-Fluoro-2-(3-nitro-phenyl)-chromen-4-one	Investigative
T51487	DRUGINFO	D0X2CC	1-(9H-beta-Carbolin-3-yl)-butan-1-one	Investigative
T51487	DRUGINFO	D0ZJ5V	N-(9H-beta-Carbolin-3-yl)-formamide	Investigative
T51487	DRUGINFO	D00OAN	9H-beta-Carboline-3-carboxylic acid propyl ester	Investigative
T51487	DRUGINFO	D00SXO	3-Methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-one	Investigative
T51487	DRUGINFO	D01BVR	5-(4-piperidyl)-4-propylisothiazol-3-ol	Investigative
T51487	DRUGINFO	D02XUD	4-(biphenyl-3-yl)-5-(piperidin-4-yl)isoxazol-3-ol	Investigative
T51487	DRUGINFO	D04PQN	N-(p-methylbenzyl)-5-nitroindol-3-ylglyoxylamide	Investigative
T51487	DRUGINFO	D05WEF	N-benzyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide	Investigative
T51487	DRUGINFO	D06QOX	1,3-Diphenyl-1H-chromeno[4,3-c]pyrazol-4-one	Investigative
T51487	DRUGINFO	D06ZOM	3-Methyl-2-phenyl-2H-chromeno[4,3-c]pyrazol-4-one	Investigative
T51487	DRUGINFO	D07BIF	[3H]CGP27492	Investigative
T51487	DRUGINFO	D09AVL	4-benzyl-5-(4-piperidyl)isothiazol-3-ol	Investigative
T51487	DRUGINFO	D0D6IU	2-(1H-Indol-3-yl)-2-oxo-N-phenethyl-acetamide	Investigative
T51487	DRUGINFO	D0GE4A	N-butyl-2-(1H-indol-3-yl)-2-oxoacetamide	Investigative
T51487	DRUGINFO	D0J9SS	6-Nitro-2-(3-nitro-phenyl)-chromen-4-one	Investigative
T51487	DRUGINFO	D0JV5L	4-Methyl-5-(4-piperidyl)isothiazol-3-ol	Investigative
T51487	DRUGINFO	D0KS2X	CGS-9895	Investigative
T51487	DRUGINFO	D0P3FZ	5-(piperidin-4-yl)isothiazol-3-ol	Investigative
T51487	DRUGINFO	D0S9YE	(beta-CCE)9H-beta-Carboline-3-carboxylic acid	Investigative
T51487	DRUGINFO	D0V2LK	6-Nitro-2-(4-nitro-phenyl)-chromen-4-one	Investigative
T51487	DRUGINFO	D00CQR	6-Methyl-2-oxa-spiro[4.4]nonan-1-one	Investigative
T51487	DRUGINFO	D00VWR	3,3-Diethyl-dihydro-furan-2-one	Investigative
T51487	DRUGINFO	D00WON	3-Ethyl-3-methyl-dihydro-furan-2-one	Investigative
T51487	DRUGINFO	D01OZS	3,3-Diisopropyl-dihydro-furan-2-one	Investigative
T51487	DRUGINFO	D01PPZ	Ridine-5-carboxylic acid ethyl ester	Investigative
T51487	DRUGINFO	D01UZT	4-(4-chlorophenyl)-1-pyrid-2-yl-pyrazole	Investigative
T51487	DRUGINFO	D02FXS	3-carboxy-6-ethyl-4-quinolone	Investigative
T51487	DRUGINFO	D02RUV	3-Isopropyl-3-methyl-dihydro-furan-2-one	Investigative
T51487	DRUGINFO	D02XXK	(9-Benzyl-9H-purin-6-yl)-cyclopropyl-amine	Investigative
T51487	DRUGINFO	D03CKN	3-ethoxycarbonyl-6-ethyl-2-methyl-4-quinolone	Investigative
T51487	DRUGINFO	D03EOK	N-Indan-1-yl-2-(1H-indol-3-yl)-2-oxo-acetamide	Investigative
T51487	DRUGINFO	D03FBS	6-ethyl-3-propoxycarbonyl-4-quinolone	Investigative
T51487	DRUGINFO	D03OEN	N-butyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide	Investigative
T51487	DRUGINFO	D03OQG	1-Methyl-5-oxa-spiro[2.4]heptan-4-one	Investigative
T51487	DRUGINFO	D03YLX	3-Methyl-9H-beta-carboline	Investigative
T51487	DRUGINFO	D04EOV	3-ethoxycarbonyl-6-propyl-4-quinolone	Investigative
T51487	DRUGINFO	D05OOA	6-ethyl-3-pentoxycarbonyl-4-quinolone	Investigative
T51487	DRUGINFO	D05SVA	5-(piperidin-4-yl)isoxazol-3-ol	Investigative
T51487	DRUGINFO	D05TVT	6-ethyl-3-(3-pentoxycarbonyl)-4-quinolone	Investigative
T51487	DRUGINFO	D06EUJ	3-butoxycarbonyl-4-quinolone	Investigative
T51487	DRUGINFO	D06GAI	1-(4-chlorophenyl)-4-phenyl-1H-imidazole	Investigative
T51487	DRUGINFO	D06OSB	6-ethyl-3-i-propoxycarbonyl-4-quinolone	Investigative
T51487	DRUGINFO	D07OON	3-Ethyl-3-isopropyl-dihydro-furan-2-one	Investigative
T51487	DRUGINFO	D07QGN	CGS-13767	Investigative
T51487	DRUGINFO	D08AID	6-ethyl-3-(2-methylbutoxycarbonyl)-4-quinolone	Investigative
T51487	DRUGINFO	D08HGK	N-Benzyl-2-(1H-indol-3-yl)-2-oxo-acetamide	Investigative
T51487	DRUGINFO	D09AYK	3-ethoxycarbonyl-4-quinolone	Investigative
T51487	DRUGINFO	D09CQO	2-Thiophen-2-yl-3H-imidazo[4,5-c]quinoline	Investigative
T51487	DRUGINFO	D09RWW	3-cyclopentoxycarbonyl-6-ethyl-4-quinolone	Investigative
T51487	DRUGINFO	D0AR4P	2-(9-Benzyl-9H-purin-6-ylamino)-ethanol	Investigative
T51487	DRUGINFO	D0B4CQ	6-benzyl-3-propylaminocarbonyl-4-quinolone	Investigative
T51487	DRUGINFO	D0B4WR	2-Isoxazol-5-yl-3H-imidazo[4,5-c]quinoline	Investigative
T51487	DRUGINFO	D0CR6M	6-bromo-3-ethoxycarbonyl-2-methyl-4-quinolone	Investigative
T51487	DRUGINFO	D0D2PJ	GNF-PF-4421	Investigative
T51487	DRUGINFO	D0ER0L	4-Benzyl-5-piperidin-4-yl-isoxazol-3-ol	Investigative
T51487	DRUGINFO	D0FQ2N	3-Isothiocyanato-9H-beta-carboline	Investigative
T51487	DRUGINFO	D0FR4S	4-(2-aminoethyl)-1,2,5-oxadiazol-3-ol	Investigative
T51487	DRUGINFO	D0G6IG	3-butoxycarbonyl-6-ethyl-4-quinolone	Investigative
T51487	DRUGINFO	D0H0DP	3-amino-3-demethoxythiocolchicine	Investigative
T51487	DRUGINFO	D0H0NE	6,9-Dimethyl-2-oxa-spiro[4.4]nonan-1-one	Investigative
T51487	DRUGINFO	D0I4HT	4-Naphthalen-1-yl-5-piperidin-4-yl-isoxazol-3-ol	Investigative
T51487	DRUGINFO	D0J0CA	BETA-CCM	Investigative
T51487	DRUGINFO	D0J9VP	3-tert-Butyl-3-ethyl-dihydro-furan-2-one	Investigative
T51487	DRUGINFO	D0K2CZ	1,1-Dimethyl-5-oxa-spiro[2.4]heptan-4-one	Investigative
T51487	DRUGINFO	D0KS3X	U-89267	Investigative
T51487	DRUGINFO	D0L2KB	RO-145974	Investigative
T51487	DRUGINFO	D0M0ZX	6-ethyl-3-(2-ethylbutoxycarbonyl)-4-quinolone	Investigative
T51487	DRUGINFO	D0M2AY	6-ethyl-3-propylaminocarbonyl-4-quinolone	Investigative
T51487	DRUGINFO	D0O9SG	2-(4-chlorophenyl)-5-phenyl-4-isoxazolin-3-one	Investigative
T51487	DRUGINFO	D0Q8UV	RO-145975	Investigative
T51487	DRUGINFO	D0R1IL	4-Naphthalen-2-yl-5-piperidin-4-yl-isoxazol-3-ol	Investigative
T51487	DRUGINFO	D0S6ME	6-benzyl-3-propoxycarbonyl-4-quinolone	Investigative
T51487	DRUGINFO	D0TJ2L	RO-147437	Investigative
T51487	DRUGINFO	D0U9ET	6,6-Dimethyl-2-oxa-spiro[4.4]nonan-1-one	Investigative
T51487	DRUGINFO	D0UQ6J	RO-194603	Investigative
T51487	DRUGINFO	D0W5IP	GNF-PF-3645	Investigative
T51487	DRUGINFO	D0WC5L	3-butylaminocarbonyl-6-ethyl-4-quinolone	Investigative
T51487	DRUGINFO	D0X4OW	2-Oxa-spiro[4.4]nonan-1-one	Investigative
T51487	DRUGINFO	D0YS9E	4-Phenyl-5-piperidin-4-yl-isoxazol-3-ol	Investigative
T51487	DRUGINFO	D01UAS	6-bromo-3-ethoxycarbonyl-4-quinolone	Investigative
T51487	DRUGINFO	D02CZO	6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone	Investigative
T51487	DRUGINFO	D03LMR	6-benzyl-3-ethoxycarbonyl-4-quinolone	Investigative
T51487	DRUGINFO	D0H4GQ	RY-066	Investigative
T51487	DRUGINFO	D01CUR	3-Ethoxy-9H-beta-carboline	Investigative
T51487	DRUGINFO	D01RLF	9H-beta-Carboline-3-carboxylic acid ethyl ester	Investigative
T51487	DRUGINFO	D03PPZ	Beta-Carboline-3-carboxylic acid t-butyl ester	Investigative
T51487	DRUGINFO	D03TMD	Barbituric acid derivative	Investigative
T51487	DRUGINFO	D04RVA	3-demethoxy-3-D-lyxopyranosylaminothiocolchicine	Investigative
T51487	DRUGINFO	D06WMM	3-Butoxy-9H-beta-carboline	Investigative
T51487	DRUGINFO	D06XGL	3-demethoxy-3-D-xylopyranosylaminothiocolchicine	Investigative
T51487	DRUGINFO	D08BOP	3-Propoxy-9H-beta-carboline	Investigative
T51487	DRUGINFO	D08BXK	3-(3-Methyl-butoxy)-9H-beta-carboline	Investigative
T51487	DRUGINFO	D08YLW	3-demethoxy-3-L-fucopyranosylaminothiocolchicine	Investigative
T51487	DRUGINFO	D09MHS	3-demethoxy-3D-glucopyranosylaminothiocolchicine	Investigative
T51487	DRUGINFO	D09MYJ	3-Isobutoxy-9H-beta-carboline	Investigative
T51487	DRUGINFO	D0C6WO	Sec-butyl 9H-pyrido[3,4-b]indole-3-carboxylate	Investigative
T51487	DRUGINFO	D0D4MM	Ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate	Investigative
T51487	DRUGINFO	D0E7PY	Ro-4938581	Investigative
T51487	DRUGINFO	D0LP2K	3-demethoxy-3-D-mannopyranosylaminothiocolchicine	Investigative
T51487	DRUGINFO	D0O9MG	L-655708	Investigative
T51487	DRUGINFO	D0P3BU	3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole	Investigative
T51487	DRUGINFO	D0R5OU	3-(benzyloxy)-9H-pyrido[3,4-b]indole	Investigative
T51487	DRUGINFO	D01IHM	CI-218872	Investigative
T51487	DRUGINFO	D07NKO	5-[(1R)-1-ammonioethyl]isoxazol-3-olate	Investigative
T51487	DRUGINFO	D09ACO	(2E,4S)-4-ammoniopent-2-enoate	Investigative
T51487	DRUGINFO	D0A8EU	(4R)-4-ammoniopentanoate	Investigative
T51487	DRUGINFO	D0N0ZK	(4S)-4-ammoniopentanoate	Investigative
T51487	DRUGINFO	D0S0RK	flavone	Investigative
T51487	DRUGINFO	D0S5PS	5-[(1S)-1-ammonioethyl]isoxazol-3-olate	Investigative
T51487	DRUGINFO	D00WHO	Ro-15-3505	Investigative
T51487	DRUGINFO	D0M4CP	[3H]Ro154513	Investigative
T51487	DRUGINFO	D0M9RM	[3H]CGS8216	Investigative
T51487	DRUGINFO	D06HRX	AMENTOFLAVONE	Investigative

T89697	TARGETID	T89697
T89697	FORMERID	TTDS00476
T89697	UNIPROID	I23O1_HUMAN
T89697	TARGNAME	Indoleamine 2,3-dioxygenase 1 (IDO1)
T89697	GENENAME	IDO1
T89697	TARGTYPE	Successful
T89697	SYNONYMS	Indoleamine-pyrrole 2,3-dioxygenase; INDO; IDO-1; IDO
T89697	FUNCTION	Involved in the peripheral immune tolerance, contributing to maintain homeostasis by preventing autoimmunity or immunopathology that would result from uncontrolled and overreacting immune responses. Tryptophan shortage inhibits T lymphocytes division and accumulation of tryptophan catabolites induces T-cell apoptosis and differentiation of regulatory T-cells. Acts as a suppressor of anti-tumor immunity. Limits the growth of intracellular pathogens by depriving tryptophan. Protects the fetus from maternal immune rejection. Catalyzes the first and rate limiting step of the catabolism of the essential amino acid tryptophan along the kynurenine pathway.
T89697	PDBSTRUC	6MQ6; 6F0A; 6DPR; 6DPQ; 6CXV
T89697	BIOCLASS	Oxygenase
T89697	ECNUMBER	EC 1.13.11.52
T89697	SEQUENCE	MAHAMENSWTISKEYHIDEEVGFALPNPQENLPDFYNDWMFIAKHLPDLIESGQLRERVEKLNMLSIDHLTDHKSQRLARLVLGCITMAYVWGKGHGDVRKVLPRNIAVPYCQLSKKLELPPILVYADCVLANWKKKDPNKPLTYENMDVLFSFRDGDCSKGFFLVSLLVEIAAASAIKVIPTVFKAMQMQERDTLLKALLEIASCLEKALQVFHQIHDHVNPKAFFSVLRIYLSGWKGNPQLSDGLVYEGFWEDPKEFAGGSAGQSSVFQCFDVLLGIQQTAGGGHAAQFLQDMRRYMPPAHRNFLCSLESNPSVREFVLSKGDAGLREAYDACVKALVSLRSYHLQIVTKYILIPASQQPKENKTSEDPSKLEAKGTGGTDLMNFLKTVRSTTEKSLLKEG
T89697	DRUGINFO	D05EJG	L-Tryptophan	Approved
T89697	DRUGINFO	D0DP5I	BMS-986205	Phase 3
T89697	DRUGINFO	D0G7MV	INCB24360	Phase 3
T89697	DRUGINFO	D0C0NH	Avastin+/-Tarceva	Phase 3
T89697	DRUGINFO	D0B5HS	NLG8189	Phase 2/3
T89697	DRUGINFO	D08XDL	KHK2455	Phase 1
T89697	DRUGINFO	D0C4PB	LY3381916	Phase 1
T89697	DRUGINFO	D0J1HB	PF-06840003	Phase 1
T89697	DRUGINFO	D0N4VB	NLG802	Phase 1
T89697	DRUGINFO	DGCQ13	MK-7162	Phase 1
T89697	DRUGINFO	D9S7XO	DN1406131	Phase 1
T89697	DRUGINFO	DB53NH	HTI-1090	Phase 1
T89697	DRUGINFO	D00JLX	Sulfonamide derivative 6	Patented
T89697	DRUGINFO	D01NST	Monofluorine derivative 1	Patented
T89697	DRUGINFO	D02XQE	PMID29473428-Compound-39	Patented
T89697	DRUGINFO	D03CTR	PMID29473428-Compound-50	Patented
T89697	DRUGINFO	D03CYB	Aryl 1,2-diamine derivative 1	Patented
T89697	DRUGINFO	D03JQL	PMID29473428-Compound-6	Patented
T89697	DRUGINFO	D03NHO	Monoaryl-1,2-diamine derivative 1	Patented
T89697	DRUGINFO	D03PQB	Imidazoleisoindoles derivative 1	Patented
T89697	DRUGINFO	D03TZE	PMID29473428-Compound-22	Patented
T89697	DRUGINFO	D03ZMX	Monoaryl-1,2-diamine derivative 3	Patented
T89697	DRUGINFO	D04VUH	PMID29473428-Compound-48	Patented
T89697	DRUGINFO	D04WCW	Hydoxyamidine derivative 1	Patented
T89697	DRUGINFO	D05BYE	Hydroxy amidine derivative 2	Patented
T89697	DRUGINFO	D05CNJ	Five-membered heteroaromatic compound 1	Patented
T89697	DRUGINFO	D05QAL	Hydroxy amidine derivative 1	Patented
T89697	DRUGINFO	D06FHJ	Sulfonamide derivative 8	Patented
T89697	DRUGINFO	D06HOA	Indazole derivative 2	Patented
T89697	DRUGINFO	D06SKI	Sulfamic acid ester derivative 1	Patented
T89697	DRUGINFO	D07JFY	PMID29473428-Compound-43	Patented
T89697	DRUGINFO	D07NFQ	PMID29473428-Compound-16	Patented
T89697	DRUGINFO	D08XQG	PMID29473428-Compound-59	Patented
T89697	DRUGINFO	D09FPV	PMID29473428-Compound-4	Patented
T89697	DRUGINFO	D09HVV	PMID29473428-Compound-58	Patented
T89697	DRUGINFO	D09LKN	PMID29473428-Compound-53	Patented
T89697	DRUGINFO	D09TSM	Imidazoleisoindoles derivative 2	Patented
T89697	DRUGINFO	D0B5FA	Benzimidazole and imadazopyridine carboximidamide compound 2	Patented
T89697	DRUGINFO	D0B7LR	Biphenyl derivative 3	Patented
T89697	DRUGINFO	D0BK2I	Pyridine derivative 1	Patented
T89697	DRUGINFO	D0CE7G	Cyclohexyl-ethyl-substituted diaza and triaza-tricyclic compound 1	Patented
T89697	DRUGINFO	D0DA8D	Hexahydro quinoline derivative 1	Patented
T89697	DRUGINFO	D0DW4P	PMID29473428-Compound-15	Patented
T89697	DRUGINFO	D0E4BN	Monoaryl-1,2-diamine derivative 4	Patented
T89697	DRUGINFO	D0F3VN	Sulfamoylamide derivative 1	Patented
T89697	DRUGINFO	D0FY1Q	PMID29473428-Compound-52	Patented
T89697	DRUGINFO	D0GV6B	Monoaryl-1,2-diamine derivative 2	Patented
T89697	DRUGINFO	D0H3ZZ	PMID29473428-Compound-71	Patented
T89697	DRUGINFO	D0IE8M	Cyclic hydroxamate derivative 1	Patented
T89697	DRUGINFO	D0IS1M	PMID29473428-Compound-34	Patented
T89697	DRUGINFO	D0IT3V	Thieno[2,3-c]pyridine derivative 1	Patented
T89697	DRUGINFO	D0IY1Z	Azetidine derivative 5	Patented
T89697	DRUGINFO	D0JR2C	PMID29473428-Compound-29	Patented
T89697	DRUGINFO	D0K4KM	PMID29473428-Compound-60	Patented
T89697	DRUGINFO	D0K8EV	PMID29473428-Compound-11	Patented
T89697	DRUGINFO	D0L4GL	Biphenyl derivative 2	Patented
T89697	DRUGINFO	D0L8KM	PMID29473428-Compound-14	Patented
T89697	DRUGINFO	D0L9BG	PMID29473428-Compound-10	Patented
T89697	DRUGINFO	D0M8KB	Amide derivative 2	Patented
T89697	DRUGINFO	D0MO3W	Pyridino tricyclic compound 1	Patented
T89697	DRUGINFO	D0N6UO	PMID29473428-Compound-47	Patented
T89697	DRUGINFO	D0OZ8W	Biphenyl derivative 1	Patented
T89697	DRUGINFO	D0P1HR	PMID29473428-Compound-21	Patented
T89697	DRUGINFO	D0Q3SU	Benzimidazole and imadazopyridine carboximidamide compound 1	Patented
T89697	DRUGINFO	D0QZ8K	Acyl piperidine derivative 1	Patented
T89697	DRUGINFO	D0R0QY	Pyrrolo[1,2-c]pyrazole derivative 1	Patented
T89697	DRUGINFO	D0R8OW	Sulfonamide derivative 7	Patented
T89697	DRUGINFO	D0RH9K	Imidazo[1,5-a]pyridine derivative 2	Patented
T89697	DRUGINFO	D0S7BW	PMID29473428-Compound-33	Patented
T89697	DRUGINFO	D0T5WX	Biphenyl 1,2-diamine derivative 1	Patented
T89697	DRUGINFO	D0T9XC	Five-membered heteroaromatic compound 2	Patented
T89697	DRUGINFO	D0U3KX	PMID29473428-Compound-70	Patented
T89697	DRUGINFO	D0UC2S	Indazole derivative 4	Patented
T89697	DRUGINFO	D0UI9T	Carbamide derivative 13	Patented
T89697	DRUGINFO	D0UZ6C	Five-membered heteroaromatic compound 3	Patented
T89697	DRUGINFO	D0V3KH	PMID29473428-Compound-41	Patented
T89697	DRUGINFO	D0WR7B	Imidazo isoindole derivative 1	Patented
T89697	DRUGINFO	D0XT4V	PMID29473428-Compound-17	Patented
T89697	DRUGINFO	D0YV6X	PMID29473428-Compound-72	Patented
T89697	DRUGINFO	D0YW4T	Aryl sulphoxide imine derivative 1	Patented
T89697	DRUGINFO	D0YY4R	PMID29473428-Compound-54	Patented
T89697	DRUGINFO	D0Z5PM	PMID29473428-Compound-80	Patented
T89697	DRUGINFO	D0ZV6F	Imidazo[1,5-a]pyridine derivative 1	Patented
T89697	DRUGINFO	D0E8XV	2,3-diamino-benzo[b]thiophene derivative 3	Patented
T89697	DRUGINFO	D0F4MN	PMID29473428-Compound-76	Patented
T89697	DRUGINFO	D0JB1V	Indazole derivative 3	Patented
T89697	DRUGINFO	D04BZI	2,3-diamino-benzo[b]thiophene derivative 4	Patented
T89697	DRUGINFO	D04MIQ	PMID27172114-Compound-30	Patented
T89697	DRUGINFO	D05TIP	2,3-diamino-benzo[b]thiophene derivative 2	Patented
T89697	DRUGINFO	D05ZGX	2,3-diamino-benzo[b]thiophene derivative 8	Patented
T89697	DRUGINFO	D0F4VD	2,3-diamino-benzo[b]thiophene derivative 7	Patented
T89697	DRUGINFO	D0FF6H	2,3-diamino-benzo[b]thiophene derivative 6	Patented
T89697	DRUGINFO	D0HV0Y	2,3-diamino-benzo[b]thiophene derivative 5	Patented
T89697	DRUGINFO	D0RA7I	2,3-diamino-benzo[b]thiophene derivative 1	Patented
T89697	DRUGINFO	D06YFT	1-methyl-L-tryptophan	Preclinical
T89697	DRUGINFO	D9P8LE	RG70099	Preclinical
T89697	DRUGINFO	DZK24C	EPL-1410	Preclinical
T89697	DRUGINFO	D00BGN	2-(1H-Imidazol-4-yl)benzene-1,3-diol	Investigative
T89697	DRUGINFO	D00GYX	BENZENEMETHANETHIOL	Investigative
T89697	DRUGINFO	D00UIK	4-(Benzylamino)-1-naphthol	Investigative
T89697	DRUGINFO	D00XOT	4-(2-Hydroxyethoxy)-1-naphthol	Investigative
T89697	DRUGINFO	D01CSZ	5-(isopropylamino)quinolin-8-ol	Investigative
T89697	DRUGINFO	D01HST	amg-1	Investigative
T89697	DRUGINFO	D02DRL	S-(2-Chlorobenzyl)isothiourea hydrochloride	Investigative
T89697	DRUGINFO	D02IVJ	S-(4-Fluorobenzyl)isothiourea hydrochloride	Investigative
T89697	DRUGINFO	D02SRL	4-phenylthiazole-2-thiol	Investigative
T89697	DRUGINFO	D02XRG	4-(ethylamino)naphthalen-1-ol	Investigative
T89697	DRUGINFO	D03ETX	S-Benzyl-brassinin	Investigative
T89697	DRUGINFO	D03JAE	S-(4-Bromobenzyl)isothiourea hydrobromide	Investigative
T89697	DRUGINFO	D03JMD	S-(4-Cyanobenzyl)isothiourea hydrobromide	Investigative
T89697	DRUGINFO	D04OXY	2-methoxy-1,4-naphthoquinone	Investigative
T89697	DRUGINFO	D05AFW	S-(4-Ethylbenzyl)isothiourea hydrochloride	Investigative
T89697	DRUGINFO	D05LFV	S-(4-Methylbenzyl)isothiourea hydrochloride	Investigative
T89697	DRUGINFO	D06BBF	BLV-0801	Investigative
T89697	DRUGINFO	D06MUL	N-[2-(Indol-3-yl)ethyl]-S-benzyl-dithiocarbamate	Investigative
T89697	DRUGINFO	D06OUR	4-(2-(diethylamino)ethylamino)-1-naphthol	Investigative
T89697	DRUGINFO	D07NSZ	S-(3-Chlorobenzyl)isothiourea hydrochloride	Investigative
T89697	DRUGINFO	D07RGV	ANNULIN B	Investigative
T89697	DRUGINFO	D08GZK	EXIGUAMINE B	Investigative
T89697	DRUGINFO	D08MOG	4-(Pent-3-ylamino)-1-naphthol	Investigative
T89697	DRUGINFO	D08MRL	4-(propylamino)naphthalen-1-ol	Investigative
T89697	DRUGINFO	D08PIF	4-Methoxybenzenemethanethiol	Investigative
T89697	DRUGINFO	D08XXD	4-aminonaphthalen-1-ol	Investigative
T89697	DRUGINFO	D08YHA	2,2-dimethyl-2H-benzo[g]chromene-5,10-dione	Investigative
T89697	DRUGINFO	D09BVH	Naphthalene-1,4-diol	Investigative
T89697	DRUGINFO	D09DSZ	2,3-dihydrobenzo[d]thiazole-2-thiol	Investigative
T89697	DRUGINFO	D09JOM	S-(2,4-Dichlorobenzyl)isothiourea hydrobromide	Investigative
T89697	DRUGINFO	D09ZJW	4-Chlorobenzenemethanethiol	Investigative
T89697	DRUGINFO	D0A7NH	4-(Cyclohexylamino)-1-naphthol	Investigative
T89697	DRUGINFO	D0B9IA	ANNULIN C	Investigative
T89697	DRUGINFO	D0DB2N	ANNULIN A	Investigative
T89697	DRUGINFO	D0DR7W	Seco-exiguamine	Investigative
T89697	DRUGINFO	D0G0EE	3-(1H-Imidazol-4-yl)benzenethiol	Investigative
T89697	DRUGINFO	D0G3RO	3-(4H-Imidazol-4-yl)benzenethiol	Investigative
T89697	DRUGINFO	D0G8IH	4-(methylamino)naphthalen-1-ol	Investigative
T89697	DRUGINFO	D0I2RW	2,3-dichloro-1,4-naphthoquinone	Investigative
T89697	DRUGINFO	D0I9AT	tryptanthrin	Investigative
T89697	DRUGINFO	D0J9DD	4-Phenylimidazole	Investigative
T89697	DRUGINFO	D0J9JH	GARVEATIN A	Investigative
T89697	DRUGINFO	D0K3SZ	4-Methylbenzenemethanethiol	Investigative
T89697	DRUGINFO	D0K4MG	2-HYDROXYGARVIN A	Investigative
T89697	DRUGINFO	D0MC4U	Exiguamine A	Investigative
T89697	DRUGINFO	D0N1ZJ	4-(tert-butylamino)naphthalen-1-ol	Investigative
T89697	DRUGINFO	D0N6QU	2-hydroxygarveatin E	Investigative
T89697	DRUGINFO	D0NI8W	2-(1H-Imidazol-4-yl)phenol	Investigative
T89697	DRUGINFO	D0O3IE	5-phenyl-1H-1,2,3-triazole	Investigative
T89697	DRUGINFO	D0O9QG	S-(4-Chlorobenzyl)isothiourea hydrochloride	Investigative
T89697	DRUGINFO	D0P1CO	S-(3,4-Dichlorobenzyl)isothiourea hydrochloride	Investigative
T89697	DRUGINFO	D0P2ET	Garveatin E	Investigative
T89697	DRUGINFO	D0P3XW	2-Chlorobenzenemethanethiol	Investigative
T89697	DRUGINFO	D0PR7L	4-Fluorobenzenemethanethiol	Investigative
T89697	DRUGINFO	D0Q9JG	S-(4-Methoxybenzyl)isothiourea hydrochloride	Investigative
T89697	DRUGINFO	D0S1FF	4-(Isopropylamino)-1-naphthol	Investigative
T89697	DRUGINFO	D0SZ9F	2,4-Dichlorobenzenemethanethiol	Investigative
T89697	DRUGINFO	D0TM0Z	1H-indole-4,7-dione	Investigative
T89697	DRUGINFO	D0UV8T	4-(1H-1,2,3-triazol-5-yl)pyridine	Investigative
T89697	DRUGINFO	D0W3ON	5-aminoquinolin-8-ol	Investigative
T89697	DRUGINFO	D0W3OY	S-(4-Nitrobenzyl)isothiourea hydrochloride	Investigative
T89697	DRUGINFO	D0W3XP	Garveatin C	Investigative
T89697	DRUGINFO	D0YU9L	4-amino-1,2,5-oxadiazole-3-carboximidamide	Investigative
T89697	DRUGINFO	D0Z0BB	3,4-Dichlorobenzenemethanethiol	Investigative
T89697	DRUGINFO	D0Z3NE	PMID24099220C5i	Investigative
T89697	DRUGINFO	D0Z4JG	4-methoxynaphthalen-1-amine	Investigative
T89697	DRUGINFO	D0DQ6Z	1,4-Naphthoquinone	Investigative
T89697	DRUGINFO	D0W9VA	1,2-NAPHTHOQUINONE	Investigative

T56365	TARGETID	T56365
T56365	FORMERID	TTDC00135
T56365	UNIPROID	CD19_HUMAN
T56365	TARGNAME	B-lymphocyte surface antigen B4 (CD19)
T56365	GENENAME	CD19
T56365	TARGTYPE	Successful
T56365	SYNONYMS	T-cell surface antigen Leu-12; Leu-12; Differentiation antigen CD19; B-lymphocyte antigen CD19
T56365	FUNCTION	Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens. Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca(2+) stores. Is not required for early steps during B cell differentiation in the blood marrow. Required for normal differentiation of B-1 cells. Required for normal B cell differentiation and proliferation in response to antigen challenges. Required for normal levels of serum immunoglobulins, and for production of high-affinity antibodies in response to antigen challenge. Functions as coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes.
T56365	PDBSTRUC	6AL5
T56365	BIOCLASS	Immunoglobulin
T56365	SEQUENCE	MPPPRLLFFLLFLTPMEVRPEEPLVVKVEEGDNAVLQCLKGTSDGPTQQLTWSRESPLKPFLKLSLGLPGLGIHMRPLAIWLFIFNVSQQMGGFYLCQPGPPSEKAWQPGWTVNVEGSGELFRWNVSDLGGLGCGLKNRSSEGPSSPSGKLMSPKLYVWAKDRPEIWEGEPPCLPPRDSLNQSLSQDLTMAPGSTLWLSCGVPPDSVSRGPLSWTHVHPKGPKSLLSLELKDDRPARDMWVMETGLLLPRATAQDAGKYYCHRGNLTMSFHLEITARPVLWHWLLRTGGWKVSAVTLAYLIFCLCSLVGILHLQRALVLRRKRKRMTDPTRRFFKVTPPPGSGPQNQYGNVLSLPTPTSGLGRAQRWAAGLGGTAPSYGNPSSDVQADGALGSRSPPGVGPEEEEGEGYEEPDSEEDSEFYENDSNLGQDQLSQDGSGYENPEDEPLGPEDEDSFSNAESYENEDEELTQPVARTMDFLSPHGSAWDPSREATSLGSQSYEDMRGILYAAPQLRSIRGQPGPNHEEDADSYENMDNPDGPDPAWGGGGRMGTWSTR
T56365	DRUGINFO	D0DK5R	Axicabtagene ciloleucel	Approved
T56365	DRUGINFO	D0M4WU	Lisocabtagene maraleucel	Approved
T56365	DRUGINFO	D0XH3V	Inebilizumab	Approved
T56365	DRUGINFO	D18SHN	Tecartus	Approved
T56365	DRUGINFO	D8L5PA	Loncastuximab tesirine	Approved
T56365	DRUGINFO	D0IM6T	Tisagenlecleucel	Approved
T56365	DRUGINFO	D0K4RK	Blinatumomab	Approved
T56365	DRUGINFO	D4I3HU	Obexelimab	Phase 3
T56365	DRUGINFO	D02CYL	MOR-208	Phase 2/3
T56365	DRUGINFO	D03IOM	CART-19	Phase 2/3
T56365	DRUGINFO	D04YSC	CD19 CAR T cells	Phase 2/3
T56365	DRUGINFO	D00UNK	Coltuximab ravtansine	Phase 2
T56365	DRUGINFO	D05MGQ	MDX-1342	Phase 2
T56365	DRUGINFO	D06TKR	CART 19	Phase 2
T56365	DRUGINFO	D07FGK	SAR-3419	Phase 2
T56365	DRUGINFO	D09BWG	CAR-T cells targeting CD19	Phase 2
T56365	DRUGINFO	D0F1HT	MB-CART19.1	Phase 2
T56365	DRUGINFO	D0G4IW	CART-19	Phase 2
T56365	DRUGINFO	D0HM1V	KYMRIAH	Phase 2
T56365	DRUGINFO	D0I0NJ	CART-19 cells	Phase 2
T56365	DRUGINFO	D0I0UM	CTL019	Phase 2
T56365	DRUGINFO	D0I8OY	XLCART001	Phase 2
T56365	DRUGINFO	D0K3XB	JCAR015	Phase 2
T56365	DRUGINFO	D0L5HM	CD19 CAR T cells	Phase 2
T56365	DRUGINFO	D0R3ZE	MEDI-551	Phase 2
T56365	DRUGINFO	D0RA1R	CD19-targeting CAR T cells	Phase 2
T56365	DRUGINFO	DLN4R8	Minjuvi	Phase 2
T56365	DRUGINFO	D00NXT	Xmab 5871	Phase 2
T56365	DRUGINFO	D02BCY	CD19 CART	Phase 1/2
T56365	DRUGINFO	D02BHW	IM19 CAR-T	Phase 1/2
T56365	DRUGINFO	D03JOA	Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes	Phase 1/2
T56365	DRUGINFO	D03UNT	Anti-CD19-CAR vector-transduced T cells	Phase 1/2
T56365	DRUGINFO	D04FPN	CD19 CAR-T lymphocytes	Phase 1/2
T56365	DRUGINFO	D04JHH	CAR-T cells targeting CD19	Phase 1/2
T56365	DRUGINFO	D05LIH	Anti-CD19 CAR-T cells	Phase 1/2
T56365	DRUGINFO	D07NHZ	CD19 CAR T cells	Phase 1/2
T56365	DRUGINFO	D08BPS	JCAR017	Phase 1/2
T56365	DRUGINFO	D0B3HF	SCRI-huCAR19v1	Phase 1/2
T56365	DRUGINFO	D0CE0Y	Anti-CD19-CAR-T cells	Phase 1/2
T56365	DRUGINFO	D0D9BL	Anti-CD19 CAR-T cells	Phase 1/2
T56365	DRUGINFO	D0EH1J	CD19.CAR-T cells	Phase 1/2
T56365	DRUGINFO	D0FF0N	TBI-1501	Phase 1/2
T56365	DRUGINFO	D0FR3J	CD19 specific CAR T cells	Phase 1/2
T56365	DRUGINFO	D0G5WV	KTE-C19 CAR	Phase 1/2
T56365	DRUGINFO	D0GT3R	Anti-CD19 CAR-T cells	Phase 1/2
T56365	DRUGINFO	D0HO1A	CD19 CAR Gene Transduced T Lymphocytes	Phase 1/2
T56365	DRUGINFO	D0J3DN	Anti-CD19-CAR PBL	Phase 1/2
T56365	DRUGINFO	D0JD4T	Anti-CD19 CAR transduced T cells	Phase 1/2
T56365	DRUGINFO	D0JV4R	TriCAR-T-CD19	Phase 1/2
T56365	DRUGINFO	D0KF9T	Anti-CD19 CAR-T	Phase 1/2
T56365	DRUGINFO	D0LF6M	Chimeric Antigen Receptor Modified T cells Targeting CD19	Phase 1/2
T56365	DRUGINFO	D0M0CO	PCAR-019	Phase 1/2
T56365	DRUGINFO	D0MV4T	CD19.CAR T Cells	Phase 1/2
T56365	DRUGINFO	D0N3GE	CD19 CART	Phase 1/2
T56365	DRUGINFO	D0NJ3T	CART-19 cells	Phase 1/2
T56365	DRUGINFO	D0O6LR	Autologous CD19-targeting CAR T cells	Phase 1/2
T56365	DRUGINFO	D0OP7I	CARCIK-CD19	Phase 1/2
T56365	DRUGINFO	D0OZ5H	CD19-CAR T cell	Phase 1/2
T56365	DRUGINFO	D0PN3M	CD19-directed CAR-T cells	Phase 1/2
T56365	DRUGINFO	D0Q5EH	Anti-CD19 CAR-T cells	Phase 1/2
T56365	DRUGINFO	D0QF0L	CD19 CAR-T Cells	Phase 1/2
T56365	DRUGINFO	D0R3IG	SJCAR19	Phase 1/2
T56365	DRUGINFO	D0S4IR	PBCAR0191	Phase 1/2
T56365	DRUGINFO	D0SV4A	CD19 targeted chimeric antigen receptor T cells	Phase 1/2
T56365	DRUGINFO	D0TE0L	4SCAR19 cells	Phase 1/2
T56365	DRUGINFO	D0U0BN	JCAR014	Phase 1/2
T56365	DRUGINFO	D0UM8Q	UCART019	Phase 1/2
T56365	DRUGINFO	D0W8WG	CD19-targeting CAR T Cells	Phase 1/2
T56365	DRUGINFO	D0XG0L	Anti-CD19 CAR T cells	Phase 1/2
T56365	DRUGINFO	D0XY6T	Humanized CD19 CAR-T cells	Phase 1/2
T56365	DRUGINFO	D0YY6O	CLIC-1901	Phase 1/2
T56365	DRUGINFO	D0Z8GD	CD19 CAR T Cells	Phase 1/2
T56365	DRUGINFO	D1HID7	ALLO-501A	Phase 1/2
T56365	DRUGINFO	DN2MC5	AUTO1	Phase 1/2
T56365	DRUGINFO	DN71VY	TAK-007	Phase 1/2
T56365	DRUGINFO	DS53MJ	TC-110	Phase 1/2
T56365	DRUGINFO	D02ONA	AUTO3	Phase 1/2
T56365	DRUGINFO	D02YRD	4SCAR19 and 4SCAR70	Phase 1/2
T56365	DRUGINFO	D03ZCH	4SCAR19 and 4SCAR20	Phase 1/2
T56365	DRUGINFO	D04GIO	Anti-CD19 and Anti-CD20 CAR-T Cells	Phase 1/2
T56365	DRUGINFO	D05OAI	CART-19/22	Phase 1/2
T56365	DRUGINFO	D05VNS	CD19 and CD22 CAR-T Cells	Phase 1/2
T56365	DRUGINFO	D08FVH	4SCAR19/22 T cells	Phase 1/2
T56365	DRUGINFO	D08JTI	Anti-CD19/22-CAR vector-transduced T cells	Phase 1/2
T56365	DRUGINFO	D0AC9S	CART-19/BCMA	Phase 1/2
T56365	DRUGINFO	D0BH2M	4SCAR19 and 4SCAR123	Phase 1/2
T56365	DRUGINFO	D0E2CS	CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells	Phase 1/2
T56365	DRUGINFO	D0I4HG	4SCAR19 and 4SCAR38	Phase 1/2
T56365	DRUGINFO	D0J7VH	4SCAR19 and 4SCAR22	Phase 1/2
T56365	DRUGINFO	D0K8YX	4SCAR19 and 4SCAR30	Phase 1/2
T56365	DRUGINFO	D0MA4O	Anti-CD20 CAR-T cells	Phase 1/2
T56365	DRUGINFO	D0QB1O	CD19 and CD20 CAR-T Cells	Phase 1/2
T56365	DRUGINFO	D0W4SM	CD19 and CD22 CAR-T Cells	Phase 1/2
T56365	DRUGINFO	D00MUC	CD19 CAR-T cells	Phase 1
T56365	DRUGINFO	D00YUQ	CART-19 T cells	Phase 1
T56365	DRUGINFO	D01HAT	CD19.CAR-aNKT cells	Phase 1
T56365	DRUGINFO	D02NFE	Anti-CD19 CART Cells	Phase 1
T56365	DRUGINFO	D02XYW	CD19-directed CAR-T cells	Phase 1
T56365	DRUGINFO	D03EIA	Anti-CD19-CAR T	Phase 1
T56365	DRUGINFO	D03LFA	Allogeneic CART-19	Phase 1
T56365	DRUGINFO	D04BVL	IM19	Phase 1
T56365	DRUGINFO	D04KWO	MEDl-551	Phase 1
T56365	DRUGINFO	D05DKT	CART19 cell	Phase 1
T56365	DRUGINFO	D05UOU	CD19-CAR-T2 Cells	Phase 1
T56365	DRUGINFO	D05XPZ	JWCAR029	Phase 1
T56365	DRUGINFO	D06TNO	CD19 CAR T-cells	Phase 1
T56365	DRUGINFO	D06UTM	Anti-CD19-CAR T cells	Phase 1
T56365	DRUGINFO	D07ITH	4SCAR19 cells	Phase 1
T56365	DRUGINFO	D07TMJ	EGFRt/19-28z/4-1BBL CAR T cells	Phase 1
T56365	DRUGINFO	D08LLB	Human CD19 targeted T Cells	Phase 1
T56365	DRUGINFO	D09SAH	PZ01 CAR-T cells	Phase 1
T56365	DRUGINFO	D0A2RX	19-28z T CELLS	Phase 1
T56365	DRUGINFO	D0A6XC	CD19-targeted CART cells	Phase 1
T56365	DRUGINFO	D0B1CU	CD19 CAR T-cells	Phase 1
T56365	DRUGINFO	D0BQ0C	CD19 CAR-T cells	Phase 1
T56365	DRUGINFO	D0C5FA	Duvortuxizumab	Phase 1
T56365	DRUGINFO	D0CS3A	CART-19	Phase 1
T56365	DRUGINFO	D0DR6N	CART-19 cells	Phase 1
T56365	DRUGINFO	D0DU4T	IC9-CAR19 cells	Phase 1
T56365	DRUGINFO	D0E2VF	CD19 Redirected Autologous T Cells	Phase 1
T56365	DRUGINFO	D0EO6G	Anti-CD19-CAR	Phase 1
T56365	DRUGINFO	D0F1OH	CD19CAT-41BBZ CAR T-cells	Phase 1
T56365	DRUGINFO	D0G8YJ	CD19-TriCAR-T	Phase 1
T56365	DRUGINFO	D0GC3U	CD19-directed CAR-T cells	Phase 1
T56365	DRUGINFO	D0J6WE	CD19-CAR-T Cells	Phase 1
T56365	DRUGINFO	D0JD6Y	CD19 CAR T	Phase 1
T56365	DRUGINFO	D0KZ0V	CD19 CAR T Cells	Phase 1
T56365	DRUGINFO	D0M5II	CART-19 autologous T-cells	Phase 1
T56365	DRUGINFO	D0MWS2	YTB323	Phase 1
T56365	DRUGINFO	D0NV6I	Anti-CD19 CAR-T cells	Phase 1
T56365	DRUGINFO	D0O7VZ	AntiCD19 CART	Phase 1
T56365	DRUGINFO	D0OC5C	ICAR19 CAR-T cells	Phase 1
T56365	DRUGINFO	D0OD8T	CD19 CAR T cells	Phase 1
T56365	DRUGINFO	D0PE3J	CAR-T Cells targeting CD19	Phase 1
T56365	DRUGINFO	D0PH6Z	CD19+ CAR T Cells	Phase 1
T56365	DRUGINFO	D0PY5I	IC9-CAR19 T cells	Phase 1
T56365	DRUGINFO	D0Q8XO	CART-19	Phase 1
T56365	DRUGINFO	D0S5BC	CART-19 cells	Phase 1
T56365	DRUGINFO	D0SD9R	ARI-0001 cells	Phase 1
T56365	DRUGINFO	D0TD0O	Anti-CD19 CAR-T	Phase 1
T56365	DRUGINFO	D0U7VS	CAR-T cells targeting CD19	Phase 1
T56365	DRUGINFO	D0U8PE	CAR19 T cells carrying cytoplasmic activated PD-1	Phase 1
T56365	DRUGINFO	D0V7BD	HuCART19	Phase 1
T56365	DRUGINFO	D0X6FU	C-CAR011	Phase 1
T56365	DRUGINFO	D2KB3W	ALLO-501	Phase 1
T56365	DRUGINFO	D2PFY3	AMG 562	Phase 1
T56365	DRUGINFO	D3DPR8	Sleeping Beauty CAR-TCR	Phase 1
T56365	DRUGINFO	D5DBU7	CarVAC	Phase 1
T56365	DRUGINFO	D67TOB	TAK-940	Phase 1
T56365	DRUGINFO	D6ONY2	KUR-502	Phase 1
T56365	DRUGINFO	DA0Q5P	ET019002	Phase 1
T56365	DRUGINFO	DB93YI	ET019003	Phase 1
T56365	DRUGINFO	DFJO04	NKX019	Phase 1
T56365	DRUGINFO	DH19QJ	CTX-101	Phase 1
T56365	DRUGINFO	DJVH04	CC-97540	Phase 1
T56365	DRUGINFO	DP0G9N	Anti-CD19 EBV CTL therapy	Phase 1
T56365	DRUGINFO	DR15DO	FT-819	Phase 1
T56365	DRUGINFO	DV3ZI0	CD19t-haNK	Phase 1
T56365	DRUGINFO	D00JCB	CD19/CD22 CAR T cells	Phase 1
T56365	DRUGINFO	D02BAA	Patient-derived CD19- and CD22 specific CAR	Phase 1
T56365	DRUGINFO	D02LNU	CART22-65s cells and huCART19 Cells	Phase 1
T56365	DRUGINFO	D03YEM	CD19/CD22 CAR T-Cells	Phase 1
T56365	DRUGINFO	D06RUK	Combotox	Phase 1
T56365	DRUGINFO	D07TCV	Anti-CD19 anti-CD20 Bispecific CAR-T	Phase 1
T56365	DRUGINFO	D0D7FV	CD19/CD22 Chimeric Antigen Receptor T Cells	Phase 1
T56365	DRUGINFO	D0MD8S	CARTmeso/19	Phase 1
T56365	DRUGINFO	D0NU9L	CAR-20/19-T Cells	Phase 1
T56365	DRUGINFO	D0QE4F	CD19-CAR and CD28-CAR T Cells	Phase 1
T56365	DRUGINFO	D0T8RV	BCMA CART and huCART19	Phase 1
T56365	DRUGINFO	D0U1HR	Donor-derived CD19/22 bispecific CAR-T cells	Phase 1
T56365	DRUGINFO	D0U7WY	Anti-CD19/BCMA CAR-T cells	Phase 1
T56365	DRUGINFO	D0V5DD	CART-meso-19 T cells	Phase 1
T56365	DRUGINFO	D0ZX6F	RG6333	Phase 1
T56365	DRUGINFO	D51HBQ	CD20-CD19 cCAR	Phase 1
T56365	DRUGINFO	D7LN0E	TNB-486	Phase 1
T56365	DRUGINFO	D8UNG2	TG-1801	Phase 1
T56365	DRUGINFO	DI6BK9	KITE-363	Phase 1
T56365	DRUGINFO	DTR05Z	BCMA-CD19 cCAR	Phase 1
T56365	DRUGINFO	DVOB28	AFM11	Phase 1
T56365	DRUGINFO	DZD4R6	RO7443904	Phase 1
T56365	DRUGINFO	D01JCT	CD19-CAR T Cells	Clinical trial
T56365	DRUGINFO	D04PDI	CD19-targeted CAR-T cells	Clinical trial
T56365	DRUGINFO	D05FZM	CD19-UCART	Clinical trial
T56365	DRUGINFO	D09IAN	Anti-CD19 Chimeric Antigen Receptor T Cells	Clinical trial
T56365	DRUGINFO	D09VYT	CD19-targeted CAR-T cells	Clinical trial
T56365	DRUGINFO	D0B8BZ	CD19CART	Clinical trial
T56365	DRUGINFO	D0U5NO	CAR-CD19 T cell	Clinical trial
T56365	DRUGINFO	D0NL9N	Anti-CD19/20-CAR vector-transduced T cells	Clinical trial
T56365	DRUGINFO	D0G5SK	Anti-CD19 CAR T cells	Phase 0
T56365	DRUGINFO	D0P4KP	CART19 cells	Phase 0
T56365	DRUGINFO	D0L4WO	SGN-19A	Preclinical
T56365	DRUGINFO	D28JEC	ATA3219	Preclinical
T56365	DRUGINFO	DY2EJ1	ATA2431	Preclinical
T56365	DRUGINFO	D0V2QU	Anti-CD22/CD19 mab-toxin conjugate	Investigative

T75498	TARGETID	T75498
T75498	FORMERID	TTDC00138
T75498	UNIPROID	NQO2_HUMAN
T75498	TARGNAME	Quinone reductase 2 (NQO2)
T75498	GENENAME	NQO2
T75498	TARGTYPE	Successful
T75498	SYNONYMS	Quinone oxidoreductase 2; Qui reductase 2; QR2; NRH:quinone oxidoreductase 2; NRH:qui oxidoreductase 2; NQO2; NAD(P)H qui oxidoreductase 2
T75498	FUNCTION	The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinones involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis.
T75498	PDBSTRUC	5LBZ; 5LBY; 5LBW; 5LBU; 5LBT
T75498	BIOCLASS	Diphenol donor oxidoreductase
T75498	ECNUMBER	EC 1.10.5.1
T75498	SEQUENCE	MAGKKVLIVYAHQEPKSFNGSLKNVAVDELSRQGCTVTVSDLYAMNLEPRATDKDITGTLSNPEVFNYGVETHEAYKQRSLASDITDEQKKVREADLVIFQFPLYWFSVPAILKGWMDRVLCQGFAFDIPGFYDSGLLQGKLALLSVTTGGTAEMYTKTGVNGDSRYFLWPLQHGTLHFCGFKVLAPQISFAPEIASEEERKGMVAAWSQRLQTIWKEEPIPCTAHWHFGQ
T75498	DRUGINFO	D0AN7B	Melatonin	Approved
T75498	DRUGINFO	D07JTD	NSC-645809	Phase 2
T75498	DRUGINFO	D0C6VV	Prolarix	Phase 2
T75498	DRUGINFO	D07ZHV	CB1954	Discontinued in Phase 2
T75498	DRUGINFO	D00DSW	NSC-640559	Investigative
T75498	DRUGINFO	D00GIU	NSC-238146	Investigative
T75498	DRUGINFO	D00GUG	NSC-665126	Investigative
T75498	DRUGINFO	D00OTC	NSC-381864	Investigative
T75498	DRUGINFO	D00SNO	NSC-645833	Investigative
T75498	DRUGINFO	D01DYZ	NSC-204996	Investigative
T75498	DRUGINFO	D01JID	NSC-660841	Investigative
T75498	DRUGINFO	D01WRT	NSC-300853	Investigative
T75498	DRUGINFO	D01ZKN	NSC-645836	Investigative
T75498	DRUGINFO	D02DOX	NSC-677939	Investigative
T75498	DRUGINFO	D02GDG	NSC-640353	Investigative
T75498	DRUGINFO	D02NED	NSC-637991	Investigative
T75498	DRUGINFO	D03GWA	NSC-669977	Investigative
T75498	DRUGINFO	D03QRT	NSC-645812	Investigative
T75498	DRUGINFO	D03SBI	NSC-660838	Investigative
T75498	DRUGINFO	D04KTJ	NSC-645834	Investigative
T75498	DRUGINFO	D04LWL	1,4-Dimethylquinolin-2(1H)-one	Investigative
T75498	DRUGINFO	D04PMX	NSC-115890	Investigative
T75498	DRUGINFO	D04UGI	NSC-645835	Investigative
T75498	DRUGINFO	D05GDD	NSC-645831	Investigative
T75498	DRUGINFO	D05TZK	NSC-693571	Investigative
T75498	DRUGINFO	D05YCI	6,7,8-Trimethoxy-4-methylquinolin-2(1H)-one	Investigative
T75498	DRUGINFO	D06CHV	NSC-77833	Investigative
T75498	DRUGINFO	D06GRP	NSC-640583	Investigative
T75498	DRUGINFO	D06UQR	5,6,8-Trimethoxy-4-methylquinolin-2(1H)-one	Investigative
T75498	DRUGINFO	D07OAH	NSC-78021	Investigative
T75498	DRUGINFO	D08FHU	6,7,8-Trimethoxy-1,4-dimethylquinolin-2(1H)-one	Investigative
T75498	DRUGINFO	D08ISK	6,8-Dimethoxy-4-methylquinolin-2(1H)-one	Investigative
T75498	DRUGINFO	D08NCP	NSC-660839	Investigative
T75498	DRUGINFO	D08NWU	NSC-660840	Investigative
T75498	DRUGINFO	D08WKQ	NSC-640566	Investigative
T75498	DRUGINFO	D09DRS	6,8-Dimethoxy-1,4-dimethylquinolin-2(1H)-one	Investigative
T75498	DRUGINFO	D09XVU	NSC-306843	Investigative
T75498	DRUGINFO	D0A0DN	NSC-637994	Investigative
T75498	DRUGINFO	D0C8KC	5,8-dimethoxy-1,4-dimethylquinolin-2(1H)-one	Investigative
T75498	DRUGINFO	D0G7MJ	NSC-640556	Investigative
T75498	DRUGINFO	D0G8VF	NSC-676468	Investigative
T75498	DRUGINFO	D0H3LU	NSC-86715	Investigative
T75498	DRUGINFO	D0I3PD	NSC-649091	Investigative
T75498	DRUGINFO	D0K0TO	NSC-78017	Investigative
T75498	DRUGINFO	D0L3AJ	8-Methoxy-1,4-dimethylquinolin-2(1H)-one	Investigative
T75498	DRUGINFO	D0M7RM	NSC-640558	Investigative
T75498	DRUGINFO	D0O4YS	6-Methyl-[1,3]dioxolo[4,5-h]quinolin-8(9H)-one	Investigative
T75498	DRUGINFO	D0O6NU	NSC-637992	Investigative
T75498	DRUGINFO	D0OT1Z	NSC-356820	Investigative
T75498	DRUGINFO	D0Q8JE	NSC-637993	Investigative
T75498	DRUGINFO	D0S1AY	5,8-Dimethoxy-4-methylquinolin-2(1H)-one	Investigative
T75498	DRUGINFO	D0S6RL	NSC-99495	Investigative
T75498	DRUGINFO	D0T5NO	5,6,8-Trimethoxy-1,4-dimethylquinolin-2(1H)-one	Investigative
T75498	DRUGINFO	D0TT3K	NSC-645811	Investigative
T75498	DRUGINFO	D0UB3V	NSC-640584	Investigative
T75498	DRUGINFO	D0W8VX	NSC-180969	Investigative
T75498	DRUGINFO	D0W9ZH	NSC-720622	Investigative
T75498	DRUGINFO	D0WW2D	NSC-356819	Investigative
T75498	DRUGINFO	D0XQ6T	7,8-Dimethoxy-1,4-dimethylquinolin-2(1H)-one	Investigative
T75498	DRUGINFO	D0Z9MG	NSC-359466	Investigative
T75498	DRUGINFO	D09MQF	3,4,5-Trimethoxy-4'-amino-trans-stilbene	Investigative
T75498	DRUGINFO	D0E0DQ	NSC-645808	Investigative
T75498	DRUGINFO	D0I5YK	decynium 22	Investigative
T75498	DRUGINFO	D0J3RB	NSC-106080	Investigative
T75498	DRUGINFO	D0M0WT	NSC-99528	Investigative
T75498	DRUGINFO	D0PG5D	10-Propargyl-5,8-Dideazafolic Acid	Investigative
T75498	DRUGINFO	D0Q8UZ	3,5-Dimethoxy-4'-amino-trans-stilbene	Investigative
T75498	DRUGINFO	D0H6YF	2-iodo-melatonin	Investigative
T75498	DRUGINFO	D00IMW	Flavin-Adenine Dinucleotide	Investigative

T94309	TARGETID	T94309
T94309	FORMERID	TTDC00295
T94309	UNIPROID	LIPP_HUMAN
T94309	TARGNAME	Pancreatic triacylglycerol lipase (PNLIP)
T94309	GENENAME	PNLIP
T94309	TARGTYPE	Successful
T94309	SYNONYMS	Pancreatic lipase; PTL; PL
T94309	FUNCTION	Catalyses the following chemical reaction:  triacylglycerol + H2O   diacylglycerol + a carboxylate. Acts only on an ester-water interface.
T94309	PDBSTRUC	1N8S; 1LPB; 1LPA; 1GPL
T94309	BIOCLASS	Carboxylic ester hydrolase
T94309	ECNUMBER	EC 3.1.1.3
T94309	SEQUENCE	MLPLWTLSLLLGAVAGKEVCYERLGCFSDDSPWSGITERPLHILPWSPKDVNTRFLLYTNENPNNFQEVAADSSSISGSNFKTNRKTRFIIHGFIDKGEENWLANVCKNLFKVESVNCICVDWKGGSRTGYTQASQNIRIVGAEVAYFVEFLQSAFGYSPSNVHVIGHSLGAHAAGEAGRRTNGTIGRITGLDPAEPCFQGTPELVRLDPSDAKFVDVIHTDGAPIVPNLGFGMSQVVGHLDFFPNGGVEMPGCKKNILSQIVDIDGIWEGTRDFAACNHLRSYKYYTDSIVNPDGFAGFPCASYNVFTANKCFPCPSGGCPQMGHYADRYPGKTNDVGQKFYLDTGDASNFARWRYKVSVTLSGKKVTGHILVSLFGNKGNSKQYEIFKGTLKPDSTHSNEFDSDVDVGDLQMVKFIWYNNVINPTLPRVGASKIIVETNVGKQFNFCSPETVREEVLLTLTPC
T94309	DRUGINFO	D07QAR	Dalbavancin	Approved
T94309	DRUGINFO	D0T9TJ	Orlistat	Approved
T94309	DRUGINFO	D0A5DJ	Pancrecarb	NDA filed
T94309	DRUGINFO	D0T9LR	Liprotamase	Phase 3
T94309	DRUGINFO	D0D7AM	MS-1819	Phase 1/2
T94309	DRUGINFO	D09VRZ	AZM-131	Terminated
T94309	DRUGINFO	D04HWJ	METHOXYUNDECYLPHOSPHINIC ACID	Investigative
T94309	DRUGINFO	D09CGL	Daio-Orengedokuto (DOT)	Investigative
T94309	DRUGINFO	D06PVF	(Hydroxyethyloxy)Tri(Ethyloxy)Octane	Investigative
T94309	DRUGINFO	D0K1UI	B-Nonylglucoside	Investigative
T94309	DRUGINFO	D02UVH	B-Octylglucoside	Investigative

T15000	TARGETID	T15000
T15000	FORMERID	TTDC00259
T15000	UNIPROID	CTLA4_HUMAN
T15000	TARGNAME	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
T15000	GENENAME	CTLA4
T15000	TARGTYPE	Successful
T15000	SYNONYMS	Cytotoxic T-lymphocyte-associated antigen 4; CTLA-4; CD152
T15000	FUNCTION	Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28.
T15000	PDBSTRUC	5XJ3; 5TRU; 5GGV; 3OSK; 3BX7
T15000	BIOCLASS	Immunoglobulin
T15000	SEQUENCE	MACLGFQRHKAQLNLATRTWPCTLLFFLLFIPVFCKAMHVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDFLLWILAAVSSGLFFYSFLLTAVSLSKMLKKRSPLTTGVYVKMPPTEPECEKQFQPYFIPIN
T15000	DRUGINFO	D07BVI	Ipilimumab	Approved
T15000	DRUGINFO	D0J6DQ	Tremelimumab	Approved
T15000	DRUGINFO	D2ELZ3	AK04	Phase 3
T15000	DRUGINFO	DLOQ25	KN046	Phase 3
T15000	DRUGINFO	DJX61M	Vudalimab	Phase 2
T15000	DRUGINFO	DR05IX	Lorigerlimab	Phase 2
T15000	DRUGINFO	DXJH93	AK104	Phase 2
T15000	DRUGINFO	D09SFX	AGEN1884	Phase 1/2
T15000	DRUGINFO	D42SLV	Zalifrelimab	Phase 1/2
T15000	DRUGINFO	D7BF8Y	BMS-986288	Phase 1/2
T15000	DRUGINFO	DZ1IL2	MK-1308	Phase 1/2
T15000	DRUGINFO	D02RPO	BMS-986249	Phase 1
T15000	DRUGINFO	D1YXQ4	YH001	Phase 1
T15000	DRUGINFO	D2P8LR	AGEN1181	Phase 1
T15000	DRUGINFO	D3B1MS	ONC-392	Phase 1
T15000	DRUGINFO	DH6GK7	ADG116	Phase 1
T15000	DRUGINFO	D0BOM7	XmAb22841	Phase 1
T15000	DRUGINFO	D0U0EC	TRemelimumab + MEDI0562	Phase 1
T15000	DRUGINFO	D1PYC8	MGD019	Phase 1
T15000	DRUGINFO	D1S7EP	SI-B003	Phase 1
T15000	DRUGINFO	D7L1MP	MEDI5752	Phase 1
T15000	DRUGINFO	D82UVG	ALPN-202	Phase 1
T15000	DRUGINFO	DD1TJ8	XmAb20717	Phase 1
T15000	DRUGINFO	DL97UQ	A337	Phase 1
T15000	DRUGINFO	D02YSO	GX-C4	Investigative
T15000	DRUGINFO	D03FSU	Concatameric CTLA4Ig	Investigative
T15000	DRUGINFO	D0EZ9C	CTLA-4-XTEN	Investigative
T15000	DRUGINFO	D0W7ZS	Del 60 tetramer	Investigative
T15000	DRUGINFO	DZ7EG5	YH006	Investigative
T15000	DRUGINFO	D0G6XS	Fucose	Investigative
T15000	DRUGINFO	D07LUR	Alpha-D-Mannose	Investigative

T41201	TARGETID	T41201
T41201	FORMERID	TTDS00230
T41201	UNIPROID	DPEP1_HUMAN
T41201	TARGNAME	Dehydropeptidase I (DPEP1)
T41201	GENENAME	DPEP1
T41201	TARGTYPE	Successful
T41201	SYNONYMS	hRDP; Renal dipeptidase; RDP; Microsomal dipeptidase; MDP; Dipeptidase 1; Dehydropeptidase-I
T41201	FUNCTION	Implicated in the renal metabolism of glutathione and its conjugates. Converts leukotriene D4 to leukotriene E4; it may play an important role in the regulation of leukotriene activity. Hydrolyzes a wide range of dipeptides.
T41201	PDBSTRUC	1ITU; 1ITQ
T41201	BIOCLASS	Peptidase
T41201	ECNUMBER	EC 3.4.13.19
T41201	SEQUENCE	MWSGWWLWPLVAVCTADFFRDEAERIMRDSPVIDGHNDLPWQLLDMFNNRLQDERANLTTLAGTHTNIPKLRAGFVGGQFWSVYTPCDTQNKDAVRRTLEQMDVVHRMCRMYPETFLYVTSSAGIRQAFREGKVASLIGVEGGHSIDSSLGVLRALYQLGMRYLTLTHSCNTPWADNWLVDTGDSEPQSQGLSPFGQRVVKELNRLGVLIDLAHVSVATMKATLQLSRAPVIFSHSSAYSVCASRRNVPDDVLRLVKQTDSLVMVNFYNNYISCTNKANLSQVADHLDHIKEVAGARAVGFGGDFDGVPRVPEGLEDVSKYPDLIAELLRRNWTEAEVKGALADNLLRVFEAVEQASNLTQAPEEEPIPLDQLGGSCRTHYGYSSGASSLHRHWGLLLASLAPLVLCLSLL
T41201	DRUGINFO	D02GIU	Cilastatin	Approved

T12808	TARGETID	T12808
T12808	FORMERID	TTDC00182
T12808	UNIPROID	KPCA_HUMAN
T12808	TARGNAME	Protein kinase C alpha (PRKCA)
T12808	GENENAME	PRKCA
T12808	TARGTYPE	Successful
T12808	SYNONYMS	Protein kinase C alpha type; PRKACA; PKCalpha; PKCA; PKC-alpha; PKC-A
T12808	FUNCTION	Involved in cell proliferation and cell growth arrest by positive and negative regulation of the cell cycle. Can promote cell growth by phosphorylating and activating RAF1, which mediates the activation of the MAPK/ERK signaling cascade, and/or by up-regulating CDKN1A, which facilitates active cyclin-dependent kinase (CDK) complex formation in glioma cells. In intestinal cells stimulated by the phorbol ester PMA, can trigger a cell cycle arrest program which is associated with the accumulation of the hyper-phosphorylated growth-suppressive form of RB1 and induction of the CDK inhibitors CDKN1A and CDKN1B. Exhibits anti-apoptotic function in glioma cells and protects them from apoptosis by suppressing the p53/TP53-mediated activation of IGFBP3, and in leukemia cells mediates anti-apoptotic action by phosphorylating BCL2. During macrophage differentiation induced by macrophage colony-stimulating factor (CSF1), is translocated to the nucleus and is associated with macrophage development. After wounding, translocates from focal contacts to lamellipodia and participates in the modulation of desmosomal adhesion. Plays a role in cell motility by phosphorylating CSPG4, which induces association of CSPG4 with extensive lamellipodia at the cell periphery and polarization of the cell accompanied by increases in cell motility. During chemokine-induced CD4(+) T cell migration, phosphorylates CDC42-guanine exchange factor DOCK8 resulting in its dissociation from LRCH1 and the activation of GTPase CDC42. Is highly expressed in a number of cancer cells where it can act as a tumor promoter and is implicated in malignant phenotypes of several tumors such as gliomas and breast cancers. Negatively regulates myocardial contractility and positively regulates angiogenesis, platelet aggregation and thrombus formation in arteries. Mediates hypertrophic growth of neonatal cardiomyocytes, in part through a MAPK1/3 (ERK1/2)-dependent signaling pathway, and upon PMA treatment, is required to induce cardiomyocyte hypertrophy up to heart failure and death, by increasing protein synthesis, protein-DNA ratio and cell surface area. Regulates cardiomyocyte function by phosphorylating cardiac troponin T (TNNT2/CTNT), which induces significant reduction in actomyosin ATPase activity, myofilament calcium sensitivity and myocardial contractility. In angiogenesis, is required for full endothelial cell migration, adhesion to vitronectin (VTN), and vascular endothelial growth factor A (VEGFA)-dependent regulation of kinase activation and vascular tube formation. Involved in the stabilization of VEGFA mRNA at post-transcriptional level and mediates VEGFA-induced cell proliferation. In the regulation of calcium-induced platelet aggregation, mediates signals from the CD36/GP4 receptor for granule release, and activates the integrin heterodimer ITGA2B-ITGB3 through the RAP1GAP pathway for adhesion. During response to lipopolysaccharides (LPS), may regulate selective LPS-induced macrophage functions involved in host defense and inflammation. But in some inflammatory responses, may negatively regulate NF-kappa-B-induced genes, through IL1A-dependent induction of NF-kappa-B inhibitor alpha (NFKBIA/IKBA). Upon stimulation with 12-O-tetradecanoylphorbol-13-acetate (TPA), phosphorylates EIF4G1, which modulates EIF4G1 binding to MKNK1 and may be involved in the regulation of EIF4E phosphorylation. Phosphorylates KIT, leading to inhibition of KIT activity. Phosphorylates ATF2 which promotes cooperation between ATF2 and JUN, activating transcription. Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that is involved in positive and negative regulation of cell proliferation, apoptosis, differentiation, migration and adhesion, tumorigenesis, cardiac hypertrophy, angiogenesis, platelet function and inflammation, by directly phosphorylating targets such as RAF1, BCL2, CSPG4, TNNT2/CTNT, or activating signaling cascade involving MAPK1/3 (ERK1/2) and RAP1GAP.
T12808	PDBSTRUC	4RA4; 4DNL; 3IW4; 2ELI
T12808	BIOCLASS	Kinase
T12808	ECNUMBER	EC 2.7.11.13
T12808	SEQUENCE	MADVFPGNDSTASQDVANRFARKGALRQKNVHEVKDHKFIARFFKQPTFCSHCTDFIWGFGKQGFQCQVCCFVVHKRCHEFVTFSCPGADKGPDTDDPRSKHKFKIHTYGSPTFCDHCGSLLYGLIHQGMKCDTCDMNVHKQCVINVPSLCGMDHTEKRGRIYLKAEVADEKLHVTVRDAKNLIPMDPNGLSDPYVKLKLIPDPKNESKQKTKTIRSTLNPQWNESFTFKLKPSDKDRRLSVEIWDWDRTTRNDFMGSLSFGVSELMKMPASGWYKLLNQEEGEYYNVPIPEGDEEGNMELRQKFEKAKLGPAGNKVISPSEDRKQPSNNLDRVKLTDFNFLMVLGKGSFGKVMLADRKGTEELYAIKILKKDVVIQDDDVECTMVEKRVLALLDKPPFLTQLHSCFQTVDRLYFVMEYVNGGDLMYHIQQVGKFKEPQAVFYAAEISIGLFFLHKRGIIYRDLKLDNVMLDSEGHIKIADFGMCKEHMMDGVTTRTFCGTPDYIAPEIIAYQPYGKSVDWWAYGVLLYEMLAGQPPFDGEDEDELFQSIMEHNVSYPKSLSKEAVSVCKGLMTKHPAKRLGCGPEGERDVREHAFFRRIDWEKLENREIQPPFKPKVCGKGAENFDKFFTRGQPVLTPPDQLVIANIDQSDFEGFSYVNPQFVHPILQSAV
T12808	DRUGINFO	D0P2GK	Sodium phenylbutyrate	Approved
T12808	DRUGINFO	D0F5HB	Sotrastaurin acetate	Phase 2
T12808	DRUGINFO	D0ZG7E	PMID28460551-Compound-3	Patented
T12808	DRUGINFO	D04DDM	ISIS 3521	Discontinued in Phase 2
T12808	DRUGINFO	D05XMY	Acteoside	Terminated
T12808	DRUGINFO	D0X0HN	LY-317644	Terminated
T12808	DRUGINFO	D0R5ZR	RO-320432	Terminated
T12808	DRUGINFO	D0R2TM	BALANOL	Terminated
T12808	DRUGINFO	D07ANB	1,2-dioctanoyl-sn-glycerol	Investigative
T12808	DRUGINFO	D07TPU	LEUCOSCEPTOSIDE A	Investigative
T12808	DRUGINFO	D0L0UY	Plantainoside D	Investigative
T12808	DRUGINFO	D0L8CK	CALCEOLARIOSIDE A	Investigative
T12808	DRUGINFO	D0P4JO	FORSYTHIASIDE	Investigative
T12808	DRUGINFO	D0W7JA	CALCEOLARIOSIDE B	Investigative
T12808	DRUGINFO	D05SLL	Diheptan-3-yl 5-(hydroxymethyl)isophthalate	Investigative
T12808	DRUGINFO	D0B1SO	TANNIN	Investigative
T12808	DRUGINFO	D0J4NI	Dihexan-3-yl 5-(hydroxymethyl)isophthalate	Investigative
T12808	DRUGINFO	D0Q3XB	PUNICAFOLIN	Investigative
T12808	DRUGINFO	D0X2DH	3-(1H-Indol-3-yl)-4-phenylamino-pyrrole-2,5-dione	Investigative
T12808	DRUGINFO	D04OHM	4-cyclopentyliden(4-hydroxyphenyl)methylphenol	Investigative
T12808	DRUGINFO	D0L1YA	(-)-Cercosporamide	Investigative
T12808	DRUGINFO	D06TLL	Go 6983	Investigative
T12808	DRUGINFO	D00TWA	[2,2':5',2'']Terthiophen-4-yl-methanol	Investigative
T12808	DRUGINFO	D02PUV	4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol	Investigative
T12808	DRUGINFO	D02QME	2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile	Investigative
T12808	DRUGINFO	D05LRV	[2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde	Investigative
T12808	DRUGINFO	D09TSC	Ro-32-0557	Investigative
T12808	DRUGINFO	D09XIE	3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile	Investigative
T12808	DRUGINFO	D0A8MN	3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile	Investigative
T12808	DRUGINFO	D0D3MR	[2,2':5',2'']Terthiophene-4-carbaldehyde	Investigative
T12808	DRUGINFO	D0Q3GQ	4-cycloheptyliden(4-hydroxyphenyl)methylphenol	Investigative
T12808	DRUGINFO	D0S9UK	2,3,3-Triphenyl-acrylonitrile	Investigative
T12808	DRUGINFO	D0T0UH	3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile	Investigative
T12808	DRUGINFO	D0V9SW	4-cyclohexyliden(4-hydroxyphenyl)methylphenol	Investigative
T12808	DRUGINFO	D04JNZ	PROSTRATIN	Investigative
T12808	DRUGINFO	D0G2VC	KT-5720	Investigative
T12808	DRUGINFO	D06ZCX	LY-326449	Investigative
T12808	DRUGINFO	D0GB4V	STAUROSPORINONE	Investigative
T12808	DRUGINFO	D06AOY	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	Investigative
T12808	DRUGINFO	D0M5FF	Ro31-8220	Investigative
T12808	DRUGINFO	D0N6ES	KN-62	Investigative
T12808	DRUGINFO	D00NYT	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	Investigative
T12808	DRUGINFO	D0C3WY	3,4-diphenyl-1H-pyrrole-2,5-dione	Investigative
T12808	DRUGINFO	D0EK0G	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	Investigative
T12808	DRUGINFO	D0B9BU	CI-1040	Investigative
T12808	DRUGINFO	D0O1YH	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	Investigative
T12808	DRUGINFO	D0L8HO	RO-316233	Investigative

T08910	TARGETID	T08910
T08910	FORMERID	TTDS00428
T08910	UNIPROID	GBRG2_HUMAN
T08910	TARGNAME	GABA(A) receptor gamma-2 (GABRG2)
T08910	GENENAME	GABRG2
T08910	TARGTYPE	Successful
T08910	SYNONYMS	Gamma-aminobutyric acid receptor subunit gamma-2; GABA(A) receptor subunit gamma-2
T08910	FUNCTION	Plays an important role in the formation of functional inhibitory GABAergic synapses in addition to mediating synaptic inhibition as a GABA-gated ion channel. The gamma2 subunit is necessary but not sufficient for a rapid formation of active synaptic contacts and the synaptogenic effect of this subunit is influenced by the type of alpha and beta subunits present in the receptor pentamer. The alpha1/beta2/gamma2 receptor and the alpha1/beta3/gamma2 receptor exhibit synaptogenic activity. The alpha2/beta2/gamma2 receptor exhibits synatogenic activity whereas the alpha2/beta3/gamma2 receptor shows very little or no synaptogenic activity. Functions also as histamine receptor and mediates cellular responses to histamine. Ligand-gated chloride channel which is a component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the brain.
T08910	PDBSTRUC	6I53; 6HUP; 6HUO; 6HUK; 6HUJ
T08910	BIOCLASS	Neurotransmitter receptor
T08910	SEQUENCE	MSSPNIWSTGSSVYSTPVFSQKMTVWILLLLSLYPGFTSQKSDDDYEDYASNKTWVLTPKVPEGDVTVILNNLLEGYDNKLRPDIGVKPTLIHTDMYVNSIGPVNAINMEYTIDIFFAQTWYDRRLKFNSTIKVLRLNSNMVGKIWIPDTFFRNSKKADAHWITTPNRMLRIWNDGRVLYTLRLTIDAECQLQLHNFPMDEHSCPLEFSSYGYPREEIVYQWKRSSVEVGDTRSWRLYQFSFVGLRNTTEVVKTTSGDYVVMSVYFDLSRRMGYFTIQTYIPCTLIVVLSWVSFWINKDAVPARTSLGITTVLTMTTLSTIARKSLPKVSYVTAMDLFVSVCFIFVFSALVEYGTLHYFVSNRKPSKDKDKKKKNPAPTIDIRPRSATIQMNNATHLQERDEEYGYECLDGKDCASFFCCFEDCRTGAWRHGRIHIRIAKMDSYARIFFPTAFCLFNLVYWVSYLYL
T08910	DRUGINFO	D00VZZ	Allopregnanolone	approved
T08910	DRUGINFO	D0IG4I	THIOCOLCHICOSIDE	Approved
T08910	DRUGINFO	D07ZCK	ZK-93423	Phase 3
T08910	DRUGINFO	D0C9XA	GSK683699	Phase 2
T08910	DRUGINFO	D0B8YZ	ELTANOLONE	Discontinued in Phase 3
T08910	DRUGINFO	D05EVI	U-78875	Discontinued in Phase 1
T08910	DRUGINFO	D06BFP	CGS-17867A	Terminated
T08910	DRUGINFO	D0V4GI	CGS-9896	Terminated
T08910	DRUGINFO	D00OAN	9H-beta-Carboline-3-carboxylic acid propyl ester	Investigative
T08910	DRUGINFO	D00SXO	3-Methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-one	Investigative
T08910	DRUGINFO	D01BVR	5-(4-piperidyl)-4-propylisothiazol-3-ol	Investigative
T08910	DRUGINFO	D02XUD	4-(biphenyl-3-yl)-5-(piperidin-4-yl)isoxazol-3-ol	Investigative
T08910	DRUGINFO	D04PQN	N-(p-methylbenzyl)-5-nitroindol-3-ylglyoxylamide	Investigative
T08910	DRUGINFO	D05WEF	N-benzyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide	Investigative
T08910	DRUGINFO	D06QOX	1,3-Diphenyl-1H-chromeno[4,3-c]pyrazol-4-one	Investigative
T08910	DRUGINFO	D06ZOM	3-Methyl-2-phenyl-2H-chromeno[4,3-c]pyrazol-4-one	Investigative
T08910	DRUGINFO	D09AVL	4-benzyl-5-(4-piperidyl)isothiazol-3-ol	Investigative
T08910	DRUGINFO	D0D6IU	2-(1H-Indol-3-yl)-2-oxo-N-phenethyl-acetamide	Investigative
T08910	DRUGINFO	D0GE4A	N-butyl-2-(1H-indol-3-yl)-2-oxoacetamide	Investigative
T08910	DRUGINFO	D0J9SS	6-Nitro-2-(3-nitro-phenyl)-chromen-4-one	Investigative
T08910	DRUGINFO	D0JV5L	4-Methyl-5-(4-piperidyl)isothiazol-3-ol	Investigative
T08910	DRUGINFO	D0KS2X	CGS-9895	Investigative
T08910	DRUGINFO	D0P3FZ	5-(piperidin-4-yl)isothiazol-3-ol	Investigative
T08910	DRUGINFO	D0S9YE	(beta-CCE)9H-beta-Carboline-3-carboxylic acid	Investigative
T08910	DRUGINFO	D0V2LK	6-Nitro-2-(4-nitro-phenyl)-chromen-4-one	Investigative
T08910	DRUGINFO	D00CQR	6-Methyl-2-oxa-spiro[4.4]nonan-1-one	Investigative
T08910	DRUGINFO	D00VWR	3,3-Diethyl-dihydro-furan-2-one	Investigative
T08910	DRUGINFO	D00WON	3-Ethyl-3-methyl-dihydro-furan-2-one	Investigative
T08910	DRUGINFO	D01OZS	3,3-Diisopropyl-dihydro-furan-2-one	Investigative
T08910	DRUGINFO	D01PPZ	Ridine-5-carboxylic acid ethyl ester	Investigative
T08910	DRUGINFO	D01UZT	4-(4-chlorophenyl)-1-pyrid-2-yl-pyrazole	Investigative
T08910	DRUGINFO	D02FXS	3-carboxy-6-ethyl-4-quinolone	Investigative
T08910	DRUGINFO	D02RUV	3-Isopropyl-3-methyl-dihydro-furan-2-one	Investigative
T08910	DRUGINFO	D02XXK	(9-Benzyl-9H-purin-6-yl)-cyclopropyl-amine	Investigative
T08910	DRUGINFO	D03CKN	3-ethoxycarbonyl-6-ethyl-2-methyl-4-quinolone	Investigative
T08910	DRUGINFO	D03EOK	N-Indan-1-yl-2-(1H-indol-3-yl)-2-oxo-acetamide	Investigative
T08910	DRUGINFO	D03FBS	6-ethyl-3-propoxycarbonyl-4-quinolone	Investigative
T08910	DRUGINFO	D03OEN	N-butyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide	Investigative
T08910	DRUGINFO	D03OQG	1-Methyl-5-oxa-spiro[2.4]heptan-4-one	Investigative
T08910	DRUGINFO	D03YLX	3-Methyl-9H-beta-carboline	Investigative
T08910	DRUGINFO	D04EOV	3-ethoxycarbonyl-6-propyl-4-quinolone	Investigative
T08910	DRUGINFO	D05OOA	6-ethyl-3-pentoxycarbonyl-4-quinolone	Investigative
T08910	DRUGINFO	D05SVA	5-(piperidin-4-yl)isoxazol-3-ol	Investigative
T08910	DRUGINFO	D05TVT	6-ethyl-3-(3-pentoxycarbonyl)-4-quinolone	Investigative
T08910	DRUGINFO	D06EUJ	3-butoxycarbonyl-4-quinolone	Investigative
T08910	DRUGINFO	D06GAI	1-(4-chlorophenyl)-4-phenyl-1H-imidazole	Investigative
T08910	DRUGINFO	D06OSB	6-ethyl-3-i-propoxycarbonyl-4-quinolone	Investigative
T08910	DRUGINFO	D07OON	3-Ethyl-3-isopropyl-dihydro-furan-2-one	Investigative
T08910	DRUGINFO	D07QGN	CGS-13767	Investigative
T08910	DRUGINFO	D08AID	6-ethyl-3-(2-methylbutoxycarbonyl)-4-quinolone	Investigative
T08910	DRUGINFO	D08HGK	N-Benzyl-2-(1H-indol-3-yl)-2-oxo-acetamide	Investigative
T08910	DRUGINFO	D09AYK	3-ethoxycarbonyl-4-quinolone	Investigative
T08910	DRUGINFO	D09CQO	2-Thiophen-2-yl-3H-imidazo[4,5-c]quinoline	Investigative
T08910	DRUGINFO	D09RWW	3-cyclopentoxycarbonyl-6-ethyl-4-quinolone	Investigative
T08910	DRUGINFO	D0AR4P	2-(9-Benzyl-9H-purin-6-ylamino)-ethanol	Investigative
T08910	DRUGINFO	D0B4CQ	6-benzyl-3-propylaminocarbonyl-4-quinolone	Investigative
T08910	DRUGINFO	D0B4WR	2-Isoxazol-5-yl-3H-imidazo[4,5-c]quinoline	Investigative
T08910	DRUGINFO	D0CR6M	6-bromo-3-ethoxycarbonyl-2-methyl-4-quinolone	Investigative
T08910	DRUGINFO	D0D2PJ	GNF-PF-4421	Investigative
T08910	DRUGINFO	D0ER0L	4-Benzyl-5-piperidin-4-yl-isoxazol-3-ol	Investigative
T08910	DRUGINFO	D0FQ2N	3-Isothiocyanato-9H-beta-carboline	Investigative
T08910	DRUGINFO	D0FR4S	4-(2-aminoethyl)-1,2,5-oxadiazol-3-ol	Investigative
T08910	DRUGINFO	D0G6IG	3-butoxycarbonyl-6-ethyl-4-quinolone	Investigative
T08910	DRUGINFO	D0H0DP	3-amino-3-demethoxythiocolchicine	Investigative
T08910	DRUGINFO	D0H0NE	6,9-Dimethyl-2-oxa-spiro[4.4]nonan-1-one	Investigative
T08910	DRUGINFO	D0I4HT	4-Naphthalen-1-yl-5-piperidin-4-yl-isoxazol-3-ol	Investigative
T08910	DRUGINFO	D0J0CA	BETA-CCM	Investigative
T08910	DRUGINFO	D0J9VP	3-tert-Butyl-3-ethyl-dihydro-furan-2-one	Investigative
T08910	DRUGINFO	D0K2CZ	1,1-Dimethyl-5-oxa-spiro[2.4]heptan-4-one	Investigative
T08910	DRUGINFO	D0KS3X	U-89267	Investigative
T08910	DRUGINFO	D0L2KB	RO-145974	Investigative
T08910	DRUGINFO	D0M0ZX	6-ethyl-3-(2-ethylbutoxycarbonyl)-4-quinolone	Investigative
T08910	DRUGINFO	D0M2AY	6-ethyl-3-propylaminocarbonyl-4-quinolone	Investigative
T08910	DRUGINFO	D0O9SG	2-(4-chlorophenyl)-5-phenyl-4-isoxazolin-3-one	Investigative
T08910	DRUGINFO	D0Q8UV	RO-145975	Investigative
T08910	DRUGINFO	D0R1IL	4-Naphthalen-2-yl-5-piperidin-4-yl-isoxazol-3-ol	Investigative
T08910	DRUGINFO	D0S6ME	6-benzyl-3-propoxycarbonyl-4-quinolone	Investigative
T08910	DRUGINFO	D0TJ2L	RO-147437	Investigative
T08910	DRUGINFO	D0U9ET	6,6-Dimethyl-2-oxa-spiro[4.4]nonan-1-one	Investigative
T08910	DRUGINFO	D0UQ6J	RO-194603	Investigative
T08910	DRUGINFO	D0W5IP	GNF-PF-3645	Investigative
T08910	DRUGINFO	D0WC5L	3-butylaminocarbonyl-6-ethyl-4-quinolone	Investigative
T08910	DRUGINFO	D0X4OW	2-Oxa-spiro[4.4]nonan-1-one	Investigative
T08910	DRUGINFO	D0YS9E	4-Phenyl-5-piperidin-4-yl-isoxazol-3-ol	Investigative
T08910	DRUGINFO	D01UAS	6-bromo-3-ethoxycarbonyl-4-quinolone	Investigative
T08910	DRUGINFO	D02CZO	6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone	Investigative
T08910	DRUGINFO	D03LMR	6-benzyl-3-ethoxycarbonyl-4-quinolone	Investigative
T08910	DRUGINFO	D0H4GQ	RY-066	Investigative
T08910	DRUGINFO	D01CUR	3-Ethoxy-9H-beta-carboline	Investigative
T08910	DRUGINFO	D01RLF	9H-beta-Carboline-3-carboxylic acid ethyl ester	Investigative
T08910	DRUGINFO	D03PPZ	Beta-Carboline-3-carboxylic acid t-butyl ester	Investigative
T08910	DRUGINFO	D04RVA	3-demethoxy-3-D-lyxopyranosylaminothiocolchicine	Investigative
T08910	DRUGINFO	D06WMM	3-Butoxy-9H-beta-carboline	Investigative
T08910	DRUGINFO	D06XGL	3-demethoxy-3-D-xylopyranosylaminothiocolchicine	Investigative
T08910	DRUGINFO	D08BOP	3-Propoxy-9H-beta-carboline	Investigative
T08910	DRUGINFO	D08BXK	3-(3-Methyl-butoxy)-9H-beta-carboline	Investigative
T08910	DRUGINFO	D08YLW	3-demethoxy-3-L-fucopyranosylaminothiocolchicine	Investigative
T08910	DRUGINFO	D09MHS	3-demethoxy-3D-glucopyranosylaminothiocolchicine	Investigative
T08910	DRUGINFO	D09MYJ	3-Isobutoxy-9H-beta-carboline	Investigative
T08910	DRUGINFO	D0C6WO	Sec-butyl 9H-pyrido[3,4-b]indole-3-carboxylate	Investigative
T08910	DRUGINFO	D0D4MM	Ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate	Investigative
T08910	DRUGINFO	D0E7PY	Ro-4938581	Investigative
T08910	DRUGINFO	D0LP2K	3-demethoxy-3-D-mannopyranosylaminothiocolchicine	Investigative
T08910	DRUGINFO	D0O9MG	L-655708	Investigative
T08910	DRUGINFO	D0P3BU	3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole	Investigative
T08910	DRUGINFO	D0R5OU	3-(benzyloxy)-9H-pyrido[3,4-b]indole	Investigative
T08910	DRUGINFO	D01IHM	CI-218872	Investigative
T08910	DRUGINFO	D07NKO	5-[(1R)-1-ammonioethyl]isoxazol-3-olate	Investigative
T08910	DRUGINFO	D09ACO	(2E,4S)-4-ammoniopent-2-enoate	Investigative
T08910	DRUGINFO	D0A8EU	(4R)-4-ammoniopentanoate	Investigative
T08910	DRUGINFO	D0N0ZK	(4S)-4-ammoniopentanoate	Investigative
T08910	DRUGINFO	D0S5PS	5-[(1S)-1-ammonioethyl]isoxazol-3-olate	Investigative
T08910	DRUGINFO	D00WHO	Ro-15-3505	Investigative
T08910	DRUGINFO	D0M4CP	[3H]Ro154513	Investigative
T08910	DRUGINFO	D0M9RM	[3H]CGS8216	Investigative
T08910	DRUGINFO	D06HRX	AMENTOFLAVONE	Investigative
T08910	DRUGINFO	D0P0TI	TBPS	Investigative

T65197	TARGETID	T65197
T65197	FORMERID	TTDS00144
T65197	UNIPROID	EPOR_HUMAN
T65197	TARGNAME	Erythropoietin Receptor (EPOR)
T65197	GENENAME	EPOR
T65197	TARGTYPE	Successful
T65197	SYNONYMS	Full-length form; EPO-R
T65197	FUNCTION	Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase. Receptor for erythropoietin.
T65197	PDBSTRUC	6E2Q; 4Y5Y; 4Y5X; 4Y5V; 2MV6
T65197	BIOCLASS	Cytokine receptor
T65197	SEQUENCE	MDHLGASLWPQVGSLCLLLAGAAWAPPPNLPDPKFESKAALLAARGPEELLCFTERLEDLVCFWEEAASAGVGPGNYSFSYQLEDEPWKLCRLHQAPTARGAVRFWCSLPTADTSSFVPLELRVTAASGAPRYHRVIHINEVVLLDAPVGLVARLADESGHVVLRWLPPPETPMTSHIRYEVDVSAGNGAGSVQRVEILEGRTECVLSNLRGRTRYTFAVRARMAEPSFGGFWSAWSEPVSLLTPSDLDPLILTLSLILVVILVLLTVLALLSHRRALKQKIWPGIPSPESEFEGLFTTHKGNFQLWLYQNDGCLWWSPCTPFTEDPPASLEVLSERCWGTMQAVEPGTDDEGPLLEPVGSEHAQDTYLVLDKWLLPRNPPSEDLPGPGGSVDIVAMDEGSEASSCSSALASKPSPEGASAASFEYTILDPSSQLLRPWTLCPELPPTPPHLKYLYLVVSDSGISTDYSSGDSQGAQGGLSDGPYSNPYENSLIPAAEPLPPSYVACS
T65197	DRUGINFO	D02LVZ	Darbepoetin alfa	Approved
T65197	DRUGINFO	D07PBZ	Epoetin alfa	Approved
T65197	DRUGINFO	D0K3XP	Methoxy polyethylene glycol-epoetin beta	Approved
T65197	DRUGINFO	D0U1TA	RHuEPO	Approved
T65197	DRUGINFO	D04YHG	ErepoXen	Phase 3
T65197	DRUGINFO	D0DV3T	Epoetin zeta	Phase 3
T65197	DRUGINFO	D0S7KQ	Hematide	Phase 3
T65197	DRUGINFO	D0F5AR	Cibinetide	Phase 2
T65197	DRUGINFO	D03PVY	GlycoPEGylated erythropoietin	Discontinued in Phase 2
T65197	DRUGINFO	D0ZV6W	Albupoietin	Terminated
T65197	DRUGINFO	D01ESC	BBT-009	Investigative
T65197	DRUGINFO	D06QIW	EPO peptide mimetics	Investigative
T65197	DRUGINFO	D0C7KB	Nova-EPO	Investigative
T65197	DRUGINFO	D0D5FB	EPO-derived peptide	Investigative
T65197	DRUGINFO	D0G5JW	Erythropoietin	Investigative
T65197	DRUGINFO	D0J0GJ	P-1116	Investigative
T65197	DRUGINFO	D0L6PZ	PT-401	Investigative
T65197	DRUGINFO	D0O6TD	BBT-021	Investigative
T65197	DRUGINFO	D0R3JO	PEG-EPO	Investigative
T65197	DRUGINFO	D0U9PX	3,5 DIBROMOTYROSINE	Investigative

T37539	TARGETID	T37539
T37539	FORMERID	TTDS00480
T37539	UNIPROID	CD22_HUMAN
T37539	TARGNAME	B-cell receptor CD22 (CD22)
T37539	GENENAME	CD22
T37539	TARGTYPE	Successful
T37539	SYNONYMS	T-cell surface antigen Leu-14; Siglec-2; Sialic acid-binding Ig-like lectin 2; SIGLEC2; Leu-14; BL-CAM; B-lymphocyte cell adhesion molecule
T37539	FUNCTION	May be involved in the localization of B-cells in lymphoid tissues. Binds sialylated glycoproteins; one of which is CD45. Preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site can be masked by cis interactions with sialic acids on the same cell surface. Upon ligand induced tyrosine phosphorylation in the immune response seems to be involved in regulation of B-cell antigen receptor signaling. Plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules. Mediates B-cell B-cell interactions.
T37539	PDBSTRUC	5VL3; 5VKM; 5VKJ
T37539	BIOCLASS	Immunoglobulin
T37539	SEQUENCE	MHLLGPWLLLLVLEYLAFSDSSKWVFEHPETLYAWEGACVWIPCTYRALDGDLESFILFHNPEYNKNTSKFDGTRLYESTKDGKVPSEQKRVQFLGDKNKNCTLSIHPVHLNDSGQLGLRMESKTEKWMERIHLNVSERPFPPHIQLPPEIQESQEVTLTCLLNFSCYGYPIQLQWLLEGVPMRQAAVTSTSLTIKSVFTRSELKFSPQWSHHGKIVTCQLQDADGKFLSNDTVQLNVKHTPKLEIKVTPSDAIVREGDSVTMTCEVSSSNPEYTTVSWLKDGTSLKKQNTFTLNLREVTKDQSGKYCCQVSNDVGPGRSEEVFLQVQYAPEPSTVQILHSPAVEGSQVEFLCMSLANPLPTNYTWYHNGKEMQGRTEEKVHIPKILPWHAGTYSCVAENILGTGQRGPGAELDVQYPPKKVTTVIQNPMPIREGDTVTLSCNYNSSNPSVTRYEWKPHGAWEEPSLGVLKIQNVGWDNTTIACAACNSWCSWASPVALNVQYAPRDVRVRKIKPLSEIHSGNSVSLQCDFSSSHPKEVQFFWEKNGRLLGKESQLNFDSISPEDAGSYSCWVNNSIGQTASKAWTLEVLYAPRRLRVSMSPGDQVMEGKSATLTCESDANPPVSHYTWFDWNNQSLPYHSQKLRLEPVKVQHSGAYWCQGTNSVGKGRSPLSTLTVYYSPETIGRRVAVGLGSCLAILILAICGLKLQRRWKRTQSQQGLQENSSGQSFFVRNKKVRRAPLSEGPHSLGCYNPMMEDGISYTTLRFPEMNIPRTGDAESSEMQRPPPDCDDTVTYSALHKRQVGDYENVIPDFPEDEGIHYSELIQFGVGERPQAQENVDYVILKH
T37539	DRUGINFO	D00HPD	Moxetumomab pasudotox	Approved
T37539	DRUGINFO	D00QEP	Inotuzumab ozogamicin	Approved
T37539	DRUGINFO	D0W9OR	OspA lipoprotein	Approved
T37539	DRUGINFO	D0I9VO	Epratuzumab	Phase 3
T37539	DRUGINFO	D01AAH	CAR-T cells targeting CD22	Phase 2
T37539	DRUGINFO	D0M3GQ	BL-22	Phase 2
T37539	DRUGINFO	D03IHD	Anti-CD22-CAR-transduced T cells	Phase 1/2
T37539	DRUGINFO	D0IN2K	CD22 CAR-T	Phase 1/2
T37539	DRUGINFO	D0P0NS	CD22-Targeted CAR-T cells	Phase 1/2
T37539	DRUGINFO	D0PD4C	CAR-T cells targeting CD22	Phase 1/2
T37539	DRUGINFO	D0ZQ3K	Anti-CD22 CAR-T cells	Phase 1/2
T37539	DRUGINFO	D02ONA	AUTO3	Phase 1/2
T37539	DRUGINFO	D05OAI	CART-19/22	Phase 1/2
T37539	DRUGINFO	D05VNS	CD19 and CD22 CAR-T Cells	Phase 1/2
T37539	DRUGINFO	D08FVH	4SCAR19/22 T cells	Phase 1/2
T37539	DRUGINFO	D08JTI	Anti-CD19/22-CAR vector-transduced T cells	Phase 1/2
T37539	DRUGINFO	D0E2CS	CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells	Phase 1/2
T37539	DRUGINFO	D0J7VH	4SCAR19 and 4SCAR22	Phase 1/2
T37539	DRUGINFO	D0W4SM	CD19 and CD22 CAR-T Cells	Phase 1/2
T37539	DRUGINFO	D01HGT	Anti-CD22	Phase 1
T37539	DRUGINFO	D02NSS	CART-22 cells	Phase 1
T37539	DRUGINFO	D09AXQ	CD22-CART	Phase 1
T37539	DRUGINFO	D09DIQ	CART22 cells expressing anti-CD22 scFv TCRz:41BB	Phase 1
T37539	DRUGINFO	D0GJ2G	Anti-CD22 CAR-T cells	Phase 1
T37539	DRUGINFO	D0GR9H	CD22-specific CAR T-cells also expressing an EGFRt	Phase 1
T37539	DRUGINFO	D0JG2X	JCAR018	Phase 1
T37539	DRUGINFO	D0PO0L	Retroviral vector-transduced autologous T cells to express CD22-specific CARs	Phase 1
T37539	DRUGINFO	D0QV9Q	CART22 cells	Phase 1
T37539	DRUGINFO	D0ZP8Z	CART22-65s cells	Phase 1
T37539	DRUGINFO	D7C3JA	UCART-22	Phase 1
T37539	DRUGINFO	DNML54	Lumoxiti	Phase 1
T37539	DRUGINFO	DQC80I	TRPH-222	Phase 1
T37539	DRUGINFO	D00JCB	CD19/CD22 CAR T cells	Phase 1
T37539	DRUGINFO	D02BAA	Patient-derived CD19- and CD22 specific CAR	Phase 1
T37539	DRUGINFO	D02LNU	CART22-65s cells and huCART19 Cells	Phase 1
T37539	DRUGINFO	D03YEM	CD19/CD22 CAR T-Cells	Phase 1
T37539	DRUGINFO	D06RUK	Combotox	Phase 1
T37539	DRUGINFO	D0D7FV	CD19/CD22 Chimeric Antigen Receptor T Cells	Phase 1
T37539	DRUGINFO	D0U1HR	Donor-derived CD19/22 bispecific CAR-T cells	Phase 1
T37539	DRUGINFO	DH7ZV4	JNJ-75348780	Phase 1
T37539	DRUGINFO	D0EI1U	DCDT-2980S	Discontinued in Phase 2
T37539	DRUGINFO	D0J9UB	RG7593	Discontinued in Phase 2
T37539	DRUGINFO	DY2EJ1	ATA2431	Preclinical
T37539	DRUGINFO	D0Q3WP	MEDI-553	Investigative
T37539	DRUGINFO	D0V2QU	Anti-CD22/CD19 mab-toxin conjugate	Investigative

T51666	TARGETID	T51666
T51666	FORMERID	TTDS00044
T51666	UNIPROID	ATP4A_HUMAN
T51666	TARGNAME	Gastric H(+)/K(+) ATPase alpha (ATP4A)
T51666	GENENAME	ATP4A
T51666	TARGTYPE	Successful
T51666	SYNONYMS	Gastric H+/K+ ATPase alpha subunit; Gastric H(+)/K(+)-ATPase; ATP4A
T51666	FUNCTION	Catalyzes the hydrolysis of ATP coupled with the exchange of H(+) and K(+) ions across the plasma membrane. Responsible for acid production in the stomach.
T51666	BIOCLASS	Acid anhydrides hydrolase
T51666	ECNUMBER	EC 7.2.2.19
T51666	SEQUENCE	MGKAENYELYSVELGPGPGGDMAAKMSKKKKAGGGGGKRKEKLENMKKEMEINDHQLSVAELEQKYQTSATKGLSASLAAELLLRDGPNALRPPRGTPEYVKFARQLAGGLQCLMWVAAAICLIAFAIQASEGDLTTDDNLYLAIALIAVVVVTGCFGYYQEFKSTNIIASFKNLVPQQATVIRDGDKFQINADQLVVGDLVEMKGGDRVPADIRILAAQGCKVDNSSLTGESEPQTRSPECTHESPLETRNIAFFSTMCLEGTVQGLVVNTGDRTIIGRIASLASGVENEKTPIAIEIEHFVDIIAGLAILFGATFFIVAMCIGYTFLRAMVFFMAIVVAYVPEGLLATVTVCLSLTAKRLASKNCVVKNLEAVETLGSTSVICSDKTGTLTQNRMTVSHLWFDNHIHTADTTEDQSGQTFDQSSETWRALCRVLTLCNRAAFKSGQDAVPVPKRIVIGDASETALLKFSELTLGNAMGYRDRFPKVCEIPFNSTNKFQLSIHTLEDPRDPRHLLVMKGAPERVLERCSSILIKGQELPLDEQWREAFQTAYLSLGGLGERVLGFCQLYLNEKDYPPGYAFDVEAMNFPSSGLCFAGLVSMIDPPRATVPDAVLKCRTAGIRVIMVTGDHPITAKAIAASVGIISEGSETVEDIAARLRVPVDQVNRKDARACVINGMQLKDMDPSELVEALRTHPEMVFARTSPQQKLVIVESCQRLGAIVAVTGDGVNDSPALKKADIGVAMGIAGSDAAKNAADMILLDDNFASIVTGVEQGRLIFDNLKKSIAYTLTKNIPELTPYLIYITVSVPLPLGCITILFIELCTDIFPSVSLAYEKAESDIMHLRPRNPKRDRLVNEPLAAYSYFQIGAIQSFAGFTDYFTAMAQEGWFPLLCVGLRAQWEDHHLQDLQDSYGQEWTFGQRLYQQYTCYTVFFISIEVCQIADVLIRKTRRLSAFQQGFFRNKILVIAIVFQVCIGCFLCYCPGMPNIFNFMPIRFQWWLVPLPYGILIFVYDEIRKLGVRCCPGSWWDQELYY
T51666	DRUGINFO	D0KL4J	Rabeprazole	Approved
T51666	DRUGINFO	D06YYD	Dexlansoprazole	Approved
T51666	DRUGINFO	D0B2ZZ	Esomeprazole magnesium + Aspirin	Phase 3
T51666	DRUGINFO	D0V3ZN	AG-SPT201	Phase 3
T51666	DRUGINFO	D0Z9NY	API-023	Phase 1
T51666	DRUGINFO	D0K1UF	Saliphenylhalamide	Preclinical
T51666	DRUGINFO	D03SSG	PA-10040	Investigative
T51666	DRUGINFO	D06ZAK	CA-50040	Investigative
T51666	DRUGINFO	D0E2MI	ARH-1029	Investigative
T51666	DRUGINFO	D0K6LA	OPC-22575	Investigative
T51666	DRUGINFO	D0N0KG	CDRI-85/92	Investigative

T35640	TARGETID	T35640
T35640	FORMERID	TTDS00444
T35640	UNIPROID	ITAL_HUMAN
T35640	TARGNAME	Integrin alpha-L (ITGAL)
T35640	GENENAME	ITGAL
T35640	TARGTYPE	Successful
T35640	SYNONYMS	Lymphocyte Function-associated Antigen-1; Leukocyte function-associated molecule 1 alpha chain; Leukocyte function associated molecule 1, alpha chain; Leukocyte adhesion glycoprotein LFA-1 alpha chain; LFA-1A; LFA-1; CD11a; CD11 antigen-like family member A
T35640	FUNCTION	Integrin ITGAL/ITGB2 is a receptor for F11R. Integin ITGAL/ITGB2 is a receptor for the secreted form of ubiquitin-like protein ISG15; the interaction is mediated by ITGAL. Involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes. Contributes to natural killer cell cytotoxicity. Involved in leukocyte adhesion and transmigration of leukocytes including T-cells and neutrophils. Required for generation of common lymphoid progenitor cells in bone marrow, indicating a role in lymphopoiesis. Integrin ITGAL/ITGB2 in association with ICAM3, contributes to apoptotic neutrophil phagocytosis by macrophages. Integrin ITGAL/ITGB2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4.
T35640	PDBSTRUC	6CKB; 6BXJ; 6BXF; 6BXB; 5E6U
T35640	BIOCLASS	Integrin
T35640	SEQUENCE	MKDSCITVMAMALLSGFFFFAPASSYNLDVRGARSFSPPRAGRHFGYRVLQVGNGVIVGAPGEGNSTGSLYQCQSGTGHCLPVTLRGSNYTSKYLGMTLATDPTDGSILACDPGLSRTCDQNTYLSGLCYLFRQNLQGPMLQGRPGFQECIKGNVDLVFLFDGSMSLQPDEFQKILDFMKDVMKKLSNTSYQFAAVQFSTSYKTEFDFSDYVKRKDPDALLKHVKHMLLLTNTFGAINYVATEVFREELGARPDATKVLIIITDGEATDSGNIDAAKDIIRYIIGIGKHFQTKESQETLHKFASKPASEFVKILDTFEKLKDLFTELQKKIYVIEGTSKQDLTSFNMELSSSGISADLSRGHAVVGAVGAKDWAGGFLDLKADLQDDTFIGNEPLTPEVRAGYLGYTVTWLPSRQKTSLLASGAPRYQHMGRVLLFQEPQGGGHWSQVQTIHGTQIGSYFGGELCGVDVDQDGETELLLIGAPLFYGEQRGGRVFIYQRRQLGFEEVSELQGDPGYPLGRFGEAITALTDINGDGLVDVAVGAPLEEQGAVYIFNGRHGGLSPQPSQRIEGTQVLSGIQWFGRSIHGVKDLEGDGLADVAVGAESQMIVLSSRPVVDMVTLMSFSPAEIPVHEVECSYSTSNKMKEGVNITICFQIKSLIPQFQGRLVANLTYTLQLDGHRTRRRGLFPGGRHELRRNIAVTTSMSCTDFSFHFPVCVQDLISPINVSLNFSLWEEEGTPRDQRAQGKDIPPILRPSLHSETWEIPFEKNCGEDKKCEANLRVSFSPARSRALRLTAFASLSVELSLSNLEEDAYWVQLDLHFPPGLSFRKVEMLKPHSQIPVSCEELPEESRLLSRALSCNVSSPIFKAGHSVALQMMFNTLVNSSWGDSVELHANVTCNNEDSDLLEDNSATTIIPILYPINILIQDQEDSTLYVSFTPKGPKIHQVKHMYQVRIQPSIHDHNIPTLEAVVGVPQPPSEGPITHQWSVQMEPPVPCHYEDLERLPDAAEPCLPGALFRCPVVFRQEILVQVIGTLELVGEIEASSMFSLCSSLSISFNSSKHFHLYGSNASLAQVVMKVDVVYEKQMLYLYVLSGIGGLLLLLLIFIVLYKVGFFKRNLKEKMEAGRGVPNGIPAEDSEQLASGQEAGDPGCLKPLHEKDSESGGGKD
T35640	DRUGINFO	D03SGR	Efalizumab	Approved
T35640	DRUGINFO	D0Q9EV	lifitegrast	Approved
T35640	DRUGINFO	D0W7GH	IC-747	Discontinued in Phase 2
T35640	DRUGINFO	D0GT8W	BMS-587101	Discontinued in Phase 2
T35640	DRUGINFO	D03RYN	Cytolin	Preclinical
T35640	DRUGINFO	D00FIV	Leukotoxin	Investigative
T35640	DRUGINFO	D0W3WW	LFA703	Investigative
T35640	DRUGINFO	D07XCA	A-286982	Investigative

T76685	TARGETID	T76685
T76685	FORMERID	TTDS00334
T76685	UNIPROID	CNR1_HUMAN
T76685	TARGNAME	Cannabinoid receptor 1 (CB1)
T76685	GENENAME	CNR1
T76685	TARGTYPE	Successful
T76685	SYNONYMS	Cannabinoid CB1 receptor; CNR; CB-R; CANN6
T76685	FUNCTION	Mediates many cannabinoid-induced effects, acting, among others, on food intake, memory loss, gastrointestinal motility, catalepsy, ambulatory activity, anxiety, chronic pain. Signaling typically involves reduction in cyclic AMP. In the hypothalamus, may have a dual effect on mitochondrial respiration depending upon the agonist dose and possibly upon the cell type. Increases respiration at low doses, while decreases respiration at high doses. At high doses, CNR1 signal transduction involves G-protein alpha-i protein activation and subsequent inhibition of mitochondrial soluble adenylate cyclase, decrease in cyclic AMP concentration, inhibition of protein kinase A (PKA)-dependent phosphorylation of specific subunits of the mitochondrial electron transport system, including NDUFS2. In the hypothalamus, inhibits leptin-induced reactive oxygen species (ROS) formation and mediates cannabinoid-induced increase in SREBF1 and FASN gene expression. In response to cannabinoids, drives the release of orexigenic beta-endorphin, but not that of melanocyte-stimulating hormone alpha/alpha-MSH, from hypothalamic POMC neurons, hence promoting food intake. In the hippocampus, regulates cellular respiration and energy production in response to cannabinoids. Involved in cannabinoid-dependent depolarization-induced suppression of inhibition (DSI), a process in which depolarization of CA1 postsynaptic pyramidal neurons mobilizes eCBs, which retrogradely activate presynaptic CB1 receptors, transiently decreasing GABAergic inhibitory neurotransmission. Also reduces excitatory synaptic transmission. In superior cervical ganglions and cerebral vascular smooth muscle cells, inhibits voltage-gated Ca(2+) channels in a constitutive, as well as agonist-dependent manner. In cerebral vascular smooth muscle cells, cannabinoid-induced inhibition of voltage-gated Ca(2+) channels leads to vasodilation and decreased vascular tone. Induces leptin production in adipocytes and reduces LRP2-mediated leptin clearance in the kidney, hence participating in hyperleptinemia. In adipose tissue, CNR1 signaling leads to increased expression of SREBF1, ACACA and FASN genes. In the liver, activation by endocannabinoids leads to increased de novo lipogenesis and reduced fatty acid catabolism, associated with increased expression of SREBF1/SREBP-1, GCK, ACACA, ACACB and FASN genes. May also affect de novo cholesterol synthesis and HDL-cholesteryl ether uptake. Peripherally modulates energy metabolism. In high carbohydrate diet-induced obesity, may decrease the expression of mitochondrial dihydrolipoyl dehydrogenase/DLD in striated muscles, as well as that of selected glucose/ pyruvate metabolic enzymes, hence affecting energy expenditure through mitochondrial metabolism. In response to cannabinoid anandamide, elicits a proinflammatory response in macrophages, which involves NLRP3 inflammasome activation and IL1B and IL18 secretion. In macrophages infiltrating pancreatic islets, this process may participate in the progression of type-2 diabetes and associated loss of pancreatic beta-cells. G-protein coupled receptor for endogenous cannabinoids (eCBs), including N-arachidonoylethanolamide (also called anandamide or AEA) and 2-arachidonoylglycerol (2-AG), as well as phytocannabinoids, such as delta(9)-tetrahydrocannabinol (THC).
T76685	PDBSTRUC	6N4B; 5XRA; 5XR8; 5U09; 5TGZ
T76685	BIOCLASS	GPCR rhodopsin
T76685	SEQUENCE	MKSILDGLADTTFRTITTDLLYVGSNDIQYEDIKGDMASKLGYFPQKFPLTSFRGSPFQEKMTAGDNPQLVPADQVNITEFYNKSLSSFKENEENIQCGENFMDIECFMVLNPSQQLAIAVLSLTLGTFTVLENLLVLCVILHSRSLRCRPSYHFIGSLAVADLLGSVIFVYSFIDFHVFHRKDSRNVFLFKLGGVTASFTASVGSLFLTAIDRYISIHRPLAYKRIVTRPKAVVAFCLMWTIAIVIAVLPLLGWNCEKLQSVCSDIFPHIDETYLMFWIGVTSVLLLFIVYAYMYILWKAHSHAVRMIQRGTQKSIIIHTSEDGKVQVTRPDQARMDIRLAKTLVLILVVLIICWGPLLAIMVYDVFGKMNKLIKTVFAFCSMLCLLNSTVNPIIYALRSKDLRHAFRSMFPSCEGTAQPLDNSMGDSDCLHKHANNAASVHRAAESCIKSTVKIAKVTMSVSTDTSAEAL
T76685	DRUGINFO	D0O3OS	SR141716A	Approved
T76685	DRUGINFO	D0P1FO	Marinol	Approved
T76685	DRUGINFO	D0L7AS	NABILONE	Approved
T76685	DRUGINFO	D0T9TJ	Orlistat	Approved
T76685	DRUGINFO	D0Y6MH	Tebipenem	Phase 3
T76685	DRUGINFO	D0W3GL	SR-147778	Phase 2
T76685	DRUGINFO	DA6NG5	Nimacimab	Phase 2
T76685	DRUGINFO	DN8VS3	AEF0117	Phase 2
T76685	DRUGINFO	D05BMC	GW-42004	Phase 2
T76685	DRUGINFO	D00WME	Conatumumab	Phase 2
T76685	DRUGINFO	D09KYZ	V-24343	Phase 1
T76685	DRUGINFO	D0D3UI	ZY01	Phase 1
T76685	DRUGINFO	D0VH3H	TM38837	Phase 1
T76685	DRUGINFO	DJ8B6F	GFB-024	Phase 1
T76685	DRUGINFO	D00BXK	Pyrazole derivative 39	Patented
T76685	DRUGINFO	D00TBI	Imidazole derivative 7	Patented
T76685	DRUGINFO	D00TMQ	Azetidine-1-carboxamide derivative 3	Patented
T76685	DRUGINFO	D00XDN	Pyrazole derivative 40	Patented
T76685	DRUGINFO	D00XFT	Pyrazole derivative 53	Patented
T76685	DRUGINFO	D01HJQ	Aminoazetidine derivative 1	Patented
T76685	DRUGINFO	D01KJZ	Pyrazole derivative 4	Patented
T76685	DRUGINFO	D01RIT	Pyrazole derivative 20	Patented
T76685	DRUGINFO	D01WWN	Pyrazole derivative 57	Patented
T76685	DRUGINFO	D01XVK	Pyrazoline derivative 2	Patented
T76685	DRUGINFO	D02NNZ	1,2,4-triazole derivative 1	Patented
T76685	DRUGINFO	D02OBW	Aminoazetidine derivative 2	Patented
T76685	DRUGINFO	D02SNQ	Pyrazole derivative 8	Patented
T76685	DRUGINFO	D02XYT	Furopyridine derivative 1	Patented
T76685	DRUGINFO	D02ZVY	Diphenyl purine derivative 4	Patented
T76685	DRUGINFO	D03FDN	PMID26161824-Compound-69	Patented
T76685	DRUGINFO	D03GLK	Imidazole derivative 1	Patented
T76685	DRUGINFO	D03HHD	Pyrazoline derivative 4	Patented
T76685	DRUGINFO	D03TDK	Sulfonamide derivative 1	Patented
T76685	DRUGINFO	D03WCJ	4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide derivative 1	Patented
T76685	DRUGINFO	D04BXA	Pyrazole derivative 32	Patented
T76685	DRUGINFO	D04KUJ	Purine derivative 1	Patented
T76685	DRUGINFO	D04MPV	Pyrazole derivative 15	Patented
T76685	DRUGINFO	D04QVK	1,2,4-tri-substituted imidazoline derivative 1	Patented
T76685	DRUGINFO	D04ZLC	N-(arylalkyl)-1H-indole-2-sulfonic acid amide derivative 1	Patented
T76685	DRUGINFO	D05GDS	N-(arylalkyl)-1H-indole-2-sulfonic acid amide derivative 2	Patented
T76685	DRUGINFO	D05NUN	Pyrazole derivative 36	Patented
T76685	DRUGINFO	D05TQG	Pyrazole derivative 30	Patented
T76685	DRUGINFO	D05VIN	Imidazole derivative 2	Patented
T76685	DRUGINFO	D06CEA	Purine derivative 3	Patented
T76685	DRUGINFO	D06FOF	Imidazole derivative 5	Patented
T76685	DRUGINFO	D06IPV	Pyrazolo[1,5-a]pyrimidine derivative 2	Patented
T76685	DRUGINFO	D06MIW	Pyrazole derivative 37	Patented
T76685	DRUGINFO	D06MPH	Pyrazole derivative 28	Patented
T76685	DRUGINFO	D06STK	Purine derivative 2	Patented
T76685	DRUGINFO	D07GJH	PMID26161824-Compound-68	Patented
T76685	DRUGINFO	D07NAA	Sulfonylated piperazine derivative 4	Patented
T76685	DRUGINFO	D07PIH	Pyrazole derivative 60	Patented
T76685	DRUGINFO	D07PND	Diphenyl purine derivative 1	Patented
T76685	DRUGINFO	D07QLD	Pyrazole derivative 7	Patented
T76685	DRUGINFO	D07SYY	Pyrazolo[1,5-a]pyrimidine derivative 3	Patented
T76685	DRUGINFO	D08RCV	Pyrido[2,3-d]pyrimidine derivative 2	Patented
T76685	DRUGINFO	D08WTW	Pyrazole derivative 12	Patented
T76685	DRUGINFO	D09IYH	Pyrazole derivative 58	Patented
T76685	DRUGINFO	D09XUI	1,5-diphenylpyrrolidin-2-one derivative 2	Patented
T76685	DRUGINFO	D0A2PY	Pyrazole derivative 35	Patented
T76685	DRUGINFO	D0AM1D	Diaryl piperazine derivative 2	Patented
T76685	DRUGINFO	D0B6NT	Pyrazolo[1,5-a]pyrimidine derivative 11	Patented
T76685	DRUGINFO	D0BB2F	Pyrazole derivative 26	Patented
T76685	DRUGINFO	D0BI0F	Imidazole derivative 3	Patented
T76685	DRUGINFO	D0C0KI	Aminoazetidine derivative 7	Patented
T76685	DRUGINFO	D0C4TB	Pyrazole derivative 22	Patented
T76685	DRUGINFO	D0CF8Y	Pyrazoline derivative 3	Patented
T76685	DRUGINFO	D0CW1J	Pyrrole derivative 5	Patented
T76685	DRUGINFO	D0CX1F	Sulfonylated piperazine derivative 1	Patented
T76685	DRUGINFO	D0D1EI	Diphenyl purine derivative 5	Patented
T76685	DRUGINFO	D0D5MQ	Pyrazole derivative 27	Patented
T76685	DRUGINFO	D0D7AJ	Pyrazoline derivative 11	Patented
T76685	DRUGINFO	D0D7ZU	Pyrazole derivative 23	Patented
T76685	DRUGINFO	D0DE0C	Diphenyl purine derivative 2	Patented
T76685	DRUGINFO	D0DF6B	Azetidine-1-carboxamide derivative 1	Patented
T76685	DRUGINFO	D0EQ3O	Pyrazolo[1,5-a]pyrimidine derivative 4	Patented
T76685	DRUGINFO	D0ET9U	Pyrazoline derivative 1	Patented
T76685	DRUGINFO	D0F0VY	Pyrazolo[1,5-a]pyrimidine derivative 5	Patented
T76685	DRUGINFO	D0F1DK	Pyridotriazolopyrimidine derivative 1	Patented
T76685	DRUGINFO	D0FC8P	Pyrazole derivative 19	Patented
T76685	DRUGINFO	D0FR1Q	Sulfonylated piperazine derivative 3	Patented
T76685	DRUGINFO	D0FS0D	1,2,3-triazole derivative 2	Patented
T76685	DRUGINFO	D0FZ5R	Imidazolidine-2,4-dione derivative 1	Patented
T76685	DRUGINFO	D0G8LH	Pyrazolo[1,5-a]pyrimidine derivative 8	Patented
T76685	DRUGINFO	D0GH4B	Pyrazolo[1,5-a]pyrimidine derivative 13	Patented
T76685	DRUGINFO	D0GW8L	Pyrrole derivative 2	Patented
T76685	DRUGINFO	D0GX6V	Pyrazole derivative 1	Patented
T76685	DRUGINFO	D0H1IX	Pyrazole derivative 5	Patented
T76685	DRUGINFO	D0H2GT	Pyrrole derivative 3	Patented
T76685	DRUGINFO	D0HD6C	Tetra-hydro-1H-1,2,6-triazaazulene derivative 1	Patented
T76685	DRUGINFO	D0HD7S	Pyrrole derivative 6	Patented
T76685	DRUGINFO	D0I0VJ	Pyrazole derivative 3	Patented
T76685	DRUGINFO	D0I1VK	Heterocyclic-substituted 3-alkyl azetidine derivative 2	Patented
T76685	DRUGINFO	D0I1XE	Diphenyl purine derivative 3	Patented
T76685	DRUGINFO	D0I5SD	Azetidine derivative 1	Patented
T76685	DRUGINFO	D0IC3K	N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 1	Patented
T76685	DRUGINFO	D0IG6J	Piperazine derivative 1	Patented
T76685	DRUGINFO	D0J5NB	Pyrazole derivative 25	Patented
T76685	DRUGINFO	D0J5XM	Pyrido[2,3-d]pyrimidine derivative 1	Patented
T76685	DRUGINFO	D0J8GO	Aminoazetidine derivative 4	Patented
T76685	DRUGINFO	D0JK3V	Imidazole derivative 4	Patented
T76685	DRUGINFO	D0JW7T	Amide derivative 1	Patented
T76685	DRUGINFO	D0K0DV	N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 2	Patented
T76685	DRUGINFO	D0K3FJ	Imidazole derivative 6	Patented
T76685	DRUGINFO	D0K6GI	Benzimidazole derivative 2	Patented
T76685	DRUGINFO	D0K7XA	Pyrazole derivative 21	Patented
T76685	DRUGINFO	D0KD5X	Pyrazole derivative 31	Patented
T76685	DRUGINFO	D0KT1Q	Pyrazole derivative 11	Patented
T76685	DRUGINFO	D0KX2W	1,2,4,5-tetra-substituted imidazole derivative 1	Patented
T76685	DRUGINFO	D0KX8N	Diaryl morpholine derivative 1	Patented
T76685	DRUGINFO	D0L2MA	Pyrazolo[1,5-a]pyrimidine derivative 12	Patented
T76685	DRUGINFO	D0LH9E	Imidazolidine-2,4-dione derivative 2	Patented
T76685	DRUGINFO	D0LU7K	Pyrazolo[1,5-a]pyrimidine derivative 6	Patented
T76685	DRUGINFO	D0LX2Y	Aminoazetidine derivative 8	Patented
T76685	DRUGINFO	D0LZ1Z	Pyrazolo[1,5-a]pyrimidine derivative 7	Patented
T76685	DRUGINFO	D0M2RT	Pyrazole derivative 2	Patented
T76685	DRUGINFO	D0M6PB	Pyrrole derivative 1	Patented
T76685	DRUGINFO	D0M9FZ	Pyrazole derivative 6	Patented
T76685	DRUGINFO	D0N0XU	Pyrazole derivative 29	Patented
T76685	DRUGINFO	D0N6GL	Pyrazoline derivative 10	Patented
T76685	DRUGINFO	D0NB2K	Pyrrole derivative 4	Patented
T76685	DRUGINFO	D0NJ0S	Pyrazole derivative 34	Patented
T76685	DRUGINFO	D0O4RN	Sulfonylated piperazine derivative 5	Patented
T76685	DRUGINFO	D0OT3G	Pyrazolo[1,5-a]pyrimidine derivative 10	Patented
T76685	DRUGINFO	D0P7HQ	Pyrazole derivative 13	Patented
T76685	DRUGINFO	D0P7LP	Azetidine derivative 3	Patented
T76685	DRUGINFO	D0P7QA	Pyrazole derivative 14	Patented
T76685	DRUGINFO	D0PK0R	Piperazine derivative 2	Patented
T76685	DRUGINFO	D0Q5FS	Pyrazole derivative 18	Patented
T76685	DRUGINFO	D0Q9AD	Pyrazole derivative 59	Patented
T76685	DRUGINFO	D0QH5I	N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 3	Patented
T76685	DRUGINFO	D0R1PX	Pyrano[2,3-b]pyridine derivative 1	Patented
T76685	DRUGINFO	D0R9PD	Hydrazide derivative 1	Patented
T76685	DRUGINFO	D0RC5I	Azetidine derivative 4	Patented
T76685	DRUGINFO	D0RV2E	Pyrazole derivative 17	Patented
T76685	DRUGINFO	D0S2ME	Pyrazoline derivative 5	Patented
T76685	DRUGINFO	D0S3RX	1,2,3-triazole derivative 1	Patented
T76685	DRUGINFO	D0S5NS	Pyrazole derivative 24	Patented
T76685	DRUGINFO	D0SV6D	Heterocyclic-substituted 3-alkyl azetidine derivative 1	Patented
T76685	DRUGINFO	D0SW2Q	Tetra-hydro-1H-1,2,6-triazaazulene derivative 2	Patented
T76685	DRUGINFO	D0T0OQ	Furopyridine derivative 2	Patented
T76685	DRUGINFO	D0T7QY	Pyrazole derivative 38	Patented
T76685	DRUGINFO	D0T8VE	Aminoazetidine derivative 5	Patented
T76685	DRUGINFO	D0TI3Q	1,2,4,5-tetra-substituted imidazole derivative 2	Patented
T76685	DRUGINFO	D0TS3S	Heterocyclic-substituted 3-alkyl azetidine derivative 3	Patented
T76685	DRUGINFO	D0TT0B	1,2,4-triazole derivative 2	Patented
T76685	DRUGINFO	D0U3VU	Aminoazetidine derivative 9	Patented
T76685	DRUGINFO	D0U3YY	Pyrano[2,3-b]pyridine derivative 2	Patented
T76685	DRUGINFO	D0U6PA	Pyrazolo[1,5-a]pyrimidine derivative 9	Patented
T76685	DRUGINFO	D0UA6W	Pyrazole derivative 33	Patented
T76685	DRUGINFO	D0UW5J	PMID27215781-Compound-1	Patented
T76685	DRUGINFO	D0V0UW	Pyridotriazolopyrimidine derivative 2	Patented
T76685	DRUGINFO	D0V5BV	Benzimidazole derivative 1	Patented
T76685	DRUGINFO	D0VB2M	1,5-diphenylpyrrolidin-2-one derivative 1	Patented
T76685	DRUGINFO	D0VL5E	Aminoazetidine derivative 3	Patented
T76685	DRUGINFO	D0WK8I	Sulfonylated piperazine derivative 2	Patented
T76685	DRUGINFO	D0X7DZ	Pyrazolo[1,5-a]pyrimidine derivative 1	Patented
T76685	DRUGINFO	D0YN2I	Pyrazole derivative 54	Patented
T76685	DRUGINFO	D0YW3K	Pyrazole derivative 16	Patented
T76685	DRUGINFO	D0Z7EV	Carboxamide derivative 1	Patented
T76685	DRUGINFO	D0Z8WF	Pyridotriazolopyrimidine derivative 3	Patented
T76685	DRUGINFO	D0ZE8B	Azetidine-1-carboxamide derivative 2	Patented
T76685	DRUGINFO	D0ZY6C	Diaryl piperazine derivative 1	Patented
T76685	DRUGINFO	D02TOI	Tricyclic phytocannabinoid derivative 2	Patented
T76685	DRUGINFO	D05CEL	2-cycloalkyl resorcinol cannabinoid ligand derivative 1	Patented
T76685	DRUGINFO	D07BFP	PMID27215781-Compound-37	Patented
T76685	DRUGINFO	D09GJQ	Tricyclic phytocannabinoid derivative 1	Patented
T76685	DRUGINFO	D09WPA	Phytocannabinoid/aminoalkylindole derivative 2	Patented
T76685	DRUGINFO	D0FA2L	N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 3	Patented
T76685	DRUGINFO	D0GQ8W	Carbazole-3-carboxamide analog 1	Patented
T76685	DRUGINFO	D0H0XC	2-cycloalkyl resorcinol cannabinoid ligand derivative 2	Patented
T76685	DRUGINFO	D0LN9D	Cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 1	Patented
T76685	DRUGINFO	D0RZ4M	Phytocannabinoid/aminoalkylindole derivative 1	Patented
T76685	DRUGINFO	D0W9PY	PMID27215781-Compound-2	Patented
T76685	DRUGINFO	D0WJ3F	N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 2	Patented
T76685	DRUGINFO	D0X5ZS	Cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 2	Patented
T76685	DRUGINFO	D06TGE	Taranabant	Discontinued in Phase 3
T76685	DRUGINFO	D0J0AE	CP-945598	Discontinued in Phase 3
T76685	DRUGINFO	D0A9OR	SLV319	Discontinued in Phase 2
T76685	DRUGINFO	D0J1TS	AZD2207	Discontinued in Phase 2
T76685	DRUGINFO	D0OM0M	AVE1625	Discontinued in Phase 2
T76685	DRUGINFO	D0P8MG	KDS-2000	Discontinued in Phase 2
T76685	DRUGINFO	D0LF5B	KN-38-7271	Discontinued in Phase 2
T76685	DRUGINFO	D0H1FL	PF-514273	Discontinued in Phase 1
T76685	DRUGINFO	D0M7LQ	CBD cannabis derivative	Discontinued in Phase 1
T76685	DRUGINFO	D0N0UY	AZD1704	Discontinued in Phase 1
T76685	DRUGINFO	D0N5SS	AZD1175	Discontinued in Phase 1
T76685	DRUGINFO	D03KTK	TAK-937	Discontinued in Phase 1
T76685	DRUGINFO	D00GES	JD-5037	Preclinical
T76685	DRUGINFO	D0H4GB	CB1 antagonist, Bayer	Preclinical
T76685	DRUGINFO	D0J7RW	WIN-55212-2	Terminated
T76685	DRUGINFO	D0N5UA	Dianicline+rimonabant	Terminated
T76685	DRUGINFO	D00VCW	ACEA	Investigative
T76685	DRUGINFO	D01PZU	N-ethyl-5,6-dip-tolylpyrazine-2-carboxamide	Investigative
T76685	DRUGINFO	D02MBV	[123I]AM251	Investigative
T76685	DRUGINFO	D03FAI	{[(9Z)-octadec-9-en-1-yl]sulfamoyl}amine	Investigative
T76685	DRUGINFO	D03LVT	SEMIPLENAMIDE B	Investigative
T76685	DRUGINFO	D03RFS	N-(3,3-Diphenyl)propyl-2-phenylacetamide	Investigative
T76685	DRUGINFO	D03RTC	BMS-812204	Investigative
T76685	DRUGINFO	D03TPB	1-[bis(4-iodophenyl)methyl]-3-(4-bromophenyl)urea	Investigative
T76685	DRUGINFO	D04YLU	AZ-599	Investigative
T76685	DRUGINFO	D05ACE	1,5-bis(4-chlorophenyl)-1H-1,2,3-triazole	Investigative
T76685	DRUGINFO	D05DFO	N-(4-methoxyphenyl)oleamide	Investigative
T76685	DRUGINFO	D05QTX	Org27569	Investigative
T76685	DRUGINFO	D05RGU	N-(4-methoxyphenethyl)oleamide	Investigative
T76685	DRUGINFO	D06RIK	N-(3,5-dimethoxyphenethyl)oleamide	Investigative
T76685	DRUGINFO	D06RKK	SEMIPLENAMIDE A	Investigative
T76685	DRUGINFO	D06YQD	N-isopentyl-5,6-dip-tolylpyrazine-2-carboxamide	Investigative
T76685	DRUGINFO	D08DZK	N-(2,4-dimethoxyphenethyl)oleamide	Investigative
T76685	DRUGINFO	D08EGA	N-(cis-9-cis-12-octadecadienyl)sulfamide	Investigative
T76685	DRUGINFO	D08JHR	N-(2-adamantyl)-N'-propylsulfamide	Investigative
T76685	DRUGINFO	D08MON	3-Benzyl-5-methoxy-7-methylchromen-2-one	Investigative
T76685	DRUGINFO	D08UKF	N-(3,5-dimethoxyphenethyl)docos-13-enamide	Investigative
T76685	DRUGINFO	D08WRU	N-octadecyl-N'-propylsulfamide	Investigative
T76685	DRUGINFO	D08YQT	AM251	Investigative
T76685	DRUGINFO	D09CJO	CXB-029	Investigative
T76685	DRUGINFO	D09DFD	CP-4497	Investigative
T76685	DRUGINFO	D09LVP	O-1812	Investigative
T76685	DRUGINFO	D09QLR	Dibenzothiazepines	Investigative
T76685	DRUGINFO	D0A2KW	1-(bis(4-bromophenyl)methyl)-3-phenylurea	Investigative
T76685	DRUGINFO	D0A9PS	Anandamide	Investigative
T76685	DRUGINFO	D0B8EP	1-[bis(4-chlorophenyl)methyl]-3-(4-chlorophenyl)-	Investigative
T76685	DRUGINFO	D0B8GY	N-methyl-5,6-dip-tolylpyrazine-2-carboxamide	Investigative
T76685	DRUGINFO	D0B9RI	3-Benzyl-5-methoxychromen-2-one	Investigative
T76685	DRUGINFO	D0D5SP	Semiplenamide G	Investigative
T76685	DRUGINFO	D0E9HC	1-(bis(4-chlorophenyl)methyl)-3-phenylurea	Investigative
T76685	DRUGINFO	D0F4BX	HU210	Investigative
T76685	DRUGINFO	D0G6BG	2-Benzylbenzo[f]chromen-3-one	Investigative
T76685	DRUGINFO	D0GS1B	1-(2-morpholinoethyl)-1H-indol-3-yl acetate	Investigative
T76685	DRUGINFO	D0H1DV	N-phenyl-5,6-dip-tolylpyrazine-2-carboxamide	Investigative
T76685	DRUGINFO	D0H6DL	1,3,5-triphenylimidazolidine-2,4-dione	Investigative
T76685	DRUGINFO	D0I1OJ	N-(4-morpholinophenyl)docos-13-enamide	Investigative
T76685	DRUGINFO	D0I4YK	Methanandamide	Investigative
T76685	DRUGINFO	D0J5KA	N-(2,4-dimethoxyphenethyl)docos-13-enamide	Investigative
T76685	DRUGINFO	D0K0EW	N-(1-adamantyl)-N'-propylsulfamide	Investigative
T76685	DRUGINFO	D0K5DA	N-(4-methoxybenzyl)oleamide	Investigative
T76685	DRUGINFO	D0LX4U	1-[bis(4-bromophenyl)methyl]-3-phenylthiourea	Investigative
T76685	DRUGINFO	D0M4UK	PMID26161824C70	Investigative
T76685	DRUGINFO	D0O4LO	1-(4-CHLOROPHENYL)-2-(2,4-DICHLOROPHENYL)-5-(METHYLSULFINYL)-N-(PIPERIDIN-1-YL)-1H-IMIDAZOLE-4-CARBOXAMIDE (ENANTIOMERIC MIX)	Investigative
T76685	DRUGINFO	D0V0YM	MK-5596	Investigative
T76685	DRUGINFO	D0V2NQ	N-(3-Phenyl)propyl-2,2-diphenylacetamide	Investigative
T76685	DRUGINFO	D0WO8A	1,3,5-tris(4-chlorophenyl)imidazolidine-2,4-dione	Investigative
T76685	DRUGINFO	D0X8FV	N-isopropyl-5,6-dip-tolylpyrazine-2-carboxamide	Investigative
T76685	DRUGINFO	D0Z9GI	1-[bis(4-chlorophenyl)methyl]-3-phenylthiourea	Investigative
T76685	DRUGINFO	D0ZU9Z	LY320135	Investigative
T76685	DRUGINFO	D00DNT	JWH-406	Investigative
T76685	DRUGINFO	D00LZJ	JWH-405	Investigative
T76685	DRUGINFO	D00QUN	Isopropyl 4-nitrophenyl dodecylphosphonate	Investigative
T76685	DRUGINFO	D00TRZ	JWH-407	Investigative
T76685	DRUGINFO	D01JHA	2'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol	Investigative
T76685	DRUGINFO	D01JQX	JWH-342	Investigative
T76685	DRUGINFO	D01MJF	JWH-404	Investigative
T76685	DRUGINFO	D01PEC	(2R)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)	Investigative
T76685	DRUGINFO	D01RWS	3-Benzyl-5-isopropyl-8-methylchromen-2-one	Investigative
T76685	DRUGINFO	D01VIA	(4-benzhydrylpiperazin-1-yl)(cyclohexyl)methanone	Investigative
T76685	DRUGINFO	D02HDI	arachidonylcyclopropylamide	Investigative
T76685	DRUGINFO	D02NAW	N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXY-2-METHYLPROPANAMIDE (ENANTIOMERIC MIX)	Investigative
T76685	DRUGINFO	D02POA	5-(1,1-dimethyl-heptyl)-2-pyridin-3-yl-phenol	Investigative
T76685	DRUGINFO	D02QTB	JWH-307	Investigative
T76685	DRUGINFO	D02VSL	JWH-133	Investigative
T76685	DRUGINFO	D03AWH	AM-4768	Investigative
T76685	DRUGINFO	D03GDP	AM-1715	Investigative
T76685	DRUGINFO	D03HFM	(1R,2R)-N-Arachidonoylcyclopropanolamide	Investigative
T76685	DRUGINFO	D03REA	5-Methoxy-3-(2-methoxybenzyl)-2H-chromen-2-one	Investigative
T76685	DRUGINFO	D03RGV	JWH-156	Investigative
T76685	DRUGINFO	D03SRV	JWH-292	Investigative
T76685	DRUGINFO	D03ZBS	4-cyanophenyl ethyl dodecylphosphonate	Investigative
T76685	DRUGINFO	D04AMC	N-arachidonoyl-N-(2-hydroxyethyl)hydroxylamine	Investigative
T76685	DRUGINFO	D04AUM	AM-1710	Investigative
T76685	DRUGINFO	D04ECZ	Rac-trans-N-oleoylcyclopropanolamide	Investigative
T76685	DRUGINFO	D04GDY	DELTA 8-TETRAHYDROCANNOBINOL	Investigative
T76685	DRUGINFO	D04ICJ	4-benzhydryl-N-cyclohexylpiperazine-1-carboxamide	Investigative
T76685	DRUGINFO	D04LZA	JWH-370	Investigative
T76685	DRUGINFO	D04TSL	JWH-392	Investigative
T76685	DRUGINFO	D04YUA	Octane-1-sulfonyl fluoride	Investigative
T76685	DRUGINFO	D06BXT	[3H]WIN55212-2	Investigative
T76685	DRUGINFO	D06DTC	(2S)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)	Investigative
T76685	DRUGINFO	D06EHU	JWH-268	Investigative
T76685	DRUGINFO	D06SKK	JWH-440	Investigative
T76685	DRUGINFO	D07KZW	JWH-364	Investigative
T76685	DRUGINFO	D07QUV	JWH-345	Investigative
T76685	DRUGINFO	D08BNY	(E)-N-(4-methoxyphenyl)undec-2-enamide	Investigative
T76685	DRUGINFO	D08GLU	4'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol	Investigative
T76685	DRUGINFO	D08OAQ	4-(1,1-dimethyl-heptyl)-3'-methoxy-biphenyl-2-ol	Investigative
T76685	DRUGINFO	D08TXL	A-796260	Investigative
T76685	DRUGINFO	D08VLG	4-(1,1-dimethyl-heptyl)-2'-methoxy-biphenyl-2-ol	Investigative
T76685	DRUGINFO	D09BYO	N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX)	Investigative
T76685	DRUGINFO	D09CKZ	AM-411	Investigative
T76685	DRUGINFO	D09FMK	AM-630	Investigative
T76685	DRUGINFO	D09JER	JWH-344	Investigative
T76685	DRUGINFO	D09KFJ	JWH-229	Investigative
T76685	DRUGINFO	D09PIQ	JWH-367	Investigative
T76685	DRUGINFO	D0A2BC	JWH-385	Investigative
T76685	DRUGINFO	D0B8AN	JWH-347	Investigative
T76685	DRUGINFO	D0C4CG	N-(2-chloroethyl)icosa-5,8,11,14-tetraenamide	Investigative
T76685	DRUGINFO	D0CO6T	NAPHTHYRIDINONE	Investigative
T76685	DRUGINFO	D0D7OR	KM-233-M	Investigative
T76685	DRUGINFO	D0DE9L	JWH-368	Investigative
T76685	DRUGINFO	D0DQ3F	JWH-365	Investigative
T76685	DRUGINFO	D0E0AA	N-(7-(2-CHLOROPHENYL)-6-(4-CHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX)	Investigative
T76685	DRUGINFO	D0E0JU	JWH-401	Investigative
T76685	DRUGINFO	D0E3ET	AM-1714	Investigative
T76685	DRUGINFO	D0E3OY	JWH-372	Investigative
T76685	DRUGINFO	D0E4OT	JWH-325	Investigative
T76685	DRUGINFO	D0EE0Q	JWH-366	Investigative
T76685	DRUGINFO	D0EX7J	JWH-442	Investigative
T76685	DRUGINFO	D0F3XG	JWH-346	Investigative
T76685	DRUGINFO	D0F4BE	O-arachidonoyl-N-(2-hydroxyethyl)hydroxylamine	Investigative
T76685	DRUGINFO	D0G2EQ	(1S,2S)-N-Arachidonoylcyclopropanolamide	Investigative
T76685	DRUGINFO	D0G4VV	SCH-356036	Investigative
T76685	DRUGINFO	D0G7GF	3'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol	Investigative
T76685	DRUGINFO	D0GG4T	JWH-150	Investigative
T76685	DRUGINFO	D0I4AF	N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXY-2,2-DIMETHYLPROPANAMIDE (ENANTIOMERIC MIX)	Investigative
T76685	DRUGINFO	D0I7MW	JWH-244	Investigative
T76685	DRUGINFO	D0J3XJ	N-(3-Phenyl)propyl-2-(4-bromophenylacetamide)	Investigative
T76685	DRUGINFO	D0J7CR	Rac-cis-N-arachidonoylcyclopropanolamide	Investigative
T76685	DRUGINFO	D0K4PV	6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-((R)-1-HYDROXYETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)	Investigative
T76685	DRUGINFO	D0K7QP	(1S,2S)-N-Oleoylcyclopropanolamide	Investigative
T76685	DRUGINFO	D0K8MN	5-Biphenyl-4-ylmethyl-2-isobutyl-2H-tetrazole	Investigative
T76685	DRUGINFO	D0K8VR	[3H]HU-243	Investigative
T76685	DRUGINFO	D0L6RT	PRAVADOLINE	Investigative
T76685	DRUGINFO	D0N0ME	4-benzhydryl-N-butylpiperazine-1-carboxamide	Investigative
T76685	DRUGINFO	D0N5VO	JWH-403	Investigative
T76685	DRUGINFO	D0O3NY	AM-1241	Investigative
T76685	DRUGINFO	D0O7ZJ	JWH-120	Investigative
T76685	DRUGINFO	D0O8IC	JWH-309	Investigative
T76685	DRUGINFO	D0P5VJ	KM-233	Investigative
T76685	DRUGINFO	D0PE8U	N-(1H-indazol-5-yl)icosa-5,8,11,14-tetraenamide	Investigative
T76685	DRUGINFO	D0Q0XV	(1R,2S)-N-Oleoylcyclopropanolamide	Investigative
T76685	DRUGINFO	D0Q9FB	JWH-308	Investigative
T76685	DRUGINFO	D0R1NR	JWH-371	Investigative
T76685	DRUGINFO	D0R3GN	JWH-373	Investigative
T76685	DRUGINFO	D0R6MB	6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)	Investigative
T76685	DRUGINFO	D0R7QF	(1R,2S)-N-Arachidonoylcyclopropanolamide	Investigative
T76685	DRUGINFO	D0R9VY	6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(1-HYDROXY-2-METHYLPROPAN-2-YL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)	Investigative
T76685	DRUGINFO	D0S2ZR	JWH-147	Investigative
T76685	DRUGINFO	D0S3UA	JWH-145	Investigative
T76685	DRUGINFO	D0T4HB	Methyl icosylphosphonofluoridate	Investigative
T76685	DRUGINFO	D0T4SE	(E)-N-(4-methoxyphenethyl)undec-2-enamide	Investigative
T76685	DRUGINFO	D0T5WY	JWH-293	Investigative
T76685	DRUGINFO	D0TN1L	JWH-146	Investigative
T76685	DRUGINFO	D0TS5I	JWH-245	Investigative
T76685	DRUGINFO	D0U0CV	Dodecane-1-sulfonyl fluoride	Investigative
T76685	DRUGINFO	D0U4JI	JWH-337	Investigative
T76685	DRUGINFO	D0U5LL	cannabinol	Investigative
T76685	DRUGINFO	D0UD9H	AM-281	Investigative
T76685	DRUGINFO	D0V3TO	JWH-348	Investigative
T76685	DRUGINFO	D0V3YB	3,4-diarylpyrazoline derivative	Investigative
T76685	DRUGINFO	D0V7QA	1,4-dihydroindeno[1,2-c]-pyrazole	Investigative
T76685	DRUGINFO	D0Y0MY	JWH-402	Investigative
T76685	DRUGINFO	D0Y1MM	N-arachidonoyl-O-(2-hydroxyethyl)hydroxylamine	Investigative
T76685	DRUGINFO	D0Y6MS	JWH-297	Investigative
T76685	DRUGINFO	D0Y9HT	JWH-363	Investigative
T76685	DRUGINFO	D0Z1NH	Cis-N-oleoylcyclopropanolamide	Investigative
T76685	DRUGINFO	D0Z1XE	JWH-324	Investigative
T76685	DRUGINFO	D0Z5CX	N-(3,3-Diphenyl)propyl-2,2-diphenylacetamide	Investigative
T76685	DRUGINFO	D0Z6BY	JWH-243	Investigative
T76685	DRUGINFO	D0Z7FF	JWH-246	Investigative
T76685	DRUGINFO	D0Z7OB	(E)-N-(3,5-dimethoxyphenethyl)undec-2-enamide	Investigative
T76685	DRUGINFO	D0ZL2P	JWH-369	Investigative
T76685	DRUGINFO	D0ZM1T	VER-156085	Investigative
T76685	DRUGINFO	D01MCD	(2R)-N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)	Investigative
T76685	DRUGINFO	D02GOH	AM-404	Investigative
T76685	DRUGINFO	D06NXC	N-[6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-YL]-4,4,4-TRIFLUORO-3-HYDROXYBUTANAMIDE (DIASTEREOMERIC MIX)	Investigative
T76685	DRUGINFO	D0D6OH	[3H]CP55940	Investigative
T76685	DRUGINFO	D0FJ1I	N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)	Investigative
T76685	DRUGINFO	D0HQ4M	Isopropyl dodecylfluorophosphonate	Investigative
T76685	DRUGINFO	D0L1UA	N-(4-hydroxybenzyl)icosa-5,8,11,14-tetraenamide	Investigative
T76685	DRUGINFO	D0OQ5H	6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)	Investigative
T76685	DRUGINFO	D0PC5A	VER-156084	Investigative
T76685	DRUGINFO	D0W6PT	Chlorphrifos oxon	Investigative
T76685	DRUGINFO	D07MBC	N-oleoylethanolamide	Investigative
T76685	DRUGINFO	D08XQI	PARAOXON	Investigative
T76685	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T22118	TARGETID	T22118
T22118	FORMERID	TTDS00011
T22118	UNIPROID	DRD1_HUMAN
T22118	TARGNAME	Dopamine D1 receptor (D1R)
T22118	GENENAME	DRD1
T22118	TARGTYPE	Successful
T22118	SYNONYMS	D(1A) dopamine receptor
T22118	FUNCTION	Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
T22118	PDBSTRUC	1OZ5
T22118	BIOCLASS	GPCR rhodopsin
T22118	SEQUENCE	MRTLNTSAMDGTGLVVERDFSVRILTACFLSLLILSTLLGNTLVCAAVIRFRHLRSKVTNFFVISLAVSDLLVAVLVMPWKAVAEIAGFWPFGSFCNIWVAFDIMCSTASILNLCVISVDRYWAISSPFRYERKMTPKAAFILISVAWTLSVLISFIPVQLSWHKAKPTSPSDGNATSLAETIDNCDSSLSRTYAISSSVISFYIPVAIMIVTYTRIYRIAQKQIRRIAALERAAVHAKNCQTTTGNGKPVECSQPESSFKMSFKRETKVLKTLSVIMGVFVCCWLPFFILNCILPFCGSGETQPFCIDSNTFDVFVWFGWANSSLNPIIYAFNADFRKAFSTLLGCYRLCPATNNAIETVSINNNGAAMFSSHHEPRGSISKECNLVYLIPHAVGSSEDLKKEEAAGIARPLEKLSPALSVILDYDTDVSLEKIQPITQNGQHPT
T22118	DRUGINFO	D05AHE	Methylergonovine	Approved
T22118	DRUGINFO	D0R6BI	Fenoldopam	Approved
T22118	DRUGINFO	D04JCN	Pergolide	Approved
T22118	DRUGINFO	D0KS6W	Phenyltoloxamine	Approved
T22118	DRUGINFO	D0Y6HW	Ecopipam	Phase 3
T22118	DRUGINFO	D02YVM	Zicronapine	Phase 3
T22118	DRUGINFO	D0BJ2W	DAS-431	Phase 2
T22118	DRUGINFO	D0D3VT	Dihydrexidine	Phase 1/2
T22118	DRUGINFO	DJ2OV7	Lu AF28996	Phase 1
T22118	DRUGINFO	D09ORU	ZELANDOPAM HYDROCHLORIDE	Discontinued in Phase 2
T22118	DRUGINFO	D0N5JJ	ADROGOLIDE HYDROCHLORIDE	Discontinued in Phase 2
T22118	DRUGINFO	D0S0GM	ADX-10061	Discontinued in Phase 2
T22118	DRUGINFO	D02KKQ	BAM-1110	Discontinued in Phase 2
T22118	DRUGINFO	D0BQ8M	CY-208243	Discontinued in Phase 2
T22118	DRUGINFO	D03DXS	Odapipam	Discontinued in Phase 1
T22118	DRUGINFO	D03PTZ	BTS-73947	Discontinued in Phase 1
T22118	DRUGINFO	D0X8MI	Berupipam	Discontinued in Phase 1
T22118	DRUGINFO	D0LE7P	SDZ-GLC-756	Discontinued in Phase 1
T22118	DRUGINFO	D0J7WO	BSF-78438	Preclinical
T22118	DRUGINFO	D01TCM	CEE-03-320	Terminated
T22118	DRUGINFO	D02DHU	SKF-81297	Terminated
T22118	DRUGINFO	D0DX6L	SDZ-PSD-958	Terminated
T22118	DRUGINFO	D0OQ4H	A-69024	Terminated
T22118	DRUGINFO	D0OU7P	SKF 38393	Terminated
T22118	DRUGINFO	D0P2YS	A 77636	Terminated
T22118	DRUGINFO	D03NPZ	NNC-22-0031	Terminated
T22118	DRUGINFO	D08IRR	Org-10490	Terminated
T22118	DRUGINFO	D0N1WM	A-68930	Terminated
T22118	DRUGINFO	D0EH2O	BIMG80	Terminated
T22118	DRUGINFO	D00MLN	(R,S)-homoaromaline hydrochloride	Investigative
T22118	DRUGINFO	D02BPV	5-(2-Amino-ethyl)-2-chloro-phenol hydrobromide	Investigative
T22118	DRUGINFO	D03OUU	6-(2-Amino-ethyl)-biphenyl-2,3,4'-triol	Investigative
T22118	DRUGINFO	D05QOF	1-Aminomethyl-3-phenyl-isochroman-5,6-diol	Investigative
T22118	DRUGINFO	D06VYA	6-(2-Dipropylamino-ethyl)-biphenyl-2,3-diol	Investigative
T22118	DRUGINFO	D08YYX	6-(2-Amino-ethyl)-biphenyl-2,3-diol	Investigative
T22118	DRUGINFO	D0A9UF	1,2,3,7,12,12a-hexahydro-1-aza-pleiaden-5-ol	Investigative
T22118	DRUGINFO	D0I0AQ	MELOSMINE	Investigative
T22118	DRUGINFO	D0L3MJ	SKF-83959	Investigative
T22118	DRUGINFO	D0L8PI	SCH-23390	Investigative
T22118	DRUGINFO	D0NY6P	TEPA (possesses cytotoxic activity)	Investigative
T22118	DRUGINFO	D0O1EY	9-Aminomethyl-9H-fluorene-2,5,6-triol	Investigative
T22118	DRUGINFO	D0P2YV	SCH-12679	Investigative
T22118	DRUGINFO	D0V1EJ	6-(2-Dipropylamino-ethyl)-biphenyl-2,3,4'-triol	Investigative
T22118	DRUGINFO	D0V4FZ	SKF-75670	Investigative
T22118	DRUGINFO	D0X7ZC	9-Aminomethyl-9H-fluorene-3,4-diol	Investigative
T22118	DRUGINFO	D00YEB	11-Butyryloxy-N-n-propylnoraporphine	Investigative
T22118	DRUGINFO	D02RAY	GLAUCINE	Investigative
T22118	DRUGINFO	D02YCY	(R)-11-Amino-2-methoxyaporphine	Investigative
T22118	DRUGINFO	D03RMB	2-{[R-(-)-Apomorphine-2'-oxy]ethoxy}-ethanol	Investigative
T22118	DRUGINFO	D03YXB	(+)-(1R,1'S)-berbamunine hydrochloride	Investigative
T22118	DRUGINFO	D04GRS	(S)-BULBOCAPNINE	Investigative
T22118	DRUGINFO	D04IIK	(R)-(-)-N-ethyl-2-methoxy-11-hydroxynoraporphine	Investigative
T22118	DRUGINFO	D04TTN	(+)-(1R,1'S)-thaligrisine hydrochloride	Investigative
T22118	DRUGINFO	D05HWC	PUKATEINE	Investigative
T22118	DRUGINFO	D05NBK	1-Aminomethyl-3-cyclohexyl-isochroman-5,6-diol	Investigative
T22118	DRUGINFO	D05OHF	(R)-(+)-coclaurine	Investigative
T22118	DRUGINFO	D06AIQ	IBZM	Investigative
T22118	DRUGINFO	D07CZJ	11-valeryloxynoraporphine	Investigative
T22118	DRUGINFO	D07IWZ	(R)-2,11-Diaminoaporphine	Investigative
T22118	DRUGINFO	D08DLP	3-Chloroboldine	Investigative
T22118	DRUGINFO	D08EMG	(S)APOMORPHINE	Investigative
T22118	DRUGINFO	D08HTJ	2-methoxyapomorphine	Investigative
T22118	DRUGINFO	D08UQU	(R)-(-)-2-methoxy-11-hydroxyaporphine	Investigative
T22118	DRUGINFO	D09CVV	NORSTEPHALAGINE	Investigative
T22118	DRUGINFO	D09KRA	[125I]SCH23982	Investigative
T22118	DRUGINFO	D09QRL	2-Methyl-8-phenyl-1,2,3,4-tetrahydro-isoquinoline	Investigative
T22118	DRUGINFO	D0A4GE	1,2,3,7,12,12a-hexahydro-1-aza-pleiadene-5,6-diol	Investigative
T22118	DRUGINFO	D0B1GJ	11-Propionyloxy-N-n-propylnoraporphine	Investigative
T22118	DRUGINFO	D0D1PR	(R)-(-)-2-methoxy-N-npropylnorapomorphine	Investigative
T22118	DRUGINFO	D0I2WQ	11-Heptanoyloxy-N-n-propylnoraporphine	Investigative
T22118	DRUGINFO	D0I7CE	SK&F-89626	Investigative
T22118	DRUGINFO	D0LR8X	SKF-83556	Investigative
T22118	DRUGINFO	D0N9DY	3-Iodoboldine	Investigative
T22118	DRUGINFO	D0NA2T	(R)-(-)-N-propyl-2-methoxy-11-hydroxynoraporphine	Investigative
T22118	DRUGINFO	D0ND8J	(-)-(1S,1'R)-O,O-dimethylgrisbine hydrochloride	Investigative
T22118	DRUGINFO	D0P4BY	SCH-24518	Investigative
T22118	DRUGINFO	D0P8AW	Ro-21-7767	Investigative
T22118	DRUGINFO	D0R8PL	11-Hexanoyloxy-N-n-propylnoraporphine	Investigative
T22118	DRUGINFO	D0TA8F	(S,S)-oxandrine hydrochloride	Investigative
T22118	DRUGINFO	D0U6IL	1-Aminomethyl-isochroman-5,6-diol	Investigative
T22118	DRUGINFO	D0V3DO	1,2-Bis-[R-(-)-apomorphine-2'-oxy]ethane	Investigative
T22118	DRUGINFO	D0X2NO	(+)-ADTN	Investigative
T22118	DRUGINFO	D0Z9JY	[R-(-)-Apomorphine-2-yl]-(2'-hydroxy-ethyl)ether	Investigative
T22118	DRUGINFO	D01ENR	4-[2-(2-Benzyl-phenoxy)-ethyl]-morpholine	Investigative
T22118	DRUGINFO	D04CPW	N-(4-Propylaminobutyl)-4-biphenylcarboxamide	Investigative
T22118	DRUGINFO	D04KGP	(R)-(-)-11-hydroxy-N-n-propylnoraporphine	Investigative
T22118	DRUGINFO	D04MVL	(R)-(-)-10-methyl-11-hydroxyaporphine	Investigative
T22118	DRUGINFO	D06FLU	3,8-dibromoboldine	Investigative
T22118	DRUGINFO	D09BSE	3-bromoboldine	Investigative
T22118	DRUGINFO	D0KX3X	MCL-516	Investigative
T22118	DRUGINFO	D0T1TU	Etoloxamine	Investigative
T22118	DRUGINFO	D06LQH	N-propylnorapomorphine	Investigative
T22118	DRUGINFO	D07RYR	1-[2-(2-Benzyl-phenoxy)-ethyl]-pyrrolidine	Investigative
T22118	DRUGINFO	D07UUQ	1-Benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine	Investigative
T22118	DRUGINFO	D0B9DR	1-Benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine	Investigative
T22118	DRUGINFO	D0H2WQ	QUINPIROLE	Investigative
T22118	DRUGINFO	D0LH4L	BOLDINE	Investigative
T22118	DRUGINFO	D0M2BB	1-(4-(1H-pyrazol-1-yl)benzyl)-4-phenylpiperazine	Investigative
T22118	DRUGINFO	D0O7DA	(+)-BUTACLAMOL	Investigative
T22118	DRUGINFO	D0V4NW	N-(4-Dipropylaminobutyl)-4-biphenylcarboxamide	Investigative
T22118	DRUGINFO	D0WD6J	1-Benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine	Investigative
T22118	DRUGINFO	D05UUW	1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine	Investigative
T22118	DRUGINFO	D08UOX	FALCARINDIOL	Investigative
T22118	DRUGINFO	D0E1RX	1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine	Investigative
T22118	DRUGINFO	D0L7OM	STEPHOLIDINE	Investigative
T22118	DRUGINFO	D0MC2R	FLUTROLINE	Investigative
T22118	DRUGINFO	D0R8UU	1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine	Investigative
T22118	DRUGINFO	D07LRJ	SB-271046	Investigative
T22118	DRUGINFO	D0HV3A	FLUMEZAPINE	Investigative
T22118	DRUGINFO	D0Q2GP	ISOLOXAPINE	Investigative
T22118	DRUGINFO	D0P0IX	ISOCLOZAPINE	Investigative
T22118	DRUGINFO	D0L5MW	(+/-)-nantenine	Investigative
T22118	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T76198	TARGETID	T76198
T76198	FORMERID	TTDS00395
T76198	UNIPROID	TA2R_HUMAN
T76198	TARGNAME	Thromboxane A2 receptor (TBXA2R)
T76198	GENENAME	TBXA2R
T76198	TARGTYPE	Successful
T76198	SYNONYMS	TXA2-R; TXA2 receptor; Prostanoid TP receptor
T76198	FUNCTION	The activity of this receptor is mediated by a G-protein that activates a phosphatidylinositol-calcium second messenger system. In the kidney, the binding of TXA2 to glomerular TP receptors causes intense vasoconstriction. Activates phospholipase C. Isoform 1 activates adenylyl cyclase. Isoform 2 inhibits adenylyl cyclase. Receptor for thromboxane A2 (TXA2), a potent stimulator of platelet aggregation.
T76198	PDBSTRUC	1LBN
T76198	BIOCLASS	GPCR rhodopsin
T76198	SEQUENCE	MWPNGSSLGPCFRPTNITLEERRLIASPWFAASFCVVGLASNLLALSVLAGARQGGSHTRSSFLTFLCGLVLTDFLGLLVTGTIVVSQHAALFEWHAVDPGCRLCRFMGVVMIFFGLSPLLLGAAMASERYLGITRPFSRPAVASQRRAWATVGLVWAAALALGLLPLLGVGRYTVQYPGSWCFLTLGAESGDVAFGLLFSMLGGLSVGLSFLLNTVSVATLCHVYHGQEAAQQRPRDSEVEMMAQLLGIMVVASVCWLPLLVFIAQTVLRNPPAMSPAGQLSRTTEKELLIYLRVATWNQILDPWVYILFRRAVLRRLQPRLSTRPRSLSLQPQLTQRSGLQ
T76198	DRUGINFO	D0E3BH	Ridogrel	Approved
T76198	DRUGINFO	D0I4DQ	Alprostadil	Approved
T76198	DRUGINFO	D0WL5V	LAROPIPRANT	Phase 4
T76198	DRUGINFO	D0GC5H	Ramatroban	Phase 2/3
T76198	DRUGINFO	D00KHD	TAK-128	Phase 2
T76198	DRUGINFO	D0B2WK	Ifetroban sodium	Phase 2
T76198	DRUGINFO	D8N9VF	Ifetroban	Phase 2
T76198	DRUGINFO	D07JKY	KP-496	Phase 2
T76198	DRUGINFO	D0WH9U	FK-070	Phase 2
T76198	DRUGINFO	D0D9LB	BIBV 308	Phase 1
T76198	DRUGINFO	D0YP0C	DT-TX-30	Phase 1
T76198	DRUGINFO	D0K2NA	YM-57158	Phase 1
T76198	DRUGINFO	D0RU7T	G-619	Phase 1
T76198	DRUGINFO	D00HTY	PGF2alpha	Clinical trial
T76198	DRUGINFO	D01HRR	Domitroban	Discontinued in Preregistration
T76198	DRUGINFO	D03QGL	DALTROBAN	Discontinued in Phase 3
T76198	DRUGINFO	D04SPK	Seratrodast	Discontinued in Phase 3
T76198	DRUGINFO	D0Z5VQ	Terutroban sodium	Discontinued in Phase 3
T76198	DRUGINFO	D00VQI	SQ-30741	Discontinued in Phase 2
T76198	DRUGINFO	D01LPX	Linotroban	Discontinued in Phase 2
T76198	DRUGINFO	D06UCV	Z-335	Discontinued in Phase 2
T76198	DRUGINFO	D0B9NA	ICI-192605	Discontinued in Phase 2
T76198	DRUGINFO	D03KST	KT2-962	Discontinued in Phase 1
T76198	DRUGINFO	D0H5KO	KW-3635	Discontinued in Phase 1
T76198	DRUGINFO	D0H5PG	CGS-22652	Discontinued in Phase 1
T76198	DRUGINFO	D03ZVW	Vapiprost	Terminated
T76198	DRUGINFO	D07JSK	Sulotroban	Terminated
T76198	DRUGINFO	D0E3UM	L-657925	Terminated
T76198	DRUGINFO	D0E8JL	ZT-386	Terminated
T76198	DRUGINFO	D0J5QW	ON-579	Terminated
T76198	DRUGINFO	D0U7HD	SQ-33961	Terminated
T76198	DRUGINFO	D0X8QI	UP-116-77	Terminated
T76198	DRUGINFO	D00OXH	U-44069	Investigative
T76198	DRUGINFO	D02IBM	SQ-29548	Investigative
T76198	DRUGINFO	D03BNO	PGH2	Investigative
T76198	DRUGINFO	D05LWE	[125I]BOP	Investigative
T76198	DRUGINFO	D07FLX	AGN 191976	Investigative
T76198	DRUGINFO	D08TWT	AGN192093	Investigative
T76198	DRUGINFO	D09IRF	[125I]PTA-OH	Investigative
T76198	DRUGINFO	D09NFY	[125I]SQ-29548	Investigative
T76198	DRUGINFO	D09TWW	EP 171	Investigative
T76198	DRUGINFO	D09XLT	SQ 26655	Investigative
T76198	DRUGINFO	D09YJR	S 18204	Investigative
T76198	DRUGINFO	D0LC8Z	[125I]SAP	Investigative
T76198	DRUGINFO	D0OE2Z	ONO-8809	Investigative
T76198	DRUGINFO	D0P3HG	ONO-3708	Investigative
T76198	DRUGINFO	D0Q9SC	10,10-difluoro TXA2	Investigative
T76198	DRUGINFO	D0RI3H	I-SAP	Investigative
T76198	DRUGINFO	D0XB3U	BM-573	Investigative
T76198	DRUGINFO	D0Y6LS	carbocyclic thromboxane A2	Investigative
T76198	DRUGINFO	D00GTU	STA2	Investigative
T76198	DRUGINFO	D07WQV	AH23848	Investigative
T76198	DRUGINFO	D05TNX	fluprostenol	Investigative
T76198	DRUGINFO	D0X5MA	I-BOP	Investigative
T76198	DRUGINFO	D0O9ES	cloprostenol	Investigative
T76198	DRUGINFO	D08MNO	butaprost (free acid form)	Investigative
T76198	DRUGINFO	D0BN1U	M&B 28767	Investigative
T76198	DRUGINFO	D0W7RI	carbacyclin	Investigative
T76198	DRUGINFO	D03PLH	U46619	Investigative

T24983	TARGETID	T24983
T24983	FORMERID	TTDC00291
T24983	UNIPROID	DRD4_HUMAN
T24983	TARGNAME	Dopamine D4 receptor (D4R)
T24983	GENENAME	DRD4
T24983	TARGTYPE	Successful
T24983	SYNONYMS	DRD4; D(2C)D(4) dopamine receptor dopamine receptor
T24983	FUNCTION	Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells.
T24983	PDBSTRUC	5WIV; 5WIU
T24983	BIOCLASS	GPCR rhodopsin
T24983	SEQUENCE	MGNRSTADADGLLAGRGPAAGASAGASAGLAGQGAAALVGGVLLIGAVLAGNSLVCVSVATERALQTPTNSFIVSLAAADLLLALLVLPLFVYSEVQGGAWLLSPRLCDALMAMDVMLCTASIFNLCAISVDRFVAVAVPLRYNRQGGSRRQLLLIGATWLLSAAVAAPVLCGLNDVRGRDPAVCRLEDRDYVVYSSVCSFFLPCPLMLLLYWATFRGLQRWEVARRAKLHGRAPRRPSGPGPPSPTPPAPRLPQDPCGPDCAPPAPGLPRGPCGPDCAPAAPSLPQDPCGPDCAPPAPGLPPDPCGSNCAPPDAVRAAALPPQTPPQTRRRRRAKITGRERKAMRVLPVVVGAFLLCWTPFFVVHITQALCPACSVPPRLVSAVTWLGYVNSALNPVIYTVFNAEFRNVFRKALRACC
T24983	DRUGINFO	D0Z1RV	Clozapine	Approved
T24983	DRUGINFO	D0KS6W	Phenyltoloxamine	Approved
T24983	DRUGINFO	D0X6XH	CM-2395	Phase 3
T24983	DRUGINFO	D0N1HW	L-745,870	Phase 2
T24983	DRUGINFO	D05XEA	RP5063	Phase 2
T24983	DRUGINFO	D0L3JI	NGD 94-1	Phase 1
T24983	DRUGINFO	D03TNA	ABT-724	Discontinued in Phase 2
T24983	DRUGINFO	D0T5MB	Lu-35138	Discontinued in Phase 2
T24983	DRUGINFO	D0Q5YH	NGD-94-4	Discontinued in Phase 1
T24983	DRUGINFO	D00MQS	PD-165167	Preclinical
T24983	DRUGINFO	D04PVN	SPI-376	Preclinical
T24983	DRUGINFO	D0WQ5S	U-99363E	Preclinical
T24983	DRUGINFO	D01RAE	Sonepiprazole	Terminated
T24983	DRUGINFO	D0I2OP	Belaperidone	Terminated
T24983	DRUGINFO	D0OW1R	YM-43611	Terminated
T24983	DRUGINFO	D0EH2O	BIMG80	Terminated
T24983	DRUGINFO	D0K9JP	A-80426	Terminated
T24983	DRUGINFO	D00NQV	RBI257	Investigative
T24983	DRUGINFO	D00VSQ	E-1455	Investigative
T24983	DRUGINFO	D03VPS	ABT-670	Investigative
T24983	DRUGINFO	D07VBS	A412997	Investigative
T24983	DRUGINFO	D08QPU	ML398	Investigative
T24983	DRUGINFO	D08ZTK	Ro 10-4548	Investigative
T24983	DRUGINFO	D09WBJ	FAUC213	Investigative
T24983	DRUGINFO	D0A2KN	[125I]L750667	Investigative
T24983	DRUGINFO	D0AX0K	U101958	Investigative
T24983	DRUGINFO	D0B0UZ	A-425444	Investigative
T24983	DRUGINFO	D0F0IA	A-381393	Investigative
T24983	DRUGINFO	D0G0IQ	JL-18	Investigative
T24983	DRUGINFO	D0G2CP	FAUC 113	Investigative
T24983	DRUGINFO	D0K3UL	CP-226269	Investigative
T24983	DRUGINFO	D0Q4DP	L-750,667	Investigative
T24983	DRUGINFO	D0S7XR	TKP-1002	Investigative
T24983	DRUGINFO	D01URS	PF-592379	Investigative
T24983	DRUGINFO	D09FTZ	(4-Phenylethynyl-cyclohex-3-enyl)-dipropyl-amine	Investigative
T24983	DRUGINFO	D00HUV	[2-(1H-Benzoimidazol-4-yloxy)-ethyl]-benzyl-amine	Investigative
T24983	DRUGINFO	D01ENR	4-[2-(2-Benzyl-phenoxy)-ethyl]-morpholine	Investigative
T24983	DRUGINFO	D01KIH	4-(4-Benzyl-piperazin-1-yl)-1H-benzoimidazole	Investigative
T24983	DRUGINFO	D03GES	1-Benzyl-4-(3-oxazol-5-yl-pyrrol-1-yl)-piperidine	Investigative
T24983	DRUGINFO	D03JOS	3-(4-Phenyl-piperazin-1-ylmethyl)-1H-indole	Investigative
T24983	DRUGINFO	D04CPW	N-(4-Propylaminobutyl)-4-biphenylcarboxamide	Investigative
T24983	DRUGINFO	D05BCJ	1-Benzyl-4-pyrrol-1-yl-piperidine	Investigative
T24983	DRUGINFO	D05QJK	Benzyl-[2-(1H-indazol-4-yloxy)-ethyl]-amine	Investigative
T24983	DRUGINFO	D06NTB	3-(4-Methyl-piperidin-1-ylmethyl)-1H-indole	Investigative
T24983	DRUGINFO	D06WLB	Benzyl-[2-(1H-indol-4-yloxy)-ethyl]-amine	Investigative
T24983	DRUGINFO	D0IU8V	4-(2-Benzylamino-ethoxy)-1,3-dihydro-indol-2-one	Investigative
T24983	DRUGINFO	D0M3PV	L-741626	Investigative
T24983	DRUGINFO	D0O1PM	(4-Ethynyl-cyclohex-3-enyl)-dipropyl-amine	Investigative
T24983	DRUGINFO	D0O9BZ	4-(4-Benzyl-piperazin-1-yl)-1H-indole	Investigative
T24983	DRUGINFO	D0Q5IP	3-(4-Phenyl-piperidin-1-ylmethyl)-1H-indole	Investigative
T24983	DRUGINFO	D0S1XN	4-(4-Benzyl-piperazin-1-yl)-7-bromo-1H-indole	Investigative
T24983	DRUGINFO	D0T3IH	[3H]N-methylspiperone	Investigative
T24983	DRUGINFO	D0TU5W	4-(4-Benzyl-piperazin-1-yl)-5-chloro-1H-indole	Investigative
T24983	DRUGINFO	D07RYR	1-[2-(2-Benzyl-phenoxy)-ethyl]-pyrrolidine	Investigative
T24983	DRUGINFO	D07UUQ	1-Benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine	Investigative
T24983	DRUGINFO	D0B9DR	1-Benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine	Investigative
T24983	DRUGINFO	D0H2WQ	QUINPIROLE	Investigative
T24983	DRUGINFO	D0M2BB	1-(4-(1H-pyrazol-1-yl)benzyl)-4-phenylpiperazine	Investigative
T24983	DRUGINFO	D0M2ZE	UH-232	Investigative
T24983	DRUGINFO	D0O4BC	3-(2-Benzylamino-ethoxy)-phenol	Investigative
T24983	DRUGINFO	D0V4NW	N-(4-Dipropylaminobutyl)-4-biphenylcarboxamide	Investigative
T24983	DRUGINFO	D0W1HM	nafadotride	Investigative
T24983	DRUGINFO	D0WD6J	1-Benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine	Investigative
T24983	DRUGINFO	D0WU9R	L-741742	Investigative
T24983	DRUGINFO	D05UUW	1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine	Investigative
T24983	DRUGINFO	D0E1RX	1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine	Investigative
T24983	DRUGINFO	D0L7OM	STEPHOLIDINE	Investigative
T24983	DRUGINFO	D0MC2R	FLUTROLINE	Investigative
T24983	DRUGINFO	D0R8UU	1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine	Investigative
T24983	DRUGINFO	D07GQP	PG-01037	Investigative
T24983	DRUGINFO	D07GXY	piribedil	Investigative
T24983	DRUGINFO	D05EQG	[3H]spiperone	Investigative
T24983	DRUGINFO	D07LRJ	SB-271046	Investigative
T24983	DRUGINFO	D0HV3A	FLUMEZAPINE	Investigative
T24983	DRUGINFO	D0Q2GP	ISOLOXAPINE	Investigative
T24983	DRUGINFO	D0P0IX	ISOCLOZAPINE	Investigative
T24983	DRUGINFO	D0L5MW	(+/-)-nantenine	Investigative

T15569	TARGETID	T15569
T15569	FORMERID	TTDS00482
T15569	UNIPROID	MUTA_HUMAN
T15569	TARGNAME	Methylmalonyl-CoA mutase (MMUT)
T15569	GENENAME	MUT
T15569	TARGTYPE	Successful
T15569	SYNONYMS	Methylmalonyl-CoA isomerase; MUT; MCM
T15569	FUNCTION	Involved in the degradation of several amino acids, odd- chain fatty acids and cholesterol via propionyl-CoA to the tricarboxylic acid cycle. MCM has different functions in other species.
T15569	PDBSTRUC	3BIC; 2XIQ; 2XIJ
T15569	BIOCLASS	Intramolecular transferases
T15569	ECNUMBER	EC 5.4.99.2
T15569	SEQUENCE	MLRAKNQLFLLSPHYLRQVKESSGSRLIQQRLLHQQQPLHPEWAALAKKQLKGKNPEDLIWHTPEGISIKPLYSKRDTMDLPEELPGVKPFTRGPYPTMYTFRPWTIRQYAGFSTVEESNKFYKDNIKAGQQGLSVAFDLATHRGYDSDNPRVRGDVGMAGVAIDTVEDTKILFDGIPLEKMSVSMTMNGAVIPVLANFIVTGEEQGVPKEKLTGTIQNDILKEFMVRNTYIFPPEPSMKIIADIFEYTAKHMPKFNSISISGYHMQEAGADAILELAYTLADGLEYSRTGLQAGLTIDEFAPRLSFFWGIGMNFYMEIAKMRAGRRLWAHLIEKMFQPKNSKSLLLRAHCQTSGWSLTEQDPYNNIVRTAIEAMAAVFGGTQSLHTNSFDEALGLPTVKSARIARNTQIIIQEESGIPKVADPWGGSYMMECLTNDVYDAALKLINEIEEMGGMAKAVAEGIPKLRIEECAARRQARIDSGSEVIVGVNKYQLEKEDAVEVLAIDNTSVRNRQIEKLKKIKSSRDQALAERCLAALTECAASGDGNILALAVDASRARCTVGEITDALKKVFGEHKANDRMVSGAYRQEFGESKEITSAIKRVHKFMEREGRRPRLLVAKMGQDGHDRGAKVIATGFADLGFDVDIGPLFQTPREVAQQAVDADVHAVGISTLAAGHKTLVPELIKELNSLGRPDILVMCGGVIPPQDYEFLFEVGVSNVFGPGTRIPKAAVQVLDDIEKCLEKKQQSV
T15569	DRUGINFO	D0VF4H	Hydroxocobalamin	Approved
T15569	DRUGINFO	DJN3E2	mRNA-3704	Phase 1/2

T62460	TARGETID	T62460
T62460	FORMERID	TTDNS00611
T62460	UNIPROID	JAK1_HUMAN
T62460	TARGNAME	Janus kinase 1 (JAK-1)
T62460	GENENAME	JAK1
T62460	TARGTYPE	Successful
T62460	SYNONYMS	Tyrosine-protein kinase JAK1; JAK1B; JAK1A
T62460	FUNCTION	Kinase partner for the interleukin (IL)-2 receptor as well as interleukin (IL)-10 receptor. Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway.
T62460	PDBSTRUC	6N7D; 6N7C; 6N7B; 6N7A; 6N79
T62460	BIOCLASS	Kinase
T62460	ECNUMBER	EC 2.7.10.2
T62460	SEQUENCE	MQYLNIKEDCNAMAFCAKMRSSKKTEVNLEAPEPGVEVIFYLSDREPLRLGSGEYTAEELCIRAAQACRISPLCHNLFALYDENTKLWYAPNRTITVDDKMSLRLHYRMRFYFTNWHGTNDNEQSVWRHSPKKQKNGYEKKKIPDATPLLDASSLEYLFAQGQYDLVKCLAPIRDPKTEQDGHDIENECLGMAVLAISHYAMMKKMQLPELPKDISYKRYIPETLNKSIRQRNLLTRMRINNVFKDFLKEFNNKTICDSSVSTHDLKVKYLATLETLTKHYGAEIFETSMLLISSENEMNWFHSNDGGNVLYYEVMVTGNLGIQWRHKPNVVSVEKEKNKLKRKKLENKHKKDEEKNKIREEWNNFSYFPEITHIVIKESVVSINKQDNKKMELKLSSHEEALSFVSLVDGYFRLTADAHHYLCTDVAPPLIVHNIQNGCHGPICTEYAINKLRQEGSEEGMYVLRWSCTDFDNILMTVTCFEKSEQVQGAQKQFKNFQIEVQKGRYSLHGSDRSFPSLGDLMSHLKKQILRTDNISFMLKRCCQPKPREISNLLVATKKAQEWQPVYPMSQLSFDRILKKDLVQGEHLGRGTRTHIYSGTLMDYKDDEGTSEEKKIKVILKVLDPSHRDISLAFFEAASMMRQVSHKHIVYLYGVCVRDVENIMVEEFVEGGPLDLFMHRKSDVLTTPWKFKVAKQLASALSYLEDKDLVHGNVCTKNLLLAREGIDSECGPFIKLSDPGIPITVLSRQECIERIPWIAPECVEDSKNLSVAADKWSFGTTLWEICYNGEIPLKDKTLIEKERFYESRCRPVTPSCKELADLMTRCMNYDPNQRPFFRAIMRDINKLEEQNPDIVSEKKPATEVDPTHFEKRFLKRIRDLGEGHFGKVELCRYDPEGDNTGEQVAVKSLKPESGGNHIADLKKEIEILRNLYHENIVKYKGICTEDGGNGIKLIMEFLPSGSLKEYLPKNKNKINLKQQLKYAVQICKGMDYLGSRQYVHRDLAARNVLVESEHQVKIGDFGLTKAIETDKEYYTVKDDRDSPVFWYAPECLMQSKFYIASDVWSFGVTLHELLTYCDSDSSPMALFLKMIGPTHGQMTVTRLVNTLKEGKRLPCPPNCPDEVYQLMRKCWEFQPSNRTSFQNLIEGFEALLK
T62460	DRUGINFO	D07JAG	Upadacitinib	Approved
T62460	DRUGINFO	D0D5ZJ	Momelotinib	Approved
T62460	DRUGINFO	D04LKS	Ruxolitinib	Approved
T62460	DRUGINFO	D05PCM	Abrocitinib	Approved
T62460	DRUGINFO	D0Y7IC	Baricitinib	Approved
T62460	DRUGINFO	DFK8Z5	SHR0302	Phase 3
T62460	DRUGINFO	D06EIC	ASP-015K	Phase 3
T62460	DRUGINFO	D06HZA	GSK2586184	Phase 2
T62460	DRUGINFO	D0HJ1R	INCB54707	Phase 2
T62460	DRUGINFO	D0SG7B	GLPG-0634	Phase 2
T62460	DRUGINFO	DD6A7P	EQ121	Phase 2
T62460	DRUGINFO	D01UAU	CTP-543	Phase 2
T62460	DRUGINFO	D09AFI	INCB039110	Phase 2
T62460	DRUGINFO	D0V4DX	PF-06700841	Phase 2
T62460	DRUGINFO	D6INZ9	ATI-501	Phase 2
T62460	DRUGINFO	D6N5UC	ATI-502	Phase 2
T62460	DRUGINFO	DH0A6O	A223	Phase 2
T62460	DRUGINFO	DU10JI	CTP-543	Phase 2
T62460	DRUGINFO	D2KTG5	TD-8236	Phase 2
T62460	DRUGINFO	D0BI3N	Cerdulatinib	Phase 2
T62460	DRUGINFO	D2JZ3U	ALXN2075	Phase 1/2
T62460	DRUGINFO	D63WFO	AZD0449	Phase 1
T62460	DRUGINFO	DI19BZ	KN-002	Phase 1
T62460	DRUGINFO	DX72LV	AZD4604	Phase 1
T62460	DRUGINFO	DXVA93	PF-07295324	Phase 1
T62460	DRUGINFO	DZ2RH6	GDC-0214	Phase 1
T62460	DRUGINFO	D00GJY	Cyclohexyl azetidine derivative 1	Patented
T62460	DRUGINFO	D0H3KF	Bipyrazole derivative 1	Patented
T62460	DRUGINFO	D0OS1N	Tricyclic compound 3	Patented
T62460	DRUGINFO	D00JUI	Triazolo-pyridine derivative 1	Patented
T62460	DRUGINFO	D00PTE	Imidazopyridazine derivative 2	Patented
T62460	DRUGINFO	D03PBI	Pyrrolo-pyridone derivative 2	Patented
T62460	DRUGINFO	D04OCD	PMID27774822-Compound-Figure7Example63	Patented
T62460	DRUGINFO	D05GEL	Cyclic cyanoethypypazole derivative 1	Patented
T62460	DRUGINFO	D06MQB	Pyrrolo-pyridone derivative 1	Patented
T62460	DRUGINFO	D07BND	Imidazopyridazine derivative 1	Patented
T62460	DRUGINFO	D0F3BK	PMID27774824-Compound-Figure6Example6	Patented
T62460	DRUGINFO	D0H6XN	Geminally-substituted cyanoethylpypazolo pyridone derivative 1	Patented
T62460	DRUGINFO	D0K2RW	Cyanomethyl pypazole carboxamide derivative 1	Patented
T62460	DRUGINFO	D0KI5F	Geminally-substituted cyanoethylpypazolo pyridone derivative 2	Patented
T62460	DRUGINFO	D0PB5X	Cycloalkyl nitrile pyrazolo pyridone derivative 1	Patented
T62460	DRUGINFO	D0PM8K	PMID27774824-Compound-Figure7Example10	Patented
T62460	DRUGINFO	D0S4TH	Cycloalkyl nitrile pyrazolo pyridone derivative 2	Patented
T62460	DRUGINFO	D0T6CY	Pyrrolo-pyridone derivative 3	Patented
T62460	DRUGINFO	D0V0KI	Cycloalkyl nitrile pyrazole carboxamide derivative 1	Patented
T62460	DRUGINFO	D0VQ7P	Pyrrolo[2,3-d]pyrimidine derivative 11	Patented
T62460	DRUGINFO	D01EYJ	Ruxolitinib derivative 2	Patented
T62460	DRUGINFO	D08WPB	Five-and-six-membered heterocyclic compound 1	Patented
T62460	DRUGINFO	D09RUN	Pyrazolopyridine derivative 4	Patented
T62460	DRUGINFO	D09UBE	Pyrrole six-membered heteroaryl ring derivative 1	Patented
T62460	DRUGINFO	D0A6RG	PMID27774824-Compound-Figure2Example4	Patented
T62460	DRUGINFO	D0G0FK	Tricyclic compound 1	Patented
T62460	DRUGINFO	D0G9MM	Isoxazole derivative 1	Patented
T62460	DRUGINFO	D0M3CB	PMID27774822-Compound-Figure1Example20	Patented
T62460	DRUGINFO	D0TX2G	Isoxazole derivative 2	Patented
T62460	DRUGINFO	D0VR6E	Pyrrolo-pyridine derivative 3	Patented
T62460	DRUGINFO	D0XH7H	N-methylmethanesulfonamide derivative 1	Patented
T62460	DRUGINFO	D0Y2IM	N-(cyanomethyl)-4-(2-(phenylamino)pyrimidin-4-yl)benzamide derivative 1	Patented
T62460	DRUGINFO	D0YJ4D	Pyrrole derivative 7	Patented
T62460	DRUGINFO	D01CRX	Benzimidazole derivative 7	Patented
T62460	DRUGINFO	D01FVC	Bis-aminopyrimidine derivative 1	Patented
T62460	DRUGINFO	D03QAY	Pyrazolopyridine derivative 3	Patented
T62460	DRUGINFO	D04BOW	Tricyclic pyrrolopyridine compound 1	Patented
T62460	DRUGINFO	D05AXE	Aminooxazole carboxamide derivative 1	Patented
T62460	DRUGINFO	D0FQ4Z	Pyrrolo[2,3-d]pyrimidine derivative 6	Patented
T62460	DRUGINFO	D0GB7G	PMID27774824-Compound-Figure6Example12	Patented
T62460	DRUGINFO	D0KL3B	Pyrrolo[2,3-d]pyrimidine derivative 8	Patented
T62460	DRUGINFO	D0LR6J	Bis-aminopyrimidine derivative 2	Patented
T62460	DRUGINFO	D0LS1O	Tricyclic compound 11	Patented
T62460	DRUGINFO	D0M2WA	Tricyclic heterocycle derivative 5	Patented
T62460	DRUGINFO	D0RJ3W	PMID27774822-Compound-Figure11Example5	Patented
T62460	DRUGINFO	D0S6XT	Bis-aminopyrimidine derivative 3	Patented
T62460	DRUGINFO	D0SJ1Q	Bis-aminopyrimidine derivative 4	Patented
T62460	DRUGINFO	D0U1HA	PMID27774824-Compound-Figure3Example18	Patented
T62460	DRUGINFO	D0U5FZ	Pyrrolo[2,3-d]pyrimidine derivative 7	Patented
T62460	DRUGINFO	D0WA1V	Pyrimidopyridazinone derivative 2	Patented
T62460	DRUGINFO	D0X1FD	Tricyclic heterocycle derivative 1	Patented
T62460	DRUGINFO	D07PTU	Imidazo[4,5-c]pyridine derivative 1	Patented
T62460	DRUGINFO	D0WZ8N	PMID27774824-Compound-Figure9Example2up	Patented
T62460	DRUGINFO	D01DBB	PMID27774824-Compound-Figure9Example2down	Patented
T62460	DRUGINFO	D09ALF	Aminotriazolopyridine derivative 1	Patented
T62460	DRUGINFO	D0VJ1R	Imidazo[4,5-c]pyridine derivative 2	Patented
T62460	DRUGINFO	D0YR8S	PMID27774824-Compound-Figure11Example1up	Patented
T62460	DRUGINFO	D09PIS	Pyrazolo[4,3-c]pyridine derivative 2	Patented
T62460	DRUGINFO	D0HB4E	INCB47986	Discontinued in Phase 2
T62460	DRUGINFO	D0YX5U	ZM-39923	Investigative
T62460	DRUGINFO	D0US9O	PMID24359159C19a	Investigative
T62460	DRUGINFO	D0E5IP	WHI-P154	Investigative

T03346	TARGETID	T03346
T03346	FORMERID	TTDC00081
T03346	UNIPROID	IL4RA_HUMAN
T03346	TARGNAME	Interleukin 4 receptor alpha (IL4R)
T03346	GENENAME	IL4R
T03346	TARGTYPE	Successful
T03346	SYNONYMS	Interleukin-4 receptor subunit alpha; IL4RA; IL-4RA; IL-4R-alpha; IL-4R subunit alpha; IL-4 receptor subunit alpha; CD124 antigen; CD124; 582J2.1
T03346	FUNCTION	Couples to the JAK1/2/3-STAT6 pathway. The IL4 response is involved in promoting Th2 differentiation. The IL4/IL13 responses are involved in regulating IgE production and, chemokine and mucus production at sites of allergic inflammation. In certain cell types, can signal through activation of insulin receptor substrates, IRS1/IRS2. Receptor for both interleukin 4 and interleukin 13.
T03346	PDBSTRUC	5E4E; 3BPO; 3BPN; 3BPL; 1ITE
T03346	BIOCLASS	Cytokine receptor
T03346	SEQUENCE	MGWLCSGLLFPVSCLVLLQVASSGNMKVLQEPTCVSDYMSISTCEWKMNGPTNCSTELRLLYQLVFLLSEAHTCIPENNGGAGCVCHLLMDDVVSADNYTLDLWAGQQLLWKGSFKPSEHVKPRAPGNLTVHTNVSDTLLLTWSNPYPPDNYLYNHLTYAVNIWSENDPADFRIYNVTYLEPSLRIAASTLKSGISYRARVRAWAQCYNTTWSEWSPSTKWHNSYREPFEQHLLLGVSVSCIVILAVCLLCYVSITKIKKEWWDQIPNPARSRLVAIIIQDAQGSQWEKRSRGQEPAKCPHWKNCLTKLLPCFLEHNMKRDEDPHKAAKEMPFQGSGKSAWCPVEISKTVLWPESISVVRCVELFEAPVECEEEEEVEEEKGSFCASPESSRDDFQEGREGIVARLTESLFLDLLGEENGGFCQQDMGESCLLPPSGSTSAHMPWDEFPSAGPKEAPPWGKEQPLHLEPSPPASPTQSPDNLTCTETPLVIAGNPAYRSFSNSLSQSPCPRELGPDPLLARHLEEVEPEMPCVPQLSEPTTVPQPEPETWEQILRRNVLQHGAAAAPVSAPTSGYQEFVHAVEQGGTQASAVVGLGPPGEAGYKAFSSLLASSAVSPEKCGFGASSGEEGYKPFQDLIPGCPGDPAPVPVPLFTFGLDREPPRSPQSSHLPSSSPEHLGLEPGEKVEDMPKPPLPQEQATDPLVDSLGSGIVYSALTCHLCGHLKQCHGQEDGGQTPVMASPCCGCCCGDRSSPPTTPLRAPDPSPGGVPLEASLCPASLAPSGISEKSKSSSSFHPAPGNAQSSSQTPKIVNFVSVGPTYMRVS
T03346	DRUGINFO	D07FUP	Dupilumab	Approved
T03346	DRUGINFO	D0O9UN	SAR231893	Phase 3
T03346	DRUGINFO	DF7Y9S	CBP-201	Phase 3
T03346	DRUGINFO	D0BW3P	Aerovant	Phase 2a
T03346	DRUGINFO	D0C5VQ	PRX-321	Phase 2
T03346	DRUGINFO	D0O5KH	Altrakincept	Phase 2
T03346	DRUGINFO	DZGI51	AZD1402	Phase 2
T03346	DRUGINFO	D0O4SH	SAR-156597	Phase 2
T03346	DRUGINFO	D09MKQ	AMG 317	Discontinued in Phase 1
T03346	DRUGINFO	D01BEX	PRS-060	Investigative
T03346	DRUGINFO	D0Y1BF	APG-201	Investigative

T00884	TARGETID	T00884
T00884	FORMERID	TTDC00190
T00884	UNIPROID	CXCR1_HUMAN
T00884	TARGNAME	C-X-C chemokine receptor type 1 (CXCR1)
T00884	GENENAME	CXCR1
T00884	TARGTYPE	Successful
T00884	SYNONYMS	Interleukin-8 receptor A; IL8RA; IL-8R A; IL-8 receptor type 1; High affinity interleukin-8 receptor A; CXCR-1; CXC-R1; CMKAR1; CDw128a; CD181
T00884	FUNCTION	Binding of IL-8 to the receptor causes activation of neutrophils. This response is mediated via a G-protein that activate a phosphatidylinositol-calcium second messenger system. This receptor binds to IL-8 with a high affinity and to MGSA (GRO) with a low affinity. Receptor to interleukin-8, which is a powerful neutrophils chemotactic factor.
T00884	PDBSTRUC	2LNL; 1ILQ; 1ILP
T00884	BIOCLASS	GPCR rhodopsin
T00884	SEQUENCE	MSNITDPQMWDFDDLNFTGMPPADEDYSPCMLETETLNKYVVIIAYALVFLLSLLGNSLVMLVILYSRVGRSVTDVYLLNLALADLLFALTLPIWAASKVNGWIFGTFLCKVVSLLKEVNFYSGILLLACISVDRYLAIVHATRTLTQKRHLVKFVCLGCWGLSMNLSLPFFLFRQAYHPNNSSPVCYEVLGNDTAKWRMVLRILPHTFGFIVPLFVMLFCYGFTLRTLFKAHMGQKHRAMRVIFAVVLIFLLCWLPYNLVLLADTLMRTQVIQESCERRNNIGRALDATEILGFLHSCLNPIIYAFIGQNFRHGFLKILAMHGLVSKEFLARHRVTSYTSSSVNVSSNL
T00884	DRUGINFO	D0R1QE	Ibuprofen	Approved
T00884	DRUGINFO	D0LJ1B	Reparixin	Phase 3
T00884	DRUGINFO	D00QKI	SCH-527123	Phase 2
T00884	DRUGINFO	DAY4L1	SX-682	Phase 1
T00884	DRUGINFO	D0Q5PL	INDOPROFEN	Withdrawn from market
T00884	DRUGINFO	D0ZL4F	R-ketoprofen	Discontinued in Phase 2
T00884	DRUGINFO	D0Q8TD	1-(2-Bromo-phenyl)-3-(2,4-dihydroxy-phenyl)-urea	Investigative
T00884	DRUGINFO	D00IPO	2-(3-Isopropyl-phenyl)-propionic acid	Investigative
T00884	DRUGINFO	D00PWV	2-[3-(1-Phenyl-ethyl)-phenyl]-propionic acid	Investigative
T00884	DRUGINFO	D05OUY	(R)-2-(4-Isobutyl-phenyl)-propionamide	Investigative
T00884	DRUGINFO	D06BBI	(R)-N-Hydroxy-2-(4-isobutyl-phenyl)-propionamide	Investigative
T00884	DRUGINFO	D08BRR	2-[3-(2-Methyl-butyl)-phenyl]-propionic acid	Investigative
T00884	DRUGINFO	D09FHA	(R)-2-(4-Isobutyl-phenyl)-N-methoxy-propionamide	Investigative
T00884	DRUGINFO	D09LFY	Il-8((3-73))K11R	Investigative
T00884	DRUGINFO	D0F8YO	2-[3-(1-Hydroxy-propyl)-phenyl]-propionic acid	Investigative
T00884	DRUGINFO	D0O5YE	2-(3-Isobutyl-phenyl)-propionic acid	Investigative
T00884	DRUGINFO	D0U2UJ	1-(2-hydroxy-4-nitrophenyl)-3-phenylurea	Investigative
T00884	DRUGINFO	D0W1WQ	(R)-3-(4-Isobutyl-phenyl)-butan-2-one	Investigative

T56923	TARGETID	T56923
T56923	FORMERID	TTDC00087
T56923	UNIPROID	CXCR2_HUMAN
T56923	TARGNAME	C-X-C chemokine receptor type 2 (CXCR2)
T56923	GENENAME	CXCR2
T56923	TARGTYPE	Successful
T56923	SYNONYMS	Interleukin-8 receptor B; IL8RB; IL-8R B; IL-8 receptor type 2; High affinity interleukin-8 receptor B; GRO/MGSA receptor; CXCR-2; CXC-R2; CDw128b; CD182
T56923	FUNCTION	Binding of IL-8 to the receptor causes activation of neutrophils. This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system. Binds to IL-8 with high affinity. Also binds with high affinity to CXCL3, GRO/MGSA and NAP-2. Receptor for interleukin-8 which is a powerful neutrophil chemotactic factor.
T56923	PDBSTRUC	5TYT; 4Q3H
T56923	BIOCLASS	GPCR rhodopsin
T56923	SEQUENCE	MEDFNMESDSFEDFWKGEDLSNYSYSSTLPPFLLDAAPCEPESLEINKYFVVIIYALVFLLSLLGNSLVMLVILYSRVGRSVTDVYLLNLALADLLFALTLPIWAASKVNGWIFGTFLCKVVSLLKEVNFYSGILLLACISVDRYLAIVHATRTLTQKRYLVKFICLSIWGLSLLLALPVLLFRRTVYSSNVSPACYEDMGNNTANWRMLLRILPQSFGFIVPLLIMLFCYGFTLRTLFKAHMGQKHRAMRVIFAVVLIFLLCWLPYNLVLLADTLMRTQVIQETCERRNHIDRALDATEILGILHSCLNPLIYAFIGQKFRHGLLKILAIHGLISKDSLPKDSRPSFVGSSSGHTSTTL
T56923	DRUGINFO	D09GOS	Clotrimazole	Approved
T56923	DRUGINFO	D0R1QE	Ibuprofen	Approved
T56923	DRUGINFO	D0LJ1B	Reparixin	Phase 3
T56923	DRUGINFO	D02JXG	SB-265610	Phase 2
T56923	DRUGINFO	D0E6SX	AZD-5069	Phase 2
T56923	DRUGINFO	D0H8GW	PS-938285	Phase 2
T56923	DRUGINFO	D0R7XD	GSK1325756	Phase 2
T56923	DRUGINFO	D0SN7I	SB-656933	Phase 2
T56923	DRUGINFO	DW8Z1M	RIST4721	Phase 2
T56923	DRUGINFO	D00QKI	SCH-527123	Phase 2
T56923	DRUGINFO	D0N3QF	AZD-5122	Phase 1
T56923	DRUGINFO	D0Q0RK	AZD4721	Phase 1
T56923	DRUGINFO	DAY4L1	SX-682	Phase 1
T56923	DRUGINFO	D0Q5PL	INDOPROFEN	Withdrawn from market
T56923	DRUGINFO	D0ZL4F	R-ketoprofen	Discontinued in Phase 2
T56923	DRUGINFO	D03PDY	SB-332235	Discontinued in Phase 1
T56923	DRUGINFO	D0F6WV	PD-157695	Preclinical
T56923	DRUGINFO	D05AZU	1-(4-cyano-2-hydroxyphenyl)-3-phenylurea	Investigative
T56923	DRUGINFO	D05CCF	1-(5-chloro-2-hydroxy-4-nitrophenyl)-3-phenylurea	Investigative
T56923	DRUGINFO	D05SNR	5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-ol	Investigative
T56923	DRUGINFO	D06WVV	1-(2-Hydroxy-3-nitro-phenyl)-3-phenyl-urea	Investigative
T56923	DRUGINFO	D09MAZ	SX-517	Investigative
T56923	DRUGINFO	D0D8LQ	1-(2-bromophenyl)-3-(4-cyano-2-hydroxyphenyl)urea	Investigative
T56923	DRUGINFO	D0J1XP	1-(2-Hydroxy-5-nitro-phenyl)-3-phenyl-urea	Investigative
T56923	DRUGINFO	D0Q6VK	SB 272844	Investigative
T56923	DRUGINFO	D0T4KC	1-(3-cyano-2-hydroxyphenyl)-3-phenylurea	Investigative
T56923	DRUGINFO	D00IPO	2-(3-Isopropyl-phenyl)-propionic acid	Investigative
T56923	DRUGINFO	D00PWV	2-[3-(1-Phenyl-ethyl)-phenyl]-propionic acid	Investigative
T56923	DRUGINFO	D05OUY	(R)-2-(4-Isobutyl-phenyl)-propionamide	Investigative
T56923	DRUGINFO	D06BBI	(R)-N-Hydroxy-2-(4-isobutyl-phenyl)-propionamide	Investigative
T56923	DRUGINFO	D07PHS	CXCL8	Investigative
T56923	DRUGINFO	D08BRR	2-[3-(2-Methyl-butyl)-phenyl]-propionic acid	Investigative
T56923	DRUGINFO	D09FHA	(R)-2-(4-Isobutyl-phenyl)-N-methoxy-propionamide	Investigative
T56923	DRUGINFO	D09LFY	Il-8((3-73))K11R	Investigative
T56923	DRUGINFO	D0F8YO	2-[3-(1-Hydroxy-propyl)-phenyl]-propionic acid	Investigative
T56923	DRUGINFO	D0O5YE	2-(3-Isobutyl-phenyl)-propionic acid	Investigative
T56923	DRUGINFO	D0U2UJ	1-(2-hydroxy-4-nitrophenyl)-3-phenylurea	Investigative
T56923	DRUGINFO	D0W1WQ	(R)-3-(4-Isobutyl-phenyl)-butan-2-one	Investigative

T47094	TARGETID	T47094
T47094	FORMERID	TTDS00194
T47094	UNIPROID	NK1R_HUMAN
T47094	TARGNAME	Substance-P receptor (TACR1)
T47094	GENENAME	TACR1
T47094	TARGTYPE	Successful
T47094	SYNONYMS	Tachykinin receptor 1; Tachykinin neurokinin 1 receptor; Tachykinin 1 receptor; TACR1; Substance P receptor; SPR; Neurokinin 1 receptor; NK-1R; NK-1 receptor
T47094	FUNCTION	This is a receptor for the tachykinin neuropeptide substance P. It is probably associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of affinity of this receptor to tachykinins is: substance P > substance K > neuromedin-K.
T47094	PDBSTRUC	6HLP; 6HLO; 6HLL; 6.00E+59; 2KSB
T47094	BIOCLASS	GPCR rhodopsin
T47094	SEQUENCE	MDNVLPVDSDLSPNISTNTSEPNQFVQPAWQIVLWAAAYTVIVVTSVVGNVVVMWIILAHKRMRTVTNYFLVNLAFAEASMAAFNTVVNFTYAVHNEWYYGLFYCKFHNFFPIAAVFASIYSMTAVAFDRYMAIIHPLQPRLSATATKVVICVIWVLALLLAFPQGYYSTTETMPSRVVCMIEWPEHPNKIYEKVYHICVTVLIYFLPLLVIGYAYTVVGITLWASEIPGDSSDRYHEQVSAKRKVVKMMIVVVCTFAICWLPFHIFFLLPYINPDLYLKKFIQQVYLAIMWLAMSSTMYNPIIYCCLNDRFRLGFKHAFRCCPFISAGDYEGLEMKSTRYLQTQGSVYKVSRLETTISTVVGAHEEEPEDGPKATPSSLDLTSNCSSRSDSKTMTESFSFSSNVLS
T47094	DRUGINFO	D0CF0Y	Rolapitant	Approved
T47094	DRUGINFO	D0GU4K	Aprepitant	Approved
T47094	DRUGINFO	D0K5IP	Palonosetron + fosnetupitant	Approved
T47094	DRUGINFO	D0S2UG	Selegiline	Approved
T47094	DRUGINFO	D0CB2B	Serlopitant	Phase 3
T47094	DRUGINFO	D0G3YC	Netupitant	Phase 3
T47094	DRUGINFO	D0N8UY	LY-686017	Phase 3
T47094	DRUGINFO	DKZ07O	Elinzanetant	Phase 3
T47094	DRUGINFO	D02DLP	VOFOPITANT HYDROCHLORIDE	Phase 2
T47094	DRUGINFO	D05SLM	LY-2590443	Phase 2
T47094	DRUGINFO	D06HCC	LANEPITANT	Phase 2
T47094	DRUGINFO	D0DM6I	DAPITANT	Phase 2
T47094	DRUGINFO	D0E6ZN	TKA-731	Phase 2
T47094	DRUGINFO	D0F1WX	SSR240600	Phase 2
T47094	DRUGINFO	D0J4PB	GW 597599	Phase 2
T47094	DRUGINFO	D0P1YE	Orvepitant	Phase 2
T47094	DRUGINFO	D0P3JF	SCH-900978	Phase 2
T47094	DRUGINFO	D0T0PN	CP-122721	Phase 2
T47094	DRUGINFO	D0V7US	NKP 608	Phase 2
T47094	DRUGINFO	D09XLS	FR139317	Phase 2
T47094	DRUGINFO	D07XDQ	Figopitant	Phase 1
T47094	DRUGINFO	D0E5GI	CJ-12255	Phase 1
T47094	DRUGINFO	D0P2KG	GSK1144814	Phase 1
T47094	DRUGINFO	D00ZGA	Casopitant	Withdrawn from market
T47094	DRUGINFO	D00XPA	L-759274	Discontinued in Phase 3
T47094	DRUGINFO	D05KFA	BL-1832	Discontinued in Phase 3
T47094	DRUGINFO	D01TBN	Ezlopitant	Discontinued in Phase 2
T47094	DRUGINFO	D05UKK	FK-888	Discontinued in Phase 2
T47094	DRUGINFO	D09RNP	GSK 679769	Discontinued in Phase 2
T47094	DRUGINFO	D0J5CX	TAK-637	Discontinued in Phase 2
T47094	DRUGINFO	D0N1PA	CGP-49823	Discontinued in Phase 2
T47094	DRUGINFO	D0ST5P	TA-5538	Discontinued in Phase 2
T47094	DRUGINFO	D0UT3F	Nolpitantium besilate	Discontinued in Phase 2
T47094	DRUGINFO	D02FIJ	FK-224	Discontinued in Phase 2
T47094	DRUGINFO	D0C9FF	DNK-333	Discontinued in Phase 2
T47094	DRUGINFO	D03ZKE	CS-003	Discontinued in Phase 2
T47094	DRUGINFO	D0Y4GJ	AVE-5883	Discontinued in Phase 1/2
T47094	DRUGINFO	D00VPU	SLV-323	Discontinued in Phase 1
T47094	DRUGINFO	D04RUP	SDZ-NKT-343	Discontinued in Phase 1
T47094	DRUGINFO	D00CQB	CI-1021	Terminated
T47094	DRUGINFO	D02TKI	L-733060	Terminated
T47094	DRUGINFO	D03SXN	CP-96345	Terminated
T47094	DRUGINFO	D04VDY	L-741671	Terminated
T47094	DRUGINFO	D05REL	GR-82334	Terminated
T47094	DRUGINFO	D07PLK	WIN-64821	Terminated
T47094	DRUGINFO	D08KXE	RP-67580	Terminated
T47094	DRUGINFO	D0KD4U	FK-355	Terminated
T47094	DRUGINFO	D0L0UF	MEN-11467	Terminated
T47094	DRUGINFO	D0T4IQ	MEN-11149	Terminated
T47094	DRUGINFO	D0T6MU	FR-113680	Terminated
T47094	DRUGINFO	D08ZBV	L-732138	Terminated
T47094	DRUGINFO	D00EEU	Arg-Pro-Lys-Pro-Ala-Ser-Phe-Phe-Gly-Leu-Met-NH2	Investigative
T47094	DRUGINFO	D00HUY	L-708568	Investigative
T47094	DRUGINFO	D00IQV	Homspera	Investigative
T47094	DRUGINFO	D00XCC	(D)-Phe-(D)-Phe-NH2	Investigative
T47094	DRUGINFO	D01MND	EU-C-001	Investigative
T47094	DRUGINFO	D01PAC	[125I]L703,606	Investigative
T47094	DRUGINFO	D01VKI	physalaemin	Investigative
T47094	DRUGINFO	D02BOG	H-Tyr(OMe)-Phe(2-Me)-NH2	Investigative
T47094	DRUGINFO	D02SNO	2-Phenyl-3-(1-phenyl-ethoxy)-piperidine	Investigative
T47094	DRUGINFO	D03DLD	H-Tyr-Ala-Phe-Phe-NH2	Investigative
T47094	DRUGINFO	D03FQU	H-Tyr-Pro-Phe-Ala-NH2	Investigative
T47094	DRUGINFO	D03UVR	[18F]SPA-RQ	Investigative
T47094	DRUGINFO	D04LHG	SP-SAP	Investigative
T47094	DRUGINFO	D05BTG	3,6-Diphenyl-1-oxa-7-aza-spiro[4.5]decane	Investigative
T47094	DRUGINFO	D05ETM	CP-99,994	Investigative
T47094	DRUGINFO	D05GAT	H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-OH	Investigative
T47094	DRUGINFO	D05MTD	Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2	Investigative
T47094	DRUGINFO	D05RGO	H-Pro-Phe-Phe-NH2	Investigative
T47094	DRUGINFO	D06IZZ	Arg-Pro-Lys-Pro-Ala-Gln-Phe-Phe-Gly-Leu-Met-NH2	Investigative
T47094	DRUGINFO	D07ARO	WIN-66306	Investigative
T47094	DRUGINFO	D07FUN	spantide II	Investigative
T47094	DRUGINFO	D07KDH	[Sar9,Met(O2)11]-SP	Investigative
T47094	DRUGINFO	D07YFY	Ac-Phe-Phe-NH2	Investigative
T47094	DRUGINFO	D08CHK	WIN-64745	Investigative
T47094	DRUGINFO	D09JDH	Septide	Investigative
T47094	DRUGINFO	D0A7SR	H-Leu-Phe-NH2	Investigative
T47094	DRUGINFO	D0BV8M	(D)-Phe-(L)-Phe-NH2	Investigative
T47094	DRUGINFO	D0DB8W	H-Tyr-Pro-Phe-Phe-OH	Investigative
T47094	DRUGINFO	D0I8HY	Arg-Pro-Lys-Pro-Gln-Ser-Phe-Phe-Gly-Leu-Met-NH2	Investigative
T47094	DRUGINFO	D0J6SX	(L)-Phe-(D)-Phe-NH2	Investigative
T47094	DRUGINFO	D0J8SU	Substance P	Investigative
T47094	DRUGINFO	D0K9GG	L-703,606	Investigative
T47094	DRUGINFO	D0L1ME	H-Phe-NH2	Investigative
T47094	DRUGINFO	D0L3SA	T2328	Investigative
T47094	DRUGINFO	D0LA6S	R116031	Investigative
T47094	DRUGINFO	D0M0ZB	H-Ala-Pro-Phe-Phe-NH2	Investigative
T47094	DRUGINFO	D0N0GT	3-Benzyloxy-2-phenyl-piperidine	Investigative
T47094	DRUGINFO	D0N3RM	befetupitant	Investigative
T47094	DRUGINFO	D0P1XM	L-736281	Investigative
T47094	DRUGINFO	D0Q7MQ	CP-100263	Investigative
T47094	DRUGINFO	D0T0IL	WIN-68577	Investigative
T47094	DRUGINFO	D0T4JO	7-METHYL-8-OXO-5-P-TOLYL-7,8-DIHYDRO-[1,7]NAPHTHYRIDINE-6-CARBOXYLIC ACID (3,5-BIS-TRIFLUOROMETHYL-BENZYL)-METHYL-AMIDE (STRUCTURAL MIX)	Investigative
T47094	DRUGINFO	D0TL4O	7-METHYL-8-OXO-5-P-TOLYL-7,8-DIHYDRO-[1,7]NAPHTHYRIDINE-6-CARBOXYLIC ACID (S)-[(S)-1-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-ETHYL]-METHYL-AMIDE (ENANTIOMERIC MIX)	Investigative
T47094	DRUGINFO	D0U8CB	SPANTIDE	Investigative
T47094	DRUGINFO	D0U8EA	S-41744	Investigative
T47094	DRUGINFO	D0UG6N	7-METHYL-8-OXO-5-P-TOLYL-7,8-DIHYDRO-[1,7]NAPHTHYRIDINE-6-CARBOXYLIC ACID (S)-[(R)-1-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-ETHYL]-METHYL-AMIDE (ENANTIOMERIC MIX)	Investigative
T47094	DRUGINFO	D0XR4J	H-Phe-Phe-NH2	Investigative
T47094	DRUGINFO	D0A1DE	MDL-28163	Investigative
T47094	DRUGINFO	D0D2JB	kassinin	Investigative
T47094	DRUGINFO	D0U9IB	eledoisin	Investigative
T47094	DRUGINFO	D0Y9RD	H-Tyr-Pro-Ala-Phe-NH2	Investigative
T47094	DRUGINFO	D0Z6TG	ZD-6021	Investigative
T47094	DRUGINFO	D01NPA	neurokinin A	Investigative
T47094	DRUGINFO	D07JAN	SCH 206272	Investigative
T47094	DRUGINFO	D08KSJ	H-Tyr-D-Ala-Gly Phe-Pro-Leu-Trp-O-3,5-Bzl(CF3)2	Investigative
T47094	DRUGINFO	D0C6RQ	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-3,5-Bzl(CF3)2	Investigative
T47094	DRUGINFO	D0CK8C	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-O-Bzl	Investigative
T47094	DRUGINFO	D0G6GC	Tyr-D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-Bzl	Investigative
T47094	DRUGINFO	D0L2CT	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-3,5-Bzl(CF3)2	Investigative
T47094	DRUGINFO	D0P0RB	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-Bzl	Investigative
T47094	DRUGINFO	D0Q7HG	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-Bzl	Investigative
T47094	DRUGINFO	D00TNR	ENDOMORPHIN 2	Investigative
T47094	DRUGINFO	D0PN9R	R-226161	Investigative
T47094	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T87023	TARGETID	T87023
T87023	FORMERID	TTDR01165
T87023	UNIPROID	PTAFR_HUMAN
T87023	TARGNAME	Platelet-activating factor receptor (PTAFR)
T87023	GENENAME	PTAFR
T87023	TARGTYPE	Successful
T87023	SYNONYMS	PTAFR; PAF-R
T87023	FUNCTION	Receptor for platelet activating factor, a chemotactic phospholipid mediator that possesses potent inflammatory, smooth- muscle contractile and hypotensive activity. Seems to mediate its action via a G protein that activates a phosphatidylinositol- calcium second messenger system.
T87023	PDBSTRUC	2B0X
T87023	BIOCLASS	GPCR rhodopsin
T87023	SEQUENCE	MEPHDSSHMDSEFRYTLFPIVYSIIFVLGVIANGYVLWVFARLYPCKKFNEIKIFMVNLTMADMLFLITLPLWIVYYQNQGNWILPKFLCNVAGCLFFINTYCSVAFLGVITYNRFQAVTRPIKTAQANTRKRGISLSLVIWVAIVGAASYFLILDSTNTVPDSAGSGNVTRCFEHYEKGSVPVLIIHIFIVFSFFLVFLIILFCNLVIIRTLLMQPVQQQRNAEVKRRALWMVCTVLAVFIICFVPHHVVQLPWTLAELGFQDSKFHQAINDAHQVTLCLLSTNCVLDPVIYCFLTKKFRKHLTEKFYSMRSSRKCSRATTDTVTEVVVPFNQIPGNSLKN
T87023	DRUGINFO	D05LBU	Ticlopidine	Approved
T87023	DRUGINFO	D0S1CQ	RUPATADINE	Phase 4
T87023	DRUGINFO	D0D4ZM	ISRAPAFANT	Phase 3
T87023	DRUGINFO	D0W6AF	YM-264	Phase 2
T87023	DRUGINFO	D0ZI0C	Dersalazine	Phase 2
T87023	DRUGINFO	DA85NC	60P002	Phase 2
T87023	DRUGINFO	D0D5ZV	CMI-392	Phase 2
T87023	DRUGINFO	D0I0UE	Lexipafant	Phase 2
T87023	DRUGINFO	D0C2HI	PegCNTF	Phase 1
T87023	DRUGINFO	D05YUK	FOROPAFANT	Discontinued in Phase 3
T87023	DRUGINFO	D0G2RE	BN 50730	Discontinued in Phase 3
T87023	DRUGINFO	D01KZC	Minopafant	Discontinued in Phase 2
T87023	DRUGINFO	D04ENK	TCV-309	Discontinued in Phase 2
T87023	DRUGINFO	D05KQE	MK-287	Discontinued in Phase 2
T87023	DRUGINFO	D0CB8W	DE-081	Discontinued in Phase 2
T87023	DRUGINFO	D0I6UU	UK-74505	Discontinued in Phase 2
T87023	DRUGINFO	D0R0EV	E-6123	Discontinued in Phase 2
T87023	DRUGINFO	D0R0TF	BN50727	Discontinued in Phase 2
T87023	DRUGINFO	D0S4JY	Ro-24-4736	Discontinued in Phase 2
T87023	DRUGINFO	D0U7DI	SM-10661	Discontinued in Phase 2
T87023	DRUGINFO	D02DVB	AGN-191743	Discontinued in Phase 1
T87023	DRUGINFO	D07SGB	ABT-299	Discontinued in Phase 1
T87023	DRUGINFO	D0C7LF	DACOPAFANT	Discontinued in Phase 1
T87023	DRUGINFO	D0W5OV	DF-1111301	Discontinued in Phase 1
T87023	DRUGINFO	D0XQ1W	SDZ-62-434	Discontinued in Phase 1
T87023	DRUGINFO	D01RFI	Ro-24-0238	Terminated
T87023	DRUGINFO	D02HCU	WEB-2347	Terminated
T87023	DRUGINFO	D05CEK	CV 6209	Terminated
T87023	DRUGINFO	D05RBL	CL-184005	Terminated
T87023	DRUGINFO	D08EVM	FR-128998	Terminated
T87023	DRUGINFO	D09FQB	UR-12460	Terminated
T87023	DRUGINFO	D0BD3U	SDZ-64-412	Terminated
T87023	DRUGINFO	D0H3XB	TULOPAFANT	Terminated
T87023	DRUGINFO	D0KW2A	BN50739	Terminated
T87023	DRUGINFO	D0MA3D	L-659989	Terminated
T87023	DRUGINFO	D0Q1UR	TIAPAFANT	Terminated
T87023	DRUGINFO	D0Q8YN	Sch-40338	Terminated
T87023	DRUGINFO	D0V7HD	BN-50726	Terminated
T87023	DRUGINFO	D0Y2ES	Bepafant	Terminated
T87023	DRUGINFO	D01LXG	KC-11425	Terminated
T87023	DRUGINFO	D04APY	KC-11404	Terminated
T87023	DRUGINFO	D0V4GT	CMI-206	Terminated
T87023	DRUGINFO	D00JJP	UR-12519	Investigative
T87023	DRUGINFO	D01CDL	L-652731	Investigative
T87023	DRUGINFO	D02QUS	RP-52770	Investigative
T87023	DRUGINFO	D03WIK	2-O-ethyl-PAF C-16	Investigative
T87023	DRUGINFO	D04FHG	PAF	Investigative
T87023	DRUGINFO	D04GGK	KO-286011	Investigative
T87023	DRUGINFO	D05BJY	7alpha-OCOCH2Ph-ginkgolide B	Investigative
T87023	DRUGINFO	D05MWB	UR-10324	Investigative
T87023	DRUGINFO	D05XSV	7alpha-OAc-ginkgolide B	Investigative
T87023	DRUGINFO	D06AUX	enantio PAF C-16	Investigative
T87023	DRUGINFO	D07DAK	7-epi-ginkgolide C	Investigative
T87023	DRUGINFO	D07FPS	7alpha-Cl-ginkgolide B	Investigative
T87023	DRUGINFO	D07TQF	7alpha-F-ginkgolide B	Investigative
T87023	DRUGINFO	D09BLB	methylcarbamyl PAF	Investigative
T87023	DRUGINFO	D09FQT	7alpha-N3-ginkgolide B	Investigative
T87023	DRUGINFO	D09PTR	FR-900452	Investigative
T87023	DRUGINFO	D0A8PD	2-O-methyl-PAF C-18	Investigative
T87023	DRUGINFO	D0AN6L	A 137491	Investigative
T87023	DRUGINFO	D0BV8A	7alpha-NHMe-ginkgolide B	Investigative
T87023	DRUGINFO	D0D1NQ	7alpha-NH2-ginkgolide B	Investigative
T87023	DRUGINFO	D0G1AK	UR-12510	Investigative
T87023	DRUGINFO	D0HJ9U	LAU-0901	Investigative
T87023	DRUGINFO	D0I7RF	10-OBn-ginkgolide B	Investigative
T87023	DRUGINFO	D0J6WM	10-OBn-ginkgolide C	Investigative
T87023	DRUGINFO	D0N0IV	VERAGUENSIN	Investigative
T87023	DRUGINFO	D0N2WK	CV-3988	Investigative
T87023	DRUGINFO	D0NB4Q	10-OBn-7alpha-F-gingkolide B	Investigative
T87023	DRUGINFO	D0OT3H	UR-11353	Investigative
T87023	DRUGINFO	D0Q6EK	7alpha-NHEt-ginkgolide B	Investigative
T87023	DRUGINFO	D0WJ1N	SRI-63-675	Investigative
T87023	DRUGINFO	D0X9RL	BB-823	Investigative
T87023	DRUGINFO	D0Z6BO	10-OBn-epi-ginkgolide C	Investigative

T36483	TARGETID	T36483
T36483	FORMERID	TTDC00071
T36483	UNIPROID	PAR1_HUMAN
T36483	TARGNAME	Proteinase activated receptor 1 (F2R)
T36483	GENENAME	F2R
T36483	TARGTYPE	Successful
T36483	SYNONYMS	Thrombin receptor; Proteinase-activated receptor 1; Protease-activated receptor-1; Protease activated receptor 1; PAR1; PAR-1; Coagulation factor II receptor; CF2R
T36483	FUNCTION	May play a role in platelets activation and in vascular development. High affinity receptor for activated thrombin coupled to G proteins that stimulate phosphoinositide hydrolysis.
T36483	PDBSTRUC	3VW7; 3LU9; 3HKJ; 3HKI; 3BEF
T36483	BIOCLASS	GPCR rhodopsin
T36483	SEQUENCE	MGPRRLLLVAACFSLCGPLLSARTRARRPESKATNATLDPRSFLLRNPNDKYEPFWEDEEKNESGLTEYRLVSINKSSPLQKQLPAFISEDASGYLTSSWLTLFVPSVYTGVFVVSLPLNIMAIVVFILKMKVKKPAVVYMLHLATADVLFVSVLPFKISYYFSGSDWQFGSELCRFVTAAFYCNMYASILLMTVISIDRFLAVVYPMQSLSWRTLGRASFTCLAIWALAIAGVVPLLLKEQTIQVPGLNITTCHDVLNETLLEGYYAYYFSAFSAVFFFVPLIISTVCYVSIIRCLSSSAVANRSKKSRALFLSAAVFCIFIICFGPTNVLLIAHYSFLSHTSTTEAAYFAYLLCVCVSSISCCIDPLIYYYASSECQRYVYSILCCKESSDPSSYNSSGQLMASKMDTCSSNLNNSIYKKLLT
T36483	DRUGINFO	D0VA0I	Vorapaxar	Approved
T36483	DRUGINFO	D0PU8T	E5555	Phase 2
T36483	DRUGINFO	D2F7JC	PZ-128	Phase 2
T36483	DRUGINFO	D08ELM	RWJ-58259	Terminated
T36483	DRUGINFO	D0Z4NX	FR-171113	Terminated
T36483	DRUGINFO	D0BV3B	SCH-602539	Investigative
T36483	DRUGINFO	D0I2VE	RWJ-56110	Investigative
T36483	DRUGINFO	D0QK2E	SCH-205831	Investigative

T14065	TARGETID	T14065
T14065	FORMERID	TTDC00031
T14065	UNIPROID	ITB7_HUMAN
T14065	TARGNAME	Integrin beta-7 (ITGB7)
T14065	GENENAME	ITGB7
T14065	TARGTYPE	Successful
T14065	SYNONYMS	Gut homing receptor beta subunit
T14065	FUNCTION	Integrin alpha-4/beta-7 interacts with the cell surface adhesion molecules MADCAM1 which is normally expressed by the vascular endothelium of the gastrointestinal tract. Interacts also with VCAM1 and fibronectin, an extracellular matrix component. It recognizes one or more domains within the alternatively spliced CS-1 region of fibronectin. Interactions involves the tripeptide L-D-T in MADCAM1, and L-D-V in fibronectin. Binds to HIV-1 gp120, thereby allowing the virus to enter GALT, which is thought to be the major trigger of AIDS disease. Interaction would involve a tripeptide L-D-I in HIV-1 gp120. Integrin alpha-E/beta-7 (HML-1) is a receptor for E-cadherin. Integrin alpha-4/beta-7 (Peyer patches-specific homing receptor LPAM-1) is an adhesion molecule that mediates lymphocyte migration and homing to gut-associated lymphoid tissue (GALT).
T14065	PDBSTRUC	3V4V; 3V4P; 2BRQ
T14065	BIOCLASS	Integrin
T14065	SEQUENCE	MVALPMVLVLLLVLSRGESELDAKIPSTGDATEWRNPHLSMLGSCQPAPSCQKCILSHPSCAWCKQLNFTASGEAEARRCARREELLARGCPLEELEEPRGQQEVLQDQPLSQGARGEGATQLAPQRVRVTLRPGEPQQLQVRFLRAEGYPVDLYYLMDLSYSMKDDLERVRQLGHALLVRLQEVTHSVRIGFGSFVDKTVLPFVSTVPSKLRHPCPTRLERCQSPFSFHHVLSLTGDAQAFEREVGRQSVSGNLDSPEGGFDAILQAALCQEQIGWRNVSRLLVFTSDDTFHTAGDGKLGGIFMPSDGHCHLDSNGLYSRSTEFDYPSVGQVAQALSAANIQPIFAVTSAALPVYQELSKLIPKSAVGELSEDSSNVVQLIMDAYNSLSSTVTLEHSSLPPGVHISYESQCEGPEKREGKAEDRGQCNHVRINQTVTFWVSLQATHCLPEPHLLRLRALGFSEELIVELHTLCDCNCSDTQPQAPHCSDGQGHLQCGVCSCAPGRLGRLCECSVAELSSPDLESGCRAPNGTGPLCSGKGHCQCGRCSCSGQSSGHLCECDDASCERHEGILCGGFGRCQCGVCHCHANRTGRACECSGDMDSCISPEGGLCSGHGRCKCNRCQCLDGYYGALCDQCPGCKTPCERHRDCAECGAFRTGPLATNCSTACAHTNVTLALAPILDDGWCKERTLDNQLFFFLVEDDARGTVVLRVRPQEKGADHTQAIVLGCVGGIVAVGLGLVLAYRLSVEIYDRREYSRFEKEQQQLNWKQDSNPLYKSAITTTINPRFQEADSPTL
T14065	DRUGINFO	D0N5ZS	Vedolizmab	Approved
T14065	DRUGINFO	D06PFT	Rhumab Beta7	Phase 3
T14065	DRUGINFO	D04WQJ	AMG-181	Phase 2
T14065	DRUGINFO	D0FU1J	PTG-100	Phase 1

T40492	TARGETID	T40492
T40492	FORMERID	TTDR00103
T40492	UNIPROID	POLG_HCV1
T40492	TARGNAME	Hepatitis C virus NS3 helicase (HCV NS3)
T40492	GENENAME	HCV NS3
T40492	TARGTYPE	Successful
T40492	SYNONYMS	HCV Hepacivirin; HCV NS3P; HCV p70
T40492	FUNCTION	Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity).
T40492	PDBSTRUC	3SU4; 3RC5; 3RC4; 3QGI; 3QGH
T40492	BIOCLASS	Peptidase
T40492	ECNUMBER	EC 3.4.21.98
T40492	SEQUENCE	APITAYAQQTRGLLGCIITSLTGRDKNQVEGEVQIVSTAAQTFLATCINGVCWTVYHGAGTRTIASPKGPVIQMYTNVDQDLVGWPAPQGSRSLTPCTCGSSDLYLVTRHADVIPVRRRGDSRGSLLSPRPISYLKGSSGGPLLCPAGHAVGIFRAAVCTRGVAKAVDFIPVENLETTMRSPVFTDNSSPPVVPQSFQVAHLHAPTGSGKSTKVPAAYAAQGYKVLVLNPSVAATLGFGAYMSKAHGIDPNIRTGVRTITTGSPITYSTYGKFLADGGCSGGAYDIIICDECHSTDATSILGIGTVLDQAETAGARLVVLATATPPGSVTVPHPNIEEVALSTTGEIPFYGKAIPLEVIKGGRHLIFCHSKKKCDELAAKLVALGINAVAYYRGLDVSVIPTSGDVVVVATDALMTGYTGDFDSVIDCNTCVTQTVDFSLDPTFTIETITLPQDAVSRTQRRGRTGRGKPGIYRFVAPGERPSGMFDSSVLCECYDAGCAWYELTPAETTVRLRAYMNTPGLPVCQDHLEFWEGVFTGLTHIDAHFLSQTKQSGENLPYLVAYQATVCARAQAPPPSWDQMWKCLIRLKPTLHGPTPLLYRLGAVQNEITLTHPVTKYIMTCMSADLEVVT
T40492	DRUGINFO	D0T9TE	Ombitasvir + paritaprevir + ritonavir	Approved
T40492	DRUGINFO	D02HTD	GS-9451	Phase 2
T40492	DRUGINFO	D07TYE	GS-9857	Phase 2
T40492	DRUGINFO	D0OZ7P	BILN-2061	Phase 2
T40492	DRUGINFO	D02YEG	VBY-376	Phase 1
T40492	DRUGINFO	D06KUY	ACH-2684	Phase 1
T40492	DRUGINFO	D0N8XL	BMS-605339	Terminated
T40492	DRUGINFO	D02HVT	AcAsp-D-Gla-Leu-Ile-Cha-Cys	Investigative
T40492	DRUGINFO	D02IYE	Cbz-Ile-Leu-L-(difluoro)aminobutyric acid	Investigative
T40492	DRUGINFO	D04DXC	AcGlu-Dif-Ile-Cha-Cys	Investigative
T40492	DRUGINFO	D04LUF	AcGlu-Dif-Glu-Cha-Cys	Investigative
T40492	DRUGINFO	D05EDA	AcAsp-Glu-Cha-Val-Prb-Cys	Investigative
T40492	DRUGINFO	D06KJR	AcAsp-Glu-Dif-Glu-Cha-Fab	Investigative
T40492	DRUGINFO	D07XFT	Ribavirin-TP	Investigative
T40492	DRUGINFO	D08AXB	Ac-Glu-Cha-Cys	Investigative
T40492	DRUGINFO	D08NOS	AcAsp-Glu-Dif-Ile-Cha-Cys	Investigative
T40492	DRUGINFO	D09JCT	AcAsp-Glu-Met-Glu-Glu-Cys	Investigative
T40492	DRUGINFO	D09KTN	Asp-D-Glu-Leu-Glu-Cha-Cys	Investigative
T40492	DRUGINFO	D0B3FI	Boc-Ile-Leu-L-(difluoro)aminobutyric aid	Investigative
T40492	DRUGINFO	D0BP1S	AcAsp-Glu-Dif-Ile-Cha-Cys-Pro-Nle-Asp-ValNH2	Investigative
T40492	DRUGINFO	D0C9GO	AcAsp-Glu-Leu-Glu-Cha-Cys	Investigative
T40492	DRUGINFO	D0D2WV	Azapeptide	Investigative
T40492	DRUGINFO	D0D3OV	AcAsp-Glu-Cha-Val-Prb-Cpg	Investigative
T40492	DRUGINFO	D0FR8Z	AcAsp-Glu-Met-Glu-Nal-Cyse	Investigative
T40492	DRUGINFO	D0H1VY	2,4,6-Trihydroxy-3-nitro-N-tridecyl-benzamide	Investigative
T40492	DRUGINFO	D0H9AV	AcAsp-Glu-Dif-Ile-Cha-Cys-Pro-Cha-Asp-ValNH2	Investigative
T40492	DRUGINFO	D0HT2D	AcAsp-Glu-Met-Glu-Cha-Cys	Investigative
T40492	DRUGINFO	D0I8WU	AcDif-Glu-Cha-Cys	Investigative
T40492	DRUGINFO	D0K9BF	AcAsp-Glu-Dif-Glu-Cha-Cys	Investigative
T40492	DRUGINFO	D0L7DB	SCH-68631	Investigative
T40492	DRUGINFO	D0L7PQ	AcDif-Ile-Cha-Cys	Investigative
T40492	DRUGINFO	D0LB4A	PATULIN	Investigative
T40492	DRUGINFO	D0M2RI	AcAsp-Gla-Leu-Ile-Cha-Cys	Investigative
T40492	DRUGINFO	D0PT8O	AcAsp-Glu-Dif-Lys-Cha-Cys	Investigative
T40492	DRUGINFO	D0R5QX	AcAsp-Glu-Dif-Ile-Cha-Cys-Iqc-Nle-Thr-TyrNH2	Investigative
T40492	DRUGINFO	D0S8BU	SE RNA	Investigative
T40492	DRUGINFO	D0VM0N	AcAsp-D-Glu-Leu-Glu-Cha-Cys	Investigative
T40492	DRUGINFO	D0VN0H	AcGlu-Asp-Val-Val-Leu-Cys-Iqc-Nle-Thr-TyrNH2	Investigative
T40492	DRUGINFO	D00PVO	GNF-PF-3464	Investigative

T05152	TARGETID	T05152
T05152	FORMERID	TTDI01926
T05152	UNIPROID	POLG_HCV1
T05152	TARGNAME	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
T05152	GENENAME	HCV NS5B
T05152	TARGTYPE	Successful
T05152	SYNONYMS	HCV NS5B; HCV p68
T05152	FUNCTION	Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity).
T05152	PDBSTRUC	3SU4; 3RC5; 3RC4; 3QGI; 3QGH
T05152	BIOCLASS	Peptidase
T05152	ECNUMBER	EC 2.7.7.48
T05152	SEQUENCE	SMSYSWTGALVTPCAAEEQKLPINALSNSLLRHHNLVYSTTSRSACQRQKKVTFDRLQVLDSHYQDVLKEVKAAASKVKANLLSVEEACSLTPPHSAKSKFGYGAKDVRCHARKAVTHINSVWKDLLEDNVTPIDTTIMAKNEVFCVQPEKGGRKPARLIVFPDLGVRVCEKMALYDVVTKLPLAVMGSSYGFQYSPGQRVEFLVQAWKSKKTPMGFSYDTRCFDSTVTESDIRTEEAIYQCCDLDPQARVAIKSLTERLYVGGPLTNSRGENCGYRRCRASGVLTTSCGNTLTCYIKARAACRAAGLQDCTMLVCGDDLVVICESAGVQEDAASLRAFTEAMTRYSAPPGDPPQPEYDLELITSCSSNVSVAHDGAGKRVYYLTRDPTTPLARAAWETARHTPVNSWLGNIIMFAPTLWARMILMTHFFSVLIARDQLEQALDCEIYGACYSIEPLDLPPIIQRLHGLSAFSLHSYSPGEINRVAACLRKLGVPPLRAWRHRARSVRARLLARGGRAAICGKYLFNWAVRTKLKLTPIAAAGQLDLSGWFTAGYSGGDIYHSVSHARPRWIWFCLLLLAAGVGIYLLPNR
T05152	DRUGINFO	D0D4YZ	PSI-7977	Approved
T05152	DRUGINFO	D0RM5Z	Sofosbuvir + velpatasvir + voxilaprevir	Approved
T05152	DRUGINFO	D06PGZ	Setrobuvir	Phase 2
T05152	DRUGINFO	D07QAF	BI 207127	Phase 2
T05152	DRUGINFO	D08GBB	Valopicitabine dihydrochloride	Phase 2
T05152	DRUGINFO	D08TQP	INX-189	Phase 2
T05152	DRUGINFO	D09RVI	Tegobuvir	Phase 2
T05152	DRUGINFO	D09ZZW	VX-759	Phase 2
T05152	DRUGINFO	D0BG3B	VX-135	Phase 2
T05152	DRUGINFO	D0F4NH	VX-222	Phase 2
T05152	DRUGINFO	D0H7QU	BMS 791325	Phase 2
T05152	DRUGINFO	D0U0GZ	Filibuvir	Phase 2
T05152	DRUGINFO	DD5NX2	AT-777	Phase 1/2
T05152	DRUGINFO	D01FUL	Balapiravir	Phase 1
T05152	DRUGINFO	D02RVC	PPI-383	Phase 1
T05152	DRUGINFO	D04KJT	ABT-333	Phase 1
T05152	DRUGINFO	D06IPZ	MK-3281	Phase 1
T05152	DRUGINFO	D06QOA	PSI-938	Phase 1
T05152	DRUGINFO	D08DPN	GSK-625433	Phase 1
T05152	DRUGINFO	D09APB	IDX-189	Phase 1
T05152	DRUGINFO	D0B5RZ	GS-6620	Phase 1
T05152	DRUGINFO	D0HN6Q	RG-7348	Phase 1
T05152	DRUGINFO	D0J2OC	MBX-700	Phase 1
T05152	DRUGINFO	D0L0HV	VX-916	Phase 1
T05152	DRUGINFO	D0NR7H	A-837093	Phase 1
T05152	DRUGINFO	D0Y7CO	ABT-072	Phase 1
T05152	DRUGINFO	D0Y8BW	TMC-647055	Phase 1
T05152	DRUGINFO	D0Z3BU	Drug 2878175	Phase 1
T05152	DRUGINFO	D0Z6GW	TMC649128	Phase 1
T05152	DRUGINFO	DO2LE6	CC-31244	Phase 1
T05152	DRUGINFO	DXO1V4	AT-787	Phase 1
T05152	DRUGINFO	D02IRL	IDX375	Discontinued in Phase 2
T05152	DRUGINFO	D05DDN	HCV-796	Discontinued in Phase 2
T05152	DRUGINFO	D06QOF	R7128	Discontinued in Phase 2
T05152	DRUGINFO	D0M2SR	R-803	Discontinued in Phase 1/2
T05152	DRUGINFO	D00JNT	HCV-086	Discontinued in Phase 1
T05152	DRUGINFO	D01ZGH	JTK-853	Discontinued in Phase 1
T05152	DRUGINFO	D0A1KR	JTK-652	Discontinued in Phase 1
T05152	DRUGINFO	D0FY6Q	JTK-109	Discontinued in Phase 1
T05152	DRUGINFO	D0QH7G	RG-7432	Discontinued in Phase 1
T05152	DRUGINFO	D0ZM5B	AG-021541	Discontinued in Phase 1
T05152	DRUGINFO	D00RFZ	PSI-6130	Terminated
T05152	DRUGINFO	D0GE2F	GSK-2485852	Terminated
T05152	DRUGINFO	D0K6ZH	PSI-661	Terminated
T05152	DRUGINFO	D00QTA	A-058	Investigative
T05152	DRUGINFO	D01GJI	GS-9256 + tegobuvir	Investigative
T05152	DRUGINFO	D0A6OO	PSI 7851	Investigative

T07806	TARGETID	T07806
T07806	FORMERID	TTDS00099
T07806	UNIPROID	5HT1B_HUMAN
T07806	TARGNAME	5-HT 1B receptor (HTR1B)
T07806	GENENAME	HTR1B
T07806	TARGTYPE	Successful
T07806	SYNONYMS	Serotonin receptor 1B; Serotonin 1D beta receptor; S12; HTR1DB; 5-hydroxytryptamine receptor 1B; 5-HT1B receptor; 5-HT1B; 5-HT-1D-beta; 5-HT-1B
T07806	FUNCTION	Functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. Arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Regulates the release of 5-hydroxytryptamine, dopamine and acetylcholine in the brain, and thereby affects neural activity, nociceptive processing, pain perception, mood and behavior. Besides, plays a role in vasoconstriction of cerebral arteries. G-protein coupled receptor for 5-hydroxytryptamine (serotonin).
T07806	PDBSTRUC	6G79; 5V54; 4IAR; 4IAQ; 2G1X
T07806	BIOCLASS	GPCR rhodopsin
T07806	SEQUENCE	MEEPGAQCAPPPPAGSETWVPQANLSSAPSQNCSAKDYIYQDSISLPWKVLLVMLLALITLATTLSNAFVIATVYRTRKLHTPANYLIASLAVTDLLVSILVMPISTMYTVTGRWTLGQVVCDFWLSSDITCCTASILHLCVIALDRYWAITDAVEYSAKRTPKRAAVMIALVWVFSISISLPPFFWRQAKAEEEVSECVVNTDHILYTVYSTVGAFYFPTLLLIALYGRIYVEARSRILKQTPNRTGKRLTRAQLITDSPGSTSSVTSINSRVPDVPSESGSPVYVNQVKVRVSDALLEKKKLMAARERKATKTLGIILGAFIVCWLPFFIISLVMPICKDACWFHLAIFDFFTWLGYLNSLINPIIYTMSNEDFKQAFHKLIRFKCTS
T07806	DRUGINFO	D03NTJ	Prolixin decanoate	Approved
T07806	DRUGINFO	D0P5SA	Fluphenazine	Approved
T07806	DRUGINFO	D0T3KI	Naratriptan	Approved
T07806	DRUGINFO	D02DMQ	Eletriptan	Approved
T07806	DRUGINFO	D06FPQ	Frovatriptan	Approved
T07806	DRUGINFO	D0NG7O	Zolmitriptan	Approved
T07806	DRUGINFO	D0UA0I	Metergolin	Approved
T07806	DRUGINFO	D06FKC	Eltoprazine	Phase 3
T07806	DRUGINFO	D0O2XJ	NXN-188	Phase 2
T07806	DRUGINFO	D0C1ZO	[N-methyl-3H(3)]AZ-10419369	Phase 1
T07806	DRUGINFO	D0Y0RW	Alniditan	Discontinued in Phase 3
T07806	DRUGINFO	D03SFN	Elzasonan hydrochloride	Discontinued in Phase 2
T07806	DRUGINFO	D09WCE	IS-159	Discontinued in Phase 2
T07806	DRUGINFO	D0G5ML	Donitriptan	Preclinical
T07806	DRUGINFO	D0E4HZ	F-12682	Terminated
T07806	DRUGINFO	D0K4PN	AZD-1134	Terminated
T07806	DRUGINFO	D0Q1ER	CGS-12066B	Terminated
T07806	DRUGINFO	D02ZPM	Anpirtoline	Terminated
T07806	DRUGINFO	D02ZSO	L-775606	Terminated
T07806	DRUGINFO	D06DZI	GR-127935	Terminated
T07806	DRUGINFO	D0UO9T	VR-147	Terminated
T07806	DRUGINFO	D04DLR	GR55562	Investigative
T07806	DRUGINFO	D09PIN	SB 224289	Investigative
T07806	DRUGINFO	D0A8NB	CP-94,253	Investigative
T07806	DRUGINFO	D0P6IV	[11C]AZ10419369	Investigative
T07806	DRUGINFO	D0V9XE	SB236057	Investigative
T07806	DRUGINFO	D00TYX	[3H]sumatriptan	Investigative
T07806	DRUGINFO	D03KPA	5-Ethyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole	Investigative
T07806	DRUGINFO	D03MVY	2-(5-Thiophen-2-yl-1H-indol-3-yl)-ethylamine	Investigative
T07806	DRUGINFO	D03XAE	[2-(5-Ethyl-1H-indol-3-yl)-ethyl]-dimethyl-amine	Investigative
T07806	DRUGINFO	D09AVG	5-amino-3-(N-methylpiperidin-4-yl)-1H-indole	Investigative
T07806	DRUGINFO	D0A2SY	[3H]GR 125,743	Investigative
T07806	DRUGINFO	D0B6WH	[3H]eletriptan	Investigative
T07806	DRUGINFO	D0C3EX	2-(5-Nonyloxy-1H-indol-3-yl)-ethylamine	Investigative
T07806	DRUGINFO	D0H6KD	[125I]GTI	Investigative
T07806	DRUGINFO	D0J3ZK	(R)-flurocarazolol	Investigative
T07806	DRUGINFO	D0K9MT	5-Isopropyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole	Investigative
T07806	DRUGINFO	D0KQ9H	L-747201	Investigative
T07806	DRUGINFO	D0O8QJ	(S)-flurocarazolol	Investigative
T07806	DRUGINFO	D01APL	lysergol	Investigative
T07806	DRUGINFO	D01HRV	L-772,405	Investigative
T07806	DRUGINFO	D03DET	SB 714786	Investigative
T07806	DRUGINFO	D0H3KU	5-OH-DPAT	Investigative
T07806	DRUGINFO	D0K0FI	7-methoxy-1-naphthylpiperazine	Investigative
T07806	DRUGINFO	D0O3GF	[3H]8-OH-DPAT	Investigative
T07806	DRUGINFO	D0PN8D	1-(7-Methoxy-naphthalen-2-yl)-piperazine	Investigative
T07806	DRUGINFO	D0QM3E	SB 272183	Investigative
T07806	DRUGINFO	D0R3GW	SB 649915	Investigative
T07806	DRUGINFO	D0D3PZ	dipropyl-5-CT	Investigative
T07806	DRUGINFO	D0W2YN	1-Naphthalen-2-yl-piperazine	Investigative
T07806	DRUGINFO	D0D9YW	SB 216641	Investigative
T07806	DRUGINFO	D0Y4MC	9-OH-risperidone	Investigative
T07806	DRUGINFO	D06VPR	WAY-466	Investigative
T07806	DRUGINFO	D0LG8A	1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine	Investigative
T07806	DRUGINFO	D00CRA	2-methyl-5-HT	Investigative
T07806	DRUGINFO	D03TDN	1-naphthylpiperazine	Investigative
T07806	DRUGINFO	D04TVG	BRL-15572	Investigative
T07806	DRUGINFO	D02UWB	5-CT	Investigative
T07806	DRUGINFO	D0V5HV	TFMPP	Investigative
T07806	DRUGINFO	D0F6CD	SEROTONIN	Investigative
T07806	DRUGINFO	D0F9QT	A-987306	Investigative
T07806	DRUGINFO	D0L5MW	(+/-)-nantenine	Investigative

T32060	TARGETID	T32060
T32060	FORMERID	TTDS00103
T32060	UNIPROID	5HT2A_HUMAN
T32060	TARGNAME	5-HT 2A receptor (HTR2A)
T32060	GENENAME	HTR2A
T32060	TARGTYPE	Successful
T32060	SYNONYMS	Serotonin receptor 2A; HTR2; 5-hydroxytryptamine receptor 2A; 5-HT-2A; 5-HT-2
T32060	FUNCTION	G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates phospholipase C and a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and promotes the release of Ca(2+) ions from intracellular stores. Affects neural activity, perception, cognition and mood. Plays a role in the regulation of behavior, including responses to anxiogenic situations and psychoactive substances. Plays a role in intestinal smooth muscle contraction, and may play a role in arterial vasoconstriction.
T32060	PDBSTRUC	6A94; 6A93
T32060	BIOCLASS	GPCR rhodopsin
T32060	SEQUENCE	MDILCEENTSLSSTTNSLMQLNDDTRLYSNDFNSGEANTSDAFNWTVDSENRTNLSCEGCLSPSCLSLLHLQEKNWSALLTAVVIILTIAGNILVIMAVSLEKKLQNATNYFLMSLAIADMLLGFLVMPVSMLTILYGYRWPLPSKLCAVWIYLDVLFSTASIMHLCAISLDRYVAIQNPIHHSRFNSRTKAFLKIIAVWTISVGISMPIPVFGLQDDSKVFKEGSCLLADDNFVLIGSFVSFFIPLTIMVITYFLTIKSLQKEATLCVSDLGTRAKLASFSFLPQSSLSSEKLFQRSIHREPGSYTGRRTMQSISNEQKACKVLGIVFFLFVVMWCPFFITNIMAVICKESCNEDVIGALLNVFVWIGYLSSAVNPLVYTLFNKTYRSAFSRYIQCQYKENKKPLQLILVNTIPALAYKSSQLQMGQKKNSKQDAKTTDNDCSMVALGKQHSEEASKDNSDGVNEKVSCV
T32060	DRUGINFO	D0G6VL	Sarpogrelate	Approved
T32060	DRUGINFO	D0J8JP	Pimavanserin	Approved
T32060	DRUGINFO	D0T6QX	ZOTEPINE	Approved
T32060	DRUGINFO	D01QGX	Lurasidone hydrochloride	Approved
T32060	DRUGINFO	D02DPU	Aniracetam	Approved
T32060	DRUGINFO	D0M8VE	Iloperidone	Approved
T32060	DRUGINFO	D0S9CB	Flibanserin	Approved
T32060	DRUGINFO	D1CWL0	lumateperone tosylate	Approved
T32060	DRUGINFO	D0UA0I	Metergolin	Approved
T32060	DRUGINFO	D04PLI	SR46349B	Phase 3
T32060	DRUGINFO	D08GJH	Blonanserin	Phase 3
T32060	DRUGINFO	D0L7TA	MIN-101	Phase 3
T32060	DRUGINFO	D0NN8N	TNX-102	Phase 3
T32060	DRUGINFO	D02YVM	Zicronapine	Phase 3
T32060	DRUGINFO	D08CJK	TRYPTAMINE	Phase 3
T32060	DRUGINFO	D0HZ2E	M100907	Phase 3
T32060	DRUGINFO	D0Q0EF	ITI-007	Phase 3
T32060	DRUGINFO	D00TLM	PRUVANSERIN	Phase 2
T32060	DRUGINFO	D03IGB	BVT.28949	Phase 2
T32060	DRUGINFO	D0GJ7B	NELOTANSERIN	Phase 2
T32060	DRUGINFO	D0SQ6A	FKW00GA	Phase 2
T32060	DRUGINFO	D9I3WE	SYN120	Phase 2
T32060	DRUGINFO	DDI6B0	Nuplazid	Phase 2
T32060	DRUGINFO	D01FQR	Ocaperidone	Phase 2
T32060	DRUGINFO	D05XEA	RP5063	Phase 2
T32060	DRUGINFO	D0R9KG	Temanogrel	Phase 1
T32060	DRUGINFO	D02JGD	SKL-10406	Phase 1
T32060	DRUGINFO	D0A7KI	Abaperidone	Phase 1
T32060	DRUGINFO	D0N4NJ	YKP-1358	Phase 1
T32060	DRUGINFO	D06NOF	ATI-9242	Phase 1
T32060	DRUGINFO	D0AI8V	DSP-1200	Phase 1
T32060	DRUGINFO	D0C7WO	1192U90	Phase 1
T32060	DRUGINFO	D00PLP	Pyrazole derivative 72	Patented
T32060	DRUGINFO	D02GTU	Benzoyl-piperidine derivative 2	Patented
T32060	DRUGINFO	D03IAB	Pyrazole derivative 68	Patented
T32060	DRUGINFO	D06RIO	Piperazine derivative 3	Patented
T32060	DRUGINFO	D09WFK	Pyrazole derivative 75	Patented
T32060	DRUGINFO	D0AQ1T	Pyrazole derivative 73	Patented
T32060	DRUGINFO	D0DW6V	Pyrazole derivative 67	Patented
T32060	DRUGINFO	D0FR1P	Benzoyl-piperidine derivative 1	Patented
T32060	DRUGINFO	D0H5XC	Pyrazole derivative 69	Patented
T32060	DRUGINFO	D0H8IH	PMID26609882-Compound-36	Patented
T32060	DRUGINFO	D0HY3K	3-phenyl pyrazole derivative 1	Patented
T32060	DRUGINFO	D0J7SD	Piperazine derivative 4	Patented
T32060	DRUGINFO	D0JT3F	PMID26609882-Compound-35	Patented
T32060	DRUGINFO	D0KM0T	Pyrazole derivative 74	Patented
T32060	DRUGINFO	D0N8PF	Pyrazole derivative 70	Patented
T32060	DRUGINFO	D0O3BR	Diarylamine and arylheteroarylamine pyrazole derivative 3	Patented
T32060	DRUGINFO	D0OR4G	Diarylamine and arylheteroarylamine pyrazole derivative 2	Patented
T32060	DRUGINFO	D0R6HF	Pyrazole derivative 71	Patented
T32060	DRUGINFO	D0WC8M	Diarylamine and arylheteroarylamine pyrazole derivative 1	Patented
T32060	DRUGINFO	D0ZF0Z	PMID26609882-Compound-34	Patented
T32060	DRUGINFO	D0BU6K	Aryl piperazine derivative 9	Patented
T32060	DRUGINFO	D00YGY	Pyrimidine derivative 29	Patented
T32060	DRUGINFO	D08DJY	Pyrimidine derivative 26	Patented
T32060	DRUGINFO	D0B7NS	Pyrimidine derivative 23	Patented
T32060	DRUGINFO	D0J4AZ	L-piperazino-3-phenyl-indane derivative 1	Patented
T32060	DRUGINFO	D0N2VA	Pyrimidine derivative 25	Patented
T32060	DRUGINFO	D0P9VX	Pyrimidine derivative 27	Patented
T32060	DRUGINFO	D0SE9K	Pyrimidine derivative 28	Patented
T32060	DRUGINFO	D0U9UH	Pyrimidine derivative 24	Patented
T32060	DRUGINFO	D0EO8F	PMID30124346-Compound-LDT8	Patented
T32060	DRUGINFO	D0M1UF	Aryl piperazine derivative 1	Patented
T32060	DRUGINFO	D0Z9WY	Aryl piperazine derivative 6	Patented
T32060	DRUGINFO	D09BCJ	PMID30124346-Compound-34TABLE4	Patented
T32060	DRUGINFO	D0F4NB	PMID30124346-Compound-13TABLE4	Patented
T32060	DRUGINFO	D0M7LV	LYSERGIC ACID DIETHYLAMIDE	Withdrawn from market
T32060	DRUGINFO	D05MFO	MDL-11939	Discontinued in Phase 3
T32060	DRUGINFO	D0B1GX	Iferanserin-Ventrus	Discontinued in Phase 3
T32060	DRUGINFO	D0E6UA	Deramciclane	Discontinued in Phase 3
T32060	DRUGINFO	D01RCS	TIOSPIRONE	Discontinued in Phase 3
T32060	DRUGINFO	D0K8NW	Ritanserin	Discontinued in Phase 3
T32060	DRUGINFO	D0B4JL	SERAZAPINE HYDROCHLORIDE	Discontinued in Phase 2
T32060	DRUGINFO	D0OQ3L	SL65.0472	Discontinued in Phase 2
T32060	DRUGINFO	D0S5ZJ	SERGOLEXOLE MALEATE	Discontinued in Phase 2
T32060	DRUGINFO	D0V7MA	AMESERGIDE	Discontinued in Phase 2
T32060	DRUGINFO	D01ESB	YM-992	Discontinued in Phase 2
T32060	DRUGINFO	D02SKA	FCE-22716	Discontinued in Phase 2
T32060	DRUGINFO	D0X2TO	Adatanserin	Discontinued in Phase 2
T32060	DRUGINFO	D01WJZ	MAZAPERTINE	Discontinued in Phase 2
T32060	DRUGINFO	D0Z4QV	DUP-734	Discontinued in Phase 1
T32060	DRUGINFO	D0A8IE	AM-831	Discontinued in Phase 1
T32060	DRUGINFO	D0N5NM	Org-23366	Preclinical
T32060	DRUGINFO	D00PXQ	Fananserin	Terminated
T32060	DRUGINFO	D07MWD	MDL-28161	Terminated
T32060	DRUGINFO	D0EN4G	R-102444	Terminated
T32060	DRUGINFO	D0ES4S	RP-68303	Terminated
T32060	DRUGINFO	D0F6XR	DV-7028	Terminated
T32060	DRUGINFO	D0V4JO	AMPEROZIDE	Terminated
T32060	DRUGINFO	D05KHN	ICI-169369	Terminated
T32060	DRUGINFO	D05RMW	ZD-3638	Terminated
T32060	DRUGINFO	D0A3OF	GMC-283	Terminated
T32060	DRUGINFO	D0B4BN	Ro-60-0175	Terminated
T32060	DRUGINFO	D0PA6K	LY53857	Terminated
T32060	DRUGINFO	D0K9JP	A-80426	Terminated
T32060	DRUGINFO	D00FJT	[11C]volinanserin	Investigative
T32060	DRUGINFO	D00SNJ	N-(1-(1-phenylethyl)piperidin-4-yl)-1-naphthamide	Investigative
T32060	DRUGINFO	D01CGM	ALTANSERIN	Investigative
T32060	DRUGINFO	D01GWH	N-(1-(4-phenylbutyl)piperidin-4-yl)-2-naphthamide	Investigative
T32060	DRUGINFO	D01TSX	(R)-1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine	Investigative
T32060	DRUGINFO	D01WNO	7-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole	Investigative
T32060	DRUGINFO	D02IEO	LY108742	Investigative
T32060	DRUGINFO	D02JPD	3-(1-Benzyl-piperidin-4-yl)-2-phenyl-1H-indole	Investigative
T32060	DRUGINFO	D02SFJ	4-(10H-Anthracen-9-ylidene)-1-methyl-piperidine	Investigative
T32060	DRUGINFO	D03IWX	2-methoxy-9-aminomethyl-9,10-dihydroanthracene	Investigative
T32060	DRUGINFO	D03JEW	N-(1-(4-nitrobenzyl)piperidin-4-yl)-2-naphthamide	Investigative
T32060	DRUGINFO	D04NAL	LY314228	Investigative
T32060	DRUGINFO	D04SIT	1-(4-Bromo-2,5-difluorophenyl)-2-aminopropane	Investigative
T32060	DRUGINFO	D04TWX	(R)-3-(4-propylmorpholin-2-yl)phenol	Investigative
T32060	DRUGINFO	D04UCV	8-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole	Investigative
T32060	DRUGINFO	D05LJF	N-(1-(4-bromobenzyl)piperidin-4-yl)-2-naphthamide	Investigative
T32060	DRUGINFO	D05ULV	4-methoxy-9-aminomethyl-9,10-dihydroanthracene	Investigative
T32060	DRUGINFO	D05USH	4-(4-Fluoro-benzyl)-piperidine hydrochloride	Investigative
T32060	DRUGINFO	D07QMR	N-(1-(4-phenylbutyl)piperidin-4-yl)-1-naphthamide	Investigative
T32060	DRUGINFO	D08AGH	[18F]altanserin	Investigative
T32060	DRUGINFO	D08CNN	1-(3-(phenylthio)propyl)-4-m-tolylpiperazine	Investigative
T32060	DRUGINFO	D08MNG	C-(5-bromo-4,7-dimethoxyindan-1-yl)methylamine	Investigative
T32060	DRUGINFO	D08VLD	Racemic DOTFM	Investigative
T32060	DRUGINFO	D08XGI	(1-Phenethyl-piperidin-4-yl)-phenyl-methanone	Investigative
T32060	DRUGINFO	D08XYR	DOM	Investigative
T32060	DRUGINFO	D08ZWM	PSILOCIN	Investigative
T32060	DRUGINFO	D09CKT	LY433222	Investigative
T32060	DRUGINFO	D09FZD	N-(1-phenethylpiperidin-4-yl)-2-naphthamide	Investigative
T32060	DRUGINFO	D09HFT	(E)-2-(4-fluorostyryl)-5-(phenylsulfonyl)pyridine	Investigative
T32060	DRUGINFO	D0AW4X	N-(1-(3-bromobenzyl)piperidin-4-yl)-1-naphthamide	Investigative
T32060	DRUGINFO	D0B3WX	CINANSERIN	Investigative
T32060	DRUGINFO	D0B9ZK	3-methoxy-9-aminomethyl-9,10-dihydroanthracene	Investigative
T32060	DRUGINFO	D0BI5Y	C-(9H-Thioxanthen-9-yl)-methylamine	Investigative
T32060	DRUGINFO	D0C0LG	N-(1-(1-phenylethyl)piperidin-4-yl)-2-naphthamide	Investigative
T32060	DRUGINFO	D0C7FL	2,2-Diphenyl-ethylamine	Investigative
T32060	DRUGINFO	D0EH5Z	2-(3,5-dimethoxy-4-phenethoxyphenyl)ethanamine	Investigative
T32060	DRUGINFO	D0F1CP	EPLIVANSERIN MESILATE	Investigative
T32060	DRUGINFO	D0F1FN	(2-Indol-1-yl-ethyl)-dimethyl-amine	Investigative
T32060	DRUGINFO	D0FK5Z	N-(1-phenethylpiperidin-4-yl)-1-naphthamide	Investigative
T32060	DRUGINFO	D0H0PL	LY215840	Investigative
T32060	DRUGINFO	D0I6KF	(S)-(-)-(4,5,6-trimethoxyindan-1-yl)methanamine	Investigative
T32060	DRUGINFO	D0I8MP	N-(1-(3-bromobenzyl)piperidin-4-yl)-2-naphthamide	Investigative
T32060	DRUGINFO	D0IX1V	1-(10-Bromoanthracen-9-yl)-2-aminopropane	Investigative
T32060	DRUGINFO	D0K6VR	6-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole	Investigative
T32060	DRUGINFO	D0K8DY	9-(N-benzylaminomethyl)-9,10-dihydroanthracene	Investigative
T32060	DRUGINFO	D0L0MU	C-(5H-Dibenzo[a,d]cyclohepten-5-yl)-methylamine	Investigative
T32060	DRUGINFO	D0L0SF	LY320954	Investigative
T32060	DRUGINFO	D0L8MR	MESCALINE	Investigative
T32060	DRUGINFO	D0L9GR	Very low dose (VLD) cyclobenzaprine	Investigative
T32060	DRUGINFO	D0M2JA	ACP-106	Investigative
T32060	DRUGINFO	D0Q1ZC	3-(1-Methyl-piperidin-4-yl)-2-phenyl-1H-indole	Investigative
T32060	DRUGINFO	D0Q6PI	PHENETHYLAMINE	Investigative
T32060	DRUGINFO	D0R5WB	2-Phenyl-3-(2-piperidin-1-yl-ethyl)-1H-indole	Investigative
T32060	DRUGINFO	D0S0PA	C-(9H-Xanthen-9-yl)-methylamine	Investigative
T32060	DRUGINFO	D0U3GZ	2,5-dimethoxy-4-bromophenethylamine	Investigative
T32060	DRUGINFO	D0U5HQ	[2-(6-Methoxy-indol-1-yl)-ethyl]-dimethyl-amine	Investigative
T32060	DRUGINFO	D0V5OY	N-(1-benzylpiperidine-4-yl)-2-naphthamide	Investigative
T32060	DRUGINFO	D0V7YD	4-Benzyl-1-methyl-piperidine hydrochloride	Investigative
T32060	DRUGINFO	D0W1CC	(R)-(+)-(4,5,6-trimethoxyindan-1-yl)methanamine	Investigative
T32060	DRUGINFO	D0XP5P	LY063518	Investigative
T32060	DRUGINFO	D0Y1UV	1-(2,6-dimethoxy-4-methylphenyl)propan-2-amine	Investigative
T32060	DRUGINFO	D0ZF1W	N-1-isopropyltryptamine	Investigative
T32060	DRUGINFO	D0ZP2D	N-1-isopropyl-5-MeOT	Investigative
T32060	DRUGINFO	D0ZQ3Q	1-(4-ethyl-2,5-dimethoxyphenyl)propan-2-amine	Investigative
T32060	DRUGINFO	D0ZZ4S	1-methoxy-9-aminomethyl-9,10-dihydroanthracene	Investigative
T32060	DRUGINFO	D00AVR	Aplysinopsin	Investigative
T32060	DRUGINFO	D00LXH	(R,S)-1-(5-bromo-1H-indol-1-yl)propan-2-amine	Investigative
T32060	DRUGINFO	D00NST	(2S)-1-(1H-furo[2,3-g]indazol-1-yl)propan-2-amine	Investigative
T32060	DRUGINFO	D00OCV	3-(2-Dimethylamino-ethyl)-2-methyl-1H-indol-4-ol	Investigative
T32060	DRUGINFO	D00YEB	11-Butyryloxy-N-n-propylnoraporphine	Investigative
T32060	DRUGINFO	D01CXD	9-(Aminomethyl)-9,10-dihydroanthracene	Investigative
T32060	DRUGINFO	D01HJZ	N,N-dimethyl-2,2-diphenylethanamine	Investigative
T32060	DRUGINFO	D01YBD	2-(4-Methyl-piperazin-1-yl)-4-phenyl-pyrimidine	Investigative
T32060	DRUGINFO	D02GNN	N-methyl-3,3-diphenylpropan-1-amine	Investigative
T32060	DRUGINFO	D02SDX	N,N-Dimethyl-3,3-diphenylpropan-1-amine	Investigative
T32060	DRUGINFO	D02XAX	LY86057	Investigative
T32060	DRUGINFO	D03PAH	1-(2-Methoxy-phenyl)-4-propyl-piperazine	Investigative
T32060	DRUGINFO	D03VUU	2-(9,10-dihydroanthracen-9-yl)-N-methylethanamine	Investigative
T32060	DRUGINFO	D03XYG	1-Methyl-1,3-dihydro-indol-2-one	Investigative
T32060	DRUGINFO	D04SCQ	4,4-Diphenylbutan-1-amine	Investigative
T32060	DRUGINFO	D05JIO	(2S)-1-(6-fluoro-1H-indazol-1-yl)propan-2-amine	Investigative
T32060	DRUGINFO	D05RKS	N-methyl-4,4-diphenylbutan-1-amine	Investigative
T32060	DRUGINFO	D05YFZ	9-(2-aminoethyl)-9,10-dihydroanthracene	Investigative
T32060	DRUGINFO	D07CZJ	11-valeryloxynoraporphine	Investigative
T32060	DRUGINFO	D07GBV	3-(1-Phenethyl-piperidin-4-yl)-2-phenyl-1H-indole	Investigative
T32060	DRUGINFO	D07XTU	Racemic DOI	Investigative
T32060	DRUGINFO	D08CZT	2-Phenyl-3-piperidin-4-yl-1H-indole	Investigative
T32060	DRUGINFO	D08FUK	(R,S)-1-(5-methyl-1H-indol-1-yl)propan-2-amine	Investigative
T32060	DRUGINFO	D0A6LB	2-(piperazin-1-yl)-5,6,7,8-tetrahydroquinoline	Investigative
T32060	DRUGINFO	D0B1GJ	11-Propionyloxy-N-n-propylnoraporphine	Investigative
T32060	DRUGINFO	D0I2WQ	11-Heptanoyloxy-N-n-propylnoraporphine	Investigative
T32060	DRUGINFO	D0J2ID	6-chloro-N-(pyridin-3-yl)indoline-1-carboxamide	Investigative
T32060	DRUGINFO	D0J2UA	6-bromoaplysinopsin	Investigative
T32060	DRUGINFO	D0J8RI	(R,S)-1-(5-fluoro-1H-indol-1-yl)propan-2-amine	Investigative
T32060	DRUGINFO	D0KU6D	(R,S)-1-(6-fluoro-1H-indol-1-yl)propan-2-amine	Investigative
T32060	DRUGINFO	D0NM6R	N-3'-ethylaplysinopsin	Investigative
T32060	DRUGINFO	D0Q3OK	(R,S)-1-(5-chloro-1H-indol-1-yl)propan-2-amine	Investigative
T32060	DRUGINFO	D0Q9FU	(S)-1-(5,6-difluoro-1H-indol-1-yl)propan-2-amine	Investigative
T32060	DRUGINFO	D0Q9KP	(2S)-1-(5-fluoro-1H-indazol-1-yl)propan-2-amine	Investigative
T32060	DRUGINFO	D0R5QM	1-Butyl-4-(2-methoxy-phenyl)-piperazine	Investigative
T32060	DRUGINFO	D0R8PL	11-Hexanoyloxy-N-n-propylnoraporphine	Investigative
T32060	DRUGINFO	D0S0WX	9-(2-aminopropyl)-9,10-dihydroanthracene	Investigative
T32060	DRUGINFO	D0S3WR	N,N-dimethyl-4,4-diphenylbutan-1-amine	Investigative
T32060	DRUGINFO	D0U1MN	1-Ethyl-4-(2-methoxy-phenyl)-piperazine	Investigative
T32060	DRUGINFO	D0U7UD	5-chloro-N-(pyridin-3-yl)indoline-1-carboxamide	Investigative
T32060	DRUGINFO	D00APD	3-(2-Dimethylamino-ethyl)-1H-indol-6-ol	Investigative
T32060	DRUGINFO	D00CGJ	2-(4-Bromo-2-methoxy-phenyl)-1-methyl-ethylamine	Investigative
T32060	DRUGINFO	D00EMF	SB 242084	Investigative
T32060	DRUGINFO	D00FUS	2-(2-Methoxy-phenyl)-1-methyl-ethylamine	Investigative
T32060	DRUGINFO	D00GOY	VER-3323	Investigative
T32060	DRUGINFO	D00NSA	5-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline	Investigative
T32060	DRUGINFO	D00QSV	2-(3-Methoxy-phenyl)-1-methyl-ethylamine	Investigative
T32060	DRUGINFO	D00WEQ	Brolamfetamine	Investigative
T32060	DRUGINFO	D00ZCU	BW723C86	Investigative
T32060	DRUGINFO	D01BGW	(2S)-1-(6-methoxy-1H-indazol-1-yl)propan-2-amine	Investigative
T32060	DRUGINFO	D01NTM	VER-5593	Investigative
T32060	DRUGINFO	D01SJL	1-((S)-2-aminopropyl)-7-chloro-1H-indazol-6-ol	Investigative
T32060	DRUGINFO	D02OZB	2-Piperazin-1-yl-phenol	Investigative
T32060	DRUGINFO	D02SAF	1-(2,5-Dimethoxy-phenyl)-piperazine	Investigative
T32060	DRUGINFO	D03DLZ	2-(1H-indol-3-yl)-N,N-dimethylethanamine	Investigative
T32060	DRUGINFO	D04AQE	5-METHOXYTRYPTAMINE	Investigative
T32060	DRUGINFO	D04KGP	(R)-(-)-11-hydroxy-N-n-propylnoraporphine	Investigative
T32060	DRUGINFO	D04YCJ	1-((S)-2-aminopropyl)-7-fluoro-1H-indazol-6-ol	Investigative
T32060	DRUGINFO	D05NWH	SB 228357	Investigative
T32060	DRUGINFO	D05SWY	3-Dimethylaminomethyl-1H-indol-4-ol	Investigative
T32060	DRUGINFO	D06ABJ	[2-(4-Fluoro-1H-indol-3-yl)-ethyl]-dimethyl-amine	Investigative
T32060	DRUGINFO	D06BAC	8-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline	Investigative
T32060	DRUGINFO	D06OJI	2-(2-Amino-propyl)-5-bromo-4-methoxy-phenol	Investigative
T32060	DRUGINFO	D06PKJ	1-(2,5-dimethoxyphenyl)propan-2-amine	Investigative
T32060	DRUGINFO	D07LJH	[125I]DOI	Investigative
T32060	DRUGINFO	D08GJS	3-(2-Dimethylamino-propyl)-1H-indol-4-ol	Investigative
T32060	DRUGINFO	D08HOJ	1,2,3,4-Tetrahydro-naphthalen-2-ylamine	Investigative
T32060	DRUGINFO	D08JCU	(E)-2-(4-fluorostyryl)-5-(phenylsulfinyl)pyridine	Investigative
T32060	DRUGINFO	D08OFG	BARETTIN	Investigative
T32060	DRUGINFO	D09HJL	AL-37350A	Investigative
T32060	DRUGINFO	D09JOE	1-(2,5-Dimethoxy-4-methyl-phenyl)-piperazine	Investigative
T32060	DRUGINFO	D09YVA	8-Methoxy-2-(4-methyl-piperazin-1-yl)-quinoline	Investigative
T32060	DRUGINFO	D0AP6N	1-Butyl-3-(2-dimethylamino-ethyl)-1H-indol-4-ol	Investigative
T32060	DRUGINFO	D0B2GS	3-Amino-1-(2-amino-5-methoxy-phenyl)-propan-1-one	Investigative
T32060	DRUGINFO	D0D3OF	1-(4-Bromo-2,5-dimethoxy-phenyl)-piperazine	Investigative
T32060	DRUGINFO	D0DY5G	SB 221284	Investigative
T32060	DRUGINFO	D0E6NW	VER-5384	Investigative
T32060	DRUGINFO	D0F5WP	1-(2-aminoethyl)-1H-indazol-6-ol	Investigative
T32060	DRUGINFO	D0G2EF	8-Bromo-4,9-dihydro-3H-beta-carboline	Investigative
T32060	DRUGINFO	D0H5XR	YM-348	Investigative
T32060	DRUGINFO	D0I9FI	2-(4-Bromo-phenyl)-1-methyl-ethylamine	Investigative
T32060	DRUGINFO	D0I9RW	1-((S)-2-aminopropyl)-7-iodo-1H-indazol-6-ol	Investigative
T32060	DRUGINFO	D0J3SN	6-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline	Investigative
T32060	DRUGINFO	D0KH5R	SB 215505	Investigative
T32060	DRUGINFO	D0L8ND	5-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline	Investigative
T32060	DRUGINFO	D0M1YU	VER-2692	Investigative
T32060	DRUGINFO	D0N0LZ	3-Naphthalen-1-yl-pyrrolidine	Investigative
T32060	DRUGINFO	D0N7HY	Org 12962	Investigative
T32060	DRUGINFO	D0N8YG	1-((S)-2-aminopropyl)-7-methyl-1H-indazol-6-ol	Investigative
T32060	DRUGINFO	D0O5KK	7,8,9,10-tetrahydro-6H-furo-[2,3-g][3]benzazepine	Investigative
T32060	DRUGINFO	D0Q3VI	8-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline	Investigative
T32060	DRUGINFO	D0R3XC	1,6-bis(4-(pyridin-2-yl)piperazin-1-yl)hexane	Investigative
T32060	DRUGINFO	D0R8VT	3-(2-Dimethylamino-ethyl)-1-methyl-1H-indol-4-ol	Investigative
T32060	DRUGINFO	D0S5ZY	3-Naphthalen-1-yl-1-propyl-pyrrolidine	Investigative
T32060	DRUGINFO	D0T3IH	[3H]N-methylspiperone	Investigative
T32060	DRUGINFO	D0T7RY	6,7-dichloro-2,3,4,5-tetrahydro-1H-3-benzazepine	Investigative
T32060	DRUGINFO	D0T8UR	3-Dimethylaminomethyl-1-methyl-1H-indol-4-ol	Investigative
T32060	DRUGINFO	D0TH8D	8-Methoxy-2-piperazin-1-yl-quinoline	Investigative
T32060	DRUGINFO	D0V5SQ	spiramide	Investigative
T32060	DRUGINFO	D0V6XA	5-Methoxy-4,9-dihydro-3H-beta-carboline	Investigative
T32060	DRUGINFO	D0W7GQ	EGIS-7625	Investigative
T32060	DRUGINFO	D0W8EB	3-(3-Dimethylamino-propyl)-1H-indol-4-ol	Investigative
T32060	DRUGINFO	D0X4RC	PHENYLPIPERAZINE	Investigative
T32060	DRUGINFO	D0XX7J	7,8,9,10-tetrahydro-6H-furo-[3,2-g][3]benzazepine	Investigative
T32060	DRUGINFO	D0Y0SA	1-((R)-2-aminopropyl)-1H-indazol-6-ol	Investigative
T32060	DRUGINFO	D0Y1GL	8-Methoxy-4,9-dihydro-3H-beta-carboline	Investigative
T32060	DRUGINFO	D0YG1E	Etisulergine	Investigative
T32060	DRUGINFO	D0ZZ4Z	3-(2-Pyrrolidin-1-yl-ethyl)-1H-indol-4-ol	Investigative
T32060	DRUGINFO	D00CCV	1,6-bis(4-m-tolylpiperazin-1-yl)hexane	Investigative
T32060	DRUGINFO	D03PIP	1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane	Investigative
T32060	DRUGINFO	D03XKL	1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane	Investigative
T32060	DRUGINFO	D08EFH	2-(5-Methoxy-1H-indol-3-yl)-1-methyl-ethylamine	Investigative
T32060	DRUGINFO	D0C2NK	norfluoxetine	Investigative
T32060	DRUGINFO	D0C5XQ	5-MEO-DMT	Investigative
T32060	DRUGINFO	D0C6BP	1,6-bis(4-phenylpiperazin-1-yl)hexane	Investigative
T32060	DRUGINFO	D0G7NW	cyamemazine	Investigative
T32060	DRUGINFO	D0I4VT	1-Propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine	Investigative
T32060	DRUGINFO	D0S8KA	3-(2-Amino-propyl)-1H-indol-5-ol	Investigative
T32060	DRUGINFO	D0W2YN	1-Naphthalen-2-yl-piperazine	Investigative
T32060	DRUGINFO	D0X4PH	LP-44	Investigative
T32060	DRUGINFO	D0Z1OF	LP-12	Investigative
T32060	DRUGINFO	D01TOU	FLUANISONE	Investigative
T32060	DRUGINFO	D0OG0R	WAY-208466	Investigative
T32060	DRUGINFO	D0P1XQ	SEL-73	Investigative
T32060	DRUGINFO	D0SP2J	bufotenine	Investigative
T32060	DRUGINFO	D03LPH	TRYPTOLINE	Investigative
T32060	DRUGINFO	D05GDP	7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline	Investigative
T32060	DRUGINFO	D07GQP	PG-01037	Investigative
T32060	DRUGINFO	D0C1SE	1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole	Investigative
T32060	DRUGINFO	D0D9YW	SB 216641	Investigative
T32060	DRUGINFO	D0V3XU	CHLOROPHENYLPIPERAZINE	Investigative
T32060	DRUGINFO	D0Y4MC	9-OH-risperidone	Investigative
T32060	DRUGINFO	D08BCF	QUIPAZINE	Investigative
T32060	DRUGINFO	D0C5GF	MPDT	Investigative
T32060	DRUGINFO	D0F5NJ	METHYLENEDIOXYMETHAMPHETAMINE	Investigative
T32060	DRUGINFO	D0I4ME	MMDA	Investigative
T32060	DRUGINFO	D0J6JT	m-chlorophenylpiperazine	Investigative
T32060	DRUGINFO	D0LG8A	1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine	Investigative
T32060	DRUGINFO	D0V4RP	1-(2-Methoxy-phenyl)-piperazine	Investigative
T32060	DRUGINFO	D0Y9TL	5-chloro-3,4-dihydroquinazolin-2-amine	Investigative
T32060	DRUGINFO	D01KAX	1-((S)-2-aminopropyl)-1H-indazol-6-ol	Investigative
T32060	DRUGINFO	D05EQG	[3H]spiperone	Investigative
T32060	DRUGINFO	D08VGJ	5,6-dichloro-3,4-dihydroquinazolin-2-amine	Investigative
T32060	DRUGINFO	D09OYA	alpha-methyl-5-HT	Investigative
T32060	DRUGINFO	D03TDN	1-naphthylpiperazine	Investigative
T32060	DRUGINFO	D04TVG	BRL-15572	Investigative
T32060	DRUGINFO	D07LRJ	SB-271046	Investigative
T32060	DRUGINFO	D02UWB	5-CT	Investigative
T32060	DRUGINFO	D0V5HV	TFMPP	Investigative
T32060	DRUGINFO	D0F6CD	SEROTONIN	Investigative
T32060	DRUGINFO	D0F9QT	A-987306	Investigative
T32060	DRUGINFO	D0P0IX	ISOCLOZAPINE	Investigative
T32060	DRUGINFO	D0L5MW	(+/-)-nantenine	Investigative
T32060	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T83813	TARGETID	T83813
T83813	FORMERID	TTDS00105
T83813	UNIPROID	5HT2C_HUMAN
T83813	TARGNAME	5-HT 2C receptor (HTR2C)
T83813	GENENAME	HTR2C
T83813	TARGTYPE	Successful
T83813	SYNONYMS	Serotonin receptor 2C; HTR1C; 5HT-1C; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 1C; 5-HTR2C; 5-HT2C receptor; 5-HT2C; 5-HT1C; 5-HT-2C; 5-HT-1C
T83813	FUNCTION	Functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and down-stream signaling cascades and promotes the release of Ca(2+) ions from intracellular stores. Regulates neuronal activity via the activation of short transient receptor potential calcium channels in the brain, and thereby modulates the activation of pro-opiomelacortin neurons and the release of CRH that then regulates the release of corticosterone. Plays a role in the regulation of appetite and eating behavior, responses to anxiogenic stimuli and stress. Plays a role in insulin sensitivity and glucose homeostasis. G-protein coupled receptor for 5-hydroxytryptamine (serotonin).
T83813	PDBSTRUC	6BQH; 6BQG
T83813	BIOCLASS	GPCR rhodopsin
T83813	SEQUENCE	MVNLRNAVHSFLVHLIGLLVWQCDISVSPVAAIVTDIFNTSDGGRFKFPDGVQNWPALSIVIIIIMTIGGNILVIMAVSMEKKLHNATNYFLMSLAIADMLVGLLVMPLSLLAILYDYVWPLPRYLCPVWISLDVLFSTASIMHLCAISLDRYVAIRNPIEHSRFNSRTKAIMKIAIVWAISIGVSVPIPVIGLRDEEKVFVNNTTCVLNDPNFVLIGSFVAFFIPLTIMVITYCLTIYVLRRQALMLLHGHTEEPPGLSLDFLKCCKRNTAEEENSANPNQDQNARRRKKKERRPRGTMQAINNERKASKVLGIVFFVFLIMWCPFFITNILSVLCEKSCNQKLMEKLLNVFVWIGYVCSGINPLVYTLFNKIYRRAFSNYLRCNYKVEKKPPVRQIPRVAATALSGRELNVNIYRHTNEPVIEKASDNEPGIEMQVENLELPVNPSSVVSERISSV
T83813	DRUGINFO	D01JMC	Lorcaserin	Approved
T83813	DRUGINFO	D05GKD	Tramadol	Approved
T83813	DRUGINFO	D05ZIK	Mirtazapine	Approved
T83813	DRUGINFO	D0O6GC	Methysergide	Approved
T83813	DRUGINFO	D0X7DE	Nefazodone	Approved
T83813	DRUGINFO	D0UA0I	Metergolin	Approved
T83813	DRUGINFO	D04PLI	SR46349B	Phase 3
T83813	DRUGINFO	D06FKC	Eltoprazine	Phase 3
T83813	DRUGINFO	D0HZ2E	M100907	Phase 3
T83813	DRUGINFO	D03TYJ	ATHX-105	Phase 2
T83813	DRUGINFO	D08QHX	PRX00933	Phase 2
T83813	DRUGINFO	D0I7MT	Puerarin	Phase 2
T83813	DRUGINFO	D02BRJ	Vabicaserin	Phase 2
T83813	DRUGINFO	DDI6B0	Nuplazid	Phase 2
T83813	DRUGINFO	D01XUE	Tedatioxetine	Phase 1
T83813	DRUGINFO	D00DFK	Heteroaryl-azepine derivative 10	Patented
T83813	DRUGINFO	D00YRD	Heteroaryl-azepine derivative 7	Patented
T83813	DRUGINFO	D01PAP	PMID26609882-Compound-83	Patented
T83813	DRUGINFO	D03IZY	Benzazepine derivative 4	Patented
T83813	DRUGINFO	D06VJM	Heteroaryl-azepine derivative 14	Patented
T83813	DRUGINFO	D06YCW	PMID26609882-Compound-58	Patented
T83813	DRUGINFO	D07KZR	Heteroaryl-azepine derivative 2	Patented
T83813	DRUGINFO	D09EPG	Heteroaryl-azepine derivative 12	Patented
T83813	DRUGINFO	D0A5FR	Benzazepine derivative 1	Patented
T83813	DRUGINFO	D0AA9F	Tricyclic pyrrolidine derivative 3	Patented
T83813	DRUGINFO	D0AI8S	Heteroaryl-azepine derivative 1	Patented
T83813	DRUGINFO	D0AJ0O	Heteroaryl-azepine derivative 5	Patented
T83813	DRUGINFO	D0AV8R	Tricyclic pyrrolidine derivative 2	Patented
T83813	DRUGINFO	D0BD3M	Heteroaryl-azepine derivative 4	Patented
T83813	DRUGINFO	D0FK0Y	Heteroaryl-azepine derivative 8	Patented
T83813	DRUGINFO	D0FS3J	Heteroaryl-azepine derivative 15	Patented
T83813	DRUGINFO	D0GW5F	Benzazepine derivative 5	Patented
T83813	DRUGINFO	D0HV0D	Aryl piperazine derivative 10	Patented
T83813	DRUGINFO	D0I3QY	Benzazepine derivative 6	Patented
T83813	DRUGINFO	D0KO2E	Heteroaryl-azepine derivative 11	Patented
T83813	DRUGINFO	D0L4UC	Benzazepine derivative 3	Patented
T83813	DRUGINFO	D0MQ7F	Heteroaryl-azepine derivative 13	Patented
T83813	DRUGINFO	D0OA6W	Aryl piperazine derivative 8	Patented
T83813	DRUGINFO	D0R6EF	Heteroaryl-azepine derivative 9	Patented
T83813	DRUGINFO	D0SO0F	Tricyclic pyrrolidine derivative 1	Patented
T83813	DRUGINFO	D0T5ER	Benzazepine derivative 2	Patented
T83813	DRUGINFO	D0UL9W	Heteroaryl-azepine derivative 3	Patented
T83813	DRUGINFO	D0WR7F	Chromene derivative 1	Patented
T83813	DRUGINFO	D0WS6Y	Tricyclic pyrrolidine derivative 4	Patented
T83813	DRUGINFO	D0YO2O	Heteroaryl-azepine derivative 6	Patented
T83813	DRUGINFO	D01LVT	Quinoline derivative 2	Patented
T83813	DRUGINFO	D0BU6K	Aryl piperazine derivative 9	Patented
T83813	DRUGINFO	D00YGY	Pyrimidine derivative 29	Patented
T83813	DRUGINFO	D08DJY	Pyrimidine derivative 26	Patented
T83813	DRUGINFO	D0B7NS	Pyrimidine derivative 23	Patented
T83813	DRUGINFO	D0N2VA	Pyrimidine derivative 25	Patented
T83813	DRUGINFO	D0P9VX	Pyrimidine derivative 27	Patented
T83813	DRUGINFO	D0SE9K	Pyrimidine derivative 28	Patented
T83813	DRUGINFO	D0U9UH	Pyrimidine derivative 24	Patented
T83813	DRUGINFO	D0E6UA	Deramciclane	Discontinued in Phase 3
T83813	DRUGINFO	D0K8NW	Ritanserin	Discontinued in Phase 3
T83813	DRUGINFO	D0S5FQ	MCPP	Discontinued in Phase 2
T83813	DRUGINFO	D04DGE	SB-247853	Discontinued in Phase 1
T83813	DRUGINFO	D0I5LM	R-1065	Discontinued in Phase 1
T83813	DRUGINFO	D0U5EY	Org-37684	Terminated
T83813	DRUGINFO	D0Z4QC	SDZ-SER-082	Terminated
T83813	DRUGINFO	D05KHN	ICI-169369	Terminated
T83813	DRUGINFO	D0B4BN	Ro-60-0175	Terminated
T83813	DRUGINFO	D0PA6K	LY53857	Terminated
T83813	DRUGINFO	D00BWZ	N-(pyridin-3-yl)indoline-1-carboxamide	Investigative
T83813	DRUGINFO	D00DHV	4-(piperazin-1-yl)thieno[3,2-d]pyrimidine	Investigative
T83813	DRUGINFO	D00OBS	Cyclo[(6-bromotryptophan)arginine]	Investigative
T83813	DRUGINFO	D01FOM	4-(piperazin-1-yl)thieno[2,3-d]pyrimidine	Investigative
T83813	DRUGINFO	D02ESW	MK-212	Investigative
T83813	DRUGINFO	D02YNH	CP-809101	Investigative
T83813	DRUGINFO	D03MHA	FR260010	Investigative
T83813	DRUGINFO	D03NKE	6-bromo-2'-de-N-methylaplysinopsin	Investigative
T83813	DRUGINFO	D04VXP	4-(piperazin-1-yl)furo[3,2-c]pyridine	Investigative
T83813	DRUGINFO	D05FKE	6-(piperazin-1-yl)-9-propyl-9H-purine	Investigative
T83813	DRUGINFO	D05RKH	6-methyl-4-(piperazin-1-yl)furo[2,3-d]pyrimidine	Investigative
T83813	DRUGINFO	D06VDN	SB 243213	Investigative
T83813	DRUGINFO	D07DQO	N-(6-phenoxypyridin-3-yl)-1H-indole-3-carboxamide	Investigative
T83813	DRUGINFO	D07LHD	1-(2-Dimethylamino-ethyl)-1H-indol-4-ol	Investigative
T83813	DRUGINFO	D08YZM	4-(piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine	Investigative
T83813	DRUGINFO	D0A2GI	LY334362	Investigative
T83813	DRUGINFO	D0J1VB	4-(piperazin-1-yl)thieno[3,2-c]pyridine	Investigative
T83813	DRUGINFO	D0KV4G	1-(piperazin-1-yl)isoquinoline	Investigative
T83813	DRUGINFO	D0Q4AQ	6-bromo-8-(piperazin-1-yl)imidazo[1,2-a]pyrazine	Investigative
T83813	DRUGINFO	D0SZ8Q	CSC-500297	Investigative
T83813	DRUGINFO	D0U3EA	BVT 933	Investigative
T83813	DRUGINFO	D0U9HE	RS-102,221	Investigative
T83813	DRUGINFO	D0W6RV	WAY-163909	Investigative
T83813	DRUGINFO	D00AVR	Aplysinopsin	Investigative
T83813	DRUGINFO	D00LXH	(R,S)-1-(5-bromo-1H-indol-1-yl)propan-2-amine	Investigative
T83813	DRUGINFO	D00NST	(2S)-1-(1H-furo[2,3-g]indazol-1-yl)propan-2-amine	Investigative
T83813	DRUGINFO	D00OCV	3-(2-Dimethylamino-ethyl)-2-methyl-1H-indol-4-ol	Investigative
T83813	DRUGINFO	D04AZE	SB 204741	Investigative
T83813	DRUGINFO	D05JIO	(2S)-1-(6-fluoro-1H-indazol-1-yl)propan-2-amine	Investigative
T83813	DRUGINFO	D08FUK	(R,S)-1-(5-methyl-1H-indol-1-yl)propan-2-amine	Investigative
T83813	DRUGINFO	D0A6LB	2-(piperazin-1-yl)-5,6,7,8-tetrahydroquinoline	Investigative
T83813	DRUGINFO	D0J2ID	6-chloro-N-(pyridin-3-yl)indoline-1-carboxamide	Investigative
T83813	DRUGINFO	D0J2UA	6-bromoaplysinopsin	Investigative
T83813	DRUGINFO	D0J8RI	(R,S)-1-(5-fluoro-1H-indol-1-yl)propan-2-amine	Investigative
T83813	DRUGINFO	D0KU6D	(R,S)-1-(6-fluoro-1H-indol-1-yl)propan-2-amine	Investigative
T83813	DRUGINFO	D0NM6R	N-3'-ethylaplysinopsin	Investigative
T83813	DRUGINFO	D0Q3OK	(R,S)-1-(5-chloro-1H-indol-1-yl)propan-2-amine	Investigative
T83813	DRUGINFO	D0Q9FU	(S)-1-(5,6-difluoro-1H-indol-1-yl)propan-2-amine	Investigative
T83813	DRUGINFO	D0Q9KP	(2S)-1-(5-fluoro-1H-indazol-1-yl)propan-2-amine	Investigative
T83813	DRUGINFO	D0U7UD	5-chloro-N-(pyridin-3-yl)indoline-1-carboxamide	Investigative
T83813	DRUGINFO	D0U8OK	[3H]mesulergine	Investigative
T83813	DRUGINFO	D00APD	3-(2-Dimethylamino-ethyl)-1H-indol-6-ol	Investigative
T83813	DRUGINFO	D00EMF	SB 242084	Investigative
T83813	DRUGINFO	D00GOY	VER-3323	Investigative
T83813	DRUGINFO	D00ZCU	BW723C86	Investigative
T83813	DRUGINFO	D01BGW	(2S)-1-(6-methoxy-1H-indazol-1-yl)propan-2-amine	Investigative
T83813	DRUGINFO	D01NTM	VER-5593	Investigative
T83813	DRUGINFO	D01SJL	1-((S)-2-aminopropyl)-7-chloro-1H-indazol-6-ol	Investigative
T83813	DRUGINFO	D04YCJ	1-((S)-2-aminopropyl)-7-fluoro-1H-indazol-6-ol	Investigative
T83813	DRUGINFO	D05NWH	SB 228357	Investigative
T83813	DRUGINFO	D05SWY	3-Dimethylaminomethyl-1H-indol-4-ol	Investigative
T83813	DRUGINFO	D06ABJ	[2-(4-Fluoro-1H-indol-3-yl)-ethyl]-dimethyl-amine	Investigative
T83813	DRUGINFO	D07LJH	[125I]DOI	Investigative
T83813	DRUGINFO	D08GJS	3-(2-Dimethylamino-propyl)-1H-indol-4-ol	Investigative
T83813	DRUGINFO	D08JCU	(E)-2-(4-fluorostyryl)-5-(phenylsulfinyl)pyridine	Investigative
T83813	DRUGINFO	D08OFG	BARETTIN	Investigative
T83813	DRUGINFO	D08YCS	TQ-1017	Investigative
T83813	DRUGINFO	D09HJL	AL-37350A	Investigative
T83813	DRUGINFO	D0AP6N	1-Butyl-3-(2-dimethylamino-ethyl)-1H-indol-4-ol	Investigative
T83813	DRUGINFO	D0DY5G	SB 221284	Investigative
T83813	DRUGINFO	D0E6NW	VER-5384	Investigative
T83813	DRUGINFO	D0F5WP	1-(2-aminoethyl)-1H-indazol-6-ol	Investigative
T83813	DRUGINFO	D0H5XR	YM-348	Investigative
T83813	DRUGINFO	D0I9RW	1-((S)-2-aminopropyl)-7-iodo-1H-indazol-6-ol	Investigative
T83813	DRUGINFO	D0KH5R	SB 215505	Investigative
T83813	DRUGINFO	D0M1YU	VER-2692	Investigative
T83813	DRUGINFO	D0N7HY	Org 12962	Investigative
T83813	DRUGINFO	D0N8YG	1-((S)-2-aminopropyl)-7-methyl-1H-indazol-6-ol	Investigative
T83813	DRUGINFO	D0O5KK	7,8,9,10-tetrahydro-6H-furo-[2,3-g][3]benzazepine	Investigative
T83813	DRUGINFO	D0R8VT	3-(2-Dimethylamino-ethyl)-1-methyl-1H-indol-4-ol	Investigative
T83813	DRUGINFO	D0T7RY	6,7-dichloro-2,3,4,5-tetrahydro-1H-3-benzazepine	Investigative
T83813	DRUGINFO	D0T8UR	3-Dimethylaminomethyl-1-methyl-1H-indol-4-ol	Investigative
T83813	DRUGINFO	D0V5SQ	spiramide	Investigative
T83813	DRUGINFO	D0W7GQ	EGIS-7625	Investigative
T83813	DRUGINFO	D0W8EB	3-(3-Dimethylamino-propyl)-1H-indol-4-ol	Investigative
T83813	DRUGINFO	D0XX7J	7,8,9,10-tetrahydro-6H-furo-[3,2-g][3]benzazepine	Investigative
T83813	DRUGINFO	D0Y0SA	1-((R)-2-aminopropyl)-1H-indazol-6-ol	Investigative
T83813	DRUGINFO	D0ZZ4Z	3-(2-Pyrrolidin-1-yl-ethyl)-1H-indol-4-ol	Investigative
T83813	DRUGINFO	D03ZHB	5-chloro-4-ethyl-3,4-dihydroquinazolin-2-amine	Investigative
T83813	DRUGINFO	D07HQZ	[3H]LSD	Investigative
T83813	DRUGINFO	D08EFH	2-(5-Methoxy-1H-indol-3-yl)-1-methyl-ethylamine	Investigative
T83813	DRUGINFO	D0C2NK	norfluoxetine	Investigative
T83813	DRUGINFO	D0C5XQ	5-MEO-DMT	Investigative
T83813	DRUGINFO	D0G7NW	cyamemazine	Investigative
T83813	DRUGINFO	D0S8KA	3-(2-Amino-propyl)-1H-indol-5-ol	Investigative
T83813	DRUGINFO	D04TPO	5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine	Investigative
T83813	DRUGINFO	D0OG0R	WAY-208466	Investigative
T83813	DRUGINFO	D0XX2U	8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine	Investigative
T83813	DRUGINFO	D07GQP	PG-01037	Investigative
T83813	DRUGINFO	D0D9YW	SB 216641	Investigative
T83813	DRUGINFO	D0V3XU	CHLOROPHENYLPIPERAZINE	Investigative
T83813	DRUGINFO	D06VPR	WAY-466	Investigative
T83813	DRUGINFO	D0C5GF	MPDT	Investigative
T83813	DRUGINFO	D0D3YN	OCTOCLOTHEPIN	Investigative
T83813	DRUGINFO	D0F5NJ	METHYLENEDIOXYMETHAMPHETAMINE	Investigative
T83813	DRUGINFO	D0J6JT	m-chlorophenylpiperazine	Investigative
T83813	DRUGINFO	D0Y9TL	5-chloro-3,4-dihydroquinazolin-2-amine	Investigative
T83813	DRUGINFO	D01KAX	1-((S)-2-aminopropyl)-1H-indazol-6-ol	Investigative
T83813	DRUGINFO	D08VGJ	5,6-dichloro-3,4-dihydroquinazolin-2-amine	Investigative
T83813	DRUGINFO	D09OYA	alpha-methyl-5-HT	Investigative
T83813	DRUGINFO	D04TVG	BRL-15572	Investigative
T83813	DRUGINFO	D07LRJ	SB-271046	Investigative
T83813	DRUGINFO	D02UWB	5-CT	Investigative
T83813	DRUGINFO	D0V5HV	TFMPP	Investigative
T83813	DRUGINFO	D0F6CD	SEROTONIN	Investigative
T83813	DRUGINFO	D0L5MW	(+/-)-nantenine	Investigative
T83813	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T10877	TARGETID	T10877
T10877	FORMERID	TTDNC00424
T10877	UNIPROID	CD38_HUMAN
T10877	TARGNAME	Cyclic ADP-ribose hydrolase 1 (CD38)
T10877	GENENAME	CD38
T10877	TARGTYPE	Successful
T10877	SYNONYMS	cADPr hydrolase 1; T10; Cyclic ADPribose hydrolase 1; ADPribosyl cyclase 1; ADPRC 1; ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1; ADP-ribosyl cyclase 1; 2'-phospho-cyclic-ADP-ribose transferase; 2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase; 2'-phospho-ADP-ribosyl cyclase
T10877	FUNCTION	Has cADPr hydrolase activity. Also moonlights as a receptor in cells of the immune system. Synthesizes the second messagers cyclic ADP-ribose and nicotinate-adenine dinucleotide phosphate, the former a second messenger for glucose-induced insulin secretion.
T10877	PDBSTRUC	6EDR; 5F21; 5F1O; 5F1K; 4XJT
T10877	BIOCLASS	Glycosylase
T10877	ECNUMBER	EC 3.2.2.6
T10877	SEQUENCE	MANCEFSPVSGDKPCCRLSRRAQLCLGVSILVLILVVVLAVVVPRWRQQWSGPGTTKRFPETVLARCVKYTEIHPEMRHVDCQSVWDAFKGAFISKHPCNITEEDYQPLMKLGTQTVPCNKILLWSRIKDLAHQFTQVQRDMFTLEDTLLGYLADDLTWCGEFNTSKINYQSCPDWRKDCSNNPVSVFWKTVSRRFAEAACDVVHVMLNGSRSKIFDKNSTFGSVEVHNLQPEKVQTLEAWVIHGGREDSRDLCQDPTIKELESIISKRNIQFSCKNIYRPDKFLQCVKNPEDSSCTSEI
T10877	DRUGINFO	D0RV4P	Daratumumab	Approved
T10877	DRUGINFO	D54QKH	Mezagitamab	Phase 2
T10877	DRUGINFO	D09UFZ	CD38 CAR T cells	Phase 1/2
T10877	DRUGINFO	D0M8EF	CD38 CAR-T Cell	Phase 1/2
T10877	DRUGINFO	D0NS1X	SAR-650984	Phase 1/2
T10877	DRUGINFO	D0O4IN	MOR-202	Phase 1/2
T10877	DRUGINFO	D0OO1S	Anti-CD38 CAR-T cells	Phase 1/2
T10877	DRUGINFO	D0UJ3C	CD38-specific gene-engineered T cells	Phase 1/2
T10877	DRUGINFO	D0G0PI	CD38 and BCMA CAR-T Cells	Phase 1/2
T10877	DRUGINFO	D0I4HG	4SCAR19 and 4SCAR38	Phase 1/2
T10877	DRUGINFO	DE0L6O	ISB 1342	Phase 1/2
T10877	DRUGINFO	D05WET	Anti-CD38 CAR-T cells	Phase 1
T10877	DRUGINFO	D06OES	CART-38 cells	Phase 1
T10877	DRUGINFO	D0GP9M	SAR444559	Phase 1
T10877	DRUGINFO	D0ZDP2	TAK-573	Phase 1
T10877	DRUGINFO	D2HE9I	TAK-169	Phase 1
T10877	DRUGINFO	D5VE7C	SAR442085	Phase 1
T10877	DRUGINFO	DECJ17	KP1237	Phase 1
T10877	DRUGINFO	DK1PA2	225Ac-labelled aCD38	Phase 1
T10877	DRUGINFO	DSWZ60	CD38 CAR-T	Phase 1
T10877	DRUGINFO	DLY65X	AMG 424	Phase 1
T10877	DRUGINFO	DBP9Q5	SAR442257	Phase 1
T10877	DRUGINFO	D0V6WU	CAR-T cells targeting CD38	Clinical trial
T10877	DRUGINFO	D0N1QH	HuMax-CD38b	Investigative

T77365	TARGETID	T77365
T77365	FORMERID	TTDS00187
T77365	UNIPROID	AA2AR_HUMAN
T77365	TARGNAME	Adenosine A2a receptor (ADORA2A)
T77365	GENENAME	ADORA2A
T77365	TARGTYPE	Successful
T77365	SYNONYMS	Adenosine receptor A2a; ADORA2; A2a Adenosine receptor; A(2A) adenosine receptor
T77365	FUNCTION	The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. Receptor for adenosine.
T77365	PDBSTRUC	6MH8; 6GDG; 6AQF; 5WF6; 5WF5
T77365	BIOCLASS	GPCR rhodopsin
T77365	SEQUENCE	MPIMGSSVYITVELAIAVLAILGNVLVCWAVWLNSNLQNVTNYFVVSLAAADIAVGVLAIPFAITISTGFCAACHGCLFIACFVLVLTQSSIFSLLAIAIDRYIAIRIPLRYNGLVTGTRAKGIIAICWVLSFAIGLTPMLGWNNCGQPKEGKNHSQGCGEGQVACLFEDVVPMNYMVYFNFFACVLVPLLLMLGVYLRIFLAARRQLKQMESQPLPGERARSTLQKEVHAAKSLAIIVGLFALCWLPLHIINCFTFFCPDCSHAPLWLMYLAIVLSHTNSVVNPFIYAYRIREFRQTFRKIIRSHVLRQQEPFKAAGTSARVLAAHGSDGEQVSLRLNGHPPGVWANGSAPHPERRPNGYALGLVSGGSAQESQGNTGLPDVELLSHELKGVCPEPPGLDDPLAQDGAGVS
T77365	DRUGINFO	D0F4ZY	Istradefylline	Approved
T77365	DRUGINFO	D0XE1C	Regadenoson	Approved
T77365	DRUGINFO	D0B3HD	Caffeine	Approved
T77365	DRUGINFO	D03OQI	Tozadenant	Phase 3
T77365	DRUGINFO	D08TJM	Binodenoson	Phase 3
T77365	DRUGINFO	D0QG9A	Apadenoson	Phase 3
T77365	DRUGINFO	D06MIQ	MRE-0094	Phase 2
T77365	DRUGINFO	D07TEP	SCH 420814	Phase 2
T77365	DRUGINFO	D0D5VJ	UK-432097	Phase 2
T77365	DRUGINFO	D0J4XV	AZD4635	Phase 2
T77365	DRUGINFO	D0Z3PO	BIIB014	Phase 2
T77365	DRUGINFO	D03QWO	Dexefaroxan	Phase 2
T77365	DRUGINFO	D0QH7H	AMP-579	Phase 2
T77365	DRUGINFO	D00SUK	Tonapofylline	Phase 2
T77365	DRUGINFO	D04AEQ	V81444	Phase 1/2
T77365	DRUGINFO	D08FHZ	ATL-313	Phase 1/2
T77365	DRUGINFO	D0E4IB	PBF509	Phase 1/2
T77365	DRUGINFO	D0J6NG	OPA-6566	Phase 1/2
T77365	DRUGINFO	D04UBI	AB928	Phase 1/2
T77365	DRUGINFO	D00OAU	GW-328267	Phase 1
T77365	DRUGINFO	DS2J7Q	EOS100850	Phase 1
T77365	DRUGINFO	DJ0P6A	PBF-999	Phase 1
T77365	DRUGINFO	D02YQO	SCH-442416	Phase 1
T77365	DRUGINFO	D0L5VS	KF-17837	Phase 1
T77365	DRUGINFO	D07ESH	PF-1913539	Discontinued in Phase 3
T77365	DRUGINFO	D09NEE	BVT-115959	Discontinued in Phase 2
T77365	DRUGINFO	D0L3YX	T-62	Discontinued in Phase 1
T77365	DRUGINFO	D0LJ0L	Lu-AA47070	Discontinued in Phase 1
T77365	DRUGINFO	D0I7BL	ARISTEROMYCIN	Terminated
T77365	DRUGINFO	D0NQ5I	METRIFUDIL	Terminated
T77365	DRUGINFO	D0Y6GJ	ZM-241385	Terminated
T77365	DRUGINFO	D0E4WF	METHYLTHIOADENOSINE	Terminated
T77365	DRUGINFO	D01RPD	(E,E)-8-(4-Phenylbutadien-1-yl)caffeine	Investigative
T77365	DRUGINFO	D01VJT	1-amino-2,4-bis(phenylthio)anthracene-9,10-dione	Investigative
T77365	DRUGINFO	D01XFR	7-Allyl-1,3-dipropyl-3,7-dihydro-purine-2,6-dione	Investigative
T77365	DRUGINFO	D01XGG	N-(7-methoxy-4-phenylbenzofuran-2-yl)acetamide	Investigative
T77365	DRUGINFO	D02XMQ	1-amino-4-methoxyanthracene-9,10-dione	Investigative
T77365	DRUGINFO	D02XPR	(S)-DHPA	Investigative
T77365	DRUGINFO	D03LJX	(3-amino-5-bromobenzofuran-2-yl)(phenyl)methanone	Investigative
T77365	DRUGINFO	D04JDQ	6-Furan-2-yl-9-phenethyl-9H-purin-2-ylamine	Investigative
T77365	DRUGINFO	D04WBU	1-Ethyl-3-methyl-3,7-dihydro-purine-2,6-dione	Investigative
T77365	DRUGINFO	D04WCH	1,3,7-Tripropyl-3,7-dihydro-purine-2,6-dione	Investigative
T77365	DRUGINFO	D04YUM	9-Butyl-9H-adenine	Investigative
T77365	DRUGINFO	D05OUG	1-amino-2-phenoxyanthracene-9,10-dione	Investigative
T77365	DRUGINFO	D06ETD	LUF-5437	Investigative
T77365	DRUGINFO	D06PYV	2-amino-3-(m-tolylamino)naphthalene-1,4-dione	Investigative
T77365	DRUGINFO	D06YJN	1,3-Diallyl-7-methyl-3,7-dihydro-purine-2,6-dione	Investigative
T77365	DRUGINFO	D06ZLL	(E,E)-8-[4-(3-Bromophenyl)butadien-1-yl]caffeine	Investigative
T77365	DRUGINFO	D07ETD	N6-(4-hydroxybenzyl)adenine riboside	Investigative
T77365	DRUGINFO	D08DPH	(E,E)-8-[4-(3-Chlorophenyl)butadien-1-yl]caffeine	Investigative
T77365	DRUGINFO	D08GLJ	1,3,8-Trimethyl-3,7-dihydro-purine-2,6-dione	Investigative
T77365	DRUGINFO	D08SJF	5-Azido-6-benzyl-2-methyl-[1,8]naphthyridine	Investigative
T77365	DRUGINFO	D08ZOV	Methyl 7-methoxy-4-phenylbenzofuran-2-ylcarbamate	Investigative
T77365	DRUGINFO	D0A0VT	7-Propyl-7H-adenine	Investigative
T77365	DRUGINFO	D0C1PS	9-(3-Hydroxypropyl)-9H-adenine	Investigative
T77365	DRUGINFO	D0C8ON	1-aminoanthracene-9,10-dione	Investigative
T77365	DRUGINFO	D0E2FV	9-Phenylethyl-9H-adenine	Investigative
T77365	DRUGINFO	D0E4UT	9-But-3-enyl-9H-adenine	Investigative
T77365	DRUGINFO	D0G5NE	(Z)-8-(3-chlorostyryl)caffeine	Investigative
T77365	DRUGINFO	D0H0AO	Phenyl 7-methoxy-4-phenylbenzofuran-2-ylcarbamate	Investigative
T77365	DRUGINFO	D0H5HP	1-amino-4-chloroanthracene-9,10-dione	Investigative
T77365	DRUGINFO	D0J6PQ	6-Furan-2-yl-9-phenyl-9H-purin-2-ylamine	Investigative
T77365	DRUGINFO	D0K1UA	1-Allyl-3,7-dimethyl-3,7-dihydro-purine-2,6-dione	Investigative
T77365	DRUGINFO	D0L4WN	1,4-diaminoanthracene-9,10-dione	Investigative
T77365	DRUGINFO	D0LM1Q	1,3-Dibenzyl-3,7-dihydro-purine-2,6-dione	Investigative
T77365	DRUGINFO	D0M7AX	3-Isopropyl-1-methyl-3,7-dihydro-purine-2,6-dione	Investigative
T77365	DRUGINFO	D0MG3U	(E,E)-8-[4-(3-Fluorophenyl)butadien-1-yl]caffeine	Investigative
T77365	DRUGINFO	D0N5IE	1-Phenyl-3-(4-pyridin-2-yl-thiazol-2-yl)-urea	Investigative
T77365	DRUGINFO	D0N8RM	9-(2-Hydroxyethyl)-9H-adenine	Investigative
T77365	DRUGINFO	D0O6NS	8-Br-adenine	Investigative
T77365	DRUGINFO	D0OR5V	9-Cyclopropyl-9H-adenine	Investigative
T77365	DRUGINFO	D0P7MU	N-(4-Pyridin-2-yl-thiazol-2-yl)-benzamide	Investigative
T77365	DRUGINFO	D0Q6KO	9-(2-Hydroxypropyl)-9H-adenine	Investigative
T77365	DRUGINFO	D0RZ5U	7-Allyl-1,3-dimethyl-3,7-dihydro-purine-2,6-dione	Investigative
T77365	DRUGINFO	D0S4JI	9-BENZYL-9H-ADENINE	Investigative
T77365	DRUGINFO	D0V7MX	9-Cycloheptyl-9H-adenine	Investigative
T77365	DRUGINFO	D0W4HJ	MSX-3	Investigative
T77365	DRUGINFO	D0YE5K	N-(3-Phenyl-[1,2,4]thiadiazol-5-yl)-benzamide	Investigative
T77365	DRUGINFO	D0Z2QM	7-Isopropyl-7H-adenine	Investigative
T77365	DRUGINFO	D0ZD4M	4-amino-2-p-tolylisoindoline-1,3-dione	Investigative
T77365	DRUGINFO	D00CJJ	8-Bromo-9-phenylethyl-9H-adenine	Investigative
T77365	DRUGINFO	D00HYS	2-Amino-4,6-diphenyl-pyrimidin-5-carbonitrile	Investigative
T77365	DRUGINFO	D00MFV	9-(sec-Butyl)-9H-adenine	Investigative
T77365	DRUGINFO	D00MPA	6-(furan-2-yl)-9H-purin-2-amine	Investigative
T77365	DRUGINFO	D00NYG	4-Amino-2,6-diphenyl-pyrimidine-5-carbonitrile	Investigative
T77365	DRUGINFO	D00OFN	4-(ethylthio)-6-phenyl-1,3,5-triazin-2-amine	Investigative
T77365	DRUGINFO	D00YOM	3-Benzyl-7-methyl-[1,8]naphthyridin-4-ol	Investigative
T77365	DRUGINFO	D02BGA	9-Methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine	Investigative
T77365	DRUGINFO	D02NBB	9-(3-nitrobenzyl)-6-(furan-2-yl)-9H-purin-2-amine	Investigative
T77365	DRUGINFO	D02RBK	9-Benzyl-8-bromo-9H-adenine	Investigative
T77365	DRUGINFO	D02TEW	2-p-tolyl-2H-pyrazolo[3,4-c]quinolin-4-amine	Investigative
T77365	DRUGINFO	D03JFX	9-Ethyl-9H-adenine	Investigative
T77365	DRUGINFO	D04AGC	Phenyl(2-(trifluoromethyl)quinolin-4-yl)methanol	Investigative
T77365	DRUGINFO	D04JIR	9-Methyl-9H-adenine	Investigative
T77365	DRUGINFO	D04MMG	N6-[(4-Nitro)-phenyl]-9-benzyl-2-phenyladenine	Investigative
T77365	DRUGINFO	D04PJO	2-m-tolyl-2H-pyrazolo[3,4-c]quinolin-4-amine	Investigative
T77365	DRUGINFO	D04XLX	2-amino-N-benzyl-6-phenyl-9H-purine-9-carboxamide	Investigative
T77365	DRUGINFO	D04ZTH	2-Amino-4,6-di-thiophen-2-yl-nicotinonitrile	Investigative
T77365	DRUGINFO	D05TFM	2-ethyl-4-(furan-2-yl)thieno[3,2-d]pyrimidine	Investigative
T77365	DRUGINFO	D05ZRR	9-(3-aminobenzyl)-6-(furan-2-yl)-9H-purin-2-amine	Investigative
T77365	DRUGINFO	D06NQD	2-amino-6-phenyl-4-p-tolylnicotinonitrile	Investigative
T77365	DRUGINFO	D07HVJ	2-(3''-(benzoimidazole-1''-yl)ethyloxy)adenosine	Investigative
T77365	DRUGINFO	D07YKU	2-ethyl-4-(thiophen-2-yl)thieno[3,2-d]pyrimidine	Investigative
T77365	DRUGINFO	D08AXT	9-(4-nitrobenzyl)-6-(furan-2-yl)-9H-purin-2-amine	Investigative
T77365	DRUGINFO	D08CIY	2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-amine	Investigative
T77365	DRUGINFO	D08INY	2,6-Diphenyl-pyrimidin-4-ylamine	Investigative
T77365	DRUGINFO	D08RGW	3-Benzyl-7-methyl-[1,8]naphthyridine-4-thiol	Investigative
T77365	DRUGINFO	D09HAM	2-phenyl-2H-pyrazolo[3,4-c]quinolin-4-amine	Investigative
T77365	DRUGINFO	D09UDF	2-chloro-4-(thiophen-2-yl)thieno[3,2-d]pyrimidine	Investigative
T77365	DRUGINFO	D0BA7Q	1-Methyl-8-phenyl-3,7-dihydro-purine-2,6-dione	Investigative
T77365	DRUGINFO	D0BC7P	2-Amino-6-phenyl-4-thiophen-2-yl-nicotinonitrile	Investigative
T77365	DRUGINFO	D0CB9B	4-(thiazol-2-yl)thieno[3,2-d]pyrimidin-2-amine	Investigative
T77365	DRUGINFO	D0D3WR	9-benzyl-6-(furan-2-yl)-9H-purin-2-amine	Investigative
T77365	DRUGINFO	D0F9JF	FR-166124	Investigative
T77365	DRUGINFO	D0HK5B	SCH-63390	Investigative
T77365	DRUGINFO	D0I6MT	N6-[(4-Amino)-phenyl]-9-benzyl-2-phenyladenine	Investigative
T77365	DRUGINFO	D0J2UW	CGS 21680	Investigative
T77365	DRUGINFO	D0J6ME	2-ethyl-4-(pyridin-2-yl)thieno[3,2-d]pyrimidine	Investigative
T77365	DRUGINFO	D0KM0Y	2-Amino-4-phenyl-6-thiophen-2-yl-nicotinonitrile	Investigative
T77365	DRUGINFO	D0M8NW	Kuanoniamine D	Investigative
T77365	DRUGINFO	D0N2VO	2-Amino-4,6-diphenyl-nicotinonitrile	Investigative
T77365	DRUGINFO	D0P5ZE	Cyclohexyl-(2-phenoxy-9H-purin-6-yl)-amine	Investigative
T77365	DRUGINFO	D0QD3O	2-Amino-4,6-diphenyl-pyrimidine	Investigative
T77365	DRUGINFO	D0QN5I	4-(furan-2-yl)thieno[3,2-d]pyrimidin-2-amine	Investigative
T77365	DRUGINFO	D0T6XM	1,3-Diisobutyl-3,7-dihydro-purine-2,6-dione	Investigative
T77365	DRUGINFO	D0UM6O	2-chloro-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine	Investigative
T77365	DRUGINFO	D0W5CZ	4-(furan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine	Investigative
T77365	DRUGINFO	D0W6TG	PSB-09120	Investigative
T77365	DRUGINFO	D0W8RB	8-Bromo-9-(but-3-enyl)-9H-adenine	Investigative
T77365	DRUGINFO	D0Y5TL	Alloxazine	Investigative
T77365	DRUGINFO	D0Y7AV	2-ethyl-4-(furan-3-yl)thieno[3,2-d]pyrimidine	Investigative
T77365	DRUGINFO	D0YR1V	5-Butyl-8-phenyl-3H-[1,2,4]triazolo[5,1-i]purine	Investigative
T77365	DRUGINFO	D0ZV1T	N-(2,6-diphenylpyrimidin-4-yl)-2-ethylbutyramide	Investigative
T77365	DRUGINFO	D00ASZ	2-(3''-pyrrolylethyloxy)adenosine	Investigative
T77365	DRUGINFO	D00GQI	N-(2,6-diphenylpyrimidin-4-yl)isobutyramide	Investigative
T77365	DRUGINFO	D00NFW	2,6-diphenyl-8-ethyl-1-deazapurine	Investigative
T77365	DRUGINFO	D01NHH	2,6-diphenyl-8-tButyl-1-deazapurine	Investigative
T77365	DRUGINFO	D01PGY	2-(hex-1-ynyl)-N6-methoxyadenosine	Investigative
T77365	DRUGINFO	D01QBK	8-Bromo-9-cyclohexyl-9H-adenine	Investigative
T77365	DRUGINFO	D01VEU	9-Ethyl-8-phenylethynyl-9H-purin-6-ylamine	Investigative
T77365	DRUGINFO	D01VXC	N-(4,6-diphenylpyrimidin-2-yl)propionamide	Investigative
T77365	DRUGINFO	D01VXP	2-ethynyl-N6-methoxyadenosine	Investigative
T77365	DRUGINFO	D01WNA	8-Bromo-9-ethyl-9H-adenine	Investigative
T77365	DRUGINFO	D02EAO	N*6*-Cyclohexyl-N*2*-phenyl-9H-purine-2,6-diamine	Investigative
T77365	DRUGINFO	D02FLH	2,6-dphenyl-8-propyl-1-deazapurine	Investigative
T77365	DRUGINFO	D02HOL	8-Bromo-9-propyl-9H-adenine	Investigative
T77365	DRUGINFO	D02HYT	N-(2,6-diphenylpyrimidin-4-yl)propionamide	Investigative
T77365	DRUGINFO	D02JMR	2-(3''-(6''-chloro-indolyl)ethyloxy)adenosine	Investigative
T77365	DRUGINFO	D02RMR	1,3-Diethyl-3,7-dihydro-purine-2,6-dione	Investigative
T77365	DRUGINFO	D02VQK	LUF-5433	Investigative
T77365	DRUGINFO	D03FVK	N6-methoxy-2-[(4-pyridinyl)ethynyl]adenosine	Investigative
T77365	DRUGINFO	D03HBG	2-(3''-(4''-bromo-indolyl)ethyloxy)adenosine	Investigative
T77365	DRUGINFO	D03KKK	1,3-Dipropyl-3,7-dihydro-purine-2,6-dione	Investigative
T77365	DRUGINFO	D03POP	N6-methoxy-2-phenylethynyladenosine	Investigative
T77365	DRUGINFO	D04TTP	5,7-dibromo-9H-pyrido[3,4-b]indol-6-ol	Investigative
T77365	DRUGINFO	D04WHE	9-Propyl-9H-adenine	Investigative
T77365	DRUGINFO	D05XGF	PSB-0788	Investigative
T77365	DRUGINFO	D06RCT	2-(3''-indolylethyloxy)adenosine	Investigative
T77365	DRUGINFO	D07DNX	PD-115199	Investigative
T77365	DRUGINFO	D07HNM	1,3-Diallyl-3,7-dihydro-purine-2,6-dione	Investigative
T77365	DRUGINFO	D07IPZ	2-(4-hydroxypent-1-yl)-N6-methoxyadenosine	Investigative
T77365	DRUGINFO	D08EZI	N-(2,6-diphenylpyrimidin-4-yl)-3-methylbutyramide	Investigative
T77365	DRUGINFO	D08HBH	N-(2,6-diphenylpyrimidin-4-yl)butyramide	Investigative
T77365	DRUGINFO	D08JUQ	2-tolyl-6-phenyl-9H-purine	Investigative
T77365	DRUGINFO	D08JYX	2-[(4-acetylphenyl)ethynyl]-N6-methoxyadenosine	Investigative
T77365	DRUGINFO	D08LZN	Cyclohexyl-(2-phenylsulfanyl-9H-purin-6-yl)-amine	Investigative
T77365	DRUGINFO	D08MRB	1H-Imidazo[4,5-c]quinolin-4-ylamine HCl	Investigative
T77365	DRUGINFO	D09IRV	LUF-5957	Investigative
T77365	DRUGINFO	D09VOP	2-(3''-(5''-methoxy-indolyl)ethyloxy)adenosine	Investigative
T77365	DRUGINFO	D09VRX	2-(4-methyl-1H-benzo[d]imidazol-2-yl)quinoxaline	Investigative
T77365	DRUGINFO	D0A6JX	9-Cyclobutyl-9H-adenine	Investigative
T77365	DRUGINFO	D0A9BZ	PSB-601	Investigative
T77365	DRUGINFO	D0B0QW	N6-methoxy-2-[(4-pentylphenyl)ethynyl]adenosine	Investigative
T77365	DRUGINFO	D0B1RV	2-Cyclopentyl-1H-imidazo[4,5-c]quinolin-4-ylamine	Investigative
T77365	DRUGINFO	D0B1YW	8-Phenyl-1-propyl-3,7-dihydro-purine-2,6-dione	Investigative
T77365	DRUGINFO	D0B3NZ	N-(5-Benzoyl-4-phenylthiazol-2-yl)benzamide	Investigative
T77365	DRUGINFO	D0B3UE	9-Cyclopentyl-9H-adenine	Investigative
T77365	DRUGINFO	D0B8RQ	LUF-5767	Investigative
T77365	DRUGINFO	D0DB7A	9-Isopropyl-9H-adenine	Investigative
T77365	DRUGINFO	D0E4LB	2-(5-cyano-1-pent-1-ynyl)-N6-methoxyadenosine	Investigative
T77365	DRUGINFO	D0E7YE	2,6,8-triphenyl-9H-purine	Investigative
T77365	DRUGINFO	D0E8RA	8-Bromo-9-(2,3-dihydroxypropyl)-9H-adenine	Investigative
T77365	DRUGINFO	D0F1AS	1-METHYLXANTHINE	Investigative
T77365	DRUGINFO	D0F4XB	2-Amino-4,6-di-furan-2-yl-nicotinonitrile	Investigative
T77365	DRUGINFO	D0G5ZF	N6-methoxy-2-[(2-pyridinyl)ethynyl]adenosine	Investigative
T77365	DRUGINFO	D0G6BI	2-(3''-(6''-bromo-indolyl)ethyloxy)adenosine	Investigative
T77365	DRUGINFO	D0G6VT	2-(3''-(5''-iodo-indolyl)ethyloxy)adenosine	Investigative
T77365	DRUGINFO	D0I1IW	2-(3''-(5''-fluoro-indolyl)ethyloxy)adenosine	Investigative
T77365	DRUGINFO	D0I2EQ	2,6-diphenyl-8-methyl-1-deazapurine	Investigative
T77365	DRUGINFO	D0I6XA	(2R,3S)-3-(6-Amino-purin-9-yl)-nonan-2-ol	Investigative
T77365	DRUGINFO	D0I7HL	2-phenylpropoxyadenosine	Investigative
T77365	DRUGINFO	D0KJ3H	2-(2''-indolylethyloxy)adenosine	Investigative
T77365	DRUGINFO	D0KT3L	2-[(4-fluorophenyl)ethynyl]-N6-methoxyadenosine	Investigative
T77365	DRUGINFO	D0L2MN	2-(4-chlorophenyl)-6-phenyl-9H-purine	Investigative
T77365	DRUGINFO	D0L6YI	2-(3''-(5''-bromo-indolyl)ethyloxy)adenosine	Investigative
T77365	DRUGINFO	D0LP5G	2-Phenyl-1H-imidazo[4,5-c]quinolin-4-ylamine	Investigative
T77365	DRUGINFO	D0LP5V	LUF-5956	Investigative
T77365	DRUGINFO	D0N1QO	N6-methoxy-2-[(4-methoxyphenyl)ethynyl]adenosine	Investigative
T77365	DRUGINFO	D0N1QP	2,6-diphenyl-1-deazapurine	Investigative
T77365	DRUGINFO	D0O0FP	ST-1535	Investigative
T77365	DRUGINFO	D0O1CW	GNF-PF-2700	Investigative
T77365	DRUGINFO	D0OX0V	2-(4-ethylthiobenzimidazol-2-yl)quinoxaline	Investigative
T77365	DRUGINFO	D0P0BV	2-(3''-(5''-hydroxyindolyl)ethyloxy)adenosine	Investigative
T77365	DRUGINFO	D0P7CS	LUF-5417	Investigative
T77365	DRUGINFO	D0P7FK	2-Amino-4-furan-2-yl-6-phenyl-nicotinonitrile	Investigative
T77365	DRUGINFO	D0P8MK	2-(6-amino-8-bromo-9H-purin-9-yl)ethanol	Investigative
T77365	DRUGINFO	D0PU6F	2-(1H-benzo[d]imidazol-2-yl)quinoxaline	Investigative
T77365	DRUGINFO	D0Q1RD	2-(3''(5''-chloro-indolyl)ethyloxy)adenosine	Investigative
T77365	DRUGINFO	D0Q3LM	N6-methoxy-2-[2-(trimethylsilyl)ethynyl]adenosine	Investigative
T77365	DRUGINFO	D0Q5CS	6-guanidino-2-(3''-indolylethyloxy)adenosine	Investigative
T77365	DRUGINFO	D0QN4U	2-(3''(7''-bromo-indolyl)ethyloxy)adenosine	Investigative
T77365	DRUGINFO	D0R8OK	8-Bromo-9-methyl-9H-adenine	Investigative
T77365	DRUGINFO	D0RZ2M	2,6-diphenyl-9H-purine	Investigative
T77365	DRUGINFO	D0S5XP	9-Allyl-8-bromo-9H-adenine	Investigative
T77365	DRUGINFO	D0S6QA	8-Bromo-9-(2-butyl)-9H-adenine	Investigative
T77365	DRUGINFO	D0U8DW	1-Butyl-8-phenyl-3,7-dihydro-purine-2,6-dione	Investigative
T77365	DRUGINFO	D0V9EE	2-Amino-6-furan-2-yl-4-phenyl-nicotinonitrile	Investigative
T77365	DRUGINFO	D0VB6X	(1H-Imidazo[4,5-c]quinolin-4-yl)-phenyl-amine HCl	Investigative
T77365	DRUGINFO	D0W3MT	8-propyl-2,6-diphenyl-9H-purine	Investigative
T77365	DRUGINFO	D0W6FC	8-Bromo-9-(2-hydroxypropyl)-9H-adenine	Investigative
T77365	DRUGINFO	D0WI4D	LUF-5962	Investigative
T77365	DRUGINFO	D0Y2RM	Isoguanosine	Investigative
T77365	DRUGINFO	D0Y6HQ	N6-methoxy-2-[(3-pyridinyl)ethynyl]-adenosine	Investigative
T77365	DRUGINFO	D0Y7HG	Galangin	Investigative
T77365	DRUGINFO	D0Z3XC	N-(2,6-diphenylpyrimidin-4-yl)acetamide	Investigative
T77365	DRUGINFO	D0ZW9L	5,7-diphenyl-3H-imidazo[4,5-b]pyridin-2-ol	Investigative
T77365	DRUGINFO	D00GNW	2,6-diphenyl-8-(1-ethylpropyl)-1-deazapurine	Investigative
T77365	DRUGINFO	D00JWA	N-(2-(furan-2-yl)-3,4'-bipyridin-6-yl)acetamide	Investigative
T77365	DRUGINFO	D02PBY	3-noradamantyl-1,3-dipropylxanthine	Investigative
T77365	DRUGINFO	D04LZN	8-Bromo-9-cyclobutyl-9H-adenine	Investigative
T77365	DRUGINFO	D05KEF	LUF-5978	Investigative
T77365	DRUGINFO	D06KYP	8-Bromo-9-isopropyl-9H-adenine	Investigative
T77365	DRUGINFO	D0AI8F	8-Bromo-9-cyclopentyl-9H-adenine	Investigative
T77365	DRUGINFO	D0B0TX	8-bromo-9-isobutyl-9H-purin-6-amine	Investigative
T77365	DRUGINFO	D0CX7N	8-Bromo-9-(3-hydroxypropyl)-9H-adenine	Investigative
T77365	DRUGINFO	D0IG5E	2,5'-dichloro-5'-deoxy-N6-cyclopentyladenosine	Investigative
T77365	DRUGINFO	D0JJ6T	N6-((+/-)-endo-norborn-2-yl)adenosine	Investigative
T77365	DRUGINFO	D0K6ZA	[3H]OSIP339391	Investigative
T77365	DRUGINFO	D0K8ZZ	[3H]NECA	Investigative
T77365	DRUGINFO	D0M3CG	R-N6-(phenylisopropyl)adenosine	Investigative
T77365	DRUGINFO	D0NO5E	Ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate	Investigative
T77365	DRUGINFO	D0O4KI	2-ethyl-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine	Investigative
T77365	DRUGINFO	D0R1XY	[3H]CCPA	Investigative
T77365	DRUGINFO	D0V8MD	8-PHENYL THEOPHYLLINE	Investigative
T77365	DRUGINFO	D0W1PF	LUF-5980	Investigative
T77365	DRUGINFO	D0Y9WZ	SB-298	Investigative
T77365	DRUGINFO	D0Z8NC	LUF-5981	Investigative
T77365	DRUGINFO	D0Z8VU	8-Bromo-9-(sec-butyl)-9H-adenine	Investigative
T77365	DRUGINFO	D0K0OT	GNF-PF-2224	Investigative
T77365	DRUGINFO	D03RFA	N6-CYCLOPENTYLADENOSINE	Investigative
T77365	DRUGINFO	D0R6MT	isobutylmethylxanthine	Investigative
T77365	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T13251	TARGETID	T13251
T13251	FORMERID	TTDC00033
T13251	UNIPROID	IL12A_HUMAN
T13251	TARGNAME	Interleukin-12 alpha (IL12A)
T13251	GENENAME	IL12A
T13251	TARGTYPE	Successful
T13251	SYNONYMS	NKSF1; NKSF; NK cell stimulatory factor chain 1; NK cell stimulatory factor; Interleukin-12 subunit alpha; IL-12A; IL-12 subunit p35; IL-12; Cytotoxic lymphocyte maturation factor 35 kDa subunit; CLMF p35
T13251	FUNCTION	Cytokine that can act as a growth factor for activated T and NK cells, enhance the lytic activity of NK/lymphokine-activated killer cells, and stimulate the production of IFN-gamma by resting PBMC.
T13251	PDBSTRUC	3HMX; 1F45
T13251	BIOCLASS	Cytokine: interleukin
T13251	SEQUENCE	MCPARSLLLVATLVLLDHLSLARNLPVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHAFRIRAVTIDRVMSYLNAS
T13251	DRUGINFO	D0E7QB	Mirikizumab	Approved
T13251	DRUGINFO	D0A2UV	Ustekinumab	Approved
T13251	DRUGINFO	D0C9NJ	STA-5326	Phase 2

T82383	TARGETID	T82383
T82383	FORMERID	TTDNR00764
T82383	UNIPROID	UFO_HUMAN
T82383	TARGNAME	Tyrosine-protein kinase UFO (AXL)
T82383	GENENAME	AXL
T82383	TARGTYPE	Successful
T82383	SYNONYMS	UFO; Tyrosine-protein kinase receptor UFO; AXL oncogene
T82383	FUNCTION	Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding growth factor GAS6 and which is thus regulating many physiological processes including cell survival, cell proliferation, migration and differentiation. Ligand binding at the cell surface induces dimerization and autophosphorylation of AXL. Following activation by ligand, ALX binds and induces tyrosine phosphorylation of PI3-kinase subunits PIK3R1, PIK3R2 and PIK3R3; but also GRB2, PLCG1, LCK and PTPN11. Other downstream substrate candidates for AXL are CBL, NCK2, SOCS1 and TNS2. Recruitment of GRB2 and phosphatidylinositol 3 kinase regulatory subunits by AXL leads to the downstream activation of the AKT kinase. GAS6/AXL signaling plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses. Plays also an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response.
T82383	PDBSTRUC	5VXZ; 5U6B; 4RA0; 2C5D
T82383	BIOCLASS	Kinase
T82383	ECNUMBER	EC 2.7.10.1
T82383	SEQUENCE	MAWRCPRMGRVPLAWCLALCGWACMAPRGTQAEESPFVGNPGNITGARGLTGTLRCQLQVQGEPPEVHWLRDGQILELADSTQTQVPLGEDEQDDWIVVSQLRITSLQLSDTGQYQCLVFLGHQTFVSQPGYVGLEGLPYFLEEPEDRTVAANTPFNLSCQAQGPPEPVDLLWLQDAVPLATAPGHGPQRSLHVPGLNKTSSFSCEAHNAKGVTTSRTATITVLPQQPRNLHLVSRQPTELEVAWTPGLSGIYPLTHCTLQAVLSDDGMGIQAGEPDPPEEPLTSQASVPPHQLRLGSLHPHTPYHIRVACTSSQGPSSWTHWLPVETPEGVPLGPPENISATRNGSQAFVHWQEPRAPLQGTLLGYRLAYQGQDTPEVLMDIGLRQEVTLELQGDGSVSNLTVCVAAYTAAGDGPWSLPVPLEAWRPGQAQPVHQLVKEPSTPAFSWPWWYVLLGAVVAAACVLILALFLVHRRKKETRYGEVFEPTVERGELVVRYRVRKSYSRRTTEATLNSLGISEELKEKLRDVMVDRHKVALGKTLGEGEFGAVMEGQLNQDDSILKVAVKTMKIAICTRSELEDFLSEAVCMKEFDHPNVMRLIGVCFQGSERESFPAPVVILPFMKHGDLHSFLLYSRLGDQPVYLPTQMLVKFMADIASGMEYLSTKRFIHRDLAARNCMLNENMSVCVADFGLSKKIYNGDYYRQGRIAKMPVKWIAIESLADRVYTSKSDVWSFGVTMWEIATRGQTPYPGVENSEIYDYLRQGNRLKQPADCLDGLYALMSRCWELNPQDRPSFTELREDLENTLKALPPAQEPDEILYVNMDEGGGYPEPPGAAGGADPPTQPDPKDSCSCLTAAEVHPAGRYVLCPSTTPSPAQPADRGSPAAPGQEDGA
T82383	DRUGINFO	D04KZY	Gilteritinib	Approved
T82383	DRUGINFO	D0U8XE	Bemcentinib	Phase 2
T82383	DRUGINFO	D0X9VR	BGB-324	Phase 2
T82383	DRUGINFO	DYI4L2	Mecbotamab vedotin	Phase 2
T82383	DRUGINFO	D08FDX	MGCD265	Phase 2
T82383	DRUGINFO	D0Q7OE	BI-505	Phase 2
T82383	DRUGINFO	D00LGR	TP-0903	Phase 1/2
T82383	DRUGINFO	DI0ZA3	Enapotamab vedotin	Phase 1/2
T82383	DRUGINFO	DA1MG8	ONO-7475	Phase 1/2
T82383	DRUGINFO	D06THG	DS-1205	Phase 1
T82383	DRUGINFO	D0Y5QA	AVB-S6-500	Phase 1
T82383	DRUGINFO	DMLY68	A416	Phase 1
T82383	DRUGINFO	D0VH4T	ONO-7475	Phase 1
T82383	DRUGINFO	D95YSW	BPI-9016 M	Phase 1
T82383	DRUGINFO	DP4KH3	PF-07265807	Phase 1
T82383	DRUGINFO	DQX83Z	INCB81776	Phase 1
T82383	DRUGINFO	D7HZ3T	RXDX-106	Phase 1
T82383	DRUGINFO	D4JS3A	Cu-anti-hAXL	Preclinical
T82383	DRUGINFO	D4K2CQ	DP-3975	Preclinical
T82383	DRUGINFO	D50NHR	YW327.6S2	Preclinical
T82383	DRUGINFO	DU9RB1	GL21.T	Preclinical
T82383	DRUGINFO	D09TFN	LDC1267	Investigative

T75440	TARGETID	T75440
T75440	FORMERID	TTDS00454
T75440	UNIPROID	TSPO_HUMAN
T75440	TARGNAME	Translocator protein (TSPO)
T75440	GENENAME	TSPO
T75440	TARGTYPE	Successful
T75440	SYNONYMS	Peripheral-type benzodiazepine receptor; Peripheral benzodiazepine receptor; PKBS; PBR; Mitochondrial benzodiazepine receptor; MBR; BZRP
T75440	FUNCTION	Promotes the transport of cholesterol across mitochondrial membranes and may play a role in lipid metabolism, but its precise physiological role is controversial. It is apparently not required for steroid hormone biosynthesis. Was initially identified as peripheral-type benzodiazepine receptor; can also bind isoquinoline carboxamides. Can bind protoporphyrin IX and may play a role in the transport of porphyrins and heme.
T75440	BIOCLASS	Cholesterol/porphyrin uptake translocator
T75440	SEQUENCE	MAPPWVPAMGFTLAPSLGCFVGSRFVHGEGLRWYAGLQKPSWHPPHWVLGPVWGTLYSAMGYGSYLVWKELGGFTEKAVVPLGLYTGQLALNWAWPPIFFGARQMGWALVDLLLVSGAAAATTVAWYQVSPLAARLLYPYLAWLAFTTTLNYCVWRDNHGWRGGRRLPE
T75440	DRUGINFO	D03NPH	Quazepam	Approved
T75440	DRUGINFO	D04BNP	Temazepam	Approved
T75440	DRUGINFO	D06BEP	Chlordiazepoxide	Approved
T75440	DRUGINFO	D06FWC	Fludiazepam	Approved
T75440	DRUGINFO	D06ZII	Eszopiclone	Approved
T75440	DRUGINFO	D07JVL	Diazepam	Approved
T75440	DRUGINFO	D08XFV	Flurazepam	Approved
T75440	DRUGINFO	D09LDR	Oxazepam	Approved
T75440	DRUGINFO	D0E0OG	Lorazepam	Approved
T75440	DRUGINFO	D0E7FS	Adinazolam	Approved
T75440	DRUGINFO	D0G3AQ	Prazepam	Approved
T75440	DRUGINFO	D0L9GG	Alprazolam	Approved
T75440	DRUGINFO	D0P2CK	Estazolam	Approved
T75440	DRUGINFO	D0P3JU	Clorazepate	Approved
T75440	DRUGINFO	D0Q9WO	Cinolazepam	Approved
T75440	DRUGINFO	D0R4DP	Clotiazepam	Approved
T75440	DRUGINFO	D0S1OE	Chlormezanone	Approved
T75440	DRUGINFO	D0U3LS	Triazolam	Approved
T75440	DRUGINFO	D0U6LM	Midazolam	Approved
T75440	DRUGINFO	D0W2NM	Flunitrazepam	Approved
T75440	DRUGINFO	D0Z9VB	Halazepam	Approved
T75440	DRUGINFO	D01XOD	Alpidem	Approved
T75440	DRUGINFO	D0D5GD	Flumazenil	Approved
T75440	DRUGINFO	D04LTF	TLN-4601	Phase 2
T75440	DRUGINFO	D05CMZ	ONO-2952	Phase 2
T75440	DRUGINFO	D09OTU	SSR-180575	Phase 2
T75440	DRUGINFO	D0G4YZ	11C-PBR-28	Phase 2
T75440	DRUGINFO	D07TXJ	Dextofisopam	Phase 2
T75440	DRUGINFO	D06OFD	BAY-85-8102	Phase 1
T75440	DRUGINFO	D0U1US	18F-FEDAA-1106	Phase 1
T75440	DRUGINFO	D00EBN	Imidazopyridine acetamide analog 7	Patented
T75440	DRUGINFO	D00UDJ	Indole-based analog 5	Patented
T75440	DRUGINFO	D01BXA	PMID27607364-Compound-65	Patented
T75440	DRUGINFO	D01DWN	PMID27599163-Compound-79	Patented
T75440	DRUGINFO	D01KPW	Isoquinoline carboxamide derivative 1	Patented
T75440	DRUGINFO	D01LOJ	Pyrazolopyrimidine acetamide analog 1	Patented
T75440	DRUGINFO	D01PXI	Indole-based analog 10	Patented
T75440	DRUGINFO	D01WQX	Imidazopyridine derivative 2	Patented
T75440	DRUGINFO	D02UMS	Quinazoline derivative 5	Patented
T75440	DRUGINFO	D02VRI	Tricyclic indole compound 11	Patented
T75440	DRUGINFO	D03ENW	Benzothiazepine analog 3	Patented
T75440	DRUGINFO	D03PTY	PMID27607364-Compound-64	Patented
T75440	DRUGINFO	D04ESE	Imidazo[1,2-b]pyridazine acetamide derivative 4	Patented
T75440	DRUGINFO	D04JEH	Aryl oxyanilide derivative 1	Patented
T75440	DRUGINFO	D04SWU	Tricyclic indole compound 12	Patented
T75440	DRUGINFO	D05GJL	Benzothiazepine analog 6	Patented
T75440	DRUGINFO	D05ZAV	PMID27607364-Compound-141	Patented
T75440	DRUGINFO	D06HIJ	PMID27607364-Compound-60	Patented
T75440	DRUGINFO	D06PPD	Imidazopyridine acetamide analog 2	Patented
T75440	DRUGINFO	D06RNU	Quinazoline derivative 2	Patented
T75440	DRUGINFO	D06WUT	Quinoline carboxamide derivative 8	Patented
T75440	DRUGINFO	D07KTM	Quinoline carboxamide derivative 9	Patented
T75440	DRUGINFO	D07RRL	PMID27599163-Compound-76	Patented
T75440	DRUGINFO	D07RWQ	Imidazo[1,2-b]pyridazine acetamide derivative 5	Patented
T75440	DRUGINFO	D08DPU	Benzimidazolone acetamide derivative 1	Patented
T75440	DRUGINFO	D08RNV	Aryl oxyanilide derivative 2	Patented
T75440	DRUGINFO	D08RTY	Imidazo[1,2-b]pyridazine acetamide derivative 3	Patented
T75440	DRUGINFO	D08XOA	Benzothiazepine analog 2	Patented
T75440	DRUGINFO	D08ZHA	PMID27599163-Compound-78	Patented
T75440	DRUGINFO	D09AKT	Imidazo[1,2-b]pyridazine acetamide derivative 6	Patented
T75440	DRUGINFO	D09GSO	PMID27599163-Compound-82	Patented
T75440	DRUGINFO	D09JTT	Quinazoline derivative 3	Patented
T75440	DRUGINFO	D0A5RG	PMID27607364-Compound-58	Patented
T75440	DRUGINFO	D0AC4P	Benzimidazolone acetamide derivative 2	Patented
T75440	DRUGINFO	D0AP1F	PMID27599163-Compound-81	Patented
T75440	DRUGINFO	D0AW8P	Quinoline carboxamide derivative 7	Patented
T75440	DRUGINFO	D0B3RK	Indole-based analog 9	Patented
T75440	DRUGINFO	D0CL2E	Iodophenyl-N-methyl-N-fluoroalkyl-3-isoquinoline carboxamide derivative 3	Patented
T75440	DRUGINFO	D0E2XN	PMID27607364-Compound-59	Patented
T75440	DRUGINFO	D0E6TQ	Tricyclic indole compound 14	Patented
T75440	DRUGINFO	D0EG4F	Imidazopyridine acetamide analog 6	Patented
T75440	DRUGINFO	D0EI2Q	Tricyclic indole compound 7	Patented
T75440	DRUGINFO	D0EY2Q	Iodophenyl-N-methyl-N-fluoroalkyl-3-isoquinoline carboxamide derivative 2	Patented
T75440	DRUGINFO	D0FF5C	Quinoline carboxamide derivative 4	Patented
T75440	DRUGINFO	D0FR9I	Aryl oxyanilide derivative 3	Patented
T75440	DRUGINFO	D0G5FS	Bidentate pyrazolopyrimidine acetamide analog 3	Patented
T75440	DRUGINFO	D0G7HK	Benzothiazepine analog 8	Patented
T75440	DRUGINFO	D0GN5R	Benzothiazepine analog 7	Patented
T75440	DRUGINFO	D0GY0E	Benzothiazepine analog 5	Patented
T75440	DRUGINFO	D0H2RG	Phenylpurine acetamide analog 2	Patented
T75440	DRUGINFO	D0HS8T	Imidazopyridine derivative 1	Patented
T75440	DRUGINFO	D0I6CF	Iodophenyl-N-methyl-N-fluoroalkyl-3-isoquinoline carboxamide derivative 1	Patented
T75440	DRUGINFO	D0IY5H	PMID27607364-Compound-62	Patented
T75440	DRUGINFO	D0JN7L	PMID27599163-Compound-77	Patented
T75440	DRUGINFO	D0K3MV	Imidazo[1,2-b]pyridazine acetamide derivative 7	Patented
T75440	DRUGINFO	D0K3QX	Tricyclic indole compound 6	Patented
T75440	DRUGINFO	D0K3ZB	Quinazoline derivative 6	Patented
T75440	DRUGINFO	D0K4UF	Imidazopyridine acetamide analog 4	Patented
T75440	DRUGINFO	D0K4VT	Benzoxazepine analog 1	Patented
T75440	DRUGINFO	D0KZ5O	Bidentate pyrazolopyrimidine acetamide analog 2	Patented
T75440	DRUGINFO	D0L5EG	Tricyclic indole compound 2	Patented
T75440	DRUGINFO	D0LB3J	Pyrazolopyrimidine acetamide analog 2	Patented
T75440	DRUGINFO	D0LE6B	PMID27599163-Compound-75	Patented
T75440	DRUGINFO	D0M9PB	Imidazo[1,2-b]pyridazine acetamide derivative 1	Patented
T75440	DRUGINFO	D0MR8D	Imidazopyridine acetamide analog 3	Patented
T75440	DRUGINFO	D0N5LW	Phenylpurine acetamide analog 1	Patented
T75440	DRUGINFO	D0N9DS	PMID27607364-Compound-4	Patented
T75440	DRUGINFO	D0NF3Y	Tricyclic indole compound 5	Patented
T75440	DRUGINFO	D0O8DG	Benzothiazepine analog 9	Patented
T75440	DRUGINFO	D0OB0Q	Quinoline carboxamide derivative 6	Patented
T75440	DRUGINFO	D0P1TH	Imidazo[1,2-b]pyridazine acetamide derivative 2	Patented
T75440	DRUGINFO	D0PE1K	Quinoline carboxamide derivative 5	Patented
T75440	DRUGINFO	D0PO3M	Imidazopyridine acetamide analog 1	Patented
T75440	DRUGINFO	D0Q5JO	Tricyclic indole compound 9	Patented
T75440	DRUGINFO	D0R0OA	Tricyclic indole compound 3	Patented
T75440	DRUGINFO	D0R2XX	Benzodiazepine derivative 1	Patented
T75440	DRUGINFO	D0RH7L	PMID27607364-Compound-162	Patented
T75440	DRUGINFO	D0RT5D	Tricyclic indole compound 10	Patented
T75440	DRUGINFO	D0S2SS	Quinazoline derivative 4	Patented
T75440	DRUGINFO	D0TB2L	PMID27607364-Compound-61	Patented
T75440	DRUGINFO	D0TP7S	Quinazoline derivative 7	Patented
T75440	DRUGINFO	D0TQ8V	Tricyclic indole compound 4	Patented
T75440	DRUGINFO	D0U0IH	PMID27599163-Compound-52	Patented
T75440	DRUGINFO	D0V9GL	Imidazopyridine acetamide analog 5	Patented
T75440	DRUGINFO	D0WL7F	Tricyclic indole compound 1	Patented
T75440	DRUGINFO	D0X1MJ	Bidentate pyrazolopyrimidine acetamide analog 1	Patented
T75440	DRUGINFO	D0X8TY	Bidentate pyrazolopyrimidine acetamide analog 4	Patented
T75440	DRUGINFO	D0XB2O	Tricyclic indole compound 8	Patented
T75440	DRUGINFO	D0Y0FR	Quinoline carboxamide derivative 10	Patented
T75440	DRUGINFO	D0Y2ZS	PMID27607364-Compound-63	Patented
T75440	DRUGINFO	D0Z1KU	Benzothiazepine analog 1	Patented
T75440	DRUGINFO	D0Z6RI	Benzothiazepine analog 4	Patented
T75440	DRUGINFO	D0ZK2Q	PMID27607364-Compound-10	Patented
T75440	DRUGINFO	D0B3LP	Ro-16-6028	Discontinued in Phase 3
T75440	DRUGINFO	D00TNC	S-8510	Discontinued in Phase 2
T75440	DRUGINFO	D05UXF	Emapunil	Discontinued in Phase 2
T75440	DRUGINFO	D0D5ZR	TRO-40303	Discontinued in Phase 2
T75440	DRUGINFO	D0O0DF	Lirequinil	Discontinued in Phase 2
T75440	DRUGINFO	D06BYS	Imepitoin	Discontinued in Phase 1
T75440	DRUGINFO	D02UOE	Miltirone	Terminated
T75440	DRUGINFO	D03XPV	Ginkgolide B (GKB)	Terminated
T75440	DRUGINFO	D0K5IQ	DAA-1097	Terminated
T75440	DRUGINFO	D0S8KE	NS-2979	Terminated
T75440	DRUGINFO	D0Y6LO	NNC-13-8119	Terminated
T75440	DRUGINFO	D01HGI	TGSC01AA(4)	Investigative
T75440	DRUGINFO	D04EGE	11C-PBR-170	Investigative
T75440	DRUGINFO	D05CYJ	N,N-Dimethyl-2-(2-phenyl-1H-indol-3-yl)-acetamide	Investigative
T75440	DRUGINFO	D07WPM	6-Thia-10b-aza-benzo[e]azulen-4-one	Investigative
T75440	DRUGINFO	D08AWL	5-Phenyl-6-thia-10b-aza-benzo[e]azulen-4-one	Investigative
T75440	DRUGINFO	D08XEQ	N,N-Dihexyl-2-(2-phenyl-1H-indol-3-yl)-acetamide	Investigative
T75440	DRUGINFO	D0A0ED	FGIN-1-27	Investigative
T75440	DRUGINFO	D0A3TE	5-Phenyl-6-thia-10b-aza-benzo[e]azulene	Investigative
T75440	DRUGINFO	D0CS6N	Benzodiazepine	Investigative
T75440	DRUGINFO	D0L2NV	U-89854	Investigative
T75440	DRUGINFO	D0M1JT	4-Methoxy-5-phenyl-6-thia-10b-aza-benzo[e]azulene	Investigative
T75440	DRUGINFO	D0N6IL	N-Hexyl-2-(2-phenyl-1H-indol-3-yl)-acetamide	Investigative
T75440	DRUGINFO	D0O6JQ	(R)PK-11195	Investigative
T75440	DRUGINFO	D0T6NJ	N,N-Diethyl-2-(2-phenyl-1H-indol-3-yl)-acetamide	Investigative
T75440	DRUGINFO	D0Z4SA	2-(2-Phenyl-1H-indol-3-yl)-N,N-dipropyl-acetamide	Investigative
T75440	DRUGINFO	D0B1PE	Ro 5-4864	Investigative
T75440	DRUGINFO	D0VN4K	PK 11195	Investigative

T32247	TARGETID	T32247
T32247	FORMERID	TTDS00485
T32247	UNIPROID	CALCR_HUMAN
T32247	TARGNAME	Calcitonin receptor (CALCR)
T32247	GENENAME	CALCR
T32247	TARGTYPE	Successful
T32247	SYNONYMS	CT-R
T32247	FUNCTION	The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. The calcitonin receptor is thought to couple to the heterotrimeric guanosine triphosphate-binding protein that is sensitive to cholera toxin. This is a receptor for calcitonin.
T32247	PDBSTRUC	6NIY; 5UZ7; 5II0
T32247	BIOCLASS	GPCR secretin
T32247	SEQUENCE	MRFTFTSRCLALFLLLNHPTPILPAFSNQTYPTIEPKPFLYVVGRKKMMDAQYKCYDRMQQLPAYQGEGPYCNRTWDGWLCWDDTPAGVLSYQFCPDYFPDFDPSEKVTKYCDEKGVWFKHPENNRTWSNYTMCNAFTPEKLKNAYVLYYLAIVGHSLSIFTLVISLGIFVFFRSLGCQRVTLHKNMFLTYILNSMIIIIHLVEVVPNGELVRRDPVSCKILHFFHQYMMACNYFWMLCEGIYLHTLIVVAVFTEKQRLRWYYLLGWGFPLVPTTIHAITRAVYFNDNCWLSVETHLLYIIHGPVMAALVVNFFFLLNIVRVLVTKMRETHEAESHMYLKAVKATMILVPLLGIQFVVFPWRPSNKMLGKIYDYVMHSLIHFQGFFVATIYCFCNNEVQTTVKRQWAQFKIQWNQRWGRRPSNRSARAAAAAAEAGDIPIYICHQEPRNEPANNQGEESAEIIPLNIIEQESSA
T32247	DRUGINFO	D02QCM	Calcitonin Human	Approved
T32247	DRUGINFO	D0I1XG	Salmon Calcitonin	Approved
T32247	DRUGINFO	D93YJK	LY 3541105	Phase 1
T32247	DRUGINFO	DW3J9N	DACRA 089	Phase 1
T32247	DRUGINFO	D00XRI	TJN-220	Terminated
T32247	DRUGINFO	D00JEO	CSNLSTCVLGKLSQELc[DKLHK]YPRTNTGSGTP-amide	Investigative
T32247	DRUGINFO	D03CEP	CGNLSTCMLGTYTQDFNKPHTFPQTAIGVGAP-amide	Investigative
T32247	DRUGINFO	D03DPD	CGNLSTCMLGTYTQDFc[DKFHK]FPQTAIGVGAP-amide	Investigative
T32247	DRUGINFO	D05AIM	CSNLSTCVLGKLSQELc[DKLHO]YPRTNTGSGTP-amide	Investigative
T32247	DRUGINFO	D08URJ	CGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP-amide	Investigative
T32247	DRUGINFO	D0A8VZ	CGNLSTCBLGTYTQDF[DKFHO]YPQTAIGVGAP-amide	Investigative
T32247	DRUGINFO	D0G0WP	CGNLSTCBLGTYTQDFNKFHZYPQTAIGVGAP-amide	Investigative
T32247	DRUGINFO	D0H0GJ	CSNLSTCVLGKLSQELNKLHBYPRTNTGSGTP-amide	Investigative
T32247	DRUGINFO	D0J2UD	CGNLSTCMLGTYTQDFc[DKFHO]FPQTAIGVGAP-amide	Investigative
T32247	DRUGINFO	D0J7CK	CSNLSTCVLGKLSQELc[DKLQK]YPRTNTGSGTP-amide	Investigative
T32247	DRUGINFO	D0K1IE	CGNLSTCMLGTYTQDFNPFHTFPQTAIGVGAP-amide	Investigative
T32247	DRUGINFO	D0O9WG	CSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP-amide	Investigative
T32247	DRUGINFO	D0Y0NM	CGNLSTCMLGTYTQDFNPKHTFPQTAIGVGAP-amide	Investigative

T26368	TARGETID	T26368
T26368	FORMERID	TTDR01042
T26368	UNIPROID	GBRA5_HUMAN
T26368	TARGNAME	GABA(A) receptor alpha-5 (GABRA5)
T26368	GENENAME	GABRA5
T26368	TARGTYPE	Successful
T26368	SYNONYMS	GABRA5; GABAA alpha 5; GABA-A alpha-5
T26368	FUNCTION	GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
T26368	PDBSTRUC	6A96; 5OJM; 5O8F
T26368	BIOCLASS	Ligand-gated ion channel
T26368	SEQUENCE	MDNGMFSGFIMIKNLLLFCISMNLSSHFGFSQMPTSSVKDETNDNITIFTRILDGLLDGYDNRLRPGLGERITQVRTDIYVTSFGPVSDTEMEYTIDVFFRQSWKDERLRFKGPMQRLPLNNLLASKIWTPDTFFHNGKKSIAHNMTTPNKLLRLEDDGTLLYTMRLTISAECPMQLEDFPMDAHACPLKFGSYAYPNSEVVYVWTNGSTKSVVVAEDGSRLNQYHLMGQTVGTENISTSTGEYTIMTAHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISARNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGWAWDGKKALEAAKIKKKREVILNKSTNAFTTGKMSHPPNIPKEQTPAGTSNTTSVSVKPSEEKTSESKKTYNSISKIDKMSRIVFPVLFGTFNLVYWATYLNREPVIKGAASPK
T26368	DRUGINFO	D0D5GD	Flumazenil	Approved
T26368	DRUGINFO	D0CH7C	Basmisanil	Phase 2
T26368	DRUGINFO	D0C9XA	GSK683699	Phase 2
T26368	DRUGINFO	D09TOL	RG-7816	Phase 1
T26368	DRUGINFO	D0D9RF	RY024	Investigative
T26368	DRUGINFO	D0GQ2G	[3H]RY80	Investigative
T26368	DRUGINFO	D0LE1F	[3H]L655708	Investigative
T26368	DRUGINFO	D0YZ0B	HT-2678	Investigative
T26368	DRUGINFO	D03PBN	tetrahydrodeoxycorticosterone	Investigative
T26368	DRUGINFO	D03ZWB	alpha3IA	Investigative
T26368	DRUGINFO	D06SOQ	alpha5IA	Investigative
T26368	DRUGINFO	D07JXC	[18F]fluoroethylflumazenil	Investigative
T26368	DRUGINFO	D0GQ1S	DMCM	Investigative
T26368	DRUGINFO	D0Q1ZT	TP003	Investigative
T26368	DRUGINFO	D0T9DS	[35S]TBPS	Investigative
T26368	DRUGINFO	D01CUR	3-Ethoxy-9H-beta-carboline	Investigative
T26368	DRUGINFO	D01RLF	9H-beta-Carboline-3-carboxylic acid ethyl ester	Investigative
T26368	DRUGINFO	D03PPZ	Beta-Carboline-3-carboxylic acid t-butyl ester	Investigative
T26368	DRUGINFO	D03TMD	Barbituric acid derivative	Investigative
T26368	DRUGINFO	D06WMM	3-Butoxy-9H-beta-carboline	Investigative
T26368	DRUGINFO	D08BOP	3-Propoxy-9H-beta-carboline	Investigative
T26368	DRUGINFO	D08BXK	3-(3-Methyl-butoxy)-9H-beta-carboline	Investigative
T26368	DRUGINFO	D09MYJ	3-Isobutoxy-9H-beta-carboline	Investigative
T26368	DRUGINFO	D0C6WO	Sec-butyl 9H-pyrido[3,4-b]indole-3-carboxylate	Investigative
T26368	DRUGINFO	D0D4MM	Ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate	Investigative
T26368	DRUGINFO	D0E7PY	Ro-4938581	Investigative
T26368	DRUGINFO	D0O9MG	L-655708	Investigative
T26368	DRUGINFO	D0P3BU	3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole	Investigative
T26368	DRUGINFO	D0R5OU	3-(benzyloxy)-9H-pyrido[3,4-b]indole	Investigative
T26368	DRUGINFO	D01IHM	CI-218872	Investigative
T26368	DRUGINFO	D07NKO	5-[(1R)-1-ammonioethyl]isoxazol-3-olate	Investigative
T26368	DRUGINFO	D09ACO	(2E,4S)-4-ammoniopent-2-enoate	Investigative
T26368	DRUGINFO	D0A8EU	(4R)-4-ammoniopentanoate	Investigative
T26368	DRUGINFO	D0N0ZK	(4S)-4-ammoniopentanoate	Investigative
T26368	DRUGINFO	D0S5PS	5-[(1S)-1-ammonioethyl]isoxazol-3-olate	Investigative
T26368	DRUGINFO	D0VW5M	piperidine-4-sulphonic acid	Investigative
T26368	DRUGINFO	D00WHO	Ro-15-3505	Investigative
T26368	DRUGINFO	D0AC2H	isonipecotic acid	Investigative
T26368	DRUGINFO	D0M4CP	[3H]Ro154513	Investigative
T26368	DRUGINFO	D0M9RM	[3H]CGS8216	Investigative
T26368	DRUGINFO	D06HRX	AMENTOFLAVONE	Investigative
T26368	DRUGINFO	D0P0TI	TBPS	Investigative

T27812	TARGETID	T27812
T27812	FORMERID	TTDC00255
T27812	UNIPROID	SC6A4_HUMAN
T27812	TARGNAME	Serotonin transporter (SERT)
T27812	GENENAME	SLC6A4
T27812	TARGTYPE	Successful
T27812	SYNONYMS	Solute carrier family 6 member 4; HTT; 5HTT; 5HT transporter
T27812	FUNCTION	Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin and recycles it in a sodium-dependent manner. Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization.
T27812	PDBSTRUC	6DZZ; 6DZY; 6DZW; 6DZV; 6AWQ
T27812	BIOCLASS	Neurotransmitter:sodium symporter
T27812	SEQUENCE	METTPLNSQKQLSACEDGEDCQENGVLQKVVPTPGDKVESGQISNGYSAVPSPGAGDDTRHSIPATTTTLVAELHQGERETWGKKVDFLLSVIGYAVDLGNVWRFPYICYQNGGGAFLLPYTIMAIFGGIPLFYMELALGQYHRNGCISIWRKICPIFKGIGYAICIIAFYIASYYNTIMAWALYYLISSFTDQLPWTSCKNSWNTGNCTNYFSEDNITWTLHSTSPAEEFYTRHVLQIHRSKGLQDLGGISWQLALCIMLIFTVIYFSIWKGVKTSGKVVWVTATFPYIILSVLLVRGATLPGAWRGVLFYLKPNWQKLLETGVWIDAAAQIFFSLGPGFGVLLAFASYNKFNNNCYQDALVTSVVNCMTSFVSGFVIFTVLGYMAEMRNEDVSEVAKDAGPSLLFITYAEAIANMPASTFFAIIFFLMLITLGLDSTFAGLEGVITAVLDEFPHVWAKRRERFVLAVVITCFFGSLVTLTFGGAYVVKLLEEYATGPAVLTVALIEAVAVSWFYGITQFCRDVKEMLGFSPGWFWRICWVAISPLFLLFIICSFLMSPPQLRLFQYNYPYWSIILGYCIGTSSFICIPTYIAYRLIITPGTFKERIIKSITPETPTEIPCGDIRLNAV
T27812	DRUGINFO	D03HFG	Fluvoxamine	Approved
T27812	DRUGINFO	D03WEX	Vortioxetine	Approved
T27812	DRUGINFO	D04WFD	Nortriptyline	Approved
T27812	DRUGINFO	D06CDO	Chlorphentermine Hydrochloride	Approved
T27812	DRUGINFO	D06CVT	Tianeptine	Approved
T27812	DRUGINFO	D06GDY	Paroxetine	Approved
T27812	DRUGINFO	D08RBC	Escitalopram	Approved
T27812	DRUGINFO	D0K0TC	Sertraline	Approved
T27812	DRUGINFO	D0M5JI	Luvox	Approved
T27812	DRUGINFO	D0O3FG	Desvenlafaxine	Approved
T27812	DRUGINFO	D0TR5X	Fluoxetine	Approved
T27812	DRUGINFO	D0Y5DO	Citalopram	Approved
T27812	DRUGINFO	D0ZS8P	Clomipramine	Approved
T27812	DRUGINFO	D00KFB	Dextromethorphan Polistirex	Approved
T27812	DRUGINFO	D00USF	Trazodone	Approved
T27812	DRUGINFO	D01AXB	Duloxetine	Approved
T27812	DRUGINFO	D02XOK	Levomilnacipran	Approved
T27812	DRUGINFO	D08KVZ	Sibutramine	Approved
T27812	DRUGINFO	D0B7OD	Amfepramone	Approved
T27812	DRUGINFO	D0P1UX	Venlafaxine	Approved
T27812	DRUGINFO	D0X4ZR	Bupropion	Approved
T27812	DRUGINFO	D0X6BV	Vilazodone	Approved
T27812	DRUGINFO	D0Y5UG	Amitriptyline	Approved
T27812	DRUGINFO	D04XPW	Cocaine	Approved
T27812	DRUGINFO	D0U5QK	Acetaminophen	Approved
T27812	DRUGINFO	D0W6KM	Dasotraline	Approved
T27812	DRUGINFO	D03QIE	Bicifadine	Phase 3
T27812	DRUGINFO	D07AHC	LITOXETINE	Phase 3
T27812	DRUGINFO	D0Z6IB	AVP-786	Phase 3
T27812	DRUGINFO	D04PXS	Amitifadine	Phase 3
T27812	DRUGINFO	D0Q0EF	ITI-007	Phase 3
T27812	DRUGINFO	D05BXO	Brasofensine	Phase 2
T27812	DRUGINFO	D0F8HN	DA-8031	Phase 2
T27812	DRUGINFO	D02JKY	TD-9855	Phase 2
T27812	DRUGINFO	D04VHK	CLR-3001	Phase 2
T27812	DRUGINFO	D0A8QM	Lu-AA34893	Phase 2
T27812	DRUGINFO	D07QXU	NS 2359	Phase 2
T27812	DRUGINFO	D0Z4FE	MIN-117	Phase 2
T27812	DRUGINFO	D02ZCE	AD-337	Phase 1
T27812	DRUGINFO	D03PRV	BGC-20-1259	Phase 1
T27812	DRUGINFO	D08SHE	SEP-228432	Phase 1
T27812	DRUGINFO	D0FM7Z	BL-1021	Phase 1
T27812	DRUGINFO	D0K7OW	GSK-1360707	Phase 1
T27812	DRUGINFO	D0R6LF	Citalopram derivative 1	Patented
T27812	DRUGINFO	D0FA3G	PMID29334795-Compound-61	Patented
T27812	DRUGINFO	D0VX6P	Piperidine derivative 1	Patented
T27812	DRUGINFO	D0C1XS	ZIMELIDINE	Withdrawn from market
T27812	DRUGINFO	D0F9SG	Dexfenfluramine	Withdrawn from market
T27812	DRUGINFO	D01ESB	YM-992	Discontinued in Phase 2
T27812	DRUGINFO	D0B2OC	R-sibutramine metabolite	Discontinued in Phase 2
T27812	DRUGINFO	D02JNX	OxycoDex	Discontinued in Phase 2
T27812	DRUGINFO	D0H9GQ	DOV-216303	Discontinued in Phase 2
T27812	DRUGINFO	D0LU6N	SPD-473	Discontinued in Phase 2
T27812	DRUGINFO	D0M9LB	NS-2389	Discontinued in Phase 2
T27812	DRUGINFO	D04VUY	RG-7166	Discontinued in Phase 1
T27812	DRUGINFO	D08UNQ	NSD-644	Discontinued in Phase 1
T27812	DRUGINFO	D0I9UH	MOXIFETIN HYDROGEN MALEATE	Terminated
T27812	DRUGINFO	D0S6PJ	6-nitroquipazine	Terminated
T27812	DRUGINFO	D0V9HI	Irindalone	Terminated
T27812	DRUGINFO	D0Q7OA	HydrocoDex	Terminated
T27812	DRUGINFO	D0K9JP	A-80426	Terminated
T27812	DRUGINFO	D00DDT	2-N,N-Dimethylamino-1-(4-methylthiophenyl)propane	Investigative
T27812	DRUGINFO	D00EUD	2-Amino-1-(4-methylthiophenyl)butane	Investigative
T27812	DRUGINFO	D00RTM	3-(1H-indol-3-yl)-N,N-dimethylpropan-1-amine	Investigative
T27812	DRUGINFO	D01OGZ	TEFLUDAZINE	Investigative
T27812	DRUGINFO	D02GSL	4-Iodo-6-nitro-2-piperazin-1-yl-quinoline	Investigative
T27812	DRUGINFO	D02HOP	6-Iodo-2-piperazin-1-yl-quinoline	Investigative
T27812	DRUGINFO	D02JOZ	4-Bromo-6-nitro-2-piperazin-1-yl-quinoline	Investigative
T27812	DRUGINFO	D02JVG	2-Amino-1-(4-ethylthiophenyl)propane	Investigative
T27812	DRUGINFO	D02MMS	2-N-(n-Propyl)amino-1-(4-methylthiophenyl)butane	Investigative
T27812	DRUGINFO	D02NMY	6-Bromo-2-piperazin-1-yl-quinoline	Investigative
T27812	DRUGINFO	D02PKR	3-Bromo-6-nitro-2-piperazin-1-yl-quinoline	Investigative
T27812	DRUGINFO	D02VHZ	2-Amino-1-(4-ethylthiophenyl)butane	Investigative
T27812	DRUGINFO	D03ETK	2-N-Hydroxyamino-1-(4-methylthiophenyl)propane	Investigative
T27812	DRUGINFO	D03FGM	3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzamide	Investigative
T27812	DRUGINFO	D03HFH	1-(4-Benzylsulfanyl-phenyl)-propylamine	Investigative
T27812	DRUGINFO	D04GHK	2-N-Hydroxyamino-1-(4-methylthiophenyl)butane	Investigative
T27812	DRUGINFO	D04IZU	4-(2-((dimethylamino)methyl)phenoxy)benzonitrile	Investigative
T27812	DRUGINFO	D04RUF	2-N-Ethylamino-1-(4-ethylthiophenyl)butane	Investigative
T27812	DRUGINFO	D04VNR	2-Naphthalen-2-ylmethyl-4,5-dihydro-1H-imidazole	Investigative
T27812	DRUGINFO	D05FMK	2-N-Propargylamino-1-(4-methylthiophenyl)propane	Investigative
T27812	DRUGINFO	D05LLP	2-N-Hydroxyamino-1-(4-ethylthiophenyl)propane	Investigative
T27812	DRUGINFO	D05MJO	2-(3-Methyl-piperazin-1-yl)-6-nitro-quinoline	Investigative
T27812	DRUGINFO	D05REQ	3-(3-aminocyclopentyl)-1H-indole-5-carbonitrile	Investigative
T27812	DRUGINFO	D05UHO	2-N-Ethylamino-1-(4-ethylthiophenyl)propane	Investigative
T27812	DRUGINFO	D05YHP	2-N-Propargylamino-1-(4-methylthiophenyl)butane	Investigative
T27812	DRUGINFO	D07GLO	4-Allyl-6-nitro-2-piperazin-1-yl-quinoline	Investigative
T27812	DRUGINFO	D07SZF	2-N-Ethylamino-1-(4-methylthiophenyl)butane	Investigative
T27812	DRUGINFO	D07TEJ	1-(1-phenyl-2-(pyridin-4-yl)ethyl)piperazine	Investigative
T27812	DRUGINFO	D09NVT	4-Benzyl-6-nitro-2-piperazin-1-yl-quinoline	Investigative
T27812	DRUGINFO	D09PEZ	6,8-Dinitro-2-piperazin-1-yl-quinoline	Investigative
T27812	DRUGINFO	D09YHS	1-Methyl-2-(4-phenylsulfanyl-phenyl)-ethylamine	Investigative
T27812	DRUGINFO	D09ZAL	6,6-dimethyl-1-phenyl-3-aza-bicyclo[3.1.0]hexane	Investigative
T27812	DRUGINFO	D0A0UC	Cyclopentyl-(3,4-dichloro-phenyl)-acetonitrile	Investigative
T27812	DRUGINFO	D0A3YK	1-(2-(naphthalen-2-yl)-1-phenylethyl)piperazine	Investigative
T27812	DRUGINFO	D0B8BC	6-Chloro-2-piperazin-1-yl-quinoline	Investigative
T27812	DRUGINFO	D0D2WN	2-N-Methylamino-1-(4-methylthiophenyl)butane	Investigative
T27812	DRUGINFO	D0E2XW	1-fluoro-5-phenyl-3-aza-bicyclo[3.1.0]hexane	Investigative
T27812	DRUGINFO	D0GZ5F	CX-1001	Investigative
T27812	DRUGINFO	D0H7PI	2-N-Cyclopropylamino-1-(4-methylthiophenyl)butane	Investigative
T27812	DRUGINFO	D0J1VS	4-Furan-2-yl-6-nitro-2-piperazin-1-yl-quinoline	Investigative
T27812	DRUGINFO	D0J8DC	1-(2-(naphthalen-1-yl)-1-phenylethyl)piperazine	Investigative
T27812	DRUGINFO	D0L4HU	Cyclohexyl-(3,4-dichloro-phenyl)-acetonitrile	Investigative
T27812	DRUGINFO	D0N1AZ	1-Methyl-4-p-tolyl-piperidine-4-carbonitrile	Investigative
T27812	DRUGINFO	D0N7IH	N*1*-(6-Nitro-quinolin-2-yl)-ethane-1,2-diamine	Investigative
T27812	DRUGINFO	D0O8QM	2-N-Allylamino-1-(4-methylthiophenyl)propan	Investigative
T27812	DRUGINFO	D0P0US	4-Chloro-6-nitro-2-piperazin-1-yl-quinoline	Investigative
T27812	DRUGINFO	D0Q3EJ	2-N-Hydroxyamino-1-(4-ethylthiophenyl)butane	Investigative
T27812	DRUGINFO	D0R8XV	2-N-Methylamino-1-(4-ethylthiophenyl)propane	Investigative
T27812	DRUGINFO	D0SA1G	2-N-Ethylamino-1-(4-methylthiophenyl)propane	Investigative
T27812	DRUGINFO	D0SD4O	2-N-Methylamino-1-(4-methylthiophenyl)propane	Investigative
T27812	DRUGINFO	D0T7VU	2-N-(Isopropyl)amino-1-(4-methylthiophenyl)butane	Investigative
T27812	DRUGINFO	D0VD4L	2-[1,4]Diazepan-1-yl-6-nitro-quinoline	Investigative
T27812	DRUGINFO	D0VX1V	2-N-Methoxyamino-1-(4-methylthiophenyl)propane	Investigative
T27812	DRUGINFO	D0W6WL	1-(1,3-diphenylpropyl)piperazine	Investigative
T27812	DRUGINFO	D0X4FO	6-Nitro-2-piperazin-1-yl-4-vinyl-quinoline	Investigative
T27812	DRUGINFO	D0X8DW	6-Nitro-4-phenyl-2-piperazin-1-yl-quinoline	Investigative
T27812	DRUGINFO	D0X8GC	N-cyclobutyl-N-(piperidin-4-yl)-2-naphthamide	Investigative
T27812	DRUGINFO	D0Y6GQ	1-(1-phenyl-2-(pyridin-2-yl)ethyl)piperazine	Investigative
T27812	DRUGINFO	D0Y7UJ	1-(2-(naphthalen-2-yl)ethyl)piperazine	Investigative
T27812	DRUGINFO	D00KKN	(2S,3S)-iodoreboxetine	Investigative
T27812	DRUGINFO	D01BPR	1-benzylpiperidine hydrochloride	Investigative
T27812	DRUGINFO	D01EIS	1-(1,2-diphenylethyl)piperazine	Investigative
T27812	DRUGINFO	D01GSG	(R)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile	Investigative
T27812	DRUGINFO	D01JVP	(2R,3R)-iodoreboxetine	Investigative
T27812	DRUGINFO	D01SHR	((3R,4R)-4-(o-tolyloxy)chroman-3-yl)methanamine	Investigative
T27812	DRUGINFO	D02ANE	1-(naphthalen-2-yl)-3-aza-bicyclo[3.1.0]hexane	Investigative
T27812	DRUGINFO	D02LQG	WIN-35065	Investigative
T27812	DRUGINFO	D03BUG	1-(benzofuran-2-yl)-3-aza-bicyclo[3.1.0]hexane	Investigative
T27812	DRUGINFO	D03MYV	2-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile	Investigative
T27812	DRUGINFO	D03ZDY	1-(2-(2-bromophenyl)-1-phenylethyl)piperazine	Investigative
T27812	DRUGINFO	D04EXA	Erythro-3,4-dichloromethylphenidate hydrochloride	Investigative
T27812	DRUGINFO	D05VTT	3-(4-Trifluoromethylphenyl)-2-nortropene	Investigative
T27812	DRUGINFO	D05WFQ	norzotepine	Investigative
T27812	DRUGINFO	D05ZFG	(cis)-1,6-diphenyl-3-aza-bicyclo[3.1.0]hexane	Investigative
T27812	DRUGINFO	D06PJD	3-(1H-indol-1-yl)-N-methyl-3-phenylpropan-1-amine	Investigative
T27812	DRUGINFO	D08IFQ	3-Phenyl-2-nortropene	Investigative
T27812	DRUGINFO	D08LAY	1-(2-(3-methoxyphenyl)-1-phenylethyl)piperazine	Investigative
T27812	DRUGINFO	D08MEN	KF-A5	Investigative
T27812	DRUGINFO	D08MUX	S33005	Investigative
T27812	DRUGINFO	D08RCH	KF-A6	Investigative
T27812	DRUGINFO	D09DWM	Isobutyl-(4-methyl-benzyl)-piperidin-4-yl-amine	Investigative
T27812	DRUGINFO	D09JRN	3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile	Investigative
T27812	DRUGINFO	D09RCL	(2R,3S)-2-[(3-Iodophenoxy)phenylmethyl]morpholine	Investigative
T27812	DRUGINFO	D09WVS	10R-hydroxylobelane	Investigative
T27812	DRUGINFO	D09ZIU	1-phenyl-3-aza-bicyclo[3.1.0]hexane	Investigative
T27812	DRUGINFO	D0A1HH	1-(1-phenyl-2-o-tolylethyl)piperazine	Investigative
T27812	DRUGINFO	D0A7GW	N-(piperidin-4-yl)-N-propyl-2-naphthamide	Investigative
T27812	DRUGINFO	D0A9QT	JNJ-28583867	Investigative
T27812	DRUGINFO	D0B1FM	3-(3,4-dichlorophenyl)-2-nortropene	Investigative
T27812	DRUGINFO	D0B6UU	8R-hydroxylobel-9-ene	Investigative
T27812	DRUGINFO	D0D8YY	N-benzyl-N-isobutylpiperidin-4-amine	Investigative
T27812	DRUGINFO	D0D9FA	(2R,3S)-2-[(4-Iodophenoxy)phenylmethyl]morpholine	Investigative
T27812	DRUGINFO	D0E3DF	(2R,3S)-2-[(2-Iodophenoxy)phenylmethyl]morpholine	Investigative
T27812	DRUGINFO	D0EO5P	1-(2-(2-ethylphenyl)-1-phenylethyl)piperazine	Investigative
T27812	DRUGINFO	D0EX2M	1-(2-(3-chlorophenyl)-1-phenylethyl)piperazine	Investigative
T27812	DRUGINFO	D0F8SA	8S-hydroxylobelane	Investigative
T27812	DRUGINFO	D0I1ME	10R-hydroxylobel-7-ene	Investigative
T27812	DRUGINFO	D0I4TO	(S)-NORDULOXETINE	Investigative
T27812	DRUGINFO	D0J4EF	1-Biphenyl-4-yl-3-aza-bicyclo[3.1.0]hexane	Investigative
T27812	DRUGINFO	D0KD9M	(S)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile	Investigative
T27812	DRUGINFO	D0M4KN	10S-hydroxylobelane	Investigative
T27812	DRUGINFO	D0N4YP	6-(3-aza-bicyclo[3.1.0]hexan-1-yl)quinoline	Investigative
T27812	DRUGINFO	D0NM1F	(R)-N-isopropyl-N-(pyrrolidin-3-yl)-2-naphthamide	Investigative
T27812	DRUGINFO	D0NW3Z	COCAINE.HCL	Investigative
T27812	DRUGINFO	D0P6SY	MDL-28618	Investigative
T27812	DRUGINFO	D0Q0MN	Threo-3,4-dichlororitalinol hydrochloride	Investigative
T27812	DRUGINFO	D0S0EE	3-alpha-Phenylmethoxy-3-beta-phenyl-nortropane	Investigative
T27812	DRUGINFO	D0S9IO	N-(2-oxazolemethyl)milnacipran	Investigative
T27812	DRUGINFO	D0T5VG	2-(Aminomethyl)-5-(1'-naphthethyl)tetrahydrofuran	Investigative
T27812	DRUGINFO	D0T6XD	10S-hydroxylobel-7-ene	Investigative
T27812	DRUGINFO	D0TE5Q	Threo-1-aza-5-phenyl[4.4.0]decane hydrochloride	Investigative
T27812	DRUGINFO	D0TO4N	1-(thiophen-2-yl)-3-aza-bicyclo[3.1.0]hexane	Investigative
T27812	DRUGINFO	D0US2X	3-(4-Fluorophenyl)-2-nortropene	Investigative
T27812	DRUGINFO	D0VC1K	N,N-dimethyl(2-phenoxyphenyl)methanamine	Investigative
T27812	DRUGINFO	D0W9JK	(S)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide	Investigative
T27812	DRUGINFO	D0Y0BB	3-(4-Chlorophenyl)-2-nortropene	Investigative
T27812	DRUGINFO	D0Z0LP	8R-hydroxylobelane	Investigative
T27812	DRUGINFO	D0Z4IH	8S-hydroxylobel-9-ene	Investigative
T27812	DRUGINFO	D0Z6YA	1-(2-(2-ethoxyphenyl)-1-phenylethyl)piperazine	Investigative
T27812	DRUGINFO	D00FMX	3-(piperidin-4-yl)-2-(o-tolyloxy)pyridine	Investigative
T27812	DRUGINFO	D00GDI	2-(N-tert-Butylamino)-3',4'-dichloropropiophenone	Investigative
T27812	DRUGINFO	D00VUT	D-257C	Investigative
T27812	DRUGINFO	D01AOI	6-(piperidin-4-ylmethoxy)-2-naphthonitrile	Investigative
T27812	DRUGINFO	D02ENH	(R)-Norfluoxetine	Investigative
T27812	DRUGINFO	D02ICX	PYROVALERONE	Investigative
T27812	DRUGINFO	D02TMK	METHYLENEDIOXYAMPHETAMINE	Investigative
T27812	DRUGINFO	D02UUC	3-p-Tolyl-8-aza-bicyclo[3.2.1]octane	Investigative
T27812	DRUGINFO	D02YOO	NISOXETINE	Investigative
T27812	DRUGINFO	D02YSN	2-Aminomethyl-5-(p-t-butylphenyl)tetrahydrofuran	Investigative
T27812	DRUGINFO	D02ZIQ	1-(3-chlorophenyl)-2-(piperidin-1-yl)propan-1-one	Investigative
T27812	DRUGINFO	D03BQV	1S,2R-milnacipran	Investigative
T27812	DRUGINFO	D03HQF	2-Aminomethyl-5-(p-bromophenyl)tetrahydrofuran	Investigative
T27812	DRUGINFO	D03JOX	1-(2-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one	Investigative
T27812	DRUGINFO	D03ZFX	D-254C	Investigative
T27812	DRUGINFO	D04KZX	2-(tert-Butylamino)-3',4'-dichlorobutyrophenone	Investigative
T27812	DRUGINFO	D05LKO	1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine	Investigative
T27812	DRUGINFO	D05UMA	(R)-DULOXETINE	Investigative
T27812	DRUGINFO	D06CMJ	Para-chloroamphetamine	Investigative
T27812	DRUGINFO	D06EMC	PF-18298	Investigative
T27812	DRUGINFO	D06KNV	[3-(3,4-Dichloro-phenyl)-indan-1-yl]-methyl-amine	Investigative
T27812	DRUGINFO	D06QGD	1-(4-nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-one	Investigative
T27812	DRUGINFO	D06UDU	4-(2-(4-fluorophenoxy)-4-methylphenyl)piperidine	Investigative
T27812	DRUGINFO	D06WIV	Biphenyl-2-ylmethyl-(S)-pyrrolidin-3-yl-amine	Investigative
T27812	DRUGINFO	D07DMN	4-(1H-indol-3-yl)-N,N-dimethylcyclohex-3-enamine	Investigative
T27812	DRUGINFO	D07DWS	1-(2-(2-fluorobenzyloxy)phenyl)piperazine	Investigative
T27812	DRUGINFO	D07RQT	8-Methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octane	Investigative
T27812	DRUGINFO	D07SAA	2-(N-Cyclopropylamino)-3-chloropropiophenone	Investigative
T27812	DRUGINFO	D07ZOP	1-(3-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one	Investigative
T27812	DRUGINFO	D08AWN	(S)-Norfluoxetine	Investigative
T27812	DRUGINFO	D08TJY	D-257A	Investigative
T27812	DRUGINFO	D09QZM	2-(Aminomethyl)-5-(2'-naphthyl)tetrahydrofuran	Investigative
T27812	DRUGINFO	D09ZAT	1-(3,4-Dichloro-phenyl)-3-methylamino-indan-5-ol	Investigative
T27812	DRUGINFO	D0G1XP	2-(tert-Butylamino)-3',4'-dichloropentanophenone	Investigative
T27812	DRUGINFO	D0G5RH	WIN-35066-2	Investigative
T27812	DRUGINFO	D0G8UA	(R)-2-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol	Investigative
T27812	DRUGINFO	D0GG2J	1-(1-(2-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX)	Investigative
T27812	DRUGINFO	D0H2TS	4-(2-((3-fluorophenoxy)methyl)phenyl)piperidine	Investigative
T27812	DRUGINFO	D0H4AD	1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one	Investigative
T27812	DRUGINFO	D0I9KV	1-(4-bromophenyl)-2-pyrrolidin-1-yl-pentan-1-one	Investigative
T27812	DRUGINFO	D0IB6Y	2-Aminomethyl-5-(p-methoxyphenyl)tetrahydrofuran	Investigative
T27812	DRUGINFO	D0J0ES	1-(3,4-Dichloro-phenyl)-3-diethylamino-indan-5-ol	Investigative
T27812	DRUGINFO	D0J5AR	2-(2'-Aminoethyl)-5-benzyltetrahydrofuran	Investigative
T27812	DRUGINFO	D0K6ZT	2-(2-fluorophenoxy)-3-(piperidin-4-yl)pyridine	Investigative
T27812	DRUGINFO	D0L0AY	2-(Aminomethyl)-5-phenethyltetrahydrofuran	Investigative
T27812	DRUGINFO	D0L7BK	1-(1,4-diphenylbutan-2-yl)piperazine	Investigative
T27812	DRUGINFO	D0LD1X	D-211B	Investigative
T27812	DRUGINFO	D0N0TQ	2-Aminomethyl-5-(phenyl)tetrahydrofuran	Investigative
T27812	DRUGINFO	D0N2RJ	1-(2-(3-fluorophenoxy)phenyl)piperazine	Investigative
T27812	DRUGINFO	D0N3DD	[3H]WIN35428	Investigative
T27812	DRUGINFO	D0NY4W	1-(4-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one	Investigative
T27812	DRUGINFO	D0O9BL	1-(3-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one	Investigative
T27812	DRUGINFO	D0Q6SH	4-(2-(3-fluorophenoxy)-4-methylphenyl)piperidine	Investigative
T27812	DRUGINFO	D0R8EV	2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one	Investigative
T27812	DRUGINFO	D0RT9B	2-Aminomethyl-5-(p-chlorophenyl)tetrahydrofuran	Investigative
T27812	DRUGINFO	D0S9AY	1-(2-(6-fluoronaphthalen-2-yl)ethyl)piperazine	Investigative
T27812	DRUGINFO	D0SB6Y	D-211A	Investigative
T27812	DRUGINFO	D0SN6R	(+/-)-3-((naphthalen-2-yloxy)methyl)pyrrolidine	Investigative
T27812	DRUGINFO	D0T8BU	3-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol	Investigative
T27812	DRUGINFO	D0V0PR	4-(2-(phenoxymethyl)phenyl)piperidine	Investigative
T27812	DRUGINFO	D0V3LR	D-166A	Investigative
T27812	DRUGINFO	D0W8BJ	Trans-3-(o-tolyloxy)-2,3-dihydro-1H-inden-1-amine	Investigative
T27812	DRUGINFO	D0WB6P	R-NORDULOXETINE	Investigative
T27812	DRUGINFO	D0X8LG	1-naphthalen-2-yl-2-pyrrolidin-1-yl-pentan-1-one	Investigative
T27812	DRUGINFO	D0Y3BI	2-(Aminomethyl)-5-(1'-naphthyl)tetrahydrofuran	Investigative
T27812	DRUGINFO	D0Y5CG	1-(2-((3-fluorophenoxy)methyl)phenyl)piperazine	Investigative
T27812	DRUGINFO	D0Z4UF	RTI-219	Investigative
T27812	DRUGINFO	D0Z9OX	1-(2-(2-chlorophenyl)-1-phenylethyl)piperazine	Investigative
T27812	DRUGINFO	D0ZE4C	2-(N-Cyclopentylamino)-3'-methoxypropiophenone	Investigative
T27812	DRUGINFO	D0ZU5W	1-(2-(benzyloxy)phenyl)piperazine	Investigative
T27812	DRUGINFO	D00DEH	4-(2-(3-chlorophenoxy)phenyl)piperidine	Investigative
T27812	DRUGINFO	D00HCC	1-(2-phenoxyphenyl)piperazine	Investigative
T27812	DRUGINFO	D00KRQ	4-(2-phenoxyphenyl)piperidine	Investigative
T27812	DRUGINFO	D01ABR	1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine	Investigative
T27812	DRUGINFO	D01FFX	4-((naphthalen-2-yloxy)methyl)piperidine	Investigative
T27812	DRUGINFO	D01JYY	(R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide	Investigative
T27812	DRUGINFO	D01MBF	4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine	Investigative
T27812	DRUGINFO	D01YNZ	4-(2-(benzyloxy)phenyl)piperidine	Investigative
T27812	DRUGINFO	D03DQQ	4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine	Investigative
T27812	DRUGINFO	D04NDO	4-(2-(2-fluorobenzyloxy)phenyl)piperidine	Investigative
T27812	DRUGINFO	D04NKQ	4-(2-(4-fluorophenoxy)phenyl)piperidine	Investigative
T27812	DRUGINFO	D04ZPF	4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine	Investigative
T27812	DRUGINFO	D05LJC	4-(2-(benzyloxy)-3-fluorophenyl)piperidine	Investigative
T27812	DRUGINFO	D08EKQ	1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX)	Investigative
T27812	DRUGINFO	D08JLB	4-(2-(benzyloxy)-6-fluorophenyl)piperidine	Investigative
T27812	DRUGINFO	D08SCH	2-Amino-1-(4-methylthiophenyl)propane	Investigative
T27812	DRUGINFO	D09FIC	1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX)	Investigative
T27812	DRUGINFO	D09IIH	4-(3-fluoro-2-phenoxyphenyl)piperidine	Investigative
T27812	DRUGINFO	D0CG2Y	2-phenoxy-3-(piperidin-4-yl)pyridine	Investigative
T27812	DRUGINFO	D0D5QV	O-DESMETHYL TRAMADOL	Investigative
T27812	DRUGINFO	D0E3DM	(S)-3-(naphthalen-2-ylmethoxy)pyrrolidine	Investigative
T27812	DRUGINFO	D0E6PQ	4-(2-fluoro-6-phenoxyphenyl)piperidine	Investigative
T27812	DRUGINFO	D0F0BS	3alpha-(bis-chloro-phenylmethoxy)tropane	Investigative
T27812	DRUGINFO	D0F6GB	2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine	Investigative
T27812	DRUGINFO	D0IC4J	4-(2-(3-fluorophenoxy)phenyl)piperidine	Investigative
T27812	DRUGINFO	D0KT2M	2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine	Investigative
T27812	DRUGINFO	D0M3TK	1-(2-(4-fluorophenoxy)phenyl)piperazine	Investigative
T27812	DRUGINFO	D0R3TA	4-(2-(4-fluorobenzyloxy)phenyl)piperidine	Investigative
T27812	DRUGINFO	D0S4JT	1-(2-(phenoxymethyl)phenyl)piperazine	Investigative
T27812	DRUGINFO	D0U7OD	PF-526014	Investigative
T27812	DRUGINFO	D0W8YO	4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine	Investigative
T27812	DRUGINFO	D0XF5P	(R)-3-(naphthalen-2-ylmethoxy)pyrrolidine	Investigative
T27812	DRUGINFO	D0Y8UC	Difluorobenztropine	Investigative
T27812	DRUGINFO	D06QIQ	7-(piperidin-4-ylmethoxy)-2-naphthonitrile	Investigative
T27812	DRUGINFO	D0FU5E	S-34324	Investigative
T27812	DRUGINFO	D0N2KU	PF-3409409	Investigative
T27812	DRUGINFO	D08BCF	QUIPAZINE	Investigative
T27812	DRUGINFO	D0F5NJ	METHYLENEDIOXYMETHAMPHETAMINE	Investigative
T27812	DRUGINFO	D0I4ME	MMDA	Investigative
T27812	DRUGINFO	D0R7ZC	Beta-methoxyamphetamine	Investigative
T27812	DRUGINFO	D0PN9R	R-226161	Investigative
T27812	DRUGINFO	D0L5MW	(+/-)-nantenine	Investigative
T27812	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T07137	TARGETID	T07137
T07137	FORMERID	TTDS00314
T07137	UNIPROID	HPPD_HUMAN
T07137	TARGNAME	Hydroxyphenylpyruvate dioxygenase (HPD)
T07137	GENENAME	HPD
T07137	TARGTYPE	Successful
T07137	SYNONYMS	HPPDase; HPD; F Alloantigen; 4HPPD
T07137	FUNCTION	Key enzyme in the degradation of tyrosine.
T07137	PDBSTRUC	5EC3; 3ISQ
T07137	BIOCLASS	Single donor oxidoreductase
T07137	ECNUMBER	EC 1.13.11.27
T07137	SEQUENCE	MTTYSDKGAKPERGRFLHFHSVTFWVGNAKQAASFYCSKMGFEPLAYRGLETGSREVVSHVIKQGKIVFVLSSALNPWNKEMGDHLVKHGDGVKDIAFEVEDCDYIVQKARERGAKIMREPWVEQDKFGKVKFAVLQTYGDTTHTLVEKMNYIGQFLPGYEAPAFMDPLLPKLPKCSLEMIDHIVGNQPDQEMVSASEWYLKNLQFHRFWSVDDTQVHTEYSSLRSIVVANYEESIKMPINEPAPGKKKSQIQEYVDYNGGAGVQHIALKTEDIITAIRHLRERGLEFLSVPSTYYKQLREKLKTAKIKVKENIDALEELKILVDYDEKGYLLQIFTKPVQDRPTLFLEVIQRHNHQGFGAGNFNSLFKAFEEEQNLRGNLTNMETNGVVPGM
T07137	DRUGINFO	D0V1UW	Nitisinone	Approved
T07137	DRUGINFO	D08QTP	BMS-433771	Terminated
T07137	DRUGINFO	D01TZT	2-(2-Nitro-benzoyl)-cyclohexane-1,3-dione	Investigative
T07137	DRUGINFO	D02CAT	2-(2-Iodo-benzoyl)-cyclohexane-1,3-dione	Investigative
T07137	DRUGINFO	D03FPH	2-(2-Bromo-benzoyl)-cyclohexane-1,3-dione	Investigative
T07137	DRUGINFO	D04QZR	Diketonitrile	Investigative
T07137	DRUGINFO	D07IWD	2-(2-Methoxy-benzoyl)-cyclohexane-1,3-dione	Investigative
T07137	DRUGINFO	D0A2EE	3-Hydroxy-4-phenyl-5H-furan-2-one	Investigative
T07137	DRUGINFO	D0B7WF	(4-Hydroxy-phenoxy)-acetic acid	Investigative
T07137	DRUGINFO	D0C2WX	2-(2-Chloro-benzoyl)-cyclohexane-1,3-dione	Investigative
T07137	DRUGINFO	D0I6SI	3-hydroxy-2-propionylcyclohex-2-enone	Investigative
T07137	DRUGINFO	D0K3BO	2-Acetyl-cyclohexane-1,3-dione	Investigative
T07137	DRUGINFO	D0L8FW	2-(2-Methyl-benzoyl)-cyclohexane-1,3-dione	Investigative
T07137	DRUGINFO	D0MZ9D	2-Propionyl-cyclohexane-1,3-dione	Investigative
T07137	DRUGINFO	D0Q7OY	2-Cyclopropanecarbonyl-cyclohexane-1,3-dione	Investigative
T07137	DRUGINFO	D0R0XE	2-acetyl-3-hydroxycyclohex-2-enone	Investigative
T07137	DRUGINFO	D0F2ME	Acetate Ion	Investigative

T62292	TARGETID	T62292
T62292	FORMERID	TTDR01178
T62292	UNIPROID	GBRA3_HUMAN
T62292	TARGNAME	GABA(A) receptor alpha-3 (GABRA3)
T62292	GENENAME	GABRA3
T62292	TARGTYPE	Successful
T62292	SYNONYMS	Gamma-aminobutyric acid receptor subunit alpha-3; GABA-A receptor alpha 3; GABA(A)Gamma-aminobutyric-acid receptor alpha-3 subunit precursor receptor; GABA(A) receptor subunit alpha-3
T62292	FUNCTION	GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
T62292	BIOCLASS	Neurotransmitter receptor
T62292	SEQUENCE	MIITQTSHCYMTSLGILFLINILPGTTGQGESRRQEPGDFVKQDIGGLSPKHAPDIPDDSTDNITIFTRILDRLLDGYDNRLRPGLGDAVTEVKTDIYVTSFGPVSDTDMEYTIDVFFRQTWHDERLKFDGPMKILPLNNLLASKIWTPDTFFHNGKKSVAHNMTTPNKLLRLVDNGTLLYTMRLTIHAECPMHLEDFPMDVHACPLKFGSYAYTTAEVVYSWTLGKNKSVEVAQDGSRLNQYDLLGHVVGTEIIRSSTGEYVVMTTHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISARNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRSWAWEGKKVPEALEMKKKTPAAPAKKTSTTFNIVGTTYPINLAKDTEFSTISKGAAPSASSTPTIIASPKATYVQDSPTETKTYNSVSKVDKISRIIFPVLFAIFNLVYWATYVNRESAIKGMIRKQ
T62292	DRUGINFO	D0D5GD	Flumazenil	Approved
T62292	DRUGINFO	D0B9OG	Adipiplon	Phase 2
T62292	DRUGINFO	D0M2WZ	NS-2710	Phase 2
T62292	DRUGINFO	D0C9XA	GSK683699	Phase 2
T62292	DRUGINFO	D0Z9HW	AZD6280	Discontinued in Phase 1
T62292	DRUGINFO	D09IHE	MRK016	Investigative
T62292	DRUGINFO	D09YOU	MK-0343	Investigative
T62292	DRUGINFO	D03PBN	tetrahydrodeoxycorticosterone	Investigative
T62292	DRUGINFO	D03ZWB	alpha3IA	Investigative
T62292	DRUGINFO	D06SOQ	alpha5IA	Investigative
T62292	DRUGINFO	D07JXC	[18F]fluoroethylflumazenil	Investigative
T62292	DRUGINFO	D0GQ1S	DMCM	Investigative
T62292	DRUGINFO	D0Q1ZT	TP003	Investigative
T62292	DRUGINFO	D0T9DS	[35S]TBPS	Investigative
T62292	DRUGINFO	D01UAS	6-bromo-3-ethoxycarbonyl-4-quinolone	Investigative
T62292	DRUGINFO	D02CZO	6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone	Investigative
T62292	DRUGINFO	D03LMR	6-benzyl-3-ethoxycarbonyl-4-quinolone	Investigative
T62292	DRUGINFO	D0H4GQ	RY-066	Investigative
T62292	DRUGINFO	D01CUR	3-Ethoxy-9H-beta-carboline	Investigative
T62292	DRUGINFO	D01RLF	9H-beta-Carboline-3-carboxylic acid ethyl ester	Investigative
T62292	DRUGINFO	D03PPZ	Beta-Carboline-3-carboxylic acid t-butyl ester	Investigative
T62292	DRUGINFO	D03TMD	Barbituric acid derivative	Investigative
T62292	DRUGINFO	D06WMM	3-Butoxy-9H-beta-carboline	Investigative
T62292	DRUGINFO	D08BOP	3-Propoxy-9H-beta-carboline	Investigative
T62292	DRUGINFO	D08BXK	3-(3-Methyl-butoxy)-9H-beta-carboline	Investigative
T62292	DRUGINFO	D09MYJ	3-Isobutoxy-9H-beta-carboline	Investigative
T62292	DRUGINFO	D0C6WO	Sec-butyl 9H-pyrido[3,4-b]indole-3-carboxylate	Investigative
T62292	DRUGINFO	D0D4MM	Ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate	Investigative
T62292	DRUGINFO	D0E7PY	Ro-4938581	Investigative
T62292	DRUGINFO	D0O9MG	L-655708	Investigative
T62292	DRUGINFO	D0P3BU	3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole	Investigative
T62292	DRUGINFO	D0R5OU	3-(benzyloxy)-9H-pyrido[3,4-b]indole	Investigative
T62292	DRUGINFO	D01IHM	CI-218872	Investigative
T62292	DRUGINFO	D07NKO	5-[(1R)-1-ammonioethyl]isoxazol-3-olate	Investigative
T62292	DRUGINFO	D09ACO	(2E,4S)-4-ammoniopent-2-enoate	Investigative
T62292	DRUGINFO	D0A8EU	(4R)-4-ammoniopentanoate	Investigative
T62292	DRUGINFO	D0N0ZK	(4S)-4-ammoniopentanoate	Investigative
T62292	DRUGINFO	D0S5PS	5-[(1S)-1-ammonioethyl]isoxazol-3-olate	Investigative
T62292	DRUGINFO	D0VW5M	piperidine-4-sulphonic acid	Investigative
T62292	DRUGINFO	D00WHO	Ro-15-3505	Investigative
T62292	DRUGINFO	D0AC2H	isonipecotic acid	Investigative
T62292	DRUGINFO	D0M4CP	[3H]Ro154513	Investigative
T62292	DRUGINFO	D0M9RM	[3H]CGS8216	Investigative
T62292	DRUGINFO	D06HRX	AMENTOFLAVONE	Investigative
T62292	DRUGINFO	D0P0TI	TBPS	Investigative

T77796	TARGETID	T77796
T77796	FORMERID	TTDR01197
T77796	UNIPROID	TRFR_HUMAN
T77796	TARGNAME	Thyrotropin-releasing hormone receptor (TRHR)
T77796	GENENAME	TRHR
T77796	TARGTYPE	Successful
T77796	SYNONYMS	Thyroliberin receptor; TRH-R
T77796	FUNCTION	Receptor for thyrotropin-releasing hormone. This receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system.
T77796	BIOCLASS	GPCR rhodopsin
T77796	SEQUENCE	MENETVSELNQTQLQPRAVVALEYQVVTILLVLIICGLGIVGNIMVVLVVMRTKHMRTPTNCYLVSLAVADLMVLVAAGLPNITDSIYGSWVYGYVGCLCITYLQYLGINASSCSITAFTIERYIAICHPIKAQFLCTFSRAKKIIIFVWAFTSLYCMLWFFLLDLNISTYKDAIVISCGYKISRNYYSPIYLMDFGVFYVVPMILATVLYGFIARILFLNPIPSDPKENSKTWKNDSTHQNTNLNVNTSNRCFNSTVSSRKQVTKMLAVVVILFALLWMPYRTLVVVNSFLSSPFQENWFLLFCRICIYLNSAINPVIYNLMSQKFRAAFRKLCNCKQKPTEKPANYSVALNYSVIKESDHFSTELDDITVTDTYLSATKVSFDDTCLASEVSFSQS
T77796	DRUGINFO	D08BTB	protirelin	Approved
T77796	DRUGINFO	D02QBT	AZETIRELIN	Phase 3
T77796	DRUGINFO	D05NBD	MONTIRELIN TETRAHYDRATE	Discontinued in Preregistration
T77796	DRUGINFO	D0J8RM	Posatirelin	Discontinued in Phase 3
T77796	DRUGINFO	D03BHO	JTP-2942	Discontinued in Phase 2
T77796	DRUGINFO	D04JSS	MK-771	Investigative
T77796	DRUGINFO	D06UIU	CORYMBONE B	Investigative
T77796	DRUGINFO	D0S9VG	C4X-101	Investigative
T77796	DRUGINFO	D0YA7R	MeTRH	Investigative

T45262	TARGETID	T45262
T45262	FORMERID	TTDC00073
T45262	UNIPROID	CRFR1_HUMAN
T45262	TARGNAME	Corticotropin-releasing factor receptor 1 (CRHR1)
T45262	GENENAME	CRHR1
T45262	TARGTYPE	Successful
T45262	SYNONYMS	Corticotropin-releasing hormone type 1 receptor; Corticotropin-releasing hormone receptor 1; CRHR1; CRH-R 1; CRF1; CRF-R1; CRF-R; CRF-1 receptor; CRF receptor
T45262	FUNCTION	G-protein coupled receptor for CRH (corticotropin- releasing factor) and UCN (urocortin). Has high affinity for CRH and UCN. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and down-stream effectors, such as adenylate cyclase. Promotes the activation of adenylate cyclase, leading to increased intracellular cAMP levels. Inhibits the activity of the calcium channel CACNA1H. Required for normal embryonic development of the adrenal gland and for normal hormonal responses to stress. Plays a role in the response to anxiogenic stimuli.
T45262	PDBSTRUC	4Z9G; 4K5Y; 3EHU; 3EHT; 3EHS
T45262	BIOCLASS	GPCR secretin
T45262	SEQUENCE	MGGHPQLRLVKALLLLGLNPVSASLQDQHCESLSLASNISGLQCNASVDLIGTCWPRSPAGQLVVRPCPAFFYGVRYNTTNNGYRECLANGSWAARVNYSECQEILNEEKKSKVHYHVAVIINYLGHCISLVALLVAFVLFLRLRPGCTHWGDQADGALEVGAPWSGAPFQVRRSIRCLRNIIHWNLISAFILRNATWFVVQLTMSPEVHQSNVGWCRLVTAAYNYFHVTNFFWMFGEGCYLHTAIVLTYSTDRLRKWMFICIGWGVPFPIIVAWAIGKLYYDNEKCWFGKRPGVYTDYIYQGPMILVLLINFIFLFNIVRILMTKLRASTTSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDEVSRVVFIYFNSFLESFQGFFVSVFYCFLNSEVRSAIRKRWHRWQDKHSIRARVARAMSIPTSPTRVSFHSIKQSTAV
T45262	DRUGINFO	D0B9JO	Telavancin	Approved
T45262	DRUGINFO	D0ZM5O	Pexacerfont	Phase 2/3
T45262	DRUGINFO	D05IIN	SSR125543	Phase 2
T45262	DRUGINFO	D08UYM	ONO-2333Ms	Phase 2
T45262	DRUGINFO	D0ZC0M	GSK561679	Phase 2
T45262	DRUGINFO	DF91UW	Tildacerfont	Phase 2
T45262	DRUGINFO	D0J1FB	GSK586529	Phase 1
T45262	DRUGINFO	D01KKE	GW876008	Discontinued in Phase 2
T45262	DRUGINFO	D0R2KV	CP-316,311	Discontinued in Phase 2
T45262	DRUGINFO	D0M5DH	CRA1000	Preclinical
T45262	DRUGINFO	D00PYP	NBI-37582	Terminated
T45262	DRUGINFO	D03KJS	Antalarmin	Terminated
T45262	DRUGINFO	D0G0GI	DMP-696	Terminated
T45262	DRUGINFO	D02BYS	N-mesityl-6-methyl-3-tosylpyridin-2-amine	Investigative
T45262	DRUGINFO	D02IOC	CP154,526	Investigative
T45262	DRUGINFO	D03KTU	BMS-561388	Investigative
T45262	DRUGINFO	D06FIF	CP-376395	Investigative
T45262	DRUGINFO	D0B2AH	DMP-695/696	Investigative
T45262	DRUGINFO	D0C0AS	PD-171729	Investigative
T45262	DRUGINFO	D0C9BZ	N-mesityl-4,6-dimethyl-3-tosylpyridin-2-amine	Investigative
T45262	DRUGINFO	D04KWH	Des-Arg(9)-[Leu(8)]-BK	Investigative

T47768	TARGETID	T47768
T47768	FORMERID	TTDS00126
T47768	UNIPROID	OPRM_HUMAN
T47768	TARGNAME	Opioid receptor mu (MOP)
T47768	GENENAME	OPRM1
T47768	TARGTYPE	Successful
T47768	SYNONYMS	hMOP; Mu-type opioid receptor; Mu opioid receptor; Mu opiate receptor; MOR1A; MOR1; MOR-1; M-OR-1
T47768	FUNCTION	Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta-gamma dimer activating downstream cellular effectors. The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extent to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15. They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B. Also couples to adenylate cyclase stimulatory G alpha proteins. The selective temporal coupling to G-proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4. Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization. Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G-protein thus terminating signal transduction. The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins. The activation of the ERK pathway occurs either in a G-protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist-specific receptor phosphorylation. Acts as a class A G-protein coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling. Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G-protein coupling. Endogenous ligands induce rapid desensitization, endocytosis and recycling whereas morphine induces only low desensitization and endocytosis. Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties. Involved in neurogenesis. Isoform 12 couples to GNAS and is proposed to be involved in excitatory effects. Isoform 16 and isoform 17 do not bind agonists but may act through oligomerization with binding-competent OPRM1 isoforms and reduce their ligand binding activity. Receptor for endogenous opioids such as beta-endorphin and endomorphin.
T47768	BIOCLASS	GPCR rhodopsin
T47768	SEQUENCE	MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCGPNRTDLGGRDSLCPPTGSPSMITAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALATSTLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDFRTPRNAKIINVCNWILSSAIGLPVMFMATTKYRQGSIDCTLTFSHPTWYWENLLKICVFIFAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVFIVCWTPIHIYVIIKALVTIPETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENFKRCFREFCIPTSSNIEQQNSTRIRQNTRDHPSTANTVDRTNHQLENLEAETAPLP
T47768	DRUGINFO	D03HCZ	Propoxyphene Hydrochloride	Approved
T47768	DRUGINFO	D05PIZ	Levomethadyl Acetate	Approved
T47768	DRUGINFO	D05ZTJ	Anileridine Hydrochloride	Approved
T47768	DRUGINFO	D06AWE	Buprenorphine	Approved
T47768	DRUGINFO	D07LCF	Naloxegol	Approved
T47768	DRUGINFO	D0D7KC	Alvimopan	Approved
T47768	DRUGINFO	D0E1WI	Fentanyl	Approved
T47768	DRUGINFO	D0G5QB	Alfentanil	Approved
T47768	DRUGINFO	D0GR0T	Methadyl Acetate	Approved
T47768	DRUGINFO	D0H2JP	Buprenorphine + naloxone	Approved
T47768	DRUGINFO	D0J2TN	Diphenoxylate	Approved
T47768	DRUGINFO	D0Q2HO	Naldemedine Tosylate	Approved
T47768	DRUGINFO	D0T5OX	Remifentanil	Approved
T47768	DRUGINFO	D0WE3O	Morphine	Approved
T47768	DRUGINFO	D0X3FX	Naloxone	Approved
T47768	DRUGINFO	D0X5KF	Hydrocodone	Approved
T47768	DRUGINFO	D0X6HD	Anileridine	Approved
T47768	DRUGINFO	D02RXG	Nalfurafine hcl	Approved
T47768	DRUGINFO	D03SKD	Oxycodone	Approved
T47768	DRUGINFO	D03YVO	Methylnaltrexone bromide	Approved
T47768	DRUGINFO	D04JHN	Hydromorphone	Approved
T47768	DRUGINFO	D09ZXR	Eluxadoline	Approved
T47768	DRUGINFO	D0HF0W	Levopropoxyphene Napsylate Anhydrous	Approved
T47768	DRUGINFO	D0K4MH	Tapentadol hydrochloride	Approved
T47768	DRUGINFO	D01UXW	Morphine-6-glucuronide	Phase 3
T47768	DRUGINFO	D03TBJ	GRT-6005	Phase 3
T47768	DRUGINFO	D0K2ID	NKTR-181	Phase 3
T47768	DRUGINFO	D02INX	TD-1211	Phase 2
T47768	DRUGINFO	D04PUO	OPNT001	Phase 2
T47768	DRUGINFO	D0T0ZW	ALKS33	Phase 2
T47768	DRUGINFO	D0V5WL	Met-enkephalin	Phase 2
T47768	DRUGINFO	DW7OF1	ORP-101	Phase 2
T47768	DRUGINFO	D03PJU	Carfentanil	Phase 2
T47768	DRUGINFO	D0LU5Q	TPM-1/Morphine	Phase 2
T47768	DRUGINFO	D05ONA	Cyt-1010	Phase 1
T47768	DRUGINFO	D0G1YO	GSK1521498	Phase 1
T47768	DRUGINFO	D0OK6F	TRV734	Phase 1
T47768	DRUGINFO	D0W4YO	NOCICEPTIN	Phase 1
T47768	DRUGINFO	D00HBR	AIKO-150	Phase 1
T47768	DRUGINFO	D01AKU	MCP-201	Phase 1
T47768	DRUGINFO	D06EXA	SALVINORIN A	Phase 1
T47768	DRUGINFO	D01PCE	BCH-2687	Discontinued in Phase 2
T47768	DRUGINFO	D01SJC	Transdur-sufentanil	Discontinued in Phase 2
T47768	DRUGINFO	D09MTC	ADL-5945	Discontinued in Phase 2
T47768	DRUGINFO	D0IW4R	TREFENTANIL HYDROCHLORIDE	Discontinued in Phase 2
T47768	DRUGINFO	D0N1HL	Frakefamide	Discontinued in Phase 2
T47768	DRUGINFO	D0O0AH	MIRFENTANIL HYDROCHLORIDE	Discontinued in Phase 2
T47768	DRUGINFO	D0G1YN	DPI-3290	Discontinued in Phase 2
T47768	DRUGINFO	D0Y8SK	Dynorphin a	Discontinued in Phase 2
T47768	DRUGINFO	D03MNS	ADL-7445	Discontinued in Phase 1
T47768	DRUGINFO	D0T9MQ	KN-203	Discontinued in Phase 1
T47768	DRUGINFO	D0J5XZ	VP004	Discontinued in Phase 1
T47768	DRUGINFO	D0X6SZ	GNTI	Preclinical
T47768	DRUGINFO	D0C2QF	LY-25582	Preclinical
T47768	DRUGINFO	D0E8SE	443C81	Terminated
T47768	DRUGINFO	D0J8XO	BCH-150	Terminated
T47768	DRUGINFO	D0K9TC	Sameridine	Terminated
T47768	DRUGINFO	D0PE1A	DBO-11	Terminated
T47768	DRUGINFO	D0XH1H	DBO-17	Terminated
T47768	DRUGINFO	D0LX5D	BIPHALIN	Terminated
T47768	DRUGINFO	D08YUP	SB-213698	Terminated
T47768	DRUGINFO	D0W8TS	SNF-9007	Terminated
T47768	DRUGINFO	D00NZP	Dmt-Sar-Phe-D-2-Nal-NH	Investigative
T47768	DRUGINFO	D00PQS	NE-2	Investigative
T47768	DRUGINFO	D00PYB	CODEINONE	Investigative
T47768	DRUGINFO	D00YMN	AIKO-152	Investigative
T47768	DRUGINFO	D01ESN	[Tyr-Pro-Phe-Phe-NH-]2	Investigative
T47768	DRUGINFO	D01MHO	DC6S	Investigative
T47768	DRUGINFO	D01MKM	Tyr-Pro-Hfe-Phe-NH2	Investigative
T47768	DRUGINFO	D02VUL	AIKO-151	Investigative
T47768	DRUGINFO	D02YXR	MM3A6S	Investigative
T47768	DRUGINFO	D03BUD	BREMAZOCINE	Investigative
T47768	DRUGINFO	D03NCF	Tyr-Pro-Hfe-Pro-NH2	Investigative
T47768	DRUGINFO	D03PCP	NCT-400	Investigative
T47768	DRUGINFO	D04IHL	Tyr-Pro-D-(NMe)Phe-D-Pro-NH2	Investigative
T47768	DRUGINFO	D04JCJ	6-(4-(2-(benzylamino)ethyl)phenoxy)picolinamide	Investigative
T47768	DRUGINFO	D04MYP	Tyr-Pro-Phe-Phg-NH2	Investigative
T47768	DRUGINFO	D05CRC	SL-3111	Investigative
T47768	DRUGINFO	D05ETG	Tyr-Pro-Phe-D-Phg-NH2	Investigative
T47768	DRUGINFO	D05HOH	Tyr-Sar-Phe-D-2-Nal-NH2	Investigative
T47768	DRUGINFO	D05XCV	Ac-D-pro-L-Phe-D-trp-L-Phe-NH2	Investigative
T47768	DRUGINFO	D05XPU	[D-Ala2]Met-enkephalinamide	Investigative
T47768	DRUGINFO	D05YXS	ORIPAVINE	Investigative
T47768	DRUGINFO	D06ESC	YGGWL-NH2	Investigative
T47768	DRUGINFO	D06LCW	KIN-4044	Investigative
T47768	DRUGINFO	D06QLG	Tyr-D-Ala-Gly-NMePhe	Investigative
T47768	DRUGINFO	D06YVE	M3B6S	Investigative
T47768	DRUGINFO	D07GZG	Endomorphins	Investigative
T47768	DRUGINFO	D07UJV	DM3A6S	Investigative
T47768	DRUGINFO	D07XXX	Tyr-Pro-Phe-Hfe-NH2	Investigative
T47768	DRUGINFO	D08QSN	(+/-)-TRANS-U-50488 METHANESULFONATE	Investigative
T47768	DRUGINFO	D08UZJ	3-(2-Methyl-2-aza-bicyclo[3.3.1]non-5-yl)-phenol	Investigative
T47768	DRUGINFO	D09FVG	AKUAMMINE	Investigative
T47768	DRUGINFO	D09MXM	Semorphone	Investigative
T47768	DRUGINFO	D09TCT	YGWFL-NH2	Investigative
T47768	DRUGINFO	D0A1XG	YRFB	Investigative
T47768	DRUGINFO	D0C0FG	NRT-300	Investigative
T47768	DRUGINFO	D0C1AN	H-Tyr-D-Ala-(R or S)Atc-Asp-Val-Val-Gly-NH2	Investigative
T47768	DRUGINFO	D0C2ZW	Tyr-Pro-Phg-Pro-NH2	Investigative
T47768	DRUGINFO	D0D0XP	C6S	Investigative
T47768	DRUGINFO	D0D1VB	Tyr-Pro-Phe-D-2-Nal-NH2	Investigative
T47768	DRUGINFO	D0E7CA	Tyr-D-Ala-Phe-Thr[-D-Glc(OAc)4]-Tyr-Pro-Ser-NH2	Investigative
T47768	DRUGINFO	D0F8CD	Tyr-Pro-Phe-D-Ala-Bn	Investigative
T47768	DRUGINFO	D0G1IF	naloxonazine	Investigative
T47768	DRUGINFO	D0G2BN	Tyr-Pro-Phg-Phe-NH2	Investigative
T47768	DRUGINFO	D0G2YV	KNT-5	Investigative
T47768	DRUGINFO	D0HL7Q	N-alpha-amidino-Tyr(Me)-D-Pro-Gly-Trp-Phe-NH2	Investigative
T47768	DRUGINFO	D0I1ZN	Ac-L-Phe-D-trp-L-Phe-D-pro-NH2	Investigative
T47768	DRUGINFO	D0IC5F	DM3B6S	Investigative
T47768	DRUGINFO	D0IQ0S	Tyr-Pro-Phe-Ala-Bn	Investigative
T47768	DRUGINFO	D0IU2K	YPAA-NH2	Investigative
T47768	DRUGINFO	D0J0ZU	KIN-3031	Investigative
T47768	DRUGINFO	D0J5IR	Tyr-Pro-Phe-D-Val-Bn	Investigative
T47768	DRUGINFO	D0J9DO	[Tyr-Pro-Phe-NH-CH2-]2	Investigative
T47768	DRUGINFO	D0JX3P	YAWF-NH2	Investigative
T47768	DRUGINFO	D0KQ8A	Tyr-Pro-Trp-D-Val-Bn	Investigative
T47768	DRUGINFO	D0KW4Y	H-Tyr-D-Ala-Tic-Asp-Val-Val-Gly-NH2	Investigative
T47768	DRUGINFO	D0N3GU	YPWA-NH2	Investigative
T47768	DRUGINFO	D0N5QC	Ethylmorphine	Investigative
T47768	DRUGINFO	D0O2LD	THEBAINE	Investigative
T47768	DRUGINFO	D0O7XU	[Tyr-Pro-Phe-Phe-NH-CH2-]2	Investigative
T47768	DRUGINFO	D0P2DF	Ac-YGGFL-NH2	Investigative
T47768	DRUGINFO	D0P2QV	Tyr-(R)-spiro-Aba-Gly-Phe-NH2	Investigative
T47768	DRUGINFO	D0P7YV	D-Phe-Cys-Tyr--Trp-Lys-Thr-Pen-Thr-NH2	Investigative
T47768	DRUGINFO	D0R0OZ	MORPHICEPTIN	Investigative
T47768	DRUGINFO	D0R1MB	DIHYDROAKUAMMINE	Investigative
T47768	DRUGINFO	D0R2VL	6-(2-benzylisoindolin-5-yloxy)nicotinamide	Investigative
T47768	DRUGINFO	D0R6VX	Tyr-Pro-Trp-Gly-Bn	Investigative
T47768	DRUGINFO	D0S3TZ	CYPRODIME	Investigative
T47768	DRUGINFO	D0S5BJ	MORPHINONE	Investigative
T47768	DRUGINFO	D0S6BX	PL017	Investigative
T47768	DRUGINFO	D0TA3V	ADC-5510	Investigative
T47768	DRUGINFO	D0TT5V	MM3B6S	Investigative
T47768	DRUGINFO	D0V0PY	M3S	Investigative
T47768	DRUGINFO	D0W3PR	Tyr-Pro-Trp-D-Ala-Bn	Investigative
T47768	DRUGINFO	D0WT7H	Beta-funaltrexamine	Investigative
T47768	DRUGINFO	D0WX3N	KRP-110	Investigative
T47768	DRUGINFO	D0X1SN	H-Tyr-D-Ala-Aic-Asp-Val-Val-Gly-NH2	Investigative
T47768	DRUGINFO	D0X4RU	KRP-100	Investigative
T47768	DRUGINFO	D0Z9YE	[Tyr-Pro-Phe-NH-]2	Investigative
T47768	DRUGINFO	D00FXL	H-Aba-ser-Gly-Phe-Leu-Thr-OH	Investigative
T47768	DRUGINFO	D00FZN	Tyr-(R)-Aba-Gly-Phe-NH2	Investigative
T47768	DRUGINFO	D00LLO	H-Dmt-Tic-Lys-NH-Ph	Investigative
T47768	DRUGINFO	D00MEM	H-Dmt-Tic-Gly-NH-CH2-Bid	Investigative
T47768	DRUGINFO	D00QLH	H-Dmt-Tic-D-Asp-N(Me)-Ph	Investigative
T47768	DRUGINFO	D00WBU	H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid	Investigative
T47768	DRUGINFO	D00WEV	H-Dmt-Tic-Glu-Dap(6DMN)-NH(2)	Investigative
T47768	DRUGINFO	D00XQV	Tyr-Pro-D-Phe-Pro-NH2	Investigative
T47768	DRUGINFO	D01HOP	H-mCpa-ala-Gly-Phe-leu-OH	Investigative
T47768	DRUGINFO	D01JSA	H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-NH2	Investigative
T47768	DRUGINFO	D01MFM	H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-OH	Investigative
T47768	DRUGINFO	D01SDX	H-Aba-ala-Gly-Phe-Met-OH	Investigative
T47768	DRUGINFO	D01TKS	Tyr-D-Ala-Gly-Phe-Met-NH2	Investigative
T47768	DRUGINFO	D02GMU	Tyr-Pro-3,5Dmp-Phe-NH2	Investigative
T47768	DRUGINFO	D02IQG	H-Dmt-Tic-NH-CH2-CH2-NH2	Investigative
T47768	DRUGINFO	D02TPK	Ac-RYYRIK-GGG-K-(NH2)-YRFB-GGGGG	Investigative
T47768	DRUGINFO	D02WUZ	Tyr-Pro-Phe-Phe-OCH2CH3	Investigative
T47768	DRUGINFO	D03BFH	N-alpha-amidino-Tyr(Me)-Pro-Trp-p-Cl-Phe-NH2	Investigative
T47768	DRUGINFO	D03BRB	(H-Dmt-Tic-Glu-NH-(CH(2))(5)-CO-Dap(6DMN)-NH(2)	Investigative
T47768	DRUGINFO	D03CKF	H-Tyr-c[D-Orn-Aic-Glu]-NH2	Investigative
T47768	DRUGINFO	D03HXN	3,6-bis(Dmt-Tic-NH-methyl)-2(1H)-pyrazinone	Investigative
T47768	DRUGINFO	D03KAQ	2-Benzylaminomethyl-3-hydroxymorphinan	Investigative
T47768	DRUGINFO	D03PMB	PTI-601	Investigative
T47768	DRUGINFO	D03RSA	M6S	Investigative
T47768	DRUGINFO	D03VSJ	Antanal 1	Investigative
T47768	DRUGINFO	D03WYO	KETOCYCLAZOCINE	Investigative
T47768	DRUGINFO	D03YDG	UFP-502	Investigative
T47768	DRUGINFO	D04BII	H-Dmt-Tic-D-Asp-NH-Ph	Investigative
T47768	DRUGINFO	D04EZN	Dimethylthiambutene	Investigative
T47768	DRUGINFO	D04IIB	H-Dmt-Tic-Asp-NH-Bzl	Investigative
T47768	DRUGINFO	D04JCK	Etorphine	Investigative
T47768	DRUGINFO	D04KHE	H-Tyr-Pro-Phe-Phe-NH-CH2-CH2-NH Tic Dmt-H	Investigative
T47768	DRUGINFO	D04POA	Tyr-Pro-L-Phe-Pro-NH2	Investigative
T47768	DRUGINFO	D04QXM	Tyr-D-Ala-Phe-Asp-Val-Val-Thr[Beta-D-Glc]-Gly-NH2	Investigative
T47768	DRUGINFO	D04RPI	Dmt-Pro-Trp-D-2-Nal-NH2	Investigative
T47768	DRUGINFO	D04SFK	H-Tyr-Tic-Phe-Phe-OH	Investigative
T47768	DRUGINFO	D04VJE	6-(2-phenethylisoindolin-5-yloxy)nicotinamide	Investigative
T47768	DRUGINFO	D05AFV	UFP-512	Investigative
T47768	DRUGINFO	D05EWZ	SPIROINDANYLOXYMORPHONE	Investigative
T47768	DRUGINFO	D05GFM	Tyr-(NMe)Ala-L-Phe-D-Pro-NH2	Investigative
T47768	DRUGINFO	D05KIQ	H-Dmt-Tic-Gly-N(Me)-Ph	Investigative
T47768	DRUGINFO	D05KIS	H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Phe-D-Asp-D-Nle-Trp-H	Investigative
T47768	DRUGINFO	D05NYR	H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-OH	Investigative
T47768	DRUGINFO	D05ZYZ	NalBzOH	Investigative
T47768	DRUGINFO	D06BAU	CTAP	Investigative
T47768	DRUGINFO	D06EES	Leucine-enkephalin	Investigative
T47768	DRUGINFO	D06SZI	MCL-457	Investigative
T47768	DRUGINFO	D06YMS	DADLE	Investigative
T47768	DRUGINFO	D07AUG	H-D-Trp-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2	Investigative
T47768	DRUGINFO	D07BPA	1-[3-(4-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol	Investigative
T47768	DRUGINFO	D07BXN	Tyr-Pro-Dmt-Phe-NH2	Investigative
T47768	DRUGINFO	D07DTN	H-Tyr-c[D-Orn-(D or L)Atc-Glu]-NH2	Investigative
T47768	DRUGINFO	D07GQE	Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2	Investigative
T47768	DRUGINFO	D07JIQ	H-Aba-Gly-Gly-Phe-Leu-OH	Investigative
T47768	DRUGINFO	D07LXZ	Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2	Investigative
T47768	DRUGINFO	D07QUY	C[L-Phe-D-pro-L-Tyr(OMe)-D-trp]	Investigative
T47768	DRUGINFO	D08BOD	D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2(CTAP)	Investigative
T47768	DRUGINFO	D08BST	N-isobutylnoroxymorphone	Investigative
T47768	DRUGINFO	D08CJB	H-Dmt-Tic-NH-(CH2)6-NH-Dmt-H	Investigative
T47768	DRUGINFO	D08COK	1,10-bis-(Dmt-Tic-amino)decane	Investigative
T47768	DRUGINFO	D08CXZ	H-Dmt-Tic-NH-CH2-Bta	Investigative
T47768	DRUGINFO	D08FGQ	Tyr-Pro-D-Phg-Phe-NH2	Investigative
T47768	DRUGINFO	D08FYQ	KNT-63	Investigative
T47768	DRUGINFO	D08LIT	SB-0304	Investigative
T47768	DRUGINFO	D08SCK	H-Dmt-Aba-Gly-NH-CH2-Ph	Investigative
T47768	DRUGINFO	D08STW	Tyr-Pro-L-(NMe)Phe-Pro-NH2	Investigative
T47768	DRUGINFO	D08VOC	3,6-bis(Dmt-Tic-NH-propyl)-2(1H)-pyrazinone	Investigative
T47768	DRUGINFO	D09BWX	C[L-Phe-D-pro-L-Phe-D-trp]	Investigative
T47768	DRUGINFO	D09CTG	Ac-RYYRIK-K-(NH2)-YRFB	Investigative
T47768	DRUGINFO	D09DAM	H-Dmt-Tic-Lys(Ac)-NH-CH2-Ph	Investigative
T47768	DRUGINFO	D09GQP	H-2',6'-dimethyltyrosine-Tic-OH	Investigative
T47768	DRUGINFO	D09GSD	H-Dmt-Aba-Gly-NH-CH2-Bid	Investigative
T47768	DRUGINFO	D09KBQ	FLUPERAMIDE	Investigative
T47768	DRUGINFO	D09MBV	H-Dmt-Tic-NH-(S)CH(CH2-COOH)-Bid(N1-Me)	Investigative
T47768	DRUGINFO	D09SBU	C[L-Ala-D-pro-L-Phe-D-trp]	Investigative
T47768	DRUGINFO	D0A9AJ	H-mCpa-ser-Gly-Phe-Leu-Thr-OH	Investigative
T47768	DRUGINFO	D0AJ9D	H-Dmt-Tic-Lys(Z)-NH-Ph	Investigative
T47768	DRUGINFO	D0B1JC	Tyr-Pro-Phe-Phe-N(CH3)2	Investigative
T47768	DRUGINFO	D0C4QH	Tyr-Pro-Mmp-Phe-NH	Investigative
T47768	DRUGINFO	D0C5RC	N-alpha-amidino-Tyr(Me)-Pro-Trp-Phe-NH2	Investigative
T47768	DRUGINFO	D0C9XB	D-PhGly-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2	Investigative
T47768	DRUGINFO	D0D1WB	Dynorphin(1-8)	Investigative
T47768	DRUGINFO	D0D5VD	C[L-Phe-D-pro-L-Tyr-D-trp]	Investigative
T47768	DRUGINFO	D0D6KZ	KNT-62	Investigative
T47768	DRUGINFO	D0D6OA	DM6S	Investigative
T47768	DRUGINFO	D0D8DZ	H-Dmt-Tic-NH-CH[(CH2)4-NH-Z]-Bid	Investigative
T47768	DRUGINFO	D0D9RL	(-)-eseroline	Investigative
T47768	DRUGINFO	D0DN6A	1,4-bis-(Dmt-Tic-amino)butane	Investigative
T47768	DRUGINFO	D0DO6P	MR-2034	Investigative
T47768	DRUGINFO	D0E3RQ	Ac-RYYRIK-GGG-K-(NH2)-YAFGYPS-GG	Investigative
T47768	DRUGINFO	D0E7NL	H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-OH	Investigative
T47768	DRUGINFO	D0ED2I	H-Dmt-Tic-Gly-NH-Ph	Investigative
T47768	DRUGINFO	D0EG7I	H-Dmt-Tic-Lys(Ac)-NH-Ph	Investigative
T47768	DRUGINFO	D0EM9A	DSLET	Investigative
T47768	DRUGINFO	D0ES7P	H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-NH2	Investigative
T47768	DRUGINFO	D0F1XY	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-Boc	Investigative
T47768	DRUGINFO	D0F8AX	1-benzhydryl-4-cyclopropylpiperidin-4-ol	Investigative
T47768	DRUGINFO	D0FT9J	Tyr-Pro-Tmp-Phe-NH	Investigative
T47768	DRUGINFO	D0H1BU	H-Dmt-Tic-Gly-NH-Bzl	Investigative
T47768	DRUGINFO	D0H2RF	Tyr-Pro-Imp-Phe-NH2	Investigative
T47768	DRUGINFO	D0H3QK	AMINOFENTANYL	Investigative
T47768	DRUGINFO	D0H6AA	M3Pr6S	Investigative
T47768	DRUGINFO	D0H8WV	Tyr-D-Ala-Phe-Gly-Tyr-Pro-Thr(Beta-D-Glc)-Gly-NH2	Investigative
T47768	DRUGINFO	D0HF0I	Tyr-Pro-Phe-Phe-NHCH3	Investigative
T47768	DRUGINFO	D0I1BJ	Dmt-Pro-Phe-D-1-Nal-NH2	Investigative
T47768	DRUGINFO	D0I9IX	Tyr-D-Ala-Phe-Thr(-D-Glc)-Tyr-Pro-Ser-NH2	Investigative
T47768	DRUGINFO	D0J2IK	3,6-bis(Dmt-Tic-NH-ethyl)-2(1H)-pyrazinone	Investigative
T47768	DRUGINFO	D0J7XM	DELTORPHIN-II	Investigative
T47768	DRUGINFO	D0K0XT	MR-1029	Investigative
T47768	DRUGINFO	D0K2OK	Tyr-Pro-Dmp-Phe-NH2	Investigative
T47768	DRUGINFO	D0K4AC	DELTORPHIN	Investigative
T47768	DRUGINFO	D0L3DM	Tyr-Pro-D-Phe-D-Pro-NH2	Investigative
T47768	DRUGINFO	D0L9NB	H-Dmt-Tic-NH-CH2-ImidPh	Investigative
T47768	DRUGINFO	D0M4DI	MR-2266	Investigative
T47768	DRUGINFO	D0M6BL	H-Tyr-Pro-Phe-Phe-NH-(CH2)5-(C=O)-Dap(6DMN)-NH2	Investigative
T47768	DRUGINFO	D0M6CZ	H-2',6'-dimethyltyrosine-Tic-Phe-Phe-OH	Investigative
T47768	DRUGINFO	D0MP7Z	Dmt-Pro-Phe-D-2-Nal-NH2	Investigative
T47768	DRUGINFO	D0MZ2A	CTOP	Investigative
T47768	DRUGINFO	D0N1AO	H-Dmt-Tic-NH-CH2-Indn	Investigative
T47768	DRUGINFO	D0N5TL	Antanal 2	Investigative
T47768	DRUGINFO	D0NB7S	Tyr-Pro-Phe-Phe-OC(CH3)3	Investigative
T47768	DRUGINFO	D0NE3U	DERMORPHIN	Investigative
T47768	DRUGINFO	D0O4KY	Tyr-Pro-Phe-Phe-OCH3	Investigative
T47768	DRUGINFO	D0O7NC	H-Dmt-Tic-NH-CH[(CH2)4-NH2]-Bid	Investigative
T47768	DRUGINFO	D0P1CP	H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-NH2	Investigative
T47768	DRUGINFO	D0P2GB	MR-1526	Investigative
T47768	DRUGINFO	D0P2KV	H-Dmt-Tic-Asp-N(Me)-Ph	Investigative
T47768	DRUGINFO	D0P2LE	2-(2-methylquinolin-4-ylamino)-N-phenylacetamide	Investigative
T47768	DRUGINFO	D0P4PM	H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-NH2	Investigative
T47768	DRUGINFO	D0P5EI	H-Dmt-Tic-Glu-NH-(CH2)5-NH2	Investigative
T47768	DRUGINFO	D0P5IH	C[L-Tyr(OMe)-D-pro-L-Phe-D-trp]	Investigative
T47768	DRUGINFO	D0P6AR	Tyr-Pro-L-(NMe)Phe-D-Pro-NH2	Investigative
T47768	DRUGINFO	D0P8NZ	H-Dmt-Tic-NH-CH2-Indl	Investigative
T47768	DRUGINFO	D0PN1A	H-Dmt-Tic-Asp-NH-Ph	Investigative
T47768	DRUGINFO	D0PN3P	H-Aba-ala-Gly-Phe-leu-OH	Investigative
T47768	DRUGINFO	D0Q0UQ	H-D-Tca-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2	Investigative
T47768	DRUGINFO	D0Q1PN	H-Tyr-D-Ala-Gly-Phe-NH-NH-(NMe)Phe-Asp-Nle-Trp-Ac	Investigative
T47768	DRUGINFO	D0Q2HZ	H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid(N1-Me)	Investigative
T47768	DRUGINFO	D0Q6CF	C[L-Tyr-D-pro-L-Phe-D-trp]	Investigative
T47768	DRUGINFO	D0Q7SS	Tyr-(S)-Aba-Gly-Phe-NH2	Investigative
T47768	DRUGINFO	D0R1DY	H-Dmt-Tic-Lys-NH-CH2-Ph	Investigative
T47768	DRUGINFO	D0R3GD	H-Dmt-Tic-NH-(D)-CH[(CH2)4-NH-Z]-Bid	Investigative
T47768	DRUGINFO	D0R4KJ	H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-OH	Investigative
T47768	DRUGINFO	D0R4YD	H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-OH	Investigative
T47768	DRUGINFO	D0R9AP	H-Apa-ala-Gly-Phe-leu-OH	Investigative
T47768	DRUGINFO	D0R9LV	1,6-bis-(N,N-dimethyl-Dmt-Tic-NH)hexane	Investigative
T47768	DRUGINFO	D0R9XD	H-Dmt-Tic-Lys(Z)-NH-CH2-Ph	Investigative
T47768	DRUGINFO	D0RR4X	H-D-Tic-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2	Investigative
T47768	DRUGINFO	D0S3LK	1,6-bis-(Dmt-Tic-amino)hexane	Investigative
T47768	DRUGINFO	D0S9UH	ZYKLOPHIN	Investigative
T47768	DRUGINFO	D0TH8E	M3P6S	Investigative
T47768	DRUGINFO	D0U3ZL	CARBOXYFENTANYL	Investigative
T47768	DRUGINFO	D0U4LU	H-Dmt-Tic-NH-(CH2)6-NH-Phe-H	Investigative
T47768	DRUGINFO	D0U5OP	1-[3-(3-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol	Investigative
T47768	DRUGINFO	D0U8YU	Tyr-Pro-Phe-Phe-OCH2OH	Investigative
T47768	DRUGINFO	D0UV1C	3,6-bis(Dmt-Tic-NH-butyl)-2(1H)-pyrazinone	Investigative
T47768	DRUGINFO	D0V2PM	H-Dmt-Tic-NH-CH2-Imid	Investigative
T47768	DRUGINFO	D0V3GN	Tyr-Pro-Phe-Phe-NHNH2	Investigative
T47768	DRUGINFO	D0V3OY	[3H]U69593	Investigative
T47768	DRUGINFO	D0V8UG	H-Dmt-Tic-NH-CH2-Boa	Investigative
T47768	DRUGINFO	D0W8MP	H-Dmt-Tic-Glu-NH2	Investigative
T47768	DRUGINFO	D0WZ7J	M3A6S	Investigative
T47768	DRUGINFO	D0X2HA	H-Dmt-Tic-NH-CH[(CH2)4-NH-Ac]-Bid	Investigative
T47768	DRUGINFO	D0X2HT	M3IBu6S	Investigative
T47768	DRUGINFO	D0X4YC	H-Dmt-Tic-NH-(CH2)6-NH-Tic-H	Investigative
T47768	DRUGINFO	D0X5TB	H-Cdp-ser-Gly-Phe-Leu-Thr-OH	Investigative
T47768	DRUGINFO	D0X9SP	D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2(CTP)	Investigative
T47768	DRUGINFO	D0X9TT	Tyr-(S)-spiro-Aba-Gly-Phe-NH2	Investigative
T47768	DRUGINFO	D0Y2HI	H-Dmt-Aba-Gly-NH-Ph	Investigative
T47768	DRUGINFO	D0Y2MT	Ac-RYYRIK-K-(NH2)-YAFGYPS	Investigative
T47768	DRUGINFO	D0Y5TF	Tyr-Pro-Emp-Phe-NH2	Investigative
T47768	DRUGINFO	D0Y5UN	Tyr-Pro-L-Phe-D-Pro-NH2	Investigative
T47768	DRUGINFO	D0Y9RD	H-Tyr-Pro-Ala-Phe-NH2	Investigative
T47768	DRUGINFO	D0YK5E	Oxymorphone semicarbazone hydrochloride	Investigative
T47768	DRUGINFO	D0Z5UG	H-Tyr-Tic-Cha-Phe-OH	Investigative
T47768	DRUGINFO	D0ZI5Z	H-Tyr-Pro-Dap(6DMN)-Phe-NH2	Investigative
T47768	DRUGINFO	D0ZQ7L	H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-NH2	Investigative
T47768	DRUGINFO	D00HIG	3-Methylthiofentanyl	Investigative
T47768	DRUGINFO	D00JAT	(-)-cyclorphan	Investigative
T47768	DRUGINFO	D00JPB	5-(4-((phenethylamino)methyl)phenoxy)picolinamide	Investigative
T47768	DRUGINFO	D00NRB	MCL-117	Investigative
T47768	DRUGINFO	D00SDP	17-(Cyclopropylmethyl)-N-phenylmorphinan-3-amine	Investigative
T47768	DRUGINFO	D00XZH	1-benzhydryl-4-isopropylpiperidin-4-ol	Investigative
T47768	DRUGINFO	D01ADK	Tyr-D-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2	Investigative
T47768	DRUGINFO	D01EPU	BUTORPHAN	Investigative
T47768	DRUGINFO	D01MUV	1-benzhydryl-4-tert-butylpiperidin-4-ol	Investigative
T47768	DRUGINFO	D01RFG	8-carboxamidocyclazocine	Investigative
T47768	DRUGINFO	D02BER	quadazocine	Investigative
T47768	DRUGINFO	D02FZW	17-methyl-4'-methyldihydromorphinone	Investigative
T47768	DRUGINFO	D02IMZ	MCL-443	Investigative
T47768	DRUGINFO	D02PIG	H-Cpa-Gly-Gly-Phe-Met-OH	Investigative
T47768	DRUGINFO	D02RYZ	MCL-450	Investigative
T47768	DRUGINFO	D03QWP	Dcp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2	Investigative
T47768	DRUGINFO	D03UFD	OXYMORPHINDOLE	Investigative
T47768	DRUGINFO	D03UHT	MCL-458	Investigative
T47768	DRUGINFO	D03WGS	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Ac	Investigative
T47768	DRUGINFO	D04JFL	Naltrexone-6-alpha-ol	Investigative
T47768	DRUGINFO	D04PPP	MCL-139	Investigative
T47768	DRUGINFO	D04UFM	Dmt-Pro-Dmt-Phe-NH2	Investigative
T47768	DRUGINFO	D04UIK	MCL-429	Investigative
T47768	DRUGINFO	D05ANN	naltriben	Investigative
T47768	DRUGINFO	D05EZE	Dmt-Pro-Phe-Phe-NH2	Investigative
T47768	DRUGINFO	D05FEQ	CYCLORPHAN	Investigative
T47768	DRUGINFO	D05JSY	MCL-145	Investigative
T47768	DRUGINFO	D05QJS	NORBINALTORPHIMINE	Investigative
T47768	DRUGINFO	D05RII	3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole	Investigative
T47768	DRUGINFO	D05TOY	Dmt-Pro-3,5Dmp-Phe-NH2	Investigative
T47768	DRUGINFO	D05YNT	[3H]diprenorphine	Investigative
T47768	DRUGINFO	D05ZIH	6beta-naltrexol HCl	Investigative
T47768	DRUGINFO	D06IXE	MCL-153	Investigative
T47768	DRUGINFO	D06KFX	C[L-Phe-D-pro-L-Phe-L-trp]	Investigative
T47768	DRUGINFO	D06MWG	Dmt-Pro-Mmp-Phe-NH2	Investigative
T47768	DRUGINFO	D06NST	CYCLAZOCINE	Investigative
T47768	DRUGINFO	D06OKE	MCL-433	Investigative
T47768	DRUGINFO	D06PVO	4-phenyl-1-(1-phenylpropyl)piperidin-4-ol	Investigative
T47768	DRUGINFO	D06WTI	NRP290	Investigative
T47768	DRUGINFO	D07AAK	M6G thiosaccharide analogue	Investigative
T47768	DRUGINFO	D07DFD	MCL-434	Investigative
T47768	DRUGINFO	D07FCB	4-phenyl-1-(1-phenylethyl)piperidin-4-ol	Investigative
T47768	DRUGINFO	D07HFU	MCL-446	Investigative
T47768	DRUGINFO	D07JZS	H-Tyr-c[D-Allylgly-Gly-Phe-L-Allylgly]NH2	Investigative
T47768	DRUGINFO	D08IWF	MCL-435	Investigative
T47768	DRUGINFO	D08KSJ	H-Tyr-D-Ala-Gly Phe-Pro-Leu-Trp-O-3,5-Bzl(CF3)2	Investigative
T47768	DRUGINFO	D08NJB	Trans-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH	Investigative
T47768	DRUGINFO	D08ORS	6-(Allyl-methyl-amino)-4,4-diphenyl-heptan-3-ol	Investigative
T47768	DRUGINFO	D08QKT	Tyr-D-Nle-Gly-Trp-NMeNle-Asp-Phe-NH2	Investigative
T47768	DRUGINFO	D08RPH	MCL-182	Investigative
T47768	DRUGINFO	D08YCS	TQ-1017	Investigative
T47768	DRUGINFO	D09DUE	MCL-447	Investigative
T47768	DRUGINFO	D09FLC	17-Methylmorphinan-3-yl 4-Iodophenyl Carbamate	Investigative
T47768	DRUGINFO	D09RUY	N-Benzyl-17-(cyclopropylmethyl)morphinan-3-amine	Investigative
T47768	DRUGINFO	D09UKS	MCL-183	Investigative
T47768	DRUGINFO	D0A5MU	Deprotected cogener of M6G	Investigative
T47768	DRUGINFO	D0B8MY	MCL-144	Investigative
T47768	DRUGINFO	D0C2UQ	MCL-428	Investigative
T47768	DRUGINFO	D0C6RQ	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-3,5-Bzl(CF3)2	Investigative
T47768	DRUGINFO	D0C7MP	MCL-448	Investigative
T47768	DRUGINFO	D0CK8C	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-O-Bzl	Investigative
T47768	DRUGINFO	D0CX0I	[Dcp1]Dyn A(1-11)-NH2	Investigative
T47768	DRUGINFO	D0D3UB	SN-23	Investigative
T47768	DRUGINFO	D0D8AN	6-desoxonaltrexone	Investigative
T47768	DRUGINFO	D0D9BB	1-benzhydryl-4-(pyridin-2-yl)piperidin-4-ol	Investigative
T47768	DRUGINFO	D0E0TD	4-(4-((phenethylamino)methyl)phenoxy)benzamide	Investigative
T47768	DRUGINFO	D0E1FQ	Dmt-Pro-Imp-Phe-NH2	Investigative
T47768	DRUGINFO	D0E6GH	14-O-phenylpropylnaltrexone	Investigative
T47768	DRUGINFO	D0F1EB	MC-CAM	Investigative
T47768	DRUGINFO	D0F4AN	MCL-432	Investigative
T47768	DRUGINFO	D0F8CV	DAMGO	Investigative
T47768	DRUGINFO	D0G4NM	DPDPE	Investigative
T47768	DRUGINFO	D0G6GC	Tyr-D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-Bzl	Investigative
T47768	DRUGINFO	D0G7FB	MCL-147	Investigative
T47768	DRUGINFO	D0H0KP	6-(4-(3-(benzylamino)propyl)phenoxy)nicotinamide	Investigative
T47768	DRUGINFO	D0H0OO	dynorphin B	Investigative
T47768	DRUGINFO	D0HB6O	H-Cdp-Gly-Gly-Phe-Leu-OH	Investigative
T47768	DRUGINFO	D0HC3H	Dimepheptanol	Investigative
T47768	DRUGINFO	D0HV6H	H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]NH2	Investigative
T47768	DRUGINFO	D0I1NG	6-(4-((phenethylamino)methyl)phenoxy)nicotinamide	Investigative
T47768	DRUGINFO	D0I2CE	C[L-mTyr-D-pro-L-Phe-D-trp]	Investigative
T47768	DRUGINFO	D0I9PH	H-Tyr-D-Ala-Gly-Phe-NH-NH-Trp-D-Nle-D-Asp-D-Phe-H	Investigative
T47768	DRUGINFO	D0I9SX	PHENAZOCINE	Investigative
T47768	DRUGINFO	D0IL9H	1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol	Investigative
T47768	DRUGINFO	D0IY2V	MCL-445	Investigative
T47768	DRUGINFO	D0J3NK	MCL-449	Investigative
T47768	DRUGINFO	D0K1BV	N-(17-Methylmorphinan-3-yl)-N'-phenylurea	Investigative
T47768	DRUGINFO	D0K4XQ	MCL-431	Investigative
T47768	DRUGINFO	D0KL5N	Dmt-Pro-Tmp-Phe-NH2	Investigative
T47768	DRUGINFO	D0L0NI	Dhp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2	Investigative
T47768	DRUGINFO	D0L2CT	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-3,5-Bzl(CF3)2	Investigative
T47768	DRUGINFO	D0L5DN	MCL-149	Investigative
T47768	DRUGINFO	D0L6QN	LOFENTANIL	Investigative
T47768	DRUGINFO	D0L8LX	H-Tyr-Gly-Gly-Phe-Met-NH2	Investigative
T47768	DRUGINFO	D0M1YV	ELAEOCARPENINE	Investigative
T47768	DRUGINFO	D0N8LP	Beta-endorphin	Investigative
T47768	DRUGINFO	D0NA7G	MCL-451	Investigative
T47768	DRUGINFO	D0NV5N	normorphine	Investigative
T47768	DRUGINFO	D0O1JD	6-(4-(2-(benzylamino)ethyl)phenoxy)nicotinamide	Investigative
T47768	DRUGINFO	D0O6SB	Diprenorphine	Investigative
T47768	DRUGINFO	D0P0RB	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-Bzl	Investigative
T47768	DRUGINFO	D0P5QI	2-Hydroxymethyl-3-hydroxymorphinan	Investigative
T47768	DRUGINFO	D0P6FF	N-Benzyl-17-(cyclobutylmethyl)morphinan-3-amine	Investigative
T47768	DRUGINFO	D0Q5AJ	MCL-154	Investigative
T47768	DRUGINFO	D0Q7HG	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-Bzl	Investigative
T47768	DRUGINFO	D0R1AB	H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]-OH	Investigative
T47768	DRUGINFO	D0R4QF	HERKINORIN	Investigative
T47768	DRUGINFO	D0R5TA	ENDOMORPHIN-1	Investigative
T47768	DRUGINFO	D0R6VF	Clocinnamox	Investigative
T47768	DRUGINFO	D0R7LY	Cis-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH	Investigative
T47768	DRUGINFO	D0S5FN	H-Cdp-ala-Gly-Phe-leu-OH	Investigative
T47768	DRUGINFO	D0S7SO	H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-Bo	Investigative
T47768	DRUGINFO	D0SC3W	Bis-((-)-N-propargylmorphinan-3-yl) sebacoylate	Investigative
T47768	DRUGINFO	D0T5EI	ethylketocyclazocine	Investigative
T47768	DRUGINFO	D0T6OQ	3-desoxy-3-carboxamidonaltrexone	Investigative
T47768	DRUGINFO	D0TB4A	Dmt-Pro-Emp-Phe-NH2	Investigative
T47768	DRUGINFO	D0TN0D	METAZOCINE	Investigative
T47768	DRUGINFO	D0TO0E	SN-28	Investigative
T47768	DRUGINFO	D0U3UM	ETONITAZENE	Investigative
T47768	DRUGINFO	D0U7JS	H-Cpa-Gly-Gly-Phe-Met-NH2	Investigative
T47768	DRUGINFO	D0UG8H	SN-11	Investigative
T47768	DRUGINFO	D0UR7D	Benzyl derivative of M6G	Investigative
T47768	DRUGINFO	D0V0RB	Tyr-D-Nle-Gly-D-Trp-Nle-Asp-Phe-NH2	Investigative
T47768	DRUGINFO	D0VO7C	HTyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-LysNH2	Investigative
T47768	DRUGINFO	D0W0CO	17-(Cyclobutylmethyl)-N-phenylmorphinan-3-amine	Investigative
T47768	DRUGINFO	D0W2DN	MCL-444	Investigative
T47768	DRUGINFO	D0W6OP	H-Tyr-c[D-Cys-Gly-Phe-D-Cys]NH2	Investigative
T47768	DRUGINFO	D0X0XV	Dmt-Pro-Dmp-Phe-NH2	Investigative
T47768	DRUGINFO	D0X6BU	H-Tyr-c[D-Cys-Gly-Phe-L-Cys]NH2	Investigative
T47768	DRUGINFO	D0X7LC	Tyr-Gly-Gly-Trp-NMeNle-Asp-Phe-NH2	Investigative
T47768	DRUGINFO	D0Y5ZP	N-(4-Iodophenyl)-N'-(17-methylmorphinan-3-yl)urea	Investigative
T47768	DRUGINFO	D0Y7KE	1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol	Investigative
T47768	DRUGINFO	D0Y8NO	RTI-5989-31	Investigative
T47768	DRUGINFO	D0YU5H	6-(4-((benzylamino)methyl)phenoxy)nicotinamide	Investigative
T47768	DRUGINFO	D0Z5JD	[Leu5]enkephalin	Investigative
T47768	DRUGINFO	D0Z8JX	C[L-Phe-D-pro-L-mTyr-D-trp]	Investigative
T47768	DRUGINFO	D0ZH3G	3-Methylfentanyl	Investigative
T47768	DRUGINFO	D00TNR	ENDOMORPHIN 2	Investigative
T47768	DRUGINFO	D00YCW	4-phenyl-1-(1-phenylbutyl)piperidin-4-ol	Investigative
T47768	DRUGINFO	D01AQC	Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2	Investigative
T47768	DRUGINFO	D01WMU	1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol	Investigative
T47768	DRUGINFO	D02EIB	4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol	Investigative
T47768	DRUGINFO	D03EPA	Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2	Investigative
T47768	DRUGINFO	D03PTV	1-benzhydryl-4-ethoxy-4-phenylpiperidine	Investigative
T47768	DRUGINFO	D03RBD	8-azabicyclo[3.2.1]octan-3-yloxy-benzamide	Investigative
T47768	DRUGINFO	D03UJW	1-benzhydryl-4-butylpiperidin-4-ol	Investigative
T47768	DRUGINFO	D04ZQX	4-phenyl-1-(1-phenylheptyl)piperidin-4-ol	Investigative
T47768	DRUGINFO	D06BRA	Tyr-D-Ala-Gly-D-Trp-Nle-Asp-Phe-NH2	Investigative
T47768	DRUGINFO	D06MQG	1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol	Investigative
T47768	DRUGINFO	D06PHT	1-benzhydryl-4-phenylpiperidin-4-ol	Investigative
T47768	DRUGINFO	D07CIU	1-benzhydryl-4-p-tolylpiperidin-4-ol	Investigative
T47768	DRUGINFO	D07ICW	Tyr-D-Ala-Gly-D-Trp-NMeNle-Asp-Phe-NH2	Investigative
T47768	DRUGINFO	D07LQQ	Tyr-D-Nle-Gly-Trp-Nle-Asp-Phe-NH2	Investigative
T47768	DRUGINFO	D07NMH	1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol	Investigative
T47768	DRUGINFO	D08DVV	1-benzhydryl-4-hexylpiperidin-4-ol	Investigative
T47768	DRUGINFO	D08QBU	1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol	Investigative
T47768	DRUGINFO	D08TFY	1-benzhydryl-4-cyclohexylpiperidin-4-ol	Investigative
T47768	DRUGINFO	D09BYD	1-benzhydryl-4-o-tolylpiperidin-4-ol	Investigative
T47768	DRUGINFO	D09EMR	Tyr-D-Phe-Gly-D-Trp-Nle-Asp-Phe-NH2	Investigative
T47768	DRUGINFO	D09FJY	4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol	Investigative
T47768	DRUGINFO	D09LRO	1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol	Investigative
T47768	DRUGINFO	D09VRT	1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol	Investigative
T47768	DRUGINFO	D0B7GU	Dihydromorphine	Investigative
T47768	DRUGINFO	D0D0UP	1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol	Investigative
T47768	DRUGINFO	D0D5QV	O-DESMETHYL TRAMADOL	Investigative
T47768	DRUGINFO	D0E2OG	Tyr-D-Nle-Gly-D-Trp-NMeNle-Asp-Phe-NH2	Investigative
T47768	DRUGINFO	D0G4FA	1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol	Investigative
T47768	DRUGINFO	D0G7DF	4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol	Investigative
T47768	DRUGINFO	D0J5JO	1-benzhydryl-4-m-tolylpiperidin-4-ol	Investigative
T47768	DRUGINFO	D0J7GJ	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-H	Investigative
T47768	DRUGINFO	D0JH5D	1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol	Investigative
T47768	DRUGINFO	D0N6DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Boc	Investigative
T47768	DRUGINFO	D0O7JV	4-phenyl-1-(1-phenylhexyl)piperidin-4-ol	Investigative
T47768	DRUGINFO	D0P3FP	4-phenyl-1-(1-phenylpentyl)piperidin-4-ol	Investigative
T47768	DRUGINFO	D0Q9TQ	1-benzhydryl-4-methoxy-4-phenylpiperidine	Investigative
T47768	DRUGINFO	D0QH4A	1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol	Investigative
T47768	DRUGINFO	D0QP2S	Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-NMeNle-D-Trp-Boc	Investigative
T47768	DRUGINFO	D0R4GI	Tyr-D-Ala-Gly-Trp-NMeNle-Asp-Phe-NH2	Investigative
T47768	DRUGINFO	D0T4ZY	1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol	Investigative
T47768	DRUGINFO	D0T9KE	1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol	Investigative
T47768	DRUGINFO	D0TR0U	Tyr-D-Phe-Gly-D-Trp-NMeNle-Asp-Phe-NH2	Investigative
T47768	DRUGINFO	D0U6OA	Tyr-D-Ala-Gly-Trp-Nle-Asp-Phe-NH2	Investigative
T47768	DRUGINFO	D0V9DY	H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-H	Investigative
T47768	DRUGINFO	D0W3VT	1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol	Investigative
T47768	DRUGINFO	D0X4SX	1-benzhydryl-4-phenyl-4-propoxypiperidine	Investigative
T47768	DRUGINFO	D0XX1Y	4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol	Investigative
T47768	DRUGINFO	D0Y5LJ	1-benzhydryl-4-(furan-2-yl)piperidin-4-ol	Investigative
T47768	DRUGINFO	D0ZE2W	1-benzhydryl-4-benzylpiperidin-4-ol	Investigative
T47768	DRUGINFO	D03SAV	ICI-199441	Investigative
T47768	DRUGINFO	D08UOX	FALCARINDIOL	Investigative
T47768	DRUGINFO	D0L9YP	4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide	Investigative
T47768	DRUGINFO	D0T5RO	SOMATOSTATIN	Investigative
T47768	DRUGINFO	D0L5MW	(+/-)-nantenine	Investigative
T47768	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T02551	TARGETID	T02551
T02551	FORMERID	TTDS00013
T02551	UNIPROID	DRD3_HUMAN
T02551	TARGNAME	Dopamine D3 receptor (D3R)
T02551	GENENAME	DRD3
T02551	TARGTYPE	Successful
T02551	SYNONYMS	D(3) dopamine receptor
T02551	FUNCTION	Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
T02551	PDBSTRUC	3PBL
T02551	BIOCLASS	GPCR rhodopsin
T02551	SEQUENCE	MASLSQLSSHLNYTCGAENSTGASQARPHAYYALSYCALILAIVFGNGLVCMAVLKERALQTTTNYLVVSLAVADLLVATLVMPWVVYLEVTGGVWNFSRICCDVFVTLDVMMCTASILNLCAISIDRYTAVVMPVHYQHGTGQSSCRRVALMITAVWVLAFAVSCPLLFGFNTTGDPTVCSISNPDFVIYSSVVSFYLPFGVTVLVYARIYVVLKQRRRKRILTRQNSQCNSVRPGFPQQTLSPDPAHLELKRYYSICQDTALGGPGFQERGGELKREEKTRNSLSPTIAPKLSLEVRKLSNGRLSTSLKLGPLQPRGVPLREKKATQMVAIVLGAFIVCWLPFFLTHVLNTHCQTCHVSPELYSATTWLGYVNSALNPVIYTTFNIEFRKAFLKILSC
T02551	DRUGINFO	D05XGO	Cariprazine	Approved
T02551	DRUGINFO	D0G8NN	Pramipexole	Approved
T02551	DRUGINFO	D0R9EQ	Ropinirole	Approved
T02551	DRUGINFO	D01NKW	P2B-001	Phase 3
T02551	DRUGINFO	D0X6XH	CM-2395	Phase 3
T02551	DRUGINFO	D03RIO	GSK598809	Phase 2
T02551	DRUGINFO	DD5VO3	TAK-906	Phase 2
T02551	DRUGINFO	D07XQS	ONC201	Phase 2
T02551	DRUGINFO	D05XEA	RP5063	Phase 2
T02551	DRUGINFO	D0H3ID	Pfizer 10	Phase 1
T02551	DRUGINFO	D0HI1K	GSK618334	Phase 1
T02551	DRUGINFO	D0M1UF	Aryl piperazine derivative 1	Patented
T02551	DRUGINFO	D0Z9WY	Aryl piperazine derivative 6	Patented
T02551	DRUGINFO	D0Z2WQ	Quinelorane	Discontinued in Phase 3
T02551	DRUGINFO	D0EE6L	BP-897	Discontinued in Phase 2
T02551	DRUGINFO	D0FH3X	A-437203	Discontinued in Phase 2
T02551	DRUGINFO	D01WJZ	MAZAPERTINE	Discontinued in Phase 2
T02551	DRUGINFO	D06ZWG	AVE-5997EF	Discontinued in Phase 1
T02551	DRUGINFO	D0UZ1I	S-33138	Discontinued in Phase 1
T02551	DRUGINFO	D0K5EE	S-33084	Preclinical
T02551	DRUGINFO	D0Q2VL	PD-157533	Preclinical
T02551	DRUGINFO	D0T3JW	U-99194A	Preclinical
T02551	DRUGINFO	D0Q3GV	S32504	Preclinical
T02551	DRUGINFO	D0R1PZ	F-15063	Preclinical
T02551	DRUGINFO	D04UXX	PD-158771	Preclinical
T02551	DRUGINFO	D0F6WV	PD-157695	Preclinical
T02551	DRUGINFO	D01ZSF	GR-218231	Terminated
T02551	DRUGINFO	D03AZY	PNU-177864	Terminated
T02551	DRUGINFO	D0G2LT	RGH-1756	Terminated
T02551	DRUGINFO	D0Y6SN	SB-277011	Terminated
T02551	DRUGINFO	D05IPO	BTS-79018	Terminated
T02551	DRUGINFO	D08KDP	AS-8112	Terminated
T02551	DRUGINFO	D0G3MH	PNU-96391A	Terminated
T02551	DRUGINFO	D0OW1R	YM-43611	Terminated
T02551	DRUGINFO	D0P3IZ	E-2040	Terminated
T02551	DRUGINFO	D0V1SD	BP4.879a	Terminated
T02551	DRUGINFO	D0N5UA	Dianicline+rimonabant	Terminated
T02551	DRUGINFO	D00XEN	NGB 2904	Investigative
T02551	DRUGINFO	D02YDU	4-Dipropylamino-cyclohex-1-enecarbonitrile	Investigative
T02551	DRUGINFO	D05NQX	PD-152255	Investigative
T02551	DRUGINFO	D08TCX	(2-Benzyl-phenyl)-(2-pyrrolidin-1-yl-ethyl)-amine	Investigative
T02551	DRUGINFO	D0C0UM	(4-Dipropylamino-cyclohexylidene)-acetonitrile	Investigative
T02551	DRUGINFO	D0J1HP	(R)-2-(Benzylamino-methyl)-chroman-7-ol	Investigative
T02551	DRUGINFO	D0T2MV	AS-9705	Investigative
T02551	DRUGINFO	D0X1QW	(+)-AJ76	Investigative
T02551	DRUGINFO	D00CDM	PD 128907	Investigative
T02551	DRUGINFO	D00QMQ	D-220	Investigative
T02551	DRUGINFO	D00SDJ	A-706149	Investigative
T02551	DRUGINFO	D01URS	PF-592379	Investigative
T02551	DRUGINFO	D03EDW	D-193	Investigative
T02551	DRUGINFO	D03PYX	[3H]7-OH-DPAT	Investigative
T02551	DRUGINFO	D03ZOJ	D-189	Investigative
T02551	DRUGINFO	D04PBA	3-(4-Benzyl-piperazin-1-yl)-phenol	Investigative
T02551	DRUGINFO	D04RBU	D-366	Investigative
T02551	DRUGINFO	D05HMW	2-(4-Dipropylamino-cyclohexylidene)-malononitrile	Investigative
T02551	DRUGINFO	D05NED	D-190	Investigative
T02551	DRUGINFO	D06HTJ	D-264	Investigative
T02551	DRUGINFO	D07ISL	D-210	Investigative
T02551	DRUGINFO	D09AQJ	D-203	Investigative
T02551	DRUGINFO	D09FTZ	(4-Phenylethynyl-cyclohex-3-enyl)-dipropyl-amine	Investigative
T02551	DRUGINFO	D09PJF	D-315	Investigative
T02551	DRUGINFO	D0B4SL	D-218	Investigative
T02551	DRUGINFO	D0D2CU	(R)-(-)-2-Methyl-apomorphine hydrochloride	Investigative
T02551	DRUGINFO	D0FU2V	D-237	Investigative
T02551	DRUGINFO	D0HG4U	(R)-(-)-2-Phenyl-apomorphine hydrochloride	Investigative
T02551	DRUGINFO	D0M5XV	D-219	Investigative
T02551	DRUGINFO	D0M7SY	SB269652	Investigative
T02551	DRUGINFO	D0M8LN	A-690344	Investigative
T02551	DRUGINFO	D0PV6G	(+)-S-14297	Investigative
T02551	DRUGINFO	D0Q7FM	Azaperone	Investigative
T02551	DRUGINFO	D0S5ZE	D-192	Investigative
T02551	DRUGINFO	D0S7WZ	(-)-3-(1-Propyl-piperidin-3-yl)-benzonitrile	Investigative
T02551	DRUGINFO	D0YB0K	7-trans-OH-PIPAT	Investigative
T02551	DRUGINFO	D00HUV	[2-(1H-Benzoimidazol-4-yloxy)-ethyl]-benzyl-amine	Investigative
T02551	DRUGINFO	D01KIH	4-(4-Benzyl-piperazin-1-yl)-1H-benzoimidazole	Investigative
T02551	DRUGINFO	D03GES	1-Benzyl-4-(3-oxazol-5-yl-pyrrol-1-yl)-piperidine	Investigative
T02551	DRUGINFO	D03JOS	3-(4-Phenyl-piperazin-1-ylmethyl)-1H-indole	Investigative
T02551	DRUGINFO	D04CPW	N-(4-Propylaminobutyl)-4-biphenylcarboxamide	Investigative
T02551	DRUGINFO	D04CTN	3-(1-Propyl-pyrrolidin-3-yl)-phenol	Investigative
T02551	DRUGINFO	D05BCJ	1-Benzyl-4-pyrrol-1-yl-piperidine	Investigative
T02551	DRUGINFO	D05QJK	Benzyl-[2-(1H-indazol-4-yloxy)-ethyl]-amine	Investigative
T02551	DRUGINFO	D06NTB	3-(4-Methyl-piperidin-1-ylmethyl)-1H-indole	Investigative
T02551	DRUGINFO	D06WLB	Benzyl-[2-(1H-indol-4-yloxy)-ethyl]-amine	Investigative
T02551	DRUGINFO	D0H3KU	5-OH-DPAT	Investigative
T02551	DRUGINFO	D0IU8V	4-(2-Benzylamino-ethoxy)-1,3-dihydro-indol-2-one	Investigative
T02551	DRUGINFO	D0LV7U	1-(4-(4-phenyl-1-piperazinyl)butyl)indolin-2-one	Investigative
T02551	DRUGINFO	D0M3PV	L-741626	Investigative
T02551	DRUGINFO	D0O1PM	(4-Ethynyl-cyclohex-3-enyl)-dipropyl-amine	Investigative
T02551	DRUGINFO	D0O9BZ	4-(4-Benzyl-piperazin-1-yl)-1H-indole	Investigative
T02551	DRUGINFO	D0Q5IP	3-(4-Phenyl-piperidin-1-ylmethyl)-1H-indole	Investigative
T02551	DRUGINFO	D0S1XN	4-(4-Benzyl-piperazin-1-yl)-7-bromo-1H-indole	Investigative
T02551	DRUGINFO	D0T1TU	Etoloxamine	Investigative
T02551	DRUGINFO	D0TU5W	4-(4-Benzyl-piperazin-1-yl)-5-chloro-1H-indole	Investigative
T02551	DRUGINFO	D06LQH	N-propylnorapomorphine	Investigative
T02551	DRUGINFO	D07RYR	1-[2-(2-Benzyl-phenoxy)-ethyl]-pyrrolidine	Investigative
T02551	DRUGINFO	D07UUQ	1-Benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine	Investigative
T02551	DRUGINFO	D0B9DR	1-Benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine	Investigative
T02551	DRUGINFO	D0H2WQ	QUINPIROLE	Investigative
T02551	DRUGINFO	D0I4VT	1-Propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine	Investigative
T02551	DRUGINFO	D0M2BB	1-(4-(1H-pyrazol-1-yl)benzyl)-4-phenylpiperazine	Investigative
T02551	DRUGINFO	D0M2ZE	UH-232	Investigative
T02551	DRUGINFO	D0O4BC	3-(2-Benzylamino-ethoxy)-phenol	Investigative
T02551	DRUGINFO	D0O7DA	(+)-BUTACLAMOL	Investigative
T02551	DRUGINFO	D0V4NW	N-(4-Dipropylaminobutyl)-4-biphenylcarboxamide	Investigative
T02551	DRUGINFO	D0W1HM	nafadotride	Investigative
T02551	DRUGINFO	D0WD6J	1-Benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine	Investigative
T02551	DRUGINFO	D0WU9R	L-741742	Investigative
T02551	DRUGINFO	D05UUW	1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine	Investigative
T02551	DRUGINFO	D0E1RX	1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine	Investigative
T02551	DRUGINFO	D0L7OM	STEPHOLIDINE	Investigative
T02551	DRUGINFO	D0MC2R	FLUTROLINE	Investigative
T02551	DRUGINFO	D0R8UU	1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine	Investigative
T02551	DRUGINFO	D07GQP	PG-01037	Investigative
T02551	DRUGINFO	D07GXY	piribedil	Investigative
T02551	DRUGINFO	D05EQG	[3H]spiperone	Investigative
T02551	DRUGINFO	D07LRJ	SB-271046	Investigative
T02551	DRUGINFO	D0PN9R	R-226161	Investigative
T02551	DRUGINFO	D0HV3A	FLUMEZAPINE	Investigative
T02551	DRUGINFO	D0Q2GP	ISOLOXAPINE	Investigative
T02551	DRUGINFO	D0F9QT	A-987306	Investigative
T02551	DRUGINFO	D0P0IX	ISOCLOZAPINE	Investigative
T02551	DRUGINFO	D0L5MW	(+/-)-nantenine	Investigative
T02551	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T79232	TARGETID	T79232
T79232	FORMERID	TTDS00109
T79232	UNIPROID	V1AR_HUMAN
T79232	TARGNAME	Vasopressin V1a receptor (V1AR)
T79232	GENENAME	AVPR1A
T79232	TARGTYPE	Successful
T79232	SYNONYMS	Vascular/hepatic-type arginine vasopressin receptor; V1aR; V1a vasopressin receptor; Antidiuretic hormone receptor 1a; AVPR1; AVPR V1a
T79232	FUNCTION	The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system. Has been involved in social behaviors, including affiliation and attachment. Receptor for arginine vasopressin.
T79232	PDBSTRUC	1YTV
T79232	BIOCLASS	GPCR rhodopsin
T79232	SEQUENCE	MRLSAGPDAGPSGNSSPWWPLATGAGNTSREAEALGEGNGPPRDVRNEELAKLEIAVLAVTFAVAVLGNSSVLLALHRTPRKTSRMHLFIRHLSLADLAVAFFQVLPQMCWDITYRFRGPDWLCRVVKHLQVFGMFASAYMLVVMTADRYIAVCHPLKTLQQPARRSRLMIAAAWVLSFVLSTPQYFVFSMIEVNNVTKARDCWATFIQPWGSRAYVTWMTGGIFVAPVVILGTCYGFICYNIWCNVRGKTASRQSKGAEQAGVAFQKGFLLAPCVSSVKSISRAKIRTVKMTFVIVTAYIVCWAPFFIIQMWSVWDPMSVWTESENPTITITALLGSLNSCCNPWIYMFFSGHLLQDCVQSFPCCQNMKEKFNKEDTDSMSRRQTFYSNNRSPTNSTGMWKDSPKSSKSIKFIPVST
T79232	DRUGINFO	D0H3MG	Felypressin	Approved
T79232	DRUGINFO	D0P4VX	Terlipressin	Approved
T79232	DRUGINFO	D0VU2X	Conivaptan	Approved
T79232	DRUGINFO	D0F4NS	Mozavaptan	Approved
T79232	DRUGINFO	D0M3FJ	Oxytocin	Approved
T79232	DRUGINFO	D0U7SH	Desmopressin	Approved
T79232	DRUGINFO	D0D8XY	ATOSIBAN	Phase 4
T79232	DRUGINFO	DY7MH5	Balovaptan	Phase 3
T79232	DRUGINFO	D00LSW	VA-111913	Phase 2
T79232	DRUGINFO	D0F4VW	SRX-246	Phase 2
T79232	DRUGINFO	D0L4HL	RG7314	Phase 2
T79232	DRUGINFO	D0S3YN	FE-202158	Phase 2
T79232	DRUGINFO	DNS58L	SRX246	Phase 2
T79232	DRUGINFO	D0SY9B	SSR149415	Phase 2
T79232	DRUGINFO	D0G2XE	PMX-53	Phase 2
T79232	DRUGINFO	D0PB0D	SRX-251	Phase 1
T79232	DRUGINFO	D8TO6D	NMRA-511	Phase 1
T79232	DRUGINFO	D01GCI	PMID25776143-Compound-7	Patented
T79232	DRUGINFO	D03TLQ	PMID25776143-Compound-1	Patented
T79232	DRUGINFO	D07WNO	Tetra-azabenzo[e]azulene derivative 1	Patented
T79232	DRUGINFO	D0GT5M	Tetra-azabenzo[e]azulene derivative 2	Patented
T79232	DRUGINFO	D0H9AU	PMID25776143-Compound-8	Patented
T79232	DRUGINFO	D0LZ5Q	PMID25776143-Compound-4	Patented
T79232	DRUGINFO	D0MQ6T	PMID25776143-Compound-3	Patented
T79232	DRUGINFO	D0TV9B	PMID25776143-Compound-2	Patented
T79232	DRUGINFO	D0BU3L	Pyrrolidine derivative 13	Patented
T79232	DRUGINFO	D0H0QR	PMID28906174-Compound-figure1g	Patented
T79232	DRUGINFO	D08ORO	OPC-21268	Discontinued in Phase 2
T79232	DRUGINFO	D0A1KU	PF-3274167	Discontinued in Phase 1
T79232	DRUGINFO	D09KAK	NOX-F37	Preclinical
T79232	DRUGINFO	D02RDE	JTV-605	Terminated
T79232	DRUGINFO	D08PAC	L-371257	Terminated
T79232	DRUGINFO	D0D9OM	V1A F/U	Investigative
T79232	DRUGINFO	D0I8ZZ	Relcovaptan	Investigative
T79232	DRUGINFO	D0Q3VN	HO-LVA	Investigative
T79232	DRUGINFO	D01WHI	L023103	Investigative
T79232	DRUGINFO	D02FXZ	DesGly-NH2,d(CH2)5[D-Tyr2,Thr4,Orn8(5/6C-Flu)]VT	Investigative
T79232	DRUGINFO	D03QUQ	LS-192629	Investigative
T79232	DRUGINFO	D09HMT	[HO1][Orn8(5/6C-Rhm)]VT	Investigative
T79232	DRUGINFO	D0BS2Q	[Thr4,Gly7]OT	Investigative
T79232	DRUGINFO	D0K5NV	[Lys8(Alexa 546) ]PVA	Investigative
T79232	DRUGINFO	D0Q0OR	SSR126768A	Investigative
T79232	DRUGINFO	D0T3YS	CL-385004	Investigative
T79232	DRUGINFO	D0Y0SO	DVDAVP	Investigative
T79232	DRUGINFO	D0Y1AJ	D(CH2)5[Tyr(Me)2,Thr4,Orn8(5/6C-Flu),Tyr-NH29]VT	Investigative
T79232	DRUGINFO	D0YG0D	1'-tosylspiro[indene-1,4'-piperidine]	Investigative
T79232	DRUGINFO	D00HAJ	Hoo-Phe-Orn-Pro-hle-Pff-Phe-NH2	Investigative
T79232	DRUGINFO	D00NIT	YM 471	Investigative
T79232	DRUGINFO	D00SGZ	YM 218	Investigative
T79232	DRUGINFO	D02VVG	D[Orn8(5/6C-Flu)]VT	Investigative
T79232	DRUGINFO	D02YBV	[Val4]AVP	Investigative
T79232	DRUGINFO	D03EBH	D(CH2)5[Tyr(Me)2,Thr4,Orn8,Tyr9-NH2]VT	Investigative
T79232	DRUGINFO	D04JXX	d[Pen1,Tyr(Me)2]AVP	Investigative
T79232	DRUGINFO	D05YHE	D[Thr4,Lys8(5/6C-Flu)]VT	Investigative
T79232	DRUGINFO	D09BWP	[HO1][Orn8(5/6C-Flu)]VT	Investigative
T79232	DRUGINFO	D09OML	D[D-3-Pal2]AVP	Investigative
T79232	DRUGINFO	D0C8XX	D[Thr4,Orn8(5/6C-Flu)]VT	Investigative
T79232	DRUGINFO	D0K0JJ	[HO1][Lys8(5/6C-Flu)]VT	Investigative
T79232	DRUGINFO	D0L0RP	[Lys8(Alexa 488) ]PVA	Investigative
T79232	DRUGINFO	D0M3BJ	D[Lys8(5/6-Flu)]VT	Investigative
T79232	DRUGINFO	D0O6WN	[HO1][Thr4,Orn8(5/6C-Flu)]VT	Investigative
T79232	DRUGINFO	D0T4ML	L-372662	Investigative
T79232	DRUGINFO	D0Y4HL	[Phe3]OT	Investigative
T79232	DRUGINFO	D0Y5FO	[HO1][Thr4,Lys8(5/6C-Flu)]VT	Investigative
T79232	DRUGINFO	D01FDW	ARGENINE VASOPRESSIN	Investigative
T79232	DRUGINFO	D03BVC	D[Arg4,Orn8]VP	Investigative
T79232	DRUGINFO	D03DXK	D[Leu4,Lys8]VP	Investigative
T79232	DRUGINFO	D04MMD	D[Arg4,Lys8]VP	Investigative
T79232	DRUGINFO	D05BHL	D[Cha4,Lys8]VP	Investigative
T79232	DRUGINFO	D05RNF	D[Cha4,Orn8]VP	Investigative
T79232	DRUGINFO	D06SDG	D[Leu4,Dab8]VP	Investigative
T79232	DRUGINFO	D09RIE	D[Cha4]AVP	Investigative
T79232	DRUGINFO	D09XWA	D[Cha4,Dap8]VP	Investigative
T79232	DRUGINFO	D0A6FK	D[Leu4]AVP	Investigative
T79232	DRUGINFO	D0HI2N	D[Cha4,Dab8]VP	Investigative
T79232	DRUGINFO	D0M4QM	d(CH2)5[Tyr(Me)2]AVP	Investigative
T79232	DRUGINFO	D0O5TK	D[Leu4,Dap8]VP	Investigative
T79232	DRUGINFO	D0O8OF	D[Orn4,Lys8]VP	Investigative
T79232	DRUGINFO	D0R7QC	D[Arg4]AVP	Investigative
T79232	DRUGINFO	D0UK0O	D[Arg4,Dab8]VP	Investigative
T79232	DRUGINFO	D0V3FF	D[Leu4,Orn8]VP	Investigative
T79232	DRUGINFO	D0W3IQ	D[Val4]AVP	Investigative
T79232	DRUGINFO	D0YJ6C	D[Orn4,Orn8]VP	Investigative
T79232	DRUGINFO	D0ZD0W	D[Orn4]AVP	Investigative
T79232	DRUGINFO	D0F9QT	A-987306	Investigative

T73495	TARGETID	T73495
T73495	FORMERID	TTDS00122
T73495	UNIPROID	GRIK1_HUMAN
T73495	TARGNAME	Glutamate receptor ionotropic kainate 1 (GRIK1)
T73495	GENENAME	GRIK1
T73495	TARGTYPE	Successful
T73495	SYNONYMS	Glutamate receptor 5; GluR5 kainate receptor; GluR5; GluR-5; GRIK1; Excitatory amino acid receptor 3; EAA3
T73495	FUNCTION	Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L- glutamate induces a conformation change, leading tothe opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist. May be involved in the transmission of light information from the retina to the hypothalamus.
T73495	PDBSTRUC	4MF3; 3FVO; 3FVN; 3FVK; 3FVG
T73495	BIOCLASS	Glutamate-gated ion channel
T73495	SEQUENCE	MEHGTLLAQPGLWTRDTSWALLYFLCYILPQTAPQVLRIGGIFETVENEPVNVEELAFKFAVTSINRNRTLMPNTTLTYDIQRINLFDSFEASRRACDQLALGVAALFGPSHSSSVSAVQSICNALEVPHIQTRWKHPSVDNKDLFYINLYPDYAAISRAILDLVLYYNWKTVTVVYEDSTGLIRLQELIKAPSRYNIKIKIRQLPSGNKDAKPLLKEMKKGKEFYVIFDCSHETAAEILKQILFMGMMTEYYHYFFTTLDLFALDLELYRYSGVNMTGFRLLNIDNPHVSSIIEKWSMERLQAPPRPETGLLDGMMTTEAALMYDAVYMVAIASHRASQLTVSSLQCHRHKPWRLGPRFMNLIKEARWDGLTGHITFNKTNGLRKDFDLDIISLKEEGTEKAAGEVSKHLYKVWKKIGIWNSNSGLNMTDSNKDKSSNITDSLANRTLIVTTILEEPYVMYRKSDKPLYGNDRFEGYCLDLLKELSNILGFIYDVKLVPDGKYGAQNDKGEWNGMVKELIDHRADLAVAPLTITYVREKVIDFSKPFMTLGISILYRKPNGTNPGVFSFLNPLSPDIWMYVLLACLGVSCVLFVIARFTPYEWYNPHPCNPDSDVVENNFTLLNSFWFGVGALMQQGSELMPKALSTRIVGGIWWFFTLIIISSYTANLAAFLTVERMESPIDSADDLAKQTKIEYGAVRDGSTMTFFKKSKISTYEKMWAFMSSRQQTALVRNSDEGIQRVLTTDYALLMESTSIEYVTQRNCNLTQIGGLIDSKGYGVGTPIGSPYRDKITIAILQLQEEGKLHMMKEKWWRGNGCPEEDNKEASALGVENIGGIFIVLAAGLVLSVFVAIGEFIYKSRKNNDIEQAFCFFYGLQCKQTHPTNSTSGTTLSTDLECGKLIREERGIRKQSSVHTV
T73495	DRUGINFO	D07VDZ	Topiramate	Approved
T73495	DRUGINFO	D0B0NQ	LY293558	Phase 2
T73495	DRUGINFO	D0H7GQ	NS 1209	Phase 2
T73495	DRUGINFO	D02VKC	NBQX	Phase 1
T73495	DRUGINFO	D02TTF	YM-90K	Discontinued in Phase 2
T73495	DRUGINFO	D01BAG	ACET	Investigative
T73495	DRUGINFO	D01DMS	(S)-5-iodowillardiine	Investigative
T73495	DRUGINFO	D01HOO	8-deoxy-neodysiherbaine	Investigative
T73495	DRUGINFO	D01KEH	Domoric acid	Investigative
T73495	DRUGINFO	D01RSH	2-(3-bromobenzoylamino)-4-chlorobenzoic acid	Investigative
T73495	DRUGINFO	D02RGB	LY339434	Investigative
T73495	DRUGINFO	D03NDD	LY466195	Investigative
T73495	DRUGINFO	D03UIR	(2S,4R)-4-(3-Methoxy-3-oxopropyl)glutamic Acid	Investigative
T73495	DRUGINFO	D04XZP	DIHYDROKAINATE	Investigative
T73495	DRUGINFO	D05ERF	TQX-173	Investigative
T73495	DRUGINFO	D05FZE	ATPA	Investigative
T73495	DRUGINFO	D09VYB	UBP-302	Investigative
T73495	DRUGINFO	D0B2VW	2S,4R-4-METHYLGLUTAMATE	Investigative
T73495	DRUGINFO	D0BN4U	MSVIII-19	Investigative
T73495	DRUGINFO	D0KD6O	(S)-4-AHCP	Investigative
T73495	DRUGINFO	D0N1CL	2-(3-(3-bromophenyl)ureido)-4-chlorobenzoic acid	Investigative
T73495	DRUGINFO	D0T1MK	LY382884	Investigative
T73495	DRUGINFO	D0T8IK	S-ATPO	Investigative
T73495	DRUGINFO	D0TT9H	NS3763	Investigative
T73495	DRUGINFO	D00VEZ	2,4-epi-neodysiherbaine	Investigative
T73495	DRUGINFO	D0J1PG	2-AMINO-3-(4-HYDROXY-1,2,5-OXADIAZOL-3-YL)PROPIONIC ACID (STRUCTURAL MIX)	Investigative
T73495	DRUGINFO	D0K5UI	UBP310	Investigative
T73495	DRUGINFO	D09KRH	domoic acid	Investigative
T73495	DRUGINFO	D0K6AF	dysiherbaine	Investigative
T73495	DRUGINFO	D05KQC	DNQX	Investigative
T73495	DRUGINFO	D0S8AN	SYM2081	Investigative
T73495	DRUGINFO	D04PFN	[3H]kainate	Investigative
T73495	DRUGINFO	D06DUE	[3H]quisqualate	Investigative

T29130	TARGETID	T29130
T29130	FORMERID	TTDS00275
T29130	UNIPROID	STAT3_HUMAN
T29130	TARGNAME	Signal transducer and activator of transcription 3 (STAT3)
T29130	GENENAME	STAT3
T29130	TARGTYPE	Successful
T29130	SYNONYMS	Acute-phase response factor; APRF
T29130	FUNCTION	Signal transducer and transcription activator that mediates cellular responses to interleukins, KITLG/SCF, LEP and other growth factors. Once activated, recruits coactivators, such as NCOA1 or MED1, to the promoter region of the target gene. May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4. Binds to the interleukin-6 (IL-6)-responsive elements identified in the promoters of various acute-phase protein genes. Activated by IL31 through IL31RA. Acts as a regulator of inflammatory response by regulating differentiation of naive CD4(+) T-cells into T-helper Th17 or regulatory T-cells (Treg): deacetylation and oxidation of lysine residues by LOXL3, leads to disrupt STAT3 dimerization and inhibit its transcription activity. Involved in cell cycle regulation by inducing the expression of key genes for the progression from G1 to S phase, such as CCND1. Mediates the effects of LEP on melanocortin production, body energy homeostasis and lactation (By similarity). May play an apoptotic role by transctivating BIRC5 expression under LEP activation. Cytoplasmic STAT3 represses macroautophagy by inhibiting EIF2AK2/PKR activity. Plays a crucial role in basal beta cell functions, such as regulation of insulin secretion (By similarity).
T29130	PDBSTRUC	5U5S; 5AX3
T29130	BIOCLASS	Transcription factor
T29130	SEQUENCE	MAQWNQLQQLDTRYLEQLHQLYSDSFPMELRQFLAPWIESQDWAYAASKESHATLVFHNLLGEIDQQYSRFLQESNVLYQHNLRRIKQFLQSRYLEKPMEIARIVARCLWEESRLLQTAATAAQQGGQANHPTAAVVTEKQQMLEQHLQDVRKRVQDLEQKMKVVENLQDDFDFNYKTLKSQGDMQDLNGNNQSVTRQKMQQLEQMLTALDQMRRSIVSELAGLLSAMEYVQKTLTDEELADWKRRQQIACIGGPPNICLDRLENWITSLAESQLQTRQQIKKLEELQQKVSYKGDPIVQHRPMLEERIVELFRNLMKSAFVVERQPCMPMHPDRPLVIKTGVQFTTKVRLLVKFPELNYQLKIKVCIDKDSGDVAALRGSRKFNILGTNTKVMNMEESNNGSLSAEFKHLTLREQRCGNGGRANCDASLIVTEELHLITFETEVYHQGLKIDLETHSLPVVVISNICQMPNAWASILWYNMLTNNPKNVNFFTKPPIGTWDQVAEVLSWQFSSTTKRGLSIEQLTTLAEKLLGPGVNYSGCQITWAKFCKENMAGKGFSFWVWLDNIIDLVKKYILALWNEGYIMGFISKERERAILSTKPPGTFLLRFSESSKEGGVTFTWVEKDISGKTQIQSVEPYTKQQLNNMSFAEIIMGYKIMDATNILVSPLVYLYPDIPKEEAFGKYCRPESQEHPEADPGSAAPYLKTKFICVTPTTCSNTIDLPMSPRTLDSLMQFGNNGEGAEPSAGGQFESLTFDMELTSECATSPM
T29130	DRUGINFO	D05QDC	Acitretin	Approved
T29130	DRUGINFO	D01IGZ	Napabucasin	Phase 3
T29130	DRUGINFO	D02MRN	Golotimod	Phase 2
T29130	DRUGINFO	D0D9LJ	Atiprimod	Phase 1/2
T29130	DRUGINFO	D0E7IM	OPB-31121	Phase 1/2
T29130	DRUGINFO	D0H7DM	IMX-110	Phase 1/2
T29130	DRUGINFO	D0P7IL	GLG-801	Phase 1/2
T29130	DRUGINFO	D0IV4C	WP-1066	Phase 1/2
T29130	DRUGINFO	DUI59O	NT219	Phase 1/2
T29130	DRUGINFO	D01FFC	OPB-51602	Phase 1
T29130	DRUGINFO	D01RCM	TAK-114	Phase 1
T29130	DRUGINFO	D3U8YR	WP1220	Phase 1
T29130	DRUGINFO	DLJN17	DSP-0337	Phase 1
T29130	DRUGINFO	DN81JB	OPB-111077	Phase 1
T29130	DRUGINFO	D00FUZ	Quinoline carboxamide derivative 2	Patented
T29130	DRUGINFO	D02CJU	Peptidomimetic analog 3	Patented
T29130	DRUGINFO	D02ILH	PMID26394986-Compound-11	Patented
T29130	DRUGINFO	D02KDA	Flavonoid derivative 5	Patented
T29130	DRUGINFO	D03ARS	Salicylic acid derivative 6	Patented
T29130	DRUGINFO	D03HEP	Gold-complexed thiosaccharide derivative 2	Patented
T29130	DRUGINFO	D03VMP	Peptidomimetic analog 1	Patented
T29130	DRUGINFO	D03XAK	Quinoline carboxamide derivative 1	Patented
T29130	DRUGINFO	D04ANB	Salicylic acid derivative 4	Patented
T29130	DRUGINFO	D04GVY	PMID26394986-Compound-12	Patented
T29130	DRUGINFO	D06RBL	PMID26394986-Compound-21	Patented
T29130	DRUGINFO	D08EID	Salicylic acid derivative 5	Patented
T29130	DRUGINFO	D08ETA	PMID26394986-Compound-20	Patented
T29130	DRUGINFO	D08SEP	PMID26394986-Compound-43	Patented
T29130	DRUGINFO	D09BOL	PMID26394986-Compound-50	Patented
T29130	DRUGINFO	D09CKU	PMID26394986-Compound-44	Patented
T29130	DRUGINFO	D09SYX	PMID26394986-Compound-51	Patented
T29130	DRUGINFO	D09ZCV	Salicylic acid derivative 3	Patented
T29130	DRUGINFO	D0D8RR	Quinoline carboxamide derivative 3	Patented
T29130	DRUGINFO	D0DC3S	Pyrazole derivative 62	Patented
T29130	DRUGINFO	D0ET3L	Pyrazole derivative 63	Patented
T29130	DRUGINFO	D0EV5U	Flavonoid derivative 3	Patented
T29130	DRUGINFO	D0EW9W	Peptide analog 7	Patented
T29130	DRUGINFO	D0EX9O	Salicylic acid derivative 1	Patented
T29130	DRUGINFO	D0FH4G	Gold-complexed thiosaccharide derivative 1	Patented
T29130	DRUGINFO	D0J1US	Gold-complexed thiosaccharide derivative 3	Patented
T29130	DRUGINFO	D0KP0U	PMID26394986-Compound-22	Patented
T29130	DRUGINFO	D0M5AR	Pyrazole derivative 65	Patented
T29130	DRUGINFO	D0M8OV	Pyrazole derivative 64	Patented
T29130	DRUGINFO	D0MA8T	PMID26394986-Compound-42	Patented
T29130	DRUGINFO	D0QR1I	Peptidomimetic analog 2	Patented
T29130	DRUGINFO	D0S0UL	Pyrazole derivative 66	Patented
T29130	DRUGINFO	D0T1GB	PMID26394986-Compound-52	Patented
T29130	DRUGINFO	D0U7LL	Salicylic acid derivative 2	Patented
T29130	DRUGINFO	D0V3PA	Salicylic acid derivative 7	Patented
T29130	DRUGINFO	D0V7HS	PMID26394986-Compound-53	Patented
T29130	DRUGINFO	D0V7NH	Flavonoid derivative 1	Patented
T29130	DRUGINFO	D0WW1Z	PMID26394986-Compound-54	Patented
T29130	DRUGINFO	D0X6QQ	Peptidomimetic analog 4	Patented
T29130	DRUGINFO	D0Y0OQ	PMID26394986-Compound-13	Patented
T29130	DRUGINFO	D0Y2PO	Tri-substituted purine derivative 1	Patented
T29130	DRUGINFO	D0Y3DN	Flavonoid derivative 4	Patented
T29130	DRUGINFO	D0Z8BD	Flavonoid derivative 2	Patented
T29130	DRUGINFO	D0ZQ8T	PMID26394986-Compound-Figure16	Patented
T29130	DRUGINFO	D0ZS8Q	PMID26394986-Compound-Figure17	Patented
T29130	DRUGINFO	D0EZ6V	Oxazole derivative 1	Patented
T29130	DRUGINFO	D0IC8O	Curcumin analog 2	Patented
T29130	DRUGINFO	D0WD1Z	Curcumin analog 1	Patented
T29130	DRUGINFO	D0XQ3F	Peptidomimetic analog 5	Patented
T29130	DRUGINFO	D01BVU	Platinum IV complexe 1	Patented
T29130	DRUGINFO	D0TU0X	PMID26394986-Compound-10	Patented
T29130	DRUGINFO	D06PZK	GNF-PF-1399	Investigative

T58992	TARGETID	T58992
T58992	FORMERID	TTDS00128
T58992	UNIPROID	OPRD_HUMAN
T58992	TARGNAME	Opioid receptor delta (OPRD1)
T58992	GENENAME	OPRD1
T58992	TARGTYPE	Successful
T58992	SYNONYMS	OPRD; Delta-type opioid receptor; Delta opioid receptor; DOR-1; D-OR-1
T58992	FUNCTION	Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. Plays a role in developing analgesic tolerance to morphine. G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids.
T58992	PDBSTRUC	4RWD; 4RWA; 4N6H; 2IQM; 1OZC
T58992	BIOCLASS	GPCR rhodopsin
T58992	SEQUENCE	MEPAPSAGAELQPPLFANASDAYPSACPSAGANASGPPGARSASSLALAIAITALYSAVCAVGLLGNVLVMFGIVRYTKMKTATNIYIFNLALADALATSTLPFQSAKYLMETWPFGELLCKAVLSIDYYNMFTSIFTLTMMSVDRYIAVCHPVKALDFRTPAKAKLINICIWVLASGVGVPIMVMAVTRPRDGAVVCMLQFPSPSWYWDTVTKICVFLFAFVVPILIITVCYGLMLLRLRSVRLLSGSKEKDRSLRRITRMVLVVVGAFVVCWAPIHIFVIVWTLVDIDRRDPLVVAALHLCIALGYANSSLNPVLYAFLDENFKRCFRQLCRKPCGRPDPSSFSRAREATARERVTACTPSDGPGGGAAA
T58992	DRUGINFO	D03DIG	Codeine	Approved
T58992	DRUGINFO	D0CS2F	Loperamide	Approved
T58992	DRUGINFO	D0X9RG	Butorphanol	Approved
T58992	DRUGINFO	D03SKD	Oxycodone	Approved
T58992	DRUGINFO	D04JHN	Hydromorphone	Approved
T58992	DRUGINFO	D09ZXR	Eluxadoline	Approved
T58992	DRUGINFO	D04DQZ	AZD-2327	Phase 2
T58992	DRUGINFO	D0N9VZ	ADL-5747	Phase 2
T58992	DRUGINFO	D0W9ZT	ADL-5859	Phase 2
T58992	DRUGINFO	D0V5WL	Met-enkephalin	Phase 2
T58992	DRUGINFO	D03PJU	Carfentanil	Phase 2
T58992	DRUGINFO	D0LU5Q	TPM-1/Morphine	Phase 2
T58992	DRUGINFO	D09FOP	MCP-202	Phase 1
T58992	DRUGINFO	D0Q1HD	TRV250	Phase 1
T58992	DRUGINFO	D00HBR	AIKO-150	Phase 1
T58992	DRUGINFO	D01AKU	MCP-201	Phase 1
T58992	DRUGINFO	D06EXA	SALVINORIN A	Phase 1
T58992	DRUGINFO	D0G1YN	DPI-3290	Discontinued in Phase 2
T58992	DRUGINFO	D0Y8SK	Dynorphin a	Discontinued in Phase 2
T58992	DRUGINFO	D0R1XI	TRK-851	Discontinued in Phase 1
T58992	DRUGINFO	D0J5XZ	VP004	Discontinued in Phase 1
T58992	DRUGINFO	D01WVJ	BIO-306	Preclinical
T58992	DRUGINFO	D0N1RG	SoRI-9409	Preclinical
T58992	DRUGINFO	D0C2QF	LY-25582	Preclinical
T58992	DRUGINFO	D0K5KL	BW 373U86	Terminated
T58992	DRUGINFO	D0Y0ZB	SB-219825	Terminated
T58992	DRUGINFO	D0LX5D	BIPHALIN	Terminated
T58992	DRUGINFO	D08YUP	SB-213698	Terminated
T58992	DRUGINFO	D0W8TS	SNF-9007	Terminated
T58992	DRUGINFO	D00BXG	TIPPpsi	Investigative
T58992	DRUGINFO	D00HDC	MCP-204	Investigative
T58992	DRUGINFO	D01GYS	Tyr-Gly-Gly-Phe-leu-c(Cys-Arg-Ile-Arg-Cys)-lys	Investigative
T58992	DRUGINFO	D02ALI	H-Tyr-c[pen-Gly-Phe-pen]OH	Investigative
T58992	DRUGINFO	D02REM	DPI-221	Investigative
T58992	DRUGINFO	D03VEQ	Tyr-Gly-Gly-Phe-c(Cys-Arg-Arg-Ile-Cys)-Arg-lys	Investigative
T58992	DRUGINFO	D04EQE	N-methylstephisoferulin	Investigative
T58992	DRUGINFO	D05EXX	AKNADILACTAM	Investigative
T58992	DRUGINFO	D05JHA	H-Tyr-c[cys-Gly-Phe(p-NO2)-cys]NH2	Investigative
T58992	DRUGINFO	D06DDA	6-cinnamoylhernandine	Investigative
T58992	DRUGINFO	D06XDA	Grandisine F	Investigative
T58992	DRUGINFO	D07ZIG	H-Tyr-Tic-OH	Investigative
T58992	DRUGINFO	D08IXN	[3H]naltrindole	Investigative
T58992	DRUGINFO	D09RJT	Grandisine C	Investigative
T58992	DRUGINFO	D09RZB	BBI-11008	Investigative
T58992	DRUGINFO	D09WKT	ARD-412	Investigative
T58992	DRUGINFO	D0A3YH	H-Tyr-NMe-D-Ala-Phe-Sar-NH2	Investigative
T58992	DRUGINFO	D0B3BJ	ICI-174864	Investigative
T58992	DRUGINFO	D0D4AU	PROSTEPHABYSSINE	Investigative
T58992	DRUGINFO	D0E4YP	SB 227122	Investigative
T58992	DRUGINFO	D0E6IT	H-mCpa-Gly-Gly-Phe-Leu-OH	Investigative
T58992	DRUGINFO	D0FT5V	(-)-isoelaeocarpiline	Investigative
T58992	DRUGINFO	D0G1XL	DSTBULET	Investigative
T58992	DRUGINFO	D0H8ID	Tonazocine mesylate	Investigative
T58992	DRUGINFO	D0J7VL	H-Cxp-ala-Gly-Phe-leu-OH	Investigative
T58992	DRUGINFO	D0LL4C	TIP	Investigative
T58992	DRUGINFO	D0M8YB	PERIPENTADENINE	Investigative
T58992	DRUGINFO	D0N6ZO	6-cinnamoyl-N-methylstephasunoline	Investigative
T58992	DRUGINFO	D0N7FU	D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2(CTOP)	Investigative
T58992	DRUGINFO	D0O7NF	MCP-205	Investigative
T58992	DRUGINFO	D0OH7D	7-benzylidenenaltrexone	Investigative
T58992	DRUGINFO	D0P2TT	H-Cpa-c[pen-Gly-Phe-pen]OH	Investigative
T58992	DRUGINFO	D0Q3XK	LONGANINE	Investigative
T58992	DRUGINFO	D0QA1M	MCP-203	Investigative
T58992	DRUGINFO	D0U5QL	Grandisine D	Investigative
T58992	DRUGINFO	D0U7PT	ANALOG OF DYNORPHIN A	Investigative
T58992	DRUGINFO	D0UA3E	N-methylstephuline	Investigative
T58992	DRUGINFO	D0W1YD	H-Poa-ser-Gly-Phe-Leu-Thr-OH	Investigative
T58992	DRUGINFO	D0Y4SP	ICI 154129	Investigative
T58992	DRUGINFO	D0Y7CI	SNC-80	Investigative
T58992	DRUGINFO	D0Z6DK	Isoelaeocarpine	Investigative
T58992	DRUGINFO	D0ZY3C	Lophocladine a	Investigative
T58992	DRUGINFO	D00FXL	H-Aba-ser-Gly-Phe-Leu-Thr-OH	Investigative
T58992	DRUGINFO	D00FZN	Tyr-(R)-Aba-Gly-Phe-NH2	Investigative
T58992	DRUGINFO	D00LLO	H-Dmt-Tic-Lys-NH-Ph	Investigative
T58992	DRUGINFO	D00MEM	H-Dmt-Tic-Gly-NH-CH2-Bid	Investigative
T58992	DRUGINFO	D00QLH	H-Dmt-Tic-D-Asp-N(Me)-Ph	Investigative
T58992	DRUGINFO	D00WBU	H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid	Investigative
T58992	DRUGINFO	D00WEV	H-Dmt-Tic-Glu-Dap(6DMN)-NH(2)	Investigative
T58992	DRUGINFO	D00XQV	Tyr-Pro-D-Phe-Pro-NH2	Investigative
T58992	DRUGINFO	D01HOP	H-mCpa-ala-Gly-Phe-leu-OH	Investigative
T58992	DRUGINFO	D01JSA	H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-NH2	Investigative
T58992	DRUGINFO	D01MFM	H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-OH	Investigative
T58992	DRUGINFO	D01SDX	H-Aba-ala-Gly-Phe-Met-OH	Investigative
T58992	DRUGINFO	D01TKS	Tyr-D-Ala-Gly-Phe-Met-NH2	Investigative
T58992	DRUGINFO	D02GMU	Tyr-Pro-3,5Dmp-Phe-NH2	Investigative
T58992	DRUGINFO	D02IQG	H-Dmt-Tic-NH-CH2-CH2-NH2	Investigative
T58992	DRUGINFO	D02WUZ	Tyr-Pro-Phe-Phe-OCH2CH3	Investigative
T58992	DRUGINFO	D03BFH	N-alpha-amidino-Tyr(Me)-Pro-Trp-p-Cl-Phe-NH2	Investigative
T58992	DRUGINFO	D03BRB	(H-Dmt-Tic-Glu-NH-(CH(2))(5)-CO-Dap(6DMN)-NH(2)	Investigative
T58992	DRUGINFO	D03CKF	H-Tyr-c[D-Orn-Aic-Glu]-NH2	Investigative
T58992	DRUGINFO	D03HXN	3,6-bis(Dmt-Tic-NH-methyl)-2(1H)-pyrazinone	Investigative
T58992	DRUGINFO	D03VSJ	Antanal 1	Investigative
T58992	DRUGINFO	D03YDG	UFP-502	Investigative
T58992	DRUGINFO	D04BII	H-Dmt-Tic-D-Asp-NH-Ph	Investigative
T58992	DRUGINFO	D04EZN	Dimethylthiambutene	Investigative
T58992	DRUGINFO	D04IIB	H-Dmt-Tic-Asp-NH-Bzl	Investigative
T58992	DRUGINFO	D04JCK	Etorphine	Investigative
T58992	DRUGINFO	D04KHE	H-Tyr-Pro-Phe-Phe-NH-CH2-CH2-NH Tic Dmt-H	Investigative
T58992	DRUGINFO	D04POA	Tyr-Pro-L-Phe-Pro-NH2	Investigative
T58992	DRUGINFO	D04QXM	Tyr-D-Ala-Phe-Asp-Val-Val-Thr[Beta-D-Glc]-Gly-NH2	Investigative
T58992	DRUGINFO	D04RPI	Dmt-Pro-Trp-D-2-Nal-NH2	Investigative
T58992	DRUGINFO	D04SFK	H-Tyr-Tic-Phe-Phe-OH	Investigative
T58992	DRUGINFO	D04VJE	6-(2-phenethylisoindolin-5-yloxy)nicotinamide	Investigative
T58992	DRUGINFO	D05AFV	UFP-512	Investigative
T58992	DRUGINFO	D05GFM	Tyr-(NMe)Ala-L-Phe-D-Pro-NH2	Investigative
T58992	DRUGINFO	D05KIQ	H-Dmt-Tic-Gly-N(Me)-Ph	Investigative
T58992	DRUGINFO	D05KIS	H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Phe-D-Asp-D-Nle-Trp-H	Investigative
T58992	DRUGINFO	D05NYR	H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-OH	Investigative
T58992	DRUGINFO	D06BAU	CTAP	Investigative
T58992	DRUGINFO	D06EES	Leucine-enkephalin	Investigative
T58992	DRUGINFO	D06NIP	Tyr-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2	Investigative
T58992	DRUGINFO	D06YMS	DADLE	Investigative
T58992	DRUGINFO	D07AUG	H-D-Trp-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2	Investigative
T58992	DRUGINFO	D07BPA	1-[3-(4-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol	Investigative
T58992	DRUGINFO	D07BXN	Tyr-Pro-Dmt-Phe-NH2	Investigative
T58992	DRUGINFO	D07DTN	H-Tyr-c[D-Orn-(D or L)Atc-Glu]-NH2	Investigative
T58992	DRUGINFO	D07GQE	Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2	Investigative
T58992	DRUGINFO	D07JIQ	H-Aba-Gly-Gly-Phe-Leu-OH	Investigative
T58992	DRUGINFO	D07LXZ	Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2	Investigative
T58992	DRUGINFO	D07PPK	4-phenyl-4-[1H-imidazol-2-yl]-piperidine	Investigative
T58992	DRUGINFO	D08BOD	D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2(CTAP)	Investigative
T58992	DRUGINFO	D08CJB	H-Dmt-Tic-NH-(CH2)6-NH-Dmt-H	Investigative
T58992	DRUGINFO	D08COK	1,10-bis-(Dmt-Tic-amino)decane	Investigative
T58992	DRUGINFO	D08CXZ	H-Dmt-Tic-NH-CH2-Bta	Investigative
T58992	DRUGINFO	D08FGQ	Tyr-Pro-D-Phg-Phe-NH2	Investigative
T58992	DRUGINFO	D08LIT	SB-0304	Investigative
T58992	DRUGINFO	D08SCK	H-Dmt-Aba-Gly-NH-CH2-Ph	Investigative
T58992	DRUGINFO	D08STW	Tyr-Pro-L-(NMe)Phe-Pro-NH2	Investigative
T58992	DRUGINFO	D08VOC	3,6-bis(Dmt-Tic-NH-propyl)-2(1H)-pyrazinone	Investigative
T58992	DRUGINFO	D09DAM	H-Dmt-Tic-Lys(Ac)-NH-CH2-Ph	Investigative
T58992	DRUGINFO	D09GQP	H-2',6'-dimethyltyrosine-Tic-OH	Investigative
T58992	DRUGINFO	D09GSD	H-Dmt-Aba-Gly-NH-CH2-Bid	Investigative
T58992	DRUGINFO	D09MBV	H-Dmt-Tic-NH-(S)CH(CH2-COOH)-Bid(N1-Me)	Investigative
T58992	DRUGINFO	D0A9AJ	H-mCpa-ser-Gly-Phe-Leu-Thr-OH	Investigative
T58992	DRUGINFO	D0AJ9D	H-Dmt-Tic-Lys(Z)-NH-Ph	Investigative
T58992	DRUGINFO	D0B1JC	Tyr-Pro-Phe-Phe-N(CH3)2	Investigative
T58992	DRUGINFO	D0C4QH	Tyr-Pro-Mmp-Phe-NH	Investigative
T58992	DRUGINFO	D0C5RC	N-alpha-amidino-Tyr(Me)-Pro-Trp-Phe-NH2	Investigative
T58992	DRUGINFO	D0C9XB	D-PhGly-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2	Investigative
T58992	DRUGINFO	D0D5SK	ethyketazocine	Investigative
T58992	DRUGINFO	D0D8DZ	H-Dmt-Tic-NH-CH[(CH2)4-NH-Z]-Bid	Investigative
T58992	DRUGINFO	D0D9RL	(-)-eseroline	Investigative
T58992	DRUGINFO	D0DN6A	1,4-bis-(Dmt-Tic-amino)butane	Investigative
T58992	DRUGINFO	D0E7NL	H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-OH	Investigative
T58992	DRUGINFO	D0ED2I	H-Dmt-Tic-Gly-NH-Ph	Investigative
T58992	DRUGINFO	D0EG7I	H-Dmt-Tic-Lys(Ac)-NH-Ph	Investigative
T58992	DRUGINFO	D0EM9A	DSLET	Investigative
T58992	DRUGINFO	D0ES7P	H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-NH2	Investigative
T58992	DRUGINFO	D0F1XY	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-Boc	Investigative
T58992	DRUGINFO	D0FT9J	Tyr-Pro-Tmp-Phe-NH	Investigative
T58992	DRUGINFO	D0H1BU	H-Dmt-Tic-Gly-NH-Bzl	Investigative
T58992	DRUGINFO	D0H2RF	Tyr-Pro-Imp-Phe-NH2	Investigative
T58992	DRUGINFO	D0H3QK	AMINOFENTANYL	Investigative
T58992	DRUGINFO	D0H8WV	Tyr-D-Ala-Phe-Gly-Tyr-Pro-Thr(Beta-D-Glc)-Gly-NH2	Investigative
T58992	DRUGINFO	D0HF0I	Tyr-Pro-Phe-Phe-NHCH3	Investigative
T58992	DRUGINFO	D0I1BJ	Dmt-Pro-Phe-D-1-Nal-NH2	Investigative
T58992	DRUGINFO	D0I3XV	RTI-5989-25	Investigative
T58992	DRUGINFO	D0I9IX	Tyr-D-Ala-Phe-Thr(-D-Glc)-Tyr-Pro-Ser-NH2	Investigative
T58992	DRUGINFO	D0J2IK	3,6-bis(Dmt-Tic-NH-ethyl)-2(1H)-pyrazinone	Investigative
T58992	DRUGINFO	D0J7XM	DELTORPHIN-II	Investigative
T58992	DRUGINFO	D0K2OK	Tyr-Pro-Dmp-Phe-NH2	Investigative
T58992	DRUGINFO	D0K4AC	DELTORPHIN	Investigative
T58992	DRUGINFO	D0L3DM	Tyr-Pro-D-Phe-D-Pro-NH2	Investigative
T58992	DRUGINFO	D0L9NB	H-Dmt-Tic-NH-CH2-ImidPh	Investigative
T58992	DRUGINFO	D0M6BL	H-Tyr-Pro-Phe-Phe-NH-(CH2)5-(C=O)-Dap(6DMN)-NH2	Investigative
T58992	DRUGINFO	D0M6CZ	H-2',6'-dimethyltyrosine-Tic-Phe-Phe-OH	Investigative
T58992	DRUGINFO	D0MP7Z	Dmt-Pro-Phe-D-2-Nal-NH2	Investigative
T58992	DRUGINFO	D0MZ2A	CTOP	Investigative
T58992	DRUGINFO	D0N0JC	RTI-5989-23	Investigative
T58992	DRUGINFO	D0N1AO	H-Dmt-Tic-NH-CH2-Indn	Investigative
T58992	DRUGINFO	D0N5TL	Antanal 2	Investigative
T58992	DRUGINFO	D0NB7S	Tyr-Pro-Phe-Phe-OC(CH3)3	Investigative
T58992	DRUGINFO	D0NE3U	DERMORPHIN	Investigative
T58992	DRUGINFO	D0O4KY	Tyr-Pro-Phe-Phe-OCH3	Investigative
T58992	DRUGINFO	D0O7NC	H-Dmt-Tic-NH-CH[(CH2)4-NH2]-Bid	Investigative
T58992	DRUGINFO	D0P1CP	H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-NH2	Investigative
T58992	DRUGINFO	D0P2KV	H-Dmt-Tic-Asp-N(Me)-Ph	Investigative
T58992	DRUGINFO	D0P4PM	H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-NH2	Investigative
T58992	DRUGINFO	D0P5EI	H-Dmt-Tic-Glu-NH-(CH2)5-NH2	Investigative
T58992	DRUGINFO	D0P6AR	Tyr-Pro-L-(NMe)Phe-D-Pro-NH2	Investigative
T58992	DRUGINFO	D0P8NZ	H-Dmt-Tic-NH-CH2-Indl	Investigative
T58992	DRUGINFO	D0PN1A	H-Dmt-Tic-Asp-NH-Ph	Investigative
T58992	DRUGINFO	D0PN3P	H-Aba-ala-Gly-Phe-leu-OH	Investigative
T58992	DRUGINFO	D0Q0UQ	H-D-Tca-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2	Investigative
T58992	DRUGINFO	D0Q1PN	H-Tyr-D-Ala-Gly-Phe-NH-NH-(NMe)Phe-Asp-Nle-Trp-Ac	Investigative
T58992	DRUGINFO	D0Q2HZ	H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid(N1-Me)	Investigative
T58992	DRUGINFO	D0Q7SS	Tyr-(S)-Aba-Gly-Phe-NH2	Investigative
T58992	DRUGINFO	D0R1DY	H-Dmt-Tic-Lys-NH-CH2-Ph	Investigative
T58992	DRUGINFO	D0R3GD	H-Dmt-Tic-NH-(D)-CH[(CH2)4-NH-Z]-Bid	Investigative
T58992	DRUGINFO	D0R4KJ	H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-OH	Investigative
T58992	DRUGINFO	D0R4YD	H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-OH	Investigative
T58992	DRUGINFO	D0R9AP	H-Apa-ala-Gly-Phe-leu-OH	Investigative
T58992	DRUGINFO	D0R9LV	1,6-bis-(N,N-dimethyl-Dmt-Tic-NH)hexane	Investigative
T58992	DRUGINFO	D0R9XD	H-Dmt-Tic-Lys(Z)-NH-CH2-Ph	Investigative
T58992	DRUGINFO	D0RR4X	H-D-Tic-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2	Investigative
T58992	DRUGINFO	D0S3LK	1,6-bis-(Dmt-Tic-amino)hexane	Investigative
T58992	DRUGINFO	D0U3ZL	CARBOXYFENTANYL	Investigative
T58992	DRUGINFO	D0U4LU	H-Dmt-Tic-NH-(CH2)6-NH-Phe-H	Investigative
T58992	DRUGINFO	D0U5OP	1-[3-(3-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol	Investigative
T58992	DRUGINFO	D0U8YU	Tyr-Pro-Phe-Phe-OCH2OH	Investigative
T58992	DRUGINFO	D0UV1C	3,6-bis(Dmt-Tic-NH-butyl)-2(1H)-pyrazinone	Investigative
T58992	DRUGINFO	D0V2PM	H-Dmt-Tic-NH-CH2-Imid	Investigative
T58992	DRUGINFO	D0V3GN	Tyr-Pro-Phe-Phe-NHNH2	Investigative
T58992	DRUGINFO	D0V8UG	H-Dmt-Tic-NH-CH2-Boa	Investigative
T58992	DRUGINFO	D0W8MP	H-Dmt-Tic-Glu-NH2	Investigative
T58992	DRUGINFO	D0X2HA	H-Dmt-Tic-NH-CH[(CH2)4-NH-Ac]-Bid	Investigative
T58992	DRUGINFO	D0X4YC	H-Dmt-Tic-NH-(CH2)6-NH-Tic-H	Investigative
T58992	DRUGINFO	D0X5TB	H-Cdp-ser-Gly-Phe-Leu-Thr-OH	Investigative
T58992	DRUGINFO	D0X9SP	D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2(CTP)	Investigative
T58992	DRUGINFO	D0X9TT	Tyr-(S)-spiro-Aba-Gly-Phe-NH2	Investigative
T58992	DRUGINFO	D0Y2HI	H-Dmt-Aba-Gly-NH-Ph	Investigative
T58992	DRUGINFO	D0Y5TF	Tyr-Pro-Emp-Phe-NH2	Investigative
T58992	DRUGINFO	D0Y5UN	Tyr-Pro-L-Phe-D-Pro-NH2	Investigative
T58992	DRUGINFO	D0Z5UG	H-Tyr-Tic-Cha-Phe-OH	Investigative
T58992	DRUGINFO	D0ZI5Z	H-Tyr-Pro-Dap(6DMN)-Phe-NH2	Investigative
T58992	DRUGINFO	D0ZQ7L	H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-NH2	Investigative
T58992	DRUGINFO	D00HIG	3-Methylthiofentanyl	Investigative
T58992	DRUGINFO	D00JAT	(-)-cyclorphan	Investigative
T58992	DRUGINFO	D00JPB	5-(4-((phenethylamino)methyl)phenoxy)picolinamide	Investigative
T58992	DRUGINFO	D00NRB	MCL-117	Investigative
T58992	DRUGINFO	D00SDP	17-(Cyclopropylmethyl)-N-phenylmorphinan-3-amine	Investigative
T58992	DRUGINFO	D01ADK	Tyr-D-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2	Investigative
T58992	DRUGINFO	D01EPU	BUTORPHAN	Investigative
T58992	DRUGINFO	D01RFG	8-carboxamidocyclazocine	Investigative
T58992	DRUGINFO	D02BER	quadazocine	Investigative
T58992	DRUGINFO	D02FZW	17-methyl-4'-methyldihydromorphinone	Investigative
T58992	DRUGINFO	D02IMZ	MCL-443	Investigative
T58992	DRUGINFO	D02PIG	H-Cpa-Gly-Gly-Phe-Met-OH	Investigative
T58992	DRUGINFO	D02RYZ	MCL-450	Investigative
T58992	DRUGINFO	D03QWP	Dcp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2	Investigative
T58992	DRUGINFO	D03UFD	OXYMORPHINDOLE	Investigative
T58992	DRUGINFO	D03UHT	MCL-458	Investigative
T58992	DRUGINFO	D03WGS	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Ac	Investigative
T58992	DRUGINFO	D04JFL	Naltrexone-6-alpha-ol	Investigative
T58992	DRUGINFO	D04PPP	MCL-139	Investigative
T58992	DRUGINFO	D04UFM	Dmt-Pro-Dmt-Phe-NH2	Investigative
T58992	DRUGINFO	D04UIK	MCL-429	Investigative
T58992	DRUGINFO	D05ANN	naltriben	Investigative
T58992	DRUGINFO	D05EZE	Dmt-Pro-Phe-Phe-NH2	Investigative
T58992	DRUGINFO	D05FEQ	CYCLORPHAN	Investigative
T58992	DRUGINFO	D05JSY	MCL-145	Investigative
T58992	DRUGINFO	D05QJS	NORBINALTORPHIMINE	Investigative
T58992	DRUGINFO	D05TOY	Dmt-Pro-3,5Dmp-Phe-NH2	Investigative
T58992	DRUGINFO	D05YNT	[3H]diprenorphine	Investigative
T58992	DRUGINFO	D05ZIH	6beta-naltrexol HCl	Investigative
T58992	DRUGINFO	D06IXE	MCL-153	Investigative
T58992	DRUGINFO	D06KFX	C[L-Phe-D-pro-L-Phe-L-trp]	Investigative
T58992	DRUGINFO	D06MWG	Dmt-Pro-Mmp-Phe-NH2	Investigative
T58992	DRUGINFO	D06NST	CYCLAZOCINE	Investigative
T58992	DRUGINFO	D06OKE	MCL-433	Investigative
T58992	DRUGINFO	D06WTI	NRP290	Investigative
T58992	DRUGINFO	D07AAK	M6G thiosaccharide analogue	Investigative
T58992	DRUGINFO	D07DFD	MCL-434	Investigative
T58992	DRUGINFO	D07HFU	MCL-446	Investigative
T58992	DRUGINFO	D07JZS	H-Tyr-c[D-Allylgly-Gly-Phe-L-Allylgly]NH2	Investigative
T58992	DRUGINFO	D08IWF	MCL-435	Investigative
T58992	DRUGINFO	D08KSJ	H-Tyr-D-Ala-Gly Phe-Pro-Leu-Trp-O-3,5-Bzl(CF3)2	Investigative
T58992	DRUGINFO	D08NJB	Trans-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH	Investigative
T58992	DRUGINFO	D08ORS	6-(Allyl-methyl-amino)-4,4-diphenyl-heptan-3-ol	Investigative
T58992	DRUGINFO	D08QKT	Tyr-D-Nle-Gly-Trp-NMeNle-Asp-Phe-NH2	Investigative
T58992	DRUGINFO	D08RPH	MCL-182	Investigative
T58992	DRUGINFO	D09DUE	MCL-447	Investigative
T58992	DRUGINFO	D09FLC	17-Methylmorphinan-3-yl 4-Iodophenyl Carbamate	Investigative
T58992	DRUGINFO	D09RUY	N-Benzyl-17-(cyclopropylmethyl)morphinan-3-amine	Investigative
T58992	DRUGINFO	D09UKS	MCL-183	Investigative
T58992	DRUGINFO	D0A5MU	Deprotected cogener of M6G	Investigative
T58992	DRUGINFO	D0B8MY	MCL-144	Investigative
T58992	DRUGINFO	D0C2UQ	MCL-428	Investigative
T58992	DRUGINFO	D0C6RQ	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-3,5-Bzl(CF3)2	Investigative
T58992	DRUGINFO	D0C7MP	MCL-448	Investigative
T58992	DRUGINFO	D0CK8C	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-O-Bzl	Investigative
T58992	DRUGINFO	D0CX0I	[Dcp1]Dyn A(1-11)-NH2	Investigative
T58992	DRUGINFO	D0D3UB	SN-23	Investigative
T58992	DRUGINFO	D0D8AN	6-desoxonaltrexone	Investigative
T58992	DRUGINFO	D0E0TD	4-(4-((phenethylamino)methyl)phenoxy)benzamide	Investigative
T58992	DRUGINFO	D0E1FQ	Dmt-Pro-Imp-Phe-NH2	Investigative
T58992	DRUGINFO	D0E6GH	14-O-phenylpropylnaltrexone	Investigative
T58992	DRUGINFO	D0F1EB	MC-CAM	Investigative
T58992	DRUGINFO	D0F4AN	MCL-432	Investigative
T58992	DRUGINFO	D0F8CV	DAMGO	Investigative
T58992	DRUGINFO	D0G4NM	DPDPE	Investigative
T58992	DRUGINFO	D0G6GC	Tyr-D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-Bzl	Investigative
T58992	DRUGINFO	D0G7FB	MCL-147	Investigative
T58992	DRUGINFO	D0H0KP	6-(4-(3-(benzylamino)propyl)phenoxy)nicotinamide	Investigative
T58992	DRUGINFO	D0H0OO	dynorphin B	Investigative
T58992	DRUGINFO	D0H3GI	4-(p-Tolyl)spiro[chromene-2,4'-piperidine]	Investigative
T58992	DRUGINFO	D0HB6O	H-Cdp-Gly-Gly-Phe-Leu-OH	Investigative
T58992	DRUGINFO	D0HC3H	Dimepheptanol	Investigative
T58992	DRUGINFO	D0HV6H	H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]NH2	Investigative
T58992	DRUGINFO	D0I1NG	6-(4-((phenethylamino)methyl)phenoxy)nicotinamide	Investigative
T58992	DRUGINFO	D0I2CE	C[L-mTyr-D-pro-L-Phe-D-trp]	Investigative
T58992	DRUGINFO	D0I9PH	H-Tyr-D-Ala-Gly-Phe-NH-NH-Trp-D-Nle-D-Asp-D-Phe-H	Investigative
T58992	DRUGINFO	D0I9SX	PHENAZOCINE	Investigative
T58992	DRUGINFO	D0IY2V	MCL-445	Investigative
T58992	DRUGINFO	D0J3NK	MCL-449	Investigative
T58992	DRUGINFO	D0K1BV	N-(17-Methylmorphinan-3-yl)-N'-phenylurea	Investigative
T58992	DRUGINFO	D0K4XQ	MCL-431	Investigative
T58992	DRUGINFO	D0KL5N	Dmt-Pro-Tmp-Phe-NH2	Investigative
T58992	DRUGINFO	D0L0NI	Dhp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2	Investigative
T58992	DRUGINFO	D0L2CT	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-3,5-Bzl(CF3)2	Investigative
T58992	DRUGINFO	D0L5DN	MCL-149	Investigative
T58992	DRUGINFO	D0L6QN	LOFENTANIL	Investigative
T58992	DRUGINFO	D0L8LX	H-Tyr-Gly-Gly-Phe-Met-NH2	Investigative
T58992	DRUGINFO	D0M1YV	ELAEOCARPENINE	Investigative
T58992	DRUGINFO	D0N2DN	4-Phenylspiro[chromene-2,4'-piperidine]	Investigative
T58992	DRUGINFO	D0N8LP	Beta-endorphin	Investigative
T58992	DRUGINFO	D0NA7G	MCL-451	Investigative
T58992	DRUGINFO	D0NV5N	normorphine	Investigative
T58992	DRUGINFO	D0O1JD	6-(4-(2-(benzylamino)ethyl)phenoxy)nicotinamide	Investigative
T58992	DRUGINFO	D0O6SB	Diprenorphine	Investigative
T58992	DRUGINFO	D0P0RB	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-Bzl	Investigative
T58992	DRUGINFO	D0P5QI	2-Hydroxymethyl-3-hydroxymorphinan	Investigative
T58992	DRUGINFO	D0P6FF	N-Benzyl-17-(cyclobutylmethyl)morphinan-3-amine	Investigative
T58992	DRUGINFO	D0Q5AJ	MCL-154	Investigative
T58992	DRUGINFO	D0Q7HG	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-Bzl	Investigative
T58992	DRUGINFO	D0R1AB	H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]-OH	Investigative
T58992	DRUGINFO	D0R4QF	HERKINORIN	Investigative
T58992	DRUGINFO	D0R5TA	ENDOMORPHIN-1	Investigative
T58992	DRUGINFO	D0R6VF	Clocinnamox	Investigative
T58992	DRUGINFO	D0R7LY	Cis-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH	Investigative
T58992	DRUGINFO	D0S2OA	1-benzhydryl-4-(benzyloxy)-4-phenylpiperidine	Investigative
T58992	DRUGINFO	D0S5FN	H-Cdp-ala-Gly-Phe-leu-OH	Investigative
T58992	DRUGINFO	D0S7SO	H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-Bo	Investigative
T58992	DRUGINFO	D0SC3W	Bis-((-)-N-propargylmorphinan-3-yl) sebacoylate	Investigative
T58992	DRUGINFO	D0T5EI	ethylketocyclazocine	Investigative
T58992	DRUGINFO	D0T6OQ	3-desoxy-3-carboxamidonaltrexone	Investigative
T58992	DRUGINFO	D0TB4A	Dmt-Pro-Emp-Phe-NH2	Investigative
T58992	DRUGINFO	D0TN0D	METAZOCINE	Investigative
T58992	DRUGINFO	D0TO0E	SN-28	Investigative
T58992	DRUGINFO	D0U3UM	ETONITAZENE	Investigative
T58992	DRUGINFO	D0U7JS	H-Cpa-Gly-Gly-Phe-Met-NH2	Investigative
T58992	DRUGINFO	D0UG8H	SN-11	Investigative
T58992	DRUGINFO	D0UR7D	Benzyl derivative of M6G	Investigative
T58992	DRUGINFO	D0V0RB	Tyr-D-Nle-Gly-D-Trp-Nle-Asp-Phe-NH2	Investigative
T58992	DRUGINFO	D0VO7C	HTyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-LysNH2	Investigative
T58992	DRUGINFO	D0W0CO	17-(Cyclobutylmethyl)-N-phenylmorphinan-3-amine	Investigative
T58992	DRUGINFO	D0W2DN	MCL-444	Investigative
T58992	DRUGINFO	D0W6OP	H-Tyr-c[D-Cys-Gly-Phe-D-Cys]NH2	Investigative
T58992	DRUGINFO	D0X0XV	Dmt-Pro-Dmp-Phe-NH2	Investigative
T58992	DRUGINFO	D0X6BU	H-Tyr-c[D-Cys-Gly-Phe-L-Cys]NH2	Investigative
T58992	DRUGINFO	D0X7LC	Tyr-Gly-Gly-Trp-NMeNle-Asp-Phe-NH2	Investigative
T58992	DRUGINFO	D0Y5ZP	N-(4-Iodophenyl)-N'-(17-methylmorphinan-3-yl)urea	Investigative
T58992	DRUGINFO	D0Y8NO	RTI-5989-31	Investigative
T58992	DRUGINFO	D0YU5H	6-(4-((benzylamino)methyl)phenoxy)nicotinamide	Investigative
T58992	DRUGINFO	D0Z5JD	[Leu5]enkephalin	Investigative
T58992	DRUGINFO	D0Z8JX	C[L-Phe-D-pro-L-mTyr-D-trp]	Investigative
T58992	DRUGINFO	D0ZH3G	3-Methylfentanyl	Investigative
T58992	DRUGINFO	D00TNR	ENDOMORPHIN 2	Investigative
T58992	DRUGINFO	D00YCW	4-phenyl-1-(1-phenylbutyl)piperidin-4-ol	Investigative
T58992	DRUGINFO	D01AQC	Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2	Investigative
T58992	DRUGINFO	D01WMU	1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol	Investigative
T58992	DRUGINFO	D02EIB	4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol	Investigative
T58992	DRUGINFO	D03EPA	Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2	Investigative
T58992	DRUGINFO	D03PTV	1-benzhydryl-4-ethoxy-4-phenylpiperidine	Investigative
T58992	DRUGINFO	D03RBD	8-azabicyclo[3.2.1]octan-3-yloxy-benzamide	Investigative
T58992	DRUGINFO	D03UJW	1-benzhydryl-4-butylpiperidin-4-ol	Investigative
T58992	DRUGINFO	D04ZQX	4-phenyl-1-(1-phenylheptyl)piperidin-4-ol	Investigative
T58992	DRUGINFO	D06BRA	Tyr-D-Ala-Gly-D-Trp-Nle-Asp-Phe-NH2	Investigative
T58992	DRUGINFO	D06MQG	1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol	Investigative
T58992	DRUGINFO	D06PHT	1-benzhydryl-4-phenylpiperidin-4-ol	Investigative
T58992	DRUGINFO	D07CIU	1-benzhydryl-4-p-tolylpiperidin-4-ol	Investigative
T58992	DRUGINFO	D07ICW	Tyr-D-Ala-Gly-D-Trp-NMeNle-Asp-Phe-NH2	Investigative
T58992	DRUGINFO	D07LQQ	Tyr-D-Nle-Gly-Trp-Nle-Asp-Phe-NH2	Investigative
T58992	DRUGINFO	D07NMH	1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol	Investigative
T58992	DRUGINFO	D08DVV	1-benzhydryl-4-hexylpiperidin-4-ol	Investigative
T58992	DRUGINFO	D08QBU	1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol	Investigative
T58992	DRUGINFO	D08TFY	1-benzhydryl-4-cyclohexylpiperidin-4-ol	Investigative
T58992	DRUGINFO	D09BYD	1-benzhydryl-4-o-tolylpiperidin-4-ol	Investigative
T58992	DRUGINFO	D09EMR	Tyr-D-Phe-Gly-D-Trp-Nle-Asp-Phe-NH2	Investigative
T58992	DRUGINFO	D09FJY	4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol	Investigative
T58992	DRUGINFO	D09LRO	1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol	Investigative
T58992	DRUGINFO	D09VRT	1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol	Investigative
T58992	DRUGINFO	D0B7GU	Dihydromorphine	Investigative
T58992	DRUGINFO	D0D0UP	1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol	Investigative
T58992	DRUGINFO	D0D5QV	O-DESMETHYL TRAMADOL	Investigative
T58992	DRUGINFO	D0E2OG	Tyr-D-Nle-Gly-D-Trp-NMeNle-Asp-Phe-NH2	Investigative
T58992	DRUGINFO	D0G4FA	1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol	Investigative
T58992	DRUGINFO	D0G7DF	4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol	Investigative
T58992	DRUGINFO	D0J5JO	1-benzhydryl-4-m-tolylpiperidin-4-ol	Investigative
T58992	DRUGINFO	D0J7GJ	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-H	Investigative
T58992	DRUGINFO	D0JH5D	1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol	Investigative
T58992	DRUGINFO	D0N6DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Boc	Investigative
T58992	DRUGINFO	D0O7JV	4-phenyl-1-(1-phenylhexyl)piperidin-4-ol	Investigative
T58992	DRUGINFO	D0P3FP	4-phenyl-1-(1-phenylpentyl)piperidin-4-ol	Investigative
T58992	DRUGINFO	D0Q9TQ	1-benzhydryl-4-methoxy-4-phenylpiperidine	Investigative
T58992	DRUGINFO	D0QH4A	1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol	Investigative
T58992	DRUGINFO	D0QP2S	Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-NMeNle-D-Trp-Boc	Investigative
T58992	DRUGINFO	D0R4GI	Tyr-D-Ala-Gly-Trp-NMeNle-Asp-Phe-NH2	Investigative
T58992	DRUGINFO	D0T4ZY	1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol	Investigative
T58992	DRUGINFO	D0T9KE	1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol	Investigative
T58992	DRUGINFO	D0TR0U	Tyr-D-Phe-Gly-D-Trp-NMeNle-Asp-Phe-NH2	Investigative
T58992	DRUGINFO	D0U6OA	Tyr-D-Ala-Gly-Trp-Nle-Asp-Phe-NH2	Investigative
T58992	DRUGINFO	D0V9DY	H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-H	Investigative
T58992	DRUGINFO	D0W3VT	1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol	Investigative
T58992	DRUGINFO	D0X4SX	1-benzhydryl-4-phenyl-4-propoxypiperidine	Investigative
T58992	DRUGINFO	D0XX1Y	4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol	Investigative
T58992	DRUGINFO	D0Y5LJ	1-benzhydryl-4-(furan-2-yl)piperidin-4-ol	Investigative
T58992	DRUGINFO	D0ZE2W	1-benzhydryl-4-benzylpiperidin-4-ol	Investigative
T58992	DRUGINFO	D03SAV	ICI-199441	Investigative
T58992	DRUGINFO	D08UOX	FALCARINDIOL	Investigative
T58992	DRUGINFO	D0L9YP	4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide	Investigative
T58992	DRUGINFO	D0T5RO	SOMATOSTATIN	Investigative

T60693	TARGETID	T60693
T60693	FORMERID	TTDS00127
T60693	UNIPROID	OPRK_HUMAN
T60693	TARGNAME	Opioid receptor kappa (OPRK1)
T60693	GENENAME	OPRK1
T60693	TARGTYPE	Successful
T60693	SYNONYMS	OPRK; Kappa-type opioid receptor; Kappa opioid receptor; KOR-1; KOR; K-OR-1
T60693	FUNCTION	Functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain. Plays a role in mediating reduced physical activity upon treatment with synthetic opioids. Plays a role in the regulation of salivation in response to synthetic opioids. May play a role in arousal and regulation of autonomic and neuroendocrine functions. G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins.
T60693	PDBSTRUC	6B73; 4DJH; 2IQN; 2A0D
T60693	BIOCLASS	GPCR rhodopsin
T60693	SEQUENCE	MDSPIQIFRGEPGPTCAPSACLPPNSSAWFPGWAEPDSNGSAGSEDAQLEPAHISPAIPVIITAVYSVVFVVGLVGNSLVMFVIIRYTKMKTATNIYIFNLALADALVTTTMPFQSTVYLMNSWPFGDVLCKIVISIDYYNMFTSIFTLTMMSVDRYIAVCHPVKALDFRTPLKAKIINICIWLLSSSVGISAIVLGGTKVREDVDVIECSLQFPDDDYSWWDLFMKICVFIFAFVIPVLIIIVCYTLMILRLKSVRLLSGSREKDRNLRRITRLVLVVVAVFVVCWTPIHIFILVEALGSTSHSTAALSSYYFCIALGYTNSSLNPILYAFLDENFKRCFRDFCFPLKMRMERQSTSRVRNTVQDPAYLRDIDGMNKPV
T60693	DRUGINFO	D01KQA	Nalbuphine	Approved
T60693	DRUGINFO	D02HWP	CHLOROXINE	Approved
T60693	DRUGINFO	D0K3OK	Difelikefalin	Approved
T60693	DRUGINFO	D0P6VV	Dezocine	Approved
T60693	DRUGINFO	D02RXG	Nalfurafine hcl	Approved
T60693	DRUGINFO	D07TQN	Asimadoline	Phase 3
T60693	DRUGINFO	DSNA01	JNJ 67953964	Phase 3
T60693	DRUGINFO	D06ZXH	PHN-131	Phase 2/3
T60693	DRUGINFO	D08NJE	CR-845	Phase 2/3
T60693	DRUGINFO	D01HBG	Apadoline	Phase 2
T60693	DRUGINFO	D07YHM	LY-2456302	Phase 2
T60693	DRUGINFO	D09ALE	Enadoline	Phase 2
T60693	DRUGINFO	D0L1KX	CR-665	Phase 2
T60693	DRUGINFO	D0PW4C	Niravoline	Phase 2
T60693	DRUGINFO	DDK53C	BTRX-335140	Phase 2
T60693	DRUGINFO	DDQH94	A277	Phase 2
T60693	DRUGINFO	DW7OF1	ORP-101	Phase 2
T60693	DRUGINFO	D03PJU	Carfentanil	Phase 2
T60693	DRUGINFO	D0LU5Q	TPM-1/Morphine	Phase 2
T60693	DRUGINFO	D00SVP	PF-4455242	Phase 1
T60693	DRUGINFO	D0RN6V	BRL-52656	Phase 1
T60693	DRUGINFO	D00HBR	AIKO-150	Phase 1
T60693	DRUGINFO	D01AKU	MCP-201	Phase 1
T60693	DRUGINFO	D06EXA	SALVINORIN A	Phase 1
T60693	DRUGINFO	D06ABW	CLIOQUINOL	Withdrawn from market
T60693	DRUGINFO	D00KUD	ADL 10-0101	Discontinued in Phase 2
T60693	DRUGINFO	D04OXU	E-2078	Discontinued in Phase 2
T60693	DRUGINFO	D0N7SG	R-84760	Discontinued in Phase 2
T60693	DRUGINFO	D0Y8SK	Dynorphin a	Discontinued in Phase 2
T60693	DRUGINFO	D0J5XZ	VP004	Discontinued in Phase 1
T60693	DRUGINFO	D0X6SZ	GNTI	Preclinical
T60693	DRUGINFO	D0C2QF	LY-25582	Preclinical
T60693	DRUGINFO	D02PIN	GR-94839	Terminated
T60693	DRUGINFO	D03EFD	KT-95	Terminated
T60693	DRUGINFO	D06FEF	Fedotozine	Terminated
T60693	DRUGINFO	D0M7BW	GR-89696	Terminated
T60693	DRUGINFO	D08YUP	SB-213698	Terminated
T60693	DRUGINFO	D01BPI	Salvinorin B fluoromethyl ether	Investigative
T60693	DRUGINFO	D01EKO	GR-86014	Investigative
T60693	DRUGINFO	D01FPD	Salvinorin B 2-fluoroethoxymethyl ether	Investigative
T60693	DRUGINFO	D02JHE	[U-13C]ascomycin	Investigative
T60693	DRUGINFO	D03PIF	Salvinorin B tetrahydropyran-2-yl ether	Investigative
T60693	DRUGINFO	D04FBZ	Nalorphine	Investigative
T60693	DRUGINFO	D04QUB	12-EPI-SALVINORIN A	Investigative
T60693	DRUGINFO	D04TZR	ICI-204448	Investigative
T60693	DRUGINFO	D04YNW	BRL 52537 hydrochloride	Investigative
T60693	DRUGINFO	D05BCY	2-EPI-2-THIOSALVINORIN B	Investigative
T60693	DRUGINFO	D05BZQ	DEOXY SALVINORIN A	Investigative
T60693	DRUGINFO	D05COL	SALVINORIN B	Investigative
T60693	DRUGINFO	D06QGJ	3-(1-benzylpiperidin-4-yloxy)benzamide	Investigative
T60693	DRUGINFO	D06TQU	GR-45809	Investigative
T60693	DRUGINFO	D06UTW	Salvinorin B butoxymethyl ether	Investigative
T60693	DRUGINFO	D07GMY	BRL 52974	Investigative
T60693	DRUGINFO	D07KTF	Salvinorin B ethoxymethyl ether	Investigative
T60693	DRUGINFO	D08HTW	Drug 7684380	Investigative
T60693	DRUGINFO	D08TDQ	Morphinan Cyclic Imine analogue	Investigative
T60693	DRUGINFO	D08VVC	N,N-dibenzyl[D-Pro-10]Dyn A-(1-11)	Investigative
T60693	DRUGINFO	D09JXT	N-allyl[D-Pro-10]Dyn A-(1-11)	Investigative
T60693	DRUGINFO	D09RSU	N-CPM[D-Pro-10]Dyn A-(1-11)	Investigative
T60693	DRUGINFO	D09WSG	Salvinorin B benzyloxymethyl ether	Investigative
T60693	DRUGINFO	D0A3KA	Salvinorin B 2,2,2-trifluoroethoxymethyl ether	Investigative
T60693	DRUGINFO	D0B6VF	GR-91272	Investigative
T60693	DRUGINFO	D0C7EI	GR-38414	Investigative
T60693	DRUGINFO	D0C9II	Salvinorin B 1-ethoxyethyl ether	Investigative
T60693	DRUGINFO	D0E0OF	Salvinorin B tert-butoxymethyl ether	Investigative
T60693	DRUGINFO	D0E9HW	Salvinorin B propoxymethyl ether	Investigative
T60693	DRUGINFO	D0ET0T	2-EPI-2-THIOSALVINORIN A	Investigative
T60693	DRUGINFO	D0G0HP	SALVINICIN B	Investigative
T60693	DRUGINFO	D0GX3K	N,N-diallyl[D-Pro-10]Dyn A-(1-11)	Investigative
T60693	DRUGINFO	D0H2CI	Salvinorin B methoxymethyl ether	Investigative
T60693	DRUGINFO	D0H3VZ	Salvinorin B methylthiomethyl ether	Investigative
T60693	DRUGINFO	D0HQ0E	spiradoline	Investigative
T60693	DRUGINFO	D0I3AH	N-benzyl[D-Pro-10]Dyn A-(1-11)	Investigative
T60693	DRUGINFO	D0IL7F	N,N-diCPM[D-Pro-10]Dyn A-(1-11)	Investigative
T60693	DRUGINFO	D0J1PJ	U50,488H	Investigative
T60693	DRUGINFO	D0K9HE	Nor-binaltorphimine dihydrochloride	Investigative
T60693	DRUGINFO	D0M9GO	tifluadom	Investigative
T60693	DRUGINFO	D0O7RK	Salvinorin B 2-methoxyethoxymethyl ether	Investigative
T60693	DRUGINFO	D0P8TI	Salvinicin A	Investigative
T60693	DRUGINFO	D0Q3CD	Salvinorin B 2-methoxy-2-propyl ether	Investigative
T60693	DRUGINFO	D0R7OE	Salvinorin B isopropoxymethyl ether	Investigative
T60693	DRUGINFO	D0S1MA	ANISOCOUMARIN H	Investigative
T60693	DRUGINFO	D0W7DM	2-THIOSALVINORIN B	Investigative
T60693	DRUGINFO	D0ZG9I	Salvinorin A (ester)	Investigative
T60693	DRUGINFO	D03KAQ	2-Benzylaminomethyl-3-hydroxymorphinan	Investigative
T60693	DRUGINFO	D03RSA	M6S	Investigative
T60693	DRUGINFO	D03WYO	KETOCYCLAZOCINE	Investigative
T60693	DRUGINFO	D05EWZ	SPIROINDANYLOXYMORPHONE	Investigative
T60693	DRUGINFO	D05ZYZ	NalBzOH	Investigative
T60693	DRUGINFO	D06SZI	MCL-457	Investigative
T60693	DRUGINFO	D07PPK	4-phenyl-4-[1H-imidazol-2-yl]-piperidine	Investigative
T60693	DRUGINFO	D07QUY	C[L-Phe-D-pro-L-Tyr(OMe)-D-trp]	Investigative
T60693	DRUGINFO	D08BST	N-isobutylnoroxymorphone	Investigative
T60693	DRUGINFO	D08FYQ	KNT-63	Investigative
T60693	DRUGINFO	D08IGF	L-685,818	Investigative
T60693	DRUGINFO	D08QBS	MK-1925	Investigative
T60693	DRUGINFO	D09BWX	C[L-Phe-D-pro-L-Phe-D-trp]	Investigative
T60693	DRUGINFO	D09SBU	C[L-Ala-D-pro-L-Phe-D-trp]	Investigative
T60693	DRUGINFO	D0D1WB	Dynorphin(1-8)	Investigative
T60693	DRUGINFO	D0D5SK	ethyketazocine	Investigative
T60693	DRUGINFO	D0D5VD	C[L-Phe-D-pro-L-Tyr-D-trp]	Investigative
T60693	DRUGINFO	D0D6KZ	KNT-62	Investigative
T60693	DRUGINFO	D0D6OA	DM6S	Investigative
T60693	DRUGINFO	D0DO6P	MR-2034	Investigative
T60693	DRUGINFO	D0H6AA	M3Pr6S	Investigative
T60693	DRUGINFO	D0I3XV	RTI-5989-25	Investigative
T60693	DRUGINFO	D0K0XT	MR-1029	Investigative
T60693	DRUGINFO	D0M4DI	MR-2266	Investigative
T60693	DRUGINFO	D0N0JC	RTI-5989-23	Investigative
T60693	DRUGINFO	D0P2GB	MR-1526	Investigative
T60693	DRUGINFO	D0P2LE	2-(2-methylquinolin-4-ylamino)-N-phenylacetamide	Investigative
T60693	DRUGINFO	D0P5IH	C[L-Tyr(OMe)-D-pro-L-Phe-D-trp]	Investigative
T60693	DRUGINFO	D0Q6CF	C[L-Tyr-D-pro-L-Phe-D-trp]	Investigative
T60693	DRUGINFO	D0S9UH	ZYKLOPHIN	Investigative
T60693	DRUGINFO	D0TH8E	M3P6S	Investigative
T60693	DRUGINFO	D0V3OY	[3H]U69593	Investigative
T60693	DRUGINFO	D0WZ7J	M3A6S	Investigative
T60693	DRUGINFO	D0X2HT	M3IBu6S	Investigative
T60693	DRUGINFO	D0YK5E	Oxymorphone semicarbazone hydrochloride	Investigative
T60693	DRUGINFO	D00HIG	3-Methylthiofentanyl	Investigative
T60693	DRUGINFO	D00JAT	(-)-cyclorphan	Investigative
T60693	DRUGINFO	D00JPB	5-(4-((phenethylamino)methyl)phenoxy)picolinamide	Investigative
T60693	DRUGINFO	D00NRB	MCL-117	Investigative
T60693	DRUGINFO	D00SDP	17-(Cyclopropylmethyl)-N-phenylmorphinan-3-amine	Investigative
T60693	DRUGINFO	D00XZH	1-benzhydryl-4-isopropylpiperidin-4-ol	Investigative
T60693	DRUGINFO	D01EPU	BUTORPHAN	Investigative
T60693	DRUGINFO	D01MUV	1-benzhydryl-4-tert-butylpiperidin-4-ol	Investigative
T60693	DRUGINFO	D01RFG	8-carboxamidocyclazocine	Investigative
T60693	DRUGINFO	D02BER	quadazocine	Investigative
T60693	DRUGINFO	D02FZW	17-methyl-4'-methyldihydromorphinone	Investigative
T60693	DRUGINFO	D02IMZ	MCL-443	Investigative
T60693	DRUGINFO	D02PIG	H-Cpa-Gly-Gly-Phe-Met-OH	Investigative
T60693	DRUGINFO	D02RYZ	MCL-450	Investigative
T60693	DRUGINFO	D03QWP	Dcp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2	Investigative
T60693	DRUGINFO	D03UFD	OXYMORPHINDOLE	Investigative
T60693	DRUGINFO	D03UHT	MCL-458	Investigative
T60693	DRUGINFO	D04JFL	Naltrexone-6-alpha-ol	Investigative
T60693	DRUGINFO	D04PPP	MCL-139	Investigative
T60693	DRUGINFO	D04UFM	Dmt-Pro-Dmt-Phe-NH2	Investigative
T60693	DRUGINFO	D04UIK	MCL-429	Investigative
T60693	DRUGINFO	D05ANN	naltriben	Investigative
T60693	DRUGINFO	D05EZE	Dmt-Pro-Phe-Phe-NH2	Investigative
T60693	DRUGINFO	D05FEQ	CYCLORPHAN	Investigative
T60693	DRUGINFO	D05JSY	MCL-145	Investigative
T60693	DRUGINFO	D05QJS	NORBINALTORPHIMINE	Investigative
T60693	DRUGINFO	D05RII	3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole	Investigative
T60693	DRUGINFO	D05TOY	Dmt-Pro-3,5Dmp-Phe-NH2	Investigative
T60693	DRUGINFO	D05YNT	[3H]diprenorphine	Investigative
T60693	DRUGINFO	D05ZIH	6beta-naltrexol HCl	Investigative
T60693	DRUGINFO	D06IXE	MCL-153	Investigative
T60693	DRUGINFO	D06KFX	C[L-Phe-D-pro-L-Phe-L-trp]	Investigative
T60693	DRUGINFO	D06MWG	Dmt-Pro-Mmp-Phe-NH2	Investigative
T60693	DRUGINFO	D06NST	CYCLAZOCINE	Investigative
T60693	DRUGINFO	D06OKE	MCL-433	Investigative
T60693	DRUGINFO	D06PVO	4-phenyl-1-(1-phenylpropyl)piperidin-4-ol	Investigative
T60693	DRUGINFO	D06WTI	NRP290	Investigative
T60693	DRUGINFO	D07AAK	M6G thiosaccharide analogue	Investigative
T60693	DRUGINFO	D07DFD	MCL-434	Investigative
T60693	DRUGINFO	D07FCB	4-phenyl-1-(1-phenylethyl)piperidin-4-ol	Investigative
T60693	DRUGINFO	D07HFU	MCL-446	Investigative
T60693	DRUGINFO	D07JZS	H-Tyr-c[D-Allylgly-Gly-Phe-L-Allylgly]NH2	Investigative
T60693	DRUGINFO	D08IWF	MCL-435	Investigative
T60693	DRUGINFO	D08NJB	Trans-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH	Investigative
T60693	DRUGINFO	D08ORS	6-(Allyl-methyl-amino)-4,4-diphenyl-heptan-3-ol	Investigative
T60693	DRUGINFO	D08RPH	MCL-182	Investigative
T60693	DRUGINFO	D09DUE	MCL-447	Investigative
T60693	DRUGINFO	D09FLC	17-Methylmorphinan-3-yl 4-Iodophenyl Carbamate	Investigative
T60693	DRUGINFO	D09RUY	N-Benzyl-17-(cyclopropylmethyl)morphinan-3-amine	Investigative
T60693	DRUGINFO	D09UKS	MCL-183	Investigative
T60693	DRUGINFO	D0A5MU	Deprotected cogener of M6G	Investigative
T60693	DRUGINFO	D0B8MY	MCL-144	Investigative
T60693	DRUGINFO	D0C2UQ	MCL-428	Investigative
T60693	DRUGINFO	D0C7MP	MCL-448	Investigative
T60693	DRUGINFO	D0CX0I	[Dcp1]Dyn A(1-11)-NH2	Investigative
T60693	DRUGINFO	D0D3UB	SN-23	Investigative
T60693	DRUGINFO	D0D8AN	6-desoxonaltrexone	Investigative
T60693	DRUGINFO	D0D9BB	1-benzhydryl-4-(pyridin-2-yl)piperidin-4-ol	Investigative
T60693	DRUGINFO	D0E0TD	4-(4-((phenethylamino)methyl)phenoxy)benzamide	Investigative
T60693	DRUGINFO	D0E1FQ	Dmt-Pro-Imp-Phe-NH2	Investigative
T60693	DRUGINFO	D0E6GH	14-O-phenylpropylnaltrexone	Investigative
T60693	DRUGINFO	D0F1EB	MC-CAM	Investigative
T60693	DRUGINFO	D0F4AN	MCL-432	Investigative
T60693	DRUGINFO	D0F8CV	DAMGO	Investigative
T60693	DRUGINFO	D0G4NM	DPDPE	Investigative
T60693	DRUGINFO	D0G7FB	MCL-147	Investigative
T60693	DRUGINFO	D0H0KP	6-(4-(3-(benzylamino)propyl)phenoxy)nicotinamide	Investigative
T60693	DRUGINFO	D0H0OO	dynorphin B	Investigative
T60693	DRUGINFO	D0H3GI	4-(p-Tolyl)spiro[chromene-2,4'-piperidine]	Investigative
T60693	DRUGINFO	D0HB6O	H-Cdp-Gly-Gly-Phe-Leu-OH	Investigative
T60693	DRUGINFO	D0HC3H	Dimepheptanol	Investigative
T60693	DRUGINFO	D0HV6H	H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]NH2	Investigative
T60693	DRUGINFO	D0I1NG	6-(4-((phenethylamino)methyl)phenoxy)nicotinamide	Investigative
T60693	DRUGINFO	D0I2CE	C[L-mTyr-D-pro-L-Phe-D-trp]	Investigative
T60693	DRUGINFO	D0I9SX	PHENAZOCINE	Investigative
T60693	DRUGINFO	D0IL9H	1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol	Investigative
T60693	DRUGINFO	D0IY2V	MCL-445	Investigative
T60693	DRUGINFO	D0J3NK	MCL-449	Investigative
T60693	DRUGINFO	D0K1BV	N-(17-Methylmorphinan-3-yl)-N'-phenylurea	Investigative
T60693	DRUGINFO	D0K4XQ	MCL-431	Investigative
T60693	DRUGINFO	D0KL5N	Dmt-Pro-Tmp-Phe-NH2	Investigative
T60693	DRUGINFO	D0L0NI	Dhp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2	Investigative
T60693	DRUGINFO	D0L5DN	MCL-149	Investigative
T60693	DRUGINFO	D0L6QN	LOFENTANIL	Investigative
T60693	DRUGINFO	D0L8LX	H-Tyr-Gly-Gly-Phe-Met-NH2	Investigative
T60693	DRUGINFO	D0M1YV	ELAEOCARPENINE	Investigative
T60693	DRUGINFO	D0N2DN	4-Phenylspiro[chromene-2,4'-piperidine]	Investigative
T60693	DRUGINFO	D0N8LP	Beta-endorphin	Investigative
T60693	DRUGINFO	D0NA7G	MCL-451	Investigative
T60693	DRUGINFO	D0NV5N	normorphine	Investigative
T60693	DRUGINFO	D0O1JD	6-(4-(2-(benzylamino)ethyl)phenoxy)nicotinamide	Investigative
T60693	DRUGINFO	D0O6SB	Diprenorphine	Investigative
T60693	DRUGINFO	D0P5QI	2-Hydroxymethyl-3-hydroxymorphinan	Investigative
T60693	DRUGINFO	D0P6FF	N-Benzyl-17-(cyclobutylmethyl)morphinan-3-amine	Investigative
T60693	DRUGINFO	D0Q5AJ	MCL-154	Investigative
T60693	DRUGINFO	D0R1AB	H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]-OH	Investigative
T60693	DRUGINFO	D0R4QF	HERKINORIN	Investigative
T60693	DRUGINFO	D0R5TA	ENDOMORPHIN-1	Investigative
T60693	DRUGINFO	D0R6VF	Clocinnamox	Investigative
T60693	DRUGINFO	D0R7LY	Cis-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH	Investigative
T60693	DRUGINFO	D0S2OA	1-benzhydryl-4-(benzyloxy)-4-phenylpiperidine	Investigative
T60693	DRUGINFO	D0S5FN	H-Cdp-ala-Gly-Phe-leu-OH	Investigative
T60693	DRUGINFO	D0SC3W	Bis-((-)-N-propargylmorphinan-3-yl) sebacoylate	Investigative
T60693	DRUGINFO	D0T5EI	ethylketocyclazocine	Investigative
T60693	DRUGINFO	D0T6OQ	3-desoxy-3-carboxamidonaltrexone	Investigative
T60693	DRUGINFO	D0TB4A	Dmt-Pro-Emp-Phe-NH2	Investigative
T60693	DRUGINFO	D0TN0D	METAZOCINE	Investigative
T60693	DRUGINFO	D0TO0E	SN-28	Investigative
T60693	DRUGINFO	D0U3UM	ETONITAZENE	Investigative
T60693	DRUGINFO	D0U7JS	H-Cpa-Gly-Gly-Phe-Met-NH2	Investigative
T60693	DRUGINFO	D0UG8H	SN-11	Investigative
T60693	DRUGINFO	D0UR7D	Benzyl derivative of M6G	Investigative
T60693	DRUGINFO	D0VO7C	HTyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-LysNH2	Investigative
T60693	DRUGINFO	D0W0CO	17-(Cyclobutylmethyl)-N-phenylmorphinan-3-amine	Investigative
T60693	DRUGINFO	D0W2DN	MCL-444	Investigative
T60693	DRUGINFO	D0W6OP	H-Tyr-c[D-Cys-Gly-Phe-D-Cys]NH2	Investigative
T60693	DRUGINFO	D0X0XV	Dmt-Pro-Dmp-Phe-NH2	Investigative
T60693	DRUGINFO	D0X6BU	H-Tyr-c[D-Cys-Gly-Phe-L-Cys]NH2	Investigative
T60693	DRUGINFO	D0Y5ZP	N-(4-Iodophenyl)-N'-(17-methylmorphinan-3-yl)urea	Investigative
T60693	DRUGINFO	D0Y7KE	1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol	Investigative
T60693	DRUGINFO	D0Y8NO	RTI-5989-31	Investigative
T60693	DRUGINFO	D0YU5H	6-(4-((benzylamino)methyl)phenoxy)nicotinamide	Investigative
T60693	DRUGINFO	D0Z5JD	[Leu5]enkephalin	Investigative
T60693	DRUGINFO	D0Z8JX	C[L-Phe-D-pro-L-mTyr-D-trp]	Investigative
T60693	DRUGINFO	D0ZH3G	3-Methylfentanyl	Investigative
T60693	DRUGINFO	D00TNR	ENDOMORPHIN 2	Investigative
T60693	DRUGINFO	D00YCW	4-phenyl-1-(1-phenylbutyl)piperidin-4-ol	Investigative
T60693	DRUGINFO	D01WMU	1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol	Investigative
T60693	DRUGINFO	D02EIB	4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol	Investigative
T60693	DRUGINFO	D03PTV	1-benzhydryl-4-ethoxy-4-phenylpiperidine	Investigative
T60693	DRUGINFO	D03RBD	8-azabicyclo[3.2.1]octan-3-yloxy-benzamide	Investigative
T60693	DRUGINFO	D03UJW	1-benzhydryl-4-butylpiperidin-4-ol	Investigative
T60693	DRUGINFO	D04ZQX	4-phenyl-1-(1-phenylheptyl)piperidin-4-ol	Investigative
T60693	DRUGINFO	D06MQG	1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol	Investigative
T60693	DRUGINFO	D06PHT	1-benzhydryl-4-phenylpiperidin-4-ol	Investigative
T60693	DRUGINFO	D07CIU	1-benzhydryl-4-p-tolylpiperidin-4-ol	Investigative
T60693	DRUGINFO	D07NMH	1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol	Investigative
T60693	DRUGINFO	D08DVV	1-benzhydryl-4-hexylpiperidin-4-ol	Investigative
T60693	DRUGINFO	D08QBU	1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol	Investigative
T60693	DRUGINFO	D08TFY	1-benzhydryl-4-cyclohexylpiperidin-4-ol	Investigative
T60693	DRUGINFO	D09BYD	1-benzhydryl-4-o-tolylpiperidin-4-ol	Investigative
T60693	DRUGINFO	D09FJY	4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol	Investigative
T60693	DRUGINFO	D09LRO	1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol	Investigative
T60693	DRUGINFO	D09VRT	1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol	Investigative
T60693	DRUGINFO	D0B7GU	Dihydromorphine	Investigative
T60693	DRUGINFO	D0D0UP	1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol	Investigative
T60693	DRUGINFO	D0D5QV	O-DESMETHYL TRAMADOL	Investigative
T60693	DRUGINFO	D0G4FA	1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol	Investigative
T60693	DRUGINFO	D0G7DF	4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol	Investigative
T60693	DRUGINFO	D0J5JO	1-benzhydryl-4-m-tolylpiperidin-4-ol	Investigative
T60693	DRUGINFO	D0JH5D	1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol	Investigative
T60693	DRUGINFO	D0O7JV	4-phenyl-1-(1-phenylhexyl)piperidin-4-ol	Investigative
T60693	DRUGINFO	D0P3FP	4-phenyl-1-(1-phenylpentyl)piperidin-4-ol	Investigative
T60693	DRUGINFO	D0Q9TQ	1-benzhydryl-4-methoxy-4-phenylpiperidine	Investigative
T60693	DRUGINFO	D0QH4A	1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol	Investigative
T60693	DRUGINFO	D0T4ZY	1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol	Investigative
T60693	DRUGINFO	D0T9KE	1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol	Investigative
T60693	DRUGINFO	D0W3VT	1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol	Investigative
T60693	DRUGINFO	D0X4SX	1-benzhydryl-4-phenyl-4-propoxypiperidine	Investigative
T60693	DRUGINFO	D0XX1Y	4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol	Investigative
T60693	DRUGINFO	D0Y5LJ	1-benzhydryl-4-(furan-2-yl)piperidin-4-ol	Investigative
T60693	DRUGINFO	D0ZE2W	1-benzhydryl-4-benzylpiperidin-4-ol	Investigative
T60693	DRUGINFO	D03SAV	ICI-199441	Investigative
T60693	DRUGINFO	D08UOX	FALCARINDIOL	Investigative
T60693	DRUGINFO	D0L9YP	4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide	Investigative

T92076	TARGETID	T92076
T92076	FORMERID	TTDS00164
T92076	UNIPROID	CASR_HUMAN
T92076	TARGNAME	Extracellular calcium-sensing receptor (CASR)
T92076	GENENAME	CASR
T92076	TARGTYPE	Successful
T92076	SYNONYMS	hCasR; Parathyroid cell calciumreceptor; Parathyroid cell calcium-sensing receptor 1; Parathyroid calcium receptor; Parathyroid Cell calcium-sensing receptor; PCaR1; GPRC2A; CaSR
T92076	FUNCTION	Senses fluctuations in the circulating calcium concentration and modulates the production of parathyroid hormone (PTH) in parathyroid glands. The activity of this receptor is mediated by a G-protein that activates a phosphatidylinositol-calcium second messenger system. The G-protein-coupled receptor activity is activated by a co-agonist mechanism: aromatic amino acids, such as Trp or Phe, act concertedly with divalent cations, such as calcium or magnesium, to achieve full receptor activation. G-protein-coupled receptor that senses changes in the extracellular concentration of calcium ions and plays a key role in maintaining calcium homeostasis.
T92076	PDBSTRUC	5K5T; 5K5S; 5FBK; 5FBH
T92076	BIOCLASS	GPCR glutamate
T92076	SEQUENCE	MAFYSCCWVLLALTWHTSAYGPDQRAQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGFRWLQAMIFAIEEINSSPALLPNLTLGYRIFDTCNTVSKALEATLSFVAQNKIDSLNLDEFCNCSEHIPSTIAVVGATGSGVSTAVANLLGLFYIPQVSYASSSRLLSNKNQFKSFLRTIPNDEHQATAMADIIEYFRWNWVGTIAADDDYGRPGIEKFREEAEERDICIDFSELISQYSDEEEIQHVVEVIQNSTAKVIVVFSSGPDLEPLIKEIVRRNITGKIWLASEAWASSSLIAMPQYFHVVGGTIGFALKAGQIPGFREFLKKVHPRKSVHNGFAKEFWEETFNCHLQEGAKGPLPVDTFLRGHEESGDRFSNSSTAFRPLCTGDENISSVETPYIDYTHLRISYNVYLAVYSIAHALQDIYTCLPGRGLFTNGSCADIKKVEAWQVLKHLRHLNFTNNMGEQVTFDECGDLVGNYSIINWHLSPEDGSIVFKEVGYYNVYAKKGERLFINEEKILWSGFSREVPFSNCSRDCLAGTRKGIIEGEPTCCFECVECPDGEYSDETDASACNKCPDDFWSNENHTSCIAKEIEFLSWTEPFGIALTLFAVLGIFLTAFVLGVFIKFRNTPIVKATNRELSYLLLFSLLCCFSSSLFFIGEPQDWTCRLRQPAFGISFVLCISCILVKTNRVLLVFEAKIPTSFHRKWWGLNLQFLLVFLCTFMQIVICVIWLYTAPPSSYRNQELEDEIIFITCHEGSLMALGFLIGYTCLLAAICFFFAFKSRKLPENFNEAKFITFSMLIFFIVWISFIPAYASTYGKFVSAVEVIAILAASFGLLACIFFNKIYIILFKPSRNTIEEVRCSTAAHAFKVAARATLRRSNVSRKRSSSLGGSTGSTPSSSISSKSNSEDPFPQPERQKQQQPLALTQQEQQQQPLTLPQQQRSQQQPRCKQKVIFGSGTVTFSLSFDEPQKNAMAHRNSTHQNSLEAQKSSDTLTRHEPLLPLQCGETDLDLTVQETGLQGPVGGDQRPEVEDPEELSPALVVSSSQSFVISGGGSTVTENVVNS
T92076	DRUGINFO	D03YGR	Cinacalcet	Approved
T92076	DRUGINFO	D07RYI	Etelcalcetide	Approved
T92076	DRUGINFO	DKP2I0	Encaleret	Phase 3
T92076	DRUGINFO	D07YRW	ASP7991	Phase 2
T92076	DRUGINFO	D0H8OA	MK-5442	Phase 2
T92076	DRUGINFO	D04CJE	ATF-936	Phase 1
T92076	DRUGINFO	D0S7VI	AXT-914	Phase 1
T92076	DRUGINFO	D03XIS	R-568	Discontinued in Phase 2
T92076	DRUGINFO	D07XPT	Ronacaleret	Discontinued in Phase 2
T92076	DRUGINFO	D0G1RH	NPS-2143	Discontinued in Phase 2
T92076	DRUGINFO	D0W0XM	NPS-2390	Preclinical
T92076	DRUGINFO	D02BCM	2-Furan-2-yl-3-phenethyl-3H-quinazolin-4-one	Investigative
T92076	DRUGINFO	D04HDO	3-Phenethyl-2-phenyl-3H-quinazolin-4-one	Investigative
T92076	DRUGINFO	D04PHG	2-methyl-3-phenethyl-3H-pyrimidin-4-one	Investigative
T92076	DRUGINFO	D0F4MI	TAK-075	Investigative
T92076	DRUGINFO	D0I1GV	1-arylmethylpyrrolidin-2-yl ethanol amine	Investigative
T92076	DRUGINFO	D0R7SM	PMID15686947C(S)-3h	Investigative
T92076	DRUGINFO	D0UO2Q	calhex 231	Investigative
T92076	DRUGINFO	D0Z5HX	PMID15300839C17	Investigative
T92076	DRUGINFO	D0Z8YZ	AC265347	Investigative
T92076	DRUGINFO	D0HS5P	calindol	Investigative

T31204	TARGETID	T31204
T31204	FORMERID	TTDS00104
T31204	UNIPROID	5HT2B_HUMAN
T31204	TARGNAME	5-HT 2B receptor (HTR2B)
T31204	GENENAME	HTR2B
T31204	TARGTYPE	Successful
T31204	SYNONYMS	Serotonin receptor 2B; 5-hydroxytryptamine receptor 2B; 5-HT2B; 5-HT-2B; 5-HT 2B
T31204	FUNCTION	Functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and down-stream signaling cascades and promotes the release of Ca(2+) ions from intracellular stores. Plays a role in the regulation of dopamine and 5-hydroxytryptamine release, 5-hydroxytryptamine uptake and in the regulation of extracellular dopamine and 5-hydroxytryptamine levels, and thereby affects neural activity. May play a role in the perception of pain. Plays a role in the regulation of behavior, including impulsive behavior. Required for normal proliferation of embryonic cardiac myocytes and normal heart development. Protects cardiomyocytes against apoptosis. Plays a role in the adaptation of pulmonary arteries to chronic hypoxia. Plays a role in vasoconstriction. Required for normal osteoblast function and proliferation, and for maintaining normal bone density. Required for normal proliferation of the interstitial cells of Cajal in the intestine. G-protein coupled receptor for 5-hydroxytryptamine (serotonin).
T31204	PDBSTRUC	6DS0; 6DRZ; 6DRY; 6DRX; 5TVN
T31204	BIOCLASS	GPCR rhodopsin
T31204	SEQUENCE	MALSYRVSELQSTIPEHILQSTFVHVISSNWSGLQTESIPEEMKQIVEEQGNKLHWAALLILMVIIPTIGGNTLVILAVSLEKKLQYATNYFLMSLAVADLLVGLFVMPIALLTIMFEAMWPLPLVLCPAWLFLDVLFSTASIMHLCAISVDRYIAIKKPIQANQYNSRATAFIKITVVWLISIGIAIPVPIKGIETDVDNPNNITCVLTKERFGDFMLFGSLAAFFTPLAIMIVTYFLTIHALQKKAYLVKNKPPQRLTWLTVSTVFQRDETPCSSPEKVAMLDGSRKDKALPNSGDETLMRRTSTIGKKSVQTISNEQRASKVLGIVFFLFLLMWCPFFITNITLVLCDSCNQTTLQMLLEIFVWIGYVSSGVNPLVYTLFNKTFRDAFGRYITCNYRATKSVKTLRKRSSKIYFRNPMAENSKFFKKHGIRNGINPAMYQSPMRLRSSTIQSSSIILLDTLLLTENEGDKTEEQVSYV
T31204	DRUGINFO	D05NOS	Triflupromazine	Approved
T31204	DRUGINFO	D0W8SJ	Minaprine	Approved
T31204	DRUGINFO	D0UA0I	Metergolin	Approved
T31204	DRUGINFO	DRL5Y7	SPN-812	Phase 4
T31204	DRUGINFO	D0W4XY	PRX-08066	Phase 2
T31204	DRUGINFO	D02BRJ	Vabicaserin	Phase 2
T31204	DRUGINFO	D0D3BL	Pyrazole-3-carboxamide derivative 1	Patented
T31204	DRUGINFO	D01LVT	Quinoline derivative 2	Patented
T31204	DRUGINFO	D00YGY	Pyrimidine derivative 29	Patented
T31204	DRUGINFO	D08DJY	Pyrimidine derivative 26	Patented
T31204	DRUGINFO	D0B7NS	Pyrimidine derivative 23	Patented
T31204	DRUGINFO	D0N2VA	Pyrimidine derivative 25	Patented
T31204	DRUGINFO	D0P9VX	Pyrimidine derivative 27	Patented
T31204	DRUGINFO	D0SE9K	Pyrimidine derivative 28	Patented
T31204	DRUGINFO	D0U9UH	Pyrimidine derivative 24	Patented
T31204	DRUGINFO	D02FEA	FENDILINE	Withdrawn from market
T31204	DRUGINFO	D0K8NW	Ritanserin	Discontinued in Phase 3
T31204	DRUGINFO	D0QF4Z	MT-500	Discontinued in Phase 1
T31204	DRUGINFO	D03YPJ	SB 206553	Terminated
T31204	DRUGINFO	D0B4BN	Ro-60-0175	Terminated
T31204	DRUGINFO	D0PA6K	LY53857	Terminated
T31204	DRUGINFO	D07RIQ	ADRENOGLOMERULOTROPIN	Investigative
T31204	DRUGINFO	D0GM9E	RQ-00310941	Investigative
T31204	DRUGINFO	D0H3MO	(-)-norfenfluramine	Investigative
T31204	DRUGINFO	D0N6AY	norfenfluramine	Investigative
T31204	DRUGINFO	D0O7MW	(5-methoxy-1H-indol-3-yl)methanamine	Investigative
T31204	DRUGINFO	D0U7BH	(+)-norfenfluramine	Investigative
T31204	DRUGINFO	D0Y4WR	R-1	Investigative
T31204	DRUGINFO	D0Z7GS	6-Fluoromelatonin	Investigative
T31204	DRUGINFO	D01NOZ	ADS-103274	Investigative
T31204	DRUGINFO	D02XAX	LY86057	Investigative
T31204	DRUGINFO	D04AZE	SB 204741	Investigative
T31204	DRUGINFO	D07XTU	Racemic DOI	Investigative
T31204	DRUGINFO	D0U8OK	[3H]mesulergine	Investigative
T31204	DRUGINFO	D0UI3L	dihydroergocryptine	Investigative
T31204	DRUGINFO	D00APD	3-(2-Dimethylamino-ethyl)-1H-indol-6-ol	Investigative
T31204	DRUGINFO	D00EMF	SB 242084	Investigative
T31204	DRUGINFO	D00GOY	VER-3323	Investigative
T31204	DRUGINFO	D00ZCU	BW723C86	Investigative
T31204	DRUGINFO	D01BGW	(2S)-1-(6-methoxy-1H-indazol-1-yl)propan-2-amine	Investigative
T31204	DRUGINFO	D01NTM	VER-5593	Investigative
T31204	DRUGINFO	D01SJL	1-((S)-2-aminopropyl)-7-chloro-1H-indazol-6-ol	Investigative
T31204	DRUGINFO	D04YCJ	1-((S)-2-aminopropyl)-7-fluoro-1H-indazol-6-ol	Investigative
T31204	DRUGINFO	D05NWH	SB 228357	Investigative
T31204	DRUGINFO	D05SWY	3-Dimethylaminomethyl-1H-indol-4-ol	Investigative
T31204	DRUGINFO	D06ABJ	[2-(4-Fluoro-1H-indol-3-yl)-ethyl]-dimethyl-amine	Investigative
T31204	DRUGINFO	D07LJH	[125I]DOI	Investigative
T31204	DRUGINFO	D08GJS	3-(2-Dimethylamino-propyl)-1H-indol-4-ol	Investigative
T31204	DRUGINFO	D09HJL	AL-37350A	Investigative
T31204	DRUGINFO	D0AP6N	1-Butyl-3-(2-dimethylamino-ethyl)-1H-indol-4-ol	Investigative
T31204	DRUGINFO	D0DY5G	SB 221284	Investigative
T31204	DRUGINFO	D0E6NW	VER-5384	Investigative
T31204	DRUGINFO	D0F5WP	1-(2-aminoethyl)-1H-indazol-6-ol	Investigative
T31204	DRUGINFO	D0H5XR	YM-348	Investigative
T31204	DRUGINFO	D0I9RW	1-((S)-2-aminopropyl)-7-iodo-1H-indazol-6-ol	Investigative
T31204	DRUGINFO	D0KH5R	SB 215505	Investigative
T31204	DRUGINFO	D0M1YU	VER-2692	Investigative
T31204	DRUGINFO	D0N6OL	ADS-103253	Investigative
T31204	DRUGINFO	D0N7HY	Org 12962	Investigative
T31204	DRUGINFO	D0N8YG	1-((S)-2-aminopropyl)-7-methyl-1H-indazol-6-ol	Investigative
T31204	DRUGINFO	D0O5KK	7,8,9,10-tetrahydro-6H-furo-[2,3-g][3]benzazepine	Investigative
T31204	DRUGINFO	D0R8VT	3-(2-Dimethylamino-ethyl)-1-methyl-1H-indol-4-ol	Investigative
T31204	DRUGINFO	D0T7RY	6,7-dichloro-2,3,4,5-tetrahydro-1H-3-benzazepine	Investigative
T31204	DRUGINFO	D0T8UR	3-Dimethylaminomethyl-1-methyl-1H-indol-4-ol	Investigative
T31204	DRUGINFO	D0V5SQ	spiramide	Investigative
T31204	DRUGINFO	D0W7GQ	EGIS-7625	Investigative
T31204	DRUGINFO	D0W8EB	3-(3-Dimethylamino-propyl)-1H-indol-4-ol	Investigative
T31204	DRUGINFO	D0XX7J	7,8,9,10-tetrahydro-6H-furo-[3,2-g][3]benzazepine	Investigative
T31204	DRUGINFO	D0Y0SA	1-((R)-2-aminopropyl)-1H-indazol-6-ol	Investigative
T31204	DRUGINFO	D0ZZ4Z	3-(2-Pyrrolidin-1-yl-ethyl)-1H-indol-4-ol	Investigative
T31204	DRUGINFO	D07HQZ	[3H]LSD	Investigative
T31204	DRUGINFO	D08EFH	2-(5-Methoxy-1H-indol-3-yl)-1-methyl-ethylamine	Investigative
T31204	DRUGINFO	D0C2NK	norfluoxetine	Investigative
T31204	DRUGINFO	D0C5XQ	5-MEO-DMT	Investigative
T31204	DRUGINFO	D0N8BJ	[3H]5-HT	Investigative
T31204	DRUGINFO	D0S8KA	3-(2-Amino-propyl)-1H-indol-5-ol	Investigative
T31204	DRUGINFO	D0Z7EA	[3H]rauwolscine	Investigative
T31204	DRUGINFO	D0MU4A	spiroxatrine	Investigative
T31204	DRUGINFO	D07GXY	piribedil	Investigative
T31204	DRUGINFO	D0D9YW	SB 216641	Investigative
T31204	DRUGINFO	D0V3XU	CHLOROPHENYLPIPERAZINE	Investigative
T31204	DRUGINFO	D0F5NJ	METHYLENEDIOXYMETHAMPHETAMINE	Investigative
T31204	DRUGINFO	D0J6JT	m-chlorophenylpiperazine	Investigative
T31204	DRUGINFO	D0LG8A	1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine	Investigative
T31204	DRUGINFO	D00CRA	2-methyl-5-HT	Investigative
T31204	DRUGINFO	D01KAX	1-((S)-2-aminopropyl)-1H-indazol-6-ol	Investigative
T31204	DRUGINFO	D09OYA	alpha-methyl-5-HT	Investigative
T31204	DRUGINFO	D03TDN	1-naphthylpiperazine	Investigative
T31204	DRUGINFO	D04TVG	BRL-15572	Investigative
T31204	DRUGINFO	D02UWB	5-CT	Investigative
T31204	DRUGINFO	D0V5HV	TFMPP	Investigative
T31204	DRUGINFO	D0F6CD	SEROTONIN	Investigative
T31204	DRUGINFO	D0F9QT	A-987306	Investigative
T31204	DRUGINFO	D0L5MW	(+/-)-nantenine	Investigative
T31204	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T50912	TARGETID	T50912
T50912	FORMERID	TTDS00490
T50912	UNIPROID	CD86_HUMAN
T50912	TARGNAME	T-lymphocyte activation antigen CD86 (FUN1)
T50912	GENENAME	CD86
T50912	TARGTYPE	Successful
T50912	SYNONYMS	FUN-1; CTLA-4 counter-receptor B7.2; CD86; CD28LG2; BU63; B70; Activation B7-2 antigen
T50912	FUNCTION	Receptor involved in the costimulatory signal essential for t-lymphocyte proliferation and interleukin-2 production, by binding cd28 or ctla-4. May play a critical role in the early events of t-cell activation and costimulationof naive t-cells, such as deciding between immunity and anergy that is made by t-cells within 24 hours after activation. Isoform 2 interferes with the formation of cd86 clusters, and thus acts as a negative regulator of t-cell activation.
T50912	PDBSTRUC	5YXK; 1NCN; 1I85
T50912	BIOCLASS	Immunoglobulin
T50912	SEQUENCE	MDPQCTMGLSNILFVMAFLLSGAAPLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSKYMGRTSFDSDSWTLRLHNLQIKDKGLYQCIIHHKKPTGMIRIHQMNSELSVLANFSQPEIVPISNITENVYINLTCSSIHGYPEPKKMSVLLRTKNSTIEYDGVMQKSQDNVTELYDVSISLSVSFPDVTSNMTIFCILETDKTRLLSSPFSIELEDPQPPPDHIPWITAVLPTVIICVMVFCLILWKWKKKKRPRNSYKCGTNTMEREESEQTKKREKIHIPERSDEAQRVFKSSKTSSCDKSDTCF
T50912	DRUGINFO	D0EW4L	Abatacept	Approved
T50912	DRUGINFO	D0T2EO	MAXY-4	Phase 1
T50912	DRUGINFO	D0V4PH	Tolerimab	Terminated

T99954	TARGETID	T99954
T99954	FORMERID	TTDS00170
T99954	UNIPROID	PI2R_HUMAN
T99954	TARGNAME	Prostacyclin receptor (PTGIR)
T99954	GENENAME	PTGIR
T99954	TARGTYPE	Successful
T99954	SYNONYMS	Prostanoid IP receptor; Prostaglandin I2 receptor; PRIPR; PGI2 receptor; PGI receptor; IP prostanoid receptor
T99954	FUNCTION	The activity of this receptor is mediated by G(s) proteins which activate adenylate cyclase. Receptor for prostacyclin (prostaglandin I2 or PGI2).
T99954	BIOCLASS	GPCR rhodopsin
T99954	SEQUENCE	MADSCRNLTYVRGSVGPATSTLMFVAGVVGNGLALGILSARRPARPSAFAVLVTGLAATDLLGTSFLSPAVFVAYARNSSLLGLARGGPALCDAFAFAMTFFGLASMLILFAMAVERCLALSHPYLYAQLDGPRCARLALPAIYAFCVLFCALPLLGLGQHQQYCPGSWCFLRMRWAQPGGAAFSLAYAGLVALLVAAIFLCNGSVTLSLCRMYRQQKRHQGSLGPRPRTGEDEVDHLILLALMTVVMAVCSLPLTIRCFTQAVAPDSSSEMGDLLAFRFYAFNPILDPWVFILFRKAVFQRLKLWVCCLCLGPAHGDSQTPLSQLASGRRDPRAPSAPVGKEGSCVPLSAWGEGQVEPLPPTQQSSGSAVGTSSKAEASVACSLC
T99954	DRUGINFO	D01WUA	Treprostinil	Approved
T99954	DRUGINFO	D04RGA	Dinoprost Tromethamine	Approved
T99954	DRUGINFO	D09ANG	Misoprostol	Approved
T99954	DRUGINFO	D0N2SR	Selexipag	Approved
T99954	DRUGINFO	D0V0IX	Epoprostenol	Approved
T99954	DRUGINFO	D4Q5AW	Beraprost	Phase 4
T99954	DRUGINFO	D0WL5V	LAROPIPRANT	Phase 4
T99954	DRUGINFO	D0CO3N	esuberaprost	Phase 3
T99954	DRUGINFO	D0M4TJ	Ralinepag	Phase 2
T99954	DRUGINFO	D0X8DU	Clinprost	Discontinued in Preregistration
T99954	DRUGINFO	D00LWS	Ataprost	Discontinued in Phase 3
T99954	DRUGINFO	D00QFY	YM533	Discontinued in Phase 3
T99954	DRUGINFO	D0G2GR	OP-2507	Discontinued in Phase 2
T99954	DRUGINFO	D0G2XM	AP-227	Terminated
T99954	DRUGINFO	D0M4LC	EPTALOPROST	Terminated
T99954	DRUGINFO	D06ENH	Prostacyclin analog	Investigative
T99954	DRUGINFO	D08WBB	BAY-73-1449	Investigative
T99954	DRUGINFO	D09AZM	TEI-9063	Investigative
T99954	DRUGINFO	D0O2WX	AFP-07	Investigative
T99954	DRUGINFO	D0U1SF	BMY 45778	Investigative
T99954	DRUGINFO	D0W4JS	RO3244794	Investigative
T99954	DRUGINFO	D0X6PY	EP 157	Investigative
T99954	DRUGINFO	D0Y1IF	FR-193262	Investigative
T99954	DRUGINFO	D0Z9XV	RO1138452	Investigative
T99954	DRUGINFO	D02YIJ	isocarbacyclin	Investigative
T99954	DRUGINFO	D0TA0L	FR-181157	Investigative
T99954	DRUGINFO	D05SFA	cicaprost	Investigative
T99954	DRUGINFO	D08MNO	butaprost (free acid form)	Investigative
T99954	DRUGINFO	D0W7RI	carbacyclin	Investigative
T99954	DRUGINFO	D03PLH	U46619	Investigative

T36075	TARGETID	T36075
T36075	FORMERID	TTDS00440
T36075	UNIPROID	GLP1R_HUMAN
T36075	TARGNAME	Glucagon-like peptide 1 receptor (GLP1R)
T36075	GENENAME	GLP1R
T36075	TARGTYPE	Successful
T36075	SYNONYMS	GLP-1R; GLP-1-R; GLP-1 receptor
T36075	FUNCTION	Ligand binding triggers activation of a signaling cascade that leads to the activation of adenylyl cyclase and increased intracellular cAMP levels. Plays a role in regulating insulin secretion in response to GLP-1. G-protein coupled receptor for glucagon-like peptide 1 (GLP-1).
T36075	PDBSTRUC	6GB1; 6B3J; 5VEX; 5VEW; 5OTX
T36075	BIOCLASS	GPCR secretin
T36075	SEQUENCE	MAGAPGPLRLALLLLGMVGRAGPRPQGATVSLWETVQKWREYRRQCQRSLTEDPPPATDLFCNRTFDEYACWPDGEPGSFVNVSCPWYLPWASSVPQGHVYRFCTAEGLWLQKDNSSLPWRDLSECEESKRGERSSPEEQLLFLYIIYTVGYALSFSALVIASAILLGFRHLHCTRNYIHLNLFASFILRALSVFIKDAALKWMYSTAAQQHQWDGLLSYQDSLSCRLVFLLMQYCVAANYYWLLVEGVYLYTLLAFSVLSEQWIFRLYVSIGWGVPLLFVVPWGIVKYLYEDEGCWTRNSNMNYWLIIRLPILFAIGVNFLIFVRVICIVVSKLKANLMCKTDIKCRLAKSTLTLIPLLGTHEVIFAFVMDEHARGTLRFIKLFTELSFTSFQGLMVAILYCFVNNEVQLEFRKSWERWRLEHLHIQRDSSMKPLKCPTSSLSSGATAGSSMYTATCQASCS
T36075	DRUGINFO	D00YVF	Exenatide	Approved
T36075	DRUGINFO	D02ULU	Semaglutide	Approved
T36075	DRUGINFO	D03GOI	Liraglutide	Approved
T36075	DRUGINFO	D03NAW	Dulaglutide	Approved
T36075	DRUGINFO	D05MKA	Lixisenatide	Approved
T36075	DRUGINFO	D0C4AM	Pramlintide	Approved
T36075	DRUGINFO	D0F1DY	Albiglutide	Approved
T36075	DRUGINFO	DA69JF	Tirzepatide	Approved
T36075	DRUGINFO	D05OZQ	Efpeglenatide	Phase 3
T36075	DRUGINFO	D08NXW	GLP-1	Phase 3
T36075	DRUGINFO	D0B1EQ	Taspoglutide	Phase 3
T36075	DRUGINFO	D0H1UW	LATIN T1D	Phase 3
T36075	DRUGINFO	DK1MX0	GMA102	Phase 3
T36075	DRUGINFO	DO78YZ	GMA105	Phase 3
T36075	DRUGINFO	DULR78	PB-119	Phase 3
T36075	DRUGINFO	DI9P5G	Orforglipron	Phase 3
T36075	DRUGINFO	DI9P5G	Orforglipron	Phase 3
T36075	DRUGINFO	DG7N3W	Retatrutide	Phase 3
T36075	DRUGINFO	D05XXF	ORMD-0901	Phase 2
T36075	DRUGINFO	D06QWM	OI338GT	Phase 2
T36075	DRUGINFO	D09FTJ	TTP-054	Phase 2
T36075	DRUGINFO	D0DI1B	TTP273	Phase 2
T36075	DRUGINFO	D0G4QL	UNI-rE-4	Phase 2
T36075	DRUGINFO	D0O3DK	GTP-010	Phase 2
T36075	DRUGINFO	D0U9LV	LY-2428757	Phase 2
T36075	DRUGINFO	D5XV9K	PF-06882961	Phase 2
T36075	DRUGINFO	DAJI68	Avexitide	Phase 2
T36075	DRUGINFO	DH08CI	RGT-075	Phase 2
T36075	DRUGINFO	DM61KY	PF-07081532	Phase 2
T36075	DRUGINFO	DX1U3C	BI 456906	Phase 2
T36075	DRUGINFO	D03MSV	PB-1023	Phase 2
T36075	DRUGINFO	D08FMK	LY2944876	Phase 2
T36075	DRUGINFO	D0Q8VM	TT-401	Phase 2
T36075	DRUGINFO	D7A5LO	NLY01	Phase 2
T36075	DRUGINFO	D7A5LO	NLY01	Phase 2
T36075	DRUGINFO	D96UBZ	Semorinemab	Phase 2
T36075	DRUGINFO	DY67HC	Efinopegdutide	Phase 2
T36075	DRUGINFO	DR76TW	LY3437943	Phase 2
T36075	DRUGINFO	D00BZZ	PF-4603629	Phase 1
T36075	DRUGINFO	D00TED	JNJ-54728518	Phase 1
T36075	DRUGINFO	D08NIN	NN-9926	Phase 1
T36075	DRUGINFO	D08PCR	CM3.1-AC100	Phase 1
T36075	DRUGINFO	D0A0FB	ZYOG1	Phase 1
T36075	DRUGINFO	D0FC4R	CVX 096	Phase 1
T36075	DRUGINFO	D0U9NN	OG987SC	Phase 1
T36075	DRUGINFO	D0W7SX	CNTO-3649	Phase 1
T36075	DRUGINFO	DN5O8K	GZR18	Phase 1
T36075	DRUGINFO	DPFY92	AZD0186	Phase 1
T36075	DRUGINFO	D0FY4L	SAR438335	Phase 1
T36075	DRUGINFO	D53BVX	Pemvidutide	Phase 1
T36075	DRUGINFO	D5V1CL	DD01	Phase 1
T36075	DRUGINFO	D6ZGP9	LY3305677	Phase 1
T36075	DRUGINFO	DEC8O3	CT 868	Phase 1
T36075	DRUGINFO	DQO46V	CT-388	Phase 1
T36075	DRUGINFO	D02URD	SAR425899	Phase 1
T36075	DRUGINFO	D0FW0B	ZP2929	Phase 1
T36075	DRUGINFO	D0L1JE	CJC-1131	Discontinued in Phase 2
T36075	DRUGINFO	D0Q9HT	LY-307161	Discontinued in Phase 2
T36075	DRUGINFO	D0M4RX	RG7685	Discontinued in Phase 2
T36075	DRUGINFO	D00NSM	CM-GLP-1	Discontinued in Phase 1/2
T36075	DRUGINFO	D0K5HD	LY-315902	Discontinued in Phase 1
T36075	DRUGINFO	D7FL3H	CIN-209	Preclinical
T36075	DRUGINFO	D0D2JD	TH-0318	Terminated
T36075	DRUGINFO	D0I0TD	AZM-134	Terminated
T36075	DRUGINFO	D00UCX	HAEGTFTSDVSSYLEGQAAKEIFAWLVKGR	Investigative
T36075	DRUGINFO	D01TMK	GX-G6	Investigative
T36075	DRUGINFO	D02TKT	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG-NH2	Investigative
T36075	DRUGINFO	D03JQD	BETP	Investigative
T36075	DRUGINFO	D03YDP	C[Glu22-Orn26][Gly8]GLP-1(7-37)-NH2	Investigative
T36075	DRUGINFO	D04LSW	C[Glu21-Lys25][Gly8]GLP-1(7-37)-NH2	Investigative
T36075	DRUGINFO	D04NUZ	C[Glu26-Lys30][Gly8]GLP-1(7-37)-NH2	Investigative
T36075	DRUGINFO	D06PZJ	[Gly8, aib22]GLP-1(7-37)-NH2	Investigative
T36075	DRUGINFO	D07MBQ	CNTO-736	Investigative
T36075	DRUGINFO	D08HSQ	C[Glu22-Lys26][Gly8]GLP-1(7-37)-NH2	Investigative
T36075	DRUGINFO	D09RUJ	SX-GLP1	Investigative
T36075	DRUGINFO	D0B3BS	C[Asp22-Lys26][Gly8]GLP-1(7-37)-NH2	Investigative
T36075	DRUGINFO	D0B4WW	C[Glu18-Lys22][Gly8]GLP-1(7-37)-NH2	Investigative
T36075	DRUGINFO	D0BL8S	[Gly8,Glu22]GLP-1(7,37)-NH2	Investigative
T36075	DRUGINFO	D0D9KV	SKL-18287	Investigative
T36075	DRUGINFO	D0ED6E	CAM-2036	Investigative
T36075	DRUGINFO	D0F2GY	Glu20-Lys24][Gly8][GLP-1(7-37)-NH2	Investigative
T36075	DRUGINFO	D0I7WD	C[hGlu22-Lys26][Gly8]GLP-1(7-37)-NH2	Investigative
T36075	DRUGINFO	D0M7LZ	C[Glu23-Lys27][Gly8]GLP-1(7-37)-NH2	Investigative
T36075	DRUGINFO	D0NY1R	AC-3174	Investigative
T36075	DRUGINFO	D0O0LF	F-18 exendin-4 derivative PET tracers	Investigative
T36075	DRUGINFO	D0O1DS	[123I] iodobenzoyl 12-Ex4	Investigative
T36075	DRUGINFO	D0Q4AR	Glucagon-like peptide-1 analog	Investigative
T36075	DRUGINFO	D0R1NH	C[Glu24-Lys28][Gly8]GLP-1(7-37)-NH2	Investigative
T36075	DRUGINFO	D0R2ZG	[Gly8]GLP-1(7-37)-NH2	Investigative
T36075	DRUGINFO	D0S2GY	C[Glu19-Lys23][Gly8]GLP-1(7-37)-NH2	Investigative
T36075	DRUGINFO	D0U2XB	PGC GLP-1	Investigative
T36075	DRUGINFO	D0W2EI	C[Glu21-Lys26][Gly8]GLP-1(7-37)-NH2	Investigative
T36075	DRUGINFO	D0W8BP	C[Cpa19-Lys26][Gly8]GLP-1(7-37)-NH2	Investigative
T36075	DRUGINFO	D0XL7R	GLP-17-(7-36) derivative	Investigative
T36075	DRUGINFO	D0Z9WP	ZP-3022	Investigative
T36075	DRUGINFO	D0D7YR	AMPE4L	Investigative

T70967	TARGETID	T70967
T70967	FORMERID	TTDS00141
T70967	UNIPROID	ACHA4_HUMAN
T70967	TARGNAME	Neuronal acetylcholine receptor alpha-4 (CHRNA4)
T70967	GENENAME	CHRNA4
T70967	TARGTYPE	Successful
T70967	SYNONYMS	Nicotinic acetylcholine receptor alpha4; CHRNA4; Alpha-4 nAChR
T70967	FUNCTION	After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasmamembrane permeable to sodium ions.
T70967	PDBSTRUC	6CNK; 6CNJ; 5KXI; 2LLY; 2GVT
T70967	BIOCLASS	Neurotransmitter receptor
T70967	SEQUENCE	MELGGPGAPRLLPPLLLLLGTGLLRASSHVETRAHAEERLLKKLFSGYNKWSRPVANISDVVLVRFGLSIAQLIDVDEKNQMMTTNVWVKQEWHDYKLRWDPADYENVTSIRIPSELIWRPDIVLYNNADGDFAVTHLTKAHLFHDGRVQWTPPAIYKSSCSIDVTFFPFDQQNCTMKFGSWTYDKAKIDLVNMHSRVDQLDFWESGEWVIVDAVGTYNTRKYECCAEIYPDITYAFVIRRLPLFYTINLIIPCLLISCLTVLVFYLPSECGEKITLCISVLLSLTVFLLLITEIIPSTSLVIPLIGEYLLFTMIFVTLSIVITVFVLNVHHRSPRTHTMPTWVRRVFLDIVPRLLLMKRPSVVKDNCRRLIESMHKMASAPRFWPEPEGEPPATSGTQSLHPPSPSFCVPLDVPAEPGPSCKSPSDQLPPQQPLEAEKASPHPSPGPCRPPHGTQAPGLAKARSLSVQHMSSPGEAVEGGVRCRSRSIQYCVPRDDAAPEADGQAAGALASRNTHSAELPPPDQPSPCKCTCKKEPSSVSPSATVKTRSTKAPPPHLPLSPALTRAVEGVQYIADHLKAEDTDFSVKEDWKYVAMVIDRIFLWMFIIVCLLGTVGLFLPPWLAGMI
T70967	DRUGINFO	D0B6CC	Trimethaphan	Approved
T70967	DRUGINFO	D0IX1A	Pentolinium	Approved
T70967	DRUGINFO	D08XPW	CYTISINE	Phase 3
T70967	DRUGINFO	D04HYP	ABT-594	Discontinued in Phase 2
T70967	DRUGINFO	D09ADT	ABT-418	Discontinued in Phase 2
T70967	DRUGINFO	D0C9KD	HOMOEPIBATIDINE	Terminated
T70967	DRUGINFO	D03FEV	N-methyl-2-(pyridin-3-yloxy)ethanamine	Investigative
T70967	DRUGINFO	D03SYO	N-methyl-4-(pyridin-3-yl)but-3-yn-1-amine	Investigative
T70967	DRUGINFO	D04HQP	N,N-dimethyl-4-(pyridin-3-yl)but-3-yn-1-amine	Investigative
T70967	DRUGINFO	D06KYM	N-methyl-N-(pyridin-3-ylmethyl)ethanamine	Investigative
T70967	DRUGINFO	D0A7HM	N,N-dimethyl-2-(pyridin-3-yloxy)ethanamine	Investigative
T70967	DRUGINFO	D0P9ED	CMI-489	Investigative
T70967	DRUGINFO	D0R8YJ	N-ethyl-N-methyl-4-(pyridin-3-yl)but-3-yn-1-amine	Investigative
T70967	DRUGINFO	D0U2HZ	6'-methylepibatidine	Investigative
T70967	DRUGINFO	D0UX5M	N,N-dimethyl(pyridin-3-yl)methanamine	Investigative
T70967	DRUGINFO	D0V2KB	Predicentrine methiodide	Investigative
T70967	DRUGINFO	D0V7HJ	3-[2-(N,N,N-trimethylammonium)ethoxy]pyridine	Investigative
T70967	DRUGINFO	D0LH4L	BOLDINE	Investigative
T70967	DRUGINFO	D00QCP	(2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol	Investigative
T70967	DRUGINFO	D03YQY	(2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol	Investigative
T70967	DRUGINFO	D03TMD	Barbituric acid derivative	Investigative
T70967	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T88887	TARGETID	T88887
T88887	FORMERID	TTDS00226
T88887	UNIPROID	RPOB_STAA8
T88887	TARGNAME	Staphylococcus Plastid RNA polymerase beta (Stap-coc rpoB)
T88887	GENENAME	Stap-coc rpoB
T88887	TARGTYPE	Successful
T88887	SYNONYMS	Transcriptase beta chain; RpoB; RNAP beta subunit; RNA polymerase beta subunit; DNA-directed RNA polymerase beta chain
T88887	FUNCTION	DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates.
T88887	BIOCLASS	Kinase
T88887	ECNUMBER	EC 2.7.7.6
T88887	SEQUENCE	MAGQVVQYGRHRKRRNYARISEVLELPNLIEIQTKSYEWFLREGLIEMFRDISPIEDFTGNLSLEFVDYRLGEPKYDLEESKNRDATYAAPLRVKVRLIIKETGEVKEQEVFMGDFPLMTDTGTFVINGAERVIVSQLVRSPSVYFNEKIDKNGRENYDATIIPNRGAWLEYETDAKDVVYVRIDRTRKLPLTVLLRALGFSSDQEIVDLLGDNEYLRNTLEKDGTENTEQALLEIYERLRPGEPPTVENAKSLLYSRFFDPKRYDLASVGRYKTNKKLHLKHRLFNQKLAEPIVNTETGEIVVEEGTVLDRRKIDEIMDVLESNANSEVFELHGSVIDEPVEIQSIKVYVPNDDEGRTTTVIGNAFPDSEVKCITPADIIASMSYFFNLLSGIGYTDDIDHLGNRRLRSVGELLQNQFRIGLSRMERVVRERMSIQDTESITPQQLINIRPVIASIKEFFGSSQLSQFMDQANPLAELTHKRRLSALGPGGLTRERAQMEVRDVHYSHYGRMCPIETPEGPNIGLINSLSSYARVNEFGFIETPYRKVDLDTHAITDQIDYLTADEEDSYVVAQANSKLDENGRFMDDEVVCRFRGNNTVMAKEKMDYMDVSPKQVVSAATACIPFLENDDSNRALMGANMQRQAVPLMNPEAPFVGTGMEHVAARDSGAAITAKHRGRVEHVESNEILVRRLVEENGVEHEGELDRYPLAKFKRSNSGTCYNQRPIVAVGDVVEYNEILADGPSMELGEMALGRNVVVGFMTWDGYNYEDAVIMSERLVKDDVYTSIHIEEYESEARDTKLGPEEITRDIPNVSESALKNLDDRGIVYIGAEVKDGDILVGKVTPKGVTELTAEERLLHAIFGEKAREVRDTSLRVPHGAGGIVLDVKVFNREEGDDTLSPGVNQLVRVYIVQKRKIHVGDKMCGRHGNKGVISKIVPEEDMPYLPDGRPIDIMLNPLGVPSRMNIGQVLELHLGMAAKNLGIHVASPVFDGANDDDVWSTIEEAGMARDGKTVLYDGRTGEPFDNRISVGVMYMLKLAHMVDDKLHARSTGPYSLVTQQPLGGKAQFGGQRFGEMEVWALEAYGAAYTLQEILTYKSDDTVGRVKTYEAIVKGENISRPSVPESFRVLMKELQSLGLDVKVMDEQDNEIEMTDVDDDDVVERKVDLQQNDAPETQKEVTD
T88887	DRUGINFO	D0FX2Q	Rifamycin	Approved
T88887	DRUGINFO	D07NQQ	Tagetitoxin	Investigative
T88887	DRUGINFO	D0T6ED	Myxopyronin B	Investigative

T80387	TARGETID	T80387
T80387	FORMERID	TTDS00410
T80387	UNIPROID	GBRB2_HUMAN
T80387	TARGNAME	GABA(A) receptor beta-2 (GABRB2)
T80387	GENENAME	GABRB2
T80387	TARGTYPE	Successful
T80387	SYNONYMS	GABRB2; GABA(A) receptor subunit beta-2
T80387	FUNCTION	Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand- gated chloride channel.
T80387	PDBSTRUC	6D6U; 6D6T
T80387	BIOCLASS	Neurotransmitter receptor
T80387	SEQUENCE	MWRVRKRGYFGIWSFPLIIAAVCAQSVNDPSNMSLVKETVDRLLKGYDIRLRPDFGGPPVAVGMNIDIASIDMVSEVNMDYTLTMYFQQAWRDKRLSYNVIPLNLTLDNRVADQLWVPDTYFLNDKKSFVHGVTVKNRMIRLHPDGTVLYGLRITTTAACMMDLRRYPLDEQNCTLEIESYGYTTDDIEFYWRGDDNAVTGVTKIELPQFSIVDYKLITKKVVFSTGSYPRLSLSFKLKRNIGYFILQTYMPSILITILSWVSFWINYDASAARVALGITTVLTMTTINTHLRETLPKIPYVKAIDMYLMGCFVFVFMALLEYALVNYIFFGRGPQRQKKAAEKAASANNEKMRLDVNKIFYKDIKQNGTQYRSLWDPTGNLSPTRRTTNYDFSLYTMDPHENILLSTLEIKNEMATSEAVMGLGDPRSTMLAYDASSIQYRKAGLPRHSFGRNALERHVAQKKSRLRRRASQLKITIPDLTDVNAIDRWSRIFFPVVFSFFNIVYWLYYVN
T80387	DRUGINFO	D03VZH	Ethchlorvynol	Approved
T80387	DRUGINFO	D00VZZ	Allopregnanolone	approved
T80387	DRUGINFO	D0IG4I	THIOCOLCHICOSIDE	Approved
T80387	DRUGINFO	D07ZCK	ZK-93423	Phase 3
T80387	DRUGINFO	D0C9XA	GSK683699	Phase 2
T80387	DRUGINFO	D0B8YZ	ELTANOLONE	Discontinued in Phase 3
T80387	DRUGINFO	D05EVI	U-78875	Discontinued in Phase 1
T80387	DRUGINFO	D0V4GI	CGS-9896	Terminated
T80387	DRUGINFO	D02XUD	4-(biphenyl-3-yl)-5-(piperidin-4-yl)isoxazol-3-ol	Investigative
T80387	DRUGINFO	D04PQN	N-(p-methylbenzyl)-5-nitroindol-3-ylglyoxylamide	Investigative
T80387	DRUGINFO	D05WEF	N-benzyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide	Investigative
T80387	DRUGINFO	D0GE4A	N-butyl-2-(1H-indol-3-yl)-2-oxoacetamide	Investigative
T80387	DRUGINFO	D00CQR	6-Methyl-2-oxa-spiro[4.4]nonan-1-one	Investigative
T80387	DRUGINFO	D00VWR	3,3-Diethyl-dihydro-furan-2-one	Investigative
T80387	DRUGINFO	D00WON	3-Ethyl-3-methyl-dihydro-furan-2-one	Investigative
T80387	DRUGINFO	D01OZS	3,3-Diisopropyl-dihydro-furan-2-one	Investigative
T80387	DRUGINFO	D01PPZ	Ridine-5-carboxylic acid ethyl ester	Investigative
T80387	DRUGINFO	D01UZT	4-(4-chlorophenyl)-1-pyrid-2-yl-pyrazole	Investigative
T80387	DRUGINFO	D02FXS	3-carboxy-6-ethyl-4-quinolone	Investigative
T80387	DRUGINFO	D02RUV	3-Isopropyl-3-methyl-dihydro-furan-2-one	Investigative
T80387	DRUGINFO	D02XXK	(9-Benzyl-9H-purin-6-yl)-cyclopropyl-amine	Investigative
T80387	DRUGINFO	D03CKN	3-ethoxycarbonyl-6-ethyl-2-methyl-4-quinolone	Investigative
T80387	DRUGINFO	D03EOK	N-Indan-1-yl-2-(1H-indol-3-yl)-2-oxo-acetamide	Investigative
T80387	DRUGINFO	D03FBS	6-ethyl-3-propoxycarbonyl-4-quinolone	Investigative
T80387	DRUGINFO	D03OEN	N-butyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide	Investigative
T80387	DRUGINFO	D03OQG	1-Methyl-5-oxa-spiro[2.4]heptan-4-one	Investigative
T80387	DRUGINFO	D03YLX	3-Methyl-9H-beta-carboline	Investigative
T80387	DRUGINFO	D04EOV	3-ethoxycarbonyl-6-propyl-4-quinolone	Investigative
T80387	DRUGINFO	D05OOA	6-ethyl-3-pentoxycarbonyl-4-quinolone	Investigative
T80387	DRUGINFO	D05SVA	5-(piperidin-4-yl)isoxazol-3-ol	Investigative
T80387	DRUGINFO	D05TVT	6-ethyl-3-(3-pentoxycarbonyl)-4-quinolone	Investigative
T80387	DRUGINFO	D06EUJ	3-butoxycarbonyl-4-quinolone	Investigative
T80387	DRUGINFO	D06GAI	1-(4-chlorophenyl)-4-phenyl-1H-imidazole	Investigative
T80387	DRUGINFO	D06OSB	6-ethyl-3-i-propoxycarbonyl-4-quinolone	Investigative
T80387	DRUGINFO	D07OON	3-Ethyl-3-isopropyl-dihydro-furan-2-one	Investigative
T80387	DRUGINFO	D07QGN	CGS-13767	Investigative
T80387	DRUGINFO	D08AID	6-ethyl-3-(2-methylbutoxycarbonyl)-4-quinolone	Investigative
T80387	DRUGINFO	D08HGK	N-Benzyl-2-(1H-indol-3-yl)-2-oxo-acetamide	Investigative
T80387	DRUGINFO	D09AYK	3-ethoxycarbonyl-4-quinolone	Investigative
T80387	DRUGINFO	D09CQO	2-Thiophen-2-yl-3H-imidazo[4,5-c]quinoline	Investigative
T80387	DRUGINFO	D09RWW	3-cyclopentoxycarbonyl-6-ethyl-4-quinolone	Investigative
T80387	DRUGINFO	D0AR4P	2-(9-Benzyl-9H-purin-6-ylamino)-ethanol	Investigative
T80387	DRUGINFO	D0B4CQ	6-benzyl-3-propylaminocarbonyl-4-quinolone	Investigative
T80387	DRUGINFO	D0B4WR	2-Isoxazol-5-yl-3H-imidazo[4,5-c]quinoline	Investigative
T80387	DRUGINFO	D0CR6M	6-bromo-3-ethoxycarbonyl-2-methyl-4-quinolone	Investigative
T80387	DRUGINFO	D0D2PJ	GNF-PF-4421	Investigative
T80387	DRUGINFO	D0ER0L	4-Benzyl-5-piperidin-4-yl-isoxazol-3-ol	Investigative
T80387	DRUGINFO	D0FQ2N	3-Isothiocyanato-9H-beta-carboline	Investigative
T80387	DRUGINFO	D0FR4S	4-(2-aminoethyl)-1,2,5-oxadiazol-3-ol	Investigative
T80387	DRUGINFO	D0G6IG	3-butoxycarbonyl-6-ethyl-4-quinolone	Investigative
T80387	DRUGINFO	D0H0DP	3-amino-3-demethoxythiocolchicine	Investigative
T80387	DRUGINFO	D0H0NE	6,9-Dimethyl-2-oxa-spiro[4.4]nonan-1-one	Investigative
T80387	DRUGINFO	D0I4HT	4-Naphthalen-1-yl-5-piperidin-4-yl-isoxazol-3-ol	Investigative
T80387	DRUGINFO	D0J0CA	BETA-CCM	Investigative
T80387	DRUGINFO	D0J9VP	3-tert-Butyl-3-ethyl-dihydro-furan-2-one	Investigative
T80387	DRUGINFO	D0K2CZ	1,1-Dimethyl-5-oxa-spiro[2.4]heptan-4-one	Investigative
T80387	DRUGINFO	D0KS3X	U-89267	Investigative
T80387	DRUGINFO	D0L2KB	RO-145974	Investigative
T80387	DRUGINFO	D0M0ZX	6-ethyl-3-(2-ethylbutoxycarbonyl)-4-quinolone	Investigative
T80387	DRUGINFO	D0M2AY	6-ethyl-3-propylaminocarbonyl-4-quinolone	Investigative
T80387	DRUGINFO	D0O9SG	2-(4-chlorophenyl)-5-phenyl-4-isoxazolin-3-one	Investigative
T80387	DRUGINFO	D0Q8UV	RO-145975	Investigative
T80387	DRUGINFO	D0R1IL	4-Naphthalen-2-yl-5-piperidin-4-yl-isoxazol-3-ol	Investigative
T80387	DRUGINFO	D0S6ME	6-benzyl-3-propoxycarbonyl-4-quinolone	Investigative
T80387	DRUGINFO	D0TJ2L	RO-147437	Investigative
T80387	DRUGINFO	D0U9ET	6,6-Dimethyl-2-oxa-spiro[4.4]nonan-1-one	Investigative
T80387	DRUGINFO	D0UQ6J	RO-194603	Investigative
T80387	DRUGINFO	D0W5IP	GNF-PF-3645	Investigative
T80387	DRUGINFO	D0WC5L	3-butylaminocarbonyl-6-ethyl-4-quinolone	Investigative
T80387	DRUGINFO	D0X4OW	2-Oxa-spiro[4.4]nonan-1-one	Investigative
T80387	DRUGINFO	D0YS9E	4-Phenyl-5-piperidin-4-yl-isoxazol-3-ol	Investigative
T80387	DRUGINFO	D01UAS	6-bromo-3-ethoxycarbonyl-4-quinolone	Investigative
T80387	DRUGINFO	D02CZO	6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone	Investigative
T80387	DRUGINFO	D03LMR	6-benzyl-3-ethoxycarbonyl-4-quinolone	Investigative
T80387	DRUGINFO	D04RVA	3-demethoxy-3-D-lyxopyranosylaminothiocolchicine	Investigative
T80387	DRUGINFO	D06XGL	3-demethoxy-3-D-xylopyranosylaminothiocolchicine	Investigative
T80387	DRUGINFO	D08YLW	3-demethoxy-3-L-fucopyranosylaminothiocolchicine	Investigative
T80387	DRUGINFO	D09MHS	3-demethoxy-3D-glucopyranosylaminothiocolchicine	Investigative
T80387	DRUGINFO	D0LP2K	3-demethoxy-3-D-mannopyranosylaminothiocolchicine	Investigative
T80387	DRUGINFO	D01IHM	CI-218872	Investigative
T80387	DRUGINFO	D07NKO	5-[(1R)-1-ammonioethyl]isoxazol-3-olate	Investigative
T80387	DRUGINFO	D09ACO	(2E,4S)-4-ammoniopent-2-enoate	Investigative
T80387	DRUGINFO	D0A8EU	(4R)-4-ammoniopentanoate	Investigative
T80387	DRUGINFO	D0N0ZK	(4S)-4-ammoniopentanoate	Investigative
T80387	DRUGINFO	D0S5PS	5-[(1S)-1-ammonioethyl]isoxazol-3-olate	Investigative
T80387	DRUGINFO	D00WHO	Ro-15-3505	Investigative
T80387	DRUGINFO	D0M4CP	[3H]Ro154513	Investigative
T80387	DRUGINFO	D0M9RM	[3H]CGS8216	Investigative
T80387	DRUGINFO	D06HRX	AMENTOFLAVONE	Investigative
T80387	DRUGINFO	D0P0TI	TBPS	Investigative

T60182	TARGETID	T60182
T60182	FORMERID	TTDS00439
T60182	UNIPROID	GLR_HUMAN
T60182	TARGNAME	Glucagon receptor (GCGR)
T60182	GENENAME	GCGR
T60182	TARGTYPE	Successful
T60182	SYNONYMS	GLR; GL-R
T60182	FUNCTION	Regulates the rate of hepatic glucose production by promoting glycogen hydrolysis and gluconeogenesis. Plays an important role in mediating the responses to fasting. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Promotes activation of adenylate cyclase. Besides, plays a role in signaling via a phosphatidylinositol-calcium second messenger system. G-protein coupled receptor for glucagon that plays a central role in the regulation of blood glucose levels and glucose homeostasis.
T60182	PDBSTRUC	5XEZ; 5EE7; 4LF3; 4L6R; 4ERS
T60182	BIOCLASS	GPCR secretin
T60182	SEQUENCE	MPPCQPQRPLLLLLLLLACQPQVPSAQVMDFLFEKWKLYGDQCHHNLSLLPPPTELVCNRTFDKYSCWPDTPANTTANISCPWYLPWHHKVQHRFVFKRCGPDGQWVRGPRGQPWRDASQCQMDGEEIEVQKEVAKMYSSFQVMYTVGYSLSLGALLLALAILGGLSKLHCTRNAIHANLFASFVLKASSVLVIDGLLRTRYSQKIGDDLSVSTWLSDGAVAGCRVAAVFMQYGIVANYCWLLVEGLYLHNLLGLATLPERSFFSLYLGIGWGAPMLFVVPWAVVKCLFENVQCWTSNDNMGFWWILRFPVFLAILINFFIFVRIVQLLVAKLRARQMHHTDYKFRLAKSTLTLIPLLGVHEVVFAFVTDEHAQGTLRSAKLFFDLFLSSFQGLLVAVLYCFLNKEVQSELRRRWHRWRLGKVLWEERNTSNHRASSSPGHGPPSKELQFGRGGGSQDSSAETPLAGGLPRLAESPF
T60182	DRUGINFO	D0H8WF	Glucagon recombinant	Approved
T60182	DRUGINFO	DE5N3K	Dasiglucagon	Approved
T60182	DRUGINFO	DG7N3W	Retatrutide	Phase 3
T60182	DRUGINFO	D0D8VU	LGD-6972	Phase 2
T60182	DRUGINFO	D0V7SO	PF-06291874	Phase 2
T60182	DRUGINFO	D0ZW5D	LY-2409021	Phase 2
T60182	DRUGINFO	DLV0Z8	REMD 477	Phase 2
T60182	DRUGINFO	D04CQK	MK-8521	Phase 2
T60182	DRUGINFO	D08FMK	LY2944876	Phase 2
T60182	DRUGINFO	D0Q8VM	TT-401	Phase 2
T60182	DRUGINFO	DY67HC	Efinopegdutide	Phase 2
T60182	DRUGINFO	DR76TW	LY3437943	Phase 2
T60182	DRUGINFO	DJCN38	REGN1193	Phase 1
T60182	DRUGINFO	D53BVX	Pemvidutide	Phase 1
T60182	DRUGINFO	D5V1CL	DD01	Phase 1
T60182	DRUGINFO	D6ZGP9	LY3305677	Phase 1
T60182	DRUGINFO	D02URD	SAR425899	Phase 1
T60182	DRUGINFO	D0FW0B	ZP2929	Phase 1
T60182	DRUGINFO	D00NCJ	Heterocycle-containing compound 5	Patented
T60182	DRUGINFO	D00QJA	Biphenyl carboxamidopropanoic acid derivative 4	Patented
T60182	DRUGINFO	D01EWH	Quinolinyl compound 1	Patented
T60182	DRUGINFO	D01TGE	Heterocycle-containing compound 2	Patented
T60182	DRUGINFO	D03KUD	Pyrrolidine derivative 6	Patented
T60182	DRUGINFO	D04ELA	Picolinamido propanoic acid derivative 2	Patented
T60182	DRUGINFO	D04NUS	Spiroimidazolone derivative 4	Patented
T60182	DRUGINFO	D05AWM	Spiroimidazolone derivative 6	Patented
T60182	DRUGINFO	D05EON	Quinolinyl compound 2	Patented
T60182	DRUGINFO	D06HMY	Biphenyl carboxamidopropanoic acid derivative 2	Patented
T60182	DRUGINFO	D07AMZ	Spiroimidazolone derivative 5	Patented
T60182	DRUGINFO	D07CLY	Heterocycle-containing compound 3	Patented
T60182	DRUGINFO	D07ZDJ	Aromatic ring compound 4	Patented
T60182	DRUGINFO	D09IGN	Pyrrolidine derivative 8	Patented
T60182	DRUGINFO	D0AJ3F	Spiroimidazolone derivative 7	Patented
T60182	DRUGINFO	D0DE4E	Spiroimidazolone derivative 2	Patented
T60182	DRUGINFO	D0F9RK	Spiroimidazolone derivative 3	Patented
T60182	DRUGINFO	D0FA5D	Aromatic ring compound 3	Patented
T60182	DRUGINFO	D0FS8K	Biphenyl carboxamidopropanoic acid derivative 3	Patented
T60182	DRUGINFO	D0FW5U	PMID25828189-Compound-21	Patented
T60182	DRUGINFO	D0HS9X	3-substituted-2-furancarboxylic acid hydrazide derivative 1	Patented
T60182	DRUGINFO	D0HV7T	Picolinamido propanoic acid derivative 3	Patented
T60182	DRUGINFO	D0IL0U	Heterocycle-containing compound 4	Patented
T60182	DRUGINFO	D0IT9C	Picolinamido propanoic acid derivative 1	Patented
T60182	DRUGINFO	D0JA0A	PMID25828189-Compound-22	Patented
T60182	DRUGINFO	D0JY2I	Pyrrolidine derivative 7	Patented
T60182	DRUGINFO	D0O0DJ	Spiroimidazolone derivative 1	Patented
T60182	DRUGINFO	D0SA6K	Biphenyl carboxamidopropanoic acid derivative 1	Patented
T60182	DRUGINFO	D0TR5T	Heterocycle-containing compound 1	Patented
T60182	DRUGINFO	D0UA4Y	PMID25828189-Compound-19	Patented
T60182	DRUGINFO	D0XT3V	Aromatic ring compound 1	Patented
T60182	DRUGINFO	D0Y5DU	Aromatic ring compound 2	Patented
T60182	DRUGINFO	D0YP5U	3-substituted-2-furancarboxylic acid hydrazide derivative 5	Patented
T60182	DRUGINFO	D04MRA	BAY-73-7977	Discontinued in Phase 1
T60182	DRUGINFO	D0N2LY	NN-2501	Discontinued in Phase 1
T60182	DRUGINFO	D0Z6AX	BAY-27-9955	Discontinued in Phase 1
T60182	DRUGINFO	D09MOD	NNC-252504	Terminated
T60182	DRUGINFO	D0V3LD	DIO-901	Terminated
T60182	DRUGINFO	D03OYY	MAR-531	Investigative
T60182	DRUGINFO	D04IUW	BI-32169	Investigative
T60182	DRUGINFO	D05OBK	DwLIP-GCGRrx	Investigative
T60182	DRUGINFO	D06ARL	[des-His1,Tyr5,Glu9,D-Tyr10]glucagon-NH2	Investigative
T60182	DRUGINFO	D07SIV	[des-His1,Tyr5,Glu9]glucagon-NH2	Investigative
T60182	DRUGINFO	D08RTR	[des-His1,Tyr5,Glu9,D-Ala10]glucagon-NH2	Investigative
T60182	DRUGINFO	D08SYL	[des-His1,Tyr5,Glu9,D-Phe10]glucagon-NH2	Investigative
T60182	DRUGINFO	D08XLL	hGCGR antagonist	Investigative
T60182	DRUGINFO	D0E0UC	DSR-17759	Investigative
T60182	DRUGINFO	D0I6HV	NNC 92-1687	Investigative
T60182	DRUGINFO	D0J4BF	glucagon-(1-6)	Investigative
T60182	DRUGINFO	D0M3AR	L-168049	Investigative
T60182	DRUGINFO	D0V9BB	Des-His1[Glu9]glucagon-NH2	Investigative

T40954	TARGETID	T40954
T40954	FORMERID	TTDS00056
T40954	UNIPROID	XDH_HUMAN
T40954	TARGNAME	Xanthine dehydrogenase/oxidase (XDH)
T40954	GENENAME	XDH
T40954	TARGTYPE	Successful
T40954	SYNONYMS	Xanthine oxidase; Xanthine dehydrogenase; XDHA
T40954	FUNCTION	Catalyzes the oxidation of hypoxanthine to xanthine. Catalyzes the oxidation of xanthine to uric acid. Contributes to the generation of reactive oxygen species. Has also low oxidase activity towards aldehydes (in vitro). Key enzyme in purine degradation.
T40954	PDBSTRUC	2E1Q; 2CKJ
T40954	BIOCLASS	CH/CH(2) oxidoreductase
T40954	SEQUENCE	MTADKLVFFVNGRKVVEKNADPETTLLAYLRRKLGLSGTKLGCGEGGCGACTVMLSKYDRLQNKIVHFSANACLAPICSLHHVAVTTVEGIGSTKTRLHPVQERIAKSHGSQCGFCTPGIVMSMYTLLRNQPEPTMEEIENAFQGNLCRCTGYRPILQGFRTFARDGGCCGGDGNNPNCCMNQKKDHSVSLSPSLFKPEEFTPLDPTQEPIFPPELLRLKDTPRKQLRFEGERVTWIQASTLKELLDLKAQHPDAKLVVGNTEIGIEMKFKNMLFPMIVCPAWIPELNSVEHGPDGISFGAACPLSIVEKTLVDAVAKLPAQKTEVFRGVLEQLRWFAGKQVKSVASVGGNIITASPISDLNPVFMASGAKLTLVSRGTRRTVQMDHTFFPGYRKTLLSPEEILLSIEIPYSREGEYFSAFKQASRREDDIAKVTSGMRVLFKPGTTEVQELALCYGGMANRTISALKTTQRQLSKLWKEELLQDVCAGLAEELHLPPDAPGGMVDFRCTLTLSFFFKFYLTVLQKLGQENLEDKCGKLDPTFASATLLFQKDPPADVQLFQEVPKGQSEEDMVGRPLPHLAADMQASGEAVYCDDIPRYENELSLRLVTSTRAHAKIKSIDTSEAKKVPGFVCFISADDVPGSNITGICNDETVFAKDKVTCVGHIIGAVVADTPEHTQRAAQGVKITYEELPAIITIEDAIKNNSFYGPELKIEKGDLKKGFSEADNVVSGEIYIGGQEHFYLETHCTIAVPKGEAGEMELFVSTQNTMKTQSFVAKMLGVPANRIVVRVKRMGGGFGGKETRSTVVSTAVALAAYKTGRPVRCMLDRDEDMLITGGRHPFLARYKVGFMKTGTVVALEVDHFSNVGNTQDLSQSIMERALFHMDNCYKIPNIRGTGRLCKTNLPSNTAFRGFGGPQGMLIAECWMSEVAVTCGMPAEEVRRKNLYKEGDLTHFNQKLEGFTLPRCWEECLASSQYHARKSEVDKFNKENCWKKRGLCIIPTKFGISFTVPFLNQAGALLHVYTDGSVLLTHGGTEMGQGLHTKMVQVASRALKIPTSKIYISETSTNTVPNTSPTAASVSADLNGQAVYAACQTILKRLEPYKKKNPSGSWEDWVTAAYMDTVSLSATGFYRTPNLGYSFETNSGNPFHYFSYGVACSEVEIDCLTGDHKNLRTDIVMDVGSSLNPAIDIGQVEGAFVQGLGLFTLEELHYSPEGSLHTRGPSTYKIPAFGSIPIEFRVSLLRDCPNKKAIYASKAVGEPPLFLAASIFFAIKDAIRAARAQHTGNNVKELFRLDSPATPEKIRNACVDKFTTLCVTGVPENCKPWSVRV
T40954	DRUGINFO	D04KYY	Allopurinol	Approved
T40954	DRUGINFO	D07GTW	Fosdenopterin	Approved
T40954	DRUGINFO	D0A5SE	Febuxostat	Approved
T40954	DRUGINFO	D07SDQ	Curcumin	Phase 3
T40954	DRUGINFO	D08FWK	Oxypurinol	Phase 2/3
T40954	DRUGINFO	D0WK0P	Topiroxostat	Phase 2
T40954	DRUGINFO	D5BMY9	TMX-049	Phase 2
T40954	DRUGINFO	D00YEV	BAICALEIN	Phase 2
T40954	DRUGINFO	D0I5JM	LC-350189	Phase 1
T40954	DRUGINFO	D00GMJ	Azaindole derivative 5	Patented
T40954	DRUGINFO	D01FMW	Fused heterocyclic compound 3	Patented
T40954	DRUGINFO	D02VYR	Azaindole derivative 7	Patented
T40954	DRUGINFO	D03JDR	Fused heterocyclic compound 4	Patented
T40954	DRUGINFO	D04BAQ	Fused heterocyclic compound 11	Patented
T40954	DRUGINFO	D04IGE	PMID27841045-Compound-130	Patented
T40954	DRUGINFO	D06XJG	Azole benzene derivative 2	Patented
T40954	DRUGINFO	D07TTT	PMID27841045-Compound-137	Patented
T40954	DRUGINFO	D08KAT	Fused heterocyclic compound 9	Patented
T40954	DRUGINFO	D0AJ5T	PMID27841045-Compound-144	Patented
T40954	DRUGINFO	D0AU8E	PMID27841045-Compound-133	Patented
T40954	DRUGINFO	D0AV1B	Fused heterocyclic compound 2	Patented
T40954	DRUGINFO	D0B5QZ	PMID27841045-Compound-132	Patented
T40954	DRUGINFO	D0D6UT	Azaindole derivative 3	Patented
T40954	DRUGINFO	D0DQ6C	Fused heterocyclic compound 5	Patented
T40954	DRUGINFO	D0EZ5O	PMID27841045-Compound-145	Patented
T40954	DRUGINFO	D0FM8Q	PMID27841045-Compound-134	Patented
T40954	DRUGINFO	D0G9OT	Fused heterocyclic compound 7	Patented
T40954	DRUGINFO	D0GQ0V	PMID27841045-Compound-131	Patented
T40954	DRUGINFO	D0J0JH	PMID27841045-Compound-156	Patented
T40954	DRUGINFO	D0J3ZM	Azole benzene derivative 3	Patented
T40954	DRUGINFO	D0J5GS	Azaindole derivative 6	Patented
T40954	DRUGINFO	D0LX9F	PMID27841045-Compound-157	Patented
T40954	DRUGINFO	D0N0MV	Fused heterocyclic compound 8	Patented
T40954	DRUGINFO	D0NS7W	Fused heterocyclic compound 6	Patented
T40954	DRUGINFO	D0QY4O	PMID27841045-Compound-136	Patented
T40954	DRUGINFO	D0RK1R	Azaindole derivative 4	Patented
T40954	DRUGINFO	D0RK3S	Fused heterocyclic compound 10	Patented
T40954	DRUGINFO	D0RN2X	PMID27841045-Compound-129	Patented
T40954	DRUGINFO	D0S0EM	PMID27841045-Compound-155	Patented
T40954	DRUGINFO	D0SY6J	Fused heterocyclic compound 1	Patented
T40954	DRUGINFO	D0VY5N	Azole benzene derivative 1	Patented
T40954	DRUGINFO	D0XY7C	Azole benzene derivative 4	Patented
T40954	DRUGINFO	D0YX0S	PMID27841045-Compound-135	Patented
T40954	DRUGINFO	D0Z2IO	PMID27841045-Compound-143	Patented
T40954	DRUGINFO	D0B8SC	BOF-4272	Discontinued in Phase 2
T40954	DRUGINFO	D0E4FM	Y-700	Discontinued in Phase 2
T40954	DRUGINFO	D00LMG	SCUTELLAREIN	Investigative
T40954	DRUGINFO	D02CWE	Dioxothiomolybdenum(VI) ion	Investigative
T40954	DRUGINFO	D05KKF	NC-2500	Investigative
T40954	DRUGINFO	D07NAY	ROBINETIN	Investigative
T40954	DRUGINFO	D08NIT	FUKUGETIN	Investigative
T40954	DRUGINFO	D0C9ZN	3,5-bis(2-methylpyridin-4-yl)-1H-1,2,4-triazole	Investigative
T40954	DRUGINFO	D0D9OC	2-chloro-6(methylamino)purine	Investigative
T40954	DRUGINFO	D0E5IM	PERSICARIN	Investigative
T40954	DRUGINFO	D0G8XL	1-(3-Cyano-phenyl)-1H-pyrazole-4-carboxylic acid	Investigative
T40954	DRUGINFO	D0IW5C	3,4'-(1H-1,2,4-triazole-3,5-diyl)dipyridine	Investigative
T40954	DRUGINFO	D0L9EF	3-O-METHYLQUERCETIN	Investigative
T40954	DRUGINFO	D0R4FM	DIHYDROKAEMPFEROL	Investigative
T40954	DRUGINFO	D0Z2NY	Aom-0763	Investigative
T40954	DRUGINFO	D0ZC8K	3,5-di(pyridin-4-yl)-1H-1,2,4-triazole	Investigative
T40954	DRUGINFO	D00MXS	Wogonin	Investigative
T40954	DRUGINFO	D01FGM	CHRYSOERIOL	Investigative
T40954	DRUGINFO	D0K4PY	LIQUIRTIGENIN	Investigative
T40954	DRUGINFO	D0NS1S	ACACETIN	Investigative
T40954	DRUGINFO	D00QDR	1,2,3,4,6-penta-O-galloyl-beta-D-glucose	Investigative
T40954	DRUGINFO	D06HRX	AMENTOFLAVONE	Investigative
T40954	DRUGINFO	D00IMW	Flavin-Adenine Dinucleotide	Investigative

T46456	TARGETID	T46456
T46456	FORMERID	TTDR01075
T46456	UNIPROID	RXRG_HUMAN
T46456	TARGNAME	Retinoic acid receptor RXR-gamma (RXRG)
T46456	GENENAME	RXRG
T46456	TARGTYPE	Successful
T46456	SYNONYMS	Retinoid X receptor gamma; Nuclear receptor subfamily 2 group B member 3; NR2B3
T46456	FUNCTION	Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. The high affinity ligand for RXRs is 9-cis retinoic acid. Receptor for retinoic acid.
T46456	PDBSTRUC	2GL8
T46456	BIOCLASS	Nuclear hormone receptor
T46456	SEQUENCE	MYGNYSHFMKFPAGYGGSPGHTGSTSMSPSAALSTGKPMDSHPSYTDTPVSAPRTLSAVGTPLNALGSPYRVITSAMGPPSGALAAPPGINLVAPPSSQLNVVNSVSSSEDIKPLPGLPGIGNMNYPSTSPGSLVKHICAICGDRSSGKHYGVYSCEGCKGFFKRTIRKDLIYTCRDNKDCLIDKRQRNRCQYCRYQKCLVMGMKREAVQEERQRSRERAESEAECATSGHEDMPVERILEAELAVEPKTESYGDMNMENSTNDPVTNICHAADKQLFTLVEWAKRIPHFSDLTLEDQVILLRAGWNELLIASFSHRSVSVQDGILLATGLHVHRSSAHSAGVGSIFDRVLTELVSKMKDMQMDKSELGCLRAIVLFNPDAKGLSNPSEVETLREKVYATLEAYTKQKYPEQPGRFAKLLLRLPALRSIGLKCLEHLFFFKLIGDTPIDTFLMEMLETPLQIT
T46456	DRUGINFO	D0S7WX	Vitamin A	Approved
T46456	DRUGINFO	D0G3PI	Alitretinoin	Approved
T46456	DRUGINFO	D06QXI	NRX-4204	Phase 2
T46456	DRUGINFO	D07OSS	9cUAB-30	Phase 1
T46456	DRUGINFO	D09DJC	IRX4204	Phase 1
T46456	DRUGINFO	D09YUQ	SR-11237	Terminated
T46456	DRUGINFO	D0GR9O	AGN-34	Investigative
T46456	DRUGINFO	D0Q9FZ	LG100754	Investigative

T16514	TARGETID	T16514
T16514	FORMERID	TTDS00295
T16514	UNIPROID	FAS_HUMAN
T16514	TARGNAME	Fatty acid synthase (FASN)
T16514	GENENAME	FASN
T16514	TARGTYPE	Successful
T16514	SYNONYMS	Yeast fatty acid synthase; Fatty-acyl-CoA synthase; Fatty acyl-CoA synthetase enzyme; FAS
T16514	FUNCTION	Fatty acid synthetase catalyzes the formation of long-chain fatty acids from acetyl-CoA, malonyl-CoA and NADPH. This multifunctional protein has 7 catalytic activities as an acyl carrier protein.
T16514	PDBSTRUC	6NNA; 5C37; 4Z49; 4W9N; 4W82
T16514	BIOCLASS	Acyltransferase
T16514	ECNUMBER	EC 2.3.1.85
T16514	SEQUENCE	MEEVVIAGMSGKLPESENLQEFWDNLIGGVDMVTDDDRRWKAGLYGLPRRSGKLKDLSRFDASFFGVHPKQAHTMDPQLRLLLEVTYEAIVDGGINPDSLRGTHTGVWVGVSGSETSEALSRDPETLVGYSMVGCQRAMMANRLSFFFDFRGPSIALDTACSSSLMALQNAYQAIHSGQCPAAIVGGINVLLKPNTSVQFLRLGMLSPEGTCKAFDTAGNGYCRSEGVVAVLLTKKSLARRVYATILNAGTNTDGFKEQGVTFPSGDIQEQLIRSLYQSAGVAPESFEYIEAHGTGTKVGDPQELNGITRALCATRQEPLLIGSTKSNMGHPEPASGLAALAKVLLSLEHGLWAPNLHFHSPNPEIPALLDGRLQVVDQPLPVRGGNVGINSFGFGGSNVHIILRPNTQPPPAPAPHATLPRLLRASGRTPEAVQKLLEQGLRHSQDLAFLSMLNDIAAVPATAMPFRGYAVLGGERGGPEVQQVPAGERPLWFICSGMGTQWRGMGLSLMRLDRFRDSILRSDEAVKPFGLKVSQLLLSTDESTFDDIVHSFVSLTAIQIGLIDLLSCMGLRPDGIVGHSLGEVACGYADGCLSQEEAVLAAYWRGQCIKEAHLPPGAMAAVGLSWEECKQRCPPGVVPACHNSKDTVTISGPQAPVFEFVEQLRKEGVFAKEVRTGGMAFHSYFMEAIAPPLLQELKKVIREPKPRSARWLSTSIPEAQWHSSLARTSSAEYNVNNLVSPVLFQEALWHVPEHAVVLEIAPHALLQAVLKRGLKPSCTIIPLMKKDHRDNLEFFLAGIGRLHLSGIDANPNALFPPVEFPAPRGTPLISPLIKWDHSLAWDVPAAEDFPNGSGSPSAAIYNIDTSSESPDHYLVDHTLDGRVLFPATGYLSIVWKTLARALGLGVEQLPVVFEDVVLHQATILPKTGTVSLEVRLLEASRAFEVSENGNLVVSGKVYQWDDPDPRLFDHPESPTPNPTEPLFLAQAEVYKELRLRGYDYGPHFQGILEASLEGDSGRLLWKDNWVSFMDTMLQMSILGSAKHGLYLPTRVTAIHIDPATHRQKLYTLQDKAQVADVVVSRWLRVTVAGGVHISGLHTESAPRRQQEQQVPILEKFCFTPHTEEGCLSERAALQEELQLCKGLVQALQTKVTQQGLKMVVPGLDGAQIPRDPSQQELPRLLSAACRLQLNGNLQLELAQVLAQERPKLPEDPLLSGLLDSPALKACLDTAVENMPSLKMKVVEVLAGHGHLYSRIPGLLSPHPLLQLSYTATDRHPQALEAAQAELQQHDVAQGQWDPADPAPSALGSADLLVCNCAVAALGDPASALSNMVAALREGGFLLLHTLLRGHPLGDIVAFLTSTEPQYGQGILSQDAWESLFSRVSLRLVGLKKSFYGSTLFLCRRPTPQDSPIFLPVDDTSFRWVESLKGILADEDSSRPVWLKAINCATSGVVGLVNCLRREPGGNRLRCVLLSNLSSTSHVPEVDPGSAELQKVLQGDLVMNVYRDGAWGAFRHFLLEEDKPEEPTAHAFVSTLTRGDLSSIRWVCSSLRHAQPTCPGAQLCTVYYASLNFRDIMLATGKLSPDAIPGKWTSQDSLLGMEFSGRDASGKRVMGLVPAKGLATSVLLSPDFLWDVPSNWTLEEAASVPVVYSTAYYALVVRGRVRPGETLLIHSGSGGVGQAAIAIALSLGCRVFTTVGSAEKRAYLQARFPQLDSTSFANSRDTSFEQHVLWHTGGKGVDLVLNSLAEEKLQASVRCLATHGRFLEIGKFDLSQNHPLGMAIFLKNVTFHGVLLDAFFNESSADWREVWALVQAGIRDGVVRPLKCTVFHGAQVEDAFRYMAQGKHIGKVVVQVLAEEPEAVLKGAKPKLMSAISKTFCPAHKSYIIAGGLGGFGLELAQWLIQRGVQKLVLTSRSGIRTGYQAKQVRRWRRQGVQVQVSTSNISSLEGARGLIAEAAQLGPVGGVFNLAVVLRDGLLENQTPEFFQDVCKPKYSGTLNLDRVTREACPELDYFVVFSSVSCGRGNAGQSNYGFANSAMERICEKRRHEGLPGLAVQWGAIGDVGILVETMSTNDTIVSGTLPQRMASCLEVLDLFLNQPHMVLSSFVLAEKAAAYRDRDSQRDLVEAVAHILGIRDLAAVNLDSSLADLGLDSLMSVEVRQTLERELNLVLSVREVRQLTLRKLQELSSKADEASELACPTPKEDGLAQQQTQLNLRSLLVNPEGPTLMRLNSVQSSERPLFLVHPIEGSTTVFHSLASRLSIPTYGLQCTRAAPLDSIHSLAAYYIDCIRQVQPEGPYRVAGYSYGACVAFEMCSQLQAQQSPAPTHNSLFLFDGSPTYVLAYTQSYRAKLTPGCEAEAETEAICFFVQQFTDMEHNRVLEALLPLKGLEERVAAAVDLIIKSHQGLDRQELSFAARSFYYKLRAAEQYTPKAKYHGNVMLLRAKTGGAYGEDLGADYNLSQVCDGKVSVHVIEGDHRTLLEGSGLESIISIIHSSLAEPRVSVREG
T16514	DRUGINFO	D03ZFG	Cerulenin	Approved
T16514	DRUGINFO	D0U2BH	Epigallocatechin gallate	Phase 3
T16514	DRUGINFO	D0K9BV	TVB-2640	Phase 2
T16514	DRUGINFO	DE2U5N	TVB-2640	Phase 2
T16514	DRUGINFO	D04RSI	FAS1	Preclinical
T16514	DRUGINFO	D0R2SW	FSA2	Preclinical
T16514	DRUGINFO	D03VGO	GSK2194069	Investigative
T16514	DRUGINFO	D06SYA	MT-061	Investigative
T16514	DRUGINFO	D07WAF	Anti-Fas mabs	Investigative
T16514	DRUGINFO	D09IGF	MG-28	Investigative
T16514	DRUGINFO	D0BY6E	4-hydroxy-8-nitro-3-phenylquinolin-2(1H)-one	Investigative
T16514	DRUGINFO	D0QP7C	4-hydroxy-6-nitro-3-phenylquinolin-2(1H)-one	Investigative
T16514	DRUGINFO	D0X6AU	FAS-031	Investigative
T16514	DRUGINFO	D07MXA	C75	Investigative
T16514	DRUGINFO	D05HRK	2-Hexadecynoic acid	Investigative
T16514	DRUGINFO	D07KXK	GALLOCATECHIN GALLATE	Investigative
T16514	DRUGINFO	D0MF5Y	3,7,3',4'-TETRAHYDROXYFLAVONE	Investigative
T16514	DRUGINFO	D0RB1V	(-)-CATECHINGALLATE	Investigative
T16514	DRUGINFO	D0S9YX	biochanin A	Investigative
T16514	DRUGINFO	D0NJ4H	MORIN	Investigative

T09909	TARGETID	T09909
T09909	FORMERID	TTDS00525
T09909	UNIPROID	AGTR2_HUMAN
T09909	TARGNAME	Angiotensin II receptor type-2 (AGTR2)
T09909	GENENAME	AGTR2
T09909	TARGTYPE	Successful
T09909	SYNONYMS	Type-2 angiotensin II receptor; Angiotensin II type-2 receptor; Angiotensin II receptor 2; AT2
T09909	FUNCTION	Cooperates with MTUS1 to inhibit ERK2 activation and cell proliferation. Receptor for angiotensin II.
T09909	PDBSTRUC	5UNH; 5UNG; 5UNF
T09909	BIOCLASS	GPCR rhodopsin
T09909	SEQUENCE	MKGNSTLATTSKNITSGLHFGLVNISGNNESTLNCSQKPSDKHLDAIPILYYIIFVIGFLVNIVVVTLFCCQKGPKKVSSIYIFNLAVADLLLLATLPLWATYYSYRYDWLFGPVMCKVFGSFLTLNMFASIFFITCMSVDRYQSVIYPFLSQRRNPWQASYIVPLVWCMACLSSLPTFYFRDVRTIEYLGVNACIMAFPPEKYAQWSAGIALMKNILGFIIPLIFIATCYFGIRKHLLKTNSYGKNRITRDQVLKMAAAVVLAFIICWLPFHVLTFLDALAWMGVINSCEVIAVIDLALPFAILLGFTNSCVNPFLYCFVGNRFQQKLRSVFRVPITWLQGKRESMSCRKSSSLREMETFVS
T09909	DRUGINFO	D0G6SE	ANGIOTENSIN II	Approved
T09909	DRUGINFO	D0K0AT	SARALASIN	Approved
T09909	DRUGINFO	D0O0JP	EMA-401	Phase 2
T09909	DRUGINFO	D03VWB	MP-157	Phase 1
T09909	DRUGINFO	D0LA6O	PMID25416646-Compound-Figure5-E	Patented
T09909	DRUGINFO	D0NF8V	Phenylpyridine derivative 3	Patented
T09909	DRUGINFO	D0U6AW	1-(biphenyl-4-yl-methyl)-1H-imidazole derivative 1	Patented
T09909	DRUGINFO	D08CKJ	Fonsartan	Discontinued in Phase 2
T09909	DRUGINFO	D0A9BX	L-158282	Discontinued in Phase 2
T09909	DRUGINFO	D0A8EG	TAK-591	Discontinued in Phase 1
T09909	DRUGINFO	D04AOA	SC-51895	Terminated
T09909	DRUGINFO	D09TED	L-162234	Terminated
T09909	DRUGINFO	D0F5VB	PD-123319	Terminated
T09909	DRUGINFO	D0RG2P	SC-50560	Terminated
T09909	DRUGINFO	D00UBK	L-159689	Terminated
T09909	DRUGINFO	D0GS7N	L-158809	Terminated
T09909	DRUGINFO	D00UWL	Sar-Arg-Val-Tyr-Ile-His-Pro-Ile	Investigative
T09909	DRUGINFO	D04UJZ	[125I]CGP42112	Investigative
T09909	DRUGINFO	D09FRL	PD123177	Investigative
T09909	DRUGINFO	D0K2EX	PMID22802221C21	Investigative
T09909	DRUGINFO	D0K7DW	Sar-Arg-Val-Tyr-Ile-His-Pro-Ala	Investigative
T09909	DRUGINFO	D0MH1K	SC-55634	Investigative
T09909	DRUGINFO	D0O0SH	SC-52892	Investigative
T09909	DRUGINFO	D0OF3M	Sar-Arg-Val-Tyr-Ile-His-Pro-Phe-OH	Investigative
T09909	DRUGINFO	D04SVT	L-159093	Investigative
T09909	DRUGINFO	D0A4NO	L-162313	Investigative
T09909	DRUGINFO	D0D9AS	angiotensin III	Investigative

T17448	TARGETID	T17448
T17448	FORMERID	TTDS00089
T17448	UNIPROID	HNMT_HUMAN
T17448	TARGNAME	Histamine N-methyltransferase (HNMT)
T17448	GENENAME	HNMT
T17448	TARGTYPE	Successful
T17448	SYNONYMS	Histamine-N-methyltransferase; HNMT; HMT
T17448	FUNCTION	Inactivates histamine by N-methylation. Plays an important role in degrading histamine and in regulating the airway response to histamine.
T17448	PDBSTRUC	2AOX; 2AOW; 2AOV; 2AOU; 2AOT
T17448	BIOCLASS	Methyltransferase
T17448	ECNUMBER	EC 2.1.1.8
T17448	SEQUENCE	MASSMRSLFSDHGKYVESFRRFLNHSTEHQCMQEFMDKKLPGIIGRIGDTKSEIKILSIGGGAGEIDLQILSKVQAQYPGVCINNEVVEPSAEQIAKYKELVAKTSNLENVKFAWHKETSSEYQSRMLEKKELQKWDFIHMIQMLYYVKDIPATLKFFHSLLGTNAKMLIIVVSGSSGWDKLWKKYGSRFPQDDLCQYITSDDLTQMLDNLGLKYECYDLLSTMDISDCFIDGNENGDLLWDFLTETCNFNATAPPDLRAELGKDLQEPEFSAKKEGKVLFNNTLSFIVIEA
T17448	DRUGINFO	D04NQI	Amodiaquine	Approved
T17448	DRUGINFO	D01FGR	Diphenhydramine	Approved
T17448	DRUGINFO	D02AIM	Metoprine	Phase 2
T17448	DRUGINFO	D0F0ZX	4-(DIMETHYLAMINO)BUTYL IMIDOTHIOCARBAMATE	Investigative
T17448	DRUGINFO	D09CLP	(L-)-S-adenosyl-L-homocysteine	Investigative

T65291	TARGETID	T65291
T65291	FORMERID	TTDS00053
T65291	UNIPROID	AL3A2_HUMAN
T65291	TARGNAME	Fatty aldehyde dehydrogenase (ALDH3A2)
T65291	GENENAME	ALDH3A2
T65291	TARGTYPE	Successful
T65291	SYNONYMS	Microsomal aldehyde dehydrogenase; Aldehyde dehydrogenase family 3 member A2; Aldehyde dehydrogenase 10; ALDH10
T65291	FUNCTION	Catalyzes the oxidation of medium and long chain aliphatic aldehydes to fatty acids. Active on a variety of saturated and unsaturated aliphatic aldehydes between 6 and 24 carbons in length. Responsible for conversion of the sphingosine 1-phosphate (S1P) degradation product hexadecenal to hexadecenoic acid.
T65291	PDBSTRUC	4QGK
T65291	BIOCLASS	Aldehyde/oxo donor oxidoreductase
T65291	ECNUMBER	EC 1.2.1.3
T65291	SEQUENCE	MELEVRRVRQAFLSGRSRPLRFRLQQLEALRRMVQEREKDILTAIAADLCKSEFNVYSQEVITVLGEIDFMLENLPEWVTAKPVKKNVLTMLDEAYIQPQPLGVVLIIGAWNYPFVLTIQPLIGAIAAGNAVIIKPSELSENTAKILAKLLPQYLDQDLYIVINGGVEETTELLKQRFDHIFYTGNTAVGKIVMEAAAKHLTPVTLELGGKSPCYIDKDCDLDIVCRRITWGKYMNCGQTCIAPDYILCEASLQNQIVWKIKETVKEFYGENIKESPDYERIINLRHFKRILSLLEGQKIAFGGETDEATRYIAPTVLTDVDPKTKVMQEEIFGPILPIVPVKNVDEAINFINEREKPLALYVFSHNHKLIKRMIDETSSGGVTGNDVIMHFTLNSFPFGGVGSSGMGAYHGKHSFDTFSHQRPCLLKSLKREGANKLRYPPNSQSKVDWGKFFLLKRFNKEKLGLLLLTFLGIVAAVLVKAEYY
T65291	DRUGINFO	D0X5SD	Disulfiram	Approved
T65291	DRUGINFO	D00DBH	NPS 1776	Discontinued in Phase 2
T65291	DRUGINFO	D04DKX	NSC-527035	Investigative
T65291	DRUGINFO	D09BUG	Aloe-emodin	Investigative
T65291	DRUGINFO	D0M0YO	S-methyl 4-methyl-4-morpholinopent-2-ynethioate	Investigative

T13259	TARGETID	T13259
T13259	FORMERID	TTDS00054
T13259	UNIPROID	SSDH_HUMAN
T13259	TARGNAME	Succinate-semialdehyde dehydrogenase (ALDH5A1)
T13259	GENENAME	ALDH5A1
T13259	TARGTYPE	Successful
T13259	SYNONYMS	Succinic dehydrogenase; Succinate-semialdehyde dehydrogenase, mitochondrial; SSADH; NAD(+)-dependent succinic semialdehyde dehydrogenase; Aldehyde dehydrogenase family 5 member A1
T13259	FUNCTION	Catalyzes one step in the degradation of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA).
T13259	PDBSTRUC	2W8R; 2W8Q; 2W8P; 2W8O; 2W8N
T13259	BIOCLASS	Aldehyde/oxo donor oxidoreductase
T13259	ECNUMBER	EC 1.2.1.24
T13259	SEQUENCE	MATCIWLRSCGARRLGSTFPGCRLRPRAGGLVPASGPAPGPAQLRCYAGRLAGLSAALLRTDSFVGGRWLPAAATFPVQDPASGAALGMVADCGVREARAAVRAAYEAFCRWREVSAKERSSLLRKWYNLMIQNKDDLARIITAESGKPLKEAHGEILYSAFFLEWFSEEARRVYGDIIHTPAKDRRALVLKQPIGVAAVITPWNFPSAMITRKVGAALAAGCTVVVKPAEDTPFSALALAELASQAGIPSGVYNVIPCSRKNAKEVGEAICTDPLVSKISFTGSTTTGKILLHHAANSVKRVSMELGGLAPFIVFDSANVDQAVAGAMASKFRNTGQTCVCSNQFLVQRGIHDAFVKAFAEAMKKNLRVGNGFEEGTTQGPLINEKAVEKVEKQVNDAVSKGATVVTGGKRHQLGKNFFEPTLLCNVTQDMLCTHEETFGPLAPVIKFDTEEEAIAIANAADVGLAGYFYSQDPAQIWRVAEQLEVGMVGVNEGLISSVECPFGGVKQSGLGREGSKYGIDEYLELKYVCYGGL
T13259	DRUGINFO	D06EMT	Chlormerodrin	Approved
T13259	DRUGINFO	D06VNK	Succinic acid	Approved
T13259	DRUGINFO	D0B5YS	T83193	Patented
T13259	DRUGINFO	D0L7RB	1-(4-hydroxyphenyl)prop-2-en-1-one	Investigative

T49526	TARGETID	T49526
T49526	FORMERID	TTDS00148
T49526	UNIPROID	KCNQ1_HUMAN
T49526	TARGNAME	Voltage-gated potassium channel Kv7.1 (KCNQ1)
T49526	GENENAME	KCNQ1
T49526	TARGTYPE	Successful
T49526	SYNONYMS	Voltage-gated potassium channel subunit Kv7.1; Potassium voltage-gated channel subfamily KQT member 1; Kv7.1; KVLQT1; KQT-like 1; KCNQ1 channel; KCNA9; KCNA8; IKs producing slow voltage-gated potassium channel subunit alpha KvLQT1; IKs producing slow voltage-gated potassium channel alpha subunit KvLQT1
T49526	FUNCTION	Associates with KCNE beta subunits that modulates current kinetics. Induces a voltage-dependent by rapidly activating and slowly deactivating potassium-selective outward current. Promotes also a delayed voltage activated potassium current showing outward rectification characteristic. During beta-adrenergic receptor stimulation participates in cardiac repolarization by associating with KCNE1 to form the I(Ks) cardiac potassium current that increases the amplitude and slows down the activation kinetics of outward potassium current I(Ks). Muscarinic agonist oxotremorine-M strongly suppresses KCNQ1/KCNE1 current. When associated with KCNE3, forms the potassium channel that is important for cyclic AMP-stimulated intestinal secretion of chloride ions. This interaction with KCNE3 is reduced by 17beta-estradiol, resulting in the reduction of currents. During conditions of increased substrate load, maintains the driving force for proximal tubular and intestinal sodium ions absorption, gastric acid secretion, and cAMP-induced jejunal chloride ions secretion. Allows the provision of potassium ions to the luminal membrane of the secretory canaliculus in the resting state as well as during stimulated acid secretion. When associated with KCNE2, forms a heterooligomer complex leading to currents with an apparently instantaneous activation, a rapid deactivation process and a linear current-voltage relationship and decreases the amplitude of the outward current. When associated with KCNE4, inhibits voltage-gated potassium channel activity. When associated with KCNE5, this complex only conducts current upon strong and continued depolarization. Also forms a heterotetramer with KCNQ5; has a voltage-gated potassium channel activity. Binds with phosphatidylinositol 4,5-bisphosphate. Potassium channel that plays an important role in a number of tissues, including heart, inner ear, stomach and colon.
T49526	PDBSTRUC	4V0C; 4UMO; 3HFE; 3HFC; 3BJ4
T49526	BIOCLASS	Voltage-gated ion channel
T49526	SEQUENCE	MAAASSPPRAERKRWGWGRLPGARRGSAGLAKKCPFSLELAEGGPAGGALYAPIAPGAPGPAPPASPAAPAAPPVASDLGPRPPVSLDPRVSIYSTRRPVLARTHVQGRVYNFLERPTGWKCFVYHFAVFLIVLVCLIFSVLSTIEQYAALATGTLFWMEIVLVVFFGTEYVVRLWSAGCRSKYVGLWGRLRFARKPISIIDLIVVVASMVVLCVGSKGQVFATSAIRGIRFLQILRMLHVDRQGGTWRLLGSVVFIHRQELITTLYIGFLGLIFSSYFVYLAEKDAVNESGRVEFGSYADALWWGVVTVTTIGYGDKVPQTWVGKTIASCFSVFAISFFALPAGILGSGFALKVQQKQRQKHFNRQIPAAASLIQTAWRCYAAENPDSSTWKIYIRKAPRSHTLLSPSPKPKKSVVVKKKKFKLDKDNGVTPGEKMLTVPHITCDPPEERRLDHFSVDGYDSSVRKSPTLLEVSMPHFMRTNSFAEDLDLEGETLLTPITHISQLREHHRATIKVIRRMQYFVAKKKFQQARKPYDVRDVIEQYSQGHLNLMVRIKELQRRLDQSIGKPSLFISVSEKSKDRGSNTIGARLNRVEDKVTQLDQRLALITDMLHQLLSLHGGSTPGSGGPPREGGAHITQPCGSGGSVDPELFLPSNTLPTYEQLTVPRRGPDEGS
T49526	DRUGINFO	D0H8FH	Indapamide	Approved
T49526	DRUGINFO	D03OFO	L-768673	Terminated
T49526	DRUGINFO	D00CAU	N-(3,3-Dimethyl-cyclopentyl)-4-hexyloxy-benzamide	Investigative
T49526	DRUGINFO	D01JJH	(3R,4S)-293B	Investigative
T49526	DRUGINFO	D04UYO	HMR-1556	Investigative
T49526	DRUGINFO	D05GQK	R-L3	Investigative
T49526	DRUGINFO	D08HPL	3S,4R-293B	Investigative
T49526	DRUGINFO	D0D0OD	N-(3,3-Dimethyl-butyl)-4-indol-1-yl-benzamide	Investigative
T49526	DRUGINFO	D0M1BJ	L-735,821	Investigative
T49526	DRUGINFO	D0MS4Z	N-(3,3-Dimethyl-butyl)-4-hexyloxy-benzamide	Investigative
T49526	DRUGINFO	D0W2FU	ML277	Investigative
T49526	DRUGINFO	D0X2ZW	IKs124	Investigative
T49526	DRUGINFO	D0X8DF	N-(2-Diethylamino-ethyl)-4-hexyloxy-benzamide	Investigative
T49526	DRUGINFO	D07FTI	zinc pyrithione	Investigative
T49526	DRUGINFO	D0P8PH	XE991	Investigative

T76497	TARGETID	T76497
T76497	FORMERID	TTDR00910
T76497	UNIPROID	6PGD_HUMAN
T76497	TARGNAME	Phosphogluconate dehydrogenase (PGD)
T76497	GENENAME	PGD
T76497	TARGTYPE	Successful
T76497	SYNONYMS	PGDH; 6PGDH; 6-phosphogluconate dehydrogenase, decarboxylating; 6-phosphogluconate dehydrogenase
T76497	FUNCTION	Catalyzes the oxidative decarboxylation of 6-phosphogluconate to ribulose 5-phosphate and CO(2), with concomitant reduction of NADP to NADPH.
T76497	PDBSTRUC	5UQ9; 4GWK; 4GWG; 2JKV
T76497	BIOCLASS	CH-OH donor oxidoreductase
T76497	ECNUMBER	EC 1.1.1.44
T76497	SEQUENCE	MAQADIALIGLAVMGQNLILNMNDHGFVVCAFNRTVSKVDDFLANEAKGTKVVGAQSLKEMVSKLKKPRRIILLVKAGQAVDDFIEKLVPLLDTGDIIIDGGNSEYRDTTRRCRDLKAKGILFVGSGVSGGEEGARYGPSLMPGGNKEAWPHIKTIFQGIAAKVGTGEPCCDWVGDEGAGHFVKMVHNGIEYGDMQLICEAYHLMKDVLGMAQDEMAQAFEDWNKTELDSFLIEITANILKFQDTDGKHLLPKIRDSAGQKGTGKWTAISALEYGVPVTLIGEAVFARCLSSLKDERIQASKKLKGPQKFQFDGDKKSFLEDIRKALYASKIISYAQGFMLLRQAATEFGWTLNYGGIALMWRGGCIIRSVFLGKIKDAFDRNPELQNLLLDDFFKSAVENCQDSWRRAVSTGVQAGIPMPCFTTALSFYDGYRHEMLPASLIQAQRDYFGAHTYELLAKPGQFIHTNWTGHGGTVSSSSYNA
T76497	DRUGINFO	D08VRX	GHRP-2	Approved
T76497	DRUGINFO	D04LDP	5-deoxy-5-phosphono-D-arabinonate	Investigative
T76497	DRUGINFO	D0C4VG	4-phospho-D-erythronate	Investigative
T76497	DRUGINFO	D0E4AN	6-Phosphogluconic Acid	Investigative
T76497	DRUGINFO	D0P9DD	(2R)-2-Methyl-4,5-dideoxy	Investigative
T76497	DRUGINFO	D0A1DU	Pyrophosphate 2-	Investigative

T79798	TARGETID	T79798
T79798	FORMERID	TTDC00044
T79798	UNIPROID	MK12_HUMAN
T79798	TARGNAME	MAP kinase p38 (MAPK12)
T79798	GENENAME	MAPK12
T79798	TARGTYPE	Successful
T79798	SYNONYMS	Stress-activated protein kinase 3; SAPK3; Mitogen-activated proteinkinase p38 gamma; Mitogen-activated proteinkinase 12; MAPK12; Extracellular signal-regulated kinase 6; ERK6; ERK5; ERK-6
T79798	FUNCTION	Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK12 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors such as ELK1 and ATF2. Accordingly, p38 MAPKs phosphorylate a broad range of proteins and it has been estimated that they may have approximately 200 to 300 substrates each. Some of the targets are downstream kinases such as MAPKAPK2, which are activated through phosphorylation and further phosphorylate additional targets. Plays a role in myoblast differentiation and also in the down-regulation of cyclin D1 in response to hypoxia in adrenal cells suggesting MAPK12 may inhibit cell proliferation while promoting differentiation. Phosphorylates DLG1. Following osmotic shock, MAPK12 in the cell nucleus increases its association with nuclear DLG1, thereby causing dissociation of DLG1-SFPQ complexes. This function is independent of its catalytic activity and could affect mRNA processing and/or gene transcription to aid cell adaptation to osmolarity changes in the environment. Regulates UV-induced checkpoint signaling and repair of UV-induced DNA damage and G2 arrest after gamma- radiation exposure. MAPK12 is involved in the regulation of SLC2A1 expression and basal glucose uptake in L6 myotubes; and negatively regulates SLC2A4 expression and contraction-mediated glucose uptake in adult skeletal muscle. C-Jun (JUN) phosphorylation is stimulated by MAPK14 and inhibited by MAPK12, leading to a distinct AP-1 regulation. MAPK12 is required for the normal kinetochore localization of PLK1, prevents chromosomal instability and supports mitotic cell viability. MAPK12-signaling is also positively regulating the expansion of transient amplifying myogenic precursor cells during muscle growth and regeneration.
T79798	PDBSTRUC	4QUM; 1CM8
T79798	BIOCLASS	Kinase
T79798	ECNUMBER	EC 2.7.11.24
T79798	SEQUENCE	MSSPPPARSGFYRQEVTKTAWEVRAVYRDLQPVGSGAYGAVCSAVDGRTGAKVAIKKLYRPFQSELFAKRAYRELRLLKHMRHENVIGLLDVFTPDETLDDFTDFYLVMPFMGTDLGKLMKHEKLGEDRIQFLVYQMLKGLRYIHAAGIIHRDLKPGNLAVNEDCELKILDFGLARQADSEMTGYVVTRWYRAPEVILNWMRYTQTVDIWSVGCIMAEMITGKTLFKGSDHLDQLKEIMKVTGTPPAEFVQRLQSDEAKNYMKGLPELEKKDFASILTNASPLAVNLLEKMLVLDAEQRVTAGEALAHPYFESLHDTEDEPQVQKYDDSFDDVDRTLDEWKRVTYKEVLSFKPPRQLGARVSKETPL
T79798	DRUGINFO	D0H6VY	SM-101	Approved (orphan drug)
T79798	DRUGINFO	D02LBK	ARRY-797	Phase 2
T79798	DRUGINFO	D02NNV	VX-745	Phase 2
T79798	DRUGINFO	D0Y2HH	KC706	Discontinued in Phase 2
T79798	DRUGINFO	D0W0AM	SB 235699	Discontinued in Phase 1
T79798	DRUGINFO	D06NUL	RWJ-68354	Investigative
T79798	DRUGINFO	D09HBZ	ML-3375	Investigative
T79798	DRUGINFO	D0W4FF	ML-3403	Investigative
T79798	DRUGINFO	D08DSJ	ML-3163	Investigative
T79798	DRUGINFO	D05BHG	Phosphonothreonine	Investigative
T79798	DRUGINFO	D0G2VC	KT-5720	Investigative
T79798	DRUGINFO	D0GB4V	STAUROSPORINONE	Investigative
T79798	DRUGINFO	D0M5FF	Ro31-8220	Investigative
T79798	DRUGINFO	D00ICA	AMP-PNP	Investigative
T79798	DRUGINFO	D0N6ES	KN-62	Investigative
T79798	DRUGINFO	D0B9BU	CI-1040	Investigative
T79798	DRUGINFO	D0O1YH	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	Investigative
T79798	DRUGINFO	D0TO6S	Bisindolylmaleimide-I	Investigative
T79798	DRUGINFO	D0L8HO	RO-316233	Investigative

T53103	TARGETID	T53103
T53103	FORMERID	TTDS00495
T53103	UNIPROID	ANAG_HUMAN
T53103	TARGNAME	Alpha-N-acetylglucosaminidase (NAGLU)
T53103	GENENAME	NAGLU
T53103	TARGTYPE	Successful
T53103	SYNONYMS	UFHSD1; NAGLU; NAG; N-acetyl-alpha-glucosaminidase; Alpha-N-acetylglucosaminidase82 kDa form; Alpha-N-acetylglucosaminidase77 kDa form
T53103	FUNCTION	Involved in the degradation of heparan sulfate.
T53103	PDBSTRUC	4XWH
T53103	BIOCLASS	Glycosylase
T53103	ECNUMBER	EC 3.2.1.50
T53103	SEQUENCE	MEAVAVAAAVGVLLLAGAGGAAGDEAREAAAVRALVARLLGPGPAADFSVSVERALAAKPGLDTYSLGGGGAARVRVRGSTGVAAAAGLHRYLRDFCGCHVAWSGSQLRLPRPLPAVPGELTEATPNRYRYYQNVCTQSYSFVWWDWARWEREIDWMALNGINLALAWSGQEAIWQRVYLALGLTQAEINEFFTGPAFLAWGRMGNLHTWDGPLPPSWHIKQLYLQHRVLDQMRSFGMTPVLPAFAGHVPEAVTRVFPQVNVTKMGSWGHFNCSYSCSFLLAPEDPIFPIIGSLFLRELIKEFGTDHIYGADTFNEMQPPSSEPSYLAAATTAVYEAMTAVDTEAVWLLQGWLFQHQPQFWGPAQIRAVLGAVPRGRLLVLDLFAESQPVYTRTASFQGQPFIWCMLHNFGGNHGLFGALEAVNGGPEAARLFPNSTMVGTGMAPEGISQNEVVYSLMAELGWRKDPVPDLAAWVTSFAARRYGVSHPDAGAAWRLLLRSVYNCSGEACRGHNRSPLVRRPSLQMNTSIWYNRSDVFEAWRLLLTSAPSLATSPAFRYDLLDLTRQAVQELVSLYYEEARSAYLSKELASLLRAGGVLAYELLPALDEVLASDSRFLLGSWLEQARAAAVSEAEADFYEQNSRYQLTLWGPEGNILDYANKQLAGLVANYYTPRWRLFLEALVDSVAQGIPFQQHQFDKNVFQLEQAFVLSKQRYPSQPRGDTVDLAKKIFLKYYPRWVAGSW
T53103	DRUGINFO	D05ZYM	N-Acetyl-D-glucosamine	Approved
T53103	DRUGINFO	DG1CX7	ABO-101	Phase 1/2
T53103	DRUGINFO	DK3U6C	BMN 250	Phase 1/2

T96079	TARGETID	T96079
T96079	FORMERID	TTDC00121
T96079	UNIPROID	CXCR4_HUMAN
T96079	TARGNAME	C-X-C chemokine receptor type 4 (CXCR4)
T96079	GENENAME	CXCR4
T96079	TARGTYPE	Successful
T96079	SYNONYMS	Stromal cell-derived factor 1 receptor; SDF-1 receptor; NPYRL; Lipopolysaccharide-associated protein 3; Leukocyte-derived seven transmembrane domain receptor; LPS-associated protein 3; LESTR; LCR1; LAP-3; HM89; Fusin; FB22; Chemokine receptor CXCR4; CXCR-4; CXC-R4; CD184 antigen; CD184
T96079	FUNCTION	Involved in the AKT signaling cascade. Plays a role in regulation of cell migration, e. g. during wound healing. Acts as a receptor for extracellular ubiquitin; leading to enhanced intracellular calcium ions and reduced cellular cAMP levels. Binds bacterial lipopolysaccharide (LPS) et mediates LPS-induced inflammatory response, including TNF secretion by monocytes. Involved in hematopoiesis and in cardiac ventricular septum formation. Also plays an essential role in vascularization of the gastrointestinal tract, probably by regulating vascular branching and/or remodeling processes in endothelial cells. Involved in cerebellar development. In the CNS, could mediate hippocampal-neuron survival. Receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation.
T96079	PDBSTRUC	4RWS; 3OE9; 3OE8; 3OE6; 3OE0
T96079	BIOCLASS	GPCR rhodopsin
T96079	SEQUENCE	MEGISIYTSDNYTEEMGSGDYDSMKEPCFREENANFNKIFLPTIYSIIFLTGIVGNGLVILVMGYQKKLRSMTDKYRLHLSVADLLFVITLPFWAVDAVANWYFGNFLCKAVHVIYTVNLYSSVLILAFISLDRYLAIVHATNSQRPRKLLAEKVVYVGVWIPALLLTIPDFIFANVSEADDRYICDRFYPNDLWVVVFQFQHIMVGLILPGIVILSCYCIIISKLSHSKGHQKRKALKTTVILILAFFACWLPYYIGISIDSFILLEIIKQGCEFENTVHKWISITEALAFFHCCLNPILYAFLGAKFKTSAQHALTSVSRGSSLKILSKGKRGGHSSVSTESESSSFHSS
T96079	DRUGINFO	D0L5RW	Plerixafor	Approved
T96079	DRUGINFO	D0T6CN	Motixafortide	Approved
T96079	DRUGINFO	D0C3LQ	Ulocuplumab	Phase 3
T96079	DRUGINFO	D0GG9P	Balixafortide	Phase 3
T96079	DRUGINFO	D0O2XQ	AMD-070	Phase 3
T96079	DRUGINFO	D06KGI	TG-0054	Phase 2
T96079	DRUGINFO	D0FV8P	POL-6326	Phase 2
T96079	DRUGINFO	D01TJM	CTCE-9908	Phase 1/2
T96079	DRUGINFO	D08XQV	USL311	Phase 1/2
T96079	DRUGINFO	D09MPD	ALX-0651	Phase 1
T96079	DRUGINFO	D0AZ3Y	CTCE-0214	Phase 1
T96079	DRUGINFO	D0E5JC	MSX-122	Phase 1
T96079	DRUGINFO	D0LC5L	PF-06747143	Phase 1
T96079	DRUGINFO	D0Z8JR	BMS-936564	Phase 1
T96079	DRUGINFO	D3KZ6M	LY2624587	Phase 1
T96079	DRUGINFO	DBDW09	GMI-1359	Phase 1
T96079	DRUGINFO	D0H5KK	Garnocestim	Discontinued in Phase 1
T96079	DRUGINFO	D0I4OX	SURADISTA	Discontinued in Phase 1
T96079	DRUGINFO	D2NU0H	MAb173	Preclinical
T96079	DRUGINFO	D00FJS	KRH-2731	Terminated
T96079	DRUGINFO	D00GII	Cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-)	Investigative
T96079	DRUGINFO	D00XBM	Cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-)	Investigative
T96079	DRUGINFO	D02UES	Cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-)	Investigative
T96079	DRUGINFO	D03QJA	GSK-812397	Investigative
T96079	DRUGINFO	D04ATE	AT-009	Investigative
T96079	DRUGINFO	D04BVW	Cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-)	Investigative
T96079	DRUGINFO	D04PDF	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-)	Investigative
T96079	DRUGINFO	D04TED	Cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-)	Investigative
T96079	DRUGINFO	D04TIO	Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-)	Investigative
T96079	DRUGINFO	D04XHX	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-)	Investigative
T96079	DRUGINFO	D05IXH	KUR-CXCR4	Investigative
T96079	DRUGINFO	D05VQJ	isothiourea-1t	Investigative
T96079	DRUGINFO	D05YHT	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-)	Investigative
T96079	DRUGINFO	D06EBJ	CX-02	Investigative
T96079	DRUGINFO	D06MBD	isothiourea-1a	Investigative
T96079	DRUGINFO	D07IZP	ND-401	Investigative
T96079	DRUGINFO	D07VDF	CXCR4 gene disrupted T cells	Investigative
T96079	DRUGINFO	D08NJD	T134	Investigative
T96079	DRUGINFO	D08XRM	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-)	Investigative
T96079	DRUGINFO	D08YYV	Cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-)	Investigative
T96079	DRUGINFO	D0A7GH	ATI-2341	Investigative
T96079	DRUGINFO	D0B8VW	Cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-)	Investigative
T96079	DRUGINFO	D0BH8K	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-)	Investigative
T96079	DRUGINFO	D0FQ3G	Cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-)	Investigative
T96079	DRUGINFO	D0I6AN	T140	Investigative
T96079	DRUGINFO	D0K0SO	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-)	Investigative
T96079	DRUGINFO	D0K9KQ	Cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-)	Investigative
T96079	DRUGINFO	D0L3GH	CTCE-0324	Investigative
T96079	DRUGINFO	D0M6RQ	Cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-)	Investigative
T96079	DRUGINFO	D0P7UV	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-)	Investigative
T96079	DRUGINFO	D0Q3MM	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-)	Investigative
T96079	DRUGINFO	D0Q7XS	LP-0067	Investigative
T96079	DRUGINFO	D0R4WT	NB-325	Investigative
T96079	DRUGINFO	D0S0GV	Cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-)	Investigative
T96079	DRUGINFO	D0S0PU	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-)	Investigative
T96079	DRUGINFO	D0ST1U	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-)	Investigative
T96079	DRUGINFO	D0TL6C	T22	Investigative
T96079	DRUGINFO	D0Y3OX	TN-14003	Investigative
T96079	DRUGINFO	D0ZO3C	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-)	Investigative
T96079	DRUGINFO	D07PHS	CXCL8	Investigative
T96079	DRUGINFO	D09PZD	viral macrophage inflammatory protein-II	Investigative

T76059	TARGETID	T76059
T76059	FORMERID	TTDC00307
T76059	UNIPROID	FKB1A_HUMAN
T76059	TARGNAME	FK506-binding protein 1A (FKBP1A)
T76059	GENENAME	FKBP1A
T76059	TARGTYPE	Successful
T76059	SYNONYMS	Rotamase; Peptidyl-prolyl cis-trans isomerase FKBP1A; PPIase FKBP1A; Immunophillin FKBP; Immunophilin FKBP12; FKBP12; FKBP1; FKBP-1A; FKBP-12; FK-binding protein 12; Calstabin-1; 12 kDa FKBP; 12 kDa FK506-binding protein
T76059	FUNCTION	Recruits SMAD7 to ACVR1B which prevents the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal. May modulate the RYR1 calcium channel activity. PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. Keeps in an inactive conformation TGFBR1, the TGF-beta type I serine/threonine kinase receptor, preventing TGF-beta receptor activation in absence of ligand.
T76059	PDBSTRUC	5I7Q; 5I7P; 4ODR; 4ODQ; 4ODP
T76059	BIOCLASS	Cis-trans-isomerase
T76059	ECNUMBER	EC 5.2.1.8
T76059	SEQUENCE	MGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLE
T76059	DRUGINFO	D0N0AR	GPI-1485	Phase 2
T76059	DRUGINFO	D0O5OF	SDZ-281-240	Phase 2
T76059	DRUGINFO	D0K8TO	AP1903	Phase 1/2
T76059	DRUGINFO	D04PGB	Gpi-1046	Terminated
T76059	DRUGINFO	D04NBE	4-Hydroxy-2-Butanone	Investigative
T76059	DRUGINFO	D04OSU	L-709,587	Investigative
T76059	DRUGINFO	D08GFY	Methyl Methylsulfinylmethyl Sulfide	Investigative
T76059	DRUGINFO	D0Q5YP	Rapamycin Immunosuppressant Drug	Investigative
T76059	DRUGINFO	D0X2LN	FKB-001	Investigative
T76059	DRUGINFO	D06IBV	Heptyl-Beta-D-Glucopyranoside	Investigative
T76059	DRUGINFO	D08OBF	MYRISTIC ACID	Investigative

T59045	TARGETID	T59045
T59045	FORMERID	TTDS00024
T59045	UNIPROID	GABT_HUMAN
T59045	TARGNAME	GABA transaminase (ABAT)
T59045	GENENAME	ABAT
T59045	TARGTYPE	Successful
T59045	SYNONYMS	L-AIBAT; Gamma-amino-N-butyrate transaminase; GABA-T; GABA-AT; GABA aminotransferase; ABAT; (S)-3-amino-2-methylpropionate transaminase
T59045	FUNCTION	Catalyzes the conversion of gamma-aminobutyrate and L- beta-aminoisobutyrate to succinate semialdehyde and methylmalonate semialdehyde, respectively. Can also convert delta-aminovalerate andbeta-alanine.
T59045	BIOCLASS	Transaminase
T59045	ECNUMBER	EC 2.6.1.19
T59045	SEQUENCE	MASMLLAQRLACSFQHSYRLLVPGSRHISQAAAKVDVEFDYDGPLMKTEVPGPRSQELMKQLNIIQNAEAVHFFCNYEESRGNYLVDVDGNRMLDLYSQISSVPIGYSHPALLKLIQQPQNASMFVNRPALGILPPENFVEKLRQSLLSVAPKGMSQLITMACGSCSNENALKTIFMWYRSKERGQRGFSQEELETCMINQAPGCPDYSILSFMGAFHGRTMGCLATTHSKAIHKIDIPSFDWPIAPFPRLKYPLEEFVKENQQEEARCLEEVEDLIVKYRKKKKTVAGIIVEPIQSEGGDNHASDDFFRKLRDIARKHGCAFLVDEVQTGGGCTGKFWAHEHWGLDDPADVMTFSKKMMTGGFFHKEEFRPNAPYRIFNTWLGDPSKNLLLAEVINIIKREDLLNNAAHAGKALLTGLLDLQARYPQFISRVRGRGTFCSFDTPDDSIRNKLILIARNKGVVLGGCGDKSIRFRPTLVFRDHHAHLFLNIFSDILADFK
T59045	DRUGINFO	D03LGY	Divalproex sodium	Approved
T59045	DRUGINFO	D09PUL	L-Alanine	Approved
T59045	DRUGINFO	D0G4JI	Pyruvic acid	Approved
T59045	DRUGINFO	D0R3QY	Vigabatrin	Approved
T59045	DRUGINFO	D06JGH	Pyridoxal Phosphate	Approved
T59045	DRUGINFO	D0EJ7U	CPP-115	Phase 2
T59045	DRUGINFO	D0YC4F	K-828-AB	Phase 2
T59045	DRUGINFO	D0TP1P	CPP -15	Phase 1
T59045	DRUGINFO	D00BRD	4-hydroxybenzaldehyde	Patented
T59045	DRUGINFO	D0B5YS	T83193	Patented
T59045	DRUGINFO	D03VZF	4-hydroxy-3-nitrobenzaldehyde	Investigative
T59045	DRUGINFO	D05TEW	(4e)-4-Aminohex-4-Enoic Acid	Investigative
T59045	DRUGINFO	D07ZBH	4-hydroxybenzylamine	Investigative
T59045	DRUGINFO	D09IHN	Gamma-acetylenic GABA	Investigative
T59045	DRUGINFO	D0L5IN	4-Amino Hexanoic Acid	Investigative
T59045	DRUGINFO	D0R5HK	Sodium valproate	Investigative
T59045	DRUGINFO	D0UT2X	3-chloro-1-(4-hydroxyphenyl)propan-1-one	Investigative
T59045	DRUGINFO	D0L7RB	1-(4-hydroxyphenyl)prop-2-en-1-one	Investigative
T59045	DRUGINFO	D0LP2H	OXAMATE	Investigative
T59045	DRUGINFO	D0RF2M	NIPECOTIC ACID	Investigative
T59045	DRUGINFO	D0F2ME	Acetate Ion	Investigative

T79068	TARGETID	T79068
T79068	FORMERID	TTDS00384
T79068	UNIPROID	INHA_MYCTU
T79068	TARGNAME	Bacterial Fatty acid synthetase I (Bact inhA)
T79068	GENENAME	Bact inhA
T79068	TARGTYPE	Successful
T79068	SYNONYMS	Enoyl-[acyl-carrier-protein] reductase [NADH]; Bacterial InhA
T79068	FUNCTION	Involved in the resistance against the antituberculosis drugs isoniazid and ethionamide.
T79068	PDBSTRUC	6GHN; 6GH4; 6GH1; 6GGM; 6EP8
T79068	BIOCLASS	CH-CH donor oxidoreductase
T79068	SEQUENCE	MTGLLDGKRILVSGIITDSSIAFHIARVAQEQGAQLVLTGFDRLRLIQRITDRLPAKAPLLELDVQNEEHLASLAGRVTEAIGAGNKLDGVVHSIGFMPQTGMGINPFFDAPYADVSKGIHISAYSYASMAKALLPIMNPGGSIVGMDFDPSRAMPAYNWMTVAKSALESVNRFVAREAGKYGVRSNLVAAGPIRTLAMSAIVGGALGEEAGAQIQLLEEGWDQRAPIGWNMKDATPVAKTVCALLSDWLPATTGDIIYADGGAHTQLL
T79068	DRUGINFO	D09XQF	Isoniazid	Approved
T79068	DRUGINFO	D0L7UQ	Prothionamide	Approved
T79068	DRUGINFO	D0P0HB	Ethionamide	Approved
T79068	DRUGINFO	D0XF8W	Pyrazinamide	Approved
T79068	DRUGINFO	D0X6NZ	AFN-1720	Phase 2
T79068	DRUGINFO	D0K1UD	MMV00/0053	Terminated
T79068	DRUGINFO	D01EFQ	2-(4,6-dimethoxypyrimidin-2-yloxy)-5-hexylphenol	Investigative
T79068	DRUGINFO	D01MLQ	(4-benzylpiperidin-1-yl)(2-fluorophenyl)methanone	Investigative
T79068	DRUGINFO	D03PJO	Diclosan	Investigative
T79068	DRUGINFO	D04BHQ	N-(2,4-dimethylphenyl)-2-nitrobenzamide	Investigative
T79068	DRUGINFO	D04XUV	5-hexyl-2-(3-nitrophenoxy)phenol	Investigative
T79068	DRUGINFO	D05DRQ	N-(4-(diethylamino)phenyl)-2-nitrobenzamide	Investigative
T79068	DRUGINFO	D05MLT	2-(4-aminophenoxy)-5-hexylphenol	Investigative
T79068	DRUGINFO	D05NWQ	4-chloro-N-(2,5-dichlorophenyl)-3-nitrobenzamide	Investigative
T79068	DRUGINFO	D05OQF	N-(3,5-dichlorophenyl)-2-nitrobenzamide	Investigative
T79068	DRUGINFO	D05SWR	N-(2,5-dichlorophenyl)-4-methoxy-3-nitrobenzamide	Investigative
T79068	DRUGINFO	D07UTV	2-nitro-N-(2,4,5-trichlorophenyl)benzamide	Investigative
T79068	DRUGINFO	D07WJX	C16-Fatty-Acyl-Substrate-Mimic	Investigative
T79068	DRUGINFO	D08AFZ	(4-benzylpiperidin-1-yl)(p-tolyl)methanone	Investigative
T79068	DRUGINFO	D08KWS	5-hexyl-2-phenoxyphenol	Investigative
T79068	DRUGINFO	D08VHO	5-hexyl-2-(pyridin-3-yloxy)phenol	Investigative
T79068	DRUGINFO	D08ZCM	5-octyl-2-phenoxyphenol	Investigative
T79068	DRUGINFO	D09ABM	5-PENTYL-2-PHENOXYPHENOL	Investigative
T79068	DRUGINFO	D09JHY	N-(4-(4-hexyl-2-hydroxyphenoxy)phenyl)acetamide	Investigative
T79068	DRUGINFO	D09LQF	N-(3,5-dimethoxyphenyl)-4-methyl-2-nitrobenzamide	Investigative
T79068	DRUGINFO	D0E9CT	Genz-10850	Investigative
T79068	DRUGINFO	D0FI4X	2-(3-aminophenoxy)-5-hexylphenol	Investigative
T79068	DRUGINFO	D0G7MC	5-hexyl-2-(pyridin-2-yloxy)phenol	Investigative
T79068	DRUGINFO	D0I1RG	(4-phenylpiperazin-1-yl)(p-tolyl)methanone	Investigative
T79068	DRUGINFO	D0IA7R	2-(2-aminophenoxy)-5-hexylphenol	Investigative
T79068	DRUGINFO	D0J1PL	5-hexyl-2-(4-nitrophenoxy)phenol	Investigative
T79068	DRUGINFO	D0JQ7W	2-bromo-4-methylphenyl 2-nitrobenzoate	Investigative
T79068	DRUGINFO	D0K9LT	5-hexyl-2-(pyrazin-2-yloxy)phenol	Investigative
T79068	DRUGINFO	D0K9LV	5-hexyl-2-(pyrimidin-2-yloxy)phenol	Investigative
T79068	DRUGINFO	D0M0EE	N-(2-(4-hexyl-2-hydroxyphenoxy)phenyl)acetamide	Investigative
T79068	DRUGINFO	D0M5EU	(4-benzylpiperidin-1-yl)(m-tolyl)methanone	Investigative
T79068	DRUGINFO	D0N0IC	N-(3,5-dichlorophenyl)-4-methoxy-3-nitrobenzamide	Investigative
T79068	DRUGINFO	D0N4IT	N-(2,4-dichlorophenyl)-2-nitrobenzamide	Investigative
T79068	DRUGINFO	D0O1BT	2-(4-hexyl-2-methoxyphenoxy)pyrimidine	Investigative
T79068	DRUGINFO	D0P9AP	5-hexyl-2-(pyridin-4-yloxy)phenol	Investigative
T79068	DRUGINFO	D0TH7L	5-hexyl-2-(2-nitrophenoxy)phenol	Investigative
T79068	DRUGINFO	D0X8JE	N-(3-(4-hexyl-2-hydroxyphenoxy)phenyl)acetamide	Investigative
T79068	DRUGINFO	D0YK5U	N-(2,4-dichlorophenyl)-4-methyl-3-nitrobenzamide	Investigative
T79068	DRUGINFO	D0ZM1Q	(4-benzylpiperidin-1-yl)(3-chlorophenyl)methanone	Investigative
T79068	DRUGINFO	D0B3UG	4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole	Investigative
T79068	DRUGINFO	D0Z7SL	Indole Naphthyridinone	Investigative
T79068	DRUGINFO	D05HRK	2-Hexadecynoic acid	Investigative
T79068	DRUGINFO	D07ONX	Beta-D-Glucose	Investigative
T79068	DRUGINFO	D0R6JE	Nicotinamide-Adenine-Dinucleotide	Investigative

T12187	TARGETID	T12187
T12187	FORMERID	TTDS00474
T12187	UNIPROID	DDL_MYCTU
T12187	TARGNAME	Mycobacterium D-alanine-D-alanine ligase A (MycB ddl)
T12187	GENENAME	MycB ddl
T12187	TARGTYPE	Successful
T12187	SYNONYMS	ddlA; D-alanylalanine synthetase A; D-Ala-D-Ala ligase A
T12187	FUNCTION	Cell wall formation.
T12187	PDBSTRUC	3LWB
T12187	BIOCLASS	Carbon-nitrogen ligase
T12187	ECNUMBER	EC 6.3.2.4
T12187	SEQUENCE	MSANDRRDRRVRVAVVFGGRSNEHAISCVSAGSILRNLDSRRFDVIAVGITPAGSWVLTDANPDALTITNRELPQVKSGSGTELALPADPRRGGQLVSLPPGAGEVLESVDVVFPVLHGPYGEDGTIQGLLELAGVPYVGAGVLASAVGMDKEFTKKLLAADGLPVGAYAVLRPPRSTLHRQECERLGLPVFVKPARGGSSIGVSRVSSWDQLPAAVARARRHDPKVIVEAAISGRELECGVLEMPDGTLEASTLGEIRVAGVRGREDSFYDFATKYLDDAAELDVPAKVDDQVAEAIRQLAIRAFAAIDCRGLARVDFFLTDDGPVINEINTMPGFTTISMYPRMWAASGVDYPTLLATMIETTLARGVGLH
T12187	DRUGINFO	D02WFK	Cycloserine	Approved

T85733	TARGETID	T85733
T85733	FORMERID	TTDR01192
T85733	UNIPROID	TOP2B_HUMAN
T85733	TARGNAME	DNA topoisomerase II beta (TOP2B)
T85733	GENENAME	TOP2B
T85733	TARGTYPE	Successful
T85733	SYNONYMS	Topo IIbeta; TOP2beta; TOP2B
T85733	FUNCTION	Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks.
T85733	PDBSTRUC	5ZRF; 5ZQF; 5ZEN; 5ZAD; 5GWJ
T85733	BIOCLASS	ATP-hydrolyzing DNA topoisomerase
T85733	ECNUMBER	EC 5.6.2.3
T85733	SEQUENCE	MAKSGGCGAGAGVGGGNGALTWVTLFDQNNAAKKEESETANKNDSSKKLSVERVYQKKTQLEHILLRPDTYIGSVEPLTQFMWVYDEDVGMNCREVTFVPGLYKIFDEILVNAADNKQRDKNMTCIKVSIDPESNIISIWNNGKGIPVVEHKVEKVYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKLCNIFSTKFTVETACKEYKHSFKQTWMNNMMKTSEAKIKHFDGEDYTCITFQPDLSKFKMEKLDKDIVALMTRRAYDLAGSCRGVKVMFNGKKLPVNGFRSYVDLYVKDKLDETGVALKVIHELANERWDVCLTLSEKGFQQISFVNSIATTKGGRHVDYVVDQVVGKLIEVVKKKNKAGVSVKPFQVKNHIWVFINCLIENPTFDSQTKENMTLQPKSFGSKCQLSEKFFKAASNCGIVESILNWVKFKAQTQLNKKCSSVKYSKIKGIPKLDDANDAGGKHSLECTLILTEGDSAKSLAVSGLGVIGRDRYGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYKKSYDDAESLKTLRYGKIMIMTDQDQDGSHIKGLLINFIHHNWPSLLKHGFLEEFITPIVKASKNKQELSFYSIPEFDEWKKHIENQKAWKIKYYKGLGTSTAKEAKEYFADMERHRILFRYAGPEDDAAITLAFSKKKIDDRKEWLTNFMEDRRQRRLHGLPEQFLYGTATKHLTYNDFINKELILFSNSDNERSIPSLVDGFKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSAYHHGEQALMMTIVNLAQNFVGSNNINLLQPIGQFGTRLHGGKDAASPRYIFTMLSTLARLLFPAVDDNLLKFLYDDNQRVEPEWYIPIIPMVLINGAEGIGTGWACKLPNYDAREIVNNVRRMLDGLDPHPMLPNYKNFKGTIQELGQNQYAVSGEIFVVDRNTVEITELPVRTWTQVYKEQVLEPMLNGTDKTPALISDYKEYHTDTTVKFVVKMTEEKLAQAEAAGLHKVFKLQTTLTCNSMVLFDHMGCLKKYETVQDILKEFFDLRLSYYGLRKEWLVGMLGAESTKLNNQARFILEKIQGKITIENRSKKDLIQMLVQRGYESDPVKAWKEAQEKAAEEDETQNQHDDSSSDSGTPSGPDFNYILNMSLWSLTKEKVEELIKQRDAKGREVNDLKRKSPSDLWKEDLAAFVEELDKVESQEREDVLAGMSGKAIKGKVGKPKVKKLQLEETMPSPYGRRIIPEITAMKADASKKLLKKKKGDLDTAAVKVEFDEEFSGAPVEGAGEEALTPSVPINKGPKPKREKKEPGTRVRKTPTSSGKPSAKKVKKRNPWSDDESKSESDLEETEPVVIPRDSLLRRAAAERPKYTFDFSEEEDDDADDDDDDNNDLEELKVKASPITNDGEDEFVPSDGLDKDEYTFSPGKSKATPEKSLHDKKSQDFGNLFSFPSYSQKSEDDSAKFDSNEEDSASVFSPSFGLKQTDKVPSKTVAAKKGKPSSDTVPKPKRAPKQKKVVEAVNSDSDSEFGIPKKTTTPKGKGRGAKKRKASGSENEGDYNPGRKTSKTTSKKPKKTSFDQDSDVDIFPSDFPTEPPSLPRTGRARKEVKYFAESDEEEDDVDFAMFN
T85733	DRUGINFO	D07XVN	Dexrazoxane	Approved
T85733	DRUGINFO	D04FMB	XK-469	Phase 1
T85733	DRUGINFO	D06SJZ	XB-947	Phase 1
T85733	DRUGINFO	D0Q1RC	A-62176	Terminated
T85733	DRUGINFO	D02MKW	3'-THIO-THYMIDINE-5'-PHOSPHATE	Investigative
T85733	DRUGINFO	D00ICA	AMP-PNP	Investigative

T62276	TARGETID	T62276
T62276	FORMERID	TTDR01259
T62276	UNIPROID	NMDZ1_HUMAN
T62276	TARGNAME	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
T62276	GENENAME	GRIN1
T62276	TARGTYPE	Successful
T62276	SYNONYMS	NmethylDaspartate receptor subunit NR1; NMDR1; NMD-R1; N-methyl-D-aspartate receptor subunit NR1; Glutamate receptor ionotropic, NMDA 1; Glutamate [NMDA] receptor subunit zeta1; Glutamate [NMDA] receptor subunit zeta-1; GluN1
T62276	FUNCTION	Channel activation requires binding of the neurotransmitter glutamate to the epsilon subunit, glycine binding to the zeta subunit, plus membrane depolarization to eliminate channel inhibition by Mg(2+). Sensitivity to glutamate and channel kinetics depend on the subunit composition. Component of NMDA receptor complexes that function as heterotetrameric, ligand-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium.
T62276	PDBSTRUC	6IRH; 6IRG; 6IRF; 6IRA; 5TPA
T62276	BIOCLASS	Glutamate-gated ion channel
T62276	SEQUENCE	MSTMRLLTLALLFSCSVARAACDPKIVNIGAVLSTRKHEQMFREAVNQANKRHGSWKIQLNATSVTHKPNAIQMALSVCEDLISSQVYAILVSHPPTPNDHFTPTPVSYTAGFYRIPVLGLTTRMSIYSDKSIHLSFLRTVPPYSHQSSVWFEMMRVYSWNHIILLVSDDHEGRAAQKRLETLLEERESKAEKVLQFDPGTKNVTALLMEAKELEARVIILSASEDDAATVYRAAAMLNMTGSGYVWLVGEREISGNALRYAPDGILGLQLINGKNESAHISDAVGVVAQAVHELLEKENITDPPRGCVGNTNIWKTGPLFKRVLMSSKYADGVTGRVEFNEDGDRKFANYSIMNLQNRKLVQVGIYNGTHVIPNDRKIIWPGGETEKPRGYQMSTRLKIVTIHQEPFVYVKPTLSDGTCKEEFTVNGDPVKKVICTGPNDTSPGSPRHTVPQCCYGFCIDLLIKLARTMNFTYEVHLVADGKFGTQERVNNSNKKEWNGMMGELLSGQADMIVAPLTINNERAQYIEFSKPFKYQGLTILVKKEIPRSTLDSFMQPFQSTLWLLVGLSVHVVAVMLYLLDRFSPFGRFKVNSEEEEEDALTLSSAMWFSWGVLLNSGIGEGAPRSFSARILGMVWAGFAMIIVASYTANLAAFLVLDRPEERITGINDPRLRNPSDKFIYATVKQSSVDIYFRRQVELSTMYRHMEKHNYESAAEAIQAVRDNKLHAFIWDSAVLEFEASQKCDLVTTGELFFRSGFGIGMRKDSPWKQNVSLSILKSHENGFMEDLDKTWVRYQECDSRSNAPATLTFENMAGVFMLVAGGIVAGIFLIFIEIAYKRHKDARRKQMQLAFAAVNVWRKNLQDRKSGRAEPDPKKKATFRAITSTLASSFKRRRSSKDTSTGGGRGALQNQKDTVLPRRAIEREEGQLQLCSRHRES
T62276	DRUGINFO	D02WFK	Cycloserine	Approved
T62276	DRUGINFO	D02UDJ	D-Serine	Phase 4
T62276	DRUGINFO	D0S8CI	ELIPRODIL	Phase 2
T62276	DRUGINFO	D02VKC	NBQX	Phase 1
T62276	DRUGINFO	D02TTF	YM-90K	Discontinued in Phase 2
T62276	DRUGINFO	D03KGJ	AM-92016	Terminated
T62276	DRUGINFO	D01PWK	RPR-104632	Terminated
T62276	DRUGINFO	D03CNT	L-698532	Terminated
T62276	DRUGINFO	D03WYF	L-695902	Terminated
T62276	DRUGINFO	D0M1WN	L-701324	Terminated
T62276	DRUGINFO	D0UB6U	L-687414	Terminated
T62276	DRUGINFO	D0X5PX	MDL-105519	Terminated
T62276	DRUGINFO	D02KLW	DIZOCILPINE	Terminated
T62276	DRUGINFO	D0AZ5V	L-698544	Terminated
T62276	DRUGINFO	D03UNN	L-689560	Terminated
T62276	DRUGINFO	D0LD9S	SPERMINE	Terminated
T62276	DRUGINFO	D04DHB	5,7-Dichlorokynurenic Acid	Investigative
T62276	DRUGINFO	D06NYB	5,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione	Investigative
T62276	DRUGINFO	D07DHN	5,7-Dibromo-1,4-dihydro-quinoxaline-2,3-dione	Investigative
T62276	DRUGINFO	D0D4IG	5,6,7-Trichloro-1,4-dihydro-quinoxaline-2,3-dione	Investigative
T62276	DRUGINFO	D0P0GT	Cycloleucine	Investigative
T62276	DRUGINFO	D0S6TW	6,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione	Investigative
T62276	DRUGINFO	D0X7BP	3-Carbamoyl-6-chloro-1H-indole-2-carboxylic acid	Investigative
T62276	DRUGINFO	D00HET	6-Methoxy-2-(4-phenoxy-benzyl)-1H-benzoimidazole	Investigative
T62276	DRUGINFO	D01BQD	2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ylamine	Investigative
T62276	DRUGINFO	D04ZFH	2-(4-Phenoxy-benzyl)-1H-benzoimidazole	Investigative
T62276	DRUGINFO	D05IGJ	2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ol	Investigative
T62276	DRUGINFO	D06NIS	4-[2-(4-Phenyl-butoxy)-ethyl]-phenol	Investigative
T62276	DRUGINFO	D07RFM	4-[2-(3-Phenyl-propylamino)-ethyl]-phenol	Investigative
T62276	DRUGINFO	D09BZV	4-[2-(4-Benzyl-piperidin-1-yl)-ethoxy]-phenol	Investigative
T62276	DRUGINFO	D0J1AE	Phenethyl-(4-phenyl-butyl)-amine	Investigative
T62276	DRUGINFO	D0J8PY	4-Benzyl-1-(2-phenoxy-ethyl)-piperidine	Investigative
T62276	DRUGINFO	D0P1YK	6-Nitro-2-(4-phenoxy-benzyl)-1H-benzoimidazole	Investigative
T62276	DRUGINFO	D0Q8PE	4-[2-(4-Phenyl-piperidin-1-yl)-ethoxy]-phenol	Investigative
T62276	DRUGINFO	D0QV0K	4-Benzyl-1-phenethyl-piperidine hydrochloride	Investigative
T62276	DRUGINFO	D0T0GA	2-(4-Phenoxy-benzyl)-3H-benzoimidazol-4-ol	Investigative
T62276	DRUGINFO	D0T1GZ	Phenethyl-(3-phenyl-propyl)-amine	Investigative
T62276	DRUGINFO	D0V5IZ	4-{2-[Ethyl-(4-phenyl-butyl)-amino]-ethyl}-phenol	Investigative
T62276	DRUGINFO	D00KGK	4-Bromo-3-hydroxy-1H-quinolin-2-one	Investigative
T62276	DRUGINFO	D01JHR	H-Gly-dmP-Glu-OH	Investigative
T62276	DRUGINFO	D01LDO	(R)-2-Amino-7-phosphono-heptanoic acid	Investigative
T62276	DRUGINFO	D01MSM	3-Hydroxy-7-nitro-1H-benzo[b]azepine-2,5-dione	Investigative
T62276	DRUGINFO	D01SHB	TRANSTORINE	Investigative
T62276	DRUGINFO	D01XWL	3-Hydroxy-8-methyl-1H-benzo[b]azepine-2,5-dione	Investigative
T62276	DRUGINFO	D03CAE	4-[2-(5-Phenyl-pentylamino)-ethyl]-phenol	Investigative
T62276	DRUGINFO	D03LWV	Nle-Pro-Glu	Investigative
T62276	DRUGINFO	D03NWI	Ala-Pro-Glu	Investigative
T62276	DRUGINFO	D04JJL	N,N'-Bis-(4-ethyl-phenyl)-guanidine	Investigative
T62276	DRUGINFO	D04ZJL	8-Bromo-3-hydroxy-1H-benzo[b]azepine-2,5-dione	Investigative
T62276	DRUGINFO	D05RRK	Phe-Pro-Glu	Investigative
T62276	DRUGINFO	D05WZA	4-[3-(4-Phenyl-butylamino)-propyl]-phenol	Investigative
T62276	DRUGINFO	D06QXT	4-[2-(6-Phenyl-hexylamino)-ethyl]-phenol	Investigative
T62276	DRUGINFO	D06RFW	N,N'-Bis-(4-isopropyl-phenyl)-guanidine	Investigative
T62276	DRUGINFO	D06SZG	6,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione	Investigative
T62276	DRUGINFO	D07OBI	H-Gly-D-dmP-Glu-OH	Investigative
T62276	DRUGINFO	D07QBQ	6-Chloro-1,4-dihydro-quinoxaline-2,3-dione	Investigative
T62276	DRUGINFO	D08FBB	8-Ethyl-3-hydroxy-1H-benzo[b]azepine-2,5-dione	Investigative
T62276	DRUGINFO	D08TAN	(+)-HA966	Investigative
T62276	DRUGINFO	D09ISB	(R)-2-Amino-5-phosphono-pentanoic acid	Investigative
T62276	DRUGINFO	D0A5ET	4-[3-(5-Phenyl-pentylamino)-propyl]-phenol	Investigative
T62276	DRUGINFO	D0BC2N	Gly-Pip-Glu	Investigative
T62276	DRUGINFO	D0D5HM	4-Bromo-5,7-dichloro-3-hydroxy-1H-quinolin-2-one	Investigative
T62276	DRUGINFO	D0E9KB	N,N'-Bis-(4-butoxy-phenyl)-guanidine	Investigative
T62276	DRUGINFO	D0FU0K	5,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione	Investigative
T62276	DRUGINFO	D0H5JV	4-Chloro-3-hydroxy-1H-quinolin-2-one	Investigative
T62276	DRUGINFO	D0H7PR	4,5,7-Trichloro-3-hydroxy-1H-quinolin-2-one	Investigative
T62276	DRUGINFO	D0J3EZ	6-Nitro-1,4-dihydro-quinoxaline-2,3-dione	Investigative
T62276	DRUGINFO	D0K7EZ	N-(2-methoxybenzyl)cinnamamidine	Investigative
T62276	DRUGINFO	D0L4QC	3-Hydroxy-6-methyl-1H-benzo[b]azepine-2,5-dione	Investigative
T62276	DRUGINFO	D0L7RU	5,7-Dichloro-4-hydroxy-3-phenyl-1H-quinolin-2-one	Investigative
T62276	DRUGINFO	D0LE0E	8-Fluoro-3-hydroxy-1H-benzo[b]azepine-2,5-dione	Investigative
T62276	DRUGINFO	D0OZ2F	AP-7	Investigative
T62276	DRUGINFO	D0P3MF	Gly-Hyp-Glu	Investigative
T62276	DRUGINFO	D0P4RL	5,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione	Investigative
T62276	DRUGINFO	D0Q5PC	PHENCYCLIDINE	Investigative
T62276	DRUGINFO	D0Q6QW	3-Benzoyl-7-chloro-4-hydroxy-1H-quinolin-2-one	Investigative
T62276	DRUGINFO	D0Q8NW	4-hydroxy-5-phenylthieno[2,3-b]pyridin-6(7H)-one	Investigative
T62276	DRUGINFO	D0S3TY	N,N'-Bis-(4-butyl-phenyl)-guanidine	Investigative
T62276	DRUGINFO	D0S5OQ	(D)-Ala-Pro-Glu	Investigative
T62276	DRUGINFO	D0S5RV	3-Hydroxy-1H-benzo[b]azepine-2,5-dione	Investigative
T62276	DRUGINFO	D0T7TB	Gly-Amp-Glu	Investigative
T62276	DRUGINFO	D0U8BM	N,N'-Bis-(4-sec-butyl-phenyl)-guanidine	Investigative
T62276	DRUGINFO	D0U8ZQ	Benzyl 4-aminobutyl(3-aminopropyl)carbamate	Investigative
T62276	DRUGINFO	D0V1PE	8-Chloro-3-hydroxy-1H-benzo[b]azepine-2,5-dione	Investigative
T62276	DRUGINFO	D0W0HN	4-[2-(4-Phenyl-butylamino)-ethyl]-phenol	Investigative
T62276	DRUGINFO	D0W0VK	3-phenyl-4-hydroxyquinolin-2(1H)-one	Investigative
T62276	DRUGINFO	D0ZD4F	N,N'-Bis-(4-hexyl-phenyl)-guanidine	Investigative
T62276	DRUGINFO	D0ZL5U	Gly-b7Pro-Glu	Investigative
T62276	DRUGINFO	D03GBO	4,6-Dichloro-1H-indole-2-carboxylic acid	Investigative
T62276	DRUGINFO	D00ZKW	[3H]CPP	Investigative
T62276	DRUGINFO	D02WJT	1,3-ditolylguanidine	Investigative
T62276	DRUGINFO	D03PGF	RPR-118723	Investigative
T62276	DRUGINFO	D05VVC	7-chloro-3-hydroxyquinazoline-2,4-dione	Investigative
T62276	DRUGINFO	D06GKL	2-Methylamino-succinic acid(NMDA)	Investigative
T62276	DRUGINFO	D07COG	[3H]MDL105519	Investigative
T62276	DRUGINFO	D08UDC	[3H]CGP39653	Investigative
T62276	DRUGINFO	D0B4DP	2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline	Investigative
T62276	DRUGINFO	D0B5ZA	homoquinolinic acid	Investigative
T62276	DRUGINFO	D0D2ZH	[3H]dizocilpine	Investigative
T62276	DRUGINFO	D0F5ZW	CGP61594	Investigative
T62276	DRUGINFO	D0FW8K	(RS)-(tetrazol-5-yl)glycine	Investigative
T62276	DRUGINFO	D0K9NW	4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline	Investigative
T62276	DRUGINFO	D0KO6Y	[3H]CGS19755	Investigative
T62276	DRUGINFO	D0OT9B	L-aspartic acid	Investigative
T62276	DRUGINFO	D05KQC	DNQX	Investigative
T62276	DRUGINFO	D08CAB	D-aspartic acid	Investigative

T94444	TARGETID	T94444
T94444	FORMERID	TTDS00078
T94444	UNIPROID	AOXA_HUMAN
T94444	TARGNAME	Aldehyde oxidase (AOX1)
T94444	GENENAME	AOX1
T94444	TARGTYPE	Successful
T94444	SYNONYMS	AOX1
T94444	FUNCTION	Oxidase with broad substrate specificity, oxidizing aromatic azaheterocycles, such as N1-methylnicotinamide and N- methylphthalazinium, as well as aldehydes, such as benzaldehyde, retinal, pyridoxal, and vanillin. Plays a key role in the metabolism of xenobiotics and drugs containing aromatic azaheterocyclic substituents. Participates in the bioactivation of prodrugs such as famciclovir, catalyzing the oxidation step from 6-deoxypenciclovir topenciclovir, which is a potent antiviral agent. Is probably involved in the regulation of reactive oxygen species homeostasis. May be a prominent source of superoxide generation via the one-electron reduction of molecular oxygen. Also may catalyze nitric oxide (NO) production via the reduction of nitrite to NO with NADH or aldehyde as electron donor. May play a role in adipogenesis.
T94444	PDBSTRUC	6Q6Q; 5EPG; 4UHX; 4UHW
T94444	BIOCLASS	Aldehyde/oxo donor oxidoreductase
T94444	ECNUMBER	EC 1.2.3.1
T94444	SEQUENCE	MDRASELLFYVNGRKVIEKNVDPETMLLPYLRKKLRLTGTKYGCGGGGCGACTVMISRYNPITKRIRHHPANACLIPICSLYGAAVTTVEGIGSTHTRIHPVQERIAKCHGTQCGFCTPGMVMSIYTLLRNHPEPTLDQLTDALGGNLCRCTGYRPIIDACKTFCKTSGCCQSKENGVCCLDQGINGLPEFEEGSKTSPKLFAEEEFLPLDPTQELIFPPELMIMAEKQSQRTRVFGSERMMWFSPVTLKELLEFKFKYPQAPVIMGNTSVGPEVKFKGVFHPVIISPDRIEELSVVNHAYNGLTLGAGLSLAQVKDILADVVQKLPEEKTQMYHALLKHLGTLAGSQIRNMASLGGHIISRHPDSDLNPILAVGNCTLNLLSKEGKRQIPLNEQFLSKCPNADLKPQEILVSVNIPYSRKWEFVSAFRQAQRQENALAIVNSGMRVFFGEGDGIIRELCISYGGVGPATICAKNSCQKLIGRHWNEQMLDIACRLILNEVSLLGSAPGGKVEFKRTLIISFLFKFYLEVSQILKKMDPVHYPSLADKYESALEDLHSKHHCSTLKYQNIGPKQHPEDPIGHPIMHLSGVKHATGEAIYCDDMPLVDQELFLTFVTSSRAHAKIVSIDLSEALSMPGVVDIMTAEHLSDVNSFCFFTEAEKFLATDKVFCVGQLVCAVLADSEVQAKRAAKRVKIVYQDLEPLILTIEESIQHNSSFKPERKLEYGNVDEAFKVVDQILEGEIHMGGQEHFYMETQSMLVVPKGEDQEMDVYVSTQFPKYIQDIVASTLKLPANKVMCHVRRVGGAFGGKVLKTGIIAAVTAFAANKHGRAVRCVLERGEDMLITGGRHPYLGKYKAGFMNDGRILALDMEHYSNAGASLDESLFVIEMGLLKMDNAYKFPNLRCRGWACRTNLPSNTAFRGFGFPQAALITESCITEVAAKCGLSPEKVRIINMYKEIDQTPYKQEINAKNLIQCWRECMAMSSYSLRKVAVEKFNAENYWKKKGLAMVPLKFPVGLGSRAAGQAAALVHIYLDGSVLVTHGGIEMGQGVHTKMIQVVSRELRMPMSNVHLRGTSTETVPNANISGGSVVADLNGLAVKDACQTLLKRLEPIISKNPKGTWKDWAQTAFDESINLSAVGYFRGYESDMNWEKGEGQPFEYFVYGAACSEVEIDCLTGDHKNIRTDIVMDVGCSINPAIDIGQIEGAFIQGMGLYTIEELNYSPQGILHTRGPDQYKIPAICDMPTELHIALLPPSQNSNTLYSSKGLGESGVFLGCSVFFAIHDAVSAARQERGLHGPLTLNSPLTPEKIRMACEDKFTKMIPRDEPGSYVPWNVPI
T94444	DRUGINFO	D0E9CD	Isovanillin	Approved
T94444	DRUGINFO	D03GET	Menadione	Approved

T02001	TARGETID	T02001
T02001	FORMERID	TTDS00499
T02001	UNIPROID	PDE4D_HUMAN
T02001	TARGNAME	Phosphodiesterase 4D (PDE4D)
T02001	GENENAME	PDE4D
T02001	TARGTYPE	Successful
T02001	SYNONYMS	cAMP-specific 3',5'-cyclic phosphodiesterase 4D; PDE43; DPDE3
T02001	FUNCTION	Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
T02001	PDBSTRUC	6NJJ; 6NJI; 6NJH; 6FW3; 6FTW
T02001	BIOCLASS	Phosphoric diester hydrolase
T02001	ECNUMBER	EC 3.1.4.53
T02001	SEQUENCE	MEAEGSSAPARAGSGEGSDSAGGATLKAPKHLWRHEQHHQYPLRQPQFRLLHPHHHLPPPPPPSPQPQPQCPLQPPPPPPLPPPPPPPGAARGRYASSGATGRVRHRGYSDTERYLYCRAMDRTSYAVETGHRPGLKKSRMSWPSSFQGLRRFDVDNGTSAGRSPLDPMTSPGSGLILQANFVHSQRRESFLYRSDSDYDLSPKSMSRNSSIASDIHGDDLIVTPFAQVLASLRTVRNNFAALTNLQDRAPSKRSPMCNQPSINKATITEEAYQKLASETLEELDWCLDQLETLQTRHSVSEMASNKFKRMLNRELTHLSEMSRSGNQVSEFISNTFLDKQHEVEIPSPTQKEKEKKKRPMSQISGVKKLMHSSSLTNSSIPRFGVKTEQEDVLAKELEDVNKWGLHVFRIAELSGNRPLTVIMHTIFQERDLLKTFKIPVDTLITYLMTLEDHYHADVAYHNNIHAADVVQSTHVLLSTPALEAVFTDLEILAAIFASAIHDVDHPGVSNQFLINTNSELALMYNDSSVLENHHLAVGFKLLQEENCDIFQNLTKKQRQSLRKMVIDIVLATDMSKHMNLLADLKTMVETKKVTSSGVLLLDNYSDRIQVLQNMVHCADLSNPTKPLQLYRQWTDRIMEEFFRQGDRERERGMEISPMCDKHNASVEKSQVGFIDYIVHPLWETWADLVHPDAQDILDTLEDNREWYQSTIPQSPSPAPDDPEEGRQGQTEKFQFELTLEEDGESDTEKDSGSQVEEDTSCSDSKTLCTQDSESTEIPLDEQVEEEAVGEEEESQPEACVIDDRSPDT
T02001	DRUGINFO	D0NJ3V	Papaverine	Approved
T02001	DRUGINFO	D01XHG	DENBUFYLLINE	Phase 3
T02001	DRUGINFO	D06VFP	SOTB07	Phase 3
T02001	DRUGINFO	D0IZ8X	BPN14770	Phase 2
T02001	DRUGINFO	D00JED	AN-2898	Phase 2
T02001	DRUGINFO	D01XFZ	GPD-1116	Phase 2
T02001	DRUGINFO	D02POH	TA-7906	Phase 2
T02001	DRUGINFO	D07OCV	HT-0712	Phase 2
T02001	DRUGINFO	D09TFB	TOFIMILAST	Phase 2
T02001	DRUGINFO	D0F4TV	AWD-12-281	Phase 2
T02001	DRUGINFO	D0F5IY	LIRIMILAST	Phase 2
T02001	DRUGINFO	D0L8KJ	Oglemilast	Phase 2
T02001	DRUGINFO	D0M7CB	MK-0873	Phase 2
T02001	DRUGINFO	D0RJ1W	OX-914	Phase 2
T02001	DRUGINFO	D0U2DH	CC-1088	Phase 2
T02001	DRUGINFO	D0X0PW	Revamilast	Phase 2
T02001	DRUGINFO	D0Z2FB	Piclamilast	Phase 2
T02001	DRUGINFO	D01WZL	AVE-8112	Phase 1
T02001	DRUGINFO	D03CWX	MEM-1414	Phase 1
T02001	DRUGINFO	D0K9DI	GSK-356278	Phase 1
T02001	DRUGINFO	D0O8JW	Ronomilast	Phase 1
T02001	DRUGINFO	D00DBE	CI-1018	Discontinued in Phase 2
T02001	DRUGINFO	D03ZVD	KW-4490	Discontinued in Phase 2
T02001	DRUGINFO	D08SNX	V-11294A	Discontinued in Phase 2
T02001	DRUGINFO	D0I0GM	Daxalipram	Discontinued in Phase 2
T02001	DRUGINFO	D0UG4T	CDP840	Discontinued in Phase 2
T02001	DRUGINFO	D0V2CN	LAS-37779	Discontinued in Phase 2
T02001	DRUGINFO	D01FXD	SCH-351591	Discontinued in Phase 1
T02001	DRUGINFO	D0C7JT	YM-976	Discontinued in Phase 1
T02001	DRUGINFO	D0K1OA	D-4418	Discontinued in Phase 1
T02001	DRUGINFO	D00YPW	ZAPRINAST	Terminated
T02001	DRUGINFO	D01OUA	TJN-598	Terminated
T02001	DRUGINFO	D01QUF	GW-3600	Terminated
T02001	DRUGINFO	D07UHY	NIK-616	Terminated
T02001	DRUGINFO	D0F7TV	Torbafylline	Terminated
T02001	DRUGINFO	D0R1QJ	D-22888	Terminated
T02001	DRUGINFO	D00JBC	1-Butyl-3-methyl-3,7-dihydro-purine-2,6-dione	Investigative
T02001	DRUGINFO	D00TQR	1-Methyl-3-propyl-3,7-dihydro-purine-2,6-dione	Investigative
T02001	DRUGINFO	D04BMR	AL-59640	Investigative
T02001	DRUGINFO	D04JNC	ZL-N-91	Investigative
T02001	DRUGINFO	D05YEL	CH-3697	Investigative
T02001	DRUGINFO	D0E5VP	KF-66490	Investigative
T02001	DRUGINFO	D0JD4C	L-454560	Investigative
T02001	DRUGINFO	D0K9PS	CHF-5480	Investigative
T02001	DRUGINFO	D0N7HS	ASP-3258	Investigative
T02001	DRUGINFO	D0S1HX	TAS-203	Investigative
T02001	DRUGINFO	D0S6MA	OCID-2987	Investigative
T02001	DRUGINFO	D0U4SS	CD-160130	Investigative
T02001	DRUGINFO	D0W7WV	L-869298	Investigative
T02001	DRUGINFO	D02ZPV	UCB-101333-3	Investigative
T02001	DRUGINFO	D0P2HX	RS-25344	Investigative
T02001	DRUGINFO	D0T5PO	ROLIPRAM	Investigative
T02001	DRUGINFO	D0R6MT	isobutylmethylxanthine	Investigative

T91480	TARGETID	T91480
T91480	FORMERID	TTDS00331
T91480	UNIPROID	ABCC8_HUMAN
T91480	TARGNAME	ATP-binding cassette transporter C8 (ABCC8)
T91480	GENENAME	ABCC8
T91480	TARGTYPE	Successful
T91480	SYNONYMS	Sulfonylurea receptor 1; SUR1-type K(ATP) channel; SUR1; Kir6.2/SUR1; ATPbinding cassette subfamily C member 8; ABCC8
T91480	FUNCTION	Putative subunit of the beta-cell ATP-sensitive potassium channel (KATP). Regulator of ATP-sensitive K(+) channels and insulin release.
T91480	PDBSTRUC	6C3P; 6C3O
T91480	BIOCLASS	ABC transporter
T91480	SEQUENCE	MPLAFCGSENHSAAYRVDQGVLNNGCFVDALNVVPHVFLLFITFPILFIGWGSQSSKVHIHHSTWLHFPGHNLRWILTFMLLFVLVCEIAEGILSDGVTESHHLHLYMPAGMAFMAAVTSVVYYHNIETSNFPKLLIALLVYWTLAFITKTIKFVKFLDHAIGFSQLRFCLTGLLVILYGMLLLVEVNVIRVRRYIFFKTPREVKPPEDLQDLGVRFLQPFVNLLSKGTYWWMNAFIKTAHKKPIDLRAIGKLPIAMRALTNYQRLCEAFDAQVRKDIQGTQGARAIWQALSHAFGRRLVLSSTFRILADLLGFAGPLCIFGIVDHLGKENDVFQPKTQFLGVYFVSSQEFLANAYVLAVLLFLALLLQRTFLQASYYVAIETGINLRGAIQTKIYNKIMHLSTSNLSMGEMTAGQICNLVAIDTNQLMWFFFLCPNLWAMPVQIIVGVILLYYILGVSALIGAAVIILLAPVQYFVATKLSQAQRSTLEYSNERLKQTNEMLRGIKLLKLYAWENIFRTRVETTRRKEMTSLRAFAIYTSISIFMNTAIPIAAVLITFVGHVSFFKEADFSPSVAFASLSLFHILVTPLFLLSSVVRSTVKALVSVQKLSEFLSSAEIREEQCAPHEPTPQGPASKYQAVPLRVVNRKRPAREDCRGLTGPLQSLVPSADGDADNCCVQIMGGYFTWTPDGIPTLSNITIRIPRGQLTMIVGQVGCGKSSLLLAALGEMQKVSGAVFWSSLPDSEIGEDPSPERETATDLDIRKRGPVAYASQKPWLLNATVEENIIFESPFNKQRYKMVIEACSLQPDIDILPHGDQTQIGERGINLSGGQRQRISVARALYQHANVVFLDDPFSALDIHLSDHLMQAGILELLRDDKRTVVLVTHKLQYLPHADWIIAMKDGTIQREGTLKDFQRSECQLFEHWKTLMNRQDQELEKETVTERKATEPPQGLSRAMSSRDGLLQDEEEEEEEAAESEEDDNLSSMLHQRAEIPWRACAKYLSSAGILLLSLLVFSQLLKHMVLVAIDYWLAKWTDSALTLTPAARNCSLSQECTLDQTVYAMVFTVLCSLGIVLCLVTSVTVEWTGLKVAKRLHRSLLNRIILAPMRFFETTPLGSILNRFSSDCNTIDQHIPSTLECLSRSTLLCVSALAVISYVTPVFLVALLPLAIVCYFIQKYFRVASRDLQQLDDTTQLPLLSHFAETVEGLTTIRAFRYEARFQQKLLEYTDSNNIASLFLTAANRWLEVRMEYIGACVVLIAAVTSISNSLHRELSAGLVGLGLTYALMVSNYLNWMVRNLADMELQLGAVKRIHGLLKTEAESYEGLLAPSLIPKNWPDQGKIQIQNLSVRYDSSLKPVLKHVNALIAPGQKIGICGRTGSGKSSFSLAFFRMVDTFEGHIIIDGIDIAKLPLHTLRSRLSIILQDPVLFSGTIRFNLDPERKCSDSTLWEALEIAQLKLVVKALPGGLDAIITEGGENFSQGQRQLFCLARAFVRKTSIFIMDEATASIDMATENILQKVVMTAFADRTVVTIAHRVHTILSADLVIVLKRGAILEFDKPEKLLSRKDSVFASFVRADK
T91480	DRUGINFO	D05LYX	Glibenclamide	Approved
T91480	DRUGINFO	D07WFK	Acetohexamide	Approved
T91480	DRUGINFO	D0M2MR	Gliclazide	Approved
T91480	DRUGINFO	D06OIV	Tolbutamide	Approved
T91480	DRUGINFO	D0B2GI	Glimepiride	Approved
T91480	DRUGINFO	D0N5YA	Repaglinide	Approved
T91480	DRUGINFO	D02ZPN	NN-414	Phase 1
T91480	DRUGINFO	D0H4BF	NS-11757	Investigative
T91480	DRUGINFO	D0U1XJ	HBR-985	Investigative

T20251	TARGETID	T20251
T20251	FORMERID	TTDS00147
T20251	UNIPROID	KCNH2_HUMAN
T20251	TARGNAME	Voltage-gated potassium channel Kv11.1 (KCNH2)
T20251	GENENAME	KCNH2
T20251	TARGTYPE	Successful
T20251	SYNONYMS	hERG1; hERG-1; Voltage-gated potassium channel subunit Kv11.1; Potassium voltage-gated channel subfamily H member 2; HERG K+ channel; HERG; H-ERG; Ether-a-go-go-related protein 1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go related protein 1; Ether-a-go-go related gene potassium channel 1; Eag related protein 1; Eag homolog; ERG-1; ERG
T20251	FUNCTION	Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel.
T20251	PDBSTRUC	5VA3; 5VA2; 5VA1; 4HQA; 4HP9
T20251	BIOCLASS	Voltage-gated ion channel
T20251	SEQUENCE	MPVRRGHVAPQNTFLDTIIRKFEGQSRKFIIANARVENCAVIYCNDGFCELCGYSRAEVMQRPCTCDFLHGPRTQRRAAAQIAQALLGAEERKVEIAFYRKDGSCFLCLVDVVPVKNEDGAVIMFILNFEVVMEKDMVGSPAHDTNHRGPPTSWLAPGRAKTFRLKLPALLALTARESSVRSGGAGGAGAPGAVVVDVDLTPAAPSSESLALDEVTAMDNHVAGLGPAEERRALVGPGSPPRSAPGQLPSPRAHSLNPDASGSSCSLARTRSRESCASVRRASSADDIEAMRAGVLPPPPRHASTGAMHPLRSGLLNSTSDSDLVRYRTISKIPQITLNFVDLKGDPFLASPTSDREIIAPKIKERTHNVTEKVTQVLSLGADVLPEYKLQAPRIHRWTILHYSPFKAVWDWLILLLVIYTAVFTPYSAAFLLKETEEGPPATECGYACQPLAVVDLIVDIMFIVDILINFRTTYVNANEEVVSHPGRIAVHYFKGWFLIDMVAAIPFDLLIFGSGSEELIGLLKTARLLRLVRVARKLDRYSEYGAAVLFLLMCTFALIAHWLACIWYAIGNMEQPHMDSRIGWLHNLGDQIGKPYNSSGLGGPSIKDKYVTALYFTFSSLTSVGFGNVSPNTNSEKIFSICVMLIGSLMYASIFGNVSAIIQRLYSGTARYHTQMLRVREFIRFHQIPNPLRQRLEEYFQHAWSYTNGIDMNAVLKGFPECLQADICLHLNRSLLQHCKPFRGATKGCLRALAMKFKTTHAPPGDTLVHAGDLLTALYFISRGSIEILRGDVVVAILGKNDIFGEPLNLYARPGKSNGDVRALTYCDLHKIHRDDLLEVLDMYPEFSDHFWSSLEITFNLRDTNMIPGSPGSTELEGGFSRQRKRKLSFRRRTDKDTEQPGEVSALGPGRAGAGPSSRGRPGGPWGESPSSGPSSPESSEDEGPGRSSSPLRLVPFSSPRPPGEPPGGEPLMEDCEKSSDTCNPLSGAFSGVSNIFSFWGDSRGRQYQELPRCPAPTPSLLNIPLSSPGRRPRGDVESRLDALQRQLNRLETRLSADMATVLQLLQRQMTLVPPAYSAVTTPGPGPTSTSPLLPVSPLPTLTLDSLSQVSQFMACEELPPGAPELPQEGPTRRLSLPGQLGALTSQPLHRHGSDPGS
T20251	DRUGINFO	D0L0ZF	VESNARINONE	Approved
T20251	DRUGINFO	D0HZ2E	M100907	Phase 3
T20251	DRUGINFO	D07MKL	ABT-229	Phase 2
T20251	DRUGINFO	D02TIK	HP-184	Phase 2
T20251	DRUGINFO	D0LI1C	NITD609	Phase 2
T20251	DRUGINFO	D03GNI	ISOQUINE	Phase 1
T20251	DRUGINFO	D01EBW	Quinoline derivative 12	Patented
T20251	DRUGINFO	D0B7KM	Quinoline derivative 13	Patented
T20251	DRUGINFO	D0L2KM	Quinoline derivative 11	Patented
T20251	DRUGINFO	D01LSP	Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1	Patented
T20251	DRUGINFO	D02NPB	Isoindoline derivative 5	Patented
T20251	DRUGINFO	D06FNA	Isoindoline derivative 3	Patented
T20251	DRUGINFO	D0EK3Z	Isoindoline derivative 4	Patented
T20251	DRUGINFO	D0F8XU	Isoindoline derivative 2	Patented
T20251	DRUGINFO	D0S3ON	Isoindoline derivative 1	Patented
T20251	DRUGINFO	D0T8WU	Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2	Patented
T20251	DRUGINFO	D02NGR	MK-499	Discontinued in Phase 2
T20251	DRUGINFO	D00YQZ	L-702958	Terminated
T20251	DRUGINFO	D0AX4E	Bertosamil	Terminated
T20251	DRUGINFO	D00FAY	4-(3-thienyl)benzene-1,2-diamine)	Investigative
T20251	DRUGINFO	D01BKS	ginsenoside Rg3	Investigative
T20251	DRUGINFO	D01IWD	MDL-74156	Investigative
T20251	DRUGINFO	D01PIU	5-Chloro-3-ethyl-1-(4-fluoro-phenyl)-1H-indole	Investigative
T20251	DRUGINFO	D01PYU	3-(1-Phenethyl-piperidin-3-yl)-2-phenyl-1H-indole	Investigative
T20251	DRUGINFO	D01WVE	KB-130015	Investigative
T20251	DRUGINFO	D02DCM	5-(3-(4-fluorobenzyl)pyrrolidin-3-yl)-1H-indole	Investigative
T20251	DRUGINFO	D03NRJ	4-Benzenesulfonyl-1-(3-phenyl-propyl)-piperidine	Investigative
T20251	DRUGINFO	D03PSY	3 9-DIHYDRO-N-DESMETHYL-N-ISOPROPYLERYTHROMYCIN A	Investigative
T20251	DRUGINFO	D03WAE	VU0405601	Investigative
T20251	DRUGINFO	D04MLU	[1-(4-p-Tolyl-butyl)-piperidin-4-yl]-methanol	Investigative
T20251	DRUGINFO	D05KUM	DESMETHYLOLANZAPINE	Investigative
T20251	DRUGINFO	D06EGM	PD-307243	Investigative
T20251	DRUGINFO	D07ETF	3-(1-Methyl-piperidin-3-yl)-2-phenyl-1H-indole	Investigative
T20251	DRUGINFO	D07LFR	3-(benzo[b]thiophen-5-yl)-3-benzylpyrrolidine	Investigative
T20251	DRUGINFO	D08ZIS	4-(2-thienyl)benzene-1,2-diamine	Investigative
T20251	DRUGINFO	D09GZH	(R)-ONDANSETRON	Investigative
T20251	DRUGINFO	D09ICL	PD-118057	Investigative
T20251	DRUGINFO	D0BW0V	3-(1H-indol-3-yl)-N-methyl-3-phenylpropan-1-amine	Investigative
T20251	DRUGINFO	D0C9UF	Desmethylastemizole	Investigative
T20251	DRUGINFO	D0DM6F	(1R,5R)-30-OXO-19-OXA-2,6,10,12-TETRAAZAHEXACYCLO[18.6.2.1^{2,5}.1^{14,18}.0^{8,12}.0^{23,27}]TRIACONTA-8,10,14(29),15,17,20(28),21,23(27)-OCTAENE-17-CARBONITRILE (STRUCTURAL MIX)	Investigative
T20251	DRUGINFO	D0FL1D	3-(1-Benzyl-piperidin-3-yl)-2-phenyl-1H-indole	Investigative
T20251	DRUGINFO	D0G7LE	4-Benzenesulfonyl-1-phenethyl-piperidine	Investigative
T20251	DRUGINFO	D0I2UC	5-(3-benzylpyrrolidin-3-yl)-1-methyl-1H-indole	Investigative
T20251	DRUGINFO	D0JY2K	NS-1643	Investigative
T20251	DRUGINFO	D0LM5H	RPR260243	Investigative
T20251	DRUGINFO	D0ND5D	3-(1-Methyl-piperidin-2-yl)-2-phenyl-1H-indole	Investigative
T20251	DRUGINFO	D0NM7S	A-935142	Investigative
T20251	DRUGINFO	D0RC9T	2-Phenyl-3-piperidin-3-yl-1H-indole	Investigative
T20251	DRUGINFO	D0S1XC	5-(3-butylpyrrolidin-3-yl)-1H-indole	Investigative
T20251	DRUGINFO	D0ZC3Q	5-(3-benzylpyrrolidin-3-yl)-1h-indole (structural mix)	Investigative
T20251	DRUGINFO	D00AWM	GW803430	Investigative
T20251	DRUGINFO	D06NXK	(R)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline	Investigative
T20251	DRUGINFO	D07GBV	3-(1-Phenethyl-piperidin-4-yl)-2-phenyl-1H-indole	Investigative
T20251	DRUGINFO	D07MAF	3-(dimethylamino)-1-(4-heptylphenyl)propan-1-one	Investigative
T20251	DRUGINFO	D07SGS	N-(4-(benzyloxy)phenethyl)pyridin-4-amine	Investigative
T20251	DRUGINFO	D08CZT	2-Phenyl-3-piperidin-4-yl-1H-indole	Investigative
T20251	DRUGINFO	D08QBS	MK-1925	Investigative
T20251	DRUGINFO	D0A7GW	N-(piperidin-4-yl)-N-propyl-2-naphthamide	Investigative
T20251	DRUGINFO	D0I0UW	1-(4-p-Tolyl-butyl)-piperidine	Investigative
T20251	DRUGINFO	D0Q8LS	2-[4-(2-Piperidin-1-ylethyl)phenoxy]benzothiazole	Investigative
T20251	DRUGINFO	D0XH1N	ICA-105574	Investigative
T20251	DRUGINFO	D0Z7TM	BMS-645737	Investigative
T20251	DRUGINFO	D00UIN	JNJ-10392980	Investigative
T20251	DRUGINFO	D01MCD	(2R)-N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)	Investigative
T20251	DRUGINFO	D06NXC	N-[6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-YL]-4,4,4-TRIFLUORO-3-HYDROXYBUTANAMIDE (DIASTEREOMERIC MIX)	Investigative
T20251	DRUGINFO	D08JCU	(E)-2-(4-fluorostyryl)-5-(phenylsulfinyl)pyridine	Investigative
T20251	DRUGINFO	D0FJ1I	N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)	Investigative
T20251	DRUGINFO	D0GG2J	1-(1-(2-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX)	Investigative
T20251	DRUGINFO	D0H3GI	4-(p-Tolyl)spiro[chromene-2,4'-piperidine]	Investigative
T20251	DRUGINFO	D0H8XV	R-dimethindene	Investigative
T20251	DRUGINFO	D0N2DN	4-Phenylspiro[chromene-2,4'-piperidine]	Investigative
T20251	DRUGINFO	D0N6OL	ADS-103253	Investigative
T20251	DRUGINFO	D0OQ5H	6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)	Investigative
T20251	DRUGINFO	D0S9AY	1-(2-(6-fluoronaphthalen-2-yl)ethyl)piperazine	Investigative
T20251	DRUGINFO	D00CCV	1,6-bis(4-m-tolylpiperazin-1-yl)hexane	Investigative
T20251	DRUGINFO	D01ABR	1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine	Investigative
T20251	DRUGINFO	D01FFX	4-((naphthalen-2-yloxy)methyl)piperidine	Investigative
T20251	DRUGINFO	D01JYY	(R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide	Investigative
T20251	DRUGINFO	D02EIB	4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol	Investigative
T20251	DRUGINFO	D03PIP	1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane	Investigative
T20251	DRUGINFO	D03RBD	8-azabicyclo[3.2.1]octan-3-yloxy-benzamide	Investigative
T20251	DRUGINFO	D03XKL	1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane	Investigative
T20251	DRUGINFO	D08EKQ	1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX)	Investigative
T20251	DRUGINFO	D09FIC	1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX)	Investigative
T20251	DRUGINFO	D0C6BP	1,6-bis(4-phenylpiperazin-1-yl)hexane	Investigative
T20251	DRUGINFO	D0E3DM	(S)-3-(naphthalen-2-ylmethoxy)pyrrolidine	Investigative
T20251	DRUGINFO	D0U7OD	PF-526014	Investigative
T20251	DRUGINFO	D0XF5P	(R)-3-(naphthalen-2-ylmethoxy)pyrrolidine	Investigative
T20251	DRUGINFO	D06QIQ	7-(piperidin-4-ylmethoxy)-2-naphthonitrile	Investigative
T20251	DRUGINFO	D0L9YP	4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide	Investigative

T22285	TARGETID	T22285
T22285	FORMERID	TTDS00123
T22285	UNIPROID	NMDE1_HUMAN
T22285	TARGNAME	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
T22285	GENENAME	GRIN2A
T22285	TARGTYPE	Successful
T22285	SYNONYMS	NR2A; NMDA receptor NR2A; N-methyl D-aspartate receptor subtype 2A; HNR2A; Glutamate receptor ionotropic, NMDA 2A; Glutamate [NMDA] receptor subunit epsilon-1; GluN2A
T22285	FUNCTION	Channel activation requires binding of the neurotransmitter glutamate to the epsilon subunit, glycine binding to the zeta subunit, plus membrane depolarization to eliminate channel inhibition by Mg(2+). Sensitivity to glutamate and channel kinetics depend on the subunit composition; channels containing GRIN1 and GRIN2A have higher sensitivity to glutamate and faster kinetics than channels formed by GRIN1 and GRIN2B. Contributes to the slow phase of excitatory postsynaptic current, long-term synaptic potentiation, and learning. Component of NMDA receptor complexes that function as heterotetrameric, ligand-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium.
T22285	PDBSTRUC	6IRH; 6IRG; 6IRF; 6IRA; 5TPA
T22285	BIOCLASS	Glutamate-gated ion channel
T22285	SEQUENCE	MGRVGYWTLLVLPALLVWRGPAPSAAAEKGPPALNIAVMLGHSHDVTERELRTLWGPEQAAGLPLDVNVVALLMNRTDPKSLITHVCDLMSGARIHGLVFGDDTDQEAVAQMLDFISSHTFVPILGIHGGASMIMADKDPTSTFFQFGASIQQQATVMLKIMQDYDWHVFSLVTTIFPGYREFISFVKTTVDNSFVGWDMQNVITLDTSFEDAKTQVQLKKIHSSVILLYCSKDEAVLILSEARSLGLTGYDFFWIVPSLVSGNTELIPKEFPSGLISVSYDDWDYSLEARVRDGIGILTTAASSMLEKFSYIPEAKASCYGQMERPEVPMHTLHPFMVNVTWDGKDLSFTEEGYQVHPRLVVIVLNKDREWEKVGKWENHTLSLRHAVWPRYKSFSDCEPDDNHLSIVTLEEAPFVIVEDIDPLTETCVRNTVPCRKFVKINNSTNEGMNVKKCCKGFCIDILKKLSRTVKFTYDLYLVTNGKHGKKVNNVWNGMIGEVVYQRAVMAVGSLTINEERSEVVDFSVPFVETGISVMVSRSNGTVSPSAFLEPFSASVWVMMFVMLLIVSAIAVFVFEYFSPVGYNRNLAKGKAPHGPSFTIGKAIWLLWGLVFNNSVPVQNPKGTTSKIMVSVWAFFAVIFLASYTANLAAFMIQEEFVDQVTGLSDKKFQRPHDYSPPFRFGTVPNGSTERNIRNNYPYMHQYMTKFNQKGVEDALVSLKTGKLDAFIYDAAVLNYKAGRDEGCKLVTIGSGYIFATTGYGIALQKGSPWKRQIDLALLQFVGDGEMEELETLWLTGICHNEKNEVMSSQLDIDNMAGVFYMLAAAMALSLITFIWEHLFYWKLRFCFTGVCSDRPGLLFSISRGIYSCIHGVHIEEKKKSPDFNLTGSQSNMLKLLRSAKNISSMSNMNSSRMDSPKRAADFIQRGSLIMDMVSDKGNLMYSDNRSFQGKESIFGDNMNELQTFVANRQKDNLNNYVFQGQHPLTLNESNPNTVEVAVSTESKANSRPRQLWKKSVDSIRQDSLSQNPVSQRDEATAENRTHSLKSPRYLPEEMAHSDISETSNRATCHREPDNSKNHKTKDNFKRSVASKYPKDCSEVERTYLKTKSSSPRDKIYTIDGEKEPGFHLDPPQFVENVTLPENVDFPDPYQDPSENFRKGDSTLPMNRNPLHNEEGLSNNDQYKLYSKHFTLKDKGSPHSETSERYRQNSTHCRSCLSNMPTYSGHFTMRSPFKCDACLRMGNLYDIDEDQMLQETGNPATGEQVYQQDWAQNNALQLQKNKLRISRQHSYDNIVDKPRELDLSRPSRSISLKDRERLLEGNFYGSLFSVPSSKLSGKKSSLFPQGLEDSKRSKSLLPDHTSDNPFLHSHRDDQRLVIGRCPSDPYKHSLPSQAVNDSYLRSSLRSTASYCSRDSRGHNDVYISEHVMPYAANKNNMYSTPRVLNSCSNRRVYKKMPSIESDV
T22285	DRUGINFO	D0M8AB	Glycine	Approved
T22285	DRUGINFO	D02VKC	NBQX	Phase 1
T22285	DRUGINFO	D02TTF	YM-90K	Discontinued in Phase 2
T22285	DRUGINFO	D01PWK	RPR-104632	Terminated
T22285	DRUGINFO	D03CNT	L-698532	Terminated
T22285	DRUGINFO	D03WYF	L-695902	Terminated
T22285	DRUGINFO	D0M1WN	L-701324	Terminated
T22285	DRUGINFO	D0UB6U	L-687414	Terminated
T22285	DRUGINFO	D0X5PX	MDL-105519	Terminated
T22285	DRUGINFO	D02KLW	DIZOCILPINE	Terminated
T22285	DRUGINFO	D0AZ5V	L-698544	Terminated
T22285	DRUGINFO	D03UNN	L-689560	Terminated
T22285	DRUGINFO	D0LD9S	SPERMINE	Terminated
T22285	DRUGINFO	D09HXX	TCN-201	Investigative
T22285	DRUGINFO	D0IX7S	MDL 100,453	Investigative
T22285	DRUGINFO	D00VKV	Tenocyclidine	Investigative
T22285	DRUGINFO	D08OMB	NVP-AAM077	Investigative
T22285	DRUGINFO	D0Z2EV	Conantokin-R	Investigative
T22285	DRUGINFO	D00KGK	4-Bromo-3-hydroxy-1H-quinolin-2-one	Investigative
T22285	DRUGINFO	D01JHR	H-Gly-dmP-Glu-OH	Investigative
T22285	DRUGINFO	D01LDO	(R)-2-Amino-7-phosphono-heptanoic acid	Investigative
T22285	DRUGINFO	D01MSM	3-Hydroxy-7-nitro-1H-benzo[b]azepine-2,5-dione	Investigative
T22285	DRUGINFO	D01SHB	TRANSTORINE	Investigative
T22285	DRUGINFO	D01XWL	3-Hydroxy-8-methyl-1H-benzo[b]azepine-2,5-dione	Investigative
T22285	DRUGINFO	D03CAE	4-[2-(5-Phenyl-pentylamino)-ethyl]-phenol	Investigative
T22285	DRUGINFO	D03LWV	Nle-Pro-Glu	Investigative
T22285	DRUGINFO	D03NWI	Ala-Pro-Glu	Investigative
T22285	DRUGINFO	D04JJL	N,N'-Bis-(4-ethyl-phenyl)-guanidine	Investigative
T22285	DRUGINFO	D04ZJL	8-Bromo-3-hydroxy-1H-benzo[b]azepine-2,5-dione	Investigative
T22285	DRUGINFO	D05RRK	Phe-Pro-Glu	Investigative
T22285	DRUGINFO	D05WZA	4-[3-(4-Phenyl-butylamino)-propyl]-phenol	Investigative
T22285	DRUGINFO	D06QXT	4-[2-(6-Phenyl-hexylamino)-ethyl]-phenol	Investigative
T22285	DRUGINFO	D06RFW	N,N'-Bis-(4-isopropyl-phenyl)-guanidine	Investigative
T22285	DRUGINFO	D06SZG	6,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione	Investigative
T22285	DRUGINFO	D07OBI	H-Gly-D-dmP-Glu-OH	Investigative
T22285	DRUGINFO	D07QBQ	6-Chloro-1,4-dihydro-quinoxaline-2,3-dione	Investigative
T22285	DRUGINFO	D08FBB	8-Ethyl-3-hydroxy-1H-benzo[b]azepine-2,5-dione	Investigative
T22285	DRUGINFO	D08TAN	(+)-HA966	Investigative
T22285	DRUGINFO	D09ISB	(R)-2-Amino-5-phosphono-pentanoic acid	Investigative
T22285	DRUGINFO	D0A5ET	4-[3-(5-Phenyl-pentylamino)-propyl]-phenol	Investigative
T22285	DRUGINFO	D0BC2N	Gly-Pip-Glu	Investigative
T22285	DRUGINFO	D0D5HM	4-Bromo-5,7-dichloro-3-hydroxy-1H-quinolin-2-one	Investigative
T22285	DRUGINFO	D0E9KB	N,N'-Bis-(4-butoxy-phenyl)-guanidine	Investigative
T22285	DRUGINFO	D0FU0K	5,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione	Investigative
T22285	DRUGINFO	D0H5JV	4-Chloro-3-hydroxy-1H-quinolin-2-one	Investigative
T22285	DRUGINFO	D0H7PR	4,5,7-Trichloro-3-hydroxy-1H-quinolin-2-one	Investigative
T22285	DRUGINFO	D0J3EZ	6-Nitro-1,4-dihydro-quinoxaline-2,3-dione	Investigative
T22285	DRUGINFO	D0K7EZ	N-(2-methoxybenzyl)cinnamamidine	Investigative
T22285	DRUGINFO	D0L4QC	3-Hydroxy-6-methyl-1H-benzo[b]azepine-2,5-dione	Investigative
T22285	DRUGINFO	D0L7RU	5,7-Dichloro-4-hydroxy-3-phenyl-1H-quinolin-2-one	Investigative
T22285	DRUGINFO	D0LE0E	8-Fluoro-3-hydroxy-1H-benzo[b]azepine-2,5-dione	Investigative
T22285	DRUGINFO	D0OZ2F	AP-7	Investigative
T22285	DRUGINFO	D0P3MF	Gly-Hyp-Glu	Investigative
T22285	DRUGINFO	D0P4RL	5,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione	Investigative
T22285	DRUGINFO	D0Q5PC	PHENCYCLIDINE	Investigative
T22285	DRUGINFO	D0Q6QW	3-Benzoyl-7-chloro-4-hydroxy-1H-quinolin-2-one	Investigative
T22285	DRUGINFO	D0Q8NW	4-hydroxy-5-phenylthieno[2,3-b]pyridin-6(7H)-one	Investigative
T22285	DRUGINFO	D0S3TY	N,N'-Bis-(4-butyl-phenyl)-guanidine	Investigative
T22285	DRUGINFO	D0S5OQ	(D)-Ala-Pro-Glu	Investigative
T22285	DRUGINFO	D0S5RV	3-Hydroxy-1H-benzo[b]azepine-2,5-dione	Investigative
T22285	DRUGINFO	D0T7TB	Gly-Amp-Glu	Investigative
T22285	DRUGINFO	D0U8BM	N,N'-Bis-(4-sec-butyl-phenyl)-guanidine	Investigative
T22285	DRUGINFO	D0U8ZQ	Benzyl 4-aminobutyl(3-aminopropyl)carbamate	Investigative
T22285	DRUGINFO	D0V1PE	8-Chloro-3-hydroxy-1H-benzo[b]azepine-2,5-dione	Investigative
T22285	DRUGINFO	D0W0HN	4-[2-(4-Phenyl-butylamino)-ethyl]-phenol	Investigative
T22285	DRUGINFO	D0W0VK	3-phenyl-4-hydroxyquinolin-2(1H)-one	Investigative
T22285	DRUGINFO	D0ZD4F	N,N'-Bis-(4-hexyl-phenyl)-guanidine	Investigative
T22285	DRUGINFO	D0ZL5U	Gly-b7Pro-Glu	Investigative
T22285	DRUGINFO	D02PXN	N1-dansyl-spermine	Investigative
T22285	DRUGINFO	D03GBO	4,6-Dichloro-1H-indole-2-carboxylic acid	Investigative
T22285	DRUGINFO	D03XLS	d-CCPene	Investigative
T22285	DRUGINFO	D04NPE	UBP141	Investigative
T22285	DRUGINFO	D08RVB	LY233053	Investigative
T22285	DRUGINFO	D0FT0J	d-AP5	Investigative
T22285	DRUGINFO	D00ZKW	[3H]CPP	Investigative
T22285	DRUGINFO	D02WJT	1,3-ditolylguanidine	Investigative
T22285	DRUGINFO	D03PGF	RPR-118723	Investigative
T22285	DRUGINFO	D05VVC	7-chloro-3-hydroxyquinazoline-2,4-dione	Investigative
T22285	DRUGINFO	D06GKL	2-Methylamino-succinic acid(NMDA)	Investigative
T22285	DRUGINFO	D07COG	[3H]MDL105519	Investigative
T22285	DRUGINFO	D08UDC	[3H]CGP39653	Investigative
T22285	DRUGINFO	D0B5ZA	homoquinolinic acid	Investigative
T22285	DRUGINFO	D0D2ZH	[3H]dizocilpine	Investigative
T22285	DRUGINFO	D0F5ZW	CGP61594	Investigative
T22285	DRUGINFO	D0FW8K	(RS)-(tetrazol-5-yl)glycine	Investigative
T22285	DRUGINFO	D0KO6Y	[3H]CGS19755	Investigative
T22285	DRUGINFO	D0OT9B	L-aspartic acid	Investigative
T22285	DRUGINFO	D05KQC	DNQX	Investigative
T22285	DRUGINFO	D08CAB	D-aspartic acid	Investigative

T76414	TARGETID	T76414
T76414	FORMERID	TTDC00299
T76414	UNIPROID	NMDE2_HUMAN
T76414	TARGNAME	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
T76414	GENENAME	GRIN2B
T76414	TARGTYPE	Successful
T76414	SYNONYMS	NR3; NR2B; NMDA receptor subunit 2B; NMDA receptor NR2B; NMDA NR2B receptor; N-methylD-aspartate receptor subtype 2B; N-methyl-D-aspartate receptor subunit 3; N-methyl D-aspartate receptor subtype 2B; HNR3; Glutamate receptor ionotropic, NMDA 2B; Glutamate receptor NR2B subunit; Glutamate [NMDA] receptor subunit epsilon-2; GluN2B
T76414	FUNCTION	Channel activation requires binding of the neurotransmitter glutamate to the epsilon subunit, glycine binding to the zeta subunit, plus membrane depolarization to eliminate channel inhibition by Mg(2+). Sensitivity to glutamate and channel kinetics depend on the subunit composition. In concert with DAPK1 at extrasynaptic sites, acts as a central mediator for stroke damage. Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them, resulting in an irreversible neuronal death. Contributes to neural pattern formation in the developing brain. Plays a role in long-term depression (LTD) of hippocampus membrane currents and in synaptic plasticity. Component of NMDA receptor complexes that function as heterotetrameric, ligand-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium.
T76414	PDBSTRUC	5EWM; 5EWL; 5EWJ; 2IPV; 1S2S
T76414	BIOCLASS	Glutamate-gated ion channel
T76414	SEQUENCE	MKPRAECCSPKFWLVLAVLAVSGSRARSQKSPPSIGIAVILVGTSDEVAIKDAHEKDDFHHLSVVPRVELVAMNETDPKSIITRICDLMSDRKIQGVVFADDTDQEAIAQILDFISAQTLTPILGIHGGSSMIMADKDESSMFFQFGPSIEQQASVMLNIMEEYDWYIFSIVTTYFPGYQDFVNKIRSTIENSFVGWELEEVLLLDMSLDDGDSKIQNQLKKLQSPIILLYCTKEEATYIFEVANSVGLTGYGYTWIVPSLVAGDTDTVPAEFPTGLISVSYDEWDYGLPARVRDGIAIITTAASDMLSEHSFIPEPKSSCYNTHEKRIYQSNMLNRYLINVTFEGRNLSFSEDGYQMHPKLVIILLNKERKWERVGKWKDKSLQMKYYVWPRMCPETEEQEDDHLSIVTLEEAPFVIVESVDPLSGTCMRNTVPCQKRIVTENKTDEEPGYIKKCCKGFCIDILKKISKSVKFTYDLYLVTNGKHGKKINGTWNGMIGEVVMKRAYMAVGSLTINEERSEVVDFSVPFIETGISVMVSRSNGTVSPSAFLEPFSADVWVMMFVMLLIVSAVAVFVFEYFSPVGYNRCLADGREPGGPSFTIGKAIWLLWGLVFNNSVPVQNPKGTTSKIMVSVWAFFAVIFLASYTANLAAFMIQEEYVDQVSGLSDKKFQRPNDFSPPFRFGTVPNGSTERNIRNNYAEMHAYMGKFNQRGVDDALLSLKTGKLDAFIYDAAVLNYMAGRDEGCKLVTIGSGKVFASTGYGIAIQKDSGWKRQVDLAILQLFGDGEMEELEALWLTGICHNEKNEVMSSQLDIDNMAGVFYMLGAAMALSLITFICEHLFYWQFRHCFMGVCSGKPGMVFSISRGIYSCIHGVAIEERQSVMNSPTATMNNTHSNILRLLRTAKNMANLSGVNGSPQSALDFIRRESSVYDISEHRRSFTHSDCKSYNNPPCEENLFSDYISEVERTFGNLQLKDSNVYQDHYHHHHRPHSIGSASSIDGLYDCDNPPFTTQSRSISKKPLDIGLPSSKHSQLSDLYGKFSFKSDRYSGHDDLIRSDVSDISTHTVTYGNIEGNAAKRRKQQYKDSLKKRPASAKSRREFDEIELAYRRRPPRSPDHKRYFRDKEGLRDFYLDQFRTKENSPHWEHVDLTDIYKERSDDFKRDSVSGGGPCTNRSHIKHGTGDKHGVVSGVPAPWEKNLTNVEWEDRSGGNFCRSCPSKLHNYSTTVTGQNSGRQACIRCEACKKAGNLYDISEDNSLQELDQPAAPVAVTSNASTTKYPQSPTNSKAQKKNRNKLRRQHSYDTFVDLQKEEAALAPRSVSLKDKGRFMDGSPYAHMFEMSAGESTFANNKSSVPTAGHHHHNNPGGGYMLSKSLYPDRVTQNPFIPTFGDDQCLLHGSKSYFFRQPTVAGASKARPDFRALVTNKPVVSALHGAVPARFQKDICIGNQSNPCVPNNKNPRAFNGSSNGHVYEKLSSIESDV
T76414	DRUGINFO	D0I0DL	Alpha 1-PI	Approved
T76414	DRUGINFO	D04WUA	CP-101,606	Phase 2
T76414	DRUGINFO	D06EMM	CERC-301	Phase 2
T76414	DRUGINFO	D0N3EJ	RGH-896	Phase 2
T76414	DRUGINFO	DD9VR3	MIJ821	Phase 2
T76414	DRUGINFO	D0S8CI	ELIPRODIL	Phase 2
T76414	DRUGINFO	D0JY2X	Neu-2000	Phase 1
T76414	DRUGINFO	D0S3EK	EVT100	Phase 1
T76414	DRUGINFO	D02VKC	NBQX	Phase 1
T76414	DRUGINFO	D0A5TS	EVT-101	Discontinued in Phase 2
T76414	DRUGINFO	D02TTF	YM-90K	Discontinued in Phase 2
T76414	DRUGINFO	D06RCS	Besonprodil	Discontinued in Phase 1
T76414	DRUGINFO	D07YKJ	EVT-103	Discontinued in Phase 1
T76414	DRUGINFO	D0K0DB	RO-25-6981	Terminated
T76414	DRUGINFO	D01PWK	RPR-104632	Terminated
T76414	DRUGINFO	D03CNT	L-698532	Terminated
T76414	DRUGINFO	D03WYF	L-695902	Terminated
T76414	DRUGINFO	D0M1WN	L-701324	Terminated
T76414	DRUGINFO	D0UB6U	L-687414	Terminated
T76414	DRUGINFO	D0X5PX	MDL-105519	Terminated
T76414	DRUGINFO	D02KLW	DIZOCILPINE	Terminated
T76414	DRUGINFO	D0AZ5V	L-698544	Terminated
T76414	DRUGINFO	D03UNN	L-689560	Terminated
T76414	DRUGINFO	D00JNH	Conantokins G	Investigative
T76414	DRUGINFO	D01ORL	2-(4-benzyl-piperidin-1-ylmethyl)-1H-indol-6-ol	Investigative
T76414	DRUGINFO	D04GDI	NP93-31	Investigative
T76414	DRUGINFO	D05ZQO	N-(3-phenethoxybenzyl)-4-hydroxybenzamide	Investigative
T76414	DRUGINFO	D06QJM	Ro 63-1908	Investigative
T76414	DRUGINFO	D09TQO	Conantokin-G	Investigative
T76414	DRUGINFO	D0HB5V	CN-2097	Investigative
T76414	DRUGINFO	D0N3LY	Conantokins T	Investigative
T76414	DRUGINFO	D00HET	6-Methoxy-2-(4-phenoxy-benzyl)-1H-benzoimidazole	Investigative
T76414	DRUGINFO	D00VKV	Tenocyclidine	Investigative
T76414	DRUGINFO	D01BQD	2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ylamine	Investigative
T76414	DRUGINFO	D04ZFH	2-(4-Phenoxy-benzyl)-1H-benzoimidazole	Investigative
T76414	DRUGINFO	D05IGJ	2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ol	Investigative
T76414	DRUGINFO	D06NIS	4-[2-(4-Phenyl-butoxy)-ethyl]-phenol	Investigative
T76414	DRUGINFO	D07RFM	4-[2-(3-Phenyl-propylamino)-ethyl]-phenol	Investigative
T76414	DRUGINFO	D07SGS	N-(4-(benzyloxy)phenethyl)pyridin-4-amine	Investigative
T76414	DRUGINFO	D08OMB	NVP-AAM077	Investigative
T76414	DRUGINFO	D09BZV	4-[2-(4-Benzyl-piperidin-1-yl)-ethoxy]-phenol	Investigative
T76414	DRUGINFO	D0J1AE	Phenethyl-(4-phenyl-butyl)-amine	Investigative
T76414	DRUGINFO	D0J8PY	4-Benzyl-1-(2-phenoxy-ethyl)-piperidine	Investigative
T76414	DRUGINFO	D0P1YK	6-Nitro-2-(4-phenoxy-benzyl)-1H-benzoimidazole	Investigative
T76414	DRUGINFO	D0Q8PE	4-[2-(4-Phenyl-piperidin-1-yl)-ethoxy]-phenol	Investigative
T76414	DRUGINFO	D0QV0K	4-Benzyl-1-phenethyl-piperidine hydrochloride	Investigative
T76414	DRUGINFO	D0T0GA	2-(4-Phenoxy-benzyl)-3H-benzoimidazol-4-ol	Investigative
T76414	DRUGINFO	D0T1GZ	Phenethyl-(3-phenyl-propyl)-amine	Investigative
T76414	DRUGINFO	D0V5IZ	4-{2-[Ethyl-(4-phenyl-butyl)-amino]-ethyl}-phenol	Investigative
T76414	DRUGINFO	D0Z2EV	Conantokin-R	Investigative
T76414	DRUGINFO	D00KGK	4-Bromo-3-hydroxy-1H-quinolin-2-one	Investigative
T76414	DRUGINFO	D01JHR	H-Gly-dmP-Glu-OH	Investigative
T76414	DRUGINFO	D01LDO	(R)-2-Amino-7-phosphono-heptanoic acid	Investigative
T76414	DRUGINFO	D01MSM	3-Hydroxy-7-nitro-1H-benzo[b]azepine-2,5-dione	Investigative
T76414	DRUGINFO	D01SHB	TRANSTORINE	Investigative
T76414	DRUGINFO	D01XWL	3-Hydroxy-8-methyl-1H-benzo[b]azepine-2,5-dione	Investigative
T76414	DRUGINFO	D03CAE	4-[2-(5-Phenyl-pentylamino)-ethyl]-phenol	Investigative
T76414	DRUGINFO	D03LWV	Nle-Pro-Glu	Investigative
T76414	DRUGINFO	D03NWI	Ala-Pro-Glu	Investigative
T76414	DRUGINFO	D04JJL	N,N'-Bis-(4-ethyl-phenyl)-guanidine	Investigative
T76414	DRUGINFO	D04ZJL	8-Bromo-3-hydroxy-1H-benzo[b]azepine-2,5-dione	Investigative
T76414	DRUGINFO	D05RRK	Phe-Pro-Glu	Investigative
T76414	DRUGINFO	D05WZA	4-[3-(4-Phenyl-butylamino)-propyl]-phenol	Investigative
T76414	DRUGINFO	D06QXT	4-[2-(6-Phenyl-hexylamino)-ethyl]-phenol	Investigative
T76414	DRUGINFO	D06RFW	N,N'-Bis-(4-isopropyl-phenyl)-guanidine	Investigative
T76414	DRUGINFO	D06SZG	6,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione	Investigative
T76414	DRUGINFO	D07OBI	H-Gly-D-dmP-Glu-OH	Investigative
T76414	DRUGINFO	D07QBQ	6-Chloro-1,4-dihydro-quinoxaline-2,3-dione	Investigative
T76414	DRUGINFO	D08FBB	8-Ethyl-3-hydroxy-1H-benzo[b]azepine-2,5-dione	Investigative
T76414	DRUGINFO	D08TAN	(+)-HA966	Investigative
T76414	DRUGINFO	D09ISB	(R)-2-Amino-5-phosphono-pentanoic acid	Investigative
T76414	DRUGINFO	D0A5ET	4-[3-(5-Phenyl-pentylamino)-propyl]-phenol	Investigative
T76414	DRUGINFO	D0BC2N	Gly-Pip-Glu	Investigative
T76414	DRUGINFO	D0D5HM	4-Bromo-5,7-dichloro-3-hydroxy-1H-quinolin-2-one	Investigative
T76414	DRUGINFO	D0E9KB	N,N'-Bis-(4-butoxy-phenyl)-guanidine	Investigative
T76414	DRUGINFO	D0FU0K	5,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione	Investigative
T76414	DRUGINFO	D0H5JV	4-Chloro-3-hydroxy-1H-quinolin-2-one	Investigative
T76414	DRUGINFO	D0H7PR	4,5,7-Trichloro-3-hydroxy-1H-quinolin-2-one	Investigative
T76414	DRUGINFO	D0HF0A	DQP-1105	Investigative
T76414	DRUGINFO	D0J3EZ	6-Nitro-1,4-dihydro-quinoxaline-2,3-dione	Investigative
T76414	DRUGINFO	D0K7EZ	N-(2-methoxybenzyl)cinnamamidine	Investigative
T76414	DRUGINFO	D0L4QC	3-Hydroxy-6-methyl-1H-benzo[b]azepine-2,5-dione	Investigative
T76414	DRUGINFO	D0L7RU	5,7-Dichloro-4-hydroxy-3-phenyl-1H-quinolin-2-one	Investigative
T76414	DRUGINFO	D0LE0E	8-Fluoro-3-hydroxy-1H-benzo[b]azepine-2,5-dione	Investigative
T76414	DRUGINFO	D0OZ2F	AP-7	Investigative
T76414	DRUGINFO	D0P3MF	Gly-Hyp-Glu	Investigative
T76414	DRUGINFO	D0P4RL	5,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione	Investigative
T76414	DRUGINFO	D0Q5PC	PHENCYCLIDINE	Investigative
T76414	DRUGINFO	D0Q6QW	3-Benzoyl-7-chloro-4-hydroxy-1H-quinolin-2-one	Investigative
T76414	DRUGINFO	D0Q8NW	4-hydroxy-5-phenylthieno[2,3-b]pyridin-6(7H)-one	Investigative
T76414	DRUGINFO	D0S3TY	N,N'-Bis-(4-butyl-phenyl)-guanidine	Investigative
T76414	DRUGINFO	D0S5OQ	(D)-Ala-Pro-Glu	Investigative
T76414	DRUGINFO	D0S5RV	3-Hydroxy-1H-benzo[b]azepine-2,5-dione	Investigative
T76414	DRUGINFO	D0T7TB	Gly-Amp-Glu	Investigative
T76414	DRUGINFO	D0U8BM	N,N'-Bis-(4-sec-butyl-phenyl)-guanidine	Investigative
T76414	DRUGINFO	D0U8ZQ	Benzyl 4-aminobutyl(3-aminopropyl)carbamate	Investigative
T76414	DRUGINFO	D0V1PE	8-Chloro-3-hydroxy-1H-benzo[b]azepine-2,5-dione	Investigative
T76414	DRUGINFO	D0W0HN	4-[2-(4-Phenyl-butylamino)-ethyl]-phenol	Investigative
T76414	DRUGINFO	D0W0VK	3-phenyl-4-hydroxyquinolin-2(1H)-one	Investigative
T76414	DRUGINFO	D0ZD4F	N,N'-Bis-(4-hexyl-phenyl)-guanidine	Investigative
T76414	DRUGINFO	D0ZL5U	Gly-b7Pro-Glu	Investigative
T76414	DRUGINFO	D02PXN	N1-dansyl-spermine	Investigative
T76414	DRUGINFO	D03GBO	4,6-Dichloro-1H-indole-2-carboxylic acid	Investigative
T76414	DRUGINFO	D03XLS	d-CCPene	Investigative
T76414	DRUGINFO	D04NPE	UBP141	Investigative
T76414	DRUGINFO	D08RVB	LY233053	Investigative
T76414	DRUGINFO	D0FT0J	d-AP5	Investigative
T76414	DRUGINFO	D00ZKW	[3H]CPP	Investigative
T76414	DRUGINFO	D02WJT	1,3-ditolylguanidine	Investigative
T76414	DRUGINFO	D03PGF	RPR-118723	Investigative
T76414	DRUGINFO	D05VVC	7-chloro-3-hydroxyquinazoline-2,4-dione	Investigative
T76414	DRUGINFO	D06GKL	2-Methylamino-succinic acid(NMDA)	Investigative
T76414	DRUGINFO	D07COG	[3H]MDL105519	Investigative
T76414	DRUGINFO	D08UDC	[3H]CGP39653	Investigative
T76414	DRUGINFO	D0B4DP	2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline	Investigative
T76414	DRUGINFO	D0B5ZA	homoquinolinic acid	Investigative
T76414	DRUGINFO	D0D2ZH	[3H]dizocilpine	Investigative
T76414	DRUGINFO	D0F5ZW	CGP61594	Investigative
T76414	DRUGINFO	D0FW8K	(RS)-(tetrazol-5-yl)glycine	Investigative
T76414	DRUGINFO	D0K9NW	4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline	Investigative
T76414	DRUGINFO	D0KO6Y	[3H]CGS19755	Investigative
T76414	DRUGINFO	D0OT9B	L-aspartic acid	Investigative
T76414	DRUGINFO	D05KQC	DNQX	Investigative
T76414	DRUGINFO	D08CAB	D-aspartic acid	Investigative

T10147	TARGETID	T10147
T10147	FORMERID	TTDS00360
T10147	UNIPROID	PTPRS_HUMAN
T10147	TARGNAME	Protein-tyrosine phosphatase sigma (R-PTP-sigma)
T10147	GENENAME	PTPRS
T10147	TARGTYPE	Successful
T10147	SYNONYMS	Receptor-type tyrosine-protein phosphatase sigma; Receptor-type tyrosine-protein phosphatase S; R-PTP-S
T10147	FUNCTION	Binding to chondroitin sulfate and heparan sulfate proteoglycans has opposite effects on PTPRS oligomerization and regulation of neurite outgrowth. Contributes to the inhibition of neurite and axonal outgrowth by chondroitin sulfate proteoglycans, also after nerve transection. Plays a role in stimulating neurite outgrowth in response to the heparan sulfate proteoglycan GPC2. Required for normal brain development, especially for normal development of the pituitary gland and the olfactory bulb. Functions as tyrosine phosphatase. Mediates dephosphorylation of NTRK1, NTRK2 and NTRK3. Plays a role in down-regulation of signaling cascades that lead to the activation of Akt and MAP kinases. Down-regulates TLR9-mediated activation of NF-kappa-B, as well as production of TNF, interferon alpha and interferon beta. Cell surface receptor that binds to glycosaminoglycans, including chondroitin sulfate proteoglycans and heparan sulfate proteoglycan.
T10147	PDBSTRUC	4PBX; 4BPC; 2YD9; 2YD3; 2YD2
T10147	BIOCLASS	Phosphoric monoester hydrolase
T10147	ECNUMBER	EC 3.1.3.48
T10147	SEQUENCE	MAPTWGPGMVSVVGPMGLLVVLLVGGCAAEEPPRFIKEPKDQIGVSGGVASFVCQATGDPKPRVTWNKKGKKVNSQRFETIEFDESAGAVLRIQPLRTPRDENVYECVAQNSVGEITVHAKLTVLREDQLPSGFPNIDMGPQLKVVERTRTATMLCAASGNPDPEITWFKDFLPVDPSASNGRIKQLRSETFESTPIRGALQIESSEETDQGKYECVATNSAGVRYSSPANLYVRELREVRRVAPRFSILPMSHEIMPGGNVNITCVAVGSPMPYVKWMQGAEDLTPEDDMPVGRNVLELTDVKDSANYTCVAMSSLGVIEAVAQITVKSLPKAPGTPMVTENTATSITITWDSGNPDPVSYYVIEYKSKSQDGPYQIKEDITTTRYSIGGLSPNSEYEIWVSAVNSIGQGPPSESVVTRTGEQAPASAPRNVQARMLSATTMIVQWEEPVEPNGLIRGYRVYYTMEPEHPVGNWQKHNVDDSLLTTVGSLLEDETYTVRVLAFTSVGDGPLSDPIQVKTQQGVPGQPMNLRAEARSETSITLSWSPPRQESIIKYELLFREGDHGREVGRTFDPTTSYVVEDLKPNTEYAFRLAARSPQGLGAFTPVVRQRTLQSKPSAPPQDVKCVSVRSTAILVSWRPPPPETHNGALVGYSVRYRPLGSEDPEPKEVNGIPPTTTQILLEALEKWTQYRITTVAHTEVGPGPESSPVVVRTDEDVPSAPPRKVEAEALNATAIRVLWRSPAPGRQHGQIRGYQVHYVRMEGAEARGPPRIKDVMLADAQWETDDTAEYEMVITNLQPETAYSITVAAYTMKGDGARSKPKVVVTKGAVLGRPTLSVQQTPEGSLLARWEPPAGTAEDQVLGYRLQFGREDSTPLATLEFPPSEDRYTASGVHKGATYVFRLAARSRGGLGEEAAEVLSIPEDTPRGHPQILEAAGNASAGTVLLRWLPPVPAERNGAIVKYTVAVREAGALGPARETELPAAAEPGAENALTLQGLKPDTAYDLQVRAHTRRGPGPFSPPVRYRTFLRDQVSPKNFKVKMIMKTSVLLSWEFPDNYNSPTPYKIQYNGLTLDVDGRTTKKLITHLKPHTFYNFVLTNRGSSLGGLQQTVTAWTAFNLLNGKPSVAPKPDADGFIMVYLPDGQSPVPVQSYFIVMVPLRKSRGGQFLTPLGSPEDMDLEELIQDISRLQRRSLRHSRQLEVPRPYIAARFSVLPPTFHPGDQKQYGGFDNRGLEPGHRYVLFVLAVLQKSEPTFAASPFSDPFQLDNPDPQPIVDGEEGLIWVIGPVLAVVFIICIVIAILLYKNKPDSKRKDSEPRTKCLLNNADLAPHHPKDPVEMRRINFQTPDSGLRSPLREPGFHFESMLSHPPIPIADMAEHTERLKANDSLKLSQEYESIDPGQQFTWEHSNLEVNKPKNRYANVIAYDHSRVILQPIEGIMGSDYINANYVDGYRCQNAYIATQGPLPETFGDFWRMVWEQRSATIVMMTRLEEKSRIKCDQYWPNRGTETYGFIQVTLLDTIELATFCVRTFSLHKNGSSEKREVRQFQFTAWPDHGVPEYPTPFLAFLRRVKTCNPPDAGPIVVHCSAGVGRTGCFIVIDAMLERIKPEKTVDVYGHVTLMRSQRNYMVQTEDQYSFIHEALLEAVGCGNTEVPARSLYAYIQKLAQVEPGEHVTGMELEFKRLANSKAHTSRFISANLPCNKFKNRLVNIMPYESTRVCLQPIRGVEGSDYINASFIDGYRQQKAYIATQGPLAETTEDFWRMLWENNSTIVVMLTKLREMGREKCHQYWPAERSARYQYFVVDPMAEYNMPQYILREFKVTDARDGQSRTVRQFQFTDWPEQGVPKSGEGFIDFIGQVHKTKEQFGQDGPISVHCSAGVGRTGVFITLSIVLERMRYEGVVDIFQTVKMLRTQRPAMVQTEDEYQFCYQAALEYLGSFDHYAT
T10147	DRUGINFO	D00NNC	Etidronic acid	Approved
T10147	DRUGINFO	D0N4XG	Orthovanadate	Investigative

T59679	TARGETID	T59679
T59679	FORMERID	TTDS00107
T59679	UNIPROID	5HT4R_HUMAN
T59679	TARGNAME	5-HT 4 receptor (HTR4)
T59679	GENENAME	HTR4
T59679	TARGTYPE	Successful
T59679	SYNONYMS	Serotonin receptor 4; 5-hydroxytryptamine receptor 4; 5-HT4 receptor; 5-HT4; 5-HT-4
T59679	FUNCTION	The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen.
T59679	PDBSTRUC	5EM9
T59679	BIOCLASS	GPCR rhodopsin
T59679	SEQUENCE	MDKLDANVSSEEGFGSVEKVVLLTFLSTVILMAILGNLLVMVAVCWDRQLRKIKTNYFIVSLAFADLLVSVLVMPFGAIELVQDIWIYGEVFCLVRTSLDVLLTTASIFHLCCISLDRYYAICCQPLVYRNKMTPLRIALMLGGCWVIPTFISFLPIMQGWNNIGIIDLIEKRKFNQNSNSTYCVFMVNKPYAITCSVVAFYIPFLLMVLAYYRIYVTAKEHAHQIQMLQRAGASSESRPQSADQHSTHRMRTETKAAKTLCIIMGCFCLCWAPFFVTNIVDPFIDYTVPGQVWTAFLWLGYINSGLNPFLYAFLNKSFRRAFLIILCCDDERYRRPSILGQTVPCSTTTINGSTHVLRDAVECGGQWESQCHPPATSPLVAAQPSDT
T59679	DRUGINFO	D00XWD	Tegaserod	Approved
T59679	DRUGINFO	D04QSJ	R0-93877	Approved
T59679	DRUGINFO	D0BD8D	Cisapride	Approved
T59679	DRUGINFO	D0O2YE	HTF 919	Approved
T59679	DRUGINFO	D06PZN	Mosapride	Phase 4
T59679	DRUGINFO	D04MKJ	Renzapride	Phase 3
T59679	DRUGINFO	D01HVZ	TD-8954	Phase 2
T59679	DRUGINFO	D01MBV	SB-207266A	Phase 2
T59679	DRUGINFO	D02ORS	YKP-GI	Phase 2
T59679	DRUGINFO	D04GMY	TD-5108	Phase 2
T59679	DRUGINFO	D05BWH	PRX-3140	Phase 2
T59679	DRUGINFO	D06HCF	SPD-557	Phase 2
T59679	DRUGINFO	D07SKN	PF-885706	Phase 2
T59679	DRUGINFO	D0D7YA	DSP-6952	Phase 2
T59679	DRUGINFO	D0X2XF	Piboserod	Phase 2
T59679	DRUGINFO	D0Q8MI	Lintopride	Phase 2
T59679	DRUGINFO	D00ZGF	DA-6886	Phase 1
T59679	DRUGINFO	D02YKI	PF-04995274	Phase 1
T59679	DRUGINFO	D03MIN	M-0004	Phase 1
T59679	DRUGINFO	D0M9RI	SUVN-D4010	Phase 1
T59679	DRUGINFO	D0S6GY	SER-101	Phase 1
T59679	DRUGINFO	D01CDE	BIMU-1	Phase 1
T59679	DRUGINFO	D08HGY	Naronapride	Discontinued in Phase 2
T59679	DRUGINFO	D09ZQX	SL65.0155	Discontinued in Phase 2
T59679	DRUGINFO	D04DMQ	Fabesetron	Discontinued in Phase 2
T59679	DRUGINFO	D0K1SZ	Norcisapride	Discontinued in Phase 2
T59679	DRUGINFO	D0Y0SY	E-3620	Discontinued in Phase 2
T59679	DRUGINFO	D0U7VZ	TD-2749	Discontinued in Phase 1
T59679	DRUGINFO	D04GSA	DAU-6285	Terminated
T59679	DRUGINFO	D09BHA	LY-353433	Terminated
T59679	DRUGINFO	D0E8KS	SB 203186	Terminated
T59679	DRUGINFO	D0PN9E	SK-951	Terminated
T59679	DRUGINFO	D0ZG9N	SC-53116	Terminated
T59679	DRUGINFO	D00LWD	AF-3473	Investigative
T59679	DRUGINFO	D01EAG	MDDR 287569	Investigative
T59679	DRUGINFO	D01KMI	RS 116 0086	Investigative
T59679	DRUGINFO	D03KNI	GR 125487	Investigative
T59679	DRUGINFO	D06DMV	ER-21018	Investigative
T59679	DRUGINFO	D06HYB	ML-10302	Investigative
T59679	DRUGINFO	D07OSA	RS67506	Investigative
T59679	DRUGINFO	D07QMY	ML 10375	Investigative
T59679	DRUGINFO	D08JLW	GR-113808	Investigative
T59679	DRUGINFO	D08MVY	R-116712	Investigative
T59679	DRUGINFO	D0AK9V	VRX-03011	Investigative
T59679	DRUGINFO	D0B5MU	SB-207710	Investigative
T59679	DRUGINFO	D0F3XQ	RS 57639	Investigative
T59679	DRUGINFO	D0FE7A	RS 67333	Investigative
T59679	DRUGINFO	D0H1UY	RQ-00000010	Investigative
T59679	DRUGINFO	D0HA6Y	[11C]SB207145	Investigative
T59679	DRUGINFO	D0M5ZE	RS 100235	Investigative
T59679	DRUGINFO	D0N8EL	SB 204070	Investigative
T59679	DRUGINFO	D0O3PE	RO 116 1148	Investigative
T59679	DRUGINFO	D0R6UI	[123I]SB 207710	Investigative
T59679	DRUGINFO	D0TU7G	SUVN-1004028	Investigative
T59679	DRUGINFO	D0W8EP	SDZ-205-557	Investigative
T59679	DRUGINFO	D00JKB	SC-54750	Investigative
T59679	DRUGINFO	D03TPY	SC-52491	Investigative
T59679	DRUGINFO	D0AJ3C	(R)-zacopride	Investigative
T59679	DRUGINFO	D08OFG	BARETTIN	Investigative
T59679	DRUGINFO	D01KAX	1-((S)-2-aminopropyl)-1H-indazol-6-ol	Investigative
T59679	DRUGINFO	D09OYA	alpha-methyl-5-HT	Investigative
T59679	DRUGINFO	D0F6CD	SEROTONIN	Investigative
T59679	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T39716	TARGETID	T39716
T39716	FORMERID	TTDS00402
T39716	UNIPROID	SCN5A_HUMAN
T39716	TARGNAME	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
T39716	GENENAME	SCN5A
T39716	TARGTYPE	Successful
T39716	SYNONYMS	Voltage-gated sodium channel subunit alpha Nav1.5; Sodium channel protein type V subunit alpha; Sodium channel protein type 5 subunit alpha; Sodium channel protein cardiac muscle subunit alpha; HH1
T39716	FUNCTION	Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-resistant Na(+) channel isoform. This channel is responsible for the initial upstroke of the action potential. Channel inactivation is regulated by intracellular calcium levels. This protein mediates the voltage-dependent sodium ion permeability of excitable membranes.
T39716	PDBSTRUC	6MUD; 5DBR; 4OVN; 4JQ0; 4DJC
T39716	BIOCLASS	Voltage-gated ion channel
T39716	SEQUENCE	MANFLLPRGTSSFRRFTRESLAAIEKRMAEKQARGSTTLQESREGLPEEEAPRPQLDLQASKKLPDLYGNPPQELIGEPLEDLDPFYSTQKTFIVLNKGKTIFRFSATNALYVLSPFHPIRRAAVKILVHSLFNMLIMCTILTNCVFMAQHDPPPWTKYVEYTFTAIYTFESLVKILARGFCLHAFTFLRDPWNWLDFSVIIMAYTTEFVDLGNVSALRTFRVLRALKTISVISGLKTIVGALIQSVKKLADVMVLTVFCLSVFALIGLQLFMGNLRHKCVRNFTALNGTNGSVEADGLVWESLDLYLSDPENYLLKNGTSDVLLCGNSSDAGTCPEGYRCLKAGENPDHGYTSFDSFAWAFLALFRLMTQDCWERLYQQTLRSAGKIYMIFFMLVIFLGSFYLVNLILAVVAMAYEEQNQATIAETEEKEKRFQEAMEMLKKEHEALTIRGVDTVSRSSLEMSPLAPVNSHERRSKRRKRMSSGTEECGEDRLPKSDSEDGPRAMNHLSLTRGLSRTSMKPRSSRGSIFTFRRRDLGSEADFADDENSTAGESESHHTSLLVPWPLRRTSAQGQPSPGTSAPGHALHGKKNSTVDCNGVVSLLGAGDPEATSPGSHLLRPVMLEHPPDTTTPSEEPGGPQMLTSQAPCVDGFEEPGARQRALSAVSVLTSALEELEESRHKCPPCWNRLAQRYLIWECCPLWMSIKQGVKLVVMDPFTDLTITMCIVLNTLFMALEHYNMTSEFEEMLQVGNLVFTGIFTAEMTFKIIALDPYYYFQQGWNIFDSIIVILSLMELGLSRMSNLSVLRSFRLLRVFKLAKSWPTLNTLIKIIGNSVGALGNLTLVLAIIVFIFAVVGMQLFGKNYSELRDSDSGLLPRWHMMDFFHAFLIIFRILCGEWIETMWDCMEVSGQSLCLLVFLLVMVIGNLVVLNLFLALLLSSFSADNLTAPDEDREMNNLQLALARIQRGLRFVKRTTWDFCCGLLRQRPQKPAALAAQGQLPSCIATPYSPPPPETEKVPPTRKETRFEEGEQPGQGTPGDPEPVCVPIAVAESDTDDQEEDEENSLGTEEESSKQQESQPVSGGPEAPPDSRTWSQVSATASSEAEASASQADWRQQWKAEPQAPGCGETPEDSCSEGSTADMTNTAELLEQIPDLGQDVKDPEDCFTEGCVRRCPCCAVDTTQAPGKVWWRLRKTCYHIVEHSWFETFIIFMILLSSGALAFEDIYLEERKTIKVLLEYADKMFTYVFVLEMLLKWVAYGFKKYFTNAWCWLDFLIVDVSLVSLVANTLGFAEMGPIKSLRTLRALRPLRALSRFEGMRVVVNALVGAIPSIMNVLLVCLIFWLIFSIMGVNLFAGKFGRCINQTEGDLPLNYTIVNNKSQCESLNLTGELYWTKVKVNFDNVGAGYLALLQVATFKGWMDIMYAAVDSRGYEEQPQWEYNLYMYIYFVIFIIFGSFFTLNLFIGVIIDNFNQQKKKLGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPLNKYQGFIFDIVTKQAFDVTIMFLICLNMVTMMVETDDQSPEKINILAKINLLFVAIFTGECIVKLAALRHYYFTNSWNIFDFVVVILSIVGTVLSDIIQKYFFSPTLFRVIRLARIGRILRLIRGAKGIRTLLFALMMSLPALFNIGLLLFLVMFIYSIFGMANFAYVKWEAGIDDMFNFQTFANSMLCLFQITTSAGWDGLLSPILNTGPPYCDPTLPNSNGSRGDCGSPAVGILFFTTYIIISFLIVVNMYIAIILENFSVATEESTEPLSEDDFDMFYEIWEKFDPEATQFIEYSVLSDFADALSEPLRIAKPNQISLINMDLPMVSGDRIHCMDILFAFTKRVLGESGEMDALKIQMEEKFMAANPSKISYEPITTTLRRKHEEVSAMVIQRAFRRHLLQRSLKHASFLFRQQAGSGLSEEDAPEREGLIAYVMSENFSRPLGPPSSSSISSTSFPPSYDSVTRATSDNLQVRGSDYSHSEDLADFPPSPDRDRESIV
T39716	DRUGINFO	D04QLR	Dyclonine	Approved
T39716	DRUGINFO	D04VPA	Moricizine	Approved
T39716	DRUGINFO	D05EPM	Ethotoin	Approved
T39716	DRUGINFO	D06LYG	Prilocaine	Approved
T39716	DRUGINFO	D07RGW	Mephenytoin	Approved
T39716	DRUGINFO	D08MRN	Hexylcaine	Approved
T39716	DRUGINFO	D0J5YC	Fosphenytoin	Approved
T39716	DRUGINFO	D0K4CQ	Indecainide	Approved
T39716	DRUGINFO	D0M4YC	Disopyramide	Approved
T39716	DRUGINFO	D0P5GE	Dibucaine	Approved
T39716	DRUGINFO	D0Q2ES	Benzonatate	Approved
T39716	DRUGINFO	D0X0RI	Mexiletine	Approved
T39716	DRUGINFO	D0C7ET	Tetrodotoxin	Approved
T39716	DRUGINFO	D0N3ZJ	LOMERIZINE	Approved
T39716	DRUGINFO	D00XWB	F-15845	Phase 1
T39716	DRUGINFO	D03WBS	Aryl carboxamide derivative 3	Patented
T39716	DRUGINFO	D0UL0K	Dihydrobenzoxazine and tetrahydroquinoxaline sulfonamide derivative 1	Patented
T39716	DRUGINFO	D0M8WO	Aryl carboxamide derivative 1	Patented
T39716	DRUGINFO	D0OP5F	Aryl carboxamide derivative 2	Patented
T39716	DRUGINFO	D06PAZ	Encainide	Withdrawn from market
T39716	DRUGINFO	D08LDS	LUBELUZOLE	Discontinued in Preregistration
T39716	DRUGINFO	D04BQR	Acecainide	Discontinued in Phase 3
T39716	DRUGINFO	D0EC2K	SIPATRIGINE	Discontinued in Phase 2
T39716	DRUGINFO	D02NLI	PD-85639	Terminated
T39716	DRUGINFO	D01SAX	KC-12291	Investigative
T39716	DRUGINFO	D06GQO	N-Butyl-N'-(4-methyl-benzoyl)-guanidine	Investigative
T39716	DRUGINFO	D0O2RN	N-(4-Methyl-benzoyl)-N'-phenethyl-guanidine	Investigative
T39716	DRUGINFO	D01AGR	1-[5-(4-Chlorophenyl)-2-furoyl]piperazine	Investigative
T39716	DRUGINFO	D0A1MW	aconitine	Investigative
T39716	DRUGINFO	D0G9WE	batrachotoxin	Investigative
T39716	DRUGINFO	D0S4MN	veratridine	Investigative

T22095	TARGETID	T22095
T22095	FORMERID	TTDC00214
T22095	UNIPROID	IL17_HUMAN
T22095	TARGNAME	Interleukin-17 (IL17)
T22095	GENENAME	IL17A
T22095	TARGTYPE	Successful
T22095	SYNONYMS	Interleukin-17A; IL-17A; IL-17; Cytotoxic T-lymphocyte-associated antigen 8; Cytotoxic T lymphocyte-associated antigen 8; CTLA8; CTLA-8
T22095	FUNCTION	The heterodimer formed by IL17A and IL17F is a ligand for the heterodimeric complex formed by IL17RA and IL17RC. Involved in inducing stromal cells to produce proinflammatory and hematopoietic cytokines. Ligand for IL17RA and IL17RC.
T22095	PDBSTRUC	5VB9; 5NAN; 5N92; 5N7W; 5HI5
T22095	BIOCLASS	Cytokine: interleukin
T22095	SEQUENCE	MTPGKTSLVSLLLLLSLEAIVKAGITIPRNPGCPNSEDKNFPRTVMVNLNIHNRNTNTNPKRSSDYYNRSTSPWNLHRNEDPERYPSVIWEAKCRHLGCINADGNVDYHMNSVPIQQEILVLRREPPHCPNSFRLEKILVSVGCTCVTPIVHHVA
T22095	DRUGINFO	D08NMV	Ixekizumab	Approved
T22095	DRUGINFO	D05CEO	Brodalumab	Approved
T22095	DRUGINFO	D0WJ5M	Bimekizumab	Approved
T22095	DRUGINFO	D0T5TN	CJM112	Phase 2
T22095	DRUGINFO	D0A7NZ	CNTO-6785	Phase 2
T22095	DRUGINFO	D0OX5H	ABT-122	Phase 2
T22095	DRUGINFO	D00BPH	COVA322	Phase 1/2a
T22095	DRUGINFO	D04EJG	SHR-1314	Phase 1/2
T22095	DRUGINFO	D08YWY	SCH-900117	Phase 1
T22095	DRUGINFO	D04DQO	ABBV-257	Phase 1
T22095	DRUGINFO	D0B5UH	ALX-0761	Phase 1
T22095	DRUGINFO	D0J8JF	RG-4934	Discontinued in Phase 1
T22095	DRUGINFO	DFU4B0	RO7040547	Discontinued in Phase 1

T84703	TARGETID	T84703
T84703	FORMERID	TTDNR00649
T84703	UNIPROID	NTRK2_HUMAN
T84703	TARGNAME	BDNF/NT-3 growth factors receptor (TrkB)
T84703	GENENAME	NTRK2
T84703	TARGTYPE	Successful
T84703	SYNONYMS	Tropomyosin-related kinase B; TrkB tyrosine kinase; Trk-B; TRKB; Neurotrophic tyrosine kinase receptor type 2; GP145-TrkB
T84703	FUNCTION	Receptor for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin-4. Alternatively can also bind NTF3/neurotrophin-3 which is less efficient in activating the receptor but regulates neuron survival through NTRK2. Upon ligand-binding, undergoes homodimerization, autophosphorylation and activation. Recruits, phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades. Through SHC1, FRS2, SH2B1, SH2B2 activates the GRB2-Ras-MAPK cascade that regulates for instance neuronal differentiation including neurite outgrowth. Through the same effectors controls the Ras-PI3 kinase-AKT1 signaling cascade that mainly regulates growth and survival. Through PLCG1 and the downstream protein kinase C-regulated pathways controls synaptic plasticity. Thereby, plays a role in learning and memory by regulating both short term synaptic function and long-term potentiation. PLCG1 also leads to NF-Kappa-B activation and the transcription of genes involved in cell survival. Hence, it is able to suppress anoikis, the apoptosis resulting from loss of cell-matrix interactions. May also play a role in neutrophin-dependent calcium signaling in glial cells and mediate communication between neurons and glia. Receptor tyrosine kinase involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity.
T84703	PDBSTRUC	5MO9; 4AT5; 4AT4; 4AT3; 4ASZ
T84703	BIOCLASS	Kinase
T84703	ECNUMBER	EC 2.7.10.1
T84703	SEQUENCE	MSSWIRWHGPAMARLWGFCWLVVGFWRAAFACPTSCKCSASRIWCSDPSPGIVAFPRLEPNSVDPENITEIFIANQKRLEIINEDDVEAYVGLRNLTIVDSGLKFVAHKAFLKNSNLQHINFTRNKLTSLSRKHFRHLDLSELILVGNPFTCSCDIMWIKTLQEAKSSPDTQDLYCLNESSKNIPLANLQIPNCGLPSANLAAPNLTVEEGKSITLSCSVAGDPVPNMYWDVGNLVSKHMNETSHTQGSLRITNISSDDSGKQISCVAENLVGEDQDSVNLTVHFAPTITFLESPTSDHHWCIPFTVKGNPKPALQWFYNGAILNESKYICTKIHVTNHTEYHGCLQLDNPTHMNNGDYTLIAKNEYGKDEKQISAHFMGWPGIDDGANPNYPDVIYEDYGTAANDIGDTTNRSNEIPSTDVTDKTGREHLSVYAVVVIASVVGFCLLVMLFLLKLARHSKFGMKGPASVISNDDDSASPLHHISNGSNTPSSSEGGPDAVIIGMTKIPVIENPQYFGITNSQLKPDTFVQHIKRHNIVLKRELGEGAFGKVFLAECYNLCPEQDKILVAVKTLKDASDNARKDFHREAELLTNLQHEHIVKFYGVCVEGDPLIMVFEYMKHGDLNKFLRAHGPDAVLMAEGNPPTELTQSQMLHIAQQIAAGMVYLASQHFVHRDLATRNCLVGENLLVKIGDFGMSRDVYSTDYYRVGGHTMLPIRWMPPESIMYRKFTTESDVWSLGVVLWEIFTYGKQPWYQLSNNEVIECITQGRVLQRPRTCPQEVYELMLGCWQREPHMRKNIKGIHTLLQNLAKASPVYLDILG
T84703	DRUGINFO	D07TOK	Larotrectinib	Approved
T84703	DRUGINFO	D0O0LS	Entrectinib	Approved
T84703	DRUGINFO	D00DRL	MK-2461	Phase 1/2
T84703	DRUGINFO	D00DXC	Macrocycle derivative 13	Patented
T84703	DRUGINFO	D0NS6S	Cyclopenta[d]pyrimidine derivative 1	Patented
T84703	DRUGINFO	D00MGO	PMID28270021-Compound-WO2016054807Example1	Patented
T84703	DRUGINFO	D07RLB	PMID28270010-Compound-Figure24-b	Patented
T84703	DRUGINFO	D0AG2A	Pyrrolo[2,3-d]pyrimidine derivative 4	Patented
T84703	DRUGINFO	D0AU4G	3-amino-5-benzyl-substituted indazole derivative 1	Patented
T84703	DRUGINFO	D0J9ZG	PMID28270010-Compound-Figure5-1	Patented
T84703	DRUGINFO	D0M8VS	PMID28270021-Compound-WO2015042088Example4	Patented
T84703	DRUGINFO	D0T2OX	PMID28270010-Compound-Figure5-2	Patented
T84703	DRUGINFO	D0V5AG	PMID28270010-Compound-Figure5-3	Patented
T84703	DRUGINFO	D0Y1NH	Azaindazole amide derivative 1	Patented
T84703	DRUGINFO	D0D1HR	TrkB NAM	Investigative
T84703	DRUGINFO	D02RWC	GNF-5837	Investigative
T84703	DRUGINFO	D0MH1X	AZD1332	Investigative
T84703	DRUGINFO	D0K5UF	PMID24432909C8e	Investigative

T69619	TARGETID	T69619
T69619	FORMERID	TTDR00742
T69619	UNIPROID	AOC3_HUMAN
T69619	TARGNAME	Membrane copper amine oxidase (AOC3)
T69619	GENENAME	AOC3
T69619	TARGTYPE	Successful
T69619	SYNONYMS	Vascular adhesion protein-1; Vascular adhesion protein 1; VAP1; VAP-1; Semicarbazide-sensitive amine oxidase; SSAO; Membrane primary amine oxidase; HPAO; Copper amine oxidase
T69619	FUNCTION	Has semicarbazide-sensitive (SSAO) monoamine oxidase activity. May play a role in adipogenesis. Cell adhesion protein that participates in lymphocyte extravasation and recirculation by mediating the binding of lymphocytes to peripheral lymph node vascular endothelial cells in an L-selectin-independent fashion.
T69619	PDBSTRUC	4BTY; 4BTX; 4BTW; 3ALA; 2Y74
T69619	BIOCLASS	CH-NH(2) donor oxidoreductase
T69619	ECNUMBER	EC 1.4.3.21
T69619	SEQUENCE	MNQKTILVLLILAVITIFALVCVLLVGRGGDGGEPSQLPHCPSVSPSAQPWTHPGQSQLFADLSREELTAVMRFLTQRLGPGLVDAAQARPSDNCVFSVELQLPPKAAALAHLDRGSPPPAREALAIVFFGRQPQPNVSELVVGPLPHPSYMRDVTVERHGGPLPYHRRPVLFQEYLDIDQMIFNRELPQASGLLHHCCFYKHRGRNLVTMTTAPRGLQSGDRATWFGLYYNISGAGFFLHHVGLELLVNHKALDPARWTIQKVFYQGRYYDSLAQLEAQFEAGLVNVVLIPDNGTGGSWSLKSPVPPGPAPPLQFYPQGPRFSVQGSRVASSLWTFSFGLGAFSGPRIFDVRFQGERLVYEISLQEALAIYGGNSPAAMTTRYVDGGFGMGKYTTPLTRGVDCPYLATYVDWHFLLESQAPKTIRDAFCVFEQNQGLPLRRHHSDLYSHYFGGLAETVLVVRSMSTLLNYDYVWDTVFHPSGAIEIRFYATGYISSAFLFGATGKYGNQVSEHTLGTVHTHSAHFKVDLDVAGLENWVWAEDMVFVPMAVPWSPEHQLQRLQVTRKLLEMEEQAAFLVGSATPRYLYLASNHSNKWGHPRGYRIQMLSFAGEPLPQNSSMARGFSWERYQLAVTQRKEEEPSSSSVFNQNDPWAPTVDFSDFINNETIAGKDLVAWVTAGFLHIPHAEDIPNTVTVGNGVGFFLRPYNFFDEDPSFYSADSIYFRGDQDAGACEVNPLACLPQAAACAPDLPAFSHGGFSHN
T69619	DRUGINFO	D0K1XK	Hydralazine	Approved
T69619	DRUGINFO	D03SKR	Clonidine	Approved
T69619	DRUGINFO	D01VLT	ASP8232	Phase 2
T69619	DRUGINFO	D06GUG	BTT-1023	Phase 2
T69619	DRUGINFO	DM3J5I	BI 1467335	Discontinued in Phase 2
T69619	DRUGINFO	D05YHW	Vapaliximab	Terminated
T69619	DRUGINFO	D00LPZ	Vapill	Investigative
T69619	DRUGINFO	D00WKL	PSX-4206	Investigative
T69619	DRUGINFO	D0F8KR	RTU-1096	Investigative
T69619	DRUGINFO	D0I1TM	FP-1102	Investigative
T69619	DRUGINFO	D0M9YH	6-hydroxydopa quinone	Investigative
T69619	DRUGINFO	D0R0FU	PXS-4159	Investigative
T69619	DRUGINFO	D0V6DF	LJP-1207	Investigative

T40696	TARGETID	T40696
T40696	FORMERID	TTDS00083
T40696	UNIPROID	PARC_STAAS
T40696	TARGNAME	Staphylococcus Topoisomerase IV (Stap-coc parC)
T40696	GENENAME	Stap-coc parC
T40696	TARGTYPE	Successful
T40696	SYNONYMS	Topoisomerase IV subunit A; DNA topoisomerase 4 subunit A
T40696	FUNCTION	Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
T40696	PDBSTRUC	2INR
T40696	BIOCLASS	Topoisomerase GyrA ParC
T40696	ECNUMBER	EC 5.6.2.3
T40696	SEQUENCE	MSEIIQDLSLEDVLGDRFGRYSKYIIQERALPDVRDGLKPVQRRILYAMYSSGNTHDKNFRKSAKTVGDVIGQYHPHGDSSVYEAMVRLSQDWKLRHVLIEMHGNNGSIDNDPPAAMRYTEAKLSLLAEELLRDINKETVSFIPNYDDTTLEPMVLPSRFPNLLVNGSTGISAGYATDIPPHNLAEVIQATLKYIDNPDITVNQLMKYIKGPDFPTGGIIQGIDGIKKAYESGKGRIIVRSKVEEETLRNGRKQLIITEIPYEVNKSSLVKRIDELRADKKVDGIVEVRDETDRTGLRIAIELKKDVNSESIKNYLYKNSDLQISYNFNMVAISDGRPKLMGIRQIIDSYLNHQIEVVANRTKFELDNAEKRMHIVEGLIKALSILDKVIELIRSSKNKRDAKENLIEVYEFTEEQAEAIVMLQLYRLTNTDIVALEGEHKELEALIKQLRHILDNHDALLNVIKEELNEIKKKFKSERLSLIEAEIEEIKIDKEVMVPSEEVILSMTRHGYIKRTSIRSFNASGVEDIGLKDGDSLLKHQEVNTQDTVLVFTNKGRYLFIPVHKLADIRWKELGQHVSQIVPIEEDEVVINVFNEKDFNTDAFYVFATQNGMIKKSTVPLFKTTRFNKPLIATKVKENDDLISVMRFEKDQLITVITNKGMSLTYNTSELSDTGLRAAGVKSINLKAEDFVVVTEGVSENDTILMATQRGSLKRISFKILQVAKRAQRGITLLKELKKNPHRIVAAHVVTGEHSQYTLYSKSNEEHGLINDIHKSEQYTNGSFIVDTDDFGEVIDMYIS
T40696	DRUGINFO	D00TRV	Besifloxacin	Approved
T40696	DRUGINFO	D01IXD	Finafloxacin	Approved
T40696	DRUGINFO	D02RSN	Levofloxacin	Approved
T40696	DRUGINFO	D03CQE	Gatifloxacin	Approved
T40696	DRUGINFO	D04XDT	Delafloxacin Meglumine	Approved
T40696	DRUGINFO	D0K6GZ	Sparfloxacin	Approved
T40696	DRUGINFO	D0VR7W	Gemifloxacin	Approved
T40696	DRUGINFO	D0ZV0Z	Moxifloxacin	Approved
T40696	DRUGINFO	D0O1WX	Ciprofloxacin XR	Approved
T40696	DRUGINFO	D0X1HE	Ozenoxacin	Approved
T40696	DRUGINFO	D04ETV	Nemonaxacin	Phase 3
T40696	DRUGINFO	D0V9BU	ABT-492	Phase 3
T40696	DRUGINFO	D07MXF	Zabofloxacin	Phase 3
T40696	DRUGINFO	D0E9RP	WCK-2349	Phase 2
T40696	DRUGINFO	D07NTC	WCK-771	Phase 2
T40696	DRUGINFO	D0Q6GD	WCK-1152	Phase 1
T40696	DRUGINFO	D07AOY	Avarofloxacin	Discontinued in Phase 2
T40696	DRUGINFO	D0T3VO	DX-619	Discontinued in Phase 2
T40696	DRUGINFO	D0QW7D	DK-507k	Discontinued in Phase 1
T40696	DRUGINFO	D01ZLI	CBR-2092	Terminated
T40696	DRUGINFO	D08ZRP	NSFQ-105	Investigative
T40696	DRUGINFO	D0PC5N	Premafloxacin	Investigative

T73676	TARGETID	T73676
T73676	FORMERID	TTDC00246
T73676	UNIPROID	SV2A_HUMAN
T73676	TARGNAME	Synaptic vesicle glycoprotein 2A (SV2A)
T73676	GENENAME	SV2A
T73676	TARGTYPE	Successful
T73676	SYNONYMS	SV2A
T73676	FUNCTION	Plays a role in the control of regulated secretion in neural and endocrine cells, enhancing selectively low-frequency neurotransmission. Positively regulates vesicle fusion by maintaining the readily releasable pool of secretory vesicles.
T73676	PDBSTRUC	4V11
T73676	BIOCLASS	Major facilitator superfamily
T73676	SEQUENCE	MEEGFRDRAAFIRGAKDIAKEVKKHAAKKVVKGLDRVQDEYSRRSYSRFEEEDDDDDFPAPSDGYYRGEGTQDEEEGGASSDATEGHDEDDEIYEGEYQGIPRAESGGKGERMADGAPLAGVRGGLSDGEGPPGGRGEAQRRKEREELAQQYEAILRECGHGRFQWTLYFVLGLALMADGVEVFVVGFVLPSAEKDMCLSDSNKGMLGLIVYLGMMVGAFLWGGLADRLGRRQCLLISLSVNSVFAFFSSFVQGYGTFLFCRLLSGVGIGGSIPIVFSYFSEFLAQEKRGEHLSWLCMFWMIGGVYAAAMAWAIIPHYGWSFQMGSAYQFHSWRVFVLVCAFPSVFAIGALTTQPESPRFFLENGKHDEAWMVLKQVHDTNMRAKGHPERVFSVTHIKTIHQEDELIEIQSDTGTWYQRWGVRALSLGGQVWGNFLSCFGPEYRRITLMMMGVWFTMSFSYYGLTVWFPDMIRHLQAVDYASRTKVFPGERVEHVTFNFTLENQIHRGGQYFNDKFIGLRLKSVSFEDSLFEECYFEDVTSSNTFFRNCTFINTVFYNTDLFEYKFVNSRLINSTFLHNKEGCPLDVTGTGEGAYMVYFVSFLGTLAVLPGNIVSALLMDKIGRLRMLAGSSVMSCVSCFFLSFGNSESAMIALLCLFGGVSIASWNALDVLTVELYPSDKRTTAFGFLNALCKLAAVLGISIFTSFVGITKAAPILFASAALALGSSLALKLPETRGQVLQ
T73676	DRUGINFO	D0CT4D	Brivaracetam	Approved
T73676	DRUGINFO	D0E1XL	Levetiracetam	Approved
T73676	DRUGINFO	DCA5M2	Padsevonil	Phase 2/3
T73676	DRUGINFO	D0L9AJ	Seletracetam	Discontinued in Phase 3

T62206	TARGETID	T62206
T62206	FORMERID	TTDR01164
T62206	UNIPROID	PCSK9_HUMAN
T62206	TARGNAME	Proprotein convertase subtilisin/kexin type 9 (PCSK9)
T62206	GENENAME	PCSK9
T62206	TARGTYPE	Successful
T62206	SYNONYMS	Subtilisin/kexin-like protease PC9; Proprotein convertase 9; PC9; Neural apoptosis-regulated convertase 1; NARC1; NARC-1
T62206	FUNCTION	Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.
T62206	PDBSTRUC	6MV5; 6F5G; 6E4Z; 6E4Y; 5VLP
T62206	BIOCLASS	Peptidase
T62206	ECNUMBER	EC 3.4.21.-
T62206	SEQUENCE	MGTVSSRRSWWPLPLLLLLLLLLGPAGARAQEDEDGDYEELVLALRSEEDGLAEAPEHGTTATFHRCAKDPWRLPGTYVVVLKEETHLSQSERTARRLQAQAARRGYLTKILHVFHGLLPGFLVKMSGDLLELALKLPHVDYIEEDSSVFAQSIPWNLERITPPRYRADEYQPPDGGSLVEVYLLDTSIQSDHREIEGRVMVTDFENVPEEDGTRFHRQASKCDSHGTHLAGVVSGRDAGVAKGASMRSLRVLNCQGKGTVSGTLIGLEFIRKSQLVQPVGPLVVLLPLAGGYSRVLNAACQRLARAGVVLVTAAGNFRDDACLYSPASAPEVITVGATNAQDQPVTLGTLGTNFGRCVDLFAPGEDIIGASSDCSTCFVSQSGTSQAAAHVAGIAAMMLSAEPELTLAELRQRLIHFSAKDVINEAWFPEDQRVLTPNLVAALPPSTHGAGWQLFCRTVWSAHSGPTRMATAVARCAPDEELLSCSSFSRSGKRRGERMEAQGGKLVCRAHNAFGGEGVYAIARCCLLPQANCSVHTAPPAEASMGTRVHCHQQGHVLTGCSSHWEVEDLGTHKPPVLRPRGQPNQCVGHREASIHASCCHAPGLECKVKEHGIPAPQEQVTVACEEGWTLTGCSALPGTSHVLGAYAVDNTCVVRSRDVSTTGSTSEGAVTAVAICCRSRHLAQASQELQ
T62206	DRUGINFO	D00GNI	REGN-727	Approved
T62206	DRUGINFO	D8MNH5	Evolocumab	Approved
T62206	DRUGINFO	D03DJT	Bococizumab	Phase 3
T62206	DRUGINFO	D03FBV	PF-04950615	Phase 3
T62206	DRUGINFO	D0OW2S	AMG 145	Phase 3
T62206	DRUGINFO	D93UYR	LIB003	Phase 3
T62206	DRUGINFO	D07SKJ	LY3015014	Phase 2
T62206	DRUGINFO	D4DMS3	MK-0616	Phase 2
T62206	DRUGINFO	D05EBY	PCSK9 Adnectin	Phase 1
T62206	DRUGINFO	D0U3GA	SPC5001	Phase 1
T62206	DRUGINFO	D2EF8M	AZD0780	Phase 1
T62206	DRUGINFO	DL69MN	NNC-0385-0434	Phase 1
T62206	DRUGINFO	D0R0RW	1D05	Investigative

T51426	TARGETID	T51426
T51426	FORMERID	TTDS00272
T51426	UNIPROID	NR1H4_HUMAN
T51426	TARGNAME	Farnesoid X-activated receptor (FXR)
T51426	GENENAME	NR1H4
T51426	TARGTYPE	Successful
T51426	SYNONYMS	Retinoid X receptor-interacting protein 14; RXR-interacting protein 14; RIP14; Nuclear receptor subfamily 1 group H member 4; HRR1; Farnesol receptor HRR-1; FXR; Bile acid receptor; BAR
T51426	FUNCTION	Ligand-activated transcription factor. Receptor for bile acids (BAs) such as chenodeoxycholic acid (CDCA), lithocholic acid, deoxycholic acid (DCA) and allocholic acid (ACA). Plays a essential role in BA homeostasis through the regulation of genes involved in BA synthesis, conjugation and enterohepatic circulation. Also regulates lipid and glucose homeostasis and is involved innate immune response. The FXR-RXR heterodimer binds predominantly to farnesoid X receptor response elements (FXREs) containing two inverted repeats of the consensus sequence 5'-AGGTCA-3' in which the monomers are spaced by 1 nucleotide (IR-1) but also to tandem repeat DR1 sites with lower affinity, and can be activated by either FXR or RXR-specific ligands. It is proposed that monomeric nuclear receptors such as NR5A2/LRH-1 bound to coregulatory nuclear responsive element (NRE) halfsites located in close proximity to FXREs modulate transcriptional activity (By similarity). In the liver activates transcription of the corepressor NR0B2 thereby indirectly inhibiting CYP7A1 and CYP8B1 (involved in BA synthesis) implicating at least in part histone demethylase KDM1A resulting in epigenomic repression, and SLC10A1/NTCP (involved in hepatic uptake of conjugated BAs). Activates transcription of the repressor MAFG (involved in regulation of BA synthesis) (By similarity). Activates transcription of SLC27A5/BACS and BAAT (involved in BA conjugation), ABCB11/BSEP (involved in bile salt export) by directly recruiting histone methyltransferase CARM1, and ABCC2/MRP2 (involved in secretion of conjugated BAs) and ABCB4 (involved in secretion of phosphatidylcholine in the small intestine). Activates transcription of SLC27A5/BACS and BAAT (involved in BA conjugation), ABCB11/BSEP (involved in bile salt export) by directly recruiting histone methyltransferase CARM1, and ABCC2/MRP2 (involved in secretion of conjugated BAs) and ABCB4 (involved in secretion of phosphatidylcholine in the small intestine). In the intestine activates FGF19 expression and secretion leading to hepatic CYP7A1 repression. The function also involves the coordinated induction of hepatic KLB/beta-klotho expression (By similarity). Regulates transcription of liver UGT2B4 and SULT2A1 involved in BA detoxification; binding to the UGT2B4 promoter seems to imply a monomeric transactivation independent of RXRA. Modulates lipid homeostasis by activating liver NR0B2/SHP-mediated repression of SREBF1 (involved in de novo lipogenesis), expression of PLTP (involved in HDL formation), SCARB1 (involved in HDL hepatic uptake), APOE, APOC1, APOC4, PPARA (involved in beta-oxidation of fatty acids), VLDLR and SDC1 (involved in the hepatic uptake of LDL and IDL remnants), and inhibiting expression of MTTP (involved in VLDL assembly. Increases expression of APOC2 (promoting lipoprotein lipase activity implicated in triglyceride clearance). Transrepresses APOA1 involving a monomeric competition with NR2A1 for binding to a DR1 element. Also reduces triglyceride clearance by inhibiting expression of ANGPTL3 and APOC3 (both involved in inhibition of lipoprotein lipase). Involved in glucose homeostasis by modulating hepatic gluconeogenesis through activation of NR0B2/SHP-mediated repression of respective genes. Modulates glycogen synthesis (inducing phosphorylation of glycogen synthase kinase-3) (By similarity). Modulates glucose-stimulated insulin secretion and is involved in insulin resistance. Involved in intestinal innate immunity. Plays a role in protecting the distal small intestine against bacterial overgrowth and preservation of the epithelial barrier (By similarity). Down-regulates inflammatory cytokine expression in several types of immune cells including macrophages and mononuclear cells. Mediates trans-repression of TLR4-induced cytokine expression; the function seems to require its sumoylation and prevents N-CoR nuclear receptor corepressor clearance from target genes such as IL1B and NOS2. Involved in the TLR9-mediated protective mechanism in intestinal inflammation. Plays an anti-inflammatory role in liver inflammation; proposed to inhibit proinflammatory (but not antiapoptotic) NF-kappa-B signaling) (By similarity).
T51426	PDBSTRUC	6A60; 6A5Z; 6A5Y; 6A5X; 6A5W
T51426	BIOCLASS	Nuclear hormone receptor
T51426	SEQUENCE	MVMQFQGLENPIQISPHCSCTPSGFFMEMMSMKPAKGVLTEQVAGPLGQNLEVEPYSQYSNVQFPQVQPQISSSSYYSNLGFYPQQPEEWYSPGIYELRRMPAETLYQGETEVAEMPVTKKPRMGASAGRIKGDELCVVCGDRASGYHYNALTCEGCKGFFRRSITKNAVYKCKNGGNCVMDMYMRRKCQECRLRKCKEMGMLAECMYTGLLTEIQCKSKRLRKNVKQHADQTVNEDSEGRDLRQVTSTTKSCREKTELTPDQQTLLHFIMDSYNKQRMPQEITNKILKEEFSAEENFLILTEMATNHVQVLVEFTKKLPGFQTLDHEDQIALLKGSAVEAMFLRSAEIFNKKLPSGHSDLLEERIRNSGISDEYITPMFSFYKSIGELKMTQEEYALLTAIVILSPDRQYIKDREAVEKLQEPLLDVLQKLCKIHQPENPQHFACLLGRLTELRTFNHHHAEMLMSWRVNDHKFTPLLCEIWDVQ
T51426	DRUGINFO	D03ZTE	Chenodiol	Approved
T51426	DRUGINFO	D0G8BV	Guggulsterone	Approved
T51426	DRUGINFO	D0M4WA	obeticholic acid	Approved
T51426	DRUGINFO	DBND71	GS-9674	Phase 3
T51426	DRUGINFO	D04SLF	Bevacizumab + Trastuzumab	Phase 3
T51426	DRUGINFO	D00HTO	Apomine	Phase 2
T51426	DRUGINFO	D05EUR	LJN452	Phase 2
T51426	DRUGINFO	DBU2W3	EYP001	Phase 2
T51426	DRUGINFO	DM4K9V	EDP-305	Phase 2
T51426	DRUGINFO	DW9ML8	LMB763	Phase 2
T51426	DRUGINFO	DX56JK	MET409	Phase 2
T51426	DRUGINFO	D01SYU	Turofexorate isopropyl	Phase 1
T51426	DRUGINFO	D4PV0B	AGN-242266	Phase 1
T51426	DRUGINFO	D7LQJ8	PX-102	Phase 1
T51426	DRUGINFO	D01QNX	PMID29649907-Compound-15	Patented
T51426	DRUGINFO	D01XIW	PMID29649907-Compound-22	Patented
T51426	DRUGINFO	D02OJH	PMID29649907-Compound-26	Patented
T51426	DRUGINFO	D02RCY	PMID29649907-Compound-41	Patented
T51426	DRUGINFO	D03DZQ	PMID30259754-Compound-WAY-362450	Patented
T51426	DRUGINFO	D03IMJ	PMID29649907-Compound-20	Patented
T51426	DRUGINFO	D04QBY	PMID29649907-Compound-27	Patented
T51426	DRUGINFO	D05QJY	PMID29649907-Compound-9	Patented
T51426	DRUGINFO	D07EDS	PMID29649907-Compound-29	Patented
T51426	DRUGINFO	D07NTP	PMID29649907-Compound-14	Patented
T51426	DRUGINFO	D08MBD	PMID29649907-Compound-24	Patented
T51426	DRUGINFO	D08MYA	PMID29649907-Compound-31	Patented
T51426	DRUGINFO	D08ZAW	PMID29649907-Compound-12	Patented
T51426	DRUGINFO	D09FOM	PMID30259754-Compound-pyrrole[2,3-d]azepines	Patented
T51426	DRUGINFO	D0A4LL	PMID29649907-Compound-25	Patented
T51426	DRUGINFO	D0BN9E	PMID29649907-Compound-13	Patented
T51426	DRUGINFO	D0E0MH	PMID30259754-Compound-INT-767	Patented
T51426	DRUGINFO	D0E5ED	PMID29649907-Compound-5	Patented
T51426	DRUGINFO	D0EB7G	PMID29649907-Compound-3	Patented
T51426	DRUGINFO	D0F2OO	PMID29649907-Compound-18	Patented
T51426	DRUGINFO	D0F3SQ	PMID29649907-Compound-2	Patented
T51426	DRUGINFO	D0F5MF	PMID29649907-Compound-33	Patented
T51426	DRUGINFO	D0FC0B	PMID29649907-Compound-21	Patented
T51426	DRUGINFO	D0HR8Y	PMID29649907-Compound-10	Patented
T51426	DRUGINFO	D0J4CL	PMID29649907-Compound-19	Patented
T51426	DRUGINFO	D0JD0G	PMID29649907-Compound-4	Patented
T51426	DRUGINFO	D0K3UO	PMID29649907-Compound-39	Patented
T51426	DRUGINFO	D0KB4T	PMID29649907-Compound-44	Patented
T51426	DRUGINFO	D0N4PL	PMID29649907-Compound-36	Patented
T51426	DRUGINFO	D0OM2M	PMID29649907-Compound-28	Patented
T51426	DRUGINFO	D0R8GK	PMID30259754-Compound-Px-102	Patented
T51426	DRUGINFO	D0RL3M	PMID29649907-Compound-35	Patented
T51426	DRUGINFO	D0TH6M	PMID30259754-Compound-LY2562175	Patented
T51426	DRUGINFO	D0TL4F	PMID29649907-Compound-23	Patented
T51426	DRUGINFO	D0U0CC	PMID29649907-Compound-11	Patented
T51426	DRUGINFO	D0UW8Q	PMID29649907-Compound-32	Patented
T51426	DRUGINFO	D0WA9U	PMID29649907-Compound-1	Patented
T51426	DRUGINFO	D0WT7M	PMID29649907-Compound-38	Patented
T51426	DRUGINFO	D0Y0LI	PMID29649907-Compound-40	Patented
T51426	DRUGINFO	D0Y3NZ	PMID29649907-Compound-42	Patented
T51426	DRUGINFO	D0YK9Q	PMID29649907-Compound-37	Patented
T51426	DRUGINFO	D0Z0FP	PMID29649907-Compound-34	Patented
T51426	DRUGINFO	D0ZG3D	PMID29649907-Compound-30	Patented
T51426	DRUGINFO	D08LIB	PMID29649907-Compound-INT767	Patented
T51426	DRUGINFO	D0AA3P	PMID29649907-Compound-8	Patented
T51426	DRUGINFO	D03LFR	SB-756050	Discontinued in Phase 2
T51426	DRUGINFO	D08TKV	SKF-97426	Discontinued in Phase 2
T51426	DRUGINFO	DNZ96J	INT-767	Preclinical
T51426	DRUGINFO	D01GUG	12-O-deacetyl-12-epi-19-deoxy-21-hydroxyscalarin	Investigative
T51426	DRUGINFO	D01MYO	Fexaramine	Investigative
T51426	DRUGINFO	D0HH9N	cholesten	Investigative
T51426	DRUGINFO	D0IO8G	GW4065	Investigative
T51426	DRUGINFO	D0X4YY	1,1-bisphosphonate esters	Investigative
T51426	DRUGINFO	D01RNA	desmosterol	Investigative
T51426	DRUGINFO	D0K4GK	22R-hydroxycholesterol	Investigative
T51426	DRUGINFO	D0GR9O	AGN-34	Investigative

T98913	TARGETID	T98913
T98913	FORMERID	TTDS00411
T98913	UNIPROID	CSF3R_HUMAN
T98913	TARGNAME	Granulocyte colony-stimulating factor receptor (G-CSF-R)
T98913	GENENAME	CSF3R
T98913	TARGTYPE	Successful
T98913	SYNONYMS	c-fms; GCSFR; GCSF receptor; G-CSF receptor; Fms proto-oncogene; CD114
T98913	FUNCTION	Plays a crucial role in the proliferation, differientation and survival of cells along the neutrophilic lineage. In addition it may function in some adhesion or recognition events at the cell surface. Receptor for granulocyte colony-stimulating factor (CSF3), essential for granulocytic maturation.
T98913	PDBSTRUC	2D9Q; 1AZ7
T98913	BIOCLASS	Cytokine receptor
T98913	SEQUENCE	MARLGNCSLTWAALIILLLPGSLEECGHISVSAPIVHLGDPITASCIIKQNCSHLDPEPQILWRLGAELQPGGRQQRLSDGTQESIITLPHLNHTQAFLSCCLNWGNSLQILDQVELRAGYPPAIPHNLSCLMNLTTSSLICQWEPGPETHLPTSFTLKSFKSRGNCQTQGDSILDCVPKDGQSHCCIPRKHLLLYQNMGIWVQAENALGTSMSPQLCLDPMDVVKLEPPMLRTMDPSPEAAPPQAGCLQLCWEPWQPGLHINQKCELRHKPQRGEASWALVGPLPLEALQYELCGLLPATAYTLQIRCIRWPLPGHWSDWSPSLELRTTERAPTVRLDTWWRQRQLDPRTVQLFWKPVPLEEDSGRIQGYVVSWRPSGQAGAILPLCNTTELSCTFHLPSEAQEVALVAYNSAGTSRPTPVVFSESRGPALTRLHAMARDPHSLWVGWEPPNPWPQGYVIEWGLGPPSASNSNKTWRMEQNGRATGFLLKENIRPFQLYEIIVTPLYQDTMGPSQHVYAYSQEMAPSHAPELHLKHIGKTWAQLEWVPEPPELGKSPLTHYTIFWTNAQNQSFSAILNASSRGFVLHGLEPASLYHIHLMAASQAGATNSTVLTLMTLTPEGSELHIILGLFGLLLLLTCLCGTAWLCCSPNRKNPLWPSVPDPAHSSLGSWVPTIMEEDAFQLPGLGTPPITKLTVLEEDEKKPVPWESHNSSETCGLPTLVQTYVLQGDPRAVSTQPQSQSGTSDQVLYGQLLGSPTSPGPGHYLRCDSTQPLLAGLTPSPKSYENLWFQASPLGTLVTPAPSQEDDCVFGPLLNFPLLQGIRVHGMEALGSF
T98913	DRUGINFO	D09WDK	Tbo-Filgrastim	Approved
T98913	DRUGINFO	D0AT8C	Pegfilgrastim	Approved
T98913	DRUGINFO	D03ZAE	Peg-G-CSF	Phase 3
T98913	DRUGINFO	D01LRM	SBC-014	Phase 2
T98913	DRUGINFO	D03GRD	AX-200	Phase 2
T98913	DRUGINFO	D05ZXS	MAXY-G34	Phase 2
T98913	DRUGINFO	D08NDE	BLZ-945	Phase 2
T98913	DRUGINFO	D08YGY	MK-6302	Phase 1
T98913	DRUGINFO	D0W1YV	PLX-5622	Phase 1
T98913	DRUGINFO	D0I8DX	AMG 820	Phase 1
T98913	DRUGINFO	D07PSL	PLX7486	Phase 1
T98913	DRUGINFO	D0B6BQ	ZD-6003	Terminated
T98913	DRUGINFO	D00WSN	N-(2-morpholinophenyl)-5-nitrofuran-2-carboxamide	Investigative
T98913	DRUGINFO	D01QXW	CSL-324	Investigative
T98913	DRUGINFO	D02ILI	ZP-G-CSF	Investigative
T98913	DRUGINFO	D06CWM	AZD-7507	Investigative
T98913	DRUGINFO	D07CNF	G-CSF	Investigative
T98913	DRUGINFO	D0LD8U	TG-3003	Investigative
T98913	DRUGINFO	D0V4EX	AC-710	Investigative

T11843	TARGETID	T11843
T11843	FORMERID	TTDS00398
T11843	UNIPROID	VKOR1_HUMAN
T11843	TARGNAME	Vitamin K epoxide reductase complex 1 (VKORC1)
T11843	GENENAME	VKORC1
T11843	TARGTYPE	Successful
T11843	SYNONYMS	Vitamin K1 2,3-epoxide reductase subunit 1; VKORC1; VKOR; UNQ308/PRO351; MSTP576; MSTP134
T11843	FUNCTION	Involved invitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development.
T11843	BIOCLASS	Short-chain dehydrogenases reductase
T11843	ECNUMBER	EC 1.17.4.4
T11843	SEQUENCE	MGSTWGSPGWVRLALCLTGLVLSLYALHVKAARARDRDYRALCDVGTAISCSRVFSSRWGRGFGLVEHVLGQDSILNQSNSIFGCIFYTLQLLLGCLRTRWASVLMLLSSLVSLAGSVYLAWILFFVLYDFCIVCITTYAINVSLMWLSFRKVQEPQGKAKRH
T11843	DRUGINFO	D02TJS	Dicumarol	Approved
T11843	DRUGINFO	D05HFY	Acenocoumarol	Approved
T11843	DRUGINFO	D08FTG	Phenindione	Approved
T11843	DRUGINFO	D0E3OF	Warfarin	Approved
T11843	DRUGINFO	D0QV5T	Phenprocoumon	Approved
T11843	DRUGINFO	D07VIB	Tecarfarin	Phase 3

T56556	TARGETID	T56556
T56556	FORMERID	TTDS00528
T56556	UNIPROID	ABCG2_HUMAN
T56556	TARGNAME	ATP-binding cassette transporter G2 (ABCG2)
T56556	GENENAME	ABCG2
T56556	TARGTYPE	Successful
T56556	SYNONYMS	Urate exporter; Placenta-specific ATP-binding cassette transporter; Mitoxantrone resistance-associated protein; MXR; CDw338; CD338; Breast cancer resistance protein; BCRP1; BCRP; ABCP
T56556	FUNCTION	Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from the brain. Appears to play a major role in the multidrug resistance phenotype of several cancer cell lines. Implicated in the efflux of numerous drugs and xenobiotics: mitoxantrone, the photosensitizer pheophorbide, camptothecin, methotrexate, azidothymidine (AZT), and the anthracyclines daunorubicin and doxorubicin. High-capacity urate exporter functioning in both renal and extrarenal urate excretion.
T56556	PDBSTRUC	6HZM; 6HIJ; 6HCO; 6HBU; 6FFC
T56556	BIOCLASS	ABC transporter
T56556	SEQUENCE	MSSSNVEVFIPVSQGNTNGFPATASNDLKAFTEGAVLSFHNICYRVKLKSGFLPCRKPVEKEILSNINGIMKPGLNAILGPTGGGKSSLLDVLAARKDPSGLSGDVLINGAPRPANFKCNSGYVVQDDVVMGTLTVRENLQFSAALRLATTMTNHEKNERINRVIQELGLDKVADSKVGTQFIRGVSGGERKRTSIGMELITDPSILFLDEPTTGLDSSTANAVLLLLKRMSKQGRTIIFSIHQPRYSIFKLFDSLTLLASGRLMFHGPAQEALGYFESAGYHCEAYNNPADFFLDIINGDSTAVALNREEDFKATEIIEPSKQDKPLIEKLAEIYVNSSFYKETKAELHQLSGGEKKKKITVFKEISYTTSFCHQLRWVSKRSFKNLLGNPQASIAQIIVTVVLGLVIGAIYFGLKNDSTGIQNRAGVLFFLTTNQCFSSVSAVELFVVEKKLFIHEYISGYYRVSSYFLGKLLSDLLPMRMLPSIIFTCIVYFMLGLKPKADAFFVMMFTLMMVAYSASSMALAIAAGQSVVSVATLLMTICFVFMMIFSGLLVNLTTIASWLSWLQYFSIPRYGFTALQHNEFLGQNFCPGLNATGNNPCNYATCTGEEYLVKQGIDLSPWGLWKNHVALACMIVIFLTIAYLKLLFLKKYS
T56556	DRUGINFO	D02ZTJ	Sulfasalazine	Approved

T02318	TARGETID	T02318
T02318	FORMERID	TTDC00196
T02318	UNIPROID	TN13B_HUMAN
T02318	TARGNAME	B-cell-activating factor (TNFSF13B)
T02318	GENENAME	TNFSF13B
T02318	TARGTYPE	Successful
T02318	SYNONYMS	ZTNF4; UNQ401/PRO738; Tumor necrosis factor ligand superfamily member 13B; TNFSF20; TNF-and APOL-related leukocyte expressed ligand 1; TNF- and APOL-related leukocyte expressed ligand 1; TALL1; TALL-1; Dendritic cell-derived TNF-like molecule; CD257; BLyS; BAFF; B lymphocyte stimulator; B cell-activating factor
T02318	FUNCTION	TNFSF13/APRIL binds to the same 2 receptors. Together, they form a 2 ligands -2 receptors pathway involved in the stimulation of B- and T-cell function and the regulation of humoral immunity. A third B-cell specific BAFF-receptor (BAFFR/BR3) promotes the survival of mature B-cells and the B-cell response. Cytokine that binds to TNFRSF13B/TACI and TNFRSF17/BCMA.
T02318	PDBSTRUC	6FXN; 5Y9J; 4ZCH; 4V46; 3V56
T02318	BIOCLASS	Cytokine: tumor necrosis factor
T02318	SEQUENCE	MDDSTEREQSRLTSCLKKREEMKLKECVSILPRKESPSVRSSKDGKLLAATLLLALLSCCLTVVSFYQVAALQGDLASLRAELQGHHAEKLPAGAGAPKAGLEEAPAVTAGLKIFEPPAPGEGNSSQNSRNKRAVQGPEETVTQDCLQLIADSETPTIQKGSYTFVPWLLSFKRGSALEEKENKILVKETGYFFIYGQVLYTDKTYAMGHLIQRKKVHVFGDELSLVTLFRCIQNMPETLPNNSCYSAGIAKLEEGDELQLAIPRENAQISLDGDVTFFGALKLL
T02318	DRUGINFO	D05IQX	Belimumab	Approved
T02318	DRUGINFO	D0I5WJ	Blisibimod	Phase 3
T02318	DRUGINFO	D0U6UK	Tabalumab	Phase 3
T02318	DRUGINFO	DV2CR7	AMG 570	Phase 2
T02318	DRUGINFO	D0YA0N	BR3-Fc	Discontinued in Phase 2
T02318	DRUGINFO	D0T8YV	LymphoRad-131	Discontinued in Phase 1
T02318	DRUGINFO	D04IEK	Receptor-Fc fusion proteins	Investigative
T02318	DRUGINFO	D08AMH	1,4-Diethylene Dioxide	Investigative

T48945	TARGETID	T48945
T48945	FORMERID	TTDR00459
T48945	UNIPROID	TERT_HUMAN
T48945	TARGNAME	TERT messenger RNA (TERT mRNA)
T48945	GENENAME	TERT
T48945	TARGTYPE	Successful
T48945	SYNONYMS	Telomerase-associated protein 2 (mRNA); Telomerase catalytic subunit (mRNA); TRT (mRNA); TP2 (mRNA); TCS1 (mRNA); HEST2 (mRNA); EST2 (mRNA)
T48945	FUNCTION	Active in progenitor and cancer cells. Inactive, or very low activity, in normal somatic cells. Catalytic component of the teleromerase holoenzyme complex whose main activity is the elongation of telomeres by acting as a reverse transcriptase that adds simple sequence repeats to chromosome ends by copying a template sequence within the RNA component of the enzyme. Catalyzes the RNA-dependent extension of 3'-chromosomal termini with the 6-nucleotide telomeric repeat unit, 5'-TTAGGG-3'. The catalytic cycle involves primer binding, primer extension and release of product once the template boundary has been reached or nascent product translocation followed by further extension. More active on substrates containing 2 or 3 telomeric repeats. Telomerase activity is regulated by a number of factors including telomerase complex-associated proteins, chaperones and polypeptide modifiers. Modulates Wnt signaling. Plays important roles in aging and antiapoptosis. Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes.
T48945	PDBSTRUC	5UGW; 5MER; 5MEQ; 5MEP; 5MEO
T48945	BIOCLASS	mRNA target
T48945	ECNUMBER	EC 2.7.7.49
T48945	SEQUENCE	MPRAPRCRAVRSLLRSHYREVLPLATFVRRLGPQGWRLVQRGDPAAFRALVAQCLVCVPWDARPPPAAPSFRQVSCLKELVARVLQRLCERGAKNVLAFGFALLDGARGGPPEAFTTSVRSYLPNTVTDALRGSGAWGLLLRRVGDDVLVHLLARCALFVLVAPSCAYQVCGPPLYQLGAATQARPPPHASGPRRRLGCERAWNHSVREAGVPLGLPAPGARRRGGSASRSLPLPKRPRRGAAPEPERTPVGQGSWAHPGRTRGPSDRGFCVVSPARPAEEATSLEGALSGTRHSHPSVGRQHHAGPPSTSRPPRPWDTPCPPVYAETKHFLYSSGDKEQLRPSFLLSSLRPSLTGARRLVETIFLGSRPWMPGTPRRLPRLPQRYWQMRPLFLELLGNHAQCPYGVLLKTHCPLRAAVTPAAGVCAREKPQGSVAAPEEEDTDPRRLVQLLRQHSSPWQVYGFVRACLRRLVPPGLWGSRHNERRFLRNTKKFISLGKHAKLSLQELTWKMSVRDCAWLRRSPGVGCVPAAEHRLREEILAKFLHWLMSVYVVELLRSFFYVTETTFQKNRLFFYRKSVWSKLQSIGIRQHLKRVQLRELSEAEVRQHREARPALLTSRLRFIPKPDGLRPIVNMDYVVGARTFRREKRAERLTSRVKALFSVLNYERARRPGLLGASVLGLDDIHRAWRTFVLRVRAQDPPPELYFVKVDVTGAYDTIPQDRLTEVIASIIKPQNTYCVRRYAVVQKAAHGHVRKAFKSHVSTLTDLQPYMRQFVAHLQETSPLRDAVVIEQSSSLNEASSGLFDVFLRFMCHHAVRIRGKSYVQCQGIPQGSILSTLLCSLCYGDMENKLFAGIRRDGLLLRLVDDFLLVTPHLTHAKTFLRTLVRGVPEYGCVVNLRKTVVNFPVEDEALGGTAFVQMPAHGLFPWCGLLLDTRTLEVQSDYSSYARTSIRASLTFNRGFKAGRNMRRKLFGVLRLKCHSLFLDLQVNSLQTVCTNIYKILLLQAYRFHACVLQLPFHQQVWKNPTFFLRVISDTASLCYSILKAKNAGMSLGAKGAAGPLPSEAVQWLCHQAFLLKLTRHRVTYVPLLGSLRTAQTQLSRKLPGTTLTALEAAANPALPSDFKTILD
T48945	DRUGINFO	D07VLY	Doxorubicin	Approved
T48945	DRUGINFO	D05LEO	Fluorouracil	Approved
T48945	DRUGINFO	D00EWP	2,7-Bis(acetamido)anthraquinone	Investigative
T48945	DRUGINFO	D00FCF	2,7-Bis(cyclohexanecarbonamido)anthraquinone	Investigative
T48945	DRUGINFO	D00SLR	2,7-Bis[2-(isopropylamino)acetamido]anthraquinone	Investigative
T48945	DRUGINFO	D01AAD	NSC-745884	Investigative
T48945	DRUGINFO	D01BAK	2,7-Bis[3-(piperidino)propionamido]anthraquinone	Investigative
T48945	DRUGINFO	D01MWX	2,7-Bis(cyclopropanecarbonamido)anthraquinone	Investigative
T48945	DRUGINFO	D01TRI	2,7-Bis(phenylacetamido)anthraquinone	Investigative
T48945	DRUGINFO	D02CSC	NSC-745887	Investigative
T48945	DRUGINFO	D02ZIO	2,7-Bis[2-(butylamino)acetamido]anthraquinone	Investigative
T48945	DRUGINFO	D03SFB	2-Methyl-1(3)H-anthrasimidazole-6,11-dione	Investigative
T48945	DRUGINFO	D04KDW	2,7-Bis[3-(pyrrolidino)propionamido]anthraquinone	Investigative
T48945	DRUGINFO	D04LTV	2,3-Dimethylnaphtho[2,3-f]quinoxaline-7,12-dione	Investigative
T48945	DRUGINFO	D04SKW	2,7-Bis[3-(ethylamino)propionamido]anthraquinone	Investigative
T48945	DRUGINFO	D04STF	NSC-745798	Investigative
T48945	DRUGINFO	D05IBW	2,7-Bis(3-chloropropionamido)anthraquinone	Investigative
T48945	DRUGINFO	D05RCG	2,7-Bis[2-(piperazino)acetamido]anthraquinone	Investigative
T48945	DRUGINFO	D06GHM	2,7-Bis[3-(butylamino)propionamido]anthraquinone	Investigative
T48945	DRUGINFO	D06TSI	2,7-Bis[3-(propylamino)propionamido]anthraquinone	Investigative
T48945	DRUGINFO	D07DAX	2,7-Dinitroantraquinone	Investigative
T48945	DRUGINFO	D07SQW	LIVIDOMYCIN A	Investigative
T48945	DRUGINFO	D07ZRU	2,7-Bis(chloroacetamido)anthraquinone	Investigative
T48945	DRUGINFO	D08ZRW	Cantide + Cisplatin	Investigative
T48945	DRUGINFO	D09IJN	NSC-745886	Investigative
T48945	DRUGINFO	D09PHV	AURASPERONE A	Investigative
T48945	DRUGINFO	D09VFQ	NSC-745794	Investigative
T48945	DRUGINFO	D0B2YF	2,7-Bis[2-(piperidino)acetamido]anthraquinone	Investigative
T48945	DRUGINFO	D0C0TI	2,7-Bis[3-(piperazino)propionamido]anthraquinone	Investigative
T48945	DRUGINFO	D0C9HB	2,7-Bis[2-(isobutylamino)acetamido]anthraquinone	Investigative
T48945	DRUGINFO	D0D0OX	2,7-Bis(propionamido)anthraquinone	Investigative
T48945	DRUGINFO	D0E8ZH	HOE-33258	Investigative
T48945	DRUGINFO	D0EB4X	2-Butyl-1(3)H-anthra[1,2-d]imidazole-6,11-dione	Investigative
T48945	DRUGINFO	D0F5MA	2,7-Bis(4-chlorobutyramido)anthraquinone	Investigative
T48945	DRUGINFO	D0G6CD	2,7-Bis[2-(diethylamino)acetamido]anthraquinone	Investigative
T48945	DRUGINFO	D0G7NE	2,7-diaminoanthraquinone	Investigative
T48945	DRUGINFO	D0I0CU	NSC-745888	Investigative
T48945	DRUGINFO	D0I6UM	NSC-745885	Investigative
T48945	DRUGINFO	D0IT1P	2,7-Bis[2-(pyrrolidino)acetamido]anthraquinone	Investigative
T48945	DRUGINFO	D0JR3Y	2-Heptyl-1(3)H-anthra[1,2-d]imidazole-6,11-dione	Investigative
T48945	DRUGINFO	D0KQ6U	2,7-Bis(phenylpropionamido)anthraquinone	Investigative
T48945	DRUGINFO	D0M6GY	NSC-745799	Investigative
T48945	DRUGINFO	D0M7VY	NSC-745796	Investigative
T48945	DRUGINFO	D0P7KL	NSC-745795	Investigative
T48945	DRUGINFO	D0Q8SP	NSC-745797	Investigative
T48945	DRUGINFO	D0S6JQ	2,7-Bis(benzoamido)anthraquinone	Investigative
T48945	DRUGINFO	D0T1ZM	NSC-745883	Investigative
T48945	DRUGINFO	D0T2JN	2,7-Bis(cyclopentanecarbonamido)anthraquinone	Investigative
T48945	DRUGINFO	D0VR4A	2,7-Bis[2-(dimethylamino)acetamido]anthraquinone	Investigative
T48945	DRUGINFO	D0WJ5T	2,7-Bis(butyramido)anthraquinone	Investigative
T48945	DRUGINFO	D0X5LN	7,8,3',4'-tetrahydroxyflavone	Investigative
T48945	DRUGINFO	D0Y2RR	1,3-bis(3,4-dihydroxyphenyl)prop-2-en-1-one	Investigative
T48945	DRUGINFO	D0Y5IW	2,7-Bis[2-(ethylamino)acetamido]anthraquinone	Investigative
T48945	DRUGINFO	D0Z5AO	2,7-Bis[2-(propylamino)acetamido]anthraquinone	Investigative

T57011	TARGETID	T57011
T57011	FORMERID	TTDC00192
T57011	UNIPROID	ICAM1_HUMAN
T57011	TARGNAME	ICAM1 messenger RNA (ICAM1 mRNA)
T57011	GENENAME	ICAM1
T57011	TARGTYPE	Successful
T57011	SYNONYMS	Major group rhinovirus receptor (mRNA); Intercellular adhesion molecule 1 (mRNA); ICAM-1 (mRNA); CD54 (mRNA)
T57011	FUNCTION	During leukocyte trans-endothelial migration, ICAM1 engagement promotes the assembly of endothelial apical cups through ARHGEF26/SGEF and RHOG activation. ICAM proteins are ligands for the leukocyte adhesion protein LFA-1 (integrin alpha-L/beta-2).
T57011	PDBSTRUC	6EIT; 5MZA; 3TCX; 2OZ4; 1Z7Z
T57011	BIOCLASS	mRNA target
T57011	SEQUENCE	MAPSSPRPALPALLVLLGALFPGPGNAQTSVSPSKVILPRGGSVLVTCSTSCDQPKLLGIETPLPKKELLLPGNNRKVYELSNVQEDSQPMCYSNCPDGQSTAKTFLTVYWTPERVELAPLPSWQPVGKNLTLRCQVEGGAPRANLTVVLLRGEKELKREPAVGEPAEVTTTVLVRRDHHGANFSCRTELDLRPQGLELFENTSAPYQLQTFVLPATPPQLVSPRVLEVDTQGTVVCSLDGLFPVSEAQVHLALGDQRLNPTVTYGNDSFSAKASVSVTAEDEGTQRLTCAVILGNQSQETLQTVTIYSFPAPNVILTKPEVSEGTEVTVKCEAHPRAKVTLNGVPAQPLGPRAQLLLKATPEDNGRSFSCSATLEVAGQLIHKNQTRELRVLYGPRLDERDCPGNWTWPENSQQTPMCQAWGNPLPELKCLKDGTFPLPIGESVTVTRDLEGTYLCRARSTQGEVTRKVTVNVLSPRYEIVIITVVAAAVIMGTAGLSTYLYNRQRKIKKYRLQQAQKGTPMKPNTQATPP
T57011	DRUGINFO	D00OTT	ISIS 1570	Approved
T57011	DRUGINFO	D0P9BT	Alicaforsen	Phase 3
T57011	DRUGINFO	D0M0UV	INXC-ICAM1	Terminated
T57011	DRUGINFO	D00FAL	ISIS 11159	Investigative
T57011	DRUGINFO	D02TKV	ISIS 3224	Investigative
T57011	DRUGINFO	D02ZMH	ISIS 1931	Investigative
T57011	DRUGINFO	D03YAG	PIPERROLEIN B	Investigative
T57011	DRUGINFO	D06SDT	ISIS 2974	Investigative
T57011	DRUGINFO	D0H0FG	Dehydropipernonaline	Investigative
T57011	DRUGINFO	D0J1FW	ISIS 3067	Investigative
T57011	DRUGINFO	D0K7HI	ISIS 11665	Investigative
T57011	DRUGINFO	D0S2UZ	PIPERNONALINE	Investigative
T57011	DRUGINFO	D0V8KH	ISIS 11158	Investigative
T57011	DRUGINFO	D0ZH9W	Pellitorin	Investigative
T57011	DRUGINFO	D07XCA	A-286982	Investigative

T92494	TARGETID	T92494
T92494	UNIPROID	EF2K_HUMAN
T92494	TARGNAME	Eukaryotic elongation factor 2 kinase (eEF-2K)
T92494	GENENAME	EEF2K
T92494	TARGTYPE	Successful
T92494	SYNONYMS	eEF-2K; eEF-2 kinase; Calcium/calmodulin-dependent eukaryotic elongation factor 2 kinase
T92494	FUNCTION	Threonine kinase that regulates protein synthesis by controlling the rate of peptide chain elongation. Upon activation by a variety of upstream kinases including AMPK or TRPM7, phosphorylates the elongation factor EEF2 at a single site, renders it unable to bind ribosomes and thus inactive. In turn, the rate of protein synthesis is reduced.
T92494	PDBSTRUC	5KS5; 5J8H
T92494	BIOCLASS	Kinase
T92494	ECNUMBER	EC 2.7.11.20
T92494	SEQUENCE	MADEDLIFRLEGVDGGQSPRAGHDGDSDGDSDDEEGYFICPITDDPSSNQNVNSKVNKYYSNLTKSERYSSSGSPANSFHFKEAWKHAIQKAKHMPDPWAEFHLEDIATERATRHRYNAVTGEWLDDEVLIKMASQPFGRGAMRECFRTKKLSNFLHAQQWKGASNYVAKRYIEPVDRDVYFEDVRLQMEAKLWGEEYNRHKPPKQVDIMQMCIIELKDRPGKPLFHLEHYIEGKYIKYNSNSGFVRDDNIRLTPQAFSHFTFERSGHQLIVVDIQGVGDLYTDPQIHTETGTDFGDGNLGVRGMALFFYSHACNRICESMGLAPFDLSPRERDAVNQNTKLLQSAKTILRGTEEKCGSPQVRTLSGSRPPLLRPLSENSGDENMSDVTFDSLPSSPSSATPHSQKLDHLHWPVFSDLDNMASRDHDHLDNHRESENSGDSGYPSEKRGELDDPEPREHGHSYSNRKYESDEDSLGSSGRVCVEKWNLLNSSRLHLPRASAVALEVQRLNALDLEKKIGKSILGKVHLAMVRYHEGGRFCEKGEEWDQESAVFHLEHAANLGELEAIVGLGLMYSQLPHHILADVSLKETEENKTKGFDYLLKAAEAGDRQSMILVARAFDSGQNLSPDRCQDWLEALHWYNTALEMTDCDEGGEYDGMQDEPRYMMLAREAEMLFTGGYGLEKDPQRSGDLYTQAAEAAMEAMKGRLANQYYQKAEEAWAQMEE
T92494	DRUGINFO	D08CDI	Lapatinib	Approved

T15023	TARGETID	T15023
T15023	FORMERID	TTDC00183
T15023	UNIPROID	NRP1_HUMAN
T15023	TARGNAME	Neuropilin-1 (NRP1)
T15023	GENENAME	NRP1
T15023	TARGTYPE	Successful
T15023	SYNONYMS	Vascular endothelial cell growth factor 165 receptor; VEGF165R; Platelet-derived endothelial cell growth factor receptor; NRP; Membrane-bound; CD304
T15023	FUNCTION	It mediates the chemorepulsant activity of semaphorins. It binds to semaphorin 3A, The PLGF-2 isoform of PGF, The VEGF165 isoform of VEGFA and VEGFB. Coexpression with KDR results in increased VEGF165 binding to KDR as well as increased chemotaxis. Regulate VEGF-induced angiogenesis. Binding to VEGFA initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development. The membrane-bound isoform 1 is a receptor involved in the development of the cardiovascular system, in angiogenesis, in the formation of certain neuronal circuits and in organogenesis outside the nervous system.
T15023	PDBSTRUC	6FMF; 6FMC; 5L73; 5JHK; 5JGQ
T15023	BIOCLASS	Neuropilin and tolloid-like
T15023	SEQUENCE	MERGLPLLCAVLALVLAPAGAFRNDKCGDTIKIESPGYLTSPGYPHSYHPSEKCEWLIQAPDPYQRIMINFNPHFDLEDRDCKYDYVEVFDGENENGHFRGKFCGKIAPPPVVSSGPFLFIKFVSDYETHGAGFSIRYEIFKRGPECSQNYTTPSGVIKSPGFPEKYPNSLECTYIVFVPKMSEIILEFESFDLEPDSNPPGGMFCRYDRLEIWDGFPDVGPHIGRYCGQKTPGRIRSSSGILSMVFYTDSAIAKEGFSANYSVLQSSVSEDFKCMEALGMESGEIHSDQITASSQYSTNWSAERSRLNYPENGWTPGEDSYREWIQVDLGLLRFVTAVGTQGAISKETKKKYYVKTYKIDVSSNGEDWITIKEGNKPVLFQGNTNPTDVVVAVFPKPLITRFVRIKPATWETGISMRFEVYGCKITDYPCSGMLGMVSGLISDSQITSSNQGDRNWMPENIRLVTSRSGWALPPAPHSYINEWLQIDLGEEKIVRGIIIQGGKHRENKVFMRKFKIGYSNNGSDWKMIMDDSKRKAKSFEGNNNYDTPELRTFPALSTRFIRIYPERATHGGLGLRMELLGCEVEAPTAGPTTPNGNLVDECDDDQANCHSGTGDDFQLTGGTTVLATEKPTVIDSTIQSEFPTYGFNCEFGWGSHKTFCHWEHDNHVQLKWSVLTSKTGPIQDHTGDGNFIYSQADENQKGKVARLVSPVVYSQNSAHCMTFWYHMSGSHVGTLRVKLRYQKPEEYDQLVWMAIGHQGDHWKEGRVLLHKSLKLYQVIFEGEIGKGNLGGIAVDDISINNHISQEDCAKPADLDKKNPEIKIDETGSTPGYEGEGEGDKNISRKPGNVLKTLDPILITIIAMSALGVLLGAVCGVVLYCACWHNGMSERNLSALENYNFELVDGVKLKKDKLNTQSTYSEA
T15023	DRUGINFO	D0UF9W	Pegaptanib	Approved
T15023	DRUGINFO	D0YH8F	RG7347	Phase 1
T15023	DRUGINFO	D4JV0H	ASP1948	Phase 1
T15023	DRUGINFO	D0GD5G	H-KPPR-OH	Investigative

T64795	TARGETID	T64795
T64795	FORMERID	TTDS00161
T64795	UNIPROID	CAC1G_HUMAN
T64795	TARGNAME	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
T64795	GENENAME	CACNA1G
T64795	TARGTYPE	Successful
T64795	SYNONYMS	Voltage-gated calcium channel alpha subunit Cav3.1; Voltage-dependent T-type calcium channel; NBR13; Cav3.1c; CACNA1G
T64795	FUNCTION	Voltage-sensitive calcium channels (vscc) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release and gene expression.
T64795	BIOCLASS	Voltage-gated ion channel
T64795	SEQUENCE	MDEEEDGAGAEESGQPRSFMRLNDLSGAGGRPGPGSAEKDPGSADSEAEGLPYPALAPVVFFYLSQDSRPRSWCLRTVCNPWFERISMLVILLNCVTLGMFRPCEDIACDSQRCRILQAFDDFIFAFFAVEMVVKMVALGIFGKKCYLGDTWNRLDFFIVIAGMLEYSLDLQNVSFSAVRTVRVLRPLRAINRVPSMRILVTLLLDTLPMLGNVLLLCFFVFFIFGIVGVQLWAGLLRNRCFLPENFSLPLSVDLERYYQTENEDESPFICSQPRENGMRSCRSVPTLRGDGGGGPPCGLDYEAYNSSSNTTCVNWNQYYTNCSAGEHNPFKGAINFDNIGYAWIAIFQVITLEGWVDIMYFVMDAHSFYNFIYFILLIIVGSFFMINLCLVVIATQFSETKQRESQLMREQRVRFLSNASTLASFSEPGSCYEELLKYLVYILRKAARRLAQVSRAAGVRVGLLSSPAPLGGQETQPSSSCSRSHRRLSVHHLVHHHHHHHHHYHLGNGTLRAPRASPEIQDRDANGSRRLMLPPPSTPALSGAPPGGAESVHSFYHADCHLEPVRCQAPPPRSPSEASGRTVGSGKVYPTVHTSPPPETLKEKALVEVAASSGPPTLTSLNIPPGPYSSMHKLLETQSTGACQSSCKISSPCLKADSGACGPDSCPYCARAGAGEVELADREMPDSDSEAVYEFTQDAQHSDLRDPHSRRQRSLGPDAEPSSVLAFWRLICDTFRKIVDSKYFGRGIMIAILVNTLSMGIEYHEQPEELTNALEISNIVFTSLFALEMLLKLLVYGPFGYIKNPYNIFDGVIVVISVWEIVGQQGGGLSVLRTFRLMRVLKLVRFLPALQRQLVVLMKTMDNVATFCMLLMLFIFIFSILGMHLFGCKFASERDGDTLPDRKNFDSLLWAIVTVFQILTQEDWNKVLYNGMASTSSWAALYFIALMTFGNYVLFNLLVAILVEGFQAEEISKREDASGQLSCIQLPVDSQGGDANKSESEPDFFSPSLDGDGDRKKCLALVSLGEHPELRKSLLPPLIIHTAATPMSLPKSTSTGLGEALGPASRRTSSSGSAEPGAAHEMKSPPSARSSPHSPWSAASSWTSRRSSRNSLGRAPSLKRRSPSGERRSLLSGEGQESQDEEESSEEERASPAGSDHRHRGSLEREAKSSFDLPDTLQVPGLHRTASGRGSASEHQDCNGKSASGRLARALRPDDPPLDGDDADDEGNLSKGERVRAWIRARLPACCLERDSWSAYIFPPQSRFRLLCHRIITHKMFDHVVLVIIFLNCITIAMERPKIDPHSAERIFLTLSNYIFTAVFLAEMTVKVVALGWCFGEQAYLRSSWNVLDGLLVLISVIDILVSMVSDSGTKILGMLRVLRLLRTLRPLRVISRAQGLKLVVETLMSSLKPIGNIVVICCAFFIIFGILGVQLFKGKFFVCQGEDTRNITNKSDCAEASYRWVRHKYNFDNLGQALMSLFVLASKDGWVDIMYDGLDAVGVDQQPIMNHNPWMLLYFISFLLIVAFFVLNMFVGVVVENFHKCRQHQEEEEARRREEKRLRRLEKKRRNLMLDDVIASGSSASAASEAQCKPYYSDYSRFRLLVHHLCTSHYLDLFITGVIGLNVVTMAMEHYQQPQILDEALKICNYIFTVIFVLESVFKLVAFGFRRFFQDRWNQLDLAIVLLSIMGITLEEIEVNASLPINPTIIRIMRVLRIARVLKLLKMAVGMRALLDTVMQALPQVGNLGLLFMLLFFIFAALGVELFGDLECDETHPCEGLGRHATFRNFGMAFLTLFRVSTGDNWNGIMKDTLRDCDQESTCYNTVISPIYFVSFVLTAQFVLVNVVIAVLMKHLEESNKEAKEEAELEAELELEMKTLSPQPHSPLGSPFLWPGVEGPDSPDSPKPGALHPAAHARSASHFSLEHPTDRQLFDTISLLIQGSLEWELKLMDELAGPGGQPSAFPSAPSLGGSDPQIPLAEMEALSLTSEIVSEPSCSLALTDDSLPDDMHTLLLSALESNMQPHPTELPGPDLLTVRKSGVSRTHSLPNDSYMCRHGSTAEGPLGHRGWGLPKAQSGSVLSVHSQPADTSYILQLPKDAPHLLQPHSAPTWGTIPKLPPPGRSPLAQRPLRRQAAIRTDSLDVQGLGSREDLLAEVSGPSPPLARAYSFWGQSSTQAQQHSRSHSKISKHMTPPAPCPGPEPNWGKGPPETRSSLELDTELSWISGDLLPPGGQEEPPSPRDLKKCYSVEAQSCQRRPTSWLDEQRRHSIAVSCLDSGSQPHLGTDPSNLGGQPLGGPGSRPKKKLSPPSITIDPPESQGPRTPPSPGICLRRRAPSSDSKDPLASGPPDSMAASPSPKKDVLSLSGLSSDPADLDP
T64795	DRUGINFO	D08EOD	Methsuximide	Approved
T64795	DRUGINFO	D09JBP	Paramethadione	Approved
T64795	DRUGINFO	D0CQ0Z	Penfluridol	Approved
T64795	DRUGINFO	D0Q4XQ	Ethosuximide	Approved
T64795	DRUGINFO	D0R0FE	Verapamil	Approved
T64795	DRUGINFO	D0U4VT	Trimethadione	Approved
T64795	DRUGINFO	D07CMN	PD-200390	Phase 2
T64795	DRUGINFO	D0L3JI	NGD 94-1	Phase 1
T64795	DRUGINFO	D02DDI	KYS-05064	Investigative
T64795	DRUGINFO	D03HCT	KKHT-10608	Investigative
T64795	DRUGINFO	D04CUL	KKHT-10613	Investigative
T64795	DRUGINFO	D05MYH	KYS-05065	Investigative
T64795	DRUGINFO	D06EPZ	KKHT-20718	Investigative
T64795	DRUGINFO	D06FWY	KYS-05070	Investigative
T64795	DRUGINFO	D06ORM	KYS-05055	Investigative
T64795	DRUGINFO	D08MKF	Nickel chloride	Investigative
T64795	DRUGINFO	D09QCD	KYS-05056	Investigative
T64795	DRUGINFO	D0A4DR	Alpha-methyl-alpha-phenylsuccinimide (MPS)	Investigative
T64795	DRUGINFO	D0JO8Q	KYS-05071	Investigative
T64795	DRUGINFO	D0K9NK	KKHT-20818	Investigative
T64795	DRUGINFO	D0QM9Y	KKHT-20918	Investigative
T64795	DRUGINFO	D0R5FO	KYS-05057	Investigative
T64795	DRUGINFO	D0V3NI	KYS-05074	Investigative
T64795	DRUGINFO	D0V9CG	KKHT-10318	Investigative
T64795	DRUGINFO	D0X3HB	KKHT-10609	Investigative
T64795	DRUGINFO	D0Y4WI	KKHT-11018	Investigative
T64795	DRUGINFO	D0Z4JL	KKHT-10618	Investigative
T64795	DRUGINFO	D02DUO	KYS-05001	Investigative
T64795	DRUGINFO	D02SSG	KYS-05077	Investigative
T64795	DRUGINFO	D06UAX	KYS-05080	Investigative
T64795	DRUGINFO	D07UBR	Cis-N,5-dibenzyl-6-oxomorpholine-3-carboxamide	Investigative
T64795	DRUGINFO	D0K5RX	KYS-05050	Investigative
T64795	DRUGINFO	D0M2EZ	KYS-05042	Investigative
T64795	DRUGINFO	D0N5RQ	KYS-05041	Investigative
T64795	DRUGINFO	D0R6PX	(-)-(R)-efonidipine	Investigative
T64795	DRUGINFO	D0S5QB	KYS-05040	Investigative
T64795	DRUGINFO	D0X7VM	KYS-05090	Investigative
T64795	DRUGINFO	D09PWJ	ML218	Investigative

T69485	TARGETID	T69485
T69485	FORMERID	TTDR01056
T69485	UNIPROID	OX2R_HUMAN
T69485	TARGNAME	Orexin receptor type 2 (HCRTR2)
T69485	GENENAME	HCRTR2
T69485	TARGTYPE	Successful
T69485	SYNONYMS	Ox2r; Ox2-R; Ox-2-R; Orexin-2 receptor; Hypocretin receptor type 2; HFGANP
T69485	FUNCTION	Triggers an increase in cytoplasmic Ca(2+) levels in response to orexin-A binding. Nonselective, high-affinity receptor for both orexin-A and orexin-B neuropeptides.
T69485	PDBSTRUC	5WS3; 5WQC; 4S0V
T69485	BIOCLASS	GPCR rhodopsin
T69485	SEQUENCE	MSGTKLEDSPPCRNWSSASELNETQEPFLNPTDYDDEEFLRYLWREYLHPKEYEWVLIAGYIIVFVVALIGNVLVCVAVWKNHHMRTVTNYFIVNLSLADVLVTITCLPATLVVDITETWFFGQSLCKVIPYLQTVSVSVSVLTLSCIALDRWYAICHPLMFKSTAKRARNSIVIIWIVSCIIMIPQAIVMECSTVFPGLANKTTLFTVCDERWGGEIYPKMYHICFFLVTYMAPLCLMVLAYLQIFRKLWCRQIPGTSSVVQRKWKPLQPVSQPRGPGQPTKSRMSAVAAEIKQIRARRKTARMLMIVLLVFAICYLPISILNVLKRVFGMFAHTEDRETVYAWFTFSHWLVYANSAANPIIYNFLSGKFREEFKAAFSCCCLGVHHRQEDRLTRGRTSTESRKSLTTQISNFDNISKLSEQVVLTSISTLPAANGAGPLQNW
T69485	DRUGINFO	D00OVU	Suvorexant	Approved
T69485	DRUGINFO	D08SCL	MK-3697	Phase 2
T69485	DRUGINFO	D0FK6O	MIN-202	Phase 2
T69485	DRUGINFO	DZ35AP	TAK-861	Phase 2
T69485	DRUGINFO	DZ2PC5	TAK-925	Phase 1
T69485	DRUGINFO	D00VEM	1,2-diamino cyclopentane-based derivative 25	Patented
T69485	DRUGINFO	D01NWU	1,2-diamino cyclopentane-based derivative 5	Patented
T69485	DRUGINFO	D02CCF	1,2-diamino cyclopentane-based derivative 20	Patented
T69485	DRUGINFO	D02LWJ	1,2-diamino cyclopentane-based derivative 15	Patented
T69485	DRUGINFO	D03JAZ	1,2-diamino cyclopentane-based derivative 13	Patented
T69485	DRUGINFO	D04DCO	1,2-diamino cyclopentane-based derivative 9	Patented
T69485	DRUGINFO	D04JLF	1,2-diamino cyclopentane-based derivative 8	Patented
T69485	DRUGINFO	D05PMY	1,2-diamino cyclopentane-based derivative 26	Patented
T69485	DRUGINFO	D05QWJ	1,2-diamino cyclopentane-based derivative 2	Patented
T69485	DRUGINFO	D05WDQ	1,2-diamino cyclopentane-based derivative 12	Patented
T69485	DRUGINFO	D06NRQ	1,2-diamino cyclopentane-based derivative 18	Patented
T69485	DRUGINFO	D06OTA	1,2-diamino cyclopentane-based derivative 29	Patented
T69485	DRUGINFO	D08KYM	1,2-diamino cyclopentane-based derivative 22	Patented
T69485	DRUGINFO	D08ZRN	1,2-diamino cyclopentane-based derivative 27	Patented
T69485	DRUGINFO	D09XLY	1,2-diamino cyclopentane-based derivative 31	Patented
T69485	DRUGINFO	D0AL3I	1,2-diamino cyclopentane-based derivative 16	Patented
T69485	DRUGINFO	D0C6GE	1,2-diamino cyclopentane-based derivative 21	Patented
T69485	DRUGINFO	D0CG0D	1,2-diamino cyclopentane-based derivative 33	Patented
T69485	DRUGINFO	D0DO4J	1,2-diamino cyclopentane-based derivative 11	Patented
T69485	DRUGINFO	D0EG3N	1,2-diamino cyclopentane-based derivative 34	Patented
T69485	DRUGINFO	D0FI1W	1,2-diamino cyclopentane-based derivative 10	Patented
T69485	DRUGINFO	D0J4YW	1,2-diamino cyclopentane-based derivative 24	Patented
T69485	DRUGINFO	D0L0YA	1,2-diamino cyclopentane-based derivative 19	Patented
T69485	DRUGINFO	D0NX4W	1,2-diamino cyclopentane-based derivative 14	Patented
T69485	DRUGINFO	D0P8AX	1,2-diamino cyclopentane-based derivative 23	Patented
T69485	DRUGINFO	D0S4UG	1,2-diamino cyclopentane-based derivative 32	Patented
T69485	DRUGINFO	D0U7VC	1,2-diamino cyclopentane-based derivative 7	Patented
T69485	DRUGINFO	D0U9WX	1,2-diamino cyclopentane-based derivative 30	Patented
T69485	DRUGINFO	D0VE3H	1,2-diamino cyclopentane-based derivative 17	Patented
T69485	DRUGINFO	D0VR1K	1,2-diamino cyclopentane-based derivative 3	Patented
T69485	DRUGINFO	D0WX1B	1,2-diamino cyclopentane-based derivative 1	Patented
T69485	DRUGINFO	D0YI3Z	1,2-diamino cyclopentane-based derivative 4	Patented
T69485	DRUGINFO	D0ZC1O	1,2-diamino cyclopentane-based derivative 6	Patented
T69485	DRUGINFO	D01SUL	JNJ-10397049	Investigative
T69485	DRUGINFO	D02MDC	EMPA	Investigative
T69485	DRUGINFO	D0U0TS	TCS-OX2-29	Investigative
T69485	DRUGINFO	D08MXD	[3H]SB-674042	Investigative
T69485	DRUGINFO	D0J3PJ	SB-408124	Investigative
T69485	DRUGINFO	D0MY0E	orexin-B	Investigative
T69485	DRUGINFO	D0R4BT	PMID15261275C1	Investigative
T69485	DRUGINFO	D0UZ4J	SB-334867	Investigative

T84040	TARGETID	T84040
T84040	FORMERID	TTDS00465
T84040	UNIPROID	TRPA1_HUMAN
T84040	TARGNAME	Transformation-sensitive protein p120 (TRPA1)
T84040	GENENAME	TRPA1
T84040	TARGTYPE	Successful
T84040	SYNONYMS	TRPA1; Ankyrin-like with transmembrane domains protein 1; ANKTM1
T84040	FUNCTION	Receptor-activated non-selective cation channel involved in detection of pain and possibly also in cold perception and inner ear function. Has a central role in the pain response to endogenous inflammatory mediators and to a diverse array of volatile irritants, such as mustard oil, garlic and acrolein, an irritant from tears gas and vehicule exhaust fumes. Acts also as a ionotropic cannabinoid receptor by being activated by delta(9)- tetrahydrocannabinol (THC), the psychoactive component of marijuana. Not involved in menthol sensation. May be a component for the mechanosensitive transduction channel of hair cells in inner ear, thereby participating in the perception of sounds. Probably operated by a phosphatidylinositol second messenger system.
T84040	PDBSTRUC	3J9P
T84040	BIOCLASS	Transient receptor potential catioin channel
T84040	SEQUENCE	MKRSLRKMWRPGEKKEPQGVVYEDVPDDTEDFKESLKVVFEGSAYGLQNFNKQKKLKRCDDMDTFFLHYAAAEGQIELMEKITRDSSLEVLHEMDDYGNTPLHCAVEKNQIESVKFLLSRGANPNLRNFNMMAPLHIAVQGMNNEVMKVLLEHRTIDVNLEGENGNTAVIIACTTNNSEALQILLKKGAKPCKSNKWGCFPIHQAAFSGSKECMEIILRFGEEHGYSRQLHINFMNNGKATPLHLAVQNGDLEMIKMCLDNGAQIDPVEKGRCTAIHFAATQGATEIVKLMISSYSGSVDIVNTTDGCHETMLHRASLFDHHELADYLISVGADINKIDSEGRSPLILATASASWNIVNLLLSKGAQVDIKDNFGRNFLHLTVQQPYGLKNLRPEFMQMQQIKELVMDEDNDGCTPLHYACRQGGPGSVNNLLGFNVSIHSKSKDKKSPLHFAASYGRINTCQRLLQDISDTRLLNEGDLHGMTPLHLAAKNGHDKVVQLLLKKGALFLSDHNGWTALHHASMGGYTQTMKVILDTNLKCTDRLDEDGNTALHFAAREGHAKAVALLLSHNADIVLNKQQASFLHLALHNKRKEVVLTIIRSKRWDECLKIFSHNSPGNKCPITEMIEYLPECMKVLLDFCMLHSTEDKSCRDYYIEYNFKYLQCPLEFTKKTPTQDVIYEPLTALNAMVQNNRIELLNHPVCKEYLLMKWLAYGFRAHMMNLGSYCLGLIPMTILVVNIKPGMAFNSTGIINETSDHSEILDTTNSYLIKTCMILVFLSSIFGYCKEAGQIFQQKRNYFMDISNVLEWIIYTTGIIFVLPLFVEIPAHLQWQCGAIAVYFYWMNFLLYLQRFENCGIFIVMLEVILKTLLRSTVVFIFLLLAFGLSFYILLNLQDPFSSPLLSIIQTFSMMLGDINYRESFLEPYLRNELAHPVLSFAQLVSFTIFVPIVLMNLLIGLAVGDIAEVQKHASLKRIAMQVELHTSLEKKLPLWFLRKVDQKSTIVYPNKPRSGGMLFHIFCFLFCTGEIRQEIPNADKSLEMEILKQKYRLKDLTFLLEKQHELIKLIIQKMEIISETEDDDSHCSFQDRFKKEQMEQRNSRWNTVLRAVKAKTHHLEP
T84040	DRUGINFO	D04CSZ	Menthol	Approved
T84040	DRUGINFO	D40GBC	LY3526318	Phase 2
T84040	DRUGINFO	D0I3QJ	HX-100	Phase 1
T84040	DRUGINFO	D01RUO	morphanthridine	Investigative
T84040	DRUGINFO	D02XOP	2-methyl-1-(thiophen-2-yl)pent-1-en-3-one oxime	Investigative
T84040	DRUGINFO	D03LVI	AMG-2504	Investigative
T84040	DRUGINFO	D04NOT	bromoacetone	Investigative
T84040	DRUGINFO	D04PKE	2-methyl-1-(pyridin-4-yl)pent-1-en-3-one oxime	Investigative
T84040	DRUGINFO	D05CRM	AMG-9090	Investigative
T84040	DRUGINFO	D05DTN	4-oxo-nonenal	Investigative
T84040	DRUGINFO	D06IOP	2-methyl-1-(thiophen-3-yl)pent-1-en-3-one oxime	Investigative
T84040	DRUGINFO	D06OLJ	AMG-7160	Investigative
T84040	DRUGINFO	D07FLG	dibutyl phthalate	Investigative
T84040	DRUGINFO	D07HHD	resolvin D2	Investigative
T84040	DRUGINFO	D07LNY	prostaglandin A2	Investigative
T84040	DRUGINFO	D07PNM	methyl isocyanate	Investigative
T84040	DRUGINFO	D08MUZ	2-pentenal	Investigative
T84040	DRUGINFO	D09SVQ	dibenzoxazepine	Investigative
T84040	DRUGINFO	D0C7WN	acetaldehyde	Investigative
T84040	DRUGINFO	D0G4GB	omega-chloroacetophenone	Investigative
T84040	DRUGINFO	D0I0AA	acrolein	Investigative
T84040	DRUGINFO	D0I0BV	1'-acetoxychavicol acetate	Investigative
T84040	DRUGINFO	D0J0BV	TCS 5861528	Investigative
T84040	DRUGINFO	D0J2UJ	chloropicrin	Investigative
T84040	DRUGINFO	D0K4ZR	oleocanthal	Investigative
T84040	DRUGINFO	D0K6RG	benzyl bromide	Investigative
T84040	DRUGINFO	D0MZ7C	isovelleral	Investigative
T84040	DRUGINFO	D0N3CZ	super cinnamaldehyde	Investigative
T84040	DRUGINFO	D0O3FC	AMG-5445	Investigative
T84040	DRUGINFO	D0S2GF	chlorobenzylidene malononitrile	Investigative
T84040	DRUGINFO	D0T1YY	3-Methyl-4-phenylbut-3-en-2-one oxime	Investigative
T84040	DRUGINFO	D0T3NP	methyl p-hydroxybenzoate	Investigative
T84040	DRUGINFO	D0U4VL	artepillin C	Investigative
T84040	DRUGINFO	D0U9UF	A-967079	Investigative
T84040	DRUGINFO	D0UD7H	1,6-hexamethylene diisocyanate	Investigative
T84040	DRUGINFO	D0V6OH	MTSEA	Investigative
T84040	DRUGINFO	D0V8DH	PF-4840154	Investigative
T84040	DRUGINFO	D0Y1YR	gingerol	Investigative
T84040	DRUGINFO	D0YI4T	2-methyl-1-(pyridin-3-yl)pent-1-en-3-one oxime	Investigative
T84040	DRUGINFO	D0Z0AA	methyl salicylate	Investigative
T84040	DRUGINFO	D01KEE	Formaldehyde	Investigative
T84040	DRUGINFO	D04ULU	icilin	Investigative
T84040	DRUGINFO	D09CSB	crotylaldehyde	Investigative
T84040	DRUGINFO	D0G4CI	methylglyoxal	Investigative
T84040	DRUGINFO	D0PJ3M	cinnamaldehyde	Investigative
T84040	DRUGINFO	D0P0KG	[3H]resolvin D1	Investigative
T84040	DRUGINFO	D08DQL	NPPB	Investigative

T69563	TARGETID	T69563
T69563	FORMERID	TTDI02094
T69563	UNIPROID	IDHC_HUMAN
T69563	TARGNAME	Oxalosuccinate decarboxylase (IDH1)
T69563	GENENAME	IDH1
T69563	TARGTYPE	Successful
T69563	SYNONYMS	PICD; NADP(+)-specific ICDH; Isocitrate dehydrogenase [NADP] cytoplasmic; IDP; IDH; Cytosolic NADP-isocitrate dehydrogenase
T69563	FUNCTION	Catalyses the NADPH-dependent reduction of alpha-ketoglutarate to R(-)-2-hydroxyglutarate (2HG).
T69563	PDBSTRUC	6BL2; 6BL1; 6BL0; 6BKZ; 6BKY
T69563	BIOCLASS	Short-chain dehydrogenases reductase
T69563	ECNUMBER	EC 1.1.1.42
T69563	SEQUENCE	MSKKISGGSVVEMQGDEMTRIIWELIKEKLIFPYVELDLHSYDLGIENRDATNDQVTKDAAEAIKKHNVGVKCATITPDEKRVEEFKLKQMWKSPNGTIRNILGGTVFREAIICKNIPRLVSGWVKPIIIGRHAYGDQYRATDFVVPGPGKVEITYTPSDGTQKVTYLVHNFEEGGGVAMGMYNQDKSIEDFAHSSFQMALSKGWPLYLSTKNTILKKYDGRFKDIFQEIYDKQYKSQFEAQKIWYEHRLIDDMVAQAMKSEGGFIWACKNYDGDVQSDSVAQGYGSLGMMTSVLVCPDGKTVEAEAAHGTVTRHYRMYQKGQETSTNPIASIFAWTRGLAHRAKLDNNKELAFFANALEEVSIETIEAGFMTKDLAACIKGLPNVQRSDYLNTFEFMDKLGENLKIKLAQAKL
T69563	DRUGINFO	D07DCG	Ivosidenib	Approved
T69563	DRUGINFO	D07VYP	Olutasidenib	Approved
T69563	DRUGINFO	D0RZ9V	IDH305	Phase 1
T69563	DRUGINFO	D6AHO2	LY3410738	Phase 1

T16688	TARGETID	T16688
T16688	FORMERID	TTDS00466
T16688	UNIPROID	DGAT1_HUMAN
T16688	TARGNAME	Diacylglycerol acyltransferase 1 (DGAT1)
T16688	GENENAME	DGAT1
T16688	TARGTYPE	Successful
T16688	SYNONYMS	Retinol O-fatty-acyltransferase; Diglyceride acyltransferase; Diacylglycerol O-acyltransferase 1; DGAT; Acyl-CoA retinol O-fatty-acyltransferase; ARAT; AGRP1; ACAT-related gene product 1
T16688	FUNCTION	Catalyzes the terminal and only committed step in triacylglycerol synthesis by using diacylglycerol and fatty acyl CoA as substrates. In contrast to DGAT2 it is not essential for survival. May be involved in VLDL (very low density lipoprotein) assembly. In liver, plays a role in esterifying exogenous fatty acids to glycerol. Functions as the major acyl-CoA retinol acyltransferase (ARAT) in the skin, where it acts to maintain retinoid homeostasis and prevent retinoid toxicity leading to skin and hair disorders.
T16688	BIOCLASS	Acyltransferase
T16688	ECNUMBER	EC 2.3.1.20
T16688	SEQUENCE	MGDRGSSRRRRTGSRPSSHGGGGPAAAEEEVRDAAAGPDVGAAGDAPAPAPNKDGDAGVGSGHWELRCHRLQDSLFSSDSGFSNYRGILNWCVVMLILSNARLFLENLIKYGILVDPIQVVSLFLKDPYSWPAPCLVIAANVFAVAAFQVEKRLAVGALTEQAGLLLHVANLATILCFPAAVVLLVESITPVGSLLALMAHTILFLKLFSYRDVNSWCRRARAKAASAGKKASSAAAPHTVSYPDNLTYRDLYYFLFAPTLCYELNFPRSPRIRKRFLLRRILEMLFFTQLQVGLIQQWMVPTIQNSMKPFKDMDYSRIIERLLKLAVPNHLIWLIFFYWLFHSCLNAVAELMQFGDREFYRDWWNSESVTYFWQNWNIPVHKWCIRHFYKPMLRRGSSKWMARTGVFLASAFFHEYLVSVPLRMFRLWAFTGMMAQIPLAWFVGRFFQGNYGNAAVWLSLIIGQPIAVLMYVHDYYVLNYEAPAAEA
T16688	DRUGINFO	D07MGA	Hesperetin	Approved
T16688	DRUGINFO	D0F1CE	LCQ908	Phase 3
T16688	DRUGINFO	D0EY0A	AZD7687	Phase 1
T16688	DRUGINFO	D0M4HL	P-7435	Phase 1
T16688	DRUGINFO	D01DHT	Azole derivative 7	Patented
T16688	DRUGINFO	D02CTG	Carbamide derivative 3	Patented
T16688	DRUGINFO	D02NRD	T863	Patented
T16688	DRUGINFO	D04EFQ	Benzamide derivative 19	Patented
T16688	DRUGINFO	D04QGW	Lactam derivative 5	Patented
T16688	DRUGINFO	D05REP	Pyridine-carboximide derivative 2	Patented
T16688	DRUGINFO	D08UCB	PMID25470667-Compound-BAY744113	Patented
T16688	DRUGINFO	D0A8SI	Lactam derivative 4	Patented
T16688	DRUGINFO	D0F6VD	Lactam derivative 1	Patented
T16688	DRUGINFO	D0H2WY	Pyrazine carboxamide derivative 1	Patented
T16688	DRUGINFO	D0H9RP	Lactam derivative 3	Patented
T16688	DRUGINFO	D0MX3Y	PMID25470667-Compound-AZD3988	Patented
T16688	DRUGINFO	D0N0WE	amidepsines	Patented
T16688	DRUGINFO	D0OT8R	Pyridine-carboximide derivative 1	Patented
T16688	DRUGINFO	D0QT3C	Azole derivative 6	Patented
T16688	DRUGINFO	D0U0MZ	Lactam derivative 2	Patented
T16688	DRUGINFO	D0UY7A	Pyridine-amide derivative 1	Patented
T16688	DRUGINFO	D0WR6N	Pyrazolo[1,5-a]pyrimidine derivative 28	Patented
T16688	DRUGINFO	D0XT7O	Pyrazolo[1,5-a]pyrimidine derivative 29	Patented
T16688	DRUGINFO	D0Z7VF	PMID25470667-Compound-PF-04620110	Patented
T16688	DRUGINFO	D0L5DV	PMID25470667-Compound-Figure4-1A	Patented
T16688	DRUGINFO	D0U5NY	JTT-553	Discontinued in Phase 1
T16688	DRUGINFO	D0Z2QR	DS-7250	Discontinued in Phase 1
T16688	DRUGINFO	D0M0NT	PF-04620110	Terminated

T54644	TARGETID	T54644
T54644	FORMERID	TTDS00413
T54644	UNIPROID	CAC1H_HUMAN
T54644	TARGNAME	Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)
T54644	GENENAME	CACNA1H
T54644	TARGTYPE	Successful
T54644	SYNONYMS	Voltage-gated calcium channel subunit alpha Cav3.2; Voltage-dependent T-type calcium channel subunit alpha-1H; Low-voltage-activated calcium channel alpha1 3.2 subunit
T54644	FUNCTION	Voltage-sensitive calcium channel that gives rise to T-type calcium currents. T-type calcium channels belong to the "low-voltage activated (LVA)" group. A particularity of this type of channel is an opening at quite negative potentials, and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle (Probable). They may also be involved in the modulation of firing patterns of neurons. In the adrenal zona glomerulosa, participates in the signaling pathway leading to aldosterone production in response to either AGT/angiotensin II, or hyperkalemia.
T54644	BIOCLASS	Voltage-gated ion channel
T54644	SEQUENCE	MTEGARAADEVRVPLGAPPPGPAALVGASPESPGAPGREAERGSELGVSPSESPAAERGAELGADEEQRVPYPALAATVFFCLGQTTRPRSWCLRLVCNPWFEHVSMLVIMLNCVTLGMFRPCEDVECGSERCNILEAFDAFIFAFFAVEMVIKMVALGLFGQKCYLGDTWNRLDFFIVVAGMMEYSLDGHNVSLSAIRTVRVLRPLRAINRVPSMRILVTLLLDTLPMLGNVLLLCFFVFFIFGIVGVQLWAGLLRNRCFLDSAFVRNNNLTFLRPYYQTEEGEENPFICSSRRDNGMQKCSHIPGRRELRMPCTLGWEAYTQPQAEGVGAARNACINWNQYYNVCRSGDSNPHNGAINFDNIGYAWIAIFQVITLEGWVDIMYYVMDAHSFYNFIYFILLIIVGSFFMINLCLVVIATQFSETKQRESQLMREQRARHLSNDSTLASFSEPGSCYEELLKYVGHIFRKVKRRSLRLYARWQSRWRKKVDPSAVQGQGPGHRQRRAGRHTASVHHLVYHHHHHHHHHYHFSHGSPRRPGPEPGACDTRLVRAGAPPSPPSPGRGPPDAESVHSIYHADCHIEGPQERARVAHAAATAAASLRLATGLGTMNYPTILPSGVGSGKGSTSPGPKGKWAGGPPGTGGHGPLSLNSPDPYEKIPHVVGEHGLGQAPGHLSGLSVPCPLPSPPAGTLTCELKSCPYCTRALEDPEGELSGSESGDSDGRGVYEFTQDVRHGDRWDPTRPPRATDTPGPGPGSPQRRAQQRAAPGEPGWMGRLWVTFSGKLRRIVDSKYFSRGIMMAILVNTLSMGVEYHEQPEELTNALEISNIVFTSMFALEMLLKLLACGPLGYIRNPYNIFDGIIVVISVWEIVGQADGGLSVLRTFRLLRVLKLVRFLPALRRQLVVLVKTMDNVATFCTLLMLFIFIFSILGMHLFGCKFSLKTDTGDTVPDRKNFDSLLWAIVTVFQILTQEDWNVVLYNGMASTSSWAALYFVALMTFGNYVLFNLLVAILVEGFQAEGDANRSDTDEDKTSVHFEEDFHKLRELQTTELKMCSLAVTPNGHLEGRGSLSPPLIMCTAATPMPTPKSSPFLDAAPSLPDSRRGSSSSGDPPLGDQKPPASLRSSPCAPWGPSGAWSSRRSSWSSLGRAPSLKRRGQCGERESLLSGEGKGSTDDEAEDGRAAPGPRATPLRRAESLDPRPLRPAALPPTKCRDRDGQVVALPSDFFLRIDSHREDAAELDDDSEDSCCLRLHKVLEPYKPQWCRSREAWALYLFSPQNRFRVSCQKVITHKMFDHVVLVFIFLNCVTIALERPDIDPGSTERVFLSVSNYIFTAIFVAEMMVKVVALGLLSGEHAYLQSSWNLLDGLLVLVSLVDIVVAMASAGGAKILGVLRVLRLLRTLRPLRVISRAPGLKLVVETLISSLRPIGNIVLICCAFFIIFGILGVQLFKGKFYYCEGPDTRNISTKAQCRAAHYRWVRRKYNFDNLGQALMSLFVLSSKDGWVNIMYDGLDAVGVDQQPVQNHNPWMLLYFISFLLIVSFFVLNMFVGVVVENFHKCRQHQEAEEARRREEKRLRRLERRRRSTFPSPEAQRRPYYADYSPTRRSIHSLCTSHYLDLFITFIICVNVITMSMEHYNQPKSLDEALKYCNYVFTIVFVFEAALKLVAFGFRRFFKDRWNQLDLAIVLLSLMGITLEEIEMSAALPINPTIIRIMRVLRIARVLKLLKMATGMRALLDTVVQALPQVGNLGLLFMLLFFIYAALGVELFGRLECSEDNPCEGLSRHATFSNFGMAFLTLFRVSTGDNWNGIMKDTLRECSREDKHCLSYLPALSPVYFVTFVLVAQFVLVNVVVAVLMKHLEESNKEAREDAELDAEIELEMAQGPGSARRVDADRPPLPQESPGARDAPNLVARKVSVSRMLSLPNDSYMFRPVVPASAPHPRPLQEVEMETYGAGTPLGSVASVHSPPAESCASLQIPLAVSSPARSGEPLHALSPRGTARSPSLSRLLCRQEAVHTDSLEGKIDSPRDTLDPAEPGEKTPVRPVTQGGSLQSPPRSPRPASVRTRKHTFGQRCVSSRPAAPGGEEAEASDPADEEVSHITSSACPWQPTAEPHGPEASPVAGGERDLRRLYSVDAQGFLDKPGRADEQWRPSAELGSGEPGEAKAWGPEAEPALGARRKKKMSPPCISVEPPAEDEGSARPSAAEGGSTTLRRRTPSCEATPHRDSLEPTEGSGAGGDPAAKGERWGQASCRAEHLTVPSFAFEPLDLGVPSGDPFLDGSHSVTPESRASSSGAIVPLEPPESEPPMPVGDPPEKRRGLYLTVPQCPLEKPGSPSATPAPGGGADDPV
T54644	DRUGINFO	D02FLB	Sodium bicarbonate	Approved
T54644	DRUGINFO	D05CEU	Flunarizine	Approved
T54644	DRUGINFO	D04TNT	ABT-639	Phase 2
T54644	DRUGINFO	D0W8XT	Mibefradil	Phase 1
T54644	DRUGINFO	D0X5OV	TTA-A8	Preclinical
T54644	DRUGINFO	D0OW2O	U-92032	Terminated
T54644	DRUGINFO	D05NSP	GNF-PF-4599	Investigative
T54644	DRUGINFO	D06HWI	GNF-PF-1967	Investigative
T54644	DRUGINFO	D08NRG	HYP-10	Investigative
T54644	DRUGINFO	D0T6NE	Z 944	Investigative
T54644	DRUGINFO	D0TW1Q	DP-3005	Investigative
T54644	DRUGINFO	D0Y5WL	TTL-1177	Investigative
T54644	DRUGINFO	D0YF6L	KST-5468	Investigative
T54644	DRUGINFO	D02DUO	KYS-05001	Investigative
T54644	DRUGINFO	D02SSG	KYS-05077	Investigative
T54644	DRUGINFO	D06UAX	KYS-05080	Investigative
T54644	DRUGINFO	D07UBR	Cis-N,5-dibenzyl-6-oxomorpholine-3-carboxamide	Investigative
T54644	DRUGINFO	D0K5RX	KYS-05050	Investigative
T54644	DRUGINFO	D0M2EZ	KYS-05042	Investigative
T54644	DRUGINFO	D0N5RQ	KYS-05041	Investigative
T54644	DRUGINFO	D0S5QB	KYS-05040	Investigative
T54644	DRUGINFO	D09PWJ	ML218	Investigative

T31751	TARGETID	T31751
T31751	FORMERID	TTDS00236
T31751	UNIPROID	DXR_PLAFX
T31751	TARGNAME	Plasmodium DOXP reductoisomerase (Malaria DXR)
T31751	GENENAME	Malaria DXR
T31751	TARGTYPE	Successful
T31751	SYNONYMS	IspC; DXR; DXP reductoisomerase; DOXP reductoisomerase; 2-C-Methyl-d-erythritol 4-phosphate synthase; 1-deoxyxylulose-5-phosphate reductoisomerase
T31751	FUNCTION	Catalyzes the NADP-dependent rearrangement and reduction of 1-deoxy-D-xylulose-5-phosphate (DXP) to 2-C-methyl-D-erythritol 4-phosphate (MEP).
T31751	PDBSTRUC	4KP7; 4GAE; 3WQS; 3WQR; 3WQQ
T31751	BIOCLASS	Short-chain dehydrogenases reductase
T31751	ECNUMBER	EC 1.1.1.267
T31751	SEQUENCE	MKKYIYIYFFFITITINDLVINNTSKCVSIERRKNNAYINYGIGYNGPDNKITKSRRCKRIKLCKKDLIDIGAIKKPINVAIFGSTGSIGTNALNIIRECNKIENVFNVKALYVNKSVNELYEQAREFLPEYLCIHDKSVYEELKELVKNIKDYKPIILCGDEGMKEICSSNSIDKIVIGIDSFQGLYSTMYAIMNNKIVALANKESIVSAGFFLKKLLNIHKNAKIIPVDSEHSAIFQCLDNNKVLKTKCLQDNFSKINNINKIFLCSSGGPFQNLTMDELKNVTSENALKHPKWKMGKKITIDSATMMNKGLEVIETHFLFDVDYNDIEVIVHKECIIHSCVEFIDKSVISQMYYPDMQIPILYSLTWPDRIKTNLKPLDLAQVSTLTFHKPSLEHFPCIKLAYQAGIKGNFYPTVLNASNEIANNLFLNNKIKYFDISSIISQVLESFNSQKVSENSEDLMKQILQIHSWAKDKATDIYNKHNSS
T31751	DRUGINFO	D09UXE	Fosmidomycin	Approved
T31751	DRUGINFO	D05MNV	Fosclin	Phase 3

T76213	TARGETID	T76213
T76213	FORMERID	TTDI01963
T76213	UNIPROID	PH4H_HUMAN
T76213	TARGNAME	Phenylalanine hydroxylase (PAH)
T76213	GENENAME	PAH
T76213	TARGTYPE	Successful
T76213	SYNONYMS	Phenylalanine4hydroxylase; Phenylalanine-4-hydroxylase; Phe4monooxygenase; Phe-4-monooxygenase
T76213	FUNCTION	Catalyzes the hydroxylation of L-phenylalanine to L-tyrosine.
T76213	PDBSTRUC	6PAH; 6N1K; 5PAH; 5FII; 4PAH
T76213	BIOCLASS	Paired donor oxygen oxidoreductase
T76213	ECNUMBER	EC 1.14.16.1
T76213	SEQUENCE	MSTAVLENPGLGRKLSDFGQETSYIEDNCNQNGAISLIFSLKEEVGALAKVLRLFEENDVNLTHIESRPSRLKKDEYEFFTHLDKRSLPALTNIIKILRHDIGATVHELSRDKKKDTVPWFPRTIQELDRFANQILSYGAELDADHPGFKDPVYRARRKQFADIAYNYRHGQPIPRVEYMEEEKKTWGTVFKTLKSLYKTHACYEYNHIFPLLEKYCGFHEDNIPQLEDVSQFLQTCTGFRLRPVAGLLSSRDFLGGLAFRVFHCTQYIRHGSKPMYTPEPDICHELLGHVPLFSDRSFAQFSQEIGLASLGAPDEYIEKLATIYWFTVEFGLCKQGDSIKAYGAGLLSSFGELQYCLSEKPKLLPLELEKTAIQNYTVTEFQPLYYVAESFNDAKEKVRNFAATIPRPFSVRYDPYTQRIEVLDNTQQLKILADSINSEIGILCSALQKIK
T76213	DRUGINFO	D0S2IQ	Sapropterin hydrochloride	Approved
T76213	DRUGINFO	D0T8HZ	Pegvaliase	Approved
T76213	DRUGINFO	D00IDR	Phenylalanine hydroxylase	Phase 2
T76213	DRUGINFO	D05XZQ	HepaStem	Phase 2
T76213	DRUGINFO	D5SZK9	HMI-102	Phase 1/2
T76213	DRUGINFO	D94DTN	BMN-307	Phase 1/2
T76213	DRUGINFO	D05TXS	BMN-168	Investigative
T76213	DRUGINFO	D07GET	ALTU-236	Investigative
T76213	DRUGINFO	D08URY	alpha-methylphenylalanine	Investigative
T76213	DRUGINFO	D0F9XO	BH4	Investigative
T76213	DRUGINFO	D0F2GG	fenclonine	Investigative

T14602	TARGETID	T14602
T14602	FORMERID	TTDS00205
T14602	UNIPROID	FA8_HUMAN
T14602	TARGNAME	Coagulation factor VIII (F8)
T14602	GENENAME	F8
T14602	TARGTYPE	Successful
T14602	SYNONYMS	Procoagulant component; F8C; Antihemophilic factor; AHF
T14602	FUNCTION	Factor VIII, along with calcium and phospholipid, acts as a cofactor for F9/factor IXa when it converts F10/factor X to the activated form, factor Xa.
T14602	PDBSTRUC	5K8D; 4XZU; 4PT6; 4KI5; 4BDV
T14602	SEQUENCE	MQIELSTCFFLCLLRFCFSATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNSRHPSTRQKQFNATTIPENDIEKTDPWFAHRTPMPKIQNVSSSDLLMLLRQSPTPHGLSLSDLQEAKYETFSDDPSPGAIDSNNSLSEMTHFRPQLHHSGDMVFTPESGLQLRLNEKLGTTAATELKKLDFKVSSTSNNLISTIPSDNLAAGTDNTSSLGPPSMPVHYDSQLDTTLFGKKSSPLTESGGPLSLSEENNDSKLLESGLMNSQESSWGKNVSSTESGRLFKGKRAHGPALLTKDNALFKVSISLLKTNKTSNNSATNRKTHIDGPSLLIENSPSVWQNILESDTEFKKVTPLIHDRMLMDKNATALRLNHMSNKTTSSKNMEMVQQKKEGPIPPDAQNPDMSFFKMLFLPESARWIQRTHGKNSLNSGQGPSPKQLVSLGPEKSVEGQNFLSEKNKVVVGKGEFTKDVGLKEMVFPSSRNLFLTNLDNLHENNTHNQEKKIQEEIEKKETLIQENVVLPQIHTVTGTKNFMKNLFLLSTRQNVEGSYDGAYAPVLQDFRSLNDSTNRTKKHTAHFSKKGEEENLEGLGNQTKQIVEKYACTTRISPNTSQQNFVTQRSKRALKQFRLPLEETELEKRIIVDDTSTQWSKNMKHLTPSTLTQIDYNEKEKGAITQSPLSDCLTRSHSIPQANRSPLPIAKVSSFPSIRPIYLTRVLFQDNSSHLPAASYRKKDSGVQESSHFLQGAKKNNLSLAILTLEMTGDQREVGSLGTSATNSVTYKKVENTVLPKPDLPKTSGKVELLPKVHIYQKDLFPTETSNGSPGHLDLVEGSLLQGTEGAIKWNEANRPGKVPFLRVATESSAKTPSKLLDPLAWDNHYGTQIPKEEWKSQEKSPEKTAFKKKDTILSLNACESNHAIAAINEGQNKPEIEVTWAKQGRTERLCSQNPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLY
T14602	DRUGINFO	D0M2BR	Factor 8	Approved
T14602	DRUGINFO	D0UQ1R	Eloctate	Approved
T14602	DRUGINFO	DMU9P2	Efanesoctocog alfa	Approved
T14602	DRUGINFO	D0PG0G	Drotrecogin alfa	Approved
T14602	DRUGINFO	D0ZL1T	SK-NBP601	Preregistration
T14602	DRUGINFO	D00UUL	N8-GP	Phase 3
T14602	DRUGINFO	D03SIA	OBI-1	Phase 3
T14602	DRUGINFO	D05LDQ	BAY 94-9027	Phase 3
T14602	DRUGINFO	D09APA	Plasma derived factor VIII PEGylated liposomal	Phase 3
T14602	DRUGINFO	D0ML8G	Turoctocog alfa	Phase 3
T14602	DRUGINFO	D7HLI1	Valoctocogene roxaparvovec	Phase 3
T14602	DRUGINFO	DGB7W9	Milademetan	Phase 3
T14602	DRUGINFO	DZ9AJ3	PF-07055480	Phase 3
T14602	DRUGINFO	D0B3XG	Recombinant von Willebrand factor/recombinant Factor VIII complex	Phase 3
T14602	DRUGINFO	D00LHI	BAY 794980	Phase 2
T14602	DRUGINFO	D09UAI	TB-402	Phase 2
T14602	DRUGINFO	D8BYU3	BAY2599023	Phase 1/2
T14602	DRUGINFO	DJ5I6L	SPK-8016	Phase 1/2
T14602	DRUGINFO	DW7PT6	SPK-8011	Phase 1/2
T14602	DRUGINFO	DX0NW9	TAK-754	Phase 1/2
T14602	DRUGINFO	D01FRK	LA-N8	Investigative
T14602	DRUGINFO	D07LRB	Factor VIII-XTEN	Investigative
T14602	DRUGINFO	D08VFX	Full-length Factor VIII molecule	Investigative
T14602	DRUGINFO	D09CTF	Human recombinant factor VIII	Investigative
T14602	DRUGINFO	D0B6EG	Simoctocog alfa	Investigative
T14602	DRUGINFO	D0C7GJ	Long-acting factor VIII	Investigative
T14602	DRUGINFO	D0D7XS	GPG-290	Investigative
T14602	DRUGINFO	D0P8ME	LG-889	Investigative
T14602	DRUGINFO	D0Q7XA	LG-888	Investigative
T14602	DRUGINFO	D0Q9UL	IATX-FVIII	Investigative
T14602	DRUGINFO	D0XK6O	SMaRT FVIII	Investigative

T38179	TARGETID	T38179
T38179	FORMERID	TTDS00228
T38179	UNIPROID	BLAC_STAAU
T38179	TARGNAME	Staphylococcus Beta-lactamase (Stap-coc blaZ)
T38179	GENENAME	Stap-coc blaZ
T38179	TARGTYPE	Successful
T38179	SYNONYMS	blaZ; Cephalosporinase
T38179	FUNCTION	This protein is a serine beta-lactamase with a substrate specificity for cephalosporins.
T38179	PDBSTRUC	3BLM; 1PIO; 1OME; 1KGG; 1KGF
T38179	BIOCLASS	Carbon-nitrogen hydrolase
T38179	ECNUMBER	EC 3.5.2.6
T38179	SEQUENCE	MKKLIFLIVIALVLSACNSNSSHAKELNDLEKKYNAHIGVYALDTKSGKEVKFNSDKRFAYASTSKAINSAILLEQVPYNKLNKKVHINKDDIVAYSPILEKYVGKDITLKALIEASMTYSDNTANNKIIKEIGGIKKVKQRLKELGDKVTNPVRYEIELNYYSPKSKKDTSTPAAFGKTLNKLIANGKLSKENKKFLLDLMLNNKSGDTLIKDGVPKDYKVADKSGQAITYASRNDVAFVYPKGQSEPIVLVIFTNKDNKSDKPNDKLISETAKSVMKEF
T38179	DRUGINFO	D0F7AJ	Ceftolozane/tazobactam	Approved
T38179	DRUGINFO	D0N5KF	Meropenem + vaborbactam	Approved
T38179	DRUGINFO	D0QQ7D	Tazobactam	Approved
T38179	DRUGINFO	D0X7JN	Clavulanate	Approved
T38179	DRUGINFO	D0S3EM	CAZ AVI	Phase 3
T38179	DRUGINFO	D1MEH5	Enmetazobactam	Phase 3
T38179	DRUGINFO	DR6BU1	Vaborbactam	Phase 3
T38179	DRUGINFO	D02VSP	MK-7655	Phase 2
T38179	DRUGINFO	D08DGW	CXL	Phase 2
T38179	DRUGINFO	D0EX1C	RASV-Sp	Phase 1
T38179	DRUGINFO	D0V3BZ	ME-1071	Phase 1
T38179	DRUGINFO	D2UE8B	QPX7831	Phase 1
T38179	DRUGINFO	DD36YG	OP-0595	Phase 1
T38179	DRUGINFO	DMQ86J	QPX7728	Phase 1
T38179	DRUGINFO	DNI5M0	XNW4107	Phase 1
T38179	DRUGINFO	DO57QB	ETX0282	Phase 1
T38179	DRUGINFO	DT30FV	VNRX-5133	Phase 1
T38179	DRUGINFO	D0I0VY	DA-7101	Discontinued in Phase 3
T38179	DRUGINFO	D0J6TN	2085-P	Discontinued in Phase 3
T38179	DRUGINFO	D0R4ML	P1A	Discontinued in Phase 2
T38179	DRUGINFO	D03YIT	CL-186659	Terminated
T38179	DRUGINFO	D08VWL	BRL-42715	Terminated
T38179	DRUGINFO	D0H3CV	Ro-48-8724	Terminated
T38179	DRUGINFO	D0OM5M	Ro-48-1220	Terminated
T38179	DRUGINFO	D0P5NW	SB-236049	Terminated
T38179	DRUGINFO	D0Y6IJ	Ro-48-5545	Terminated
T38179	DRUGINFO	D00WZI	5-methyl-benzo[b]thiophen-2-ylboronic acid	Investigative
T38179	DRUGINFO	D00YUO	4-iodo-acetamido phenylboronic acid	Investigative
T38179	DRUGINFO	D00ZBH	Alpha-Sulfanyl(4-fluorobenzyl)phosphonic acid	Investigative
T38179	DRUGINFO	D01ULE	Alpha-Sulfanylbenzylphosphonic acid	Investigative
T38179	DRUGINFO	D02DOQ	Diisopropyl 2-(sulfanylmethyl)phenylphosphonate	Investigative
T38179	DRUGINFO	D02OVN	Acylated Ceftazidime	Investigative
T38179	DRUGINFO	D03JFU	Alpha-Sulfanylpropylphosphonic acid	Investigative
T38179	DRUGINFO	D03XOB	5-hydroxymethylbenzo[b]thiophen-2-ylboronic acid	Investigative
T38179	DRUGINFO	D05BCF	Clavulanate+Amoxicillin	Investigative
T38179	DRUGINFO	D05LMB	Alpha-Sulfanyl(2-methoxybenzyl)phosphonic acid	Investigative
T38179	DRUGINFO	D05PVX	Thiophene-2-ylboronic acid	Investigative
T38179	DRUGINFO	D06BUM	4-Carboxyphenylboronic Acid	Investigative
T38179	DRUGINFO	D06CUF	Hydrolyzed Cephalothin	Investigative
T38179	DRUGINFO	D06GYI	N-2-Thiophen-2-Yl-Acetamide Boronic Acid	Investigative
T38179	DRUGINFO	D06OGZ	Degraded Cephaloridine	Investigative
T38179	DRUGINFO	D06UHZ	2-mercaptophenylphosphonic acid	Investigative
T38179	DRUGINFO	D07OSW	2-(Sulfanylmethyl)phenylphosphonic acid	Investigative
T38179	DRUGINFO	D08KUO	1-Aminopropane-1,2,3-tricarboxylic acid	Investigative
T38179	DRUGINFO	D08LLS	4-(Carboxyvin-2-Yl)Phenylboronic Acid	Investigative
T38179	DRUGINFO	D08TCV	Sucrose	Investigative
T38179	DRUGINFO	D09EHR	5-Fluoro-2-sulfanyl-phenylphosphonic acid	Investigative
T38179	DRUGINFO	D0E1XD	M-Aminophenylboronic Acid	Investigative
T38179	DRUGINFO	D0EK8U	[[N-(Benzyloxycarbonyl)Amino]Methyl]Phosphate	Investigative
T38179	DRUGINFO	D0F1RL	Alpha-Sulfanyl(4-bromobenzyl)phosphonic acid	Investigative
T38179	DRUGINFO	D0H9UT	Carbamic Acid	Investigative
T38179	DRUGINFO	D0I6QE	Alpha-Sulfanyl(4-chlorobenzyl)phosphonic acid	Investigative
T38179	DRUGINFO	D0I7DN	Tribenzyl 2-aminopropane-1,2,3-tricarboxylate	Investigative
T38179	DRUGINFO	D0IN7A	Alpha-Sulfanyl(2,4-dichlorobenzyl)phosphonic acid	Investigative
T38179	DRUGINFO	D0J7EL	3-Nitrophenylboronic Acid	Investigative
T38179	DRUGINFO	D0N5WV	4-[(METHYLSULFONYL)AMINO]BENZOIC ACID	Investigative
T38179	DRUGINFO	D0R5FE	(P-Iodophenylacetylamino)Methylphosphinic Acid	Investigative
T38179	DRUGINFO	D0R6DA	3-ethoxycarbonylpyroglutamate	Investigative
T38179	DRUGINFO	D0W4OF	Diisopropyl mercapto(phenyl)methylphosphonate	Investigative
T38179	DRUGINFO	D0W9RM	4-Methyl-3-(2-oxo-azetidin-1-yl)-benzoic acid	Investigative
T38179	DRUGINFO	D0X0KZ	4,4'-Biphenyldiboronic Acid	Investigative
T38179	DRUGINFO	D0XF5X	3-Amino-3-(methoxycarbonyl)-1,5-pentandioic acid	Investigative
T38179	DRUGINFO	D0XF6C	2-phenyl-1H-imidazole-4-carboxylic acid	Investigative
T38179	DRUGINFO	D0YY2L	Diisopropyl 1-mercaptopropylphosphonate	Investigative
T38179	DRUGINFO	D0Z7IJ	Triethyl 2-aminopropane-1,2,3-tricarboxylate	Investigative
T38179	DRUGINFO	D04BWH	Benzo[b]thiophen-2-ylboronic acid	Investigative
T38179	DRUGINFO	D08JUW	PCNOTAXIME GROUP	Investigative
T38179	DRUGINFO	D07KZA	2-(N-Morpholino)-Ethanesulfonic Acid	Investigative
T38179	DRUGINFO	D06GOK	2-Methyl-2,4-Pentanediol	Investigative
T38179	DRUGINFO	D0F2ME	Acetate Ion	Investigative

T27445	TARGETID	T27445
T27445	FORMERID	TTDS00223
T27445	UNIPROID	SYI_ECOLI
T27445	TARGNAME	Bacterial Isoleucyl-tRNA synthetase (Bact ileS)
T27445	GENENAME	Bact ileS
T27445	TARGTYPE	Successful
T27445	SYNONYMS	ileS; Isoleucine--tRNA ligase of Escherichia coli; IRS of Escherichia coli
T27445	FUNCTION	Catalyzes the attachment of isoleucine to tRNA(Ile). As IleRS can inadvertently accommodate and process structurally similar amino acids such as valine, to avoid such errors it has two additional distinct tRNA(Ile)-dependent editing activities. One activity is designated as 'pretransfer' editing and involves the hydrolysis of activated Val-AMP. The other activity is designated 'posttransfer' editing and involves deacylation of mischarged Val-tRNA(Ile).
T27445	BIOCLASS	Carbon-oxygen ligase
T27445	ECNUMBER	EC 6.1.1.5
T27445	SEQUENCE	MSDYKSTLNLPETGFPMRGDLAKREPGMLARWTDDDLYGIIRAAKKGKKTFILHDGPPYANGSIHIGHSVNKILKDIIVKSKGLSGYDSPYVPGWDCHGLPIELKVEQEYGKPGEKFTAAEFRAKCREYAATQVDGQRKDFIRLGVLGDWSHPYLTMDFKTEANIIRALGKIIGNGHLHKGAKPVHWCVDCRSALAEAEVEYYDKTSPSIDVAFQAVDQDALKAKFAVSNVNGPISLVIWTTTPWTLPANRAISIAPDFDYALVQIDGQAVILAKDLVESVMQRIGVTDYTILGTVKGAELELLRFTHPFMGFDVPAILGDHVTLDAGTGAVHTAPGHGPDDYVIGQKYGLETANPVGPDGTYLPGTYPTLDGVNVFKANDIVVALLQEKGALLHVEKMQHSYPCCWRHKTPIIFRATPQWFVSMDQKGLRAQSLKEIKGVQWIPDWGQARIESMVANRPDWCISRQRTWGVPMSLFVHKDTEELHPRTLELMEEVAKRVEVDGIQAWWDLDAKEILGDEADQYVKVPDTLDVWFDSGSTHSSVVDVRPEFAGHAADMYLEGSDQHRGWFMSSLMISTAMKGKAPYRQVLTHGFTVDGQGRKMSKSIGNTVSPQDVMNKLGADILRLWVASTDYTGEMAVSDEILKRAADSYRRIRNTARFLLANLNGFDPAKDMVKPEEMVVLDRWAVGCAKAAQEDILKAYEAYDFHEVVQRLMRFCSVEMGSFYLDIIKDRQYTAKADSVARRSCQTALYHIAEALVRWMAPILSFTADEVWGYLPGEREKYVFTGEWYEGLFGLADSEAMNDAFWDELLKVRGEVNKVIEQARADKKVGGSLEAAVTLYAEPELSAKLTALGDELRFVLLTSGATVADYNDAPADAQQSEVLKGLKVALSKAEGEKCPRCWHYTQDVGKVAEHAEICGRCVSNVAGDGEKRKFA
T27445	DRUGINFO	D03JSJ	Mupirocin	Approved
T27445	DRUGINFO	D0N1BC	Reveromycin A	Terminated

T73476	TARGETID	T73476
T73476	FORMERID	TTDS00467
T73476	UNIPROID	ANT3_HUMAN
T73476	TARGNAME	Antithrombin-III (ATIII)
T73476	GENENAME	SERPINC1
T73476	TARGTYPE	Successful
T73476	SYNONYMS	SERPINC1; ATIII; AT3
T73476	FUNCTION	Most important serine protease inhibitorin plasma that regulates the blood coagulation cascade. At-iii inhibits thrombin as well as factors ixa, xa and xia. Its inhibitory activity is greatly enhanced in the presence of heparin.
T73476	PDBSTRUC	4EB1; 3KCG; 3EVJ; 2ZNH; 2HIJ
T73476	BIOCLASS	Serpin protein
T73476	SEQUENCE	MYSNVIGTVTSGKRKVYLLSLLLIGFWDCVTCHGSPVDICTAKPRDIPMNPMCIYRSPEKKATEDEGSEQKIPEATNRRVWELSKANSRFATTFYQHLADSKNDNDNIFLSPLSISTAFAMTKLGACNDTLQQLMEVFKFDTISEKTSDQIHFFFAKLNCRLYRKANKSSKLVSANRLFGDKSLTFNETYQDISELVYGAKLQPLDFKENAEQSRAAINKWVSNKTEGRITDVIPSEAINELTVLVLVNTIYFKGLWKSKFSPENTRKELFYKADGESCSASMMYQEGKFRYRRVAEGTQVLELPFKGDDITMVLILPKPEKSLAKVEKELTPEVLQEWLDELEEMMLVVHMPRFRIEDGFSLKEQLQDMGLVDLFSPEKSKLPGIVAEGRDDLYVSDAFHKAFLEVNEEGSEAAASTAVVIAGRSLNPNRVTFKANRPFLVFIREVPLNTIIFMGRVANPCVK
T73476	DRUGINFO	D01ZJK	Ardeparin	Approved
T73476	DRUGINFO	D0A2GM	Heparin Calcium	Approved
T73476	DRUGINFO	D0E9TP	Sulodexide	Approved
T73476	DRUGINFO	D0UX6Z	Heparin Sodium	Approved
T73476	DRUGINFO	D02WST	Unfractionated heparin	Phase 3
T73476	DRUGINFO	D0C3YN	Heparin low molecular weight	Phase 3
T73476	DRUGINFO	D0C6ZX	KW-3357	Phase 3
T73476	DRUGINFO	D00AKQ	O-desulfated heparin	Phase 2
T73476	DRUGINFO	D07XJJ	M118	Phase 2
T73476	DRUGINFO	D08HXG	PMX-60056	Phase 2
T73476	DRUGINFO	D06LEA	MER-102	Phase 1
T73476	DRUGINFO	D08FNJ	RO-14	Phase 1
T73476	DRUGINFO	D0O8SB	OPK-0018	Phase 1
T73476	DRUGINFO	D09EDW	Deligoparin sodium	Discontinued in Phase 3
T73476	DRUGINFO	D02JGZ	Heparin Pentasaccharide	Investigative
T73476	DRUGINFO	D0A3WQ	Org-36764	Investigative
T73476	DRUGINFO	D0AZ5O	LHD-4	Investigative
T73476	DRUGINFO	D0X5SQ	PNU-87663	Investigative
T73476	DRUGINFO	D0GV9Q	N-Formylmethionine	Investigative
T73476	DRUGINFO	D07LUR	Alpha-D-Mannose	Investigative

T28265	TARGETID	T28265
T28265	FORMERID	TTDS00285
T28265	UNIPROID	A1AT_HUMAN
T28265	TARGNAME	Alpha-1-antitrypsin (SERPINA1)
T28265	GENENAME	SERPINA1
T28265	TARGTYPE	Successful
T28265	SYNONYMS	SERPINA1; PRO0684/PRO2209; Alpha1-proteinase; Alpha-1-antiproteinase; Alpha-1 protease inhibitor
T28265	FUNCTION	Inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin.
T28265	PDBSTRUC	9API; 8API; 7API; 5NBV; 5NBU
T28265	BIOCLASS	Serpin protein
T28265	SEQUENCE	MPSSVSWGILLLAGLCCLVPVSLAEDPQGDAAQKTDTSHHDQDHPTFNKITPNLAEFAFSLYRQLAHQSNSTNIFFSPVSIATAFAMLSLGTKADTHDEILEGLNFNLTEIPEAQIHEGFQELLRTLNQPDSQLQLTTGNGLFLSEGLKLVDKFLEDVKKLYHSEAFTVNFGDTEEAKKQINDYVEKGTQGKIVDLVKELDRDTVFALVNYIFFKGKWERPFEVKDTEEEDFHVDQVTTVKVPMMKRLGMFNIQHCKKLSSWVLLMKYLGNATAIFFLPDEGKLQHLENELTHDIITKFLENEDRRSASLHLPKLSITGTYDLKSVLGQLGITKVFSNGADLSGVTEEAPLKLSKAVHKAVLTIDEKGTEAAGAMFLEAIPMSIPPEVKFNKPFVFLMIEQNTKSPLFMGKVVNPTQK
T28265	DRUGINFO	D04ELD	Glassia	Approved
T28265	DRUGINFO	D9EC0G	Zemaira	Approved
T28265	DRUGINFO	D0QF2W	AGTC-0106	Phase 2
T28265	DRUGINFO	D0N5LJ	Igmesine	Phase 2
T28265	DRUGINFO	D0Q5FV	2-Sulfhydryl-Ethanol	Investigative

T94692	TARGETID	T94692
T94692	FORMERID	TTDR00225
T94692	UNIPROID	LDLR_HUMAN
T94692	TARGNAME	Low-density lipoprotein receptor (LDL-R)
T94692	GENENAME	LDLR
T94692	TARGTYPE	Successful
T94692	SYNONYMS	LDL receptor
T94692	FUNCTION	In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. Binds LDL, the major cholesterol-carrying lipoprotein of plasma, and transports it into cells by endocytosis.
T94692	PDBSTRUC	5OYL; 5OY9; 4NE9; 3SO6; 3P5C
T94692	BIOCLASS	Low density lipoprotein receptor
T94692	SEQUENCE	MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA
T94692	DRUGINFO	D02JDL	Porfimer Sodium	Approved
T94692	DRUGINFO	D07LUR	Alpha-D-Mannose	Investigative

T97257	TARGETID	T97257
T97257	FORMERID	TTDR00511
T97257	UNIPROID	TGFB1_HUMAN
T97257	TARGNAME	Transforming growth factor beta 1 (TGFB1)
T97257	GENENAME	TGFB1
T97257	TARGTYPE	Successful
T97257	SYNONYMS	Transforming growth factor beta-1 proprotein; Transforming growth factor beta-1; TGFB; TGF-beta1; TGF-beta 1
T97257	FUNCTION	Transforming growth factor beta-1 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-1 (TGF-beta-1) chains, which constitute the regulatory and active subunit of TGF-beta-1, respectively.
T97257	PDBSTRUC	5VQP; 5FFO; 4KV5; 3KFD; 1KLD
T97257	BIOCLASS	Growth factor
T97257	SEQUENCE	MPPSGLRLLLLLLPLLWLLVLTPGRPAAGLSTCKTIDMELVKRKRIEAIRGQILSKLRLASPPSQGEVPPGPLPEAVLALYNSTRDRVAGESAEPEPEPEADYYAKEVTRVLMVETHNEIYDKFKQSTHSIYMFFNTSELREAVPEPVLLSRAELRLLRLKLKVEQHVELYQKYSNNSWRYLSNRLLAPSDSPEWLSFDVTGVVRQWLSRGGEIEGFRLSAHCSCDSRDNTLQVDINGFTTGRRGDLATIHGMNRPFLLLMATPLERAQHLQSSRHRRALDTNYCFSSTEKNCCVRQLYIDFRKDLGWKWIHEPKGYHANFCLGPCPYIWSLDTQYSKVLALYNQHNPGASAAPCCVPQALEPLPIVYYVGRKPKVEQLSNMIVRSCKCS
T97257	DRUGINFO	D02WCI	Pirfenidone	Approved
T97257	DRUGINFO	D8UKA4	A435	IND submitted
T97257	DRUGINFO	D0DP3V	TG-C	Phase 3
T97257	DRUGINFO	D06TFI	LY2157299	Phase 2/3
T97257	DRUGINFO	D0C4WC	Disitertide	Phase 2
T97257	DRUGINFO	D8NZ7T	ACE-1334	Phase 1
T97257	DRUGINFO	DFZJ79	SRK-181	Phase 1
T97257	DRUGINFO	DKCI94	ABBV-151	Phase 1
T97257	DRUGINFO	D0U3DX	Mannose phosphate	Discontinued in Phase 2
T97257	DRUGINFO	D08OLR	ART-144	Investigative

T63934	TARGETID	T63934
T63934	FORMERID	TTDI01921
T63934	UNIPROID	IFNA2_HUMAN
T63934	TARGNAME	Interferon-alpha 2 (IFNA2)
T63934	GENENAME	IFNA2
T63934	TARGTYPE	Successful
T63934	SYNONYMS	LeIF A; Interferon alphaA; Interferon alpha2; Interferon alpha-A; Interferon alpha-2; IFNalpha2; IFNA2C; IFNA2B; IFNA2A; IFN-alpha-2
T63934	FUNCTION	Produced by macrophages, IFN-alpha have antiviral activities.
T63934	PDBSTRUC	4Z5R; 4YPG; 3SE3; 3S9D; 2LMS
T63934	BIOCLASS	Cytokine: interferon
T63934	SEQUENCE	MALTFALLVALLVLSCKSSCSVGCDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
T63934	DRUGINFO	D08NWC	Peginterferon alfa-2b	Approved
T63934	DRUGINFO	D0P0WV	Interferon Alfa-2b	Approved
T63934	DRUGINFO	D0Y8OK	Peginterferon alfa-2a	Approved
T63934	DRUGINFO	D00TJX	Albinterferon alfa-2b	Phase 3
T63934	DRUGINFO	D05DZK	Interferon alpha 2a	Phase 3
T63934	DRUGINFO	D0M2IS	Hebergel	Phase 3
T63934	DRUGINFO	D0V8KD	P-1101	Phase 3
T63934	DRUGINFO	D00EFO	Interferon alpha-2b	Phase 2
T63934	DRUGINFO	D04PIH	Novaferon	Phase 2
T63934	DRUGINFO	D07CNY	Instiladrin	Phase 2
T63934	DRUGINFO	D0NI0X	SCH-721015	Phase 1
T63934	DRUGINFO	D06NDP	CIGB-128	Phase 1
T63934	DRUGINFO	D04DVA	HAp-IFN	Investigative
T63934	DRUGINFO	D0Q5UM	subalin	Investigative

T02808	TARGETID	T02808
T02808	FORMERID	TTDI01922
T02808	UNIPROID	IFNB_HUMAN
T02808	TARGNAME	Interferon-beta (IFNB1)
T02808	GENENAME	IFNB1
T02808	TARGTYPE	Successful
T02808	SYNONYMS	Interferon beta; IFNbeta; IFNB; IFN-beta; IFB; Fibroblast interferon
T02808	FUNCTION	Has antiviral, antibacterial and anticancer activities.
T02808	PDBSTRUC	1AU1
T02808	BIOCLASS	Cytokine: interferon
T02808	SEQUENCE	MTNKCLLQIALLLCFSTTALSMSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN
T02808	DRUGINFO	D04YXL	PEGylated IFN beta 1-a	Approved
T02808	DRUGINFO	D0LW4O	PLEGRIDY	Approved
T02808	DRUGINFO	D0V4JQ	Interferon beta-1a	Approved
T02808	DRUGINFO	D05LOB	FP-1201	Phase 3
T02808	DRUGINFO	D0D0LH	NU-100	Phase 3
T02808	DRUGINFO	D0L8PH	Biferonex	Phase 3
T02808	DRUGINFO	D04HJE	AZ-01, PEGylated interferon-beta	Phase 2
T02808	DRUGINFO	D08RDD	PF-06823859	Phase 2
T02808	DRUGINFO	D0V5KJ	Interferon beta 1a	Phase 2
T02808	DRUGINFO	D0F7ZR	ARX-424	Phase 1
T02808	DRUGINFO	D0Q3BG	Gene therapy, IFN-b	Phase 1
T02808	DRUGINFO	D00TEN	TV-1390	Preclinical
T02808	DRUGINFO	D05BIT	Maxy-10	Terminated

T63068	TARGETID	T63068
T63068	FORMERID	TTDS00336
T63068	UNIPROID	ALBU_HUMAN
T63068	TARGNAME	Serum albumin (ALB)
T63068	GENENAME	ALB
T63068	TARGTYPE	Successful
T63068	SYNONYMS	Serum albumin
T63068	FUNCTION	Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
T63068	PDBSTRUC	6JE7; 6EZQ; 6A7P; 5Z0B; 5YOQ
T63068	SEQUENCE	MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL
T63068	DRUGINFO	D01OIL	Gadobenate Dimeglumine	Approved
T63068	DRUGINFO	D05ATI	Sodium lauryl sulfate	Approved
T63068	DRUGINFO	D06ZPS	Oxyphenbutazone	Approved
T63068	DRUGINFO	D07OIX	Iodipamide	Approved
T63068	DRUGINFO	D0B1FE	SPI-1005	Approved
T63068	DRUGINFO	D0H0WK	Gadofosveset	Approved
T63068	DRUGINFO	D0I0VI	Albumin Human	Approved
T63068	DRUGINFO	D0OG5K	Bismuth	Approved
T63068	DRUGINFO	D0P2CS	EVANS BLUE	Approved
T63068	DRUGINFO	D0C0CE	Activated recombinant FVII-albumin fusion protein	Phase 2/3
T63068	DRUGINFO	D9J6XV	Vobarilizumab	Phase 2
T63068	DRUGINFO	D0YW6P	RU-101	Phase 1/2

T14342	TARGETID	T14342
T14342	FORMERID	TTDS00317
T14342	UNIPROID	POL_HV1B1
T14342	TARGNAME	Human immunodeficiency virus Reverse transcriptase (HIV RT)
T14342	GENENAME	HIV RT
T14342	TARGTYPE	Successful
T14342	SYNONYMS	HIV p66 RT; HIV Exoribonuclease H
T14342	FUNCTION	Gag-Pol polyprotein: Mediates, with Gag polyprotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi). Gag-Pol polyprotein may regulate its own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, the polyprotein would promote translation, whereas at high concentration, the polyprotein would encapsidate genomic RNA and then shut off translation.
T14342	PDBSTRUC	6OE3; 6HAK; 6ELI; 6DUH; 6DUG
T14342	ECNUMBER	EC 2.7.7.49
T14342	SEQUENCE	PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKITTESIVIWGKTPKFKLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTNKGRQKVVPLTNTTNQKTELQAIYLALQDSGLEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKEKVYLAWVPAHKGIGGNEQVDKLVSAGIRKIL
T14342	DRUGINFO	D03TGJ	Sorivudine	Approved
T14342	DRUGINFO	D06FDR	Didanosine	Approved
T14342	DRUGINFO	D07HVY	Efavirenz	Approved
T14342	DRUGINFO	D07TQV	Lamivudine	Approved
T14342	DRUGINFO	D0A4IJ	Abacavir	Approved
T14342	DRUGINFO	D0BP9C	Etravirine	Approved
T14342	DRUGINFO	D0D1BR	GS-7340	Approved
T14342	DRUGINFO	D0D9HW	Tenofovir	Approved
T14342	DRUGINFO	D0G6SD	Delavirdine	Approved
T14342	DRUGINFO	D0O2EM	Nevirapine	Approved
T14342	DRUGINFO	D0R0TS	MK-1439	Approved
T14342	DRUGINFO	D0R3FP	Tenofovir disoproxil fumarate	Approved
T14342	DRUGINFO	D0S9SD	Emtricitabine	Approved
T14342	DRUGINFO	D0Z8EX	Stavudine	Approved
T14342	DRUGINFO	D0Z9QR	Zalcitabine	Approved
T14342	DRUGINFO	D01IRG	Bictegravir, emtricitabine and tenofovir alafenamide	Approved
T14342	DRUGINFO	D01XYJ	Zidovudine	Approved
T14342	DRUGINFO	D0T6WN	Rilpivirine	Approved
T14342	DRUGINFO	D0I0ZP	Glyminox	Phase 3
T14342	DRUGINFO	D0V9QR	Apricitabine	Phase 3
T14342	DRUGINFO	D0ZL0Z	PT-304	Phase 3
T14342	DRUGINFO	D0U2BH	Epigallocatechin gallate	Phase 3
T14342	DRUGINFO	D01BBB	VM-1500	Phase 2/3
T14342	DRUGINFO	D02SPX	IDX899	Phase 2
T14342	DRUGINFO	D02SUR	L-697,661	Phase 2
T14342	DRUGINFO	D05NDN	Alovudine	Phase 2
T14342	DRUGINFO	D06ZWL	Amdoxovir	Phase 2
T14342	DRUGINFO	D08SSP	Lersivirine	Phase 2
T14342	DRUGINFO	D0GK4E	EMIVIRINE	Phase 2
T14342	DRUGINFO	D0L6KC	BILR-355	Phase 2
T14342	DRUGINFO	D0ML2V	RALURIDINE	Phase 2
T14342	DRUGINFO	D0O4WB	OBP-601	Phase 2
T14342	DRUGINFO	D0I0UE	Lexipafant	Phase 2
T14342	DRUGINFO	D05GBH	F4co vaccine	Phase 2
T14342	DRUGINFO	D04GSV	TRICIRIBINE	Phase 1/2
T14342	DRUGINFO	D0DC6U	Dapivirine	Phase 1/2
T14342	DRUGINFO	D0W9IH	Ad35-GRIN	Phase 1/2
T14342	DRUGINFO	D00BTW	UC-781	Phase 1
T14342	DRUGINFO	D01JTL	KM-023	Phase 1
T14342	DRUGINFO	D03MLA	PT-302	Phase 1
T14342	DRUGINFO	D03PKJ	MK-6186	Phase 1
T14342	DRUGINFO	D05HGL	GW-695634	Phase 1
T14342	DRUGINFO	D06KXS	PT-112	Phase 1
T14342	DRUGINFO	D08DFU	CMX-157	Phase 1
T14342	DRUGINFO	D09PRN	TROVIRDINE HYDROCHLORIDE	Phase 1
T14342	DRUGINFO	D0D0PB	AIC-292	Phase 1
T14342	DRUGINFO	D0KR5K	Capravirine	Phase 1
T14342	DRUGINFO	D0S0OI	ATEVIRDINE	Phase 1
T14342	DRUGINFO	D0S6KA	CALANOLIDE A	Phase 1
T14342	DRUGINFO	D0XB1M	MSH-372	Phase 1
T14342	DRUGINFO	D3NTA9	MK-8504	Phase 1
T14342	DRUGINFO	DF6Y1J	MK-8583	Phase 1
T14342	DRUGINFO	D09ZKB	Ad35-GRIN/ENV	Phase 1
T14342	DRUGINFO	D0V4RH	Lobucavir	Discontinued in Phase 3
T14342	DRUGINFO	D05SFD	DMP-961	Discontinued in Phase 2
T14342	DRUGINFO	D06HKB	Lodenosine	Discontinued in Phase 2
T14342	DRUGINFO	D07QWZ	AZT-P-DDI	Discontinued in Phase 2
T14342	DRUGINFO	D09TYS	Loviride	Discontinued in Phase 2
T14342	DRUGINFO	D0A0MU	FOZIVUDINE TIDOXIL	Discontinued in Phase 2
T14342	DRUGINFO	D0E3NZ	L-696229	Discontinued in Phase 2
T14342	DRUGINFO	D0K2PH	Elvucitabine	Discontinued in Phase 2
T14342	DRUGINFO	D0Q1KP	R-18893	Discontinued in Phase 2
T14342	DRUGINFO	D0V3CM	Opaviraline	Discontinued in Phase 2
T14342	DRUGINFO	D01AUL	L-697639	Discontinued in Phase 1
T14342	DRUGINFO	D09PSB	DPC-082	Discontinued in Phase 1
T14342	DRUGINFO	D09SFH	R-82150	Discontinued in Phase 1
T14342	DRUGINFO	D0L9PF	LY-73497	Discontinued in Phase 1
T14342	DRUGINFO	D0T5SZ	PNU-142721	Discontinued in Phase 1
T14342	DRUGINFO	D0V6HS	R-82913	Discontinued in Phase 1
T14342	DRUGINFO	D01VCW	MEN-10690	Terminated
T14342	DRUGINFO	D04AUA	MIV-170	Terminated
T14342	DRUGINFO	D04NFB	DMP-963	Terminated
T14342	DRUGINFO	D05DNH	A-79296	Terminated
T14342	DRUGINFO	D05IZG	BAY-Z-4305	Terminated
T14342	DRUGINFO	D05MQO	BEA-005	Terminated
T14342	DRUGINFO	D05SVQ	C-AFG	Terminated
T14342	DRUGINFO	D0A8BK	MEN-10979	Terminated
T14342	DRUGINFO	D0B0QX	MSC-204	Terminated
T14342	DRUGINFO	D0JI1S	RDEA-640	Terminated
T14342	DRUGINFO	D0K3YG	ANX-201	Terminated
T14342	DRUGINFO	D0L0NE	DPC-A78277	Terminated
T14342	DRUGINFO	D0L2QJ	UC-84	Terminated
T14342	DRUGINFO	D0L9PL	UC-38	Terminated
T14342	DRUGINFO	D0M0UJ	GS-9148	Terminated
T14342	DRUGINFO	D0M4HM	MEN-10880	Terminated
T14342	DRUGINFO	D0M9VZ	Navuridine	Terminated
T14342	DRUGINFO	D0S7DS	SPD-756	Terminated
T14342	DRUGINFO	D0T9KF	RDEA-427	Terminated
T14342	DRUGINFO	D0U6NV	ISIS-1082	Terminated
T14342	DRUGINFO	D00DSQ	HI-244	Investigative
T14342	DRUGINFO	D00JWR	PT-312	Investigative
T14342	DRUGINFO	D00NNP	HI-172	Investigative
T14342	DRUGINFO	D01KPX	PT-315	Investigative
T14342	DRUGINFO	D01VSM	6-Benzyl-2-isobutylsulfanyl-3H-pyrimidin-4-one	Investigative
T14342	DRUGINFO	D01YRL	6-Benzyl-2-cyclohexylsulfanyl-3H-pyrimidin-4-one	Investigative
T14342	DRUGINFO	D02MIH	PT-104	Investigative
T14342	DRUGINFO	D02MJN	2-Amino-6-(3-cyano-benzenesulfonyl)-benzonitrile	Investigative
T14342	DRUGINFO	D02MZZ	2-Amino-6-(toluene-2-sulfonyl)-benzonitrile	Investigative
T14342	DRUGINFO	D02POV	1-(2-Phenyl-propyl)-3-thiazol-2-yl-thiourea	Investigative
T14342	DRUGINFO	D02PPQ	Ethyl 1-[(1H-benzimidazol-5(6)-yl)sulfonyl]-1H-pyrrole-2-carboxylate	Investigative
T14342	DRUGINFO	D02VFQ	HI-241	Investigative
T14342	DRUGINFO	D03BNC	HI-240	Investigative
T14342	DRUGINFO	D03DZP	HI-242	Investigative
T14342	DRUGINFO	D03KLW	PT-109	Investigative
T14342	DRUGINFO	D03OQK	NSC-380292	Investigative
T14342	DRUGINFO	D03TYE	PT-108	Investigative
T14342	DRUGINFO	D03VYO	10-Ethyl-10H-dibenzo[b,f][1,4]oxazepin-11-one	Investigative
T14342	DRUGINFO	D03XBA	PT-102	Investigative
T14342	DRUGINFO	D04AQW	10-Isopropyl-10H-dibenzo[b,f][1,4]oxazepin-11-one	Investigative
T14342	DRUGINFO	D04BHR	PT-313	Investigative
T14342	DRUGINFO	D04JYI	1-Benzothiazol-2-yl-3-phenethyl-thiourea	Investigative
T14342	DRUGINFO	D04MYC	NSC-625487	Investigative
T14342	DRUGINFO	D04PGW	[(40-OH)MeLeu]4-Cyclosporin A	Investigative
T14342	DRUGINFO	D04PHR	UK-129485	Investigative
T14342	DRUGINFO	D05DQF	Indole N -acetamide	Investigative
T14342	DRUGINFO	D05GOC	PT-306	Investigative
T14342	DRUGINFO	D05NBU	2-Benzylsulfanyl-6-chloro-pyrimidin-4-ylamine	Investigative
T14342	DRUGINFO	D05UTC	PT-103	Investigative
T14342	DRUGINFO	D06DTQ	2-Amino-6-(3-bromo-benzenesulfinyl)-benzonitrile	Investigative
T14342	DRUGINFO	D06PAA	1-Thiazol-2-yl-3-(2-p-tolyl-ethyl)-thiourea	Investigative
T14342	DRUGINFO	D06ZGS	1-Adamantan-1-ylmethyl-3-thiazol-2-yl-thiourea	Investigative
T14342	DRUGINFO	D07ABJ	[(D)MeSer]3-[(40-OH) MeLeu]4-Cyclosporin A	Investigative
T14342	DRUGINFO	D07BXD	HI-281	Investigative
T14342	DRUGINFO	D07DPX	2-Amino-6-(3-chloro-benzenesulfonyl)-benzonitrile	Investigative
T14342	DRUGINFO	D07DQD	Tetrahydroimidazo[4,5,1-jk]-[1,4]benzodiazepin-2(1H)-one	Investigative
T14342	DRUGINFO	D07HEZ	2-Amino-6-phenylsulfanyl-benzonitrile	Investigative
T14342	DRUGINFO	D07IUX	2-Amino-6-(3-methoxy-phenylsulfanyl)-benzonitrile	Investigative
T14342	DRUGINFO	D07TYK	2'-3'-dideoxy-7-deaza-guaninetriphosphate	Investigative
T14342	DRUGINFO	D08CZE	Dihydropyrone	Investigative
T14342	DRUGINFO	D08EXA	2-Amino-6-(3-cyano-phenylsulfanyl)-benzonitrile	Investigative
T14342	DRUGINFO	D08FZQ	E-EBU-dM	Investigative
T14342	DRUGINFO	D08QLC	2-Amino-6-(2-cyano-phenylsulfanyl)-benzonitrile	Investigative
T14342	DRUGINFO	D08TVG	PT-307	Investigative
T14342	DRUGINFO	D08ZZJ	R-87027	Investigative
T14342	DRUGINFO	D09CNT	1-(2-Furan-2-yl-ethyl)-3-thiazol-2-yl-thiourea	Investigative
T14342	DRUGINFO	D09GBA	Ethyl 1-[(1H-benzotriazol-5(6)-yl)sulfonyl]-1H-pyrrole-2-carboxylate	Investigative
T14342	DRUGINFO	D09GYC	2-Amino-6-(2-cyano-benzenesulfinyl)-benzonitrile	Investigative
T14342	DRUGINFO	D09UTR	2-Amino-6-(4-chloro-phenylsulfanyl)-benzonitrile	Investigative
T14342	DRUGINFO	D09WOX	2-Amino-6-(naphthalene-1-sulfonyl)-benzonitrile	Investigative
T14342	DRUGINFO	D09XKC	PT-113	Investigative
T14342	DRUGINFO	D0A2SA	10-Allyl-10H-dibenzo[b,f][1,4]oxazepin-11-one	Investigative
T14342	DRUGINFO	D0A3CB	2-Amino-6-(2-chloro-phenylsulfanyl)-benzonitrile	Investigative
T14342	DRUGINFO	D0A8BJ	2-Amino-6-(toluene-3-sulfinyl)-benzonitrile	Investigative
T14342	DRUGINFO	D0A9LX	Deoxyfluorothymidine	Investigative
T14342	DRUGINFO	D0A9WC	PT-319	Investigative
T14342	DRUGINFO	D0AZ7V	PT-309	Investigative
T14342	DRUGINFO	D0B2BD	1-Furan-2-ylmethyl-3-thiazol-2-yl-thiourea	Investigative
T14342	DRUGINFO	D0B8FZ	1-(3-Phenyl-propyl)-3-thiazol-2-yl-thiourea	Investigative
T14342	DRUGINFO	D0BT5E	PT-314	Investigative
T14342	DRUGINFO	D0C0PL	PT-115	Investigative
T14342	DRUGINFO	D0C5HP	2-Amino-6-(3-bromo-phenylsulfanyl)-benzonitrile	Investigative
T14342	DRUGINFO	D0C9VN	10-Propyl-10H-dibenzo[b,f][1,4]oxazepin-11-one	Investigative
T14342	DRUGINFO	D0D4QL	Benzimidazole 5-carboxamide	Investigative
T14342	DRUGINFO	D0D6FR	2-Amino-6-(naphthalene-2-sulfonyl)-benzonitrile	Investigative
T14342	DRUGINFO	D0E3PF	PT-320	Investigative
T14342	DRUGINFO	D0E9TU	ISODISPAR B	Investigative
T14342	DRUGINFO	D0ET0J	PT-322	Investigative
T14342	DRUGINFO	D0F0RO	[(40-OH) MeLeu]4-CsA derivatives	Investigative
T14342	DRUGINFO	D0F9KX	PT-101	Investigative
T14342	DRUGINFO	D0H0WL	PT-106	Investigative
T14342	DRUGINFO	D0H4PN	1-(1-Phenyl-propyl)-3-thiazol-2-yl-thiourea	Investigative
T14342	DRUGINFO	D0I5TQ	2-Amino-6-(toluene-4-sulfonyl)-benzonitrile	Investigative
T14342	DRUGINFO	D0I7HP	PT-308	Investigative
T14342	DRUGINFO	D0J0CU	2-Amino-6-(2-cyano-benzenesulfonyl)-benzonitrile	Investigative
T14342	DRUGINFO	D0JZ8P	10-Propyl-10H-dibenzo[b,f][1,4]thiazepin-11-one	Investigative
T14342	DRUGINFO	D0K8EZ	2-Amino-6-(3-fluoro-phenylsulfanyl)-benzonitrile	Investigative
T14342	DRUGINFO	D0KF0N	1-Benzenesulfonyl-2-nitro-benzene	Investigative
T14342	DRUGINFO	D0L2CG	1-Benzyl-3-thiazol-2-yl-thiourea	Investigative
T14342	DRUGINFO	D0MR4N	1-(4-Butyl-thiazol-2-yl)-3-phenethyl-thiourea	Investigative
T14342	DRUGINFO	D0N8KZ	1-nitro-2-(2-nitrophenylsulfonyl)benzene	Investigative
T14342	DRUGINFO	D0N8MN	TNK-651	Investigative
T14342	DRUGINFO	D0N8PI	2-Amino-6-(3-chloro-phenylsulfanyl)-benzonitrile	Investigative
T14342	DRUGINFO	D0O6JB	HI-443	Investigative
T14342	DRUGINFO	D0OV0I	2-Amino-6-m-tolylsulfanyl-benzonitrile	Investigative
T14342	DRUGINFO	D0P0CX	2-Amino-6-(toluene-3-sulfonyl)-benzonitrile	Investigative
T14342	DRUGINFO	D0P7CD	1-(4-Cyano-thiazol-2-yl)-3-phenethyl-thiourea	Investigative
T14342	DRUGINFO	D0PJ9J	1-(2-Phenoxy-ethyl)-3-thiazol-2-yl-thiourea	Investigative
T14342	DRUGINFO	D0Q0IE	PT-110	Investigative
T14342	DRUGINFO	D0Q9OR	HI-445	Investigative
T14342	DRUGINFO	D0QU1E	PT-311	Investigative
T14342	DRUGINFO	D0QW6X	3'thiacytidine	Investigative
T14342	DRUGINFO	D0RD5U	PT-114	Investigative
T14342	DRUGINFO	D0T7IG	RTI-20	Investigative
T14342	DRUGINFO	D0T9PE	PT-310	Investigative
T14342	DRUGINFO	D0U0LL	PT-316	Investigative
T14342	DRUGINFO	D0U3GH	2-Amino-6-p-tolylsulfanyl-benzonitrile	Investigative
T14342	DRUGINFO	D0U4BQ	2-Amino-6-(2-chloro-benzenesulfonyl)-benzonitrile	Investigative
T14342	DRUGINFO	D0UO3I	HEPT	Investigative
T14342	DRUGINFO	D0V9EH	PT-317	Investigative
T14342	DRUGINFO	D0W8JP	1-Phenethyl-3-[1,3,4]thiadiazol-2-yl-thiourea	Investigative
T14342	DRUGINFO	D0W9YC	2-Amino-6-(2-methoxy-phenylsulfanyl)-benzonitrile	Investigative
T14342	DRUGINFO	D0WT5M	3-Benzylamino-5-ethyl-6-methyl-1H-pyridin-2-one	Investigative
T14342	DRUGINFO	D0WZ3T	1-(2-Pyridin-2-yl-ethyl)-3-thiazol-2-yl-thiourea	Investigative
T14342	DRUGINFO	D0X2IG	2-Amino-6-benzenesulfonyl-benzonitrile	Investigative
T14342	DRUGINFO	D0X4SF	2-Amino-6-(2-bromo-benzenesulfonyl)-benzonitrile	Investigative
T14342	DRUGINFO	D0XO2E	HI-236	Investigative
T14342	DRUGINFO	D0Y2FF	1-Thiazol-2-yl-3-(2-o-tolyl-ethyl)-thiourea	Investigative
T14342	DRUGINFO	D0Y4ZF	6-Benzyl-2-cyclopentylsulfanyl-3H-pyrimidin-4-one	Investigative
T14342	DRUGINFO	D0YP0P	2-Amino-6-(2-fluoro-benzenesulfonyl)-benzonitrile	Investigative
T14342	DRUGINFO	D0Z2MJ	2-Amino-6-(3-bromo-benzenesulfonyl)-benzonitrile	Investigative
T14342	DRUGINFO	D0Z8XJ	6-Benzyl-2-sec-butylsulfanyl-3H-pyrimidin-4-one	Investigative
T14342	DRUGINFO	D0ZY8H	HI-280	Investigative
T14342	DRUGINFO	D03SPJ	CORILAGIN	Investigative
T14342	DRUGINFO	D0BK8V	2',3'-ddATP	Investigative
T14342	DRUGINFO	D09WYY	2'-deoxythymidine triphosphate	Investigative
T14342	DRUGINFO	D0W1ST	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	Investigative

T86674	TARGETID	T86674
T86674	FORMERID	TTDC00002
T86674	UNIPROID	HEMA_I34A1
T86674	TARGNAME	Influenza Hemagglutinin (Influ HA)
T86674	GENENAME	Influ HA
T86674	TARGTYPE	Successful
T86674	SYNONYMS	Hemagglutinin
T86674	FUNCTION	Binds to sialic acid-containing receptors on the cell surface, bringing about the attachment of the virus particle to the cell. This attachment induces virion internalization either through clathrin-dependent endocytosis or through clathrin- and caveolin-independent pathway. Plays a major role in the determination of host range restriction and virulence. Class I viral fusion protein. Responsible for penetration of the virus into the cell cytoplasm by mediating the fusion of the membrane of the endocytosed virus particle with the endosomal membrane. Low pH in endosomes induces an irreversible conformational change in HA2, releasing the fusion hydrophobic peptide. Several trimers are required to form a competent fusion pore.
T86674	PDBSTRUC	1RVZ; 1RVX; 1RU7
T86674	BIOCLASS	Influenza viruses hemagglutinin
T86674	SEQUENCE	MKANLLVLLCALAAADADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHNGKLCRLKGIAPLQLGKCNIAGWLLGNPECDPLLPVRSWSYIVETPNSENGICYPGDFIDYEELREQLSSVSSFERFEIFPKESSWPNHNTNGVTAACSHEGKSSFYRNLLWLTEKEGSYPKLKNSYVNKKGKEVLVLWGIHHPPNSKEQQNLYQNENAYVSVVTSNYNRRFTPEIAERPKVRDQAGRMNYYWTLLKPGDTIIFEANGNLIAPMYAFALSRGFGSGIITSNASMHECNTKCQTPLGAINSSLPYQNIHPVTIGECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNTVIEKMNIQFTAVGKEFNKLEKRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCDNECMESVRNGTYDYPKYSEESKLNREKVDGVKLESMGIYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI
T86674	DRUGINFO	D02VIT	Arbidol	Approved
T86674	DRUGINFO	D0B1IC	CR8020	Phase 2
T86674	DRUGINFO	D0Q1WI	RG7745	Phase 2
T86674	DRUGINFO	DQ45GY	VIS410	Phase 2
T86674	DRUGINFO	D01AYF	ND-1.1	Phase 1
T86674	DRUGINFO	D03TAY	VGX-3400	Phase 1
T86674	DRUGINFO	D0LF3K	A/Anhui/05	Phase 1
T86674	DRUGINFO	D3G2BO	VIR-2482	Phase 1
T86674	DRUGINFO	D04HHR	BMY-27709	Investigative
T86674	DRUGINFO	D08UNZ	PXVX-0103	Investigative
T86674	DRUGINFO	D0DQ2G	2-tert-butylbenzene-1,4-diol	Investigative
T86674	DRUGINFO	D0LH1A	CL 385319	Investigative
T86674	DRUGINFO	D0Z2SL	Stachyflin	Investigative
T86674	DRUGINFO	D07LUR	Alpha-D-Mannose	Investigative

T74002	TARGETID	T74002
T74002	FORMERID	TTDR00322
T74002	UNIPROID	CSF2_HUMAN
T74002	TARGNAME	Granulocyte-macrophage colony-stimulating factor (CSF2)
T74002	GENENAME	CSF2
T74002	TARGTYPE	Successful
T74002	SYNONYMS	Sargramostim; Molgramostin; GM-CSF; Colony-stimulating factor; CSF2; CSF
T74002	FUNCTION	Cytokine that stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes.
T74002	PDBSTRUC	6BFS; 6BFQ; 5D72; 5D71; 5D70
T74002	BIOCLASS	Growth factor
T74002	SEQUENCE	MWLQSLLLLGTVACSISAPARSPSPSTQPWEHVNAIQEARRLLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRLELYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFDCWEPVQE
T74002	DRUGINFO	D05BXY	Talimogene Laherparepvec	Approved
T74002	DRUGINFO	D0HB0V	JX-594	Phase 3
T74002	DRUGINFO	D02SYV	Lenzilumab	Phase 2
T74002	DRUGINFO	D09SJE	KB002/003	Phase 2
T74002	DRUGINFO	D0C7ZB	GSK3196165	Phase 2
T74002	DRUGINFO	D0F0ZK	KB-003	Phase 2
T74002	DRUGINFO	D0H6SH	MT203	Phase 2
T74002	DRUGINFO	D06KCF	Mavrilimumab	Phase 2
T74002	DRUGINFO	D0YO4B	Cabiralizumab	Phase 2
T74002	DRUGINFO	D07RIJ	Autologous melanoma cell vaccine	Phase 1
T74002	DRUGINFO	D09JCH	CDNA vaccine	Phase 1
T74002	DRUGINFO	D0F4NN	CGTG-102	Phase 1
T74002	DRUGINFO	D0B0VD	MORAb-022	Phase 1
T74002	DRUGINFO	D09CRQ	RPK-739	Terminated
T74002	DRUGINFO	D06TJO	human monoclonal antibodies (GM-CSF)	Investigative

T26203	TARGETID	T26203
T26203	FORMERID	TTDI01933
T26203	UNIPROID	ICAM1_HUMAN
T26203	TARGNAME	Intercellular adhesion molecule ICAM-1 (ICAM1)
T26203	GENENAME	ICAM1
T26203	TARGTYPE	Successful
T26203	SYNONYMS	Major group rhinovirus receptor; Intercellular adhesion molecule 1; ICAM-1; CD54
T26203	FUNCTION	During leukocyte trans-endothelial migration, ICAM1 engagement promotes the assembly of endothelial apical cups through ARHGEF26/SGEF and RHOG activation. ICAM proteins are ligands for the leukocyte adhesion protein LFA-1 (integrin alpha-L/beta-2).
T26203	PDBSTRUC	6EIT; 5MZA; 3TCX; 2OZ4; 1Z7Z
T26203	BIOCLASS	Immunoglobulin
T26203	SEQUENCE	MAPSSPRPALPALLVLLGALFPGPGNAQTSVSPSKVILPRGGSVLVTCSTSCDQPKLLGIETPLPKKELLLPGNNRKVYELSNVQEDSQPMCYSNCPDGQSTAKTFLTVYWTPERVELAPLPSWQPVGKNLTLRCQVEGGAPRANLTVVLLRGEKELKREPAVGEPAEVTTTVLVRRDHHGANFSCRTELDLRPQGLELFENTSAPYQLQTFVLPATPPQLVSPRVLEVDTQGTVVCSLDGLFPVSEAQVHLALGDQRLNPTVTYGNDSFSAKASVSVTAEDEGTQRLTCAVILGNQSQETLQTVTIYSFPAPNVILTKPEVSEGTEVTVKCEAHPRAKVTLNGVPAQPLGPRAQLLLKATPEDNGRSFSCSATLEVAGQLIHKNQTRELRVLYGPRLDERDCPGNWTWPENSQQTPMCQAWGNPLPELKCLKDGTFPLPIGESVTVTRDLEGTYLCRARSTQGEVTRKVTVNVLSPRYEIVIITVVAAAVIMGTAGLSTYLYNRQRKIKKYRLQQAQKGTPMKPNTQATPP
T26203	DRUGINFO	D0Q9EV	lifitegrast	Approved
T26203	DRUGINFO	D0P9BT	Alicaforsen	Phase 3
T26203	DRUGINFO	D0XH8X	APC-8015F	Phase 2
T26203	DRUGINFO	D0Q7OE	BI-505	Phase 2
T26203	DRUGINFO	DP0NU9	AIC100	Phase 1
T26203	DRUGINFO	D09GGO	A-252444.0	Terminated
T26203	DRUGINFO	D0M8JF	MOR-102	Terminated
T26203	DRUGINFO	D0RR4T	GI-270384X	Terminated
T26203	DRUGINFO	D02BRA	ISIS-1939	Investigative

T60433	TARGETID	T60433
T60433	FORMERID	TTDS00472
T60433	UNIPROID	CD1A_HUMAN
T60433	TARGNAME	T-cell surface glycoprotein CD1a (CD1A)
T60433	GENENAME	CD1A
T60433	TARGTYPE	Successful
T60433	SYNONYMS	hTa1 thymocyteantigen; hTa1 thymocyte antigen; T-cell surfaceantigen T6/Leu-6; T-cell surface antigen T6/Leu-6; CD1a
T60433	FUNCTION	Antigen-presenting protein that binds self and non-self lipid and glycolipid antigens and presents them to T-cell receptors on natural killer T-cells.
T60433	PDBSTRUC	5J1A; 4X6F; 4X6E; 4X6D; 4X6C
T60433	BIOCLASS	Immunoglobulin
T60433	SEQUENCE	MLFLLLPLLAVLPGDGNADGLKEPLSFHVTWIASFYNHSWKQNLVSGWLSDLQTHTWDSNSSTIVFLCPWSRGNFSNEEWKELETLFRIRTIRSFEGIRRYAHELQFEYPFEIQVTGGCELHSGKVSGSFLQLAYQGSDFVSFQNNSWLPYPVAGNMAKHFCKVLNQNQHENDITHNLLSDTCPRFILGLLDAGKAHLQRQVKPEAWLSHGPSPGPGHLQLVCHVSGFYPKPVWVMWMRGEQEQQGTQRGDILPSADGTWYLRATLEVAAGEAADLSCRVKHSSLEGQDIVLYWEHHSSVGFIILAVIVPLLLLIGLALWFRKRCFC
T60433	DRUGINFO	D0M7XS	Antithymocyte globulin	Approved
T60433	DRUGINFO	DUJ16L	PF-07242813	Phase 1

T87075	TARGETID	T87075
T87075	FORMERID	TTDS00473
T87075	UNIPROID	CD3E_HUMAN
T87075	TARGNAME	T-cell surface glycoprotein CD3 epsilon (CD3E)
T87075	GENENAME	CD3E
T87075	TARGTYPE	Successful
T87075	SYNONYMS	T3E; T-cell surface glycoprotein CD3 epsilon chain; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e
T87075	FUNCTION	When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain. Upon TCR engagement, these motifs become phosphorylated by Src family protein tyrosine kinases LCK and FYN, resulting in the activation of downstream signaling pathways. In addition of this role of signal transduction in T-cell activation, CD3E plays an essential role in correct T-cell development. Initiates the TCR-CD3 complex assembly by forming the two heterodimers CD3D/CD3E and CD3G/CD3E. Participates also in internalization and cell surface down-regulation of TCR-CD3 complexes via endocytosis sequences present in CD3E cytosolic region. Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response.
T87075	PDBSTRUC	2ROL; 1XIW; 1SY6; 1A81
T87075	SEQUENCE	MQSGTHWRVLGLCLLSVGVWGQDGNEEMGGITQTPYKVSISGTTVILTCPQYPGSEILWQHNDKNIGGDEDDKNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRARVCENCMEMDVMSVATIVIVDICITGGLLLLVYYWSKNRKAKAKPVTRGAGAGGRQRGQNKERPPPVPNPDYEPIRKGQRDLYSGLNQRRI
T87075	DRUGINFO	D0C6PS	Muromonab	Approved
T87075	DRUGINFO	D0C3TI	Resimmune	Phase 2
T87075	DRUGINFO	D0O2JI	Ertumaxomab	Phase 2
T87075	DRUGINFO	D00YOV	MT-110	Phase 1
T87075	DRUGINFO	D04UWG	Autologous T-cell therapy	Phase 1

T88452	TARGETID	T88452
T88452	FORMERID	TTDS00068
T88452	UNIPROID	CBG_HUMAN
T88452	TARGNAME	Corticosteroid-binding globulin (SERPINA6)
T88452	GENENAME	SERPINA6
T88452	TARGTYPE	Successful
T88452	SYNONYMS	Transcortin; SERPINA6; CBG
T88452	FUNCTION	Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
T88452	PDBSTRUC	4C49; 4C41; 4BB2; 2VDY; 2VDX
T88452	BIOCLASS	Serpin protein
T88452	SEQUENCE	MPLLLYTCLLWLPTSGLWTVQAMDPNAAYVNMSNHHRGLASANVDFAFSLYKHLVALSPKKNIFISPVSISMALAMLSLGTCGHTRAQLLQGLGFNLTERSETEIHQGFQHLHQLFAKSDTSLEMTMGNALFLDGSLELLESFSADIKHYYESEVLAMNFQDWATASRQINSYVKNKTQGKIVDLFSGLDSPAILVLVNYIFFKGTWTQPFDLASTREENFYVDETTVVKVPMMLQSSTISYLHDSELPCQLVQMNYVGNGTVFFILPDKGKMNTVIAALSRDTINRWSAGLTSSQVDLYIPKVTISGVYDLGDVLEEMGIADLFTNQANFSRITQDAQLKSSKVVHKAVLQLNEEGVDTAGSTGVTLNLTSKPIILRFNQPFIIMIFDHFTWSSLFLARVMNPV
T88452	DRUGINFO	D03IKT	Paramethasone	Approved
T88452	DRUGINFO	D0F1EX	Alclometasone	Approved
T88452	DRUGINFO	D0K7HU	Ciclesonide	Approved
T88452	DRUGINFO	D09TSD	I-vation	Phase 2

T44068	TARGETID	T44068
T44068	FORMERID	TTDS00036
T44068	UNIPROID	ADRB1_HUMAN
T44068	TARGNAME	Adrenergic receptor beta-1 (ADRB1)
T44068	GENENAME	ADRB1
T44068	TARGTYPE	Successful
T44068	SYNONYMS	Beta-1 adrenoreceptor; Beta-1 adrenoceptor; Beta-1 adrenergic receptor; B1AR; ADRB1R
T44068	FUNCTION	Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
T44068	PDBSTRUC	2LSQ
T44068	BIOCLASS	GPCR rhodopsin
T44068	SEQUENCE	MGAGVLVLGASEPGNLSSAAPLPDGAATAARLLVPASPPASLLPPASESPEPLSQQWTAGMGLLMALIVLLIVAGNVLVIVAIAKTPRLQTLTNLFIMSLASADLVMGLLVVPFGATIVVWGRWEYGSFFCELWTSVDVLCVTASIETLCVIALDRYLAITSPFRYQSLLTRARARGLVCTVWAISALVSFLPILMHWWRAESDEARRCYNDPKCCDFVTNRAYAIASSVVSFYVPLCIMAFVYLRVFREAQKQVKKIDSCERRFLGGPARPPSPSPSPVPAPAPPPGPPRPAAAAATAPLANGRAGKRRPSRLVALREQKALKTLGIIMGVFTLCWLPFFLANVVKAFHRELVPDRLFVFFNWLGYANSAFNPIIYCRSPDFRKAFQRLLCCARRAARRRHATHGDRPRASGCLARPGPPPSPGAASDDDDDDVVGATPPARLLEPWAGCNGGAAADSDSSLDEPCRPGFASESKV
T44068	DRUGINFO	D00IUG	Levobunolol	Approved
T44068	DRUGINFO	D01JFT	Dipivefrin	Approved
T44068	DRUGINFO	D01JGV	Ajmalicine	Approved
T44068	DRUGINFO	D01UXC	Atenolol	Approved
T44068	DRUGINFO	D02FCQ	Protokylol Hydrochloride	Approved
T44068	DRUGINFO	D02YYF	Bretylium	Approved
T44068	DRUGINFO	D03GCJ	Carteolol	Approved
T44068	DRUGINFO	D03ROX	Betaxolol	Approved
T44068	DRUGINFO	D03XTC	Esmolol	Approved
T44068	DRUGINFO	D04JEE	Propranolol	Approved
T44068	DRUGINFO	D04PHC	Epinephrine	Approved
T44068	DRUGINFO	D04VMT	Sotalol	Approved
T44068	DRUGINFO	D05SHK	Nadolol	Approved
T44068	DRUGINFO	D05UVD	Timolol	Approved
T44068	DRUGINFO	D06KYN	Arbutamine	Approved
T44068	DRUGINFO	D06VFO	Anisodamine	Approved
T44068	DRUGINFO	D07MOX	Norepinephrine	Approved
T44068	DRUGINFO	D0A6CQ	Levobetaxolol	Approved
T44068	DRUGINFO	D0F2PO	Pindolol	Approved
T44068	DRUGINFO	D0HD9K	Acebutolol	Approved
T44068	DRUGINFO	D0I2MK	Metoprolol	Approved
T44068	DRUGINFO	D0J7RK	Dobutamine	Approved
T44068	DRUGINFO	D0K3ZR	Bisoprolol	Approved
T44068	DRUGINFO	D0KD1U	Practolol	Approved
T44068	DRUGINFO	D0L5FY	Metipranolol	Approved
T44068	DRUGINFO	D0W8SB	Penbutolol	Approved
T44068	DRUGINFO	D0X2MB	Oxprenolol	Approved
T44068	DRUGINFO	D0Z1UA	Nebivolol	Approved
T44068	DRUGINFO	D05ZJG	Anisodine	Approved
T44068	DRUGINFO	D0I8FI	Isoproterenol	Approved
T44068	DRUGINFO	D03MZJ	BUCINDOLOL	Phase 2/3
T44068	DRUGINFO	D05NZV	BRL 35135	Phase 2
T44068	DRUGINFO	D0H9MA	COR-1	Phase 2
T44068	DRUGINFO	D0P5FA	Galnobax	Phase 1/2
T44068	DRUGINFO	D0I2XM	L-796568	Phase 1
T44068	DRUGINFO	D0P9KA	YM-16151-4	Phase 1
T44068	DRUGINFO	D01VAB	Alprenolol	Withdrawn from market
T44068	DRUGINFO	D0JP4H	Bethanidine	Withdrawn from market
T44068	DRUGINFO	D0CY4V	Cetamolol	Terminated
T44068	DRUGINFO	D04YJU	L-755507	Terminated
T44068	DRUGINFO	D0D6AC	Cebutolol	Investigative
T44068	DRUGINFO	D0J2CR	CGP 20712A	Investigative
T44068	DRUGINFO	D02QPP	(R,S)-(-)-fenoterol	Investigative
T44068	DRUGINFO	D04JGC	(R,R)-(-)-fenoterol	Investigative
T44068	DRUGINFO	D0A9ED	Carazolol	Investigative
T44068	DRUGINFO	D0F7BV	1-(1H-Indol-4-yloxy)-3-phenethylamino-propan-2-ol	Investigative
T44068	DRUGINFO	D0XX5S	Dichloroisoproterenol	Investigative
T44068	DRUGINFO	D03BZW	[3H]CGP12177	Investigative
T44068	DRUGINFO	D04HXF	1-(2-isopropylphenoxy)-3-morpholinopropan-2-ol	Investigative
T44068	DRUGINFO	D0A4FU	1-(2-allylphenoxy)-3-morpholinopropan-2-ol	Investigative
T44068	DRUGINFO	D0L5MW	(+/-)-nantenine	Investigative
T44068	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T28076	TARGETID	T28076
T28076	FORMERID	TTDI01961
T28076	UNIPROID	FGF4_HUMAN
T28076	TARGNAME	Fibroblast growth factor-4 (FGF4)
T28076	GENENAME	FGF4
T28076	TARGTYPE	Successful
T28076	SYNONYMS	Transforming protein KS3; Heparinbinding growth factor 4; Heparin secretorytransforming protein 1; HST1; HST; HBGF4; Fibroblast growth factor 4; FGF4
T28076	FUNCTION	Plays an important role in the regulation of embryonic development, cell proliferation, and cell differentiation. Required for normal limb and cardiac valve development during embryogenesis.
T28076	PDBSTRUC	1IJT
T28076	BIOCLASS	Heparin-binding growth factors family
T28076	SEQUENCE	MSGPGTAAVALLPAVLLALLAPWAGRGGAAAPTAPNGTLEAELERRWESLVALSLARLPVAAQPKEAAVQSGAGDYLLGIKRLRRLYCNVGIGFHLQALPDGRIGGAHADTRDSLLELSPVERGVVSIFGVASRFFVAMSSKGKLYGSPFFTDECTFKEILLPNNYNAYESYKYPGMFIALSKNGKTKKGNRVSPTMKVTHFLPRL
T28076	DRUGINFO	D0F8CM	Pentosan Polysulfate	Approved
T28076	DRUGINFO	D0ER5F	Ad5FGF-4	Phase 3
T28076	DRUGINFO	D0G8UL	Alferminogene tadenovec	Phase 3
T28076	DRUGINFO	DZ0DT2	Generx	Phase 3

T93440	TARGETID	T93440
T93440	FORMERID	TTDS00521
T93440	UNIPROID	IL6RA_HUMAN; IL6RB_HUMAN
T93440	TARGNAME	Interleukin 6 receptor (IL6R)
T93440	GENENAME	IL6R; IL6ST
T93440	TARGTYPE	Successful
T93440	SYNONYMS	Membrane glycoprotein; Interleukin-6 receptor; IL-6R; IL-6 receptor
T93440	FUNCTION	Low concentration of a soluble form of IL6 receptor acts as an agonist of IL6 activity.
T93440	BIOCLASS	Cytokine receptor
T93440	SEQUENCE	MLAVGCALLAALLAAPGAALAPRRCPAQEVARGVLTSLPGDSVTLTCPGVEPEDNATVHWVLRKPAAGSHPSRWAGMGRRLLLRSVQLHDSGNYSCYRAGRPAGTVHLLVDVPPEEPQLSCFRKSPLSNVVCEWGPRSTPSLTTKAVLLVRKFQNSPAEDFQEPCQYSQESQKFSCQLAVPEGDSSFYIVSMCVASSVGSKFSKTQTFQGCGILQPDPPANITVTAVARNPRWLSVTWQDPHSWNSSFYRLRFELRYRAERSKTFTTWMVKDLQHHCVIHDAWSGLRHVVQLRAQEEFGQGEWSEWSPEAMGTPWTESRSPPAENEVSTPMQALTTNKDDDNILFRDSANATSLPVQDSSSVPLPTFLVAGGSLAFGTLLCIAIVLRFKKTWKLRALKEGKTSMHPPYSLGQLVPERPRPTPVLVPLISPPVSPSSLGSDNTSSHNRPDARDPRSPYDISNTDYFFPR
T93440	DRUGINFO	D08HPZ	Tocilizumab	Approved
T93440	DRUGINFO	D0Z8CQ	Sarilumab	Approved
T93440	DRUGINFO	D09HTB	SAR153191	Phase 3
T93440	DRUGINFO	D0Y1ZU	SA-237	Phase 3
T93440	DRUGINFO	D01XVF	Sirukumab	Phase 3
T93440	DRUGINFO	D05NIR	ALX-0061	Phase 2
T93440	DRUGINFO	D9J6XV	Vobarilizumab	Phase 2
T93440	DRUGINFO	D0G0UZ	SBP-002	Terminated
T93440	DRUGINFO	D07CIX	FM-101	Investigative
T93440	DRUGINFO	D07VQW	Sant7	Investigative
T93440	DRUGINFO	D09PLZ	NI-1201	Investigative
T93440	DRUGINFO	D07LUR	Alpha-D-Mannose	Investigative

T11448	TARGETID	T11448
T11448	FORMERID	TTDS00032
T11448	UNIPROID	ADA2A_HUMAN
T11448	TARGNAME	Adrenergic receptor alpha-2A (ADRA2A)
T11448	GENENAME	ADRA2A
T11448	TARGTYPE	Successful
T11448	SYNONYMS	Alpha-2AAR; Alpha-2A adrenoreceptor; Alpha-2A adrenoceptor; Alpha-2A adrenergic receptor; Alpha-2 adrenergic receptor subtype C10; ADRAR; ADRA2R
T11448	FUNCTION	The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol. Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
T11448	PDBSTRUC	1HOF; 1HOD; 1HO9; 1HLL
T11448	BIOCLASS	GPCR rhodopsin
T11448	SEQUENCE	MFRQEQPLAEGSFAPMGSLQPDAGNASWNGTEAPGGGARATPYSLQVTLTLVCLAGLLMLLTVFGNVLVIIAVFTSRALKAPQNLFLVSLASADILVATLVIPFSLANEVMGYWYFGKAWCEIYLALDVLFCTSSIVHLCAISLDRYWSITQAIEYNLKRTPRRIKAIIITVWVISAVISFPPLISIEKKGGGGGPQPAEPRCEINDQKWYVISSCIGSFFAPCLIMILVYVRIYQIAKRRTRVPPSRRGPDAVAAPPGGTERRPNGLGPERSAGPGGAEAEPLPTQLNGAPGEPAPAGPRDTDALDLEESSSSDHAERPPGPRRPERGPRGKGKARASQVKPGDSLPRRGPGATGIGTPAAGPGEERVGAAKASRWRGRQNREKRFTFVLAVVIGVFVVCWFPFFFTYTLTAVGCSVPRTLFKFFFWFGYCNSSLNPVIYTIFNHDFRRAFKKILCRGDRKRIV
T11448	DRUGINFO	D0WD8M	Connexyn	Approved
T11448	DRUGINFO	D0K0MW	Lofexidine	Approved
T11448	DRUGINFO	D0E9PK	MOXONIDINE	Approved
T11448	DRUGINFO	DJC4L7	A295	IND submitted
T11448	DRUGINFO	D8NY3J	Guanfacine	Phase 3
T11448	DRUGINFO	D0F2ML	MEDETOMIDINE	Phase 2
T11448	DRUGINFO	D0AI8V	DSP-1200	Phase 1
T11448	DRUGINFO	D0ZI0K	NMI-870	Discontinued in Phase 2
T11448	DRUGINFO	D01WJZ	MAZAPERTINE	Discontinued in Phase 2
T11448	DRUGINFO	D0KC5X	S-18616	Terminated
T11448	DRUGINFO	D08OWQ	SK&F-104078	Terminated
T11448	DRUGINFO	D03QMR	WB-4101	Terminated
T11448	DRUGINFO	D06HRY	SNAP-5089	Terminated
T11448	DRUGINFO	D0K9JP	A-80426	Terminated
T11448	DRUGINFO	D01SRL	7-Nitro-1,2,3,4-tetrahydro-isoquinoline	Investigative
T11448	DRUGINFO	D01SRS	3-Methyl-7-nitro-1,2,3,4-tetrahydro-isoquinoline	Investigative
T11448	DRUGINFO	D03DMN	AKUAMMIGINE	Investigative
T11448	DRUGINFO	D08OLL	BRL 44408	Investigative
T11448	DRUGINFO	D0H1WR	SK&F-29661	Investigative
T11448	DRUGINFO	D05QTJ	Chloroethylclonidine	Investigative
T11448	DRUGINFO	D0S4VR	(1H-Benzoimidazol-5-yl)-(1H-imidazol-2-yl)-amine	Investigative
T11448	DRUGINFO	D0ZC4S	(1H-Imidazol-2-yl)-quinoxalin-6-yl-amine	Investigative
T11448	DRUGINFO	D02KIS	(S)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline	Investigative
T11448	DRUGINFO	D02QXT	8-Methoxy-1,2,3,4-tetrahydro-benzo[h]isoquinoline	Investigative
T11448	DRUGINFO	D03EPY	1,2,3,4-tetrahydroisoquinoline	Investigative
T11448	DRUGINFO	D03HBZ	(3-Ethyl-indol-1-yl)-propyl-pyridin-4-yl-amine	Investigative
T11448	DRUGINFO	D03LRY	C-(6-Methoxy-naphthalen-1-yl)-methylamine	Investigative
T11448	DRUGINFO	D04PYQ	PIPEROXAN	Investigative
T11448	DRUGINFO	D04RBQ	1,2,3,4-Tetrahydro-benzo[h]isoquinolin-8-ol	Investigative
T11448	DRUGINFO	D06BWZ	MEZILAMINE	Investigative
T11448	DRUGINFO	D06SYS	METHYLNORADRENALINE	Investigative
T11448	DRUGINFO	D07ICV	GNF-PF-3878	Investigative
T11448	DRUGINFO	D07RLW	5-Aminomethyl-naphthalen-2-ol	Investigative
T11448	DRUGINFO	D07SYG	2,3-Dihydro-1H-isoindole	Investigative
T11448	DRUGINFO	D08ZRA	C-Naphthalen-1-yl-methylamine	Investigative
T11448	DRUGINFO	D09JZG	1,2,3,4,5,6-Hexahydro-benzo[c]azocine	Investigative
T11448	DRUGINFO	D0AE9M	Butyl-indol-1-yl-pyridin-4-yl-amine	Investigative
T11448	DRUGINFO	D0B2BO	6,7,8,9-Tetrahydro-5-thia-8-aza-benzocycloheptene	Investigative
T11448	DRUGINFO	D0C9DC	SK&F-64139	Investigative
T11448	DRUGINFO	D0D1RU	Indol-1-yl-pyridin-4-yl-amine	Investigative
T11448	DRUGINFO	D0E0KG	(R)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline	Investigative
T11448	DRUGINFO	D0E3OL	GNF-PF-2857	Investigative
T11448	DRUGINFO	D0E8HU	3-Fluoromethyl-1,2,3,4-tetrahydro-isoquinoline	Investigative
T11448	DRUGINFO	D0F5TA	Ethyl-indol-1-yl-pyridin-4-yl-amine	Investigative
T11448	DRUGINFO	D0K0KR	AR-129330	Investigative
T11448	DRUGINFO	D0L7IZ	JP1302	Investigative
T11448	DRUGINFO	D0M8FL	2,3,4,5-Tetrahydro-benzo[f][1,4]oxazepine	Investigative
T11448	DRUGINFO	D0P3HP	1,2,3,4,4a,5,10,10a-Octahydro-benzo[g]quinoline	Investigative
T11448	DRUGINFO	D0P8BE	(3-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine	Investigative
T11448	DRUGINFO	D0QH0X	2,3,4,5-Tetrahydro-1H-benzo[c]azepine	Investigative
T11448	DRUGINFO	D0QO8X	1,2,3,4-Tetrahydro-isoquinolin-7-ol	Investigative
T11448	DRUGINFO	D0R1XT	Indol-1-yl-methyl-pyridin-4-yl-amine	Investigative
T11448	DRUGINFO	D0TN2R	3-Methoxymethyl-1,2,3,4-tetrahydro-isoquinoline	Investigative
T11448	DRUGINFO	D0V0NJ	2,3,4,5-Tetrahydro-1H-benzo[e][1,4]diazepine	Investigative
T11448	DRUGINFO	D0V3IT	SNAP-5150	Investigative
T11448	DRUGINFO	D0W5IN	(2-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine	Investigative
T11448	DRUGINFO	D0Y8DJ	(1,2,3,4-Tetrahydro-isoquinolin-3-yl)-methanol	Investigative
T11448	DRUGINFO	D0Z7XI	3-Methyl-1,2,3,4-tetrahydro-isoquinoline	Investigative
T11448	DRUGINFO	D0ZS3M	Indol-1-yl-prop-2-ynyl-pyridin-4-yl-amine	Investigative
T11448	DRUGINFO	D0ZT8D	Tramazoline	Investigative
T11448	DRUGINFO	D08UDY	1',2',3',6'-Tetrahydro-[2,4']bipyridinyl	Investigative
T11448	DRUGINFO	D0I3XA	Ciproxifan	Investigative
T11448	DRUGINFO	D0MH0S	1-(3-Fluoro-pyridin-2-yl)-4-methyl-piperazine	Investigative
T11448	DRUGINFO	D06HHJ	(2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine	Investigative
T11448	DRUGINFO	D07JMN	1-(pyridin-2-yl)piperazine	Investigative
T11448	DRUGINFO	D09BIV	TRACIZOLINE	Investigative
T11448	DRUGINFO	D0A6GK	(2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine	Investigative
T11448	DRUGINFO	D0FU5E	S-34324	Investigative
T11448	DRUGINFO	D0H3NA	4-Benzo[b]thiophen-4-yl-1H-imidazole	Investigative
T11448	DRUGINFO	D0LI3J	2-BFi	Investigative
T11448	DRUGINFO	D03LPH	TRYPTOLINE	Investigative
T11448	DRUGINFO	D05GDP	7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline	Investigative
T11448	DRUGINFO	D08KLH	[3H]RX821002	Investigative
T11448	DRUGINFO	D0C1SE	1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole	Investigative
T11448	DRUGINFO	D0L9WN	4-(4-Methyl-indan-1-yl)-1H-imidazole	Investigative
T11448	DRUGINFO	D0P5PW	4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole	Investigative
T11448	DRUGINFO	D01KAX	1-((S)-2-aminopropyl)-1H-indazol-6-ol	Investigative
T11448	DRUGINFO	D0R7ZC	Beta-methoxyamphetamine	Investigative
T11448	DRUGINFO	D0PN9R	R-226161	Investigative
T11448	DRUGINFO	D0L5MW	(+/-)-nantenine	Investigative
T11448	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T31621	TARGETID	T31621
T31621	FORMERID	TTDR00567
T31621	UNIPROID	FGF2_HUMAN
T31621	TARGNAME	Fibroblast growth factor-2 (FGF2)
T31621	GENENAME	FGF2
T31621	TARGTYPE	Successful
T31621	SYNONYMS	bFGF; Heparin-binding growth factor 2; HBGF-2; Fibroblast growth factor 2; FGFB; FGF-2; Basic fibroblast growth factor
T31621	FUNCTION	Acts as a ligand for FGFR1, FGFR2, FGFR3 and FGFR4. Also acts as an integrin ligand which is required for FGF2 signaling. Binds to integrin ITGAV:ITGB3. Plays an important role in the regulation of cell survival, cell division, cell differentiation and cell migration. Functions as a potent mitogen in vitro. Can induce angiogenesis.
T31621	PDBSTRUC	5X1O; 4OEG; 4OEF; 4OEE; 4FGF
T31621	BIOCLASS	Growth factor
T31621	SEQUENCE	MVGVGGGDVEDVTPRPGGCQISGRGARGCNGIPGAAAWEAALPRRRPRRHPSVNPRSRAAGSPRTRGRRTEERPSGSRLGDRGRGRALPGGRLGGRGRGRAPERVGGRGRGRGTAAPRAAPAARGSRPGPAGTMAAGSITTLPALPEDGGSGAFPPGHFKDPKRLYCKNGGFFLRIHPDGRVDGVREKSDPHIKLQLQAEERGVVSIKGVCANRYLAMKEDGRLLASKCVTDECFFFERLESNNYNTYRSRKYTSWYVALKRTGQYKLGSKTGPGQKAILFLPMSAKS
T31621	DRUGINFO	D06ULU	Sucralfate	Approved
T31621	DRUGINFO	D07PVB	Squalamine	Phase 3
T31621	DRUGINFO	D00IZD	DVC1-0101	Phase 2
T31621	DRUGINFO	D05ISO	Bemarituzumab	Phase 2
T31621	DRUGINFO	D06NND	FPA144	Phase 1
T31621	DRUGINFO	D0B4XU	TGP-580	Discontinued in Phase 2
T31621	DRUGINFO	D09ZAV	RG-8803	Terminated
T31621	DRUGINFO	D0KL1I	1,4-Dideoxy-O2-Sulfo-Glucuronic Acid	Investigative
T31621	DRUGINFO	D0X4AL	1,4-Dideoxy-5-Dehydro-O2-Sulfo-Glucuronic Acid	Investigative
T31621	DRUGINFO	D0N1RE	BIBF100	Investigative
T31621	DRUGINFO	D0B0SV	N,O6-Disulfo-Glucosamine	Investigative
T31621	DRUGINFO	D0Q5FV	2-Sulfhydryl-Ethanol	Investigative

T19615	TARGETID	T19615
T19615	FORMERID	TTDR01234
T19615	UNIPROID	CSF3_HUMAN
T19615	TARGNAME	Granulocyte colony-stimulating factor (CSF3)
T19615	GENENAME	CSF3
T19615	TARGTYPE	Successful
T19615	SYNONYMS	Pluripoietin; Lenograstim; G-CSF; CSF3
T19615	FUNCTION	Granulocyte/macrophage colony-stimulating factors are cytokines that act in hematopoiesis by controlling the production, differentiation, and function of 2 related white cell populations of the blood, the granulocytes and the monocytes-macrophages. This CSF induces granulocytes.
T19615	PDBSTRUC	5ZO6; 5GW9; 2D9Q; 1RHG; 1PGR
T19615	BIOCLASS	Cytokine: interleukin
T19615	SEQUENCE	MAGPATQSPMKLMALQLLLWHSALWTVQEATPLGPASSLPQSFLLKCLEQVRKIQGDGAALQEKLVSECATYKLCHPEELVLLGHSLGIPWAPLSSCPSQALQLAGCLSQLHSGLFLYQGLLQALEGISPELGPTLDTLQLDVADFATTIWQQMEELGMAPALQPTQGAMPAFASAFQRRAGGVLVASHLQSFLEVSYRVLRHLAQP
T19615	DRUGINFO	D07BUH	Efbemalenograstim	Approved
T19615	DRUGINFO	D0CH1U	Interleukin-3	Approved
T19615	DRUGINFO	D0FP8S	Neugranin	Preregistration
T19615	DRUGINFO	D01REE	DA-3031	Phase 3
T19615	DRUGINFO	D07FPJ	MK-4214	Phase 3
T19615	DRUGINFO	D07JZT	LA-EP2006	Phase 3

T24634	TARGETID	T24634
T24634	FORMERID	TTDS00233
T24634	UNIPROID	MURA_ECOLI
T24634	TARGNAME	Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA)
T24634	GENENAME	Bact murA
T24634	TARGTYPE	Successful
T24634	SYNONYMS	UDP-N-acetylglucosamine enolpyruvyl transferase; UDP-GlcNAcenolpyruvyl transferase; MurA protein; MurA; Enoylpyruvate transferase; EPT
T24634	FUNCTION	Cell wall formation. Adds enolpyruvyl to UDP-n- acetylglucosamine. Target for the antibiotic phosphomycin.
T24634	PDBSTRUC	3SWD; 3KR6; 3KQJ; 3ISS; 2Z2C
T24634	BIOCLASS	Alkyl aryl transferase
T24634	SEQUENCE	MDKFRVQGPTKLQGEVTISGAKNAALPILFAALLAEEPVEIQNVPKLKDVDTSMKLLSQLGAKVERNGSVHIDARDVNVFCAPYDLVKTMRASIWALGPLVARFGQGQVSLPGGCTIGARPVDLHISGLEQLGATIKLEEGYVKASVDGRLKGAHIVMDKVSVGATVTIMCAATLAEGTTIIENAAREPEIVDTANFLITLGAKISGQGTDRIVIEGVERLGGGVYRVLPDRIETGTFLVAAAISRGKIICRNAQPDTLDAVLAKLRDAGADIEVGEDWISLDMHGKRPKAVNVRTAPHPAFPTDMQAQFTLLNLVAEGTGFITETVFENRFMHVPELSRMGAHAEIESNTVICHGVEKLSGAQVMATDLRASASLVLAGCIAEGTTVVDRIYHIDRGYERIEDKLRALGANIERVKGE
T24634	DRUGINFO	D01GYT	Fosfomycin	Approved
T24634	DRUGINFO	D04SDN	RWJ-3981	Investigative
T24634	DRUGINFO	D05BIJ	RWJ-140998	Investigative
T24634	DRUGINFO	D06FHW	Aminomethylcyclohexane	Investigative
T24634	DRUGINFO	D06HIW	EUPATORIOPICRIN	Investigative
T24634	DRUGINFO	D09RZX	CNICIN	Investigative
T24634	DRUGINFO	D0E9IM	L-Iso-Aspartate	Investigative
T24634	DRUGINFO	D0G2MM	Cyclohexylammonium Ion	Investigative
T24634	DRUGINFO	D0S2TZ	CYNAROPICRIN	Investigative
T24634	DRUGINFO	D0KC2Z	Uridine-Diphosphate-N-Acetylglucosamine	Investigative

T61657	TARGETID	T61657
T61657	FORMERID	TTDR01191
T61657	UNIPROID	RARB_HUMAN
T61657	TARGNAME	Retinoic acid receptor beta (RARB)
T61657	GENENAME	RARB
T61657	TARGTYPE	Successful
T61657	SYNONYMS	RAR-epsilon; RAR-beta; Nuclear receptor subfamily 1 group B member 2; NR1B2; HBV-activated protein; HAP
T61657	FUNCTION	Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to corepressors. In concert with RARG, required for skeletal growth, matrix homeostasis and growth plate function. Receptor for retinoic acid.
T61657	PDBSTRUC	5UAN; 4JYI; 4JYH; 4JYG; 4DM8
T61657	BIOCLASS	Nuclear hormone receptor
T61657	SEQUENCE	MTTSGHACPVPAVNGHMTHYPATPYPLLFPPVIGGLSLPPLHGLHGHPPPSGCSTPSPATIETQSTSSEELVPSPPSPLPPPRVYKPCFVCQDKSSGYHYGVSACEGCKGFFRRSIQKNMIYTCHRDKNCVINKVTRNRCQYCRLQKCFEVGMSKESVRNDRNKKKKETSKQECTESYEMTAELDDLTEKIRKAHQETFPSLCQLGKYTTNSSADHRVRLDLGLWDKFSELATKCIIKIVEFAKRLPGFTGLTIADQITLLKAACLDILILRICTRYTPEQDTMTFSDGLTLNRTQMHNAGFGPLTDLVFTFANQLLPLEMDDTETGLLSAICLICGDRQDLEEPTKVDKLQEPLLEALKIYIRKRRPSKPHMFPKILMKITDLRSISAKGAERVITLKMEIPGSMPPLIQEMLENSEGHEPLTPSSSGNTAEHSPSISPSSVENSGVSQSPLVQ
T61657	DRUGINFO	D0G3PI	Alitretinoin	Approved
T61657	DRUGINFO	D02GTY	Tamibarotene	Phase 3
T61657	DRUGINFO	D0E2AD	PMID27336223-Compound-10	Patented
T61657	DRUGINFO	D0M5EC	PMID27336223-Compound-8	Patented
T61657	DRUGINFO	D0PU1L	PMID27336223-Compound-7	Patented
T61657	DRUGINFO	D05QYR	AC55649	Investigative
T61657	DRUGINFO	D09RNF	BMS641	Investigative
T61657	DRUGINFO	D09RRF	AC261066	Investigative
T61657	DRUGINFO	D0G6JM	TTNPB	Investigative
T61657	DRUGINFO	D0F8CC	CD666	Investigative
T61657	DRUGINFO	D0Q0IR	AGN193109	Investigative

T79591	TARGETID	T79591
T79591	FORMERID	TTDS00381
T79591	UNIPROID	THA_HUMAN
T79591	TARGNAME	Thyroid hormone receptor alpha (THRA)
T79591	GENENAME	THRA
T79591	TARGTYPE	Successful
T79591	SYNONYMS	V-erbA-related protein 7; THRA2; THRA1; Nuclear receptor subfamily 1 group A member 1; NR1A1; ERBA1; EAR7; EAR-7; C-erbA-alpha; C-erbA-1
T79591	FUNCTION	High affinity receptor for thyroid hormones, including triiodothyronine and thyroxine. Isoform Alpha-1: Nuclear hormone receptor that can act as a repressor or activator of transcription.
T79591	PDBSTRUC	4LNX; 4LNW; 3JZB; 3ILZ; 3HZF
T79591	BIOCLASS	Nuclear hormone receptor
T79591	SEQUENCE	MEQKPSKVECGSDPEENSARSPDGKRKRKNGQCSLKTSMSGYIPSYLDKDEQCVVCGDKATGYHYRCITCEGCKGFFRRTIQKNLHPTYSCKYDSCCVIDKITRNQCQLCRFKKCIAVGMAMDLVLDDSKRVAKRKLIEQNRERRRKEEMIRSLQQRPEPTPEEWDLIHIATEAHRSTNAQGSHWKQRRKFLPDDIGQSPIVSMPDGDKVDLEAFSEFTKIITPAITRVVDFAKKLPMFSELPCEDQIILLKGCCMEIMSLRAAVRYDPESDTLTLSGEMAVKREQLKNGGLGVVSDAIFELGKSLSAFNLDDTEVALLQAVLLMSTDRSGLLCVDKIEKSQEAYLLAFEHYVNHRKHNIPHFWPKLLMKEREVQSSILYKGAAAEGRPGGSLGVHPEGQQLLGMHVVQGPQVRQLEQQLGEAGSLQGPVLQHQSPKSPQQRLLELLHRSGILHARAVCGEDDSSEADSPSSSEEEPEVCEDLAGNAASP
T79591	DRUGINFO	D06RGG	Levothyroxine	Approved
T79591	DRUGINFO	D0S6JG	Liothyronine	Approved
T79591	DRUGINFO	D03TPR	Dextrothyroxine Sodium	Approved
T79591	DRUGINFO	D03KVY	BCT303	Phase 2
T79591	DRUGINFO	D0J6XC	tiratricol	Clinical trial
T79591	DRUGINFO	D01HAZ	3-(dibutylamino)-1-(4-hexylphenyl)propan-1-one	Investigative
T79591	DRUGINFO	D01NTN	3-(3,5-Dibromo-4-hexyloxy-phenyl)-propionic acid	Investigative
T79591	DRUGINFO	D03VOM	3-(dimethylamino)-1-(4-hexylphenyl)propan-1-one	Investigative
T79591	DRUGINFO	D04FQZ	4-(4-hexylphenyl)-4-oxobut-2-enoic acid	Investigative
T79591	DRUGINFO	D05FRX	(3,5-Dibromo-4-hexyloxy-phenyl)-acetic acid	Investigative
T79591	DRUGINFO	D06IJW	1-(4-hexylphenyl)-3-morpholinopropan-1-one	Investigative
T79591	DRUGINFO	D09XOC	3-bromo-1-(4-hexylphenyl)propan-1-one	Investigative
T79591	DRUGINFO	D0I2GK	Detrothyronine	Investigative
T79591	DRUGINFO	D0I7DH	(E)-1-(4-heptylphenyl)but-2-en-1-one	Investigative
T79591	DRUGINFO	D0J0MD	(Z)-4-(4-hexylphenylamino)-4-oxobut-2-enoic acid	Investigative
T79591	DRUGINFO	D0Q0YS	rT3	Investigative
T79591	DRUGINFO	D0Q9ZN	3-(4-(benzyloxy)-3,5-dibromophenyl)propanoic acid	Investigative
T79591	DRUGINFO	D0ZX0Y	4-hexylphenyl propiolate	Investigative

T98933	TARGETID	T98933
T98933	FORMERID	TTDR01227
T98933	UNIPROID	THB_HUMAN
T98933	TARGNAME	Thyroid hormone receptor beta (THRB)
T98933	GENENAME	THRB
T98933	TARGTYPE	Successful
T98933	SYNONYMS	c-erbA-beta; c-erbA-2; THR1; Nuclear receptor subfamily 1 group A member 2; NR1A2; ERBA2
T98933	FUNCTION	High affinity receptor for thyroid hormones, including triiodothyronine and thyroxine. Nuclear hormone receptor that can act as a repressor or activator of transcription.
T98933	PDBSTRUC	4ZO1; 3JZC; 3IMY; 3GWS; 3D57
T98933	BIOCLASS	Nuclear hormone receptor
T98933	SEQUENCE	MTPNSMTENGLTAWDKPKHCPDREHDWKLVGMSEACLHRKSHSERRSTLKNEQSSPHLIQTTWTSSIFHLDHDDVNDQSVSSAQTFQTEEKKCKGYIPSYLDKDELCVVCGDKATGYHYRCITCEGCKGFFRRTIQKNLHPSYSCKYEGKCVIDKVTRNQCQECRFKKCIYVGMATDLVLDDSKRLAKRKLIEENREKRRREELQKSIGHKPEPTDEEWELIKTVTEAHVATNAQGSHWKQKRKFLPEDIGQAPIVNAPEGGKVDLEAFSHFTKIITPAITRVVDFAKKLPMFCELPCEDQIILLKGCCMEIMSLRAAVRYDPESETLTLNGEMAVTRGQLKNGGLGVVSDAIFDLGMSLSSFNLDDTEVALLQAVLLMSSDRPGLACVERIEKYQDSFLLAFEHYINYRKHHVTHFWPKLLMKVTDLRMIGACHASRFLHMKVECPTELFPPLFLEVFED
T98933	DRUGINFO	D03TPR	Dextrothyroxine Sodium	Approved
T98933	DRUGINFO	D03MYO	MGL-3196	Phase 2
T98933	DRUGINFO	D07ZTD	MB-07811	Phase 2
T98933	DRUGINFO	D0E7AK	VK-2809	Phase 2
T98933	DRUGINFO	D03KVY	BCT303	Phase 2
T98933	DRUGINFO	D05DCL	ZYT-1	Phase 1
T98933	DRUGINFO	D0V5FQ	Axitirome	Phase 1
T98933	DRUGINFO	DJ74CB	VK-0214	Phase 1
T98933	DRUGINFO	D0J6XC	tiratricol	Clinical trial
T98933	DRUGINFO	D02CGG	2-hexylphenyl acrylate	Investigative
T98933	DRUGINFO	D03XCG	1-(4-hexylphenyl)-3-(propylamino)propan-1-one	Investigative
T98933	DRUGINFO	D05XMM	4-(3-(Dimethylamino)propanoyl)-N-hexylbenzamide	Investigative
T98933	DRUGINFO	D05ZJC	(3,5-Dibromo-4-butoxy-phenyl)-acetic acid	Investigative
T98933	DRUGINFO	D06WJC	GC-24	Investigative
T98933	DRUGINFO	D08BQI	(3,5-Dibromo-4-pentyloxy-phenyl)-acetic acid	Investigative
T98933	DRUGINFO	D0G7HF	(4-hexylphenyl)(oxiran-2-yl)methanone	Investigative
T98933	DRUGINFO	D0H6BV	1-(4-(Hexyloxy)phenyl)-3-morpholinopropan-1-one	Investigative
T98933	DRUGINFO	D0U0GY	1-(4-heptylphenyl)prop-2-en-1-one	Investigative
T98933	DRUGINFO	D0U9JC	1-(4-octylphenyl)prop-2-en-1-one	Investigative
T98933	DRUGINFO	D0YU9Z	1-(4-HEXYLPHENYL)PROP-2-EN-1-ONE	Investigative
T98933	DRUGINFO	D01HAZ	3-(dibutylamino)-1-(4-hexylphenyl)propan-1-one	Investigative
T98933	DRUGINFO	D01NTN	3-(3,5-Dibromo-4-hexyloxy-phenyl)-propionic acid	Investigative
T98933	DRUGINFO	D03VOM	3-(dimethylamino)-1-(4-hexylphenyl)propan-1-one	Investigative
T98933	DRUGINFO	D04FQZ	4-(4-hexylphenyl)-4-oxobut-2-enoic acid	Investigative
T98933	DRUGINFO	D05FRX	(3,5-Dibromo-4-hexyloxy-phenyl)-acetic acid	Investigative
T98933	DRUGINFO	D06IJW	1-(4-hexylphenyl)-3-morpholinopropan-1-one	Investigative
T98933	DRUGINFO	D07MAF	3-(dimethylamino)-1-(4-heptylphenyl)propan-1-one	Investigative
T98933	DRUGINFO	D09XOC	3-bromo-1-(4-hexylphenyl)propan-1-one	Investigative
T98933	DRUGINFO	D0I2GK	Detrothyronine	Investigative
T98933	DRUGINFO	D0I7DH	(E)-1-(4-heptylphenyl)but-2-en-1-one	Investigative
T98933	DRUGINFO	D0J0MD	(Z)-4-(4-hexylphenylamino)-4-oxobut-2-enoic acid	Investigative
T98933	DRUGINFO	D0Q0YS	rT3	Investigative
T98933	DRUGINFO	D0Q9ZN	3-(4-(benzyloxy)-3,5-dibromophenyl)propanoic acid	Investigative
T98933	DRUGINFO	D0ZX0Y	4-hexylphenyl propiolate	Investigative
T98933	DRUGINFO	D09TVP	Cacodylate Ion	Investigative

T02333	TARGETID	T02333
T02333	FORMERID	TTDS00076
T02333	UNIPROID	GHR_HUMAN
T02333	TARGNAME	Growth hormone receptor (GHR)
T02333	GENENAME	GHR
T02333	TARGTYPE	Successful
T02333	SYNONYMS	Somatotropin receptor; Serum bindingprotein; GH receptor
T02333	FUNCTION	On ligand binding, couples to the JAK2/STAT5 pathway. Receptor for pituitary gland growth hormone involved in regulating postnatal body growth.
T02333	PDBSTRUC	5OHD; 5OEK; 3HHR; 2AEW; 1KF9
T02333	BIOCLASS	Cytokine receptor
T02333	SEQUENCE	MDLWQLLLTLALAGSSDAFSGSEATAAILSRAPWSLQSVNPGLKTNSSKEPKFTKCRSPERETFSCHWTDEVHHGTKNLGPIQLFYTRRNTQEWTQEWKECPDYVSAGENSCYFNSSFTSIWIPYCIKLTSNGGTVDEKCFSVDEIVQPDPPIALNWTLLNVSLTGIHADIQVRWEAPRNADIQKGWMVLEYELQYKEVNETKWKMMDPILTTSVPVYSLKVDKEYEVRVRSKQRNSGNYGEFSEVLYVTLPQMSQFTCEEDFYFPWLLIIIFGIFGLTVMLFVFLFSKQQRIKMLILPPVPVPKIKGIDPDLLKEGKLEEVNTILAIHDSYKPEFHSDDSWVEFIELDIDEPDEKTEESDTDRLLSSDHEKSHSNLGVKDGDSGRTSCCEPDILETDFNANDIHEGTSEVAQPQRLKGEADLLCLDQKNQNNSPYHDACPATQQPSVIQAEKNKPQPLPTEGAESTHQAAHIQLSNPSSLSNIDFYAQVSDITPAGSVVLSPGQKNKAGMSQCDMHPEMVSLCQENFLMDNAYFCEADAKKCIPVAPHIKVESHIQPSLNQEDIYITTESLTTAAGRPGTGEHVPGSEMPVPDYTSIHIVQSPQGLILNATALPLPDKEFLSSCGYVSTDQLNKIMP
T02333	DRUGINFO	D0D6VE	Pegvisomant	Approved
T02333	DRUGINFO	D0P4DJ	Somatropin recombinant	Approved
T02333	DRUGINFO	D05ECK	SKF-110679	Phase 2
T02333	DRUGINFO	D0K1SR	PH-794428	Phase 2
T02333	DRUGINFO	DU26QH	IONIS-GHR-LRx	Phase 2
T02333	DRUGINFO	D03MWZ	Syntropin	Phase 1
T02333	DRUGINFO	D0O1LU	EP-51389	Phase 1
T02333	DRUGINFO	D0Z6WI	EP-51216	Phase 1
T02333	DRUGINFO	D0O7XO	AOD-9604	Discontinued in Phase 2
T02333	DRUGINFO	D00LWR	BVT-A	Preclinical
T02333	DRUGINFO	D0BW2C	NNC-26-0194	Investigative

T06455	TARGETID	T06455
T06455	FORMERID	TTDR01443
T06455	UNIPROID	CP2A6_HUMAN
T06455	TARGNAME	Cytochrome P450 2A6 (CYP2A6)
T06455	GENENAME	CYP2A6
T06455	TARGTYPE	Successful
T06455	SYNONYMS	Cytochrome P450(I); Cytochrome P450 IIA3; Coumarin 7-hydroxylase; CYPIIA6; CYP2A6; CYP2A3
T06455	FUNCTION	Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Possesses low phenacetin O-deethylation activity.
T06455	PDBSTRUC	4RUI; 4EJJ; 3T3R; 3T3Q; 3EBS
T06455	BIOCLASS	Paired donor oxygen oxidoreductase
T06455	ECNUMBER	EC 1.14.13.-
T06455	SEQUENCE	MLASGMLLVALLVCLTVMVLMSVWQQRKSKGKLPPGPTPLPFIGNYLQLNTEQMYNSLMKISERYGPVFTIHLGPRRVVVLCGHDAVREALVDQAEEFSGRGEQATFDWVFKGYGVVFSNGERAKQLRRFSIATLRDFGVGKRGIEERIQEEAGFLIDALRGTGGANIDPTFFLSRTVSNVISSIVFGDRFDYKDKEFLSLLRMMLGIFQFTSTSTGQLYEMFSSVMKHLPGPQQQAFQLLQGLEDFIAKKVEHNQRTLDPNSPRDFIDSFLIRMQEEEKNPNTEFYLKNLVMTTLNLFIGGTETVSTTLRYGFLLLMKHPEVEAKVHEEIDRVIGKNRQPKFEDRAKMPYMEAVIHEIQRFGDVIPMSLARRVKKDTKFRDFFLPKGTEVYPMLGSVLRDPSFFSNPQDFNPQHFLNEKGQFKKSDAFVPFSIGKRNCFGEGLARMELFLFFTTVMQNFRLKSSQSPKDIDVSPKHVGFATIPRNYTMSFLPR
T06455	DRUGINFO	D08SKH	Methoxsalen	Approved

T37510	TARGETID	T37510
T37510	FORMERID	TTDS00204
T37510	UNIPROID	FA5_HUMAN
T37510	TARGNAME	Coagulation factor Va (F5)
T37510	GENENAME	F5
T37510	TARGTYPE	Successful
T37510	SYNONYMS	Factor Va; F5
T37510	FUNCTION	Central regulator of hemostasis. It serves as a critical cofactor for the prothrombinase activity of factor Xa that results in the activation of prothrombin to thrombin.
T37510	PDBSTRUC	3S9C; 3P70; 3P6Z; 1Y61; 1FV4
T37510	SEQUENCE	MFPGCPRLWVLVVLGTSWVGWGSQGTEAAQLRQFYVAAQGISWSYRPEPTNSSLNLSVTSFKKIVYREYEPYFKKEKPQSTISGLLGPTLYAEVGDIIKVHFKNKADKPLSIHPQGIRYSKLSEGASYLDHTFPAEKMDDAVAPGREYTYEWSISEDSGPTHDDPPCLTHIYYSHENLIEDFNSGLIGPLLICKKGTLTEGGTQKTFDKQIVLLFAVFDESKSWSQSSSLMYTVNGYVNGTMPDITVCAHDHISWHLLGMSSGPELFSIHFNGQVLEQNHHKVSAITLVSATSTTANMTVGPEGKWIISSLTPKHLQAGMQAYIDIKNCPKKTRNLKKITREQRRHMKRWEYFIAAEEVIWDYAPVIPANMDKKYRSQHLDNFSNQIGKHYKKVMYTQYEDESFTKHTVNPNMKEDGILGPIIRAQVRDTLKIVFKNMASRPYSIYPHGVTFSPYEDEVNSSFTSGRNNTMIRAVQPGETYTYKWNILEFDEPTENDAQCLTRPYYSDVDIMRDIASGLIGLLLICKSRSLDRRGIQRAADIEQQAVFAVFDENKSWYLEDNINKFCENPDEVKRDDPKFYESNIMSTINGYVPESITTLGFCFDDTVQWHFCSVGTQNEILTIHFTGHSFIYGKRHEDTLTLFPMRGESVTVTMDNVGTWMLTSMNSSPRSKKLRLKFRDVKCIPDDDEDSYEIFEPPESTVMATRKMHDRLEPEDEESDADYDYQNRLAAALGIRSFRNSSLNQEEEEFNLTALALENGTEFVSSNTDIIVGSNYSSPSNISKFTVNNLAEPQKAPSHQQATTAGSPLRHLIGKNSVLNSSTAEHSSPYSEDPIEDPLQPDVTGIRLLSLGAGEFKSQEHAKHKGPKVERDQAAKHRFSWMKLLAHKVGRHLSQDTGSPSGMRPWEDLPSQDTGSPSRMRPWKDPPSDLLLLKQSNSSKILVGRWHLASEKGSYEIIQDTDEDTAVNNWLISPQNASRAWGESTPLANKPGKQSGHPKFPRVRHKSLQVRQDGGKSRLKKSQFLIKTRKKKKEKHTHHAPLSPRTFHPLRSEAYNTFSERRLKHSLVLHKSNETSLPTDLNQTLPSMDFGWIASLPDHNQNSSNDTGQASCPPGLYQTVPPEEHYQTFPIQDPDQMHSTSDPSHRSSSPELSEMLEYDRSHKSFPTDISQMSPSSEHEVWQTVISPDLSQVTLSPELSQTNLSPDLSHTTLSPELIQRNLSPALGQMPISPDLSHTTLSPDLSHTTLSLDLSQTNLSPELSQTNLSPALGQMPLSPDLSHTTLSLDFSQTNLSPELSHMTLSPELSQTNLSPALGQMPISPDLSHTTLSLDFSQTNLSPELSQTNLSPALGQMPLSPDPSHTTLSLDLSQTNLSPELSQTNLSPDLSEMPLFADLSQIPLTPDLDQMTLSPDLGETDLSPNFGQMSLSPDLSQVTLSPDISDTTLLPDLSQISPPPDLDQIFYPSESSQSLLLQEFNESFPYPDLGQMPSPSSPTLNDTFLSKEFNPLVIVGLSKDGTDYIEIIPKEEVQSSEDDYAEIDYVPYDDPYKTDVRTNINSSRDPDNIAAWYLRSNNGNRRNYYIAAEEISWDYSEFVQRETDIEDSDDIPEDTTYKKVVFRKYLDSTFTKRDPRGEYEEHLGILGPIIRAEVDDVIQVRFKNLASRPYSLHAHGLSYEKSSEGKTYEDDSPEWFKEDNAVQPNSSYTYVWHATERSGPESPGSACRAWAYYSAVNPEKDIHSGLIGPLLICQKGILHKDSNMPMDMREFVLLFMTFDEKKSWYYEKKSRSSWRLTSSEMKKSHEFHAINGMIYSLPGLKMYEQEWVRLHLLNIGGSQDIHVVHFHGQTLLENGNKQHQLGVWPLLPGSFKTLEMKASKPGWWLLNTEVGENQRAGMQTPFLIMDRDCRMPMGLSTGIISDSQIKASEFLGYWEPRLARLNNGGSYNAWSVEKLAAEFASKPWIQVDMQKEVIITGIQTQGAKHYLKSCYTTEFYVAYSSNQINWQIFKGNSTRNVMYFNGNSDASTIKENQFDPPIVARYIRISPTRAYNRPTLRLELQGCEVNGCSTPLGMENGKIENKQITASSFKKSWWGDYWEPFRARLNAQGRVNAWQAKANNNKQWLEIDLLKIKKITAIITQGCKSLSSEMYVKSYTIHYSEQGVEWKPYRLKSSMVDKIFEGNTNTKGHVKNFFNPPIISRFIRVIPKTWNQSIALRLELFGCDIY
T37510	DRUGINFO	D0PG0G	Drotrecogin alfa	Approved
T37510	DRUGINFO	D0MY1A	Phenylmercury	Investigative
T37510	DRUGINFO	D0ON2Z	RAZAXABAN	Investigative

T22212	TARGETID	T22212
T22212	FORMERID	TTDS00515
T22212	UNIPROID	FCG2A_HUMAN
T22212	TARGNAME	Immunoglobulin gamma Fc receptor IIA (FCGR2A)
T22212	GENENAME	FCGR2A
T22212	TARGTYPE	Successful
T22212	SYNONYMS	Low affinity immunoglobulin gamma Fc region receptor II-a; IgG Fc receptor II-a; FcRII-a; Fc-gamma-RIIa; Fc-gamma RII-a; FCGR2A1; FCG2A; CDw32 A; CD32 A
T22212	FUNCTION	Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens.
T22212	PDBSTRUC	3RY6; 3RY5; 3RY4; 3D5O; 1H9V
T22212	BIOCLASS	Immunoglobulin
T22212	SEQUENCE	MTMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTLTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVLSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSHLDPTFSIPQANHSHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDDKNIYLTLPPNDHVNSNN
T22212	DRUGINFO	D0H6VY	SM-101	Approved (orphan drug)

T55654	TARGETID	T55654
T55654	FORMERID	TTDNS00605
T55654	UNIPROID	CFTR_HUMAN
T55654	TARGNAME	cAMP-dependent chloride channel (CFTR)
T55654	GENENAME	CFTR
T55654	TARGTYPE	Successful
T55654	SYNONYMS	cAMPdependent chloride channel; Cystic fibrosis transmembrane conductance regulator; Channel conductancecontrolling ATPase; ATPbinding cassette subfamily C member 7; ATP-binding cassette sub-family C member 7; ABCC7
T55654	FUNCTION	Mediates the transport of chloride ions across the cell membrane. Channel activity is coupled to ATP hydrolysis. The ion channel is also permeable to HCO(3-); selectivity depends on the extracellular chloride concentration. Exerts its function also by modulating the activity of other ion channels and transporters. Plays an important role in airway fluid homeostasis. Contributes to the regulation of the pH and the ion content of the airway surface fluid layer and thereby plays an important role in defense against pathogens. Modulates the activity of the epithelial sodium channel (ENaC) complex, in part by regulating the cell surface expression of the ENaC complex. Inhibits the activity of the ENaC channel containing subunits SCNN1A, SCNN1B and SCNN1G. Inhibits the activity of the ENaC channel containing subunits SCNN1D, SCNN1B and SCNN1G, but not of the ENaC channel containing subunits SCNN1A, SCNN1B and SCNN1G. May regulate bicarbonate secretion and salvage in epithelial cells by regulating the transporter SLC4A7. Can inhibit the chloride channel activity of ANO1. Plays a role in the chloride and bicarbonate homeostasis during sperm epididymal maturation and capacitation. Epithelial ion channel that plays an important role in the regulation of epithelial ion and water transport and fluid homeostasis.
T55654	PDBSTRUC	6MSM; 6HEP; 5UAK; 5TGK; 5TFJ
T55654	BIOCLASS	ABC transporter
T55654	ECNUMBER	EC 5.6.1.6
T55654	SEQUENCE	MQRSPLEKASVVSKLFFSWTRPILRKGYRQRLELSDIYQIPSVDSADNLSEKLEREWDRELASKKNPKLINALRRCFFWRFMFYGIFLYLGEVTKAVQPLLLGRIIASYDPDNKEERSIAIYLGIGLCLLFIVRTLLLHPAIFGLHHIGMQMRIAMFSLIYKKTLKLSSRVLDKISIGQLVSLLSNNLNKFDEGLALAHFVWIAPLQVALLMGLIWELLQASAFCGLGFLIVLALFQAGLGRMMMKYRDQRAGKISERLVITSEMIENIQSVKAYCWEEAMEKMIENLRQTELKLTRKAAYVRYFNSSAFFFSGFFVVFLSVLPYALIKGIILRKIFTTISFCIVLRMAVTRQFPWAVQTWYDSLGAINKIQDFLQKQEYKTLEYNLTTTEVVMENVTAFWEEGFGELFEKAKQNNNNRKTSNGDDSLFFSNFSLLGTPVLKDINFKIERGQLLAVAGSTGAGKTSLLMVIMGELEPSEGKIKHSGRISFCSQFSWIMPGTIKENIIFGVSYDEYRYRSVIKACQLEEDISKFAEKDNIVLGEGGITLSGGQRARISLARAVYKDADLYLLDSPFGYLDVLTEKEIFESCVCKLMANKTRILVTSKMEHLKKADKILILHEGSSYFYGTFSELQNLQPDFSSKLMGCDSFDQFSAERRNSILTETLHRFSLEGDAPVSWTETKKQSFKQTGEFGEKRKNSILNPINSIRKFSIVQKTPLQMNGIEEDSDEPLERRLSLVPDSEQGEAILPRISVISTGPTLQARRRQSVLNLMTHSVNQGQNIHRKTTASTRKVSLAPQANLTELDIYSRRLSQETGLEISEEINEEDLKECFFDDMESIPAVTTWNTYLRYITVHKSLIFVLIWCLVIFLAEVAASLVVLWLLGNTPLQDKGNSTHSRNNSYAVIITSTSSYYVFYIYVGVADTLLAMGFFRGLPLVHTLITVSKILHHKMLHSVLQAPMSTLNTLKAGGILNRFSKDIAILDDLLPLTIFDFIQLLLIVIGAIAVVAVLQPYIFVATVPVIVAFIMLRAYFLQTSQQLKQLESEGRSPIFTHLVTSLKGLWTLRAFGRQPYFETLFHKALNLHTANWFLYLSTLRWFQMRIEMIFVIFFIAVTFISILTTGEGEGRVGIILTLAMNIMSTLQWAVNSSIDVDSLMRSVSRVFKFIDMPTEGKPTKSTKPYKNGQLSKVMIIENSHVKKDDIWPSGGQMTVKDLTAKYTEGGNAILENISFSISPGQRVGLLGRTGSGKSTLLSAFLRLLNTEGEIQIDGVSWDSITLQQWRKAFGVIPQKVFIFSGTFRKNLDPYEQWSDQEIWKVADEVGLRSVIEQFPGKLDFVLVDGGCVLSHGHKQLMCLARSVLSKAKILLLDEPSAHLDPVTYQIIRRTLKQAFADCTVILCEHRIEAMLECQQFLVIEENKVRQYDSIQKLLNERSLFRQAISPSDRVKLFPHRNSSKCKSKPQIAALKEETEEEVQDTRL
T55654	DRUGINFO	D0E1HC	Tezacaftor and ivacaftor	Approved
T55654	DRUGINFO	D0W7WC	Ivacaftor	Approved
T55654	DRUGINFO	D09VXM	Crofelemer	Approved
T55654	DRUGINFO	D0S9WB	Lumacaftor + ivacaftor	Approved
T55654	DRUGINFO	D0Z5HR	VX-661	Phase 3
T55654	DRUGINFO	D01DGZ	ABBV-2222	Phase 2
T55654	DRUGINFO	D0E0JO	GLPG-1837	Phase 2
T55654	DRUGINFO	D0N4PW	iOWH032	Phase 2
T55654	DRUGINFO	D0X0CB	Lumacaftor	Phase 2
T55654	DRUGINFO	DFV1I4	QBW251	Phase 2
T55654	DRUGINFO	D0A1YF	ABBV-3067	Phase 1
T55654	DRUGINFO	D0U0QC	ABBV-2737	Phase 1
T55654	DRUGINFO	D0VT6X	ABBV-2451	Phase 1
T55654	DRUGINFO	D62RIY	VX-522	Phase 1
T55654	DRUGINFO	D03PGV	phenylglycine-01	Investigative
T55654	DRUGINFO	D04ZIP	CBIQ	Investigative
T55654	DRUGINFO	D05PDF	sulfonamide-01	Investigative
T55654	DRUGINFO	D0C6YC	UCCF-339	Investigative
T55654	DRUGINFO	D0P3ZK	CFTRinh-172	Investigative
T55654	DRUGINFO	D0S0NB	UCCF-853	Investigative
T55654	DRUGINFO	D0S1FV	GlyH-101	Investigative
T55654	DRUGINFO	D0T9DI	UCCF-029	Investigative

T20514	TARGETID	T20514
T20514	FORMERID	TTDS00342
T20514	UNIPROID	HEM2_HUMAN
T20514	TARGNAME	Delta-aminolevulinic acid dehydratase (ALAD)
T20514	GENENAME	ALAD
T20514	TARGTYPE	Successful
T20514	SYNONYMS	Porphobilinogen synthase; Delta-aminolevulinate dehydratase; ALADH; ALAD
T20514	FUNCTION	Catalyzes an early step in the biosynthesis of tetrapyrroles. Binds two molecules of 5-aminolevulinate per subunit, each at a distinct site, and catalyzes their condensation to form porphobilinogen.
T20514	PDBSTRUC	5HNR; 5HMS; 1PV8; 1.00E+51
T20514	BIOCLASS	Alpha-carbonic anhydrase
T20514	ECNUMBER	EC 4.2.1.24
T20514	SEQUENCE	MQPQSVLHSGYFHPLLRAWQTATTTLNASNLIYPIFVTDVPDDIQPITSLPGVARYGVKRLEEMLRPLVEEGLRCVLIFGVPSRVPKDERGSAADSEESPAIEAIHLLRKTFPNLLVACDVCLCPYTSHGHCGLLSENGAFRAEESRQRLAEVALAYAKAGCQVVAPSDMMDGRVEAIKEALMAHGLGNRVSVMSYSAKFASCFYGPFRDAAKSSPAFGDRRCYQLPPGARGLALRAVDRDVREGADMLMVKPGMPYLDIVREVKDKHPDLPLAVYHVSGEFAMLWHGAQAGAFDLKAAVLEAMTAFRRAGADIIITYYTPQLLQWLKEE
T20514	DRUGINFO	D0Y7ZD	Aminolevulinic acid hci	Approved
T20514	DRUGINFO	D0U6QC	Porphobilinogen	Phase 2
T20514	DRUGINFO	D06KOT	Delta-Amino Valeric Acid	Investigative
T20514	DRUGINFO	D06UYC	4,7-Dioxosebacic Acid	Investigative
T20514	DRUGINFO	D0A1PW	Laevulinic Acid	Investigative
T20514	DRUGINFO	D0MD4U	3-(2-Aminoethyl)-4-(Aminomethyl)Heptanedioic Acid	Investigative
T20514	DRUGINFO	D0NV2V	5-Fluorolevulinic Acid	Investigative
T20514	DRUGINFO	D0VG6L	4-Oxosebacic Acid	Investigative
T20514	DRUGINFO	D0Y4TF	5-hydroxyvaleric acid	Investigative
T20514	DRUGINFO	D0P7JE	S,S-(2-Hydroxyethyl)Thiocysteine	Investigative
T20514	DRUGINFO	D06EWG	Formic Acid	Investigative
T20514	DRUGINFO	D0Q5FV	2-Sulfhydryl-Ethanol	Investigative

T86528	TARGETID	T86528
T86528	FORMERID	TTDI02575
T86528	UNIPROID	FPPS_HUMAN
T86528	TARGNAME	Geranyltranstransferase (FDPS)
T86528	GENENAME	FDPS
T86528	TARGTYPE	Successful
T86528	SYNONYMS	KIAA1293; Geranylgeranyl pyrophosphate synthase; Geranylgeranyl diphosphate synthase; GGPS1; GGPPSase; GGPP synthase; Farnesyltranstransferase; Farnesyl pyrophosphate synthase; Farnesyl diphosphate synthase; FPS protein; FPP synthase; Dimethylallyltranstransferase; (2E,6E)-farnesyl diphosphate synthase
T86528	FUNCTION	FPP also serves as substrate for protein farnesylation and geranylgeranylation. Catalyzes the sequential condensation of isopentenyl pyrophosphate with the allylic pyrophosphates, dimethylallyl pyrophosphate, and then with the resultant geranylpyrophosphate to the ultimate product farnesyl pyrophosphate. Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones.
T86528	PDBSTRUC	5YGI; 5KSX; 5JV2; 5JV1; 5JV0
T86528	BIOCLASS	Alkyl aryl transferase
T86528	ECNUMBER	EC 2.5.1.10
T86528	SEQUENCE	MPLSRWLRSVGVFLLPAPYWAPRERWLGSLRRPSLVHGYPVLAWHSARCWCQAWTEEPRALCSSLRMNGDQNSDVYAQEKQDFVQHFSQIVRVLTEDEMGHPEIGDAIARLKEVLEYNAIGGKYNRGLTVVVAFRELVEPRKQDADSLQRAWTVGWCVELLQAFFLVADDIMDSSLTRRGQICWYQKPGVGLDAINDANLLEACIYRLLKLYCREQPYYLNLIELFLQSSYQTEIGQTLDLLTAPQGNVDLVRFTEKRYKSIVKYKTAFYSFYLPIAAAMYMAGIDGEKEHANAKKILLEMGEFFQIQDDYLDLFGDPSVTGKIGTDIQDNKCSWLVVQCLQRATPEQYQILKENYGQKEAEKVARVKALYEELDLPAVFLQYEEDSYSHIMALIEQYAAPLPPAVFLGLARKIYKRRK
T86528	DRUGINFO	D00NPT	Minodronate	Approved
T86528	DRUGINFO	D08SJZ	Ibandronate	Approved
T86528	DRUGINFO	D09KLR	Alendronate	Approved
T86528	DRUGINFO	D0BF8G	Pamidronate	Approved
T86528	DRUGINFO	D0N4PZ	Incadronate	Approved
T86528	DRUGINFO	D0PA5S	Risedronate	Approved
T86528	DRUGINFO	D0V8PA	NERIDRONIC ACID	Approved
T86528	DRUGINFO	D0VM2L	Zoledronate	Approved
T86528	DRUGINFO	D07NPS	Zarnestra	Phase 3
T86528	DRUGINFO	D00ZMS	1-(but-2-ylamino)ethyl 1,I-bisphosphonic acid	Investigative
T86528	DRUGINFO	D01GAR	1-[(n-hex-1-ylamino)ethyl]-1,1-bisphosphonic acid	Investigative
T86528	DRUGINFO	D01WWK	(2E, 6E)-farnesylbisphosphonate	Investigative
T86528	DRUGINFO	D01XBZ	Dimethylallyl Diphosphate	Investigative
T86528	DRUGINFO	D02CYZ	[2-(Pyrazol-1-yl)ethyl]-bisphosphonic acid	Investigative
T86528	DRUGINFO	D02PVD	PMID12014956C12 	Investigative
T86528	DRUGINFO	D02QWB	[2-(Imidazol-1-yl)ethyl]-bisphosphonic acid	Investigative
T86528	DRUGINFO	D02SNU	NE97220	Investigative
T86528	DRUGINFO	D02YHA	Geranyl Diphosphate	Investigative
T86528	DRUGINFO	D03ZDC	NE21650	Investigative
T86528	DRUGINFO	D04TIS	PMID18800762C11	Investigative
T86528	DRUGINFO	D05DDS	Isopentyl Pyrophosphate	Investigative
T86528	DRUGINFO	D05ONZ	PMID17975902C5e	Investigative
T86528	DRUGINFO	D05XLD	Piridronic acid	Investigative
T86528	DRUGINFO	D05YIK	(1-hydroxy-1-phosphono-heptyl)-phosphonic acid	Investigative
T86528	DRUGINFO	D06III	NE10790	Investigative
T86528	DRUGINFO	D06MYN	PMID18295483C2	Investigative
T86528	DRUGINFO	D06QJG	PG-1014491	Investigative
T86528	DRUGINFO	D06UVF	1-[(n-but-1-ylamino)ethyl]-1,1-bisphosphonic acid	Investigative
T86528	DRUGINFO	D08CSK	PMID18800762C16	Investigative
T86528	DRUGINFO	D09KGN	PMID18800762C51	Investigative
T86528	DRUGINFO	D09USO	(biphenyl-3-ylamino)methylenediphosphonic acid	Investigative
T86528	DRUGINFO	D0A4MM	NE-10575	Investigative
T86528	DRUGINFO	D0B0LU	[2-(Imidazol-2-yl-thio)ethyl]-bisphosphonic acid	Investigative
T86528	DRUGINFO	D0B2YN	1-[(cyclohexylamino)ethyl]-1,1-bisphosphonicacid	Investigative
T86528	DRUGINFO	D0B6DV	CT-10	Investigative
T86528	DRUGINFO	D0B9ZZ	1-[(n-oct-1-ylamino)ethyl]-1,1-bisphosphonic acid	Investigative
T86528	DRUGINFO	D0C9LF	PMID18800762C19	Investigative
T86528	DRUGINFO	D0DC3N	digeranyl bisphosphonate	Investigative
T86528	DRUGINFO	D0DL1F	1-[(tert-butylamino)ethyl]-1,1-bisphosphonicacid	Investigative
T86528	DRUGINFO	D0E3GI	BPH-629	Investigative
T86528	DRUGINFO	D0E4DR	[2-(Purin-9-yl)ethyl]-bisphosphonic acid	Investigative
T86528	DRUGINFO	D0E9AL	BPH-628	Investigative
T86528	DRUGINFO	D0F4NK	BPH-676	Investigative
T86528	DRUGINFO	D0H4MO	NE58027	Investigative
T86528	DRUGINFO	D0I6YD	BPH-252	Investigative
T86528	DRUGINFO	D0J1XZ	BPH-675	Investigative
T86528	DRUGINFO	D0L1RM	1-[(prop-1-ylamino)ethyl]-1,1-bisphosphonic acid	Investigative
T86528	DRUGINFO	D0L8QX	Homorisedronate	Investigative
T86528	DRUGINFO	D0MY0R	[2-(6-Chloro-purin-9-yl)ethyl]-bisphosphonic acid	Investigative
T86528	DRUGINFO	D0N0JL	diphosphoric acid	Investigative
T86528	DRUGINFO	D0N4AH	BPH-608	Investigative
T86528	DRUGINFO	D0OJ5M	OLPADRONIC ACID SODIUM SALT	Investigative
T86528	DRUGINFO	D0P2BY	[2-(Benzoimidazol-1-yl)ethyl]-bisphosphonic acid	Investigative
T86528	DRUGINFO	D0R0UV	PMID17963374C31	Investigative
T86528	DRUGINFO	D0R9ZY	3-azageranylgeranyl diphosphate	Investigative
T86528	DRUGINFO	D0S7YD	NE58062	Investigative
T86528	DRUGINFO	D0TK4X	PMID18800762C47	Investigative
T86528	DRUGINFO	D0U9LD	PMID18800762C14	Investigative
T86528	DRUGINFO	D0W0FX	NE11808	Investigative
T86528	DRUGINFO	D0X1FT	BPH-715	Investigative
T86528	DRUGINFO	D0X8YK	BPH-742	Investigative
T86528	DRUGINFO	D0Y3XR	NE58043	Investigative
T86528	DRUGINFO	D0Y7XQ	1-[(prop-2-ylamino)ethyl]-1,1-bisphosphonicacid	Investigative
T86528	DRUGINFO	D0Z8EU	NE58018	Investigative
T86528	DRUGINFO	D0J8KR	ISOPENTENYL PYROPHOSPHATE	Investigative
T86528	DRUGINFO	D0QX6B	GERANYLGERANYL DIPHOSPHATE	Investigative

T83386	TARGETID	T83386
T83386	FORMERID	TTDI01918
T83386	UNIPROID	FOLR1_HUMAN
T83386	TARGNAME	Folate receptor alpha (FOLR1)
T83386	GENENAME	FOLR1
T83386	TARGTYPE	Successful
T83386	SYNONYMS	Ovarian tumorassociated antigen MOv18; KB cells FBP; Folate receptor, adult; Folate receptor 1; FRalpha; FOLR1; Adult folatebinding protein
T83386	FUNCTION	Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate and folate analogs into the interior of cells. Has high affinity for folate and folic acid analogs at neutral pH. Exposure to slightly acidic pHafter receptor endocytosis triggers a conformation change that strongly reduces its affinity for folates and mediates their release. Required for normal embryonic development and normal cell proliferation.
T83386	PDBSTRUC	5IZQ; 4LRH; 4KMX; 4KM7; 4KM6
T83386	BIOCLASS	Folate receptor
T83386	SEQUENCE	MAQRMTTQLLLLLVWVAVVGEAQTRIAWARTELLNVCMNAKHHKEKPGPEDKLHEQCRPWRKNACCSTNTSQEAHKDVSYLYRFNWNHCGEMAPACKRHFIQDTCLYECSPNLGPWIQQVDQSWRKERVLNVPLCKEDCEQWWEDCRTSYTCKSNWHKGWNWTSGFNKCAVGAACQPFHFYFPTPTVLCNEIWTHSYKVSNYSRGSGRCIQMWFDPAQGNPNEEVARFYAAAMSGAGPWAAWPFLLSLALMLLWLLS
T83386	DRUGINFO	D0C0SK	Pyrimethamine	Approved
T83386	DRUGINFO	D0RP2W	Mirvetuximab soravtansine	Approved
T83386	DRUGINFO	D00BHL	EC20	Phase 3
T83386	DRUGINFO	D02TJT	MK-8109	Phase 3
T83386	DRUGINFO	D06XVN	Farletuzumab	Phase 3
T83386	DRUGINFO	D09JGH	EC-145	Phase 2
T83386	DRUGINFO	D0N8JG	FolateImmune	Phase 2
T83386	DRUGINFO	D0GL7H	Talotrexin	Phase 1/2
T83386	DRUGINFO	D0N2GC	BMS-753493	Phase 1/2
T83386	DRUGINFO	D06CVN	EC0489	Phase 1
T83386	DRUGINFO	D07DPC	IMGN-853	Phase 1
T83386	DRUGINFO	D10GPJ	STRO-002	Phase 1

T73097	TARGETID	T73097
T73097	FORMERID	TTDS00442
T73097	UNIPROID	CSF2R_HUMAN
T73097	TARGNAME	GMCSFR-alpha (CSF2RA)
T73097	GENENAME	CSF2RA
T73097	TARGTYPE	Successful
T73097	SYNONYMS	GMR; GM-CSFR; GM-CSF-R-alpha; CSF2RA; CDw116; CD116 antigen
T73097	FUNCTION	Low affinity receptor for granulocyte-macrophage colony- stimulating factor. Transduces a signal that results in the proliferation, differentiation, and functional activation of hematopoietic cells.
T73097	PDBSTRUC	4RS1; 4NKQ
T73097	BIOCLASS	Type I cytokine receptor family
T73097	SEQUENCE	MLLLVTSLLLCELPHPAFLLIPEKSDLRTVAPASSLNVRFDSRTMNLSWDCQENTTFSKCFLTDKKNRVVEPRLSNNECSCTFREICLHEGVTFEVHVNTSQRGFQQKLLYPNSGREGTAAQNFSCFIYNADLMNCTWARGPTAPRDVQYFLYIRNSKRRREIRCPYYIQDSGTHVGCHLDNLSGLTSRNYFLVNGTSREIGIQFFDSLLDTKKIERFNPPSNVTVRCNTTHCLVRWKQPRTYQKLSYLDFQYQLDVHRKNTQPGTENLLINVSGDLENRYNFPSSEPRAKHSVKIRAADVRILNWSSWSEAIEFGSDDGNLGSVYIYVLLIVGTLVCGIVLGFLFKRFLRIQRLFPPVPQIKDKLNDNHEVEDEIIWEEFTPEEGKGYREEVLTVKEIT
T73097	DRUGINFO	D0XT5Y	Sargramostim	Approved
T73097	DRUGINFO	D0A5SJ	B-cell lymphoma vaccine	Preregistration
T73097	DRUGINFO	D04INP	Pixykine	Phase 3
T73097	DRUGINFO	D0U0HX	Molgramostim	Phase 3
T73097	DRUGINFO	D09SHX	GM-CSF cancer vaccine	Phase 2
T73097	DRUGINFO	D0M0OT	Leukemia cancer vaccine	Phase 2
T73097	DRUGINFO	D0U0NS	Myeloma cancer vaccine	Phase 2
T73097	DRUGINFO	D05YFL	AFTVac	Phase 2
T73097	DRUGINFO	D06KCF	Mavrilimumab	Phase 2
T73097	DRUGINFO	D05ORA	MOR-103	Phase 1/2
T73097	DRUGINFO	D0C4BD	KH-901	Phase 1
T73097	DRUGINFO	D0C5YQ	SDZ-62-826	Terminated
T73097	DRUGINFO	D0B6OG	BBT-007	Investigative

T20761	TARGETID	T20761
T20761	FORMERID	TTDNS00542
T20761	UNIPROID	VEGFA_HUMAN
T20761	TARGNAME	Vascular endothelial growth factor A (VEGFA)
T20761	GENENAME	VEGFA
T20761	TARGTYPE	Successful
T20761	SYNONYMS	Vascular permeability factor; VPF; VEGF-A; VEGF
T20761	FUNCTION	Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development. Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth.
T20761	PDBSTRUC	6D3O; 6BFT; 5T89; 5O4E; 5HHD
T20761	BIOCLASS	Growth factor
T20761	SEQUENCE	MNFLLSWVHWSLALLLYLHHAKWSQAAPMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGEMSFLQHNKCECRPKKDRARQEKKSVRGKGKGQKRKRKKSRYKSWSVYVGARCCLMPWSLPGPHPCGPCSERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR
T20761	DRUGINFO	D04EYG	Ranibizumab	Approved
T20761	DRUGINFO	D04KBL	Bevacizumab	Approved
T20761	DRUGINFO	D5DO9L	Brolucizumab	Approved
T20761	DRUGINFO	D9MWL4	Faricimab	Approved
T20761	DRUGINFO	D0C9ET	Aflibercept	Approved
T20761	DRUGINFO	D08CGU	Bevacizumab + Rituximab	Phase 3
T20761	DRUGINFO	D09BKY	Bevacizumab + Erlotinib	Phase 3
T20761	DRUGINFO	D04SLF	Bevacizumab + Trastuzumab	Phase 3
T20761	DRUGINFO	D0C0NH	Avastin+/-Tarceva	Phase 3
T20761	DRUGINFO	D0CJ7Z	Abicipar pegol	Phase 2
T20761	DRUGINFO	D05VVX	PTC299	Phase 2
T20761	DRUGINFO	D06FTM	RG7221	Phase 2
T20761	DRUGINFO	D0I8YS	RO5520985	Phase 2
T20761	DRUGINFO	D0E7RQ	SNN-0029	Phase 1/2
T20761	DRUGINFO	D0ME7Q	MP0250	Phase 1/2
T20761	DRUGINFO	D0NO1A	AT001/r84	Phase 1
T20761	DRUGINFO	D0V3HP	MP-0112	Phase 1
T20761	DRUGINFO	D00IVN	Navicixizumab	Phase 1
T20761	DRUGINFO	D0YZ4T	SFLT-01	Phase 1
T20761	DRUGINFO	D0P4KU	ABI-011	Phase 1
T20761	DRUGINFO	D00ZFY	Carbamide derivative 17	Patented
T20761	DRUGINFO	D01CKB	Carbamide derivative 16	Patented
T20761	DRUGINFO	D01DJZ	Indoline derivative 18	Patented
T20761	DRUGINFO	D01IFD	Antibodie derivative 11	Patented
T20761	DRUGINFO	D01OEF	Pyridine derivative 2	Patented
T20761	DRUGINFO	D03HPW	Indoline derivative 16	Patented
T20761	DRUGINFO	D03SZN	Carbamide derivative 22	Patented
T20761	DRUGINFO	D03VXQ	Oxetane 3,3-dicarboxamide compound 1	Patented
T20761	DRUGINFO	D04PKQ	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	Patented
T20761	DRUGINFO	D04UKD	1,6-naphyridine-4-ketone fused heterocyclic derivative 1	Patented
T20761	DRUGINFO	D05GVV	Pyrimidine derivative 5	Patented
T20761	DRUGINFO	D05LBH	PMID28621580-Compound-WO2013112959C68	Patented
T20761	DRUGINFO	D05WTW	Carbamide derivative 23	Patented
T20761	DRUGINFO	D06ARD	Quinoline and quinazoline derivative 7	Patented
T20761	DRUGINFO	D07AVU	PMID28621580-Compound-WO2015089220C70	Patented
T20761	DRUGINFO	D07ESG	Pyrimidine derivative 9	Patented
T20761	DRUGINFO	D07UJJ	Quinoline and quinazoline derivative 4	Patented
T20761	DRUGINFO	D08INZ	Pyridine derivative 5	Patented
T20761	DRUGINFO	D08XDA	Carbamide derivative 15	Patented
T20761	DRUGINFO	D09GWR	Antibodie derivative 3	Patented
T20761	DRUGINFO	D09KYB	Pyrimidine derivative 7	Patented
T20761	DRUGINFO	D0A5NC	Carbamide derivative 18	Patented
T20761	DRUGINFO	D0A8SH	Indoline derivative 21	Patented
T20761	DRUGINFO	D0A9RY	Pyrimidine derivative 10	Patented
T20761	DRUGINFO	D0BA5J	Pyridine derivative 7	Patented
T20761	DRUGINFO	D0BL4H	Quinoline and quinazoline derivative 6	Patented
T20761	DRUGINFO	D0CE1R	Antibodie derivative 7	Patented
T20761	DRUGINFO	D0D0AX	Antibodie derivative 2	Patented
T20761	DRUGINFO	D0D7SL	Pyridine derivative 3	Patented
T20761	DRUGINFO	D0DA6B	Pyridine derivative 8	Patented
T20761	DRUGINFO	D0DI5S	Carbamide derivative 19	Patented
T20761	DRUGINFO	D0E5IJ	Indoline derivative 13	Patented
T20761	DRUGINFO	D0EE3P	Pyrimidine derivative 11	Patented
T20761	DRUGINFO	D0FK5P	Pyrimidine derivative 8	Patented
T20761	DRUGINFO	D0FK6Y	Quinoline and quinazoline derivative 10	Patented
T20761	DRUGINFO	D0FL6P	Quinoline and quinazoline derivative 8	Patented
T20761	DRUGINFO	D0FY2Q	Pyridine derivative 10	Patented
T20761	DRUGINFO	D0HO5B	Indoline derivative 14	Patented
T20761	DRUGINFO	D0HX9S	PMID28621580-Compound-WO2014079545C69	Patented
T20761	DRUGINFO	D0I6WJ	Carbamide derivative 14	Patented
T20761	DRUGINFO	D0IZ8B	Pyridine derivative 11	Patented
T20761	DRUGINFO	D0KW0F	Pyridine derivative 9	Patented
T20761	DRUGINFO	D0M2XJ	Quinoline and quinazoline derivative 5	Patented
T20761	DRUGINFO	D0M9KZ	Pyridine derivative 4	Patented
T20761	DRUGINFO	D0MA6I	Quinoline and quinazoline derivative 3	Patented
T20761	DRUGINFO	D0O5IA	Quinoline and quinazoline derivative 2	Patented
T20761	DRUGINFO	D0O8RZ	Indoline derivative 17	Patented
T20761	DRUGINFO	D0Q4XV	Indoline derivative 19	Patented
T20761	DRUGINFO	D0S4XH	Pyridine derivative 6	Patented
T20761	DRUGINFO	D0SH2Y	Quinoline and quinazoline derivative 9	Patented
T20761	DRUGINFO	D0T1GG	3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivative 1	Patented
T20761	DRUGINFO	D0T9DV	PMID28621580-Compound-WO2013036866C66	Patented
T20761	DRUGINFO	D0U6PW	Antibodie derivative 8	Patented
T20761	DRUGINFO	D0V7OF	Pyrimidine derivative 6	Patented
T20761	DRUGINFO	D0VI1V	Carbamide derivative 20	Patented
T20761	DRUGINFO	D0VX5Y	Indoline derivative 15	Patented
T20761	DRUGINFO	D0WL5P	Antibodie derivative 9	Patented
T20761	DRUGINFO	D0X2BP	Antibodie derivative 1	Patented
T20761	DRUGINFO	D0X2MF	Indoline derivative 20	Patented
T20761	DRUGINFO	D0XS0Z	Carbamide derivative 21	Patented
T20761	DRUGINFO	D0Y2IV	Antibodie derivative 4	Patented
T20761	DRUGINFO	D0Z0SY	Indoline derivative 12	Patented
T20761	DRUGINFO	D0ZE2J	Oxetane 3,3-dicarboxamide compound 2	Patented
T20761	DRUGINFO	D0YG4I	Bevasiranib	Discontinued in Phase 3

T60606	TARGETID	T60606
T60606	FORMERID	TTDS00452
T60606	UNIPROID	TSHR_HUMAN
T60606	TARGNAME	Thyrotropin receptor (TSHR)
T60606	GENENAME	TSHR
T60606	TARGTYPE	Successful
T60606	SYNONYMS	Thyroid stimulating hormone receptor; TSHR; TSH-R; TSH receptor
T60606	FUNCTION	Receptor for thyrothropin. Plays a central role in controlling thyroid cell metabolism. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Also acts as a receptor for thyrostimulin (gpa2+gpb5).
T60606	PDBSTRUC	3G04; 2XWT; 1XUM
T60606	BIOCLASS	GPCR rhodopsin
T60606	SEQUENCE	MRPADLLQLVLLLDLPRDLGGMGCSSPPCECHQEEDFRVTCKDIQRIPSLPPSTQTLKLIETHLRTIPSHAFSNLPNISRIYVSIDVTLQQLESHSFYNLSKVTHIEIRNTRNLTYIDPDALKELPLLKFLGIFNTGLKMFPDLTKVYSTDIFFILEITDNPYMTSIPVNAFQGLCNETLTLKLYNNGFTSVQGYAFNGTKLDAVYLNKNKYLTVIDKDAFGGVYSGPSLLDVSQTSVTALPSKGLEHLKELIARNTWTLKKLPLSLSFLHLTRADLSYPSHCCAFKNQKKIRGILESLMCNESSMQSLRQRKSVNALNSPLHQEYEENLGDSIVGYKEKSKFQDTHNNAHYYVFFEEQEDEIIGFGQELKNPQEETLQAFDSHYDYTICGDSEDMVCTPKSDEFNPCEDIMGYKFLRIVVWFVSLLALLGNVFVLLILLTSHYKLNVPRFLMCNLAFADFCMGMYLLLIASVDLYTHSEYYNHAIDWQTGPGCNTAGFFTVFASELSVYTLTVITLERWYAITFAMRLDRKIRLRHACAIMVGGWVCCFLLALLPLVGISSYAKVSICLPMDTETPLALAYIVFVLTLNIVAFVIVCCCYVKIYITVRNPQYNPGDKDTKIAKRMAVLIFTDFICMAPISFYALSAILNKPLITVSNSKILLVLFYPLNSCANPFLYAIFTKAFQRDVFILLSKFGICKRQAQAYRGQRVPPKNSTDIQVQKVTHDMRQGLHNMEDVYELIENSHLTPKKQGQISEEYMQTVL
T60606	DRUGINFO	D03EER	Thyrotropin	Approved
T60606	DRUGINFO	D0H4TQ	Thyrotropin Alfa	Approved
T60606	DRUGINFO	D0U2DY	Recombinant TSH superagonists	Investigative

T41580	TARGETID	T41580
T41580	FORMERID	TTDC00293
T41580	UNIPROID	ADA2B_HUMAN
T41580	TARGNAME	Adrenergic receptor alpha-2B (ADRA2B)
T41580	GENENAME	ADRA2B
T41580	TARGTYPE	Successful
T41580	SYNONYMS	Subtype C2; Alpha-2BAR; Alpha-2B adrenoreceptor; Alpha-2B adrenoceptor; Alpha-2B adrenergic receptor; Alpha-2 adrenergic receptor subtype C2; ADRA2RL1; ADRA2L1
T41580	FUNCTION	The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phentolamine > mianserine > spiperone > prazosin > alprenolol > propanolol > pindolol. Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
T41580	PDBSTRUC	2CVA
T41580	BIOCLASS	GPCR rhodopsin
T41580	SEQUENCE	MDHQDPYSVQATAAIAAAITFLILFTIFGNALVILAVLTSRSLRAPQNLFLVSLAAADILVATLIIPFSLANELLGYWYFRRTWCEVYLALDVLFCTSSIVHLCAISLDRYWAVSRALEYNSKRTPRRIKCIILTVWLIAAVISLPPLIYKGDQGPQPRGRPQCKLNQEAWYILASSIGSFFAPCLIMILVYLRIYLIAKRSNRRGPRAKGGPGQGESKQPRPDHGGALASAKLPALASVASAREVNGHSKSTGEKEEGETPEDTGTRALPPSWAALPNSGQGQKEGVCGASPEDEAEEEEEEEEEEEECEPQAVPVSPASACSPPLQQPQGSRVLATLRGQVLLGRGVGAIGGQWWRRRAQLTREKRFTFVLAVVIGVFVLCWFPFFFSYSLGAICPKHCKVPHGLFQFFFWIGYCNSSLNPVIYTIFNQDFRRAFRRILCRPWTQTAW
T41580	DRUGINFO	D0E9PK	MOXONIDINE	Approved
T41580	DRUGINFO	D05CFH	AGN-199981	Phase 2
T41580	DRUGINFO	D0F2ML	MEDETOMIDINE	Phase 2
T41580	DRUGINFO	D02LHR	INDORAMIN	Withdrawn from market
T41580	DRUGINFO	D01WJZ	MAZAPERTINE	Discontinued in Phase 2
T41580	DRUGINFO	D08OWQ	SK&F-104078	Terminated
T41580	DRUGINFO	D03QMR	WB-4101	Terminated
T41580	DRUGINFO	D06HRY	SNAP-5089	Terminated
T41580	DRUGINFO	D0K9JP	A-80426	Terminated
T41580	DRUGINFO	D03IVG	imiloxan	Investigative
T41580	DRUGINFO	D0GP1I	[3H]MK-912	Investigative
T41580	DRUGINFO	D0Y2JI	xylazine	Investigative
T41580	DRUGINFO	D02KIS	(S)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline	Investigative
T41580	DRUGINFO	D02QXT	8-Methoxy-1,2,3,4-tetrahydro-benzo[h]isoquinoline	Investigative
T41580	DRUGINFO	D03EPY	1,2,3,4-tetrahydroisoquinoline	Investigative
T41580	DRUGINFO	D03HBZ	(3-Ethyl-indol-1-yl)-propyl-pyridin-4-yl-amine	Investigative
T41580	DRUGINFO	D03LRY	C-(6-Methoxy-naphthalen-1-yl)-methylamine	Investigative
T41580	DRUGINFO	D04PYQ	PIPEROXAN	Investigative
T41580	DRUGINFO	D04RBQ	1,2,3,4-Tetrahydro-benzo[h]isoquinolin-8-ol	Investigative
T41580	DRUGINFO	D06BWZ	MEZILAMINE	Investigative
T41580	DRUGINFO	D06SYS	METHYLNORADRENALINE	Investigative
T41580	DRUGINFO	D07ICV	GNF-PF-3878	Investigative
T41580	DRUGINFO	D07RLW	5-Aminomethyl-naphthalen-2-ol	Investigative
T41580	DRUGINFO	D07SYG	2,3-Dihydro-1H-isoindole	Investigative
T41580	DRUGINFO	D08ZRA	C-Naphthalen-1-yl-methylamine	Investigative
T41580	DRUGINFO	D09JZG	1,2,3,4,5,6-Hexahydro-benzo[c]azocine	Investigative
T41580	DRUGINFO	D0AE9M	Butyl-indol-1-yl-pyridin-4-yl-amine	Investigative
T41580	DRUGINFO	D0B2BO	6,7,8,9-Tetrahydro-5-thia-8-aza-benzocycloheptene	Investigative
T41580	DRUGINFO	D0C9DC	SK&F-64139	Investigative
T41580	DRUGINFO	D0D1RU	Indol-1-yl-pyridin-4-yl-amine	Investigative
T41580	DRUGINFO	D0E0KG	(R)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline	Investigative
T41580	DRUGINFO	D0E3OL	GNF-PF-2857	Investigative
T41580	DRUGINFO	D0E8HU	3-Fluoromethyl-1,2,3,4-tetrahydro-isoquinoline	Investigative
T41580	DRUGINFO	D0F5TA	Ethyl-indol-1-yl-pyridin-4-yl-amine	Investigative
T41580	DRUGINFO	D0L7IZ	JP1302	Investigative
T41580	DRUGINFO	D0M8FL	2,3,4,5-Tetrahydro-benzo[f][1,4]oxazepine	Investigative
T41580	DRUGINFO	D0P3HP	1,2,3,4,4a,5,10,10a-Octahydro-benzo[g]quinoline	Investigative
T41580	DRUGINFO	D0P8BE	(3-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine	Investigative
T41580	DRUGINFO	D0QH0X	2,3,4,5-Tetrahydro-1H-benzo[c]azepine	Investigative
T41580	DRUGINFO	D0QO8X	1,2,3,4-Tetrahydro-isoquinolin-7-ol	Investigative
T41580	DRUGINFO	D0R1XT	Indol-1-yl-methyl-pyridin-4-yl-amine	Investigative
T41580	DRUGINFO	D0TN2R	3-Methoxymethyl-1,2,3,4-tetrahydro-isoquinoline	Investigative
T41580	DRUGINFO	D0V0NJ	2,3,4,5-Tetrahydro-1H-benzo[e][1,4]diazepine	Investigative
T41580	DRUGINFO	D0V3IT	SNAP-5150	Investigative
T41580	DRUGINFO	D0W5IN	(2-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine	Investigative
T41580	DRUGINFO	D0Y8DJ	(1,2,3,4-Tetrahydro-isoquinolin-3-yl)-methanol	Investigative
T41580	DRUGINFO	D0Z7XI	3-Methyl-1,2,3,4-tetrahydro-isoquinoline	Investigative
T41580	DRUGINFO	D0ZS3M	Indol-1-yl-prop-2-ynyl-pyridin-4-yl-amine	Investigative
T41580	DRUGINFO	D0ZT8D	Tramazoline	Investigative
T41580	DRUGINFO	D08UDY	1',2',3',6'-Tetrahydro-[2,4']bipyridinyl	Investigative
T41580	DRUGINFO	D0MH0S	1-(3-Fluoro-pyridin-2-yl)-4-methyl-piperazine	Investigative
T41580	DRUGINFO	D0Z7EA	[3H]rauwolscine	Investigative
T41580	DRUGINFO	D07JMN	1-(pyridin-2-yl)piperazine	Investigative
T41580	DRUGINFO	D09BIV	TRACIZOLINE	Investigative
T41580	DRUGINFO	D0FU5E	S-34324	Investigative
T41580	DRUGINFO	D0H3NA	4-Benzo[b]thiophen-4-yl-1H-imidazole	Investigative
T41580	DRUGINFO	D0LI3J	2-BFi	Investigative
T41580	DRUGINFO	D0MU4A	spiroxatrine	Investigative
T41580	DRUGINFO	D03LPH	TRYPTOLINE	Investigative
T41580	DRUGINFO	D05GDP	7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline	Investigative
T41580	DRUGINFO	D08KLH	[3H]RX821002	Investigative
T41580	DRUGINFO	D0C1SE	1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole	Investigative
T41580	DRUGINFO	D0L9WN	4-(4-Methyl-indan-1-yl)-1H-imidazole	Investigative
T41580	DRUGINFO	D0P5PW	4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole	Investigative
T41580	DRUGINFO	D0PN9R	R-226161	Investigative
T41580	DRUGINFO	D0L5MW	(+/-)-nantenine	Investigative

T01777	TARGETID	T01777
T01777	FORMERID	TTDR01180
T01777	UNIPROID	ADA2C_HUMAN
T01777	TARGNAME	Adrenergic receptor alpha-2C (ADRA2C)
T01777	GENENAME	ADRA2C
T01777	TARGTYPE	Successful
T01777	SYNONYMS	Subtype C4; Alpha-2CAR; Alpha-2C adrenoreceptor; Alpha-2C adrenoceptor; Alpha-2C adrenergic receptor; Alpha-2 adrenergic receptor subtype C4; ADRA2RL2; ADRA2L2
T01777	FUNCTION	Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
T01777	BIOCLASS	GPCR rhodopsin
T01777	SEQUENCE	MASPALAAALAVAAAAGPNASGAGERGSGGVANASGASWGPPRGQYSAGAVAGLAAVVGFLIVFTVVGNVLVVIAVLTSRALRAPQNLFLVSLASADILVATLVMPFSLANELMAYWYFGQVWCGVYLALDVLFCTSSIVHLCAISLDRYWSVTQAVEYNLKRTPRRVKATIVAVWLISAVISFPPLVSLYRQPDGAAYPQCGLNDETWYILSSCIGSFFAPCLIMGLVYARIYRVAKLRTRTLSEKRAPVGPDGASPTTENGLGAAAGAGENGHCAPPPADVEPDESSAAAERRRRRGALRRGGRRRAGAEGGAGGADGQGAGPGAAESGALTASRSPGPGGRLSRASSRSVEFFLSRRRRARSSVCRRKVAQAREKRFTFVLAVVMGVFVLCWFPFFFSYSLYGICREACQVPGPLFKFFFWIGYCNSSLNPVIYTVFNQDFRRSFKHILFRRRRRGFRQ
T01777	DRUGINFO	D00DPJ	Amezinium	Approved
T01777	DRUGINFO	D03DVJ	Propylhexedrine	Approved
T01777	DRUGINFO	D05IHU	Tetrahydrozoline	Approved
T01777	DRUGINFO	D06OFS	Rilmenidine	Approved
T01777	DRUGINFO	D09NNH	Dihydroergocristine	Approved
T01777	DRUGINFO	D0AE3X	Brimonidine	Approved
T01777	DRUGINFO	D0D0YM	Amosulalol	Approved
T01777	DRUGINFO	D0E9PK	MOXONIDINE	Approved
T01777	DRUGINFO	D0Y4DY	Xylometazoline	Phase 4
T01777	DRUGINFO	D01ZNH	IDAZOXAN HYDROCHLORIDE	Phase 3
T01777	DRUGINFO	D0NN8N	TNX-102	Phase 3
T01777	DRUGINFO	D00BWF	AGN-XX/YY	Phase 2
T01777	DRUGINFO	D01BVI	V-101	Phase 2
T01777	DRUGINFO	D02VTB	BAY1193397	Phase 2
T01777	DRUGINFO	D0B3ZF	ORM-12741	Phase 2
T01777	DRUGINFO	D0U1NA	Fadolmidine	Phase 2
T01777	DRUGINFO	D0F2ML	MEDETOMIDINE	Phase 2
T01777	DRUGINFO	D02LHR	INDORAMIN	Withdrawn from market
T01777	DRUGINFO	D0Y0ZQ	Ecabapide	Discontinued in Preregistration
T01777	DRUGINFO	D02VCK	FLUPAROXAN	Discontinued in Phase 3
T01777	DRUGINFO	D0L7SY	Delequamine hydrochloride	Discontinued in Phase 3
T01777	DRUGINFO	D02ALD	NOLOMIROLE HYDROCHLORIDE	Discontinued in Phase 3
T01777	DRUGINFO	D0A5TM	SGB-1534	Discontinued in Phase 2
T01777	DRUGINFO	D0Y4LU	MK-912	Discontinued in Phase 2
T01777	DRUGINFO	D03ABH	Deriglidole	Discontinued in Phase 2
T01777	DRUGINFO	D06WOJ	JTH-601	Discontinued in Phase 2
T01777	DRUGINFO	D0U0QI	GYKI-16084	Discontinued in Phase 2
T01777	DRUGINFO	D0ZI0K	NMI-870	Discontinued in Phase 2
T01777	DRUGINFO	D01WJZ	MAZAPERTINE	Discontinued in Phase 2
T01777	DRUGINFO	D0M6YW	GYKI-12743	Discontinued in Phase 1
T01777	DRUGINFO	D02YIW	5-(N,N-hexamethylene)-amiloride	Preclinical
T01777	DRUGINFO	D02XMM	Midaglizole	Terminated
T01777	DRUGINFO	D07SZJ	A-75169	Terminated
T01777	DRUGINFO	D08VJI	F-14413	Terminated
T01777	DRUGINFO	D0V8NS	ARC239	Terminated
T01777	DRUGINFO	D08OWQ	SK&F-104078	Terminated
T01777	DRUGINFO	D03QMR	WB-4101	Terminated
T01777	DRUGINFO	D06HRY	SNAP-5089	Terminated
T01777	DRUGINFO	D0K9JP	A-80426	Terminated
T01777	DRUGINFO	D06QKW	cirazoline	Investigative
T01777	DRUGINFO	D07OAF	A61603	Investigative
T01777	DRUGINFO	D09CUJ	6-fluoro-noradrenaline	Investigative
T01777	DRUGINFO	D0B6FM	SKF 89748	Investigative
T01777	DRUGINFO	D0F8NE	V-103	Investigative
T01777	DRUGINFO	D0R2HZ	ETHOXY-IDAZOXAN	Investigative
T01777	DRUGINFO	D0SG6A	amidephrine	Investigative
T01777	DRUGINFO	D0U9IJ	indanidine	Investigative
T01777	DRUGINFO	D02EMH	all-trans-4-oxo-retinoic acid	Investigative
T01777	DRUGINFO	D03YLQ	[125I]BE-2254	Investigative
T01777	DRUGINFO	D05QTJ	Chloroethylclonidine	Investigative
T01777	DRUGINFO	D09DKC	[125I]HEAT	Investigative
T01777	DRUGINFO	D0GP1I	[3H]MK-912	Investigative
T01777	DRUGINFO	D0S4VR	(1H-Benzoimidazol-5-yl)-(1H-imidazol-2-yl)-amine	Investigative
T01777	DRUGINFO	D0V6DJ	5-methylurapidil	Investigative
T01777	DRUGINFO	D0Y2JI	xylazine	Investigative
T01777	DRUGINFO	D0ZC4S	(1H-Imidazol-2-yl)-quinoxalin-6-yl-amine	Investigative
T01777	DRUGINFO	D02KIS	(S)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline	Investigative
T01777	DRUGINFO	D02QXT	8-Methoxy-1,2,3,4-tetrahydro-benzo[h]isoquinoline	Investigative
T01777	DRUGINFO	D03EPY	1,2,3,4-tetrahydroisoquinoline	Investigative
T01777	DRUGINFO	D03HBZ	(3-Ethyl-indol-1-yl)-propyl-pyridin-4-yl-amine	Investigative
T01777	DRUGINFO	D03LRY	C-(6-Methoxy-naphthalen-1-yl)-methylamine	Investigative
T01777	DRUGINFO	D04PYQ	PIPEROXAN	Investigative
T01777	DRUGINFO	D04RBQ	1,2,3,4-Tetrahydro-benzo[h]isoquinolin-8-ol	Investigative
T01777	DRUGINFO	D06BWZ	MEZILAMINE	Investigative
T01777	DRUGINFO	D06SYS	METHYLNORADRENALINE	Investigative
T01777	DRUGINFO	D07ICV	GNF-PF-3878	Investigative
T01777	DRUGINFO	D07RLW	5-Aminomethyl-naphthalen-2-ol	Investigative
T01777	DRUGINFO	D07SYG	2,3-Dihydro-1H-isoindole	Investigative
T01777	DRUGINFO	D08ZRA	C-Naphthalen-1-yl-methylamine	Investigative
T01777	DRUGINFO	D09JZG	1,2,3,4,5,6-Hexahydro-benzo[c]azocine	Investigative
T01777	DRUGINFO	D0AE9M	Butyl-indol-1-yl-pyridin-4-yl-amine	Investigative
T01777	DRUGINFO	D0B2BO	6,7,8,9-Tetrahydro-5-thia-8-aza-benzocycloheptene	Investigative
T01777	DRUGINFO	D0C9DC	SK&F-64139	Investigative
T01777	DRUGINFO	D0D1RU	Indol-1-yl-pyridin-4-yl-amine	Investigative
T01777	DRUGINFO	D0E0KG	(R)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline	Investigative
T01777	DRUGINFO	D0E3OL	GNF-PF-2857	Investigative
T01777	DRUGINFO	D0E8HU	3-Fluoromethyl-1,2,3,4-tetrahydro-isoquinoline	Investigative
T01777	DRUGINFO	D0F5TA	Ethyl-indol-1-yl-pyridin-4-yl-amine	Investigative
T01777	DRUGINFO	D0L7IZ	JP1302	Investigative
T01777	DRUGINFO	D0M8FL	2,3,4,5-Tetrahydro-benzo[f][1,4]oxazepine	Investigative
T01777	DRUGINFO	D0M9IC	CONESSINE	Investigative
T01777	DRUGINFO	D0P3HP	1,2,3,4,4a,5,10,10a-Octahydro-benzo[g]quinoline	Investigative
T01777	DRUGINFO	D0P8BE	(3-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine	Investigative
T01777	DRUGINFO	D0QH0X	2,3,4,5-Tetrahydro-1H-benzo[c]azepine	Investigative
T01777	DRUGINFO	D0QO8X	1,2,3,4-Tetrahydro-isoquinolin-7-ol	Investigative
T01777	DRUGINFO	D0R1XT	Indol-1-yl-methyl-pyridin-4-yl-amine	Investigative
T01777	DRUGINFO	D0TN2R	3-Methoxymethyl-1,2,3,4-tetrahydro-isoquinoline	Investigative
T01777	DRUGINFO	D0V0NJ	2,3,4,5-Tetrahydro-1H-benzo[e][1,4]diazepine	Investigative
T01777	DRUGINFO	D0V3IT	SNAP-5150	Investigative
T01777	DRUGINFO	D0W5IN	(2-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine	Investigative
T01777	DRUGINFO	D0Y8DJ	(1,2,3,4-Tetrahydro-isoquinolin-3-yl)-methanol	Investigative
T01777	DRUGINFO	D0Z7XI	3-Methyl-1,2,3,4-tetrahydro-isoquinoline	Investigative
T01777	DRUGINFO	D0ZS3M	Indol-1-yl-prop-2-ynyl-pyridin-4-yl-amine	Investigative
T01777	DRUGINFO	D0ZT8D	Tramazoline	Investigative
T01777	DRUGINFO	D0I3XA	Ciproxifan	Investigative
T01777	DRUGINFO	D0Z7EA	[3H]rauwolscine	Investigative
T01777	DRUGINFO	D06HHJ	(2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine	Investigative
T01777	DRUGINFO	D09BIV	TRACIZOLINE	Investigative
T01777	DRUGINFO	D0A6GK	(2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine	Investigative
T01777	DRUGINFO	D0FU5E	S-34324	Investigative
T01777	DRUGINFO	D0LI3J	2-BFi	Investigative
T01777	DRUGINFO	D0MU4A	spiroxatrine	Investigative
T01777	DRUGINFO	D03LPH	TRYPTOLINE	Investigative
T01777	DRUGINFO	D05GDP	7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline	Investigative
T01777	DRUGINFO	D07GXY	piribedil	Investigative
T01777	DRUGINFO	D08KLH	[3H]RX821002	Investigative
T01777	DRUGINFO	D0C1SE	1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole	Investigative
T01777	DRUGINFO	D0L9WN	4-(4-Methyl-indan-1-yl)-1H-imidazole	Investigative
T01777	DRUGINFO	D0P5PW	4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole	Investigative
T01777	DRUGINFO	D01KAX	1-((S)-2-aminopropyl)-1H-indazol-6-ol	Investigative
T01777	DRUGINFO	D0PN9R	R-226161	Investigative
T01777	DRUGINFO	D0L5MW	(+/-)-nantenine	Investigative

T13726	TARGETID	T13726
T13726	FORMERID	TTDR01073
T13726	UNIPROID	RXRA_HUMAN
T13726	TARGNAME	Retinoic acid receptor RXR-alpha (RXRA)
T13726	GENENAME	RXRA
T13726	TARGTYPE	Successful
T13726	SYNONYMS	Retinoid X receptor alpha; RXRalpha; Nuclear receptor subfamily 2 group B member 1; NR2B1
T13726	FUNCTION	Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. The high affinity ligand for RXRs is 9-cis retinoic acid. RXRA serves as a common heterodimeric partner for a number of nuclear receptors. In the absence of ligand, the RXR-RAR heterodimers associate with a multiprotein complex containing transcription corepressors that induce histone acetylation, chromatin condensation and transcriptional suppression. On ligand binding, the corepressors dissociate from the receptors and associate with the coactivators leading to transcriptional activation. The RXRA/PPARA heterodimer is required for PPARA transcriptional activity on fatty acid oxidation genes such as ACOX1 and the P450 system genes. Receptor for retinoic acid.
T13726	PDBSTRUC	6HN6; 6FBR; 6FBQ; 6A60; 6A5Z
T13726	BIOCLASS	Nuclear hormone receptor
T13726	SEQUENCE	MDTKHFLPLDFSTQVNSSLTSPTGRGSMAAPSLHPSLGPGIGSPGQLHSPISTLSSPINGMGPPFSVISSPMGPHSMSVPTTPTLGFSTGSPQLSSPMNPVSSSEDIKPPLGLNGVLKVPAHPSGNMASFTKHICAICGDRSSGKHYGVYSCEGCKGFFKRTVRKDLTYTCRDNKDCLIDKRQRNRCQYCRYQKCLAMGMKREAVQEERQRGKDRNENEVESTSSANEDMPVERILEAELAVEPKTETYVEANMGLNPSSPNDPVTNICQAADKQLFTLVEWAKRIPHFSELPLDDQVILLRAGWNELLIASFSHRSIAVKDGILLATGLHVHRNSAHSAGVGAIFDRVLTELVSKMRDMQMDKTELGCLRAIVLFNPDSKGLSNPAEVEALREKVYASLEAYCKHKYPEQPGRFAKLLLRLPALRSIGLKCLEHLFFFKLIGDTPIDTFLMEMLEAPHQMT
T13726	DRUGINFO	D0N0RU	Bexarotene	Approved
T13726	DRUGINFO	D0G3PI	Alitretinoin	Approved
T13726	DRUGINFO	D03ZEL	CD3254	Investigative
T13726	DRUGINFO	D05JXE	phytanic acid	Investigative
T13726	DRUGINFO	D09IEN	UVI3003	Investigative
T13726	DRUGINFO	D0CQ3A	Tributylstannanyl	Investigative
T13726	DRUGINFO	D0CT1F	methoprene acid	Investigative
T13726	DRUGINFO	D0IY9H	PA451	Investigative
T13726	DRUGINFO	D05DMH	(5BETA)-PREGNANE-3,20-DIONE	Investigative
T13726	DRUGINFO	D00ACX	2-chloro-5-nitro-N-phenylbenzamide	Investigative
T13726	DRUGINFO	D0GR9O	AGN-34	Investigative
T13726	DRUGINFO	D0Q9FZ	LG100754	Investigative

T83145	TARGETID	T83145
T83145	FORMERID	TTDC00046
T83145	UNIPROID	NFKB1_HUMAN; NFKB2_HUMAN; TF65_HUMAN; RELB_HUMAN; REL_HUMAN
T83145	TARGNAME	Nuclear factor NF-kappa-B (NFKB)
T83145	GENENAME	NFKB1; NFKB2; RELA; RELB; REL
T83145	TARGTYPE	Successful
T83145	SYNONYMS	Nuclear factor of kappa light polypeptide gene enhancer in B-cells; DNA-binding factor KBF
T83145	FUNCTION	NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65. In concert with RELB, regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer. NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis.
T83145	SEQUENCE	MAEDDPYLGRPEQMFHLDPSLTHTIFNPEVFQPQMALPTDGPYLQILEQPKQRGFRFRYVCEGPSHGGLPGASSEKNKKSYPQVKICNYVGPAKVIVQLVTNGKNIHLHAHSLVGKHCEDGICTVTAGPKDMVVGFANLGILHVTKKKVFETLEARMTEACIRGYNPGLLVHPDLAYLQAEGGGDRQLGDREKELIRQAALQQTKEMDLSVVRLMFTAFLPDSTGSFTRRLEPVVSDAIYDSKAPNASNLKIVRMDRTAGCVTGGEEIYLLCDKVQKDDIQIRFYEEEENGGVWEGFGDFSPTDVHRQFAIVFKTPKYKDINITKPASVFVQLRRKSDLETSEPKPFLYYPEIKDKEEVQRKRQKLMPNFSDSFGGGSGAGAGGGGMFGSGGGGGGTGSTGPGYSFPHYGFPTYGGITFHPGTTKSNAGMKHGTMDTESKKDPEGCDKSDDKNTVNLFGKVIETTEQDQEPSEATVGNGEVTLTYATGTKEESAGVQDNLFLEKAMQLAKRHANALFDYAVTGDVKMLLAVQRHLTAVQDENGDSVLHLAIIHLHSQLVRDLLEVTSGLISDDIINMRNDLYQTPLHLAVITKQEDVVEDLLRAGADLSLLDRLGNSVLHLAAKEGHDKVLSILLKHKKAALLLDHPNGDGLNAIHLAMMSNSLPCLLLLVAAGADVNAQEQKSGRTALHLAVEHDNISLAGCLLLEGDAHVDSTTYDGTTPLHIAAGRGSTRLAALLKAAGADPLVENFEPLYDLDDSWENAGEDEGVVPGTTPLDMATSWQVFDILNGKPYEPEFTSDDLLAQGDMKQLAEDVKLQLYKLLEIPDPDKNWATLAQKLGLGILNNAFRLSPAPSKTLMDNYEVSGGTVRELVEALRQMGYTEAIEVIQAASSPVKTTSQAHSLPLSPASTRQQIDELRDSDSVCDSGVETSFRKLSFTESLTSGASLLTLNKMPHDYGQEGPLEGKI
T83145	DRUGINFO	D02ZTJ	Sulfasalazine	Approved
T83145	DRUGINFO	D0I6LH	Triptolide	Phase 3
T83145	DRUGINFO	D0JN5N	Laquinimod	Phase 3
T83145	DRUGINFO	D0QR3X	Edasalonexent	Phase 3
T83145	DRUGINFO	D0R7UL	MD1003	Phase 3
T83145	DRUGINFO	D00SBD	Recoflavone	Phase 2
T83145	DRUGINFO	D01KHW	CZEN-002	Phase 2
T83145	DRUGINFO	D02RDX	XP-23829	Phase 2
T83145	DRUGINFO	D05MJS	PRO22	Phase 2
T83145	DRUGINFO	D06HFI	L-ornithine phenylacetate	Phase 2
T83145	DRUGINFO	D08UOY	Vadimezan	Phase 2
T83145	DRUGINFO	D06TZZ	CAT 1004	Phase 2
T83145	DRUGINFO	D0M4KE	Parthenolide	Phase 2
T83145	DRUGINFO	D08JOY	Avrina	Phase 1/2
T83145	DRUGINFO	D0V5AL	LC-1	Phase 1
T83145	DRUGINFO	D00THJ	1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 3	Patented
T83145	DRUGINFO	D01LTK	PMID25553724-Compound-WO2011152671 2	Patented
T83145	DRUGINFO	D02CEY	PMID25553724-Compound-WO2013082253 33	Patented
T83145	DRUGINFO	D02WOW	PMID25553724-Compound-WO2011127048 32	Patented
T83145	DRUGINFO	D03WHA	N-quinolin-benzene sulphonamide derivative 1	Patented
T83145	DRUGINFO	D04GMP	N-quinolin-benzene sulphonamide derivative 3	Patented
T83145	DRUGINFO	D04NKE	Tihourea derivative 1	Patented
T83145	DRUGINFO	D04NMJ	PMID25553724-Compound-US2012830453910	Patented
T83145	DRUGINFO	D05CGR	PMID25553724-Compound-WO2013082253 31	Patented
T83145	DRUGINFO	D05UGL	1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 1	Patented
T83145	DRUGINFO	D05WCW	Quinoxaline derivative 6	Patented
T83145	DRUGINFO	D06YEK	1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 4	Patented
T83145	DRUGINFO	D07NCJ	PMID25553724-Compound-EP20132578214 2	Patented
T83145	DRUGINFO	D08NGV	PMID25553724-Compound-US2012820715110	Patented
T83145	DRUGINFO	D08RUK	PMID25553724-Compound-WO2011127048 31	Patented
T83145	DRUGINFO	D08YMD	Quinoxaline derivative 5	Patented
T83145	DRUGINFO	D09OGV	PMID25553724-Compound-WO2011127048 34	Patented
T83145	DRUGINFO	D09VXA	Quinoxaline derivative 1	Patented
T83145	DRUGINFO	D0BL3X	PMID25553724-Compound-US2011799419010	Patented
T83145	DRUGINFO	D0BQ8A	PMID25553724-Compound-US2011796857710	Patented
T83145	DRUGINFO	D0D6DE	PMID25553724-Compound-US20138552206 4	Patented
T83145	DRUGINFO	D0DL3R	PMID25553724-Compound-US2011801300410	Patented
T83145	DRUGINFO	D0E7ZN	PMID25553724-Compound-US2011000295210	Patented
T83145	DRUGINFO	D0ED5S	PMID25553724-Compound-US20130116324 2	Patented
T83145	DRUGINFO	D0F5TR	PMID25553724-Compound-US2012832440110	Patented
T83145	DRUGINFO	D0F9GL	PMID25553724-Compound-US2011806744710	Patented
T83145	DRUGINFO	D0GN7U	PMID25553724-Compound-US2011803494010	Patented
T83145	DRUGINFO	D0J2VS	1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 2	Patented
T83145	DRUGINFO	D0K0TL	PMID25553724-Compound-WO2013082253 34	Patented
T83145	DRUGINFO	D0KO3I	Olenolic acid acetate derivative 1	Patented
T83145	DRUGINFO	D0LT6Z	PMID25553724-Compound-US2012810604610	Patented
T83145	DRUGINFO	D0O5TC	Quinoxaline derivative 2	Patented
T83145	DRUGINFO	D0OY0Q	Tihotungstate derivative 1	Patented
T83145	DRUGINFO	D0P0KY	PMID25553724-Compound-WO2011127048 33	Patented
T83145	DRUGINFO	D0PB2J	PMID25553724-Compound-WO2013082253 32	Patented
T83145	DRUGINFO	D0Q5YJ	PMID25553724-Compound-US2012819831110	Patented
T83145	DRUGINFO	D0Q6JK	Quinoxaline derivative 3	Patented
T83145	DRUGINFO	D0R4RV	PMID25553724-Compound-US20138552206 5	Patented
T83145	DRUGINFO	D0X2ZY	N-quinolin-benzene sulphonamide derivative 2	Patented
T83145	DRUGINFO	D0XQ5E	Quinoxaline derivative 4	Patented
T83145	DRUGINFO	D0Y2RN	PMID25553724-Compound-US2011788838110	Patented
T83145	DRUGINFO	D03HVN	P-1	Discontinued in Phase 3
T83145	DRUGINFO	D0W7ZN	SIM-916	Discontinued in Phase 1
T83145	DRUGINFO	D01OLO	AS602868	Discontinued in Phase 1
T83145	DRUGINFO	D00ARN	Tyloxapol	Terminated
T83145	DRUGINFO	D0N1XD	Gliotoxin	Terminated
T83145	DRUGINFO	D0P1YO	MOL-218	Terminated
T83145	DRUGINFO	D0Q6YP	HELENALIN	Terminated
T83145	DRUGINFO	D00EOD	Centratherin	Investigative
T83145	DRUGINFO	D00RAO	4,5-ISOBUDLEIN A	Investigative
T83145	DRUGINFO	D00SRS	BUDLEIN A	Investigative
T83145	DRUGINFO	D01FYY	SP-650003	Investigative
T83145	DRUGINFO	D01NVL	9-chloro-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide	Investigative
T83145	DRUGINFO	D02EHZ	5-chloro-N-(quinolin-8-yl)thiophene-2-sulfonamide	Investigative
T83145	DRUGINFO	D03VYU	Isohelenin	Investigative
T83145	DRUGINFO	D04VQM	5-bromo-N-(quinolin-8-yl)thiophene-2-sulfonamide	Investigative
T83145	DRUGINFO	D04YTE	ROCAGLAMIDE	Investigative
T83145	DRUGINFO	D05DHX	HELENALINMETHACRYLATE	Investigative
T83145	DRUGINFO	D05OPF	4-nitro-N-(quinolin-8-yl)benzenesulfonamide	Investigative
T83145	DRUGINFO	D05RCK	Miller-9E-enolide	Investigative
T83145	DRUGINFO	D06FRZ	15-ACETOXY-EREMANTHOLIDE B	Investigative
T83145	DRUGINFO	D06MAL	ATRIPLICIOLIDTIGLATE	Investigative
T83145	DRUGINFO	D06YGF	Caffeic acid phenethyl ester	Investigative
T83145	DRUGINFO	D06ZIE	SCANDENOLIDE	Investigative
T83145	DRUGINFO	D06ZYQ	2beta-methoxy-2-deethoxyphantomolin	Investigative
T83145	DRUGINFO	D07JDD	ARTORIGIDIN A	Investigative
T83145	DRUGINFO	D07PWA	IkappaB-alphaM	Investigative
T83145	DRUGINFO	D08KJM	9-methyl-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide	Investigative
T83145	DRUGINFO	D08ZBD	9-fluoro-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide	Investigative
T83145	DRUGINFO	D09FBD	MOLEPHANTIN	Investigative
T83145	DRUGINFO	D09SZJ	Pycnogenol	Investigative
T83145	DRUGINFO	D0B0IJ	Pyrrolidine dithiocarbamate	Investigative
T83145	DRUGINFO	D0B7EP	1beta-methoxy-miller-9Z-enolide	Investigative
T83145	DRUGINFO	D0B8RN	4beta,15-epoxy-miller-9E-enolide	Investigative
T83145	DRUGINFO	D0CQ5F	3,4-epoxydehydroleucodin	Investigative
T83145	DRUGINFO	D0E7FU	2-amino-N-(quinolin-8-yl)benzenesulfonamide	Investigative
T83145	DRUGINFO	D0F0VD	ACHP	Investigative
T83145	DRUGINFO	D0F7UW	4beta,15-epoxy-miller-9Z-enolide	Investigative
T83145	DRUGINFO	D0G8GL	Miller-9Z-enolide	Investigative
T83145	DRUGINFO	D0J0ZF	15-isobutyrylmiguanin	Investigative
T83145	DRUGINFO	D0J2PO	ARTOBILOXANTHONE	Investigative
T83145	DRUGINFO	D0J7XB	ENHYDRIN	Investigative
T83145	DRUGINFO	D0L2XO	BAY11-7082	Investigative
T83145	DRUGINFO	D0LH9A	ISOGOIAZENSOLIDE	Investigative
T83145	DRUGINFO	D0M6DV	MOLEPHANTININ	Investigative
T83145	DRUGINFO	D0MY0M	15-DEOXYBUDLEIN A	Investigative
T83145	DRUGINFO	D0N2GO	7-hydroxycostunolide	Investigative
T83145	DRUGINFO	D0O5HF	Helenalin-2-methylbutyrate	Investigative
T83145	DRUGINFO	D0Q2KK	5H-6-thia-4,5-diaza-chrysene 6,6-dioxide	Investigative
T83145	DRUGINFO	D0R2MO	2-oxoguaia-1,4,11(13)-trien-12,8alpha-olide	Investigative
T83145	DRUGINFO	D0V4PJ	9alpha-acetoxy-miller-1(10)Z-enolide	Investigative
T83145	DRUGINFO	D0V6QZ	2-nitro-N-(quinolin-8-yl)benzenesulfonamide	Investigative
T83145	DRUGINFO	D0VD3M	15-deoxygoiazensolide	Investigative
T83145	DRUGINFO	D0X8OL	N-(quinolin-8-yl)thiophene-2-sulfonamide	Investigative
T83145	DRUGINFO	D0Y0CA	2-oxoguaia-1,4(15), 11(13)-trien-12,8beta-olide	Investigative
T83145	DRUGINFO	D0Y0LD	DTD	Investigative
T83145	DRUGINFO	D07MQC	PS-1145	Investigative
T83145	DRUGINFO	D08JPU	G6976	Investigative

T38950	TARGETID	T38950
T38950	FORMERID	TTDS00091
T38950	UNIPROID	CD33_HUMAN
T38950	TARGNAME	Myeloid cell surface antigen CD33 (CD33)
T38950	GENENAME	CD33
T38950	TARGTYPE	Successful
T38950	SYNONYMS	Siglec-3; Sialic acid-binding Ig-like lectin 3; SIGLEC3; Gp67
T38950	FUNCTION	Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans. Upon engagement of ligands such as C1q or syalylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK. These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2. In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules. One of the repressive effect of CD33 on monocyte activation requires phosphoinositide 3-kinase/PI3K. Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state.
T38950	PDBSTRUC	6D4A; 6D49; 6D48; 5J0B; 5J06
T38950	BIOCLASS	Immunoglobulin
T38950	SEQUENCE	MPLLLLLPLLWAGALAMDPNFWLQVQESVTVQEGLCVLVPCTFFHPIPYYDKNSPVHGYWFREGAIISRDSPVATNKLDQEVQEETQGRFRLLGDPSRNNCSLSIVDARRRDNGSYFFRMERGSTKYSYKSPQLSVHVTDLTHRPKILIPGTLEPGHSKNLTCSVSWACEQGTPPIFSWLSAAPTSLGPRTTHSSVLIITPRPQDHGTNLTCQVKFAGAGVTTERTIQLNVTYVPQNPTTGIFPGDGSGKQETRAGVVHGAIGGAGVTALLALCLCLIFFIVKTHRRKAARTAVGRNDTHPTTGSASPKHQKKSKLHGPTETSSCSGAAPTVEMDEELHYASLNFHGMNPSKDTSTEYSEVRTQ
T38950	DRUGINFO	D06EWO	Gemtuzumab ozogamicin	Approved
T38950	DRUGINFO	D0W2BF	Vadastuximab talirine	Phase 3
T38950	DRUGINFO	D03HSA	Actimab-A	Phase 2
T38950	DRUGINFO	D04MGW	BI-836858	Phase 2
T38950	DRUGINFO	DSIT20	Actimab-MDS	Phase 2
T38950	DRUGINFO	D01KKI	SGN-CD33A	Phase 1/2
T38950	DRUGINFO	D04VCQ	CART33 cells	Phase 1/2
T38950	DRUGINFO	D0G9MY	CD33-specific gene-engineered T cells	Phase 1/2
T38950	DRUGINFO	D0K8WE	Anti-CD33 CAR-T cells	Phase 1/2
T38950	DRUGINFO	D0TV6H	HuM-195-Ac-225	Phase 1/2
T38950	DRUGINFO	D9O7GC	GTB-3550	Phase 1/2
T38950	DRUGINFO	D06JQS	HuM195/rGel	Phase 1
T38950	DRUGINFO	D0C4GN	CD33-CAR-T Cell	Phase 1
T38950	DRUGINFO	D0LP7U	AMV564	Phase 1
T38950	DRUGINFO	D0P6YN	CART-33 cells	Phase 1
T38950	DRUGINFO	D0XE4W	Actimab-M	Phase 1
T38950	DRUGINFO	D0ZL3U	Allogeneic CART-33	Phase 1
T38950	DRUGINFO	D5QKY2	AL003	Phase 1
T38950	DRUGINFO	D9OZ3B	JNJ-67571244	Phase 1
T38950	DRUGINFO	DSI4G9	225Ac-labelled aCD33	Phase 1
T38950	DRUGINFO	D5T9GZ	CLL1-CD33 cCART cell therapy	Phase 1
T38950	DRUGINFO	D8AOC1	AMG 330	Phase 1
T38950	DRUGINFO	DB4C5H	CD123-CD33 Ccar	Phase 1
T38950	DRUGINFO	DNS2P1	AMG 673	Phase 1
T38950	DRUGINFO	DQD1T2	GEM333	Phase 1
T38950	DRUGINFO	D01RNL	Lintuzumab	Discontinued in Phase 2
T38950	DRUGINFO	D0IJ1D	HuM-195-Bi-213	Discontinued in Phase 1/2
T38950	DRUGINFO	D0E4EP	Oncolysin M	Discontinued in Phase 1
T38950	DRUGINFO	D0JT0U	CAR-T cells targeting CD33	Preclinical

T40111	TARGETID	T40111
T40111	FORMERID	TTDS00062
T40111	UNIPROID	IMDH1_HUMAN
T40111	TARGNAME	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
T40111	GENENAME	IMPDH1
T40111	TARGTYPE	Successful
T40111	SYNONYMS	Superoxide-inducible protein 12; SOI12; Probable inosine-5'-monophosphate dehydrogenase IMD1; NAD-dependent inosine monophosphate dehydrogenase; Inosine dehydrogenase; IMPDH-I; IMPDH 1; IMPDH; IMPD1; IMPD 1; IMPD; IMP dehydrogenase 1; IMP dehydrogenase
T40111	FUNCTION	Could also have a single-stranded nucleic acid-binding activity and could play a role in RNA and/or DNA metabolism. It may also have a role in the development of malignancy and the growth progression of some tumors. Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth.
T40111	PDBSTRUC	1JCN
T40111	BIOCLASS	CH-OH donor oxidoreductase
T40111	ECNUMBER	EC 1.1.1.205
T40111	SEQUENCE	MADYLISGGTGYVPEDGLTAQQLFASADGLTYNDFLILPGFIDFIADEVDLTSALTRKITLKTPLISSPMDTVTEADMAIAMALMGGIGFIHHNCTPEFQANEVRKVKKFEQGFITDPVVLSPSHTVGDVLEAKMRHGFSGIPITETGTMGSKLVGIVTSRDIDFLAEKDHTTLLSEVMTPRIELVVAPAGVTLKEANEILQRSKKGKLPIVNDCDELVAIIARTDLKKNRDYPLASKDSQKQLLCGAAVGTREDDKYRLDLLTQAGVDVIVLDSSQGNSVYQIAMVHYIKQKYPHLQVIGGNVVTAAQAKNLIDAGVDGLRVGMGCGSICITQEVMACGRPQGTAVYKVAEYARRFGVPIIADGGIQTVGHVVKALALGASTVMMGSLLAATTEAPGEYFFSDGVRLKKYRGMGSLDAMEKSSSSQKRYFSEGDKVKIAQGVSGSIQDKGSIQKFVPYLIAGIQHGCQDIGARSLSVLRSMMYSGELKFEKRTMSAQIEGGVHGLHSYEKRLY
T40111	DRUGINFO	D0G5AG	Mizoribine	Approved
T40111	DRUGINFO	D0H3WI	Ribavirin	Approved
T40111	DRUGINFO	D0S7DV	Tiazofurin	Approved
T40111	DRUGINFO	D09UZO	Mercaptopurine	Approved
T40111	DRUGINFO	D0F0ZE	Merimepodib	Approved
T40111	DRUGINFO	D09XUB	Viramidine	Phase 3
T40111	DRUGINFO	D05QIS	VX-944	Phase 2
T40111	DRUGINFO	D00RJA	VX-148	Patented
T40111	DRUGINFO	D00XRN	PMID28074661-Compound-US20100022547C81	Patented
T40111	DRUGINFO	D01FPR	PMID28074661-Compound-US20120264760C80	Patented
T40111	DRUGINFO	D01XUI	Carbamide derivative 9	Patented
T40111	DRUGINFO	D03GSK	Carbamide derivative 7	Patented
T40111	DRUGINFO	D03KFN	PMID28074661-Compound-US20100022547C88	Patented
T40111	DRUGINFO	D03XKM	PMID28074661-Compound-US20100022547C82	Patented
T40111	DRUGINFO	D04DRI	Mycophenolic acid/nucleotide derivative 10	Patented
T40111	DRUGINFO	D05BGS	Urea and carbamate bioisostere derivative 7	Patented
T40111	DRUGINFO	D05QMA	Urea and carbamate bioisostere derivative 18	Patented
T40111	DRUGINFO	D05YHV	Mycophenolic acid/nucleotide derivative 11	Patented
T40111	DRUGINFO	D06HLW	PMID28074661-Compound-US20120264760C82	Patented
T40111	DRUGINFO	D06KXL	Quinazolinone derivative 2	Patented
T40111	DRUGINFO	D06UKM	PMID28074661-Compound-US20120264760C87	Patented
T40111	DRUGINFO	D07IOO	Urea and carbamate bioisostere derivative 11	Patented
T40111	DRUGINFO	D07NDT	PMID28074661-Compound-US20100022547C80	Patented
T40111	DRUGINFO	D07WXU	Urea and carbamate bioisostere derivative 6	Patented
T40111	DRUGINFO	D07ZCP	Carbamide derivative 4	Patented
T40111	DRUGINFO	D08EIA	Carbamide derivative 6	Patented
T40111	DRUGINFO	D0B7FH	PMID28074661-Compound-US20120264760C88	Patented
T40111	DRUGINFO	D0C8GW	Quinolone derivative 1	Patented
T40111	DRUGINFO	D0D5YK	Urea and carbamate bioisostere derivative 16	Patented
T40111	DRUGINFO	D0EX3N	PMID28074661-Compound-WO2009018344C78	Patented
T40111	DRUGINFO	D0FY8B	Carbamide derivative 8	Patented
T40111	DRUGINFO	D0FZ1H	Mycophenolic acid/nucleotide derivative 4	Patented
T40111	DRUGINFO	D0G9BO	Mycophenolic acid/nucleotide derivative 8	Patented
T40111	DRUGINFO	D0GR7W	Mycophenolic acid/nucleotide derivative 2	Patented
T40111	DRUGINFO	D0H5UL	PMID28074661-Compound-US20128202889C90	Patented
T40111	DRUGINFO	D0HO8C	Urea and carbamate bioisostere derivative 2	Patented
T40111	DRUGINFO	D0IQ5V	PMID28074661-Compound-US20100022547C86	Patented
T40111	DRUGINFO	D0J0EP	PMID28074661-Compound-US20120264760C86	Patented
T40111	DRUGINFO	D0J4CI	Mycophenolic acid/nucleotide derivative 12	Patented
T40111	DRUGINFO	D0J9WP	PMID28074661-Compound-US20100022547C87	Patented
T40111	DRUGINFO	D0K4AQ	Mycophenolic acid/nucleotide derivative 6	Patented
T40111	DRUGINFO	D0KN3S	Carbamide derivative 5	Patented
T40111	DRUGINFO	D0L5UM	Urea and carbamate bioisostere derivative 9	Patented
T40111	DRUGINFO	D0L7QE	Mycophenolic acid/nucleotide derivative 9	Patented
T40111	DRUGINFO	D0LH0O	Carbamide derivative 11	Patented
T40111	DRUGINFO	D0NK9Y	Quinazolinone derivative 1	Patented
T40111	DRUGINFO	D0NN4P	Urea and carbamate bioisostere derivative 5	Patented
T40111	DRUGINFO	D0OI4X	Mycophenolic acid/nucleotide derivative 1	Patented
T40111	DRUGINFO	D0OS2M	Mycophenolic acid/nucleotide derivative 5	Patented
T40111	DRUGINFO	D0P6WN	Carbamide derivative 10	Patented
T40111	DRUGINFO	D0P8WC	PMID28074661-Compound-US20169447134C85	Patented
T40111	DRUGINFO	D0PN7H	PMID28074661-Compound-US20120264760C83	Patented
T40111	DRUGINFO	D0QA8T	Urea and carbamate bioisostere derivative 4	Patented
T40111	DRUGINFO	D0QL7X	Urea and carbamate bioisostere derivative 10	Patented
T40111	DRUGINFO	D0R3QC	PMID28074661-Compound-WO2009018344C79	Patented
T40111	DRUGINFO	D0S7VL	Urea and carbamate bioisostere derivative 15	Patented
T40111	DRUGINFO	D0SG2L	PMID28074661-Compound-US20120264760C81	Patented
T40111	DRUGINFO	D0TZ1Y	Mycophenolic acid/nucleotide derivative 7	Patented
T40111	DRUGINFO	D0UD3K	Urea and carbamate bioisostere derivative 3	Patented
T40111	DRUGINFO	D0V3HE	PMID28074661-Compound-US20158969342C84	Patented
T40111	DRUGINFO	D0W3KK	Urea and carbamate bioisostere derivative 13	Patented
T40111	DRUGINFO	D0X6FX	PMID28074661-Compound-US20100022547C83	Patented
T40111	DRUGINFO	D0XQ3W	Mycophenolic acid/nucleotide derivative 3	Patented
T40111	DRUGINFO	D0Z7SK	Urea and carbamate bioisostere derivative 14	Patented
T40111	DRUGINFO	D0O2IE	Phenacetin	Withdrawn from market
T40111	DRUGINFO	D03LIS	Selenazofurin	Investigative
T40111	DRUGINFO	D0F5TV	TAD	Investigative
T40111	DRUGINFO	D05EHM	6-Cl-IMP	Investigative
T40111	DRUGINFO	D0H2YT	Inosinic Acid	Investigative

T46828	TARGETID	T46828
T46828	FORMERID	TTDS00015
T46828	UNIPROID	DRD5_HUMAN
T46828	TARGNAME	Dopamine D5 receptor (D5R)
T46828	GENENAME	DRD5
T46828	TARGTYPE	Successful
T46828	SYNONYMS	Dopamine receptor 5; DRD5; D1beta dopamine receptor; D(5)D(1B) dopamine receptor dopamine receptor; D(5) dopamine receptor
T46828	FUNCTION	Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
T46828	BIOCLASS	GPCR rhodopsin
T46828	SEQUENCE	MLPPGSNGTAYPGQFALYQQLAQGNAVGGSAGAPPLGPSQVVTACLLTLLIIWTLLGNVLVCAAIVRSRHLRANMTNVFIVSLAVSDLFVALLVMPWKAVAEVAGYWPFGAFCDVWVAFDIMCSTASILNLCVISVDRYWAISRPFRYKRKMTQRMALVMVGLAWTLSILISFIPVQLNWHRDQAASWGGLDLPNNLANWTPWEEDFWEPDVNAENCDSSLNRTYAISSSLISFYIPVAIMIVTYTRIYRIAQVQIRRISSLERAAEHAQSCRSSAACAPDTSLRASIKKETKVLKTLSVIMGVFVCCWLPFFILNCMVPFCSGHPEGPPAGFPCVSETTFDVFVWFGWANSSLNPVIYAFNADFQKVFAQLLGCSHFCSRTPVETVNISNELISYNQDIVFHKEIAAAYIHMMPNAVTPGNREVDNDEEEGPFDRMFQIYQTSPDGDPVAESVWELDCEGEISLDKITPFTPNGFH
T46828	DRUGINFO	D0KS6W	Phenyltoloxamine	Approved
T46828	DRUGINFO	D07YLK	LE-300	Preclinical
T46828	DRUGINFO	D05RMW	ZD-3638	Terminated
T46828	DRUGINFO	D0A3OF	GMC-283	Terminated
T46828	DRUGINFO	D08EXR	beta-ergocriptine	Investigative
T46828	DRUGINFO	D09KRA	[125I]SCH23982	Investigative
T46828	DRUGINFO	D0LR8X	SKF-83556	Investigative
T46828	DRUGINFO	D0X2NO	(+)-ADTN	Investigative
T46828	DRUGINFO	D01ENR	4-[2-(2-Benzyl-phenoxy)-ethyl]-morpholine	Investigative
T46828	DRUGINFO	D0LV7U	1-(4-(4-phenyl-1-piperazinyl)butyl)indolin-2-one	Investigative
T46828	DRUGINFO	D06LQH	N-propylnorapomorphine	Investigative
T46828	DRUGINFO	D07RYR	1-[2-(2-Benzyl-phenoxy)-ethyl]-pyrrolidine	Investigative
T46828	DRUGINFO	D05UUW	1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine	Investigative
T46828	DRUGINFO	D0E1RX	1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine	Investigative
T46828	DRUGINFO	D0L7OM	STEPHOLIDINE	Investigative
T46828	DRUGINFO	D0MC2R	FLUTROLINE	Investigative
T46828	DRUGINFO	D0R8UU	1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine	Investigative
T46828	DRUGINFO	D0HV3A	FLUMEZAPINE	Investigative
T46828	DRUGINFO	D0Q2GP	ISOLOXAPINE	Investigative
T46828	DRUGINFO	D0P0IX	ISOCLOZAPINE	Investigative
T46828	DRUGINFO	D0L5MW	(+/-)-nantenine	Investigative

T28993	TARGETID	T28993
T28993	FORMERID	TTDI02286
T28993	UNIPROID	IDS_HUMAN
T28993	TARGNAME	Iduronate 2-sulfatase (IDS)
T28993	GENENAME	IDS
T28993	TARGTYPE	Successful
T28993	SYNONYMS	Idursulfase; Iduronate 2sulfatase 14 kDa chain; IDS; AlphaLiduronate sulfate sulfatase
T28993	FUNCTION	Required for the lysosomal degradation ofheparan sulfate and dermatan sulfate.
T28993	PDBSTRUC	6IOZ; 5FQL
T28993	BIOCLASS	Sulfuric ester hydrolase
T28993	ECNUMBER	EC 3.1.6.13
T28993	SEQUENCE	MPPPRTGRGLLWLGLVLSSVCVALGSETQANSTTDALNVLLIIVDDLRPSLGCYGDKLVRSPNIDQLASHSLLFQNAFAQQAVCAPSRVSFLTGRRPDTTRLYDFNSYWRVHAGNFSTIPQYFKENGYVTMSVGKVFHPGISSNHTDDSPYSWSFPPYHPSSEKYENTKTCRGPDGELHANLLCPVDVLDVPEGTLPDKQSTEQAIQLLEKMKTSASPFFLAVGYHKPHIPFRYPKEFQKLYPLENITLAPDPEVPDGLPPVAYNPWMDIRQREDVQALNISVPYGPIPVDFQRKIRQSYFASVSYLDTQVGRLLSALDDLQLANSTIIAFTSDHGWALGEHGEWAKYSNFDVATHVPLIFYVPGRTASLPEAGEKLFPYLDPFDSASQLMEPGRQSMDLVELVSLFPTLAGLAGLQVPPRCPVPSFHVELCREGKNLLKHFRFRDLEEDPYLPGNPRELIAYSQYPRPSDIPQWNSDKPSLKDIKIMGYSIRTIDYRYTVWVGFNPDEFLANFSDIHAGELYFVDSDPLQDHNMYNDSQGGDLFQLLMP
T28993	DRUGINFO	D06CZJ	Idursulfase	Approved
T28993	DRUGINFO	D0L1DR	Recombinant human iduronate-2-sulfatase	Phase 3
T28993	DRUGINFO	DTV58L	DNL310	Phase 2/3
T28993	DRUGINFO	DY21QW	RGX-121	Phase 1/2
T28993	DRUGINFO	DY9DX8	SB-913	Phase 1/2

T17569	TARGETID	T17569
T17569	FORMERID	TTDC00303
T17569	UNIPROID	KCNA5_HUMAN
T17569	TARGNAME	Voltage-gated potassium channel Kv1.5 (KCNA5)
T17569	GENENAME	KCNA5
T17569	TARGTYPE	Successful
T17569	SYNONYMS	Voltage-gatedpotassium channel subunit Kv1.5; Voltage-gated potassium channel subunit Kv1.5; Voltage-gated potassium channel HK2; Potassium voltage-gated channel subfamily A member 5; Potassium channel Kv1.5; HPCN1; HK2; 02-Sensitive Potassium Channel Kv1.5
T17569	FUNCTION	Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage difference across the membrane. Can form functional homotetrameric channels and heterotetrameric channels that contain variable proportions of KCNA1, KCNA2, KCNA4, KCNA5, and possibly other family members as well; channel properties depend on the type of alpha subunits that are part of the channel. Channel properties are modulated by cytoplasmic beta subunits that regulate the subcellular location of the alpha subunits and promote rapid inactivation. Homotetrameric channels display rapid activation and slow inactivation. May play a role in regulating the secretion of insulin in normal pancreatic islets. Isoform 2 exhibits a voltage-dependent recovery from inactivation and an excessive cumulative inactivation. Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes.
T17569	BIOCLASS	Voltage-gated ion channel
T17569	SEQUENCE	MEIALVPLENGGAMTVRGGDEARAGCGQATGGELQCPPTAGLSDGPKEPAPKGRGAQRDADSGVRPLPPLPDPGVRPLPPLPEELPRPRRPPPEDEEEEGDPGLGTVEDQALGTASLHHQRVHINISGLRFETQLGTLAQFPNTLLGDPAKRLRYFDPLRNEYFFDRNRPSFDGILYYYQSGGRLRRPVNVSLDVFADEIRFYQLGDEAMERFREDEGFIKEEEKPLPRNEFQRQVWLIFEYPESSGSARAIAIVSVLVILISIITFCLETLPEFRDERELLRHPPAPHQPPAPAPGANGSGVMAPPSGPTVAPLLPRTLADPFFIVETTCVIWFTFELLVRFFACPSKAGFSRNIMNIIDVVAIFPYFITLGTELAEQQPGGGGGGQNGQQAMSLAILRVIRLVRVFRIFKLSRHSKGLQILGKTLQASMRELGLLIFFLFIGVILFSSAVYFAEADNQGTHFSSIPDAFWWAVVTMTTVGYGDMRPITVGGKIVGSLCAIAGVLTIALPVPVIVSNFNYFYHRETDHEEPAVLKEEQGTQSQGPGLDRGVQRKVSGSRGSFCKAGGTLENADSARRGSCPLEKCNVKAKSNVDLRRSLYALCLDTSRETDL
T17569	DRUGINFO	D05CPV	Dronedarone	Approved
T17569	DRUGINFO	D04LOR	BMS-919373	Phase 2
T17569	DRUGINFO	D00RNB	IQB-9302	Phase 1
T17569	DRUGINFO	D05DXT	XEN-D0103	Phase 1
T17569	DRUGINFO	D06ERY	BMS-394136	Phase 1
T17569	DRUGINFO	D0X6ZG	XEN-D0101	Phase 1
T17569	DRUGINFO	D0TV4N	T-226296	Preclinical
T17569	DRUGINFO	D0NR3V	Zatebradine	Terminated
T17569	DRUGINFO	D00UCP	N-Phenethyl-2-(toluene-4-sulfonylamino)-benzamide	Investigative
T17569	DRUGINFO	D00WKK	2-morpholino-2-phenyl-1,1-di(pyridin-3-yl)ethanol	Investigative
T17569	DRUGINFO	D06BMZ	2-morpholino-1,1,2-triphenylethanol	Investigative
T17569	DRUGINFO	D07VWP	S-9947	Investigative
T17569	DRUGINFO	D08LZZ	DPO-1	Investigative
T17569	DRUGINFO	D0A5KP	2-morpholino-1,1-di(pyridin-3-yl)hexan-1-ol	Investigative
T17569	DRUGINFO	D0D8JU	2-phenyl-1,1-di(pyridin-3-yl)ethanol	Investigative
T17569	DRUGINFO	D0H7JE	RS-100302	Investigative
T17569	DRUGINFO	D0I2NX	N-Benzyl-2-(toluene-4-sulfonylamino)-benzamide	Investigative
T17569	DRUGINFO	D0J0OY	3-(benzyloxy)-2-(4-chlorophenyl)thiazolidin-4-one	Investigative
T17569	DRUGINFO	D0K7RO	2-morpholino-1,1-di(pyridin-3-yl)octan-1-ol	Investigative
T17569	DRUGINFO	D0QG6A	NIP-142	Investigative
T17569	DRUGINFO	D0R5OF	3-methyl-2-morpholino-1,1-diphenylbutan-1-ol	Investigative
T17569	DRUGINFO	D0T0VZ	XEN-D0104	Investigative
T17569	DRUGINFO	D0U9DD	2-phenoxy-1-(2-p-tolylthiazolidin-3-yl)ethanone	Investigative
T17569	DRUGINFO	D0XB2Z	3-(4-methoxybenzyloxy)-2-phenylthiazolidin-4-one	Investigative
T17569	DRUGINFO	D0Y8AB	2-amino-2-phenyl-1,1-di(pyridin-3-yl)ethanol	Investigative
T17569	DRUGINFO	D02QJW	clofilium	Investigative
T17569	DRUGINFO	D0R9CF	4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one	Investigative
T17569	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T42822	TARGETID	T42822
T42822	FORMERID	TTDS00437
T42822	UNIPROID	HEMH_HUMAN
T42822	TARGNAME	Ferrochelatase (FECH)
T42822	GENENAME	FECH
T42822	TARGTYPE	Successful
T42822	SYNONYMS	Protoheme ferro-lyase; Heme synthetase; FECH
T42822	FUNCTION	Catalyzes the ferrous insertion into protoporphyrin IX.
T42822	PDBSTRUC	4MK4; 4KMM; 4KLR; 4KLC; 4KLA
T42822	BIOCLASS	Ferrochelatase
T42822	ECNUMBER	EC 4.99.1.1
T42822	SEQUENCE	MRSLGANMAAALRAAGVLLRDPLASSSWRVCQPWRWKSGAAAAAVTTETAQHAQGAKPQVQPQKRKPKTGILMLNMGGPETLGDVHDFLLRLFLDRDLMTLPIQNKLAPFIAKRRTPKIQEQYRRIGGGSPIKIWTSKQGEGMVKLLDELSPNTAPHKYYIGFRYVHPLTEEAIEEMERDGLERAIAFTQYPQYSCSTTGSSLNAIYRYYNQVGRKPTMKWSTIDRWPTHHLLIQCFADHILKELDHFPLEKRSEVVILFSAHSLPMSVVNRGDPYPQEVSATVQKVMERLEYCNPYRLVWQSKVGPMPWLGPQTDESIKGLCERGRKNILLVPIAFTSDHIETLYELDIEYSQVLAKECGVENIRRAESLNGNPLFSKALADLVHSHIQSNELCSKQLTLSCPLCVNPVCRETKSFFTSQQL
T42822	DRUGINFO	D0OL6O	Methyl aminolevulinate	Approved
T42822	DRUGINFO	D0OR2L	Cholic Acid	Approved
T42822	DRUGINFO	D00GJZ	N-Methylmesoporphyrin Containing Copper	Investigative
T42822	DRUGINFO	D0S4VW	Lead acetate	Investigative
T42822	DRUGINFO	D0X5ZA	N-Methylmesoporphyrin	Investigative

T79473	TARGETID	T79473
T79473	FORMERID	TTDS00254
T79473	UNIPROID	LSHR_HUMAN
T79473	TARGNAME	Luteinizing hormone receptor (LHCGR)
T79473	GENENAME	LHCGR
T79473	TARGTYPE	Successful
T79473	SYNONYMS	Luteinizing hormone-releasing hormone receptor; LSH-R; LHRH receptor; LHCGR; LH/CG-R
T79473	FUNCTION	Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase.
T79473	PDBSTRUC	1XUL; 1LUT
T79473	BIOCLASS	GPCR rhodopsin
T79473	SEQUENCE	MKQRFSALQLLKLLLLLQPPLPRALREALCPEPCNCVPDGALRCPGPTAGLTRLSLAYLPVKVIPSQAFRGLNEVIKIEISQIDSLERIEANAFDNLLNLSEILIQNTKNLRYIEPGAFINLPRLKYLSICNTGIRKFPDVTKVFSSESNFILEICDNLHITTIPGNAFQGMNNESVTLKLYGNGFEEVQSHAFNGTTLTSLELKENVHLEKMHNGAFRGATGPKTLDISSTKLQALPSYGLESIQRLIATSSYSLKKLPSRETFVNLLEATLTYPSHCCAFRNLPTKEQNFSHSISENFSKQCESTVRKVNNKTLYSSMLAESELSGWDYEYGFCLPKTPRCAPEPDAFNPCEDIMGYDFLRVLIWLINILAIMGNMTVLFVLLTSRYKLTVPRFLMCNLSFADFCMGLYLLLIASVDSQTKGQYYNHAIDWQTGSGCSTAGFFTVFASELSVYTLTVITLERWHTITYAIHLDQKLRLRHAILIMLGGWLFSSLIAMLPLVGVSNYMKVSICFPMDVETTLSQVYILTILILNVVAFFIICACYIKIYFAVRNPELMATNKDTKIAKKMAILIFTDFTCMAPISFFAISAAFKVPLITVTNSKVLLVLFYPINSCANPFLYAIFTKTFQRDFFLLLSKFGCCKRRAELYRRKDFSAYTSNCKNGFTGSNKPSQSTLKLSTLHCQGTALLDKTRYTEC
T79473	DRUGINFO	D0J0LI	Chorionic Gonadotropin	Approved
T79473	DRUGINFO	D0W6SS	Choriogonadotropin alfa	Approved
T79473	DRUGINFO	D0Z2CM	Lutropin alfa	Approved
T79473	DRUGINFO	D08DOE	ML-04	Phase 2
T79473	DRUGINFO	D0M3TD	Org-43902	Phase 1
T79473	DRUGINFO	D0K0GN	LDI-200	Discontinued in Phase 3
T79473	DRUGINFO	D00TTS	Human chorionic gonadotropin	Terminated
T79473	DRUGINFO	D04CTP	EP-200	Investigative

T25847	TARGETID	T25847
T25847	FORMERID	TTDS00417
T25847	UNIPROID	PPIB_HUMAN
T25847	TARGNAME	Rotamase B (PPIB)
T25847	GENENAME	PPIB
T25847	TARGTYPE	Successful
T25847	SYNONYMS	SCYLP; S-cyclophilin; Peptidyl-prolyl cis-trans isomerase B; PPIase B; Cyclophilin B; CYPB; CYP-S1
T25847	FUNCTION	PPIase that catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides and may therefore assist protein folding.
T25847	PDBSTRUC	3ICI; 3ICH; 1CYN
T25847	BIOCLASS	Cis-trans-isomerase
T25847	ECNUMBER	EC 5.2.1.8
T25847	SEQUENCE	MLRLSERNMKVLLAAALIAGSVFFLLLPGPSAADEKKKGPKVTVKVYFDLRIGDEDVGRVIFGLFGKTVPKTVDNFVALATGEKGFGYKNSKFHRVIKDFMIQGGDFTRGDGTGGKSIYGERFPDENFKLKHYGPGWVSMANAGKDTNGSQFFITTVKTAWLDGKHVVFGKVLEGMEVVRKVESTKTDSRDKPLKDVIIADCGKIEVEKPFAIAKE
T25847	DRUGINFO	D0DZ3X	L-Proline	Approved
T25847	DRUGINFO	D01GMJ	1,4-Dithiothreitol	Investigative

T50269	TARGETID	T50269
T50269	FORMERID	TTDR00771
T50269	UNIPROID	GLRA1_HUMAN
T50269	TARGNAME	Strychnine-binding glycine receptor (GLRA1)
T50269	GENENAME	GLRA1
T50269	TARGTYPE	Successful
T50269	SYNONYMS	Strychnine-insensitive glycine receptor; Strychnine binding subunit; Glycine receptor 48 kDa subunit; GLRA1
T50269	FUNCTION	The glycine receptor is a neurotransmitter-gated ion channel. Binding of glycine to its receptor increases the chloride conductance and thus produces hyperpolarization (inhibition of neuronal firing).
T50269	PDBSTRUC	4X5T; 2M6I; 2M6B; 1VRY; 1MOT
T50269	BIOCLASS	Neurotransmitter receptor
T50269	SEQUENCE	MYSFNTLRLYLWETIVFFSLAASKEAEAARSAPKPMSPSDFLDKLMGRTSGYDARIRPNFKGPPVNVSCNIFINSFGSIAETTMDYRVNIFLRQQWNDPRLAYNEYPDDSLDLDPSMLDSIWKPDLFFANEKGAHFHEITTDNKLLRISRNGNVLYSIRITLTLACPMDLKNFPMDVQTCIMQLESFGYTMNDLIFEWQEQGAVQVADGLTLPQFILKEEKDLRYCTKHYNTGKFTCIEARFHLERQMGYYLIQMYIPSLLIVILSWISFWINMDAAPARVGLGITTVLTMTTQSSGSRASLPKVSYVKAIDIWMAVCLLFVFSALLEYAAVNFVSRQHKELLRFRRKRRHHKSPMLNLFQEDEAGEGRFNFSAYGMGPACLQAKDGISVKGANNSNTTNPPPAPSKSPEEMRKLFIQRAKKIDKISRIGFPMAFLIFNMFYWIIYKIVRREDVHNQ
T50269	DRUGINFO	D0IG4I	THIOCOLCHICOSIDE	Approved
T50269	DRUGINFO	D02UDJ	D-Serine	Phase 4
T50269	DRUGINFO	D04ZCZ	GINKOLIDE B	Terminated
T50269	DRUGINFO	D04IEW	GINKGOLIDE A	Investigative
T50269	DRUGINFO	D0D1EE	Ginkgolide J	Investigative
T50269	DRUGINFO	D0G2OJ	Ginkgolide C	Investigative
T50269	DRUGINFO	D0H0BD	[3H]strychnine	Investigative
T50269	DRUGINFO	D0JU4G	Ginkgolide M	Investigative
T50269	DRUGINFO	D0M4ZK	10-methoxy-ginkgolide C	Investigative
T50269	DRUGINFO	D0X3TL	3,14-DIDEHYDROGINKGOLIDE A	Investigative
T50269	DRUGINFO	D04RVA	3-demethoxy-3-D-lyxopyranosylaminothiocolchicine	Investigative
T50269	DRUGINFO	D06XGL	3-demethoxy-3-D-xylopyranosylaminothiocolchicine	Investigative
T50269	DRUGINFO	D08YLW	3-demethoxy-3-L-fucopyranosylaminothiocolchicine	Investigative
T50269	DRUGINFO	D09MHS	3-demethoxy-3D-glucopyranosylaminothiocolchicine	Investigative
T50269	DRUGINFO	D0LP2K	3-demethoxy-3-D-mannopyranosylaminothiocolchicine	Investigative

T55285	TARGETID	T55285
T55285	FORMERID	TTDC00039
T55285	UNIPROID	GLRA1_HUMAN; GLRA2_HUMAN; GLRA3_HUMAN; GLRA4_HUMAN; GLRB_HUMAN
T55285	TARGNAME	Glycine receptor (GlyR)
T55285	GENENAME	GLRA1; GLRA2; GLRA3; GLRA4; GLRB
T55285	TARGTYPE	Successful
T55285	SYNONYMS	Glycine receptor
T55285	FUNCTION	The glycine receptor is a neurotransmitter-gated ion channel. Binding of glycine to its receptor increases the chloride conductance and thus produces hyperpolarization (inhibition of neuronal firing).
T55285	BIOCLASS	Neurotransmitter receptor
T55285	SEQUENCE	MYSFNTLRLYLWETIVFFSLAASKEAEAARSAPKPMSPSDFLDKLMGRTSGYDARIRPNFKGPPVNVSCNIFINSFGSIAETTMDYRVNIFLRQQWNDPRLAYNEYPDDSLDLDPSMLDSIWKPDLFFANEKGAHFHEITTDNKLLRISRNGNVLYSIRITLTLACPMDLKNFPMDVQTCIMQLESFGYTMNDLIFEWQEQGAVQVADGLTLPQFILKEEKDLRYCTKHYNTGKFTCIEARFHLERQMGYYLIQMYIPSLLIVILSWISFWINMDAAPARVGLGITTVLTMTTQSSGSRASLPKVSYVKAIDIWMAVCLLFVFSALLEYAAVNFVSRQHKELLRFRRKRRHHKSPMLNLFQEDEAGEGRFNFSAYGMGPACLQAKDGISVKGANNSNTTNPPPAPSKSPEEMRKLFIQRAKKIDKISRIGFPMAFLIFNMFYWIIYKIVRREDVHNQ
T55285	DRUGINFO	D0IG4I	THIOCOLCHICOSIDE	Approved
T55285	DRUGINFO	D06RYY	ZD-9379	Phase 1
T55285	DRUGINFO	D0N7BL	UK-240455	Phase 1
T55285	DRUGINFO	D0TT5K	MDL-27531	Phase 1
T55285	DRUGINFO	D05ERT	GV-196771	Discontinued in Phase 2
T55285	DRUGINFO	D0O0FF	GW 468816	Discontinued in Phase 2
T55285	DRUGINFO	D0O6AQ	Gavestinel	Discontinued in Phase 2
T55285	DRUGINFO	D02NVF	M-241247	Terminated
T55285	DRUGINFO	D04ZCZ	GINKOLIDE B	Terminated
T55285	DRUGINFO	D05OAE	(12E,20Z,18S)-8-hydroxyvariabilin	Investigative
T55285	DRUGINFO	D07QEH	ginkgolide X	Investigative
T55285	DRUGINFO	D09BKM	alkylbenzene sulfonate	Investigative
T55285	DRUGINFO	D09SZL	NV-31	Investigative
T55285	DRUGINFO	D0AD1L	PMBA	Investigative
T55285	DRUGINFO	D0C6IE	taurine	Investigative
T55285	DRUGINFO	D0H2XJ	alpha-Emtbl	Investigative
T55285	DRUGINFO	D0V9XF	PICROTIN	Investigative
T55285	DRUGINFO	D0Z3FP	NBBCC	Investigative
T55285	DRUGINFO	D04IEW	GINKGOLIDE A	Investigative
T55285	DRUGINFO	D0D1EE	Ginkgolide J	Investigative
T55285	DRUGINFO	D0G2OJ	Ginkgolide C	Investigative
T55285	DRUGINFO	D0H0BD	[3H]strychnine	Investigative
T55285	DRUGINFO	D0JU4G	Ginkgolide M	Investigative
T55285	DRUGINFO	D0M4ZK	10-methoxy-ginkgolide C	Investigative
T55285	DRUGINFO	D0X3TL	3,14-DIDEHYDROGINKGOLIDE A	Investigative
T55285	DRUGINFO	D0B0TK	bilobalide	Investigative
T55285	DRUGINFO	D04RVA	3-demethoxy-3-D-lyxopyranosylaminothiocolchicine	Investigative
T55285	DRUGINFO	D06XGL	3-demethoxy-3-D-xylopyranosylaminothiocolchicine	Investigative
T55285	DRUGINFO	D08YLW	3-demethoxy-3-L-fucopyranosylaminothiocolchicine	Investigative
T55285	DRUGINFO	D09MHS	3-demethoxy-3D-glucopyranosylaminothiocolchicine	Investigative
T55285	DRUGINFO	D0LP2K	3-demethoxy-3-D-mannopyranosylaminothiocolchicine	Investigative

T21945	TARGETID	T21945
T21945	FORMERID	TTDC00304
T21945	UNIPROID	SC6A2_HUMAN
T21945	TARGNAME	Norepinephrine transporter (NET)
T21945	GENENAME	SLC6A2
T21945	TARGTYPE	Successful
T21945	SYNONYMS	Solute carrier family 6 member 2; Sodium-dependent noradrenaline transporter; SLC6A2; NET1; NET; NAT1
T21945	FUNCTION	Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
T21945	BIOCLASS	Neurotransmitter:sodium symporter
T21945	SEQUENCE	MLLARMNPQVQPENNGADTGPEQPLRARKTAELLVVKERNGVQCLLAPRDGDAQPRETWGKKIDFLLSVVGFAVDLANVWRFPYLCYKNGGGAFLIPYTLFLIIAGMPLFYMELALGQYNREGAATVWKICPFFKGVGYAVILIALYVGFYYNVIIAWSLYYLFSSFTLNLPWTDCGHTWNSPNCTDPKLLNGSVLGNHTKYSKYKFTPAAEFYERGVLHLHESSGIHDIGLPQWQLLLCLMVVVIVLYFSLWKGVKTSGKVVWITATLPYFVLFVLLVHGVTLPGASNGINAYLHIDFYRLKEATVWIDAATQIFFSLGAGFGVLIAFASYNKFDNNCYRDALLTSSINCITSFVSGFAIFSILGYMAHEHKVNIEDVATEGAGLVFILYPEAISTLSGSTFWAVVFFVMLLALGLDSSMGGMEAVITGLADDFQVLKRHRKLFTFGVTFSTFLLALFCITKGGIYVLTLLDTFAAGTSILFAVLMEAIGVSWFYGVDRFSNDIQQMMGFRPGLYWRLCWKFVSPAFLLFVVVVSIINFKPLTYDDYIFPPWANWVGWGIALSSMVLVPIYVIYKFLSTQGSLWERLAYGITPENEHHLVAQRDIRQFQLQHWLAI
T21945	DRUGINFO	D00HZV	Trimipramine	Approved
T21945	DRUGINFO	D00MYQ	Protriptyline	Approved
T21945	DRUGINFO	D01UTL	Desipramine	Approved
T21945	DRUGINFO	D02JIS	Iobenguane I-123	Approved
T21945	DRUGINFO	D03CEF	Desvenalfaxine succinate	Approved
T21945	DRUGINFO	D03KQF	Maprotiline	Approved
T21945	DRUGINFO	D04CRN	Atomoxetine	Approved
T21945	DRUGINFO	D06ZUK	Imipramine	Approved
T21945	DRUGINFO	D09IOI	Amoxapine	Approved
T21945	DRUGINFO	D09VGC	Milnacipran	Approved
T21945	DRUGINFO	D0H8QL	Mazindol	Approved
T21945	DRUGINFO	D0N8FQ	Reboxetine	Approved
T21945	DRUGINFO	D0U0RZ	Phentermine	Approved
T21945	DRUGINFO	D01AXB	Duloxetine	Approved
T21945	DRUGINFO	D02XOK	Levomilnacipran	Approved
T21945	DRUGINFO	D08KVZ	Sibutramine	Approved
T21945	DRUGINFO	D0B7OD	Amfepramone	Approved
T21945	DRUGINFO	D0K4MH	Tapentadol hydrochloride	Approved
T21945	DRUGINFO	D0M2MC	Phenmetrazine	Approved
T21945	DRUGINFO	D0P1UX	Venlafaxine	Approved
T21945	DRUGINFO	D0X4ZR	Bupropion	Approved
T21945	DRUGINFO	D0Y5UG	Amitriptyline	Approved
T21945	DRUGINFO	D04WYX	Netarsudil	Approved
T21945	DRUGINFO	D04XPW	Cocaine	Approved
T21945	DRUGINFO	D0U5QK	Acetaminophen	Approved
T21945	DRUGINFO	D0W6KM	Dasotraline	Approved
T21945	DRUGINFO	D08BYK	Hypericum	Phase 4
T21945	DRUGINFO	DRL5Y7	SPN-812	Phase 4
T21945	DRUGINFO	D03QIE	Bicifadine	Phase 3
T21945	DRUGINFO	D0BN7W	Roclatan	Phase 3
T21945	DRUGINFO	D0MZ9A	Suronacrine maleate	Phase 3
T21945	DRUGINFO	D01TMQ	Bupropion+naltrexone	Phase 3
T21945	DRUGINFO	D04PXS	Amitifadine	Phase 3
T21945	DRUGINFO	D01BAU	SPN-812	Phase 2
T21945	DRUGINFO	D02GWJ	MCT-125	Phase 2
T21945	DRUGINFO	D04IKF	18F-LMI-1195	Phase 2
T21945	DRUGINFO	D05FQD	Metaiodobenzylguanidine I-131	Phase 2
T21945	DRUGINFO	D0E2EY	BLI-1005	Phase 2
T21945	DRUGINFO	D0U2XU	XEN-2174	Phase 2
T21945	DRUGINFO	DC2DO5	PDC-1421	Phase 2
T21945	DRUGINFO	D02JKY	TD-9855	Phase 2
T21945	DRUGINFO	D04KHY	Spiroglumide	Phase 2
T21945	DRUGINFO	D07QXU	NS 2359	Phase 2
T21945	DRUGINFO	D0FM7Z	BL-1021	Phase 1
T21945	DRUGINFO	D0K7OW	GSK-1360707	Phase 1
T21945	DRUGINFO	D01NJT	Esreboxetine	Discontinued in Phase 2
T21945	DRUGINFO	D06KOL	Napitane mesilate	Discontinued in Phase 2
T21945	DRUGINFO	D0A5RD	Radafaxine	Discontinued in Phase 2
T21945	DRUGINFO	D0B2OC	R-sibutramine metabolite	Discontinued in Phase 2
T21945	DRUGINFO	D0O6QW	Manifaxine	Discontinued in Phase 2
T21945	DRUGINFO	D0H9GQ	DOV-216303	Discontinued in Phase 2
T21945	DRUGINFO	D0LU6N	SPD-473	Discontinued in Phase 2
T21945	DRUGINFO	D0M9LB	NS-2389	Discontinued in Phase 2
T21945	DRUGINFO	D04VUY	RG-7166	Discontinued in Phase 1
T21945	DRUGINFO	D08UNQ	NSD-644	Discontinued in Phase 1
T21945	DRUGINFO	D05CBG	4-(3'-furyl)-aniline	Investigative
T21945	DRUGINFO	D0D1KK	(R)-1-((S)-morpholin-2-yl)-1,2-diphenylethanol	Investigative
T21945	DRUGINFO	D0GE9U	3-(3'-furyl)-aniline	Investigative
T21945	DRUGINFO	D0H3CQ	[3H]nisoxetine	Investigative
T21945	DRUGINFO	D0KS0I	WAY-256805	Investigative
T21945	DRUGINFO	D0TH6L	N-desalkylquetiapine	Investigative
T21945	DRUGINFO	D0V4FW	{2-[3-(Phenylsulfonyl)-1H-indol-4-yl]ethyl}amine	Investigative
T21945	DRUGINFO	D0V9SV	POLYGALATENOSIDE B	Investigative
T21945	DRUGINFO	D0X5AA	AMIFLAMINE	Investigative
T21945	DRUGINFO	D00WMS	2-(N-tert-Butylamino)propiophenone	Investigative
T21945	DRUGINFO	D01EIS	1-(1,2-diphenylethyl)piperazine	Investigative
T21945	DRUGINFO	D01GSG	(R)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile	Investigative
T21945	DRUGINFO	D01RWY	2-(N-tert-Butylamino)-3'-chloroheptanophenone	Investigative
T21945	DRUGINFO	D01SHR	((3R,4R)-4-(o-tolyloxy)chroman-3-yl)methanamine	Investigative
T21945	DRUGINFO	D01YED	2-(N-Pyrrolidinyl)-3'-methoxypropiophenone	Investigative
T21945	DRUGINFO	D03MYV	2-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile	Investigative
T21945	DRUGINFO	D03PMB	PTI-601	Investigative
T21945	DRUGINFO	D03ZDY	1-(2-(2-bromophenyl)-1-phenylethyl)piperazine	Investigative
T21945	DRUGINFO	D05WFQ	norzotepine	Investigative
T21945	DRUGINFO	D06GFV	1-(2,3-Dihydro-1H-indol-5-ylmethyl)-propylamine	Investigative
T21945	DRUGINFO	D06LCK	2-(N-Pyrrolidinyl)-3'-fluoropropiophenone	Investigative
T21945	DRUGINFO	D06PJD	3-(1H-indol-1-yl)-N-methyl-3-phenylpropan-1-amine	Investigative
T21945	DRUGINFO	D07IOX	2-(N-tert-Butylamino)-3'-chlorooctanophenone	Investigative
T21945	DRUGINFO	D08LAY	1-(2-(3-methoxyphenyl)-1-phenylethyl)piperazine	Investigative
T21945	DRUGINFO	D08MEN	KF-A5	Investigative
T21945	DRUGINFO	D08MUX	S33005	Investigative
T21945	DRUGINFO	D09BYB	2-(tert-butylamino)-1-p-tolylpropan-1-one	Investigative
T21945	DRUGINFO	D09DWM	Isobutyl-(4-methyl-benzyl)-piperidin-4-yl-amine	Investigative
T21945	DRUGINFO	D09JRN	3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile	Investigative
T21945	DRUGINFO	D09XWL	2-(N-Cyclopentylamino)-3'-fluoropropiophenone	Investigative
T21945	DRUGINFO	D0A1HH	1-(1-phenyl-2-o-tolylethyl)piperazine	Investigative
T21945	DRUGINFO	D0B4FN	2pyrrolidin-1-yl-1-phenylpentan-1-one	Investigative
T21945	DRUGINFO	D0B5AG	Cis-3-phenoxy-2,3-dihydro-1H-inden-1-amine	Investigative
T21945	DRUGINFO	D0C0GL	1-(3-bromophenyl)-2-(tert-butylamino)propan-1-one	Investigative
T21945	DRUGINFO	D0D8YY	N-benzyl-N-isobutylpiperidin-4-amine	Investigative
T21945	DRUGINFO	D0EO5P	1-(2-(2-ethylphenyl)-1-phenylethyl)piperazine	Investigative
T21945	DRUGINFO	D0EX2M	1-(2-(3-chlorophenyl)-1-phenylethyl)piperazine	Investigative
T21945	DRUGINFO	D0G0CJ	2-(N-Cyclopentylamino)-3'-bromopropiophenone	Investigative
T21945	DRUGINFO	D0G0NB	2-(2,3-Dihydro-1H-indol-5-yl)-1-methyl-ethylamine	Investigative
T21945	DRUGINFO	D0GY8R	2-(N-Pyrrolidinyl)-3'-methylpropiophenone	Investigative
T21945	DRUGINFO	D0I4TO	(S)-NORDULOXETINE	Investigative
T21945	DRUGINFO	D0KD9M	(S)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile	Investigative
T21945	DRUGINFO	D0L6RY	1-(4-fluorophenyl)-2-pyrrolidin-1-yl-pentan-1-one	Investigative
T21945	DRUGINFO	D0M4AQ	2-((2-iodophenoxy)(phenyl)methyl)morpholine	Investigative
T21945	DRUGINFO	D0NM1F	(R)-N-isopropyl-N-(pyrrolidin-3-yl)-2-naphthamide	Investigative
T21945	DRUGINFO	D0O2LC	2-(N-Cyclopentylamino)-3'-chloropropiophenone	Investigative
T21945	DRUGINFO	D0P6SY	MDL-28618	Investigative
T21945	DRUGINFO	D0P9EO	2-(N-Cyclopentylamino)-3'-methylpropiophenone	Investigative
T21945	DRUGINFO	D0Q8IQ	1-(3-chlorophenyl)-2-(dimethylamino)propan-1-one	Investigative
T21945	DRUGINFO	D0Q9UZ	2-((3-iodophenyl)(o-tolyloxy)methyl)morpholine	Investigative
T21945	DRUGINFO	D0R5AD	2-(N,N-Diethylamino)-3'-chloropropiophenone	Investigative
T21945	DRUGINFO	D0S9IO	N-(2-oxazolemethyl)milnacipran	Investigative
T21945	DRUGINFO	D0T5VG	2-(Aminomethyl)-5-(1'-naphthethyl)tetrahydrofuran	Investigative
T21945	DRUGINFO	D0U3SB	2-(N-Pyrrolidinyl)-3'-bromopropiophenone	Investigative
T21945	DRUGINFO	D0V8IZ	2-(N-tert-Butylamino)-3'-chlorohexanophenone	Investigative
T21945	DRUGINFO	D0VC1K	N,N-dimethyl(2-phenoxyphenyl)methanamine	Investigative
T21945	DRUGINFO	D0VY9K	2-(N-Pyrrolidinyl)-3'-nitropropiophenone	Investigative
T21945	DRUGINFO	D0W9JK	(S)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide	Investigative
T21945	DRUGINFO	D0XY9E	2-(N-tert-Butylamino)-3'-chloropentanophenone	Investigative
T21945	DRUGINFO	D0Y7CS	2-(tert-butylamino)-1-m-tolylpropan-1-one	Investigative
T21945	DRUGINFO	D0Z5GR	1-(2-(2-chlorophenoxy)pyridin-3-yl)piperazine	Investigative
T21945	DRUGINFO	D0Z6YA	1-(2-(2-ethoxyphenyl)-1-phenylethyl)piperazine	Investigative
T21945	DRUGINFO	D00FMX	3-(piperidin-4-yl)-2-(o-tolyloxy)pyridine	Investigative
T21945	DRUGINFO	D00GDI	2-(N-tert-Butylamino)-3',4'-dichloropropiophenone	Investigative
T21945	DRUGINFO	D00VUT	D-257C	Investigative
T21945	DRUGINFO	D01AOI	6-(piperidin-4-ylmethoxy)-2-naphthonitrile	Investigative
T21945	DRUGINFO	D02ENH	(R)-Norfluoxetine	Investigative
T21945	DRUGINFO	D02ICX	PYROVALERONE	Investigative
T21945	DRUGINFO	D02TMK	METHYLENEDIOXYAMPHETAMINE	Investigative
T21945	DRUGINFO	D02UUC	3-p-Tolyl-8-aza-bicyclo[3.2.1]octane	Investigative
T21945	DRUGINFO	D02YOO	NISOXETINE	Investigative
T21945	DRUGINFO	D02YSN	2-Aminomethyl-5-(p-t-butylphenyl)tetrahydrofuran	Investigative
T21945	DRUGINFO	D02ZIQ	1-(3-chlorophenyl)-2-(piperidin-1-yl)propan-1-one	Investigative
T21945	DRUGINFO	D03BQV	1S,2R-milnacipran	Investigative
T21945	DRUGINFO	D03HQF	2-Aminomethyl-5-(p-bromophenyl)tetrahydrofuran	Investigative
T21945	DRUGINFO	D03JOX	1-(2-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one	Investigative
T21945	DRUGINFO	D03ZFX	D-254C	Investigative
T21945	DRUGINFO	D04KZX	2-(tert-Butylamino)-3',4'-dichlorobutyrophenone	Investigative
T21945	DRUGINFO	D05LKO	1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine	Investigative
T21945	DRUGINFO	D05UMA	(R)-DULOXETINE	Investigative
T21945	DRUGINFO	D06CMJ	Para-chloroamphetamine	Investigative
T21945	DRUGINFO	D06EMC	PF-18298	Investigative
T21945	DRUGINFO	D06KNV	[3-(3,4-Dichloro-phenyl)-indan-1-yl]-methyl-amine	Investigative
T21945	DRUGINFO	D06QGD	1-(4-nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-one	Investigative
T21945	DRUGINFO	D06UDU	4-(2-(4-fluorophenoxy)-4-methylphenyl)piperidine	Investigative
T21945	DRUGINFO	D06WIV	Biphenyl-2-ylmethyl-(S)-pyrrolidin-3-yl-amine	Investigative
T21945	DRUGINFO	D07DMN	4-(1H-indol-3-yl)-N,N-dimethylcyclohex-3-enamine	Investigative
T21945	DRUGINFO	D07DWS	1-(2-(2-fluorobenzyloxy)phenyl)piperazine	Investigative
T21945	DRUGINFO	D07RQT	8-Methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octane	Investigative
T21945	DRUGINFO	D07SAA	2-(N-Cyclopropylamino)-3-chloropropiophenone	Investigative
T21945	DRUGINFO	D07ZOP	1-(3-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one	Investigative
T21945	DRUGINFO	D08AWN	(S)-Norfluoxetine	Investigative
T21945	DRUGINFO	D08TJY	D-257A	Investigative
T21945	DRUGINFO	D08YCS	TQ-1017	Investigative
T21945	DRUGINFO	D09QZM	2-(Aminomethyl)-5-(2'-naphthyl)tetrahydrofuran	Investigative
T21945	DRUGINFO	D09ZAT	1-(3,4-Dichloro-phenyl)-3-methylamino-indan-5-ol	Investigative
T21945	DRUGINFO	D0G1XP	2-(tert-Butylamino)-3',4'-dichloropentanophenone	Investigative
T21945	DRUGINFO	D0G5RH	WIN-35066-2	Investigative
T21945	DRUGINFO	D0G8UA	(R)-2-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol	Investigative
T21945	DRUGINFO	D0GG2J	1-(1-(2-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX)	Investigative
T21945	DRUGINFO	D0H2TS	4-(2-((3-fluorophenoxy)methyl)phenyl)piperidine	Investigative
T21945	DRUGINFO	D0H4AD	1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one	Investigative
T21945	DRUGINFO	D0I9KV	1-(4-bromophenyl)-2-pyrrolidin-1-yl-pentan-1-one	Investigative
T21945	DRUGINFO	D0IB6Y	2-Aminomethyl-5-(p-methoxyphenyl)tetrahydrofuran	Investigative
T21945	DRUGINFO	D0J0ES	1-(3,4-Dichloro-phenyl)-3-diethylamino-indan-5-ol	Investigative
T21945	DRUGINFO	D0J5AR	2-(2'-Aminoethyl)-5-benzyltetrahydrofuran	Investigative
T21945	DRUGINFO	D0K6ZT	2-(2-fluorophenoxy)-3-(piperidin-4-yl)pyridine	Investigative
T21945	DRUGINFO	D0L0AY	2-(Aminomethyl)-5-phenethyltetrahydrofuran	Investigative
T21945	DRUGINFO	D0L7BK	1-(1,4-diphenylbutan-2-yl)piperazine	Investigative
T21945	DRUGINFO	D0LD1X	D-211B	Investigative
T21945	DRUGINFO	D0N0TQ	2-Aminomethyl-5-(phenyl)tetrahydrofuran	Investigative
T21945	DRUGINFO	D0N2RJ	1-(2-(3-fluorophenoxy)phenyl)piperazine	Investigative
T21945	DRUGINFO	D0N3DD	[3H]WIN35428	Investigative
T21945	DRUGINFO	D0NY4W	1-(4-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one	Investigative
T21945	DRUGINFO	D0O9BL	1-(3-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one	Investigative
T21945	DRUGINFO	D0Q6SH	4-(2-(3-fluorophenoxy)-4-methylphenyl)piperidine	Investigative
T21945	DRUGINFO	D0R8EV	2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one	Investigative
T21945	DRUGINFO	D0RT9B	2-Aminomethyl-5-(p-chlorophenyl)tetrahydrofuran	Investigative
T21945	DRUGINFO	D0S9AY	1-(2-(6-fluoronaphthalen-2-yl)ethyl)piperazine	Investigative
T21945	DRUGINFO	D0SB6Y	D-211A	Investigative
T21945	DRUGINFO	D0SN6R	(+/-)-3-((naphthalen-2-yloxy)methyl)pyrrolidine	Investigative
T21945	DRUGINFO	D0T8BU	3-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol	Investigative
T21945	DRUGINFO	D0V0PR	4-(2-(phenoxymethyl)phenyl)piperidine	Investigative
T21945	DRUGINFO	D0V3LR	D-166A	Investigative
T21945	DRUGINFO	D0W8BJ	Trans-3-(o-tolyloxy)-2,3-dihydro-1H-inden-1-amine	Investigative
T21945	DRUGINFO	D0WB6P	R-NORDULOXETINE	Investigative
T21945	DRUGINFO	D0X8LG	1-naphthalen-2-yl-2-pyrrolidin-1-yl-pentan-1-one	Investigative
T21945	DRUGINFO	D0Y3BI	2-(Aminomethyl)-5-(1'-naphthyl)tetrahydrofuran	Investigative
T21945	DRUGINFO	D0Y5CG	1-(2-((3-fluorophenoxy)methyl)phenyl)piperazine	Investigative
T21945	DRUGINFO	D0Z4UF	RTI-219	Investigative
T21945	DRUGINFO	D0Z9OX	1-(2-(2-chlorophenyl)-1-phenylethyl)piperazine	Investigative
T21945	DRUGINFO	D0ZE4C	2-(N-Cyclopentylamino)-3'-methoxypropiophenone	Investigative
T21945	DRUGINFO	D0ZU5W	1-(2-(benzyloxy)phenyl)piperazine	Investigative
T21945	DRUGINFO	D00DEH	4-(2-(3-chlorophenoxy)phenyl)piperidine	Investigative
T21945	DRUGINFO	D00HCC	1-(2-phenoxyphenyl)piperazine	Investigative
T21945	DRUGINFO	D00KRQ	4-(2-phenoxyphenyl)piperidine	Investigative
T21945	DRUGINFO	D01ABR	1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine	Investigative
T21945	DRUGINFO	D01FFX	4-((naphthalen-2-yloxy)methyl)piperidine	Investigative
T21945	DRUGINFO	D01JYY	(R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide	Investigative
T21945	DRUGINFO	D01MBF	4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine	Investigative
T21945	DRUGINFO	D01YNZ	4-(2-(benzyloxy)phenyl)piperidine	Investigative
T21945	DRUGINFO	D03DQQ	4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine	Investigative
T21945	DRUGINFO	D04NDO	4-(2-(2-fluorobenzyloxy)phenyl)piperidine	Investigative
T21945	DRUGINFO	D04NKQ	4-(2-(4-fluorophenoxy)phenyl)piperidine	Investigative
T21945	DRUGINFO	D04ZPF	4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine	Investigative
T21945	DRUGINFO	D05LJC	4-(2-(benzyloxy)-3-fluorophenyl)piperidine	Investigative
T21945	DRUGINFO	D08EKQ	1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX)	Investigative
T21945	DRUGINFO	D08JLB	4-(2-(benzyloxy)-6-fluorophenyl)piperidine	Investigative
T21945	DRUGINFO	D08SCH	2-Amino-1-(4-methylthiophenyl)propane	Investigative
T21945	DRUGINFO	D09FIC	1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX)	Investigative
T21945	DRUGINFO	D09IIH	4-(3-fluoro-2-phenoxyphenyl)piperidine	Investigative
T21945	DRUGINFO	D0CG2Y	2-phenoxy-3-(piperidin-4-yl)pyridine	Investigative
T21945	DRUGINFO	D0E3DM	(S)-3-(naphthalen-2-ylmethoxy)pyrrolidine	Investigative
T21945	DRUGINFO	D0E6PQ	4-(2-fluoro-6-phenoxyphenyl)piperidine	Investigative
T21945	DRUGINFO	D0F0BS	3alpha-(bis-chloro-phenylmethoxy)tropane	Investigative
T21945	DRUGINFO	D0F6GB	2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine	Investigative
T21945	DRUGINFO	D0IC4J	4-(2-(3-fluorophenoxy)phenyl)piperidine	Investigative
T21945	DRUGINFO	D0KT2M	2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine	Investigative
T21945	DRUGINFO	D0M3TK	1-(2-(4-fluorophenoxy)phenyl)piperazine	Investigative
T21945	DRUGINFO	D0R3TA	4-(2-(4-fluorobenzyloxy)phenyl)piperidine	Investigative
T21945	DRUGINFO	D0S4JT	1-(2-(phenoxymethyl)phenyl)piperazine	Investigative
T21945	DRUGINFO	D0U7OD	PF-526014	Investigative
T21945	DRUGINFO	D0W8YO	4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine	Investigative
T21945	DRUGINFO	D0XF5P	(R)-3-(naphthalen-2-ylmethoxy)pyrrolidine	Investigative
T21945	DRUGINFO	D0Y8UC	Difluorobenztropine	Investigative
T21945	DRUGINFO	D00QCP	(2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol	Investigative
T21945	DRUGINFO	D03YQY	(2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol	Investigative
T21945	DRUGINFO	D06QIQ	7-(piperidin-4-ylmethoxy)-2-naphthonitrile	Investigative
T21945	DRUGINFO	D0FU5E	S-34324	Investigative
T21945	DRUGINFO	D0N2KU	PF-3409409	Investigative
T21945	DRUGINFO	D0F5NJ	METHYLENEDIOXYMETHAMPHETAMINE	Investigative
T21945	DRUGINFO	D0I4ME	MMDA	Investigative
T21945	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T92828	TARGETID	T92828
T92828	FORMERID	TTDS00199
T92828	UNIPROID	EDNRB_HUMAN
T92828	TARGNAME	Endothelin B receptor (EDNRB)
T92828	GENENAME	EDNRB
T92828	TARGTYPE	Successful
T92828	SYNONYMS	Endothelin receptor type B; Endothelin receptor Non-selective type; Endothelin receptor B; ETRB; ET-BR; ET-B
T92828	FUNCTION	Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Non-specific receptor for endothelin 1, 2, and 3.
T92828	PDBSTRUC	6IGL; 6IGK; 5XPR; 5X93; 5GLI
T92828	BIOCLASS	GPCR rhodopsin
T92828	SEQUENCE	MQPPPSLCGRALVALVLACGLSRIWGEERGFPPDRATPLLQTAEIMTPPTKTLWPKGSNASLARSLAPAEVPKGDRTAGSPPRTISPPPCQGPIEIKETFKYINTVVSCLVFVLGIIGNSTLLRIIYKNKCMRNGPNILIASLALGDLLHIVIDIPINVYKLLAEDWPFGAEMCKLVPFIQKASVGITVLSLCALSIDRYRAVASWSRIKGIGVPKWTAVEIVLIWVVSVVLAVPEAIGFDIITMDYKGSYLRICLLHPVQKTAFMQFYKTAKDWWLFSFYFCLPLAITAFFYTLMTCEMLRKKSGMQIALNDHLKQRREVAKTVFCLVLVFALCWLPLHLSRILKLTLYNQNDPNRCELLSFLLVLDYIGINMASLNSCINPIALYLVSKRFKNCFKSCLCCWCQSFEEKQSLEEKQSCLKFKANDHGYDNFRSSNKYSSS
T92828	DRUGINFO	D0S7JH	Macitentan	Approved
T92828	DRUGINFO	D0U4CE	Bosentan	Approved
T92828	DRUGINFO	D08IXA	BQ788	Phase 3
T92828	DRUGINFO	D07WYI	SPI-1620	Phase 2
T92828	DRUGINFO	D0OW4A	PD-145065	Phase 2
T92828	DRUGINFO	DUOX13	ENB003	Phase 1/2
T92828	DRUGINFO	D05VZJ	J-104132	Discontinued in Phase 2
T92828	DRUGINFO	D07YHT	ENRASENTAN	Discontinued in Phase 2
T92828	DRUGINFO	D0W6XL	SB-209670	Discontinued in Phase 2
T92828	DRUGINFO	D05OEO	ET-1	Phase 0
T92828	DRUGINFO	D01EDE	IRL-2500	Terminated
T92828	DRUGINFO	D03ATH	RES-701-1	Terminated
T92828	DRUGINFO	D0S9JH	PD142893	Terminated
T92828	DRUGINFO	D05GYG	BQ 3020	Investigative
T92828	DRUGINFO	D05HIH	Linear peptide of RES-701-1	Investigative
T92828	DRUGINFO	D05KPH	Endothelin-3	Investigative
T92828	DRUGINFO	D07TIH	RES-701-1-C-terminal analogue	Investigative
T92828	DRUGINFO	D0G5UD	Ro 46-8443	Investigative
T92828	DRUGINFO	D0I1ZB	ENDG-4010	Investigative
T92828	DRUGINFO	D0M6CC	Sarafotoxin 6C	Investigative
T92828	DRUGINFO	D0MS8T	IRL-1722	Investigative
T92828	DRUGINFO	D0T1BU	[125I]IRL1620	Investigative
T92828	DRUGINFO	D0X1ZC	IRL-1841	Investigative
T92828	DRUGINFO	D0Y1HN	A192621	Investigative
T92828	DRUGINFO	D00RGL	W-F-F-N--Y-Y-W	Investigative
T92828	DRUGINFO	D06OSN	Bhg-F-N-Y-Y-W	Investigative
T92828	DRUGINFO	D07OMS	PD-163140	Investigative
T92828	DRUGINFO	D0F8BZ	Ac-bhg-F-N-Y-Y-W	Investigative
T92828	DRUGINFO	D0M2TB	Trp-Ile-Ile-Asp-Leu-Hisc(Cys-Ser-Val-Tyr-Phe-Cys)	Investigative
T92828	DRUGINFO	D0NI1W	Trp-Ile-Ile-Asp-Leu-Hisc(Cys-Val-Tyr-Phe-Cys)	Investigative
T92828	DRUGINFO	D0X1XM	LU302872	Investigative
T92828	DRUGINFO	D0Y8UY	Ac-w-F-F-N-Y-Y-W	Investigative

T30985	TARGETID	T30985
T30985	FORMERID	TTDS00087
T30985	UNIPROID	HRH2_HUMAN
T30985	TARGNAME	Histamine H2 receptor (H2R)
T30985	GENENAME	HRH2
T30985	TARGTYPE	Successful
T30985	SYNONYMS	Histamine receptor 2; HH2R; Gastric receptor I
T30985	FUNCTION	Appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and differentiation. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and, through a separate G protein-dependent mechanism, the phosphoinositide/protein kinase (PKC) signaling pathway. The H2 subclass of histamine receptors mediates gastric acid secretion.
T30985	BIOCLASS	GPCR rhodopsin
T30985	SEQUENCE	MAPNGTASSFCLDSTACKITITVVLAVLILITVAGNVVVCLAVGLNRRLRNLTNCFIVSLAITDLLLGLLVLPFSAIYQLSCKWSFGKVFCNIYTSLDVMLCTASILNLFMISLDRYCAVMDPLRYPVLVTPVRVAISLVLIWVISITLSFLSIHLGWNSRNETSKGNHTTSKCKVQVNEVYGLVDGLVTFYLPLLIMCITYYRIFKVARDQAKRINHISSWKAATIREHKATVTLAAVMGAFIICWFPYFTAFVYRGLRGDDAINEVLEAIVLWLGYANSALNPILYAALNRDFRTGYQQLFCCRLANRNSHKTSLRSNASQLSRTQSREPRQQEEKPLKLQVWSGTEVTAPQGATDR
T30985	DRUGINFO	D01OUE	Betazole	Approved
T30985	DRUGINFO	D02DPA	Cimetidine	Approved
T30985	DRUGINFO	D0B8WN	Ranitidine	Approved
T30985	DRUGINFO	D0K0OZ	Famotidine	Approved
T30985	DRUGINFO	D0Q9DK	Nizatidine	Approved
T30985	DRUGINFO	D0R8FM	Ebrotidine	Withdrawn from market
T30985	DRUGINFO	D01YDF	Pibutidine	Discontinued in Phase 3
T30985	DRUGINFO	D09YTY	Osutidine	Discontinued in Phase 3
T30985	DRUGINFO	D0A2IH	KU-1257	Discontinued in Phase 3
T30985	DRUGINFO	D08OQQ	Lavoltidine	Discontinued in Phase 2
T30985	DRUGINFO	D0D1YY	IGN-2098	Discontinued in Phase 2
T30985	DRUGINFO	D0L9PY	CP-66948	Discontinued in Phase 1
T30985	DRUGINFO	D0N3TO	TRM-115	Discontinued in Phase 1
T30985	DRUGINFO	D0T2MN	Z-300	Discontinued in Phase 1
T30985	DRUGINFO	D03RGO	CP-331	Terminated
T30985	DRUGINFO	D0J0JC	FRG-8701	Terminated
T30985	DRUGINFO	D02NWL	[125I]iodoaminopotentidine	Investigative
T30985	DRUGINFO	D0E7AZ	tiotidine	Investigative
T30985	DRUGINFO	D0I5CT	amthamine	Investigative
T30985	DRUGINFO	D0O3NG	Dimaprit	Investigative
T30985	DRUGINFO	D0W9LJ	Metiamide	Investigative
T30985	DRUGINFO	D0Z9WK	iodoaminopotentidine	Investigative
T30985	DRUGINFO	D03SNI	VUF-10148	Investigative
T30985	DRUGINFO	D04WXI	oxo-arpromidine	Investigative
T30985	DRUGINFO	D08SLS	arpromidine	Investigative
T30985	DRUGINFO	D0AU0F	UR-PG146	Investigative
T30985	DRUGINFO	D06RNM	burimamide	Investigative
T30985	DRUGINFO	D0C7LY	WAY-207024	Investigative
T30985	DRUGINFO	D0B4SF	impromidine	Investigative
T30985	DRUGINFO	D0L5MW	(+/-)-nantenine	Investigative
T30985	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T97947	TARGETID	T97947
T97947	FORMERID	TTDC00171
T97947	UNIPROID	GUC2C_HUMAN
T97947	TARGNAME	Guanylyl cyclase C (GUCY2C)
T97947	GENENAME	GUCY2C
T97947	TARGTYPE	Successful
T97947	SYNONYMS	hSTAR; STA receptor; Intestinal guanylate cyclase; Heat-stable enterotoxin receptor; GUC2C; GC-C
T97947	FUNCTION	Receptor for the E.coli heat-stable enterotoxin (E.coli enterotoxin markedly stimulates the accumulation of cGMP in mammalian cells expressing GC-C). Also activated by the endogenous peptides guanylin and uroguanylin.
T97947	BIOCLASS	Phosphorus-oxygen lyase
T97947	ECNUMBER	EC 4.6.1.2
T97947	SEQUENCE	MKTLLLDLALWSLLFQPGWLSFSSQVSQNCHNGSYEISVLMMGNSAFAEPLKNLEDAVNEGLEIVRGRLQNAGLNVTVNATFMYSDGLIHNSGDCRSSTCEGLDLLRKISNAQRMGCVLIGPSCTYSTFQMYLDTELSYPMISAGSFGLSCDYKETLTRLMSPARKLMYFLVNFWKTNDLPFKTYSWSTSYVYKNGTETEDCFWYLNALEASVSYFSHELGFKVVLRQDKEFQDILMDHNRKSNVIIMCGGPEFLYKLKGDRAVAEDIVIILVDLFNDQYFEDNVTAPDYMKNVLVLTLSPGNSLLNSSFSRNLSPTKRDFALAYLNGILLFGHMLKIFLENGENITTPKFAHAFRNLTFEGYDGPVTLDDWGDVDSTMVLLYTSVDTKKYKVLLTYDTHVNKTYPVDMSPTFTWKNSKLPNDITGRGPQILMIAVFTLTGAVVLLLLVALLMLRKYRKDYELRQKKWSHIPPENIFPLETNETNHVSLKIDDDKRRDTIQRLRQCKYDKKRVILKDLKHNDGNFTEKQKIELNKLLQIDYYNLTKFYGTVKLDTMIFGVIEYCERGSLREVLNDTISYPDGTFMDWEFKISVLYDIAKGMSYLHSSKTEVHGRLKSTNCVVDSRMVVKITDFGCNSILPPKKDLWTAPEHLRQANISQKGDVYSYGIIAQEIILRKETFYTLSCRDRNEKIFRVENSNGMKPFRPDLFLETAEEKELEVYLLVKNCWEEDPEKRPDFKKIETTLAKIFGLFHDQKNESYMDTLIRRLQLYSRNLEHLVEERTQLYKAERDRADRLNFMLLPRLVVKSLKEKGFVEPELYEEVTIYFSDIVGFTTICKYSTPMEVVDMLNDIYKSFDHIVDHHDVYKVETIGDAYMVASGLPKRNGNRHAIDIAKMALEILSFMGTFELEHLPGLPIWIRIGVHSGPCAAGVVGIKMPRYCLFGDTVNTASRMESTGLPLRIHVSGSTIAILKRTECQFLYEVRGETYLKGRGNETTYWLTGMKDQKFNLPTPPTVENQQRLQAEFSDMIANSLQKRQAAGIRSQKPRRVASYKKGTLEYLQLNTTDKESTYF
T97947	DRUGINFO	D00GNJ	Linaclotide	Approved
T97947	DRUGINFO	D06WKA	MD-1100	Approved
T97947	DRUGINFO	D07FEC	Plecanatide	Approved
T97947	DRUGINFO	D05YLP	SP-333	Phase 2
T97947	DRUGINFO	D0U7VU	MLN0264	Phase 2
T97947	DRUGINFO	DK87UQ	PF-07062119	Phase 1

T23499	TARGETID	T23499
T23499	FORMERID	TTDS00198
T23499	UNIPROID	EDNRA_HUMAN
T23499	TARGNAME	Endothelin A receptor (EDNRA)
T23499	GENENAME	EDNRA
T23499	TARGTYPE	Successful
T23499	SYNONYMS	HET-AR; Endothelin-1 receptor; Endothelin receptor type A; Endothelin receptor A; ETRA; ETA-R; ETA receptor; ETA; ET-A
T23499	FUNCTION	Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of binding affinities for ET-A is: ET1 > ET2 >> ET3. Receptor for endothelin-1.
T23499	BIOCLASS	GPCR rhodopsin
T23499	SEQUENCE	METLCLRASFWLALVGCVISDNPERYSTNLSNHVDDFTTFRGTELSFLVTTHQPTNLVLPSNGSMHNYCPQQTKITSAFKYINTVISCTIFIVGMVGNATLLRIIYQNKCMRNGPNALIASLALGDLIYVVIDLPINVFKLLAGRWPFDHNDFGVFLCKLFPFLQKSSVGITVLNLCALSVDRYRAVASWSRVQGIGIPLVTAIEIVSIWILSFILAIPEAIGFVMVPFEYRGEQHKTCMLNATSKFMEFYQDVKDWWLFGFYFCMPLVCTAIFYTLMTCEMLNRRNGSLRIALSEHLKQRREVAKTVFCLVVIFALCWFPLHLSRILKKTVYNEMDKNRCELLSFLLLMDYIGINLATMNSCINPIALYFVSKKFKNCFQSCLCCCCYQSKSLMTSVPMNGTSIQWKNHDQNNHNTDRSSHKDSMN
T23499	DRUGINFO	D0X5ZI	Ambrisentan	Approved
T23499	DRUGINFO	D0Y7OJ	LU302146	Approved
T23499	DRUGINFO	D0S7JH	Macitentan	Approved
T23499	DRUGINFO	D0U4CE	Bosentan	Approved
T23499	DRUGINFO	D0YS1U	Sparsentan	Approved
T23499	DRUGINFO	D08JWJ	PF-1228305	Phase 3
T23499	DRUGINFO	D0R7YY	Darusentan	Phase 3
T23499	DRUGINFO	D0Y6UU	Atrasentan	Phase 3
T23499	DRUGINFO	D0H2RJ	Clazosentan	Phase 3
T23499	DRUGINFO	D03LAB	TBC-3711	Phase 2
T23499	DRUGINFO	D09LQK	BQ-123	Phase 2
T23499	DRUGINFO	D0XR7C	YM-598	Phase 2
T23499	DRUGINFO	D09XLS	FR139317	Phase 2
T23499	DRUGINFO	D0OW4A	PD-145065	Phase 2
T23499	DRUGINFO	D04OXG	PMZ-2123	Phase 1
T23499	DRUGINFO	D02EAS	TBC 11251 (TBC)	Withdrawn from market
T23499	DRUGINFO	D0T1RG	Sitaxsentan	Withdrawn from market
T23499	DRUGINFO	D02HVW	Zibotentan	Discontinued in Phase 3
T23499	DRUGINFO	D03FVI	97-139	Discontinued in Phase 2
T23499	DRUGINFO	D03MUM	EDONENTAN HYDRATE	Discontinued in Phase 2
T23499	DRUGINFO	D0B5PU	BMS-193884	Discontinued in Phase 2
T23499	DRUGINFO	D0J2IH	Avosentan	Discontinued in Phase 2
T23499	DRUGINFO	D05VZJ	J-104132	Discontinued in Phase 2
T23499	DRUGINFO	D07YHT	ENRASENTAN	Discontinued in Phase 2
T23499	DRUGINFO	D0W6XL	SB-209670	Discontinued in Phase 2
T23499	DRUGINFO	D02QQB	A-216546	Discontinued in Phase 1
T23499	DRUGINFO	D04NPX	ZD-1611	Discontinued in Phase 1
T23499	DRUGINFO	D08AMQ	SB-234551	Discontinued in Phase 1
T23499	DRUGINFO	D05OEO	ET-1	Phase 0
T23499	DRUGINFO	D01VUE	BMS-182874	Terminated
T23499	DRUGINFO	D07DGM	BQ-518	Terminated
T23499	DRUGINFO	D0H0KK	PD-155080	Terminated
T23499	DRUGINFO	D0L3AR	PD156707	Terminated
T23499	DRUGINFO	D0NC1D	MX-6120	Terminated
T23499	DRUGINFO	D0P5UE	50-235	Terminated
T23499	DRUGINFO	D0Q9XI	BQ610	Terminated
T23499	DRUGINFO	D0S9JH	PD142893	Terminated
T23499	DRUGINFO	D02OPG	[3H]BQ123	Investigative
T23499	DRUGINFO	D07QBJ	HJP-272	Investigative
T23499	DRUGINFO	D0A8MD	2-HYDROXY-3,5-DIIODOBENZOIC ACID	Investigative
T23499	DRUGINFO	D0F6TS	Endothelin-2	Investigative
T23499	DRUGINFO	D0I7OD	Asterric acid	Investigative
T23499	DRUGINFO	D0M2YL	[125I]PD151242	Investigative
T23499	DRUGINFO	D0NA5S	[3H]S0139	Investigative
T23499	DRUGINFO	D0OC1W	sarafotoxin S6b	Investigative
T23499	DRUGINFO	D0W1HZ	PD164333	Investigative
T23499	DRUGINFO	D0W4UX	BMS-187308	Investigative
T23499	DRUGINFO	D00RGL	W-F-F-N--Y-Y-W	Investigative
T23499	DRUGINFO	D06OSN	Bhg-F-N-Y-Y-W	Investigative
T23499	DRUGINFO	D07OMS	PD-163140	Investigative
T23499	DRUGINFO	D0F8BZ	Ac-bhg-F-N-Y-Y-W	Investigative
T23499	DRUGINFO	D0M2TB	Trp-Ile-Ile-Asp-Leu-Hisc(Cys-Ser-Val-Tyr-Phe-Cys)	Investigative
T23499	DRUGINFO	D0NI1W	Trp-Ile-Ile-Asp-Leu-Hisc(Cys-Val-Tyr-Phe-Cys)	Investigative
T23499	DRUGINFO	D0X1XM	LU302872	Investigative
T23499	DRUGINFO	D0Y8UY	Ac-w-F-F-N-Y-Y-W	Investigative
T23499	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T30372	TARGETID	T30372
T30372	FORMERID	TTDR00982
T30372	UNIPROID	CYSP_TRYCR
T30372	TARGNAME	Trypanosoma Cruzipain (Trypano CYSP)
T30372	GENENAME	Trypano CYSP
T30372	TARGTYPE	Successful
T30372	SYNONYMS	Cruzaine; Major cysteine proteinase
T30372	FUNCTION	The cysteine protease may play an important role in the development and differentiation of the parasites at several stages of their life cycle.
T30372	PDBSTRUC	4XUI; 4W5C; 4W5B; 4QH6; 4PI3
T30372	BIOCLASS	Peptidase
T30372	ECNUMBER	EC 3.4.22.51
T30372	SEQUENCE	MSGWARALLLAAVLVVMACLVPAATASLHAEETLTSQFAEFKQKHGRVYESAAEEAFRLSVFRENLFLARLHAAANPHATFGVTPFSDLTREEFRSRYHNGAAHFAAAQERARVPVKVEVVGAPAAVDWRARGAVTAVKDQGQCGSCWAFSAIGNVECQWFLAGHPLTNLSEQMLVSCDKTDSGCSGGLMNNAFEWIVQENNGAVYTEDSYPYASGEGISPPCTTSGHTVGATITGHVELPQDEAQIAAWLAVNGPVAVAVDASSWMTYTGGVMTSCVSEQLDHGVLLVGYNDSAAVPYWIIKNSWTTQWGEEGYIRIAKGSNQCLVKEEASSAVVGGPGPTPEPTTTTTTSAPGPSPSYFVQMSCTDAACIVGCENVTLPTGQCLLTTSGVSAIVTCGAETLTEEVFLTSTHCSGPSVRSSVPLNKCNRLLRGSVEFFCGSSSSGRLADVDRQRRHQPYHSRHRRL
T30372	DRUGINFO	D02VMJ	TRICLABENDAZOLE	Approved
T30372	DRUGINFO	D08TVA	MANIDIPINE	Phase 3
T30372	DRUGINFO	D04YJU	L-755507	Terminated
T30372	DRUGINFO	D01BQI	1-(3-Methoxy-benzyl)-5-methyl-1H-indole-2,3-dione	Investigative
T30372	DRUGINFO	D04FMU	3-amino-5-(furan-2-yl)biphenyl-2,4-dicarbonitrile	Investigative
T30372	DRUGINFO	D05VOH	VITAMIN K2	Investigative
T30372	DRUGINFO	D06LSC	WRR-204	Investigative
T30372	DRUGINFO	D07LMK	2-(trifluoromethyl)benzaldehyde thiosemicarbazone	Investigative
T30372	DRUGINFO	D07NVK	1-(1-(3-nitrophenyl)propylidene)thiosemicarbazide	Investigative
T30372	DRUGINFO	D07PZF	1-(bis(3-bromophenyl)methylene)thiosemicarbazide	Investigative
T30372	DRUGINFO	D07XQR	N1,N4-bis(5-chloro-2-methylphenyl)succinamide	Investigative
T30372	DRUGINFO	D08DEG	5-(3,4-dichlorophenyl)-1H-pyrazol-3-ol	Investigative
T30372	DRUGINFO	D08NYF	5-(4-bromophenyl)-2-furaldehyde thiosemicarbazone	Investigative
T30372	DRUGINFO	D09BXH	2-(cycloheptylamino)-2-oxoethyl 2-aminonicotinate	Investigative
T30372	DRUGINFO	D0DT5K	2-methoxy-1-naphthaldehyde thiosemicarbazone	Investigative
T30372	DRUGINFO	D0J3HR	1-(3,4-dihydronaphthalen-1-yl)ethanone	Investigative
T30372	DRUGINFO	D0L7GI	3-chloro-N-(4-(phenyldiazenyl)phenyl)benzamide	Investigative
T30372	DRUGINFO	D0N2QX	3-(trifluoromethyl)benzaldehyde thiosemicarbazone	Investigative
T30372	DRUGINFO	D0O5TA	5-Chloro-1-(4-chloro-benzyl)-1H-indole-2,3-dione	Investigative
T30372	DRUGINFO	D0S2IS	3'-bromopropiophenonethiosemicarbazone	Investigative
T30372	DRUGINFO	D0S2NU	3,5-dichlorobenzaldehyde thiosemicarbazone	Investigative
T30372	DRUGINFO	D0TZ5V	(3Z)-1H-indole-2,3-dione 3-thiosemicarbazone	Investigative
T30372	DRUGINFO	D0UL6C	3,4-dichlorobenzaldehyde thiosemicarbazone	Investigative
T30372	DRUGINFO	D0V8DQ	3',4'-dichloroacetophenonethiosemicarbazone	Investigative
T30372	DRUGINFO	D06DKB	GNF-PF-4478	Investigative
T30372	DRUGINFO	D08TMM	K-777	Investigative
T30372	DRUGINFO	D0B5IL	WRR-99	Investigative
T30372	DRUGINFO	D0L5WS	Benzoyl-Arginine-Alanine-Methyl Ketone	Investigative
T30372	DRUGINFO	D0PB3X	Vinylsulphones	Investigative
T30372	DRUGINFO	D0T0IX	WRR-112	Investigative

T71377	TARGETID	T71377
T71377	FORMERID	TTDR00012
T71377	UNIPROID	IL3RA_HUMAN
T71377	TARGNAME	Interleukin 3 receptor alpha (IL3RA)
T71377	GENENAME	IL3RA
T71377	TARGTYPE	Successful
T71377	SYNONYMS	Interleukin-3 receptor subunit alpha; IL3R; IL-3RA; IL-3R-alpha; IL-3R subunit alpha; IL-3 receptor subunit alpha; CD123 antigen; CD123
T71377	FUNCTION	This is a receptor for interleukin-3.
T71377	PDBSTRUC	5UWC; 5UV8; 4JZJ
T71377	BIOCLASS	Cytokine receptor
T71377	SEQUENCE	MVLLWLTLLLIALPCLLQTKEDPNPPITNLRMKAKAQQLTWDLNRNVTDIECVKDADYSMPAVNNSYCQFGAISLCEVTNYTVRVANPPFSTWILFPENSGKPWAGAENLTCWIHDVDFLSCSWAVGPGAPADVQYDLYLNVANRRQQYECLHYKTDAQGTRIGCRFDDISRLSSGSQSSHILVRGRSAAFGIPCTDKFVVFSQIEILTPPNMTAKCNKTHSFMHWKMRSHFNRKFRYELQIQKRMQPVITEQVRDRTSFQLLNPGTYTVQIRARERVYEFLSAWSTPQRFECDQEEGANTRAWRTSLLIALGTLLALVCVFVICRRYLVMQRLFPRIPHMKDPIGDSFQNDKLVVWEAGKAGLEECLVTEVQVVQKT
T71377	DRUGINFO	D0R7NI	Tagraxofusp	Approved
T71377	DRUGINFO	D04GGG	CD123/CLL1 CAR-T Cells	Phase 2/3
T71377	DRUGINFO	D07MGC	Talacotuzumab	Phase 2
T71377	DRUGINFO	D0C3JB	MB-102	Phase 2
T71377	DRUGINFO	D0YA1B	Flotetuzumab	Phase 2
T71377	DRUGINFO	D04MLR	CD123-specific gene-engineered T cells	Phase 1/2
T71377	DRUGINFO	D0N6PE	CART-123 cells	Phase 1/2
T71377	DRUGINFO	D0S1CR	Anti-CD123-CAR-transduced T cells	Phase 1/2
T71377	DRUGINFO	D0BH2M	4SCAR19 and 4SCAR123	Phase 1/2
T71377	DRUGINFO	DL1FG3	SAR440234	Phase 1/2
T71377	DRUGINFO	D00HAN	IM23	Phase 1
T71377	DRUGINFO	D02SAC	Anti-CD123 CAR-T cells	Phase 1
T71377	DRUGINFO	D0AW4T	CART-123 cells	Phase 1
T71377	DRUGINFO	D0JX7M	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	Phase 1
T71377	DRUGINFO	D0P2GU	CSL-362-AML	Phase 1
T71377	DRUGINFO	D0R5NU	CART123 cells	Phase 1
T71377	DRUGINFO	D0UP8U	Anti-CD123 CAR-T treatment	Phase 1
T71377	DRUGINFO	D0Z7QK	UCART123	Phase 1
T71377	DRUGINFO	D00JDL	MGD006	Phase 1
T71377	DRUGINFO	D2GY5C	APVO436	Phase 1
T71377	DRUGINFO	D3Q0FU	CSL311	Phase 1
T71377	DRUGINFO	D9TG4H	JNJ-63709178	Phase 1
T71377	DRUGINFO	DB4C5H	CD123-CD33 Ccar	Phase 1
T71377	DRUGINFO	D0H8UT	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	Phase 0
T71377	DRUGINFO	D0N4VG	CAR-T cells targeting CD123	Preclinical
T71377	DRUGINFO	D0D4XF	Daniplestim	Terminated

T11072	TARGETID	T11072
T11072	FORMERID	TTDS00100
T11072	UNIPROID	5HT1D_HUMAN
T11072	TARGNAME	5-HT 1D receptor (HTR1D)
T11072	GENENAME	HTR1D
T11072	TARGTYPE	Successful
T11072	SYNONYMS	Serotonin receptor 1D; Serotonin 1D alpha receptor; HTRL; HTR1DA; 5HT1D; 5-hydroxytryptamine receptor 1D; 5-HT1D receptor; 5-HT1D; 5-HT-1D-alpha; 5-HT-1D
T11072	FUNCTION	Functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. Regulates the release of 5-hydroxytryptamine in the brain, and thereby affects neural activity. May also play a role in regulating the release of other neurotransmitters. May play a role in vasoconstriction. G-protein coupled receptor for 5-hydroxytryptamine (serotonin).
T11072	BIOCLASS	GPCR rhodopsin
T11072	SEQUENCE	MSPLNQSAEGLPQEASNRSLNATETSEAWDPRTLQALKISLAVVLSVITLATVLSNAFVLTTILLTRKLHTPANYLIGSLATTDLLVSILVMPISIAYTITHTWNFGQILCDIWLSSDITCCTASILHLCVIALDRYWAITDALEYSKRRTAGHAATMIAIVWAISICISIPPLFWRQAKAQEEMSDCLVNTSQISYTIYSTCGAFYIPSVLLIILYGRIYRAARNRILNPPSLYGKRFTTAHLITGSAGSSLCSLNSSLHEGHSHSAGSPLFFNHVKIKLADSALERKRISAARERKATKILGIILGAFIICWLPFFVVSLVLPICRDSCWIHPALFDFFTWLGYLNSLINPIIYTVFNEEFRQAFQKIVPFRKAS
T11072	DRUGINFO	D0P0SM	Almogran	Approved
T11072	DRUGINFO	D0S9MU	Rizatriptan	Approved
T11072	DRUGINFO	D0Z6UC	Sumatriptan	Approved
T11072	DRUGINFO	D02DMQ	Eletriptan	Approved
T11072	DRUGINFO	D06FPQ	Frovatriptan	Approved
T11072	DRUGINFO	D0NG7O	Zolmitriptan	Approved
T11072	DRUGINFO	D0UA0I	Metergolin	Approved
T11072	DRUGINFO	D0E8IZ	Tonabersat	Phase 2
T11072	DRUGINFO	D04FVD	TGBA01AD	Phase 2
T11072	DRUGINFO	D00CVJ	Neu-P11	Phase 2
T11072	DRUGINFO	D0MT8G	FKB01MD	Phase 2
T11072	DRUGINFO	D0O2XJ	NXN-188	Phase 2
T11072	DRUGINFO	D01BPF	Avitriptan	Discontinued in Phase 3
T11072	DRUGINFO	D0Y0RW	Alniditan	Discontinued in Phase 3
T11072	DRUGINFO	D00QXV	BMS-181101	Discontinued in Phase 2
T11072	DRUGINFO	D03SWH	PNU-142633	Discontinued in Phase 2
T11072	DRUGINFO	D0SU1F	CP-122288	Discontinued in Phase 2
T11072	DRUGINFO	D03SFN	Elzasonan hydrochloride	Discontinued in Phase 2
T11072	DRUGINFO	D09WCE	IS-159	Discontinued in Phase 2
T11072	DRUGINFO	D03JSS	Tidembersat	Discontinued in Phase 1
T11072	DRUGINFO	D08XWZ	ALX-0646	Discontinued in Phase 1
T11072	DRUGINFO	D0G5ML	Donitriptan	Preclinical
T11072	DRUGINFO	D00NLD	L-741604	Terminated
T11072	DRUGINFO	D0G1RT	L-694247	Terminated
T11072	DRUGINFO	D0Q7TH	BMS-181885	Terminated
T11072	DRUGINFO	D0T1SF	PNU-109291	Terminated
T11072	DRUGINFO	D02ZSO	L-775606	Terminated
T11072	DRUGINFO	D06DZI	GR-127935	Terminated
T11072	DRUGINFO	D0UO9T	VR-147	Terminated
T11072	DRUGINFO	D02EPZ	2-(2,6-Dimethyl-benzyl)-4,5-dihydro-1H-imidazole	Investigative
T11072	DRUGINFO	D0V7OO	L-760790	Investigative
T11072	DRUGINFO	D00TYX	[3H]sumatriptan	Investigative
T11072	DRUGINFO	D02AVN	(3-Chloro-phenyl)-piperazin-1-yl-methanone	Investigative
T11072	DRUGINFO	D02PLD	1-(2-Butoxy-phenyl)-piperazine	Investigative
T11072	DRUGINFO	D02YFZ	2-Piperazin-1-yl-benzonitrile	Investigative
T11072	DRUGINFO	D03CEZ	AGROCLAVINE	Investigative
T11072	DRUGINFO	D03KPA	5-Ethyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole	Investigative
T11072	DRUGINFO	D03MVY	2-(5-Thiophen-2-yl-1H-indol-3-yl)-ethylamine	Investigative
T11072	DRUGINFO	D03NWV	1-(2-Ethoxy-phenyl)-piperazine	Investigative
T11072	DRUGINFO	D03XAE	[2-(5-Ethyl-1H-indol-3-yl)-ethyl]-dimethyl-amine	Investigative
T11072	DRUGINFO	D07LSC	1-(3-Fluoro-phenyl)-piperazine	Investigative
T11072	DRUGINFO	D08YJP	1-(2-Fluoro-phenyl)-piperazine	Investigative
T11072	DRUGINFO	D09AVG	5-amino-3-(N-methylpiperidin-4-yl)-1H-indole	Investigative
T11072	DRUGINFO	D0A2SY	[3H]GR 125,743	Investigative
T11072	DRUGINFO	D0B6WH	[3H]eletriptan	Investigative
T11072	DRUGINFO	D0C3EX	2-(5-Nonyloxy-1H-indol-3-yl)-ethylamine	Investigative
T11072	DRUGINFO	D0E2FY	1-(2-Isopropoxy-phenyl)-piperazine	Investigative
T11072	DRUGINFO	D0H6KD	[125I]GTI	Investigative
T11072	DRUGINFO	D0K9MT	5-Isopropyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole	Investigative
T11072	DRUGINFO	D0KQ9H	L-747201	Investigative
T11072	DRUGINFO	D0L9ZQ	lysergic acid	Investigative
T11072	DRUGINFO	D0ND2Y	1-(3-Nitro-phenyl)-piperazine	Investigative
T11072	DRUGINFO	D0P4KF	2-(4-tert-Butyl-phenyl)-4,5-dihydro-1H-imidazole	Investigative
T11072	DRUGINFO	D00CGJ	2-(4-Bromo-2-methoxy-phenyl)-1-methyl-ethylamine	Investigative
T11072	DRUGINFO	D00FUS	2-(2-Methoxy-phenyl)-1-methyl-ethylamine	Investigative
T11072	DRUGINFO	D00QSV	2-(3-Methoxy-phenyl)-1-methyl-ethylamine	Investigative
T11072	DRUGINFO	D00WEQ	Brolamfetamine	Investigative
T11072	DRUGINFO	D01APL	lysergol	Investigative
T11072	DRUGINFO	D01HRV	L-772,405	Investigative
T11072	DRUGINFO	D02OZB	2-Piperazin-1-yl-phenol	Investigative
T11072	DRUGINFO	D02SAF	1-(2,5-Dimethoxy-phenyl)-piperazine	Investigative
T11072	DRUGINFO	D03DET	SB 714786	Investigative
T11072	DRUGINFO	D06OJI	2-(2-Amino-propyl)-5-bromo-4-methoxy-phenol	Investigative
T11072	DRUGINFO	D06PKJ	1-(2,5-dimethoxyphenyl)propan-2-amine	Investigative
T11072	DRUGINFO	D08HOJ	1,2,3,4-Tetrahydro-naphthalen-2-ylamine	Investigative
T11072	DRUGINFO	D09JOE	1-(2,5-Dimethoxy-4-methyl-phenyl)-piperazine	Investigative
T11072	DRUGINFO	D09YVA	8-Methoxy-2-(4-methyl-piperazin-1-yl)-quinoline	Investigative
T11072	DRUGINFO	D0B2GS	3-Amino-1-(2-amino-5-methoxy-phenyl)-propan-1-one	Investigative
T11072	DRUGINFO	D0D2PL	8-Methoxy-quinolin-2-ylamine	Investigative
T11072	DRUGINFO	D0D3OF	1-(4-Bromo-2,5-dimethoxy-phenyl)-piperazine	Investigative
T11072	DRUGINFO	D0I9FI	2-(4-Bromo-phenyl)-1-methyl-ethylamine	Investigative
T11072	DRUGINFO	D0K0FI	7-methoxy-1-naphthylpiperazine	Investigative
T11072	DRUGINFO	D0O3GF	[3H]8-OH-DPAT	Investigative
T11072	DRUGINFO	D0PN8D	1-(7-Methoxy-naphthalen-2-yl)-piperazine	Investigative
T11072	DRUGINFO	D0QM3E	SB 272183	Investigative
T11072	DRUGINFO	D0R3GW	SB 649915	Investigative
T11072	DRUGINFO	D0TH8D	8-Methoxy-2-piperazin-1-yl-quinoline	Investigative
T11072	DRUGINFO	D0X4RC	PHENYLPIPERAZINE	Investigative
T11072	DRUGINFO	D0YG1E	Etisulergine	Investigative
T11072	DRUGINFO	D0D3PZ	dipropyl-5-CT	Investigative
T11072	DRUGINFO	D0N8BJ	[3H]5-HT	Investigative
T11072	DRUGINFO	D0W2YN	1-Naphthalen-2-yl-piperazine	Investigative
T11072	DRUGINFO	D04TPO	5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine	Investigative
T11072	DRUGINFO	D08PJK	[3H]5-CT	Investigative
T11072	DRUGINFO	D0SP2J	bufotenine	Investigative
T11072	DRUGINFO	D0XX2U	8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine	Investigative
T11072	DRUGINFO	D0CK9K	EDMT	Investigative
T11072	DRUGINFO	D0D9YW	SB 216641	Investigative
T11072	DRUGINFO	D0V3XU	CHLOROPHENYLPIPERAZINE	Investigative
T11072	DRUGINFO	D0Y4MC	9-OH-risperidone	Investigative
T11072	DRUGINFO	D06VPR	WAY-466	Investigative
T11072	DRUGINFO	D08BCF	QUIPAZINE	Investigative
T11072	DRUGINFO	D0C5GF	MPDT	Investigative
T11072	DRUGINFO	D0J6JT	m-chlorophenylpiperazine	Investigative
T11072	DRUGINFO	D0LG8A	1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine	Investigative
T11072	DRUGINFO	D0V4RP	1-(2-Methoxy-phenyl)-piperazine	Investigative
T11072	DRUGINFO	D0Y9TL	5-chloro-3,4-dihydroquinazolin-2-amine	Investigative
T11072	DRUGINFO	D00CRA	2-methyl-5-HT	Investigative
T11072	DRUGINFO	D01KAX	1-((S)-2-aminopropyl)-1H-indazol-6-ol	Investigative
T11072	DRUGINFO	D08VGJ	5,6-dichloro-3,4-dihydroquinazolin-2-amine	Investigative
T11072	DRUGINFO	D09OYA	alpha-methyl-5-HT	Investigative
T11072	DRUGINFO	D03TDN	1-naphthylpiperazine	Investigative
T11072	DRUGINFO	D04TVG	BRL-15572	Investigative
T11072	DRUGINFO	D02UWB	5-CT	Investigative
T11072	DRUGINFO	D0V5HV	TFMPP	Investigative
T11072	DRUGINFO	D0F6CD	SEROTONIN	Investigative
T11072	DRUGINFO	D0L5MW	(+/-)-nantenine	Investigative

T86679	TARGETID	T86679
T86679	FORMERID	TTDS00188
T86679	UNIPROID	AA2BR_HUMAN
T86679	TARGNAME	Adenosine A2b receptor (ADORA2B)
T86679	GENENAME	ADORA2B
T86679	TARGTYPE	Successful
T86679	SYNONYMS	Adenosine receptor A2b; A2b Adenosine receptor
T86679	FUNCTION	The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. Receptor for adenosine.
T86679	BIOCLASS	GPCR rhodopsin
T86679	SEQUENCE	MLLETQDALYVALELVIAALSVAGNVLVCAAVGTANTLQTPTNYFLVSLAAADVAVGLFAIPFAITISLGFCTDFYGCLFLACFVLVLTQSSIFSLLAVAVDRYLAICVPLRYKSLVTGTRARGVIAVLWVLAFGIGLTPFLGWNSKDSATNNCTEPWDGTTNESCCLVKCLFENVVPMSYMVYFNFFGCVLPPLLIMLVIYIKIFLVACRQLQRTELMDHSRTTLQREIHAAKSLAMIVGIFALCWLPVHAVNCVTLFQPAQGKNKPKWAMNMAILLSHANSVVNPIVYAYRNRDFRYTFHKIISRYLLCQADVKSGNGQAGVQPALGVGL
T86679	DRUGINFO	D06IAR	Adenosine	Approved
T86679	DRUGINFO	D0NI0C	Vidarabine	Approved
T86679	DRUGINFO	DJC4L7	A295	IND submitted
T86679	DRUGINFO	D0W9NO	YT-146	Phase 2
T86679	DRUGINFO	D00SUK	Tonapofylline	Phase 2
T86679	DRUGINFO	D04UBI	AB928	Phase 1/2
T86679	DRUGINFO	D0G4CF	CVT-6883	Phase 1
T86679	DRUGINFO	D0HF2D	PBF-1129	Phase 1
T86679	DRUGINFO	D0M3IN	Xanthine	Phase 1
T86679	DRUGINFO	D0L5VS	KF-17837	Phase 1
T86679	DRUGINFO	D07ESH	PF-1913539	Discontinued in Phase 3
T86679	DRUGINFO	D08ECB	LAS-101057	Preclinical
T86679	DRUGINFO	D0HE1P	BAY 60-6583	Preclinical
T86679	DRUGINFO	D0Y6GJ	ZM-241385	Terminated
T86679	DRUGINFO	D0E4WF	METHYLTHIOADENOSINE	Terminated
T86679	DRUGINFO	D01CQU	MRS1706	Investigative
T86679	DRUGINFO	D01KNZ	[125I]ABOPX	Investigative
T86679	DRUGINFO	D01QYQ	ATL-844	Investigative
T86679	DRUGINFO	D02UHS	CGS 24012	Investigative
T86679	DRUGINFO	D03NVE	CVT-6694	Investigative
T86679	DRUGINFO	D03NXZ	CV-1674	Investigative
T86679	DRUGINFO	D03WPE	AB-NECA	Investigative
T86679	DRUGINFO	D04DVT	XCC	Investigative
T86679	DRUGINFO	D06GOE	AS74	Investigative
T86679	DRUGINFO	D06GTI	AS96	Investigative
T86679	DRUGINFO	D06NRX	CV-1808	Investigative
T86679	DRUGINFO	D06SGU	CVT-7124	Investigative
T86679	DRUGINFO	D0A8EK	APNEA	Investigative
T86679	DRUGINFO	D0I2MU	3-isobutyl-8-pyrrolidinoxanthine	Investigative
T86679	DRUGINFO	D0J4EZ	AS95	Investigative
T86679	DRUGINFO	D0M5TM	8-(3-Fluoro-phenyl)-9-methyl-9H-purin-6-ylamine	Investigative
T86679	DRUGINFO	D0O0HR	KF 17837S	Investigative
T86679	DRUGINFO	D0O3SA	ATL-801	Investigative
T86679	DRUGINFO	D0PB2W	BETA-HYDROXYETHYL THEOPHYLLINE	Investigative
T86679	DRUGINFO	D0U7TR	[125I]ZM-241385	Investigative
T86679	DRUGINFO	D0W4JC	[3H]ZM 241385	Investigative
T86679	DRUGINFO	D0X5PJ	AS16	Investigative
T86679	DRUGINFO	D0Y8LD	AS94	Investigative
T86679	DRUGINFO	D00MFV	9-(sec-Butyl)-9H-adenine	Investigative
T86679	DRUGINFO	D04GFX	MRS1132	Investigative
T86679	DRUGINFO	D04RHI	MRS1086	Investigative
T86679	DRUGINFO	D07DOE	2'-Me-tecadenoson	Investigative
T86679	DRUGINFO	D07FZA	AS99	Investigative
T86679	DRUGINFO	D07HKU	DEPX	Investigative
T86679	DRUGINFO	D07RSH	MRS923	Investigative
T86679	DRUGINFO	D08FOT	PSB-1115	Investigative
T86679	DRUGINFO	D08RSU	[3H]DPCPX	Investigative
T86679	DRUGINFO	D09NEP	MRS1088	Investigative
T86679	DRUGINFO	D09TBE	MRS1065	Investigative
T86679	DRUGINFO	D0A4MK	AS100	Investigative
T86679	DRUGINFO	D0B9CC	3-Methyl-1-phenethyl-3,7-dihydro-purine-2,6-dione	Investigative
T86679	DRUGINFO	D0D9YL	1-Benzyl-3-methyl-3,7-dihydro-purine-2,6-dione	Investigative
T86679	DRUGINFO	D0G2JG	CPFPX	Investigative
T86679	DRUGINFO	D0J2UW	CGS 21680	Investigative
T86679	DRUGINFO	D0L3BI	MRS1084	Investigative
T86679	DRUGINFO	D0MH4R	visnagin	Investigative
T86679	DRUGINFO	D0PM5R	AB-MECA	Investigative
T86679	DRUGINFO	D0Q9GL	AS70	Investigative
T86679	DRUGINFO	D0W6TG	PSB-09120	Investigative
T86679	DRUGINFO	D0X3PD	I-ABOPX	Investigative
T86679	DRUGINFO	D0Y5TL	Alloxazine	Investigative
T86679	DRUGINFO	D00IOF	PSB36	Investigative
T86679	DRUGINFO	D01AAI	VUF5574	Investigative
T86679	DRUGINFO	D01WNA	8-Bromo-9-ethyl-9H-adenine	Investigative
T86679	DRUGINFO	D02HOL	8-Bromo-9-propyl-9H-adenine	Investigative
T86679	DRUGINFO	D02JCM	N(6)-cyclohexyladenosine	Investigative
T86679	DRUGINFO	D02RMR	1,3-Diethyl-3,7-dihydro-purine-2,6-dione	Investigative
T86679	DRUGINFO	D02SKN	MRS1041	Investigative
T86679	DRUGINFO	D03KKK	1,3-Dipropyl-3,7-dihydro-purine-2,6-dione	Investigative
T86679	DRUGINFO	D04WHE	9-Propyl-9H-adenine	Investigative
T86679	DRUGINFO	D05QNV	ATL802	Investigative
T86679	DRUGINFO	D05XGF	PSB-0788	Investigative
T86679	DRUGINFO	D06KMJ	MRS5151	Investigative
T86679	DRUGINFO	D07DNX	PD-115199	Investigative
T86679	DRUGINFO	D07HNM	1,3-Diallyl-3,7-dihydro-purine-2,6-dione	Investigative
T86679	DRUGINFO	D07PPM	PSB-10	Investigative
T86679	DRUGINFO	D07VCN	4-Ethoxy-7-((E)-styryl)-furo[3,2-g]chromen-5-one	Investigative
T86679	DRUGINFO	D08BCH	TCPA	Investigative
T86679	DRUGINFO	D08EBT	[3H]HEMADO	Investigative
T86679	DRUGINFO	D08MRB	1H-Imidazo[4,5-c]quinolin-4-ylamine HCl	Investigative
T86679	DRUGINFO	D09RKX	PSB-11	Investigative
T86679	DRUGINFO	D0A6IO	MRE 3008F20	Investigative
T86679	DRUGINFO	D0A6JX	9-Cyclobutyl-9H-adenine	Investigative
T86679	DRUGINFO	D0A9BZ	PSB-601	Investigative
T86679	DRUGINFO	D0B1RV	2-Cyclopentyl-1H-imidazo[4,5-c]quinolin-4-ylamine	Investigative
T86679	DRUGINFO	D0B1YW	8-Phenyl-1-propyl-3,7-dihydro-purine-2,6-dione	Investigative
T86679	DRUGINFO	D0B7OW	sakuranetin	Investigative
T86679	DRUGINFO	D0B8DR	MRS1093	Investigative
T86679	DRUGINFO	D0C2UJ	2-chloroadenosine	Investigative
T86679	DRUGINFO	D0DB7A	9-Isopropyl-9H-adenine	Investigative
T86679	DRUGINFO	D0E8RA	8-Bromo-9-(2,3-dihydroxypropyl)-9H-adenine	Investigative
T86679	DRUGINFO	D0E9QX	(S)-PIA	Investigative
T86679	DRUGINFO	D0F1AS	1-METHYLXANTHINE	Investigative
T86679	DRUGINFO	D0F4XB	2-Amino-4,6-di-furan-2-yl-nicotinonitrile	Investigative
T86679	DRUGINFO	D0H9BP	xanthine amine congener	Investigative
T86679	DRUGINFO	D0I1EP	MRS928	Investigative
T86679	DRUGINFO	D0I3HE	KF26777	Investigative
T86679	DRUGINFO	D0J1BA	MRS1191	Investigative
T86679	DRUGINFO	D0L0VU	MRE 2029F20	Investigative
T86679	DRUGINFO	D0LD0X	1-Propyl-3,7-dihydro-purine-2,6-dione	Investigative
T86679	DRUGINFO	D0LP5G	2-Phenyl-1H-imidazo[4,5-c]quinolin-4-ylamine	Investigative
T86679	DRUGINFO	D0O0FP	ST-1535	Investigative
T86679	DRUGINFO	D0O1CW	GNF-PF-2700	Investigative
T86679	DRUGINFO	D0P7FK	2-Amino-4-furan-2-yl-6-phenyl-nicotinonitrile	Investigative
T86679	DRUGINFO	D0P8MK	2-(6-amino-8-bromo-9H-purin-9-yl)ethanol	Investigative
T86679	DRUGINFO	D0R8OK	8-Bromo-9-methyl-9H-adenine	Investigative
T86679	DRUGINFO	D0S5XP	9-Allyl-8-bromo-9H-adenine	Investigative
T86679	DRUGINFO	D0S6QA	8-Bromo-9-(2-butyl)-9H-adenine	Investigative
T86679	DRUGINFO	D0T7GG	LUF-5816	Investigative
T86679	DRUGINFO	D0TC7N	PENECA	Investigative
T86679	DRUGINFO	D0U8DW	1-Butyl-8-phenyl-3,7-dihydro-purine-2,6-dione	Investigative
T86679	DRUGINFO	D0V9EE	2-Amino-6-furan-2-yl-4-phenyl-nicotinonitrile	Investigative
T86679	DRUGINFO	D0V9OO	(R,S)-PHPNECA	Investigative
T86679	DRUGINFO	D0VB6X	(1H-Imidazo[4,5-c]quinolin-4-yl)-phenyl-amine HCl	Investigative
T86679	DRUGINFO	D0W6FC	8-Bromo-9-(2-hydroxypropyl)-9H-adenine	Investigative
T86679	DRUGINFO	D0XC9U	MRS1042	Investigative
T86679	DRUGINFO	D0Y2RM	Isoguanosine	Investigative
T86679	DRUGINFO	D0Y5WQ	PSB603	Investigative
T86679	DRUGINFO	D0Z1WY	2-chloro-2'-C-methyl-tecadenoson	Investigative
T86679	DRUGINFO	D0ZL2A	MRS1523	Investigative
T86679	DRUGINFO	D00GNW	2,6-diphenyl-8-(1-ethylpropyl)-1-deazapurine	Investigative
T86679	DRUGINFO	D00JWA	N-(2-(furan-2-yl)-3,4'-bipyridin-6-yl)acetamide	Investigative
T86679	DRUGINFO	D02PBY	3-noradamantyl-1,3-dipropylxanthine	Investigative
T86679	DRUGINFO	D04LZN	8-Bromo-9-cyclobutyl-9H-adenine	Investigative
T86679	DRUGINFO	D05KEF	LUF-5978	Investigative
T86679	DRUGINFO	D06KYP	8-Bromo-9-isopropyl-9H-adenine	Investigative
T86679	DRUGINFO	D0AI8F	8-Bromo-9-cyclopentyl-9H-adenine	Investigative
T86679	DRUGINFO	D0B0TX	8-bromo-9-isobutyl-9H-purin-6-amine	Investigative
T86679	DRUGINFO	D0CX7N	8-Bromo-9-(3-hydroxypropyl)-9H-adenine	Investigative
T86679	DRUGINFO	D0IG5E	2,5'-dichloro-5'-deoxy-N6-cyclopentyladenosine	Investigative
T86679	DRUGINFO	D0JJ6T	N6-((+/-)-endo-norborn-2-yl)adenosine	Investigative
T86679	DRUGINFO	D0K6ZA	[3H]OSIP339391	Investigative
T86679	DRUGINFO	D0K8ZZ	[3H]NECA	Investigative
T86679	DRUGINFO	D0M3CG	R-N6-(phenylisopropyl)adenosine	Investigative
T86679	DRUGINFO	D0NO5E	Ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate	Investigative
T86679	DRUGINFO	D0O4KI	2-ethyl-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine	Investigative
T86679	DRUGINFO	D0R1XY	[3H]CCPA	Investigative
T86679	DRUGINFO	D0TU7I	(E)-8-(3-chlorostyryl)-caffeine	Investigative
T86679	DRUGINFO	D0V8MD	8-PHENYL THEOPHYLLINE	Investigative
T86679	DRUGINFO	D0W1PF	LUF-5980	Investigative
T86679	DRUGINFO	D0Y9WZ	SB-298	Investigative
T86679	DRUGINFO	D0Z8NC	LUF-5981	Investigative
T86679	DRUGINFO	D0Z8VU	8-Bromo-9-(sec-butyl)-9H-adenine	Investigative
T86679	DRUGINFO	D0K0OT	GNF-PF-2224	Investigative
T86679	DRUGINFO	D03RFA	N6-CYCLOPENTYLADENOSINE	Investigative
T86679	DRUGINFO	D0S0RK	flavone	Investigative
T86679	DRUGINFO	D0R6MT	isobutylmethylxanthine	Investigative

T95385	TARGETID	T95385
T95385	FORMERID	TTDI01746
T95385	UNIPROID	IL12B_HUMAN
T95385	TARGNAME	Interleukin-12 beta (IL12B)
T95385	GENENAME	IL12B
T95385	TARGTYPE	Successful
T95385	SYNONYMS	NKSF2; NK cell stimulatory factor chain 2; Interleukin12 subunit beta; Interleukin-12 subunit beta; IL12 subunit p40; IL-12B; IL-12 subunit p40; Cytotoxic lymphocyte maturation factor 40 kDa subunit; CLMF p40
T95385	FUNCTION	Cytokine that can act as a growth factor for activated T and NK cells, enhance the lytic activity of NK/lymphokine-activated killer cells, and stimulate the production of IFN-gamma by resting PBMC.
T95385	PDBSTRUC	5NJD; 5MZV; 5MXA; 5MJ4; 5MJ3
T95385	BIOCLASS	Cytokine: interleukin
T95385	SEQUENCE	MCHQQLVISWFSLVFLASPLVAIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWTLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSAERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKPDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFCVQVQGKSKREKKDRVFTDKTSATVICRKNASISVRAQDRYYSSSWSEWASVPCS
T95385	DRUGINFO	D0I8FI	Isoproterenol	Approved
T95385	DRUGINFO	D0H1TL	ABT-874	Phase 3
T95385	DRUGINFO	D0OS7K	EGEN-001	Phase 2
T95385	DRUGINFO	D0P7MO	SFV IL-12 gene therapy	Phase 2
T95385	DRUGINFO	D06LUI	Ad-IL-12 DNA therapeutic	Phase 1/2
T95385	DRUGINFO	D00BVJ	NHS-IL 12	Phase 1
T95385	DRUGINFO	DMA7E5	PF-07261271	Phase 1

T23714	TARGETID	T23714
T23714	FORMERID	TTDC00111
T23714	UNIPROID	BKRB2_HUMAN
T23714	TARGNAME	B2 bradykinin receptor (BDKRB2)
T23714	GENENAME	BDKRB2
T23714	TARGTYPE	Successful
T23714	SYNONYMS	Bradykinin B2 receptor; BKR2; BK-2 receptor; BK B(2) receptor; B2R
T23714	FUNCTION	It is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. Receptor for bradykinin.
T23714	BIOCLASS	GPCR rhodopsin
T23714	SEQUENCE	MFSPWKISMFLSVREDSVPTTASFSADMLNVTLQGPTLNGTFAQSKCPQVEWLGWLNTIQPPFLWVLFVLATLENIFVLSVFCLHKSSCTVAEIYLGNLAAADLILACGLPFWAITISNNFDWLFGETLCRVVNAIISMNLYSSICFLMLVSIDRYLALVKTMSMGRMRGVRWAKLYSLVIWGCTLLLSSPMLVFRTMKEYSDEGHNVTACVISYPSLIWEVFTNMLLNVVGFLLPLSVITFCTMQIMQVLRNNEMQKFKEIQTERRATVLVLVVLLLFIICWLPFQISTFLDTLHRLGILSSCQDERIIDVITQIASFMAYSNSCLNPLVYVIVGKRFRKKSWEVYQGVCQKGGCRSEPIQMENSMGTLRTSISVERQIHKLQDWAGSRQ
T23714	DRUGINFO	D04ZBT	Icatibant	Approved
T23714	DRUGINFO	D05ENJ	Fasitibant chloride	Phase 2
T23714	DRUGINFO	D05XTQ	DELTIBANT	Phase 2
T23714	DRUGINFO	D09BPN	Anatibant	Phase 2
T23714	DRUGINFO	DS70MP	DM199	Phase 2
T23714	DRUGINFO	D0X0BI	BRADYKININ	Phase 1
T23714	DRUGINFO	D03ZBM	NPC-567	Discontinued in Phase 2
T23714	DRUGINFO	D0G0IZ	Labradimil	Discontinued in Phase 2
T23714	DRUGINFO	D03WMY	NPC-17731	Terminated
T23714	DRUGINFO	D07OCC	JSM-10292	Terminated
T23714	DRUGINFO	D0H5PD	CP-0597	Terminated
T23714	DRUGINFO	D0NN5B	FR-172357	Terminated
T23714	DRUGINFO	D0ON2X	FR-173657	Terminated
T23714	DRUGINFO	D00FUT	[Leu8,des-Arg9]bradykinin	Investigative
T23714	DRUGINFO	D01APZ	(D)Arg-Arg-Pro-Hyp-Gly-Thi-Cys-(D)Phe-Phe-Cys-Arg	Investigative
T23714	DRUGINFO	D03RYY	NPC-349	Investigative
T23714	DRUGINFO	D04ULY	bradyzide	Investigative
T23714	DRUGINFO	D04WHO	PMID12812482C11	Investigative
T23714	DRUGINFO	D05IBQ	(D)Arg-Arg-Pro-Hyp-Gly-Thi-Ser-(D)Tic-Tic-Arg	Investigative
T23714	DRUGINFO	D06JXH	Met-Lys-bradykinin	Investigative
T23714	DRUGINFO	D06QYV	FR167344	Investigative
T23714	DRUGINFO	D07COX	T-kinin	Investigative
T23714	DRUGINFO	D08HBN	kallidin	Investigative
T23714	DRUGINFO	D09IEO	[des-Arg9]bradykinin	Investigative
T23714	DRUGINFO	D0A3YN	FR191413	Investigative
T23714	DRUGINFO	D0BR7M	Breceptin	Investigative
T23714	DRUGINFO	D0DU5S	Quinapril analogue	Investigative
T23714	DRUGINFO	D0GW6V	[Sar,D-Phe8,des-Arg9]bradykinin	Investigative
T23714	DRUGINFO	D0I8HL	(D)Arg-Arg-Pro-Hyp-Gly-Thi-Ser-(D)Tic-Aoc-Arg	Investigative
T23714	DRUGINFO	D0J4GG	LF-160335	Investigative
T23714	DRUGINFO	D0L3GT	chroman 28	Investigative
T23714	DRUGINFO	D0LL7N	FR190997	Investigative
T23714	DRUGINFO	D0LM7P	(D)Arg-Arg-Pro-Hyp-Gly-Phe-Ser-(d)Phe-Phe-Arg	Investigative
T23714	DRUGINFO	D0NY1V	WIN 64338	Investigative
T23714	DRUGINFO	D0U4SG	PMID12723943C12	Investigative
T23714	DRUGINFO	D0VF5V	PS020990	Investigative
T23714	DRUGINFO	D00FAE	H-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1638)	Investigative
T23714	DRUGINFO	D02DGP	H-Lys-Arg-Pro-Hyp-Gly-Thi-Ser-D-BT-OH(JMV1669)	Investigative
T23714	DRUGINFO	D0C3KW	H-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1645)	Investigative
T23714	DRUGINFO	D0N2GM	JMV1431	Investigative

T66237	TARGETID	T66237
T66237	FORMERID	TTDS00111
T66237	UNIPROID	V2R_HUMAN
T66237	TARGNAME	Vasopressin V2 receptor (V2R)
T66237	GENENAME	AVPR2
T66237	TARGTYPE	Successful
T66237	SYNONYMS	Renal-type arginine vasopressin receptor; DIR3; DIR; Antidiuretic hormone receptor; AVPR V2; ADHR
T66237	FUNCTION	The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Involved in renal water reabsorption. Receptor for arginine vasopressin.
T66237	PDBSTRUC	4JQI
T66237	BIOCLASS	GPCR rhodopsin
T66237	SEQUENCE	MLMASTTSAVPGHPSLPSLPSNSSQERPLDTRDPLLARAELALLSIVFVAVALSNGLVLAALARRGRRGHWAPIHVFIGHLCLADLAVALFQVLPQLAWKATDRFRGPDALCRAVKYLQMVGMYASSYMILAMTLDRHRAICRPMLAYRHGSGAHWNRPVLVAWAFSLLLSLPQLFIFAQRNVEGGSGVTDCWACFAEPWGRRTYVTWIALMVFVAPTLGIAACQVLIFREIHASLVPGPSERPGGRRRGRRTGSPGEGAHVSAAVAKTVRMTLVIVVVYVLCWAPFFLVQLWAAWDPEAPLEGAPFVLLMLLASLNSCTNPWIYASFSSSVSSELRSLLCCARGRTPPSLGPQDESCTTASSSLAKDTSS
T66237	DRUGINFO	D03KZM	Tolvaptan	Approved
T66237	DRUGINFO	D0N4OW	Vasopressin	Approved
T66237	DRUGINFO	D0VU2X	Conivaptan	Approved
T66237	DRUGINFO	D0F4NS	Mozavaptan	Approved
T66237	DRUGINFO	D0M3FJ	Oxytocin	Approved
T66237	DRUGINFO	D0U7SH	Desmopressin	Approved
T66237	DRUGINFO	D0D8XY	ATOSIBAN	Phase 4
T66237	DRUGINFO	D0L9NX	Satavaptan	Phase 3
T66237	DRUGINFO	D07EEN	Lixivaptan	Phase 3
T66237	DRUGINFO	D01OXH	ASP-7035	Phase 2
T66237	DRUGINFO	D06VWL	VA-106483	Phase 2
T66237	DRUGINFO	D0Z8DO	SPD-556	Phase 2
T66237	DRUGINFO	D0SY9B	SSR149415	Phase 2
T66237	DRUGINFO	D03RYS	VNA-932	Discontinued in Phase 1
T66237	DRUGINFO	D0AV0O	OPC-51803	Discontinued in Phase 1
T66237	DRUGINFO	D0DI0B	OX 19	Discontinued in Phase 1
T66237	DRUGINFO	D02RDE	JTV-605	Terminated
T66237	DRUGINFO	D05WHD	FR161282	Investigative
T66237	DRUGINFO	D08JNK	d(CH2)5[D-Ile2,Ile4]AVP	Investigative
T66237	DRUGINFO	D0KU5D	YM-35278	Investigative
T66237	DRUGINFO	D0ZJ5K	VP-343	Investigative
T66237	DRUGINFO	D0T3YS	CL-385004	Investigative
T66237	DRUGINFO	D0Y0SO	DVDAVP	Investigative
T66237	DRUGINFO	D00NIT	YM 471	Investigative
T66237	DRUGINFO	D00SGZ	YM 218	Investigative
T66237	DRUGINFO	D02YBV	[Val4]AVP	Investigative
T66237	DRUGINFO	D03EBH	D(CH2)5[Tyr(Me)2,Thr4,Orn8,Tyr9-NH2]VT	Investigative
T66237	DRUGINFO	D04JXX	d[Pen1,Tyr(Me)2]AVP	Investigative
T66237	DRUGINFO	D09OML	D[D-3-Pal2]AVP	Investigative
T66237	DRUGINFO	D0T4ML	L-372662	Investigative
T66237	DRUGINFO	D0Y4HL	[Phe3]OT	Investigative
T66237	DRUGINFO	D01FDW	ARGENINE VASOPRESSIN	Investigative
T66237	DRUGINFO	D03BVC	D[Arg4,Orn8]VP	Investigative
T66237	DRUGINFO	D03DXK	D[Leu4,Lys8]VP	Investigative
T66237	DRUGINFO	D04MMD	D[Arg4,Lys8]VP	Investigative
T66237	DRUGINFO	D05BHL	D[Cha4,Lys8]VP	Investigative
T66237	DRUGINFO	D05RNF	D[Cha4,Orn8]VP	Investigative
T66237	DRUGINFO	D06SDG	D[Leu4,Dab8]VP	Investigative
T66237	DRUGINFO	D09RIE	D[Cha4]AVP	Investigative
T66237	DRUGINFO	D09XWA	D[Cha4,Dap8]VP	Investigative
T66237	DRUGINFO	D0A6FK	D[Leu4]AVP	Investigative
T66237	DRUGINFO	D0HI2N	D[Cha4,Dab8]VP	Investigative
T66237	DRUGINFO	D0M4QM	d(CH2)5[Tyr(Me)2]AVP	Investigative
T66237	DRUGINFO	D0O5TK	D[Leu4,Dap8]VP	Investigative
T66237	DRUGINFO	D0O8OF	D[Orn4,Lys8]VP	Investigative
T66237	DRUGINFO	D0R7QC	D[Arg4]AVP	Investigative
T66237	DRUGINFO	D0UK0O	D[Arg4,Dab8]VP	Investigative
T66237	DRUGINFO	D0V3FF	D[Leu4,Orn8]VP	Investigative
T66237	DRUGINFO	D0W3IQ	D[Val4]AVP	Investigative
T66237	DRUGINFO	D0YJ6C	D[Orn4,Orn8]VP	Investigative
T66237	DRUGINFO	D0ZD0W	D[Orn4]AVP	Investigative

T62184	TARGETID	T62184
T62184	FORMERID	TTDR01179
T62184	UNIPROID	SC6A1_HUMAN
T62184	TARGNAME	GABA transporter GAT-1 (SLC6A1)
T62184	GENENAME	SLC6A1
T62184	TARGTYPE	Successful
T62184	SYNONYMS	Solute carrier family 6 member 1; Sodium- and chloride-dependent GABA transporter 1; GAT1; GAT-1; GABT1; GABATR; GABA transporter 1
T62184	FUNCTION	Terminates the action of GABA by its high affinity sodium-dependent reuptake into presynaptic terminals.
T62184	BIOCLASS	Neurotransmitter:sodium symporter
T62184	SEQUENCE	MATNGSKVADGQISTEVSEAPVANDKPKTLVVKVQKKAADLPDRDTWKGRFDFLMSCVGYAIGLGNVWRFPYLCGKNGGGAFLIPYFLTLIFAGVPLFLLECSLGQYTSIGGLGVWKLAPMFKGVGLAAAVLSFWLNIYYIVIISWAIYYLYNSFTTTLPWKQCDNPWNTDRCFSNYSMVNTTNMTSAVVEFWERNMHQMTDGLDKPGQIRWPLAITLAIAWILVYFCIWKGVGWTGKVVYFSATYPYIMLIILFFRGVTLPGAKEGILFYITPNFRKLSDSEVWLDAATQIFFSYGLGLGSLIALGSYNSFHNNVYRDSIIVCCINSCTSMFAGFVIFSIVGFMAHVTKRSIADVAASGPGLAFLAYPEAVTQLPISPLWAILFFSMLLMLGIDSQFCTVEGFITALVDEYPRLLRNRRELFIAAVCIISYLIGLSNITQGGIYVFKLFDYYSASGMSLLFLVFFECVSISWFYGVNRFYDNIQEMVGSRPCIWWKLCWSFFTPIIVAGVFIFSAVQMTPLTMGNYVFPKWGQGVGWLMALSSMVLIPGYMAYMFLTLKGSLKQRIQVMVQPSEDIVRPENGPEQPQAGSSTSKEAYI
T62184	DRUGINFO	D0YH0N	Metadoxine	Approved
T62184	DRUGINFO	D0ED7U	Tiagabine	Approved
T62184	DRUGINFO	D0C9XA	GSK683699	Phase 2
T62184	DRUGINFO	D08ESA	CI-966	Phase 1
T62184	DRUGINFO	D03IWW	(S)-Piperidine-3-carboxylic acid	Investigative
T62184	DRUGINFO	D08YGM	SKF89976A	Investigative
T62184	DRUGINFO	D02SDM	LU32-176B	Investigative
T62184	DRUGINFO	D0D2EF	(R)-nipecotic acid	Investigative
T62184	DRUGINFO	D0ER1G	4-Hydroxy-piperidine-3-carboxylic acid	Investigative
T62184	DRUGINFO	D0H2HC	(R/S) EF-1500	Investigative
T62184	DRUGINFO	D0I7AL	(R)-EF-1520	Investigative
T62184	DRUGINFO	D0WT5D	(S)-EF-1520	Investigative
T62184	DRUGINFO	D09TTI	2,4-Diamino-butyric acid(GABA)	Investigative
T62184	DRUGINFO	D0RF2M	NIPECOTIC ACID	Investigative

T16633	TARGETID	T16633
T16633	FORMERID	TTDC00112
T16633	UNIPROID	SSR1_HUMAN
T16633	TARGNAME	Somatostatin receptor type 1 (SSTR1)
T16633	GENENAME	SSTR1
T16633	TARGTYPE	Successful
T16633	SYNONYMS	Sst(1); Somatostatin receptor 1; SSTR1; SS1R; SRIF-2
T16633	FUNCTION	Receptor for somatostatin with higher affinity for somatostatin-14 than -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. In addition it stimulates phosphotyrosine phosphataseand Na(+)/H(+) exchanger via pertussis toxin insensitive G proteins.
T16633	BIOCLASS	GPCR rhodopsin
T16633	SEQUENCE	MFPNGTASSPSSSPSPSPGSCGEGGGSRGPGAGAADGMEEPGRNASQNGTLSEGQGSAILISFIYSVVCLVGLCGNSMVIYVILRYAKMKTATNIYILNLAIADELLMLSVPFLVTSTLLRHWPFGALLCRLVLSVDAVNMFTSIYCLTVLSVDRYVAVVHPIKAARYRRPTVAKVVNLGVWVLSLLVILPIVVFSRTAANSDGTVACNMLMPEPAQRWLVGFVLYTFLMGFLLPVGAICLCYVLIIAKMRMVALKAGWQQRKRSERKITLMVMMVVMVFVICWMPFYVVQLVNVFAEQDDATVSQLSVILGYANSCANPILYGFLSDNFKRSFQRILCLSWMDNAAEEPVDYYATALKSRAYSVEDFQPENLESGGVFRNGTCTSRITTL
T16633	DRUGINFO	D0DQ7V	Lutetium Lu 177 dotatate	Approved
T16633	DRUGINFO	D0TV0C	Pasireotide	Approved
T16633	DRUGINFO	D06JFI	ODT-8	Phase 3
T16633	DRUGINFO	D05EKM	FR-121196	Terminated
T16633	DRUGINFO	D00MGT	SRA880	Investigative
T16633	DRUGINFO	D01NID	Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Ser13]SRIF	Investigative
T16633	DRUGINFO	D03SXC	Des-AA1,2,5-[(NalphaMe)D-Nal8,IAmp9]SRIF	Investigative
T16633	DRUGINFO	D03VHX	Des-AA1,2,5-[D-Nal8,(NalphaMe)IAmp9,Tyr11]SRIF	Investigative
T16633	DRUGINFO	D04EWA	Des-AA1,2,5-[(NalphaMe)Lys4,D-Nal8,IAmp9]SRIF	Investigative
T16633	DRUGINFO	D05XZA	Des-AA1,2,5-[(NalphaMe)Cys3,D-Trp8,IAmp9]SRIF	Investigative
T16633	DRUGINFO	D06JWT	Des-AA1,2,5-[D-Trp8,IAmp9,(NalphaMe)Thr12]SRIF	Investigative
T16633	DRUGINFO	D07DUF	Des-AA1,2,5-[D-Nal8,IAmp9]SRIF	Investigative
T16633	DRUGINFO	D07OSF	Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Phe11]SRIF	Investigative
T16633	DRUGINFO	D0A0DO	Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Cys14]SRIF	Investigative
T16633	DRUGINFO	D0BE3D	Des-AA1,2,5-[D-Trp8,IAmp9,Tyr11]Cbm-SRIF	Investigative
T16633	DRUGINFO	D0CC1P	Des-AA1,2,5-[D-Nal8,(NalphaMe)IAmp9]SRIF	Investigative
T16633	DRUGINFO	D0I9ME	Des-AA1,2,5-[D-Trp8,(NalphaMe)IAmp9,Tyr11]SRIF	Investigative
T16633	DRUGINFO	D0N4LH	Des-AA1,2,5-[D-Trp8,IAmp9,(NalphaMe)Cys14]SRIF	Investigative
T16633	DRUGINFO	D0O2DN	L-797,591	Investigative
T16633	DRUGINFO	D0R4IS	Des-AA1,2,5-[(NalphaMe)Cys3,D-Nal8,IAmp9]SRIF	Investigative
T16633	DRUGINFO	D0S7YR	Des-AA1,5-[Tyr2,D-Trp8,IAmp9]SRIF CH-288	Investigative
T16633	DRUGINFO	D0Z1XY	Des-AA1,2,5-[D-Trp8,IAmp9,(NalphaMe)Ser13]SRIF	Investigative
T16633	DRUGINFO	D02WOX	Des-AA1,2,5-[D-Trp8,IAmp9]SRIF CH-275	Investigative
T16633	DRUGINFO	D03DRL	Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Thr12]SRIF	Investigative
T16633	DRUGINFO	D04FPW	Des-AA1,4,5,13-[Tyr2,D-Trp8]-SRIF	Investigative
T16633	DRUGINFO	D05PKR	L-817,818	Investigative
T16633	DRUGINFO	D09LHN	Des-AA1,2,5-[IAmp9,Tyr11]-SRIF	Investigative
T16633	DRUGINFO	D0A1XX	Des-AA1,5-[Tyr2,D-Trp8,(NalphaMe)IAmp9]Cbm-SRIF	Investigative
T16633	DRUGINFO	D0N2MA	Des-AA1,5-[Tyr2,D-Trp8,IAmp9]Cbm-SRIF	Investigative
T16633	DRUGINFO	D0R0OX	Des-AA1,5-[Tyr2,D-Trp8,(NalphaMe)IAmp9]SRIF	Investigative
T16633	DRUGINFO	D0Z0OF	Des-AA1,2,5-[D-Trp8,IAmp9,m-I-Tyr11]Cbm-SRIF	Investigative
T16633	DRUGINFO	D02NJV	Des-AA1,2,5,12,13-[D-Trp8,IAmp9]SRIF	Investigative
T16633	DRUGINFO	D0W0AF	Des-AA1,2,5-[D-Trp8,(NalphaMe)IAmp9]SRIF	Investigative
T16633	DRUGINFO	D02OJQ	Des-AA1,2,5-[D-Trp8,Tyr11]SRIF	Investigative
T16633	DRUGINFO	D04ORV	Des-AA1,2,5,12,13-[D-Trp8]SRIF	Investigative
T16633	DRUGINFO	D06WCI	SRIF-28	Investigative
T16633	DRUGINFO	D06WYG	99mTc-MIP-1407	Investigative
T16633	DRUGINFO	D09DAC	Des-AA1,2,4,12,13-[D-Trp8]SRIF	Investigative
T16633	DRUGINFO	D0B5AZ	Cytotoxin Peptide Conjugate	Investigative
T16633	DRUGINFO	D0C5RH	Des-AA1,2,4,13-[D-Trp8]SRIF	Investigative
T16633	DRUGINFO	D0H4WH	Des-AA5-[D-Trp8]SRIF	Investigative
T16633	DRUGINFO	D0J5OY	Des-AA1,2,4,5-[D-Trp8]SRIF	Investigative
T16633	DRUGINFO	D0P3WF	CGP 23996	Investigative
T16633	DRUGINFO	D0R7OD	SRIF-14	Investigative
T16633	DRUGINFO	D0Z3LZ	Des-AA1,2,4,5,13-[D-Trp8]-SRIF	Investigative
T16633	DRUGINFO	D0T5RO	SOMATOSTATIN	Investigative

T53024	TARGETID	T53024
T53024	FORMERID	TTDS00394
T53024	UNIPROID	SSR2_HUMAN
T53024	TARGNAME	Somatostatin receptor type 2 (SSTR2)
T53024	GENENAME	SSTR2
T53024	TARGTYPE	Successful
T53024	SYNONYMS	Sst(2); Somatostatin receptor 2; SS2R; SS2-R; SS-2-R; SRIF-1
T53024	FUNCTION	Receptor for somatostatin-14 and -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. In addition it stimulates phosphotyrosine phosphatase and PLC via pertussis toxin insensitive as well as sensitive G proteins. Inhibits calcium entry by suppressing voltage-dependent calcium channels. Acts as the functionally dominant somatostatin receptor in pancreatic alpha- and beta-cells where it mediates the inhibitory effect of somatostatin-14 on hormone secretion. Inhibits cell growth through enhancement of MAPK1 and MAPK2 phosphorylation and subsequent up-regulation of CDKN1B. Stimulates neuronal migration and axon outgrowth and may participate in neuron development and maturation during brain development. Mediates negative regulation of insulin receptor signaling through PTPN6. Inactivates SSTR3 receptor function following heterodimerization.
T53024	BIOCLASS	GPCR rhodopsin
T53024	SEQUENCE	MDMADEPLNGSHTWLSIPFDLNGSVVSTNTSNQTEPYYDLTSNAVLTFIYFVVCIIGLCGNTLVIYVILRYAKMKTITNIYILNLAIADELFMLGLPFLAMQVALVHWPFGKAICRVVMTVDGINQFTSIFCLTVMSIDRYLAVVHPIKSAKWRRPRTAKMITMAVWGVSLLVILPIMIYAGLRSNQWGRSSCTINWPGESGAWYTGFIIYTFILGFLVPLTIICLCYLFIIIKVKSSGIRVGSSKRKKSEKKVTRMVSIVVAVFIFCWLPFYIFNVSSVSMAISPTPALKGMFDFVVVLTYANSCANPILYAFLSDNFKKSFQNVLCLVKVSGTDDGERSDSKQDKSRLNETTETQRTLLNGDLQTSI
T53024	DRUGINFO	D02XIY	Octreotide	Approved
T53024	DRUGINFO	D0M2YE	Lanreotide acetate	Approved
T53024	DRUGINFO	D1HEN2	Ga-68-DOTATOC	Approved
T53024	DRUGINFO	D9E6KQ	Copper dotatate Cu-64	Approved
T53024	DRUGINFO	D0TV0C	Pasireotide	Approved
T53024	DRUGINFO	DHTL97	Paltusotine	Phase 3
T53024	DRUGINFO	D06JFI	ODT-8	Phase 3
T53024	DRUGINFO	D2L8NT	TBR-760	Phase 2
T53024	DRUGINFO	D0PX7X	Re-188-P-2045	Phase 1/2
T53024	DRUGINFO	D0Z4CY	PEN-221	Phase 1/2
T53024	DRUGINFO	D05EKM	FR-121196	Terminated
T53024	DRUGINFO	D00OSB	Ala7-SRIF-14-amide	Investigative
T53024	DRUGINFO	D02EWR	L-779,976	Investigative
T53024	DRUGINFO	D05CRG	L-054852	Investigative
T53024	DRUGINFO	D07WRP	L-054,522	Investigative
T53024	DRUGINFO	D0HY4Q	98mTc-CIM-ANT	Investigative
T53024	DRUGINFO	D0M5LA	Des-AA1,2,4,5,11,12,13-[D-Trp8]SRIF	Investigative
T53024	DRUGINFO	D0P6ZZ	H-c[Cys-Phe-DTrp-Lys-Thr-Cys]-OH	Investigative
T53024	DRUGINFO	D02IXC	D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH2	Investigative
T53024	DRUGINFO	D09EIG	Pyz6-D-Trp8-SRIF	Investigative
T53024	DRUGINFO	D0GN3M	Ala11-SRIF-14-amide	Investigative
T53024	DRUGINFO	D0K9TS	Pyz11-D-Trp8-SRIF	Investigative
T53024	DRUGINFO	D0O4GU	H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2	Investigative
T53024	DRUGINFO	D0WG0O	Des-AA1,2,4,5,6,12,13-[D-Trp8]SRIF	Investigative
T53024	DRUGINFO	D0Y1PT	Ala6-SRIF-14-amide	Investigative
T53024	DRUGINFO	D02CQW	H-D-Phe-c[Cys-Ala-D-Trp-Lys-Thr-Cys]-Thr-NH2	Investigative
T53024	DRUGINFO	D05COQ	H-DPhe-c[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-NH2	Investigative
T53024	DRUGINFO	D02OJQ	Des-AA1,2,5-[D-Trp8,Tyr11]SRIF	Investigative
T53024	DRUGINFO	D04ORV	Des-AA1,2,5,12,13-[D-Trp8]SRIF	Investigative
T53024	DRUGINFO	D06WCI	SRIF-28	Investigative
T53024	DRUGINFO	D06WYG	99mTc-MIP-1407	Investigative
T53024	DRUGINFO	D09DAC	Des-AA1,2,4,12,13-[D-Trp8]SRIF	Investigative
T53024	DRUGINFO	D0B5AZ	Cytotoxin Peptide Conjugate	Investigative
T53024	DRUGINFO	D0C5RH	Des-AA1,2,4,13-[D-Trp8]SRIF	Investigative
T53024	DRUGINFO	D0H4WH	Des-AA5-[D-Trp8]SRIF	Investigative
T53024	DRUGINFO	D0J5OY	Des-AA1,2,4,5-[D-Trp8]SRIF	Investigative
T53024	DRUGINFO	D0P3WF	CGP 23996	Investigative
T53024	DRUGINFO	D0R7OD	SRIF-14	Investigative
T53024	DRUGINFO	D0Z3LZ	Des-AA1,2,4,5,13-[D-Trp8]-SRIF	Investigative
T53024	DRUGINFO	D0T5RO	SOMATOSTATIN	Investigative

T12475	TARGETID	T12475
T12475	FORMERID	TTDS00273
T12475	UNIPROID	GNRHR_HUMAN
T12475	TARGNAME	Gonadotropin-releasing hormone receptor (GNRHR)
T12475	GENENAME	GNRHR
T12475	TARGTYPE	Successful
T12475	SYNONYMS	Hypothalamic gonadotropin-releasing hormone receptor; Gonadotrophin releasing hormone receptor; GnRH-R; GnRH receptor; GRHR
T12475	FUNCTION	Receptor for gonadotropin releasing hormone (GnRH) that mediates the action of GnRH to stimulate the secretion of the gonadotropic hormones luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This receptor mediates its action by association with G-proteins that activate a phosphatidylinositol-calcium second messenger system. Isoform 2 may act as an inhibitor of GnRH-R signaling.
T12475	BIOCLASS	GPCR rhodopsin
T12475	SEQUENCE	MANSASPEQNQNHCSAINNSIPLMQGNLPTLTLSGKIRVTVTFFLFLLSATFNASFLLKLQKWTQKKEKGKKLSRMKLLLKHLTLANLLETLIVMPLDGMWNITVQWYAGELLCKVLSYLKLFSMYAPAFMMVVISLDRSLAITRPLALKSNSKVGQSMVGLAWILSSVFAGPQLYIFRMIHLADSSGQTKVFSQCVTHCSFSQWWHQAFYNFFTFSCLFIIPLFIMLICNAKIIFTLTRVLHQDPHELQLNQSKNNIPRARLKTLKMTVAFATSFTVCWTPYYVLGIWYWFDPEMLNRLSDPVNHFFFLFAFLNPCFDPLIYGYFSL
T12475	DRUGINFO	D00RJJ	Ganirelix	Approved
T12475	DRUGINFO	D01AHO	Abarelix	Approved
T12475	DRUGINFO	D03QRS	Triptorelin	Approved
T12475	DRUGINFO	D04ASH	Leuprorelin acetate	Approved
T12475	DRUGINFO	D04ODH	Gonadorelin	Approved
T12475	DRUGINFO	D08WYM	Nafarelin	Approved
T12475	DRUGINFO	D09OLZ	Cetrorelix	Approved
T12475	DRUGINFO	D0F2WP	Relugolix	Approved
T12475	DRUGINFO	D0VG7Y	Elagolix sodium	Approved
T12475	DRUGINFO	D0Y7KH	Degarelix	Approved
T12475	DRUGINFO	D02HBB	AEZS-108	Phase 3
T12475	DRUGINFO	D0R9VC	GnRH	Phase 3
T12475	DRUGINFO	D0UI3T	Elagolix	Phase 3
T12475	DRUGINFO	D02ROU	ASP-1707	Phase 2
T12475	DRUGINFO	D08FKH	KLH-2109	Phase 2
T12475	DRUGINFO	D0F0UT	ACYLINE	Phase 2
T12475	DRUGINFO	D0S9BH	Ozarelix	Phase 2
T12475	DRUGINFO	D0S8HD	PEP-223/CoVaccine HT	Phase 1/2
T12475	DRUGINFO	D49LPT	VERU-100	Phase 1/2
T12475	DRUGINFO	D00VPV	TAK-013	Discontinued in Phase 2
T12475	DRUGINFO	D07RYX	Antide	Discontinued in Phase 2
T12475	DRUGINFO	D0Z5AC	Gonadimmune	Discontinued in Phase 2
T12475	DRUGINFO	D09MON	A-75998	Discontinued in Phase 1
T12475	DRUGINFO	D0B7PY	Prostate cancer vaccine	Discontinued in Phase 1
T12475	DRUGINFO	D0D3ZP	NBI-42902	Discontinued in Phase 1
T12475	DRUGINFO	D0S6AQ	Ramorelix	Discontinued in Phase 1
T12475	DRUGINFO	D02YIW	5-(N,N-hexamethylene)-amiloride	Preclinical
T12475	DRUGINFO	D01WJM	D-26344	Terminated
T12475	DRUGINFO	D0Y3ZX	D-21775	Terminated
T12475	DRUGINFO	D00HNG	furan-1	Investigative
T12475	DRUGINFO	D00JYL	[D-Ncy(isopropyl)7]acyline	Investigative
T12475	DRUGINFO	D00TSY	[D-Dap(CO-NH-OCH3)3]degarelix	Investigative
T12475	DRUGINFO	D01BUT	LXT-101	Investigative
T12475	DRUGINFO	D01DBW	[Ncy(isopropyl)7]acyline	Investigative
T12475	DRUGINFO	D01XHU	AN-207	Investigative
T12475	DRUGINFO	D02NCO	T-98475	Investigative
T12475	DRUGINFO	D03JDY	[Ncy(SO,methyl)4]acyline	Investigative
T12475	DRUGINFO	D03YHT	[Ncy(SO,methyl)10]acyline	Investigative
T12475	DRUGINFO	D04BVX	[D-Ncy(SO,methyl)10]acyline	Investigative
T12475	DRUGINFO	D04HPP	[D-Gln3,D-Ncy(isopropyl)7]acyline	Investigative
T12475	DRUGINFO	D04LMF	[125I]cetrorelix	Investigative
T12475	DRUGINFO	D04TDF	[4Aph(CO-NH-OCH3)5,D-4Aph(CO-NH-OCH3)6]degarelix	Investigative
T12475	DRUGINFO	D05ELQ	[Ncy(SO,isopropyl)7]acyline	Investigative
T12475	DRUGINFO	D05UTO	[D-Dap(CO-NH-OH)3]degarelix	Investigative
T12475	DRUGINFO	D05VEH	detirelix	Investigative
T12475	DRUGINFO	D07DPW	[D-Ncy(SO,isopropyl)7]acyline	Investigative
T12475	DRUGINFO	D07NBK	AZALINE B	Investigative
T12475	DRUGINFO	D07XFF	[4Aph(CO-NH-OH)5]degarelix	Investigative
T12475	DRUGINFO	D08JEK	Org-30850	Investigative
T12475	DRUGINFO	D08XDH	[4Aph(CO-(C2H4O)3-C2H4-NH-CO-NH-OCH3)5]degarelix	Investigative
T12475	DRUGINFO	D08XFR	AEZS-115	Investigative
T12475	DRUGINFO	D09UXO	[D-Dab(CO-NH-OCH3)3]degarelix	Investigative
T12475	DRUGINFO	D0B2PW	antarelix	Investigative
T12475	DRUGINFO	D0B4NU	PGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2	Investigative
T12475	DRUGINFO	D0B6LL	[4Aph(CO-NH-OCH3)5]degarelix	Investigative
T12475	DRUGINFO	D0C0HP	IN-3	Investigative
T12475	DRUGINFO	D0C2JJ	[D-4Aph(CO-NH-OCH3)6]degarelix	Investigative
T12475	DRUGINFO	D0G6IX	[D-Gln3,Ncy(SO,isopropyl)7]acyline	Investigative
T12475	DRUGINFO	D0I9JL	[Ncy(methyl)4]acyline	Investigative
T12475	DRUGINFO	D0K1AT	[D-Ncy(methyl)4]acyline	Investigative
T12475	DRUGINFO	D0K2MC	[D-Ncy(methyl)10] acyline	Investigative
T12475	DRUGINFO	D0K8AP	[4Aph(CO-NH-(C2H4O)2-C2H5)5]degarelix	Investigative
T12475	DRUGINFO	D0KA9Y	[Ncy(methyl)10]acyline	Investigative
T12475	DRUGINFO	D0L8WJ	[D-4Aph(CO-NH-OH)6]degarelix	Investigative
T12475	DRUGINFO	D0O5VA	PGlu-His-Trp-Ser-His-D-Tyr-Leu-Arg-Pro-Gly-NH2	Investigative
T12475	DRUGINFO	D0R9JG	[D-Dab(CO-NH-OH)3]degarelix	Investigative
T12475	DRUGINFO	D0RB5Z	[Ncy(2-naphthyl)1]acyline	Investigative
T12475	DRUGINFO	D0V6KF	LHRH	Investigative
T12475	DRUGINFO	D0W5JT	[D-Gln3,Ncy(isopropyl)7]acyline	Investigative
T12475	DRUGINFO	D0WG8L	[D-Gln3,D-Ncy(SO,isopropyl)7]acyline	Investigative
T12475	DRUGINFO	D0X1RZ	[D-4Aph(CO-NH-(C2H4O)2-C2H5)6]degarelix	Investigative
T12475	DRUGINFO	D0XL0H	[D-Gln3,D-Ncy(SO2,isopropyl)7]acyline	Investigative
T12475	DRUGINFO	D0Y1WD	[D-Ncy(2-naphthyl)1]acyline	Investigative
T12475	DRUGINFO	D0Y2NA	[D-Gln3,Ncy(SO2,isopropyl)7]acyline	Investigative
T12475	DRUGINFO	D0Z5TP	[D-Ncy(SO,methyl)4]acyline	Investigative
T12475	DRUGINFO	D0Z5WP	FD-1	Investigative
T12475	DRUGINFO	D0C7LY	WAY-207024	Investigative

T71390	TARGETID	T71390
T71390	FORMERID	TTDR01183
T71390	UNIPROID	S5A2_HUMAN
T71390	TARGNAME	Steroid 5-alpha-reductase 2 (SRD5A2)
T71390	GENENAME	SRD5A2
T71390	TARGTYPE	Successful
T71390	SYNONYMS	Type 2 steroid 5alpha-reductase (5alpha-R); SRD5A2; SR type 2; 5-alpha reductase 2; 5 alpha-SR2
T71390	FUNCTION	Converts testosterone (T) into 5-alpha- dihydrotestosterone (DHT) and progesterone or corticosterone into their corresponding 5-alpha-3-oxosteroids. It plays a central role in sexual differentiation and androgen physiology.
T71390	BIOCLASS	CH-CH donor oxidoreductase
T71390	ECNUMBER	EC 1.3.1.22
T71390	SEQUENCE	MQVQCQQSPVLAGSATLVALGALALYVAKPSGYGKHTESLKPAATRLPARAAWFLQELPSFAVPAGILARQPLSLFGPPGTVLLGLFCVHYFHRTFVYSLLNRGRPYPAILILRGTAFCTGNGVLQGYYLIYCAEYPDGWYTDIRFSLGVFLFILGMGINIHSDYILRQLRKPGEISYRIPQGGLFTYVSGANFLGEIIEWIGYALATWSLPALAFAFFSLCFLGLRAFHHHRFYLKMFEDYPKSRKALIPFIF
T71390	DRUGINFO	D08IWD	Finasteride	Approved
T71390	DRUGINFO	D04GZD	4-(4-phenoxybenzoyl)phenylacetic acid	Investigative
T71390	DRUGINFO	D04LXR	3-[4-(4-phenoxybenzoyl)phenyl]propanoic acid	Investigative
T71390	DRUGINFO	D05JGX	4-[4-(benzylamino)benzoyl]benzoic acid	Investigative
T71390	DRUGINFO	D09XLZ	4-[4-(benzoylamino)benzoyl]benzoic acid	Investigative
T71390	DRUGINFO	D0Z6BT	4-[3-(benzyloxy)benzoyl]benzoic acid	Investigative
T71390	DRUGINFO	D01AUS	4-[4-benzyloxy)benzoyl]benzoic acid	Investigative
T71390	DRUGINFO	D04AED	4-[4-(benzhydryloxy)benzoyl]benzoic acid	Investigative
T71390	DRUGINFO	D05XPT	(3-methyl-4-(4-phenoxybenzoyl)phenyl)acetic acid	Investigative
T71390	DRUGINFO	D07BHS	(3-fluoro-4-(4-phenoxybenzoyl)phenyl)acetic acid	Investigative
T71390	DRUGINFO	D07BQG	{4-[4-(4-bromophenoxy)benzoyl]phenyl}acetic acid	Investigative
T71390	DRUGINFO	D0Q4GH	(E)-3-(4-(4-phenoxybenzoyl)phenyl)acrylic acid	Investigative
T71390	DRUGINFO	D0VR9L	4,4'-dihydroxyoctafluoroazobenzene	Investigative
T71390	DRUGINFO	D0W6HB	4-(4-phenoxybenzoyl)benzoic acid	Investigative
T71390	DRUGINFO	D07OAC	GP515	Investigative
T71390	DRUGINFO	D07ZNR	2,3,5,6-Tetrafluoro-4-pentafluorophenylazo-phenol	Investigative

T25163	TARGETID	T25163
T25163	FORMERID	TTDS00533
T25163	UNIPROID	CPSM_HUMAN
T25163	TARGNAME	Carbamoyl-phosphate synthetase I (CPS1)
T25163	GENENAME	CPS1
T25163	TARGTYPE	Successful
T25163	SYNONYMS	Carbamoyl-phosphate synthase [ammonia], mitochondrial; CPSase I; CPS1
T25163	FUNCTION	Involved in the urea cycle of ureotelic animals where the enzyme plays an important role in removing excess ammonia from the cell.
T25163	PDBSTRUC	5OJO; 5DOU; 5DOT; 4UUB; 4UUA
T25163	BIOCLASS	Carbon-nitrogen ligase
T25163	ECNUMBER	EC 6.3.4.16
T25163	SEQUENCE	MTRILTAFKVVRTLKTGFGFTNVTAHQKWKFSRPGIRLLSVKAQTAHIVLEDGTKMKGYSFGHPSSVAGEVVFNTGLGGYPEAITDPAYKGQILTMANPIIGNGGAPDTTALDELGLSKYLESNGIKVSGLLVLDYSKDYNHWLATKSLGQWLQEEKVPAIYGVDTRMLTKIIRDKGTMLGKIEFEGQPVDFVDPNKQNLIAEVSTKDVKVYGKGNPTKVVAVDCGIKNNVIRLLVKRGAEVHLVPWNHDFTKMEYDGILIAGGPGNPALAEPLIQNVRKILESDRKEPLFGISTGNLITGLAAGAKTYKMSMANRGQNQPVLNITNKQAFITAQNHGYALDNTLPAGWKPLFVNVNDQTNEGIMHESKPFFAVQFHPEVTPGPIDTEYLFDSFFSLIKKGKATTITSVLPKPALVASRVEVSKVLILGSGGLSIGQAGEFDYSGSQAVKAMKEENVKTVLMNPNIASVQTNEVGLKQADTVYFLPITPQFVTEVIKAEQPDGLILGMGGQTALNCGVELFKRGVLKEYGVKVLGTSVESIMATEDRQLFSDKLNEINEKIAPSFAVESIEDALKAADTIGYPVMIRSAYALGGLGSGICPNRETLMDLSTKAFAMTNQILVEKSVTGWKEIEYEVVRDADDNCVTVCNMENVDAMGVHTGDSVVVAPAQTLSNAEFQMLRRTSINVVRHLGIVGECNIQFALHPTSMEYCIIEVNARLSRSSALASKATGYPLAFIAAKIALGIPLPEIKNVVSGKTSACFEPSLDYMVTKIPRWDLDRFHGTSSRIGSSMKSVGEVMAIGRTFEESFQKALRMCHPSIEGFTPRLPMNKEWPSNLDLRKELSEPSSTRIYAIAKAIDDNMSLDEIEKLTYIDKWFLYKMRDILNMEKTLKGLNSESMTEETLKRAKEIGFSDKQISKCLGLTEAQTRELRLKKNIHPWVKQIDTLAAEYPSVTNYLYVTYNGQEHDVNFDDHGMMVLGCGPYHIGSSVEFDWCAVSSIRTLRQLGKKTVVVNCNPETVSTDFDECDKLYFEELSLERILDIYHQEACGGCIISVGGQIPNNLAVPLYKNGVKIMGTSPLQIDRAEDRSIFSAVLDELKVAQAPWKAVNTLNEALEFAKSVDYPCLLRPSYVLSGSAMNVVFSEDEMKKFLEEATRVSQEHPVVLTKFVEGAREVEMDAVGKDGRVISHAISEHVEDAGVHSGDATLMLPTQTISQGAIEKVKDATRKIAKAFAISGPFNVQFLVKGNDVLVIECNLRASRSFPFVSKTLGVDFIDVATKVMIGENVDEKHLPTLDHPIIPADYVAIKAPMFSWPRLRDADPILRCEMASTGEVACFGEGIHTAFLKAMLSTGFKIPQKGILIGIQQSFRPRFLGVAEQLHNEGFKLFATEATSDWLNANNVPATPVAWPSQEGQNPSLSSIRKLIRDGSIDLVINLPNNNTKFVHDNYVIRRTAVDSGIPLLTNFQVTKLFAEAVQKSRKVDSKSLFHYRQYSAGKAA
T25163	DRUGINFO	D0LW9U	Polidocanol - BioForm Medical/Chemische Fabrik Kreussler & Co	Approved
T25163	DRUGINFO	D0Z0MG	Carglumic acid	Approved

T13644	TARGETID	T13644
T13644	FORMERID	TTDC00254
T13644	UNIPROID	SSR3_HUMAN
T13644	TARGNAME	Somatostatin receptor type 3 (SSTR3)
T13644	GENENAME	SSTR3
T13644	TARGTYPE	Successful
T13644	SYNONYMS	SSTR3; SSR-28; SS3R
T13644	FUNCTION	Receptor for somatostatin-14 and -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase.
T13644	BIOCLASS	GPCR rhodopsin
T13644	SEQUENCE	MDMLHPSSVSTTSEPENASSAWPPDATLGNVSAGPSPAGLAVSGVLIPLVYLVVCVVGLLGNSLVIYVVLRHTASPSVTNVYILNLALADELFMLGLPFLAAQNALSYWPFGSLMCRLVMAVDGINQFTSIFCLTVMSVDRYLAVVHPTRSARWRTAPVARTVSAAVWVASAVVVLPVVVFSGVPRGMSTCHMQWPEPAAAWRAGFIIYTAALGFFGPLLVICLCYLLIVVKVRSAGRRVWAPSCQRRRRSERRVTRMVVAVVALFVLCWMPFYVLNIVNVVCPLPEEPAFFGLYFLVVALPYANSCANPILYGFLSYRFKQGFRRVLLRPSRRVRSQEPTVGPPEKTEEEDEEEEDGEESREGGKGKEMNGRVSQITQPGTSGQERPPSRVASKEQQLLPQEASTGEKSSTMRISYL
T13644	DRUGINFO	D0TV0C	Pasireotide	Approved
T13644	DRUGINFO	D06JFI	ODT-8	Phase 3
T13644	DRUGINFO	D05EKM	FR-121196	Terminated
T13644	DRUGINFO	D01BWV	BN-81,644	Investigative
T13644	DRUGINFO	D02MLI	NVP ACQ090	Investigative
T13644	DRUGINFO	D05JKQ	L-796,778	Investigative
T13644	DRUGINFO	D05JMJ	BN-81,674	Investigative
T13644	DRUGINFO	D02WOX	Des-AA1,2,5-[D-Trp8,IAmp9]SRIF CH-275	Investigative
T13644	DRUGINFO	D04FPW	Des-AA1,4,5,13-[Tyr2,D-Trp8]-SRIF	Investigative
T13644	DRUGINFO	D0H0DC	Des-AA1,2,4,5,10,12,13-[D-Trp8]SRIF	Investigative
T13644	DRUGINFO	D0N2MA	Des-AA1,5-[Tyr2,D-Trp8,IAmp9]Cbm-SRIF	Investigative
T13644	DRUGINFO	D0Z0OF	Des-AA1,2,5-[D-Trp8,IAmp9,m-I-Tyr11]Cbm-SRIF	Investigative
T13644	DRUGINFO	D02CQW	H-D-Phe-c[Cys-Ala-D-Trp-Lys-Thr-Cys]-Thr-NH2	Investigative
T13644	DRUGINFO	D02NJV	Des-AA1,2,5,12,13-[D-Trp8,IAmp9]SRIF	Investigative
T13644	DRUGINFO	D05COQ	H-DPhe-c[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-NH2	Investigative
T13644	DRUGINFO	D0W0AF	Des-AA1,2,5-[D-Trp8,(NalphaMe)IAmp9]SRIF	Investigative
T13644	DRUGINFO	D02OJQ	Des-AA1,2,5-[D-Trp8,Tyr11]SRIF	Investigative
T13644	DRUGINFO	D04ORV	Des-AA1,2,5,12,13-[D-Trp8]SRIF	Investigative
T13644	DRUGINFO	D06WCI	SRIF-28	Investigative
T13644	DRUGINFO	D06WYG	99mTc-MIP-1407	Investigative
T13644	DRUGINFO	D09DAC	Des-AA1,2,4,12,13-[D-Trp8]SRIF	Investigative
T13644	DRUGINFO	D0B5AZ	Cytotoxin Peptide Conjugate	Investigative
T13644	DRUGINFO	D0C5RH	Des-AA1,2,4,13-[D-Trp8]SRIF	Investigative
T13644	DRUGINFO	D0H4WH	Des-AA5-[D-Trp8]SRIF	Investigative
T13644	DRUGINFO	D0J5OY	Des-AA1,2,4,5-[D-Trp8]SRIF	Investigative
T13644	DRUGINFO	D0P3WF	CGP 23996	Investigative
T13644	DRUGINFO	D0R7OD	SRIF-14	Investigative
T13644	DRUGINFO	D0Z3LZ	Des-AA1,2,4,5,13-[D-Trp8]-SRIF	Investigative
T13644	DRUGINFO	D0T5RO	SOMATOSTATIN	Investigative

T58238	TARGETID	T58238
T58238	FORMERID	TTDS00453
T58238	UNIPROID	CD80_HUMAN
T58238	TARGNAME	Activation B7-1 antigen (CD80)
T58238	GENENAME	CD80
T58238	TARGTYPE	Successful
T58238	SYNONYMS	T-lymphocyte activation antigen CD80; LAB7; CTLA-4 counter-receptor B7.1; CD28LG1; CD28LG; BB1; B7
T58238	FUNCTION	T-cell proliferation and cytokine production is induced by the binding of CD28, binding to CTLA-4 has opposite effects and inhibits T-cell activation. Involved in the costimulatory signal essential for T-lymphocyte activation.
T58238	PDBSTRUC	1I8L; 1DR9
T58238	SEQUENCE	MGHTRRQGTSPSKCPYLNFFQLLVLAGLSHFCSGVIHVTKEVKEVATLSCGHNVSVEELAQTRIYWQKEKKMVLTMMSGDMNIWPEYKNRTIFDITNNLSIVILALRPSDEGTYECVVLKYEKDAFKREHLAEVTLSVKADFPTPSISDFEIPTSNIRRIICSTSGGFPEPHLSWLENGEELNAINTTVSQDPETELYAVSSKLDFNMTTNHSFMCLIKYGHLRVNQTFNWNTTKQEHFPDNLLPSWAITLISVNGIFVICCLTYCFAPRCRERRRNERLRRESVRPV
T58238	DRUGINFO	D0EW4L	Abatacept	Approved
T58238	DRUGINFO	D0J0KT	RhuDex	Phase 2a
T58238	DRUGINFO	D0P2SI	Galiximab	Phase 2
T58238	DRUGINFO	D0F3EO	HS-110	Phase 2
T58238	DRUGINFO	D0T6KI	CAR-T cells targeting CD80/86	Phase 1
T58238	DRUGINFO	D0T2EO	MAXY-4	Phase 1
T58238	DRUGINFO	D0V4PH	Tolerimab	Terminated

T23292	TARGETID	T23292
T23292	FORMERID	TTDI02272
T23292	UNIPROID	GALNS_HUMAN
T23292	TARGNAME	N-acetylgalactosamine 6 sulfatase (GALNS)
T23292	GENENAME	GALNS
T23292	TARGTYPE	Successful
T23292	SYNONYMS	N-acetylgalactosamine-6-sulfate sulfatase; N-acetylgalactosamine-6-sulfatase; Galactose-6-sulfate sulfatase; GalNAc6S sulfatase; GalN6S; Chondroitinsulfatase; Chondroitinase
T23292	FUNCTION	Catalyzes the chemical reaction of cleaving off the 6-sulfate groups of the N-acetyl-D-galactosamine 6-sulfate units of the macromolecule chondroitin sulfate and, similarly, of the D-galactose 6-sulfate units of the macromolecule keratan sulfate.
T23292	PDBSTRUC	4FDJ; 4FDI
T23292	BIOCLASS	Sulfuric ester hydrolase
T23292	ECNUMBER	EC 3.1.6.4
T23292	SEQUENCE	MAAVVAATRWWQLLLVLSAAGMGASGAPQPPNILLLLMDDMGWGDLGVYGEPSRETPNLDRMAAEGLLFPNFYSANPLCSPSRAALLTGRLPIRNGFYTTNAHARNAYTPQEIVGGIPDSEQLLPELLKKAGYVSKIVGKWHLGHRPQFHPLKHGFDEWFGSPNCHFGPYDNKARPNIPVYRDWEMVGRYYEEFPINLKTGEANLTQIYLQEALDFIKRQARHHPFFLYWAVDATHAPVYASKPFLGTSQRGRYGDAVREIDDSIGKILELLQDLHVADNTFVFFTSDNGAALISAPEQGGSNGPFLCGKQTTFEGGMREPALAWWPGHVTAGQVSHQLGSIMDLFTTSLALAGLTPPSDRAIDGLNLLPTLLQGRLMDRPIFYYRGDTLMAATLGQHKAHFWTWTNSWENFRQGIDFCPGQNVSGVTTHNLEDHTKLPLIFHLGRDPGERFPLSFASAEYQEALSRITSVVQQHQEALVPAQPQLNVCNWAVMNWAPPGCEKLGKCLTPPESIPKKCLWSH
T23292	DRUGINFO	D0J1UA	Elosulfase alfa	Approved
T23292	DRUGINFO	D0OQ9V	BMN-110	Phase 3

T64830	TARGETID	T64830
T64830	FORMERID	TTDC00253
T64830	UNIPROID	SSR5_HUMAN
T64830	TARGNAME	Somatostatin receptor type 5 (SSTR5)
T64830	GENENAME	SSTR5
T64830	TARGTYPE	Successful
T64830	SYNONYMS	Somatostatin receptor 5; SSTR5; SS5R
T64830	FUNCTION	Receptor for somatostatin 28 and to a lesser extent for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. Increases cell growth inhibition activity of SSTR2 following heterodimerization.
T64830	BIOCLASS	GPCR rhodopsin
T64830	SEQUENCE	MEPLFPASTPSWNASSPGAASGGGDNRTLVGPAPSAGARAVLVPVLYLLVCAAGLGGNTLVIYVVLRFAKMKTVTNIYILNLAVADVLYMLGLPFLATQNAASFWPFGPVLCRLVMTLDGVNQFTSVFCLTVMSVDRYLAVVHPLSSARWRRPRVAKLASAAAWVLSLCMSLPLLVFADVQEGGTCNASWPEPVGLWGAVFIIYTAVLGFFAPLLVICLCYLLIVVKVRAAGVRVGCVRRRSERKVTRMVLVVVLVFAGCWLPFFTVNIVNLAVALPQEPASAGLYFFVVILSYANSCANPVLYGFLSDNFRQSFQKVLCLRKGSGAKDADATEPRPDRIRQQQEATPPAHRAAANGLMQTSKL
T64830	DRUGINFO	D0TV0C	Pasireotide	Approved
T64830	DRUGINFO	D06JFI	ODT-8	Phase 3
T64830	DRUGINFO	D05EKM	FR-121196	Terminated
T64830	DRUGINFO	D0H6LR	PTR-3046	Investigative
T64830	DRUGINFO	D02IXC	D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH2	Investigative
T64830	DRUGINFO	D05PKR	L-817,818	Investigative
T64830	DRUGINFO	D0O4GU	H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2	Investigative
T64830	DRUGINFO	D02CQW	H-D-Phe-c[Cys-Ala-D-Trp-Lys-Thr-Cys]-Thr-NH2	Investigative
T64830	DRUGINFO	D05COQ	H-DPhe-c[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-NH2	Investigative
T64830	DRUGINFO	D02OJQ	Des-AA1,2,5-[D-Trp8,Tyr11]SRIF	Investigative
T64830	DRUGINFO	D04ORV	Des-AA1,2,5,12,13-[D-Trp8]SRIF	Investigative
T64830	DRUGINFO	D06WCI	SRIF-28	Investigative
T64830	DRUGINFO	D06WYG	99mTc-MIP-1407	Investigative
T64830	DRUGINFO	D09DAC	Des-AA1,2,4,12,13-[D-Trp8]SRIF	Investigative
T64830	DRUGINFO	D0B5AZ	Cytotoxin Peptide Conjugate	Investigative
T64830	DRUGINFO	D0C5RH	Des-AA1,2,4,13-[D-Trp8]SRIF	Investigative
T64830	DRUGINFO	D0H4WH	Des-AA5-[D-Trp8]SRIF	Investigative
T64830	DRUGINFO	D0J5OY	Des-AA1,2,4,5-[D-Trp8]SRIF	Investigative
T64830	DRUGINFO	D0P3WF	CGP 23996	Investigative
T64830	DRUGINFO	D0R7OD	SRIF-14	Investigative
T64830	DRUGINFO	D0Z3LZ	Des-AA1,2,4,5,13-[D-Trp8]-SRIF	Investigative
T64830	DRUGINFO	D0T5RO	SOMATOSTATIN	Investigative

T92609	TARGETID	T92609
T92609	FORMERID	TTDC00292
T92609	UNIPROID	ADA1A_HUMAN
T92609	TARGNAME	Adrenergic receptor alpha-1A (ADRA1A)
T92609	GENENAME	ADRA1A
T92609	TARGTYPE	Successful
T92609	SYNONYMS	Alpha-adrenergic receptor 1c; Alpha-1C adrenergic receptor; Alpha-1A adrenoreceptor; Alpha-1A adrenoceptor; Alpha-1A adrenergic receptor; Alpha adrenergic receptor 1c; Alpha 1A-adrenoreceptor; Alpha 1A-adrenoceptor; ADRA1C
T92609	FUNCTION	Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes. This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
T92609	BIOCLASS	GPCR rhodopsin
T92609	SEQUENCE	MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILSVACHRHLHSVTHYYIVNLAVADLLLTSTVLPFSAIFEVLGYWAFGRVFCNIWAAVDVLCCTASIMGLCIISIDRYIGVSYPLRYPTIVTQRRGLMALLCVWALSLVISIGPLFGWRQPAPEDETICQINEEPGYVLFSALGSFYLPLAIILVMYCRVYVVAKRESRGLKSGLKTDKSDSEQVTLRIHRKNAPAGGSGMASAKTKTHFSVRLLKFSREKKAAKTLGIVVGCFVLCWLPFFLVMPIGSFFPDFKPSETVFKIVFWLGYLNSCINPIIYPCSSQEFKKAFQNVLRIQCLCRKQSSKHALGYTLHPPSQAVEGQHKDMVRIPVGSRETFYRISKTDGVCEWKFFSSMPRGSARITVSKDQSSCTTARVRSKSFLQVCCCVGPSTPSLDKNHQVPTIKVHTISLSENGEEV
T92609	DRUGINFO	D04DKH	NAFTOPIDIL	Approved
T92609	DRUGINFO	D05MBZ	Tamsulosin	Approved
T92609	DRUGINFO	D0H1YQ	Xatral	Approved
T92609	DRUGINFO	D0U0VU	SILODOSIN	Approved
T92609	DRUGINFO	D0C6QQ	Besipirdine	Phase 3
T92609	DRUGINFO	D09JFY	Dutasteride + tamsulosin	Phase 3
T92609	DRUGINFO	D0F2ML	MEDETOMIDINE	Phase 2
T92609	DRUGINFO	D0SG8X	PMID30124346-Compound-LDT66	Patented
T92609	DRUGINFO	D0EO8F	PMID30124346-Compound-LDT8	Patented
T92609	DRUGINFO	D03ITI	Sunepitron	Discontinued in Phase 3
T92609	DRUGINFO	D01RCS	TIOSPIRONE	Discontinued in Phase 3
T92609	DRUGINFO	D0LL9K	L-771688	Discontinued in Phase 2
T92609	DRUGINFO	D0S1PM	RBx-2258	Discontinued in Phase 2
T92609	DRUGINFO	D0V9HH	Taprizosin	Discontinued in Phase 2
T92609	DRUGINFO	D0P9FT	REC-15-2739	Discontinued in Phase 2
T92609	DRUGINFO	D08OJU	SOU-001	Discontinued in Phase 2
T92609	DRUGINFO	D01WJZ	MAZAPERTINE	Discontinued in Phase 2
T92609	DRUGINFO	D0C3CF	SDZ-NVI-085	Discontinued in Phase 1
T92609	DRUGINFO	D0Z2UD	RS-100975	Discontinued in Phase 1
T92609	DRUGINFO	D02CJA	CM-2236	Preclinical
T92609	DRUGINFO	D04XCQ	SNAP-6201	Terminated
T92609	DRUGINFO	D09YUS	KRG-3332	Terminated
T92609	DRUGINFO	D0L5TJ	A-131701	Terminated
T92609	DRUGINFO	D0M4HC	L-757464	Terminated
T92609	DRUGINFO	D0O7DB	A-204176	Terminated
T92609	DRUGINFO	D0BC6Q	AGN-193080	Terminated
T92609	DRUGINFO	D0N7LZ	SK&F-104856	Terminated
T92609	DRUGINFO	D0U3HP	ABANOQUIL	Terminated
T92609	DRUGINFO	D0XK2K	Siramesine	Terminated
T92609	DRUGINFO	D00KZF	BMY-7378	Terminated
T92609	DRUGINFO	D05IML	NIGULDIPINE	Terminated
T92609	DRUGINFO	D08OWQ	SK&F-104078	Terminated
T92609	DRUGINFO	D03QMR	WB-4101	Terminated
T92609	DRUGINFO	D06HRY	SNAP-5089	Terminated
T92609	DRUGINFO	D00MCY	REC2615	Investigative
T92609	DRUGINFO	D01BJZ	SNAP-5036	Investigative
T92609	DRUGINFO	D09ZUW	L-765314	Investigative
T92609	DRUGINFO	D0A0JU	A-315456	Investigative
T92609	DRUGINFO	D0D8GV	SNAP-7915	Investigative
T92609	DRUGINFO	D0N0SN	RWJ-68141	Investigative
T92609	DRUGINFO	D0O6MG	RS-100329	Investigative
T92609	DRUGINFO	D0R4MH	RS-513815	Investigative
T92609	DRUGINFO	D0V8XD	(-)-SNAP-5399	Investigative
T92609	DRUGINFO	D0XL9J	Ro-11-04253	Investigative
T92609	DRUGINFO	D0Z1PA	GG-818	Investigative
T92609	DRUGINFO	D00RLE	4-(4-chlorobenzyl)-2-methylphthalazin-1(2H)-one	Investigative
T92609	DRUGINFO	D0C7SE	SNAP-94847	Investigative
T92609	DRUGINFO	D0E5CI	8-Piperazin-1-yl-imidazo[1,2-a]pyrazine	Investigative
T92609	DRUGINFO	D0EO4F	A-123189	Investigative
T92609	DRUGINFO	D0J9ZF	4-benzyl-2-methylphthalazin-1(2H)-one	Investigative
T92609	DRUGINFO	D0JC4Q	4-(4-chlorobenzyl)-2-allylphthalazin-1(2H)-one	Investigative
T92609	DRUGINFO	D0P4KF	2-(4-tert-Butyl-phenyl)-4,5-dihydro-1H-imidazole	Investigative
T92609	DRUGINFO	D0Q2SI	4-(4-chlorobenzyl)phthalazin-1(2H)-one	Investigative
T92609	DRUGINFO	D0Q7ZR	A-119637	Investigative
T92609	DRUGINFO	D0R2YM	5-Bromo-8-piperazin-1-yl-imidazo[1,2-a]pyrazine	Investigative
T92609	DRUGINFO	D0Z8OD	RWJ-38063	Investigative
T92609	DRUGINFO	D02TQC	N-(5-Bromo-quinoxalin-6-yl)-guanidine	Investigative
T92609	DRUGINFO	D06QKD	4-(4-Isopropyl-morpholin-2-yl)-benzene-1,2-diol	Investigative
T92609	DRUGINFO	D06UBB	SK&F-86466	Investigative
T92609	DRUGINFO	D07QCC	SK&F-106686	Investigative
T92609	DRUGINFO	D07XDL	4-(1-Naphthalen-1-yl-vinyl)-1H-imidazole	Investigative
T92609	DRUGINFO	D08XTL	RWJ-69736	Investigative
T92609	DRUGINFO	D09NXU	4-(2,3-Dihydro-1H-phenalen-1-yl)-1H-imidazole	Investigative
T92609	DRUGINFO	D09PIF	Imidazolidin-2-ylidene-o-tolyl-amine	Investigative
T92609	DRUGINFO	D0E9VU	LEVONORDEFRIN	Investigative
T92609	DRUGINFO	D0F3AR	4-((Z)-1-Naphthalen-1-yl-propenyl)-1H-imidazole	Investigative
T92609	DRUGINFO	D0H3CW	SK&F-105854	Investigative
T92609	DRUGINFO	D0L6JS	AGN-192172	Investigative
T92609	DRUGINFO	D0N7UE	Imidazolidin-2-ylidene-quinoxalin-6-yl-amine	Investigative
T92609	DRUGINFO	D0O9HS	1-(2-Chloro-phenyl)-piperazine	Investigative
T92609	DRUGINFO	D0Q4PY	RWJ-68157	Investigative
T92609	DRUGINFO	D0RX6I	4-((E)-1-Naphthalen-1-yl-propenyl)-1H-imidazole	Investigative
T92609	DRUGINFO	D0S1GH	4-Morpholin-2-yl-benzene-1,2-diol	Investigative
T92609	DRUGINFO	D0T5KJ	4-(3-Hydroxy-piperidin-3-yl)-benzene-1,2-diol	Investigative
T92609	DRUGINFO	D0ZP5X	4-(1-Naphthalen-1-yl-propyl)-1H-imidazole	Investigative
T92609	DRUGINFO	D02NNS	SNAP-8719	Investigative
T92609	DRUGINFO	D08UDY	1',2',3',6'-Tetrahydro-[2,4']bipyridinyl	Investigative
T92609	DRUGINFO	D09CKI	CORYNANTHEINE	Investigative
T92609	DRUGINFO	D0MH0S	1-(3-Fluoro-pyridin-2-yl)-4-methyl-piperazine	Investigative
T92609	DRUGINFO	D01TOU	FLUANISONE	Investigative
T92609	DRUGINFO	D06HHJ	(2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine	Investigative
T92609	DRUGINFO	D06ROA	UH-301	Investigative
T92609	DRUGINFO	D07JMN	1-(pyridin-2-yl)piperazine	Investigative
T92609	DRUGINFO	D0A6GK	(2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine	Investigative
T92609	DRUGINFO	D0B4DP	2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline	Investigative
T92609	DRUGINFO	D0H3NA	4-Benzo[b]thiophen-4-yl-1H-imidazole	Investigative
T92609	DRUGINFO	D0K9NW	4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline	Investigative
T92609	DRUGINFO	D08KLH	[3H]RX821002	Investigative
T92609	DRUGINFO	D0L9WN	4-(4-Methyl-indan-1-yl)-1H-imidazole	Investigative
T92609	DRUGINFO	D0P5PW	4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole	Investigative
T92609	DRUGINFO	D0D3YN	OCTOCLOTHEPIN	Investigative
T92609	DRUGINFO	D0V4RP	1-(2-Methoxy-phenyl)-piperazine	Investigative
T92609	DRUGINFO	D05EQG	[3H]spiperone	Investigative
T92609	DRUGINFO	D0R7ZC	Beta-methoxyamphetamine	Investigative
T92609	DRUGINFO	D0PN9R	R-226161	Investigative
T92609	DRUGINFO	D0P0IX	ISOCLOZAPINE	Investigative
T92609	DRUGINFO	D0L5MW	(+/-)-nantenine	Investigative
T92609	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T66665	TARGETID	T66665
T66665	UNIPROID	PGH2_HUMAN
T66665	TARGNAME	Prostaglandin G/H synthase 2 (COX-2)
T66665	GENENAME	PTGS2
T66665	TARGTYPE	Successful
T66665	SYNONYMS	Prostaglandin-endoperoxide synthase 2; Prostaglandin H2 synthase 2; PHS II; PGHS-2; PGH synthase 2; Cyclooxygenase-2; COX2; COX-2
T66665	FUNCTION	Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, phenotypic changes, resistance to apoptosis and tumor angiogenesis. In cancer cells, PTGS2 is a key step in the production of prostaglandin E2 (PGE2), which plays important roles in modulating motility, proliferation and resistance to apoptosis. During neuroinflammation, plays a role in neuronal secretion of specialized preresolving mediators (SPMs), especially 15-R-lipoxin A4, that regulates phagocytic microglia (By similarity).
T66665	PDBSTRUC	5KIR; 5IKV; 5IKT; 5IKR; 5IKQ
T66665	BIOCLASS	Paired donor oxygen oxidoreductase
T66665	ECNUMBER	EC 1.14.99.1
T66665	SEQUENCE	MLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFLTRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADYGYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGSNMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKYQIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCDVLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQNRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRVAGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEALYGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEVGFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKERSTEL
T66665	DRUGINFO	D00HGB	Niflumic Acid	Approved
T66665	DRUGINFO	D03RTS	Celecoxib	Approved
T66665	DRUGINFO	D04YMH	Lumiracoxib	Approved
T66665	DRUGINFO	D05CKR	Nabumetone	Approved
T66665	DRUGINFO	D05FTJ	Mefenamic acid	Approved
T66665	DRUGINFO	D05VLS	Rofecoxib	Approved
T66665	DRUGINFO	D07VHR	Phenylbutazone	Approved
T66665	DRUGINFO	D08LFZ	Diflunisal	Approved
T66665	DRUGINFO	D09BHB	Tolmetin	Approved
T66665	DRUGINFO	D09MGR	Etoricoxib	Approved
T66665	DRUGINFO	D0A1PX	Flurbiprofen	Approved
T66665	DRUGINFO	D0G7FJ	Meloxicam	Approved
T66665	DRUGINFO	D0I6IB	Tenoxicam	Approved
T66665	DRUGINFO	D0IT2X	Carprofen	Approved
T66665	DRUGINFO	D0L6DA	Valdecoxib	Approved
T66665	DRUGINFO	D0N1WU	Etodolac	Approved
T66665	DRUGINFO	D0R1RS	Indomethacin	Approved
T66665	DRUGINFO	D0S7VO	Tiaprofenic acid	Approved
T66665	DRUGINFO	D0W9WF	Ketoprofen	Approved
T66665	DRUGINFO	D06LHG	FENBUFEN	Approved
T66665	DRUGINFO	D0DJ1B	Naproxen	Approved
T66665	DRUGINFO	D0MN9K	Meclofenamate Sodium	Approved
T66665	DRUGINFO	D0Q5XX	Eicosapentaenoic acid/docosa-hexaenoic acid	Approved
T66665	DRUGINFO	D01WJL	Aminosalicylic Acid	Approved
T66665	DRUGINFO	D0B2WJ	Flufenamic Acid	Approved
T66665	DRUGINFO	D0R1QE	Ibuprofen	Approved
T66665	DRUGINFO	D0AL8M	IMRECOXIB	Phase 4
T66665	DRUGINFO	D0G2IC	(S)-FLURBIPROFEN	Preregistration
T66665	DRUGINFO	D0C4DZ	ThermoProfen	Phase 3
T66665	DRUGINFO	D0W2CX	CG-100649	Phase 3
T66665	DRUGINFO	D07SDQ	Curcumin	Phase 3
T66665	DRUGINFO	D0AL8T	Darbufelone	Phase 2/3
T66665	DRUGINFO	D02DYU	SC-75416	Phase 2
T66665	DRUGINFO	D0U8OD	CIMICOXIB	Phase 2
T66665	DRUGINFO	D0Z9YW	FK-3311	Phase 2
T66665	DRUGINFO	D06OZJ	RWJ-67657	Phase 1
T66665	DRUGINFO	DTYP21	CA102N	Phase 1
T66665	DRUGINFO	D0JE1M	PMID29130358-Compound-LonimacranthoideVI	Patented
T66665	DRUGINFO	D0S8TB	Carbamate derivative 2	Patented
T66665	DRUGINFO	D0Q5PL	INDOPROFEN	Withdrawn from market
T66665	DRUGINFO	D00RSK	GW-406381	Discontinued in Phase 3
T66665	DRUGINFO	D0V7HI	PRINOMIDE TROMETHAMINE	Discontinued in Phase 3
T66665	DRUGINFO	D0I9LH	PMI-001	Discontinued in Phase 3
T66665	DRUGINFO	D02HLL	RQ-00317076	Discontinued in Phase 2
T66665	DRUGINFO	D04DUJ	S-2474	Discontinued in Phase 2
T66665	DRUGINFO	D05HVY	GSK-644784	Discontinued in Phase 2
T66665	DRUGINFO	D0S7IZ	Apricoxib	Discontinued in Phase 2
T66665	DRUGINFO	D0Z5LZ	Tilmacoxib	Discontinued in Phase 2
T66665	DRUGINFO	D0BZ1Q	CRx-401	Discontinued in Phase 2
T66665	DRUGINFO	D0P3KA	TEBUFELONE	Discontinued in Phase 2
T66665	DRUGINFO	D0ZL4F	R-ketoprofen	Discontinued in Phase 2
T66665	DRUGINFO	D02OHR	SC-57666	Discontinued in Phase 1
T66665	DRUGINFO	D07RUC	E-6087	Discontinued in Phase 1
T66665	DRUGINFO	D08GRY	DUP 697	Discontinued in Phase 1
T66665	DRUGINFO	D0C2HF	GR-253035	Discontinued in Phase 1
T66665	DRUGINFO	D01QRG	RPR 200765A	Terminated
T66665	DRUGINFO	D02KQE	ON-09300	Terminated
T66665	DRUGINFO	D03NZV	SC-236	Terminated
T66665	DRUGINFO	D05EYG	L-745337	Terminated
T66665	DRUGINFO	D05REH	Flosulide	Terminated
T66665	DRUGINFO	D07TZM	SC-58125	Terminated
T66665	DRUGINFO	D09BKE	NS398	Terminated
T66665	DRUGINFO	D0B0TO	L-768277	Terminated
T66665	DRUGINFO	D0DR3I	S-33516	Terminated
T66665	DRUGINFO	D0R5TT	FR-123826	Terminated
T66665	DRUGINFO	D0Z5OJ	NMI-150	Terminated
T66665	DRUGINFO	D03AKL	ATLIPROFEN METHYL ESTER	Terminated
T66665	DRUGINFO	D08JKK	RWJ-63556	Terminated
T66665	DRUGINFO	D0O9JX	SC-58451	Terminated
T66665	DRUGINFO	D0C0JT	Nimesulide	Terminated
T66665	DRUGINFO	D0F8DL	SB 203580	Terminated
T66665	DRUGINFO	D00LWQ	3-Bromo-2'-hydroxy-4-methoxychalcone	Investigative
T66665	DRUGINFO	D00TKO	1-(4-(methylsulfonyl)phenyl)-1H-pyrrole	Investigative
T66665	DRUGINFO	D01MFK	DFU	Investigative
T66665	DRUGINFO	D01SNR	Firocoxib	Investigative
T66665	DRUGINFO	D02FEF	4-(3-methoxy-benzylideneamino)-benzenesulfonamide	Investigative
T66665	DRUGINFO	D02FYN	(E)-4-(2-(furan-2-yl)vinyl)benzenesulfonamide	Investigative
T66665	DRUGINFO	D02IPX	Prostaglandin G2	Investigative
T66665	DRUGINFO	D02VXW	(E)-4-(2-(thiophen-2-yl)vinyl)benzenesulfonamide	Investigative
T66665	DRUGINFO	D03ETD	Nectamazin C	Investigative
T66665	DRUGINFO	D03FXI	4-(4-nitro-benzylideneamino)-benzenesulfonamide	Investigative
T66665	DRUGINFO	D03GHR	C-myb	Investigative
T66665	DRUGINFO	D03KSL	L-761000	Investigative
T66665	DRUGINFO	D03XZJ	(E)-3-(4-(methylsulfonyl)styryl)thiophene	Investigative
T66665	DRUGINFO	D04IXJ	Bimetopyrole	Investigative
T66665	DRUGINFO	D05JRZ	NSC-27236	Investigative
T66665	DRUGINFO	D05UPM	4-benzyloxy-2'-hydroxychalcone	Investigative
T66665	DRUGINFO	D05ZDQ	1-(2-hydroxyphenyl)-3-p-tolylprop-2-en-1-one	Investigative
T66665	DRUGINFO	D06BHC	4-amino-N-(4-iodophenyl)benzenesulfonamide	Investigative
T66665	DRUGINFO	D06JCT	5-thia-8,11,14,17-eicosatetraenoic acid	Investigative
T66665	DRUGINFO	D07AFA	1-(4-(methylsulfonyl)phenyl)-1H-indole	Investigative
T66665	DRUGINFO	D07HKJ	CLEMATOMANDSHURICA SAPONIN A	Investigative
T66665	DRUGINFO	D07QIU	4-(4-methoxy-benzylideneamino)-benzenesulfonamide	Investigative
T66665	DRUGINFO	D08HRA	(E)-2-(4-(methylsulfonyl)styryl)thiophene	Investigative
T66665	DRUGINFO	D08LYB	SB 239063	Investigative
T66665	DRUGINFO	D09DMR	4-phenyliminomethyl-benzenesulfonamide	Investigative
T66665	DRUGINFO	D0C1GO	SC-558	Investigative
T66665	DRUGINFO	D0C6WN	2,4-dimethoxy-2'-hydroxychalcone	Investigative
T66665	DRUGINFO	D0EI8V	GW-637185X	Investigative
T66665	DRUGINFO	D0F3UR	4-(4-methyl-benzylideneamino)-benzenesulfonamide	Investigative
T66665	DRUGINFO	D0FQ3N	3,4-dihydroxyxanthone	Investigative
T66665	DRUGINFO	D0H4BT	2-(4-(methylsulfonyl)phenyl)pyridine	Investigative
T66665	DRUGINFO	D0J1AW	4-(3-hydroxy-benzylideneamino)-benzenesulfonamide	Investigative
T66665	DRUGINFO	D0JQ3X	4-fluoro-N-(4-(methylsulfonyl)phenyl)aniline	Investigative
T66665	DRUGINFO	D0JT8Y	4-(3-nitro-benzylideneamino)-benzenesulfonamide	Investigative
T66665	DRUGINFO	D0K4QW	1,3-bis(nitrooxy)propan-2-yl 2-acetoxybenzoate	Investigative
T66665	DRUGINFO	D0KX7A	CR-4174	Investigative
T66665	DRUGINFO	D0LB6L	2,3-dimethoxy-2'-hydroxychalcone	Investigative
T66665	DRUGINFO	D0M6UZ	NEOLIGNAN 9-NOR-7,8-DEHYDRO-ISOLICARIN B	Investigative
T66665	DRUGINFO	D0N0GX	(E)-4-(2-(thiophen-3-yl)vinyl)benzenesulfonamide	Investigative
T66665	DRUGINFO	D0N8TM	XGP-110	Investigative
T66665	DRUGINFO	D0NB0I	2,4'-Dimethoxy-5,3'-dipropyl-biphenyl	Investigative
T66665	DRUGINFO	D0P4QS	5-methoxy-2-(4-(methylsulfonyl)phenyl)-1H-indole	Investigative
T66665	DRUGINFO	D0P9BG	3-benzyloxy-4-methoxy-2'-hydroxychalcone	Investigative
T66665	DRUGINFO	D0Q4CT	2'-hydroxy-3,4,5-trimethoxychalcone	Investigative
T66665	DRUGINFO	D0Q4FH	L-748780	Investigative
T66665	DRUGINFO	D0Q4LI	Furan-3-yl(4-(methylsulfonyl)phenyl)methanone	Investigative
T66665	DRUGINFO	D0QV6M	LM-4108	Investigative
T66665	DRUGINFO	D0S7LD	2,6-dihydroxy-1,7-dimethoxyxanthone	Investigative
T66665	DRUGINFO	D0S9YA	2'-Hydroxychalcone	Investigative
T66665	DRUGINFO	D0T2SD	4-(4-methyl-phenyliminomethyl)-benzenesulfonamide	Investigative
T66665	DRUGINFO	D0T3KZ	TENOSAL	Investigative
T66665	DRUGINFO	D0U1IJ	6,7'-oxybis(2-phenyl-4H-chromen-4-one)	Investigative
T66665	DRUGINFO	D0U1UP	3,4-dibenzyloxy-2'-hydroxychalcone	Investigative
T66665	DRUGINFO	D0UD5X	(E)-2-(4-(methylsulfonyl)styryl)furan	Investigative
T66665	DRUGINFO	D0UH3D	Fluoro loxoprofen	Investigative
T66665	DRUGINFO	D0UH3W	OCOPHYLLALS A	Investigative
T66665	DRUGINFO	D0V2QP	2-(4-(methylsulfonyl)phenyl)-3-phenylquinoline	Investigative
T66665	DRUGINFO	D0V8ZU	8alpha,19-dihydroxylabd-13 E-en-15-oic acid	Investigative
T66665	DRUGINFO	D0X6RO	4-(4-fluoro-benzylideneamino)-benzenesulfonamide	Investigative
T66665	DRUGINFO	D0XC1F	CX-9051	Investigative
T66665	DRUGINFO	D0Y1UG	Ocophyllals b	Investigative
T66665	DRUGINFO	D0Y4ZI	Silicon-modified indomethacin	Investigative
T66665	DRUGINFO	D0Y9ZO	4-(4-fluoro-phenyliminomethyl)-benzenesulfonamide	Investigative
T66665	DRUGINFO	D0YK4L	PAC-10649	Investigative
T66665	DRUGINFO	D0Z1WF	4-((4-methoxyphenyl)diazenyl)benzenesulfonamide	Investigative
T66665	DRUGINFO	D0Z7BK	CLEMATOMANDSHURICA SAPONIN B	Investigative
T66665	DRUGINFO	D00GBX	Prifelone	Investigative
T66665	DRUGINFO	D00MXS	Wogonin	Investigative
T66665	DRUGINFO	D00VBX	2-(p-Methylsulfonylbenzoyl)furan	Investigative
T66665	DRUGINFO	D01VRB	4,5-Bis(4-chlorophenyl)isothiazole	Investigative
T66665	DRUGINFO	D01WLL	N-(3-(phenylthio)pyridin-4-yl)methanesulfonamide	Investigative
T66665	DRUGINFO	D02CCB	2-(2,3,4-trimethoxyphenyl)-1H-indene	Investigative
T66665	DRUGINFO	D02DYG	4-amino-N-(4-chlorophenyl)benzenesulfonamide	Investigative
T66665	DRUGINFO	D02FGY	2-(N-(2-Ffuorophenyl)pyrrol-3-yl) acetic acid	Investigative
T66665	DRUGINFO	D03VUQ	4-(4-hydroxy-benzylideneamino)-benzenesulfonamide	Investigative
T66665	DRUGINFO	D04TNI	Nitroflurbiprofen	Investigative
T66665	DRUGINFO	D04YPP	5-Methyl-3,4-diphenyl-isoxazole	Investigative
T66665	DRUGINFO	D06DRL	N-(3-phenylamino-4-pyridinyl)methanesulfonamide	Investigative
T66665	DRUGINFO	D06WML	5-Ethyl-3,4-diphenyl-isoxazole	Investigative
T66665	DRUGINFO	D07ARK	5-Phenyl-pentanoic acid benzyl-hydroxy-amide	Investigative
T66665	DRUGINFO	D07RTV	5-(4-Methoxyphenyl)-4-p-tolyl-1,2-selenazole	Investigative
T66665	DRUGINFO	D07STC	2-(N-(2-fluorophenyl)pyrrol-2-yl) acetic acid	Investigative
T66665	DRUGINFO	D08JML	Microxine	Investigative
T66665	DRUGINFO	D08RYB	5-(4-Chlorophenyl)-4-p-tolyl-1,2-selenazole	Investigative
T66665	DRUGINFO	D09HWQ	3-(4-Methanesulfonyl-phenyl)-1-phenyl-propynone	Investigative
T66665	DRUGINFO	D09MDB	4-(4-Chlorophenyl)-5-p-tolyl-1,2-selenazole	Investigative
T66665	DRUGINFO	D0A4LW	(R)-2-(4-Isobutyl-phenyl)-N-phenyl-propionamide	Investigative
T66665	DRUGINFO	D0BO9W	N-(3-phenoxy-4-pyridinyl)ethanesulfonamide	Investigative
T66665	DRUGINFO	D0CW3A	Resveratrol Potassium3-Sulfate	Investigative
T66665	DRUGINFO	D0D0JE	4,5-Bis(4-methoxyphenyl)-1,2-selenazole	Investigative
T66665	DRUGINFO	D0D6UC	(Z)-2'-des-methyl sulindac sulfide	Investigative
T66665	DRUGINFO	D0E5MK	4,5-Bis(4-chlorophenyl)-1,2-selenazole	Investigative
T66665	DRUGINFO	D0F0JU	4,5-Bis(4-methoxyphenyl)isothiazole	Investigative
T66665	DRUGINFO	D0GF9J	(11H-Dibenzo[b,e][1,4]dioxepin-8-yl)-acetic acid	Investigative
T66665	DRUGINFO	D0J7YE	N-(1H-indazol-5-yl)acetamide	Investigative
T66665	DRUGINFO	D0LL9E	1-(4-(methylsulfonyl)phenyl)-3-phenylurea	Investigative
T66665	DRUGINFO	D0N0YS	(11H-Dibenzo[b,e][1,4]dioxepin-2-yl)-acetic acid	Investigative
T66665	DRUGINFO	D0OX0B	1,2-dihydro-3-(2,3,4-trimethoxyphenyl)naphthalene	Investigative
T66665	DRUGINFO	D0P6PQ	THIOCTIC ACID	Investigative
T66665	DRUGINFO	D0S2II	4-(benzylideneamino)benzenesulfonamide	Investigative
T66665	DRUGINFO	D0T4VL	Primary alcohol metabolite of celecoxib	Investigative
T66665	DRUGINFO	D0T7BP	1-(4-(methylsulfonyl)phenyl)-3-p-tolylurea	Investigative
T66665	DRUGINFO	D0T9QW	Oxametacin	Investigative
T66665	DRUGINFO	D0U0YE	2-(2-(2,6-dimethylphenylamino)phenyl)acetic acid	Investigative
T66665	DRUGINFO	D0V9AU	1-(4-aminosulfonylphenyl)-2-(2-pyridyl)acetylene	Investigative
T66665	DRUGINFO	D0X4LI	4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiol-3-one	Investigative
T66665	DRUGINFO	D0X5RR	(11H-Dibenzo[b,e][1,4]dioxepin-7-yl)-acetic acid	Investigative
T66665	DRUGINFO	D0ZI8Y	3 beta-O-acetyloleanolic acid	Investigative
T66665	DRUGINFO	D01JYF	2,4'-Dimethoxy-5,3'-di-(2-propenyl)-biphenyl	Investigative
T66665	DRUGINFO	D01OFH	METHYLHONOKIOL	Investigative
T66665	DRUGINFO	D04DQJ	HONOKIOL	Investigative
T66665	DRUGINFO	D04JZY	Resveratrol Potassium4,-Sulfate	Investigative
T66665	DRUGINFO	D04ZGF	5-(2-Imidazol-1-yl-ethyl)-7,8-dihydro-quinoline	Investigative
T66665	DRUGINFO	D06HUQ	2-Phenethyl-1,2-dihydro-indazol-3-one	Investigative
T66665	DRUGINFO	D0C5SV	alpha-linolenic acid	Investigative
T66665	DRUGINFO	D0J7YU	2-Benzyl-1,2-dihydro-indazol-3-one	Investigative
T66665	DRUGINFO	D0L4TM	2-(3-Phenyl-propyl)-1,2-dihydro-indazol-3-one	Investigative
T66665	DRUGINFO	D0P1LP	PHENIDONE	Investigative
T66665	DRUGINFO	D0R6ZC	5,3'-Dipropyl-biphenyl-2,4'-diol	Investigative
T66665	DRUGINFO	D0S0PB	2-Phenyl-1,2-dihydro-indazol-3-one	Investigative
T66665	DRUGINFO	D0SJ3W	2-Furan-2-ylmethyl-1,2-dihydro-indazol-3-one	Investigative
T66665	DRUGINFO	D0U8CM	2-Methyl-1,2-dihydro-indazol-3-one	Investigative
T66665	DRUGINFO	D0VC0I	Oxindole 94	Investigative
T66665	DRUGINFO	D0X6SA	2-Naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one	Investigative
T66665	DRUGINFO	D0UU1I	Heme	Investigative
T66665	DRUGINFO	D02UVH	B-Octylglucoside	Investigative

T34429	TARGETID	T34429
T34429	FORMERID	TTDS00520
T34429	UNIPROID	ACHA7_HUMAN
T34429	TARGNAME	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
T34429	GENENAME	CHRNA7
T34429	TARGTYPE	Successful
T34429	SYNONYMS	Nicotinic acetylcholine receptor subunit alpha 7; Nicotinic acetylcholine receptor alpha7; CHRNA7; Alpha7 nicotinic receptor; Alpha7 nAChR; Alpha-7 nAChR; Alpha(7) nicotinic receptor
T34429	FUNCTION	After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.
T34429	PDBSTRUC	5AFN; 5AFM; 5AFL; 5AFK; 5AFJ
T34429	BIOCLASS	Neurotransmitter receptor
T34429	SEQUENCE	MRCSPGGVWLALAASLLHVSLQGEFQRKLYKELVKNYNPLERPVANDSQPLTVYFSLSLLQIMDVDEKNQVLTTNIWLQMSWTDHYLQWNVSEYPGVKTVRFPDGQIWKPDILLYNSADERFDATFHTNVLVNSSGHCQYLPPGIFKSSCYIDVRWFPFDVQHCKLKFGSWSYGGWSLDLQMQEADISGYIPNGEWDLVGIPGKRSERFYECCKEPYPDVTFTVTMRRRTLYYGLNLLIPCVLISALALLVFLLPADSGEKISLGITVLLSLTVFMLLVAEIMPATSDSVPLIAQYFASTMIIVGLSVVVTVIVLQYHHHDPDGGKMPKWTRVILLNWCAWFLRMKRPGEDKVRPACQHKQRRCSLASVEMSAVAPPPASNGNLLYIGFRGLDGVHCVPTPDSGVVCGRMACSPTHDEHLLHGGQPPEGDPDLAKILEEVRYIANRFRCQDESEAVCSEWKFAACVVDRLCLMAFSVFTIICTIGILMSAPNFVEAVSKDFA
T34429	DRUGINFO	D0L1OY	ALCURONIUM	Approved
T34429	DRUGINFO	D0R1JV	Ziprasidone	Approved
T34429	DRUGINFO	D0D3TX	EVP-6124	Phase 3
T34429	DRUGINFO	D08XPW	CYTISINE	Phase 3
T34429	DRUGINFO	D0K8NR	AMG 386	Phase 3
T34429	DRUGINFO	D02NTS	JNJ-39393406	Phase 2
T34429	DRUGINFO	D08XOY	ABT-126	Phase 2
T34429	DRUGINFO	D0G4GA	TC-6987	Phase 2
T34429	DRUGINFO	D0H1AY	AQW-051	Phase 2
T34429	DRUGINFO	D0U5JP	MEM-3454	Phase 2
T34429	DRUGINFO	D0ZC3C	GTS-21	Phase 2
T34429	DRUGINFO	D9PC0O	Bradanicline	Phase 2
T34429	DRUGINFO	D05LRD	BMS-933043	Phase 1
T34429	DRUGINFO	D07FPR	R4996	Phase 1
T34429	DRUGINFO	D0C3ZZ	BNC375	Phase 1
T34429	DRUGINFO	D0O3OI	AVL-3288	Phase 1
T34429	DRUGINFO	D0Q9RR	AZD0328	Discontinued in Phase 2
T34429	DRUGINFO	D0F7FX	AZD-9684	Discontinued in Phase 2
T34429	DRUGINFO	D0Z0LJ	ABT-107	Discontinued in Phase 1
T34429	DRUGINFO	D0A5MD	PHA-568487	Preclinical
T34429	DRUGINFO	D0I2LX	RMG-40083	Preclinical
T34429	DRUGINFO	D06LKM	PNU-282987	Terminated
T34429	DRUGINFO	D03FPQ	PNU-120596	Investigative
T34429	DRUGINFO	D03JPN	A-582941	Investigative
T34429	DRUGINFO	D04LJH	[3H]A-585539	Investigative
T34429	DRUGINFO	D08HTF	JNJ-1930942	Investigative
T34429	DRUGINFO	D0C9TY	PSAB-OFP	Investigative
T34429	DRUGINFO	D0F2XI	4BP-TQS	Investigative
T34429	DRUGINFO	D0M8JZ	TOXIFERINE	Investigative
T34429	DRUGINFO	D0O7IS	[3H]AZ11637326	Investigative
T34429	DRUGINFO	D0SR3T	JN-711	Investigative
T34429	DRUGINFO	D0VE4O	EVP-4473	Investigative
T34429	DRUGINFO	D0X2NB	AZD-6319	Investigative
T34429	DRUGINFO	D0Z0EH	PheTQS	Investigative
T34429	DRUGINFO	D02LWF	GCCSHPACAGNNQHIC*	Investigative
T34429	DRUGINFO	D0IP9V	PH-709829	Investigative
T34429	DRUGINFO	D0X7HD	CP-810123	Investigative
T34429	DRUGINFO	D04MIG	LY2087101	Investigative
T34429	DRUGINFO	D06FLU	3,8-dibromoboldine	Investigative
T34429	DRUGINFO	D09BSE	3-bromoboldine	Investigative
T34429	DRUGINFO	D09VJI	[3H]methyllycaconitine	Investigative
T34429	DRUGINFO	D0D4LF	NS1738	Investigative
T34429	DRUGINFO	D0DA1E	A-867744	Investigative
T34429	DRUGINFO	D0UH8F	GCCSNPVCHLEHSNLC*	Investigative
T34429	DRUGINFO	D0R4RN	[125I]epibatidine	Investigative
T34429	DRUGINFO	D03TMD	Barbituric acid derivative	Investigative

T30284	TARGETID	T30284
T30284	FORMERID	TTDS00477
T30284	UNIPROID	INGR2_HUMAN
T30284	TARGNAME	Interferon gamma receptor (IFNGR2)
T30284	GENENAME	IFNGR2
T30284	TARGTYPE	Successful
T30284	SYNONYMS	Interferon gamma transducer 1; Interferon gamma receptor beta-chain; Interferon gamma receptor accessory factor 1; Interferon gamma receptor 2; IFNGT1; IFNGR; IFN-gamma-R2; IFN-gamma-R-beta; IFN-gamma-R; IFN-gamma receptor 2; CDw119; CD119; AF-1
T30284	FUNCTION	Ligand binding stimulates activation of the JAK/STAT signaling pathway. Required for signal transduction in contrast to other receptor subunit responsible for ligand binding. Associates with IFNGR1 to form a receptor for the cytokine interferon gamma (IFNG) (, ,).
T30284	PDBSTRUC	6E3L; 6E3K; 5EH1
T30284	BIOCLASS	Cytokine receptor
T30284	SEQUENCE	MRPTLLWSLLLLLGVFAAAAAAPPDPLSQLPAPQHPKIRLYNAEQVLSWEPVALSNSTRPVVYQVQFKYTDSKWFTADIMSIGVNCTQITATECDFTAASPSAGFPMDFNVTLRLRAELGALHSAWVTMPWFQHYRNVTVGPPENIEVTPGEGSLIIRFSSPFDIADTSTAFFCYYVHYWEKGGIQQVKGPFRSNSISLDNLKPSRVYCLQVQAQLLWNKSNIFRVGHLSNISCYETMADASTELQQVILISVGTFSLLSVLAGACFFLVLKYRGLIKYWFHTPPSIPLQIEEYLKDPTQPILEALDKDSSPKDDVWDSVSIISFPEKEQEDVLQTL
T30284	DRUGINFO	D0U8US	Interferon gamma-1b	Approved
T30284	DRUGINFO	D0FU8R	Anifrolumab	Approved

T99616	TARGETID	T99616
T99616	FORMERID	TTDR00585
T99616	UNIPROID	TYTR_TRYBB
T99616	TARGNAME	Trypanosoma Trypanothione reductase (Trypano TPR)
T99616	GENENAME	Trypano TPR
T99616	TARGTYPE	Successful
T99616	SYNONYMS	TRYR; TPR; Parasite-specific trypanothione reductase; N(1),N(8)-bis(glutathionyl)spermidine reductase
T99616	FUNCTION	Trypanothione is the parasite analog of glutathione; this enzyme is the equivalent of glutathione reductase.
T99616	PDBSTRUC	2WBA
T99616	BIOCLASS	Sulfur donor oxidoreductase
T99616	ECNUMBER	EC 1.8.1.12
T99616	SEQUENCE	MSKIFDLVVIGAGSGGLEAGWNAATLYKKRVAVIDVQTHHGPPHYAALGGTCVNVGCVPKKLMVTGAQYMDHLRESAGFGWEFDGSSVKANWKKLIAAKNEAVLDINKSYEGMFNDTEGLDFFLGWGSLESKNVVVVRETADPKSAVKERLQADHILLATGSWPQMPAIPGVEHCISSNEAFYLPEPPRRVLTVGGGFISVEFAGIFNAYKPPGGKVTLCYRNNLILRGFDETIREEVTKQLTANGIEIMTNENPAKVSLNTDGSKHVTFESGKTLDVDVVMMAIGRIPRTNDLQLGNVGVKLTPKGGVQVDEFSRTNVPNIYAIGDITDRLMLTPVAINEGAALVDTVFGNKPRKTDHTRVASAVFSIPPIGTCGLIEEVAAKEFEKVAVYMSSFTPLMHNISGSKYKKFVAKIVTNHSDGTVLGVHLLGDGAPEIIQAVGVCLRLNAKISDFYNTIGVHPTSAEELCSMRTPSYYYLKGEKMETLPESSL
T99616	DRUGINFO	D09HVL	Bivalirudin	Approved
T99616	DRUGINFO	D0S7WX	Vitamin A	Approved
T99616	DRUGINFO	D0E0JN	CEPHARANTINE	Investigative
T99616	DRUGINFO	D0P4IP	Trypanothione	Investigative
T99616	DRUGINFO	D0P9YV	N-(5-chloro-2-(phenylthio)phenyl)butyramide	Investigative
T99616	DRUGINFO	D0R3TU	N1,N2-bis(dihydrocaffeoyl)spermine	Investigative
T99616	DRUGINFO	D0E7UH	Maleic Acid	Investigative
T99616	DRUGINFO	D0I8HK	1-(2'-chlorophenyl)penta-1,4-dien-3-one	Investigative
T99616	DRUGINFO	D0M9IC	CONESSINE	Investigative
T99616	DRUGINFO	D00IMW	Flavin-Adenine Dinucleotide	Investigative

T16156	TARGETID	T16156
T16156	FORMERID	TTDS00524
T16156	UNIPROID	TPOR_HUMAN
T16156	TARGNAME	Thrombopoietin receptor (MPL)
T16156	GENENAME	MPL
T16156	TARGTYPE	Successful
T16156	SYNONYMS	TPOR; TPO-R; Proto-oncogene c-Mpl; Myeloproliferative leukemia protein; CD110 antigen; CD110; C-mpl
T16156	FUNCTION	May represent a regulatory molecule specific for TPO-R-dependent immune responses. Receptor for thrombopoietin that acts as a primary regulator of megakaryopoiesis and platelet production.
T16156	BIOCLASS	Cytokine receptor
T16156	SEQUENCE	MPSWALFMVTSCLLLAPQNLAQVSSQDVSLLASDSEPLKCFSRTFEDLTCFWDEEEAAPSGTYQLLYAYPREKPRACPLSSQSMPHFGTRYVCQFPDQEEVRLFFPLHLWVKNVFLNQTRTQRVLFVDSVGLPAPPSIIKAMGGSQPGELQISWEEPAPEISDFLRYELRYGPRDPKNSTGPTVIQLIATETCCPALQRPHSASALDQSPCAQPTMPWQDGPKQTSPSREASALTAEGGSCLISGLQPGNSYWLQLRSEPDGISLGGSWGSWSLPVTVDLPGDAVALGLQCFTLDLKNVTCQWQQQDHASSQGFFYHSRARCCPRDRYPIWENCEEEEKTNPGLQTPQFSRCHFKSRNDSIIHILVEVTTAPGTVHSYLGSPFWIHQAVRLPTPNLHWREISSGHLELEWQHPSSWAAQETCYQLRYTGEGHQDWKVLEPPLGARGGTLELRPRSRYRLQLRARLNGPTYQGPWSSWSDPTRVETATETAWISLVTALHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPLCSSQAQMDYRRLQPSCLGTMPLSVCPPMAESGSCCTTHIANHSYLPLSYWQQP
T16156	DRUGINFO	D00PEH	Eltrombopag	Approved
T16156	DRUGINFO	D08VSI	Revolade/Promacta	Approved
T16156	DRUGINFO	D0TD1R	Lusutrombopag	Approved
T16156	DRUGINFO	D0W1DI	AS-1670542	Approved
T16156	DRUGINFO	D01PZD	Romiplostim	Approved
T16156	DRUGINFO	D04BFI	LGD-4665	Phase 2
T16156	DRUGINFO	D00CLM	NIP-004	Phase 1
T16156	DRUGINFO	D04KVA	BVI-007	Phase 1
T16156	DRUGINFO	D00OEG	RhTPO	Discontinued in Phase 3
T16156	DRUGINFO	D04TJP	Totrombopag	Discontinued in Phase 1
T16156	DRUGINFO	D00LWX	Promegapoietin	Terminated
T16156	DRUGINFO	D09WOY	SB-559457	Investigative
T16156	DRUGINFO	D0C3GZ	STS-T4	Investigative
T16156	DRUGINFO	D0EI7H	ThromboMer	Investigative
T16156	DRUGINFO	D0G6TR	RI-TPO	Investigative
T16156	DRUGINFO	D0GL7O	HL-034	Investigative
T16156	DRUGINFO	D0KP0L	SE-ET-TP020d	Investigative
T16156	DRUGINFO	D0QI6W	Non-peptide TPO mimics	Investigative

T33584	TARGETID	T33584
T33584	FORMERID	TTDC00250
T33584	UNIPROID	GRIA1_HUMAN
T33584	TARGNAME	Glutamate receptor AMPA 1 (GRIA1)
T33584	GENENAME	GRIA1
T33584	TARGTYPE	Successful
T33584	SYNONYMS	Glutamate receptor ionotropic, AMPA 1; Glutamate receptor 1; GluR-K1; GluR-A; GluR-1; GluA1; GLUR1; GLUH1; AMPA-selective glutamate receptor 1
T33584	FUNCTION	L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist. In the presence of CACNG4 or CACNG7 or CACNG8, shows resensitization which is characterized by a delayed accumulation of current flux upon continued application of glutamate. Ionotropic glutamate receptor.
T33584	BIOCLASS	Glutamate-gated ion channel
T33584	SEQUENCE	MQHIFAFFCTGFLGAVVGANFPNNIQIGGLFPNQQSQEHAAFRFALSQLTEPPKLLPQIDIVNISDSFEMTYRFCSQFSKGVYAIFGFYERRTVNMLTSFCGALHVCFITPSFPVDTSNQFVLQLRPELQDALISIIDHYKWQKFVYIYDADRGLSVLQKVLDTAAEKNWQVTAVNILTTTEEGYRMLFQDLEKKKERLVVVDCESERLNAILGQIIKLEKNGIGYHYILANLGFMDIDLNKFKESGANVTGFQLVNYTDTIPAKIMQQWKNSDARDHTRVDWKRPKYTSALTYDGVKVMAEAFQSLRRQRIDISRRGNAGDCLANPAVPWGQGIDIQRALQQVRFEGLTGNVQFNEKGRRTNYTLHVIEMKHDGIRKIGYWNEDDKFVPAATDAQAGGDNSSVQNRTYIVTTILEDPYVMLKKNANQFEGNDRYEGYCVELAAEIAKHVGYSYRLEIVSDGKYGARDPDTKAWNGMVGELVYGRADVAVAPLTITLVREEVIDFSKPFMSLGISIMIKKPQKSKPGVFSFLDPLAYEIWMCIVFAYIGVSVVLFLVSRFSPYEWHSEEFEEGRDQTTSDQSNEFGIFNSLWFSLGAFMQQGCDISPRSLSGRIVGGVWWFFTLIIISSYTANLAAFLTVERMVSPIESAEDLAKQTEIAYGTLEAGSTKEFFRRSKIAVFEKMWTYMKSAEPSVFVRTTEEGMIRVRKSKGKYAYLLESTMNEYIEQRKPCDTMKVGGNLDSKGYGIATPKGSALRNPVNLAVLKLNEQGLLDKLKNKWWYDKGECGSGGGDSKDKTSALSLSNVAGVFYILIGGLGLAMLVALIEFCYKSRSESKRMKGFCLIPQQSINEAIRTSTLPRNSGAGASSGGSGENGRVVSHDFPKSMQSIPCMSHSSGMPLGATGL
T33584	DRUGINFO	D0U3ED	E-2007	Approved
T33584	DRUGINFO	D02VKC	NBQX	Phase 1
T33584	DRUGINFO	D02TTF	YM-90K	Discontinued in Phase 2
T33584	DRUGINFO	D0Z4KX	Farampator	Discontinued in Phase 1
T33584	DRUGINFO	D08QYJ	SORETOLIDE	Terminated
T33584	DRUGINFO	D0A9VO	GYKI-52466	Terminated
T33584	DRUGINFO	D0M7MW	GYKI-53655	Terminated
T33584	DRUGINFO	D0Z9CC	Zonampanel	Terminated
T33584	DRUGINFO	D08SCF	Philanthotoxin-343	Investigative
T33584	DRUGINFO	D0O7OE	Argiotoxin-636	Investigative
T33584	DRUGINFO	D04SMQ	(S)-WILLARDIINE	Investigative
T33584	DRUGINFO	D08SYX	Piriqualone	Investigative
T33584	DRUGINFO	D0AA9A	N-(4-hydroxyphenylpropanyl)-spermine	Investigative
T33584	DRUGINFO	D0T5SU	(S)-AMPA	Investigative
T33584	DRUGINFO	D0SB9H	joro toxin	Investigative
T33584	DRUGINFO	D03VBJ	ATPO	Investigative
T33584	DRUGINFO	D09LXQ	(S)-5-fluorowillardiine	Investigative
T33584	DRUGINFO	D0G1UE	[3H]AMPA	Investigative
T33584	DRUGINFO	D03PGF	RPR-118723	Investigative
T33584	DRUGINFO	D05VVC	7-chloro-3-hydroxyquinazoline-2,4-dione	Investigative
T33584	DRUGINFO	D0E5UQ	[3H]CNQX	Investigative
T33584	DRUGINFO	D05KQC	DNQX	Investigative
T33584	DRUGINFO	D04PFN	[3H]kainate	Investigative

T42392	TARGETID	T42392
T42392	FORMERID	TTDI01970
T42392	UNIPROID	GRIA2_HUMAN
T42392	TARGNAME	Glutamate receptor AMPA 2 (GRIA2)
T42392	GENENAME	GRIA2
T42392	TARGTYPE	Successful
T42392	SYNONYMS	Glutamate receptor ionotropic, AMPA 2; Glutamate receptor 2; GluRK2; GluRB; GluR2; GluR-K2; GluR-B; GluR-2; GluA2; AMPAselective glutamate receptor 2; AMPA-selective glutamate receptor 2
T42392	FUNCTION	L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist. In the presence of CACNG4 or CACNG7 or CACNG8, shows resensitization which is characterized by a delayed accumulation of current flux upon continued application of glutamate. Through complex formation with NSG1, GRIP1 and STX12 controls the intracellular fate of AMPAR and the endosomal sorting of the GRIA2 subunit toward recycling and membrane targeting. Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission.
T42392	PDBSTRUC	5ZG3; 5ZG2; 5ZG1; 5ZG0; 5YBG
T42392	BIOCLASS	Glutamate-gated ion channel
T42392	SEQUENCE	MQKIMHISVLLSPVLWGLIFGVSSNSIQIGGLFPRGADQEYSAFRVGMVQFSTSEFRLTPHIDNLEVANSFAVTNAFCSQFSRGVYAIFGFYDKKSVNTITSFCGTLHVSFITPSFPTDGTHPFVIQMRPDLKGALLSLIEYYQWDKFAYLYDSDRGLSTLQAVLDSAAEKKWQVTAINVGNINNDKKDEMYRSLFQDLELKKERRVILDCERDKVNDIVDQVITIGKHVKGYHYIIANLGFTDGDLLKIQFGGANVSGFQIVDYDDSLVSKFIERWSTLEEKEYPGAHTTTIKYTSALTYDAVQVMTEAFRNLRKQRIEISRRGNAGDCLANPAVPWGQGVEIERALKQVQVEGLSGNIKFDQNGKRINYTINIMELKTNGPRKIGYWSEVDKMVVTLTELPSGNDTSGLENKTVVVTTILESPYVMMKKNHEMLEGNERYEGYCVDLAAEIAKHCGFKYKLTIVGDGKYGARDADTKIWNGMVGELVYGKADIAIAPLTITLVREEVIDFSKPFMSLGISIMIKKPQKSKPGVFSFLDPLAYEIWMCIVFAYIGVSVVLFLVSRFSPYEWHTEEFEDGRETQSSESTNEFGIFNSLWFSLGAFMQQGCDISPRSLSGRIVGGVWWFFTLIIISSYTANLAAFLTVERMVSPIESAEDLSKQTEIAYGTLDSGSTKEFFRRSKIAVFDKMWTYMRSAEPSVFVRTTAEGVARVRKSKGKYAYLLESTMNEYIEQRKPCDTMKVGGNLDSKGYGIATPKGSSLRNAVNLAVLKLNEQGLLDKLKNKWWYDKGECGSGGGDSKEKTSALSLSNVAGVFYILVGGLGLAMLVALIEFCYKSRAEAKRMKVAKNAQNINPSSSQNSQNFATYKEGYNVYGIESVKI
T42392	DRUGINFO	D0U3ED	E-2007	Approved
T42392	DRUGINFO	D05KVC	Paliroden	Phase 2
T42392	DRUGINFO	D03VBJ	ATPO	Investigative
T42392	DRUGINFO	D09LXQ	(S)-5-fluorowillardiine	Investigative
T42392	DRUGINFO	D0G1UE	[3H]AMPA	Investigative
T42392	DRUGINFO	D0E5UQ	[3H]CNQX	Investigative

T75797	TARGETID	T75797
T75797	FORMERID	TTDS00169
T75797	UNIPROID	PF2R_HUMAN
T75797	TARGNAME	Prostaglandin F2-alpha receptor (PTGFR)
T75797	GENENAME	PTGFR
T75797	TARGTYPE	Successful
T75797	SYNONYMS	Prostanoid FP receptor; PGF2-alpha receptor; PGF2 alpha receptor; PGF receptor; FP prostanoid receptor; FP prostaglandin receptor
T75797	FUNCTION	The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. Initiates luteolysis in the corpus luteum. Isoforms 2 to 7 do not bind PGF2-alpha but are proposed to modulate signaling by participating in variant receptor complexes; heterodimers between isoform 1 and isoform 5 are proposed to be a receptor for prostamides including the synthetic analog bimatoprost. Receptor for prostaglandin F2-alpha (PGF2-alpha).
T75797	BIOCLASS	GPCR rhodopsin
T75797	SEQUENCE	MSMNNSKQLVSPAAALLSNTTCQTENRLSVFFSVIFMTVGILSNSLAIAILMKAYQRFRQKSKASFLLLASGLVITDFFGHLINGAIAVFVYASDKEWIRFDQSNVLCSIFGICMVFSGLCPLLLGSVMAIERCIGVTKPIFHSTKITSKHVKMMLSGVCLFAVFIALLPILGHRDYKIQASRTWCFYNTEDIKDWEDRFYLLLFSFLGLLALGVSLLCNAITGITLLRVKFKSQQHRQGRSHHLEMVIQLLAIMCVSCICWSPFLVTMANIGINGNHSLETCETTLFALRMATWNQILDPWVYILLRKAVLKNLYKLASQCCGVHVISLHIWELSSIKNSLKVAAISESPVAEKSAST
T75797	DRUGINFO	D04LCQ	Tafluprost	Approved
T75797	DRUGINFO	D05LQX	BOL-303259-X	Approved
T75797	DRUGINFO	D07PCI	Carboprost Tromethamine	Approved
T75797	DRUGINFO	D09CZA	Travoprost	Approved
T75797	DRUGINFO	D0C6NM	Latanoprost	Approved
T75797	DRUGINFO	D06FEA	Dinoprostone	Approved
T75797	DRUGINFO	D0WL5V	LAROPIPRANT	Phase 4
T75797	DRUGINFO	D00JRD	PGF2ALPHA-IE	Phase 3
T75797	DRUGINFO	D0V5QH	ONO-9054	Phase 2
T75797	DRUGINFO	D0TJ7S	PDC-41	Phase 1
T75797	DRUGINFO	D08QWQ	bimatoprost (free acid form)	Clinical trial
T75797	DRUGINFO	D00HTY	PGF2alpha	Clinical trial
T75797	DRUGINFO	D0W2OT	BUTAPROST	Patented
T75797	DRUGINFO	D03OYD	13,14-dihydro-16-m-chlorophenoxy-w-tetranor-PGF1alpha	Investigative
T75797	DRUGINFO	D04ULI	[3H]PGF2alpha	Investigative
T75797	DRUGINFO	D05DRG	PDC-31	Investigative
T75797	DRUGINFO	D05VOG	AL-8810	Investigative
T75797	DRUGINFO	D08MXB	NCX-125	Investigative
T75797	DRUGINFO	D0L4IV	AL12180	Investigative
T75797	DRUGINFO	D0MR1B	AS604872	Investigative
T75797	DRUGINFO	D05TNX	fluprostenol	Investigative
T75797	DRUGINFO	D0X5MA	I-BOP	Investigative
T75797	DRUGINFO	D0O9ES	cloprostenol	Investigative
T75797	DRUGINFO	D0BN1U	M&B 28767	Investigative
T75797	DRUGINFO	D06KBO	PGD2	Investigative
T75797	DRUGINFO	D0W7RI	carbacyclin	Investigative
T75797	DRUGINFO	D03PLH	U46619	Investigative

T38529	TARGETID	T38529
T38529	FORMERID	TTDS00168
T38529	UNIPROID	PE2R2_HUMAN
T38529	TARGNAME	Prostaglandin E2 receptor EP2 (PTGER2)
T38529	GENENAME	PTGER2
T38529	TARGTYPE	Successful
T38529	SYNONYMS	Prostanoid EP2 receptor; Prostaglandin E2 receptor EP2 subtype; PGE2 receptor EP2 subtype; PGE receptor, EP2 subtype; PGE receptor EP2 subtype; EP2 receptor
T38529	FUNCTION	The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. The subsequent raise in intracellular cAMP is responsible for the relaxing effect of this receptor on smooth muscle. Receptor for prostaglandin E2 (PGE2).
T38529	BIOCLASS	GPCR rhodopsin
T38529	SEQUENCE	MGNASNDSQSEDCETRQWLPPGESPAISSVMFSAGVLGNLIALALLARRWRGDVGCSAGRRSSLSLFHVLVTELVFTDLLGTCLISPVVLASYARNQTLVALAPESRACTYFAFAMTFFSLATMLMLFAMALERYLSIGHPYFYQRRVSRSGGLAVLPVIYAVSLLFCSLPLLDYGQYVQYCPGTWCFIRHGRTAYLQLYATLLLLLIVSVLACNFSVILNLIRMHRRSRRSRCGPSLGSGRGGPGARRRGERVSMAEETDHLILLAIMTITFAVCSLPFTIFAYMNETSSRKEKWDLQALRFLSINSIIDPWVFAILRPPVLRLMRSVLCCRISLRTQDATQTSCSTQSDASKQADL
T38529	DRUGINFO	D00SOZ	Omidenepag isopropyl	Approved
T38529	DRUGINFO	D05ZTH	Iloprost	Approved
T38529	DRUGINFO	D04FBR	Mycophenolate mofetil	Approved
T38529	DRUGINFO	D06FEA	Dinoprostone	Approved
T38529	DRUGINFO	D0I4DQ	Alprostadil	Approved
T38529	DRUGINFO	D0WL5V	LAROPIPRANT	Phase 4
T38529	DRUGINFO	D0G6EI	CP-533536	Phase 2
T38529	DRUGINFO	D0Y3LL	Taprenepag	Phase 2
T38529	DRUGINFO	D0U7WF	16,16-dimethyl-PGE2	Phase 2
T38529	DRUGINFO	D0S5EF	PF-4418948	Phase 1
T38529	DRUGINFO	D54FYW	TPST-1495	Phase 1
T38529	DRUGINFO	D00HTY	PGF2alpha	Clinical trial
T38529	DRUGINFO	D01ERV	PMID25772215-Compound-US02014179750TG7-170	Patented
T38529	DRUGINFO	D01FIM	PMID25772215-Compound-WO2012177618M6	Patented
T38529	DRUGINFO	D01JJN	PMID25772215-Compound-EP2149552diaminopyrimidines	Patented
T38529	DRUGINFO	D03IKW	PMID25772215-Compound-WO2012177618M4	Patented
T38529	DRUGINFO	D06ZEI	PMID25772215-Compound-US02014179750TG8-15	Patented
T38529	DRUGINFO	D0A2VQ	PMID25772215-Compound-US02014179750M2	Patented
T38529	DRUGINFO	D0D0PF	PMID25772215-Compound-US02014179750TG7-112-2	Patented
T38529	DRUGINFO	D0G6UA	PMID25772215-Compound-WO2012177618M5	Patented
T38529	DRUGINFO	D0H6QG	PMID25772215-Compound-US02014179750TG7-74	Patented
T38529	DRUGINFO	D0HJ1O	PMID25772215-Compound-US02014179750M1	Patented
T38529	DRUGINFO	D0NQ6N	PMID25772215-Compound-US02014179750TG6-10-1	Patented
T38529	DRUGINFO	D0O2EN	PMID25772215-Compound-US02014179750TG6-129	Patented
T38529	DRUGINFO	D0RD5O	PMID25772215-Compound-US02014179750TG7-76	Patented
T38529	DRUGINFO	D0Y8GN	PMID25772215-Compound-US02014179750M3	Patented
T38529	DRUGINFO	D0ZT9N	PMID25772215-Compound-EP20082149552C9	Patented
T38529	DRUGINFO	D0W2OT	BUTAPROST	Patented
T38529	DRUGINFO	D02RUO	ONO-8815Ly	Terminated
T38529	DRUGINFO	D01IJD	AH13205	Investigative
T38529	DRUGINFO	D03WTU	TG4-155	Investigative
T38529	DRUGINFO	D06PVN	R-65	Investigative
T38529	DRUGINFO	D0NY1J	TG7-171	Investigative
T38529	DRUGINFO	D0ST1M	PMID20080612C1	Investigative
T38529	DRUGINFO	D0YD9E	PF-00212062	Investigative
T38529	DRUGINFO	D05MXO	19(R)-OH-PGE2	Investigative
T38529	DRUGINFO	D0CW4T	ONO-AE-248	Investigative
T38529	DRUGINFO	D02LXJ	3-(2-cinnamylphenyl)acrylic acid	Investigative
T38529	DRUGINFO	D02SAD	3-(2-(4-methoxycinnamyl)phenyl)acrylic acid	Investigative
T38529	DRUGINFO	D02YIJ	isocarbacyclin	Investigative
T38529	DRUGINFO	D06VZS	ONO-AE1-329	Investigative
T38529	DRUGINFO	D0G5MT	11-deoxy-PGE1	Investigative
T38529	DRUGINFO	D0W4GQ	3-(2-((E)-3-phenylprop-1-enyl)phenyl)acrylic acid	Investigative
T38529	DRUGINFO	D0X2MQ	17-phenyl-omega-trinor-PGE2	Investigative
T38529	DRUGINFO	D0Z3XJ	3-(2-(naphthalen-2-ylmethyl)phenyl)acrylic acid	Investigative
T38529	DRUGINFO	D0J9PG	AH6809	Investigative
T38529	DRUGINFO	D05SFA	cicaprost	Investigative
T38529	DRUGINFO	D08MNO	butaprost (free acid form)	Investigative
T38529	DRUGINFO	D0BN1U	M&B 28767	Investigative
T38529	DRUGINFO	D06KBO	PGD2	Investigative
T38529	DRUGINFO	D0W7RI	carbacyclin	Investigative
T38529	DRUGINFO	D03PLH	U46619	Investigative

T64591	TARGETID	T64591
T64591	FORMERID	TTDS00399
T64591	UNIPROID	5HT3A_HUMAN
T64591	TARGNAME	5-HT 3A receptor (HTR3A)
T64591	GENENAME	HTR3A
T64591	TARGTYPE	Successful
T64591	SYNONYMS	Serotonin-gated ion channel receptor; Serotonin receptor 3A; HTR3; 5HT3R; 5-hydroxytryptamine receptor 3A; 5-HT3RA; 5-HT3A; 5-HT3-A; 5-HT 3A
T64591	FUNCTION	This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
T64591	BIOCLASS	GPCR rhodopsin
T64591	SEQUENCE	MLLWVQQALLALLLPTLLAQGEARRSRNTTRPALLRLSDYLLTNYRKGVRPVRDWRKPTTVSIDVIVYAILNVDEKNQVLTTYIWYRQYWTDEFLQWNPEDFDNITKLSIPTDSIWVPDILINEFVDVGKSPNIPYVYIRHQGEVQNYKPLQVVTACSLDIYNFPFDVQNCSLTFTSWLHTIQDINISLWRLPEKVKSDRSVFMNQGEWELLGVLPYFREFSMESSNYYAEMKFYVVIRRRPLFYVVSLLLPSIFLMVMDIVGFYLPPNSGERVSFKITLLLGYSVFLIIVSDTLPATAIGTPLIGVYFVVCMALLVISLAETIFIVRLVHKQDLQQPVPAWLRHLVLERIAWLLCLREQSTSQRPPATSQATKTDDCSAMGNHCSHMGGPQDFEKSPRDRCSPPPPPREASLAVCGLLQELSSIRQFLEKRDEIREVARDWLRVGSVLDKLLFHIYLLAVLAYSITLVMLWSIWQYA
T64591	DRUGINFO	D00YLW	Dolasetron	Approved
T64591	DRUGINFO	D04FVU	Palonosetron	Approved
T64591	DRUGINFO	D06GKN	Alosetron	Approved
T64591	DRUGINFO	D0K0KH	Tropisetron	Approved
T64591	DRUGINFO	D0TZ1G	Procaine	Approved
T64591	DRUGINFO	D0E1XL	Levetiracetam	Approved
T64591	DRUGINFO	D0K5IP	Palonosetron + fosnetupitant	Approved
T64591	DRUGINFO	D0Z2MB	Cilansetron	Phase 3
T64591	DRUGINFO	D0V3GT	BEMESETRON	Discontinued in Phase 3
T64591	DRUGINFO	D02WGN	YM-114	Discontinued in Phase 2
T64591	DRUGINFO	D0K1SZ	Norcisapride	Discontinued in Phase 2
T64591	DRUGINFO	D0M1YN	ATI-17000	Preclinical
T64591	DRUGINFO	D08KDP	AS-8112	Terminated
T64591	DRUGINFO	D0V1SD	BP4.879a	Terminated
T64591	DRUGINFO	D00EJS	5-hydroxyindole	Investigative
T64591	DRUGINFO	D01WXA	TMB-8	Investigative
T64591	DRUGINFO	D02OYL	1-(biphenyl-4-yl)-3-(4-(piperidin-1-yl)butyl)urea	Investigative
T64591	DRUGINFO	D04KGK	10,11-dihydro-5H-dibenzo[b,f]azepine	Investigative
T64591	DRUGINFO	D07ZZD	4-Benzoxazo-2-yl-1,4-diazabicyclo[3.2.2]nonane	Investigative
T64591	DRUGINFO	D0C3AJ	3alpha-(2'-Indolecarbonyloxy)-nortropane	Investigative
T64591	DRUGINFO	D0M4RW	FLUPENTIXOLE	Investigative
T64591	DRUGINFO	D0O5PQ	[3H]ramosetron	Investigative
T64591	DRUGINFO	D0S8ZJ	3alpha-(1'-Methyl-2'-Indolecarbonyloxy)-tropane	Investigative
T64591	DRUGINFO	D0T3QZ	[3H]GR65630	Investigative
T64591	DRUGINFO	D0UV6L	[3H](S)-zacopride	Investigative
T64591	DRUGINFO	D00PCE	BRL-24682	Investigative
T64591	DRUGINFO	D04AXY	6-(4-Methyl-piperazin-1-yl)-phenanthridine	Investigative
T64591	DRUGINFO	D06IRE	trichloroethanol	Investigative
T64591	DRUGINFO	D0G3MD	(4-Quinolin-2-ylpiperazin-1-yl)acetic Acid	Investigative
T64591	DRUGINFO	D0H4NK	1-phenylbiguanide	Investigative
T64591	DRUGINFO	D0I4BZ	(S)-zacopride	Investigative
T64591	DRUGINFO	D0IP9V	PH-709829	Investigative
T64591	DRUGINFO	D0L1NS	2-(4-Benzyl-piperazin-1-yl)-benzothiazole	Investigative
T64591	DRUGINFO	D0P2HR	[3H]granisetron	Investigative
T64591	DRUGINFO	D0SA4A	meta-chlorphenylbiguanide	Investigative
T64591	DRUGINFO	D0TJ6Z	2-(1H-Imidazol-4-ylmethyl)-4-phenyl-thiazole	Investigative
T64591	DRUGINFO	D0X7HD	CP-810123	Investigative
T64591	DRUGINFO	D0B0TK	bilobalide	Investigative
T64591	DRUGINFO	D0G2BS	2-(4-Methyl-piperazin-1-yl)-quinoline	Investigative
T64591	DRUGINFO	D01FFX	4-((naphthalen-2-yloxy)methyl)piperidine	Investigative
T64591	DRUGINFO	D0K5NZ	MESULERGINE	Investigative
T64591	DRUGINFO	D06QIQ	7-(piperidin-4-ylmethoxy)-2-naphthonitrile	Investigative
T64591	DRUGINFO	D08BCF	QUIPAZINE	Investigative
T64591	DRUGINFO	D0Y9TL	5-chloro-3,4-dihydroquinazolin-2-amine	Investigative
T64591	DRUGINFO	D00CRA	2-methyl-5-HT	Investigative
T64591	DRUGINFO	D08VGJ	5,6-dichloro-3,4-dihydroquinazolin-2-amine	Investigative
T64591	DRUGINFO	D0F6CD	SEROTONIN	Investigative
T64591	DRUGINFO	D0F9QT	A-987306	Investigative
T64591	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T59881	TARGETID	T59881
T59881	FORMERID	TTDC00298
T59881	UNIPROID	V1BR_HUMAN
T59881	TARGNAME	Vasopressin V1b receptor (V1BR)
T59881	GENENAME	AVPR1B
T59881	TARGTYPE	Successful
T59881	SYNONYMS	Vasopressin V3 receptor; Vasopressin V(1b) Receptor; VPR3; V1bR; Antidiuretic hormone receptor 1b; AVPR3; AVPR V3; AVPR V1b
T59881	FUNCTION	The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system. Receptor for arginine vasopressin.
T59881	BIOCLASS	GPCR rhodopsin
T59881	SEQUENCE	MDSGPLWDANPTPRGTLSAPNATTPWLGRDEELAKVEIGVLATVLVLATGGNLAVLLTLGQLGRKRSRMHLFVLHLALTDLAVALFQVLPQLLWDITYRFQGPDLLCRAVKYLQVLSMFASTYMLLAMTLDRYLAVCHPLRSLQQPGQSTYLLIAAPWLLAAIFSLPQVFIFSLREVIQGSGVLDCWADFGFPWGPRAYLTWTTLAIFVLPVTMLTACYSLICHEICKNLKVKTQAWRVGGGGWRTWDRPSPSTLAATTRGLPSRVSSINTISRAKIRTVKMTFVIVLAYIACWAPFFSVQMWSVWDKNAPDEDSTNVAFTISMLLGNLNSCCNPWIYMGFNSHLLPRPLRHLACCGGPQPRMRRRLSDGSLSSRHTTLLTRSSCPATLSLSLSLTLSGRPRPEESPRDLELADGEGTAETIIF
T59881	DRUGINFO	D0F4NS	Mozavaptan	Approved
T59881	DRUGINFO	D0M3FJ	Oxytocin	Approved
T59881	DRUGINFO	D0U7SH	Desmopressin	Approved
T59881	DRUGINFO	D0D8XY	ATOSIBAN	Phase 4
T59881	DRUGINFO	D0RC0J	ABT-436	Phase 2
T59881	DRUGINFO	D0SY9B	SSR149415	Phase 2
T59881	DRUGINFO	D01CSM	[3H]nelivaptan	Investigative
T59881	DRUGINFO	D00NIT	YM 471	Investigative
T59881	DRUGINFO	D00SGZ	YM 218	Investigative
T59881	DRUGINFO	D02VVG	D[Orn8(5/6C-Flu)]VT	Investigative
T59881	DRUGINFO	D02YBV	[Val4]AVP	Investigative
T59881	DRUGINFO	D04JXX	d[Pen1,Tyr(Me)2]AVP	Investigative
T59881	DRUGINFO	D05YHE	D[Thr4,Lys8(5/6C-Flu)]VT	Investigative
T59881	DRUGINFO	D09BWP	[HO1][Orn8(5/6C-Flu)]VT	Investigative
T59881	DRUGINFO	D09OML	D[D-3-Pal2]AVP	Investigative
T59881	DRUGINFO	D0C8XX	D[Thr4,Orn8(5/6C-Flu)]VT	Investigative
T59881	DRUGINFO	D0K0JJ	[HO1][Lys8(5/6C-Flu)]VT	Investigative
T59881	DRUGINFO	D0L0RP	[Lys8(Alexa 488) ]PVA	Investigative
T59881	DRUGINFO	D0M3BJ	D[Lys8(5/6-Flu)]VT	Investigative
T59881	DRUGINFO	D0O6WN	[HO1][Thr4,Orn8(5/6C-Flu)]VT	Investigative
T59881	DRUGINFO	D0Y5FO	[HO1][Thr4,Lys8(5/6C-Flu)]VT	Investigative
T59881	DRUGINFO	D01FDW	ARGENINE VASOPRESSIN	Investigative
T59881	DRUGINFO	D03BVC	D[Arg4,Orn8]VP	Investigative
T59881	DRUGINFO	D03DXK	D[Leu4,Lys8]VP	Investigative
T59881	DRUGINFO	D04MMD	D[Arg4,Lys8]VP	Investigative
T59881	DRUGINFO	D05BHL	D[Cha4,Lys8]VP	Investigative
T59881	DRUGINFO	D05RNF	D[Cha4,Orn8]VP	Investigative
T59881	DRUGINFO	D06SDG	D[Leu4,Dab8]VP	Investigative
T59881	DRUGINFO	D09RIE	D[Cha4]AVP	Investigative
T59881	DRUGINFO	D09XWA	D[Cha4,Dap8]VP	Investigative
T59881	DRUGINFO	D0A6FK	D[Leu4]AVP	Investigative
T59881	DRUGINFO	D0HI2N	D[Cha4,Dab8]VP	Investigative
T59881	DRUGINFO	D0M4QM	d(CH2)5[Tyr(Me)2]AVP	Investigative
T59881	DRUGINFO	D0O5TK	D[Leu4,Dap8]VP	Investigative
T59881	DRUGINFO	D0O8OF	D[Orn4,Lys8]VP	Investigative
T59881	DRUGINFO	D0R7QC	D[Arg4]AVP	Investigative
T59881	DRUGINFO	D0UK0O	D[Arg4,Dab8]VP	Investigative
T59881	DRUGINFO	D0V3FF	D[Leu4,Orn8]VP	Investigative
T59881	DRUGINFO	D0W3IQ	D[Val4]AVP	Investigative
T59881	DRUGINFO	D0YJ6C	D[Orn4,Orn8]VP	Investigative
T59881	DRUGINFO	D0ZD0W	D[Orn4]AVP	Investigative

T17163	TARGETID	T17163
T17163	FORMERID	TTDR00238
T17163	UNIPROID	LEPR_HUMAN
T17163	TARGNAME	Leptin receptor (LEPR)
T17163	GENENAME	LEPR
T17163	TARGTYPE	Successful
T17163	SYNONYMS	OBR; OB-R; OB receptor; LEP-R; HuB219; DB; CD295
T17163	FUNCTION	On ligand binding, mediates LEP central and peripheral effects through the activation of different signaling pathways such as JAK2/STAT3 and MAPK cascade/FOS. In the hypothalamus, LEP acts as an appetite-regulating factor that induces a decrease in food intake and an increase in energy consumption by inducing anorexinogenic factors and suppressing orexigenic neuropeptides, also regulates bone mass and secretion of hypothalamo-pituitary-adrenal hormones. In the periphery, increases basal metabolism, influences reproductive function, regulates pancreatic beta-cell function and insulin secretion, is pro-angiogenic and affects innate and adaptive immunity. Control of energy homeostasis and melanocortin production (stimulation of POMC and full repression of AgRP transcription) is mediated by STAT3 signaling, whereas distinct signals regulate NPY and the control of fertility, growth and glucose homeostasis. Involved in the regulation of counter-regulatory response to hypoglycemia by inhibiting neurons of the parabrachial nucleus. Has a specific effect on T lymphocyte responses, differentially regulating the proliferation of naive and memory T -ells. Leptin increases Th1 and suppresses Th2 cytokine production. Receptor for hormone LEP/leptin.
T17163	PDBSTRUC	6E2P; 3V6O
T17163	BIOCLASS	Cytokine receptor
T17163	SEQUENCE	MICQKFCVVLLHWEFIYVITAFNLSYPITPWRFKLSCMPPNSTYDYFLLPAGLSKNTSNSNGHYETAVEPKFNSSGTHFSNLSKTTFHCCFRSEQDRNCSLCADNIEGKTFVSTVNSLVFQQIDANWNIQCWLKGDLKLFICYVESLFKNLFRNYNYKVHLLYVLPEVLEDSPLVPQKGSFQMVHCNCSVHECCECLVPVPTAKLNDTLLMCLKITSGGVIFQSPLMSVQPINMVKPDPPLGLHMEITDDGNLKISWSSPPLVPFPLQYQVKYSENSTTVIREADKIVSATSLLVDSILPGSSYEVQVRGKRLDGPGIWSDWSTPRVFTTQDVIYFPPKILTSVGSNVSFHCIYKKENKIVPSKEIVWWMNLAEKIPQSQYDVVSDHVSKVTFFNLNETKPRGKFTYDAVYCCNEHECHHRYAELYVIDVNINISCETDGYLTKMTCRWSTSTIQSLAESTLQLRYHRSSLYCSDIPSIHPISEPKDCYLQSDGFYECIFQPIFLLSGYTMWIRINHSLGSLDSPPTCVLPDSVVKPLPPSSVKAEITINIGLLKISWEKPVFPENNLQFQIRYGLSGKEVQWKMYEVYDAKSKSVSLPVPDLCAVYAVQVRCKRLDGLGYWSNWSNPAYTVVMDIKVPMRGPEFWRIINGDTMKKEKNVTLLWKPLMKNDSLCSVQRYVINHHTSCNGTWSEDVGNHTKFTFLWTEQAHTVTVLAINSIGASVANFNLTFSWPMSKVNIVQSLSAYPLNSSCVIVSWILSPSDYKLMYFIIEWKNLNEDGEIKWLRISSSVKKYYIHDHFIPIEKYQFSLYPIFMEGVGKPKIINSFTQDDIEKHQSDAGLYVIVPVIISSSILLLGTLLISHQRMKKLFWEDVPNPKNCSWAQGLNFQKPETFEHLFIKHTASVTCGPLLLEPETISEDISVDTSWKNKDEMMPTTVVSLLSTTDLEKGSVCISDQFNSVNFSEAEGTEVTYEDESQRQPFVKYATLISNSKPSETGEEQGLINSSVTKCFSSKNSPLKDSFSNSSWEIEAQAFFILSDQHPNIISPHLTFSEGLDELLKLEGNFPEENNDKKSIYYLGVTSIKKRESGVLLTDKSRVSCPFPAPCLFTDIRVLQDSCSHFVENNINLGTSSKKTFASYMPQFQTCSTQTHKIMENKMCDLTV
T17163	DRUGINFO	D0Z9EO	Metreleptin	Approved
T17163	DRUGINFO	D06GZW	PEGylated leptin	Investigative
T17163	DRUGINFO	D07OED	BL-5040	Investigative
T17163	DRUGINFO	D08HUB	ANG-2004	Investigative
T17163	DRUGINFO	D0B3IZ	AMPSL	Investigative
T17163	DRUGINFO	D0C6TL	Leptin	Investigative
T17163	DRUGINFO	D0D1PQ	EDP-21	Investigative
T17163	DRUGINFO	D0G8BE	AMPPL	Investigative
T17163	DRUGINFO	D0J3AV	PEG-LPA-2	Investigative
T17163	DRUGINFO	D0D7YR	AMPE4L	Investigative

T06421	TARGETID	T06421
T06421	FORMERID	TTDS00492
T06421	UNIPROID	INAR2_HUMAN
T06421	TARGNAME	Interferon alpha/beta receptor 2 (IFNAR2)
T06421	GENENAME	IFNAR2
T06421	TARGTYPE	Successful
T06421	SYNONYMS	Type I interferon receptor 2; Type I interferon receptor; Interferon alpha/beta receptor; Interferon alpha binding protein; IFNARB; IFNABR; IFN-alpha/beta receptor 2; IFN-alpha-REC; IFN-alpha binding protein; IFN-R-2; IFN-R
T06421	FUNCTION	Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity. Associates with IFNAR1 to form the type I interferon receptor.
T06421	PDBSTRUC	3SE4; 3SE3; 3S9D; 3S8W; 2LAG
T06421	BIOCLASS	Cytokine receptor
T06421	SEQUENCE	MLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHSIVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLFSCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKKHKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAESAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMDMVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLIDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGRITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPTFPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR
T06421	DRUGINFO	D03QCW	Interferon alfa-n1	Approved
T06421	DRUGINFO	D04RZD	Interferon Alfa-2b, Recombinant	Approved
T06421	DRUGINFO	D05NDR	Sifalimumab	Approved
T06421	DRUGINFO	D0CQ2O	Interferon beta-1b	Approved
T06421	DRUGINFO	D0GA0A	Interferon alfacon-1	Approved
T06421	DRUGINFO	D0FU8R	Anifrolumab	Approved
T06421	DRUGINFO	D0SX9C	Alfa-interferon	Phase 1

T70792	TARGETID	T70792
T70792	FORMERID	TTDNS00541
T70792	UNIPROID	PLGF_HUMAN
T70792	TARGNAME	Placenta growth factor (PlGF)
T70792	GENENAME	PGF
T70792	TARGTYPE	Successful
T70792	SYNONYMS	SHGC-10760; PlGF-2; PLGF; PGFL; D12S1900
T70792	FUNCTION	It binds to the receptor FLT1/VEGFR-1. Isoform PlGF-2 binds NRP1/neuropilin-1 and NRP2/neuropilin-2 in a heparin-dependent manner. Also promotes cell tumor growth. Growth factor active in angiogenesis and endothelial cell growth, stimulating their proliferation and migration.
T70792	PDBSTRUC	1RV6; 1FZV
T70792	BIOCLASS	Growth factor
T70792	SEQUENCE	MPVMRLFPCFLQLLAGLALPAVPPQQWALSAGNGSSEVEVVPFQEVWGRSYCRALERLVDVVSEYPSEVEHMFSPSCVSLLRCTGCCGDENLHCVPVETANVTMQLLKIRSGDRPSYVELTFSQHVRCECRHSPGRQSPDMPGDFRADAPSFLPPRRSLPMLFRMEWGCALTGSQSAVWPSSPVPEEIPRMHPGRNGKKQQRKPLREKMKPERCGDAVPRR
T70792	DRUGINFO	D0C9ET	Aflibercept	Approved
T70792	DRUGINFO	D04TPU	RO-5323441	Phase 2
T70792	DRUGINFO	D06TWA	TB-403	Phase 2
T70792	DRUGINFO	D0E9HQ	R7334	Phase 1
T70792	DRUGINFO	D0YZ4T	SFLT-01	Phase 1
T70792	DRUGINFO	D06GOK	2-Methyl-2,4-Pentanediol	Investigative

T30040	TARGETID	T30040
T30040	FORMERID	TTDR00926
T30040	UNIPROID	VEGFB_HUMAN
T30040	TARGNAME	Vascular endothelial growth factor B (VEGFB)
T30040	GENENAME	VEGFB
T30040	TARGTYPE	Successful
T30040	SYNONYMS	VRF; VEGF-related factor; VEGF-B
T30040	FUNCTION	VEGF-B167 binds heparin and neuropilin-1 whereas the binding to neuropilin-1 of VEGF-B186 is regulated by proteolysis. Growth factor for endothelial cells.
T30040	PDBSTRUC	2XAC; 2VWE; 2C7W
T30040	BIOCLASS	Growth factor
T30040	SEQUENCE	MSPLLRRLLLAALLQLAPAQAPVSQPDAPGHQRKVVSWIDVYTRATCQPREVVVPLTVELMGTVAKQLVPSCVTVQRCGGCCPDDGLECVPTGQHQVRMQILMIRYPSSQLGEMSLEEHSQCECRPKKKDSAVKPDRAATPHHRPQPRSVPGWDSAPGAPSPADITHPTPAPGPSAHAAPSTTSALTPGPAAAAADAAASSVAKGGA
T30040	DRUGINFO	D0C9ET	Aflibercept	Approved
T30040	DRUGINFO	DD4E9T	CSL346	Phase 2

T06955	TARGETID	T06955
T06955	FORMERID	TTDC00226
T06955	UNIPROID	CCR4_HUMAN
T06955	TARGNAME	C-C chemokine receptor type 4 (CCR4)
T06955	GENENAME	CCR4
T06955	TARGTYPE	Successful
T06955	SYNONYMS	K5-5; CMKBR4; CD194; CCR-4; CC-CKR-4; CC chemokine receptor 4; C-CCKR-4; C-C CKR-4
T06955	FUNCTION	The activity of this receptor is mediated by G(i) proteins which activate a phosphatidylinositol-calcium second messenger system. Can function as a chemoattractant homing receptor on circulating memory lymphocytes and as a coreceptor for some primary HIV-2 isolates. In the CNS, could mediate hippocampal-neuron survival. High affinity receptor for the C-C type chemokines CCL17/TARC, CCL22/MDC and CKLF isoform 1/CKLF1.
T06955	BIOCLASS	GPCR rhodopsin
T06955	SEQUENCE	MNPTDIADTTLDESIYSNYYLYESIPKPCTKEGIKAFGELFLPPLYSLVFVFGLLGNSVVVLVLFKYKRLRSMTDVYLLNLAISDLLFVFSLPFWGYYAADQWVFGLGLCKMISWMYLVGFYSGIFFVMLMSIDRYLAIVHAVFSLRARTLTYGVITSLATWSVAVFASLPGFLFSTCYTERNHTYCKTKYSLNSTTWKVLSSLEINILGLVIPLGIMLFCYSMIIRTLQHCKNEKKNKAVKMIFAVVVLFLGFWTPYNIVLFLETLVELEVLQDCTFERYLDYAIQATETLAFVHCCLNPIIYFFLGEKFRKYILQLFKTCRGLFVLCQYCGLLQIYSADTPSSSYTQSTMDHDLHDAL
T06955	DRUGINFO	D0W2HD	Mogamulizumab	Approved
T06955	DRUGINFO	D5SDZ0	RPT193	Phase 2
T06955	DRUGINFO	D0XD7V	FLX475	Phase 1/2
T06955	DRUGINFO	D00XBC	GSK-2239633	Phase 1
T06955	DRUGINFO	D0U5AQ	ATLCAR.CD30.CCR4 cells	Phase 1
T06955	DRUGINFO	D0E2QN	AZD-1678	Preclinical
T06955	DRUGINFO	D01RGG	N-(4-tert-butylthiazol-2-yl)-1H-indol-4-amine	Investigative
T06955	DRUGINFO	D02MTK	AT-008	Investigative
T06955	DRUGINFO	D03VIS	4-tert-butyl-N-phenylthiazol-2-amine	Investigative
T06955	DRUGINFO	D06AJH	4-methyl-N-(naphthalen-1-yl)thiazol-2-amine	Investigative
T06955	DRUGINFO	D0B3JB	4-tert-butyl-N-(naphthalen-1-yl)oxazol-2-amine	Investigative
T06955	DRUGINFO	D0CX7I	4-tert-butyl-N-m-tolylthiazol-2-amine	Investigative
T06955	DRUGINFO	D0EV1I	C-014C	Investigative
T06955	DRUGINFO	D0G6NY	4-tert-butyl-N-(naphthalen-1-yl)thiazol-2-amine	Investigative
T06955	DRUGINFO	D0K2UA	4-tert-butyl-N-(2-isopropylphenyl)thiazol-2-amine	Investigative
T06955	DRUGINFO	D0M7HQ	4-isopropyl-N-(naphthalen-1-yl)thiazol-2-amine	Investigative
T06955	DRUGINFO	D0U7FE	N-(4-tert-butylthiazol-2-yl)quinolin-5-amine	Investigative
T06955	DRUGINFO	D0W1VL	N-(naphthalen-1-yl)-4-phenylthiazol-2-amine	Investigative
T06955	DRUGINFO	D0W5OM	4-tert-butyl-N-o-tolylthiazol-2-amine	Investigative
T06955	DRUGINFO	D0W6GE	N-(naphthalen-1-yl)-4-neopentylthiazol-2-amine	Investigative
T06955	DRUGINFO	D0XH2N	RS-1748	Investigative
T06955	DRUGINFO	D0ZE9M	N-(4-tert-butylthiazol-2-yl)isoquinolin-5-amine	Investigative

T37046	TARGETID	T37046
T37046	FORMERID	TTDS00494
T37046	UNIPROID	BIEA_HUMAN
T37046	TARGNAME	Biliverdin reductase A (BLVRA)
T37046	GENENAME	BLVRA
T37046	TARGTYPE	Successful
T37046	SYNONYMS	Biliverdin-IX alpha-reductase; BVR A; BVR; BLVRA; BLVR
T37046	FUNCTION	Reduces the gamma-methene bridge of the open tetrapyrrole, biliverdin IX alpha, to bilirubin with the concomitant oxidation of a NADH or NADPH cofactor.
T37046	PDBSTRUC	2H63
T37046	BIOCLASS	CH-CH donor oxidoreductase
T37046	ECNUMBER	EC 1.3.1.24
T37046	SEQUENCE	MNAEPERKFGVVVVGVGRAGSVRMRDLRNPHPSSAFLNLIGFVSRRELGSIDGVQQISLEDALSSQEVEVAYICSESSSHEDYIRQFLNAGKHVLVEYPMTLSLAAAQELWELAEQKGKVLHEEHVELLMEEFAFLKKEVVGKDLLKGSLLFTAGPLEEERFGFPAFSGISRLTWLVSLFGELSLVSATLEERKEDQYMKMTVCLETEKKSPLSWIEEKGPGLKRNRYLSFHFKSGSLENVPNVGVNKNIFLKDQNIFVQKLLGQFSEKELAAEKKRILHCLGLAEEIQKYCCSRK
T37046	DRUGINFO	D0G3SH	Ursodeoxycholic acid	Approved
T37046	DRUGINFO	D0R6JE	Nicotinamide-Adenine-Dinucleotide	Investigative

T84316	TARGETID	T84316
T84316	FORMERID	TTDS00415
T84316	UNIPROID	CA2D1_HUMAN
T84316	TARGNAME	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
T84316	GENENAME	CACNA2D1
T84316	TARGTYPE	Successful
T84316	SYNONYMS	Voltage-gated calcium channel subunit alpha-2/delta-1; Voltage-dependent calcium channel subunit delta-1; Voltage-dependent calcium channel subunit alpha-2-1; MHS3; CCHL2A; CACNL2A; CACNA2D1
T84316	FUNCTION	The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-contraction coupling.
T84316	BIOCLASS	Voltage-gated ion channel
T84316	SEQUENCE	MAAGCLLALTLTLFQSLLIGPSSEEPFPSAVTIKSWVDKMQEDLVTLAKTASGVNQLVDIYEKYQDLYTVEPNNARQLVEIAARDIEKLLSNRSKALVRLALEAEKVQAAHQWREDFASNEVVYYNAKDDLDPEKNDSEPGSQRIKPVFIEDANFGRQISYQHAAVHIPTDIYEGSTIVLNELNWTSALDEVFKKNREEDPSLLWQVFGSATGLARYYPASPWVDNSRTPNKIDLYDVRRRPWYIQGAASPKDMLILVDVSGSVSGLTLKLIRTSVSEMLETLSDDDFVNVASFNSNAQDVSCFQHLVQANVRNKKVLKDAVNNITAKGITDYKKGFSFAFEQLLNYNVSRANCNKIIMLFTDGGEERAQEIFNKYNKDKKVRVFTFSVGQHNYDRGPIQWMACENKGYYYEIPSIGAIRINTQEYLDVLGRPMVLAGDKAKQVQWTNVYLDALELGLVITGTLPVFNITGQFENKTNLKNQLILGVMGVDVSLEDIKRLTPRFTLCPNGYYFAIDPNGYVLLHPNLQPKPIGVGIPTINLRKRRPNIQNPKSQEPVTLDFLDAELENDIKVEIRNKMIDGESGEKTFRTLVKSQDERYIDKGNRTYTWTPVNGTDYSLALVLPTYSFYYIKAKLEETITQARYSETLKPDNFEESGYTFIAPRDYCNDLKISDNNTEFLLNFNEFIDRKTPNNPSCNADLINRVLLDAGFTNELVQNYWSKQKNIKGVKARFVVTDGGITRVYPKEAGENWQENPETYEDSFYKRSLDNDNYVFTAPYFNKSGPGAYESGIMVSKAVEIYIQGKLLKPAVVGIKIDVNSWIENFTKTSIRDPCAGPVCDCKRNSDVMDCVILDDGGFLLMANHDDYTNQIGRFFGEIDPSLMRHLVNISVYAFNKSYDYQSVCEPGAAPKQGAGHRSAYVPSVADILQIGWWATAAAWSILQQFLLSLTFPRLLEAVEMEDDDFTASLSKQSCITEQTQYFFDNDSKSFSGVLDCGNCSRIFHGEKLMNTNLIFIMVESKGTCPCDTRLLIQAEQTSDGPNPCDMVKQPRYRKGPDVCFDNNVLEDYTDCGGVSGLNPSLWYIIGIQFLLLWLVSGSTHRLL
T84316	DRUGINFO	D00WUF	Pregabalin	Approved
T84316	DRUGINFO	D08JIV	Amlodipine	Approved
T84316	DRUGINFO	D0A1DH	Nitrendipine	Approved
T84316	DRUGINFO	D0OB1J	Diltiazem	Approved
T84316	DRUGINFO	D0P6ZH	Lercanidipine	Approved
T84316	DRUGINFO	D07VFD	Mirogabalin	Registered
T84316	DRUGINFO	D05DBY	Imagabalin	Phase 3
T84316	DRUGINFO	D06FSC	NP-118809	Discontinued in Phase 2
T84316	DRUGINFO	D00XUE	(S)-2-amino-3-cyclohexylpropanoic acid	Investigative
T84316	DRUGINFO	D01PWO	4-(2-nitrobenzylthio)-2-aminobutanoic acid	Investigative
T84316	DRUGINFO	D02ANL	4-(3-fluorobenzylthio)-2-aminobutanoic acid	Investigative
T84316	DRUGINFO	D02IRC	4-(2-cyanobenzylthio)-2-aminobutanoic acid	Investigative
T84316	DRUGINFO	D03KKH	(S)-phenylglycine	Investigative
T84316	DRUGINFO	D04YNS	2-amino-4-(2-methyl-benzylsulfanyl)-butyric acid	Investigative
T84316	DRUGINFO	D05JAZ	2-amino-2-(3-chloro-4-fluorophenyl)acetic acid	Investigative
T84316	DRUGINFO	D05WDV	2-amino-2-(3-bromophenyl)acetic acid	Investigative
T84316	DRUGINFO	D06EUM	Rac-2-amino-5-cyclohexylpentanoic acid	Investigative
T84316	DRUGINFO	D06NUU	1-benzhydryl-4-(3,3-diphenylpropyl)piperazine	Investigative
T84316	DRUGINFO	D06RSF	4-(3-methoxybenzylthio)-2-aminobutanoic acid	Investigative
T84316	DRUGINFO	D06VUC	4-(3,4-dichlorobenzylthio)-2-aminobutanoic acid	Investigative
T84316	DRUGINFO	D07BMX	(S)-2-amino-3-(benzylthio)propanoic acid	Investigative
T84316	DRUGINFO	D07QDU	1-benzhydryl-4-(4,4-diphenylbutyl)piperazine	Investigative
T84316	DRUGINFO	D07QGX	2-amino-2-(2,4-difluorophenyl)acetic acid	Investigative
T84316	DRUGINFO	D08BOL	3-(aminomethyl)-4-(thiophen-2-yl)butanoic acid	Investigative
T84316	DRUGINFO	D08ZGW	2-amino-2-(3-chlorophenyl)acetic acid	Investigative
T84316	DRUGINFO	D09CKV	4-(3,4-dimethylbenzylthio)-2-aminobutanoic acid	Investigative
T84316	DRUGINFO	D09EQN	4-(3,5-dimethylbenzylthio)-2-aminobutanoic acid	Investigative
T84316	DRUGINFO	D09QVD	4-(2-bromobenzylthio)-2-aminobutanoic acid	Investigative
T84316	DRUGINFO	D09UXA	Trans-dimethyl gababutin	Investigative
T84316	DRUGINFO	D09VTR	4-(4-tert-butylbenzylthio)-2-aminobutanoic acid	Investigative
T84316	DRUGINFO	D0C6FW	4-(3-nitrobenzylthio)-2-aminobutanoic acid	Investigative
T84316	DRUGINFO	D0CU9Y	(S)-2-amino-2-o-tolylacetic acid	Investigative
T84316	DRUGINFO	D0D7FX	Rac-2-amino-4-phenylbutanoic acid	Investigative
T84316	DRUGINFO	D0GB8J	(S)-2-amino-2-cyclohexylacetic acid	Investigative
T84316	DRUGINFO	D0GU5E	4-(3-cyanobenzylthio)-2-aminobutanoic acid	Investigative
T84316	DRUGINFO	D0H2VW	N,4-dibenzhydrylpiperazine-1-carboxamide	Investigative
T84316	DRUGINFO	D0I0SK	4-(4-chlorobenzylthio)-2-aminobutanoic acid	Investigative
T84316	DRUGINFO	D0J3NS	3-(aminomethyl)-4-(thiophen-3-yl)butanoic acid	Investigative
T84316	DRUGINFO	D0KZ7A	3-(aminomethyl)-4-(furan-2-yl)butanoic acid	Investigative
T84316	DRUGINFO	D0L2VI	4-(3,5-dichlorobenzylthio)-2-aminobutanoic acid	Investigative
T84316	DRUGINFO	D0L7AO	Gababutin	Investigative
T84316	DRUGINFO	D0LN2D	ETHIONINE	Investigative
T84316	DRUGINFO	D0N6QW	4-(3-bromobenzylthio)-2-aminobutanoic acid	Investigative
T84316	DRUGINFO	D0O6HW	4-(4-bromobenzylthio)-2-aminobutanoic acid	Investigative
T84316	DRUGINFO	D0OI6B	4-(2-methoxybenzylthio)-2-aminobutanoic acid	Investigative
T84316	DRUGINFO	D0Q3KV	2-amino-2-(2,3-difluorophenyl)acetic acid	Investigative
T84316	DRUGINFO	D0R1QW	(R)-3-(aminomethyl)-4-(furan-2-yl)butanoic acid	Investigative
T84316	DRUGINFO	D0RA0P	2-amino-2-(thiophen-2-yl)acetic acid	Investigative
T84316	DRUGINFO	D0RC5X	(S)-2-amino-2-p-tolylacetic acid	Investigative
T84316	DRUGINFO	D0RS3R	2-(1-(aminomethyl)-3-ethylcyclopentyl)acetic acid	Investigative
T84316	DRUGINFO	D0S0WU	4-(2,3-dichlorobenzylthio)-2-aminobutanoic acid	Investigative
T84316	DRUGINFO	D0T2VK	3-(aminomethyl)-4-(furan-3-yl)butanoic acid	Investigative
T84316	DRUGINFO	D0T6YJ	4-(3-chlorobenzylthio)-2-aminobutanoic acid	Investigative
T84316	DRUGINFO	D0V2ZB	2-(1-(aminomethyl)-3-butylcyclopentyl)acetic acid	Investigative
T84316	DRUGINFO	D0V6SS	2-amino-2-(2-fluorophenyl)acetic acid	Investigative
T84316	DRUGINFO	D0VA2O	4-(2,5-dichlorobenzylthio)-2-aminobutanoic acid	Investigative
T84316	DRUGINFO	D0VQ4G	N'-Acridin-9-yl-N,N-diethyl-butane-1,4-diamine	Investigative
T84316	DRUGINFO	D0W2EX	(S)-2-amino-4-(benzylthio)butanoic acid	Investigative
T84316	DRUGINFO	D0X1BT	(S)-3-(aminomethyl)-4-(furan-2-yl)butanoic acid	Investigative
T84316	DRUGINFO	D0Z0VF	(S)-2-amino-2-phenylpropanoic acid	Investigative
T84316	DRUGINFO	D0D1EU	PD-144550	Investigative
T84316	DRUGINFO	D0T6DR	3-Aminomethyl-5-methyl-hexanoic acid	Investigative

T61698	TARGETID	T61698
T61698	FORMERID	TTDR00141
T61698	UNIPROID	IL2_HUMAN
T61698	TARGNAME	Interleukin-2 (IL2)
T61698	GENENAME	IL2
T61698	TARGTYPE	Successful
T61698	SYNONYMS	TCGF; T-cell growth factor; IL-2; Aldesleukin
T61698	FUNCTION	Produced by T-cells in response to antigenic or mitogenic stimulation, this protein is required for T-cell proliferation and other activities crucial to regulation of the immune response. Can stimulate B-cells, monocytes, lymphokine-activated killer cells, natural killer cells, and glioma cells.
T61698	PDBSTRUC	5UTZ; 5M5E; 5LQB; 4NEM; 4NEJ
T61698	BIOCLASS	Cytokine: interleukin
T61698	SEQUENCE	MYRMQLLSCIALSLALVTNSAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT
T61698	DRUGINFO	D05PUD	Aldesleukin	Approved
T61698	DRUGINFO	D0P1BZ	Daclizumab	Approved
T61698	DRUGINFO	D0C6ND	AIR-insulin	Phase 3
T61698	DRUGINFO	D0ZW3R	TG-4010	Phase 2/3
T61698	DRUGINFO	D00DAE	Carboxyamidotriazole orotate	Phase 2
T61698	DRUGINFO	D01WHC	Leuvectin	Phase 2
T61698	DRUGINFO	D04OJM	Human interleukin-2	Phase 2
T61698	DRUGINFO	D07KAQ	L19-IL-2 fusion protein	Phase 2
T61698	DRUGINFO	D0J4LI	Thymoctonan	Phase 2
T61698	DRUGINFO	D0NS7A	APN-301	Phase 2
T61698	DRUGINFO	D05RRU	IL-2/CD40L-expressing leukemia vaccine	Phase 2
T61698	DRUGINFO	DE09IO	BNZ-1	Phase 2
T61698	DRUGINFO	D01VWB	IL-2/gene-modified lymphocytes	Phase 1/2
T61698	DRUGINFO	D07XYT	Medusa IL-2	Phase 1/2
T61698	DRUGINFO	D08XFA	IL-2 XL	Phase 1/2
T61698	DRUGINFO	D0ZM5E	VCL-1M01	Phase 1
T61698	DRUGINFO	DPJ70I	SAR444245	Phase 1
T61698	DRUGINFO	D1FUQ2	ASP9801	Phase 1
T61698	DRUGINFO	D0PE0D	Nuleusin	Discontinued in Phase 3
T61698	DRUGINFO	D0I9LH	PMI-001	Discontinued in Phase 3
T61698	DRUGINFO	D0C7OQ	BIWB-1	Discontinued in Phase 2
T61698	DRUGINFO	D0EY5A	VLTS-587	Discontinued in Phase 2
T61698	DRUGINFO	D01OWJ	TG-1024	Discontinued in Phase 1
T61698	DRUGINFO	D0G9ZW	Roquinimex	Discontinued in Phase 1
T61698	DRUGINFO	D0WD6K	VPM-4-001	Preclinical
T61698	DRUGINFO	D05NUC	SP4160	Investigative
T61698	DRUGINFO	D08TGB	interleukin-2, Roussel Uclaf	Investigative
T61698	DRUGINFO	D0AJ7H	TG-2001	Investigative
T61698	DRUGINFO	D0VS0Z	SP2456	Investigative
T61698	DRUGINFO	D0Y9MP	IL-2 antibody (anti-tumor)	Investigative
T61698	DRUGINFO	D0GF2L	TG-1031	Investigative

T59845	TARGETID	T59845
T59845	FORMERID	TTDR00717
T59845	UNIPROID	PP1A_HUMAN
T59845	TARGNAME	Serine/threonine PP1-alpha (PPP1CA)
T59845	GENENAME	PPP1CA
T59845	TARGTYPE	Successful
T59845	SYNONYMS	Serine/threonine-protein phosphatase PP1-alpha catalytic subunit; Protein phosphatase 1alpha; PPP1A; PP-1A
T59845	FUNCTION	Protein phosphatase 1 (PP1) is essential for cell division, and participates in the regulation of glycogen metabolism, muscle contractility and protein synthesis. Involved in regulation of ionic conductances and long-term synaptic plasticity. May play an important role in dephosphorylating substrates such as the postsynaptic density-associated Ca(2+)/calmodulin dependent protein kinase II. Component of the PTW/PP1 phosphatase complex, which plays a role in the control of chromatin structure and cell cycle progression during the transition from mitosis into interphase. Regulates NEK2 function in terms of kinase activity and centrosome number and splitting, both in the presence and absence of radiation-induced DNA damage. Regulator of neural tube and optic fissure closure, and enteric neural crest cell (ENCCs) migration during development. In balance with CSNK1D and CSNK1E, determines the circadian period length, through the regulation of the speed and rhythmicity of PER1 and PER2 phosphorylation. May dephosphorylate CSNK1D and CSNK1E. Dephosphorylates the 'Ser-418' residue of FOXP3 in regulatory T-cells (Treg) from patients with rheumatoid arthritis, thereby inactivating FOXP3 and rendering Treg cells functionally defective. Dephosphorylates CENPA. Dephosphorylates the 'Ser-139' residue of ATG16L1 causing dissociation of ATG12-ATG5-ATG16L1 complex, thereby inhibiting autophagy. Protein phosphatase that associates with over 200 regulatory proteins to form highly specific holoenzymes which dephosphorylate hundreds of biological targets.
T59845	PDBSTRUC	6GHM; 6G0J; 6G0I; 6DNO; 6DCX
T59845	BIOCLASS	Phosphoric monoester hydrolase
T59845	ECNUMBER	EC 3.1.3.16
T59845	SEQUENCE	MSDSEKLNLDSIIGRLLEVQGSRPGKNVQLTENEIRGLCLKSREIFLSQPILLELEAPLKICGDIHGQYYDLLRLFEYGGFPPESNYLFLGDYVDRGKQSLETICLLLAYKIKYPENFFLLRGNHECASINRIYGFYDECKRRYNIKLWKTFTDCFNCLPIAAIVDEKIFCCHGGLSPDLQSMEQIRRIMRPTDVPDQGLLCDLLWSDPDKDVQGWGENDRGVSFTFGAEVVAKFLHKHDLDLICRAHQVVEDGYEFFAKRQLVTLFSAPNYCGEFDNAGAMMSVDETLMCSFQILKPADKNKGKYGQFSGLNPGGRPITPPRNSAKAKK
T59845	DRUGINFO	D0Z2RA	Cantharidin	Approved
T59845	DRUGINFO	D06EUA	PALASONIN	Investigative
T59845	DRUGINFO	D09CAI	TAUTOMYCIN	Investigative
T59845	DRUGINFO	D0M0TM	CANTHARIDIC_ACID	Investigative
T59845	DRUGINFO	D0O1BJ	MICROCYSTIN-LR	Investigative
T59845	DRUGINFO	D0W4IL	NORCANTHARIDIN	Investigative

T47081	TARGETID	T47081
T47081	FORMERID	TTDS00323
T47081	UNIPROID	PPIA_HUMAN
T47081	TARGNAME	Rotamase A (PPIA)
T47081	GENENAME	PPIA
T47081	TARGTYPE	Successful
T47081	SYNONYMS	PPIA; Cyclophilin A; CyPA
T47081	FUNCTION	Ppiases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides.
T47081	PDBSTRUC	6GJY; 6GJR; 6GJP; 6GJN; 6GJM
T47081	BIOCLASS	Cis-trans-isomerases
T47081	ECNUMBER	EC 5.2.1.8
T47081	SEQUENCE	MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE
T47081	DRUGINFO	D0DZ3X	L-Proline	Approved
T47081	DRUGINFO	D07IQR	3-[3-(3-benzyloxy-pyridin-2-yl)-ureido]-benzamide	Investigative
T47081	DRUGINFO	D0DQ4D	(3r)-1-Acetyl-3-Methylpiperidine	Investigative
T47081	DRUGINFO	D0L5XK	7-AMINO-4-METHYL-CHROMEN-2-ONE	Investigative
T47081	DRUGINFO	D0P6TX	1-(3-benzyloxy-pyridin-2-yl)-3-phenyl-urea	Investigative
T47081	DRUGINFO	D0P8IK	Ethyl Oxo(Piperidin-1-Yl)Acetate	Investigative
T47081	DRUGINFO	D0X5JR	4-[3-(3-benzyloxy-pyridin-2-yl)-ureido]-benzamide	Investigative

T49493	TARGETID	T49493
T49493	FORMERID	TTDS00498
T49493	UNIPROID	HBA_HUMAN
T49493	TARGNAME	Hemoglobin (HB)
T49493	GENENAME	HBA2
T49493	TARGTYPE	Successful
T49493	SYNONYMS	Hemoglobin subunit alpha; Hemoglobin alpha chain; HBA1; Alpha-globin
T49493	FUNCTION	Involved in oxygen transport from the lung to the various peripheral tissues.
T49493	PDBSTRUC	6NBD; 6NBC; 6HBW; 6HAL; 6DI4
T49493	BIOCLASS	Pore-forming globin
T49493	SEQUENCE	MVLSPADKTNVKAAWGKVGAHAGEYGAEALERMFLSFPTTKTYFPHFDLSHGSAQVKGHGKKVADALTNAVAHVDDMPNALSALSDLHAHKLRVDPVNFKLLSHCLLVTLAAHLPAEFTPAVHASLDKFLASVSTVLTSKYR
T49493	DRUGINFO	D08OKJ	Iron Dextran	Approved
T49493	DRUGINFO	D09RII	Voxelotor	Approved
T49493	DRUGINFO	D0Y3TM	Iron	Approved
T49493	DRUGINFO	D00IWL	PolyHeme	Phase 3
T49493	DRUGINFO	D03HVV	Efaproxyn	Phase 3
T49493	DRUGINFO	D0H4CB	Hemoglobin raffimer	Phase 2/3
T49493	DRUGINFO	DWR4I7	GBT021601	Phase 2/3
T49493	DRUGINFO	D0D8TE	FBS-0701	Phase 2
T49493	DRUGINFO	D0E6SB	HQK-1001	Phase 2
T49493	DRUGINFO	D0E9BF	5-hydroxymethyl-2-furfural	Phase 2
T49493	DRUGINFO	D00YBW	OXY-111A	Phase 1/2
T49493	DRUGINFO	D09VBN	CTX110	Phase 1/2
T49493	DRUGINFO	D0G6EO	Hemoximer	Discontinued in Phase 3
T49493	DRUGINFO	D0AL3O	VX-366	Discontinued in Phase 2
T49493	DRUGINFO	D0S3WK	HRC-302	Discontinued in Phase 1
T49493	DRUGINFO	D00HNK	RHb1.1	Terminated
T49493	DRUGINFO	D00XQK	HRC-102	Terminated
T49493	DRUGINFO	D09ZCH	HRC-201	Terminated
T49493	DRUGINFO	D09ZFF	HRC-101	Terminated
T49493	DRUGINFO	D0Q5QE	AN-10	Terminated
T49493	DRUGINFO	D0ZL9B	Diaspirin crosslinked hemoglobin	Terminated
T49493	DRUGINFO	D05QIT	SEBACIC ACID	Investigative
T49493	DRUGINFO	D06EEJ	4-Carboxycinnamic Acid	Investigative
T49493	DRUGINFO	D06KMP	2,6-DICARBOXYNAPHTHALENE	Investigative
T49493	DRUGINFO	D0A1GE	4-[(5-methoxy-2-methylphenoxy)methyl]pyridine	Investigative
T49493	DRUGINFO	D0F2WQ	1,3,5-BENZENETRICARBOXYLIC ACID	Investigative
T49493	DRUGINFO	D0TM1Z	2-[(2-methoxy-5-methylphenoxy)methyl]pyridine	Investigative
T49493	DRUGINFO	D0UU1I	Heme	Investigative

T55959	TARGETID	T55959
T55959	FORMERID	TTDS00017
T55959	UNIPROID	SC6A3_HUMAN
T55959	TARGNAME	Dopamine transporter (DAT)
T55959	GENENAME	SLC6A3
T55959	TARGTYPE	Successful
T55959	SYNONYMS	Solute carrier family 6 member 3; Sodium-dependent dopamine transporter; DAT1; DAT; DA transporter
T55959	FUNCTION	Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
T55959	BIOCLASS	Neurotransmitter:sodium symporter
T55959	SEQUENCE	MSKSKCSVGLMSSVVAPAKEPNAVGPKEVELILVKEQNGVQLTSSTLTNPRQSPVEAQDRETWGKKIDFLLSVIGFAVDLANVWRFPYLCYKNGGGAFLVPYLLFMVIAGMPLFYMELALGQFNREGAAGVWKICPILKGVGFTVILISLYVGFFYNVIIAWALHYLFSSFTTELPWIHCNNSWNSPNCSDAHPGDSSGDSSGLNDTFGTTPAAEYFERGVLHLHQSHGIDDLGPPRWQLTACLVLVIVLLYFSLWKGVKTSGKVVWITATMPYVVLTALLLRGVTLPGAIDGIRAYLSVDFYRLCEASVWIDAATQVCFSLGVGFGVLIAFSSYNKFTNNCYRDAIVTTSINSLTSFSSGFVVFSFLGYMAQKHSVPIGDVAKDGPGLIFIIYPEAIATLPLSSAWAVVFFIMLLTLGIDSAMGGMESVITGLIDEFQLLHRHRELFTLFIVLATFLLSLFCVTNGGIYVFTLLDHFAAGTSILFGVLIEAIGVAWFYGVGQFSDDIQQMTGQRPSLYWRLCWKLVSPCFLLFVVVVSIVTFRPPHYGAYIFPDWANALGWVIATSSMAMVPIYAAYKFCSLPGSFREKLAYAIAPEKDRELVDRGEVRQFTLRHWLKV
T55959	DRUGINFO	D02GJZ	Ioflupane i-123	Approved
T55959	DRUGINFO	D02PPN	Methylphenidate	Approved
T55959	DRUGINFO	D02QCD	DEXMETHYLPHENIDATE HYDROCHLORIDE	Approved
T55959	DRUGINFO	D07HQC	Modafinil	Approved
T55959	DRUGINFO	D0A8XY	Altropane	Approved
T55959	DRUGINFO	D0M2MC	Phenmetrazine	Approved
T55959	DRUGINFO	D04XPW	Cocaine	Approved
T55959	DRUGINFO	D0W6KM	Dasotraline	Approved
T55959	DRUGINFO	D0X8HB	NAV5001	Phase 3
T55959	DRUGINFO	D01TMQ	Bupropion+naltrexone	Phase 3
T55959	DRUGINFO	D04PXS	Amitifadine	Phase 3
T55959	DRUGINFO	D04KHY	Spiroglumide	Phase 2
T55959	DRUGINFO	D07QXU	NS 2359	Phase 2
T55959	DRUGINFO	D0Z4FE	MIN-117	Phase 2
T55959	DRUGINFO	D04KWY	RTI-336	Phase 1
T55959	DRUGINFO	D0K7OW	GSK-1360707	Phase 1
T55959	DRUGINFO	D08QUV	Amineptine	Withdrawn from market
T55959	DRUGINFO	D0A5RD	Radafaxine	Discontinued in Phase 2
T55959	DRUGINFO	D0O6QW	Manifaxine	Discontinued in Phase 2
T55959	DRUGINFO	D0H9GQ	DOV-216303	Discontinued in Phase 2
T55959	DRUGINFO	D0LU6N	SPD-473	Discontinued in Phase 2
T55959	DRUGINFO	D0M9LB	NS-2389	Discontinued in Phase 2
T55959	DRUGINFO	D0N2HF	Vanoxerine	Discontinued in Phase 1
T55959	DRUGINFO	D0W6WD	KP106	Discontinued in Phase 1
T55959	DRUGINFO	D04VUY	RG-7166	Discontinued in Phase 1
T55959	DRUGINFO	D08UNQ	NSD-644	Discontinued in Phase 1
T55959	DRUGINFO	D00JSG	Fluoratec	Terminated
T55959	DRUGINFO	D0U5PR	Seridopidine	Terminated
T55959	DRUGINFO	D00KIK	1-(1-Benzo[b]thiophen-2-yl-cyclohexyl)-azepane	Investigative
T55959	DRUGINFO	D00NEE	Bip-tyr-thr-pro-lys-thr	Investigative
T55959	DRUGINFO	D00QGB	O-2442	Investigative
T55959	DRUGINFO	D01DNN	Bip-tyr(3bzl)-thr-pro-lys-thr	Investigative
T55959	DRUGINFO	D01EOU	(+/-)-threo-N-(3-Chlorobenzyl)methylphenidate	Investigative
T55959	DRUGINFO	D01XHX	(+/-)-threo-N-(2-Phenylethyl)methylphenidate	Investigative
T55959	DRUGINFO	D02BXG	1-Benzo[b]thiophen-2-yl-cyclohexylamine	Investigative
T55959	DRUGINFO	D02EHL	1-Benzo[b]thiophen-2-yl-cyclopentylamine	Investigative
T55959	DRUGINFO	D02EKR	2-(N-Isopropylamino)-3'-chloropropiophenone	Investigative
T55959	DRUGINFO	D02NUR	2-(tert-Butylamino)-3',5'-difluoropropiophenone	Investigative
T55959	DRUGINFO	D02QWO	HOMOAROMOLINE	Investigative
T55959	DRUGINFO	D02XSH	DIMETHYLGRISABINE	Investigative
T55959	DRUGINFO	D02ZFN	(+/-)-threo-3',4'-Dichlororitalinol methyl ether	Investigative
T55959	DRUGINFO	D03EMO	(RS/SR)-2-[1-(4-chlorophenyl)hexyl]piperidine	Investigative
T55959	DRUGINFO	D03NUN	(+/-)-threo-Methylphenidate amide	Investigative
T55959	DRUGINFO	D05KJH	COCLAURINE	Investigative
T55959	DRUGINFO	D05PLF	2-(N-tert-Butylamino)-4'-chloropropiophenone	Investigative
T55959	DRUGINFO	D05TWV	(+/-)-threo-N-Methyl-30-methylmethylphenidate	Investigative
T55959	DRUGINFO	D06FYY	(+/-)-threo-3-Fluororitalinol	Investigative
T55959	DRUGINFO	D06MFY	(+/-)-threo-Benzylphenidate	Investigative
T55959	DRUGINFO	D06OIU	Threo-N-ethylritalinol hydrochloride	Investigative
T55959	DRUGINFO	D06QDX	Bip-tyr-thr-ala-pro-phe	Investigative
T55959	DRUGINFO	D07CQD	1-(1-(benzo[b]thiophen-2-yl)cyclohexyl)piperidine	Investigative
T55959	DRUGINFO	D07LRZ	(+/-)-threo-N-(6-Phenylhexyl)methylphenidate	Investigative
T55959	DRUGINFO	D07PAT	(RS/SR)-2-[1-(4-chlorophenyl)pentyl]piperidine	Investigative
T55959	DRUGINFO	D07YGR	(+/-)-threo-N-(4-Methylpyridine)methylphenidate	Investigative
T55959	DRUGINFO	D08JCK	1-phenyl-1-(piperidin-2-yl)propan-2-one	Investigative
T55959	DRUGINFO	D08NZE	Indatraline	Investigative
T55959	DRUGINFO	D08SLZ	(RS/SR)-2-[1-(3,4-dichlorophenyl)butyl]piperidine	Investigative
T55959	DRUGINFO	D08SWN	(+/-)-threo-3',5'-Dimethylmethylphenidate	Investigative
T55959	DRUGINFO	D08WVJ	[N-[2-[(3'-N'-PROPYL-3''ALPHA-(BIS(4-FLUORORPHENYL)METHOXY)TROPANE-2''BETA-CARBOXYLIC ACID METHYL ESTER)(2-MERCAPTOETHYL)AMINO]ACETYL]-2-AMINOETHANETHIOLATO]RHENIUM(V) OXIDE (DIASTEREOMERIC MIX)	Investigative
T55959	DRUGINFO	D08XGL	(+/-)-threo-N-(3-Phenylpropyl)ritalinol	Investigative
T55959	DRUGINFO	D08YJE	(+/-)-threo-N-(4-Phenylbutyl)methylphenidate	Investigative
T55959	DRUGINFO	D09BJN	(+/-)-threo-3',4'-Dichloromethylphenidate amide	Investigative
T55959	DRUGINFO	D09FTL	(+/-)-threo-N-(3-Methylfuran)methylphenidate	Investigative
T55959	DRUGINFO	D09GXL	NORBOLDINE	Investigative
T55959	DRUGINFO	D09OOO	(+/-)-threo-N-(4-Methoxybenzyl)methylphenidate	Investigative
T55959	DRUGINFO	D09QSO	(+/-)-threo-N-(2-Phenylethyl)ritalinol	Investigative
T55959	DRUGINFO	D09ZQW	(+/-)-threo-3',5'-Dichloromethylphenidate	Investigative
T55959	DRUGINFO	D0A0LZ	(+/-)-threo-N-Benzylmethylphenidate amide	Investigative
T55959	DRUGINFO	D0AN2Q	ISOTETRANDRINE	Investigative
T55959	DRUGINFO	D0B1KJ	(+/-)-threo-4'-Ethylmethylphenidate	Investigative
T55959	DRUGINFO	D0B1WF	N-Benzylmethylphenidate	Investigative
T55959	DRUGINFO	D0B9LI	(+/-)-threo-N-(2-Methylpyridine)methylphenidate	Investigative
T55959	DRUGINFO	D0BM0M	N,Ndimethyl milnacipran	Investigative
T55959	DRUGINFO	D0D3QE	4-(2-pyrrolidin-1-yl-pentanoyl)benzonitrile	Investigative
T55959	DRUGINFO	D0DH9G	2-phenylpiperidine hydrochloride	Investigative
T55959	DRUGINFO	D0DX0R	ISOPILINE	Investigative
T55959	DRUGINFO	D0E8FG	1-(1-Benzo[b]thiophen-2-yl-cycloheptyl)-azepane	Investigative
T55959	DRUGINFO	D0FS4V	Bip-tyr-thr-pro-thr(obzl)-gly	Investigative
T55959	DRUGINFO	D0G8ZD	(1-Phenyl-ethyl)-(2-phenyl-quinazolin-4-yl)-amine	Investigative
T55959	DRUGINFO	D0H2RD	(+/-)-threo-N-(4-Phenylbutyl)ritalinol	Investigative
T55959	DRUGINFO	D0H7RH	ANTIOQUINE	Investigative
T55959	DRUGINFO	D0I9ON	(+/-)-threo-N-Allylmethylphenidate	Investigative
T55959	DRUGINFO	D0IR0R	(RS/SR)-2-[1-(4-chlorophenyl)butyl]piperidine	Investigative
T55959	DRUGINFO	D0J5EF	2-(tert-Butylamino)-3'-fluoropropiophenone	Investigative
T55959	DRUGINFO	D0K9OK	PSEUDOCOCAINE	Investigative
T55959	DRUGINFO	D0L2JS	(+/-)-threo-N-(2-Methylfuran)methylphenidate	Investigative
T55959	DRUGINFO	D0M3YA	(+/-)-threo-N-(2-Methylthiopene)methylphenidate	Investigative
T55959	DRUGINFO	D0N6OH	(+/-)-threo-N-Propargylmethylphenidate	Investigative
T55959	DRUGINFO	D0O1WV	Threo-ritalinol hydrochloride	Investigative
T55959	DRUGINFO	D0O8MA	(+/-)-threo-N-(3-Methylpyridine)methylphenidate	Investigative
T55959	DRUGINFO	D0P1HA	OBABERINE	Investigative
T55959	DRUGINFO	D0P7NW	(+/-)-threo-N-Benzyl-3'-chloromethylphenidate	Investigative
T55959	DRUGINFO	D0P9MQ	(+/-)-threo-N-(4-Nitrobenzyl)methylphenidate	Investigative
T55959	DRUGINFO	D0Q9NW	Threo-ritalinol methyl ether hydrochloride	Investigative
T55959	DRUGINFO	D0R1AE	Methyl 2-(naphthalen-2-yl)benzoate	Investigative
T55959	DRUGINFO	D0R2BM	1-(4-aminophenyl)-2-pyrrolidin-1-yl-pentan-1-one	Investigative
T55959	DRUGINFO	D0R8TH	(RS/SR)-2-[1-(4-chlorophenyl)propyl]piperidine	Investigative
T55959	DRUGINFO	D0R9ZS	(+/-)-threo-N-(2-Chlorobenzyl)methylphenidate	Investigative
T55959	DRUGINFO	D0S6CT	(+/-)-threo-N-(5-Phenylpentyl)methylphenidate	Investigative
T55959	DRUGINFO	D0U3PC	1-Benzo[b]thiophen-2-yl-cycloheptylamine	Investigative
T55959	DRUGINFO	D0U5DH	(+/-)-threo-N-(4-Chlorobenzyl)methylphenidate	Investigative
T55959	DRUGINFO	D0U6PD	Bip-tyr-ala-pro-lys-thr(obzl)-gly	Investigative
T55959	DRUGINFO	D0UV1S	O-methyldauricine	Investigative
T55959	DRUGINFO	D0V0NO	(+/-)-threo-N-(3-Methylthiopene)methylphenidate	Investigative
T55959	DRUGINFO	D0V0RS	SECOCULARIDINE	Investigative
T55959	DRUGINFO	D0Y1MJ	(RS/SR)-2-[1-(4-chlorophenyl)ethyl]piperidine	Investigative
T55959	DRUGINFO	D0Y2YH	(+/-)-threo-N-Benzyl-3',4'-dichlororitalinol	Investigative
T55959	DRUGINFO	D0Y3DR	1-(1-Benzo[b]thiophen-2-yl-cyclopentyl)-azepane	Investigative
T55959	DRUGINFO	D0Y5WA	Bip-tyr-thr-pro-lys-thr(obzl)-gly	Investigative
T55959	DRUGINFO	D0YD9W	(+/-)-threo-N-(3-Phenylpropyl)methylphenidate	Investigative
T55959	DRUGINFO	D0Z8DJ	Bip-tyr-thr-pro-ala-thr(obzl)-gly	Investigative
T55959	DRUGINFO	D00KKN	(2S,3S)-iodoreboxetine	Investigative
T55959	DRUGINFO	D00WMS	2-(N-tert-Butylamino)propiophenone	Investigative
T55959	DRUGINFO	D01BPR	1-benzylpiperidine hydrochloride	Investigative
T55959	DRUGINFO	D01JVP	(2R,3R)-iodoreboxetine	Investigative
T55959	DRUGINFO	D01RWY	2-(N-tert-Butylamino)-3'-chloroheptanophenone	Investigative
T55959	DRUGINFO	D01YED	2-(N-Pyrrolidinyl)-3'-methoxypropiophenone	Investigative
T55959	DRUGINFO	D02ANE	1-(naphthalen-2-yl)-3-aza-bicyclo[3.1.0]hexane	Investigative
T55959	DRUGINFO	D02LQG	WIN-35065	Investigative
T55959	DRUGINFO	D03BUG	1-(benzofuran-2-yl)-3-aza-bicyclo[3.1.0]hexane	Investigative
T55959	DRUGINFO	D03WGD	AMINOBENZTROPINE	Investigative
T55959	DRUGINFO	D04EXA	Erythro-3,4-dichloromethylphenidate hydrochloride	Investigative
T55959	DRUGINFO	D05VTT	3-(4-Trifluoromethylphenyl)-2-nortropene	Investigative
T55959	DRUGINFO	D05ZFG	(cis)-1,6-diphenyl-3-aza-bicyclo[3.1.0]hexane	Investigative
T55959	DRUGINFO	D06GFV	1-(2,3-Dihydro-1H-indol-5-ylmethyl)-propylamine	Investigative
T55959	DRUGINFO	D06LCK	2-(N-Pyrrolidinyl)-3'-fluoropropiophenone	Investigative
T55959	DRUGINFO	D07IOX	2-(N-tert-Butylamino)-3'-chlorooctanophenone	Investigative
T55959	DRUGINFO	D07OOI	[3H]GBR12935	Investigative
T55959	DRUGINFO	D08IFQ	3-Phenyl-2-nortropene	Investigative
T55959	DRUGINFO	D09BYB	2-(tert-butylamino)-1-p-tolylpropan-1-one	Investigative
T55959	DRUGINFO	D09CVV	NORSTEPHALAGINE	Investigative
T55959	DRUGINFO	D09RCL	(2R,3S)-2-[(3-Iodophenoxy)phenylmethyl]morpholine	Investigative
T55959	DRUGINFO	D09WVS	10R-hydroxylobelane	Investigative
T55959	DRUGINFO	D09XWL	2-(N-Cyclopentylamino)-3'-fluoropropiophenone	Investigative
T55959	DRUGINFO	D09ZIU	1-phenyl-3-aza-bicyclo[3.1.0]hexane	Investigative
T55959	DRUGINFO	D0B1FM	3-(3,4-dichlorophenyl)-2-nortropene	Investigative
T55959	DRUGINFO	D0B4FN	2pyrrolidin-1-yl-1-phenylpentan-1-one	Investigative
T55959	DRUGINFO	D0B5AG	Cis-3-phenoxy-2,3-dihydro-1H-inden-1-amine	Investigative
T55959	DRUGINFO	D0B6UU	8R-hydroxylobel-9-ene	Investigative
T55959	DRUGINFO	D0C0GL	1-(3-bromophenyl)-2-(tert-butylamino)propan-1-one	Investigative
T55959	DRUGINFO	D0C4XQ	GB-12819	Investigative
T55959	DRUGINFO	D0D9FA	(2R,3S)-2-[(4-Iodophenoxy)phenylmethyl]morpholine	Investigative
T55959	DRUGINFO	D0E3DF	(2R,3S)-2-[(2-Iodophenoxy)phenylmethyl]morpholine	Investigative
T55959	DRUGINFO	D0F8SA	8S-hydroxylobelane	Investigative
T55959	DRUGINFO	D0G0CJ	2-(N-Cyclopentylamino)-3'-bromopropiophenone	Investigative
T55959	DRUGINFO	D0G0NB	2-(2,3-Dihydro-1H-indol-5-yl)-1-methyl-ethylamine	Investigative
T55959	DRUGINFO	D0GY8R	2-(N-Pyrrolidinyl)-3'-methylpropiophenone	Investigative
T55959	DRUGINFO	D0HO7I	ANONAINE	Investigative
T55959	DRUGINFO	D0I1ME	10R-hydroxylobel-7-ene	Investigative
T55959	DRUGINFO	D0J4EF	1-Biphenyl-4-yl-3-aza-bicyclo[3.1.0]hexane	Investigative
T55959	DRUGINFO	D0L6RY	1-(4-fluorophenyl)-2-pyrrolidin-1-yl-pentan-1-one	Investigative
T55959	DRUGINFO	D0M1OE	ANOLOBINE	Investigative
T55959	DRUGINFO	D0M4AQ	2-((2-iodophenoxy)(phenyl)methyl)morpholine	Investigative
T55959	DRUGINFO	D0M4KN	10S-hydroxylobelane	Investigative
T55959	DRUGINFO	D0M6UK	PMID25037917C58	Investigative
T55959	DRUGINFO	D0N4YP	6-(3-aza-bicyclo[3.1.0]hexan-1-yl)quinoline	Investigative
T55959	DRUGINFO	D0NW3Z	COCAINE.HCL	Investigative
T55959	DRUGINFO	D0O2LC	2-(N-Cyclopentylamino)-3'-chloropropiophenone	Investigative
T55959	DRUGINFO	D0P9EO	2-(N-Cyclopentylamino)-3'-methylpropiophenone	Investigative
T55959	DRUGINFO	D0Q0MN	Threo-3,4-dichlororitalinol hydrochloride	Investigative
T55959	DRUGINFO	D0Q8IQ	1-(3-chlorophenyl)-2-(dimethylamino)propan-1-one	Investigative
T55959	DRUGINFO	D0Q9UZ	2-((3-iodophenyl)(o-tolyloxy)methyl)morpholine	Investigative
T55959	DRUGINFO	D0R5AD	2-(N,N-Diethylamino)-3'-chloropropiophenone	Investigative
T55959	DRUGINFO	D0RE7T	4-[(diphenylmethyl)amino]-2-phenylquinazoline	Investigative
T55959	DRUGINFO	D0S0EE	3-alpha-Phenylmethoxy-3-beta-phenyl-nortropane	Investigative
T55959	DRUGINFO	D0T6XD	10S-hydroxylobel-7-ene	Investigative
T55959	DRUGINFO	D0TE5Q	Threo-1-aza-5-phenyl[4.4.0]decane hydrochloride	Investigative
T55959	DRUGINFO	D0TO4N	1-(thiophen-2-yl)-3-aza-bicyclo[3.1.0]hexane	Investigative
T55959	DRUGINFO	D0U3SB	2-(N-Pyrrolidinyl)-3'-bromopropiophenone	Investigative
T55959	DRUGINFO	D0US2X	3-(4-Fluorophenyl)-2-nortropene	Investigative
T55959	DRUGINFO	D0V8IZ	2-(N-tert-Butylamino)-3'-chlorohexanophenone	Investigative
T55959	DRUGINFO	D0VY9K	2-(N-Pyrrolidinyl)-3'-nitropropiophenone	Investigative
T55959	DRUGINFO	D0XY9E	2-(N-tert-Butylamino)-3'-chloropentanophenone	Investigative
T55959	DRUGINFO	D0Y0BB	3-(4-Chlorophenyl)-2-nortropene	Investigative
T55959	DRUGINFO	D0Y7CS	2-(tert-butylamino)-1-m-tolylpropan-1-one	Investigative
T55959	DRUGINFO	D0Z0LP	8R-hydroxylobelane	Investigative
T55959	DRUGINFO	D0Z4IH	8S-hydroxylobel-9-ene	Investigative
T55959	DRUGINFO	D00GDI	2-(N-tert-Butylamino)-3',4'-dichloropropiophenone	Investigative
T55959	DRUGINFO	D00VUT	D-257C	Investigative
T55959	DRUGINFO	D01AOI	6-(piperidin-4-ylmethoxy)-2-naphthonitrile	Investigative
T55959	DRUGINFO	D02ENH	(R)-Norfluoxetine	Investigative
T55959	DRUGINFO	D02ICX	PYROVALERONE	Investigative
T55959	DRUGINFO	D02TMK	METHYLENEDIOXYAMPHETAMINE	Investigative
T55959	DRUGINFO	D02UUC	3-p-Tolyl-8-aza-bicyclo[3.2.1]octane	Investigative
T55959	DRUGINFO	D02YOO	NISOXETINE	Investigative
T55959	DRUGINFO	D02YSN	2-Aminomethyl-5-(p-t-butylphenyl)tetrahydrofuran	Investigative
T55959	DRUGINFO	D02ZIQ	1-(3-chlorophenyl)-2-(piperidin-1-yl)propan-1-one	Investigative
T55959	DRUGINFO	D03BQV	1S,2R-milnacipran	Investigative
T55959	DRUGINFO	D03HQF	2-Aminomethyl-5-(p-bromophenyl)tetrahydrofuran	Investigative
T55959	DRUGINFO	D03JOX	1-(2-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one	Investigative
T55959	DRUGINFO	D03ZFX	D-254C	Investigative
T55959	DRUGINFO	D04KZX	2-(tert-Butylamino)-3',4'-dichlorobutyrophenone	Investigative
T55959	DRUGINFO	D05LKO	1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine	Investigative
T55959	DRUGINFO	D05UMA	(R)-DULOXETINE	Investigative
T55959	DRUGINFO	D06CMJ	Para-chloroamphetamine	Investigative
T55959	DRUGINFO	D06EMC	PF-18298	Investigative
T55959	DRUGINFO	D06KNV	[3-(3,4-Dichloro-phenyl)-indan-1-yl]-methyl-amine	Investigative
T55959	DRUGINFO	D06QGD	1-(4-nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-one	Investigative
T55959	DRUGINFO	D06UDU	4-(2-(4-fluorophenoxy)-4-methylphenyl)piperidine	Investigative
T55959	DRUGINFO	D06WIV	Biphenyl-2-ylmethyl-(S)-pyrrolidin-3-yl-amine	Investigative
T55959	DRUGINFO	D07DMN	4-(1H-indol-3-yl)-N,N-dimethylcyclohex-3-enamine	Investigative
T55959	DRUGINFO	D07RQT	8-Methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octane	Investigative
T55959	DRUGINFO	D07SAA	2-(N-Cyclopropylamino)-3-chloropropiophenone	Investigative
T55959	DRUGINFO	D07ZOP	1-(3-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one	Investigative
T55959	DRUGINFO	D08AWN	(S)-Norfluoxetine	Investigative
T55959	DRUGINFO	D08TJY	D-257A	Investigative
T55959	DRUGINFO	D09QZM	2-(Aminomethyl)-5-(2'-naphthyl)tetrahydrofuran	Investigative
T55959	DRUGINFO	D09ZAT	1-(3,4-Dichloro-phenyl)-3-methylamino-indan-5-ol	Investigative
T55959	DRUGINFO	D0G1XP	2-(tert-Butylamino)-3',4'-dichloropentanophenone	Investigative
T55959	DRUGINFO	D0G5RH	WIN-35066-2	Investigative
T55959	DRUGINFO	D0G8UA	(R)-2-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol	Investigative
T55959	DRUGINFO	D0H2TS	4-(2-((3-fluorophenoxy)methyl)phenyl)piperidine	Investigative
T55959	DRUGINFO	D0H4AD	1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one	Investigative
T55959	DRUGINFO	D0I9KV	1-(4-bromophenyl)-2-pyrrolidin-1-yl-pentan-1-one	Investigative
T55959	DRUGINFO	D0IB6Y	2-Aminomethyl-5-(p-methoxyphenyl)tetrahydrofuran	Investigative
T55959	DRUGINFO	D0J0ES	1-(3,4-Dichloro-phenyl)-3-diethylamino-indan-5-ol	Investigative
T55959	DRUGINFO	D0J5AR	2-(2'-Aminoethyl)-5-benzyltetrahydrofuran	Investigative
T55959	DRUGINFO	D0J7GF	Benzyl-(2-phenyl-quinazolin-4-yl)-amine	Investigative
T55959	DRUGINFO	D0L0AY	2-(Aminomethyl)-5-phenethyltetrahydrofuran	Investigative
T55959	DRUGINFO	D0L7BK	1-(1,4-diphenylbutan-2-yl)piperazine	Investigative
T55959	DRUGINFO	D0LD1X	D-211B	Investigative
T55959	DRUGINFO	D0N0TQ	2-Aminomethyl-5-(phenyl)tetrahydrofuran	Investigative
T55959	DRUGINFO	D0N3DD	[3H]WIN35428	Investigative
T55959	DRUGINFO	D0NY4W	1-(4-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one	Investigative
T55959	DRUGINFO	D0O9BL	1-(3-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one	Investigative
T55959	DRUGINFO	D0Q6SH	4-(2-(3-fluorophenoxy)-4-methylphenyl)piperidine	Investigative
T55959	DRUGINFO	D0R8EV	2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one	Investigative
T55959	DRUGINFO	D0RT9B	2-Aminomethyl-5-(p-chlorophenyl)tetrahydrofuran	Investigative
T55959	DRUGINFO	D0SB6Y	D-211A	Investigative
T55959	DRUGINFO	D0SN6R	(+/-)-3-((naphthalen-2-yloxy)methyl)pyrrolidine	Investigative
T55959	DRUGINFO	D0T8BU	3-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol	Investigative
T55959	DRUGINFO	D0V0PR	4-(2-(phenoxymethyl)phenyl)piperidine	Investigative
T55959	DRUGINFO	D0V3LR	D-166A	Investigative
T55959	DRUGINFO	D0W8BJ	Trans-3-(o-tolyloxy)-2,3-dihydro-1H-inden-1-amine	Investigative
T55959	DRUGINFO	D0WB6P	R-NORDULOXETINE	Investigative
T55959	DRUGINFO	D0X8LG	1-naphthalen-2-yl-2-pyrrolidin-1-yl-pentan-1-one	Investigative
T55959	DRUGINFO	D0Y3BI	2-(Aminomethyl)-5-(1'-naphthyl)tetrahydrofuran	Investigative
T55959	DRUGINFO	D0Z4UF	RTI-219	Investigative
T55959	DRUGINFO	D0Z9OX	1-(2-(2-chlorophenyl)-1-phenylethyl)piperazine	Investigative
T55959	DRUGINFO	D0ZE4C	2-(N-Cyclopentylamino)-3'-methoxypropiophenone	Investigative
T55959	DRUGINFO	D00DEH	4-(2-(3-chlorophenoxy)phenyl)piperidine	Investigative
T55959	DRUGINFO	D00HCC	1-(2-phenoxyphenyl)piperazine	Investigative
T55959	DRUGINFO	D00KRQ	4-(2-phenoxyphenyl)piperidine	Investigative
T55959	DRUGINFO	D01ABR	1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine	Investigative
T55959	DRUGINFO	D01JYY	(R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide	Investigative
T55959	DRUGINFO	D01MBF	4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine	Investigative
T55959	DRUGINFO	D01YNZ	4-(2-(benzyloxy)phenyl)piperidine	Investigative
T55959	DRUGINFO	D03DQQ	4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine	Investigative
T55959	DRUGINFO	D04NDO	4-(2-(2-fluorobenzyloxy)phenyl)piperidine	Investigative
T55959	DRUGINFO	D04NKQ	4-(2-(4-fluorophenoxy)phenyl)piperidine	Investigative
T55959	DRUGINFO	D04ZPF	4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine	Investigative
T55959	DRUGINFO	D05LJC	4-(2-(benzyloxy)-3-fluorophenyl)piperidine	Investigative
T55959	DRUGINFO	D08EKQ	1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX)	Investigative
T55959	DRUGINFO	D08JLB	4-(2-(benzyloxy)-6-fluorophenyl)piperidine	Investigative
T55959	DRUGINFO	D08SCH	2-Amino-1-(4-methylthiophenyl)propane	Investigative
T55959	DRUGINFO	D09FIC	1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX)	Investigative
T55959	DRUGINFO	D09IIH	4-(3-fluoro-2-phenoxyphenyl)piperidine	Investigative
T55959	DRUGINFO	D0CG2Y	2-phenoxy-3-(piperidin-4-yl)pyridine	Investigative
T55959	DRUGINFO	D0E3DM	(S)-3-(naphthalen-2-ylmethoxy)pyrrolidine	Investigative
T55959	DRUGINFO	D0E6PQ	4-(2-fluoro-6-phenoxyphenyl)piperidine	Investigative
T55959	DRUGINFO	D0F0BS	3alpha-(bis-chloro-phenylmethoxy)tropane	Investigative
T55959	DRUGINFO	D0F6GB	2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine	Investigative
T55959	DRUGINFO	D0IC4J	4-(2-(3-fluorophenoxy)phenyl)piperidine	Investigative
T55959	DRUGINFO	D0KT2M	2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine	Investigative
T55959	DRUGINFO	D0M3TK	1-(2-(4-fluorophenoxy)phenyl)piperazine	Investigative
T55959	DRUGINFO	D0R3TA	4-(2-(4-fluorobenzyloxy)phenyl)piperidine	Investigative
T55959	DRUGINFO	D0S4JT	1-(2-(phenoxymethyl)phenyl)piperazine	Investigative
T55959	DRUGINFO	D0U7OD	PF-526014	Investigative
T55959	DRUGINFO	D0W8YO	4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine	Investigative
T55959	DRUGINFO	D0XF5P	(R)-3-(naphthalen-2-ylmethoxy)pyrrolidine	Investigative
T55959	DRUGINFO	D0Y8UC	Difluorobenztropine	Investigative
T55959	DRUGINFO	D00QCP	(2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol	Investigative
T55959	DRUGINFO	D03YQY	(2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol	Investigative
T55959	DRUGINFO	D06QIQ	7-(piperidin-4-ylmethoxy)-2-naphthonitrile	Investigative
T55959	DRUGINFO	D0N2KU	PF-3409409	Investigative
T55959	DRUGINFO	D0F5NJ	METHYLENEDIOXYMETHAMPHETAMINE	Investigative
T55959	DRUGINFO	D0I4ME	MMDA	Investigative
T55959	DRUGINFO	D0R7ZC	Beta-methoxyamphetamine	Investigative
T55959	DRUGINFO	D0PN9R	R-226161	Investigative
T55959	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T61400	TARGETID	T61400
T61400	FORMERID	TTDI00862
T61400	UNIPROID	PYRD_HUMAN
T61400	TARGNAME	Dihydroorotate dehydrogenase (DHODH)
T61400	GENENAME	DHODH
T61400	TARGTYPE	Successful
T61400	SYNONYMS	Dihydroorotate oxidase; Dihydroorotate dehydrogenase (quinone), mitochondrial; DHOdehase; DHODH
T61400	FUNCTION	Catalyzes the conversion of dihydroorotate to orotate with quinone as electron acceptor.
T61400	PDBSTRUC	6FMD; 6ET4; 6CJG; 6CJF; 5ZFB
T61400	BIOCLASS	CH-CH donor oxidoreductase
T61400	ECNUMBER	EC 1.3.5.2
T61400	SEQUENCE	MAWRHLKKRAQDAVIILGGGGLLFASYLMATGDERFYAEHLMPTLQGLLDPESAHRLAVRFTSLGLLPRARFQDSDMLEVRVLGHKFRNPVGIAAGFDKHGEAVDGLYKMGFGFVEIGSVTPKPQEGNPRPRVFRLPEDQAVINRYGFNSHGLSVVEHRLRARQQKQAKLTEDGLPLGVNLGKNKTSVDAAEDYAEGVRVLGPLADYLVVNVSSPNTAGLRSLQGKAELRRLLTKVLQERDGLRRVHRPAVLVKIAPDLTSQDKEDIASVVKELGIDGLIVTNTTVSRPAGLQGALRSETGGLSGKPLRDLSTQTIREMYALTQGRVPIIGVGGVSSGQDALEKIRAGASLVQLYTALTFWGPPVVGKVKRELEALLKEQGFGGVTDAIGADHRR
T61400	DRUGINFO	D07QFP	Teriflunomide	Approved
T61400	DRUGINFO	D00LSI	Vidofludimus	Phase 2
T61400	DRUGINFO	D0N3XT	BREQUINAR	Phase 2
T61400	DRUGINFO	D08DMH	BAY2402234	Phase 1
T61400	DRUGINFO	D0F1JY	LAS-186323	Phase 1
T61400	DRUGINFO	D0SX4K	HR325	Discontinued in Phase 2
T61400	DRUGINFO	D0X4IA	FK778	Discontinued in Phase 2

T67710	TARGETID	T67710
T67710	FORMERID	TTDS00258
T67710	UNIPROID	PTH1R_HUMAN
T67710	TARGNAME	Parathyroid hormone 1 receptor (PTH1R)
T67710	GENENAME	PTH1R
T67710	TARGTYPE	Successful
T67710	SYNONYMS	Parathyroid hormone-related peptide (PTHRP); PTH1R; PTH/PTHrP type I receptor; PTH/PTHr receptor
T67710	FUNCTION	This is a receptor for parathyroid hormone and for parathyroid hormone-related peptide. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and also a phosphatidylinositol-calcium second messenger system.
T67710	PDBSTRUC	6NBI; 6NBH; 6NBF; 5EMB; 4Z8J
T67710	BIOCLASS	GPCR secretin
T67710	SEQUENCE	MGTARIAPGLALLLCCPVLSSAYALVDADDVMTKEEQIFLLHRAQAQCEKRLKEVLQRPASIMESDKGWTSASTSGKPRKDKASGKLYPESEEDKEAPTGSRYRGRPCLPEWDHILCWPLGAPGEVVAVPCPDYIYDFNHKGHAYRRCDRNGSWELVPGHNRTWANYSECVKFLTNETREREVFDRLGMIYTVGYSVSLASLTVAVLILAYFRRLHCTRNYIHMHLFLSFMLRAVSIFVKDAVLYSGATLDEAERLTEEELRAIAQAPPPPATAAAGYAGCRVAVTFFLYFLATNYYWILVEGLYLHSLIFMAFFSEKKYLWGFTVFGWGLPAVFVAVWVSVRATLANTGCWDLSSGNKKWIIQVPILASIVLNFILFINIVRVLATKLRETNAGRCDTRQQYRKLLKSTLVLMPLFGVHYIVFMATPYTEVSGTLWQVQMHYEMLFNSFQGFFVAIIYCFCNGEVQAEIKKSWSRWTLALDFKRKARSGSSSYSYGPMVSHTSVTNVGPRVGLGLPLSPRLLPTATTNGHPQLPGHAKPGTPALETLETTPPAMAAPKDDGFLNGSCSGLDEEASGPERPPALLQEEWETVM
T67710	DRUGINFO	D02CII	Abaloparatide	Approved
T67710	DRUGINFO	D03NHS	PCO371	Phase 1

T55689	TARGETID	T55689
T55689	FORMERID	TTDR00917
T55689	UNIPROID	LIPS_HUMAN
T55689	TARGNAME	Hormone sensitive lipase (LIPE)
T55689	GENENAME	LIPE
T55689	TARGTYPE	Successful
T55689	SYNONYMS	Hormone-sensitive lipase; HSL
T55689	FUNCTION	In adipose tissue and heart, it primarily hydrolyzes stored triglycerides to free fatty acids, while in steroidogenic tissues, it principally converts cholesteryl esters to free cholesterol for steroid hormone production.
T55689	BIOCLASS	Carboxylic ester hydrolase
T55689	ECNUMBER	EC 3.1.1.79
T55689	SEQUENCE	MEPGSKSVSRSDWQPEPHQRPITPLEPGPEKTPIAQPESKTLQGSNTQQKPASNQRPLTQQETPAQHDAESQKEPRAQQKSASQEEFLAPQKPAPQQSPYIQRVLLTQQEAASQQGPGLGKESITQQEPALRQRHVAQPGPGPGEPPPAQQEAESTPAAQAKPGAKREPSAPTESTSQETPEQSDKQTTPVQGAKSKQGSLTELGFLTKLQELSIQRSALEWKALSEWVTDSESESDVGSSSDTDSPATMGGMVAQGVKLGFKGKSGYKVMSGYSGTSPHEKTSARNHRHYQDTASRLIHNMDLRTMTQSLVTLAEDNIAFFSSQGPGETAQRLSGVFAGVREQALGLEPALGRLLGVAHLFDLDPETPANGYRSLVHTARCCLAHLLHKSRYVASNRRSIFFRTSHNLAELEAYLAALTQLRALVYYAQRLLVTNRPGVLFFEGDEGLTADFLREYVTLHKGCFYGRCLGFQFTPAIRPFLQTISIGLVSFGEHYKRNETGLSVAASSLFTSGRFAIDPELRGAEFERITQNLDVHFWKAFWNITEMEVLSSLANMASATVRVSRLLSLPPEAFEMPLTADPTLTVTISPPLAHTGPGPVLVRLISYDLREGQDSEELSSLIKSNGQRSLELWPRPQQAPRSRSLIVHFHGGGFVAQTSRSHEPYLKSWAQELGAPIISIDYSLAPEAPFPRALEECFFAYCWAIKHCALLGSTGERICLAGDSAGGNLCFTVALRAAAYGVRVPDGIMAAYPATMLQPAASPSRLLSLMDPLLPLSVLSKCVSAYAGAKTEDHSNSDQKALGMMGLVRRDTALLLRDFRLGASSWLNSFLELSGRKSQKMSEPIAEPMRRSVSEAALAQPQGPLGTDSLKNLTLRDLSLRGNSETSSDTPEMSLSAETLSPSTPSDVNFLLPPEDAGEEAEAKNELSPMDRGLGVRAAFPEGFHPRRSSQGATQMPLYSSPIVKNPFMSPLLAPDSMLKSLPPVHIVACALDPMLDDSVMLARRLRNLGQPVTLRVVEDLPHGFLTLAALCRETRQAAELCVERIRLVLTPPAGAGPSGETGAAGVDGGCGGRH
T55689	DRUGINFO	D0G1VX	BENZYL BENZOATE	Approved
T55689	DRUGINFO	D0A8UP	PMID15026062C41	Clinical trial
T55689	DRUGINFO	D02CWR	OXYBENZONE	Investigative
T55689	DRUGINFO	D02XQX	ETHIOFENCARB	Investigative
T55689	DRUGINFO	D0B4KG	NCI-58425	Investigative
T55689	DRUGINFO	D0F3WR	2-(3-methoxybenzylthio)-2-phenylacetic acid	Investigative
T55689	DRUGINFO	D0KH3M	BIFENOX	Investigative
T55689	DRUGINFO	D0R0AX	NCI-159878	Investigative
T55689	DRUGINFO	D0T8QY	PMI-008	Investigative

T48873	TARGETID	T48873
T48873	FORMERID	TTDS00118
T48873	UNIPROID	VMAT2_HUMAN
T48873	TARGNAME	Synaptic vesicle amine transporter (SLC18A2)
T48873	GENENAME	SLC18A2
T48873	TARGTYPE	Successful
T48873	SYNONYMS	Vesicular amine transporter; Vesicular Monoamine Transporter; VMAT; VAT; Solute carrier family 18 member 2; SLC18A2; Monoamine transporter
T48873	FUNCTION	Involved in the ATP-dependent vesicular transport of biogenic amine neurotransmitters. Pumps cytosolic monoamines including dopamine, norepinephrine, serotonin, and histamine into synaptic vesicles. Requisite for vesicular amine storage prior to secretion via exocytosis.
T48873	BIOCLASS	Major facilitator superfamily
T48873	SEQUENCE	MALSELALVRWLQESRRSRKLILFIVFLALLLDNMLLTVVVPIIPSYLYSIKHEKNATEIQTARPVHTASISDSFQSIFSYYDNSTMVTGNATRDLTLHQTATQHMVTNASAVPSDCPSEDKDLLNENVQVGLLFASKATVQLITNPFIGLLTNRIGYPIPIFAGFCIMFVSTIMFAFSSSYAFLLIARSLQGIGSSCSSVAGMGMLASVYTDDEERGNVMGIALGGLAMGVLVGPPFGSVLYEFVGKTAPFLVLAALVLLDGAIQLFVLQPSRVQPESQKGTPLTTLLKDPYILIAAGSICFANMGIAMLEPALPIWMMETMCSRKWQLGVAFLPASISYLIGTNIFGILAHKMGRWLCALLGMIIVGVSILCIPFAKNIYGLIAPNFGVGFAIGMVDSSMMPIMGYLVDLRHVSVYGSVYAIADVAFCMGYAIGPSAGGAIAKAIGFPWLMTIIGIIDILFAPLCFFLRSPPAKEEKMAILMDHNCPIKTKMYTQNNIQSYPIGEDEESESD
T48873	DRUGINFO	D09PJX	Tetrabenazine	Approved
T48873	DRUGINFO	D0E7ZU	Deutetrabenazine	Approved
T48873	DRUGINFO	D0I3IG	Alseroxylon	Approved
T48873	DRUGINFO	D0J4JM	Reserpine	Approved
T48873	DRUGINFO	D0JJ7S	Valbenazine Tosylate	Approved
T48873	DRUGINFO	D0Y2MC	Alkavervir	Approved
T48873	DRUGINFO	D63WMQ	Ingrezza	Phase 4
T48873	DRUGINFO	D09NAF	AV 133	Phase 3
T48873	DRUGINFO	D0IX1I	NBI-98854	Phase 3
T48873	DRUGINFO	D01IVE	Lobeline	Phase 2
T48873	DRUGINFO	D0XT8W	SOM3355	Phase 2
T48873	DRUGINFO	D03TJJ	[125I]7-azido-8-iodoketanserine	Investigative
T48873	DRUGINFO	D07QQY	[11C]DTBZ	Investigative
T48873	DRUGINFO	D0F5NJ	METHYLENEDIOXYMETHAMPHETAMINE	Investigative
T48873	DRUGINFO	D0I4ME	MMDA	Investigative
T48873	DRUGINFO	D0R7ZC	Beta-methoxyamphetamine	Investigative

T97713	TARGETID	T97713
T97713	FORMERID	TTDS00401
T97713	UNIPROID	PUR1_HUMAN
T97713	TARGNAME	Amidophosphoribosyltransferase (PPAT)
T97713	GENENAME	PPAT
T97713	TARGTYPE	Successful
T97713	SYNONYMS	Glutamine phosphoribosylpyrophosphate amidotransferase; GPAT; ATase
T97713	FUNCTION	Catalyzes the conversion of 5-phosphoribosyl-1-pyrophosphate (PRPP) into 5-phosphoribosyl-1-amine (PRA), using the amine group from a glutamine side-chain.
T97713	BIOCLASS	Short-chain dehydrogenases reductase
T97713	ECNUMBER	EC 2.4.2.14
T97713	SEQUENCE	MELEELGIREECGVFGCIASGEWPTQLDVPHVITLGLVGLQHRGQESAGIVTSDGSSVPTFKSHKGMGLVNHVFTEDNLKKLYVSNLGIGHTRYATTGKCELENCQPFVVETLHGKIAVAHNGELVNAARLRKKLLRHGIGLSTSSDSEMITQLLAYTPPQEQDDTPDWVARIKNLMKEAPTAYSLLIMHRDVIYAVRDPYGNRPLCIGRLIPVSDINDKEKKTSETEGWVVSSESCSFLSIGARYYREVLPGEIVEISRHNVQTLDIISRSEGNPVAFCIFEYVYFARPDSMFEDQMVYTVRYRCGQQLAIEAPVDADLVSTVPESATPAALAYAGKCGLPYVEVLCKNRYVGRTFIQPNMRLRQLGVAKKFGVLSDNFKGKRIVLVDDSIVRGNTISPIIKLLKESGAKEVHIRVASPPIKYPCFMGINIPTKEELIANKPEFDHLAEYLGANSVVYLSVEGLVSSVQEGIKFKKQKEKKHDIMIQENGNGLECFEKSGHCTACLTGKYPVELEW
T97713	DRUGINFO	D07QCE	Azathioprine	Approved
T97713	DRUGINFO	D09UZO	Mercaptopurine	Approved
T97713	DRUGINFO	D01LDQ	Mycophenolic hydroxamic acid	Investigative
T97713	DRUGINFO	D0S4BK	Tiazofurin adenine dinucleotide	Investigative
T97713	DRUGINFO	D0T4UE	Mycophenolic bis(sulfonamide)	Investigative
T97713	DRUGINFO	D0VD5N	6-Chloropurine Riboside, 5'-Monophosphate	Investigative

T63609	TARGETID	T63609
T63609	FORMERID	TTDS00500
T63609	UNIPROID	ADCY1_HUMAN
T63609	TARGNAME	Adenylate cyclase type 1 (ADCY1)
T63609	GENENAME	ADCY1
T63609	TARGTYPE	Successful
T63609	SYNONYMS	Ca(2+)/calmodulin-activated adenylyl cyclase; Adenylyl cyclase 1; Adenylate cyclase type I; ATP pyrophosphate-lyase 1
T63609	FUNCTION	Mediates responses to increased cellular Ca(2+)/calmodulin levels. May be involved in regulatory processes in the central nervous system. May play a role in memory and learning. Plays a role in the regulation of the circadian rhythm of daytime contrast sensitivity probably by modulating the rhythmic synthesis of cyclic AMP in the retina. Catalyzes the formation of the signaling molecule cAMP in response to G-protein signaling.
T63609	BIOCLASS	Phosphorus-oxygen lyase
T63609	ECNUMBER	EC 4.6.1.1
T63609	SEQUENCE	MAGAPRGGGGGGGGAGEPGGAERAAGTSRRRGLRACDEEFACPELEALFRGYTLRLEQAATLKALAVLSLLAGALALAELLGAPGPAPGLAKGSHPVHCVLFLALLVVTNVRSLQVPQLQQVGQLALLFSLTFALLCCPFALGGPARGSAGAAGGPATAEQGVWQLLLVTFVSYALLPVRSLLAIGFGLVVAASHLLVTATLVPAKRPRLWRTLGANALLFVGVNMYGVFVRILTERSQRKAFLQARSCIEDRLRLEDENEKQERLLMSLLPRNVAMEMKEDFLKPPERIFHKIYIQRHDNVSILFADIVGFTGLASQCTAQELVKLLNELFGKFDELATENHCRRIKILGDCYYCVSGLTQPKTDHAHCCVEMGLDMIDTITSVAEATEVDLNMRVGLHTGRVLCGVLGLRKWQYDVWSNDVTLANVMEAAGLPGKVHITKTTLACLNGDYEVEPGYGHERNSFLKTHNIETFFIVPSHRRKIFPGLILSDIKPAKRMKFKTVCYLLVQLMHCRKMFKAEIPFSNVMTCEDDDKRRALRTASEKLRNRSSFSTNVVYTTPGTRVNRYISRLLEARQTELEMADLNFFTLKYKHVEREQKYHQLQDEYFTSAVVLTLILAALFGLVYLLIFPQSVVVLLLLVFCICFLVACVLYLHITRVQCFPGCLTIQIRTVLCIFIVVLIYSVAQGCVVGCLPWAWSSKPNSSLVVLSSGGQRTALPTLPCESTHHALLCCLVGTLPLAIFFRVSSLPKMILLSGLTTSYILVLELSGYTRTGGGAVSGRSYEPIVAILLFSCALALHARQVDIRLRLDYLWAAQAEEEREDMEKVKLDNRRILFNLLPAHVAQHFLMSNPRNMDLYYQSYSQVGVMFASIPNFNDFYIELDGNNMGVECLRLLNEIIADFDELMEKDFYKDIEKIKTIGSTYMAAVGLAPTSGTKAKKSISSHLSTLADFAIEMFDVLDEINYQSYNDFVLRVGINVGPVVAGVIGARRPQYDIWGNTVNVASRMDSTGVQGRIQVTEEVHRLLRRCPYHFVCRGKVSVKGKGEMLTYFLEGRTDGNGSQIRSLGLDRKMCPFGRAGLQGRRPPVCPMPGVSVRAGLPPHSPGQYLPSAAAGKEA
T63609	DRUGINFO	D06ACW	Adenosine monophosphate	Approved

T51115	TARGETID	T51115
T51115	FORMERID	TTDS00414
T51115	UNIPROID	CAC1C_HUMAN
T51115	TARGNAME	Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)
T51115	GENENAME	CACNA1C
T51115	TARGTYPE	Successful
T51115	SYNONYMS	Voltage-gated calcium channel subunit alpha Cav1.2; Voltage-dependent L-type calcium channel subunit alpha-1C; Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; CCHL1A1; CACNL1A1; CACN2; CACH2
T51115	FUNCTION	Mediates influx of calcium ions into the cytoplasm, and thereby triggers calcium release from the sarcoplasm. Plays an important role in excitation-contraction coupling in the heart. Required for normal heart development and normal regulation of heart rhythm. Required for normal contraction of smooth muscle cells in blood vessels and in the intestine. Essential for normal blood pressure regulation via its role in the contraction of arterial smooth muscle cells. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group. Pore-forming, alpha-1C subunit of the voltage-gated calcium channel that gives rise to L-type calcium currents.
T51115	PDBSTRUC	6DAF; 6DAE; 6DAD; 6C0A; 5V2Q
T51115	BIOCLASS	Voltage-gated ion channel
T51115	SEQUENCE	MVNENTRMYIPEENHQGSNYGSPRPAHANMNANAAAGLAPEHIPTPGAALSWQAAIDAARQAKLMGSAGNATISTVSSTQRKRQQYGKPKKQGSTTATRPPRALLCLTLKNPIRRACISIVEWKPFEIIILLTIFANCVALAIYIPFPEDDSNATNSNLERVEYLFLIIFTVEAFLKVIAYGLLFHPNAYLRNGWNLLDFIIVVVGLFSAILEQATKADGANALGGKGAGFDVKALRAFRVLRPLRLVSGVPSLQVVLNSIIKAMVPLLHIALLVLFVIIIYAIIGLELFMGKMHKTCYNQEGIADVPAEDDPSPCALETGHGRQCQNGTVCKPGWDGPKHGITNFDNFAFAMLTVFQCITMEGWTDVLYWVNDAVGRDWPWIYFVTLIIIGSFFVLNLVLGVLSGEFSKEREKAKARGDFQKLREKQQLEEDLKGYLDWITQAEDIDPENEDEGMDEEKPRNMSMPTSETESVNTENVAGGDIEGENCGARLAHRISKSKFSRYWRRWNRFCRRKCRAAVKSNVFYWLVIFLVFLNTLTIASEHYNQPNWLTEVQDTANKALLALFTAEMLLKMYSLGLQAYFVSLFNRFDCFVVCGGILETILVETKIMSPLGISVLRCVRLLRIFKITRYWNSLSNLVASLLNSVRSIASLLLLLFLFIIIFSLLGMQLFGGKFNFDEMQTRRSTFDNFPQSLLTVFQILTGEDWNSVMYDGIMAYGGPSFPGMLVCIYFIILFICGNYILLNVFLAIAVDNLADAESLTSAQKEEEEEKERKKLARTASPEKKQELVEKPAVGESKEEKIELKSITADGESPPATKINMDDLQPNENEDKSPYPNPETTGEEDEEEPEMPVGPRPRPLSELHLKEKAVPMPEASAFFIFSSNNRFRLQCHRIVNDTIFTNLILFFILLSSISLAAEDPVQHTSFRNHILFYFDIVFTTIFTIEIALKILGNADYVFTSIFTLEIILKMTAYGAFLHKGSFCRNYFNILDLLVVSVSLISFGIQSSAINVVKILRVLRVLRPLRAINRAKGLKHVVQCVFVAIRTIGNIVIVTTLLQFMFACIGVQLFKGKLYTCSDSSKQTEAECKGNYITYKDGEVDHPIIQPRSWENSKFDFDNVLAAMMALFTVSTFEGWPELLYRSIDSHTEDKGPIYNYRVEISIFFIIYIIIIAFFMMNIFVGFVIVTFQEQGEQEYKNCELDKNQRQCVEYALKARPLRRYIPKNQHQYKVWYVVNSTYFEYLMFVLILLNTICLAMQHYGQSCLFKIAMNILNMLFTGLFTVEMILKLIAFKPKGYFSDPWNVFDFLIVIGSIIDVILSETNHYFCDAWNTFDALIVVGSIVDIAITEVNPAEHTQCSPSMNAEENSRISITFFRLFRVMRLVKLLSRGEGIRTLLWTFIKSFQALPYVALLIVMLFFIYAVIGMQVFGKIALNDTTEINRNNNFQTFPQAVLLLFRCATGEAWQDIMLACMPGKKCAPESEPSNSTEGETPCGSSFAVFYFISFYMLCAFLIINLFVAVIMDNFDYLTRDWSILGPHHLDEFKRIWAEYDPEAKGRIKHLDVVTLLRRIQPPLGFGKLCPHRVACKRLVSMNMPLNSDGTVMFNATLFALVRTALRIKTEGNLEQANEELRAIIKKIWKRTSMKLLDQVVPPAGDDEVTVGKFYATFLIQEYFRKFKKRKEQGLVGKPSQRNALSLQAGLRTLHDIGPEIRRAISGDLTAEEELDKAMKEAVSAASEDDIFRRAGGLFGNHVSYYQSDGRSAFPQTFTTQRPLHINKAGSSQGDTESPSHEKLVDSTFTPSSYSSTGSNANINNANNTALGRLPRPAGYPSTVSTVEGHGPPLSPAIRVQEVAWKLSSNRERHVPMCEDLELRRDSGSAGTQAHCLLLRKANPSRCHSRESQAAMAGQEETSQDETYEVKMNHDTEACSEPSLLSTEMLSYQDDENRQLTLPEEDKRDIRQSPKRGFLRSASLGRRASFHLECLKRQKDRGGDISQKTVLPLHLVHHQALAVAGLSPLLQRSHSPASFPRPFATPPATPGSRGWPPQPVPTLRLEGVESSEKLNSSFPSIHCGSWAETTPGGGGSSAARRVRPVSLMVPSQAGAPGRQFHGSASSLVEAVLISEGLGQFAQDPKFIEVTTQELADACDMTIEEMESAADNILSGGAPQSPNGALLPFVNCRDAGQDRAGGEEDAGCVRARGRPSEEELQDSRVYVSSL
T51115	DRUGINFO	D0U7GP	RAUWOLFIA SERPENTINA ROOT	Approved
T51115	DRUGINFO	D06GRK	ARC029	Phase 3
T51115	DRUGINFO	D08MJX	R-56865	Terminated
T51115	DRUGINFO	D00JMZ	CGS-27830	Terminated
T51115	DRUGINFO	D05IML	NIGULDIPINE	Terminated
T51115	DRUGINFO	D0QQ7N	TH-9229	Terminated
T51115	DRUGINFO	D06HRY	SNAP-5089	Terminated
T51115	DRUGINFO	D04ALU	[3H](+)-cis-diltiazem	Investigative
T51115	DRUGINFO	D04UDT	MEBUDIPINE	Investigative
T51115	DRUGINFO	D06XTT	FPL64176	Investigative
T51115	DRUGINFO	D0I9VY	CV-4093	Investigative
T51115	DRUGINFO	D0R6PX	(-)-(R)-efonidipine	Investigative
T51115	DRUGINFO	D0U7BI	SZ(+)-(S)-202-791	Investigative
T51115	DRUGINFO	D03UJT	[3H](-)devapamil	Investigative
T51115	DRUGINFO	D0S3YP	[3H](+)-isradipine	Investigative
T51115	DRUGINFO	D02RIH	(-)-(S)-BayK8644	Investigative
T51115	DRUGINFO	D09CKI	CORYNANTHEINE	Investigative
T51115	DRUGINFO	D09YTH	CPU-228	Investigative
T51115	DRUGINFO	D08RJC	PD-32577	Investigative

T59631	TARGETID	T59631
T59631	FORMERID	TTDNC00489
T59631	UNIPROID	PDCD1_HUMAN
T59631	TARGNAME	Programmed cell death protein 1 (PD-1)
T59631	GENENAME	PDCD1
T59631	TARGTYPE	Successful
T59631	SYNONYMS	hPD1; hPD-1; Protein PD1; Protein PD-1; PD1; CD279
T59631	FUNCTION	Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2. Following T-cell receptor (TCR) engagement, PDCD1 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation. Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta. Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self.
T59631	PDBSTRUC	5WT9; 5JXE; 5IUS; 5GGS; 5GGR
T59631	BIOCLASS	Immunoglobulin
T59631	SEQUENCE	MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQTLVVGVVGGLLGSLVLLVWVLAVICSRAARGTIGARRTGQPLKEDPSAVPVFSVDYGELDFQWREKTPEPPVPCVPEQTEYATIVFPSGMGTSSPARRGSADGPRSAQPLRPEDGHCSWPL
T59631	DRUGINFO	D00GOV	Nivolumab	Approved
T59631	DRUGINFO	D02KSP	Tislelizumab	Approved
T59631	DRUGINFO	D07DMY	MK-3475	Approved
T59631	DRUGINFO	D08ANZ	Pembrolizumab	Approved
T59631	DRUGINFO	D0KG4Q	Cemiplimab	Approved
T59631	DRUGINFO	D0PG5O	Retifanlimab	Approved
T59631	DRUGINFO	D92OCI	Toripalimab	Approved in China
T59631	DRUGINFO	DFLK16	Sintilimab	Approved
T59631	DRUGINFO	DGQU43	Dostarlimab	Approved
T59631	DRUGINFO	D05BAJ	PDR001	Phase 3
T59631	DRUGINFO	D08HWV	BGB-A317	Phase 3
T59631	DRUGINFO	D08JLH	Spartalizumab	Phase 3
T59631	DRUGINFO	D0B0UF	IBI-308	Phase 3
T59631	DRUGINFO	D0BO0K	INCSHR1210	Phase 3
T59631	DRUGINFO	D32ZQU	Balstilimab	Phase 3
T59631	DRUGINFO	D4L5NW	CS-1003	Phase 3
T59631	DRUGINFO	DP2Z0X	Sasanlimab	Phase 3
T59631	DRUGINFO	DX9GT7	Nofazinlimab	Phase 3
T59631	DRUGINFO	D2ELZ3	AK04	Phase 3
T59631	DRUGINFO	D02XFH	Peresolimab	Phase 2
T59631	DRUGINFO	D08UGS	JNJ 63723283	Phase 2
T59631	DRUGINFO	D0WJ7H	AGEN2034	Phase 2
T59631	DRUGINFO	DZMO76	JTX-4014	Phase 2
T59631	DRUGINFO	D53YZV	SAR445877	Phase 2
T59631	DRUGINFO	DJX61M	Vudalimab	Phase 2
T59631	DRUGINFO	DNI7E3	AZD7789	Phase 2
T59631	DRUGINFO	DQM48O	RO7121661	Phase 2
T59631	DRUGINFO	DR05IX	Lorigerlimab	Phase 2
T59631	DRUGINFO	DXJH93	AK104	Phase 2
T59631	DRUGINFO	D05FPZ	M7824	Phase 2
T59631	DRUGINFO	D0MY0F	MGD013	Phase 1/2
T59631	DRUGINFO	DQ43PA	Cetrelimab	Phase 1/2
T59631	DRUGINFO	D4RMC9	Rilvegostomig	Phase 1/2
T59631	DRUGINFO	D00JMY	AMP-224	Phase 1
T59631	DRUGINFO	D00NEL	BI-754091	Phase 1
T59631	DRUGINFO	D01CXW	MEDI0680	Phase 1
T59631	DRUGINFO	D03XRA	GSK2661380	Phase 1
T59631	DRUGINFO	D05BPO	PF-06801591	Phase 1
T59631	DRUGINFO	D0BX5L	LZM009	Phase 1
T59631	DRUGINFO	D0D4TC	Sym021	Phase 1
T59631	DRUGINFO	D0L5ZH	CC-90006	Phase 1
T59631	DRUGINFO	D0N5VK	TSR-042	Phase 1
T59631	DRUGINFO	D0Y3ZC	CBT-501	Phase 1
T59631	DRUGINFO	D5T6DY	AMG 404	Phase 1
T59631	DRUGINFO	D5WB0F	RG6279	Phase 1
T59631	DRUGINFO	DDKY53	BI 754091	Phase 1
T59631	DRUGINFO	DG4YF6	SYN125	Phase 1
T59631	DRUGINFO	DL1XC2	609A	Phase 1
T59631	DRUGINFO	DVO4H2	APL-501	Phase 1
T59631	DRUGINFO	D1PYC8	MGD019	Phase 1
T59631	DRUGINFO	D1S7EP	SI-B003	Phase 1
T59631	DRUGINFO	D28MNU	CDX-527	Phase 1
T59631	DRUGINFO	D4CGN3	RG6139	Phase 1
T59631	DRUGINFO	D7L1MP	MEDI5752	Phase 1
T59631	DRUGINFO	D8FJ9K	XmAb23104	Phase 1
T59631	DRUGINFO	DD1TJ8	XmAb20717	Phase 1
T59631	DRUGINFO	DMEQ73	ADPT01	Phase 1
T59631	DRUGINFO	DX30BA	IBI318	Phase 1
T59631	DRUGINFO	D00ZRO	Cyclic compound 3	Patented
T59631	DRUGINFO	D03PSA	1,2,4-oxadiazole derivative 2	Patented
T59631	DRUGINFO	D03XZT	Cyclic compound 1	Patented
T59631	DRUGINFO	D07PJR	Cyclic compound 2	Patented
T59631	DRUGINFO	D08VDV	PMID30107136-Compound-Example15	Patented
T59631	DRUGINFO	D0K7NC	PMID30107136-Compound-Example16	Patented
T59631	DRUGINFO	D0LM6D	1,3,4-oxadiazole derivative 1	Patented
T59631	DRUGINFO	D0MZ4V	1,2,4-oxadiazole derivative 1	Patented
T59631	DRUGINFO	D0P3EG	1,3,4-oxadiazole derivative 2	Patented
T59631	DRUGINFO	D04QQG	AUNP-12	Preclinical
T59631	DRUGINFO	D04BON	PMID30247903-Compound-General structure25	Investigative
T59631	DRUGINFO	D07FEF	PMID30247903-Compound-General structure13	Investigative
T59631	DRUGINFO	D0BU2V	PMID30247903-Compound-General structure22	Investigative
T59631	DRUGINFO	D0BX6Z	PMID30247903-Compound-General structure20	Investigative
T59631	DRUGINFO	D0D8DV	PMID30247903-Compound-General structure17	Investigative
T59631	DRUGINFO	D0E4UM	PMID30247903-Compound-General structure14	Investigative
T59631	DRUGINFO	D0L0DQ	PMID30247903-Compound-General structure24	Investigative
T59631	DRUGINFO	D0L1BZ	PMID30247903-Compound-General structure21	Investigative
T59631	DRUGINFO	D0N6MD	PMID30247903-Compound-General structure23	Investigative
T59631	DRUGINFO	D0T9HE	PMID30247903-Compound-General structure15	Investigative
T59631	DRUGINFO	D0UJ9J	PMID30247903-Compound-General structure16	Investigative
T59631	DRUGINFO	DH0JW9	YH008	Investigative

T55815	TARGETID	T55815
T55815	FORMERID	TTDS00400
T55815	UNIPROID	ACHA2_HUMAN
T55815	TARGNAME	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
T55815	GENENAME	CHRNA2
T55815	TARGTYPE	Successful
T55815	SYNONYMS	CHRNA2
T55815	FUNCTION	After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
T55815	PDBSTRUC	5FJV
T55815	BIOCLASS	Neurotransmitter receptor
T55815	SEQUENCE	MGPSCPVFLSFTKLSLWWLLLTPAGGEEAKRPPPRAPGDPLSSPSPTALPQGGSHTETEDRLFKHLFRGYNRWARPVPNTSDVVIVRFGLSIAQLIDVDEKNQMMTTNVWLKQEWSDYKLRWNPTDFGNITSLRVPSEMIWIPDIVLYNNADGEFAVTHMTKAHLFSTGTVHWVPPAIYKSSCSIDVTFFPFDQQNCKMKFGSWTYDKAKIDLEQMEQTVDLKDYWESGEWAIVNATGTYNSKKYDCCAEIYPDVTYAFVIRRLPLFYTINLIIPCLLISCLTVLVFYLPSDCGEKITLCISVLLSLTVFLLLITEIIPSTSLVIPLIGEYLLFTMIFVTLSIVITVFVLNVHHRSPSTHTMPHWVRGALLGCVPRWLLMNRPPPPVELCHPLRLKLSPSYHWLESNVDAEEREVVVEEEDRWACAGHVAPSVGTLCSHGHLHSGASGPKAEALLQEGELLLSPHMQKALEGVHYIADHLRSEDADSSVKEDWKYVAMVIDRIFLWLFIIVCFLGTIGLFLPPFLAGMI
T55815	DRUGINFO	D04QWE	Levallorphan	Approved
T55815	DRUGINFO	D05HSC	Tubocurarine	Approved
T55815	DRUGINFO	D0L5CZ	Rocuronium	Approved
T55815	DRUGINFO	D0OB2M	Mivacurium	Approved
T55815	DRUGINFO	D0U7BW	Carbachol	Approved
T55815	DRUGINFO	D0XX6Y	Pipecuronium	Approved
T55815	DRUGINFO	D0Z8HG	Vecuronium	Approved
T55815	DRUGINFO	D08ALK	Cisatracurium	Approved
T55815	DRUGINFO	D08XPW	CYTISINE	Phase 3
T55815	DRUGINFO	D03ZVM	5-(1-Methyl-pyrrolidin-2-yl)-2-phenethyl-pyridine	Investigative
T55815	DRUGINFO	D08AGA	3-((S)-Azetidin-2-yloxy)-5-iodo-pyridine	Investigative
T55815	DRUGINFO	D08DAE	CHOLINE	Investigative
T55815	DRUGINFO	D0A9RZ	1,1-Dimethyl-4-phenyl-piperazin-1-ium iodide	Investigative
T55815	DRUGINFO	D0C7GB	1-(piperidin-3-ylmethyl)pyridin-2(1H)-one	Investigative
T55815	DRUGINFO	D0L1IB	(S)-3-(azetidin-2-ylmethoxy)-2-fluoropyridine	Investigative
T55815	DRUGINFO	D0QE7J	1-(piperidin-4-ylmethyl)pyridin-2(1H)-one	Investigative
T55815	DRUGINFO	D0R6YB	2-Pyridin-3-yl-7-aza-bicyclo[2.2.1]heptane	Investigative
T55815	DRUGINFO	D04MIG	LY2087101	Investigative
T55815	DRUGINFO	D0Y3DW	[3H]cytisine	Investigative
T55815	DRUGINFO	D0R4RN	[125I]epibatidine	Investigative

T14908	TARGETID	T14908
T14908	FORMERID	TTDS00377
T14908	UNIPROID	CEGT_HUMAN
T14908	TARGNAME	Ceramide glucosyltransferase (UGCG)
T14908	GENENAME	UGCG
T14908	TARGTYPE	Successful
T14908	SYNONYMS	UGCG; UDP-glucose:N-acylsphingosine D-glucosyltransferase; UDP-glucose ceramideglucosyltransferase; Glucosylceramide synthase; GLCT-1
T14908	FUNCTION	Catalyzes the first glycosylation step in glycosphingolipid biosynthesis, the transfer of glucose to ceramide. May also serve as a "flippase".
T14908	BIOCLASS	Hexosyltransferase
T14908	ECNUMBER	EC 2.4.1.80
T14908	SEQUENCE	MALLDLALEGMAVFGFVLFLVLWLMHFMAIIYTRLHLNKKATDKQPYSKLPGVSLLKPLKGVDPNLINNLETFFELDYPKYEVLLCVQDHDDPAIDVCKKLLGKYPNVDARLFIGGKKVGINPKINNLMPGYEVAKYDLIWICDSGIRVIPDTLTDMVNQMTEKVGLVHGLPYVADRQGFAATLEQVYFGTSHPRYYISANVTGFKCVTGMSCLMRKDVLDQAGGLIAFAQYIAEDYFMAKAIADRGWRFAMSTQVAMQNSGSYSISQFQSRMIRWTKLRINMLPATIICEPISECFVASLIIGWAAHHVFRWDIMVFFMCHCLAWFIFDYIQLRGVQGGTLCFSKLDYAVAWFIRESMTIYIFLSALWDPTISWRTGRYRLRCGGTAEEILDV
T14908	DRUGINFO	D0HR8Z	Miglustat	Approved
T14908	DRUGINFO	D0J8IJ	Eliglustat tartrate	Approved
T14908	DRUGINFO	D07WEN	Venglustat	Phase 2
T14908	DRUGINFO	D00KJV	N-butylgalactonojirimycin	Investigative

T84581	TARGETID	T84581
T84581	FORMERID	TTDS00276
T84581	UNIPROID	TRXR1_HUMAN
T84581	TARGNAME	Cytoplasmic thioredoxin reductase (TXNRD1)
T84581	GENENAME	TXNRD1
T84581	TARGTYPE	Successful
T84581	SYNONYMS	Thioredoxin reductase TR1; Thioredoxin reductase 1, cytoplasmic; KM-102-derived reductase-like factor; KDRF; Gene associated with retinoic and interferon-induced mortality 12 protein; Gene associated with retinoic and IFN-induced mortality 12 protein; GRIM12; GRIM-12
T84581	FUNCTION	Isoform 1 may possess glutaredoxin activity as well as thioredoxin reductase activity and induces actin and tubulin polymerization, leading to formation of cell membrane protrusions. Isoform 4 enhances the transcriptional activity of estrogen receptors alpha and beta while isoform 5 enhances the transcriptional activity of the beta receptor only. Isoform 5 also mediates cell death induced by a combination of interferon-beta and retinoic acid.
T84581	PDBSTRUC	3QFB; 3QFA; 2ZZC; 2ZZB; 2ZZ0
T84581	BIOCLASS	Sulfur donor oxidoreductase
T84581	ECNUMBER	EC 1.8.1.9
T84581	SEQUENCE	MGCAEGKAVAAAAPTELQTKGKNGDGRRRSAKDHHPGKTLPENPAGFTSTATADSRALLQAYIDGHSVVIFSRSTCTRCTEVKKLFKSLCVPYFVLELDQTEDGRALEGTLSELAAETDLPVVFVKQRKIGGHGPTLKAYQEGRLQKLLKMNGPEDLPKSYDYDLIIIGGGSGGLAAAKEAAQYGKKVMVLDFVTPTPLGTRWGLGGTCVNVGCIPKKLMHQAALLGQALQDSRNYGWKVEETVKHDWDRMIEAVQNHIGSLNWGYRVALREKKVVYENAYGQFIGPHRIKATNNKGKEKIYSAERFLIATGERPRYLGIPGDKEYCISSDDLFSLPYCPGKTLVVGASYVALECAGFLAGIGLDVTVMVRSILLRGFDQDMANKIGEHMEEHGIKFIRQFVPIKVEQIEAGTPGRLRVVAQSTNSEEIIEGEYNTVMLAIGRDACTRKIGLETVGVKINEKTGKIPVTDEEQTNVPYIYAIGDILEDKVELTPVAIQAGRLLAQRLYAGSTVKCDYENVPTTVFTPLEYGACGLSEEKAVEKFGEENIEVYHSYFWPLEWTIPSRDNNKCYAKIICNTKDNERVVGFHVLGPNAGEVTQGFAAALKCGLTKKQLDSTIGIHPVCAEVFTTLSVTKRSGASILQAGCUG
T84581	DRUGINFO	D0S1ZB	Fotemustine	Approved
T84581	DRUGINFO	D08BXT	Spermidine	Phase 3
T84581	DRUGINFO	D00CLK	PMID27977313-Compound-18	Patented
T84581	DRUGINFO	D00LBC	Triazole gold complexe 1	Patented
T84581	DRUGINFO	D00TXZ	4-aryl quinol derivative 2	Patented
T84581	DRUGINFO	D01BXV	PMID27977313-Compound-46	Patented
T84581	DRUGINFO	D01IPU	Triazole gold complexe 2	Patented
T84581	DRUGINFO	D01PYM	PMID27977313-Compound-48	Patented
T84581	DRUGINFO	D01WCU	4-aryl quinol derivative 4	Patented
T84581	DRUGINFO	D01XRW	PMID27977313-Compound-31	Patented
T84581	DRUGINFO	D02ODA	Palmarumycin derivative 4	Patented
T84581	DRUGINFO	D02UTG	Binuclear gold(I) compound 1	Patented
T84581	DRUGINFO	D03CQQ	PMID27977313-Compound-17	Patented
T84581	DRUGINFO	D04ONQ	4-aryl quinol derivative 7	Patented
T84581	DRUGINFO	D05HHG	PMID27977313-Compound-32	Patented
T84581	DRUGINFO	D07CDS	Metal complex derivative 3	Patented
T84581	DRUGINFO	D07PKU	4-aryl quinol derivative 3	Patented
T84581	DRUGINFO	D08BVX	PMID27977313-Compound-27	Patented
T84581	DRUGINFO	D08VQU	Metal complex derivative 1	Patented
T84581	DRUGINFO	D09ACU	PMID27977313-Compound-8	Patented
T84581	DRUGINFO	D0CV1Q	PMID27977313-Compound-5	Patented
T84581	DRUGINFO	D0D1LI	PMID27977313-Compound-45	Patented
T84581	DRUGINFO	D0E0EF	Terpyridineplatinum(II) complexe 5	Patented
T84581	DRUGINFO	D0F3BO	Binuclear gold(I) compound 3	Patented
T84581	DRUGINFO	D0G9QO	PMID27977313-Compound-7	Patented
T84581	DRUGINFO	D0HH1K	Palmarumycin derivative 1	Patented
T84581	DRUGINFO	D0I2HK	Bis-sulfonamide derivative 1	Patented
T84581	DRUGINFO	D0J4PE	Acyl oxymethyl acrylamide ester derivative 2	Patented
T84581	DRUGINFO	D0K2GG	PMID27977313-Compound-44	Patented
T84581	DRUGINFO	D0K8NP	Terpyridineplatinum(II) complexe 1	Patented
T84581	DRUGINFO	D0KM8V	PMID27977313-Compound-47	Patented
T84581	DRUGINFO	D0KV5Z	Benzisoselenazolone difluorocytidine derivative 1	Patented
T84581	DRUGINFO	D0L2LF	PMID27977313-Compound-42	Patented
T84581	DRUGINFO	D0L2NG	4-aryl quinol derivative 1	Patented
T84581	DRUGINFO	D0LB6Q	PMID27977313-Compound-19	Patented
T84581	DRUGINFO	D0NM0B	PMID27977313-Compound-Figure4b	Patented
T84581	DRUGINFO	D0NU8U	PMID27977313-Compound-Figure6C	Patented
T84581	DRUGINFO	D0NX8E	Triazole gold complexe 3	Patented
T84581	DRUGINFO	D0PT8T	PMID27977313-Compound-29	Patented
T84581	DRUGINFO	D0Q6PR	PMID27977313-Compound-39	Patented
T84581	DRUGINFO	D0QA9N	PMID27977313-Compound-28	Patented
T84581	DRUGINFO	D0RC5J	Disulfide compound 2	Patented
T84581	DRUGINFO	D0RE1D	Terpyridineplatinum(II) complexe 2	Patented
T84581	DRUGINFO	D0RK3P	Bis-sulfonamide derivative 2	Patented
T84581	DRUGINFO	D0RR2D	Golden phosphorous acetyletic compound 3	Patented
T84581	DRUGINFO	D0S2AY	PMID27977313-Compound-6	Patented
T84581	DRUGINFO	D0S3QX	PMID27977313-Compound-30	Patented
T84581	DRUGINFO	D0SC3B	Palmarumycin derivative 2	Patented
T84581	DRUGINFO	D0V1XY	PMID27977313-Compound-43	Patented
T84581	DRUGINFO	D0VA1R	4-aryl quinol derivative 5	Patented
T84581	DRUGINFO	D0VK1L	Metal complex derivative 2	Patented
T84581	DRUGINFO	D0WK9J	Binuclear gold(I) compound 2	Patented
T84581	DRUGINFO	D0XV4L	Disulfide compound 1	Patented
T84581	DRUGINFO	D0ZZ6N	Palmarumycin derivative 3	Patented
T84581	DRUGINFO	D02NYT	Golden phosphorous acetyletic compound 2	Patented
T84581	DRUGINFO	D03BPZ	Terpyridineplatinum(II) complexe 3	Patented
T84581	DRUGINFO	D05SHW	Terpyridineplatinum(II) complexe 4	Patented
T84581	DRUGINFO	D0W1DK	Golden phosphorous acetyletic compound 1	Patented
T84581	DRUGINFO	D0Z2MX	Acyl oxymethyl acrylamide ester derivative 1	Patented
T84581	DRUGINFO	D05ABT	3-formyl-4-phenyl-1,2,5-oxadiazole 2-oxide	Investigative
T84581	DRUGINFO	D09GTJ	Bis(2,4-dinitrophenyl)sulfane	Investigative
T84581	DRUGINFO	D0AA8E	4,6-dinitrobenzo[c][1,2,5]thiadiazole	Investigative
T84581	DRUGINFO	D0AS0V	5,8-Dihydroxy-1,4-naphthoquinone	Investigative
T84581	DRUGINFO	D00IMW	Flavin-Adenine Dinucleotide	Investigative

T64410	TARGETID	T64410
T64410	FORMERID	TTDS00182
T64410	UNIPROID	VANY_ENTFA
T64410	TARGNAME	Bacterial DD-carboxypeptidase (Bact vanYB)
T64410	GENENAME	Bact vanYB
T64410	TARGTYPE	Successful
T64410	SYNONYMS	vanYB; DD-peptidase; DD-carboxypeptidase; D-alanyl-D-alanine carboxypeptidase-transpeptidase
T64410	FUNCTION	Vancomycin-inducible, penicillin-resistant, DD- carboxypeptidase that hydrolyzes depsipeptide- and D-alanyl-D- alanine-containing peptidoglycan precursors. Insensitive to beta- lactams.
T64410	PDBSTRUC	6A6A; 5ZHW; 5ZHF; 5HNM
T64410	BIOCLASS	Peptidase
T64410	ECNUMBER	EC 3.4.16.4
T64410	SEQUENCE	MEKSNYHSNVNHHKRHMKQSGEKRAFLWAFIISFTVCTLFLGWRLVSVLEATQLPPIPATHTGSGTGVAENPEENTLATAKEQGDEQEWSLILVNRQNPIPAQYDVELEQLSNGERIDIRISPYLQDLFDAARADGVYPIVASGYRTTEKQQEIMDEKVAEYKAKGYTSAQAKAEAETWVAVPGTSEHQLGLAVDINADGIHSTGNEVYRWLDENSYRFGFIRRYPPDKTEITGVSNEPWHYRYVGIEAATKIYHQGLCLEEYLNTEK
T64410	DRUGINFO	D01PLN	Cefalotin	Approved
T64410	DRUGINFO	D07JVS	Cephalosporin	Approved
T64410	DRUGINFO	D0D1HA	Cefotaxime	Approved
T64410	DRUGINFO	D04AIT	B-Lactams	Approved
T64410	DRUGINFO	D0Q6RG	TD-1792	Phase 3
T64410	DRUGINFO	D01BCI	D-Alanine	Investigative
T64410	DRUGINFO	D02KJI	3-boronobenzoic acid	Investigative
T64410	DRUGINFO	D02TXD	NITROCEFIN	Investigative
T64410	DRUGINFO	D05PXD	2-[(Dioxidophosphino)Oxy]Benzoate	Investigative
T64410	DRUGINFO	D07CUI	Glycyl-L-Alpha-Amino-Epsilon-Pimelyl-D-Alanine	Investigative
T64410	DRUGINFO	D0G0ZI	Benzo[c][1,2]oxaborol-1(3H)-ol	Investigative
T64410	DRUGINFO	D0JV5J	5-boronothiophene-2-carboxylic acid	Investigative
T64410	DRUGINFO	D01KEE	Formaldehyde	Investigative
T64410	DRUGINFO	D0O4TL	Cephalosporin C	Investigative
T64410	DRUGINFO	D0EJ9B	Phenyl Boronic acid	Investigative

T78277	TARGETID	T78277
T78277	FORMERID	TTDI01982
T78277	UNIPROID	ASGL1_HUMAN
T78277	TARGNAME	Asparaginase (ASRGL1)
T78277	GENENAME	ASRGL1
T78277	TARGTYPE	Successful
T78277	SYNONYMS	Lasparagine amidohydrolase; Isoaspartyl peptidase/Lasparaginase beta chain; Isoaspartyl peptidase/Lasparaginase; Isoaspartyl dipeptidase; Betaaspartylpeptidase; Asparaginaselike protein 1; ASRGL1
T78277	FUNCTION	Has both L-asparaginase and beta-aspartyl peptidase activity. May be involved in the production of L-aspartate, which can act as an excitatory neurotransmitter in some brain regions. Is highly active with L-Asp beta-methyl ester. Besides, has catalytic activity toward beta-aspartyl dipeptides and their methyl esters, including beta-L-Asp-L-Phe, beta-L-Asp-L-Phe methyl ester (aspartame), beta-L-Asp-L-Ala, beta-L-Asp-L-Leu and beta-L- Asp-L-Lys. Does not have aspartylglucosaminidase activity and is inactive toward GlcNAc-L-Asn. Likewise, has no activity toward glutamine.
T78277	PDBSTRUC	4ZM9; 4PVS; 4PVR; 4PVQ; 4PVP
T78277	BIOCLASS	Peptidase
T78277	ECNUMBER	EC 3.4.19.5
T78277	SEQUENCE	MNPIVVVHGGGAGPISKDRKERVHQGMVRAATVGYGILREGGSAVDAVEGAVVALEDDPEFNAGCGSVLNTNGEVEMDASIMDGKDLSAGAVSAVQCIANPIKLARLVMEKTPHCFLTDQGAAQFAAAMGVPEIPGEKLVTERNKKRLEKEKHEKGAQKTDCQKNLGTVGAVALDCKGNVAYATSTGGIVNKMVGRVGDSPCLGAGGYADNDIGAVSTTGHGESILKVNLARLTLFHIEQGKTVEEAADLSLGYMKSRVKGLGGLIVVSKTGDWVAKWTSTSMPWAAAKDGKLHFGIDPDDTTITDLP
T78277	DRUGINFO	D0C9DA	Calaspargase pegol	Approved
T78277	DRUGINFO	D09JKS	GRASPA	Phase 3

T83193	TARGETID	T83193
T83193	FORMERID	TTDC00049
T83193	UNIPROID	TRPV1_HUMAN
T83193	TARGNAME	Transient receptor potential cation channel V1 (TRPV1)
T83193	GENENAME	TRPV1
T83193	TARGTYPE	Successful
T83193	SYNONYMS	Vanilloid receptor 1; VR1; TrpV1; Transient receptor potential cation channel subfamily V member 1; Osm-9-like TRP channel 1; OTRPC1; Capsaicin receptor
T83193	FUNCTION	Ligand-activated non-selective calcium permeant cation channel involved in detection of noxious chemical and thermal stimuli. Seems to mediate proton influx and may be involved in intracellular acidosis in nociceptive neurons. Involved in mediation of inflammatory pain and hyperalgesia. Sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL. Activation by vanilloids, like capsaicin, and temperatures higher than 42 degrees Celsius, exhibits a time- and Ca(2+)-dependent outward rectification, followed by a long-lasting refractory state. Mild extracellular acidic pH (6.5) potentiates channel activation by noxious heat and vanilloids, whereas acidic conditions (pH <6) directly activate the channel. Can be activated by endogenous compounds, including 12-hydroperoxytetraenoic acid and bradykinin. Acts as ionotropic endocannabinoid receptor with central neuromodulatory effects. Triggers a form of long-term depression (TRPV1-LTD) mediated by the endocannabinoid anandamine in the hippocampus and nucleus accumbens by affecting AMPA receptors endocytosis.
T83193	BIOCLASS	Transient receptor potential catioin channel
T83193	SEQUENCE	MKKWSSTDLGAAADPLQKDTCPDPLDGDPNSRPPPAKPQLSTAKSRTRLFGKGDSEEAFPVDCPHEEGELDSCPTITVSPVITIQRPGDGPTGARLLSQDSVAASTEKTLRLYDRRSIFEAVAQNNCQDLESLLLFLQKSKKHLTDNEFKDPETGKTCLLKAMLNLHDGQNTTIPLLLEIARQTDSLKELVNASYTDSYYKGQTALHIAIERRNMALVTLLVENGADVQAAAHGDFFKKTKGRPGFYFGELPLSLAACTNQLGIVKFLLQNSWQTADISARDSVGNTVLHALVEVADNTADNTKFVTSMYNEILMLGAKLHPTLKLEELTNKKGMTPLALAAGTGKIGVLAYILQREIQEPECRHLSRKFTEWAYGPVHSSLYDLSCIDTCEKNSVLEVIAYSSSETPNRHDMLLVEPLNRLLQDKWDRFVKRIFYFNFLVYCLYMIIFTMAAYYRPVDGLPPFKMEKTGDYFRVTGEILSVLGGVYFFFRGIQYFLQRRPSMKTLFVDSYSEMLFFLQSLFMLATVVLYFSHLKEYVASMVFSLALGWTNMLYYTRGFQQMGIYAVMIEKMILRDLCRFMFVYIVFLFGFSTAVVTLIEDGKNDSLPSESTSHRWRGPACRPPDSSYNSLYSTCLELFKFTIGMGDLEFTENYDFKAVFIILLLAYVILTYILLLNMLIALMGETVNKIAQESKNIWKLQRAITILDTEKSFLKCMRKAFRSGKLLQVGYTPDGKDDYRWCFRVDEVNWTTWNTNVGIINEDPGNCEGVKRTLSFSLRSSRVSGRHWKNFALVPLLREASARDRQSAQPEEVYLRQFSGSLKPEDAEVFKSPAASGEK
T83193	DRUGINFO	D0U5CE	Capsaicin	Approved
T83193	DRUGINFO	D0XW8Y	CNTX-4975	Phase 3
T83193	DRUGINFO	D04VQH	XEN-D0501	Phase 2
T83193	DRUGINFO	D05XJW	Resiniferatoxin	Phase 2
T83193	DRUGINFO	D09BDE	PAC-14028	Phase 2
T83193	DRUGINFO	D0A3EX	GRC-15300	Phase 2
T83193	DRUGINFO	D0FC8O	DWP-05195	Phase 2
T83193	DRUGINFO	D0VJ5N	SB-705498	Phase 2
T83193	DRUGINFO	D00CMV	ABT-102	Phase 1
T83193	DRUGINFO	D01SZA	MR-1817	Phase 1
T83193	DRUGINFO	D02XGC	PF-3864086	Phase 1
T83193	DRUGINFO	D0EK1C	PHE-377	Phase 1
T83193	DRUGINFO	D0EM4S	JNJ-39439335	Phase 1
T83193	DRUGINFO	D0KK9D	CA-011	Phase 1
T83193	DRUGINFO	D0W8NP	SAR-115740	Phase 1
T83193	DRUGINFO	D00MAN	GRC-6211	Phase 1
T83193	DRUGINFO	DF63BG	BIO-017	Phase 1
T83193	DRUGINFO	D00KTN	PMID25666693-Compound-121	Patented
T83193	DRUGINFO	D00ODY	PMID25666693-Compound-95	Patented
T83193	DRUGINFO	D00OLY	PMID25666693-Compound-149	Patented
T83193	DRUGINFO	D00QEZ	PMID25666693-Compound-60	Patented
T83193	DRUGINFO	D00YXA	PMID25666693-Compound-2	Patented
T83193	DRUGINFO	D01DNH	PMID25666693-Compound-150	Patented
T83193	DRUGINFO	D01GEK	PMID25666693-Compound-133	Patented
T83193	DRUGINFO	D01HED	PMID25666693-Compound-158	Patented
T83193	DRUGINFO	D01LGQ	PMID25666693-Compound-103	Patented
T83193	DRUGINFO	D01PLJ	PMID25666693-Compound-58	Patented
T83193	DRUGINFO	D01RUK	PMID25666693-Compound-104	Patented
T83193	DRUGINFO	D02EKO	PMID25666693-Compound-126	Patented
T83193	DRUGINFO	D02JQB	PMID25666693-Compound-140	Patented
T83193	DRUGINFO	D02OAH	PMID25666693-Compound-5	Patented
T83193	DRUGINFO	D02QJE	PMID25666693-Compound-23	Patented
T83193	DRUGINFO	D03EEA	PMID25666693-Compound-70	Patented
T83193	DRUGINFO	D03FSF	PMID25666693-Compound-73	Patented
T83193	DRUGINFO	D03QAW	PMID25666693-Compound-61	Patented
T83193	DRUGINFO	D03SHM	PMID25666693-Compound-88	Patented
T83193	DRUGINFO	D03VXP	PMID25666693-Compound-145	Patented
T83193	DRUGINFO	D03YFL	PMID25666693-Compound-71	Patented
T83193	DRUGINFO	D03ZOZ	PMID25666693-Compound-97	Patented
T83193	DRUGINFO	D04FRL	PMID25666693-Compound-44	Patented
T83193	DRUGINFO	D04HCS	PMID25666693-Compound-93	Patented
T83193	DRUGINFO	D04TIU	PMID25666693-Compound-154	Patented
T83193	DRUGINFO	D05RBF	PMID25666693-Compound-99	Patented
T83193	DRUGINFO	D05SMP	PMID25666693-Compound-116	Patented
T83193	DRUGINFO	D05SWL	PMID25666693-Compound-28	Patented
T83193	DRUGINFO	D05ZWR	PMID25666693-Compound-90	Patented
T83193	DRUGINFO	D06JHW	PMID25666693-Compound-37	Patented
T83193	DRUGINFO	D06VYF	PMID25666693-Compound-3	Patented
T83193	DRUGINFO	D07BZW	PMID25666693-Compound-85	Patented
T83193	DRUGINFO	D07EAV	PMID25666693-Compound-41	Patented
T83193	DRUGINFO	D07EGF	PMID25666693-Compound-56	Patented
T83193	DRUGINFO	D07FIY	PMID25666693-Compound-50	Patented
T83193	DRUGINFO	D07FWF	PMID25666693-Compound-117	Patented
T83193	DRUGINFO	D07JNJ	PMID25666693-Compound-17	Patented
T83193	DRUGINFO	D07MNI	PMID25666693-Compound-127	Patented
T83193	DRUGINFO	D07RYM	PMID25666693-Compound-131	Patented
T83193	DRUGINFO	D07XVL	PMID25666693-Compound-119	Patented
T83193	DRUGINFO	D07XZR	PMID25666693-Compound-134	Patented
T83193	DRUGINFO	D08CLA	PMID25666693-Compound-123	Patented
T83193	DRUGINFO	D08ICT	PMID25666693-Compound-13	Patented
T83193	DRUGINFO	D08UEC	PMID25666693-Compound-135	Patented
T83193	DRUGINFO	D08YAL	PMID25666693-Compound-111	Patented
T83193	DRUGINFO	D08ZBB	PMID25666693-Compound-84	Patented
T83193	DRUGINFO	D09QXC	PMID25666693-Compound-79	Patented
T83193	DRUGINFO	D09SMA	PMID25666693-Compound-128	Patented
T83193	DRUGINFO	D09ZWU	PMID25666693-Compound-40	Patented
T83193	DRUGINFO	D0A0YI	PMID25666693-Compound-34	Patented
T83193	DRUGINFO	D0A3XC	PMID25666693-Compound-25	Patented
T83193	DRUGINFO	D0A8LU	PMID25666693-Compound-113	Patented
T83193	DRUGINFO	D0AQ3U	PMID25666693-Compound-153	Patented
T83193	DRUGINFO	D0B0WJ	PMID25666693-Compound-51	Patented
T83193	DRUGINFO	D0B4NI	PMID25666693-Compound-77	Patented
T83193	DRUGINFO	D0C1MZ	PMID25666693-Compound-10	Patented
T83193	DRUGINFO	D0C5NT	PMID25666693-Compound-114	Patented
T83193	DRUGINFO	D0C8ZZ	PMID25666693-Compound-12	Patented
T83193	DRUGINFO	D0C9FN	PMID25666693-Compound-87	Patented
T83193	DRUGINFO	D0CR0H	PMID25666693-Compound-138	Patented
T83193	DRUGINFO	D0CX4C	PMID25666693-Compound-76	Patented
T83193	DRUGINFO	D0D2CF	PMID25666693-Compound-115	Patented
T83193	DRUGINFO	D0D4NX	PMID25666693-Compound-108	Patented
T83193	DRUGINFO	D0DC4O	PMID25666693-Compound-74	Patented
T83193	DRUGINFO	D0DE5I	PMID25666693-Compound-78	Patented
T83193	DRUGINFO	D0DE5K	PMID25666693-Compound-42	Patented
T83193	DRUGINFO	D0DI1R	PMID25666693-Compound-130	Patented
T83193	DRUGINFO	D0DT7M	PMID25666693-Compound-124	Patented
T83193	DRUGINFO	D0E0SA	PMID25666693-Compound-110	Patented
T83193	DRUGINFO	D0E8UP	PMID25666693-Compound-69	Patented
T83193	DRUGINFO	D0EC3Z	PMID25666693-Compound-82	Patented
T83193	DRUGINFO	D0EH2T	PMID25666693-Compound-118	Patented
T83193	DRUGINFO	D0EV3G	PMID25666693-Compound-26	Patented
T83193	DRUGINFO	D0F3HP	PMID25666693-Compound-101	Patented
T83193	DRUGINFO	D0F4DI	PMID25666693-Compound-30	Patented
T83193	DRUGINFO	D0F4YX	PMID25666693-Compound-15	Patented
T83193	DRUGINFO	D0F5NQ	PMID25666693-Compound-65	Patented
T83193	DRUGINFO	D0G3UV	PMID25666693-Compound-55	Patented
T83193	DRUGINFO	D0G6IQ	PMID25666693-Compound-143	Patented
T83193	DRUGINFO	D0GV5G	PMID25666693-Compound-66	Patented
T83193	DRUGINFO	D0GZ4G	PMID25666693-Compound-4	Patented
T83193	DRUGINFO	D0H4TR	PMID25666693-Compound-80	Patented
T83193	DRUGINFO	D0H6CX	PMID25666693-Compound-72	Patented
T83193	DRUGINFO	D0HE7X	PMID25666693-Compound-11	Patented
T83193	DRUGINFO	D0HS1D	PMID25666693-Compound-20	Patented
T83193	DRUGINFO	D0I3ZW	PMID25666693-Compound-159	Patented
T83193	DRUGINFO	D0IK1S	PMID25666693-Compound-102	Patented
T83193	DRUGINFO	D0IN5E	PMID25666693-Compound-48	Patented
T83193	DRUGINFO	D0IP5E	PMID25666693-Compound-9	Patented
T83193	DRUGINFO	D0IR7H	PMID25666693-Compound-27	Patented
T83193	DRUGINFO	D0IT4N	PMID25666693-Compound-94	Patented
T83193	DRUGINFO	D0IU1H	PMID25666693-Compound-52	Patented
T83193	DRUGINFO	D0J9CS	PMID25666693-Compound-59	Patented
T83193	DRUGINFO	D0JC8L	PMID25666693-Compound-31	Patented
T83193	DRUGINFO	D0JK2N	PMID25666693-Compound-22	Patented
T83193	DRUGINFO	D0JT8B	PMID25666693-Compound-147	Patented
T83193	DRUGINFO	D0JX4I	PMID25666693-Compound-62	Patented
T83193	DRUGINFO	D0K0ZI	PMID25666693-Compound-141	Patented
T83193	DRUGINFO	D0K3KE	PMID25666693-Compound-155	Patented
T83193	DRUGINFO	D0K3KM	PMID25666693-Compound-148	Patented
T83193	DRUGINFO	D0K4SZ	PMID25666693-Compound-46	Patented
T83193	DRUGINFO	D0KB2Z	PMID25666693-Compound-1	Patented
T83193	DRUGINFO	D0KF3A	PMID25666693-Compound-98	Patented
T83193	DRUGINFO	D0KM0W	PMID25666693-Compound-137	Patented
T83193	DRUGINFO	D0LA0Q	PMID25666693-Compound-162	Patented
T83193	DRUGINFO	D0M4WY	PMID25666693-Compound-29	Patented
T83193	DRUGINFO	D0MU3S	PMID25666693-Compound-47	Patented
T83193	DRUGINFO	D0MY3K	PMID25666693-Compound-109	Patented
T83193	DRUGINFO	D0N0QN	PMID25666693-Compound-146	Patented
T83193	DRUGINFO	D0N0TF	PMID25666693-Compound-156	Patented
T83193	DRUGINFO	D0N2UQ	PMID25666693-Compound-24	Patented
T83193	DRUGINFO	D0N9FJ	PMID25666693-Compound-7	Patented
T83193	DRUGINFO	D0NB5M	PMID25666693-Compound-35	Patented
T83193	DRUGINFO	D0NH2M	PMID25666693-Compound-142	Patented
T83193	DRUGINFO	D0NM3D	PMID25666693-Compound-19	Patented
T83193	DRUGINFO	D0NV2M	PMID25666693-Compound-157	Patented
T83193	DRUGINFO	D0O0UG	PMID25666693-Compound-86	Patented
T83193	DRUGINFO	D0O3TG	PMID25666693-Compound-136	Patented
T83193	DRUGINFO	D0O6VU	PMID25666693-Compound-92	Patented
T83193	DRUGINFO	D0O7IQ	PMID25666693-Compound-6	Patented
T83193	DRUGINFO	D0O9GI	PMID25666693-Compound-63	Patented
T83193	DRUGINFO	D0OA1P	PMID25666693-Compound-53	Patented
T83193	DRUGINFO	D0OC6A	PMID25666693-Compound-75	Patented
T83193	DRUGINFO	D0ON4M	PMID25666693-Compound-8	Patented
T83193	DRUGINFO	D0P0MR	PMID25666693-Compound-57	Patented
T83193	DRUGINFO	D0P5SB	PMID25666693-Compound-49	Patented
T83193	DRUGINFO	D0P9KJ	PMID25666693-Compound-43	Patented
T83193	DRUGINFO	D0PJ8O	PMID25666693-Compound-129	Patented
T83193	DRUGINFO	D0PT0U	PMID25666693-Compound-112	Patented
T83193	DRUGINFO	D0QP4N	PMID25666693-Compound-81	Patented
T83193	DRUGINFO	D0R2QV	PMID25666693-Compound-122	Patented
T83193	DRUGINFO	D0R2VB	PMID25666693-Compound-106	Patented
T83193	DRUGINFO	D0R8GA	PMID25666693-Compound-14	Patented
T83193	DRUGINFO	D0R9RP	PMID25666693-Compound-32	Patented
T83193	DRUGINFO	D0RC7L	PMID25666693-Compound-139	Patented
T83193	DRUGINFO	D0SD4G	PMID25666693-Compound-16	Patented
T83193	DRUGINFO	D0TZ2W	PMID25666693-Compound-38	Patented
T83193	DRUGINFO	D0U5CQ	PMID25666693-Compound-54	Patented
T83193	DRUGINFO	D0U5ON	PMID25666693-Compound-125	Patented
T83193	DRUGINFO	D0U8YZ	PMID25666693-Compound-45	Patented
T83193	DRUGINFO	D0UE9K	PMID25666693-Compound-83	Patented
T83193	DRUGINFO	D0V3PI	PMID25666693-Compound-36	Patented
T83193	DRUGINFO	D0V9RM	PMID25666693-Compound-89	Patented
T83193	DRUGINFO	D0W4AA	PMID25666693-Compound-33	Patented
T83193	DRUGINFO	D0WJ8R	PMID25666693-Compound-91	Patented
T83193	DRUGINFO	D0WT1W	PMID25666693-Compound-132	Patented
T83193	DRUGINFO	D0WX4W	PMID25666693-Compound-120	Patented
T83193	DRUGINFO	D0X1OO	PMID25666693-Compound-39	Patented
T83193	DRUGINFO	D0XX8R	PMID25666693-Compound-161	Patented
T83193	DRUGINFO	D0Y1SI	PMID25666693-Compound-100	Patented
T83193	DRUGINFO	D0Y9ST	PMID25666693-Compound-64	Patented
T83193	DRUGINFO	D0YM1M	PMID25666693-Compound-67	Patented
T83193	DRUGINFO	D0YR4E	PMID25666693-Compound-21	Patented
T83193	DRUGINFO	D0YU9B	PMID25666693-Compound-151	Patented
T83193	DRUGINFO	D0Z4QQ	PMID25666693-Compound-160	Patented
T83193	DRUGINFO	D0Z5HH	PMID25666693-Compound-144	Patented
T83193	DRUGINFO	D0ZE1M	PMID25666693-Compound-107	Patented
T83193	DRUGINFO	D0ZM8H	PMID25666693-Compound-18	Patented
T83193	DRUGINFO	D0ZP2C	PMID25666693-Compound-105	Patented
T83193	DRUGINFO	D0ZQ2W	PMID25666693-Compound-96	Patented
T83193	DRUGINFO	D0ZS3E	PMID25666693-Compound-152	Patented
T83193	DRUGINFO	D0ZZ8F	PMID25666693-Compound-68	Patented
T83193	DRUGINFO	D00FJC	Nuvanil	Discontinued in Phase 2
T83193	DRUGINFO	D04PMM	AZD1386	Discontinued in Phase 2
T83193	DRUGINFO	D06GDH	DA-5018	Discontinued in Phase 2
T83193	DRUGINFO	D06PYP	JTS-653	Discontinued in Phase 2
T83193	DRUGINFO	D0Z0PB	NGD-8243	Discontinued in Phase 2
T83193	DRUGINFO	D0L5XI	AMG-517	Discontinued in Phase 1
T83193	DRUGINFO	D07LRT	A-425619	Preclinical
T83193	DRUGINFO	D01QIA	BL-1872	Terminated
T83193	DRUGINFO	D07IEM	AMG-8562	Terminated
T83193	DRUGINFO	D00RDS	4-tert-butyl-N-(quinolin-3-yl)benzamide	Investigative
T83193	DRUGINFO	D00XZZ	4-butyl-N-(pyridin-3-yl)benzamide	Investigative
T83193	DRUGINFO	D00ZWU	4-butyl-N-(quinolin-3-yl)benzamide	Investigative
T83193	DRUGINFO	D01WDS	4-(cyclohexylamino)-N-(quinolin-3-yl)benzamide	Investigative
T83193	DRUGINFO	D02ANZ	phenylacetylrinvanil	Investigative
T83193	DRUGINFO	D02GNL	KMJ-372	Investigative
T83193	DRUGINFO	D03SJY	N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]undecanamide	Investigative
T83193	DRUGINFO	D04FFY	AMG-8563	Investigative
T83193	DRUGINFO	D04IJB	[125I]resiniferatoxin	Investigative
T83193	DRUGINFO	D05APW	ABT-116	Investigative
T83193	DRUGINFO	D05NTO	6'-Iodononivamide	Investigative
T83193	DRUGINFO	D06CDW	PPAHV	Investigative
T83193	DRUGINFO	D06MRN	4-(methyl(octyl)amino)-N-(quinolin-3-yl)benzamide	Investigative
T83193	DRUGINFO	D07BKU	A-795614	Investigative
T83193	DRUGINFO	D07LCG	4-butyl-N-phenylbenzamide	Investigative
T83193	DRUGINFO	D08KRX	4-nonyl-N-(quinolin-3-yl)benzamide	Investigative
T83193	DRUGINFO	D08KYH	4-(hexyl(methyl)amino)-N-(quinolin-3-yl)benzamide	Investigative
T83193	DRUGINFO	D08WAW	4-pentyl-N-pyridin-3-yl benzamide	Investigative
T83193	DRUGINFO	D08WTR	6-iodo-nordihydrocapsaicin	Investigative
T83193	DRUGINFO	D09AZO	4-(3-methylpyridin-2-yl)-N-p-tolylbenzamide	Investigative
T83193	DRUGINFO	D09BEW	N-methyl-4-pentyl-N-(pyridin-3-yl)benzamide	Investigative
T83193	DRUGINFO	D09SXM	(R)-1-(1H-indazol-4-yl)-3-(1-p-tolylethyl)urea	Investigative
T83193	DRUGINFO	D09WYF	2-(4-pentylphenyl)-N-(pyridin-3-yl)acetamide	Investigative
T83193	DRUGINFO	D0BB7F	4-butyl-N-(isoquinolin-5-yl)benzamide	Investigative
T83193	DRUGINFO	D0BY9X	A778317	Investigative
T83193	DRUGINFO	D0C3XF	4-decyl-N-(pyridin-3-yl)benzamide	Investigative
T83193	DRUGINFO	D0D0DW	1-(4-Bromo-benzyl)-3-quinazolin-8-yl-urea	Investigative
T83193	DRUGINFO	D0D2FP	[3H]A778317	Investigative
T83193	DRUGINFO	D0D4SO	4-octyl-N-(quinolin-3-yl)benzamide	Investigative
T83193	DRUGINFO	D0D7QH	arvanil	Investigative
T83193	DRUGINFO	D0D9MW	4-propyl-N-(quinolin-3-yl)benzamide	Investigative
T83193	DRUGINFO	D0DJ6G	4-butyl-N-(7-hydroxynaphthalen-1-yl)benzamide	Investigative
T83193	DRUGINFO	D0DL4Y	(5E,8E,11E,14E)-Icosa-5,8,11,14-tetraenal	Investigative
T83193	DRUGINFO	D0DY4E	JNJ-17203212	Investigative
T83193	DRUGINFO	D0E2XP	N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]linoleamide	Investigative
T83193	DRUGINFO	D0E4FJ	(E)-Octadec-9-enal	Investigative
T83193	DRUGINFO	D0F4LI	LASSBio-881	Investigative
T83193	DRUGINFO	D0F4NA	N-(4-iodophenyl)-4-(trifluoromethyl)benzamide	Investigative
T83193	DRUGINFO	D0F9NL	12S-HPETE	Investigative
T83193	DRUGINFO	D0GL2X	1,3-dibenzyl urea	Investigative
T83193	DRUGINFO	D0H6GW	4-heptyl-N-(pyridin-3-yl)benzamide	Investigative
T83193	DRUGINFO	D0H6TX	(S)-1-(1H-indazol-4-yl)-3-(1-p-tolylethyl)urea	Investigative
T83193	DRUGINFO	D0J3VX	1-(isoquinolin-5-yl)-3-(4-morpholinobenzyl)urea	Investigative
T83193	DRUGINFO	D0J8NC	ASP-8370	Investigative
T83193	DRUGINFO	D0KH9W	15S-HPETE	Investigative
T83193	DRUGINFO	D0L9DR	SB-782443	Investigative
T83193	DRUGINFO	D0M7NA	A-993610	Investigative
T83193	DRUGINFO	D0M7TC	agatoxin 489	Investigative
T83193	DRUGINFO	D0N8EI	4-(butyl(methyl)amino)-N-(quinolin-3-yl)benzamide	Investigative
T83193	DRUGINFO	D0P0MN	NE-28345	Investigative
T83193	DRUGINFO	D0P7VQ	BCTC	Investigative
T83193	DRUGINFO	D0Q2ZO	4-octyl-N-(pyridin-3-yl)benzamide	Investigative
T83193	DRUGINFO	D0R8XX	N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]lauramide	Investigative
T83193	DRUGINFO	D0SH1L	1-benzhydryl-3-(isoquinolin-5-yl)urea	Investigative
T83193	DRUGINFO	D0SO5A	ATC-120	Investigative
T83193	DRUGINFO	D0T8DR	4-hexyl-N-(quinolin-3-yl)benzamide	Investigative
T83193	DRUGINFO	D0U3WK	SB452533	Investigative
T83193	DRUGINFO	D0VM5U	KJM429	Investigative
T83193	DRUGINFO	D0W3VM	N-(4-tert-butylphenyl)-4-(pyridin-2-yl)benzamide	Investigative
T83193	DRUGINFO	D0W6TX	N-(4-iodophenyl)-4-(trifluoromethoxy)benzamide	Investigative
T83193	DRUGINFO	D0W8UW	AMG-628	Investigative
T83193	DRUGINFO	D0WK3N	4-(methyl(nonyl)amino)-N-(quinolin-3-yl)benzamide	Investigative
T83193	DRUGINFO	D0X8XU	1-(isoquinolin-5-yl)-3-(1-phenylpropyl)urea	Investigative
T83193	DRUGINFO	D0XO2G	AMG 9810	Investigative
T83193	DRUGINFO	D0Y7QY	(E)-3-(4-tert-Butyl-phenyl)-N-phenyl-acrylamide	Investigative
T83193	DRUGINFO	D0Y9EU	4-heptyl-N-(quinolin-3-yl)benzamide	Investigative
T83193	DRUGINFO	D00ESG	4-Pyridin-2-yl-piperazine-1-carboxylic acid amide	Investigative
T83193	DRUGINFO	D03KQG	Pyrrolidin-1-yl-thiourea	Investigative
T83193	DRUGINFO	D07YQG	NADA	Investigative
T83193	DRUGINFO	D0G8BN	CAPSAZEPINE	Investigative
T83193	DRUGINFO	D0Q2LG	5S-HPETE	Investigative
T83193	DRUGINFO	D0X7AM	SC-0030	Investigative
T83193	DRUGINFO	D03TWR	diphenylboronic anhydride	Investigative
T83193	DRUGINFO	D07CJR	5S-HETE	Investigative
T83193	DRUGINFO	D00HCI	2-APB	Investigative

T75888	TARGETID	T75888
T75888	FORMERID	TTDS00433
T75888	UNIPROID	CPT1B_HUMAN
T75888	TARGNAME	Carnitine O-palmitoyltransferase I (CPT1B)
T75888	GENENAME	CPT1B
T75888	TARGTYPE	Successful
T75888	SYNONYMS	KIAA1670; Carnitine palmitoyltransferase I-like protein; Carnitine palmitoyltransferase I; Carnitine palmitoyltransferase 1B; Carnitine palmitoyl-transferase I; Carnitine o-palmitoyltransferase-1; Carnitine O-palmitoyltransferase I, muscle isoform; Carnitine O-palmitoyltransferase 1, muscle isoform; CPTI-M; CPTI-L; CPT1-M; CPT-1; CPT I; CPT
T75888	FUNCTION	mitochondrial outer membrane, mitochondrion, carnitine O-palmitoyltransferase activity, carnitine metabolic process, carnitine shuttle, fatty acid beta-oxidation, long-chain fatty acid transport.
T75888	BIOCLASS	Acyltransferase
T75888	ECNUMBER	EC 2.3.1.21
T75888	SEQUENCE	MAEAHQAVAFQFTVTPDGVDFRLSREALKHVYLSGINSWKKRLIRIKNGILRGVYPGSPTSWLVVIMATVGSSFCNVDISLGLVSCIQRCLPQGCGPYQTPQTRALLSMAIFSTGVWVTGIFFFRQTLKLLLCYHGWMFEMHGKTSNLTRIWAMCIRLLSSRHPMLYSFQTSLPKLPVPRVSATIQRYLESVRPLLDDEEYYRMELLAKEFQDKTAPRLQKYLVLKSWWASNYVSDWWEEYIYLRGRSPLMVNSNYYVMDLVLIKNTDVQAARLGNIIHAMIMYRRKLDREEIKPVMALGIVPMCSYQMERMFNTTRIPGKDTDVLQHLSDSRHVAVYHKGRFFKLWLYEGARLLKPQDLEMQFQRILDDPSPPQPGEEKLAALTAGGRVEWAQARQAFFSSGKNKAALEAIERAAFFVALDEESYSYDPEDEASLSLYGKALLHGNCYNRWFDKSFTLISFKNGQLGLNAEHAWADAPIIGHLWEFVLGTDSFHLGYTETGHCLGKPNPALAPPTRLQWDIPKQCQAVIESSYQVAKALADDVELYCFQFLPFGKGLIKKCRTSPDAFVQIALQLAHFRDRGKFCLTYEASMTRMFREGRTETVRSCTSESTAFVQAMMEGSHTKADLRDLFQKAAKKHQNMYRLAMTGAGIDRHLFCLYLVSKYLGVSSPFLAEVLSEPWRLSTSQIPQSQIRMFDPEQHPNHLGAGGGFGPVADDGYGVSYMIAGENTIFFHISSKFSSSETNAQRFGNHIRKALLDIADLFQVPKAYS
T75888	DRUGINFO	D00SBN	Perhexiline	Approved
T75888	DRUGINFO	D0G8SQ	Levacecarnine hci	Approved
T75888	DRUGINFO	D0I3PG	SDZ-CPI-975	Discontinued in Phase 1
T75888	DRUGINFO	D00UEQ	Etomoxir	Terminated
T75888	DRUGINFO	D0SG0N	DB-200	Terminated
T75888	DRUGINFO	D07MXA	C75	Investigative

T59604	TARGETID	T59604
T59604	FORMERID	TTDC00127
T59604	UNIPROID	GHSR_HUMAN
T59604	TARGNAME	Growth hormone secretagogue receptor 1 (GHSR)
T59604	GENENAME	GHSR
T59604	TARGTYPE	Successful
T59604	SYNONYMS	Growth hormone secretagogue receptor; Ghrelin receptor; GHSR; GHS-R; GHRP; GH-releasing peptide receptor
T59604	FUNCTION	Receptor for ghrelin, coupled to G-alpha-11 proteins. Stimulates growth hormone secretion. Binds also other growth hormone releasing peptides (GHRP) (e.g. Met-enkephalin and GHRP-6) as well as non-peptide, low molecular weight secretagogues (e.g. L-692,429, MK-0677, adenosine).
T59604	BIOCLASS	GPCR rhodopsin
T59604	SEQUENCE	MWNATPSEEPGFNLTLADLDWDASPGNDSLGDELLQLFPAPLLAGVTATCVALFVVGIAGNLLTMLVVSRFRELRTTTNLYLSSMAFSDLLIFLCMPLDLVRLWQYRPWNFGDLLCKLFQFVSESCTYATVLTITALSVERYFAICFPLRAKVVVTKGRVKLVIFVIWAVAFCSAGPIFVLVGVEHENGTDPWDTNECRPTEFAVRSGLLTVMVWVSSIFFFLPVFCLTVLYSLIGRKLWRRRRGDAVVGASLRDQNHKQTVKMLAVVVFAFILCWLPFHVGRYLFSKSFEPGSLEIAQISQYCNLVSFVLFYLSAAINPILYNIMSKKYRVAVFRLLGFEPFSQRKLSTLKDESSRAWTESSINT
T59604	DRUGINFO	D02NEH	Ibutamoren	Approved
T59604	DRUGINFO	D0BV3J	Macimorelin	Approved
T59604	DRUGINFO	D08VRX	GHRP-2	Approved
T59604	DRUGINFO	D03WAU	Anamorelin	Phase 3
T59604	DRUGINFO	D0W9VW	TZP-101	Phase 2b
T59604	DRUGINFO	D03RFK	GTP-200	Phase 2
T59604	DRUGINFO	D0UO4B	RQ-00000005	Phase 2
T59604	DRUGINFO	D0XH9B	Tabimorelin	Phase 2
T59604	DRUGINFO	D9OR7F	Ibutamoren mesylate	Phase 2
T59604	DRUGINFO	D08BEA	Ipamorelin	Phase 1/2
T59604	DRUGINFO	D01HLO	PF-05190457	Phase 1
T59604	DRUGINFO	D03BGG	ST-1141	Phase 1
T59604	DRUGINFO	D08KVK	CYT-009-GhrQb	Discontinued in Phase 1/2
T59604	DRUGINFO	D0LR1M	LY-444711	Discontinued in Phase 1
T59604	DRUGINFO	D09DKY	AEZS-123	Preclinical
T59604	DRUGINFO	D0N3RC	TZP-301	Preclinical
T59604	DRUGINFO	D0T8YK	EP-01492	Preclinical
T59604	DRUGINFO	D0G2VT	SUN-11031	Terminated
T59604	DRUGINFO	D01LKO	WFwGG-NH2	Investigative
T59604	DRUGINFO	D01WVV	[35S]ibutamoren	Investigative
T59604	DRUGINFO	D02NZI	SM-130,686	Investigative
T59604	DRUGINFO	D06GIL	JMV3008	Investigative
T59604	DRUGINFO	D07JZB	RwFwLL-NH2	Investigative
T59604	DRUGINFO	D07QLZ	AwFwLL-NH2	Investigative
T59604	DRUGINFO	D08GTH	WFwLL-NH2	Investigative
T59604	DRUGINFO	D09QPV	QwFwLL-NH2	Investigative
T59604	DRUGINFO	D0C3OY	RPKPfQwFwLL-NH2	Investigative
T59604	DRUGINFO	D0C4BI	EX-1314	Investigative
T59604	DRUGINFO	D0E7PZ	NOX-B11	Investigative
T59604	DRUGINFO	D0G8TL	HwFwLL-NH2	Investigative
T59604	DRUGINFO	D0J2YB	YIL781	Investigative
T59604	DRUGINFO	D0L3AP	DwFwLL-NH2	Investigative
T59604	DRUGINFO	D0L3EP	GSK1614343	Investigative
T59604	DRUGINFO	D0PQ7A	DprwFwLL-NH2	Investigative
T59604	DRUGINFO	D0U2QP	4-(3-hexylureido)-N-phenylbenzenesulfonamide	Investigative
T59604	DRUGINFO	D0UV9F	GSK-894281	Investigative
T59604	DRUGINFO	D0XR6A	KwFwLL-NH2	Investigative
T59604	DRUGINFO	D0YJ5H	EX-1311	Investigative
T59604	DRUGINFO	D0ZG7W	Abbott 14c	Investigative

T46937	TARGETID	T46937
T46937	FORMERID	TTDS00113
T46937	UNIPROID	P2Y12_HUMAN
T46937	TARGNAME	P2Y purinoceptor 12 (P2RY12)
T46937	GENENAME	P2RY12
T46937	TARGTYPE	Successful
T46937	SYNONYMS	SP1999; P2Y12 platelet ADP receptor; P2Y12; P2Y(cyc); P2Y(ADP)P2Y purinoceptor 12; P2Y(ADP); P2Y(AC); P2T(AC); P2RY12; Nucleotide P2Y(12) receptor; Adenosine P2Y12 receptor; ADPG-R; ADP-glucose receptor
T46937	FUNCTION	Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation.
T46937	PDBSTRUC	4PY0; 4PXZ; 4NTJ; 1Y9C; 1VZ1
T46937	BIOCLASS	GPCR rhodopsin
T46937	SEQUENCE	MQAVDNLTSAPGNTSLCTRDYKITQVLFPLLYTVLFFVGLITNGLAMRIFFQIRSKSNFIIFLKNTVISDLLMILTFPFKILSDAKLGTGPLRTFVCQVTSVIFYFTMYISISFLGLITIDRYQKTTRPFKTSNPKNLLGAKILSVVIWAFMFLLSLPNMILTNRQPRDKNVKKCSFLKSEFGLVWHEIVNYICQVIFWINFLIVIVCYTLITKELYRSYVRTRGVGKVPRKKVNVKVFIIIAVFFICFVPFHFARIPYTLSQTRDVFDCTAENTLFYVKESTLWLTSLNACLDPFIYFFLCKSFRNSLISMLKCPNSATSLSQDNRKKEQDGGDPNEETPM
T46937	DRUGINFO	D07IRF	Prasugrel	Approved
T46937	DRUGINFO	D09QBG	Cangrelor	Approved
T46937	DRUGINFO	D0N0TZ	Clopidogrel	Approved
T46937	DRUGINFO	D0WF7L	Brilinta	Approved
T46937	DRUGINFO	D0W4JI	INS-50589	Phase 2
T46937	DRUGINFO	D09VBE	Elinogrel	Phase 1
T46937	DRUGINFO	D0KE4Z	ARL-67085	Phase 1
T46937	DRUGINFO	D00YAZ	R-138727	Investigative
T46937	DRUGINFO	D01APA	PMID22984835C20o	Investigative
T46937	DRUGINFO	D01IEX	PSB-0739	Investigative
T46937	DRUGINFO	D02TXW	BX 667	Investigative
T46937	DRUGINFO	D03HLK	PRT-060096	Investigative
T46937	DRUGINFO	D05KHS	pCMPS	Investigative
T46937	DRUGINFO	D08MDL	INS49266	Investigative
T46937	DRUGINFO	D0E4YW	ARL66096	Investigative
T46937	DRUGINFO	D0KF2P	PMID22984835C4	Investigative
T46937	DRUGINFO	D0M7HH	[3H]PSB-0413	Investigative
T46937	DRUGINFO	D0N3FL	PSB-0702	Investigative
T46937	DRUGINFO	D0U2CJ	PMID23083103C4	Investigative
T46937	DRUGINFO	D0U4VW	BX 048	Investigative
T46937	DRUGINFO	D01GRB	2MeSAMP	Investigative
T46937	DRUGINFO	D0BB0O	2MeSADP	Investigative
T46937	DRUGINFO	D05NWF	adenosine diphosphate	Investigative

T06841	TARGETID	T06841
T06841	FORMERID	TTDI01808
T06841	UNIPROID	IL23A_HUMAN
T06841	TARGNAME	Interleukin-23 (IL23)
T06841	GENENAME	IL23A
T06841	TARGTYPE	Successful
T06841	SYNONYMS	UNQ2498/PRO5798; SGRF; P40 subunit of interleukin-23; Interleukin-23 subunit p19; Interleukin-23 subunit alpha; Interleukin 23 subunit alpha; IL-23p19; IL-23-A; IL-23 subunit alpha; IL-23
T06841	FUNCTION	IL-23 may constitute with IL-17 an acute response to infection in peripheral tissues. IL-23 binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R, activates the Jak-Stat signaling cascade, stimulates memory rather than naive T-cells and promotes production of proinflammatory cytokines. IL-23 induces autoimmune inflammation and thus may be responsible for autoimmune inflammatory diseases and may be important for tumorigenesis. Associates with IL12B to form the IL-23 interleukin, a heterodimeric cytokine which functions in innate and adaptive immunity.
T06841	PDBSTRUC	5NJD; 5MZV; 5MXA; 5MJ4; 5MJ3
T06841	BIOCLASS	Cytokine: interleukin
T06841	SEQUENCE	MLGSRAVMLLLLLPWTAQGRAVPGGSSPAWTQCQQLSQKLCTLAWSAHPLVGHMDLREEGDEETTNDVPHIQCGDGCDPQGLRDNSQFCLQRIHQGLIFYEKLLGSDIFTGEPSLLPDSPVGQLHASLLGLSQLLQPEGHHWETQQIPSLSPSQPWQRLLLRFKILRSLQAFVAVAARVFAHGAATLSP
T06841	DRUGINFO	D03HSN	CNTO-1959	Approved
T06841	DRUGINFO	D0GP8Q	Risankizumab	Approved
T06841	DRUGINFO	D0FT3R	Tildrakizumab	Approved
T06841	DRUGINFO	D0A2UV	Ustekinumab	Approved
T06841	DRUGINFO	D0A0MS	BI 655066	Phase 3
T06841	DRUGINFO	D0P1ME	MK-3222	Phase 3
T06841	DRUGINFO	DMS12U	Brazikumab	Phase 3
T06841	DRUGINFO	DVT8O0	ABP 654	Phase 3
T06841	DRUGINFO	D0HT2X	CNT0-1959	Phase 2
T06841	DRUGINFO	D0G3EU	AMG-139	Phase 1
T06841	DRUGINFO	DC5A9Q	mRNA-2752	Phase 1

T46482	TARGETID	T46482
T46482	FORMERID	TTDS00311
T46482	UNIPROID	TLR7_HUMAN
T46482	TARGNAME	Toll-like receptor 7 (TLR7)
T46482	GENENAME	TLR7
T46482	TARGTYPE	Successful
T46482	SYNONYMS	Toll-like receptor 7
T46482	FUNCTION	Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR7 is a nucleotide-sensing TLR which is activated by single-stranded RNA. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response (By similarity).
T46482	BIOCLASS	Toll-like receptor
T46482	SEQUENCE	MVFPMWTLKRQILILFNIILISKLLGARWFPKTLPCDVTLDVPKNHVIVDCTDKHLTEIPGGIPTNTTNLTLTINHIPDISPASFHRLDHLVEIDFRCNCVPIPLGSKNNMCIKRLQIKPRSFSGLTYLKSLYLDGNQLLEIPQGLPPSLQLLSLEANNIFSIRKENLTELANIEILYLGQNCYYRNPCYVSYSIEKDAFLNLTKLKVLSLKDNNVTAVPTVLPSTLTELYLYNNMIAKIQEDDFNNLNQLQILDLSGNCPRCYNAPFPCAPCKNNSPLQIPVNAFDALTELKVLRLHSNSLQHVPPRWFKNINKLQELDLSQNFLAKEIGDAKFLHFLPSLIQLDLSFNFELQVYRASMNLSQAFSSLKSLKILRIRGYVFKELKSFNLSPLHNLQNLEVLDLGTNFIKIANLSMFKQFKRLKVIDLSVNKISPSGDSSEVGFCSNARTSVESYEPQVLEQLHYFRYDKYARSCRFKNKEASFMSVNESCYKYGQTLDLSKNSIFFVKSSDFQHLSFLKCLNLSGNLISQTLNGSEFQPLAELRYLDFSNNRLDLLHSTAFEELHKLEVLDISSNSHYFQSEGITHMLNFTKNLKVLQKLMMNDNDISSSTSRTMESESLRTLEFRGNHLDVLWREGDNRYLQLFKNLLKLEELDISKNSLSFLPSGVFDGMPPNLKNLSLAKNGLKSFSWKKLQCLKNLETLDLSHNQLTTVPERLSNCSRSLKNLILKNNQIRSLTKYFLQDAFQLRYLDLSSNKIQMIQKTSFPENVLNNLKMLLLHHNRFLCTCDAVWFVWWVNHTEVTIPYLATDVTCVGPGAHKGQSVISLDLYTCELDLTNLILFSLSISVSLFLMVMMTASHLYFWDVWYIYHFCKAKIKGYQRLISPDCCYDAFIVYDTKDPAVTEWVLAELVAKLEDPREKHFNLCLEERDWLPGQPVLENLSQSIQLSKKTVFVMTDKYAKTENFKIAFYLSHQRLMDEKVDVIILIFLEKPFQKSKFLQLRKRLCGSSVLEWPTNPQAHPYFWQCLKNALATDNHVAYSQVFKETV
T46482	DRUGINFO	D06CTE	Imiquimod	Approved
T46482	DRUGINFO	D0OJ4L	Hydroxychloroquine	Approved
T46482	DRUGINFO	D04TIL	ANA773	Phase 2a
T46482	DRUGINFO	D04EIF	LOXORIBINE	Phase 2
T46482	DRUGINFO	D04PAU	GSK2245035	Phase 2
T46482	DRUGINFO	D04XCO	AZD-8848	Phase 2
T46482	DRUGINFO	D05AAD	Isatoribine	Phase 2
T46482	DRUGINFO	D08JWC	GS-9620	Phase 2
T46482	DRUGINFO	D0T1FC	PF-4878691	Phase 2
T46482	DRUGINFO	D08OXU	IMO-3100	Phase 2
T46482	DRUGINFO	D0C8KF	Resiquimod	Phase 2
T46482	DRUGINFO	DW0ZV1	Afimetoran	Phase 2
T46482	DRUGINFO	D52NOH	BNT411	Phase 1/2
T46482	DRUGINFO	DZL8S6	DSP-0509	Phase 1/2
T46482	DRUGINFO	D8JN5H	NKTR-262	Phase 1/2
T46482	DRUGINFO	D12EFM	RG7854	Phase 1
T46482	DRUGINFO	D6QRJ2	RG6115	Phase 1
T46482	DRUGINFO	DU2G0C	LHC165	Phase 1
T46482	DRUGINFO	D00CGX	DV-1179	Phase 1
T46482	DRUGINFO	D0L8HB	MEDI9197	Phase 1
T46482	DRUGINFO	D0G1TY	CPG 52364	Phase 1
T46482	DRUGINFO	DVU2H8	CV8102	Phase 1
T46482	DRUGINFO	D0H4XV	IM0-8400	Discontinued in Phase 1/2
T46482	DRUGINFO	D03GNR	ANA-975	Discontinued in Phase 1
T46482	DRUGINFO	D0J3VV	IPH-3201	Terminated
T46482	DRUGINFO	D05TCC	TMX-202	Investigative
T46482	DRUGINFO	D0I2GT	TMX-30X	Investigative
T46482	DRUGINFO	D0Z2IY	TMX-201	Investigative

T99948	TARGETID	T99948
T99948	FORMERID	TTDNC00468
T99948	UNIPROID	PD1L1_HUMAN
T99948	TARGNAME	Programmed cell death 1 ligand 1 (PD-L1)
T99948	GENENAME	CD274
T99948	TARGTYPE	Successful
T99948	SYNONYMS	hPD-L1; Programmed death ligand 1; PDL1; PDCD1LG1; PDCD1L1; PDCD1 ligand 1; B7H1; B7-H1; B7 homolog 1
T99948	FUNCTION	As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). Plays a critical role in induction and maintenance of immune tolerance to self.
T99948	PDBSTRUC	6R3K; 6NP9; 6NOS; 6NOJ; 6NNV
T99948	BIOCLASS	Immunoglobulin
T99948	SEQUENCE	MRIFAVFIFMTYWHLLNAFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERTHLVILGAILLCLGVALTFIFRLRKGRMMDVKKCGIQDTNSKKQSDTHLEET
T99948	DRUGINFO	D0K7SX	Avelumab	Approved
T99948	DRUGINFO	D0LS9E	Durvalumab	Approved
T99948	DRUGINFO	D0OZ4J	RG-7446	Approved
T99948	DRUGINFO	D0W8HN	Bavencio	Approved
T99948	DRUGINFO	D0YM2K	Atezolizumab	Approved
T99948	DRUGINFO	DDZ48Y	Sugemalimab	Approved in China
T99948	DRUGINFO	D04RRZ	MEDI4736	Phase 3
T99948	DRUGINFO	D0Y5IH	MPDL-3280A	Phase 3
T99948	DRUGINFO	D3MP1S	CS1001	Phase 3
T99948	DRUGINFO	DI89WD	A167	Phase 3
T99948	DRUGINFO	DLOQ25	KN046	Phase 3
T99948	DRUGINFO	D09MRL	Pidilizumab	Phase 2
T99948	DRUGINFO	D0GF2R	KN035	Phase 2
T99948	DRUGINFO	D0Z2BO	CX-072	Phase 2
T99948	DRUGINFO	DKM79E	INCB86550	Phase 2
T99948	DRUGINFO	D5J3BL	Bintrafusp alfa	Phase 2
T99948	DRUGINFO	D05FPZ	M7824	Phase 2
T99948	DRUGINFO	DC5VW9	BGB-A333	Phase 1/2
T99948	DRUGINFO	DS6VD0	GS-4224	Phase 1/2
T99948	DRUGINFO	DUVH60	NM21-1480	Phase 1/2
T99948	DRUGINFO	D08HSS	LY3300054	Phase 1
T99948	DRUGINFO	D0A8AU	MSB2311	Phase 1
T99948	DRUGINFO	D0KP9A	Anti-PD-L1	Phase 1
T99948	DRUGINFO	D0LU1O	FAZ053	Phase 1
T99948	DRUGINFO	D0W7UD	Anti-PD-L1 CSR T cells	Phase 1
T99948	DRUGINFO	D0X1GN	BMS-986189	Phase 1
T99948	DRUGINFO	D17URP	Cosibelimab	Phase 1
T99948	DRUGINFO	D2Z6WF	CA-170	Phase 1
T99948	DRUGINFO	DH42RF	PD-L1 t-haNK	Phase 1
T99948	DRUGINFO	DJVR06	KD033	Phase 1
T99948	DRUGINFO	D03GTO	C-Met/PD-L1 CAR-T Cell	Phase 1
T99948	DRUGINFO	D09PPU	CA-170	Phase 1
T99948	DRUGINFO	D0XO9F	FS118	Phase 1
T99948	DRUGINFO	D1A7OP	PF-07257876	Phase 1
T99948	DRUGINFO	D2QY0Z	MCLA-145	Phase 1
T99948	DRUGINFO	D3HBJ1	GEN1046	Phase 1
T99948	DRUGINFO	D82UVG	ALPN-202	Phase 1
T99948	DRUGINFO	D9SL1N	TAK-252	Phase 1
T99948	DRUGINFO	DA1X5W	INBRX-105	Phase 1
T99948	DRUGINFO	DC8HR6	LY3415244	Phase 1
T99948	DRUGINFO	DL97UQ	A337	Phase 1
T99948	DRUGINFO	DX30BA	IBI318	Phase 1
T99948	DRUGINFO	D0OK1S	PMID30107136-Compound-Example2	Patented
T99948	DRUGINFO	D0WQ9X	PMID30107136-Compound-Example1	Patented
T99948	DRUGINFO	D01TGF	PMID30247903-Compound-General structure7	Investigative
T99948	DRUGINFO	D04ILU	CA-327	Investigative
T99948	DRUGINFO	D04QGF	PMID30247903-Compound-General structure8	Investigative
T99948	DRUGINFO	D07BOF	PMID30247903-Compound-General structure5	Investigative
T99948	DRUGINFO	D09BYN	PMID30247903-Compound-General structure12	Investigative
T99948	DRUGINFO	D0GG6N	PMID30247903-Compound-General structure9	Investigative
T99948	DRUGINFO	D0TN4F	PMID30247903-Compound-General structure6	Investigative
T99948	DRUGINFO	D0XL3N	PMID30247903-Compound-General structure10	Investigative
T99948	DRUGINFO	DA91UG	YH011	Investigative
T99948	DRUGINFO	DBTI39	YH010	Investigative

T42446	TARGETID	T42446
T42446	FORMERID	TTDS00022
T42446	UNIPROID	GABR1_HUMAN; GABR2_HUMAN
T42446	TARGNAME	Gamma-aminobutyric acid B receptor (GABBR)
T42446	GENENAME	GABBR1; GABBR2
T42446	TARGTYPE	Successful
T42446	SYNONYMS	Gamma-aminobutyric acid type B receptor; GPRC3; GABABR; GABA-BR; GABA-B-R; GABA-B receptor
T42446	FUNCTION	Within the heterodimeric GABA receptor, only GABBR1 seems to bind agonists, while GABBR2 mediates coupling to G proteins. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase, stimulates phospholipase A2, activates potassium channels, inactivates voltage-dependent calcium-channels and modulates inositol phospholipid hydrolysis. Plays a critical role in the fine-tuning of inhibitory synaptic transmission. Pre-synaptic GABA receptor inhibits neurotransmitter release by down-regulating high-voltage activated calcium channels, whereas postsynaptic GABA receptor decreases neuronal excitability by activating a prominent inwardly rectifying potassium (Kir) conductance that underlies the late inhibitory postsynaptic potentials. Not only implicated in synaptic inhibition but also in hippocampal long-term potentiation, slow wave sleep, muscle relaxation and antinociception. Component of a heterodimeric G-protein coupled receptor for GABA, formed by GABBR1 and GABBR2.
T42446	BIOCLASS	GPCR glutamate
T42446	SEQUENCE	MLLLLLLAPLFLRPPGAGGAQTPNATSEGCQIIHPPWEGGIRYRGLTRDQVKAINFLPVDYEIEYVCRGEREVVGPKVRKCLANGSWTDMDTPSRCVRICSKSYLTLENGKVFLTGGDLPALDGARVDFRCDPDFHLVGSSRSICSQGQWSTPKPHCQVNRTPHSERRAVYIGALFPMSGGWPGGQACQPAVEMALEDVNSRRDILPDYELKLIHHDSKCDPGQATKYLYELLYNDPIKIILMPGCSSVSTLVAEAARMWNLIVLSYGSSSPALSNRQRFPTFFRTHPSATLHNPTRVKLFEKWGWKKIATIQQTTEVFTSTLDDLEERVKEAGIEITFRQSFFSDPAVPVKNLKRQDARIIVGLFYETEARKVFCEVYKERLFGKKYVWFLIGWYADNWFKIYDPSINCTVDEMTEAVEGHITTEIVMLNPANTRSISNMTSQEFVEKLTKRLKRHPEETGGFQEAPLAYDAIWALALALNKTSGGGGRSGVRLEDFNYNNQTITDQIYRAMNSSSFEGVSGHVVFDASGSRMAWTLIEQLQGGSYKKIGYYDSTKDDLSWSKTDKWIGGSPPADQTLVIKTFRFLSQKLFISVSVLSSLGIVLAVVCLSFNIYNSHVRYIQNSQPNLNNLTAVGCSLALAAVFPLGLDGYHIGRNQFPFVCQARLWLLGLGFSLGYGSMFTKIWWVHTVFTKKEEKKEWRKTLEPWKLYATVGLLVGMDVLTLAIWQIVDPLHRTIETFAKEEPKEDIDVSILPQLEHCSSRKMNTWLGIFYGYKGLLLLLGIFLAYETKSVSTEKINDHRAVGMAIYNVAVLCLITAPVTMILSSQQDAAFAFASLAIVFSSYITLVVLFVPKMRRLITRGEWQSEAQDTMKTGSSTNNNEEEKSRLLEKENRELEKIIAEKEERVSELRHQLQSRQQLRSRRHPPTPPEPSGGLPRGPPEPPDRLSCDGSRVHLLYK
T42446	DRUGINFO	D01AJY	Baclofen	Approved
T42446	DRUGINFO	D0EP8X	Gamma Hydroxybutyric Acid	Approved
T42446	DRUGINFO	D0J0ZS	Gabapentin	Approved
T42446	DRUGINFO	D0O5LA	Progabide	Approved
T42446	DRUGINFO	D0H5JW	[3H](R)-(-)-baclofen	Phase 3
T42446	DRUGINFO	DV3H6T	Arabaclofen	Phase 3
T42446	DRUGINFO	D0GX3L	Arbaclofen placarbil	Phase 3
T42446	DRUGINFO	D01RBR	SGS742	Phase 2
T42446	DRUGINFO	D09YRA	SSTarbaclofen	Phase 2
T42446	DRUGINFO	D0JM7Z	ASP8062	Phase 2
T42446	DRUGINFO	D0C9XA	GSK683699	Phase 2
T42446	DRUGINFO	D05VYJ	SUN-09	Discontinued in Phase 3
T42446	DRUGINFO	D03FFY	AZD3355	Discontinued in Phase 2
T42446	DRUGINFO	D01OYR	AZD-9343	Discontinued in Phase 1
T42446	DRUGINFO	D0B2RZ	ADX-71943	Preclinical
T42446	DRUGINFO	D04KMO	CGP-35348	Terminated
T42446	DRUGINFO	D0K9OL	SCH 50911	Terminated
T42446	DRUGINFO	D00KXZ	CGP 54626A	Investigative
T42446	DRUGINFO	D00TYI	TG-3030	Investigative
T42446	DRUGINFO	D02ALQ	PMID25050158C14	Investigative
T42446	DRUGINFO	D02BBN	4-Amino-3-benzofuran-2-yl-butyric acid	Investigative
T42446	DRUGINFO	D02HNM	Phaclofen	Investigative
T42446	DRUGINFO	D02WUY	[125I]CGP 64213	Investigative
T42446	DRUGINFO	D03KZK	CGP-34938	Investigative
T42446	DRUGINFO	D04LZJ	(3-Amino-propyl)-phosphonic acid	Investigative
T42446	DRUGINFO	D06NMP	CGP-29030A	Investigative
T42446	DRUGINFO	D06VMV	BHF-177	Investigative
T42446	DRUGINFO	D06WWN	AVE-1876	Investigative
T42446	DRUGINFO	D07KYZ	GABA-B receptor PAM	Investigative
T42446	DRUGINFO	D07YSJ	(3-Amino-1-ethyl-propyl)-methyl-phosphinic acid	Investigative
T42446	DRUGINFO	D08LFC	CGP-35024	Investigative
T42446	DRUGINFO	D08PXU	4-Amino-3-(5-bromo-thiophen-2-yl)-butyric acid	Investigative
T42446	DRUGINFO	D09IVS	((Z)-3-Amino-propenyl)-methyl-phosphinic acid	Investigative
T42446	DRUGINFO	D09QOE	CGP 55845	Investigative
T42446	DRUGINFO	D09WJO	4-Amino-3-thiophen-2-yl-butyric acid	Investigative
T42446	DRUGINFO	D09YCW	4-Amino-3-(5-methyl-thiophen-2-yl)-butyric acid	Investigative
T42446	DRUGINFO	D0AK9X	4-Amino-3-(5-chloro-thiophen-2-yl)-butyric acid	Investigative
T42446	DRUGINFO	D0B8SE	CGP 46381	Investigative
T42446	DRUGINFO	D0E0LI	amino-propylphosphinic acid	Investigative
T42446	DRUGINFO	D0E5QN	CGP 71872	Investigative
T42446	DRUGINFO	D0E7YK	(R)-5-Amino-3-(4-chloro-phenyl)-pentanoic acid	Investigative
T42446	DRUGINFO	D0GK6Q	[125I]CGP 71872	Investigative
T42446	DRUGINFO	D0H2IA	CGP 56999A	Investigative
T42446	DRUGINFO	D0H2LT	4-Amino-3-(2-chloro-phenyl)-butyric acid	Investigative
T42446	DRUGINFO	D0H7KP	(3-Amino-1-hydroxy-propyl)-methyl-phosphinic acid	Investigative
T42446	DRUGINFO	D0J6PV	CGP 47656	Investigative
T42446	DRUGINFO	D0L4CB	CGP 64213	Investigative
T42446	DRUGINFO	D0N4WZ	CGP-36216	Investigative
T42446	DRUGINFO	D0S5YH	saclofen	Investigative
T42446	DRUGINFO	D0T8SD	2-hydroxy-saclofen	Investigative
T42446	DRUGINFO	D0U9XC	(3-Amino-phenyl)-phosphonic acid diphenyl ester	Investigative
T42446	DRUGINFO	D0V0LA	CGP-35582	Investigative
T42446	DRUGINFO	D0VR3K	4-Amino-3-(4-fluoro-phenyl)-butyric acid	Investigative
T42446	DRUGINFO	D0WZ9T	CGP-44532	Investigative
T42446	DRUGINFO	D0XX9G	(3-Amino-propyl)-hydroxymethyl-phosphinic acid	Investigative
T42446	DRUGINFO	D0Y8YN	(3-Amino-propyl)-hexyl-phosphinic acid	Investigative
T42446	DRUGINFO	D0Z9QI	CGP 62349	Investigative
T42446	DRUGINFO	D05WZL	((E)-3-Amino-propenyl)-methyl-phosphinic acid	Investigative
T42446	DRUGINFO	D0N4EZ	3-ammoniopropane-1-sulfinate	Investigative
T42446	DRUGINFO	D07BIF	[3H]CGP27492	Investigative

T33901	TARGETID	T33901
T33901	FORMERID	TTDS00328
T33901	UNIPROID	NPCL1_HUMAN
T33901	TARGNAME	Niemann-Pick C1-like protein 1 (NPC1L1)
T33901	GENENAME	NPC1L1
T33901	TARGTYPE	Successful
T33901	SYNONYMS	Niemann-Pick C1 Like 1; NPC1L1
T33901	FUNCTION	Plays a major role in cholesterol homeostasis. Is critical for the uptake of cholesterol across the plasma membrane of the intestinal enterocyte. Is the direct molecular target of ezetimibe, a drug that inhibits cholesterol absorption. Lack of activity leads to multiple lipid transport defects. The protein may have a function in the transport of multiple lipids and their homeostasis, and may play a critical role in regulating lipid metabolism. Acts as a negative regulator of NPC2 and down- regulates its expression and secretion by inhibiting its maturation and accelerating its degradation.
T33901	PDBSTRUC	3QNT
T33901	SEQUENCE	MAEAGLRGWLLWALLLRLAQSEPYTTIHQPGYCAFYDECGKNPELSGSLMTLSNVSCLSNTPARKITGDHLILLQKICPRLYTGPNTQACCSAKQLVSLEASLSITKALLTRCPACSDNFVNLHCHNTCSPNQSLFINVTRVAQLGAGQLPAVVAYEAFYQHSFAEQSYDSCSRVRVPAAATLAVGTMCGVYGSALCNAQRWLNFQGDTGNGLAPLDITFHLLEPGQAVGSGIQPLNEGVARCNESQGDDVATCSCQDCAASCPAIARPQALDSTFYLGQMPGSLVLIIILCSVFAVVTILLVGFRVAPARDKSKMVDPKKGTSLSDKLSFSTHTLLGQFFQGWGTWVASWPLTILVLSVIPVVALAAGLVFTELTTDPVELWSAPNSQARSEKAFHDQHFGPFFRTNQVILTAPNRSSYRYDSLLLGPKNFSGILDLDLLLELLELQERLRHLQVWSPEAQRNISLQDICYAPLNPDNTSLYDCCINSLLQYFQNNRTLLLLTANQTLMGQTSQVDWKDHFLYCANAPLTFKDGTALALSCMADYGAPVFPFLAIGGYKGKDYSEAEALIMTFSLNNYPAGDPRLAQAKLWEEAFLEEMRAFQRRMAGMFQVTFMAERSLEDEINRTTAEDLPIFATSYIVIFLYISLALGSYSSWSRVMVDSKATLGLGGVAVVLGAVMAAMGFFSYLGIRSSLVILQVVPFLVLSVGADNIFIFVLEYQRLPRRPGEPREVHIGRALGRVAPSMLLCSLSEAICFFLGALTPMPAVRTFALTSGLAVILDFLLQMSAFVALLSLDSKRQEASRLDVCCCVKPQELPPPGQGEGLLLGFFQKAYAPFLLHWITRGVVLLLFLALFGVSLYSMCHISVGLDQELALPKDSYLLDYFLFLNRYFEVGAPVYFVTTLGYNFSSEAGMNAICSSAGCNNFSFTQKIQYATEFPEQSYLAIPASSWVDDFIDWLTPSSCCRLYISGPNKDKFCPSTVNSLNCLKNCMSITMGSVRPSVEQFHKYLPWFLNDRPNIKCPKGGLAAYSTSVNLTSDGQVLDTVAILSPRLEYSGTISAHCNLYLLDSTSRFMAYHKPLKNSQDYTEALRAARELAANITADLRKVPGTDPAFEVFPYTITNVFYEQYLTILPEGLFMLSLCLVPTFAVSCLLLGLDLRSGLLNLLSIVMILVDTVGFMALWGISYNAVSLINLVSAVGMSVEFVSHITRSFAISTKPTWLERAKEATISMGSAVFAGVAMTNLPGILVLGLAKAQLIQIFFFRLNLLITLLGLLHGLVFLPVILSYVGPDVNPALALEQKRAEEAVAAVMVASCPNHPSRVSTADNIYVNHSFEGSIKGAGAISNFLPNNGRQF
T33901	DRUGINFO	D09LWS	Ezetimibe	Approved
T33901	DRUGINFO	D09XJH	Ezetimibe-glucuronide	Investigative

T22839	TARGETID	T22839
T22839	FORMERID	TTDR00230
T22839	UNIPROID	CELA1_HUMAN
T22839	TARGNAME	Pancreatic elastase 1 (CELA1)
T22839	GENENAME	CELA1
T22839	TARGTYPE	Successful
T22839	SYNONYMS	Elastase; CELA1
T22839	FUNCTION	Acts upon elastin.
T22839	BIOCLASS	Peptidase
T22839	ECNUMBER	EC 3.4.21.36
T22839	SEQUENCE	MLVLYGHSTQDLPETNARVVGGTEAGRNSWPSQISLQYRSGGSRYHTCGGTLIRQNWVMTAAHCVDYQKTFRVVAGDHNLSQNDGTEQYVSVQKIVVHPYWNSDNVAAGYDIALLRLAQSVTLNSYVQLGVLPQEGAILANNSPCYITGWGKTKTNGQLAQTLQQAYLPSVDYAICSSSSYWGSTVKNTMVCAGGDGVRSGCQGDSGGPLHCLVNGKYSVHGVTSFVSSRGCNVSRKPTVFTQVSAYISWINNVIASN
T22839	DRUGINFO	D0K3VA	Erdosteine	Approved
T22839	DRUGINFO	D0I0DL	Alpha 1-PI	Approved
T22839	DRUGINFO	D0FT4R	Sivelestat	Phase 3
T22839	DRUGINFO	D00AWA	WIN-63759	Terminated
T22839	DRUGINFO	D0B3MV	SSR-69071	Terminated
T22839	DRUGINFO	D0PQ3V	SYN-1134	Terminated
T22839	DRUGINFO	D0V6LH	PBI-1101	Terminated
T22839	DRUGINFO	D0O6GN	Mdl 101,146	Terminated
T22839	DRUGINFO	D05UHB	(Tert-Butyloxycarbonyl)-Alanyl-Alanyl-Amine	Investigative
T22839	DRUGINFO	D06RRT	Acetyl-Pro-Ala-Pro-Ala-trifluoro methane	Investigative
T22839	DRUGINFO	D08EBC	(2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE	Investigative
T22839	DRUGINFO	D0D7HZ	Para-Isopropylaniline	Investigative
T22839	DRUGINFO	D0E9EH	Acetyl-Ala-Ala-Pro-Ala-trifluromethane	Investigative
T22839	DRUGINFO	D0W5EF	MOLASSAMIDE	Investigative
T22839	DRUGINFO	D0E1KX	Dimethylformamide	Investigative
T22839	DRUGINFO	D0Y5IQ	Grassystatin a	Investigative
T22839	DRUGINFO	D0F2ME	Acetate Ion	Investigative

T71192	TARGETID	T71192
T71192	FORMERID	TTDS00183
T71192	UNIPROID	CLTR1_HUMAN
T71192	TARGNAME	Leukotriene CysLT1 receptor (CYSLTR1)
T71192	GENENAME	CYSLTR1
T71192	TARGTYPE	Successful
T71192	SYNONYMS	Leukotriene D4-receptor; LTD4 receptor; HMTMF81; HG55; G-protein coupled receptor HG55; Cysteinyl leukotriene receptor 1; Cysteinyl leukotriene D4 receptor; CysLTR1; CYSLT1
T71192	FUNCTION	Stimulation by LTD4 results in the contraction and proliferation of smooth muscle, edema, eosinophil migration and damage to the mucus layer in the lung. This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system. The rank order of affinities for the leukotrienes is LTD4 >> LTE4 = LTC4 >> LTB4. Receptor for cysteinyl leukotrienes mediating bronchoconstriction of individuals with and without asthma.
T71192	BIOCLASS	GPCR rhodopsin
T71192	SEQUENCE	MDETGNLTVSSATCHDTIDDFRNQVYSTLYSMISVVGFFGNGFVLYVLIKTYHKKSAFQVYMINLAVADLLCVCTLPLRVVYYVHKGIWLFGDFLCRLSTYALYVNLYCSIFFMTAMSFFRCIAIVFPVQNINLVTQKKARFVCVGIWIFVILTSSPFLMAKPQKDEKNNTKCFEPPQDNQTKNHVLVLHYVSLFVGFIIPFVIIIVCYTMIILTLLKKSMKKNLSSHKKAIGMIMVVTAAFLVSFMPYHIQRTIHLHFLHNETKPCDSVLRMQKSVVITLSLAASNCCFDPLLYFFSGGNFRKRLSTFRKHSLSSVTYVPRKKASLPEKGEEICKV
T71192	DRUGINFO	D00QET	Montelukast	Approved
T71192	DRUGINFO	D05DVP	Zafirlukast	Approved
T71192	DRUGINFO	D06PEB	Cinalukast	Approved
T71192	DRUGINFO	D08QIP	Pranlukast	Approved
T71192	DRUGINFO	D0C2XI	Claritin/Singulair	Phase 3
T71192	DRUGINFO	D05BHF	Masilukast	Phase 2
T71192	DRUGINFO	D0OG6N	LM-1507.NA	Phase 2
T71192	DRUGINFO	D0X9LK	Iralukast	Phase 2
T71192	DRUGINFO	D07JKY	KP-496	Phase 2
T71192	DRUGINFO	D0GY0O	BAY-X-7195	Phase 2
T71192	DRUGINFO	D07ZUX	CR-3465	Phase 1
T71192	DRUGINFO	D0K2NA	YM-57158	Phase 1
T71192	DRUGINFO	D09DIG	Ablukast	Discontinued in Phase 3
T71192	DRUGINFO	D04HHW	FK-011	Discontinued in Phase 2
T71192	DRUGINFO	D07GTB	L-660771	Discontinued in Phase 2
T71192	DRUGINFO	D09RON	LY-2300559	Discontinued in Phase 2
T71192	DRUGINFO	D0B6EU	AS-35	Discontinued in Phase 2
T71192	DRUGINFO	D0F4IG	DS-4574	Discontinued in Phase 2
T71192	DRUGINFO	D0G8UG	Sulukast	Discontinued in Phase 2
T71192	DRUGINFO	D0B7KF	RG-7152	Discontinued in Phase 1
T71192	DRUGINFO	D00YOW	LM-1376	Terminated
T71192	DRUGINFO	D0AB7G	MCI-826	Terminated
T71192	DRUGINFO	D0J4EG	L-648051	Terminated
T71192	DRUGINFO	D0PL5F	OT-4003	Terminated
T71192	DRUGINFO	D0S8YL	Tomelukast	Terminated
T71192	DRUGINFO	D09ZVR	MDL-43291	Terminated
T71192	DRUGINFO	D0D0XX	LY-290154	Terminated
T71192	DRUGINFO	D0ZE5V	FPL-55712	Terminated
T71192	DRUGINFO	D0J7UI	ICI-198615	Terminated
T71192	DRUGINFO	D0R8IQ	WY-46016	Investigative
T71192	DRUGINFO	D0X8PD	XGP-510	Investigative
T71192	DRUGINFO	D03VGR	N-methyl LTC4	Investigative
T71192	DRUGINFO	D04CZQ	CGP-57698	Investigative
T71192	DRUGINFO	D05CNT	BAYu9773	Investigative
T71192	DRUGINFO	D09JQU	BayCysLT2	Investigative
T71192	DRUGINFO	D0G7OZ	pobilukast	Investigative
T71192	DRUGINFO	D03YBH	LTD4	Investigative
T71192	DRUGINFO	D0EW6H	LTC4	Investigative
T71192	DRUGINFO	D0C0KJ	LTE4	Investigative

T43739	TARGETID	T43739
T43739	FORMERID	TTDS00514
T43739	UNIPROID	SCNAA_HUMAN
T43739	TARGNAME	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
T43739	GENENAME	SCN10A
T43739	TARGTYPE	Successful
T43739	SYNONYMS	hPN3; Voltage-gated sodium channel subunit alpha Nav1.8; Sodium channel protein type X subunit alpha; Sodium channel protein type 10 subunit alpha; Peripheral nerve sodium channel 3; PN3
T43739	FUNCTION	Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. Plays a role in neuropathic pain mechanisms.
T43739	BIOCLASS	Voltage-gated ion channel
T43739	SEQUENCE	MEFPIGSLETNNFRRFTPESLVEIEKQIAAKQGTKKAREKHREQKDQEEKPRPQLDLKACNQLPKFYGELPAELIGEPLEDLDPFYSTHRTFMVLNKGRTISRFSATRALWLFSPFNLIRRTAIKVSVHSWFSLFITVTILVNCVCMTRTDLPEKIEYVFTVIYTFEALIKILARGFCLNEFTYLRDPWNWLDFSVITLAYVGTAIDLRGISGLRTFRVLRALKTVSVIPGLKVIVGALIHSVKKLADVTILTIFCLSVFALVGLQLFKGNLKNKCVKNDMAVNETTNYSSHRKPDIYINKRGTSDPLLCGNGSDSGHCPDGYICLKTSDNPDFNYTSFDSFAWAFLSLFRLMTQDSWERLYQQTLRTSGKIYMIFFVLVIFLGSFYLVNLILAVVTMAYEEQNQATTDEIEAKEKKFQEALEMLRKEQEVLAALGIDTTSLHSHNGSPLTSKNASERRHRIKPRVSEGSTEDNKSPRSDPYNQRRMSFLGLASGKRRASHGSVFHFRSPGRDISLPEGVTDDGVFPGDHESHRGSLLLGGGAGQQGPLPRSPLPQPSNPDSRHGEDEHQPPPTSELAPGAVDVSAFDAGQKKTFLSAEYLDEPFRAQRAMSVVSIITSVLEELEESEQKCPPCLTSLSQKYLIWDCCPMWVKLKTILFGLVTDPFAELTITLCIVVNTIFMAMEHHGMSPTFEAMLQIGNIVFTIFFTAEMVFKIIAFDPYYYFQKKWNIFDCIIVTVSLLELGVAKKGSLSVLRSFRLLRVFKLAKSWPTLNTLIKIIGNSVGALGNLTIILAIIVFVFALVGKQLLGENYRNNRKNISAPHEDWPRWHMHDFFHSFLIVFRILCGEWIENMWACMEVGQKSICLILFLTVMVLGNLVVLNLFIALLLNSFSADNLTAPEDDGEVNNLQVALARIQVFGHRTKQALCSFFSRSCPFPQPKAEPELVVKLPLSSSKAENHIAANTARGSSGGLQAPRGPRDEHSDFIANPTVWVSVPIAEGESDLDDLEDDGGEDAQSFQQEVIPKGQQEQLQQVERCGDHLTPRSPGTGTSSEDLAPSLGETWKDESVPQVPAEGVDDTSSSEGSTVDCLDPEEILRKIPELADDLEEPDDCFTEGCIRHCPCCKLDTTKSPWDVGWQVRKTCYRIVEHSWFESFIIFMILLSSGSLAFEDYYLDQKPTVKALLEYTDRVFTFIFVFEMLLKWVAYGFKKYFTNAWCWLDFLIVNISLISLTAKILEYSEVAPIKALRTLRALRPLRALSRFEGMRVVVDALVGAIPSIMNVLLVCLIFWLIFSIMGVNLFAGKFWRCINYTDGEFSLVPLSIVNNKSDCKIQNSTGSFFWVNVKVNFDNVAMGYLALLQVATFKGWMDIMYAAVDSREVNMQPKWEDNVYMYLYFVIFIIFGGFFTLNLFVGVIIDNFNQQKKKLGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPLNKFQGFVFDIVTRQAFDITIMVLICLNMITMMVETDDQSEEKTKILGKINQFFVAVFTGECVMKMFALRQYYFTNGWNVFDFIVVVLSIASLIFSAILKSLQSYFSPTLFRVIRLARIGRILRLIRAAKGIRTLLFALMMSLPALFNIGLLLFLVMFIYSIFGMSSFPHVRWEAGIDDMFNFQTFANSMLCLFQITTSAGWDGLLSPILNTGPPYCDPNLPNSNGTRGDCGSPAVGIIFFTTYIIISFLIMVNMYIAVILENFNVATEESTEPLSEDDFDMFYETWEKFDPEATQFITFSALSDFADTLSGPLRIPKPNRNILIQMDLPLVPGDKIHCLDILFAFTKNVLGESGELDSLKANMEEKFMATNLSKSSYEPIATTLRWKQEDISATVIQKAYRSYVLHRSMALSNTPCVPRAEEEAASLPDEGFVAFTANENCVLPDKSETASATSFPPSYESVTRGLSDRVNMRTSSSIQNEDEATSMELIAPGP
T43739	DRUGINFO	D08HQK	Tetracaine	Approved
T43739	DRUGINFO	D09RHQ	Ropivacaine	Approved
T43739	DRUGINFO	D0A0FL	Bupivacaine	Approved
T43739	DRUGINFO	D0Q7ZG	Proparacaine	Approved
T43739	DRUGINFO	D02LCR	Tiapride	Approved
T43739	DRUGINFO	D0T6WN	Rilpivirine	Approved
T43739	DRUGINFO	D01KWJ	VX-150	Phase 2
T43739	DRUGINFO	D00WME	Conatumumab	Phase 2
T43739	DRUGINFO	D04JZH	PF-01247324	Phase 1
T43739	DRUGINFO	D0V5HA	VX-128	Phase 1
T43739	DRUGINFO	D0VE7B	DSP-2230	Phase 1
T43739	DRUGINFO	D08FZT	Corus 1030	Discontinued in Phase 2
T43739	DRUGINFO	D0EC2K	SIPATRIGINE	Discontinued in Phase 2
T43739	DRUGINFO	D01EQU	SCH-725739	Investigative
T43739	DRUGINFO	D02CQN	5-(4-chlorophenyl)-N-(2-methylbenzyl)nicotinamide	Investigative
T43739	DRUGINFO	D09ZUM	CR-4892	Investigative
T43739	DRUGINFO	D0F5WY	SCH-725737	Investigative
T43739	DRUGINFO	D0FF6S	A-803467	Investigative
T43739	DRUGINFO	D0O0JO	N-(2-chlorobenzyl)-5-(4-chlorophenyl)nicotinamide	Investigative
T43739	DRUGINFO	D0W2BP	N-benzyl-5-(4-chlorophenyl)nicotinamide	Investigative
T43739	DRUGINFO	D01AGR	1-[5-(4-Chlorophenyl)-2-furoyl]piperazine	Investigative
T43739	DRUGINFO	D0B9UU	BW-202W92	Investigative
T43739	DRUGINFO	D08RJC	PD-32577	Investigative
T43739	DRUGINFO	D0G9WE	batrachotoxin	Investigative
T43739	DRUGINFO	D0S4MN	veratridine	Investigative

T09507	TARGETID	T09507
T09507	FORMERID	TTDR01360
T09507	UNIPROID	APOB_HUMAN
T09507	TARGNAME	APOB messenger RNA (APOB mRNA)
T09507	GENENAME	APOB
T09507	TARGTYPE	Successful
T09507	SYNONYMS	Apolipoprotein B48 (mRNA); Apolipoprotein B-100 (mRNA); Apo B48 (mRNA); Apo B100 (mRNA); Apo B-100 (mRNA)
T09507	FUNCTION	Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor. Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100).
T09507	BIOCLASS	mRNA target
T09507	SEQUENCE	MDPPRPALLALLALPALLLLLLAGARAEEEMLENVSLVCPKDATRFKHLRKYTYNYEAESSSGVPGTADSRSATRINCKVELEVPQLCSFILKTSQCTLKEVYGFNPEGKALLKKTKNSEEFAAAMSRYELKLAIPEGKQVFLYPEKDEPTYILNIKRGIISALLVPPETEEAKQVLFLDTVYGNCSTHFTVKTRKGNVATEISTERDLGQCDRFKPIRTGISPLALIKGMTRPLSTLISSSQSCQYTLDAKRKHVAEAICKEQHLFLPFSYKNKYGMVAQVTQTLKLEDTPKINSRFFGEGTKKMGLAFESTKSTSPPKQAEAVLKTLQELKKLTISEQNIQRANLFNKLVTELRGLSDEAVTSLLPQLIEVSSPITLQALVQCGQPQCSTHILQWLKRVHANPLLIDVVTYLVALIPEPSAQQLREIFNMARDQRSRATLYALSHAVNNYHKTNPTGTQELLDIANYLMEQIQDDCTGDEDYTYLILRVIGNMGQTMEQLTPELKSSILKCVQSTKPSLMIQKAAIQALRKMEPKDKDQEVLLQTFLDDASPGDKRLAAYLMLMRSPSQADINKIVQILPWEQNEQVKNFVASHIANILNSEELDIQDLKKLVKEALKESQLPTVMDFRKFSRNYQLYKSVSLPSLDPASAKIEGNLIFDPNNYLPKESMLKTTLTAFGFASADLIEIGLEGKGFEPTLEALFGKQGFFPDSVNKALYWVNGQVPDGVSKVLVDHFGYTKDDKHEQDMVNGIMLSVEKLIKDLKSKEVPEARAYLRILGEELGFASLHDLQLLGKLLLMGARTLQGIPQMIGEVIRKGSKNDFFLHYIFMENAFELPTGAGLQLQISSSGVIAPGAKAGVKLEVANMQAELVAKPSVSVEFVTNMGIIIPDFARSGVQMNTNFFHESGLEAHVALKAGKLKFIIPSPKRPVKLLSGGNTLHLVSTTKTEVIPPLIENRQSWSVCKQVFPGLNYCTSGAYSNASSTDSASYYPLTGDTRLELELRPTGEIEQYSVSATYELQREDRALVDTLKFVTQAEGAKQTEATMTFKYNRQSMTLSSEVQIPDFDVDLGTILRVNDESTEGKTSYRLTLDIQNKKITEVALMGHLSCDTKEERKIKGVISIPRLQAEARSEILAHWSPAKLLLQMDSSATAYGSTVSKRVAWHYDEEKIEFEWNTGTNVDTKKMTSNFPVDLSDYPKSLHMYANRLLDHRVPQTDMTFRHVGSKLIVAMSSWLQKASGSLPYTQTLQDHLNSLKEFNLQNMGLPDFHIPENLFLKSDGRVKYTLNKNSLKIEIPLPFGGKSSRDLKMLETVRTPALHFKSVGFHLPSREFQVPTFTIPKLYQLQVPLLGVLDLSTNVYSNLYNWSASYSGGNTSTDHFSLRARYHMKADSVVDLLSYNVQGSGETTYDHKNTFTLSYDGSLRHKFLDSNIKFSHVEKLGNNPVSKGLLIFDASSSWGPQMSASVHLDSKKKQHLFVKEVKIDGQFRVSSFYAKGTYGLSCQRDPNTGRLNGESNLRFNSSYLQGTNQITGRYEDGTLSLTSTSDLQSGIIKNTASLKYENYELTLKSDTNGKYKNFATSNKMDMTFSKQNALLRSEYQADYESLRFFSLLSGSLNSHGLELNADILGTDKINSGAHKATLRIGQDGISTSATTNLKCSLLVLENELNAELGLSGASMKLTTNGRFREHNAKFSLDGKAALTELSLGSAYQAMILGVDSKNIFNFKVSQEGLKLSNDMMGSYAEMKFDHTNSLNIAGLSLDFSSKLDNIYSSDKFYKQTVNLQLQPYSLVTTLNSDLKYNALDLTNNGKLRLEPLKLHVAGNLKGAYQNNEIKHIYAISSAALSASYKADTVAKVQGVEFSHRLNTDIAGLASAIDMSTNYNSDSLHFSNVFRSVMAPFTMTIDAHTNGNGKLALWGEHTGQLYSKFLLKAEPLAFTFSHDYKGSTSHHLVSRKSISAALEHKVSALLTPAEQTGTWKLKTQFNNNEYSQDLDAYNTKDKIGVELTGRTLADLTLLDSPIKVPLLLSEPINIIDALEMRDAVEKPQEFTIVAFVKYDKNQDVHSINLPFFETLQEYFERNRQTIIVVLENVQRNLKHINIDQFVRKYRAALGKLPQQANDYLNSFNWERQVSHAKEKLTALTKKYRITENDIQIALDDAKINFNEKLSQLQTYMIQFDQYIKDSYDLHDLKIAIANIIDEIIEKLKSLDEHYHIRVNLVKTIHDLHLFIENIDFNKSGSSTASWIQNVDTKYQIRIQIQEKLQQLKRHIQNIDIQHLAGKLKQHIEAIDVRVLLDQLGTTISFERINDILEHVKHFVINLIGDFEVAEKINAFRAKVHELIERYEVDQQIQVLMDKLVELAHQYKLKETIQKLSNVLQQVKIKDYFEKLVGFIDDAVKKLNELSFKTFIEDVNKFLDMLIKKLKSFDYHQFVDETNDKIREVTQRLNGEIQALELPQKAEALKLFLEETKATVAVYLESLQDTKITLIINWLQEALSSASLAHMKAKFRETLEDTRDRMYQMDIQQELQRYLSLVGQVYSTLVTYISDWWTLAAKNLTDFAEQYSIQDWAKRMKALVEQGFTVPEIKTILGTMPAFEVSLQALQKATFQTPDFIVPLTDLRIPSVQINFKDLKNIKIPSRFSTPEFTILNTFHIPSFTIDFVEMKVKIIRTIDQMLNSELQWPVPDIYLRDLKVEDIPLARITLPDFRLPEIAIPEFIIPTLNLNDFQVPDLHIPEFQLPHISHTIEVPTFGKLYSILKIQSPLFTLDANADIGNGTTSANEAGIAASITAKGESKLEVLNFDFQANAQLSNPKINPLALKESVKFSSKYLRTEHGSEMLFFGNAIEGKSNTVASLHTEKNTLELSNGVIVKINNQLTLDSNTKYFHKLNIPKLDFSSQADLRNEIKTLLKAGHIAWTSSGKGSWKWACPRFSDEGTHESQISFTIEGPLTSFGLSNKINSKHLRVNQNLVYESGSLNFSKLEIQSQVDSQHVGHSVLTAKGMALFGEGKAEFTGRHDAHLNGKVIGTLKNSLFFSAQPFEITASTNNEGNLKVRFPLRLTGKIDFLNNYALFLSPSAQQASWQVSARFNQYKYNQNFSAGNNENIMEAHVGINGEANLDFLNIPLTIPEMRLPYTIITTPPLKDFSLWEKTGLKEFLKTTKQSFDLSVKAQYKKNKHRHSITNPLAVLCEFISQSIKSFDRHFEKNRNNALDFVTKSYNETKIKFDKYKAEKSHDELPRTFQIPGYTVPVVNVEVSPFTIEMSAFGYVFPKAVSMPSFSILGSDVRVPSYTLILPSLELPVLHVPRNLKLSLPDFKELCTISHIFIPAMGNITYDFSFKSSVITLNTNAELFNQSDIVAHLLSSSSSVIDALQYKLEGTTRLTRKRGLKLATALSLSNKFVEGSHNSTVSLTTKNMEVSVATTTKAQIPILRMNFKQELNGNTKSKPTVSSSMEFKYDFNSSMLYSTAKGAVDHKLSLESLTSYFSIESSTKGDVKGSVLSREYSGTIASEANTYLNSKSTRSSVKLQGTSKIDDIWNLEVKENFAGEATLQRIYSLWEHSTKNHLQLEGLFFTNGEHTSKATLELSPWQMSALVQVHASQPSSFHDFPDLGQEVALNANTKNQKIRWKNEVRIHSGSFQSQVELSNDQEKAHLDIAGSLEGHLRFLKNIILPVYDKSLWDFLKLDVTTSIGRRQHLRVSTAFVYTKNPNGYSFSIPVKVLADKFIIPGLKLNDLNSVLVMPTFHVPFTDLQVPSCKLDFREIQIYKKLRTSSFALNLPTLPEVKFPEVDVLTKYSQPEDSLIPFFEITVPESQLTVSQFTLPKSVSDGIAALDLNAVANKIADFELPTIIVPEQTIEIPSIKFSVPAGIVIPSFQALTARFEVDSPVYNATWSASLKNKADYVETVLDSTCSSTVQFLEYELNVLGTHKIEDGTLASKTKGTFAHRDFSAEYEEDGKYEGLQEWEGKAHLNIKSPAFTDLHLRYQKDKKGISTSAASPAVGTVGMDMDEDDDFSKWNFYYSPQSSPDKKLTIFKTELRVRESDEETQIKVNWEEEAASGLLTSLKDNVPKATGVLYDYVNKYHWEHTGLTLREVSSKLRRNLQNNAEWVYQGAIRQIDDIDVRFQKAASGTTGTYQEWKDKAQNLYQELLTQEGQASFQGLKDNVFDGLVRVTQEFHMKVKHLIDSLIDFLNFPRFQFPGKPGIYTREELCTMFIREVGTVLSQVYSKVHNGSEILFSYFQDLVITLPFELRKHKLIDVISMYRELLKDLSKEAQEVFKAIQSLKTTEVLRNLQDLLQFIFQLIEDNIKQLKEMKFTYLINYIQDEINTIFSDYIPYVFKLLKENLCLNLHKFNEFIQNELQEASQELQQIHQYIMALREEYFDPSIVGWTVKYYELEEKIVSLIKNLLVALKDFHSEYIVSASNFTSQLSSQVEQFLHRNIQEYLSILTDPDGKGKEKIAELSATAQEIIKSQAIATKKIISDYHQQFRYKLQDFSDQLSDYYEKFIAESKRLIDLSIQNYHTFLIYITELLKKLQSTTVMNPYMKLAPGELTIIL
T09507	DRUGINFO	D08CVQ	Mipomersen	Approved
T09507	DRUGINFO	D04VOZ	TKM-ApoB	Phase 4
T09507	DRUGINFO	D09YRP	ISIS 147788	Investigative
T09507	DRUGINFO	D0S3JF	ISIS 147483	Investigative

T34949	TARGETID	T34949
T34949	FORMERID	TTDR00199
T34949	UNIPROID	CAC1A_HUMAN
T34949	TARGNAME	Voltage-gated calcium channel alpha Cav2.1 (CACNA1A)
T34949	GENENAME	CACNA1A
T34949	TARGTYPE	Successful
T34949	SYNONYMS	Voltage-gated calcium channel alpha subunit Cav2.1; Voltage-dependent P/Q-type calcium channel; RBA-I; RAT brain class A; Calcium channel, L type, alpha-1 polypeptide, isoform 4; Calcium channel, L type, alpha-1 polypeptide isoform 4; CACNA1A; Brain calcium channel I; BI
T34949	FUNCTION	Voltage-sensitive calcium channels (vscc) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release and gene expression.
T34949	PDBSTRUC	3BXK
T34949	BIOCLASS	Voltage-gated ion channel
T34949	SEQUENCE	MARFGDEMPARYGGGGSGAAAGVVVGSGGGRGAGGSRQGGQPGAQRMYKQSMAQRARTMALYNPIPVRQNCLTVNRSLFLFSEDNVVRKYAKKITEWPPFEYMILATIIANCIVLALEQHLPDDDKTPMSERLDDTEPYFIGIFCFEAGIKIIALGFAFHKGSYLRNGWNVMDFVVVLTGILATVGTEFDLRTLRAVRVLRPLKLVSGIPSLQVVLKSIMKAMIPLLQIGLLLFFAILIFAIIGLEFYMGKFHTTCFEEGTDDIQGESPAPCGTEEPARTCPNGTKCQPYWEGPNNGITQFDNILFAVLTVFQCITMEGWTDLLYNSNDASGNTWNWLYFIPLIIIGSFFMLNLVLGVLSGEFAKERERVENRRAFLKLRRQQQIERELNGYMEWISKAEEVILAEDETDGEQRHPFDALRRTTIKKSKTDLLNPEEAEDQLADIASVGSPFARASIKSAKLENSTFFHKKERRMRFYIRRMVKTQAFYWTVLSLVALNTLCVAIVHYNQPEWLSDFLYYAEFIFLGLFMSEMFIKMYGLGTRPYFHSSFNCFDCGVIIGSIFEVIWAVIKPGTSFGISVLRALRLLRIFKVTKYWASLRNLVVSLLNSMKSIISLLFLLFLFIVVFALLGMQLFGGQFNFDEGTPPTNFDTFPAAIMTVFQILTGEDWNEVMYDGIKSQGGVQGGMVFSIYFIVLTLFGNYTLLNVFLAIAVDNLANAQELTKDEQEEEEAANQKLALQKAKEVAEVSPLSAANMSIAVKEQQKNQKPAKSVWEQRTSEMRKQNLLASREALYNEMDPDERWKAAYTRHLRPDMKTHLDRPLVVDPQENRNNNTNKSRAAEPTVDQRLGQQRAEDFLRKQARYHDRARDPSGSAGLDARRPWAGSQEAELSREGPYGRESDHHAREGSLEQPGFWEGEAERGKAGDPHRRHVHRQGGSRESRSGSPRTGADGEHRRHRAHRRPGEEGPEDKAERRARHREGSRPARGGEGEGEGPDGGERRRRHRHGAPATYEGDARREDKERRHRRRKENQGSGVPVSGPNLSTTRPIQQDLGRQDPPLAEDIDNMKNNKLATAESAAPHGSLGHAGLPQSPAKMGNSTDPGPMLAIPAMATNPQNAASRRTPNNPGNPSNPGPPKTPENSLIVTNPSGTQTNSAKTARKPDHTTVDIPPACPPPLNHTVVQVNKNANPDPLPKKEEEKKEEEEDDRGEDGPKPMPPYSSMFILSTTNPLRRLCHYILNLRYFEMCILMVIAMSSIALAAEDPVQPNAPRNNVLRYFDYVFTGVFTFEMVIKMIDLGLVLHQGAYFRDLWNILDFIVVSGALVAFAFTGNSKGKDINTIKSLRVLRVLRPLKTIKRLPKLKAVFDCVVNSLKNVFNILIVYMLFMFIFAVVAVQLFKGKFFHCTDESKEFEKDCRGKYLLYEKNEVKARDREWKKYEFHYDNVLWALLTLFTVSTGEGWPQVLKHSVDATFENQGPSPGYRMEMSIFYVVYFVVFPFFFVNIFVALIIITFQEQGDKMMEEYSLEKNERACIDFAISAKPLTRHMPQNKQSFQYRMWQFVVSPPFEYTIMAMIALNTIVLMMKFYGASVAYENALRVFNIVFTSLFSLECVLKVMAFGILNYFRDAWNIFDFVTVLGSITDILVTEFGNNFINLSFLRLFRAARLIKLLRQGYTIRILLWTFVQSFKALPYVCLLIAMLFFIYAIIGMQVFGNIGIDVEDEDSDEDEFQITEHNNFRTFFQALMLLFRSATGEAWHNIMLSCLSGKPCDKNSGILTRECGNEFAYFYFVSFIFLCSFLMLNLFVAVIMDNFEYLTRDSSILGPHHLDEYVRVWAEYDPAAWGRMPYLDMYQMLRHMSPPLGLGKKCPARVAYKRLLRMDLPVADDNTVHFNSTLMALIRTALDIKIAKGGADKQQMDAELRKEMMAIWPNLSQKTLDLLVTPHKSTDLTVGKIYAAMMIMEYYRQSKAKKLQAMREEQDRTPLMFQRMEPPSPTQEGGPGQNALPSTQLDPGGALMAHESGLKESPSWVTQRAQEMFQKTGTWSPEQGPPTDMPNSQPNSQSVEMREMGRDGYSDSEHYLPMEGQGRAASMPRLPAENQRRRGRPRGNNLSTISDTSPMKRSASVLGPKARRLDDYSLERVPPEENQRHHQRRRDRSHRASERSLGRYTDVDTGLGTDLSMTTQSGDLPSKERDQERGRPKDRKHRQHHHHHHHHHHPPPPDKDRYAQERPDHGRARARDQRWSRSPSEGREHMAHRQGSSSVSGSPAPSTSGTSTPRRGRRQLPQTPSTPRPHVSYSPVIRKAGGSGPPQQQQQQQQQQQQQAVARPGRAATSGPRRYPGPTAEPLAGDRPPTGGHSSGRSPRMERRVPGPARSESPRACRHGGARWPASGPHVSEGPPGPRHHGYYRGSDYDEADGPGSGGGEEAMAGAYDAPPPVRHASSGATGRSPRTPRASGPACASPSRHGRRLPNGYYPAHGLARPRGPGSRKGLHEPYSESDDDWC
T34949	DRUGINFO	D05CEU	Flunarizine	Approved
T34949	DRUGINFO	D0A3MJ	XEN007	Phase 1
T34949	DRUGINFO	D0QQ7N	TH-9229	Terminated
T34949	DRUGINFO	D0N1MY	Alpha-eudesmol	Investigative
T34949	DRUGINFO	D09LRA	omega-conotoxin GVIA	Investigative
T34949	DRUGINFO	D09YTH	CPU-228	Investigative

T27376	TARGETID	T27376
T27376	FORMERID	TTDI01909
T27376	UNIPROID	GBRD_HUMAN
T27376	TARGNAME	GABA(A) receptor delta (GABRD)
T27376	GENENAME	GABRD
T27376	TARGTYPE	Successful
T27376	SYNONYMS	Gammaaminobutyric acid receptor subunit delta; GABRD; GABA(A) receptor subunit delta
T27376	FUNCTION	GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
T27376	BIOCLASS	Ligand-gated ion channel
T27376	SEQUENCE	MDAPARLLAPLLLLCAQQLRGTRAMNDIGDYVGSNLEISWLPNLDGLIAGYARNFRPGIGGPPVNVALALEVASIDHISEANMEYTMTVFLHQSWRDSRLSYNHTNETLGLDSRFVDKLWLPDTFIVNAKSAWFHDVTVENKLIRLQPDGVILYSIRITSTVACDMDLAKYPMDEQECMLDLESYGYSSEDIVYYWSESQEHIHGLDKLQLAQFTITSYRFTTELMNFKSAGQFPRLSLHFHLRRNRGVYIIQSYMPSVLLVAMSWVSFWISQAAVPARVSLGITTVLTMTTLMVSARSSLPRASAIKALDVYFWICYVFVFAALVEYAFAHFNADYRKKQKAKVKVSRPRAEMDVRNAIVLFSLSAAGVTQELAISRRQRRVPGNLMGSYRSVGVETGETKKEGAARSGGQGGIRARLRPIDADTIDIYARAVFPAAFAAVNVIYWAAYAM
T27376	DRUGINFO	D00EEL	Gaboxadol	Approved
T27376	DRUGINFO	D00VZZ	Allopregnanolone	approved
T27376	DRUGINFO	D05PDJ	SAGE-217b	Phase 2
T27376	DRUGINFO	D00AJI	PF-4480682	Discontinued in Phase 2
T27376	DRUGINFO	D0T2QN	PF-2393296	Discontinued in Phase 1
T27376	DRUGINFO	D03ZGV	Co-60549	Terminated
T27376	DRUGINFO	D0SE4D	Org-20599	Terminated
T27376	DRUGINFO	D04TVU	RU-5135	Investigative
T27376	DRUGINFO	D0P0TI	TBPS	Investigative

T56262	TARGETID	T56262
T56262	UNIPROID	TPP1_HUMAN
T56262	TARGNAME	Tripeptidyl-peptidase I (TPP1)
T56262	GENENAME	TPP1
T56262	TARGTYPE	Successful
T56262	SYNONYMS	TPP1
T56262	FUNCTION	Lysosomal serine protease with tripeptidyl-peptidase I activity. May act as a non-specific lysosomal peptidase which generates tripeptides from the breakdown products produced by lysosomal proteinases. Requires substrates with an unsubstituted N-terminus.
T56262	PDBSTRUC	3EE6; 3EDY; 1R60
T56262	BIOCLASS	Peptidase
T56262	ECNUMBER	EC 3.4.14.9
T56262	SEQUENCE	MGLQACLLGLFALILSGKCSYSPEPDQRRTLPPGWVSLGRADPEEELSLTFALRQQNVERLSELVQAVSDPSSPQYGKYLTLENVADLVRPSPLTLHTVQKWLLAAGAQKCHSVITQDFLTCWLSIRQAELLLPGAEFHHYVGGPTETHVVRSPHPYQLPQALAPHVDFVGGLHRFPPTSSLRQRPEPQVTGTVGLHLGVTPSVIRKRYNLTSQDVGSGTSNNSQACAQFLEQYFHDSDLAQFMRLFGGNFAHQASVARVVGQQGRGRAGIEASLDVQYLMSAGANISTWVYSSPGRHEGQEPFLQWLMLLSNESALPHVHTVSYGDDEDSLSSAYIQRVNTELMKAAARGLTLLFASGDSGAGCWSVSGRHQFRPTFPASSPYVTTVGGTSFQEPFLITNEIVDYISGGGFSNVFPRPSYQEEAVTKFLSSSPHLPPSSYFNASGRAYPDVAALSDGYWVVSNRVPIPWVSGTSASTPVFGGILSLINEHRILSGRPPLGFLNPRLYQQHGAGLFDVTRGCHESCLDEEVEGQGFCSGPGWDPVTGWGTPNFPALLKTLLNP
T56262	DRUGINFO	D06CAS	Cerliponase Alfa	Approved
T56262	DRUGINFO	DZ1XV8	LX1004	Phase 1/2

T02777	TARGETID	T02777
T02777	FORMERID	TTDS00332
T02777	UNIPROID	ABCC9_HUMAN
T02777	TARGNAME	ATP-binding cassette transporter C9 (ABCC9)
T02777	GENENAME	ABCC9
T02777	TARGTYPE	Successful
T02777	SYNONYMS	Sulfonylurea receptor 2; SUR2; ATP-binding cassette sub-family C member 9
T02777	FUNCTION	Subunit of ATP-sensitive potassium channels (KATP). Can form cardiac and smooth muscle-type KATP channels with KCNJ11. KCNJ11 forms the channel pore while ABCC9 is required for activation and regulation.
T02777	BIOCLASS	ABC transporter
T02777	SEQUENCE	MSLSFCGNNISSYNINDGVLQNSCFVDALNLVPHVFLLFITFPILFIGWGSQSSKVQIHHNTWLHFPGHNLRWILTFALLFVHVCEIAEGIVSDSRRESRHLHLFMPAVMGFVATTTSIVYYHNIETSNFPKLLLALFLYWVMAFITKTIKLVKYCQSGLDISNLRFCITGMMVILNGLLMAVEINVIRVRRYVFFMNPQKVKPPEDLQDLGVRFLQPFVNLLSKATYWWMNTLIISAHKKPIDLKAIGKLPIAMRAVTNYVCLKDAYEEQKKKVADHPNRTPSIWLAMYRAFGRPILLSSTFRYLADLLGFAGPLCISGIVQRVNETQNGTNNTTGISETLSSKEFLENAYVLAVLLFLALILQRTFLQASYYVTIETGINLRGALLAMIYNKILRLSTSNLSMGEMTLGQINNLVAIETNQLMWFLFLCPNLWAMPVQIIMGVILLYNLLGSSALVGAAVIVLLAPIQYFIATKLAEAQKSTLDYSTERLKKTNEILKGIKLLKLYAWEHIFCKSVEETRMKELSSLKTFALYTSLSIFMNAAIPIAAVLATFVTHAYASGNNLKPAEAFASLSLFHILVTPLFLLSTVVRFAVKAIISVQKLNEFLLSDEIGDDSWRTGESSLPFESCKKHTGVQPKTINRKQPGRYHLDSYEQSTRRLRPAETEDIAIKVTNGYFSWGSGLATLSNIDIRIPTGQLTMIVGQVGCGKSSLLLAILGEMQTLEGKVHWSNVNESEPSFEATRSRNRYSVAYAAQKPWLLNATVEENITFGSPFNKQRYKAVTDACSLQPDIDLLPFGDQTEIGERGINLSGGQRQRICVARALYQNTNIVFLDDPFSALDIHLSDHLMQEGILKFLQDDKRTLVLVTHKLQYLTHADWIIAMKDGSVLREGTLKDIQTKDVELYEHWKTLMNRQDQELEKDMEADQTTLERKTLRRAMYSREAKAQMEDEDEEEEEEEDEDDNMSTVMRLRTKMPWKTCWRYLTSGGFFLLILMIFSKLLKHSVIVAIDYWLATWTSEYSINNTGKADQTYYVAGFSILCGAGIFLCLVTSLTVEWMGLTAAKNLHHNLLNKIILGPIRFFDTTPLGLILNRFSADTNIIDQHIPPTLESLTRSTLLCLSAIGMISYATPVFLVALLPLGVAFYFIQKYFRVASKDLQELDDSTQLPLLCHFSETAEGLTTIRAFRHETRFKQRMLELTDTNNIAYLFLSAANRWLEVRTDYLGACIVLTASIASISGSSNSGLVGLGLLYALTITNYLNWVVRNLADLEVQMGAVKKVNSFLTMESENYEGTMDPSQVPEHWPQEGEIKIHDLCVRYENNLKPVLKHVKAYIKPGQKVGICGRTGSGKSSLSLAFFRMVDIFDGKIVIDGIDISKLPLHTLRSRLSIILQDPILFSGSIRFNLDPECKCTDDRLWEALEIAQLKNMVKSLPGGLDAVVTEGGENFSVGQRQLFCLARAFVRKSSILIMDEATASIDMATENILQKVVMTAFADRTVVTIAHRVSSIMDAGLVLVFSEGILVECDTVPNLLAHKNGLFSTLVMTNK
T02777	DRUGINFO	D0O2SR	Nicorandil	Approved
T02777	DRUGINFO	D06OIV	Tolbutamide	Approved
T02777	DRUGINFO	D0B2GI	Glimepiride	Approved
T02777	DRUGINFO	D0N5YA	Repaglinide	Approved
T02777	DRUGINFO	D0P2MH	BTS-67582	Discontinued in Phase 2
T02777	DRUGINFO	D0S6SU	KRN-2391	Discontinued in Phase 2
T02777	DRUGINFO	D04JGA	BMS-191095	Discontinued in Phase 1
T02777	DRUGINFO	D0MT0A	CCX915	Discontinued in Phase 1

T20808	TARGETID	T20808
T20808	FORMERID	TTDI02095
T20808	UNIPROID	IDHC_HUMAN; IDHP_HUMAN; IDH3A_HUMAN; IDH3B_HUMAN; IDH3G_HUMAN
T20808	TARGNAME	Isocitrate dehydrogenase (IDH)
T20808	GENENAME	IDH1; IDH2; IDH3A; IDH3B; IDH3G
T20808	TARGTYPE	Successful
T20808	SYNONYMS	Isocitrate dehydrogenase [NAD]
T20808	FUNCTION	It may tightly associate or interact with the pyruvate dehydrogenase complex. Plays a role in intermediary metabolism and energy production.
T20808	BIOCLASS	CH-OH donor oxidoreductase
T20808	SEQUENCE	MSKKISGGSVVEMQGDEMTRIIWELIKEKLIFPYVELDLHSYDLGIENRDATNDQVTKDAAEAIKKHNVGVKCATITPDEKRVEEFKLKQMWKSPNGTIRNILGGTVFREAIICKNIPRLVSGWVKPIIIGRHAYGDQYRATDFVVPGPGKVEITYTPSDGTQKVTYLVHNFEEGGGVAMGMYNQDKSIEDFAHSSFQMALSKGWPLYLSTKNTILKKYDGRFKDIFQEIYDKQYKSQFEAQKIWYEHRLIDDMVAQAMKSEGGFIWACKNYDGDVQSDSVAQGYGSLGMMTSVLVCPDGKTVEAEAAHGTVTRHYRMYQKGQETSTNPIASIFAWTRGLAHRAKLDNNKELAFFANALEEVSIETIEAGFMTKDLAACIKGLPNVQRSDYLNTFEFMDKLGENLKIKLAQAKL
T20808	DRUGINFO	D0WH4P	ENASIDENIB MESYLATE	Approved
T20808	DRUGINFO	D0K7FT	AG-221	Phase 3
T20808	DRUGINFO	D0K9PC	AG-881	Phase 3

T34843	TARGETID	T34843
T34843	FORMERID	TTDNS00544
T34843	UNIPROID	GLP2R_HUMAN
T34843	TARGNAME	Glucagon-like peptide 2 receptor (GLP2R)
T34843	GENENAME	GLP2R
T34843	TARGTYPE	Successful
T34843	SYNONYMS	GLP2R; GLP2 receptor
T34843	FUNCTION	This is a receptor for glucagon-like peptide 2. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.
T34843	BIOCLASS	GPCR secretin
T34843	SEQUENCE	MKLGSSRAGPGRGSAGLLPGVHELPMGIPAPWGTSPLSFHRKCSLWAPGRPFLTLVLLVSIKQVTGSLLEETTRKWAQYKQACLRDLLKEPSGIFCNGTFDQYVCWPHSSPGNVSVPCPSYLPWWSEESSGRAYRHCLAQGTWQTIENATDIWQDDSECSENHSFKQNVDRYALLSTLQLMYTVGYSFSLISLFLALTLLLFLRKLHCTRNYIHMNLFASFILRTLAVLVKDVVFYNSYSKRPDNENGWMSYLSEMSTSCRSVQVLLHYFVGANYLWLLVEGLYLHTLLEPTVLPERRLWPRYLLLGWAFPVLFVVPWGFARAHLENTGCWTTNGNKKIWWIIRGPMMLCVTVNFFIFLKILKLLISKLKAHQMCFRDYKYRLAKSTLVLIPLLGVHEILFSFITDDQVEGFAKLIRLFIQLTLSSFHGFLVALQYGFANGEVKAELRKYWVRFLLARHSGCRACVLGKDFRFLGKCPKKLSEGDGAEKLRKLQPSLNSGRLLHLAMRGLGELGAQPQQDHARWPRGSSLSECSEGDVTMANTMEEILEESEI
T34843	DRUGINFO	D00RCI	Teduglutide	Approved
T34843	DRUGINFO	D0EV1L	Elsiglutide	Phase 2
T34843	DRUGINFO	D01JWH	SAN-134	Phase 1
T34843	DRUGINFO	D09NVU	ZP-1848	Phase 1
T34843	DRUGINFO	D0L2VB	FE-203799	Investigative
T34843	DRUGINFO	D0P3PF	AMX-256	Investigative

T33425	TARGETID	T33425
T33425	FORMERID	TTDI01986
T33425	UNIPROID	EGF_HUMAN
T33425	TARGNAME	Epidermal growth factor (EGF)
T33425	GENENAME	EGF
T33425	TARGTYPE	Successful
T33425	SYNONYMS	Proepidermal growth factor; Pro-epidermal growth factor
T33425	FUNCTION	Magnesiotropic hormone that stimulates magnesium reabsorption in the renal distal convoluted tubule via engagement of EGFR and activation of the magnesium channel TRPM6. Can induce neurite outgrowth in motoneurons of the pond snail Lymnaea stagnalis in vitro. EGF stimulates the growth of various epidermal and epithelial tissues in vivo and in vitro and of some fibroblasts in cell culture.
T33425	PDBSTRUC	3NJP; 2KV4; 1P9J; 1NQL; 1JL9
T33425	BIOCLASS	Growth factor
T33425	SEQUENCE	MLLTLIILLPVVSKFSFVSLSAPQHWSCPEGTLAGNGNSTCVGPAPFLIFSHGNSIFRIDTEGTNYEQLVVDAGVSVIMDFHYNEKRIYWVDLERQLLQRVFLNGSRQERVCNIEKNVSGMAINWINEEVIWSNQQEGIITVTDMKGNNSHILLSALKYPANVAVDPVERFIFWSSEVAGSLYRADLDGVGVKALLETSEKITAVSLDVLDKRLFWIQYNREGSNSLICSCDYDGGSVHISKHPTQHNLFAMSLFGDRIFYSTWKMKTIWIANKHTGKDMVRINLHSSFVPLGELKVVHPLAQPKAEDDTWEPEQKLCKLRKGNCSSTVCGQDLQSHLCMCAEGYALSRDRKYCEDVNECAFWNHGCTLGCKNTPGSYYCTCPVGFVLLPDGKRCHQLVSCPRNVSECSHDCVLTSEGPLCFCPEGSVLERDGKTCSGCSSPDNGGCSQLCVPLSPVSWECDCFPGYDLQLDEKSCAASGPQPFLLFANSQDIRHMHFDGTDYGTLLSQQMGMVYALDHDPVENKIYFAHTALKWIERANMDGSQRERLIEEGVDVPEGLAVDWIGRRFYWTDRGKSLIGRSDLNGKRSKIITKENISQPRGIAVHPMAKRLFWTDTGINPRIESSSLQGLGRLVIASSDLIWPSGITIDFLTDKLYWCDAKQSVIEMANLDGSKRRRLTQNDVGHPFAVAVFEDYVWFSDWAMPSVMRVNKRTGKDRVRLQGSMLKPSSLVVVHPLAKPGADPCLYQNGGCEHICKKRLGTAWCSCREGFMKASDGKTCLALDGHQLLAGGEVDLKNQVTPLDILSKTRVSEDNITESQHMLVAEIMVSDQDDCAPVGCSMYARCISEGEDATCQCLKGFAGDGKLCSDIDECEMGVPVCPPASSKCINTEGGYVCRCSEGYQGDGIHCLDIDECQLGEHSCGENASCTNTEGGYTCMCAGRLSEPGLICPDSTPPPHLREDDHHYSVRNSDSECPLSHDGYCLHDGVCMYIEALDKYACNCVVGYIGERCQYRDLKWWELRHAGHGQQQKVIVVAVCVVVLVMLLLLSLWGAHYYRTQKLLSKNPKNPYEESSRDVRSRRPADTEDGMSSCPQPWFVVIKEHQDLKNGGQPVAGEDGQAADGSMQPTSWRQEPQLCGMGTEQGCWIPVSSDKGSCPQVMERSFHMPSYGTQTLEGGVEKPHSLLSANPLWQQRALDPPHQMELTQ
T33425	DRUGINFO	D08TPS	Epidermal growth factor	Approved
T33425	DRUGINFO	D09SBY	Hebervis	Investigative

T18950	TARGETID	T18950
T18950	FORMERID	TTDS00244
T18950	UNIPROID	GON1_HUMAN
T18950	TARGNAME	Leutinizing-hormone-releasing hormone (GNRH1)
T18950	GENENAME	GNRH1
T18950	TARGTYPE	Successful
T18950	SYNONYMS	Progonadoliberin-1; Progonadoliberin I; LHRH; GRH; GNRH
T18950	FUNCTION	Stimulates the secretion of gonadotropins; it stimulates the secretion of both luteinizing and follicle-stimulating hormones.
T18950	PDBSTRUC	4D5M
T18950	BIOCLASS	Gonadotropin-releasing hormone
T18950	SEQUENCE	MKPIQKLLAGLILLTWCVEGCSSQHWSYGLRPGGKRDAENLIDSFQEIVKEVGQLAETQRFECTTHQPRSPLRDLKGALESLIEEETGQKKI
T18950	DRUGINFO	D00BCG	Goserelin	Approved
T18950	DRUGINFO	D0U5FF	Leuprolide	Approved
T18950	DRUGINFO	D01FDN	NAL-GLU	Phase 2/3
T18950	DRUGINFO	D08LMS	CG201	Phase 2
T18950	DRUGINFO	D0B3DX	Norelin	Discontinued in Phase 2
T18950	DRUGINFO	D06IYV	TAK-810	Discontinued in Phase 1
T18950	DRUGINFO	D07IAU	Anti-GnRH Spiegelmer	Investigative

T98708	TARGETID	T98708
T98708	FORMERID	TTDI01944
T98708	UNIPROID	PTHY_HUMAN
T98708	TARGNAME	Parathyroid hormone (PTH)
T98708	GENENAME	PTH
T98708	TARGTYPE	Successful
T98708	SYNONYMS	Parathyrin; Parathormone
T98708	FUNCTION	Stimulates [1-14C]-2-deoxy-D-glucose (2DG) transport and glycogen synthesis in osteoblastic cells. PTH elevates calcium level by dissolving the salts in bone and preventing their renal excretion.
T98708	PDBSTRUC	3C4M; 2L1X; 1ZWG; 1ZWF; 1ZWE
T98708	SEQUENCE	MIPAKDMAKVMIVMLAICFLTKSDGKSVKKRSVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKEDNVLVESHEKSLGEADKADVNVLTKAKSQ
T98708	DRUGINFO	D0YA2L	Teriparatide	Approved
T98708	DRUGINFO	D0F4SN	KUR-111	Phase 2
T98708	DRUGINFO	D0S7FR	Ostabolin-C	Phase 2
T98708	DRUGINFO	D02RAI	ABX-PTH	Terminated
T98708	DRUGINFO	D0F2PZ	SUN-E3001	Terminated
T98708	DRUGINFO	D01VGQ	MG-1101	Investigative
T98708	DRUGINFO	D04PRM	parathyroid hormone	Investigative

T82841	TARGETID	T82841
T82841	FORMERID	TTDNC00576
T82841	UNIPROID	INS_HUMAN
T82841	TARGNAME	Insulin (INS)
T82841	GENENAME	INS
T82841	TARGTYPE	Successful
T82841	SYNONYMS	Insulin
T82841	FUNCTION	Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver.
T82841	PDBSTRUC	6HN5; 6CK2; 6CEB; 6CE9; 6CE7
T82841	SEQUENCE	MALWMRLLPLLALLALWGPDPAAAFVNQHLCGSHLVEALYLVCGERGFFYTPKTRREAEDLQVGQVELGGGPGAGSLQPLALEGSLQKRGIVEQCCTSICSLYQLENYCN
T82841	DRUGINFO	D01IWS	Inulin	Approved
T82841	DRUGINFO	D03FIL	Insulin Zinc Susp Recombinant Human	Approved
T82841	DRUGINFO	D07NGZ	Insulin-glargine	Approved
T82841	DRUGINFO	D08ENK	Insulin Susp Isophane Recombinant Human	Approved
T82841	DRUGINFO	D0F3LS	Insulin determir	Approved
T82841	DRUGINFO	D0I1PY	Insulin Susp Protamine Zinc Beef/Pork	Approved
T82841	DRUGINFO	D0I3LE	Insulin-aspart	Approved
T82841	DRUGINFO	D0L2CI	Insulin degludec	Approved
T82841	DRUGINFO	D0QE5U	Insulin-detemir	Approved
T82841	DRUGINFO	D01LOE	LY2963016	Phase 3
T82841	DRUGINFO	D09VFX	SAR342434	Phase 3
T82841	DRUGINFO	D0L6NW	LY2605541	Phase 3
T82841	DRUGINFO	D0V2WO	PC-DAC:Insulin	Phase 3
T82841	DRUGINFO	D0X5AN	U300	Phase 3
T82841	DRUGINFO	D00ARS	MER-3001	Phase 2
T82841	DRUGINFO	D0M2LI	NNC-0123-0000-0338	Phase 2
T82841	DRUGINFO	D0PT1Y	SAR-161271	Phase 1/2
T82841	DRUGINFO	D00KMQ	OI362GT	Phase 1
T82841	DRUGINFO	D00ROY	Adjustable basal insulin	Phase 1
T82841	DRUGINFO	D05NUP	SBS-1000	Phase 1
T82841	DRUGINFO	D0B2HF	OI287GT	Phase 1
T82841	DRUGINFO	D0D6OO	NP-500	Phase 1
T82841	DRUGINFO	D0I8TW	IBC-VS01	Phase 1
T82841	DRUGINFO	D01VWR	S-15261	Discontinued in Phase 2
T82841	DRUGINFO	D0B3MX	NBI-6024	Discontinued in Phase 2
T82841	DRUGINFO	D0QX0K	FT-105	Discontinued in Phase 1
T82841	DRUGINFO	D0SG4W	Oral insulin	Terminated
T82841	DRUGINFO	D0AE1E	Insulin molecules, Novo	Investigative

T56518	TARGETID	T56518
T56518	FORMERID	TTDR00970
T56518	UNIPROID	DPOL_HBVA3
T56518	TARGNAME	Hepatitis B virus Reverse transcriptase (HBV RT)
T56518	GENENAME	HBV RT
T56518	TARGTYPE	Successful
T56518	SYNONYMS	P; HBV reverse transcriptase
T56518	FUNCTION	Multifunctional enzyme that converts the viral RNA genome into dsDNA in viral cytoplasmic capsids. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3'- to 5'-endonucleasic mode. Neo-synthesized pregenomic RNA (pgRNA) are encapsidated together with the P protein, and reverse- transcribed inside the nucleocapsid. Initiation of reverse- transcription occurs first by binding the epsilon loop on the pgRNA genome, and is initiated by protein priming, thereby the 5'- end of (-)DNA is covalently linked to P protein. Partial (+)DNA is synthesized from the (-)DNA template and generates the relaxed circular DNA (RC-DNA) genome. After budding and infection, theRC- DNA migrates in the nucleus, and is converted into a plasmid-like covalently closed circular DNA (cccDNA). The activity of P protein does not seem to be necessary for cccDNA generation, and is presumably released from (+)DNA by host nuclear DNA repair machinery.
T56518	BIOCLASS	DNA-directed DNA polymerase
T56518	ECNUMBER	EC 2.7.7.49
T56518	SEQUENCE	EHHIRIPRTPARVTGGVFLVDKNPHNTAESRLVVDFSQFSRGISRVSWPKFAVPNLQSLTNLLSSNLSWLSLDVSAAFYHIPLHPAAMPHLLIGSSGLSRYVARLSSNSRINNNQYGTMQNLHDSCSRQLYVSLMLLYKTYGWKLHLYSHPIVLGFRKIPMGVGLSPFLLAQFTSAICSVVRRAFPHCLAFSYMDDVVLGAKSVQHRESLYTAVTNFLLSLGIHLNPNKTKRWGYSLNFMGYII
T56518	DRUGINFO	D0KR2J	Entecavir	Approved
T56518	DRUGINFO	D0ML1F	Adefovir Dipivoxil	Approved
T56518	DRUGINFO	D0T1WY	Clevudine	Phase 3
T56518	DRUGINFO	D0G9XP	LB80380	Phase 2b
T56518	DRUGINFO	D02FCU	MIV-210	Phase 2
T56518	DRUGINFO	D0D5CY	Pradefovir	Phase 2

T83611	TARGETID	T83611
T83611	FORMERID	TTDS00471
T83611	UNIPROID	2B11_HUMAN
T83611	TARGNAME	MHC class II antigen DRB1*1 (HLA-DRB1)
T83611	GENENAME	HLA-DRB1
T83611	TARGTYPE	Successful
T83611	SYNONYMS	HLA class II histocompatibility antigen, DRB1-1 beta chain; DR1; DR-1
T83611	FUNCTION	Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route; where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules; and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments; exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides; autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs; other cells of the gastrointestinal tract; such as epithelial cells; express MHC class II molecules and CD74 and act as APCs; which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen; three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs; CD74 undergoes a sequential degradation by various proteases; including CTSS and CTSL; leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells; the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules; increased acidification produces increased proteolysis and efficient peptide loading.
T83611	PDBSTRUC	6CQR; 6CQJ; 4X5X; 4X5W; 4OV5
T83611	BIOCLASS	MHC class II
T83611	SEQUENCE	MVCLKLPGGSCMTALTVTLMVLSSPLALSGDTRPRFLWQPKRECHFFNGTERVRFLDRYFYNQEESVRFDSDVGEFRAVTELGRPDAEYWNSQKDILEQARAAVDTYCRHNYGVVESFTVQRRVQPKVTVYPSKTQPLQHHNLLVCSVSGFYPGSIEVRWFLNGQEEKAGMVSTGLIQNGDWTFQTLVMLETVPRSGEVYTCQVEHPSVTSPLTVEWRARSESAQSKMLSGVGGFVLGLLFLGAGLFIYFRNQKGHSGLQPTGFLS
T83611	DRUGINFO	D04CRL	Glatiramer Acetate	Approved

T03917	TARGETID	T03917
T03917	FORMERID	TTDS00046
T03917	UNIPROID	AT1A1_HUMAN; AT1A2_HUMAN; AT1A3_HUMAN; AT1B1_HUMAN; AT1B2_HUMAN; AT1B3_HUMAN
T03917	TARGNAME	Sodium/potassium-transporting ATPase (SPT ATPase)
T03917	GENENAME	ATP1A1; ATP1A2; ATP1A3; ATP1B1; ATP1B2; ATP1B3
T03917	TARGTYPE	Successful
T03917	SYNONYMS	Na(+)/K(+) ATPase
T03917	FUNCTION	Maintain resting potential, affects transport, and regulates cellular volume. Function as a signal transducer/integrator to regulate the MAPK pathway, ROS, as well as intracellular calcium. 
T03917	BIOCLASS	Acid anhydrides hydrolase
T03917	SEQUENCE	MGKGVGRDKYEPAAVSEQGDKKGKKGKKDRDMDELKKEVSMDDHKLSLDELHRKYGTDLSRGLTSARAAEILARDGPNALTPPPTTPEWIKFCRQLFGGFSMLLWIGAILCFLAYSIQAATEEEPQNDNLYLGVVLSAVVIITGCFSYYQEAKSSKIMESFKNMVPQQALVIRNGEKMSINAEEVVVGDLVEVKGGDRIPADLRIISANGCKVDNSSLTGESEPQTRSPDFTNENPLETRNIAFFSTNCVEGTARGIVVYTGDRTVMGRIATLASGLEGGQTPIAAEIEHFIHIITGVAVFLGVSFFILSLILEYTWLEAVIFLIGIIVANVPEGLLATVTVCLTLTAKRMARKNCLVKNLEAVETLGSTSTICSDKTGTLTQNRMTVAHMWFDNQIHEADTTENQSGVSFDKTSATWLALSRIAGLCNRAVFQANQENLPILKRAVAGDASESALLKCIELCCGSVKEMRERYAKIVEIPFNSTNKYQLSIHKNPNTSEPQHLLVMKGAPERILDRCSSILLHGKEQPLDEELKDAFQNAYLELGGLGERVLGFCHLFLPDEQFPEGFQFDTDDVNFPIDNLCFVGLISMIDPPRAAVPDAVGKCRSAGIKVIMVTGDHPITAKAIAKGVGIISEGNETVEDIAARLNIPVSQVNPRDAKACVVHGSDLKDMTSEQLDDILKYHTEIVFARTSPQQKLIIVEGCQRQGAIVAVTGDGVNDSPALKKADIGVAMGIAGSDVSKQAADMILLDDNFASIVTGVEEGRLIFDNLKKSIAYTLTSNIPEITPFLIFIIANIPLPLGTVTILCIDLGTDMVPAISLAYEQAESDIMKRQPRNPKTDKLVNERLISMAYGQIGMIQALGGFFTYFVILAENGFLPIHLLGLRVDWDDRWINDVEDSYGQQWTYEQRKIVEFTCHTAFFVSIVVVQWADLVICKTRRNSVFQQGMKNKILIFGLFEETALAAFLSYCPGMGVALRMYPLKPTWWFCAFPYSLLIFVYDEVRKLIIRRRPGGWVEKETYY
T03917	DRUGINFO	D0M3QP	Digitoxin	Approved
T03917	DRUGINFO	D0T3NB	Sanguinarine	Approved
T03917	DRUGINFO	D02OZE	Digoxin	Approved
T03917	DRUGINFO	D08UUK	Rostafuroxin	Phase 2
T03917	DRUGINFO	D0A4YK	PBI-05204	Phase 2
T03917	DRUGINFO	D3OUH0	RX108	Phase 1
T03917	DRUGINFO	D06HIO	Istaroxime	Discontinued in Phase 2
T03917	DRUGINFO	D0P6EL	Cordil	Terminated

T73712	TARGETID	T73712
T73712	FORMERID	TTDR00634
T73712	UNIPROID	FABPL_HUMAN
T73712	TARGNAME	Fatty acid-binding protein 1 (FABP1)
T73712	GENENAME	FABP1
T73712	TARGTYPE	Successful
T73712	SYNONYMS	L-FABP; FABP1; 14-kDa fatty-acid binding protein; 14 kDa selenium-binding protein
T73712	FUNCTION	Binds free fatty acids andtheir coenzyme A derivatives, bilirubin, and some other small molecules in the cytoplasm. May be involved in intracellular lipid transport.
T73712	PDBSTRUC	6DRG; 6DO7; 6DO6; 3VG7; 3VG6
T73712	SEQUENCE	MSFSGKYQLQSQENFEAFMKAIGLPEELIQKGKDIKGVSEIVQNGKHFKFTITAGSKVIQNEFTVGEECELETMTGEKVKTVVQLEGDNKLVTTFKNIKSVTELNGDIITNTMTLGDIVFKRISKRI
T73712	DRUGINFO	D0NF1U	FENOFIBRIC ACID	Approved
T73712	DRUGINFO	D0Q5PL	INDOPROFEN	Withdrawn from market
T73712	DRUGINFO	D0C7RS	1-anilinonaphthalene-8-sulfonic acid	Investigative
T73712	DRUGINFO	D0A4EA	OLEIC ACID	Investigative

T96413	TARGETID	T96413
T96413	FORMERID	TTDI01288
T96413	UNIPROID	BGLR_HUMAN
T96413	TARGNAME	Beta-glucuronidase (GUSB)
T96413	GENENAME	GUSB
T96413	TARGTYPE	Successful
T96413	SYNONYMS	Beta-G1
T96413	FUNCTION	Plays an important role in the degradation of dermatan and keratan sulfates.
T96413	PDBSTRUC	3HN3; 1BHG
T96413	ECNUMBER	EC 3.2.1.31
T96413	SEQUENCE	MARGSAVAWAALGPLLWGCALGLQGGMLYPQESPSRECKELDGLWSFRADFSDNRRRGFEEQWYRRPLWESGPTVDMPVPSSFNDISQDWRLRHFVGWVWYEREVILPERWTQDLRTRVVLRIGSAHSYAIVWVNGVDTLEHEGGYLPFEADISNLVQVGPLPSRLRITIAINNTLTPTTLPPGTIQYLTDTSKYPKGYFVQNTYFDFFNYAGLQRSVLLYTTPTTYIDDITVTTSVEQDSGLVNYQISVKGSNLFKLEVRLLDAENKVVANGTGTQGQLKVPGVSLWWPYLMHERPAYLYSLEVQLTAQTSLGPVSDFYTLPVGIRTVAVTKSQFLINGKPFYFHGVNKHEDADIRGKGFDWPLLVKDFNLLRWLGANAFRTSHYPYAEEVMQMCDRYGIVVIDECPGVGLALPQFFNNVSLHHHMQVMEEVVRRDKNHPAVVMWSVANEPASHLESAGYYLKMVIAHTKSLDPSRPVTFVSNSNYAADKGAPYVDVICLNSYYSWYHDYGHLELIQLQLATQFENWYKKYQKPIIQSEYGAETIAGFHQDPPLMFTEEYQKSLLEQYHLGLDQKRRKYVVGELIWNFADFMTEQSPTRVLGNKKGIFTRQRQPKSAAFLLRERYWKIANETRYPHSVAKSQCLENSLFT
T96413	DRUGINFO	D0OY4K	Vestronidase alfa	Approved
T96413	DRUGINFO	D0U8IU	PerioPatch	Phase 2

T50688	TARGETID	T50688
T50688	FORMERID	TTDS00077
T50688	UNIPROID	ITA2B_HUMAN; ITB3_HUMAN
T50688	TARGNAME	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
T50688	GENENAME	ITGA2B; ITGB3
T50688	TARGTYPE	Successful
T50688	SYNONYMS	Platelet membrane glycoprotein IIb; Platelet membrane glycoprotein IIIa; GP
T50688	FUNCTION	Integrin alpha-IIb/beta-3 is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. It recognizes the sequence R-G-D in a wide array of ligands. It recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha- IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial cell surface.
T50688	SEQUENCE	MARALCPLQALWLLEWVLLLLGPCAAPPAWALNLDPVQLTFYAGPNGSQFGFSLDFHKDSHGRVAIVVGAPRTLGPSQEETGGVFLCPWRAEGGQCPSLLFDLRDETRNVGSQTLQTFKARQGLGASVVSWSDVIVACAPWQHWNVLEKTEEAEKTPVGSCFLAQPESGRRAEYSPCRGNTLSRIYVENDFSWDKRYCEAGFSSVVTQAGELVLGAPGGYYFLGLLAQAPVADIFSSYRPGILLWHVSSQSLSFDSSNPEYFDGYWGYSVAVGEFDGDLNTTEYVVGAPTWSWTLGAVEILDSYYQRLHRLRGEQMASYFGHSVAVTDVNGDGRHDLLVGAPLYMESRADRKLAEVGRVYLFLQPRGPHALGAPSLLLTGTQLYGRFGSAIAPLGDLDRDGYNDIAVAAPYGGPSGRGQVLVFLGQSEGLRSRPSQVLDSPFPTGSAFGFSLRGAVDIDDNGYPDLIVGAYGANQVAVYRAQPVVKASVQLLVQDSLNPAVKSCVLPQTKTPVSCFNIQMCVGATGHNIPQKLSLNAELQLDRQKPRQGRRVLLLGSQQAGTTLNLDLGGKHSPICHTTMAFLRDEADFRDKLSPIVLSLNVSLPPTEAGMAPAVVLHGDTHVQEQTRIVLDCGEDDVCVPQLQLTASVTGSPLLVGADNVLELQMDAANEGEGAYEAELAVHLPQGAHYMRALSNVEGFERLICNQKKENETRVVLCELGNPMKKNAQIGIAMLVSVGNLEEAGESVSFQLQIRSKNSQNPNSKIVLLDVPVRAEAQVELRGNSFPASLVVAAEEGEREQNSLDSWGPKVEHTYELHNNGPGTVNGLHLSIHLPGQSQPSDLLYILDIQPQGGLQCFPQPPVNPLKVDWGLPIPSPSPIHPAHHKRDRRQIFLPEPEQPSRLQDPVLVSCDSAPCTVVQCDLQEMARGQRAMVTVLAFLWLPSLYQRPLDQFVLQSHAWFNVSSLPYAVPPLSLPRGEAQVWTQLLRALEERAIPIWWVLVGVLGGLLLLTILVLAMWKVGFFKRNRPPLEEDDEEGE
T50688	DRUGINFO	D09ZIO	Eptifibatide	Approved
T50688	DRUGINFO	D0BN9X	Tirofiban	Approved
T50688	DRUGINFO	D0P3TX	Abciximab	Approved
T50688	DRUGINFO	D03UOT	Hydroquinone	Approved
T50688	DRUGINFO	D04FYU	DMP-444	Phase 3
T50688	DRUGINFO	D0UZ4G	99mTc-rBitistatin	Phase 1/2
T50688	DRUGINFO	D02PYB	SDZ-GPI-562	Phase 1
T50688	DRUGINFO	D05MVA	RGD-891	Phase 1
T50688	DRUGINFO	D0V7PL	Lefradafiban	Phase 1
T50688	DRUGINFO	D0VO7R	AjvW2	Phase 1
T50688	DRUGINFO	D00VAJ	ORBOFIBAN	Discontinued in Phase 3
T50688	DRUGINFO	D01QQM	LAMIFIBAN	Discontinued in Phase 3
T50688	DRUGINFO	D0N0BI	SIBRAFIBAN	Discontinued in Phase 3
T50688	DRUGINFO	D0SV7D	LOTRAFIBAN	Discontinued in Phase 3
T50688	DRUGINFO	D07EXV	XEMILOFIBAN	Discontinued in Phase 3
T50688	DRUGINFO	D03CKX	Cromafiban	Discontinued in Phase 2
T50688	DRUGINFO	D06LGC	ZD-2486	Discontinued in Phase 2
T50688	DRUGINFO	D09AFJ	SR-121787	Discontinued in Phase 2
T50688	DRUGINFO	D0H9WO	Gantofiban	Discontinued in Phase 2
T50688	DRUGINFO	D0M5CU	YM-337	Discontinued in Phase 2
T50688	DRUGINFO	D0N6PV	MK-852	Discontinued in Phase 2
T50688	DRUGINFO	D0S3RB	ELAROFIBAN	Discontinued in Phase 2
T50688	DRUGINFO	D0W4OL	FK-633	Discontinued in Phase 2
T50688	DRUGINFO	D05JXR	SC-52012	Discontinued in Phase 1
T50688	DRUGINFO	D0C7JH	TP-9201	Discontinued in Phase 1
T50688	DRUGINFO	D0D7GE	TAK-029	Discontinued in Phase 1
T50688	DRUGINFO	D0F8QM	FR-158999	Discontinued in Phase 1
T50688	DRUGINFO	D0H1PN	ME-3277	Discontinued in Phase 1
T50688	DRUGINFO	D0II5S	DMP-728	Discontinued in Phase 1
T50688	DRUGINFO	D0P8JX	L-734217	Discontinued in Phase 1
T50688	DRUGINFO	D0I7EU	SB-208651	Terminated
T50688	DRUGINFO	D0J6MS	BIBU-251	Terminated
T50688	DRUGINFO	D0LK9N	Fradafiban	Terminated
T50688	DRUGINFO	D0M6YE	SKF-106760	Terminated
T50688	DRUGINFO	D0U6BB	L-703014	Terminated
T50688	DRUGINFO	D0Y0AP	GR-144053	Terminated
T50688	DRUGINFO	D0Z7PI	GR-233548	Terminated
T50688	DRUGINFO	D0Z9LD	SC-49992	Terminated
T50688	DRUGINFO	D06PYZ	XV454	Investigative
T50688	DRUGINFO	D07WDB	RGD	Investigative
T50688	DRUGINFO	D0H3UO	RGD-039	Investigative

T82240	TARGETID	T82240
T82240	FORMERID	TTDS00518
T82240	UNIPROID	FCG3A_HUMAN; FCG3B_HUMAN
T82240	TARGNAME	Immunoglobulin gamma Fc receptor III (FCGR3)
T82240	GENENAME	FCGR3A; FCGR3B
T82240	TARGTYPE	Successful
T82240	SYNONYMS	Low affinity immunoglobulin gamma Fc region receptor III; IgG Fc receptor III; IGFR3; FcRIIIb; FcRIIIa; FcRIII; FcR-10; Fc-gamma RIII; FCGR3; FCG3; CD16
T82240	FUNCTION	Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis.
T82240	BIOCLASS	Immunoglobulin
T82240	SEQUENCE	MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQWFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKEEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKNVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDWKDHKFKWRKDPQDK
T82240	DRUGINFO	D09WZV	GMA-161	Approved (orphan drug)
T82240	DRUGINFO	D9O7GC	GTB-3550	Phase 1/2

T66040	TARGETID	T66040
T66040	FORMERID	TTDS00211
T66040	UNIPROID	MRDA_ECOLI
T66040	TARGNAME	Bacterial Penicillin binding protein 2 (Bact mrdA)
T66040	GENENAME	Bact mrdA
T66040	TARGTYPE	Successful
T66040	SYNONYMS	PBP-2
T66040	FUNCTION	Cell wall formation; PBP-2 is responsible for the determination of the rod shape of the cell. It synthesizes cross- linked peptidoglycan from lipid intermediates.
T66040	PDBSTRUC	6G9S
T66040	ECNUMBER	EC 3.4.16.4
T66040	SEQUENCE	MKLQNSFRDYTAESALFVRRALVAFLGILLLTGVLIANLYNLQIVRFTDYQTRSNENRIKLVPIAPSRGIIYDRNGIPLALNRTIYQIEMMPEKVDNVQQTLDALRSVVDLTDDDIAAFRKERARSHRFTSIPVKTNLTEVQVARFAVNQYRFPGVEVKGYKRRYYPYGSALTHVIGYVSKINDKDVERLNNDGKLANYAATHDIGKLGIERYYEDVLHGQTGYEEVEVNNRGRVIRQLKEVPPQAGHDIYLTLDLKLQQYIETLLAGSRAAVVVTDPRTGGVLALVSTPSYDPNLFVDGISSKDYSALLNDPNTPLVNRATQGVYPPASTVKPYVAVSALSAGVITRNTTLFDPGWWQLPGSEKRYRDWKKWGHGRLNVTRSLEESADTFFYQVAYDMGIDRLSEWMGKFGYGHYTGIDLAEERSGNMPTREWKQKRFKKPWYQGDTIPVGIGQGYWTATPIQMSKALMILINDGIVKVPHLLMSTAEDGKQVPWVQPHEPPVGDIHSGYWELAKDGMYGVANRPNGTAHKYFASAPYKIAAKSGTAQVFGLKANETYNAHKIAERLRDHKLMTAFAPYNNPQVAVAMILENGGAGPAVGTLMRQILDHIMLGDNNTDLPAENPAVAAAEDH
T66040	DRUGINFO	D0A1CB	Cefepime	Approved
T66040	DRUGINFO	D0H3TD	Imipenem	Approved
T66040	DRUGINFO	D0M1VC	Amdinocillin	Approved

T33193	TARGETID	T33193
T33193	FORMERID	TTDS00212
T33193	UNIPROID	FTSI_ECOLI
T33193	TARGNAME	Bacterial Penicillin binding protein 3 (Bact mrcA)
T33193	GENENAME	Bact mrcA
T33193	TARGTYPE	Successful
T33193	SYNONYMS	mrcA; Peptidoglycan synthetase ftsI; Peptidoglycan glycosyltransferase 3; Penicillin-binding protein 3; PSPB20; PBP-3; PBP 3
T33193	FUNCTION	Cell wall formation. Essential for the formation of a septum of the murein sacculus. Synthesis of cross-linked peptidoglycan from the lipid intermediates.
T33193	BIOCLASS	Hexosyltransferase
T33193	ECNUMBER	EC 3.4.16.4
T33193	SEQUENCE	MKAAAKTQKPKRQEEHANFISWRFALLCGCILLALAFLLGRVAWLQVISPDMLVKEGDMRSLRVQQVSTSRGMITDRSGRPLAVSVPVKAIWADPKEVHDAGGISVGDRWKALANALNIPLDQLSARINANPKGRFIYLARQVNPDMADYIKKLKLPGIHLREESRRYYPSGEVTAHLIGFTNVDSQGIEGVEKSFDKWLTGQPGERIVRKDRYGRVIEDISSTDSQAAHNLALSIDERLQALVYRELNNAVAFNKAESGSAVLVDVNTGEVLAMANSPSYNPNNLSGTPKEAMRNRTITDVFEPGSTVKPMVVMTALQRGVVRENSVLNTIPYRINGHEIKDVARYSELTLTGVLQKSSNVGVSKLALAMPSSALVDTYSRFGLGKATNLGLVGERSGLYPQKQRWSDIERATFSFGYGLMVTPLQLARVYATIGSYGIYRPLSITKVDPPVPGERVFPESIVRTVVHMMESVALPGGGGVKAAIKGYRIAIKTGTAKKVGPDGRYINKYIAYTAGVAPASQPRFALVVVINDPQAGKYYGGAVSAPVFGAIMGGVLRTMNIEPDALTTGDKNEFVINQGEGTGGRS
T33193	DRUGINFO	D00NJJ	Mezlocillin	Approved
T33193	DRUGINFO	D04VXN	Moxalactam Disodium	Approved
T33193	DRUGINFO	D05UBX	Cefmetazole	Approved
T33193	DRUGINFO	D06QCC	Cefmenoxime	Approved
T33193	DRUGINFO	D0F2XV	Aztreonam	Approved
T33193	DRUGINFO	D0K3DQ	Cefotiam	Approved
T33193	DRUGINFO	D0O5LU	Latamoxef	Approved
T33193	DRUGINFO	D00QAR	Benzylpenicillin	Phase 3
T33193	DRUGINFO	DO75VX	LYS228	Phase 2
T33193	DRUGINFO	D0L7GN	Acylureido penicillin mezlocillin	Investigative
T33193	DRUGINFO	D08JUW	PCNOTAXIME GROUP	Investigative
T33193	DRUGINFO	D0O4TL	Cephalosporin C	Investigative

T39610	TARGETID	T39610
T39610	FORMERID	TTDS00432
T39610	UNIPROID	CALM1_HUMAN; CALM2_HUMAN; CALM3_HUMAN
T39610	TARGNAME	Calmodulin (CALM)
T39610	GENENAME	CALM
T39610	TARGTYPE	Successful
T39610	SYNONYMS	CaM; CALM2
T39610	FUNCTION	Calmodulin mediates the control of a largenumber of enzymes by ca(2+). Among the enzymes to be stimulated by the calmodulin-ca(2+) complex are a number of protein kinases and phosphatases.
T39610	BIOCLASS	Calmodulin-dependent secretion
T39610	SEQUENCE	MADQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQDMINEVDADGNGTIDFPEFLTMMARKMKDTDSEEEIREAFRVFDKDGNGYISAAELRHVMTNLGEKLTDEEVDEMIREADIDGDGQVNYEEFVQMMTAK
T39610	DRUGINFO	D07MVK	Halofantrine	Approved
T39610	DRUGINFO	D0R4OM	Trifluoperazine	Approved
T39610	DRUGINFO	D0W7OE	Aprindine	Approved
T39610	DRUGINFO	D01UJL	N-Trimethyllysine	Investigative
T39610	DRUGINFO	DW56QV	Calmidazolium	Investigative
T39610	DRUGINFO	D0Q7LD	2-Methyl-2-Propanol	Investigative
T39610	DRUGINFO	D09TVP	Cacodylate Ion	Investigative
T39610	DRUGINFO	D08OBF	MYRISTIC ACID	Investigative
T39610	DRUGINFO	D06GOK	2-Methyl-2,4-Pentanediol	Investigative
T39610	DRUGINFO	D0F2ME	Acetate Ion	Investigative

T73726	TARGETID	T73726
T73726	FORMERID	TTDS00359
T73726	UNIPROID	CP51_CANAL
T73726	TARGNAME	Candida Cytochrome P450 51 (Candi ERG11)
T73726	GENENAME	Candi ERG11
T73726	TARGTYPE	Successful
T73726	SYNONYMS	Sterol 14alpha-demethylase; Sterol 14-alpha demethylase; P450LI; P450L1; P450-14DM; Lanosterol 14 alpha-demethylase; LDM; Erg11p; ERG11; Cytochrome P450-dependent lanosterol 14-demethylase; Cytochrome P-450 lanosterol 14-alpha-demethylase; Cyt P450 14DM; CYPLI; CYPL1
T73726	FUNCTION	Catalyzes C14-demethylation of lanosterol which is critical for ergosterol biosynthesis. It transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol.
T73726	PDBSTRUC	5V5Z; 5TZ1; 5FSA
T73726	BIOCLASS	Paired donor oxygen oxidoreductase
T73726	SEQUENCE	MAIVETVIDGINYFLSLSVTQQISILLGVPFVYNLVWQYLYSLRKDRAPLVFYWIPWFGSAASYGQQPYEFFESCRQKYGDVFSFMLLGKIMTVYLGPKGHEFVFNAKLSDVSAEDAYKHLTTPVFGKGVIYDCPNSRLMEQKKFAKFALTTDSFKRYVPKIREEILNYFVTDESFKLKEKTHGVANVMKTQPEITIFTASRSLFGDEMRRIFDRSFAQLYSDLDKGFTPINFVFPNLPLPHYWRRDAAQKKISATYMKEIKSRRERGDIDPNRDLIDSLLIHSTYKDGVKMTDQEIANLLIGILMGGQHTSASTSAWFLLHLGEKPHLQDVIYQEVVELLKEKGGDLNDLTYEDLQKLPSVNNTIKETLRMHMPLHSIFRKVTNPLRIPETNYIVPKGHYVLVSPGYAHTSERYFDNPEDFDPTRWDTAAAKANSVSFNSSDEVDYGFGKVSKGVSSPYLPFGGGRHRCIGEQFAYVQLGTILTTFVYNLRWTIDGYKVPDPDYSSMVVLPTEPAEIIWEKRETCMF
T73726	DRUGINFO	D00AXJ	Miconazole	Approved
T73726	DRUGINFO	D01AQT	Terconazole	Approved
T73726	DRUGINFO	D04GYO	Oxiconazole	Approved
T73726	DRUGINFO	D07ABV	Posaconazole	Approved
T73726	DRUGINFO	D09LNI	Fluconazole	Approved
T73726	DRUGINFO	D0AA2D	Bifonazole	Approved
T73726	DRUGINFO	D0B4IF	Ketoconazole	Approved
T73726	DRUGINFO	D0CA6J	Tioconazole	Approved
T73726	DRUGINFO	D0EV8E	Econazole	Approved
T73726	DRUGINFO	D0G4BI	Efinaconazole	Approved
T73726	DRUGINFO	D0N3SP	Butoconazole	Approved
T73726	DRUGINFO	D0N3VR	Voriconazole	Approved
T73726	DRUGINFO	D0O6UZ	Sertaconazole	Approved
T73726	DRUGINFO	D0U4XJ	Luliconazole	Approved
T73726	DRUGINFO	DM8BN1	Oteseconazole	Approved
T73726	DRUGINFO	D0V4IB	Itraconazole	Approved
T73726	DRUGINFO	D07QKK	CHLORIDE	Phase 3
T73726	DRUGINFO	D01ZBF	E-1224	Phase 2
T73726	DRUGINFO	D0J1CL	EcoNail	Phase 2
T73726	DRUGINFO	D0Y2HA	Pramiconazole	Phase 2
T73726	DRUGINFO	D05QIU	Embeconazole	Phase 1
T73726	DRUGINFO	D0CE8J	Genaconazole	Phase 1
T73726	DRUGINFO	DUAI04	VT-1598	Phase 1
T73726	DRUGINFO	D08MTG	Abafungin	Discontinued in Phase 3
T73726	DRUGINFO	D0SX7F	AZALANSTAT	Discontinued in Phase 2
T73726	DRUGINFO	D00UMG	ANALOGUE A	Investigative
T73726	DRUGINFO	D0S0AN	CP-320626	Investigative
T73726	DRUGINFO	D02RTS	citric acid	Investigative

T85529	TARGETID	T85529
T85529	FORMERID	TTDC00208
T85529	UNIPROID	CD28_HUMAN
T85529	TARGNAME	T-cell-specific surface glycoprotein CD28 (CD28)
T85529	GENENAME	CD28
T85529	TARGTYPE	Successful
T85529	SYNONYMS	TP44; CD28-S2
T85529	FUNCTION	Enhances the production of IL4 and IL10 in T-cells in conjunction with TCR/CD3 ligation and CD40L costimulation. Isoform 3 enhances CD40L-mediated activation of NF-kappa-B and kinases MAPK8 and PAK2 in T-cells. Involved in T-cell activation, the induction of cell proliferation and cytokine production and promotion of T-cell survival.
T85529	PDBSTRUC	5GJI; 5GJH; 5AUL; 3WA4; 1YJD
T85529	SEQUENCE	MLRLLLALNLFPSIQVTGNKILVKQSPMLVAYDNAVNLSCKYSYNLFSREFRASLHKGLDSAVEVCVVYGNYSQQLQVYSKTGFNCDGKLGNESVTFYLQNLYVNQTDIYFCKIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS
T85529	DRUGINFO	D0N4HB	Belatacept	Approved
T85529	DRUGINFO	D04HQJ	AB-103	Phase 3
T85529	DRUGINFO	D0GB5X	Lulizumab pegol	Phase 2
T85529	DRUGINFO	D0T9JW	AU101	Phase 1/2
T85529	DRUGINFO	D8UZM7	REGN5678	Phase 1/2
T85529	DRUGINFO	DT1R9E	REGN5668	Phase 1/2
T85529	DRUGINFO	D0JY0M	CD28 and CD137 CAR-T Cells	Phase 1
T85529	DRUGINFO	D0QE4F	CD19-CAR and CD28-CAR T Cells	Phase 1
T85529	DRUGINFO	D0ZX6F	RG6333	Phase 1
T85529	DRUGINFO	DZD4R6	RO7443904	Phase 1
T85529	DRUGINFO	DBP9Q5	SAR442257	Phase 1
T85529	DRUGINFO	DL6F3E	SAR443216	Phase 1
T85529	DRUGINFO	D00PNU	TGN-1412	Discontinued in Phase 1
T85529	DRUGINFO	D0A2MA	FR-104	Investigative
T85529	DRUGINFO	D0V9LF	Anti-CD28	Investigative

T96144	TARGETID	T96144
T96144	FORMERID	TTDS00080
T96144	UNIPROID	TOP2A_HUMAN; TOP2B_HUMAN
T96144	TARGNAME	DNA topoisomerase II (TOP2)
T96144	GENENAME	TOP2A; TOP2B
T96144	TARGTYPE	Successful
T96144	SYNONYMS	TOP2; DNA topoisomerase 2
T96144	FUNCTION	Cut both strands of the DNA helix simultaneously in order to manage DNA tangles and supercoils.
T96144	BIOCLASS	ATP-hydrolyzing DNA topoisomerase
T96144	SEQUENCE	MEVSPLQPVNENMQVNKIKKNEDAKKRLSVERIYQKKTQLEHILLRPDTYIGSVELVTQQMWVYDEDVGINYREVTFVPGLYKIFDEILVNAADNKQRDPKMSCIRVTIDPENNLISIWNNGKGIPVVEHKVEKMYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKLCNIFSTKFTVETASREYKKMFKQTWMDNMGRAGEMELKPFNGEDYTCITFQPDLSKFKMQSLDKDIVALMVRRAYDIAGSTKDVKVFLNGNKLPVKGFRSYVDMYLKDKLDETGNSLKVIHEQVNHRWEVCLTMSEKGFQQISFVNSIATSKGGRHVDYVADQIVTKLVDVVKKKNKGGVAVKAHQVKNHMWIFVNALIENPTFDSQTKENMTLQPKSFGSTCQLSEKFIKAAIGCGIVESILNWVKFKAQVQLNKKCSAVKHNRIKGIPKLDDANDAGGRNSTECTLILTEGDSAKTLAVSGLGVVGRDKYGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYKKNYEDEDSLKTLRYGKIMIMTDQDQDGSHIKGLLINFIHHNWPSLLRHRFLEEFITPIVKVSKNKQEMAFYSLPEFEEWKSSTPNHKKWKVKYYKGLGTSTSKEAKEYFADMKRHRIQFKYSGPEDDAAISLAFSKKQIDDRKEWLTNFMEDRRQRKLLGLPEDYLYGQTTTYLTYNDFINKELILFSNSDNERSIPSMVDGLKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSSYHHGEMSLMMTIINLAQNFVGSNNLNLLQPIGQFGTRLHGGKDSASPRYIFTMLSSLARLLFPPKDDHTLKFLYDDNQRVEPEWYIPIIPMVLINGAEGIGTGWSCKIPNFDVREIVNNIRRLMDGEEPLPMLPSYKNFKGTIEELAPNQYVISGEVAILNSTTIEISELPVRTWTQTYKEQVLEPMLNGTEKTPPLITDYREYHTDTTVKFVVKMTEEKLAEAERVGLHKVFKLQTSLTCNSMVLFDHVGCLKKYDTVLDILRDFFELRLKYYGLRKEWLLGMLGAESAKLNNQARFILEKIDGKIIIENKPKKELIKVLIQRGYDSDPVKAWKEAQQKVPDEEENEESDNEKETEKSDSVTDSGPTFNYLLDMPLWYLTKEKKDELCRLRNEKEQELDTLKRKSPSDLWKEDLATFIEELEAVEAKEKQDEQVGLPGKGGKAKGKKTQMAEVLPSPRGQRVIPRITIEMKAEAEKKNKKKIKNENTEGSPQEDGVELEGLKQRLEKKQKREPGTKTKKQTTLAFKPIKKGKKRNPWSDSESDRSSDESNFDVPPRETEPRRAATKTKFTMDLDSDEDFSDFDEKTDDEDFVPSDASPPKTKTSPKLSNKELKPQKSVVSDLEADDVKGSVPLSSSPPATHFPDETEITNPVPKKNVTVKKTAAKSQSSTSTTGAKKRAAPKGTKRDPALNSGVSQKPDPAKTKNRRKRKPSTSDDSDSNFEKIVSKAVTSKKSKGESDDFHMDFDSAVAPRAKSVRAKKPIKYLEESDEDDLF
T96144	DRUGINFO	D01DBQ	Teniposide	Approved
T96144	DRUGINFO	D01UBX	Aclarubicin	Approved
T96144	DRUGINFO	D01XDL	Idarubicin	Approved
T96144	DRUGINFO	D02KOF	Lomefloxacin	Approved
T96144	DRUGINFO	D03KPZ	Ciprofloxacin+dexamethasone	Approved
T96144	DRUGINFO	D04NXQ	Pefloxacin	Approved
T96144	DRUGINFO	D06GAM	Fleroxacin	Approved
T96144	DRUGINFO	D07CPU	Rosoxacin	Approved
T96144	DRUGINFO	D07IPB	Valrubicin	Approved
T96144	DRUGINFO	D07JGT	Nalidixic Acid	Approved
T96144	DRUGINFO	D07UXP	Cinoxacin	Approved
T96144	DRUGINFO	D08FPM	Dhaq diacetate	Approved
T96144	DRUGINFO	D09OZC	Lucanthone	Approved
T96144	DRUGINFO	D0B7EB	Etoposide	Approved
T96144	DRUGINFO	D0C9XJ	Epirubicin	Approved
T96144	DRUGINFO	D0D4HN	Podofilox	Approved
T96144	DRUGINFO	D0G9YH	Amsacrine	Approved
T96144	DRUGINFO	D0Q0PR	Novobiocin	Approved
T96144	DRUGINFO	D0R3JB	Mitoxantrone	Approved
T96144	DRUGINFO	D0R8ER	Enoxacin	Approved
T96144	DRUGINFO	D0Z3EI	Quinolones	Approved
T96144	DRUGINFO	D07VLY	Doxorubicin	Approved
T96144	DRUGINFO	D07XVN	Dexrazoxane	Approved
T96144	DRUGINFO	D00NVM	SNS-595	Phase 3
T96144	DRUGINFO	D09XQU	Tirapazamine	Phase 3
T96144	DRUGINFO	D0C3CZ	Aldoxorubicin	Phase 3
T96144	DRUGINFO	D0Q4OW	Pixantrone	Phase 3
T96144	DRUGINFO	D0R9US	GSK2140944	Phase 3
T96144	DRUGINFO	D0W9AI	MTC-DOX	Phase 2/3
T96144	DRUGINFO	D01UGG	Sabarubicin	Phase 2
T96144	DRUGINFO	D03AZR	Berubicin	Phase 2
T96144	DRUGINFO	D03FVS	Salvicine	Phase 2
T96144	DRUGINFO	D07QIT	GPX-150D	Phase 2
T96144	DRUGINFO	D0E3EY	Elsamitrucin	Phase 2
T96144	DRUGINFO	D0L5MF	PYRAZOLOACRIDINE	Phase 2
T96144	DRUGINFO	D0M2WQ	CAP-7.1	Phase 2
T96144	DRUGINFO	D0M5CD	Doxorubicin-eluting beads	Phase 2
T96144	DRUGINFO	D08EES	XR-5000	Phase 2
T96144	DRUGINFO	D0NS8T	13-DEOXYADRIAMYCIN HYDROCHLORIDE	Phase 2
T96144	DRUGINFO	D04BSV	L-377202	Phase 1/2
T96144	DRUGINFO	D05BIN	F-14512	Phase 1/2
T96144	DRUGINFO	D03OFN	NK-314	Phase 1
T96144	DRUGINFO	D0E2LA	TAS-103	Phase 1
T96144	DRUGINFO	D0GV0Q	BMY-43748	Phase 1
T96144	DRUGINFO	D0Q5TH	XR-5944	Phase 1
T96144	DRUGINFO	D00MAN	GRC-6211	Phase 1
T96144	DRUGINFO	D07BXE	Daniquidone	Phase 1
T96144	DRUGINFO	D07DAU	Tafluposide	Phase 1
T96144	DRUGINFO	D0F3PU	Iboctadekin + Doxil	Phase 1
T96144	DRUGINFO	D0VO7R	AjvW2	Phase 1
T96144	DRUGINFO	D0Y1GJ	MLN-576	Phase 1
T96144	DRUGINFO	D00VZF	Merbarone	Discontinued in Phase 2
T96144	DRUGINFO	D01ORM	Mitonafide	Discontinued in Phase 2
T96144	DRUGINFO	D03WPI	NC-190	Discontinued in Phase 2
T96144	DRUGINFO	D04MRV	Amifloxacin	Discontinued in Phase 2
T96144	DRUGINFO	D04ZLJ	LOSOXANTRONE	Discontinued in Phase 2
T96144	DRUGINFO	D07BKL	KW-2170	Discontinued in Phase 2
T96144	DRUGINFO	D07HTX	GL-331	Discontinued in Phase 2
T96144	DRUGINFO	D07VPG	BW-773U82	Discontinued in Phase 2
T96144	DRUGINFO	D09WRI	ELINAFIDE MESILATE	Discontinued in Phase 2
T96144	DRUGINFO	D0T3CE	SUPER-LEU-DOX	Discontinued in Phase 2
T96144	DRUGINFO	D00PIE	Banoxantrone	Discontinued in Phase 1
T96144	DRUGINFO	D0B7CZ	Teloxantrone	Discontinued in Phase 1
T96144	DRUGINFO	D0H5NX	TOP-53	Discontinued in Phase 1
T96144	DRUGINFO	D0K2CR	Nemorubicin	Preclinical
T96144	DRUGINFO	D03RQI	ER-37328	Terminated
T96144	DRUGINFO	D04OKJ	Garenoxacin	Terminated
T96144	DRUGINFO	D08IHF	A-74932	Terminated
T96144	DRUGINFO	D0H1YE	BE-22179	Terminated
T96144	DRUGINFO	D0FZ1Z	Doxorubicin-CEA conjugate	Terminated
T96144	DRUGINFO	D0Q1RC	A-62176	Terminated
T96144	DRUGINFO	D0T7WQ	Datelliptium chloride	Terminated
T96144	DRUGINFO	D00DNY	Ellipticine	Investigative
T96144	DRUGINFO	D00FIE	2-(2-Hydroxyethyl)anthra[1,9-cd]pyrazol-6(2H)-one	Investigative
T96144	DRUGINFO	D01QCJ	4,4'-(4-phenylpyridine-2,6-diyl)diphenol	Investigative
T96144	DRUGINFO	D01VDB	Howiinol A (GHM-10)	Investigative
T96144	DRUGINFO	D02GSX	2-(2-Aminoethyl)anthra[1,9-cd]pyrazol-6(2H)-one	Investigative
T96144	DRUGINFO	D02NCW	Olean-12-en-3beta,15alpha-diol	Investigative
T96144	DRUGINFO	D02PDP	3-(2,6-diphenylpyridin-4-yl)phenol	Investigative
T96144	DRUGINFO	D03CVY	4-(furan-3-yl)-2,6-di(thiophen-2-yl)pyridine	Investigative
T96144	DRUGINFO	D03NXV	Ametantrone	Investigative
T96144	DRUGINFO	D03YCW	4'-Demethyl-epipodophyllotoxin	Investigative
T96144	DRUGINFO	D05HUX	ICRF-154	Investigative
T96144	DRUGINFO	D06KOJ	1,3,7-trihydroxyacridone	Investigative
T96144	DRUGINFO	D08NFP	3-(6-(furan-2-yl)-4-phenylpyridin-2-yl)-phenol	Investigative
T96144	DRUGINFO	D08YKN	3-(2-phenyl-6-(thiophen-2-yl)pyridin-4-yl)-phenol	Investigative
T96144	DRUGINFO	D0C9BH	Clorobiocin	Investigative
T96144	DRUGINFO	D0DS0O	1-Methoxy-3-(oxiran-2-ylmethoxy)-9H-xanthen-9-one	Investigative
T96144	DRUGINFO	D0I0HL	DEMETHYLZEYLASTERONE	Investigative
T96144	DRUGINFO	D0J8ZH	4'-Demethyl-4beta-amino-4-desoxypodophyllotoxin	Investigative
T96144	DRUGINFO	D0O2CH	Makaluvamine N	Investigative
T96144	DRUGINFO	D0P0UM	7-chloro-1,3-dihydroxyacridone	Investigative
T96144	DRUGINFO	D0RA6H	LUPEOL	Investigative
T96144	DRUGINFO	D0V2KV	3-(2-phenyl-6-(thiophen-3-yl)pyridin-4-yl)-phenol	Investigative
T96144	DRUGINFO	D00WYS	3-(4-phenyl-6-(thiophen-2-yl)pyridin-2-yl)-phenol	Investigative
T96144	DRUGINFO	D03JZQ	3-(4-phenyl-6-(thiophen-3-yl)pyridin-2-yl)-phenol	Investigative
T96144	DRUGINFO	D04ACC	doxorubicin-peptide-PEG conjugate	Investigative
T96144	DRUGINFO	D0K4QL	doxorubicin-LL2 conjugate	Investigative
T96144	DRUGINFO	D0MI5C	3,3'-(4-phenylpyridine-2,6-diyl)diphenol	Investigative
T96144	DRUGINFO	D0V6EY	Pumiliotoxin 251D	Investigative
T96144	DRUGINFO	D0L8BN	TOPOSTATIN	Investigative
T96144	DRUGINFO	D00ICA	AMP-PNP	Investigative

T19244	TARGETID	T19244
T19244	UNIPROID	CP2C9_HUMAN
T19244	TARGNAME	S-mephenytoin 4-hydroxylase (CYP2C9)
T19244	GENENAME	CYP2C9
T19244	TARGTYPE	Successful
T19244	SYNONYMS	Cytochrome P450 PB-1; Cytochrome P450 MP-8; Cytochrome P450 MP-4; Cytochrome P450 2C9; Cytochrome P-450MP; Cholesterol 25-hydroxylase; CYPIIC9; CYP2C10; (S)-limonene 7-monooxygenase; (S)-limonene 6-monooxygenase; (R)-limonene 6-monooxygenase
T19244	FUNCTION	In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan. Cytochromes P450 are a group of heme-thiolate monooxygenases.
T19244	PDBSTRUC	5XXI; 5X24; 5X23; 5W0C; 5K7K
T19244	BIOCLASS	Paired donor oxygen oxidoreductase
T19244	ECNUMBER	EC 1.14.14.-
T19244	SEQUENCE	MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKVYGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKWKEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICSIIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFMKSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTETTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYIDLLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFKKSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVPPFYQLCFIPV
T19244	DRUGINFO	D0A4YE	Sulfaphenazole	Approved

T27999	TARGETID	T27999
T27999	FORMERID	TTDR00859
T27999	UNIPROID	PAG_BACAN
T27999	TARGNAME	Bacterial Protective antigen (Bact pagA)
T27999	GENENAME	Bact pagA
T27999	TARGTYPE	Successful
T27999	SYNONYMS	pagA; PA of Bacillus anthracis; Bacterial toxins translocating protein; Bacterial anthracis protective antigen; Bact PA83; Bact PA-83
T27999	FUNCTION	One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death wheninjected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.
T27999	PDBSTRUC	5FR3; 4NAM; 4H2A; 4EE2; 3TEZ
T27999	BIOCLASS	Bacillus anthracis protective antigen
T27999	SEQUENCE	MKKRKVLIPLMALSTILVSSTGNLEVIQAEVKQENRLLNESESSSQGLLGYYFSDLNFQAPMVVTSSTTGDLSIPSSELENIPSENQYFQSAIWSGFIKVKKSDEYTFATSADNHVTMWVDDQEVINKASNSNKIRLEKGRLYQIKIQYQRENPTEKGLDFKLYWTDSQNKKEVISSDNLQLPELKQKSSNSRKKRSTSAGPTVPDRDNDGIPDSLEVEGYTVDVKNKRTFLSPWISNIHEKKGLTKYKSSPEKWSTASDPYSDFEKVTGRIDKNVSPEARHPLVAAYPIVHVDMENIILSKNEDQSTQNTDSQTRTISKNTSTSRTHTSEVHGNAEVHASFFDIGGSVSAGFSNSNSSTVAIDHSLSLAGERTWAETMGLNTADTARLNANIRYVNTGTAPIYNVLPTTSLVLGKNQTLATIKAKENQLSQILAPNNYYPSKNLAPIALNAQDDFSSTPITMNYNQFLELEKTKQLRLDTDQVYGNIATYNFENGRVRVDTGSNWSEVLPQIQETTARIIFNGKDLNLVERRIAAVNPSDPLETTKPDMTLKEALKIAFGFNEPNGNLQYQGKDITEFDFNFDQQTSQNIKNQLAELNATNIYTVLDKIKLNAKMNILIRDKRFHYDRNNIAVGADESVVKEAHREVINSSTEGLLLNIDKDIRKILSGYIVEIEDTEGLKEVINDRYDMLNISSLRQDGKTFIDFKKYNDKLPLYISNPNYKVNVYAVTKENTIINPSENGDTSTNGIKKILIFSKKGYEIG
T27999	DRUGINFO	D02JYA	Raxibacumab	Approved
T27999	DRUGINFO	D06FPF	Valortim	Phase 1
T27999	DRUGINFO	D0L8OP	AVP-21D9	Phase 1
T27999	DRUGINFO	D09SZY	IQ-DAA	Phase 1
T27999	DRUGINFO	D07TRV	Anthrax vaccine	Discontinued in Phase 1

T97621	TARGETID	T97621
T97621	UNIPROID	CFTR_HUMAN
T97621	TARGNAME	cAMP-dependent chloride channel F508 deletion (CFTR del F508)
T97621	GENENAME	CFTR
T97621	TARGTYPE	Successful
T97621	SYNONYMS	cAMP-dependent chloride channel (del F508); Cystic fibrosis transmembrane conductance regulator (del F508); Channel conductance-controlling ATPase; CFTR; ATP-binding cassette sub-family C member 7 (del F508); ABCC7 (del F508)
T97621	FUNCTION	Epithelial ion channel that plays an important role in the regulation of epithelial ion and water transport and fluid homeostasis. Mediates the transport of chloride ions across the cell membrane. Channel activity is coupled to ATP hydrolysis. The ion channel is also permeable to HCO(3-); selectivity depends on the extracellular chloride concentration. Exerts its function also by modulating the activity of other ion channels and transporters. Plays an important role in airway fluid homeostasis. Contributes to the regulation of the pH and the ion content of the airway surface fluid layer and thereby plays an important role in defense against pathogens. Modulates the activity of the epithelial sodium channel (ENaC) complex, in part by regulating the cell surface expression of the ENaC complex. Inhibits the activity of the ENaC channel containing subunits SCNN1A, SCNN1B and SCNN1G. Inhibits the activity of the ENaC channel containing subunits SCNN1D, SCNN1B and SCNN1G, but not of the ENaC channel containing subunits SCNN1A, SCNN1B and SCNN1G. May regulate bicarbonate secretion and salvage in epithelial cells by regulating the transporter SLC4A7. Can inhibit the chloride channel activity of ANO1. Plays a role in the chloride and bicarbonate homeostasis during sperm epididymal maturation and capacitation.
T97621	PDBSTRUC	6MSM; 6HEP; 5UAK; 5TGK; 5TFJ
T97621	BIOCLASS	ABC transporter
T97621	ECNUMBER	EC 5.6.1.6
T97621	SEQUENCE	MQRSPLEKASVVSKLFFSWTRPILRKGYRQRLELSDIYQIPSVDSADNLSEKLEREWDRELASKKNPKLINALRRCFFWRFMFYGIFLYLGEVTKAVQPLLLGRIIASYDPDNKEERSIAIYLGIGLCLLFIVRTLLLHPAIFGLHHIGMQMRIAMFSLIYKKTLKLSSRVLDKISIGQLVSLLSNNLNKFDEGLALAHFVWIAPLQVALLMGLIWELLQASAFCGLGFLIVLALFQAGLGRMMMKYRDQRAGKISERLVITSEMIENIQSVKAYCWEEAMEKMIENLRQTELKLTRKAAYVRYFNSSAFFFSGFFVVFLSVLPYALIKGIILRKIFTTISFCIVLRMAVTRQFPWAVQTWYDSLGAINKIQDFLQKQEYKTLEYNLTTTEVVMENVTAFWEEGFGELFEKAKQNNNNRKTSNGDDSLFFSNFSLLGTPVLKDINFKIERGQLLAVAGSTGAGKTSLLMVIMGELEPSEGKIKHSGRISFCSQFSWIMPGTIKENIIFGVSYDEYRYRSVIKACQLEEDISKFAEKDNIVLGEGGITLSGGQRARISLARAVYKDADLYLLDSPFGYLDVLTEKEIFESCVCKLMANKTRILVTSKMEHLKKADKILILHEGSSYFYGTFSELQNLQPDFSSKLMGCDSFDQFSAERRNSILTETLHRFSLEGDAPVSWTETKKQSFKQTGEFGEKRKNSILNPINSIRKFSIVQKTPLQMNGIEEDSDEPLERRLSLVPDSEQGEAILPRISVISTGPTLQARRRQSVLNLMTHSVNQGQNIHRKTTASTRKVSLAPQANLTELDIYSRRLSQETGLEISEEINEEDLKECFFDDMESIPAVTTWNTYLRYITVHKSLIFVLIWCLVIFLAEVAASLVVLWLLGNTPLQDKGNSTHSRNNSYAVIITSTSSYYVFYIYVGVADTLLAMGFFRGLPLVHTLITVSKILHHKMLHSVLQAPMSTLNTLKAGGILNRFSKDIAILDDLLPLTIFDFIQLLLIVIGAIAVVAVLQPYIFVATVPVIVAFIMLRAYFLQTSQQLKQLESEGRSPIFTHLVTSLKGLWTLRAFGRQPYFETLFHKALNLHTANWFLYLSTLRWFQMRIEMIFVIFFIAVTFISILTTGEGEGRVGIILTLAMNIMSTLQWAVNSSIDVDSLMRSVSRVFKFIDMPTEGKPTKSTKPYKNGQLSKVMIIENSHVKKDDIWPSGGQMTVKDLTAKYTEGGNAILENISFSISPGQRVGLLGRTGSGKSTLLSAFLRLLNTEGEIQIDGVSWDSITLQQWRKAFGVIPQKVFIFSGTFRKNLDPYEQWSDQEIWKVADEVGLRSVIEQFPGKLDFVLVDGGCVLSHGHKQLMCLARSVLSKAKILLLDEPSAHLDPVTYQIIRRTLKQAFADCTVILCEHRIEAMLECQQFLVIEENKVRQYDSIQKLLNERSLFRQAISPSDRVKLFPHRNSSKCKSKPQIAALKEETEEEVQDTRL
T97621	DRUGINFO	D0S9WB	Lumacaftor + ivacaftor	Approved

T02119	TARGETID	T02119
T02119	FORMERID	TTDI02288
T02119	UNIPROID	ARSB_HUMAN
T02119	TARGNAME	N-acetylgalactosamine-4-sulfatase (G4S)
T02119	GENENAME	ARSB
T02119	TARGTYPE	Successful
T02119	SYNONYMS	Nacetylgalactosamine4sulfatase; G4S; ASB; ARSB
T02119	FUNCTION	Removes sulfate groups from chondroitin-4-sulfate (C4S) and regulates its degradation (PubMed:19306108). Involved in the regulation of cell adhesion, cell migration and invasion in colonic epithelium (PubMed:19306108). In the central nervous system, is a regulator of neurite outgrowth and neuronal plasticity, acting through the control of sulfate glycosaminoglycans and neurocan levels.
T02119	PDBSTRUC	1FSU
T02119	BIOCLASS	Sulfuric ester hydrolase
T02119	ECNUMBER	EC 3.1.6.12
T02119	SEQUENCE	MGPRGAASLPRGPGPRRLLLPVVLPLLLLLLLAPPGSGAGASRPPHLVFLLADDLGWNDVGFHGSRIRTPHLDALAAGGVLLDNYYTQPLCTPSRSQLLTGRYQIRTGLQHQIIWPCQPSCVPLDEKLLPQLLKEAGYTTHMVGKWHLGMYRKECLPTRRGFDTYFGYLLGSEDYYSHERCTLIDALNVTRCALDFRDGEEVATGYKNMYSTNIFTKRAIALITNHPPEKPLFLYLALQSVHEPLQVPEEYLKPYDFIQDKNRHHYAGMVSLMDEAVGNVTAALKSSGLWNNTVFIFSTDNGGQTLAGGNNWPLRGRKWSLWEGGVRGVGFVASPLLKQKGVKNRELIHISDWLPTLVKLARGHTNGTKPLDGFDVWKTISEGSPSPRIELLHNIDPNFVDSSPCPRNSMAPAKDDSSLPEYSAFNTSVHAAIRHGNWKLLTGYPGCGYWFPPPSQYNVSEIPSSDPPTKTLWLFDIDRDPEERHDLSREYPHIVTKLLSRLQFYHKHSVPVYFPAQDPRCDPKATGVWGPWM
T02119	DRUGINFO	D05UHF	Galsulfase	Approved

T28869	TARGETID	T28869
T28869	FORMERID	TTDS00479
T28869	UNIPROID	URE1_KLEAE
T28869	TARGNAME	Bacterial Urease (Bact ureC)
T28869	GENENAME	Bact ureC
T28869	TARGTYPE	Successful
T28869	SYNONYMS	Urease subunit alpha; Urea amidohydrolase subunit alpha
T28869	FUNCTION	Catalyzes the hydrolysis of urea, leading to the production of carbon dioxide and ammonia. Allows many soil bacteria to use urea as a nitrogen source. An important virulence factor that improves survival of pathogenic bacteria under acidic conditions within the host and can also cause direct damage to the host tissue due to ammonia, CO2 or alkali production.
T28869	PDBSTRUC	4EPE; 4EPD; 4EPB; 4EP8; 2KAU
T28869	BIOCLASS	Carbon-nitrogen hydrolase
T28869	SEQUENCE	MSNISRQAYADMFGPTVGDKVRLADTELWIEVEDDLTTYGEEVKFGGGKVIRDGMGQGQMLAADCVDLVLTNALIVDHWGIVKADIGVKDGRIFAIGKAGNPDIQPNVTIPIGAATEVIAAEGKIVTAGGIDTHIHWICPQQAEEALVSGVTTMVGGGTGPAAGTHATTCTPGPWYISRMLQAADSLPVNIGLLGKGNVSQPDALREQVAAGVIGLKIHEDWGATPAAIDCALTVADEMDIQVALHSDTLNESGFVEDTLAAIGGRTIHTFHTEGAGGGHAPDIITACAHPNILPSSTNPTLPYTLNTIDEHLDMLMVCHHLDPDIAEDVAFAESRIRRETIAAEDVLHDLGAFSLTSSDSQAMGRVGEVILRTWQVAHRMKVQRGALAEETGDNDNFRVKRYIAKYTINPALTHGIAHEVGSIEVGKLADLVVWSPAFFGVKPATVIKGGMIAIAPMGDINASIPTPQPVHYRPMFGALGSARHHCRLTFLSQAAAANGVAERLNLRSAIAVVKGCRTVQKADMVHNSLQPNITVDAQTYEVRVDGELITSEPADVLPMAQRYFLF
T28869	DRUGINFO	D0R9BG	Acetohydroxamic Acid	Approved
T28869	DRUGINFO	D03NMB	3-(4-bromobenzyl)-1,1-dimethylselenourea	Investigative
T28869	DRUGINFO	D03PVM	1-cyclohexyl-1-isopropyl-3,3-dimethylselenourea	Investigative
T28869	DRUGINFO	D06KWQ	3-dodecyl-1,1-dimethylthiourea	Investigative
T28869	DRUGINFO	D09YRL	N-glycylglycinehydroxamic acid	Investigative
T28869	DRUGINFO	D0RL0F	3-(4-bromophenyl)-1,1-dimethylthiourea	Investigative

T27265	TARGETID	T27265
T27265	FORMERID	TTDS00240
T27265	UNIPROID	S5A1_HUMAN; S5A2_HUMAN; PORED_HUMAN
T27265	TARGNAME	Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)
T27265	GENENAME	SRD5A1; SRD5A2; SRD5A3
T27265	TARGTYPE	Successful
T27265	SYNONYMS	Steroid 5-alpha-reductase; SR; S5AR; 3-oxo-5-alpha-steroid 4-dehydrogenase
T27265	FUNCTION	Converts testosterone into 5-alpha-dihydrotestosterone and progesterone or corticosterone into their corresponding 5-alpha-3-oxosteroids. It plays a central role in sexual differentiation and androgen physiology.
T27265	BIOCLASS	CH-CH donor oxidoreductase
T27265	SEQUENCE	MATATGVAEERLLAALAYLQCAVGCAVFARNRQTNSVYGRHALPSHRLRVPARAAWVVQELPSLALPLYQYASESAPRLRSAPNCILLAMFLVHYGHRCLIYPFLMRGGKPMPLLACTMAIMFCTCNGYLQSRYLSHCAVYADDWVTDPRFLIGFGLWLTGMLINIHSDHILRNLRKPGDTGYKIPRGGLFEYVTAANYFGEIMEWCGYALASWSVQGAAFAFFTFCFLSGRAKEHHEWYLRKFEEYPKFRKIIIPFLF
T27265	DRUGINFO	D03DXN	Polyestradiol Phosphate	Approved
T27265	DRUGINFO	D0A9YA	Dutasteride	Approved
T27265	DRUGINFO	D0E4WR	Azelaic Acid	Approved
T27265	DRUGINFO	D08IWD	Finasteride	Approved
T27265	DRUGINFO	D02KRI	Epristeride	Phase 3
T27265	DRUGINFO	D09JFY	Dutasteride + tamsulosin	Phase 3
T27265	DRUGINFO	D0J3CT	FK-143	Phase 2
T27265	DRUGINFO	D0S3XE	Turosteride	Phase 2
T27265	DRUGINFO	D07BXC	IZONSTERIDE	Phase 1/2
T27265	DRUGINFO	D08JCL	ONO-3805	Discontinued in Phase 3
T27265	DRUGINFO	D06AVN	CS-891B	Discontinued in Phase 2
T27265	DRUGINFO	D06AGD	MK-0963	Discontinued in Phase 1
T27265	DRUGINFO	D07UOS	MK-434	Discontinued in Phase 1
T27265	DRUGINFO	D0O8SY	GI-197111	Terminated

T97174	TARGETID	T97174
T97174	FORMERID	TTDS00481
T97174	UNIPROID	MPRD_HUMAN
T97174	TARGNAME	Mannose-6-phosphate receptor (M6PR)
T97174	GENENAME	M6PR
T97174	TARGTYPE	Successful
T97174	SYNONYMS	MPRD; MPR46; MPR 46; Cation-dependent mannose-6-phosphate receptor; CDMan-6-P receptor; CD-MPR; CD Man-6-P receptor; 46kDa mannose 6-phosphate receptor; 46 kDa mannose 6-phosphate receptor
T97174	FUNCTION	Lysosomal enzymes bearing phosphomannosyl residues bind specifically to mannose-6-phosphate receptors in the Golgi apparatus and the resulting receptor-ligand complex is transported to an acidic prelyosomal compartment where the low pH mediates the dissociation of the complex. Transport of phosphorylated lysosomal enzymes from the Golgi complex and the cell surface to lysosomes.
T97174	PDBSTRUC	1JUQ
T97174	BIOCLASS	Mannose 6-phosphate receptor
T97174	SEQUENCE	MFPFYSCWRTGLLLLLLAVAVRESWQTEEKTCDLVGEKGKESEKELALVKRLKPLFNKSFESTVGQGSDTYIYIFRVCREAGNHTSGAGLVQINKSNGKETVVGRLNETHIFNGSNWIMLIYKGGDEYDNHCGKEQRRAVVMISCNRHTLADNFNPVSEERGKVQDCFYLFEMDSSLACSPEISHLSVGSILLVTFASLVAVYVVGGFLYQRLVVGAKGMEQFPHLAFWQDLGNLVADGCDFVCRSKPRNVPAAYRGVGDDQLGEESEERDDHLLPM
T97174	DRUGINFO	D07DUU	Alglucosidase alfa	Approved
T97174	DRUGINFO	D06WSW	1-3 Sugar Ring of Pentamannosyl 6-Phosphate	Investigative
T97174	DRUGINFO	D0Q0OH	Alpha-D-Mannose-6-Phosphate	Investigative

T03403	TARGETID	T03403
T03403	FORMERID	TTDS00039
T03403	UNIPROID	PGH1_HUMAN; PGH2_HUMAN
T03403	TARGNAME	Prostaglandin G/H synthase (COX)
T03403	GENENAME	PTGS1; PTGS2
T03403	TARGTYPE	Successful
T03403	SYNONYMS	Prostaglandin-endoperoxide synthase; Prostaglandin H2 synthase; PHS; PGHS; PGH synthase; Cyclooxygenase; COX
T03403	FUNCTION	Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. PTGS1 is involved in the constitutive production of prostanoids in particular in the stomach and platelets. It is a key step in the generation of prostaglandins in gastric epithelial cells  and the generation of thromboxane A2 (TXA2) in platelets. PTGS2 is constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, phenotypic changes, resistance to apoptosis and tumor angiogenesis.
T03403	BIOCLASS	Paired donor oxygen oxidoreductase
T03403	SEQUENCE	MSRSLLLWFLLFLLLLPPLPVLLADPGAPTPVNPCCYYPCQHQGICVRFGLDRYQCDCTRTGYSGPNCTIPGLWTWLRNSLRPSPSFTHFLLTHGRWFWEFVNATFIREMLMRLVLTVRSNLIPSPPTYNSAHDYISWESFSNVSYYTRILPSVPKDCPTPMGTKGKKQLPDAQLLARRFLLRRKFIPDPQGTNLMFAFFAQHFTHQFFKTSGKMGPGFTKALGHGVDLGHIYGDNLERQYQLRLFKDGKLKYQVLDGEMYPPSVEEAPVLMHYPRGIPPQSQMAVGQEVFGLLPGLMLYATLWLREHNRVCDLLKAEHPTWGDEQLFQTTRLILIGETIKIVIEEYVQQLSGYFLQLKFDPELLFGVQFQYRNRIAMEFNHLYHWHPLMPDSFKVGSQEYSYEQFLFNTSMLVDYGVEALVDAFSRQIAGRIGGGRNMDHHILHVAVDVIRESREMRLQPFNEYRKRFGMKPYTSFQELVGEKEMAAELEELYGDIDALEFYPGLLLEKCHPNSIFGESMIEIGAPFSLKGLLGNPICSPEYWKPSTFGGEVGFNIVKTATLKKLVCLNTKTCPYVSFRVPDASQDDGPAVERPSTEL
T03403	DRUGINFO	D00BDC	Morniflumate	Approved
T03403	DRUGINFO	D02IHW	Nepafenac	Approved
T03403	DRUGINFO	D03XYW	Fenoprofen	Approved
T03403	DRUGINFO	D06YPU	Dexibuprofen	Approved
T03403	DRUGINFO	D07OHO	Ampiroxicam	Approved
T03403	DRUGINFO	D08IFL	Meclofenamic acid	Approved
T03403	DRUGINFO	D0D9JW	Ketorolac	Approved
T03403	DRUGINFO	D0F3IP	Asasantin	Approved
T03403	DRUGINFO	D0G2MW	Icosapent	Approved
T03403	DRUGINFO	D0LR4B	Loxoprofen gel	Approved
T03403	DRUGINFO	D0M9DC	Oxaprozin	Approved
T03403	DRUGINFO	D0N3UL	Fosfosal	Approved
T03403	DRUGINFO	D0S5RZ	Amtolmetin guacil	Approved
T03403	DRUGINFO	D0T8VY	Aceclofenac	Approved
T03403	DRUGINFO	D0TG1H	Diclofenac	Approved
T03403	DRUGINFO	D0UL2L	Lornoxicam	Approved
T03403	DRUGINFO	D0X4JN	Pelubiprofen	Approved
T03403	DRUGINFO	D0Y7EM	Felbinac	Approved
T03403	DRUGINFO	D0GY5Z	Aspirin	Approved
T03403	DRUGINFO	D0U5QK	Acetaminophen	Approved
T03403	DRUGINFO	D0R4OI	K-103-IP	Phase 3
T03403	DRUGINFO	D0U5OU	Naproxcinod	Phase 3
T03403	DRUGINFO	D05OQX	NCX-4016	Phase 2
T03403	DRUGINFO	D0E8YH	NCX 1022	Phase 2
T03403	DRUGINFO	D0B6VN	TZI-41078	Phase 2
T03403	DRUGINFO	D0I8QS	BN82451	Phase 2
T03403	DRUGINFO	D0Q3QS	4-aminosalicylate sodium	Phase 1
T03403	DRUGINFO	D0Y4OI	SKF-105809	Phase 1
T03403	DRUGINFO	D0R6AB	Droxicam	Withdrawn from market
T03403	DRUGINFO	D0SU1G	Zomepirac	Withdrawn from market
T03403	DRUGINFO	D01IRW	Bermoprofen	Discontinued in Preregistration
T03403	DRUGINFO	D0E0JF	Pirazolac	Discontinued in Preregistration
T03403	DRUGINFO	D0S6GJ	KC-764	Discontinued in Phase 3
T03403	DRUGINFO	D03CFJ	NCX-701	Discontinued in Phase 2
T03403	DRUGINFO	D06FJO	Benzydamine	Discontinued in Phase 2
T03403	DRUGINFO	D0E2CZ	FS-205-397	Discontinued in Phase 2
T03403	DRUGINFO	D0L7OY	D-7193	Discontinued in Phase 2
T03403	DRUGINFO	D0X4IV	PSD-508	Discontinued in Phase 2
T03403	DRUGINFO	D0E8MW	D-1367	Discontinued in Phase 1
T03403	DRUGINFO	D0JF6O	Eltenac	Discontinued in Phase 1
T03403	DRUGINFO	D0O2EB	F-11105	Discontinued in Phase 1
T03403	DRUGINFO	D04SHO	NMI-1182	Terminated
T03403	DRUGINFO	D0M6JP	S-14080	Terminated
T03403	DRUGINFO	D0Y2MP	E-5110	Terminated
T03403	DRUGINFO	D0Y7BV	Florifenine	Terminated
T03403	DRUGINFO	D05BBQ	RP-66364	Terminated
T03403	DRUGINFO	D0H0IA	WY-28342	Terminated

T53381	TARGETID	T53381
T53381	FORMERID	TTDS00030
T53381	UNIPROID	ADA1D_HUMAN
T53381	TARGNAME	Adrenergic receptor alpha-1D (ADRA1D)
T53381	GENENAME	ADRA1D
T53381	TARGTYPE	Successful
T53381	SYNONYMS	Alpha-adrenergic receptor 1a; Alpha-1D adrenoreceptor; Alpha-1D adrenoceptor; Alpha-1D adrenergic receptor; Alpha adrenergic receptor 1a; Alpha 1D-adrenoreceptor; Alpha 1D-adrenoceptor; ADRA1A
T53381	FUNCTION	This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
T53381	BIOCLASS	GPCR rhodopsin
T53381	SEQUENCE	MTFRDLLSVSFEGPRPDSSAGGSSAGGGGGSAGGAAPSEGPAVGGVPGGAGGGGGVVGAGSGEDNRSSAGEPGSAGAGGDVNGTAAVGGLVVSAQGVGVGVFLAAFILMAVAGNLLVILSVACNRHLQTVTNYFIVNLAVADLLLSATVLPFSATMEVLGFWAFGRAFCDVWAAVDVLCCTASILSLCTISVDRYVGVRHSLKYPAIMTERKAAAILALLWVVALVVSVGPLLGWKEPVPPDERFCGITEEAGYAVFSSVCSFYLPMAVIVVMYCRVYVVARSTTRSLEAGVKRERGKASEVVLRIHCRGAATGADGAHGMRSAKGHTFRSSLSVRLLKFSREKKAAKTLAIVVGVFVLCWFPFFFVLPLGSLFPQLKPSEGVFKVIFWLGYFNSCVNPLIYPCSSREFKRAFLRLLRCQCRRRRRRRPLWRVYGHHWRASTSGLRQDCAPSSGDAPPGAPLALTALPDPDPEPPGTPEMQAPVASRRKPPSAFREWRLLGPFRRPTTQLRAKVSSLSHKIRAGGAQRAEAACAQRSEVEAVSLGVPHEVAEGATCQAYELADYSNLRETDI
T53381	DRUGINFO	D03MIR	Doxazosin	Approved
T53381	DRUGINFO	D09MWJ	Alfuzosin	Approved
T53381	DRUGINFO	D0A7QN	Moxisylyte	Approved
T53381	DRUGINFO	D0J5RN	Armodafinil	Approved
T53381	DRUGINFO	D0P9RF	Terazosin	Approved
T53381	DRUGINFO	D0S0AF	Bunazosin	Approved
T53381	DRUGINFO	D0T4WA	Trimazosin	Approved
T53381	DRUGINFO	D0F2ML	MEDETOMIDINE	Phase 2
T53381	DRUGINFO	D00POS	DL-017	Phase 1
T53381	DRUGINFO	D0SG8X	PMID30124346-Compound-LDT66	Patented
T53381	DRUGINFO	D0EO8F	PMID30124346-Compound-LDT8	Patented
T53381	DRUGINFO	D02LHR	INDORAMIN	Withdrawn from market
T53381	DRUGINFO	D03ITI	Sunepitron	Discontinued in Phase 3
T53381	DRUGINFO	D01RCS	TIOSPIRONE	Discontinued in Phase 3
T53381	DRUGINFO	D02ZSU	NS-49	Discontinued in Phase 2
T53381	DRUGINFO	D04CON	SL-89.0591	Discontinued in Phase 2
T53381	DRUGINFO	D06WJI	OPC-28326	Discontinued in Phase 2
T53381	DRUGINFO	D0A6VE	FIDUXOSIN HYDROCHLORIDE	Discontinued in Phase 2
T53381	DRUGINFO	D0F0YL	SL-25.1039	Discontinued in Phase 2
T53381	DRUGINFO	D0Z3UP	Dabuzalgron	Discontinued in Phase 2
T53381	DRUGINFO	D02SKA	FCE-22716	Discontinued in Phase 2
T53381	DRUGINFO	D03ABH	Deriglidole	Discontinued in Phase 2
T53381	DRUGINFO	D06WOJ	JTH-601	Discontinued in Phase 2
T53381	DRUGINFO	D0P9FT	REC-15-2739	Discontinued in Phase 2
T53381	DRUGINFO	D0U0QI	GYKI-16084	Discontinued in Phase 2
T53381	DRUGINFO	D08OJU	SOU-001	Discontinued in Phase 2
T53381	DRUGINFO	D01WJZ	MAZAPERTINE	Discontinued in Phase 2
T53381	DRUGINFO	D0C1CU	SUN-9221	Discontinued in Phase 1
T53381	DRUGINFO	D01EWC	CR-2991	Terminated
T53381	DRUGINFO	D0C5LI	SL-91.0893	Terminated
T53381	DRUGINFO	D0BC6Q	AGN-193080	Terminated
T53381	DRUGINFO	D0N7LZ	SK&F-104856	Terminated
T53381	DRUGINFO	D0U3HP	ABANOQUIL	Terminated
T53381	DRUGINFO	D0XK2K	Siramesine	Terminated
T53381	DRUGINFO	D00KZF	BMY-7378	Terminated
T53381	DRUGINFO	D05IML	NIGULDIPINE	Terminated
T53381	DRUGINFO	D08OWQ	SK&F-104078	Terminated
T53381	DRUGINFO	D03QMR	WB-4101	Terminated
T53381	DRUGINFO	D06HRY	SNAP-5089	Terminated
T53381	DRUGINFO	D00YGP	6-hydroxy-3-(3',5'-dihydroxyphenyl)coumarin	Investigative
T53381	DRUGINFO	D00RLE	4-(4-chlorobenzyl)-2-methylphthalazin-1(2H)-one	Investigative
T53381	DRUGINFO	D0E5CI	8-Piperazin-1-yl-imidazo[1,2-a]pyrazine	Investigative
T53381	DRUGINFO	D0J9ZF	4-benzyl-2-methylphthalazin-1(2H)-one	Investigative
T53381	DRUGINFO	D0JC4Q	4-(4-chlorobenzyl)-2-allylphthalazin-1(2H)-one	Investigative
T53381	DRUGINFO	D0Q2SI	4-(4-chlorobenzyl)phthalazin-1(2H)-one	Investigative
T53381	DRUGINFO	D0R2YM	5-Bromo-8-piperazin-1-yl-imidazo[1,2-a]pyrazine	Investigative
T53381	DRUGINFO	D0Z8OD	RWJ-38063	Investigative
T53381	DRUGINFO	D02TQC	N-(5-Bromo-quinoxalin-6-yl)-guanidine	Investigative
T53381	DRUGINFO	D06QKD	4-(4-Isopropyl-morpholin-2-yl)-benzene-1,2-diol	Investigative
T53381	DRUGINFO	D06UBB	SK&F-86466	Investigative
T53381	DRUGINFO	D07QCC	SK&F-106686	Investigative
T53381	DRUGINFO	D07XDL	4-(1-Naphthalen-1-yl-vinyl)-1H-imidazole	Investigative
T53381	DRUGINFO	D08XTL	RWJ-69736	Investigative
T53381	DRUGINFO	D09NXU	4-(2,3-Dihydro-1H-phenalen-1-yl)-1H-imidazole	Investigative
T53381	DRUGINFO	D09PIF	Imidazolidin-2-ylidene-o-tolyl-amine	Investigative
T53381	DRUGINFO	D0E9VU	LEVONORDEFRIN	Investigative
T53381	DRUGINFO	D0F3AR	4-((Z)-1-Naphthalen-1-yl-propenyl)-1H-imidazole	Investigative
T53381	DRUGINFO	D0H3CW	SK&F-105854	Investigative
T53381	DRUGINFO	D0L6JS	AGN-192172	Investigative
T53381	DRUGINFO	D0N7UE	Imidazolidin-2-ylidene-quinoxalin-6-yl-amine	Investigative
T53381	DRUGINFO	D0O9HS	1-(2-Chloro-phenyl)-piperazine	Investigative
T53381	DRUGINFO	D0Q4PY	RWJ-68157	Investigative
T53381	DRUGINFO	D0RX6I	4-((E)-1-Naphthalen-1-yl-propenyl)-1H-imidazole	Investigative
T53381	DRUGINFO	D0S1GH	4-Morpholin-2-yl-benzene-1,2-diol	Investigative
T53381	DRUGINFO	D0T5KJ	4-(3-Hydroxy-piperidin-3-yl)-benzene-1,2-diol	Investigative
T53381	DRUGINFO	D0ZP5X	4-(1-Naphthalen-1-yl-propyl)-1H-imidazole	Investigative
T53381	DRUGINFO	D02NNS	SNAP-8719	Investigative
T53381	DRUGINFO	D08UDY	1',2',3',6'-Tetrahydro-[2,4']bipyridinyl	Investigative
T53381	DRUGINFO	D09CKI	CORYNANTHEINE	Investigative
T53381	DRUGINFO	D0MH0S	1-(3-Fluoro-pyridin-2-yl)-4-methyl-piperazine	Investigative
T53381	DRUGINFO	D01TOU	FLUANISONE	Investigative
T53381	DRUGINFO	D06HHJ	(2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine	Investigative
T53381	DRUGINFO	D06ROA	UH-301	Investigative
T53381	DRUGINFO	D07JMN	1-(pyridin-2-yl)piperazine	Investigative
T53381	DRUGINFO	D0A6GK	(2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine	Investigative
T53381	DRUGINFO	D0B4DP	2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline	Investigative
T53381	DRUGINFO	D0H3NA	4-Benzo[b]thiophen-4-yl-1H-imidazole	Investigative
T53381	DRUGINFO	D0K9NW	4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline	Investigative
T53381	DRUGINFO	D08KLH	[3H]RX821002	Investigative
T53381	DRUGINFO	D0L9WN	4-(4-Methyl-indan-1-yl)-1H-imidazole	Investigative
T53381	DRUGINFO	D0P5PW	4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole	Investigative
T53381	DRUGINFO	D0D3YN	OCTOCLOTHEPIN	Investigative
T53381	DRUGINFO	D0V4RP	1-(2-Methoxy-phenyl)-piperazine	Investigative
T53381	DRUGINFO	D0R7ZC	Beta-methoxyamphetamine	Investigative
T53381	DRUGINFO	D0P0IX	ISOCLOZAPINE	Investigative
T53381	DRUGINFO	D0L5MW	(+/-)-nantenine	Investigative
T53381	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T60077	TARGETID	T60077
T60077	FORMERID	TTDI03515
T60077	UNIPROID	RXRB_HUMAN
T60077	TARGNAME	Retinoic acid receptor RXR-beta (RXRB)
T60077	GENENAME	RXRB
T60077	TARGTYPE	Successful
T60077	SYNONYMS	Retinoid X receptor beta; Nuclear receptor subfamily 2 group B member 2; NR2B2
T60077	FUNCTION	Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE). Receptor for retinoic acid.
T60077	PDBSTRUC	5KYJ; 5KYA; 5I4V; 5HJP; 1UHL
T60077	BIOCLASS	Nuclear hormone receptor
T60077	SEQUENCE	MSWAARPPFLPQRHAAGQCGPVGVRKEMHCGVASRWRRRRPWLDPAAAAAAAVAGGEQQTPEPEPGEAGRDGMGDSGRDSRSPDSSSPNPLPQGVPPPSPPGPPLPPSTAPSLGGSGAPPPPPMPPPPLGSPFPVISSSMGSPGLPPPAPPGFSGPVSSPQINSTVSLPGGGSGPPEDVKPPVLGVRGLHCPPPPGGPGAGKRLCAICGDRSSGKHYGVYSCEGCKGFFKRTIRKDLTYSCRDNKDCTVDKRQRNRCQYCRYQKCLATGMKREAVQEERQRGKDKDGDGEGAGGAPEEMPVDRILEAELAVEQKSDQGVEGPGGTGGSGSSPNDPVTNICQAADKQLFTLVEWAKRIPHFSSLPLDDQVILLRAGWNELLIASFSHRSIDVRDGILLATGLHVHRNSAHSAGVGAIFDRVLTELVSKMRDMRMDKTELGCLRAIILFNPDAKGLSNPSEVEVLREKVYASLETYCKQKYPEQQGRFAKLLLRLPALRSIGLKCLEHLFFFKLIGDTPIDTFLMEMLEAPHQLA
T60077	DRUGINFO	D0G3PI	Alitretinoin	Approved
T60077	DRUGINFO	D0GR9O	AGN-34	Investigative
T60077	DRUGINFO	D0Q9FZ	LG100754	Investigative

T77009	TARGETID	T77009
T77009	FORMERID	TTDI00956
T77009	UNIPROID	PRDX5_HUMAN
T77009	TARGNAME	Thioredoxin reductase (PRDX5)
T77009	GENENAME	PRDX5
T77009	TARGTYPE	Successful
T77009	SYNONYMS	Thioredoxin peroxidase PMP20; TPx type VI; SBBI10; PrxV; Prx-V; Peroxisomal antioxidant enzyme; Peroxiredoxin5, mitochondrial; Peroxiredoxin-5, mitochondrial; Peroxiredoxin V; PLP; Liver tissue 2Dpage spot 71B; Liver tissue 2D-page spot 71B; Antioxidant enzyme B166; Alu corepressor 1; AOEB166; ACR1
T77009	FUNCTION	Plays a role in cell protection against oxidative stress by detoxifying peroxides and as sensor of hydrogen peroxide-mediated signaling events. Thiol-specific peroxidase that catalyzes the reduction of hydrogen peroxide and organic hydroperoxides to water and alcohols, respectively.
T77009	PDBSTRUC	4MMM; 4K7O; 4K7N; 4K7I; 3MNG
T77009	BIOCLASS	Peroxide acceptor oxidoreductase
T77009	ECNUMBER	EC 1.11.1.15
T77009	SEQUENCE	MGLAGVCALRRSAGYILVGGAGGQSAAAAARRYSEGEWASGGVRSFSRAAAAMAPIKVGDAIPAVEVFEGEPGNKVNLAELFKGKKGVLFGVPGAFTPGCSKTHLPGFVEQAEALKAKGVQVVACLSVNDAFVTGEWGRAHKAEGKVRLLADPTGAFGKETDLLLDDSLVSIFGNRRLKRFSMVVQDGIVKALNVEPDGTGLTCSLAPNIISQL
T77009	DRUGINFO	D05BJD	Motexafin gadolinium	Approved
T77009	DRUGINFO	DNXH76	Eptacog beta	Phase 1/2
T77009	DRUGINFO	D0CF4R	Diterpene triepoxide derivative 1	Patented

T84486	TARGETID	T84486
T84486	FORMERID	TTDS00264
T84486	UNIPROID	OXYR_HUMAN
T84486	TARGNAME	Oxytocin receptor (OTR)
T84486	GENENAME	OXTR
T84486	TARGTYPE	Successful
T84486	SYNONYMS	OT-R
T84486	FUNCTION	The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. Receptor for oxytocin.
T84486	BIOCLASS	GPCR rhodopsin
T84486	SEQUENCE	MEGALAANWSAEAANASAAPPGAEGNRTAGPPRRNEALARVEVAVLCLILLLALSGNACVLLALRTTRQKHSRLFFFMKHLSIADLVVAVFQVLPQLLWDITFRFYGPDLLCRLVKYLQVVGMFASTYLLLLMSLDRCLAICQPLRSLRRRTDRLAVLATWLGCLVASAPQVHIFSLREVADGVFDCWAVFIQPWGPKAYITWITLAVYIVPVIVLAACYGLISFKIWQNLRLKTAAAAAAEAPEGAAAGDGGRVALARVSSVKLISKAKIRTVKMTFIIVLAFIVCWTPFFFVQMWSVWDANAPKEASAFIIVMLLASLNSCCNPWIYMLFTGHLFHELVQRFLCCSASYLKGRRLGETSASKKSNSSSFVLSHRSSSQRSCSQPSTA
T84486	DRUGINFO	D08FJL	Carbetocin	Approved
T84486	DRUGINFO	D0M3FJ	Oxytocin	Approved
T84486	DRUGINFO	D0U7SH	Desmopressin	Approved
T84486	DRUGINFO	D0D8XY	ATOSIBAN	Phase 4
T84486	DRUGINFO	D04QZI	Retosiban	Phase 3
T84486	DRUGINFO	D04TQT	Barusiban	Phase 2
T84486	DRUGINFO	D07LWT	FE-202767	Phase 2
T84486	DRUGINFO	D09WYL	GSK-557296	Phase 2
T84486	DRUGINFO	D0SY9B	SSR149415	Phase 2
T84486	DRUGINFO	D02CAU	Triazole derivative 7	Patented
T84486	DRUGINFO	D03AOX	Triazole derivative 5	Patented
T84486	DRUGINFO	D03ZGF	Pyrrolidine derivative 10	Patented
T84486	DRUGINFO	D0J5IB	Pyrrolidine derivative 11	Patented
T84486	DRUGINFO	D0J5QP	Triazole derivative 6	Patented
T84486	DRUGINFO	D0LW9R	Pyrrolidine derivative 9	Patented
T84486	DRUGINFO	D0N4RI	Pyrrolidine derivative 12	Patented
T84486	DRUGINFO	D0RF1V	Triazole derivative 4	Patented
T84486	DRUGINFO	D0BU3L	Pyrrolidine derivative 13	Patented
T84486	DRUGINFO	D0H0QR	PMID28906174-Compound-figure1g	Patented
T84486	DRUGINFO	D0P6OS	TT-235	Discontinued in Phase 1
T84486	DRUGINFO	D0Q8RX	L-368899	Discontinued in Phase 1
T84486	DRUGINFO	D0A1KU	PF-3274167	Discontinued in Phase 1
T84486	DRUGINFO	D0SK1W	AS-602305	Terminated
T84486	DRUGINFO	D08PAC	L-371257	Terminated
T84486	DRUGINFO	D00TBJ	PF-271836	Investigative
T84486	DRUGINFO	D01EDA	[Mpa1, D-Tyr(Et)2, Pip7]OT	Investigative
T84486	DRUGINFO	D03BDK	L-366,948	Investigative
T84486	DRUGINFO	D05JIS	L-365,209	Investigative
T84486	DRUGINFO	D06SMJ	[Mpa1, D-Tyr(Et)2, Gly(But)3, Gly(But)7]OT	Investigative
T84486	DRUGINFO	D07HTH	[Mpa1, D-Tyr(Et)2, D-Tic7]OT	Investigative
T84486	DRUGINFO	D07KWZ	L-367,773	Investigative
T84486	DRUGINFO	D07NPZ	[Mpa1, D-Tyr(Et)2, Gly(But)7]OT	Investigative
T84486	DRUGINFO	D07XKF	[Mpa1, L-Tic7]OT	Investigative
T84486	DRUGINFO	D08MTW	[Pip7]OT	Investigative
T84486	DRUGINFO	D08ZAK	L-366,682	Investigative
T84486	DRUGINFO	D09LXI	[Mpa1, D-Tyr(Et)2, D-Tic7, D-Tic9]OT	Investigative
T84486	DRUGINFO	D0D5QP	L-366,509	Investigative
T84486	DRUGINFO	D0F9QJ	[Gly(But)7]OT	Investigative
T84486	DRUGINFO	D0H0MK	[Mpa1, D-Tyr(Et)2, Aib7]OT	Investigative
T84486	DRUGINFO	D0I3HV	[Mpa1, D-Tyr(Et)2, L-Tic7]OT	Investigative
T84486	DRUGINFO	D0IB4H	[Mpa1, D-Tic7]OT	Investigative
T84486	DRUGINFO	D0NC8V	PMID16250654C37	Investigative
T84486	DRUGINFO	D0O1KA	[Aib7]OT	Investigative
T84486	DRUGINFO	D0O9FA	[Mpa1, D-Tyr(Et)2, Aib7, D-Tic9]OT	Investigative
T84486	DRUGINFO	D0R1WH	[L-Tic7]OT	Investigative
T84486	DRUGINFO	D0R2JA	[35S]-non-peptide OT antagonist	Investigative
T84486	DRUGINFO	D0S3GE	[D-Tic7]OT	Investigative
T84486	DRUGINFO	D0YL6T	[Mpa1, D-Tic2, Aib7]OT	Investigative
T84486	DRUGINFO	D0ZV3Y	[Mpa1, D-Tyr(Et)2, D-Tic7, Aib9]OT	Investigative
T84486	DRUGINFO	D01WHI	L023103	Investigative
T84486	DRUGINFO	D02FXZ	DesGly-NH2,d(CH2)5[D-Tyr2,Thr4,Orn8(5/6C-Flu)]VT	Investigative
T84486	DRUGINFO	D03QUQ	LS-192629	Investigative
T84486	DRUGINFO	D09HMT	[HO1][Orn8(5/6C-Rhm)]VT	Investigative
T84486	DRUGINFO	D0BS2Q	[Thr4,Gly7]OT	Investigative
T84486	DRUGINFO	D0K5NV	[Lys8(Alexa 546) ]PVA	Investigative
T84486	DRUGINFO	D0Q0OR	SSR126768A	Investigative
T84486	DRUGINFO	D0Y1AJ	D(CH2)5[Tyr(Me)2,Thr4,Orn8(5/6C-Flu),Tyr-NH29]VT	Investigative
T84486	DRUGINFO	D0YG0D	1'-tosylspiro[indene-1,4'-piperidine]	Investigative
T84486	DRUGINFO	D02VVG	D[Orn8(5/6C-Flu)]VT	Investigative
T84486	DRUGINFO	D03EBH	D(CH2)5[Tyr(Me)2,Thr4,Orn8,Tyr9-NH2]VT	Investigative
T84486	DRUGINFO	D05YHE	D[Thr4,Lys8(5/6C-Flu)]VT	Investigative
T84486	DRUGINFO	D09BWP	[HO1][Orn8(5/6C-Flu)]VT	Investigative
T84486	DRUGINFO	D0C8XX	D[Thr4,Orn8(5/6C-Flu)]VT	Investigative
T84486	DRUGINFO	D0K0JJ	[HO1][Lys8(5/6C-Flu)]VT	Investigative
T84486	DRUGINFO	D0L0RP	[Lys8(Alexa 488) ]PVA	Investigative
T84486	DRUGINFO	D0M3BJ	D[Lys8(5/6-Flu)]VT	Investigative
T84486	DRUGINFO	D0O6WN	[HO1][Thr4,Orn8(5/6C-Flu)]VT	Investigative
T84486	DRUGINFO	D0T4ML	L-372662	Investigative
T84486	DRUGINFO	D0Y4HL	[Phe3]OT	Investigative
T84486	DRUGINFO	D0Y5FO	[HO1][Thr4,Lys8(5/6C-Flu)]VT	Investigative
T84486	DRUGINFO	D01FDW	ARGENINE VASOPRESSIN	Investigative
T84486	DRUGINFO	D03BVC	D[Arg4,Orn8]VP	Investigative
T84486	DRUGINFO	D03DXK	D[Leu4,Lys8]VP	Investigative
T84486	DRUGINFO	D04MMD	D[Arg4,Lys8]VP	Investigative
T84486	DRUGINFO	D05BHL	D[Cha4,Lys8]VP	Investigative
T84486	DRUGINFO	D05RNF	D[Cha4,Orn8]VP	Investigative
T84486	DRUGINFO	D06SDG	D[Leu4,Dab8]VP	Investigative
T84486	DRUGINFO	D09RIE	D[Cha4]AVP	Investigative
T84486	DRUGINFO	D09XWA	D[Cha4,Dap8]VP	Investigative
T84486	DRUGINFO	D0A6FK	D[Leu4]AVP	Investigative
T84486	DRUGINFO	D0HI2N	D[Cha4,Dab8]VP	Investigative
T84486	DRUGINFO	D0M4QM	d(CH2)5[Tyr(Me)2]AVP	Investigative
T84486	DRUGINFO	D0O5TK	D[Leu4,Dap8]VP	Investigative
T84486	DRUGINFO	D0O8OF	D[Orn4,Lys8]VP	Investigative
T84486	DRUGINFO	D0R7QC	D[Arg4]AVP	Investigative
T84486	DRUGINFO	D0UK0O	D[Arg4,Dab8]VP	Investigative
T84486	DRUGINFO	D0V3FF	D[Leu4,Orn8]VP	Investigative
T84486	DRUGINFO	D0W3IQ	D[Val4]AVP	Investigative
T84486	DRUGINFO	D0YJ6C	D[Orn4,Orn8]VP	Investigative
T84486	DRUGINFO	D0ZD0W	D[Orn4]AVP	Investigative

T78656	TARGETID	T78656
T78656	FORMERID	TTDR01194
T78656	UNIPROID	5HT1F_HUMAN
T78656	TARGNAME	5-HT 1F receptor (HTR1F)
T78656	GENENAME	HTR1F
T78656	TARGTYPE	Successful
T78656	SYNONYMS	Serotonin receptor 1F; HTR1EL; 5-hydroxytryptamine receptor 1F; 5-HT1F receptor; 5-HT1F; 5-HT-1F
T78656	FUNCTION	Functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. G-protein coupled receptor for 5-hydroxytryptamine (serotonin).
T78656	BIOCLASS	GPCR rhodopsin
T78656	SEQUENCE	MDFLNSSDQNLTSEELLNRMPSKILVSLTLSGLALMTTTINSLVIAAIIVTRKLHHPANYLICSLAVTDFLVAVLVMPFSIVYIVRESWIMGQVVCDIWLSVDITCCTCSILHLSAIALDRYRAITDAVEYARKRTPKHAGIMITIVWIISVFISMPPLFWRHQGTSRDDECIIKHDHIVSTIYSTFGAFYIPLALILILYYKIYRAAKTLYHKRQASRIAKEEVNGQVLLESGEKSTKSVSTSYVLEKSLSDPSTDFDKIHSTVRSLRSEFKHEKSWRRQKISGTRERKAATTLGLILGAFVICWLPFFVKELVVNVCDKCKISEEMSNFLAWLGYLNSLINPLIYTIFNEDFKKAFQKLVRCRC
T78656	DRUGINFO	D01NQM	Lasmiditan	Approved
T78656	DRUGINFO	D0UA0I	Metergolin	Approved
T78656	DRUGINFO	D09GHO	LY-334370	Phase 2
T78656	DRUGINFO	D0O9TT	LY344864	Investigative
T78656	DRUGINFO	D03RHW	5-BODMT	Investigative
T78656	DRUGINFO	D0BW9V	[125I]LSD	Investigative
T78656	DRUGINFO	D0D3PZ	dipropyl-5-CT	Investigative
T78656	DRUGINFO	D06VPR	WAY-466	Investigative
T78656	DRUGINFO	D00CRA	2-methyl-5-HT	Investigative
T78656	DRUGINFO	D09OYA	alpha-methyl-5-HT	Investigative
T78656	DRUGINFO	D03TDN	1-naphthylpiperazine	Investigative
T78656	DRUGINFO	D04TVG	BRL-15572	Investigative
T78656	DRUGINFO	D02UWB	5-CT	Investigative
T78656	DRUGINFO	D0V5HV	TFMPP	Investigative

T34287	TARGETID	T34287
T34287	FORMERID	TTDS00450
T34287	UNIPROID	MPI_CANAL
T34287	TARGNAME	Candida Mannose-6-phosphate isomerase (Candi PMI1)
T34287	GENENAME	Candi PMI1
T34287	TARGTYPE	Successful
T34287	SYNONYMS	Phosphomannose isomerase; Phosphohexomutase; PMI1; PMI
T34287	FUNCTION	Involved in the synthesis of the GDP-mannose and dolichol-phosphate-mannose required for a number of critical mannosyl transfer reactions.
T34287	PDBSTRUC	5NW7; 1PMI
T34287	BIOCLASS	Intramolecular oxidoreductases
T34287	SEQUENCE	MSSEKLFRIQCGYQNYDWGKIGSSSAVAQFVHNSDPSITIDETKPYAELWMGTHPSVPSKAIDLNNQTLRDLVTAKPQEYLGESIITKFGSSKELPFLFKVLSIEKVLSIQAHPDKKLGAQLHAADPKNYPDDNHKPEMAIAVTDFEGFCGFKPLDQLAKTLATVPELNEIIGQELVDEFISGIKLPAEVGSQDDVNNRKLLQKVFGKLMNTDDDVIKQQTAKLLERTDREPQVFKDIDSRLPELIQRLNKQFPNDIGLFCGCLLLNHVGLNKGEAMFLQAKDPHAYISGDIIECMAASDNVVRAGFTPKFKDVKNLVEMLTYSYESVEKQKMPLQEFPRSKGDAVKSVLYDPPIAEFSVLQTIFDKSKGGKQVIEGLNGPSIVIATNGKGTIQITGDDSTKQKIDTGYVFFVAPGSSIELTADSANQDQDFTTYRAFVEA
T34287	DRUGINFO	D0M4VM	Sulfacetamide	Approved
T34287	DRUGINFO	D0PI2E	Sulfoxone	Approved
T34287	DRUGINFO	D0IK4V	GNF-PF-5134	Investigative
T34287	DRUGINFO	D0P0CM	GNF-PF-2272	Investigative
T34287	DRUGINFO	D0XU4Y	NSC-66209	Investigative
T34287	DRUGINFO	D06EWG	Formic Acid	Investigative
T34287	DRUGINFO	D0F2ME	Acetate Ion	Investigative

T82795	TARGETID	T82795
T82795	FORMERID	TTDR00713
T82795	UNIPROID	CTNB1_HUMAN
T82795	TARGNAME	Beta-catenin (CTNNB1)
T82795	GENENAME	CTNNB1
T82795	TARGTYPE	Successful
T82795	SYNONYMS	Wnt/beta-catenin signaling pathway; PRO2286; OK/SW-cl.35; Catenin beta-1; CTNNB
T82795	FUNCTION	In the absence of Wnt, forms a complex with AXIN1, AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on N-terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and its subsequent degradation by the proteasome. In the presence of Wnt ligand, CTNNB1 is not ubiquitinated and accumulates in the nucleus, where it acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. Involved in the regulation of cell adhesion, as component of an E-cadherin:catenin adhesion complex. Acts as a negative regulator of centrosome cohesion. Involved in the CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. Blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2. Disrupts PML function and PML-NB formation by inhibiting RANBP2-mediated sumoylation of PML. Promotes neurogenesis by maintaining sympathetic neuroblasts within the cell cycle. Key downstream component of the canonical Wnt signaling pathway.
T82795	PDBSTRUC	6M94; 6M93; 6M92; 6M91; 6M90
T82795	BIOCLASS	Beta-catenin
T82795	SEQUENCE	MATQADLMELDMAMEPDRKAAVSHWQQQSYLDSGIHSGATTTAPSLSGKGNPEEEDVDTSQVLYEWEQGFSQSFTQEQVADIDGQYAMTRAQRVRAAMFPETLDEGMQIPSTQFDAAHPTNVQRLAEPSQMLKHAVVNLINYQDDAELATRAIPELTKLLNDEDQVVVNKAAVMVHQLSKKEASRHAIMRSPQMVSAIVRTMQNTNDVETARCTAGTLHNLSHHREGLLAIFKSGGIPALVKMLGSPVDSVLFYAITTLHNLLLHQEGAKMAVRLAGGLQKMVALLNKTNVKFLAITTDCLQILAYGNQESKLIILASGGPQALVNIMRTYTYEKLLWTTSRVLKVLSVCSSNKPAIVEAGGMQALGLHLTDPSQRLVQNCLWTLRNLSDAATKQEGMEGLLGTLVQLLGSDDINVVTCAAGILSNLTCNNYKNKMMVCQVGGIEALVRTVLRAGDREDITEPAICALRHLTSRHQEAEMAQNAVRLHYGLPVVVKLLHPPSHWPLIKATVGLIRNLALCPANHAPLREQGAIPRLVQLLVRAHQDTQRRTSMGGTQQQFVEGVRMEEIVEGCTGALHILARDVHNRIVIRGLNTIPLFVQLLYSPIENIQRVAAGVLCELAQDKEAAEAIEAEGATAPLTELLHSRNEGVATYAAAVLFRMSEDKPQDYKKRLSVELTSSLFRTEPMAWNETADLGLDIGAQGEPLGYRQDDPSYRSFHSGGYGQDALGMDPMMEHEMGGHHPGADYPVDGLPDLGHAQDLMDGLPPGDSNQLAWFDTDL
T82795	DRUGINFO	D05YAG	Recombinant human endostatin	Approved
T82795	DRUGINFO	D00GBZ	CEQ-508	Phase 1/2
T82795	DRUGINFO	D0DA5M	C 82	Phase 1/2
T82795	DRUGINFO	D54WUR	Tegavivint	Phase 1

T29500	TARGETID	T29500
T29500	FORMERID	TTDS00029
T29500	UNIPROID	ADA1B_HUMAN
T29500	TARGNAME	Adrenergic receptor alpha-1B (ADRA1B)
T29500	GENENAME	ADRA1B
T29500	TARGTYPE	Successful
T29500	SYNONYMS	Alpha-1B adrenoreceptor; Alpha-1B adrenoceptor; Alpha-1B adrenergic receptor; Alpha 1B-adrenoreceptor; Alpha 1B-adrenoceptor
T29500	FUNCTION	Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes. This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
T29500	BIOCLASS	GPCR rhodopsin
T29500	SEQUENCE	MNPDLDTGHNTSAPAHWGELKNANFTGPNQTSSNSTLPQLDITRAISVGLVLGAFILFAIVGNILVILSVACNRHLRTPTNYFIVNLAMADLLLSFTVLPFSAALEVLGYWVLGRIFCDIWAAVDVLCCTASILSLCAISIDRYIGVRYSLQYPTLVTRRKAILALLSVWVLSTVISIGPLLGWKEPAPNDDKECGVTEEPFYALFSSLGSFYIPLAVILVMYCRVYIVAKRTTKNLEAGVMKEMSNSKELTLRIHSKNFHEDTLSSTKAKGHNPRSSIAVKLFKFSREKKAAKTLGIVVGMFILCWLPFFIALPLGSLFSTLKPPDAVFKVVFWLGYFNSCLNPIIYPCSSKEFKRAFVRILGCQCRGRGRRRRRRRRRLGGCAYTYRPWTRGGSLERSQSRKDSLDDSGSCLSGSQRTLPSASPSPGYLGRGAPPPVELCAFPEWKAPGALLSLPAPEPPGRRGRHDSGPLFTFKLLTEPESPGTDGGASNGGCEAAADVANGQPGFKSNMPLAPGQF
T29500	DRUGINFO	D00AWT	Propericiazine	Approved
T29500	DRUGINFO	D09GYT	Methoxamine	Approved
T29500	DRUGINFO	D0T6SU	Phendimetrazine	Approved
T29500	DRUGINFO	D0P6UB	Methamphetamine	Approved
T29500	DRUGINFO	D0F2ML	MEDETOMIDINE	Phase 2
T29500	DRUGINFO	D03ITI	Sunepitron	Discontinued in Phase 3
T29500	DRUGINFO	D01RCS	TIOSPIRONE	Discontinued in Phase 3
T29500	DRUGINFO	D08OJU	SOU-001	Discontinued in Phase 2
T29500	DRUGINFO	D01WJZ	MAZAPERTINE	Discontinued in Phase 2
T29500	DRUGINFO	D0BC6Q	AGN-193080	Terminated
T29500	DRUGINFO	D0N7LZ	SK&F-104856	Terminated
T29500	DRUGINFO	D0U3HP	ABANOQUIL	Terminated
T29500	DRUGINFO	D0XK2K	Siramesine	Terminated
T29500	DRUGINFO	D00KZF	BMY-7378	Terminated
T29500	DRUGINFO	D05IML	NIGULDIPINE	Terminated
T29500	DRUGINFO	D08OWQ	SK&F-104078	Terminated
T29500	DRUGINFO	D03QMR	WB-4101	Terminated
T29500	DRUGINFO	D06HRY	SNAP-5089	Terminated
T29500	DRUGINFO	D04BYL	6-fluoronorepinehprine	Investigative
T29500	DRUGINFO	D06ABL	Rec 15/2615	Investigative
T29500	DRUGINFO	D0DP8I	Cyclazosin	Investigative
T29500	DRUGINFO	D0FH7B	AH 11110	Investigative
T29500	DRUGINFO	D03YLQ	[125I]BE-2254	Investigative
T29500	DRUGINFO	D09DKC	[125I]HEAT	Investigative
T29500	DRUGINFO	D0EO4F	A-123189	Investigative
T29500	DRUGINFO	D0Q7ZR	A-119637	Investigative
T29500	DRUGINFO	D0V6DJ	5-methylurapidil	Investigative
T29500	DRUGINFO	D02TQC	N-(5-Bromo-quinoxalin-6-yl)-guanidine	Investigative
T29500	DRUGINFO	D06QKD	4-(4-Isopropyl-morpholin-2-yl)-benzene-1,2-diol	Investigative
T29500	DRUGINFO	D06UBB	SK&F-86466	Investigative
T29500	DRUGINFO	D07QCC	SK&F-106686	Investigative
T29500	DRUGINFO	D07XDL	4-(1-Naphthalen-1-yl-vinyl)-1H-imidazole	Investigative
T29500	DRUGINFO	D08XTL	RWJ-69736	Investigative
T29500	DRUGINFO	D09NXU	4-(2,3-Dihydro-1H-phenalen-1-yl)-1H-imidazole	Investigative
T29500	DRUGINFO	D09PIF	Imidazolidin-2-ylidene-o-tolyl-amine	Investigative
T29500	DRUGINFO	D0E9VU	LEVONORDEFRIN	Investigative
T29500	DRUGINFO	D0F3AR	4-((Z)-1-Naphthalen-1-yl-propenyl)-1H-imidazole	Investigative
T29500	DRUGINFO	D0H3CW	SK&F-105854	Investigative
T29500	DRUGINFO	D0L6JS	AGN-192172	Investigative
T29500	DRUGINFO	D0N7UE	Imidazolidin-2-ylidene-quinoxalin-6-yl-amine	Investigative
T29500	DRUGINFO	D0Q4PY	RWJ-68157	Investigative
T29500	DRUGINFO	D0RX6I	4-((E)-1-Naphthalen-1-yl-propenyl)-1H-imidazole	Investigative
T29500	DRUGINFO	D0S1GH	4-Morpholin-2-yl-benzene-1,2-diol	Investigative
T29500	DRUGINFO	D0T5KJ	4-(3-Hydroxy-piperidin-3-yl)-benzene-1,2-diol	Investigative
T29500	DRUGINFO	D0ZP5X	4-(1-Naphthalen-1-yl-propyl)-1H-imidazole	Investigative
T29500	DRUGINFO	D02NNS	SNAP-8719	Investigative
T29500	DRUGINFO	D09CKI	CORYNANTHEINE	Investigative
T29500	DRUGINFO	D01TOU	FLUANISONE	Investigative
T29500	DRUGINFO	D06HHJ	(2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine	Investigative
T29500	DRUGINFO	D06ROA	UH-301	Investigative
T29500	DRUGINFO	D0A6GK	(2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine	Investigative
T29500	DRUGINFO	D0B4DP	2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline	Investigative
T29500	DRUGINFO	D0H3NA	4-Benzo[b]thiophen-4-yl-1H-imidazole	Investigative
T29500	DRUGINFO	D0K9NW	4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline	Investigative
T29500	DRUGINFO	D0MU4A	spiroxatrine	Investigative
T29500	DRUGINFO	D08KLH	[3H]RX821002	Investigative
T29500	DRUGINFO	D0L9WN	4-(4-Methyl-indan-1-yl)-1H-imidazole	Investigative
T29500	DRUGINFO	D0P5PW	4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole	Investigative
T29500	DRUGINFO	D0D3YN	OCTOCLOTHEPIN	Investigative
T29500	DRUGINFO	D0P0IX	ISOCLOZAPINE	Investigative
T29500	DRUGINFO	D0L5MW	(+/-)-nantenine	Investigative
T29500	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T52173	TARGETID	T52173
T52173	FORMERID	TTDS00158
T52173	UNIPROID	SCNNA_HUMAN; SCNNB_HUMAN; SCNNG_HUMAN; SCNND_HUMAN
T52173	TARGNAME	Amiloride-sensitive sodium channel (ENaC)
T52173	GENENAME	SCNN1A; SCNN1B; SCNN1G; SCNN1D
T52173	TARGTYPE	Successful
T52173	SYNONYMS	SCNE; Nonvoltage-gated sodium channel 1; NaCH; Epithelial Na(+) channel; ENaC
T52173	FUNCTION	Sodium permeable non-voltage-sensitive ion channel inhibited by the diuretic amiloride. Mediates the electrodiffusion of the luminal sodium (and water, which follows osmotically) through the apical membrane of epithelial cells. Plays an essential role in electrolyte and blood pressure homeostasis, but also in airway surface liquid homeostasis, which is important for proper clearance of mucus. Controls the reabsorption ofsodium in kidney, colon, lung and sweat glands. Also plays a role in taste perception.
T52173	BIOCLASS	Epithelial sodium channel
T52173	SEQUENCE	MEGNKLEEQDSSPPQSTPGLMKGNKREEQGLGPEPAAPQQPTAEEEALIEFHRSYRELFEFFCNNTTIHGAIRLVCSQHNRMKTAFWAVLWLCTFGMMYWQFGLLFGEYFSYPVSLNINLNSDKLVFPAVTICTLNPYRYPEIKEELEELDRITEQTLFDLYKYSSFTTLVAGSRSRRDLRGTLPHPLQRLRVPPPPHGARRARSVASSLRDNNPQVDWKDWKIGFQLCNQNKSDCFYQTYSSGVDAVREWYRFHYINILSRLPETLPSLEEDTLGNFIFACRFNQVSCNQANYSHFHHPMYGNCYTFNDKNNSNLWMSSMPGINNGLSLMLRAEQNDFIPLLSTVTGARVMVHGQDEPAFMDDGGFNLRPGVETSISMRKETLDRLGGDYGDCTKNGSDVPVENLYPSKYTQQVCIHSCFQESMIKECGCAYIFYPRPQNVEYCDYRKHSSWGYCYYKLQVDFSSDHLGCFTKCRKPCSVTSYQLSAGYSRWPSVTSQEWVFQMLSRQNNYTVNNKRNGVAKVNIFFKELNYKTNSESPSVTMVTLLSNLGSQWSLWFGSSVLSVVEMAELVFDLLVIMFLMLLRRFRSRYWSPGRGGRGAQEVASTLASSPPSHFCPHPMSLSLSQPGPAPSPALTAPPPAYATLGPRPSPGGSAGASSSTCPLGGP
T52173	DRUGINFO	D00NKB	Triamterene	Approved
T52173	DRUGINFO	DAD95G	VX-371	Phase 2
T52173	DRUGINFO	D0L9JE	S3969	Investigative
T52173	DRUGINFO	D02ACL	benzamil	Investigative

T88182	TARGETID	T88182
T88182	FORMERID	TTDS00486
T88182	UNIPROID	VKGC_HUMAN
T88182	TARGNAME	Vitamin K-dependent gamma-carboxylase (GGCX)
T88182	GENENAME	GGCX
T88182	TARGTYPE	Successful
T88182	SYNONYMS	Vitamin K gamma glutamyl carboxylase; Gamma-glutamyl carboxylase; GGCX
T88182	FUNCTION	Mediates the vitamin K-dependent carboxylation of glutamate residues to calcium-binding gamma-carboxyglutamate (Gla) residues with the concomitant conversion of the reduced hydroquinone form of vitamin K to vitamin K epoxide.
T88182	BIOCLASS	Carbon-carbon lyase
T88182	ECNUMBER	EC 4.1.1.90
T88182	SEQUENCE	MAVSAGSARTSPSSDKVQKDKAELISGPRQDSRIGKLLGFEWTDLSSWRRLVTLLNRPTDPASLAVFRFLFGFLMVLDIPQERGLSSLDRKYLDGLDVCRFPLLDALRPLPLDWMYLVYTIMFLGALGMMLGLCYRISCVLFLLPYWYVFLLDKTSWNNHSYLYGLLAFQLTFMDANHYWSVDGLLNAHRRNAHVPLWNYAVLRGQIFIVYFIAGVKKLDADWVEGYSMEYLSRHWLFSPFKLLLSEELTSLLVVHWGGLLLDLSAGFLLFFDVSRSIGLFFVSYFHCMNSQLFSIGMFSYVMLASSPLFCSPEWPRKLVSYCPRRLQQLLPLKAAPQPSVSCVYKRSRGKSGQKPGLRHQLGAAFTLLYLLEQLFLPYSHFLTQGYNNWTNGLYGYSWDMMVHSRSHQHVKITYRDGRTGELGYLNPGVFTQSRRWKDHADMLKQYATCLSRLLPKYNVTEPQIYFDIWVSINDRFQQRIFDPRVDIVQAAWSPFQRTSWVQPLLMDLSPWRAKLQEIKSSLDNHTEVVFIADFPGLHLENFVSEDLGNTSIQLLQGEVTVELVAEQKNQTLREGEKMQLPAGEYHKVYTTSPSPSCYMYVYVNTTELALEQDLAYLQELKEKVENGSETGPLPPELQPLLEGEVKGGPEPTPLVQTFLRRQQRLQEIERRRNTPFHERFFRFLLRKLYVFRRSFLMTCISLRNLILGRPSLEQLAQEVTYANLRPFEAVGELNPSNTDSSHSNPPESNPDPVHSEF
T88182	DRUGINFO	D00FSV	Phytonadione	Approved

T24373	TARGETID	T24373
T24373	FORMERID	TTDI02303
T24373	UNIPROID	LICH_HUMAN
T24373	TARGNAME	Lysosomal acid lipase (LIPA)
T24373	GENENAME	LIPA
T24373	TARGTYPE	Successful
T24373	SYNONYMS	Sterol esterase; Lysosomal acid lipase/cholesteryl ester hydrolase; Lipase A; LIPA; LAL; Cholesteryl esterase; Acid cholesteryl ester hydrolase
T24373	FUNCTION	Crucial for the intracellular hydrolysis of cholesteryl esters and triglycerides that have been internalized via receptor- mediated endocytosis of lipoprotein particles. Important in mediating the effect of LDL (low density lipoprotein) uptake on suppression of hydroxymethylglutaryl-CoA reductase and activation of endogenous cellular cholesteryl ester formation.
T24373	BIOCLASS	Carboxylic ester hydrolase
T24373	ECNUMBER	EC 3.1.1.13
T24373	SEQUENCE	MKMRFLGLVVCLVLWTLHSEGSGGKLTAVDPETNMNVSEIISYWGFPSEEYLVETEDGYILCLNRIPHGRKNHSDKGPKPVVFLQHGLLADSSNWVTNLANSSLGFILADAGFDVWMGNSRGNTWSRKHKTLSVSQDEFWAFSYDEMAKYDLPASINFILNKTGQEQVYYVGHSQGTTIGFIAFSQIPELAKRIKMFFALGPVASVAFCTSPMAKLGRLPDHLIKDLFGDKEFLPQSAFLKWLGTHVCTHVILKELCGNLCFLLCGFNERNLNMSRVDVYTTHSPAGTSVQNMLHWSQAVKFQKFQAFDWGSSAKNYFHYNQSYPPTYNVKDMLVPTAVWSGGHDWLADVYDVNILLTQITNLVFHESIPEWEHLDFIWGLDAPWRLYNKIINLMRKYQ
T24373	DRUGINFO	D0CH4A	SBC-102	Approved

T73189	TARGETID	T73189
T73189	FORMERID	TTDI01942
T73189	UNIPROID	FKS2_YEAST
T73189	TARGNAME	Fungal 1,3-beta-glucan synthase (Fung GSC2)
T73189	GENENAME	Fung GSC2
T73189	TARGTYPE	Successful
T73189	SYNONYMS	GSC2
T73189	FUNCTION	Alternate catalytic subunit of the 1,3-beta-glucan synthase (GS). Synthesizes 1,3-beta-glucan, a major structural component of the yeast cell wall. Involved in cell wall synthesis, maintenance and cell wall remodeling.
T73189	BIOCLASS	Hexosyltransferase
T73189	ECNUMBER	EC 2.4.1.34
T73189	SEQUENCE	MSYNDPNLNGQYYSNGDGTGDGNYPTYQVTQDQSAYDEYGQPIYTQNQLDDGYYDPNEQYVDGTQFPQGQDPSQDQGPYNNDASYYNQPPNMMNPSSQDGENFSDFSSYGPPSGTYPNDQYTPSQMSYPDQDGSSGASTPYGNGVVNGNGQYYDPNAIEMALPNDPYPAWTADPQSPLPIEQIEDIFIDLTNKFGFQRDSMRNMFDHFMTLLDSRSSRMSPEQALLSLHADYIGGDTANYKKWYFAAQLDMDDEIGFRNMKLGKLSRKARKAKKKNKKAMQEASPEDTEETLNQIEGDNSLEAADFRWKSKMNQLSPFEMVRQIALFLLCWGEANQVRFTPECLCFIYKCASDYLDSAQCQQRPDPLPEGDFLNRVITPLYRFIRSQVYEIVDGRYVKSEKDHNKVIGYDDVNQLFWYPEGIAKIVMEDGTRLIDLPAEERYLKLGEIPWDDVFFKTYKETRSWLHLVTNFNRIWIMHISVYWMYCAYNAPTFYTHNYQQLVDNQPLAAYKWATAALGGTVASLIQVAATLCEWSFVPRKWAGAQHLSRRFWFLCVIMGINLGPVIFVFAYDKDTVYSTAAHVVGAVMFFVAVATLVFFSVMPLGGLFTSYMKKSTRSYVASQTFTASFAPLHGLDRWMSYLVWVTVFAAKYAESYFFLILSLRDPIRILSTTSMRCTGEYWWGNKICKVQPKIVLGLMIATDFILFFLDTYLWYIVVNTVFSVGKSFYLGISILTPWRNIFTRLPKRIYSKILATTDMEIKYKPKVLISQIWNAIIISMYREHLLAIDHVQKLLYHQVPSEIEGKRTLRAPTFFVSQDDNNFETEFFPRDSEAERRISFFAQSLSTPIPEPLPVDNMPTFTVLTPHYAERILLSLREIIREDDQFSRVTLLEYLKQLHPVEWDCFVKDTKILAEETAAYENNEDEPEKEDALKSQIDDLPFYCIGFKSAAPEYTLRTRIWASLRSQTLYRTISGFMNYSRAIKLLYRVENPEIVQMFGGNADGLERELEKMARRKFKFLVSMQRLAKFKPHELENAEFLLRAYPDLQIAYLDEEPPLNEGEEPRIYSALIDGHCEILENGRRRPKFRVQLSGNPILGDGKSDNQNHALIFYRGEYIQLIDANQDNYLEECLKIRSVLAEFEELGIEQIHPYTPGLKYEDQSTNHPVAIVGAREYIFSENSGVLGDVAAGKEQTFGTLFARTLAQIGGKLHYGHPDFINATFMTTRGGVSKAQKGLHLNEDIYAGMNAVLRGGRIKHCEYYQCGKGRDLGFGTILNFTTKIGAGMGEQMLSREYYYLGTQLPIDRFLTFYYAHPGFHLNNLFIQLSLQMFMLTLVNLHALAHESILCVYDRDKPITDVLYPIGCYNFHPAIDWVRRYTLSIFIVFWIAFVPIVVQELIERGLWKATQRFFRHILSLSPMFEVFAGQIYSSALLSDIAVGGARYISTGRGFATSRIPFSILYSRFAGSAIYMGSRSMLMLLFGTVAHWQAPLLWFWASLSALIFAPFIFNPHQFAWEDFFLDYRDYIRWLSRGNNKYHRNSWIGYVRMSRSRVTGFKRKLVGDESEKSAGDASRAHRTNLIMAEIIPCAIYAAGCFIAFTFINAQTGVKTTDEDRVNSTLRIIICTLAPIVIDIGVLFFCMGLSCCSGPLLGMCCKKTGSVMAGIAHGIAVVVHIVFFIVMWVLEGFSFVRMLIGVVTCIQCQRLIFHCMTVLLLTREFKNDHANTAFWTGKWYSTGLGYMAWTQPTRELTAKVIELSEFAADFVLGHVILIFQLPVICIPKIDKFHSIMLFWLKPSRQIRPPIYSLKQARLRKRMVRRYCSLYFLVLIIFAGCIVGPAVASAHVPKDLGSGLTGTFHNLVQPRNVSNNDTGSQMSTYKSHYYTHTPSLKTWSTIK
T73189	DRUGINFO	D00ZCN	Caspofungin	Approved
T73189	DRUGINFO	D02URM	Rezafungin	Approved
T73189	DRUGINFO	D06TOE	Micafungin	Approved
T73189	DRUGINFO	D07INL	Ibrexafungerp	Approved
T73189	DRUGINFO	D0F9BY	Anidulafungin	Approved
T73189	DRUGINFO	D07TDT	L-733560	Terminated

T51452	TARGETID	T51452
T51452	FORMERID	TTDR01177
T51452	UNIPROID	GBRA2_HUMAN
T51452	TARGNAME	GABA(A) receptor alpha-2 (GABRA2)
T51452	GENENAME	GABRA2
T51452	TARGTYPE	Successful
T51452	SYNONYMS	GABRA2; GABA-A receptor alpha 2; GABA(A)Gamma-aminobutyric-acid receptor alpha-2 subunit precursor receptor
T51452	FUNCTION	GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
T51452	BIOCLASS	Neurotransmitter receptor
T51452	SEQUENCE	MKTKLNIYNMQFLLFVFLVWDPARLVLANIQEDEAKNNITIFTRILDRLLDGYDNRLRPGLGDSITEVFTNIYVTSFGPVSDTDMEYTIDVFFRQKWKDERLKFKGPMNILRLNNLMASKIWTPDTFFHNGKKSVAHNMTMPNKLLRIQDDGTLLYTMRLTVQAECPMHLEDFPMDAHSCPLKFGSYAYTTSEVTYIWTYNASDSVQVAPDGSRLNQYDLLGQSIGKETIKSSTGEYTVMTAHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISARNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGWAWDGKSVVNDKKKEKASVMIQNNAYAVAVANYAPNLSKDPVLSTISKSATTPEPNKKPENKPAEAKKTFNSVSKIDRMSRIVFPVLFGTFNLVYWATYLNREPVLGVSP
T51452	DRUGINFO	D0D5GD	Flumazenil	Approved
T51452	DRUGINFO	D0C9XA	GSK683699	Phase 2
T51452	DRUGINFO	D00AJI	PF-4480682	Discontinued in Phase 2
T51452	DRUGINFO	D06BFP	CGS-17867A	Terminated
T51452	DRUGINFO	D09IHE	MRK016	Investigative
T51452	DRUGINFO	D09YOU	MK-0343	Investigative
T51452	DRUGINFO	D03PBN	tetrahydrodeoxycorticosterone	Investigative
T51452	DRUGINFO	D03ZWB	alpha3IA	Investigative
T51452	DRUGINFO	D06SOQ	alpha5IA	Investigative
T51452	DRUGINFO	D07JXC	[18F]fluoroethylflumazenil	Investigative
T51452	DRUGINFO	D0GQ1S	DMCM	Investigative
T51452	DRUGINFO	D0Q1ZT	TP003	Investigative
T51452	DRUGINFO	D0T9DS	[35S]TBPS	Investigative
T51452	DRUGINFO	D0H4GQ	RY-066	Investigative
T51452	DRUGINFO	D01CUR	3-Ethoxy-9H-beta-carboline	Investigative
T51452	DRUGINFO	D01RLF	9H-beta-Carboline-3-carboxylic acid ethyl ester	Investigative
T51452	DRUGINFO	D03PPZ	Beta-Carboline-3-carboxylic acid t-butyl ester	Investigative
T51452	DRUGINFO	D03TMD	Barbituric acid derivative	Investigative
T51452	DRUGINFO	D06WMM	3-Butoxy-9H-beta-carboline	Investigative
T51452	DRUGINFO	D08BOP	3-Propoxy-9H-beta-carboline	Investigative
T51452	DRUGINFO	D08BXK	3-(3-Methyl-butoxy)-9H-beta-carboline	Investigative
T51452	DRUGINFO	D09MYJ	3-Isobutoxy-9H-beta-carboline	Investigative
T51452	DRUGINFO	D0C6WO	Sec-butyl 9H-pyrido[3,4-b]indole-3-carboxylate	Investigative
T51452	DRUGINFO	D0D4MM	Ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate	Investigative
T51452	DRUGINFO	D0E7PY	Ro-4938581	Investigative
T51452	DRUGINFO	D0O9MG	L-655708	Investigative
T51452	DRUGINFO	D0P3BU	3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole	Investigative
T51452	DRUGINFO	D0R5OU	3-(benzyloxy)-9H-pyrido[3,4-b]indole	Investigative
T51452	DRUGINFO	D01IHM	CI-218872	Investigative
T51452	DRUGINFO	D07NKO	5-[(1R)-1-ammonioethyl]isoxazol-3-olate	Investigative
T51452	DRUGINFO	D09ACO	(2E,4S)-4-ammoniopent-2-enoate	Investigative
T51452	DRUGINFO	D0A8EU	(4R)-4-ammoniopentanoate	Investigative
T51452	DRUGINFO	D0N0ZK	(4S)-4-ammoniopentanoate	Investigative
T51452	DRUGINFO	D0S5PS	5-[(1S)-1-ammonioethyl]isoxazol-3-olate	Investigative
T51452	DRUGINFO	D0VW5M	piperidine-4-sulphonic acid	Investigative
T51452	DRUGINFO	D00WHO	Ro-15-3505	Investigative
T51452	DRUGINFO	D0AC2H	isonipecotic acid	Investigative
T51452	DRUGINFO	D0M4CP	[3H]Ro154513	Investigative
T51452	DRUGINFO	D0M9RM	[3H]CGS8216	Investigative
T51452	DRUGINFO	D06HRX	AMENTOFLAVONE	Investigative
T51452	DRUGINFO	D0P0TI	TBPS	Investigative

T15571	TARGETID	T15571
T15571	FORMERID	TTDR00565
T15571	UNIPROID	5HT5A_HUMAN
T15571	TARGNAME	5-HT 5A receptor (HTR5A)
T15571	GENENAME	HTR5A
T15571	TARGTYPE	Successful
T15571	SYNONYMS	Serotonin receptor 5A; 5-hydroxytryptamine receptor 5A; 5-HT5A; 5-HT-5A; 5-HT-5; 5-HT 5A
T15571	FUNCTION	The activity of this receptor is mediated by G proteins. This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen.
T15571	BIOCLASS	GPCR rhodopsin
T15571	SEQUENCE	MDLPVNLTSFSLSTPSPLETNHSLGKDDLRPSSPLLSVFGVLILTLLGFLVAATFAWNLLVLATILRVRTFHRVPHNLVASMAVSDVLVAALVMPLSLVHELSGRRWQLGRRLCQLWIACDVLCCTASIWNVTAIALDRYWSITRHMEYTLRTRKCVSNVMIALTWALSAVISLAPLLFGWGETYSEGSEECQVSREPSYAVFSTVGAFYLPLCVVLFVYWKIYKAAKFRVGSRKTNSVSPISEAVEVKDSAKQPQMVFTVRHATVTFQPEGDTWREQKEQRAALMVGILIGVFVLCWIPFFLTELISPLCSCDIPAIWKSIFLWLGYSNSFFNPLIYTAFNKNYNSAFKNFFSRQH
T15571	DRUGINFO	D0UA0I	Metergolin	Approved
T15571	DRUGINFO	D03XKU	4-ethyl-3,4-dihydroquinazolin-2-amine	Investigative
T15571	DRUGINFO	D03XMD	SB 699551	Investigative
T15571	DRUGINFO	D04UTQ	N,N-dimethyl-3,4-dihydroquinazolin-2-amine	Investigative
T15571	DRUGINFO	D06LIA	N,4-dimethyl-3,4-dihydroquinazolin-2-amine	Investigative
T15571	DRUGINFO	D07DLW	4-methyl-N-propyl-3,4-dihydroquinazolin-2-amine	Investigative
T15571	DRUGINFO	D0C3AR	8-chloro-3,4-dihydroquinazolin-2-amine	Investigative
T15571	DRUGINFO	D0E4ON	N-butyl-4-methyl-3,4-dihydroquinazolin-2-amine	Investigative
T15571	DRUGINFO	D0EA7Z	4-propyl-3,4-dihydroquinazolin-2-amine	Investigative
T15571	DRUGINFO	D0I6II	3,4-dihydroquinazolin-2-amine hydrobromide	Investigative
T15571	DRUGINFO	D0W1TU	SB-699551-A	Investigative
T15571	DRUGINFO	D0L9ZQ	lysergic acid	Investigative
T15571	DRUGINFO	D0X6MT	METHIOTHEPIN	Investigative
T15571	DRUGINFO	D03ZHB	5-chloro-4-ethyl-3,4-dihydroquinazolin-2-amine	Investigative
T15571	DRUGINFO	D0BW9V	[125I]LSD	Investigative
T15571	DRUGINFO	D04TPO	5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine	Investigative
T15571	DRUGINFO	D08PJK	[3H]5-CT	Investigative
T15571	DRUGINFO	D0SP2J	bufotenine	Investigative
T15571	DRUGINFO	D0XX2U	8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine	Investigative
T15571	DRUGINFO	D0CK9K	EDMT	Investigative
T15571	DRUGINFO	D0C5GF	MPDT	Investigative
T15571	DRUGINFO	D0Y9TL	5-chloro-3,4-dihydroquinazolin-2-amine	Investigative
T15571	DRUGINFO	D08VGJ	5,6-dichloro-3,4-dihydroquinazolin-2-amine	Investigative
T15571	DRUGINFO	D02UWB	5-CT	Investigative
T15571	DRUGINFO	D0V5HV	TFMPP	Investigative
T15571	DRUGINFO	D0F6CD	SEROTONIN	Investigative
T15571	DRUGINFO	D0L5MW	(+/-)-nantenine	Investigative

T59720	TARGETID	T59720
T59720	FORMERID	TTDR00659
T59720	UNIPROID	FHIT_HUMAN
T59720	TARGNAME	Fragile histidine triad protein (FHIT)
T59720	GENENAME	FHIT
T59720	TARGTYPE	Successful
T59720	SYNONYMS	Fragile histidinetriad protein; Fragile histidinetriad (FHIT) gene; Dinucleosidetriphosphatase; Diadenosine 5',5'''-P1,P3-triphosphate hydrolase; Bis(5'-adenosyl)-triphosphatase; AP3AASE; AP3A hydrolase
T59720	FUNCTION	Can also hydrolyze P(1)-P(4)-bis(5'-adenosyl) tetraphosphate (Ap4A), but has extremely low activity with ATP. Modulates transcriptional activation by CTNNB1 and thereby contributes to regulate the expression of genes essential for cell proliferation and survival, such as CCND1 and BIRC5. Plays a role in the induction of apoptosis via SRC and AKT1 signaling pathways. Inhibits MDM2-mediated proteasomal degradation of p53/TP53 and thereby plays a role in p53/TP53-mediated apoptosis. Induction of apoptosis depends on the ability of FHIT to bind P(1)-P(3)-bis(5'-adenosyl) triphosphate or related compounds, but does not require its catalytic activity, it may in part come from the mitochondrial form, which sensitizes the low-affinity Ca(2+) transporters, enhancing mitochondrial calcium uptake. Functions as tumor suppressor. Cleaves P(1)-P(3)-bis(5'-adenosyl) triphosphate (Ap3A) to yield AMP and ADP.
T59720	PDBSTRUC	6FIT; 5FIT; 4FIT; 3FIT; 2FIT
T59720	BIOCLASS	Acid anhydride hydrolase
T59720	ECNUMBER	EC 3.6.1.29
T59720	SEQUENCE	MSFRFGQHLIKPSVVFLKTELSFALVNRKPVVPGHVLVCPLRPVERFHDLRPDEVADLFQTTQRVGTVVEKHFHGTSLTFSMQDGPEAGQTVKHVHVHVLPRKAGDFHRNDSIYEELQKHDKEDFPASWRSEEEMAAEAAALRVYFQ
T59720	DRUGINFO	D06HZY	Fructose	Approved
T59720	DRUGINFO	D08IHM	Adenosine Monotungstate	Investigative
T59720	DRUGINFO	D09KQT	Ado-P-Ch2-P-Ps-Ado	Investigative

T34318	TARGETID	T34318
T34318	FORMERID	TTDNS00564
T34318	UNIPROID	CAMP_HUMAN
T34318	TARGNAME	Cathelicidin antimicrobial peptide (CAMP)
T34318	GENENAME	CAMP
T34318	TARGTYPE	Successful
T34318	SYNONYMS	upregulating cAMP; hCAP18; CAP18; CAMP; Antibacterial protein LL37; 18 kDa cationic antimicrobial protein
T34318	FUNCTION	Binds to bacterial lipopolysaccharides (LPS), has antibacterial activity.
T34318	BIOCLASS	Cathelicidin family
T34318	SEQUENCE	MKTQRDGHSLGRWSLVLLLLGLVMPLAIIAQVLSYKEAVLRAIDGINQRSSDANLYRLLDLDPRPTMDGDPDTPKPVSFTVKETVCPRTTQQSPEDCDFKKDGLVKRCMGTVTLNQARGSFDISCDKDNKRFALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES
T34318	DRUGINFO	D0H2MO	Colforsin daropate hci	Approved

T66350	TARGETID	T66350
T66350	FORMERID	TTDR00036
T66350	UNIPROID	RAB9A_HUMAN
T66350	TARGNAME	Ras-related protein Rab-9A (RAB9A)
T66350	GENENAME	RAB9A
T66350	TARGTYPE	Successful
T66350	SYNONYMS	RAB9A
T66350	FUNCTION	Involved in the transport of proteins between the endosomes and the trans Golgi network.
T66350	PDBSTRUC	1WMS
T66350	BIOCLASS	Small GTPase superfamily
T66350	SEQUENCE	MAGKSSLFKVILLGDGGVGKSSLMNRYVTNKFDTQLFHTIGVEFLNKDLEVDGHFVTMQIWDTAGQERFRSLRTPFYRGSDCCLLTFSVDDSQSFQNLSNWKKEFIYYADVKEPESFPFVILGNKIDISERQVSTEEAQAWCRDNGDYPYFETSAKDATNVAAAFEEAVRRVLATEDRSDHLIQTDTVNLHRKPKPSSSCC
T66350	DRUGINFO	D0X9RY	Benzoic Acid	Approved
T66350	DRUGINFO	D0C7LS	Guanosine-5'-Diphosphate	Investigative

T50066	TARGETID	T50066
T50066	FORMERID	TTDS00287
T50066	UNIPROID	CLCN2_HUMAN
T50066	TARGNAME	Chloride channel protein 2 (CLC-2)
T50066	GENENAME	CLCN2
T50066	TARGTYPE	Successful
T50066	SYNONYMS	ClC-2 chloride channel; ClC-2 Cl- channel; ClC-2; CLCN2
T50066	FUNCTION	Voltage-gated chloride channel. Chloride channels have several functions including the regulation of cell volume; membrane potential stabilization, signal transduction and transepithelial transport.
T50066	BIOCLASS	Chloride channel
T50066	SEQUENCE	MAAAAAEEGMEPRALQYEQTLMYGRYTQDLGAFAKEEAARIRLGGPEPWKGPPSSRAAPELLEYGRSRCARCRVCSVRCHKFLVSRVGEDWIFLVLLGLLMALVSWVMDYAIAACLQAQQWMSRGLNTSILLQYLAWVTYPVVLITFSAGFTQILAPQAVGSGIPEMKTILRGVVLKEYLTLKTFIAKVIGLTCALGSGMPLGKEGPFVHIASMCAALLSKFLSLFGGIYENESRNTEMLAAACAVGVGCCFAAPIGGVLFSIEVTSTFFAVRNYWRGFFAATFSAFIFRVLAVWNRDEETITALFKTRFRLDFPFDLQELPAFAVIGIASGFGGALFVYLNRKIVQVMRKQKTINRFLMRKRLLFPALVTLLISTLTFPPGFGQFMAGQLSQKETLVTLFDNRTWVRQGLVEELEPPSTSQAWNPPRANVFLTLVIFILMKFWMSALATTIPVPCGAFMPVFVIGAAFGRLVGESMAAWFPDGIHTDSSTYRIVPGGYAVVGAAALAGAVTHTVSTAVIVFELTGQIAHILPVMIAVILANAVAQSLQPSLYDSIIRIKKLPYLPELGWGRHQQYRVRVEDIMVRDVPHVALSCTFRDLRLALHRTKGRMLALVESPESMILLGSIERSQVVALLGAQLSPARRRQHMQERRATQTSPLSDQEGPPTPEASVCFQVNTEDSAFPAARGETHKPLKPALKRGPSVTRNLGESPTGSAESAGIALRSLFCGSPPPEAASEKLESCEKRKLKRVRISLASDADLEGEMSPEEILEWEEQQLDEPVNFSDCKIDPAPFQLVERTSLHKTHTIFSLLGVDHAYVTSIGRLIGIVTLKELRKAIEGSVTAQGVKVRPPLASFRDSATSSSDTETTEVHALWGPHSRHGLPREGSPSDSDDKCQ
T50066	DRUGINFO	D00CTS	Lubiprostone	Approved
T50066	DRUGINFO	D0E2QC	RK-023	Phase 2
T50066	DRUGINFO	D03APP	diphenylamine-2-carboxylic acid	Investigative
T50066	DRUGINFO	D0L1UK	Acid-activated omeprazole	Investigative
T50066	DRUGINFO	D08DQL	NPPB	Investigative

T84886	TARGETID	T84886
T84886	FORMERID	TTDS00117
T84886	UNIPROID	S12A3_HUMAN
T84886	TARGNAME	Solute carrier family 12 member 3 (SLC12A3)
T84886	GENENAME	SLC12A3
T84886	TARGTYPE	Successful
T84886	SYNONYMS	Thiazide-sensitive sodium-chloride cotransporter; Thiazide-sensitive Na-Cl cotransporter; SLC12A3; Na-Cl symporter
T84886	FUNCTION	Key mediator of sodium and chloride reabsorption in this nephron segment, accounting for a significant fraction of renal sodium reabsorption.
T84886	BIOCLASS	Cation-chloride cotransporter
T84886	SEQUENCE	MAELPTTETPGDATLCSGRFTISTLLSSDEPSPPAAYDSSHPSHLTHSSTFCMRTFGYNTIDVVPTYEHYANSTQPGEPRKVRPTLADLHSFLKQEGRHLHALAFDSRPSHEMTDGLVEGEAGTSSEKNPEEPVRFGWVKGVMIRCMLNIWGVILYLRLPWITAQAGIVLTWIIILLSVTVTSITGLSISAISTNGKVKSGGTYFLISRSLGPELGGSIGLIFAFANAVGVAMHTVGFAETVRDLLQEYGAPIVDPINDIRIIAVVSVTVLLAISLAGMEWESKAQVLFFLVIMVSFANYLVGTLIPPSEDKASKGFFSYRADIFVQNLVPDWRGPDGTFFGMFSIFFPSATGILAGANISGDLKDPAIAIPKGTLMAIFWTTISYLAISATIGSCVVRDASGVLNDTVTPGWGACEGLACSYGWNFTECTQQHSCHYGLINYYQTMSMVSGFAPLITAGIFGATLSSALACLVSAAKVFQCLCEDQLYPLIGFFGKGYGKNKEPVRGYLLAYAIAVAFIIIAELNTIAPIISNFFLCSYALINFSCFHASITNSPGWRPSFQYYNKWAALFGAIISVVIMFLLTWWAALIAIGVVLFLLLYVIYKKPEVNWGSSVQAGSYNLALSYSVGLNEVEDHIKNYRPQCLVLTGPPNFRPALVDFVGTFTRNLSLMICGHVLIGPHKQRMPELQLIANGHTKWLNKRKIKAFYSDVIAEDLRRGVQILMQAAGLGRMKPNILVVGFKKNWQSAHPATVEDYIGILHDAFDFNYGVCVMRMREGLNVSKMMQAHINPVFDPAEDGKEASARVDPKALVKEEQATTIFQSEQGKKTIDIYWLFDDGGLTLLIPYLLGRKRRWSKCKIRVFVGGQINRMDQERKAIISLLSKFRLGFHEVHILPDINQNPRAEHTKRFEDMIAPFRLNDGFKDEATVNEMRRDCPWKISDEEITKNRVKSLRQVRLNEIVLDYSRDAALIVITLPIGRKGKCPSSLYMAWLETLSQDLRPPVILIRGNQENVLTFYCQ
T84886	DRUGINFO	D01WLC	Metolazone	Approved
T84886	DRUGINFO	D06TNG	Polythiazide	Approved
T84886	DRUGINFO	D02PAH	Bendroflumethiazide	Approved

T46628	TARGETID	T46628
T46628	FORMERID	TTDC00123
T46628	UNIPROID	MTP_HUMAN
T46628	TARGNAME	Microsomal triglyceride transfer protein (MTTP)
T46628	GENENAME	MTTP
T46628	TARGTYPE	Successful
T46628	SYNONYMS	Microsomal triglyceride transfer protein large subunit; MTP
T46628	FUNCTION	Required for the secretion of plasma lipoproteins that contain apolipoprotein B. Catalyzes the transport of triglyceride, cholesteryl ester, and phospholipid between phospholipid surfaces.
T46628	SEQUENCE	MILLAVLFLCFISSYSASVKGHTTGLSLNNDRLYKLTYSTEVLLDRGKGKLQDSVGYRISSNVDVALLWRNPDGDDDQLIQITMKDVNVENVNQQRGEKSIFKGKSPSKIMGKENLEALQRPTLLHLIHGKVKEFYSYQNEAVAIENIKRGLASLFQTQLSSGTTNEVDISGNCKVTYQAHQDKVIKIKALDSCKIARSGFTTPNQVLGVSSKATSVTTYKIEDSFVIAVLAEETHNFGLNFLQTIKGKIVSKQKLELKTTEAGPRLMSGKQAAAIIKAVDSKYTAIPIVGQVFQSHCKGCPSLSELWRSTRKYLQPDNLSKAEAVRNFLAFIQHLRTAKKEEILQILKMENKEVLPQLVDAVTSAQTSDSLEAILDFLDFKSDSSIILQERFLYACGFASHPNEELLRALISKFKGSIGSSDIRETVMIITGTLVRKLCQNEGCKLKAVVEAKKLILGGLEKAEKKEDTRMYLLALKNALLPEGIPSLLKYAEAGEGPISHLATTALQRYDLPFITDEVKKTLNRIYHQNRKVHEKTVRTAAAAIILNNNPSYMDVKNILLSIGELPQEMNKYMLAIVQDILRFEMPASKIVRRVLKEMVAHNYDRFSRSGSSSAYTGYIERSPRSASTYSLDILYSGSGILRRSNLNIFQYIGKAGLHGSQVVIEAQGLEALIAATPDEGEENLDSYAGMSAILFDVQLRPVTFFNGYSDLMSKMLSASGDPISVVKGLILLIDHSQELQLQSGLKANIEVQGGLAIDISGAMEFSLWYRESKTRVKNRVTVVITTDITVDSSFVKAGLETSTETEAGLEFISTVQFSQYPFLVCMQMDKDEAPFRQFEKKYERLSTGRGYVSQKRKESVLAGCEFPLHQENSEMCKVVFAPQPDSTSSGWF
T46628	DRUGINFO	D0H8VY	BMS-201038	Approved
T46628	DRUGINFO	D05YTG	SLx-4090	Phase 2
T46628	DRUGINFO	D0F2KX	Granotapide	Phase 2
T46628	DRUGINFO	D0F6YK	Implitapide	Phase 2
T46628	DRUGINFO	D0M5WS	JNJ-16269110	Phase 2
T46628	DRUGINFO	D0S7AW	KD020	Phase 1/2
T46628	DRUGINFO	D0SS6J	GR-328713	Discontinued in Phase 1
T46628	DRUGINFO	D0J0TP	DIRLOTAPIDE	Investigative

T71023	TARGETID	T71023
T71023	FORMERID	TTDS00496
T71023	UNIPROID	SNP25_HUMAN
T71023	TARGNAME	Synaptosomal-associated protein 25 (SNAP25)
T71023	GENENAME	SNAP25
T71023	TARGTYPE	Successful
T71023	SYNONYMS	Synaptosomal-associated 25 kDa protein; Super protein; SUP; SNAP-25; SNAP
T71023	FUNCTION	May play an important role in the synaptic function of specific neuronal systems. Associates with proteins involved in vesicle docking and membrane fusion. Regulates plasma membrane recycling through its interaction with CENPF. Modulates the gating characteristics of the delayed rectifier voltage-dependent potassium channel KCNB1 in pancreatic beta cells. t-SNARE involved in the molecular regulation of neurotransmitter release.
T71023	PDBSTRUC	5W7J; 5W7I; 3ZUR; 3RL0; 3RK3
T71023	BIOCLASS	Synaptosomal vesicle fusion pore
T71023	SEQUENCE	MAEDADMRNELEEMQRRADQLADESLESTRRMLQLVEESKDAGIRTLVMLDEQGEQLERIEEGMDQINKDMKEAEKNLTDLGKFCGLCVCPCNKLKSSDAYKKAWGNNQDGVVASQPARVVDEREQMAISGGFIRRVTNDARENEMDENLEQVSGIIGNLRHMALDMGNEIDTQNRQIDRIMEKADSNKTRIDEANQRATKMLGSG
T71023	DRUGINFO	D0D1RM	Botulinum Toxin Type A	Approved

T95479	TARGETID	T95479
T95479	FORMERID	TTDS00497
T95479	UNIPROID	SMS_HUMAN
T95479	TARGNAME	Somatostatin (SST)
T95479	GENENAME	SST
T95479	TARGTYPE	Successful
T95479	SYNONYMS	Somatostatin-28; Somatostatin-14; SST; Growth hormone release-inhibiting factor
T95479	FUNCTION	Somatostatin inhibits the release of somatotropin.
T95479	PDBSTRUC	2MI1; 1P2W
T95479	BIOCLASS	Somatostatin cortistatin
T95479	SEQUENCE	MLSCRLQCALAALSIVLALGCVTGAPSDPRLRQFLQKSLAAAAGKQELAKYFLAELLSEPNQTENDALEPEDLSQAAEQDEMRLELQRSANSNPAMAPRERKAGCKNFFWKTFTSC
T95479	DRUGINFO	D0V0LB	Cysteamine	Approved

T12966	TARGETID	T12966
T12966	FORMERID	TTDS00409
T12966	UNIPROID	TNNC1_HUMAN
T12966	TARGNAME	Troponin C (TN-C)
T12966	GENENAME	TNNC1
T12966	TARGTYPE	Successful
T12966	SYNONYMS	Troponin C, slow skeletal and cardiac muscles; TNNC
T12966	FUNCTION	Troponin is the central regulatory protein of striated muscle contraction. Tn consists of three components: Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site for tropomyosin and Tn-C. The binding of calcium to Tn-C abolishes the inhibitory action of Tn on actin filaments.
T12966	PDBSTRUC	6MV3; 5WCL; 5W88; 5VLN; 4Y99
T12966	SEQUENCE	MDDIYKAAVEQLTEEQKNEFKAAFDIFVLGAEDGCISTKELGKVMRMLGQNPTPEELQEMIDEVDEDGSGTVDFDEFLVMMVRCMKDDSKGKSEEELSDLFRMFDKNADGYIDLDELKIMLQATGETITEDDIEELMKDGDKNNDGRIDYDEFLEFMKGVE
T12966	DRUGINFO	D0C4HG	Levosimendan	Approved
T12966	DRUGINFO	D0L9YX	Dihydroxyaluminium	Approved

T09423	TARGETID	T09423
T09423	FORMERID	TTDS00431
T09423	UNIPROID	KCJ10_HUMAN
T09423	TARGNAME	Inward rectifier potassium channel Kir1.2 (KCNJ10)
T09423	GENENAME	KCNJ10
T09423	TARGTYPE	Successful
T09423	SYNONYMS	Potassiumchannel, inwardly rectifying, subfamily J, member 10; Potassium channel, inwardly rectifying subfamily J member 10; Inward rectifier K+ channel Kir1.2; Inward rectifier K(+) channel Kir1.2; ATP-sensitive inward rectifier potassium channel 10; ATP-dependent inwardly rectifying potassium channel Kir4.1; ATP dependent K+ channel
T09423	FUNCTION	Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. Can be blocked by extracellular barium and cesium. In the kidney, together with KCNJ16, mediates basolateral K(+) recycling in distal tubules; this process is critical for Na(+) reabsorption at the tubules. May be responsible for potassium buffering action of glial cells in the brain.
T09423	BIOCLASS	Inward rectifier potassium channel
T09423	SEQUENCE	MTSVAKVYYSQTTQTESRPLMGPGIRRRRVLTKDGRSNVRMEHIADKRFLYLKDLWTTFIDMQWRYKLLLFSATFAGTWFLFGVVWYLVAVAHGDLLELDPPANHTPCVVQVHTLTGAFLFSLESQTTIGYGFRYISEECPLAIVLLIAQLVLTTILEIFITGTFLAKIARPKKRAETIRFSQHAVVASHNGKPCLMIRVANMRKSLLIGCQVTGKLLQTHQTKEGENIRLNQVNVTFQVDTASDSPFLILPLTFYHVVDETSPLKDLPLRSGEGDFELVLILSGTVESTSATCQVRTSYLPEEILWGYEFTPAISLSASGKYIADFSLFDQVVKVASPSGLRDSTVRYGDPEKLKLEESLREQAEKEGSALSVRISNV
T09423	DRUGINFO	D00BCP	Chlorpropamide	Approved
T09423	DRUGINFO	D03JAA	Glycodiazine	Approved
T09423	DRUGINFO	D04NTJ	Glisoxepide	Approved
T09423	DRUGINFO	D06HBQ	Gliquidone	Approved
T09423	DRUGINFO	D09FJB	Tolazamide	Approved
T09423	DRUGINFO	D0P2YU	Mitiglinide	Approved
T09423	DRUGINFO	D0Z4SB	Glipizide	Approved
T09423	DRUGINFO	D0K4HI	Sulfonylthioureas	Investigative

T30578	TARGETID	T30578
T30578	FORMERID	TTDS00383
T30578	UNIPROID	EMBC_MYCTU
T30578	TARGNAME	Mycobacterium Arabinosyltransferase C (MycB embC)
T30578	GENENAME	MycB embC
T30578	TARGTYPE	Successful
T30578	SYNONYMS	Probable arabinosyltransferase C
T30578	FUNCTION	Arabinosyl transferase responsible for the polymerization of arabinose into the arabinan of arabinogalactan.
T30578	PDBSTRUC	3PTY
T30578	ECNUMBER	EC 2.4.2.-
T30578	SEQUENCE	MATEAAPPRIAVRLPSTSVRDAGANYRIARYVAVVAGLLGAVLAIATPLLPVNQTTAQLNWPQNGTFASVEAPLIGYVATDLNITVPCQAAAGLAGSQNTGKTVLLSTVPKQAPKAVDRGLLLQRANDDLVLVVRNVPLVTAPLSQVLGPTCQRLTFTAHADRVAAEFVGLVQGPNAEHPGAPLRGERSGYDFRPQIVGVFTDLAGPAPPGLSFSASVDTRYSSSPTPLKMAAMILGVALTGAALVALHILDTADGMRHRRFLPARWWSTGGLDTLVIAVLVWWHFVGANTSDDGYILTMARVSEHAGYMANYYRWFGTPEAPFGWYYDLLALWAHVSTASIWMRLPTLAMALTCWWVISREVIPRLGHAVKTSRAAAWTAAGMFLAVWLPLDNGLRPEPIIALGILLTWCSVERAVATSRLLPVAIACIIGALTLFSGPTGIASIGALLVAIGPLRTILHRRSRRFGVLPLVAPILAAATVTAIPIFRDQTFAGEIQANLLKRAVGPSLKWFDEHIRYERLFMASPDGSIARRFAVLALVLALAVSVAMSLRKGRIPGTAAGPSRRIIGITIISFLAMMFTPTKWTHHFGVFAGLAGSLGALAAVAVTGAAMRSRRNRTVFAAVVVFVLALSFASVNGWWYVSNFGVPWSNSFPKWRWSLTTALLELTVLVLLLAAWFHFVANGDGRRTARPTRFRARLAGIVQSPLAIATWLLVLFEVVSLTQAMISQYPAWSVGRSNLQALAGKTCGLAEDVLVELDPNAGMLAPVTAPLADALGAGLSEAFTPNGIPADVTADPVMERPGDRSFLNDDGLITGSEPGTEGGTTAAPGINGSRARLPYNLDPARTPVLGSWRAGVQVPAMLRSGWYRLPTNEQRDRAPLLVVTAAGRFDSREVRLQWATDEQAAAGHHGGSMEFADVGAAPAWRNLRAPLSAIPSTATQVRLVADDQDLAPQHWIALTPPRIPRVRTLQNVVGAADPVFLDWLVGLAFPCQRPFGHQYGVDETPKWRILPDRFGAEANSPVMDHNGGGPLGITELLMRATTVASYLKDDWFRDWGALQRLTPYYPDAQPADLNLGTVTRSGLWSPAPLRRG
T30578	DRUGINFO	D08QME	Ethambutol	Approved

T68253	TARGETID	T68253
T68253	FORMERID	TTDR00165
T68253	UNIPROID	DDL_MYCTO
T68253	TARGNAME	Mycobacterium D-alanine-D-alanine ligase (MycB ddl)
T68253	GENENAME	MycB ddl
T68253	TARGTYPE	Successful
T68253	SYNONYMS	ddl; D-alanylalanine synthetase; D-alanine:D-alanine ligase; D-Ala-D-Ala ligase
T68253	FUNCTION	Cell wall formation.
T68253	BIOCLASS	Carbon-nitrogen ligase
T68253	ECNUMBER	EC 6.3.2.4
T68253	SEQUENCE	MSANDRRDRRVRVAVVFGGRSNEHAISCVSAGSILRNLDSRRFDVIAVGITPAGSWVLTDANPDALTITNRELPQVKSGSGTELALPADPRRGGQLVSLPPGAGEVLESVDVVFPVLHGPYGEDGTIQGLLELAGVPYVGAGVLASAVGMDKEFTKKLLAADGLPVGAYAVLRPPRSTLHRQECERLGLPVFVKPARGGSSIGVSRVSSWDQLPAAVARARRHDPKVIVEAAISGRELECGVLEMPDGTLEASTLGEIRVAGVRGREDSFYDFATKYLDDAAELDVPAKVDDQVAEAIRQLAIRAFAAIDCRGLARVDFFLTDDGPVINEINTMPGFTTISMYPRMWAASGVDYPTLLATMIETALARGVGLH

T70449	TARGETID	T70449
T70449	FORMERID	TTDS00446
T70449	UNIPROID	GHRHR_HUMAN
T70449	TARGNAME	Growth hormone-releasing hormone receptor (GHRHR)
T70449	GENENAME	GHRHR
T70449	TARGTYPE	Successful
T70449	SYNONYMS	GRFR; GRF receptor; GHRHR; GHRH receptor
T70449	FUNCTION	Receptor for GRF,coupled to G proteins which activate adenylyl cyclase. Stimulates somatotroph cell growth, growth hormone gene transcription and growth hormone secretion.
T70449	PDBSTRUC	2XDG
T70449	BIOCLASS	GPCR secretin
T70449	SEQUENCE	MDRRMWGAHVFCVLSPLPTVLGHMHPECDFITQLREDESACLQAAEEMPNTTLGCPATWDGLLCWPTAGSGEWVTLPCPDFFSHFSSESGAVKRDCTITGWSEPFPPYPVACPVPLELLAEEESYFSTVKIIYTVGHSISIVALFVAITILVALRRLHCPRNYVHTQLFTTFILKAGAVFLKDAALFHSDDTDHCSFSTVLCKVSVAASHFATMTNFSWLLAEAVYLNCLLASTSPSSRRAFWWLVLAGWGLPVLFTGTWVSCKLAFEDIACWDLDDTSPYWWIIKGPIVLSVGVNFGLFLNIIRILVRKLEPAQGSLHTQSQYWRLSKSTLFLIPLFGIHYIIFNFLPDNAGLGIRLPLELGLGSFQGFIVAILYCFLNQEVRTEISRKWHGHDPELLPAWRTRAKWTTPSRSAAKVLTSMC
T70449	DRUGINFO	D04AQH	Sermorelin	Approved
T70449	DRUGINFO	D0UL9R	Tesamorelin	Approved
T70449	DRUGINFO	D09TGZ	Examorelin	Discontinued in Phase 2
T70449	DRUGINFO	D0J8WJ	AKL-0707	Discontinued in Phase 2
T70449	DRUGINFO	D0B3CY	L-692429	Discontinued in Phase 1
T70449	DRUGINFO	D01GCY	NNC-26-0762	Terminated
T70449	DRUGINFO	D0F2CH	Mutated growth hormone	Investigative

T75890	TARGETID	T75890
T75890	FORMERID	TTDR01187
T75890	UNIPROID	DPYD_HUMAN
T75890	TARGNAME	Dihydrothymine dehydrogenase (DPYD)
T75890	GENENAME	DPYD
T75890	TARGTYPE	Successful
T75890	SYNONYMS	Dihydrouracil dehydrogenase; Dihydropyrimidine dehydrogenase [NADP(+)]; Dihydropyrimidine dehydrogenase; DPD; DHPDHase
T75890	FUNCTION	Catalyzes the reduction of uracil and thymine. Also involved the degradation of the chemotherapeutic drug 5-fluorouracil. Involved in pyrimidine base degradation.
T75890	BIOCLASS	CH/CH donor oxidoreductase
T75890	ECNUMBER	EC 1.3.1.2
T75890	SEQUENCE	MAPVLSKDSADIESILALNPRTQTHATLCSTSAKKLDKKHWKRNPDKNCFNCEKLENNFDDIKHTTLGERGALREAMRCLKCADAPCQKSCPTNLDIKSFITSIANKNYYGAAKMIFSDNPLGLTCGMVCPTSDLCVGGCNLYATEEGPINIGGLQQFATEVFKAMSIPQIRNPSLPPPEKMSEAYSAKIALFGAGPASISCASFLARLGYSDITIFEKQEYVGGLSTSEIPQFRLPYDVVNFEIELMKDLGVKIICGKSLSVNEMTLSTLKEKGYKAAFIGIGLPEPNKDAIFQGLTQDQGFYTSKDFLPLVAKGSKAGMCACHSPLPSIRGVVIVLGAGDTAFDCATSALRCGARRVFIVFRKGFVNIRAVPEEMELAKEEKCEFLPFLSPRKVIVKGGRIVAMQFVRTEQDETGKWNEDEDQMVHLKADVVISAFGSVLSDPKVKEALSPIKFNRWGLPEVDPETMQTSEAWVFAGGDVVGLANTTVESVNDGKQASWYIHKYVQSQYGASVSAKPELPLFYTPIDLVDISVEMAGLKFINPFGLASATPATSTSMIRRAFEAGWGFALTKTFSLDKDIVTNVSPRIIRGTTSGPMYGPGQSSFLNIELISEKTAAYWCQSVTELKADFPDNIVIASIMCSYNKNDWTELAKKSEDSGADALELNLSCPHGMGERGMGLACGQDPELVRNICRWVRQAVQIPFFAKLTPNVTDIVSIARAAKEGGANGVTATNTVSGLMGLKSDGTPWPAVGIAKRTTYGGVSGTAIRPIALRAVTSIARALPGFPILATGGIDSAESGLQFLHSGASVLQVCSAIQNQDFTVIEDYCTGLKALLYLKSIEELQDWDGQSPATVSHQKGKPVPRIAELMDKKLPSFGPYLEQRKKIIAENKIRLKEQNVAFSPLKRNCFIPKRPIPTIKDVIGKALQYLGTFGELSNVEQVVAMIDEEMCINCGKCYMTCNDSGYQAIQFDPETHLPTITDTCTGCTLCLSVCPIVDCIKMVSRTTPYEPKRGVPLSVNPVC
T75890	DRUGINFO	D05LEO	Fluorouracil	Approved
T75890	DRUGINFO	D09QOR	Eniluracil	Phase 2
T75890	DRUGINFO	D03GGN	RO-09-4889	Phase 1
T75890	DRUGINFO	D05YLL	FL-386	Discontinued in Phase 2
T75890	DRUGINFO	D08EZR	5-Iodouracil	Investigative
T75890	DRUGINFO	D0HR8H	(5s)-5-Iododihydro-2,4(1h,3h)-Pyrimidinedione	Investigative
T75890	DRUGINFO	D0O0AI	6-Carboxymethyluracil	Investigative
T75890	DRUGINFO	D0Y0DG	Uracil	Investigative
T75890	DRUGINFO	D00IMW	Flavin-Adenine Dinucleotide	Investigative

T93878	TARGETID	T93878
T93878	FORMERID	TTDS00116
T93878	UNIPROID	S12A1_HUMAN
T93878	TARGNAME	Solute carrier family 12 member 1 (SLC12A1)
T93878	GENENAME	SLC12A1
T93878	TARGTYPE	Successful
T93878	SYNONYMS	Solute carrier family 12 member; SLC12A1; Na+/K+/2CL- co-transporter; NKCC2; Kidney-specific Na-K-Cl symporter; Bumetanide-sensitive sodium-(potassium)Solute carrier family 12 member 1-chloride cotransporter 2; Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2
T93878	FUNCTION	Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
T93878	BIOCLASS	Cation-chloride cotransporter
T93878	SEQUENCE	MSLNNSSNVFLDSVPSNTNRFQVSVINENHESSAAADDNTDPPHYEETSFGDEAQKRLRISFRPGNQECYDNFLQSGETAKTDASFHAYDSHTNTYYLQTFGHNTMDAVPKIEYYRNTGSISGPKVNRPSLLEIHEQLAKNVAVTPSSADRVANGDGIPGDEQAENKEDDQAGVVKFGWVKGVLVRCMLNIWGVMLFIRLSWIVGEAGIGLGVLIILLSTMVTSITGLSTSAIATNGFVRGGGAYYLISRSLGPEFGGSIGLIFAFANAVAVAMYVVGFAETVVDLLKESDSMMVDPTNDIRIIGSITVVILLGISVAGMEWEAKAQVILLVILLIAIANFFIGTVIPSNNEKKSRGFFNYQASIFAENFGPRFTKGEGFFSVFAIFFPAATGILAGANISGDLEDPQDAIPRGTMLAIFITTVAYLGVAICVGACVVRDATGNMNDTIISGMNCNGSAACGLGYDFSRCRHEPCQYGLMNNFQVMSMVSGFGPLITAGIFSATLSSALASLVSAPKVFQALCKDNIYKALQFFAKGYGKNNEPLRGYILTFLIAMAFILIAELNTIAPIISNFFLASYALINFSCFHASYAKSPGWRPAYGIYNMWVSLFGAVLCCAVMFVINWWAAVITYVIEFFLYVYVTCKKPDVNWGSSTQALSYVSALDNALELTTVEDHVKNFRPQCIVLTGGPMTRPALLDITHAFTKNSGLCICCEVFVGPRKLCVKEMNSGMAKKQAWLIKNKIKAFYAAVAADCFRDGVRSLLQASGLGRMKPNTLVIGYKKNWRKAPLTEIENYVGIIHDAFDFEIGVVIVRISQGFDISQVLQVQEELERLEQERLALEATIKDNECEEESGGIRGLFKKAGKLNITKTTPKKDGSINTSQSMHVGEFNQKLVEASTQFKKKQEKGTIDVWWLFDDGGLTLLIPYILTLRKKWKDCKLRIYVGGKINRIEEEKIVMASLLSKFRIKFADIHIIGDINIRPNKESWKVFEEMIEPYRLHESCKDLTTAEKLKRETPWKITDAELEAVKEKSYRQVRLNELLQEHSRAANLIVLSLPVARKGSISDLLYMAWLEILTKNLPPVLLVRGNHKNVLTFYS
T93878	DRUGINFO	D00WAM	Hydroflumethiazide	Approved
T93878	DRUGINFO	D03GVC	Methyclothiazide	Approved
T93878	DRUGINFO	D06TNL	Ethacrynic acid	Approved
T93878	DRUGINFO	D09NIA	Chlorthalidone	Approved
T93878	DRUGINFO	D0E9JM	Potassium Chloride	Approved
T93878	DRUGINFO	D0J9XZ	Torasemide	Approved
T93878	DRUGINFO	D0PQ3G	Furosemide	Approved
T93878	DRUGINFO	D0R7HO	Bumetanide	Approved
T93878	DRUGINFO	D0W5UV	Ethacrynate Sodium	Approved
T93878	DRUGINFO	D0Y2IZ	Trichlormethiazide	Approved
T93878	DRUGINFO	D02PAH	Bendroflumethiazide	Approved
T93878	DRUGINFO	D0I1LH	Aldosterone	Approved
T93878	DRUGINFO	D07NWZ	CL-301	Investigative
T93878	DRUGINFO	D09NNS	Piretanide	Investigative
T93878	DRUGINFO	D0O7ZE	Calyculin-A	Investigative

T47610	TARGETID	T47610
T47610	FORMERID	TTDS00501
T47610	UNIPROID	I11RA_HUMAN
T47610	TARGNAME	Interleukin 11 receptor alpha (IL11RA)
T47610	GENENAME	IL11RA
T47610	TARGTYPE	Successful
T47610	SYNONYMS	Interleukin-11 receptor subunit alpha; IL-11RA; IL-11R-alpha; IL-11R subunit alpha; IL-11 receptor subunit alpha
T47610	FUNCTION	The receptor systems for IL6, LIF, OSM, CNTF, IL11 and CT1 can utilize IL6ST for initiating signal transmission. The IL11/IL11RA/IL6ST complex may be involved in the control of proliferation and/or differentiation of skeletogenic progenitor or other mesenchymal cells. Essential for the normal development of craniofacial bones and teeth. Restricts suture fusion and tooth number. Receptor for interleukin-11.
T47610	BIOCLASS	Cytokine receptor
T47610	SEQUENCE	MSSSCSGLSRVLVAVATALVSASSPCPQAWGPPGVQYGQPGRSVKLCCPGVTAGDPVSWFRDGEPKLLQGPDSGLGHELVLAQADSTDEGTYICQTLDGALGGTVTLQLGYPPARPVVSCQAADYENFSCTWSPSQISGLPTRYLTSYRKKTVLGADSQRRSPSTGPWPCPQDPLGAARCVVHGAEFWSQYRINVTEVNPLGASTRLLDVSLQSILRPDPPQGLRVESVPGYPRRLRASWTYPASWPCQPHFLLKFRLQYRPAQHPAWSTVEPAGLEEVITDAVAGLPHAVRVSARDFLDAGTWSTWSPEAWGTPSTGTIPKEIPAWGQLHTQPEVEPQVDSPAPPRPSLQPHPRLLDHRDSVEQVAVLASLGILSFLGLVAGALALGLWLRLRRGGKDGSPKPGFLASVIPVDRRPGAPNL
T47610	DRUGINFO	D0T1IJ	Oprelvekin	Approved
T47610	DRUGINFO	D0E2YL	UNI-rhIL-11	Phase 3
T47610	DRUGINFO	D0D2YZ	BMTP-11	Phase 1

T69506	TARGETID	T69506
T69506	FORMERID	TTDS00351
T69506	UNIPROID	NR1I3_HUMAN
T69506	TARGNAME	Orphan nuclear receptor NR1I3 (NR1I3)
T69506	GENENAME	NR1I3
T69506	TARGTYPE	Successful
T69506	SYNONYMS	Orphan nuclear receptor MB67; Orphan nuclear receptor CAR; Nuclear receptor subfamily 1 group I member 3; Nuclear receptor CAR; Constitutive androstane receptor; Constitutive active response; Constitutive activator of retinoid response; CAR
T69506	FUNCTION	Transactivates both the phenobarbital responsive element module of the human CYP2B6 gene and the CYP3A4 xenobiotic response element. Binds and transactivates the retinoic acid response elements that control expression of the retinoic acid receptor beta 2 and alcohol dehydrogenase 3 genes.
T69506	PDBSTRUC	1XVP; 1XV9
T69506	BIOCLASS	Nuclear hormone receptor
T69506	SEQUENCE	MASREDELRNCVVCGDQATGYHFNALTCEGCKGFFRRTVSKSIGPTCPFAGSCEVSKTQRRHCPACRLQKCLDAGMRKDMILSAEALALRRAKQAQRRAQQTPVQLSKEQEELIRTLLGAHTRHMGTMFEQFVQFRPPAHLFIHHQPLPTLAPVLPLVTHFADINTFMVLQVIKFTKDLPVFRSLPIEDQISLLKGAAVEICHIVLNTTFCLQTQNFLCGPLRYTIEDGARVSPTVGFQVEFLELLFHFHGTLRKLQLQEPEYVLLAAMALFSPDRPGVTQRDEIDQLQEEMALTLQSYIKGQQRRPRDRFLYAKLLGLLAELRSINEAYGYQIQHIQGLSAMMPLLQEICS
T69506	DRUGINFO	D0T1XW	Meclizine	Approved
T69506	DRUGINFO	D01BXE	CITCO	Investigative
T69506	DRUGINFO	D02BPI	TCPOBOP	Investigative
T69506	DRUGINFO	D08XML	androstenol	Investigative
T69506	DRUGINFO	D0V7WD	androstanol	Investigative
T69506	DRUGINFO	D05DMH	(5BETA)-PREGNANE-3,20-DIONE	Investigative

T41955	TARGETID	T41955
T41955	FORMERID	TTDS00507
T41955	UNIPROID	TRPM8_HUMAN
T41955	TARGNAME	Long transient receptor potential channel 8 (TRPM8)
T41955	GENENAME	TRPM8
T41955	TARGTYPE	Successful
T41955	SYNONYMS	Trp-p8; Transient receptor potential-p8; Transient receptor potential cation channel subfamily M member 8; TRPP8; TRPM8; LTrpC6
T41955	FUNCTION	Receptor-activated non-selective cation channel involved in detection of sensations such as coolness, by being activated by cold temperature below 25 degrees Celsius. Activated by icilin, eucalyptol, menthol, cold and modulation of intracellular pH. Involved in menthol sensation. Permeable for monovalent cations sodium, potassium, and cesium and divalent cation calcium. Temperature sensing is tightly linked to voltage-dependent gating. Activated upon depolarization, changes in temperature resulting in graded shifts of its voltage-dependent activation curves. The chemical agonist menthol functions as a gating modifier, shifting activation curves towards physiological membrane potentials. Temperature sensitivity arises from a tenfold difference in the activation energies associated with voltage-dependent opening and closing. In prostate cancer cells, shows strong inward rectification and high calcium selectivity in contrast to its behavior in normal cells which is characterized by outward rectification and poor cationic selectivity. Plays a role in prostate cancer cell migration (PubMed:25559186). Isoform 2 and isoform 3 negatively regulate menthol- and cold-induced channel activity by stabilizing the closed state of the channel.
T41955	BIOCLASS	Transient receptor potential catioin channel
T41955	SEQUENCE	MSFRAARLSMRNRRNDTLDSTRTLYSSASRSTDLSYSESDLVNFIQANFKKRECVFFTKDSKATENVCKCGYAQSQHMEGTQINQSEKWNYKKHTKEFPTDAFGDIQFETLGKKGKYIRLSCDTDAEILYELLTQHWHLKTPNLVISVTGGAKNFALKPRMRKIFSRLIYIAQSKGAWILTGGTHYGLMKYIGEVVRDNTISRSSEENIVAIGIAAWGMVSNRDTLIRNCDAEGYFLAQYLMDDFTRDPLYILDNNHTHLLLVDNGCHGHPTVEAKLRNQLEKYISERTIQDSNYGGKIPIVCFAQGGGKETLKAINTSIKNKIPCVVVEGSGQIADVIASLVEVEDALTSSAVKEKLVRFLPRTVSRLPEEETESWIKWLKEILECSHLLTVIKMEEAGDEIVSNAISYALYKAFSTSEQDKDNWNGQLKLLLEWNQLDLANDEIFTNDRRWESADLQEVMFTALIKDRPKFVRLFLENGLNLRKFLTHDVLTELFSNHFSTLVYRNLQIAKNSYNDALLTFVWKLVANFRRGFRKEDRNGRDEMDIELHDVSPITRHPLQALFIWAILQNKKELSKVIWEQTRGCTLAALGASKLLKTLAKVKNDINAAGESEELANEYETRAVELFTECYSSDEDLAEQLLVYSCEAWGGSNCLELAVEATDQHFIAQPGVQNFLSKQWYGEISRDTKNWKIILCLFIIPLVGCGFVSFRKKPVDKHKKLLWYYVAFFTSPFVVFSWNVVFYIAFLLLFAYVLLMDFHSVPHPPELVLYSLVFVLFCDEVRQWYVNGVNYFTDLWNVMDTLGLFYFIAGIVFRLHSSNKSSLYSGRVIFCLDYIIFTLRLIHIFTVSRNLGPKIIMLQRMLIDVFFFLFLFAVWMVAFGVARQGILRQNEQRWRWIFRSVIYEPYLAMFGQVPSDVDGTTYDFAHCTFTGNESKPLCVELDEHNLPRFPEWITIPLVCIYMLSTNILLVNLLVAMFGYTVGTVQENNDQVWKFQRYFLVQEYCSRLNIPFPFIVFAYFYMVVKKCFKCCCKEKNMESSVCCFKNEDNETLAWEGVMKENYLVKINTKANDTSEEMRHRFRQLDTKLNDLKGLLKEIANKIK
T41955	DRUGINFO	D04CSZ	Menthol	Approved
T41955	DRUGINFO	D04FKX	D-3263	Phase 1
T41955	DRUGINFO	D09NAW	PF-05105679	Phase 1
T41955	DRUGINFO	D00AVT	Perillaldehyde	Investigative
T41955	DRUGINFO	D01PZP	hydroxycitronellal	Investigative
T41955	DRUGINFO	D03NZW	PMD38	Investigative
T41955	DRUGINFO	D04LSR	thio-BCTC	Investigative
T41955	DRUGINFO	D04NGL	WS-12	Investigative
T41955	DRUGINFO	D05WZK	frescolat ML	Investigative
T41955	DRUGINFO	D05YAR	eucalyptol	Investigative
T41955	DRUGINFO	D06NGQ	5-Benzyloxytryptamine	Investigative
T41955	DRUGINFO	D08KPQ	M8-B	Investigative
T41955	DRUGINFO	D09GBL	isopulegol	Investigative
T41955	DRUGINFO	D09QSY	frescolat MGA	Investigative
T41955	DRUGINFO	D0A1UL	RQ-00203078	Investigative
T41955	DRUGINFO	D0A4TS	WS-5	Investigative
T41955	DRUGINFO	D0B4ZT	WS-23	Investigative
T41955	DRUGINFO	D0D8FW	PBMC	Investigative
T41955	DRUGINFO	D0G8FU	CPS125	Investigative
T41955	DRUGINFO	D0J9CR	AMTB	Investigative
T41955	DRUGINFO	D0Q4GB	geraniol	Investigative
T41955	DRUGINFO	D0T6XB	WS-3	Investigative
T41955	DRUGINFO	D0V1PD	cooling agent 10	Investigative
T41955	DRUGINFO	D0X5DC	linalool	Investigative
T41955	DRUGINFO	D04ULU	icilin	Investigative
T41955	DRUGINFO	D05DAG	2-(5-fluoro-1H-indol-3-yl)ethanamine	Investigative
T41955	DRUGINFO	D07YQG	NADA	Investigative
T41955	DRUGINFO	D0C8MT	2-(7-(benzyloxy)-1H-indol-3-yl)ethanamine	Investigative
T41955	DRUGINFO	D04AQE	5-METHOXYTRYPTAMINE	Investigative
T41955	DRUGINFO	D0N7MS	ACAA	Investigative
T41955	DRUGINFO	D00HCI	2-APB	Investigative

T70680	TARGETID	T70680
T70680	FORMERID	TTDS00504
T70680	UNIPROID	S22A8_HUMAN
T70680	TARGNAME	Solute carrier family 22 member 8 (SLC22A8)
T70680	GENENAME	SLC22A8
T70680	TARGTYPE	Successful
T70680	SYNONYMS	hROAT1; hPAHT; hOAT1; Solute carrier family 22 member 6; SLC22A8; SLC22A6; Renal organic anion transporter 1; PAHT; PAH transporter; OAT1
T70680	FUNCTION	Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc).
T70680	BIOCLASS	Major facilitator superfamily
T70680	SEQUENCE	MTFSEILDRVGSMGHFQFLHVAILGLPILNMANHNLLQIFTAATPVHHCRPPHNASTGPWVLPMGPNGKPERCLRFVHPPNASLPNDTQRAMEPCLDGWVYNSTKDSIVTEWDLVCNSNKLKEMAQSIFMAGILIGGLVLGDLSDRFGRRPILTCSYLLLAASGSGAAFSPTFPIYMVFRFLCGFGISGITLSTVILNVEWVPTRMRAIMSTALGYCYTFGQFILPGLAYAIPQWRWLQLTVSIPFFVFFLSSWWTPESIRWLVLSGKSSKALKILRRVAVFNGKKEEGERLSLEELKLNLQKEISLAKAKYTASDLFRIPMLRRMTFCLSLAWFATGFAYYSLAMGVEEFGVNLYILQIIFGGVDVPAKFITILSLSYLGRHTTQAAALLLAGGAILALTFVPLDLQTVRTVLAVFGKGCLSSSFSCLFLYTSELYPTVIRQTGMGVSNLWTRVGSMVSPLVKITGEVQPFIPNIIYGITALLGGSAALFLPETLNQPLPETIEDLENWSLRAKKPKQEPEVEKASQRIPLQPHGPGLGSS
T70680	DRUGINFO	D0L7FM	Probenecid	Approved
T70680	DRUGINFO	D06TJJ	FLUORESCEIN	Approved
T70680	DRUGINFO	D04LTQ	Buproprion+zonisamide	Phase 2
T70680	DRUGINFO	D04DLM	AMINOHIPPURIC ACID	Investigative
T70680	DRUGINFO	D04XDS	GLUTARATE	Investigative
T70680	DRUGINFO	D05KFG	ADIPATE	Investigative
T70680	DRUGINFO	D0KN6Q	3R14S-OCHRATOXIN A	Investigative
T70680	DRUGINFO	D0L7UB	HEPTANOATE	Investigative

T88185	TARGETID	T88185
T88185	FORMERID	TTDC00317
T88185	UNIPROID	HCAR2_HUMAN
T88185	TARGNAME	Nicotinic acid receptor (HCAR2)
T88185	GENENAME	HCAR2
T88185	TARGTYPE	Successful
T88185	SYNONYMS	Niacin receptor 1; NIACR1; Hydroxycarboxylic acid receptor 2; HM74A; HCA2; GPR109A; G-protein coupled receptor HM74A; G-protein coupled receptor 109A
T88185	FUNCTION	Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide.
T88185	BIOCLASS	GPCR rhodopsin
T88185	SEQUENCE	MNRHHLQDHFLEIDKKNCCVFRDDFIVKVLPPVLGLEFIFGLLGNGLALWIFCFHLKSWKSSRIFLFNLAVADFLLIICLPFLMDNYVRRWDWKFGDIPCRLMLFMLAMNRQGSIIFLTVVAVDRYFRVVHPHHALNKISNRTAAIISCLLWGITIGLTVHLLKKKMPIQNGGANLCSSFSICHTFQWHEAMFLLEFFLPLGIILFCSARIIWSLRQRQMDRHAKIKRAITFIMVVAIVFVICFLPSVVVRIRIFWLLHTSGTQNCEVYRSVDLAFFITLSFTYMNSMLDPVVYYFSSPSFPNFFSTLINRCLQRKMTGEPDNNRSTSVELTGDPNKTRGAPEALMANSGEPWSPSYLGPTSP
T88185	DRUGINFO	D0N0ES	Vitamin B3	Approved
T88185	DRUGINFO	D01DDN	SCH-900271	Phase 2
T88185	DRUGINFO	D04ODO	GSK-256073	Phase 2
T88185	DRUGINFO	D09TGC	MK-1903	Phase 2
T88185	DRUGINFO	D0A5MR	MK-0354	Phase 2
T88185	DRUGINFO	D01VMZ	ARI-3037MO	Phase 2
T88185	DRUGINFO	D0V0WE	NIA-114	Clinical trial
T88185	DRUGINFO	D0E5MJ	INCB19602	Discontinued in Phase 2
T88185	DRUGINFO	D00TPG	5-Benzyl-1H-pyrazole-3-carboxylic acid	Investigative
T88185	DRUGINFO	D00WPU	Sazetidine-A	Investigative
T88185	DRUGINFO	D01AUX	2-(3-biphenyl-4-yl-propionylamino)-benzoic acid	Investigative
T88185	DRUGINFO	D02EBQ	3-pyridine-acetic acid	Investigative
T88185	DRUGINFO	D02YVZ	2-(6-phenylhexyl)pyrido[2,3-d]pyrimidin-4(3H)-one	Investigative
T88185	DRUGINFO	D05VGC	PMID21185185C21	Investigative
T88185	DRUGINFO	D06UZK	4,5,6,7-Tetrahydro-1H-indazole-3-carboxylic acid	Investigative
T88185	DRUGINFO	D06WXN	PMID20615702C8f	Investigative
T88185	DRUGINFO	D07BFA	2-(2-(4-tert-butylphenoxy)acetamido)benzoic acid	Investigative
T88185	DRUGINFO	D07NDW	PMID18752940C9n	Investigative
T88185	DRUGINFO	D07ONY	5-(3-Chloro-benzyl)-1H-pyrazole-3-carboxylic acid	Investigative
T88185	DRUGINFO	D07TVE	PMID20363624C(+)17a	Investigative
T88185	DRUGINFO	D07XKG	2-(4-phenylbutyl)pyrido[2,3-d]pyrimidin-4(3H)-one	Investigative
T88185	DRUGINFO	D09UXZ	5-Phenethyl-1H-pyrazole-3-carboxylic acid	Investigative
T88185	DRUGINFO	D09ZPN	MK-6892	Investigative
T88185	DRUGINFO	D0ET2F	5-methyl nicotinic acid	Investigative
T88185	DRUGINFO	D0FF9F	5-Butyl-1H-pyrazole-3-carboxylic acid	Investigative
T88185	DRUGINFO	D0G2LQ	5-(4-Chloro-benzyl)-1H-pyrazole-3-carboxylic acid	Investigative
T88185	DRUGINFO	D0G8TM	(+)-5-(5-bromothiophen-3-yl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid	Investigative
T88185	DRUGINFO	D0IC7C	5-Isopropyl-1H-pyrazole-3-carboxylic acid	Investigative
T88185	DRUGINFO	D0M4BZ	2-(3-(naphthalen-2-yl)propanamido)benzoic acid	Investigative
T88185	DRUGINFO	D0M7DC	1H-Pyrazole-3-carboxylic acid	Investigative
T88185	DRUGINFO	D0Q0PN	PMID19309152C2g	Investigative
T88185	DRUGINFO	D0R4GX	beta-D-hydroxybutyric acid	Investigative
T88185	DRUGINFO	D0S3XI	monomethylfumarate	Investigative
T88185	DRUGINFO	D0U6SQ	5-Propyl-1H-pyrazole-3-carboxylic acid	Investigative
T88185	DRUGINFO	D0V9LR	PMID22420767C42	Investigative
T88185	DRUGINFO	D0W5CQ	ISONICOTINIC ACID	Investigative
T88185	DRUGINFO	D0W5TY	5-(3-Phenyl-propyl)-1H-pyrazole-3-carboxylic acid	Investigative
T88185	DRUGINFO	D0Y7XK	2-(cinnamyloxy)pyrido[2,3-d]pyrimidin-4(3H)-one	Investigative
T88185	DRUGINFO	D0T2QL	cinnamic acid	Investigative

T93788	TARGETID	T93788
T93788	FORMERID	TTDC00050
T93788	UNIPROID	GP119_HUMAN
T93788	TARGNAME	Glucose-dependent insulinotropic receptor (GPR119)
T93788	GENENAME	GPR119
T93788	TARGTYPE	Successful
T93788	SYNONYMS	GPR119; G-protein coupled receptor 119
T93788	FUNCTION	Receptor for the endogenous fatty-acid ethanolamide oleoylethanolamide (OEA) and lysophosphatidylcholine (LPC). Functions as a glucose-dependent insulinotropic receptor. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Seems to act through a G(s) mediated pathway.
T93788	BIOCLASS	GPCR rhodopsin
T93788	SEQUENCE	MESSFSFGVILAVLASLIIATNTLVAVAVLLLIHKNDGVSLCFTLNLAVADTLIGVAISGLLTDQLSSPSRPTQKTLCSLRMAFVTSSAAASVLTVMLITFDRYLAIKQPFRYLKIMSGFVAGACIAGLWLVSYLIGFLPLGIPMFQQTAYKGQCSFFAVFHPHFVLTLSCVGFFPAMLLFVFFYCDMLKIASMHSQQIRKMEHAGAMAGGYRSPRTPSDFKALRTVSVLIGSFALSWTPFLITGIVQVACQECHLYLVLERYLWLLGVGNSLLNPLIYAYWQKEVRLQLYHMALGVKKVLTSFLLFLSARNCGPERPRESSCHIVTISSSEFDG
T93788	DRUGINFO	D07ILQ	Guanfacine extended release	Approved
T93788	DRUGINFO	D03AOP	DS-8500	Phase 2
T93788	DRUGINFO	D07QHF	SAR-260093	Phase 2
T93788	DRUGINFO	D0S4II	GSK1292263	Phase 2
T93788	DRUGINFO	D00WDY	BMS-903452	Phase 1
T93788	DRUGINFO	D0O9XN	APD-597	Phase 1
T93788	DRUGINFO	DX4A3Q	DA-1241	Phase 1
T93788	DRUGINFO	D0Q3ES	APD668	Discontinued in Phase 1
T93788	DRUGINFO	D0F1KP	PSN821	Terminated
T93788	DRUGINFO	D00GTC	AS1269574	Investigative
T93788	DRUGINFO	D00LMY	RO-5212651	Investigative
T93788	DRUGINFO	D00WVI	AS-1907417	Investigative
T93788	DRUGINFO	D01GPC	PMID21273063C58	Investigative
T93788	DRUGINFO	D01URR	PMID21939274C2	Investigative
T93788	DRUGINFO	D01VZL	PSN632408	Investigative
T93788	DRUGINFO	D02GEQ	lysophosphatidylethanolamine	Investigative
T93788	DRUGINFO	D02HWL	oleoyl-lysophosphatidylcholine	Investigative
T93788	DRUGINFO	D02KIM	PMID21536438C36j	Investigative
T93788	DRUGINFO	D02UXK	MBX-3254	Investigative
T93788	DRUGINFO	D02XKE	1-oleoyl glycerol	Investigative
T93788	DRUGINFO	D03PVV	1-palmitoyl-lysophosphatidylcholine	Investigative
T93788	DRUGINFO	D05FOV	2-oleoyl glycerol	Investigative
T93788	DRUGINFO	D06KHW	PMID21939274C1	Investigative
T93788	DRUGINFO	D06QYM	PMID21310611C3	Investigative
T93788	DRUGINFO	D07TAL	PMID21536438C20f	Investigative
T93788	DRUGINFO	D08HOK	PMID21444206C3a	Investigative
T93788	DRUGINFO	D09ROS	PMID21444206C23	Investigative
T93788	DRUGINFO	D0B8SS	1-stearoyl-lysophosphatidylcholine	Investigative
T93788	DRUGINFO	D0HI5B	PSN375963	Investigative
T93788	DRUGINFO	D0I2EL	PMID21444206C3j	Investigative
T93788	DRUGINFO	D0K0LA	LC34AD3	Investigative
T93788	DRUGINFO	D0LX6R	(S)-N-oleoyltyrosinol	Investigative
T93788	DRUGINFO	D0NL5K	SEA	Investigative
T93788	DRUGINFO	D0R5QF	AR231453	Investigative
T93788	DRUGINFO	D0R6PF	PMID22545772C42	Investigative
T93788	DRUGINFO	D0S4FV	(R)-N-oleoyltyrosinol	Investigative
T93788	DRUGINFO	D0VA7C	PMID21273063C1	Investigative
T93788	DRUGINFO	D0X3NW	PMID21444206C8g	Investigative
T93788	DRUGINFO	D0XM1U	PMID21273063C36	Investigative
T93788	DRUGINFO	D0YT3Z	AR-7947	Investigative
T93788	DRUGINFO	D0M1UA	lysophosphatidylinositol	Investigative
T93788	DRUGINFO	D07MBC	N-oleoylethanolamide	Investigative

T53748	TARGETID	T53748
T53748	FORMERID	TTDS00235
T53748	UNIPROID	Q965D5_PLAFA
T53748	TARGNAME	Plasmodium Enoyl-ACP reductase (Malaria fabI)
T53748	GENENAME	Malaria fabI
T53748	TARGTYPE	Successful
T53748	SYNONYMS	fabI; NADH-dependent enoyl-ACP reductase; Enoyl-acyl-carrier protein reductase; Enoyl-acyl carrier reductase; Enoyl-acyl carrier protein reductase; Enoyl-ACP reductase FabI
T53748	FUNCTION	Catalyzes the reduction of a carbon-carbon double bond in an enoyl moiety that is covalently linked to an acyl carrier protein (ACP). Involved in the elongation cycle of fatty acid which are used in the lipid metabolism and in the biotin biosynthesis.
T53748	BIOCLASS	CH-CH donor oxidoreductase
T53748	ECNUMBER	EC 1.3.1.9
T53748	SEQUENCE	MNKISQRLLFLFLHFYTTVCFIQNNTQKTFHNVLQNEQIRGKEKAFYRKEKRENIFIGNKMKHVHNMNNTHNNNHYMEKEEQDASNINKIKEENKNEDICFIAGIGDTNGYGWGIAKELSKRNVKIIFGIWPPVYNIFMKNYKNGKFDNDMIIDKDKKMNILDMLPFDASFDTANDIDEETKNNKRYNMLQNYPIEDVANLIHQKYGKINMLVHSLANAKEVQKDLLNTSRKGYLDALSKSSYSLISLCKYFVNIMKPQSSIISLTYHASQKVVPGYGGGMSSAKAALESDTRVLAYHLGRNYNIRINTISAGPLKSRAATAINKLNNTYENNTNQNKNRNSHDVHNIMNNSGEKEEKKNSASQNYTFIDYAIEYSEKYAPLRQKLLSTDIGSVASFLLSRESRAITGQTIYVDNGLNIMFLPDDIYRNENE
T53748	DRUGINFO	D00CSQ	Triclosan	Approved
T53748	DRUGINFO	D0U2BH	Epigallocatechin gallate	Phase 3
T53748	DRUGINFO	D00TWC	4-(2,4-dichloro-phenoxy)-2'-methyl-biphenyl-3-ol	Investigative
T53748	DRUGINFO	D01DTE	5-chloro-2-(2-chloro-4-hydroxyphenoxy)phenol	Investigative
T53748	DRUGINFO	D01TGI	4-(2,4-dichloro-phenoxy)-biphenyl-3-ol	Investigative
T53748	DRUGINFO	D03DND	2-(2,4-dichlorophenoxy)-5-propylphenol	Investigative
T53748	DRUGINFO	D05VXX	5-butyl-2-(2,4-dichlorophenoxy)phenol	Investigative
T53748	DRUGINFO	D08EME	4-(2,4-dichlorophenoxy)-4'-methylbiphenyl-3-ol	Investigative
T53748	DRUGINFO	D08FBM	2-(2,4-dichlorophenoxy)-5-phenethylphenol	Investigative
T53748	DRUGINFO	D08KNJ	4-(2,4-dichlorophenoxy)-3'-methylbiphenyl-3-ol	Investigative
T53748	DRUGINFO	D09QZL	3-chloro-4-(4-chloro-2-hydroxyphenoxy)benzamide	Investigative
T53748	DRUGINFO	D0A1XH	2-(2,4-dichlorophenoxy)-5-(2-methylbutyl)phenol	Investigative
T53748	DRUGINFO	D0A7US	2-(2,4-dichlorophenoxy)-5-isopentylphenol	Investigative
T53748	DRUGINFO	D0A9HU	2-(4-chloro-2-hydroxyphenoxy)benzenaminium	Investigative
T53748	DRUGINFO	D0D9ES	2-(2-((benzylamino)methyl)phenoxy)-5-chlorophenol	Investigative
T53748	DRUGINFO	D0FW2W	4-(2,4-dichloro-phenoxy)-4'-fluoro-biphenyl-3-ol	Investigative
T53748	DRUGINFO	D0JL2T	3,7-dihydroxy-flavone	Investigative
T53748	DRUGINFO	D0L0AZ	2-(2,4-dichlorophenoxy)-5-isobutylphenol	Investigative
T53748	DRUGINFO	D0L7HD	5-benzyl-2-(2,4-dichlorophenoxy)phenol	Investigative
T53748	DRUGINFO	D0LU2N	2-(2,4-dichlorophenoxy)-5-ethylphenol	Investigative
T53748	DRUGINFO	D0O9UI	2-(2,4-dichlorophenoxy)-5-methylphenol	Investigative
T53748	DRUGINFO	D0QV8V	2-(2,4-dichlorophenoxy)-5-(3-phenylpropyl)phenol	Investigative
T53748	DRUGINFO	D0U7MR	4-(2,4-dichlorophenoxy)-3-hydroxybenzonitrile	Investigative
T53748	DRUGINFO	D0X4BJ	2-(4-amino-2-chlorophenoxy)-5-chlorophenol	Investigative
T53748	DRUGINFO	D0Z7FM	5-chloro-2-(2-chloro-4-nitrophenoxy)phenol	Investigative
T53748	DRUGINFO	D08BMM	OROIDIN	Investigative
T53748	DRUGINFO	D0B3UG	4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole	Investigative
T53748	DRUGINFO	D0EW3L	BUTEIN	Investigative
T53748	DRUGINFO	D0Z7SL	Indole Naphthyridinone	Investigative
T53748	DRUGINFO	D07YDN	ISORHAMNETIN	Investigative
T53748	DRUGINFO	D04JTY	Thiolactomycin	Investigative
T53748	DRUGINFO	D07KXK	GALLOCATECHIN GALLATE	Investigative
T53748	DRUGINFO	D08ZHT	Diazaborines	Investigative
T53748	DRUGINFO	D0MF5Y	3,7,3',4'-TETRAHYDROXYFLAVONE	Investigative
T53748	DRUGINFO	D0RB1V	(-)-CATECHINGALLATE	Investigative
T53748	DRUGINFO	D0NJ4H	MORIN	Investigative
T53748	DRUGINFO	D07ONX	Beta-D-Glucose	Investigative
T53748	DRUGINFO	D0R6JE	Nicotinamide-Adenine-Dinucleotide	Investigative

T95558	TARGETID	T95558
T95558	FORMERID	TTDS00531
T95558	UNIPROID	DGAT2_HUMAN
T95558	TARGNAME	Diacylglycerol O-acyltransferase 2 (DGAT2)
T95558	GENENAME	DGAT2
T95558	TARGTYPE	Successful
T95558	SYNONYMS	UNQ738/PRO1433; HMFN1045; Diglyceride acyltransferase 2
T95558	FUNCTION	Required for synthesis and storage of intracellular triglycerides. Probably plays a central role in cytosolic lipid accumulation. In liver, is primarily responsible for incorporating endogenously synthesized fatty acids into triglycerides. Functions also as an acyl-CoA retinol acyltransferase (ARAT). Essential acyltransferase that catalyzes the terminal and only committed step in triacylglycerol synthesis by using diacylglycerol and fatty acyl CoA as substrates.
T95558	BIOCLASS	Acyltransferase
T95558	ECNUMBER	EC 2.3.1.20
T95558	SEQUENCE	MKTLIAAYSGVLRGERQAEADRSQRSHGGPALSREGSGRWGTGSSILSALQDLFSVTWLNRSKVEKQLQVISVLQWVLSFLVLGVACSAILMYIFCTDCWLIAVLYFTWLVFDWNTPKKGGRRSQWVRNWAVWRYFRDYFPIQLVKTHNLLTTRNYIFGYHPHGIMGLGAFCNFSTEATEVSKKFPGIRPYLATLAGNFRMPVLREYLMSGGICPVSRDTIDYLLSKNGSGNAIIIVVGGAAESLSSMPGKNAVTLRNRKGFVKLALRHGADLVPIYSFGENEVYKQVIFEEGSWGRWVQKKFQKYIGFAPCIFHGRGLFSSDTWGLVPYSKPITTVVGEPITIPKLEHPTQQDIDLYHTMYMEALVKLFDKHKTKFGLPETEVLEVN
T95558	DRUGINFO	D0N0ES	Vitamin B3	Approved
T95558	DRUGINFO	D8VP6R	PF-06865571	Phase 2
T95558	DRUGINFO	D01VMZ	ARI-3037MO	Phase 2
T95558	DRUGINFO	D0UL2I	PF-06427878	Phase 1
T95558	DRUGINFO	D0Z4RS	PMID25470667-Compound-roselipins	Patented
T95558	DRUGINFO	D0L5DV	PMID25470667-Compound-Figure4-1A	Patented

T99524	TARGETID	T99524
T99524	FORMERID	TTDI01906
T99524	UNIPROID	TAAR1_HUMAN
T99524	TARGNAME	Trace amine-associated receptor-1 (TAAR1)
T99524	GENENAME	TAAR1
T99524	TARGTYPE	Successful
T99524	SYNONYMS	Trace amine receptor 1; TaR-1; TAAR1
T99524	FUNCTION	Receptor for trace amines, including beta- phenylethylamine (b-PEA), p-tyramine (p-TYR), octopamine and tryptamine, with highest affinity for b-PEA and p-TYR. Unresponsive to classical biogenic amines,such as epinephrine and histamine and only partially activated by dopamine and serotonine. Trace amines are biogenic amines present in very low levels in mammalian tissues. Although some trace amineshave clearly defined roles as neurotransmitters in invertebrates, the extent to which they function as true neurotransmitters in vertebrates has remained speculative. Trace amines are likely to be involved in a variety of physiological functions that have yet to be fully understood. The signal transduced by this receptor is mediated by the G(s)-class of G-proteins which activate adenylate cyclase.
T99524	BIOCLASS	GPCR rhodopsin
T99524	SEQUENCE	MMPFCHNIINISCVKNNWSNDVRASLYSLMVLIILTTLVGNLIVIVSISHFKQLHTPTNWLIHSMATVDFLLGCLVMPYSMVRSAEHCWYFGEVFCKIHTSTDIMLSSASIFHLSFISIDRYYAVCDPLRYKAKMNILVICVMIFISWSVPAVFAFGMIFLELNFKGAEEIYYKHVHCRGGCSVFFSKISGVLTFMTSFYIPGSIMLCVYYRIYLIAKEQARLISDANQKLQIGLEMKNGISQSKERKAVKTLGIVMGVFLICWCPFFICTVMDPFLHYIIPPTLNDVLIWFGYLNSTFNPMVYAFFYPWFRKALKMMLFGKIFQKDSSRCKLFLELSS
T99524	DRUGINFO	D00DEF	Lisdexamfetamine	Approved
T99524	DRUGINFO	D05BMG	Amphetamine	Approved
T99524	DRUGINFO	D0T3LF	Dextroamphetamine	Approved
T99524	DRUGINFO	D0W1RY	Hydroxyamphetamine Hydrobromide	Approved
T99524	DRUGINFO	D04IUB	NT0202	Phase 3
T99524	DRUGINFO	D0CZ5Z	SPD-465	Phase 3
T99524	DRUGINFO	D04ZKY	SEP-363856	Phase 3
T99524	DRUGINFO	D0L4ZK	RG-7351	Phase 1
T99524	DRUGINFO	D05GOP	EPPTB	Investigative
T99524	DRUGINFO	D07BAH	R(-)amphetamine	Investigative
T99524	DRUGINFO	D0C5RZ	tyramine	Investigative
T99524	DRUGINFO	D0HR1V	3-iodothyronamine	Investigative
T99524	DRUGINFO	D0O9ZY	RO5166017	Investigative

T86057	TARGETID	T86057
T86057	FORMERID	TTDC00243
T86057	UNIPROID	S22AC_HUMAN
T86057	TARGNAME	Urate anion exchanger 1 (URAT1)
T86057	GENENAME	SLC22A12
T86057	TARGTYPE	Successful
T86057	SYNONYMS	UNQ6453/PRO34004; Solute carrier family 22 member 12; Renal-specific transporter; RST; Organic anion transporter 4-like protein; OATL4
T86057	FUNCTION	Regulates blood urate levels. Mediates saturable urate uptake by facilitating the exchange of urate against organic anions. Required for efficient urate re-absorption in the kidney.
T86057	BIOCLASS	Major facilitator
T86057	SEQUENCE	MAFSELLDLVGGLGRFQVLQTMALMVSIMWLCTQSMLENFSAAVPSHRCWAPLLDNSTAQASILGSLSPEALLAISIPPGPNQRPHQCRRFRQPQWQLLDPNATATSWSEADTEPCVDGWVYDRSIFTSTIVAKWNLVCDSHALKPMAQSIYLAGILVGAAACGPASDRFGRRLVLTWSYLQMAVMGTAAAFAPAFPVYCLFRFLLAFAVAGVMMNTGTLLMEWTAARARPLVMTLNSLGFSFGHGLTAAVAYGVRDWTLLQLVVSVPFFLCFLYSWWLAESARWLLTTGRLDWGLQELWRVAAINGKGAVQDTLTPEVLLSAMREELSMGQPPASLGTLLRMPGLRFRTCISTLCWFAFGFTFFGLALDLQALGSNIFLLQMFIGVVDIPAKMGALLLLSHLGRRPTLAASLLLAGLCILANTLVPHEMGALRSALAVLGLGGVGAAFTCITIYSSELFPTVLRMTAVGLGQMAARGGAILGPLVRLLGVHGPWLPLLVYGTVPVLSGLAALLLPETQSLPLPDTIQDVQNQAVKKATHGTLGNSVLKSTQF
T86057	DRUGINFO	D0C3SW	Lesinurad	Approved
T86057	DRUGINFO	DA29IM	Dotinurad	Phase 3
T86057	DRUGINFO	D03BSK	URC102	Phase 2
T86057	DRUGINFO	D06UTH	RDEA-684	Phase 2
T86057	DRUGINFO	D0P3ZN	RDEA3170	Phase 2
T86057	DRUGINFO	D62LZO	AR882	Phase 2
T86057	DRUGINFO	D02JOK	Sulfonamide derivative 11	Patented
T86057	DRUGINFO	D02USA	Cycloalkyl acid derivative 1	Patented
T86057	DRUGINFO	D03PZX	2-ethyl-3-(4-hydroxy) benzoyl benzofuran derivative 1	Patented
T86057	DRUGINFO	D03QGH	Tihoacetate derivative 1	Patented
T86057	DRUGINFO	D03UNB	Cycloalkyl acid derivative 2	Patented
T86057	DRUGINFO	D04ULX	Succinamide derivative 1	Patented
T86057	DRUGINFO	D06LEZ	Benzene sulfonamide derivative 16	Patented
T86057	DRUGINFO	D06RFO	Benzofurans derivative 1	Patented
T86057	DRUGINFO	D07FCV	PMID27414413-Compound-Figure6right	Patented
T86057	DRUGINFO	D07IZC	Ring-fused compound 1	Patented
T86057	DRUGINFO	D0CK1D	3-benzyloxyphenyloxoacetic acid derivative 1	Patented
T86057	DRUGINFO	D0D5YG	PMID27414413-Compound-Figure8right	Patented
T86057	DRUGINFO	D0FX9D	Tetrazole acetic acid derivative 1	Patented
T86057	DRUGINFO	D0HG2S	Sulfonamide derivative 10	Patented
T86057	DRUGINFO	D0JM7W	Phenylthioacetate derivative 1	Patented
T86057	DRUGINFO	D0KD6U	Benzoic acid derivative 1	Patented
T86057	DRUGINFO	D0ND8U	Fused heterocyclic compound 12	Patented
T86057	DRUGINFO	D0R5DH	Triazole propanedioic acid derivative 1	Patented
T86057	DRUGINFO	D0NJ4H	MORIN	Investigative

T96215	TARGETID	T96215
T96215	FORMERID	TTDS00058
T96215	UNIPROID	Q9NGT0_PLAFA
T96215	TARGNAME	Plasmodium Glutamate dehydrogenase (Malaria gdh)
T96215	GENENAME	Malaria gdh
T96215	TARGTYPE	Successful
T96215	SYNONYMS	Glutamate dehydrogenase
T96215	FUNCTION	Catalyses the reversible oxidative deamination of L-glutamate to form -ketoglutarate and ammonia using NADP(H) or NAD(H) as co-factors
T96215	BIOCLASS	CH-NH(2) donor oxidoreductase
T96215	ECNUMBER	EC 1.4.1.2
T96215	SEQUENCE	MDIDRRSALSCSPNNMECGFGSGHFSNNSITWKEKYEQTKELLKSYNLFSDHLINYSIDFYFNKLGFNKFHFEETSPELISKVVVCIITAKINEQYSSDKYFPTFEETHDNVIFIITRVFADDNKTRLNYKMEKKIEEKYFNFSDMSKDCYRLKSFRSVHSVFDKEHTYQEPLRTYILELPTYNDDIIKENETDLKKLMDVNFYNYIKGTRSEQIYYELNKAVLYDLTGQFLQTHYYETSSSTFTLTIAVKRSNVISSIFSLIGDCLNMHRCFSYSKYVEPLKNGVLLIILNVKVIVNNEMEREKQKLDLKDKIYKVVKSLKTLCLFNDSKFIQLSVKRTFTAQESAYLFMIIKFITFFSTFTLSSYKNVEHALNLRNYNNNIMDTTTNSSSSPSSVLNDVYIIKEKLKSSKYTKEEILRCAQSNVRTIKMLFANFEKKLNHQRNKCNQMKYGENNMKNSGDLLKEYSTNNRNVDHPTLSSLASSSSSCSSSFSLHSYLSGSYESPYYHHNKDSKDIIDEIEDNHDKKILQYFYMFEKYALKTNFFLTHKISLAVAFDGALLKDSIYEAQPYSIIMILGLHFVGFHIRFSKISRGGVRIVISNNVNSYMHNSDNLFDEAYNLAYTQNFKNKDIPEGGSKGIILLDADVCNVANTKYIKNLSFYSYVNSILDLLINEDLNEERASSISVHSTKGANNTTITFDNVMSSVENMVDRGGVEGEHLNITLPYDANMACNNNTTNDNLSNMHDTYNLNNSGEATLDHHSVDNRIVSNSSGTNNMNAQKGEGEDEKAKDKEMSNNRKNEENERKRCDNVSNSNYNYVNGTTEDAVQKIMGSKCKGGRNNNGEEKDGDMNGHNNNNNDNNNIDDDEHIEECYKGAGCVINGENKTRKMILQEKMNEEEDLIFLGPDENTGSDQLMDWACIIAKREYIHIGKPFQQGKLRKNGGVPHDMYGMTTLGIETYISKLCEKLNIKEESISRSLVGGPDGDLGSNAILQSKTKIISIIDGSGILYDKQGLNKEELIRLAKRRNNKDKSKAITCCTLYDEKYFSKDGFKISIEDHNVDIFGNKIRNGLDFRNTFFLNPLNKCELFNPCGGRPHSINIFNVNNIIKNGECIYKYIVEGANVFISDDARNILESKNVILFKDAATNKGGVISSSLEVLAGLVLDDKQYIDYMCSPDSDILQVDENEINFVHQNQKMNHSLSFKRGSINNLEEDEKKDTSNNEKNKNIIKTVNKNDTQDNSHHHNNSNKCNEDQQDVSDFYKAYVKEIQKKITHYCELEFESLWKETRRTKTPISKAINILSNKISELKKDILSSDTLCRDYKLLKKVLERVIPPTLLKIVTFEQILERVPYVYIKSLLASARASKLLLFTTILE
T96215	DRUGINFO	D0ZX2G	Hexachlorophene	Approved

T76937	TARGETID	T76937
T76937	FORMERID	TTDR01255
T76937	UNIPROID	SCN3A_HUMAN
T76937	TARGNAME	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
T76937	GENENAME	SCN3A
T76937	TARGTYPE	Successful
T76937	SYNONYMS	Voltage-gated sodium channel subunit alpha Nav1.3; Voltage-gated sodium channel subtype III; Sodium channel protein, brain III subunit alpha; Sodium channel protein type III subunit alpha; Sodium channel protein type 3 subunit alpha; Sodium channel protein brain III subunit alpha; NAC3; KIAA1356
T76937	FUNCTION	Assuming opened or closed conformations in response to the voltage difference across the membrane, forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. May contribute to the regulation of serotonin/5-hydroxytryptamine release by enterochromaffin cells. In pancreatic endocrine cells, required for both glucagon and glucose-induced insulin secretion. Mediates the voltage-dependent sodium ion permeability of excitable membranes.
T76937	BIOCLASS	Voltage-gated ion channel
T76937	SEQUENCE	MAQALLVPPGPESFRLFTRESLAAIEKRAAEEKAKKPKKEQDNDDENKPKPNSDLEAGKNLPFIYGDIPPEMVSEPLEDLDPYYINKKTFIVMNKGKAIFRFSATSALYILTPLNPVRKIAIKILVHSLFSMLIMCTILTNCVFMTLSNPPDWTKNVEYTFTGIYTFESLIKILARGFCLEDFTFLRDPWNWLDFSVIVMAYVTEFVSLGNVSALRTFRVLRALKTISVIPGLKTIVGALIQSVKKLSDVMILTVFCLSVFALIGLQLFMGNLRNKCLQWPPSDSAFETNTTSYFNGTMDSNGTFVNVTMSTFNWKDYIGDDSHFYVLDGQKDPLLCGNGSDAGQCPEGYICVKAGRNPNYGYTSFDTFSWAFLSLFRLMTQDYWENLYQLTLRAAGKTYMIFFVLVIFLGSFYLVNLILAVVAMAYEEQNQATLEEAEQKEAEFQQMLEQLKKQQEEAQAVAAASAASRDFSGIGGLGELLESSSEASKLSSKSAKEWRNRRKKRRQREHLEGNNKGERDSFPKSESEDSVKRSSFLFSMDGNRLTSDKKFCSPHQSLLSIRGSLFSPRRNSKTSIFSFRGRAKDVGSENDFADDEHSTFEDSESRRDSLFVPHRHGERRNSNVSQASMSSRMVPGLPANGKMHSTVDCNGVVSLVGGPSALTSPTGQLPPEGTTTETEVRKRRLSSYQISMEMLEDSSGRQRAVSIASILTNTMEELEESRQKCPPCWYRFANVFLIWDCCDAWLKVKHLVNLIVMDPFVDLAITICIVLNTLFMAMEHYPMTEQFSSVLTVGNLVFTGIFTAEMVLKIIAMDPYYYFQEGWNIFDGIIVSLSLMELGLSNVEGLSVLRSFRLLRVFKLAKSWPTLNMLIKIIGNSVGALGNLTLVLAIIVFIFAVVGMQLFGKSYKECVCKINDDCTLPRWHMNDFFHSFLIVFRVLCGEWIETMWDCMEVAGQTMCLIVFMLVMVIGNLVVLNLFLALLLSSFSSDNLAATDDDNEMNNLQIAVGRMQKGIDYVKNKMRECFQKAFFRKPKVIEIHEGNKIDSCMSNNTGIEISKELNYLRDGNGTTSGVGTGSSVEKYVIDENDYMSFINNPSLTVTVPIAVGESDFENLNTEEFSSESELEESKEKLNATSSSEGSTVDVVLPREGEQAETEPEEDLKPEACFTEGCIKKFPFCQVSTEEGKGKIWWNLRKTCYSIVEHNWFETFIVFMILLSSGALAFEDIYIEQRKTIKTMLEYADKVFTYIFILEMLLKWVAYGFQTYFTNAWCWLDFLIVDVSLVSLVANALGYSELGAIKSLRTLRALRPLRALSRFEGMRVVVNALVGAIPSIMNVLLVCLIFWLIFSIMGVNLFAGKFYHCVNMTTGNMFDISDVNNLSDCQALGKQARWKNVKVNFDNVGAGYLALLQVATFKGWMDIMYAAVDSRDVKLQPVYEENLYMYLYFVIFIIFGSFFTLNLFIGVIIDNFNQQKKKFGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPANKFQGMVFDFVTRQVFDISIMILICLNMVTMMVETDDQGKYMTLVLSRINLVFIVLFTGEFVLKLVSLRHYYFTIGWNIFDFVVVILSIVGMFLAEMIEKYFVSPTLFRVIRLARIGRILRLIKGAKGIRTLLFALMMSLPALFNIGLLLFLVMFIYAIFGMSNFAYVKKEAGIDDMFNFETFGNSMICLFQITTSAGWDGLLAPILNSAPPDCDPDTIHPGSSVKGDCGNPSVGIFFFVSYIIISFLVVVNMYIAVILENFSVATEESAEPLSEDDFEMFYEVWEKFDPDATQFIEFSKLSDFAAALDPPLLIAKPNKVQLIAMDLPMVSGDRIHCLDILFAFTKRVLGESGEMDALRIQMEDRFMASNPSKVSYEPITTTLKRKQEEVSAAIIQRNFRCYLLKQRLKNISSNYNKEAIKGRIDLPIKQDMIIDKLNGNSTPEKTDGSSSTTSPPSYDSVTKPDKEKFEKDKPEKESKGKEVRENQK
T76937	DRUGINFO	D0L7VL	LIDOFLAZINE	Approved
T76937	DRUGINFO	D03GPV	Pyrimidine derivative 1	Patented
T76937	DRUGINFO	D06VYB	Pyrrolo-pyridinone derivative 6	Patented
T76937	DRUGINFO	D09YJV	Pyrrolo-pyridinone derivative 5	Patented
T76937	DRUGINFO	D0M8WO	Aryl carboxamide derivative 1	Patented
T76937	DRUGINFO	D0OP5F	Aryl carboxamide derivative 2	Patented
T76937	DRUGINFO	D0EC2K	SIPATRIGINE	Discontinued in Phase 2
T76937	DRUGINFO	D02NLI	PD-85639	Terminated
T76937	DRUGINFO	D0OW2O	U-92032	Terminated
T76937	DRUGINFO	D0NC0G	RQ-00203066	Investigative
T76937	DRUGINFO	D05XEF	5-Hexyl-5-phenyl-imidazolidine-2,4-dione	Investigative
T76937	DRUGINFO	D08KBV	4-Biphenyl-4-yl-2-cyclohexylmethyl-1H-imidazole	Investigative
T76937	DRUGINFO	D08RNW	2-Hydroxy-2-phenyl-nonanoic acid amide	Investigative
T76937	DRUGINFO	D08VUM	2-Hexyl-4-(4-isobutyl-phenyl)-1H-imidazole	Investigative
T76937	DRUGINFO	D08WQO	2-(1-Pentyl-hexyl)-4-phenyl-1H-imidazole	Investigative
T76937	DRUGINFO	D0B8GI	5-Heptyl-5-phenyl-imidazolidine-2,4-dione	Investigative
T76937	DRUGINFO	D0FL7O	4-Biphenyl-4-yl-2-(1-pentyl-hexyl)-1H-imidazole	Investigative
T76937	DRUGINFO	D0K1UR	4-Biphenyl-4-yl-2-(1-propyl-butyl)-1H-imidazole	Investigative
T76937	DRUGINFO	D0K8DH	4-Biphenyl-4-yl-2-hexyl-1H-imidazole	Investigative
T76937	DRUGINFO	D0L5UC	5-Ethyl-3-methyl-5-phenyl-oxazolidine-2,4-dione	Investigative
T76937	DRUGINFO	D0N0KO	CCNCSSKWCRDHSRCC	Investigative
T76937	DRUGINFO	D0Q7GZ	5-Nonyl-5-phenyl-imidazolidine-2,4-dione	Investigative
T76937	DRUGINFO	D0S7ZU	4-Biphenyl-4-yl-2-methyl-1H-imidazole	Investigative
T76937	DRUGINFO	D0B9UU	BW-202W92	Investigative
T76937	DRUGINFO	D0WU9R	L-741742	Investigative
T76937	DRUGINFO	D0G9WE	batrachotoxin	Investigative
T76937	DRUGINFO	D0S4MN	veratridine	Investigative

T96845	TARGETID	T96845
T96845	UNIPROID	IL37_HUMAN
T96845	TARGNAME	Interleukin-37 (IL37)
T96845	GENENAME	IL37
T96845	TARGTYPE	Successful
T96845	SYNONYMS	Interleukin-1-related protein; Interleukin-1 zeta; Interleukin-1 homolog 4; Interleukin-1 family member 7; IL1RP1; IL1H4; IL1F7; IL-37; IL-1X; IL-1RP1; IL-1H4; IL-1H; IL-1F7; IL-1 zeta; FIL1Z; FIL1 zeta
T96845	FUNCTION	Suppressor of innate inflammatory and immune responses involved in curbing excessive inflammation. This function requires SMAD3. Suppresses, or reduces, proinflammatory cytokine production, including IL1A and IL6, as well as CCL12, CSF1, CSF2, CXCL13, IL1B, IL23A and IL1RN, but spares anti-inflammatory cytokines. Inhibits dendritic cell activation.
T96845	PDBSTRUC	6NCU; 5HN1
T96845	BIOCLASS	Cytokine: interleukin
T96845	SEQUENCE	MSFVGENSGVKMGSEDWEKDEPQCCLEDPAGSPLEPGPSLPTMNFVHTSPKVKNLNPKKFSIHDQDHKVLVLDSGNLIAVPDKNYIRPEIFFALASSLSSASAEKGSPILLGVSKGEFCLYCDKDKGQSHPSLQLKKEKLMKLAAQKESARRPFIFYRAQVGSWNMLESAAHPGWFICTSCNCNEPVGVTDKFENRKHIEFSFQPVCKAEMSPSEVSD
T96845	DRUGINFO	D0FT3R	Tildrakizumab	Approved

T98917	TARGETID	T98917
T98917	UNIPROID	MRM2_HUMAN
T98917	TARGNAME	Mitochondrial rRNA methyltransferase 2 (MRM2)
T98917	GENENAME	MRM2
T98917	TARGTYPE	Successful
T98917	SYNONYMS	rRNA methyltransferase 2, mitochondrial; Protein ftsJ homolog 2; 16S rRNA [Um1369] 2'-O-methyltransferase; 16S rRNA (uridine(1369)-2'-O)-methyltransferase
T98917	FUNCTION	S-adenosyl-L-methionine-dependent 2'-O-ribose methyltransferase that catalyzes the formation of 2'-O-methyluridine at position 1369 (Um1369) in the 16S mitochondrial large subunit ribosomal RNA (mtLSU rRNA), a universally conserved modification in the peptidyl transferase domain of the mtLSU rRNA.
T98917	PDBSTRUC	2NYU
T98917	BIOCLASS	Methyltransferase
T98917	ECNUMBER	EC 2.1.1.-
T98917	SEQUENCE	MAGYLKLVCVSFQRQGFHTVGSRCKNRTGAEHLWLTRHLRDPFVKAAKVESYRCRSAFKLLEVNERHQILRPGLRVLDCGAAPGAWSQVAVQKVNAAGTDPSSPVGFVLGVDLLHIFPLEGATFLCPADVTDPRTSQRILEVLPGRRADVILSDMAPNATGFRDLDHDRLISLCLTLLSVTPDILQPGGTFLCKTWAGSQSRRLQRRLTEEFQNVRIIKPEASRKESSEVYFLATQYHGRKGTVKQ
T98917	DRUGINFO	D0E6BB	Plazomicin	Approved

T74500	TARGETID	T74500
T74500	FORMERID	TTDS00412
T74500	UNIPROID	KCND3_HUMAN
T74500	TARGNAME	Voltage-gated potassium channel Kv4.3 (KCND3)
T74500	GENENAME	KCND3
T74500	TARGTYPE	Successful
T74500	SYNONYMS	Voltage-gated potassium channel subunit Kv4.3; KCND3
T74500	FUNCTION	Pore-forming (alpha) subunit of voltage-gated rapidly inactivating A-type potassium channels. May contribute to I(To) current in heart and I(Sa) current in neurons. Channel properties are modulated by interactions with other alpha subunits and with regulatory subunits.
T74500	PDBSTRUC	2NZ0; 1S1G
T74500	BIOCLASS	Voltage-gated ion channel
T74500	SEQUENCE	MAAGVAAWLPFARAAAIGWMPVANCPMPLAPADKNKRQDELIVLNVSGRRFQTWRTTLERYPDTLLGSTEKEFFFNEDTKEYFFDRDPEVFRCVLNFYRTGKLHYPRYECISAYDDELAFYGILPEIIGDCCYEEYKDRKRENAERLMDDNDSENNQESMPSLSFRQTMWRAFENPHTSTLALVFYYVTGFFIAVSVITNVVETVPCGTVPGSKELPCGERYSVAFFCLDTACVMIFTVEYLLRLFAAPSRYRFIRSVMSIIDVVAIMPYYIGLVMTNNEDVSGAFVTLRVFRVFRIFKFSRHSQGLRILGYTLKSCASELGFLLFSLTMAIIIFATVMFYAEKGSSASKFTSIPASFWYTIVTMTTLGYGDMVPKTIAGKIFGSICSLSGVLVIALPVPVIVSNFSRIYHQNQRADKRRAQKKARLARIRVAKTGSSNAYLHSKRNGLLNEALELTGTPEEEHMGKTTSLIESQHHHLLHCLEKTTGLSYLVDDPLLSVRTSTIKNHEFIDEQMFEQNCMESSMQNYPSTRSPSLSSHPGLTTTCCSRRSKKTTHLPNSNLPATRLRSMQELSTIHIQGSEQPSLTTSRSSLNLKADDGLRPNCKTSQITTAIISIPTPPALTPEGESRPPPASPGPNTNIPSIASNVVKVSAL
T74500	DRUGINFO	D02FLB	Sodium bicarbonate	Approved
T74500	DRUGINFO	D0N4MR	CDE-5498	Terminated

T23389	TARGETID	T23389
T23389	FORMERID	TTDC00329
T23389	UNIPROID	TTHY_HUMAN
T23389	TARGNAME	Transthyretin messenger RNA (TTR mRNA)
T23389	GENENAME	TTR
T23389	TARGTYPE	Successful
T23389	SYNONYMS	Transthyretin (mRNA); TBPA (mRNA); Prealbumin (mRNA); PALB (mRNA); ATTR (mRNA)
T23389	FUNCTION	Probably transports thyroxine from the bloodstream to the brain. Thyroid hormone-binding protein.
T23389	PDBSTRUC	6IMY; 6IMX; 6GRP; 6GR7; 6FZL
T23389	BIOCLASS	mRNA target
T23389	SEQUENCE	MASHRLLLLCLAGLVFVSEAGPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE
T23389	DRUGINFO	D02UYB	Patisiran	Approved
T23389	DRUGINFO	DE2CW9	Eplontersen	Approved
T23389	DRUGINFO	DXRP68	Vutrisiran	Approved
T23389	DRUGINFO	D01ZHB	Revusiran	Phase 3
T23389	DRUGINFO	D0Y9HW	ISIS-TTR	Phase 3
T23389	DRUGINFO	DJ0E7P	ALN-TTR01	Phase 1

T65414	TARGETID	T65414
T65414	FORMERID	TTDC00283
T65414	UNIPROID	ENV_HV1H2
T65414	TARGNAME	Human immunodeficiency virus Envelope messenger RNA (HIV env mRNA)
T65414	GENENAME	HIV env mRNA
T65414	TARGTYPE	Successful
T65414	SYNONYMS	HIV-1 HXB2 envelope glycoprotein gp160 (mRNA); HIV-1 HXB2 env polyprotein (mRNA)
T65414	FUNCTION	Envelope glycoprotein gp160: Oligomerizes in the host endoplasmic reticulum into predominantly trimers. In a second time, gp160 transits in the host Golgi, where glycosylation is completed. The precursor is then proteolytically cleaved in the trans-Golgi and thereby activated by cellular furin or furin-like proteases to produce gp120 and gp41.
T65414	PDBSTRUC	6DLN; 6DE7; 6BXQ; 6BXP; 6B9K
T65414	BIOCLASS	mRNA target
T65414	SEQUENCE	MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVVLVNVTENFNMWKNDMVEQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTNTNSSSGRMIMEKGEIKNCSFNISTSIRGKVQKEYAFFYKLDIIPIDNDTTSYKLTSCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSVNFTDNAKTIIVQLNTSVEINCTRPNNNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKLREQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNSTWSTEGSNNTEGSDTITLPCRIKQIINMWQKVGKAMYAPPISGQIRCSSNITGLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTKAKRRVVQREKRAVGIGALFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLEQIWNHTTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNWLWYIKLFIMIVGGLVGLRIVFAVLSIVNRVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDRDRSIRLVNGSLALIWDDLRSLCLFSYHRLRDLLLIVTRIVELLGRRGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEVVQGACRAIRHIPRRIRQGLERILL
T65414	DRUGINFO	D0L3MP	VRX496	Approved

T79249	TARGETID	T79249
T79249	FORMERID	TTDR01172
T79249	UNIPROID	TYSY_HUMAN
T79249	TARGNAME	Thymidylate synthase messenger RNA (TYMS mRNA)
T79249	GENENAME	TYMS
T79249	TARGTYPE	Successful
T79249	SYNONYMS	TSase (mRNA); TS (mRNA); OK/SW-cl.29 (mRNA)
T79249	FUNCTION	Contributes to the de novo mitochondrial thymidylate biosynthesis pathway.
T79249	PDBSTRUC	6R2E; 6QYQ; 6QXH; 6QXG; 5X69
T79249	BIOCLASS	mRNA target
T79249	ECNUMBER	EC 2.1.1.45
T79249	SEQUENCE	MPVAGSELPRRPLPPAAQERDAEPRPPHGELQYLGQIQHILRCGVRKDDRTGTGTLSVFGMQARYSLRDEFPLLTTKRVFWKGVLEELLWFIKGSTNAKELSSKGVKIWDANGSRDFLDSLGFSTREEGDLGPVYGFQWRHFGAEYRDMESDYSGQGVDQLQRVIDTIKTNPDDRRIIMCAWNPRDLPLMALPPCHALCQFYVVNSELSCQLYQRSGDMGLGVPFNIASYALLTYMIAHITGLKPGDFIHTLGDAHIYLNHIEPLKIQLQREPRPFPKLRILRKVEKIDDFKAEDFQIEGYNPHPTIKMEMAV
T79249	DRUGINFO	D05LEO	Fluorouracil	Approved
T79249	DRUGINFO	D0V5YQ	TS antisense + raltitrexed	Investigative

T72171	TARGETID	T72171
T72171	FORMERID	TTDI02236
T72171	UNIPROID	CCR5_HUMAN
T72171	TARGNAME	CCR5 messenger RNA (CCR5 mRNA)
T72171	GENENAME	CCR5
T72171	TARGTYPE	Successful
T72171	SYNONYMS	HIV-1 fusion coreceptor (mRNA); HIV-1 fusion co-receptor (mRNA); Chemokine receptor CCR5 (mRNA); CMKBR5 (mRNA); CHEMR13 (mRNA); CD195 antigen (mRNA); CD195 (mRNA); CCR-5 (mRNA); CC-CKR-5 (mRNA); C-C chemokine receptor type 5 (mRNA); C-C CKR-5 (mRNA)
T72171	FUNCTION	May play a role in the control of granulocytic lineage proliferation or differentiation. Receptor for a number of inflammatory CC-chemokines including CCL3/MIP-1-alpha, CCL4/MIP-1-beta and RANTES and subsequently transduces a signal by increasing the intracellular calcium ion level.
T72171	PDBSTRUC	6MET; 6MEO; 6FGP; 5YY4; 5YD5
T72171	BIOCLASS	mRNA target
T72171	SEQUENCE	MDYQVSSPIYDINYYTSEPCQKINVKQIAARLLPPLYSLVFIFGFVGNMLVILILINCKRLKSMTDIYLLNLAISDLFFLLTVPFWAHYAAAQWDFGNTMCQLLTGLYFIGFFSGIFFIILLTIDRYLAVVHAVFALKARTVTFGVVTSVITWVVAVFASLPGIIFTRSQKEGLHYTCSSHFPYSQYQFWKNFQTLKIVILGLVLPLLVMVICYSGILKTLLRCRNEKKRHRAVRLIFTIMIVYFLFWAPYNIVLLLNTFQEFFGLNNCSSSNRLDQAMQVTETLGMTHCCINPIIYAFVGEKFRNYLLVFFQKHIAKRFCKCCSIFQQEAPERASSVYTRSTGEQEISVGL
T72171	DRUGINFO	D0NR6S	Maraviroc	Approved
T72171	DRUGINFO	D0O4RB	DdRNAi therapy rHIV7-shl-TAR-CCR5RZ, stem cells	Phase 1/2
T72171	DRUGINFO	D0G6JE	SCH-C	Discontinued in Phase 1
T72171	DRUGINFO	D09PZD	viral macrophage inflammatory protein-II	Investigative

T67282	TARGETID	T67282
T67282	FORMERID	TTDI01958
T67282	UNIPROID	SYL_STAAE
T67282	TARGNAME	Staphylococcus Leucyl-tRNA synthetase (Stap-coc leuS)
T67282	GENENAME	Stap-coc leuS
T67282	TARGTYPE	Successful
T67282	SYNONYMS	Leucyl-tRNA synthetase; Leucine--tRNA ligase; LeuRS
T67282	FUNCTION	Catalyzes the chemical reaction: ATP + L-leucine + Trna = AMP + diphosphate + L-leucyl-tRNALeu
T67282	BIOCLASS	Carbon-oxygen ligase
T67282	ECNUMBER	EC 6.1.1.4
T67282	SEQUENCE	MLNYNHNQIEKKWQDYWDENKTFKTNDNLGQKKFYALDMFPYPSGAGLHVGHPEGYTATDIISRYKRMQGYNVLHPMGWDAFGLPAEQYALDTGNDPREFTKKNIQTFKRQIKELGFSYDWDREVNTTDPEYYKWTQWIFIQLYNKGLAYVDEVAVNWCPALGTVLSNEEVIDGVSERGGHPVYRKPMKQWVLKITEYADQLLADLDDLDWPESLKDMQRNWIGRSEGAKVSFDVDNTEGKVEVFTTRPDTIYGASFLVLSPEHALVNSITTDEYKEKVKAYQTEASKKSDLERTDLAKDKSGVFTGAYATNPLSGEKVQIWIADYVLSTYGTGAIMAVPAHDDRDYEFAKKFDLPIIEVIEGGNVEEAAYTGEGKHINSGELDGLENEAAITKAIQLLEQKGAGEKKVNYKLRDWLFSRQRYWGEPIPVIHWEDGTMTTVPEEELPLLLPETDEIKPSGTGESPLANIDSFVNVVDEKTGMKGRRETNTMPQWAGSCWYYLRYIDPKNENMLADPEKLKHWLPVDLYIGGVEHAVLHLLYARFWHKVLYDLAIVPTKEPFQKLFNQGMILGEGNEKMSKSKGNVINPDDIVQSHGADTLRLYEMFMGPLDAAIAWSEKGLDGSRRFLDRVWRLMVNEDGTLSSKIVTTNNKSLDKVYNQTVKKVTEDFETLGFNTAISQLMVFINECYKVDEVYKPYIEGFVKMLAPIAPHIGEELWSKLGHEESITYQPWPTYDEALLVDDEVEIVVQVNGKLRAKIKIAKDTSKEEMQEIALSNDNVKASIEGKDIMKVIAVPQKLVNIVAK
T67282	DRUGINFO	D05VGL	Tavaborole	Approved
T67282	DRUGINFO	D00NXM	GSK-2251052	Phase 2
T67282	DRUGINFO	D09DUQ	AN-2718	Phase 1

T72657	TARGETID	T72657
T72657	FORMERID	TTDS00219
T72657	UNIPROID	F4NA87_STAAU
T72657	TARGNAME	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
T72657	GENENAME	Stap-coc pbp2
T72657	TARGTYPE	Successful
T72657	SYNONYMS	Penicillin-binding protein 2; Penicillin-binding protein; Penicillin binding protein PBP 2
T72657	FUNCTION	Subunite of bacterial 70s ribosomes. Invovled in protein biosynthesis.
T72657	SEQUENCE	MTENKGSSQPKKNGNNGGKSNSKKNRNVKRTIIKIIGFMIIAFFVVLLLGILLFAYYAWKAPAFTEAKLQDPIPAKIYDKNGELVKTLDNGQRHEHVNLKDVPKSMKDAVLATEDNRFYEHGALDYKRLFGAIGKNLTGGFGSEGASTLTQQVVKDAFLSQHKSIGRKAQEAYLSYRLEQEYSKDDIFQVYLNKIYYSDGVTGIKAAAKYYFNKDLKDLNLAEEAYLAGLPQVPNNYNIYDHPKAAEDRKNTVLYLMHYHKRITDKQWEDAKKIDLKANLVNRTAEERQNIDTNQDSEYNSYVNFVKSELMNNKAFKDENLGNVLQSGIKIYTNMDKDVQKTLQNDVDNGSFYKNKDQQVGATILDSKTGGLVAISGGRDFKDVVNRNQATDPHPTGSSLKPFLAYGPAIENMKWATNHAIQDESSYQVDGSTFRNYDVKSHGTVSIYDALRQSFNIPALKAWQSVKQNAGNDAPKKFAAKLGLNYEGDIGPSEVLGGSASEFSPTQLASAFAAIANGGTYNNAHSIQKVVTRDGETIEYDHTSHKAMSDYTAYMLAEMLKGTFKPYGSAYGHGVSGVNMGAKTGTGTYGAETYSQYNLPDNAAKDVWINGFTPQYTMSVWMGFSKVKQYGENSFVGHSQQEYPQFLYENVMSKISSRDGEDFKRPSSVSGSIPSINVSGSQDNNTTNRSTHGGSDTSANSSGTAQSNNNTRSQQSRNSGGLTGIFN
T72657	DRUGINFO	D02GAC	Clomocycline	Approved
T72657	DRUGINFO	D02PCR	Spectinomycin	Approved
T72657	DRUGINFO	D04NDM	Paromomycin	Approved
T72657	DRUGINFO	D04VEJ	Lymecycline	Approved
T72657	DRUGINFO	D05AFR	Rolitetracycline	Approved
T72657	DRUGINFO	D07JHH	Meclocycline	Approved
T72657	DRUGINFO	D07JZF	Netilmicin	Approved
T72657	DRUGINFO	D08LTU	Minocycline	Approved
T72657	DRUGINFO	D08NQZ	Tetracycline	Approved
T72657	DRUGINFO	D0G4OD	Tigecycline	Approved
T72657	DRUGINFO	D0H1AR	Methacycline	Approved
T72657	DRUGINFO	D0J2NK	Oxytetracycline	Approved
T72657	DRUGINFO	D0N0EQ	Streptomycin	Approved
T72657	DRUGINFO	D0R9WP	Demeclocycline	Approved
T72657	DRUGINFO	D0Y3MO	Amikacin	Approved
T72657	DRUGINFO	D0YV1Q	Kanamycin	Approved
T72657	DRUGINFO	D05JNI	Framycetin	Approved

T31230	TARGETID	T31230
T31230	FORMERID	TTDS00307
T31230	UNIPROID	FRDA_HELPY
T31230	TARGNAME	Bacterial Fumarate reductase flavoprotein (Bact frdA)
T31230	GENENAME	Bact frdA
T31230	TARGTYPE	Successful
T31230	SYNONYMS	Fumarate reductase; FRDA
T31230	FUNCTION	Two distinct, membrane-bound, fad-containing enzymes are responsible for the catalysis of fumarate and succinate interconversion; The fumarate reductase is used in anaerobic growth, and the succinate dehydrogenase is used in aerobic growth.
T31230	BIOCLASS	CH-CH donor oxidoreductase
T31230	ECNUMBER	EC 1.3.5.4
T31230	SEQUENCE	MKITYCDALIIGGGLAGLRASIACKQKGLNTIVLSLVPVRRSHSAAAQGGMQASLANAKKSEGDNEDLHFLDTVKGSDWGCDQQVARMFVTTAPKAIRELASWGVPWTRIKKGDRPAVVNGEHVTITERDDRHGYILSRDFGGTKKWRTCFTADATGHTMLYAVANEALHHKVDIQDRKDMLAFIHHDNKCYGAVVRDLITGEISAYVSKGTLLATGGYGRVYKHTTNAVICDGAGAASALETGVAKLGNMEAVQFHPTALVPSGILMTEGCRGDGGVLRDKFGRRFMPAYEPEKKELASRDVVSRRILEHIQKGYGAKSPYGDHVWLDIAILGRNHVEKNLRDVRDIAMTFAGIDPADSKEQTKDNMQGVPANEPEYGQAMAKQKGWIPIKPMQHYSMGGVRTNPKGETHLKGLFCAGEAACWDLHGFNRLGGNSVSEAVVAGMIIGDYFASHCLEAQIEINTQKVEAFIKESQDYMHFLLHNEGKEDVYEIRERMKEVMDEKVGVFREGKRLEEALKELQELYARSKNICVKNKVLHNNPELEDAYRTKKMLKLALCITQGALLRTESRGAHTRIDYPKRDDEKWLNRTLASWPSAEQDMPTIEYEELDVMKMEISPDFRGYGKKGNFIPHPKKEERDAEILKTILELEKLGKDRIEVQHALMPFELQEKYKARNMRLEDEEVRARGEHLYSFNVHELLDQHNANLKGEHHE
T31230	DRUGINFO	D08PCE	Oxantel pamoate	Approved
T31230	DRUGINFO	D08QCJ	Thiabendazole	Approved
T31230	DRUGINFO	D0Q4TK	Morantel tartrate	Approved
T31230	DRUGINFO	D01MDE	Fumarate	Investigative
T31230	DRUGINFO	D05PZL	2,3-DIMETHYL-1,4-NAPHTHOQUINONE	Investigative
T31230	DRUGINFO	D09KCU	Citraconic acid	Investigative
T31230	DRUGINFO	D0B9FP	2-[1-(4-CHLORO-PHENYL)-ETHYL]-4,6-DINITRO-PHENOL	Investigative
T31230	DRUGINFO	D0BW1H	2-HEPTYL-4-HYDROXY QUINOLINE N-OXIDE	Investigative
T31230	DRUGINFO	D0E0TK	Malate Like Intermediate	Investigative
T31230	DRUGINFO	D0UU1I	Heme	Investigative
T31230	DRUGINFO	D00IMW	Flavin-Adenine Dinucleotide	Investigative

T04689	TARGETID	T04689
T04689	UNIPROID	ACHA_HUMAN
T04689	TARGNAME	Neuronal acetylcholine receptor alpha-1 (CHRNA1)
T04689	GENENAME	CHRNA1
T04689	TARGTYPE	Successful
T04689	SYNONYMS	CHNRA; Acetylcholine receptor subunit alpha; ACHRA
T04689	FUNCTION	After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
T04689	PDBSTRUC	5HBT; 4ZJS; 1Y6C; 1Y5T; 1Y5P
T04689	BIOCLASS	Neurotransmitter receptor
T04689	SEQUENCE	MEPWPLLLLFSLCSAGLVLGSEHETRLVAKLFKDYSSVVRPVEDHRQVVEVTVGLQLIQLINVDEVNQIVTTNVRLKQGDMVDLPRPSCVTLGVPLFSHLQNEQWVDYNLKWNPDDYGGVKKIHIPSEKIWRPDLVLYNNADGDFAIVKFTKVLLQYTGHITWTPPAIFKSYCEIIVTHFPFDEQNCSMKLGTWTYDGSVVAINPESDQPDLSNFMESGEWVIKESRGWKHSVTYSCCPDTPYLDITYHFVMQRLPLYFIVNVIIPCLLFSFLTGLVFYLPTDSGEKMTLSISVLLSLTVFLLVIVELIPSTSSAVPLIGKYMLFTMVFVIASIIITVIVINTHHRSPSTHVMPNWVRKVFIDTIPNIMFFSTMKRPSREKQDKKIFTEDIDISDISGKPGPPPMGFHSPLIKHPEVKSAIEGIKYIAETMKSDQESNNAAAEWKYVAMVMDHILLGVFMLVCIIGTLAVFAGRLIELNQQG
T04689	DRUGINFO	D05QNO	Decamethonium	Approved

T86462	TARGETID	T86462
T86462	FORMERID	TTDNC00670
T86462	UNIPROID	TTHY_HUMAN
T86462	TARGNAME	Transthyretin (TTR)
T86462	GENENAME	TTR
T86462	TARGTYPE	Successful
T86462	SYNONYMS	TBPA; Prealbumin; PALB; ATTR
T86462	FUNCTION	Probably transports thyroxine from the bloodstream to the brain. Thyroid hormone-binding protein.
T86462	PDBSTRUC	6IMY; 6IMX; 6GRP; 6GR7; 6FZL
T86462	SEQUENCE	MASHRLLLLCLAGLVFVSEAGPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE
T86462	DRUGINFO	D0R3BV	Inotersen	Approved
T86462	DRUGINFO	D0E9AF	ALN-TTRsc	Phase 3
T86462	DRUGINFO	D5EHL4	Acoramidis	Phase 3
T86462	DRUGINFO	DW95VT	NTLA-2001	Phase 1
T86462	DRUGINFO	DZ1W4B	NI006	Phase 1

T32369	TARGETID	T32369
T32369	FORMERID	TTDI01569
T32369	UNIPROID	PA_I34A1
T32369	TARGNAME	Influenza Polymerase acidic endonuclease (Influ PA)
T32369	GENENAME	Influ PA
T32369	TARGTYPE	Successful
T32369	SYNONYMS	RNA-directed RNA polymerase subunit P2; Polymerase acidic protein
T32369	FUNCTION	Plays an essential role in viral RNA transcription and replication by forming the heterotrimeric polymerase complex together with PB1 and PB2 subunits. The complex transcribes viral mRNAs by using a unique mechanism called cap-snatching. It consists in the hijacking and cleavage of host capped pre-mRNAs. These short capped RNAs are then used as primers for viral mRNAs. The PB2 subunit is responsible for the binding of the 5' cap of cellular pre-mRNAs which are subsequently cleaved after 10-13 nucleotides by the PA subunit that carries the endonuclease activity.
T32369	PDBSTRUC	5JHV; 5JHT; 5I13; 5FDG; 5FDD
T32369	ECNUMBER	EC 3.1.-.-
T32369	SEQUENCE	MEDFVRQCFNPMIVELAEKTMKEYGEDLKIETNKFAAICTHLEVCFMYSDFHFINEQGESIIVELGDPNALLKHRFEIIEGRDRTMAWTVVNSICNTTGAEKPKFLPDLYDYKENRFIEIGVTRREVHIYYLEKANKIKSEKTHIHIFSFTGEEMATKADYTLDEESRARIKTRLFTIRQEMASRGLWDSFRQSERGEETIEERFEITGTMRKLADQSLPPNFSSLENFRAYVDGFEPNGYIEGKLSQMSKEVNARIEPFLKTTPRPLRLPNGPPCSQRSKFLLMDALKLSIEDPSHEGEGIPLYDAIKCMRTFFGWKEPNVVKPHEKGINPNYLLSWKQVLAELQDIENEEKIPKTKNMKKTSQLKWALGENMAPEKVDFDDCKDVGDLKQYDSDEPELRSLASWIQNEFNKACELTDSSWIELDEIGEDVAPIEHIASMRRNYFTSEVSHCRATEYIMKGVYINTALLNASCAAMDDFQLIPMISKCRTKEGRRKTNLYGFIIKGRSHLRNDTDVVNFVSMEFSLTDPRLEPHKWEKYCVLEIGDMLIRSAIGQVSRPMFLYVRTNGTSKIKMKWGMEMRRCLLQSLQQIESMIEAESSVKEKDMTKEFFENKSETWPIGESPKGVEESSIGKVCRTLLAKSVFNSLYASPQLEGFSAESRKLLLIVQALRDNLEPGTFDLGGLYEAIEECLINDPWVLLNASWFNSFLTHALS
T32369	DRUGINFO	D0O5AG	Baloxavir marboxil	Approved

T37847	TARGETID	T37847
T37847	FORMERID	TTDS00310
T37847	UNIPROID	DPOL_HHV11
T37847	TARGNAME	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
T37847	GENENAME	HSV UL30
T37847	TARGTYPE	Successful
T37847	SYNONYMS	HSV DNA polymerase catalytic subunit
T37847	FUNCTION	Replicates viral genomic DNA. The replication complex is composed of six viral proteins: the DNA polymerase, processivity factor, primase, primase-associated factor, helicase, and ssDNA-binding protein. Additionally, the polymerase contains an intrinsic ribonuclease H (RNase H) activity that specifically degrades RNA/DNA heteroduplexes or duplex DNA substrates in the 5' to 3' direction. Therefore, it can catalyze the excision of the RNA primers that initiate the synthesis of Okazaki fragments at a replication fork during viral DNA replication.
T37847	BIOCLASS	DNA polymerase type-B
T37847	SEQUENCE	MFSGGGGPLSPGGKSAARAASGFFAPAGPRGASRGPPPCLRQNFYNPYLAPVGTQQKPTGPTQRHTYYSECDEFRFIAPRVLDEDAPPEKRAGVHDGHLKRAPKVYCGGDERDVLRVGSGGFWPRRSRLWGGVDHAPAGFNPTVTVFHVYDILENVEHAYGMRAAQFHARFMDAITPTGTVITLLGLTPEGHRVAVHVYGTRQYFYMNKEEVDRHLQCRAPRDLCERMAAALRESPGASFRGISADHFEAEVVERTDVYYYETRPALFYRVYVRSGRVLSYLCDNFCPAIKKYEGGVDATTRFILDNPGFVTFGWYRLKPGRNNTLAQPAAPMAFGTSSDVEFNCTADNLAIEGGMSDLPAYKLMCFDIECKAGGEDELAFPVAGHPEDLVIQISCLLYDLSTTALEHVLLFSLGSCDLPESHLNELAARGLPTPVVLEFDSEFEMLLAFMTLVKQYGPEFVTGYNIINFDWPFLLAKLTDIYKVPLDGYGRMNGRGVFRVWDIGQSHFQKRSKIKVNGMVNIDMYGIITDKIKLSSYKLNAVAEAVLKDKKKDLSYRDIPAYYAAGPAQRGVIGEYCIQDSLLVGQLFFKFLPHLELSAVARLAGINITRTIYDGQQIRVFTCLLRLADQKGFILPDTQGRFRGAGGEAPKRPAAAREDEERPEEEGEDEDEREEGGGEREPEGARETAGRHVGYQGARVLDPTSGFHVNPVVVFDFASLYPSIIQAHNLCFSTLSLRADAVAHLEAGKDYLEIEVGGRRLFFVKAHVRESLLSILLRDWLAMRKQIRSRIPQSSPEEAVLLDKQQAAIKVVCNSVYGFTGVQHGLLPCLHVAATVTTIGREMLLATREYVHARWAAFEQLLADFPEAADMRAPGPYSMRIIYGDTDSIFVLCRGLTAAGLTAVGDKMASHISRALFLPPIKLECEKTFTKLLLIAKKKYIGVIYGGKMLIKGVDLVRKNNCAFINRTSRALVDLLFYDDTVSGAAAALAERPAEEWLARPLPEGLQAFGAVLVDAHRRITDPERDIQDFVLTAELSRHPRAYTNKRLAHLTVYYKLMARRAQVPSIKDRIPYVIVAQTREVEETVARLAALRELDAAAPGDEPAPPAALPSPAKRPRETPSPADPPGGASKPRKLLVSELAEDPAYAIAHGVALNTDYYFSHLLGAACVTFKALFGNNAKITESLLKRFIPEVWHPPDDVAARLRTAGFGAVGAGATAEETRRMLHRAFDTLA
T37847	DRUGINFO	D04AAW	Cidofovir	Approved
T37847	DRUGINFO	D04QJD	Valaciclovir	Approved
T37847	DRUGINFO	D05ARP	Ganciclovir	Approved
T37847	DRUGINFO	D05MFA	Valacyclovir Hydrochloride	Approved
T37847	DRUGINFO	D06GWF	Valganciclovir	Approved
T37847	DRUGINFO	D07XSN	Cytarabine	Approved
T37847	DRUGINFO	D0OT0O	Foscavir	Approved
T37847	DRUGINFO	D0VT8P	Famciclovir	Approved
T37847	DRUGINFO	D07BYK	Penciclovir	Approved
T37847	DRUGINFO	D0B5MP	Aciclovir	Approved
T37847	DRUGINFO	D04OXD	Netivudine	Phase 3
T37847	DRUGINFO	D06CCR	Fialuridine	Phase 2
T37847	DRUGINFO	D0M7DS	Valomaciclovir stearate	Phase 2
T37847	DRUGINFO	D07LUJ	URSOLIC ACID	Phase 2
T37847	DRUGINFO	D00LHF	GS-9219	Phase 1/2
T37847	DRUGINFO	D0R9YR	BETULINIC ACID	Phase 1
T37847	DRUGINFO	D0V4YO	ROCICLOVIR	Phase 1
T37847	DRUGINFO	D0H1OL	Guanosine	Phase 1
T37847	DRUGINFO	D0WF1S	Tomeglovir	Discontinued in Phase 2
T37847	DRUGINFO	D05RQB	Aphidicolin	Discontinued in Phase 1
T37847	DRUGINFO	D0H5LC	CHPMPC	Discontinued in Phase 1
T37847	DRUGINFO	D03LNN	IDX136	Preclinical
T37847	DRUGINFO	D0T4HS	GR-95168	Terminated
T37847	DRUGINFO	D0U0FH	Amitivir	Terminated
T37847	DRUGINFO	D00NQQ	Alpha,beta-methylene-dATP	Investigative
T37847	DRUGINFO	D00UUM	PMEA	Investigative
T37847	DRUGINFO	D00XVS	3beta-hydroxyrus-18,20(30)-dien-28-oic acid	Investigative
T37847	DRUGINFO	D01NBF	3alpha-O-trans-p-coumaroyl-7-labden-15-oic acid	Investigative
T37847	DRUGINFO	D02NCY	6-(4-Chloro-phenylamino)-1H-pyrimidine-2,4-dione	Investigative
T37847	DRUGINFO	D05YDK	PENICILLIOL A	Investigative
T37847	DRUGINFO	D06CSI	Alpha,beta-methylene-dTTP	Investigative
T37847	DRUGINFO	D06GWR	(24E)-3beta-hydroxy-7,24-euphadien-26-oic acid	Investigative
T37847	DRUGINFO	D06QWO	TALAROFLAVONE	Investigative
T37847	DRUGINFO	D06WRC	3-cis-p-coumaroyl maslinic acid	Investigative
T37847	DRUGINFO	D07GFI	Gallic acid 5,6-dihydroxy-3-carboxyphenylester	Investigative
T37847	DRUGINFO	D09OIO	(+)-Myristinin A	Investigative
T37847	DRUGINFO	D0B7WO	5-propenyl-arabinofuranosyluracil 5'-triphosphate	Investigative
T37847	DRUGINFO	D0D8QY	6-(4-Bromo-phenylamino)-1H-pyrimidine-2,4-dione	Investigative
T37847	DRUGINFO	D0H1VJ	DdCTP SODIUM	Investigative
T37847	DRUGINFO	D0MG5N	Mahureone D	Investigative
T37847	DRUGINFO	D0P9KI	5-propenyl-2'-deoxyuridine triphosphate	Investigative
T37847	DRUGINFO	D0T7CB	Alpha,beta-methylene-dCTP	Investigative
T37847	DRUGINFO	D0TL0V	3-Oximo-olean-12-en-29-oic acid	Investigative
T37847	DRUGINFO	D0U7XP	Alpha,beta-methylene-dGTP	Investigative
T37847	DRUGINFO	D0W1OQ	3beta-hydroxyrus-12,19(29)-dien-28-oic acid	Investigative
T37847	DRUGINFO	D0WV3D	(+)-Myristinin D	Investigative
T37847	DRUGINFO	D0XS0X	3-trans-p-coumaroyl maslinic acid	Investigative
T37847	DRUGINFO	D0H6VK	6-(3-Ethyl-phenylamino)-1H-pyrimidine-2,4-dione	Investigative
T37847	DRUGINFO	D0SJ2Q	OLEANOLIC_ACID	Investigative
T37847	DRUGINFO	D09WYY	2'-deoxythymidine triphosphate	Investigative
T37847	DRUGINFO	D04AWP	Guanosine-5'-Monophosphate	Investigative

T93783	TARGETID	T93783
T93783	FORMERID	TTDS00322
T93783	UNIPROID	TAT_HV1H2
T93783	TARGNAME	Human immunodeficiency virus Tat protein (HIV tat)
T93783	GENENAME	HIV tat
T93783	TARGTYPE	Successful
T93783	SYNONYMS	Transactivating regulatory protein; TAT protein
T93783	FUNCTION	Extracellular circulating Tat can be endocytosed by surrounding uninfected cells via the binding to several surface receptors such as CD26, CXCR4, heparan sulfate proteoglycans (HSPG) or LDLR. Neurons are rarely infected, but they internalize Tat via their LDLR. Endosomal low pH allows Tat to cross the endosome membrane to enter the cytosol and eventually further translocate into the nucleus, thereby inducing severe celldysfunctions ranging from cell activation to cell death. Through its interaction with nuclear HATs, Tat is potentially able to control the acetylation-dependent cellular gene expression. Tat seems toinhibit the HAT activity of KAT5/Tip60 and TAF1, and consequently modify the expression of specific cellular genes. Modulates the expression of many cellular genes involved in cell survival, proliferation or in coding for cytokines (such as IL10) or cytokine receptors. May be involved in the derepression of host interleukin IL2 expression. Mediates the activation of cyclin- dependent kinases and dysregulation of microtubule network. Tat plays a role in T-cell and neurons apoptosis. Tat induced neurotoxicity and apoptosis probably contribute to neuroAIDS. Host extracellular matrix metalloproteinase MMP1 cleaves Tat and decreases Tat's mediated neurotoxicity. Circulating Tat also acts as a chemokine-like and/or growth factor-like molecule that binds to specific receptors on the surface of the cells, affecting many cellular pathways. In the vascular system, Tat binds to ITGAV/ITGB3 and ITGA5/ITGB1 integrins dimers at the surface of endothelial cells and competes with bFGF for heparin-binding sites, leading to an excess of soluble bFGF. Binds to KDR/VEGFR-2. All these Tat-mediated effects enhance angiogenesis in Kaposi's sarcoma lesions.
T93783	PDBSTRUC	6MCF; 6MCE; 5V61; 4OR5; 3MIA
T93783	BIOCLASS	Lentiviruses Tat family
T93783	SEQUENCE	MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKALGISYGRKKRRQRRRAHQNSQTHQASLSKQPTSQPRGDPTGPKE
T93783	DRUGINFO	D08HZC	Penicillamine	Approved
T93783	DRUGINFO	D0XP3W	Ro-24-7429	Phase 2
T93783	DRUGINFO	D0Y2NU	ALX-40-4C	Phase 2
T93783	DRUGINFO	D0W5QJ	Anti-HIV ribozyme therapy	Phase 1/2
T93783	DRUGINFO	D09QOF	EM-2487	Terminated
T93783	DRUGINFO	D0O7QV	Durhamycin A	Investigative
T93783	DRUGINFO	D0X3XE	CGP 40336A	Investigative

T24211	TARGETID	T24211
T24211	FORMERID	TTDI02289
T24211	UNIPROID	IC1_HUMAN
T24211	TARGNAME	C1 esterase inhibitor (SERPING1)
T24211	GENENAME	SERPING1
T24211	TARGTYPE	Successful
T24211	SYNONYMS	Serpin G1; SERPING1; Plasma protease C1 inhibitor; C1inhibiting factor; C1Inh; C1 Inh
T24211	FUNCTION	Activation of the C1 complex is under control of the C1- inhibitor. It forms a proteolytically inactive stoichiometric complex with the C1r or C1s proteases. May play a potentially crucial role in regulating important physiological pathways including complement activation, blood coagulation, fibrinolysis and the generation of kinins. Very efficient inhibitor of FXIIa. Inhibits chymotrypsin and kallikrein. {ECO:0000269|PubMed:8495195}.
T24211	PDBSTRUC	5DUQ; 5DU3; 2OAY; 1M6Q
T24211	BIOCLASS	Serpin protein
T24211	SEQUENCE	MASRLTLLTLLLLLLAGDRASSNPNATSSSSQDPESLQDRGEGKVATTVISKMLFVEPILEVSSLPTTNSTTNSATKITANTTDEPTTQPTTEPTTQPTIQPTQPTTQLPTDSPTQPTTGSFCPGPVTLCSDLESHSTEAVLGDALVDFSLKLYHAFSAMKKVETNMAFSPFSIASLLTQVLLGAGENTKTNLESILSYPKDFTCVHQALKGFTTKGVTSVSQIFHSPDLAIRDTFVNASRTLYSSSPRVLSNNSDANLELINTWVAKNTNNKISRLLDSLPSDTRLVLLNAIYLSAKWKTTFDPKKTRMEPFHFKNSVIKVPMMNSKKYPVAHFIDQTLKAKVGQLQLSHNLSLVILVPQNLKHRLEDMEQALSPSVFKAIMEKLEMSKFQPTLLTLPRIKVTTSQDMLSIMEKLEFFDFSYDLNLCGLTEDPDLQVSAMQHQTVLELTETGVEAAAASAISVARTLLVFEVQQPFLFVLWDQQHKFPVFMGRVYDPRA
T24211	DRUGINFO	D0BK4X	Cinryze	Approved
T24211	DRUGINFO	D0Z7ZM	Rhucin	Approved

T65570	TARGETID	T65570
T65570	UNIPROID	ADH1A_HUMAN
T65570	TARGNAME	Alcohol dehydrogenase 1A (ADH1A)
T65570	GENENAME	ADH1A
T65570	TARGTYPE	Successful
T65570	SYNONYMS	Alcohol dehydrogenase subunit alpha; ADH1
T65570	FUNCTION	Facilitates the interconversion between alcohols and aldehydes or ketones with the reduction of nicotinamide adenine dinucleotide (NAD+) to NADH.
T65570	PDBSTRUC	1U3T; 1HSO
T65570	ECNUMBER	EC 1.1.1.1
T65570	SEQUENCE	MSTAGKVIKCKAAVLWELKKPFSIEEVEVAPPKAHEVRIKMVAVGICGTDDHVVSGTMVTPLPVILGHEAAGIVESVGEGVTTVKPGDKVIPLAIPQCGKCRICKNPESNYCLKNDVSNPQGTLQDGTSRFTCRRKPIHHFLGISTFSQYTVVDENAVAKIDAASPLEKVCLIGCGFSTGYGSAVNVAKVTPGSTCAVFGLGGVGLSAIMGCKAAGAARIIAVDINKDKFAKAKELGATECINPQDYKKPIQEVLKEMTDGGVDFSFEVIGRLDTMMASLLCCHEACGTSVIVGVPPDSQNLSMNPMLLLTGRTWKGAILGGFKSKECVPKLVADFMAKKFSLDALITHVLPFEKINEGFDLLHSGKSIRTILMF
T65570	DRUGINFO	D02NJA	Fomepizole	Approved

T79961	TARGETID	T79961
T79961	FORMERID	TTDI01755
T79961	UNIPROID	ACM5_HUMAN
T79961	TARGNAME	Muscarinic acetylcholine receptor M5 (CHRM5)
T79961	GENENAME	CHRM5
T79961	TARGTYPE	Successful
T79961	SYNONYMS	CHRM5
T79961	FUNCTION	After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
T79961	BIOCLASS	GPCR rhodopsin
T79961	SEQUENCE	MEGDSYHNATTVNGTPVNHQPLERHRLWEVITIAAVTAVVSLITIVGNVLVMISFKVNSQLKTVNNYYLLSLACADLIIGIFSMNLYTTYILMGRWALGSLACDLWLALDYVASNASVMNLLVISFDRYFSITRPLTYRAKRTPKRAGIMIGLAWLISFILWAPAILCWQYLVGKRTVPLDECQIQFLSEPTITFGTAIAAFYIPVSVMTILYCRIYRETEKRTKDLADLQGSDSVTKAEKRKPAHRALFRSCLRCPRPTLAQRERNQASWSSSRRSTSTTGKPSQATGPSANWAKAEQLTTCSSYPSSEDEDKPATDPVLQVVYKSQGKESPGEEFSAEETEETFVKAETEKSDYDTPNYLLSPAAAHRPKSQKCVAYKFRLVVKADGNQETNNGCHKVKIMPCPFPVAKEPSTKGLNPNPSHQMTKRKRVVLVKERKAAQTLSAILLAFIITWTPYNIMVLVSTFCDKCVPVTLWHLGYWLCYVNSTVNPICYALCNRTFRKTFKMLLLCRWKKKKVEEKLYWQGNSKLP
T79961	DRUGINFO	D00NAX	Promazine	Approved
T79961	DRUGINFO	D00SLY	Umeclidinium	Approved
T79961	DRUGINFO	D02KIE	Cimetropium bromide	Approved
T79961	DRUGINFO	D05EMG	Butylscopolamine	Approved
T79961	DRUGINFO	D05TIB	Trospium	Approved
T79961	DRUGINFO	D06HLY	Pilocarpine	Approved
T79961	DRUGINFO	D06QDR	Choline alfoscerate	Approved
T79961	DRUGINFO	D07CNL	Anisotropine Methylbromide	Approved
T79961	DRUGINFO	D07ZTO	Bethanechol	Approved
T79961	DRUGINFO	D0B1EV	Cyclopentolate	Approved
T79961	DRUGINFO	D0D4IH	Oxitropium bromide	Approved
T79961	DRUGINFO	D0E8LT	Prifinium	Approved
T79961	DRUGINFO	D0F7AT	Cryptenamine Acetates	Approved
T79961	DRUGINFO	D0FV3V	Mepenzolate	Approved
T79961	DRUGINFO	D0H5DU	Oxyphencyclimine	Approved
T79961	DRUGINFO	D0J6WX	Flutropium bromide	Approved
T79961	DRUGINFO	D0JY5S	Methantheline	Approved
T79961	DRUGINFO	D0MG1Y	Belladonna	Approved
T79961	DRUGINFO	D0ND2J	Flavoxate	Approved
T79961	DRUGINFO	D0O5SZ	Homatropine Methylbromide	Approved
T79961	DRUGINFO	D0OK5I	Tridihexethyl	Approved
T79961	DRUGINFO	D0P7VJ	Pramiracetam	Approved (orphan drug)
T79961	DRUGINFO	D0Q0JG	Ispaghula	Approved
T79961	DRUGINFO	D0R1WR	Procyclidine	Approved
T79961	DRUGINFO	D0RD5W	Hyoscyamine	Approved
T79961	DRUGINFO	D0RG3O	Atropine	Approved
T79961	DRUGINFO	D0TV9K	Propiverine	Approved
T79961	DRUGINFO	D0VU8Q	Mebeverine	Approved
T79961	DRUGINFO	D0W2AN	Emepronium	Approved
T79961	DRUGINFO	D05ZJG	Anisodine	Approved
T79961	DRUGINFO	D0R7WU	ACECLIDINE	Approved
T79961	DRUGINFO	D05IIP	L-651582	Phase 3
T79961	DRUGINFO	D06CVO	OrM3	Phase 2b
T79961	DRUGINFO	D05KXJ	GSK233705	Phase 2
T79961	DRUGINFO	D0L3CQ	Dexpirronium	Phase 1
T79961	DRUGINFO	D07KYU	Benactyzine	Withdrawn from market
T79961	DRUGINFO	D04SOS	BMS-181168	Discontinued in Phase 2
T79961	DRUGINFO	D05PZZ	DDP-200	Discontinued in Phase 2
T79961	DRUGINFO	D0IJ2H	FK-584	Discontinued in Phase 2
T79961	DRUGINFO	D0A8IE	AM-831	Discontinued in Phase 1
T79961	DRUGINFO	D0N5NM	Org-23366	Preclinical
T79961	DRUGINFO	D05HKB	RS 86	Terminated
T79961	DRUGINFO	D0R5ZJ	SU-740	Terminated
T79961	DRUGINFO	D00IDV	CRTX-070	Investigative
T79961	DRUGINFO	D01OMY	BHT-3034	Investigative
T79961	DRUGINFO	D03DKZ	VU0238429	Investigative
T79961	DRUGINFO	D03IJZ	Recombinant botulinum toxin	Investigative
T79961	DRUGINFO	D04VNS	alpha-conotoxin AuIB	Investigative
T79961	DRUGINFO	D0B2JL	JWB-1-84-1	Investigative
T79961	DRUGINFO	D0H4BJ	Muscarine	Investigative
T79961	DRUGINFO	D0I4PC	alpha-conotoxin GI	Investigative
T79961	DRUGINFO	D0JV2S	VU0119498	Investigative
T79961	DRUGINFO	D0P1FJ	Aprophen	Investigative
T79961	DRUGINFO	D00YUX	alpha-conotoxin PnIA	Investigative
T79961	DRUGINFO	D0D4LF	NS1738	Investigative
T79961	DRUGINFO	D0DA1E	A-867744	Investigative
T79961	DRUGINFO	D0Y3DW	[3H]cytisine	Investigative
T79961	DRUGINFO	D0R4RN	[125I]epibatidine	Investigative
T79961	DRUGINFO	D0Z5RQ	Cremastrine	Investigative
T79961	DRUGINFO	D01UDC	Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester	Investigative
T79961	DRUGINFO	D02EXX	GNF-PF-5618	Investigative
T79961	DRUGINFO	D02PFJ	1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea	Investigative
T79961	DRUGINFO	D05EML	1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione	Investigative
T79961	DRUGINFO	D05MDY	2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one	Investigative
T79961	DRUGINFO	D06IUC	FM1-10	Investigative
T79961	DRUGINFO	D06VST	3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one	Investigative
T79961	DRUGINFO	D07DEY	3-(3-benzylamino)-piperidin-2-one	Investigative
T79961	DRUGINFO	D07VZG	BRL-55473	Investigative
T79961	DRUGINFO	D08ZTA	6-Dimethylamino-2-methyl-hex-4-ynal oxime	Investigative
T79961	DRUGINFO	D0AR0H	FM1-43	Investigative
T79961	DRUGINFO	D0B8AQ	7-Pyrrolidin-1-yl-hept-5-yn-2-one	Investigative
T79961	DRUGINFO	D0C9VH	N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide	Investigative
T79961	DRUGINFO	D0C9ZE	Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester	Investigative
T79961	DRUGINFO	D0N2KU	PF-3409409	Investigative
T79961	DRUGINFO	D0O1BN	SULFOARECOLINE	Investigative
T79961	DRUGINFO	D0OE0K	3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane	Investigative
T79961	DRUGINFO	D0QL1X	7-Dimethylamino-3-methyl-hept-5-yn-2-one	Investigative
T79961	DRUGINFO	D0R2JE	N-methoxyquinuclidine-3-carboximidoyl chloride	Investigative
T79961	DRUGINFO	D0R8FS	7-Dimethylamino-hept-5-yn-2-one	Investigative
T79961	DRUGINFO	D0U2IL	2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime	Investigative
T79961	DRUGINFO	D0X2JU	N-methoxyquinuclidine-3-carboximidoyl fluoride	Investigative
T79961	DRUGINFO	D0HV3A	FLUMEZAPINE	Investigative
T79961	DRUGINFO	D0Q2GP	ISOLOXAPINE	Investigative
T79961	DRUGINFO	D0P0IX	ISOCLOZAPINE	Investigative
T79961	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T46904	TARGETID	T46904
T46904	FORMERID	TTDS00491
T46904	UNIPROID	SECR_HUMAN
T46904	TARGNAME	Secretin receptor (SCT)
T46904	GENENAME	SCT
T46904	TARGTYPE	Successful
T46904	SYNONYMS	SCTR; SCT-R; SCT
T46904	FUNCTION	This is a receptor for secretin. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.
T46904	BIOCLASS	GPCR secretin
T46904	SEQUENCE	MAPRPLLLLLLLLGGSAARPAPPRARRHSDGTFTSELSRLREGARLQRLLQGLVGKRSEQDAENSMAWTRLSAGLLCPSGSNMPILQAWMPLDGTWSPWLPPGPMVSEPAGAAAEGTLRPR
T46904	DRUGINFO	D0O8JB	Secretin	Approved

T71690	TARGETID	T71690
T71690	FORMERID	TTDS00530
T71690	UNIPROID	ODP1_ECOLI
T71690	TARGNAME	Bacterial Pyruvate decarboxylase (Bact aceE)
T71690	GENENAME	Bact aceE
T71690	TARGTYPE	Successful
T71690	SYNONYMS	aceE; Pyruvate decarboxylase E1 component
T71690	FUNCTION	The pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate to acetyl-coa and co(2). It contains multiple copies of three enzymatic components: pyruvate dehydrogenase (e1), dihydrolipoamide acetyltransferase (e2) and lipoamide dehydrogenase.
T71690	PDBSTRUC	2QTC; 2QTA; 2IEA; 2G67; 2G28
T71690	BIOCLASS	Aldehyde/oxo donor oxidoreductase
T71690	SEQUENCE	MSERFPNDVDPIETRDWLQAIESVIREEGVERAQYLIDQLLAEARKGGVNVAAGTGISNYINTIPVEEQPEYPGNLELERRIRSAIRWNAIMTVLRASKKDLELGGHMASFQSSATIYDVCFNHFFRARNEQDGGDLVYFQGHISPGVYARAFLEGRLTQEQLDNFRQEVHGNGLSSYPHPKLMPEFWQFPTVSMGLGPIGAIYQAKFLKYLEHRGLKDTSKQTVYAFLGDGEMDEPESKGAITIATREKLDNLVFVINCNLQRLDGPVTGNGKIINELEGIFEGAGWNVIKVMWGSRWDELLRKDTSGKLIQLMNETVDGDYQTFKSKDGAYVREHFFGKYPETAALVADWTDEQIWALNRGGHDPKKIYAAFKKAQETKGKATVILAHTIKGYGMGDAAEGKNIAHQVKKMNMDGVRHIRDRFNVPVSDADIEKLPYITFPEGSEEHTYLHAQRQKLHGYLPSRQPNFTEKLELPSLQDFGALLEEQSKEISTTIAFVRALNVMLKNKSIKDRLVPIIADEARTFGMEGLFRQIGIYSPNGQQYTPQDREQVAYYKEDEKGQILQEGINELGAGCSWLAAATSYSTNNLPMIPFYIYYSMFGFQRIGDLCWAAGDQQARGFLIGGTSGRTTLNGEGLQHEDGHSHIQSLTIPNCISYDPAYAYEVAVIMHDGLERMYGEKQENVYYYITTLNENYHMPAMPEGAEEGIRKGIYKLETIEGSKGKVQLLGSGSILRHVREAAEILAKDYGVGSDVYSVTSFTELARDGQDCERWNMLHPLETPRVPYIAQVMNDAPAVASTDYMKLFAEQVRTYVPADDYRVLGTDGFGRSDSRENLRHHFEVDASYVVVAALGELAKRGEIDKKVVADAIAKFNIDADKVNPRLA
T71690	DRUGINFO	D06PQT	Vitamin B1	Approved

T68461	TARGETID	T68461
T68461	FORMERID	TTDS00405
T68461	UNIPROID	ADT1_HUMAN
T68461	TARGNAME	Adenine nucleotide translocator 1 (SLC25A4)
T68461	GENENAME	SLC25A4
T68461	TARGTYPE	Successful
T68461	SYNONYMS	Solute carrier family 25 member 4; SLC25A4; ANT1; ANT 1; ADP/ATP translocase 1; ADP,ATP carrier protein, heart/skeletal muscle isoform T1; ADP,ATP carrier protein 1
T68461	FUNCTION	Catalyzes the exchange of cytoplasmic ADP with mitochondrial ATP across the mitochondrial inner membrane.
T68461	BIOCLASS	Mitochondrial carrier
T68461	SEQUENCE	MGDHAWSFLKDFLAGGVAAAVSKTAVAPIERVKLLLQVQHASKQISAEKQYKGIIDCVVRIPKEQGFLSFWRGNLANVIRYFPTQALNFAFKDKYKQLFLGGVDRHKQFWRYFAGNLASGGAAGATSLCFVYPLDFARTRLAADVGKGAAQREFHGLGDCIIKIFKSDGLRGLYQGFNVSVQGIIIYRAAYFGVYDTAKGMLPDPKNVHIFVSWMIAQSVTAVAGLVSYPFDTVRRRMMMQSGRKGADIMYTGTVDCWRKIAKDEGAKAFFKGAWSNVLRGMGGAFVLVLYDEIKKYV
T68461	DRUGINFO	D00HNB	Clodronate	Approved
T68461	DRUGINFO	D06LYY	Di-Stearoyl-3-Sn-Phosphatidylcholine	Investigative
T68461	DRUGINFO	D07GHW	bongkrek acid	Investigative
T68461	DRUGINFO	D0V6RT	Cardiolipin	Investigative
T68461	DRUGINFO	D0Z0VL	Carboxyatractyloside	Investigative

T71230	TARGETID	T71230
T71230	FORMERID	TTDS00478
T71230	UNIPROID	ANPRA_HUMAN
T71230	TARGNAME	Atrial natriuretic peptide receptor A (NPR1)
T71230	GENENAME	NPR1
T71230	TARGTYPE	Successful
T71230	SYNONYMS	NPR1; NPR-A; GC-A; Atrial natriuretic peptide A-type receptor; ANPRA; ANP-A
T71230	FUNCTION	Receptor for the atrial natriuretic peptide NPPA/ANP and the brain natriuretic peptide NPPB/BNP which are potent vasoactive hormones playing a key role in cardiovascular homeostasis. Has guanylate cyclase activity upon binding of the ligand.
T71230	BIOCLASS	Phosphorus-oxygen lyase
T71230	ECNUMBER	EC 4.6.1.2
T71230	SEQUENCE	MPGPRRPAGSRLRLLLLLLLPPLLLLLRGSHAGNLTVAVVLPLANTSYPWSWARVGPAVELALAQVKARPDLLPGWTVRTVLGSSENALGVCSDTAAPLAAVDLKWEHNPAVFLGPGCVYAAAPVGRFTAHWRVPLLTAGAPALGFGVKDEYALTTRAGPSYAKLGDFVAALHRRLGWERQALMLYAYRPGDEEHCFFLVEGLFMRVRDRLNITVDHLEFAEDDLSHYTRLLRTMPRKGRVIYICSSPDAFRTLMLLALEAGLCGEDYVFFHLDIFGQSLQGGQGPAPRRPWERGDGQDVSARQAFQAAKIITYKDPDNPEYLEFLKQLKHLAYEQFNFTMEDGLVNTIPASFHDGLLLYIQAVTETLAHGGTVTDGENITQRMWNRSFQGVTGYLKIDSSGDRETDFSLWDMDPENGAFRVVLNYNGTSQELVAVSGRKLNWPLGYPPPDIPKCGFDNEDPACNQDHLSTLEVLALVGSLSLLGILIVSFFIYRKMQLEKELASELWRVRWEDVEPSSLERHLRSAGSRLTLSGRGSNYGSLLTTEGQFQVFAKTAYYKGNLVAVKRVNRKRIELTRKVLFELKHMRDVQNEHLTRFVGACTDPPNICILTEYCPRGSLQDILENESITLDWMFRYSLTNDIVKGMLFLHNGAICSHGNLKSSNCVVDGRFVLKITDYGLESFRDLDPEQGHTVYAKKLWTAPELLRMASPPVRGSQAGDVYSFGIILQEIALRSGVFHVEGLDLSPKEIIERVTRGEQPPFRPSLALQSHLEELGLLMQRCWAEDPQERPPFQQIRLTLRKFNRENSSNILDNLLSRMEQYANNLEELVEERTQAYLEEKRKAEALLYQILPHSVAEQLKRGETVQAEAFDSVTIYFSDIVGFTALSAESTPMQVVTLLNDLYTCFDAVIDNFDVYKVETIGDAYMVVSGLPVRNGRLHACEVARMALALLDAVRSFRIRHRPQEQLRLRIGIHTGPVCAGVVGLKMPRYCLFGDTVNTASRMESNGEALKIHLSSETKAVLEEFGGFELELRGDVEMKGKGKVRTYWLLGERGSSTRG
T71230	DRUGINFO	D05GRY	Nesiritide	Approved
T71230	DRUGINFO	D0L5WD	Ularitide	Phase 3
T71230	DRUGINFO	D0C2ZL	Ataciguat	Phase 2
T71230	DRUGINFO	D0OK3O	Cenderitide	Phase 2
T71230	DRUGINFO	D0X8QO	PL-3994	Phase 2

T94429	TARGETID	T94429
T94429	FORMERID	TTDI02314
T94429	UNIPROID	TRM1_HCMVA
T94429	TARGNAME	Cytomegalovirus Terminase UL56 (CMV TRM1)
T94429	GENENAME	CMV TRM1
T94429	TARGTYPE	Successful
T94429	SYNONYMS	UL56; Tripartite terminase subunit UL28 homolog; TRM1; Protein HFLF0
T94429	FUNCTION	Component of the terminase, molecular motor that packages genomic DNA in empty capsid during assembly.
T94429	BIOCLASS	Herpesviridae UL28
T94429	SEQUENCE	MEMNLLQKLCVVCSKCNEYAMELECLKYCDPNVLLAESTPFKRNAAAIVYLYRKIYPEVVAQNRTQSSLLTLYLEMLLKALHEDTALLDRALMAYSRQPDRAAFYRTVLRLDRCDRHHTVELQFTDNVRFSVSLATLNDIERFLCKMNYVYGILAPEAGLEVCAQLLELLRRLCGISPVARQEVYVEGTTCAQCYEELTIIPNQGRSLNKRLQGLLCNHIAVHRPSSQSDVNIQTVEQDLLDLTTRIPHLAGVLSALKSLFSSSSAYHSYIQEAEEALREYNLFTDIPERIYSLSDFTYWSRTSEVIVKRVGITIQQLNVYHQLCRALMNGISRHLYGEDVEDIFVLGEKALDGEERMFVGSVFAAPNRIIDLITSLSIQAFEDNPVFNKLHESNEMYTKIKHILEEIRRPLPDGTGGDGPEGEAIHLRGREAMSGTGTTLMTASNSSNSSTHSQRNNGGGGRARGGGKKVVGGGVNGQDGDGSENGLRVRNCDEHEALDLVDARSRIHNVTREVNVRKRAYLQKVSEVGYGKVIRCIKTQERLTSKLIDVNLVGPLCLDFISKLMNGFLYRSQYHQDQDVVDVGDQFTYDEHLYVVNNLIHKSLPVESLPLLGQQIYELCNGPLFTHCTDRYPLSHNVDMAYACDNAGVLPHVKDDLVKCAEGTVYPSEWMVVKYMGFFNFSDCQDLNVLQKEMWMHVRELVLSVALYNETFGKQLSIACLRDELHPDRDVILTYNKEWPLLLRHEGSLYKSKDLYLLLYRHLSRPDESGDVPTAPVAKPSTLTAAAAVSGVFREPDRPWLPSPYPSSSTAGVSRRVRATRKRPRRASSLLDLARDEHGIQDLVPGSLR
T94429	DRUGINFO	D0G8PA	MK-8228	Approved

T14541	TARGETID	T14541
T14541	UNIPROID	TOXB_CLODI
T14541	TARGNAME	Clostridium difficile Toxin B (CD toxB)
T14541	GENENAME	CD toxB
T14541	TARGTYPE	Successful
T14541	SYNONYMS	Toxin B
T14541	FUNCTION	Cytotoxin.
T14541	PDBSTRUC	6C0B; 6AR6; 5UQT; 5UQN; 5UQM
T14541	ECNUMBER	EC 3.4.22.-
T14541	SEQUENCE	MSLVNRKQLEKMANVRFRTQEDEYVAILDALEEYHNMSENTVVEKYLKLKDINSLTDIYIDTYKKSGRNKALKKFKEYLVTEVLELKNNNLTPVEKNLHFVWIGGQINDTAINYINQWKDVNSDYNVNVFYDSNAFLINTLKKTVVESAINDTLESFRENLNDPRFDYNKFFRKRMEIIYDKQKNFINYYKAQREENPELIIDDIVKTYLSNEYSKEIDELNTYIEESLNKITQNSGNDVRNFEEFKNGESFNLYEQELVERWNLAAASDILRISALKEIGGMYLDVDMLPGIQPDLFESIEKPSSVTVDFWEMTKLEAIMKYKEYIPEYTSEHFDMLDEEVQSSFESVLASKSDKSEIFSSLGDMEASPLEVKIAFNSKGIINQGLISVKDSYCSNLIVKQIENRYKILNNSLNPAISEDNDFNTTTNTFIDSIMAEANADNGRFMMELGKYLRVGFFPDVKTTINLSGPEAYAAAYQDLLMFKEGSMNIHLIEADLRNFEISKTNISQSTEQEMASLWSFDDARAKAQFEEYKRNYFEGSLGEDDNLDFSQNIVVDKEYLLEKISSLARSSERGYIHYIVQLQGDKISYEAACNLFAKTPYDSVLFQKNIEDSEIAYYYNPGDGEIQEIDKYKIPSIISDRPKIKLTFIGHGKDEFNTDIFAGFDVDSLSTEIEAAIDLAKEDISPKSIEINLLGCNMFSYSINVEETYPGKLLLKVKDKISELMPSISQDSIIVSANQYEVRINSEGRRELLDHSGEWINKEESIIKDISSKEYISFNPKENKITVKSKNLPELSTLLQEIRNNSNSSDIELEEKVMLTECEINVISNIDTQIVEERIEEAKNLTSDSINYIKDEFKLIESISDALCDLKQQNELEDSHFISFEDISETDEGFSIRFINKETGESIFVETEKTIFSEYANHITEEISKIKGTIFDTVNGKLVKKVNLDTTHEVNTLNAAFFIQSLIEYNSSKESLSNLSVAMKVQVYAQLFSTGLNTITDAAKVVELVSTALDETIDLLPTLSEGLPIIATIIDGVSLGAAIKELSETSDPLLRQEIEAKIGIMAVNLTTATTAIITSSLGIASGFSILLVPLAGISAGIPSLVNNELVLRDKATKVVDYFKHVSLVETEGVFTLLDDKIMMPQDDLVISEIDFNNNSIVLGKCEIWRMEGGSGHTVTDDIDHFFSAPSITYREPHLSIYDVLEVQKEELDLSKDLMVLPNAPNRVFAWETGWTPGLRSLENDGTKLLDRIRDNYEGEFYWRYFAFIADALITTLKPRYEDTNIRINLDSNTRSFIVPIITTEYIREKLSYSFYGSGGTYALSLSQYNMGINIELSESDVWIIDVDNVVRDVTIESDKIKKGDLIEGILSTLSIEENKIILNSHEINFSGEVNGSNGFVSLTFSILEGINAIIEVDLLSKSYKLLISGELKILMLNSNHIQQKIDYIGFNSELQKNIPYSFVDSEGKENGFINGSTKEGLFVSELPDVVLISKVYMDDSKPSFGYYSNNLKDVKVITKDNVNILTGYYLKDDIKISLSLTLQDEKTIKLNSVHLDESGVAEILKFMNRKGNTNTSDSLMSFLESMNIKSIFVNFLQSNIKFILDANFIISGTTSIGQFEFICDENDNIQPYFIKFNTLETNYTLYVGNRQNMIVEPNYDLDDSGDISSTVINFSQKYLYGIDSCVNKVVISPNIYTDEINITPVYETNNTYPEVIVLDANYINEKINVNINDLSIRYVWSNDGNDFILMSTSEENKVSQVKIRFVNVFKDKTLANKLSFNFSDKQDVPVSEIILSFTPSYYEDGLIGYDLGLVSLYNEKFYINNFGMMVSGLIYINDSLYYFKPPVNNLITGFVTVGDDKYYFNPINGGAASIGETIIDDKNYYFNQSGVLQTGVFSTEDGFKYFAPANTLDENLEGEAIDFTGKLIIDENIYYFDDNYRGAVEWKELDGEMHYFSPETGKAFKGLNQIGDYKYYFNSDGVMQKGFVSINDNKHYFDDSGVMKVGYTEIDGKHFYFAENGEMQIGVFNTEDGFKYFAHHNEDLGNEEGEEISYSGILNFNNKIYYFDDSFTAVVGWKDLEDGSKYYFDEDTAEAYIGLSLINDGQYYFNDDGIMQVGFVTINDKVFYFSDSGIIESGVQNIDDNYFYIDDNGIVQIGVFDTSDGYKYFAPANTVNDNIYGQAVEYSGLVRVGEDVYYFGETYTIETGWIYDMENESDKYYFNPETKKACKGINLIDDIKYYFDEKGIMRTGLISFENNNYYFNENGEMQFGYINIEDKMFYFGEDGVMQIGVFNTPDGFKYFAHQNTLDENFEGESINYTGWLDLDEKRYYFTDEYIAATGSVIIDGEEYYFDPDTAQLVISE
T14541	DRUGINFO	D09KRE	Bezlotoxumab	Approved
T14541	DRUGINFO	D06IBG	MK-3415A	Phase 3

T75273	TARGETID	T75273
T75273	UNIPROID	GYRA_STAAU
T75273	TARGNAME	Staphylococcus DNA gyrase A (Stap-coc gyrA)
T75273	GENENAME	Stap-coc gyrA
T75273	TARGTYPE	Successful
T75273	SYNONYMS	Stap-coc DNA gyrase subunit A
T75273	FUNCTION	A type II topoisomerase that negatively supercoils closed circular double-stranded (ds) DNA in an ATP-dependent manner to modulate DNA topology and maintain chromosomes in an underwound state. Negative supercoiling favors strand separation, and DNA replication, transcription, recombination and repair, all of which involve strand separation. Also able to catalyze the interconversion of other topological isomers of dsDNA rings, including catenanes and knotted rings. Type II topoisomerases break and join 2 DNA strands simultaneously in an ATP-dependent manner.
T75273	PDBSTRUC	5BS3; 4PLB
T75273	ECNUMBER	EC 5.6.2.3
T75273	SEQUENCE	MAELPQSRINERNITSEMRESFLDYAMSVIVARALPDVRDGLKPVHRRILYGLNEQGMTPDKSYKKSARIVGDVMGKYHPHGDSSIYEAMVRMAQDFSYRYPLVDGQGNFGSMDGDGAAAMRYTEARMTKITLELLRDINKDTIDFIDNYDGNEREPSVLPARFPNLLANGASGIAVGMATNIPPHNLTELINGVLSLSKNPDISIAELMEDIEGPDFPTAGLILGKSGIRRAYETGRGSIQMRSRAVIEERGGGRQRIVVTEIPFQVNKARMIEKIAELVRDKKIDGITDLRDETSLRTGVRVVIDVRKDANASVILNNLYKQTPLQTSFGVNMIALVNGRPKLINLKEALVHYLEHQKTVVRRRTQYNLRKAKDRAHILEGLRIALDHIDEIISTIRESDTDKVAMESLQQRFKLSEKQAQAILDMRLRRLTGLERDKIEAEYNELLNYISELEAILADEEVLLQLVRDELTEIRDRFGDDRRTEIQLGGFEDLEDEDLIPEEQIVITLSHNNYIKRLPVSTYRAQNRGGRGVQGMNTLEEDFVSQLVTLSTHDHVLFFTNKGRVYKLKGYEVPELSRQSKGIPVVNAIELENDEVISTMIAVKDLESEDNFLVFATKRGVVKRSALSNFSRINRNGKIAISFREDDELIAVRLTSGQEDILIGTSHASLIRFPESTLRPLGRTATGVKGITLREGDEVVGLDVAHANSVDEVLVVTENGYGKRTPVNDYRLSNRGGKGIKTATITERNGNVVCITTVTGEEDLMIVTNAGVIIRLDVADISQNGRAAQGVRLIRLGDDQFVSTVAKVKEDAEDETNEDEQSTSTVSEDGTEQQREAVVNDETPGNAIHTEVIDSEENDEDGRIEVRQDFMDRVEEDIQQSLDEDEE
T75273	DRUGINFO	D0X1HE	Ozenoxacin	Approved

T51146	TARGETID	T51146
T51146	FORMERID	TTDI01872
T51146	UNIPROID	FUT4_HUMAN
T51146	TARGNAME	Fucosyltransferase IV (CD15)
T51146	GENENAME	FUT4
T51146	TARGTYPE	Successful
T51146	SYNONYMS	Galactoside 3-L-fucosyltransferase; Fucosyltransferase 4; FucT-IV; Fuc-TIV; FCT3A; ELFT; ELAM-1 ligand fucosyltransferase; Alpha-(1,3)-fucosyltransferase 4
T51146	FUNCTION	May catalyze alpha-1,3 glycosidic linkages involved in the expression of Lewis X/SSEA-1 and VIM-2 antigens.
T51146	BIOCLASS	Glycosyltransferases
T51146	ECNUMBER	EC 2.4.1.-
T51146	SEQUENCE	MRRLWGAARKPSGAGWEKEWAEAPQEAPGAWSGRLGPGRSGRKGRAVPGWASWPAHLALAARPARHLGGAGQGPRPLHSGTAPFHSRASGERQRRLEPQLQHESRCRSSTPADAWRAEAALPVRAMGAPWGSPTAAAGGRRGWRRGRGLPWTVCVLAAAGLTCTALITYACWGQLPPLPWASPTPSRPVGVLLWWEPFGGRDSAPRPPPDCRLRFNISGCRLLTDRASYGEAQAVLFHHRDLVKGPPDWPPPWGIQAHTAEEVDLRVLDYEEAAAAAEALATSSPRPPGQRWVWMNFESPSHSPGLRSLASNLFNWTLSYRADSDVFVPYGYLYPRSHPGDPPSGLAPPLSRKQGLVAWVVSHWDERQARVRYYHQLSQHVTVDVFGRGGPGQPVPEIGLLHTVARYKFYLAFENSQHLDYITEKLWRNALLAGAVPVVLGPDRANYERFVPRGAFIHVDDFPSASSLASYLLFLDRNPAVYRRYFHWRRSYAVHITSFWDEPWCRVCQAVQRAGDRPKSIRNLASWFER
T51146	DRUGINFO	D07WLI	99mTc-fanolesomab	Approved

T73342	TARGETID	T73342
T73342	FORMERID	TTDS00246
T73342	UNIPROID	RIR1_HUMAN; RIR2_HUMAN; RIR2B_HUMAN
T73342	TARGNAME	Ribonucleotide reductase (RIR)
T73342	GENENAME	RIR
T73342	TARGTYPE	Successful
T73342	SYNONYMS	Ribonucleoside diphosphate reductase; RIR1
T73342	FUNCTION	Ribonucleoside-diphosphate reductase holoenzyme provides the precursors necessary for viral DNA synthesis. Allows virus growth in non-dividing cells, as well as reactivation from latency in infected hosts. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides. The N-terminal region confers antiapoptotic activity in differentiated cells such as neurons and is importantfor viral reactivation to increase neural survivability.
T73342	BIOCLASS	CH/CH(2) oxidoreductase
T73342	SEQUENCE	MHVIKRDGRQERVMFDKITSRIQKLCYGLNMDFVDPAQITMKVIQGLYSGVTTVELDTLAAETAATLTTKHPDYAILAARIAVSNLHKETKKVFSDVMEDLYNYINPHNGKHSPMVAKSTLDIVLANKDRLNSAIIYDRDFSYNYFGFKTLERSYLLKINGKVAERPQHMLMRVSVGIHKEDIDAAIETYNLLSERWFTHASPTLFNAGTNRPQLSSCFLLSMKDDSIEGIYDTLKQCALISKSAGGIGVAVSCIRATGSYIAGTNGNSNGLVPMLRVYNNTARYVDQGGNKRPGAFAIYLEPWHLDIFEFLDLKKNTGKEEQRARDLFFALWIPDLFMKRVETNQDWSLMCPNECPGLDEVWGEEFEKLYASYEKQGRVRKVVKAQQLWYAIIESQTETGTPYMLYKDSCNRKSNQQNLGTIKCSNLCTEIVEYTSKDEVAVCNLASLALNMYVTSEHTYDFKKLAEVTKVVVRNLNKIIDINYYPVPEACLSNKRHRPIGIGVQGLADAFILMRYPFESAEAQLLNKQIFETIYYGALEASCDLAKEQGPYETYEGSPVSKGILQYDMWNVTPTDLWDWKVLKEKIAKYGIRNSLLIAPMPTASTAQILGNNESIEPYTSNIYTRRVLSGEFQIVNPHLLKDLTERGLWHEEMKNQIIACNGSIQSIPEIPDDLKQLYKTVWEISQKTVLKMAAERGAFIDQSQSLNIHIAEPNYGKLTSMHFYGWKQGLKTGMYYLRTRPAANPIQFTLNKEKLKDKEKVSKEEEEKERNTAAMVCSLENRDECLMCGS
T73342	DRUGINFO	D0R5RR	Clofarabine	Approved
T73342	DRUGINFO	D7K3FB	CPX-POM	Phase 2
T73342	DRUGINFO	D0YU1M	G-207 virus construct	Phase 1/2
T73342	DRUGINFO	D0NS6Z	COH29	Phase 1
T73342	DRUGINFO	D04FXS	Didox	Discontinued in Phase 2
T73342	DRUGINFO	D0X1ZV	Trimidox	Preclinical
T73342	DRUGINFO	D06PWA	Amidox	Terminated

T40555	TARGETID	T40555
T40555	FORMERID	TTDC00322
T40555	UNIPROID	POLG_HCV1
T40555	TARGNAME	Hepatitis C virus Non-structural 5A (HCV NS5A)
T40555	GENENAME	HCV NS5A
T40555	TARGTYPE	Successful
T40555	SYNONYMS	HCV NS5A
T40555	FUNCTION	Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity).
T40555	PDBSTRUC	3SU4; 3RC5; 3RC4; 3QGI; 3QGH
T40555	BIOCLASS	Hepacivirus polyprotein
T40555	SEQUENCE	SGSWLRDIWDWICEVLSDFKTWLKAKLMPQLPGIPFVSCQRGYKGVWRVDGIMHTRCHCGAEITGHVKNGTMRIVGPRTCRNMWSGTFPINAYTTGPCTPLPAPNYTFALWRVSAEEYVEIRQVGDFHYVTGMTTDNLKCPCQVPSPEFFTELDGVRLHRFAPPCKPLLREEVSFRVGLHEYPVGSQLPCEPEPDVAVLTSMLTDPSHITAEAAGRRLARGSPPSVASSSASQLSAPSLKATCTANHDSPDAELIEANLLWRQEMGGNITRVESENKVVILDSFDPLVAEEDEREISVPAEILRKSRRFAQALPVWARPDYNPPLVETWKKPDYEPPVVHGCPLPPPKSPPVPPPRKKRTVVLTESTLSTALAELATRSFGSSSTSGITGDNTTTSSEPAPSGCPPDSDAESYSSMPPLEGEPGDPDLSDGSWSTVSSEANAEDVVCC
T40555	DRUGINFO	D09SGV	Daclatasvir	Approved
T40555	DRUGINFO	D0C4DH	Glecaprevir; pibrentasvir	Approved
T40555	DRUGINFO	D0RM5Z	Sofosbuvir + velpatasvir + voxilaprevir	Approved
T40555	DRUGINFO	D03GCR	MK-8742	Phase 3
T40555	DRUGINFO	D0LF5Q	ABT-267	Phase 3
T40555	DRUGINFO	DGJD82	Ravidasvir	Phase 2/3
T40555	DRUGINFO	D06LUZ	GS-5885	Phase 2
T40555	DRUGINFO	D0D6MV	PPI-668	Phase 2
T40555	DRUGINFO	D0U6QN	ACH-3102	Phase 2
T40555	DRUGINFO	D0V1KS	AZD-2836	Phase 1/2
T40555	DRUGINFO	D0AR5N	BMS-824383	Phase 1
T40555	DRUGINFO	D0C0QT	PPI-461	Phase 1
T40555	DRUGINFO	D0D0KZ	AV4025	Phase 1
T40555	DRUGINFO	D0N9TY	AZD-7295	Phase 1
T40555	DRUGINFO	D0P6NP	EDP-239	Phase 1
T40555	DRUGINFO	DN18SP	MB-110	Phase 1
T40555	DRUGINFO	D01VCB	ACH-2928	Discontinued in Phase 1

T84117	TARGETID	T84117
T84117	FORMERID	TTDR00564
T84117	UNIPROID	5HT1E_HUMAN
T84117	TARGNAME	5-HT 1E receptor (HTR1E)
T84117	GENENAME	HTR1E
T84117	TARGTYPE	Successful
T84117	SYNONYMS	Serotonin receptor 1E; S31; 5-hydroxytryptamine receptor 1E; 5-HT1E; 5-HT-1E; 5-HT 1E
T84117	FUNCTION	Functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. G-protein coupled receptor for 5-hydroxytryptamine (serotonin).
T84117	BIOCLASS	GPCR rhodopsin
T84117	SEQUENCE	MNITNCTTEASMAIRPKTITEKMLICMTLVVITTLTTLLNLAVIMAIGTTKKLHQPANYLICSLAVTDLLVAVLVMPLSIIYIVMDRWKLGYFLCEVWLSVDMTCCTCSILHLCVIALDRYWAITNAIEYARKRTAKRAALMILTVWTISIFISMPPLFWRSHRRLSPPPSQCTIQHDHVIYTIYSTLGAFYIPLTLILILYYRIYHAAKSLYQKRGSSRHLSNRSTDSQNSFASCKLTQTFCVSDFSTSDPTTEFEKFHASIRIPPFDNDLDHPGERQQISSTRERKAARILGLILGAFILSWLPFFIKELIVGLSIYTVSSEVADFLTWLGYVNSLINPLLYTSFNEDFKLAFKKLIRCREHT
T84117	DRUGINFO	D0UA0I	Metergolin	Approved
T84117	DRUGINFO	D0Q5SL	BRL54443	Investigative
T84117	DRUGINFO	D0S2BB	B173	Investigative
T84117	DRUGINFO	D03RHW	5-BODMT	Investigative
T84117	DRUGINFO	D05DAG	2-(5-fluoro-1H-indol-3-yl)ethanamine	Investigative
T84117	DRUGINFO	D01APL	lysergol	Investigative
T84117	DRUGINFO	D0N8BJ	[3H]5-HT	Investigative
T84117	DRUGINFO	D0CK9K	EDMT	Investigative
T84117	DRUGINFO	D0Y4MC	9-OH-risperidone	Investigative
T84117	DRUGINFO	D0J6JT	m-chlorophenylpiperazine	Investigative
T84117	DRUGINFO	D00CRA	2-methyl-5-HT	Investigative
T84117	DRUGINFO	D09OYA	alpha-methyl-5-HT	Investigative
T84117	DRUGINFO	D03TDN	1-naphthylpiperazine	Investigative
T84117	DRUGINFO	D04TVG	BRL-15572	Investigative
T84117	DRUGINFO	D02UWB	5-CT	Investigative
T84117	DRUGINFO	D0V5HV	TFMPP	Investigative

T88023	TARGETID	T88023
T88023	FORMERID	TTDR00192
T88023	UNIPROID	TNR8_HUMAN
T88023	TARGNAME	Lymphocyte activation antigen CD30 (TNFRSF8)
T88023	GENENAME	TNFRSF8
T88023	TARGTYPE	Successful
T88023	SYNONYMS	Tumor necrosis factor receptor superfamily member 8; KI-1 antigen; D1S166E; CD30L receptor; CD30
T88023	FUNCTION	May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa-B. Receptor for TNFSF8/CD30L.
T88023	PDBSTRUC	1D01
T88023	SEQUENCE	MRVLLAALGLLFLGALRAFPQDRPFEDTCHGNPSHYYDKAVRRCCYRCPMGLFPTQQCPQRPTDCRKQCEPDYYLDEADRCTACVTCSRDDLVEKTPCAWNSSRVCECRPGMFCSTSAVNSCARCFFHSVCPAGMIVKFPGTAQKNTVCEPASPGVSPACASPENCKEPSSGTIPQAKPTPVSPATSSASTMPVRGGTRLAQEAASKLTRAPDSPSSVGRPSSDPGLSPTQPCPEGSGDCRKQCEPDYYLDEAGRCTACVSCSRDDLVEKTPCAWNSSRTCECRPGMICATSATNSCARCVPYPICAAETVTKPQDMAEKDTTFEAPPLGTQPDCNPTPENGEAPASTSPTQSLLVDSQASKTLPIPTSAPVALSSTGKPVLDAGPVLFWVILVLVVVVGSSAFLLCHRRACRKRIRQKLHLCYPVQTSQPKLELVDSRPRRSSTQLRSGASVTEPVAEERGLMSQPLMETCHSVGAAYLESLPLQDASPAGGPSSPRDLPEPRVSTEHTNNKIEKIYIMKADTVIVGTVKAELPEGRGLAGPAEPELEEELEADHTPHYPEQETEPPLGSCSDVMLSVEEEGKEDPLPTAASGK
T88023	DRUGINFO	D03TIS	Brentuximab vedotin	Approved
T88023	DRUGINFO	D00MBR	Iratumumab	Phase 2
T88023	DRUGINFO	D0J7KD	TT11X	Phase 2
T88023	DRUGINFO	D0S0MP	SGN-30	Phase 2
T88023	DRUGINFO	D0T4FY	CAR-T cells targeting CD30	Phase 2
T88023	DRUGINFO	DIKA27	TT20X	Phase 2
T88023	DRUGINFO	DZM2L1	AFM13	Phase 2
T88023	DRUGINFO	D04ACK	Anti-CD30 CAR T cells	Phase 1/2
T88023	DRUGINFO	D0FZ1Y	CART30	Phase 1/2
T88023	DRUGINFO	D0I5GS	CAR.CD30 cells	Phase 1/2
T88023	DRUGINFO	D0UA0U	CAR-T cells targeting CD30	Phase 1/2
T88023	DRUGINFO	D0W2MI	Anti-CD30-CAR-transduced T cells	Phase 1/2
T88023	DRUGINFO	D0K8YX	4SCAR19 and 4SCAR30	Phase 1/2
T88023	DRUGINFO	D06ALK	Xmab-2513	Phase 1
T88023	DRUGINFO	D08ZAC	ICAR30 T cells	Phase 1
T88023	DRUGINFO	D0GA8I	ATLCAR.CD30 cells	Phase 1
T88023	DRUGINFO	D0H2LC	Anti-CD30 CAR-T cells	Phase 1
T88023	DRUGINFO	D0N2AM	CAR CD30 T cells	Phase 1
T88023	DRUGINFO	D0S3YV	CD30 CAR T Cells	Phase 1
T88023	DRUGINFO	D0TC6X	Anti-CD30-CAR T cells	Phase 1
T88023	DRUGINFO	DDG8W9	SGN-CD30C	Phase 1
T88023	DRUGINFO	D0U5AQ	ATLCAR.CD30.CCR4 cells	Phase 1
T88023	DRUGINFO	D0A9QL	Ber-H2/saporin	Terminated
T88023	DRUGINFO	D02SJG	VT-362	Investigative
T88023	DRUGINFO	D0LE2E	H22xKi-4	Investigative

T95400	TARGETID	T95400
T95400	FORMERID	TTDS00484
T95400	UNIPROID	FCERG_HUMAN
T95400	TARGNAME	Immunoglobulin epsilon Fc receptor gamma (FCERG)
T95400	GENENAME	FCER1G
T95400	TARGTYPE	Successful
T95400	SYNONYMS	IgE Fc receptor subunit gamma; High affinity immunoglobulin epsilon receptor subunit gamma; FceRI gamma; FcRgamma; Fc receptor gamma-chain
T95400	FUNCTION	As a component of the high-affinity immunoglobulin E (IgE) receptor, mediates allergic inflammatory signaling in mast cells. As a constitutive component of interleukin-3 receptor complex, selectively mediates interleukin 4/IL4 production by basophils, priming T-cells toward effector T-helper 2 subset. Associates with pattern recognition receptors CLEC4D and CLEC4E to form a functional signaling complex in myeloid cells. Binding of mycobacterial trehalose 6,6'-dimycolate (TDM) to this receptor complex leads to phosphorylation of ITAM, triggering activation of SYK, CARD9 and NF-kappa-B, consequently driving maturation of antigen-presenting cells and shaping antigen-specific priming of T-cells toward effector T-helper 1 and T-helper 17 cell subtypes. May function cooperatively with other activating receptors. Functionally linked to integrin beta-2/ITGB2-mediated neutrophil activation. Also involved in integrin alpha-2/ITGA2-mediated platelet activation. Adapter protein containing an immunoreceptor tyrosine-based activation motif (ITAM) that transduces activation signals from various immunoreceptors.
T95400	BIOCLASS	Immunoglobulin
T95400	SEQUENCE	MIPAVVLLLLLLVEQAAALGEPQLCYILDAILFLYGIVLTLLYCRLKIQVRKAAITSYEKSDGVYTGLSTRNQETYETLKHEKPPQ
T95400	DRUGINFO	D02GEC	Omalizumab	Approved
T95400	DRUGINFO	D0J7TM	Benzylpenicilloyl Polylysine	Approved
T95400	DRUGINFO	D0G6XS	Fucose	Investigative
T95400	DRUGINFO	D07LUR	Alpha-D-Mannose	Investigative

T76630	TARGETID	T76630
T76630	FORMERID	TTDS00096
T76630	UNIPROID	CD52_HUMAN
T76630	TARGNAME	Cambridge pathology 1 antigen (CD52)
T76630	GENENAME	CD52
T76630	TARGTYPE	Successful
T76630	SYNONYMS	Epididymal secretory protein E5; CDW52; CD52 antigen; CD52
T76630	FUNCTION	May play a role in carrying and orienting carbohydrate, as well as having a more specific role.
T76630	SEQUENCE	MKRFLFLLLTISLLVMVQIQTGLSGQNDTSQTSSPSASSNISGGIFLFFVANAIIHLFCFS
T76630	DRUGINFO	D01ZYG	Alemtuzumab	Approved
T76630	DRUGINFO	D0U0SK	GZ402668	Phase 1

T30085	TARGETID	T30085
T30085	FORMERID	TTDNC00579
T30085	UNIPROID	SC5A2_HUMAN
T30085	TARGNAME	Sodium/glucose cotransporter 2 (SGLT2)
T30085	GENENAME	SLC5A2
T30085	TARGTYPE	Successful
T30085	SYNONYMS	Solute carrier family 5 member 2; Na(+)/glucose cotransporter 2; Low affinity sodium-glucose cotransporter
T30085	FUNCTION	Has a Na(+) to glucose coupling ratio of 1:1. Sodium-dependent glucose transporter.
T30085	BIOCLASS	Solute:sodium symporter
T30085	SEQUENCE	MEEHTEAGSAPEMGAQKALIDNPADILVIAAYFLLVIGVGLWSMCRTNRGTVGGYFLAGRSMVWWPVGASLFASNIGSGHFVGLAGTGAASGLAVAGFEWNALFVVLLLGWLFAPVYLTAGVITMPQYLRKRFGGRRIRLYLSVLSLFLYIFTKISVDMFSGAVFIQQALGWNIYASVIALLGITMIYTVTGGLAALMYTDTVQTFVILGGACILMGYAFHEVGGYSGLFDKYLGAATSLTVSEDPAVGNISSFCYRPRPDSYHLLRHPVTGDLPWPALLLGLTIVSGWYWCSDQVIVQRCLAGKSLTHIKAGCILCGYLKLTPMFLMVMPGMISRILYPDEVACVVPEVCRRVCGTEVGCSNIAYPRLVVKLMPNGLRGLMLAVMLAALMSSLASIFNSSSTLFTMDIYTRLRPRAGDRELLLVGRLWVVFIVVVSVAWLPVVQAAQGGQLFDYIQAVSSYLAPPVSAVFVLALFVPRVNEQGAFWGLIGGLLMGLARLIPEFSFGSGSCVQPSACPAFLCGVHYLYFAIVLFFCSGLLTLTVSLCTAPIPRKHLHRLVFSLRHSKEEREDLDADEQQGSSLPVQNGCPESAMEMNEPQAPAPSLFRQCLLWFCGMSRGGVGSPPPLTQEEAAAAARRLEDISEDPSWARVVNLNALLMMAVAVFLWGFYA
T30085	DRUGINFO	D01TNW	Dapagliflozin	Approved
T30085	DRUGINFO	D06ALD	Empagliflozin	Approved
T30085	DRUGINFO	D08DFX	Canagliflozin	Approved
T30085	DRUGINFO	D0Q3VE	PF-04971729	Approved
T30085	DRUGINFO	D0U7IL	Sotagliflozin	Approved
T30085	DRUGINFO	D0Y6QC	Dapagliflozin Propanediol; Saxagliptin Hydrochloride	Approved
T30085	DRUGINFO	D07FBM	ASP1941	Phase 3
T30085	DRUGINFO	D0B6QZ	AVE-2268	Phase 2
T30085	DRUGINFO	D0H2NI	YM-543	Phase 2
T30085	DRUGINFO	D0U7SR	RO-4998452	Phase 2
T30085	DRUGINFO	D0V4MB	Remogliflozin etabonate	Phase 2
T30085	DRUGINFO	D0X2UI	LIK-066	Phase 2
T30085	DRUGINFO	D6KEW7	YG1699	Phase 2
T30085	DRUGINFO	D00SFY	BI-44847	Phase 1
T30085	DRUGINFO	D08OUL	EGT-0001474	Phase 1
T30085	DRUGINFO	D08WGZ	TS-033	Discontinued in Phase 2
T30085	DRUGINFO	D07UEJ	Empagli ozin	Investigative
T30085	DRUGINFO	D0X1TN	sergliflozin	Investigative

T21890	TARGETID	T21890
T21890	FORMERID	TTDS00487
T21890	UNIPROID	CEAM3_HUMAN
T21890	TARGNAME	Carcinoembryonic antigen CGM1 (CD66d)
T21890	GENENAME	CEACAM3
T21890	TARGTYPE	Successful
T21890	SYNONYMS	CGM1; CEACAM3; CD66d
T21890	FUNCTION	Major granulocyte receptor mediating recognition and efficient opsonin-independent phagocytosis of CEACAM-binding microorganisms, including Neissiria, Moxarella and Haemophilus species, thus playing an important role in the clearance of pathogens by the innate immune system. Responsible for RAC1 stimulation in the course of pathogen phagocytosis.
T21890	PDBSTRUC	6AW3; 6AW1; 6AW0; 6AVZ
T21890	BIOCLASS	Immunoglobulin
T21890	SEQUENCE	MGPPSASPHRECIPWQGLLLTASLLNFWNPPTTAKLTIESMPLSVAEGKEVLLLVHNLPQHLFGYSWYKGERVDGNSLIVGYVIGTQQATPGAAYSGRETIYTNASLLIQNVTQNDIGFYTLQVIKSDLVNEEATGQFHVYQENAPGLPVGAVAGIVTGVLVGVALVAALVCFLLLAKTGRTSIQRDLKEQQPQALAPGRGPSHSSAFSMSPLSTAQAPLPNPRTAASIYEELLKHDTNIYCRMDHKAEVAS
T21890	DRUGINFO	D06URS	Arcitumomab	Approved

T62391	TARGETID	T62391
T62391	FORMERID	TTDI01974
T62391	UNIPROID	GRIA3_HUMAN
T62391	TARGNAME	Glutamate receptor AMPA 3 (GRIA3)
T62391	GENENAME	GRIA3
T62391	TARGTYPE	Successful
T62391	SYNONYMS	Glutamate receptor ionotropic, AMPA 3; GluRK3; GluRC; GluR3; GluA3; GRIA3; AMPAselective glutamate receptor 3
T62391	FUNCTION	Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L- glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist. In the presence of CACNG4 or CACNG7 or CACNG8, shows resensitization which is characterized by a delayed accumulation of current flux upon continued application of glutamate.
T62391	BIOCLASS	Glutamate-gated ion channel
T62391	SEQUENCE	MARQKKMGQSVLRAVFFLVLGLLGHSHGGFPNTISIGGLFMRNTVQEHSAFRFAVQLYNTNQNTTEKPFHLNYHVDHLDSSNSFSVTNAFCSQFSRGVYAIFGFYDQMSMNTLTSFCGALHTSFVTPSFPTDADVQFVIQMRPALKGAILSLLGHYKWEKFVYLYDTERGFSILQAIMEAAVQNNWQVTARSVGNIKDVQEFRRIIEEMDRRQEKRYLIDCEVERINTILEQVVILGKHSRGYHYMLANLGFTDILLERVMHGGANITGFQIVNNENPMVQQFIQRWVRLDEREFPEAKNAPLKYTSALTHDAILVIAEAFRYLRRQRVDVSRRGSAGDCLANPAVPWSQGIDIERALKMVQVQGMTGNIQFDTYGRRTNYTIDVYEMKVSGSRKAGYWNEYERFVPFSDQQISNDSASSENRTIVVTTILESPYVMYKKNHEQLEGNERYEGYCVDLAYEIAKHVRIKYKLSIVGDGKYGARDPETKIWNGMVGELVYGRADIAVAPLTITLVREEVIDFSKPFMSLGISIMIKKPQKSKPGVFSFLDPLAYEIWMCIVFAYIGVSVVLFLVSRFSPYEWHLEDNNEEPRDPQSPPDPPNEFGIFNSLWFSLGAFMQQGCDISPRSLSGRIVGGVWWFFTLIIISSYTANLAAFLTVERMVSPIESAEDLAKQTEIAYGTLDSGSTKEFFRRSKIAVYEKMWSYMKSAEPSVFTKTTADGVARVRKSKGKFAFLLESTMNEYIEQRKPCDTMKVGGNLDSKGYGVATPKGSALRNAVNLAVLKLNEQGLLDKLKNKWWYDKGECGSGGGDSKDKTSALSLSNVAGVFYILVGGLGLAMMVALIEFCYKSRAESKRMKLTKNTQNFKPAPATNTQNYATYREGYNVYGTESVKI
T62391	DRUGINFO	D0U3ED	E-2007	Approved
T62391	DRUGINFO	D0SB9H	joro toxin	Investigative
T62391	DRUGINFO	D03VBJ	ATPO	Investigative
T62391	DRUGINFO	D09LXQ	(S)-5-fluorowillardiine	Investigative
T62391	DRUGINFO	D0G1UE	[3H]AMPA	Investigative
T62391	DRUGINFO	D0E5UQ	[3H]CNQX	Investigative

T63967	TARGETID	T63967
T63967	UNIPROID	ACHA4_HUMAN; ACHB2_HUMAN
T63967	TARGNAME	Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2)
T63967	GENENAME	CHRNA4-CHRNB2
T63967	TARGTYPE	Successful
T63967	SYNONYMS	CHRN; nAChR
T63967	FUNCTION	After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodiun ions.
T63967	BIOCLASS	Neurotransmitter receptor
T63967	SEQUENCE	MELGGPGAPRLLPPLLLLLGTGLLRASSHVETRAHAEERLLKKLFSGYNKWSRPVANISDVVLVRFGLSIAQLIDVDEKNQMMTTNVWVKQEWHDYKLRWDPADYENVTSIRIPSELIWRPDIVLYNNADGDFAVTHLTKAHLFHDGRVQWTPPAIYKSSCSIDVTFFPFDQQNCTMKFGSWTYDKAKIDLVNMHSRVDQLDFWESGEWVIVDAVGTYNTRKYECCAEIYPDITYAFVIRRLPLFYTINLIIPCLLISCLTVLVFYLPSECGEKITLCISVLLSLTVFLLLITEIIPSTSLVIPLIGEYLLFTMIFVTLSIVITVFVLNVHHRSPRTHTMPTWVRRVFLDIVPRLLLMKRPSVVKDNCRRLIESMHKMASAPRFWPEPEGEPPATSGTQSLHPPSPSFCVPLDVPAEPGPSCKSPSDQLPPQQPLEAEKASPHPSPGPCRPPHGTQAPGLAKARSLSVQHMSSPGEAVEGGVRCRSRSIQYCVPRDDAAPEADGQAAGALASRNTHSAELPPPDQPSPCKCTCKKEPSSVSPSATVKTRSTKAPPPHLPLSPALTRAVEGVQYIADHLKAEDTDFSVKEDWKYVAMVIDRIFLWMFIIVCLLGTVGLFLPPWLAGMI
T63967	DRUGINFO	D0LM4A	Varenicline	Approved
T63967	DRUGINFO	D0Y6CE	Metocurine Iodide	Approved
T63967	DRUGINFO	D01MAU	AZD-1446	Phase 2
T63967	DRUGINFO	D04SHH	TC-6499-12	Phase 2
T63967	DRUGINFO	D05RSC	Sofinicline	Phase 2
T63967	DRUGINFO	D0R7AK	CP-601927	Phase 2
T63967	DRUGINFO	D00EZO	TC-2216	Phase 1
T63967	DRUGINFO	D4AY6B	SUVN 911	Phase 1
T63967	DRUGINFO	D00LVA	Dianicline	Discontinued in Phase 3
T63967	DRUGINFO	D05OFO	TC-2696	Discontinued in Phase 2
T63967	DRUGINFO	D0AB4Q	Ispronicline	Discontinued in Phase 2
T63967	DRUGINFO	D0L1DP	ABT-089	Discontinued in Phase 2
T63967	DRUGINFO	D0TF1E	A-366833	Preclinical
T63967	DRUGINFO	D0Y9HH	SIB-1508Y	Terminated

T96235	TARGETID	T96235
T96235	FORMERID	TTDI01975
T96235	UNIPROID	GRIA4_HUMAN
T96235	TARGNAME	Glutamate receptor AMPA 4 (GRIA4)
T96235	GENENAME	GRIA4
T96235	TARGTYPE	Successful
T96235	SYNONYMS	Glutamate receptor ionotropic, AMPA 4; GluRD; GluR4; GluA4; GRIA4; AMPAselective glutamate receptor 4
T96235	FUNCTION	Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the centralnervous system. Binding of the excitatory neurotransmitter L- glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist. In the presence of CACNG4 or CACNG7 or CACNG8, shows resensitization which is characterized by a delayed accumulation of current flux upon continued application of glutamate.
T96235	BIOCLASS	Glutamate-gated ion channel
T96235	SEQUENCE	MRIISRQIVLLFSGFWGLAMGAFPSSVQIGGLFIRNTDQEYTAFRLAIFLHNTSPNASEAPFNLVPHVDNIETANSFAVTNAFCSQYSRGVFAIFGLYDKRSVHTLTSFCSALHISLITPSFPTEGESQFVLQLRPSLRGALLSLLDHYEWNCFVFLYDTDRGYSILQAIMEKAGQNGWHVSAICVENFNDVSYRQLLEELDRRQEKKFVIDCEIERLQNILEQIVSVGKHVKGYHYIIANLGFKDISLERFIHGGANVTGFQLVDFNTPMVIKLMDRWKKLDQREYPGSETPPKYTSALTYDGVLVMAETFRSLRRQKIDISRRGNAGDCLANPAAPWGQGIDMERTLKQVRIQGLTGNVQFDHYGRRVNYTMDVFELKSTGPRKVGYWNDMDKLVLIQDVPTLGNDTAAIENRTVVVTTIMESPYVMYKKNHEMFEGNDKYEGYCVDLASEIAKHIGIKYKIAIVPDGKYGARDADTKIWNGMVGELVYGKAEIAIAPLTITLVREEVIDFSKPFMSLGISIMIKKPQKSKPGVFSFLDPLAYEIWMCIVFAYIGVSVVLFLVSRFSPYEWHTEEPEDGKEGPSDQPPNEFGIFNSLWFSLGAFMQQGCDISPRSLSGRIVGGVWWFFTLIIISSYTANLAAFLTVERMVSPIESAEDLAKQTEIAYGTLDSGSTKEFFRRSKIAVYEKMWTYMRSAEPSVFTRTTAEGVARVRKSKGKFAFLLESTMNEYIEQRKPCDTMKVGGNLDSKGYGVATPKGSSLRTPVNLAVLKLSEAGVLDKLKNKWWYDKGECGPKDSGSKDKTSALSLSNVAGVFYILVGGLGLAMLVALIEFCYKSRAEAKRMKLTFSEAIRNKARLSITGSVGENGRVLTPDCPKAVHTGTAIRQSSGLAVIASDLP
T96235	DRUGINFO	D0U3ED	E-2007	Approved
T96235	DRUGINFO	D0W6EP	AMG-889436	Investigative
T96235	DRUGINFO	D0SB9H	joro toxin	Investigative
T96235	DRUGINFO	D03VBJ	ATPO	Investigative
T96235	DRUGINFO	D09LXQ	(S)-5-fluorowillardiine	Investigative
T96235	DRUGINFO	D0G1UE	[3H]AMPA	Investigative
T96235	DRUGINFO	D0E5UQ	[3H]CNQX	Investigative

T16792	TARGETID	T16792
T16792	FORMERID	TTDS00426
T16792	UNIPROID	IOD1_HUMAN
T16792	TARGNAME	Iodothyronine deiodinase type I (DIO1)
T16792	GENENAME	DIO1
T16792	TARGTYPE	Successful
T16792	SYNONYMS	Type-I 5'-deiodinase; Type I iodothyronine deiodinase; Type 1 DI; TXDI1; ITDI1; DIOI; 5DI
T16792	FUNCTION	Plays a role in providing a source of plasma T3 by deiodination of T4 in peripheral tissues such as liver and kidney. Responsible for the deiodination of T4 (3,5,3',5'-tetraiodothyronine) into T3 (3,5,3'-triiodothyronine) and of T3 into T2 (3,3'-diiodothyronine).
T16792	ECNUMBER	EC 1.21.99.4
T16792	SEQUENCE	MGLPQPGLWLKRLWVLLEVAVHVVVGKVLLILFPDRVKRNILAMGEKTGMTRNPHFSHDNWIPTFFSTQYFWFVLKVRWQRLEDTTELGGLAPNCPVVRLSGQRCNIWEFMQGNRPLVLNFGSCTUPSFMFKFDQFKRLIEDFSSIADFLVIYIEEAHASDGWAFKNNMDIRNHQNLQDRLQAAHLLLARSPQCPVVVDTMQNQSSQLYAALPERLYIIQEGRILYKGKSGPWNYNPEEVRAVLEKLHS
T16792	DRUGINFO	D00MIN	Propylthiouracil	Approved

T34239	TARGETID	T34239
T34239	UNIPROID	PPOX_HUMAN
T34239	TARGNAME	Protoporphyrinogen oxidase (PPOX)
T34239	GENENAME	PPOX
T34239	TARGTYPE	Successful
T34239	SYNONYMS	PPO
T34239	FUNCTION	Catalyzes the 6-electron oxidation of protoporphyrinogen-IX to form protoporphyrin-IX.
T34239	PDBSTRUC	4IVO; 4IVM; 3NKS
T34239	ECNUMBER	EC 1.3.3.4
T34239	SEQUENCE	MGRTVVVLGGGISGLAASYHLSRAPCPPKVVLVESSERLGGWIRSVRGPNGAIFELGPRGIRPAGALGARTLLLVSELGLDSEVLPVRGDHPAAQNRFLYVGGALHALPTGLRGLLRPSPPFSKPLFWAGLRELTKPRGKEPDETVHSFAQRRLGPEVASLAMDSLCRGVFAGNSRELSIRSCFPSLFQAEQTHRSILLGLLLGAGRTPQPDSALIRQALAERWSQWSLRGGLEMLPQALETHLTSRGVSVLRGQPVCGLSLQAEGRWKVSLRDSSLEADHVISAIPASVLSELLPAEAAPLARALSAITAVSVAVVNLQYQGAHLPVQGFGHLVPSSEDPGVLGIVYDSVAFPEQDGSPPGLRVTVMLGGSWLQTLEASGCVLSQELFQQRAQEAAATQLGLKEMPSHCLVHLHKNCIPQYTLGHWQKLESARQFLTAHRLPLTLAGASYEGVAVNDCIESGRQAAVSVLGTEPNS
T34239	DRUGINFO	D0O4GY	Aminolevulinic Acid Hydrochloride	Approved

T55094	TARGETID	T55094
T55094	FORMERID	TTDR01256
T55094	UNIPROID	ASIC1_HUMAN
T55094	TARGNAME	Acid-sensing ion channel 1 (ASIC1)
T55094	GENENAME	ASIC1
T55094	TARGTYPE	Successful
T55094	SYNONYMS	Brain sodium channel 2; BNaC2; Amiloride-sensitive cation channel 2, neuronal; ASIC1; ACCN2
T55094	FUNCTION	Isoform 1 does not display proton-gated cation channel activity.
T55094	BIOCLASS	Amiloride-sensitive sodium channel
T55094	SEQUENCE	MELKAEEEEVGGVQPVSIQAFASSSTLHGLAHIFSYERLSLKRALWALCFLGSLAVLLCVCTERVQYYFHYHHVTKLDEVAASQLTFPAVTLCNLNEFRFSQVSKNDLYHAGELLALLNNRYEIPDTQMADEKQLEILQDKANFRSFKPKPFNMREFYDRAGHDIRDMLLSCHFRGEVCSAEDFKVVFTRYGKCYTFNSGRDGRPRLKTMKGGTGNGLEIMLDIQQDEYLPVWGETDETSFEAGIKVQIHSQDEPPFIDQLGFGVAPGFQTFVACQEQRLIYLPPPWGTCKAVTMDSDLDFFDSYSITACRIDCETRYLVENCNCRMVHMPGDAPYCTPEQYKECADPALDFLVEKDQEYCVCEMPCNLTRYGKELSMVKIPSKASAKYLAKKFNKSEQYIGENILVLDIFFEVLNYETIEQKKAYEIAGLLGDIGGQMGLFIGASILTVLELFDYAYEVIKHKLCRRGKCQKEAKRSSADKGVALSLDDVKRHNPCESLRGHPAGMTYAANILPHHPARGTFEDFTC
T55094	DRUGINFO	D0I0RJ	Amiloride	Approved
T55094	DRUGINFO	D0E2ZA	PPC-5650	Phase 1
T55094	DRUGINFO	D0I8OE	PcTx1	Investigative

T14582	TARGETID	T14582
T14582	FORMERID	TTDR00158
T14582	UNIPROID	ALR_MYCSM
T14582	TARGNAME	Mycobacterium Biosynthetic alanine racemase (MycB alr)
T14582	GENENAME	MycB alr
T14582	TARGTYPE	Successful
T14582	SYNONYMS	D-alanine racemase; Alr; Alanine racemase; AlaR
T14582	FUNCTION	Catalyzes the interconversion of L-alanine and D- alanine. Overexpression due to a natural mutation in the promoter is responsible for mediating resistance to D-cycloserine (DCS) in mycobacteria.
T14582	BIOCLASS	Racemases and epimerases
T14582	ECNUMBER	EC 5.1.1.1
T14582	SEQUENCE	MQTTEPMTPPAPLASAQTVIDLGAIDHNVRVLRELAGSADVMAVVKADAYGHGALPVARTALAAGAAALGVATIPEALALREGGITAPVLAWLHPPGTDFAPAIAADVEVAVSSRRQLEQVTAAAAEVGRTATVTVKVDTGLSRNGVGAADYPEVLDVLRRAQADGAIRVRGLMSHLVHGDDPENPFNGLQGQRLADMRVYAREHGVDYEVAHLCNSPAAMTRPDLAFEMVRPGISLYGLSPIPERGDMGLRPAMTLKCPVALVRSVHAGDGVSYGHRWVADRDTTLGLLPIGYADGVYRALSGRIDVLIKGRRRRAVGRICMDQFVVDLGPDADDVAVGDDAILFGPGANGEPTAQDWAELLDTIHYEVVTSPRGRVTRTYLPAGQQD
T14582	DRUGINFO	D02WFK	Cycloserine	Approved
T14582	DRUGINFO	D02XZI	Pyridoxyl-N,O-Cycloserylamide-5-Monophosphate	Investigative
T14582	DRUGINFO	D0B0SD	Propionate	Investigative
T14582	DRUGINFO	D0I7PG	N-(5'-Phosphopyridoxyl)-D-Alanine	Investigative
T14582	DRUGINFO	D0J1AY	Pyridoxyl-Alanine-5-Phosphate	Investigative
T14582	DRUGINFO	D0S5BG	Propanoic Acid	Investigative
T14582	DRUGINFO	D0T7UP	3-fluorovinylglycine	Investigative
T14582	DRUGINFO	D01NBK	Pyridoxamine-5'-Phosphate	Investigative
T14582	DRUGINFO	D0CC0B	Lysine Nz-Carboxylic Acid	Investigative
T14582	DRUGINFO	D0F2ME	Acetate Ion	Investigative

T90828	TARGETID	T90828
T90828	UNIPROID	IL5RA_HUMAN
T90828	TARGNAME	Interleukin 5 receptor alpha (IL5RA)
T90828	GENENAME	IL5RA
T90828	TARGTYPE	Successful
T90828	SYNONYMS	Interleukin-5 receptor subunit alpha; IL5R; IL-5RA; IL-5R-alpha; IL-5R subunit alpha; IL-5 receptor subunit alpha; CDw125; CD125
T90828	FUNCTION	The alpha chain binds to IL5. This is the receptor for interleukin-5.
T90828	PDBSTRUC	6H41; 3VA2; 3QT2; 1OBZ; 1OBX
T90828	BIOCLASS	Cytokine receptor
T90828	SEQUENCE	MIIVAHVLLILLGATEILQADLLPDEKISLLPPVNFTIKVTGLAQVLLQWKPNPDQEQRNVNLEYQVKINAPKEDDYETRITESKCVTILHKGFSASVRTILQNDHSLLASSWASAELHAPPGSPGTSIVNLTCTTNTTEDNYSRLRSYQVSLHCTWLVGTDAPEDTQYFLYYRYGSWTEECQEYSKDTLGRNIACWFPRTFILSKGRDWLAVLVNGSSKHSAIRPFDQLFALHAIDQINPPLNVTAEIEGTRLSIQWEKPVSAFPIHCFDYEVKIHNTRNGYLQIEKLMTNAFISIIDDLSKYDVQVRAAVSSMCREAGLWSEWSQPIYVGNDEHKPLREWFVIVIMATICFILLILSLICKICHLWIKLFPPIPAPKSNIKDLFVTTNYEKAGSSETEIEVICYIEKPGVETLEDSVF
T90828	DRUGINFO	D02PIO	Benralizumab	Approved
T90828	DRUGINFO	D3Q0FU	CSL311	Phase 1
T90828	DRUGINFO	D0S2TI	YM90709	Investigative

T08898	TARGETID	T08898
T08898	FORMERID	TTDS00286
T08898	UNIPROID	ACTHR_HUMAN
T08898	TARGNAME	Melanocortin receptor 2 (MC2R)
T08898	GENENAME	MC2R
T08898	TARGTYPE	Successful
T08898	SYNONYMS	Melanocortin-2 receptor; MC2-R; Adrenocorticotropin receptor; Adrenocorticotropic hormone receptor; ACTHR; ACTH-R; ACTH receptor
T08898	FUNCTION	Receptor for corticotropin (ACTH). This receptor is mediated by G proteins (G(s)) which activate adenylate cyclase (cAMP).
T08898	BIOCLASS	GPCR rhodopsin
T08898	SEQUENCE	MKHIINSYENINNTARNNSDCPRVVLPEEIFFTISIVGVLENLIVLLAVFKNKNLQAPMYFFICSLAISDMLGSLYKILENILIILRNMGYLKPRGSFETTADDIIDSLFVLSLLGSIFSLSVIAADRYITIFHALRYHSIVTMRRTVVVLTVIWTFCTGTGITMVIFSHHVPTVITFTSLFPLMLVFILCLYVHMFLLARSHTRKISTLPRANMKGAITLTILLGVFIFCWAPFVLHVLLMTFCPSNPYCACYMSLFQVNGMLIMCNAVIDPFIYAFRSPELRDAFKKMIFCSRYW
T08898	DRUGINFO	D0W6LI	Cosyntropin	Approved

T19693	TARGETID	T19693
T19693	FORMERID	TTDI03001
T19693	UNIPROID	GUC2D_HUMAN
T19693	TARGNAME	Soluble guanylyl cyclase (GUCY2D)
T19693	GENENAME	GUCY2D
T19693	TARGTYPE	Successful
T19693	SYNONYMS	Rod outer segment membrane guanylate cyclase; Retinal guanylyl cyclase 1; ROS-GC; RETGC1; RETGC-1; RETGC; Guanylate cyclase 2D, retinal; GUC2D; GUC1A4; CORD6
T19693	FUNCTION	Probably plays a specific functional role in the rods and/or cones of photoreceptors. It may be the enzyme involved in the resynthesis of cGMP required for recovery of the dark state after phototransduction.
T19693	PDBSTRUC	1AWL
T19693	ECNUMBER	EC 4.6.1.2
T19693	SEQUENCE	MTACARRAGGLPDPGLCGPAWWAPSLPRLPRALPRLPLLLLLLLLQPPALSAVFTVGVLGPWACDPIFSRARPDLAARLAAARLNRDPGLAGGPRFEVALLPEPCRTPGSLGAVSSALARVSGLVGPVNPAACRPAELLAEEAGIALVPWGCPWTQAEGTTAPAVTPAADALYALLRAFGWARVALVTAPQDLWVEAGRSLSTALRARGLPVASVTSMEPLDLSGAREALRKVRDGPRVTAVIMVMHSVLLGGEEQRYLLEAAEELGLTDGSLVFLPFDTIHYALSPGPEALAALANSSQLRRAHDAVLTLTRHCPSEGSVLDSLRRAQERRELPSDLNLQQVSPLFGTIYDAVFLLARGVAEARAAAGGRWVSGAAVARHIRDAQVPGFCGDLGGDEEPPFVLLDTDAAGDRLFATYMLDPARGSFLSAGTRMHFPRGGSAPGPDPSCWFDPNNICGGGLEPGLVFLGFLLVVGMGLAGAFLAHYVRHRLLHMQMVSGPNKIILTVDDITFLHPHGGTSRKVAQGSRSSLGARSMSDIRSGPSQHLDSPNIGVYEGDRVWLKKFPGDQHIAIRPATKTAFSKLQELRHENVALYLGLFLARGAEGPAALWEGNLAVVSEHCTRGSLQDLLAQREIKLDWMFKSSLLLDLIKGIRYLHHRGVAHGRLKSRNCIVDGRFVLKITDHGHGRLLEAQKVLPEPPRAEDQLWTAPELLRDPALERRGTLAGDVFSLAIIMQEVVCRSAPYAMLELTPEEVVQRVRSPPPLCRPLVSMDQAPVECILLMKQCWAEQPELRPSMDHTFDLFKNINKGRKTNIIDSMLRMLEQYSSNLEDLIRERTEELELEKQKTDRLLTQMLPPSVAEALKTGTPVEPEYFEQVTLYFSDIVGFTTISAMSEPIEVVDLLNDLYTLFDAIIGSHDVYKVETIGDAYMVASGLPQRNGQRHAAEIANMSLDILSAVGTFRMRHMPEVPVRIRIGLHSGPCVAGVVGLTMPRYCLFGDTVNTASRMESTGLPYRIHVNLSTVGILRALDSGYQVELRGRTELKGKGAEDTFWLVGRRGFNKPIPKPPDLQPGSSNHGISLQEIPPERRRKLEKARPGQFS
T19693	DRUGINFO	D04UKC	Riociguat	Approved
T19693	DRUGINFO	D06ZEO	Vericiguat	Approved
T19693	DRUGINFO	D0ZM8B	FK-409	Phase 2
T19693	DRUGINFO	D0O9CZ	BAY412272	Investigative
T19693	DRUGINFO	D0R3FS	ODQ	Investigative
T19693	DRUGINFO	D0U3YQ	NS 2028	Investigative

T07289	TARGETID	T07289
T07289	FORMERID	TTDI01985
T07289	UNIPROID	ACKR1_HUMAN
T07289	TARGNAME	Duffy antigen chemokine receptor (ACKR1)
T07289	GENENAME	ACKR1
T07289	TARGTYPE	Successful
T07289	SYNONYMS	Plasmodium vivax receptor; GpFy; Glycoprotein D; Fy glycoprotein; Duffy antigen/chemokine receptor; DARC; CD234; ACKR1
T07289	FUNCTION	Atypical chemokine receptor that controls chemokine levels and localization via high-affinity chemokine binding that is uncoupled from classic ligand-driven signal transduction cascades, resulting instead in chemokine sequestration, degradation, or transcytosis. Also known as interceptor (internalizing receptor) or chemokine-scavenging receptor or chemokine decoy receptor. Has a promiscuous chemokine-binding profile, interacting with inflammatory chemokines of both the CXC and the CC subfamilies but not with homeostatic chemokines. Acts as a receptor for chemokines including CCL2, CCL5, CCL7, CCL11, CCL13, CCL14, CCL17, CXCL5, CXCL6, IL8/CXCL8, CXCL11, GRO, RANTES, MCP-1, TARC and also for the malaria parasites P.vivax and P.knowlesi. May regulate chemokine bioavailability and, consequently, leukocyte recruitment through two distinct mechanisms: when expressed in endothelial cells, it sustains the abluminal to luminal transcytosis of tissue-derived chemokines and their subsequent presentation to circulating leukocytes; when expressed in erythrocytes, serves as blood reservoir of cognate chemokines but also as a chemokine sink, buffering potential surges in plasma chemokine levels.
T07289	PDBSTRUC	4NUV; 4NUU
T07289	BIOCLASS	GPCR duffy
T07289	SEQUENCE	MGNCLHRAELSPSTENSSQLDFEDVWNSSYGVNDSFPDGDYGANLEAAAPCHSCNLLDDSALPFFILTSVLGILASSTVLFMLFRPLFRWQLCPGWPVLAQLAVGSALFSIVVPVLAPGLGSTRSSALCSLGYCVWYGSAFAQALLLGCHASLGHRLGAGQVPGLTLGLTVGIWGVAALLTLPVTLASGASGGLCTLIYSTELKALQATHTVACLAIFVLLPLGLFGAKGLKKALGMGPGPWMNILWAWFIFWWPHGVVLGLDFLVRSKLLLLSTCLAQQALDLLLNLAEALAILHCVATPLLLALFCHQATRTLLPSLPLPEGWSSHLDTLGSKS
T07289	DRUGINFO	D09EGZ	Chloroquine	Approved
T07289	DRUGINFO	D0L1VI	AQ-13	Phase 2

T93955	TARGETID	T93955
T93955	FORMERID	TTDS00506
T93955	UNIPROID	MTLD_ASPFU
T93955	TARGNAME	Aspergillus Mannitol-1-phosphate 5-dehydrogenase (Asperg mpdA)
T93955	GENENAME	Asperg mpdA
T93955	TARGTYPE	Successful
T93955	SYNONYMS	mpdA; MPDH; MPD; M1PDH
T93955	FUNCTION	Catalyzes the NAD(H)-dependent interconversion of D- fructose 6-phosphate and D-mannitol 1-phosphate in the mannitol metabolic pathway. Has a strong preference for NADH over NADPH.
T93955	BIOCLASS	Short-chain dehydrogenases reductase
T93955	ECNUMBER	EC 1.1.1.17
T93955	SEQUENCE	MGKKAIQFGGGNIGRGFVAEFLHEAGYEVVFIDVVDKIIDALKSTPSYEVTEVSEEGEKTKTITNYRAINSKTNEEDVVKEIGTADVVTCAVGPNVLKFIAPVIAKGIDARTASKPVAVIACENAIGATDTLRGFIEQNTDKDRLSSMSERARFANSAIDRIVPNQPPNAGLNVRIEKFYEWTVEQTPFGEFGHPDIPAIHWVDDLKPYIERKLFTVNTGHATTAYYGHMRGKKMIADALADAEIRQIVHKVLEQTAKLITTKHEITEQEQNEYVDTIVKRMSNPFLEDNVERVGRAPLRKLSRNERFIGPASQLAEKGLPFDALLGSIEMALRFQNVPGDEESAELAKILKEMSAEEATGKLTGLEKHHPLYEPVQNVIAKVQKDSK
T93955	DRUGINFO	D0P7EK	Mannitol	Approved

T71501	TARGETID	T71501
T71501	FORMERID	TTDS00309
T71501	UNIPROID	Q67889_HBV
T71501	TARGNAME	Hepatitis B virus Polymerase (HBV P)
T71501	GENENAME	HBV P
T71501	TARGTYPE	Successful
T71501	SYNONYMS	Protein P
T71501	FUNCTION	Multifunctional enzyme that converts the viral RNA genome into dsDNA in viral cytoplasmic capsids. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3'- to 5'-endonucleasic mode. Neo-synthesized pregenomic RNA (pgRNA) are encapsidated together with the P protein, and reverse-transcribed inside the nucleocapsid. Initiation of reverse-transcription occurs first by binding the epsilon loop on the pgRNA genome, and is initiated by protein priming, thereby the 5'-end of (-)DNA is covalently linked to P protein. Partial (+)DNA is synthesized from the (-)DNA template and generates the relaxed circular DNA (RC-DNA) genome. After budding and infection, the RC-DNA migrates in the nucleus, and is converted into a plasmid-like covalently closed circular DNA (cccDNA). The activity of P protein does not seem to be necessary for cccDNA generation, and is presumably released from (+)DNA by host nuclear DNA repair machinery.
T71501	BIOCLASS	DNA-directed DNA polymerase
T71501	SEQUENCE	MPLSYQHFRKLLLLDDGTGPLEEELPRLADEGLNRRVAEDLNLGNLNVSIPWTHKVGNFTGLYSSTVPVFNPHWKTPSFPNIHLHQDIIKKCEQFVGPLTVNEKRRLQLIMPARFYPKVTKYLPLDKGIKPYYPEHLVNHYFQTRHYLHTLWKAGILYKRETTHSASFCGSPYSWEQDLQHGAESIHQQSSGILSRPPVGSSLQSKHRKSRLGLQSQQGHLARRQQGRSWSIRAGFHPTARRPFGVEPSGSGHTTNFASKSASCLHQSPVRKAAYPSVSTFEKHSSSGHAVELHNLPPNSARSKSERPVFPCWWLQFRNSKPCSDYCLSLIVNLREDWGPCDDHGEHHIRIPRTPARVRGGVFLVDKNPHNTAESRLVVDFSQFSRGNYRVSWPKFAVPNLPSLTNLLSSNLSWLSLDVSAAFYHIPLHPAAMPHLLVGSSGLSRYVARLSSNSRYFNNQHGTMQNLHDSCSRNLYVSLLLLYQTFGRKLHLYSHPIILGFRKIPMAVGLSPFLLAQFTSAICSVVRRAFPHCLGFSYMDDVVLGAKSVQHRESLYTAVTNFLLSLGIHLNPNKTKRWGYSLNFMGYIIGSWGTLPQDHIVQKIKHCFRKLPVNRPIDWKVWQRIVGLLGFAAPFTQCGYPALMPLYACIQAKQAFTFSPTYKAFLSKQYMNLYPVARQRPGLCQVFADATPTGWGLA
T71501	DRUGINFO	D0CL9S	Telbivudine	Approved
T71501	DRUGINFO	D5R6AG	ATI-2173	Phase 2
T71501	DRUGINFO	DY1H2Z	NCO-48	Phase 1
T71501	DRUGINFO	D0X3LD	Valtorcitabine	Discontinued in Phase 2

T09005	TARGETID	T09005
T09005	FORMERID	TTDS00532
T09005	UNIPROID	Q6NK15_CORDI
T09005	TARGNAME	Corynebacterium Mutated CRM197 (Cory mTOX)
T09005	GENENAME	Cory mTOX
T09005	TARGTYPE	Successful
T09005	SYNONYMS	Diphtheria toxin; DIP0222
T09005	FUNCTION	Contains a single base change in the structural gene resulting in the substitution of glutamic acid for glycine which blocks ADP-ribosylation.
T09005	PDBSTRUC	5I82
T09005	ECNUMBER	EC 2.4.2.36
T09005	SEQUENCE	MSRKLFASILIGALLGIGAPPSAHAGADDVVDSSKSFVMENFSSYHGTKPGYVDSIQKGIQKPKSGTQGNYDDDWKGFYSTDNKYDAAGYSVDNENPLSGKAGGVVKVTYPGLTKVLALKVDNAETIKKELGLSLTEPLMEQVGTEEFIKRFGDGASRVVLSLPFAEGSSSVEYINNWEQAKALSVELEINFETRGKRGQDAMYEYMAQACAGNRVRRSVGSSLSCINLDWDVIRDKTKTKIESLKEHGPIKNKMSESPNKTVSEEKAKQYLEEFHQTALEHPELSELKTVTGTNPVFAGANYAAWAVNVAQVIDSETADNLEKTTAALSILPGIGSVMGIADGAVHHNTEEIVAQSIALSSLMVAQAIPLVGELVDIGFAAYNFVESIINLFQVVHNSYNRPAYSPGHKTQPFLHDGYAVSWNTVEDSIIRTGFQGESGHDIKITAENTPLPIAGVLLPTIPGKLDVNKSKTHISVNGRKIRMRCRAIDGDVTFCRPKSPVYVGNGVHANLHVAFHRSSSEKIHSNEISSDSIGVLGYQKTVDHTKVNSKLSLFFEIKS
T09005	DRUGINFO	D09LEN	Pneumococcal 13-valent conjugate vaccine	Approved
T09005	DRUGINFO	D0V7DW	Meningococcal groups A, C, Y and W-135 conjugate vaccine	Approved

T38052	TARGETID	T38052
T38052	FORMERID	TTDR00758
T38052	UNIPROID	PNO_CRYPV
T38052	TARGNAME	Cryptosporidium Pyruvate:ferredoxin oxidoreductase (Crypto CpPNO)
T38052	GENENAME	Crypto CpPNO
T38052	TARGTYPE	Successful
T38052	SYNONYMS	Pyruvate:NADP+ oxidoreductase; PFOR; CpPNO
T38052	FUNCTION	May have an important role in respiratorymetabolism. Cryptosporidium have a relic mitochondrion with no function in energy metabolism so it is not known if PFOR has a function.
T38052	BIOCLASS	Aldehyde/oxo donor oxidoreductase
T38052	ECNUMBER	EC 1.2.1.51
T38052	SEQUENCE	MGEKEIVDGCVAACHIAYACSEVAFTYPITPSSTISEVADSWMSRGRRNIFDQVVSVVEMQSEMGSAGALHGSLSVGCSTTTFTASQGLLLMIPNMYKIAGELWPCVFHVTARAIATSSLSIFGDHNDIMAARQTGWAFLGAMTVQEVMDLALVSHVSTFECSVPFVNFFDGFRTSHELQKIDMISYETIKKIFPYEKLKEFRERALNPTHPTLRGTATSSDVYFQLAEARNKYYESTPDIVQSVMDRLAKLIGRSYHLFDYYGHPDAEFLIVVMGSGGLTIEEMIDYLMEKSNEKVGMIKVRLFRPWSIDAFVKKIPKTTKRITVLERCKESGSLGEPLCLDVSTSIMRSELSSNNILVLGGRYGLASKEFTPGMALAVWENMISENPINNFSVGIDDDVTFKSLFVRQPRLDLLTSETKQCLFWGLGSDGTVSANKNAIKIIGESTDLQVQGYFAYDAKKAGGATMSHLRFGPKPIKSAYLLQRCDYVAVHHPSYVHKFDVLENIKQGGCFVLNCPWSTLEELNHELPSKIKHQIASRDVKFYVIDAQRIAQESNLGRRINNILMVVFFSLTNIIPLDLAIKLVKEAIKKTYGKKGDAVVNSNWKAVDLTLESLIQISYDKSQWISKDKCGEKSLPATAVETGNKDQEITKSTVLKQKPEHDVNQFVKDILGPVNALKGDELPVSMFEPTGTVPLGTTAYEKRGIAMSIPIVDMNKCTQCNYCSIVCPHAAIRPFLLDEAEFKNAPETMHIPKAKGGQEFSSYYYRIQVTPLDCTGCELCVHACPDDALHMEGLQKMEAVEKTHWDYLIGLPNKAEKFDRTTVKGSQFQQPLLEFSAACEGCGETPYVKLLTQLFGERMVIANATGCSSIWGASYPSVPYTKNQKGYGPAWGNSLFEDNAEYGLGMVVGYRQRRDRFRELVSNEILKDITEEEEFLKDDNASVQGRNEIITKYDHLKDYLRSWLKNIRNGEACQSLFEEISKLLEDNLINSNNFAQVLKKDRIELLEKLYDSRDLIPKISHWIVGGDGWAYDIGYAGLDHVLSFGEDVNIIILDTEVYSNTGGQASKSTPFGAIAKFAQSGNLRQKKDIGSIAMEYGSVYVASVALGANYSQTIKSLLEAEKYPGTSLIVAYSTCIEHGYTKYNLQQESVKLAVESGYWPLYRYNPELVRTEVVDNLTTIVSSGFTLDSKKVKVDIENFLKRENRFLQLIRSNPELASMAKDKLKAHSDKRFQKMKDMSENVTVTALKDQIKKLKDQLISIQNASKTGELAASGLINADLFIEQEMHVLYGTETGNSEEVAQYIQSQLVSRGYSSSSLNLDDLDIDEFLNPDKFSTVIIVTSTSGQGEFPGSSGILYEALLKKHLENQDDKFCSFMRFGIFGLGDSNYVFFNEAAKKWDKLLLDCGAVRIGAVGMGDDQSEEKYETELIEWLPDYLQLINAPEPKHDEKSEIPKATTFKVTILDSCRNDILNESTGTLCEKLDENNNIGNSHYKPIIPPNSVLLPVIENKRITNQDYDKDVRHIVFKLIGDGGDTPSLSYCLGDSLALYGQNPVNEAIKAIEMFGYNPYSLLRLSINEENEANNTNKVNQRYSSLFGYDITVLQLFVECLDLWGKPNRKFFQEFYRYCSNPEEKIQAKKWAQNEGKKLIEEFSSKTGTYLDVFKMFESARPTLAQLLDIVPFIKSRSYSIASCNKFVNGEKIELCVGIVDWKLESGEIRYGQCTGFLNRLPILDSESKIDSIPRLPSNIKASAFNLPFDYRSPVIMACMGTGIAPFRAFVQNKKYIRDVLKEEIGPVILYFGCRYYDNDYLYREELENYVKEGVITSLNIAFSRDPKGYKTSNCENIRYAQKMYVQHLMLENSQEIYENMIEKCGYFYLCGTKQVPIDIRKAIIQIIIKHSSTTEQVTSEEDANSILNSIQIMGRYNVEAWS
T38052	DRUGINFO	D08EBN	Nitazoxanide	Approved

T33846	TARGETID	T33846
T33846	FORMERID	TTDI02425
T33846	UNIPROID	I17RA_HUMAN; I17RB_HUMAN; I17RC_HUMAN; I17RD_HUMAN; I17RE_HUMAN
T33846	TARGNAME	Interleukin 17 receptor (IL17R)
T33846	GENENAME	IL17RA; IL17RB; IL17RC; IL17RD; IL17RE
T33846	TARGTYPE	Successful
T33846	SYNONYMS	Interleukin-17 receptor; IL-17R; IL-17 receptor
T33846	FUNCTION	Receptor for IL17A, IL17F and, in dimer withIL17RE, for IL17C. Binds its IL17A ligand with low affinity, suggesting that additional components are involved in IL17A-induced signaling.
T33846	BIOCLASS	Cytokine receptor
T33846	SEQUENCE	MGAARSPPSAVPGPLLGLLLLLLGVLAPGGASLRLLDHRALVCSQPGLNCTVKNSTCLDDSWIHPRNLTPSSPKDLQIQLHFAHTQQGDLFPVAHIEWTLQTDASILYLEGAELSVLQLNTNERLCVRFEFLSKLRHHHRRWRFTFSHFVVDPDQEYEVTVHHLPKPIPDGDPNHQSKNFLVPDCEHARMKVTTPCMSSGSLWDPNITVETLEAHQLRVSFTLWNESTHYQILLTSFPHMENHSCFEHMHHIPAPRPEEFHQRSNVTLTLRNLKGCCRHQVQIQPFFSSCLNDCLRHSATVSCPEMPDTPEPIPDYMPLWVYWFITGISILLVGSVILLIVCMTWRLAGPGSEKYSDDTKYTDGLPAADLIPPPLKPRKVWIIYSADHPLYVDVVLKFAQFLLTACGTEVALDLLEEQAISEAGVMTWVGRQKQEMVESNSKIIVLCSRGTRAKWQALLGRGAPVRLRCDHGKPVGDLFTAAMNMILPDFKRPACFGTYVVCYFSEVSCDGDVPDLFGAAPRYPLMDRFEEVYFRIQDLEMFQPGRMHRVGELSGDNYLRSPGGRQLRAALDRFRDWQVRCPDWFECENLYSADDQDAPSLDEEVFEEPLLPPGTGIVKRAPLVREPGSQACLAIDPLVGEEGGAAVAKLEPHLQPRGQPAPQPLHTLVLAAEEGALVAAVEPGPLADGAAVRLALAGEGEACPLLGSPGAGRNSVLFLPVDPEDSPLGSSTPMASPDLLPEDVREHLEGLMLSLFEQSLSCQAQGGCSRPAMVLTDPHTPYEEEQRQSVQSDQGYISRSSPQPPEGLTEMEEEEEEEQDPGKPALPLSPEDLESLRSLQRQLLFRQLQKNSGWDTMGSESEGPSA
T33846	DRUGINFO	D05CEO	Brodalumab	Approved
T33846	DRUGINFO	D0A7NZ	CNTO-6785	Phase 2
T33846	DRUGINFO	D00XNC	CAT-2200	Investigative
T33846	DRUGINFO	D04PAF	ANA-04	Investigative
T33846	DRUGINFO	D0LT4D	NI-1401	Investigative

T65236	TARGETID	T65236
T65236	FORMERID	TTDNR00682
T65236	UNIPROID	GPER1_HUMAN
T65236	TARGNAME	G-protein coupled estrogen receptor 1 (GPER1)
T65236	GENENAME	GPER1
T65236	TARGTYPE	Successful
T65236	SYNONYMS	Membrane estrogen receptor; Lymphocyte-derived G-protein coupled receptor; LYGPR; IL8-related receptor DRY12; GPER1; GPER; GPCR-BR; G-protein coupled receptor 30; Flow-induced endothelial G-protein coupled receptor 1; FEG-1; Chemoattractant receptor-like 2
T65236	FUNCTION	Receptor for estrogen. .
T65236	BIOCLASS	GPCR rhodopsin
T65236	SEQUENCE	MDVTSQARGVGLEMYPGTAQPAAPNTTSPELNLSHPLLGTALANGTGELSEHQQYVIGLFLSCLYTIFLFPIGFVGNILILVVNISFREKMTIPDLYFINLAVADLILVADSLIEVFNLHERYYDIAVLCTFMSLFLQVNMYSSVFFLTWMSFDRYIALARAMRCSLFRTKHHARLSCGLIWMASVSATLVPFTAVHLQHTDEACFCFADVREVQWLEVTLGFIVPFAIIGLCYSLIVRVLVRAHRHRGLRPRRQKALRMILAVVLVFFVCWLPENVFISVHLLQRTQPGAAPCKQSFRHAHPLTGHIVNLAAFSNSCLNPLIYSFLGETFRDKLRLYIEQKTNLPALNRFCHAALKAVIPDSTEQSDVRFSSAV
T65236	DRUGINFO	D06LDT	Segesterone acetate; ethinyl estradiol	Approved
T65236	DRUGINFO	D0WM5O	G1	Phase 1/2
T65236	DRUGINFO	D02WIL	G15	Investigative
T65236	DRUGINFO	D06CAL	G36	Investigative

T13491	TARGETID	T13491
T13491	FORMERID	TTDS00430
T13491	UNIPROID	S29A1_HUMAN
T13491	TARGNAME	Solute carrier family 29 member 1 (SLC29A1)
T13491	GENENAME	SLC29A1
T13491	TARGTYPE	Successful
T13491	SYNONYMS	SLC29A1; Nucleoside transporter, es-type; Nucleoside transporter 1; Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter; Equilibrative NBMPR-sensitive nucleoside transporter; ENT1
T13491	FUNCTION	Mediates both influx and efflux of nucleosides across the membrane (equilibrative transporter). It is sensitive to low concentrations of the inhibitor nitrobenzylmercaptopurine riboside (nbmpr) and is sodium-independent.
T13491	SEQUENCE	MTTSHQPQDRYKAVWLIFFMLGLGTLLPWNFFMTATQYFTNRLDMSQNVSLVTAELSKDAQASAAPAAPLPERNSLSAIFNNVMTLCAMLPLLLFTYLNSFLHQRIPQSVRILGSLVAILLVFLITAILVKVQLDALPFFVITMIKIVLINSFGAILQGSLFGLAGLLPASYTAPIMSGQGLAGFFASVAMICAIASGSELSESAFGYFITACAVIILTIICYLGLPRLEFYRYYQQLKLEGPGEQETKLDLISKGEEPRAGKEESGVSVSNSQPTNESHSIKAILKNISVLAFSVCFIFTITIGMFPAVTVEVKSSIAGSSTWERYFIPVSCFLTFNIFDWLGRSLTAVFMWPGKDSRWLPSLVLARLVFVPLLLLCNIKPRRYLTVVFEHDAWFIFFMAAFAFSNGYLASLCMCFGPKKVKPAEAETAGAIMAFFLCLGLALGAVFSFLFRAIV
T13491	DRUGINFO	D0L7VL	LIDOFLAZINE	Approved
T13491	DRUGINFO	D00GUM	Dilazep	Investigative
T13491	DRUGINFO	D02TOP	S6-nitrobenzyl mercaptopurine riboside	Investigative
T13491	DRUGINFO	D07EVI	[3H]nitrobenzylmercaptopurine ribonucleoside	Investigative
T13491	DRUGINFO	D08GKT	KF24345	Investigative
T13491	DRUGINFO	D09FHE	NBTGR	Investigative
T13491	DRUGINFO	D0I7ON	9-Benzyl-6-(4-nitro-benzylsulfanyl)-9H-purine	Investigative
T13491	DRUGINFO	D0S0PI	Nitrobenzylthioinosine	Investigative
T13491	DRUGINFO	D0V8DJ	6-(4-Nitro-benzylsulfanyl)-9-phenethyl-9H-purine	Investigative
T13491	DRUGINFO	D03RFA	N6-CYCLOPENTYLADENOSINE	Investigative

T28722	TARGETID	T28722
T28722	FORMERID	TTDI01774
T28722	UNIPROID	GBRG3_HUMAN
T28722	TARGNAME	GABA(A) receptor gamma-3 (GABRG3)
T28722	GENENAME	GABRG3
T28722	TARGTYPE	Successful
T28722	SYNONYMS	GABRG3
T28722	FUNCTION	Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functionsas receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand- gated chloride channel.
T28722	BIOCLASS	Ligand-gated ion channel
T28722	SEQUENCE	MAPKLLLLLCLFSGLHARSRKVEEDEYEDSSSNQKWVLAPKSQDTDVTLILNKLLREYDKKLRPDIGIKPTVIDVDIYVNSIGPVSSINMEYQIDIFFAQTWTDSRLRFNSTMKILTLNSNMVGLIWIPDTIFRNSKTAEAHWITTPNQLLRIWNDGKILYTLRLTINAECQLQLHNFPMDEHSCPLIFSSYGYPKEEMIYRWRKNSVEAADQKSWRLYQFDFMGLRNTTEIVTTSAGDYVVMTIYFELSRRMGYFTIQTYIPCILTVVLSWVSFWIKKDATPARTALGITTVLTMTTLSTIARKSLPRVSYVTAMDLFVTVCFLFVFAALMEYATLNYYSSCRKPTTTKKTTSLLHPDSSRWIPERISLQAPSNYSLLDMRPPPTAMITLNNSVYWQEFEDTCVYECLDGKDCQSFFCCYEECKSGSWRKGRIHIDILELDSYSRVFFPTSFLLFNLVYWVGYLYL
T28722	DRUGINFO	D02KBD	Mebutamate	Approved
T28722	DRUGINFO	D02OZY	Metharbital	Approved
T28722	DRUGINFO	D02XSA	Stiripentol	Approved
T28722	DRUGINFO	D02YPG	Etomidate	Approved
T28722	DRUGINFO	D06NSA	Thiamylal	Approved
T28722	DRUGINFO	D0L5KU	Remimazolam	Approved
T28722	DRUGINFO	D0N8DP	Bentazepam	Approved
T28722	DRUGINFO	D0S5IR	Zuranolone	Approved
T28722	DRUGINFO	D0W0MF	Talbutal	Approved
T28722	DRUGINFO	D0S9MC	Clobazam - Lundbeck	Approved
T28722	DRUGINFO	D0T1WN	Zolpidem	Approved
T28722	DRUGINFO	D0D5GD	Flumazenil	Approved
T28722	DRUGINFO	D00VZZ	Allopregnanolone	approved
T28722	DRUGINFO	D0G3LM	Clomethiazole	Phase 3
T28722	DRUGINFO	D0GX3L	Arbaclofen placarbil	Phase 3
T28722	DRUGINFO	D0O0PY	Pagoclone	Phase 2/3
T28722	DRUGINFO	D02XYB	SARIPIDEM	Phase 2
T28722	DRUGINFO	D08KDK	T-2007	Phase 2
T28722	DRUGINFO	D0J6LN	Etazolate	Phase 2
T28722	DRUGINFO	D00OVC	EVT-201	Phase 2
T28722	DRUGINFO	D04ZWQ	Org-25435	Phase 1
T28722	DRUGINFO	D05RWL	NSD-788	Phase 1
T28722	DRUGINFO	D06SUS	AZD-3043	Phase 1
T28722	DRUGINFO	D02HKL	Suriclone	Discontinued in Preregistration
T28722	DRUGINFO	D08YYY	Ocinaplon	Discontinued in Phase 3
T28722	DRUGINFO	D0C9JL	Y-23684	Discontinued in Phase 3
T28722	DRUGINFO	D0ZE9C	Pazinaclone	Discontinued in Phase 3
T28722	DRUGINFO	D01EDS	SL-65.1498	Discontinued in Phase 2
T28722	DRUGINFO	D07OMK	RO-48-6791	Discontinued in Phase 2
T28722	DRUGINFO	D08CLN	Suritozole	Discontinued in Phase 2
T28722	DRUGINFO	D08LQD	RESEQUINIL	Discontinued in Phase 2
T28722	DRUGINFO	D0H6PN	LORECLEZOLE	Discontinued in Phase 2
T28722	DRUGINFO	D0S9KM	NGD 91-3	Discontinued in Phase 2
T28722	DRUGINFO	D04KCT	Org-21465	Discontinued in Phase 1
T28722	DRUGINFO	D04KZN	CTP-354	Discontinued in Phase 1
T28722	DRUGINFO	D0AM1S	CCD-3693	Discontinued in Phase 1
T28722	DRUGINFO	D0MT9G	RO-48-8684	Discontinued in Phase 1
T28722	DRUGINFO	D02VOJ	RWJ-51204	Preclinical
T28722	DRUGINFO	D01SBP	Co-152791	Terminated
T28722	DRUGINFO	D02UIE	ZK-91296	Terminated
T28722	DRUGINFO	D05IVZ	RU-33965	Terminated
T28722	DRUGINFO	D0II9K	Girisopam	Terminated
T28722	DRUGINFO	D0P3IE	ZK-93426	Terminated
T28722	DRUGINFO	D0P6YO	NSD-721	Terminated
T28722	DRUGINFO	D0Z7AN	Ro-19-8022	Terminated
T28722	DRUGINFO	D00EFD	C-21191	Investigative
T28722	DRUGINFO	D01FJA	UC-2024	Investigative
T28722	DRUGINFO	D01VNL	JM-1232(-)	Investigative
T28722	DRUGINFO	D01YGY	UC-1011	Investigative
T28722	DRUGINFO	D02FBG	UC-2029	Investigative
T28722	DRUGINFO	D02ZMI	AA-29504	Investigative
T28722	DRUGINFO	D04UMT	CP-409092	Investigative
T28722	DRUGINFO	D06SAT	HZ-166	Investigative
T28722	DRUGINFO	D09JET	NGD 96-3	Investigative
T28722	DRUGINFO	D0D3TK	PNU 101017	Investigative
T28722	DRUGINFO	D0O7NV	DOV-51892	Investigative
T28722	DRUGINFO	D0SD3Q	GIDAZEPAM	Investigative
T28722	DRUGINFO	D03PBN	tetrahydrodeoxycorticosterone	Investigative
T28722	DRUGINFO	D03ZWB	alpha3IA	Investigative
T28722	DRUGINFO	D06SOQ	alpha5IA	Investigative
T28722	DRUGINFO	D07JXC	[18F]fluoroethylflumazenil	Investigative
T28722	DRUGINFO	D0GQ1S	DMCM	Investigative
T28722	DRUGINFO	D0Q1ZT	TP003	Investigative
T28722	DRUGINFO	D0T9DS	[35S]TBPS	Investigative
T28722	DRUGINFO	D0VW5M	piperidine-4-sulphonic acid	Investigative
T28722	DRUGINFO	D00WHO	Ro-15-3505	Investigative
T28722	DRUGINFO	D0AC2H	isonipecotic acid	Investigative
T28722	DRUGINFO	D0M4CP	[3H]Ro154513	Investigative
T28722	DRUGINFO	D0M9RM	[3H]CGS8216	Investigative
T28722	DRUGINFO	D0P0TI	TBPS	Investigative

T14853	TARGETID	T14853
T14853	FORMERID	TTDI02072
T14853	UNIPROID	FGF23_HUMAN
T14853	TARGNAME	Fibroblast growth factor-23 (FGF23)
T14853	GENENAME	FGF23
T14853	TARGTYPE	Successful
T14853	SYNONYMS	Tumor-derived hypophosphatemia-inducing factor; Phosphatonin; HYPF; Fibroblast growth factor 23; FGF-23
T14853	FUNCTION	Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Upregulates EGR1 expression in the presence of KL (By similarity). Acts directly on the parathyroid to decrease PTH secretion (By similarity). Regulator of vitamin-D metabolism. Negatively regulates osteoblast differentiation and matrix mineralization.
T14853	PDBSTRUC	5W21; 2P39
T14853	BIOCLASS	Growth factor
T14853	SEQUENCE	MLGARLRLWVCALCSVCSMSVLRAYPNASPLLGSSWGGLIHLYTATARNSYHLQIHKNGHVDGAPHQTIYSALMIRSEDAGFVVITGVMSRRYLCMDFRGNIFGSHYFDPENCRFQHQTLENGYDVYHSPQYHFLVSLGRAKRAFLPGMNPPPYSQFLSRRNEIPLIHFNTPIPRRHTRSAEDDSERDPLNVLKPRARMTPAPASCSQELPSAEDNSPMASDPLGVVRGGRVNTHAGGTGPEGCRPFAKFI
T14853	DRUGINFO	D0DJ9D	Burosumab	Approved

T98052	TARGETID	T98052
T98052	FORMERID	TTDI02305
T98052	UNIPROID	SLAF7_HUMAN
T98052	TARGNAME	SLAM family member 7 SLAMF7 (CS1)
T98052	GENENAME	SLAMF7
T98052	TARGTYPE	Successful
T98052	SYNONYMS	UNQ576/PRO1138; SLAM family member 7; Protein 19A; Novel Ly9; Membrane protein FOAP-12; CRACC; CD319; CD2-like receptor-activating cytotoxic cells; CD2 subset 1
T98052	FUNCTION	SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Isoform 1 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway. Positively regulates NK cell functions by a mechanism dependent on phosphorylated SH2D1B. Downstream signaling implicates PLCG1, PLCG2 and PI3K. In addition to heterotypic NK cells-target cells interactions also homotypic interactions between NK cells may contribute to activation. However, in the absence of SH2D1B, inhibits NK cell function. Acts also inhibitory in T-cells. May play a role in lymphocyte adhesion. In LPS-activated monocytes negatively regulates production of proinflammatory cytokines. Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family.
T98052	BIOCLASS	Immunoglobulin
T98052	SEQUENCE	MAGSPTCLTLIYILWQLTGSAASGPVKELVGSVGGAVTFPLKSKVKQVDSIVWTFNTTPLVTIQPEGGTIIVTQNRNRERVDFPDGGYSLKLSKLKKNDSGIYYVGIYSSSLQQPSTQEYVLHVYEHLSKPKVTMGLQSNKNGTCVTNLTCCMEHGEEDVIYTWKALGQAANESHNGSILPISWRWGESDMTFICVARNPVSRNFSSPILARKLCEGAADDPDSSMVLLCLLLVPLLLSLFVLGLFLWFLKRERQEEYIEEKKRVDICRETPNICPHSGENTEYDTIPHTNRTILKEDPANTVYSTVEIPKKMENPHSLLTMPDTPRLFAYENVI
T98052	DRUGINFO	D05DZR	Elotuzumab	Approved
T98052	DRUGINFO	D06DUS	PVX-410	Phase 2
T98052	DRUGINFO	D0B5RU	CS1-CAR T Therapy	Phase 1
T98052	DRUGINFO	D0BB2V	ABBV-838	Phase 1
T98052	DRUGINFO	DRU0M6	MB-104	Phase 1
T98052	DRUGINFO	DS6W8Z	UCARTCS1	Phase 1
T98052	DRUGINFO	DX1LD3	BCMA-CS1 cCAR	Phase 1

T34123	TARGETID	T34123
T34123	FORMERID	TTDR01254
T34123	UNIPROID	SCNBA_HUMAN
T34123	TARGNAME	Voltage-gated sodium channel alpha Nav1.9 (SCN11A)
T34123	GENENAME	SCN11A
T34123	TARGTYPE	Successful
T34123	SYNONYMS	hNaN; Sodium channel protein type XIsubunit alpha; Sodium channel protein type 11subunit alpha; Sensory neuron sodium channel 2; SNS2; SCN12A; SCN11A; Peripheral nerve sodium channel 5; PN5
T34123	FUNCTION	This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-resistant sodium channel isoform. Also involved, with the contribution of the receptor tyrosine kinase NTRK2, in rapid BDNF-evoked neuronal depolarization.
T34123	BIOCLASS	Voltage-gated ion channel
T34123	SEQUENCE	MDDRCYPVIFPDERNFRPFTSDSLAAIEKRIAIQKEKKKSKDQTGEVPQPRPQLDLKASRKLPKLYGDIPRELIGKPLEDLDPFYRNHKTFMVLNRKRTIYRFSAKHALFIFGPFNSIRSLAIRVSVHSLFSMFIIGTVIINCVFMATGPAKNSNSNNTDIAECVFTGIYIFEALIKILARGFILDEFSFLRDPWNWLDSIVIGIAIVSYIPGITIKLLPLRTFRVFRALKAISVVSRLKVIVGALLRSVKKLVNVIILTFFCLSIFALVGQQLFMGSLNLKCISRDCKNISNPEAYDHCFEKKENSPEFKMCGIWMGNSACSIQYECKHTKINPDYNYTNFDNFGWSFLAMFRLMTQDSWEKLYQQTLRTTGLYSVFFFIVVIFLGSFYLINLTLAVVTMAYEEQNKNVAAEIEAKEKMFQEAQQLLKEEKEALVAMGIDRSSLTSLETSYFTPKKRKLFGNKKRKSFFLRESGKDQPPGSDSDEDCQKKPQLLEQTKRLSQNLSLDHFDEHGDPLQRQRALSAVSILTITMKEQEKSQEPCLPCGENLASKYLVWNCCPQWLCVKKVLRTVMTDPFTELAITICIIINTVFLAMEHHKMEASFEKMLNIGNLVFTSIFIAEMCLKIIALDPYHYFRRGWNIFDSIVALLSFADVMNCVLQKRSWPFLRSFRVLRVFKLAKSWPTLNTLIKIIGNSVGALGSLTVVLVIVIFIFSVVGMQLFGRSFNSQKSPKLCNPTGPTVSCLRHWHMGDFWHSFLVVFRILCGEWIENMWECMQEANASSSLCVIVFILITVIGKLVVLNLFIALLLNSFSNEERNGNLEGEARKTKVQLALDRFRRAFCFVRHTLEHFCHKWCRKQNLPQQKEVAGGCAAQSKDIIPLVMEMKRGSETQEELGILTSVPKTLGVRHDWTWLAPLAEEEDDVEFSGEDNAQRITQPEPEQQAYELHQENKKPTSQRVQSVEIDMFSEDEPHLTIQDPRKKSDVTSILSECSTIDLQDGFGWLPEMVPKKQPERCLPKGFGCCFPCCSVDKRKPPWVIWWNLRKTCYQIVKHSWFESFIIFVILLSSGALIFEDVHLENQPKIQELLNCTDIIFTHIFILEMVLKWVAFGFGKYFTSAWCCLDFIIVIVSVTTLINLMELKSFRTLRALRPLRALSQFEGMKVVVNALIGAIPAILNVLLVCLIFWLVFCILGVYFFSGKFGKCINGTDSVINYTIITNKSQCESGNFSWINQKVNFDNVGNAYLALLQVATFKGWMDIIYAAVDSTEKEQQPEFESNSLGYIYFVVFIIFGSFFTLNLFIGVIIDNFNQQQKKLGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPLNKCQGLVFDIVTSQIFDIIIISLIILNMISMMAESYNQPKAMKSILDHLNWVFVVIFTLECLIKIFALRQYYFTNGWNLFDCVVVLLSIVSTMISTLENQEHIPFPPTLFRIVRLARIGRILRLVRAARGIRTLLFALMMSLPSLFNIGLLLFLIMFIYAILGMNWFSKVNPESGIDDIFNFKTFASSMLCLFQISTSAGWDSLLSPMLRSKESCNSSSENCHLPGIATSYFVSYIIISFLIVVNMYIAVILENFNTATEESEDPLGEDDFDIFYEVWEKFDPEATQFIKYSALSDFADALPEPLRVAKPNKYQFLVMDLPMVSEDRLHCMDILFAFTARVLGGSDGLDSMKAMMEEKFMEANPLKKLYEPIVTTTKRKEEERGAAIIQKAFRKYMMKVTKGDQGDQNDLENGPHSPLQTLCNGDLSSFGVAKGKVHCD
T34123	DRUGINFO	D03FLC	Lamotrigine	Approved
T34123	DRUGINFO	D0H0KB	Riluzole	Approved
T34123	DRUGINFO	D0QL3P	Oxcarbazepine	Approved
T34123	DRUGINFO	D0X4RN	Lidocaine	Approved
T34123	DRUGINFO	D0X0WU	Tolperisone	Approved
T34123	DRUGINFO	D04QZD	Eslicarbazepine	Approved
T34123	DRUGINFO	D05OFX	Lacosamide	Approved
T34123	DRUGINFO	D02TIK	HP-184	Phase 2
T34123	DRUGINFO	D0J2VB	Iboctadekin + rituximab	Phase 1
T34123	DRUGINFO	D0C4JX	QX-314	Terminated
T34123	DRUGINFO	D0D9CO	SB-221420-A	Investigative
T34123	DRUGINFO	D08RJC	PD-32577	Investigative

T87670	TARGETID	T87670
T87670	FORMERID	TTDNR00683
T87670	UNIPROID	GPR55_HUMAN
T87670	TARGNAME	G-protein coupled receptor 55 (GPR55)
T87670	GENENAME	GPR55
T87670	TARGTYPE	Successful
T87670	SYNONYMS	LPIR1
T87670	FUNCTION	Receptor for L-alpha-lysophosphatidylinositol (LPI). LPI induces Ca(2+) release from intracellular stores via the heterotrimeric G protein GNA13 and RHOA. Putative cannabinoid receptor. May play a role in bone physiology by regulating osteoclast number and function. May be involved in hyperalgesia associated with inflammatory and neuropathic pain.
T87670	BIOCLASS	GPCR rhodopsin
T87670	SEQUENCE	MSQQNTSGDCLFDGVNELMKTLQFAVHIPTFVLGLLLNLLAIHGFSTFLKNRWPDYAATSIYMINLAVFDLLLVLSLPFKMVLSQVQSPFPSLCTLVECLYFVSMYGSVFTICFISMDRFLAIRYPLLVSHLRSPRKIFGICCTIWVLVWTGSIPIYSFHGKVEKYMCFHNMSDDTWSAKVFFPLEVFGFLLPMGIMGFCCSRSIHILLGRRDHTQDWVQQKACIYSIAASLAVFVVSFLPVHLGFFLQFLVRNSFIVECRAKQSISFFLQLSMCFSNVNCCLDVFCYYFVIKEFRMNIRAHRPSRVQLVLQDTTISRG
T87670	DRUGINFO	D07ILQ	Guanfacine extended release	Approved
T87670	DRUGINFO	DF63BG	BIO-017	Phase 1
T87670	DRUGINFO	D00UZO	O-arachidonoyl ethanolamine	Investigative
T87670	DRUGINFO	D02SMK	CID1172084	Investigative
T87670	DRUGINFO	D04MAP	CID16020046	Investigative
T87670	DRUGINFO	D08JYT	2-arachidonyl glyceryl ether	Investigative
T87670	DRUGINFO	D09SCS	CP55,244	Investigative
T87670	DRUGINFO	D0C2DN	2-arachidonoylglycerolphosphoinositol	Investigative
T87670	DRUGINFO	D0G3TV	CID2440433	Investigative
T87670	DRUGINFO	D0Q9GU	CID1792197	Investigative
T87670	DRUGINFO	D0R1ZD	GSK575594A	Investigative
T87670	DRUGINFO	D0X2ZM	T1117	Investigative
T87670	DRUGINFO	D0X3TF	CP55,667	Investigative
T87670	DRUGINFO	D0Z0KY	GSK494581A	Investigative
T87670	DRUGINFO	D06NAM	O-1602	Investigative
T87670	DRUGINFO	D0S3UM	abnormal cannabidiol	Investigative
T87670	DRUGINFO	D0D6OH	[3H]CP55940	Investigative
T87670	DRUGINFO	D0M1UA	lysophosphatidylinositol	Investigative
T87670	DRUGINFO	D07MBC	N-oleoylethanolamide	Investigative

T33765	TARGETID	T33765
T33765	FORMERID	TTDR01173
T33765	UNIPROID	MCL1_HUMAN
T33765	TARGNAME	Mcl-1 messenger RNA (MCL-1 mRNA)
T33765	GENENAME	MCL1
T33765	TARGTYPE	Successful
T33765	SYNONYMS	mcl1/EAT (mRNA); Induced myeloid leukemia cell differentiation protein Mcl-1 (mRNA); Bcl2-L-3 (mRNA); Bcl-2-related protein EAT/mcl1 (mRNA); Bcl-2-like protein 3 (mRNA); BCL2L3 (mRNA)
T33765	FUNCTION	Mediates its effects by interactions with a number of other regulators of apoptosis. Isoform 1 inhibits apoptosis. Isoform 2 promotes apoptosis. Involved in the regulation of apoptosis versus cell survival, and in the maintenance of viability but not of proliferation.
T33765	PDBSTRUC	6OVC; 6OQN; 6OQD; 6OQC; 6OQB
T33765	BIOCLASS	mRNA target
T33765	SEQUENCE	MFGLKRNAVIGLNLYCGGAGLGAGSGGATRPGGRLLATEKEASARREIGGGEAGAVIGGSAGASPPSTLTPDSRRVARPPPIGAEVPDVTATPARLLFFAPTRRAAPLEEMEAPAADAIMSPEEELDGYEPEPLGKRPAVLPLLELVGESGNNTSTDGSLPSTPPPAEEEEDELYRQSLEIISRYLREQATGAKDTKPMGRSGATSRKALETLRRVGDGVQRNHETAFQGMLRKLDIKNEDDVKSLSRVMIHVFSDGVTNWGRIVTLISFGAFVAKHLKTINQESCIEPLAESITDVLVRTKRDWLVKQRGWDGFVEFFHVEDLEGGIRNVLLAFAGVAGVGAGLAYLIR
T33765	DRUGINFO	D0AZ3C	Imatinib	Approved
T33765	DRUGINFO	D06GGT	MCL-1-specific antisense oligonucleotide + nilotinib (AMN107)	Investigative
T33765	DRUGINFO	D0KL7G	MCL-1-specific antisense oligonucleotide + midostaurin(PKC412)	Investigative

T84972	TARGETID	T84972
T84972	FORMERID	TTDS00436
T84972	UNIPROID	EFG_STRZJ
T84972	TARGNAME	Streptococcus Elongation factor G (Stre-coc fusA)
T84972	GENENAME	Stre-coc fusA
T84972	TARGTYPE	Successful
T84972	SYNONYMS	fusA; EF-G
T84972	FUNCTION	Catalyzes the GTP-dependent ribosomal translocation step during translation elongation. During this step, the ribosome changes from the pre-translocational (PRE) to the post- translocational (POST) state as the newly formed A-site-bound peptidyl-tRNA and P-site-bound deacylated tRNA move to the P and E sites, respectively. Catalyzes the coordinated movement of the two tRNA molecules, the mRNA and conformational changes in the ribosome.
T84972	BIOCLASS	Acid anhydrides hydrolase
T84972	SEQUENCE	MAREFSLEKTRNIGIMAHVDAGKTTTTERILYYTGKIHKIGETHEGASQMDWMEQEQERGITITSAATTAQWNNHRVNIIDTPGHVDFTIEVQRSLRVLDGAVTVLDSQSGVEPQTETVWRQATEYGVPRIVFANKMDKIGADFLYSVSTLHDRLQANAHPIQLPIGSEDDFRGIIDLIKMKAEIYTNDLGTDILEEDIPAEYLDQAQEYREKLIEAVAETDEELMMKYLEGEEITNEELKAGIRKATINVEFFPVLCGSAFKNKGVQLMLDAVIDYLPSPLDIPAIKGINPDTDAEETRPASDEEPFAALAFKIMTDPFVGRLTFFRVYSGVLQSGSYVLNTSKGKRERIGRILQMHANSRQEIDTVYSGDIAAAVGLKDTTTGDSLTDEKAKIILESINVPEPVIQLMVEPKSKADQDKMGIALQKLAEEDPTFRVETNVETGETVISGMGELHLDVLVDRMRREFKVEANVGAPQVSYRETFRASTQARGFFKRQSGGKGQFGDVWIEFTPNEEGKGFEFENAIVGGVVPREFIPAVEKGLVESMANGVLAGYPMVDVKAKLYDGSYHDVDSSETAFKIAASLSLKEAAKSAQPAILEPMMLVTITVPEENLGDVMGHVTARRGRVDGMEAHGNSQIVRAYVPLAEMFGYATVLRSASQGRGTFMMVFDHYEDVPKSVQEEIIKKNKGED
T84972	DRUGINFO	D0X7XG	Fusidic Acid	Approved
T84972	DRUGINFO	D0C7LS	Guanosine-5'-Diphosphate	Investigative

T99641	TARGETID	T99641
T99641	FORMERID	TTDR01184
T99641	UNIPROID	AL1A1_HUMAN; ALDH2_HUMAN; AL1B1_HUMAN
T99641	TARGNAME	Acetaldehyde dehydrogenase (ALDH)
T99641	GENENAME	ALDH1A1; ALDH2; ALDH1B1
T99641	TARGTYPE	Successful
T99641	SYNONYMS	Aldehyde dehydrogenase; ALDH
T99641	FUNCTION	Catalyzes the conversion of acetaldehyde to acetyl-CoA, using NAD(+) and coenzyme A. Is the final enzyme in the meta- cleavage pathway for the degradation of 3-phenylpropanoate. Functionsas a chaperone protein for folding of MhpE.
T99641	BIOCLASS	Aldehyde/oxo donor oxidoreductase
T99641	SEQUENCE	MSSSGTPDLPVLLTDLKIQYTKIFINNEWHDSVSGKKFPVFNPATEEELCQVEEGDKEDVDKAVKAARQAFQIGSPWRTMDASERGRLLYKLADLIERDRLLLATMESMNGGKLYSNAYLNDLAGCIKTLRYCAGWADKIQGRTIPIDGNFFTYTRHEPIGVCGQIIPWNFPLVMLIWKIGPALSCGNTVVVKPAEQTPLTALHVASLIKEAGFPPGVVNIVPGYGPTAGAAISSHMDIDKVAFTGSTEVGKLIKEAAGKSNLKRVTLELGGKSPCIVLADADLDNAVEFAHHGVFYHQGQCCIAASRIFVEESIYDEFVRRSVERAKKYILGNPLTPGVTQGPQIDKEQYDKILDLIESGKKEGAKLECGGGPWGNKGYFVQPTVFSNVTDEMRIAKEEIFGPVQQIMKFKSLDDVIKRANNTFYGLSAGVFTKDIDKAITISSALQAGTVWVNCYGVVSAQCPFGGFKMSGNGRELGEYGFHEYTEVKTVTVKISQKNS
T99641	DRUGINFO	D0A9KF	Calcium carbimide	Approved

T07485	TARGETID	T07485
T07485	FORMERID	TTDI01919
T07485	UNIPROID	FUS_HRSVA
T07485	TARGNAME	Respiratory syncytial virus protein F (RSV F)
T07485	GENENAME	RSV F
T07485	TARGTYPE	Successful
T07485	SYNONYMS	Protein F; Fusion glycoprotein F1; Fusion glycoprotein F0; F
T07485	FUNCTION	Class I viral fusion protein. Under the current model, the protein has at least 3 conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During viral and plasma cell membrane fusion, the heptad repeat (HR) regions assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C- terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and plasma cell membranes. Directs fusion of viral and cellular membranes leading to delivery of the nucleocapsid into the cytoplasm. This fusion is pH independent and occurs directly at the outer cell membrane. The trimer of F1-F2 (protein F) interacts with glycoprotein G at the virion surface. Upon binding of G to heparan sulfate, the hydrophobic fusion peptide is unmasked and interacts with the cellular membrane, inducing the fusion between host cell and virion membranes. Notably, RSV fusion protein is able to interact directly with heparan sulfate and therefore actively participates in virus attachment. Furthermore, the F2 subunit was identifed as the major determinant of RSV host cell specificity. Later in infection, proteins F expressed at the plasma membrane of infected cells mediate fusion with adjacent cells to form syncytia, a cytopathic effect that could lead to tissue necrosis. The fusion protein is also able to trigger p53- dependent apoptosis.
T07485	PDBSTRUC	6OE5; 6OE4; 6APD; 6APB; 5W23
T07485	SEQUENCE	MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPPTNNRARRELPRFMNYTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQLLPIVNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEINLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGMDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTNIMITTIIIVIIVILLSLIAVGLLLYCKARSTPVTLSKDQLSGINNIAFSN
T07485	DRUGINFO	D0A1AS	Palivizumab	Approved
T07485	DRUGINFO	D09NMD	Lasofoxifene	Approved
T07485	DRUGINFO	D08NAI	SAR438584	Phase 3
T07485	DRUGINFO	D0O3OK	Motavizumab	Phase 3
T07485	DRUGINFO	DOST52	MK-1654	Phase 2/3
T07485	DRUGINFO	D0QY1M	GS-5806	Phase 2
T07485	DRUGINFO	DENO49	RV521	Phase 2
T07485	DRUGINFO	DRH80V	JNJ-53718678	Phase 2
T07485	DRUGINFO	D08DSF	MEDI-557	Phase 1
T07485	DRUGINFO	D02TNS	TMC-353121	Preclinical
T07485	DRUGINFO	D0T7EZ	CL-387626	Terminated

T38161	TARGETID	T38161
T38161	FORMERID	TTDI01878
T38161	UNIPROID	ANXA1_HUMAN
T38161	TARGNAME	Phospholipase A2 inhibitory protein (PA2IP)
T38161	GENENAME	ANXA1
T38161	TARGTYPE	Successful
T38161	SYNONYMS	p35; Lipocortin I; LPC1; Chromobindin-9; Calpactin-2; Calpactin II; Annexin-1; Annexin I; Annexin A1; ANX1
T38161	FUNCTION	Plays important roles in the innate immune response as effector of glucocorticoid-mediated responses and regulator of the inflammatory process. Has anti-inflammatory activity. Plays a role in glucocorticoid-mediated down-regulation of the early phase of the inflammatory response (By similarity). Promotes resolution of inflammation and wound healing. Functions at least in part by activating the formyl peptide receptors and downstream signaling cascades. Promotes chemotaxis of granulocytes and monocytes via activation of the formyl peptide receptors. Contributes to the adaptive immune response by enhancing signaling cascades that are triggered by T-cell activation, regulates differentiation and proliferation of activated T-cells. Promotes the differentiation of T-cells into Th1 cells and negatively regulates differentiation into Th2 cells. Has no effect on unstimulated T cells. Promotes rearrangement of the actin cytoskeleton, cell polarization and cell migration. Negatively regulates hormone exocytosis via activation of the formyl peptide receptors and reorganization of the actin cytoskeleton. Has high affinity for Ca(2+) and can bind up to eight Ca(2+) ions (By similarity). Displays Ca(2+)-dependent binding to phospholipid membranes. Plays a role in the formation of phagocytic cups and phagosomes. Plays a role in phagocytosis by mediating the Ca(2+)-dependent interaction between phagosomes and the actin cytoskeleton (By similarity).
T38161	PDBSTRUC	5VFW; 1QLS; 1BO9; 1AIN
T38161	SEQUENCE	MAMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSSDVAALHKAIMVKGVDEATIIDILTKRNNAQRQQIKAAYLQETGKPLDETLKKALTGHLEEVVLALLKTPAQFDADELRAAMKGLGTDEDTLIEILASRTNKEIRDINRVYREELKRDLAKDITSDTSGDFRNALLSLAKGDRSEDFGVNEDLADSDARALYEAGERRKGTDVNVFNTILTTRSYPQLRRVFQKYTKYSKHDMNKVLDLELKGDIEKCLTAIVKCATSKPAFFAEKLHQAMKGVGTRHKALIRIMVSRSEIDMNDIKAFYQKMYGISLCQAILDETKGDYEKILVALCGGN
T38161	DRUGINFO	D01ZOG	Difluprednate	Approved

T06770	TARGETID	T06770
T06770	FORMERID	TTDS00325
T06770	UNIPROID	ENV_HV1H2
T06770	TARGNAME	Human immunodeficiency virus Glycoprotein 41 (HIV gp41)
T06770	GENENAME	HIV gp41
T06770	TARGTYPE	Successful
T06770	SYNONYMS	Env polyprotein gp41 (33-511)
T06770	FUNCTION	Transmembrane protein gp41: Acts as a class I viral fusion protein. Under the current model, the protein has at least 3 conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of viral and target intracellular membranes, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C- terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes. Complete fusion occurs in host cell endosomes and is dynamin-dependent, however some lipid transfer might occur at the plasma membrane. The virus undergoes clathrin- dependent internalization long before endosomal fusion, thus minimizing the surface exposure of conserved viral epitopes during fusion and reducing the efficacy of inhibitors targeting these epitopes. Membranes fusion leads to delivery of the nucleocapsid into the cytoplasm.
T06770	PDBSTRUC	6DLN; 6DE7; 6BXQ; 6BXP; 6B9K
T06770	SEQUENCE	AVGIGALFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLEQIWNHTTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNWLWYIKLFIMIVGGLVGLRIVFAVLSIVNRVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDRDRSIRLVNGSLALIWDDLRSLCLFSYHRLRDLLLIVTRIVELLGRRGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEVVQGACRAIRHIPRRIRQGLERILL
T06770	DRUGINFO	D06GBQ	Enfuvirtide	Approved
T06770	DRUGINFO	D0CF3M	Sifuvirtide	Phase 3
T06770	DRUGINFO	D03DAY	ITV-1	Phase 2
T06770	DRUGINFO	D08DUY	T-1249	Phase 1/2
T06770	DRUGINFO	D0IL0H	MaC46/M87o	Phase 1/2
T06770	DRUGINFO	D0O4UZ	Gp41 HIV-1 vaccine	Phase 1
T06770	DRUGINFO	D01NGH	Multi-envelope HIV vaccine	Phase 1
T06770	DRUGINFO	DO61WZ	Combinectin	Phase 1

T91442	TARGETID	T91442
T91442	FORMERID	TTDI01984
T91442	UNIPROID	DPOL_VZVD
T91442	TARGNAME	Varicella-zoster virus DNA polymerase (VZV ORF28)
T91442	GENENAME	VZV ORF28
T91442	TARGTYPE	Successful
T91442	SYNONYMS	VZV DNA polymerase catalytic subunit; ORF28
T91442	FUNCTION	Replicates viral genomic DNA. The replication complex is composed of six viral proteins: the DNA polymerase, processivity factor, primase, primase-associated factor, helicase, and ssDNA- binding protein. Additionally, the polymerase contains an intrinsic ribonuclease H (RNase H) activity that specifically degrades RNA/DNA heteroduplexes or duplex DNA substrates in the 5' to 3' direction. Therefore, it can catalyze the excision of the RNA primers that initiate the synthesis of Okazaki fragments at a replication fork during viral DNA replication.
T91442	BIOCLASS	Kinase
T91442	SEQUENCE	MAIRTGFCNPFLTQASGIKYNPRTGRGSNREFLHSYKTTMSSFQFLAPKCLDEDVPMEERKGVHVGTLSRPPKVYCNGKEVPILDFRCSSPWPRRVNIWGEIDFRGDKFDPRFNTFHVYDIVETTEAASNGDVSRFATATRPLGTVITLLGMSRCGKRVAVHVYGICQYFYINKAEVDTACGIRSGSELSVLLAECLRSSMITQNDATLNGDKNAFHGTSFKSASPESFRVEVIERTDVYYYDTQPCAFYRVYSPSSKFTNYLCDNFHPELKKYEGRVDATTRFLMDNPGFVSFGWYQLKPGVDGERVRVRPASRQLTLSDVEIDCMSDNLQAIPNDDSWPDYKLLCFDIECKSGGSNELAFPDATHLEDLVIQISCLLYSIPRQSLEHILLFSLGSCDLPQRYVQEMKDAGLPEPTVLEFDSEFELLIAFMTLVKQYAPEFATGYNIVNFDWAFIMEKLNSIYSLKLDGYGSINRGGLFKIWDVGKSGFQRRSKVKINGLISLDMYAIATEKLKLSSYKLDSVAREALNESKRDLPYKDIPGYYASGPNTRGIIGEYCIQDSALVGKLFFKYLPHLELSAVARLARITLTKAIYDGQQVRIYTCLLGLASSRGFILPDGGYPATFEYKDVIPDVGDVEEEMDEDESVSPTGTSSGRNVGYKGARVFDPDTGFYIDPVVVLDFASLYPSIIQAHNLCFTTLTLNFETVKRLNPSDYATFTVGGKRLFFVRSNVRESLLGVLLKDWLAMRKAIRARIPGSSSDEAVLLDKQQAAIKVVCNSVYGFTGVAQGFLPCLYVAATVTTIGRQMLLSTRDYIHNNWAAFERFITAFPDIESSVLSQKAYEVKVIYGDTDSVFIRFKGVSVEGIAKIGEKMAHIISTALFCPPIKLECEKTFIKLLLITKKKYIGVIYGGKVLMKGVDLVRKNNCQFINDYARKLVELLLYDDTVSRAAAEASCVSIAEWNRRAMPSGMAGFGRIIADAHRQITSPKLDINKFVMTAELSRPPSAYINRRLAHLTVYYKLVMRQGQIPNVRERIPYVIVAPTDEVEADAKSVALLRGDPLQNTAGKRCGEAKRKLIISDLAEDPIHVTSHGLSLNIDYYFSHLIGTASVTFKALFGNDTKLTERLLKRFIPETRVVNVKMLNRLQAAGFVCIHAPCWDNKMNTEAEITEEEQSHQIMRRVFCIPKAILHQS
T91442	DRUGINFO	D0B5MP	Aciclovir	Approved

T42354	TARGETID	T42354
T42354	UNIPROID	SIGA_STAA8
T42354	TARGNAME	Bacterial RNA polymerase sigma factor SigA (Bact sigA)
T42354	GENENAME	Bact sigA
T42354	TARGTYPE	Successful
T42354	SYNONYMS	RNA polymerase sigma factor SigA
T42354	FUNCTION	Sigma factors are initiation factors that promote the attachment of RNA polymerase to specific initiation sites and are then released. This sigma factor is the primary sigma factor during exponential growth.
T42354	PDBSTRUC	4G94; 4G8X; 4G6D
T42354	SEQUENCE	MSDNTVKIKKQTIDPTLTLEDVKKQLIEKGKKEGHLSHEEIAEKLQNFDIDSDQMDDFFDQLNDNDISLVNEKDSSDTDEKLNPSDLSAPPGVKINDPVRMYLKEIGRVNLLSAQEEIELAKRIEQGDEVAKSRLAEANLRLVVSIAKRYVGRGMLFLDLIQEGNMGLIKAVEKFDFNKGFKFSTYATWWIRQAITRAIADQARTIRIPVHMVETINKLIRVQRQLLQDLGRDPAPEEIGEEMDLPAEKVREILKIAQEPVSLETPIGEEDDSHLGDFIEDQEAQSPSDHAAYELLKEQLEDVLDTLTDREENVLRLRFGLDDGRTRTLEEVGKVFGVTRERIRQIEAKALRKLRHPSRSKRLKDFMD
T42354	DRUGINFO	D0FX2Q	Rifamycin	Approved

T38284	TARGETID	T38284
T38284	UNIPROID	BCR_HUMAN-ABL1_HUMAN
T38284	TARGNAME	Fusion protein Bcr-Abl (Bcr-Abl)
T38284	GENENAME	BCR-ABL1
T38284	TARGTYPE	Successful
T38284	SYNONYMS	BCR-ABL fusion protein; BCR-ABL
T38284	FUNCTION	Activates downstream signaling pathways such as STAT5, PI3K/Akt, and Erk1/2 to lead to increased cell transformation, survival, and proliferation.
T38284	BIOCLASS	Kinase
T38284	SEQUENCE	MVDPVGFAEAWKAQFPDSEPPRMELRSVGDIEQELERCKASIRRLEQEVNQERFRMIYLQTLLAKEKKSYDRQRWGFRRAAQAPDGASEPRASASRPQPAPADGADPPPAEEPEARPDGEGSPGKARPGTARRPGAAASGERDDRGPPASVAALRSNFERIRKGHGQPGADAEKPFYVNVEFHHERGLVKVNDKEVSDRISSLGSQAMQMERKKSQHGAGSSVGDASRPPYRGRSSESSCGVDGDYEDAELNPRFLKDNLIDANGGSRPPWPPLEYQPYQSIYVGGMMEGEGKGPLLRSQSTSEQEKRLTWPRRSYSPRSFEDCGGGYTPDCSSNENLTSSEEDFSSGQSSRVSPSPTTYRMFRDKSRSPSQNSQQSFDSSSPPTPQCHKRHRHCPVVVSEATIVGVRKTGQIWPNDGEGAFHGDADGSFGTPPGYGCAADRAEEQRRHQDGLPYIDDSPSSSPHLSSKGRGSRDALVSGALESTKASELDLEKGLEMRKWVLSGILASEETYLSHLEALLLPMKPLKAAATTSQPVLTSQQIETIFFKVPELYEIHKEFYDGLFPRVQQWSHQQRVGDLFQKLASQLGVYRAFVDNYGVAMEMAEKCCQANAQFAEISENLRARSNKDAKDPTTKNSLETLLYKPVDRVTRSTLVLHDLLKHTPASHPDHPLLQDALRISQNFLSSINEEITPRRQSMTVKKGEHRQLLKDSFMVELVEGARKLRHVFLFTDLLLCTKLKKQSGGKTQQYDCKWYIPLTDLSFQMVDELEAVPNIPLVPDEELDALKIKISQIKNDIQREKRANKGSKATERLKKKLSEQESLLLLMSPSMAFRVHSRNGKSYTFLISSDYERAEWRENIREQQKKCFRSFSLTSVELQMLTNSCVKLQTVHSIPLTINKEDDESPGLYGFLNVIVHSATGFKQSSNLYCTLEVDSFGYFVNKAKTRVYRDTAEPNWNEEFEIELEGSQTLRILCYEKCYNKTKIPKEDGESTDRLMGKGQVQLDPQALQDRDWQRTVIAMNGIEVKLSVKFNSREFSLKRMPSRKQTGVFGVKIAVVTKRERSKVPYIVRQCVEEIERRGMEEVGIYRVSGVATDIQALKAAFDVNNKDVSVMMSEMDVNAIAGTLKLYFRELPEPLFTDEFYPNFAEGIALSDPVAKESCMLNLLLSLPEANLLTFLFLLDHLKRVAEKEAVNKMSLHNLATVFGPTLLRPSEKESKLPANPSQPITMTDSWSLEVMSQVQVLLYFLQLEAIPAPDSKRQSILFSTEVMLEICLKLVGCKSKKGLSSSSSCYLEEALQRPVASDFEPQGLSEAARWNSKENLLAGPSENDPNLFVALYDFVASGDNTLSITKGEKLRVLGYNHNGEWCEAQTKNGQGWVPSNYITPVNSLEKHSWYHGPVSRNAAEYLLSSGINGSFLVRESESSPGQRSISLRYEGRVYHYRINTASDGKLYVSSESRFNTLAELVHHHSTVADGLITTLHYPAPKRNKPTVYGVSPNYDKWEMERTDITMKHKLGGGQYGEVYEGVWKKYSLTVAVKTLKEDTMEVEEFLKEAAVMKEIKHPNLVQLLGVCTREPPFYIITEFMTYGNLLDYLRECNRQEVNAVVLLYMATQISSAMEYLEKKNFIHRDLAARNCLVGENHLVKVADFGLSRLMTGDTYTAHAGAKFPIKWTAPESLAYNKFSIKSDVWAFGVLLWEIATYGMSPYPGIDLSQVYELLEKDYRMERPEGCPEKVYELMRACWQWNPSDRPSFAEIHQAFETMFQESSISDEVEKELGKQGVRGAVSTLLQAPELPTKTRTSRRAAEHRDTTDVPEMPHSKGQGESDPLDHEPAVSPLLPRKERGPPEGGLNEDERLLPKDKKTNLFSALIKKKKKTAPTPPKRSSSFREMDGQPERRGAGEEEGRDISNGALAFTPLDTADPAKSPKPSNGAGVPNGALRESGGSGFRSPHLWKKSSTLTSSRLATGEEEGGGSSSKRFLRSCSASCVPHGAKDTEWRSVTLPRDLQSTGRQFDSSTFGGHKSEKPALPRKRAGENRSDQVTRGTVTPPPRLVKKNEEAADEVFKDIMESSPGSSPPNLTPKPLRRQVTVAPASGLPHKEEAGKGSALGTPAAAEPVTPTSKAGSGAPGGTSKGPAEESRVRRHKHSSESPGRDKGKLSRLKPAPPPPPAASAGKAGGKPSQSPSQEAAGEAVLGAKTKATSLVDAVNSDAAKPSQPGEGLKKPVLPATPKPQSAKPSGTPISPAPVPSTLPSASSALAGDQPSSTAFIPLISTRVSLRKTRQPPERIASGAITKGVVLDSTEALCLAISRNSEQMASHSAVLEAGKNLYTFCVSYVDSIQQMRNKFAFREAINKLENNLRELQICPATAGSGPAATQDFSKLLSSVKEISDIVQR
T38284	DRUGINFO	D00STL	Nilotinib	Approved
T38284	DRUGINFO	DSHT18	Asciminib	Approved
T38284	DRUGINFO	D0AZ3C	Imatinib	Approved
T38284	DRUGINFO	D0E6XR	Dasatinib	Approved
T38284	DRUGINFO	D01NIR	Radotinib	Phase 3
T38284	DRUGINFO	D0LB3Z	ABL 001	Phase 3
T38284	DRUGINFO	DQ84IT	ICLUSIG	Phase 3
T38284	DRUGINFO	D04BXX	AN-019	Phase 2
T38284	DRUGINFO	DH5RN1	HQP1351	Phase 2
T38284	DRUGINFO	D0G0VV	Bafetinib	Phase 2
T38284	DRUGINFO	D01SCR	NPB-001-056	Phase 1/2
T38284	DRUGINFO	D0Z1RJ	Adaphostin	Phase 1
T38284	DRUGINFO	DL8T4I	SCO-088	Phase 1
T38284	DRUGINFO	D00AIO	Pyridoindole derivative 3	Patented
T38284	DRUGINFO	D01OYY	PMID25656651-Compound-16a	Patented
T38284	DRUGINFO	D01UBA	PMID25656651-Compound-30a	Patented
T38284	DRUGINFO	D03EMY	Pyrrolo[2,3-b]pyridine carboxamide derivative 1	Patented
T38284	DRUGINFO	D04UXO	PMID25656651-Compound-15a	Patented
T38284	DRUGINFO	D04ZXR	PMID25656651-Compound-23a	Patented
T38284	DRUGINFO	D05HDJ	PMID25656651-Compound-20a	Patented
T38284	DRUGINFO	D05YAD	PMID25656651-Compound-11c	Patented
T38284	DRUGINFO	D08PXF	Aminopyrimidine derivative 1	Patented
T38284	DRUGINFO	D0AP4V	Pyridoindole derivative 2	Patented
T38284	DRUGINFO	D0B0BJ	Pyridoindole derivative 1	Patented
T38284	DRUGINFO	D0B5DX	Aminopyrimidine derivative 3	Patented
T38284	DRUGINFO	D0BE9U	Pyrimidinyl pyrazolamine derivative 1	Patented
T38284	DRUGINFO	D0BJ6M	PMID25656651-Compound-25	Patented
T38284	DRUGINFO	D0C9ZW	PMID25656651-Compound-26a	Patented
T38284	DRUGINFO	D0CJ7F	PMID25656651-Compound-15c	Patented
T38284	DRUGINFO	D0DC7I	PMID25656651-Compound-11b	Patented
T38284	DRUGINFO	D0EF5T	PMID25656651-Compound-10	Patented
T38284	DRUGINFO	D0F5HC	PMID25656651-Compound-40	Patented
T38284	DRUGINFO	D0HF0R	Aminopyrimidine derivative 4	Patented
T38284	DRUGINFO	D0I5VG	PMID25656651-Compound-29b	Patented
T38284	DRUGINFO	D0JR7X	PMID25656651-Compound-29a	Patented
T38284	DRUGINFO	D0K3BR	PMID25656651-Compound-26b	Patented
T38284	DRUGINFO	D0KL5M	PMID25656651-Compound-38	Patented
T38284	DRUGINFO	D0KR7K	PMID25656651-Compound-16b	Patented
T38284	DRUGINFO	D0KT5W	PMID25656651-Compound-30b	Patented
T38284	DRUGINFO	D0L7XM	PMID25656651-Compound-20b	Patented
T38284	DRUGINFO	D0O0YI	PMID25656651-Compound-7	Patented
T38284	DRUGINFO	D0O2HW	PMID25656651-Compound-27	Patented
T38284	DRUGINFO	D0OY0U	PMID25656651-Compound-26c	Patented
T38284	DRUGINFO	D0PF2F	PMID25656651-Compound-15b	Patented
T38284	DRUGINFO	D0U2LO	PMID25656651-Compound-23b	Patented
T38284	DRUGINFO	D0VD5I	Aminopyrimidine derivative 2	Patented
T38284	DRUGINFO	D0WL1U	PMID25656651-Compound-5	Patented
T38284	DRUGINFO	D0XU3A	PMID25656651-Compound-23c	Patented
T38284	DRUGINFO	D0Y4EU	PMID25656651-Compound-11a	Patented
T38284	DRUGINFO	D0Z7DA	PMID25656651-Compound-18	Patented
T38284	DRUGINFO	D01KIJ	PMID25656651-Compound-37b	Patented
T38284	DRUGINFO	D02KNW	PMID25656651-Compound-36a	Patented
T38284	DRUGINFO	D02VDD	Deuterated 3-cyanoquinoline derivative 1	Patented
T38284	DRUGINFO	D08IUE	PMID25656651-Compound-37c	Patented
T38284	DRUGINFO	D09WKF	PMID25656651-Compound-36d	Patented
T38284	DRUGINFO	D09ZFM	PMID25656651-Compound-36b	Patented
T38284	DRUGINFO	D0BK6R	PMID25656651-Compound-36c	Patented
T38284	DRUGINFO	D0E6EP	PMID25656651-Compound-19b	Patented
T38284	DRUGINFO	D0IA4G	PMID25656651-Compound-37a	Patented
T38284	DRUGINFO	D0JY1I	PMID25656651-Compound-19a	Patented
T38284	DRUGINFO	D0D3FB	PMID25656651-Compound-21a	Patented
T38284	DRUGINFO	D0XQ5F	PMID25656651-Compound-21b	Patented
T38284	DRUGINFO	D0H4YH	4,3'',5''-trimethoxy-[1,1':3',1'']-terphenyl	Investigative
T38284	DRUGINFO	D0PI0R	3'',5''-dimethoxy-[1,1':2',1'']-terphenyl-4-ol	Investigative
T38284	DRUGINFO	D0QG6G	3'',5''-dimethoxy-[1,1':3',1'']-terphenyl-4-ol	Investigative
T38284	DRUGINFO	D00AII	(E)-4-(3,5-dimethoxystyryl)phenol	Investigative
T38284	DRUGINFO	D0AW4W	4,3'',5''-trimethoxy-[1,1':2',1'']-terphenyl	Investigative
T38284	DRUGINFO	D03NPX	PD-0173955	Investigative
T38284	DRUGINFO	D0D5EW	HKI-9924129	Investigative

T68066	TARGETID	T68066
T68066	UNIPROID	ERR1_HUMAN; ERR2_HUMAN; ERR3_HUMAN
T68066	TARGNAME	Steroid hormone receptor ERR (ESRR)
T68066	GENENAME	ESRRA; ESRRB; ESRRG
T68066	TARGTYPE	Successful
T68066	SYNONYMS	Nuclear receptor subfamily 3 group B; NR3B; ERR
T68066	FUNCTION	Intracellular receptors (typically cytoplasmic or nuclear). Initiates signal transduction for steroid hormones which lead to changes in gene expression over a time period of hours to days
T68066	BIOCLASS	Nuclear hormone receptor
T68066	SEQUENCE	MSSQVVGIEPLYIKAEPASPDSPKGSSETETEPPVALAPGPAPTRCLPGHKEEEDGEGAGPGEQGGGKLVLSSLPKRLCLVCGDVASGYHYGVASCEACKAFFKRTIQGSIEYSCPASNECEITKRRRKACQACRFTKCLRVGMLKEGVRLDRVRGGRQKYKRRPEVDPLPFPGPFPAGPLAVAGGPRKTAAPVNALVSHLLVVEPEKLYAMPDPAGPDGHLPAVATLCDLFDREIVVTISWAKSIPGFSSLSLSDQMSVLQSVWMEVLVLGVAQRSLPLQDELAFAEDLVLDEEGARAAGLGELGAALLQLVRRLQALRLEREEYVLLKALALANSDSVHIEDAEAVEQLREALHEALLEYEAGRAGPGGGAERRRAGRLLLTLPLLRQTAGKVLAHFYGVKLEGKVPMHKLFLEMLEAMMD
T68066	DRUGINFO	D00XPC	Halobetasol Propionate	Approved
T68066	DRUGINFO	D02JNM	Desonide	Approved
T68066	DRUGINFO	D03ZZK	Fluocinonide	Approved
T68066	DRUGINFO	D04SFH	Medrysone	Approved
T68066	DRUGINFO	D06IIB	Halcinonide	Approved
T68066	DRUGINFO	D06XHC	Amcinonide	Approved
T68066	DRUGINFO	D07DVK	Beclomethasone	Approved
T68066	DRUGINFO	D09IEE	Prednicarbate	Approved
T68066	DRUGINFO	D0CZ1Q	Desoximetasone	Approved
T68066	DRUGINFO	D0F7NQ	Flumethasone Pivalate	Approved
T68066	DRUGINFO	D0L2UN	Auranofin	Approved
T68066	DRUGINFO	D0X4RS	Cortisone Acetate	Approved
T68066	DRUGINFO	D0X6GN	Loteprednol Etabonate	Approved
T68066	DRUGINFO	D0Y2YP	Flurandrenolide	Approved
T68066	DRUGINFO	D0RR2E	IDP-122	Phase 3
T68066	DRUGINFO	D0Z7MJ	Prednisolone sodium metazoate	Discontinued in Phase 2

T30956	TARGETID	T30956
T30956	FORMERID	TTDI01685
T30956	UNIPROID	PAG_BACAN
T30956	TARGNAME	Bacillus anthracis Protective antigen (Anthrax PA)
T30956	GENENAME	Anthrax PA
T30956	TARGTYPE	Successful
T30956	SYNONYMS	Protective antigen; Anthrax toxins translocating protein; Anthrax PA83; Anthrax PA-83; Anthrax PA
T30956	FUNCTION	One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.
T30956	PDBSTRUC	5FR3; 4NAM; 4H2A; 4EE2; 3TEZ
T30956	SEQUENCE	MKKRKVLIPLMALSTILVSSTGNLEVIQAEVKQENRLLNESESSSQGLLGYYFSDLNFQAPMVVTSSTTGDLSIPSSELENIPSENQYFQSAIWSGFIKVKKSDEYTFATSADNHVTMWVDDQEVINKASNSNKIRLEKGRLYQIKIQYQRENPTEKGLDFKLYWTDSQNKKEVISSDNLQLPELKQKSSNSRKKRSTSAGPTVPDRDNDGIPDSLEVEGYTVDVKNKRTFLSPWISNIHEKKGLTKYKSSPEKWSTASDPYSDFEKVTGRIDKNVSPEARHPLVAAYPIVHVDMENIILSKNEDQSTQNTDSQTRTISKNTSTSRTHTSEVHGNAEVHASFFDIGGSVSAGFSNSNSSTVAIDHSLSLAGERTWAETMGLNTADTARLNANIRYVNTGTAPIYNVLPTTSLVLGKNQTLATIKAKENQLSQILAPNNYYPSKNLAPIALNAQDDFSSTPITMNYNQFLELEKTKQLRLDTDQVYGNIATYNFENGRVRVDTGSNWSEVLPQIQETTARIIFNGKDLNLVERRIAAVNPSDPLETTKPDMTLKEALKIAFGFNEPNGNLQYQGKDITEFDFNFDQQTSQNIKNQLAELNATNIYTVLDKIKLNAKMNILIRDKRFHYDRNNIAVGADESVVKEAHREVINSSTEGLLLNIDKDIRKILSGYIVEIEDTEGLKEVINDRYDMLNISSLRQDGKTFIDFKKYNDKLPLYISNPNYKVNVYAVTKENTIINPSENGDTSTNGIKKILIFSKKGYEIG
T30956	DRUGINFO	D09VOS	ETI-204	Approved
T30956	DRUGINFO	D0P8MB	AIGIV	Phase 1/2

T07403	TARGETID	T07403
T07403	UNIPROID	ITA4_HUMAN-ITB7_HUMAN
T07403	TARGNAME	Integrin alpha-4/beta-7 (ITGA4/B7)
T07403	GENENAME	ITGA4-ITGB7
T07403	TARGTYPE	Successful
T07403	SYNONYMS	alpha(4)beta(7) integrin; Alpha 4 beta 7 integrin
T07403	FUNCTION	It is expressed on lymphocytes and is responsible for T-cell homing into gut-associated lymphoid tissues through its binding to mucosal addressin cell adhesion molecule (MAdCAM), which is present on high endothelial venules of mucosal lymphoid organs.
T07403	BIOCLASS	Integrin
T07403	SEQUENCE	MVALPMVLVLLLVLSRGESELDAKIPSTGDATEWRNPHLSMLGSCQPAPSCQKCILSHPSCAWCKQLNFTASGEAEARRCARREELLARGCPLEELEEPRGQQEVLQDQPLSQGARGEGATQLAPQRVRVTLRPGEPQQLQVRFLRAEGYPVDLYYLMDLSYSMKDDLERVRQLGHALLVRLQEVTHSVRIGFGSFVDKTVLPFVSTVPSKLRHPCPTRLERCQSPFSFHHVLSLTGDAQAFEREVGRQSVSGNLDSPEGGFDAILQAALCQEQIGWRNVSRLLVFTSDDTFHTAGDGKLGGIFMPSDGHCHLDSNGLYSRSTEFDYPSVGQVAQALSAANIQPIFAVTSAALPVYQELSKLIPKSAVGELSEDSSNVVQLIMDAYNSLSSTVTLEHSSLPPGVHISYESQCEGPEKREGKAEDRGQCNHVRINQTVTFWVSLQATHCLPEPHLLRLRALGFSEELIVELHTLCDCNCSDTQPQAPHCSDGQGHLQCGVCSCAPGRLGRLCECSVAELSSPDLESGCRAPNGTGPLCSGKGHCQCGRCSCSGQSSGHLCECDDASCERHEGILCGGFGRCQCGVCHCHANRTGRACECSGDMDSCISPEGGLCSGHGRCKCNRCQCLDGYYGALCDQCPGCKTPCERHRDCAECGAFRTGPLATNCSTACAHTNVTLALAPILDDGWCKERTLDNQLFFFLVEDDARGTVVLRVRPQEKGADHTQAIVLGCVGGIVAVGLGLVLAYRLSVEIYDRREYSRFEKEQQQLNWKQDSNPLYKSAITTTINPRFQEADSPTLMAWEARREPGPRRAAVRETVMLLLCLGVPTGRPYNVDTESALLYQGPHNTLFGYSVVLHSHGANRWLLVGAPTANWLANASVINPGAIYRCRIGKNPGQTCEQLQLGSPNGEPCGKTCLEERDNQWLGVTLSRQPGENGSIVTCGHRWKNIFYIKNENKLPTGGCYGVPPDLRTELSKRIAPCYQDYVKKFGENFASCQAGISSFYTKDLIVMGAPGSSYWTGSLFVYNITTNKYKAFLDKQNQVKFGSYLGYSVGAGHFRSQHTTEVVGGAPQHEQIGKAYIFSIDEKELNILHEMKGKKLGSYFGASVCAVDLNADGFSDLLVGAPMQSTIREEGRVFVYINSGSGAVMNAMETNLVGSDKYAARFGESIVNLGDIDNDGFEDVAIGAPQEDDLQGAIYIYNGRADGISSTFSQRIEGLQISKSLSMFGQSISGQIDADNNGYVDVAVGAFRSDSAVLLRTRPVVIVDASLSHPESVNRTKFDCVENGWPSVCIDLTLCFSYKGKEVPGYIVLFYNMSLDVNRKAESPPRFYFSSNGTSDVITGSIQVSSREANCRTHQAFMRKDVRDILTPIQIEAAYHLGPHVISKRSTEEFPPLQPILQQKKEKDIMKKTINFARFCAHENCSADLQVSAKIGFLKPHENKTYLAVGSMKTLMLNVSLFNAGDDAYETTLHVKLPVGLYFIKILELEEKQINCEVTDNSGVVQLDCSIGYIYVDHLSRIDISFLLDVSSLSRAEEDLSITVHATCENEEEMDNLKHSRVTVAIPLKYEVKLTVHGFVNPTSFVYGSNDENEPETCMVEKMNLTFHVINTGNSMAPNVSVEIMVPNSFSPQTDKLFNILDVQTTTGECHFENYQRVCALEQQKSAMQTLKGIVRFLSKTDKRLLYCIKADPHCLNFLCNFGKMESGKEASVHIQLEGRPSILEMDETSALKFEIRATGFPEPNPRVIELNKDENVAHVLLEGLHHQRPKRYFTIVIISSSLLLGLIVLLLISYVMWKAGFFKRQYKSILQEENRRDSWSYINSKSNDD
T07403	DRUGINFO	D0PK5M	MLN0002	Approved
T07403	DRUGINFO	D1W8RK	PN-943	Phase 2
T07403	DRUGINFO	DYZA20	MORF-057	Phase 2
T07403	DRUGINFO	D0A2KH	TRK-170	Phase 2
T07403	DRUGINFO	D2MFD0	GS-1427	Phase 1
T07403	DRUGINFO	D04XJM	R1295	Discontinued in Phase 1
T07403	DRUGINFO	D02WII	TR-14035	Discontinued in Phase 1

T51593	TARGETID	T51593
T51593	FORMERID	TTDR01331
T51593	UNIPROID	TPH1_HUMAN; TPH2_HUMAN
T51593	TARGNAME	Tryptophan hydroxylase (TPH)
T51593	GENENAME	TPH1; TPH2
T51593	TARGTYPE	Successful
T51593	SYNONYMS	Tryptophan 5-monooxygenase; TPH
T51593	FUNCTION	Responsible for addition of the -HO group (hydroxylation) to the 5 position to form the amino acid 5-hydroxytryptophan (5-HTP), which is the initial and rate-limiting step in the synthesis of the neurotransmitter serotonin.
T51593	BIOCLASS	Paired donor oxygen oxidoreductase
T51593	SEQUENCE	MIEDNKENKDHSLERGRASLIFSLKNEVGGLIKALKIFQEKHVNLLHIESRKSKRRNSEFEIFVDCDINREQLNDIFHLLKSHTNVLSVNLPDNFTLKEDGMETVPWFPKKISDLDHCANRVLMYGSELDADHPGFKDNVYRKRRKYFADLAMNYKHGDPIPKVEFTEEEIKTWGTVFQELNKLYPTHACREYLKNLPLLSKYCGYREDNIPQLEDVSNFLKERTGFSIRPVAGYLSPRDFLSGLAFRVFHCTQYVRHSSDPFYTPEPDTCHELLGHVPLLAEPSFAQFSQEIGLASLGASEEAVQKLATCYFFTVEFGLCKQDGQLRVFGAGLLSSISELKHALSGHAKVKPFDPKITCKQECLITTFQDVYFVSESFEDAKEKMREFTKTIKRPFGVKYNPYTRSIQILKDTKSITSAMNELQHDLDVVSDALAKVSRKPSI
T51593	DRUGINFO	D0RE6T	Telotristat ethyl	Approved

T59122	TARGETID	T59122
T59122	FORMERID	TTDI02398
T59122	UNIPROID	LFA3_HUMAN
T59122	TARGNAME	Surface glycoprotein LFA-3 (CD58)
T59122	GENENAME	CD58
T59122	TARGTYPE	Successful
T59122	SYNONYMS	Surface glycoprotein LFA3; Lymphocyte functionassociated antigen 3; Lymphocyte function-associated antigen 3; LFA3; Ag3
T59122	FUNCTION	Ligand of the T-lymphocyte CD2 glycoprotein. This interaction is important in mediating thymocyte interactions with thymic epithelial cells, antigen-independent and -dependent interactions of T-lymphocytes with target cells and antigen-presenting cells and the T-lymphocyte rosetting with erythrocytes. In addition, the LFA-3/CD2 interaction may prime response by both the CD2+ and LFA-3+ cells.
T59122	PDBSTRUC	1QA9; 1CI5; 1CCZ
T59122	SEQUENCE	MVAGSDAGRALGVLSVVCLLHCFGFISCFSQQIYGVVYGNVTFHVPSNVPLKEVLWKKQKDKVAELENSEFRAFSSFKNRVYLDTVSGSLTIYNLTSSDEDEYEMESPNITDTMKFFLYVLESLPSPTLTCALTNGSIEVQCMIPEHYNSHRGLIMYSWDCPMEQCKRNSTSIYFKMENDLPQKIQCTLSNPLFNTTSSIILTTCIPSSGHSRHRYALIPIPLAVITTCIVLYMNGILKCDRKPDRTNSN
T59122	DRUGINFO	D09ZSO	Alefacept	Approved

T92687	TARGETID	T92687
T92687	UNIPROID	ATP4A_HUMAN; ATP4B_HUMAN
T92687	TARGNAME	Gastric H(+)/K(+) ATPase (Proton pump)
T92687	GENENAME	ATP4A; ATP4B
T92687	TARGTYPE	Successful
T92687	SYNONYMS	Proton pump; Potassium-transporting ATPase
T92687	FUNCTION	Proton pump of the stomach. Exchanges potassium from the intestinal lumen with cytoplasmic hydronium and is the enzyme primarily responsible for the acidification of the stomach contents and the activation of the digestive enzyme pepsin.
T92687	SEQUENCE	MGKAENYELYSVELGPGPGGDMAAKMSKKKKAGGGGGKRKEKLENMKKEMEINDHQLSVAELEQKYQTSATKGLSASLAAELLLRDGPNALRPPRGTPEYVKFARQLAGGLQCLMWVAAAICLIAFAIQASEGDLTTDDNLYLAIALIAVVVVTGCFGYYQEFKSTNIIASFKNLVPQQATVIRDGDKFQINADQLVVGDLVEMKGGDRVPADIRILAAQGCKVDNSSLTGESEPQTRSPECTHESPLETRNIAFFSTMCLEGTVQGLVVNTGDRTIIGRIASLASGVENEKTPIAIEIEHFVDIIAGLAILFGATFFIVAMCIGYTFLRAMVFFMAIVVAYVPEGLLATVTVCLSLTAKRLASKNCVVKNLEAVETLGSTSVICSDKTGTLTQNRMTVSHLWFDNHIHTADTTEDQSGQTFDQSSETWRALCRVLTLCNRAAFKSGQDAVPVPKRIVIGDASETALLKFSELTLGNAMGYRDRFPKVCEIPFNSTNKFQLSIHTLEDPRDPRHLLVMKGAPERVLERCSSILIKGQELPLDEQWREAFQTAYLSLGGLGERVLGFCQLYLNEKDYPPGYAFDVEAMNFPSSGLCFAGLVSMIDPPRATVPDAVLKCRTAGIRVIMVTGDHPITAKAIAASVGIISEGSETVEDIAARLRVPVDQVNRKDARACVINGMQLKDMDPSELVEALRTHPEMVFARTSPQQKLVIVESCQRLGAIVAVTGDGVNDSPALKKADIGVAMGIAGSDAAKNAADMILLDDNFASIVTGVEQGRLIFDNLKKSIAYTLTKNIPELTPYLIYITVSVPLPLGCITILFIELCTDIFPSVSLAYEKAESDIMHLRPRNPKRDRLVNEPLAAYSYFQIGAIQSFAGFTDYFTAMAQEGWFPLLCVGLRAQWEDHHLQDLQDSYGQEWTFGQRLYQQYTCYTVFFISIEVCQIADVLIRKTRRLSAFQQGFFRNKILVIAIVFQVCIGCFLCYCPGMPNIFNFMPIRFQWWLVPLPYGILIFVYDEIRKLGVRCCPGSWWDQELYY
T92687	DRUGINFO	D01XNB	Omeprazole	Approved
T92687	DRUGINFO	D02CPP	Vonoprazan	Approved
T92687	DRUGINFO	D0C6DT	Esomeprazole	Approved
T92687	DRUGINFO	D0T6XX	Pantoprazole	Approved
T92687	DRUGINFO	D06YYD	Dexlansoprazole	Approved
T92687	DRUGINFO	D05BCU	RQ-00000004	Phase 3
T92687	DRUGINFO	D03RVC	YH-4808	Phase 2
T92687	DRUGINFO	D0N1PZ	S-tenatoprazole	Phase 2
T92687	DRUGINFO	D0S0EQ	AZD-0865	Phase 2
T92687	DRUGINFO	D0QZ4S	LEMINOPRAZOLE	Discontinued in Preregistration
T92687	DRUGINFO	D02THB	SKF-96067	Discontinued in Phase 3
T92687	DRUGINFO	D0M8HH	PUMAPRAZOLE	Discontinued in Phase 3
T92687	DRUGINFO	D03EZB	AR-H047108	Discontinued in Phase 2
T92687	DRUGINFO	D0GY4V	TY-11345	Discontinued in Phase 2
T92687	DRUGINFO	D0Q0YN	SORAPRAZAN	Discontinued in Phase 2
T92687	DRUGINFO	D0R2EY	SKF-97574	Discontinued in Phase 1
T92687	DRUGINFO	D0R7GH	CS-526	Discontinued in Phase 1
T92687	DRUGINFO	D03CCH	SK&F-95601	Terminated
T92687	DRUGINFO	D0FN1P	Saviprazole	Terminated
T92687	DRUGINFO	D0C7SC	YH-1238	Investigative

T22348	TARGETID	T22348
T22348	FORMERID	TTDI01914
T22348	UNIPROID	GYRA_STAAU; GYRB_STAAU
T22348	TARGNAME	Bacterial DNA gyrase (Bact gyrase)
T22348	GENENAME	Bact gyrA; Bact gyrB
T22348	TARGTYPE	Successful
T22348	SYNONYMS	DNA gyrase
T22348	FUNCTION	DNA gyrase negatively supercoils closed circular double- stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings.
T22348	BIOCLASS	ATP-hydrolyzing DNA topoisomerase
T22348	SEQUENCE	MAELPQSRINERNITSEMRESFLDYAMSVIVARALPDVRDGLKPVHRRILYGLNEQGMTPDKSYKKSARIVGDVMGKYHPHGDSSIYEAMVRMAQDFSYRYPLVDGQGNFGSMDGDGAAAMRYTEARMTKITLELLRDINKDTIDFIDNYDGNEREPSVLPARFPNLLANGASGIAVGMATNIPPHNLTELINGVLSLSKNPDISIAELMEDIEGPDFPTAGLILGKSGIRRAYETGRGSIQMRSRAVIEERGGGRQRIVVTEIPFQVNKARMIEKIAELVRDKKIDGITDLRDETSLRTGVRVVIDVRKDANASVILNNLYKQTPLQTSFGVNMIALVNGRPKLINLKEALVHYLEHQKTVVRRRTQYNLRKAKDRAHILEGLRIALDHIDEIISTIRESDTDKVAMESLQQRFKLSEKQAQAILDMRLRRLTGLERDKIEAEYNELLNYISELEAILADEEVLLQLVRDELTEIRDRFGDDRRTEIQLGGFEDLEDEDLIPEEQIVITLSHNNYIKRLPVSTYRAQNRGGRGVQGMNTLEEDFVSQLVTLSTHDHVLFFTNKGRVYKLKGYEVPELSRQSKGIPVVNAIELENDEVISTMIAVKDLESEDNFLVFATKRGVVKRSALSNFSRINRNGKIAISFREDDELIAVRLTSGQEDILIGTSHASLIRFPESTLRPLGRTATGVKGITLREGDEVVGLDVAHANSVDEVLVVTENGYGKRTPVNDYRLSNRGGKGIKTATITERNGNVVCITTVTGEEDLMIVTNAGVIIRLDVADISQNGRAAQGVRLIRLGDDQFVSTVAKVKEDAEDETNEDEQSTSTVSEDGTEQQREAVVNDETPGNAIHTEVIDSEENDEDGRIEVRQDFMDRVEEDIQQSLDEDEE
T22348	DRUGINFO	D03NHW	Ofloxacin	Approved
T22348	DRUGINFO	D03WPA	Trovafloxacin	Approved
T22348	DRUGINFO	D0JL2K	Grepafloxacin	Approved
T22348	DRUGINFO	D0P0RX	Nemonoxacin	Approved
T22348	DRUGINFO	D0Q2PE	Norfloxacin	Approved
T22348	DRUGINFO	D00TRV	Besifloxacin	Approved
T22348	DRUGINFO	D01IXD	Finafloxacin	Approved
T22348	DRUGINFO	D02RSN	Levofloxacin	Approved
T22348	DRUGINFO	D03CQE	Gatifloxacin	Approved
T22348	DRUGINFO	D0K6GZ	Sparfloxacin	Approved
T22348	DRUGINFO	D0VR7W	Gemifloxacin	Approved
T22348	DRUGINFO	D0ZV0Z	Moxifloxacin	Approved
T22348	DRUGINFO	DR36YB	Prulifloxacin	Approved
T22348	DRUGINFO	D0O1WX	Ciprofloxacin XR	Approved
T22348	DRUGINFO	D0X1HE	Ozenoxacin	Approved
T22348	DRUGINFO	D00HBE	AZD0914	Phase 3
T22348	DRUGINFO	D01ODU	BAY-35-3377	Phase 3
T22348	DRUGINFO	D05STQ	Pazufloxacin	Phase 3
T22348	DRUGINFO	D07MXF	Zabofloxacin	Phase 3
T22348	DRUGINFO	D07NTC	WCK-771	Phase 2
T22348	DRUGINFO	D2FCM4	VB 1953	Phase 2
T22348	DRUGINFO	D39VXL	JNJ-32729463	Phase 2
T22348	DRUGINFO	D4M8RS	TNP-2092	Phase 2
T22348	DRUGINFO	D6DT3X	Sitafloxacin	Phase 2
T22348	DRUGINFO	D04SBX	Temafloxacin	Withdrawn from market
T22348	DRUGINFO	D0Q0SZ	OLAMUFLOXACIN MESILATE	Discontinued in Phase 3
T22348	DRUGINFO	D09CFM	DANOFLOXACIN	Discontinued in Phase 2
T22348	DRUGINFO	D0D2SG	99mTc-ciprofloxacin	Discontinued in Phase 2
T22348	DRUGINFO	D0E6NR	BAY-Y-3118	Discontinued in Phase 2
T22348	DRUGINFO	D0K4ED	Ro-23-9424	Discontinued in Phase 2
T22348	DRUGINFO	D0Q4UY	CFC-222	Discontinued in Phase 2
T22348	DRUGINFO	D0R6MH	Cadrofloxacin	Discontinued in Phase 2
T22348	DRUGINFO	D0W7KD	FANDOFLOXACIN HYDROCHLORIDE	Discontinued in Phase 2
T22348	DRUGINFO	D0W8VY	A-86719.1	Discontinued in Phase 2
T22348	DRUGINFO	D0T3VO	DX-619	Discontinued in Phase 2
T22348	DRUGINFO	D03ESW	Cetefloxacin	Discontinued in Phase 1
T22348	DRUGINFO	D06GMJ	GSK945237	Discontinued in Phase 1
T22348	DRUGINFO	D09KXA	PD-131112	Discontinued in Phase 1
T22348	DRUGINFO	D0D1LG	AZD-5099	Discontinued in Phase 1
T22348	DRUGINFO	D0T6PV	DV-7751A	Discontinued in Phase 1
T22348	DRUGINFO	D0IY0R	Viquidacin	Preclinical
T22348	DRUGINFO	D00ITG	Clinafloxacin	Terminated
T22348	DRUGINFO	D00MLQ	Protosufloxacin	Terminated
T22348	DRUGINFO	D03GQC	PD-117596	Terminated
T22348	DRUGINFO	D03HSF	Ro-23-7777	Terminated
T22348	DRUGINFO	D03YLN	CP-67015	Terminated
T22348	DRUGINFO	D0C7FN	BMY-40062	Terminated
T22348	DRUGINFO	D0IA7K	MF-5137	Terminated
T22348	DRUGINFO	D0L2BH	S-34109	Terminated
T22348	DRUGINFO	D0PM9P	KB-5246	Terminated
T22348	DRUGINFO	D0V2WK	A-70826	Terminated
T22348	DRUGINFO	D01ZLI	CBR-2092	Terminated
T22348	DRUGINFO	D0Q8YO	PD-117558	Investigative
T22348	DRUGINFO	D08ZRP	NSFQ-105	Investigative

T61997	TARGETID	T61997
T61997	FORMERID	TTDR00362
T61997	UNIPROID	PSA1_HUMAN; PSA2_HUMAN
T61997	TARGNAME	Core proteasome 20S complex (PS 20S)
T61997	GENENAME	PSMA1; PSMA2
T61997	TARGTYPE	Successful
T61997	SYNONYMS	Proteasome subunit alpha; Proteasome component; PSC; Multicatalytic endopeptidase complex; Macropain; HC
T61997	FUNCTION	Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins. The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex).
T61997	BIOCLASS	Peptidase
T61997	SEQUENCE	MFRNQYDNDVTVWSPQGRIHQIEYAMEAVKQGSATVGLKSKTHAVLVALKRAQSELAAHQKKILHVDNHIGISIAGLTADARLLCNFMRQECLDSRFVFDRPLPVSRLVSLIGSKTQIPTQRYGRRPYGVGLLIAGYDDMGPHIFQTCPSANYFDCRAMSIGARSQSARTYLERHMSEFMECNLNELVKHGLRALRETLPAEQDLTTKNVSIGIVGKDLEFTIYDDDDVSPFLEGLEERPQRKAQPAQPADEPAEKADEPMEH

T03896	TARGETID	T03896
T03896	UNIPROID	POLG_HCV1
T03896	TARGNAME	Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A)
T03896	GENENAME	HCV NS3/4A
T03896	TARGTYPE	Successful
T03896	SYNONYMS	HCV Hepacivirin/NS4A; HCV NS3P/NS4A; HCV p70/NS4A
T03896	FUNCTION	Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity).
T03896	PDBSTRUC	3SU4; 3RC5; 3RC4; 3QGI; 3QGH
T03896	SEQUENCE	APITAYAQQTRGLLGCIITSLTGRDKNQVEGEVQIVSTAAQTFLATCINGVCWTVYHGAGTRTIASPKGPVIQMYTNVDQDLVGWPAPQGSRSLTPCTCGSSDLYLVTRHADVIPVRRRGDSRGSLLSPRPISYLKGSSGGPLLCPAGHAVGIFRAAVCTRGVAKAVDFIPVENLETTMRSPVFTDNSSPPVVPQSFQVAHLHAPTGSGKSTKVPAAYAAQGYKVLVLNPSVAATLGFGAYMSKAHGIDPNIRTGVRTITTGSPITYSTYGKFLADGGCSGGAYDIIICDECHSTDATSILGIGTVLDQAETAGARLVVLATATPPGSVTVPHPNIEEVALSTTGEIPFYGKAIPLEVIKGGRHLIFCHSKKKCDELAAKLVALGINAVAYYRGLDVSVIPTSGDVVVVATDALMTGYTGDFDSVIDCNTCVTQTVDFSLDPTFTIETITLPQDAVSRTQRRGRTGRGKPGIYRFVAPGERPSGMFDSSVLCECYDAGCAWYELTPAETTVRLRAYMNTPGLPVCQDHLEFWEGVFTGLTHIDAHFLSQTKQSGENLPYLVAYQATVCARAQAPPPSWDQMWKCLIRLKPTLHGPTPLLYRLGAVQNEITLTHPVTKYIMTCMSADLEVVTSTWVLVGGVLAALAAYCLSTGCVVIVGRVVLSGKPAIIPDREVLYREFDEMEEC
T03896	DRUGINFO	D00TLP	Simeprevir	Approved
T03896	DRUGINFO	D0V3YT	BOCEPREVIR	Approved
T03896	DRUGINFO	D0X9CH	Telaprevir	Approved
T03896	DRUGINFO	D0C4DH	Glecaprevir; pibrentasvir	Approved
T03896	DRUGINFO	D0RM5Z	Sofosbuvir + velpatasvir + voxilaprevir	Approved

T16761	TARGETID	T16761
T16761	UNIPROID	FOL1_PNECA
T16761	TARGNAME	Pneumocystis carinii Dihydropteroate synthase (PC DHPS)
T16761	GENENAME	PC DHPS
T16761	TARGTYPE	Successful
T16761	SYNONYMS	PC DHPS
T16761	FUNCTION	Catalyzes three sequential steps of tetrahydrofolate biosynthesis.
T16761	ECNUMBER	EC 2.5.1.15
T16761	SEQUENCE	SFRSYKAPTYIMAILNLTPDSFFDGGIHSYDSVLIDVEKFINAGATIIDIGGQSTRPGSYIIPLEEEIFRVIPAIKYLQKTYPDILISIDTFRSEVAEQAVKAGASLVNDISGGRYDPKMFNTVARLKVPICIMHMRGNFLNMDNLTDYGTDIIEQITIELEKLLNSAEKSGIPRWNIILDPGLGFSKTLHQNIELLRRFNELKSKNCFNGLPWLLGPSRKRFTGFITGDNMPKDRIWGTVAAVVASISGGCDIIRVHDVYEMYKISKMSDAIWKEIY
T16761	DRUGINFO	D0MA9N	Dapsone	Approved

T74166	TARGETID	T74166
T74166	UNIPROID	ACHA3_HUMAN-ACHB4_HUMAN
T74166	TARGNAME	Neuronal acetylcholine receptor alpha-3/beta-4 (CHRNA3/B4)
T74166	GENENAME	CHRNA3-CHRNB4
T74166	TARGTYPE	Successful
T74166	SYNONYMS	Neuronal acetylcholine receptor
T74166	FUNCTION	A type of nicotinic acetylcholine receptor, consisting of 3 and 4 subunits.
T74166	BIOCLASS	Neurotransmitter receptor
T74166	SEQUENCE	MRRAPSLVLFFLVALCGRGNCRVANAEEKLMDDLLNKTRYNNLIRPATSSSQLISIKLQLSLAQLISVNEREQIMTTNVWLKQEWTDYRLTWNSSRYEGVNILRIPAKRIWLPDIVLYNNADGTYEVSVYTNLIVRSNGSVLWLPPAIYKSACKIEVKYFPFDQQNCTLKFRSWTYDHTEIDMVLMTPTASMDDFTPSGEWDIVALPGRRTVNPQDPSYVDVTYDFIIKRKPLFYTINLIIPCVLTTLLAILVFYLPSDCGEKMTLCISVLLALTFFLLLISKIVPPTSLDVPLIGKYLMFTMVLVTFSIVTSVCVLNVHHRSPSTHTMAPWVKRCFLHKLPTFLFMKRPGPDSSPARAFPPSKSCVTKPEATATSTSPSNFYGNSMYFVNPASAASKSPAGSTPVAIPRDFWLRSSGRFRQDVQEALEGVSFIAQHMKNDDEDQSVVEDWKYVAMVVDRLFLWVFMFVCVLGTVGLFLPPLFQTHAASEGPYAAQRDMGSGPLSLPLALSPPRLLLLLLLSLLPVARASEAEHRLFERLFEDYNEIIRPVANVSDPVIIHFEVSMSQLVKVDEVNQIMETNLWLKQIWNDYKLKWNPSDYGGAEFMRVPAQKIWKPDIVLYNNAVGDFQVDDKTKALLKYTGEVTWIPPAIFKSSCKIDVTYFPFDYQNCTMKFGSWSYDKAKIDLVLIGSSMNLKDYWESGEWAIIKAPGYKHDIKYNCCEEIYPDITYSLYIRRLPLFYTINLIIPCLLISFLTVLVFYLPSDCGEKVTLCISVLLSLTVFLLVITETIPSTSLVIPLIGEYLLFTMIFVTLSIVITVFVLNVHYRTPTTHTMPSWVKTVFLNLLPRVMFMTRPTSNEGNAQKPRPLYGAELSNLNCFSRAESKGCKEGYPCQDGMCGYCHHRRIKISNFSANLTRSSSSESVDAVLSLSALSPEIKEAIQSVKYIAENMKAQNEAKEIQDDWKYVAMVIDRIFLWVFTLVCILGTAGLFLQPLMAREDA
T74166	DRUGINFO	D0HF0W	Levopropoxyphene Napsylate Anhydrous	Approved
T74166	DRUGINFO	D0D7YW	TC-5214	Phase 2
T74166	DRUGINFO	D0DS3J	18-MC	Phase 1

T14121	TARGETID	T14121
T14121	FORMERID	TTDI02064
T14121	UNIPROID	F13_VAR67
T14121	TARGNAME	Virus Major envelope p37 (Viru p37)
T14121	GENENAME	Viru p37
T14121	TARGTYPE	Successful
T14121	SYNONYMS	Viru p37K; Viru Palmitoylated EV membrane protein; Viru Envelope protein F13; C17L, F13L; 37 kDa protein
T14121	FUNCTION	Envelope protein associated with the inner side of the enveloped virion (EV) membrane.
T14121	BIOCLASS	Phospholipase D phosphodiesterase
T14121	SEQUENCE	MWPFTSAPAGAKCRLVETLPENMDFRSDHLTTFECFNEIITLAKKYIYIASFCCNPLSTTRGALIFDKLKEASEKGIKIIVLLDERGKRNLGELQSHCPDINFITVNIDKKNNVGLLLGCFWVSDDERCYVGNASFTGGSIHTIKTLGVYSDYPPLATDLRRRFDTFKAFNSVKNSWLNLYSSACCLPVSTAYHIKNPIGGVFFTDSPEHLLGYSRDLDTDVVIDKLRSAKTSIDIEHLAIVPTTRVDGNSYYWPDIYNSIIEAAINRGVKIRLLVGNWDKNDVYSMATAESLDALCVQNDLSVKVFTIQNNTKLLIVDDEYVHITSANFDGTHYQNHGFVSFNSIDKQLVSEAKKIFERDWVSSHSKSLKI

T23666	TARGETID	T23666
T23666	FORMERID	TTDI02013
T23666	UNIPROID	AHR_HUMAN
T23666	TARGNAME	Aryl hydrocarbon receptor (AHR)
T23666	GENENAME	AHR
T23666	TARGTYPE	Successful
T23666	SYNONYMS	bHLHe76; Class E basic helixloophelix protein 76; Class E basic helix-loop-helix protein 76; AhR; Ah receptor
T23666	FUNCTION	Binds to the XRE promoter region of genes it activates. Activates the expression of multiple phase I and II xenobiotic chemical metabolizing enzyme genes (such as the CYP1A1 gene). Mediates biochemical and toxic effects of halogenated aromatic hydrocarbons. Involved in cell-cycle regulation. Likely to play an important role in the development and maturation of many tissues. Regulates the circadian clock by inhibiting the basal and circadian expression of the core circadian component PER1. Inhibits PER1 by repressing the CLOCK-ARNTL/BMAL1 heterodimer mediated transcriptional activation of PER1. The heterodimer ARNT:AHR binds to core DNA sequence 5'-TGCGTG-3' within the dioxin response element (DRE) of target gene promoters and activates their transcription. Ligand-activated transcriptional activator.
T23666	PDBSTRUC	5NJ8
T23666	SEQUENCE	MNSSSANITYASRKRRKPVQKTVKPIPAEGIKSNPSKRHRDRLNTELDRLASLLPFPQDVINKLDKLSVLRLSVSYLRAKSFFDVALKSSPTERNGGQDNCRAANFREGLNLQEGEFLLQALNGFVLVVTTDALVFYASSTIQDYLGFQQSDVIHQSVYELIHTEDRAEFQRQLHWALNPSQCTESGQGIEEATGLPQTVVCYNPDQIPPENSPLMERCFICRLRCLLDNSSGFLAMNFQGKLKYLHGQKKKGKDGSILPPQLALFAIATPLQPPSILEIRTKNFIFRTKHKLDFTPIGCDAKGRIVLGYTEAELCTRGSGYQFIHAADMLYCAESHIRMIKTGESGMIVFRLLTKNNRWTWVQSNARLLYKNGRPDYIIVTQRPLTDEEGTEHLRKRNTKLPFMFTTGEAVLYEATNPFPAIMDPLPLRTKNGTSGKDSATTSTLSKDSLNPSSLLAAMMQQDESIYLYPASSTSSTAPFENNFFNESMNECRNWQDNTAPMGNDTILKHEQIDQPQDVNSFAGGHPGLFQDSKNSDLYSIMKNLGIDFEDIRHMQNEKFFRNDFSGEVDFRDIDLTDEILTYVQDSLSKSPFIPSDYQQQQSLALNSSCMVQEHLHLEQQQQHHQKQVVVEPQQQLCQKMKHMQVNGMFENWNSNQFVPFNCPQQDPQQYNVFTDLHGISQEFPYKSEMDSMPYTQNFISCNQPVLPQHSKCTELDYPMGSFEPSPYPTTSSLEDFVTCLQLPENQKHGLNPQSAIITPQTCYAGAVSMYQCQPEPQHTHVGQMQYNPVLPGQQAFLNKFQNGVLNETYPAELNNINNTQTTTHLQPLHHPSEARPFPDLTSSGFL
T23666	DRUGINFO	D03DMB	Tapinarof	Approved
T23666	DRUGINFO	D01PZD	Romiplostim	Approved
T23666	DRUGINFO	D0AF5P	RVT-505	Phase 2
T23666	DRUGINFO	D5D6ZM	IK-175	Phase 1
T23666	DRUGINFO	DMVR61	BAY 2416964	Phase 1
T23666	DRUGINFO	DNEH27	AT-177	Clinical trial
T23666	DRUGINFO	D49AGF	CB7993113	Preclinical
T23666	DRUGINFO	DQ3NC4	2-(1H-indole-3,-carbonyl)-thiazole-4-carboxylic acid methyl ester	Preclinical
T23666	DRUGINFO	DFBJ28	6-Formylindolo[3,2-b]carbazole	Investigative
T23666	DRUGINFO	DL36FJ	CH-223191	Investigative

T35465	TARGETID	T35465
T35465	FORMERID	TTDI03511
T35465	UNIPROID	S19A1_HUMAN
T35465	TARGNAME	Solute carrier family 19 member 1 (SLC19A1)
T35465	GENENAME	SLC19A1
T35465	TARGTYPE	Successful
T35465	SYNONYMS	Reduced folate carrier protein; RFC1; RFC; Placental folate transporter; Intestinal folate carrier 1; IFC-1; Folate transporter 1; FOLT; FLOT1
T35465	FUNCTION	Transporter for the intake of folate. Uptake of folate in human placental choriocarcinoma cells occurs by a novel mechanism called potocytosis which functionally couples three components, namely the folate receptor, the folate transporter, and a V-type H(+)-pump.
T35465	SEQUENCE	MVPSSPAVEKQVPVEPGPDPELRSWRHLVCYLCFYGFMAQIRPGESFITPYLLGPDKNFTREQVTNEITPVLSYSYLAVLVPVFLLTDYLRYTPVLLLQGLSFVSVWLLLLLGHSVAHMQLMELFYSVTMAARIAYSSYIFSLVRPARYQRVAGYSRAAVLLGVFTSSVLGQLLVTVGRVSFSTLNYISLAFLTFSVVLALFLKRPKRSLFFNRDDRGRCETSASELERMNPGPGGKLGHALRVACGDSVLARMLRELGDSLRRPQLRLWSLWWVFNSAGYYLVVYYVHILWNEVDPTTNSARVYNGAADAASTLLGAITSFAAGFVKIRWARWSKLLIAGVTATQAGLVFLLAHTRHPSSIWLCYAAFVLFRGSYQFLVPIATFQIASSLSKELCALVFGVNTFFATIVKTIITFIVSDVRGLGLPVRKQFQLYSVYFLILSIIYFLGAMLDGLRHCQRGHHPRQPPAQGLRSAAEEKAAQALSVQDKGLGGLQPAQSPPLSPEDSLGAVGPASLEQRQSDPYLAQAPAPQAAEFLSPVTTPSPCTLCSAQASGPEAADETCPQLAVHPPGVSKLGLQCLPSDGVQNVNQ
T35465	DRUGINFO	D0SV8E	Methotrexate	Approved
T35465	DRUGINFO	D0Z0DW	Folic Acid	Approved

T30938	TARGETID	T30938
T30938	FORMERID	TTDI00934
T30938	UNIPROID	RPOA_MYCTU; RPOB_MYCTU; RPOC_MYCTU; RPOZ_MYCTU
T30938	TARGNAME	Mycobacterium RNA polymerase (MycB RNAP)
T30938	GENENAME	MycB rpoA; MycB rpoB; MycB rpoC; MycB rpoZ
T30938	TARGTYPE	Successful
T30938	SYNONYMS	Transcriptase; RNAP; RNA polymerase; Mycobacterium DNA-directed RNA polymerase
T30938	FUNCTION	DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates.
T30938	SEQUENCE	MLISQRPTLSEDVLTDNRSQFVIEPLEPGFGYTLGNSLRRTLLSSIPGAAVTSIRIDGVLHEFTTVPGVKEDVTEIILNLKSLVVSSEEDEPVTMYLRKQGPGEVTAGDIVPPAGVTVHNPGMHIATLNDKGKLEVELVVERGRGYVPAVQNRASGAEIGRIPVDSIYSPVLKVTYKVDATRVEQRTDFDKLILDVETKNSISPRDALASAGKTLVELFGLARELNVEAEGIEIGPSPAEADHIASFALPIDDLDLTVRSYNCLKREGVHTVGELVARTESDLLDIRNFGQKSIDEVKIKLHQLGLSLKDSPPSFDPSEVAGYDVATGTWSTEGAYDEQDYAETEQL
T30938	DRUGINFO	D0FX2Q	Rifamycin	Approved
T30938	DRUGINFO	D0Y4LX	Favipiravir	Registered
T30938	DRUGINFO	D0OR5P	TAS-106	Phase 2
T30938	DRUGINFO	D00TQN	JTK-003	Discontinued in Phase 2
T30938	DRUGINFO	D01ZJM	R-1479	Discontinued in Phase 1
T30938	DRUGINFO	D0S5AL	XTL-2125	Discontinued in Phase 1

T57680	TARGETID	T57680
T57680	FORMERID	TTDR00186
T57680	UNIPROID	GCYA1_HUMAN; GCYB1_HUMAN
T57680	TARGNAME	Soluble guanylate cyclase (GCS)
T57680	GENENAME	GUCY1A1; GUCY1B1
T57680	TARGTYPE	Successful
T57680	SYNONYMS	GUCY1; GUCS; GUC1; GCS
T57680	FUNCTION	Probably plays a specific functional role in the rods and/or cones of photoreceptors. It may be the enzyme involved in the resynthesis of cGMP required for recovery of the dark state after phototransduction.
T57680	BIOCLASS	Phosphorus-oxygen lyase
T57680	SEQUENCE	MFCTKLKDLKITGECPFSLLAPGQVPNESSEEAAGSSESCKATVPICQDIPEKNIQESLPQRKTSRSRVYLHTLAESICKLIFPEFERLNVALQRTLAKHKIKESRKSLEREDFEKTIAEQAVAAGVPVEVIKESLGEEVFKICYEEDENILGVVGGTLKDFLNSFSTLLKQSSHCQEAGKRGRLEDASILCLDKEDDFLHVYYFFPKRTTSLILPGIIKAAAHVLYETEVEVSLMPPCFHNDCSEFVNQPYLLYSVHMKSTKPSLSPSKPQSSLVIPTSLFCKTFPFHFMFDKDMTILQFGNGIRRLMNRRDFQGKPNFEEYFEILTPKINQTFSGIMTMLNMQFVVRVRRWDNSVKKSSRVMDLKGQMIYIVESSAILFLGSPCVDRLEDFTGRGLYLSDIPIHNALRDVVLIGEQARAQDGLKKRLGKLKATLEQAHQALEEEKKKTVDLLCSIFPCEVAQQLWQGQVVQAKKFSNVTMLFSDIVGFTAICSQCSPLQVITMLNALYTRFDQQCGELDVYKVETIGDAYCVAGGLHKESDTHAVQIALMALKMMELSDEVMSPHGEPIKMRIGLHSGSVFAGVVGVKMPRYCLFGNNVTLANKFESCSVPRKINVSPTTYRLLKDCPGFVFTPRSREELPPNFPSEIPGICHFLDAYQQGTNSKPCFQKKDVEDGNANFLGKASGID
T57680	DRUGINFO	D07XVR	Sodium nitroprusside	Approved
T57680	DRUGINFO	D07YDE	Nitroglycerin	Approved
T57680	DRUGINFO	D0A5FM	Nitric Oxide	Approved
T57680	DRUGINFO	D04EMB	IW-1973	Phase 2
T57680	DRUGINFO	D2RG4D	Runcaciguat	Phase 2
T57680	DRUGINFO	DVCB87	MK-5475	Phase 2
T57680	DRUGINFO	DW5UI2	CTI-1601	Phase 2
T57680	DRUGINFO	DO37EF	CY6463	Phase 2
T57680	DRUGINFO	DO37EF	CY6463	Phase 2
T57680	DRUGINFO	D00REK	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	Investigative

T74363	TARGETID	T74363
T74363	FORMERID	TTDR00369
T74363	UNIPROID	UPAR_HUMAN
T74363	TARGNAME	Urokinase plasminogen activator surface receptor (PLAUR)
T74363	GENENAME	PLAUR
T74363	TARGTYPE	Successful
T74363	SYNONYMS	Urokinase-type plasminogen activator receptor; Urokinase plasminogen activator receptor; Monocyte activation antigenMo3; CD87 antigen; CD87
T74363	FUNCTION	Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form. Acts as a receptor for urokinase plasminogen activator.
T74363	PDBSTRUC	4QTI; 4K24; 3U74; 3U73; 3BT2
T74363	SEQUENCE	MGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEELELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISCGSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNGFHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGPMNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDVQYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT
T74363	DRUGINFO	D04LKS	Ruxolitinib	Approved

T28661	TARGETID	T28661
T28661	FORMERID	TTDS00389
T28661	UNIPROID	TBB2A_HUMAN
T28661	TARGNAME	Tubulin beta-2 chain (TUBB2)
T28661	GENENAME	TUBB2A
T28661	TARGTYPE	Successful
T28661	SYNONYMS	Tubulin beta-2A chain; Tubulin beta class IIa; TUBB4B; BetaII-Tubulin; Beta(II)-Tubulin; Beta(II) isotype of Tubulin
T28661	FUNCTION	It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain. Tubulin is the major constituent of microtubules.
T28661	SEQUENCE	MREIVHIQAGQCGNQIGAKFWEVISDEHGIDPTGSYHGDSDLQLERINVYYNEAAGNKYVPRAILVDLEPGTMDSVRSGPFGQIFRPDNFVFGQSGAGNNWAKGHYTEGAELVDSVLDVVRKESESCDCLQGFQLTHSLGGGTGSGMGTLLISKIREEYPDRIMNTFSVMPSPKVSDTVVEPYNATLSVHQLVENTDETYSIDNEALYDICFRTLKLTTPTYGDLNHLVSATMSGVTTCLRFPGQLNADLRKLAVNMVPFPRLHFFMPGFAPLTSRGSQQYRALTVPELTQQMFDSKNMMAACDPRHGRYLTVAAIFRGRMSMKEVDEQMLNVQNKNSSYFVEWIPNNVKTAVCDIPPRGLKMSATFIGNSTAIQELFKRISEQFTAMFRRKAFLHWYTGEGMDEMEFTEAESNMNDLVSEYQQYQDATADEQGEFEEEEGEDEA
T28661	DRUGINFO	D0W9MM	Vinblastine	Approved
T28661	DRUGINFO	D0PF3J	DOLASTATIN-10	Phase 2
T28661	DRUGINFO	D02XKD	3-bromo-4,4',5-trimethoxy-(Z)-stilbene	Investigative
T28661	DRUGINFO	D03CYV	6-ile-ustiloxin	Investigative
T28661	DRUGINFO	D03NTD	3,4',5-trimethoxy-(Z)-stilbene	Investigative
T28661	DRUGINFO	D07UWD	Ustiloxin D	Investigative
T28661	DRUGINFO	D0C6EW	Ustiloxin F	Investigative
T28661	DRUGINFO	D0LH3S	3,4,4',5-tetramethoxy-(Z)-stilbene	Investigative
T28661	DRUGINFO	D0OW6Q	2,3'-diamino-3,4,4',5-tetramethoxy-(Z)-stillbene	Investigative
T28661	DRUGINFO	D0S6FK	USTILOXIN A	Investigative
T28661	DRUGINFO	D0VH8A	N-(4-(3-(pyridin-2-yl)acryloyl)phenyl)acetamide	Investigative
T28661	DRUGINFO	D0W5RQ	2'-amino-3,4,4',5-tetramethoxy-(Z)-stillbene	Investigative
T28661	DRUGINFO	D0X9OV	2-amino-3,4',5-trimethoxy-(Z)-stillbene	Investigative

T82624	TARGETID	T82624
T82624	FORMERID	TTDS00502
T82624	UNIPROID	ITPR1_HUMAN; ITPR2_HUMAN; ITPR3_HUMAN
T82624	TARGNAME	Inositol 1,4,5-trisphosphate receptor (ITPR)
T82624	GENENAME	ITPR1; ITPR2; ITPR3
T82624	TARGTYPE	Successful
T82624	SYNONYMS	InsP3R; InsP3 receptor; IP3R; IP3 receptor
T82624	FUNCTION	Intracellular channel that mediates calcium release from the endoplasmic reticulum following stimulation by inositol 1,4,5-trisphosphate.
T82624	SEQUENCE	MSDKMSSFLHIGDICSLYAEGSTNGFISTLGLVDDRCVVQPETGDLNNPPKKFRDCLFKLCPMNRYSAQKQFWKAAKPGANSTTDAVLLNKLHHAADLEKKQNETENRKLLGTVIQYGNVIQLLHLKSNKYLTVNKRLPALLEKNAMRVTLDEAGNEGSWFYIQPFYKLRSIGDSVVIGDKVVLNPVNAGQPLHASSHQLVDNPGCNEVNSVNCNTSWKIVLFMKWSDNKDDILKGGDVVRLFHAEQEKFLTCDEHRKKQHVFLRTTGRQSATSATSSKALWEVEVVQHDPCRGGAGYWNSLFRFKHLATGHYLAAEVDPDFEEECLEFQPSVDPDQDASRSRLRNAQEKMVYSLVSVPEGNDISSIFELDPTTLRGGDSLVPRNSYVRLRHLCTNTWVHSTNIPIDKEEEKPVMLKIGTSPVKEDKEAFAIVPVSPAEVRDLDFANDASKVLGSIAGKLEKGTITQNERRSVTKLLEDLVYFVTGGTNSGQDVLEVVFSKPNRERQKLMREQNILKQIFKLLQAPFTDCGDGPMLRLEELGDQRHAPFRHICRLCYRVLRHSQQDYRKNQEYIAKQFGFMQKQIGYDVLAEDTITALLHNNRKLLEKHITAAEIDTFVSLVRKNREPRFLDYLSDLCVSMNKSIPVTQELICKAVLNPTNADILIETKLVLSRFEFEGVSSTGENALEAGEDEEEVWLFWRDSNKEIRSKSVRELAQDAKEGQKEDRDVLSYYRYQLNLFARMCLDRQYLAINEISGQLDVDLILRCMSDENLPYDLRASFCRLMLHMHVDRDPQEQVTPVKYARLWSEIPSEIAIDDYDSSGASKDEIKERFAQTMEFVEEYLRDVVCQRFPFSDKEKNKLTFEVVNLARNLIYFGFYNFSDLLRLTKILLAILDCVHVTTIFPISKMAKGEENKGNNDVEKLKSSNVMRSIHGVGELMTQVVLRGGGFLPMTPMAAAPEGNVKQAEPEKEDIMVMDTKLKIIEILQFILNVRLDYRISCLLCIFKREFDESNSQTSETSSGNSSQEGPSNVPGALDFEHIEEQAEGIFGGSEENTPLDLDDHGGRTFLRVLLHLTMHDYPPLVSGALQLLFRHFSQRQEVLQAFKQVQLLVTSQDVDNYKQIKQDLDQLRSIVEKSELWVYKGQGPDETMDGASGENEHKKTEEGNNKPQKHESTSSYNYRVVKEILIRLSKLCVQESASVRKSRKQQQRLLRNMGAHAVVLELLQIPYEKAEDTKMQEIMRLAHEFLQNFCAGNQQNQALLHKHINLFLNPGILEAVTMQHIFMNNFQLCSEINERVVQHFVHCIETHGRNVQYIKFLQTIVKAEGKFIKKCQDMVMAELVNSGEDVLVFYNDRASFQTLIQMMRSERDRMDENSPLMYHIHLVELLAVCTEGKNVYTEIKCNSLLPLDDIVRVVTHEDCIPEVKIAYINFLNHCYVDTEVEMKEIYTSNHMWKLFENFLVDICRACNNTSDRKHADSILEKYVTEIVMSIVTTFFSSPFSDQSTTLQTRQPVFVQLLQGVFRVYHCNWLMPSQKASVESCIRVLSDVAKSRAIAIPVDLDSQVNNLFLKSHSIVQKTAMNWRLSARNAARRDSVLAASRDYRNIIERLQDIVSALEDRLRPLVQAELSVLVDVLHRPELLFPENTDARRKCESGGFICKLIKHTKQLLEENEEKLCIKVLQTLREMMTKDRGYGEKLISIDELDNAELPPAPDSENATEELEPSPPLRQLEDHKRGEALRQVLVNRYYGNVRPSGRRESLTSFGNGPLSAGGPGKPGGGGGGSGSSSMSRGEMSLAEVQCHLDKEGASNLVIDLIMNASSDRVFHESILLAIALLEGGNTTIQHSFFCRLTEDKKSEKFFKVFYDRMKVAQQEIKATVTVNTSDLGNKKKDDEVDRDAPSRKKAKEPTTQITEEVRDQLLEASAATRKAFTTFRREADPDDHYQPGEGTQATADKAKDDLEMSAVITIMQPILRFLQLLCENHNRDLQNFLRCQNNKTNYNLVCETLQFLDCICGSTTGGLGLLGLYINEKNVALINQTLESLTEYCQGPCHENQNCIATHESNGIDIITALILNDINPLGKKRMDLVLELKNNASKLLLAIMESRHDSENAERILYNMRPKELVEVIKKAYMQGEVEFEDGENGEDGAASPRNVGHNIYILAHQLARHNKELQSMLKPGGQVDGDEALEFYAKHTAQIEIVRLDRTMEQIVFPVPSICEFLTKESKLRIYYTTERDEQGSKINDFFLRSEDLFNEMNWQKKLRAQPVLYWCARNMSFWSSISFNLAVLMNLLVAFFYPFKGVRGGTLEPHWSGLLWTAMLISLAIVIALPKPHGIRALIASTILRLIFSVGLQPTLFLLGAFNVCNKIIFLMSFVGNCGTFTRGYRAMVLDVEFLYHLLYLVICAMGLFVHEFFYSLLLFDLVYREETLLNVIKSVTRNGRSIILTAVLALILVYLFSIVGYLFFKDDFILEVDRLPNETAVPETGESLASEFLFSDVCRVESGENCSSPAPREELVPAEETEQDKEHTCETLLMCIVTVLSHGLRSGGGVGDVLRKPSKEEPLFAARVIYDLLFFFMVIIIVLNLIFGVIIDTFADLRSEKQKKEEILKTTCFICGLERDKFDNKTVTFEEHIKEEHNMWHYLCFIVLVKVKDSTEYTGPESYVAEMIKERNLDWFPRMRAMSLVSSDSEGEQNELRNLQEKLESTMKLVTNLSGQLSELKDQMTEQRKQKQRIGLLGHPPHMNVNPQQPA
T82624	DRUGINFO	D00PLV	Nitroprusside	Approved
T82624	DRUGINFO	D0A0RR	ADENOPHOSTIN A	Investigative
T82624	DRUGINFO	D0G5CI	5'-Deoxy-5'-phenyladenophostin A	Investigative
T82624	DRUGINFO	D0MR1K	D-myo-inositol 1,4,5-trisphosphate	Investigative

T92078	TARGETID	T92078
T92078	FORMERID	TTDI01962
T92078	UNIPROID	DPYL2_HUMAN
T92078	TARGNAME	Dihydropyrimidinase related protein 2 (DPYSL2)
T92078	GENENAME	DPYSL2
T92078	TARGTYPE	Successful
T92078	SYNONYMS	Unc33like phosphoprotein 2; Unc-33-like phosphoprotein 2; ULIP2; ULIP-2; N2A3; Dihydropyrimidinaserelated protein 2; Dihydropyrimidinase-related protein 2; DRP2; DRP-2; Collapsin response mediator protein 2; CRMP2; CRMP-2
T92078	FUNCTION	Necessary for signaling by class 3 semaphorins and subsequent remodeling of the cytoskeleton. May play a role in endocytosis. Plays a role in neuronal development and polarity, as well as in axon growth and guidance, neuronal growth cone collapse and cell migration.
T92078	PDBSTRUC	5YZB; 5YZA; 5YZ5; 5X1D; 5X1C
T92078	SEQUENCE	MSYQGKKNIPRITSDRLLIKGGKIVNDDQSFYADIYMEDGLIKQIGENLIVPGGVKTIEAHSRMVIPGGIDVHTRFQMPDQGMTSADDFFQGTKAALAGGTTMIIDHVVPEPGTSLLAAFDQWREWADSKSCCDYSLHVDISEWHKGIQEEMEALVKDHGVNSFLVYMAFKDRFQLTDCQIYEVLSVIRDIGAIAQVHAENGDIIAEEQQRILDLGITGPEGHVLSRPEEVEAEAVNRAITIANQTNCPLYITKVMSKSSAEVIAQARKKGTVVYGEPITASLGTDGSHYWSKNWAKAAAFVTSPPLSPDPTTPDFLNSLLSCGDLQVTGSAHCTFNTAQKAVGKDNFTLIPEGTNGTEERMSVIWDKAVVTGKMDENQFVAVTSTNAAKVFNLYPRKGRIAVGSDADLVIWDPDSVKTISAKTHNSSLEYNIFEGMECRGSPLVVISQGKIVLEDGTLHVTEGSGRYIPRKPFPDFVYKRIKARSRLAELRGVPRGLYDGPVCEVSVTPKTVTPASSAKTSPAKQQAPPVRNLHQSGFSLSGAQIDDNIPRRTTQRIVAPPGGRANITSLG
T92078	DRUGINFO	D05OFX	Lacosamide	Approved

T16047	TARGETID	T16047
T16047	FORMERID	TTDS00120
T16047	UNIPROID	Q25634_ONCVO
T16047	TARGNAME	Onchocerca Glutamate-gated chloride channel (Onchoc GluCl)
T16047	GENENAME	Onchoc GluCl
T16047	TARGTYPE	Successful
T16047	SYNONYMS	Glutamate-gated chloride channel
T16047	FUNCTION	As postsynaptic receptors within the crustacean stomatogastric ganglion.
T16047	BIOCLASS	Ion transport
T16047	SEQUENCE	MNSFPIVCWNLAFLILVVAKKKLKEQEIIQRTLKDYDWRVRPRGNNLSWPDTGGPVLVSVNIYLRSISKIDDVNMEYSAQFTFREEWNDARLGYERLADENTQVPPFVVLAASEQPDLTQQIWMPDTFFQNEKEARRHLIDKPNVLIRIHPDGQILYSVRLSLVLSCPMSLEYYPLDRQTCLIDLASYAYTTDDIKYEWKVKNPIQQKEGLRQSLPSFELQDVLTEYCTSKTNTGEYSCARVLLLLRREYRFSYYLIQLYIPCIMLVVVSWVSFWLDKDAVPARVSLGVTTLLTMTTQASGINAKLPPVSYIKAVDVWIGVCLAFIFGALLEYALVNYHGRQEFLKKEKKK
T16047	DRUGINFO	D09YHJ	Ivermectin	Approved
T16047	DRUGINFO	D05AWP	Moxidectin 	Approved

T08735	TARGETID	T08735
T08735	FORMERID	TTDS00505
T08735	UNIPROID	M2DH_ASPFU
T08735	TARGNAME	Aspergillus Mannitol 2-dehydrogenase (Asperg M2DH)
T08735	GENENAME	Asperg M2DH
T08735	TARGTYPE	Successful
T08735	SYNONYMS	MDH; M2DH
T08735	FUNCTION	Catalyzes the NAD(H)-dependent interconversion of D- fructose and D-mannitol in the mannitol metabolic pathway. Has a preference for NADH over NADPH.
T08735	BIOCLASS	Short-chain dehydrogenases reductase
T08735	SEQUENCE	MAPLKLNSRNLSQIAAAGGALVKIPTYQRGRAVKEGIVHIGVGGFHRAHLAVYIDQLMQKHGVNDYAICGVGLQPFDSAMRDALASQDHLYTLIERSAKGSFAHVIGSINSYLFAPDNREAVIAKMAHPDTKIVSLTITESGYYYNENTHELQSEHPDIQFDLDPANEKAPRTTFGFLYAGLTRRYQQGLKPFTVMSCDNMQKNGSITRHMLESFARLRNPEVAEWIAEEGAFPNAMVDRITPQTSETDKTALAEKFGIVDSWPVVTEPFTQWVIEDQFSDGRPPFEKVGVQVVKDVHAVEQFEKHKLRLLNGSHSALGYPGQLAGFQYVHEVMANPLFRKFVWQMMQEEVKPLLPEIPGVDIDEYCNTLIERFTNPTIMDQLPRICLNASGKIPQFIMPSIAEAIWETGPFRRLCFVAAAWFHYIKGVDDRGKPFEVVDPMREELQAKARAGGNDPSELLSIKSLFGDDLRNDERFLREITTAMNDIARDGIMKTLPKYIN
T08735	DRUGINFO	D0P7EK	Mannitol	Approved

T05089	TARGETID	T05089
T05089	FORMERID	TTDNS00606
T05089	UNIPROID	ANO1_HUMAN
T05089	TARGNAME	Calcium-dependent chloride channel anoctamin (ANO)
T05089	GENENAME	ANO1
T05089	TARGTYPE	Successful
T05089	SYNONYMS	Tumoramplified and overexpressed sequence 2; Tumor-amplified and overexpressed sequence 2; Transmembrane protein 16A; TMEM16A; TAOS2; Oral cancer overexpressed protein 2; ORAOV2; Discovered on gastrointestinal stromal tumors protein 1; DOG1; Anoctamin1; Anoctamin-1
T05089	FUNCTION	Required for the normal functioning of the interstitial cells of Cajal (ICCs) which generate electrical pacemaker activity in gastrointestinal smooth muscles. Acts as a major contributor to basal and stimulated chloride conductance in airway epithelial cells and plays an important role in tracheal cartilage development. Calcium-activated chloride channel (CaCC) which plays a role in transepithelial anion transport and smooth muscle contraction.
T05089	SEQUENCE	MRVNEKYSTLPAEDRSVHIINICAIEDIGYLPSEGTLLNSLSVDPDAECKYGLYFRDGRRKVDYILVYHHKRPSGNRTLVRRVQHSDTPSGARSVKQDHPLPGKGASLDAGSGEPPMDYHEDDKRFRREEYEGNLLEAGLELERDEDTKIHGVGFVKIHAPWNVLCREAEFLKLKMPTKKMYHINETRGLLKKINSVLQKITDPIQPKVAEHRPQTMKRLSYPFSREKQHLFDLSDKDSFFDSKTRSTIVYEILKRTTCTKAKYSMGITSLLANGVYAAAYPLHDGDYNGENVEFNDRKLLYEEWARYGVFYKYQPIDLVRKYFGEKIGLYFAWLGVYTQMLIPASIVGIIVFLYGCATMDENIPSMEMCDQRHNITMCPLCDKTCSYWKMSSACATARASHLFDNPATVFFSVFMALWAATFMEHWKRKQMRLNYRWDLTGFEEEEEAVKDHPRAEYEARVLEKSLKKESRNKEKRRHIPEESTNKWKQRVKTAMAGVKLTDKVKLTWRDRFPAYLTNLVSIIFMIAVTFAIVLGVIIYRISMAAALAMNSSPSVRSNIRVTVTATAVIINLVVIILLDEVYGCIARWLTKIEVPKTEKSFEERLIFKAFLLKFVNSYTPIFYVAFFKGRFVGRPGDYVYIFRSFRMEECAPGGCLMELCIQLSIIMLGKQLIQNNLFEIGIPKMKKLIRYLKLKQQSPPDHEECVKRKQRYEVDYNLEPFAGLTPEYMEMIIQFGFVTLFVASFPLAPLFALLNNIIEIRLDAKKFVTELRRPVAVRAKDIGIWYNILRGIGKLAVIINAFVISFTSDFIPRLVYLYMYSKNGTMHGFVNHTLSSFNVSDFQNGTAPNDPLDLGYEVQICRYKDYREPPWSENKYDISKDFWAVLAARLAFVIVFQNLVMFMSDFVDWVIPDIPKDISQQIHKEKVLMVELFMREEQDKQQLLETWMEKERQKDEPPCNHHNTKACPDSLGSPAPSHAYHGGVL
T05089	DRUGINFO	D09VXM	Crofelemer	Approved
T05089	DRUGINFO	D0Z3DY	Benzbromarone	Approved
T05089	DRUGINFO	D02DAJ	DCDPC	Investigative
T05089	DRUGINFO	D0R4WJ	tannic acid	Investigative
T05089	DRUGINFO	D0W1GH	Ins(3,4,5,6)P4	Investigative
T05089	DRUGINFO	D0A2UX	SITS	Investigative
T05089	DRUGINFO	D0O6KR	9-anthroic acid	Investigative
T05089	DRUGINFO	D08DQL	NPPB	Investigative
T05089	DRUGINFO	D0PW7B	DIDS	Investigative

T96914	TARGETID	T96914
T96914	FORMERID	TTDR00076
T96914	UNIPROID	Q8I0X3_PLAF7
T96914	TARGNAME	Plasmodium DNA gyrase (Malaria gyrase)
T96914	GENENAME	Malaria gyrase
T96914	TARGTYPE	Successful
T96914	SYNONYMS	Malaria DNA gyrase subunit A
T96914	FUNCTION	Essential for replication and transcription in prokaryotes. Catalyses ATP-dependent DNA supercoiling activity.
T96914	ECNUMBER	EC 5.99.1.3
T96914	SEQUENCE	MSFKFSIVFVLYLLFLLKFNKRFIFLKSEKITSYINTQIPNYSSSPPFFLKKEAKNNIKKCYFIKREGYRNIGTKNASNAFVLNFKSNRSTYTDNAFSCTSLCSEKKERKKVQDPYDLKAKKKEKTYELNDIKNNEKKKDDIVNASNDITNDKLDNINNNINESRKLIKGEYYDVEICEILSKSFLSYANFLILNRCLCDYRDGLKTVQRRIIWSMYEINKGIDKKGYKKCARIVGEVIGKYHPHGDKSVYDALVRLAQKHHNNNLLIKGYGNFGSVEYNAAAMRYTEAKISSFCYDILLDEINDENVEYIKNFDGNEREPKVLCSKIPLLLINGCSGIAVSILSSIPCHNLIDVANCCINFLINENIRDDELFHIIKGPDFSTGGIIISKYDILKNIYNSGKGNFEIRSNVFFEYIKNDKKVITKHINDLSSIENSDIDKLTKKIIIKNLPPNVKPNELIENIINLLNDKKNEHDNILLRIRDESEKEDMRIVLELKKHSQIEQIHNFLSYLFKYTNMQISYHCNFVCIGYENTYTQFSLKSFIKLWCNNRIKFIKTNYEIKNKNLQKQLNIIDLYLIIQNKILDIITFFQKNQNIEQIQLYLKNNFKLNPEQIKYILSIKLQKLINIKNIDFISQRNKIMHQIKLNDEIINNVQNIKNLIIQELIYIKNKYGIHNLNKQCIIPSTPKYKYSYINSEYHPNFSKNKQIIDTYNTVSTNDNNINHSNYTHDLPNTDNVTKDKNVVETNVHKNIHISSDISNNIKNSDKNSSLTKNQDSDNMMPYRNTYIDSLDNNMKDIYNNDEVLILITYGGYIKKIKINEKLKNHSNNIIKLSNVKYILKENEEKLNENNKRLKFNDLQKGNEQEKYKDNEQKLNNDIGHNINIQNNNNDNNNNNNDNNNVLLLNEEEYNSYKIKKSILVRNRDKILLTDNYNKAFLLNVYDLHLSSYDSKGTPINQIIHSSKNITGITKFQENKKYLIVCSENGKMKVINNDVFLKRKKKGIKLFKNKKNIYFSYCNFNDNCIVGTKNGYIIQFPLSSFKISKKNSLGNKCISLAKNDKVVDLLSYENNEKNLKNYKIIFVTKNGFGKMINLNELKIQKKKGKGHRIMKFKKSKTRKDNKKDIEKKQINAINNKDKDKDIPSNNDDNNILHNTKVDEFLGFKLYDMNKQNEKDILIMITDHAVLIRKNMSLLKEKNKKHSSQIYAKMNKINQLVYFDII
T96914	DRUGINFO	D04XDT	Delafloxacin Meglumine	Approved

T30653	TARGETID	T30653
T30653	FORMERID	TTDS00133
T30653	UNIPROID	PCAT1_HUMAN; PCAT2_HUMAN
T30653	TARGNAME	Acetyl-CoA:lyso-PAF acetyltransferase (PCAT)
T30653	GENENAME	LPCAT1; LPCAT2
T30653	TARGTYPE	Successful
T30653	SYNONYMS	Lysophosphatidylcholine acyltransferase; LysoPC acyltransferase; LysoPAFAT; Lyso-PAF acetyltransferase; LPCAT; LPC acyltransferase; Acyltransferase-like; Acetyl-CoA:lyso-platelet-activating factor acetyltransferase; AYTL; 1-alkylglycerophosphocholine O-acetyltransferase; 1-acylglycerophosphocholine O-acyltransferase
T30653	FUNCTION	Possesses both acyltransferase and acetyltransferase activities.  Mediates the conversion of 1-acyl-sn-glycero-3-phosphocholine (LPC) into phosphatidylcholine (PC), a major component of cell membranes and a PAF precursor. 
T30653	SEQUENCE	MRLRGCGPRAAPASSAGASDARLLAPPGRNPFVHELRLSALQKAQVALMTLTLFPVRLLVAAAMMLLAWPLALVASLGSAEKEPEQPPALWRKVVDFLLKAIMRTMWFAGGFHRVAVKGRQALPTEAAILTLAPHSSYFDAIPVTMTMSSIVMKAESRDIPIWGTLIQYIRPVFVSRSDQDSRRKTVEEIKRRAQSNGKWPQIMIFPEGTCTNRTCLITFKPGAFIPGAPVQPVVLRYPNKLDTITWTWQGPGALEILWLTLCQFHNQVEIEFLPVYSPSEEEKRNPALYASNVRRVMAEALGVSVTDYTFEDCQLALAEGQLRLPADTCLLEFARLVRGLGLKPEKLEKDLDRYSERARMKGGEKIGIAEFAASLEVPVSDLLEDMFSLFDESGSGEVDLRECVVALSVVCRPARTLDTIQLAFKMYGAQEDGSVGEGDLSCILKTALGVAELTVTDLFRAIDQEEKGKITFADFHRFAEMYPAFAEEYLYPDQTHFESCAETSPAPIPNGFCADFSPENSDAGRKPVRKKLD
T30653	DRUGINFO	D0K8KX	Quercetin	Approved
T30653	DRUGINFO	D04AIT	B-Lactams	Approved

T78173	TARGETID	T78173
T78173	UNIPROID	ERG1_CANAL
T78173	TARGNAME	Candida Squalene epoxidase (Candi ERG1)
T78173	GENENAME	Candi ERG1
T78173	TARGTYPE	Successful
T78173	SYNONYMS	Candi Squalene monooxygenase; Candi Squalene epoxidase; Candi SE
T78173	FUNCTION	Catalyzes the stereospecific oxidation of squalene to (S)-2,3-epoxysqualene, and is considered to be a rate-limiting enzyme in steroid biosynthesis.
T78173	SEQUENCE	MSSVKYDAIIIGAGVIGPTIATAFARQGRKVLIVERDWSKPDRIVGELMQPAGIKALRELGMIKAINNIRAVDCTGYYIKYYDETITIPYPLKKDACITNPVKPVPDAVDGVNDKLDSDSTLNVDDWDFDERVRGAAFHHGDFLMNLRQICRDEPNVTAVEATVTKILRDPSDPNTVIGVQTKQPSGTVDYHAKLTISCDGIYSKFRKELSPTNVPTIGSYFIGLYLKNAELPAKGKGHVLLGGHAPALIYSVSPTETRVLCVYVSSKPPSAANDAVYKYLRDNILPAIPKETVPAFKEALEERKFRIMPNQYLSAMKQGSENHKGFILLGDSLNMRHPLTGGGMTVGLNDSVLLAKLLHPKFVEDFDDHQLIAKRLKTFHRKRKNLDAVINTLSISLYSLFAADKKPLRILRNGCFKYFQRGGECVNGPIGLLSGMLPFPMLLFNHFFSVAFYSVYLNFIERGLLGFPLALFEAFEVLFTAIVIFTPYLWNEIVR
T78173	DRUGINFO	D01AYJ	Terbinafine	Approved
T78173	DRUGINFO	D0B4DC	Butenafine	Approved

T08378	TARGETID	T08378
T08378	FORMERID	TTDS00513
T08378	UNIPROID	S23A2_HUMAN
T08378	TARGNAME	Solute carrier family 23 member 2 (SLC23A2)
T08378	GENENAME	SLC23A2
T08378	TARGTYPE	Successful
T08378	SYNONYMS	hSVCT2; Yolksac permease-like molecule 2; YSPL2; SVCT2; SLC23A2; Nucleobase transporter-like 1 protein; Na(+)/L-ascorbic acid transporter 2; NBTL1; KIAA0238
T08378	FUNCTION	Sodium/ascorbate cotransporter. Mediates electrogenic uptake of vitamin C, with a stoichiometry of 2 Na(+) for each ascorbate.
T08378	BIOCLASS	Nucleobase ascorbate transporter
T08378	SEQUENCE	MMGIGKNTTSKSMEAGSSTEGKYEDEAKHPAFFTLPVVINGGATSSGEQDNEDTELMAIYTTENGIAEKSSLAETLDSTGSLDPQRSDMIYTIEDVPPWYLCIFLGLQHYLTCFSGTIAVPFLLADAMCVGYDQWATSQLIGTIFFCVGITTLLQTTFGCRLPLFQASAFAFLAPARAILSLDKWKCNTTDVSVANGTAELLHTEHIWYPRIREIQGAIIMSSLIEVVIGLLGLPGALLKYIGPLTITPTVALIGLSGFQAAGERAGKHWGIAMLTIFLVLLFSQYARNVKFPLPIYKSKKGWTAYKLQLFKMFPIILAILVSWLLCFIFTVTDVFPPDSTKYGFYARTDARQGVLLVAPWFKVPYPFQWGLPTVSAAGVIGMLSAVVASIIESIGDYYACARLSCAPPPPIHAINRGIFVEGLSCVLDGIFGTGNGSTSSSPNIGVLGITKVGSRRVIQCGAALMLALGMIGKFSALFASLPDPVLGALFCTLFGMITAVGLSNLQFIDLNSSRNLFVLGFSIFFGLVLPSYLRQNPLVTGITGIDQVLNVLLTTAMFVGGCVAFILDNTIPGTPEERGIRKWKKGVGKGNKSLDGMESYNLPFGMNIIKKYRCFSYLPISPTFVGYTWKGLRKSDNSRSSDEDSQATG
T08378	DRUGINFO	D0G3SH	Ursodeoxycholic acid	Approved
T08378	DRUGINFO	D07AHW	Vitamin C	Approved

T54055	TARGETID	T54055
T54055	FORMERID	TTDI01989
T54055	UNIPROID	LYVE1_HUMAN
T54055	TARGNAME	Hyaluronic acid receptor (LYVE1)
T54055	GENENAME	LYVE1
T54055	TARGTYPE	Successful
T54055	SYNONYMS	Lymphatic vessel endothelial hyaluronic acid receptor 1; LYVE1; Extracellular link domaincontaining protein 1; Cell surface retention sequencebindingprotein 1; CRSBP1
T54055	FUNCTION	Ligand-specific transporter trafficking between intracellular organelles (TGN) and the plasma membrane. Plays a role in autocrine regulation of cell growth mediated by growth regulators containing cell surface retention sequence binding (CRS). May act as a hyaluronan (HA) transporter, either mediating its uptake for catabolism within lymphatic endothelial cells themselves, or its transport into the lumen of afferent lymphatic vessels for subsequent re-uptake and degradation in lymph nodes.
T54055	SEQUENCE	MARCFSLVLLLTSIWTTRLLVQGSLRAEELSIQVSCRIMGITLVSKKANQQLNFTEAKEACRLLGLSLAGKDQVETALKASFETCSYGWVGDGFVVISRISPNPKCGKNGVGVLIWKVPVSRQFAAYCYNSSDTWTNSCIPEIITTKDPIFNTQTATQTTEFIVSDSTYSVASPYSTIPAPTTTPPAPASTSIPRRKKLICVTEVFMETSTMSTETEPFVENKAAFKNEAAGFGGVPTALLVLALLFFGAAAGLGFCYVKRYVKAFPFTNKNQQKEMIETKVVKEEKANDSNPNEESKKTDKNPEESKSPSKTTVRCLEAEV
T54055	DRUGINFO	D07BSE	Hyaluronate sodium	Approved
T54055	DRUGINFO	D0DC1I	RG-7356	Discontinued in Phase 1

T07035	TARGETID	T07035
T07035	FORMERID	TTDS00526
T07035	UNIPROID	VIE2_HCMVA
T07035	TARGNAME	Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA)
T07035	GENENAME	CMV IE2 mRNA
T07035	TARGTYPE	Successful
T07035	SYNONYMS	Viral transcription factor IE2 (mRNA); UL122 (mRNA); Protein UL122 (mRNA); IE2 (mRNA)
T07035	FUNCTION	Stimulates viral early and late gene expression and thus play a crucial role in the regulation of productive infection. In addition, activates quiescent cells to reenter the cell cycle and upregulates several E2F-responsive genes, which are responsible for pushing the cell into S phase. In S-phase, inhibits cellular DNA synthesis and blocks further cell cycle progression.
T07035	BIOCLASS	mRNA target
T07035	SEQUENCE	MESSAKRKMDPDNPDEGPSSKVPRPETPVTKATTFLQTMLRKEVNSQLSLGDPLFPELAEESLKTFEQVTEDCNENPEKDVLAELGDILAQAVNHAGIDSSSTGPTLTTHSCSVSSAPLNKPTPTSVAVTNTPLPGASATPELSPRKKPRKTTRPFKVIIKPPVPPAPIMLPLIKQEDIKPEPDFTIQYRNKIIDTAGCIVISDSEEEQGEEVETRGATASSPSTGSGTPRVTSPTHPLSQMNHPPLPDPLGRPDEDSSSSSSSSCSSASDSESESEEMKCSSGGGASVTSSHHGRGGFGGAASSSLLSCGHQSSGGASTGPRKKKSKRISELDNEKVRNIMKDKNTPFCTPNVQTRRGRVKIDEVSRMFRNTNRSLEYKNLPFTIPSMHQVLDEAIKACKTMQVNNKGIQIIYTRNHEVKSEVDAVRCRLGTMCNLALSTPFLMEHTMPVTHPPEVAQRTADACNEGVKAAWSLKELHTHQLCPRSSDYRNMIIHAATPVDLLGALNLCLPLMQKFPKQVMVRIFSTNQGGFMLPIYETAAKAYAVGQFEQPTETPPEDLDTLSLAIEAAIQDLRNKSQ
T07035	DRUGINFO	D0ID4Z	Fomivirsen sodium	Approved
T07035	DRUGINFO	D00XFY	ISIS 2922 + foscarnet 3' -azido-3'-deoxythymidine 2'-3'-dideoxycytidine	Investigative
T07035	DRUGINFO	D01LAP	ISIS 2922 + Ganciclovir	Investigative
T07035	DRUGINFO	D02DXY	ISIS 12659	Investigative
T07035	DRUGINFO	D04WRK	ISIS 2921	Investigative
T07035	DRUGINFO	D06REI	ISIS 3246	Investigative
T07035	DRUGINFO	D08NVD	ISIS 2919	Investigative
T07035	DRUGINFO	D09JXY	ISIS 2920	Investigative
T07035	DRUGINFO	D0BY9R	ISIS 2918	Investigative
T07035	DRUGINFO	D0HV7V	ISIS 12660	Investigative
T07035	DRUGINFO	D0P0JE	ISIS 3300	Investigative

T52771	TARGETID	T52771
T52771	FORMERID	TTDNS00614
T52771	UNIPROID	A0A1Q4HQH4_9MYCO
T52771	TARGNAME	Mycobacterium Proton pump (MycB Prop)
T52771	GENENAME	MycB Prop
T52771	TARGTYPE	Successful
T52771	SYNONYMS	Nicotinamide nucleotide transhydrogenase subunit beta; NAD(P) transhydrogenase subunit beta
T52771	FUNCTION	The transhydrogenation between NADH and NADP is coupled to respiration and ATP hydrolysis and functions as a proton pump across the membrane.
T52771	SEQUENCE	MNYLVTVLYIISFALFIYGLMGLTGPKTAVRGNLIAAVGMAIAVAATLIKIRHTESWVLIIAGLVVGVALGVPPARYTKMTAMPQLVAFFNGVGGGTVALIALSEFIETKGFSAFQHGESPTVHIVVASLFAAIIGSISFWGSIIAFGKLQEIISGSPIGFGKAQQPINLLLLAAAVAAAVVIGLGAHPGTGGVALWWMIGLLAAAGVLGLMVVLPIGGADMPVVISLLNAMTGLSAAAAGLALNNTAMIVAGMIVGASGSILTNLMAKAMNRSIPAIVAGGFGGGGVAPSGGGGGDKHVKATSAADAAIQMAYANQVIVVPGYGLAVAQAQHAVKDMASLLEDKGVPVKYAIHPVAGRMPGHMNVLLAEAEVDYDAMKDMDDINDEFARTDVAIVIGANDVTNPAARNEQSSPIYGMPILNVDRAKSVIVLKRSMNSGFAGIDNPLFYADGTTMLFGDAKKSVTEVAEELKAL
T52771	DRUGINFO	D0Y4QG	Bedaquiline	Approved

T63598	TARGETID	T63598
T63598	FORMERID	TTDI01884
T63598	UNIPROID	E0VDF4_PEDHC
T63598	TARGNAME	Pediculus humanus Nicotinic acetylcholine receptor (Pedhc nAChR)
T63598	GENENAME	Pedhc nAChR
T63598	TARGTYPE	Successful
T63598	SYNONYMS	Acetylcholine receptor protein alpha 1, 2, 3, 4invertebrate, putative; Acetylcholine receptor protein alpha 1, 2, 3, 4 invertebrate, putative
T63598	FUNCTION	Mediates the fast actions ofacetylcholine (ACh) in the nervous system and at neuromuscular junctions.
T63598	SEQUENCE	MCLCLCLTPFLDIPGFKPVQMEANPDAKRLYDDLLSNYNRLIRPVVNNTETLTVRLGLKLSQLIEVNLKSQVMTTNVWVEQKWTDYKLRWNPEEYGGVEMLYVPSEHIWLPDIVLYNNADGNYEVTLMTKATLNYNGEVYWKPPAIYKSSCEINVLYFPFDEQSCYMKFGSWTYHGYQVDLKHMDQKPGTNLVPVGVDLKEFYLSVEWDILEVPARKNEEYYPCCAEPYSDITFNLKMRRKTLFYTVNLIIPCVGITFLTVLVFYLPSDSGEKVTLTVSILLSLTVFFLLLAEIIPPTSLAVPLLGKYLLFTMMLVTLSIFITVCVLNIYFRSPSTHKMSPWVRNVFLNFIPRLLMMRRPPYSVRRDGYDDSGDNGYASALDYRDGIGEPFPPELKGSPEFESVTTVCKSTFGTESDDNLGTTFRHAQPSDSENIIPRNLSSDVLSALQGVCFIAQHIRNADKDNEVIEDWKYVSMVLDRFFLWVFTLACIGGTCAIIFQAPSLYDQRIPIDQEISLIQFGKIFLNIPREQNSD
T63598	DRUGINFO	D09WCM	Spinosad	Approved

T60708	TARGETID	T60708
T60708	UNIPROID	CO5_HUMAN
T60708	TARGNAME	Complement C5 (CO5)
T60708	GENENAME	C5
T60708	TARGTYPE	Successful
T60708	SYNONYMS	C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4
T60708	FUNCTION	Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes (PubMed:8182049). C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.
T60708	BIOCLASS	Complement system
T60708	SEQUENCE	MGLLGILCFLIFLGKTWGQEQTYVISAPKIFRVGASENIVIQVYGYTEAFDATISIKSYPDKKFSYSSGHVHLSSENKFQNSAILTIQPKQLPGGQNPVSYVYLEVVSKHFSKSKRMPITYDNGFLFIHTDKPVYTPDQSVKVRVYSLNDDLKPAKRETVLTFIDPEGSEVDMVEEIDHIGIISFPDFKIPSNPRYGMWTIKAKYKEDFSTTGTAYFEVKEYVLPHFSVSIEPEYNFIGYKNFKNFEITIKARYFYNKVVTEADVYITFGIREDLKDDQKEMMQTAMQNTMLINGIAQVTFDSETAVKELSYYSLEDLNNKYLYIAVTVIESTGGFSEEAEIPGIKYVLSPYKLNLVATPLFLKPGIPYPIKVQVKDSLDQLVGGVPVTLNAQTIDVNQETSDLDPSKSVTRVDDGVASFVLNLPSGVTVLEFNVKTDAPDLPEENQAREGYRAIAYSSLSQSYLYIDWTDNHKALLVGEHLNIIVTPKSPYIDKITHYNYLILSKGKIIHFGTREKFSDASYQSINIPVTQNMVPSSRLLVYYIVTGEQTAELVSDSVWLNIEEKCGNQLQVHLSPDADAYSPGQTVSLNMATGMDSWVALAAVDSAVYGVQRGAKKPLERVFQFLEKSDLGCGAGGGLNNANVFHLAGLTFLTNANADDSQENDEPCKEILRPRRTLQKKIEEIAAKYKHSVVKKCCYDGACVNNDETCEQRAARISLGPRCIKAFTECCVVASQLRANISHKDMQLGRLHMKTLLPVSKPEIRSYFPESWLWEVHLVPRRKQLQFALPDSLTTWEIQGVGISNTGICVADTVKAKVFKDVFLEMNIPYSVVRGEQIQLKGTVYNYRTSGMQFCVKMSAVEGICTSESPVIDHQGTKSSKCVRQKVEGSSSHLVTFTVLPLEIGLHNINFSLETWFGKEILVKTLRVVPEGVKRESYSGVTLDPRGIYGTISRRKEFPYRIPLDLVPKTEIKRILSVKGLLVGEILSAVLSQEGINILTHLPKGSAEAELMSVVPVFYVFHYLETGNHWNIFHSDPLIEKQKLKKKLKEGMLSIMSYRNADYSYSVWKGGSASTWLTAFALRVLGQVNKYVEQNQNSICNSLLWLVENYQLDNGSFKENSQYQPIKLQGTLPVEARENSLYLTAFTVIGIRKAFDICPLVKIDTALIKADNFLLENTLPAQSTFTLAISAYALSLGDKTHPQFRSIVSALKREALVKGNPPIYRFWKDNLQHKDSSVPNTGTARMVETTAYALLTSLNLKDINYVNPVIKWLSEEQRYGGGFYSTQDTINAIEGLTEYSLLVKQLRLSMDIDVSYKHKGALHNYKMTDKNFLGRPVEVLLNDDLIVSTGFGSGLATVHVTTVVHKTSTSEEVCSFYLKIDTQDIEASHYRGYGNSDYKRIVACASYKPSREESSSGSSHAVMDISLPTGISANEEDLKALVEGVDQLFTDYQIKDGHVILQLNSIPSSDFLCVRFRIFELFEVGFLSPATFTVYEYHRPDKQCTMFYSTSNIKIQKVCEGAACKCVEADCGQMQEELDLTISAETRKQTACKPEIAYAYKVSITSITVENVFVKYKATLLDIYKTGEAVAEKDSEITFIKKVTCTNAELVKGRQYLIMGKEALQIKYNFSFRYIYPLDSLTWIEYWPRDTTCSSCQAFLANLDEFAEDIFLNGC
T60708	DRUGINFO	D0NW7Y	Ravulizumab	Approved
T60708	DRUGINFO	D0W8BO	Zilucoplan	Approved
T60708	DRUGINFO	D4XBR9	Pozelimab	Approved
T60708	DRUGINFO	D75AZJ	Avacincaptad pegol	Approved
T60708	DRUGINFO	D1O9XQ	SKY59	Phase 3
T60708	DRUGINFO	D2RTQ0	SB12	Phase 3
T60708	DRUGINFO	DCOP72	Nomacopan	Phase 3
T60708	DRUGINFO	DH3YK4	Zimura	Phase 3
T60708	DRUGINFO	DRQ18X	ABP959	Phase 3
T60708	DRUGINFO	DY14KR	ALXN1720	Phase 3
T60708	DRUGINFO	DYG0W5	Coversin	Phase 3
T60708	DRUGINFO	D04HOT	LFG-316	Phase 2
T60708	DRUGINFO	D05YWJ	IFX-1	Phase 2
T60708	DRUGINFO	D0J4PM	NNC-0151-0000-0000	Phase 2
T60708	DRUGINFO	D76INB	Tesidolumab	Phase 2
T60708	DRUGINFO	D08FMR	ARC-1905	Phase 1
T60708	DRUGINFO	D0H0ZV	MEDI7814	Phase 1
T60708	DRUGINFO	D0H6VZ	REV-576	Phase 1
T60708	DRUGINFO	D0P6MB	Pexelizumab	Discontinued in Phase 3
T60708	DRUGINFO	D0H0ZU	MP-435	Discontinued in Phase 2
T60708	DRUGINFO	D0B1DA	SAND-5	Preclinical
T60708	DRUGINFO	D0I1BX	CGS-32359	Terminated

T19414	TARGETID	T19414
T19414	FORMERID	TTDR01242
T19414	UNIPROID	FIBA_HUMAN; FIBB_HUMAN
T19414	TARGNAME	Fibrin (FG)
T19414	GENENAME	FGA; FGB
T19414	TARGTYPE	Successful
T19414	SYNONYMS	Fibrinogen (31-44)
T19414	FUNCTION	A fibrous, non-globular protein involved in the clotting of blood. Formed by the action of the protease thrombin on fibrinogen which causes it to polymerize.
T19414	SEQUENCE	MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDWNYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSANNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSCRGSCSRALAREVDLKDYEDQQKQLEQVIAKDLLPSRDRQHLPLIKMKPVPDLVPGNFKSQLQKVPPEWKALTDMPQMRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSWNSGSSGPGSTGNRNPGSSGTGGTATWKPGSSGPGSTGSWNSGSSGTGSTGNQNPGSPRPGSTGTWNPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNVSPGTRREYHTEKLVTSKGDKELRTGKEKVTSGSTTTTRRSCSKTVTKTVIGPDGHKEVTKEVVTSEDGSDCPEAMDLGTLSGIGTLDGFRHRHPDEAAFFDTASTGKTFPGFFSPMLGEFVSETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYSKQFTSSTSYNRGDSTFESKSYKMADEAGSEADHEGTHSTKRGHAKSRPVRDCDDVLQTHPSGTQSGIFNIKLPGSSKIFSVYCDQETSLGGWLLIQQRMDGSLNFNRTWQDYKRGFGSLNDEGEGEFWLGNDYLHLLTQRGSVLRVELEDWAGNEAYAEYHFRVGSEAEGYALQVSSYEGTAGDALIEGSVEEGAEYTSHNNMQFSTFDRDADQWEENCAEVYGGGWWYNNCQAANLNGIYYPGGSYDPRNNSPYEIENGVVWVSFRGADYSLRAVRMKIRPLVTQ
T19414	DRUGINFO	D0DV4J	Beriplast-P	Approved
T19414	DRUGINFO	D0G3EC	Baquting	Approved
T19414	DRUGINFO	D0J0KD	Fibrinolysin	Approved
T19414	DRUGINFO	D0KT3X	Thrombin/fibrinogen matrix patch	Approved
T19414	DRUGINFO	D0M3AH	TachoComb	Approved
T19414	DRUGINFO	D09KRV	Adhexil	Phase 3
T19414	DRUGINFO	D0O9UZ	Alfimeprase	Phase 3
T19414	DRUGINFO	D04BHS	Recombinant batroxobin	Phase 2
T19414	DRUGINFO	D09BAP	KUR-212	Phase 2
T19414	DRUGINFO	D0L9XS	Plasmin	Phase 2
T19414	DRUGINFO	D0W4AR	KUR-211	Phase 2
T19414	DRUGINFO	D0YQ3M	EP-2104R	Discontinued in Phase 2
T19414	DRUGINFO	D09WVR	FX-107	Preclinical

T07569	TARGETID	T07569
T07569	UNIPROID	CY1_HUMAN-CYB_HUMAN
T07569	TARGNAME	Electron transport complex III (Complex III)
T07569	GENENAME	CYC1-MT-CYB
T07569	TARGTYPE	Successful
T07569	SYNONYMS	Cytochrome bc1 complex; CoQH2-cytochrome c reductase
T07569	FUNCTION	Produces a transmembrane proton electrochemical gradient as a result of the redox reactions
T07569	SEQUENCE	MTPMRKTNPLMKLINHSFIDLPTPSNISAWWNFGSLLGACLILQITTGLFLAMHYSPDASTAFSSIAHITRDVNYGWIIRYLHANGASMFFICLFLHIGRGLYYGSFLYSETWNIGIILLLATMATAFMGYVLPWGQMSFWGATVITNLLSAIPYIGTDLVQWIWGGYSVDSPTLTRFFTFHFILPFIIAALATLHLLFLHETGSNNPLGITSHSDKITFHPYYTIKDALGLLLFLLSLMTLTLFSPDLLGDPDNYTLANPLNTPPHIKPEWYFLFAYTILRSVPNKLGGVLALLLSILILAMIPILHMSKQQSMMFRPLSQSLYWLLAADLLILTWIGGQPVSYPFTIIGQVASVLYFTTILILMPTISLIENKMLKWAMAAAAASLRGVVLGPRGAGLPGARARGLLCSARPGQLPLRTPQAVALSSKSGLSRGRKVMLSALGMLAAGGAGLAMALHSAVSASDLELHPPSYPWSHRGLLSSLDHTSIRRGFQVYKQVCASCHSMDFVAYRHLVGVCYTEDEAKELAAEVEVQDGPNEDGEMFMRPGKLFDYFPKPYPNSEAARAANNGALPPDLSYIVRARHGGEDYVFSLLTGYCEPPTGVSLREGLYFNPYFPGQAIAMAPPIYTDVLEFDDGTPATMSQIAKDVCTFLRWASEPEHDHRKRMGLKMLMMMALLVPLVYTIKRHKWSVLKSRKLAYRPPK
T07569	DRUGINFO	D07TWN	Tafenoquine	Approved

T30028	TARGETID	T30028
T30028	FORMERID	TTDS00483
T30028	UNIPROID	VAMP1_HUMAN; VAMP2_HUMAN
T30028	TARGNAME	Vesicle-associated membrane protein (VAMP)
T30028	GENENAME	VAMP1; VAMP2
T30028	TARGTYPE	Successful
T30028	SYNONYMS	VAMP; Synaptobrevin; SYB
T30028	FUNCTION	Involved in the targeting and/or fusion of transport vesicles to their target membrane.
T30028	SEQUENCE	MSAPAQPPAEGTEGTAPGGGPPGPPPNMTSNRRLQQTQAQVEEVVDIIRVNVDKVLERDQKLSELDDRADALQAGASQFESSAAKLKRKYWWKNCKMMIMLGAICAIIVVVIVIYFFT
T30028	DRUGINFO	D02FXK	Botulinum Toxin Type B	Approved

T27495	TARGETID	T27495
T27495	UNIPROID	F13_VAR67
T27495	TARGNAME	Variola virus Envelope phospholipase F13 (VARV p37)
T27495	GENENAME	VARV p37
T27495	TARGTYPE	Successful
T27495	SYNONYMS	Variola 37 kDa protein; VARV p37K; VARV Palmitoylated EV membrane protein; VARV Envelope protein F13
T27495	FUNCTION	Envelope protein associated with the inner side of the enveloped virion (EV) membrane.
T27495	SEQUENCE	MWPFTSAPAGAKCRLVETLPENMDFRSDHLTTFECFNEIITLAKKYIYIASFCCNPLSTTRGALIFDKLKEASEKGIKIIVLLDERGKRNLGELQSHCPDINFITVNIDKKNNVGLLLGCFWVSDDERCYVGNASFTGGSIHTIKTLGVYSDYPPLATDLRRRFDTFKAFNSVKNSWLNLYSSACCLPVSTAYHIKNPIGGVFFTDSPEHLLGYSRDLDTDVVIDKLRSAKTSIDIEHLAIVPTTRVDGNSYYWPDIYNSIIEAAINRGVKIRLLVGNWDKNDVYSMATAESLDALCVQNDLSVKVFTIQNNTKLLIVDDEYVHITSANFDGTHYQNHGFVSFNSIDKQLVSEAKKIFERDWVSSHSKSLKI
T27495	DRUGINFO	D0MD8D	Tecovirimat 	Approved

T23459	TARGETID	T23459
T23459	UNIPROID	VGP3_EBVP3
T23459	TARGNAME	Epstein-Barr virus Envelope glycoprotein gp340 (EBV BLLF1)
T23459	GENENAME	EBV BLLF1
T23459	TARGTYPE	Successful
T23459	SYNONYMS	Membrane antigen; MA; Envelope glycoprotein GP340
T23459	FUNCTION	Responsible for EBV binding to the CR2 receptor on human B-cells.
T23459	SEQUENCE	MEAALLVCQYTIQSLIQLTRDDPGFFNVEILEFPFYPACNVCTADVNATINFDVGGKKHKLNLDFGLLTPHTKAVYQPRGAFGGSENATNLFLLELLGAGELALTMRSKKLPINITTGEEQQVSLESVDVYFQDVFGTMWCHHAEMQNPVYLIPETVPYIKWDNCNSTNITAVVRAQGLDVTLPLSLPTSAQDSNFSVKTEMLGNEIDIECIMEDGEISQVLPGDNKFNITCSGYESHVPSGGILTSTSPVATPIPGTGYAYSLRLTPRPVSRFLGNNSILYVFYSGNGPKASGGDYCIQSNIVFSDEIPASQDMPTNTTDITYVGDNATYSVPMVTSEDANSPNVTVTAFWAWPNNTETDFKCKWTLTSGTPSGCENISGAFASNRTFDITVSGLGTAPKTLIITRTATNATTTTHKVIFSKAPESTTTSPTLNTTGFAAPNTTTGLPSSTHVPTNLTAPASTGPTVSTADVTSPTPAGTTSGASPVTPSPSPRDNGTESKAPDMTSPTSAVTTPTPNATSPTPAVTTPTPNATSPTLGKTSPTSAVTTPTPNATSPTPAVTTPTPNATIPTLGKTSPTSAVTTPTPNATSPTVGETSPQANTTNHTLGGTSSTPVVTSPPKNATSAVTTGQHNITSSSTSSMSLRPSSISETLSPSTSDNSTSHMPLLTSAHPTGGENITQVTPASTSTHHVSTSSPAPRPGTTSQASGPGNSSTSTKPGEVNVTKGTPPKNATSPQAPSGQKTAVPTVTSTGGKANSTTGGKHTTGHGARTSTEPTTDYGGDSTTPRTRYNATTYLPPSTSSKLRPRWTFTSPPVTTAQATVPVPPTSQPRFSNLSMLVLQWASLAVLTLLLLLVMADCAFRRNLSTSHTYTTPPYDDAETYV
T23459	DRUGINFO	D00AOJ	Docosanol	Approved

T64258	TARGETID	T64258
T64258	FORMERID	TTDR01215
T64258	UNIPROID	MAP1A_HUMAN; MAP1B_HUMAN
T64258	TARGNAME	Microtubule-associated protein (MAP)
T64258	GENENAME	MAP1A; MAP1B
T64258	TARGTYPE	Successful
T64258	SYNONYMS	Microtubule-associated protein 1; MAP-1
T64258	FUNCTION	Binds to the tubulin subunits that make up microtubules to regulate their stability. Invovled in stabilizing and destabilizing microtubules, guiding microtubules towards specific cellular locations, cross-linking microtubules and mediating the interactions of microtubules with other proteins in the cell.
T64258	SEQUENCE	MDGVAEFSEYVSETVDVPSPFDLLEPPTSGGFLKLSKPCCYIFPGGRGDSALFAVNGFNILVDGGSDRKSCFWKLVRHLDRIDSVLLTHIGADNLPGINGLLQRKVAELEEEQSQGSSSYSDWVKNLISPELGVVFFNVPEKLRLPDASRKAKRSIEEACLTLQHLNRLGIQAEPLYRVVSNTIEPLTLFHKMGVGRLDMYVLNPVKDSKEMQFLMQKWAGNSKAKTGIVLPNGKEAEISVPYLTSITALVVWLPANPTEKIVRVLFPGNAPQNKILEGLEKLRHLDFLRYPVATQKDLASGAVPTNLKPSKIKQRADSKESLKATTKTAVSKLAKREEVVEEGAKEARSELAKELAKTEKKAKESSEKPPEKPAKPERVKTESSEALKAEKRKLIKDKVGKKHLKEKISKLEEKKDKEKKEIKKERKELKKDEGRKEEKKDAKKEEKRKDTKPELKKISKPDLKPFTPEVRKTLYKAKVPGRVKIDRSRAIRGEKELSSEPQTPPAQKGTVPLPTISGHRELVLSSPEDLTQDFEEMKREERALLAEQRDTGLGDKPFPLDTAEEGPPSTAIQGTPPSVPGLGQEEHVMKEKELVPEVPEEQGSKDRGLDSGAETEEEKDTWEEKKQREAERLPDRTEAREESEPEVKEDVIEKAELEEMEEVHPSDEEEEDATKAEGFYQKHMQEPLKVTPRSREAFGGRELGLQGKAPEKETSLFLSSLTTPAGATEHVSYIQDETIPGYSETEQTISDEEIHDEPEERPAPPRFHTSTYDLPGPEGAGPFEASQPADSAVPATSGKVYGTPETELTYPTNIVAAPLAEEEHVSSATSITECDKLSSFATSVAEDQSVASLTAPQTEETGKSSLLLDTVTSIPSSRTEATQGLDYVPSAGTISPTSSLEEDKGFKSPPCEDFSVTGESEKRGEIIGKGLSGERAVEEEEEETANVEMSEKLCSQYGTPVFSAPGHALHPGEPALGEAEERCLSPDDSTVKMASPPPSGPPSATHTPFHQSPVEEKSEPQDFQEADSWGDTKRTPGVGKEDAAEETVKPGPEEGTLEKEEKVPPPRSPQAQEAPVNIDEGLTGCTIQLLPAQDKAIVFEIMEAGEPTGPILGAEALPGGLRTLPQEPGKPQKDEVLRYPDRSLSPEDAESLSVLSVPSPDTANQEPTPKSPCGLTEQYLHKDRWPEVSPEDTQSLSLSEESPSKETSLDVSSKQLSPESLGTLQFGELNLGKEEMGHLMQAEDTSHHTAPMSVPEPHAATASPPTDGTTRYSAQTDITDDSLDRKSPASSFSHSTPSGNGKYLPGAITSPDEHILTPDSSFSKSPESLPGPALEDIAIKWEDKVPGLKDRTSEQKKEPEPKDEVLQQKDKTLEHKEVVEPKDTAIYQKDEALHVKNEAVKQQDKALEQKGRDLEQKDTALEQKDKALEPKDKDLEEKDKALEQKDKIPEEKDKALEQKDTALEQKDKALEPKDKDLEQKDRVLEQKEKIPEEKDKALDQKVRSVEHKAPEDTVAEMKDRDLEQTDKAPEQKHQAQEQKDKVSEKKDQALEQKYWALGQKDEALEQNIQALEENHQTQEQESLVQEDKTRKPKMLEEKSPEKVKAMEEKLEALLEKTKALGLEESLVQEGRAREQEEKYWRGQDVVQEWQETSPTREEPAGEQKELAPAWEDTSPEQDNRYWRGREDVALEQDTYWRELSCERKVWFPHELDGQGARPHYTEERESTFLDEGPDDEQEVPLREHATRSPWASDFKDFQESSPQKGLEVERWLAESPVGLPPEEEDKLTRSPFEIISPPASPPEMVGQRVPSAPGQESPIPDPKLMPHMKNEPTTPSWLADIPPWVPKDRPLPPAPLSPAPGPPTPAPESHTPAPFSWGTAEYDSVVAAVQEGAAELEGGPYSPLGKDYRKAEGEREEEGRAEAPDKSSHSSKVPEASKSHATTEPEQTEPEQREPTPYPDERSFQYADIYEQMMLTGLGPACPTREPPLGAAGDWPPCLSTKEAAAGRNTSAEKELSSPISPKSLQSDTPTFSYAALAGPTVPPRPEPGPSMEPSLTPPAVPPRAPILSKGPSPPLNGNILSCSPDRRSPSPKESGRSHWDDSTSDSELEKGAREQPEKEAQSPSPPHPIPMGSPTLWPETEAHVSPPLDSHLGPARPSLDFPASAFGFSSLQPAPPQLPSPAEPRSAPCGSLAFSGDRALALAPGPPTRTRHDEYLEVTKAPSLDSSLPQLPSPSSPGAPLLSNLPRPASPALSEGSSSEATTPVISSVAERFSPSLEAAEQESGELDPGMEPAAHSLWDLTPLSPAPPASLDLALAPAPSLPGDMGDGILPCHLECSEAATEKPSPFQVPSEDCAANGPTETSPNPPGPAPAKAENEEAAACPAWERGAWPEGAERSSRPDTLLSPEQPVCPAGGSGGPPSSASPEVEAGPQGCATEPRPHRGELSPSFLNPPLPPSIDDRDLSTEEVRLVGRGGRRRVGGPGTTGGPCPVTDETPPTSASDSGSSQSDSDVPPETEECPSITAEAALDSDEDGDFLPVDKAGGVSGTHHPRPGHDPPPLPQPDPRPSPPRPDVCMADPEGLSSESGRVERLREKEKVQGRVGRRAPGKAKPASPARRLDLRGKRSPTPGKGPADRASRAPPRPRSTTSQVTPAEEKDGHSPMSKGLVNGLKAGPMALSSKGSSGAPVYVDLAYIPNHCSGKTADLDFFRRVRASYYVVSGNDPANGEPSRAVLDALLEGKAQWGENLQVTLIPTHDTEVTREWYQQTHEQQQQLNVLVLASSSTVVMQDESFPACKIEF
T64258	DRUGINFO	D02LZB	Demecolcine	Approved
T64258	DRUGINFO	D06EFW	RG7304	Phase 1
T64258	DRUGINFO	D07KNG	Costunolide	Investigative

T51282	TARGETID	T51282
T51282	UNIPROID	ROCK1_HUMAN
T51282	TARGNAME	Rho-associated protein kinase 1 (ROCK1)
T51282	GENENAME	ROCK1
T51282	TARGTYPE	Successful
T51282	SYNONYMS	Rok; Rho-associated, coiled-coil containing protein kinase 1; Rho-associated kinase 1; Rho kinase; ROCK1; ROCK; P160ROCK; P160(rock); P160 ROCK-1; Let-502 kinase
T51282	FUNCTION	Protein kinase which is a key regulator of actin cytoskeleton and cell polarity. Involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber and focal adhesion formation, neurite retraction, cell adhesion and motility via phosphorylation of DAPK3, GFAP, LIMK1, LIMK2, MYL9/MLC2, PFN1 and PPP1R12A. Phosphorylates FHOD1 and acts synergistically with it to promote SRC-dependent non-apoptotic plasma membrane blebbing. Phosphorylates JIP3 and regulates the recruitment of JNK to JIP3 upon UVB-induced stress. Acts as a suppressor of inflammatory cell migration by regulating PTEN phosphorylation and stability. Acts as a negative regulator of VEGF-induced angiogenic endothelial cell activation. Required for centrosome positioning and centrosome-dependent exit from mitosis. Plays a role in terminal erythroid differentiation. May regulate closure of the eyelids and ventral body wall by inducing the assembly of actomyosin bundles. Promotes keratinocyte terminal differentiation. Involved in osteoblast compaction through the fibronectin fibrillogenesis cell-mediated matrix assembly process, essential for osteoblast mineralization.
T51282	BIOCLASS	Kinase
T51282	SEQUENCE	MSTGDSFETRFEKMDNLLRDPKSEVNSDCLLDGLDALVYDLDFPALRKNKNIDNFLSRYKDTINKIRDLRMKAEDYEVVKVIGRGAFGEVQLVRHKSTRKVYAMKLLSKFEMIKRSDSAFFWEERDIMAFANSPWVVQLFYAFQDDRYLYMVMEYMPGGDLVNLMSNYDVPEKWARFYTAEVVLALDAIHSMGFIHRDVKPDNMLLDKSGHLKLADFGTCMKMNKEGMVRCDTAVGTPDYISPEVLKSQGGDGYYGRECDWWSVGVFLYEMLVGDTPFYADSLVGTYSKIMNHKNSLTFPDDNDISKEAKNLICAFLTDREVRLGRNGVEEIKRHLFFKNDQWAWETLRDTVAPVVPDLSSDIDTSNFDDLEEDKGEEETFPIPKAFVGNQLPFVGFTYYSNRRYLSSANPNDNRTSSNADKSLQESLQKTIYKLEEQLHNEMQLKDEMEQKCRTSNIKLDKIMKELDEEGNQRRNLESTVSQIEKEKMLLQHRINEYQRKAEQENEKRRNVENEVSTLKDQLEDLKKVSQNSQLANEKLSQLQKQLEEANDLLRTESDTAVRLRKSHTEMSKSISQLESLNRELQERNRILENSKSQTDKDYYQLQAILEAERRDRGHDSEMIGDLQARITSLQEEVKHLKHNLEKVEGERKEAQDMLNHSEKEKNNLEIDLNYKLKSLQQRLEQEVNEHKVTKARLTDKHQSIEEAKSVAMCEMEKKLKEEREAREKAENRVVQIEKQCSMLDVDLKQSQQKLEHLTGNKERMEDEVKNLTLQLEQESNKRLLLQNELKTQAFEADNLKGLEKQMKQEINTLLEAKRLLEFELAQLTKQYRGNEGQMRELQDQLEAEQYFSTLYKTQVKELKEEIEEKNRENLKKIQELQNEKETLATQLDLAETKAESEQLARGLLEEQYFELTQESKKAASRNRQEITDKDHTVSRLEEANSMLTKDIEILRRENEELTEKMKKAEEEYKLEKEEEISNLKAAFEKNINTERTLKTQAVNKLAEIMNRKDFKIDRKKANTQDLRKKEKENRKLQLELNQEREKFNQMVVKHQKELNDMQAQLVEECAHRNELQMQLASKESDIEQLRAKLLDLSDSTSVASFPSADETDGNLPESRIEGWLSVPNRGNIKRYGWKKQYVVVSSKKILFYNDEQDKEQSNPSMVLDIDKLFHVRPVTQGDVYRAETEEIPKIFQILYANEGECRKDVEMEPVQQAEKTNFQNHKGHEFIPTLYHFPANCDACAKPLWHVFKPPPALECRRCHVKCHRDHLDKKEDLICPCKVSYDVTSARDMLLLACSQDEQKKWVTHLVKKIPKNPPSGFVRASPRTLSTRSTANQSFRKVVKNTSGKTS
T51282	DRUGINFO	D04WYX	Netarsudil	Approved
T51282	DRUGINFO	D00UET	SAR-407899	Phase 2
T51282	DRUGINFO	D08ZPO	H-1152	Phase 2
T51282	DRUGINFO	D08JXW	INS-117548	Phase 1
T51282	DRUGINFO	D02ZQS	GSK269962A	Clinical trial
T51282	DRUGINFO	D08YGE	PMID28048944-Compound-21	Patented
T51282	DRUGINFO	D0S0VF	PMID28048944-Compound-20	Patented
T51282	DRUGINFO	D0CW9Q	PMID28048944-Compound-19	Patented
T51282	DRUGINFO	D0DO1U	PMID28048944-Compound-3	Patented
T51282	DRUGINFO	D0QC6H	PMID28048944-Compound-7	Patented
T51282	DRUGINFO	D0QX0O	PMID28048944-Compound-4	Patented
T51282	DRUGINFO	D0V6OK	PMID28048944-Compound-5	Patented
T51282	DRUGINFO	D0VK6S	PMID28048944-Compound-6	Patented
T51282	DRUGINFO	D0YV6S	PMID28048944-Compound-2	Patented
T51282	DRUGINFO	D00ZNS	CDE-5110	Terminated
T51282	DRUGINFO	D01WIH	(4-Fluoro-phenyl)-(9H-purin-6-yl)-amine	Investigative
T51282	DRUGINFO	D03KKR	Fasudil	Investigative
T51282	DRUGINFO	D07UBK	AS-1892802	Investigative
T51282	DRUGINFO	D02RYE	AMA-237	Investigative
T51282	DRUGINFO	D02WRE	ATS-907	Investigative
T51282	DRUGINFO	D0J2GG	SR-3850	Investigative
T51282	DRUGINFO	D0L1UK	Acid-activated omeprazole	Investigative
T51282	DRUGINFO	D0X8UW	TRN-101	Investigative
T51282	DRUGINFO	D0I1FJ	SB-747651A	Investigative
T51282	DRUGINFO	D0R3MO	PMID20684608C35	Investigative
T51282	DRUGINFO	D0V0KA	PMID20462760C22	Investigative
T51282	DRUGINFO	D01YWE	PMID19364658C33	Investigative
T51282	DRUGINFO	D03CPB	RKI-1447	Investigative
T51282	DRUGINFO	D0G2VC	KT-5720	Investigative
T51282	DRUGINFO	D0M5FF	Ro31-8220	Investigative
T51282	DRUGINFO	D0N6ES	KN-62	Investigative
T51282	DRUGINFO	D0B9BU	CI-1040	Investigative
T51282	DRUGINFO	D0O1YH	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	Investigative
T51282	DRUGINFO	D0TO6S	Bisindolylmaleimide-I	Investigative
T51282	DRUGINFO	D0L8HO	RO-316233	Investigative

T36053	TARGETID	T36053
T36053	FORMERID	TTDI03425
T36053	UNIPROID	SO4C1_HUMAN
T36053	TARGNAME	Organic anion transporter M1 (SLCO4C1)
T36053	GENENAME	SLCO4C1
T36053	TARGTYPE	Successful
T36053	SYNONYMS	Solute carrier organic anion transporter family member 4C1; Solute carrier family 21 member 20; OATPX; OATP4C1; OATP-M1; OATP-H
T36053	FUNCTION	Organic anion transporter, capable of transporting pharmacological substances such as digoxin, ouabain, thyroxine, methotrexate and cAMP. May participate in the regulation of membrane transport of ouabain. Involved in the uptake of the dipeptidyl peptidase-4 inhibitor sitagliptin and hence may play a role in its transport into and out of renal proximal tubule cells. May be involved in the first step of the transport pathway of digoxin and various compounds into the urine in the kidney. May be involved in sperm maturation by enabling directed movement of organic anions and compounds within or between cells. This ion-transporting process is important to maintain the strict epididymal homeostasis necessary for sperm maturation. May have a role in secretory functions since seminal vesicle epithelial cells are assumed to secrete proteins involved in decapacitation by modifying surface proteins to facilitate the acquisition of the ability to fertilize the egg.
T36053	SEQUENCE	MKSAKGIENLAFVPSSPDILRRLSASPSQIEVSALSSDPQRENSQPQELQKPQEPQKSPEPSLPSAPPNVSEEKLRSLSLSEFEEGSYGWRNFHPQCLQRCNTPGGFLLHYCLLAVTQGIVVNGLVNISISTVEKRYEMKSSLTGLISSSYDISFCLLSLFVSFFGERGHKPRWLAFAAFMIGLGALVFSLPQFFSGEYKLGSLFEDTCVTTRNSTSCTSSTSSLSNYLYVFILGQLLLGAGGTPLYTLGTAFLDDSVPTHKSSLYIGTGYAMSILGPAIGYVLGGQLLTIYIDVAMGESTDVTEDDPRWLGAWWIGFLLSWIFAWSLIIPFSCFPKHLPGTAEIQAGKTSQAHQSNSNADVKFGKSIKDFPAALKNLMKNAVFMCLVLSTSSEALITTGFATFLPKFIENQFGLTSSFAATLGGAVLIPGAALGQILGGFLVSKFRMTCKNTMKFALFTSGVALTLSFVFMYAKCENEPFAGVSESYNGTGELGNLIAPCNANCNCSRSYYYPVCGDGVQYFSPCFAGCSNPVAHRKPKVYYNCSCIERKTEITSTAETFGFEAKAGKCETHCAKLPIFLCIFFIVIIFTFMAGTPITVSILRCVNHRQRSLALGIQFMVLRLLGTIPGPIIFGFTIDSTCILWDINDCGIKGACWIYDNIKMAHMLVAISVTCKVITMFFNGFAIFLYKPPPSATDVSFHKENAVVTNVLAEQDLNKIVKEG
T36053	DRUGINFO	D02OZE	Digoxin	Approved

T41263	TARGETID	T41263
T41263	FORMERID	TTDNS00579
T41263	UNIPROID	TS1R1_HUMAN; TS1R2_HUMAN; TS1R3_HUMAN
T41263	TARGNAME	Taste receptor (TASR)
T41263	GENENAME	TAS1R1; TAS1R2; TAS1R3
T41263	TARGTYPE	Successful
T41263	SYNONYMS	TR; Sweet taste receptor; G-protein coupled receptor
T41263	FUNCTION	Putative taste receptor. TAS1R1/TAS1R3 responds to the umami taste stimulus (the taste of monosodium glutamate). TAS1R2/TAS1R3 recognizes diverse natural and synthetic sweeteners. TAS1R3 is essential for the recognition and response to the disaccharide trehalose (By similarity). Sequence differences within and between species can significantly influence the selectivity and specificity of taste responses.
T41263	SEQUENCE	MLLCTARLVGLQLLISCCWAFACHSTESSPDFTLPGDYLLAGLFPLHSGCLQVRHRPEVTLCDRSCSFNEHGYHLFQAMRLGVEEINNSTALLPNITLGYQLYDVCSDSANVYATLRVLSLPGQHHIELQGDLLHYSPTVLAVIGPDSTNRAATTAALLSPFLVPMISYAASSETLSVKRQYPSFLRTIPNDKYQVETMVLLLQKFGWTWISLVGSSDDYGQLGVQALENQATGQGICIAFKDIMPFSAQVGDERMQCLMRHLAQAGATVVVVFSSRQLARVFFESVVLTNLTGKVWVASEAWALSRHITGVPGIQRIGMVLGVAIQKRAVPGLKAFEEAYARADKKAPRPCHKGSWCSSNQLCRECQAFMAHTMPKLKAFSMSSAYNAYRAVYAVAHGLHQLLGCASGACSRGRVYPWQLLEQIHKVHFLLHKDTVAFNDNRDPLSSYNIIAWDWNGPKWTFTVLGSSTWSPVQLNINETKIQWHGKDNQVPKSVCSSDCLEGHQRVVTGFHHCCFECVPCGAGTFLNKSDLYRCQPCGKEEWAPEGSQTCFPRTVVFLALREHTSWVLLAANTLLLLLLLGTAGLFAWHLDTPVVRSAGGRLCFLMLGSLAAGSGSLYGFFGEPTRPACLLRQALFALGFTIFLSCLTVRSFQLIIIFKFSTKVPTFYHAWVQNHGAGLFVMISSAAQLLICLTWLVVWTPLPAREYQRFPHLVMLECTETNSLGFILAFLYNGLLSISAFACSYLGKDLPENYNEAKCVTFSLLFNFVSWIAFFTTASVYDGKYLPAANMMAGLSSLSSGFGGYFLPKCYVILCRPDLNSTEHFQASIQDYTRRCGST
T41263	DRUGINFO	D0KN2M	Cynarin	Approved

T39676	TARGETID	T39676
T39676	FORMERID	TTDI03395
T39676	UNIPROID	S47A1_HUMAN
T39676	TARGNAME	Solute carrier family 47 member 1 (SLC47A1)
T39676	GENENAME	SLC47A1
T39676	TARGTYPE	Successful
T39676	SYNONYMS	hMATE-1; Multidrug and toxin extrusion protein 1; MATE1; MATE-1
T39676	FUNCTION	Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide (NMN), metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfate, acyclovir, ganciclovir and also the zwitterionic cephalosporin, cephalexin and cephradin. Seems to also play a role in the uptake of oxaliplatin (a new platinum anticancer agent). Able to transport paraquat (PQ or N,N-dimethyl-4-4'-bipiridinium); a widely used herbicid. Responsible for the secretion of cationic drugs across the brush border membranes.
T39676	SEQUENCE	MEAPEEPAPVRGGPEATLEVRGSRCLRLSAFREELRALLVLAGPAFLVQLMVFLISFISSVFCGHLGKLELDAVTLAIAVINVTGVSVGFGLSSACDTLISQTYGSQNLKHVGVILQRSALVLLLCCFPCWALFLNTQHILLLFRQDPDVSRLTQTYVTIFIPALPATFLYMLQVKYLLNQGIVLPQIVTGVAANLVNALANYLFLHQLHLGVIGSALANLISQYTLALLLFLYILGKKLHQATWGGWSLECLQDWASFLRLAIPSMLMLCMEWWAYEVGSFLSGILGMVELGAQSIVYELAIIVYMVPAGFSVAASVRVGNALGAGDMEQARKSSTVSLLITVLFAVAFSVLLLSCKDHVGYIFTTDRDIINLVAQVVPIYAVSHLFEALACTSGGVLRGSGNQKVGAIVNTIGYYVVGLPIGIALMFATTLGVMGLWSGIIICTVFQAVCFLGFIIQLNWKKACQQAQVHANLKVNNVPRSGNSALPQDPLHPGCPENLEGILTNDVGKTGEPQSDQQMRQEEPLPEHPQDGAKLSRKQLVLRRGLLLLGVFLILLVGILVRFYVRIQ
T39676	DRUGINFO	D0D7LA	Metformin	Approved
T39676	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T19229	TARGETID	T19229
T19229	FORMERID	TTDI03501
T19229	UNIPROID	PCFT_HUMAN
T19229	TARGNAME	Proton-coupled folate transporter (SLC46A1)
T19229	GENENAME	SLC46A1
T19229	TARGTYPE	Successful
T19229	SYNONYMS	Solute carrier family 46 member 1; PCFT/HCP1; PCFT; Heme carrier protein 1; HCP1; G21
T19229	FUNCTION	Has been shown to act both as an intestinal proton-coupled high-affinity folate transporter and as an intestinal heme transporter which mediates heme uptake from the gut lumen into duodenal epithelial cells. The iron is then released from heme and may be transported into the bloodstream. Dietary heme iron is an important nutritional source of iron. Shows a higher affinity for folate than heme.
T19229	SEQUENCE	MEGSASPPEKPRARPAAAVLCRGPVEPLVFLANFALVLQGPLTTQYLWHRFSADLGYNGTRQRGGCSNRSADPTMQEVETLTSHWTLYMNVGGFLVGLFSSTLLGAWSDSVGRRPLLVLASLGLLLQALVSVFVVQLQLHVGYFVLGRILCALLGDFGGLLAASFASVADVSSSRSRTFRMALLEASIGVAGMLASLLGGHWLRAQGYANPFWLALALLIAMTLYAAFCFGETLKEPKSTRLFTFRHHRSIVQLYVAPAPEKSRKHLALYSLAIFVVITVHFGAQDILTLYELSTPLCWDSKLIGYGSAAQHLPYLTSLLALKLLQYCLADAWVAEIGLAFNILGMVVFAFATITPLMFTGYGLLFLSLVITPVIRAKLSKLVRETEQGALFSAVACVNSLAMLTASGIFNSLYPATLNFMKGFPFLLGAGLLLIPAVLIGMLEKADPHLEFQQFPQSP
T19229	DRUGINFO	D0SV8E	Methotrexate	Approved
T19229	DRUGINFO	D0Z0DW	Folic Acid	Approved
T19229	DRUGINFO	D0C2VP	[3H]N5-methylfolate	Investigative
T19229	DRUGINFO	D0R4PS	[3H]folinic acid	Investigative
T19229	DRUGINFO	D0UZ9U	PREMETREXED	Investigative

T63140	TARGETID	T63140
T63140	FORMERID	TTDS00510
T63140	UNIPROID	Q9CDQ3_LACLA
T63140	TARGNAME	Bacterial Integral membrane LmrP (Bact lmrP)
T63140	GENENAME	Bact lmrP
T63140	TARGTYPE	Successful
T63140	SYNONYMS	lmrP; L24511; Integral membrane protein LmrP
T63140	FUNCTION	Major facilitator superfamily multidrug transporter from Lactococcus lactis that mediates the efflux of cationic amphiphilic substrates from the cell in a proton-motive force-dependent fashion.
T63140	SEQUENCE	MKEFWNLDKNLQLRLGIVFLGAFSYGTVFSSMTIYYNQHLGSAITGILLALSAVATFVAGILSGFFADRNGRKPVMVFGTVIQLLGALLAIDSNLPGHVNPWSTFIAFLLISFGYNLVITAGNAMIIDASNAENRKVVFMLDYWAQNLSVILGAALSAWLFRPAFEALLVILLLTVLVSFFLTTFVMTETFRPIVKAKEEAENIFQAYKTVLQDKTYMIFMGANIATTFIIMQFDNFLPVHLSNSFKTITFFGFEIYGQRMLTIYLILACVLVVLLMTTLNRLTKDWSHQKGFIWGSLFMAIGMIFSFLTTTFTPIFIAGIVYTLGEIVYTPSVQTLGVDLMNPEKIGSYNGVAAIKMPIASILAGLLVSISPMIKATGVSLVLALTEVLAIILVLIAVNRHQKTKIN
T63140	DRUGINFO	D0E2OU	Quinupristin	Approved

T37382	TARGETID	T37382
T37382	FORMERID	TTDI03558
T37382	UNIPROID	S23A1_HUMAN
T37382	TARGNAME	Solute carrier family 23 member 1 (SLC23A1)
T37382	GENENAME	SLC23A1
T37382	TARGTYPE	Successful
T37382	SYNONYMS	hSVCT1; Yolk sac permease-like molecule 3; YSPL3; Sodium-dependent vitamin C transporter 1; SVCT1; Na(+)/L-ascorbic acid transporter 1
T37382	FUNCTION	Sodium/ascorbate cotransporter. Mediates electrogenic uptake of vitamin C, with a stoichiometry of 2 Na(+) for each ascorbate.
T37382	SEQUENCE	MRAQEDLEGRTQHETTRDPSTPLPTEPKFDMLYKIEDVPPWYLCILLGFQHYLTCFSGTIAVPFLLAEALCVGHDQHMVSQLIGTIFTCVGITTLIQTTVGIRLPLFQASAFAFLVPAKAILALERWKCPPEEEIYGNWSLPLNTSHIWHPRIREVQGAIMVSSVVEVVIGLLGLPGALLNYIGPLTVTPTVSLIGLSVFQAAGDRAGSHWGISACSILLIILFSQYLRNLTFLLPVYRWGKGLTLLRIQIFKMFPIMLAIMTVWLLCYVLTLTDVLPTDPKAYGFQARTDARGDIMAIAPWIRIPYPCQWGLPTVTAAAVLGMFSATLAGIIESIGDYYACARLAGAPPPPVHAINRGIFTEGICCIIAGLLGTGNGSTSSSPNIGVLGITKVGSRRVVQYGAAIMLVLGTIGKFTALFSSLPDPILGGMFCTLFGMITAVGLSNLQFVDMNSSRNLFVLGFSMFFGLTLPNYLESNPGAINTGILEVDQILIVLLTTEMFVGGCLAFILDNTVPGSPEERGLIQWKAGAHANSDMSSSLKSYDFPIGMGIVKRITFLKYIPICPVFKGFSSSSKDQIAIPEDTPENTETASVCTKV
T37382	DRUGINFO	D07AHW	Vitamin C	Approved
T37382	DRUGINFO	D0HD2G	phloretin	Investigative

T62905	TARGETID	T62905
T62905	UNIPROID	SC5A6_HUMAN
T62905	TARGNAME	Sodium-dependent multivitamin transporter (SLC5A6)
T62905	GENENAME	SLC5A6
T62905	TARGTYPE	Successful
T62905	SYNONYMS	Solute carrier family 5 member 6; SMVT; Na(+)-dependent multivitamin transporter
T62905	FUNCTION	Transports pantothenate, biotin and lipoate in the presence of sodium.
T62905	SEQUENCE	MSVGVSTSAPLSPTSGTSVGMSTFSIMDYVVFVLLLVLSLAIGLYHACRGWGRHTVGELLMADRKMGCLPVALSLLATFQSAVAILGVPSEIYRFGTQYWFLGCCYFLGLLIPAHIFIPVFYRLHLTSAYEYLELRFNKTVRVCGTVTFIFQMVIYMGVVLYAPSLALNAVTGFDLWLSVLALGIVCTVYTALGGLKAVIWTDVFQTLVMFLGQLAVIIVGSAKVGGLGRVWAVASQHGRISGFELDPDPFVRHTFWTLAFGGVFMMLSLYGVNQAQVQRYLSSRTEKAAVLSCYAVFPFQQVSLCVGCLIGLVMFAYYQEYPMSIQQAQAAPDQFVLYFVMDLLKGLPGLPGLFIACLFSGSLSTISSAFNSLATVTMEDLIRPWFPEFSEARAIMLSRGLAFGYGLLCLGMAYISSQMGPVLQAAISIFGMVGGPLLGLFCLGMFFPCANPPGAVVGLLAGLVMAFWIGIGSIVTSMGSSMPPSPSNGSSFSLPTNLTVATVTTLMPLTTFSKPTGLQRFYSLSYLWYSAHNSTTVIVVGLIVSLLTGRMRGRSLNPATIYPVLPKLLSLLPLSCQKRLHCRSYGQDHLDTGLFPEKPRNGVLGDSRDKEAMALDGTAYQGSSSTCILQETSL
T62905	DRUGINFO	D05KBU	Gabapentin enacarbil	Phase 2

T71905	TARGETID	T71905
T71905	FORMERID	TTDS00216
T71905	TARGNAME	Bacterial 16S ribosomal RNA (Bact 16S rRNA)
T71905	TARGTYPE	Successful
T71905	SYNONYMS	RrnS; Plastid 16S rRNA; 16S rRNA
T71905	DRUGINFO	D05JNI	Framycetin	Approved
T71905	DRUGINFO	D0F9FR	Oxazolidinones	Phase 2
T71905	DRUGINFO	D0B0FU	Apramycin	Phase 1
T71905	DRUGINFO	D08PVY	Ribostamycin	Investigative
T71905	DRUGINFO	D0I1NU	Neamine	Investigative
T71905	DRUGINFO	D0KE3S	Butirosin B	Investigative
T71905	DRUGINFO	D0M5WG	Aminodeoxykanamycin	Investigative
T71905	DRUGINFO	D03LMM	G418	Investigative
T71905	DRUGINFO	D0S6RD	Hygromycin B	Investigative

T88338	TARGETID	T88338
T88338	FORMERID	TTDS00217
T88338	TARGNAME	Bacterial 23S ribosomal RNA (Bact 23S rRNA)
T88338	TARGTYPE	Successful
T88338	SYNONYMS	RrnL; Plastid 23S rRNA
T88338	DRUGINFO	D03YLZ	Thiamphenicol	Approved
T88338	DRUGINFO	D07UYO	Linezolid	Approved
T88338	DRUGINFO	D0EB5N	Lefamulin	Approved
T88338	DRUGINFO	D0F5OR	Spiramycin	Approved
T88338	DRUGINFO	D0Q6OS	Macrolides	Approved
T88338	DRUGINFO	D0U5GB	Lopinavir	Approved
T88338	DRUGINFO	D0X6IU	Chloramphenicol	Approved
T88338	DRUGINFO	D0D7TD	Cethromycin	Phase 3
T88338	DRUGINFO	D03PVQ	EDP-420	Phase 2
T88338	DRUGINFO	D0F9FR	Oxazolidinones	Phase 2
T88338	DRUGINFO	D07IQU	Micrococcin	Investigative
T88338	DRUGINFO	D0G5FV	Thiostrepton	Investigative

T53601	TARGETID	T53601
T53601	FORMERID	TTDI01915
T53601	TARGNAME	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
T53601	TARGTYPE	Successful
T53601	FUNCTION	Protein L1 is also a translational repressor protein, it controls the translation of the L11 operon by binding to its mRNA.
T53601	DRUGINFO	D02YIZ	Erythromycin	Approved
T53601	DRUGINFO	D03HJK	Zithromax	Approved
T53601	DRUGINFO	D03UQM	Retapamulin	Approved
T53601	DRUGINFO	D05AFC	Dalfopristin	Approved
T53601	DRUGINFO	D06IGU	Troleandomycin	Approved
T53601	DRUGINFO	D06ZUP	Dirithromycin	Approved
T53601	DRUGINFO	D08KBK	Tedizolid	Approved
T53601	DRUGINFO	D09HNR	Telithromycin	Approved
T53601	DRUGINFO	D09PEQ	Gentamicine sulfate	Approved
T53601	DRUGINFO	D0Q0EX	Lincomycin	Approved
T53601	DRUGINFO	D0R0ZL	Clindamycin	Approved
T53601	DRUGINFO	D0X1WJ	Josamycin	Approved
T53601	DRUGINFO	D0Z1ZM	Clarithromycin	Approved
T53601	DRUGINFO	D0W2FZ	Solithromycin	Phase 3
T53601	DRUGINFO	DVA7X9	DARE-BV1	Phase 3
T53601	DRUGINFO	D0J1GA	GSK-1399686	Phase 2
T53601	DRUGINFO	D0R6EC	BC-7013	Phase 2
T53601	DRUGINFO	D0T9FU	BC-3205	Phase 1
T53601	DRUGINFO	D0Y4FL	Roxithromycin	Withdrawn from market
T53601	DRUGINFO	D06FBB	Azithromycin/chloroquine	Discontinued in Phase 3
T53601	DRUGINFO	D0LA5G	Evernimicin	Discontinued in Phase 3
T53601	DRUGINFO	D0YE2N	Eperezolid	Discontinued in Phase 3
T53601	DRUGINFO	D03VHI	HMR-3562	Discontinued in Phase 1
T53601	DRUGINFO	D01GHV	RANBEZOLID HYDROCHLORIDE	Preclinical
T53601	DRUGINFO	D02FHP	RX-01-423	Preclinical
T53601	DRUGINFO	D03HTI	HMR-3787	Terminated
T53601	DRUGINFO	D09XQR	Erythromycin salnacedin	Investigative

T62094	TARGETID	T62094
T62094	FORMERID	TTDI01930
T62094	TARGNAME	Bacterial 30S ribosomal RNA (Bact 30S rRNA)
T62094	TARGTYPE	Successful
T62094	DRUGINFO	D07BCT	Tobramycin	Approved
T62094	DRUGINFO	D09GUJ	Omadacycline	Approved
T62094	DRUGINFO	D0IE1E	Nitrofurazone	Approved
T62094	DRUGINFO	D0L9UU	Gentamicin	Approved
T62094	DRUGINFO	D0S0LZ	Doxycycline	Approved
T62094	DRUGINFO	D0T6EI	Sarecycline 	Approved
T62094	DRUGINFO	D0LZ7E	TP-434	Approved
T62094	DRUGINFO	D01CYK	ME1100	Phase 1
T62094	DRUGINFO	DA3F2X	TP-6076	Phase 1
T62094	DRUGINFO	DU3GQ9	TP-271	Phase 1
T62094	DRUGINFO	DUI1N7	TP 6076	Phase 1
T62094	DRUGINFO	D07ZXE	Wetimicin	Discontinued in Phase 1
T62094	DRUGINFO	D07TNU	DACTIMICIN	Terminated

T48472	TARGETID	T48472
T48472	FORMERID	TTDS00221
T48472	TARGNAME	Bacterial 70S ribosomal RNA (Bact 70S rRNA)
T48472	TARGTYPE	Successful
T48472	DRUGINFO	D06EZI	Capreomycin Sulfate	Approved
T48472	DRUGINFO	D0E7MV	Capreomycin	Approved
T48472	DRUGINFO	D0Q8NJ	Viomycin sulfate	Approved

T49814	TARGETID	T49814
T49814	FORMERID	TTDI01534
T49814	TARGNAME	Bacterial Deoxyribonucleic acid (Bact DNA)
T49814	TARGTYPE	Successful
T49814	DRUGINFO	D02RIV	Hydroxystilbamidine Isethionate	Approved
T49814	DRUGINFO	D03CUF	Furazolidone	Approved
T49814	DRUGINFO	D08GSF	Proflavine	Approved
T49814	DRUGINFO	D0A2ZX	Metronidazole	Approved
T49814	DRUGINFO	D0R0BX	Nitrofurantoin	Approved
T49814	DRUGINFO	D0S5UH	Clofazimine	Approved
T49814	DRUGINFO	DIK8W5	MGB-BP-3	Phase 2

T74429	TARGETID	T74429
T74429	TARGNAME	Calcium (Ca)
T74429	TARGTYPE	Successful
T74429	DRUGINFO	D0V4AS	Cellulose Sodium Phosphate	Approved
T74429	DRUGINFO	D00XUN	Etidronate Disodium	Approved

T32862	TARGETID	T32862
T32862	TARGNAME	Fungal Cell membrane ergosterol (Fung CME)
T32862	TARGTYPE	Successful
T32862	DRUGINFO	D02DWM	Amphotericin B	Approved
T32862	DRUGINFO	D08XAC	Nystatin	Approved
T32862	DRUGINFO	D0I6IP	Candicidin	Approved

T86836	TARGETID	T86836
T86836	FORMERID	TTDI01911
T86836	TARGNAME	Human Deoxyribonucleic acid (hDNA)
T86836	TARGTYPE	Successful
T86836	DRUGINFO	D00FGO	Melphalan	Approved
T86836	DRUGINFO	D01CYA	Bendamustine hydrochloride	Approved
T86836	DRUGINFO	D01HPY	Melphalan flufenamide	Approved
T86836	DRUGINFO	D01OXI	DTI-015	Approved
T86836	DRUGINFO	D02LPF	Altretamine	Approved
T86836	DRUGINFO	D02TLO	Ifosfamide	Approved
T86836	DRUGINFO	D03FNJ	Pipobroman	Approved
T86836	DRUGINFO	D03SSE	Mechlorethamine	Approved
T86836	DRUGINFO	D04JPJ	Lomustine	Approved
T86836	DRUGINFO	D06UVD	Bleomycin	Approved
T86836	DRUGINFO	D07SUG	Busulfan	Approved
T86836	DRUGINFO	D08GYO	Procarbazine	Approved
T86836	DRUGINFO	D08IBS	Adenine	Approved
T86836	DRUGINFO	D0B9EJ	Mitomycin A	Approved
T86836	DRUGINFO	D0C8EU	Temozolomide	Approved
T86836	DRUGINFO	D0CT9C	Cyclophosphamide	Approved
T86836	DRUGINFO	D0E6AF	Radium-223-Dichloride	Approved
T86836	DRUGINFO	D0H0SJ	Neocarzinostatin	Approved
T86836	DRUGINFO	D0I8RR	Streptozocin	Approved
T86836	DRUGINFO	D0J9UN	Uracil mustard	Approved
T86836	DRUGINFO	D0JE4D	Dornase Alfa	Approved
T86836	DRUGINFO	D0P8IV	Dactinomycin	Approved
T86836	DRUGINFO	D0T8EH	Pirarubicin	Approved
T86836	DRUGINFO	D0U5HU	Cisplatin	Approved
T86836	DRUGINFO	D0X5XU	Decitabine	Approved
T86836	DRUGINFO	D0X7HM	Carboplatin	Approved
T86836	DRUGINFO	D0Y0GH	Mitomycin	Approved
T86836	DRUGINFO	D0Y3ME	Oxaliplatin	Approved
T86836	DRUGINFO	D0Y7ZU	Dacarbazine	Approved
T86836	DRUGINFO	D0Z4PE	Zinostatin stimalamer	Approved
T86836	DRUGINFO	D01XWG	Daunorubicin	Approved
T86836	DRUGINFO	D0V6OA	Lurbinectedin	Approved
T86836	DRUGINFO	D04ZXP	Dicycloplatin	Registered
T86836	DRUGINFO	D09DJO	Pafuramidine	Phase 3
T86836	DRUGINFO	D0A1IL	VAL-083	Phase 3
T86836	DRUGINFO	D0E5DB	Laromustine	Phase 3
T86836	DRUGINFO	D0FP0R	Apaziquone	Phase 3
T86836	DRUGINFO	D0L9IA	Glufosfamide	Phase 3
T86836	DRUGINFO	D0J6PY	Taxol/Paraplatin/Herceptin	Phase 3
T86836	DRUGINFO	D00HUZ	NDDP	Phase 2
T86836	DRUGINFO	D02ZZU	DM-CHOC-PEN	Phase 2
T86836	DRUGINFO	D05XUY	JM216	Phase 2
T86836	DRUGINFO	D07WRW	LADIRUBICIN	Phase 2
T86836	DRUGINFO	D08EUS	CGC-11047	Phase 2
T86836	DRUGINFO	D09WND	TETRAPLATIN TETRANITRATE	Phase 2
T86836	DRUGINFO	D0D6SZ	TROXACITABINE	Phase 2
T86836	DRUGINFO	D0H1EA	TH-302	Phase 2
T86836	DRUGINFO	D0M2QR	TOL-3021	Phase 2
T86836	DRUGINFO	D0M7PU	PM-00104	Phase 2
T86836	DRUGINFO	D0N3RK	CYSTEMUSTINE	Phase 2
T86836	DRUGINFO	D0VO6J	FAD-104	Phase 2
T86836	DRUGINFO	D0X0PQ	NHS-IL2-LT	Phase 2
T86836	DRUGINFO	DQ9OL5	OBI-3424	Phase 2
T86836	DRUGINFO	D0NS8T	13-DEOXYADRIAMYCIN HYDROCHLORIDE	Phase 2
T86836	DRUGINFO	D0V0CJ	CO-101	Phase 2
T86836	DRUGINFO	D01MQP	SECTA belomycin	Phase 1/2
T86836	DRUGINFO	D0AH6V	BN-2629	Phase 1/2
T86836	DRUGINFO	D0C3MW	MBO7133	Phase 1/2
T86836	DRUGINFO	D0P5SC	GTU-TB vaccine	Phase 1/2
T86836	DRUGINFO	D00JJW	RH 1	Phase 1
T86836	DRUGINFO	D02ONT	5-FP	Phase 1
T86836	DRUGINFO	D03DKR	GALAMUSTINE HYDROCHLORIDE	Phase 1
T86836	DRUGINFO	D05ZEW	INO-3510	Phase 1
T86836	DRUGINFO	D09HJS	BIZELESIN	Phase 1
T86836	DRUGINFO	D09URP	DABIS MALEATE	Phase 1
T86836	DRUGINFO	D0D7XM	NC-4016	Phase 1
T86836	DRUGINFO	D0E1HF	FFC-14A	Phase 1
T86836	DRUGINFO	D0K6JQ	INO-3401	Phase 1
T86836	DRUGINFO	D0PR6H	PENCLOMEDINE	Phase 1
T86836	DRUGINFO	D0SF5Q	Pennvax-B	Phase 1
T86836	DRUGINFO	D0V5JO	T-0128	Phase 1
T86836	DRUGINFO	D0X0OF	Pennvax-G	Phase 1
T86836	DRUGINFO	D0X3CD	Thiarabine	Phase 1
T86836	DRUGINFO	D0F2JY	LY-2334737	Phase 1
T86836	DRUGINFO	DE8S2F	DFP-14927	Phase 1
T86836	DRUGINFO	D0L5BK	KW-2149	Discontinued in Phase 3
T86836	DRUGINFO	D0RT5T	ARANOSE	Discontinued in Phase 3
T86836	DRUGINFO	D0WR3D	Abetimus sodium	Discontinued in Phase 3
T86836	DRUGINFO	D01VPR	BBR-3438	Discontinued in Phase 2
T86836	DRUGINFO	D05BTR	Tallimustine	Discontinued in Phase 2
T86836	DRUGINFO	D05UIL	TV-4710	Discontinued in Phase 2
T86836	DRUGINFO	D06DWQ	TOPIXANTRONE HYDROCHLORIDE	Discontinued in Phase 2
T86836	DRUGINFO	D0H2JQ	NB-506	Discontinued in Phase 2
T86836	DRUGINFO	D0J0PR	PIBROZELESIN HYDROCHLORIDE	Discontinued in Phase 2
T86836	DRUGINFO	D0M0VN	BISNAFIDE MESILATE	Discontinued in Phase 2
T86836	DRUGINFO	D0O1MP	CARZELESIN	Discontinued in Phase 2
T86836	DRUGINFO	D0U1IR	AP-5346	Discontinued in Phase 2
T86836	DRUGINFO	D0X5UH	ADOZELESIN	Discontinued in Phase 2
T86836	DRUGINFO	D01GTB	ZD-2767	Discontinued in Phase 1
T86836	DRUGINFO	D07NGJ	S-23906-1	Discontinued in Phase 1
T86836	DRUGINFO	D0G6XC	SW-33377	Discontinued in Phase 1
T86836	DRUGINFO	D0K8HF	PLD-147	Discontinued in Phase 1
T86836	DRUGINFO	D0NK2U	FK-973	Discontinued in Phase 1
T86836	DRUGINFO	D0R3HX	RB-6145	Discontinued in Phase 1
T86836	DRUGINFO	D0S0XS	SR-271425	Discontinued in Phase 1
T86836	DRUGINFO	D0Y7HW	Clomet	Discontinued in Phase 1
T86836	DRUGINFO	D0J6VN	Indol-3-carbinol	Preclinical
T86836	DRUGINFO	D0FT9P	Talisomycin	Terminated
T86836	DRUGINFO	D0G2JZ	Bisbenzimide (Hoechst 33258)	Terminated
T86836	DRUGINFO	D0R7GL	BW-A502U	Terminated
T86836	DRUGINFO	D0FZ1Z	Doxorubicin-CEA conjugate	Terminated
T86836	DRUGINFO	D02CWZ	AMBAZONE	Investigative
T86836	DRUGINFO	D04UPU	2-(3,4-Dihydroxyphenyl)Acetic Acid	Investigative
T86836	DRUGINFO	D08ATQ	Nitracrine	Investigative
T86836	DRUGINFO	D0AU4H	Thiamin Diphosphate	Investigative
T86836	DRUGINFO	D0N6FL	Lipid Fragment	Investigative
T86836	DRUGINFO	D0P0WG	Ethidium	Investigative
T86836	DRUGINFO	D04ACC	doxorubicin-peptide-PEG conjugate	Investigative
T86836	DRUGINFO	D0K4QL	doxorubicin-LL2 conjugate	Investigative
T86836	DRUGINFO	D0O9GJ	alphabeta-methyleneADP	Investigative
T86836	DRUGINFO	D07ONX	Beta-D-Glucose	Investigative

T75499	TARGETID	T75499
T75499	FORMERID	TTDNS00588
T75499	TARGNAME	Human Deoxyribonucleic acid major groove (hDNA maj)
T75499	TARGTYPE	Successful
T75499	DRUGINFO	D0J5TS	Carzinophilin	Approved

T51038	TARGETID	T51038
T51038	FORMERID	TTDI01874
T51038	TARGNAME	Hyaluronic acid (HA)
T51038	TARGTYPE	Successful
T51038	DRUGINFO	D04GPZ	Hyaluronidase (ovine)	Approved
T51038	DRUGINFO	D0N3UG	Hylenex	Approved

T02246	TARGETID	T02246
T02246	FORMERID	TTDI01910
T02246	TARGNAME	Iron (Fe)
T02246	TARGTYPE	Successful
T02246	DRUGINFO	D0FJ8A	Deferoxamine Mesylate	Approved
T02246	DRUGINFO	D0N0OU	Deferiprone	Approved
T02246	DRUGINFO	D0Q5UQ	Exjade	Approved
T02246	DRUGINFO	D00XUN	Etidronate Disodium	Approved
T02246	DRUGINFO	D0Y2JM	Soluble ferric pyrophosphate	Phase 3
T02246	DRUGINFO	D02SNJ	SPD602	Phase 2
T02246	DRUGINFO	D00DIM	Monohydroxyethylrutoside	Phase 1
T02246	DRUGINFO	D7L8JC	DpC	Phase 1

T85889	TARGETID	T85889
T85889	FORMERID	TTDI01976
T85889	TARGNAME	Phosphate (PHO)
T85889	TARGTYPE	Successful
T85889	DRUGINFO	D0H1LO	Lanthanum carbonate	Approved

T28658	TARGETID	T28658
T28658	FORMERID	TTDS00460
T28658	TARGNAME	Plasmodium 80S ribosome (Malaria 80S)
T28658	TARGTYPE	Successful
T28658	DRUGINFO	D0GQ7K	Mefloquine	Approved

T20089	TARGETID	T20089
T20089	FORMERID	TTDI01265
T20089	TARGNAME	Plasmodium Deoxyribonucleic acid (Malaria DNA)
T20089	TARGTYPE	Successful
T20089	DRUGINFO	D0T1LK	Primaquine	Approved

T31133	TARGETID	T31133
T31133	FORMERID	TTDI01287
T31133	TARGNAME	Potassium (K)
T31133	TARGTYPE	Successful
T31133	DRUGINFO	D03AZK	Sodium zirconium cyclosilicate	Approved
T31133	DRUGINFO	D0Z2YQ	Patiromer calcium	Approved

T20796	TARGETID	T20796
T20796	FORMERID	TTDI01161
T20796	TARGNAME	Reactive oxygen species (ROS)
T20796	TARGTYPE	Successful
T20796	DRUGINFO	D07TWN	Tafenoquine	Approved
T20796	DRUGINFO	D0M0UT	Procysteine	Phase 2
T20796	DRUGINFO	D1FR3T	Mitoquinone	Phase 2
T20796	DRUGINFO	D02ECG	Sodium pyruvate	Phase 1/2

T84575	TARGETID	T84575
T84575	TARGNAME	Samarium (SAM)
T84575	TARGTYPE	Successful
T84575	DRUGINFO	D04YHR	Samarium Sm-153 Lexidronam Pentasodium	Approved

T66023	TARGETID	T66023
T66023	TARGNAME	Schistosoma Deoxyribonucleic acid (Schist DNA)
T66023	TARGTYPE	Successful
T66023	DRUGINFO	D0P4MT	Oxamniquine	Approved

T62501	TARGETID	T62501
T62501	FORMERID	TTDI01889
T62501	TARGNAME	Toxic methotrexate (TM)
T62501	TARGTYPE	Successful
T62501	DRUGINFO	D0P4PZ	Glucarpidase	Approved

T89086	TARGETID	T89086
T89086	FORMERID	TTDI01846
T89086	TARGNAME	Toxic reactive metabolite (TRM)
T89086	TARGTYPE	Successful
T89086	DRUGINFO	D06CIE	Amifostine	Approved

T05196	TARGETID	T05196
T05196	FORMERID	TTDI01977
T05196	TARGNAME	Uric acid (URA)
T05196	TARGTYPE	Successful
T05196	DRUGINFO	D06ZIT	Pegloticase	Approved
T05196	DRUGINFO	D0S3BF	Pegadricase	Phase 1

T28848	TARGETID	T28848
T28848	FORMERID	TTDI01148
T28848	TARGNAME	Virus Deoxyribonucleic acid (Viru DNA)
T28848	TARGTYPE	Successful
T28848	DRUGINFO	D09PZO	Idoxuridine	Approved

T63966	TARGETID	T63966
T63966	FORMERID	TTDS00007
T63966	UNIPROID	VGFR1_HUMAN
T63966	TARGNAME	Vascular endothelial growth factor receptor 1 (FLT-1)
T63966	GENENAME	FLT1
T63966	TARGTYPE	Successful
T63966	SYNONYMS	Vascular permeability factor receptor; VEGFR1; VEGFR-1; VEGF-1 receptor; Tyrosine-protein kinase receptor FLT; Tyrosine-protein kinase FRT; Fms-like tyrosine kinase 1; FRT; FLT
T63966	FUNCTION	May play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. Can promote endothelial cell proliferation, survival and angiogenesis in adulthood. Its function in promoting cell proliferation seems to be cell-type specific. Promotes PGF-mediated proliferation of endothelial cells, proliferation of some types of cancer cells, but does not promote proliferation of normal fibroblasts (in vitro). Has very high affinity for VEGFA and relatively low protein kinase activity; may function as a negative regulator of VEGFA signaling by limiting the amount of free VEGFA and preventing its binding to KDR. Likewise, isoforms lacking a transmembrane domain, such as isoform 2, isoform 3 and isoform 4, may function as decoy receptors for VEGFA. Modulates KDR signaling by forming heterodimers with KDR. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leading to activation of phosphatidylinositol kinase and the downstream signaling pathway. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Phosphorylates SRC and YES1, and may also phosphorylate CBL. Isoform 1 phosphorylates PLCG. Promotes phosphorylation of AKT1 at 'Ser-473'. Promotes phosphorylation of PTK2/FAK1. Isoform 7 has a truncated kinase domain; it increases phosphorylation of SRC at 'Tyr-418' by unknown means and promotes tumor cell invasion. Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion.
T63966	PDBSTRUC	5T89; 5EX3; 5ABD; 4CL7; 4CKV
T63966	BIOCLASS	Kinase
T63966	ECNUMBER	EC 2.7.10.1
T63966	SEQUENCE	MVSYWDTGVLLCALLSCLLLTGSSSGSKLKDPELSLKGTQHIMQAGQTLHLQCRGEAAHKWSLPEMVSKESERLSITKSACGRNGKQFCSTLTLNTAQANHTGFYSCKYLAVPTSKKKETESAIYIFISDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVQISTPRPVKLLRGHTLVLNCTATTPLNTRVQMTWSYPDEKNKRASVRRRIDQSNSHANIFYSVLTIDKMQNKDKGLYTCRVRSGPSFKSVNTSVHIYDKAFITVKHRKQQVLETVAGKRSYRLSMKVKAFPSPEVVWLKDGLPATEKSARYLTRGYSLIIKDVTEEDAGNYTILLSIKQSNVFKNLTATLIVNVKPQIYEKAVSSFPDPALYPLGSRQILTCTAYGIPQPTIKWFWHPCNHNHSEARCDFCSNNEESFILDADSNMGNRIESITQRMAIIEGKNKMASTLVVADSRISGIYICIASNKVGTVGRNISFYITDVPNGFHVNLEKMPTEGEDLKLSCTVNKFLYRDVTWILLRTVNNRTMHYSISKQKMAITKEHSITLNLTIMNVSLQDSGTYACRARNVYTGEEILQKKEITIRDQEAPYLLRNLSDHTVAISSSTTLDCHANGVPEPQITWFKNNHKIQQEPGIILGPGSSTLFIERVTEEDEGVYHCKATNQKGSVESSAYLTVQGTSDKSNLELITLTCTCVAATLFWLLLTLFIRKMKRSSSEIKTDYLSIIMDPDEVPLDEQCERLPYDASKWEFARERLKLGKSLGRGAFGKVVQASAFGIKKSPTCRTVAVKMLKEGATASEYKALMTELKILTHIGHHLNVVNLLGACTKQGGPLMVIVEYCKYGNLSNYLKSKRDLFFLNKDAALHMEPKKEKMEPGLEQGKKPRLDSVTSSESFASSGFQEDKSLSDVEEEEDSDGFYKEPITMEDLISYSFQVARGMEFLSSRKCIHRDLAARNILLSENNVVKICDFGLARDIYKNPDYVRKGDTRLPLKWMAPESIFDKIYSTKSDVWSYGVLLWEIFSLGGSPYPGVQMDEDFCSRLREGMRMRAPEYSTPEIYQIMLDCWHRDPKERPRFAELVEKLGDLLQANVQQDGKDYIPINAILTGNSGFTYSTPAFSEDFFKESISAPKFNSGSSDDVRYVNAFKFMSLERIKTFEELLPNATSMFDDYQGDSSTLLASPMLKRFTWTDSKPKASLKIDLRVTSKSKESGLSDVSRPSFCHSSCGHVSEGKRRFTYDHAELERKIACCSPPPDYNSVVLYSTPPI
T63966	DRUGINFO	D0W7JZ	Tivozanib	Approved
T63966	DRUGINFO	D05PWX	Sulfatinib	Phase 3
T63966	DRUGINFO	D02WVT	E-3810	Phase 3
T63966	DRUGINFO	D0LX8Z	OCV-101	Phase 2
T63966	DRUGINFO	D0X2RL	LY3012212	Phase 2
T63966	DRUGINFO	D0L2ZY	X-82	Phase 2
T63966	DRUGINFO	D0Z6MT	Famitinib	Phase 2
T63966	DRUGINFO	D04NOE	OTSGC-A24	Phase 1/2
T63966	DRUGINFO	D04SQJ	EW-A-401	Phase 1
T63966	DRUGINFO	D0FD6D	CEP-11981	Phase 1
T63966	DRUGINFO	D07HAD	Telbermin	Discontinued in Phase 2
T63966	DRUGINFO	D0M8PL	Angiozyme	Discontinued in Phase 2
T63966	DRUGINFO	D09LPL	SU-11652	Investigative
T63966	DRUGINFO	D0EE6A	AAL-993	Investigative

T91331	TARGETID	T91331
T91331	FORMERID	TTDC00131
T91331	UNIPROID	FGFR3_HUMAN
T91331	TARGNAME	Fibroblast growth factor receptor 3 (FGFR3)
T91331	GENENAME	FGFR3
T91331	TARGTYPE	Successful
T91331	SYNONYMS	JTK4; FGFR-3; CD333
T91331	FUNCTION	Plays an essential role in the regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. Regulates both osteogenesis and postnatal bone mineralization by osteoblasts. Promotes apoptosis in chondrocytes, but can also promote cancer cell proliferation. Required for normal development of the inner ear. Phosphorylates PLCG1, CBL and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Plays a role in the regulation of vitamin D metabolism. Mutations that lead to constitutive kinase activation or impair normal FGFR3 maturation, internalization and degradation lead to aberrant signaling. Over-expressed or constitutively activated FGFR3 promotes activation of PTPN11/SHP2, STAT1, STAT5A and STAT5B. Secreted isoform 3 retains its capacity to bind FGF1 and FGF2 and hence may interfere with FGF signaling. Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis.
T91331	PDBSTRUC	4K33; 2LZL; 1RY7
T91331	BIOCLASS	Kinase
T91331	ECNUMBER	EC 2.7.10.1
T91331	SEQUENCE	MGAPACALALCVAVAIVAGASSESLGTEQRVVGRAAEVPGPEPGQQEQLVFGSGDAVELSCPPPGGGPMGPTVWVKDGTGLVPSERVLVGPQRLQVLNASHEDSGAYSCRQRLTQRVLCHFSVRVTDAPSSGDDEDGEDEAEDTGVDTGAPYWTRPERMDKKLLAVPAANTVRFRCPAAGNPTPSISWLKNGREFRGEHRIGGIKLRHQQWSLVMESVVPSDRGNYTCVVENKFGSIRQTYTLDVLERSPHRPILQAGLPANQTAVLGSDVEFHCKVYSDAQPHIQWLKHVEVNGSKVGPDGTPYVTVLKTAGANTTDKELEVLSLHNVTFEDAGEYTCLAGNSIGFSHHSAWLVVLPAEEELVEADEAGSVYAGILSYGVGFFLFILVVAAVTLCRLRSPPKKGLGSPTVHKISRFPLKRQVSLESNASMSSNTPLVRIARLSSGEGPTLANVSELELPADPKWELSRARLTLGKPLGEGCFGQVVMAEAIGIDKDRAAKPVTVAVKMLKDDATDKDLSDLVSEMEMMKMIGKHKNIINLLGACTQGGPLYVLVEYAAKGNLREFLRARRPPGLDYSFDTCKPPEEQLTFKDLVSCAYQVARGMEYLASQKCIHRDLAARNVLVTEDNVMKIADFGLARDVHNLDYYKKTTNGRLPVKWMAPEALFDRVYTHQSDVWSFGVLLWEIFTLGGSPYPGIPVEELFKLLKEGHRMDKPANCTHDLYMIMRECWHAAPSQRPTFKQLVEDLDRVLTVTSTDEYLDLSAPFEQYSPGGQDTPSSSSSGDDSVFAHDLLPPAPPSSGGSRT
T91331	DRUGINFO	D0O6UY	Pemigatinib	Approved
T91331	DRUGINFO	D0U2CV	Trapidil	Phase 4
T91331	DRUGINFO	D03WQS	BMS-582664	Phase 3
T91331	DRUGINFO	D07OZR	TKI258	Phase 3
T91331	DRUGINFO	D02WVT	E-3810	Phase 3
T91331	DRUGINFO	D0G6CF	B-701	Phase 2
T91331	DRUGINFO	DBA40S	Recifercept	Phase 2
T91331	DRUGINFO	D0XT0W	Debio 1347	Phase 2
T91331	DRUGINFO	D0G2QH	AEE-788	Phase 1/2
T91331	DRUGINFO	D00DRL	MK-2461	Phase 1/2
T91331	DRUGINFO	D0V0BO	Anti-FGFR3	Phase 1
T91331	DRUGINFO	D9FMA2	SAR442501	Phase 1
T91331	DRUGINFO	D0Z0KD	PD-0183812	Terminated
T91331	DRUGINFO	D03HGW	AV-370	Investigative
T91331	DRUGINFO	D0A4XJ	SU5402	Investigative
T91331	DRUGINFO	D05FFB	5,11-Dimethyl-6H-pyrido[4,3-b]carbazol-9-ol	Investigative
T91331	DRUGINFO	D0R6OM	ACTB-1003	Investigative
T91331	DRUGINFO	D02NNT	PMID21493067C1d	Investigative
T91331	DRUGINFO	D09XIL	Ro-4396686	Investigative

T67619	TARGETID	T67619
T67619	FORMERID	TTDI00350
T67619	UNIPROID	AKT1_HUMAN
T67619	TARGNAME	RAC-alpha serine/threonine-protein kinase (AKT1)
T67619	GENENAME	AKT1
T67619	TARGTYPE	Successful
T67619	SYNONYMS	RAC-PK-alpha; RAC; Proto-oncogene c-Akt; Protein kinase B alpha; PKB alpha
T67619	FUNCTION	AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. Phosphorylation of PTPN1 at 'Ser-50' negatively modulates its phosphatase activity preventing dephosphorylation of the insulin receptor and the attenuation of insulin signaling. Phosphorylation of TBC1D4 triggers the binding of this effector to inhibitory 14-3-3 proteins, which is required for insulin-stimulated glucose transport. AKT regulates also the storage of glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity. Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven. AKT regulates also cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related kinase). Phosphorylation of 'Ser-83' decreases MAP3K5 kinase activity stimulated by oxidative stress and thereby prevents apoptosis. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT is involved in the phosphorylation of members of the FOXO factors (Forkhead family of transcription factors), leading to binding of 14-3-3 proteins and cytoplasmic localization. In particular, FOXO1 is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 and FOXO4 are phosphorylated on equivalent sites. AKT has an important role in the regulation of NF-kappa-B-dependent gene transcription and positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein). The phosphorylation of CREB1 induces the binding of accessory proteins that are necessary for the transcription of pro-survival genes such as BCL2 and MCL1. AKT phosphorylates 'Ser-454' on ATP citrate lyase (ACLY), thereby potentially regulating ACLY activity and fatty acid synthesis. Activates the 3B isoform of cyclic nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', resulting in reduced cyclic AMP levels and inhibition of lipolysis. Phosphorylates PIKFYVE on 'Ser-318', which results in increased PI(3)P-5 activity. The Rho GTPase-activating protein DLC1 is another substrate and its phosphorylation is implicated in the regulation cell proliferation and cell growth. AKT plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). AKT mediates the antiapoptotic effects of IGF-I. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. May be involved in the regulation of the placental development. Phosphorylates STK4/MST1 at 'Thr-120' and 'Thr-387' leading to inhibition of its: kinase activity, nuclear translocation, autophosphorylation and ability to phosphorylate FOXO3. Phosphorylates STK3/MST2 at 'Thr-117' and 'Thr-384' leading to inhibition of its: cleavage, kinase activity, autophosphorylation at Thr-180, binding to RASSF1 and nuclear translocation. Phosphorylates SRPK2 and enhances its kinase activity towards SRSF2 and ACIN1 and promotes its nuclear translocation. Phosphorylates RAF1 at 'Ser-259' and negatively regulates its activity. Phosphorylation of BAD stimulates its pro-apoptotic activity. Phosphorylates KAT6A at 'Thr-369' and this phosphorylation inhibits the interaction of KAT6A with PML and negatively regulates its acetylation activity towards p53/TP53.
T67619	PDBSTRUC	6NPZ; 6HHJ; 6HHI; 6HHH; 6HHG
T67619	BIOCLASS	Kinase
T67619	ECNUMBER	EC 2.7.11.1
T67619	SEQUENCE	MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA
T67619	DRUGINFO	D01ZAQ	Capivasertib	Approved
T67619	DRUGINFO	D0I4TH	GDC-0068	Phase 3
T67619	DRUGINFO	D0I6VU	Enzastaurin	Phase 3
T67619	DRUGINFO	D02NXM	GSK2110183	Phase 2
T67619	DRUGINFO	D07SYZ	RX-0201	Phase 2
T67619	DRUGINFO	D0S5WP	Trametinib + 2141795	Phase 2
T67619	DRUGINFO	D0X7CV	PTX-200	Phase 2
T67619	DRUGINFO	D01TBJ	CMX-2043	Phase 2
T67619	DRUGINFO	D07DWF	ARQ 092	Phase 2
T67619	DRUGINFO	D0YB3W	CI-1033	Phase 2
T67619	DRUGINFO	D09CCZ	Triciribine prodrug	Phase 1/2
T67619	DRUGINFO	D02QWY	BMS-754807	Phase 1
T67619	DRUGINFO	D0L8PZ	ARQ 751	Phase 1
T67619	DRUGINFO	D06HYF	M2698	Phase 1
T67619	DRUGINFO	D07QBF	PMID28460551-Compound-6	Patented
T67619	DRUGINFO	D0O1AV	Squalestatin 1	Terminated
T67619	DRUGINFO	D07MQF	MYRIOCIN	Investigative
T67619	DRUGINFO	D09DGE	LD-101	Investigative
T67619	DRUGINFO	D0CM6T	A-674563	Investigative
T67619	DRUGINFO	D0F8HX	Lactoquinomycin	Investigative
T67619	DRUGINFO	D0N7CY	VLI-27	Investigative
T67619	DRUGINFO	D0OX1T	A-443654	Investigative
T67619	DRUGINFO	D0PX5F	NU-1001-41	Investigative
T67619	DRUGINFO	D0RZ1H	4,5,6-trihydroxy-3-methylphthalide	Investigative
T67619	DRUGINFO	D0V1ES	ALM-301	Investigative
T67619	DRUGINFO	D0L5AB	BX-517	Investigative
T67619	DRUGINFO	D0MH9X	Inositol 1,3,4,5-Tetrakisphosphate	Investigative
T67619	DRUGINFO	D00ATA	(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one	Investigative
T67619	DRUGINFO	D05APZ	Akt inhibitor VIII	Investigative
T67619	DRUGINFO	D0I1FJ	SB-747651A	Investigative
T67619	DRUGINFO	D0L2WP	PMID20005102C1	Investigative
T67619	DRUGINFO	D0GB4V	STAUROSPORINONE	Investigative
T67619	DRUGINFO	D0M5FF	Ro31-8220	Investigative
T67619	DRUGINFO	D0M4SY	BMS-536924	Investigative
T67619	DRUGINFO	D0N6ES	KN-62	Investigative
T67619	DRUGINFO	D0B9BU	CI-1040	Investigative
T67619	DRUGINFO	D0O1YH	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	Investigative
T67619	DRUGINFO	D0A5RM	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	Investigative
T67619	DRUGINFO	D0TO6S	Bisindolylmaleimide-I	Investigative
T67619	DRUGINFO	D0L8HO	RO-316233	Investigative

T31514	TARGETID	T31514
T31514	FORMERID	TTDC00023
T31514	UNIPROID	LYAG_HUMAN
T31514	TARGNAME	Lysosomal alpha-glucosidase (GAA)
T31514	GENENAME	GAA
T31514	TARGTYPE	Successful
T31514	SYNONYMS	GAA; Aglucosidase alfa; Acid maltase
T31514	FUNCTION	Essential for the degradation of glygogen to glucose in lysosomes.
T31514	PDBSTRUC	5NN8; 5NN6; 5NN5; 5NN4; 5NN3
T31514	BIOCLASS	Glycosylase
T31514	ECNUMBER	EC 3.2.1.20
T31514	SEQUENCE	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC
T31514	DRUGINFO	D34SXJ	Avalglucosidase alfa	Approved
T31514	DRUGINFO	D05JEG	BMN-701	Phase 3
T31514	DRUGINFO	D0S5LT	Deoxynojirimycin	Phase 3
T31514	DRUGINFO	DG4X8E	AT845	Phase 2
T31514	DRUGINFO	D3O5XK	SPK-3006	Phase 1/2
T31514	DRUGINFO	D07TSW	SALACINOL	Phase 1/2
T31514	DRUGINFO	D0Q1UB	GZ402666	Phase 1
T31514	DRUGINFO	DW68KF	5-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)-6-chloroindolin-2-one	Preclinical
T31514	DRUGINFO	D03TYC	Alpha-Homonojirimycin	Investigative
T31514	DRUGINFO	D07JCA	7-O-b-D-Glucopyranosyl-a-homonojirimycin	Investigative
T31514	DRUGINFO	D08TQA	VALIOLAMINE	Investigative
T31514	DRUGINFO	D0J2JM	UNIFLORINE B	Investigative
T31514	DRUGINFO	D0KE8R	(-)-uniflorine A	Investigative
T31514	DRUGINFO	D0N9IX	N-adamantanemethyloxypentyl-1-deoxynojirimycin	Investigative
T31514	DRUGINFO	D0Q1KL	(R)-2,6-Bis-hydroxymethyl-piperidine-3,4,5-triol	Investigative
T31514	DRUGINFO	D0X6BK	2,5-imino-2,5,6-trideoxy-D-manno-heptitol	Investigative
T31514	DRUGINFO	D0ZC7V	Alpha-7-Deoxyhomonojirimycin	Investigative

T07303	TARGETID	T07303
T07303	FORMERID	TTDC00290
T07303	UNIPROID	VGFR3_HUMAN
T07303	TARGNAME	Vascular endothelial growth factor receptor 3 (FLT-4)
T07303	GENENAME	FLT4
T07303	TARGTYPE	Successful
T07303	SYNONYMS	VEGFR3; VEGFR-3; VEGF-3 receptor; Tyrosine-protein kinase receptor FLT4; Fms-like tyrosine kinase 4
T07303	FUNCTION	Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced production of VEGFC, and to a lesser degree VEGFA, thereby creating a positive feedback loop that enhances FLT4 signaling. Modulates KDR signaling by forming heterodimers. The secreted isoform 3 may function as a decoy receptor for VEGFC and/or VEGFD and play an important role as a negative regulator of VEGFC-mediated lymphangiogenesis and angiogenesis. Binding of vascular growth factors to isoform 1 or isoform 2 leads to the activation of several signaling cascades; isoform 2 seems to be less efficient in signal transduction, because it has a truncated C-terminus and therefore lacks several phosphorylation sites. Mediates activation of the MAPK1/ERK2, MAPK3/ERK1 signaling pathway, of MAPK8 and the JUN signaling pathway, and of the AKT1 signaling pathway. Phosphorylates SHC1. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Promotes phosphorylation of MAPK8 at 'Thr-183' and 'Tyr-185', and of AKT1 at 'Ser-473'. Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development.
T07303	PDBSTRUC	4BSK; 4BSJ
T07303	BIOCLASS	Kinase
T07303	ECNUMBER	EC 2.7.10.1
T07303	SEQUENCE	MQRGAALCLRLWLCLGLLDGLVSGYSMTPPTLNITEESHVIDTGDSLSISCRGQHPLEWAWPGAQEAPATGDKDSEDTGVVRDCEGTDARPYCKVLLLHEVHANDTGSYVCYYKYIKARIEGTTAASSYVFVRDFEQPFINKPDTLLVNRKDAMWVPCLVSIPGLNVTLRSQSSVLWPDGQEVVWDDRRGMLVSTPLLHDALYLQCETTWGDQDFLSNPFLVHITGNELYDIQLLPRKSLELLVGEKLVLNCTVWAEFNSGVTFDWDYPGKQAERGKWVPERRSQQTHTELSSILTIHNVSQHDLGSYVCKANNGIQRFRESTEVIVHENPFISVEWLKGPILEATAGDELVKLPVKLAAYPPPEFQWYKDGKALSGRHSPHALVLKEVTEASTGTYTLALWNSAAGLRRNISLELVVNVPPQIHEKEASSPSIYSRHSRQALTCTAYGVPLPLSIQWHWRPWTPCKMFAQRSLRRRQQQDLMPQCRDWRAVTTQDAVNPIESLDTWTEFVEGKNKTVSKLVIQNANVSAMYKCVVSNKVGQDERLIYFYVTTIPDGFTIESKPSEELLEGQPVLLSCQADSYKYEHLRWYRLNLSTLHDAHGNPLLLDCKNVHLFATPLAASLEEVAPGARHATLSLSIPRVAPEHEGHYVCEVQDRRSHDKHCHKKYLSVQALEAPRLTQNLTDLLVNVSDSLEMQCLVAGAHAPSIVWYKDERLLEEKSGVDLADSNQKLSIQRVREEDAGRYLCSVCNAKGCVNSSASVAVEGSEDKGSMEIVILVGTGVIAVFFWVLLLLIFCNMRRPAHADIKTGYLSIIMDPGEVPLEEQCEYLSYDASQWEFPRERLHLGRVLGYGAFGKVVEASAFGIHKGSSCDTVAVKMLKEGATASEHRALMSELKILIHIGNHLNVVNLLGACTKPQGPLMVIVEFCKYGNLSNFLRAKRDAFSPCAEKSPEQRGRFRAMVELARLDRRRPGSSDRVLFARFSKTEGGARRASPDQEAEDLWLSPLTMEDLVCYSFQVARGMEFLASRKCIHRDLAARNILLSESDVVKICDFGLARDIYKDPDYVRKGSARLPLKWMAPESIFDKVYTTQSDVWSFGVLLWEIFSLGASPYPGVQINEEFCQRLRDGTRMRAPELATPAIRRIMLNCWSGDPKARPAFSELVEILGDLLQGRGLQEEEEVCMAPRSSQSSEEGSFSQVSTMALHIAQADAEDSPPSLQRHSLAARYYNWVSFPGCLARGAETRGSSRMKTFEEFPMTPTTYKGSVDNQTDSGMVLASEEFEQIESRHRQESGFSCKGPGQNVAVTRAHPDSQGRRRRPERGARGGQVFYNSEYGELSEPSEEDHCSPSARVTFFTDNSY
T07303	DRUGINFO	D0W7JZ	Tivozanib	Approved
T07303	DRUGINFO	D04ZJG	PI-88	Phase 3
T07303	DRUGINFO	D0GY4H	Taberminogene vadenovec	Phase 3
T07303	DRUGINFO	D0M9QZ	ABT-869	Phase 3
T07303	DRUGINFO	D05PWX	Sulfatinib	Phase 3
T07303	DRUGINFO	D02WVT	E-3810	Phase 3
T07303	DRUGINFO	D05BLN	MGCD516	Phase 2/3
T07303	DRUGINFO	D0P6DJ	VATALANIB	Phase 2
T07303	DRUGINFO	D0Z6MT	Famitinib	Phase 2
T07303	DRUGINFO	D00DRL	MK-2461	Phase 1/2
T07303	DRUGINFO	D09JSM	IMC-3C5	Phase 1
T07303	DRUGINFO	D0U3XL	JNJ-26483327	Phase 1
T07303	DRUGINFO	D07DJR	Pyrimidine derivative 15	Patented
T07303	DRUGINFO	D07VCG	Anti-VEGFR 3 mab	Investigative
T07303	DRUGINFO	D08GBT	SAR-131675	Investigative
T07303	DRUGINFO	D03HQK	2-(5-Phenyl-oxazol-2-ylamino)-benzonitrile	Investigative
T07303	DRUGINFO	D05THI	4-Chloro-N-(3-chloro-benzoyl)-benzenesulfonamide	Investigative
T07303	DRUGINFO	D06GJO	(2-Methoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine	Investigative
T07303	DRUGINFO	D07XBW	N-(2,4-Dichloro-benzoyl)-benzenesulfonamide	Investigative
T07303	DRUGINFO	D09LEK	4-(5-Phenyl-oxazol-2-ylamino)-benzenesulfonamide	Investigative
T07303	DRUGINFO	D09MSA	4-Chloro-N-(4-chloro-benzoyl)-benzenesulfonamide	Investigative
T07303	DRUGINFO	D0BM4F	Phenyl-(5-phenyl-oxazol-2-yl)-amine	Investigative
T07303	DRUGINFO	D0C6KI	CB-676475	Investigative
T07303	DRUGINFO	D0C6OD	4-Chloro-N-(4-nitro-benzoyl)-benzenesulfonamide	Investigative
T07303	DRUGINFO	D0D3YL	(5-Phenyl-oxazol-2-yl)-m-tolyl-amine	Investigative
T07303	DRUGINFO	D0J2XD	3-(5-Phenyl-oxazol-2-ylamino)-benzonitrile	Investigative
T07303	DRUGINFO	D0M2QA	N-(3-Bromo-benzoyl)-4-chloro-benzenesulfonamide	Investigative
T07303	DRUGINFO	D0UZ5W	4-Chloro-N-(2-chloro-benzoyl)-benzenesulfonamide	Investigative
T07303	DRUGINFO	D0V4BR	4-Chloro-N-(2-methyl-benzoyl)-benzenesulfonamide	Investigative
T07303	DRUGINFO	D0V9DQ	[3-(5-Phenyl-oxazol-2-ylamino)-phenyl]-methanol	Investigative
T07303	DRUGINFO	D0YN1E	3,6-Di-pyridin-4-yl-pyrazolo[1,5-a]pyrimidine	Investigative
T07303	DRUGINFO	D07IHM	CEP-6331	Investigative
T07303	DRUGINFO	D0C2GE	PMID22765894C8h	Investigative

T71266	TARGETID	T71266
T71266	FORMERID	TTDI02016
T71266	UNIPROID	AKT3_HUMAN
T71266	TARGNAME	RAC-gamma serine/threonine-protein kinase (AKT3)
T71266	GENENAME	AKT3
T71266	TARGTYPE	Successful
T71266	SYNONYMS	STK-2; RAC-PK-gamma; Protein kinase B gamma; Protein kinase Akt-3; PKBG; PKB gamma
T71266	FUNCTION	AKT3 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT3 is the least studied AKT isoform. It plays an important role in brain development and is crucial for the viability of malignant glioma cells. AKT3 isoform may also be the key molecule in up-regulation and down-regulation of MMP13 via IL13. Required for the coordination of mitochondrial biogenesis with growth factor-induced increases in cellular energy demands. Down-regulation by RNA interference reduces the expression of the phosphorylated form of BAD, resulting in the induction of caspase-dependent apoptosis.
T71266	PDBSTRUC	2X18
T71266	BIOCLASS	Kinase
T71266	ECNUMBER	EC 2.7.11.1
T71266	SEQUENCE	MSDVTIVKEGWVQKRGEYIKNWRPRYFLLKTDGSFIGYKEKPQDVDLPYPLNNFSVAKCQLMKTERPKPNTFIIRCLQWTTVIERTFHVDTPEEREEWTEAIQAVADRLQRQEEERMNCSPTSQIDNIGEEEMDASTTHHKRKTMNDFDYLKLLGKGTFGKVILVREKASGKYYAMKILKKEVIIAKDEVAHTLTESRVLKNTRHPFLTSLKYSFQTKDRLCFVMEYVNGGELFFHLSRERVFSEDRTRFYGAEIVSALDYLHSGKIVYRDLKLENLMLDKDGHIKITDFGLCKEGITDAATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEDIKFPRTLSSDAKSLLSGLLIKDPNKRLGGGPDDAKEIMRHSFFSGVNWQDVYDKKLVPPFKPQVTSETDTRYFDEEFTAQTITITPPEKYDEDGMDCMDNERRPHFPQFSYSASGRE
T71266	DRUGINFO	D01ZAQ	Capivasertib	Approved
T71266	DRUGINFO	D01NEC	GSK2141795	Phase 2
T71266	DRUGINFO	D07DWF	ARQ 092	Phase 2
T71266	DRUGINFO	D0W3RW	MK-2206	Phase 2
T71266	DRUGINFO	D03AVS	SR13668	Phase 1
T71266	DRUGINFO	D07TWK	TCN-P	Phase 1
T71266	DRUGINFO	D0MS3Z	GSK690693	Phase 1
T71266	DRUGINFO	D0S9IE	BAY1125976	Phase 1
T71266	DRUGINFO	D00DXH	LYS-6KAKT1	Phase 1
T71266	DRUGINFO	D0Q0PO	LY2780301	Phase 1
T71266	DRUGINFO	D0X2JM	XL418	Phase 1
T71266	DRUGINFO	D06HYF	M2698	Phase 1
T71266	DRUGINFO	D0C4JV	ISC-4	Investigative
T71266	DRUGINFO	D05APZ	Akt inhibitor VIII	Investigative
T71266	DRUGINFO	D0L2WP	PMID20005102C1	Investigative

T21960	TARGETID	T21960
T21960	FORMERID	TTDC00210
T21960	UNIPROID	ANGP2_HUMAN
T21960	TARGNAME	Angiopoietin-2 (ANGPT2)
T21960	GENENAME	ANGPT2
T21960	TARGTYPE	Successful
T21960	SYNONYMS	ANG-2
T21960	FUNCTION	Can induce tyrosine phosphorylation of TEK/TIE2 in the absence of ANGPT1. In the absence of angiogenic inducers, such as VEGF, ANGPT2-mediated loosening of cell-matrix contacts may induce endothelial cell apoptosis with consequent vascular regression. In concert with VEGF, it may facilitate endothelial cell migration and proliferation, thus serving as a permissive angiogenic signal. Binds to TEK/TIE2, competing for the ANGPT1 binding site, and modulating ANGPT1 signaling.
T21960	PDBSTRUC	4ZFG; 4JZC; 2GY7; 1Z3U; 1Z3S
T21960	BIOCLASS	Fibrinogen protein
T21960	SEQUENCE	MWQIVFFTLSCDLVLAAAYNNFRKSMDSIGKKQYQVQHGSCSYTFLLPEMDNCRSSSSPYVSNAVQRDAPLEYDDSVQRLQVLENIMENNTQWLMKLENYIQDNMKKEMVEIQQNAVQNQTAVMIEIGTNLLNQTAEQTRKLTDVEAQVLNQTTRLELQLLEHSLSTNKLEKQILDQTSEINKLQDKNSFLEKKVLAMEDKHIIQLQSIKEEKDQLQVLVSKQNSIIEELEKKIVTATVNNSVLQKQQHDLMETVNNLLTMMSTSNSAKDPTVAKEEQISFRDCAEVFKSGHTTNGIYTLTFPNSTEEIKAYCDMEAGGGGWTIIQRREDGSVDFQRTWKEYKVGFGNPSGEYWLGNEFVSQLTNQQRYVLKIHLKDWEGNEAYSLYEHFYLSSEELNYRIHLKGLTGTAGKISSISQPGNDFSTKDGDNDKCICKCSQMLTGGWWFDACGPSNLNGMYYPQRQNTNKFNGIKWYYWKGSGYSLKATTMMIRPADF
T21960	DRUGINFO	D9MWL4	Faricimab	Approved
T21960	DRUGINFO	D9NL3R	Trebananib	Phase 3
T21960	DRUGINFO	D0K8NR	AMG 386	Phase 3
T21960	DRUGINFO	DS68GD	REGN910-3	Phase 2
T21960	DRUGINFO	D06FTM	RG7221	Phase 2
T21960	DRUGINFO	D0I8YS	RO5520985	Phase 2
T21960	DRUGINFO	D02WSY	CVX-060	Phase 1/2
T21960	DRUGINFO	D02EOS	CVX-241	Phase 1
T21960	DRUGINFO	D03WOQ	LY3127804	Phase 1
T21960	DRUGINFO	D03YEG	REGN-910	Phase 1
T21960	DRUGINFO	DP7J0Z	MEDI3617	Phase 1
T21960	DRUGINFO	DP7Z9Q	Nesvacumab	Phase 1
T21960	DRUGINFO	D57NHD	Zifibancimig	Phase 1
T21960	DRUGINFO	D62LKT	BI 836880	Phase 1
T21960	DRUGINFO	D1JS9X	ABTAA	Investigative

T06093	TARGETID	T06093
T06093	FORMERID	TTDI02162
T06093	UNIPROID	ROCK2_HUMAN
T06093	TARGNAME	Rho-associated protein kinase 2 (ROCK2)
T06093	GENENAME	ROCK2
T06093	TARGTYPE	Successful
T06093	SYNONYMS	p164 ROCK-2; Rho-associated, coiled-coil-containing protein kinase II; Rho-associated, coiled-coil-containing protein kinase 2; Rho kinase 2; ROCK-II; KIAA0619
T06093	FUNCTION	Involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber and focal adhesion formation, neurite retraction, cell adhesion and motility via phosphorylation of ADD1, BRCA2, CNN1, EZR, DPYSL2, EP300, MSN, MYL9/MLC2, NPM1, RDX, PPP1R12A and VIM. Phosphorylates SORL1 and IRF4. Acts as a negative regulator of VEGF-induced angiogenic endothelial cell activation. Positively regulates the activation of p42/MAPK1-p44/MAPK3 and of p90RSK/RPS6KA1 during myogenic differentiation. Plays an important role in the timely initiation of centrosome duplication. Inhibits keratinocyte terminal differentiation. May regulate closure of the eyelids and ventral body wall through organization of actomyosin bundles. Plays a critical role in the regulation of spine and synaptic properties in the hippocampus. Plays an important role in generating the circadian rhythm of the aortic myofilament Ca(2+) sensitivity and vascular contractility by modulating the myosin light chain phosphorylation. Protein kinase which is a key regulator of actin cytoskeleton and cell polarity.
T06093	PDBSTRUC	6ED6; 5U7R; 5U7Q; 4WOT; 4L6Q
T06093	BIOCLASS	Kinase
T06093	ECNUMBER	EC 2.7.11.1
T06093	SEQUENCE	MSRPPPTGKMPGAPETAPGDGAGASRQRKLEALIRDPRSPINVESLLDGLNSLVLDLDFPALRKNKNIDNFLNRYEKIVKKIRGLQMKAEDYDVVKVIGRGAFGEVQLVRHKASQKVYAMKLLSKFEMIKRSDSAFFWEERDIMAFANSPWVVQLFYAFQDDRYLYMVMEYMPGGDLVNLMSNYDVPEKWAKFYTAEVVLALDAIHSMGLIHRDVKPDNMLLDKHGHLKLADFGTCMKMDETGMVHCDTAVGTPDYISPEVLKSQGGDGFYGRECDWWSVGVFLYEMLVGDTPFYADSLVGTYSKIMDHKNSLCFPEDAEISKHAKNLICAFLTDREVRLGRNGVEEIRQHPFFKNDQWHWDNIRETAAPVVPELSSDIDSSNFDDIEDDKGDVETFPIPKAFVGNQLPFIGFTYYRENLLLSDSPSCRETDSIQSRKNEESQEIQKKLYTLEEHLSNEMQAKEELEQKCKSVNTRLEKTAKELEEEITLRKSVESALRQLEREKALLQHKNAEYQRKADHEADKKRNLENDVNSLKDQLEDLKKRNQNSQISTEKVNQLQRQLDETNALLRTESDTAARLRKTQAESSKQIQQLESNNRDLQDKNCLLETAKLKLEKEFINLQSALESERRDRTHGSEIINDLQGRICGLEEDLKNGKILLAKVELEKRQLQERFTDLEKEKSNMEIDMTYQLKVIQQSLEQEEAEHKATKARLADKNKIYESIEEAKSEAMKEMEKKLLEERTLKQKVENLLLEAEKRCSLLDCDLKQSQQKINELLKQKDVLNEDVRNLTLKIEQETQKRCLTQNDLKMQTQQVNTLKMSEKQLKQENNHLMEMKMNLEKQNAELRKERQDADGQMKELQDQLEAEQYFSTLYKTQVRELKEECEEKTKLGKELQQKKQELQDERDSLAAQLEITLTKADSEQLARSIAEEQYSDLEKEKIMKELEIKEMMARHKQELTEKDATIASLEETNRTLTSDVANLANEKEELNNKLKDVQEQLSRLKDEEISAAAIKAQFEKQLLTERTLKTQAVNKLAEIMNRKEPVKRGNDTDVRRKEKENRKLHMELKSEREKLTQQMIKYQKELNEMQAQIAEESQIRIELQMTLDSKDSDIEQLRSQLQALHIGLDSSSIGSGPGDAEADDGFPESRLEGWLSLPVRNNTKKFGWVKKYVIVSSKKILFYDSEQDKEQSNPYMVLDIDKLFHVRPVTQTDVYRADAKEIPRIFQILYANEGESKKEQEFPVEPVGEKSNYICHKGHEFIPTLYHFPTNCEACMKPLWHMFKPPPALECRRCHIKCHKDHMDKKEEIIAPCKVYYDISTAKNLLLLANSTEEQQKWVSRLVKKIPKKPPAPDPFARSSPRTSMKIQQNQSIRRPSRQLAPNKPS
T06093	DRUGINFO	D0U5UC	Belumosudil	Approved
T06093	DRUGINFO	D08JXW	INS-117548	Phase 1
T06093	DRUGINFO	D02ZQS	GSK269962A	Clinical trial
T06093	DRUGINFO	D06RBE	Tricyclic compound 7	Patented
T06093	DRUGINFO	D0E1KS	Tricyclic compound 5	Patented
T06093	DRUGINFO	D0E9PE	Tricyclic compound 6	Patented
T06093	DRUGINFO	D0G3DM	Indazolyl-thiadiazolamine derivative 1	Patented
T06093	DRUGINFO	D0T0RV	PMID28048944-Compound-11	Patented
T06093	DRUGINFO	D0U4LI	Tricyclic compound 4	Patented
T06093	DRUGINFO	D0CW9Q	PMID28048944-Compound-19	Patented
T06093	DRUGINFO	D0DO1U	PMID28048944-Compound-3	Patented
T06093	DRUGINFO	D0QC6H	PMID28048944-Compound-7	Patented
T06093	DRUGINFO	D0QX0O	PMID28048944-Compound-4	Patented
T06093	DRUGINFO	D0V6OK	PMID28048944-Compound-5	Patented
T06093	DRUGINFO	D0VK6S	PMID28048944-Compound-6	Patented
T06093	DRUGINFO	D0YV6S	PMID28048944-Compound-2	Patented
T06093	DRUGINFO	D00ZNS	CDE-5110	Terminated
T06093	DRUGINFO	D02RYE	AMA-237	Investigative
T06093	DRUGINFO	D02WRE	ATS-907	Investigative
T06093	DRUGINFO	D0J2GG	SR-3850	Investigative
T06093	DRUGINFO	D0X8UW	TRN-101	Investigative
T06093	DRUGINFO	D0Y8DT	Glycyl-H 1152	Investigative
T06093	DRUGINFO	D0N1UU	PMID20471253C32	Investigative
T06093	DRUGINFO	D0R3MO	PMID20684608C35	Investigative
T06093	DRUGINFO	D0V0KA	PMID20462760C22	Investigative
T06093	DRUGINFO	D03CPB	RKI-1447	Investigative

T29143	TARGETID	T29143
T29143	FORMERID	TTDC00177
T29143	UNIPROID	IL13_HUMAN
T29143	TARGNAME	Interleukin-13 (IL13)
T29143	GENENAME	IL13
T29143	TARGTYPE	Successful
T29143	SYNONYMS	NC30; IL-13
T29143	FUNCTION	Inhibits inflammatory cytokine production. Synergizes with IL2 in regulating interferon-gamma synthesis. May be critical in regulating inflammatory and immune responses. Positively regulates IL31RA expression in macrophages. Cytokine.
T29143	PDBSTRUC	5L6Y; 5E4E; 4PS4; 4I77; 3LB6
T29143	BIOCLASS	Cytokine: interleukin
T29143	SEQUENCE	MHPLLNPLLLALGLMALLLTTVIALTCLGGFASPGPVPPSTALRELIEELVNITQNQKAPLCNGSMVWSINLTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFN
T29143	DRUGINFO	D0I1ZY	Tralokinumab	Approved
T29143	DRUGINFO	D0SM8S	Lebrikizumab	Phase 3
T29143	DRUGINFO	D2R3ZX	Cendakimab	Phase 3
T29143	DRUGINFO	DP2UR8	Dexpramipexole	Phase 3
T29143	DRUGINFO	D02QDQ	QAX-576	Phase 2
T29143	DRUGINFO	D03ING	Anrukinzumab	Phase 2
T29143	DRUGINFO	DTQ3Z8	Dectrekumab	Phase 2
T29143	DRUGINFO	D00KQN	PEGylated pitrakinra	Phase 2
T29143	DRUGINFO	DF5R7E	Romilkimab	Phase 2
T29143	DRUGINFO	D0O4SH	SAR-156597	Phase 2
T29143	DRUGINFO	D0K0WA	CNTO-5825	Phase 1
T29143	DRUGINFO	D9TW0X	SAR443765	Phase 1
T29143	DRUGINFO	D1LP4B	PF-07264660	Phase 1
T29143	DRUGINFO	DIWU14	PF-07275315	Phase 1
T29143	DRUGINFO	DFU4B0	RO7040547	Discontinued in Phase 1

T25265	TARGETID	T25265
T25265	FORMERID	TTDI02063
T25265	UNIPROID	EZH2_HUMAN
T25265	TARGNAME	Enhancer of zeste homolog 2 (EZH2)
T25265	GENENAME	EZH2
T25265	TARGTYPE	Successful
T25265	SYNONYMS	Lysine Nmethyltransferase 6; Lysine N-methyltransferase 6; KMT6; Histonelysine Nmethyltransferase EZH2; Histone-lysine N-methyltransferase EZH2; EZH2; ENX1; ENX-1
T25265	FUNCTION	Catalytic subunit of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. Displays a preference for substrates with less methylation, loses activity when progressively more methyl groups are incorporated into H3K27, H3K27me0 > H3K27me1 > H3K27me2. Compared to EZH1-containing complexes, it is more abundant in embryonic stem cells and plays a major role in forming H3K27me3, which is required for embryonic stem cell identity and proper differentiation. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1, CDKN2A and retinoic acid target genes. EZH2 can also methylate non-histone proteins such as the transcription factor GATA4 and the nuclear receptor RORA. Regulates the circadian clock via histone methylation at the promoter of the circadian genes. Essential for the CRY1/2-mediated repression of the transcriptional activation of PER1/2 by the CLOCK-ARNTL/BMAL1 heterodimer; involved in the di and trimethylation of 'Lys-27' of histone H3 on PER1/2 promoters which is necessary for the CRY1/2 proteins to inhibit transcription. Polycomb group (PcG) protein.
T25265	PDBSTRUC	6C24; 6C23; 5WUK; 5WG6; 5U62
T25265	BIOCLASS	Methyltransferase
T25265	ECNUMBER	EC 2.1.1.43
T25265	SEQUENCE	MGQTGKKSEKGPVCWRKRVKSEYMRLRQLKRFRRADEVKSMFSSNRQKILERTEILNQEWKQRRIQPVHILTSVSSLRGTRECSVTSDLDFPTQVIPLKTLNAVASVPIMYSWSPLQQNFMVEDETVLHNIPYMGDEVLDQDGTFIEELIKNYDGKVHGDRECGFINDEIFVELVNALGQYNDDDDDDDGDDPEEREEKQKDLEDHRDDKESRPPRKFPSDKIFEAISSMFPDKGTAEELKEKYKELTEQQLPGALPPECTPNIDGPNAKSVQREQSLHSFHTLFCRRCFKYDCFLHPFHATPNTYKRKNTETALDNKPCGPQCYQHLEGAKEFAAALTAERIKTPPKRPGGRRRGRLPNNSSRPSTPTINVLESKDTDSDREAGTETGGENNDKEEEEKKDETSSSSEANSRCQTPIKMKPNIEPPENVEWSGAEASMFRVLIGTYYDNFCAIARLIGTKTCRQVYEFRVKESSIIAPAPAEDVDTPPRKKKRKHRLWAAHCRKIQLKKDGSSNHVYNYQPCDHPRQPCDSSCPCVIAQNFCEKFCQCSSECQNRFPGCRCKAQCNTKQCPCYLAVRECDPDLCLTCGAADHWDSKNVSCKNCSIQRGSKKHLLLAPSDVAGWGIFIKDPVQKNEFISEYCGEIISQDEADRRGKVYDKYMCSFLFNLNNDFVVDATRKGNKIRFANHSVNPNCYAKVMMVNGDHRIGIFAKRAIQTGEELFFDYRYSQADALKYVGIEREMEIP
T25265	DRUGINFO	D00EQL	Tazemetostat	Approved
T25265	DRUGINFO	DNM79H	DS-3201b	Phase 2
T25265	DRUGINFO	D0E6AG	CPI-1205	Phase 1/2
T25265	DRUGINFO	DM5X0L	SHR2554	Phase 1/2
T25265	DRUGINFO	DXL38G	CPI-0209	Phase 1/2
T25265	DRUGINFO	D05FIJ	GSK2816126	Phase 1
T25265	DRUGINFO	DI1L7M	PF-06821497	Phase 1
T25265	DRUGINFO	D0LG8T	DS-3201	Phase 1
T25265	DRUGINFO	D6EU7R	HH2853	Phase 1
T25265	DRUGINFO	D03MYI	PMID28394193-Compound-33	Patented
T25265	DRUGINFO	D04PCW	PMID28394193-Compound-Figure3bI	Patented
T25265	DRUGINFO	D05MAR	PMID28394193-Compound-35	Patented
T25265	DRUGINFO	D07CZI	PMID28394193-Compound-54	Patented
T25265	DRUGINFO	D08MXO	PMID28394193-Compound-24	Patented
T25265	DRUGINFO	D09GFF	PMID28394193-Compound-27	Patented
T25265	DRUGINFO	D09PQQ	PMID28394193-Compound-25	Patented
T25265	DRUGINFO	D0A0VH	PMID28394193-Compound-50	Patented
T25265	DRUGINFO	D0B4TX	PMID28394193-Compound-47	Patented
T25265	DRUGINFO	D0BL8W	PMID28394193-Compound-21	Patented
T25265	DRUGINFO	D0BT6Y	PMID28394193-Compound-41	Patented
T25265	DRUGINFO	D0CH4O	PMID28394193-Compound-53	Patented
T25265	DRUGINFO	D0D1QD	PMID28394193-Compound-Figure5aVIII	Patented
T25265	DRUGINFO	D0DQ6N	PMID28394193-Compound-38	Patented
T25265	DRUGINFO	D0FC9J	PMID28394193-Compound-51	Patented
T25265	DRUGINFO	D0FI3A	PMID28394193-Compound-31	Patented
T25265	DRUGINFO	D0H4HR	PMID28394193-Compound-42	Patented
T25265	DRUGINFO	D0KR2T	PMID28394193-Compound-15	Patented
T25265	DRUGINFO	D0LR5O	PMID28394193-Compound-52	Patented
T25265	DRUGINFO	D0M1TG	PMID28394193-Compound-32	Patented
T25265	DRUGINFO	D0M9BY	PMID28394193-Compound-23	Patented
T25265	DRUGINFO	D0MH8G	PMID28394193-Compound-29	Patented
T25265	DRUGINFO	D0MO2X	PMID28394193-Compound-30	Patented
T25265	DRUGINFO	D0MZ8D	PMID28394193-Compound-39	Patented
T25265	DRUGINFO	D0PB6T	PMID28394193-Compound-49	Patented
T25265	DRUGINFO	D0PI5O	PMID28394193-Compound-43	Patented
T25265	DRUGINFO	D0QH1J	PMID28394193-Compound-40	Patented
T25265	DRUGINFO	D0R2TQ	PMID28394193-Compound-Figure3bIII	Patented
T25265	DRUGINFO	D0RD5P	PMID28394193-Compound-36	Patented
T25265	DRUGINFO	D0S4OP	PMID28394193-Compound-28	Patented
T25265	DRUGINFO	D0SQ1R	PMID28394193-Compound-22	Patented
T25265	DRUGINFO	D0SY6P	PMID28394193-Compound-18	Patented
T25265	DRUGINFO	D0T8QL	PMID28394193-Compound-16	Patented
T25265	DRUGINFO	D0U9OH	PMID28394193-Compound-44	Patented
T25265	DRUGINFO	D0UG5O	PMID28394193-Compound-20	Patented
T25265	DRUGINFO	D0VF0M	PMID28394193-Compound-19	Patented
T25265	DRUGINFO	D0W2KL	PMID28394193-Compound-37	Patented
T25265	DRUGINFO	D0W4MW	PMID28394193-Compound-Figure3bII	Patented
T25265	DRUGINFO	D0Z0NC	PMID28394193-Compound-26	Patented
T25265	DRUGINFO	D0Z0QS	PMID28394193-Compound-17	Patented
T25265	DRUGINFO	D0Z7GN	PMID28394193-Compound-34	Patented
T25265	DRUGINFO	D01PZZ	PMID28394193-Compound-56	Patented
T25265	DRUGINFO	D0D4UH	PMID28394193-Compound-46	Patented
T25265	DRUGINFO	D0G1JR	PMID28394193-Compound-57	Patented
T25265	DRUGINFO	D0GT7A	PMID28394193-Compound-14	Patented
T25265	DRUGINFO	D0H8VN	PMID28394193-Compound-12	Patented
T25265	DRUGINFO	D0L1TA	PMID26882240-Compound-1	Patented
T25265	DRUGINFO	D0M4LK	PMID28394193-Compound-55	Patented
T25265	DRUGINFO	D0M8AA	PMID28394193-Compound-45	Patented
T25265	DRUGINFO	D0TA4N	PMID28394193-Compound-13	Patented
T25265	DRUGINFO	D02BBA	EPZ005687	Investigative
T25265	DRUGINFO	D02CIT	EI1	Investigative
T25265	DRUGINFO	D02YXP	UNC1999	Investigative
T25265	DRUGINFO	D65IMT	MS1943	Investigative
T25265	DRUGINFO	D02TVQ	GSK343	Investigative

T53904	TARGETID	T53904
T53904	FORMERID	TTDC00054
T53904	UNIPROID	EGLN2_HUMAN
T53904	TARGNAME	HIF-prolyl hydroxylase 1 (HPH-1)
T53904	GENENAME	EGLN2
T53904	TARGTYPE	Successful
T53904	SYNONYMS	Prolyl hydroxylase domain-containing protein 1; PHD1; Hypoxia-inducible factor prolyl hydroxylase 1; HPH-3; HIF-PH1; HIF-PH; Estrogen-induced tag6; Estrogen-induced tag 6; Egl nine homolog 2; EIT6; EIT-6
T53904	FUNCTION	Hydroxylates a specific proline found in each of the oxygen-dependent degradation (ODD) domains (N-terminal, NODD, and C-terminal, CODD) of HIF1A. Also hydroxylates HIF2A. Has a preference for the CODD site for both HIF1A and HIF2A. Hydroxylated HIFs are then targeted for proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Under hypoxic conditions, the hydroxylation reaction is attenuated allowing HIFs to escape degradation resulting in their translocation to the nucleus, heterodimerization with HIF1B, and increased expression of hypoxy-inducible genes. EGLN2 is involved in regulating hypoxia tolerance and apoptosis in cardiac and skeletal muscle. Also regulates susceptibility to normoxic oxidative neuronal death. Links oxygen sensing to cell cycle and primary cilia formation by hydroxylating the critical centrosome component CEP192 which promotes its ubiquitination and subsequent proteasomal degradation. Hydroxylates IKBKB, mediating NF-kappaB activation in hypoxic conditions. Target proteins are preferentially recognized via a LXXLAP motif. Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins.
T53904	PDBSTRUC	5V1B
T53904	BIOCLASS	Paired donor oxygen oxidoreductase
T53904	ECNUMBER	EC 1.14.11.29
T53904	SEQUENCE	MDSPCQPQPLSQALPQLPGSSSEPLEPEPGRARMGVESYLPCPLLPSYHCPGVPSEASAGSGTPRATATSTTASPLRDGFGGQDGGELRPLQSEGAAALVTKGCQRLAAQGARPEAPKRKWAEDGGDAPSPSKRPWARQENQEAEREGGMSCSCSSGSGEASAGLMEEALPSAPERLALDYIVPCMRYYGICVKDSFLGAALGGRVLAEVEALKRGGRLRDGQLVSQRAIPPRSIRGDQIAWVEGHEPGCRSIGALMAHVDAVIRHCAGRLGSYVINGRTKAMVACYPGNGLGYVRHVDNPHGDGRCITCIYYLNQNWDVKVHGGLLQIFPEGRPVVANIEPLFDRLLIFWSDRRNPHEVKPAYATRYAITVWYFDAKERAAAKDKYQLASGQKGVQVPVSQPPTPT
T53904	DRUGINFO	D0F6JC	Daprodustat	Approved
T53904	DRUGINFO	D03YKE	FG-4592	Phase 3
T53904	DRUGINFO	D01SPD	BAY-85-3934	Phase 2
T53904	DRUGINFO	D07IOY	Pyridine-2,4-dicarboxylic acid	Investigative
T53904	DRUGINFO	D08IZY	2-(carboxymethylamino)-2-oxoacetic acid	Investigative

T64765	TARGETID	T64765
T64765	FORMERID	TTDC00079
T64765	UNIPROID	HRH3_HUMAN
T64765	TARGNAME	Histamine H3 receptor (H3R)
T64765	GENENAME	HRH3
T64765	TARGTYPE	Successful
T64765	SYNONYMS	Histamine receptor 3; HH3R; GPCR97; G-protein coupled receptor 97; G protein-coupled receptor 97
T64765	FUNCTION	Signals through the inhibition of adenylate cyclase and displays high constitutive activity (spontaneous activity in the absence of agonist). Agonist stimulation of isoform 3 neither modified adenylate cyclase activity nor induced intracellular calcium mobilization. The H3 subclass of histamine receptors could mediate the histamine signals in CNS and peripheral nervous system.
T64765	BIOCLASS	GPCR rhodopsin
T64765	SEQUENCE	MERAPPDGPLNASGALAGEAAAAGGARGFSAAWTAVLAALMALLIVATVLGNALVMLAFVADSSLRTQNNFFLLNLAISDFLVGAFCIPLYVPYVLTGRWTFGRGLCKLWLVVDYLLCTSSAFNIVLISYDRFLSVTRAVSYRAQQGDTRRAVRKMLLVWVLAFLLYGPAILSWEYLSGGSSIPEGHCYAEFFYNWYFLITASTLEFFTPFLSVTFFNLSIYLNIQRRTRLRLDGAREAAGPEPPPEAQPSPPPPPGCWGCWQKGHGEAMPLHRYGVGEAAVGAEAGEATLGGGGGGGSVASPTSSSGSSSRGTERPRSLKRGSKPSASSASLEKRMKMVSQSFTQRFRLSRDRKVAKSLAVIVSIFGLCWAPYTLLMIIRAACHGHCVPDYWYETSFWLLWANSAVNPVLYPLCHHSFRRAFTKLLCPQKLKIQPHSSLEHCWK
T64765	DRUGINFO	D01UUD	Pitolisant	Approved
T64765	DRUGINFO	D04KMP	SUVN-G3031	Phase 3
T64765	DRUGINFO	D02REJ	JNJ-17216498	Phase 2
T64765	DRUGINFO	D07YGH	GSK239512	Phase 2
T64765	DRUGINFO	D0EQ9T	JNJ-39220675	Phase 2
T64765	DRUGINFO	D0I6ZO	AZD-5213	Phase 2
T64765	DRUGINFO	D0M8OC	Bavisant	Phase 2
T64765	DRUGINFO	D0N8QK	ABT-288	Phase 2
T64765	DRUGINFO	D0O0EX	SAR-110894	Phase 2
T64765	DRUGINFO	D0S5BV	ABT-652	Phase 2
T64765	DRUGINFO	D0XW6Y	S-38093	Phase 2
T64765	DRUGINFO	D00GCA	MK-7288	Phase 1
T64765	DRUGINFO	D04LSD	ABT-239	Phase 1
T64765	DRUGINFO	D0N1GB	APD-916	Phase 1
T64765	DRUGINFO	D0OW9L	MK-3134	Phase 1
T64765	DRUGINFO	D0P2OK	HPP404	Phase 1
T64765	DRUGINFO	D0R2OU	Irdabisant	Phase 1
T64765	DRUGINFO	D0M9RQ	MK-0249	Clinical trial
T64765	DRUGINFO	D01EHZ	Piperazine carbamate/urea derivative 5	Patented
T64765	DRUGINFO	D01IJA	Piperazine carbamate/urea derivative 3	Patented
T64765	DRUGINFO	D02SKQ	PMID29334795-Compound-28	Patented
T64765	DRUGINFO	D03EHI	Acrylamide compound 3	Patented
T64765	DRUGINFO	D04DUF	Phenylsulfonyl derivative 2	Patented
T64765	DRUGINFO	D08EYN	Acrylamide compound 2	Patented
T64765	DRUGINFO	D09AQZ	PMID29334795-Compound-57	Patented
T64765	DRUGINFO	D09QCB	PMID29334795-Compound-56	Patented
T64765	DRUGINFO	D09STY	PMID29334795-Compound-55	Patented
T64765	DRUGINFO	D0A2ZO	Phenoxypiperidine derivative 2	Patented
T64765	DRUGINFO	D0A8VU	PMID29334795-Compound-58	Patented
T64765	DRUGINFO	D0AX9N	Biphenyl derivative 4	Patented
T64765	DRUGINFO	D0B2NV	PMID29334795-Compound-22	Patented
T64765	DRUGINFO	D0CE7X	4-benzylidene-1-(cyclobutylo)piperidine derivative 1	Patented
T64765	DRUGINFO	D0D8LP	Phenylsulfonyl derivative 3	Patented
T64765	DRUGINFO	D0DS9D	Acrylamide compound 4	Patented
T64765	DRUGINFO	D0EP0M	PMID29334795-Compound-24	Patented
T64765	DRUGINFO	D0F7UB	Triazolo-benzodiazepine derivative 1	Patented
T64765	DRUGINFO	D0F8PG	PMID29334795-Compound-21	Patented
T64765	DRUGINFO	D0FJ3N	Piperazine carbamate/urea derivative 2	Patented
T64765	DRUGINFO	D0GB3P	Pyridazin-3(2H)-one derivative 1	Patented
T64765	DRUGINFO	D0H7OC	Piperazine carbamate/urea derivative 4	Patented
T64765	DRUGINFO	D0K9MH	Acrylamide compound 1	Patented
T64765	DRUGINFO	D0KP0I	Piperazine carbamate/urea derivative 1	Patented
T64765	DRUGINFO	D0QV0P	Phenoxypiperidine derivative 1	Patented
T64765	DRUGINFO	D0R0GY	Piperazine carbamate/urea derivative 7	Patented
T64765	DRUGINFO	D0RV0O	PMID29334795-Compound-23	Patented
T64765	DRUGINFO	D0SZ1L	Triazolo-benzodiazepine derivative 2	Patented
T64765	DRUGINFO	D0TE2D	PMID29334795-Compound-25	Patented
T64765	DRUGINFO	D0TM4R	Piperazine carbamate/urea derivative 6	Patented
T64765	DRUGINFO	D0V2WE	Steroidal carboxamide derivative 1	Patented
T64765	DRUGINFO	D0W3RA	Phenylsulfonyl derivative 1	Patented
T64765	DRUGINFO	D0ZC7W	Phenylsulfonyl derivative 4	Patented
T64765	DRUGINFO	D05KKZ	PMID29334795-Compound-67	Patented
T64765	DRUGINFO	D0BZ0N	Benzo[d]oxazol-2(3H)-one derivative 2	Patented
T64765	DRUGINFO	D0D5AH	PMID29334795-Compound-62	Patented
T64765	DRUGINFO	D0N8CU	Benzo[d]oxazol-2(3H)-one derivative 3	Patented
T64765	DRUGINFO	D0RP1J	PMID29334795-Compound-66	Patented
T64765	DRUGINFO	D0SO4O	Benzo[d]oxazol-2(3H)-one derivative 1	Patented
T64765	DRUGINFO	D0FA3G	PMID29334795-Compound-61	Patented
T64765	DRUGINFO	D0VX6P	Piperidine derivative 1	Patented
T64765	DRUGINFO	D0P9LO	BP-2.94	Discontinued in Phase 2
T64765	DRUGINFO	D0Q5YF	Cipralisant	Discontinued in Phase 2
T64765	DRUGINFO	D04IFU	GSK835726	Discontinued in Phase 2
T64765	DRUGINFO	D02EVT	SAR-152954	Discontinued in Phase 1
T64765	DRUGINFO	D0B4TT	GSK1004723	Discontinued in Phase 1
T64765	DRUGINFO	D02KAF	GT-2203	Terminated
T64765	DRUGINFO	D02YXQ	GT-2016	Terminated
T64765	DRUGINFO	D06TEO	UCL-1390	Terminated
T64765	DRUGINFO	D0N2CN	GR-175737	Terminated
T64765	DRUGINFO	D05FYA	Thioperamide	Terminated
T64765	DRUGINFO	D00HWF	Proxyfan	Investigative
T64765	DRUGINFO	D00IIQ	(S)-1-(4-nitrophenethyl)-2-methylpyrrolidine	Investigative
T64765	DRUGINFO	D00PSJ	2-(3-Methyl-3H-imidazol-4-yl)-ethylamine	Investigative
T64765	DRUGINFO	D00RUN	4-(7,7-Dimethyl-oct-3-ynyl)-1H-imidazole	Investigative
T64765	DRUGINFO	D00SHX	1-[2-(2,4,6-trimethyl-phenyl)-ethyl]-pyrrolidine	Investigative
T64765	DRUGINFO	D01CJZ	VUF 5681	Investigative
T64765	DRUGINFO	D01RJV	4-((2S,3R)-2-Methyl-pyrrolidin-3-yl)-1H-imidazole	Investigative
T64765	DRUGINFO	D01RTR	(R)-3-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine	Investigative
T64765	DRUGINFO	D02BXA	2-(2-(pyrrolidin-1-yl)ethyl)pyridine	Investigative
T64765	DRUGINFO	D02HNE	5-(2-(pyrrolidin-1-yl)ethyl)isothiazole	Investigative
T64765	DRUGINFO	D02IJW	(S)-4-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine	Investigative
T64765	DRUGINFO	D02INJ	4-(2-(Phenylamino)ethyl)-1H-imidazole	Investigative
T64765	DRUGINFO	D02LZL	4-(6-Cyclohexyl-hex-3-ynyl)-1H-imidazole	Investigative
T64765	DRUGINFO	D02SWF	(1R,2R)-2-(1H-Imidazol-4-yl)-1-methyl-propylamine	Investigative
T64765	DRUGINFO	D03QGB	JNJ-5207852	Investigative
T64765	DRUGINFO	D04ATN	4-[3-(4-Ethynyl-phenoxy)-propyl]-1H-imidazole	Investigative
T64765	DRUGINFO	D04FUZ	1-(3-(2-(3-methoxyphenoxy)ethoxy)propyl)azepane	Investigative
T64765	DRUGINFO	D04LFK	2-(2-(pyrrolidin-1-yl)ethyl)-1H-indole	Investigative
T64765	DRUGINFO	D04MKB	ST-1025	Investigative
T64765	DRUGINFO	D04NWI	(R)-2-methyl-1-(2-m-tolyl-ethyl)-pyrrolidine	Investigative
T64765	DRUGINFO	D04ZOI	4-(8-Phenyl-oct-3-ynyl)-1H-imidazole	Investigative
T64765	DRUGINFO	D05ANV	1-(2-p-tolyl-ethyl)-pyrrolidine	Investigative
T64765	DRUGINFO	D05BYD	A-304121	Investigative
T64765	DRUGINFO	D05JZQ	2-(2-(pyrrolidin-1-yl)ethyl)phenol	Investigative
T64765	DRUGINFO	D05OHN	4-isopropyl-2-(phenoxymethyl)morpholine	Investigative
T64765	DRUGINFO	D05PBN	(R)-2-methyl-1-(2-p-tolyl-ethyl)-pyrrolidine	Investigative
T64765	DRUGINFO	D05RGW	Methimepip	Investigative
T64765	DRUGINFO	D06MGO	(S)-1-(2-methoxyphenethyl)-2-methylpyrrolidine	Investigative
T64765	DRUGINFO	D06RPY	2-[4-(1-Ethyl-propyl)-piperazin-1-yl]-quinoline	Investigative
T64765	DRUGINFO	D06ZBV	CARCININE	Investigative
T64765	DRUGINFO	D07JHD	VUF5391	Investigative
T64765	DRUGINFO	D07KTP	SCH79687	Investigative
T64765	DRUGINFO	D07LCM	1-(3-methoxyphenethyl)pyrrolidine	Investigative
T64765	DRUGINFO	D07PSG	5-phenyl-2-(4-(piperidin-1-yl)butyl)oxazole	Investigative
T64765	DRUGINFO	D07TST	4-(2-(Cyclohexylamino)ethyl)-1H-imidazole	Investigative
T64765	DRUGINFO	D07UCE	4-Benzyl-1-[3-phenylpropoxy)propyl]piperidine	Investigative
T64765	DRUGINFO	D08BSG	IODOPROXYFAN	Investigative
T64765	DRUGINFO	D08HYX	4-Hex-3-ynyl-1H-imidazole	Investigative
T64765	DRUGINFO	D09DDQ	FUB-130	Investigative
T64765	DRUGINFO	D09JSA	1-(3-(3-phenylpropoxy)propyl)piperidine	Investigative
T64765	DRUGINFO	D09NSH	JB 98064	Investigative
T64765	DRUGINFO	D09ROG	UCL-2138	Investigative
T64765	DRUGINFO	D09WQL	Immethridine	Investigative
T64765	DRUGINFO	D0A2WT	4-((2R,3S)-2-Methyl-pyrrolidin-3-yl)-1H-imidazole	Investigative
T64765	DRUGINFO	D0B5SF	4-(2-(3,4-Dimethylphenylamino)ethyl)-1H-imidazole	Investigative
T64765	DRUGINFO	D0B6CA	4-(2-(pyrrolidin-1-yl)ethyl)pyridine	Investigative
T64765	DRUGINFO	D0CI9W	GSK-334429	Investigative
T64765	DRUGINFO	D0D0FV	(R)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine	Investigative
T64765	DRUGINFO	D0D9JL	1-(2-m-tolyl-ethyl)-pyrrolidine	Investigative
T64765	DRUGINFO	D0DC1P	1-(3-(4-(2-fluoroethyl)phenoxy)propyl)piperidine	Investigative
T64765	DRUGINFO	D0DG5A	4-(7-Methyl-oct-3-ynyl)-1H-imidazole	Investigative
T64765	DRUGINFO	D0E5EB	impentamine	Investigative
T64765	DRUGINFO	D0E5XM	imbutamine	Investigative
T64765	DRUGINFO	D0F2XZ	(S)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine	Investigative
T64765	DRUGINFO	D0F9OP	Aerophobin-1	Investigative
T64765	DRUGINFO	D0FK6T	2-(4-Cyclopentyl-piperazin-1-yl)-quinoline	Investigative
T64765	DRUGINFO	D0FN7I	Des-bromoaplysamine-1	Investigative
T64765	DRUGINFO	D0G3RN	VUF-10214	Investigative
T64765	DRUGINFO	D0G5DU	4-Propyl-1-[3-(phenylpropoxy)propyl]piperidine	Investigative
T64765	DRUGINFO	D0G5GV	[123I]iodoproxyfan	Investigative
T64765	DRUGINFO	D0G5TD	(S)-1-(3-methoxyphenethyl)-2-methylpyrrolidine	Investigative
T64765	DRUGINFO	D0H3DY	VUF-5297	Investigative
T64765	DRUGINFO	D0H3LF	2-(4-Isopropyl-piperazin-1-yl)-quinoline	Investigative
T64765	DRUGINFO	D0H4ID	(S)-3-(1H-imidazol-4-yl)propyl sec-butylcarbamate	Investigative
T64765	DRUGINFO	D0H4TP	GSK189254A	Investigative
T64765	DRUGINFO	D0H9IH	(R)-1-(3-methoxyphenethyl)-2-methylpyrrolidine	Investigative
T64765	DRUGINFO	D0HF4I	4-(2-(4-Methoxyphenylamino)ethyl)-1H-imidazole	Investigative
T64765	DRUGINFO	D0HM7G	SUVN-G1031	Investigative
T64765	DRUGINFO	D0I3TN	(1S,2S)-2-(1H-Imidazol-4-yl)-cyclopentylamine	Investigative
T64765	DRUGINFO	D0I4BC	1-(2-(naphthalen-2-yl)ethyl)pyrrolidine	Investigative
T64765	DRUGINFO	D0I4UU	FUB 349	Investigative
T64765	DRUGINFO	D0J6NI	4-((1H-Imidazol-4-yl)methyl)-1-phenylpiperidine	Investigative
T64765	DRUGINFO	D0J6XO	A-331440	Investigative
T64765	DRUGINFO	D0K1PS	(1R,2S)-2-(1H-Imidazol-4-yl)-1-methyl-propylamine	Investigative
T64765	DRUGINFO	D0K7XM	APLYSAMINE	Investigative
T64765	DRUGINFO	D0K8DZ	VUF 5207	Investigative
T64765	DRUGINFO	D0K9WJ	2-(4-Cyclopropyl-piperazin-1-yl)-quinoline	Investigative
T64765	DRUGINFO	D0KK4C	2-[2-(1H-Imidazol-4-yl)-cyclopropyl]-ethylamine	Investigative
T64765	DRUGINFO	D0M2HC	4-(2-(4-Methylphenylamino)ethyl)-1H-imidazole	Investigative
T64765	DRUGINFO	D0M4JK	UCB-2892	Investigative
T64765	DRUGINFO	D0M7QR	5-ethyl-2-(2-(pyrrolidin-1-yl)ethyl)pyridine	Investigative
T64765	DRUGINFO	D0M7TW	PF-3900422	Investigative
T64765	DRUGINFO	D0MR0Z	(R)-1-(4-methoxyphenethyl)-2-methylpyrrolidine	Investigative
T64765	DRUGINFO	D0MX0Z	(R)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)phenol	Investigative
T64765	DRUGINFO	D0N3OH	A-317920	Investigative
T64765	DRUGINFO	D0N6CB	ST-1093	Investigative
T64765	DRUGINFO	D0N7KK	5-methoxy-2-(2-(pyrrolidin-1-yl)ethyl)-1H-indole	Investigative
T64765	DRUGINFO	D0O3GR	4-[3-(4-Methoxy-phenoxy)-propyl]-1H-imidazole	Investigative
T64765	DRUGINFO	D0O9LR	4-[3-(4-Butyl-phenoxy)-propyl]-1H-imidazole	Investigative
T64765	DRUGINFO	D0O9YL	(R)-1-(2-methoxyphenethyl)-2-methylpyrrolidine	Investigative
T64765	DRUGINFO	D0OB7B	2-(1,4'-bipiperidin-1'-yl)thiazolo[4,5-b]pyridine	Investigative
T64765	DRUGINFO	D0OM9G	Immepip	Investigative
T64765	DRUGINFO	D0P2UM	2-(ethoxycarbonyl)-1H-indole-5-carboxylic acid	Investigative
T64765	DRUGINFO	D0P8SU	(R)-1-(4-nitrophenethyl)-2-methylpyrrolidine	Investigative
T64765	DRUGINFO	D0P8UI	(S)-2-methyl-1-(2-p-tolyl-ethyl)-pyrrolidine	Investigative
T64765	DRUGINFO	D0Q0YC	2-(4-Propyl-piperazin-1-yl)-quinoline	Investigative
T64765	DRUGINFO	D0Q6TU	GT2394	Investigative
T64765	DRUGINFO	D0Q8CE	4-(2-(3-tert-Butylphenylamino)ethyl)-1H-imidazole	Investigative
T64765	DRUGINFO	D0Q8LU	2-(1,4'-bipiperidin-1'-yl)thiazolo[4,5-c]pyridine	Investigative
T64765	DRUGINFO	D0Q8NO	VUF 8328	Investigative
T64765	DRUGINFO	D0QP3A	1-(4-(benzyloxy)phenethyl)pyrrolidine	Investigative
T64765	DRUGINFO	D0R2TU	4-(3-Phenoxy-propyl)-1H-imidazole	Investigative
T64765	DRUGINFO	D0RP8X	UCL1972	Investigative
T64765	DRUGINFO	D0S0HT	3-((1H-imidazol-4-yl)methyl)pyridine	Investigative
T64765	DRUGINFO	D0S5ON	1-(4-nitrophenethyl)pyrrolidine	Investigative
T64765	DRUGINFO	D0S5VI	N-benzyl-4-cyclopentylpiperazine-1-carboxamide	Investigative
T64765	DRUGINFO	D0SQ0T	C-[2-(1H-Imidazol-4-yl)-cyclopropyl]-methylamine	Investigative
T64765	DRUGINFO	D0T5KC	(S)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)phenol	Investigative
T64765	DRUGINFO	D0T6TH	EVT-501	Investigative
T64765	DRUGINFO	D0T8MV	(S)-1-(4-methoxyphenethyl)-2-methylpyrrolidine	Investigative
T64765	DRUGINFO	D0TW9N	2-((2-ethoxyphenoxy)methyl)-4-isopropylmorpholine	Investigative
T64765	DRUGINFO	D0U1DR	VUF 4904	Investigative
T64765	DRUGINFO	D0UO2Z	4-(2-(4-Cyclohexylphenylamino)ethyl)-1H-imidazole	Investigative
T64765	DRUGINFO	D0UW9I	(S)-2-methyl-1-(2-m-tolyl-ethyl)-pyrrolidine	Investigative
T64765	DRUGINFO	D0V4XA	ATH-90879	Investigative
T64765	DRUGINFO	D0V7YQ	4-((1H-imidazol-4-yl)methyl)-1-heptylpiperidine	Investigative
T64765	DRUGINFO	D0V8MJ	4-(6-Cyclopentyl-hex-3-ynyl)-1H-imidazole	Investigative
T64765	DRUGINFO	D0V9AJ	1-(2-methoxyphenethyl)pyrrolidine	Investigative
T64765	DRUGINFO	D0W1GR	4-Hept-3-ynyl-1H-imidazole	Investigative
T64765	DRUGINFO	D0W2HJ	1-(4-methoxyphenethyl)pyrrolidine	Investigative
T64765	DRUGINFO	D0W7OR	2-((1H-imidazol-4-yl)methyl)pyridine	Investigative
T64765	DRUGINFO	D0X5DB	4-(2-(4-tert-Butylphenylamino)ethyl)-1H-imidazole	Investigative
T64765	DRUGINFO	D0X6SR	(R)-4-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine	Investigative
T64765	DRUGINFO	D0XW9U	N-methyl-2-(pyridin-2-yl)ethanamine	Investigative
T64765	DRUGINFO	D0Y5MS	Verongamine	Investigative
T64765	DRUGINFO	D0Y5WD	1-(3-(4-(fluoromethyl)phenoxy)propyl)piperidine	Investigative
T64765	DRUGINFO	D0ZY8V	4-Butyl-1-[3-(phenylpropoxy)propyl]piperidine	Investigative
T64765	DRUGINFO	D02RAN	Imetit	Investigative
T64765	DRUGINFO	D03ECU	[125I]iodophenpropit	Investigative
T64765	DRUGINFO	D03SAM	(R)-alpha-methylhistamine	Investigative
T64765	DRUGINFO	D06NXK	(R)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline	Investigative
T64765	DRUGINFO	D08ECP	N-[3H]alpha-methylhistamine	Investigative
T64765	DRUGINFO	D0A4XL	N-[3H]methylhistamine	Investigative
T64765	DRUGINFO	D0A9QT	JNJ-28583867	Investigative
T64765	DRUGINFO	D0C8IB	(R)-3-(1H-imidazol-4-yl)propyl sec-butylcarbamate	Investigative
T64765	DRUGINFO	D0H2KD	(1H-indol-2-yl)(piperazin-1-yl)methanone	Investigative
T64765	DRUGINFO	D0Q8BS	(S)-alpha-methylhistamine	Investigative
T64765	DRUGINFO	D0T6SC	N-methylhistamine	Investigative
T64765	DRUGINFO	D0T8OD	Clobenpropit	Investigative
T64765	DRUGINFO	D06RNM	burimamide	Investigative
T64765	DRUGINFO	D0G2BS	2-(4-Methyl-piperazin-1-yl)-quinoline	Investigative
T64765	DRUGINFO	D0M9IC	CONESSINE	Investigative
T64765	DRUGINFO	D01JXM	2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole	Investigative
T64765	DRUGINFO	D0B4SF	impromidine	Investigative
T64765	DRUGINFO	D0I3XA	Ciproxifan	Investigative
T64765	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T29024	TARGETID	T29024
T29024	FORMERID	TTDC00325
T29024	UNIPROID	SODC_HUMAN
T29024	TARGNAME	SOD1 messenger RNA (SOD1 mRNA)
T29024	GENENAME	SOD1
T29024	TARGTYPE	Successful
T29024	SYNONYMS	hSod1 (mRNA); Superoxide dismutase [Cu-Zn] (mRNA); Superoxide dismutase 1 (mRNA); Superoxide dismutase (mRNA)
T29024	FUNCTION	Destroys radicals which are normally produced within the cells and which are toxic to biological systems.
T29024	PDBSTRUC	6FP6; 6FON; 6FOL; 6FOI; 6FLH
T29024	BIOCLASS	mRNA target
T29024	ECNUMBER	EC 1.15.1.1
T29024	SEQUENCE	MATKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAGCTSAGPHFNPLSRKHGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCIIGRTLVVHEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQ
T29024	DRUGINFO	D0I1CQ	Tofersen	Approved
T29024	DRUGINFO	D05BYO	ISIS-SOD1	Phase 1
T29024	DRUGINFO	D05EJO	ISIS 150463	Investigative
T29024	DRUGINFO	D05RSX	ISIS 150454	Investigative
T29024	DRUGINFO	D07AGD	ISIS 150450	Investigative
T29024	DRUGINFO	D07MGX	ISIS 150451	Investigative
T29024	DRUGINFO	D0A3RM	ISIS 150452	Investigative
T29024	DRUGINFO	D0BP6T	ISIS 150464	Investigative
T29024	DRUGINFO	D0F4SF	ISIS 150453	Investigative

T30687	TARGETID	T30687
T30687	FORMERID	TTDR01436
T30687	UNIPROID	GCR_HUMAN
T30687	TARGNAME	Glucocorticoid receptor messenger RNA (GCR mRNA)
T30687	GENENAME	NR3C1
T30687	TARGTYPE	Successful
T30687	SYNONYMS	Nuclear receptor subfamily 3 group C member 1 (mRNA); Glucocorticoid receptor (mRNA); GRL (mRNA); GR (mRNA); Alpha-A (mRNA)
T30687	FUNCTION	Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Involved in chromatin remodeling. Plays a role in rapid mRNA degradation by binding to the 5' UTR of target mRNAs and interacting with PNRC2 in a ligand-dependent manner which recruits the RNA helicase UPF1 and the mRNA-decapping enzyme DCP1A, leading to RNA decay. Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth. Receptor for glucocorticoids (GC).
T30687	PDBSTRUC	6EL9; 6EL7; 6EL6; 6DXK; 6CFN
T30687	BIOCLASS	mRNA target
T30687	SEQUENCE	MDSKESLTPGREENPSSVLAQERGDVMDFYKTLRGGATVKVSASSPSLAVASQSDSKQRRLLVDFPKGSVSNAQQPDLSKAVSLSMGLYMGETETKVMGNDLGFPQQGQISLSSGETDLKLLEESIANLNRSTSVPENPKSSASTAVSAAPTEKEFPKTHSDVSSEQQHLKGQTGTNGGNVKLYTTDQSTFDILQDLEFSSGSPGKETNESPWRSDLLIDENCLLSPLAGEDDSFLLEGNSNEDCKPLILPDTKPKIKDNGDLVLSSPSNVTLPQVKTEKEDFIELCTPGVIKQEKLGTVYCQASFPGANIIGNKMSAISVHGVSTSGGQMYHYDMNTASLSQQQDQKPIFNVIPPIPVGSENWNRCQGSGDDNLTSLGTLNFPGRTVFSNGYSSPSMRPDVSSPPSSSSTATTGPPPKLCLVCSDEASGCHYGVLTCGSCKVFFKRAVEGQHNYLCAGRNDCIIDKIRRKNCPACRYRKCLQAGMNLEARKTKKKIKGIQQATTGVSQETSENPGNKTIVPATLPQLTPTLVSLLEVIEPEVLYAGYDSSVPDSTWRIMTTLNMLGGRQVIAAVKWAKAIPGFRNLHLDDQMTLLQYSWMFLMAFALGWRSYRQSSANLLCFAPDLIINEQRMTLPCMYDQCKHMLYVSSELHRLQVSYEEYLCMKTLLLLSSVPKDGLKSQELFDEIRMTYIKELGKAIVKREGNSSQNWQRFYQLTKLLDSMHEVVENLLNYCFQTFLDKTMSIEFPEMLAEIITNQIPKYSNGNIKKLLFHQK
T30687	DRUGINFO	D0F6YM	Vamorolone	Approved
T30687	DRUGINFO	D07UIS	CORT125281	Phase 2
T30687	DRUGINFO	D0F8XK	ISIS-GCCR	Phase 2
T30687	DRUGINFO	D0HE7C	ORIC-101	Phase 1
T30687	DRUGINFO	D0SZ1G	AZD9567	Phase 1
T30687	DRUGINFO	D0W8OJ	A-348441	Phase 1
T30687	DRUGINFO	D05XVM	1-Methoxy-6-phenyl-6H-benzo[c]chromen-8-ylamine	Investigative
T30687	DRUGINFO	D06TOI	RU26988	Investigative
T30687	DRUGINFO	D09FQL	ENDIANDRIN A	Investigative
T30687	DRUGINFO	D0D6GI	1-(3-CHLORO-4-FLUOROPHENYL)-2,2,2-TRIFLUORO-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (ENANTIOMERIC MIX)	Investigative
T30687	DRUGINFO	D0EG5G	1-(2,3-DICHLOROPHENYL)-2,2,2-TRIFLUORO-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (ENANTIOMERIC MIX)	Investigative
T30687	DRUGINFO	D0N8UD	2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (DIASTEREOMERIC MIX)	Investigative
T30687	DRUGINFO	D0O5ZG	1-Methoxy-6-phenyl-6H-benzo[c]chromene	Investigative
T30687	DRUGINFO	D0PR2T	DI-O-METHYLENDIANDRIN A	Investigative
T30687	DRUGINFO	D0S9KH	OXDEX	Investigative
T30687	DRUGINFO	D0Z7YK	RU28362	Investigative
T30687	DRUGINFO	D04SQY	deoxycorticosterone	Investigative
T30687	DRUGINFO	D07KWO	RU-43044	Investigative
T30687	DRUGINFO	D03TNT	(11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE	Investigative
T30687	DRUGINFO	D09OKK	LG-120838	Investigative
T30687	DRUGINFO	D0XS0R	Epierenone	Investigative
T30687	DRUGINFO	D08KQM	LGD-5552	Investigative
T30687	DRUGINFO	D0GR5L	AL-43	Investigative
T30687	DRUGINFO	D0J7XZ	CP-409069	Investigative
T30687	DRUGINFO	D0L5IC	CP-394531	Investigative
T30687	DRUGINFO	D0V4RZ	WAY-214950	Investigative
T30687	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T86652	TARGETID	T86652
T86652	FORMERID	TTDR01439
T86652	UNIPROID	PCSK9_HUMAN
T86652	TARGNAME	PCSK9 messenger RNA (PCSK9 mRNA)
T86652	GENENAME	PCSK9
T86652	TARGTYPE	Successful
T86652	SYNONYMS	Subtilisin/kexin-like protease PC9 (mRNA); Proprotein convertase subtilisin/kexin type 9 (mRNA); Proprotein convertase 9 (mRNA); PSEC0052 (mRNA); PC9 (mRNA); Neural apoptosis-regulated convertase 1 (mRNA); NARC1 (mRNA); NARC-1 (mRNA)
T86652	FUNCTION	Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways. Crucial player in the regulation of plasma cholesterol homeostasis.
T86652	PDBSTRUC	6MV5; 6F5G; 6E4Z; 6E4Y; 5VLP
T86652	BIOCLASS	mRNA target
T86652	ECNUMBER	EC 3.4.21.-
T86652	SEQUENCE	MGTVSSRRSWWPLPLLLLLLLLLGPAGARAQEDEDGDYEELVLALRSEEDGLAEAPEHGTTATFHRCAKDPWRLPGTYVVVLKEETHLSQSERTARRLQAQAARRGYLTKILHVFHGLLPGFLVKMSGDLLELALKLPHVDYIEEDSSVFAQSIPWNLERITPPRYRADEYQPPDGGSLVEVYLLDTSIQSDHREIEGRVMVTDFENVPEEDGTRFHRQASKCDSHGTHLAGVVSGRDAGVAKGASMRSLRVLNCQGKGTVSGTLIGLEFIRKSQLVQPVGPLVVLLPLAGGYSRVLNAACQRLARAGVVLVTAAGNFRDDACLYSPASAPEVITVGATNAQDQPVTLGTLGTNFGRCVDLFAPGEDIIGASSDCSTCFVSQSGTSQAAAHVAGIAAMMLSAEPELTLAELRQRLIHFSAKDVINEAWFPEDQRVLTPNLVAALPPSTHGAGWQLFCRTVWSAHSGPTRMATAVARCAPDEELLSCSSFSRSGKRRGERMEAQGGKLVCRAHNAFGGEGVYAIARCCLLPQANCSVHTAPPAEASMGTRVHCHQQGHVLTGCSSHWEVEDLGTHKPPVLRPRGQPNQCVGHREASIHASCCHAPGLECKVKEHGIPAPQEQVTVACEEGWTLTGCSALPGTSHVLGAYAVDNTCVVRSRDVSTTGSTSEGAVTAVAICCRSRHLAQASQELQ
T86652	DRUGINFO	D00COJ	Inclisiran	Approved
T86652	DRUGINFO	D0B1TI	MPSK3169A	Phase 2
T86652	DRUGINFO	D81WHA	AZD8233	Phase 2
T86652	DRUGINFO	D0G9OC	BMS-PCSK9	Preclinical
T86652	DRUGINFO	D0H5HJ	ALN-PCS	Preclinical

T26851	TARGETID	T26851
T26851	FORMERID	TTDR01153
T26851	UNIPROID	CO3_HUMAN
T26851	TARGNAME	Complement C3 (CO3)
T26851	GENENAME	C3
T26851	TARGTYPE	Successful
T26851	SYNONYMS	C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1; C3
T26851	FUNCTION	Acylation stimulating protein: adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial TG clearance. Appears to stimulate TG synthesis via activation of the PLC, MAPK and AKT signaling pathways. Ligand for C5AR2. Promotes the phosphorylation, ARRB2-mediated internalization and recycling of C5AR2 (PubMed:8376604, PubMed:2909530, PubMed:9059512, PubMed:10432298, PubMed:15833747, PubMed:16333141, PubMed:19615750).
T26851	PDBSTRUC	6EHG; 5O35; 5O32; 5NBQ; 5M6W
T26851	BIOCLASS	Complement system
T26851	SEQUENCE	MGPTSGPSLLLLLLTHLPLALGSPMYSIITPNILRLESEETMVLEAHDAQGDVPVTVTVHDFPGKKLVLSSEKTVLTPATNHMGNVTFTIPANREFKSEKGRNKFVTVQATFGTQVVEKVVLVSLQSGYLFIQTDKTIYTPGSTVLYRIFTVNHKLLPVGRTVMVNIENPEGIPVKQDSLSSQNQLGVLPLSWDIPELVNMGQWKIRAYYENSPQQVFSTEFEVKEYVLPSFEVIVEPTEKFYYIYNEKGLEVTITARFLYGKKVEGTAFVIFGIQDGEQRISLPESLKRIPIEDGSGEVVLSRKVLLDGVQNPRAEDLVGKSLYVSATVILHSGSDMVQAERSGIPIVTSPYQIHFTKTPKYFKPGMPFDLMVFVTNPDGSPAYRVPVAVQGEDTVQSLTQGDGVAKLSINTHPSQKPLSITVRTKKQELSEAEQATRTMQALPYSTVGNSNNYLHLSVLRTELRPGETLNVNFLLRMDRAHEAKIRYYTYLIMNKGRLLKAGRQVREPGQDLVVLPLSITTDFIPSFRLVAYYTLIGASGQREVVADSVWVDVKDSCVGSLVVKSGQSEDRQPVPGQQMTLKIEGDHGARVVLVAVDKGVFVLNKKNKLTQSKIWDVVEKADIGCTPGSGKDYAGVFSDAGLTFTSSSGQQTAQRAELQCPQPAARRRRSVQLTEKRMDKVGKYPKELRKCCEDGMRENPMRFSCQRRTRFISLGEACKKVFLDCCNYITELRRQHARASHLGLARSNLDEDIIAEENIVSRSEFPESWLWNVEDLKEPPKNGISTKLMNIFLKDSITTWEILAVSMSDKKGICVADPFEVTVMQDFFIDLRLPYSVVRNEQVEIRAVLYNYRQNQELKVRVELLHNPAFCSLATTKRRHQQTVTIPPKSSLSVPYVIVPLKTGLQEVEVKAAVYHHFISDGVRKSLKVVPEGIRMNKTVAVRTLDPERLGREGVQKEDIPPADLSDQVPDTESETRILLQGTPVAQMTEDAVDAERLKHLIVTPSGCGEQNMIGMTPTVIAVHYLDETEQWEKFGLEKRQGALELIKKGYTQQLAFRQPSSAFAAFVKRAPSTWLTAYVVKVFSLAVNLIAIDSQVLCGAVKWLILEKQKPDGVFQEDAPVIHQEMIGGLRNNNEKDMALTAFVLISLQEAKDICEEQVNSLPGSITKAGDFLEANYMNLQRSYTVAIAGYALAQMGRLKGPLLNKFLTTAKDKNRWEDPGKQLYNVEATSYALLALLQLKDFDFVPPVVRWLNEQRYYGGGYGSTQATFMVFQALAQYQKDAPDHQELNLDVSLQLPSRSSKITHRIHWESASLLRSEETKENEGFTVTAEGKGQGTLSVVTMYHAKAKDQLTCNKFDLKVTIKPAPETEKRPQDAKNTMILEICTRYRGDQDATMSILDISMMTGFAPDTDDLKQLANGVDRYISKYELDKAFSDRNTLIIYLDKVSHSEDDCLAFKVHQYFNVELIQPGAVKVYAYYNLEESCTRFYHPEKEDGKLNKLCRDELCRCAEENCFIQKSDDKVTLEERLDKACEPGVDYVYKTRLVKVQLSNDFDEYIMAIEQTIKSGSDEVQVGQQRTFISPIKCREALKLEEKKHYLMWGLSSDFWGEKPNLSYIIGKDTWVEHWPEEDECQDEENQKQCQDLGAFTESMVVFGCPN
T26851	DRUGINFO	D0P5LH	Pegcetacoplan	Approved
T26851	DRUGINFO	D0P6MW	Imprime PGG	Phase 2/3
T26851	DRUGINFO	D01SQI	POT-4	Phase 2
T26851	DRUGINFO	D4ME2Z	NGM621	Phase 2
T26851	DRUGINFO	DSI31T	AMY-101	Phase 2
T26851	DRUGINFO	D00BCO	Ac-I[CV(Bta)QDWGAHRC]T	Investigative
T26851	DRUGINFO	D00CYF	Ac-I[CVWQDWGWHRC]T-NH2	Investigative
T26851	DRUGINFO	D01DQT	Ac-ICVWQDWGAHRCT-NH2	Investigative
T26851	DRUGINFO	D01ZRJ	Ac-I[CV(Bta)QDWGAHRC]T-NH2	Investigative
T26851	DRUGINFO	D02AWT	Ac-I[CV(Bpa)QDWGAHRC]T	Investigative
T26851	DRUGINFO	D02CSO	Ac-I[CVWQDWG(Abu)HRC]T-NH2	Investigative
T26851	DRUGINFO	D03SHO	Ac-I[CVVQDWGAHRC]T-NH2	Investigative
T26851	DRUGINFO	D05AIB	Ac-I[CVHQDWGHHRC]T-NH2	Investigative
T26851	DRUGINFO	D05LJY	Ac-I[CV(2Nal)QDWGAHRC]T	Investigative
T26851	DRUGINFO	D07VEA	Ac-ICV(1MeW)QDWGAHRCT-NH2	Investigative
T26851	DRUGINFO	D0B4JO	Ac-I[CVWQDWGAHRC]T	Investigative
T26851	DRUGINFO	D0D3VF	Ac-ICV(5fW)QDWGAHRCT-NH2	Investigative
T26851	DRUGINFO	D0DR3X	Ac-I[CV(2Igl)QDWGAHRC]T	Investigative
T26851	DRUGINFO	D0G4VH	Ac-I[CVSQDWGHHRC]T-NH2	Investigative
T26851	DRUGINFO	D0J3BV	Ac-I[CV(Bpa)QDWGAHRC]T-NH2	Investigative
T26851	DRUGINFO	D0N6LH	Ac-I[CV(1Nal)QDWGAHRC]T	Investigative
T26851	DRUGINFO	D0O2BI	Ac-I[CVWQDWGHHRC]T-NH2	Investigative
T26851	DRUGINFO	D0PD8G	Ac-I[CV(Dht)QDWGAHRC]T	Investigative
T26851	DRUGINFO	D0Q0HE	Ac-I[CVTQDWGHHRC]T-NH2	Investigative
T26851	DRUGINFO	D0R1MR	Ac-I[CVFQDWGHHRC]T-NH2	Investigative
T26851	DRUGINFO	D0R2FS	Ac-I[CVWQDWGAHRC]dT	Investigative
T26851	DRUGINFO	D0T0PR	Ac-I[CV(Yphs)QDWGAHRC]I-NH2	Investigative
T26851	DRUGINFO	D0T6ST	Ac-I[CV(2Nal)QDWGAHRC]T-NH2	Investigative
T26851	DRUGINFO	D0T7CN	Ac-ICVWQD(5fW)GAHRCT-NH2	Investigative
T26851	DRUGINFO	D0UK9D	Ac-I[CV(2Igl)QDWGAHRC]T-NH2	Investigative
T26851	DRUGINFO	D0V0RO	Ac-I[CVYQDWGAHRC]T-NH2	Investigative
T26851	DRUGINFO	D0Y9TF	Ac-ICV(5MeW)QDWGAHRCT-NH2	Investigative
T26851	DRUGINFO	D0V6UC	Cysteine Sulfenic Acid	Investigative

T23348	TARGETID	T23348
T23348	FORMERID	TTDC00108
T23348	UNIPROID	VWF_HUMAN
T23348	TARGNAME	von Willebrand factor (VWF)
T23348	GENENAME	VWF
T23348	TARGTYPE	Successful
T23348	SYNONYMS	vWF; F8VWF
T23348	FUNCTION	Acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma. Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V.
T23348	PDBSTRUC	6N29; 6FWN; 5BV8; 4NT5; 4DMU
T23348	SEQUENCE	MIPARFAGVLLALALILPGTLCAEGTRGRSSTARCSLFGSDFVNTFDGSMYSFAGYCSYLLAGGCQKRSFSIIGDFQNGKRVSLSVYLGEFFDIHLFVNGTVTQGDQRVSMPYASKGLYLETEAGYYKLSGEAYGFVARIDGSGNFQVLLSDRYFNKTCGLCGNFNIFAEDDFMTQEGTLTSDPYDFANSWALSSGEQWCERASPPSSSCNISSGEMQKGLWEQCQLLKSTSVFARCHPLVDPEPFVALCEKTLCECAGGLECACPALLEYARTCAQEGMVLYGWTDHSACSPVCPAGMEYRQCVSPCARTCQSLHINEMCQERCVDGCSCPEGQLLDEGLCVESTECPCVHSGKRYPPGTSLSRDCNTCICRNSQWICSNEECPGECLVTGQSHFKSFDNRYFTFSGICQYLLARDCQDHSFSIVIETVQCADDRDAVCTRSVTVRLPGLHNSLVKLKHGAGVAMDGQDVQLPLLKGDLRIQHTVTASVRLSYGEDLQMDWDGRGRLLVKLSPVYAGKTCGLCGNYNGNQGDDFLTPSGLAEPRVEDFGNAWKLHGDCQDLQKQHSDPCALNPRMTRFSEEACAVLTSPTFEACHRAVSPLPYLRNCRYDVCSCSDGRECLCGALASYAAACAGRGVRVAWREPGRCELNCPKGQVYLQCGTPCNLTCRSLSYPDEECNEACLEGCFCPPGLYMDERGDCVPKAQCPCYYDGEIFQPEDIFSDHHTMCYCEDGFMHCTMSGVPGSLLPDAVLSSPLSHRSKRSLSCRPPMVKLVCPADNLRAEGLECTKTCQNYDLECMSMGCVSGCLCPPGMVRHENRCVALERCPCFHQGKEYAPGETVKIGCNTCVCQDRKWNCTDHVCDATCSTIGMAHYLTFDGLKYLFPGECQYVLVQDYCGSNPGTFRILVGNKGCSHPSVKCKKRVTILVEGGEIELFDGEVNVKRPMKDETHFEVVESGRYIILLLGKALSVVWDRHLSISVVLKQTYQEKVCGLCGNFDGIQNNDLTSSNLQVEEDPVDFGNSWKVSSQCADTRKVPLDSSPATCHNNIMKQTMVDSSCRILTSDVFQDCNKLVDPEPYLDVCIYDTCSCESIGDCACFCDTIAAYAHVCAQHGKVVTWRTATLCPQSCEERNLRENGYECEWRYNSCAPACQVTCQHPEPLACPVQCVEGCHAHCPPGKILDELLQTCVDPEDCPVCEVAGRRFASGKKVTLNPSDPEHCQICHCDVVNLTCEACQEPGGLVVPPTDAPVSPTTLYVEDISEPPLHDFYCSRLLDLVFLLDGSSRLSEAEFEVLKAFVVDMMERLRISQKWVRVAVVEYHDGSHAYIGLKDRKRPSELRRIASQVKYAGSQVASTSEVLKYTLFQIFSKIDRPEASRITLLLMASQEPQRMSRNFVRYVQGLKKKKVIVIPVGIGPHANLKQIRLIEKQAPENKAFVLSSVDELEQQRDEIVSYLCDLAPEAPPPTLPPDMAQVTVGPGLLGVSTLGPKRNSMVLDVAFVLEGSDKIGEADFNRSKEFMEEVIQRMDVGQDSIHVTVLQYSYMVTVEYPFSEAQSKGDILQRVREIRYQGGNRTNTGLALRYLSDHSFLVSQGDREQAPNLVYMVTGNPASDEIKRLPGDIQVVPIGVGPNANVQELERIGWPNAPILIQDFETLPREAPDLVLQRCCSGEGLQIPTLSPAPDCSQPLDVILLLDGSSSFPASYFDEMKSFAKAFISKANIGPRLTQVSVLQYGSITTIDVPWNVVPEKAHLLSLVDVMQREGGPSQIGDALGFAVRYLTSEMHGARPGASKAVVILVTDVSVDSVDAAADAARSNRVTVFPIGIGDRYDAAQLRILAGPAGDSNVVKLQRIEDLPTMVTLGNSFLHKLCSGFVRICMDEDGNEKRPGDVWTLPDQCHTVTCQPDGQTLLKSHRVNCDRGLRPSCPNSQSPVKVEETCGCRWTCPCVCTGSSTRHIVTFDGQNFKLTGSCSYVLFQNKEQDLEVILHNGACSPGARQGCMKSIEVKHSALSVELHSDMEVTVNGRLVSVPYVGGNMEVNVYGAIMHEVRFNHLGHIFTFTPQNNEFQLQLSPKTFASKTYGLCGICDENGANDFMLRDGTVTTDWKTLVQEWTVQRPGQTCQPILEEQCLVPDSSHCQVLLLPLFAECHKVLAPATFYAICQQDSCHQEQVCEVIASYAHLCRTNGVCVDWRTPDFCAMSCPPSLVYNHCEHGCPRHCDGNVSSCGDHPSEGCFCPPDKVMLEGSCVPEEACTQCIGEDGVQHQFLEAWVPDHQPCQICTCLSGRKVNCTTQPCPTAKAPTCGLCEVARLRQNADQCCPEYECVCDPVSCDLPPVPHCERGLQPTLTNPGECRPNFTCACRKEECKRVSPPSCPPHRLPTLRKTQCCDEYECACNCVNSTVSCPLGYLASTATNDCGCTTTTCLPDKVCVHRSTIYPVGQFWEEGCDVCTCTDMEDAVMGLRVAQCSQKPCEDSCRSGFTYVLHEGECCGRCLPSACEVVTGSPRGDSQSSWKSVGSQWASPENPCLINECVRVKEEVFIQQRNVSCPQLEVPVCPSGFQLSCKTSACCPSCRCERMEACMLNGTVIGPGKTVMIDVCTTCRCMVQVGVISGFKLECRKTTCNPCPLGYKEENNTGECCGRCLPTACTIQLRGGQIMTLKRDETLQDGCDTHFCKVNERGEYFWEKRVTGCPPFDEHKCLAEGGKIMKIPGTCCDTCEEPECNDITARLQYVKVGSCKSEVEVDIHYCQGKCASKAMYSIDINDVQDQCSCCSPTRTEPMQVALHCTNGSVVYHEVLNAMECKCSPRKCSK
T23348	DRUGINFO	D4Y0SB	Vonvendi	Approved
T23348	DRUGINFO	DUCA08	Caplacizumab	Approved
T23348	DRUGINFO	D08POF	ALX-0081	Phase 3
T23348	DRUGINFO	D0B3XG	Recombinant von Willebrand factor/recombinant Factor VIII complex	Phase 3
T23348	DRUGINFO	D41PKY	BT-200	Phase 2
T23348	DRUGINFO	DH8FY6	ARC1779	Phase 2
T23348	DRUGINFO	D0HX1T	DA-697b	Phase 1
T23348	DRUGINFO	DYZ76K	DTRI-031	Phase 1
T23348	DRUGINFO	D0KN7H	Mitoflaxone	Terminated
T23348	DRUGINFO	D0F1EF	Auryntricarboxylic acid (ATA)	Investigative

T20333	TARGETID	T20333
T20333	UNIPROID	CSF1R_HUMAN
T20333	TARGNAME	Macrophage colony-stimulating factor 1 receptor (CSF1R)
T20333	GENENAME	CSF1R
T20333	TARGTYPE	Successful
T20333	SYNONYMS	Proto-oncogene c-Fms; M-CSF-R; FMS; CSF-1R; CSF-1-R; CSF-1 receptor; CD115
T20333	FUNCTION	Promotes the release of proinflammatory chemokines in response to IL34 and CSF1, and thereby plays an important role in innate immunity and in inflammatory processes. Plays an important role in the regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone and tooth development. Required for normal male and female fertility, and for normal development of milk ducts and acinar structures in the mammary gland during pregnancy. Promotes reorganization of the actin cytoskeleton, regulates formation of membrane ruffles, cell adhesion and cell migration, and promotes cancer cell invasion. Activates several signaling pathways in response to ligand binding. Phosphorylates PIK3R1, PLCG2, GRB2, SLA2 and CBL. Activation of PLCG2 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, that then lead to the activation of protein kinase C family members, especially PRKCD. Phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leads to activation of the AKT1 signaling pathway. Activated CSF1R also mediates activation of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1, and of the SRC family kinases SRC, FYN and YES1. Activated CSF1R transmits signals both via proteins that directly interact with phosphorylated tyrosine residues in its intracellular domain, or via adapter proteins, such as GRB2. Promotes activation of STAT family members STAT3, STAT5A and/or STAT5B. Promotes tyrosine phosphorylation of SHC1 and INPP5D/SHIP-1. Receptor signaling is down-regulated by protein phosphatases, such as INPP5D/SHIP-1, that dephosphorylate the receptor and its downstream effectors, and by rapid internalization of the activated receptor. Tyrosine-protein kinase that acts as cell-surface receptor for CSF1 and IL34 and plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes.
T20333	PDBSTRUC	4WRM; 4WRL; 4R7I; 4R7H; 4LIQ
T20333	BIOCLASS	Kinase
T20333	ECNUMBER	EC 2.7.10.1
T20333	SEQUENCE	MGPGVLLLLLVATAWHGQGIPVIEPSVPELVVKPGATVTLRCVGNGSVEWDGPPSPHWTLYSDGSSSILSTNNATFQNTGTYRCTEPGDPLGGSAAIHLYVKDPARPWNVLAQEVVVFEDQDALLPCLLTDPVLEAGVSLVRVRGRPLMRHTNYSFSPWHGFTIHRAKFIQSQDYQCSALMGGRKVMSISIRLKVQKVIPGPPALTLVPAELVRIRGEAAQIVCSASSVDVNFDVFLQHNNTKLAIPQQSDFHNNRYQKVLTLNLDQVDFQHAGNYSCVASNVQGKHSTSMFFRVVESAYLNLSSEQNLIQEVTVGEGLNLKVMVEAYPGLQGFNWTYLGPFSDHQPEPKLANATTKDTYRHTFTLSLPRLKPSEAGRYSFLARNPGGWRALTFELTLRYPPEVSVIWTFINGSGTLLCAASGYPQPNVTWLQCSGHTDRCDEAQVLQVWDDPYPEVLSQEPFHKVTVQSLLTVETLEHNQTYECRAHNSVGSGSWAFIPISAGAHTHPPDEFLFTPVVVACMSIMALLLLLLLLLLYKYKQKPKYQVRWKIIESYEGNSYTFIDPTQLPYNEKWEFPRNNLQFGKTLGAGAFGKVVEATAFGLGKEDAVLKVAVKMLKSTAHADEKEALMSELKIMSHLGQHENIVNLLGACTHGGPVLVITEYCCYGDLLNFLRRKAEAMLGPSLSPGQDPEGGVDYKNIHLEKKYVRRDSGFSSQGVDTYVEMRPVSTSSNDSFSEQDLDKEDGRPLELRDLLHFSSQVAQGMAFLASKNCIHRDVAARNVLLTNGHVAKIGDFGLARDIMNDSNYIVKGNARLPVKWMAPESIFDCVYTVQSDVWSYGILLWEIFSLGLNPYPGILVNSKFYKLVKDGYQMAQPAFAPKNIYSIMQACWALEPTHRPTFQQICSFLQEQAQEDRRERDYTNLPSSSRSGGSGSSSSELEEESSSEHLTCCEQGDIAQPLLQPNNYQFC
T20333	DRUGINFO	D09TAB	Pexidartinib	Approved
T20333	DRUGINFO	D05PWX	Sulfatinib	Phase 3
T20333	DRUGINFO	DWD3V2	AMB-05X	Phase 2
T20333	DRUGINFO	D05JAA	ARRY-382	Phase 2
T20333	DRUGINFO	D08NDE	BLZ-945	Phase 2
T20333	DRUGINFO	D0YO4B	Cabiralizumab	Phase 2
T20333	DRUGINFO	D9RH0V	DCC-3014	Phase 1/2
T20333	DRUGINFO	D08ZQI	FPA-008	Phase 1/2
T20333	DRUGINFO	D04CTD	SNDX-6352	Phase 1
T20333	DRUGINFO	D0M5XJ	DCC-3014	Phase 1
T20333	DRUGINFO	D3ZN5U	Axatilamab	Phase 1
T20333	DRUGINFO	D6FTN1	ABSK021	Phase 1
T20333	DRUGINFO	DYK5U6	EI1071	Phase 1
T20333	DRUGINFO	D07PSL	PLX7486	Phase 1
T20333	DRUGINFO	D7M8LI	TPX-0022	Phase 1
T20333	DRUGINFO	D0X9VS	PMID28270010-Compound-Figure24-a	Patented
T20333	DRUGINFO	D0NB1V	Pyridine derivative 20	Patented
T20333	DRUGINFO	D0O0AW	Pyridine derivative 21	Patented
T20333	DRUGINFO	D0O4TA	Pyridine derivative 22	Patented
T20333	DRUGINFO	D0T7BE	Pyridine derivative 19	Patented
T20333	DRUGINFO	D0AK1F	Pyridine derivative 18	Patented

T98157	TARGETID	T98157
T98157	FORMERID	TTDI02021
T98157	UNIPROID	ARSA_HUMAN
T98157	TARGNAME	Cerebroside-sulfatase (ARSA)
T98157	GENENAME	ARSA
T98157	TARGTYPE	Successful
T98157	SYNONYMS	Cerebrosidesulfatase; Arylsulfatase A component C; ASA; ARSA
T98157	FUNCTION	Hydrolyzes cerebroside sulfate.
T98157	PDBSTRUC	2HI8; 2AIK; 2AIJ; 1N2L; 1N2K
T98157	BIOCLASS	Sulfuric ester hydrolase
T98157	ECNUMBER	EC 3.1.6.8
T98157	SEQUENCE	MGAPRSLLLALAAGLAVARPPNIVLIFADDLGYGDLGCYGHPSSTTPNLDQLAAGGLRFTDFYVPVSLCTPSRAALLTGRLPVRMGMYPGVLVPSSRGGLPLEEVTVAEVLAARGYLTGMAGKWHLGVGPEGAFLPPHQGFHRFLGIPYSHDQGPCQNLTCFPPATPCDGGCDQGLVPIPLLANLSVEAQPPWLPGLEARYMAFAHDLMADAQRQDRPFFLYYASHHTHYPQFSGQSFAERSGRGPFGDSLMELDAAVGTLMTAIGDLGLLEETLVIFTADNGPETMRMSRGGCSGLLRCGKGTTYEGGVREPALAFWPGHIAPGVTHELASSLDLLPTLAALAGAPLPNVTLDGFDLSPLLLGTGKSPRQSLFFYPSYPDEVRGVFAVRTGKYKAHFFTQGSAHSDTTADPACHASSSLTAHEPPLLYDLSKDPGENYNLLGGVAGATPEVLQALKQLQLLKAQLDAAVTFGPSQVARGEDPALQICCHPGCTPRPACCHCPDPHA
T98157	DRUGINFO	DQ4TO3	OTL-200	Approved
T98157	DRUGINFO	D0E5RA	HGT-1111	Phase 2

T10965	TARGETID	T10965
T10965	FORMERID	TTDC00197
T10965	UNIPROID	LYAM3_HUMAN
T10965	TARGNAME	P-selectin (SELP)
T10965	GENENAME	SELP
T10965	TARGTYPE	Successful
T10965	SYNONYMS	SELP; PADGEM; Leukocyte-endothelial cell adhesion molecule 3; LECAM3; Granule membrane protein 140; GMP-140; CD62P
T10965	FUNCTION	Ca(2+)-dependent receptor for myeloid cells that binds to carbohydrates on neutrophils and monocytes. Mediates the interaction of activated endothelial cells or platelets with leukocytes. The ligand recognized is sialyl-Lewis X. Mediates rapid rolling of leukocyte rolling over vascular surfaces during the initial steps in inflammation through interaction with PSGL1.
T10965	PDBSTRUC	1KJD; 1HES; 1G1S; 1G1R; 1G1Q
T10965	SEQUENCE	MANCQIAILYQRFQRVVFGISQLLCFSALISELTNQKEVAAWTYHYSTKAYSWNISRKYCQNRYTDLVAIQNKNEIDYLNKVLPYYSSYYWIGIRKNNKTWTWVGTKKALTNEAENWADNEPNNKRNNEDCVEIYIKSPSAPGKWNDEHCLKKKHALCYTASCQDMSCSKQGECLETIGNYTCSCYPGFYGPECEYVRECGELELPQHVLMNCSHPLGNFSFNSQCSFHCTDGYQVNGPSKLECLASGIWTNKPPQCLAAQCPPLKIPERGNMTCLHSAKAFQHQSSCSFSCEEGFALVGPEVVQCTASGVWTAPAPVCKAVQCQHLEAPSEGTMDCVHPLTAFAYGSSCKFECQPGYRVRGLDMLRCIDSGHWSAPLPTCEAISCEPLESPVHGSMDCSPSLRAFQYDTNCSFRCAEGFMLRGADIVRCDNLGQWTAPAPVCQALQCQDLPVPNEARVNCSHPFGAFRYQSVCSFTCNEGLLLVGASVLQCLATGNWNSVPPECQAIPCTPLLSPQNGTMTCVQPLGSSSYKSTCQFICDEGYSLSGPERLDCTRSGRWTDSPPMCEAIKCPELFAPEQGSLDCSDTRGEFNVGSTCHFSCDNGFKLEGPNNVECTTSGRWSATPPTCKGIASLPTPGLQCPALTTPGQGTMYCRHHPGTFGFNTTCYFGCNAGFTLIGDSTLSCRPSGQWTAVTPACRAVKCSELHVNKPIAMNCSNLWGNFSYGSICSFHCLEGQLLNGSAQTACQENGHWSTTVPTCQAGPLTIQEALTYFGGAVASTIGLIMGGTLLALLRKRFRQKDDGKCPLNPHSHLGTYGVFTNAAFDPSP
T10965	DRUGINFO	DU47SF	Crizanlizumab	Approved
T10965	DRUGINFO	DWY87T	Inclacumab	Phase 3
T10965	DRUGINFO	D0N4EO	GMI-1070	Phase 3
T10965	DRUGINFO	D0B7LK	CY-1503	Phase 2/3
T10965	DRUGINFO	D0A9ML	SelG1	Phase 2
T10965	DRUGINFO	D0Z6DE	RPSGL-Ig	Phase 2
T10965	DRUGINFO	D00YEV	BAICALEIN	Phase 2
T10965	DRUGINFO	D0Z0AM	PSI-697	Phase 1
T10965	DRUGINFO	D00WOT	CDP-850	Discontinued in Phase 2
T10965	DRUGINFO	D0G1MZ	CY-1787	Discontinued in Phase 1
T10965	DRUGINFO	D0L3XV	SMART anti-E/P selectin	Discontinued in Phase 1
T10965	DRUGINFO	D0R7MJ	PURPUROGALLIN	Terminated
T10965	DRUGINFO	D08RYE	Efomycine M	Investigative
T10965	DRUGINFO	D0E9NT	2,3,4-trihydroxybenzoic acid	Investigative
T10965	DRUGINFO	D0U7DO	1na	Investigative
T10965	DRUGINFO	D08WQM	O-Sialic Acid	Investigative
T10965	DRUGINFO	D0Y3TZ	GALLICACID	Investigative
T10965	DRUGINFO	D06GOK	2-Methyl-2,4-Pentanediol	Investigative
T10965	DRUGINFO	D0G6XS	Fucose	Investigative

T15439	TARGETID	T15439
T15439	FORMERID	TTDNC00518
T15439	UNIPROID	C5AR1_HUMAN
T15439	TARGNAME	C5a anaphylatoxin chemotactic receptor (C5AR1)
T15439	GENENAME	C5AR1
T15439	TARGTYPE	Successful
T15439	SYNONYMS	CD88; C5aR; C5a-R; C5a anaphylatoxin chemotactic receptor 1; C5R1
T15439	FUNCTION	The ligand interacts with at least two sites on the receptor: a high-affinity site on the extracellular N-terminus, and a second site in the transmembrane region which activates downstream signaling events. Receptor activation stimulates chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion production. Receptor for the chemotactic and inflammatory peptide anaphylatoxin C5a.
T15439	PDBSTRUC	6C1R; 6C1Q; 5O9H
T15439	BIOCLASS	GPCR rhodopsin
T15439	SEQUENCE	MDSFNYTTPDYGHYDDKDTLDLNTPVDKTSNTLRVPDILALVIFAVVFLVGVLGNALVVWVTAFEAKRTINAIWFLNLAVADFLSCLALPILFTSIVQHHHWPFGGAACSILPSLILLNMYASILLLATISADRFLLVFKPIWCQNFRGAGLAWIACAVAWGLALLLTIPSFLYRVVREEYFPPKVLCGVDYSHDKRRERAVAIVRLVLGFLWPLLTLTICYTFILLRTWSRRATRSTKTLKVVVAVVASFFIFWLPYQVTGIMMSFLEPSSPTFLLLKKLDSLCVSFAYINCCINPIIYVVAGQGFQGRLRKSLPSLLRNVLTEESVVRESKSFTRSTVDTMAQKTQAV
T15439	DRUGINFO	D0MR4Q	Avacopan	Approved
T15439	DRUGINFO	D0G2XE	PMX-53	Phase 2
T15439	DRUGINFO	D05ILZ	NN8209	Discontinued in Phase 2
T15439	DRUGINFO	D0MT7W	NN8210	Discontinued in Phase 1
T15439	DRUGINFO	DBA5M7	PMX205	Preclinical
T15439	DRUGINFO	D03TBA	RPR121154	Investigative
T15439	DRUGINFO	D04JXA	W54011	Investigative
T15439	DRUGINFO	D0G9EX	C5aR pepducins	Investigative
T15439	DRUGINFO	D0J3FH	NDT9520492	Investigative

T29683	TARGETID	T29683
T29683	FORMERID	TTDC00117
T29683	UNIPROID	NK3R_HUMAN
T29683	TARGNAME	Neuromedin-K receptor (TACR3)
T29683	GENENAME	TACR3
T29683	TARGTYPE	Successful
T29683	SYNONYMS	Tachykinin receptor 3; TACR3; Neuromedin K receptor; Neurokinin-3 receptor; Neurokinin B receptor; NKR; NK-3R; NK-3 receptor
T29683	FUNCTION	This is a receptor for the tachykinin neuropeptide neuromedin-K (neurokinin B). It is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of affinity of this receptor to tachykinins is: neuromedin-K > substance K > substance P.
T29683	BIOCLASS	GPCR rhodopsin
T29683	SEQUENCE	MATLPAAETWIDGGGGVGADAVNLTASLAAGAATGAVETGWLQLLDQAGNLSSSPSALGLPVASPAPSQPWANLTNQFVQPSWRIALWSLAYGVVVAVAVLGNLIVIWIILAHKRMRTVTNYFLVNLAFSDASMAAFNTLVNFIYALHSEWYFGANYCRFQNFFPITAVFASIYSMTAIAVDRYMAIIDPLKPRLSATATKIVIGSIWILAFLLAFPQCLYSKTKVMPGRTLCFVQWPEGPKQHFTYHIIVIILVYCFPLLIMGITYTIVGITLWGGEIPGDTCDKYHEQLKAKRKVVKMMIIVVMTFAICWLPYHIYFILTAIYQQLNRWKYIQQVYLASFWLAMSSTMYNPIIYCCLNKRFRAGFKRAFRWCPFIKVSSYDELELKTTRFHPNRQSSMYTVTRMESMTVVFDPNDADTTRSSRKKRATPRDPSFNGCSRRNSKSASATSSFISSPYTSVDEYS
T29683	DRUGINFO	DUS06I	Fezolinetant	Approved
T29683	DRUGINFO	DKZ07O	Elinzanetant	Phase 3
T29683	DRUGINFO	D02IWC	AZD2624	Phase 2
T29683	DRUGINFO	D0K5HI	Talnetant	Phase 2
T29683	DRUGINFO	D05ZWG	Senktide	Phase 2
T29683	DRUGINFO	D0P2KG	GSK1144814	Phase 1
T29683	DRUGINFO	D0IP6X	Osanetant	Discontinued in Phase 2b
T29683	DRUGINFO	D03ZKE	CS-003	Discontinued in Phase 2
T29683	DRUGINFO	D0C3AN	SSR-146977	Discontinued in Phase 1
T29683	DRUGINFO	D00VPT	SB222200	Preclinical
T29683	DRUGINFO	D02CCA	GSK-172981	Investigative
T29683	DRUGINFO	D02UCT	R-820	Investigative
T29683	DRUGINFO	D02UJO	GR138676	Investigative
T29683	DRUGINFO	D04TXE	PD-157672	Investigative
T29683	DRUGINFO	D07NNN	NEUROKININ B	Investigative
T29683	DRUGINFO	D09FAO	PD 154740	Investigative
T29683	DRUGINFO	D09NBN	PD-161182	Investigative
T29683	DRUGINFO	D0G2AK	3-methoxy-N',2-diphenylquinoline-4-carbohydrazide	Investigative
T29683	DRUGINFO	D0G4PZ	N-phenethyl-2-phenylquinoline-4-carboxamide	Investigative
T29683	DRUGINFO	D0J3AO	PD-160946	Investigative
T29683	DRUGINFO	D0O8RG	2-phenyl-N-(1-phenylethyl)quinoline-4-carboxamide	Investigative
T29683	DRUGINFO	D0S9CI	N',2-diphenylquinoline-4-carbohydrazide 8m	Investigative
T29683	DRUGINFO	D0W3XD	N',2-diphenylquinoline-4-carbohydrazide	Investigative
T29683	DRUGINFO	D0D2JB	kassinin	Investigative
T29683	DRUGINFO	D0U9IB	eledoisin	Investigative
T29683	DRUGINFO	D01NPA	neurokinin A	Investigative
T29683	DRUGINFO	D07JAN	SCH 206272	Investigative

T78932	TARGETID	T78932
T78932	FORMERID	TTDNC00412
T78932	UNIPROID	TYK2_HUMAN
T78932	TARGNAME	TYK2 tyrosine kinase (TYK2)
T78932	GENENAME	TYK2
T78932	TARGTYPE	Successful
T78932	SYNONYMS	Non-receptor tyrosine-protein kinase TYK2
T78932	FUNCTION	Probably involved in intracellular signal transduction by being involved in the initiation of type I IFN signaling. Phosphorylates the interferon-alpha/beta receptor alpha chain.
T78932	PDBSTRUC	6DBM; 6DBK; 6AAM; 5WAL; 5TKD
T78932	BIOCLASS	Kinase
T78932	ECNUMBER	EC 2.7.10.2
T78932	SEQUENCE	MPLRHWGMARGSKPVGDGAQPMAAMGGLKVLLHWAGPGGGEPWVTFSESSLTAEEVCIHIAHKVGITPPCFNLFALFDAQAQVWLPPNHILEIPRDASLMLYFRIRFYFRNWHGMNPREPAVYRCGPPGTEASSDQTAQGMQLLDPASFEYLFEQGKHEFVNDVASLWELSTEEEIHHFKNESLGMAFLHLCHLALRHGIPLEEVAKKTSFKDCIPRSFRRHIRQHSALTRLRLRNVFRRFLRDFQPGRLSQQMVMVKYLATLERLAPRFGTERVPVCHLRLLAQAEGEPCYIRDSGVAPTDPGPESAAGPPTHEVLVTGTGGIQWWPVEEEVNKEEGSSGSSGRNPQASLFGKKAKAHKAVGQPADRPREPLWAYFCDFRDITHVVLKEHCVSIHRQDNKCLELSLPSRAAALSFVSLVDGYFRLTADSSHYLCHEVAPPRLVMSIRDGIHGPLLEPFVQAKLRPEDGLYLIHWSTSHPYRLILTVAQRSQAPDGMQSLRLRKFPIEQQDGAFVLEGWGRSFPSVRELGAALQGCLLRAGDDCFSLRRCCLPQPGETSNLIIMRGARASPRTLNLSQLSFHRVDQKEITQLSHLGQGTRTNVYEGRLRVEGSGDPEEGKMDDEDPLVPGRDRGQELRVVLKVLDPSHHDIALAFYETASLMSQVSHTHLAFVHGVCVRGPENIMVTEYVEHGPLDVWLRRERGHVPMAWKMVVAQQLASALSYLENKNLVHGNVCGRNILLARLGLAEGTSPFIKLSDPGVGLGALSREERVERIPWLAPECLPGGANSLSTAMDKWGFGATLLEICFDGEAPLQSRSPSEKEHFYQRQHRLPEPSCPQLATLTSQCLTYEPTQRPSFRTILRDLTRLQPHNLADVLTVNPDSPASDPTVFHKRYLKKIRDLGEGHFGKVSLYCYDPTNDGTGEMVAVKALKADCGPQHRSGWKQEIDILRTLYHEHIIKYKGCCEDQGEKSLQLVMEYVPLGSLRDYLPRHSIGLAQLLLFAQQICEGMAYLHAQHYIHRDLAARNVLLDNDRLVKIGDFGLAKAVPEGHEYYRVREDGDSPVFWYAPECLKEYKFYYASDVWSFGVTLYELLTHCDSSQSPPTKFLELIGIAQGQMTVLRLTELLERGERLPRPDKCPCEVYHLMKNCWETEASFRPTFENLIPILKTVHEKYQGQAPSVFSVC
T78932	DRUGINFO	D0S1XX	Deucravacitinib	Approved
T78932	DRUGINFO	D5XJ7F	NDI-034858	Phase 2
T78932	DRUGINFO	D7TA4P	PF-06826647	Phase 2
T78932	DRUGINFO	D0V4DX	PF-06700841	Phase 2
T78932	DRUGINFO	D0M3XE	PF-06826647	Phase 1
T78932	DRUGINFO	D01GNL	Pyrazolopyridine derivative 5	Patented
T78932	DRUGINFO	D0C3HN	PMID27774822-Compound-Figure9Example15	Patented
T78932	DRUGINFO	D0IB3R	Imidazopyridine derivative 3	Patented
T78932	DRUGINFO	D0M2JK	Aminopyridine derivative 1	Patented
T78932	DRUGINFO	D0M8YW	Aminopyrimidine derivative 5	Patented
T78932	DRUGINFO	D0UG8S	Thiazolopyridine derivative 1	Patented
T78932	DRUGINFO	D0M2OK	Bis-aminopyrimidine derivative 5	Patented
T78932	DRUGINFO	D0NY6M	PMID27774822-Compound-Figure3CompoundI-165	Patented
T78932	DRUGINFO	D0T6CY	Pyrrolo-pyridone derivative 3	Patented
T78932	DRUGINFO	D0XH7H	N-methylmethanesulfonamide derivative 1	Patented
T78932	DRUGINFO	D0YJ4D	Pyrrole derivative 7	Patented
T78932	DRUGINFO	D01CRX	Benzimidazole derivative 7	Patented
T78932	DRUGINFO	D01FVC	Bis-aminopyrimidine derivative 1	Patented
T78932	DRUGINFO	D03QAY	Pyrazolopyridine derivative 3	Patented
T78932	DRUGINFO	D04BOW	Tricyclic pyrrolopyridine compound 1	Patented
T78932	DRUGINFO	D05AXE	Aminooxazole carboxamide derivative 1	Patented
T78932	DRUGINFO	D0FQ4Z	Pyrrolo[2,3-d]pyrimidine derivative 6	Patented
T78932	DRUGINFO	D0GB7G	PMID27774824-Compound-Figure6Example12	Patented
T78932	DRUGINFO	D0KL3B	Pyrrolo[2,3-d]pyrimidine derivative 8	Patented
T78932	DRUGINFO	D0LR6J	Bis-aminopyrimidine derivative 2	Patented
T78932	DRUGINFO	D0LS1O	Tricyclic compound 11	Patented
T78932	DRUGINFO	D0M2WA	Tricyclic heterocycle derivative 5	Patented
T78932	DRUGINFO	D0RJ3W	PMID27774822-Compound-Figure11Example5	Patented
T78932	DRUGINFO	D0S6XT	Bis-aminopyrimidine derivative 3	Patented
T78932	DRUGINFO	D0SJ1Q	Bis-aminopyrimidine derivative 4	Patented
T78932	DRUGINFO	D0U1HA	PMID27774824-Compound-Figure3Example18	Patented
T78932	DRUGINFO	D0U5FZ	Pyrrolo[2,3-d]pyrimidine derivative 7	Patented
T78932	DRUGINFO	D0X1FD	Tricyclic heterocycle derivative 1	Patented
T78932	DRUGINFO	D07PTU	Imidazo[4,5-c]pyridine derivative 1	Patented
T78932	DRUGINFO	D0WZ8N	PMID27774824-Compound-Figure9Example2up	Patented
T78932	DRUGINFO	D01DBB	PMID27774824-Compound-Figure9Example2down	Patented
T78932	DRUGINFO	D09ALF	Aminotriazolopyridine derivative 1	Patented
T78932	DRUGINFO	D0VJ1R	Imidazo[4,5-c]pyridine derivative 2	Patented
T78932	DRUGINFO	D0YR8S	PMID27774824-Compound-Figure11Example1up	Patented
T78932	DRUGINFO	D09PIS	Pyrazolo[4,3-c]pyridine derivative 2	Patented
T78932	DRUGINFO	D0IR6U	CMP-6	Investigative

T41750	TARGETID	T41750
T41750	FORMERID	TTDI02342
T41750	UNIPROID	GIPR_HUMAN
T41750	TARGNAME	Gastric inhibitory polypeptide receptor (GIPR)
T41750	GENENAME	GIPR
T41750	TARGTYPE	Successful
T41750	SYNONYMS	Glucosedependent insulinotropic polypeptide receptor; GIPR
T41750	FUNCTION	This is a receptor for GIP. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.
T41750	PDBSTRUC	6DKJ; 4HJ0; 2QKH
T41750	BIOCLASS	GPCR secretin
T41750	SEQUENCE	MTTSPILQLLLRLSLCGLLLQRAETGSKGQTAGELYQRWERYRRECQETLAAAEPPSGLACNGSFDMYVCWDYAAPNATARASCPWYLPWHHHVAAGFVLRQCGSDGQWGLWRDHTQCENPEKNEAFLDQRLILERLQVMYTVGYSLSLATLLLALLILSLFRRLHCTRNYIHINLFTSFMLRAAAILSRDRLLPRPGPYLGDQALALWNQALAACRTAQIVTQYCVGANYTWLLVEGVYLHSLLVLVGGSEEGHFRYYLLLGWGAPALFVIPWVIVRYLYENTQCWERNEVKAIWWIIRTPILMTILINFLIFIRILGILLSKLRTRQMRCRDYRLRLARSTLTLVPLLGVHEVVFAPVTEEQARGALRFAKLGFEIFLSSFQGFLVSVLYCFINKEVQSEIRRGWHHCRLRRSLGEEQRQLPERAFRALPSGSGPGEVPTSRGLSSGTLPGPGNEASRELESYC
T41750	DRUGINFO	DA69JF	Tirzepatide	Approved
T41750	DRUGINFO	DG7N3W	Retatrutide	Phase 3
T41750	DRUGINFO	DF58YX	AMG 133	Phase 2
T41750	DRUGINFO	DR76TW	LY3437943	Phase 2
T41750	DRUGINFO	D6V9SI	LY3537021	Phase 1
T41750	DRUGINFO	DEQW79	LY3532226	Phase 1
T41750	DRUGINFO	D0FY4L	SAR438335	Phase 1
T41750	DRUGINFO	DEC8O3	CT 868	Phase 1
T41750	DRUGINFO	DQO46V	CT-388	Phase 1
T41750	DRUGINFO	D00YFP	RG7697	Discontinued in Phase 2
T41750	DRUGINFO	D0M4RX	RG7685	Discontinued in Phase 2

T92403	TARGETID	T92403
T92403	FORMERID	TTDR00035
T92403	UNIPROID	SL9A3_HUMAN
T92403	TARGNAME	Sodium/hydrogen exchanger 3 (SLC9A3)
T92403	GENENAME	SLC9A3
T92403	TARGTYPE	Successful
T92403	SYNONYMS	SLC9A3; Na(+)/H(+) exchanger 3; NHE-3
T92403	FUNCTION	Involved in pH regulation to eliminate acids generated by active metabolism or to counter adverse environmental conditions. Major proton extruding system driven by the inward sodium ion chemical gradient. Plays an important role in signal transduction.
T92403	BIOCLASS	Monovalent cation:proton antiporter
T92403	SEQUENCE	MWGLGARGPDRGLLLALALGGLARAGGVEVEPGGAHGESGGFQVVTFEWAHVQDPYVIALWILVASLAKIGFHLSHKVTSVVPESALLIVLGLVLGGIVWAADHIASFTLTPTVFFFYLLPPIVLDAGYFMPNRLFFGNLGTILLYAVVGTVWNAATTGLSLYGVFLSGLMGDLQIGLLDFLLFGSLMAAVDPVAVLAVFEEVHVNEVLFIIVFGESLLNDAVTVVLYNVFESFVALGGDNVTGVDCVKGIVSFFVVSLGGTLVGVVFAFLLSLVTRFTKHVRIIEPGFVFIISYLSYLTSEMLSLSAILAITFCGICCQKYVKANISEQSATTVRYTMKMLASSAETIIFMFLGISAVNPFIWTWNTAFVLLTLVFISVYRAIGVVLQTWLLNRYRMVQLEPIDQVVLSYGGLRGAVAFALVVLLDGDKVKEKNLFVSTTIIVVFFTVIFQGLTIKPLVQWLKVKRSEHREPRLNEKLHGRAFDHILSAIEDISGQIGHNYLRDKWSHFDRKFLSRVLMRRSAQKSRDRILNVFHELNLKDAISYVAEGERRGSLAFIRSPSTDNVVNVDFTPRSSTVEASVSYLLRENVSAVCLDMQSLEQRRRSIRDAEDMVTHHTLQQYLYKPRQEYKHLYSRHELTPTEDEKQDREIFHRTMRKRLESFKSTKLGLNQNKKAAKLYKRERAQKRRNSSIPNGKLPMESPAQNFTIKEKDLELSDTEEPPNYDEEMSGGIEFLASVTKDTASDSPAGIDNPVFSPDEALDRSLLARLPPWLSPGETVVPSQRARTQIPYSPGTFCRLMPFRLSSKSVDSFLQADGPEERPPAALPESTHM
T92403	DRUGINFO	D04TQO	Tenapanor	Approved
T92403	DRUGINFO	D01ICY	AVE-0657	Phase 2
T92403	DRUGINFO	D04AIB	AZD1772//RDX5791	Phase 2
T92403	DRUGINFO	D0N8QQ	CARIPORIDE	Discontinued in Phase 2
T92403	DRUGINFO	D0V9RU	ENIPORIDE	Discontinued in Phase 2
T92403	DRUGINFO	D0K2CV	HOE-694	Terminated
T92403	DRUGINFO	D03AGV	N-(3-Methanesulfonyl-4-methyl-benzoyl)-guanidine	Investigative
T92403	DRUGINFO	D04OTF	N-(4-Chloro-3-methanesulfonyl-benzoyl)-guanidine	Investigative
T92403	DRUGINFO	D04UMY	N-(4-Cyano-3-methanesulfonyl-benzoyl)-guanidine	Investigative
T92403	DRUGINFO	D05CQR	N-(4-Bromo-3-methanesulfonyl-benzoyl)-guanidine	Investigative
T92403	DRUGINFO	D07DUW	N-(3-Methanesulfonyl-4-methoxy-benzoyl)-guanidine	Investigative
T92403	DRUGINFO	D0T1OG	N-(5-Methanesulfonyl-2-methyl-benzoyl)-guanidine	Investigative

T13127	TARGETID	T13127
T13127	UNIPROID	FNTA_HUMAN; FNTB_HUMAN
T13127	TARGNAME	Farnesyl protein transferase (Ftase)
T13127	GENENAME	FNTB; FNTA
T13127	TARGTYPE	Successful
T13127	SYNONYMS	Ras proteins prenyltransferase; Protein farnesyltransferase; Ftase; CAAX farnesyltransferase
T13127	FUNCTION	Essential subunit of both the farnesyltransferase and the geranylgeranyltransferase complex. Contributes to the transfer of a farnesyl or geranylgeranyl moiety from farnesyl or geranylgeranyl diphosphate to a cysteine at the fourth position from the C-terminus of several proteins having the C-terminal sequence Cys-aliphatic-aliphatic-X. May positively regulate neuromuscular junction development downstream of MUSK via its function in RAC1prenylation and activation.
T13127	BIOCLASS	Alkyl aryl transferase
T13127	SEQUENCE	MAATEGVGEAAQGGEPGQPAQPPPQPHPPPPQQQHKEEMAAEAGEAVASPMDDGFVSLDSPSYVLYRDRAEWADIDPVPQNDGPNPVVQIIYSDKFRDVYDYFRAVLQRDERSERAFKLTRDAIELNAANYTVWHFRRVLLKSLQKDLHEEMNYITAIIEEQPKNYQVWHHRRVLVEWLRDPSQELEFIADILNQDAKNYHAWQHRQWVIQEFKLWDNELQYVDQLLKEDVRNNSVWNQRYFVISNTTGYNDRAVLEREVQYTLEMIKLVPHNESAWNYLKGILQDRGLSKYPNLLNQLLDLQPSHSSPYLIAFLVDIYEDMLENQCDNKEDILNKALELCEILAKEKDTIRKEYWRYIGRSLQSKHSTENDSPTNVQQ
T13127	DRUGINFO	D0W4HZ	Lonafarnib	Approved
T13127	DRUGINFO	D07NPS	Zarnestra	Phase 3
T13127	DRUGINFO	D07RKN	GGTI-2418	Phase 1
T13127	DRUGINFO	D0Z1NY	BMS214662	Phase 1
T13127	DRUGINFO	D0Q5VW	L-778123	Phase 1
T13127	DRUGINFO	D0NE3C	AZD3409	Terminated
T13127	DRUGINFO	D04DYZ	ABT-839	Terminated
T13127	DRUGINFO	D0C2UY	MANUMYCIN A	Terminated
T13127	DRUGINFO	D0EY9P	SCH-44342	Terminated
T13127	DRUGINFO	D0H5VF	RPR-113829	Terminated
T13127	DRUGINFO	D0L5AS	RPR-114334	Terminated
T13127	DRUGINFO	D0W2ED	L-731735	Terminated
T13127	DRUGINFO	D03OLA	L-745631	Terminated
T13127	DRUGINFO	D00LAR	BMS-404683	Investigative
T13127	DRUGINFO	D01DTW	FARNESYL	Investigative
T13127	DRUGINFO	D01OFD	ACTINOPLANIC ACID A	Investigative
T13127	DRUGINFO	D06JMV	PB-27	Investigative
T13127	DRUGINFO	D0H4QM	PB-80	Investigative
T13127	DRUGINFO	D0L4RX	PB-81	Investigative
T13127	DRUGINFO	D0R3PD	CLAVARINONE	Investigative
T13127	DRUGINFO	D0TC4Z	ALPHA-HYDROXYFARNESYLPHOSPHONIC ACID	Investigative
T13127	DRUGINFO	D0VD2C	(Z)-2-Methyl-3-tetradecyl-but-2-enedioic acid	Investigative
T13127	DRUGINFO	D06DSE	PD-83176	Investigative
T13127	DRUGINFO	D0QX6B	GERANYLGERANYL DIPHOSPHATE	Investigative

T35842	TARGETID	T35842
T35842	FORMERID	TTDR00530
T35842	UNIPROID	MSHR_HUMAN
T35842	TARGNAME	Melanocortin receptor 1 (MC1R)
T35842	GENENAME	MC1R
T35842	TARGTYPE	Successful
T35842	SYNONYMS	Melanotropin receptor; Melanocyte-stimulating hormone receptor; Melanocortin-1 receptor; MSHR; MSH-R; MC1-R
T35842	FUNCTION	The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Receptor for MSH (alpha, beta and gamma) and ACTH.
T35842	BIOCLASS	GPCR rhodopsin
T35842	SEQUENCE	MAVQGSQRRLLGSLNSTPTAIPQLGLAANQTGARCLEVSISDGLFLSLGLVSLVENALVVATIAKNRNLHSPMYCFICCLALSDLLVSGSNVLETAVILLLEAGALVARAAVLQQLDNVIDVITCSSMLSSLCFLGAIAVDRYISIFYALRYHSIVTLPRARRAVAAIWVASVVFSTLFIAYYDHVAVLLCLVVFFLAMLVLMAVLYVHMLARACQHAQGIARLHKRQRPVHQGFGLKGAVTLTILLGIFFLCWGPFFLHLTLIVLCPEHPTCGCIFKNFNLFLALIICNAIIDPLIYAFHSQELRRTLKEVLTCSW
T35842	DRUGINFO	D0V2OX	Afamelanotide	Approved
T35842	DRUGINFO	D0X9PF	Bremelanotide	Approved
T35842	DRUGINFO	D7M3WV	Dersimelagon	Phase 3
T35842	DRUGINFO	DVI21W	PL8177	Phase 2
T35842	DRUGINFO	D0H3HV	AP-1030	Phase 1/2
T35842	DRUGINFO	D09QPE	AP-1189	Investigative
T35842	DRUGINFO	D09XCH	Ac-YR[CEHFRWC]-NH2	Investigative
T35842	DRUGINFO	D0GN9K	C[CO-2,3-pyrazine-CO-D-Phe-Arg-Trp-Lys]-NH2	Investigative
T35842	DRUGINFO	D0R3GC	D-Phe-Arg-2-Nal-NHCH3	Investigative
T35842	DRUGINFO	D0U5KM	Ac-His-DPhe-Arg-Trp-NH2	Investigative
T35842	DRUGINFO	D0U6XP	Ac-Nle-c[Asp-His-DNaI(2')-Pro-Trp-Lys]-NH2	Investigative
T35842	DRUGINFO	D00VYC	Ac-YR[CEHdFRWC]-NH2	Investigative
T35842	DRUGINFO	D05XRI	Ac-R[CEHdFRWC]-NH2	Investigative
T35842	DRUGINFO	D06PNU	Tic-D-Phe-Arg-2-Nal-NHCH3	Investigative
T35842	DRUGINFO	D07DWH	Ac-dR[CEHdFRWC]-NH2	Investigative
T35842	DRUGINFO	D09OMI	Ac-YK[CEHdFRWC]-NH2	Investigative
T35842	DRUGINFO	D0A8ME	Ac-[CEHdFRWC]-NH2	Investigative
T35842	DRUGINFO	D0B8GR	Ac-His-D-Phe-Arg-2-Nal-NHCH3	Investigative
T35842	DRUGINFO	D0C7VI	Ac-YR[CEHdFRWC]SPPKD-NH2	Investigative
T35842	DRUGINFO	D0F6GX	Ac-Tyr-D-Phe-Arg-2-Nal-NHCH3	Investigative
T35842	DRUGINFO	D0W1SM	C[Nle-Gln-D-Phe-Arg-Trp-Glu]-NH2	Investigative
T35842	DRUGINFO	D0XQ5U	C[CO-2,3-pyrazine-CO-D-Nal(2)-Arg-Trp-Lys]-NH2	Investigative
T35842	DRUGINFO	D0ZD3M	Ac-YCit[CEHdFRWC]-NH2	Investigative
T35842	DRUGINFO	D02JVA	C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T35842	DRUGINFO	D03AZC	Ac-YRMEHdFRWG-NH2	Investigative
T35842	DRUGINFO	D05LLI	C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T35842	DRUGINFO	D06RTP	C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T35842	DRUGINFO	D07SFD	C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2	Investigative
T35842	DRUGINFO	D07TBR	Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2	Investigative
T35842	DRUGINFO	D09PDT	C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2	Investigative
T35842	DRUGINFO	D0AU4C	AEKKDEGPYRMEHFRWGSPPKD	Investigative
T35842	DRUGINFO	D0B4OL	Ac-YRMEHdFRWGSPPKD-NH2	Investigative
T35842	DRUGINFO	D0CK0K	Ac-Nle-c[Asp-His-DNal(2')-Pro-Trp-Lys]-NH2	Investigative
T35842	DRUGINFO	D0I8SJ	NDP-SYSMEHFRWGKPVG	Investigative
T35842	DRUGINFO	D0ID5M	GPYRMEHFRWGSPPKD-NH2	Investigative
T35842	DRUGINFO	D0L1MJ	C[Nle-Nle-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T35842	DRUGINFO	D0R0BY	Ac-YR[CEH(pCl-dF)RWC]-NH2	Investigative
T35842	DRUGINFO	D0WG8P	Ac-YR[CEH(pF-dF)RWC]-NH2	Investigative
T35842	DRUGINFO	D0WI8M	C[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2	Investigative
T35842	DRUGINFO	D0X1YL	Ac-YRC(Me)*EHdFRWC(Me)NH2	Investigative
T35842	DRUGINFO	D0YB7F	MT-II	Investigative

T88505	TARGETID	T88505
T88505	FORMERID	TTDNR00714
T88505	UNIPROID	NF2L2_HUMAN
T88505	TARGNAME	Nuclear factor erythroid 2-related factor 2 (Nrf2)
T88505	GENENAME	NFE2L2
T88505	TARGTYPE	Successful
T88505	SYNONYMS	Nuclear factor, erythroid derived 2, like 2; NRF2; NFE2-related factor 2; NF-E2-related factor 2; HEBP1
T88505	FUNCTION	Important for the coordinated up-regulation of genes in response to oxidative stress and the regulation of cellular redox conditions. May be involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region. Transcription activator that binds to antioxidant response (ARE) elements in the promoter regions of target genes.
T88505	PDBSTRUC	5WFV; 4IFL; 3ZGC; 2LZ1; 2FLU
T88505	BIOCLASS	Basic leucine zipper bZIP
T88505	SEQUENCE	MMDLELPPPGLPSQQDMDLIDILWRQDIDLGVSREVFDFSQRRKEYELEKQKKLEKERQEQLQKEQEKAFFAQLQLDEETGEFLPIQPAQHIQSETSGSANYSQVAHIPKSDALYFDDCMQLLAQTFPFVDDNEVSSATFQSLVPDIPGHIESPVFIATNQAQSPETSVAQVAPVDLDGMQQDIEQVWEELLSIPELQCLNIENDKLVETTMVPSPEAKLTEVDNYHFYSSIPSMEKEVGNCSPHFLNAFEDSFSSILSTEDPNQLTVNSLNSDATVNTDFGDEFYSAFIAEPSISNSMPSPATLSHSLSELLNGPIDVSDLSLCKAFNQNHPESTAEFNDSDSGISLNTSPSVASPEHSVESSSYGDTLLGLSDSEVEELDSAPGSVKQNGPKTPVHSSGDMVQPLSPSQGQSTHVHDAQCENTPEKELPVSPGHRKTPFTKDKHSSRLEAHLTRDELRAKALHIPFPVEKIINLPVVDFNEMMSKEQFNEAQLALIRDIRRRGKNKVAAQNCRKRKLENIVELEQDLDHLKDEKEKLLKEKGENDKSLHLLKKQLSTLYLEVFSMLRDEDGKPYSPSEYSLQQTRDGNVFLVPKSKKPDVKKN
T88505	DRUGINFO	D0JB3H	Omaveloxolone	Approved
T88505	DRUGINFO	D02NMR	SFX-01	Phase 2
T88505	DRUGINFO	D0K7NI	ABT-RTA-408	Phase 2
T88505	DRUGINFO	D0P1IX	OT-551	Phase 2
T88505	DRUGINFO	DHG2O3	OT551	Phase 2
T88505	DRUGINFO	DF1JO7	CXA10	Phase 2
T88505	DRUGINFO	D9ZEM7	HPP971	Phase 1
T88505	DRUGINFO	D00PGP	Benzamide derivative 6	Patented
T88505	DRUGINFO	D03RTM	Benzo[d]oxazole derivative 1	Patented
T88505	DRUGINFO	D04YKV	PMID28454500-Compound-93	Patented
T88505	DRUGINFO	D05EMI	PMID28454500-Compound-92	Patented
T88505	DRUGINFO	D06KOH	4-(2-cyclohexylethoxy) aniline derivative 3	Patented
T88505	DRUGINFO	D07TEZ	Benzo[d]oxazole derivative 2	Patented
T88505	DRUGINFO	D0D8KO	Thiazole derivative 3	Patented
T88505	DRUGINFO	D0DE0Y	Benzamide derivative 5	Patented
T88505	DRUGINFO	D0G8CF	Benzo[d]oxazole derivative 3	Patented
T88505	DRUGINFO	D0M2ZX	Benzo[d]oxazole derivative 4	Patented
T88505	DRUGINFO	D0ND6T	4-(2-cyclohexylethoxy) aniline derivative 2	Patented
T88505	DRUGINFO	D0O5ZK	PMID28454500-Compound-96	Patented
T88505	DRUGINFO	D0P9ZD	PMID28454500-Compound-94	Patented
T88505	DRUGINFO	D0PF4H	PMID28454500-Compound-91	Patented
T88505	DRUGINFO	D0R2AI	4-(2-cyclohexylethoxy) aniline derivative 1	Patented
T88505	DRUGINFO	D0RO7A	PMID28454500-Compound-95	Patented
T88505	DRUGINFO	D0T2LN	Thiazole derivative 2	Patented
T88505	DRUGINFO	D0T7WW	4-(2-cyclohexylethoxy) aniline derivative 4	Patented
T88505	DRUGINFO	D00TVL	PMID28454500-Compound-57	Patented
T88505	DRUGINFO	D01GTU	PMID28454500-Compound-8	Patented
T88505	DRUGINFO	D01MZI	Pyrazino[2,1-a]isoquinolin derivative 4	Patented
T88505	DRUGINFO	D01PKZ	PMID28454500-Compound-36	Patented
T88505	DRUGINFO	D02FWA	Naphthalene derivative 1	Patented
T88505	DRUGINFO	D02JFV	PMID28454500-Compound-58	Patented
T88505	DRUGINFO	D02SPI	Chalcone derivative 4	Patented
T88505	DRUGINFO	D02YNU	2-hydroxybenzamide derivative 1	Patented
T88505	DRUGINFO	D04ILM	Vinyl sulfone derivative 1	Patented
T88505	DRUGINFO	D06LEF	Pyrazino[2,1-a]isoquinolin derivative 2	Patented
T88505	DRUGINFO	D09FZF	Diterpenoid derivative 1	Patented
T88505	DRUGINFO	D09MSN	1-phenyl-1,3,4-triazole derivative 1	Patented
T88505	DRUGINFO	D0AJ2T	PMID28454500-Compound-13	Patented
T88505	DRUGINFO	D0AR0L	1-phenyl-1,3,4-triazole derivative 2	Patented
T88505	DRUGINFO	D0AX4Q	PMID28454500-Compound-12	Patented
T88505	DRUGINFO	D0AZ8T	Pyrazino[2,1-a]isoquinolin derivative 1	Patented
T88505	DRUGINFO	D0C1PB	PMID28454500-Compound-41	Patented
T88505	DRUGINFO	D0EO3S	Chalcone derivative 2	Patented
T88505	DRUGINFO	D0FH6P	PMID28454500-Compound-34	Patented
T88505	DRUGINFO	D0FM3Q	PMID28454500-Compound-33	Patented
T88505	DRUGINFO	D0G1LS	Chalcone derivative 3	Patented
T88505	DRUGINFO	D0G4EK	PMID28454500-Compound-50	Patented
T88505	DRUGINFO	D0I2DV	1-phenyl-1,3,4-triazole derivative 3	Patented
T88505	DRUGINFO	D0JH8Z	PMID28454500-Compound-3	Patented
T88505	DRUGINFO	D0KX0J	Pyridyl compound 1	Patented
T88505	DRUGINFO	D0L1JQ	PMID28454500-Compound-32	Patented
T88505	DRUGINFO	D0LL7V	PMID28454500-Compound-60	Patented
T88505	DRUGINFO	D0MQ3X	PMID28454500-Compound-40	Patented
T88505	DRUGINFO	D0MS7G	3-phenyl propanoic derivative 2	Patented
T88505	DRUGINFO	D0MX0Q	PMID28454500-Compound-35	Patented
T88505	DRUGINFO	D0N1VC	PMID28454500-Compound-49	Patented
T88505	DRUGINFO	D0N9GH	PMID28454500-Compound-9	Patented
T88505	DRUGINFO	D0O3KN	PMID28454500-Compound-59	Patented
T88505	DRUGINFO	D0O6LW	3-phenyl propanoic derivative 1	Patented
T88505	DRUGINFO	D0Q8JZ	3-phenyl propanoic derivative 3	Patented
T88505	DRUGINFO	D0Q9QQ	Diterpenoid derivative 2	Patented
T88505	DRUGINFO	D0RM4V	PMID28454500-Compound-11	Patented
T88505	DRUGINFO	D0SA1N	PMID28454500-Compound-37	Patented
T88505	DRUGINFO	D0U9TR	Chalcone derivative 1	Patented
T88505	DRUGINFO	D0VA2G	Pyrazino[2,1-a]isoquinolin derivative 3	Patented
T88505	DRUGINFO	D0VW9H	2-hydroxybenzamide derivative 2	Patented
T88505	DRUGINFO	D0WN1Y	PMID28454500-Compound-10	Patented
T88505	DRUGINFO	D0WR1I	1,2,3,4-tetrahydroisoquinoline derivative 1	Patented
T88505	DRUGINFO	D0XL2V	Trepenoid derivative 1	Patented
T88505	DRUGINFO	D24EPJ	CAT4001	Preclinical
T88505	DRUGINFO	DA85KQ	M102	Preclinical
T88505	DRUGINFO	DPJ05C	TFM735	Preclinical

T32262	TARGETID	T32262
T32262	FORMERID	TTDC00093
T32262	UNIPROID	CALRL_HUMAN
T32262	TARGNAME	Calcitonin gene-related peptide receptor (CGRPR)
T32262	GENENAME	CALCRL
T32262	TARGTYPE	Successful
T32262	SYNONYMS	Calcitonin receptor-like receptor; Calcitonin gene-related peptide type 1 receptor; CGRPR; CGRP type 1 receptor
T32262	FUNCTION	Receptor for calcitonin-gene-related peptide (CGRP) together with RAMP1 and receptor for adrenomedullin together with RAMP3 (By similarity). Receptor for adrenomedullin together with RAMP2. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.
T32262	PDBSTRUC	6E3Y; 6D1U; 5V6Y; 4RWG; 4RWF
T32262	BIOCLASS	GPCR secretin
T32262	SEQUENCE	MEKKCTLNFLVLLPFFMILVTAELEESPEDSIQLGVTRNKIMTAQYECYQKIMQDPIQQAEGVYCNRTWDGWLCWNDVAAGTESMQLCPDYFQDFDPSEKVTKICDQDGNWFRHPASNRTWTNYTQCNVNTHEKVKTALNLFYLTIIGHGLSIASLLISLGIFFYFKSLSCQRITLHKNLFFSFVCNSVVTIIHLTAVANNQALVATNPVSCKVSQFIHLYLMGCNYFWMLCEGIYLHTLIVVAVFAEKQHLMWYYFLGWGFPLIPACIHAIARSLYYNDNCWISSDTHLLYIIHGPICAALLVNLFFLLNIVRVLITKLKVTHQAESNLYMKAVRATLILVPLLGIEFVLIPWRPEGKIAEEVYDYIMHILMHFQGLLVSTIFCFFNGEVQAILRRNWNQYKIQFGNSFSNSEALRSASYTVSTISDGPGYSHDCPSEHLNGKSIHDIENVLLKPENLYN
T32262	DRUGINFO	D02ZUG	Atogepant	Approved
T32262	DRUGINFO	D07GXR	Ubrogepant	Approved
T32262	DRUGINFO	D08PLK	Fremanezumab	Approved
T32262	DRUGINFO	D0C8VF	Galcanezumab	Approved
T32262	DRUGINFO	D0IA9Y	Zavegepant	Approved
T32262	DRUGINFO	D0KX1Y	Erenumab	Approved
T32262	DRUGINFO	D0V9VG	Rimegepant	Approved
T32262	DRUGINFO	D00MXN	MK-3207	Phase 2
T32262	DRUGINFO	D04YLQ	AMG 334	Phase 2
T32262	DRUGINFO	D0G5ME	Telcagepant	Phase 2
T32262	DRUGINFO	D0L5GH	Olcegepant	Phase 2
T32262	DRUGINFO	D0VZ5X	BI-44370	Phase 2
T32262	DRUGINFO	D05YQT	LBR-101	Phase 1
T32262	DRUGINFO	D02NMK	FVPTDVGAFAF	Investigative
T32262	DRUGINFO	D03WBD	FV-Hyp-TDVGPFAF	Investigative
T32262	DRUGINFO	D07ZZZ	FV-Tic-TDVGPFAF	Investigative
T32262	DRUGINFO	D09TDY	EPIMER A	Investigative
T32262	DRUGINFO	D0B8HD	FVPTDVGPFAF	Investigative
T32262	DRUGINFO	D0E1YT	ISOMER A	Investigative
T32262	DRUGINFO	D0E7CV	FVATDVGPFAF	Investigative
T32262	DRUGINFO	D0G0YT	HCGRPalpha	Investigative
T32262	DRUGINFO	D0K8ZD	FVPTDVG-Tic-FAF-Tic	Investigative
T32262	DRUGINFO	D05MSG	BMS-694153	Investigative
T32262	DRUGINFO	D0I2KW	FV-Aib-TDVGPFAF	Investigative

T86115	TARGETID	T86115
T86115	FORMERID	TTDC00328
T86115	UNIPROID	APOC3_HUMAN
T86115	TARGNAME	ApoC-III messenger RNA (APOC3 mRNA)
T86115	GENENAME	APOC3
T86115	TARGTYPE	Successful
T86115	SYNONYMS	Apolipoprotein CIII (mRNA); Apolipoprotein C3 (mRNA); Apolipoprotein C-III (mRNA); ApoC-III (mRNA); Apo-CIII (mRNA)
T86115	FUNCTION	Plays a multifaceted role in triglyceride homeostasis. Intracellularly, promotes hepatic very low density lipoprotein 1 (VLDL1) assembly and secretion; extracellularly, attenuates hydrolysis and clearance of triglyceride-rich lipoproteins (TRLs). Impairs the lipolysis of TRLs by inhibiting lipoprotein lipase and the hepatic uptake of TRLs by remnant receptors. Formed of several curved helices connected via semiflexible hinges, so that it can wrap tightly around the curved micelle surface and easily adapt to the different diameters of its natural binding partners. Component of triglyceride-rich very low density lipoproteins (VLDL) and high density lipoproteins (HDL) in plasma.
T86115	PDBSTRUC	2JQ3
T86115	BIOCLASS	mRNA target
T86115	SEQUENCE	MQPRVLLVVALLALLASARASEAEDASLLSFMQGYMKHATKTAKDALSSVQESQVAQQARGWVTDGFSSLKDYWSTVKDKFSEFWDLDPEVRPTSAVAA
T86115	DRUGINFO	D0A8TA	Volanesorsen	Approved
T86115	DRUGINFO	DNF8Z1	ARO-APOC3	Phase 3
T86115	DRUGINFO	DVA8R9	Olezarsen	Phase 3
T86115	DRUGINFO	D0F6KM	ISIS-APOCIII	Phase 1

T81100	TARGETID	T81100
T81100	FORMERID	TTDC00336
T81100	UNIPROID	SC5A2_HUMAN
T81100	TARGNAME	SLC5A2 messenger RNA (SLC5A2 mRNA)
T81100	GENENAME	SLC5A2
T81100	TARGTYPE	Successful
T81100	SYNONYMS	Solute carrier family 5 member 2 (mRNA); Na(+)/glucose cotransporter 2 (mRNA); Low affinity sodium-glucose cotransporter (mRNA)
T81100	FUNCTION	Has a Na(+) to glucose coupling ratio of 1:1. Sodium-dependent glucose transporter.
T81100	BIOCLASS	mRNA target
T81100	SEQUENCE	MEEHTEAGSAPEMGAQKALIDNPADILVIAAYFLLVIGVGLWSMCRTNRGTVGGYFLAGRSMVWWPVGASLFASNIGSGHFVGLAGTGAASGLAVAGFEWNALFVVLLLGWLFAPVYLTAGVITMPQYLRKRFGGRRIRLYLSVLSLFLYIFTKISVDMFSGAVFIQQALGWNIYASVIALLGITMIYTVTGGLAALMYTDTVQTFVILGGACILMGYAFHEVGGYSGLFDKYLGAATSLTVSEDPAVGNISSFCYRPRPDSYHLLRHPVTGDLPWPALLLGLTIVSGWYWCSDQVIVQRCLAGKSLTHIKAGCILCGYLKLTPMFLMVMPGMISRILYPDEVACVVPEVCRRVCGTEVGCSNIAYPRLVVKLMPNGLRGLMLAVMLAALMSSLASIFNSSSTLFTMDIYTRLRPRAGDRELLLVGRLWVVFIVVVSVAWLPVVQAAQGGQLFDYIQAVSSYLAPPVSAVFVLALFVPRVNEQGAFWGLIGGLLMGLARLIPEFSFGSGSCVQPSACPAFLCGVHYLYFAIVLFFCSGLLTLTVSLCTAPIPRKHLHRLVFSLRHSKEEREDLDADEQQGSSLPVQNGCPESAMEMNEPQAPAPSLFRQCLLWFCGMSRGGVGSPPPLTQEEAAAAARRLEDISEDPSWARVVNLNALLMMAVAVFLWGFYA
T81100	DRUGINFO	D0OR3G	Bexagliflozin	Approved
T81100	DRUGINFO	D0G8LN	ISIS-SGLT2	Phase 1
T81100	DRUGINFO	D03AJS	SERGLIFLOZIN A	Investigative
T81100	DRUGINFO	D05ODW	MAACKIAIN	Investigative
T81100	DRUGINFO	D0M7BR	FORMONONETIN	Investigative
T81100	DRUGINFO	D0M8VV	Acerogenin C	Investigative
T81100	DRUGINFO	D00HFT	10-methoxy-N(1)-methylburnamine-17-O-veratrate	Investigative
T81100	DRUGINFO	D01DIQ	Alstiphyllanine F	Investigative
T81100	DRUGINFO	D03VSQ	Kushenol N	Investigative
T81100	DRUGINFO	D05AZW	Alstiphyllanine E	Investigative
T81100	DRUGINFO	D0I2FC	Burnamine-17-O-3',4',5'-trimethoxybenzoate	Investigative
T81100	DRUGINFO	D0L8OJ	Alstiphyllanine D	Investigative
T81100	DRUGINFO	D0M8EH	O-spiroketal glucoside	Investigative
T81100	DRUGINFO	D0S1MI	ACEROGENIN B	Investigative
T81100	DRUGINFO	D0VE0Q	Sophoraflavanone G	Investigative
T81100	DRUGINFO	D01PNM	KURARINONE	Investigative
T81100	DRUGINFO	D06GUJ	KURAIDIN	Investigative

T72702	TARGETID	T72702
T72702	FORMERID	TTDR00396
T72702	UNIPROID	TF_HUMAN
T72702	TARGNAME	Tissue factor (F3)
T72702	GENENAME	F3
T72702	TARGTYPE	Successful
T72702	SYNONYMS	Thromboplastin; TF; F3; Coagulation factor III; CD142 antigen
T72702	FUNCTION	Initiates blood coagulation by forming a complex with circulating factor VII or VIIa. The [TF:VIIa] complex activates factors IX or X by specific limited protolysis. TF plays a role in normal hemostasis by initiating the cell-surface assemblyand propagation of the coagulation protease cascade.
T72702	PDBSTRUC	5W06; 4ZMA; 4Z6A; 4YLQ; 4M7L
T72702	SEQUENCE	METPAWPRVPRPETAVARTLLLGWVFAQVAGASGTTNTVAAYNLTWKSTNFKTILEWEPKPVNQVYTVQISTKSGDWKSKCFYTTDTECDLTDEIVKDVKQTYLARVFSYPAGNVESTGSAGEPLYENSPEFTPYLETNLGQPTIQSFEQVGTKVNVTVEDERTLVRRNNTFLSLRDVFGKDLIYTLYYWKSSSSGKKTAKTNTNEFLIDVDKGENYCFSVQAVIPSRTVNRKSTDSPVECMGQEKGEFREIFYIIGAVVFVVIILVIILAISLHKCRKAGVGQSWKENSPLNVS
T72702	DRUGINFO	D0A4GQ	Tisotumab vedotin	Approved
T72702	DRUGINFO	D04DKL	ALT-836	Phase 2
T72702	DRUGINFO	D0E2LH	TT-173	Phase 2
T72702	DRUGINFO	D0H8PX	MORAb-066	Phase 1
T72702	DRUGINFO	D0M4VZ	D-Pro-Phe-Arg chloromethyl ketone	Investigative

T17234	TARGETID	T17234
T17234	FORMERID	TTDR00589
T17234	UNIPROID	UL97_HCMVA
T17234	TARGNAME	Cytomegalovirus Ganciclovir kinase (CMV UL97)
T17234	GENENAME	CMV UL97
T17234	TARGTYPE	Successful
T17234	SYNONYMS	UL97; Human cytomegalovirus UL97 protein kinase; HSRF3 protein
T17234	FUNCTION	Phosphorylates the antiviral nucleoside analog ganciclovir.
T17234	BIOCLASS	Kinase
T17234	ECNUMBER	EC 2.7.1.-
T17234	SEQUENCE	MSSALRSRARSASLGTTTQGWDPPPLRRPSRARRRQWMREAAQAAAQAAVQAAQAAAAQVAQAHVDENEVVDLMADEAGGGVTTLTTLSSVSTTTVLGHATFSACVRSDVMRDGEKEDAASDKENLRRPVVPSTSSRGSAASGDGYHGLRCRETSAMWSFEYDRDGDVTSVRRALFTGGSDPSDSVSGVRGGRKRPLRPPLVSLARTPLCRRRVGGVDAVLEENDVELRAESQDSAVASGPGRIPQPLSGSSGEESATAVEADSTSHDDVHCTCSNDQIITTSIRGLTCDPRMFLRLTHPELCELSISYLLVYVPKEDDFCHKICYAVDMSDESYRLGQGSFGEVWPLDRYRVVKVARKHSETVLTVWMSGLIRTRAAGEQQQPPSLVGTGVHRGLLTATGCCLLHNVTVHRRFHTDMFHHDQWKLACIDSYRRAFCTLADAIKFLNHQCRVCHFDITPMNVLIDVNPHNPSEIVRAALCDYSLSEPYPDYNERCVAVFQETGTARRIPNCSHRLRECYHPAFRPMPLQKLLICDPHARFPVAGLRRYCMSELSALGNVLGFCLMRLLDRRGLDEVRMGTEALLFKHAGAACRALENGKLTHCSDACLLILAAQMSYGACLLGEHGAALVSHTLRFVEAKMSSCRVRAFRRFYHECSQTMLHEYVRKNVERLLATSDGLYLYNAFRRTTSIICEEDLDGDCRQLFPE
T17234	DRUGINFO	D07WXI	Maribavir	Approved

T08306	TARGETID	T08306
T08306	FORMERID	TTDNC00634
T08306	UNIPROID	CD79B_HUMAN
T08306	TARGNAME	B-cell-specific glycoprotein B29 (CD79B)
T08306	GENENAME	CD79B
T08306	TARGTYPE	Successful
T08306	SYNONYMS	Immunoglobulinassociated B29 protein; Immunoglobulin-associated B29 protein; Igbeta; Ig-beta; IGB; CD79b; Bcellspecific glycoprotein B29; Bcell antigen receptor complexassociated protein beta chain; B29; B-cell antigen receptor complex-associated protein beta chain
T08306	FUNCTION	Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation.
T08306	PDBSTRUC	3KG5
T08306	BIOCLASS	Immunoglobulin
T08306	SEQUENCE	MARLALSPVPSHWMVALLLLLSAEPVPAARSEDRYRNPKGSACSRIWQSPRFIARKRGFTVKMHCYMNSASGNVSWLWKQEMDENPQQLKLEKGRMEESQNESLATLTIQGIRFEDNGIYFCQQKCNNTSEVYQGCGTELRVMGFSTLAQLKQRNTLKDGIIMIQTLLIILFIIVPIFLLLDKDDSKAGMEEDHTYEGLDIDQTATYEDIVTLRTGEVKWSVGEHPGQE
T08306	DRUGINFO	D05QOL	Polatuzumab vedotin	Approved
T08306	DRUGINFO	D03KIZ	RG7596	Phase 2
T08306	DRUGINFO	D0PA1B	DCDS-4501A	Phase 2
T08306	DRUGINFO	D50ESV	Polivy	Phase 2
T08306	DRUGINFO	D0QO6N	MGD010	Phase 1
T08306	DRUGINFO	D0M7EP	CD79-targeted immunotoxins	Investigative

T85857	TARGETID	T85857
T85857	FORMERID	TTDNC00460
T85857	UNIPROID	TSLP_HUMAN
T85857	TARGNAME	Thymic stromal lymphopoietin (TSLP)
T85857	GENENAME	TSLP
T85857	TARGTYPE	Successful
T85857	SYNONYMS	Thymic stromal lymphopoietin
T85857	FUNCTION	Isoform 1: Cytokine that induces the release of T-cell-attracting chemokines from monocytes and, in particular, enhances the maturation of CD11c(+) dendritic cells. Can induce allergic inflammation by directly activating mast cells.
T85857	PDBSTRUC	5J13; 5J12; 5J11
T85857	SEQUENCE	MFPFALLYVLSVSFRKIFILQLVGLVLTYDFTNCDFEKIKAAYLSTISKDLITYMSGTKSTEFNNTVSCSNRPHCLTEIQSLTFNPTAGCASLAKEMFAMKTKAALAIWCPGYSETQINATQAMKKRRKRKVTTNKCLEQVSQLQGLWRRFNRPLLKQQ
T85857	DRUGINFO	DMOF95	Tezepelumab	Approved
T85857	DRUGINFO	DX8M3T	A378	IND submitted
T85857	DRUGINFO	D00CTZ	MEDI9929	Phase 2
T85857	DRUGINFO	DU6O4B	CSJ117	Phase 2
T85857	DRUGINFO	D94LRF	AMG 104	Phase 1
T85857	DRUGINFO	DYC40H	AZD8630	Phase 1
T85857	DRUGINFO	D9TW0X	SAR443765	Phase 1
T85857	DRUGINFO	DIWU14	PF-07275315	Phase 1

T99840	TARGETID	T99840
T99840	FORMERID	TTDC00051
T99840	UNIPROID	APH1A_HUMAN; APH1B_HUMAN; PEN2_HUMAN; NICA_HUMAN; PSN1_HUMAN
T99840	TARGNAME	Gamma-secretase (GS)
T99840	GENENAME	APH1A; APH1B; NCSTN; PSENEN; PSEN1
T99840	TARGTYPE	Successful
T99840	SYNONYMS	Presenilin-stabilization factor-like; PSFL; Aph-1beta
T99840	FUNCTION	Probable subunit of the gamma-secretase complex, an endoprotease complex that catalyzes the intramembrane cleavage of integral proteins such as Notch receptors and APP (beta-amyloid precursor protein). It probably represents a stabilizing cofactor for the presenilin homodimer that promotes the formation of a stable complex. Probably present in a minority of gamma-secretase complexes compared to APH1A.
T99840	SEQUENCE	MGAAVFFGCTFVAFGPAFALFLITVAGDPLRVIILVAGAFFWLVSLLLASVVWFILVHVTDRSDARLQYGLLIFGAAVSVLLQEVFRFAYYKLLKKADEGLASLSEDGRSPISIRQMAYVSGLSFGIISGVFSVINILADALGPGVVGIHGDSPYYFLTSAFLTAAIILLHTFWGVVFFDACERRRYWALGLVVGSHLLTSGLTFLNPWYEASLLPIYAVTVSMGLWAFITAGGSLRSIQRSLLCRRQEDSRVMVYSALRIPPED
T99840	DRUGINFO	D00GPQ	Nirogacestat	Approved
T99840	DRUGINFO	D0G2IC	(S)-FLURBIPROFEN	Preregistration
T99840	DRUGINFO	D01LXD	Semagacestat	Phase 3
T99840	DRUGINFO	D0K8NR	AMG 386	Phase 3
T99840	DRUGINFO	D02HNG	MK-0752	Phase 2
T99840	DRUGINFO	D02JOH	BMS-708163	Phase 2
T99840	DRUGINFO	D03MFQ	CHF-5074	Phase 2
T99840	DRUGINFO	D0I3WC	RO-4929097	Phase 2
T99840	DRUGINFO	DT3OE6	AL102	Phase 2
T99840	DRUGINFO	D05FGR	R-flurbiprofen	Phase 2
T99840	DRUGINFO	D08XKL	SPI-014	Phase 1
T99840	DRUGINFO	D09ZVC	Begacestat	Phase 1
T99840	DRUGINFO	D0EV5O	NGP 555	Phase 1
T99840	DRUGINFO	D0F0JJ	E2012	Phase 1
T99840	DRUGINFO	D0I1OS	E-2212	Phase 1
T99840	DRUGINFO	D0TQ4Y	PF-06648671	Phase 1
T99840	DRUGINFO	D0U6FT	GSI-136	Phase 1
T99840	DRUGINFO	DZ76PB	PF-06648671	Phase 1
T99840	DRUGINFO	D00DFR	(5R,6S)-5,6-bis(benzyloxy)cyclohex-2-enone	Investigative
T99840	DRUGINFO	D04TWU	(5R,6S)-6-(benzyloxy)-5-methoxycyclohex-2-enone	Investigative
T99840	DRUGINFO	D06TPT	Drug 311951	Investigative
T99840	DRUGINFO	D09HAD	Drug 311383	Investigative
T99840	DRUGINFO	D0I8BA	1-benzoyl-2-benzyl-1,2-dihydropyridin-3(6H)-one	Investigative
T99840	DRUGINFO	D0M2LV	(2S,3R)-2-(benzyloxy)-3-methoxycyclohexanone	Investigative
T99840	DRUGINFO	D0V7YM	Drug 311952	Investigative
T99840	DRUGINFO	D0XQ2T	Drug 311440	Investigative

T06542	TARGETID	T06542
T06542	UNIPROID	IL17F_HUMAN
T06542	TARGNAME	Cytokine ML-1 (IL17F)
T06542	GENENAME	IL17F
T06542	TARGTYPE	Successful
T06542	SYNONYMS	Interleukin-17F; IL-17F
T06542	FUNCTION	The heterodimer formed by IL17A and IL17F is a ligand for the heterodimeric complex formed by IL17RA and IL17RC. Involved in stimulating the production of other cytokines such as IL6, IL8 and CSF2, and in regulation of cartilage matrix turnover. Also involved in stimulating the proliferation of peripheral blood mononuclear cells and T-cells and in inhibition of angiogenesis. Plays a role in the induction of neutrophilia in the lungs and in the exacerbation of antigen-induced pulmonary allergic inflammation. Ligand for IL17RA and IL17RC.
T06542	PDBSTRUC	5NAN; 5N92; 3JVF; 1JPY
T06542	BIOCLASS	Cytokine: interleukin
T06542	SEQUENCE	MTVKTLHGPAMVKYLLLSILGLAFLSEAAARKIPKVGHTFFQKPESCPPVPGGSMKLDIGIINENQRVSMSRNIESRSTSPWNYTVTWDPNRYPSEVVQAQCRNLGCINAQGKEDISMNSVPIQQETLVVRRKHQGCSVSFQLEKVLVTVGCTCVTPVIHHVQ
T06542	DRUGINFO	D0WJ5M	Bimekizumab	Approved

T60724	TARGETID	T60724
T60724	FORMERID	TTDNC00461
T60724	UNIPROID	SOST_HUMAN
T60724	TARGNAME	Sclerostin (SOST)
T60724	GENENAME	SOST
T60724	TARGTYPE	Successful
T60724	SYNONYMS	UNQ2976/PRO7455/PRO7476
T60724	FUNCTION	Negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation.
T60724	PDBSTRUC	3SOV; 2K8P
T60724	SEQUENCE	MQLPLALCLVCLLVHTAFRVVEGQGWQAFKNDATEIIPELGEYPEPPPELENNKTMNRAENGGRPPHHPFETKDVSEYSCRELHFTRYVTDGPCRSAKPVTELVCSGQCGPARLLPNAIGRGKWWRPSGPDFRCIPDRYRAQRVQLLCPGGEAPRARKVRLVASCKCKRLTRFHNQSELKDFGTEAARPQKGRKPRPRARSAKANQAELENAY
T60724	DRUGINFO	D0K3LO	Romosozumab	Approved
T60724	DRUGINFO	DG8VN2	UX143	Phase 3
T60724	DRUGINFO	D08PKG	LY2541546	Phase 2
T60724	DRUGINFO	D0XY4A	BPS-804	Phase 2
T60724	DRUGINFO	D02DJR	AMG 167	Phase 1

T46128	TARGETID	T46128
T46128	FORMERID	TTDI02331
T46128	UNIPROID	PMEL_HUMAN
T46128	TARGNAME	Melanocytes lineage-specific antigen GP100 (PMEL)
T46128	GENENAME	PMEL
T46128	TARGTYPE	Successful
T46128	SYNONYMS	Silver locus protein homolog; SILV; Premelanosome protein; PMEL17; P100; P1; Melanomaassociated ME20 antigen; Melanoma-associated ME20 antigen; Melanocyte protein Pmel 17; Melanocyte protein PMEL; Mbeta; ME20S; ME20M; ME20-M; D12S53E
T46128	FUNCTION	Involved in the maturation of melanosomes from stage I to II. The transition from stage I melanosomes to stage II melanosomes involves an elongation of the vesicle, and the appearance within of distinct fibrillar structures. Release of the soluble form, ME20-S, could protect tumor cells from antibody mediated immunity. Plays a central role in the biogenesis of melanosomes.
T46128	PDBSTRUC	5EU6; 5EU5; 5EU4; 5EU3; 4IS6
T46128	SEQUENCE	MDLVLKRCLLHLAVIGALLAVGATKVPRNQDWLGVSRQLRTKAWNRQLYPEWTEAQRLDCWRGGQVSLKVSNDGPTLIGANASFSIALNFPGSQKVLPDGQVIWVNNTIINGSQVWGGQPVYPQETDDACIFPDGGPCPSGSWSQKRSFVYVWKTWGQYWQVLGGPVSGLSIGTGRAMLGTHTMEVTVYHRRGSRSYVPLAHSSSAFTITDQVPFSVSVSQLRALDGGNKHFLRNQPLTFALQLHDPSGYLAEADLSYTWDFGDSSGTLISRALVVTHTYLEPGPVTAQVVLQAAIPLTSCGSSPVPGTTDGHRPTAEAPNTTAGQVPTTEVVGTTPGQAPTAEPSGTTSVQVPTTEVISTAPVQMPTAESTGMTPEKVPVSEVMGTTLAEMSTPEATGMTPAEVSIVVLSGTTAAQVTTTEWVETTARELPIPEPEGPDASSIMSTESITGSLGPLLDGTATLRLVKRQVPLDCVLYRYGSFSVTLDIVQGIESAEILQAVPSGEGDAFELTVSCQGGLPKEACMEISSPGCQPPAQRLCQPVLPSPACQLVLHQILKGGSGTYCLNVSLADTNSLAVVSTQLIMPGQEAGLGQVPLIVGILLVLMAVVLASLIYRRRLMKQDFSVPQLPHSSSHWLRLPRIFCSCPIGENSPLLSGQQV
T46128	DRUGINFO	D0S0BJ	Tebentafusp	Approved
T46128	DRUGINFO	D0P5TG	Multi-epitope peptide melanoma vaccine	Phase 3
T46128	DRUGINFO	D0U9MJ	Melanoma vaccine	Phase 3
T46128	DRUGINFO	D08DWM	Gp100:209-217(210M) peptide vaccine	Phase 2
T46128	DRUGINFO	D0N7FD	Multi-epitope tyrosinase/gp100 vaccine	Phase 2
T46128	DRUGINFO	D0F5GF	AE-08	Phase 1
T46128	DRUGINFO	D0C1EO	Melanoma vaccine (ALVAC)	Discontinued in Phase 2

T24982	TARGETID	T24982
T24982	FORMERID	TTDNC00442
T24982	UNIPROID	NTCP2_HUMAN
T24982	TARGNAME	Ileal sodium/bile acid cotransporter (SLC10A2)
T24982	GENENAME	SLC10A2
T24982	TARGTYPE	Successful
T24982	SYNONYMS	Solute carrier family 10 member 2; Sodium/taurocholate cotransporting polypeptide, ileal; SLC10A2; Na(+)dependent ileal bile acid transporter; Ileal sodiumdependent bile acid transporter; Ileal Na(+)/bile acid cotransporter; ISBT; IBAT; Apical sodiumdependent bile acid transporter; ASBT
T24982	FUNCTION	Plays a critical role in the sodium-dependent reabsorption of bile acids from the lumen of the small intestine. Plays a key role in cholesterol metabolism.
T24982	SEQUENCE	MNDPNSCVDNATVCSGASCVVPESNFNNILSVVLSTVLTILLALVMFSMGCNVEIKKFLGHIKRPWGICVGFLCQFGIMPLTGFILSVAFDILPLQAVVVLIIGCCPGGTASNILAYWVDGDMDLSVSMTTCSTLLALGMMPLCLLIYTKMWVDSGSIVIPYDNIGTSLVSLVVPVSIGMFVNHKWPQKAKIILKIGSIAGAILIVLIAVVGGILYQSAWIIAPKLWIIGTIFPVAGYSLGFLLARIAGLPWYRCRTVAFETGMQNTQLCSTIVQLSFTPEELNVVFTFPLIYSIFQLAFAAIFLGFYVAYKKCHGKNKAEIPESKENGTEPESSFYKANGGFQPDEK
T24982	DRUGINFO	DEWC27	Odevixibat	Approved
T24982	DRUGINFO	DZB84T	Maralixibat	Approved
T24982	DRUGINFO	D04BLE	A-3309	Phase 3
T24982	DRUGINFO	D02FEV	S-8921	Phase 2
T24982	DRUGINFO	D02JIN	264W94	Phase 2
T24982	DRUGINFO	D0X8CH	GSK2330672	Phase 2
T24982	DRUGINFO	D09JXH	LUM001	Phase 2
T24982	DRUGINFO	D09NTG	Taurocholic Acid	Phase 1/2
T24982	DRUGINFO	D0D2WX	1614235 + 2330672	Phase 1
T24982	DRUGINFO	D06FCT	AZD-7806	Investigative

T99189	TARGETID	T99189
T99189	UNIPROID	NTCP_HUMAN
T99189	TARGNAME	Sodium/bile acid cotransporter (SLC10A1)
T99189	GENENAME	SLC10A1
T99189	TARGTYPE	Successful
T99189	SYNONYMS	Solute carrier family 10 member 1; Sodium/taurocholate cotransporting polypeptide; Na(+)/taurocholate transport protein; Na(+)/bile acid cotransporter; Cell growth-inhibiting gene 29 protein
T99189	FUNCTION	The hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. It is strictly dependent on the extracellular presence of sodium.
T99189	BIOCLASS	Bile acid:sodium symporter (BASS) (TC 2.A.28) family
T99189	SEQUENCE	MEAHNASAPFNFTLPPNFGKRPTDLALSVILVFMLFFIMLSLGCTMEFSKIKAHLWKPKGLAIALVAQYGIMPLTAFVLGKVFRLKNIEALAILVCGCSPGGNLSNVFSLAMKGDMNLSIVMTTCSTFCALGMMPLLLYIYSRGIYDGDLKDKVPYKGIVISLVLVLIPCTIGIVLKSKRPQYMRYVIKGGMIIILLCSVAVTVLSAINVGKSIMFAMTPLLIATSSLMPFIGFLLGYVLSALFCLNGRCRRTVSMETGCQNVQLCSTILNVAFPPEVIGPLFFFPLLYMIFQLGEGLLLIAIFWCYEKFKTPKDKTKMIYTAATTEETIPGALGNGTYKGEDCSPCTA
T99189	DRUGINFO	D2G4HB	Bulevirtide	Approved
T99189	DRUGINFO	D09JXH	LUM001	Phase 2

T71907	TARGETID	T71907
T71907	FORMERID	TTDI02176
T71907	UNIPROID	SMN_HUMAN
T71907	TARGNAME	Survival motor neuron protein (SMN1)
T71907	GENENAME	SMN1
T71907	TARGTYPE	Successful
T71907	SYNONYMS	SMNT; SMNC; SMN2; SMN; Gemin-1; Component of gems 1
T71907	FUNCTION	Thereby, plays an important role in the splicing of cellular pre-mRNAs. Most spliceosomal snRNPs contain a common set of Sm proteins SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG that assemble in a heptameric protein ring on the Sm site of the small nuclear RNA to form the core snRNP. In the cytosol, the Sm proteins SNRPD1, SNRPD2, SNRPE, SNRPF and SNRPG are trapped in an inactive 6S pICln-Sm complex by the chaperone CLNS1A that controls the assembly of the core snRNP. Dissociation by the SMN complex of CLNS1A from the trapped Sm proteins and their transfer to an SMN-Sm complex triggers the assembly of core snRNPs and their transport to the nucleus. Ensures the correct splicing of U12 intron-containing genes that may be important for normal motor and proprioceptive neurons development. Also required for resolving RNA-DNA hybrids created by RNA polymerase II, that form R-loop in transcription terminal regions, an important step in proper transcription termination. May also play a role in the metabolism of small nucleolar ribonucleoprotein (snoRNPs). The SMN complex plays a catalyst role in the assembly of small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome.
T71907	PDBSTRUC	5XJU; 5XJT; 5XJS; 5XJR; 5XJQ
T71907	SEQUENCE	MAMSSGGSGGGVPEQEDSVLFRRGTGQSDDSDIWDDTALIKAYDKAVASFKHALKNGDICETSGKPKTTPKRKPAKKNKSQKKNTAASLQQWKVGDKCSAIWSEDGCIYPATIASIDFKRETCVVVYTGYGNREEQNLSDLLSPICEVANNIEQNAQENENESQVSTDESENSRSPGNKSDNIKPKSAPWNSFLPPPPPMPGPRLGPGKPGLKFNGPPPPPPPPPPHLLSCWLPPFPSGPPIIPPPPPICPDSLDDADALGSMLISWYMSGYHTGYYMGFRQNQKEGRCSHSLN
T71907	DRUGINFO	DP07NC	Zolgensma	Approved
T71907	DRUGINFO	D0CE6C	LMI070	Phase 3
T71907	DRUGINFO	D09OTX	RG7800	Phase 1/2

T35591	TARGETID	T35591
T35591	FORMERID	TTDC00343
T35591	UNIPROID	NECT4_HUMAN
T35591	TARGNAME	Nectin cell adhesion molecule 4 (NECTIN4)
T35591	GENENAME	NECTIN4
T35591	TARGTYPE	Successful
T35591	SYNONYMS	Poliovirus receptor-related protein 4; PVRL4; PRR4; Nectin-4; LNIR; Ig superfamily receptor LNIR
T35591	FUNCTION	Does not act as receptor for alpha-herpesvirus entry into cells. Seems to be involved in cell adhesion through trans-homophilic and -heterophilic interactions, the latter including specifically interactions with NECTIN1.
T35591	PDBSTRUC	4JJH; 4GJT; 4FRW
T35591	SEQUENCE	MPLSLGAEMWGPEAWLLLLLLLASFTGRCPAGELETSDVVTVVLGQDAKLPCFYRGDSGEQVGQVAWARVDAGEGAQELALLHSKYGLHVSPAYEGRVEQPPPPRNPLDGSVLLRNAVQADEGEYECRVSTFPAGSFQARLRLRVLVPPLPSLNPGPALEEGQGLTLAASCTAEGSPAPSVTWDTEVKGTTSSRSFKHSRSAAVTSEFHLVPSRSMNGQPLTCVVSHPGLLQDQRITHILHVSFLAEASVRGLEDQNLWHIGREGAMLKCLSEGQPPPSYNWTRLDGPLPSGVRVDGDTLGFPPLTTEHSGIYVCHVSNEFSSRDSQVTVDVLDPQEDSGKQVDLVSASVVVVGVIAALLFCLLVVVVVLMSRYHRRKAQQMTQKYEEELTLTRENSIRRLHSHHTDPRSQPEESVGLRAEGHPDSLKDNSSCSVMSEEPEGRSYSTLTTVREIETQTELLSPGSGRAEEEEDQDEGIKQAMNHFVQENGTLRAKPTGNGIYINGRGHLV
T35591	DRUGINFO	DAG87H	Enfortumab vedotin	Approved
T35591	DRUGINFO	DORB45	Enfortumab	Approved
T35591	DRUGINFO	DC57TE	BT8009	Phase 1/2
T35591	DRUGINFO	D0R1CG	ASG-22ME	Phase 1

T21123	TARGETID	T21123
T21123	UNIPROID	EPAS1_HUMAN
T21123	TARGNAME	Hypoxia-inducible factor 2 alpha (HIF-2A)
T21123	GENENAME	EPAS1
T21123	TARGTYPE	Successful
T21123	SYNONYMS	bHLHe73; PASD2; PAS domain-containing protein 2; Member of PAS protein 2; MOP2; Hypoxia-inducible factor 2-alpha; HLF; HIF2A; HIF2-alpha; HIF-2-alpha; HIF-1-alpha-like factor; Endothelial PAS domain-containing protein 1; EPAS-1; Class E basic helix-loop-helix protein 73; Basic-helix-loop-helix-PAS protein MOP2
T21123	FUNCTION	Heterodimerizes with ARNT; heterodimer binds to core DNA sequence 5'-TACGTG-3' within the hypoxia response element (HRE) of target gene promoters. Regulates the vascular endothelial growth factor (VEGF) expression and seems to be implicated in the development of blood vessels and the tubular system of lung. May also play a role in the formation of the endothelium that gives rise to the blood brain barrier. Potent activator of the Tie-2 tyrosine kinase expression. Activation requires recruitment of transcriptional coactivators such as CREBBP and probably EP300. Interaction with redox regulatory protein APEX seems to activate CTAD. Transcription factor involved in the induction of oxygen regulated genes.
T21123	PDBSTRUC	6D0C; 6D0B; 6D09; 6CZW; 6BVB
T21123	SEQUENCE	MTADKEKKRSSSERRKEKSRDAARCRRSKETEVFYELAHELPLPHSVSSHLDKASIMRLAISFLRTHKLLSSVCSENESEAEADQQMDNLYLKALEGFIAVVTQDGDMIFLSENISKFMGLTQVELTGHSIFDFTHPCDHEEIRENLSLKNGSGFGKKSKDMSTERDFFMRMKCTVTNRGRTVNLKSATWKVLHCTGQVKVYNNCPPHNSLCGYKEPLLSCLIIMCEPIQHPSHMDIPLDSKTFLSRHSMDMKFTYCDDRITELIGYHPEELLGRSAYEFYHALDSENMTKSHQNLCTKGQVVSGQYRMLAKHGGYVWLETQGTVIYNPRNLQPQCIMCVNYVLSEIEKNDVVFSMDQTESLFKPHLMAMNSIFDSSGKGAVSEKSNFLFTKLKEEPEELAQLAPTPGDAIISLDFGNQNFEESSAYGKAILPPSQPWATELRSHSTQSEAGSLPAFTVPQAAAPGSTTPSATSSSSSCSTPNSPEDYYTSLDNDLKIEVIEKLFAMDTEAKDQCSTQTDFNELDLETLAPYIPMDGEDFQLSPICPEERLLAENPQSTPQHCFSAMTNIFQPLAPVAPHSPFLLDKFQQQLESKKTEPEHRPMSSIFFDAGSKASLPPCCGQASTPLSSMGGRSNTQWPPDPPLHFGPTKWAVGDQRTEFLGAAPLGPPVSPPHVSTFKTRSAKGFGARGPDVLSPAMVALSNKLKLKRQLEYEEQAFQDLSGGDPPGGSTSHLMWKRMKNLRGGSCPLMPDKPLSANVPNDKFTQNPMRGLGHPLRHLPLPQPPSAISPGENSKSRFPPQCYATQYQDYSLSSAHKVSGMASRLLGPSFESYLLPELTRYDCEVNVPVLGSSTLLQGGDLLRALDQAT
T21123	DRUGINFO	D0NU8J	Belzutifan	Approved
T21123	DRUGINFO	D0C9PZ	PT2385	Phase 2

T10988	TARGETID	T10988
T10988	UNIPROID	ILRL2_HUMAN
T10988	TARGNAME	IL-1 receptor-like 2 (IL1RL2)
T10988	GENENAME	IL1RL2
T10988	TARGTYPE	Successful
T10988	SYNONYMS	Interleukin-1 receptor-related protein 2; Interleukin-1 receptor-like 2; IL1RRP2; IL1R-rp2; IL-36R; IL-36 receptor; IL-1Rrp2
T10988	FUNCTION	After binding to interleukin-36 associates with the coreceptor IL1RAP to form the interleukin-36 receptor complex which mediates interleukin-36-dependent activation of NF-kappa-B, MAPK and other pathways. The IL-36 signaling system is thought to be present in epithelial barriers and to take part in local inflammatory response; it is similar to the IL-1 system. Seems to be involved in skin inflammatory response by induction of the IL-23/IL-17/IL-22 pathway. Receptor for interleukin-36 (IL36A, IL36B and IL36G).
T10988	BIOCLASS	Cytokine receptor
T10988	SEQUENCE	MWSLLLCGLSIALPLSVTADGCKDIFMKNEILSASQPFAFNCTFPPITSGEVSVTWYKNSSKIPVSKIIQSRIHQDETWILFLPMEWGDSGVYQCVIKGRDSCHRIHVNLTVFEKHWCDTSIGGLPNLSDEYKQILHLGKDDSLTCHLHFPKSCVLGPIKWYKDCNEIKGERFTVLETRLLVSNVSAEDRGNYACQAILTHSGKQYEVLNGITVSITERAGYGGSVPKIIYPKNHSIEVQLGTTLIVDCNVTDTKDNTNLRCWRVNNTLVDDYYDESKRIREGVETHVSFREHNLYTVNITFLEVKMEDYGLPFMCHAGVSTAYIILQLPAPDFRAYLIGGLIALVAVAVSVVYIYNIFKIDIVLWYRSAFHSTETIVDGKLYDAYVLYPKPHKESQRHAVDALVLNILPEVLERQCGYKLFIFGRDEFPGQAVANVIDENVKLCRRLIVIVVPESLGFGLLKNLSEEQIAVYSALIQDGMKVILIELEKIEDYTVMPESIQYIKQKHGAIRWHGDFTEQSQCMKTKFWKTVRYHMPPRRCRPFPPVQLLQHTPCYRTAGPELGSRRKKCTLTTG
T10988	DRUGINFO	D0W9YW	Spesolimab	Approved
T10988	DRUGINFO	D1I0LQ	Nemvaleukin alfa	Phase 3
T10988	DRUGINFO	DZ49IJ	Imsidolimab	Phase 3

T53139	TARGETID	T53139
T53139	FORMERID	TTDNR00642
T53139	UNIPROID	ANGL3_HUMAN
T53139	TARGNAME	Angiopoietin-related protein 3 (ANGPTL3)
T53139	GENENAME	ANGPTL3
T53139	TARGTYPE	Successful
T53139	SYNONYMS	UNQ153/PRO179; Angiopoietin-like protein 3; Angiopoietin-5; ANGPT5; ANG-5
T53139	FUNCTION	Acts in part as a hepatokine that is involved in regulation of lipid and glucose metabolism. Proposed to play a role in the trafficking of energy substrates to either storage or oxidative tissues in response to food intake (By similarity). Has a stimulatory effect on plasma triglycerides (TG), which is achieved by suppressing plasma TG clearance via inhibition of LPL activity. The inhibition of LPL activity appears to be an indirect mechanism involving recruitment of proprotein convertases PCSK6 and FURIN to LPL leading to cleavage and dissociation of LPL from the cell surface; the function does not require ANGPTL3 proteolytic cleavage but seems to be mediated by the N-terminal domain, and is not inhibited by GPIHBP1. Can inhibit endothelial lipase, causing increased plasma levels of high density lipoprotein (HDL) cholesterol and phospholipids. Can bind to adipocytes to activate lipolysis, releasing free fatty acids and glycerol. Suppresses LPL specifically in oxidative tissues which is required to route very low density lipoprotein (VLDL)-TG to white adipose tissue (WAT) for storage in response to food; the function may involve cooperation with circulating, liver-derived ANGPTL8 and ANGPTL4 expression in WAT (By similarity). Contributes to lower plasma levels of low density lipoprotein (LDL)-cholesterol by a mechanism that is independent of the canonical pathway implicating APOE and LDLR. May stimulate hypothalamic LPL activity (By similarity).
T53139	PDBSTRUC	6EUA
T53139	BIOCLASS	Fibrinogen protein
T53139	SEQUENCE	MFTIKLLLFIVPLVISSRIDQDNSSFDSLSPEPKSRFAMLDDVKILANGLLQLGHGLKDFVHKTKGQINDIFQKLNIFDQSFYDLSLQTSEIKEEEKELRRTTYKLQVKNEEVKNMSLELNSKLESLLEEKILLQQKVKYLEEQLTNLIQNQPETPEHPEVTSLKTFVEKQDNSIKDLLQTVEDQYKQLNQQHSQIKEIENQLRRTSIQEPTEISLSSKPRAPRTTPFLQLNEIRNVKHDGIPAECTTIYNRGEHTSGMYAIRPSNSQVFHVYCDVISGSPWTLIQHRIDGSQNFNETWENYKYGFGRLDGEFWLGLEKIYSIVKQSNYVLRIELEDWKDNKHYIEYSFYLGNHETNYTLHLVAITGNVPNAIPENKDLVFSTWDHKAKGHFNCPEGYSGGWWWHDECGENNLNGKYNKPRAKSKPERRRGLSWKSQNGRLYSIKSTKMLIHPTDSESFE
T53139	DRUGINFO	D03WOG	Evinacumab	Approved
T53139	DRUGINFO	D0H3ST	AKCEA-ANGPTL3-LRX	Phase 2
T53139	DRUGINFO	D49KHP	LNA043	Phase 2

T23343	TARGETID	T23343
T23343	FORMERID	TTDI02212
T23343	UNIPROID	POL_HV1B1
T23343	TARGNAME	Human immunodeficiency virus Capsid p24 (HIV p24)
T23343	GENENAME	HIV p24
T23343	TARGTYPE	Successful
T23343	SYNONYMS	CA
T23343	FUNCTION	Integrase: Catalyzes viral DNA integration into the host chromosome, by performing a series of DNA cutting and joining reactions. This enzyme activity takes place after virion entry into a cell and reverse transcription of the RNA genome in dsDNA. The first step in the integration process is 3' processing. This step requires a complex comprising the viral genome, matrix protein, Vpr and integrase. This complex is called the pre- integration complex (PIC). The integrase protein removes 2 nucleotides from each 3' end of the viral DNA, leaving recessed CA OH's at the 3' ends. In the second step, the PIC enters cell nucleus. This processis mediated through integrase and Vpr proteins, and allows the virus to infect a non dividing cell. This ability to enter the nucleus is specific of lentiviruses, other retroviruses cannot and rely on cell division to access cell chromosomes. In the third step, termed strand transfer, the integrase protein joins the previously processed 3' ends to the 5' ends of strands of target cellular DNA at the site of integration. The 5'-ends are produced by integrase-catalyzed staggered cuts, 5 bp apart. A Y-shaped, gapped, recombination intermediate results, with the 5'-ends of the viral DNA strands and the 3' ends of target DNA strands remaining unjoined, flanking a gap of 5 bp. The last step is viral DNA integration into host chromosome. This involves host DNA repair synthesis in which the 5 bp gaps between the unjoined strands are filled in and then ligated. Since this process occurs at both cuts flanking the HIV genome, a 5 bp duplication of host DNA is produced at the ends of HIV-1 integration. Alternatively, Integrase may catalyze the excision of viral DNA just after strand transfer, this is termed disintegration.
T23343	PDBSTRUC	6OE3; 6HAK; 6ELI; 6DUH; 6DUG
T23343	SEQUENCE	PIVQNIQGQMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAAEWDRVHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKARVL
T23343	DRUGINFO	D24GYL	Lenacapavir	Approved
T23343	DRUGINFO	D0F3GL	Vacc-4x	Phase 2
T23343	DRUGINFO	D05GBH	F4co vaccine	Phase 2
T23343	DRUGINFO	D8ID3Y	VH4004280	Phase 1
T23343	DRUGINFO	DB2VY6	VH4011499	Phase 1

T00972	TARGETID	T00972
T00972	FORMERID	TTDI01924
T00972	UNIPROID	ENV_HV1H2
T00972	TARGNAME	Human immunodeficiency virus Envelope glycoprotein gp120 (HIV gp120)
T00972	GENENAME	HIV gp120
T00972	TARGTYPE	Successful
T00972	SYNONYMS	Env polyprotein gp120 (33-511)
T00972	FUNCTION	Transmembrane protein gp41: Acts as a class I viral fusion protein. Under the current model, the protein has at least 3 conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of viral and target intracellular membranes, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C- terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes. Complete fusion occurs in host cell endosomes and is dynamin-dependent, however some lipid transfer might occur at the plasma membrane. The virus undergoes clathrin- dependent internalization long before endosomal fusion, thus minimizing the surface exposure of conserved viral epitopes during fusion and reducing the efficacy of inhibitors targeting these epitopes. Membranes fusion leads to delivery of the nucleocapsid into the cytoplasm.
T00972	PDBSTRUC	6DLN; 6DE7; 6BXQ; 6BXP; 6B9K
T00972	SEQUENCE	KLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVVLVNVTENFNMWKNDMVEQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTNTNSSSGRMIMEKGEIKNCSFNISTSIRGKVQKEYAFFYKLDIIPIDNDTTSYKLTSCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSVNFTDNAKTIIVQLNTSVEINCTRPNNNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKLREQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNSTWSTEGSNNTEGSDTITLPCRIKQIINMWQKVGKAMYAPPISGQIRCSSNITGLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTKAKRRVVQREKR
T00972	DRUGINFO	D00ZCT	Fostemsavir	Approved
T00972	DRUGINFO	D06BGS	AIDSVAX	Phase 3
T00972	DRUGINFO	D01NGH	Multi-envelope HIV vaccine	Phase 1
T00972	DRUGINFO	D09EVZ	BMS-488043	Discontinued in Phase 2
T00972	DRUGINFO	D0ZR3N	Pro 542	Discontinued in Phase 2
T00972	DRUGINFO	D04MGI	PF-821385	Preclinical
T00972	DRUGINFO	D0U6NR	CD4 red blood cell electroinsertion	Investigative

T61339	TARGETID	T61339
T61339	FORMERID	TTDR00001
T61339	UNIPROID	LYAG_HUMAN; GANAB_HUMAN; GANC_HUMAN
T61339	TARGNAME	Alpha-glucosidase (GLA)
T61339	GENENAME	GAA; GANAB; GANC
T61339	TARGTYPE	Successful
T61339	SYNONYMS	Maltase-glucoamylase; Maltase; Glucosidosucrase; Glucosidoinvertase; Glucoinvertase; Alpha-glucoside hydrolase; Alpha-glucopyranosidase; Alpha-D-glucoside glucohydrolase; Alpha-D-glucosidase; Alpha-1;4-glucosidase
T61339	FUNCTION	Breaks down starch and disaccharides to glucose.
T61339	SEQUENCE	MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLEETHPAHQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC
T61339	DRUGINFO	D67KYA	Cipaglucosidase alfa	Approved
T61339	DRUGINFO	DW7EN6	Cipaglucosidase alfa	Approved in EU
T61339	DRUGINFO	D03WAU	Anamorelin	Phase 3
T61339	DRUGINFO	D0S5LT	Deoxynojirimycin	Phase 3
T61339	DRUGINFO	D04RYY	Maltose	Phase 1/2
T61339	DRUGINFO	DFV71O	AAV2/8-LSPhGAA	Phase 1
T61339	DRUGINFO	D0IT1M	4,6-Dideoxyglucose	Investigative
T61339	DRUGINFO	D0P6IA	Tendamistat	Investigative
T61339	DRUGINFO	D0E0VN	6-Deoxy-Alpha-D-Glucose	Investigative
T61339	DRUGINFO	D08SMN	POP-1	Investigative
T61339	DRUGINFO	D0JR9V	JBP-1	Investigative
T61339	DRUGINFO	D07ONX	Beta-D-Glucose	Investigative
T61339	DRUGINFO	D0H1GU	Double Oxidized Cysteine	Investigative
T61339	DRUGINFO	D0R6JE	Nicotinamide-Adenine-Dinucleotide	Investigative

T94718	TARGETID	T94718
T94718	FORMERID	TTDNC00414
T94718	UNIPROID	LAG3_HUMAN
T94718	TARGNAME	Lymphocyte activation gene 3 protein (LAG3)
T94718	GENENAME	LAG3
T94718	TARGTYPE	Successful
T94718	SYNONYMS	Protein FDC; LAG-3; FDC; CD223
T94718	FUNCTION	Delivers inhibitory signals upon binding to ligands, such as FGL1. FGL1 constitutes a major ligand of LAG3 and is responsible for LAG3 T-cell inhibitory function. Following TCR engagement, LAG3 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation. May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1, possibly by acting as a coreceptor for PDCD1/PD-1. Negatively regulates the proliferation, activation, effector function and homeostasis of both CD8(+) and CD4(+) T-cells. Also mediates immune tolerance: constitutively expressed on a subset of regulatory T-cells (Tregs) and contributes to their suppressive function. Also acts as a negative regulator of plasmacytoid dendritic cell (pDCs) activation. Binds MHC class II (MHC-II); the precise role of MHC-II-binding is however unclear. Lymphocyte activation gene 3 protein: Inhibitory receptor on antigen activated T-cells.
T94718	BIOCLASS	Immunoglobulin
T94718	SEQUENCE	MWEAQFLGLLFLQPLWVAPVKPLQPGAEVPVVWAQEGAPAQLPCSPTIPLQDLSLLRRAGVTWQHQPDSGPPAAAPGHPLAPGPHPAAPSSWGPRPRRYTVLSVGPGGLRSGRLPLQPRVQLDERGRQRGDFSLWLRPARRADAGEYRAAVHLRDRALSCRLRLRLGQASMTASPPGSLRASDWVILNCSFSRPDRPASVHWFRNRGQGRVPVRESPHHHLAESFLFLPQVSPMDSGPWGCILTYRDGFNVSIMYNLTVLGLEPPTPLTVYAGAGSRVGLPCRLPAGVGTRSFLTAKWTPPGGGPDLLVTGDNGDFTLRLEDVSQAQAGTYTCHIHLQEQQLNATVTLAIITVTPKSFGSPGSLGKLLCEVTPVSGQERFVWSSLDTPSQRSFSGPWLEAQEAQLLSQPWQCQLYQGERLLGAAVYFTELSSPGAQRSGRAPGALPAGHLLLFLILGVLSLLLLVTGAFGFHLWRRQWRPRRFSALEQGIHPPQAQSKIEELEQEPEPEPEPEPEPEPEPEPEQL
T94718	DRUGINFO	D0A3WJ	Relatlimab	Approved
T94718	DRUGINFO	D0T7OI	Anti-LAG3	Phase 2
T94718	DRUGINFO	D03ZSA	BMS-986016	Phase 1/2
T94718	DRUGINFO	D0P9MW	IMP-321	Phase 1/2
T94718	DRUGINFO	DS6MP8	Favezelimab	Phase 1/2
T94718	DRUGINFO	D02IYC	IMP-701	Phase 1
T94718	DRUGINFO	D0ZX2L	GSK2831781	Phase 1
T94718	DRUGINFO	D4KTA9	INCAGN2385	Phase 1
T94718	DRUGINFO	D4L3IZ	Sym022	Phase 1
T94718	DRUGINFO	D7TV5I	MK-4280	Phase 1
T94718	DRUGINFO	DF5PB0	A289	Phase 1
T94718	DRUGINFO	DL07ZP	GSK4074386	Phase 1
T94718	DRUGINFO	D0BOM7	XmAb22841	Phase 1
T94718	DRUGINFO	D0XO9F	FS118	Phase 1
T94718	DRUGINFO	D4CGN3	RG6139	Phase 1
T94718	DRUGINFO	DMEQ73	ADPT01	Phase 1
T94718	DRUGINFO	D05ZLH	IMP-731	Investigative
T94718	DRUGINFO	D0DB2F	Concatameric LAG3Ig	Investigative

T66693	TARGETID	T66693
T66693	FORMERID	TTDR00934
T66693	UNIPROID	TNR17_HUMAN
T66693	TARGNAME	B-cell maturation protein (TNFRSF17)
T66693	GENENAME	TNFRSF17
T66693	TARGTYPE	Successful
T66693	SYNONYMS	Tumor necrosis factor receptor superfamily member 17; CD269; BCMA; BCM
T66693	FUNCTION	Promotes B-cell survival and plays a role in the regulation of humoral immunity. Activates NF-kappa-B and JNK. Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL.
T66693	PDBSTRUC	6J7W; 4ZFO; 2KN1; 1XU2; 1OQD
T66693	SEQUENCE	MLQMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQRYCNASVTNSVKGTNAILWTCLGLSLIISLAVFVLMFLLRKINSEPLKDEFKNTGSGLLGMANIDLEKSRTGDEIILPRGLEYTVEECTCEDCIKSKPKVDSDHCFPLPAMEEGATILVTTKTNDYCKSLPAALSATEIEKSISAR
T66693	DRUGINFO	D03AFF	Teclistamab	Approved
T66693	DRUGINFO	D03NPI	Idecabtagene vicleucel	Approved
T66693	DRUGINFO	D52NZX	Belantamab mafodotin	Approved
T66693	DRUGINFO	D3KO5Y	Elranatamab	Approved
T66693	DRUGINFO	DXV06E	Ciltacabtagene autoleucel	Phase 3
T66693	DRUGINFO	D07CUR	Bb2121	Phase 2
T66693	DRUGINFO	D0K1AK	LCAR-B38M CAR-T Cell	Phase 2
T66693	DRUGINFO	D0Z6AR	Descartes-08	Phase 2
T66693	DRUGINFO	DN28SH	Descartes-11	Phase 2
T66693	DRUGINFO	D01CUC	BCMA CAR T cells	Phase 1/2
T66693	DRUGINFO	D02JNC	BCMA CAR-T	Phase 1/2
T66693	DRUGINFO	D04PIU	CART-BCMA cells	Phase 1/2
T66693	DRUGINFO	D07PJS	JNJ-68284528	Phase 1/2
T66693	DRUGINFO	D07QIQ	Anti-BCMA-CAR-transduced T cells	Phase 1/2
T66693	DRUGINFO	D0D4ZN	CAR-T cells targeting BCMA	Phase 1/2
T66693	DRUGINFO	D0EQ6D	JCARH125	Phase 1/2
T66693	DRUGINFO	D0MK7H	Anti-BCMA CAR-T cells	Phase 1/2
T66693	DRUGINFO	D7LU8R	PBCAR269A	Phase 1/2
T66693	DRUGINFO	D0AC9S	CART-19/BCMA	Phase 1/2
T66693	DRUGINFO	D0B8UW	AUTO2	Phase 1/2
T66693	DRUGINFO	D0G0PI	CD38 and BCMA CAR-T Cells	Phase 1/2
T66693	DRUGINFO	DR7Q5N	REGN5458	Phase 1/2
T66693	DRUGINFO	DY9G1D	REGN5459	Phase 1/2
T66693	DRUGINFO	D00OXP	Bb21217	Phase 1
T66693	DRUGINFO	D01YZF	CART-BCMA	Phase 1
T66693	DRUGINFO	D05XNF	IM21 CART	Phase 1
T66693	DRUGINFO	D07HJS	Anti-BCMA CAR-T cells	Phase 1
T66693	DRUGINFO	D0B2WU	CAR-T cells targeting BCMA	Phase 1
T66693	DRUGINFO	D0C8QA	KITE-585	Phase 1
T66693	DRUGINFO	D0F0VW	Anti-BCMA CAR-T cells	Phase 1
T66693	DRUGINFO	D0I1PF	LCAR-B4822M CAR-T Cell	Phase 1
T66693	DRUGINFO	D0J7OU	C-CAR088	Phase 1
T66693	DRUGINFO	D0MS2T	BCMA-specific CAR-expressing T Lymphocytes	Phase 1
T66693	DRUGINFO	D0NG3T	BCMA CAR-T Cells	Phase 1
T66693	DRUGINFO	D0NK6K	P-BCMA-101 CAR-T cells	Phase 1
T66693	DRUGINFO	D0RA7L	Anti-BCMA CART Cells	Phase 1
T66693	DRUGINFO	D0RD0D	BCMA CART	Phase 1
T66693	DRUGINFO	D0T9CE	BCMA nanobody CAR-T cells	Phase 1
T66693	DRUGINFO	D0U2PU	Anti-BCMA CAR T cells	Phase 1
T66693	DRUGINFO	D0W1GP	Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143	Phase 1
T66693	DRUGINFO	D0W7AB	Anti-BCMA CAR T cells	Phase 1
T66693	DRUGINFO	D12DYT	HPN217	Phase 1
T66693	DRUGINFO	D1WOX4	CT053	Phase 1
T66693	DRUGINFO	D3T7NY	CART-ddBCMA	Phase 1
T66693	DRUGINFO	D4QZ3O	SEA-BCMA	Phase 1
T66693	DRUGINFO	D5YN8U	ALLO-715	Phase 1
T66693	DRUGINFO	D67ZDJ	PHE885	Phase 1
T66693	DRUGINFO	DE49RW	CTX120	Phase 1
T66693	DRUGINFO	DG80IS	MEDI2228	Phase 1
T66693	DRUGINFO	DH5BX2	CC-99712	Phase 1
T66693	DRUGINFO	DN68MW	P-PSMA-101	Phase 1
T66693	DRUGINFO	DOQ13X	CC-93269	Phase 1
T66693	DRUGINFO	DS86KN	RG6538	Phase 1
T66693	DRUGINFO	DUZ0F7	AMG 420	Phase 1
T66693	DRUGINFO	DX6J8M	CC-98633	Phase 1
T66693	DRUGINFO	D0T8RV	BCMA CART and huCART19	Phase 1
T66693	DRUGINFO	D0U7WY	Anti-CD19/BCMA CAR-T cells	Phase 1
T66693	DRUGINFO	D81YIK	WVT078	Phase 1
T66693	DRUGINFO	DC3Y7O	RG6296	Phase 1
T66693	DRUGINFO	DF43EH	AMG 701	Phase 1
T66693	DRUGINFO	DTR05Z	BCMA-CD19 cCAR	Phase 1
T66693	DRUGINFO	DW1H9O	TNB-383B	Phase 1
T66693	DRUGINFO	DX1LD3	BCMA-CS1 cCAR	Phase 1
T66693	DRUGINFO	D09ZGK	BCMA-CART	Clinical trial
T66693	DRUGINFO	D0LP1L	CAR-T cells targeting BCMA	Clinical trial
T66693	DRUGINFO	D0N8NT	BCMA-UCART	Clinical trial
T66693	DRUGINFO	D0PF1A	CAR-BCMA T cell	Clinical trial
T66693	DRUGINFO	D01SNU	P-BCMA-ALL01	Preclinical

T71536	TARGETID	T71536
T71536	FORMERID	TTDI01205
T71536	TARGNAME	Human Deoxyribonucleic acid minor groove (hDNA min)
T71536	TARGTYPE	Successful
T71536	DRUGINFO	D0V6OA	Lurbinectedin	Approved
T71536	DRUGINFO	D0OY5G	Brostallicin	Phase 2
T71536	DRUGINFO	D01YRT	Di-imidazole lexitropsin	Investigative
T71536	DRUGINFO	D05ITH	Duocarmycin	Investigative
T71536	DRUGINFO	D05ZVR	Netropsin	Investigative
T71536	DRUGINFO	D0BS6Q	Distamycin A	Investigative

T16538	TARGETID	T16538
T16538	UNIPROID	EGFR_HUMAN
T16538	TARGNAME	EGFR T790M mutant (EGFR T790M)
T16538	GENENAME	EGFR
T16538	TARGTYPE	Successful
T16538	SYNONYMS	Receptor tyrosine-protein kinase erbB-1 T790M mutant; Proto-oncogene c-ErbB-1 T790M mutant; HER1 T790M mutant; Epidermal growth factor receptor T790M mutant; ERBB1 T790M mutant; ERBB T790M mutant
T16538	FUNCTION	Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin. Plays a role in enhancing learning and memory performance.
T16538	PDBSTRUC	6D8E; 6B3S; 6ARU; 5ZWJ; 5YU9
T16538	BIOCLASS	Kinase
T16538	ECNUMBER	EC 2.7.10.1
T16538	SEQUENCE	MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALAVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDFQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRVAPQSSEFIGA
T16538	DRUGINFO	D0O8GK	Osimertinib	Approved
T16538	DRUGINFO	D01DBB	PMID27774824-Compound-Figure9Example2down	Patented

T66011	TARGETID	T66011
T66011	FORMERID	TTDI02354
T66011	UNIPROID	CFAB_HUMAN
T66011	TARGNAME	Complement factor B (CFB)
T66011	GENENAME	CFB
T66011	TARGTYPE	Successful
T66011	SYNONYMS	Properdin factor B; PBF2; Glycinerich beta glycoprotein; Glycine-rich beta glycoprotein; GBG; Complement factor B Bb fragment; C3/C5 convertase; BFD; BF
T66011	FUNCTION	Factor B which is part of the alternate pathway of the complement system is cleaved by factor D into 2 fragments: Ba and Bb. Bb, a serine protease, then combines with complement factor 3b to generate the C3 or C5 convertase. It has also been implicated in proliferation and differentiation of preactivated B-lymphocytes, rapid spreading of peripheral blood monocytes, stimulation of lymphocyte blastogenesis and lysis of erythrocytes. Ba inhibits the proliferation of preactivated B-lymphocytes.
T66011	PDBSTRUC	6RAV; 6QSX; 6QSW; 5M6W; 3HS0
T66011	BIOCLASS	Peptidase
T66011	ECNUMBER	EC 3.4.21.47
T66011	SEQUENCE	MGSNLSPQLCLMPFILGLLSGGVTTTPWSLARPQGSCSLEGVEIKGGSFRLLQEGQALEYVCPSGFYPYPVQTRTCRSTGSWSTLKTQDQKTVRKAECRAIHCPRPHDFENGEYWPRSPYYNVSDEISFHCYDGYTLRGSANRTCQVNGRWSGQTAICDNGAGYCSNPGIPIGTRKVGSQYRLEDSVTYHCSRGLTLRGSQRRTCQEGGSWSGTEPSCQDSFMYDTPQEVAEAFLSSLTETIEGVDAEDGHGPGEQQKRKIVLDPSGSMNIYLVLDGSDSIGASNFTGAKKCLVNLIEKVASYGVKPRYGLVTYATYPKIWVKVSEADSSNADWVTKQLNEINYEDHKLKSGTNTKKALQAVYSMMSWPDDVPPEGWNRTRHVIILMTDGLHNMGGDPITVIDEIRDLLYIGKDRKNPREDYLDVYVFGVGPLVNQVNINALASKKDNEQHVFKVKDMENLEDVFYQMIDESQSLSLCGMVWEHRKGTDYHKQPWQAKISVIRPSKGHESCMGAVVSEYFVLTAAHCFTVDDKEHSIKVSVGGEKRDLEIEVVLFHPNYNINGKKEAGIPEFYDYDVALIKLKNKLKYGQTIRPICLPCTEGTTRALRLPPTTTCQQQKEELLPAQDIKALFVSEEEKKLTRKEVYIKNGDKKGSCERDAQYAPGYDKVKDISEVVTPRFLCTGGVSPYADPNTCRGDSGGPLIVHKRSRFIQVGVISWGVVDVCKNQKRQKQVPAHARDFHINLFQVLPWLKEKLQDEDLGFL
T66011	DRUGINFO	DJ48HT	Iptacopan	Approved
T66011	DRUGINFO	D7PVH4	LPN023	Phase 2
T66011	DRUGINFO	DZ7Q8I	RG6299	Phase 2
T66011	DRUGINFO	DJ0P6Z	SAR443809	Phase 1
T66011	DRUGINFO	D0Q0OP	CAB-2	Discontinued in Phase 1
T66011	DRUGINFO	D01ODC	TA-106	Investigative
T66011	DRUGINFO	D09JGO	PMID19743866C51	Investigative
T66011	DRUGINFO	D09PKZ	NM-9308	Investigative

T52189	TARGETID	T52189
T52189	FORMERID	TTDR01004
T52189	UNIPROID	ACLY_HUMAN
T52189	TARGNAME	ATP-citrate synthase (ACLY)
T52189	GENENAME	ACLY
T52189	TARGTYPE	Successful
T52189	SYNONYMS	Citrate cleavage enzyme; ATP-citrate (pro-S-)-lyase; ACL
T52189	FUNCTION	ATP-citrate synthase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Has a central role in de novo lipid synthesis. In nervous tissue it may be involved in the biosynthesis of acetylcholine.
T52189	PDBSTRUC	6QFB; 6O0H; 6HXM; 6HXL; 6HXK
T52189	BIOCLASS	Acyltransferase
T52189	ECNUMBER	EC 2.3.3.8
T52189	SEQUENCE	MSAKAISEQTGKELLYKFICTTSAIQNRFKYARVTPDTDWARLLQDHPWLLSQNLVVKPDQLIKRRGKLGLVGVNLTLDGVKSWLKPRLGQEATVGKATGFLKNFLIEPFVPHSQAEEFYVCIYATREGDYVLFHHEGGVDVGDVDAKAQKLLVGVDEKLNPEDIKKHLLVHAPEDKKEILASFISGLFNFYEDLYFTYLEINPLVVTKDGVYVLDLAAKVDATADYICKVKWGDIEFPPPFGREAYPEEAYIADLDAKSGASLKLTLLNPKGRIWTMVAGGGASVVYSDTICDLGGVNELANYGEYSGAPSEQQTYDYAKTILSLMTREKHPDGKILIIGGSIANFTNVAATFKGIVRAIRDYQGPLKEHEVTIFVRRGGPNYQEGLRVMGEVGKTTGIPIHVFGTETHMTAIVGMALGHRPIPNQPPTAAHTANFLLNASGSTSTPAPSRTASFSESRADEVAPAKKAKPAMPQDSVPSPRSLQGKSTTLFSRHTKAIVWGMQTRAVQGMLDFDYVCSRDEPSVAAMVYPFTGDHKQKFYWGHKEILIPVFKNMADAMRKHPEVDVLINFASLRSAYDSTMETMNYAQIRTIAIIAEGIPEALTRKLIKKADQKGVTIIGPATVGGIKPGCFKIGNTGGMLDNILASKLYRPGSVAYVSRSGGMSNELNNIISRTTDGVYEGVAIGGDRYPGSTFMDHVLRYQDTPGVKMIVVLGEIGGTEEYKICRGIKEGRLTKPIVCWCIGTCATMFSSEVQFGHAGACANQASETAVAKNQALKEAGVFVPRSFDELGEIIQSVYEDLVANGVIVPAQEVPPPTVPMDYSWARELGLIRKPASFMTSICDERGQELIYAGMPITEVFKEEMGIGGVLGLLWFQKRLPKYSCQFIEMCLMVTADHGPAVSGAHNTIICARAGKDLVSSLTSGLLTIGDRFGGALDAAAKMFSKAFDSGIIPMEFVNKMKKEGKLIMGIGHRVKSINNPDMRVQILKDYVRQHFPATPLLDYALEVEKITTSKKPNLILNVDGLIGVAFVDMLRNCGSFTREEADEYIDIGALNGIFVLGRSMGFIGHYLDQKRLKQGLYRHPWDDISYVLPEHMSM
T52189	DRUGINFO	D0D9NY	Bempedoic acid	Approved
T52189	DRUGINFO	D09AXB	SB-201076	Investigative
T52189	DRUGINFO	D0IC1N	(-)-hydroxycitrate	Investigative

T72545	TARGETID	T72545
T72545	FORMERID	TTDR01169
T72545	UNIPROID	PARC_ECOLI
T72545	TARGNAME	Bacterial DNA topoisomerase 4A (Bact parC)
T72545	GENENAME	Bact parC
T72545	TARGTYPE	Successful
T72545	SYNONYMS	parC; Topoisomerase IV subunit A of Escherichia coli
T72545	FUNCTION	Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule. MukB stimulates the relaxation activity of topoisomeraseIV and also has a modest effect on decatenation.
T72545	PDBSTRUC	4MN4; 1ZVU; 1ZVT
T72545	BIOCLASS	Topoisomerase GyrA ParC
T72545	ECNUMBER	EC 5.6.2.3
T72545	SEQUENCE	MSDMAERLALHEFTENAYLNYSMYVIMDRALPFIGDGLKPVQRRIVYAMSELGLNASAKFKKSARTVGDVLGKYHPHGDSACYEAMVLMAQPFSYRYPLVDGQGNWGAPDDPKSFAAMRYTESRLSKYSELLLSELGQGTADWVPNFDGTLQEPKMLPARLPNILLNGTTGIAVGMATDIPPHNLREVAQAAIALIDQPKTTLDQLLDIVQGPDYPTEAEIITSRAEIRKIYENGRGSVRMRAVWKKEDGAVVISALPHQVSGARVLEQIAAQMRNKKLPMVDDLRDESDHENPTRLVIVPRSNRVDMDQVMNHLFATTDLEKSYRINLNMIGLDGRPAVKNLLEILSEWLVFRRDTVRRRLNYRLEKVLKRLHILEGLLVAFLNIDEVIEIIRNEDEPKPALMSRFGLTETQAEAILELKLRHLAKLEEMKIRGEQSELEKERDQLQGILASERKMNNLLKKELQADAQAYGDDRRSPLQEREEAKAMSEHDMLPSEPVTIVLSQMGWVRSAKGHDIDAPGLNYKAGDSFKAAVKGKSNQPVVFVDSTGRSYAIDPITLPSARGQGEPLTGKLTLPPGATVDHMLMESDDQKLLMASDAGYGFVCTFNDLVARNRAGKALITLPENAHVMPPVVIEDASDMLLAITQAGRMLMFPVSDLPQLSKGKGNKIINIPSAEAARGEDGLAQLYVLPPQSTLTIHVGKRKIKLRPEELQKVTGERGRRGTLMRGLQRIDRVEIDSPRRASSGDSEE
T72545	DRUGINFO	DR36YB	Prulifloxacin	Approved
T72545	DRUGINFO	D05STQ	Pazufloxacin	Phase 3
T72545	DRUGINFO	D2FCM4	VB 1953	Phase 2
T72545	DRUGINFO	D39VXL	JNJ-32729463	Phase 2
T72545	DRUGINFO	D4M8RS	TNP-2092	Phase 2
T72545	DRUGINFO	D6DT3X	Sitafloxacin	Phase 2
T72545	DRUGINFO	D04QJK	A-62824	Investigative

T06020	TARGETID	T06020
T06020	FORMERID	TTDR00482
T06020	UNIPROID	FCGRN_HUMAN
T06020	TARGNAME	Neonatal Fc receptor (FCGRT)
T06020	GENENAME	FCGRT
T06020	TARGTYPE	Successful
T06020	SYNONYMS	Neonatal FcR; MHC class I family-like Fc receptor; IgG Fc fragment receptor transporter, alpha chain; FcRn; FCGRT
T06020	FUNCTION	Binds to the Fc region of monomericimmunoglobulins gamma. Mediates the uptake of IgG from milk. Possible role in transfer of immunoglobulin G from mother to fetus.
T06020	PDBSTRUC	6ILM; 6FGB; 6C99; 6C98; 6C97
T06020	BIOCLASS	Immunoglobulin
T06020	SEQUENCE	MGVPRPQPWALGLLLFLLPGSLGAESHLSLLYHLTAVSSPAPGTPAFWVSGWLGPQQYLSYNSLRGEAEPCGAWVWENQVSWYWEKETTDLRIKEKLFLEAFKALGGKGPYTLQGLLGCELGPDNTSVPTAKFALNGEEFMNFDLKQGTWGGDWPEALAISQRWQQQDKAANKELTFLLFSCPHRLREHLERGRGNLEWKEPPSMRLKARPSSPGFSVLTCSAFSFYPPELQLRFLRNGLAAGTGQGDFGPNSDGSFHASSSLTVKSGDEHHYCCIVQHAGLAQPLRVELESPAKSSVLVVGIVIGVLLLTAAAVGGALLWRRMRSGLPAPWISLRGDDTGVLLPTPGEAQDADLKDVNVIPATA
T06020	DRUGINFO	D0P0LD	Efgartigimod alfa	Approved
T06020	DRUGINFO	DMWA10	Batoclimab	Phase 3
T06020	DRUGINFO	DR5V8I	Nipocalimab?	Phase 3
T06020	DRUGINFO	DZA98D	ARGX-113	Phase 3
T06020	DRUGINFO	D0QR7C	SYN-1327	Investigative

T99989	TARGETID	T99989
T99989	FORMERID	TTDI03081
T99989	UNIPROID	KC1E_HUMAN
T99989	TARGNAME	Casein kinase I epsilon (CSNK1E)
T99989	GENENAME	CSNK1E
T99989	TARGTYPE	Successful
T99989	SYNONYMS	Casein kinase I isoform epsilon; CKIe; CKI-epsilon
T99989	FUNCTION	Can phosphorylate a large number of proteins. Participates in Wnt signaling. Phosphorylates DVL1 and DVL2. Central component of the circadian clock. In balance with PP1, determines the circadian period length, through the regulation of the speed and rhythmicity of PER1 and PER2 phosphorylation. Controls PER1 and PER2 nuclear transport and degradation. Inhibits cytokine-induced granuloytic differentiation. Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates.
T99989	PDBSTRUC	4HOK; 4HNI
T99989	BIOCLASS	Kinase
T99989	ECNUMBER	EC 2.7.11.1
T99989	SEQUENCE	MELRVGNKYRLGRKIGSGSFGDIYLGANIASGEEVAIKLECVKTKHPQLHIESKFYKMMQGGVGIPSIKWCGAEGDYNVMVMELLGPSLEDLFNFCSRKFSLKTVLLLADQMISRIEYIHSKNFIHRDVKPDNFLMGLGKKGNLVYIIDFGLAKKYRDARTHQHIPYRENKNLTGTARYASINTHLGIEQSRRDDLESLGYVLMYFNLGSLPWQGLKAATKRQKYERISEKKMSTPIEVLCKGYPSEFSTYLNFCRSLRFDDKPDYSYLRQLFRNLFHRQGFSYDYVFDWNMLKFGAARNPEDVDRERREHEREERMGQLRGSATRALPPGPPTGATANRLRSAAEPVASTPASRIQPAGNTSPRAISRVDRERKVSMRLHRGAPANVSSSDLTGRQEVSRIPASQTSVPFDHLGK
T99989	DRUGINFO	D0O8SJ	Umbralisib	Approved
T99989	DRUGINFO	D06QYR	PF-4800567	Preclinical
T99989	DRUGINFO	DZK7E0	PF-670462	Preclinical
T99989	DRUGINFO	D0UN8H	IC261	Preclinical

T53242	TARGETID	T53242
T53242	FORMERID	TTDI01357
T53242	UNIPROID	CMAS1_MYCTU; CMAS2_MYCTU; CMAS3_MYCTU
T53242	TARGNAME	Mycobacterium Mycolic acid synthase (MycB cma)
T53242	GENENAME	MycB cmaA1; MycB cmaA2; MycB pcaA
T53242	TARGTYPE	Successful
T53242	SYNONYMS	cma; SAM-MT; S-adenosylmethionine-dependent methyltransferase; Mycolic acid methyltransferase; MA-MT; Cyclopropane-fatty-acyl-phospholipid synthase; Cyclopropane mycolic acid synthase; Cyclopropane fatty acid synthase; CMAS; CFA synthase; AdoMet-MT
T53242	FUNCTION	Catalyzes the conversion of a double bond to a cyclopropane ring at the distal position of an alpha mycolic acid via the transfer of a methylene group from S-adenosyl-L-methionine. Cyclopropanated mycolic acids are key factors participating in cell envelope permeability, host immunomodulation and persistence.
T53242	SEQUENCE	MPDELKPHFANVQAHYDLSDDFFRLFLDPTQTYSCAYFERDDMTLQEAQIAKIDLALGKLGLQPGMTLLDVGCGWGATMMRAVEKYDVNVVGLTLSKNQANHVQQLVANSENLRSKRVLLAGWEQFDEPVDRIVSIGAFEHFGHERYDAFFSLAHRLLPADGVMLLHTITGLHPKEIHERGLPMSFTFARFLKFIVTEIFPGGRLPSIPMVQECASANGFTVTRVQSLQPHYAKTLDLWSAALQANKGQAIALQSEEVYERYMKYLTGCAEMFRIGYIDVNQFTCQK
T53242	DRUGINFO	D02AYL	Pretomanid	Approved

T78111	TARGETID	T78111
T78111	FORMERID	TTDS00303
T78111	TARGNAME	Nicotinic acetylcholine receptor (nAChR)
T78111	TARGTYPE	Successful
T78111	SYNONYMS	nAChR; Nicotinergic acetylcholine receptor
T78111	FUNCTION	After binding acetylcholine, the AChRresponds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
T78111	BIOCLASS	Ion transport
T78111	DRUGINFO	D0AA0L	Pancuronium	Approved
T78111	DRUGINFO	D0Q1PR	Atracurium	Approved
T78111	DRUGINFO	D0T8GD	Nicotine	Approved
T78111	DRUGINFO	D0TY5N	Cotinine	Approved
T78111	DRUGINFO	D0V8HA	Mecamylamine	Approved
T78111	DRUGINFO	D08XPW	CYTISINE	Phase 3
T78111	DRUGINFO	D00QKS	BMS-954561	Phase 2
T78111	DRUGINFO	D08NYZ	ASM-024	Phase 2
T78111	DRUGINFO	D0MC2S	NIC-002	Phase 2
T78111	DRUGINFO	D0X8HP	TRIDMAC	Phase 2
T78111	DRUGINFO	D0Y6OE	A-85380	Phase 2
T78111	DRUGINFO	D03QWO	Dexefaroxan	Phase 2
T78111	DRUGINFO	D03JJY	GANTACURIUM CHLORIDE	Phase 1/2
T78111	DRUGINFO	D0E7MA	ATG002	Phase 1/2
T78111	DRUGINFO	D0UI4L	ND-0801	Phase 1/2
T78111	DRUGINFO	D05FVK	RPI-78M	Phase 1
T78111	DRUGINFO	D0K3JQ	RPI-MN	Phase 1
T78111	DRUGINFO	D06TVG	Inaperisone	Discontinued in Preregistration
T78111	DRUGINFO	D03UID	RJR-2403	Discontinued in Phase 2
T78111	DRUGINFO	D0C2HR	ORG-9273	Discontinued in Phase 2
T78111	DRUGINFO	D00ECO	SIB-1553A	Discontinued in Phase 2
T78111	DRUGINFO	D04HYP	ABT-594	Discontinued in Phase 2
T78111	DRUGINFO	D09ADT	ABT-418	Discontinued in Phase 2
T78111	DRUGINFO	D08VUJ	ABT-202	Discontinued in Phase 1
T78111	DRUGINFO	D0N1DQ	ANQ-9040	Discontinued in Phase 1
T78111	DRUGINFO	D03DMI	SIB-1663	Terminated
T78111	DRUGINFO	D04JNR	SIB-1765F	Terminated
T78111	DRUGINFO	D09GRB	NNC-90-0270	Terminated
T78111	DRUGINFO	D0A4RM	DBO-83	Terminated
T78111	DRUGINFO	D0N5UA	Dianicline+rimonabant	Terminated
T78111	DRUGINFO	D0O5EZ	Epibatidine	Investigative
T78111	DRUGINFO	D0Q5AD	PROTOSTEMODIOL	Investigative
T78111	DRUGINFO	D0YN5P	8-aminoquinolines	Investigative

T11754	TARGETID	T11754
T11754	FORMERID	TTDS00177
T11754	TARGNAME	Fatty acid amide hydrolase (FAAH)
T11754	TARGTYPE	Successful
T11754	SYNONYMS	Oleamidehydrolase; Anandamide amidohydrolase
T11754	FUNCTION	Degradesbioactive fatty acid amides like oleamide, the endogenous cannabinoid, anandamide and myristic amide to their corresponding acids, thereby serving to terminate the signaling functions of these molecules. Hydrolyzes polyunsaturated substrate anandamide preferentially as compared to monounsaturated substrates.
T11754	DRUGINFO	D00MYT	Thiopental	Approved
T11754	DRUGINFO	D0A3HB	Propofol	Approved
T11754	DRUGINFO	D02GPG	JNJ-42165279	Phase 2
T11754	DRUGINFO	D03DSX	SSR411298	Phase 2
T11754	DRUGINFO	D0FH5N	IW-6118	Phase 2
T11754	DRUGINFO	D0JT5I	PF-04457845	Phase 2
T11754	DRUGINFO	D0CR4Z	IPI-940	Phase 1
T11754	DRUGINFO	D00PFD	Benzyl pyrrolyloxoacetamide derivative 1	Patented
T11754	DRUGINFO	D00RKV	Carbamate derivative 8	Patented
T11754	DRUGINFO	D00ZGG	Azole derivative 2	Patented
T11754	DRUGINFO	D02JER	Tetra-substituted urea derivative 2	Patented
T11754	DRUGINFO	D02LJQ	Boronic acid derivative 1	Patented
T11754	DRUGINFO	D02ZPG	Aryl urea derivative 1	Patented
T11754	DRUGINFO	D03MCC	Tetra-hydro-naphthalene derivative 1	Patented
T11754	DRUGINFO	D04USU	Heteroaryl-substituted urea derivative 2	Patented
T11754	DRUGINFO	D04VYE	Benzyl pyrrolyloxoacetamide derivative 2	Patented
T11754	DRUGINFO	D05FQX	N-alkyl-4-oxazolecar boxamide derivative 1	Patented
T11754	DRUGINFO	D05HJF	Boronic acid derivative 5	Patented
T11754	DRUGINFO	D05IZN	Azole derivative 4	Patented
T11754	DRUGINFO	D05KXF	Tetra-hydro-naphthyridine derivative 1	Patented
T11754	DRUGINFO	D05LBM	Azole derivative 5	Patented
T11754	DRUGINFO	D05MKN	Azetidine urea derivative 3	Patented
T11754	DRUGINFO	D05RQF	Benzoxazole derivative 1	Patented
T11754	DRUGINFO	D07JMG	Boronic acid derivative 4	Patented
T11754	DRUGINFO	D07MIY	Aryl urea derivative 3	Patented
T11754	DRUGINFO	D07VNW	Enol carbamate derivative 1	Patented
T11754	DRUGINFO	D08JES	Piperazine urea derivative 1	Patented
T11754	DRUGINFO	D09AAB	Imidazolyl urea derivative 1	Patented
T11754	DRUGINFO	D09SWG	Azole derivative 1	Patented
T11754	DRUGINFO	D09VEY	Spirocyclic diamine urea derivative 2	Patented
T11754	DRUGINFO	D0BN7S	Azetidine urea derivative 1	Patented
T11754	DRUGINFO	D0DD7K	Aryl urea derivative 5	Patented
T11754	DRUGINFO	D0GI7I	Spirocyclic diamine urea derivative 1	Patented
T11754	DRUGINFO	D0H8LZ	Boronic acid derivative 6	Patented
T11754	DRUGINFO	D0HZ7J	N-alkyl-4-oxazolecar boxamide derivative 2	Patented
T11754	DRUGINFO	D0IK9V	Ketoheterocycle derivative 3	Patented
T11754	DRUGINFO	D0J1KT	Azetidine urea derivative 2	Patented
T11754	DRUGINFO	D0K2WP	Aryl urea derivative 2	Patented
T11754	DRUGINFO	D0KE8U	Carbamate derivative 3	Patented
T11754	DRUGINFO	D0LB8Y	Heteroaryl-substituted urea derivative 1	Patented
T11754	DRUGINFO	D0LR7Z	Carbamate derivative 1	Patented
T11754	DRUGINFO	D0LZ8I	Tetra-hydro-naphthalene derivative 3	Patented
T11754	DRUGINFO	D0OI8P	Isoxazoline derivative 4	Patented
T11754	DRUGINFO	D0P2AB	Azole derivative 3	Patented
T11754	DRUGINFO	D0P3MU	Boronic acid derivative 2	Patented
T11754	DRUGINFO	D0PU2A	Boronic acid derivative 3	Patented
T11754	DRUGINFO	D0Q6GP	Isoxazoline derivative 2	Patented
T11754	DRUGINFO	D0R3JK	Isoxazoline derivative 1	Patented
T11754	DRUGINFO	D0RZ5O	Tetrazolyl urea derivative 1	Patented
T11754	DRUGINFO	D0U0QQ	Tetra-substituted urea derivative 1	Patented
T11754	DRUGINFO	D0UD4X	Ketoheterocycle derivative 1	Patented
T11754	DRUGINFO	D0V1VT	Tetra-hydro-naphthalene derivative 2	Patented
T11754	DRUGINFO	D0W9GL	Carbamate derivative 7	Patented
T11754	DRUGINFO	D0WJ0T	Ketoheterocycle derivative 2	Patented
T11754	DRUGINFO	D0X7MV	Pyrrolidinyl urea derivative 1	Patented
T11754	DRUGINFO	D0X8VL	Isoxazoline derivative 3	Patented
T11754	DRUGINFO	D0XQ4B	Aryl urea derivative 4	Patented
T11754	DRUGINFO	D0Z5MJ	Ketoheterocycle derivative 4	Patented
T11754	DRUGINFO	D00IPI	Carbamide derivative 24	Patented
T11754	DRUGINFO	D01THA	Ethylaminopyrimidine derivative 1	Patented
T11754	DRUGINFO	D02ZUW	Carbamide derivative 26	Patented
T11754	DRUGINFO	D05DBG	Carbamate derivative 16	Patented
T11754	DRUGINFO	D08SMT	Carbamate derivative 17	Patented
T11754	DRUGINFO	D09RGE	Carbamide derivative 25	Patented
T11754	DRUGINFO	D0B7CW	PMID26413912-Compound-84	Patented
T11754	DRUGINFO	D0IA7Z	Carbamide derivative 1	Patented
T11754	DRUGINFO	D0L6XG	Carbamate derivative 9	Patented
T11754	DRUGINFO	D0M1ND	Pyrimidinyl ethylenediamine derivative 1	Patented
T11754	DRUGINFO	D0S2JF	Pyrazole derivative 83	Patented
T11754	DRUGINFO	D0V7PO	PMID29053063-Compound-14	Patented
T11754	DRUGINFO	D0Y7LM	Carbamate derivative 10	Patented
T11754	DRUGINFO	D0YM0G	Pyrazole derivative 84	Patented
T11754	DRUGINFO	D0GT0I	PMID29053063-Compound-11d	Patented
T11754	DRUGINFO	D0J6TA	Piperazine carbamic compound 1	Patented
T11754	DRUGINFO	D0LC5Y	Piperazine carbamic compound 2	Patented
T11754	DRUGINFO	D0LL0X	Pyrazole derivative 82	Patented
T11754	DRUGINFO	D0O9DS	Pyrazole derivative 81	Patented
T11754	DRUGINFO	D0TL1G	PMID29053063-Compound-15	Patented
T11754	DRUGINFO	D0X9GC	Pyrazole derivative 80	Patented
T11754	DRUGINFO	D00CKY	7-Phenyl-1-(1,3,4-thiadiazol-2-yl)-heptan-1-one	Investigative
T11754	DRUGINFO	D00FOZ	Propan-2-one O-3-butoxyphenylcarbamoyl oxime	Investigative
T11754	DRUGINFO	D00NXA	Benzofuran-2-ylboronic acid	Investigative
T11754	DRUGINFO	D00UBR	Cyclohexylmethylcarbamic Acid Biphenyl-3-yl Ester	Investigative
T11754	DRUGINFO	D00ULT	1,1,1-Trifluoro-undecan-2-one	Investigative
T11754	DRUGINFO	D00VVB	Propan-2-one O-4-(heptyloxy)phenylcarbamoyl oxime	Investigative
T11754	DRUGINFO	D00ZMY	2-Cyclohexylacetic acidbiphenyl-3-yl ester	Investigative
T11754	DRUGINFO	D01BGK	1-(4-methoxyoxazol-2-yl)-7-phenylheptan-1-one	Investigative
T11754	DRUGINFO	D01DIT	N-(2-hydroxyethyl)linoleoylamide	Investigative
T11754	DRUGINFO	D01FLQ	2-methoxyphenylboronic acid	Investigative
T11754	DRUGINFO	D01HBS	Cyclohexylcarbamic acidbiphenyl-3-yl ester	Investigative
T11754	DRUGINFO	D01HCR	Benzaldehyde O-4-(octyloxy)phenylcarbamoyl oxime	Investigative
T11754	DRUGINFO	D01IGL	(+/-)-3-allyl-1-pent-4-enoylazetidin-2-one	Investigative
T11754	DRUGINFO	D01JCJ	1-(oxazolo[4,5-b]pyridin-2-yl)octan-1-one	Investigative
T11754	DRUGINFO	D01NWS	3-(biphenyl-4-yl)-1-(oxazol-2-yl)propan-1-one	Investigative
T11754	DRUGINFO	D01UVD	N-(2-iodoethyl)linoleoylamide	Investigative
T11754	DRUGINFO	D01YWD	4-fluorophenyl 1-(4-butoxyphenyl)propylcarbamate	Investigative
T11754	DRUGINFO	D01ZUN	3,3-di(pent-4-enyl)azetidin-2-one	Investigative
T11754	DRUGINFO	D02AIH	1-(5-(pyridin-2-yl)oxazol-2-yl)pentan-1-one	Investigative
T11754	DRUGINFO	D02BZV	BMS-1	Investigative
T11754	DRUGINFO	D02DKM	Propan-2-one O-4-(hexyloxy)phenylcarbamoyl oxime	Investigative
T11754	DRUGINFO	D02ENI	(Z)-1-(benzo[d]oxazol-2-yl)octadec-9-en-1-one	Investigative
T11754	DRUGINFO	D02IQP	1-(oxazolo[4,5-b]pyridin-2-yl)pentan-1-one	Investigative
T11754	DRUGINFO	D02JRK	Phenyl 1-(4-butoxyphenyl)propylcarbamate	Investigative
T11754	DRUGINFO	D02JVI	1-Benzooxazol-2-yl-6-phenyl-hexan-1-one	Investigative
T11754	DRUGINFO	D02XGS	2-fluorophenyl 4-(hexyloxy)phenylcarbamate	Investigative
T11754	DRUGINFO	D03AYF	3-chlorophenyl 4-butoxybenzylcarbamate	Investigative
T11754	DRUGINFO	D03DFG	1-(1,3,4-thiadiazol-2-yl)octadec-9-en-1-one	Investigative
T11754	DRUGINFO	D03DXV	4-(1,2,3-thiadiazol-4-yl)phenyl butylcarbamate	Investigative
T11754	DRUGINFO	D03EYI	Phenylcarbamic Acid Biphenyl-3-yl Ester	Investigative
T11754	DRUGINFO	D03JFC	3-(benzo[d]oxazol-2-yl)phenyl propylcarbamate	Investigative
T11754	DRUGINFO	D03NTQ	7-Phenyl-1-(pyridazin-3-yl)-heptan-1-one	Investigative
T11754	DRUGINFO	D03NUC	Cyclopentylcarbamic Acid Biphenyl-3-yl Ester	Investigative
T11754	DRUGINFO	D03OGD	Methyl 2-(7-phenylheptanoyl)oxazole-4-carboxylate	Investigative
T11754	DRUGINFO	D03SNN	2-fluorophenyl 4-butoxyphenylcarbamate	Investigative
T11754	DRUGINFO	D03SUI	Pyridin-3-yl 4-butoxybenzylcarbamate	Investigative
T11754	DRUGINFO	D03XIY	7-Phenyl-1-(thiazol-2-yl)-heptan-1-one	Investigative
T11754	DRUGINFO	D03YHF	Propan-2-one O-4-butoxybenzylcarbamoyl oxime	Investigative
T11754	DRUGINFO	D03YUT	2-chloro-1-(5-(pyridin-2-yl)oxazol-2-yl)ethanone	Investigative
T11754	DRUGINFO	D04AUL	Propan-2-one O-4-(decyloxy)phenylcarbamoyl oxime	Investigative
T11754	DRUGINFO	D04BIH	4-Phenylbutylcarbamic Acid Biphenyl-3-yl Ester	Investigative
T11754	DRUGINFO	D04FFS	Benzaldehyde O-4-(pentyloxy)phenylcarbamoyl oxime	Investigative
T11754	DRUGINFO	D04GAX	3-(4,5-Dihydrooxazol-2-yl)phenyl propylcarbamate	Investigative
T11754	DRUGINFO	D04JWW	1-(4-iodooxazol-2-yl)-7-phenylheptan-1-one	Investigative
T11754	DRUGINFO	D04JYW	(+/-)-oxiran-2-ylmethyl (9Z)-hexadec-9-enoate	Investigative
T11754	DRUGINFO	D04OMK	Nicotinaldehyde O-4-butoxyphenylcarbamoyl oxime	Investigative
T11754	DRUGINFO	D04PMA	1,1,1-Trifluoro-tridecan-2-one	Investigative
T11754	DRUGINFO	D05FZP	3-(ethoxycarbonyl)phenylboronic acid	Investigative
T11754	DRUGINFO	D05GPK	Biphenyl-3-ylboronic acid	Investigative
T11754	DRUGINFO	D05HIG	6-Phenylhexylcarbamic Acid Biphenyl-3-yl Ester	Investigative
T11754	DRUGINFO	D05ICC	2-fluorophenyl 4-butoxybenzylcarbamate	Investigative
T11754	DRUGINFO	D05MBJ	1-(4-acetyloxazol-2-yl)-7-phenylheptan-1-one	Investigative
T11754	DRUGINFO	D06BGU	(+/-)-3-(but-3-enyl)-1-pent-4-enoylazetidin-2-one	Investigative
T11754	DRUGINFO	D06JBN	2-arachidonoylglycerol	Investigative
T11754	DRUGINFO	D06MNW	1-(oxazol-2-yl)octadec-9-en-1-one	Investigative
T11754	DRUGINFO	D06QER	Benzaldehyde O-4-(nonyloxy)phenylcarbamoyl oxime	Investigative
T11754	DRUGINFO	D06VSA	Methyl 2-(7-phenylheptanoyl)oxazole-5-carboxylate	Investigative
T11754	DRUGINFO	D07BGB	Propan-2-one O-4-propoxyphenylcarbamoyl oxime	Investigative
T11754	DRUGINFO	D07CER	1-Biphenyl-4-ylmethylmaleimide	Investigative
T11754	DRUGINFO	D07GOA	OL-92	Investigative
T11754	DRUGINFO	D07LQX	2-fluorophenyl 4-(undecyloxy)phenylcarbamate	Investigative
T11754	DRUGINFO	D07MQJ	(Z)-1-(4-phenyloxazol-2-yl)octadec-9-en-1-one	Investigative
T11754	DRUGINFO	D07MSJ	1-(5-Pyridin-2-yl-oxazol-2-yl)-octadec-9-yn-1-one	Investigative
T11754	DRUGINFO	D07PAF	PHENMEDIPHAM	Investigative
T11754	DRUGINFO	D07PLS	2-fluorophenyl 4-(heptyloxy)phenylcarbamate	Investigative
T11754	DRUGINFO	D07QOG	2-(7-phenylheptanoyl)oxazole-4-carbaldehyde	Investigative
T11754	DRUGINFO	D07RDB	2,4-difluorophenyl 4-butoxybenzylcarbamate	Investigative
T11754	DRUGINFO	D07XWB	4-(thiazol-2-yl)phenyl butylcarbamate	Investigative
T11754	DRUGINFO	D08ILW	Cyclohexyl biphenyl-4-ylcarbamate	Investigative
T11754	DRUGINFO	D08KJN	Phenethylcarbamic Acid Biphenyl-3-yl Ester	Investigative
T11754	DRUGINFO	D08TFH	Indan-2-ylcarbamic Acid Biphenyl-3-yl Ester	Investigative
T11754	DRUGINFO	D08UST	(Z)-2,2-Dimethyl-1-oxazol-2-yl-octadec-9-en-1-one	Investigative
T11754	DRUGINFO	D09CIX	8-Phenyloctylcarbamic Acid Biphenyl-3-yl Ester	Investigative
T11754	DRUGINFO	D09GVB	OL-135	Investigative
T11754	DRUGINFO	D09NFX	Nicotinaldehyde O-4-propoxyphenylcarbamoyl oxime	Investigative
T11754	DRUGINFO	D09YVZ	Benzaldehyde O-4-(heptyloxy)phenylcarbamoyl oxime	Investigative
T11754	DRUGINFO	D0A2SK	(Z)-1-(pyridazin-3-yl)octadec-9-en-1-one	Investigative
T11754	DRUGINFO	D0A5OS	Phenyl-1,4-bismaleimide	Investigative
T11754	DRUGINFO	D0A6RL	Benzylcarbamic Acid Biphenyl-3-yl Ester	Investigative
T11754	DRUGINFO	D0AR1Y	1,4-bis(malimido)xylene	Investigative
T11754	DRUGINFO	D0AV1T	N-(2-iodethyl)arachidonylamide	Investigative
T11754	DRUGINFO	D0AW4G	4-cyanophenylboronic acid	Investigative
T11754	DRUGINFO	D0B0IO	Nicotinaldehyde O-4-ethoxyphenylcarbamoyl oxime	Investigative
T11754	DRUGINFO	D0B0KP	1-Oxazolo[4,5-b]pyridin-2-yl-octadec-9-yn-1-one	Investigative
T11754	DRUGINFO	D0B1BQ	1,1,1-Trifluoro-nonadecan-2-one	Investigative
T11754	DRUGINFO	D0B4GP	Propan-2-one O-4-(nonyloxy)phenylcarbamoyl oxime	Investigative
T11754	DRUGINFO	D0C3JV	1,8-bis-maleimidodiethyleneglycol	Investigative
T11754	DRUGINFO	D0C6HH	6-fluoropyridin-3-ylboronic acid	Investigative
T11754	DRUGINFO	D0C9FO	2-(7-phenylheptanoyl)oxazole-5-carboxylic acid	Investigative
T11754	DRUGINFO	D0CH0K	1-(5-(pyridin-2-yl)oxazol-2-yl)octadec-9-en-1-one	Investigative
T11754	DRUGINFO	D0D0FX	1-(1,3,4-oxadiazol-2-yl)octadec-9-en-1-one	Investigative
T11754	DRUGINFO	D0D0NG	4-(cyclohexylmethylcarbamoyloxy)benzoic acid	Investigative
T11754	DRUGINFO	D0D4IJ	N-Hexylcarbamic Acid Biphenyl-3-yl Ester	Investigative
T11754	DRUGINFO	D0D6TB	1-(oxazol-2-yl)-4-(piperidin-4-yl)butan-1-one	Investigative
T11754	DRUGINFO	D0D7HU	7-Phenyl-1-(2H-tetrazol-5-yl)-heptan-1-one	Investigative
T11754	DRUGINFO	D0D7MP	(+/-)-oxiran-2-ylmethyl (9Z)-octadec-9-enoate	Investigative
T11754	DRUGINFO	D0D8OR	3-cyanophenylboronic acid	Investigative
T11754	DRUGINFO	D0D9GS	1-(1,2,4-Oxadiazol-3-yl)-7-phenylheptan-1-one	Investigative
T11754	DRUGINFO	D0E0JC	7-phenyl-1-(5-phenyloxazol-2-yl)heptan-1-one	Investigative
T11754	DRUGINFO	D0E1YQ	2-(7-phenylheptanoyl)oxazole-4-carboxamide	Investigative
T11754	DRUGINFO	D0E2BI	2-fluorophenyl 4'-ethylbiphenyl-4-ylcarbamate	Investigative
T11754	DRUGINFO	D0E9UX	PF3845	Investigative
T11754	DRUGINFO	D0F1BD	1-Biphenyl-4-ylmaleimide	Investigative
T11754	DRUGINFO	D0F1UD	4-nonylphenylboronic acid	Investigative
T11754	DRUGINFO	D0F7OX	Benzaldehyde O-4-methoxyphenylcarbamoyl oxime	Investigative
T11754	DRUGINFO	D0F9LO	1-(4-chlorooxazol-2-yl)-7-phenylheptan-1-one	Investigative
T11754	DRUGINFO	D0G2CY	(+/-)-3-allylazetidin-2-one	Investigative
T11754	DRUGINFO	D0GM1P	Phenyl 4-(hexyloxy)phenylcarbamate	Investigative
T11754	DRUGINFO	D0H5RS	1-(oxazol-2-yl)-7-phenylheptan-1-one	Investigative
T11754	DRUGINFO	D0H5WN	Isopropylcarbamic Acid Biphenyl-3-yl Ester	Investigative
T11754	DRUGINFO	D0H6FG	Methoxy arachidonyl fluorophosphonate	Investigative
T11754	DRUGINFO	D0H6OO	HTS-00798	Investigative
T11754	DRUGINFO	D0HP2H	2-fluorophenyl 4-(decyloxy)phenylcarbamate	Investigative
T11754	DRUGINFO	D0I0MR	(Z)-1,1,1-Trifluoro-nonadec-10-en-2-one	Investigative
T11754	DRUGINFO	D0I1WN	1,10-(methylenedi-4,1-phenylene)bismaleimide	Investigative
T11754	DRUGINFO	D0I3XN	4-nitrophenylboronic acid	Investigative
T11754	DRUGINFO	D0I8BO	1-(5-(furan-2-yl)oxazol-2-yl)octadec-9-en-1-one	Investigative
T11754	DRUGINFO	D0I9MF	Benzaldehyde O-4-ethoxyphenylcarbamoyl oxime	Investigative
T11754	DRUGINFO	D0IV9K	3-(trifluoromethyl)phenyl 4-butoxybenzylcarbamate	Investigative
T11754	DRUGINFO	D0J3CJ	2-fluorophenyl 4-(octyloxy)phenylcarbamate	Investigative
T11754	DRUGINFO	D0J7FJ	1-(5-fluorooxazol-2-yl)-7-phenylheptan-1-one	Investigative
T11754	DRUGINFO	D0J8VU	4-(1,2,3-thiadiazol-4-yl)phenyl hexylcarbamate	Investigative
T11754	DRUGINFO	D0JL3O	NICARBAZIN	Investigative
T11754	DRUGINFO	D0K0JP	Phenyl 4-(octyloxy)phenylcarbamate	Investigative
T11754	DRUGINFO	D0K0OR	1-(5-(pyridin-2-yl)oxazol-2-yl)octan-1-one	Investigative
T11754	DRUGINFO	D0K0YF	4-fluorophenylboronic acid	Investigative
T11754	DRUGINFO	D0K5EI	Naphthalen-2-yl cyclohexylcarbamate	Investigative
T11754	DRUGINFO	D0K6MH	2-(7-phenylheptanoyl)oxazole-4-carbonitrile	Investigative
T11754	DRUGINFO	D0K9HO	N-arachidonylmaleimide	Investigative
T11754	DRUGINFO	D0KI3F	1-(4-bromooxazol-2-yl)-7-phenylheptan-1-one	Investigative
T11754	DRUGINFO	D0KQ6L	Phenyl 4-(dodecyloxy)phenylcarbamate	Investigative
T11754	DRUGINFO	D0L1YC	1-DODECANOL	Investigative
T11754	DRUGINFO	D0L2LQ	Allylcarbamic Acid Biphenyl-3-yl Ester	Investigative
T11754	DRUGINFO	D0L6VM	2-fluorophenyl 4-(dodecyloxy)phenylcarbamate	Investigative
T11754	DRUGINFO	D0L7AW	Benzaldehyde O-4-(decyloxy)phenylcarbamoyl oxime	Investigative
T11754	DRUGINFO	D0L7TW	Phenyl 4-(heptyloxy)phenylcarbamate	Investigative
T11754	DRUGINFO	D0M7KD	Cyclobutylcarbamic Acid Biphenyl-3-yl Ester	Investigative
T11754	DRUGINFO	D0M7SQ	1,1,1-Trifluoro-9-phenyl-nonan-2-one	Investigative
T11754	DRUGINFO	D0M8AR	1-(5-phenyloxazol-2-yl)octadec-9-en-1-one	Investigative
T11754	DRUGINFO	D0MR1Z	Benzaldehyde O-4-butoxyphenylcarbamoyl oxime	Investigative
T11754	DRUGINFO	D0N8RT	Cyclopentyl(5-(pyridin-2-yl)oxazol-2-yl)methanone	Investigative
T11754	DRUGINFO	D0NH1E	Org-231295	Investigative
T11754	DRUGINFO	D0O1UQ	4-(trifluoromethyl)phenylboronic acid	Investigative
T11754	DRUGINFO	D0OD3U	3-(trifluoromethyl)phenylboronic acid	Investigative
T11754	DRUGINFO	D0OJ7E	3'-carbamoylbiphenyl-3-yl 6-phenylhexylcarbamate	Investigative
T11754	DRUGINFO	D0P9ZZ	Phenyl 4-(undecyloxy)phenylcarbamate	Investigative
T11754	DRUGINFO	D0PJ3R	(Z)-2-Methyl-1-oxazol-2-yl-octadec-9-en-1-one	Investigative
T11754	DRUGINFO	D0PN9S	7-phenyl-1-(4-phenyloxazol-2-yl)heptan-1-one	Investigative
T11754	DRUGINFO	D0Q2CR	1-(1,3,4-Oxadiazol-2-yl)-7-phenylheptan-1-one	Investigative
T11754	DRUGINFO	D0Q9JN	1-(5-methyloxazol-2-yl)-7-phenylheptan-1-one	Investigative
T11754	DRUGINFO	D0R5RW	4-Nitrophenyl 4-Benzylpiperazine-1-carboxylate	Investigative
T11754	DRUGINFO	D0R8JR	Propan-2-one O-4-butoxyphenylcarbamoyl oxime	Investigative
T11754	DRUGINFO	D0S6FJ	Benzaldehyde O-4-(hexyloxy)phenylcarbamoyl oxime	Investigative
T11754	DRUGINFO	D0TN0A	1-Oxazolo[4,5-b]pyridin-2-yl-6-phenyl-hexan-1-one	Investigative
T11754	DRUGINFO	D0TP1H	2-(7-phenylheptanoyl)oxazole-4-carboxylic acid	Investigative
T11754	DRUGINFO	D0TV9X	Propan-2-one O-4-(octyloxy)phenylcarbamoyl oxime	Investigative
T11754	DRUGINFO	D0U1WH	N-Butylcarbamic Acid Biphenyl-3-yl Ester	Investigative
T11754	DRUGINFO	D0U3YC	LY-2318912	Investigative
T11754	DRUGINFO	D0U7RS	2-fluorophenylboronic acid	Investigative
T11754	DRUGINFO	D0U8YV	1-(1,2,4-Oxadiazol-5-yl)-7-phenylheptan-1-one	Investigative
T11754	DRUGINFO	D0V8WE	4-(4,5-dihydrothiazol-2-yl)phenyl butylcarbamate	Investigative
T11754	DRUGINFO	D0VN9U	Phenyl 4-(decyloxy)phenylcarbamate	Investigative
T11754	DRUGINFO	D0VQ3O	1-(oxazol-2-yl)-3-(4-phenoxyphenyl)propan-1-one	Investigative
T11754	DRUGINFO	D0W0SE	PF750	Investigative
T11754	DRUGINFO	D0W0XK	(+/-)-3-(pent-4-enyl)azetidin-2-one	Investigative
T11754	DRUGINFO	D0W1OX	Biphenyl-3-ylcarbamic acid cyclohexyl ester	Investigative
T11754	DRUGINFO	D0W5WG	JNJ-1661010	Investigative
T11754	DRUGINFO	D0W7NY	2-(7-phenylheptanoyl)oxazole-5-carbonitrile	Investigative
T11754	DRUGINFO	D0W7XR	LY-2183240	Investigative
T11754	DRUGINFO	D0W9JC	1-(5-(pyridin-2-yl)oxazol-2-yl)dodecan-1-one	Investigative
T11754	DRUGINFO	D0WW5X	N-Octylcarbamic Acid Biphenyl-3-yl Ester	Investigative
T11754	DRUGINFO	D0X6WV	1-(4-methyloxazol-2-yl)-7-phenylheptan-1-one	Investigative
T11754	DRUGINFO	D0X7HP	2-fluorophenyl 4-phenoxyphenylcarbamate	Investigative
T11754	DRUGINFO	D0X8ZO	1-(oxazolo[4,5-b]pyridin-2-yl)dodecan-1-one	Investigative
T11754	DRUGINFO	D0XH1F	4-fluorophenyl 4-butoxybenzylcarbamate	Investigative
T11754	DRUGINFO	D0Y2UR	Methylcarbamic Acid Biphenyl-3-yl Ester	Investigative
T11754	DRUGINFO	D0Y5MR	2-fluorophenyl 1-(4-butoxyphenyl)propylcarbamate	Investigative
T11754	DRUGINFO	D0YU4D	Propan-2-one O-4-(pentyloxy)phenylcarbamoyl oxime	Investigative
T11754	DRUGINFO	D0Z0LX	4-methoxyphenyl 1-(4-butoxyphenyl)propylcarbamate	Investigative
T11754	DRUGINFO	D0Z0QC	Propan-2-one O-4-ethoxyphenylcarbamoyl oxime	Investigative
T11754	DRUGINFO	D0Z1ID	Furan-2-ylmethylcarbamic Acid Biphenyl-3-yl Ester	Investigative
T11754	DRUGINFO	D0Z4RZ	Adamant-1-ylcarbamic Acid Biphenyl-3-yl Ester	Investigative
T11754	DRUGINFO	D0Z5QM	Benzaldehyde O-4-propoxyphenylcarbamoyl oxime	Investigative
T11754	DRUGINFO	D0Z6BZ	Biphenyl-3-ylcarbamic Acid Biphenyl-3-yl Ester	Investigative
T11754	DRUGINFO	D0ZD6Z	3-methoxyphenylboronic acid	Investigative
T11754	DRUGINFO	D00IAK	1,1,1-trifluoro-3-(octylsulfonyl)propan-2-one	Investigative
T11754	DRUGINFO	D00QUN	Isopropyl 4-nitrophenyl dodecylphosphonate	Investigative
T11754	DRUGINFO	D00VKB	3-(decylsulfinyl)-1,1,1-trifluoropropan-2-one	Investigative
T11754	DRUGINFO	D01NDE	2,2-dimethyl-3-methyleneheptadecane	Investigative
T11754	DRUGINFO	D02SDT	3-(dodecylsulfonyl)-1,1,1-trifluoropropan-2-one	Investigative
T11754	DRUGINFO	D03ZBS	4-cyanophenyl ethyl dodecylphosphonate	Investigative
T11754	DRUGINFO	D04BWH	Benzo[b]thiophen-2-ylboronic acid	Investigative
T11754	DRUGINFO	D04UEN	1,1,1-trifluoro-3-(octylsulfinyl)propan-2-one	Investigative
T11754	DRUGINFO	D04YUA	Octane-1-sulfonyl fluoride	Investigative
T11754	DRUGINFO	D08YHD	1,1,1-Trifluoro-7-phenylheptan-2-one	Investigative
T11754	DRUGINFO	D09YUL	bromoenol lactone	Investigative
T11754	DRUGINFO	D0B4GJ	3-(dodecylsulfinyl)-1,1,1-trifluoropropan-2-one	Investigative
T11754	DRUGINFO	D0E5CF	3-(decylthio)-1,1,1-trifluoropropan-2-one	Investigative
T11754	DRUGINFO	D0FD8G	2-(biphenyl-4-yl)vinylboronic acid	Investigative
T11754	DRUGINFO	D0I7FF	1,1,1-trifluorododecan-2-one	Investigative
T11754	DRUGINFO	D0J8TY	ARACHIDONYL TRIFLUOROMETHYLKETONE	Investigative
T11754	DRUGINFO	D0K6GY	Ethyl octylfluorophosphonate	Investigative
T11754	DRUGINFO	D0N1CK	1,1,1-Trifluoro-8-phenyl-octan-2-one	Investigative
T11754	DRUGINFO	D0Q3GH	1,1,1-trifluoro-3-(octylthio)propan-2-one	Investigative
T11754	DRUGINFO	D0T4HB	Methyl icosylphosphonofluoridate	Investigative
T11754	DRUGINFO	D0U0CV	Dodecane-1-sulfonyl fluoride	Investigative
T11754	DRUGINFO	D0W4VM	AR-C70484XX	Investigative
T11754	DRUGINFO	D0Y0FN	3-(decylsulfonyl)-1,1,1-trifluoropropan-2-one	Investigative
T11754	DRUGINFO	D0Y2BD	1-Imidazol-1-yl-3-(4-octylphenoxy)propan-2-one	Investigative
T11754	DRUGINFO	D0Z7WK	1,1,1-trifluoro-3-(hexylthio)propan-2-one	Investigative
T11754	DRUGINFO	D02GOH	AM-404	Investigative
T11754	DRUGINFO	D06ORV	Phenethylboronic acid	Investigative
T11754	DRUGINFO	D0HQ4M	Isopropyl dodecylfluorophosphonate	Investigative
T11754	DRUGINFO	D0L1UA	N-(4-hydroxybenzyl)icosa-5,8,11,14-tetraenamide	Investigative
T11754	DRUGINFO	D0PC5A	VER-156084	Investigative
T11754	DRUGINFO	D0W6PT	Chlorphrifos oxon	Investigative
T11754	DRUGINFO	D09OSN	Biphenyl-4-ylboronic acid	Investigative
T11754	DRUGINFO	D0A4HS	4-methoxyphenylboronic acid	Investigative
T11754	DRUGINFO	D08XQI	PARAOXON	Investigative
T11754	DRUGINFO	D0EJ9B	Phenyl Boronic acid	Investigative

T54128	TARGETID	T54128
T54128	FORMERID	TTDS00121
T54128	TARGNAME	Glutamate receptor AMPA (GRIA)
T54128	TARGTYPE	Successful
T54128	SYNONYMS	Glutamate receptor ionotropic, AMPA; Glutamate receptor; AMPA selective glutamate receptor; AMPA receptor
T54128	BIOCLASS	Chloride channel
T54128	DRUGINFO	D02EZM	Fospropofol disodium	Approved
T54128	DRUGINFO	D03WAJ	Heptabarbital	Approved
T54128	DRUGINFO	D05TMQ	Aprobarbital	Approved
T54128	DRUGINFO	D0AO9S	Enflurane	Approved
T54128	DRUGINFO	D0D8VE	Halothane	Approved
T54128	DRUGINFO	D0DP6L	Isoflurane	Approved
T54128	DRUGINFO	D0E3FD	Bromazepam	Approved
T54128	DRUGINFO	D0GC2M	Acamprosate	Approved
T54128	DRUGINFO	D0H4GN	Desflurane	Approved
T54128	DRUGINFO	D0Q5IN	Lindane	Approved
T54128	DRUGINFO	D0W6ZF	Sevoflurane	Approved
T54128	DRUGINFO	D0ZB7K	Zopiclone	Approved
T54128	DRUGINFO	D03KEK	Artemisinin SP	Approved
T54128	DRUGINFO	D0SP3D	Dihydroergotoxine	Approved
T54128	DRUGINFO	D0WB9V	Barbiturate	Approved
T54128	DRUGINFO	D0U3ED	E-2007	Approved
T54128	DRUGINFO	D07WHN	FASORACETAM	Phase 3
T54128	DRUGINFO	D03DHQ	CX-516	Phase 2/3
T54128	DRUGINFO	D0MM3A	BIIB104	Phase 2a
T54128	DRUGINFO	D01MHI	Coluracetam	Phase 2
T54128	DRUGINFO	D01WBD	Mibampator	Phase 2
T54128	DRUGINFO	D02RVN	Selurampanel	Phase 2
T54128	DRUGINFO	D05PZN	TRO-19622	Phase 2
T54128	DRUGINFO	D08BEO	Talampanel	Phase 2
T54128	DRUGINFO	D0FR7E	CX1789	Phase 2
T54128	DRUGINFO	D0G3AR	CX-717	Phase 2
T54128	DRUGINFO	D0G8UY	PF-04958242	Phase 2
T54128	DRUGINFO	D0HO2T	AZD7325	Phase 2
T54128	DRUGINFO	D0J8DD	TAK-653	Phase 2
T54128	DRUGINFO	D0R6JV	CX-1739	Phase 2
T54128	DRUGINFO	D00VNH	ZK-200775	Phase 1
T54128	DRUGINFO	D0D3XM	TAK-137	Phase 1
T54128	DRUGINFO	D0IV7Z	AZD-8418	Phase 1
T54128	DRUGINFO	D02VKC	NBQX	Phase 1
T54128	DRUGINFO	D01NAM	ELB-139	Discontinued in Phase 2
T54128	DRUGINFO	D0B4EV	IPENOXAZONE	Discontinued in Phase 2
T54128	DRUGINFO	D0M0HJ	S-18986	Discontinued in Phase 2
T54128	DRUGINFO	D0P1QW	Becampanel	Discontinued in Phase 2
T54128	DRUGINFO	D02TTF	YM-90K	Discontinued in Phase 2
T54128	DRUGINFO	D04LEK	GSK729327	Discontinued in Phase 1
T54128	DRUGINFO	D0P1YH	S-1746	Discontinued in Phase 1
T54128	DRUGINFO	D04RAT	BIIR-777	Preclinical
T54128	DRUGINFO	D06DFU	TP-023	Preclinical
T54128	DRUGINFO	D0V9YW	GYKI-47261	Preclinical
T54128	DRUGINFO	D0XM3S	CX-1501	Preclinical
T54128	DRUGINFO	D0YH9A	TPT-43	Preclinical
T54128	DRUGINFO	D02QZL	PNQX	Terminated
T54128	DRUGINFO	D06WHL	NS-257	Terminated
T54128	DRUGINFO	D0B4AB	ACEA-2085	Terminated
T54128	DRUGINFO	D0EP5O	NS-377	Terminated
T54128	DRUGINFO	D0A9VO	GYKI-52466	Terminated
T54128	DRUGINFO	D0M7MW	GYKI-53655	Terminated
T54128	DRUGINFO	D0S0VZ	IDRA-21	Terminated
T54128	DRUGINFO	D0Z9CC	Zonampanel	Terminated
T54128	DRUGINFO	D0AZ5V	L-698544	Terminated
T54128	DRUGINFO	D00XNY	4,5,6,7-tetrahydroisoxazolo-[5,4-c]-pyridin-3-ol	Investigative
T54128	DRUGINFO	D08RAZ	N-methylbicuculline	Investigative
T54128	DRUGINFO	D0C5WK	LY-392098	Investigative
T54128	DRUGINFO	D0E4GJ	LY-314657	Investigative
T54128	DRUGINFO	D00LBX	Bicuculline	Investigative
T54128	DRUGINFO	D04SMQ	(S)-WILLARDIINE	Investigative
T54128	DRUGINFO	D08SYX	Piriqualone	Investigative
T54128	DRUGINFO	D0AA9A	N-(4-hydroxyphenylpropanyl)-spermine	Investigative
T54128	DRUGINFO	D0J1PG	2-AMINO-3-(4-HYDROXY-1,2,5-OXADIAZOL-3-YL)PROPIONIC ACID (STRUCTURAL MIX)	Investigative
T54128	DRUGINFO	D0T5SU	(S)-AMPA	Investigative
T54128	DRUGINFO	D0Z8IJ	Muscimol	Investigative
T54128	DRUGINFO	D03PGF	RPR-118723	Investigative
T54128	DRUGINFO	D05VVC	7-chloro-3-hydroxyquinazoline-2,4-dione	Investigative
T54128	DRUGINFO	D0E5UQ	[3H]CNQX	Investigative
T54128	DRUGINFO	D05KQC	DNQX	Investigative
T54128	DRUGINFO	D04PFN	[3H]kainate	Investigative

T20710	TARGETID	T20710
T20710	FORMERID	TTDS00139
T20710	TARGNAME	Interleukin 2 receptor (IL2R)
T20710	TARGTYPE	Successful
T20710	SYNONYMS	p64; gammaC; Interleukin2 receptor subunit gamma; Interleukin-2 receptor subunit gamma; IL2R subunit gamma; IL2 receptor subunit gamma; IL-2RG; IL-2R subunit gamma; IL-2R; IL-2 receptor subunit gamma; Cytokine receptor common subunit gamma; CD132
T20710	FUNCTION	Probably in association with IL15RA, involved in the stimulation of neutrophil phagocytosis by IL15. Common subunit for the receptors for a variety of interleukins.
T20710	BIOCLASS	Cytokine receptor
T20710	DRUGINFO	D0J3RY	Denileukin diftitox	Approved
T20710	DRUGINFO	DQGF20	ALKS 4230	Phase 2
T20710	DRUGINFO	D09JHT	Ro26-4550	Investigative

T29303	TARGETID	T29303
T29303	FORMERID	TTDS00155
T29303	TARGNAME	Sodium channel unspecific (NaC)
T29303	TARGTYPE	Successful
T29303	FUNCTION	Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient.
T29303	DRUGINFO	D04MSM	Carbamazepine	Approved
T29303	DRUGINFO	D06ORU	Butacaine	Approved
T29303	DRUGINFO	D07ONP	Phenacemide	Approved
T29303	DRUGINFO	D09QUQ	Levobupivacaine	Approved
T29303	DRUGINFO	D09ZIS	Zonisamide	Approved
T29303	DRUGINFO	D0E4DW	Phenytoin	Approved
T29303	DRUGINFO	D0H2SY	Oxybuprocaine	Approved
T29303	DRUGINFO	D0H7AV	Pilsicainide	Approved
T29303	DRUGINFO	D0K8MP	Permethrin	Approved
T29303	DRUGINFO	D0L0MK	Pachycarpine	Approved
T29303	DRUGINFO	D0MD2L	Rufinamide	Approved
T29303	DRUGINFO	D0Q8ZX	Benzocaine	Approved
T29303	DRUGINFO	D0T7WL	Pirmenol	Approved
T29303	DRUGINFO	D0WO8W	Mepivacaine	Approved
T29303	DRUGINFO	D04QZD	Eslicarbazepine	Approved
T29303	DRUGINFO	D0C7ET	Tetrodotoxin	Approved
T29303	DRUGINFO	D0L7VL	LIDOFLAZINE	Approved
T29303	DRUGINFO	D0N3ZJ	LOMERIZINE	Approved
T29303	DRUGINFO	D0S0FZ	Carisbamate	Phase 3
T29303	DRUGINFO	D00GEG	Ralfinamide	Phase 3
T29303	DRUGINFO	D00EJP	GSK2339345	Phase 2
T29303	DRUGINFO	D04XZE	NS-7	Phase 2
T29303	DRUGINFO	D05OTL	NW-3509	Phase 2
T29303	DRUGINFO	D0E8DK	COL-1077	Phase 2
T29303	DRUGINFO	D0K4MU	Crobenetine	Phase 2
T29303	DRUGINFO	D05OTZ	SMP-986	Phase 2
T29303	DRUGINFO	D0I8QS	BN82451	Phase 2
T29303	DRUGINFO	D02SVQ	HBI-3000	Phase 2
T29303	DRUGINFO	D0B7CH	Phenylbutyrate	Phase 2
T29303	DRUGINFO	D0N1TH	ATI-2042	Phase 2
T29303	DRUGINFO	D0Q7JC	P-552-02	Phase 1/2
T29303	DRUGINFO	D0I6AU	BDD-10103	Phase 1
T29303	DRUGINFO	D0P5CM	AZD-3161	Phase 1
T29303	DRUGINFO	D03JRO	ADCI	Phase 1
T29303	DRUGINFO	D08LDS	LUBELUZOLE	Discontinued in Preregistration
T29303	DRUGINFO	D04DZD	Bidisomide	Discontinued in Phase 3
T29303	DRUGINFO	D08NLQ	Licarbazepine	Discontinued in Phase 3
T29303	DRUGINFO	D01EBJ	4991W93	Discontinued in Phase 2
T29303	DRUGINFO	D02GMT	Org-7797	Discontinued in Phase 2
T29303	DRUGINFO	D04VIP	4030W92	Discontinued in Phase 2
T29303	DRUGINFO	D08XQA	RSD-921	Discontinued in Phase 2
T29303	DRUGINFO	D0A9CY	Pentisomide	Discontinued in Phase 2
T29303	DRUGINFO	D0D3BO	SOLPECAINOL HYDROCHLORIDE	Discontinued in Phase 2
T29303	DRUGINFO	D0R3WG	SILPERISONE HYDROCHLORIDE	Discontinued in Phase 2
T29303	DRUGINFO	D0V9OL	534U87	Discontinued in Phase 2
T29303	DRUGINFO	D0W9PG	Pyrazinoylguanidine	Discontinued in Phase 2
T29303	DRUGINFO	D0B7HX	Levosemotiadil	Discontinued in Phase 2
T29303	DRUGINFO	D0EC2K	SIPATRIGINE	Discontinued in Phase 2
T29303	DRUGINFO	D06WSQ	AWD-140-190	Discontinued in Phase 1
T29303	DRUGINFO	D07IIX	AMELTOLIDE	Discontinued in Phase 1
T29303	DRUGINFO	D0B4ZQ	SL-90.0571	Discontinued in Phase 1
T29303	DRUGINFO	D0JJ1B	Artilide	Discontinued in Phase 1
T29303	DRUGINFO	D00KWA	Recainam	Terminated
T29303	DRUGINFO	D00LYW	BW-1003C87	Terminated
T29303	DRUGINFO	D01NBX	RS-2135	Terminated
T29303	DRUGINFO	D05VXQ	SRSC-355	Terminated
T29303	DRUGINFO	D09VHA	BDF-9148	Terminated
T29303	DRUGINFO	D0B7HJ	U-54494A	Terminated
T29303	DRUGINFO	D0B8QA	RP-66055	Terminated
T29303	DRUGINFO	D0EF9I	A-76895	Terminated
T29303	DRUGINFO	D0K0KP	GE-68	Terminated
T29303	DRUGINFO	D0NF7S	R-59494	Terminated
T29303	DRUGINFO	D0T7XN	E-2070	Terminated
T29303	DRUGINFO	D0V1HK	Berlafenone	Terminated
T29303	DRUGINFO	D0V1NI	AM-66	Terminated
T29303	DRUGINFO	D0X6MO	Ralitoline	Terminated
T29303	DRUGINFO	D05ZGW	DPI-201-106	Terminated
T29303	DRUGINFO	D02NLI	PD-85639	Terminated
T29303	DRUGINFO	D0OW2O	U-92032	Terminated
T29303	DRUGINFO	D0P8TL	Saxitoxin	Investigative
T29303	DRUGINFO	D05XEF	5-Hexyl-5-phenyl-imidazolidine-2,4-dione	Investigative
T29303	DRUGINFO	D08KBV	4-Biphenyl-4-yl-2-cyclohexylmethyl-1H-imidazole	Investigative
T29303	DRUGINFO	D08RNW	2-Hydroxy-2-phenyl-nonanoic acid amide	Investigative
T29303	DRUGINFO	D08VUM	2-Hexyl-4-(4-isobutyl-phenyl)-1H-imidazole	Investigative
T29303	DRUGINFO	D08WQO	2-(1-Pentyl-hexyl)-4-phenyl-1H-imidazole	Investigative
T29303	DRUGINFO	D0B8GI	5-Heptyl-5-phenyl-imidazolidine-2,4-dione	Investigative
T29303	DRUGINFO	D0FL7O	4-Biphenyl-4-yl-2-(1-pentyl-hexyl)-1H-imidazole	Investigative
T29303	DRUGINFO	D0K1UR	4-Biphenyl-4-yl-2-(1-propyl-butyl)-1H-imidazole	Investigative
T29303	DRUGINFO	D0K8DH	4-Biphenyl-4-yl-2-hexyl-1H-imidazole	Investigative
T29303	DRUGINFO	D0L5UC	5-Ethyl-3-methyl-5-phenyl-oxazolidine-2,4-dione	Investigative
T29303	DRUGINFO	D0Q7GZ	5-Nonyl-5-phenyl-imidazolidine-2,4-dione	Investigative
T29303	DRUGINFO	D0S7ZU	4-Biphenyl-4-yl-2-methyl-1H-imidazole	Investigative
T29303	DRUGINFO	D0B9UU	BW-202W92	Investigative
T29303	DRUGINFO	D0WU9R	L-741742	Investigative

T68536	TARGETID	T68536
T68536	FORMERID	TTDS00308
T68536	TARGNAME	Tubulin beta (TUBB)
T68536	TARGTYPE	Successful
T68536	SYNONYMS	Major cysteine proteinase; Cysteine proteinase cruzipain; Cruzaine; Congopain; Beta-tubulin
T68536	FUNCTION	Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
T68536	BIOCLASS	Tubulin family
T68536	DRUGINFO	D00KVO	Albendazole	Approved
T68536	DRUGINFO	D04RLY	Vindesine	Approved
T68536	DRUGINFO	D09QVV	Vincristine	Approved
T68536	DRUGINFO	D0J1MI	Mebendazole	Approved
T68536	DRUGINFO	D0C4RB	Taxol	Approved
T68536	DRUGINFO	D0ZE1O	Plinabulin	Phase 3
T68536	DRUGINFO	D08NAD	Batabulin	Phase 2/3
T68536	DRUGINFO	D01AZP	BNC-105	Phase 2
T68536	DRUGINFO	D01JNE	Lexibulin	Phase 2
T68536	DRUGINFO	D04AMD	ZD-6126	Phase 2
T68536	DRUGINFO	D07QFU	T-607	Phase 2
T68536	DRUGINFO	D09BOH	Verubulin	Phase 2
T68536	DRUGINFO	D09EHO	ABT-751	Phase 2
T68536	DRUGINFO	D0PF3J	DOLASTATIN-10	Phase 2
T68536	DRUGINFO	D04EON	BAL-101553	Phase 1/2
T68536	DRUGINFO	D01RRF	STA-5312	Phase 1
T68536	DRUGINFO	D03RMN	1069C	Phase 1
T68536	DRUGINFO	D03XCR	Simotaxel	Phase 1
T68536	DRUGINFO	D05KNG	ALB-109564(a)	Phase 1
T68536	DRUGINFO	D07JAI	NSC-639829	Phase 1
T68536	DRUGINFO	D08OVG	CKD-516	Phase 1
T68536	DRUGINFO	D0J4MY	Tasidotin hydrochloride	Phase 1
T68536	DRUGINFO	D0K5CJ	DAVLB-HYDRAZIDE	Phase 1
T68536	DRUGINFO	D0P4KU	ABI-011	Phase 1
T68536	DRUGINFO	D09TXG	CEMADOTIN HYDROCHLORIDE	Discontinued in Phase 2
T68536	DRUGINFO	D0KX9Z	S-12363	Discontinued in Phase 2
T68536	DRUGINFO	D0N4OZ	Epothilone D	Discontinued in Phase 2
T68536	DRUGINFO	D01HBE	RHIZOXIN	Discontinued in Phase 2
T68536	DRUGINFO	D0X1BJ	Denibulin	Discontinued in Phase 1
T68536	DRUGINFO	D03TJN	KOS-1803	Preclinical
T68536	DRUGINFO	D00ZBQ	TL-1892	Investigative
T68536	DRUGINFO	D04EPS	ON-24160	Investigative
T68536	DRUGINFO	D04RKH	APH-0911	Investigative
T68536	DRUGINFO	D06QRY	IDN-5390	Investigative
T68536	DRUGINFO	D07XBZ	ARC-200	Investigative
T68536	DRUGINFO	D09EQZ	XN-0502	Investigative
T68536	DRUGINFO	D0XA1B	RTA-301	Investigative
T68536	DRUGINFO	D00BEM	2-m-Tolyl-1H-[1,8]naphthyridin-4-one	Investigative
T68536	DRUGINFO	D00CPM	2-(4-Methoxy-phenyl)-1H-indole-3-carbaldehyde	Investigative
T68536	DRUGINFO	D00GCN	2-Naphthalen-2-yl-1H-[1,8]naphthyridin-4-one	Investigative
T68536	DRUGINFO	D02BXC	GNF-PF-117	Investigative
T68536	DRUGINFO	D02XKD	3-bromo-4,4',5-trimethoxy-(Z)-stilbene	Investigative
T68536	DRUGINFO	D03CYV	6-ile-ustiloxin	Investigative
T68536	DRUGINFO	D03NTD	3,4',5-trimethoxy-(Z)-stilbene	Investigative
T68536	DRUGINFO	D04XJT	2-Methoxy-5-(3,4,5-trimethoxy-phenoxy)-phenol	Investigative
T68536	DRUGINFO	D05HFW	CENTAUREIDIN	Investigative
T68536	DRUGINFO	D05MPS	MYOSEVERIN	Investigative
T68536	DRUGINFO	D06JNW	NSC-106970	Investigative
T68536	DRUGINFO	D07UWD	Ustiloxin D	Investigative
T68536	DRUGINFO	D07XJB	PHENSTATIN	Investigative
T68536	DRUGINFO	D08BLV	Isopropyl 3-(phenylthio)-1H-indole-2-carboxylate	Investigative
T68536	DRUGINFO	D08CQQ	NSC-679036	Investigative
T68536	DRUGINFO	D09HKD	2-Naphthalen-1-yl-1H-[1,8]naphthyridin-4-one	Investigative
T68536	DRUGINFO	D09IEG	6-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one	Investigative
T68536	DRUGINFO	D0B1CM	2-Methoxy-5-(3,4,5-trimethoxy-benzyl)-phenol	Investigative
T68536	DRUGINFO	D0B6OH	COMBETASTATIN	Investigative
T68536	DRUGINFO	D0C6EW	Ustiloxin F	Investigative
T68536	DRUGINFO	D0K1MS	2-Methoxy-5-(5,6,7-trimethoxy-indan-1-yl)-phenol	Investigative
T68536	DRUGINFO	D0K4TV	5-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one	Investigative
T68536	DRUGINFO	D0K5CK	5,7-Dimethyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one	Investigative
T68536	DRUGINFO	D0LH3S	3,4,4',5-tetramethoxy-(Z)-stilbene	Investigative
T68536	DRUGINFO	D0M4ZQ	2-(3-Chloro-phenyl)-1H-[1,8]naphthyridin-4-one	Investigative
T68536	DRUGINFO	D0OW6Q	2,3'-diamino-3,4,4',5-tetramethoxy-(Z)-stillbene	Investigative
T68536	DRUGINFO	D0PT2D	MR-22388	Investigative
T68536	DRUGINFO	D0QP5D	NSC-664171	Investigative
T68536	DRUGINFO	D0S6FK	USTILOXIN A	Investigative
T68536	DRUGINFO	D0U7EG	7-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one	Investigative
T68536	DRUGINFO	D0VH8A	N-(4-(3-(pyridin-2-yl)acryloyl)phenyl)acetamide	Investigative
T68536	DRUGINFO	D0VI1H	COLCHINOL	Investigative
T68536	DRUGINFO	D0W5RQ	2'-amino-3,4,4',5-tetramethoxy-(Z)-stillbene	Investigative
T68536	DRUGINFO	D0X9OV	2-amino-3,4',5-trimethoxy-(Z)-stillbene	Investigative
T68536	DRUGINFO	D0Y8UP	2-Furan-2-yl-7-methyl-1H-[1,8]naphthyridin-4-one	Investigative
T68536	DRUGINFO	D0Z3KA	Thiocolchicine	Investigative

T56367	TARGETID	T56367
T56367	FORMERID	TTDS00167
T56367	TARGNAME	Phosphodiesterase 1 (PDE1)
T56367	TARGTYPE	Successful
T56367	SYNONYMS	PDE-I; Cam-PDE 1
T56367	FUNCTION	Has a higher affinity for cgmp than for camp.
T56367	BIOCLASS	Phosphoric diester hydrolase
T56367	DRUGINFO	D06BCB	Vinpocetine	Approved
T56367	DRUGINFO	D00XVL	ITI-214	Phase 1/2
T56367	DRUGINFO	D0E1SQ	BIBW-22	Terminated
T56367	DRUGINFO	D00YPW	ZAPRINAST	Terminated
T56367	DRUGINFO	D0RC4F	BUFROLIN	Investigative
T56367	DRUGINFO	D0P7JE	S,S-(2-Hydroxyethyl)Thiocysteine	Investigative
T56367	DRUGINFO	D0R6MT	isobutylmethylxanthine	Investigative

T43189	TARGETID	T43189
T43189	FORMERID	TTDS00271
T43189	TARGNAME	Tubulin (TUB)
T43189	TARGTYPE	Successful
T43189	SYNONYMS	Human tubulin
T43189	FUNCTION	Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain. TUBB3 plays a critical role in proper axon guidance and mantainance.
T43189	DRUGINFO	D01HTL	Vinorelbine	Approved
T43189	DRUGINFO	D02HSB	Cabazitaxel	Approved
T43189	DRUGINFO	D09DHY	Colchicine	Approved
T43189	DRUGINFO	D0KK2E	Eribulin	Approved
T43189	DRUGINFO	D0O5WP	Docetaxel	Approved
T43189	DRUGINFO	D0W2EK	Ixabepilone	Approved
T43189	DRUGINFO	D07WPE	Epothilon	Phase 3
T43189	DRUGINFO	D00AYA	BMS-188797	Phase 2
T43189	DRUGINFO	D04NXL	Indibulin	Phase 2
T43189	DRUGINFO	D04TLJ	Soblidotin	Phase 2
T43189	DRUGINFO	D07LAP	BMS-184476	Phase 2
T43189	DRUGINFO	D0DI8J	BMS-275183	Phase 2
T43189	DRUGINFO	D0J8WE	CRYPTOPHYCIN 52	Phase 2
T43189	DRUGINFO	D0JI8B	Milataxel	Phase 2
T43189	DRUGINFO	D0PF3J	DOLASTATIN-10	Phase 2
T43189	DRUGINFO	D04EON	BAL-101553	Phase 1/2
T43189	DRUGINFO	D00FMK	SDZ-LAV-694	Phase 1
T43189	DRUGINFO	D05HBZ	E 7974	Phase 1
T43189	DRUGINFO	D0CV7Z	Epothilone B	Discontinued in Phase 3
T43189	DRUGINFO	D0J0RV	Larotaxel	Discontinued in Phase 3
T43189	DRUGINFO	D09PKU	ERBULOZOLE	Discontinued in Phase 2
T43189	DRUGINFO	D0LI3C	Cryptophycin	Discontinued in Phase 2
T43189	DRUGINFO	D0Q1IH	ATX-201	Discontinued in Phase 2
T43189	DRUGINFO	D01HBE	RHIZOXIN	Discontinued in Phase 2
T43189	DRUGINFO	D09FZI	TALTOBULIN	Discontinued in Phase 1
T43189	DRUGINFO	D0FD2I	Discodermolide	Discontinued in Phase 1
T43189	DRUGINFO	D0V9ZL	FCE-28161	Discontinued in Phase 1
T43189	DRUGINFO	D0X5LG	ABJ-879	Discontinued in Phase 1
T43189	DRUGINFO	D0Y4BO	ABI-013	Preclinical
T43189	DRUGINFO	D0GO7W	21-AMINOEPOTHILONE B	Terminated
T43189	DRUGINFO	D02FNJ	AL-309	Investigative
T43189	DRUGINFO	D09ZSA	WR85915	Investigative
T43189	DRUGINFO	D0O5SC	Eleutherobin	Investigative
T43189	DRUGINFO	D0Z2FX	AL-209	Investigative
T43189	DRUGINFO	D0Z9TO	Sarcodictyin A	Investigative
T43189	DRUGINFO	D00BEM	2-m-Tolyl-1H-[1,8]naphthyridin-4-one	Investigative
T43189	DRUGINFO	D00CPM	2-(4-Methoxy-phenyl)-1H-indole-3-carbaldehyde	Investigative
T43189	DRUGINFO	D00GCN	2-Naphthalen-2-yl-1H-[1,8]naphthyridin-4-one	Investigative
T43189	DRUGINFO	D02BXC	GNF-PF-117	Investigative
T43189	DRUGINFO	D04XJT	2-Methoxy-5-(3,4,5-trimethoxy-phenoxy)-phenol	Investigative
T43189	DRUGINFO	D05HFW	CENTAUREIDIN	Investigative
T43189	DRUGINFO	D05MPS	MYOSEVERIN	Investigative
T43189	DRUGINFO	D06JNW	NSC-106970	Investigative
T43189	DRUGINFO	D07XJB	PHENSTATIN	Investigative
T43189	DRUGINFO	D08BLV	Isopropyl 3-(phenylthio)-1H-indole-2-carboxylate	Investigative
T43189	DRUGINFO	D08CQQ	NSC-679036	Investigative
T43189	DRUGINFO	D09HKD	2-Naphthalen-1-yl-1H-[1,8]naphthyridin-4-one	Investigative
T43189	DRUGINFO	D09IEG	6-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one	Investigative
T43189	DRUGINFO	D0B1CM	2-Methoxy-5-(3,4,5-trimethoxy-benzyl)-phenol	Investigative
T43189	DRUGINFO	D0B6OH	COMBETASTATIN	Investigative
T43189	DRUGINFO	D0K1MS	2-Methoxy-5-(5,6,7-trimethoxy-indan-1-yl)-phenol	Investigative
T43189	DRUGINFO	D0K4TV	5-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one	Investigative
T43189	DRUGINFO	D0K5CK	5,7-Dimethyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one	Investigative
T43189	DRUGINFO	D0M4ZQ	2-(3-Chloro-phenyl)-1H-[1,8]naphthyridin-4-one	Investigative
T43189	DRUGINFO	D0PT2D	MR-22388	Investigative
T43189	DRUGINFO	D0QP5D	NSC-664171	Investigative
T43189	DRUGINFO	D0U7EG	7-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one	Investigative
T43189	DRUGINFO	D0VI1H	COLCHINOL	Investigative
T43189	DRUGINFO	D0Y8UP	2-Furan-2-yl-7-methyl-1H-[1,8]naphthyridin-4-one	Investigative
T43189	DRUGINFO	D0Z3KA	Thiocolchicine	Investigative

T75984	TARGETID	T75984
T75984	FORMERID	TTDI01743
T75984	TARGNAME	5-HT 2 receptor (5HT2R)
T75984	TARGTYPE	Successful
T75984	SYNONYMS	Serotonin receptor 2; 5-hydroxytryptamine receptor 2; 5-HT2 receptor
T75984	FUNCTION	G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5- dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates phospholipase C and a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and promotes the release of Ca(2+) ions from intracellular stores. Affects neural activity, perception, cognition and mood. Plays a role in the regulation of behavior, including responses to anxiogenic situations and psychoactive substances. Plays a role in intestinal smooth muscle contraction, and may play a role in arterial vasoconstriction.
T75984	BIOCLASS	GPCR rhodopsin
T75984	DRUGINFO	D01KHH	Cyclobenzaprine	Approved
T75984	DRUGINFO	D08VRO	Ketanserin	Approved
T75984	DRUGINFO	D0F6GV	Perospirone	Approved
T75984	DRUGINFO	D0R6RO	Mianserin	Approved
T75984	DRUGINFO	D05UAV	Bis(olanzapine) pamoate monohydrate	Phase 3
T75984	DRUGINFO	D06FQS	TGOF02N	Phase 2
T75984	DRUGINFO	D06BUA	Nexopamil	Phase 2
T75984	DRUGINFO	D0S8DU	TGWOOAA	Phase 2
T75984	DRUGINFO	D0MT8G	FKB01MD	Phase 2
T75984	DRUGINFO	D0G7BR	AMAP-102	Phase 1
T75984	DRUGINFO	D0M1RM	Heterocyclic-tetracyclic tetrahydrofuran derivative 1	Patented
T75984	DRUGINFO	D0K8NW	Ritanserin	Discontinued in Phase 3
T75984	DRUGINFO	D00EBH	ICI-170809	Discontinued in Phase 2
T75984	DRUGINFO	D0A6YN	SUN-C5174	Discontinued in Phase 2
T75984	DRUGINFO	D0W2PK	Beloxepin	Discontinued in Phase 1
T75984	DRUGINFO	D0C1CU	SUN-9221	Discontinued in Phase 1
T75984	DRUGINFO	D04PGO	MDL-28133A	Terminated
T75984	DRUGINFO	D05NTY	NPC-18166	Terminated
T75984	DRUGINFO	D05SSJ	Dotarizine	Terminated
T75984	DRUGINFO	D05KRC	Emopamil	Terminated
T75984	DRUGINFO	D0Q6EN	AHR-16303B	Terminated
T75984	DRUGINFO	D0P3IZ	E-2040	Terminated
T75984	DRUGINFO	D04EYR	Metrenperone	Investigative

T84160	TARGETID	T84160
T84160	FORMERID	TTDS00106
T84160	TARGNAME	5-HT 3 receptor (5HT3R)
T84160	TARGTYPE	Successful
T84160	SYNONYMS	5-hydroxytryptamine receptor type 3; 5-hydroxytryptamine receptor 3; 5-HT3R; 5-HT3 receptor; 5-HT-3
T84160	FUNCTION	This is one of the several different receptors for 5- hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel.
T84160	BIOCLASS	GPCR rhodopsin
T84160	DRUGINFO	D00SVU	Y-25130	Approved
T84160	DRUGINFO	D0J5KF	Granisetron	Approved
T84160	DRUGINFO	D0K7WK	Ondansetron	Approved
T84160	DRUGINFO	D0RA9E	Ramosetron	Approved
T84160	DRUGINFO	D00IJQ	Zatosetron maleate	Phase 3
T84160	DRUGINFO	D00RJE	Pancopride	Phase 3
T84160	DRUGINFO	D06QZL	Lerisetron	Phase 3
T84160	DRUGINFO	D04MKJ	Renzapride	Phase 3
T84160	DRUGINFO	D07AHC	LITOXETINE	Phase 3
T84160	DRUGINFO	D04EFK	DDP-225	Phase 2
T84160	DRUGINFO	D08KTO	AD04	Phase 2
T84160	DRUGINFO	D0E2JN	KB-6806	Phase 2
T84160	DRUGINFO	D0N5KS	Pumosetrag	Phase 2
T84160	DRUGINFO	D0Q8MI	Lintopride	Phase 2
T84160	DRUGINFO	D01RVA	ADR-851	Phase 1
T84160	DRUGINFO	D02NIP	ITASETRON	Phase 1
T84160	DRUGINFO	D0OU3Q	TAK-058	Phase 1
T84160	DRUGINFO	DO2P5G	CVN058	Phase 1
T84160	DRUGINFO	D01CDE	BIMU-1	Phase 1
T84160	DRUGINFO	D01XUE	Tedatioxetine	Phase 1
T84160	DRUGINFO	D0D5ZX	RG-12915	Discontinued in Phase 3
T84160	DRUGINFO	D07QAA	BRL-46470	Discontinued in Phase 2
T84160	DRUGINFO	D0SB6K	DAT-582	Discontinued in Phase 2
T84160	DRUGINFO	D0T1MP	Lurosetron	Discontinued in Phase 2
T84160	DRUGINFO	D0ZX7I	SR-57227	Discontinued in Phase 2
T84160	DRUGINFO	D04DMQ	Fabesetron	Discontinued in Phase 2
T84160	DRUGINFO	D0Y0SY	E-3620	Discontinued in Phase 2
T84160	DRUGINFO	D03CFR	SEP-226332	Discontinued in Phase 1
T84160	DRUGINFO	D0S7VZ	WAY-100289	Discontinued in Phase 1
T84160	DRUGINFO	D0YT6Z	Mirisetron maleate	Discontinued in Phase 1
T84160	DRUGINFO	D01JHN	CR-3124	Terminated
T84160	DRUGINFO	D0C5DM	SC-52150	Terminated
T84160	DRUGINFO	D0I8RY	SDZ-ICM-567	Terminated
T84160	DRUGINFO	D0L3OE	SRSS-021	Terminated
T84160	DRUGINFO	D0M7VW	GR-65630	Terminated
T84160	DRUGINFO	D0Y5QO	GK-128	Terminated
T84160	DRUGINFO	D0V1SD	BP4.879a	Terminated
T84160	DRUGINFO	D04NLG	BRL 43694A	Investigative
T84160	DRUGINFO	D0S0XK	S-21007	Investigative
T84160	DRUGINFO	D00JKB	SC-54750	Investigative
T84160	DRUGINFO	D03TPY	SC-52491	Investigative
T84160	DRUGINFO	D0AJ3C	(R)-zacopride	Investigative
T84160	DRUGINFO	D0I3XA	Ciproxifan	Investigative

T81183	TARGETID	T81183
T81183	FORMERID	TTDS00027
T81183	TARGNAME	Adrenergic receptor Alpha-1 (ADRA1)
T81183	TARGTYPE	Successful
T81183	SYNONYMS	Alpha1-adrenoceptor; Alpha(1)-adrenoceptor
T81183	BIOCLASS	GPCR rhodopsin
T81183	DRUGINFO	D01TSI	Ergotamine	Approved
T81183	DRUGINFO	D02XJY	Midodrine	Approved
T81183	DRUGINFO	D0A8XN	Labetalol	Approved
T81183	DRUGINFO	D0W9LX	Carvedilol	Approved
T81183	DRUGINFO	D0WV3U	Prazosin	Approved
T81183	DRUGINFO	D0K0VO	Urapidil	Approved
T81183	DRUGINFO	D09JXM	Phenylpropanolamine	Withdrawn from market
T81183	DRUGINFO	D00LBD	Metazosin	Discontinued in Phase 3
T81183	DRUGINFO	D07ODD	DC-015	Terminated

T39078	TARGETID	T39078
T39078	FORMERID	TTDS00145
T39078	TARGNAME	Calcium-activated potassium channel (KCN)
T39078	TARGTYPE	Successful
T39078	SYNONYMS	Ca-activated K channel
T39078	FUNCTION	Forms a voltage-independent potassium channel that is activated by intracellular calcium. activation is followed by membrane hyperpolarization which promotes calcium influx. The channel is blocked by clotrimazole and charybdotoxin.
T39078	DRUGINFO	D08ZEB	Chlorzoxazone	Approved
T39078	DRUGINFO	D0U5OB	Charybdotoxin	Approved
T39078	DRUGINFO	D00BUR	ICA-17043	Phase 2
T39078	DRUGINFO	D02CZC	4-fluorophenyl-2,2-diphenylacetamide	Investigative
T39078	DRUGINFO	D02LML	N-methyl-2,2,2-triphenylacetamide	Investigative
T39078	DRUGINFO	D03FAG	TRIPHENYLMETHANAMINE	Investigative
T39078	DRUGINFO	D05MDB	N,N-dimethyl-2,2,2-triphenylacetamide	Investigative
T39078	DRUGINFO	D06XXG	(2-fluorophenyl)-(4-fluorophenyl)phenylacetamide	Investigative
T39078	DRUGINFO	D06ZNX	2,2,2-tris-(3-fluorophenyl)-acetamide	Investigative
T39078	DRUGINFO	D07EYJ	2-fluorophenyl-2,2-diphenylacetamide	Investigative
T39078	DRUGINFO	D09LVX	Bis(4-fluorophenyl)-2-fluorophenylacetamide	Investigative
T39078	DRUGINFO	D09TSB	N-ethyl-2,2,2-triphenylacetamide	Investigative
T39078	DRUGINFO	D0A4LH	5-tosyl-5H-dibenzo[b,d]azepin-7(6H)-one	Investigative
T39078	DRUGINFO	D0F7DQ	Triphenylacetic acid methyl ester	Investigative
T39078	DRUGINFO	D0HR0O	2,2,2-tris-(4-fluorophenyl)-acetamide	Investigative
T39078	DRUGINFO	D0I5YS	2-(2-chlorophenyl)-2,2-diphenylethanamide	Investigative
T39078	DRUGINFO	D0K1QB	2-(2,4-difluorophenyl)-2,2-diphenylacetamide	Investigative
T39078	DRUGINFO	D0N2BP	2,2-bis-(3-fluorophenyl)-2-phenylacetamide	Investigative
T39078	DRUGINFO	D0T5IP	2-trityl-4,5-dihydrooxazole	Investigative
T39078	DRUGINFO	D0UF2B	2-(3,4-Difluorophenyl)-2,2-diphenylacetamide	Investigative
T39078	DRUGINFO	D0V7RI	2,2-bis-(2-fluorophenyl)-2-phenylacetamide	Investigative
T39078	DRUGINFO	D05RLR	1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole	Investigative
T39078	DRUGINFO	D0R9CF	4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one	Investigative

T47941	TARGETID	T47941
T47941	FORMERID	TTDC00170
T47941	TARGNAME	Phosphodiesterase 4 (PDE4)
T47941	TARGTYPE	Successful
T47941	SYNONYMS	PDE-4
T47941	FUNCTION	Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes||Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to antiasthmatic and anti-inflammatory agents
T47941	BIOCLASS	Phosphoric diester hydrolase
T47941	DRUGINFO	D08NWF	crisaborole	Approved
T47941	DRUGINFO	D0R4UW	Roflumilast	Approved
T47941	DRUGINFO	D03QJL	Ibudilast	Approved
T47941	DRUGINFO	D0B0SH	Oxtriphylline	Approved
T47941	DRUGINFO	D07ESC	Apremilast	Approved
T47941	DRUGINFO	D0T0NG	Arofylline	Phase 3
T47941	DRUGINFO	DST04F	ARQ-151	Phase 3
T47941	DRUGINFO	D09USN	IC-485	Phase 2
T47941	DRUGINFO	D0M5BS	ONO-6126	Phase 2
T47941	DRUGINFO	D0TT4H	E6005	Phase 2
T47941	DRUGINFO	D0U9WS	LEO-32731	Phase 2
T47941	DRUGINFO	D5ON9Z	ASP9831	Phase 2
T47941	DRUGINFO	D81WBS	PF-07038124	Phase 2
T47941	DRUGINFO	DH82BG	ARQ-154	Phase 2
T47941	DRUGINFO	D0I8FV	SUN13834	Phase 2
T47941	DRUGINFO	DRG3B4	TAK-648	Phase 1
T47941	DRUGINFO	D02EMR	Cilomilast	Discontinued in Phase 3
T47941	DRUGINFO	D0F3BY	GW842470X	Discontinued in Phase 2
T47941	DRUGINFO	D07FHZ	Ro 20-1724	Terminated
T47941	DRUGINFO	D03FJS	S-(-)-enantiomer of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP)	Investigative
T47941	DRUGINFO	D0KM1H	Iso-caffeine	Investigative
T47941	DRUGINFO	D0M5DY	SDZ-PDI-747	Investigative
T47941	DRUGINFO	D0U0EX	CT-5357	Investigative
T47941	DRUGINFO	D01RUN	(R)-Rolipram	Investigative
T47941	DRUGINFO	D02FZD	(S)-Rolipram	Investigative

T43920	TARGETID	T43920
T43920	FORMERID	TTDS00304
T43920	TARGNAME	Carbonic anhydrase (CA)
T43920	TARGTYPE	Successful
T43920	SYNONYMS	Carbonate dehydratase
T43920	DRUGINFO	D0J8ZA	Quinethazone	Approved
T43920	DRUGINFO	D0K1QD	Sulfamylon	Approved
T43920	DRUGINFO	D07HBX	Salicyclic acid	Approved
T43920	DRUGINFO	D0VA4Y	Phentermine+topiramate	Phase 3
T43920	DRUGINFO	D0A8JP	PARABEN	Phase 3
T43920	DRUGINFO	D07SDQ	Curcumin	Phase 3
T43920	DRUGINFO	D0L6HN	PHENOL	Phase 2/3
T43920	DRUGINFO	D0Y6OA	Coumate	Phase 2
T43920	DRUGINFO	D0V0UK	SULFAMIDE	Phase 1
T43920	DRUGINFO	D02VIR	PMID30074415-Compound-21	Patented
T43920	DRUGINFO	D07DGA	Imatinib and nilotinib derivative 2	Patented
T43920	DRUGINFO	D0CE8B	PMID30074415-Compound-19	Patented
T43920	DRUGINFO	D0F8XZ	PMID30074415-Compound-20	Patented
T43920	DRUGINFO	D0OE4F	Imatinib and nilotinib derivative 1	Patented
T43920	DRUGINFO	D03SLR	FERULIC ACID	Patented
T43920	DRUGINFO	D06ABW	CLIOQUINOL	Withdrawn from market
T43920	DRUGINFO	D0LD9S	SPERMINE	Terminated
T43920	DRUGINFO	D01BUB	2,5-difluorophenol	Investigative
T43920	DRUGINFO	D07MQB	4-amino-3-fluoro-5-iodobenzenesulfonamide	Investigative
T43920	DRUGINFO	D0Q1EI	4-amino-3,5-dibromobenzenesulfonamide	Investigative
T43920	DRUGINFO	D0Q2XB	3,5-difluorophenol	Investigative
T43920	DRUGINFO	D0W2XO	Sodium maleate	Investigative
T43920	DRUGINFO	D05PRS	4-Thiocyanato-benzenesulfonamide	Investigative
T43920	DRUGINFO	D06LVE	4-Nitro-benzenesulfonamide	Investigative
T43920	DRUGINFO	D07MTM	4-AMINOPHENOL	Investigative
T43920	DRUGINFO	D07ZHE	3-Nitro-benzenesulfonamide	Investigative
T43920	DRUGINFO	D0L8ZG	P-tolylboronic acid	Investigative
T43920	DRUGINFO	D0M6RM	Phenylarsonic acid	Investigative
T43920	DRUGINFO	D0SV6C	PRONTOCIL	Investigative
T43920	DRUGINFO	D00GVA	4-(2-Pyridin-4-ylacetamido)benzenesulfonamide	Investigative
T43920	DRUGINFO	D01ISX	4-[2-(2-Thienyl)acetamidoethyl]benzenesulfonamide	Investigative
T43920	DRUGINFO	D05NFU	4-butylphenylboronic acid	Investigative
T43920	DRUGINFO	D06XNT	4-(2-Phenylacetamidomethyl)benzenesulfonamide	Investigative
T43920	DRUGINFO	D07CYN	2-amino-2,3-dihydro-1H-indene-5-sulfonamide	Investigative
T43920	DRUGINFO	D09CSP	3-(4-sulfamoylphenyl)propanoic acid	Investigative
T43920	DRUGINFO	D09LWR	4-(2-Phenylacetamidoethyl)benzenesulfonamide	Investigative
T43920	DRUGINFO	D09TES	2-acetamido-2,3-dihydro-1H-indene-5-sulfonic acid	Investigative
T43920	DRUGINFO	D0A3JR	4-(2-Phenylacetamido)-3-chlorobenzenesulfonamide	Investigative
T43920	DRUGINFO	D0C8ZY	Beta-naphthylboronic acid	Investigative
T43920	DRUGINFO	D0D2JA	4-phenoxyphenylboronic acid	Investigative
T43920	DRUGINFO	D0N7WP	4-(2-Pyridin-2-ylacetamido)benzenesulfonamide	Investigative
T43920	DRUGINFO	D0O0UE	4-(2-Phenylacetamido)benzenesulfonamide	Investigative
T43920	DRUGINFO	D0O9VU	4-(2-Phenylacetamido)-3-fluorobenzenesulfonamide	Investigative
T43920	DRUGINFO	D0T0YI	4-nitrophenyl phosphate	Investigative
T43920	DRUGINFO	D0W9VC	4-[2-(2-Thienyl)acetamido]benzenesulfonamide	Investigative
T43920	DRUGINFO	D0XL5K	Benzothiazole-2-sulfonic acid amide	Investigative
T43920	DRUGINFO	D0Z1CL	4-bromophenylboronic acid	Investigative
T43920	DRUGINFO	D0Z5GE	4-(2-Phenylacetamido)-3-bromobenzenesulfonamide	Investigative
T43920	DRUGINFO	D00IUB	4-CYANOPHENOL	Investigative
T43920	DRUGINFO	D01JTI	3-bromophenyl-difluoromethanesulfonamide	Investigative
T43920	DRUGINFO	D04JIN	(2-bromophenyl)difluoromethanesulfonamide	Investigative
T43920	DRUGINFO	D04PSK	N-[5-(methylthio)-1,3,4-thiadiazol-2-yl]sulfamide	Investigative
T43920	DRUGINFO	D05QUG	7-phenethoxy-2H-chromen-2-one	Investigative
T43920	DRUGINFO	D05VSK	ETHOXYCOUMARIN	Investigative
T43920	DRUGINFO	D06GPL	4-methylphenyl-difluoromethanesulfonamide	Investigative
T43920	DRUGINFO	D06JVR	N-(5-phenyl-1,3,4-thiadiazol-2-yl)sulfamide	Investigative
T43920	DRUGINFO	D07QJJ	CATECHOL	Investigative
T43920	DRUGINFO	D07SIA	PHENYLMETHANESULFONAMIDE	Investigative
T43920	DRUGINFO	D09OSN	Biphenyl-4-ylboronic acid	Investigative
T43920	DRUGINFO	D09UQM	1-(3,4-dichlorophenyl)-3-hydroxyurea	Investigative
T43920	DRUGINFO	D0A4HS	4-methoxyphenylboronic acid	Investigative
T43920	DRUGINFO	D0E3VJ	N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]sulfamide	Investigative
T43920	DRUGINFO	D0I5YQ	4-nitrophenyl-difluoromethanesulfonamide	Investigative
T43920	DRUGINFO	D0IU3X	(4-bromophenyl)difluoromethanesulfonamide	Investigative
T43920	DRUGINFO	D0S4NO	N-(5-ethyl-1,3,4-thiadiazol-2-yl)sulfamide	Investigative
T43920	DRUGINFO	D0T2VH	N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)sulfamide	Investigative
T43920	DRUGINFO	D0UN0E	PHENYLDIFLUOROMETHANESULFONAMIDE	Investigative
T43920	DRUGINFO	D0Z6TM	4-azidobenzenesulfonamide	Investigative
T43920	DRUGINFO	D00RNZ	7-(benzyloxy)-2H-chromen-2-one	Investigative
T43920	DRUGINFO	D02DBP	RESORCINOL	Investigative
T43920	DRUGINFO	D03VDJ	SULFAMATE	Investigative
T43920	DRUGINFO	D06DYP	8-methoxy-2-oxo-2H-chromene-3-carboxylic acid	Investigative
T43920	DRUGINFO	D09WVV	N1-(2-aminoethyl)ethane-1,2-diamine	Investigative
T43920	DRUGINFO	D0A0YX	SACCHARIN	Investigative
T43920	DRUGINFO	D0C4QB	2-Amino-indan-5-sulfonic acid	Investigative
T43920	DRUGINFO	D0G0FJ	2-hydrazinylbenzenesulfonamide	Investigative
T43920	DRUGINFO	D0LC0F	2,3-dihydro-1H-indene-5-sulfonamide	Investigative
T43920	DRUGINFO	D0LU4S	7-butoxy-2H-chromen-2-one	Investigative
T43920	DRUGINFO	D0OT5L	7-propoxy-2H-chromen-2-one	Investigative
T43920	DRUGINFO	D0RB0D	7-methoxy-2-oxo-2H-chromene-4-carboxylic acid	Investigative
T43920	DRUGINFO	D0TY8X	4-(2-aminopyrimidin-4-ylamino)benzenesulfonamide	Investigative
T43920	DRUGINFO	D0X6IE	4-amino-N-(4-sulfamoylbenzyl)benzenesulfonamide	Investigative
T43920	DRUGINFO	D0Z1HY	4-amino-6-chlorobenzene-1,3-disulfonamide	Investigative
T43920	DRUGINFO	D0ZC3W	P-toluenesulfonamide	Investigative
T43920	DRUGINFO	D00XJA	6-methoxy-2-oxo-2H-chromene-3-carboxylic acid	Investigative
T43920	DRUGINFO	D04VLI	4-(2-Hydroxy-ethyl)-benzenesulfonamide	Investigative
T43920	DRUGINFO	D07TAJ	Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate	Investigative
T43920	DRUGINFO	D08XQI	PARAOXON	Investigative
T43920	DRUGINFO	D0D6UR	2-oxo-2H-thiochromene-3-carboxylic acid	Investigative
T43920	DRUGINFO	D0EJ9B	Phenyl Boronic acid	Investigative
T43920	DRUGINFO	D0H3NS	2-oxo-2H-chromene-3-carboxylic acid	Investigative
T43920	DRUGINFO	D0J2AE	3-Amino-benzenesulfonamide	Investigative
T43920	DRUGINFO	D0OI1H	2-Amino-benzenesulfonamide	Investigative
T43920	DRUGINFO	D0X5HL	N1-(naphthalen-1-yl)ethane-1,2-diamine	Investigative
T43920	DRUGINFO	D04NSN	4-(2-AMINOETHYL)BENZENESULFONAMIDE	Investigative
T43920	DRUGINFO	D05XZM	4-(hydroxymethyl)benzenesulfonamide	Investigative
T43920	DRUGINFO	D09JPC	Hexane-1,6-diamine	Investigative
T43920	DRUGINFO	D09PWX	Carzenide	Investigative
T43920	DRUGINFO	D0G3BI	6-methyl-2-oxo-2H-chromene-3-carboxylic acid	Investigative
T43920	DRUGINFO	D0L5TZ	6-(hydroxymethyl)-2H-chromen-2-one	Investigative
T43920	DRUGINFO	D0Q2LL	6-Hydroxy-benzothiazole-2-sulfonic acid amide	Investigative
T43920	DRUGINFO	D0U4BB	HERNIARIN	Investigative
T43920	DRUGINFO	D00YEF	Decane-1,10-diyl disulfamate	Investigative
T43920	DRUGINFO	D01STY	4-Amino-3-iodo-benzenesulfonamide	Investigative
T43920	DRUGINFO	D02QGI	Pentane-1,5-diamine	Investigative
T43920	DRUGINFO	D03ZMQ	COUMARIN	Investigative
T43920	DRUGINFO	D04CVC	4-Amino-3-fluoro-benzenesulfonamide	Investigative
T43920	DRUGINFO	D05TLB	Octyl sulfamate	Investigative
T43920	DRUGINFO	D09WSJ	Decyl sulfamate	Investigative
T43920	DRUGINFO	D0AU0M	P-Coumaric Acid	Investigative
T43920	DRUGINFO	D0D4OV	Octane-1,8-diyl disulfamate	Investigative
T43920	DRUGINFO	D0E8CC	BENZOLAMIDE	Investigative
T43920	DRUGINFO	D0M3PO	2,4-Disulfamyltrifluoromethylaniline	Investigative
T43920	DRUGINFO	D0N1AW	6-(aminomethyl)-2H-chromen-2-one	Investigative
T43920	DRUGINFO	D0NN3Q	4-Hydrazino-benzenesulfonamide	Investigative
T43920	DRUGINFO	D0P6AM	4-Amino-3-bromo-benzenesulfonamide	Investigative
T43920	DRUGINFO	D0Q7DJ	Syringic Acid	Investigative
T43920	DRUGINFO	D0VD7H	CL-5343	Investigative
T43920	DRUGINFO	D0YU8J	4-Amino-3-chloro-benzenesulfonamide	Investigative
T43920	DRUGINFO	D0V7AA	CATECHIN	Investigative
T43920	DRUGINFO	D0Y3TZ	GALLICACID	Investigative
T43920	DRUGINFO	D0Q5FV	2-Sulfhydryl-Ethanol	Investigative
T43920	DRUGINFO	D0A1CM	ELLAGIC ACID	Investigative

T52624	TARGETID	T52624
T52624	FORMERID	TTDS00261
T52624	TARGNAME	Platelet-derived growth factor receptor (PDGFR)
T52624	TARGTYPE	Successful
T52624	SYNONYMS	Platelet-derived growth factor receptor tyrosine kinase; PDGFR kinase; PDGF-R
T52624	DRUGINFO	D0U5SC	CT-102	Approved
T52624	DRUGINFO	D0F0ZY	Pazopanib HCl	Approved
T52624	DRUGINFO	D09HNV	Intedanib	Approved
T52624	DRUGINFO	D0AZ3C	Imatinib	Approved
T52624	DRUGINFO	D0U2CV	Trapidil	Phase 4
T52624	DRUGINFO	D07OZR	TKI258	Phase 3
T52624	DRUGINFO	D0A1AQ	Rosiglitazone + metformin	Phase 3
T52624	DRUGINFO	D8AG3S	Vorolanib	Phase 2
T52624	DRUGINFO	D07NOI	BAY-57-9352	Phase 2
T52624	DRUGINFO	D0L2ZY	X-82	Phase 2
T52624	DRUGINFO	D0S6IA	PMID25623274-Compound-WO2014132220C2	Patented
T52624	DRUGINFO	D0Z4QJ	PMID25623274-Compound-WO2014132220C1	Patented
T52624	DRUGINFO	D00DQX	Motesanib	Discontinued in Phase 3
T52624	DRUGINFO	D01EFO	CGP-53716	Terminated
T52624	DRUGINFO	D08NYO	PDGF gene therapy	Investigative

T57361	TARGETID	T57361
T57361	FORMERID	TTDR00005
T57361	TARGNAME	Kallikrein-related peptidase (KLK)
T57361	TARGTYPE	Successful
T57361	SYNONYMS	Human kallikrein
T57361	BIOCLASS	Peptidase
T57361	DRUGINFO	D0V9ZG	Cetraxate	Approved
T57361	DRUGINFO	D0P5AE	Ecallantide	Approved
T57361	DRUGINFO	D0SH3I	Bortezomib	Approved
T57361	DRUGINFO	D0ND3F	LM-030	Phase 2
T57361	DRUGINFO	D02YUQ	Benzyl amine derivative 1	Patented
T57361	DRUGINFO	D0JO6Z	Benzyl amine derivative 2	Patented
T57361	DRUGINFO	D0QH9W	Heteroaryl-carboxamide derivative 11	Patented
T57361	DRUGINFO	D02MGJ	Benzoxazinone derivative 2	Patented

T65755	TARGETID	T65755
T65755	FORMERID	TTDC00297
T65755	TARGNAME	Histone deacetylase (HDAC)
T65755	TARGTYPE	Successful
T65755	SYNONYMS	Human histone deacetylase
T65755	FUNCTION	Responsible for the deacetylation of lysine residues on the n-terminal part of the core histones (H2a, H2b, H3 and H4). Histone deacetylation givesa tag for epigenetic repression and plays an important role in transcriptional regulation.
T65755	DRUGINFO	D0P2GK	Sodium phenylbutyrate	Approved
T65755	DRUGINFO	D0Y3KG	Valproate	Approved
T65755	DRUGINFO	D00SQN	HBI-8000	Registered
T65755	DRUGINFO	D0D2TZ	CMS-024-02	Phase 3
T65755	DRUGINFO	D0L2UQ	Pracinostat	Phase 3
T65755	DRUGINFO	D0V0SL	Abexinostat	Phase 3
T65755	DRUGINFO	D0B3FV	NVP-LAQ824	Phase 3
T65755	DRUGINFO	D0M8FD	SNDX-275	Phase 3
T65755	DRUGINFO	D0GH3Q	ITF2357	Phase 3
T65755	DRUGINFO	D00GIR	DAC-060	Phase 2
T65755	DRUGINFO	D00NBJ	Remetinostat	Phase 2
T65755	DRUGINFO	D05KED	Rocilinostat	Phase 2
T65755	DRUGINFO	D09XIZ	JNJ-26481585	Phase 2
T65755	DRUGINFO	D0N6AC	SHAPE	Phase 2
T65755	DRUGINFO	D0XT6W	PDX-101	Phase 2
T65755	DRUGINFO	D00FHR	MGCD-0103	Phase 2
T65755	DRUGINFO	D08VAR	APH-0812	Phase 2
T65755	DRUGINFO	D09RYU	Tractinostat	Phase 1/2
T65755	DRUGINFO	D0Q1SQ	EDO-S101	Phase 1/2
T65755	DRUGINFO	D39TVC	Tinostamustine	Phase 1/2
T65755	DRUGINFO	D0E6UZ	CUDC-907	Phase 1/2
T65755	DRUGINFO	D04ERQ	CXD-101	Phase 1
T65755	DRUGINFO	D04KMQ	GSK3117391	Phase 1
T65755	DRUGINFO	D07JBE	CG-200745	Phase 1
T65755	DRUGINFO	D0O3XS	GSK311739	Phase 1
T65755	DRUGINFO	D0Q1GL	CT-200	Phase 1
T65755	DRUGINFO	DZL3F8	VTR-297	Phase 1
T65755	DRUGINFO	DZU72C	OKI 179	Phase 1
T65755	DRUGINFO	D00SSZ	OBP-801	Phase 1
T65755	DRUGINFO	D01JPM	PMID28092474-Compound-33	Patented
T65755	DRUGINFO	D01LDP	Ampicidin analog 2	Patented
T65755	DRUGINFO	D0H2UJ	Ampicidin analog 1	Patented
T65755	DRUGINFO	D0RF1Z	PMID29671355-Compound-69	Patented
T65755	DRUGINFO	D0SO8W	PMID28092474-Compound-32	Patented
T65755	DRUGINFO	D0T7RJ	PMID28092474-Compound-34	Patented
T65755	DRUGINFO	D0TT4A	PMID29671355-Compound-53	Patented
T65755	DRUGINFO	D01KCA	PMID27376512-Compound-PG-11047	Patented
T65755	DRUGINFO	D02KWX	Indole-based analog 11	Patented
T65755	DRUGINFO	D06QPW	Aniline derivative 1	Patented
T65755	DRUGINFO	D08FOG	PMID27376512-Compound-PG-11048	Patented
T65755	DRUGINFO	D0M5DX	Oxazolyl methylthiothiazole derivative 1	Patented
T65755	DRUGINFO	D0G8NP	CS-00028	Preclinical
T65755	DRUGINFO	D0RO0T	MKC-1313	Terminated
T65755	DRUGINFO	D08PMD	N-(5-Hydroxycarbamoyl-pentyl)-benzamide	Investigative
T65755	DRUGINFO	D08VPK	Suberic bishydroxamic acid	Investigative
T65755	DRUGINFO	D0K7QR	ST-5732	Investigative
T65755	DRUGINFO	D0LK8U	CG-1521	Investigative
T65755	DRUGINFO	D0ME6Y	N-(5-Hydroxycarbamoyl-pentyl)-4-methoxy-benzamide	Investigative
T65755	DRUGINFO	D0NF6F	Trichostatin A	Investigative
T65755	DRUGINFO	D0P1HZ	CHAP1	Investigative
T65755	DRUGINFO	D0PQ5T	Azelaic bishydroxamic acid	Investigative
T65755	DRUGINFO	D0T3PR	Trifluoromethylketone	Investigative
T65755	DRUGINFO	D0W1PV	Apicidin	Investigative
T65755	DRUGINFO	D0X1CB	Trapoxin	Investigative
T65755	DRUGINFO	D0Y2DW	CHAP31	Investigative
T65755	DRUGINFO	D00HFS	N-Hydroxy-N'-(4-methylphenyl)octanediamide	Investigative
T65755	DRUGINFO	D01AMS	N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide	Investigative
T65755	DRUGINFO	D01ZMJ	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide	Investigative
T65755	DRUGINFO	D03BQS	N-hydroxy-9,10-dihydroanthracene-9-carboxamide	Investigative
T65755	DRUGINFO	D03QOD	N-hydroxy-2,2-diphenylacetamide	Investigative
T65755	DRUGINFO	D05GRZ	N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide	Investigative
T65755	DRUGINFO	D06IMY	N-hydroxy-9H-xanthene-9-carboxamide	Investigative
T65755	DRUGINFO	D08ICY	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide	Investigative
T65755	DRUGINFO	D08TIJ	N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide	Investigative
T65755	DRUGINFO	D0A4HF	2,2-bis(3-fluorophenyl)-N-hydroxyacetamide	Investigative
T65755	DRUGINFO	D0B8RC	N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide	Investigative
T65755	DRUGINFO	D0FN5D	2,2-bis(4-fluorophenyl)-N-hydroxyacetamide	Investigative
T65755	DRUGINFO	D0H7QA	N-Hydroxy-N'-(3-methylphenyl)octanediamide	Investigative
T65755	DRUGINFO	D0I4RK	N-hydroxy-2,2-diphenylpropanamide	Investigative
T65755	DRUGINFO	D0J3CY	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide	Investigative
T65755	DRUGINFO	D0L5KP	N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide	Investigative
T65755	DRUGINFO	D0L6YF	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide	Investigative
T65755	DRUGINFO	D0PK9V	2,2-bis(4-chlorophenyl)-N-hydroxyacetamide	Investigative
T65755	DRUGINFO	D0Q2CC	N-Hydroxy-N'-(2-methylphenyl)octanediamide	Investigative
T65755	DRUGINFO	D0SQ1F	N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide	Investigative
T65755	DRUGINFO	D04DOL	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	Investigative
T65755	DRUGINFO	D04UVL	N-(2-aminophenyl)nicotinamide	Investigative
T65755	DRUGINFO	D0M9LJ	N-(4-aminobiphenyl-3-yl)nicotinamide	Investigative
T65755	DRUGINFO	D0Q2GM	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	Investigative
T65755	DRUGINFO	D0YO6M	N-(2-aminophenyl)-4-methoxybenzamide	Investigative
T65755	DRUGINFO	D02NWS	4-Phenylbutyrohydroxamic acid	Investigative
T65755	DRUGINFO	D0S0WK	8-Oxo-8-phenyl-octanoic acid hydroxyamide	Investigative
T65755	DRUGINFO	D01YBR	ST-3050	Investigative
T65755	DRUGINFO	D07YZZ	Octanedioic acid bis-hydroxyamide	Investigative
T65755	DRUGINFO	D0N9AK	ST-2986	Investigative
T65755	DRUGINFO	D00KFF	9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide	Investigative
T65755	DRUGINFO	D00SEE	7-Mercapto-heptanoic acid phenylamide	Investigative
T65755	DRUGINFO	D00ZSD	6-benzenesulfinylhexanoic acid hydroxamide	Investigative
T65755	DRUGINFO	D01MFV	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	Investigative
T65755	DRUGINFO	D01XWZ	7-Mercapto-heptanoic acid biphenyl-4-ylamide	Investigative
T65755	DRUGINFO	D01XXN	N-Hydroxy-4-phenylacetylamino-benzamide	Investigative
T65755	DRUGINFO	D02MQM	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	Investigative
T65755	DRUGINFO	D02UTC	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	Investigative
T65755	DRUGINFO	D02WZK	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	Investigative
T65755	DRUGINFO	D04GGW	Octanedioic acid hydroxyamide pyridin-4-ylamide	Investigative
T65755	DRUGINFO	D04HSS	N-(6-Mercapto-hexyl)-benzamide	Investigative
T65755	DRUGINFO	D04NSP	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	Investigative
T65755	DRUGINFO	D04ZDI	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	Investigative
T65755	DRUGINFO	D05AHZ	6-benzenesulfonylhexanoic acid hydroxamide	Investigative
T65755	DRUGINFO	D05FEJ	9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one	Investigative
T65755	DRUGINFO	D05GVY	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	Investigative
T65755	DRUGINFO	D05LLX	4-Butyrylamino-N-hydroxy-benzamide	Investigative
T65755	DRUGINFO	D05VFP	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	Investigative
T65755	DRUGINFO	D05XAN	7-Mercapto-heptanoic acid biphenyl-3-ylamide	Investigative
T65755	DRUGINFO	D06IQB	5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione	Investigative
T65755	DRUGINFO	D06VBN	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	Investigative
T65755	DRUGINFO	D06XNP	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	Investigative
T65755	DRUGINFO	D07FJU	7-Mercapto-heptanoic acid pyridin-3-ylamide	Investigative
T65755	DRUGINFO	D09YBN	6-Phenoxy-hexane-1-thiol	Investigative
T65755	DRUGINFO	D09ZNU	4-Benzoylamino-N-hydroxy-benzamide	Investigative
T65755	DRUGINFO	D0A5LS	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	Investigative
T65755	DRUGINFO	D0AX7B	8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one	Investigative
T65755	DRUGINFO	D0B2ZJ	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	Investigative
T65755	DRUGINFO	D0B3ZM	6-Mercapto-hexanoic acid phenylamide	Investigative
T65755	DRUGINFO	D0C0VP	Cyclostellettamine derivative	Investigative
T65755	DRUGINFO	D0C2KD	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	Investigative
T65755	DRUGINFO	D0D2KE	5-Mercapto-pentanoic acid phenylamide	Investigative
T65755	DRUGINFO	D0E8KR	Octanedioic acid hydroxyamide pyridin-2-ylamide	Investigative
T65755	DRUGINFO	D0F0KS	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	Investigative
T65755	DRUGINFO	D0H1FZ	2-(methylsulfonylthio)ethyl 2-propylpentanoate	Investigative
T65755	DRUGINFO	D0KE3I	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	Investigative
T65755	DRUGINFO	D0QO0L	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	Investigative
T65755	DRUGINFO	D0R4BS	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	Investigative
T65755	DRUGINFO	D0R5VG	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	Investigative
T65755	DRUGINFO	D0RU1X	8-Oxo-8-phenyl-octanoic acid	Investigative
T65755	DRUGINFO	D0S7WQ	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	Investigative
T65755	DRUGINFO	D0S9JF	6-phenylsulfanylhexanoic acid hydroxamide	Investigative
T65755	DRUGINFO	D0T0SK	ST-2987	Investigative
T65755	DRUGINFO	D0T4IY	7-Mercapto-heptanoic acid quinolin-3-ylamide	Investigative
T65755	DRUGINFO	D0V2ZO	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	Investigative
T65755	DRUGINFO	D0XZ9Q	8-Mercapto-octanoic acid phenylamide	Investigative
T65755	DRUGINFO	D0YY9M	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	Investigative
T65755	DRUGINFO	D0Z3BM	7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one	Investigative
T65755	DRUGINFO	D0Z5KX	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	Investigative
T65755	DRUGINFO	D0Z7YS	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	Investigative
T65755	DRUGINFO	D0N0TS	PSAMMAPLIN A	Investigative

T92308	TARGETID	T92308
T92308	FORMERID	TTDS00312
T92308	TARGNAME	DNA [cytosine-5]-methyltransferase (DNMT)
T92308	TARGTYPE	Successful
T92308	SYNONYMS	DNA MTase
T92308	FUNCTION	This methylase recognizes the double-stranded sequence ccwgg, causes specific methylation on c-2 on both strands.
T92308	DRUGINFO	D09FAZ	Azacitidine	Approved
T92308	DRUGINFO	D0NH3R	ASTX727	Phase 3
T92308	DRUGINFO	D0A2BO	S-110	Phase 3
T92308	DRUGINFO	D07SDQ	Curcumin	Phase 3
T92308	DRUGINFO	D04LBL	PMID27376512-Compound-MTC-434	Patented
T92308	DRUGINFO	D05NMG	PMID27376512-Compound-CROs	Patented
T92308	DRUGINFO	D01KCA	PMID27376512-Compound-PG-11047	Patented
T92308	DRUGINFO	D08FOG	PMID27376512-Compound-PG-11048	Patented
T92308	DRUGINFO	D01VNN	NSC-622444	Investigative
T92308	DRUGINFO	D03PWU	NSC-138419	Investigative
T92308	DRUGINFO	D06RGX	NSC-319745	Investigative
T92308	DRUGINFO	D06VVV	NSC-348926	Investigative
T92308	DRUGINFO	D07VWC	NSC-401077	Investigative
T92308	DRUGINFO	D08TGQ	S-tubercidinylhomocysteine	Investigative
T92308	DRUGINFO	D0A2ZH	NSC-106084	Investigative
T92308	DRUGINFO	D0C4NA	NSC-154957	Investigative
T92308	DRUGINFO	D0FN7C	NSC-54162	Investigative
T92308	DRUGINFO	D0G9NS	NSC-57893	Investigative
T92308	DRUGINFO	D0H1YK	NSC-56071	Investigative
T92308	DRUGINFO	D0I5JP	NSC-137546	Investigative
T92308	DRUGINFO	D0LS2U	NSC-623548	Investigative
T92308	DRUGINFO	D0MP7N	NSC-345763	Investigative
T92308	DRUGINFO	D0W5SZ	NSC-158324	Investigative
T92308	DRUGINFO	D09CLP	(L-)-S-adenosyl-L-homocysteine	Investigative
T92308	DRUGINFO	D0J5VK	NSC-622445	Investigative

T85605	TARGETID	T85605
T85605	FORMERID	TTDS00097
T85605	TARGNAME	5-HT receptor (5HTR)
T85605	TARGTYPE	Successful
T85605	SYNONYMS	5-Hydroxytryptamine receptor
T85605	BIOCLASS	GPCR rhodopsin
T85605	DRUGINFO	D06OSM	Tandospirone	Approved
T85605	DRUGINFO	D06XZR	Pizotyline	Approved
T85605	DRUGINFO	D07YWY	Nafronyl	Approved
T85605	DRUGINFO	D0B3UJ	Paliperidone	Approved
T85605	DRUGINFO	D0RA9E	Ramosetron	Approved
T85605	DRUGINFO	D0UA0I	Metergolin	Approved
T85605	DRUGINFO	D09WNK	Fenfluramine	Phase 3
T85605	DRUGINFO	D0Q0EF	ITI-007	Phase 3
T85605	DRUGINFO	D0H4GU	EPX-200	Phase 2
T85605	DRUGINFO	D0X4PP	EPX-300	Phase 2
T85605	DRUGINFO	D0A8QM	Lu-AA34893	Phase 2
T85605	DRUGINFO	DS31JZ	SEP--4199	Phase 2
T85605	DRUGINFO	D0Z4FE	MIN-117	Phase 2
T85605	DRUGINFO	D00BND	BF-1	Phase 1
T85605	DRUGINFO	D07YKQ	EPX-100	Phase 1
T85605	DRUGINFO	D0Y8RS	DSP-6745	Phase 1
T85605	DRUGINFO	D0K8NW	Ritanserin	Discontinued in Phase 3
T85605	DRUGINFO	D01DRL	RGH-2721	Terminated
T85605	DRUGINFO	D00TRL	REV-598	Terminated
T85605	DRUGINFO	D09XYA	SB 203106	Investigative
T85605	DRUGINFO	D0F0UA	MCI	Investigative
T85605	DRUGINFO	D0R1RK	EpiCept	Investigative

T25663	TARGETID	T25663
T25663	FORMERID	TTDS00185
T25663	TARGNAME	Adenosine receptor (ADOR)
T25663	TARGTYPE	Successful
T25663	SYNONYMS	P1 receptor
T25663	BIOCLASS	GPCR rhodopsin
T25663	DRUGINFO	D0F8RA	Theophylline	Approved
T25663	DRUGINFO	D0LJ4E	NIR178	Phase 2
T25663	DRUGINFO	D0UF2N	DIADENOSINE TETRAPHOSPHATE	Phase 2
T25663	DRUGINFO	D0F7XN	M-216765	Terminated
T25663	DRUGINFO	D09QLB	8-sulfophenyl theophylline	Investigative
T25663	DRUGINFO	D0X7AZ	SPT	Investigative
T25663	DRUGINFO	D0K0OT	GNF-PF-2224	Investigative

T31424	TARGETID	T31424
T31424	FORMERID	TTDS00031
T31424	TARGNAME	Adrenergic receptor Alpha-2 (ADRA2)
T31424	TARGTYPE	Successful
T31424	SYNONYMS	Alpha-2 adrenergic receptor; Alpha(2)-adrenoceptor
T31424	BIOCLASS	GPCR rhodopsin
T31424	DRUGINFO	D00UYE	Meperidine	Approved
T31424	DRUGINFO	D01MDT	Tizanidine	Approved
T31424	DRUGINFO	D04YZL	Sodium chloride	Approved
T31424	DRUGINFO	D09EBS	Oxymetazoline	Approved
T31424	DRUGINFO	D0F7NZ	Guanidine Hydrochloride	Approved
T31424	DRUGINFO	D0H4JM	Yohimbine	Approved
T31424	DRUGINFO	D0L4HY	Guanabenz	Approved
T31424	DRUGINFO	D0MT0M	Apraclonidine	Approved
T31424	DRUGINFO	D0U3DU	Dexmedetomidine	Approved
T31424	DRUGINFO	D0V2GH	Nicergoline	Approved
T31424	DRUGINFO	D0Y6KO	Methyldopate Hydrochloride	Approved
T31424	DRUGINFO	D03SKR	Clonidine	Approved
T31424	DRUGINFO	D0AE3X	Brimonidine	Approved
T31424	DRUGINFO	D0K0MW	Lofexidine	Approved
T31424	DRUGINFO	D07ILQ	Guanfacine extended release	Approved
T31424	DRUGINFO	D05LGX	Fipamezole	Phase 2
T31424	DRUGINFO	D0U1NA	Fadolmidine	Phase 2
T31424	DRUGINFO	D0V1RX	Mivazerol	Discontinued in Phase 3
T31424	DRUGINFO	D05OVC	Atipamezole	Discontinued in Phase 2
T31424	DRUGINFO	D0N8UU	ADX415	Terminated
T31424	DRUGINFO	D00ARM	Brominide tartrate	Investigative
T31424	DRUGINFO	D0Z7EA	[3H]rauwolscine	Investigative

T87467	TARGETID	T87467
T87467	FORMERID	TTDS00489
T87467	TARGNAME	Folate receptor (FOLR)
T87467	TARGTYPE	Successful
T87467	SYNONYMS	FR; FOLR
T87467	FUNCTION	Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate to the interior of cells. Isoform short does not bind folate.
T87467	BIOCLASS	Folate receptor
T87467	DRUGINFO	D0H2QO	Tetrahydrofolic acid	Approved
T87467	DRUGINFO	D0Z0DW	Folic Acid	Approved

T71398	TARGETID	T71398
T71398	FORMERID	TTDS00443
T71398	TARGNAME	Guanylate cyclase (GC)
T71398	TARGTYPE	Successful
T71398	SYNONYMS	Guanylyl Cyclase
T71398	BIOCLASS	Phosphorus-oxygen lyase
T71398	DRUGINFO	D06IZM	Erythrityl Tetranitrate	Approved
T71398	DRUGINFO	D0I1SK	Isosorbide Dinitrate	Approved
T71398	DRUGINFO	D0YS7D	Isosorbide Mononitrate	Approved
T71398	DRUGINFO	D09NYS	Methylene blue	Approved
T71398	DRUGINFO	D0A5FM	Nitric Oxide	Approved
T71398	DRUGINFO	D0O2AG	Pirsidomine	Phase 2
T71398	DRUGINFO	D2SPH4	IW-1701	Phase 2

T45598	TARGETID	T45598
T45598	FORMERID	TTDI01799
T45598	TARGNAME	Interferon alpha (IFNA)
T45598	TARGTYPE	Successful
T45598	SYNONYMS	IFN-A
T45598	FUNCTION	Produced by macrophages, IFN-alpha have antiviral activities. Interferon stimulates the production of two enzymes: a protein kinase and an oligoadenylate synthetase.
T45598	DRUGINFO	D07CMM	Interferon alfa-n3	Approved
T45598	DRUGINFO	D0L7QB	Alfaferone	Approved
T45598	DRUGINFO	DA74SC	P1101	Phase 3
T45598	DRUGINFO	D00QGV	Human interferon alpha oral	Phase 2
T45598	DRUGINFO	D02JDN	IFN-alpha	Phase 2
T45598	DRUGINFO	D0H5ES	Rontalizumab	Phase 2
T45598	DRUGINFO	D0U7SU	Interferon-alpha lozenge	Phase 2
T45598	DRUGINFO	D0V0HU	IFN alpha kinoid	Phase 1/2
T45598	DRUGINFO	D03BLG	AGS-009	Phase 1
T45598	DRUGINFO	D03QWG	Ad-IFN-alpha	Phase 1
T45598	DRUGINFO	D1A8NU	NG-641	Phase 1
T45598	DRUGINFO	D05TGV	PEG-Infergen	Discontinued in Phase 2
T45598	DRUGINFO	D0I8NM	Gene therapy, IFN-alpha	Terminated
T45598	DRUGINFO	D0Q5MU	R-7025	Terminated

T33754	TARGETID	T33754
T33754	FORMERID	TTDS00200
T33754	TARGNAME	Phosphodiesterase 3 (PDE3)
T33754	TARGTYPE	Successful
T33754	SYNONYMS	Phosphodiesterase III; PDE3; Cyclic GMP inhibited phosphodiesterase; Cyclic AMP phosphodiesterase III; CGI-PDE; CAMP phosphodiesterase III
T33754	BIOCLASS	Phosphoric diester hydrolase
T33754	DRUGINFO	D03ZBN	Olprinone	Approved
T33754	DRUGINFO	D0R6TI	Inamrinone Lactate	Approved
T33754	DRUGINFO	D0Y9ZE	Milrinone	Approved
T33754	DRUGINFO	D03QJL	Ibudilast	Approved
T33754	DRUGINFO	D03VPC	Cilostazol	Approved
T33754	DRUGINFO	D0B0SH	Oxtriphylline	Approved
T33754	DRUGINFO	D0E0SW	Enoximone	Approved
T33754	DRUGINFO	D08VHG	RPL-554	Phase 2
T33754	DRUGINFO	D09PLF	Org-30029	Phase 2
T33754	DRUGINFO	D0S4SX	K-134	Phase 2
T33754	DRUGINFO	D0Q7UG	Tipelukast	Phase 2
T33754	DRUGINFO	DB82TO	Tofisopam	Phase 2
T33754	DRUGINFO	D02ADC	SDZ-MKS-492	Phase 1
T33754	DRUGINFO	D0F7NT	349U85.HCL	Phase 1
T33754	DRUGINFO	D05YAS	Tolafentrine	Discontinued in Phase 2
T33754	DRUGINFO	D06PQR	OPC-8490	Discontinued in Phase 2
T33754	DRUGINFO	D0LC2B	NSP-805	Discontinued in Phase 2
T33754	DRUGINFO	D0S8DB	Org-9731	Discontinued in Phase 2
T33754	DRUGINFO	D0V7IS	Pumafentrine	Discontinued in Phase 2
T33754	DRUGINFO	D0J4WW	NIP-520	Discontinued in Phase 1
T33754	DRUGINFO	D0W0TH	R 80122	Discontinued in Phase 1
T33754	DRUGINFO	D0F0CS	ZARDAVERINE	Terminated
T33754	DRUGINFO	D0J5UC	SDZ-ISQ-844	Terminated
T33754	DRUGINFO	D0N6OE	Benafentrine dimaleate	Terminated
T33754	DRUGINFO	D0PB6P	Org-9935	Terminated
T33754	DRUGINFO	D0Q7VI	Siguazodan	Terminated
T33754	DRUGINFO	D0Z4VA	UD-CG-212	Terminated
T33754	DRUGINFO	D0J0CB	Cilostamide	Investigative

T23761	TARGETID	T23761
T23761	FORMERID	TTDS00517
T23761	TARGNAME	Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A)
T23761	TARGTYPE	Successful
T23761	SYNONYMS	SERCA pump; SERCA; Calcium-transporting ATPase; Calcium pump; Ca2+-ATPase; Ca(2+)-ATPase; ATP4
T23761	BIOCLASS	Acid anhydrides hydrolase
T23761	DRUGINFO	D00ZTD	OZ277	Approved
T23761	DRUGINFO	D0D4JO	Artesunate	Approved
T23761	DRUGINFO	D0E0KQ	Pyronaridine	Approved
T23761	DRUGINFO	D0N6FH	Dihydroartemisinin	Approved
T23761	DRUGINFO	D0P0SZ	Piperaquine	Approved
T23761	DRUGINFO	D03KEK	Artemisinin SP	Approved
T23761	DRUGINFO	D0S3WH	Artemisinin	Approved
T23761	DRUGINFO	D08NCO	Vanadate	Phase 3
T23761	DRUGINFO	D02KGR	THAPSIGARGIN	Preclinical
T23761	DRUGINFO	D0K6HL	Cyclopiazonic acid	Investigative

T82266	TARGETID	T82266
T82266	FORMERID	TTDS00160
T82266	TARGNAME	Voltage-gated L-type calcium channel (L-CaC)
T82266	TARGTYPE	Successful
T82266	SYNONYMS	L-type voltage-dependent Ca(2+) channel; L-type Ca2+ channel; L-type Ca(2+) channel
T82266	BIOCLASS	Voltage-gated ion channel
T82266	DRUGINFO	D04OSE	Nifedipine	Approved
T82266	DRUGINFO	D0K8CI	Otilonium bromide	Approved
T82266	DRUGINFO	D03KOZ	Epalrestat	Approved
T82266	DRUGINFO	D09ELP	Clevidipine butyrate	Approved
T82266	DRUGINFO	D0I2WV	Levamlodipine	Phase 4
T82266	DRUGINFO	D0J1NQ	Pinaverium bromide	Phase 3
T82266	DRUGINFO	D0N3SR	Cilnidipine	Phase 3
T82266	DRUGINFO	D08UQS	MEM-1003	Phase 2a
T82266	DRUGINFO	D0K4QT	BAY-Y-5959	Phase 2
T82266	DRUGINFO	D00ERV	Gallopamil	Phase 2
T82266	DRUGINFO	D0X9VP	Furnidipine	Discontinued in Phase 3
T82266	DRUGINFO	D01RAD	Bay K 8644	Investigative
T82266	DRUGINFO	D02LIY	Euro-Celtique 2	Investigative
T82266	DRUGINFO	D03IVC	S 202 791	Investigative
T82266	DRUGINFO	D05BLQ	Neuromed 2	Investigative
T82266	DRUGINFO	D06PJK	Euro-Celtique 3	Investigative
T82266	DRUGINFO	D07APX	Neuromed 5	Investigative
T82266	DRUGINFO	D08UEJ	Ajinomoto 2	Investigative
T82266	DRUGINFO	D08ZSQ	Parke-Davis 1	Investigative
T82266	DRUGINFO	D09TRN	Dihydropyridines	Investigative
T82266	DRUGINFO	D0A6MS	Parke-Davis 9	Investigative
T82266	DRUGINFO	D0M3ON	Euro-Celtique 4	Investigative
T82266	DRUGINFO	D0PE8P	PD173212	Investigative
T82266	DRUGINFO	D0Q8TX	Ajinomoto 1	Investigative
T82266	DRUGINFO	D0S6YO	Ajinomoto 3	Investigative
T82266	DRUGINFO	D0T3CB	Ono 1	Investigative
T82266	DRUGINFO	D0UB0T	PD176078	Investigative
T82266	DRUGINFO	D0V8ZD	SQ32,910	Investigative
T82266	DRUGINFO	D0V9MO	Ono 3	Investigative
T82266	DRUGINFO	D0Y9OS	Euro-Celtique 1	Investigative
T82266	DRUGINFO	D03UJT	[3H](-)devapamil	Investigative

T23003	TARGETID	T23003
T23003	FORMERID	TTDI01775
T23003	TARGNAME	MAPK/ERK kinase kinase (MAP3K)
T23003	TARGTYPE	Successful
T23003	FUNCTION	Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERK cascade, and catalyze the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in the extracellular signal-regulated kinases MAPK3/ERK1 and MAPK1/ERK2, leadingto their activation and further transduction of the signal within the MAPK/ERK cascade. Depending on the cellular context, this pathway mediates diverse biological functions such as cell growth, adhesion, survival and differentiation, predominantly through the regulation of transcription, metabolism and cytoskeletal rearrangements. One target of the MAPK/ERK cascade is peroxisome proliferator- activated receptor gamma (PPARG), a nuclear receptor that promotes differentiation and apoptosis. MAP2K1/MEK1 has been shown to export PPARG from the nucleus. The MAPK/ERK cascade is also involved in the regulation of endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC), as well as in the fragmentation of the Golgi apparatus during mitosis.
T23003	BIOCLASS	Kinase
T23003	DRUGINFO	D04XVN	Trametinib	Approved
T23003	DRUGINFO	D0C4LF	ARRY-162	Approved
T23003	DRUGINFO	D03SKL	BAY 86-9766	Phase 3
T23003	DRUGINFO	D0T5DP	Selumetinib	Phase 3
T23003	DRUGINFO	D01CNB	E6201	Phase 2
T23003	DRUGINFO	D03CHM	MSC1936369B	Phase 2
T23003	DRUGINFO	D0K0YC	PD-0325901	Phase 2
T23003	DRUGINFO	D0M6BD	RO-5126766	Phase 2
T23003	DRUGINFO	D0O4QS	WX-554	Phase 1/2
T23003	DRUGINFO	D05NLD	ARRY-300	Phase 1
T23003	DRUGINFO	D0I3RD	TAK-733	Phase 1
T23003	DRUGINFO	D08DCP	BI-847325	Phase 1
T23003	DRUGINFO	D06EFW	RG7304	Phase 1
T23003	DRUGINFO	D09GHB	RO-4987655	Discontinued in Phase 1
T23003	DRUGINFO	D0P0HI	AZD8330	Discontinued in Phase 1
T23003	DRUGINFO	D0ZG1Y	RG-7167	Discontinued in Phase 1
T23003	DRUGINFO	D04WPA	SL-327	Investigative
T23003	DRUGINFO	D0HR5Q	CIP-137401	Investigative
T23003	DRUGINFO	D0K3ES	MEK inhibitor I	Investigative
T23003	DRUGINFO	D0M7IG	RO-4920506	Investigative
T23003	DRUGINFO	D0TY0P	G-573	Investigative
T23003	DRUGINFO	D0V0QJ	NSC-686549	Investigative

T96721	TARGETID	T96721
T96721	FORMERID	TTDS00339
T96721	UNIPROID	VEGFA_HUMAN; VEGFB_HUMAN; VEGFC_HUMAN; VEGFD_HUMAN
T96721	TARGNAME	Vascular endothelial growth factor (VEGF)
T96721	TARGTYPE	Successful
T96721	SYNONYMS	Vascular endothelial cell growth factor
T96721	BIOCLASS	Growth factor
T96721	DRUGINFO	D5DO9L	Brolucizumab	Approved
T96721	DRUGINFO	D02MUA	PF-06439535	Phase 3
T96721	DRUGINFO	D2KVG4	TRS003	Phase 3
T96721	DRUGINFO	D4Z5CU	M710	Phase 3
T96721	DRUGINFO	D7GYE9	SB15	Phase 3
T96721	DRUGINFO	D8F6PB	FKB238	Phase 3
T96721	DRUGINFO	DO7QK1	KSI-301	Phase 3
T96721	DRUGINFO	DYH3Q6	MYL-1402O	Phase 3
T96721	DRUGINFO	D07PVB	Squalamine	Phase 3
T96721	DRUGINFO	D0B1VZ	ALG-1001	Phase 2
T96721	DRUGINFO	D0GP9Q	TG100801	Phase 2
T96721	DRUGINFO	D0X3QR	AVA-101	Phase 2
T96721	DRUGINFO	DMEV15	Dilpacimab	Phase 2
T96721	DRUGINFO	D09HFJ	NM-3	Phase 1
T96721	DRUGINFO	D0U6XE	PAN-90806	Phase 1
T96721	DRUGINFO	D0V7QO	BI-836880	Phase 1
T96721	DRUGINFO	D0PP6A	ABT-165	Phase 1
T96721	DRUGINFO	D57NHD	Zifibancimig	Phase 1
T96721	DRUGINFO	D62LKT	BI 836880	Phase 1
T96721	DRUGINFO	DIPY14	NOV1501	Phase 1
T96721	DRUGINFO	D0N1RE	BIBF100	Investigative

T11822	TARGETID	T11822
T11822	FORMERID	TTDS00072
T11822	TARGNAME	Retinoic acid receptor (RAR)
T11822	TARGTYPE	Successful
T11822	SYNONYMS	Retinoic acid receptor
T11822	DRUGINFO	D00DKK	Isotretinoin	Approved
T11822	DRUGINFO	D0JC9N	Adapalene	Approved
T11822	DRUGINFO	D02DGU	Tretinoin	Approved
T11822	DRUGINFO	D0S7WX	Vitamin A	Approved
T11822	DRUGINFO	D05TOJ	Peretinoin	Phase 3
T11822	DRUGINFO	D07PTH	13-cis-retinoic acid	Phase 3
T11822	DRUGINFO	D08JAC	Fenretinide	Phase 3
T11822	DRUGINFO	D0D0QQ	Velac Gel	Phase 3
T11822	DRUGINFO	D0I9HG	Amsilarotene	Phase 2
T11822	DRUGINFO	D04DAL	LAS-41001	Discontinued in Preregistration
T11822	DRUGINFO	D0T0LE	IRX-4310	Discontinued in Phase 3
T11822	DRUGINFO	D08GRF	LG-1550	Discontinued in Phase 2
T11822	DRUGINFO	D0W9JH	BMY-30123	Discontinued in Phase 2
T11822	DRUGINFO	D0Y8IF	MX-781	Terminated

T43415	TARGETID	T43415
T43415	FORMERID	TTDC00316
T43415	TARGNAME	Tyrosine-protein kinase (PTK)
T43415	TARGTYPE	Successful
T43415	SYNONYMS	Protein-tyrosine kinase; PTK
T43415	DRUGINFO	D0Y7IC	Baricitinib	Approved
T43415	DRUGINFO	D0MW0N	Masitinib	Phase 3
T43415	DRUGINFO	D06EIC	ASP-015K	Phase 3
T43415	DRUGINFO	D05UGH	LEO 124249	Phase 2
T43415	DRUGINFO	D0CG0K	ATI-502	Phase 2
T43415	DRUGINFO	D06WRF	KD019	Phase 2
T43415	DRUGINFO	D0Z1QR	TD-1473	Phase 1
T43415	DRUGINFO	D04XNL	Ruxolitinib derivative 1	Patented
T43415	DRUGINFO	D05PDI	Tetra-cyclic compound 1	Patented
T43415	DRUGINFO	D0D8MK	PMID27774822-Compound-Figure10CompoundA	Patented
T43415	DRUGINFO	D0GH8D	PMID27774822-Compound-Figure10Example1	Patented
T43415	DRUGINFO	D07PTU	Imidazo[4,5-c]pyridine derivative 1	Patented
T43415	DRUGINFO	D09ALF	Aminotriazolopyridine derivative 1	Patented
T43415	DRUGINFO	D0VJ1R	Imidazo[4,5-c]pyridine derivative 2	Patented
T43415	DRUGINFO	D0YR8S	PMID27774824-Compound-Figure11Example1up	Patented
T43415	DRUGINFO	D0D5CJ	SDZ-LAP-977	Discontinued in Phase 2
T43415	DRUGINFO	D06BUI	PN-355	Discontinued in Phase 1
T43415	DRUGINFO	D06KJG	CLX-0301	Terminated
T43415	DRUGINFO	D0HV6O	AP-23588	Terminated

T69494	TARGETID	T69494
T69494	FORMERID	TTDS00135
T69494	TARGNAME	N-methyl-D-aspartate receptor (NMDAR)
T69494	TARGTYPE	Successful
T69494	SYNONYMS	NMDA-R
T69494	DRUGINFO	D00ENY	L-Glutamic Acid	Approved
T69494	DRUGINFO	D01JEU	Memantine	Approved
T69494	DRUGINFO	D02LDN	Magnesium Sulfate	Approved
T69494	DRUGINFO	D05KON	Felbamate	Approved
T69494	DRUGINFO	D0B8QB	Magnesium	Approved
T69494	DRUGINFO	D0D9FV	Orphenadrine	Approved
T69494	DRUGINFO	D0O8DI	Nitrous oxide	Approved
T69494	DRUGINFO	D0T5UL	Benzphetamine	Approved
T69494	DRUGINFO	D0UM7O	Ketamine	Approved
T69494	DRUGINFO	D06XWB	Huperzine A	Approved
T69494	DRUGINFO	D0T3HY	Levorphanol	Approved
T69494	DRUGINFO	D02WFK	Cycloserine	Approved
T69494	DRUGINFO	D01YVZ	GLYX-13	Phase 3
T69494	DRUGINFO	D05JET	Remacemide	Phase 3
T69494	DRUGINFO	D0F1UZ	Amitriptyline+ketamine	Phase 3
T69494	DRUGINFO	D0QNS3	REL-1017	Phase 3
T69494	DRUGINFO	D0TP5H	Esketamine	Phase 3
T69494	DRUGINFO	D0Y9RO	Dexanabinol	Phase 3
T69494	DRUGINFO	D3PD8C	AXS-05	Phase 3
T69494	DRUGINFO	D0M9EV	NBTX-001	Phase 2/3
T69494	DRUGINFO	D00YLM	TRAXOPRODIL MESYLATE	Phase 2
T69494	DRUGINFO	D01KMR	Neramexane	Phase 2
T69494	DRUGINFO	D03RHZ	MDL-27192	Phase 2
T69494	DRUGINFO	D03ZLR	Apimostinel	Phase 2
T69494	DRUGINFO	D09BEG	CNS-5161	Phase 2
T69494	DRUGINFO	D0T9DN	Dimiracetam	Phase 2
T69494	DRUGINFO	D0U0AY	AV-101	Phase 2
T69494	DRUGINFO	D0U2TZ	NYX-2925	Phase 2
T69494	DRUGINFO	D12THW	AGN-241751	Phase 2
T69494	DRUGINFO	D3IK7O	NYX-783	Phase 2
T69494	DRUGINFO	DB18SE	SAGE-718	Phase 2
T69494	DRUGINFO	DB8V4Z	NYX-458	Phase 2
T69494	DRUGINFO	DI54FM	SAGE‐718	Phase 2
T69494	DRUGINFO	DLG95A	NYX-2925	Phase 2
T69494	DRUGINFO	DNI61P	CP101	Phase 2
T69494	DRUGINFO	D0J8RR	Dextromethorphan+quinidine	Phase 2
T69494	DRUGINFO	D04RCT	CHF-3381	Phase 2
T69494	DRUGINFO	D06YUM	AZD6423	Phase 1
T69494	DRUGINFO	D0AY8D	NBXT-001+Nobilis inhalation device	Phase 1
T69494	DRUGINFO	D0F9AO	BHV-5000	Phase 1
T69494	DRUGINFO	D0L1UH	ASP-0777	Phase 1
T69494	DRUGINFO	D03JRO	ADCI	Phase 1
T69494	DRUGINFO	D0H1FV	Selfotel	Discontinued in Phase 3
T69494	DRUGINFO	D0HK7R	Midafotel	Discontinued in Phase 3
T69494	DRUGINFO	D0G2GT	SGS-111	Discontinued in Phase 2
T69494	DRUGINFO	D0N4YX	EAA-090	Discontinued in Phase 2
T69494	DRUGINFO	D0OK9X	AZD6765	Discontinued in Phase 2
T69494	DRUGINFO	D06DLQ	CGP-37849	Discontinued in Phase 1
T69494	DRUGINFO	D0MF9H	Delucemine	Discontinued in Phase 1
T69494	DRUGINFO	D0P1YH	S-1746	Discontinued in Phase 1
T69494	DRUGINFO	D04BXJ	ED-1812	Preclinical
T69494	DRUGINFO	D04MMJ	ADX-2 series	Preclinical
T69494	DRUGINFO	D09HDV	AD-529	Preclinical
T69494	DRUGINFO	D00MFY	GPI-3000	Terminated
T69494	DRUGINFO	D02OTH	FR-115427	Terminated
T69494	DRUGINFO	D03HDP	ACEA-1416	Terminated
T69494	DRUGINFO	D03RZU	CNS-5788	Terminated
T69494	DRUGINFO	D04LIR	PD-159913	Terminated
T69494	DRUGINFO	D07GLX	CNS-1531	Terminated
T69494	DRUGINFO	D09OTF	ACEA-1031	Terminated
T69494	DRUGINFO	D0KJ4U	ACEA-1011	Terminated
T69494	DRUGINFO	D0N5YX	PD-158473	Terminated
T69494	DRUGINFO	D0O4JH	ACEA-1328	Terminated
T69494	DRUGINFO	D0Q3SP	NPS-1392	Terminated
T69494	DRUGINFO	D0X6PG	LY-274614	Terminated
T69494	DRUGINFO	D02NVF	M-241247	Terminated
T69494	DRUGINFO	D0S0VZ	IDRA-21	Terminated
T69494	DRUGINFO	D0AZ5V	L-698544	Terminated
T69494	DRUGINFO	D03UNN	L-689560	Terminated
T69494	DRUGINFO	D01HTH	Aptiganel HCl	Investigative
T69494	DRUGINFO	D0T6NS	ACPC	Investigative

T99031	TARGETID	T99031
T99031	FORMERID	TTDC00164
T99031	TARGNAME	ERK activator kinase (MEK)
T99031	TARGTYPE	Successful
T99031	SYNONYMS	MEK; MAPKK; MAP kinase kinase
T99031	DRUGINFO	D0C4LF	ARRY-162	Approved
T99031	DRUGINFO	DHM3X5	NFX-179	Phase 2
T99031	DRUGINFO	DJ8TN2	HL-085	Phase 1/2
T99031	DRUGINFO	D0R3VK	GDC-0623	Phase 1
T99031	DRUGINFO	DL5UR0	BI 3011441	Phase 1
T99031	DRUGINFO	D06EFW	RG7304	Phase 1
T99031	DRUGINFO	D01GWS	Pyridinone compound 1	Patented
T99031	DRUGINFO	D03WFE	Quinazolines and azaquinazoline derivative 1	Patented
T99031	DRUGINFO	D05VVZ	PMID28594589-Compound-TABLE3C2	Patented
T99031	DRUGINFO	D0A8KL	Benzoheterocyclic compound 1	Patented
T99031	DRUGINFO	D0DB3L	Benzoimidazole derivative 1	Patented
T99031	DRUGINFO	D0J7DA	PMID28594589-Compound-TABLE3C12	Patented
T99031	DRUGINFO	D0K6HD	Azetidine derivative 2	Patented
T99031	DRUGINFO	D0KV2U	P-toluenesulfonate derivative 1	Patented
T99031	DRUGINFO	D0OR2V	N-(arylamino)sulfonamide derivative 1	Patented
T99031	DRUGINFO	D0PK6X	Pyridopyrimidine derivative 1	Patented
T99031	DRUGINFO	D0R8DW	Benzoimidazole derivative 2	Patented
T99031	DRUGINFO	D0UU5N	PMID28594589-Compound-TABLE3C14	Patented
T99031	DRUGINFO	D0V3MX	PMID28594589-Compound-TABLE3C1	Patented

T15117	TARGETID	T15117
T15117	FORMERID	TTDNS00566
T15117	TARGNAME	Adrenergic receptor (ADR)
T15117	TARGTYPE	Successful
T15117	SYNONYMS	Adrenoceptor
T15117	BIOCLASS	GPCR rhodopsin
T15117	DRUGINFO	D05ZSB	Ovine corticotropin-releasing hormone	Approved
T15117	DRUGINFO	D06REO	Befunolol hci	Approved
T15117	DRUGINFO	D07QLG	Oxilofrine	Approved
T15117	DRUGINFO	D0AY7K	Celiprolol hcl	Approved
T15117	DRUGINFO	D0Q2WS	Terbutyline	Approved
T15117	DRUGINFO	D0U3CR	Guanadrel Sulfate	Approved
T15117	DRUGINFO	D01FDL	Dabelotine	Phase 3
T15117	DRUGINFO	D0MY3C	AR08	Phase 2
T15117	DRUGINFO	D0E7FT	PMID30124346-Compound-60TABLE5	Patented
T15117	DRUGINFO	D01MXV	Etilefrine	Withdrawn from market
T15117	DRUGINFO	D01DQR	AIR-Epinephrine	Discontinued in Phase 1

T34743	TARGETID	T34743
T34743	FORMERID	TTDS00213
T34743	TARGNAME	Bacterial Penicillin binding protein (Bact PBP)
T34743	TARGTYPE	Successful
T34743	FUNCTION	Cell wall formation.
T34743	DRUGINFO	D00HWO	Cyclacillin	Approved
T34743	DRUGINFO	D00XHD	Balofloxacin	Approved
T34743	DRUGINFO	D01BQC	Cefonicid	Approved
T34743	DRUGINFO	D01DSP	Cephapirin	Approved
T34743	DRUGINFO	D01ZEC	Cefacetrile	Approved
T34743	DRUGINFO	D02IIE	Penicillin V Potassium	Approved
T34743	DRUGINFO	D02MZY	Cefpiramide	Approved
T34743	DRUGINFO	D02TBI	Carbenicillin	Approved
T34743	DRUGINFO	D02VFC	Cefoxitin	Approved
T34743	DRUGINFO	D04CFW	Bacampicillin	Approved
T34743	DRUGINFO	D04KAQ	Pivampicillin	Approved
T34743	DRUGINFO	D04KTZ	Cloxacillin	Approved
T34743	DRUGINFO	D04ZAH	Piperacillin	Approved
T34743	DRUGINFO	D05JDR	Ceftibuten	Approved
T34743	DRUGINFO	D06KKS	Cefradine	Approved
T34743	DRUGINFO	D06OUL	Ceforanide	Approved
T34743	DRUGINFO	D06OVY	Cefixime	Approved
T34743	DRUGINFO	D06TQZ	Meticillin	Approved
T34743	DRUGINFO	D06YHL	Cefamandole	Approved
T34743	DRUGINFO	D07ACT	Ceftriaxone	Approved
T34743	DRUGINFO	D07WZH	Cephaloglycin	Approved
T34743	DRUGINFO	D08HDY	Pivmecillinam	Approved
T34743	DRUGINFO	D08USU	Ticarcillin	Approved
T34743	DRUGINFO	D09CPR	Penicillin V	Approved
T34743	DRUGINFO	D09KDN	Cefazolin	Approved
T34743	DRUGINFO	D0A0JH	Nafcillin	Approved
T34743	DRUGINFO	D0A5LH	Penicillin G Procaine	Approved
T34743	DRUGINFO	D0AP9T	Cefotetan	Approved
T34743	DRUGINFO	D0C2YB	Cefoperazone	Approved
T34743	DRUGINFO	D0DT5E	Cephalothin Sodium	Approved
T34743	DRUGINFO	D0E3RW	Cefditoren	Approved
T34743	DRUGINFO	D0E9WL	Loracarbef	Approved
T34743	DRUGINFO	D0K5OT	Penicillin G Sodium	Approved
T34743	DRUGINFO	D0MB8I	Oxacillin	Approved
T34743	DRUGINFO	D0O5FY	Meropenem	Approved
T34743	DRUGINFO	D0PA2N	Azlocillin	Approved
T34743	DRUGINFO	D0PH5Z	Ceftazidime	Approved
T34743	DRUGINFO	D0PN1F	Carbenicillin Indanyl Sodium	Approved
T34743	DRUGINFO	D0PW7C	Cefaclor	Approved
T34743	DRUGINFO	D0Q1MS	Ertapenem	Approved
T34743	DRUGINFO	D0Q2AT	Flucloxacillin	Approved
T34743	DRUGINFO	D0R1BD	Penicillin	Approved
T34743	DRUGINFO	D0R2KJ	Dicloxacillin	Approved
T34743	DRUGINFO	D0U4YG	Penicillin G Benzathine	Approved
T34743	DRUGINFO	D0W6CA	Cefpodoxime	Approved
T34743	DRUGINFO	D0W7RJ	Hetacillin	Approved
T34743	DRUGINFO	D0WS1X	Cefdinir	Approved
T34743	DRUGINFO	D0X9ZC	Cefadroxil	Approved
T34743	DRUGINFO	D0Y2IE	Cefuroxime	Approved
T34743	DRUGINFO	D0Y7BD	Ceftizoxime	Approved
T34743	DRUGINFO	D0YA9Z	Ampicillin	Approved
T34743	DRUGINFO	D0YX4S	Cefprozil	Approved
T34743	DRUGINFO	D0Z5EM	Cephalexin	Approved
T34743	DRUGINFO	D4LOR2	Tebipenem pivoxil	Approved
T34743	DRUGINFO	D0R5RR	Clofarabine	Approved
T34743	DRUGINFO	D0O1WX	Ciprofloxacin XR	Approved
T34743	DRUGINFO	D03IUD	Ceftolozane sulfate	Phase 4
T34743	DRUGINFO	D08KYQ	Sulopenem	Phase 3
T34743	DRUGINFO	D0CI9T	Ceftobiprole	Phase 3
T34743	DRUGINFO	D0Z1BQ	Cefluprenam	Phase 3
T34743	DRUGINFO	D4H2CP	Ceftobiprole medocaril	Phase 3
T34743	DRUGINFO	D0A5SR	Lenapenem hydrochloride hydrate	Phase 2
T34743	DRUGINFO	DQ18VG	BOS-228	Phase 2
T34743	DRUGINFO	D07PRC	BAL-30072	Phase 1
T34743	DRUGINFO	D0H9RD	DZ-2640	Phase 1
T34743	DRUGINFO	D04KHH	CEFCANEL DALOXATE HYDROCHLORIDE	Discontinued in Phase 3
T34743	DRUGINFO	D0K1QO	CEFETECOL	Discontinued in Phase 3
T34743	DRUGINFO	D0S4LL	Sanfetrinem	Discontinued in Phase 3
T34743	DRUGINFO	D03REC	KP-736	Discontinued in Phase 2
T34743	DRUGINFO	D07XDS	Tomopenem	Discontinued in Phase 2
T34743	DRUGINFO	D0Q1HG	PA-1806	Discontinued in Phase 2
T34743	DRUGINFO	D00ROV	FK-041	Discontinued in Phase 1
T34743	DRUGINFO	D04KXF	CEFTRAZONAL BOPENTIL	Discontinued in Phase 1
T34743	DRUGINFO	D04MDJ	Cefdaloxime pentexil tosilate	Discontinued in Phase 1
T34743	DRUGINFO	D09ANC	MC-02,479	Discontinued in Phase 1
T34743	DRUGINFO	D0B6SO	BRL-44154	Discontinued in Phase 1
T34743	DRUGINFO	D0YJ9T	DU-6681	Discontinued in Phase 1
T34743	DRUGINFO	D0ZA2L	ER-35786	Discontinued in Phase 1
T34743	DRUGINFO	D00ZZH	BK-218	Terminated
T34743	DRUGINFO	D02SAE	Sanfetrinem cilexetil	Investigative
T34743	DRUGINFO	D0I3BL	Naphthyridinomycin	Investigative
T34743	DRUGINFO	D0Q7GG	Anthramycin	Investigative
T34743	DRUGINFO	D0SK5C	RO 244383	Investigative
T34743	DRUGINFO	D0Y5KQ	Cis-[PtCl(NH3)2(N7-acyclovir)]+	Investigative

T45993	TARGETID	T45993
T45993	FORMERID	TTDS00163
T45993	TARGNAME	Calcium channel unspecific (CaC)
T45993	TARGTYPE	Successful
T45993	DRUGINFO	D0S5CU	Nisoldipine	Approved
T45993	DRUGINFO	D0T0KA	Nicardipine	Approved
T45993	DRUGINFO	D0WN0U	Felodipine	Approved
T45993	DRUGINFO	D0XN1F	Nimodipine	Approved
T45993	DRUGINFO	D0Y4JJ	Bepridil	Approved
T45993	DRUGINFO	D0Z7KE	Isradipine	Approved
T45993	DRUGINFO	D09ELP	Clevidipine butyrate	Approved
T45993	DRUGINFO	D06RBJ	DIPROTEVERINE HYDROCHLORIDE	Phase 3
T45993	DRUGINFO	D01MPE	S-2150	Phase 2
T45993	DRUGINFO	D0N1CH	Arverapamil	Phase 2
T45993	DRUGINFO	D06BUA	Nexopamil	Phase 2
T45993	DRUGINFO	D02SVQ	HBI-3000	Phase 2
T45993	DRUGINFO	D0N1TH	ATI-2042	Phase 2
T45993	DRUGINFO	D04MGD	Elpetrigine	Phase 1
T45993	DRUGINFO	D06EDP	DSP-0565	Phase 1
T45993	DRUGINFO	D0G4ES	Tetrandrine	Phase 1
T45993	DRUGINFO	D0W3JH	CM2489	Phase 1
T45993	DRUGINFO	D0P9KA	YM-16151-4	Phase 1
T45993	DRUGINFO	D00KOV	Monatepil maleate	Discontinued in Preregistration
T45993	DRUGINFO	D06LDC	Palonidipine hydrochloride	Discontinued in Preregistration
T45993	DRUGINFO	D07EGW	AE-0047	Discontinued in Preregistration
T45993	DRUGINFO	D0KT8U	Semotiadil	Discontinued in Preregistration
T45993	DRUGINFO	D09ESW	Anipamil	Discontinued in Phase 3
T45993	DRUGINFO	D0G2XN	S-12968	Discontinued in Phase 3
T45993	DRUGINFO	D0HQ3A	ELGODIPINE HYDROCHLORIDE	Discontinued in Phase 3
T45993	DRUGINFO	D00ECB	CD-349	Discontinued in Phase 2
T45993	DRUGINFO	D07FNG	AM336	Discontinued in Phase 2
T45993	DRUGINFO	D0A4OT	TAMOLARIZINE HYDROCHLORIDE	Discontinued in Phase 2
T45993	DRUGINFO	D0B3IC	Dopropidil	Discontinued in Phase 2
T45993	DRUGINFO	D0G0LH	S-312-d	Discontinued in Phase 2
T45993	DRUGINFO	D0LK8O	Lifarizine	Discontinued in Phase 2
T45993	DRUGINFO	D0TX8Z	FLOSATIDIL	Discontinued in Phase 2
T45993	DRUGINFO	D08WSW	BRL-32872A	Discontinued in Phase 2
T45993	DRUGINFO	D0B7HX	Levosemotiadil	Discontinued in Phase 2
T45993	DRUGINFO	D00UCW	CEREBROCRAST	Discontinued in Phase 1
T45993	DRUGINFO	D06HCD	SM-6586	Discontinued in Phase 1
T45993	DRUGINFO	D06JWO	KT-362	Discontinued in Phase 1
T45993	DRUGINFO	D07JHJ	IGANIDIPINE HYDROCHLORIDE	Discontinued in Phase 1
T45993	DRUGINFO	D07NTN	CERM-11956	Discontinued in Phase 1
T45993	DRUGINFO	D08AFD	NP-252	Discontinued in Phase 1
T45993	DRUGINFO	D0A8ZD	SR-33805	Discontinued in Phase 1
T45993	DRUGINFO	D06KYU	Rycals	Preclinical
T45993	DRUGINFO	D00ICM	Naltiazem hydrochloride	Terminated
T45993	DRUGINFO	D00ZWG	NS-638	Terminated
T45993	DRUGINFO	D03SDH	Siratiazem	Terminated
T45993	DRUGINFO	D03ZPY	SQ-33351	Terminated
T45993	DRUGINFO	D04LRU	AHR-16462B	Terminated
T45993	DRUGINFO	D04MFY	AJ-3941	Terminated
T45993	DRUGINFO	D06BBZ	ZM-224832	Terminated
T45993	DRUGINFO	D07AGR	SB-206284A	Terminated
T45993	DRUGINFO	D07SDE	Pranidipine	Terminated
T45993	DRUGINFO	D08LLR	UK-51656	Terminated
T45993	DRUGINFO	D08ZAX	RS-93522	Terminated
T45993	DRUGINFO	D08ZZO	NS-696	Terminated
T45993	DRUGINFO	D0B9TX	Darodipine	Terminated
T45993	DRUGINFO	D0BX1S	CD-832	Terminated
T45993	DRUGINFO	D0DI3E	DHP-218	Terminated
T45993	DRUGINFO	D0DM5A	SIM-6080	Terminated
T45993	DRUGINFO	D0E6VL	RWJ-22108	Terminated
T45993	DRUGINFO	D0F6GR	Clentiazem	Terminated
T45993	DRUGINFO	D0F9KI	LAS-30538	Terminated
T45993	DRUGINFO	D0FF7A	Z-6568	Terminated
T45993	DRUGINFO	D0G7HO	NS-649	Terminated
T45993	DRUGINFO	D0HQ1W	SKF-96365	Terminated
T45993	DRUGINFO	D0KE1V	SDZ-249482	Terminated
T45993	DRUGINFO	D0NH6F	VUF-8929	Terminated
T45993	DRUGINFO	D0R3SI	NNC-09-0026	Terminated
T45993	DRUGINFO	D0UU3J	RWJ-37868	Terminated
T45993	DRUGINFO	D0W6MA	E-2050	Terminated
T45993	DRUGINFO	D05KRC	Emopamil	Terminated
T45993	DRUGINFO	D06VXY	SB-237376	Terminated
T45993	DRUGINFO	D0Q6EN	AHR-16303B	Terminated
T45993	DRUGINFO	D01BMA	BELFOSDIL	Investigative
T45993	DRUGINFO	D01QSU	leualacin	Investigative
T45993	DRUGINFO	D0G0EA	AGN-190744	Investigative
T45993	DRUGINFO	D0I0MJ	CD-832.HCL	Investigative
T45993	DRUGINFO	D0LN9P	TELUDIPINE HYDROCHLORIDE	Investigative
T45993	DRUGINFO	D0V6YT	SR-33805A	Investigative

T99727	TARGETID	T99727
T99727	FORMERID	TTDI02003
T99727	TARGNAME	Hyperpolarization cyclic nucleotide-gated channel (HCN)
T99727	TARGTYPE	Successful
T99727	FUNCTION	Hyperpolarization-activated ion channel exhibiting weak selectivity for potassium over sodium ions. Contributes to the native pacemaker currents in heart (If) and in neurons (Ih). May mediate responses to sour stimuli.
T99727	BIOCLASS	Voltage-gated ion channel
T99727	DRUGINFO	D0S9QA	Ivabradine	Approved
T99727	DRUGINFO	D03YJC	SKL-NP	Phase 2
T99727	DRUGINFO	D06TKE	ZD-7288	Phase 2
T99727	DRUGINFO	D0PO0B	Cilobradine	Phase 1

T28925	TARGETID	T28925
T28925	FORMERID	TTDI01771
T28925	TARGNAME	Inosine-5'-monophosphate dehydrogenase (IMPDH)
T28925	TARGTYPE	Successful
T28925	BIOCLASS	Short-chain dehydrogenases reductase
T28925	DRUGINFO	D02ZXM	Thioguanine	Approved
T28925	DRUGINFO	D06MRY	Enteric-coated mycophenolate sodium	Approved
T28925	DRUGINFO	D05QIS	VX-944	Phase 2
T28925	DRUGINFO	D00CGU	IMS	Discontinued in Phase 1
T28925	DRUGINFO	D0V7XC	R-1518	Discontinued in Phase 1
T28925	DRUGINFO	D04WCO	EPB-415	Investigative

T16422	TARGETID	T16422
T16422	FORMERID	TTDS00255
T16422	TARGNAME	Multidrug resistance protein (MDR)
T16422	TARGTYPE	Successful
T16422	SYNONYMS	P-glycoprotein
T16422	BIOCLASS	ABC transporter
T16422	DRUGINFO	D02DKD	Benzquinamide	Approved
T16422	DRUGINFO	D07SDQ	Curcumin	Phase 3
T16422	DRUGINFO	D09ALR	MM36	Phase 2
T16422	DRUGINFO	D0YX7E	Ortataxel	Phase 2
T16422	DRUGINFO	D09TGX	Valspodar	Discontinued in Phase 3
T16422	DRUGINFO	D03OPW	WK-X-34	Investigative
T16422	DRUGINFO	D0I8ON	KP772	Investigative
T16422	DRUGINFO	D0P2OZ	Chemosensitizers	Investigative

T09130	TARGETID	T09130
T09130	FORMERID	TTDI01749
T09130	TARGNAME	Muscarinic acetylcholine receptor (CHRM)
T09130	TARGTYPE	Successful
T09130	FUNCTION	The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through theaction of G proteins. Primary transducing effect is Pi turnover.
T09130	DRUGINFO	D09ZOQ	Incruse Ellipta	Approved
T09130	DRUGINFO	D0B7YT	Scopolamine	Approved
T09130	DRUGINFO	D0K1ST	Revefenacin	Approved
T09130	DRUGINFO	D0Q9HF	Acetylcholine	Approved
T09130	DRUGINFO	D0R1DH	Oxybutynin hydrochloride	Approved
T09130	DRUGINFO	D0Z9PX	Isopropamide iodide	Approved
T09130	DRUGINFO	D0P1WA	Tiotropium	Approved
T09130	DRUGINFO	D0Q1BT	Clidinium	Approved
T09130	DRUGINFO	D0Y5AM	Darifenacin	Approved
T09130	DRUGINFO	D0M6VK	Methylscopolamine	Approved
T09130	DRUGINFO	D04RNN	SUN-101	Phase 3
T09130	DRUGINFO	D09FQW	THVD-201	Phase 3
T09130	DRUGINFO	D04XVE	QAX-028	Phase 2
T09130	DRUGINFO	D05GNW	AZD-9164	Phase 2
T09130	DRUGINFO	D08WSG	AZD-8683	Phase 2
T09130	DRUGINFO	D0KX9B	EP-101	Phase 2
T09130	DRUGINFO	D0XQ6V	APD-515	Phase 2
T09130	DRUGINFO	D05OTZ	SMP-986	Phase 2
T09130	DRUGINFO	D0L9CD	AZD-2115	Phase 2
T09130	DRUGINFO	D09ZRB	PUR0200	Phase 1
T09130	DRUGINFO	D0FX4J	Telenzepine	Discontinued in Preregistration
T09130	DRUGINFO	D0UX0T	Milameline	Discontinued in Phase 3
T09130	DRUGINFO	D07RUV	Terflavoxate	Discontinued in Phase 2
T09130	DRUGINFO	D02VHE	A-72055	Terminated
T09130	DRUGINFO	D0X3KX	U-80816	Terminated
T09130	DRUGINFO	D00CUZ	[3H]pirenzepine	Investigative
T09130	DRUGINFO	D02DPM	[3H]dimethyl-W84	Investigative
T09130	DRUGINFO	D02KZD	ML375	Investigative
T09130	DRUGINFO	D02QQD	VU0010010	Investigative
T09130	DRUGINFO	D03RMI	LY2033298	Investigative
T09130	DRUGINFO	D03XVJ	C7/3-phth	Investigative
T09130	DRUGINFO	D04ZSZ	DS-AH-14	Investigative
T09130	DRUGINFO	D09KDI	THRX160209	Investigative
T09130	DRUGINFO	D0A6ZC	[11C]butylthio-TZTP	Investigative
T09130	DRUGINFO	D0BM7O	Duo3	Investigative
T09130	DRUGINFO	D0C2DM	LY593093	Investigative
T09130	DRUGINFO	D0F3AN	LY2119620	Investigative
T09130	DRUGINFO	D0FX4W	iperoxo	Investigative
T09130	DRUGINFO	D0G8IA	Cy3B-telenzepine	Investigative
T09130	DRUGINFO	D0I1EE	Alexa-488-telenzepine	Investigative
T09130	DRUGINFO	D0K3HY	VU0152100	Investigative
T09130	DRUGINFO	D0K5ME	levetimide	Investigative
T09130	DRUGINFO	D0L5AG	VU0029767	Investigative
T09130	DRUGINFO	D0L5OU	[11C]xanomeline	Investigative
T09130	DRUGINFO	D0M0VI	BODIPY-pirenzepine	Investigative
T09130	DRUGINFO	D0O0OP	[18F](R,R)-quinuclidinyl-4-fluoromethyl-benzilate	Investigative
T09130	DRUGINFO	D0O6BD	VU0090157	Investigative
T09130	DRUGINFO	D0O9KA	W-84	Investigative
T09130	DRUGINFO	D0OY7A	RBx-343E48F0	Investigative
T09130	DRUGINFO	D0Q2VN	[3H]4NMPB	Investigative
T09130	DRUGINFO	D0V0OM	[18F]FP-TZTP	Investigative
T09130	DRUGINFO	D0WV0Q	ML169	Investigative
T09130	DRUGINFO	D0Y1VB	VU0152099	Investigative
T09130	DRUGINFO	D0Y7RV	benzoquinazolinone 12	Investigative
T09130	DRUGINFO	D0Y9SE	KT 5823	Investigative
T09130	DRUGINFO	D0Z6VT	ML380	Investigative
T09130	DRUGINFO	D0Z9KR	WDuo3	Investigative
T09130	DRUGINFO	D00NRJ	silahexocyclium	Investigative
T09130	DRUGINFO	D00WNA	ML381	Investigative
T09130	DRUGINFO	D02BOW	McN-A-343	Investigative
T09130	DRUGINFO	D02IIN	WIN 62,577	Investigative
T09130	DRUGINFO	D02MJE	NNC 11-1314	Investigative
T09130	DRUGINFO	D02UNX	VU0255035	Investigative
T09130	DRUGINFO	D02VGM	[3H]QNB	Investigative
T09130	DRUGINFO	D03DMR	lithocholylcholine	Investigative
T09130	DRUGINFO	D03LSH	UH-AH 37	Investigative
T09130	DRUGINFO	D05PSD	WIN 51,708	Investigative
T09130	DRUGINFO	D05WXF	thiochrome	Investigative
T09130	DRUGINFO	D07CAB	NNC 11-1585	Investigative
T09130	DRUGINFO	D07GPQ	tripitramine	Investigative
T09130	DRUGINFO	D07LDP	hexahydrosiladifenidol	Investigative
T09130	DRUGINFO	D07OAK	Go7874	Investigative
T09130	DRUGINFO	D08BGK	N-chloromethyl-brucine	Investigative
T09130	DRUGINFO	D08KNP	N-benzyl brucine	Investigative
T09130	DRUGINFO	D08XBQ	NNC 11-1607	Investigative
T09130	DRUGINFO	D0G4CG	[3H]oxotremorine-M	Investigative
T09130	DRUGINFO	D0H2UT	brucine	Investigative
T09130	DRUGINFO	D0I9AL	guanylpirenzepine	Investigative
T09130	DRUGINFO	D0I9LU	arecaidine propargyl ester	Investigative
T09130	DRUGINFO	D0K3VR	p-F-HHSiD	Investigative
T09130	DRUGINFO	D0PL0Y	furtrethonium	Investigative
T09130	DRUGINFO	D0S4DT	vinburnine	Investigative
T09130	DRUGINFO	D0T6ID	pentylthio-TZTP	Investigative
T09130	DRUGINFO	D0W8XI	hexahydrodifenidol	Investigative
T09130	DRUGINFO	D0WO3A	methylfurmethide	Investigative
T09130	DRUGINFO	D0HP1O	AF-DX-384	Investigative

T23547	TARGETID	T23547
T23547	FORMERID	TTDS00125
T23547	TARGNAME	Opioid receptor (OPR)
T23547	TARGTYPE	Successful
T23547	SYNONYMS	Opioid receptor
T23547	DRUGINFO	D02NSF	Oxymorphone	Approved
T23547	DRUGINFO	D04BCW	Ketobemidone	Approved
T23547	DRUGINFO	D05VIL	Nalmefene	Approved
T23547	DRUGINFO	D09OJQ	Methadone	Approved
T23547	DRUGINFO	D0D4PB	Dextropropoxyphene	Approved
T23547	DRUGINFO	D0D8DD	Sufentanil	Approved
T23547	DRUGINFO	D0PG8O	Naltrexone	Approved
T23547	DRUGINFO	D0U9MR	Tilidine	Approved
T23547	DRUGINFO	D0W6DG	Pentazocine	Approved
T23547	DRUGINFO	D0T3HY	Levorphanol	Approved
T23547	DRUGINFO	D0T6RC	Dihydrocodeine	Phase 4
T23547	DRUGINFO	D03YZJ	ALO-02	Phase 3
T23547	DRUGINFO	D01TMQ	Bupropion+naltrexone	Phase 3
T23547	DRUGINFO	D0K8NR	AMG 386	Phase 3
T23547	DRUGINFO	D03GVG	NP-2	Phase 2
T23547	DRUGINFO	D04GLJ	OCFENTANIL	Phase 2
T23547	DRUGINFO	D0D8XG	AeroLEF	Phase 2
T23547	DRUGINFO	D0K2OV	Oxytrex	Phase 2
T23547	DRUGINFO	D0Q3PD	S-297995	Phase 2
T23547	DRUGINFO	D0R0EF	AZD-7268	Phase 2
T23547	DRUGINFO	D0RK8U	JKB-122	Phase 2
T23547	DRUGINFO	D0S6SQ	Odelepran	Phase 2
T23547	DRUGINFO	D0D7MJ	CNSB-001	Phase 2
T23547	DRUGINFO	D0C8KY	SYN-1001	Phase 1
T23547	DRUGINFO	D0YN4Y	PTI-202	Phase 1
T23547	DRUGINFO	D08LIF	Propiram fumarate	Discontinued in Phase 3
T23547	DRUGINFO	D01YLF	PTI-701	Discontinued in Phase 2
T23547	DRUGINFO	D03KJV	Ultramorph	Discontinued in Phase 2
T23547	DRUGINFO	D0RW4F	CereCRIB	Discontinued in Phase 2
T23547	DRUGINFO	D02JNX	OxycoDex	Discontinued in Phase 2
T23547	DRUGINFO	D06MXY	BL-1827	Discontinued in Phase 1
T23547	DRUGINFO	D0P6LP	CB-01-16	Preclinical
T23547	DRUGINFO	D07ULK	OX-23	Terminated
T23547	DRUGINFO	D09ENA	Org-30035	Terminated
T23547	DRUGINFO	D0H1TA	EK-399	Terminated
T23547	DRUGINFO	D0Y8GL	APF-580	Terminated
T23547	DRUGINFO	D0H2NH	BRIFENTANIL	Investigative
T23547	DRUGINFO	D0L1VT	Cyprodine	Investigative

T31946	TARGETID	T31946
T31946	FORMERID	TTDR00073
T31946	TARGNAME	Vascular endothelial growth factor receptor (VEGFR)
T31946	TARGTYPE	Successful
T31946	BIOCLASS	Kinase
T31946	DRUGINFO	D03JTG	Fruquintinib	Approved
T31946	DRUGINFO	D09HNV	Intedanib	Approved
T31946	DRUGINFO	D0O9XO	KH-902	Phase 3
T31946	DRUGINFO	D58JRA	ABP 938	Phase 3
T31946	DRUGINFO	D05PWX	Sulfatinib	Phase 3
T31946	DRUGINFO	D04OTY	BFH-772	Phase 2
T31946	DRUGINFO	D0K4CD	ASP-8477	Phase 2
T31946	DRUGINFO	D8AG3S	Vorolanib	Phase 2
T31946	DRUGINFO	D07NOI	BAY-57-9352	Phase 2
T31946	DRUGINFO	D0L2ZY	X-82	Phase 2
T31946	DRUGINFO	D00NSD	XL-820	Phase 2
T31946	DRUGINFO	D03CGQ	AG-013958	Phase 1/2
T31946	DRUGINFO	DRF94Z	AIV001	Phase 1/2
T31946	DRUGINFO	D1TNJ2	XL092	Phase 1
T31946	DRUGINFO	D0P0QG	HuMV833	Discontinued in Phase 1
T31946	DRUGINFO	D08OUU	Genevx	Terminated
T31946	DRUGINFO	D0L5YF	ZD-4190	Terminated
T31946	DRUGINFO	D09ZAV	RG-8803	Terminated
T31946	DRUGINFO	D0Y1YX	AZD-9935	Terminated

T30374	TARGETID	T30374
T30374	FORMERID	TTDS00023
T30374	TARGNAME	Gamma-aminobutyric acid uptake (GABAU)
T30374	TARGTYPE	Successful
T30374	SYNONYMS	GABA uptake
T30374	DRUGINFO	D0ED7U	Tiagabine	Approved
T30374	DRUGINFO	D0H5YE	NNC 05-2045	Terminated
T30374	DRUGINFO	D06YXT	NNC 711	Investigative
T30374	DRUGINFO	D0E5ON	Cis-4-hydroxynipecotic acid	Investigative
T30374	DRUGINFO	D0M4FW	THPO	Investigative
T30374	DRUGINFO	D0D2EF	(R)-nipecotic acid	Investigative
T30374	DRUGINFO	D0V7RG	4-substituted 2,4-dioxobutanoic acids	Investigative

T34867	TARGETID	T34867
T34867	TARGNAME	Poly [ADP-ribose] polymerase (PARP)
T34867	TARGTYPE	Successful
T34867	SYNONYMS	Poly-ADP-ribose polymerase
T34867	DRUGINFO	D01SHZ	Rucaparib	Approved
T34867	DRUGINFO	D0GV8J	Talazoparib	Approved
T34867	DRUGINFO	D0J9HW	Olaparib	Approved
T34867	DRUGINFO	D00BMF	MK-4827	Phase 3
T34867	DRUGINFO	D0IK5F	BSI-201	Phase 3
T34867	DRUGINFO	D0NA8B	Rubraca rucaparib	Phase 3
T34867	DRUGINFO	D0Q7UD	ABT-888	Phase 3
T34867	DRUGINFO	D0ZY3E	INO-1001	Phase 3
T34867	DRUGINFO	D06DHB	E7016	Phase 2
T34867	DRUGINFO	DC23ER	AZD9574	Phase 2
T34867	DRUGINFO	D08LRV	BGP-15	Phase 2
T34867	DRUGINFO	D0D9IQ	BGB-290	Phase 2
T34867	DRUGINFO	D0SZ9R	2X-121	Phase 2
T34867	DRUGINFO	D0Q9IK	CEP-9722	Phase 1/2
T34867	DRUGINFO	D0HH0G	ABT-767	Phase 1
T34867	DRUGINFO	D0YU1L	MP-124	Phase 1
T34867	DRUGINFO	D00JAH	PMID27841036-Compound-24	Patented
T34867	DRUGINFO	D01PSK	PMID27841036-Compound-23	Patented
T34867	DRUGINFO	D06UXE	PMID27841036-Compound-V	Patented
T34867	DRUGINFO	D06VZX	PMID27841036-Compound-38	Patented
T34867	DRUGINFO	D09OSS	Dihydropyrido phthalazinone derivative 4	Patented
T34867	DRUGINFO	D0A9HR	Phthalazine derivative 1	Patented
T34867	DRUGINFO	D0AE5G	Phthalazine derivative 2	Patented
T34867	DRUGINFO	D0C7HZ	PMID27841036-Compound-XI	Patented
T34867	DRUGINFO	D0IL3B	PMID27841036-Compound-XVII	Patented
T34867	DRUGINFO	D0IL3C	Tetra/penta-cyclic pyridophthalazinone derivative 1	Patented
T34867	DRUGINFO	D0JA4K	PMID27841036-Compound-36	Patented
T34867	DRUGINFO	D0JY0L	7-azaindole derivative 9	Patented
T34867	DRUGINFO	D0SS2O	Dihydrodiazepinocarbazolone derivative 2	Patented
T34867	DRUGINFO	D0W8EC	Dihydropyrido phthalazinone derivative 3	Patented
T34867	DRUGINFO	D0YA6M	Aza-phenalene-3-ketone derivative 1	Patented
T34867	DRUGINFO	D0U2WO	ONO-2231	Discontinued in Phase 1

T62151	TARGETID	T62151
T62151	TARGNAME	Monoamine oxidase (MAO)
T62151	TARGTYPE	Successful
T62151	SYNONYMS	Human monoamine oxidase
T62151	DRUGINFO	D02IQY	Ergoloid mesylate	Approved
T62151	DRUGINFO	D01ZSO	Moclobemide	Approved
T62151	DRUGINFO	D09NYS	Methylene blue	Approved
T62151	DRUGINFO	D09QDP	Clorgyline	Approved
T62151	DRUGINFO	D0P9AC	Phenelzine	Approved
T62151	DRUGINFO	D0R0UJ	Pargyline	Approved
T62151	DRUGINFO	D0H0HJ	Tranylcypromine	Approved
T62151	DRUGINFO	D0S2UG	Selegiline	Approved
T62151	DRUGINFO	D0S7KA	(-)-deprenyl	Patented
T62151	DRUGINFO	D02CIX	Cyclopropylamine derivative 11	Patented
T62151	DRUGINFO	D03MPD	PMID27019002-Compound-20a	Patented
T62151	DRUGINFO	D04PWX	Cyclopropylamine derivative 9	Patented
T62151	DRUGINFO	D06QRW	Lazabemide	Patented
T62151	DRUGINFO	D07DIJ	Cyclopropylamine derivative 13	Patented
T62151	DRUGINFO	D0R2YA	Cyclopropylamine derivative 12	Patented
T62151	DRUGINFO	D0W9VF	Cyclopropylamine derivative 10	Patented
T62151	DRUGINFO	D0WT1Z	PMID27019002-Compound-17	Patented
T62151	DRUGINFO	D0XH9M	N-(2-phenylcyclopropyl) amino acid derivative 2	Patented

T84726	TARGETID	T84726
T84726	TARGNAME	Rho-associated protein kinase (ROCK)
T84726	TARGTYPE	Successful
T84726	SYNONYMS	Rho-associated, coiled-coil-containing protein kinase; Rho associated protein kinase
T84726	DRUGINFO	D0B5LF	Ximelegatran	Approved
T84726	DRUGINFO	D04WYX	Netarsudil	Approved
T84726	DRUGINFO	D0BN7W	Roclatan	Phase 3
T84726	DRUGINFO	D07EJY	AR-12286	Phase 2
T84726	DRUGINFO	D08MPA	AMA-76	Phase 2
T84726	DRUGINFO	D0AD4H	Cethrin	Phase 1/2
T84726	DRUGINFO	D0U9LT	Y-39983	Phase 1/2
T84726	DRUGINFO	D09IYM	AT13148	Phase 1
T84726	DRUGINFO	D0X6DC	STM 434	Phase 1
T84726	DRUGINFO	D05OEZ	Hexahydro azepinone derivative 1	Patented
T84726	DRUGINFO	D0FX7I	Isoquinoline sulfonyl derivative 2	Patented
T84726	DRUGINFO	D0IF5M	Isoquinoline derivative 4	Patented
T84726	DRUGINFO	D0N0YE	Isoquinoline sulfonamide derivative 2	Patented
T84726	DRUGINFO	D0OS9O	Isoquinoline sulfonamide derivative 1	Patented
T84726	DRUGINFO	D0P6GJ	Isoquinoline sulfonyl derivative 3	Patented
T84726	DRUGINFO	D0QF4V	Isoquinoline derivative 5	Patented
T84726	DRUGINFO	D0VX0H	Isoquinoline sulfonyl derivative 1	Patented

T95139	TARGETID	T95139
T95139	FORMERID	TTDR00070
T95139	TARGNAME	Cysteine protease (CYP)
T95139	TARGTYPE	Successful
T95139	DRUGINFO	D06HCP	MELARSOPROL	Approved
T95139	DRUGINFO	D0D0JU	S-hexyl hexane-1-sulfinothioate	Investigative
T95139	DRUGINFO	D0S4EI	S-benzyl phenylmethanesulfinothioate	Investigative
T95139	DRUGINFO	D0T0IR	S-isopentyl 3-methylbutane-1-sulfinothioate	Investigative
T95139	DRUGINFO	D0V7LZ	S-propyl propane-1-sulfinothioate	Investigative
T95139	DRUGINFO	D0X9YD	ALLICIN	Investigative
T95139	DRUGINFO	D08TMM	K-777	Investigative
T95139	DRUGINFO	D0M7AU	N-methyl-Pip-F-homoF-vinyl sulfonyl phenyl (N-methyl-Pip-F-hF-VS phi)	Investigative

T71484	TARGETID	T71484
T71484	FORMERID	TTDS00300
T71484	TARGNAME	Fungal Microtubule (Fung MicroTU)
T71484	TARGTYPE	Successful
T71484	SYNONYMS	Keratin
T71484	DRUGINFO	D0C1SF	Griseofulvin	Approved

T64382	TARGETID	T64382
T64382	FORMERID	TTDS00018
T64382	TARGNAME	Gamma-aminobutyric acid receptor (GAR)
T64382	TARGTYPE	Successful
T64382	DRUGINFO	D01XLM	Piperazine	Approved
T64382	DRUGINFO	D0CP4E	Clonazepam	Approved
T64382	DRUGINFO	D0D9FW	DP-VPA	Approved
T64382	DRUGINFO	D0Y7RW	Phenobarbital	Approved
T64382	DRUGINFO	D01XOD	Alpidem	Approved
T64382	DRUGINFO	D05AWP	Moxidectin 	Approved
T64382	DRUGINFO	D00VZZ	Allopregnanolone	approved
T64382	DRUGINFO	D0IG4I	THIOCOLCHICOSIDE	Approved
T64382	DRUGINFO	D0H5HO	ANDROSTERONE	Phase 3
T64382	DRUGINFO	D0VA4Y	Phentermine+topiramate	Phase 3
T64382	DRUGINFO	D07ZCK	ZK-93423	Phase 3
T64382	DRUGINFO	D03YXI	PIKAMILONE	Phase 2
T64382	DRUGINFO	D0U2DA	BNC-210	Phase 2
T64382	DRUGINFO	D07TXJ	Dextofisopam	Phase 2
T64382	DRUGINFO	D0L6OA	BL-1020	Phase 2
T64382	DRUGINFO	D0B7CH	Phenylbutyrate	Phase 2
T64382	DRUGINFO	D0C9XA	GSK683699	Phase 2
T64382	DRUGINFO	D0B8YZ	ELTANOLONE	Discontinued in Phase 3
T64382	DRUGINFO	D01BBR	Dezinamide	Discontinued in Phase 2
T64382	DRUGINFO	D0U0TD	Gedocarnil	Discontinued in Phase 1
T64382	DRUGINFO	D05EVI	U-78875	Discontinued in Phase 1
T64382	DRUGINFO	D05CTS	C-202	Terminated
T64382	DRUGINFO	D08BCU	U-90042	Terminated
T64382	DRUGINFO	D0P6CN	XR-368	Terminated
T64382	DRUGINFO	D01BCQ	Divaplon	Terminated
T64382	DRUGINFO	D06BFP	CGS-17867A	Terminated
T64382	DRUGINFO	D0V4GI	CGS-9896	Terminated
T64382	DRUGINFO	D00EPL	Pitrazepine	Investigative
T64382	DRUGINFO	D00PUF	4-Amino-3-hydroxy-butyric acid	Investigative
T64382	DRUGINFO	D01XXZ	6-Ethyl-2-phenyl-chromen-4-one	Investigative
T64382	DRUGINFO	D02IQH	7-Diazonium-naphthalene-1-sulfonic acid anion	Investigative
T64382	DRUGINFO	D02YGZ	5-tert-Butyl-2-(4-fluoro-phenyl)-[1,3]dithiane	Investigative
T64382	DRUGINFO	D04HZW	8-Diazonium-naphthalene-1-sulfonic acid anion	Investigative
T64382	DRUGINFO	D04XOT	2-(3-Hydroxy-phenyl)-6-methyl-chromen-4-one	Investigative
T64382	DRUGINFO	D06PWM	Acetic acid 2,6-diisopropyl-phenyl ester	Investigative
T64382	DRUGINFO	D06PZU	2-(2-Amino-phenyl)-6-methyl-chromen-4-one	Investigative
T64382	DRUGINFO	D06UBH	ALFAXALONE	Investigative
T64382	DRUGINFO	D07RRZ	2,6-Diisopropyl-4-nitro-phenol	Investigative
T64382	DRUGINFO	D08IEE	3-Hydroxy-piperidine-4-carboxylic acid	Investigative
T64382	DRUGINFO	D08QCQ	4-(5-tert-Butyl-[1,3]dithian-2-yl)-benzonitrile	Investigative
T64382	DRUGINFO	D09CKP	3,3-Dimethyl-dihydro-furan-2-one	Investigative
T64382	DRUGINFO	D09EVY	4-Methyl-5-piperidin-4-yl-isoxazol-3-ol	Investigative
T64382	DRUGINFO	D09MWG	ETIOCHOLANOLONE	Investigative
T64382	DRUGINFO	D09RPY	Benzoic acid 2,6-diisopropyl-phenyl ester	Investigative
T64382	DRUGINFO	D0E1DB	5-Aminomethyl-4,5-dihydro-isoxazol-3-ol	Investigative
T64382	DRUGINFO	D0E5WS	6-Methyl-2-p-tolyl-chromen-4-one	Investigative
T64382	DRUGINFO	D0E6TO	2-(3-Butoxy-phenyl)-6-methyl-chromen-4-one	Investigative
T64382	DRUGINFO	D0E8IH	2-(2-Methoxy-phenyl)-6-methyl-chromen-4-one	Investigative
T64382	DRUGINFO	D0EQ8X	2-Phenyl-6-propyl-chromen-4-one	Investigative
T64382	DRUGINFO	D0ER1D	2-(3-Methoxy-phenyl)-6-methyl-chromen-4-one	Investigative
T64382	DRUGINFO	D0F8QJ	WEDELOLACTONE	Investigative
T64382	DRUGINFO	D0G8XR	4-Iodo-2,6-diisopropyl-phenol	Investigative
T64382	DRUGINFO	D0GG7Z	AFLATREME	Investigative
T64382	DRUGINFO	D0H1VB	5-tert-Butyl-2-(4-ethynyl-phenyl)-[1,3]dithiane	Investigative
T64382	DRUGINFO	D0IM4E	2-(3-Amino-phenyl)-6-methyl-chromen-4-one	Investigative
T64382	DRUGINFO	D0J5TL	4-Ethyl-5-piperidin-4-yl-isoxazol-3-ol	Investigative
T64382	DRUGINFO	D0L1BW	SR95531	Investigative
T64382	DRUGINFO	D0L4AR	2-(4-Amino-phenyl)-6-methyl-chromen-4-one	Investigative
T64382	DRUGINFO	D0L8CX	4-Bromo-2,6-diisopropyl-phenol	Investigative
T64382	DRUGINFO	D0NW7F	2-(3-Bromo-phenyl)-6-methyl-chromen-4-one	Investigative
T64382	DRUGINFO	D0O1OZ	BRL-54504AX	Investigative
T64382	DRUGINFO	D0O4IM	(R)-4-amino-2-methylbutanoic acid	Investigative
T64382	DRUGINFO	D0P3CX	6-Methyl-2-phenyl-chromen-4-one	Investigative
T64382	DRUGINFO	D0R7QZ	2-(2-Hydroxy-phenyl)-6-methyl-chromen-4-one	Investigative
T64382	DRUGINFO	D0U1PE	6-Isopropyl-2-phenyl-chromen-4-one	Investigative
T64382	DRUGINFO	D0U2XR	4-Hydroxy-3,5-diisopropyl-benzaldehyde	Investigative
T64382	DRUGINFO	D0U6FH	4-Chloro-2,6-diisopropyl-phenol	Investigative
T64382	DRUGINFO	D0VG9P	4-Dimethylamino-2,6-diisopropyl-phenol	Investigative
T64382	DRUGINFO	D0Y5KJ	6-Methyl-2-pyridin-3-yl-chromen-4-one	Investigative
T64382	DRUGINFO	D0Y6MY	Toluene-1-diazonium-3-sulfonic acid anion	Investigative
T64382	DRUGINFO	D00ASA	2-(3-Chloro-phenyl)-chromen-4-one	Investigative
T64382	DRUGINFO	D00LBX	Bicuculline	Investigative
T64382	DRUGINFO	D02ANG	(2-Amino-4,5-dihydro-thiazol-4-yl)-acetic acid	Investigative
T64382	DRUGINFO	D02CHG	6-Chloro-2-phenyl-chromen-4-one	Investigative
T64382	DRUGINFO	D02HEK	1-(9H-beta-Carbolin-3-yl)-ethanone	Investigative
T64382	DRUGINFO	D02HRB	RWJ-16979	Investigative
T64382	DRUGINFO	D02LLU	2-Phenyl-6H-pyrazolo[1,5-c]quinazolin-5-one	Investigative
T64382	DRUGINFO	D02ONZ	6-Bromo-2-(4-nitro-phenyl)-chromen-4-one	Investigative
T64382	DRUGINFO	D03EQH	RIPAZEPAM	Investigative
T64382	DRUGINFO	D03NWH	2-(3-Bromo-phenyl)-chromen-4-one	Investigative
T64382	DRUGINFO	D04JTK	(6-Benzylamino-9H-beta-carbolin-3-yl)-methanol	Investigative
T64382	DRUGINFO	D04JUH	NSC-73613	Investigative
T64382	DRUGINFO	D04UUT	2-Furan-2-yl-6H-pyrazolo[1,5-c]quinazolin-5-one	Investigative
T64382	DRUGINFO	D04WIA	2-Pyridin-2-yl-6H-pyrazolo[1,5-c]quinazolin-5-one	Investigative
T64382	DRUGINFO	D04YHZ	3-Methoxycarbonyl-2-methyl-9H-beta-carbolin-2-ium	Investigative
T64382	DRUGINFO	D05AEG	N-(9H-beta-Carbolin-3-yl)-acetamide	Investigative
T64382	DRUGINFO	D05LXP	7,12-Dihydro-7,12-diaza-indeno[1,2-a]fluorene	Investigative
T64382	DRUGINFO	D05WZL	((E)-3-Amino-propenyl)-methyl-phosphinic acid	Investigative
T64382	DRUGINFO	D05YQE	3-(2,2-Dimethyl-propoxy)-9H-beta-carboline	Investigative
T64382	DRUGINFO	D06BNI	(9H-beta-Carbolin-3-yl)-methanol	Investigative
T64382	DRUGINFO	D06DTT	RO-054520	Investigative
T64382	DRUGINFO	D06JBP	Benzyl-(9H-beta-carbolin-6-yl)-amine	Investigative
T64382	DRUGINFO	D07CUW	6-Bromo-2-(3-nitro-phenyl)-chromen-4-one	Investigative
T64382	DRUGINFO	D07LCC	4-Methoxymethyl-3,6-dipropoxy-9H-beta-carboline	Investigative
T64382	DRUGINFO	D07MRF	3-Nitro-9H-beta-carboline	Investigative
T64382	DRUGINFO	D08LJJ	6-Bromo-2-(2-nitro-phenyl)-chromen-4-one	Investigative
T64382	DRUGINFO	D09NNI	3-Methoxy-9H-beta-carboline	Investigative
T64382	DRUGINFO	D09PKJ	2-Isoxazol-3-yl-3H-imidazo[4,5-c]quinoline	Investigative
T64382	DRUGINFO	D0A4UQ	6-Bromo-2-(3-bromo-phenyl)-chromen-4-one	Investigative
T64382	DRUGINFO	D0A6AX	(9H-beta-Carbolin-3-yl)-carbamic acid ethyl ester	Investigative
T64382	DRUGINFO	D0AU7Y	2-p-Tolyl-6H-pyrazolo[1,5-c]quinazolin-5-one	Investigative
T64382	DRUGINFO	D0C5XB	NSC-93394	Investigative
T64382	DRUGINFO	D0C8CR	9H-beta-Carbolin-6-ylamine	Investigative
T64382	DRUGINFO	D0D2NV	Pyrrolidin-3-yl-acetic acid	Investigative
T64382	DRUGINFO	D0F8AP	9H-beta-Carbolin-3-ol	Investigative
T64382	DRUGINFO	D0K6WD	(9H-beta-Carbolin-3-yl)-ethyl-amine	Investigative
T64382	DRUGINFO	D0N4EZ	3-ammoniopropane-1-sulfinate	Investigative
T64382	DRUGINFO	D0N9DG	3-Isopropoxy-9H-beta-carboline	Investigative
T64382	DRUGINFO	D0O4MK	3-Chloro-9H-beta-carboline	Investigative
T64382	DRUGINFO	D0P2DB	7,12-Dihydro-5,7,12-triaza-indeno[1,2-a]fluorene	Investigative
T64382	DRUGINFO	D0Q6CJ	2-(3-Bromo-phenyl)-6-nitro-chromen-4-one	Investigative
T64382	DRUGINFO	D0R2ES	2-Phenyl-5,6-dihydro-pyrazolo[1,5-c]quinazoline	Investigative
T64382	DRUGINFO	D0R2HJ	Isoquinoline-3-carboxylic acid methyl ester	Investigative
T64382	DRUGINFO	D0R6FJ	NORHARMANE	Investigative
T64382	DRUGINFO	D0S4RQ	3-sec-Butoxy-9H-beta-carboline	Investigative
T64382	DRUGINFO	D0S6GS	6-Bromo-2-phenyl-chromen-4-one	Investigative
T64382	DRUGINFO	D0T4ZI	6-Chloro-2-(3-nitro-phenyl)-chromen-4-one	Investigative
T64382	DRUGINFO	D0V4AR	2-(4-Chloro-phenyl)-3H-imidazo[4,5-c]quinoline	Investigative
T64382	DRUGINFO	D0W3FQ	6-Nitro-2-phenyl-chromen-4-one	Investigative
T64382	DRUGINFO	D0W7ND	2-Phenyl-3H-imidazo[4,5-c]quinoline	Investigative
T64382	DRUGINFO	D0W9WW	6-Fluoro-2-(3-nitro-phenyl)-chromen-4-one	Investigative
T64382	DRUGINFO	D0X2CC	1-(9H-beta-Carbolin-3-yl)-butan-1-one	Investigative
T64382	DRUGINFO	D0Z8IJ	Muscimol	Investigative
T64382	DRUGINFO	D0ZJ5V	N-(9H-beta-Carbolin-3-yl)-formamide	Investigative
T64382	DRUGINFO	D00OAN	9H-beta-Carboline-3-carboxylic acid propyl ester	Investigative
T64382	DRUGINFO	D00SXO	3-Methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-one	Investigative
T64382	DRUGINFO	D01BVR	5-(4-piperidyl)-4-propylisothiazol-3-ol	Investigative
T64382	DRUGINFO	D06QOX	1,3-Diphenyl-1H-chromeno[4,3-c]pyrazol-4-one	Investigative
T64382	DRUGINFO	D06ZOM	3-Methyl-2-phenyl-2H-chromeno[4,3-c]pyrazol-4-one	Investigative
T64382	DRUGINFO	D07BIF	[3H]CGP27492	Investigative
T64382	DRUGINFO	D09AVL	4-benzyl-5-(4-piperidyl)isothiazol-3-ol	Investigative
T64382	DRUGINFO	D09TTI	2,4-Diamino-butyric acid(GABA)	Investigative
T64382	DRUGINFO	D0D6IU	2-(1H-Indol-3-yl)-2-oxo-N-phenethyl-acetamide	Investigative
T64382	DRUGINFO	D0J9SS	6-Nitro-2-(3-nitro-phenyl)-chromen-4-one	Investigative
T64382	DRUGINFO	D0JV5L	4-Methyl-5-(4-piperidyl)isothiazol-3-ol	Investigative
T64382	DRUGINFO	D0KS2X	CGS-9895	Investigative
T64382	DRUGINFO	D0P3FZ	5-(piperidin-4-yl)isothiazol-3-ol	Investigative
T64382	DRUGINFO	D0S9YE	(beta-CCE)9H-beta-Carboline-3-carboxylic acid	Investigative
T64382	DRUGINFO	D0V2LK	6-Nitro-2-(4-nitro-phenyl)-chromen-4-one	Investigative
T64382	DRUGINFO	D00CQR	6-Methyl-2-oxa-spiro[4.4]nonan-1-one	Investigative
T64382	DRUGINFO	D00VWR	3,3-Diethyl-dihydro-furan-2-one	Investigative
T64382	DRUGINFO	D00WON	3-Ethyl-3-methyl-dihydro-furan-2-one	Investigative
T64382	DRUGINFO	D01OZS	3,3-Diisopropyl-dihydro-furan-2-one	Investigative
T64382	DRUGINFO	D01PPZ	Ridine-5-carboxylic acid ethyl ester	Investigative
T64382	DRUGINFO	D01UZT	4-(4-chlorophenyl)-1-pyrid-2-yl-pyrazole	Investigative
T64382	DRUGINFO	D02FXS	3-carboxy-6-ethyl-4-quinolone	Investigative
T64382	DRUGINFO	D02RUV	3-Isopropyl-3-methyl-dihydro-furan-2-one	Investigative
T64382	DRUGINFO	D02XXK	(9-Benzyl-9H-purin-6-yl)-cyclopropyl-amine	Investigative
T64382	DRUGINFO	D03CKN	3-ethoxycarbonyl-6-ethyl-2-methyl-4-quinolone	Investigative
T64382	DRUGINFO	D03EOK	N-Indan-1-yl-2-(1H-indol-3-yl)-2-oxo-acetamide	Investigative
T64382	DRUGINFO	D03FBS	6-ethyl-3-propoxycarbonyl-4-quinolone	Investigative
T64382	DRUGINFO	D03OEN	N-butyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide	Investigative
T64382	DRUGINFO	D03OQG	1-Methyl-5-oxa-spiro[2.4]heptan-4-one	Investigative
T64382	DRUGINFO	D03YLX	3-Methyl-9H-beta-carboline	Investigative
T64382	DRUGINFO	D04EOV	3-ethoxycarbonyl-6-propyl-4-quinolone	Investigative
T64382	DRUGINFO	D05OOA	6-ethyl-3-pentoxycarbonyl-4-quinolone	Investigative
T64382	DRUGINFO	D05SVA	5-(piperidin-4-yl)isoxazol-3-ol	Investigative
T64382	DRUGINFO	D05TVT	6-ethyl-3-(3-pentoxycarbonyl)-4-quinolone	Investigative
T64382	DRUGINFO	D06EUJ	3-butoxycarbonyl-4-quinolone	Investigative
T64382	DRUGINFO	D06GAI	1-(4-chlorophenyl)-4-phenyl-1H-imidazole	Investigative
T64382	DRUGINFO	D06OSB	6-ethyl-3-i-propoxycarbonyl-4-quinolone	Investigative
T64382	DRUGINFO	D07OON	3-Ethyl-3-isopropyl-dihydro-furan-2-one	Investigative
T64382	DRUGINFO	D07QGN	CGS-13767	Investigative
T64382	DRUGINFO	D08AID	6-ethyl-3-(2-methylbutoxycarbonyl)-4-quinolone	Investigative
T64382	DRUGINFO	D08HGK	N-Benzyl-2-(1H-indol-3-yl)-2-oxo-acetamide	Investigative
T64382	DRUGINFO	D09AYK	3-ethoxycarbonyl-4-quinolone	Investigative
T64382	DRUGINFO	D09CQO	2-Thiophen-2-yl-3H-imidazo[4,5-c]quinoline	Investigative
T64382	DRUGINFO	D09RWW	3-cyclopentoxycarbonyl-6-ethyl-4-quinolone	Investigative
T64382	DRUGINFO	D0AR4P	2-(9-Benzyl-9H-purin-6-ylamino)-ethanol	Investigative
T64382	DRUGINFO	D0B4CQ	6-benzyl-3-propylaminocarbonyl-4-quinolone	Investigative
T64382	DRUGINFO	D0B4WR	2-Isoxazol-5-yl-3H-imidazo[4,5-c]quinoline	Investigative
T64382	DRUGINFO	D0CR6M	6-bromo-3-ethoxycarbonyl-2-methyl-4-quinolone	Investigative
T64382	DRUGINFO	D0D2PJ	GNF-PF-4421	Investigative
T64382	DRUGINFO	D0ER0L	4-Benzyl-5-piperidin-4-yl-isoxazol-3-ol	Investigative
T64382	DRUGINFO	D0FQ2N	3-Isothiocyanato-9H-beta-carboline	Investigative
T64382	DRUGINFO	D0FR4S	4-(2-aminoethyl)-1,2,5-oxadiazol-3-ol	Investigative
T64382	DRUGINFO	D0G6IG	3-butoxycarbonyl-6-ethyl-4-quinolone	Investigative
T64382	DRUGINFO	D0H0DP	3-amino-3-demethoxythiocolchicine	Investigative
T64382	DRUGINFO	D0H0NE	6,9-Dimethyl-2-oxa-spiro[4.4]nonan-1-one	Investigative
T64382	DRUGINFO	D0I4HT	4-Naphthalen-1-yl-5-piperidin-4-yl-isoxazol-3-ol	Investigative
T64382	DRUGINFO	D0J0CA	BETA-CCM	Investigative
T64382	DRUGINFO	D0J9VP	3-tert-Butyl-3-ethyl-dihydro-furan-2-one	Investigative
T64382	DRUGINFO	D0K2CZ	1,1-Dimethyl-5-oxa-spiro[2.4]heptan-4-one	Investigative
T64382	DRUGINFO	D0KS3X	U-89267	Investigative
T64382	DRUGINFO	D0L2KB	RO-145974	Investigative
T64382	DRUGINFO	D0M0ZX	6-ethyl-3-(2-ethylbutoxycarbonyl)-4-quinolone	Investigative
T64382	DRUGINFO	D0M2AY	6-ethyl-3-propylaminocarbonyl-4-quinolone	Investigative
T64382	DRUGINFO	D0O9SG	2-(4-chlorophenyl)-5-phenyl-4-isoxazolin-3-one	Investigative
T64382	DRUGINFO	D0Q8UV	RO-145975	Investigative
T64382	DRUGINFO	D0R1IL	4-Naphthalen-2-yl-5-piperidin-4-yl-isoxazol-3-ol	Investigative
T64382	DRUGINFO	D0S6ME	6-benzyl-3-propoxycarbonyl-4-quinolone	Investigative
T64382	DRUGINFO	D0TJ2L	RO-147437	Investigative
T64382	DRUGINFO	D0U9ET	6,6-Dimethyl-2-oxa-spiro[4.4]nonan-1-one	Investigative
T64382	DRUGINFO	D0UQ6J	RO-194603	Investigative
T64382	DRUGINFO	D0W5IP	GNF-PF-3645	Investigative
T64382	DRUGINFO	D0WC5L	3-butylaminocarbonyl-6-ethyl-4-quinolone	Investigative
T64382	DRUGINFO	D0X4OW	2-Oxa-spiro[4.4]nonan-1-one	Investigative
T64382	DRUGINFO	D0YS9E	4-Phenyl-5-piperidin-4-yl-isoxazol-3-ol	Investigative
T64382	DRUGINFO	D01UAS	6-bromo-3-ethoxycarbonyl-4-quinolone	Investigative
T64382	DRUGINFO	D02CZO	6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone	Investigative
T64382	DRUGINFO	D03LMR	6-benzyl-3-ethoxycarbonyl-4-quinolone	Investigative
T64382	DRUGINFO	D0H4GQ	RY-066	Investigative
T64382	DRUGINFO	D0RF2M	NIPECOTIC ACID	Investigative
T64382	DRUGINFO	D01CUR	3-Ethoxy-9H-beta-carboline	Investigative
T64382	DRUGINFO	D01RLF	9H-beta-Carboline-3-carboxylic acid ethyl ester	Investigative
T64382	DRUGINFO	D03PPZ	Beta-Carboline-3-carboxylic acid t-butyl ester	Investigative
T64382	DRUGINFO	D04RVA	3-demethoxy-3-D-lyxopyranosylaminothiocolchicine	Investigative
T64382	DRUGINFO	D06WMM	3-Butoxy-9H-beta-carboline	Investigative
T64382	DRUGINFO	D06XGL	3-demethoxy-3-D-xylopyranosylaminothiocolchicine	Investigative
T64382	DRUGINFO	D08BOP	3-Propoxy-9H-beta-carboline	Investigative
T64382	DRUGINFO	D08BXK	3-(3-Methyl-butoxy)-9H-beta-carboline	Investigative
T64382	DRUGINFO	D08YLW	3-demethoxy-3-L-fucopyranosylaminothiocolchicine	Investigative
T64382	DRUGINFO	D09MHS	3-demethoxy-3D-glucopyranosylaminothiocolchicine	Investigative
T64382	DRUGINFO	D09MYJ	3-Isobutoxy-9H-beta-carboline	Investigative
T64382	DRUGINFO	D0C6WO	Sec-butyl 9H-pyrido[3,4-b]indole-3-carboxylate	Investigative
T64382	DRUGINFO	D0D4MM	Ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate	Investigative
T64382	DRUGINFO	D0E7PY	Ro-4938581	Investigative
T64382	DRUGINFO	D0LP2K	3-demethoxy-3-D-mannopyranosylaminothiocolchicine	Investigative
T64382	DRUGINFO	D0O9MG	L-655708	Investigative
T64382	DRUGINFO	D0P3BU	3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole	Investigative
T64382	DRUGINFO	D0R5OU	3-(benzyloxy)-9H-pyrido[3,4-b]indole	Investigative
T64382	DRUGINFO	D01IHM	CI-218872	Investigative
T64382	DRUGINFO	D07NKO	5-[(1R)-1-ammonioethyl]isoxazol-3-olate	Investigative
T64382	DRUGINFO	D09ACO	(2E,4S)-4-ammoniopent-2-enoate	Investigative
T64382	DRUGINFO	D0A8EU	(4R)-4-ammoniopentanoate	Investigative
T64382	DRUGINFO	D0N0ZK	(4S)-4-ammoniopentanoate	Investigative
T64382	DRUGINFO	D0S0RK	flavone	Investigative
T64382	DRUGINFO	D0S5PS	5-[(1S)-1-ammonioethyl]isoxazol-3-olate	Investigative
T64382	DRUGINFO	D00WHO	Ro-15-3505	Investigative
T64382	DRUGINFO	D0AC2H	isonipecotic acid	Investigative
T64382	DRUGINFO	D0M4CP	[3H]Ro154513	Investigative
T64382	DRUGINFO	D0M9RM	[3H]CGS8216	Investigative
T64382	DRUGINFO	D06HRX	AMENTOFLAVONE	Investigative

T48940	TARGETID	T48940
T48940	TARGNAME	HIF-prolyl hydroxylase (HPH)
T48940	TARGTYPE	Successful
T48940	DRUGINFO	D07GRH	Ciclopirox	Approved
T48940	DRUGINFO	D07KEH	AKB-6548	Phase 3
T48940	DRUGINFO	D0B8WU	JTZ-951	Phase 3
T48940	DRUGINFO	D32XRQ	BAY 853934	Phase 3
T48940	DRUGINFO	D0N6CS	FG-2216	Phase 2
T48940	DRUGINFO	D0E6VR	DS-1093	Phase 1
T48940	DRUGINFO	DE8OJ0	ZYAN1	Phase 1
T48940	DRUGINFO	D6VLX2	JNJ-42905343	Preclinical

T81905	TARGETID	T81905
T81905	FORMERID	TTDS00085
T81905	TARGNAME	Histamine receptor (HR)
T81905	TARGTYPE	Successful
T81905	BIOCLASS	GPCR rhodopsin
T81905	DRUGINFO	D0EN0G	Histamine Phosphate	Approved
T81905	DRUGINFO	D0O6KE	Repirinast	Approved
T81905	DRUGINFO	D0L2JM	Levomequitazine	Phase 3
T81905	DRUGINFO	D00EGN	ETX-9101	Phase 2
T81905	DRUGINFO	D01KNY	LCB-2183	Phase 2
T81905	DRUGINFO	D02JZJ	ETS-6218	Phase 2
T81905	DRUGINFO	D09ZMV	Votucalis	Phase 2
T81905	DRUGINFO	D0L8ZX	OX-NLA	Discontinued in Phase 3
T81905	DRUGINFO	D0R6RM	CP-118	Discontinued in Phase 2
T81905	DRUGINFO	D0X9PW	Tesmilifene	Discontinued in Phase 2
T81905	DRUGINFO	D0H6VG	KF-15766	Terminated
T81905	DRUGINFO	D00TRL	REV-598	Terminated

T93662	TARGETID	T93662
T93662	FORMERID	TTDI02275
T93662	TARGNAME	Hyaluronidase (HYAL)
T93662	TARGTYPE	Successful
T93662	BIOCLASS	Glycosylase
T93662	DRUGINFO	D00JRA	Asenapine	Approved
T93662	DRUGINFO	D0IP9E	Hyqvia	Approved
T93662	DRUGINFO	D05INV	PEGPH20	Phase 2
T93662	DRUGINFO	D0L5IA	PEGylated hyaluronidase (human recombinant)	Phase 1/2

T99905	TARGETID	T99905
T99905	FORMERID	TTDI01883
T99905	TARGNAME	Immunoglobulin G (IgG)
T99905	TARGTYPE	Successful
T99905	BIOCLASS	Immunoglobulin

T67952	TARGETID	T67952
T67952	FORMERID	TTDR00174
T67952	TARGNAME	Potassium channel unspecific (KC)
T67952	TARGTYPE	Successful
T67952	DRUGINFO	D02KMO	Pinacidil	Approved
T67952	DRUGINFO	D02MLW	Ibutilide	Approved
T67952	DRUGINFO	D06PSS	Nateglinide	Approved
T67952	DRUGINFO	D07WEP	Diazoxide	Approved
T67952	DRUGINFO	D08YIN	Dalfampridine	Approved
T67952	DRUGINFO	D0HE0Y	Amifampridine	Approved
T67952	DRUGINFO	D0L5WM	Amiodarone	Approved
T67952	DRUGINFO	D0NW3X	Dofetilide	Approved
T67952	DRUGINFO	D0Y2CJ	Minoxidil	Approved
T67952	DRUGINFO	D05CPV	Dronedarone	Approved
T67952	DRUGINFO	D08PGC	Andolast	Phase 3
T67952	DRUGINFO	D0J6II	Azimilide	Phase 3
T67952	DRUGINFO	D01ISE	Bimakalim	Phase 2
T67952	DRUGINFO	D03OGQ	AZD-7009	Phase 2
T67952	DRUGINFO	D05RZW	YM-934	Phase 2
T67952	DRUGINFO	D09KYR	RP-49356	Phase 2
T67952	DRUGINFO	D0MT1Q	K-201	Phase 2
T67952	DRUGINFO	D0Q5BU	MSH-1001	Phase 2
T67952	DRUGINFO	D02SVQ	HBI-3000	Phase 2
T67952	DRUGINFO	D0N1TH	ATI-2042	Phase 2
T67952	DRUGINFO	D07LWK	AVE0118	Phase 1
T67952	DRUGINFO	D08LLM	NS-8	Phase 1
T67952	DRUGINFO	D09BZY	Nibentan	Phase 1
T67952	DRUGINFO	D0GU4Z	CLP-1004	Phase 1
T67952	DRUGINFO	D0J0RG	UK-66914	Phase 1
T67952	DRUGINFO	D0S1BN	Iptakalim	Phase 1
T67952	DRUGINFO	D08DKA	Levcromakalim	Discontinued in Preregistration
T67952	DRUGINFO	D03LQQ	Alinidine	Discontinued in Phase 3
T67952	DRUGINFO	D0S6QR	BMS-204352	Discontinued in Phase 3
T67952	DRUGINFO	D0Z0CH	Almokalant	Discontinued in Phase 3
T67952	DRUGINFO	D04BQR	Acecainide	Discontinued in Phase 3
T67952	DRUGINFO	D00LWF	P-1075	Discontinued in Phase 2
T67952	DRUGINFO	D03NDI	KCO-912	Discontinued in Phase 2
T67952	DRUGINFO	D06QHT	Risotilide	Discontinued in Phase 2
T67952	DRUGINFO	D08HFA	Y-27152	Discontinued in Phase 2
T67952	DRUGINFO	D08PIJ	JTV-506	Discontinued in Phase 2
T67952	DRUGINFO	D08WCU	BMS-180448	Discontinued in Phase 2
T67952	DRUGINFO	D0E2PX	E-4031	Discontinued in Phase 2
T67952	DRUGINFO	D0GT4N	BRL-55834	Discontinued in Phase 2
T67952	DRUGINFO	D0I3BB	KW-7158	Discontinued in Phase 2
T67952	DRUGINFO	D0NF0Q	ZD-0947	Discontinued in Phase 2
T67952	DRUGINFO	D0X7HV	ZD-6169	Discontinued in Phase 2
T67952	DRUGINFO	D0ZF1D	Ambasilide	Discontinued in Phase 2
T67952	DRUGINFO	D08WSW	BRL-32872A	Discontinued in Phase 2
T67952	DRUGINFO	D00LCT	Symakalim	Discontinued in Phase 1
T67952	DRUGINFO	D01KHX	Rilmakalim	Discontinued in Phase 1
T67952	DRUGINFO	D0B6ER	Ro-31-6930	Discontinued in Phase 1
T67952	DRUGINFO	D0LG4V	SR-47063	Discontinued in Phase 1
T67952	DRUGINFO	D0N0KR	Emakalim	Discontinued in Phase 1
T67952	DRUGINFO	D0O1UC	NTC-801	Discontinued in Phase 1
T67952	DRUGINFO	D0U8IJ	SDZ-PCO-400	Discontinued in Phase 1
T67952	DRUGINFO	D0V8RY	KR-30450	Discontinued in Phase 1
T67952	DRUGINFO	D01BQJ	TCV-295	Terminated
T67952	DRUGINFO	D01SEO	ICI-181037	Terminated
T67952	DRUGINFO	D03BVH	AWD-23-111	Terminated
T67952	DRUGINFO	D03WUH	YM-099	Terminated
T67952	DRUGINFO	D04WWG	S-1389	Terminated
T67952	DRUGINFO	D06IVH	Org-20781	Terminated
T67952	DRUGINFO	D06MLZ	WAY-123223	Terminated
T67952	DRUGINFO	D07JOS	NS-004	Terminated
T67952	DRUGINFO	D09BWC	E-4080	Terminated
T67952	DRUGINFO	D0B7ND	UR-8225	Terminated
T67952	DRUGINFO	D0C8DC	Ki-1769	Terminated
T67952	DRUGINFO	D0E6OA	TERIKALANT	Terminated
T67952	DRUGINFO	D0OY1V	NS-1608	Terminated
T67952	DRUGINFO	D0Q7WW	UR-8328	Terminated
T67952	DRUGINFO	D0R7UK	UR-8308	Terminated
T67952	DRUGINFO	D0TB1X	AL-0671	Terminated
T67952	DRUGINFO	D0U5GI	RP-66784	Terminated
T67952	DRUGINFO	D0V4UR	NS-1546	Terminated
T67952	DRUGINFO	D0X9FO	KC-399	Terminated
T67952	DRUGINFO	D06VXY	SB-237376	Terminated
T67952	DRUGINFO	D00MIG	MJ-451	Investigative
T67952	DRUGINFO	D01UUW	Trecetilide fumarate	Investigative
T67952	DRUGINFO	D03EBZ	HMR1883	Investigative
T67952	DRUGINFO	D05GPX	Y-26763	Investigative
T67952	DRUGINFO	D07SYP	L 691121	Investigative
T67952	DRUGINFO	D0J0KR	RP-66471	Investigative
T67952	DRUGINFO	D0UZ5N	WAY-125971	Investigative
T67952	DRUGINFO	D0XL9W	CGS-7181	Investigative

T20297	TARGETID	T20297
T20297	FORMERID	TTDR01271
T20297	TARGNAME	Serine protease unspecific (SP)
T20297	TARGTYPE	Successful
T20297	DRUGINFO	D05PHH	Gabexate	Approved
T20297	DRUGINFO	D08XYX	Aprotinin	Approved
T20297	DRUGINFO	D07XHO	Nafamostat	Approved
T20297	DRUGINFO	D05QHL	Sivelestat sodium hydrate	Phase 4
T20297	DRUGINFO	D0O2XW	VT-111a	Phase 2
T20297	DRUGINFO	D0Y6SQ	Camostat	Phase 2
T20297	DRUGINFO	D0N7WR	Sepimostat mesylate	Discontinued in Phase 3
T20297	DRUGINFO	D0V9ME	VT-111	Preclinical
T20297	DRUGINFO	D0B6QO	NPI-1999	Terminated
T20297	DRUGINFO	D0C0EX	SDZ-MTH-958	Terminated

T60345	TARGETID	T60345
T60345	TARGNAME	T-cell surface glycoprotein CD3 (CD3)
T60345	TARGTYPE	Successful
T60345	SYNONYMS	Cluster of differentiation 3
T60345	DRUGINFO	D0VH4V	Teplizumab	Approved
T60345	DRUGINFO	D0K4RK	Blinatumomab	Approved
T60345	DRUGINFO	D2HDB8	Mosunetuzumab	Approved
T60345	DRUGINFO	D3KO5Y	Elranatamab	Approved
T60345	DRUGINFO	DB4M9J	Epcoritamab	Approved
T60345	DRUGINFO	DKF7G0	Glofitamab	Approved
T60345	DRUGINFO	DXR1A6	Talquetamab	Approved
T60345	DRUGINFO	D0O2VZ	Otelixizumab	Phase 2
T60345	DRUGINFO	DDIO36	Odronextamab	Phase 2
T60345	DRUGINFO	DHN9I5	TAK-280	Phase 2
T60345	DRUGINFO	DI57MF	Nivatrotamab	Phase 2
T60345	DRUGINFO	DLM8G6	Plamotamab	Phase 2
T60345	DRUGINFO	DRH03S	Tarlatamab	Phase 2
T60345	DRUGINFO	D0LA9K	REGN4018	Phase 1/2
T60345	DRUGINFO	D5MV0R	Acapatamab	Phase 1/2
T60345	DRUGINFO	D6L5YT	REGN4336	Phase 1/2
T60345	DRUGINFO	D9OMQ3	GEN3013	Phase 1/2
T60345	DRUGINFO	DE0L6O	ISB 1342	Phase 1/2
T60345	DRUGINFO	DL1FG3	SAR440234	Phase 1/2
T60345	DRUGINFO	DNC79U	ISB 1302	Phase 1/2
T60345	DRUGINFO	DR7Q5N	REGN5458	Phase 1/2
T60345	DRUGINFO	DY9G1D	REGN5459	Phase 1/2
T60345	DRUGINFO	D7QHV6	ABBV-184	Phase 1
T60345	DRUGINFO	D00JDL	MGD006	Phase 1
T60345	DRUGINFO	D0DBS7	GBR1302	Phase 1
T60345	DRUGINFO	D0NQ1S	JNJ-78278343	Phase 1
T60345	DRUGINFO	D0TW3L	CD20Bi aATC	Phase 1
T60345	DRUGINFO	D2GY5C	APVO436	Phase 1
T60345	DRUGINFO	D2Q3VY	Tepoditamab	Phase 1
T60345	DRUGINFO	D3FYE1	M802	Phase 1
T60345	DRUGINFO	D6RT9L	RG6234	Phase 1
T60345	DRUGINFO	D73FNL	CX-904	Phase 1
T60345	DRUGINFO	D7FPZ4	A-337	Phase 1
T60345	DRUGINFO	D7IA0N	AMG 757	Phase 1
T60345	DRUGINFO	D7LN0E	TNB-486	Phase 1
T60345	DRUGINFO	D7WMF3	PF-07260437	Phase 1
T60345	DRUGINFO	D81YIK	WVT078	Phase 1
T60345	DRUGINFO	D8AOC1	AMG 330	Phase 1
T60345	DRUGINFO	D91CMX	AMG 427	Phase 1
T60345	DRUGINFO	D9TG4H	JNJ-63709178	Phase 1
T60345	DRUGINFO	DEDP81	AMG 910	Phase 1
T60345	DRUGINFO	DEP3Z8	AMG 199	Phase 1
T60345	DRUGINFO	DF43EH	AMG 701	Phase 1
T60345	DRUGINFO	DF8X5N	RG6156	Phase 1
T60345	DRUGINFO	DH7ZV4	JNJ-75348780	Phase 1
T60345	DRUGINFO	DHWF68	RG6007	Phase 1
T60345	DRUGINFO	DK87UQ	PF-07062119	Phase 1
T60345	DRUGINFO	DKX1U6	AMG 340	Phase 1
T60345	DRUGINFO	DLY65X	AMG 424	Phase 1
T60345	DRUGINFO	DN91RC	IGM-2323	Phase 1
T60345	DRUGINFO	DNS2P1	AMG 673	Phase 1
T60345	DRUGINFO	DOJ6E8	AMG 596	Phase 1
T60345	DRUGINFO	DOY4E6	AMG 160	Phase 1
T60345	DRUGINFO	DQ15HJ	GEN1044	Phase 1
T60345	DRUGINFO	DQD1T2	GEM333	Phase 1
T60345	DRUGINFO	DRI97M	MGD014	Phase 1
T60345	DRUGINFO	DTQL30	ASP2138	Phase 1
T60345	DRUGINFO	DVOB28	AFM11	Phase 1
T60345	DRUGINFO	DW1H9O	TNB-383B	Phase 1
T60345	DRUGINFO	DY4X5W	CCW702	Phase 1
T60345	DRUGINFO	D2L9MD	RG6524	Phase 1
T60345	DRUGINFO	DBP9Q5	SAR442257	Phase 1
T60345	DRUGINFO	DL6F3E	SAR443216	Phase 1
T60345	DRUGINFO	DCUQ32	Runimotamab	Phase 1
T60345	DRUGINFO	DCUQ32	Runimotamab	Phase 1
T60345	DRUGINFO	DNUS02	IM1240	Preclinical

T04394	TARGETID	T04394
T04394	FORMERID	TTDR00370
T04394	TARGNAME	Vasopressin receptor (VR)
T04394	TARGTYPE	Successful
T04394	SYNONYMS	Human vasopressin receptor
T04394	DRUGINFO	D0U7SH	Desmopressin	Approved
T04394	DRUGINFO	D00XVE	BR6819	Phase 1
T04394	DRUGINFO	D0N6ZP	SKF-105494	Phase 1
T04394	DRUGINFO	D0U7NG	BAY 86-8050	Phase 1
T04394	DRUGINFO	D06QJE	F-992	Terminated

T29999	TARGETID	T29999
T29999	FORMERID	TTDR00176
T29999	TARGNAME	Vasopressin V1 receptor (V1R)
T29999	TARGTYPE	Successful
T29999	SYNONYMS	Vasopressin receptor 1; ADH V1 receptor
T29999	DRUGINFO	D09PZZ	Lypressin	Approved
T29999	DRUGINFO	D03GET	Menadione	Approved
T29999	DRUGINFO	D0F4NS	Mozavaptan	Approved
T29999	DRUGINFO	D08ORO	OPC-21268	Discontinued in Phase 2

T62945	TARGETID	T62945
T62945	FORMERID	TTDI01618
T62945	TARGNAME	Voltage-gated calcium channel (Cav)
T62945	TARGTYPE	Successful
T62945	BIOCLASS	Voltage-gated ion channel
T62945	DRUGINFO	D0X0WU	Tolperisone	Approved
T62945	DRUGINFO	D0P8TS	Eperisone	Phase 3
T62945	DRUGINFO	D07HYR	GCC-1290K	Phase 1

T72065	TARGETID	T72065
T72065	FORMERID	TTDI01857
T72065	TARGNAME	Voltage-gated sodium channel (Nav)
T72065	TARGTYPE	Successful
T72065	BIOCLASS	Voltage-gated ion channel
T72065	DRUGINFO	D01PJR	Tocainide	Approved
T72065	DRUGINFO	D03DAP	Flecainide	Approved
T72065	DRUGINFO	D0J2KV	Propafenone	Approved
T72065	DRUGINFO	D0U5SI	Procainamide	Approved
T72065	DRUGINFO	DU8CF6	Cenobamate	Approved
T72065	DRUGINFO	D04QZD	Eslicarbazepine	Approved
T72065	DRUGINFO	D05OFX	Lacosamide	Approved
T72065	DRUGINFO	D0C7ET	Tetrodotoxin	Approved
T72065	DRUGINFO	DDKF39	Evenamide	Phase 2
T72065	DRUGINFO	D06HYG	Barucainide	Terminated

T30520	TARGETID	T30520
T30520	FORMERID	TTDS00227
T30520	TARGNAME	Bacterial RNA polymerase switch region (Bact RNAP-SR)
T30520	TARGTYPE	Successful
T30520	DRUGINFO	D06LNW	Fidaxomicin	Approved
T30520	DRUGINFO	D0G3DL	Rifampin	Approved
T30520	DRUGINFO	D0XW9L	Rifalazil	Phase 3

T32387	TARGETID	T32387
T32387	FORMERID	TTDNS00610
T32387	TARGNAME	Endothelium of blood vessels (Endothelium)
T32387	TARGTYPE	Successful
T32387	SYNONYMS	Endothelium of blood vessels
T32387	DRUGINFO	D05ZPL	Polidocanol	Approved

T83051	TARGETID	T83051
T83051	FORMERID	TTDI01623
T83051	TARGNAME	Bacterial Ribosome (Bact RIBS)
T83051	TARGTYPE	Successful
T83051	DRUGINFO	D0LZ7E	TP-434	Approved
T83051	DRUGINFO	DEN52G	OTB-658	Preclinical

T44351	TARGETID	T44351
T44351	FORMERID	TTDR00168
T44351	TARGNAME	Cannabinoid receptor (CB)
T44351	TARGTYPE	Successful
T44351	DRUGINFO	D0O1UZ	Cannabidiol	Approved
T44351	DRUGINFO	D00OZC	THX-TS01	Phase 3

T57585	TARGETID	T57585
T57585	FORMERID	TTDI01571
T57585	TARGNAME	Chloride channel unspecific (ClC)
T57585	TARGTYPE	Successful
T57585	DRUGINFO	D01LWO	TM-601	Phase 2
T57585	DRUGINFO	D0H8XB	Lancovutide	Phase 2
T57585	DRUGINFO	D0K9WP	131I-TM-601	Phase 2
T57585	DRUGINFO	D0I8KA	BLZ-100	Phase 1/2
T57585	DRUGINFO	D00NWT	GR-213487	Discontinued in Phase 2
T57585	DRUGINFO	D09BLW	TgAAV-CFTR	Discontinued in Phase 2
T57585	DRUGINFO	D0Y4ZS	Endovion	Terminated

T18632	TARGETID	T18632
T18632	FORMERID	TTDR01239
T18632	TARGNAME	Cholinergic receptor unspecific (CHR)
T18632	TARGTYPE	Successful
T18632	DRUGINFO	D08ALK	Cisatracurium	Approved
T18632	DRUGINFO	D0VK9O	Sofpironium bromide	Phase 3

T68934	TARGETID	T68934
T68934	FORMERID	TTDS00434
T68934	TARGNAME	Collagen (CO)
T68934	TARGTYPE	Successful
T68934	DRUGINFO	D0Y4KE	Collagenase	Approved
T68934	DRUGINFO	D07AHW	Vitamin C	Approved
T68934	DRUGINFO	D08WZQ	MRG-201	Phase 2
T68934	DRUGINFO	D00HAM	Clostridial collagenase	Investigative

T67977	TARGETID	T67977
T67977	FORMERID	TTDNC00352
T67977	TARGNAME	Cytochrome P450 3A (CYP3A)
T67977	TARGTYPE	Successful
T67977	DRUGINFO	D02VJP	Cobicistat	Approved
T67977	DRUGINFO	D0V4ZN	Cobicistat/darunavir	Approved

T39147	TARGETID	T39147
T39147	TARGNAME	Cytomegalovirus Terminase (CMV TRM)
T39147	TARGTYPE	Successful
T39147	DRUGINFO	D0G8PA	MK-8228	Approved
T39147	DRUGINFO	D0GH9Z	GW-275175	Terminated

T17003	TARGETID	T17003
T17003	FORMERID	TTDS00225
T17003	TARGNAME	DNA-directed RNA polymerase (RNAP)
T17003	TARGTYPE	Successful
T17003	DRUGINFO	D05CHI	Rifabutin	Approved
T17003	DRUGINFO	D0G9IU	Rifapentine	Approved
T17003	DRUGINFO	D0AJ5E	Rifaximin DR	Phase 3

T34772	TARGETID	T34772
T34772	FORMERID	TTDI01701
T34772	TARGNAME	Endopeptidase (ENP)
T34772	TARGTYPE	Successful
T34772	DRUGINFO	D0JY3V	Racecadotril	Approved

T10362	TARGETID	T10362
T10362	FORMERID	TTDI01629
T10362	TARGNAME	Enzyme unspecific (Enz)
T10362	TARGTYPE	Successful
T10362	DRUGINFO	D02HFD	Glutathione	Approved
T10362	DRUGINFO	D0U6BJ	Desoxyribonuclease	Approved
T10362	DRUGINFO	D01VWD	HTI-101	Phase 2
T10362	DRUGINFO	D0UA9J	VT-1129	Phase 2
T10362	DRUGINFO	D06PZO	ASC-101	Phase 1/2
T10362	DRUGINFO	D0KG1U	BXCL702	Phase 1
T10362	DRUGINFO	D00YEO	NZ-1002	Terminated
T10362	DRUGINFO	D03XHD	A-11259	Terminated
T10362	DRUGINFO	D09PTL	SRI-3072	Terminated
T10362	DRUGINFO	D0T2OT	GW-278884	Terminated
T10362	DRUGINFO	D0W2DV	BM-13677	Terminated
T10362	DRUGINFO	D0Y6HY	A-364	Terminated
T10362	DRUGINFO	D0Z0RU	APC-6336	Terminated
T10362	DRUGINFO	D09LTO	A-76341	Investigative

T87975	TARGETID	T87975
T87975	TARGNAME	Fungal Proton pump (FPPCM)
T87975	TARGTYPE	Successful
T87975	DRUGINFO	D0C8FX	Pyrithione Zinc	Approved

T21447	TARGETID	T21447
T21447	FORMERID	TTDNS00559
T21447	TARGNAME	Glutamine receptor (GluR)
T21447	TARGTYPE	Successful
T21447	DRUGINFO	D07WXE	L-alanyl-l-glutamine	Approved

T30014	TARGETID	T30014
T30014	FORMERID	TTDI01900
T30014	TARGNAME	Immunoglobulin unspecific (Ig)
T30014	TARGTYPE	Successful
T30014	DRUGINFO	D01PQM	Vaccinia immune globulin	Approved

T83717	TARGETID	T83717
T83717	FORMERID	TTDS00349
T83717	TARGNAME	Neuronal acetylcholine receptor alpha (NACHRA)
T83717	TARGTYPE	Successful
T83717	DRUGINFO	D0Y7TO	Doxacurium	Approved

T06438	TARGETID	T06438
T06438	FORMERID	TTDI01899
T06438	TARGNAME	Oxidoreductase unspecific (OR)
T06438	TARGTYPE	Successful
T06438	DRUGINFO	D00KRE	Olsalazine	Approved
T06438	DRUGINFO	D05TPI	EPICATECHIN	Phase 1/2

T47077	TARGETID	T47077
T47077	FORMERID	TTDI01591
T47077	TARGNAME	Prostaglandin receptor (PTGR)
T47077	TARGTYPE	Successful
T47077	DRUGINFO	D09SRR	Unoprostone	Approved
T47077	DRUGINFO	D0Q2XF	Bimatoprost	Approved
T47077	DRUGINFO	D04LBC	Iclaprim	Phase 3
T47077	DRUGINFO	D0Y5JZ	JB991	Phase 2
T47077	DRUGINFO	D06YXD	Taprostene	Discontinued in Phase 3
T47077	DRUGINFO	D0I7LB	ZD-4953	Discontinued in Phase 2
T47077	DRUGINFO	D0SX3X	TEI-6122	Discontinued in Phase 2
T47077	DRUGINFO	D01AJM	YP-009	Terminated
T47077	DRUGINFO	D0L8TL	YP-008	Terminated
T47077	DRUGINFO	D0M7TT	IP-1200	Investigative

T01840	TARGETID	T01840
T01840	FORMERID	TTDNC00449
T01840	TARGNAME	Protease unspecific (PRO)
T01840	TARGTYPE	Successful
T01840	DRUGINFO	D0V3SB	Prolastin	Approved
T01840	DRUGINFO	D02ALZ	ONO-3307	Phase 2
T01840	DRUGINFO	D0J6ZA	SRD-441	Phase 2
T01840	DRUGINFO	D0E4GE	AZD-2551	Phase 1
T01840	DRUGINFO	D01CAJ	AZD-3342	Discontinued in Phase 1
T01840	DRUGINFO	D02WQZ	Aprosulate sodium	Discontinued in Phase 1
T01840	DRUGINFO	D02ERH	EP-2060	Terminated
T01840	DRUGINFO	D04RDT	CEP-431	Terminated
T01840	DRUGINFO	D04YNI	WY-48989	Terminated
T01840	DRUGINFO	D05OVR	ALP-242	Terminated

T69707	TARGETID	T69707
T69707	FORMERID	TTDNC00646
T69707	TARGNAME	Proteasome (PS)
T69707	TARGTYPE	Successful
T69707	DRUGINFO	D00UVA	Carfilzomib	Approved
T69707	DRUGINFO	D01MML	MLN9708	Approved
T69707	DRUGINFO	D0SH3I	Bortezomib	Approved
T69707	DRUGINFO	D0N0RN	Marizomib	Phase 3
T69707	DRUGINFO	D02BLD	Oprozomib	Phase 2
T69707	DRUGINFO	D0VO0T	Delanzomib	Phase 2
T69707	DRUGINFO	DM8RI3	GSK3494245	Phase 1
T69707	DRUGINFO	D00QIK	PS-519	Terminated
T69707	DRUGINFO	D06FFP	MG-101	Investigative

T78937	TARGETID	T78937
T78937	FORMERID	TTDNS00539
T78937	TARGNAME	Ribosome A (hRA)
T78937	TARGTYPE	Successful
T78937	DRUGINFO	D07JPC	Arbekacin	Approved
T78937	DRUGINFO	D0M4XY	Omacetaxine mepesuccinate	Approved

T89883	TARGETID	T89883
T89883	TARGNAME	Ryanodine receptor (RYR)
T89883	TARGTYPE	Successful
T89883	DRUGINFO	D0I8DD	Dantrolene	Approved
T89883	DRUGINFO	D0U1OO	ARM210	Phase 1

T12427	TARGETID	T12427
T12427	FORMERID	TTDNS00570
T12427	TARGNAME	Sodium pump (NaP)
T12427	TARGTYPE	Successful
T12427	DRUGINFO	D0L4SD	Alpha-acetyldigoxin	Approved
T12427	DRUGINFO	D0M9QK	Beta-acetyldigoxin	Approved

T26240	TARGETID	T26240
T26240	FORMERID	TTDS00459
T26240	TARGNAME	Estramustine binding protein (EMBP)
T26240	TARGTYPE	Successful
T26240	DRUGINFO	D03SRY	Estramustine	Approved

T52007	TARGETID	T52007
T52007	FORMERID	TTDS00457
T52007	TARGNAME	Peripheral carotid chemoreceptor (PCC)
T52007	TARGTYPE	Successful
T52007	DRUGINFO	D0M7BT	Doxapram	Approved

T06042	TARGETID	T06042
T06042	FORMERID	TTDI01903
T06042	TARGNAME	Sinus node I(f) channel (SA node IfC)
T06042	TARGTYPE	Successful
T06042	DRUGINFO	D0S9QA	Ivabradine	Approved

T95212	TARGETID	T95212
T95212	FORMERID	TTDI01158
T95212	TARGNAME	Streptococcus Diphtheria protein (Stre DIPP)
T95212	TARGTYPE	Successful
T95212	DRUGINFO	D0M1PR	Prevnar	Approved
T95212	DRUGINFO	D0I2MA	IO-21	Discontinued in Phase 2

T75041	TARGETID	T75041
T75041	FORMERID	TTDS00458
T75041	TARGNAME	Tumor-associated glycoprotein 72 (TAG-72)
T75041	TARGTYPE	Successful
T75041	DRUGINFO	D0V6RC	Satumomab Pendetide	Approved

T74654	TARGETID	T74654
T74654	FORMERID	TTDS00527
T74654	TARGNAME	Adrenergic neuron (AD neuro)
T74654	TARGTYPE	Successful
T74654	DRUGINFO	D0MP5H	Debrisoquin	Approved
T74654	DRUGINFO	D0N3PE	Guanethidine	Approved

T82349	TARGETID	T82349
T82349	TARGNAME	Bacterial Cell membrane (Bact CM)
T82349	TARGTYPE	Successful
T82349	DRUGINFO	D0B6GW	Diphtheria-tetanus vaccine	Approved
T82349	DRUGINFO	D0F6EO	Amoxicillin	Approved
T82349	DRUGINFO	D0K6MW	Teicoplanin	Approved
T82349	DRUGINFO	D0S3NU	Delamanid	Approved
T82349	DRUGINFO	D03RCV	D2A21	Phase 3
T82349	DRUGINFO	D06XMW	DPK-060	Phase 2
T82349	DRUGINFO	D08CQY	Brilacidin	Phase 2
T82349	DRUGINFO	D0J5ED	LTX-109	Phase 2
T82349	DRUGINFO	D0G6HI	Friulimicin	Phase 1
T82349	DRUGINFO	D0O7RY	IDR-1018	Phase 1
T82349	DRUGINFO	D0PK3W	Lotilibcin	Phase 1
T82349	DRUGINFO	D02QWJ	EREMOMYCIN	Discontinued in Phase 2
T82349	DRUGINFO	D0L8EQ	CB-182804	Discontinued in Phase 1
T82349	DRUGINFO	D0BW9R	BMS-181184	Terminated
T82349	DRUGINFO	D0F6ZS	Ro-25-6833	Terminated

T87119	TARGETID	T87119
T87119	FORMERID	TTDS00463
T87119	TARGNAME	Fungal Cell membrane (Fung CM)
T87119	TARGTYPE	Successful
T87119	DRUGINFO	D02FEM	Natamycin	Approved
T87119	DRUGINFO	D06ZAY	Haloprogin	Approved

T03006	TARGETID	T03006
T03006	FORMERID	TTDI01879
T03006	TARGNAME	Acetylcholine release (Ach rele)
T03006	TARGTYPE	Successful
T03006	DRUGINFO	D0H3AB	Incobotulinum toxin A	Approved
T03006	DRUGINFO	D0M7IH	Abobotulinum toxin A	Approved
T03006	DRUGINFO	D01DPD	KW-6055	Discontinued in Phase 1
T03006	DRUGINFO	D0K7TX	HOE-065	Discontinued in Phase 1

T29064	TARGETID	T29064
T29064	FORMERID	TTDI01890
T29064	TARGNAME	Angiogenesis/myeloma cell growth (AMCG)
T29064	TARGTYPE	Successful
T29064	DRUGINFO	D0A3ZU	Pomalidomide	Approved

T95339	TARGETID	T95339
T95339	FORMERID	TTDI01182
T95339	TARGNAME	Beta-hematin formation (BHF)
T95339	TARGTYPE	Successful
T95339	DRUGINFO	D0Y5ZA	Arteether	Approved
T95339	DRUGINFO	D06OZW	Artemisone	Phase 2/3

T60810	TARGETID	T60810
T60810	FORMERID	TTDI01189
T60810	TARGNAME	Cell mediated immunity response (CMIR)
T60810	TARGTYPE	Successful
T60810	DRUGINFO	D02QQT	Quattvaxem	Approved
T60810	DRUGINFO	D04SOA	H1N1 pandemic influenza A vaccine	Approved
T60810	DRUGINFO	D09AWJ	H5N1 influenza vaccine	Approved
T60810	DRUGINFO	D0BI1C	Live attenuated influenza vaccine	Approved
T60810	DRUGINFO	D0D6NQ	HEV-239	Approved
T60810	DRUGINFO	D0F0ID	Polyoxidonium	Approved
T60810	DRUGINFO	D0F0RR	GSK2592984A	Approved
T60810	DRUGINFO	D0O4RQ	Focetria A(H1N1)	Approved
T60810	DRUGINFO	D0TL1L	Fendrix	Approved
T60810	DRUGINFO	D0Y6NL	Arepanrix	Approved
T60810	DRUGINFO	D0Z4BH	Celtura	Approved
T60810	DRUGINFO	D03FFA	HB-AS02V	Phase 3
T60810	DRUGINFO	D04SNL	Grippol Plus	Phase 3
T60810	DRUGINFO	D05ZAI	Grippol TC	Phase 3
T60810	DRUGINFO	D0HE7I	H1N1 influenza vaccine	Phase 3
T60810	DRUGINFO	D0QO0D	H5N1 influenza vaccine	Phase 3
T60810	DRUGINFO	D06OFZ	LEISH-F1	Phase 2
T60810	DRUGINFO	D0Q1XV	HBV vaccine	Phase 2
T60810	DRUGINFO	D0Y5VR	H5N1 influenza vaccine	Phase 2
T60810	DRUGINFO	D0PY7Z	Aflunov	Phase 1/2
T60810	DRUGINFO	D00HHU	AFO-18	Phase 1
T60810	DRUGINFO	D0O1WR	GMZ-2	Phase 1
T60810	DRUGINFO	D0R2KO	CAF-01	Phase 1
T60810	DRUGINFO	D06IQE	H1N1 influenza vaccine	Discontinued in Phase 3
T60810	DRUGINFO	D0V2GZ	BioVant	Investigative

T21112	TARGETID	T21112
T21112	TARGNAME	DNA replication (DNA repli)
T21112	TARGTYPE	Successful
T21112	DRUGINFO	D0JO3U	Elliptinium acetate	Approved
T21112	DRUGINFO	D0V8QT	Chlorambucil	Approved
T21112	DRUGINFO	D01XWG	Daunorubicin	Approved
T21112	DRUGINFO	D0X1HE	Ozenoxacin	Approved
T21112	DRUGINFO	D0KE1F	DFP-10917	Phase 3

T30418	TARGETID	T30418
T30418	FORMERID	TTDI01179
T30418	TARGNAME	DNA synthesis (DNA synth)
T30418	TARGTYPE	Successful
T30418	DRUGINFO	D0B8UJ	Nelarabine	Approved
T30418	DRUGINFO	D0M1IN	acelarin	Phase 3
T30418	DRUGINFO	D0L9IA	Glufosfamide	Phase 3
T30418	DRUGINFO	D0U1KE	FF-10502-01	Phase 1
T30418	DRUGINFO	D0WM3D	TAR-200	Phase 1
T30418	DRUGINFO	D0T2EP	CLOTURIN	Discontinued in Phase 2
T30418	DRUGINFO	D05PTG	EPD-clofarabine	Terminated

T69189	TARGETID	T69189
T69189	FORMERID	TTDI01547
T69189	TARGNAME	Hedgehog signaling pathway (HS pathway)
T69189	TARGTYPE	Successful
T69189	DRUGINFO	D0V4IB	Itraconazole	Approved
T69189	DRUGINFO	D0S5LO	PF-04449913	Approved
T69189	DRUGINFO	D0GD4Q	Patidegib	Phase 2
T69189	DRUGINFO	D6A7KB	ENV-101	Phase 2

T90848	TARGETID	T90848
T90848	TARGNAME	HGF/Met signaling pathway (HGF/Met pathway)
T90848	TARGTYPE	Successful
T90848	DRUGINFO	D03ZBT	Crizotinib	Approved
T90848	DRUGINFO	DDBY18	Fosgonimeton	Phase 2/3
T90848	DRUGINFO	D07QNH	SAIT301	Investigative

T71556	TARGETID	T71556
T71556	FORMERID	TTDI01858
T71556	TARGNAME	Lymphoid cell adhesion molecule expression (LCDME)
T71556	TARGTYPE	Successful
T71556	DRUGINFO	D00OGX	Anapsos	Approved

T66030	TARGETID	T66030
T66030	FORMERID	TTDI01862
T66030	TARGNAME	Natural killer cell activation (NKA)
T66030	TARGTYPE	Successful
T66030	DRUGINFO	D0X4BZ	Virulizin	Approved

T95498	TARGETID	T95498
T95498	FORMERID	TTDI01894
T95498	TARGNAME	NFE2-related factor 2 pathway (Nrf2 pathway)
T95498	TARGTYPE	Successful
T95498	DRUGINFO	D0A7MY	TECFIDERA	Approved

T90695	TARGETID	T90695
T90695	TARGNAME	PI3K/AKT/mTOR pathway (PAm pathway)
T90695	TARGTYPE	Successful
T90695	DRUGINFO	D03LJR	Sirolimus	Approved
T90695	DRUGINFO	D02ESL	ON-01210.Na	Phase 1
T90695	DRUGINFO	D0D6EW	Glypromate	Discontinued in Phase 2

T65868	TARGETID	T65868
T65868	FORMERID	TTDNS00584
T65868	TARGNAME	RNA synthesis (hRNA synth)
T65868	TARGTYPE	Successful
T65868	DRUGINFO	D06EPF	Plicamycin	Approved

T42748	TARGETID	T42748
T42748	FORMERID	TTDI01832
T42748	TARGNAME	Serotoninnorepinephrinedopamine reuptake (SNDR)
T42748	TARGTYPE	Successful
T42748	DRUGINFO	D01VJN	Olanzapine/fluoxetine combination	Approved
T42748	DRUGINFO	D0W6KM	Dasotraline	Approved
T42748	DRUGINFO	DSIW85	OPC-64005	Phase 2
T42748	DRUGINFO	D05XEA	RP5063	Phase 2
T42748	DRUGINFO	D15BZU	Brilaroxazine	Phase 1

T73760	TARGETID	T73760
T73760	FORMERID	TTDI01856
T73760	TARGNAME	T(H2) cytokine production (TH2 produ)
T73760	TARGTYPE	Successful
T73760	DRUGINFO	D0P8MI	Suplatast tosilate	Approved

T84665	TARGETID	T84665
T84665	FORMERID	TTDI01853
T84665	TARGNAME	Tromboxane A2 synthesis (TA2 synth)
T84665	TARGTYPE	Successful
T84665	DRUGINFO	D0F5ZM	Imidazole salicylate	Approved

T17687	TARGETID	T17687
T17687	FORMERID	TTDR00314
T17687	TARGNAME	Fibroblast growth factor receptor (FGFR)
T17687	TARGTYPE	Successful
T17687	SYNONYMS	FGF receptor
T17687	DRUGINFO	D01ZLU	Futibatinib	Approved
T17687	DRUGINFO	D03LWG	Infigratinib	Approved
T17687	DRUGINFO	D0NW0T	Erdafitinib	Approved
T17687	DRUGINFO	D0B0AX	HIF-1alpha	Phase 4
T17687	DRUGINFO	D07PQJ	ARQ-087	Phase 3
T17687	DRUGINFO	D0NU0U	AZD4547	Phase 2/3
T17687	DRUGINFO	D0E8PR	BAY1163877	Phase 2
T17687	DRUGINFO	DZM65T	ICP-192	Phase 2
T17687	DRUGINFO	D0XT0W	Debio 1347	Phase 2
T17687	DRUGINFO	D0H9FR	PRN1371	Phase 1
T17687	DRUGINFO	D06SKN	SU5403	Investigative
T17687	DRUGINFO	D0HE0E	SU4984	Investigative
T17687	DRUGINFO	D0O5CL	ARO 087	Investigative
T17687	DRUGINFO	D0VF6E	PD173074	Investigative

T49049	TARGETID	T49049
T49049	FORMERID	TTDR00940
T49049	TARGNAME	Immunoglobulin Fc receptor (FCR)
T49049	TARGTYPE	Successful
T49049	BIOCLASS	Immunoglobulin
T49049	DRUGINFO	D01TWG	Rozanolixizumab	Approved
T49049	DRUGINFO	DS69NO	Nipocalimab	Phase 3
T49049	DRUGINFO	D0R3KS	DX-2500	Investigative

T80942	TARGETID	T80942
T80942	FORMERID	TTDI01565
T80942	TARGNAME	Matrix metalloproteinase (MMP)
T80942	TARGTYPE	Successful
T80942	SYNONYMS	Matrix metalloproteinase
T80942	DRUGINFO	D5IS6V	Abametapir	Approved
T80942	DRUGINFO	D0N4IV	S-3304	Phase 1/2
T80942	DRUGINFO	D0I8KA	BLZ-100	Phase 1/2
T80942	DRUGINFO	D00UCC	ABT-518	Discontinued in Phase 1
T80942	DRUGINFO	D01JOA	D-1927	Discontinued in Phase 1
T80942	DRUGINFO	D08NES	S-3536	Discontinued in Phase 1
T80942	DRUGINFO	D0RJ2P	BB-2983	Discontinued in Phase 1
T80942	DRUGINFO	D0W8QH	ONO-4817	Discontinued in Phase 1
T80942	DRUGINFO	D0EF9B	DFD-11	Application submitted
T80942	DRUGINFO	D06NOU	D-9120	Terminated
T80942	DRUGINFO	D09TRM	D-5410	Terminated
T80942	DRUGINFO	D0G2CL	AG-2024	Terminated
T80942	DRUGINFO	D0GA3M	BE-16627B	Terminated
T80942	DRUGINFO	D0H5CD	GI-129471	Terminated
T80942	DRUGINFO	D0L0CL	CP-471358	Terminated
T80942	DRUGINFO	D0L4GF	AG-3296	Terminated
T80942	DRUGINFO	D0V0RW	BB-1433	Terminated
T80942	DRUGINFO	D05QAA	PNU-248686A	Investigative

T97617	TARGETID	T97617
T97617	TARGNAME	Sphingosine-1 phosphate receptor (S1PR)
T97617	TARGTYPE	Successful
T97617	BIOCLASS	GPCR rhodopsin
T97617	DRUGINFO	D07FKQ	Siponimod	Approved
T97617	DRUGINFO	D0WB0R	KPP203	Phase 2

T89950	TARGETID	T89950
T89950	TARGNAME	Calcitonin gene-related peptide (CALC)
T89950	TARGTYPE	Successful
T89950	DRUGINFO	D0H6QD	Eptinezumab	Approved
T89950	DRUGINFO	DM6KV2	TEV-48125	Phase 3
T89950	DRUGINFO	D0Z1OT	ALD-403	Phase 2
T89950	DRUGINFO	D04JAT	PF-4427429	Phase 1
T89950	DRUGINFO	D01SPI	CGRP	Discontinued in Phase 2

T84457	TARGETID	T84457
T84457	TARGNAME	GABA(A) receptor (GABAR)
T84457	TARGTYPE	Successful
T84457	DRUGINFO	D0X0CH	Ganaxolone	Approved
T84457	DRUGINFO	D0J1ZH	PH94B NS	Phase 3
T84457	DRUGINFO	DKI03V	OV101	Phase 3
T84457	DRUGINFO	DCA5M2	Padsevonil	Phase 2/3
T84457	DRUGINFO	D0EV9B	BTD-001	Phase 2
T84457	DRUGINFO	D4A2DQ	SAGE-324	Phase 2
T84457	DRUGINFO	DUAO82	Evt201	Phase 2

T88637	TARGETID	T88637
T88637	TARGNAME	Myosin (MYO)
T88637	TARGTYPE	Successful
T88637	DRUGINFO	D0D1ZF	Mavacamten	Approved
T88637	DRUGINFO	DT52FI	MYK-491	Phase 2

T27021	TARGETID	T27021
T27021	FORMERID	TTDI01578
T27021	TARGNAME	Transferase unspecific (TF)
T27021	TARGTYPE	Successful
T27021	DRUGINFO	D0U3YU	Ademetionine	Approved
T27021	DRUGINFO	D0B2WQ	Lomeguatrib	Discontinued in Phase 2
T27021	DRUGINFO	D0V2ZJ	BCX-25	Terminated

T13712	TARGETID	T13712
T13712	FORMERID	TTDI01206
T13712	TARGNAME	Cholesterol synthesis (Chole synth)
T13712	TARGTYPE	Successful
T13712	DRUGINFO	D0D9NY	Bempedoic acid	Approved

T81774	TARGETID	T81774
T81774	FORMERID	TTDI01211
T81774	TARGNAME	Tubulin polymerization (TubP)
T81774	TARGTYPE	Successful
T81774	DRUGINFO	D02LJW	Tirbanibulin	Approved
T81774	DRUGINFO	D05BGY	PM184	Phase 2

T86671	TARGETID	T86671
T86671	FORMERID	TTDI01806
T86671	TARGNAME	Orexin receptor (HCRTR)
T86671	TARGTYPE	Successful
T86671	SYNONYMS	Hypocretin receptor
T86671	FUNCTION	Moderately selective excitatory receptor for orexin-A and, with a lower affinity, for orexin-B neuropeptide. Seems to be exclusively coupled to the G(q) subclass of heteromeric G proteins, which activates the phospholipase C mediated signaling cascade.
T86671	DRUGINFO	DFN1D5	Daridorexant	Approved
T86671	DRUGINFO	D0ZO9C	1,2-diamino cyclopentane-based derivative 28	Patented

T05876	TARGETID	T05876
T05876	UNIPROID	VGP_EBOZM
T05876	TARGNAME	Ebola virus Envelope glycoprotein (EV GP)
T05876	GENENAME	EV GP
T05876	TARGTYPE	Successful
T05876	SYNONYMS	GP1,2; GP
T05876	FUNCTION	Trimeric GP1,2 complexes form the virion surface spikes and mediate the viral entry processes, with GP1 acting as the receptor-binding subunit and GP2 as the membrane fusion subunit. At later times of infection, downregulates the expression of various host cell surface molecules that are essential for immune surveillance and cell adhesion. Down-modulates several integrins including ITGA1, ITGA2, ITGA3, ITGA4, ITGA5, ITGA6, ITGAV and ITGB1. This decrease in cell adhesion molecules may lead to cell detachment, contributing to the disruption of blood vessel integrity and hemorrhages developed during infection (cytotoxicity) (Probable). Interacts with host TLR4 and thereby stimulates the differentiation and activation of monocytes leading to bystander death of T-lymphocytes. Downregulates as well the function of host natural killer cells. Counteracts the antiviral effect of host BST2/tetherin that restricts release of progeny virions from infected cells. However, cooperates with VP40 and host BST2 to activate canonical NF-kappa-B pathway in a manner dependent on neddylation.
T05876	SEQUENCE	MGVTGILQLPRDRFKRTSFFLWVIILFQRTFSIPLGVIHNSTLQVSDVDKLVCRDKLSSTNQLRSVGLNLEGNGVATDVPSATKRWGFRSGVPPKVVNYEAGEWAENCYNLEIKKPDGSECLPAAPDGIRGFPRCRYVHKVSGTGPCAGDFAFHKEGAFFLYDRLASTVIYRGTTFAEGVVAFLILPQAKKDFFSSHPLREPVNATEDPSSGYYSTTIRYQATGFGTNETEYLFEVDNLTYVQLESRFTPQFLLQLNETIYTSGKRSNTTGKLIWKVNPEIDTTIGEWAFWETKKNLTRKIRSEELSFTVVSNGAKNISGQSPARTSSDPGTNTTTEDHKIMASENSSAMVQVHSQGREAAVSHLTTLATISTSPQSLTTKPGPDNSTHNTPVYKLDISEATQVEQHHRRTDNDSTASDTPSATTAAGPPKAENTNTSKSTDFLDPATTTSPQNHSETAGNNNTHHQDTGEESASSGKLGLITNTIAGVAGLITGGRRTRREAIVNAQPKCNPNLHYWTTQDEGAAIGLAWIPYFGPAAEGIYIEGLMHNQDGLICGLRQLANETTQALQLFLRATTELRTFSILNRKAIDFLLQRWGGTCHILGPDCCIEPHDWTKNITDKIDQIIHDFVDKTLPDQGDNDNWWTGWRQWIPAGIGVTGVIIAVIALFCICKFVF
T05876	DRUGINFO	DRM1X5	Ansuvimab	Approved
T05876	DRUGINFO	D1U3EG	MAb114	Phase 2/3

T07341	TARGETID	T07341
T07341	TARGNAME	Dabigatran (Dabi)
T07341	TARGTYPE	Successful
T07341	DRUGINFO	D0B9FW	Idarucizumab	Approved

T17629	TARGETID	T17629
T17629	UNIPROID	TACD2_HUMAN
T17629	TARGNAME	Tumor associated calcium signal transducer 2 (TACSTD2)
T17629	GENENAME	TACSTD2
T17629	TARGTYPE	Successful
T17629	SYNONYMS	Cell surface glycoprotein Trop-2; Membrane component chromosome 1 surface marker 1; Pancreatic carcinoma marker protein GA733-1
T17629	FUNCTION	May function as a growth factor receptor.
T17629	SEQUENCE	MARGPGLAPPPLRLPLLLLVLAAVTGHTAAQDNCTCPTNKMTVCSPDGPGGRCQCRALGSGMAVDCSTLTSKCLLLKARMSAPKNARTLVRPSEHALVDNDGLYDPDCDPEGRFKARQCNQTSVCWCVNSVGVRRTDKGDLSLRCDELVRTHHILIDLRHRPTAGAFNHSDLDAELRRLFRERYRLHPKFVAAVHYEQPTIQIELRQNTSQKAAGDVDIGDAAYYFERDIKGESLFQGRGGLDLRVRGEPLQVERTLIYYLDEIPPKFSMKRLTAGLIAVIVVVVVALVAGMAVLVITNRRKSGKYKKVEIKELGELRKEPSL
T17629	DRUGINFO	D8LAE2	Sacituzumab govitecan	Approved
T17629	DRUGINFO	DOS62C	SKB264	Phase 1/2
T17629	DRUGINFO	DKHL40	YH012	Investigative

T20563	TARGETID	T20563
T20563	UNIPROID	EGFR_HUMAN
T20563	TARGNAME	EGFR Exon20ins mutant (EGFR Exon20ins)
T20563	GENENAME	EGFR
T20563	TARGTYPE	Successful
T20563	BIOCLASS	Kinase
T20563	SEQUENCE	MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALAVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDFQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRVAPQSSEFIGA
T20563	DRUGINFO	DI4HA7	Mobocertinib	Approved
T20563	DRUGINFO	DM8Y2N	DZD9008	Phase 1/2

T23519	TARGETID	T23519
T23519	UNIPROID	GPC5D_HUMAN
T23519	TARGNAME	G-protein coupled receptor C 5D (GPRC5D)
T23519	GENENAME	GPRC5D
T23519	TARGTYPE	Successful
T23519	FUNCTION	extracellular exosome, intracellular membrane-bounded organelle, plasma membrane, receptor complex, protein kinase activator activity
T23519	SEQUENCE	MYKDCIESTGDYFLLCDAEGPWGIILESLAILGIVVTILLLLAFLFLMRKIQDCSQWNVLPTQLLFLLSVLGLFGLAFAFIIELNQQTAPVRYFLFGVLFALCFSCLLAHASNLVKLVRGCVSFSWTTILCIAIGCSLLQIIIATEYVTLIMTRGMMFVNMTPCQLNVDFVVLLVYVLFLMALTFFVSKATFCGPCENWKQHGRLIFITVLFSIIIWVVWISMLLRGNPQFQRQPQWDDPVVCIALVTNAWVFLLLYIVPELCILYRSCRQECPLQGNACPVTAYQHSFQVENQELSRARDSDGAEEDVALTSYGTPIQPQTVDPTQECFIPQAKLSPQQDAGGV
T23519	DRUGINFO	DXR1A6	Talquetamab	Approved
T23519	DRUGINFO	DV9M0Y	GPRC5D CAR-T cell therapy	Phase 1
T23519	DRUGINFO	D6RT9L	RG6234	Phase 1

T32790	TARGETID	T32790
T32790	UNIPROID	LDHA_HUMAN
T32790	TARGNAME	LDHA messenger RNA (LDHA mRNA)
T32790	GENENAME	LDHA
T32790	TARGTYPE	Successful
T32790	SYNONYMS	LDH-A; Cell proliferation-inducing gene 19 protein; LDH muscle subunit; LDH-M; Renal carcinoma antigen NY-REN-59
T32790	BIOCLASS	mRNA target
T32790	ECNUMBER	EC 1.1.1.27
T32790	SEQUENCE	MATLKDQLIYNLLKEEQTPQNKITVVGVGAVGMACAISILMKDLADELALVDVIEDKLKGEMMDLQHGSLFLRTPKIVSGKDYNVTANSKLVIITAGARQQEGESRLNLVQRNVNIFKFIIPNVVKYSPNCKLLIVSNPVDILTYVAWKISGFPKNRVIGSGCNLDSARFRYLMGERLGVHPLSCHGWVLGEHGDSSVPVWSGMNVAGVSLKTLHPDLGTDKDKEQWKEVHKQVVESAYEVIKLKGYTSWAIGLSVADLAESIMKNLRRVHPVSTMIKGLYGIKDDVFLSVPCILGQNGISDLVKVTLTSEEEARLKKSADTLWGIQKELQF
T32790	DRUGINFO	DZ8DF0	Nedosiran	Approved

T59480	TARGETID	T59480
T59480	UNIPROID	RASK_HUMAN
T59480	TARGNAME	KRAS G12C mutant (KRAS G12C)
T59480	GENENAME	KRAS
T59480	TARGTYPE	Successful
T59480	SEQUENCE	MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM
T59480	DRUGINFO	D0R7LD	Sotorasib	Approved
T59480	DRUGINFO	DUQV41	Adagrasib	Approved
T59480	DRUGINFO	D37IQM	JDQ443	Phase 3
T59480	DRUGINFO	DEXM29	LY3499446	Phase 1/2
T59480	DRUGINFO	DDZ6B0	RG6330	Phase 1
T59480	DRUGINFO	DZY4R2	JNJ-74699157	Phase 1

T86041	TARGETID	T86041
T86041	UNIPROID	HEM1_HUMAN
T86041	TARGNAME	ALAS1 messenger RNA (ALAS1 mRNA)
T86041	GENENAME	ALAS1
T86041	TARGTYPE	Successful
T86041	SYNONYMS	ALAS-H; 5-aminolevulinic acid synthase 1; Delta-ALA synthase 1; Delta-aminolevulinate synthase 1
T86041	BIOCLASS	mRNA target
T86041	ECNUMBER	EC 2.3.1.37
T86041	SEQUENCE	MESVVRRCPFLSRVPQAFLQKAGKSLLFYAQNCPKMMEVGAKPAPRALSTAAVHYQQIKETPPASEKDKTAKAKVQQTPDGSQQSPDGTQLPSGHPLPATSQGTASKCPFLAAQMNQRGSSVFCKASLELQEDVQEMNAVRKEVAETSAGPSVVSVKTDGGDPSGLLKNFQDIMQKQRPERVSHLLQDNLPKSVSTFQYDRFFEKKIDEKKNDHTYRVFKTVNRRAHIFPMADDYSDSLITKKQVSVWCSNDYLGMSRHPRVCGAVMDTLKQHGAGAGGTRNISGTSKFHVDLERELADLHGKDAALLFSSCFVANDSTLFTLAKMMPGCEIYSDSGNHASMIQGIRNSRVPKYIFRHNDVSHLRELLQRSDPSVPKIVAFETVHSMDGAVCPLEELCDVAHEFGAITFVDEVHAVGLYGARGGGIGDRDGVMPKMDIISGTLGKAFGCVGGYIASTSSLIDTVRSYAAGFIFTTSLPPMLLAGALESVRILKSAEGRVLRRQHQRNVKLMRQMLMDAGLPVVHCPSHIIPVRVADAAKNTEVCDELMSRHNIYVQAINYPTVPRGEELLRIAPTPHHTPQMMNYFLENLLVTWKQVGLELKPHSSAECNFCRRPLHFEVMSEREKSYFSGLSKLVSAQA
T86041	DRUGINFO	DF36DY	Givosiran	Approved

T63155	TARGETID	T63155
T63155	UNIPROID	KPYR_HUMAN
T63155	TARGNAME	Pyruvate kinase PKLR (PKLR)
T63155	GENENAME	PKLR
T63155	TARGTYPE	Successful
T63155	SYNONYMS	Pyruvate kinase 1; Pyruvate kinase isozymes L/R; R-type/L-type pyruvate kinase; Red cell/liver pyruvate kinase
T63155	FUNCTION	Pyruvate kinase that catalyzes the conversion of phosphoenolpyruvate to pyruvate with the synthesis of ATP, and which plays a key role in glycolysis. {ECO:0000269|PubMed:11960989}.
T63155	PDBSTRUC	2VGB;2VGF;2VGG;2VGI;4IMA;4IP7;5SC8;5SC9;5SCA;5SCB;5SCC;5SCD;5SCE;5SCF;5SCG;5SCH;5SCI;5SCJ;5SCK;5SCL;5SDT;6NN4;6NN5;6NN7;6NN8;7FRV;7FRW;7FRX;7FRY;7FRZ;7FS0;7FS1;7FS2;7FS3;7FS4;7FS5;7FS6;7FS7;7FS8;7FS9;7FSA;7FSB;7FSC;7FSD;7QDN;7QZU
T63155	BIOCLASS	Kinase
T63155	ECNUMBER	EC 2.7.1.40
T63155	SEQUENCE	MSIQENISSLQLRSWVSKSQRDLAKSILIGAPGGPAGYLRRASVAQLTQELGTAFFQQQQLPAAMADTFLEHLCLLDIDSEPVAARSTSIIATIGPASRSVERLKEMIKAGMNIARLNFSHGSHEYHAESIANVREAVESFAGSPLSYRPVAIALDTKGPEIRTGILQGGPESEVELVKGSQVLVTVDPAFRTRGNANTVWVDYPNIVRVVPVGGRIYIDDGLISLVVQKIGPEGLVTQVENGGVLGSRKGVNLPGAQVDLPGLSEQDVRDLRFGVEHGVDIVFASFVRKASDVAAVRAALGPEGHGIKIISKIENHEGVKRFDEILEVSDGIMVARGDLGIEIPAEKVFLAQKMMIGRCNLAGKPVVCATQMLESMITKPRPTRAETSDVANAVLDGADCIMLSGETAKGNFPVEAVKMQHAIAREAEAAVYHRQLFEELRRAAPLSRDPTEVTAIGAVEAAFKCCAAAIIVLTTTGRSAQLLSRYRPRAAVIAVTRSAQAARQVHLCRGVFPLLYREPPEAIWADDVDRRVQFGIESGKLRGFLRVGDLVIVVTGWRPGSGYTNIMRVLSIS
T63155	DRUGINFO	D0C8AP	Mitapivat	Approved
T63155	DRUGINFO	D0YX3D	Olipudase alfa	Approved
T63155	DRUGINFO	D6DO9A	RP-L301	Phase 1

T63156	TARGETID	T63156
T63156	UNIPROID	MA2B1_HUMAN
T63156	TARGNAME	Lysosomal alpha-mannosidase (MAN2B1)
T63156	GENENAME	MAN2B1
T63156	TARGTYPE	Successful
T63156	SYNONYMS	Laman; Lysosomal acid alpha-mannosidase; Mannosidase alpha class 2B member 1; Mannosidase alpha-B
T63156	FUNCTION	Necessary for the catabolism of N-linked carbohydrates released during glycoprotein turnover. Cleaves all known types of alpha-mannosidic linkages.
T63156	BIOCLASS	Glycosyl hydrolase
T63156	ECNUMBER	EC 3.2.1.24
T63156	SEQUENCE	MGAYARASGVCARGCLDSAGPWTMSRALRPPLPPLCFFLLLLAAAGARAGGYETCPTVQPNMLNVHLLPHTHDDVGWLKTVDQYFYGIKNDIQHAGVQYILDSVISALLADPTRRFIYVEIAFFSRWWHQQTNATQEVVRDLVRQGRLEFANGGWVMNDEAATHYGAIVDQMTLGLRFLEDTFGNDGRPRVAWHIDPFGHSREQASLFAQMGFDGFFFGRLDYQDKWVRMQKLEMEQVWRASTSLKPPTADLFTGVLPNGYNPPRNLCWDVLCVDQPLVEDPRSPEYNAKELVDYFLNVATAQGRYYRTNHTVMTMGSDFQYENANMWFKNLDKLIRLVNAQQAKGSSVHVLYSTPACYLWELNKANLTWSVKHDDFFPYADGPHQFWTGYFSSRPALKRYERLSYNFLQVCNQLEALVGLAANVGPYGSGDSAPLNEAMAVLQHHDAVSGTSRQHVANDYARQLAAGWGPCEVLLSNALARLRGFKDHFTFCQQLNISICPLSQTAARFQVIVYNPLGRKVNWMVRLPVSEGVFVVKDPNGRTVPSDVVIFPSSDSQAHPPELLFSASLPALGFSTYSVAQVPRWKPQARAPQPIPRRSWSPALTIENEHIRATFDPDTGLLMEIMNMNQQLLLPVRQTFFWYNASIGDNESDQASGAYIFRPNQQKPLPVSRWAQIHLVKTPLVQEVHQNFSAWCSQVVRLYPGQRHLELEWSVGPIPVGDTWGKEVISRFDTPLETKGRFYTDSNGREILERRRDYRPTWKLNQTEPVAGNYYPVNTRIYITDGNMQLTVLTDRSQGGSSLRDGSLELMVHRRLLKDDGRGVSEPLMENGSGAWVRGRHLVLLDTAQAAAAGHRLLAEQEVLAPQVVLAPGGGAAYNLGAPPRTQFSGLRRDLPPSVHLLTLASWGPEMVLLRLEHQFAVGEDSGRNLSAPVTLNLRDLFSTFTITRLQETTLVANQLREAASRLKWTTNTGPTPHQTPYQLDPANITLEPMEIRTFLASVQWKEVDG
T63156	DRUGINFO	D96DLV	Velmanase alfa	Approved

T63158	TARGETID	T63158
T63158	UNIPROID	ASM_HUMAN
T63158	TARGNAME	Sphingomyelin phosphodiesterase (SMPD1)
T63158	GENENAME	SMPD1
T63158	TARGTYPE	Successful
T63158	SYNONYMS	Acid sphingomyelinase; aSMase
T63158	FUNCTION	Converts sphingomyelin to ceramide (PubMed:1840600, PubMed:18815062, PubMed:27659707, PubMed:25920558, PubMed:25339683, PubMed:33163980, PubMed:12563314). Exists as two enzymatic forms that arise from alternative trafficking of a single protein precursor, one that is targeted to the endolysosomal compartment, whereas the other is released extracellularly (PubMed:21098024, PubMed:9660788, PubMed:20807762). However, in response to various forms of stress, lysosomal exocytosis may represent a major source of the secretory form (PubMed:20530211, PubMed:12563314, PubMed:20807762, PubMed:9393854, PubMed:22573858). {ECO:0000269|PubMed:12563314, ECO:0000269|PubMed:1840600, ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:20530211, ECO:0000269|PubMed:20807762, ECO:0000269|PubMed:21098024, ECO:0000269|PubMed:22573858, ECO:0000269|PubMed:25339683, ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707, ECO:0000269|PubMed:33163980, ECO:0000269|PubMed:9393854, ECO:0000269|PubMed:9660788, ECO:0000305}.; In the lysosomes, converts sphingomyelin to ceramide (PubMed:20807762, PubMed:21098024). Plays an important role in the export of cholesterol from the intraendolysosomal membranes (PubMed:25339683). Also has phospholipase C activities toward 1,2-diacylglycerolphosphocholine and 1,2-diacylglycerolphosphoglycerol (PubMed:25339683). Modulates stress-induced apoptosis through the production of ceramide (PubMed:8706124). {ECO:0000269|PubMed:20807762, ECO:0000269|PubMed:21098024, ECO:0000269|PubMed:25339683, ECO:0000269|PubMed:8706124}.; When secreted, modulates cell signaling with its ability to reorganize the plasma membrane by converting sphingomyelin to ceramide (PubMed:12563314, PubMed:20807762, PubMed:17303575). Secreted form is increased in response to stress and inflammatory mediators such as IL1B, IFNG or TNF as well as upon infection with bacteria and viruses (PubMed:12563314, PubMed:20807762, PubMed:9393854). Produces the release of ceramide in the outer leaflet of the plasma membrane playing a central role in host defense (PubMed:12563314, PubMed:20807762, PubMed:9393854). Ceramide reorganizes these rafts into larger signaling platforms that are required to internalize P. aeruginosa, induce apoptosis and regulate the cytokine response in infected cells (PubMed:12563314). In wounded cells, the lysosomal form is released extracellularly in the presence of Ca(2+) and promotes endocytosis and plasma membrane repair (PubMed:20530211). {ECO:0000269|PubMed:12563314, ECO:0000269|PubMed:17303575, ECO:0000269|PubMed:20530211, ECO:0000269|PubMed:20807762, ECO:0000269|PubMed:9393854}.; [Sphingomyelin phosphodiesterase, processed form]: This form is generated following cleavage by CASP7 in the extracellular milieu in response to bacterial infection (PubMed:21157428). It shows increased ability to convert sphingomyelin to ceramide and promotes plasma membrane repair (By similarity). Plasma membrane repair by ceramide counteracts the action of gasdermin-D (GSDMD) perforin (PRF1) pores that are formed in response to bacterial infection (By similarity). {ECO:0000250|UniProtKB:Q04519, ECO:0000269|PubMed:21157428}.; (Microbial infection) Secretion is activated by bacteria such as P. aeruginos, N. gonorrhoeae and others, this activation results in the release of ceramide in the outer leaflet of the plasma membrane which facilitates the infection. {ECO:0000269|PubMed:12563314, ECO:0000269|PubMed:9393854, ECO:0000305|PubMed:31155842}.; (Microbial infection) Secretion is activated by human coronaviruses SARS-CoV and SARS-CoV-2 as well as Zaire ebolavirus, this activation results in the release of ceramide in the outer leaflet of the plasma membrane which facilitates the infection. {ECO:0000269|PubMed:22573858, ECO:0000269|PubMed:33163980}.; [Isoform 2]: Lacks residues that bind the cofactor Zn(2+) and has no enzyme activity. {ECO:0000269|PubMed:1840600, ECO:0000305}.; [Isoform 3]: Lacks residues that bind the cofactor Zn(2+) and has no enzyme activity. {ECO:0000269|PubMed:1840600, ECO:0000305}.
T63158	PDBSTRUC	5I81;5I85;5I8R;5JG8
T63158	ECNUMBER	EC 3.1.4.12; EC 3.1.4.3
T63158	SEQUENCE	MPRYGASLRQSCPRSGREQGQDGTAGAPGLLWMGLVLALALALALALALSDSRVLWAPAEAHPLSPQGHPARLHRIVPRLRDVFGWGNLTCPICKGLFTAINLGLKKEPNVARVGSVAIKLCNLLKIAPPAVCQSIVHLFEDDMVEVWRRSVLSPSEACGLLLGSTCGHWDIFSSWNISLPTVPKPPPKPPSPPAPGAPVSRILFLTDLHWDHDYLEGTDPDCADPLCCRRGSGLPPASRPGAGYWGEYSKCDLPLRTLESLLSGLGPAGPFDMVYWTGDIPAHDVWHQTRQDQLRALTTVTALVRKFLGPVPVYPAVGNHESTPVNSFPPPFIEGNHSSRWLYEAMAKAWEPWLPAEALRTLRIGGFYALSPYPGLRLISLNMNFCSRENFWLLINSTDPAGQLQWLVGELQAAEDRGDKVHIIGHIPPGHCLKSWSWNYYRIVARYENTLAAQFFGHTHVDEFEVFYDEETLSRPLAVAFLAPSATTYIGLNPGYRVYQIDGNYSGSSHVVLDHETYILNLTQANIPGAIPHWQLLYRARETYGLPNTLPTAWHNLVYRMRGDMQLFQTFWFLYHKGHPPSEPCGTPCRLATLCAQLSARADSPALCRHLMPDGSLPEAQSLWPRPLFC
T63158	DRUGINFO	D0YX3D	Olipudase alfa	Approved

T25258	TARGETID	T25258
T25258	FORMERID	TTDR00007
T25258	UNIPROID	MDR1_HUMAN
T25258	TARGNAME	Multidrug resistance protein 1 (ABCB1)
T25258	GENENAME	ABCB1
T25258	TARGTYPE	Clinical trial
T25258	SYNONYMS	PGY1; P-glycoprotein 1; P-gp; Pgp; MDR1; CD243 antigen; CD243; ATP-binding cassette sub-family B member 1
T25258	FUNCTION	Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
T25258	PDBSTRUC	6QEX; 6FN4; 6FN1; 6C0V
T25258	BIOCLASS	ABC transporter
T25258	ECNUMBER	EC 7.6.2.2
T25258	SEQUENCE	MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLYMVVGTLAAIIHGAGLPLMMLVFGEMTDIFANAGNLEDLMSNITNRSDINDTGFFMNLEEDMTRYAYYYSGIGAGVLVAAYIQVSFWCLAAGRQIHKIRKQFFHAIMRQEIGWFDVHDVGELNTRLTDDVSKINEGIGDKIGMFFQSMATFFTGFIVGFTRGWKLTLVILAISPVLGLSAAVWAKILSSFTDKELLAYAKAGAVAEEVLAAIRTVIAFGGQKKELERYNKNLEEAKRIGIKKAITANISIGAAFLLIYASYALAFWYGTTLVLSGEYSIGQVLTVFFSVLIGAFSVGQASPSIEAFANARGAAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLEFRNVHFSYPSRKEVKILKGLNLKVQSGQTVALVGNSGCGKSTTVQLMQRLYDPTEGMVSVDGQDIRTINVRFLREIIGVVSQEPVLFATTIAENIRYGRENVTMDEIEKAVKEANAYDFIMKLPHKFDTLVGERGAQLSGGQKQRIAIARALVRNPKILLLDEATSALDTESEAVVQVALDKARKGRTTIVIAHRLSTVRNADVIAGFDDGVIVEKGNHDELMKEKGIYFKLVTMQTAGNEVELENAADESKSEIDALEMSSNDSRSSLIRKRSTRRSVRGSQAQDRKLSTKEALDESIPPVSFWRIMKLNLTEWPYFVVGVFCAIINGGLQPAFAIIFSKIIGVFTRIDDPETKRQNSNLFSLLFLALGIISFITFFLQGFTFGKAGEILTKRLRYMVFRSMLRQDVSWFDDPKNTTGALTTRLANDAAQVKGAIGSRLAVITQNIANLGTGIIISFIYGWQLTLLLLAIVPIIAIAGVVEMKMLSGQALKDKKELEGSGKIATEAIENFRTVVSLTQEQKFEHMYAQSLQVPYRNSLRKAHIFGITFSFTQAMMYFSYAGCFRFGAYLVAHKLMSFEDVLLVFSAVVFGAMAVGQVSSFAPDYAKAKISAAHIIMIIEKTPLIDSYSTEGLMPNTLEGNVTFGEVVFNYPTRPDIPVLQGLSLEVKKGQTLALVGSSGCGKSTVVQLLERFYDPLAGKVLLDGKEIKRLNVQWLRAHLGIVSQEPILFDCSIAENIAYGDNSRVVSQEEIVRAAKEANIHAFIESLPNKYSTKVGDKGTQLSGGQKQRIAIARALVRQPHILLLDEATSALDTESEKVVQEALDKAREGRTCIVIAHRLSTIQNADLIVVFQNGRVKEHGTHQQLLAQKGIYFSMVSVQAGTKRQ
T25258	DRUGINFO	D09LSY	EDP-322	Phase 1
T25258	DRUGINFO	D0GS2W	W-198	Phase 1
T25258	DRUGINFO	D06XVF	CBT-1	Discontinued in Phase 3
T25258	DRUGINFO	D06DCL	LY335979	Discontinued in Phase 3
T25258	DRUGINFO	D02VJY	Biricodar	Discontinued in Phase 2
T25258	DRUGINFO	D04RLX	Tariquidar	Discontinued in Phase 2
T25258	DRUGINFO	D0CO2M	S-9788	Discontinued in Phase 2
T25258	DRUGINFO	D01GDH	XR-9051	Discontinued in Phase 1
T25258	DRUGINFO	D09FGX	Elacridar	Discontinued in Phase 1
T25258	DRUGINFO	D0SR4G	ONT-093	Discontinued in Phase 1
T25258	DRUGINFO	D05XGZ	6-(3,5-dimethoxy-phenyl)-naphthalen-2-ol	Investigative
T25258	DRUGINFO	D03PLP	[1,1':2',1'']-terphenyl-4,3'',5''-triol	Investigative
T25258	DRUGINFO	D04GYT	XR-9456	Investigative
T25258	DRUGINFO	D09HIM	XR-9504	Investigative
T25258	DRUGINFO	D0A4TF	XR-9544	Investigative
T25258	DRUGINFO	D0AW4W	4,3'',5''-trimethoxy-[1,1':2',1'']-terphenyl	Investigative
T25258	DRUGINFO	D0S8CE	XR-9577	Investigative
T25258	DRUGINFO	D0O9NE	TRISMETHOXYRESVERATROL	Investigative

T22274	TARGETID	T22274
T22274	FORMERID	TTDNC00542
T22274	UNIPROID	HDAC6_HUMAN
T22274	TARGNAME	Histone deacetylase 6 (HDAC6)
T22274	GENENAME	HDAC6
T22274	TARGTYPE	Clinical trial
T22274	SYNONYMS	KIAA0901; JM21; HD6
T22274	FUNCTION	Gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Plays a central role in microtubule-dependent cell motility via deacetylation of tubulin. Involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4).
T22274	PDBSTRUC	6CEF; 6CEE; 6CED; 6CEC; 6CEA
T22274	BIOCLASS	Carbon-nitrogen hydrolase
T22274	ECNUMBER	EC 3.5.1.98
T22274	SEQUENCE	MTSTGQDSTTTRQRRSRQNPQSPPQDSSVTSKRNIKKGAVPRSIPNLAEVKKKGKMKKLGQAMEEDLIVGLQGMDLNLEAEALAGTGLVLDEQLNEFHCLWDDSFPEGPERLHAIKEQLIQEGLLDRCVSFQARFAEKEELMLVHSLEYIDLMETTQYMNEGELRVLADTYDSVYLHPNSYSCACLASGSVLRLVDAVLGAEIRNGMAIIRPPGHHAQHSLMDGYCMFNHVAVAARYAQQKHRIRRVLIVDWDVHHGQGTQFTFDQDPSVLYFSIHRYEQGRFWPHLKASNWSTTGFGQGQGYTINVPWNQVGMRDADYIAAFLHVLLPVALEFQPQLVLVAAGFDALQGDPKGEMAATPAGFAQLTHLLMGLAGGKLILSLEGGYNLRALAEGVSASLHTLLGDPCPMLESPGAPCRSAQASVSCALEALEPFWEVLVRSTETVERDNMEEDNVEESEEEGPWEPPVLPILTWPVLQSRTGLVYDQNMMNHCNLWDSHHPEVPQRILRIMCRLEELGLAGRCLTLTPRPATEAELLTCHSAEYVGHLRATEKMKTRELHRESSNFDSIYICPSTFACAQLATGAACRLVEAVLSGEVLNGAAVVRPPGHHAEQDAACGFCFFNSVAVAARHAQTISGHALRILIVDWDVHHGNGTQHMFEDDPSVLYVSLHRYDHGTFFPMGDEGASSQIGRAAGTGFTVNVAWNGPRMGDADYLAAWHRLVLPIAYEFNPELVLVSAGFDAARGDPLGGCQVSPEGYAHLTHLLMGLASGRIILILEGGYNLTSISESMAACTRSLLGDPPPLLTLPRPPLSGALASITETIQVHRRYWRSLRVMKVEDREGPSSSKLVTKKAPQPAKPRLAERMTTREKKVLEAGMGKVTSASFGEESTPGQTNSETAVVALTQDQPSEAATGGATLAQTISEAAIGGAMLGQTTSEEAVGGATPDQTTSEETVGGAILDQTTSEDAVGGATLGQTTSEEAVGGATLAQTTSEAAMEGATLDQTTSEEAPGGTELIQTPLASSTDHQTPPTSPVQGTTPQISPSTLIGSLRTLELGSESQGASESQAPGEENLLGEAAGGQDMADSMLMQGSRGLTDQAIFYAVTPLPWCPHLVAVCPIPAAGLDVTQPCGDCGTIQENWVCLSCYQVYCGRYINGHMLQHHGNSGHPLVLSYIDLSAWCYYCQAYVHHQALLDVKNIAHQNKFGEDMPHPH
T22274	DRUGINFO	D01WKZ	Citarinostat	Phase 1
T22274	DRUGINFO	D0O6SA	KA2507	Phase 1
T22274	DRUGINFO	D05OKZ	Sulfonamide derivative 16	Patented
T22274	DRUGINFO	D0H5GP	PMID29671355-Compound-15	Patented
T22274	DRUGINFO	D0N6WW	PMID29671355-Compound-14	Patented
T22274	DRUGINFO	D0TO3O	PMID29671355-Compound-16	Patented
T22274	DRUGINFO	D00ACL	PMID28092474-Compound-33d	Patented
T22274	DRUGINFO	D00GLJ	PMID28092474-Compound-32u	Patented
T22274	DRUGINFO	D00LLN	PMID28092474-Compound-33a	Patented
T22274	DRUGINFO	D00XWZ	PMID28092474-Compound-32a	Patented
T22274	DRUGINFO	D01LCZ	PMID28092474-Compound-32j	Patented
T22274	DRUGINFO	D02YDG	PMID28092474-Compound-32z	Patented
T22274	DRUGINFO	D03EUD	PMID28092474-Compound-32g	Patented
T22274	DRUGINFO	D04AMI	PMID28092474-Compound-34c	Patented
T22274	DRUGINFO	D04KQU	PMID28092474-Compound-32x	Patented
T22274	DRUGINFO	D04MVN	PMID28092474-Compound-33b	Patented
T22274	DRUGINFO	D04VQE	PMID28092474-Compound-32b	Patented
T22274	DRUGINFO	D06IIL	PMID28092474-Compound-32o	Patented
T22274	DRUGINFO	D08GBR	PMID28092474-Compound-33g	Patented
T22274	DRUGINFO	D08GQL	PMID28092474-Compound-33j	Patented
T22274	DRUGINFO	D08SNJ	PMID28092474-Compound-33p	Patented
T22274	DRUGINFO	D08XLK	PMID28092474-Compound-33m	Patented
T22274	DRUGINFO	D08ZJZ	PMID28092474-Compound-32v	Patented
T22274	DRUGINFO	D09PVH	PMID29671355-Compound-24	Patented
T22274	DRUGINFO	D0BY1R	PMID28092474-Compound-34b	Patented
T22274	DRUGINFO	D0CH4M	PMID28092474-Compound-33e	Patented
T22274	DRUGINFO	D0CX1Y	PMID28092474-Compound-32t	Patented
T22274	DRUGINFO	D0DH7R	PMID28092474-Compound-32c	Patented
T22274	DRUGINFO	D0E5CO	PMID28092474-Compound-33i	Patented
T22274	DRUGINFO	D0ET4U	PMID28092474-Compound-32r	Patented
T22274	DRUGINFO	D0EU5A	PMID28092474-Compound-32h	Patented
T22274	DRUGINFO	D0F3TB	PMID29671355-Compound-65a	Patented
T22274	DRUGINFO	D0HM6Y	PMID28092474-Compound-32y	Patented
T22274	DRUGINFO	D0JN0A	PMID28092474-Compound-33h	Patented
T22274	DRUGINFO	D0JR9L	PMID29671355-Compound-38a	Patented
T22274	DRUGINFO	D0K2UF	PMID28092474-Compound-33f	Patented
T22274	DRUGINFO	D0KA3X	Diaryl amine derivative 3	Patented
T22274	DRUGINFO	D0L3CU	PMID28092474-Compound-33c	Patented
T22274	DRUGINFO	D0L7HG	PMID29671355-Compound-39	Patented
T22274	DRUGINFO	D0LV6K	PMID29671355-Compound-19	Patented
T22274	DRUGINFO	D0M7XL	PMID28092474-Compound-32e	Patented
T22274	DRUGINFO	D0MQ2D	PMID28092474-Compound-32m	Patented
T22274	DRUGINFO	D0MR7U	PMID28092474-Compound-32p	Patented
T22274	DRUGINFO	D0N1RX	PMID28092474-Compound-32d	Patented
T22274	DRUGINFO	D0N2FN	PMID29671355-Compound-74	Patented
T22274	DRUGINFO	D0O6SJ	PMID28092474-Compound-32n	Patented
T22274	DRUGINFO	D0Q9XK	PMID28092474-Compound-33k	Patented
T22274	DRUGINFO	D0QF0Y	PMID28092474-Compound-32k	Patented
T22274	DRUGINFO	D0QN8W	PMID28092474-Compound-34a	Patented
T22274	DRUGINFO	D0QX3G	PMID29671355-Compound-22	Patented
T22274	DRUGINFO	D0R3RJ	PMID29671355-Compound-26	Patented
T22274	DRUGINFO	D0RD7T	PMID28092474-Compound-33o	Patented
T22274	DRUGINFO	D0S3ZB	PMID28092474-Compound-32f	Patented
T22274	DRUGINFO	D0S7NE	Diaryl amine derivative 2	Patented
T22274	DRUGINFO	D0SF8N	PMID28092474-Compound-33l	Patented
T22274	DRUGINFO	D0SK9K	PMID28092474-Compound-32i	Patented
T22274	DRUGINFO	D0TH3L	PMID28092474-Compound-32q	Patented
T22274	DRUGINFO	D0TN6E	PMID29671355-Compound-18	Patented
T22274	DRUGINFO	D0V5IQ	PMID29671355-Compound-27	Patented
T22274	DRUGINFO	D0W1AX	PMID28092474-Compound-32l	Patented
T22274	DRUGINFO	D0XN2W	Diaryl amine derivative 4	Patented
T22274	DRUGINFO	D0YC2M	PMID28092474-Compound-32s	Patented
T22274	DRUGINFO	D0YD7B	PMID29671355-Compound-38b	Patented
T22274	DRUGINFO	D0Z7QI	PMID29671355-Compound-28	Patented
T22274	DRUGINFO	D0T7OQ	PMID29671355-Compound-73	Patented
T22274	DRUGINFO	D0ZG5X	PMID29671355-Compound-13	Patented
T22274	DRUGINFO	D0EH2K	PMID29671355-Compound-11	Patented
T22274	DRUGINFO	D0Q1QY	PMID29671355-Compound-9	Patented
T22274	DRUGINFO	D0LN1T	PMID29671355-Compound-8	Patented
T22274	DRUGINFO	D0JB4S	PMID29671355-Compound-61	Patented
T22274	DRUGINFO	D00HXJ	PMID29671355-Compound-23	Patented
T22274	DRUGINFO	D0N2DK	PMID29671355-Compound-44	Patented
T22274	DRUGINFO	D0CH8Q	PMID29671355-Compound-56	Patented
T22274	DRUGINFO	D0M0RE	PMID29671355-Compound-67	Patented
T22274	DRUGINFO	D0DI9S	PMID29671355-Compound-31	Patented
T22274	DRUGINFO	D0LP1K	PMID29671355-Compound-21	Patented
T22274	DRUGINFO	D07WAT	PMID29671355-Compound-62	Patented
T22274	DRUGINFO	D0BP8I	PMID29671355-Compound-43	Patented
T22274	DRUGINFO	D0RA0D	PMID29671355-Compound-25	Patented
T22274	DRUGINFO	D00JIX	IKH-25	Investigative
T22274	DRUGINFO	D01DOV	(S)-2-Amino-N-cyclopentyl-7-mercaptoheptanamide	Investigative
T22274	DRUGINFO	D04KQF	Tubacin	Investigative
T22274	DRUGINFO	D05OVV	ST-2741	Investigative
T22274	DRUGINFO	D0G3ZH	N-(quinolin-8-yl)-6-(sulfamoylamino)hexanamide	Investigative
T22274	DRUGINFO	D0G6DH	PMID19111466C7d	Investigative
T22274	DRUGINFO	D0L0LR	UCL-67022	Investigative
T22274	DRUGINFO	D0MC9C	PMID20947351C16	Investigative
T22274	DRUGINFO	D0Q4AV	N-(quinolin-6-yl)-6-(sulfamoylamino)hexanamide	Investigative
T22274	DRUGINFO	D0Q4EG	NQN-1	Investigative
T22274	DRUGINFO	D0R8JK	N-phenyl-6-(sulfamoylamino)hexanamide	Investigative
T22274	DRUGINFO	D0T8AJ	N-(biphenyl-3-yl)-6-(sulfamoylamino)hexanamide	Investigative
T22274	DRUGINFO	D0X4VO	N-[5-(Formyl-hydroxy-amino)-pentyl]-benzamide	Investigative
T22274	DRUGINFO	D0XU0G	N-(quinolin-3-yl)-6-(sulfamoylamino)hexanamide	Investigative
T22274	DRUGINFO	D06FAK	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide	Investigative
T22274	DRUGINFO	D08XMS	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide	Investigative
T22274	DRUGINFO	D0L7HP	NILTUBACIN	Investigative
T22274	DRUGINFO	D0Q5DI	nexturastat A	Investigative
T22274	DRUGINFO	D0YP4F	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide	Investigative
T22274	DRUGINFO	D00VXM	droxinostat	Investigative
T22274	DRUGINFO	D00XTC	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	Investigative
T22274	DRUGINFO	D02HVH	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	Investigative
T22274	DRUGINFO	D02NAF	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	Investigative
T22274	DRUGINFO	D02NVY	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	Investigative
T22274	DRUGINFO	D03PRG	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	Investigative
T22274	DRUGINFO	D04CDZ	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	Investigative
T22274	DRUGINFO	D04DOL	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide	Investigative
T22274	DRUGINFO	D09RKA	santacruzamate A	Investigative
T22274	DRUGINFO	D0E8UH	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	Investigative
T22274	DRUGINFO	D0G1EX	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	Investigative
T22274	DRUGINFO	D0N5RV	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	Investigative
T22274	DRUGINFO	D0R3XO	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	Investigative
T22274	DRUGINFO	D0U0EZ	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	Investigative
T22274	DRUGINFO	D0X4QC	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	Investigative
T22274	DRUGINFO	D0Z6HR	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	Investigative
T22274	DRUGINFO	D0Z6MI	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	Investigative
T22274	DRUGINFO	D02NWS	4-Phenylbutyrohydroxamic acid	Investigative
T22274	DRUGINFO	D0S0WK	8-Oxo-8-phenyl-octanoic acid hydroxyamide	Investigative
T22274	DRUGINFO	D01YBR	ST-3050	Investigative
T22274	DRUGINFO	D07YZZ	Octanedioic acid bis-hydroxyamide	Investigative
T22274	DRUGINFO	D0N9AK	ST-2986	Investigative
T22274	DRUGINFO	D00KFF	9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide	Investigative
T22274	DRUGINFO	D00SEE	7-Mercapto-heptanoic acid phenylamide	Investigative
T22274	DRUGINFO	D00ZSD	6-benzenesulfinylhexanoic acid hydroxamide	Investigative
T22274	DRUGINFO	D01MFV	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	Investigative
T22274	DRUGINFO	D01XWZ	7-Mercapto-heptanoic acid biphenyl-4-ylamide	Investigative
T22274	DRUGINFO	D01XXN	N-Hydroxy-4-phenylacetylamino-benzamide	Investigative
T22274	DRUGINFO	D02MQM	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	Investigative
T22274	DRUGINFO	D02UTC	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	Investigative
T22274	DRUGINFO	D02WZK	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	Investigative
T22274	DRUGINFO	D04GGW	Octanedioic acid hydroxyamide pyridin-4-ylamide	Investigative
T22274	DRUGINFO	D04HSS	N-(6-Mercapto-hexyl)-benzamide	Investigative
T22274	DRUGINFO	D04NSP	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	Investigative
T22274	DRUGINFO	D04ZDI	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	Investigative
T22274	DRUGINFO	D05AHZ	6-benzenesulfonylhexanoic acid hydroxamide	Investigative
T22274	DRUGINFO	D05FEJ	9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one	Investigative
T22274	DRUGINFO	D05GVY	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	Investigative
T22274	DRUGINFO	D05LLX	4-Butyrylamino-N-hydroxy-benzamide	Investigative
T22274	DRUGINFO	D05VFP	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	Investigative
T22274	DRUGINFO	D05XAN	7-Mercapto-heptanoic acid biphenyl-3-ylamide	Investigative
T22274	DRUGINFO	D06IQB	5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione	Investigative
T22274	DRUGINFO	D06VBN	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	Investigative
T22274	DRUGINFO	D06XNP	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	Investigative
T22274	DRUGINFO	D07FJU	7-Mercapto-heptanoic acid pyridin-3-ylamide	Investigative
T22274	DRUGINFO	D09YBN	6-Phenoxy-hexane-1-thiol	Investigative
T22274	DRUGINFO	D09ZNU	4-Benzoylamino-N-hydroxy-benzamide	Investigative
T22274	DRUGINFO	D0A5LS	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	Investigative
T22274	DRUGINFO	D0AX7B	8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one	Investigative
T22274	DRUGINFO	D0B2ZJ	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	Investigative
T22274	DRUGINFO	D0B3ZM	6-Mercapto-hexanoic acid phenylamide	Investigative
T22274	DRUGINFO	D0C0VP	Cyclostellettamine derivative	Investigative
T22274	DRUGINFO	D0C2KD	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	Investigative
T22274	DRUGINFO	D0D2KE	5-Mercapto-pentanoic acid phenylamide	Investigative
T22274	DRUGINFO	D0E8KR	Octanedioic acid hydroxyamide pyridin-2-ylamide	Investigative
T22274	DRUGINFO	D0F0KS	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	Investigative
T22274	DRUGINFO	D0H1FZ	2-(methylsulfonylthio)ethyl 2-propylpentanoate	Investigative
T22274	DRUGINFO	D0KE3I	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	Investigative
T22274	DRUGINFO	D0QO0L	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	Investigative
T22274	DRUGINFO	D0R4BS	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	Investigative
T22274	DRUGINFO	D0R5VG	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	Investigative
T22274	DRUGINFO	D0RU1X	8-Oxo-8-phenyl-octanoic acid	Investigative
T22274	DRUGINFO	D0S7WQ	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	Investigative
T22274	DRUGINFO	D0S9JF	6-phenylsulfanylhexanoic acid hydroxamide	Investigative
T22274	DRUGINFO	D0T0SK	ST-2987	Investigative
T22274	DRUGINFO	D0T4IY	7-Mercapto-heptanoic acid quinolin-3-ylamide	Investigative
T22274	DRUGINFO	D0V2ZO	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	Investigative
T22274	DRUGINFO	D0XZ9Q	8-Mercapto-octanoic acid phenylamide	Investigative
T22274	DRUGINFO	D0YY9M	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	Investigative
T22274	DRUGINFO	D0Z3BM	7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one	Investigative
T22274	DRUGINFO	D0Z5KX	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	Investigative
T22274	DRUGINFO	D0Z7YS	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	Investigative
T22274	DRUGINFO	D0N0TS	PSAMMAPLIN A	Investigative

T86052	TARGETID	T86052
T86052	FORMERID	TTDC00195
T86052	UNIPROID	TERT_HUMAN
T86052	TARGNAME	Telomerase reverse transcriptase (TERT)
T86052	GENENAME	TERT
T86052	TARGTYPE	Clinical trial
T86052	SYNONYMS	Telomerase-associated protein 2; Telomerase catalytic subunit; TRT; TP2; TCS1; HEST2; EST2
T86052	FUNCTION	Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. Active in progenitor and cancer cells. Inactive, or very low activity, in normal somatic cells. Catalytic component of the teleromerase holoenzyme complex whose main activity is the elongation of telomeres by acting as a reverse transcriptase that adds simple sequence repeats to chromosome ends by copying a template sequence within the RNA component of the enzyme. Catalyzes the RNA-dependent extension of 3'-chromosomal termini with the 6-nucleotide telomeric repeat unit, 5'-TTAGGG-3'. The catalytic cycle involves primer binding, primer extension and release of product once the template boundary has been reached or nascent product translocation followed by further extension. More active on substrates containing 2 or 3 telomeric repeats. Telomerase activity is regulated by a number of factors including telomerase complex-associated proteins, chaperones and polypeptide modifiers. Modulates Wnt signaling. Plays important roles in aging and antiapoptosis.
T86052	PDBSTRUC	5UGW; 5MER; 5MEQ; 5MEP; 5MEO
T86052	BIOCLASS	Kinase
T86052	ECNUMBER	EC 2.7.7.49
T86052	SEQUENCE	MPRAPRCRAVRSLLRSHYREVLPLATFVRRLGPQGWRLVQRGDPAAFRALVAQCLVCVPWDARPPPAAPSFRQVSCLKELVARVLQRLCERGAKNVLAFGFALLDGARGGPPEAFTTSVRSYLPNTVTDALRGSGAWGLLLRRVGDDVLVHLLARCALFVLVAPSCAYQVCGPPLYQLGAATQARPPPHASGPRRRLGCERAWNHSVREAGVPLGLPAPGARRRGGSASRSLPLPKRPRRGAAPEPERTPVGQGSWAHPGRTRGPSDRGFCVVSPARPAEEATSLEGALSGTRHSHPSVGRQHHAGPPSTSRPPRPWDTPCPPVYAETKHFLYSSGDKEQLRPSFLLSSLRPSLTGARRLVETIFLGSRPWMPGTPRRLPRLPQRYWQMRPLFLELLGNHAQCPYGVLLKTHCPLRAAVTPAAGVCAREKPQGSVAAPEEEDTDPRRLVQLLRQHSSPWQVYGFVRACLRRLVPPGLWGSRHNERRFLRNTKKFISLGKHAKLSLQELTWKMSVRDCAWLRRSPGVGCVPAAEHRLREEILAKFLHWLMSVYVVELLRSFFYVTETTFQKNRLFFYRKSVWSKLQSIGIRQHLKRVQLRELSEAEVRQHREARPALLTSRLRFIPKPDGLRPIVNMDYVVGARTFRREKRAERLTSRVKALFSVLNYERARRPGLLGASVLGLDDIHRAWRTFVLRVRAQDPPPELYFVKVDVTGAYDTIPQDRLTEVIASIIKPQNTYCVRRYAVVQKAAHGHVRKAFKSHVSTLTDLQPYMRQFVAHLQETSPLRDAVVIEQSSSLNEASSGLFDVFLRFMCHHAVRIRGKSYVQCQGIPQGSILSTLLCSLCYGDMENKLFAGIRRDGLLLRLVDDFLLVTPHLTHAKTFLRTLVRGVPEYGCVVNLRKTVVNFPVEDEALGGTAFVQMPAHGLFPWCGLLLDTRTLEVQSDYSSYARTSIRASLTFNRGFKAGRNMRRKLFGVLRLKCHSLFLDLQVNSLQTVCTNIYKILLLQAYRFHACVLQLPFHQQVWKNPTFFLRVISDTASLCYSILKAKNAGMSLGAKGAAGPLPSEAVQWLCHQAFLLKLTRHRVTYVPLLGSLRTAQTQLSRKLPGTTLTALEAAANPALPSDFKTILD
T86052	DRUGINFO	D0W8WB	Berberine	Phase 4
T86052	DRUGINFO	D0N0QC	GV1001	Phase 3
T86052	DRUGINFO	D04XEQ	Imetelstat	Phase 2/3
T86052	DRUGINFO	DK5VM1	VM1500A	Phase 2/3
T86052	DRUGINFO	D09NFW	Dendritic cell vaccine	Phase 2
T86052	DRUGINFO	D0I6RI	GRNVAC1	Phase 2
T86052	DRUGINFO	D0I8BH	Vx-001	Phase 2
T86052	DRUGINFO	D0NT1S	CB-10-01	Phase 2
T86052	DRUGINFO	D07JRL	Epithalon	Phase 1/2
T86052	DRUGINFO	D0D8ZK	OBP-301	Phase 1/2
T86052	DRUGINFO	D03BKV	KML-001	Phase 1
T86052	DRUGINFO	D04HDZ	GRN163	Phase 1
T86052	DRUGINFO	D04VVD	TeloB-Vax	Phase 1
T86052	DRUGINFO	D0RH3S	DC/I540/KLH vaccine	Phase 1
T86052	DRUGINFO	DI9X5U	AAV-hTERT	Phase 1
T86052	DRUGINFO	DI9X5U	AAV-hTERT	Phase 1
T86052	DRUGINFO	D01GEO	Telomestatin	Investigative
T86052	DRUGINFO	D08UZL	TMPyP4	Investigative
T86052	DRUGINFO	D0E6BA	2,3,7-trichloro-5-nitroquinoxaline (TNQX)	Investigative
T86052	DRUGINFO	D0XI2Z	PPA	Investigative

T37848	TARGETID	T37848
T37848	FORMERID	TTDS00418
T37848	UNIPROID	CP3A4_HUMAN
T37848	TARGNAME	Albendazole monooxygenase (CYP3A4)
T37848	GENENAME	CYP3A4
T37848	TARGTYPE	Clinical trial
T37848	SYNONYMS	Taurochenodeoxycholate 6-alpha-hydroxylase; Quinine 3-monooxygenase; P450-PCN1; Nifedipine oxidase; NF-25; HLp; Cytochrome P450-PCN1; Cytochrome P450 NF-25; Cytochrome P450 HLp; Cytochrome P450 3A4; Cytochrome P450 3A3; CYPIIIA4; CYPIIIA3; CYP3A3; Albendazole sulfoxidase; Albendazole monooxygenase (sulfoxide-forming); 1,8-cineole 2-exo-monooxygenase
T37848	FUNCTION	In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e. g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide. Catalyzes 4-beta-hydroxylation of cholesterol. May catalyze 25-hydroxylation of cholesterol in vitro. Catalyzes sulfoxidation of the anthelmintics albendazole and fenbendazole. Cytochromes P450 are a group of heme-thiolate monooxygenases.
T37848	PDBSTRUC	6BDM; 6BDK; 6BDI; 6BDH; 6BD8
T37848	BIOCLASS	Paired donor oxygen oxidoreductase
T37848	ECNUMBER	EC 1.14.14.-
T37848	SEQUENCE	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMFDMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISIAEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYSMDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICVFPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSIIFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVVNETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFSKKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLGGLLQPEKPVVLKVESRDGTVSGA
T37848	DRUGINFO	D07SDQ	Curcumin	Phase 3
T37848	DRUGINFO	D0G2XE	PMX-53	Phase 2
T37848	DRUGINFO	D00GOQ	Alpha-methylcubebin	Investigative
T37848	DRUGINFO	D00RGP	MEDIORESINOL	Investigative
T37848	DRUGINFO	D01FBL	(-)-yatein	Investigative
T37848	DRUGINFO	D02EAP	3-(5-[1,3]dithiolan-2-yl-furan-2-yl)pyridine	Investigative
T37848	DRUGINFO	D02HSP	(-)-cubebinin	Investigative
T37848	DRUGINFO	D02SGJ	PALMATINE	Investigative
T37848	DRUGINFO	D02TKC	1,2-Diacetoxylycorine	Investigative
T37848	DRUGINFO	D03DMA	Geranylcoumarin	Investigative
T37848	DRUGINFO	D05KIF	(-)-cubebininolide	Investigative
T37848	DRUGINFO	D06MLU	(-)-dihydroclusin	Investigative
T37848	DRUGINFO	D06TRS	3-(3-methylthiophen-2-yl)pyridine	Investigative
T37848	DRUGINFO	D08BOH	(-)-thujaplicatintrimethyl ether	Investigative
T37848	DRUGINFO	D08FZC	DIETHOXYFLOURESCEIN	Investigative
T37848	DRUGINFO	D08TSE	1-Acetoxy-2-tert-butyldimethylsilyl-oxylycorine	Investigative
T37848	DRUGINFO	D09REF	1-Acetoxylycorine	Investigative
T37848	DRUGINFO	D09VMS	(-)-clusin	Investigative
T37848	DRUGINFO	D0A1SJ	ETHOXYCLUSIN	Investigative
T37848	DRUGINFO	D0B2ZB	(8R,8'R)-4-hydroxycubebinone	Investigative
T37848	DRUGINFO	D0C7JC	5-Pyridin-3-yl-thiophene-2-carbaldehyde oxime	Investigative
T37848	DRUGINFO	D0D5YP	BERGAPTOL	Investigative
T37848	DRUGINFO	D0E2GV	2-tert-Butyldimethylsilyloxylycorine	Investigative
T37848	DRUGINFO	D0F5AQ	5-(2-phenethylpiperazin-1-yl)-1H-indazole	Investigative
T37848	DRUGINFO	D0G9YL	GSK-8062	Investigative
T37848	DRUGINFO	D0IB3K	TILIROSIDE	Investigative
T37848	DRUGINFO	D0J1IE	3-(5-((methylthio)methyl)furan-2-yl)pyridine	Investigative
T37848	DRUGINFO	D0K4LS	Go-Y026	Investigative
T37848	DRUGINFO	D0NC3P	(-)-cubebin	Investigative
T37848	DRUGINFO	D0O1HH	3-(pyridin-3-yl)prop-2-yn-1-amine	Investigative
T37848	DRUGINFO	D0Q7QU	Alpha-Hydroxy-Midazolam	Investigative
T37848	DRUGINFO	D0S0QN	2,5-bis(4-hydroxybenzylidene)cyclopentanone	Investigative
T37848	DRUGINFO	D0T4AC	(8R,8'R,9'S)-5-methoxyclusin	Investigative
T37848	DRUGINFO	D0V0NM	JATRORRHIZINE	Investigative
T37848	DRUGINFO	D0VD5O	2-fluoro-5-(3-methylthiophen-2-yl)pyridine	Investigative
T37848	DRUGINFO	D0X3CF	HINOKININ	Investigative
T37848	DRUGINFO	D00PYW	4-[2-(4-Imidazol-1-yl-phenoxy)-ethyl]-morpholine	Investigative
T37848	DRUGINFO	D00TOF	DIHYDROCUBEBIN	Investigative
T37848	DRUGINFO	D00YNA	3,3-(1,3-Thiazole-2,5-diyl)diphenol	Investigative
T37848	DRUGINFO	D01ARE	Methyl-(5-pyridin-3-yl-thiophen-2-yl)-amine	Investigative
T37848	DRUGINFO	D02DTR	3-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine	Investigative
T37848	DRUGINFO	D03KXT	4-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine	Investigative
T37848	DRUGINFO	D06CWR	4-(6-Methoxynaphthalen-2-yl)isoquinoline	Investigative
T37848	DRUGINFO	D06JYY	3-[3-(4-Methoxybenzyl)naphthalen-2-yl]pyridine	Investigative
T37848	DRUGINFO	D07ANY	1H-1,2,3-benzotriazol-1-amine	Investigative
T37848	DRUGINFO	D07JOZ	1,1':4',1''-terphenyl-3,3''-diol	Investigative
T37848	DRUGINFO	D07VHB	1-(4-Butoxy-phenyl)-1H-imidazole	Investigative
T37848	DRUGINFO	D07WLT	6-Pyridin-3-yl-3,4-dihydronaphthalen-2(1H)-one	Investigative
T37848	DRUGINFO	D08IDC	3-methoxy-5-(6-methoxynaphthalen-2-yl)pyridine	Investigative
T37848	DRUGINFO	D0B0LC	2-(4-Imidazol-1-yl-phenoxymethyl)-pyridine	Investigative
T37848	DRUGINFO	D0G6BJ	1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)	Investigative
T37848	DRUGINFO	D0J4CB	1-(METHOXYMETHYL)-6-(NAPHTHALEN-2-YL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)	Investigative
T37848	DRUGINFO	D0K3EW	6-(3,4-DICHLOROPHENYL)-1-[1-(METHYLOXY)-3-BUTEN-1-YL]-3-AZABICYCLO[4.1.0]HEPTANE (DIASTEREOMERIC MIX)	Investigative
T37848	DRUGINFO	D0NM0P	3-[5-(4-Hydroxyphenyl)-3-thienyl]phenol	Investigative
T37848	DRUGINFO	D0U7BJ	2-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine	Investigative
T37848	DRUGINFO	D0YP4A	(5-pyridin-3-yl-furan-2-yl)methanethiol	Investigative
T37848	DRUGINFO	D01RZP	4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol	Investigative
T37848	DRUGINFO	D0M0KX	2-Fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol	Investigative
T37848	DRUGINFO	D0Y2RL	4-[5-(3-Hydroxyphenyl)-2-thienyl)-2-methyl]phenol	Investigative
T37848	DRUGINFO	D01JXM	2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole	Investigative
T37848	DRUGINFO	D09HBZ	ML-3375	Investigative
T37848	DRUGINFO	D0W4FF	ML-3403	Investigative
T37848	DRUGINFO	D08DSJ	ML-3163	Investigative
T37848	DRUGINFO	D0P8PK	6-(3-Hydroxy-phenyl)-naphthalen-2-ol	Investigative
T37848	DRUGINFO	D0M4SY	BMS-536924	Investigative
T37848	DRUGINFO	D0UU1I	Heme	Investigative

T54156	TARGETID	T54156
T54156	FORMERID	TTDC00076
T54156	UNIPROID	MMP9_HUMAN
T54156	TARGNAME	Matrix metalloproteinase-9 (MMP-9)
T54156	GENENAME	MMP9
T54156	TARGTYPE	Clinical trial
T54156	SYNONYMS	Matrix metalloproteinase 9; GELB; CLG4B; 92 kDa type IV collagenase; 92 kDa gelatinase
T54156	FUNCTION	Could play a role in bone osteoclastic resorption. Cleaves KiSS1 at a Gly-|-Leu bond. Cleaves type IV and type V collagen into large C-terminal three quarter fragments and shorter N-terminal one quarter fragments. Degrades fibronectin but not laminin or Pz-peptide. May play an essential role in local proteolysis of the extracellular matrix and in leukocyte migration.
T54156	PDBSTRUC	6ESM; 5UE4; 5UE3; 5TH9; 5TH6
T54156	BIOCLASS	Peptidase
T54156	ECNUMBER	EC 3.4.24.35
T54156	SEQUENCE	MSLWQPLVLVLLVLGCCFAAPRQRQSTLVLFPGDLRTNLTDRQLAEEYLYRYGYTRVAEMRGESKSLGPALLLLQKQLSLPETGELDSATLKAMRTPRCGVPDLGRFQTFEGDLKWHHHNITYWIQNYSEDLPRAVIDDAFARAFALWSAVTPLTFTRVYSRDADIVIQFGVAEHGDGYPFDGKDGLLAHAFPPGPGIQGDAHFDDDELWSLGKGVVVPTRFGNADGAACHFPFIFEGRSYSACTTDGRSDGLPWCSTTANYDTDDRFGFCPSERLYTQDGNADGKPCQFPFIFQGQSYSACTTDGRSDGYRWCATTANYDRDKLFGFCPTRADSTVMGGNSAGELCVFPFTFLGKEYSTCTSEGRGDGRLWCATTSNFDSDKKWGFCPDQGYSLFLVAAHEFGHALGLDHSSVPEALMYPMYRFTEGPPLHKDDVNGIRHLYGPRPEPEPRPPTTTTPQPTAPPTVCPTGPPTVHPSERPTAGPTGPPSAGPTGPPTAGPSTATTVPLSPVDDACNVNIFDAIAEIGNQLYLFKDGKYWRFSEGRGSRPQGPFLIADKWPALPRKLDSVFEERLSKKLFFFSGRQVWVYTGASVLGPRRLDKLGLGADVAQVTGALRSGRGKMLLFSGRRLWRFDVKAQMVDPRSASEVDRMFPGVPLDTHDVFQYREKAYFCQDRFYWRVSSRSELNQVDQVGYVTYDILQCPED
T54156	DRUGINFO	D04PWT	DP-b99	Phase 3
T54156	DRUGINFO	D0WL0Q	GS-5745	Phase 3
T54156	DRUGINFO	D0Z6SP	Andecaliximab	Phase 3
T54156	DRUGINFO	D07SDQ	Curcumin	Phase 3
T54156	DRUGINFO	D0I8KA	BLZ-100	Phase 1/2
T54156	DRUGINFO	D0T4BL	Neovastat	Phase 1
T54156	DRUGINFO	D0LP0D	PMID29130358-Compound-Figure17(13)	Patented
T54156	DRUGINFO	D00ZZJ	PMID29130358-Compound-Figure17(12)	Patented
T54156	DRUGINFO	D09ATD	PMID29130358-Compound-Figure17(10)	Patented
T54156	DRUGINFO	D0DB0Z	PMID29130358-Compound-SB-3CT	Patented
T54156	DRUGINFO	D0L6HL	PMID29130358-Compound-Figure17(11)	Patented
T54156	DRUGINFO	D0Q4QB	PMID29130358-Compound-Figure13(4)	Patented
T54156	DRUGINFO	D0W7HO	PMID29130358-Compound-LonimacranthoideVII	Patented
T54156	DRUGINFO	D0X6GG	PMID29130358-Compound-Figure18(14a)	Patented
T54156	DRUGINFO	D05WTZ	Galarubicin	Discontinued in Phase 2
T54156	DRUGINFO	D03BOZ	RS-130830	Discontinued in Phase 2
T54156	DRUGINFO	D0T9HG	GM6001	Discontinued in Phase 2
T54156	DRUGINFO	D05VEP	DX-2802	Preclinical
T54156	DRUGINFO	D0O7DU	CT-1746	Terminated
T54156	DRUGINFO	D02GYD	CDP-845	Terminated
T54156	DRUGINFO	D0E5GY	RO-319790	Terminated
T54156	DRUGINFO	D0Y1XT	SC-44463	Terminated
T54156	DRUGINFO	D00CWH	2-Amino-N,3,3-Trimethylbutanamide	Investigative
T54156	DRUGINFO	D03WJG	PMID15055993C1a	Investigative
T54156	DRUGINFO	D03ZDZ	Carboxylated glucosamine	Investigative
T54156	DRUGINFO	D04PAW	Methotrexate gamma-L-phenylalaninehydroxamic acid	Investigative
T54156	DRUGINFO	D09GIL	5-Methyl-5-phenyl-pyrimidine-2,4,6-trione	Investigative
T54156	DRUGINFO	D0Q4TA	ARP100	Investigative
T54156	DRUGINFO	D0Z4LO	Ro 28-2653	Investigative
T54156	DRUGINFO	D01HKU	Methotrexate gamma-L-proline-hydroxamic acid	Investigative
T54156	DRUGINFO	D07DRT	PMID23631440C29e	Investigative
T54156	DRUGINFO	D07LTB	5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione	Investigative
T54156	DRUGINFO	D0B0UI	Methotrexate gamma-hydroxamic acid	Investigative
T54156	DRUGINFO	D0E5MB	2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid	Investigative
T54156	DRUGINFO	D0K4TI	5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione	Investigative
T54156	DRUGINFO	D0Q9LC	5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione	Investigative
T54156	DRUGINFO	D0U7CD	Roche 28-2653	Investigative
T54156	DRUGINFO	D00RNA	N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide	Investigative
T54156	DRUGINFO	D03SNK	2-(biphenyl-4-ylsulfonamido)pentanedioic acid	Investigative
T54156	DRUGINFO	D07SPC	N-hydroxy-2,3-bis(phenylsulfonamido)propanamide	Investigative
T54156	DRUGINFO	D08ICI	N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)	Investigative
T54156	DRUGINFO	D0A5MV	3-(4-Phenylethynylbenzoyl)nonanoic acid	Investigative
T54156	DRUGINFO	D0P8EY	Folate gamma-hydroxamic acid	Investigative
T54156	DRUGINFO	D0V9GS	4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid	Investigative
T54156	DRUGINFO	D0Y7NV	5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione	Investigative
T54156	DRUGINFO	D0G3YZ	(+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid	Investigative
T54156	DRUGINFO	D0L4EO	3-(4-(2-phenylethynyl)benzoyl)pentanoic acid	Investigative
T54156	DRUGINFO	D0NP8A	UK-356618	Investigative
T54156	DRUGINFO	D0XL8K	Ro-37-9790	Investigative
T54156	DRUGINFO	D05THD	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	Investigative
T54156	DRUGINFO	D07GEL	SL422	Investigative
T54156	DRUGINFO	D07MJD	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	Investigative
T54156	DRUGINFO	D0S9OL	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	Investigative
T54156	DRUGINFO	D03AMR	SR-973	Investigative
T54156	DRUGINFO	D0W2UK	IK-862	Investigative
T54156	DRUGINFO	D0A4TC	MMI270	Investigative

T08856	TARGETID	T08856
T08856	FORMERID	TTDR01266
T08856	UNIPROID	MMP8_HUMAN
T08856	TARGNAME	Matrix metalloproteinase-8 (MMP-8)
T08856	GENENAME	MMP8
T08856	TARGTYPE	Clinical trial
T08856	SYNONYMS	PMNL-CL; PMNL collagenase; Neutrophil collagenase; CLG1
T08856	FUNCTION	Can degrade fibrillar type I, II, and III collagens.
T08856	PDBSTRUC	5H8X; 4QKZ; 3TT4; 3DPF; 3DPE
T08856	BIOCLASS	Peptidase
T08856	ECNUMBER	EC 3.4.24.34
T08856	SEQUENCE	MFSLKTLPFLLLLHVQISKAFPVSSKEKNTKTVQDYLEKFYQLPSNQYQSTRKNGTNVIVEKLKEMQRFFGLNVTGKPNEETLDMMKKPRCGVPDSGGFMLTPGNPKWERTNLTYRIRNYTPQLSEAEVERAIKDAFELWSVASPLIFTRISQGEADINIAFYQRDHGDNSPFDGPNGILAHAFQPGQGIGGDAHFDAEETWTNTSANYNLFLVAAHEFGHSLGLAHSSDPGALMYPNYAFRETSNYSLPQDDIDGIQAIYGLSSNPIQPTGPSTPKPCDPSLTFDAITTLRGEILFFKDRYFWRRHPQLQRVEMNFISLFWPSLPTGIQAAYEDFDRDLIFLFKGNQYWALSGYDILQGYPKDISNYGFPSSVQAIDAAVFYRSKTYFFVNDQFWRYDNQRQFMEPGYPKSISGAFPGIESKVDAVFQQEHFFHVFSGPRYYAFDLIAQRVTRVARGNKWLNCRYG
T08856	DRUGINFO	D0MW3H	CIPEMASTAT	Phase 3
T08856	DRUGINFO	D0T9HG	GM6001	Discontinued in Phase 2
T08856	DRUGINFO	D05VNG	BB-1101	Terminated
T08856	DRUGINFO	D0Y1XT	SC-44463	Terminated
T08856	DRUGINFO	D0H2CS	Glycinamid	Investigative
T08856	DRUGINFO	D0L2AW	1-Hydroxyamine-2-Isobutylmalonic Acid	Investigative
T08856	DRUGINFO	D0MM6L	2-HYDROXYCARBAMOYL-4-METHYL-PENTANOIC ACID	Investigative
T08856	DRUGINFO	D0SS8M	3-AMINO-AZACYCLOTRIDECAN-2-ONE	Investigative
T08856	DRUGINFO	D00KSS	3-(4-Methoxy-benzenesulfonyl)-propane-1-thiol	Investigative
T08856	DRUGINFO	D0R2BO	METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID	Investigative
T08856	DRUGINFO	D0W3UL	2-Thiomethyl-3-Phenylpropanoic Acid	Investigative
T08856	DRUGINFO	D03SNK	2-(biphenyl-4-ylsulfonamido)pentanedioic acid	Investigative
T08856	DRUGINFO	D0D7UA	3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol	Investigative
T08856	DRUGINFO	D0K3RC	3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol	Investigative
T08856	DRUGINFO	D0N0FX	3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol	Investigative
T08856	DRUGINFO	D0V9GS	4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid	Investigative
T08856	DRUGINFO	D0XL8K	Ro-37-9790	Investigative
T08856	DRUGINFO	D05THD	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	Investigative
T08856	DRUGINFO	D07GEL	SL422	Investigative
T08856	DRUGINFO	D07MJD	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	Investigative
T08856	DRUGINFO	D0S9OL	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	Investigative
T08856	DRUGINFO	D0W2UK	IK-862	Investigative
T08856	DRUGINFO	D0A4TC	MMI270	Investigative

T34296	TARGETID	T34296
T34296	FORMERID	TTDC00150
T34296	UNIPROID	MMP13_HUMAN
T34296	TARGNAME	Matrix metalloproteinase-13 (MMP-13)
T34296	GENENAME	MMP13
T34296	TARGTYPE	Clinical trial
T34296	SYNONYMS	Matrix metalloproteinase 13; Collagenase-3; Collagenase 3
T34296	FUNCTION	Cleaves triple helical collagens, including type I, type II and type III collagen, but has the highest activity with soluble type II collagen. Can also degrade collagen type IV, type XIV and type X. May also function by activating or degrading key regulatory proteins, such as TGFB1 and CTGF. Plays a role in wound healing, tissue remodeling, cartilage degradation, bone development, bone mineralization and ossification. Required for normal embryonic bone development and ossification. Plays a role in the healing of bone fractures via endochondral ossification. Plays a role in wound healing, probably by a mechanism that involves proteolytic activation of TGFB1 and degradation of CTGF. Plays a role in keratinocyte migration during wound healing. May play a role in cell migration and in tumor cell invasion. Plays a role in the degradation of extracellular matrix proteins including fibrillar collagen, fibronectin, TNC and ACAN.
T34296	PDBSTRUC	830C; 5UWN; 5UWM; 5UWL; 5UWK
T34296	BIOCLASS	Peptidase
T34296	ECNUMBER	EC 3.4.24.-
T34296	SEQUENCE	MHPGVLAAFLFLSWTHCRALPLPSGGDEDDLSEEDLQFAERYLRSYYHPTNLAGILKENAASSMTERLREMQSFFGLEVTGKLDDNTLDVMKKPRCGVPDVGEYNVFPRTLKWSKMNLTYRIVNYTPDMTHSEVEKAFKKAFKVWSDVTPLNFTRLHDGIADIMISFGIKEHGDFYPFDGPSGLLAHAFPPGPNYGGDAHFDDDETWTSSSKGYNLFLVAAHEFGHSLGLDHSKDPGALMFPIYTYTGKSHFMLPDDDVQGIQSLYGPGDEDPNPKHPKTPDKCDPSLSLDAITSLRGETMIFKDRFFWRLHPQQVDAELFLTKSFWPELPNRIDAAYEHPSHDLIFIFRGRKFWALNGYDILEGYPKKISELGLPKEVKKISAAVHFEDTGKTLLFSGNQVWRYDDTNHIMDKDYPRLIEEDFPGIGDKVDAVYEKNGYIYFFNGPIQFEYSIWSNRIVRVMPANSILWC
T34296	DRUGINFO	D07SDQ	Curcumin	Phase 3
T34296	DRUGINFO	D0HG5M	Apratastat	Phase 2
T34296	DRUGINFO	D0A4RF	PMID17935984C1	Clinical trial
T34296	DRUGINFO	D0A9ZW	PMID29130358-Compound-Figure16(9b)	Patented
T34296	DRUGINFO	D0LS4Y	PMID29130358-Compound-Figure16(9a)	Patented
T34296	DRUGINFO	D0O8RQ	PMID29130358-Compound-Figure18(14)	Patented
T34296	DRUGINFO	D0S3PN	PMID29130358-Compound-Figure16(9c)	Patented
T34296	DRUGINFO	D0X6GG	PMID29130358-Compound-Figure18(14a)	Patented
T34296	DRUGINFO	D03BOZ	RS-130830	Discontinued in Phase 2
T34296	DRUGINFO	D0T9HG	GM6001	Discontinued in Phase 2
T34296	DRUGINFO	D02PKO	3-(4-Methoxy-benzenesulfonyl)-cyclopentanethiol	Investigative
T34296	DRUGINFO	D03FEI	1-(4-Methoxy-benzenesulfonyl)-heptane-3-thiol	Investigative
T34296	DRUGINFO	D04GOO	N1,N3-bis(3-methoxybenzyl)isophthalamide	Investigative
T34296	DRUGINFO	D04VPH	PMID22017539C15	Investigative
T34296	DRUGINFO	D05DBJ	2-(4-methoxybenzylthio)-6-methylpyrimidin-4-ol	Investigative
T34296	DRUGINFO	D05PZV	4-(2,2'-bithiophen-5-ylmethyleneamino)phenol	Investigative
T34296	DRUGINFO	D09GLA	WAY-151693	Investigative
T34296	DRUGINFO	D0D6LF	PD-156	Investigative
T34296	DRUGINFO	D0E9JR	Ethyl 2-cyano-2-(quinoxalin-2(1H)-ylidene)acetate	Investigative
T34296	DRUGINFO	D0I0WP	4-(methyl(4-phenylthiazol-2-yl)amino)phenol	Investigative
T34296	DRUGINFO	D0LL8I	WAY170523	Investigative
T34296	DRUGINFO	D0R5MR	N4,N6-dibenzylpyrimidine-4,6-dicarboxamide	Investigative
T34296	DRUGINFO	D0Z7EF	CL82198	Investigative
T34296	DRUGINFO	D00KSS	3-(4-Methoxy-benzenesulfonyl)-propane-1-thiol	Investigative
T34296	DRUGINFO	D01OCR	3-(4-Methoxy-benzenesulfonyl)-pentane-1-thiol	Investigative
T34296	DRUGINFO	D05HOS	Hydroxyaminovaline	Investigative
T34296	DRUGINFO	D07OME	1-Methyloxy-4-Sulfone-Benzene	Investigative
T34296	DRUGINFO	D09XUQ	3-(4-Methoxy-benzenesulfonyl)-hexane-1-thiol	Investigative
T34296	DRUGINFO	D0JM0Z	3-Methylpyridine	Investigative
T34296	DRUGINFO	D0K0YX	5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid	Investigative
T34296	DRUGINFO	D0LM2K	2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid	Investigative
T34296	DRUGINFO	D0XE4B	4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol	Investigative
T34296	DRUGINFO	D03SNK	2-(biphenyl-4-ylsulfonamido)pentanedioic acid	Investigative
T34296	DRUGINFO	D0D7UA	3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol	Investigative
T34296	DRUGINFO	D0K3RC	3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol	Investigative
T34296	DRUGINFO	D0N0FX	3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol	Investigative
T34296	DRUGINFO	D0V9GS	4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid	Investigative
T34296	DRUGINFO	D08ELY	3-Benzenesulfonyl-heptanoic acid hydroxyamide	Investigative
T34296	DRUGINFO	D0G3YZ	(+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid	Investigative
T34296	DRUGINFO	D0N6CD	3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide	Investigative
T34296	DRUGINFO	D0H2PA	PKF-242-484	Investigative
T34296	DRUGINFO	D0NP8A	UK-356618	Investigative
T34296	DRUGINFO	D0XL8K	Ro-37-9790	Investigative
T34296	DRUGINFO	D05THD	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	Investigative
T34296	DRUGINFO	D07GEL	SL422	Investigative
T34296	DRUGINFO	D07MJD	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	Investigative
T34296	DRUGINFO	D0S9OL	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	Investigative
T34296	DRUGINFO	D03AMR	SR-973	Investigative
T34296	DRUGINFO	D0W2UK	IK-862	Investigative
T34296	DRUGINFO	D0A4TC	MMI270	Investigative

T70977	TARGETID	T70977
T70977	FORMERID	TTDC00162
T70977	UNIPROID	GSK3B_HUMAN
T70977	TARGNAME	Glycogen synthase kinase-3 beta (GSK-3B)
T70977	GENENAME	GSK3B
T70977	TARGTYPE	Clinical trial
T70977	SYNONYMS	Serine/threonine-protein kinase GSK3B; GSK-3 beta
T70977	FUNCTION	Requires primed phosphorylation of the majority of its substrates. In skeletal muscle, contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glycogen synthesis. May also mediate the development of insulin resistance by regulating activation of transcription factors. Regulates protein synthesis by controlling the activity of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as glycogen synthase. In Wnt signaling, GSK3B forms a multimeric complex with APC, AXIN1 and CTNNB1/beta-catenin and phosphorylates the N-terminus of CTNNB1 leading to its degradation mediated by ubiquitin/proteasomes. Phosphorylates JUN at sites proximal to its DNA-binding domain, thereby reducing its affinity for DNA. Phosphorylates NFATC1/NFATC on conserved serine residues promoting NFATC1/NFATC nuclear export, shutting off NFATC1/NFATC gene regulation, and thereby opposing the action of calcineurin. Phosphorylates MAPT/TAU on 'Thr-548', decreasing significantly MAPT/TAU ability to bind and stabilize microtubules. MAPT/TAU is the principal component of neurofibrillary tangles in Alzheimer disease. Plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. Phosphorylates MACF1, inhibiting its binding to microtubules which is critical for its role in bulge stem cell migration and skin wound repair. Probably regulates NF-kappa-B (NFKB1) at the transcriptional level and is required for the NF-kappa-B-mediated anti-apoptotic response to TNF-alpha (TNF/TNFA). Negatively regulates replication in pancreatic beta-cells, resulting in apoptosis, loss of beta-cells and diabetes. Through phosphorylation of the anti-apoptotic protein MCL1, may control cell apoptosis in response to growth factors deprivation. Phosphorylates MUC1 in breast cancer cells, decreasing the interaction of MUC1 with CTNNB1/beta-catenin. Is necessary for the establishment of neuronal polarity and axon outgrowth. Phosphorylates MARK2, leading to inhibit its activity. Phosphorylates SIK1 at 'Thr-182', leading to sustain its activity. Phosphorylates ZC3HAV1 which enhances its antiviral activity. Phosphorylates SNAI1, leading to its BTRC-triggered ubiquitination and proteasomal degradation. Phosphorylates SFPQ at 'Thr-687' upon T-cell activation. Phosphorylates NR1D1 st 'Ser-55' and 'Ser-59' and stabilizes it by protecting it from proteasomal degradation. Regulates the circadian clock via phosphorylation of the major clock components including ARNTL/BMAL1, CLOCK and PER2. Phosphorylates CLOCK AT 'Ser-427' and targets it for proteasomal degradation. Phosphorylates ARNTL/BMAL1 at 'Ser-17' and 'Ser-21' and primes it for ubiquitination and proteasomal degradation. Phosphorylates OGT at 'Ser-3' or 'Ser-4' which positively regulates its activity. Phosphorylates MYCN in neuroblastoma cells which may promote its degradation. Regulates the circadian rhythmicity of hippocampal long-term potentiation and ARNTL/BMLA1 and PER2 expression. Acts as a regulator of autophagy by mediating phosphorylation of KAT5/TIP60 under starvation conditions, leading to activate KAT5/TIP60 acetyltransferase activity and promote acetylation of key autophagy regulators, such as ULK1 and RUBCNL/Pacer. Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1.
T70977	PDBSTRUC	6NPZ; 6H0U; 6GN1; 6GJO; 6BUU
T70977	BIOCLASS	Kinase
T70977	ECNUMBER	EC 2.7.11.26
T70977	SEQUENCE	MSGRPRTTSFAESCKPVQQPSAFGSMKVSRDKDGSKVTTVVATPGQGPDRPQEVSYTDTKVIGNGSFGVVYQAKLCDSGELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFYSSGEKKDEVYLNLVLDYVPETVYRVARHYSRAKQTLPVIYVKLYMYQLFRSLAYIHSFGICHRDIKPQNLLLDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSSIDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIKAHPWTKVFRPRTPPEAIALCSRLLEYTPTARLTPLEACAHSFFDELRDPNVKLPNGRDTPALFNFTTQELSSNPPLATILIPPHARIQAAASTPTNATAASDANTGDRGQTNNAASASASNST
T70977	DRUGINFO	D0BS5E	AMO-02	Phase 2/3
T70977	DRUGINFO	D0UT7X	Tideglusib	Phase 2
T70977	DRUGINFO	D4USX5	9-ING-41	Phase 2
T70977	DRUGINFO	D0Z1DH	LY2090314	Phase 2
T70977	DRUGINFO	D5MF8Y	Lithium	Phase 2
T70977	DRUGINFO	D0D1UQ	Neu-120	Phase 1/2
T70977	DRUGINFO	D06KNK	TDZD-8	Patented
T70977	DRUGINFO	D0A3MV	AR-A014418	Patented
T70977	DRUGINFO	D0F7DS	PMID26161698-Compound-18	Patented
T70977	DRUGINFO	D0YK9D	CHIR-99021	Patented
T70977	DRUGINFO	D00PWQ	KENPAULLONE	Patented
T70977	DRUGINFO	D0MC0O	AZD-1080	Discontinued in Phase 1
T70977	DRUGINFO	D07YNH	SAN-61	Terminated
T70977	DRUGINFO	D0R5ZR	RO-320432	Terminated
T70977	DRUGINFO	D00AAN	8-O-(4-chlorobenzenesulfonyl)manzamine F	Investigative
T70977	DRUGINFO	D00HUP	N,8-diphenyl-9H-purin-6-amine	Investigative
T70977	DRUGINFO	D00XUF	N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide	Investigative
T70977	DRUGINFO	D01IPF	N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide	Investigative
T70977	DRUGINFO	D01MEP	GSK-3beta inhibitor II	Investigative
T70977	DRUGINFO	D01OJG	3-phenyl-4-(phenylamino)-1H-pyrrole-2,5-dione	Investigative
T70977	DRUGINFO	D01RKI	8-O-(4-bromobenzenesulfonyl)manzamine F	Investigative
T70977	DRUGINFO	D02OPH	I-5	Investigative
T70977	DRUGINFO	D02ZIY	GSK-3beta inhibitor XI	Investigative
T70977	DRUGINFO	D03GQF	Manzamine E	Investigative
T70977	DRUGINFO	D03OED	N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide	Investigative
T70977	DRUGINFO	D04ACJ	N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide	Investigative
T70977	DRUGINFO	D04VBD	N-(6-bromo-1H-indazol-3-yl)butyramide	Investigative
T70977	DRUGINFO	D05GIC	Manzamine Y	Investigative
T70977	DRUGINFO	D05SXF	IM-12	Investigative
T70977	DRUGINFO	D06YMZ	N-(6-phenethyl-1H-indazol-3-yl)butyramide	Investigative
T70977	DRUGINFO	D07IVD	N-(6-benzyl-1H-indazol-3-yl)butyramide	Investigative
T70977	DRUGINFO	D07MZD	(2'Z,3'E)-7-Azaindirubin-3'-oxime	Investigative
T70977	DRUGINFO	D07PTD	N-(6-phenyl-1H-indazol-3-yl)butyramide	Investigative
T70977	DRUGINFO	D09AEV	Neo-kauluamine	Investigative
T70977	DRUGINFO	D09BQY	(E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide	Investigative
T70977	DRUGINFO	D09ITI	8-OH-MANZAMINE A	Investigative
T70977	DRUGINFO	D09RYG	6-deoxymanzamine X	Investigative
T70977	DRUGINFO	D0A9MY	N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide	Investigative
T70977	DRUGINFO	D0C9OT	N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide	Investigative
T70977	DRUGINFO	D0D5ZL	PAULLONE	Investigative
T70977	DRUGINFO	D0E2XM	12,13-DEHYDRO-8-O-ACETYLMANZAMINE A	Investigative
T70977	DRUGINFO	D0E6GC	N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide	Investigative
T70977	DRUGINFO	D0F5EI	4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine	Investigative
T70977	DRUGINFO	D0I3US	9-N-METHYL-8-METHOXY-MANZAMINE A	Investigative
T70977	DRUGINFO	D0IL0G	N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide	Investigative
T70977	DRUGINFO	D0M3SC	N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide	Investigative
T70977	DRUGINFO	D0NL1F	12,13-DEHYDROMANZAMINE A	Investigative
T70977	DRUGINFO	D0Q3KS	CT-98024	Investigative
T70977	DRUGINFO	D0R5EF	N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide	Investigative
T70977	DRUGINFO	D0R6TL	N-(6-chloro-1H-indazol-3-yl)butyramide	Investigative
T70977	DRUGINFO	D0R7QL	9-N-ETHYL-8-ETHOXY-MANZAMINE A	Investigative
T70977	DRUGINFO	D0S3RP	N-(6-(4-hydroxyphenyl)-1H-indazol-3-yl)butyramide	Investigative
T70977	DRUGINFO	D0T1CE	N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide	Investigative
T70977	DRUGINFO	D0T8CQ	CP-70949	Investigative
T70977	DRUGINFO	D0V6HG	3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile	Investigative
T70977	DRUGINFO	D0WN1N	DM-204	Investigative
T70977	DRUGINFO	D0X4CO	CHIR-98023	Investigative
T70977	DRUGINFO	D0X4KR	8-O-(4-toluenesulfonyl)manzamine A	Investigative
T70977	DRUGINFO	D0YM4A	N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide	Investigative
T70977	DRUGINFO	D04ZWF	CHIR-98014	Investigative
T70977	DRUGINFO	D05NKG	alsterpaullone 2-cyanoethyl	Investigative
T70977	DRUGINFO	D0B3ZB	indirubin deriv. 8a	Investigative
T70977	DRUGINFO	D0K1DR	LEUCETTAMINE B	Investigative
T70977	DRUGINFO	D0N4WB	SB-415286	Investigative
T70977	DRUGINFO	D0Q4QF	MANZAMINE A	Investigative
T70977	DRUGINFO	D02DLC	PYRAZOLOPYRIDAZINE 1	Investigative
T70977	DRUGINFO	D0J4ON	RGB-286147	Investigative
T70977	DRUGINFO	D0O0VP	PYRAZOLOPYRIDAZINE 2	Investigative
T70977	DRUGINFO	D0Q7TO	K00244	Investigative
T70977	DRUGINFO	D0R5FH	Quinoxaline1	Investigative
T70977	DRUGINFO	D0T8KR	TWS-119	Investigative
T70977	DRUGINFO	D04QCF	AS-601245	Investigative
T70977	DRUGINFO	D0DR8N	AZAKENPAULLONE	Investigative
T70977	DRUGINFO	D0TF9P	Thieno analogue of kenpaullone	Investigative
T70977	DRUGINFO	D06WJA	L-779450	Investigative
T70977	DRUGINFO	D0Y5RO	NU-6102	Investigative
T70977	DRUGINFO	D02QAZ	PF-228	Investigative
T70977	DRUGINFO	D0IX7Y	BX-912	Investigative
T70977	DRUGINFO	D0RG0Z	BX-795	Investigative
T70977	DRUGINFO	D0T8NU	PMID19115845C89S	Investigative
T70977	DRUGINFO	D0GB4V	STAUROSPORINONE	Investigative
T70977	DRUGINFO	D0M5FF	Ro31-8220	Investigative
T70977	DRUGINFO	D00ICA	AMP-PNP	Investigative
T70977	DRUGINFO	D0A1CM	ELLAGIC ACID	Investigative
T70977	DRUGINFO	D0B9BU	CI-1040	Investigative
T70977	DRUGINFO	D0O1YH	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	Investigative
T70977	DRUGINFO	D0A5RM	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	Investigative
T70977	DRUGINFO	D0TO6S	Bisindolylmaleimide-I	Investigative

T82393	TARGETID	T82393
T82393	FORMERID	TTDR00847
T82393	UNIPROID	ADA17_HUMAN
T82393	TARGNAME	TNF alpha converting enzyme (ADAM17)
T82393	GENENAME	ADAM17
T82393	TARGTYPE	Clinical trial
T82393	SYNONYMS	TNFalpha converting enzyme; TNF-alpha-converting enzyme; TNF-alpha converting enzyme; TNF-alpha convertase; TACE; Snake venom-like protease; Disintegrin and metalloproteinase domain-containing protein 17; CSVP; CD156b antigen; CD156b; ADAM 17; A disintegrin and metalloproteinase domain 17
T82393	FUNCTION	Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface. Responsible for the proteolytic release of several other cell-surface proteins, including p75 TNF-receptor, interleukin 1 receptor type II, p55 TNF-receptor, transforming growth factor-alpha, L-selectin, growth hormone receptor, MUC1 and the amyloid precursor protein. Acts as an activator of Notch pathway by mediating cleavage of Notch, generating the membrane-associated intermediate fragment called Notch extracellular truncation (NEXT). Plays a role in the proteolytic processing of ACE2. Plays a role in hemostasis through shedding of GP1BA, the platelet glycoprotein Ib alpha chain. Mediates the proteolytic cleavage of LAG3, leading to release the secreted form of LAG3. Cleaves the membrane-bound precursor of TNF-alpha to its mature soluble form.
T82393	PDBSTRUC	3O64; 3LGP; 3LEA; 3LE9; 3L0V
T82393	BIOCLASS	Peptidase
T82393	ECNUMBER	EC 3.4.24.86
T82393	SEQUENCE	MRQSLLFLTSVVPFVLAPRPPDDPGFGPHQRLEKLDSLLSDYDILSLSNIQQHSVRKRDLQTSTHVETLLTFSALKRHFKLYLTSSTERFSQNFKVVVVDGKNESEYTVKWQDFFTGHVVGEPDSRVLAHIRDDDVIIRINTDGAEYNIEPLWRFVNDTKDKRMLVYKSEDIKNVSRLQSPKVCGYLKVDNEELLPKGLVDREPPEELVHRVKRRADPDPMKNTCKLLVVADHRFYRYMGRGEESTTTNYLIELIDRVDDIYRNTSWDNAGFKGYGIQIEQIRILKSPQEVKPGEKHYNMAKSYPNEEKDAWDVKMLLEQFSFDIAEEASKVCLAHLFTYQDFDMGTLGLAYVGSPRANSHGGVCPKAYYSPVGKKNIYLNSGLTSTKNYGKTILTKEADLVTTHELGHNFGAEHDPDGLAECAPNEDQGGKYVMYPIAVSGDHENNKMFSNCSKQSIYKTIESKAQECFQERSNKVCGNSRVDEGEECDPGIMYLNNDTCCNSDCTLKEGVQCSDRNSPCCKNCQFETAQKKCQEAINATCKGVSYCTGNSSECPPPGNAEDDTVCLDLGKCKDGKCIPFCEREQQLESCACNETDNSCKVCCRDLSGRCVPYVDAEQKNLFLRKGKPCTVGFCDMNGKCEKRVQDVIERFWDFIDQLSINTFGKFLADNIVGSVLVFSLIFWIPFSILVHCVDKKLDKQYESLSLFHPSNVEMLSSMDSASVRIIKPFPAPQTPGRLQPAPVIPSAPAAPKLDHQRMDTIQEDPSTDSHMDEDGFEKDPFPNSSTAAKSFEDLTDHPVTRSEKAASFKLQRQNRVDSKETEC
T82393	DRUGINFO	D0HG5M	Apratastat	Phase 2
T82393	DRUGINFO	D02CZF	Aderbasib	Phase 1/2
T82393	DRUGINFO	D03ESO	GW-3333	Preclinical
T82393	DRUGINFO	D01DVX	DPC-333	Terminated
T82393	DRUGINFO	D04WWO	IM-491	Investigative
T82393	DRUGINFO	D08VFY	Batimistat	Investigative
T82393	DRUGINFO	D0DD7N	CH4474	Investigative
T82393	DRUGINFO	D02UYR	PKF-241-466	Investigative
T82393	DRUGINFO	D09ZOA	2-(biphenyl-4-ylsulfonamido)-N-hydroxyacetamide	Investigative
T82393	DRUGINFO	D0NV9C	2-(4-bromophenylsulfonamido)-N-hydroxyacetamide	Investigative
T82393	DRUGINFO	D0XK7G	N-hydroxy-2-(4-methoxyphenylsulfonamido)acetamide	Investigative
T82393	DRUGINFO	D00RNA	N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide	Investigative
T82393	DRUGINFO	D08ICI	N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)	Investigative
T82393	DRUGINFO	D0H2PA	PKF-242-484	Investigative
T82393	DRUGINFO	D07GEL	SL422	Investigative
T82393	DRUGINFO	D03AMR	SR-973	Investigative
T82393	DRUGINFO	D0W2UK	IK-862	Investigative

T35940	TARGETID	T35940
T35940	FORMERID	TTDR00148
T35940	UNIPROID	MP2K1_HUMAN
T35940	TARGNAME	ERK activator kinase 1 (MEK1)
T35940	GENENAME	MAP2K1
T35940	TARGTYPE	Clinical trial
T35940	SYNONYMS	PRKMK1; Mitogen-activated protein kinase kinase 1; MKK1; MEK 1; MAPKK 1; MAPK/ERKkinase 1; MAPK/ERK kinase 1; MAP kinase kinase 1; Dual specificity mitogen-activated protein kinase kinase 1
T35940	FUNCTION	Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERK cascade, and catalyze the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in the extracellular signal-regulated kinases MAPK3/ERK1 and MAPK1/ERK2, leading to their activation and further transduction of the signal within the MAPK/ERK cascade. Depending on the cellular context, this pathway mediates diverse biological functions such as cell growth, adhesion, survival and differentiation, predominantly through the regulation of transcription, metabolism and cytoskeletal rearrangements. One target of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotes differentiation and apoptosis. MAP2K1/MEK1 has been shown to export PPARG from the nucleus. The MAPK/ERK cascade is also involved in the regulation of endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC), as well as in the fragmentation of the Golgi apparatus during mitosis. Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway.
T35940	PDBSTRUC	5YT3; 5HZE; 5EYM; 5BX0; 4U81
T35940	BIOCLASS	Kinase
T35940	ECNUMBER	EC 2.7.12.2
T35940	SEQUENCE	MPKKKPTPIQLNPAPDGSAVNGTSSAETNLEALQKKLEELELDEQQRKRLEAFLTQKQKVGELKDDDFEKISELGAGNGGVVFKVSHKPSGLVMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKKAGRIPEQILGKVSIAVIKGLTYLREKHKIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMSPERLQGTHYSVQSDIWSMGLSLVEMAVGRYPIPPPDAKELELMFGCQVEGDAAETPPRPRTPGRPLSSYGMDSRPPMAIFELLDYIVNEPPPKLPSGVFSLEFQDFVNKCLIKNPAERADLKQLMVHAFIKRSDAEEVDFAGWLCSTIGLNQPSTPTHAAGV
T35940	DRUGINFO	D0T5DP	Selumetinib	Phase 3
T35940	DRUGINFO	D0XW4G	Pyridic ketone derivative 1	Patented
T35940	DRUGINFO	D0LR2Y	Diamidothiazole derivative 1	Patented
T35940	DRUGINFO	D02UQG	RDEA-436	Discontinued in Phase 1
T35940	DRUGINFO	D0I4NN	4,5-Dibromo-1H-pyrrole-2-carboxylic acid amide	Investigative
T35940	DRUGINFO	D0T0VC	5-phenylamino-4-cyano-3-hydroxy-isothiazole	Investigative
T35940	DRUGINFO	D0TF0V	ALDISIN	Investigative
T35940	DRUGINFO	D00JMT	REVERSINE	Investigative
T35940	DRUGINFO	D08BMM	OROIDIN	Investigative
T35940	DRUGINFO	D9ILC1	PD98059	Investigative
T35940	DRUGINFO	D01WAI	DEBROMOHYMENIALDISINE	Investigative
T35940	DRUGINFO	D0O1YH	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	Investigative

T64567	TARGETID	T64567
T64567	FORMERID	TTDR00211
T64567	UNIPROID	CAH9_HUMAN
T64567	TARGNAME	Carbonic anhydrase IX (CA-IX)
T64567	GENENAME	CA9
T64567	TARGTYPE	Clinical trial
T64567	SYNONYMS	Renal cell carcinoma-associated antigen G250; RCC-associated antigen G250; PMW1; P54/58N; Membrane antigen MN; MN; G250 antigen (MN/CA IX/G250); G250; Carbonic anhydrase 9; Carbonate dehydratase IX; CAIX
T64567	FUNCTION	Participates in pH regulation. May be involved in the control of cell proliferation and transformation. Appears to be a novel specific biomarker for a cervical neoplasia. Reversible hydration of carbon dioxide.
T64567	PDBSTRUC	6G9U; 6G98; 6FE2; 6FE1; 6FE0
T64567	BIOCLASS	Alpha-carbonic anhydrase
T64567	ECNUMBER	EC 4.2.1.1
T64567	SEQUENCE	MAPLCPSPWLPLLIPAPAPGLTVQLLLSLLLLVPVHPQRLPRMQEDSPLGGGSSGEDDPLGEEDLPSEEDSPREEDPPGEEDLPGEEDLPGEEDLPEVKPKSEEEGSLKLEDLPTVEAPGDPQEPQNNAHRDKEGDDQSHWRYGGDPPWPRVSPACAGRFQSPVDIRPQLAAFCPALRPLELLGFQLPPLPELRLRNNGHSVQLTLPPGLEMALGPGREYRALQLHLHWGAAGRPGSEHTVEGHRFPAEIHVVHLSTAFARVDEALGRPGGLAVLAAFLEEGPEENSAYEQLLSRLEEIAEEGSETQVPGLDISALLPSDFSRYFQYEGSLTTPPCAQGVIWTVFNQTVMLSAKQLHTLSDTLWGPGDSRLQLNFRATQPLNGRVIEASFPAGVDSSPRAAEPVQLNSCLAAGDILALVFGLLFAVTSVAFLVQMRRQHRRGTKGGVSYRPAEVAETGA
T64567	DRUGINFO	D0A8JP	PARABEN	Phase 3
T64567	DRUGINFO	D07SDQ	Curcumin	Phase 3
T64567	DRUGINFO	D0L6HN	PHENOL	Phase 2/3
T64567	DRUGINFO	D04IIU	INDISULAM	Phase 2
T64567	DRUGINFO	D0BH7Z	Girentuximab I-124	Phase 2
T64567	DRUGINFO	D0Y6OA	Coumate	Phase 2
T64567	DRUGINFO	D03PQW	BAY 79-4620	Phase 1
T64567	DRUGINFO	D05CVC	90Y-cG250	Phase 1
T64567	DRUGINFO	D0V0UK	SULFAMIDE	Phase 1
T64567	DRUGINFO	D01YQE	PMID30074415-Compound-GS3	Patented
T64567	DRUGINFO	D06LLY	Sulfonamide-thiadiazole derivative 2	Patented
T64567	DRUGINFO	D08RPE	Sulfonamide derivative 12	Patented
T64567	DRUGINFO	D0UK9U	PMID30074415-Compound-12	Patented
T64567	DRUGINFO	D0W9VU	Sulfonamide-thiadiazole derivative 1	Patented
T64567	DRUGINFO	D03SLR	FERULIC ACID	Patented
T64567	DRUGINFO	D01BUS	CA9-ADC	Discontinued in Phase 1
T64567	DRUGINFO	D0LD9S	SPERMINE	Terminated
T64567	DRUGINFO	D00TRF	2-(benzyloxyamino)-N-hydroxyacetamide	Investigative
T64567	DRUGINFO	D01CXM	6-Acetyl-7-ethoxy-2H-chromen-2-one	Investigative
T64567	DRUGINFO	D01FOK	7-ethoxy-8-propionyl-2H-chromen-2-one	Investigative
T64567	DRUGINFO	D02MAK	6-Acetyl-7-hydroxy-2H-chromen-2-one	Investigative
T64567	DRUGINFO	D03LHJ	8-acetyl-7-propoxy-2H-chromen-2-one	Investigative
T64567	DRUGINFO	D05VUA	6-acetyl-7-methoxy-2H-chromen-2-one	Investigative
T64567	DRUGINFO	D06WZG	8-acetyl-7-ethoxy-2H-chromen-2-one	Investigative
T64567	DRUGINFO	D07VXX	2-(benzyloxyamino)-N-hydroxy-3-methylpentanamide	Investigative
T64567	DRUGINFO	D08JNO	8-acetyl-7-butoxy-2H-chromen-2-one	Investigative
T64567	DRUGINFO	D09JAR	BICARBONATE	Investigative
T64567	DRUGINFO	D0BM2T	(4-sulfamoylphenylethylthioureido)fluorescein	Investigative
T64567	DRUGINFO	D0EH0S	7-hydroxy-8-propionyl-2H-chromen-2-one	Investigative
T64567	DRUGINFO	D0EY2F	7-hydroxy-6-propionyl-2H-chromen-2-one	Investigative
T64567	DRUGINFO	D0F7KC	8-acetyl-7-methoxy-2H-chromen-2-one	Investigative
T64567	DRUGINFO	D0J7KJ	6-acetyl-7-propoxy-2H-chromen-2-one	Investigative
T64567	DRUGINFO	D0K1FG	8-Acetyl-7-hydroxy-2H-chromen-2-one	Investigative
T64567	DRUGINFO	D0O6ZD	8-acetyl-7-(benzyloxy)-2H-chromen-2-one	Investigative
T64567	DRUGINFO	D0T9BB	7-methoxy-8-propionyl-2H-chromen-2-one	Investigative
T64567	DRUGINFO	D0V0FY	8-Propionyl-7-propoxy-2H-chromen-2-one	Investigative
T64567	DRUGINFO	D00RDE	4-(4'-N-Methylphenyl)diazenylbenzenesulfonamide	Investigative
T64567	DRUGINFO	D02JEZ	7-hydroxycoumarin	Investigative
T64567	DRUGINFO	D02KDH	2-(N''-Acetyl-hydrazino)-benzenesulfonamide	Investigative
T64567	DRUGINFO	D06KTD	2-Hydrazinocarbonyl-benzenesulfonamide	Investigative
T64567	DRUGINFO	D07CQI	2-Sulfamoyl-benzoic acid methyl ester	Investigative
T64567	DRUGINFO	D07UCQ	Sodium phenylaminomethanesulfonate	Investigative
T64567	DRUGINFO	D0C6ED	1,4-phenylene disulfamate	Investigative
T64567	DRUGINFO	D0F7SO	Quinoline-8-sulfonamide	Investigative
T64567	DRUGINFO	D0M9IQ	Sodium N-methylphenylaminomethanesulfonate	Investigative
T64567	DRUGINFO	D0N5KX	Sulfamic acid 4-sulfamoyloxymethyl-benzyl ester	Investigative
T64567	DRUGINFO	D0Y1XM	2-(benzyloxyamino)-N-hydroxyhexanamide	Investigative
T64567	DRUGINFO	D00FGB	2-acetamido-5-sulfonamidoindane	Investigative
T64567	DRUGINFO	D00XIB	1-acetamido-5-sulfonamidoindane	Investigative
T64567	DRUGINFO	D01EEM	2-Mercapto-N-(4-sulfamoyl-phenyl)-benzamide	Investigative
T64567	DRUGINFO	D01UDU	3-Chloro-4-hydrazino-benzenesulfonamide	Investigative
T64567	DRUGINFO	D01YHK	3-Fluoro-4-hydrazino-benzenesulfonamide	Investigative
T64567	DRUGINFO	D03DAM	2,2-Dimethyl-N-(4-sulfamoyl-phenyl)-propionamide	Investigative
T64567	DRUGINFO	D04BKU	Sulfamic acid 4-sulfamoyloxy-butyl ester	Investigative
T64567	DRUGINFO	D04HRS	4-((4-hydroxyphenyl)diazenyl)benzenesulfonamide	Investigative
T64567	DRUGINFO	D04POB	ACETYLSULFANILAMIDE	Investigative
T64567	DRUGINFO	D05BMD	2-(4-chlorobenzyloxyamino)-N-hydroxyacetamide	Investigative
T64567	DRUGINFO	D05FNN	Sulfamic acid 7-sulfamoyloxy-heptyl ester	Investigative
T64567	DRUGINFO	D05QEK	Aminobenzolamide derivative	Investigative
T64567	DRUGINFO	D06NDR	2-(4-chlorobenzyloxyamino)-N-hydroxyhexanamide	Investigative
T64567	DRUGINFO	D07CBA	Sulfamic acid 16-sulfamoyloxy-hexadecyl ester	Investigative
T64567	DRUGINFO	D07IHP	Sulfamic acid 3-sulfamoyloxy-phenyl ester	Investigative
T64567	DRUGINFO	D07LYW	2-valproylamido-5-sulfonamidoindane	Investigative
T64567	DRUGINFO	D07PNA	2-nonylamido-5-sulfonamidoindane	Investigative
T64567	DRUGINFO	D07YSQ	N-(4-sulfamoylphenylethyl)-4-sulfamoylbenzamide	Investigative
T64567	DRUGINFO	D07ZXR	Sulfamic acid 12-sulfamoyloxy-dodecyl ester	Investigative
T64567	DRUGINFO	D08AOA	2-ethylamido-5-sulfonamidoindane	Investigative
T64567	DRUGINFO	D09JHA	Azide	Investigative
T64567	DRUGINFO	D0B4IN	NSC-654077	Investigative
T64567	DRUGINFO	D0BD0K	3-(4'-Hydroxyphenyl)diazenylbenzenesulfonamide	Investigative
T64567	DRUGINFO	D0C7WG	3-((4-hydroxyphenyl)diazenyl)benzenesulfonamide	Investigative
T64567	DRUGINFO	D0D0BO	2-Morpholin-4-yl-N-(4-sulfamoyl-phenyl)-acetamide	Investigative
T64567	DRUGINFO	D0DY9U	3-mercapto-N-(4-sulfamoyl-phenyl)-propionamide	Investigative
T64567	DRUGINFO	D0G0OP	2-(4-chlorobenzyloxyamino)-N-hydroxypropanamide	Investigative
T64567	DRUGINFO	D0G9NE	1-cyclohexylamido-5-sulfonamidoindane	Investigative
T64567	DRUGINFO	D0H4CF	3-((4-aminophenyl)diazenyl)benzenesulfonamide	Investigative
T64567	DRUGINFO	D0HN0R	2-cyclohexylamido-5-sulfonamidoindane	Investigative
T64567	DRUGINFO	D0J1PZ	N-(5-Mercapto-[1,3,4]thiadiazol-2-yl)-acetamide	Investigative
T64567	DRUGINFO	D0J3SP	2-pentafluorophenylamido-5-sulfonamidoindane	Investigative
T64567	DRUGINFO	D0KZ2D	1-valproylamido-5-sulfonamidoindane	Investigative
T64567	DRUGINFO	D0L4FM	PHENYLSULFAMATE	Investigative
T64567	DRUGINFO	D0LJ5P	4-ethynyl benzene sulfonamide	Investigative
T64567	DRUGINFO	D0O4KL	1-pentafluorophenylamido-5-sulfonamidoindane	Investigative
T64567	DRUGINFO	D0O8WV	2-propylamido-5-sulfonamidoindane	Investigative
T64567	DRUGINFO	D0Q0EK	4-Hydrazinocarbonyl-benzenesulfonamide	Investigative
T64567	DRUGINFO	D0SF3B	2-butylamido-5-sulfonamidoindane	Investigative
T64567	DRUGINFO	D0T2YZ	N-(4-Sulfamoyl-phenyl)-isobutyramide	Investigative
T64567	DRUGINFO	D0T6ZX	HYDROSULFIDE	Investigative
T64567	DRUGINFO	D0X0PO	Sulfamic acid 6-sulfamoyloxy-hexyl ester	Investigative
T64567	DRUGINFO	D0X1MY	5-Amino-[1,3,4]thiadiazole-2-thiol	Investigative
T64567	DRUGINFO	D0X9LJ	4-fluoro-N-(4-sulfamoylbenzyl)benzenesulfonamide	Investigative
T64567	DRUGINFO	D00IKQ	4-Methoxy-3-pyridinesulfonamide	Investigative
T64567	DRUGINFO	D00NUK	4-Methanesulfonylamino-benzenesulfonamide	Investigative
T64567	DRUGINFO	D01JTI	3-bromophenyl-difluoromethanesulfonamide	Investigative
T64567	DRUGINFO	D02NQK	4-(N-Oxide-2-pyridylthio)pyridine-3-sulfonamide	Investigative
T64567	DRUGINFO	D04JIN	(2-bromophenyl)difluoromethanesulfonamide	Investigative
T64567	DRUGINFO	D04SNH	1-Benzyl-1,4-dihydro-4-oxo-3-pyridinesulfonamide	Investigative
T64567	DRUGINFO	D05EBZ	4-(4-Cyanophenoxy)-3-pyridinesulfonamide	Investigative
T64567	DRUGINFO	D05QUG	7-phenethoxy-2H-chromen-2-one	Investigative
T64567	DRUGINFO	D05RAB	1,4-Dihydro-1-methyl-4-oxo-3-pyridinesulfonamide	Investigative
T64567	DRUGINFO	D05VSK	ETHOXYCOUMARIN	Investigative
T64567	DRUGINFO	D06GPL	4-methylphenyl-difluoromethanesulfonamide	Investigative
T64567	DRUGINFO	D06ZMH	3-(3-Phenyl-ureido)-benzenesulfonamide	Investigative
T64567	DRUGINFO	D07SIA	PHENYLMETHANESULFONAMIDE	Investigative
T64567	DRUGINFO	D08JCC	4-(4-Fluorophenoxy)-3-pyridinesulfonamide	Investigative
T64567	DRUGINFO	D09CXX	N-hydroxysulfamide	Investigative
T64567	DRUGINFO	D09LUD	4-[2-(3-Phenyl-ureido)-ethyl]-benzenesulfonamide	Investigative
T64567	DRUGINFO	D09UQM	1-(3,4-dichlorophenyl)-3-hydroxyurea	Investigative
T64567	DRUGINFO	D0I5YQ	4-nitrophenyl-difluoromethanesulfonamide	Investigative
T64567	DRUGINFO	D0IU3X	(4-bromophenyl)difluoromethanesulfonamide	Investigative
T64567	DRUGINFO	D0K3LN	N-(4-Sulfamoyl-phenyl)-butyramide	Investigative
T64567	DRUGINFO	D0KB6T	N-(4-Sulfamoyl-phenyl)-benzamide	Investigative
T64567	DRUGINFO	D0M4EV	N-(4-cyanophenyl)sulfamide	Investigative
T64567	DRUGINFO	D0N8LR	N-(4-Sulfamoyl-phenyl)-propionamide	Investigative
T64567	DRUGINFO	D0PA5L	N-(pentafluorophenyl)sulfamide	Investigative
T64567	DRUGINFO	D0Q0XO	Pentanoic acid (4-sulfamoyl-phenyl)-amide	Investigative
T64567	DRUGINFO	D0RK7J	2,2,2-Trifluoro-N-(4-sulfamoyl-phenyl)-acetamide	Investigative
T64567	DRUGINFO	D0UN0E	PHENYLDIFLUOROMETHANESULFONAMIDE	Investigative
T64567	DRUGINFO	D0YD9F	4-Benzenesulfonylamino-benzenesulfonamide	Investigative
T64567	DRUGINFO	D0Z6TM	4-azidobenzenesulfonamide	Investigative
T64567	DRUGINFO	D00IAE	Prop-2-ynyl 4-sulfamoylbenzoate	Investigative
T64567	DRUGINFO	D00RNZ	7-(benzyloxy)-2H-chromen-2-one	Investigative
T64567	DRUGINFO	D01OTW	4-(Cyanomethylthio)pyridine-3-sulfonamide	Investigative
T64567	DRUGINFO	D01XFH	N-propynyl amidebenzenesulphonide	Investigative
T64567	DRUGINFO	D02BMV	4-(2-Propynylthio)pyridine-3-sulfonamide	Investigative
T64567	DRUGINFO	D03KRB	4,4'-thiodipyridine-3-sulfonamide	Investigative
T64567	DRUGINFO	D03VDJ	SULFAMATE	Investigative
T64567	DRUGINFO	D04VSP	4-Ethoxy-3-pyridinesulfonamide	Investigative
T64567	DRUGINFO	D05ETN	4-(2-Methyl-8-quinolinoxy)-3-pyridinesulfonamide	Investigative
T64567	DRUGINFO	D05JAJ	4-(Quinolinoxy)-3-pyridinesulfonamide	Investigative
T64567	DRUGINFO	D06DYP	8-methoxy-2-oxo-2H-chromene-3-carboxylic acid	Investigative
T64567	DRUGINFO	D06IOI	4-Benzythiopyridine-3-sulfonamide	Investigative
T64567	DRUGINFO	D09TKG	4-(Allylamino)-3-pyridinesulfonamide	Investigative
T64567	DRUGINFO	D09WVV	N1-(2-aminoethyl)ethane-1,2-diamine	Investigative
T64567	DRUGINFO	D0A0YX	SACCHARIN	Investigative
T64567	DRUGINFO	D0G0FJ	2-hydrazinylbenzenesulfonamide	Investigative
T64567	DRUGINFO	D0J7GU	4-Methylthiopyridine-3-sulfonamide	Investigative
T64567	DRUGINFO	D0LU4S	7-butoxy-2H-chromen-2-one	Investigative
T64567	DRUGINFO	D0OT5L	7-propoxy-2H-chromen-2-one	Investigative
T64567	DRUGINFO	D0Q5VB	4-(Methylhydrazino)-3-pyridinesulfonamide	Investigative
T64567	DRUGINFO	D0R4KQ	4-(5-Methyl-2-pirazolino)-3-pyridinesulfonamide	Investigative
T64567	DRUGINFO	D0RB0D	7-methoxy-2-oxo-2H-chromene-4-carboxylic acid	Investigative
T64567	DRUGINFO	D0TY8X	4-(2-aminopyrimidin-4-ylamino)benzenesulfonamide	Investigative
T64567	DRUGINFO	D0UM1I	4-Hydrazino-3-pyridinesulfonamide	Investigative
T64567	DRUGINFO	D0V5OW	4-(Carbamolymethylthio)pyridine-3-sulfonamide	Investigative
T64567	DRUGINFO	D0X6IE	4-amino-N-(4-sulfamoylbenzyl)benzenesulfonamide	Investigative
T64567	DRUGINFO	D0Z1HY	4-amino-6-chlorobenzene-1,3-disulfonamide	Investigative
T64567	DRUGINFO	D0ZC3W	P-toluenesulfonamide	Investigative
T64567	DRUGINFO	D00XJA	6-methoxy-2-oxo-2H-chromene-3-carboxylic acid	Investigative
T64567	DRUGINFO	D04VLI	4-(2-Hydroxy-ethyl)-benzenesulfonamide	Investigative
T64567	DRUGINFO	D07TAJ	Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate	Investigative
T64567	DRUGINFO	D0D6UR	2-oxo-2H-thiochromene-3-carboxylic acid	Investigative
T64567	DRUGINFO	D0H3NS	2-oxo-2H-chromene-3-carboxylic acid	Investigative
T64567	DRUGINFO	D0J2AE	3-Amino-benzenesulfonamide	Investigative
T64567	DRUGINFO	D0OI1H	2-Amino-benzenesulfonamide	Investigative
T64567	DRUGINFO	D0X5HL	N1-(naphthalen-1-yl)ethane-1,2-diamine	Investigative
T64567	DRUGINFO	D04NSN	4-(2-AMINOETHYL)BENZENESULFONAMIDE	Investigative
T64567	DRUGINFO	D05XZM	4-(hydroxymethyl)benzenesulfonamide	Investigative
T64567	DRUGINFO	D09JPC	Hexane-1,6-diamine	Investigative
T64567	DRUGINFO	D09PWX	Carzenide	Investigative
T64567	DRUGINFO	D0G3BI	6-methyl-2-oxo-2H-chromene-3-carboxylic acid	Investigative
T64567	DRUGINFO	D0L5TZ	6-(hydroxymethyl)-2H-chromen-2-one	Investigative
T64567	DRUGINFO	D0Q2LL	6-Hydroxy-benzothiazole-2-sulfonic acid amide	Investigative
T64567	DRUGINFO	D0U4BB	HERNIARIN	Investigative
T64567	DRUGINFO	D00YEF	Decane-1,10-diyl disulfamate	Investigative
T64567	DRUGINFO	D01STY	4-Amino-3-iodo-benzenesulfonamide	Investigative
T64567	DRUGINFO	D02QGI	Pentane-1,5-diamine	Investigative
T64567	DRUGINFO	D03ZMQ	COUMARIN	Investigative
T64567	DRUGINFO	D04CVC	4-Amino-3-fluoro-benzenesulfonamide	Investigative
T64567	DRUGINFO	D05TLB	Octyl sulfamate	Investigative
T64567	DRUGINFO	D09WSJ	Decyl sulfamate	Investigative
T64567	DRUGINFO	D0AU0M	P-Coumaric Acid	Investigative
T64567	DRUGINFO	D0D4OV	Octane-1,8-diyl disulfamate	Investigative
T64567	DRUGINFO	D0E8CC	BENZOLAMIDE	Investigative
T64567	DRUGINFO	D0M3PO	2,4-Disulfamyltrifluoromethylaniline	Investigative
T64567	DRUGINFO	D0N1AW	6-(aminomethyl)-2H-chromen-2-one	Investigative
T64567	DRUGINFO	D0NN3Q	4-Hydrazino-benzenesulfonamide	Investigative
T64567	DRUGINFO	D0P6AM	4-Amino-3-bromo-benzenesulfonamide	Investigative
T64567	DRUGINFO	D0Q7DJ	Syringic Acid	Investigative
T64567	DRUGINFO	D0VD7H	CL-5343	Investigative
T64567	DRUGINFO	D0YU8J	4-Amino-3-chloro-benzenesulfonamide	Investigative
T64567	DRUGINFO	D0V7AA	CATECHIN	Investigative
T64567	DRUGINFO	D0Y3TZ	GALLICACID	Investigative
T64567	DRUGINFO	D0A4TC	MMI270	Investigative
T64567	DRUGINFO	D0A1CM	ELLAGIC ACID	Investigative

T51191	TARGETID	T51191
T51191	FORMERID	TTDR01156
T51191	UNIPROID	HDAC2_HUMAN
T51191	TARGNAME	Histone deacetylase 2 (HDAC2)
T51191	GENENAME	HDAC2
T51191	TARGTYPE	Clinical trial
T51191	SYNONYMS	HD2
T51191	FUNCTION	Gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Forms transcriptional repressor complexes by associating with MAD, SIN3, YY1 and N-COR. Interacts in the late S-phase of DNA-replication with DNMT1 in the other transcriptional repressor complex composed of DNMT1, DMAP1, PCNA, CAF1. Deacetylates TSHZ3 and regulates its transcriptional repressor activity. Component of a RCOR/GFI/KDM1A/HDAC complex that suppresses, via histone deacetylase (HDAC) recruitment, a number of genes implicated in multilineage blood cell development. May be involved in the transcriptional repression of circadian target genes, such as PER1, mediated by CRY1 through histone deacetylation. Involved in MTA1-mediated transcriptional corepression of TFF1 and CDKN1A. Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4).
T51191	PDBSTRUC	6G3O; 5IX0; 5IWG; 4LY1; 4LXZ
T51191	BIOCLASS	Carbon-nitrogen hydrolase
T51191	ECNUMBER	EC 3.5.1.98
T51191	SEQUENCE	MAYSQGGGKKKVCYYYDGDIGNYYYGQGHPMKPHRIRMTHNLLLNYGLYRKMEIYRPHKATAEEMTKYHSDEYIKFLRSIRPDNMSEYSKQMQRFNVGEDCPVFDGLFEFCQLSTGGSVAGAVKLNRQQTDMAVNWAGGLHHAKKSEASGFCYVNDIVLAILELLKYHQRVLYIDIDIHHGDGVEEAFYTTDRVMTVSFHKYGEYFPGTGDLRDIGAGKGKYYAVNFPMRDGIDDESYGQIFKPIISKVMEMYQPSAVVLQCGADSLSGDRLGCFNLTVKGHAKCVEVVKTFNLPLLMLGGGGYTIRNVARCWTYETAVALDCEIPNELPYNDYFEYFGPDFKLHISPSNMTNQNTPEYMEKIKQRLFENLRMLPHAPGVQMQAIPEDAVHEDSGDEDGEDPDKRISIRASDKRIACDEEFSDSEDEGEGGRRNVADHKKGAKKARIEEDKKETEDKKTDVKEEDKSKDNSGEKTDTKGTKSEQLSNP
T51191	DRUGINFO	D06TKI	CHR-3996	Phase 1/2
T51191	DRUGINFO	D0N2FN	PMID29671355-Compound-74	Patented
T51191	DRUGINFO	D0C9NX	PMID29671355-Compound-59	Patented
T51191	DRUGINFO	D0OU0J	PMID29671355-Compound-55	Patented
T51191	DRUGINFO	D0EH2K	PMID29671355-Compound-11	Patented
T51191	DRUGINFO	D0Q1QY	PMID29671355-Compound-9	Patented
T51191	DRUGINFO	D0LN1T	PMID29671355-Compound-8	Patented
T51191	DRUGINFO	D0JB4S	PMID29671355-Compound-61	Patented
T51191	DRUGINFO	D00HXJ	PMID29671355-Compound-23	Patented
T51191	DRUGINFO	D0N2DK	PMID29671355-Compound-44	Patented
T51191	DRUGINFO	D0CH8Q	PMID29671355-Compound-56	Patented
T51191	DRUGINFO	D0M0RE	PMID29671355-Compound-67	Patented
T51191	DRUGINFO	D0DI9S	PMID29671355-Compound-31	Patented
T51191	DRUGINFO	D0LP1K	PMID29671355-Compound-21	Patented
T51191	DRUGINFO	D07WAT	PMID29671355-Compound-62	Patented
T51191	DRUGINFO	D0BP8I	PMID29671355-Compound-43	Patented
T51191	DRUGINFO	D0RA0D	PMID29671355-Compound-25	Patented
T51191	DRUGINFO	D01AVS	N8-hydroxy-2-methoxy-N1-phenyloctanediamide	Investigative
T51191	DRUGINFO	D01TSM	N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide	Investigative
T51191	DRUGINFO	D02TQA	N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide	Investigative
T51191	DRUGINFO	D03TNE	N7-hydroxy-2-methoxy-N1-phenylheptanediamide	Investigative
T51191	DRUGINFO	D03TQD	N7-hydroxy-N1-phenyl-2-propoxyheptanediamide	Investigative
T51191	DRUGINFO	D05RWU	N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide	Investigative
T51191	DRUGINFO	D06IWR	N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide	Investigative
T51191	DRUGINFO	D06YYY	KAR-1880	Investigative
T51191	DRUGINFO	D07BMT	N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide	Investigative
T51191	DRUGINFO	D07WSB	N-(4-amino-3'-methylbiphenyl-3-yl)benzamide	Investigative
T51191	DRUGINFO	D08USK	N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide	Investigative
T51191	DRUGINFO	D08YLO	N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide	Investigative
T51191	DRUGINFO	D09SVH	N8,2-dihydroxy-N1-phenyloctanediamide	Investigative
T51191	DRUGINFO	D0A4KW	N-(2-amino-5-(furan-3-yl)phenyl)benzamide	Investigative
T51191	DRUGINFO	D0AK8Q	N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide	Investigative
T51191	DRUGINFO	D0D2US	2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide	Investigative
T51191	DRUGINFO	D0FI2F	2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide	Investigative
T51191	DRUGINFO	D0H4SC	N-(4-amino-4'-bromobiphenyl-3-yl)benzamide	Investigative
T51191	DRUGINFO	D0I2KC	N-(2-amino-5-(furan-2-yl)phenyl)benzamide	Investigative
T51191	DRUGINFO	D0K3MR	5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide	Investigative
T51191	DRUGINFO	D0MD7H	N-(4-aminobiphenyl-3-yl)benzamide	Investigative
T51191	DRUGINFO	D0Q4LX	N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide	Investigative
T51191	DRUGINFO	D0U8FC	N-(2-aminophenyl)benzamide	Investigative
T51191	DRUGINFO	D0W2PX	N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide	Investigative
T51191	DRUGINFO	D0W9BH	N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide	Investigative
T51191	DRUGINFO	D0Y4SD	N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide	Investigative
T51191	DRUGINFO	D01FYB	N-(2-aminophenyl)quinoxaline-6-carboxamide	Investigative
T51191	DRUGINFO	D01RJY	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	Investigative
T51191	DRUGINFO	D03XXI	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	Investigative
T51191	DRUGINFO	D04ETX	1,1,1-Trifluoro-8-phenoxy-octan-2-one	Investigative
T51191	DRUGINFO	D04LLD	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	Investigative
T51191	DRUGINFO	D05ZGM	7-Phenoxy-heptanoic acid hydroxyamide	Investigative
T51191	DRUGINFO	D06BKA	1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one	Investigative
T51191	DRUGINFO	D0E0TA	N-(4-hydroxybiphenyl-3-yl)benzamide	Investigative
T51191	DRUGINFO	D0H9DS	8-Phenyl-octanoic acid hydroxyamide	Investigative
T51191	DRUGINFO	D0NL6C	8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one	Investigative
T51191	DRUGINFO	D04UVL	N-(2-aminophenyl)nicotinamide	Investigative
T51191	DRUGINFO	D09RKA	santacruzamate A	Investigative
T51191	DRUGINFO	D0M9LJ	N-(4-aminobiphenyl-3-yl)nicotinamide	Investigative
T51191	DRUGINFO	D0Q2GM	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	Investigative
T51191	DRUGINFO	D0YO6M	N-(2-aminophenyl)-4-methoxybenzamide	Investigative
T51191	DRUGINFO	D02NWS	4-Phenylbutyrohydroxamic acid	Investigative
T51191	DRUGINFO	D0S0WK	8-Oxo-8-phenyl-octanoic acid hydroxyamide	Investigative
T51191	DRUGINFO	D07YZZ	Octanedioic acid bis-hydroxyamide	Investigative
T51191	DRUGINFO	D0N9AK	ST-2986	Investigative
T51191	DRUGINFO	D00KFF	9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide	Investigative
T51191	DRUGINFO	D00SEE	7-Mercapto-heptanoic acid phenylamide	Investigative
T51191	DRUGINFO	D00ZSD	6-benzenesulfinylhexanoic acid hydroxamide	Investigative
T51191	DRUGINFO	D01MFV	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	Investigative
T51191	DRUGINFO	D01XWZ	7-Mercapto-heptanoic acid biphenyl-4-ylamide	Investigative
T51191	DRUGINFO	D01XXN	N-Hydroxy-4-phenylacetylamino-benzamide	Investigative
T51191	DRUGINFO	D02MQM	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	Investigative
T51191	DRUGINFO	D02UTC	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	Investigative
T51191	DRUGINFO	D02WZK	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	Investigative
T51191	DRUGINFO	D04GGW	Octanedioic acid hydroxyamide pyridin-4-ylamide	Investigative
T51191	DRUGINFO	D04HSS	N-(6-Mercapto-hexyl)-benzamide	Investigative
T51191	DRUGINFO	D04NSP	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	Investigative
T51191	DRUGINFO	D04ZDI	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	Investigative
T51191	DRUGINFO	D05AHZ	6-benzenesulfonylhexanoic acid hydroxamide	Investigative
T51191	DRUGINFO	D05FEJ	9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one	Investigative
T51191	DRUGINFO	D05GVY	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	Investigative
T51191	DRUGINFO	D05LLX	4-Butyrylamino-N-hydroxy-benzamide	Investigative
T51191	DRUGINFO	D05VFP	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	Investigative
T51191	DRUGINFO	D05XAN	7-Mercapto-heptanoic acid biphenyl-3-ylamide	Investigative
T51191	DRUGINFO	D06IQB	5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione	Investigative
T51191	DRUGINFO	D06VBN	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	Investigative
T51191	DRUGINFO	D06XNP	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	Investigative
T51191	DRUGINFO	D07FJU	7-Mercapto-heptanoic acid pyridin-3-ylamide	Investigative
T51191	DRUGINFO	D09YBN	6-Phenoxy-hexane-1-thiol	Investigative
T51191	DRUGINFO	D09ZNU	4-Benzoylamino-N-hydroxy-benzamide	Investigative
T51191	DRUGINFO	D0A5LS	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	Investigative
T51191	DRUGINFO	D0AX7B	8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one	Investigative
T51191	DRUGINFO	D0B2ZJ	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	Investigative
T51191	DRUGINFO	D0B3ZM	6-Mercapto-hexanoic acid phenylamide	Investigative
T51191	DRUGINFO	D0C0VP	Cyclostellettamine derivative	Investigative
T51191	DRUGINFO	D0C2KD	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	Investigative
T51191	DRUGINFO	D0D2KE	5-Mercapto-pentanoic acid phenylamide	Investigative
T51191	DRUGINFO	D0E8KR	Octanedioic acid hydroxyamide pyridin-2-ylamide	Investigative
T51191	DRUGINFO	D0F0KS	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	Investigative
T51191	DRUGINFO	D0H1FZ	2-(methylsulfonylthio)ethyl 2-propylpentanoate	Investigative
T51191	DRUGINFO	D0KE3I	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	Investigative
T51191	DRUGINFO	D0QO0L	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	Investigative
T51191	DRUGINFO	D0R4BS	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	Investigative
T51191	DRUGINFO	D0R5VG	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	Investigative
T51191	DRUGINFO	D0RU1X	8-Oxo-8-phenyl-octanoic acid	Investigative
T51191	DRUGINFO	D0S7WQ	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	Investigative
T51191	DRUGINFO	D0S9JF	6-phenylsulfanylhexanoic acid hydroxamide	Investigative
T51191	DRUGINFO	D0T0SK	ST-2987	Investigative
T51191	DRUGINFO	D0T4IY	7-Mercapto-heptanoic acid quinolin-3-ylamide	Investigative
T51191	DRUGINFO	D0V2ZO	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	Investigative
T51191	DRUGINFO	D0XZ9Q	8-Mercapto-octanoic acid phenylamide	Investigative
T51191	DRUGINFO	D0YY9M	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	Investigative
T51191	DRUGINFO	D0Z3BM	7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one	Investigative
T51191	DRUGINFO	D0Z5KX	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	Investigative
T51191	DRUGINFO	D0Z7YS	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	Investigative
T51191	DRUGINFO	D0N0TS	PSAMMAPLIN A	Investigative

T02562	TARGETID	T02562
T02562	FORMERID	TTDR00630
T02562	UNIPROID	PTGES_HUMAN
T02562	TARGNAME	Prostaglandin E synthase (PTGES)
T02562	GENENAME	PTGES
T02562	TARGTYPE	Clinical trial
T02562	SYNONYMS	p53-induced gene 12 protein; PIG12; PGES; PGE synthase; P53-induced apoptosis protein 12; Microsomal prostaglandin E synthase 1; Microsomal glutathione S-transferase 1-like 1; MPGES1; MPGES-1; MGST1L1; MGST1-L1
T02562	FUNCTION	Catalyzes the oxidoreduction of prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2).
T02562	PDBSTRUC	5TL9; 5T37; 5T36; 5K0I; 5BQI
T02562	BIOCLASS	Intramolecular oxidoreductase
T02562	ECNUMBER	EC 5.3.99.3
T02562	SEQUENCE	MPAHSLVMSSPALPAFLLCSTLLVIKMYVVAIITGQVRLRKKAFANPEDALRHGGPQYCRSDPDVERCLRAHRNDMETIYPFLFLGFVYSFLGPNPFVAWMHFLVFLVGRVAHTVAYLGKLRAPIRSVTYTLAQLPCASMALQILWEAARHL
T02562	DRUGINFO	D00MBY	AAD-2004	Phase 1
T02562	DRUGINFO	D00PHK	Carboxylic acid derivative 1	Patented
T02562	DRUGINFO	D00XFM	Phthalazinone derivative 1	Patented
T02562	DRUGINFO	D02DXA	Benzamide derivative 18	Patented
T02562	DRUGINFO	D07WOT	Betais-sulfonylamino derivative 1	Patented
T02562	DRUGINFO	D07YPE	Benzimidazole derivative 13	Patented
T02562	DRUGINFO	D0AH1A	Benzamide derivative 16	Patented
T02562	DRUGINFO	D0BR7G	Imidazopyridine derivative 5	Patented
T02562	DRUGINFO	D0C3ZN	Imidazopyridine derivative 6	Patented
T02562	DRUGINFO	D0EB9M	PMID28627961-Compound-22	Patented
T02562	DRUGINFO	D0F8KE	Imidazole benzamide derivative 1	Patented
T02562	DRUGINFO	D0FX6I	Benzamide derivative 15	Patented
T02562	DRUGINFO	D0HH5B	Benzimidazole derivative 15	Patented
T02562	DRUGINFO	D0I1GO	PMID28627961-Compound-32	Patented
T02562	DRUGINFO	D0I5DE	Benzimidazole derivative 14	Patented
T02562	DRUGINFO	D0JH7Q	PMID28627961-Compound-33	Patented
T02562	DRUGINFO	D0KY1Y	Benzimidazole derivative 16	Patented
T02562	DRUGINFO	D0LY6S	PMID28627961-Compound-31	Patented
T02562	DRUGINFO	D0N2DJ	Benzimidazole derivative 11	Patented
T02562	DRUGINFO	D0O2DY	PMID28627961-Compound-41	Patented
T02562	DRUGINFO	D0OE9W	Alpha-substituted pirinixic acid and pirinixic acid ester derivative 1	Patented
T02562	DRUGINFO	D0RM0U	Boswellia acid derivative 1	Patented
T02562	DRUGINFO	D0S2UD	PMID28627961-Compound-30	Patented
T02562	DRUGINFO	D0T1UU	Benzimidazole derivative 17	Patented
T02562	DRUGINFO	D0U9LS	Polycyclic compound 1	Patented
T02562	DRUGINFO	D0UJ5D	Imidazopyridine derivative 7	Patented
T02562	DRUGINFO	D0V4FE	Piperidine carboxamide derivative 1	Patented
T02562	DRUGINFO	D0WG5P	PMID28627961-Compound-44	Patented
T02562	DRUGINFO	D0WR0Q	Pyrimidine derivative 2	Patented
T02562	DRUGINFO	D0XM9M	Methyl-piperidine compound 1	Patented
T02562	DRUGINFO	D0YO3X	Benzamide derivative 14	Patented
T02562	DRUGINFO	D0ZT9I	Benzimidazole derivative 12	Patented
T02562	DRUGINFO	D0I9JH	L-655240	Terminated

T62449	TARGETID	T62449
T62449	FORMERID	TTDC00005
T62449	UNIPROID	CHK1_HUMAN
T62449	TARGNAME	Checkpoint kinase-1 (CHK1)
T62449	GENENAME	CHEK1
T62449	TARGTYPE	Clinical trial
T62449	SYNONYMS	Serine/threonine-protein kinase Chk1; Chk1; Cell cycle checkpoint kinase; CHK1 checkpoint homolog
T62449	FUNCTION	May also negatively regulate cell cycle progression during unperturbed cell cycles. This regulation is achieved by a number of mechanisms that together help to preserve the integrity of the genome. Recognizes the substrate consensus sequence [R-X-X-S/T]. Binds to and phosphorylates CDC25A, CDC25B and CDC25C. Phosphorylation of CDC25A at 'Ser-178' and 'Thr-507' and phosphorylation of CDC25C at 'Ser-216' creates binding sites for 14-3-3 proteins which inhibit CDC25A and CDC25C. Phosphorylation of CDC25A at 'Ser-76', 'Ser-124', 'Ser-178', 'Ser-279' and 'Ser-293' promotes proteolysis of CDC25A. Phosphorylation of CDC25A at 'Ser-76' primes the protein for subsequent phosphorylation at 'Ser-79', 'Ser-82' and 'Ser-88' by NEK11, which is required for polyubiquitination and degradation of CDCD25A. Inhibition of CDC25 leads to increased inhibitory tyrosine phosphorylation of CDK-cyclin complexes and blocks cell cycle progression. Also phosphorylates NEK6. Binds to and phosphorylates RAD51 at 'Thr-309', which promotes the release of RAD51 from BRCA2 and enhances the association of RAD51 with chromatin, thereby promoting DNA repair by homologous recombination. Phosphorylates multiple sites within the C-terminus of TP53, which promotes activation of TP53 by acetylation and promotes cell cycle arrest and suppression of cellular proliferation. Also promotes repair of DNA cross-links through phosphorylation of FANCE. Binds to and phosphorylates TLK1 at 'Ser-743', which prevents the TLK1-dependent phosphorylation of the chromatin assembly factor ASF1A. This may enhance chromatin assembly both in the presence or absence of DNA damage. May also play a role in replication fork maintenance through regulation of PCNA. May regulate the transcription of genes that regulate cell-cycle progression through the phosphorylation of histones. Phosphorylates histone H3. 1 (to form H3T11ph), which leads to epigenetic inhibition of a subset of genes. May also phosphorylate RB1 to promote its interaction with the E2F family of transcription factors and subsequent cell cycle arrest. Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest and activation of DNA repair in response to the presence of DNA damage or unreplicated DNA.
T62449	PDBSTRUC	6FCK; 6FCF; 6FC8; 5WI2; 5OQ8
T62449	BIOCLASS	Kinase
T62449	ECNUMBER	EC 2.7.11.1
T62449	SEQUENCE	MAVPFVEDWDLVQTLGEGAYGEVQLAVNRVTEEAVAVKIVDMKRAVDCPENIKKEICINKMLNHENVVKFYGHRREGNIQYLFLEYCSGGELFDRIEPDIGMPEPDAQRFFHQLMAGVVYLHGIGITHRDIKPENLLLDERDNLKISDFGLATVFRYNNRERLLNKMCGTLPYVAPELLKRREFHAEPVDVWSCGIVLTAMLAGELPWDQPSDSCQEYSDWKEKKTYLNPWKKIDSAPLALLHKILVENPSARITIPDIKKDRWYNKPLKKGAKRPRVTSGGVSESPSGFSKHIQSNLDFSPVNSASSEENVKYSSSQPEPRTGLSLWDTSPSYIDKLVQGISFSQPTCPDHMLLNSQLLGTPGSSQNPWQRLVKRMTRFFTKLDADKSYQCLKETCEKLGYQWKKSCMNQVTISTTDRRNNKLIFKVNLLEMDDKILVDFRLSKGDGLEFKRHFLKIKGKLIDIVSSQKIWLPAT
T62449	DRUGINFO	D00NZL	LY2603618	Phase 2
T62449	DRUGINFO	D05FWH	SCH-900776	Phase 2
T62449	DRUGINFO	D08UUL	LY2606368	Phase 2
T62449	DRUGINFO	D0Z9VY	UCN-01	Phase 2
T62449	DRUGINFO	DXJ4B7	LY2880070	Phase 1/2
T62449	DRUGINFO	D00UQW	RG7741	Phase 1
T62449	DRUGINFO	D01ZUV	GDC-0425	Phase 1
T62449	DRUGINFO	D0PM7Q	AZD7762	Phase 1
T62449	DRUGINFO	D4MW3O	MK-8776	Phase 1
T62449	DRUGINFO	D0LR2Y	Diamidothiazole derivative 1	Patented
T62449	DRUGINFO	D0O3KA	RG7602	Discontinued in Phase 1
T62449	DRUGINFO	D0U9IQ	PF-477736	Discontinued in Phase 1
T62449	DRUGINFO	D05UGJ	XL844	Discontinued in Phase 1
T62449	DRUGINFO	D00KDF	SB 218078	Investigative
T62449	DRUGINFO	D01HUO	BIS-IMIDE A	Investigative
T62449	DRUGINFO	D03CQN	Chk1-A	Investigative
T62449	DRUGINFO	D06EZQ	GRANULATIMIDE	Investigative
T62449	DRUGINFO	D08OPW	ARRY-575	Investigative
T62449	DRUGINFO	D08XCD	2-(cyclohexylamino)benzoic acid	Investigative
T62449	DRUGINFO	D09YHQ	9-chlorobenzo[h]isoquinolin-1(2H)-one	Investigative
T62449	DRUGINFO	D09YVU	6-(3-aminopropyl)benzo[h]isoquinolin-1(2H)-one	Investigative
T62449	DRUGINFO	D0D6DH	A-432411	Investigative
T62449	DRUGINFO	D0FO2K	N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE	Investigative
T62449	DRUGINFO	D0OC6H	S-024	Investigative
T62449	DRUGINFO	D0S3TJ	6-MORPHOLIN-4-YL-9H-PURINE	Investigative
T62449	DRUGINFO	D0Z2CN	Isogranulatimide	Investigative
T62449	DRUGINFO	D3U1LH	V158411	Investigative
T62449	DRUGINFO	DYS56C	SB218078	Investigative
T62449	DRUGINFO	D0M9OF	3-(1H-Indol-2-yl)-1H-quinolin-2-one	Investigative
T62449	DRUGINFO	D0P4DG	S-070	Investigative
T62449	DRUGINFO	D0Y3PH	9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione	Investigative
T62449	DRUGINFO	D00ERW	PMID17935989C25	Investigative
T62449	DRUGINFO	D0ME9B	PMID20855207C25	Investigative
T62449	DRUGINFO	D0Z8PT	CCT244747	Investigative
T62449	DRUGINFO	D01WAI	DEBROMOHYMENIALDISINE	Investigative
T62449	DRUGINFO	D0XC6G	2-(1H-indazol-3-yl)-1H-benzo[d]imidazole	Investigative
T62449	DRUGINFO	D0Y5RO	NU-6102	Investigative
T62449	DRUGINFO	D01YWE	PMID19364658C33	Investigative
T62449	DRUGINFO	D0IX7Y	BX-912	Investigative
T62449	DRUGINFO	D0RG0Z	BX-795	Investigative
T62449	DRUGINFO	D0N6ES	KN-62	Investigative
T62449	DRUGINFO	D0B9BU	CI-1040	Investigative
T62449	DRUGINFO	D0O1YH	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	Investigative
T62449	DRUGINFO	D0A5RM	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	Investigative
T62449	DRUGINFO	D0TO6S	Bisindolylmaleimide-I	Investigative
T62449	DRUGINFO	D0L8HO	RO-316233	Investigative

T78429	TARGETID	T78429
T78429	FORMERID	TTDR01206
T78429	UNIPROID	IKKB_HUMAN
T78429	TARGNAME	Inhibitor of nuclear factor kappa-B kinase beta (IKKB)
T78429	GENENAME	IKBKB
T78429	TARGTYPE	Clinical trial
T78429	SYNONYMS	Nuclear factor NF-kappa-B inhibitor kinase beta; NFKBIKB; Inhibitor of nuclear factor kappa-B kinase subunit beta; IkBKB; IKKB; IKK2; IKK-beta; IKK-B; I-kappa-B-kinase beta; I-kappa-B kinase 2
T78429	FUNCTION	Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation. Phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues. These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome. In turn, free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. In addition to the NF-kappa-B inhibitors, phosphorylates several other components of the signaling pathway including NEMO/IKBKG, NF-kappa-B subunits RELA and NFKB1, as well as IKK-related kinases TBK1 and IKBKE. IKK-related kinase phosphorylations may prevent the overproduction of inflammatory mediators since they exert a negative regulation on canonical IKKs. Phosphorylates FOXO3, mediating the TNF-dependent inactivation of this pro-apoptotic transcription factor. Also phosphorylates other substrates including NCOA3, BCL10 and IRS1. Within the nucleus, acts as an adapter protein for NFKBIA degradation in UV-induced NF-kappa-B activation.
T78429	PDBSTRUC	4KIK; 4E3C; 3BRV; 3BRT
T78429	BIOCLASS	Kinase
T78429	ECNUMBER	EC 2.7.11.10
T78429	SEQUENCE	MSWSPSLTTQTCGAWEMKERLGTGGFGNVIRWHNQETGEQIAIKQCRQELSPRNRERWCLEIQIMRRLTHPNVVAARDVPEGMQNLAPNDLPLLAMEYCQGGDLRKYLNQFENCCGLREGAILTLLSDIASALRYLHENRIIHRDLKPENIVLQQGEQRLIHKIIDLGYAKELDQGSLCTSFVGTLQYLAPELLEQQKYTVTVDYWSFGTLAFECITGFRPFLPNWQPVQWHSKVRQKSEVDIVVSEDLNGTVKFSSSLPYPNNLNSVLAERLEKWLQLMLMWHPRQRGTDPTYGPNGCFKALDDILNLKLVHILNMVTGTIHTYPVTEDESLQSLKARIQQDTGIPEEDQELLQEAGLALIPDKPATQCISDGKLNEGHTLDMDLVFLFDNSKITYETQISPRPQPESVSCILQEPKRNLAFFQLRKVWGQVWHSIQTLKEDCNRLQQGQRAAMMNLLRNNSCLSKMKNSMASMSQQLKAKLDFFKTSIQIDLEKYSEQTEFGITSDKLLLAWREMEQAVELCGRENEVKLLVERMMALQTDIVDLQRSPMGRKQGGTLDDLEEQARELYRRLREKPRDQRTEGDSQEMVRLLLQAIQSFEKKVRVIYTQLSKTVVCKQKALELLPKVEEVVSLMNEDEKTVVRLQEKRQKELWNLLKIACSKVRGPVSGSPDSMNASRLSQPGQLMSQPSTASNSLPEPAKKSEELVAEAHNLCTLLENAIQDTVREQDQSFTALDWSWLQTEEEEHSCLEQAS
T78429	DRUGINFO	D07VIK	Arsenic trioxide	Approved
T78429	DRUGINFO	D0AE3U	SAR-113945	Phase 2
T78429	DRUGINFO	D0V3CK	IMD-1041	Phase 2
T78429	DRUGINFO	D0M4KE	Parthenolide	Phase 2
T78429	DRUGINFO	D0Z5DM	IMD-0354	Phase 1
T78429	DRUGINFO	D06ZYC	MLN0415	Discontinued in Phase 1
T78429	DRUGINFO	D00XDG	5-amino-2-phenyl-oxazole-4-carboxylic acid amide	Investigative
T78429	DRUGINFO	D01FPX	5-amino-2-p-tolyl-oxazole-4-carboxylic acid amide	Investigative
T78429	DRUGINFO	D03PVS	3-amino-benzo[b]thiophene-2-carboxylic acid amide	Investigative
T78429	DRUGINFO	D06CBR	2-amino-5-phenylthiophene-3-carboxamide	Investigative
T78429	DRUGINFO	D08VQM	3-amino-5-(4-chlorophenyl)thiophene-2-carboxamide	Investigative
T78429	DRUGINFO	D09PLJ	6-phenyl-thieno[3,2-d]pyrimidin-4-ylamine	Investigative
T78429	DRUGINFO	D0N1UB	2-amino-quinoline-3-carboxylic acid amide	Investigative
T78429	DRUGINFO	D0T6VA	SC-514	Investigative
T78429	DRUGINFO	D0UP6G	4-amino-biphenyl-3-carboxylic acid amide	Investigative
T78429	DRUGINFO	D0E3TC	Staurosporine	Investigative
T78429	DRUGINFO	D01OBJ	5-Bromo-6-methoxy-9H-beta-carboline	Investigative
T78429	DRUGINFO	D02QAZ	PF-228	Investigative

T87675	TARGETID	T87675
T87675	FORMERID	TTDC00006
T87675	UNIPROID	AURKA_HUMAN
T87675	TARGNAME	Aurora kinase A (AURKA)
T87675	GENENAME	AURKA
T87675	TARGTYPE	Clinical trial
T87675	SYNONYMS	hARK1; Serine/threonine-protein kinase aurora-A; Serine/threonine-protein kinase 6; Serine/threonine-protein kinase 15; Serine/threonine kinase 15; STK6; STK15; IAK1; Breast tumor-amplified kinase; BTAK; Aurora/IPL1-related kinase 1; Aurora-related kinase 1; Aurora-A; Aurora 2; AYK1; AURA; ARK1; ARK-1; AIRK1; AIK
T87675	FUNCTION	Associates with the centrosome and the spindle microtubules during mitosis and plays a critical role in various mitotic events including the establishment of mitotic spindle, centrosome duplication, centrosome separation as well as maturation, chromosomal alignment, spindle assembly checkpoint, and cytokinesis. Required for normal spindle positioning during mitosis and for the localization of NUMA1 and DCTN1 to the cell cortex during metaphase. Required for initial activation of CDK1 at centrosomes. Phosphorylates numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B, DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3, p53/TP53 and TPX2. Regulates KIF2A tubulin depolymerase activity. Required for normal axon formation. Plays a role in microtubule remodeling during neurite extension. Important for microtubule formation and/or stabilization. Also acts as a key regulatory component of the p53/TP53 pathway, and particularly the checkpoint-response pathways critical for oncogenic transformation of cells, by phosphorylating and stabilizing p53/TP53. Phosphorylates its own inhibitors, the protein phosphatase type 1 (PP1) isoforms, to inhibit their activity. Necessary for proper cilia disassembly prior to mitosis. Mitotic serine/threonine kinase that contributes to the regulation of cell cycle progression.
T87675	PDBSTRUC	6R4D; 6R4C; 6R4B; 6R4A; 6R49
T87675	BIOCLASS	Kinase
T87675	ECNUMBER	EC 2.7.11.1
T87675	SEQUENCE	MDRSKENCISGPVKATAPVGGPKRVLVTQQFPCQNPLPVNSGQAQRVLCPSNSSQRVPLQAQKLVSSHKPVQNQKQKQLQATSVPHPVSRPLNNTQKSKQPLPSAPENNPEEELASKQKNEESKKRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLCGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPSNCQNKESASKQS
T87675	DRUGINFO	D0S4JK	MLN8237	Phase 3
T87675	DRUGINFO	D05PZB	AT9283	Phase 3
T87675	DRUGINFO	D0A1AQ	Rosiglitazone + metformin	Phase 3
T87675	DRUGINFO	D0S7HM	ENMD-2076	Phase 2
T87675	DRUGINFO	D02XNW	VX-680	Phase 2
T87675	DRUGINFO	D08HOM	ABT-348	Phase 2
T87675	DRUGINFO	D02RJY	PHA-739358	Phase 2
T87675	DRUGINFO	D3QEZ2	LY3295668	Phase 1/2
T87675	DRUGINFO	D0A5MC	MLN8054	Phase 1
T87675	DRUGINFO	D0L3RO	TAS-119	Phase 1
T87675	DRUGINFO	D6FX2G	VIC-1911	Phase 1
T87675	DRUGINFO	D0E5XA	R763	Phase 1
T87675	DRUGINFO	D0J6AB	MK-5108	Phase 1
T87675	DRUGINFO	D05LKZ	HPP-607	Phase 1
T87675	DRUGINFO	D0CY1B	CYC116	Phase 1
T87675	DRUGINFO	D0EJ3B	AMG 900	Phase 1
T87675	DRUGINFO	D0OA5G	SNS-314	Phase 1
T87675	DRUGINFO	D0H7AC	PF-03814735	Discontinued in Phase 1
T87675	DRUGINFO	D04YQF	2-(1H-pyrazol-3-yl)-1H-benzimidazole	Investigative
T87675	DRUGINFO	D0QC0W	ZM-447439	Investigative
T87675	DRUGINFO	D04MYT	4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine	Investigative
T87675	DRUGINFO	D00TKJ	7-fluoroindirubin-3-oxime	Investigative
T87675	DRUGINFO	D06AGN	Indirubin-3-acetoxime	Investigative
T87675	DRUGINFO	D0V6LP	Indirubin-3-methoxime	Investigative
T87675	DRUGINFO	D06OAH	6-bromoindirubin-3-oxime	Investigative
T87675	DRUGINFO	D05BHG	Phosphonothreonine	Investigative
T87675	DRUGINFO	D0Y0ES	Indirubin-3'-monoxime	Investigative

T78198	TARGETID	T78198
T78198	FORMERID	TTDC00091
T78198	UNIPROID	PNPH_HUMAN
T78198	TARGNAME	Purine nucleoside phosphorylase (PNP)
T78198	GENENAME	PNP
T78198	TARGTYPE	Clinical trial
T78198	SYNONYMS	PNP; Inosine phosphorylase
T78198	FUNCTION	The purine nucleoside phosphorylases catalyze the phosphorolytic breakdown of the N-glycosidic bond in the beta- (deoxy)ribonucleoside molecules, with the formation of the corresponding free purine bases and pentose-1-phosphate.
T78198	PDBSTRUC	5UGF; 5ETJ; 4GKA; 4ECE; 4EB8
T78198	BIOCLASS	Pentosyltransferase
T78198	ECNUMBER	EC 2.4.2.1
T78198	SEQUENCE	MENGYTYEDYKNTAEWLLSHTKHRPQVAIICGSGLGGLTDKLTQAQIFDYGEIPNFPRSTVPGHAGRLVFGFLNGRACVMMQGRFHMYEGYPLWKVTFPVRVFHLLGVDTLVVTNAAGGLNPKFEVGDIMLIRDHINLPGFSGQNPLRGPNDERFGDRFPAMSDAYDRTMRQRALSTWKQMGEQRELQEGTYVMVAGPSFETVAECRVLQKLGADAVGMSTVPEVIVARHCGLRVFGFSLITNKVIMDYESLEKANHEEVLAAGKQAAQKLEQFVSILMASIPLPDKAS
T78198	DRUGINFO	D02ZKR	BCX-3408	Phase 2
T78198	DRUGINFO	D04XYL	2'3'-Dideoxyinosine	Phase 2
T78198	DRUGINFO	D02ZUO	Forodesine	Phase 1/2
T78198	DRUGINFO	D08OBT	Peldesine	Phase 1
T78198	DRUGINFO	D0H1OL	Guanosine	Phase 1
T78198	DRUGINFO	D05UPB	CI-972	Discontinued in Phase 1
T78198	DRUGINFO	D01NTY	8-Iodo-Guanine	Investigative
T78198	DRUGINFO	D01OHV	8-Azaguanine	Investigative
T78198	DRUGINFO	D03HVE	Hypoxanthine	Investigative
T78198	DRUGINFO	D04JOV	MT-Immucillin-H	Investigative
T78198	DRUGINFO	D04LUI	Ribose-1-Phosphate	Investigative
T78198	DRUGINFO	D06KVV	2-Hydroxymethyl-Pyrrolidine-3,4-Diol	Investigative
T78198	DRUGINFO	D07BGQ	(+/-)-5'-deoxy-4'-fluoro-5'-methylthio-DADMe-ImmH	Investigative
T78198	DRUGINFO	D07BNM	9-(5,5-Difluoro-5-Phosphonopentyl)Guanine	Investigative
T78198	DRUGINFO	D07VEW	DADMe-ImmG	Investigative
T78198	DRUGINFO	D08TGC	GUANOSINE-2',3'-O-ETHYLIDENEPHOSPHONATE	Investigative
T78198	DRUGINFO	D0A9WP	Immucillin-G	Investigative
T78198	DRUGINFO	D0BP5T	Aza-C-nucleosides	Investigative
T78198	DRUGINFO	D0D7PF	3-((2-Pyrrolidine-1-yl)-ethyl)uracil	Investigative
T78198	DRUGINFO	D0E6BI	5'-Methylthio-ImmH	Investigative
T78198	DRUGINFO	D0F7DM	9-DEAZAINOSINE-2',3'-O-ETHYLIDENEPHOSPHONATE	Investigative
T78198	DRUGINFO	D0FI2L	8-aminoguanosine	Investigative
T78198	DRUGINFO	D0I8JJ	9-Deazainosine	Investigative
T78198	DRUGINFO	D0J0HK	3-Deoxyguanosine	Investigative
T78198	DRUGINFO	D0N2AA	8-aza-DADMe-ImmH	Investigative
T78198	DRUGINFO	D0N2LE	GUANOSINE-2',3'-O-METHYLIDENEPHOSPHONATE	Investigative
T78198	DRUGINFO	D0N5BA	9-Deazahypoxanthine	Investigative
T78198	DRUGINFO	D0R5RF	5'-phenylthio-ImmH	Investigative
T78198	DRUGINFO	D0R6UA	8-AMINOGUANINE	Investigative
T78198	DRUGINFO	D0SO9G	5'-methylthio-immucillin-H	Investigative
T78198	DRUGINFO	D0T7LB	5'-deoxy-4'-hydroxy-5'-methylthio-DADMe-ImmH	Investigative
T78198	DRUGINFO	D0Z3OD	8-amino-9-benzylguanine	Investigative
T78198	DRUGINFO	D02COM	7-tert-butyl-2, 3-dihydro-3, 3-dimethyl substituted dihydrofuran 30 (DHDMBF30)	Investigative

T23471	TARGETID	T23471
T23471	FORMERID	TTDC00199
T23471	UNIPROID	PERM_HUMAN
T23471	TARGNAME	Myeloperoxidase (MPO)
T23471	GENENAME	MPO
T23471	TARGTYPE	Clinical trial
T23471	SYNONYMS	MPO
T23471	FUNCTION	Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acidin physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.
T23471	PDBSTRUC	6BMT; 6AZP; 5UZU; 5MFA; 5FIW
T23471	BIOCLASS	Peroxidases
T23471	ECNUMBER	EC 1.11.2.2
T23471	SEQUENCE	MGVPFFSSLRCMVDLGPCWAGGLTAEMKLLLALAGLLAILATPQPSEGAAPAVLGEVDTSLVLSSMEEAKQLVDKAYKERRESIKQRLRSGSASPMELLSYFKQPVAATRTAVRAADYLHVALDLLERKLRSLWRRPFNVTDVLTPAQLNVLSKSSGCAYQDVGVTCPEQDKYRTITGMCNNRRSPTLGASNRAFVRWLPAEYEDGFSLPYGWTPGVKRNGFPVALARAVSNEIVRFPTDQLTPDQERSLMFMQWGQLLDHDLDFTPEPAARASFVTGVNCETSCVQQPPCFPLKIPPNDPRIKNQADCIPFFRSCPACPGSNITIRNQINALTSFVDASMVYGSEEPLARNLRNMSNQLGLLAVNQRFQDNGRALLPFDNLHDDPCLLTNRSARIPCFLAGDTRSSEMPELTSMHTLLLREHNRLATELKSLNPRWDGERLYQEARKIVGAMVQIITYRDYLPLVLGPTAMRKYLPTYRSYNDSVDPRIANVFTNAFRYGHTLIQPFMFRLDNRYQPMEPNPRVPLSRVFFASWRVVLEGGIDPILRGLMATPAKLNRQNQIAVDEIRERLFEQVMRIGLDLPALNMQRSRDHGLPGYNAWRRFCGLPQPETVGQLGTVLRNLKLARKLMEQYGTPNNIDIWMGGVSEPLKRKGRVGPLLACIIGTQFRKLRDGDRFWWENEGVFSMQQRQALAQISLPRIICDNTGITTVSKNNIFMSNSYPRDFVNCSTLPALNLASWREAS
T23471	DRUGINFO	D0XD5A	E-101	Phase 3
T23471	DRUGINFO	D87IQS	Mitiperstat	Phase 2/3
T23471	DRUGINFO	D08TRG	AZD-3241	Phase 2
T23471	DRUGINFO	D07SBP	AZD4831	Phase 1
T23471	DRUGINFO	D0Y3LJ	AZD5904	Discontinued in Phase 1
T23471	DRUGINFO	D01ZZG	INV-311	Investigative
T23471	DRUGINFO	D05OZR	4-aminobenzoic acid hydrazide	Investigative

T49898	TARGETID	T49898
T49898	FORMERID	TTDC00166
T49898	UNIPROID	CDK1_HUMAN
T49898	TARGNAME	Cyclin-dependent kinase 1 (CDK1)
T49898	GENENAME	CDK1
T49898	TARGTYPE	Clinical trial
T49898	SYNONYMS	P34CDC2; P34 protein kinase; CDKN1; CDC28A; CDC2
T49898	FUNCTION	Required in higher cells for entry into S-phase and mitosis. Phosphorylates PARVA/actopaxin, APC, AMPH, APC, BARD1, Bcl-xL/BCL2L1, BRCA2, CALD1, CASP8, CDC7, CDC20, CDC25A, CDC25C, CC2D1A, CENPA, CSNK2 proteins/CKII, FZR1/CDH1, CDK7, CEBPB, CHAMP1, DMD/dystrophin, EEF1 proteins/EF-1, EZH2, KIF11/EG5, EGFR, FANCG, FOS, GFAP, GOLGA2/GM130, GRASP1, UBE2A/hHR6A, HIST1H1 proteins/histone H1, HMGA1, HIVEP3/KRC, LMNA, LMNB, LMNC, LBR, LATS1, MAP1B, MAP4, MARCKS, MCM2, MCM4, MKLP1, MYB, NEFH, NFIC, NPC/nuclear pore complex, PITPNM1/NIR2, NPM1, NCL, NUCKS1, NPM1/numatrin, ORC1, PRKAR2A, EEF1E1/p18, EIF3F/p47, p53/TP53, NONO/p54NRB, PAPOLA, PLEC/plectin, RB1, UL40/R2, RAB4A, RAP1GAP, RCC1, RPS6KB1/S6K1, KHDRBS1/SAM68, ESPL1, SKI, BIRC5/survivin, STIP1, TEX14, beta-tubulins, MAPT/TAU, NEDD1, VIM/vimentin, TK1, FOXO1, RUNX1/AML1, SAMHD1, SIRT2 and RUNX2. CDK1/CDC2-cyclin-B controls pronuclear union in interphase fertilized eggs. Essential for early stages of embryonic development. During G2 and early mitosis, CDC25A/B/C-mediated dephosphorylation activates CDK1/cyclin complexes which phosphorylate several substrates that trigger at least centrosome separation, Golgi dynamics, nuclear envelope breakdown and chromosome condensation. Once chromosomes are condensed and aligned at the metaphase plate, CDK1 activity is switched off by WEE1- and PKMYT1-mediated phosphorylation to allow sister chromatid separation, chromosome decondensation, reformation of the nuclear envelope and cytokinesis. Inactivated by PKR/EIF2AK2- and WEE1-mediated phosphorylation upon DNA damage to stop cell cycle and genome replication at the G2 checkpoint thus facilitating DNA repair. Reactivated after successful DNA repair through WIP1-dependent signaling leading to CDC25A/B/C-mediated dephosphorylation and restoring cell cycle progression. In proliferating cells, CDK1-mediated FOXO1 phosphorylation at the G2-M phase represses FOXO1 interaction with 14-3-3 proteins and thereby promotes FOXO1 nuclear accumulation and transcription factor activity, leading to cell death of postmitotic neurons. The phosphorylation of beta-tubulins regulates microtubule dynamics during mitosis. NEDD1 phosphorylation promotes PLK1-mediated NEDD1 phosphorylation and subsequent targeting of the gamma-tubulin ring complex (gTuRC) to the centrosome, an important step for spindle formation. In addition, CC2D1A phosphorylation regulates CC2D1A spindle pole localization and association with SCC1/RAD21 and centriole cohesion during mitosis. The phosphorylation of Bcl-xL/BCL2L1 after prolongated G2 arrest upon DNA damage triggers apoptosis. In contrast, CASP8 phosphorylation during mitosis prevents its activation by proteolysis and subsequent apoptosis. This phosphorylation occurs in cancer cell lines, as well as in primary breast tissues and lymphocytes. EZH2 phosphorylation promotes H3K27me3 maintenance and epigenetic gene silencing. CALD1 phosphorylation promotes Schwann cell migration during peripheral nerve regeneration. CDK1-cyclin-B complex phosphorylates NCKAP5L and mediates its dissociation from centrosomes during mitosis. Regulates the amplitude of the cyclic expression of the core clock gene ARNTL/BMAL1 by phosphorylating its transcriptional repressor NR1D1, and this phosphorylation is necessary for SCF(FBXW7)-mediated ubiquitination and proteasomal degradation of NR1D1. Plays a key role in the control of the eukaryotic cell cycle by modulating the centrosome cycle as well as mitotic onset; promotes G2-M transition, and regulates G1 progress and G1-S transition via association with multiple interphase cyclins.
T49898	PDBSTRUC	6GU7; 6GU6; 6GU4; 6GU3; 6GU2
T49898	BIOCLASS	Kinase
T49898	ECNUMBER	EC 2.7.11.22
T49898	SEQUENCE	MEDYTKIEKIGEGTYGVVYKGRHKTTGQVVAMKKIRLESEEEGVPSTAIREISLLKELRHPNIVSLQDVLMQDSRLYLIFEFLSMDLKKYLDSIPPGQYMDSSLVKSYLYQILQGIVFCHSRRVLHRDLKPQNLLIDDKGTIKLADFGLARAFGIPIRVYTHEVVTLWYRSPEVLLGSARYSTPVDIWSIGTIFAELATKKPLFHGDSEIDQLFRIFRALGTPNNEVWPEVESLQDYKNTFPKWKPGSLASHVKNLDENGLDLLSKMLIYDPAKRISGKMALNHPYFNDLDNQIKKM
T49898	DRUGINFO	D0W8IY	P-276	Phase 2
T49898	DRUGINFO	D01UMT	Ro 31-7453	Phase 2
T49898	DRUGINFO	D05IRT	P276-00	Phase 2
T49898	DRUGINFO	D05ADP	R-roscovitine	Phase 2
T49898	DRUGINFO	D0IX4B	AG-024322	Phase 1
T49898	DRUGINFO	D0P1CV	PHA-793887	Phase 1
T49898	DRUGINFO	D03DKV	RGB-286638	Phase 1
T49898	DRUGINFO	D04AKA	Pyrrolo[2,3-d]pyrimidine derivative 10	Patented
T49898	DRUGINFO	D08KKC	Pyrrolo[2,3-d]pyrimidine derivative 9	Patented
T49898	DRUGINFO	D08WJG	Naphthyridine and isoquinoline derivative 1	Patented
T49898	DRUGINFO	D01CJE	4-(thiazol-5-yl)-pyrimidine derivative 2	Patented
T49898	DRUGINFO	D0LX6X	Indole-based analog 13	Patented
T49898	DRUGINFO	D0NB7Y	Pyrazolo[1,5-a]-1,3,5-triazine derivative 1	Patented
T49898	DRUGINFO	D0W4MN	Isoquinoline 1,3-dione derivative 1	Patented
T49898	DRUGINFO	D0YK9D	CHIR-99021	Patented
T49898	DRUGINFO	D07DUX	Roscovitine derivative 1	Patented
T49898	DRUGINFO	D0NY7M	Tricyclic benzimidazole derivative 1	Patented
T49898	DRUGINFO	D00PWQ	KENPAULLONE	Patented
T49898	DRUGINFO	D0H4HD	PMID25991433-Compound-A1	Patented
T49898	DRUGINFO	D0M5DX	Oxazolyl methylthiothiazole derivative 1	Patented
T49898	DRUGINFO	D0D3PX	SCH 727965	Discontinued in Phase 3
T49898	DRUGINFO	D0NV9O	BAY 10-00394	Discontinued in Phase 2
T49898	DRUGINFO	D04FHB	R547	Discontinued in Phase 1
T49898	DRUGINFO	D00VBT	ZK 304709	Discontinued in Phase 1
T49898	DRUGINFO	D02MNY	ON-01135	Preclinical
T49898	DRUGINFO	D0WS1V	L-751250	Preclinical
T49898	DRUGINFO	D0U2TQ	CGP-60474	Terminated
T49898	DRUGINFO	D00BPA	Olomoucine	Terminated
T49898	DRUGINFO	D03XGJ	(2,6-Diamino-pyridin-3-yl)-phenyl-methanone	Investigative
T49898	DRUGINFO	D03YVL	Cdk1 inhibitor	Investigative
T49898	DRUGINFO	D0D2FC	CGP74514A	Investigative
T49898	DRUGINFO	D0DM5S	IN1535	Investigative
T49898	DRUGINFO	D04NGS	JNJ-7706621	Investigative
T49898	DRUGINFO	D05NKG	alsterpaullone 2-cyanoethyl	Investigative
T49898	DRUGINFO	D05SZH	BMS-265246	Investigative
T49898	DRUGINFO	D06BVH	4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile	Investigative
T49898	DRUGINFO	D07HRP	3,4-bis(indol-3-yl)maleimide derivative	Investigative
T49898	DRUGINFO	D08JML	Microxine	Investigative
T49898	DRUGINFO	D0E9DI	2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile	Investigative
T49898	DRUGINFO	D0L5GS	4-(Quinolin-4-yl)-N-p-tolylpyrimidin-2-amine	Investigative
T49898	DRUGINFO	D0P2WA	CVT-313	Investigative
T49898	DRUGINFO	D0Y7QZ	4-(Quinolin-3-yl)-N-p-tolylpyrimidin-2-amine	Investigative
T49898	DRUGINFO	D07OAT	Purvalanol A	Investigative
T49898	DRUGINFO	D07OCA	Cdk1/2 inhibitor III	Investigative
T49898	DRUGINFO	D0D5HQ	K00024	Investigative
T49898	DRUGINFO	D0F0AX	10Z-Hymenialdisine	Investigative
T49898	DRUGINFO	D0G2GA	aminopurvalanol A	Investigative
T49898	DRUGINFO	D0H3EV	9-Nitropaullone	Investigative
T49898	DRUGINFO	D0L3FK	SU9516	Investigative
T49898	DRUGINFO	D0R5FH	Quinoxaline1	Investigative
T49898	DRUGINFO	D0DR8N	AZAKENPAULLONE	Investigative
T49898	DRUGINFO	D0P6JS	PMID18986805C9b	Investigative
T49898	DRUGINFO	D0TF9P	Thieno analogue of kenpaullone	Investigative
T49898	DRUGINFO	D0G2CT	Indirubin-5-sulfonate	Investigative
T49898	DRUGINFO	D02QAZ	PF-228	Investigative
T49898	DRUGINFO	D02XHC	aloisine A	Investigative
T49898	DRUGINFO	D04WFN	NU6140	Investigative
T49898	DRUGINFO	D0T8NU	PMID19115845C89S	Investigative
T49898	DRUGINFO	D0Y0ES	Indirubin-3'-monoxime	Investigative
T49898	DRUGINFO	D06AOY	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	Investigative
T49898	DRUGINFO	D00NYT	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	Investigative
T49898	DRUGINFO	D0C3WY	3,4-diphenyl-1H-pyrrole-2,5-dione	Investigative
T49898	DRUGINFO	D0EK0G	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	Investigative
T49898	DRUGINFO	D0TO6S	Bisindolylmaleimide-I	Investigative
T49898	DRUGINFO	D0L8HO	RO-316233	Investigative

T67102	TARGETID	T67102
T67102	FORMERID	TTDR00447
T67102	UNIPROID	CATD_HUMAN
T67102	TARGNAME	Cathepsin D (CTSD)
T67102	GENENAME	CTSD
T67102	TARGTYPE	Clinical trial
T67102	SYNONYMS	CPSD; CD
T67102	FUNCTION	Plays a role in APP processing following cleavage and activation by ADAM30 which leads to APP degradation. Involved in the pathogenesis of several diseases such as breast cancer and possibly Alzheimer disease. Acid protease active in intracellular protein breakdown.
T67102	PDBSTRUC	4OD9; 4OC6; 4OBZ; 1LYW; 1LYB
T67102	BIOCLASS	Peptidase
T67102	ECNUMBER	EC 3.4.23.5
T67102	SEQUENCE	MQPSSLLPLALCLLAAPASALVRIPLHKFTSIRRTMSEVGGSVEDLIAKGPVSKYSQAVPAVTEGPIPEVLKNYMDAQYYGEIGIGTPPQCFTVVFDTGSSNLWVPSIHCKLLDIACWIHHKYNSDKSSTYVKNGTSFDIHYGSGSLSGYLSQDTVSVPCQSASSASALGGVKVERQVFGEATKQPGITFIAAKFDGILGMAYPRISVNNVLPVFDNLMQQKLVDQNIFSFYLSRDPDAQPGGELMLGGTDSKYYKGSLSYLNVTRKAYWQVHLDQVEVASGLTLCKEGCEAIVDTGTSLMVGPVDEVRELQKAIGAVPLIQGEYMIPCEKVSTLPAITLKLGGKGYKLSPEDYTLKVSQAGKTLCLSGFMGMDIPPPSGPLWILGDVFIGRYYTVFDRDNNRVGFAEAARL
T67102	DRUGINFO	D0FE7H	PMID10498202C1	Clinical trial
T67102	DRUGINFO	D04TSV	CI-992	Terminated
T67102	DRUGINFO	D07DYJ	N-Aminoethylmorpholine	Investigative
T67102	DRUGINFO	D0W5NB	1h-Benoximidazole-2-Carboxylic Acid	Investigative
T67102	DRUGINFO	D02LCH	GRL-7234	Investigative
T67102	DRUGINFO	D0CU4Q	S-Methylcysteine	Investigative
T67102	DRUGINFO	D0H3EJ	Carbocyclic Peptidomimetic	Investigative
T67102	DRUGINFO	D0S3BO	KNI-10006	Investigative
T67102	DRUGINFO	D0P6RT	PMID8410973C3	Investigative
T67102	DRUGINFO	D0Y5IQ	Grassystatin a	Investigative
T67102	DRUGINFO	D07LUR	Alpha-D-Mannose	Investigative

T75570	TARGETID	T75570
T75570	FORMERID	TTDS00408
T75570	UNIPROID	YES_HUMAN
T75570	TARGNAME	Yes tyrosine kinase (YES)
T75570	GENENAME	YES1
T75570	TARGTYPE	Clinical trial
T75570	SYNONYMS	p61-Yes; Yes p59-Fyn; Yes Protooncogene Syn; Tyrosine-protein kinase Yes; Proto-oncogene c-Yes
T75570	FUNCTION	Stimulation by receptor tyrosine kinases (RTKs) including EGRF, PDGFR, CSF1R and FGFR leads to recruitment of YES1 to the phosphorylated receptor, and activation and phosphorylation of downstream substrates. Upon EGFR activation, promotes the phosphorylation of PARD3 to favor epithelial tight junction assembly. Participates in the phosphorylation of specific junctional components such as CTNND1 by stimulating the FYN and FER tyrosine kinases at cell-cell contacts. Upon T-cell stimulation by CXCL12, phosphorylates collapsin response mediator protein 2/DPYSL2 and induces T-cell migration. Participates in CD95L/FASLG signaling pathway and mediates AKT-mediated cell migration. Plays a role in cell cycle progression by phosphorylating the cyclin-dependent kinase 4/CDK4 thus regulating the G1 phase. Also involved in G2/M progression and cytokinesis. Non-receptor protein tyrosine kinase that is involved in the regulation of cell growth and survival, apoptosis, cell-cell adhesion, cytoskeleton remodeling, and differentiation.
T75570	PDBSTRUC	2HDA
T75570	BIOCLASS	Kinase
T75570	ECNUMBER	EC 2.7.10.2
T75570	SEQUENCE	MGCIKSKENKSPAIKYRPENTPEPVSTSVSHYGAEPTTVSPCPSSSAKGTAVNFSSLSMTPFGGSSGVTPFGGASSSFSVVPSSYPAGLTGGVTIFVALYDYEARTTEDLSFKKGERFQIINNTEGDWWEARSIATGKNGYIPSNYVAPADSIQAEEWYFGKMGRKDAERLLLNPGNQRGIFLVRESETTKGAYSLSIRDWDEIRGDNVKHYKIRKLDNGGYYITTRAQFDTLQKLVKHYTEHADGLCHKLTTVCPTVKPQTQGLAKDAWEIPRESLRLEVKLGQGCFGEVWMGTWNGTTKVAIKTLKPGTMMPEAFLQEAQIMKKLRHDKLVPLYAVVSEEPIYIVTEFMSKGSLLDFLKEGDGKYLKLPQLVDMAAQIADGMAYIERMNYIHRDLRAANILVGENLVCKIADFGLARLIEDNEYTARQGAKFPIKWTAPEAALYGRFTIKSDVWSFGILQTELVTKGRVPYPGMVNREVLEQVERGYRMPCPQGCPESLHELMNLCWKKDPDERPTFEYIQSFLEDYFTATEPQYQPGENL
T75570	DRUGINFO	D0U3XL	JNJ-26483327	Phase 1
T75570	DRUGINFO	D0H1OK	TG-100435	Investigative

T40332	TARGETID	T40332
T40332	FORMERID	TTDS00448
T40332	UNIPROID	ELNE_HUMAN
T40332	TARGNAME	Neutrophil elastase (NE)
T40332	GENENAME	ELANE
T40332	TARGTYPE	Clinical trial
T40332	SYNONYMS	PMN elastase; Medullasin; Human leukocyte elastase; HLE; Elastase-2; ELA2; Bone marrow serine protease
T40332	FUNCTION	Inhibits C5a-dependent neutrophil enzyme release and chemotaxis. Modifies the functions of natural killer cells, monocytes and granulocytes.
T40332	PDBSTRUC	6F5M; 5ABW; 5A8Z; 5A8Y; 5A8X
T40332	BIOCLASS	Peptidase
T40332	ECNUMBER	EC 3.4.21.37
T40332	SEQUENCE	MTLGRRLACLFLACVLPALLLGGTALASEIVGGRRARPHAWPFMVSLQLRGGHFCGATLIAPNFVMSAAHCVANVNVRAVRVVLGAHNLSRREPTRQVFAVQRIFENGYDPVNLLNDIVILQLNGSATINANVQVAQLPAQGRRLGNGVQCLAMGWGLLGRNRGIASVLQELNVTVVTSLCRRSNVCTLVRGRQAGVCFGDSGSPLVCNGLIHGIASFVRGGCASGLYPDAFAPVAQFVNWIDSIIQRSEDNPCPHPRDPDPASRTH
T40332	DRUGINFO	D05QHL	Sivelestat sodium hydrate	Phase 4
T40332	DRUGINFO	D0FT4R	Sivelestat	Phase 3
T40332	DRUGINFO	D0U2BH	Epigallocatechin gallate	Phase 3
T40332	DRUGINFO	D02PHE	AZD9668	Phase 2
T40332	DRUGINFO	D08PBB	L-694,458	Phase 2
T40332	DRUGINFO	D0A0SI	BAY 85-8501	Phase 2
T40332	DRUGINFO	D0M0PY	DX-890	Phase 2
T40332	DRUGINFO	D05BPC	Tiprelestat	Phase 2
T40332	DRUGINFO	D01OGV	POL-6014	Phase 1
T40332	DRUGINFO	D0U0AU	AZD-9819	Phase 1
T40332	DRUGINFO	D8PO7Y	BI 1323495	Phase 1
T40332	DRUGINFO	D00CDI	Peptide analog 67	Patented
T40332	DRUGINFO	D00WHH	4-pyridone derivative 2	Patented
T40332	DRUGINFO	D00YXL	2-pyrazinone derivative 1	Patented
T40332	DRUGINFO	D02IXA	Uracil derivative 1	Patented
T40332	DRUGINFO	D02UCA	Pyrimidine derivative 34	Patented
T40332	DRUGINFO	D06TAS	2-pyrazinone derivative 2	Patented
T40332	DRUGINFO	D07RRV	Tetra-hydro-triazolopyrimidine derivative 2	Patented
T40332	DRUGINFO	D08HBW	Peptide analog 64	Patented
T40332	DRUGINFO	D09EPZ	4-pyridone derivative 1	Patented
T40332	DRUGINFO	D09VDQ	Pyrimidinone derivative 4	Patented
T40332	DRUGINFO	D0A6AJ	Peptide analog 65	Patented
T40332	DRUGINFO	D0B5QU	2-pyrazinone derivative 5	Patented
T40332	DRUGINFO	D0EE5S	2-pyrazinone derivative 7	Patented
T40332	DRUGINFO	D0HU0O	Tetra-hydro-pyrrolopyrimidinedione derivative 1	Patented
T40332	DRUGINFO	D0L9AS	Peptide analog 66	Patented
T40332	DRUGINFO	D0M3EA	2-pyrazinone derivative 6	Patented
T40332	DRUGINFO	D0M3NR	Peptide analog 68	Patented
T40332	DRUGINFO	D0NS8V	Dihydropyrimidinone derivative 2	Patented
T40332	DRUGINFO	D0R2TH	2-pyrazinone derivative 3	Patented
T40332	DRUGINFO	D0S9NB	2-pyrazinone derivative 4	Patented
T40332	DRUGINFO	D0TP0X	Peptide analog 63	Patented
T40332	DRUGINFO	D0VU3I	Hypersulfated disaccharide compound 1	Patented
T40332	DRUGINFO	D0W3EJ	Peptide analog 69	Patented
T40332	DRUGINFO	D0W6PE	Dihydropyrimidinone derivative 1	Patented
T40332	DRUGINFO	D00TCL	Peptide analog 59	Patented
T40332	DRUGINFO	D09ZUJ	Peptide analog 61	Patented
T40332	DRUGINFO	D0IL0Y	Peptide analog 55	Patented
T40332	DRUGINFO	D0K2RX	Peptide analog 60	Patented
T40332	DRUGINFO	D0M6WD	Peptide analog 70	Patented
T40332	DRUGINFO	D0O8MI	Peptide analog 56	Patented
T40332	DRUGINFO	D0R7UI	Peptide analog 57	Patented
T40332	DRUGINFO	D0ZA3S	Peptide analog 58	Patented
T40332	DRUGINFO	D0ZW9O	Peptide analog 62	Patented
T40332	DRUGINFO	D0R9ON	MR-889	Discontinued in Phase 3
T40332	DRUGINFO	D08ZCW	ZD-8321	Discontinued in Phase 2
T40332	DRUGINFO	D0P4IK	FK-706	Discontinued in Phase 2
T40332	DRUGINFO	D0T5GT	CE-1037	Discontinued in Phase 2
T40332	DRUGINFO	D0B9EH	Dermolastin	Discontinued in Phase 2
T40332	DRUGINFO	D06DET	AE-3763	Discontinued in Phase 1
T40332	DRUGINFO	D0Q9UO	GW-311616	Discontinued in Phase 1
T40332	DRUGINFO	D0WY9H	ZD-0892	Discontinued in Phase 1
T40332	DRUGINFO	D0X7WK	AZD-6553	Discontinued in Phase 1
T40332	DRUGINFO	D05QMG	FR167653	Discontinued in Phase 1
T40332	DRUGINFO	D02YSI	FR-901277	Terminated
T40332	DRUGINFO	D03GII	SR-26831	Terminated
T40332	DRUGINFO	D0I0FM	FR-901451	Terminated
T40332	DRUGINFO	D0O6GN	Mdl 101,146	Terminated
T40332	DRUGINFO	D00QBV	DD7	Investigative
T40332	DRUGINFO	D00TYW	6-Heptyl-4-hydroxy-3-octanoyl-pyran-2-one	Investigative
T40332	DRUGINFO	D01NJE	ED45	Investigative
T40332	DRUGINFO	D01UNT	ICI 200,880	Investigative
T40332	DRUGINFO	D02NRY	(4-bromo-1H-pyrazol-1-yl)(o-tolyl)methanone	Investigative
T40332	DRUGINFO	D03BNM	Cbz-Val-Pro-Val-(2-benzoxazole)	Investigative
T40332	DRUGINFO	D03MNO	L-658,758	Investigative
T40332	DRUGINFO	D03STO	1-benzyl-3,3-diethylazetidine-2,4-dione	Investigative
T40332	DRUGINFO	D04KAS	Ac-Ala-Pro-Val-(2-benzoxazole)	Investigative
T40332	DRUGINFO	D04ODG	3-Ethyl-3-isobutyl-1-phenylazetidine-2,4-dione	Investigative
T40332	DRUGINFO	D04SPO	E-6-O-p-methoxycinnamoyl scandoside methyl ester	Investigative
T40332	DRUGINFO	D05CWG	TEI-8362	Investigative
T40332	DRUGINFO	D06JMS	3-Benzyl-3-methyl-1-phenylazetidine-2,4-dione	Investigative
T40332	DRUGINFO	D07DOW	(1H-pyrazol-1-yl)(o-tolyl)methanone	Investigative
T40332	DRUGINFO	D07HLC	1-benzyl-3,3-dimethylazetidine-2,4-dione	Investigative
T40332	DRUGINFO	D08RPN	(4-bromo-1H-pyrazol-1-yl)(m-tolyl)methanone	Investigative
T40332	DRUGINFO	D0A5ZF	3,3-Diethyl-1-(pyridin-3-yl)azetidine-2,4-dione	Investigative
T40332	DRUGINFO	D0B4WZ	3-Benzyl-3-ethyl-1-phenylazetidine-2,4-dione	Investigative
T40332	DRUGINFO	D0B5VN	ICI 200,355	Investigative
T40332	DRUGINFO	D0D6ZB	AX-9657	Investigative
T40332	DRUGINFO	D0E0EQ	2-methylbut-3-yn-2-yl 4-methoxybenzoate	Investigative
T40332	DRUGINFO	D0F3CA	3,4-dichloroisocoumarin	Investigative
T40332	DRUGINFO	D0G1SN	ED1	Investigative
T40332	DRUGINFO	D0H8EO	3,3-diethyl-1-phenylazetidine-2,4-dione	Investigative
T40332	DRUGINFO	D0I1AC	(4-chloro-1H-pyrazol-1-yl)(o-tolyl)methanone	Investigative
T40332	DRUGINFO	D0J1LX	Bornyl (3,4,5-trihydroxy)-cinnamate	Investigative
T40332	DRUGINFO	D0K2MT	ADC-7828	Investigative
T40332	DRUGINFO	D0L8DL	WIN-63395	Investigative
T40332	DRUGINFO	D0MQ8A	3-butyl-3-ethyl-1-phenylazetidine-2,4-dione	Investigative
T40332	DRUGINFO	D0N9DP	4-Hydroxy-3-nonanoyl-6-octyl-pyran-2-one	Investigative
T40332	DRUGINFO	D0O8PM	N,N-bis(cyanomethyl)-3,4-dimethoxybenzamide	Investigative
T40332	DRUGINFO	D0PQ8B	3-Decanoyl-4-hydroxy-6-nonyl-pyran-2-one	Investigative
T40332	DRUGINFO	D0Z7LS	3,3-Diethyl-1-o-tolylazetidine-2,4-dione	Investigative
T40332	DRUGINFO	D02AKP	4-methoxy-N'-(2-phenylacetyl)benzohydrazide	Investigative
T40332	DRUGINFO	D06GTS	PMID24556381C10l	Investigative
T40332	DRUGINFO	D0T9WZ	PMID24556381C10f	Investigative
T40332	DRUGINFO	D0VP6M	1-(3,3-Dimethyl-2-oxo-butyl)-1H-indole-2,3-dione	Investigative
T40332	DRUGINFO	D00WFQ	(4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone	Investigative
T40332	DRUGINFO	D02PAU	ZK-814048	Investigative
T40332	DRUGINFO	D06LPR	(4-nitro-1H-pyrazol-1-yl)(phenyl)methanone	Investigative
T40332	DRUGINFO	D08WQJ	(3-nitro-1H-pyrazol-1-yl)(phenyl)methanone	Investigative
T40332	DRUGINFO	D0C1NP	PMID22595175C4g	Investigative
T40332	DRUGINFO	D05ZIP	(4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone	Investigative
T40332	DRUGINFO	D08OCS	(3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone	Investigative
T40332	DRUGINFO	D0IU5E	1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide	Investigative
T40332	DRUGINFO	D0X1OY	(3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone	Investigative
T40332	DRUGINFO	D0G6XS	Fucose	Investigative

T86385	TARGETID	T86385
T86385	FORMERID	TTDC00019
T86385	UNIPROID	CATG_HUMAN
T86385	TARGNAME	Cathepsin G (CTSG)
T86385	GENENAME	CTSG
T86385	TARGTYPE	Clinical trial
T86385	SYNONYMS	CG
T86385	FUNCTION	Cleaves complement C3. Has antibacterial activity against the Gram-negative bacterium P. aeruginosa, antibacterial activity is inhibited by LPS from P. aeruginosa, Z-Gly-Leu-Phe-CH2Cl and phenylmethylsulfonyl fluoride. Serine protease with trypsin- and chymotrypsin-like specificity.
T86385	PDBSTRUC	1T32; 1KYN; 1CGH; 1AU8
T86385	BIOCLASS	Peptidase
T86385	ECNUMBER	EC 3.4.21.20
T86385	SEQUENCE	MQPLLLLLAFLLPTGAEAGEIIGGRESRPHSRPYMAYLQIQSPAGQSRCGGFLVREDFVLTAAHCWGSNINVTLGAHNIQRRENTQQHITARRAIRHPQYNQRTIQNDIMLLQLSRRVRRNRNVNPVALPRAQEGLRPGTLCTVAGWGRVSMRRGTDTLREVQLRVQRDRQCLRIFGSYDPRRQICVGDRRERKAAFKGDSGGPLLCNNVAHGIVSYGKSSGVPPEVFTRVSSFLPWIRTTMRSFKLLDQMETPL
T86385	DRUGINFO	D01YIO	JNJ-10311795	Phase 2
T86385	DRUGINFO	D00TCL	Peptide analog 59	Patented
T86385	DRUGINFO	D09ZUJ	Peptide analog 61	Patented
T86385	DRUGINFO	D0IL0Y	Peptide analog 55	Patented
T86385	DRUGINFO	D0K2RX	Peptide analog 60	Patented
T86385	DRUGINFO	D0M6WD	Peptide analog 70	Patented
T86385	DRUGINFO	D0O8MI	Peptide analog 56	Patented
T86385	DRUGINFO	D0R7UI	Peptide analog 57	Patented
T86385	DRUGINFO	D0ZA3S	Peptide analog 58	Patented
T86385	DRUGINFO	D0ZW9O	Peptide analog 62	Patented
T86385	DRUGINFO	D0NJ1A	Aloxistatin	Discontinued in Phase 3
T86385	DRUGINFO	D0B9EH	Dermolastin	Discontinued in Phase 2
T86385	DRUGINFO	D05EGR	Bis-Napthyl Beta-Ketophosphonic Acid	Investigative
T86385	DRUGINFO	D0F2YC	1,3-Dibenzyl-[1,3]diazetidine-2,4-dione	Investigative
T86385	DRUGINFO	D0C1NP	PMID22595175C4g	Investigative

T43115	TARGETID	T43115
T43115	FORMERID	TTDR00611
T43115	UNIPROID	PTPRC_HUMAN
T43115	TARGNAME	Leukocyte common antigen (PTPRC)
T43115	GENENAME	PTPRC
T43115	TARGTYPE	Clinical trial
T43115	SYNONYMS	T200; Receptor-type tyrosine-protein phosphatase C; L-CA; CD45 antigen; CD45
T43115	FUNCTION	Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN. Dephosphorylates LYN, and thereby modulates LYN activity. Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor.
T43115	PDBSTRUC	5FN7; 5FN6; 5FMV; 1YGU; 1YGR
T43115	BIOCLASS	Phosphoric monoester hydrolase
T43115	ECNUMBER	EC 3.1.3.48
T43115	SEQUENCE	MTMYLWLKLLAFGFAFLDTEVFVTGQSPTPSPTGLTTAKMPSVPLSSDPLPTHTTAFSPASTFERENDFSETTTSLSPDNTSTQVSPDSLDNASAFNTTGVSSVQTPHLPTHADSQTPSAGTDTQTFSGSAANAKLNPTPGSNAISDVPGERSTASTFPTDPVSPLTTTLSLAHHSSAALPARTSNTTITANTSDAYLNASETTTLSPSGSAVISTTTIATTPSKPTCDEKYANITVDYLYNKETKLFTAKLNVNENVECGNNTCTNNEVHNLTECKNASVSISHNSCTAPDKTLILDVPPGVEKFQLHDCTQVEKADTTICLKWKNIETFTCDTQNITYRFQCGNMIFDNKEIKLENLEPEHEYKCDSEILYNNHKFTNASKIIKTDFGSPGEPQIIFCRSEAAHQGVITWNPPQRSFHNFTLCYIKETEKDCLNLDKNLIKYDLQNLKPYTKYVLSLHAYIIAKVQRNGSAAMCHFTTKSAPPSQVWNMTVSMTSDNSMHVKCRPPRDRNGPHERYHLEVEAGNTLVRNESHKNCDFRVKDLQYSTDYTFKAYFHNGDYPGEPFILHHSTSYNSKALIAFLAFLIIVTSIALLVVLYKIYDLHKKRSCNLDEQQELVERDDEKQLMNVEPIHADILLETYKRKIADEGRLFLAEFQSIPRVFSKFPIKEARKPFNQNKNRYVDILPYDYNRVELSEINGDAGSNYINASYIDGFKEPRKYIAAQGPRDETVDDFWRMIWEQKATVIVMVTRCEEGNRNKCAEYWPSMEEGTRAFGDVVVKINQHKRCPDYIIQKLNIVNKKEKATGREVTHIQFTSWPDHGVPEDPHLLLKLRRRVNAFSNFFSGPIVVHCSAGVGRTGTYIGIDAMLEGLEAENKVDVYGYVVKLRRQRCLMVQVEAQYILIHQALVEYNQFGETEVNLSELHPYLHNMKKRDPPSEPSPLEAEFQRLPSYRSWRTQHIGNQEENKSKNRNSNVIPYDYNRVPLKHELEMSKESEHDSDESSDDDSDSEEPSKYINASFIMSYWKPEVMIAAQGPLKETIGDFWQMIFQRKVKVIVMLTELKHGDQEICAQYWGEGKQTYGDIEVDLKDTDKSSTYTLRVFELRHSKRKDSRTVYQYQYTNWSVEQLPAEPKELISMIQVVKQKLPQKNSSEGNKHHKSTPLLIHCRDGSQQTGIFCALLNLLESAETEEVVDIFQVVKALRKARPGMVSTFEQYQFLYDVIASTYPAQNGQVKKNNHQEDKIEFDNEVDKVKQDANCVNPLGAPEKLPEAKEQAEGSEPTSGTEGPEHSVNGPASPALNQGS
T43115	DRUGINFO	D08BBL	Iomab-B	Phase 3
T43115	DRUGINFO	DC8EN0	131I-labelled aCD45	Phase 3
T43115	DRUGINFO	D0G5OE	[131I]-BC8	Phase 2
T43115	DRUGINFO	D06MMU	LM-CD45	Phase 1
T43115	DRUGINFO	D0I0ZO	Anti-CD45 mabs	Phase 1
T43115	DRUGINFO	DZ7OC3	Iomab-ACT	Phase 1
T43115	DRUGINFO	D0V4FP	OX-30	Terminated
T43115	DRUGINFO	D0N7VL	Asp-BrPmp-Leu	Investigative

T36059	TARGETID	T36059
T36059	FORMERID	TTDS00189
T36059	UNIPROID	AA3R_HUMAN
T36059	TARGNAME	Adenosine A3 receptor (ADORA3)
T36059	GENENAME	ADORA3
T36059	TARGTYPE	Clinical trial
T36059	SYNONYMS	Adenosine receptor A3A; Adenosine receptor A3; Adenosine 3 receptor; A3AR; A3 Adenosine receptor
T36059	FUNCTION	The activity of this receptor is mediated by G proteins which inhibits adenylyl cyclase. Isoform 2: Receptor for adenosine.
T36059	PDBSTRUC	1R7N; 1OEA
T36059	BIOCLASS	GPCR rhodopsin
T36059	SEQUENCE	MPNNSTALSLANVTYITMEIFIGLCAIVGNVLVICVVKLNPSLQTTTFYFIVSLALADIAVGVLVMPLAIVVSLGITIHFYSCLFMTCLLLIFTHASIMSLLAIAVDRYLRVKLTVRYKRVTTHRRIWLALGLCWLVSFLVGLTPMFGWNMKLTSEYHRNVTFLSCQFVSVMRMDYMVYFSFLTWIFIPLVVMCAIYLDIFYIIRNKLSLNLSNSKETGAFYGREFKTAKSLFLVLFLFALSWLPLSIINCIIYFNGEVPQLVLYMGILLSHANSMMNPIVYAYKIKKFKETYLLILKACVVCHPSDSLDTSIEKNSE
T36059	DRUGINFO	D0Y6ZK	IB-MECA	Phase 3
T36059	DRUGINFO	D0U0KR	CF102	Phase 2
T36059	DRUGINFO	D0LI1C	NITD609	Phase 2
T36059	DRUGINFO	D00SUK	Tonapofylline	Phase 2
T36059	DRUGINFO	D7FJX0	AST-004	Phase 1
T36059	DRUGINFO	D02YQO	SCH-442416	Phase 1
T36059	DRUGINFO	D0V3GT	BEMESETRON	Discontinued in Phase 3
T36059	DRUGINFO	D06PXT	CF602	Preclinical
T36059	DRUGINFO	D0I5VA	CF502	Preclinical
T36059	DRUGINFO	D0HE1P	BAY 60-6583	Preclinical
T36059	DRUGINFO	D0NQ5I	METRIFUDIL	Terminated
T36059	DRUGINFO	D02KLW	DIZOCILPINE	Terminated
T36059	DRUGINFO	D0E4WF	METHYLTHIOADENOSINE	Terminated
T36059	DRUGINFO	D00CVD	MRS1067	Investigative
T36059	DRUGINFO	D00HVX	[1,2,4]triazolo[1,5-a]quinoxalin-4(5H)-one	Investigative
T36059	DRUGINFO	D00YXE	2-(5-chloro-1H-benzo[d]imidazol-2-yl)quinoxaline	Investigative
T36059	DRUGINFO	D01DPF	MRS1505	Investigative
T36059	DRUGINFO	D01NTI	N*2*-Benzyl-N*6*-cyclohexyl-9H-purine-2,6-diamine	Investigative
T36059	DRUGINFO	D02OMP	I-ABA	Investigative
T36059	DRUGINFO	D02ZZQ	8-Hydroxy-5,7,9-trimethyl-delta-carboline	Investigative
T36059	DRUGINFO	D04SDD	N6-(3-Iodobenzyl)-2'-O-methyladenosine	Investigative
T36059	DRUGINFO	D04UCF	MRE 3010F20	Investigative
T36059	DRUGINFO	D04VYZ	2-(3''-(benzotriazole-1''-yl)ethyloxy)adenosine	Investigative
T36059	DRUGINFO	D05CEJ	N-(4,6-diphenylpyrimidin-2-yl)-4-chlorobenzamide	Investigative
T36059	DRUGINFO	D05NEM	1-phenyl-3-(2-(pyridin-3-yl)quinazolin-4-yl)urea	Investigative
T36059	DRUGINFO	D05TMJ	1-phenyl-3-(2-(pyridin-2-yl)quinazolin-4-yl)urea	Investigative
T36059	DRUGINFO	D05XKT	1,2-dihydro-2-oxoquinazoline-4-carboxyanilide	Investigative
T36059	DRUGINFO	D06FNT	VUF-8504	Investigative
T36059	DRUGINFO	D06MWU	LUF-5833	Investigative
T36059	DRUGINFO	D06NRZ	CIRSIMARITIN	Investigative
T36059	DRUGINFO	D06QID	2,6-bis(4-chlorophenyl)-9H-purine	Investigative
T36059	DRUGINFO	D06TXS	1-phenyl-3-(quinazolin-4-yl)urea	Investigative
T36059	DRUGINFO	D06ZLJ	MRS1476	Investigative
T36059	DRUGINFO	D07IYH	NSC-407228	Investigative
T36059	DRUGINFO	D07ZQB	MPC-MECA	Investigative
T36059	DRUGINFO	D08FSF	1-Allyl-3,7-dihydro-purine-2,6-dione	Investigative
T36059	DRUGINFO	D08NQA	MRS5698	Investigative
T36059	DRUGINFO	D08TSA	MRS1177	Investigative
T36059	DRUGINFO	D09JKT	2-acetylaminoquinazoline-4-carboxyanilide	Investigative
T36059	DRUGINFO	D09SUZ	2-aminoquinazoline-4-carboxyanilide	Investigative
T36059	DRUGINFO	D0A0GA	2,6-bis(4-methoxyphenyl)-9H-purine	Investigative
T36059	DRUGINFO	D0A2WH	1-Butyl-3,7-dihydro-purine-2,6-dione	Investigative
T36059	DRUGINFO	D0AT5L	[125I]AB-MECA	Investigative
T36059	DRUGINFO	D0B2NE	2-phenylethylyl-adenosine derivative	Investigative
T36059	DRUGINFO	D0C8FY	MRS1097	Investigative
T36059	DRUGINFO	D0D4NS	2-(1H-imidazo[4,5-c]pyridin-2-yl)quinoxaline	Investigative
T36059	DRUGINFO	D0E5QE	8-Hydroxy-7,9-dimethyl-delta-carboline	Investigative
T36059	DRUGINFO	D0F4EN	2-Phenyl-2H-pyrazolo[4,3-c]quinoline	Investigative
T36059	DRUGINFO	D0G4WF	5,6,7-Trimethyl-2-p-tolyl-chromen-4-one	Investigative
T36059	DRUGINFO	D0GC7S	1-phenyl-3-(3-(pyridin-2-yl)isoquinolin-1-yl)urea	Investigative
T36059	DRUGINFO	D0GR6H	2-benzoylaminoquinazoline-4-carboxyanilide	Investigative
T36059	DRUGINFO	D0H4RE	1-(2-(diethylamino)quinazolin-4-yl)-3-phenylurea	Investigative
T36059	DRUGINFO	D0H9EY	2'-Me-CCPA	Investigative
T36059	DRUGINFO	D0I8GD	MRS1186	Investigative
T36059	DRUGINFO	D0IJ2X	1-Prop-2-ynyl-3,7-dihydro-purine-2,6-dione	Investigative
T36059	DRUGINFO	D0J0UT	9H-purine derivative	Investigative
T36059	DRUGINFO	D0J9FK	[3H]PSB-11	Investigative
T36059	DRUGINFO	D0K5WC	6-Hydroxy-5,7-dimethyl-beta-carboline	Investigative
T36059	DRUGINFO	D0K8ZW	1-Cyclopentyl-3,7-dihydro-purine-2,6-dione	Investigative
T36059	DRUGINFO	D0NF3E	2-(4-nitro-1H-benzo[d]imidazol-2-yl)quinoxaline	Investigative
T36059	DRUGINFO	D0O2AV	MRS1486	Investigative
T36059	DRUGINFO	D0RI4S	2-benzyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one	Investigative
T36059	DRUGINFO	D0U2EF	ACN-1052	Investigative
T36059	DRUGINFO	D0U6NZ	[125I]APNEA	Investigative
T36059	DRUGINFO	D0V1TS	1-Benzyl-1H-1,3,4b,9-tetraaza-fluorene-2,4-dione	Investigative
T36059	DRUGINFO	D0V2NH	1-Phenethyl-3,7-dihydro-purine-2,6-dione	Investigative
T36059	DRUGINFO	D0V7TA	2-phenyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one	Investigative
T36059	DRUGINFO	D0Y8EU	MRS-1220	Investigative
T36059	DRUGINFO	D0Z2CL	2-aminoquinazoline-4-carboxy-(4-bromophenyl)amide	Investigative
T36059	DRUGINFO	D0ZF8N	4-Methoxy-2-phenyl-2H-pyrazolo[4,3-c]quinoline	Investigative
T36059	DRUGINFO	D00JMT	REVERSINE	Investigative
T36059	DRUGINFO	D01WXR	N-(4,5-diphenylpyrimidin-2-yl)acetamide	Investigative
T36059	DRUGINFO	D02HHW	CP608,039	Investigative
T36059	DRUGINFO	D02HZJ	N-(2,6-diphenylpyrimidin-4-yl)benzamide	Investigative
T36059	DRUGINFO	D02WTN	Hexanoic Acid (2,6-diphenylpyrimidin-4-yl)amide	Investigative
T36059	DRUGINFO	D04PLH	VUF-8507	Investigative
T36059	DRUGINFO	D06UXW	METHOCTRAMINE	Investigative
T36059	DRUGINFO	D07FGB	2,6-bis(4-tolyl)-9H-purine	Investigative
T36059	DRUGINFO	D07HVJ	2-(3''-(benzoimidazole-1''-yl)ethyloxy)adenosine	Investigative
T36059	DRUGINFO	D08AJS	3-(3-chloro-1H-pyrazol-5-yl)quinoxalin-2(1H)-one	Investigative
T36059	DRUGINFO	D09NEP	MRS1088	Investigative
T36059	DRUGINFO	D0A5KG	2-azido-N6-methyl-9-(beta-D-ribofuranosyl)adenine	Investigative
T36059	DRUGINFO	D0B9CC	3-Methyl-1-phenethyl-3,7-dihydro-purine-2,6-dione	Investigative
T36059	DRUGINFO	D0D9YL	1-Benzyl-3-methyl-3,7-dihydro-purine-2,6-dione	Investigative
T36059	DRUGINFO	D0MH4R	visnagin	Investigative
T36059	DRUGINFO	D0N1PT	2-(4-chloro-1H-benzo[d]imidazol-2-yl)quinoxaline	Investigative
T36059	DRUGINFO	D0N2DP	N*6*-Cyclooctyl-N*2*-phenyl-9H-purine-2,6-diamine	Investigative
T36059	DRUGINFO	D0O8QS	4-Methoxy-N-(3-phenyl-isoquinolin-1-yl)-benzamide	Investigative
T36059	DRUGINFO	D0P1JJ	6-ethylamino-2-(3''-indolyl)ethyloxy)adenosine	Investigative
T36059	DRUGINFO	D0P5ZE	Cyclohexyl-(2-phenoxy-9H-purin-6-yl)-amine	Investigative
T36059	DRUGINFO	D0PM5R	AB-MECA	Investigative
T36059	DRUGINFO	D0Q5HW	N6-methoxy-2-[(4-methylphenyl)ethynyl]adenosine	Investigative
T36059	DRUGINFO	D0R4LZ	2-(4-methoxyphenyl)-6-phenyl-9H-purine	Investigative
T36059	DRUGINFO	D0X3PD	I-ABOPX	Investigative
T36059	DRUGINFO	D0Y8SB	L-249313	Investigative
T36059	DRUGINFO	D0YR1V	5-Butyl-8-phenyl-3H-[1,2,4]triazolo[5,1-i]purine	Investigative
T36059	DRUGINFO	D0Z3IZ	N*6*-Cyclohexyl-N*2*-ethyl-9H-purine-2,6-diamine	Investigative
T36059	DRUGINFO	D00ASZ	2-(3''-pyrrolylethyloxy)adenosine	Investigative
T36059	DRUGINFO	D00GQI	N-(2,6-diphenylpyrimidin-4-yl)isobutyramide	Investigative
T36059	DRUGINFO	D00IOF	PSB36	Investigative
T36059	DRUGINFO	D00NFW	2,6-diphenyl-8-ethyl-1-deazapurine	Investigative
T36059	DRUGINFO	D01AAI	VUF5574	Investigative
T36059	DRUGINFO	D01NHH	2,6-diphenyl-8-tButyl-1-deazapurine	Investigative
T36059	DRUGINFO	D01PGY	2-(hex-1-ynyl)-N6-methoxyadenosine	Investigative
T36059	DRUGINFO	D01QBK	8-Bromo-9-cyclohexyl-9H-adenine	Investigative
T36059	DRUGINFO	D01VEU	9-Ethyl-8-phenylethynyl-9H-purin-6-ylamine	Investigative
T36059	DRUGINFO	D01VXC	N-(4,6-diphenylpyrimidin-2-yl)propionamide	Investigative
T36059	DRUGINFO	D01VXP	2-ethynyl-N6-methoxyadenosine	Investigative
T36059	DRUGINFO	D02EAO	N*6*-Cyclohexyl-N*2*-phenyl-9H-purine-2,6-diamine	Investigative
T36059	DRUGINFO	D02FLH	2,6-dphenyl-8-propyl-1-deazapurine	Investigative
T36059	DRUGINFO	D02HYT	N-(2,6-diphenylpyrimidin-4-yl)propionamide	Investigative
T36059	DRUGINFO	D02JCM	N(6)-cyclohexyladenosine	Investigative
T36059	DRUGINFO	D02JMR	2-(3''-(6''-chloro-indolyl)ethyloxy)adenosine	Investigative
T36059	DRUGINFO	D02SKN	MRS1041	Investigative
T36059	DRUGINFO	D02VQK	LUF-5433	Investigative
T36059	DRUGINFO	D03FVK	N6-methoxy-2-[(4-pyridinyl)ethynyl]adenosine	Investigative
T36059	DRUGINFO	D03HBG	2-(3''-(4''-bromo-indolyl)ethyloxy)adenosine	Investigative
T36059	DRUGINFO	D03POP	N6-methoxy-2-phenylethynyladenosine	Investigative
T36059	DRUGINFO	D04TTP	5,7-dibromo-9H-pyrido[3,4-b]indol-6-ol	Investigative
T36059	DRUGINFO	D05QNV	ATL802	Investigative
T36059	DRUGINFO	D06KMJ	MRS5151	Investigative
T36059	DRUGINFO	D06RCT	2-(3''-indolylethyloxy)adenosine	Investigative
T36059	DRUGINFO	D07IPZ	2-(4-hydroxypent-1-yl)-N6-methoxyadenosine	Investigative
T36059	DRUGINFO	D07PPM	PSB-10	Investigative
T36059	DRUGINFO	D07VCN	4-Ethoxy-7-((E)-styryl)-furo[3,2-g]chromen-5-one	Investigative
T36059	DRUGINFO	D08BCH	TCPA	Investigative
T36059	DRUGINFO	D08EBT	[3H]HEMADO	Investigative
T36059	DRUGINFO	D08EZI	N-(2,6-diphenylpyrimidin-4-yl)-3-methylbutyramide	Investigative
T36059	DRUGINFO	D08HBH	N-(2,6-diphenylpyrimidin-4-yl)butyramide	Investigative
T36059	DRUGINFO	D08JUQ	2-tolyl-6-phenyl-9H-purine	Investigative
T36059	DRUGINFO	D08JYX	2-[(4-acetylphenyl)ethynyl]-N6-methoxyadenosine	Investigative
T36059	DRUGINFO	D08LZN	Cyclohexyl-(2-phenylsulfanyl-9H-purin-6-yl)-amine	Investigative
T36059	DRUGINFO	D09IRV	LUF-5957	Investigative
T36059	DRUGINFO	D09RKX	PSB-11	Investigative
T36059	DRUGINFO	D09VOP	2-(3''-(5''-methoxy-indolyl)ethyloxy)adenosine	Investigative
T36059	DRUGINFO	D09VRX	2-(4-methyl-1H-benzo[d]imidazol-2-yl)quinoxaline	Investigative
T36059	DRUGINFO	D0A6IO	MRE 3008F20	Investigative
T36059	DRUGINFO	D0B0QW	N6-methoxy-2-[(4-pentylphenyl)ethynyl]adenosine	Investigative
T36059	DRUGINFO	D0B3NZ	N-(5-Benzoyl-4-phenylthiazol-2-yl)benzamide	Investigative
T36059	DRUGINFO	D0B3UE	9-Cyclopentyl-9H-adenine	Investigative
T36059	DRUGINFO	D0B7OW	sakuranetin	Investigative
T36059	DRUGINFO	D0B8DR	MRS1093	Investigative
T36059	DRUGINFO	D0B8RQ	LUF-5767	Investigative
T36059	DRUGINFO	D0C2UJ	2-chloroadenosine	Investigative
T36059	DRUGINFO	D0E4LB	2-(5-cyano-1-pent-1-ynyl)-N6-methoxyadenosine	Investigative
T36059	DRUGINFO	D0E7YE	2,6,8-triphenyl-9H-purine	Investigative
T36059	DRUGINFO	D0E9QX	(S)-PIA	Investigative
T36059	DRUGINFO	D0G5ZF	N6-methoxy-2-[(2-pyridinyl)ethynyl]adenosine	Investigative
T36059	DRUGINFO	D0G6BI	2-(3''-(6''-bromo-indolyl)ethyloxy)adenosine	Investigative
T36059	DRUGINFO	D0G6VT	2-(3''-(5''-iodo-indolyl)ethyloxy)adenosine	Investigative
T36059	DRUGINFO	D0H9BP	xanthine amine congener	Investigative
T36059	DRUGINFO	D0I1EP	MRS928	Investigative
T36059	DRUGINFO	D0I1IW	2-(3''-(5''-fluoro-indolyl)ethyloxy)adenosine	Investigative
T36059	DRUGINFO	D0I2EQ	2,6-diphenyl-8-methyl-1-deazapurine	Investigative
T36059	DRUGINFO	D0I3HE	KF26777	Investigative
T36059	DRUGINFO	D0I6XA	(2R,3S)-3-(6-Amino-purin-9-yl)-nonan-2-ol	Investigative
T36059	DRUGINFO	D0I7HL	2-phenylpropoxyadenosine	Investigative
T36059	DRUGINFO	D0J1BA	MRS1191	Investigative
T36059	DRUGINFO	D0KJ3H	2-(2''-indolylethyloxy)adenosine	Investigative
T36059	DRUGINFO	D0KT3L	2-[(4-fluorophenyl)ethynyl]-N6-methoxyadenosine	Investigative
T36059	DRUGINFO	D0L0VU	MRE 2029F20	Investigative
T36059	DRUGINFO	D0L2MN	2-(4-chlorophenyl)-6-phenyl-9H-purine	Investigative
T36059	DRUGINFO	D0L6YI	2-(3''-(5''-bromo-indolyl)ethyloxy)adenosine	Investigative
T36059	DRUGINFO	D0LD0X	1-Propyl-3,7-dihydro-purine-2,6-dione	Investigative
T36059	DRUGINFO	D0LP5V	LUF-5956	Investigative
T36059	DRUGINFO	D0N1QO	N6-methoxy-2-[(4-methoxyphenyl)ethynyl]adenosine	Investigative
T36059	DRUGINFO	D0N1QP	2,6-diphenyl-1-deazapurine	Investigative
T36059	DRUGINFO	D0OX0V	2-(4-ethylthiobenzimidazol-2-yl)quinoxaline	Investigative
T36059	DRUGINFO	D0P0BV	2-(3''-(5''-hydroxyindolyl)ethyloxy)adenosine	Investigative
T36059	DRUGINFO	D0P7CS	LUF-5417	Investigative
T36059	DRUGINFO	D0PU6F	2-(1H-benzo[d]imidazol-2-yl)quinoxaline	Investigative
T36059	DRUGINFO	D0Q1RD	2-(3''(5''-chloro-indolyl)ethyloxy)adenosine	Investigative
T36059	DRUGINFO	D0Q3LM	N6-methoxy-2-[2-(trimethylsilyl)ethynyl]adenosine	Investigative
T36059	DRUGINFO	D0Q5CS	6-guanidino-2-(3''-indolylethyloxy)adenosine	Investigative
T36059	DRUGINFO	D0QN4U	2-(3''(7''-bromo-indolyl)ethyloxy)adenosine	Investigative
T36059	DRUGINFO	D0RZ2M	2,6-diphenyl-9H-purine	Investigative
T36059	DRUGINFO	D0T7GG	LUF-5816	Investigative
T36059	DRUGINFO	D0TC7N	PENECA	Investigative
T36059	DRUGINFO	D0V9OO	(R,S)-PHPNECA	Investigative
T36059	DRUGINFO	D0W3MT	8-propyl-2,6-diphenyl-9H-purine	Investigative
T36059	DRUGINFO	D0WI4D	LUF-5962	Investigative
T36059	DRUGINFO	D0XC9U	MRS1042	Investigative
T36059	DRUGINFO	D0Y5WQ	PSB603	Investigative
T36059	DRUGINFO	D0Y6HQ	N6-methoxy-2-[(3-pyridinyl)ethynyl]-adenosine	Investigative
T36059	DRUGINFO	D0Y7HG	Galangin	Investigative
T36059	DRUGINFO	D0Z1WY	2-chloro-2'-C-methyl-tecadenoson	Investigative
T36059	DRUGINFO	D0Z3XC	N-(2,6-diphenylpyrimidin-4-yl)acetamide	Investigative
T36059	DRUGINFO	D0ZL2A	MRS1523	Investigative
T36059	DRUGINFO	D0ZW9L	5,7-diphenyl-3H-imidazo[4,5-b]pyridin-2-ol	Investigative
T36059	DRUGINFO	D00GNW	2,6-diphenyl-8-(1-ethylpropyl)-1-deazapurine	Investigative
T36059	DRUGINFO	D00JWA	N-(2-(furan-2-yl)-3,4'-bipyridin-6-yl)acetamide	Investigative
T36059	DRUGINFO	D02PBY	3-noradamantyl-1,3-dipropylxanthine	Investigative
T36059	DRUGINFO	D04LZN	8-Bromo-9-cyclobutyl-9H-adenine	Investigative
T36059	DRUGINFO	D05KEF	LUF-5978	Investigative
T36059	DRUGINFO	D06KYP	8-Bromo-9-isopropyl-9H-adenine	Investigative
T36059	DRUGINFO	D0AI8F	8-Bromo-9-cyclopentyl-9H-adenine	Investigative
T36059	DRUGINFO	D0B0TX	8-bromo-9-isobutyl-9H-purin-6-amine	Investigative
T36059	DRUGINFO	D0CX7N	8-Bromo-9-(3-hydroxypropyl)-9H-adenine	Investigative
T36059	DRUGINFO	D0IG5E	2,5'-dichloro-5'-deoxy-N6-cyclopentyladenosine	Investigative
T36059	DRUGINFO	D0JJ6T	N6-((+/-)-endo-norborn-2-yl)adenosine	Investigative
T36059	DRUGINFO	D0K5NZ	MESULERGINE	Investigative
T36059	DRUGINFO	D0K6ZA	[3H]OSIP339391	Investigative
T36059	DRUGINFO	D0K8ZZ	[3H]NECA	Investigative
T36059	DRUGINFO	D0M3CG	R-N6-(phenylisopropyl)adenosine	Investigative
T36059	DRUGINFO	D0NO5E	Ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate	Investigative
T36059	DRUGINFO	D0O4KI	2-ethyl-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine	Investigative
T36059	DRUGINFO	D0O7DA	(+)-BUTACLAMOL	Investigative
T36059	DRUGINFO	D0R1XY	[3H]CCPA	Investigative
T36059	DRUGINFO	D0TU7I	(E)-8-(3-chlorostyryl)-caffeine	Investigative
T36059	DRUGINFO	D0V8MD	8-PHENYL THEOPHYLLINE	Investigative
T36059	DRUGINFO	D0W1PF	LUF-5980	Investigative
T36059	DRUGINFO	D0Y9WZ	SB-298	Investigative
T36059	DRUGINFO	D0Z8NC	LUF-5981	Investigative
T36059	DRUGINFO	D0Z8VU	8-Bromo-9-(sec-butyl)-9H-adenine	Investigative
T36059	DRUGINFO	D0K0OT	GNF-PF-2224	Investigative
T36059	DRUGINFO	D0RF2M	NIPECOTIC ACID	Investigative
T36059	DRUGINFO	D03RFA	N6-CYCLOPENTYLADENOSINE	Investigative
T36059	DRUGINFO	D0S0RK	flavone	Investigative
T36059	DRUGINFO	D04PFN	[3H]kainate	Investigative
T36059	DRUGINFO	D0R6MT	isobutylmethylxanthine	Investigative
T36059	DRUGINFO	D0F6CD	SEROTONIN	Investigative
T36059	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T94085	TARGETID	T94085
T94085	FORMERID	TTDS00073
T94085	UNIPROID	RARA_HUMAN
T94085	TARGNAME	Retinoic acid receptor alpha (RARA)
T94085	GENENAME	RARA
T94085	TARGTYPE	Clinical trial
T94085	SYNONYMS	RAR-alpha; RAR alpha; Nuclear receptor subfamily 1 group B member 1; NR1B1
T94085	FUNCTION	Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence of ligand, the RXR-RAR heterodimers associate with a multiprotein complex containing transcription corepressors that induce histone acetylation, chromatin condensation and transcriptional suppression. On ligand binding, the corepressors dissociate from the receptors and associate with the coactivators leading to transcriptional activation. RARA plays an essential role in the regulation of retinoic acid-induced germ cell development during spermatogenesis. Has a role in the survival of early spermatocytes at the beginning prophase of meiosis. In Sertoli cells, may promote the survival and development of early meiotic prophase spermatocytes. In concert with RARG, required for skeletal growth, matrix homeostasis and growth plate function. Receptor for retinoic acid.
T94085	PDBSTRUC	5K13; 4DQM; 3KMZ; 3KMR; 3A9E
T94085	BIOCLASS	Nuclear hormone receptor
T94085	SEQUENCE	MASNSSSCPTPGGGHLNGYPVPPYAFFFPPMLGGLSPPGALTTLQHQLPVSGYSTPSPATIETQSSSSEEIVPSPPSPPPLPRIYKPCFVCQDKSSGYHYGVSACEGCKGFFRRSIQKNMVYTCHRDKNCIINKVTRNRCQYCRLQKCFEVGMSKESVRNDRNKKKKEVPKPECSESYTLTPEVGELIEKVRKAHQETFPALCQLGKYTTNNSSEQRVSLDIDLWDKFSELSTKCIIKTVEFAKQLPGFTTLTIADQITLLKAACLDILILRICTRYTPEQDTMTFSDGLTLNRTQMHNAGFGPLTDLVFAFANQLLPLEMDDAETGLLSAICLICGDRQDLEQPDRVDMLQEPLLEALKVYVRKRRPSRPHMFPKMLMKITDLRSISAKGAERVITLKMEIPGSMPPLIQEMLENSEGLDTLSGQPGGGGRDGGGLAPPPGSCSPSLSPSSNRSSPATHSP
T94085	DRUGINFO	D02GTY	Tamibarotene	Phase 3
T94085	DRUGINFO	D0HY3D	SY-1425	Phase 1
T94085	DRUGINFO	D0T3DO	IRX-5183	Phase 1
T94085	DRUGINFO	D02FAA	PMID27336223-Compound-4	Patented
T94085	DRUGINFO	D0AW3F	PMID27336223-Compound-5	Patented
T94085	DRUGINFO	D0YO4D	LG100268	Discontinued in Phase 1
T94085	DRUGINFO	D02OAI	AGN193836	Investigative
T94085	DRUGINFO	D03DEJ	BMS614	Investigative
T94085	DRUGINFO	D07TPL	Ro-40-0655	Investigative
T94085	DRUGINFO	D07YTL	BMS753	Investigative
T94085	DRUGINFO	D0JQ1D	Ro 41-5253	Investigative
T94085	DRUGINFO	D0RD0R	Ro 40-6055	Investigative
T94085	DRUGINFO	D0F8CC	CD666	Investigative
T94085	DRUGINFO	D0Q0IR	AGN193109	Investigative

T44011	TARGETID	T44011
T44011	FORMERID	TTDR00587
T44011	UNIPROID	DHB1_HUMAN
T44011	TARGNAME	Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
T44011	GENENAME	HSD17B1
T44011	TARGTYPE	Clinical trial
T44011	SYNONYMS	Short chain dehydrogenase/reductase family 28C member 1; SDR28C1; Placental 17-beta-hydroxysteroid dehydrogenase; Estradiol 17-beta-dehydrogenase 1; EDHB17; EDH17B2; EDH17B1; E2DH; E17KSR; 20-alpha-HSD; 20 alpha-hydroxysteroid dehydrogenase; 17-beta-Hydroxysteroid dehydrogenase type 1; 17-beta-HSD 1
T44011	FUNCTION	Has 20-alpha-HSD activity. Uses preferentially NADH. Favors the reduction of estrogens and androgens.
T44011	PDBSTRUC	6MNE; 6MNC; 6DTP; 6CGE; 6CGC
T44011	BIOCLASS	CH-OH donor oxidoreductase
T44011	ECNUMBER	EC 1.1.1.62
T44011	SEQUENCE	MARTVVLITGCSSGIGLHLAVRLASDPSQSFKVYATLRDLKTQGRLWEAARALACPPGSLETLQLDVRDSKSVAAARERVTEGRVDVLVCNAGLGLLGPLEALGEDAVASVLDVNVVGTVRMLQAFLPDMKRRGSGRVLVTGSVGGLMGLPFNDVYCASKFALEGLCESLAVLLLPFGVHLSLIECGPVHTAFMEKVLGSPEEVLDRTDIHTFHRFYQYLAHSKQVFREAAQNPEEVAEVFLTALRAPKPTLRYFTTERFLPLLRMRLDDPSGSNYVTAMHREVFGDVPAKAEAGAEAGGGAGPGAEDEAGRGAVGDPELGDPPAAPQ
T44011	DRUGINFO	D02ABO	NARINGENIN	Phase 1
T44011	DRUGINFO	D00PUR	3'-(1-Benzothien-2-yl)biphenyl-3-ol	Investigative
T44011	DRUGINFO	D00SLE	3-[5-(4-hydroxyphenyl)-1,3-thiazol-2-yl]phenol	Investigative
T44011	DRUGINFO	D01AVM	Ethyl estrone-16-methylcarboxylate	Investigative
T44011	DRUGINFO	D01ERB	16-(pyridin-4-yl)methylene-estradiol	Investigative
T44011	DRUGINFO	D01JVG	3-Fluoro-5-[5-(4-hydroxyphenyl)-2-thienyl]phenol	Investigative
T44011	DRUGINFO	D01OCZ	16-isobutylidene-estrone	Investigative
T44011	DRUGINFO	D01SGP	N-methyl estrone-16-methyl carboxamide	Investigative
T44011	DRUGINFO	D01ZCG	3-[5-(4-hydroxyphenyl)-2-thienyl]phenol	Investigative
T44011	DRUGINFO	D02BEJ	3-[5-(3,4-Difluorophenyl)-2-thienyl]phenol	Investigative
T44011	DRUGINFO	D02DYZ	N-(pyridin-4-ylmethyl) estradiol-16-carboxamide	Investigative
T44011	DRUGINFO	D02JRB	6-oxo-16-formyl-estrone	Investigative
T44011	DRUGINFO	D02MQT	16-(4-dimethylamino-benzylidene)-estrone	Investigative
T44011	DRUGINFO	D02MZN	N-N-diethyl estradiol-16-methyl carboxamide	Investigative
T44011	DRUGINFO	D02QLY	2-Hydroxy-N,6-bis(3-hydroxyphenyl)-1-naphthamide	Investigative
T44011	DRUGINFO	D02UUR	3-[3-(4-hydroxyphenyl)isoxazol-5-yl]phenol	Investigative
T44011	DRUGINFO	D02XZO	16-(pyridin-2-yl)methylene-estradiol	Investigative
T44011	DRUGINFO	D03BZT	6-oxo-estrone	Investigative
T44011	DRUGINFO	D03XHF	2-Fluoro-5-[5-(4-hydroxyphenyl)-2-thienyl]phenol	Investigative
T44011	DRUGINFO	D03XMR	N-methyl-N-ethyl estrone-16-methyl carboxamide	Investigative
T44011	DRUGINFO	D04CQM	N-(1'-Phenyl-ethyl) estradiol-16-carboxamide	Investigative
T44011	DRUGINFO	D04EPO	7-Hydroxy-3-(3-hydroxyphenyl)-1-naphthonitrile	Investigative
T44011	DRUGINFO	D05AIT	3-[6-(5-Chloro-2-thienyl)pyridin-2-yl]phenol	Investigative
T44011	DRUGINFO	D06AYL	N-(pyridin-3-ylmethyl) estradiol-16-carboxamide	Investigative
T44011	DRUGINFO	D06CED	3'-(5-Chloro-2-thienyl)biphenyl-3-ol	Investigative
T44011	DRUGINFO	D06FPP	16-(pyridin-4-yl)methyl-estradiol	Investigative
T44011	DRUGINFO	D06NDT	3-(3-hydroxyphenyl)quinolin-7-ol	Investigative
T44011	DRUGINFO	D06ZNI	16-(2',2'-Dimethyl)-propylidene-estradiol	Investigative
T44011	DRUGINFO	D07VXQ	3,3'-Pyridine-2,5-diyldiphenol	Investigative
T44011	DRUGINFO	D08CXO	N-isopropyl estradiol-16-carboxamide	Investigative
T44011	DRUGINFO	D08EHR	16-(pyridin-3-yl)methylene-estradiol	Investigative
T44011	DRUGINFO	D08NFA	N-(4'-methyl-piperazinyl) estradiol-16-carboxamide	Investigative
T44011	DRUGINFO	D08OKP	4-[5-(3-Hydroxyphenyl)-2-thienyl]benzene-1,2-diol	Investigative
T44011	DRUGINFO	D08OQX	3,3'-Thiene-2,4-diyldiphenol	Investigative
T44011	DRUGINFO	D08PDK	1-Bromo-6-(3-hydroxyphenyl)-2-naphthol	Investigative
T44011	DRUGINFO	D09GQE	3-[5-(4-Hydroxyphenyl)-2-thienyl]-5-methylphenol	Investigative
T44011	DRUGINFO	D0A0CG	16-(thiophen-2-yl)methylene-estrone	Investigative
T44011	DRUGINFO	D0A2GN	3-[5-(3-Fluorophenyl)-2-thienyl]phenol	Investigative
T44011	DRUGINFO	D0A4XA	3,3'-(1,2,4-thiadiazole-3,5-diyl)diphenol	Investigative
T44011	DRUGINFO	D0A5CD	N,N-diethyl estrone-16-methyl carboxamide	Investigative
T44011	DRUGINFO	D0A7PU	3-[4-(5-Chloro-2-thienyl)pyridin-2-yl]phenol	Investigative
T44011	DRUGINFO	D0B6SA	N-isopropyl estradiol-16-methyl carboxamide	Investigative
T44011	DRUGINFO	D0B6SF	3,3'-(3-Phenylthiene-2,5-diyl)diphenol	Investigative
T44011	DRUGINFO	D0B9HX	16-beta-ethoxymethyl-estrone	Investigative
T44011	DRUGINFO	D0BF3Y	4-Fluoro-1,1':4',1''-terphenyl-3,3''-diol	Investigative
T44011	DRUGINFO	D0C9KZ	1,1':4',1''-terphenyl-3,4''-diol	Investigative
T44011	DRUGINFO	D0D1KA	3-Hydroxy-7-(3-hydroxyphenyl)-1-naphthonitrile	Investigative
T44011	DRUGINFO	D0DC3E	3,3'-pyrazine-2,5-diyldiphenol	Investigative
T44011	DRUGINFO	D0EK5U	16beta-cyano-estradiol	Investigative
T44011	DRUGINFO	D0EL1Y	3-[5-(4-hydroxyphenyl)-1,3-oxazol-2-yl]phenol	Investigative
T44011	DRUGINFO	D0F0EI	3-(6-hydroxy-2-naphthyl)benzoic acid	Investigative
T44011	DRUGINFO	D0F6ZH	3-(2-naphthyl)phenol	Investigative
T44011	DRUGINFO	D0G1DN	3-(5-phenyl-2-thienyl)phenol	Investigative
T44011	DRUGINFO	D0G4KT	16-isobutylidene-estradiol	Investigative
T44011	DRUGINFO	D0G5CP	4'-(6-Methoxypyridin-3-yl)biphenyl-3-ol	Investigative
T44011	DRUGINFO	D0G7PB	N-methyl-N-ethyl estradiol-16-carboxamide	Investigative
T44011	DRUGINFO	D0HR7O	16-(4-dimethylamino-benzylidene)-estradiol	Investigative
T44011	DRUGINFO	D0I0KV	16-(2',2'-Dimethyl)-propylidene-estrone	Investigative
T44011	DRUGINFO	D0I5YT	3,4'-(thiophene-2,4-diyl)diphenol	Investigative
T44011	DRUGINFO	D0IZ4Z	3-[4-(4-Hydroxyphenyl)-1,3-oxazol-2-yl]phenol	Investigative
T44011	DRUGINFO	D0J8LU	4-Methyl-1,1':4',1''-terphenyl-3,4''-diol	Investigative
T44011	DRUGINFO	D0JI0Q	N-methyl estradiol-16-methyl carboxamide	Investigative
T44011	DRUGINFO	D0K6MM	N-(furan-2-ylmethyl)estradiol-16-carboxamide	Investigative
T44011	DRUGINFO	D0K8VL	N-(furan-2-ylmethyl)-estrone-16-methyl carboxamide	Investigative
T44011	DRUGINFO	D0KG1D	2-(3-hydroxyphenyl)quinolin-6-ol	Investigative
T44011	DRUGINFO	D0M3RQ	5-(6-hydroxy-2-naphthyl)pyridin-3-ol	Investigative
T44011	DRUGINFO	D0M4SL	N-isopropyl estrone-16-methyl carboxamide	Investigative
T44011	DRUGINFO	D0N1LT	16-(pyridin-3-yl)methyl-estradiol	Investigative
T44011	DRUGINFO	D0P6JE	3,3'-(3-Methylthiene-2,5-diyl]diphenol	Investigative
T44011	DRUGINFO	D0Q3AN	2-Fluoro-4-[5-(3-hydroxyphenyl)-3-thienyl]phenol	Investigative
T44011	DRUGINFO	D0Q6AD	4'-(5-Chloro-2-thienyl)biphenyl-3-ol	Investigative
T44011	DRUGINFO	D0Q9CI	N-methoxyethyl estrone-16-methyl carboxamide	Investigative
T44011	DRUGINFO	D0QX5D	3-[2-(5-Chloro-2-thienyl)pyridin-4-yl]phenol	Investigative
T44011	DRUGINFO	D0R3HP	3,3'-(1,2,4,5-tetrazine-3,6-diyl)diphenol	Investigative
T44011	DRUGINFO	D0R5WV	3,3'-(1,2,4-Thiadiazol-2,5-diyl)diphenol	Investigative
T44011	DRUGINFO	D0R6DT	Equilin	Investigative
T44011	DRUGINFO	D0S2BW	Methyl estradiol-16-beta-carboxylate	Investigative
T44011	DRUGINFO	D0T6WL	3,3'-(1,3-Thiazol-2,4-diyl)diphenol	Investigative
T44011	DRUGINFO	D0TA0J	3,3'-thiene-2,5-diyldiphenol	Investigative
T44011	DRUGINFO	D0U7DJ	16-(4-cyano-benzylidene)-estradiol	Investigative
T44011	DRUGINFO	D0UR6C	3-[5-(4-Fluorophenyl)-2-thienyl]phenol	Investigative
T44011	DRUGINFO	D0V2QH	6-(3-Hydroxyphenyl)-1-phenyl-2-naphthol	Investigative
T44011	DRUGINFO	D0V4BE	N-ethyl estrone-16-methyl carboxamide	Investigative
T44011	DRUGINFO	D0V5JV	N-ethyl estradiol-16-methyl carboxamide	Investigative
T44011	DRUGINFO	D0W5CR	EM-1745	Investigative
T44011	DRUGINFO	D0WM4K	16-(pyridin-2-yl)methyl-estradiol	Investigative
T44011	DRUGINFO	D0Z1AT	16-beta-hydroxymethyl-estradiol	Investigative
T44011	DRUGINFO	D0Z1MJ	3,3',3''-Thiene-2,3,5-triyltriphenol	Investigative
T44011	DRUGINFO	D00YNA	3,3-(1,3-Thiazole-2,5-diyl)diphenol	Investigative
T44011	DRUGINFO	D07JOZ	1,1':4',1''-terphenyl-3,3''-diol	Investigative
T44011	DRUGINFO	D0NM0P	3-[5-(4-Hydroxyphenyl)-3-thienyl]phenol	Investigative
T44011	DRUGINFO	D0T5MO	5alpha-Androstan-3,17-Dione	Investigative
T44011	DRUGINFO	D01IAT	7-(3-Hydroxy-phenyl)-naphthalen-2-ol	Investigative
T44011	DRUGINFO	D01KKU	NSC-94258	Investigative
T44011	DRUGINFO	D01RZP	4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol	Investigative
T44011	DRUGINFO	D0H8PI	6-(4-Hydroxy-phenyl)-naphthalen-1-ol	Investigative
T44011	DRUGINFO	D0M0KX	2-Fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol	Investigative
T44011	DRUGINFO	D0Y2RL	4-[5-(3-Hydroxyphenyl)-2-thienyl)-2-methyl]phenol	Investigative
T44011	DRUGINFO	D0M8RO	4-ANDROSTENE-3-17-DIONE	Investigative
T44011	DRUGINFO	D0P8PK	6-(3-Hydroxy-phenyl)-naphthalen-2-ol	Investigative
T44011	DRUGINFO	D00RIX	APIGENIN	Investigative
T44011	DRUGINFO	D0G3TK	KAEMPFEROL	Investigative
T44011	DRUGINFO	D0J2FY	2'-Monophosphoadenosine 5'-Diphosphoribose	Investigative
T44011	DRUGINFO	D0R6JE	Nicotinamide-Adenine-Dinucleotide	Investigative

T19160	TARGETID	T19160
T19160	FORMERID	TTDC00025
T19160	UNIPROID	PA2GA_HUMAN
T19160	TARGNAME	Group IIA phospholipase A2 (GIIA sPLA2)
T19160	GENENAME	PLA2G2A
T19160	TARGTYPE	Clinical trial
T19160	SYNONYMS	RASF-A; Phospholipase A2, membrane associated; Phosphatidylcholine 2-acylhydrolase 2A; PLA2L; PLA2B; Non-pancreatic secretory phospholipase A2; NPS-PLA2; GIIC sPLA2
T19160	FUNCTION	Catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. Thought to participate in the regulation of phospholipid metabolism in biomembranes including eicosanoid biosynthesis. Independent of its catalytic activity, acts as a ligand for integrins. Binds to and activates integrins ITGAV:ITGB3, ITGA4:ITGB1 and ITGA5:ITGB1. Binds to a site (site 2) which is distinct from the classical ligand-binding site (site 1) and induces integrin conformational changes and enhanced ligand binding to site 1. Induces cell proliferation in an integrin-dependent manner.
T19160	PDBSTRUC	5G3N; 3U8I; 3U8H; 3U8D; 3U8B
T19160	BIOCLASS	Carboxylic ester hydrolase
T19160	ECNUMBER	EC 3.1.1.4
T19160	SEQUENCE	MKTLLLLAVIMIFGLLQAHGNLVNFHRMIKLTTGKEAALSYGFYGCHCGVGGRGSPKDATDRCCVTHDCCYKRLEKRGCGTKFLSYKFSNSGSRITCAKQDSCRSQLCECDKAAATCFARNKTTYNKKYQYYSNKHCRGSTPRC
T19160	DRUGINFO	D0LB0X	KH064	Clinical trial
T19160	DRUGINFO	D04TKG	LUFFARIELLOLIDE	Investigative
T19160	DRUGINFO	D0J2EE	DIDODECANOYLPHLOROGLUCINOL	Investigative
T19160	DRUGINFO	D0O6SI	1,4-Butanediol	Investigative
T19160	DRUGINFO	D0Y0OA	Ochnaflavone	Investigative
T19160	DRUGINFO	D02AYI	2-(4-phenoxyphenoxy)ethanamine	Investigative
T19160	DRUGINFO	D02IVU	CACOSPONGIONOLIDE	Investigative
T19160	DRUGINFO	D03AHJ	Elaidoylamide	Investigative
T19160	DRUGINFO	D03BAB	Cacospongionolide E	Investigative
T19160	DRUGINFO	D06YGT	N-Tridecanoic Acid	Investigative
T19160	DRUGINFO	D0B9VV	CACOSPONGIONOLIDE B	Investigative
T19160	DRUGINFO	D0T3CM	BOLINAQUINONE	Investigative
T19160	DRUGINFO	D0U9HN	DYSIDINE	Investigative
T19160	DRUGINFO	D0W7LK	2-Propanol, Isopropanol	Investigative
T19160	DRUGINFO	D0N0UC	Lauric Acid	Investigative
T19160	DRUGINFO	D02UVH	B-Octylglucoside	Investigative

T67272	TARGETID	T67272
T67272	FORMERID	TTDR00784
T67272	UNIPROID	AMPN_HUMAN
T67272	TARGNAME	Aminopeptidase N (ANPEP)
T67272	GENENAME	ANPEP
T67272	TARGTYPE	Clinical trial
T67272	SYNONYMS	Myeloid plasma membrane glycoprotein CD13; Microsomal aminopeptidase; HAPN; Gp150; Aminopeptidase M; Alanyl aminopeptidase; ANPEP
T67272	FUNCTION	Broad specificity aminopeptidase. Plays a role in the final digestion of peptides generated from hydrolysis of proteins by gastric and pancreatic proteases. May play a critical role in the pathogenesis of cholesterol gallstone disease. May be involved in the metabolism of regulatory peptides of diverse cell types, responsible for the processing of peptide hormones, such as angiotensin III and IV, neuropeptides, and chemokines. Found to cleave antigen peptides bound to major histocompatibility complex class II molecules of presenting cells and to degrade neurotransmitters at synaptic junctions. Is also implicated as a regulator of IL-8 bioavailability in the endometrium, and therefore may contribute to the regulation of angiogenesis. Is used as a marker for acute myeloid leukemia and plays a role in tumor invasion. In case of human coronavirus 229E (HCoV-229E) infection, serves as receptor for HCoV-229E spike glycoprotein. Mediates as well human cytomegalovirus (HCMV) infection.
T67272	PDBSTRUC	6ATK; 5LHD; 4FYT; 4FYS; 4FYR
T67272	BIOCLASS	Peptidase
T67272	ECNUMBER	EC 3.4.11.2
T67272	SEQUENCE	MAKGFYISKSLGILGILLGVAAVCTIIALSVVYSQEKNKNANSSPVASTTPSASATTNPASATTLDQSKAWNRYRLPNTLKPDSYRVTLRPYLTPNDRGLYVFKGSSTVRFTCKEATDVIIIHSKKLNYTLSQGHRVVLRGVGGSQPPDIDKTELVEPTEYLVVHLKGSLVKDSQYEMDSEFEGELADDLAGFYRSEYMEGNVRKVVATTQMQAADARKSFPCFDEPAMKAEFNITLIHPKDLTALSNMLPKGPSTPLPEDPNWNVTEFHTTPKMSTYLLAFIVSEFDYVEKQASNGVLIRIWARPSAIAAGHGDYALNVTGPILNFFAGHYDTPYPLPKSDQIGLPDFNAGAMENWGLVTYRENSLLFDPLSSSSSNKERVVTVIAHELAHQWFGNLVTIEWWNDLWLNEGFASYVEYLGADYAEPTWNLKDLMVLNDVYRVMAVDALASSHPLSTPASEINTPAQISELFDAISYSKGASVLRMLSSFLSEDVFKQGLASYLHTFAYQNTIYLNLWDHLQEAVNNRSIQLPTTVRDIMNRWTLQMGFPVITVDTSTGTLSQEHFLLDPDSNVTRPSEFNYVWIVPITSIRDGRQQQDYWLIDVRAQNDLFSTSGNEWVLLNLNVTGYYRVNYDEENWRKIQTQLQRDHSAIPVINRAQIINDAFNLASAHKVPVTLALNNTLFLIEERQYMPWEAALSSLSYFKLMFDRSEVYGPMKNYLKKQVTPLFIHFRNNTNNWREIPENLMDQYSEVNAISTACSNGVPECEEMVSGLFKQWMENPNNNPIHPNLRSTVYCNAIAQGGEEEWDFAWEQFRNATLVNEADKLRAALACSKELWILNRYLSYTLNPDLIRKQDATSTIISITNNVIGQGLVWDFVQSNWKKLFNDYGGGSFSFSNLIQAVTRRFSTEYELQQLEQFKKDNEETGFGSGTRALEQALEKTKANIKWVKENKEVVLQWFTENSK
T67272	DRUGINFO	D0E3HY	IP10 C8	Phase 2
T67272	DRUGINFO	D00KIV	(1-Amino-3-phenyl-propyl)-phosphinic acid	Investigative
T67272	DRUGINFO	D00SLJ	N1-(3,3-diphenylpropyl)-N3-hydroxymalonamide	Investigative
T67272	DRUGINFO	D01LFP	N1-(4-chlorobenzyl)-2-benzyl-N3-hydroxymalonamide	Investigative
T67272	DRUGINFO	D02EFK	N1,2-dibenzyl-N3-hydroxy-N1-phenethylmalonamide	Investigative
T67272	DRUGINFO	D03JAL	1-aminohexylphosphonic acid	Investigative
T67272	DRUGINFO	D04KOZ	(S)-2-Amino-3-phenyl-propane-1-thiol	Investigative
T67272	DRUGINFO	D04MKQ	(Amino-phenyl-methyl)-phosphinic acid	Investigative
T67272	DRUGINFO	D04XBZ	1-aminohexylphosphonic acid monophenyl ester	Investigative
T67272	DRUGINFO	D05EPO	1-aminobutylphosphonic acid	Investigative
T67272	DRUGINFO	D06AFP	N-Hydroxy-2-(naphthalen-2-ylsulfanyl)-acetamide	Investigative
T67272	DRUGINFO	D06RLF	(1-Amino-ethyl)-phosphinic acid	Investigative
T67272	DRUGINFO	D06TVS	N1-benzyl-N3-hydroxy-2-isobutylmalonamide	Investigative
T67272	DRUGINFO	D06VON	(S)-2-Amino-2-phenyl-ethanethiol	Investigative
T67272	DRUGINFO	D0D8FZ	2-benzyl-N1-hydroxy-N3-phenethylmalonamide	Investigative
T67272	DRUGINFO	D0DS7F	(S)-2-Amino-4-phenyl-butane-1-thiol	Investigative
T67272	DRUGINFO	D0EG8X	(1-Amino-3-methylsulfanyl-propyl)-phosphinic acid	Investigative
T67272	DRUGINFO	D0F2HJ	2-Cinnamamido-N1-hydroxy-N4-pentylsuccinamide	Investigative
T67272	DRUGINFO	D0GB8I	N1-hydroxy-2-isobutyl-N3-phenethylmalonamide	Investigative
T67272	DRUGINFO	D0GI9S	(S)-2-Amino-4-methylsulfanyl-butane-1-thiol	Investigative
T67272	DRUGINFO	D0H5BG	PMID23428964CI3	Investigative
T67272	DRUGINFO	D0J0WJ	N4-Butyl-2-cinnamamido-N1-hydroxysuccinamide	Investigative
T67272	DRUGINFO	D0J9TD	N-biphenyl-3-ylmethyl-N'-hydroxy-malonamide	Investigative
T67272	DRUGINFO	D0K9XV	N1-(4-fluorobenzyl)-2-benzyl-N3-hydroxymalonamide	Investigative
T67272	DRUGINFO	D0L3PY	Angiotensin IV	Investigative
T67272	DRUGINFO	D0N3UO	(1-Amino-3-methyl-butyl)-phosphinic acid	Investigative
T67272	DRUGINFO	D0NL7J	N1-(4-chlorobenzyl)-2-amino-N3-hydroxymalonamide	Investigative
T67272	DRUGINFO	D0P9YU	(1-Amino-2-phenyl-ethyl)-phosphinic acid	Investigative
T67272	DRUGINFO	D0Q0EY	(S)-2-Amino-4-methyl-pentane-1-thiol	Investigative
T67272	DRUGINFO	D0R9AA	(S)-2-Amino-propane-1-thiol	Investigative
T67272	DRUGINFO	D0RH4S	1-aminopentylphosphonic acid monophenyl ester	Investigative
T67272	DRUGINFO	D0UI1P	2-Cinnamamido-N4-hexyl-N1-hydroxysuccinamide	Investigative
T67272	DRUGINFO	D0UT7Y	N1-(3-phenoxybenzyl)-N3-hydroxymalonamide	Investigative
T67272	DRUGINFO	D0YA8C	2-benzyl-N1-hydroxy-N3-(3-phenylpropyl)malonamide	Investigative
T67272	DRUGINFO	D0YO0R	2-benzyl-N1-hydroxy-N3-(4-phenylbutyl)malonamide	Investigative
T67272	DRUGINFO	D0Z2JN	N1,2-dibenzyl-N3-hydroxymalonamide	Investigative
T67272	DRUGINFO	D0Z4AC	2-amino-N1-benzyl-N3-hydroxymalonamide	Investigative
T67272	DRUGINFO	D0Z4NU	2-Cinnamamido-N1-hydroxy-N4-octylsuccinamide	Investigative
T67272	DRUGINFO	D04QJY	KELATORPHAN	Investigative
T67272	DRUGINFO	D0U8IF	[(125)I] RB129	Investigative

T52389	TARGETID	T52389
T52389	FORMERID	TTDC00200
T52389	UNIPROID	NQO1_HUMAN
T52389	TARGNAME	Quinone reductase 1 (NQO1)
T52389	GENENAME	NQO1
T52389	TARGTYPE	Clinical trial
T52389	SYNONYMS	Qui reductase 1; QR1; Phylloquinone reductase; Phylloqui reductase; NMOR1; NAD(P)H:quinone oxidoreductase 1; NAD(P)H dehydrogenase [quinone] 1; Menadione reductase; DTD; DT-diaphorase 1; DT-diaphorase; DIA4; Azoreductase
T52389	FUNCTION	The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinons involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis.
T52389	PDBSTRUC	6FY4; 5FUQ; 5EAI; 5EA2; 5A4K
T52389	BIOCLASS	NADH/NADPH oxidoreductase
T52389	ECNUMBER	EC 1.6.5.2
T52389	SEQUENCE	MVGRRALIVLAHSERTSFNYAMKEAAAAALKKKGWEVVESDLYAMNFNPIISRKDITGKLKDPANFQYPAESVLAYKEGHLSPDIVAEQKKLEAADLVIFQFPLQWFGVPAILKGWFERVFIGEFAYTYAAMYDKGPFRSKKAVLSITTGGSGSMYSLQGIHGDMNVILWPIQSGILHFCGFQVLEPQLTYSIGHTPADARIQILEGWKKRLENIWDETPLYFAPSSLFDLNFQAGFLMKKEVQDEEKNKKFGLSVGHHLGKSIPTDNQIKARK
T52389	DRUGINFO	D0DR0P	ARQ 761	Phase 2
T52389	DRUGINFO	D0MM6A	Coenzyme Q10 analog	Phase 2
T52389	DRUGINFO	D0RI4I	BioE-743	Phase 2
T52389	DRUGINFO	D00SRM	NSC-354279	Investigative
T52389	DRUGINFO	D01WPJ	Duroquinone	Investigative
T52389	DRUGINFO	D02ONP	Ethyl Bis(4-hydroxy-2-oxo-2H-chromen-3-yl)acetate	Investigative
T52389	DRUGINFO	D03CDH	3-Benzyl-4-hydroxy-2H-benzo[h]chromen-2-one	Investigative
T52389	DRUGINFO	D05GWI	NSC-106547	Investigative
T52389	DRUGINFO	D06BHJ	3-(3,4-Dimethylbenzyl)-4-hydroxy-2H-chromen-2-one	Investigative
T52389	DRUGINFO	D07DGS	NSC-2113	Investigative
T52389	DRUGINFO	D07JNQ	NSC-73410	Investigative
T52389	DRUGINFO	D07MGN	NSC-224124	Investigative
T52389	DRUGINFO	D08XJX	3-Benzyl-4-hydroxy-6,7-dimethyl-2H-chromen-2-one	Investigative
T52389	DRUGINFO	D09CYJ	4-Hydroxy-3-(1-naphthylmethyl)-2H-chromen-2-one	Investigative
T52389	DRUGINFO	D09FMZ	3-Benzyl-4-hydroxy-2H-chromen-2-one	Investigative
T52389	DRUGINFO	D09ITX	2-Benzyl-1-hydroxy-3H-benzo[f]chromen-3-one	Investigative
T52389	DRUGINFO	D0A5TD	NSC-621351	Investigative
T52389	DRUGINFO	D0AN7U	NSC-316158	Investigative
T52389	DRUGINFO	D0B4GV	4-amino-2H-chromen-2-one	Investigative
T52389	DRUGINFO	D0E2LU	NSC-275420	Investigative
T52389	DRUGINFO	D0GE8S	ES-936	Investigative
T52389	DRUGINFO	D0H1BY	Bishydroxy[2h-1-Benzopyran-2-One,1,2-Benzopyrone]	Investigative
T52389	DRUGINFO	D0H4YP	4-Hydroxy-3-(2-naphthylmethyl)-2H-chromen-2-one	Investigative
T52389	DRUGINFO	D0L3VV	NSC-339583	Investigative
T52389	DRUGINFO	D0O8YZ	NSC-65069	Investigative
T52389	DRUGINFO	D0T4RW	NSC-645827	Investigative
T52389	DRUGINFO	D0VB8K	NSC-339580	Investigative
T52389	DRUGINFO	D0E0DQ	NSC-645808	Investigative
T52389	DRUGINFO	D0J3RB	NSC-106080	Investigative
T52389	DRUGINFO	D0M0WT	NSC-99528	Investigative
T52389	DRUGINFO	D00IMW	Flavin-Adenine Dinucleotide	Investigative

T24587	TARGETID	T24587
T24587	FORMERID	TTDR00624
T24587	UNIPROID	MGMT_HUMAN
T24587	TARGNAME	O-6-methylguanine-DNA-alkyltransferase (MGMT)
T24587	GENENAME	MGMT
T24587	TARGTYPE	Clinical trial
T24587	SYNONYMS	Methylated-DNA--protein-cysteine methyltransferase; Human O(6)-alkylguanine-DNA alkyltransferase; 6-O-methylguanine-DNA methyltransferase
T24587	FUNCTION	Repairs the methylated nucleobase in DNA by stoichiometrically transferring the methyl group to a cysteine residue in the enzyme. This is a suicide reaction: the enzyme is irreversibly inactivated. Involved in the cellular defense against the biological effects of O6-methylguanine (O6-MeG) and O4-methylthymine (O4-MeT) in DNA.
T24587	PDBSTRUC	1YFH; 1T39; 1T38; 1QNT; 1EH8
T24587	BIOCLASS	Methyltransferase
T24587	ECNUMBER	EC 2.1.1.63
T24587	SEQUENCE	MDKDCEMKRTTLDSPLGKLELSGCEQGLHEIKLLGKGTSAADAVEVPAPAAVLGGPEPLMQCTAWLNAYFHQPEAIEEFPVPALHHPVFQQESFTRQVLWKLLKVVKFGEVISYQQLAALAGNPKAARAVGGAMRGNPVPILIPCHRVVCSSGAVGNYSGGLAVKEWLLAHEGHRLGKPGLGGSSGLAGAWLKGAGATSGSPPAGRN
T24587	DRUGINFO	D0S0HA	O6-Benzylguanine alkylade	Phase 3
T24587	DRUGINFO	D04RNU	6-Benzyloxy-5-nitroso-pyrimidine-2,4-diamine	Investigative
T24587	DRUGINFO	D07BTU	6-Benzyloxy-5-nitro-pyrimidine-2,4-diamine	Investigative
T24587	DRUGINFO	D0B5BG	6-Benzyloxy-9H-purin-2-ylamine	Investigative
T24587	DRUGINFO	D0S0JL	Benzylcysteine	Investigative
T24587	DRUGINFO	D0Z8EI	6-Allyloxy-9H-purin-2-ylamine	Investigative
T24587	DRUGINFO	D0CU4Q	S-Methylcysteine	Investigative

T10735	TARGETID	T10735
T10735	FORMERID	TTDC00027
T10735	UNIPROID	DCHS_HUMAN
T10735	TARGNAME	Histidine decarboxylase (HDC)
T10735	GENENAME	HDC
T10735	TARGTYPE	Clinical trial
T10735	SYNONYMS	Human histidine decarboxylase
T10735	FUNCTION	Catalyzes the biosynthesis of histamine from histidine.
T10735	PDBSTRUC	4E1O
T10735	BIOCLASS	Carbon-carbon lyase
T10735	ECNUMBER	EC 4.1.1.22
T10735	SEQUENCE	MMEPEEYRERGREMVDYICQYLSTVRERRVTPDVQPGYLRAQLPESAPEDPDSWDSIFGDIERIIMPGVVHWQSPHMHAYYPALTSWPSLLGDMLADAINCLGFTWASSPACTELEMNVMDWLAKMLGLPEHFLHHHPSSQGGGVLQSTVSESTLIALLAARKNKILEMKTSEPDADESCLNARLVAYASDQAHSSVEKAGLISLVKMKFLPVDDNFSLRGEALQKAIEEDKQRGLVPVFVCATLGTTGVCAFDCLSELGPICAREGLWLHIDAAYAGTAFLCPEFRGFLKGIEYADSFTFNPSKWMMVHFDCTGFWVKDKYKLQQTFSVNPIYLRHANSGVATDFMHWQIPLSRRFRSVKLWFVIRSFGVKNLQAHVRHGTEMAKYFESLVRNDPSFEIPAKRHLGLVVFRLKGPNCLTENVLKEIAKAGRLFLIPATIQDKLIIRFTVTSQFTTRDDILRDWNLIRDAATLILSQHCTSQPSPRVGNLISQIRGARAWACGTSLQSVSGAGDDPVQARKIIKQPQRVGAGPMKRENGLHLETLLDPVDDCFSEEAPDATKHKLSSFLFSYLSVQTKKKTVRSLSCNSVPVSAQKPLPTEASVKNGGSSRVRIFSRFPEDMMMLKKSAFKKLIKFYSVPSFPECSSQCGLQLPCCPLQAMV
T10735	DRUGINFO	D07EEN	Lixivaptan	Phase 3
T10735	DRUGINFO	D0U5BF	ALPHA-FMH	Phase 1
T10735	DRUGINFO	D05BKG	AMA	Investigative
T10735	DRUGINFO	D06KMO	Brocresine	Investigative

T01908	TARGETID	T01908
T01908	FORMERID	TTDC00028
T01908	UNIPROID	KLK2_HUMAN
T01908	TARGNAME	Tissue kallikrein (KLK2)
T01908	GENENAME	KLK2
T01908	TARGTYPE	Clinical trial
T01908	SYNONYMS	hGK-1; Tissue kallikrein-2; Kallikrein-2; Glandular kallikrein-1
T01908	FUNCTION	Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin.
T01908	PDBSTRUC	4NFF; 4NFE
T01908	BIOCLASS	Peptidase
T01908	ECNUMBER	EC 3.4.21.35
T01908	SEQUENCE	MWDLVLSIALSVGCTGAVPLIQSRIVGGWECEKHSQPWQVAVYSHGWAHCGGVLVHPQWVLTAAHCLKKNSQVWLGRHNLFEPEDTGQRVPVSHSFPHPLYNMSLLKHQSLRPDEDSSHDLMLLRLSEPAKITDVVKVLGLPTQEPALGTTCYASGWGSIEPEEFLRPRSLQCVSLHLLSNDMCARAYSEKVTEFMLCAGLWTGGKDTCGGDSGGPLVCNGVLQGITSWGPEPCALPEKPAVYTKVVHYRKWIKDTIAANP
T01908	DRUGINFO	D0V4HO	Avoralstat	Phase 2/3
T01908	DRUGINFO	DK6P5A	VDA-1102	Phase 2
T01908	DRUGINFO	D4NGM6	JNJ-75229414	Phase 1
T01908	DRUGINFO	D4TI9A	JNJ-69086420	Phase 1
T01908	DRUGINFO	D0NQ1S	JNJ-78278343	Phase 1
T01908	DRUGINFO	D0B9EH	Dermolastin	Discontinued in Phase 2
T01908	DRUGINFO	D03OMK	DM-107	Investigative
T01908	DRUGINFO	D05FYR	hK2p01 derivative KLK2 inhibitor	Investigative

T65116	TARGETID	T65116
T65116	FORMERID	TTDR01229
T65116	UNIPROID	5NTD_HUMAN
T65116	TARGNAME	Ecto-5'-nucleotidase (CD73)
T65116	GENENAME	NT5E
T65116	TARGTYPE	Clinical trial
T65116	SYNONYMS	NT5; CD73 antigen; 5'-nucleotidase; 5'-NT
T65116	FUNCTION	Exhibits AMP-, NAD-, and NMN-nucleosidase activities. Hydrolyzes extracellular nucleotides into membrane permeable nucleosides.
T65116	PDBSTRUC	4H2I; 4H2G; 4H2F; 4H2B; 4H1Y
T65116	BIOCLASS	Phosphoric monoester hydrolase
T65116	ECNUMBER	EC 3.1.3.5
T65116	SEQUENCE	MCPRAARAPATLLLALGAVLWPAAGAWELTILHTNDVHSRLEQTSEDSSKCVNASRCMGGVARLFTKVQQIRRAEPNVLLLDAGDQYQGTIWFTVYKGAEVAHFMNALRYDAMALGNHEFDNGVEGLIEPLLKEAKFPILSANIKAKGPLASQISGLYLPYKVLPVGDEVVGIVGYTSKETPFLSNPGTNLVFEDEITALQPEVDKLKTLNVNKIIALGHSGFEMDKLIAQKVRGVDVVVGGHSNTFLYTGNPPSKEVPAGKYPFIVTSDDGRKVPVVQAYAFGKYLGYLKIEFDERGNVISSHGNPILLNSSIPEDPSIKADINKWRIKLDNYSTQELGKTIVYLDGSSQSCRFRECNMGNLICDAMINNNLRHTDEMFWNHVSMCILNGGGIRSPIDERNNGTITWENLAAVLPFGGTFDLVQLKGSTLKKAFEHSVHRYGQSTGEFLQVGGIHVVYDLSRKPGDRVVKLDVLCTKCRVPSYDPLKMDEVYKVILPNFLANGGDGFQMIKDELLRHDSGDQDINVVSTYISKMKVIYPAVEGRIKFSTGSHCHGSFSLIFLSLWAVIFVLYQ
T65116	DRUGINFO	DFYL50	TJ004309	Phase 2
T65116	DRUGINFO	D02GRR	Oleclumab	Phase 1
T65116	DRUGINFO	D7CE6N	AB680	Phase 1
T65116	DRUGINFO	D9IQ6N	TJ4309	Phase 1
T65116	DRUGINFO	DKL13E	CPI-006	Phase 1
T65116	DRUGINFO	DN65GW	LY3475070	Phase 1
T65116	DRUGINFO	DP6GC3	NZV930	Phase 1
T65116	DRUGINFO	DG6V7E	GS-1423	Phase 1
T65116	DRUGINFO	D00BQR	PMID28870136-Compound-57	Patented
T65116	DRUGINFO	D01ADE	PMID28870136-Compound-46	Patented
T65116	DRUGINFO	D01NBW	PMID28870136-Compound-53	Patented
T65116	DRUGINFO	D01OIQ	PMID28870136-Compound-45	Patented
T65116	DRUGINFO	D02DLG	PMID28870136-Compound-38	Patented
T65116	DRUGINFO	D03VLV	PMID28870136-Compound-36	Patented
T65116	DRUGINFO	D03XTA	PMID28870136-Compound-49	Patented
T65116	DRUGINFO	D04GYR	PMID28870136-Compound-61	Patented
T65116	DRUGINFO	D04TGG	PMID28870136-Compound-68	Patented
T65116	DRUGINFO	D06YAB	PMID28870136-Compound-51	Patented
T65116	DRUGINFO	D07DGB	PMID28870136-Compound-55	Patented
T65116	DRUGINFO	D08LPX	PMID28870136-Compound-69	Patented
T65116	DRUGINFO	D08ZDR	PMID28870136-Compound-67	Patented
T65116	DRUGINFO	D09QNH	PMID28870136-Compound-50	Patented
T65116	DRUGINFO	D09XUJ	PMID28870136-Compound-59	Patented
T65116	DRUGINFO	D0AF4A	PMID28870136-Compound-40	Patented
T65116	DRUGINFO	D0C2UP	PMID28870136-Compound-42	Patented
T65116	DRUGINFO	D0C7ON	PMID28870136-Compound-43	Patented
T65116	DRUGINFO	D0CH7Z	PMID28870136-Compound-44	Patented
T65116	DRUGINFO	D0DF2M	PMID28870136-Compound-48	Patented
T65116	DRUGINFO	D0FK2Q	PMID28870136-Compound-47	Patented
T65116	DRUGINFO	D0H9IX	PMID28870136-Compound-52	Patented
T65116	DRUGINFO	D0JF6W	PMID28870136-Compound-65	Patented
T65116	DRUGINFO	D0KS3G	PMID29166791-Compound-AMPCP	Patented
T65116	DRUGINFO	D0LB7I	PMID28870136-Compound-64	Patented
T65116	DRUGINFO	D0MA9U	PMID28870136-Compound-60	Patented
T65116	DRUGINFO	D0QL7B	PMID28870136-Compound-41	Patented
T65116	DRUGINFO	D0SK3R	PMID28870136-Compound-39	Patented
T65116	DRUGINFO	D0U2YE	PMID28870136-Compound-56	Patented
T65116	DRUGINFO	D0V5NK	PMID28870136-Compound-54	Patented
T65116	DRUGINFO	D0V7OE	PMID28870136-Compound-58	Patented
T65116	DRUGINFO	D0X1MK	PMID28870136-Compound-37	Patented
T65116	DRUGINFO	D0Y2QO	PMID28870136-Compound-62	Patented
T65116	DRUGINFO	D0Y9TP	PMID28870136-Compound-63	Patented
T65116	DRUGINFO	D08DXA	Acid blue 25	Investigative
T65116	DRUGINFO	D0DZ1K	PSB-0952	Investigative
T65116	DRUGINFO	D0O9GJ	alphabeta-methyleneADP	Investigative
T65116	DRUGINFO	D06GQY	PSB-0963	Investigative
T65116	DRUGINFO	D0B0ZQ	RB 2	Investigative

T94479	TARGETID	T94479
T94479	FORMERID	TTDC00145
T94479	UNIPROID	KS6B1_HUMAN
T94479	TARGNAME	Ribosomal protein S6 kinase beta-1 (S6K1)
T94479	GENENAME	RPS6KB1
T94479	TARGTYPE	Clinical trial
T94479	SYNONYMS	p70-S6K 1; p70 ribosomal S6 kinase alpha; p70 S6KA; p70 S6K-alpha; p70 S6 kinase alpha; Serine/threonine-protein kinase 14A; STK14A; S6K-beta-1; S6K; Ribosomal protein S6 kinase I; P70S6K1; P70-S6K; 70 kDa ribosomal protein S6 kinase 1
T94479	FUNCTION	Regulates protein synthesis through phosphorylation of EIF4B, RPS6 and EEF2K, and contributes to cell survival by repressing the pro-apoptotic function of BAD. Under conditions of nutrient depletion, the inactive form associates with the EIF3 translation initiation complex. Upon mitogenic stimulation, phosphorylation by the mammalian target of rapamycin complex 1 (mTORC1) leads to dissociation from the EIF3 complex and activation. The active form then phosphorylates and activates several substrates in the pre-initiation complex, including the EIF2B complex and the cap-binding complex component EIF4B. Also controls translation initiation by phosphorylating a negative regulator of EIF4A, PDCD4, targeting it for ubiquitination and subsequent proteolysis. Promotes initiation of the pioneer round of protein synthesis by phosphorylating POLDIP3/SKAR. In response to IGF1, activates translation elongation by phosphorylating EEF2 kinase (EEF2K), which leads to its inhibition and thus activation of EEF2. Also plays a role in feedback regulation of mTORC2 by mTORC1 by phosphorylating RICTOR, resulting in the inhibition of mTORC2 and AKT1 signaling. Mediates cell survival by phosphorylating the pro-apoptotic protein BAD and suppressing its pro-apoptotic function. Phosphorylates mitochondrial URI1 leading to dissociation of a URI1-PPP1CC complex. The free mitochondrial PPP1CC can then dephosphorylate RPS6KB1 at Thr-412, which is proposed to be a negative feedback mechanism for the RPS6KB1 anti-apoptotic function. Mediates TNF-alpha-induced insulin resistance by phosphorylating IRS1 at multiple serine residues, resulting in accelerated degradation of IRS1. In cells lacking functional TSC1-2 complex, constitutively phosphorylates and inhibits GSK3B. May be involved in cytoskeletal rearrangement through binding to neurabin. Phosphorylates and activates the pyrimidine biosynthesis enzyme CAD, downstream of MTOR. Following activation by mTORC1, phosphorylates EPRS and thereby plays a key role in fatty acid uptake by adipocytes and also most probably in interferon-gamma-induced translation inhibition. Serine/threonine-protein kinase that acts downstream of mTOR signaling in response to growth factors and nutrients to promote cell proliferation, cell growth and cell cycle progression.
T94479	PDBSTRUC	5WBK; 5WBH; 4RLP; 4RLO; 4L46
T94479	BIOCLASS	Kinase
T94479	ECNUMBER	EC 2.7.11.1
T94479	SEQUENCE	MRRRRRRDGFYPAPDFRDREAEDMAGVFDIDLDQPEDAGSEDELEEGGQLNESMDHGGVGPYELGMEHCEKFEISETSVNRGPEKIRPECFELLRVLGKGGYGKVFQVRKVTGANTGKIFAMKVLKKAMIVRNAKDTAHTKAERNILEEVKHPFIVDLIYAFQTGGKLYLILEYLSGGELFMQLEREGIFMEDTACFYLAEISMALGHLHQKGIIYRDLKPENIMLNHQGHVKLTDFGLCKESIHDGTVTHTFCGTIEYMAPEILMRSGHNRAVDWWSLGALMYDMLTGAPPFTGENRKKTIDKILKCKLNLPPYLTQEARDLLKKLLKRNAASRLGAGPGDAGEVQAHPFFRHINWEELLARKVEPPFKPLLQSEEDVSQFDSKFTRQTPVDSPDDSTLSESANQVFLGFTYVAPSVLESVKEKFSFEPKIRSPRRFIGSPRTPVSPVKFSPGDFWGRGASASTANPQTPVEYPMETSGIEQMDVTMSGEASAPLPIRQPNSGPYKKQAFPMISKRPEHLRMNL
T94479	DRUGINFO	D6KWF3	NNI‐362	Phase 1
T94479	DRUGINFO	D06HYF	M2698	Phase 1
T94479	DRUGINFO	D0Y4LI	PF-4708671	Clinical trial
T94479	DRUGINFO	D02ABC	PMID27410995-Compound-Figure3c	Patented
T94479	DRUGINFO	D0BN4A	Pyrimido[4,5-d] pyrimidines and pyrido[4,3-d] pyrimidine derivative 1	Patented
T94479	DRUGINFO	D0N4WB	SB-415286	Investigative
T94479	DRUGINFO	D0I1FJ	SB-747651A	Investigative
T94479	DRUGINFO	D0R6OM	ACTB-1003	Investigative
T94479	DRUGINFO	D0L2WP	PMID20005102C1	Investigative
T94479	DRUGINFO	D0G2VC	KT-5720	Investigative
T94479	DRUGINFO	D0GB4V	STAUROSPORINONE	Investigative
T94479	DRUGINFO	D0M5FF	Ro31-8220	Investigative
T94479	DRUGINFO	D0N6ES	KN-62	Investigative
T94479	DRUGINFO	D0B9BU	CI-1040	Investigative
T94479	DRUGINFO	D0O1YH	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	Investigative
T94479	DRUGINFO	D0A5RM	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	Investigative
T94479	DRUGINFO	D0L8HO	RO-316233	Investigative

T05114	TARGETID	T05114
T05114	FORMERID	TTDR00197
T05114	UNIPROID	CMA1_HUMAN
T05114	TARGNAME	Chymase (CYM)
T05114	GENENAME	CMA1
T05114	TARGTYPE	Clinical trial
T05114	SYNONYMS	Mast cell protease I; CYH; Alpha-chymase
T05114	FUNCTION	Major secreted protease of mast cells with suspected roles in vasoactive peptide generation, extracellular matrix degradation, and regulation of gland secretion.
T05114	PDBSTRUC	5YJP; 5YJM; 4KP0; 4K69; 4K60
T05114	BIOCLASS	Peptidase
T05114	ECNUMBER	EC 3.4.21.39
T05114	SEQUENCE	MLLLPLPLLLFLLCSRAEAGEIIGGTECKPHSRPYMAYLEIVTSNGPSKFCGGFLIRRNFVLTAAHCAGRSITVTLGAHNITEEEDTWQKLEVIKQFRHPKYNTSTLHHDIMLLKLKEKASLTLAVGTLPFPSQFNFVPPGRMCRVAGWGRTGVLKPGSDTLQEVKLRLMDPQACSHFRDFDHNLQLCVGNPRKTKSAFKGDSGGPLLCAGVAQGIVSYGRSDAKPPAVFTRISHYRPWINQILQAN
T05114	DRUGINFO	D0B1OH	ASB17061	Phase 2
T05114	DRUGINFO	D0M0YB	BAY 11-42524	Phase 2
T05114	DRUGINFO	DGD72N	BAY 1142524	Phase 2
T05114	DRUGINFO	D01YIO	JNJ-10311795	Phase 2
T05114	DRUGINFO	D0I8FV	SUN13834	Phase 2
T05114	DRUGINFO	D05QCE	KM-01221	Investigative
T05114	DRUGINFO	D08QZD	Y-40613	Investigative
T05114	DRUGINFO	D0C8UF	Rac-2q	Investigative
T05114	DRUGINFO	D0F3CS	Phenylalanylmethane	Investigative
T05114	DRUGINFO	D0H3SL	NK3201	Investigative
T05114	DRUGINFO	D0J3SW	BCEAB	Investigative
T05114	DRUGINFO	D0L0QR	CHYMOSTATIN	Investigative
T05114	DRUGINFO	D0S1HT	SUN-C8257	Investigative
T05114	DRUGINFO	D0PA1G	Benzylsulfinic Acid	Investigative
T05114	DRUGINFO	D07KZA	2-(N-Morpholino)-Ethanesulfonic Acid	Investigative

T11487	TARGETID	T11487
T11487	FORMERID	TTDC00313
T11487	UNIPROID	THIL_HUMAN
T11487	TARGNAME	Acetoacetyl-CoA thiolase (ACAT1)
T11487	GENENAME	ACAT1
T11487	TARGTYPE	Clinical trial
T11487	SYNONYMS	T2; MAT; Acetyl-CoA acetyltransferase, mitochondrial
T11487	FUNCTION	Plays a major role in ketone body metabolism.
T11487	PDBSTRUC	2IBY; 2IBW; 2IBU; 2IB9; 2IB8
T11487	BIOCLASS	Acyltransferase
T11487	ECNUMBER	EC 2.3.1.9
T11487	SEQUENCE	MAVLAALLRSGARSRSPLLRRLVQEIRYVERSYVSKPTLKEVVIVSATRTPIGSFLGSLSLLPATKLGSIAIQGAIEKAGIPKEEVKEAYMGNVLQGGEGQAPTRQAVLGAGLPISTPCTTINKVCASGMKAIMMASQSLMCGHQDVMVAGGMESMSNVPYVMNRGSTPYGGVKLEDLIVKDGLTDVYNKIHMGSCAENTAKKLNIARNEQDAYAINSYTRSKAAWEAGKFGNEVIPVTVTVKGQPDVVVKEDEEYKRVDFSKVPKLKTVFQKENGTVTAANASTLNDGAAALVLMTADAAKRLNVTPLARIVAFADAAVEPIDFPIAPVYAASMVLKDVGLKKEDIAMWEVNEAFSLVVLANIKMLEIDPQKVNINGGAVSLGHPIGMSGARIVGHLTHALKQGEYGLASICNGGGGASAMLIQKL
T11487	DRUGINFO	D0LM4U	ATR-01	Phase 1
T11487	DRUGINFO	D04TSP	PMID25470667-Compound-K-604	Patented
T11487	DRUGINFO	D00CCI	Benoxaprofen	Withdrawn from market
T11487	DRUGINFO	D00EYY	PMID16242323C18a	Investigative
T11487	DRUGINFO	D00MJG	PMID16242323C16	Investigative
T11487	DRUGINFO	D01UWZ	PMID16242323C22c	Investigative
T11487	DRUGINFO	D04SPQ	PMID16242323C26a	Investigative
T11487	DRUGINFO	D07LER	Nonanoic acid biphenyl-2-ylamide	Investigative
T11487	DRUGINFO	D0A7YE	Octanoic acid biphenyl-2-ylamide	Investigative
T11487	DRUGINFO	D0IY3E	PMID16242323C22d	Investigative
T11487	DRUGINFO	D0K6SD	PMID16242323C15a	Investigative
T11487	DRUGINFO	D0KS1Z	PMID16242323C26c	Investigative
T11487	DRUGINFO	D0M8SY	PMID16242323C18b	Investigative
T11487	DRUGINFO	D0RG1F	PMID16242323C26b	Investigative
T11487	DRUGINFO	D0T9RD	(Z)-2,6-diisopropyl-N-phenyloctadec-9-enamide	Investigative
T11487	DRUGINFO	D0W5HL	PMID16242323C15b	Investigative

T70176	TARGETID	T70176
T70176	FORMERID	TTDC00088
T70176	UNIPROID	CDK2_HUMAN
T70176	TARGNAME	Cyclin-dependent kinase 2 (CDK2)
T70176	GENENAME	CDK2
T70176	TARGTYPE	Clinical trial
T70176	SYNONYMS	Sin3 associated polypeptide; SIN3-associated protein; P33 protein kinase; Cell division protein kinase 2; CDKN2
T70176	FUNCTION	Phosphorylates CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2. Triggers duplication of centrosomes and DNA. Acts at the G1-S transition to promote the E2F transcriptional program and the initiation of DNA synthesis, and modulates G2 progression; controls the timing of entry into mitosis/meiosis by controlling the subsequent activation of cyclin B/CDK1 by phosphorylation, and coordinates the activation of cyclin B/CDK1 at the centrosome and in the nucleus. Crucial role in orchestrating a fine balance between cellular proliferation, cell death, and DNA repair in human embryonic stem cells (hESCs). Activity of CDK2 is maximal during S phase and G2; activated by interaction with cyclin E during the early stages of DNA synthesis to permit G1-S transition, and subsequently activated by cyclin A2 (cyclin A1 in germ cells) during the late stages of DNA replication to drive the transition from S phase to mitosis, the G2 phase. EZH2 phosphorylation promotes H3K27me3 maintenance and epigenetic gene silencing. Phosphorylates CABLES1. Cyclin E/CDK2 prevents oxidative stress-mediated Ras-induced senescence by phosphorylating MYC. Involved in G1-S phase DNA damage checkpoint that prevents cells with damaged DNA from initiating mitosis; regulates homologous recombination-dependent repair by phosphorylating BRCA2, this phosphorylation is low in S phase when recombination is active, but increases as cells progress towards mitosis. In response to DNA damage, double-strand break repair by homologous recombination a reduction of CDK2-mediated BRCA2 phosphorylation. Phosphorylation of RB1 disturbs its interaction with E2F1. NPM1 phosphorylation by cyclin E/CDK2 promotes its dissociates from unduplicated centrosomes, thus initiating centrosome duplication. Cyclin E/CDK2-mediated phosphorylation of NPAT at G1-S transition and until prophase stimulates the NPAT-mediated activation of histone gene transcription during S phase. Required for vitamin D-mediated growth inhibition by being itself inactivated. Involved in the nitric oxide- (NO) mediated signaling in a nitrosylation/activation-dependent manner. USP37 is activated by phosphorylation and thus triggers G1-S transition. CTNNB1 phosphorylation regulates insulin internalization. Phosphorylates FOXP3 and negatively regulates its transcriptional activity and protein stability. Phosphorylates CDK2AP2. Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis.
T70176	PDBSTRUC	6Q4K; 6Q4J; 6Q4I; 6Q4H; 6Q4G
T70176	BIOCLASS	Kinase
T70176	ECNUMBER	EC 2.7.11.22
T70176	SEQUENCE	MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL
T70176	DRUGINFO	D0Q9UX	PHA848125	Phase 2
T70176	DRUGINFO	D01UMT	Ro 31-7453	Phase 2
T70176	DRUGINFO	D05ADP	R-roscovitine	Phase 2
T70176	DRUGINFO	D0P0KN	TG02	Phase 1/2
T70176	DRUGINFO	D70HZT	NUV-422	Phase 1/2
T70176	DRUGINFO	D06WHY	AZD-5438	Phase 1
T70176	DRUGINFO	D07DTV	AT7519	Phase 1
T70176	DRUGINFO	D5TH2B	PF-07104091	Phase 1
T70176	DRUGINFO	D0PL7P	CYC065	Phase 1
T70176	DRUGINFO	D0IX4B	AG-024322	Phase 1
T70176	DRUGINFO	D0P1CV	PHA-793887	Phase 1
T70176	DRUGINFO	D0S5RC	SNS-032	Phase 1
T70176	DRUGINFO	DYH94Z	RGT-419B	Phase 1
T70176	DRUGINFO	DKCU40	FN-1501	Phase 1
T70176	DRUGINFO	D03DKV	RGB-286638	Phase 1
T70176	DRUGINFO	D09ISI	Fluorinated compound 1	Patented
T70176	DRUGINFO	D0JU4Z	4-amino-3,5-di-substituted-thiazole derivative 1	Patented
T70176	DRUGINFO	D02KWX	Indole-based analog 11	Patented
T70176	DRUGINFO	D03EYT	N-(pyridin-2-yl)pyridine methylsulfone derivative 1	Patented
T70176	DRUGINFO	D03HED	Palbociclib/ribociclib analog 1	Patented
T70176	DRUGINFO	D05UJQ	Alkyl sulfone derivative 1	Patented
T70176	DRUGINFO	D06QPW	Aniline derivative 1	Patented
T70176	DRUGINFO	D07QIP	4-(thiazol-5-yl)-pyrimidine derivative 1	Patented
T70176	DRUGINFO	D0AY5G	N-phenyl-pyrimidin-4-amine derivative 1	Patented
T70176	DRUGINFO	D0GQ7L	PMID26161698-Compound-25	Patented
T70176	DRUGINFO	D0P4NP	Diaryl amine derivative 1	Patented
T70176	DRUGINFO	D0P9WR	Flavopiridol analog 1	Patented
T70176	DRUGINFO	D0QR1Z	Isosteric imidazolyl pyrimidine derivative 1	Patented
T70176	DRUGINFO	D0QS2B	N-(pyridin-2-yl)pyrimidin-4-amine derivative 2	Patented
T70176	DRUGINFO	D0T6CM	Pyrazolo-triazine derivative 2	Patented
T70176	DRUGINFO	D0UU0V	1,5-di-substituted pyridine derivative 1	Patented
T70176	DRUGINFO	D0V7RP	5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivative 1	Patented
T70176	DRUGINFO	D08KKC	Pyrrolo[2,3-d]pyrimidine derivative 9	Patented
T70176	DRUGINFO	D08WJG	Naphthyridine and isoquinoline derivative 1	Patented
T70176	DRUGINFO	D0LK4L	Nitrogen mustard derivative 1	Patented
T70176	DRUGINFO	D01CJE	4-(thiazol-5-yl)-pyrimidine derivative 2	Patented
T70176	DRUGINFO	D0LR2Y	Diamidothiazole derivative 1	Patented
T70176	DRUGINFO	D0LX6X	Indole-based analog 13	Patented
T70176	DRUGINFO	D0NB7Y	Pyrazolo[1,5-a]-1,3,5-triazine derivative 1	Patented
T70176	DRUGINFO	D0W4MN	Isoquinoline 1,3-dione derivative 1	Patented
T70176	DRUGINFO	D07DUX	Roscovitine derivative 1	Patented
T70176	DRUGINFO	D0H4HD	PMID25991433-Compound-A1	Patented
T70176	DRUGINFO	D0M5DX	Oxazolyl methylthiothiazole derivative 1	Patented
T70176	DRUGINFO	D0D3PX	SCH 727965	Discontinued in Phase 3
T70176	DRUGINFO	D0NV9O	BAY 10-00394	Discontinued in Phase 2
T70176	DRUGINFO	D04FHB	R547	Discontinued in Phase 1
T70176	DRUGINFO	D00VBT	ZK 304709	Discontinued in Phase 1
T70176	DRUGINFO	D07ZJC	INOC-005	Preclinical
T70176	DRUGINFO	D0WS1V	L-751250	Preclinical
T70176	DRUGINFO	D00BPA	Olomoucine	Terminated
T70176	DRUGINFO	D0Z0KD	PD-0183812	Terminated
T70176	DRUGINFO	D01LPG	4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide	Investigative
T70176	DRUGINFO	D03BZV	PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE	Investigative
T70176	DRUGINFO	D06FIQ	6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE	Investigative
T70176	DRUGINFO	D07ADR	BOHEMINE	Investigative
T70176	DRUGINFO	D07ODE	N-phenyl-1H-pyrazole-3-carboxamide	Investigative
T70176	DRUGINFO	D07SGT	5-hydroxynaphthalene-1-sulfonamide	Investigative
T70176	DRUGINFO	D0D3HB	N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide	Investigative
T70176	DRUGINFO	D0I1SZ	N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE	Investigative
T70176	DRUGINFO	D0I9VN	1-Amino-6-Cyclohex-3-Enylmethyloxypurine	Investigative
T70176	DRUGINFO	D0M5PI	Benzyl-(9-isopropyl-9H-purin-6-yl)-amine	Investigative
T70176	DRUGINFO	D0MK6D	N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide	Investigative
T70176	DRUGINFO	D0P7RO	TRIAZOLOPYRIMIDINE	Investigative
T70176	DRUGINFO	D0QI7H	2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE	Investigative
T70176	DRUGINFO	D0T4SJ	SCH-546909	Investigative
T70176	DRUGINFO	D0T5AH	PHA-690509	Investigative
T70176	DRUGINFO	D0U0GE	4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine	Investigative
T70176	DRUGINFO	D0V1NK	VER-54505	Investigative
T70176	DRUGINFO	D0W0PF	2-Amino-6-Chloropyrazine	Investigative
T70176	DRUGINFO	D0Y6DX	6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine	Investigative
T70176	DRUGINFO	D01FJB	6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine	Investigative
T70176	DRUGINFO	D01PSU	(2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime	Investigative
T70176	DRUGINFO	D02ZYA	6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine	Investigative
T70176	DRUGINFO	D03KLM	(2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime	Investigative
T70176	DRUGINFO	D03XKK	6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine	Investigative
T70176	DRUGINFO	D04AGE	(2'Z,3'E)-5-Fluoro-5'-methoxy-indirubin-3'-oxime	Investigative
T70176	DRUGINFO	D04NGS	JNJ-7706621	Investigative
T70176	DRUGINFO	D04RBG	GW-8510	Investigative
T70176	DRUGINFO	D05SZH	BMS-265246	Investigative
T70176	DRUGINFO	D06GLV	(2'Z,3'E)-5-Fluoro-5'-fluoro-indirubin-3'-oxime	Investigative
T70176	DRUGINFO	D06XIW	(2'Z,3'E)-5-Fluoro-5'-chloro-indirubin-3'-oxime	Investigative
T70176	DRUGINFO	D07AEC	RESCOVITINE	Investigative
T70176	DRUGINFO	D07HPE	Cdk4 inhibitor III	Investigative
T70176	DRUGINFO	D07JHG	6-(3-Amino-benzyloxy)-9H-purin-2-ylamine	Investigative
T70176	DRUGINFO	D0B1LM	(2'Z,3'E)-5-Chloro-5'-fluoro-indirubin-3'-oxime	Investigative
T70176	DRUGINFO	D0F3OM	2-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol	Investigative
T70176	DRUGINFO	D0GP3R	5-nitroindirubin-3'-oxime	Investigative
T70176	DRUGINFO	D0H0EN	(2'Z,3'E)-5-Nitro-5'-methyl-indirubin-3'-oxime	Investigative
T70176	DRUGINFO	D0I6AE	(2'Z,3'E)-5-Nitro-5'-chloro-indirubin-3'-oxime	Investigative
T70176	DRUGINFO	D0J3RS	(2'Z,3'E)-5-Fluoro-5'-hydroxy-indirubin-3'-oxime	Investigative
T70176	DRUGINFO	D0JR0G	(2'Z,3'E)-5-Chloro-5'-hydroxy-indirubin-3'-oxime	Investigative
T70176	DRUGINFO	D0KH5T	4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline	Investigative
T70176	DRUGINFO	D0L5PI	(2'Z,3'E)-5-Nitro-5'-fluoro-indirubin-3'-oxime	Investigative
T70176	DRUGINFO	D0M4XD	(2'Z,3'E)-5-Nitro-5'-methoxy-indirubin-3'-oxime	Investigative
T70176	DRUGINFO	D0MS4R	Oxindole 95	Investigative
T70176	DRUGINFO	D0P2WA	CVT-313	Investigative
T70176	DRUGINFO	D0R1FT	6-O-Cyclohexylmethyl Guanine	Investigative
T70176	DRUGINFO	D0U8YN	NU-6027	Investigative
T70176	DRUGINFO	D0VD8B	NSC-625987	Investigative
T70176	DRUGINFO	D0W2FM	(2'Z,3'E)-5-Fluoro-5'-methyl-indirubin-3'-oxime	Investigative
T70176	DRUGINFO	D0YZ9Y	(2'Z,3'E)-5-Nitro-5'-hydroxy-indirubin-3'-oxime	Investigative
T70176	DRUGINFO	D00SEC	aloisine	Investigative
T70176	DRUGINFO	D01PEF	MERIOLIN 8	Investigative
T70176	DRUGINFO	D02DLC	PYRAZOLOPYRIDAZINE 1	Investigative
T70176	DRUGINFO	D07OAT	Purvalanol A	Investigative
T70176	DRUGINFO	D07OCA	Cdk1/2 inhibitor III	Investigative
T70176	DRUGINFO	D08KSQ	MERIOLIN 1	Investigative
T70176	DRUGINFO	D0B9YR	MERIOLIN 4	Investigative
T70176	DRUGINFO	D0CC0B	Lysine Nz-Carboxylic Acid	Investigative
T70176	DRUGINFO	D0D0ZQ	MERIOLIN 6	Investigative
T70176	DRUGINFO	D0D5HQ	K00024	Investigative
T70176	DRUGINFO	D0F0AX	10Z-Hymenialdisine	Investigative
T70176	DRUGINFO	D0G2GA	aminopurvalanol A	Investigative
T70176	DRUGINFO	D0H3EV	9-Nitropaullone	Investigative
T70176	DRUGINFO	D0H6CQ	MERIOLIN 5	Investigative
T70176	DRUGINFO	D0L3FK	SU9516	Investigative
T70176	DRUGINFO	D0O0VP	PYRAZOLOPYRIDAZINE 2	Investigative
T70176	DRUGINFO	D0S8VE	MERIOLIN 3	Investigative
T70176	DRUGINFO	D0U1WL	MERIOLIN 2	Investigative
T70176	DRUGINFO	D0P6JS	PMID18986805C9b	Investigative
T70176	DRUGINFO	D0W0BL	3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol	Investigative
T70176	DRUGINFO	D0G2CT	Indirubin-5-sulfonate	Investigative
T70176	DRUGINFO	D0S7IE	N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide	Investigative
T70176	DRUGINFO	D0Y5RO	NU-6102	Investigative
T70176	DRUGINFO	D02QAZ	PF-228	Investigative
T70176	DRUGINFO	D02XHC	aloisine A	Investigative
T70176	DRUGINFO	D04WFN	NU6140	Investigative
T70176	DRUGINFO	D0IX7Y	BX-912	Investigative
T70176	DRUGINFO	D0RG0Z	BX-795	Investigative
T70176	DRUGINFO	D0T8NU	PMID19115845C89S	Investigative
T70176	DRUGINFO	D0Y0ES	Indirubin-3'-monoxime	Investigative
T70176	DRUGINFO	D0H1GU	Double Oxidized Cysteine	Investigative
T70176	DRUGINFO	D06AOY	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	Investigative
T70176	DRUGINFO	D0M4SY	BMS-536924	Investigative
T70176	DRUGINFO	D00NYT	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	Investigative
T70176	DRUGINFO	D0C3WY	3,4-diphenyl-1H-pyrrole-2,5-dione	Investigative
T70176	DRUGINFO	D0EK0G	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	Investigative
T70176	DRUGINFO	D0A5RM	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	Investigative

T90553	TARGETID	T90553
T90553	FORMERID	TTDC00281
T90553	UNIPROID	MARK3_HUMAN
T90553	TARGNAME	Microtubule affinity regulating kinase 3 (MARK3)
T90553	GENENAME	MARK3
T90553	TARGTYPE	Clinical trial
T90553	SYNONYMS	cTAK1; Serine/threonine-protein kinase p78; Ser/Thr protein kinase PAR-1; Protein kinase STK10); Protein kinase STK10; Par-1a; MAP/microtubule affinity-regulating kinase 3; EMK2; EMK-2; ELKL motif kinase 2; Cdc25C-associated protein kinase 1; C-TAK1
T90553	FUNCTION	Involved in the specific phosphorylation of microtubule-associated proteins for MAP2 and MAP4. Phosphorylates the microtubule-associated protein MAPT/TAU. Phosphorylates CDC25C on 'Ser-216'. Regulates localization and activity of some histone deacetylases by mediating phosphorylation of HDAC7, promoting subsequent interaction between HDAC7 and 14-3-3 and export from the nucleus. Negatively regulates the Hippo signaling pathway and antagonizes the phosphorylation of LATS1. Cooperates with DLG5 to inhibit the kinase activity of STK3/MST2 toward LATS1. Serine/threonine-protein kinase.
T90553	PDBSTRUC	3FE3; 2QNJ
T90553	BIOCLASS	Kinase
T90553	ECNUMBER	EC 2.7.11.1
T90553	SEQUENCE	MSTRTPLPTVNERDTENHTSHGDGRQEVTSRTSRSGARCRNSIASCADEQPHIGNYRLLKTIGKGNFAKVKLARHILTGREVAIKIIDKTQLNPTSLQKLFREVRIMKILNHPNIVKLFEVIETEKTLYLIMEYASGGEVFDYLVAHGRMKEKEARSKFRQIVSAVQYCHQKRIVHRDLKAENLLLDADMNIKIADFGFSNEFTVGGKLDTFCGSPPYAAPELFQGKKYDGPEVDVWSLGVILYTLVSGSLPFDGQNLKELRERVLRGKYRIPFYMSTDCENLLKRFLVLNPIKRGTLEQIMKDRWINAGHEEDELKPFVEPELDISDQKRIDIMVGMGYSQEEIQESLSKMKYDEITATYLLLGRKSSELDASDSSSSSNLSLAKVRPSSDLNNSTGQSPHHKVQRSVSSSQKQRRYSDHAGPAIPSVVAYPKRSQTSTADSDLKEDGISSRKSSGSAVGGKGIAPASPMLGNASNPNKADIPERKKSSTVPSSNTASGGMTRRNTYVCSERTTADRHSVIQNGKENSTIPDQRTPVASTHSISSAATPDRIRFPRGTASRSTFHGQPRERRTATYNGPPASPSLSHEATPLSQTRSRGSTNLFSKLTSKLTRRNMSFRFIKRLPTEYERNGRYEGSSRNVSAEQKDENKEAKPRSLRFTWSMKTTSSMDPGDMMREIRKVLDANNCDYEQRERFLLFCVHGDGHAENLVQWEMEVCKLPRLSLNGVRFKRISGTSIAFKNIASKIANELKL
T90553	DRUGINFO	D02NNN	CBP-501	Phase 1/2
T90553	DRUGINFO	D03BJF	PMID23099093C17d	Investigative

T58970	TARGETID	T58970
T58970	FORMERID	TTDR00372
T58970	UNIPROID	MK01_HUMAN
T58970	TARGNAME	Extracellular signal-regulated kinase 2 (ERK2)
T58970	GENENAME	MAPK1
T58970	TARGTYPE	Clinical trial
T58970	SYNONYMS	PRKM2; PRKM1; P42-MAPK; P42 Mitogen-activated protein kinase; Mitogen-activated protein kinase 2; Mitogen-activated protein kinase 1; MAPK 2; MAPK 1; MAP kinase isoform p42; MAP kinase 2; MAP kinase 1; ERT1; ERK-2
T58970	FUNCTION	MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signaling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, cytoskeletal rearrangements. The MAPK/ERK cascade plays also a role in initiation and regulation of meiosis, mitosis, and postmitotic functions in differentiated cells by phosphorylating a number of transcription factors. About 160 substrates have already been discovered for ERKs. Many of these substrates are localized in the nucleus, and seem to participate in the regulation of transcription upon stimulation. However, other substrates are found in the cytosol as well as in other cellular organelles, and those are responsible for processes such as translation, mitosis and apoptosis. Moreover, the MAPK/ERK cascade is also involved in the regulation of the endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC); as well as in the fragmentation of the Golgi apparatus during mitosis. The substrates include transcription factors (such as ATF2, BCL6, ELK1, ERF, FOS, HSF4 or SPZ1), cytoskeletal elements (such as CANX, CTTN, GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1), regulators of apoptosis (such as BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG), regulators of translation (such as EIF4EBP1) and a variety of other signaling-related molecules (like ARHGEF2, DCC, FRS2 or GRB10). Protein kinases (such as RAF1, RPS6KA1/RSK1, RPS6KA3/RSK2, RPS6KA2/RSK3, RPS6KA6/RSK4, SYK, MKNK1/MNK1, MKNK2/MNK2, RPS6KA5/MSK1, RPS6KA4/MSK2, MAPKAPK3 or MAPKAPK5) and phosphatases (such as DUSP1, DUSP4, DUSP6 or DUSP16) are other substrates which enable the propagation the MAPK/ERK signal to additional cytosolic and nuclear targets, thereby extending the specificity of the cascade. Mediates phosphorylation of TPR in respons to EGF stimulation. May play a role in the spindle assembly checkpoint. Phosphorylates PML and promotes its interaction with PIN1, leading to PML degradation. Phosphorylates CDK2AP2. Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway.
T58970	PDBSTRUC	6QAW; 6QAQ; 6QAL; 6QAG; 6Q7K
T58970	BIOCLASS	Kinase
T58970	ECNUMBER	EC 2.7.11.24
T58970	SEQUENCE	MAAAAAAGAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNVNKVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRS
T58970	DRUGINFO	D01IED	BVD-523	Phase 2
T58970	DRUGINFO	D1KIY9	HH2710	Phase 1/2
T58970	DRUGINFO	DM1FD5	ASTX029	Phase 1/2
T58970	DRUGINFO	D0TN3Q	LY3214996	Phase 1
T58970	DRUGINFO	D08KNG	VAN-10-4-eluting stent	Phase 1
T58970	DRUGINFO	D0Q4IX	GDC-0994	Phase 1
T58970	DRUGINFO	DBU16T	JSI-1187	Phase 1
T58970	DRUGINFO	D0YK9D	CHIR-99021	Patented
T58970	DRUGINFO	DOJ6D9	COR-D	Preclinical
T58970	DRUGINFO	D09ICC	SB220025	Terminated
T58970	DRUGINFO	D07NEE	AEZS-131	Investigative
T58970	DRUGINFO	D08XVZ	SCH772984	Investigative
T58970	DRUGINFO	D0C5AD	ERK inhibitor III	Investigative
T58970	DRUGINFO	D0Q1AC	(4-Fluoro-phenyl)-(9-methyl-9H-purin-6-yl)-amine	Investigative
T58970	DRUGINFO	D0ZG4G	FR-180204	Investigative
T58970	DRUGINFO	D01WAI	DEBROMOHYMENIALDISINE	Investigative
T58970	DRUGINFO	D05BHG	Phosphonothreonine	Investigative
T58970	DRUGINFO	D0G2VC	KT-5720	Investigative
T58970	DRUGINFO	D0M5FF	Ro31-8220	Investigative
T58970	DRUGINFO	D09XIL	Ro-4396686	Investigative
T58970	DRUGINFO	D0M4SY	BMS-536924	Investigative
T58970	DRUGINFO	D0N6ES	KN-62	Investigative
T58970	DRUGINFO	D0B9BU	CI-1040	Investigative
T58970	DRUGINFO	D0O1YH	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	Investigative
T58970	DRUGINFO	D0A5RM	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	Investigative
T58970	DRUGINFO	D0TO6S	Bisindolylmaleimide-I	Investigative
T58970	DRUGINFO	D0L8HO	RO-316233	Investigative

T65200	TARGETID	T65200
T65200	FORMERID	TTDC00070
T65200	UNIPROID	DHI1_HUMAN
T65200	TARGNAME	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
T65200	GENENAME	HSD11B1
T65200	TARGTYPE	Clinical trial
T65200	SYNONYMS	HSD11B1; 11beta-HSD1A; 11HSD1; 11-beta-hydroxysteroid dehydrogenase 1; 11-beta-HSD1; 11-DH; 11 beta-hydroxysteroid dehydrogenase type 1
T65200	FUNCTION	Catalyzes reversibly the conversion of cortisol to the inactive metabolite cortisone. Catalyzes reversibly the conversion of 7-ketocholesterol to 7-beta-hydroxycholesterol. In intact cells, the reaction runs only in one direction, from 7- ketocholesterol to 7-beta-hydroxycholesterol.
T65200	PDBSTRUC	5QII; 5PGY; 5PGX; 5PGW; 5PGV
T65200	BIOCLASS	Short-chain dehydrogenases reductase
T65200	ECNUMBER	EC 1.1.1.146
T65200	SEQUENCE	MAFMKKYLLPILGLFMAYYYYSANEEFRPEMLQGKKVIVTGASKGIGREMAYHLAKMGAHVVVTARSKETLQKVVSHCLELGAASAHYIAGTMEDMTFAEQFVAQAGKLMGGLDMLILNHITNTSLNLFHDDIHHVRKSMEVNFLSYVVLTVAALPMLKQSNGSIVVVSSLAGKVAYPMVAAYSASKFALDGFFSSIRKEYSVSRVNVSITLCVLGLIDTETAMKAVSGIVHMQAAPKEECALEIIKGGALRQEEVYYDSSLWTTLLIRNPCRKILEFLYSTSYNMDRFINK
T65200	DRUGINFO	D02ENG	BVT.2733	Phase 3
T65200	DRUGINFO	D0T8QB	GLYCYRRHIZIN	Phase 3
T65200	DRUGINFO	D05XLO	INCB13739	Phase 2a
T65200	DRUGINFO	D01THN	JTT-654	Phase 2
T65200	DRUGINFO	D09DIB	RG-4929	Phase 2
T65200	DRUGINFO	D0L4US	BMS-770767	Phase 2
T65200	DRUGINFO	D0OE5S	UE-2343	Phase 2
T65200	DRUGINFO	D0R8IU	AZD-4017	Phase 2
T65200	DRUGINFO	D07LUJ	URSOLIC ACID	Phase 2
T65200	DRUGINFO	DJMK69	Xanamem	Phase 1/2
T65200	DRUGINFO	D08VSQ	BMS-816336	Phase 1
T65200	DRUGINFO	D0B5HF	BI-135585	Phase 1
T65200	DRUGINFO	D0O1ZI	AZD8329	Phase 1
T65200	DRUGINFO	D01MYN	LY-2523199	Discontinued in Phase 2
T65200	DRUGINFO	D07EBU	AMG-221	Discontinued in Phase 1
T65200	DRUGINFO	D07FHW	PF-915275	Discontinued in Phase 1
T65200	DRUGINFO	D0U1BU	HPP-851	Preclinical
T65200	DRUGINFO	D0E0GW	BVT-3498	Terminated
T65200	DRUGINFO	D00DDJ	Adamantan-1-yl-piperazin-1-yl-methanone	Investigative
T65200	DRUGINFO	D00PSW	MERCK-544	Investigative
T65200	DRUGINFO	D00QOL	3-benzyl-1-cyclohexylpyrrolidin-2-one	Investigative
T65200	DRUGINFO	D01CAC	(4-methoxyphenyl)(4-phenylazepan-1-yl)methanone	Investigative
T65200	DRUGINFO	D01EBV	3-epicorosolic acid methyl ester	Investigative
T65200	DRUGINFO	D02KXX	1-(4-chlorophenyl)-2-(phenylsulfonyl)ethanone	Investigative
T65200	DRUGINFO	D02WUU	2-(phenylsulfonyl)-1-p-tolylethanone	Investigative
T65200	DRUGINFO	D03JWH	2-(o-toluidino)-5-ethylthiazol-4(5H)-one	Investigative
T65200	DRUGINFO	D03KRW	1-(4-methoxyphenylsulfonyl)-4-phenylazepan-4-ol	Investigative
T65200	DRUGINFO	D03PVF	2-(4-tosylpiperazin-1-yl)nicotinonitrile	Investigative
T65200	DRUGINFO	D03QYZ	PF-877423	Investigative
T65200	DRUGINFO	D04KAZ	1-phenyl-3-(phenylsulfonyl)propan-1-one	Investigative
T65200	DRUGINFO	D04LGV	1-(4-ethylphenylsulfonyl)-4-phenylazepan-4-ol	Investigative
T65200	DRUGINFO	D04WVV	FIG 1	Investigative
T65200	DRUGINFO	D04ZEP	A-849531	Investigative
T65200	DRUGINFO	D05ADD	1-(4-fluorophenyl)-3-(phenylsulfonyl)propan-1-one	Investigative
T65200	DRUGINFO	D05NSB	Adamantan-2-yl-piperidin-1-yl-methanone	Investigative
T65200	DRUGINFO	D06CPL	1-phenyl-4-(1-phenyl-1H-tetrazol-5-yl)butan-2-one	Investigative
T65200	DRUGINFO	D06GVN	Tormentic acid methyl ester	Investigative
T65200	DRUGINFO	D06RKS	1-(phenylsulfonyl)butan-2-one	Investigative
T65200	DRUGINFO	D06UPR	1-(4-nitrophenyl)-2-(phenylsulfonyl)ethanone	Investigative
T65200	DRUGINFO	D07IRZ	1,1-diphenyl-3-(phenylsulfonyl)propan-2-one	Investigative
T65200	DRUGINFO	D08EDV	N-benzyl-N-(phenylsulfonyl)benzamide	Investigative
T65200	DRUGINFO	D09KDS	Adamantan-1-yl-(4-ethyl-piperazin-1-yl)-methanone	Investigative
T65200	DRUGINFO	D09VPP	11-keto-ursolic acid	Investigative
T65200	DRUGINFO	D0A4ZR	2-(cyclooctylamino)-5,5-diethyloxazol-4(5H)-one	Investigative
T65200	DRUGINFO	D0A5JU	Piperidine-1-carboxylic acid adamantan-2-yl ester	Investigative
T65200	DRUGINFO	D0B6HE	SKI-2852	Investigative
T65200	DRUGINFO	D0BN7E	5-isopropyl-2-(phenylamino)thiazol-4(5H)-one	Investigative
T65200	DRUGINFO	D0D3NV	Adamantan-1-yl-piperidin-1-yl-methanone	Investigative
T65200	DRUGINFO	D0D3PY	1-(3,4-dichlorophenyl)-2-(phenylsulfonyl)ethanone	Investigative
T65200	DRUGINFO	D0DS7W	1-(3-chloropyridin-2-yl)-4-tosylpiperazine	Investigative
T65200	DRUGINFO	D0E3ST	1-(4-ethylpiperazin-1-yl)-2-phenylethanone	Investigative
T65200	DRUGINFO	D0EU9W	1-(3-methoxyphenyl)-2-(phenylsulfonyl)ethanone	Investigative
T65200	DRUGINFO	D0F9RO	Corosolic acid	Investigative
T65200	DRUGINFO	D0I5ND	CNX-010	Investigative
T65200	DRUGINFO	D0J3DW	Piperidine-1-carboxylic acid adamantan-2-ylamide	Investigative
T65200	DRUGINFO	D0J5RQ	3-acetyl-11-keto-ursolic acid	Investigative
T65200	DRUGINFO	D0J6IE	2-(2-chlorophenylamino)-5-methylthiazol-4(5H)-one	Investigative
T65200	DRUGINFO	D0KG3M	1-(4-chlorophenylsulfonyl)-4-phenylazepan-4-ol	Investigative
T65200	DRUGINFO	D0L4VR	Carbenoxolone	Investigative
T65200	DRUGINFO	D0L5KQ	2-(benzylamino)-5,5-diethyloxazol-4(5H)-one	Investigative
T65200	DRUGINFO	D0M3XF	1-(4-tert-butylphenylsulfonyl)-4-methoxyazepane	Investigative
T65200	DRUGINFO	D0M4PP	1-(4-methoxyphenyl)-2-(phenylsulfonyl)ethanone	Investigative
T65200	DRUGINFO	D0O8RL	EQ-1280	Investigative
T65200	DRUGINFO	D0P7RN	1-(4-fluorophenyl)-2-(phenylsulfonyl)ethanone	Investigative
T65200	DRUGINFO	D0Q2MI	1-(3,5-dimethylphenyl)-2-(phenylsulfonyl)ethanone	Investigative
T65200	DRUGINFO	D0Q2TF	1-(4-tert-butylphenylsulfonyl)azepan-4-ol	Investigative
T65200	DRUGINFO	D0R4DK	1-(1-phenyl-1H-tetrazol-5-ylthio)propan-2-one	Investigative
T65200	DRUGINFO	D0T3FW	1-(2-adamantyl)-3-benzylpyrrolidin-2-one	Investigative
T65200	DRUGINFO	D0T9NX	1-(3-methylpyridin-2-yl)-4-tosylpiperazine	Investigative
T65200	DRUGINFO	D0TF9R	2-(o-toluidino)-5-isopropylthiazol-4(5H)-one	Investigative
T65200	DRUGINFO	D0UJ2C	2-(phenylsulfonyl)-1-(thiophen-3-yl)ethanone	Investigative
T65200	DRUGINFO	D0UQ6U	Abietic acid	Investigative
T65200	DRUGINFO	D0V5TC	1-(3-nitropyridin-2-yl)-4-tosylpiperazine	Investigative
T65200	DRUGINFO	D0VC2M	Adamantan-1-yl-pyrrolidin-1-yl-methanone	Investigative
T65200	DRUGINFO	D0W9WG	5,5-diethyl-2-(phenethylamino)oxazol-4(5H)-one	Investigative
T65200	DRUGINFO	D0Y9XK	1-phenyl-2-(1-phenyl-1H-tetrazol-5-yloxy)ethanone	Investigative
T65200	DRUGINFO	D0ZG3Q	2-(adamantan-1-ylamino)-5,5-diethyl-oxazol-4-one	Investigative
T65200	DRUGINFO	D02XEX	3-acetyl-11-keto-beta-boswellic acid	Investigative
T65200	DRUGINFO	D09VYW	11-keto-beta-boswellicacid	Investigative
T65200	DRUGINFO	D0B4VE	Flavanone	Investigative
T65200	DRUGINFO	D03TNT	(11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE	Investigative
T65200	DRUGINFO	D0U8IF	[(125)I] RB129	Investigative
T65200	DRUGINFO	D07KZA	2-(N-Morpholino)-Ethanesulfonic Acid	Investigative
T65200	DRUGINFO	D0J2FY	2'-Monophosphoadenosine 5'-Diphosphoribose	Investigative

T06046	TARGETID	T06046
T06046	FORMERID	TTDC00097
T06046	UNIPROID	NOS3_HUMAN
T06046	TARGNAME	Nitric-oxide synthase endothelial (NOS3)
T06046	GENENAME	NOS3
T06046	TARGTYPE	Clinical trial
T06046	SYNONYMS	Nitric oxide synthase, endothelial; NOSIII; NOS,type III; NOS type III; Endothelial nitric oxide synthase; Endothelial NOS; ENOS; EC-NOS; Constitutive NOS; CNOS
T06046	FUNCTION	NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets. Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway.
T06046	PDBSTRUC	6CIF; 6CIE; 6AV7; 6AV6; 5XOF
T06046	BIOCLASS	Paired donor oxygen oxidoreductase
T06046	ECNUMBER	EC 1.14.13.39
T06046	SEQUENCE	MGNLKSVAQEPGPPCGLGLGLGLGLCGKQGPATPAPEPSRAPASLLPPAPEHSPPSSPLTQPPEGPKFPRVKNWEVGSITYDTLSAQAQQDGPCTPRRCLGSLVFPRKLQGRPSPGPPAPEQLLSQARDFINQYYSSIKRSGSQAHEQRLQEVEAEVAATGTYQLRESELVFGAKQAWRNAPRCVGRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGDFRIWNSQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWTPGNGRFDVLPLLLQAPDDPPELFLLPPELVLEVPLEHPTLEWFAALGLRWYALPAVSNMLLEIGGLEFPAAPFSGWYMSTEIGTRNLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLHSYQLAKVTIVDHHAATASFMKHLENEQKARGGCPADWAWIVPPISGSLTPVFHQEMVNYFLSPAFRYQPDPWKGSAAKGTGITRKKTFKEVANAVKISASLMGTVMAKRVKATILYGSETGRAQSYAQQLGRLFRKAFDPRVLCMDEYDVVSLEHETLVLVVTSTFGNGDPPENGESFAAALMEMSGPYNSSPRPEQHKSYKIRFNSISCSDPLVSSWRRKRKESSNTDSAGALGTLRFCVFGLGSRAYPHFCAFARAVDTRLEELGGERLLQLGQGDELCGQEEAFRGWAQAAFQAACETFCVGEDAKAAARDIFSPKRSWKRQRYRLSAQAEGLQLLPGLIHVHRRKMFQATIRSVENLQSSKSTRATILVRLDTGGQEGLQYQPGDHIGVCPPNRPGLVEALLSRVEDPPAPTEPVAVEQLEKGSPGGPPPGWVRDPRLPPCTLRQALTFFLDITSPPSPQLLRLLSTLAEEPREQQELEALSQDPRRYEEWKWFRCPTLLEVLEQFPSVALPAPLLLTQLPLLQPRYYSVSSAPSTHPGEIHLTVAVLAYRTQDGLGPLHYGVCSTWLSQLKPGDPVPCFIRGAPSFRLPPDPSLPCILVGPGTGIAPFRGFWQERLHDIESKGLQPTPMTLVFGCRCSQLDHLYRDEVQNAQQRGVFGRVLTAFSREPDNPKTYVQDILRTELAAEVHRVLCLERGHMFVCGDVTMATNVLQTVQRILATEGDMELDEAGDVIGVLRDQQRYHEDIFGLTLRTQEVTSRIRTQSFSLQERQLRGAVPWAFDPPGSDTNSP
T06046	DRUGINFO	D06OQI	Tilarginine acetate	Phase 3
T06046	DRUGINFO	D0D3AI	L-NAME	Phase 2
T06046	DRUGINFO	D0J7EH	ACCLAIM	Phase 2
T06046	DRUGINFO	D0N2JI	VAS-203	Phase 2
T06046	DRUGINFO	D0X1RQ	MTR105	Phase 2
T06046	DRUGINFO	D0H3GK	Autologous cell based gene therapy	Phase 1
T06046	DRUGINFO	D0Y7VJ	L-NIL	Terminated
T06046	DRUGINFO	D01FMS	AP-Cav	Investigative
T06046	DRUGINFO	D02RNH	Se-Ethyl-Isoselenourea	Investigative
T06046	DRUGINFO	D03EBE	6s-5,6,7,8-Tetrahydrobiopterin	Investigative
T06046	DRUGINFO	D03RGI	1,2,4-Triazole-Carboxamidine	Investigative
T06046	DRUGINFO	D06PFL	4-Methyl-3,6-dihydro-1H-pyridin-(2Z)-ylideneamine	Investigative
T06046	DRUGINFO	D08DNK	N-(Chlorophenyl)-N'-Hydroxyguanidine	Investigative
T06046	DRUGINFO	D0DI7W	4-Methyl-5,6-dihydro-1H-pyridin-(2Z)-ylideneamine	Investigative
T06046	DRUGINFO	D0F8VS	L-Homoarginine	Investigative
T06046	DRUGINFO	D0FK0A	2,4-Diamino-6-Phenyl-5,6,7,8,-Tetrahydropteridine	Investigative
T06046	DRUGINFO	D0J1LO	S-Isopropyl-Isothiourea	Investigative
T06046	DRUGINFO	D0N5LD	7-Nitroindazole-2-Carboxamidine	Investigative
T06046	DRUGINFO	D0P6IL	5,6-Cyclic-Tetrahydropteridine	Investigative
T06046	DRUGINFO	D0V9FZ	L-2-Amino-4-(Guanidinooxy)Butyric Acid	Investigative
T06046	DRUGINFO	D0Y8DZ	4-Ethyl-5,6-dihydro-1H-pyridin-(2Z)-ylideneamine	Investigative
T06046	DRUGINFO	D0Z3JI	N1,N14-Bis((S-Methyl)Isothioureido)Tetradecane	Investigative
T06046	DRUGINFO	D00TDJ	1-(2-amino-benzothiazol-5-yl)-2-ethyl-isothiourea	Investigative
T06046	DRUGINFO	D01TDG	S-Ethyl-N-Phenyl-Isothiourea	Investigative
T06046	DRUGINFO	D02DQQ	N,N-dimethylarginine	Investigative
T06046	DRUGINFO	D06YEV	Hydroxydimethylarsine Oxide	Investigative
T06046	DRUGINFO	D0D2WC	5-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T06046	DRUGINFO	D0GC1Y	Nitroarginine	Investigative
T06046	DRUGINFO	D0I7VD	Ethylisothiourea	Investigative
T06046	DRUGINFO	D0VB2W	5-Nitroindazole	Investigative
T06046	DRUGINFO	D0X2XQ	1-(2-amino-benzothiazol-6-yl)-2-ethyl-isothiourea	Investigative
T06046	DRUGINFO	D0Y0FS	6-Nitroindazole	Investigative
T06046	DRUGINFO	D00EVC	6-isobutyl-4-methylpyridin-2-amine	Investigative
T06046	DRUGINFO	D01EHS	7-Methyl-[1,4]thiazepan-(5E)-ylideneamine	Investigative
T06046	DRUGINFO	D01ILO	2-Aminothiazoline	Investigative
T06046	DRUGINFO	D01XOR	(5-Imino-[1,4]thiazepan-3-yl)-methanol	Investigative
T06046	DRUGINFO	D02ELA	L-NIO	Investigative
T06046	DRUGINFO	D02EOF	4-Ethyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T06046	DRUGINFO	D02TMX	4-methyl-6-propylpyridin-2-amine	Investigative
T06046	DRUGINFO	D02TYS	[1,4]Thiazepan-(3E)-ylideneamine	Investigative
T06046	DRUGINFO	D03CAJ	7-(2-Nitro-ethyl)-azepan-(2Z)-ylideneamine	Investigative
T06046	DRUGINFO	D03EHB	3-Bromo-1H-indazole-7-carbonitrile	Investigative
T06046	DRUGINFO	D03FJM	2-Amino-5-(N-nitro-guanidino)-pentanoic acid	Investigative
T06046	DRUGINFO	D03JXX	4,5-Dimethyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T06046	DRUGINFO	D03WOZ	7-nitro-1H-indazole	Investigative
T06046	DRUGINFO	D04JZV	(6r,1'r,2's)-5,6,7,8 Tetrahydrobiopterin	Investigative
T06046	DRUGINFO	D04PBI	N5-(1-iminopropyl)-L-ornithine	Investigative
T06046	DRUGINFO	D06VYU	(S)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine	Investigative
T06046	DRUGINFO	D07VFC	6-(2-Fluoropropyl)-4-methylpyridin-2-amine	Investigative
T06046	DRUGINFO	D08ALG	Azepan-(2Z)-ylideneamine	Investigative
T06046	DRUGINFO	D08FXW	6-(3-Fluoropropyl)-4-methylpyridin-2-amine	Investigative
T06046	DRUGINFO	D08TGY	S-(Dimethylarsenic)Cysteine	Investigative
T06046	DRUGINFO	D08WEI	3-Methyl-[1,4]thiazepan-(5E)-ylideneamine	Investigative
T06046	DRUGINFO	D09NRX	3-Ethyl-[1,4]thiazepan-(5E)-ylideneamine	Investigative
T06046	DRUGINFO	D0AO5D	1400W	Investigative
T06046	DRUGINFO	D0C1OB	Pyrrolidin-(2Z)-ylideneamine	Investigative
T06046	DRUGINFO	D0D0TO	Piperidin-(2E)-ylideneamine	Investigative
T06046	DRUGINFO	D0D7PK	4-Methyl-piperidin-(2E)-ylideneamine	Investigative
T06046	DRUGINFO	D0D9LT	5-Methyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T06046	DRUGINFO	D0DD9E	N-omega-allyl-L-arginine	Investigative
T06046	DRUGINFO	D0E0QG	THIOCITRULLINE	Investigative
T06046	DRUGINFO	D0G4ZL	3,4-Dimethyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T06046	DRUGINFO	D0GL9I	N-Omega-Hydroxy-L-Arginine	Investigative
T06046	DRUGINFO	D0GX7G	N5-(1-iminobutyl)-L-ornithine	Investigative
T06046	DRUGINFO	D0I3ZP	[1,4]Oxazepan-(3E)-ylideneamine	Investigative
T06046	DRUGINFO	D0J7NS	4-Methyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T06046	DRUGINFO	D0K4YY	(5S,6R)-[Octahydro-quinolin-(2E)-ylidene]amine	Investigative
T06046	DRUGINFO	D0L4RU	N-omega-propargyl-L-arginine	Investigative
T06046	DRUGINFO	D0L5KY	N5-(1-iminobut-3-enyl)-L-ornithine	Investigative
T06046	DRUGINFO	D0LE6N	Hexahydro-cyclopenta[c]pyrrol-(1Z)-ylideneamine	Investigative
T06046	DRUGINFO	D0M4BM	[1,3]Oxazinan-(2E)-ylideneamine	Investigative
T06046	DRUGINFO	D0N3HU	[1,4]Thiazepan-(5E)-ylideneamine	Investigative
T06046	DRUGINFO	D0N8EU	(S)-2-Amino-5-(N-methyl-guanidino)-pentanoic acid	Investigative
T06046	DRUGINFO	D0O3XZ	2-amino-4-methylpyridine	Investigative
T06046	DRUGINFO	D0O9II	[1,3]Thiazinan-(2E)-ylideneamine	Investigative
T06046	DRUGINFO	D0R9KX	(5S,6S)-[Octahydro-quinolin-(2E)-ylidene]amine	Investigative
T06046	DRUGINFO	D0SB5H	2-Methyl-[1,4]thiazepan-(5E)-ylideneamine	Investigative
T06046	DRUGINFO	D0T3QN	(S)-6-Amino-2-(2-imino-ethylamino)-hexanoic acid	Investigative
T06046	DRUGINFO	D0V5HI	N-(5-Amino-6-oxo-heptyl)-acetamidine	Investigative
T06046	DRUGINFO	D0X5QJ	3-bromo-7-nitro-1H-indazole	Investigative
T06046	DRUGINFO	D0X6MB	3-Methyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T06046	DRUGINFO	D0X6QY	4-Ethyl-5-methyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T06046	DRUGINFO	D0XJ1C	5-Ethyl-4-methyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T06046	DRUGINFO	D09TVP	Cacodylate Ion	Investigative
T06046	DRUGINFO	D0W7LK	2-Propanol, Isopropanol	Investigative
T06046	DRUGINFO	D06GOK	2-Methyl-2,4-Pentanediol	Investigative
T06046	DRUGINFO	D0UU1I	Heme	Investigative
T06046	DRUGINFO	D0F2ME	Acetate Ion	Investigative

T16117	TARGETID	T16117
T16117	FORMERID	TTDC00063
T16117	UNIPROID	NOS1_HUMAN
T16117	TARGNAME	Nitric-oxide synthase brain (NOS1)
T16117	GENENAME	NOS1
T16117	TARGTYPE	Clinical trial
T16117	SYNONYMS	Peptidyl-cysteine S-nitrosylase NOS1; Nitric oxide synthase, brain; Neuronal NOS; NOS, type I; NOS type I; NNOS; NC-NOS; N-NOS; BNOS
T16117	FUNCTION	In the brain and peripheral nervous system, NO displays many properties of a neurotransmitter. Probably has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such SRR. Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body.
T16117	PDBSTRUC	6NHC; 6NHB; 6NGI; 6NGH; 6NGF
T16117	BIOCLASS	Paired donor oxygen oxidoreductase
T16117	ECNUMBER	EC 1.14.13.39
T16117	SEQUENCE	MEDHMFGVQQIQPNVISVRLFKRKVGGLGFLVKERVSKPPVIISDLIRGGAAEQSGLIQAGDIILAVNGRPLVDLSYDSALEVLRGIASETHVVLILRGPEGFTTHLETTFTGDGTPKTIRVTQPLGPPTKAVDLSHQPPAGKEQPLAVDGASGPGNGPQHAYDDGQEAGSLPHANGLAPRPPGQDPAKKATRVSLQGRGENNELLKEIEPVLSLLTSGSRGVKGGAPAKAEMKDMGIQVDRDLDGKSHKPLPLGVENDRVFNDLWGKGNVPVVLNNPYSEKEQPPTSGKQSPTKNGSPSKCPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVRTKGQLFPLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRCVGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVWNSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQIPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGVRDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAVLYSFQSDKVTIVDHHSATESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPSFEYQPDPWNTHVWKGTNGTPTKRRAIGFKKLAEAVKFSAKLMGQAMAKRVKATILYATETGKSQAYAKTLCEIFKHAFDAKVMSMEEYDIVHLEHETLVLVVTSTFGNGDPPENGEKFGCALMEMRHPNSVQEERKSYKVRFNSVSSYSDSQKSSGDGPDLRDNFESAGPLANVRFSVFGLGSRAYPHFCAFGHAVDTLLEELGGERILKMREGDELCGQEEAFRTWAKKVFKAACDVFCVGDDVNIEKANNSLISNDRSWKRNKFRLTFVAEAPELTQGLSNVHKKRVSAARLLSRQNLQSPKSSRSTIFVRLHTNGSQELQYQPGDHLGVFPGNHEDLVNALIERLEDAPPVNQMVKVELLEERNTALGVISNWTDELRLPPCTIFQAFKYYLDITTPPTPLQLQQFASLATSEKEKQRLLVLSKGLQEYEEWKWGKNPTIVEVLEEFPSIQMPATLLLTQLSLLQPRYYSISSSPDMYPDEVHLTVAIVSYRTRDGEGPIHHGVCSSWLNRIQADELVPCFVRGAPSFHLPRNPQVPCILVGPGTGIAPFRSFWQQRQFDIQHKGMNPCPMVLVFGCRQSKIDHIYREETLQAKNKGVFRELYTAYSREPDKPKKYVQDILQEQLAESVYRALKEQGGHIYVCGDVTMAADVLKAIQRIMTQQGKLSAEDAGVFISRMRDDNRYHEDIFGVTLRTYEVTNRLRSESIAFIEESKKDTDEVFSS
T16117	DRUGINFO	D0W9IT	NXN-462	Phase 2
T16117	DRUGINFO	D0O2XJ	NXN-188	Phase 2
T16117	DRUGINFO	D0Y7VJ	L-NIL	Terminated
T16117	DRUGINFO	D01KAH	1-[(3-Methoxybenzyl)amino]ethaniminium chloride	Investigative
T16117	DRUGINFO	D01RGM	S-Ethyl-N-[4-(Trifluoromethyl)Phenyl]Isothiourea	Investigative
T16117	DRUGINFO	D02OAB	5-bromo-1H-indazole	Investigative
T16117	DRUGINFO	D03UTI	4-iodo-1H-indazole	Investigative
T16117	DRUGINFO	D04EIE	N5-(1-iminopent-3-enyl)-L-ornithine	Investigative
T16117	DRUGINFO	D04KUP	6-bromo-1H-indazole	Investigative
T16117	DRUGINFO	D04QFO	Hexahydro-cyclopenta[b]pyrrol-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D05BGM	Eusynstyelamide C	Investigative
T16117	DRUGINFO	D06BCG	EUSYNSTYELAMIDE B	Investigative
T16117	DRUGINFO	D07GEN	4-chloro-1H-indazole	Investigative
T16117	DRUGINFO	D07LMI	1-Benzyl-2-methyl-1H-imidazole	Investigative
T16117	DRUGINFO	D07OVY	5-iodo-1H-indazole	Investigative
T16117	DRUGINFO	D07PYV	2-aminopyridine	Investigative
T16117	DRUGINFO	D08JSR	Tetrahydro-pyrimidin-2-ylideneamine	Investigative
T16117	DRUGINFO	D08WHV	5-N-Allyl-Arginine	Investigative
T16117	DRUGINFO	D09BPC	N5-(1-Imino-3-Butenyl)-L-Ornithine	Investigative
T16117	DRUGINFO	D0A6RU	7-chloro-1H-indazole	Investigative
T16117	DRUGINFO	D0D4US	4-bromo-1H-indazole	Investigative
T16117	DRUGINFO	D0IX0N	N*1*-(5-Methyl-2-nitro-phenyl)-butane-1,4-diamine	Investigative
T16117	DRUGINFO	D0LL3D	7-bromo-1H-indazole	Investigative
T16117	DRUGINFO	D0P5OF	7-Methoxy-1H-indazole	Investigative
T16117	DRUGINFO	D0Q7NZ	1-(Benzhydrylamino)ethaniminium bromide	Investigative
T16117	DRUGINFO	D0Q7VU	N-Butyl-N'-Hydroxyguanidine	Investigative
T16117	DRUGINFO	D0Q8EX	N-Isopropyl-N'-Hydroxyguanidine	Investigative
T16117	DRUGINFO	D0T9ZQ	5-chloro-1H-indazole	Investigative
T16117	DRUGINFO	D0VN7G	Hexahydro-pyrrolizin-(3E)-ylideneamine	Investigative
T16117	DRUGINFO	D0W0OJ	6-chloro-1H-indazole	Investigative
T16117	DRUGINFO	D0W9UV	2-amino-4,6-dimethylpyridine	Investigative
T16117	DRUGINFO	D0Z3ZZ	(+/-)-2-Methyl-1-(1-phenylethyl)-1H-imidazole	Investigative
T16117	DRUGINFO	D00KOE	4-Isopropyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D00TDJ	1-(2-amino-benzothiazol-5-yl)-2-ethyl-isothiourea	Investigative
T16117	DRUGINFO	D01DFX	4-[(2-Methyl-1H-imidazol-1-yl)methyl]pyridine	Investigative
T16117	DRUGINFO	D01MEA	3-Butyl-[1,4]thiazepan-(5E)-ylideneamine	Investigative
T16117	DRUGINFO	D01TDG	S-Ethyl-N-Phenyl-Isothiourea	Investigative
T16117	DRUGINFO	D01YNT	((E)-7-But-2-enyl)-azepan-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D02FHX	4-Ethyl-oxazolidin-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D02MFQ	Azonan-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D03ODQ	[1,4]Oxazepan-(5E)-ylideneamine	Investigative
T16117	DRUGINFO	D03QMU	7-Butyl-azepan-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D03QSQ	5-Ethyl-4-propyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D03YZT	5-Ethyl-oxazolidin-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D05APC	4-Methyl-5-propyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D05LPK	5-Methyl-oxazolidin-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D05VAB	AR-C102222	Investigative
T16117	DRUGINFO	D05ZYA	5-Bromomethyl-oxazolidin-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D06EXH	(4S,5S)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D07INO	Octahydro-isoindol-(1Z)-ylideneamine	Investigative
T16117	DRUGINFO	D07MFH	3-(2-Amino-ethyl)-5-imino-[1,4]oxazepane	Investigative
T16117	DRUGINFO	D07OQX	4-Butyl-thiazolidin-(2E)-ylideneamine	Investigative
T16117	DRUGINFO	D08CMQ	3-Isobutyl-[1,4]thiazepan-(5E)-ylideneamine	Investigative
T16117	DRUGINFO	D08DQZ	4-Methyl-oxazolidin-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D08PZX	(R)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine	Investigative
T16117	DRUGINFO	D08UWE	(4S,5R)-4,5-Dimethyl-oxazolidin-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D09BKV	3-Propyl-[1,4]thiazepan-(5E)-ylideneamine	Investigative
T16117	DRUGINFO	D0C3CS	4,5,6,7-tetrafluoro-3-methyl-1H-indazole	Investigative
T16117	DRUGINFO	D0D2WC	5-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D0GC1Y	Nitroarginine	Investigative
T16117	DRUGINFO	D0IR4Y	2-(2-Amino-ethyl)-7-imino-azepane	Investigative
T16117	DRUGINFO	D0J2RI	4-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D0K1CM	Azocan-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D0K4SV	3,4-Dihydro-1H-quinolin-(2E)-ylideneamine	Investigative
T16117	DRUGINFO	D0LB9U	3-(2-Nitro-ethyl)-[1,4]oxazepan-(5Z)-ylideneamine	Investigative
T16117	DRUGINFO	D0O2KO	N-Omega-Propyl-L-Arginine	Investigative
T16117	DRUGINFO	D0OW8M	AR-C133057XX	Investigative
T16117	DRUGINFO	D0UP8X	(4S,5R)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D0X2XQ	1-(2-amino-benzothiazol-6-yl)-2-ethyl-isothiourea	Investigative
T16117	DRUGINFO	D00EVC	6-isobutyl-4-methylpyridin-2-amine	Investigative
T16117	DRUGINFO	D01EHS	7-Methyl-[1,4]thiazepan-(5E)-ylideneamine	Investigative
T16117	DRUGINFO	D01ILO	2-Aminothiazoline	Investigative
T16117	DRUGINFO	D01XOR	(5-Imino-[1,4]thiazepan-3-yl)-methanol	Investigative
T16117	DRUGINFO	D02ELA	L-NIO	Investigative
T16117	DRUGINFO	D02EOF	4-Ethyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D02TMX	4-methyl-6-propylpyridin-2-amine	Investigative
T16117	DRUGINFO	D02TYS	[1,4]Thiazepan-(3E)-ylideneamine	Investigative
T16117	DRUGINFO	D03CAJ	7-(2-Nitro-ethyl)-azepan-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D03EHB	3-Bromo-1H-indazole-7-carbonitrile	Investigative
T16117	DRUGINFO	D03FJM	2-Amino-5-(N-nitro-guanidino)-pentanoic acid	Investigative
T16117	DRUGINFO	D03JXX	4,5-Dimethyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D03WOZ	7-nitro-1H-indazole	Investigative
T16117	DRUGINFO	D04JZV	(6r,1'r,2's)-5,6,7,8 Tetrahydrobiopterin	Investigative
T16117	DRUGINFO	D04PBI	N5-(1-iminopropyl)-L-ornithine	Investigative
T16117	DRUGINFO	D06VYU	(S)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine	Investigative
T16117	DRUGINFO	D07VFC	6-(2-Fluoropropyl)-4-methylpyridin-2-amine	Investigative
T16117	DRUGINFO	D08ALG	Azepan-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D08FXW	6-(3-Fluoropropyl)-4-methylpyridin-2-amine	Investigative
T16117	DRUGINFO	D08WEI	3-Methyl-[1,4]thiazepan-(5E)-ylideneamine	Investigative
T16117	DRUGINFO	D09NRX	3-Ethyl-[1,4]thiazepan-(5E)-ylideneamine	Investigative
T16117	DRUGINFO	D0AO5D	1400W	Investigative
T16117	DRUGINFO	D0C1OB	Pyrrolidin-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D0D0TO	Piperidin-(2E)-ylideneamine	Investigative
T16117	DRUGINFO	D0D7PK	4-Methyl-piperidin-(2E)-ylideneamine	Investigative
T16117	DRUGINFO	D0D9LT	5-Methyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D0DD9E	N-omega-allyl-L-arginine	Investigative
T16117	DRUGINFO	D0E0QG	THIOCITRULLINE	Investigative
T16117	DRUGINFO	D0G4ZL	3,4-Dimethyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D0GL9I	N-Omega-Hydroxy-L-Arginine	Investigative
T16117	DRUGINFO	D0GX7G	N5-(1-iminobutyl)-L-ornithine	Investigative
T16117	DRUGINFO	D0I3ZP	[1,4]Oxazepan-(3E)-ylideneamine	Investigative
T16117	DRUGINFO	D0J7NS	4-Methyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D0K4YY	(5S,6R)-[Octahydro-quinolin-(2E)-ylidene]amine	Investigative
T16117	DRUGINFO	D0L4RU	N-omega-propargyl-L-arginine	Investigative
T16117	DRUGINFO	D0L5KY	N5-(1-iminobut-3-enyl)-L-ornithine	Investigative
T16117	DRUGINFO	D0LE6N	Hexahydro-cyclopenta[c]pyrrol-(1Z)-ylideneamine	Investigative
T16117	DRUGINFO	D0M4BM	[1,3]Oxazinan-(2E)-ylideneamine	Investigative
T16117	DRUGINFO	D0N3HU	[1,4]Thiazepan-(5E)-ylideneamine	Investigative
T16117	DRUGINFO	D0N8EU	(S)-2-Amino-5-(N-methyl-guanidino)-pentanoic acid	Investigative
T16117	DRUGINFO	D0O3XZ	2-amino-4-methylpyridine	Investigative
T16117	DRUGINFO	D0O9II	[1,3]Thiazinan-(2E)-ylideneamine	Investigative
T16117	DRUGINFO	D0R9KX	(5S,6S)-[Octahydro-quinolin-(2E)-ylidene]amine	Investigative
T16117	DRUGINFO	D0SB5H	2-Methyl-[1,4]thiazepan-(5E)-ylideneamine	Investigative
T16117	DRUGINFO	D0T3QN	(S)-6-Amino-2-(2-imino-ethylamino)-hexanoic acid	Investigative
T16117	DRUGINFO	D0V5HI	N-(5-Amino-6-oxo-heptyl)-acetamidine	Investigative
T16117	DRUGINFO	D0X5QJ	3-bromo-7-nitro-1H-indazole	Investigative
T16117	DRUGINFO	D0X6MB	3-Methyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D0X6QY	4-Ethyl-5-methyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D0XJ1C	5-Ethyl-4-methyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T16117	DRUGINFO	D06EWG	Formic Acid	Investigative
T16117	DRUGINFO	D0J2FY	2'-Monophosphoadenosine 5'-Diphosphoribose	Investigative
T16117	DRUGINFO	D0UU1I	Heme	Investigative
T16117	DRUGINFO	D00IMW	Flavin-Adenine Dinucleotide	Investigative
T16117	DRUGINFO	D0F2ME	Acetate Ion	Investigative
T16117	DRUGINFO	D07LUR	Alpha-D-Mannose	Investigative

T69991	TARGETID	T69991
T69991	FORMERID	TTDC00256
T69991	UNIPROID	WEE1_HUMAN
T69991	TARGNAME	Wee1-like protein kinase (WEE1)
T69991	GENENAME	WEE1
T69991	TARGTYPE	Clinical trial
T69991	SYNONYMS	Wee1A kinase; WEE1hu
T69991	FUNCTION	Specifically phosphorylates and inactivates cyclin B1-complexed CDK1 reaching a maximum during G2 phase and a minimum as cells enter M phase. Phosphorylation of cyclin B1-CDK1 occurs exclusively on 'Tyr-15' and phosphorylation of monomeric CDK1 does not occur. Its activity increases during S and G2 phases and decreases at M phase when it is hyperphosphorylated. A correlated decrease in protein level occurs at M/G1 phase, probably due to its degradation. Acts as a negative regulator of entry into mitosis (G2 to M transition) by protecting the nucleus from cytoplasmically activated cyclin B1-complexed CDK1 before the onset of mitosis by mediating phosphorylation of CDK1 on 'Tyr-15'.
T69991	PDBSTRUC	5VDA; 5VD9; 5VD8; 5VD7; 5VD5
T69991	BIOCLASS	Kinase
T69991	ECNUMBER	EC 2.7.10.2
T69991	SEQUENCE	MSFLSRQQPPPPRRAGAACTLRQKLIFSPCSDCEEEEEEEEEEGSGHSTGEDSAFQEPDSPLPPARSPTEPGPERRRSPGPAPGSPGELEEDLLLPGACPGADEAGGGAEGDSWEEEGFGSSSPVKSPAAPYFLGSSFSPVRCGGPGDASPRGCGARRAGEGRRSPRPDHPGTPPHKTFRKLRLFDTPHTPKSLLSKARGIDSSSVKLRGSSLFMDTEKSGKREFDVRQTPQVNINPFTPDSLLLHSSGQCRRRKRTYWNDSCGEDMEASDYELEDETRPAKRITITESNMKSRYTTEFHELEKIGSGEFGSVFKCVKRLDGCIYAIKRSKKPLAGSVDEQNALREVYAHAVLGQHSHVVRYFSAWAEDDHMLIQNEYCNGGSLADAISENYRIMSYFKEAELKDLLLQVGRGLRYIHSMSLVHMDIKPSNIFISRTSIPNAASEEGDEDDWASNKVMFKIGDLGHVTRISSPQVEEGDSRFLANEVLQENYTHLPKADIFALALTVVCAAGAEPLPRNGDQWHEIRQGRLPRIPQVLSQEFTELLKVMIHPDPERRPSAMALVKHSVLLSASRKSAEQLRIELNAEKFKNSLLQKELKKAQMAKAAAEERALFTDRMATRSTTQSNRTSRLIGKKMNRSVSLTIY
T69991	DRUGINFO	D02KKA	MK-1775	Phase 2
T69991	DRUGINFO	DRQN21	ZN-c3	Phase 2
T69991	DRUGINFO	D0Y3PH	9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione	Investigative

T28330	TARGETID	T28330
T28330	FORMERID	TTDC00082
T28330	UNIPROID	CCKAR_HUMAN
T28330	TARGNAME	Cholecystokinin receptor type A (CCKAR)
T28330	GENENAME	CCKAR
T28330	TARGTYPE	Clinical trial
T28330	SYNONYMS	CCKAR; CCK-AR; CCK-A receptor
T28330	FUNCTION	Receptor forcholecystokinin. Mediates pancreatic growth and enzyme secretion, smooth muscle contraction of the gall bladder and stomach. Has a 1000-fold higher affinity for CCK rather than for gastrin. It modulates feeding and dopamine-induced behavior in the central and peripheral nervous system. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
T28330	PDBSTRUC	1PB2; 1HZN; 1D6G
T28330	BIOCLASS	GPCR rhodopsin
T28330	SEQUENCE	MDVVDSLLVNGSNITPPCELGLENETLFCLDQPRPSKEWQPAVQILLYSLIFLLSVLGNTLVITVLIRNKRMRTVTNIFLLSLAVSDLMLCLFCMPFNLIPNLLKDFIFGSAVCKTTTYFMGTSVSVSTFNLVAISLERYGAICKPLQSRVWQTKSHALKVIAATWCLSFTIMTPYPIYSNLVPFTKNNNQTANMCRFLLPNDVMQQSWHTFLLLILFLIPGIVMMVAYGLISLELYQGIKFEASQKKSAKERKPSTTSSGKYEDSDGCYLQKTRPPRKLELRQLSTGSSSRANRIRSNSSAANLMAKKRVIRMLIVIVVLFFLCWMPIFSANAWRAYDTASAERRLSGTPISFILLLSYTSSCVNPIIYCFMNKRFRLGFMATFPCCPNPGPPGARGEVGEEEEGGTTGASLSRFSYSHMSASVPPQ
T28330	DRUGINFO	D04HQT	proglumide	Phase 2
T28330	DRUGINFO	D0TL7L	Dexloxiglumide	Phase 2
T28330	DRUGINFO	D01ZXW	Lintitript	Discontinued in Phase 2
T28330	DRUGINFO	D03XDX	Tarazepide	Discontinued in Phase 2
T28330	DRUGINFO	D0F6CT	GI 181771	Discontinued in Phase 2
T28330	DRUGINFO	D0RL4M	Pranazepide	Discontinued in Phase 2
T28330	DRUGINFO	D0W9ZY	CE-326597	Discontinued in Phase 2
T28330	DRUGINFO	D03JIH	SSR-125180	Discontinued in Phase 1
T28330	DRUGINFO	D05HSI	T-0632	Discontinued in Phase 1
T28330	DRUGINFO	D0T3EV	SR-146131	Discontinued in Phase 1
T28330	DRUGINFO	D0T7CM	UCL-2000; butabindide	Discontinued in Phase 1
T28330	DRUGINFO	D02PSZ	A-74498	Preclinical
T28330	DRUGINFO	D08GNX	FPL-14294	Preclinical
T28330	DRUGINFO	D09IJP	A-71378	Preclinical
T28330	DRUGINFO	D0A1VL	AR-R-1589	Preclinical
T28330	DRUGINFO	D06DPS	PD-170292	Preclinical
T28330	DRUGINFO	D0W4OZ	GG-8573	Preclinical
T28330	DRUGINFO	D05LCX	A-70276	Terminated
T28330	DRUGINFO	D06UXL	GI-248573	Terminated
T28330	DRUGINFO	D0C8ZD	A-71623	Terminated
T28330	DRUGINFO	D0K5UH	CR-1795	Terminated
T28330	DRUGINFO	D0R3OR	SR-27950	Terminated
T28330	DRUGINFO	D0Y7WL	Lorglumide	Terminated
T28330	DRUGINFO	D01ZDR	FR-208419	Terminated
T28330	DRUGINFO	D05HGU	IQM-95333	Terminated
T28330	DRUGINFO	D0I3BT	PD-135666	Terminated
T28330	DRUGINFO	D0W8TS	SNF-9007	Terminated
T28330	DRUGINFO	D00ODL	IQM-97423	Investigative
T28330	DRUGINFO	D00OFV	Asperlicin	Investigative
T28330	DRUGINFO	D00UKA	Boc-D-Glu-Tyr(SO3H)-Nle-D-Nle-Trp-Nle-Asp-Phe-NH2	Investigative
T28330	DRUGINFO	D01FHK	Boc-Tyr(SO3H)-Nle-Gly-Trp-Nle-Asp-Phe-NH2	Investigative
T28330	DRUGINFO	D03EHS	Boc-D-Glu-Tyr(SO3H)-Nle-D-Lys-Trp-Nle-Asp-Phe-NH2	Investigative
T28330	DRUGINFO	D03GPH	1-(4-Chloro-phenyl)-3-(3-pentyl-oct-2-enyl)-urea	Investigative
T28330	DRUGINFO	D03MOQ	1-(4-Chloro-phenyl)-3-(3,3-diphenyl-allyl)-urea	Investigative
T28330	DRUGINFO	D03ZWL	L-740093	Investigative
T28330	DRUGINFO	D05QBF	Devazepide	Investigative
T28330	DRUGINFO	D05RRZ	Glaxo-11p	Investigative
T28330	DRUGINFO	D05YZC	[3H]devazepide	Investigative
T28330	DRUGINFO	D06CIH	VL-1499	Investigative
T28330	DRUGINFO	D06FIK	JNJ-17156516	Investigative
T28330	DRUGINFO	D06KWA	VL-0699	Investigative
T28330	DRUGINFO	D09PNV	KSG-504	Investigative
T28330	DRUGINFO	D0D2UA	2-NAP	Investigative
T28330	DRUGINFO	D0EZ2W	CR-2345	Investigative
T28330	DRUGINFO	D0F0MN	Boc-Glu-Tyr(SO3H)-Nle-D-Lys-Trp-Nle-Asp-Phe-NH2	Investigative
T28330	DRUGINFO	D0F1VP	VL-2799	Investigative
T28330	DRUGINFO	D0GC9B	JMV180	Investigative
T28330	DRUGINFO	D0H9AX	L-736380	Investigative
T28330	DRUGINFO	D0N4QT	L-708474	Investigative
T28330	DRUGINFO	D0O5OM	VL-0395	Investigative
T28330	DRUGINFO	D0O8HW	FR-175985	Investigative
T28330	DRUGINFO	D0P9OL	Boc-cyclo-(Glu-Tyr-Nle-D-Lys)-Trp-Nle-Asp-Phe-NH2	Investigative
T28330	DRUGINFO	D0S4CE	VL-0494	Investigative
T28330	DRUGINFO	D0SY6T	1-(3,3-Diphenyl-allyl)-3-m-tolyl-urea	Investigative
T28330	DRUGINFO	D0VA0J	3,4-Dichloro-N-(3,3-diphenyl-allyl)-benzamide	Investigative
T28330	DRUGINFO	D0Z6UK	SC-50998	Investigative
T28330	DRUGINFO	D00FLQ	PD-140547	Investigative
T28330	DRUGINFO	D02MIN	PD-138915	Investigative
T28330	DRUGINFO	D02ZML	GW-5823	Investigative
T28330	DRUGINFO	D04VOM	PD-136621	Investigative
T28330	DRUGINFO	D05OUQ	CCK-33	Investigative
T28330	DRUGINFO	D05XXE	Tetragastrin	Investigative
T28330	DRUGINFO	D08EYZ	PD-140548	Investigative
T28330	DRUGINFO	D0C2KS	CI-1015	Investigative
T28330	DRUGINFO	D0CE9U	Asp-Tyr(OSO3H)-Met-Gly-Trp-Met-Asp-Phe	Investigative
T28330	DRUGINFO	D0D2ZM	PD-135158	Investigative
T28330	DRUGINFO	D0E4JX	PD-137337	Investigative
T28330	DRUGINFO	D0ES2U	TP-680	Investigative
T28330	DRUGINFO	D0G1CK	PD-140723	Investigative
T28330	DRUGINFO	D0G7RE	PD-137342	Investigative
T28330	DRUGINFO	D0I8AF	CCK-8	Investigative
T28330	DRUGINFO	D0L9OU	PD-138916	Investigative
T28330	DRUGINFO	D0M6ZF	Boc-Asp-Tyr(So3-)-Nle-Gly-Trp-Asp-Phe-NH2	Investigative
T28330	DRUGINFO	D0O0IZ	PD-135118	Investigative
T28330	DRUGINFO	D0I9PH	H-Tyr-D-Ala-Gly-Phe-NH-NH-Trp-D-Nle-D-Asp-D-Phe-H	Investigative
T28330	DRUGINFO	D0O7PT	Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)]	Investigative
T28330	DRUGINFO	D01AQC	Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2	Investigative
T28330	DRUGINFO	D03EPA	Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2	Investigative
T28330	DRUGINFO	D06BRA	Tyr-D-Ala-Gly-D-Trp-Nle-Asp-Phe-NH2	Investigative
T28330	DRUGINFO	D07ICW	Tyr-D-Ala-Gly-D-Trp-NMeNle-Asp-Phe-NH2	Investigative
T28330	DRUGINFO	D07LQQ	Tyr-D-Nle-Gly-Trp-Nle-Asp-Phe-NH2	Investigative
T28330	DRUGINFO	D09EMR	Tyr-D-Phe-Gly-D-Trp-Nle-Asp-Phe-NH2	Investigative
T28330	DRUGINFO	D0E2OG	Tyr-D-Nle-Gly-D-Trp-NMeNle-Asp-Phe-NH2	Investigative
T28330	DRUGINFO	D0J7GJ	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-H	Investigative
T28330	DRUGINFO	D0N6DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Boc	Investigative
T28330	DRUGINFO	D0QP2S	Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-NMeNle-D-Trp-Boc	Investigative
T28330	DRUGINFO	D0R4GI	Tyr-D-Ala-Gly-Trp-NMeNle-Asp-Phe-NH2	Investigative
T28330	DRUGINFO	D0TR0U	Tyr-D-Phe-Gly-D-Trp-NMeNle-Asp-Phe-NH2	Investigative
T28330	DRUGINFO	D0U6OA	Tyr-D-Ala-Gly-Trp-Nle-Asp-Phe-NH2	Investigative
T28330	DRUGINFO	D0V9DY	H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-H	Investigative

T02703	TARGETID	T02703
T02703	FORMERID	TTDS00337
T02703	UNIPROID	NOS2_HUMAN
T02703	TARGNAME	Nitric-oxide synthase inducible (NOS2)
T02703	GENENAME	NOS2
T02703	TARGTYPE	Clinical trial
T02703	SYNONYMS	iNOS; Peptidyl-cysteine S-nitrosylase NOS2; Nitric oxide synthase, inducible; NOS2A; NOS type II; Inducible NOS; Inducible NO synthase; Hepatocyte NOS; HEP-NOS
T02703	FUNCTION	Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such PTGS2/COX2 (By similarity). As component of the iNOS-S100A8/9 transnitrosylase complex involved in the selective inflammatory stimulus-dependent S-nitrosylation of GAPDH on 'Cys-247' implicated in regulation of the GAIT complex activity and probably multiple targets including ANXA5, EZR, MSN and VIM. Involved in inflammation, enhances the synthesis of proinflammatory mediators such as IL6 and IL8.
T02703	PDBSTRUC	5XN3; 5TP6; 4NOS; 4CX7; 3HR4
T02703	BIOCLASS	Paired donor oxygen oxidoreductase
T02703	ECNUMBER	EC 1.14.13.39
T02703	SEQUENCE	MACPWKFLFKTKFHQYAMNGEKDINNNVEKAPCATSSPVTQDDLQYHNLSKQQNESPQPLVETGKKSPESLVKLDATPLSSPRHVRIKNWGSGMTFQDTLHHKAKGILTCRSKSCLGSIMTPKSLTRGPRDKPTPPDELLPQAIEFVNQYYGSFKEAKIEEHLARVEAVTKEIETTGTYQLTGDELIFATKQAWRNAPRCIGRIQWSNLQVFDARSCSTAREMFEHICRHVRYSTNNGNIRSAITVFPQRSDGKHDFRVWNAQLIRYAGYQMPDGSIRGDPANVEFTQLCIDLGWKPKYGRFDVVPLVLQANGRDPELFEIPPDLVLEVAMEHPKYEWFRELELKWYALPAVANMLLEVGGLEFPGCPFNGWYMGTEIGVRDFCDVQRYNILEEVGRRMGLETHKLASLWKDQAVVEINIAVLHSFQKQNVTIMDHHSAAESFMKYMQNEYRSRGGCPADWIWLVPPMSGSITPVFHQEMLNYVLSPFYYYQVEAWKTHVWQDEKRRPKRREIPLKVLVKAVLFACMLMRKTMASRVRVTILFATETGKSEALAWDLGALFSCAFNPKVVCMDKYRLSCLEEERLLLVVTSTFGNGDCPGNGEKLKKSLFMLKELNNKFRYAVFGLGSSMYPRFCAFAHDIDQKLSHLGASQLTPMGEGDELSGQEDAFRSWAVQTFKAACETFDVRGKQHIQIPKLYTSNVTWDPHHYRLVQDSQPLDLSKALSSMHAKNVFTMRLKSRQNLQSPTSSRATILVELSCEDGQGLNYLPGEHLGVCPGNQPALVQGILERVVDGPTPHQTVRLEALDESGSYWVSDKRLPPCSLSQALTYFLDITTPPTQLLLQKLAQVATEEPERQRLEALCQPSEYSKWKFTNSPTFLEVLEEFPSLRVSAGFLLSQLPILKPRFYSISSSRDHTPTEIHLTVAVVTYHTRDGQGPLHHGVCSTWLNSLKPQDPVPCFVRNASGFHLPEDPSHPCILIGPGTGIAPFRSFWQQRLHDSQHKGVRGGRMTLVFGCRRPDEDHIYQEEMLEMAQKGVLHAVHTAYSRLPGKPKVYVQDILRQQLASEVLRVLHKEPGHLYVCGDVRMARDVAHTLKQLVAAKLKLNEEQVEDYFFQLKSQKRYHEDIFGAVFPYEAKKDRVAVQPSSLEMSAL
T02703	DRUGINFO	D02MBN	SD-6010	Phase 3
T02703	DRUGINFO	D0T4GZ	MPL-S	Phase 3
T02703	DRUGINFO	D07SDQ	Curcumin	Phase 3
T02703	DRUGINFO	D0J3BY	Pimagedine HCl	Phase 2/3
T02703	DRUGINFO	D05QJT	GW274150	Phase 2
T02703	DRUGINFO	D07NCV	BXT-51072	Phase 2
T02703	DRUGINFO	D09ZKS	HP-228	Phase 2
T02703	DRUGINFO	D0I8ZM	CR-3294	Phase 2
T02703	DRUGINFO	D0MJ2H	KD-7040	Phase 2
T02703	DRUGINFO	D06HBT	LT-1951	Phase 1/2
T02703	DRUGINFO	D0V0NL	Aminoguanidine	Phase 1
T02703	DRUGINFO	D0KM3P	NOStentin	Discontinued in Phase 1
T02703	DRUGINFO	D0R5XK	ONO-1714	Discontinued in Phase 1
T02703	DRUGINFO	D0Y7VJ	L-NIL	Terminated
T02703	DRUGINFO	D00GYE	6-(4-Fluorobutyl)-4-methylpyridin-2-amine	Investigative
T02703	DRUGINFO	D00PEC	PIBTU	Investigative
T02703	DRUGINFO	D01EBY	L-Thiocitrulline	Investigative
T02703	DRUGINFO	D01TDC	6-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine	Investigative
T02703	DRUGINFO	D02ZGN	1-(6-Amino-4-methylpyridin-2-yl)propan-2-ol	Investigative
T02703	DRUGINFO	D03HCR	(4S,5S)-4,5-Dipropyl-oxazolidin-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D03MJJ	Thiocoumarin	Investigative
T02703	DRUGINFO	D03YRO	(4S,5R)-4,5-Dipropyl-oxazolidin-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D05PZA	N-benzylacetimidamide hydrobromide	Investigative
T02703	DRUGINFO	D05SCE	CDDO	Investigative
T02703	DRUGINFO	D06JZQ	4-Methyl-6-(2-methylprop-1-enyl)pyridin-2-amine	Investigative
T02703	DRUGINFO	D07BLJ	[1,5]Thiazocan-(4E)-ylideneamine	Investigative
T02703	DRUGINFO	D07FVL	Oxazolidin-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D08ISP	5-Methyl-4-propyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D09OWC	SKLB-010	Investigative
T02703	DRUGINFO	D0D3CJ	BYK-191023	Investigative
T02703	DRUGINFO	D0H4DU	KD-7332	Investigative
T02703	DRUGINFO	D0JZ3S	4r-Fluoro-N6-Ethanimidoyl-L-Lysine	Investigative
T02703	DRUGINFO	D0L9SL	3-Butyl-[1,4]oxazepan-(5Z)-ylideneamine	Investigative
T02703	DRUGINFO	D0S7MJ	(S)-N-(1-phenylethyl)acetimidamide hydrobromide	Investigative
T02703	DRUGINFO	D0U8OA	(E)-4-Methyl-6-(prop-1-enyl)pyridin-2-amine	Investigative
T02703	DRUGINFO	D0U8TM	4,5,6,7-tetrafluoro-3-perfluorophenyl-1H-indazole	Investigative
T02703	DRUGINFO	D0W5UJ	(S)-2-Amino-6-[(E)-ethylimino]-hexanoic acid	Investigative
T02703	DRUGINFO	D0W6VA	4-(1H-IMIDAZOL-1-YL)PHENOL	Investigative
T02703	DRUGINFO	D0Y2AO	Aminothiazoline	Investigative
T02703	DRUGINFO	D00KOE	4-Isopropyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D01DFX	4-[(2-Methyl-1H-imidazol-1-yl)methyl]pyridine	Investigative
T02703	DRUGINFO	D01MEA	3-Butyl-[1,4]thiazepan-(5E)-ylideneamine	Investigative
T02703	DRUGINFO	D01YNT	((E)-7-But-2-enyl)-azepan-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D02DQQ	N,N-dimethylarginine	Investigative
T02703	DRUGINFO	D02FHX	4-Ethyl-oxazolidin-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D02MFQ	Azonan-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D03ODQ	[1,4]Oxazepan-(5E)-ylideneamine	Investigative
T02703	DRUGINFO	D03QMU	7-Butyl-azepan-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D03QSQ	5-Ethyl-4-propyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D03YZT	5-Ethyl-oxazolidin-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D05APC	4-Methyl-5-propyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D05LPK	5-Methyl-oxazolidin-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D05VAB	AR-C102222	Investigative
T02703	DRUGINFO	D05ZYA	5-Bromomethyl-oxazolidin-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D06EXH	(4S,5S)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D07INO	Octahydro-isoindol-(1Z)-ylideneamine	Investigative
T02703	DRUGINFO	D07MFH	3-(2-Amino-ethyl)-5-imino-[1,4]oxazepane	Investigative
T02703	DRUGINFO	D07OQX	4-Butyl-thiazolidin-(2E)-ylideneamine	Investigative
T02703	DRUGINFO	D08CMQ	3-Isobutyl-[1,4]thiazepan-(5E)-ylideneamine	Investigative
T02703	DRUGINFO	D08DQZ	4-Methyl-oxazolidin-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D08PZX	(R)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine	Investigative
T02703	DRUGINFO	D08UWE	(4S,5R)-4,5-Dimethyl-oxazolidin-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D09BKV	3-Propyl-[1,4]thiazepan-(5E)-ylideneamine	Investigative
T02703	DRUGINFO	D0C3CS	4,5,6,7-tetrafluoro-3-methyl-1H-indazole	Investigative
T02703	DRUGINFO	D0I7VD	Ethylisothiourea	Investigative
T02703	DRUGINFO	D0IR4Y	2-(2-Amino-ethyl)-7-imino-azepane	Investigative
T02703	DRUGINFO	D0J2RI	4-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D0K1CM	Azocan-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D0K4SV	3,4-Dihydro-1H-quinolin-(2E)-ylideneamine	Investigative
T02703	DRUGINFO	D0LB9U	3-(2-Nitro-ethyl)-[1,4]oxazepan-(5Z)-ylideneamine	Investigative
T02703	DRUGINFO	D0O2KO	N-Omega-Propyl-L-Arginine	Investigative
T02703	DRUGINFO	D0OW8M	AR-C133057XX	Investigative
T02703	DRUGINFO	D0UP8X	(4S,5R)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D0VB2W	5-Nitroindazole	Investigative
T02703	DRUGINFO	D0Y0FS	6-Nitroindazole	Investigative
T02703	DRUGINFO	D00EVC	6-isobutyl-4-methylpyridin-2-amine	Investigative
T02703	DRUGINFO	D01EHS	7-Methyl-[1,4]thiazepan-(5E)-ylideneamine	Investigative
T02703	DRUGINFO	D01ILO	2-Aminothiazoline	Investigative
T02703	DRUGINFO	D01XOR	(5-Imino-[1,4]thiazepan-3-yl)-methanol	Investigative
T02703	DRUGINFO	D02ELA	L-NIO	Investigative
T02703	DRUGINFO	D02EOF	4-Ethyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D02TMX	4-methyl-6-propylpyridin-2-amine	Investigative
T02703	DRUGINFO	D02TYS	[1,4]Thiazepan-(3E)-ylideneamine	Investigative
T02703	DRUGINFO	D03CAJ	7-(2-Nitro-ethyl)-azepan-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D03EHB	3-Bromo-1H-indazole-7-carbonitrile	Investigative
T02703	DRUGINFO	D03FJM	2-Amino-5-(N-nitro-guanidino)-pentanoic acid	Investigative
T02703	DRUGINFO	D03JXX	4,5-Dimethyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D03WOZ	7-nitro-1H-indazole	Investigative
T02703	DRUGINFO	D04JZV	(6r,1'r,2's)-5,6,7,8 Tetrahydrobiopterin	Investigative
T02703	DRUGINFO	D04JZY	Resveratrol Potassium4,-Sulfate	Investigative
T02703	DRUGINFO	D04PBI	N5-(1-iminopropyl)-L-ornithine	Investigative
T02703	DRUGINFO	D06VYU	(S)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine	Investigative
T02703	DRUGINFO	D07VFC	6-(2-Fluoropropyl)-4-methylpyridin-2-amine	Investigative
T02703	DRUGINFO	D08ALG	Azepan-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D08FXW	6-(3-Fluoropropyl)-4-methylpyridin-2-amine	Investigative
T02703	DRUGINFO	D08WEI	3-Methyl-[1,4]thiazepan-(5E)-ylideneamine	Investigative
T02703	DRUGINFO	D09NRX	3-Ethyl-[1,4]thiazepan-(5E)-ylideneamine	Investigative
T02703	DRUGINFO	D0AO5D	1400W	Investigative
T02703	DRUGINFO	D0C1OB	Pyrrolidin-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D0D0TO	Piperidin-(2E)-ylideneamine	Investigative
T02703	DRUGINFO	D0D7PK	4-Methyl-piperidin-(2E)-ylideneamine	Investigative
T02703	DRUGINFO	D0D9LT	5-Methyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D0DD9E	N-omega-allyl-L-arginine	Investigative
T02703	DRUGINFO	D0E0QG	THIOCITRULLINE	Investigative
T02703	DRUGINFO	D0F3XT	7,8-dihydrobiopterin	Investigative
T02703	DRUGINFO	D0G4ZL	3,4-Dimethyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D0GL9I	N-Omega-Hydroxy-L-Arginine	Investigative
T02703	DRUGINFO	D0GX7G	N5-(1-iminobutyl)-L-ornithine	Investigative
T02703	DRUGINFO	D0I3ZP	[1,4]Oxazepan-(3E)-ylideneamine	Investigative
T02703	DRUGINFO	D0J7NS	4-Methyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D0K4YY	(5S,6R)-[Octahydro-quinolin-(2E)-ylidene]amine	Investigative
T02703	DRUGINFO	D0L4RU	N-omega-propargyl-L-arginine	Investigative
T02703	DRUGINFO	D0L5KY	N5-(1-iminobut-3-enyl)-L-ornithine	Investigative
T02703	DRUGINFO	D0LE6N	Hexahydro-cyclopenta[c]pyrrol-(1Z)-ylideneamine	Investigative
T02703	DRUGINFO	D0M4BM	[1,3]Oxazinan-(2E)-ylideneamine	Investigative
T02703	DRUGINFO	D0N3HU	[1,4]Thiazepan-(5E)-ylideneamine	Investigative
T02703	DRUGINFO	D0N8EU	(S)-2-Amino-5-(N-methyl-guanidino)-pentanoic acid	Investigative
T02703	DRUGINFO	D0O3XZ	2-amino-4-methylpyridine	Investigative
T02703	DRUGINFO	D0O9II	[1,3]Thiazinan-(2E)-ylideneamine	Investigative
T02703	DRUGINFO	D0R9KX	(5S,6S)-[Octahydro-quinolin-(2E)-ylidene]amine	Investigative
T02703	DRUGINFO	D0SB5H	2-Methyl-[1,4]thiazepan-(5E)-ylideneamine	Investigative
T02703	DRUGINFO	D0T3QN	(S)-6-Amino-2-(2-imino-ethylamino)-hexanoic acid	Investigative
T02703	DRUGINFO	D0V5HI	N-(5-Amino-6-oxo-heptyl)-acetamidine	Investigative
T02703	DRUGINFO	D0X5QJ	3-bromo-7-nitro-1H-indazole	Investigative
T02703	DRUGINFO	D0X6MB	3-Methyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D0X6QY	4-Ethyl-5-methyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D0XJ1C	5-Ethyl-4-methyl-pyrrolidin-(2Z)-ylideneamine	Investigative
T02703	DRUGINFO	D0UU1I	Heme	Investigative
T02703	DRUGINFO	D02UVH	B-Octylglucoside	Investigative

T87166	TARGETID	T87166
T87166	FORMERID	TTDC00141
T87166	UNIPROID	HXK4_HUMAN
T87166	TARGNAME	Glucokinase (GCK)
T87166	GENENAME	GCK
T87166	TARGTYPE	Clinical trial
T87166	SYNONYMS	Hexokinase type IV; Hexokinase D; HK4; HK IV
T87166	FUNCTION	Catalyzes the initial step in utilization of glucose by the beta-cell and liver at physiological glucose concentration. Glucokinase has a high Km for glucose, and so it is effective only when glucose is abundant. The role of GCK is to provide G6P for the synthesis of glycogen. Pancreatic glucokinase plays an important role in modulating insulin secretion. Hepatic glucokinase helps to facilitate the uptake and conversion of glucose by acting asan insulin-sensitive determinant of hepatic glucose usage.
T87166	PDBSTRUC	5V4X; 5V4W; 4RCH; 4NO7; 4MLH
T87166	BIOCLASS	Kinase
T87166	ECNUMBER	EC 2.7.1.2
T87166	SEQUENCE	MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ
T87166	DRUGINFO	D01CGV	LY-2599506	Phase 2
T87166	DRUGINFO	D07JHK	AMG 151	Phase 2
T87166	DRUGINFO	D0C6MS	PF-04991532	Phase 2
T87166	DRUGINFO	D0D7VO	GK1-399	Phase 2
T87166	DRUGINFO	D0E1WH	LY-2608204	Phase 2
T87166	DRUGINFO	D0M5PH	PF-04937319	Phase 2
T87166	DRUGINFO	D0O8BS	AZD1656	Phase 2
T87166	DRUGINFO	DG68CL	TTP399	Phase 2
T87166	DRUGINFO	D00AYW	HMS5552	Phase 1
T87166	DRUGINFO	D02AVC	BMS-820132	Phase 1
T87166	DRUGINFO	D03MDW	DS-7309	Phase 1
T87166	DRUGINFO	D05LOV	ADV-1002401	Phase 1
T87166	DRUGINFO	D0G0ZE	TTP-547	Phase 1
T87166	DRUGINFO	D0L5FB	TAK-329	Phase 1
T87166	DRUGINFO	D0M0UU	ZYGK-1	Phase 1
T87166	DRUGINFO	D0O9OC	AZD5658	Phase 1
T87166	DRUGINFO	D08BVM	TTP-355	Discontinued in Phase 2
T87166	DRUGINFO	D08RGA	AZD6370	Discontinued in Phase 2
T87166	DRUGINFO	D0SN2Q	AZD-6714	Discontinued in Phase 1
T87166	DRUGINFO	D04JPQ	PSN-101	Investigative
T87166	DRUGINFO	D04MLE	GKA-23	Investigative
T87166	DRUGINFO	D04QGH	Piragliatin	Investigative
T87166	DRUGINFO	D0P0PP	GKA1	Investigative
T87166	DRUGINFO	D0Q3OM	SKL-19014	Investigative
T87166	DRUGINFO	D07ONX	Beta-D-Glucose	Investigative

T55709	TARGETID	T55709
T55709	FORMERID	TTDR00805
T55709	UNIPROID	CHKA_HUMAN
T55709	TARGNAME	Choline kinase (CHKA)
T55709	GENENAME	CHKA
T55709	TARGTYPE	Clinical trial
T55709	SYNONYMS	ChoK; CHKA; CHETK-alpha
T55709	FUNCTION	Has a key role in phospholipid biosynthesis and may contribute to tumor cell growth. Catalyzes the first step in phosphatidylcholine biosynthesis. Contributes to phosphatidylethanolamine biosynthesis. Phosphorylates choline and ethanolamine. Has higher activity with choline.
T55709	PDBSTRUC	5W6O; 5FUT; 5FTG; 5EQY; 5EQP
T55709	BIOCLASS	Kinase
T55709	ECNUMBER	EC 2.7.1.32
T55709	SEQUENCE	MKTKFCTGGEAEPSPLGLLLSCGSGSAAPAPGVGQQRDAASDLESKQLGGQQPPLALPPPPPLPLPLPLPQPPPPQPPADEQPEPRTRRRAYLWCKEFLPGAWRGLREDEFHISVIRGGLSNMLFQCSLPDTTATLGDEPRKVLLRLYGAILQMRSCNKEGSEQAQKENEFQGAEAMVLESVMFAILAERSLGPKLYGIFPQGRLEQFIPSRRLDTEELSLPDISAEIAEKMATFHGMKMPFNKEPKWLFGTMEKYLKEVLRIKFTEESRIKKLHKLLSYNLPLELENLRSLLESTPSPVVFCHNDCQEGNILLLEGRENSEKQKLMLIDFEYSSYNYRGFDIGNHFCEWMYDYSYEKYPFFRANIRKYPTKKQQLHFISSYLPAFQNDFENLSTEEKSIIKEEMLLEVNRFALASHFLWGLWSIVQAKISSIEFGYMDYAQARFDAYFHQKRKLGV
T55709	DRUGINFO	D0G2XR	TCD-717	Phase 1

T89055	TARGETID	T89055
T89055	FORMERID	TTDNC00613
T89055	UNIPROID	MP2K2_HUMAN
T89055	TARGNAME	ERK activator kinase 2 (MEK2)
T89055	GENENAME	MAP2K2
T89055	TARGTYPE	Clinical trial
T89055	SYNONYMS	PRKMK2; MKK2; MEK 2; MAPKK 2; MAPK/ERK kinase 2; MAP kinase kinase 2; Dual specificity mitogenactivated protein kinase kinase 2; Dual specificity mitogen-activated protein kinase kinase 2
T89055	FUNCTION	Activates the ERK1 and ERK2 MAP kinases. Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases.
T89055	PDBSTRUC	4H3Q; 1S9I
T89055	BIOCLASS	Kinase
T89055	ECNUMBER	EC 2.7.12.2
T89055	SEQUENCE	MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQKAKVGELKDDDFERISELGAGNGGVVTKVQHRPSGLIMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIAVLRGLAYLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQGTHYSVQSDIWSMGLSLVELAVGRYPIPPPDAKELEAIFGRPVVDGEEGEPHSISPRPRPPGRPVSGHGMDSRPAMAIFELLDYIVNEPPPKLPNGVFTPDFQEFVNKCLIKNPAERADLKMLTNHTFIKRSEVEEVDFAGWLCKTLRLNQPGTPTRTAV
T89055	DRUGINFO	D0T5DP	Selumetinib	Phase 3
T89055	DRUGINFO	D0XW4G	Pyridic ketone derivative 1	Patented
T89055	DRUGINFO	D02UQG	RDEA-436	Discontinued in Phase 1
T89055	DRUGINFO	D9ILC1	PD98059	Investigative

T53389	TARGETID	T53389
T53389	FORMERID	TTDR00998
T53389	UNIPROID	TGFR1_HUMAN
T53389	TARGNAME	TGF-beta receptor type I (TGFBR1)
T53389	GENENAME	TGFBR1
T53389	TARGTYPE	Clinical trial
T53389	SYNONYMS	Type I TGFbeta receptor kinase; Transforming growth factor-beta receptor type I; TbetaRI; TbetaR-I; TGFR-1; TGF-beta type I receptor; TGF-beta receptor type-1; Serine/threonine-protein kinase receptor R4; SKR4; Activin receptor-like kinase 5; Activin A receptor type II-like protein kinase of 53kD; ALK5; ALK-5
T53389	FUNCTION	Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. For instance, TGFBR1 induces TRAF6 autoubiquitination which in turn results in MAP3K7 ubiquitination and activation to trigger apoptosis. Also regulates epithelial to mesenchymal transition through a SMAD-independent signaling pathway through PARD6A phosphorylation and activation. Transmembrane serine/threonine kinase forming with the TGF-beta type II serine/threonine kinase receptor, TGFBR2, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3.
T53389	PDBSTRUC	6B8Y; 5USQ; 5QIM; 5QIL; 5QIK
T53389	BIOCLASS	Kinase
T53389	ECNUMBER	EC 2.7.11.30
T53389	SEQUENCE	MEAAVAAPRPRLLLLVLAAAAAAAAALLPGATALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAEIDLIPRDRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLGPVELAAVIAGPVCFVCISLMLMVYICHNRTVIHHRVPNEEDPSLDRPFISEGTTLKDLIYDMTTSGSGSGLPLLVQRTIARTIVLQESIGKGRFGEVWRGKWRGEEVAVKIFSSREERSWFREAEIYQTVMLRHENILGFIAADNKDNGTWTQLWLVSDYHEHGSLFDYLNRYTVTVEGMIKLALSTASGLAHLHMEIVGTQGKPAIAHRDLKSKNILVKKNGTCCIADLGLAVRHDSATDTIDIAPNHRVGTKRYMAPEVLDDSINMKHFESFKRADIYAMGLVFWEIARRCSIGGIHEDYQLPYYDLVPSDPSVEEMRKVVCEQKLRPNIPNRWQSCEALRVMAKIMRECWYANGAARLTALRIKKTLSQLSQQEGIKM
T53389	DRUGINFO	D06TFI	LY2157299	Phase 2/3
T53389	DRUGINFO	D0MR0B	TEW-7197	Phase 2
T53389	DRUGINFO	D06FAA	Metelimumab	Phase 1/2
T53389	DRUGINFO	D02USG	P-2745	Phase 1
T53389	DRUGINFO	D06BGZ	LY3200882	Phase 1
T53389	DRUGINFO	DQ5Y6Z	PF-06952229	Phase 1
T53389	DRUGINFO	DNI28K	TP-0184	Phase 1
T53389	DRUGINFO	D0C7WP	SB-431542	Preclinical
T53389	DRUGINFO	D0I4LB	SM-16	Terminated
T53389	DRUGINFO	D0ID0R	LF-984	Terminated
T53389	DRUGINFO	D00ZFC	WilVent	Investigative
T53389	DRUGINFO	D03ANS	SB-525334	Investigative
T53389	DRUGINFO	D05BMP	5''-Quinolin-4-yl-[2,4'']bithiazolyl-2''-ylamine	Investigative
T53389	DRUGINFO	D07ZMW	4-Pyridin-2-yl-5-quinolin-2-yl-thiazol-2-ylamine	Investigative
T53389	DRUGINFO	D0H5CE	4-Pyridin-3-yl-5-quinolin-4-yl-thiazol-2-ylamine	Investigative
T53389	DRUGINFO	D0I4VX	DRP-049	Investigative
T53389	DRUGINFO	D0J6JC	PTL-101	Investigative
T53389	DRUGINFO	D0Q5UH	SB-505124	Investigative
T53389	DRUGINFO	D0QJ4Y	TGF-beta Shield	Investigative
T53389	DRUGINFO	D0S5TT	ACE-435	Investigative
T53389	DRUGINFO	D0V3OJ	2-phenyl-N-(pyridin-4-yl)quinazolin-4-amine	Investigative
T53389	DRUGINFO	D0V8AC	SD-208	Investigative
T53389	DRUGINFO	D0XB4P	HTS-466284	Investigative
T53389	DRUGINFO	D0XL7C	4-Pyridin-2-yl-5-quinolin-4-yl-thiazol-2-ylamine	Investigative
T53389	DRUGINFO	D06KKN	LY2109761	Investigative
T53389	DRUGINFO	D0K6YK	IN-1130	Investigative
T53389	DRUGINFO	D06BDC	PMID16539403C15b	Investigative
T53389	DRUGINFO	D0C3AD	GW-788388	Investigative
T53389	DRUGINFO	D0H6ZP	IN-1166	Investigative
T53389	DRUGINFO	D06CMG	LDN-214117	Investigative
T53389	DRUGINFO	D05NEC	PMID23639540C13r	Investigative
T53389	DRUGINFO	D0F2MP	PMID23639540C13d	Investigative

T03500	TARGETID	T03500
T03500	FORMERID	TTDC00157
T03500	UNIPROID	MMP12_HUMAN
T03500	TARGNAME	Matrix metalloproteinase-12 (MMP-12)
T03500	GENENAME	MMP12
T03500	TARGTYPE	Clinical trial
T03500	SYNONYMS	Macrophage metalloelastase; Macrophage elastase; MME; ME; HME
T03500	FUNCTION	Has significant elastolytic activity. Can accept large and small amino acids at the P1' site, but has a preference for leucine. Aromatic or hydrophobic residues are preferred at the P1 site, with small hydrophobic residues (preferably alanine) occupying P3. May be involved in tissue injury and remodeling.
T03500	PDBSTRUC	6EOX; 6ENM; 6ELA; 6EKN; 5N5K
T03500	BIOCLASS	Peptidase
T03500	ECNUMBER	EC 3.4.24.65
T03500	SEQUENCE	MKFLLILLLQATASGALPLNSSTSLEKNNVLFGERYLEKFYGLEINKLPVTKMKYSGNLMKEKIQEMQHFLGLKVTGQLDTSTLEMMHAPRCGVPDVHHFREMPGGPVWRKHYITYRINNYTPDMNREDVDYAIRKAFQVWSNVTPLKFSKINTGMADILVVFARGAHGDFHAFDGKGGILAHAFGPGSGIGGDAHFDEDEFWTTHSGGTNLFLTAVHEIGHSLGLGHSSDPKAVMFPTYKYVDINTFRLSADDIRGIQSLYGDPKENQRLPNPDNSEPALCDPNLSFDAVTTVGNKIFFFKDRFFWLKVSERPKTSVNLISSLWPTLPSGIEAAYEIEARNQVFLFKDDKYWLISNLRPEPNYPKSIHSFGFPNFVKKIDAAVFNPRFYRTYFFVDNQYWRYDERRQMMDPGYPKLITKNFQGIGPKIDAVFYSKNKYYYFFQGSNQFEYDFLLQRITKTLKSNSWFGC
T03500	DRUGINFO	D0F470	FP-025	Phase 1
T03500	DRUGINFO	D0T4BL	Neovastat	Phase 1
T03500	DRUGINFO	D00ZZJ	PMID29130358-Compound-Figure17(12)	Patented
T03500	DRUGINFO	D09ATD	PMID29130358-Compound-Figure17(10)	Patented
T03500	DRUGINFO	D0L6HL	PMID29130358-Compound-Figure17(11)	Patented
T03500	DRUGINFO	D0E5YG	AZD1236	Discontinued in Phase 2
T03500	DRUGINFO	D0T9HG	GM6001	Discontinued in Phase 2
T03500	DRUGINFO	D06CZS	V85546	Discontinued in Phase 1
T03500	DRUGINFO	D00NPE	MMP-408	Investigative
T03500	DRUGINFO	D02ECA	PF-00356231	Investigative
T03500	DRUGINFO	D03QXD	RXP-470	Investigative
T03500	DRUGINFO	D04UBY	5-(3'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid	Investigative
T03500	DRUGINFO	D05OZZ	N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide	Investigative
T03500	DRUGINFO	D06MGJ	N-(biphenyl-4-ylsulfonyl)-D-leucine	Investigative
T03500	DRUGINFO	D07KZL	PMID24900526C5 	Investigative
T03500	DRUGINFO	D07NDK	WAY-644	Investigative
T03500	DRUGINFO	D09MLQ	PMID22153340C20	Investigative
T03500	DRUGINFO	D0A0FY	N-Hydroxy-2-(4-methoxy-benzenesulfonyl)benzamide	Investigative
T03500	DRUGINFO	D0B3UN	RXP470.1	Investigative
T03500	DRUGINFO	D0C1EQ	2-(2-(biphenyl-4-yl)ethylthio)acetic acid	Investigative
T03500	DRUGINFO	D0F4UT	2-(2-(biphenyl-4-yl)ethylsulfinyl)acetic acid	Investigative
T03500	DRUGINFO	D0K4ZP	N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine	Investigative
T03500	DRUGINFO	D0L6ND	AGELADINE A	Investigative
T03500	DRUGINFO	D0LB0N	5-(biphenyl-4-yl)-3-oxopentanoic acid	Investigative
T03500	DRUGINFO	D0M2RC	N-[(4-methoxyphenyl)sulfonyl]-D-alanine	Investigative
T03500	DRUGINFO	D0TL3N	5-(biphenyl-4-yl)-3-methoxypentanoic acid	Investigative
T03500	DRUGINFO	D0W9TD	N-oxo-2-(phenylsulfonylamino)ethanamide	Investigative
T03500	DRUGINFO	D0Y0BZ	PUP-1	Investigative
T03500	DRUGINFO	D0Y4GL	CP-271485	Investigative
T03500	DRUGINFO	D0YN1A	PMID24900526C1	Investigative
T03500	DRUGINFO	D05JPV	4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid	Investigative
T03500	DRUGINFO	D0K0YX	5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid	Investigative
T03500	DRUGINFO	D0LM2K	2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid	Investigative
T03500	DRUGINFO	D0A5MV	3-(4-Phenylethynylbenzoyl)nonanoic acid	Investigative
T03500	DRUGINFO	D08ELY	3-Benzenesulfonyl-heptanoic acid hydroxyamide	Investigative
T03500	DRUGINFO	D0G3YZ	(+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid	Investigative
T03500	DRUGINFO	D0L4EO	3-(4-(2-phenylethynyl)benzoyl)pentanoic acid	Investigative
T03500	DRUGINFO	D0N6CD	3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide	Investigative
T03500	DRUGINFO	D05THD	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	Investigative
T03500	DRUGINFO	D07MJD	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	Investigative
T03500	DRUGINFO	D0S9OL	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	Investigative
T03500	DRUGINFO	D0F2ME	Acetate Ion	Investigative

T11388	TARGETID	T11388
T11388	FORMERID	TTDC00068
T11388	UNIPROID	CATK_HUMAN
T11388	TARGNAME	Cathepsin K (CTSK)
T11388	GENENAME	CTSK
T11388	TARGTYPE	Clinical trial
T11388	SYNONYMS	Cathepsin X; Cathepsin O2; Cathepsin O; CTSO2; CTSO
T11388	FUNCTION	Displays potent endoprotease activity against fibrinogen at acid pH. May play an important role in extracellular matrix degradation. Closely involved in osteoclastic bone resorption and may participate partially in the disorder of bone remodeling.
T11388	PDBSTRUC	7PCK; 6QBS; 6ASH; 5Z5O; 5TUN
T11388	BIOCLASS	Peptidase
T11388	ECNUMBER	EC 3.4.22.38
T11388	SEQUENCE	MWGLKVLLLPVVSFALYPEEILDTHWELWKKTHRKQYNNKVDEISRRLIWEKNLKYISIHNLEASLGVHTYELAMNHLGDMTSEEVVQKMTGLKVPLSHSRSNDTLYIPEWEGRAPDSVDYRKKGYVTPVKNQGQCGSCWAFSSVGALEGQLKKKTGKLLNLSPQNLVDCVSENDGCGGGYMTNAFQYVQKNRGIDSEDAYPYVGQEESCMYNPTGKAAKCRGYREIPEGNEKALKRAVARVGPVSVAIDASLTSFQFYSKGVYYDESCNSDNLNHAVLAVGYGIQKGNKHWIIKNSWGENWGNKGYILMARNKNNACGIANLASFPKM
T11388	DRUGINFO	D0J6AU	Odanacatib	Phase 3
T11388	DRUGINFO	D07BIK	VEL-0230	Phase 1
T11388	DRUGINFO	D08KIB	SAR-114137	Phase 1
T11388	DRUGINFO	D00KGL	PMID27998201-Compound-8	Patented
T11388	DRUGINFO	D0BR6D	PMID27998201-Compound-10	Patented
T11388	DRUGINFO	D0MR9V	PMID27998201-Compound-15	Patented
T11388	DRUGINFO	D0QM0D	Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1	Patented
T11388	DRUGINFO	D04VGR	PMID27998201-Compound-9	Patented
T11388	DRUGINFO	D06LLT	PMID25399719-Compound-17	Patented
T11388	DRUGINFO	D05OIU	PMID27998201-Compound-5	Patented
T11388	DRUGINFO	D06XCD	PMID27998201-Compound-12	Patented
T11388	DRUGINFO	D00ZUU	ONO-5334	Discontinued in Phase 2
T11388	DRUGINFO	D01LNG	Balicatib	Discontinued in Phase 2
T11388	DRUGINFO	D0T5PH	Relacatib	Discontinued in Phase 2
T11388	DRUGINFO	D0J5FU	MIV-701	Discontinued in Phase 1
T11388	DRUGINFO	D0FJ3P	GW-2592X	Preclinical
T11388	DRUGINFO	D0Z0PR	L-006235-1	Preclinical
T11388	DRUGINFO	D00FGA	Pyrrolidine-1-carbonitrile	Investigative
T11388	DRUGINFO	D00QIA	(S)-tert-butyl 4-methyl-1-oxopentan-2-ylcarbamate	Investigative
T11388	DRUGINFO	D00TRY	Tert-Butyl(1s)-1-Cyclohexyl-2-Oxoethylcarbamate	Investigative
T11388	DRUGINFO	D02QOT	3-Amino-5-Phenylpentane	Investigative
T11388	DRUGINFO	D02TNR	N-(1-((cyanomethyl)carbamoyl)cyclohexyl)benzamide	Investigative
T11388	DRUGINFO	D04HBH	AM-3701	Investigative
T11388	DRUGINFO	D04QHB	2-cyclohexylamino-pyrimidine-4-carbonitrile	Investigative
T11388	DRUGINFO	D06AZJ	4-cyclohexylamino-pyrimidine-2-carbonitrile	Investigative
T11388	DRUGINFO	D0A8PI	Boc-Agly-Val-Agly-OEt	Investigative
T11388	DRUGINFO	D0B2FE	4-phenyl-6-propylpyrimidine-2-carbonitrile	Investigative
T11388	DRUGINFO	D0FC7L	2-cyclohexylamino-pyridine-2-carbonitrile	Investigative
T11388	DRUGINFO	D0H8CC	Tert-butyl (2S)-1-cyanopyrrolidine-2-carboxylate	Investigative
T11388	DRUGINFO	D0MM4X	MIV-710	Investigative
T11388	DRUGINFO	D0P5BY	N-(cyanomethyl)cyclohex-1-ene-1-carboxamide	Investigative
T11388	DRUGINFO	D0V1UZ	BF/PC-21	Investigative
T11388	DRUGINFO	D0W0BK	TERT-BUTYL 2-CYANO-2-METHYLHYDRAZINECARBOXYLATE	Investigative
T11388	DRUGINFO	D0Y5LX	4-cyclohexyl-6-propylpyrimidine-2-carbonitrile	Investigative
T11388	DRUGINFO	D00NVC	Z-Ala-Leu-Nal-Agly-Ile-Val-OMe	Investigative
T11388	DRUGINFO	D01BIZ	Z-Arg-Leu-Val-Agly-Trp-Val-Ala-NH2	Investigative
T11388	DRUGINFO	D01JGB	4-cyclooctyl-6-propylpyrimidine-2-carbonitrile	Investigative
T11388	DRUGINFO	D01TFO	Z-Ala-Leu-lle-Agly-Ile-Val-OMe	Investigative
T11388	DRUGINFO	D03ETT	Z-Ala-Leu-His-Agly-Ile-Val-OMe	Investigative
T11388	DRUGINFO	D03FJH	Z-Arg-Leu-Val-Agly-Ile-Val-Trp-NH2	Investigative
T11388	DRUGINFO	D03VHO	Z-Ala-Leu-Tyr(Me)-Agly-Ile-Val-OMe	Investigative
T11388	DRUGINFO	D04BGT	4-propyl-6-m-tolylpyrimidine-2-carbonitrile	Investigative
T11388	DRUGINFO	D05WZF	P2,P3 Ketoamide derivative	Investigative
T11388	DRUGINFO	D06QJT	Z-leu-Val-Agly-Val-OBzl	Investigative
T11388	DRUGINFO	D07JLV	Z-Ala-Leu-lle-Agly-Ile-Val-NHBzl	Investigative
T11388	DRUGINFO	D07RDV	Z-Ala-Leu-Phe-Agly-Ile-Val-OMe	Investigative
T11388	DRUGINFO	D0A7ER	N-(tert-butoxycarbonyl)-norvalyl-glycine-nitrile	Investigative
T11388	DRUGINFO	D0G2QG	PMID16290936C1b	Investigative
T11388	DRUGINFO	D0H8TE	Z-Arg-Leu-Val-Agly-Ala-Gly-NH2	Investigative
T11388	DRUGINFO	D0N7BP	Z-Arg-Leu-Val-Agly-Val-Ala-NH2	Investigative
T11388	DRUGINFO	D0Q4YY	Z-Arg-Leu-Val-Agly-Ileu-Val-OMe	Investigative
T11388	DRUGINFO	D0T7QF	(S)-tert-butyl 1-oxohexan-2-ylcarbamate	Investigative
T11388	DRUGINFO	D0U4TY	4-cycloheptyl-6-propylpyrimidine-2-carbonitrile	Investigative
T11388	DRUGINFO	D01YNC	N-(tert-butoxycarbonyl)-isoleucyl-glycine-nitrile	Investigative
T11388	DRUGINFO	D06VIP	N-(tert-butoxycarbonyl)-valyl-glycine-nitrile	Investigative
T11388	DRUGINFO	D07FLB	N-(tert-butoxycarbonyl)-norleucyl-glycine-nitrile	Investigative
T11388	DRUGINFO	D07RSA	N-(4-phenylbenzoyl)-phenylalanyl-glycine-nitrile	Investigative
T11388	DRUGINFO	D09AHN	N-(tert-butoxycarbonyl)-leucyl-glycine-nitrile	Investigative
T11388	DRUGINFO	D0A8OV	N-acetyl-phenylalanyl-glycine-nitrile	Investigative
T11388	DRUGINFO	D0G8OD	N-(benzyloxycarbonyl)-leucyl-glycine-nitrile	Investigative
T11388	DRUGINFO	D0JN8Q	N-benzoyl-phenylalanyl-glycine-nitrile	Investigative
T11388	DRUGINFO	D0U0XG	N-(tert-butoxycarbonyl)-methionyl-glycine-nitrile	Investigative
T11388	DRUGINFO	D0VE0F	(S)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate	Investigative
T11388	DRUGINFO	D0D0LD	L-873724	Investigative
T11388	DRUGINFO	D0L9VP	GNF-PF-5434	Investigative

T40097	TARGETID	T40097
T40097	FORMERID	TTDC00102
T40097	UNIPROID	MK08_HUMAN
T40097	TARGNAME	Stress-activated protein kinase JNK1 (JNK1)
T40097	GENENAME	MAPK8
T40097	TARGTYPE	Clinical trial
T40097	SYNONYMS	Stress-activated protein kinase 1c; SAPK1c; PRKM8; Mitogen-activated protein kinase 8; MAPK 8; MAP kinase 8; JNK-46; C-Jun N-terminal kinase 1
T40097	FUNCTION	Extracellular stimuli such as proinflammatory cytokines or physical stress stimulate the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and MAP2K7/MKK7 phosphorylate and activate MAPK8/JNK1. In turn, MAPK8/JNK1 phosphorylates a number of transcription factors, primarily components of AP-1 such as JUN, JDP2 and ATF2 and thus regulates AP-1 transcriptional activity. Phosphorylates the replication licensing factor CDT1, inhibiting the interaction between CDT1 and the histone H4 acetylase HBO1 to replication origins. Loss of this interaction abrogates the acetylation required for replication initiation. Promotes stressed cell apoptosis by phosphorylating key regulatory factors including p53/TP53 and Yes-associates protein YAP1. In T-cells, MAPK8 and MAPK9 are required for polarized differentiation of T-helper cells into Th1 cells. Contributes to the survival of erythroid cells by phosphorylating the antagonist of cell death BAD upon EPO stimulation. Mediates starvation-induced BCL2 phosphorylation, BCL2 dissociation from BECN1, and thus activation of autophagy. Phosphorylates STMN2 and hence regulates microtubule dynamics, controlling neurite elongation in cortical neurons. In the developing brain, through its cytoplasmic activity on STMN2, negatively regulates the rate of exit from multipolar stage and of radial migration from the ventricular zone. Phosphorylates several other substrates including heat shock factor protein 4 (HSF4), the deacetylase SIRT1, ELK1, or the E3 ligase ITCH. Phosphorylates the CLOCK-ARNTL/BMAL1 heterodimer and plays a role in the regulation of the circadian clock. Phosphorylates the heat shock transcription factor HSF1, suppressing HSF1-induced transcriptional activity. Phosphorylates POU5F1, which results in the inhibition of POU5F1's transcriptional activity and enhances its proteosomal degradation. Serine/threonine-protein kinase involved in various processes such as cell proliferation, differentiation, migration, transformation and programmed cell death.
T40097	PDBSTRUC	6F5E; 5LW1; 4YR8; 4UX9; 4QTD
T40097	BIOCLASS	Kinase
T40097	ECNUMBER	EC 2.7.11.24
T40097	SEQUENCE	MSRSKRDNNFYSVEIGDSTFTVLKRYQNLKPIGSGAQGIVCAAYDAILERNVAIKKLSRPFQNQTHAKRAYRELVLMKCVNHKNIIGLLNVFTPQKSLEEFQDVYIVMELMDANLCQVIQMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTAGTSFMMTPYVVTRYYRAPEVILGMGYKENVDLWSVGCIMGEMVCHKILFPGRDYIDQWNKVIEQLGTPCPEFMKKLQPTVRTYVENRPKYAGYSFEKLFPDVLFPADSEHNKLKASQARDLLSKMLVIDASKRISVDEALQHPYINVWYDPSEAEAPPPKIPDKQLDEREHTIEEWKELIYKEVMDLEERTKNGVIRGQPSPLGAAVINGSQHPSSSSSVNDVSSMSTDPTLASDTDSSLEAAAGPLGCCR
T40097	DRUGINFO	D08SIT	NKP-1339	Phase 1
T40097	DRUGINFO	D00JGN	PMID25991433-Compound-H3	Patented
T40097	DRUGINFO	D01GSU	PMID25991433-Compound-H2	Patented
T40097	DRUGINFO	D06WAW	PMID25991433-Compound-E5	Patented
T40097	DRUGINFO	D09QKG	PMID25991433-Compound-E1	Patented
T40097	DRUGINFO	D0EA5P	PMID25991433-Compound-G4	Patented
T40097	DRUGINFO	D0EA6L	PMID25991433-Compound-K2	Patented
T40097	DRUGINFO	D0I3NS	PMID25991433-Compound-G2	Patented
T40097	DRUGINFO	D0J8DR	PMID25991433-Compound-G1	Patented
T40097	DRUGINFO	D0MW7D	PMID25991433-Compound-Eb	Patented
T40097	DRUGINFO	D0TK0L	PMID25991433-Compound-E2	Patented
T40097	DRUGINFO	D0V0WT	PMID25991433-Compound-G5	Patented
T40097	DRUGINFO	D0XB1S	PMID25991433-Compound-H1	Patented
T40097	DRUGINFO	D0XH9K	PMID25991433-Compound-E4	Patented
T40097	DRUGINFO	D0Y4HR	PMID25991433-Compound-E3	Patented
T40097	DRUGINFO	D0Y7QW	PMID25991433-Compound-K1	Patented
T40097	DRUGINFO	D03HEK	PMID25991433-Compound-A10	Patented
T40097	DRUGINFO	D04JUD	PMID25991433-Compound-A6	Patented
T40097	DRUGINFO	D07JQX	PMID25991433-Compound-D2	Patented
T40097	DRUGINFO	D08JIS	PMID25991433-Compound-N3	Patented
T40097	DRUGINFO	D09YEH	PMID25991433-Compound-A11	Patented
T40097	DRUGINFO	D0AM2B	PMID25991433-Compound-A8	Patented
T40097	DRUGINFO	D0B4IH	PMID25991433-Compound-D1	Patented
T40097	DRUGINFO	D0ID4H	PMID25991433-Compound-N1	Patented
T40097	DRUGINFO	D0RV2Z	PMID25991433-Compound-A2	Patented
T40097	DRUGINFO	D0S1OV	PMID25991433-Compound-A7	Patented
T40097	DRUGINFO	D0S3AP	PMID25991433-Compound-A9	Patented
T40097	DRUGINFO	D0V1CB	PMID25991433-Compound-A5	Patented
T40097	DRUGINFO	D0VE3Y	PMID25991433-Compound-A3	Patented
T40097	DRUGINFO	D05SJB	7-azaindole derivative 1	Patented
T40097	DRUGINFO	D07KMK	7-azaindole derivative 5	Patented
T40097	DRUGINFO	D08DNZ	PMID25991433-Compound-P6	Patented
T40097	DRUGINFO	D08JOC	PMID25991433-Compound-J3	Patented
T40097	DRUGINFO	D0L2MS	PMID25991433-Compound-P1	Patented
T40097	DRUGINFO	D0Q4WA	PMID25991433-Compound-O3	Patented
T40097	DRUGINFO	D0Q8CR	PMID25991433-Compound-L1	Patented
T40097	DRUGINFO	D0RQ8Q	PMID25991433-Compound-J2	Patented
T40097	DRUGINFO	D0T6IZ	7-azaindole derivative 3	Patented
T40097	DRUGINFO	D0VR1O	7-azaindole derivative 2	Patented
T40097	DRUGINFO	D0W8BL	PMID25991433-Compound-P5	Patented
T40097	DRUGINFO	D0X2SG	PMID25991433-Compound-P4	Patented
T40097	DRUGINFO	D0ZU8L	PMID25991433-Compound-J5	Patented
T40097	DRUGINFO	D06JRV	PMID25991433-Compound-F2	Patented
T40097	DRUGINFO	D0H4HD	PMID25991433-Compound-A1	Patented
T40097	DRUGINFO	DOJ6D9	COR-D	Preclinical
T40097	DRUGINFO	D01HCO	2-(2-propoxypyrimidin-4-ylamino)benzoic acid	Investigative
T40097	DRUGINFO	D03UUO	2-(2-(butylamino)pyrimidin-4-ylamino)benzoic acid	Investigative
T40097	DRUGINFO	D07HNL	2-(2-phenoxypyrimidin-4-ylamino)benzoic acid	Investigative
T40097	DRUGINFO	D08IOV	2-(2-butoxypyrimidin-4-ylamino)benzoic acid	Investigative
T40097	DRUGINFO	D08UVX	2-(2-(phenylamino)pyrimidin-4-ylamino)benzamide	Investigative
T40097	DRUGINFO	D0E8KF	N-(6-ethoxypyridin-2-yl)acetamide	Investigative
T40097	DRUGINFO	D0KB8D	2-(2-sec-butoxypyrimidin-4-ylamino)benzoic acid	Investigative
T40097	DRUGINFO	D0SV1F	2-(2-(pentyloxy)pyrimidin-4-ylamino)benzoic acid	Investigative
T40097	DRUGINFO	D0Y5BR	Phylomers	Investigative
T40097	DRUGINFO	D0F5BY	N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide	Investigative
T40097	DRUGINFO	D00HVA	Aminopyridine deriv. 2	Investigative
T40097	DRUGINFO	D0Q3NG	N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide	Investigative
T40097	DRUGINFO	D0VJ2S	JNK-IN-8	Investigative
T40097	DRUGINFO	D04QCF	AS-601245	Investigative
T40097	DRUGINFO	D02PVB	2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One	Investigative
T40097	DRUGINFO	D0GT8N	NM-PP1	Investigative
T40097	DRUGINFO	D0S7IE	N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide	Investigative
T40097	DRUGINFO	D0G2VC	KT-5720	Investigative
T40097	DRUGINFO	D0GB4V	STAUROSPORINONE	Investigative
T40097	DRUGINFO	D0M5FF	Ro31-8220	Investigative
T40097	DRUGINFO	D0N6ES	KN-62	Investigative
T40097	DRUGINFO	D0B9BU	CI-1040	Investigative
T40097	DRUGINFO	D0O1YH	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	Investigative
T40097	DRUGINFO	D0TO6S	Bisindolylmaleimide-I	Investigative
T40097	DRUGINFO	D0L8HO	RO-316233	Investigative

T86161	TARGETID	T86161
T86161	FORMERID	TTDR00015
T86161	UNIPROID	PPCE_HUMAN
T86161	TARGNAME	Prolyl endopeptidase (PREP)
T86161	GENENAME	PREP
T86161	TARGTYPE	Clinical trial
T86161	SYNONYMS	Post-proline cleaving enzyme; PREP; PE
T86161	FUNCTION	Cleaves peptide bonds on the C-terminal side of prolyl residues within peptides that are up to approximately 30 amino acids long.
T86161	PDBSTRUC	3DDU
T86161	BIOCLASS	Peptidase
T86161	ECNUMBER	EC 3.4.21.26
T86161	SEQUENCE	MLSLQYPDVYRDETAVQDYHGHKICDPYAWLEDPDSEQTKAFVEAQNKITVPFLEQCPIRGLYKERMTELYDYPKYSCHFKKGKRYFYFYNTGLQNQRVLYVQDSLEGEARVFLDPNILSDDGTVALRGYAFSEDGEYFAYGLSASGSDWVTIKFMKVDGAKELPDVLERVKFSCMAWTHDGKGMFYNSYPQQDGKSDGTETSTNLHQKLYYHVLGTDQSEDILCAEFPDEPKWMGGAELSDDGRYVLLSIREGCDPVNRLWYCDLQQESSGIAGILKWVKLIDNFEGEYDYVTNEGTVFTFKTNRQSPNYRVINIDFRDPEESKWKVLVPEHEKDVLEWIACVRSNFLVLCYLHDVKNILQLHDLTTGALLKTFPLDVGSIVGYSGQKKDTEIFYQFTSFLSPGIIYHCDLTKEELEPRVFREVTVKGIDASDYQTVQIFYPSKDGTKIPMFIVHKKGIKLDGSHPAFLYGYGGFNISITPNYSVSRLIFVRHMGGILAVANIRGGGEYGETWHKGGILANKQNCFDDFQCAAEYLIKEGYTSPKRLTINGGSNGGLLVAACANQRPDLFGCVIAQVGVMDMLKFHKYTIGHAWTTDYGCSDSKQHFEWLVKYSPLHNVKLPEADDIQYPSMLLLTADHDDRVVPLHSLKFIATLQYIVGRSRKQSNPLLIHVDTKAGHGAGKPTAKVIEEVSDMFAFIARCLNVDWIP
T86161	DRUGINFO	D00WBN	ALV-003	Phase 2
T86161	DRUGINFO	D0F5JR	ONO-1603	Phase 2
T86161	DRUGINFO	D00YEV	BAICALEIN	Phase 2
T86161	DRUGINFO	D09RJN	S-17092-1	Phase 1
T86161	DRUGINFO	D01XGX	JTP-4819	Discontinued in Phase 2
T86161	DRUGINFO	D08RUX	Z-321	Discontinued in Phase 1
T86161	DRUGINFO	D08PUW	BAICALIN	Terminated
T86161	DRUGINFO	D0M8AS	Y-29794	Terminated
T86161	DRUGINFO	D01WXB	Monothioglycerol	Investigative
T86161	DRUGINFO	D06FNK	Z-Pro-Prolinal	Investigative
T86161	DRUGINFO	D0M9VP	1-Hydroxy-1-Thio-Glycerol	Investigative
T86161	DRUGINFO	D0N2UF	ARI-3531	Investigative
T86161	DRUGINFO	D0H1GU	Double Oxidized Cysteine	Investigative

T65019	TARGETID	T65019
T65019	FORMERID	TTDC00042
T65019	UNIPROID	MMP14_HUMAN
T65019	TARGNAME	Matrix metalloproteinase-14 (MMP-14)
T65019	GENENAME	MMP14
T65019	TARGTYPE	Clinical trial
T65019	SYNONYMS	Membrane-type-1 matrix metalloproteinase; Membrane-type matrix metalloproteinase 1; MTMMP1; MT1MMP; MT1-MMP; MT-MMP 1; MMP-X1
T65019	FUNCTION	Activates progelatinase A. Essential for pericellular collagenolysis and modeling of skeletal and extraskeletal connective tissues during development. May be involved in actin cytoskeleton reorganization by cleaving PTK7. Acts as a positive regulator of cell growth and migration via activation of MMP15. Involved in the formation of the fibrovascular tissues in association with pro-MMP2. Cleaves ADGRB1 to release vasculostatin-40 which inhibits angiogenesis. Endopeptidase that degrades various components of the extracellular matrix such as collagen.
T65019	PDBSTRUC	6CM1; 6CLZ; 5H0U; 4QXU; 4P3D
T65019	BIOCLASS	Peptidase
T65019	ECNUMBER	EC 3.4.24.80
T65019	SEQUENCE	MSPAPRPPRCLLLPLLTLGTALASLGSAQSSSFSPEAWLQQYGYLPPGDLRTHTQRSPQSLSAAIAAMQKFYGLQVTGKADADTMKAMRRPRCGVPDKFGAEIKANVRRKRYAIQGLKWQHNEITFCIQNYTPKVGEYATYEAIRKAFRVWESATPLRFREVPYAYIREGHEKQADIMIFFAEGFHGDSTPFDGEGGFLAHAYFPGPNIGGDTHFDSAEPWTVRNEDLNGNDIFLVAVHELGHALGLEHSSDPSAIMAPFYQWMDTENFVLPDDDRRGIQQLYGGESGFPTKMPPQPRTTSRPSVPDKPKNPTYGPNICDGNFDTVAMLRGEMFVFKERWFWRVRNNQVMDGYPMPIGQFWRGLPASINTAYERKDGKFVFFKGDKHWVFDEASLEPGYPKHIKELGRGLPTDKIDAALFWMPNGKTYFFRGNKYYRFNEELRAVDSEYPKNIKVWEGIPESPRGSFMGSDEVFTYFYKGNKYWKFNNQKLKVEPGYPKSALRDWMGCPSGGRPDEGTEEETEVIIIEVDEEGGGAVSAAAVVLPVLLLLLVLAVGLAVFFFRRHGTPRRLLYCQRSLLDKV
T65019	DRUGINFO	D0U2BH	Epigallocatechin gallate	Phase 3
T65019	DRUGINFO	DE2Z7V	BT1718	Phase 1/2a
T65019	DRUGINFO	D0T9HG	GM6001	Discontinued in Phase 2
T65019	DRUGINFO	D03XBB	DX-2400	Investigative
T65019	DRUGINFO	D07DRT	PMID23631440C29e	Investigative
T65019	DRUGINFO	D09ZOA	2-(biphenyl-4-ylsulfonamido)-N-hydroxyacetamide	Investigative
T65019	DRUGINFO	D0NV9C	2-(4-bromophenylsulfonamido)-N-hydroxyacetamide	Investigative
T65019	DRUGINFO	D0XK7G	N-hydroxy-2-(4-methoxyphenylsulfonamido)acetamide	Investigative
T65019	DRUGINFO	D0NP8A	UK-356618	Investigative
T65019	DRUGINFO	D05THD	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	Investigative
T65019	DRUGINFO	D07MJD	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	Investigative
T65019	DRUGINFO	D0S9OL	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	Investigative
T65019	DRUGINFO	D03AMR	SR-973	Investigative
T65019	DRUGINFO	D0W2UK	IK-862	Investigative
T65019	DRUGINFO	D0A4TC	MMI270	Investigative

T44458	TARGETID	T44458
T44458	FORMERID	TTDC00095
T44458	UNIPROID	CDK9_HUMAN
T44458	TARGNAME	Cyclin-dependent kinase 9 (CDK9)
T44458	GENENAME	CDK9
T44458	TARGTYPE	Clinical trial
T44458	SYNONYMS	Tat-associated kinase complex catalytic subunit; TAK; Similar to cyclin-dependent kinase 9; Serine/threonine-protein kinase PITALRE; Cyclin-dependent protein kinase Cdk9; Cell division protein kinase 9; Cell division cycle 2-like protein kinase 4; CDC2L4; CDC2-related kinase; C-2K
T44458	FUNCTION	Member of the cyclin-dependent kinase pair (CDK9/cyclin-T) complex, also called positive transcription elongation factor b (P-TEFb), which facilitates the transition from abortive to productive elongation by phosphorylating the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNAP II) POLR2A, SUPT5H and RDBP. This complex is inactive when in the 7SK snRNP complex form. Phosphorylates EP300, MYOD1, RPB1/POLR2A and AR, and the negative elongation factors DSIF and NELF. Regulates cytokine inducible transcription networks by facilitating promoter recognition of target transcription factors (e. g. TNF-inducible RELA/p65 activation and IL-6-inducible STAT3 signaling). Promotes RNA synthesis in genetic programs for cell growth, differentiation and viral pathogenesis. P-TEFb is also involved in cotranscriptional histone modification, mRNA processing and mRNA export. Modulates a complex network of chromatin modifications including histone H2B monoubiquitination (H2Bub1), H3 lysine 4 trimethylation (H3K4me3) and H3K36me3; integrates phosphorylation during transcription with chromatin modifications to control co-transcriptional histone mRNA processing. The CDK9/cyclin-K complex has also a kinase activity towards CTD of RNAP II and can substitute for CDK9/cyclin-T P-TEFb in vitro. Replication stress response protein; the CDK9/cyclin-K complex is required for genome integrity maintenance, by promoting cell cycle recovery from replication arrest and limiting single-stranded DNA amount in response to replication stress, thus reducing the breakdown of stalled replication forks and avoiding DNA damage. In addition, probable function in DNA repair of isoform 2 via interaction with KU70/XRCC6. Promotes cardiac myocyte enlargement. RPB1/POLR2A phosphorylation on 'Ser-2' in CTD activates transcription. AR phosphorylation modulates AR transcription factor promoter selectivity and cell growth. DSIF and NELF phosphorylation promotes transcription by inhibiting their negative effect. The phosphorylation of MYOD1 enhances its transcriptional activity and thus promotes muscle differentiation. Protein kinase involved in the regulation of transcription.
T44458	PDBSTRUC	6GZH; 6CYT; 5L1Z; 4OR5; 4OGR
T44458	BIOCLASS	Kinase
T44458	ECNUMBER	EC 2.7.11.22
T44458	SEQUENCE	MAKQYDSVECPFCDEVSKYEKLAKIGQGTFGEVFKARHRKTGQKVALKKVLMENEKEGFPITALREIKILQLLKHENVVNLIEICRTKASPYNRCKGSIYLVFDFCEHDLAGLLSNVLVKFTLSEIKRVMQMLLNGLYYIHRNKILHRDMKAANVLITRDGVLKLADFGLARAFSLAKNSQPNRYTNRVVTLWYRPPELLLGERDYGPPIDLWGAGCIMAEMWTRSPIMQGNTEQHQLALISQLCGSITPEVWPNVDNYELYEKLELVKGQKRKVKDRLKAYVRDPYALDLIDKLLVLDPAQRIDSDDALNHDFFWSDPMPSDLKGMLSTHLTSMFEYLAPPRRKGSQITQQSTNQSRNPATTNQTEFERVF
T44458	DRUGINFO	D05IRT	P276-00	Phase 2
T44458	DRUGINFO	D0LF1U	Flavopiridol	Phase 2
T44458	DRUGINFO	D07KBM	AZD4573	Phase 1
T44458	DRUGINFO	D2GJ4P	TP-1287	Phase 1
T44458	DRUGINFO	D2YGA4	AZD7503	Phase 1
T44458	DRUGINFO	D34RXC	VIP-152	Phase 1
T44458	DRUGINFO	D0PL7P	CYC065	Phase 1
T44458	DRUGINFO	D0S5RC	SNS-032	Phase 1
T44458	DRUGINFO	D5VMP4	BTX-A51	Phase 1
T44458	DRUGINFO	D03DKV	RGB-286638	Phase 1
T44458	DRUGINFO	D00DDX	N-(pyridin-2-yl)pyrimidin-4-amine derivative 1	Patented
T44458	DRUGINFO	D03YMA	Aryl pyrimidine derivative 1	Patented
T44458	DRUGINFO	D07VPQ	Pyrazinylpyridine derivative 1	Patented
T44458	DRUGINFO	D08DWG	Phenylpyridine derivative 1	Patented
T44458	DRUGINFO	D09PGP	Phenylpyridine derivative 2	Patented
T44458	DRUGINFO	D0FR3Z	Aminoarylpyridine derivative 1	Patented
T44458	DRUGINFO	D0SV2E	PMID26161698-Compound-32	Patented
T44458	DRUGINFO	D0TH7T	Bipyridine derivative 1	Patented
T44458	DRUGINFO	D00BFF	Benzothiazine derivative 1	Patented
T44458	DRUGINFO	D03EYT	N-(pyridin-2-yl)pyridine methylsulfone derivative 1	Patented
T44458	DRUGINFO	D05UJQ	Alkyl sulfone derivative 1	Patented
T44458	DRUGINFO	D07QIP	4-(thiazol-5-yl)-pyrimidine derivative 1	Patented
T44458	DRUGINFO	D0AY5G	N-phenyl-pyrimidin-4-amine derivative 1	Patented
T44458	DRUGINFO	D0GQ7L	PMID26161698-Compound-25	Patented
T44458	DRUGINFO	D0P4NP	Diaryl amine derivative 1	Patented
T44458	DRUGINFO	D0P9WR	Flavopiridol analog 1	Patented
T44458	DRUGINFO	D0QS2B	N-(pyridin-2-yl)pyrimidin-4-amine derivative 2	Patented
T44458	DRUGINFO	D0UU0V	1,5-di-substituted pyridine derivative 1	Patented
T44458	DRUGINFO	D0V7RP	5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivative 1	Patented
T44458	DRUGINFO	D0LK4L	Nitrogen mustard derivative 1	Patented
T44458	DRUGINFO	D01CJE	4-(thiazol-5-yl)-pyrimidine derivative 2	Patented
T44458	DRUGINFO	D0LX6X	Indole-based analog 13	Patented
T44458	DRUGINFO	D0NB7Y	Pyrazolo[1,5-a]-1,3,5-triazine derivative 1	Patented
T44458	DRUGINFO	D07DUX	Roscovitine derivative 1	Patented
T44458	DRUGINFO	D0NY7M	Tricyclic benzimidazole derivative 1	Patented
T44458	DRUGINFO	D0M5DX	Oxazolyl methylthiothiazole derivative 1	Patented
T44458	DRUGINFO	D0D3PX	SCH 727965	Discontinued in Phase 3
T44458	DRUGINFO	D0NV9O	BAY 10-00394	Discontinued in Phase 2
T44458	DRUGINFO	D00VBT	ZK 304709	Discontinued in Phase 1
T44458	DRUGINFO	D0D5CQ	NVP-2	Preclinical
T44458	DRUGINFO	D04UNQ	4-(phenyldiazenyl)-1H-pyrazole-3,5-diamine	Investigative
T44458	DRUGINFO	D0CI3C	Deschloroflavopiridol	Investigative
T44458	DRUGINFO	D0E3FK	MERIOLIN 7	Investigative
T44458	DRUGINFO	D01PEF	MERIOLIN 8	Investigative
T44458	DRUGINFO	D08HFG	PMID20873740C18	Investigative
T44458	DRUGINFO	D08KSQ	MERIOLIN 1	Investigative
T44458	DRUGINFO	D0B9YR	MERIOLIN 4	Investigative
T44458	DRUGINFO	D0D0ZQ	MERIOLIN 6	Investigative
T44458	DRUGINFO	D0H6CQ	MERIOLIN 5	Investigative
T44458	DRUGINFO	D0S8VE	MERIOLIN 3	Investigative
T44458	DRUGINFO	D0U1WL	MERIOLIN 2	Investigative
T44458	DRUGINFO	D0W0BL	3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol	Investigative
T44458	DRUGINFO	D0T8NU	PMID19115845C89S	Investigative
T44458	DRUGINFO	D0A5RM	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	Investigative

T40694	TARGETID	T40694
T40694	FORMERID	TTDC00160
T40694	UNIPROID	PLK1_HUMAN
T40694	TARGNAME	Polo-like kinase 1 (PLK1)
T40694	GENENAME	PLK1
T40694	TARGTYPE	Clinical trial
T40694	SYNONYMS	Serine/threonine-protein kinase PLK1; Serine/threonine-protein kinase 13; Serine-threonine protein kinase 13; STPK13; Plk1; PLK-1; PLK; Mitoticserine-threonine kinase polo-like kinase 1
T40694	FUNCTION	Polo-like kinase proteins acts by binding and phosphorylating proteins are that already phosphorylated on a specific motif recognized by the POLO box domains. Phosphorylates BORA, BUB1B/BUBR1, CCNB1, CDC25C, CEP55, ECT2, ERCC6L, FBXO5/EMI1, FOXM1, KIF20A/MKLP2, CENPU, NEDD1, NINL, NPM1, NUDC, PKMYT1/MYT1, KIZ, PPP1R12A/MYPT1, PRC1, RACGAP1/CYK4, SGO1, STAG2/SA2, TEX14, TOPORS, p73/TP73, TPT1, WEE1 and HNRNPU. Plays a key role in centrosome functions and the assembly of bipolar spindles by phosphorylating KIZ, NEDD1 and NINL. NEDD1 phosphorylation promotes subsequent targeting of the gamma-tubulin ring complex (gTuRC) to the centrosome, an important step for spindle formation. Phosphorylation of NINL component of the centrosome leads to NINL dissociation from other centrosomal proteins. Involved in mitosis exit and cytokinesis by phosphorylating CEP55, ECT2, KIF20A/MKLP2, CENPU, PRC1 and RACGAP1. Recruited at the central spindle by phosphorylating and docking PRC1 and KIF20A/MKLP2; creates its own docking sites on PRC1 and KIF20A/MKLP2 by mediating phosphorylation of sites subsequently recognized by the POLO box domains. Phosphorylates RACGAP1, thereby creating a docking site for the Rho GTP exchange factor ECT2 that is essential for the cleavage furrow formation. Promotes the central spindle recruitment of ECT2. Plays a central role in G2/M transition of mitotic cell cycle by phosphorylating CCNB1, CDC25C, FOXM1, CENPU, PKMYT1/MYT1, PPP1R12A/MYPT1 and WEE1. Part of a regulatory circuit that promotes the activation of CDK1 by phosphorylating the positive regulator CDC25C and inhibiting the negative regulators WEE1 and PKMYT1/MYT1. Also acts by mediating phosphorylation of cyclin-B1 (CCNB1) on centrosomes in prophase. Phosphorylates FOXM1, a key mitotic transcription regulator, leading to enhance FOXM1 transcriptional activity. Involved in kinetochore functions and sister chromatid cohesion by phosphorylating BUB1B/BUBR1, FBXO5/EMI1 and STAG2/SA2. PLK1 is high on non-attached kinetochores suggesting a role of PLK1 in kinetochore attachment or in spindle assembly checkpoint (SAC) regulation. Required for kinetochore localization of BUB1B. Regulates the dissociation of cohesin from chromosomes by phosphorylating cohesin subunits such as STAG2/SA2. Phosphorylates SGO1: required for spindle pole localization of isoform 3 of SGO1 and plays a role in regulating its centriole cohesion function. Mediates phosphorylation of FBXO5/EMI1, a negative regulator of the APC/C complex during prophase, leading to FBXO5/EMI1 ubiquitination and degradation by the proteasome. Acts as a negative regulator of p53 family members: phosphorylates TOPORS, leading to inhibit the sumoylation of p53/TP53 and simultaneously enhance the ubiquitination and subsequent degradation of p53/TP53. Phosphorylates the transactivation domain of the transcription factor p73/TP73, leading to inhibit p73/TP73-mediated transcriptional activation and pro-apoptotic functions. Phosphorylates BORA, and thereby promotes the degradation of BORA. Contributes to the regulation of AURKA function. Also required for recovery after DNA damage checkpoint and entry into mitosis. Phosphorylates MISP, leading to stabilization of cortical and astral microtubule attachments required for proper spindle positioning. Together with MEIKIN, acts as a regulator of kinetochore function during meiosis I: required both for mono-orientation of kinetochores on sister chromosomes and protection of centromeric cohesin from separase-mediated cleavage. Phosphorylates CEP68 and is required for its degradation. Regulates nuclear envelope breakdown during prophase by phosphorylating DCTN1 resulting in its localization in the nuclear envelope. Phosphorylates the heat shock transcription factor HSF1, promoting HSF1 nuclear translocation upon heat shock. Phosphorylates HSF1 also in the early mitotic period; this phosphorylation regulates HSF1 localization to the spindle pole, the recruitment of the SCF(BTRC) ubiquitin ligase complex induicing HSF1 degradation, and hence mitotic progression. Regulates mitotic progression by phosphorylating RIOK2. Serine/threonine-protein kinase that performs several important functions throughout M phase of the cell cycle, including the regulation of centrosome maturation and spindle assembly, the removal of cohesins from chromosome arms, the inactivation of anaphase-promoting complex/cyclosome (APC/C) inhibitors, and the regulation of mitotic exit and cytokinesis.
T40694	PDBSTRUC	6AX4; 5TA8; 5TA6; 5NN2; 5NN1
T40694	BIOCLASS	Kinase
T40694	ECNUMBER	EC 2.7.11.21
T40694	SEQUENCE	MSAAVTAGKLARAPADPGKAGVPGVAAPGAPAAAPPAKEIPEVLVDPRSRRRYVRGRFLGKGGFAKCFEISDADTKEVFAGKIVPKSLLLKPHQREKMSMEISIHRSLAHQHVVGFHGFFEDNDFVFVVLELCRRRSLLELHKRRKALTEPEARYYLRQIVLGCQYLHRNRVIHRDLKLGNLFLNEDLEVKIGDFGLATKVEYDGERKKTLCGTPNYIAPEVLSKKGHSFEVDVWSIGCIMYTLLVGKPPFETSCLKETYLRIKKNEYSIPKHINPVAASLIQKMLQTDPTARPTINELLNDEFFTSGYIPARLPITCLTIPPRFSIAPSSLDPSNRKPLTVLNKGLENPLPERPREKEEPVVRETGEVVDCHLSDMLQQLHSVNASKPSERGLVRQEEAEDPACIPIFWVSKWVDYSDKYGLGYQLCDNSVGVLFNDSTRLILYNDGDSLQYIERDGTESYLTVSSHPNSLMKKITLLKYFRNYMSEHLLKAGANITPREGDELARLPYLRTWFRTRSAIILHLSNGSVQINFFQDHTKLILCPLMAAVTYIDEKRDFRTYRLSLLEEYGCCKELASRLRYARTMVDKLLSSRSASNRLKAS
T40694	DRUGINFO	D00BYM	Volasertib	Phase 3
T40694	DRUGINFO	D0KF9Q	Rigosertib	Phase 3
T40694	DRUGINFO	D03HUX	PCM-075	Phase 2
T40694	DRUGINFO	D0O0LQ	BI 2536	Phase 2
T40694	DRUGINFO	D05RGV	MK-1496	Phase 1
T40694	DRUGINFO	D08RMJ	GSK461364	Phase 1
T40694	DRUGINFO	D09JGK	TAK-960	Phase 1
T40694	DRUGINFO	DK26FL	CYC140	Phase 1
T40694	DRUGINFO	D0F3GC	Dihydropyrido pyrazinone compound 3	Patented
T40694	DRUGINFO	D0S0HQ	Dihydropyrido pyrazinone compound 2	Patented
T40694	DRUGINFO	D0R7ID	HMN-214	Discontinued in Phase 1
T40694	DRUGINFO	D05ZCQ	DAP-81	Preclinical
T40694	DRUGINFO	D07RMX	ZK-thiazolidinone	Preclinical
T40694	DRUGINFO	D0WZ4J	CYC-800	Preclinical
T40694	DRUGINFO	D01HHH	CHR-4125	Investigative
T40694	DRUGINFO	D03BQD	NMS-1	Investigative
T40694	DRUGINFO	D05QMQ	MLN-0905	Investigative
T40694	DRUGINFO	D05WDM	Ro5203280	Investigative
T40694	DRUGINFO	D09ZKY	GW853606	Investigative
T40694	DRUGINFO	D0H8WY	PMID19097784C2	Investigative
T40694	DRUGINFO	D0X5ZH	LC-445	Investigative
T40694	DRUGINFO	D0X1RH	GSK579289A	Investigative

T49507	TARGETID	T49507
T49507	FORMERID	TTDC00045
T49507	UNIPROID	EPHB4_HUMAN
T49507	TARGNAME	Ephrin type-B receptor 4 (EPHB4)
T49507	GENENAME	EPHB4
T49507	TARGTYPE	Clinical trial
T49507	SYNONYMS	Tyrosine-protein kinase TYRO11; TYRO11; MYK1; Hepatoma transmembrane kinase; HTK
T49507	FUNCTION	Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Together with its cognate ligand/functional ligand EFNB2 it is involved in the regulation of cell adhesion and migration, and plays a central role in heart morphogenesis, angiogenesis and blood vessel remodeling and permeability. EPHB4-mediated forward signaling controls cellular repulsion and segregation from EFNB2-expressing cells.
T49507	PDBSTRUC	6FNM; 6FNL; 6FNK; 6FNJ; 6FNI
T49507	BIOCLASS	Kinase
T49507	ECNUMBER	EC 2.7.10.1
T49507	SEQUENCE	MELRVLLCWASLAAALEETLLNTKLETADLKWVTFPQVDGQWEELSGLDEEQHSVRTYEVCDVQRAPGQAHWLRTGWVPRRGAVHVYATLRFTMLECLSLPRAGRSCKETFTVFYYESDADTATALTPAWMENPYIKVDTVAAEHLTRKRPGAEATGKVNVKTLRLGPLSKAGFYLAFQDQGACMALLSLHLFYKKCAQLTVNLTRFPETVPRELVVPVAGSCVVDAVPAPGPSPSLYCREDGQWAEQPVTGCSCAPGFEAAEGNTKCRACAQGTFKPLSGEGSCQPCPANSHSNTIGSAVCQCRVGYFRARTDPRGAPCTTPPSAPRSVVSRLNGSSLHLEWSAPLESGGREDLTYALRCRECRPGGSCAPCGGDLTFDPGPRDLVEPWVVVRGLRPDFTYTFEVTALNGVSSLATGPVPFEPVNVTTDREVPPAVSDIRVTRSSPSSLSLAWAVPRAPSGAVLDYEVKYHEKGAEGPSSVRFLKTSENRAELRGLKRGASYLVQVRARSEAGYGPFGQEHHSQTQLDESEGWREQLALIAGTAVVGVVLVLVVIVVAVLCLRKQSNGREAEYSDKHGQYLIGHGTKVYIDPFTYEDPNEAVREFAKEIDVSYVKIEEVIGAGEFGEVCRGRLKAPGKKESCVAIKTLKGGYTERQRREFLSEASIMGQFEHPNIIRLEGVVTNSMPVMILTEFMENGALDSFLRLNDGQFTVIQLVGMLRGIASGMRYLAEMSYVHRDLAARNILVNSNLVCKVSDFGLSRFLEENSSDPTYTSSLGGKIPIRWTAPEAIAFRKFTSASDAWSYGIVMWEVMSFGERPYWDMSNQDVINAIEQDYRLPPPPDCPTSLHQLMLDCWQKDRNARPRFPQVVSALDKMIRNPASLKIVARENGGASHPLLDQRQPHYSAFGSVGEWLRAIKMGRYEESFAAAGFGSFELVSQISAEDLLRIGVTLAGHQKKILASVQHMKSQAKPGTPGGTGGPAPQY
T49507	DRUGINFO	D06WRF	KD019	Phase 2
T49507	DRUGINFO	D0Q6GK	EphB4-131	Investigative
T49507	DRUGINFO	D0H1OK	TG-100435	Investigative
T49507	DRUGINFO	D05FXD	PMID19788238C66	Investigative
T49507	DRUGINFO	D0X8BU	PMID23489211C20	Investigative

T91661	TARGETID	T91661
T91661	FORMERID	TTDR00529
T91661	UNIPROID	ADK_HUMAN
T91661	TARGNAME	Adenosine kinase (ADK)
T91661	GENENAME	ADK
T91661	TARGTYPE	Clinical trial
T91661	SYNONYMS	Adenosine 5'-phosphotransferase; AK
T91661	FUNCTION	Serves as a potential regulator of concentrations of extracellular adenosine and intracellular adenine nucleotides. ATP dependent phosphorylation of adenosine and other related nucleoside analogs to monophosphate derivatives.
T91661	PDBSTRUC	4O1L; 2I6B; 2I6A; 1BX4
T91661	BIOCLASS	Kinase
T91661	ECNUMBER	EC 2.7.1.20
T91661	SEQUENCE	MAAAEEEPKPKKLKVEAPQALRENILFGMGNPLLDISAVVDKDFLDKYSLKPNDQILAEDKHKELFDELVKKFKVEYHAGGSTQNSIKVAQWMIQQPHKAATFFGCIGIDKFGEILKRKAAEAHVDAHYYEQNEQPTGTCAACITGDNRSLIANLAAANCYKKEKHLDLEKNWMLVEKARVCYIAGFFLTVSPESVLKVAHHASENNRIFTLNLSAPFISQFYKESLMKVMPYVDILFGNETEAATFAREQGFETKDIKEIAKKTQALPKMNSKRQRIVIFTQGRDDTIMATESEVTAFAVLDQDQKEIIDTNGAGDAFVGGFLSQLVSDKPLTECIRAGHYAASIIIRRTGCTFPEKPDFH
T91661	DRUGINFO	D01GVC	GP-3269	Phase 1
T91661	DRUGINFO	D08LUT	ABT-702	Terminated
T91661	DRUGINFO	D0JI1J	GP-683	Terminated
T91661	DRUGINFO	D0S9XV	A-134974	Terminated
T91661	DRUGINFO	D00RDY	5'-iodotubercidin	Investigative
T91661	DRUGINFO	D00WHC	MB-03966	Investigative
T91661	DRUGINFO	D03SHX	5-iodo,5'-deoxytubercidin	Investigative
T91661	DRUGINFO	D0K1YY	6-Benzylthioinosine	Investigative
T91661	DRUGINFO	D0S2FW	Iodotubercidin	Investigative
T91661	DRUGINFO	D07OAC	GP515	Investigative

T63816	TARGETID	T63816
T63816	FORMERID	TTDC00159
T63816	UNIPROID	HDAC4_HUMAN
T63816	TARGNAME	Histone deacetylase 4 (HDAC4)
T63816	GENENAME	HDAC4
T63816	TARGTYPE	Clinical trial
T63816	SYNONYMS	KIAA0288; HD4
T63816	FUNCTION	Gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Involved in muscle maturation via its interaction with the myocyte enhancer factors such as MEF2A, MEF2C and MEF2D. Involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. Deacetylates HSPA1A and HSPA1B at 'Lys-77' leading to their preferential binding to co-chaperone STUB1. Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4).
T63816	PDBSTRUC	6FYZ; 5ZOP; 5ZOO; 5A2S; 4CBY
T63816	BIOCLASS	Carbon-nitrogen hydrolase
T63816	ECNUMBER	EC 3.5.1.98
T63816	SEQUENCE	MSSQSHPDGLSGRDQPVELLNPARVNHMPSTVDVATALPLQVAPSAVPMDLRLDHQFSLPVAEPALREQQLQQELLALKQKQQIQRQILIAEFQRQHEQLSRQHEAQLHEHIKQQQEMLAMKHQQELLEHQRKLERHRQEQELEKQHREQKLQQLKNKEKGKESAVASTEVKMKLQEFVLNKKKALAHRNLNHCISSDPRYWYGKTQHSSLDQSSPPQSGVSTSYNHPVLGMYDAKDDFPLRKTASEPNLKLRSRLKQKVAERRSSPLLRRKDGPVVTALKKRPLDVTDSACSSAPGSGPSSPNNSSGSVSAENGIAPAVPSIPAETSLAHRLVAREGSAAPLPLYTSPSLPNITLGLPATGPSAGTAGQQDAERLTLPALQQRLSLFPGTHLTPYLSTSPLERDGGAAHSPLLQHMVLLEQPPAQAPLVTGLGALPLHAQSLVGADRVSPSIHKLRQHRPLGRTQSAPLPQNAQALQHLVIQQQHQQFLEKHKQQFQQQQLQMNKIIPKPSEPARQPESHPEETEEELREHQALLDEPYLDRLPGQKEAHAQAGVQVKQEPIESDEEEAEPPREVEPGQRQPSEQELLFRQQALLLEQQRIHQLRNYQASMEAAGIPVSFGGHRPLSRAQSSPASATFPVSVQEPPTKPRFTTGLVYDTLMLKHQCTCGSSSSHPEHAGRIQSIWSRLQETGLRGKCECIRGRKATLEELQTVHSEAHTLLYGTNPLNRQKLDSKKLLGSLASVFVRLPCGGVGVDSDTIWNEVHSAGAARLAVGCVVELVFKVATGELKNGFAVVRPPGHHAEESTPMGFCYFNSVAVAAKLLQQRLSVSKILIVDWDVHHGNGTQQAFYSDPSVLYMSLHRYDDGNFFPGSGAPDEVGTGPGVGFNVNMAFTGGLDPPMGDAEYLAAFRTVVMPIASEFAPDVVLVSSGFDAVEGHPTPLGGYNLSARCFGYLTKQLMGLAGGRIVLALEGGHDLTAICDASEACVSALLGNELDPLPEKVLQQRPNANAVRSMEKVMEIHSKYWRCLQRTTSTAGRSLIEAQTCENEEAETVTAMASLSVGVKPAEKRPDEEPMEEEPPL
T63816	DRUGINFO	D02YLT	PMID29671355-Compound-52	Patented
T63816	DRUGINFO	D03KOH	PMID29671355-Compound-72a	Patented
T63816	DRUGINFO	D07KQB	PMID29671355-Compound-47c	Patented
T63816	DRUGINFO	D08CYC	PMID29671355-Compound-70	Patented
T63816	DRUGINFO	D0BV4M	PMID29671355-Compound-71b	Patented
T63816	DRUGINFO	D0E7TU	PMID29671355-Compound-72b	Patented
T63816	DRUGINFO	D0L1NO	PMID29671355-Compound-47a	Patented
T63816	DRUGINFO	D0M7GG	PMID29671355-Compound-50	Patented
T63816	DRUGINFO	D0NG9V	PMID29671355-Compound-47b	Patented
T63816	DRUGINFO	D0O1LX	PMID29671355-Compound-71a	Patented
T63816	DRUGINFO	D0SP7T	PMID29671355-Compound-47d	Patented
T63816	DRUGINFO	D0UE9B	PMID29671355-Compound-12	Patented
T63816	DRUGINFO	D0GD6R	PMID29671355-Compound-68b	Patented
T63816	DRUGINFO	D0YN2T	PMID29671355-Compound-45a	Patented
T63816	DRUGINFO	D0JB4S	PMID29671355-Compound-61	Patented
T63816	DRUGINFO	D00HXJ	PMID29671355-Compound-23	Patented
T63816	DRUGINFO	D0CH8Q	PMID29671355-Compound-56	Patented
T63816	DRUGINFO	D0M0RE	PMID29671355-Compound-67	Patented
T63816	DRUGINFO	D0DI9S	PMID29671355-Compound-31	Patented
T63816	DRUGINFO	D0LP1K	PMID29671355-Compound-21	Patented
T63816	DRUGINFO	D07WAT	PMID29671355-Compound-62	Patented
T63816	DRUGINFO	D0BP8I	PMID29671355-Compound-43	Patented
T63816	DRUGINFO	D0RA0D	PMID29671355-Compound-25	Patented
T63816	DRUGINFO	D03BQS	N-hydroxy-9,10-dihydroanthracene-9-carboxamide	Investigative
T63816	DRUGINFO	D03QOD	N-hydroxy-2,2-diphenylacetamide	Investigative
T63816	DRUGINFO	D06IMY	N-hydroxy-9H-xanthene-9-carboxamide	Investigative
T63816	DRUGINFO	D0A4HF	2,2-bis(3-fluorophenyl)-N-hydroxyacetamide	Investigative
T63816	DRUGINFO	D0E9DD	AZUMAMIDE E	Investigative
T63816	DRUGINFO	D0FN5D	2,2-bis(4-fluorophenyl)-N-hydroxyacetamide	Investigative
T63816	DRUGINFO	D0I4RK	N-hydroxy-2,2-diphenylpropanamide	Investigative
T63816	DRUGINFO	D0M1ZI	AZUMAMIDE B	Investigative
T63816	DRUGINFO	D0PK9V	2,2-bis(4-chlorophenyl)-N-hydroxyacetamide	Investigative
T63816	DRUGINFO	D0Q9PO	AZUMAMIDE C	Investigative
T63816	DRUGINFO	D0Z8PX	LARGAZOLE	Investigative
T63816	DRUGINFO	D00XTC	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)	Investigative
T63816	DRUGINFO	D02HVH	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide	Investigative
T63816	DRUGINFO	D02NAF	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)	Investigative
T63816	DRUGINFO	D02NVY	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)	Investigative
T63816	DRUGINFO	D03PRG	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)	Investigative
T63816	DRUGINFO	D04CDZ	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)	Investigative
T63816	DRUGINFO	D09RKA	santacruzamate A	Investigative
T63816	DRUGINFO	D0E8UH	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)	Investigative
T63816	DRUGINFO	D0G1EX	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)	Investigative
T63816	DRUGINFO	D0N5RV	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)	Investigative
T63816	DRUGINFO	D0R3XO	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)	Investigative
T63816	DRUGINFO	D0U0EZ	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)	Investigative
T63816	DRUGINFO	D0X4QC	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)	Investigative
T63816	DRUGINFO	D0Z6HR	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)	Investigative
T63816	DRUGINFO	D0Z6MI	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)	Investigative
T63816	DRUGINFO	D0R7JA	TMP269	Investigative
T63816	DRUGINFO	D0S0WK	8-Oxo-8-phenyl-octanoic acid hydroxyamide	Investigative
T63816	DRUGINFO	D01YBR	ST-3050	Investigative
T63816	DRUGINFO	D07YZZ	Octanedioic acid bis-hydroxyamide	Investigative
T63816	DRUGINFO	D00KFF	9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide	Investigative
T63816	DRUGINFO	D00SEE	7-Mercapto-heptanoic acid phenylamide	Investigative
T63816	DRUGINFO	D00ZSD	6-benzenesulfinylhexanoic acid hydroxamide	Investigative
T63816	DRUGINFO	D01MFV	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	Investigative
T63816	DRUGINFO	D01XWZ	7-Mercapto-heptanoic acid biphenyl-4-ylamide	Investigative
T63816	DRUGINFO	D01XXN	N-Hydroxy-4-phenylacetylamino-benzamide	Investigative
T63816	DRUGINFO	D02MQM	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	Investigative
T63816	DRUGINFO	D02UTC	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	Investigative
T63816	DRUGINFO	D02WZK	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	Investigative
T63816	DRUGINFO	D04GGW	Octanedioic acid hydroxyamide pyridin-4-ylamide	Investigative
T63816	DRUGINFO	D04HSS	N-(6-Mercapto-hexyl)-benzamide	Investigative
T63816	DRUGINFO	D04NSP	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	Investigative
T63816	DRUGINFO	D04ZDI	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	Investigative
T63816	DRUGINFO	D05AHZ	6-benzenesulfonylhexanoic acid hydroxamide	Investigative
T63816	DRUGINFO	D05FEJ	9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one	Investigative
T63816	DRUGINFO	D05GVY	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	Investigative
T63816	DRUGINFO	D05LLX	4-Butyrylamino-N-hydroxy-benzamide	Investigative
T63816	DRUGINFO	D05VFP	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	Investigative
T63816	DRUGINFO	D05XAN	7-Mercapto-heptanoic acid biphenyl-3-ylamide	Investigative
T63816	DRUGINFO	D06IQB	5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione	Investigative
T63816	DRUGINFO	D06VBN	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	Investigative
T63816	DRUGINFO	D06XNP	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	Investigative
T63816	DRUGINFO	D07FJU	7-Mercapto-heptanoic acid pyridin-3-ylamide	Investigative
T63816	DRUGINFO	D09YBN	6-Phenoxy-hexane-1-thiol	Investigative
T63816	DRUGINFO	D09ZNU	4-Benzoylamino-N-hydroxy-benzamide	Investigative
T63816	DRUGINFO	D0A5LS	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	Investigative
T63816	DRUGINFO	D0AX7B	8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one	Investigative
T63816	DRUGINFO	D0B2ZJ	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	Investigative
T63816	DRUGINFO	D0B3ZM	6-Mercapto-hexanoic acid phenylamide	Investigative
T63816	DRUGINFO	D0C0VP	Cyclostellettamine derivative	Investigative
T63816	DRUGINFO	D0C2KD	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	Investigative
T63816	DRUGINFO	D0D2KE	5-Mercapto-pentanoic acid phenylamide	Investigative
T63816	DRUGINFO	D0E8KR	Octanedioic acid hydroxyamide pyridin-2-ylamide	Investigative
T63816	DRUGINFO	D0F0KS	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	Investigative
T63816	DRUGINFO	D0H1FZ	2-(methylsulfonylthio)ethyl 2-propylpentanoate	Investigative
T63816	DRUGINFO	D0KE3I	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	Investigative
T63816	DRUGINFO	D0QO0L	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	Investigative
T63816	DRUGINFO	D0R4BS	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	Investigative
T63816	DRUGINFO	D0R5VG	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	Investigative
T63816	DRUGINFO	D0RU1X	8-Oxo-8-phenyl-octanoic acid	Investigative
T63816	DRUGINFO	D0S7WQ	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	Investigative
T63816	DRUGINFO	D0S9JF	6-phenylsulfanylhexanoic acid hydroxamide	Investigative
T63816	DRUGINFO	D0T0SK	ST-2987	Investigative
T63816	DRUGINFO	D0T4IY	7-Mercapto-heptanoic acid quinolin-3-ylamide	Investigative
T63816	DRUGINFO	D0V2ZO	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	Investigative
T63816	DRUGINFO	D0XZ9Q	8-Mercapto-octanoic acid phenylamide	Investigative
T63816	DRUGINFO	D0YY9M	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	Investigative
T63816	DRUGINFO	D0Z3BM	7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one	Investigative
T63816	DRUGINFO	D0Z5KX	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	Investigative
T63816	DRUGINFO	D0Z7YS	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	Investigative
T63816	DRUGINFO	D0N0TS	PSAMMAPLIN A	Investigative

T51565	TARGETID	T51565
T51565	FORMERID	TTDR00257
T51565	UNIPROID	CSK21_HUMAN
T51565	TARGNAME	Casein kinase II alpha (CSNK2A1)
T51565	GENENAME	CSNK2A1
T51565	TARGTYPE	Clinical trial
T51565	SYNONYMS	Protein kinase CK2; Casein kinase II subunit alpha; CK2A1; CK II alpha; CK II
T51565	FUNCTION	Regulates numerous cellular processes, such as cell cycle progression, apoptosis and transcription, as well as viral infection. May act as a regulatory node which integrates and coordinates numerous signals leading to an appropriate cellular response. During mitosis, functions as a component of the p53/TP53-dependent spindle assembly checkpoint (SAC) that maintains cyclin-B-CDK1 activity and G2 arrest in response to spindle damage. Also required for p53/TP53-mediated apoptosis, phosphorylating 'Ser-392' of p53/TP53 following UV irradiation. Can also negatively regulate apoptosis. Phosphorylates the caspases CASP9 and CASP2 and the apoptotic regulator NOL3. Phosphorylation protects CASP9 from cleavage and activation by CASP8, and inhibits the dimerization of CASP2 and activation of CASP8. Regulates transcription by direct phosphorylation of RNA polymerases I, II, III and IV. Also phosphorylates and regulates numerous transcription factors including NF-kappa-B, STAT1, CREB1, IRF1, IRF2, ATF1, SRF, MAX, JUN, FOS, MYC and MYB. Phosphorylates Hsp90 and its co-chaperones FKBP4 and CDC37, which is essential for chaperone function. Regulates Wnt signaling by phosphorylating CTNNB1 and the transcription factor LEF1. Acts as an ectokinase that phosphorylates several extracellular proteins. During viral infection, phosphorylates various proteins involved in the viral life cycles of EBV, HSV, HBV, HCV, HIV, CMV and HPV. Phosphorylates PML at 'Ser-565' and primes it for ubiquitin-mediated degradation. Plays an important role in the circadian clock function by phosphorylating ARNTL/BMAL1 at 'Ser-90' which is pivotal for its interaction with CLOCK and which controls CLOCK nuclear entry. Phosphorylates CCAR2 at 'Thr-454' in gastric carcinoma tissue. Catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine.
T51565	PDBSTRUC	6Q4Q; 6Q38; 6HME; 6HBN; 6GMD
T51565	BIOCLASS	Kinase
T51565	ECNUMBER	EC 2.7.11.1
T51565	SEQUENCE	MSGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKDQARMGSSSMPGGSTPVSSANMMSGISSVPTPSPLGPLAGSPVIAAANPLGMPVPAAAGAQQ
T51565	DRUGINFO	D09JEJ	CX-4945	Phase 2
T51565	DRUGINFO	D0U7OU	EMODIN	Terminated
T51565	DRUGINFO	D0R2TM	BALANOL	Terminated
T51565	DRUGINFO	D04BNM	5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole	Investigative
T51565	DRUGINFO	D06SEA	CX-7000	Investigative
T51565	DRUGINFO	D09ZNV	CGP-029482	Investigative
T51565	DRUGINFO	D0CP3M	4,5,6,7-tetrabromo-1H-benzimidazole	Investigative
T51565	DRUGINFO	D0CR9I	CX-5011	Investigative
T51565	DRUGINFO	D0V5HG	7,8-dichloroquinoline-4-one-3-carboxylic acid	Investigative
T51565	DRUGINFO	D0Y8CU	5,6,8-trichloroquinoline-4-one-3-carboxylic acid	Investigative
T51565	DRUGINFO	D0K6BI	PMID22115617C2c	Investigative
T51565	DRUGINFO	D07MMG	AdoC(Dpr)2AlaArg6	Investigative
T51565	DRUGINFO	D04TPA	PMID24900749C1a	Investigative
T51565	DRUGINFO	D00RIX	APIGENIN	Investigative
T51565	DRUGINFO	D0A1CM	ELLAGIC ACID	Investigative
T51565	DRUGINFO	D0O1YH	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	Investigative
T51565	DRUGINFO	D0A5RM	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	Investigative

T19760	TARGETID	T19760
T19760	FORMERID	TTDR00339
T19760	UNIPROID	M3K9_HUMAN
T19760	TARGNAME	Mixed lineage kinase 1 (MAP3K9)
T19760	GENENAME	MAP3K9
T19760	TARGTYPE	Clinical trial
T19760	SYNONYMS	PRKE1; Mitogen-activated protein kinase kinase kinase 9; MLK1
T19760	FUNCTION	Plays an important role in the cascades of cellular responses evoked by changes in the environment. Once activated, acts as an upstream activator of the MKK/JNK signal transduction cascade through the phosphorylation of MAP2K4/MKK4 and MAP2K7/MKK7 which in turn activate the JNKs. The MKK/JNK signaling pathway regulates stress response via activator protein-1 (JUN) and GATA4 transcription factors. Plays also a role in mitochondrial death signaling pathway, including the release cytochrome c, leading to apoptosis. Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway.
T19760	PDBSTRUC	4UY9; 3DTC
T19760	BIOCLASS	Kinase
T19760	ECNUMBER	EC 2.7.11.25
T19760	SEQUENCE	MEPSRALLGCLASAAAAAPPGEDGAGAGAEEEEEEEEEAAAAVGPGELGCDAPLPYWTAVFEYEAAGEDELTLRLGDVVEVLSKDSQVSGDEGWWTGQLNQRVGIFPSNYVTPRSAFSSRCQPGGEDPSCYPPIQLLEIDFAELTLEEIIGIGGFGKVYRAFWIGDEVAVKAARHDPDEDISQTIENVRQEAKLFAMLKHPNIIALRGVCLKEPNLCLVMEFARGGPLNRVLSGKRIPPDILVNWAVQIARGMNYLHDEAIVPIIHRDLKSSNILILQKVENGDLSNKILKITDFGLAREWHRTTKMSAAGTYAWMAPEVIRASMFSKGSDVWSYGVLLWELLTGEVPFRGIDGLAVAYGVAMNKLALPIPSTCPEPFAKLMEDCWNPDPHSRPSFTNILDQLTTIEESGFFEMPKDSFHCLQDNWKHEIQEMFDQLRAKEKELRTWEEELTRAALQQKNQEELLRRREQELAEREIDILERELNIIIHQLCQEKPRVKKRKGKFRKSRLKLKDGNRISLPSDFQHKFTVQASPTMDKRKSLINSRSSPPASPTIIPRLRAIQLTPGESSKTWGRSSVVPKEEGEEEEKRAPKKKGRTWGPGTLGQKELASGDEGSPQRREKANGLSTPSESPHFHLGLKSLVDGYKQWSSSAPNLVKGPRSSPALPGFTSLMEMEDEDSEGPGSGESRLQHSPSQSYLCIPFPRGEDGDGPSSDGIHEEPTPVNSATSTPQLTPTNSLKRGGAHHRRCEVALLGCGAVLAATGLGFDLLEAGKCQLLPLEEPEPPAREEKKRREGLFQRSSRPRRSTSPPSRKLFKKEEPMLLLGDPSASLTLLSLSSISECNSTRSLLRSDSDEIVVYEMPVSPVEAPPLSPCTHNPLVNVRVERFKRDPNQSLTPTHVTLTTPSQPSSHRRTPSDGALKPETLLASRSPSSNGLSPSPGAGMLKTPSPSRDPGEFPRLPDPNVVFPPTPRRWNTQQDSTLERPKTLEFLPRPRPSANRQRLDPWWFVSPSHARSTSPANSSSTETPSNLDSCFASSSSTVEERPGLPALLPFQAGPLPPTERTLLDLDAEGQSQDSTVPLCRAELNTHRPAPYEIQQEFWS
T19760	DRUGINFO	D03QLG	CEP1347	Phase 2/3
T19760	DRUGINFO	D07IHM	CEP-6331	Investigative
T19760	DRUGINFO	D09QBA	CEP-5104	Investigative
T19760	DRUGINFO	D07ADX	URMC-099	Investigative

T00176	TARGETID	T00176
T00176	FORMERID	TTDC00206
T00176	UNIPROID	MDM2_HUMAN
T00176	TARGNAME	Ubiquitin-protein ligase E3 Mdm2 (MDM2)
T00176	GENENAME	MDM2
T00176	TARGTYPE	Clinical trial
T00176	SYNONYMS	RING-type E3 ubiquitin transferase Mdm2; P53-binding protein Mdm2; Oncoprotein Mdm2; MDM2 protein; Hdm2; E3 ubiquitin-protein ligase Mdm2; Double minute 2 protein
T00176	FUNCTION	Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. Also acts as a ubiquitin ligase E3 toward itself and ARRB1. Permits the nuclear export of p53/TP53. Promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. Inhibits DAXX-mediated apoptosis by inducing its ubiquitination and degradation. Component of the TRIM28/KAP1-MDM2-p53/TP53 complex involved in stabilizing p53/TP53. Also component of the TRIM28/KAP1-ERBB4-MDM2 complex which links growth factor and DNA damage response pathways. Mediates ubiquitination and subsequent proteasome degradation of DYRK2 in nucleus. Ubiquitinates IGF1R and SNAI1 and promotes them to proteasomal degradation. Ubiquitinates DCX, leading to DCX degradation and reduction of the dendritic spine density of olfactory bulb granule cells. Ubiquitinates DLG4, leading to proteasomal degradation of DLG4 which is required for AMPA receptor endocytosis. E3 ubiquitin-protein ligase that mediates ubiquitination of p53/TP53, leading to its degradation by the proteasome.
T00176	PDBSTRUC	6Q9O; 6Q9L; 6Q9H; 6Q96; 6IM9
T00176	BIOCLASS	Acyltransferase
T00176	ECNUMBER	EC 2.3.2.27
T00176	SEQUENCE	MCNTNMSVPTDGAVTTSQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQESSDSGTSVSENRCHLEGGSDQKDLVQELQEEKPSSSHLVSRPSTSSRRRAISETEENSDELSGERQRKRHKSDSISLSFDESLALCVIREICCERSSSSESTGTPSNPDLDAGVSEHSGDWLDQDSVSDQFSVEFEVESLDSEDYSLSEEGQELSDEDDEVYQVTVYQAGESDTDSFEEDPEISLADYWKCTSCNEMNPPLPSHCNRCWALRENWLPEDKGKDKGEISEKAKLENSTQAEEGFDVPDCKKTIVNDSRESCVEENDDKITQASQSQESEDYSQPSTSSSIIYSSQEDVKEFEREETQDKEESVESSLPLNAIEPCVICQGRPKNGCIVHGKTGHLMACFTCAKKLKKRNKPCPVCRQPIQMIVLTYFP
T00176	DRUGINFO	D0OC4O	RG7388	Phase 3
T00176	DRUGINFO	D0C1WR	AMG 232	Phase 2
T00176	DRUGINFO	D04SXL	APG-115	Phase 2
T00176	DRUGINFO	D07UKT	ALRN-6924	Phase 2
T00176	DRUGINFO	DE7N6F	ASTX295	Phase 1/2
T00176	DRUGINFO	D08JSQ	DS-3032	Phase 1
T00176	DRUGINFO	D08TNG	RG7775	Phase 1
T00176	DRUGINFO	D0B3GF	JNJ-26854165	Phase 1
T00176	DRUGINFO	DW3AX4	BI 907828	Phase 1
T00176	DRUGINFO	D01KTG	HDM201	Phase 1
T00176	DRUGINFO	DNY16U	MI-219	Investigative

T92144	TARGETID	T92144
T92144	FORMERID	TTDC00161
T92144	UNIPROID	TIE2_HUMAN
T92144	TARGNAME	Angiopoietin 1 receptor (TEK)
T92144	GENENAME	TEK
T92144	TARGTYPE	Clinical trial
T92144	SYNONYMS	hTIE2; VMCM1; VMCM; Tyrosine-protein kinase receptor TIE-2; Tyrosine-protein kinase receptor TEK; Tyrosine kinase with Ig and EGF homology domains-2; Tunica interna endothelial cell kinase; TIE2; P140 TEK; Endothelial tyrosine kinase; Endothelial Cell-Specific Receptor TIE-2; CD202b antigen; CD202b
T92144	FUNCTION	Has anti-inflammatory effects by preventing the leakage of proinflammatory plasma proteins and leukocytes from blood vessels. Required for normal angiogenesis and heart development during embryogenesis. Required for post-natal hematopoiesis. After birth, activates or inhibits angiogenesis, depending on the context. Inhibits angiogenesis and promotes vascular stability in quiescent vessels, where endothelial cells have tight contacts. In quiescent vessels, ANGPT1 oligomers recruit TEK to cell-cell contacts, forming complexes with TEK molecules from adjoining cells, and this leads to preferential activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascades. In migrating endothelial cells that lack cell-cell adhesions, ANGT1 recruits TEK to contacts with the extracellular matrix, leading to the formation of focal adhesion complexes, activation of PTK2/FAK and of the downstream kinases MAPK1/ERK2 and MAPK3/ERK1, and ultimately to the stimulation of sprouting angiogenesis. ANGPT1 signaling triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Signaling is modulated by ANGPT2 that has lower affinity for TEK, can promote TEK autophosphorylation in the absence of ANGPT1, but inhibits ANGPT1-mediated signaling by competing for the same binding site. Signaling is also modulated by formation of heterodimers with TIE1, and by proteolytic processing that gives rise to a soluble TEK extracellular domain. The soluble extracellular domain modulates signaling by functioning as decoy receptor for angiopoietins. TEK phosphorylates DOK2, GRB7, GRB14, PIK3R1; SHC1 and TIE1. Tyrosine-protein kinase that acts as cell-surface receptor for ANGPT1, ANGPT2 and ANGPT4 and regulates angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton, but also maintenance of vascular quiescence.
T92144	PDBSTRUC	6MWE; 5UTK; 5MYB; 5MYA; 4X3J
T92144	BIOCLASS	Kinase
T92144	ECNUMBER	EC 2.7.10.1
T92144	SEQUENCE	MDSLASLVLCGVSLLLSGTVEGAMDLILINSLPLVSDAETSLTCIASGWRPHEPITIGRDFEALMNQHQDPLEVTQDVTREWAKKVVWKREKASKINGAYFCEGRVRGEAIRIRTMKMRQQASFLPATLTMTVDKGDNVNISFKKVLIKEEDAVIYKNGSFIHSVPRHEVPDILEVHLPHAQPQDAGVYSARYIGGNLFTSAFTRLIVRRCEAQKWGPECNHLCTACMNNGVCHEDTGECICPPGFMGRTCEKACELHTFGRTCKERCSGQEGCKSYVFCLPDPYGCSCATGWKGLQCNEACHPGFYGPDCKLRCSCNNGEMCDRFQGCLCSPGWQGLQCEREGIQRMTPKIVDLPDHIEVNSGKFNPICKASGWPLPTNEEMTLVKPDGTVLHPKDFNHTDHFSVAIFTIHRILPPDSGVWVCSVNTVAGMVEKPFNISVKVLPKPLNAPNVIDTGHNFAVINISSEPYFGDGPIKSKKLLYKPVNHYEAWQHIQVTNEIVTLNYLEPRTEYELCVQLVRRGEGGEGHPGPVRRFTTASIGLPPPRGLNLLPKSQTTLNLTWQPIFPSSEDDFYVEVERRSVQKSDQQNIKVPGNLTSVLLNNLHPREQYVVRARVNTKAQGEWSEDLTAWTLSDILPPQPENIKISNITHSSAVISWTILDGYSISSITIRYKVQGKNEDQHVDVKIKNATITQYQLKGLEPETAYQVDIFAENNIGSSNPAFSHELVTLPESQAPADLGGGKMLLIAILGSAGMTCLTVLLAFLIILQLKRANVQRRMAQAFQNVREEPAVQFNSGTLALNRKVKNNPDPTIYPVLDWNDIKFQDVIGEGNFGQVLKARIKKDGLRMDAAIKRMKEYASKDDHRDFAGELEVLCKLGHHPNIINLLGACEHRGYLYLAIEYAPHGNLLDFLRKSRVLETDPAFAIANSTASTLSSQQLLHFAADVARGMDYLSQKQFIHRDLAARNILVGENYVAKIADFGLSRGQEVYVKKTMGRLPVRWMAIESLNYSVYTTNSDVWSYGVLLWEIVSLGGTPYCGMTCAELYEKLPQGYRLEKPLNCDDEVYDLMRQCWREKPYERPSFAQILVSLNRMLEERKTYVNTTLYEKFTYAGIDCSAEEAA
T92144	DRUGINFO	D08VIS	AKB-9778	Phase 2
T92144	DRUGINFO	D0E0NM	DCC-2036	Phase 1/2
T92144	DRUGINFO	D0FD6D	CEP-11981	Phase 1
T92144	DRUGINFO	D0FA6S	Altiratinib	Phase 1
T92144	DRUGINFO	D0ML0L	ARRY-614	Discontinued in Phase 1
T92144	DRUGINFO	D0K5QY	AP-101	Investigative
T92144	DRUGINFO	D1JS9X	ABTAA	Investigative
T92144	DRUGINFO	D07AIB	(4-Phenoxy-phenyl)-quinazolin-4-yl-amine	Investigative
T92144	DRUGINFO	D0BS6R	A-420983	Investigative
T92144	DRUGINFO	D02BXJ	PMID21561767C8h	Investigative
T92144	DRUGINFO	D06AOY	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	Investigative
T92144	DRUGINFO	D00NYT	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	Investigative
T92144	DRUGINFO	D0C3WY	3,4-diphenyl-1H-pyrrole-2,5-dione	Investigative
T92144	DRUGINFO	D0EK0G	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	Investigative

T23995	TARGETID	T23995
T23995	FORMERID	TTDC00178
T23995	UNIPROID	KPCT_HUMAN
T23995	TARGNAME	Protein kinase C theta (PRKCQ)
T23995	GENENAME	PRKCQ
T23995	TARGTYPE	Clinical trial
T23995	SYNONYMS	Protein kinase C theta type; PRKCT; NPKC-theta
T23995	FUNCTION	In TCR-CD3/CD28-co-stimulated T-cells, is required for the activation of NF-kappa-B and JUN, which in turn are essential for IL2 production, and participates in the calcium-dependent NFATC1 and NFATC2 transactivation. Mediates the activation of the canonical NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11 on several serine residues, inducing CARD11 association with lipid rafts and recruitment of the BCL10-MALT1 complex, which then activates IKK complex, resulting in nuclear translocation and activation of NFKB1. May also play an indirect role in activation of the non-canonical NF-kappa-B (NFKB2) pathway. In the signaling pathway leading to JUN activation, acts by phosphorylating the mediator STK39/SPAK and may not act through MAP kinases signaling. Plays a critical role in TCR/CD28-induced NFATC1 and NFATC2 transactivation by participating in the regulation of reduced inositol 1,4,5-trisphosphate generation and intracellular calcium mobilization. After costimulation of T-cells through CD28 can phosphorylate CBLB and is required for the ubiquitination and subsequent degradation of CBLB, which is a prerequisite for the activation of TCR. During T-cells differentiation, plays an important role in the development of T-helper 2 (Th2) cells following immune and inflammatory responses, and, in the development of inflammatory autoimmune diseases, is necessary for the activation of IL17-producing Th17 cells. May play a minor role in Th1 response. Upon TCR stimulation, mediates T-cell protective survival signal by phosphorylating BAD, thus protecting T-cells from BAD-induced apoptosis, and by up-regulating BCL-X(L)/BCL2L1 levels through NF-kappa-B and JUN pathways. In platelets, regulates signal transduction downstream of the ITGA2B, CD36/GP4, F2R/PAR1 and F2RL3/PAR4 receptors, playing a positive role in 'outside-in' signaling and granule secretion signal transduction. May relay signals from the activated ITGA2B receptor by regulating the uncoupling of WASP and WIPF1, thereby permitting the regulation of actin filament nucleation and branching activity of the Arp2/3 complex. May mediate inhibitory effects of free fatty acids on insulin signaling by phosphorylating IRS1, which in turn blocks IRS1 tyrosine phosphorylation and downstream activation of the PI3K/AKT pathway. Phosphorylates MSN (moesin) in the presence of phosphatidylglycerol or phosphatidylinositol. Phosphorylates PDPK1 at 'Ser-504' and 'Ser-532' and negatively regulates its ability to phosphorylate PKB/AKT1. Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that mediates non-redundant functions in T-cell receptor (TCR) signaling, including T-cells activation, proliferation, differentiation and survival, by mediating activation of multiple transcription factors such as NF-kappa-B, JUN, NFATC1 and NFATC2.
T23995	PDBSTRUC	5F9E; 4RA5; 4Q9Z; 2JED; 2ENZ
T23995	BIOCLASS	Kinase
T23995	ECNUMBER	EC 2.7.11.13
T23995	SEQUENCE	MSPFLRIGLSNFDCGSCQSCQGEAVNPYCAVLVKEYVESENGQMYIQKKPTMYPPWDSTFDAHINKGRVMQIIVKGKNVDLISETTVELYSLAERCRKNNGKTEIWLELKPQGRMLMNARYFLEMSDTKDMNEFETEGFFALHQRRGAIKQAKVHHVKCHEFTATFFPQPTFCSVCHEFVWGLNKQGYQCRQCNAAIHKKCIDKVIAKCTGSAINSRETMFHKERFKIDMPHRFKVYNYKSPTFCEHCGTLLWGLARQGLKCDACGMNVHHRCQTKVANLCGINQKLMAEALAMIESTQQARCLRDTEQIFREGPVEIGLPCSIKNEARPPCLPTPGKREPQGISWESPLDEVDKMCHLPEPELNKERPSLQIKLKIEDFILHKMLGKGSFGKVFLAEFKKTNQFFAIKALKKDVVLMDDDVECTMVEKRVLSLAWEHPFLTHMFCTFQTKENLFFVMEYLNGGDLMYHIQSCHKFDLSRATFYAAEIILGLQFLHSKGIVYRDLKLDNILLDKDGHIKIADFGMCKENMLGDAKTNTFCGTPDYIAPEILLGQKYNHSVDWWSFGVLLYEMLIGQSPFHGQDEEELFHSIRMDNPFYPRWLEKEAKDLLVKLFVREPEKRLGVRGDIRQHPLFREINWEELERKEIDPPFRPKVKSPFDCSNFDKEFLNEKPRLSFADRALINSMDQNMFRNFSFMNPGMERLIS
T23995	DRUGINFO	D0F5HB	Sotrastaurin acetate	Phase 2
T23995	DRUGINFO	D0J7CE	CDE-6960	Terminated
T23995	DRUGINFO	D0X0HN	LY-317644	Terminated
T23995	DRUGINFO	D0R5ZR	RO-320432	Terminated
T23995	DRUGINFO	D05BHG	Phosphonothreonine	Investigative
T23995	DRUGINFO	D00TWA	[2,2':5',2'']Terthiophen-4-yl-methanol	Investigative
T23995	DRUGINFO	D02PUV	4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol	Investigative
T23995	DRUGINFO	D02QME	2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile	Investigative
T23995	DRUGINFO	D05LRV	[2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde	Investigative
T23995	DRUGINFO	D09TSC	Ro-32-0557	Investigative
T23995	DRUGINFO	D09XIE	3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile	Investigative
T23995	DRUGINFO	D0A8MN	3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile	Investigative
T23995	DRUGINFO	D0D3MR	[2,2':5',2'']Terthiophene-4-carbaldehyde	Investigative
T23995	DRUGINFO	D0Q3GQ	4-cycloheptyliden(4-hydroxyphenyl)methylphenol	Investigative
T23995	DRUGINFO	D0S9UK	2,3,3-Triphenyl-acrylonitrile	Investigative
T23995	DRUGINFO	D0T0UH	3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile	Investigative
T23995	DRUGINFO	D0V9SW	4-cyclohexyliden(4-hydroxyphenyl)methylphenol	Investigative
T23995	DRUGINFO	D07PZQ	L-serine-O-phosphate	Investigative
T23995	DRUGINFO	D06ZCX	LY-326449	Investigative
T23995	DRUGINFO	D0L8HO	RO-316233	Investigative

T44861	TARGETID	T44861
T44861	FORMERID	TTDNC00553
T44861	UNIPROID	KPCD_HUMAN
T44861	TARGNAME	Protein kinase C delta (PRKCD)
T44861	GENENAME	PRKCD
T44861	TARGTYPE	Clinical trial
T44861	SYNONYMS	nPKC-delta; Tyrosine-protein kinase PRKCD; SDK1; Protein kinase C delta type catalytic subunit; Protein kinase C delta type; PKC-delta
T44861	FUNCTION	Negatively regulates B cell proliferation and also has an important function in self-antigen induced B cell tolerance induction. Upon DNA damage, activates the promoter of the death-promoting transcription factor BCLAF1/Btf to trigger BCLAF1-mediated p53/TP53 gene transcription and apoptosis. In response to oxidative stress, interact with and activate CHUK/IKKA in the nucleus, causing the phosphorylation of p53/TP53. In the case of ER stress or DNA damage-induced apoptosis, can form a complex with the tyrosine-protein kinase ABL1 which trigger apoptosis independently of p53/TP53. In cytosol can trigger apoptosis by activating MAPK11 or MAPK14, inhibiting AKT1 and decreasing the level of X-linked inhibitor of apoptosis protein (XIAP), whereas in nucleus induces apoptosis via the activation of MAPK8 or MAPK9. Upon ionizing radiation treatment, is required for the activation of the apoptosis regulators BAX and BAK, which trigger the mitochondrial cell death pathway. Can phosphorylate MCL1 and target it for degradation which is sufficient to trigger for BAX activation and apoptosis. Is required for the control of cell cycle progression both at G1/S and G2/M phases. Mediates phorbol 12-myristate 13-acetate (PMA)-induced inhibition of cell cycle progression at G1/S phase by up-regulating the CDK inhibitor CDKN1A/p21 and inhibiting the cyclin CCNA2 promoter activity. In response to UV irradiation can phosphorylate CDK1, which is important for the G2/M DNA damage checkpoint activation. Can protect glioma cells from the apoptosis induced by TNFSF10/TRAIL, probably by inducing increased phosphorylation and subsequent activation of AKT1. Is highly expressed in a number of cancer cells and promotes cell survival and resistance against chemotherapeutic drugs by inducing cyclin D1 (CCND1) and hyperphosphorylation of RB1, and via several pro-survival pathways, including NF-kappa-B, AKT1 and MAPK1/3 (ERK1/2). Can also act as tumor suppressor upon mitogenic stimulation with PMA or TPA. In N-formyl-methionyl-leucyl-phenylalanine (fMLP)-treated cells, is required for NCF1 (p47-phox) phosphorylation and activation of NADPH oxidase activity, and regulates TNF-elicited superoxide anion production in neutrophils, by direct phosphorylation and activation of NCF1 or indirectly through MAPK1/3 (ERK1/2) signaling pathways. May also play a role in the regulation of NADPH oxidase activity in eosinophil after stimulation with IL5, leukotriene B4 or PMA. In collagen-induced platelet aggregation, acts a negative regulator of filopodia formation and actin polymerization by interacting with and negatively regulating VASP phosphorylation. Downstream of PAR1, PAR4 and CD36/GP4 receptors, regulates differentially platelet dense granule secretion; acts as a positive regulator in PAR-mediated granule secretion, whereas it negatively regulates CD36/GP4-mediated granule release. Phosphorylates MUC1 in the C-terminal and regulates the interaction between MUC1 and beta-catenin. The catalytic subunit phosphorylates 14-3-3 proteins (YWHAB, YWHAZ and YWHAH) in a sphingosine-dependent fashion. Phosphorylates ELAVL1 in response to angiotensin-2 treatment. Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays contrasting roles in cell death and cell survival by functioning as a pro-apoptotic protein during DNA damage-induced apoptosis, but acting as an anti-apoptotic protein during cytokine receptor-initiated cell death, is involved in tumor suppression as well as survival of several cancers, is required for oxygen radical production by NADPH oxidase and acts as positive or negative regulator in platelet functional responses.
T44861	PDBSTRUC	2YUU; 1YRK
T44861	BIOCLASS	Kinase
T44861	ECNUMBER	EC 2.7.11.13
T44861	SEQUENCE	MAPFLRIAFNSYELGSLQAEDEANQPFCAVKMKEALSTERGKTLVQKKPTMYPEWKSTFDAHIYEGRVIQIVLMRAAEEPVSEVTVGVSVLAERCKKNNGKAEFWLDLQPQAKVLMSVQYFLEDVDCKQSMRSEDEAKFPTMNRRGAIKQAKIHYIKNHEFIATFFGQPTFCSVCKDFVWGLNKQGYKCRQCNAAIHKKCIDKIIGRCTGTAANSRDTIFQKERFNIDMPHRFKVHNYMSPTFCDHCGSLLWGLVKQGLKCEDCGMNVHHKCREKVANLCGINQKLLAEALNQVTQRASRRSDSASSEPVGIYQGFEKKTGVAGEDMQDNSGTYGKIWEGSSKCNINNFIFHKVLGKGSFGKVLLGELKGRGEYFAIKALKKDVVLIDDDVECTMVEKRVLTLAAENPFLTHLICTFQTKDHLFFVMEFLNGGDLMYHIQDKGRFELYRATFYAAEIMCGLQFLHSKGIIYRDLKLDNVLLDRDGHIKIADFGMCKENIFGESRASTFCGTPDYIAPEILQGLKYTFSVDWWSFGVLLYEMLIGQSPFHGDDEDELFESIRVDTPHYPRWITKESKDILEKLFEREPTKRLGVTGNIKIHPFFKTINWTLLEKRRLEPPFRPKVKSPRDYSNFDQEFLNEKARLSYSDKNLIDSMDQSAFAGFSFVNPKFEHLLED
T44861	DRUGINFO	D0O6HP	KAI-9803	Phase 1/2
T44861	DRUGINFO	D04VPV	AD 198	Terminated
T44861	DRUGINFO	D0X0HN	LY-317644	Terminated
T44861	DRUGINFO	D0R5ZR	RO-320432	Terminated
T44861	DRUGINFO	D02KPV	Phorbol 12,13-butyrate	Investigative
T44861	DRUGINFO	D0G3BJ	Ingenol-3-bezoate	Investigative
T44861	DRUGINFO	D0J1SA	13-Acetylphorbol	Investigative
T44861	DRUGINFO	D0K5ZY	INDOLACTUM	Investigative
T44861	DRUGINFO	D0M3UR	THYMELEATOXIN	Investigative
T44861	DRUGINFO	D00TWA	[2,2':5',2'']Terthiophen-4-yl-methanol	Investigative
T44861	DRUGINFO	D02PUV	4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol	Investigative
T44861	DRUGINFO	D02QME	2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile	Investigative
T44861	DRUGINFO	D05LRV	[2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde	Investigative
T44861	DRUGINFO	D09TSC	Ro-32-0557	Investigative
T44861	DRUGINFO	D09XIE	3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile	Investigative
T44861	DRUGINFO	D0A8MN	3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile	Investigative
T44861	DRUGINFO	D0D3MR	[2,2':5',2'']Terthiophene-4-carbaldehyde	Investigative
T44861	DRUGINFO	D0Q3GQ	4-cycloheptyliden(4-hydroxyphenyl)methylphenol	Investigative
T44861	DRUGINFO	D0S9UK	2,3,3-Triphenyl-acrylonitrile	Investigative
T44861	DRUGINFO	D0T0UH	3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile	Investigative
T44861	DRUGINFO	D0V9SW	4-cyclohexyliden(4-hydroxyphenyl)methylphenol	Investigative
T44861	DRUGINFO	D04JNZ	PROSTRATIN	Investigative
T44861	DRUGINFO	D06ZCX	LY-326449	Investigative
T44861	DRUGINFO	D0L8HO	RO-316233	Investigative

T10265	TARGETID	T10265
T10265	FORMERID	TTDR00466
T10265	UNIPROID	PDE4B_HUMAN
T10265	TARGNAME	Phosphodiesterase 4B (PDE4B)
T10265	GENENAME	PDE4B
T10265	TARGTYPE	Clinical trial
T10265	SYNONYMS	cAMP-specific 3',5'-cyclic phosphodiesterase 4B; Type 4B cAMP phosphodiesterase; Type 4 cyclic adenosine monophosphate phosphodiesterase (type 4 PDE); PDE32; DPDE4
T10265	FUNCTION	May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to antiasthmatic and anti-inflammatory agents. Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
T10265	PDBSTRUC	6BOJ; 5OHJ; 5LAQ; 5K6J; 4X0F
T10265	BIOCLASS	Phosphoric diester hydrolase
T10265	ECNUMBER	EC 3.1.4.53
T10265	SEQUENCE	MKKSRSVMTVMADDNVKDYFECSLSKSYSSSSNTLGIDLWRGRRCCSGNLQLPPLSQRQSERARTPEGDGISRPTTLPLTTLPSIAITTVSQECFDVENGPSPGRSPLDPQASSSAGLVLHATFPGHSQRRESFLYRSDSDYDLSPKAMSRNSSLPSEQHGDDLIVTPFAQVLASLRSVRNNFTILTNLHGTSNKRSPAASQPPVSRVNPQEESYQKLAMETLEELDWCLDQLETIQTYRSVSEMASNKFKRMLNRELTHLSEMSRSGNQVSEYISNTFLDKQNDVEIPSPTQKDREKKKKQQLMTQISGVKKLMHSSSLNNTSISRFGVNTENEDHLAKELEDLNKWGLNIFNVAGYSHNRPLTCIMYAIFQERDLLKTFRISSDTFITYMMTLEDHYHSDVAYHNSLHAADVAQSTHVLLSTPALDAVFTDLEILAAIFAAAIHDVDHPGVSNQFLINTNSELALMYNDESVLENHHLAVGFKLLQEEHCDIFMNLTKKQRQTLRKMVIDMVLATDMSKHMSLLADLKTMVETKKVTSSGVLLLDNYTDRIQVLRNMVHCADLSNPTKSLELYRQWTDRIMEEFFQQGDKERERGMEISPMCDKHTASVEKSQVGFIDYIVHPLWETWADLVQPDAQDILDTLEDNRNWYQSMIPQSPSPPLDEQNRDCQGLMEKFQFELTLDEEDSEGPEKEGEGHSYFSSTKTLCVIDPENRDSLGETDIDIATEDKSPVDT
T10265	DRUGINFO	D02EOZ	BI 1015550	Phase 3
T10265	DRUGINFO	D01XHG	DENBUFYLLINE	Phase 3
T10265	DRUGINFO	D06VFP	SOTB07	Phase 3
T10265	DRUGINFO	D00JED	AN-2898	Phase 2
T10265	DRUGINFO	D01XFZ	GPD-1116	Phase 2
T10265	DRUGINFO	D02POH	TA-7906	Phase 2
T10265	DRUGINFO	D07OCV	HT-0712	Phase 2
T10265	DRUGINFO	D09TFB	TOFIMILAST	Phase 2
T10265	DRUGINFO	D0F4TV	AWD-12-281	Phase 2
T10265	DRUGINFO	D0F5IY	LIRIMILAST	Phase 2
T10265	DRUGINFO	D0L8KJ	Oglemilast	Phase 2
T10265	DRUGINFO	D0M7CB	MK-0873	Phase 2
T10265	DRUGINFO	D0RJ1W	OX-914	Phase 2
T10265	DRUGINFO	D0U2DH	CC-1088	Phase 2
T10265	DRUGINFO	D0X0PW	Revamilast	Phase 2
T10265	DRUGINFO	D0Z2FB	Piclamilast	Phase 2
T10265	DRUGINFO	D01WZL	AVE-8112	Phase 1
T10265	DRUGINFO	D03CWX	MEM-1414	Phase 1
T10265	DRUGINFO	D0K9DI	GSK-356278	Phase 1
T10265	DRUGINFO	D0O8JW	Ronomilast	Phase 1
T10265	DRUGINFO	D0H9KW	Filaminast	Discontinued in Phase 2
T10265	DRUGINFO	D00DBE	CI-1018	Discontinued in Phase 2
T10265	DRUGINFO	D03ZVD	KW-4490	Discontinued in Phase 2
T10265	DRUGINFO	D08SNX	V-11294A	Discontinued in Phase 2
T10265	DRUGINFO	D0I0GM	Daxalipram	Discontinued in Phase 2
T10265	DRUGINFO	D0UG4T	CDP840	Discontinued in Phase 2
T10265	DRUGINFO	D0V2CN	LAS-37779	Discontinued in Phase 2
T10265	DRUGINFO	D01FXD	SCH-351591	Discontinued in Phase 1
T10265	DRUGINFO	D0C7JT	YM-976	Discontinued in Phase 1
T10265	DRUGINFO	D0K1OA	D-4418	Discontinued in Phase 1
T10265	DRUGINFO	D01OUA	TJN-598	Terminated
T10265	DRUGINFO	D01QUF	GW-3600	Terminated
T10265	DRUGINFO	D07UHY	NIK-616	Terminated
T10265	DRUGINFO	D0F7TV	Torbafylline	Terminated
T10265	DRUGINFO	D0R1QJ	D-22888	Terminated
T10265	DRUGINFO	D06PUS	3-(2-Bromophenyl)-2-thioxo-(1H )-quinazolin-4-one	Investigative
T10265	DRUGINFO	D0R5ZH	8-Bromo-Adenosine-5'-Monophosphate	Investigative
T10265	DRUGINFO	D02NKD	8-(3-Nitro-phenyl)-6-phenyl-[1,7]naphthyridine	Investigative
T10265	DRUGINFO	D02NWF	Benzyl-(2-thiophen-2-yl-quinazolin-4-yl)-amine	Investigative
T10265	DRUGINFO	D09AUL	Benzyl-(2-imidazol-1-yl-quinazolin-4-yl)-amine	Investigative
T10265	DRUGINFO	D0DL6J	CI-1044	Investigative
T10265	DRUGINFO	D0O3BL	RS-14491	Investigative
T10265	DRUGINFO	D0V5BX	NITRAQUAZONE	Investigative
T10265	DRUGINFO	D01RUN	(R)-Rolipram	Investigative
T10265	DRUGINFO	D01TOR	Benzyl-(2-pyridin-3-yl-quinazolin-4-yl)-amine	Investigative
T10265	DRUGINFO	D02FZD	(S)-Rolipram	Investigative
T10265	DRUGINFO	D04BMR	AL-59640	Investigative
T10265	DRUGINFO	D04JNC	ZL-N-91	Investigative
T10265	DRUGINFO	D05YEL	CH-3697	Investigative
T10265	DRUGINFO	D0E5VP	KF-66490	Investigative
T10265	DRUGINFO	D0J7GF	Benzyl-(2-phenyl-quinazolin-4-yl)-amine	Investigative
T10265	DRUGINFO	D0JD4C	L-454560	Investigative
T10265	DRUGINFO	D0K9PS	CHF-5480	Investigative
T10265	DRUGINFO	D0N7HS	ASP-3258	Investigative
T10265	DRUGINFO	D0S1HX	TAS-203	Investigative
T10265	DRUGINFO	D0S6MA	OCID-2987	Investigative
T10265	DRUGINFO	D0U4SS	CD-160130	Investigative
T10265	DRUGINFO	D0U8YQ	Benzyl-(2-pyridin-4-yl-quinazolin-4-yl)-amine	Investigative
T10265	DRUGINFO	D0W7WV	L-869298	Investigative
T10265	DRUGINFO	D00QCL	SOPHOFLAVESCENOL	Investigative
T10265	DRUGINFO	D02ZPV	UCB-101333-3	Investigative
T10265	DRUGINFO	D0P2HX	RS-25344	Investigative
T10265	DRUGINFO	D0T5PO	ROLIPRAM	Investigative
T10265	DRUGINFO	D0W4ZU	KURARINOL	Investigative
T10265	DRUGINFO	D06GUJ	KURAIDIN	Investigative
T10265	DRUGINFO	D0P7JE	S,S-(2-Hydroxyethyl)Thiocysteine	Investigative
T10265	DRUGINFO	D0R6MT	isobutylmethylxanthine	Investigative

T69912	TARGETID	T69912
T69912	FORMERID	TTDC00116
T69912	UNIPROID	PAFA_HUMAN
T69912	TARGNAME	Platelet-activating factor acetylhydrolase (PLA2G7)
T69912	GENENAME	PLA2G7
T69912	TARGTYPE	Clinical trial
T69912	SYNONYMS	gVIIA-PLA2; PAFAH; PAF acetylhydrolase; PAF 2-acylhydrolase; Lipoprotein-associated phospholipase A2; LDL-associated phospholipase A2; LDL-PLA(2); Group-VIIA phospholipase A2; 2-acetyl-1-alkylglycerophosphocholine esterase; 1-alkyl-2-acetylglycerophosphocholine esterase
T69912	FUNCTION	Has a specificity for substrates with a short residue at the sn-2 position. It is inactive against long-chain phospholipids. Modulates the action of platelet-activating factor (PAF) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF.
T69912	PDBSTRUC	5YEA; 5YE9; 5YE8; 5YE7; 5LZ9
T69912	BIOCLASS	Carboxylic ester hydrolase
T69912	ECNUMBER	EC 3.1.1.47
T69912	SEQUENCE	MVPPKLHVLFCLCGCLAVVYPFDWQYINPVAHMKSSAWVNKIQVLMAAASFGQTKIPRGNGPYSVGCTDLMFDHTNKGTFLRLYYPSQDNDRLDTLWIPNKEYFWGLSKFLGTHWLMGNILRLLFGSMTTPANWNSPLRPGEKYPLVVFSHGLGAFRTLYSAIGIDLASHGFIVAAVEHRDRSASATYYFKDQSAAEIGDKSWLYLRTLKQEEETHIRNEQVRQRAKECSQALSLILDIDHGKPVKNALDLKFDMEQLKDSIDREKIAVIGHSFGGATVIQTLSEDQRFRCGIALDAWMFPLGDEVYSRIPQPLFFINSEYFQYPANIIKMKKCYSPDKERKMITIRGSVHQNFADFTFATGKIIGHMLKLKGDIDSNVAIDLSNKASLAFLQKHLGLHKDFDQWDCLIEGDDENLIPGTNINTTNQHIMLQNSSGIEKYN
T69912	DRUGINFO	D0E6KN	GSK2647544	Phase 1
T69912	DRUGINFO	D05GZD	Rilapladib	Phase 1
T69912	DRUGINFO	D0N8BA	Bicyclic pyrimidine derivative 2	Patented
T69912	DRUGINFO	D00CKV	Indolizine derivative 1	Patented
T69912	DRUGINFO	D0AK5G	RPAF-AH	Discontinued in Phase 3
T69912	DRUGINFO	D0CA3J	GSK568859	Discontinued in Phase 1
T69912	DRUGINFO	D0MC3R	Goxalapladib	Discontinued in Phase 1
T69912	DRUGINFO	D0A1SO	Benzaldehyde O-benzoyloxime	Investigative
T69912	DRUGINFO	D0D7AS	(E)-(thiophen-2-ylmethylidene)amino benzoate	Investigative
T69912	DRUGINFO	D0JI8S	3,4-difluorobenzaldehyde O-benzoyloxime	Investigative
T69912	DRUGINFO	D0WW7A	SB-381320	Investigative
T69912	DRUGINFO	D0X6UV	4-fluorobenzaldehyde O-benzoyloxime	Investigative
T69912	DRUGINFO	D0Y8RM	(1r)-1,2,2-trimethylpropyl (r)-methylphosphinate	Investigative

T55729	TARGETID	T55729
T55729	FORMERID	TTDR00352
T55729	UNIPROID	MK11_HUMAN
T55729	TARGNAME	Stress-activated protein kinase 2b (p38 beta)
T55729	GENENAME	MAPK11
T55729	TARGTYPE	Clinical trial
T55729	SYNONYMS	Stress-activated protein kinase-2; SAPK2b; SAPK2; PRKM11; P38b; P38-2; P38 Mitogen-activated protein kinase beta; Mitogen-activated protein kinase p38 beta; Mitogen-activated protein kinase 11; MAPK 11; MAP kinase p38 beta; MAP kinase 11
T55729	FUNCTION	MAPK11 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors. Accordingly, p38 MAPKs phosphorylate a broad range of proteins and it has been estimated that they may have approximately 200 to 300 substrates each. MAPK11 functions are mostly redundant with those of MAPK14. Some of the targets are downstream kinases which are activated through phosphorylation and further phosphorylate additional targets. RPS6KA5/MSK1 and RPS6KA4/MSK2 can directly phosphorylate and activate transcription factors such as CREB1, ATF1, the NF-kappa-B isoform RELA/NFKB3, STAT1 and STAT3, but can also phosphorylate histone H3 and the nucleosomal protein HMGN1. RPS6KA5/MSK1 and RPS6KA4/MSK2 play important roles in the rapid induction of immediate-early genes in response to stress or mitogenic stimuli, either by inducing chromatin remodeling or by recruiting the transcription machinery. On the other hand, two other kinase targets, MAPKAPK2/MK2 and MAPKAPK3/MK3, participate in the control of gene expression mostly at the post-transcriptional level, by phosphorylating ZFP36 (tristetraprolin) and ELAVL1, and by regulating EEF2K, which is important for the elongation of mRNA during translation. MKNK1/MNK1 and MKNK2/MNK2, two other kinases activated by p38 MAPKs, regulate protein synthesis by phosphorylating the initiation factor EIF4E2. In the cytoplasm, the p38 MAPK pathway is an important regulator of protein turnover. For example, CFLAR is an inhibitor of TNF-induced apoptosis whose proteasome-mediated degradation is regulated by p38 MAPK phosphorylation. Ectodomain shedding of transmembrane proteins is regulated by p38 MAPKs as well. In response to inflammatory stimuli, p38 MAPKs phosphorylate the membrane-associated metalloprotease ADAM17. Such phosphorylation is required for ADAM17-mediated ectodomain shedding of TGF-alpha family ligands, which results in the activation of EGFR signaling and cell proliferation. Additional examples of p38 MAPK substrates are the FGFR1. FGFR1 can be translocated from the extracellular space into the cytosol and nucleus of target cells, and regulates processes such as rRNA synthesis and cell growth. FGFR1 translocation requires p38 MAPK activation. In the nucleus, many transcription factors are phosphorylated and activated by p38 MAPKs in response to different stimuli. Classical examples include ATF1, ATF2, ATF6, ELK1, PTPRH, DDIT3, TP53/p53 and MEF2C and MEF2A. The p38 MAPKs are emerging as important modulators of gene expression by regulating chromatin modifiers and remodelers. The promoters of several genes involved in the inflammatory response, such as IL6, IL8 and IL12B, display a p38 MAPK-dependent enrichment of histone H3 phosphorylation on 'Ser-10' (H3S10ph) in LPS-stimulated myeloid cells. This phosphorylation enhances the accessibility of the cryptic NF-kappa-B-binding sites marking promoters for increased NF-kappa-B recruitment. Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway.
T55729	PDBSTRUC	3GP0; 3GC9; 3GC8
T55729	BIOCLASS	Kinase
T55729	ECNUMBER	EC 2.7.11.24
T55729	SEQUENCE	MSGPRAGFYRQELNKTVWEVPQRLQGLRPVGSGAYGSVCSAYDARLRQKVAVKKLSRPFQSLIHARRTYRELRLLKHLKHENVIGLLDVFTPATSIEDFSEVYLVTTLMGADLNNIVKCQALSDEHVQFLVYQLLRGLKYIHSAGIIHRDLKPSNVAVNEDCELRILDFGLARQADEEMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLQGKALFPGSDYIDQLKRIMEVVGTPSPEVLAKISSEHARTYIQSLPPMPQKDLSSIFRGANPLAIDLLGRMLVLDSDQRVSAAEALAHAYFSQYHDPEDEPEAEPYDESVEAKERTLEEWKELTYQEVLSFKPPEPPKPPGSLEIEQ
T55729	DRUGINFO	D02NNV	VX-745	Phase 2
T55729	DRUGINFO	D0W0AM	SB 235699	Discontinued in Phase 1
T55729	DRUGINFO	D06NUL	RWJ-68354	Investigative
T55729	DRUGINFO	D09HBZ	ML-3375	Investigative
T55729	DRUGINFO	D0W4FF	ML-3403	Investigative
T55729	DRUGINFO	D06WJA	L-779450	Investigative
T55729	DRUGINFO	D08DSJ	ML-3163	Investigative
T55729	DRUGINFO	D0G2VC	KT-5720	Investigative
T55729	DRUGINFO	D0GB4V	STAUROSPORINONE	Investigative
T55729	DRUGINFO	D0M5FF	Ro31-8220	Investigative
T55729	DRUGINFO	D0N6ES	KN-62	Investigative
T55729	DRUGINFO	D0B9BU	CI-1040	Investigative
T55729	DRUGINFO	D0O1YH	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	Investigative
T55729	DRUGINFO	D0TO6S	Bisindolylmaleimide-I	Investigative
T55729	DRUGINFO	D0L8HO	RO-316233	Investigative

T12119	TARGETID	T12119
T12119	FORMERID	TTDS00503
T12119	UNIPROID	SCN9A_HUMAN
T12119	TARGNAME	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
T12119	GENENAME	SCN9A
T12119	TARGTYPE	Clinical trial
T12119	SYNONYMS	hNE-Na; Voltage-gated sodium channel subunit alpha Nav1.7; Sodium channel proteintype IX subunit alpha; Sodium channel proteintype 9 subunit alpha; Sodium channel protein type IX subunit alpha; Sodium channel protein type 9 subunit alpha; Peripheral sodium channel 1; PN1; Neuroendocrine sodium channel; NENA
T12119	FUNCTION	Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-sensitive Na(+) channel isoform. Plays a role in pain mechanisms, especially in the development of inflammatory pain. Mediates the voltage-dependent sodium ion permeability of excitable membranes.
T12119	PDBSTRUC	6NT4; 6NT3; 6N4R; 6N4Q; 6J8J
T12119	BIOCLASS	Voltage-gated ion channel
T12119	SEQUENCE	MAMLPPPGPQSFVHFTKQSLALIEQRIAERKSKEPKEEKKDDDEEAPKPSSDLEAGKQLPFIYGDIPPGMVSEPLEDLDPYYADKKTFIVLNKGKTIFRFNATPALYMLSPFSPLRRISIKILVHSLFSMLIMCTILTNCIFMTMNNPPDWTKNVEYTFTGIYTFESLVKILARGFCVGEFTFLRDPWNWLDFVVIVFAYLTEFVNLGNVSALRTFRVLRALKTISVIPGLKTIVGALIQSVKKLSDVMILTVFCLSVFALIGLQLFMGNLKHKCFRNSLENNETLESIMNTLESEEDFRKYFYYLEGSKDALLCGFSTDSGQCPEGYTCVKIGRNPDYGYTSFDTFSWAFLALFRLMTQDYWENLYQQTLRAAGKTYMIFFVVVIFLGSFYLINLILAVVAMAYEEQNQANIEEAKQKELEFQQMLDRLKKEQEEAEAIAAAAAEYTSIRRSRIMGLSESSSETSKLSSKSAKERRNRRKKKNQKKLSSGEEKGDAEKLSKSESEDSIRRKSFHLGVEGHRRAHEKRLSTPNQSPLSIRGSLFSARRSSRTSLFSFKGRGRDIGSETEFADDEHSIFGDNESRRGSLFVPHRPQERRSSNISQASRSPPMLPVNGKMHSAVDCNGVVSLVDGRSALMLPNGQLLPEVIIDKATSDDSGTTNQIHKKRRCSSYLLSEDMLNDPNLRQRAMSRASILTNTVEELEESRQKCPPWWYRFAHKFLIWNCSPYWIKFKKCIYFIVMDPFVDLAITICIVLNTLFMAMEHHPMTEEFKNVLAIGNLVFTGIFAAEMVLKLIAMDPYEYFQVGWNIFDSLIVTLSLVELFLADVEGLSVLRSFRLLRVFKLAKSWPTLNMLIKIIGNSVGALGNLTLVLAIIVFIFAVVGMQLFGKSYKECVCKINDDCTLPRWHMNDFFHSFLIVFRVLCGEWIETMWDCMEVAGQAMCLIVYMMVMVIGNLVVLNLFLALLLSSFSSDNLTAIEEDPDANNLQIAVTRIKKGINYVKQTLREFILKAFSKKPKISREIRQAEDLNTKKENYISNHTLAEMSKGHNFLKEKDKISGFGSSVDKHLMEDSDGQSFIHNPSLTVTVPIAPGESDLENMNAEELSSDSDSEYSKVRLNRSSSSECSTVDNPLPGEGEEAEAEPMNSDEPEACFTDGCVWRFSCCQVNIESGKGKIWWNIRKTCYKIVEHSWFESFIVLMILLSSGALAFEDIYIERKKTIKIILEYADKIFTYIFILEMLLKWIAYGYKTYFTNAWCWLDFLIVDVSLVTLVANTLGYSDLGPIKSLRTLRALRPLRALSRFEGMRVVVNALIGAIPSIMNVLLVCLIFWLIFSIMGVNLFAGKFYECINTTDGSRFPASQVPNRSECFALMNVSQNVRWKNLKVNFDNVGLGYLSLLQVATFKGWTIIMYAAVDSVNVDKQPKYEYSLYMYIYFVVFIIFGSFFTLNLFIGVIIDNFNQQKKKLGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPGNKIQGCIFDLVTNQAFDISIMVLICLNMVTMMVEKEGQSQHMTEVLYWINVVFIILFTGECVLKLISLRHYYFTVGWNIFDFVVVIISIVGMFLADLIETYFVSPTLFRVIRLARIGRILRLVKGAKGIRTLLFALMMSLPALFNIGLLLFLVMFIYAIFGMSNFAYVKKEDGINDMFNFETFGNSMICLFQITTSAGWDGLLAPILNSKPPDCDPKKVHPGSSVEGDCGNPSVGIFYFVSYIIISFLVVVNMYIAVILENFSVATEESTEPLSEDDFEMFYEVWEKFDPDATQFIEFSKLSDFAAALDPPLLIAKPNKVQLIAMDLPMVSGDRIHCLDILFAFTKRVLGESGEMDSLRSQMEERFMSANPSKVSYEPITTTLKRKQEDVSATVIQRAYRRYRLRQNVKNISSIYIKDGDRDDDLLNKKDMAFDNVNENSSPEKTDATSSTTSPPSYDSVTKPDKEKYEQDRTEKEDKGKDSKESKK
T12119	DRUGINFO	D04PER	XEN-402	Phase 2
T12119	DRUGINFO	D0O7QA	PF-05089771	Phase 2
T12119	DRUGINFO	D0OX9F	BIIB074	Phase 2
T12119	DRUGINFO	D00FSB	BIIB095	Phase 1
T12119	DRUGINFO	D01FZZ	GDC0310	Phase 1
T12119	DRUGINFO	D09INX	DSP-3905	Phase 1
T12119	DRUGINFO	D0BT0Z	PF-05241328	Phase 1
T12119	DRUGINFO	D0G0ER	DWJ-208	Phase 1
T12119	DRUGINFO	D0PB0U	RG7893	Phase 1
T12119	DRUGINFO	D0SD3E	PF-05186462	Phase 1
T12119	DRUGINFO	D0XO1O	CC8464	Phase 1
T12119	DRUGINFO	D0VE7B	DSP-2230	Phase 1
T12119	DRUGINFO	D01RJL	Cyclopropyl-spiro piperidine derivative 4	Patented
T12119	DRUGINFO	D02GCY	Cyclopropyl-spiro piperidine derivative 3	Patented
T12119	DRUGINFO	D06QWY	Benzene sulfonamide derivative 9	Patented
T12119	DRUGINFO	D07NQG	Methylsulfonylbenzamide derivative 2	Patented
T12119	DRUGINFO	D0D8NX	Cyclopropyl-spiro piperidine derivative 1	Patented
T12119	DRUGINFO	D0E9ZW	Tarizine derivative 1	Patented
T12119	DRUGINFO	D0I0MT	Aryl carboxamide derivative 4	Patented
T12119	DRUGINFO	D0OX5S	Cyclopropyl-spiro piperidine derivative 2	Patented
T12119	DRUGINFO	D0TA8W	Benzene sulfonamide derivative 11	Patented
T12119	DRUGINFO	D0VY1Y	Benzene sulfonamide derivative 12	Patented
T12119	DRUGINFO	D0W6ZS	Pyrrolo-benzo-diazine derivative 1	Patented
T12119	DRUGINFO	D0XJ0B	Enzoxazolinone sulfonamide derivative 1	Patented
T12119	DRUGINFO	D0Y7MC	Benzene sulfonamide derivative 15	Patented
T12119	DRUGINFO	D03GPV	Pyrimidine derivative 1	Patented
T12119	DRUGINFO	D06VYB	Pyrrolo-pyridinone derivative 6	Patented
T12119	DRUGINFO	D09YJV	Pyrrolo-pyridinone derivative 5	Patented
T12119	DRUGINFO	D0UL0K	Dihydrobenzoxazine and tetrahydroquinoxaline sulfonamide derivative 1	Patented
T12119	DRUGINFO	D0M8WO	Aryl carboxamide derivative 1	Patented
T12119	DRUGINFO	D0OP5F	Aryl carboxamide derivative 2	Patented
T12119	DRUGINFO	D08FZT	Corus 1030	Discontinued in Phase 2
T12119	DRUGINFO	D0EC2K	SIPATRIGINE	Discontinued in Phase 2
T12119	DRUGINFO	D07EQF	V-102862	Discontinued in Phase 1
T12119	DRUGINFO	D00TGC	N-Me-aminopyrimidinone 9	Investigative
T12119	DRUGINFO	D02HMZ	4-(2'-(trifluoromethoxy)biphenyl-3-yl)thiazole	Investigative
T12119	DRUGINFO	D02PZJ	4-(2'-(trifluoromethoxy)biphenyl-3-yl)oxazole	Investigative
T12119	DRUGINFO	D0F5MZ	4-(2'-(trifluoromethyl)biphenyl-3-yl)oxazole	Investigative
T12119	DRUGINFO	D0M1OU	XEN-907	Investigative
T12119	DRUGINFO	D0R8KA	pyrrolopyrimidine 48	Investigative
T12119	DRUGINFO	D0G9WE	batrachotoxin	Investigative
T12119	DRUGINFO	D0S4MN	veratridine	Investigative

T65864	TARGETID	T65864
T65864	FORMERID	TTDC00201
T65864	UNIPROID	MK14_HUMAN
T65864	TARGNAME	Stress-activated protein kinase 2a (p38 alpha)
T65864	GENENAME	MAPK14
T65864	TARGTYPE	Clinical trial
T65864	SYNONYMS	SAPK2A; P38 mitogen activatedprotein kinase; P38 Mitogen-activatedprotein kinase alpha; Mitogen-activated protein kinase p38 alpha; Mitogen-activated protein kinase 14; MXI2; MAX-interacting protein 2; MAPK 14; MAP kinase p38alpha; MAP kinase p38 alpha; MAP kinase MXI2; MAP kinase 14; Cytokine suppressive anti-inflammatory drug-binding protein; Cytokine suppressive anti-inflammatory drug binding protein; CSPB1; CSBP2; CSBP1; CSBP; CSAID-binding protein; CSAID binding protein; CRK1
T65864	FUNCTION	MAPK14 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors. Accordingly, p38 MAPKs phosphorylate a broad range of proteins and it has been estimated that they may have approximately 200 to 300 substrates each. Some of the targets are downstream kinases which are activated through phosphorylation and further phosphorylate additional targets. RPS6KA5/MSK1 and RPS6KA4/MSK2 can directly phosphorylate and activate transcription factors such as CREB1, ATF1, the NF-kappa-B isoform RELA/NFKB3, STAT1 and STAT3, but can also phosphorylate histone H3 and the nucleosomal protein HMGN1. RPS6KA5/MSK1 and RPS6KA4/MSK2 play important roles in the rapid induction of immediate-early genes in response to stress or mitogenic stimuli, either by inducing chromatin remodeling or by recruiting the transcription machinery. On the other hand, two other kinase targets, MAPKAPK2/MK2 and MAPKAPK3/MK3, participate in the control of gene expression mostly at the post-transcriptional level, by phosphorylating ZFP36 (tristetraprolin) and ELAVL1, and by regulating EEF2K, which is important for the elongation of mRNA during translation. MKNK1/MNK1 and MKNK2/MNK2, two other kinases activated by p38 MAPKs, regulate protein synthesis by phosphorylating the initiation factor EIF4E2. MAPK14 interacts also with casein kinase II, leading to its activation through autophosphorylation and further phosphorylation of TP53/p53. In the cytoplasm, the p38 MAPK pathway is an important regulator of protein turnover. For example, CFLAR is an inhibitor of TNF-induced apoptosis whose proteasome-mediated degradation is regulated by p38 MAPK phosphorylation. In a similar way, MAPK14 phosphorylates the ubiquitin ligase SIAH2, regulating its activity towards EGLN3. MAPK14 may also inhibit the lysosomal degradation pathway of autophagy by interfering with the intracellular trafficking of the transmembrane protein ATG9. Another function of MAPK14 is to regulate the endocytosis of membrane receptors by different mechanisms that impinge on the small GTPase RAB5A. In addition, clathrin-mediated EGFR internalization induced by inflammatory cytokines and UV irradiation depends on MAPK14-mediated phosphorylation of EGFR itself as well as of RAB5A effectors. Ectodomain shedding of transmembrane proteins is regulated by p38 MAPKs as well. In response to inflammatory stimuli, p38 MAPKs phosphorylate the membrane-associated metalloprotease ADAM17. Such phosphorylation is required for ADAM17-mediated ectodomain shedding of TGF-alpha family ligands, which results in the activation of EGFR signaling and cell proliferation. Another p38 MAPK substrate is FGFR1. FGFR1 can be translocated from the extracellular space into the cytosol and nucleus of target cells, and regulates processes such as rRNA synthesis and cell growth. FGFR1 translocation requires p38 MAPK activation. In the nucleus, many transcription factors are phosphorylated and activated by p38 MAPKs in response to different stimuli. Classical examples include ATF1, ATF2, ATF6, ELK1, PTPRH, DDIT3, TP53/p53 and MEF2C and MEF2A. The p38 MAPKs are emerging as important modulators of gene expression by regulating chromatin modifiers and remodelers. The promoters of several genes involved in the inflammatory response, such as IL6, IL8 and IL12B, display a p38 MAPK-dependent enrichment of histone H3 phosphorylation on 'Ser-10' (H3S10ph) in LPS-stimulated myeloid cells. This phosphorylation enhances the accessibility of the cryptic NF-kappa-B-binding sites marking promoters for increased NF-kappa-B recruitment. Phosphorylates CDC25B and CDC25C which is required for binding to 14-3-3 proteins and leads to initiation of a G2 delay after ultraviolet radiation. Phosphorylates TIAR following DNA damage, releasing TIAR from GADD45A mRNA and preventing mRNA degradation. The p38 MAPKs may also have kinase-independent roles, which are thought to be due to the binding to targets in the absence of phosphorylation. Protein O-Glc-N-acylation catalyzed by the OGT is regulated by MAPK14, and, although OGT does not seem to be phosphorylated by MAPK14, their interaction increases upon MAPK14 activation induced by glucose deprivation. This interaction may regulate OGT activity by recruiting it to specific targets such as neurofilament H, stimulating its O-Glc-N-acylation. Required in mid-fetal development for the growth of embryo-derived blood vessels in the labyrinth layer of the placenta. Also plays an essential role in developmental and stress-induced erythropoiesis, through regulation of EPO gene expression. Isoform MXI2 activation is stimulated by mitogens and oxidative stress and only poorly phosphorylates ELK1 and ATF2. Isoform EXIP may play a role in the early onset of apoptosis. Phosphorylates S100A9 at 'Thr-113'. Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway.
T65864	PDBSTRUC	6M9L; 6M95; 6HWV; 6HWU; 6HWT
T65864	BIOCLASS	Kinase
T65864	ECNUMBER	EC 2.7.11.24
T65864	SEQUENCE	MSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGLRVAVKKLSRPFQSIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQKLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVGTPGAELLKKISSESARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES
T65864	DRUGINFO	D0C7AA	Ozagrel	Phase 4
T65864	DRUGINFO	D0C8DD	Losmapimod	Phase 3
T65864	DRUGINFO	D0D9AH	VX-702	Phase 2a
T65864	DRUGINFO	D0K0JQ	Dilmapimod	Phase 2
T65864	DRUGINFO	D02NNV	VX-745	Phase 2
T65864	DRUGINFO	D03JFK	PMID25991433-Compound-O2	Patented
T65864	DRUGINFO	D08OJQ	PMID25991433-Compound-L2	Patented
T65864	DRUGINFO	D0G7LB	PMID25991433-Compound-L3	Patented
T65864	DRUGINFO	D0Q8CR	PMID25991433-Compound-L1	Patented
T65864	DRUGINFO	D06JRV	PMID25991433-Compound-F2	Patented
T65864	DRUGINFO	D0H4HD	PMID25991433-Compound-A1	Patented
T65864	DRUGINFO	D04WCI	PAMAPIMOD	Discontinued in Phase 2
T65864	DRUGINFO	D04YHW	R-1487	Discontinued in Phase 1
T65864	DRUGINFO	D05QMG	FR167653	Discontinued in Phase 1
T65864	DRUGINFO	D0A9KI	SB-242235	Discontinued in Phase 1
T65864	DRUGINFO	D0W0AM	SB 235699	Discontinued in Phase 1
T65864	DRUGINFO	D0O7BW	SC-102	Terminated
T65864	DRUGINFO	D09ICC	SB220025	Terminated
T65864	DRUGINFO	D0F8DL	SB 203580	Terminated
T65864	DRUGINFO	D00ODN	9-Benzyl-6-phenylsulfanyl-9H-purine	Investigative
T65864	DRUGINFO	D00PPB	N-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide	Investigative
T65864	DRUGINFO	D00YRF	UCB-1277763	Investigative
T65864	DRUGINFO	D01CRK	Small molecule 34	Investigative
T65864	DRUGINFO	D02NKV	SB-218655	Investigative
T65864	DRUGINFO	D03XYK	9-Benzyl-6-(4-fluoro-phenylsulfanyl)-9H-purine	Investigative
T65864	DRUGINFO	D04CRB	6-Phenylsulfanyl-9H-purine	Investigative
T65864	DRUGINFO	D04HWF	Talmapimod	Investigative
T65864	DRUGINFO	D07TTR	N-(4-fluorobenzyl)-N-(pyridin-4-yl)-2-naphthamide	Investigative
T65864	DRUGINFO	D08BIP	Dihydro-quinolinone	Investigative
T65864	DRUGINFO	D08WFC	(5-amino-1-phenyl-1H-pyrazol-4-yl)phenylmethanone	Investigative
T65864	DRUGINFO	D09GQO	3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE	Investigative
T65864	DRUGINFO	D09OKU	PMID22521646C12	Investigative
T65864	DRUGINFO	D09XVY	N-(4-methyl-benzyl)-4-phenoxy-benzamide	Investigative
T65864	DRUGINFO	D09ZZI	2-Chlorophenol	Investigative
T65864	DRUGINFO	D0DK2X	GSK-280	Investigative
T65864	DRUGINFO	D0E4LU	SB-216995	Investigative
T65864	DRUGINFO	D0H8RU	N-(4-(trifluoromethyl)benzyl)-4-phenoxybenzamide	Investigative
T65864	DRUGINFO	D0L1NU	PHA-666859	Investigative
T65864	DRUGINFO	D0L3DF	9-(4-Fluoro-benzyl)-6-phenylsulfanyl-9H-purine	Investigative
T65864	DRUGINFO	D0M2OL	SB-227931	Investigative
T65864	DRUGINFO	D0N9HX	N-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide	Investigative
T65864	DRUGINFO	D0Q8HM	6-(4-Fluoro-phenylsulfanyl)-9H-purine	Investigative
T65864	DRUGINFO	D0QS9T	4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE	Investigative
T65864	DRUGINFO	D0S4BP	DP-802	Investigative
T65864	DRUGINFO	D0S6GE	Ro-3201195	Investigative
T65864	DRUGINFO	D0S9SX	4-(2-Ethyl-4-m-tolyl-thiazol-5-yl)-pyridine	Investigative
T65864	DRUGINFO	D0X5CM	Triazolopyridine	Investigative
T65864	DRUGINFO	D09DRF	3-(Benzyloxy)Pyridin-2-Amine	Investigative
T65864	DRUGINFO	D0BH7S	6-Benzylsulfanyl-9H-purine	Investigative
T65864	DRUGINFO	D0H2PE	Phenyl-(3-phenyl-1H-indazol-6-yl)-amine	Investigative
T65864	DRUGINFO	D0K6YK	IN-1130	Investigative
T65864	DRUGINFO	D0M3CT	4-Phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine	Investigative
T65864	DRUGINFO	D0ZH1U	Tyrphostin ag-1478	Investigative
T65864	DRUGINFO	D06NUL	RWJ-68354	Investigative
T65864	DRUGINFO	D0C3AD	GW-788388	Investigative
T65864	DRUGINFO	D0H6ZP	IN-1166	Investigative
T65864	DRUGINFO	D0VC0I	Oxindole 94	Investigative
T65864	DRUGINFO	D00NWF	ZM-336372	Investigative
T65864	DRUGINFO	D09HBZ	ML-3375	Investigative
T65864	DRUGINFO	D09HXU	6-o-tolylquinazolin-2-amine	Investigative
T65864	DRUGINFO	D0W4FF	ML-3403	Investigative
T65864	DRUGINFO	D06WJA	L-779450	Investigative
T65864	DRUGINFO	D08DSJ	ML-3163	Investigative
T65864	DRUGINFO	D0G2VC	KT-5720	Investigative
T65864	DRUGINFO	D0GW4Q	PD-0173956	Investigative
T65864	DRUGINFO	D0P3JW	PD-0166326	Investigative
T65864	DRUGINFO	D0GB4V	STAUROSPORINONE	Investigative
T65864	DRUGINFO	D0M5FF	Ro31-8220	Investigative
T65864	DRUGINFO	D0N6ES	KN-62	Investigative
T65864	DRUGINFO	D0B9BU	CI-1040	Investigative
T65864	DRUGINFO	D0O1YH	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	Investigative
T65864	DRUGINFO	D02UVH	B-Octylglucoside	Investigative
T65864	DRUGINFO	D0A5RM	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	Investigative
T65864	DRUGINFO	D0TO6S	Bisindolylmaleimide-I	Investigative
T65864	DRUGINFO	D0L8HO	RO-316233	Investigative

T14731	TARGETID	T14731
T14731	FORMERID	TTDC00052
T14731	UNIPROID	SIR1_HUMAN
T14731	TARGNAME	NAD-dependent deacetylase sirtuin-1 (SIRT1)
T14731	GENENAME	SIRT1
T14731	TARGTYPE	Clinical trial
T14731	SYNONYMS	hSIRT1; hSIR2; SIR2L1; SIR2-like protein 1; Regulatory protein SIR2 homolog 1; NAD-dependent protein deacetylase sirtuin-1
T14731	FUNCTION	Can modulate chromatin function through deacetylation of histones and can promote alterations in the methylation of histones and DNA, leading to transcriptional repression. Deacetylates a broad range of transcription factors and coregulators, thereby regulating target gene expression positively and negatively. Serves as a sensor of the cytosolic ratio of NAD(+)/NADH which is altered by glucose deprivation and metabolic changes associated with caloric restriction. Is essential in skeletal muscle cell differentiation and in response to low nutrients mediates the inhibitory effect on skeletal myoblast differentiation which also involves 5'-AMP-activated protein kinase (AMPK) and nicotinamide phosphoribosyltransferase (NAMPT). Component of the eNoSC (energy-dependent nucleolar silencing) complex, a complex that mediates silencing of rDNA in response to intracellular energy status and acts by recruiting histone-modifying enzymes. The eNoSC complex is able to sense the energy status of cell: upon glucose starvation, elevation of NAD(+)/NADP(+) ratio activates SIRT1, leading to histone H3 deacetylation followed by dimethylation of H3 at 'Lys-9' (H3K9me2) by SUV39H1 and the formation of silent chromatin in the rDNA locus. Deacetylates 'Lys-266' of SUV39H1, leading to its activation. Inhibits skeletal muscle differentiation by deacetylating PCAF and MYOD1. Deacetylates H2A and 'Lys-26' of HIST1H1E. Deacetylates 'Lys-16' of histone H4 (in vitro). Involved in NR0B2/SHP corepression function through chromatin remodeling: Recruited to LRH1 target gene promoters by NR0B2/SHP thereby stimulating histone H3 and H4 deacetylation leading to transcriptional repression. Proposed to contribute to genomic integrity via positive regulation of telomere length; however, reports on localization to pericentromeric heterochromatin are conflicting. Proposed to play a role in constitutive heterochromatin (CH) formation and/or maintenance through regulation of the available pool of nuclear SUV39H1. Upon oxidative/metabolic stress decreases SUV39H1 degradation by inhibiting SUV39H1 polyubiquitination by MDM2. This increase in SUV39H1 levels enhances SUV39H1 turnover in CH, which in turn seems to accelerate renewal of the heterochromatin which correlates with greater genomic integrity during stress response. Deacetylates 'Lys-382' of p53/TP53 and impairs its ability to induce transcription-dependent proapoptotic program and modulate cell senescence. Deacetylates TAF1B and thereby represses rDNA transcription by the RNA polymerase I. Deacetylates MYC, promotes the association of MYC with MAX and decreases MYC stability leading to compromised transformational capability. Deacetylates FOXO3 in response to oxidative stress thereby increasing its ability to induce cell cycle arrest and resistance to oxidative stress but inhibiting FOXO3-mediated induction of apoptosis transcriptional activity; also leading to FOXO3 ubiquitination and protesomal degradation. Appears to have a similar effect on MLLT7/FOXO4 in regulation of transcriptional activity and apoptosis. Deacetylates DNMT1; thereby impairs DNMT1 methyltransferase-independent transcription repressor activity, modulates DNMT1 cell cycle regulatory function and DNMT1-mediated gene silencing. Deacetylates RELA/NF-kappa-B p65 thereby inhibiting its transactivating potential and augments apoptosis in response to TNF-alpha. Deacetylates HIF1A, KAT5/TIP60, RB1 and HIC1. Deacetylates FOXO1 resulting in its nuclear retention and enhancement of its transcriptional activity leading to increased gluconeogenesis in liver. Inhibits E2F1 transcriptional activity and apoptotic function, possibly by deacetylation. Involved in HES1- and HEY2-mediated transcriptional repression. In cooperation with MYCN seems to be involved in transcriptional repression of DUSP6/MAPK3 leading to MYCN stabilization by phosphorylation at 'Ser-62'. Deacetylates MEF2D. Required for antagonist-mediated transcription suppression of AR-dependent genes which may be linked to local deacetylation of histone H3. Represses HNF1A-mediated transcription. Required for the repression of ESRRG by CREBZF. Deacetylates NR1H3 and NR1H2 and deacetylation of NR1H3 at 'Lys-434' positively regulates transcription of NR1H3:RXR target genes, promotes NR1H3 proteosomal degradation and results in cholesterol efflux; a promoter clearing mechanism after reach round of transcription is proposed. Involved in lipid metabolism. Implicated in regulation of adipogenesis and fat mobilization in white adipocytes by repression of PPARG which probably involves association with NCOR1 and SMRT/NCOR2. Deacetylates p300/EP300 and PRMT1. Deacetylates ACSS2 leading to its activation, and HMGCS1 deacetylation. Involved in liver and muscle metabolism. Through deacteylation and activation of PPARGC1A is required to activate fatty acid oxidation in skeletel muscle under low-glucose conditions and is involved in glucose homeostasis. Involved in regulation of PPARA and fatty acid beta-oxidation in liver. Involved in positive regulation of insulin secretion in pancreatic beta cells in response to glucose; the function seems to imply transcriptional repression of UCP2. Proposed to deacetylate IRS2 thereby facilitating its insulin-induced tyrosine phosphorylation. Deacetylates SREBF1 isoform SREBP-1C thereby decreasing its stability and transactivation in lipogenic gene expression. Involved in DNA damage response by repressing genes which are involved in DNA repair, such as XPC and TP73, deacetylating XRCC6/Ku70, and faciliting recruitment of additional factors to sites of damaged DNA, such as SIRT1-deacetylated NBN can recruit ATM to initiate DNA repair and SIRT1-deacetylated XPA interacts with RPA2. Also involved in DNA repair of DNA double-strand breaks by homologous recombination and specifically single-strand annealing independently of XRCC6/Ku70 and NBN. Transcriptional suppression of XPC probably involves an E2F4:RBL2 suppressor complex and protein kinase B (AKT) signaling. Transcriptional suppression of TP73 probably involves E2F4 and PCAF. Deacetylates WRN thereby regulating its helicase and exonuclease activities and regulates WRN nuclear translocation in response to DNA damage. Deacetylates APEX1 at 'Lys-6' and 'Lys-7' and stimulates cellular AP endonuclease activity by promoting the association of APEX1 to XRCC1. Increases p53/TP53-mediated transcription-independent apoptosis by blocking nuclear translocation of cytoplasmic p53/TP53 and probably redirecting it to mitochondria. Deacetylates XRCC6/Ku70 at 'Lys-539' and 'Lys-542' causing it to sequester BAX away from mitochondria thereby inhibiting stress-induced apoptosis. Is involved in autophagy, presumably by deacetylating ATG5, ATG7 and MAP1LC3B/ATG8. Deacetylates AKT1 which leads to enhanced binding of AKT1 and PDK1 to PIP3 and promotes their activation. Proposed to play role in regulation of STK11/LBK1-dependent AMPK signaling pathways implicated in cellular senescence which seems to involve the regulation of the acetylation status of STK11/LBK1. Can deacetylate STK11/LBK1 and thereby increase its activity, cytoplasmic localization and association with STRAD; however, the relevance of such activity in normal cells is unclear. In endothelial cells is shown to inhibit STK11/LBK1 activity and to promote its degradation. Deacetylates SMAD7 at 'Lys-64' and 'Lys-70' thereby promoting its degradation. Deacetylates CIITA and augments its MHC class II transactivation and contributes to its stability. Deacteylates MECOM/EVI1. Deacetylates PML at 'Lys-487' and this deacetylation promotes PML control of PER2 nuclear localization. During the neurogenic transition, repress selective NOTCH1-target genes through histone deacetylation in a BCL6-dependent manner and leading to neuronal differentiation. Regulates the circadian expression of several core clock genes, including ARNTL/BMAL1, RORC, PER2 and CRY1 and plays a critical role in maintaining a controlled rhythmicity in histone acetylation, thereby contributing to circadian chromatin remodeling. Deacetylates ARNTL/BMAL1 and histones at the circadian gene promoters in order to facilitate repression by inhibitory components of the circadian oscillator. Deacetylates PER2, facilitating its ubiquitination and degradation by the proteosome. Protects cardiomyocytes against palmitate-induced apoptosis. Deacetylates XBP1 isoform 2; deacetylation decreases protein stability of XBP1 isoform 2 and inhibits its transcriptional activity. Deacetylates PCK1 and directs its activity toward phosphoenolpyruvate production promoting gluconeogenesis. Involved in the CCAR2-mediated regulation of PCK1 and NR1D1. Deacetylates CTNB1 at 'Lys-49'. In POMC (pro-opiomelanocortin) neurons, required for leptin-induced activation of PI3K signaling.  NAD-dependent protein deacetylase that links transcriptional regulation directly to intracellular energetics and participates in the coordination of several separated cellular functions such as cell cycle, response to DNA damage, metobolism, apoptosis and autophagy.
T14731	PDBSTRUC	5BTR; 4ZZJ; 4ZZI; 4ZZH; 4KXQ
T14731	BIOCLASS	Carbon-nitrogen hydrolase
T14731	ECNUMBER	EC 3.5.1.-
T14731	SEQUENCE	MADEAALALQPGGSPSAAGADREAASSPAGEPLRKRPRRDGPGLERSPGEPGGAAPEREVPAAARGCPGAAAAALWREAEAEAAAAGGEQEAQATAAAGEGDNGPGLQGPSREPPLADNLYDEDDDDEGEEEEEAAAAAIGYRDNLLFGDEIITNGFHSCESDEEDRASHASSSDWTPRPRIGPYTFVQQHLMIGTDPRTILKDLLPETIPPPELDDMTLWQIVINILSEPPKRKKRKDINTIEDAVKLLQECKKIIVLTGAGVSVSCGIPDFRSRDGIYARLAVDFPDLPDPQAMFDIEYFRKDPRPFFKFAKEIYPGQFQPSLCHKFIALSDKEGKLLRNYTQNIDTLEQVAGIQRIIQCHGSFATASCLICKYKVDCEAVRGDIFNQVVPRCPRCPADEPLAIMKPEIVFFGENLPEQFHRAMKYDKDEVDLLIVIGSSLKVRPVALIPSSIPHEVPQILINREPLPHLHFDVELLGDCDVIINELCHRLGGEYAKLCCNPVKLSEITEKPPRTQKELAYLSELPPTPLHVSEDSSSPERTSPPDSSVIVTLLDQAAKSNDDLDVSESKGCMEEKPQEVQTSRNVESIAEQMENPDLKNVGSSTGEKNERTSVAGTVRKCWPNRVAKEQISRRLDGNQYLFLPPNRYIFHGAEVYSDSEDDVLSSSSCGSNSDSGTCQSPSLEEPMEDESEIEEFYNGLEDEPDVPERAGGAGFGTDGDDQEAINEAISVKQEVTDMNYPSNKS
T14731	DRUGINFO	D0U3EP	Resveratrol	Phase 3
T14731	DRUGINFO	D04JNI	GSK2245840	Phase 2
T14731	DRUGINFO	D0E3LP	SEN-196	Phase 2
T14731	DRUGINFO	D0TU7V	MB-12066	Phase 2
T14731	DRUGINFO	D0O3EP	SRT2379	Phase 1
T14731	DRUGINFO	D0X3TI	SRT3025	Phase 1
T14731	DRUGINFO	D02QKC	PMID25435179-Compound-WO2012106509Salermide	Patented
T14731	DRUGINFO	D04JZE	CAMBINOL	Patented
T14731	DRUGINFO	D06IHB	PMID25435179-Compound-WO2012106509CAY10602	Patented
T14731	DRUGINFO	D0PE8E	PMID25435179-Compound-WO2012106509Tenovin-6	Patented
T14731	DRUGINFO	D0R3EL	GSK184072	Discontinued in Phase 2
T14731	DRUGINFO	D00LYI	Meta-sirtinol	Investigative
T14731	DRUGINFO	D02AYX	2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione	Investigative
T14731	DRUGINFO	D02EWM	(R)-sirtinol	Investigative
T14731	DRUGINFO	D03EGA	SRT1720	Investigative
T14731	DRUGINFO	D05UDU	YK-3237	Investigative
T14731	DRUGINFO	D09SUO	splitomicin	Investigative
T14731	DRUGINFO	D0E1QP	2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide	Investigative
T14731	DRUGINFO	D0F1KR	(S)-sirtinol	Investigative
T14731	DRUGINFO	D0UO1E	Para-sirtinol	Investigative
T14731	DRUGINFO	D0M5FF	Ro31-8220	Investigative
T14731	DRUGINFO	D0L8HO	RO-316233	Investigative

T46781	TARGETID	T46781
T46781	FORMERID	TTDC00139
T46781	UNIPROID	AURKB_HUMAN
T46781	TARGNAME	Aurora kinase B (AURKB)
T46781	GENENAME	AURKB
T46781	TARGTYPE	Clinical trial
T46781	SYNONYMS	Serine/threonine-protein kinase aurora-B; Serine/threonine-protein kinase 5; Serine/threonine-protein kinase 12; Serine/threonine protein kinase 12; STK5; STK12; Aurora/IPL1-related kinase 2; Aurora-related kinase 2; Aurora-B; Aurora-2 kinase; Aurora-2; Aurora- and Ipl1-like midbody-associated protein 1; Aurora 1; ARK2; ARK-2; AIRK2; AIM1; AIM-1; AIK2
T46781	FUNCTION	The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Involved in the bipolar attachment of spindle microtubules to kinetochores and is a key regulator for the onset of cytokinesis during mitosis. Required for central/midzone spindle assembly and cleavage furrow formation. Key component of the cytokinesis checkpoint, a process required to delay abscission to prevent both premature resolution of intercellular chromosome bridges and accumulation of DNA damage: phosphorylates CHMP4C, leading to retain abscission-competent VPS4 (VPS4A and/or VPS4B) at the midbody ring until abscission checkpoint signaling is terminated at late cytokinesis. AURKB phosphorylates the CPC complex subunits BIRC5/survivin, CDCA8/borealin and INCENP. Phosphorylation of INCENP leads to increased AURKB activity. Other known AURKB substrates involved in centromeric functions and mitosis are CENPA, DES/desmin, GPAF, KIF2C, NSUN2, RACGAP1, SEPT1, VIM/vimentin, HASPIN, and histone H3. A positive feedback loop involving HASPIN and AURKB contributes to localization of CPC to centromeres. Phosphorylation of VIM controls vimentin filament segregation in cytokinetic process, whereas histone H3 is phosphorylated at 'Ser-10' and 'Ser-28' during mitosis (H3S10ph and H3S28ph, respectively). A positive feedback between HASPIN and AURKB contributes to CPC localization. AURKB is also required for kinetochore localization of BUB1 and SGO1. Phosphorylation of p53/TP53 negatively regulates its transcriptional activity. Key regulator of active promoters in resting B- and T-lymphocytes: acts by mediating phosphorylation of H3S28ph at active promoters in resting B-cells, inhibiting RNF2/RING1B-mediated ubiquitination of histone H2A and enhancing binding and activity of the USP16 deubiquitinase at transcribed genes. Serine/threonine-protein kinase component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis.
T46781	PDBSTRUC	4AF3
T46781	BIOCLASS	Kinase
T46781	ECNUMBER	EC 2.7.11.1
T46781	SEQUENCE	MAQKENSYPWPYGRQTAPSGLSTLPQRVLRKEPVTPSALVLMSRSNVQPTAAPGQKVMENSSGTPDILTRHFTIDDFEIGRPLGKGKFGNVYLAREKKSHFIVALKVLFKSQIEKEGVEHQLRREIEIQAHLHHPNILRLYNYFYDRRRIYLILEYAPRGELYKELQKSCTFDEQRTATIMEELADALMYCHGKKVIHRDIKPENLLLGLKGELKIADFGWSVHAPSLRRKTMCGTLDYLPPEMIEGRMHNEKVDLWCIGVLCYELLVGNPPFESASHNETYRRIVKVDLKFPASVPMGAQDLISKLLRHNPSERLPLAQVSAHPWVRANSRRVLPPSALQSVA
T46781	DRUGINFO	D05PZB	AT9283	Phase 3
T46781	DRUGINFO	D0A1AQ	Rosiglitazone + metformin	Phase 3
T46781	DRUGINFO	D02XNW	VX-680	Phase 2
T46781	DRUGINFO	D08HOM	ABT-348	Phase 2
T46781	DRUGINFO	D02RJY	PHA-739358	Phase 2
T46781	DRUGINFO	D08HFW	TAK-901	Phase 1
T46781	DRUGINFO	D09KRU	BI-831266	Phase 1
T46781	DRUGINFO	D0P5IZ	BI-811283	Phase 1
T46781	DRUGINFO	D0Q7RE	AZD-1152-HQPA	Phase 1
T46781	DRUGINFO	D08DCP	BI-847325	Phase 1
T46781	DRUGINFO	D0E5XA	R763	Phase 1
T46781	DRUGINFO	D0IQ0Z	GSK1070916	Phase 1
T46781	DRUGINFO	D0J6AB	MK-5108	Phase 1
T46781	DRUGINFO	D0P0HU	GSK1070916A	Phase 1
T46781	DRUGINFO	D05LKZ	HPP-607	Phase 1
T46781	DRUGINFO	D0CY1B	CYC116	Phase 1
T46781	DRUGINFO	D0EJ3B	AMG 900	Phase 1
T46781	DRUGINFO	D0OA5G	SNS-314	Phase 1
T46781	DRUGINFO	D0H7AC	PF-03814735	Discontinued in Phase 1
T46781	DRUGINFO	D14NDZ	Deguelin	Investigative

T98896	TARGETID	T98896
T98896	FORMERID	TTDR00697
T98896	UNIPROID	ATS5_HUMAN
T98896	TARGNAME	Aggrecanase (ADAMTS5)
T98896	GENENAME	ADAMTS5
T98896	TARGTYPE	Clinical trial
T98896	SYNONYMS	Aggrecanase-2; ADMP-2; ADAMTS5; ADAMTS-5; ADAM-TS5; ADAM-TS 5; ADAM-TS 11; A disintegrin and metalloproteinase with thrombospondinmotifs 5
T98896	FUNCTION	Cleaves aggrecan, a cartilage proteoglycan, and may be involved in its turnover. May play an important role in the destruction of aggrecan in arthritic diseases. May play a role in proteolytic processing mostly during the peri-implantation period.
T98896	PDBSTRUC	3LJT; 3HYG; 3HY9; 3HY7; 3B8Z
T98896	BIOCLASS	Peptidase
T98896	ECNUMBER	EC 3.4.24.-
T98896	SEQUENCE	MLLGWASLLLCAFRLPLAAVGPAATPAQDKAGQPPTAAAAAQPRRRQGEEVQERAEPPGHPHPLAQRRRSKGLVQNIDQLYSGGGKVGYLVYAGGRRFLLDLERDGSVGIAGFVPAGGGTSAPWRHRSHCFYRGTVDGSPRSLAVFDLCGGLDGFFAVKHARYTLKPLLRGPWAEEEKGRVYGDGSARILHVYTREGFSFEALPPRASCETPASTPEAHEHAPAHSNPSGRAALASQLLDQSALSPAGGSGPQTWWRRRRRSISRARQVELLLVADASMARLYGRGLQHYLLTLASIANRLYSHASIENHIRLAVVKVVVLGDKDKSLEVSKNAATTLKNFCKWQHQHNQLGDDHEEHYDAAILFTREDLCGHHSCDTLGMADVGTICSPERSCAVIEDDGLHAAFTVAHEIGHLLGLSHDDSKFCEETFGSTEDKRLMSSILTSIDASKPWSKCTSATITEFLDDGHGNCLLDLPRKQILGPEELPGQTYDATQQCNLTFGPEYSVCPGMDVCARLWCAVVRQGQMVCLTKKLPAVEGTPCGKGRICLQGKCVDKTKKKYYSTSSHGNWGSWGSWGQCSRSCGGGVQFAYRHCNNPAPRNNGRYCTGKRAIYRSCSLMPCPPNGKSFRHEQCEAKNGYQSDAKGVKTFVEWVPKYAGVLPADVCKLTCRAKGTGYYVVFSPKVTDGTECRLYSNSVCVRGKCVRTGCDGIIGSKLQYDKCGVCGGDNSSCTKIVGTFNKKSKGYTDVVRIPEGATHIKVRQFKAKDQTRFTAYLALKKKNGEYLINGKYMISTSETIIDINGTVMNYSGWSHRDDFLHGMGYSATKEILIVQILATDPTKPLDVRYSFFVPKKSTPKVNSVTSHGSNKVGSHTSQPQWVTGPWLACSRTCDTGWHTRTVQCQDGNRKLAKGCPLSQRPSAFKQCLLKKC
T98896	DRUGINFO	D0C5NP	AGG-523	Phase 1
T98896	DRUGINFO	D0Y1XT	SC-44463	Terminated
T98896	DRUGINFO	D0FD9M	PMID21536437C15c	Investigative
T98896	DRUGINFO	D0MI1N	CR-5259	Investigative

T97592	TARGETID	T97592
T97592	FORMERID	TTDC00059
T97592	UNIPROID	AURKC_HUMAN
T97592	TARGNAME	Aurora kinase C (AURKC)
T97592	GENENAME	AURKC
T97592	TARGTYPE	Clinical trial
T97592	SYNONYMS	Serine/threonine-protein kinase aurora-C; STK13; Aurora/Ipl1/Eg2 protein 2; Aurora/Ipl1-related kinase 3; Aurora-related kinase 3; Aurora-C; Aurora 3; ARK3; ARK-3; AIRK3; AIK3; AIE2
T97592	FUNCTION	The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Plays also a role in meiosis and more particularly in spermatogenesis. Has redundant cellular functions with AURKB and can rescue an AURKB knockdown. Like AURKB, AURKC phosphorylates histone H3 at 'Ser-10' and 'Ser-28'. AURKC phosphorylates the CPC complex subunits BIRC5/survivin and INCENP leading to increased AURKC activity. Phosphorylates TACC1, another protein involved in cell division, at 'Ser-228'. Serine/threonine-protein kinase component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis.
T97592	PDBSTRUC	6GR9; 6GR8
T97592	BIOCLASS	Kinase
T97592	ECNUMBER	EC 2.7.11.1
T97592	SEQUENCE	MSSPRAVVQLGKAQPAGEELATANQTAQQPSSPAMRRLTVDDFEIGRPLGKGKFGNVYLARLKESHFIVALKVLFKSQIEKEGLEHQLRREIEIQAHLQHPNILRLYNYFHDARRVYLILEYAPRGELYKELQKSEKLDEQRTATIIEELADALTYCHDKKVIHRDIKPENLLLGFRGEVKIADFGWSVHTPSLRRKTMCGTLDYLPPEMIEGRTYDEKVDLWCIGVLCYELLVGYPPFESASHSETYRRILKVDVRFPLSMPLGARDLISRLLRYQPLERLPLAQILKHPWVQAHSRRVLPPCAQMAS
T97592	DRUGINFO	D08HOM	ABT-348	Phase 2
T97592	DRUGINFO	D02RJY	PHA-739358	Phase 2
T97592	DRUGINFO	D0IQ0Z	GSK1070916	Phase 1
T97592	DRUGINFO	D0P0HU	GSK1070916A	Phase 1
T97592	DRUGINFO	D05LKZ	HPP-607	Phase 1
T97592	DRUGINFO	D0EJ3B	AMG 900	Phase 1
T97592	DRUGINFO	D0OA5G	SNS-314	Phase 1
T97592	DRUGINFO	D0M0KB	MK-6592	Discontinued in Phase 1
T97592	DRUGINFO	D00UTU	7-bromoindirubin-3-acetoxime	Investigative
T97592	DRUGINFO	D06XLC	BMS-739562	Investigative
T97592	DRUGINFO	D08VMW	MP-529	Investigative
T97592	DRUGINFO	D09VAB	BPR1K-0224	Investigative
T97592	DRUGINFO	D0Q3EW	2np8	Investigative
T97592	DRUGINFO	D06LJL	PMID16451062C46	Investigative
T97592	DRUGINFO	D0I1IK	7-fluoroindirubin-3-acetoxime	Investigative
T97592	DRUGINFO	D0K6VW	7-iodoindirubin-3-oxime	Investigative
T97592	DRUGINFO	D0K8YI	7-chloroindirubin-3-oxime	Investigative
T97592	DRUGINFO	D0L1GF	7-bromoindirubin-3-oxime	Investigative
T97592	DRUGINFO	D0U8VY	quinazoline deriv. 1	Investigative
T97592	DRUGINFO	D0Y8DT	Glycyl-H 1152	Investigative
T97592	DRUGINFO	D00TKJ	7-fluoroindirubin-3-oxime	Investigative
T97592	DRUGINFO	D06AGN	Indirubin-3-acetoxime	Investigative
T97592	DRUGINFO	D0ME9B	PMID20855207C25	Investigative
T97592	DRUGINFO	D0Q7TO	K00244	Investigative
T97592	DRUGINFO	D0V6LP	Indirubin-3-methoxime	Investigative
T97592	DRUGINFO	D06OAH	6-bromoindirubin-3-oxime	Investigative
T97592	DRUGINFO	D0CE3R	SU 6656	Investigative
T97592	DRUGINFO	D0Y0ES	Indirubin-3'-monoxime	Investigative

T96788	TARGETID	T96788
T96788	FORMERID	TTDR01361
T96788	UNIPROID	ERBB2_HUMAN
T96788	TARGNAME	ERBB2 messenger RNA (HER2 mRNA)
T96788	GENENAME	ERBB2
T96788	TARGTYPE	Clinical trial
T96788	SYNONYMS	Tyrosine kinase-type cell surface receptor HER2 (mRNA); Tyrosine kinase receptor ErbB2 (mRNA); Receptor tyrosine-protein kinase erbB-2 (mRNA); Proto-oncogene c-ErbB-2 (mRNA); Proto-oncogene Neu (mRNA); P185erbB2 (mRNA); NGL (mRNA); NEU proto-oncogene (mRNA); NEU (mRNA); Metastatic lymph node gene 19 protein (mRNA); MLN19 (mRNA); MLN 19 (mRNA); HER2/neu (mRNA); HER2 (erbB2/neu) (mRNA); HER-2 (mRNA); Erb2 (mRNA); Epidermal growth factor receptor 2 (mRNA); CD340 (mRNA); C-erbB-2 oncoprotein (mRNA); C-erbB-2 (mRNA)
T96788	FUNCTION	Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization. Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding.
T96788	PDBSTRUC	6OGE; 6J71; 6BGT; 6ATT; 5TQS
T96788	BIOCLASS	mRNA target
T96788	ECNUMBER	EC 2.7.10.1
T96788	SEQUENCE	MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNLELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNGDPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLALTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQCAAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACPYNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSANIQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLPDLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTVPWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQECVEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARCPSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVGILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETELRKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFTHQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDAEEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEGAGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYVNQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQGGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV
T96788	DRUGINFO	D0Q9CY	HKI-272	Phase 3
T96788	DRUGINFO	D0R6UV	BMS-690514	Phase 2
T96788	DRUGINFO	D01OKF	4-(Bis(2-chloroethyl)amino)-N-p-tolylbenzamide	Investigative
T96788	DRUGINFO	D06JEJ	ISIS 9002	Investigative
T96788	DRUGINFO	D06VFH	ISIS 12883	Investigative
T96788	DRUGINFO	D09HJE	ISIS 12884	Investigative
T96788	DRUGINFO	D09RFE	4-(3-phenoxylphenyl)-5-cyano-2H-1,2,3-triazole	Investigative
T96788	DRUGINFO	D0AA2X	PNT-500	Investigative
T96788	DRUGINFO	D0B7ZB	4-(4-isopropylphenyl)-5-cyano-2H-1,2,3-triazole	Investigative
T96788	DRUGINFO	D0C0EE	ISIS 9005	Investigative
T96788	DRUGINFO	D0C2SF	4-(4-chlorophenyl)-5-cyano-2H-1,2,3-triazole	Investigative
T96788	DRUGINFO	D0EE7R	ISIS 9003	Investigative
T96788	DRUGINFO	D0H2DD	4-(4-bromophenyl)-5-cyano-2H-1,2,3-triazole	Investigative
T96788	DRUGINFO	D0S3AR	ISIS 12882	Investigative
T96788	DRUGINFO	D01VFR	PD-168393	Investigative
T96788	DRUGINFO	D01WYI	N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide	Investigative
T96788	DRUGINFO	D02ARA	(1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine	Investigative
T96788	DRUGINFO	D0Q3GG	AG-213	Investigative
T96788	DRUGINFO	D0X4OU	4557W	Investigative
T96788	DRUGINFO	D00TZD	CL-387785	Investigative
T96788	DRUGINFO	D05FFT	HDS-029	Investigative
T96788	DRUGINFO	D0H6OS	Geldanamycin-estradiol hybrid	Investigative
T96788	DRUGINFO	D06BJG	PMID24915291C38	Investigative
T96788	DRUGINFO	D06AOY	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	Investigative
T96788	DRUGINFO	D0M4SY	BMS-536924	Investigative
T96788	DRUGINFO	D00NYT	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	Investigative
T96788	DRUGINFO	D0C3WY	3,4-diphenyl-1H-pyrrole-2,5-dione	Investigative
T96788	DRUGINFO	D0EK0G	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	Investigative

T90648	TARGETID	T90648
T90648	FORMERID	TTDR01373
T90648	UNIPROID	BRAF_HUMAN
T90648	TARGNAME	B-Raf messenger RNA (BRAF mRNA)
T90648	GENENAME	BRAF
T90648	TARGTYPE	Clinical trial
T90648	SYNONYMS	V-Raf murine sarcoma viral oncogene homolog B1 (mRNA); Serine/threonine-protein kinase B-raf (mRNA); RAFB1 (mRNA); Proto-oncogene B-Raf (mRNA); P94 (mRNA); BRAF1 (mRNA); BRAF(V599E) (mRNA); BRAF serine/threonine kinase (mRNA); B-raf protein (mRNA); B-Raf (mRNA)
T90648	FUNCTION	May play a role in the postsynaptic responses of hippocampal neuron. Phosphorylates MAP2K1, and thereby contributes to the MAP kinase signal transduction pathway. Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus.
T90648	PDBSTRUC	6CAD; 6B8U; 5VYK; 5VR3; 5VAM
T90648	BIOCLASS	mRNA target
T90648	ECNUMBER	EC 2.7.11.1
T90648	SEQUENCE	MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH
T90648	DRUGINFO	D07IEU	MLN2480	Phase 2
T90648	DRUGINFO	D02DXC	SPN-803	Phase 1
T90648	DRUGINFO	D0F5JZ	PLX-4720	Phase 1
T90648	DRUGINFO	D06EFW	RG7304	Phase 1
T90648	DRUGINFO	D01DDB	2-(Phenylamino)-6-(3-acetamidophenyl)pyrazine	Investigative
T90648	DRUGINFO	D07LZP	ISIS 13741	Investigative
T90648	DRUGINFO	D07TDZ	ISIS 14144	Investigative
T90648	DRUGINFO	D07UFK	PMID26061392C2	Investigative
T90648	DRUGINFO	D09AIJ	ISIS 13740	Investigative
T90648	DRUGINFO	D0C5BL	ISIS 13730	Investigative
T90648	DRUGINFO	D0O9XE	ISIS 13743	Investigative
T90648	DRUGINFO	D0OR5S	2-(Benzylamino)-6-(3-acetamidophenyl)pyrazine	Investigative
T90648	DRUGINFO	D0P5VF	Pyrazolo[1,5-a]pyrimidine-3-carboxylate	Investigative
T90648	DRUGINFO	D0X7MU	ISIS 13727	Investigative
T90648	DRUGINFO	D06YMT	PLX-ORI3	Investigative
T90648	DRUGINFO	D00NWF	ZM-336372	Investigative
T90648	DRUGINFO	D06WJA	L-779450	Investigative

T77764	TARGETID	T77764
T77764	FORMERID	TTDR01420
T77764	UNIPROID	AURKB_HUMAN
T77764	TARGNAME	Aurora B messenger RNA (AURKB mRNA)
T77764	GENENAME	AURKB
T77764	TARGTYPE	Clinical trial
T77764	SYNONYMS	Serine/threonine-protein kinase aurora-B (mRNA); Serine/threonine-protein kinase 5 (mRNA); Serine/threonine-protein kinase 12 (mRNA); Serine/threonine protein kinase 12 (mRNA); STK5 (mRNA); STK12 (mRNA); Aurora/IPL1-related kinase 2 (mRNA); Aurora-related kinase 2 (mRNA); Aurora-B (mRNA); Aurora-2 kinase (mRNA); Aurora-2 (mRNA); Aurora- and Ipl1-like midbody-associated protein 1 (mRNA); Aurora 1 (mRNA); ARK2 (mRNA); ARK-2 (mRNA); AIRK2 (mRNA); AIM1 (mRNA); AIM-1 (mRNA); AIK2 (mRNA)
T77764	FUNCTION	The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Involved in the bipolar attachment of spindle microtubules to kinetochores and is a key regulator for the onset of cytokinesis during mitosis. Required for central/midzone spindle assembly and cleavage furrow formation. Key component of the cytokinesis checkpoint, a process required to delay abscission to prevent both premature resolution of intercellular chromosome bridges and accumulation of DNA damage: phosphorylates CHMP4C, leading to retain abscission-competent VPS4 (VPS4A and/or VPS4B) at the midbody ring until abscission checkpoint signaling is terminated at late cytokinesis. AURKB phosphorylates the CPC complex subunits BIRC5/survivin, CDCA8/borealin and INCENP. Phosphorylation of INCENP leads to increased AURKB activity. Other known AURKB substrates involved in centromeric functions and mitosis are CENPA, DES/desmin, GPAF, KIF2C, NSUN2, RACGAP1, SEPT1, VIM/vimentin, HASPIN, and histone H3. A positive feedback loop involving HASPIN and AURKB contributes to localization of CPC to centromeres. Phosphorylation of VIM controls vimentin filament segregation in cytokinetic process, whereas histone H3 is phosphorylated at 'Ser-10' and 'Ser-28' during mitosis (H3S10ph and H3S28ph, respectively). A positive feedback between HASPIN and AURKB contributes to CPC localization. AURKB is also required for kinetochore localization of BUB1 and SGO1. Phosphorylation of p53/TP53 negatively regulates its transcriptional activity. Key regulator of active promoters in resting B- and T-lymphocytes: acts by mediating phosphorylation of H3S28ph at active promoters in resting B-cells, inhibiting RNF2/RING1B-mediated ubiquitination of histone H2A and enhancing binding and activity of the USP16 deubiquitinase at transcribed genes. Serine/threonine-protein kinase component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis.
T77764	PDBSTRUC	4AF3
T77764	BIOCLASS	mRNA target
T77764	ECNUMBER	EC 2.7.11.1
T77764	SEQUENCE	MAQKENSYPWPYGRQTAPSGLSTLPQRVLRKEPVTPSALVLMSRSNVQPTAAPGQKVMENSSGTPDILTRHFTIDDFEIGRPLGKGKFGNVYLAREKKSHFIVALKVLFKSQIEKEGVEHQLRREIEIQAHLHHPNILRLYNYFYDRRRIYLILEYAPRGELYKELQKSCTFDEQRTATIMEELADALMYCHGKKVIHRDIKPENLLLGLKGELKIADFGWSVHAPSLRRKTMCGTLDYLPPEMIEGRMHNEKVDLWCIGVLCYELLVGNPPFESASHNETYRRIVKVDLKFPASVPMGAQDLISKLLRHNPSERLPLAQVSAHPWVRANSRRVLPPSALQSVA
T77764	DRUGINFO	D02RJY	PHA-739358	Phase 2
T77764	DRUGINFO	D05WSM	HESPERADIN	Investigative
T77764	DRUGINFO	D07PVS	ISIS 173848	Investigative
T77764	DRUGINFO	D0K1JI	ISIS 173813	Investigative
T77764	DRUGINFO	D0PI2A	ISIS 173831	Investigative
T77764	DRUGINFO	D0Y5UO	ISIS 173840	Investigative
T77764	DRUGINFO	D04MYT	4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine	Investigative
T77764	DRUGINFO	D06LJL	PMID16451062C46	Investigative
T77764	DRUGINFO	D0I1IK	7-fluoroindirubin-3-acetoxime	Investigative
T77764	DRUGINFO	D0K6VW	7-iodoindirubin-3-oxime	Investigative
T77764	DRUGINFO	D0K8YI	7-chloroindirubin-3-oxime	Investigative
T77764	DRUGINFO	D0L1GF	7-bromoindirubin-3-oxime	Investigative
T77764	DRUGINFO	D0U8VY	quinazoline deriv. 1	Investigative
T77764	DRUGINFO	D00TKJ	7-fluoroindirubin-3-oxime	Investigative
T77764	DRUGINFO	D01TDV	PMID21742770C1	Investigative
T77764	DRUGINFO	D06AGN	Indirubin-3-acetoxime	Investigative
T77764	DRUGINFO	D0A7FQ	CGP-57380	Investigative
T77764	DRUGINFO	D0ME9B	PMID20855207C25	Investigative
T77764	DRUGINFO	D0V6LP	Indirubin-3-methoxime	Investigative
T77764	DRUGINFO	D06OAH	6-bromoindirubin-3-oxime	Investigative
T77764	DRUGINFO	D0CE3R	SU 6656	Investigative
T77764	DRUGINFO	D0Y0ES	Indirubin-3'-monoxime	Investigative

T64682	TARGETID	T64682
T64682	FORMERID	TTDR01250
T64682	UNIPROID	SGK1_HUMAN
T64682	TARGNAME	Serine/threonine-protein kinase Sgk1 (SGK1)
T64682	GENENAME	SGK1
T64682	TARGTYPE	Clinical trial
T64682	SYNONYMS	Serum/glucocorticoid-regulated kinase 1; SGK1
T64682	FUNCTION	Plays an important role in cellular stress response. Contributes to regulation of renal Na(+) retention, renal K(+) elimination, salt appetite, gastric acid secretion, intestinal Na(+)/H(+) exchange and nutrient transport, insulin-dependent salt sensitivity of blood pressure, salt sensitivity of peripheral glucose uptake, cardiac repolarization and memory consolidation. Up-regulates Na(+) channels: SCNN1A/ENAC, SCN5A and ASIC1/ACCN2, K(+) channels: KCNJ1/ROMK1, KCNA1-5, KCNQ1-5 and KCNE1, epithelial Ca(2+) channels: TRPV5 and TRPV6, chloride channels: BSND, CLCN2 and CFTR, glutamate transporters: SLC1A3/EAAT1, SLC1A2 /EAAT2, SLC1A1/EAAT3, SLC1A6/EAAT4 and SLC1A7/EAAT5, amino acid transporters: SLC1A5/ASCT2, SLC38A1/SN1 and SLC6A19, creatine transporter: SLC6A8, Na(+)/dicarboxylate cotransporter: SLC13A2/NADC1, Na(+)-dependent phosphate cotransporter: SLC34A2/NAPI-2B, glutamate receptor: GRIK2/GLUR6. Up-regulates carriers: SLC9A3/NHE3, SLC12A1/NKCC2, SLC12A3/NCC, SLC5A3/SMIT, SLC2A1/GLUT1, SLC5A1/SGLT1 and SLC15A2/PEPT2. Regulates enzymes: GSK3A/B, PMM2 and Na(+)/K(+) ATPase, and transcription factors: CTNNB1 and nuclear factor NF-kappa-B. Stimulates sodium transport into epithelial cells by enhancing the stability and expression of SCNN1A/ENAC. This is achieved by phosphorylating the NEDD4L ubiquitin E3 ligase, promoting its interaction with 14-3-3 proteins, thereby preventing it from binding to SCNN1A/ENAC and targeting it for degradation. Regulates store-operated Ca(+2) entry (SOCE) by stimulating ORAI1 and STIM1. Regulates KCNJ1/ROMK1 directly via its phosphorylation or indirectly via increased interaction with SLC9A3R2/NHERF2. Phosphorylates MDM2 and activates MDM2-dependent ubiquitination of p53/TP53. Phosphorylates MAPT/TAU and mediates microtubule depolymerization and neurite formation in hippocampal neurons. Phosphorylates SLC2A4/GLUT4 and up-regulates its activity. Phosphorylates APBB1/FE65 and promotes its localization to the nucleus. Phosphorylates MAPK1/ERK2 and activates it by enhancing its interaction with MAP2K1/MEK1 and MAP2K2/MEK2. Phosphorylates FBXW7 and plays an inhibitory role in the NOTCH1 signaling. Phosphorylates FOXO1 resulting in its relocalization from the nucleus to the cytoplasm. Phosphorylates FOXO3, promoting its exit from the nucleus and interference with FOXO3-dependent transcription. Phosphorylates BRAF and MAP3K3/MEKK3 and inhibits their activity. Phosphorylates SLC9A3/NHE3 in response to dexamethasone, resulting in its activation and increased localization at the cell membrane. Phosphorylates CREB1. Necessary for vascular remodeling during angiogenesis. Sustained high levels and activity may contribute to conditions such as hypertension and diabetic nephropathy. Isoform 2 exhibited a greater effect on cell plasma membrane expression of SCNN1A/ENAC and Na(+) transport than isoform 1. Serine/threonine-protein kinase which is involved in the regulation of a wide variety of ion channels, membrane transporters, cellular enzymes, transcription factors, neuronal excitability, cell growth, proliferation, survival, migration and apoptosis.
T64682	PDBSTRUC	3HDN; 3HDM; 2R5T
T64682	BIOCLASS	Kinase
T64682	ECNUMBER	EC 2.7.11.1
T64682	SEQUENCE	MTVKTEAAKGTLTYSRMRGMVAILIAFMKQRRMGLNDFIQKIANNSYACKHPEVQSILKISQPQEPELMNANPSPPPSPSQQINLGPSSNPHAKPSDFHFLKVIGKGSFGKVLLARHKAEEVFYAVKVLQKKAILKKKEEKHIMSERNVLLKNVKHPFLVGLHFSFQTADKLYFVLDYINGGELFYHLQRERCFLEPRARFYAAEIASALGYLHSLNIVYRDLKPENILLDSQGHIVLTDFGLCKENIEHNSTTSTFCGTPEYLAPEVLHKQPYDRTVDWWCLGAVLYEMLYGLPPFYSRNTAEMYDNILNKPLQLKPNITNSARHLLEGLLQKDRTKRLGAKDDFMEIKSHVFFSLINWDDLINKKITPPFNPNVSGPNDLRHFDPEFTEEPVPNSIGKSPDSVLVTASVKEAAEAFLGFSYAPPTDSFL
T64682	DRUGINFO	D0F3FC	GSK-650394	Investigative
T64682	DRUGINFO	D0A7FQ	CGP-57380	Investigative
T64682	DRUGINFO	D0N6ES	KN-62	Investigative
T64682	DRUGINFO	D0B9BU	CI-1040	Investigative
T64682	DRUGINFO	D0O1YH	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	Investigative
T64682	DRUGINFO	D0TO6S	Bisindolylmaleimide-I	Investigative
T64682	DRUGINFO	D0L8HO	RO-316233	Investigative

T81443	TARGETID	T81443
T81443	FORMERID	TTDC00209
T81443	UNIPROID	TLR4_HUMAN
T81443	TARGNAME	Toll-like receptor 4 (TLR4)
T81443	GENENAME	TLR4
T81443	TARGTYPE	Clinical trial
T81443	SYNONYMS	TLR-4; HToll; CD284
T81443	FUNCTION	Acts via MYD88, TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Also involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni(2+). Responses triggered by Ni(2+) require non-conserved histidines and are, therefore, species-specific. Both M. tuberculosis HSP70 (dnaK) and HSP65 (groEL-2) act via this protein to stimulate NF-kappa-B expression. In complex with TLR6, promotes sterile inflammation in monocytes/macrophages in response to oxidized low-density lipoprotein (oxLDL) or amyloid-beta 42. In this context, the initial signal is provided by oxLDL- or amyloid-beta 42-binding to CD36. This event induces the formation of a heterodimer of TLR4 and TLR6, which is rapidly internalized and triggers inflammatory response, leading to the NF-kappa-B-dependent production of CXCL1, CXCL2 and CCL9 cytokines, via MYD88 signaling pathway, and CCL5 cytokine, via TICAM1 signaling pathway, as well as IL1B secretion. Binds electronegative LDL (LDL(-)) and mediates the cytokine release induced by LDL(-). Stimulation of monocytes in vitro with M. tuberculosis PstS1 induces p38 MAPK and ERK1/2 activation primarily via TLR2, but also partially via this receptor. Cooperates with LY96 and CD14 to mediate the innate immune response to bacterial lipopolysaccharide (LPS).
T81443	PDBSTRUC	5NAO; 5NAM; 4G8A; 3ULA; 3UL9
T81443	BIOCLASS	Toll-like receptor
T81443	SEQUENCE	MMSASRLAGTLIPAMAFLSCVRPESWEPCVEVVPNITYQCMELNFYKIPDNLPFSTKNLDLSFNPLRHLGSYSFFSFPELQVLDLSRCEIQTIEDGAYQSLSHLSTLILTGNPIQSLALGAFSGLSSLQKLVAVETNLASLENFPIGHLKTLKELNVAHNLIQSFKLPEYFSNLTNLEHLDLSSNKIQSIYCTDLRVLHQMPLLNLSLDLSLNPMNFIQPGAFKEIRLHKLTLRNNFDSLNVMKTCIQGLAGLEVHRLVLGEFRNEGNLEKFDKSALEGLCNLTIEEFRLAYLDYYLDDIIDLFNCLTNVSSFSLVSVTIERVKDFSYNFGWQHLELVNCKFGQFPTLKLKSLKRLTFTSNKGGNAFSEVDLPSLEFLDLSRNGLSFKGCCSQSDFGTTSLKYLDLSFNGVITMSSNFLGLEQLEHLDFQHSNLKQMSEFSVFLSLRNLIYLDISHTHTRVAFNGIFNGLSSLEVLKMAGNSFQENFLPDIFTELRNLTFLDLSQCQLEQLSPTAFNSLSSLQVLNMSHNNFFSLDTFPYKCLNSLQVLDYSLNHIMTSKKQELQHFPSSLAFLNLTQNDFACTCEHQSFLQWIKDQRQLLVEVERMECATPSDKQGMPVLSLNITCQMNKTIIGVSVLSVLVVSVVAVLVYKFYFHLMLLAGCIKYGRGENIYDAFVIYSSQDEDWVRNELVKNLEEGVPPFQLCLHYRDFIPGVAIAANIIHEGFHKSRKVIVVVSQHFIQSRWCIFEYEIAQTWQFLSSRAGIIFIVLQKVEKTLLRQQVELYRLLSRNTYLEWEDSVLGRHIFWRRLRKALLDGKSWNPEGTVGTGCNWQEATSI
T81443	DRUGINFO	D08KNK	MPL-containing Pollinex allergy desensitization vaccine	Preregistration
T81443	DRUGINFO	D0E4GG	Resatorvid	Phase 3
T81443	DRUGINFO	D0SJ8Q	ERITORAN	Phase 3
T81443	DRUGINFO	D0V0JR	Cadi-05	Phase 3
T81443	DRUGINFO	D0MD5M	G100	Phase 2
T81443	DRUGINFO	D04MZP	NI-0101	Phase 1
T81443	DRUGINFO	D0MM4H	GSK1795091	Phase 1
T81443	DRUGINFO	D0O2MO	CRX-675	Phase 1
T81443	DRUGINFO	D09POQ	OM-174	Phase 1
T81443	DRUGINFO	D09LZA	CS-4771	Discontinued in Phase 1
T81443	DRUGINFO	D06TTS	LZ-8	Terminated
T81443	DRUGINFO	D00GLW	OM-294-DP	Investigative
T81443	DRUGINFO	D02SGT	OM-197-MP-AC	Investigative
T81443	DRUGINFO	D06MKE	CRX-526	Investigative
T81443	DRUGINFO	D0J0GM	6-(2-aminophenoxy)benzo[d]isothiazol-3-amine	Investigative
T81443	DRUGINFO	D0NB4V	Fibronectin extra domain A	Investigative
T81443	DRUGINFO	D0Q7RV	AS04	Investigative
T81443	DRUGINFO	D0A0GD	3-Hydroxy-Myristic Acid	Investigative
T81443	DRUGINFO	D04PFD	TriMixDC	Investigative
T81443	DRUGINFO	D0N0UC	Lauric Acid	Investigative
T81443	DRUGINFO	D08OBF	MYRISTIC ACID	Investigative

T77645	TARGETID	T77645
T77645	FORMERID	TTDC00267
T77645	UNIPROID	TR10A_HUMAN
T77645	TARGNAME	TRAIL receptor 1 (TRAIL-R1)
T77645	GENENAME	TNFRSF10A
T77645	TARGTYPE	Clinical trial
T77645	SYNONYMS	Tumor necrosis factor receptor superfamily member 10A; TRAILR1; TNF-related apoptosis-inducing ligand receptor 1; Death receptor 4; DR4; CD261; APO2
T77645	FUNCTION	The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B. Receptor for the cytotoxic ligand TNFSF10/TRAIL.
T77645	PDBSTRUC	5CIR
T77645	BIOCLASS	Cytokine receptor
T77645	SEQUENCE	MAPPPARVHLGAFLAVTPNPGSAASGTEAAAATPSKVWGSSAGRIEPRGGGRGALPTSMGQHGPSARARAGRAPGPRPAREASPRLRVHKTFKFVVVGVLLQVVPSSAATIKLHDQSIGTQQWEHSPLGELCPPGSHRSEHPGACNRCTEGVGYTNASNNLFACLPCTACKSDEEERSPCTTTRNTACQCKPGTFRNDNSAEMCRKCSRGCPRGMVKVKDCTPWSDIECVHKESGNGHNIWVILVVTLVVPLLLVAVLIVCCCIGSGCGGDPKCMDRVCFWRLGLLRGPGAEDNAHNEILSNADSLSTFVSEQQMESQEPADLTGVTVQSPGEAQCLLGPAEAEGSQRRRLLVPANGADPTETLMLFFDKFANIVPFDSWDQLMRQLDLTKNEIDVVRAGTAGPGDALYAMLMKWVNKTGRNASIHTLLDALERMEERHAREKIQDLLVDSGKFIYLEDGTGSAVSLE
T77645	DRUGINFO	D0KG5D	Mapatumumab	Phase 2
T77645	DRUGINFO	D08JRT	RhApo2L/TRAIL	Discontinued in Phase 1/2
T77645	DRUGINFO	D0X3PN	DR-5/DR-4 cross reactive mabs	Investigative

T77400	TARGETID	T77400
T77400	FORMERID	TTDR00256
T77400	UNIPROID	PDE2A_HUMAN
T77400	TARGNAME	Phosphodiesterase 2A (PDE2A)
T77400	GENENAME	PDE2A
T77400	TARGTYPE	Clinical trial
T77400	SYNONYMS	cGMP-dependent 3',5'-cyclic phosphodiesterase; PDE-II; Cyclic-GMP phosphodiesterase; Cyclic GMP-stimulated phosphodiesterase; Cyclic GMP stimulated phosphodiesterase; CGSPDE; CGS-PDE
T77400	FUNCTION	Plays an important role in growth and invasion of malignant melanoma cells (e. g. pseudomyxoma peritonei (PMP) cell line). Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes.
T77400	PDBSTRUC	6CYD; 6CYC; 6CYB; 6C7J; 6C7I
T77400	BIOCLASS	Phosphoric diester hydrolase
T77400	ECNUMBER	EC 3.1.4.17
T77400	SEQUENCE	MGQACGHSILCRSQQYPAARPAEPRGQQVFLKPDEPPPPPQPCADSLQDALLSLGSVIDISGLQRAVKEALSAVLPRVETVYTYLLDGESQLVCEDPPHELPQEGKVREAIISQKRLGCNGLGFSDLPGKPLARLVAPLAPDTQVLVMPLADKEAGAVAAVILVHCGQLSDNEEWSLQAVEKHTLVALRRVQVLQQRGPREAPRAVQNPPEGTAEDQKGGAAYTDRDRKILQLCGELYDLDASSLQLKVLQYLQQETRASRCCLLLVSEDNLQLSCKVIGDKVLGEEVSFPLTGCLGQVVEDKKSIQLKDLTSEDVQQLQSMLGCELQAMLCVPVISRATDQVVALACAFNKLEGDLFTDEDEHVIQHCFHYTSTVLTSTLAFQKEQKLKCECQALLQVAKNLFTHLDDVSVLLQEIITEARNLSNAEICSVFLLDQNELVAKVFDGGVVDDESYEIRIPADQGIAGHVATTGQILNIPDAYAHPLFYRGVDDSTGFRTRNILCFPIKNENQEVIGVAELVNKINGPWFSKFDEDLATAFSIYCGISIAHSLLYKKVNEAQYRSHLANEMMMYHMKVSDDEYTKLLHDGIQPVAAIDSNFASFTYTPRSLPEDDTSMAILSMLQDMNFINNYKIDCPTLARFCLMVKKGYRDPPYHNWMHAFSVSHFCYLLYKNLELTNYLEDIEIFALFISCMCHDLDHRGTNNSFQVASKSVLAALYSSEGSVMERHHFAQAIAILNTHGCNIFDHFSRKDYQRMLDLMRDIILATDLAHHLRIFKDLQKMAEVGYDRNNKQHHRLLLCLLMTSCDLSDQTKGWKTTRKIAELIYKEFFSQGDLEKAMGNRPMEMMDREKAYIPELQISFMEHIAMPIYKLLQDLFPKAAELYERVASNREHWTKVSHKFTIRGLPSNNSLDFLDEEYEVPDLDGTRAPINGCCSLDAE
T77400	DRUGINFO	D0M7OU	CP-461	Phase 2
T77400	DRUGINFO	DB82TO	Tofisopam	Phase 2
T77400	DRUGINFO	D0I2VT	ND7001	Phase 1
T77400	DRUGINFO	D00ONN	Imidazo triazine derivative 1	Patented
T77400	DRUGINFO	D01IRA	Pyrazolo[3,4-d]pyrimidine derivative 3	Patented
T77400	DRUGINFO	D05UNO	Imidazo triazine derivative 4	Patented
T77400	DRUGINFO	D07OOA	Pyrazolo[3,4-d]pyrimidine derivative 2	Patented
T77400	DRUGINFO	D07YWQ	Pyrazolo[3,4-d]pyrimidine derivative 1	Patented
T77400	DRUGINFO	D08CEK	Imidazo triazine derivative 5	Patented
T77400	DRUGINFO	D09PMC	PMID27321640-Compound-75	Patented
T77400	DRUGINFO	D0A5YE	PMID27321640-Compound-74	Patented
T77400	DRUGINFO	D0AK5Y	Oxindole derivative 1	Patented
T77400	DRUGINFO	D0ET2A	Imidazo triazine derivative 3	Patented
T77400	DRUGINFO	D0H4LG	1,2,4-triazole [1,5-a]pyrimidin-7-yl derivative 1	Patented
T77400	DRUGINFO	D0HC5P	1,2,4-triazole [1,5-a]pyrimidin-7-yl derivative 3	Patented
T77400	DRUGINFO	D0K3QR	Purin-6-one derivative 1	Patented
T77400	DRUGINFO	D0KN9S	PMID27321640-Compound-76	Patented
T77400	DRUGINFO	D0KZ5Q	Imidazo triazine derivative 2	Patented
T77400	DRUGINFO	D0L0MI	Imidazotriazinone derivative 1	Patented
T77400	DRUGINFO	D0MA2R	Triazolo-phthalazine derivative 1	Patented
T77400	DRUGINFO	D0OC1S	Pyrido[2,3-d]pyrimidine-2,4-diamine derivative 1	Patented
T77400	DRUGINFO	D0T8MJ	1,2,4-triazole [1,5-a]pyrimidin-7-yl derivative 2	Patented
T77400	DRUGINFO	D0TK5G	Benzodiazepine derivative 2	Patented
T77400	DRUGINFO	D0UR7K	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 1	Patented
T77400	DRUGINFO	D0V6LW	Pyrazolo[3,4-d]pyrimidine derivative 4	Patented
T77400	DRUGINFO	D0XJ4J	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 2	Patented
T77400	DRUGINFO	D00YOY	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 2	Patented
T77400	DRUGINFO	D01ITP	Triazolo-pyridine derivative 5	Patented
T77400	DRUGINFO	D02PFP	PMID27321640-Compound-58	Patented
T77400	DRUGINFO	D05VBJ	Triazolo-pyridine derivative 4	Patented
T77400	DRUGINFO	D07EUB	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 3	Patented
T77400	DRUGINFO	D07NRP	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 4	Patented
T77400	DRUGINFO	D07ZTT	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 5	Patented
T77400	DRUGINFO	D09BDD	1,2,4-triazole [4,3-a]quinoxaline derivative 1	Patented
T77400	DRUGINFO	D09RWM	PMID27321640-Compound-59	Patented
T77400	DRUGINFO	D0A8EV	Triazolo-pyridine derivative 6	Patented
T77400	DRUGINFO	D0D0QT	Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 2	Patented
T77400	DRUGINFO	D0D4YR	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 1	Patented
T77400	DRUGINFO	D0FV3G	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 6	Patented
T77400	DRUGINFO	D0I5UY	Imidazo[5,1-c][1,2,4]benzotriazine derivative 2	Patented
T77400	DRUGINFO	D0J6KS	1,2,4-triazole [4,3-a]quinoxaline derivative 3	Patented
T77400	DRUGINFO	D0J8YF	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 8	Patented
T77400	DRUGINFO	D0JJ8K	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 7	Patented
T77400	DRUGINFO	D0L6AM	Imidazo[5,1-c][1,2,4]benzotriazine derivative 4	Patented
T77400	DRUGINFO	D0LI6Z	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 3	Patented
T77400	DRUGINFO	D0MK7X	Imidazo[5,1-c][1,2,4]benzotriazine derivative 3	Patented
T77400	DRUGINFO	D0PP8O	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 6	Patented
T77400	DRUGINFO	D0QE7X	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 4	Patented
T77400	DRUGINFO	D0QI8G	Imidazo[5,1-c][1,2,4]benzotriazine derivative 1	Patented
T77400	DRUGINFO	D0RI3W	1,2,4-triazole [4,3-a]quinoxaline derivative 2	Patented
T77400	DRUGINFO	D0SV1I	Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 3	Patented
T77400	DRUGINFO	D0U3KV	Triazolo-pyridine derivative 2	Patented
T77400	DRUGINFO	D0X2UO	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 5	Patented
T77400	DRUGINFO	D0Z4IA	Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 1	Patented
T77400	DRUGINFO	D0Z8VY	Triazolo-pyridine derivative 3	Patented
T77400	DRUGINFO	D01LSP	Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1	Patented
T77400	DRUGINFO	D0T8WU	Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2	Patented
T77400	DRUGINFO	D09UMA	IMAZODAN	Terminated
T77400	DRUGINFO	D0V9MI	BAY-60-7550	Investigative
T77400	DRUGINFO	D05ZHQ	EHNA	Investigative
T77400	DRUGINFO	D09LAQ	Cyclic Guanosine Monophosphate	Investigative
T77400	DRUGINFO	D0W3RR	2-Morpholin-4-yl-8-phenylethynyl-chromen-4-one	Investigative
T77400	DRUGINFO	D01TOR	Benzyl-(2-pyridin-3-yl-quinazolin-4-yl)-amine	Investigative
T77400	DRUGINFO	D0I6XA	(2R,3S)-3-(6-Amino-purin-9-yl)-nonan-2-ol	Investigative
T77400	DRUGINFO	D0U8YQ	Benzyl-(2-pyridin-4-yl-quinazolin-4-yl)-amine	Investigative
T77400	DRUGINFO	D0R6MT	isobutylmethylxanthine	Investigative

T31902	TARGETID	T31902
T31902	FORMERID	TTDI02327
T31902	UNIPROID	ADA10_HUMAN
T31902	TARGNAME	Mammalian disintegrin-metalloprotease (ADAM10)
T31902	GENENAME	ADAM10
T31902	TARGTYPE	Clinical trial
T31902	SYNONYMS	Mammalian disintegrinmetalloprotease; MADM; Kuzbanian protein homolog; KUZ; Disintegrin and metalloproteinase domaincontaining protein 10; Disintegrin and metalloproteinase domain-containing protein 10; CDw156; CD156c; ADAM 10
T31902	FUNCTION	Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface. Responsible for the proteolytic release of several other cell-surface proteins, including heparin-binding epidermal growth-like factor, ephrin-A2, CD44, CDH2 and for constitutive and regulated alpha-secretase cleavage of amyloid precursor protein (APP). Contributes to the normal cleavage of the cellular prion protein. Involved in the cleavage of the adhesion molecule L1 at the cell surface and in released membrane vesicles, suggesting a vesicle-based protease activity. Controls also the proteolytic processing of Notch and mediates lateral inhibition during neurogenesis. Responsible for the FasL ectodomain shedding and for the generation of the remnant ADAM10-processed FasL (FasL APL) transmembrane form. Also cleaves the ectodomain of the integral membrane proteins CORIN and ITM2B. Mediates the proteolytic cleavage of LAG3, leading to release the secreted form of LAG3. May regulate the EFNA5-EPHA3 signaling. Cleaves the membrane-bound precursor of TNF-alpha at '76-Ala-|-Val-77' to its mature soluble form.
T31902	PDBSTRUC	6BE6; 6BDZ; 1M1I
T31902	BIOCLASS	Peptidase
T31902	ECNUMBER	EC 3.4.24.81
T31902	SEQUENCE	MVLLRVLILLLSWAAGMGGQYGNPLNKYIRHYEGLSYNVDSLHQKHQRAKRAVSHEDQFLRLDFHAHGRHFNLRMKRDTSLFSDEFKVETSNKVLDYDTSHIYTGHIYGEEGSFSHGSVIDGRFEGFIQTRGGTFYVEPAERYIKDRTLPFHSVIYHEDDINYPHKYGPQGGCADHSVFERMRKYQMTGVEEVTQIPQEEHAANGPELLRKKRTTSAEKNTCQLYIQTDHLFFKYYGTREAVIAQISSHVKAIDTIYQTTDFSGIRNISFMVKRIRINTTADEKDPTNPFRFPNIGVEKFLELNSEQNHDDYCLAYVFTDRDFDDGVLGLAWVGAPSGSSGGICEKSKLYSDGKKKSLNTGIITVQNYGSHVPPKVSHITFAHEVGHNFGSPHDSGTECTPGESKNLGQKENGNYIMYARATSGDKLNNNKFSLCSIRNISQVLEKKRNNCFVESGQPICGNGMVEQGEECDCGYSDQCKDECCFDANQPEGRKCKLKPGKQCSPSQGPCCTAQCAFKSKSEKCRDDSDCAREGICNGFTALCPASDPKPNFTDCNRHTQVCINGQCAGSICEKYGLEECTCASSDGKDDKELCHVCCMKKMDPSTCASTGSVQWSRHFSGRTITLQPGSPCNDFRGYCDVFMRCRLVDADGPLARLKKAIFSPELYENIAEWIVAHWWAVLLMGIALIMLMAGFIKICSVHTPSSNPKLPPPKPLPGTLKRRRPPQPIQQPQRQRPRESYQMGHMRR
T31902	DRUGINFO	D02CZF	Aderbasib	Phase 1/2
T31902	DRUGINFO	D06EHW	IAI-100	Investigative

T70067	TARGETID	T70067
T70067	FORMERID	TTDC00266
T70067	UNIPROID	TR10B_HUMAN
T70067	TARGNAME	TRAIL receptor 2 (TRAIL-R2)
T70067	GENENAME	TNFRSF10B
T70067	TARGTYPE	Clinical trial
T70067	SYNONYMS	ZTNFR9; UNQ160/PRO186; Tumor necrosis factor receptor superfamily member 10B; TRICK2; TRAILR2; TNF-related apoptosis-inducing ligand receptor 2; KILLER; Death receptor 5; DR5; CD262
T70067	FUNCTION	The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B. Essential for ER stress-induced apoptosis. Receptor for the cytotoxic ligand TNFSF10/TRAIL.
T70067	PDBSTRUC	6NHY; 6NHW; 4OD2; 4N90; 4I9X
T70067	BIOCLASS	Cytokine receptor
T70067	SEQUENCE	MEQRGQNAPAASGARKRHGPGPREARGARPGPRVPKTLVLVVAAVLLLVSAESALITQQDLAPQQRAAPQQKRSSPSEGLCPPGHHISEDGRDCISCKYGQDYSTHWNDLLFCLRCTRCDSGEVELSPCTTTRNTVCQCEEGTFREEDSPEMCRKCRTGCPRGMVKVGDCTPWSDIECVHKESGTKHSGEVPAVEETVTSSPGTPASPCSLSGIIIGVTVAAVVLIVAVFVCKSLLWKKVLPYLKGICSGGGGDPERVDRSSQRPGAEDNVLNEIVSILQPTQVPEQEMEVQEPAEPTGVNMLSPGESEHLLEPAEAERSQRRRLLVPANEGDPTETLRQCFDDFADLVPFDSWEPLMRKLGLMDNEIKVAKAEAAGHRDTLYTMLIKWVNKTGRDASVHTLLDALETLGERLAKQKIEDHLLSSGKFMYLEGNADSAMS
T70067	DRUGINFO	D0MW7S	Lexatumumab	Phase 2
T70067	DRUGINFO	D00WME	Conatumumab	Phase 2
T70067	DRUGINFO	D0LW4A	Anti-DR5 cells	Phase 1/2
T70067	DRUGINFO	D48UEV	IGM-8444	Phase 1
T70067	DRUGINFO	D56ERU	INBRX-109	Phase 1
T70067	DRUGINFO	D9Y8ZU	BI 905711	Phase 1
T70067	DRUGINFO	DH17JI	DS-8273	Phase 1
T70067	DRUGINFO	DVX4P3	GEN1029	Phase 1
T70067	DRUGINFO	D08JRT	RhApo2L/TRAIL	Discontinued in Phase 1/2
T70067	DRUGINFO	D05CHR	LBY-135	Discontinued in Phase 1
T70067	DRUGINFO	D06JBA	HGS-TR2J	Discontinued in Phase 1
T70067	DRUGINFO	D04UYY	AD5-10	Investigative
T70067	DRUGINFO	D0X3PN	DR-5/DR-4 cross reactive mabs	Investigative

T25608	TARGETID	T25608
T25608	FORMERID	TTDNC00653
T25608	UNIPROID	FFAR1_HUMAN
T25608	TARGNAME	Free fatty acid receptor 1 (GPR40)
T25608	GENENAME	FFAR1
T25608	TARGTYPE	Clinical trial
T25608	SYNONYMS	Gprotein coupled receptor 40; FFAR1
T25608	FUNCTION	G-protein coupled receptor for medium and long chain saturated and unsaturated fatty acids that plays an important role in glucose homeostasis. Fatty acid binding increases glucose- stimulated insulin secretion, and may also enhance the secretion of glucagon-like peptide 1 (GLP-1). May also play a role in bone homeostasis; receptor signaling activates pathways that inhibit osteoclast differentiation. Ligand binding leads to a conformation change that triggers signaling via G-proteins that activate phospholipase C, leading to an increase of the intracellular calcium concentration. Seems to act through a G(q) and G(i)-mediated pathway.
T25608	PDBSTRUC	5TZY; 5TZR; 5KW2; 4PHU
T25608	BIOCLASS	GPCR rhodopsin
T25608	SEQUENCE	MDLPPQLSFGLYVAAFALGFPLNVLAIRGATAHARLRLTPSLVYALNLGCSDLLLTVSLPLKAVEALASGAWPLPASLCPVFAVAHFFPLYAGGGFLAALSAGRYLGAAFPLGYQAFRRPCYSWGVCAAIWALVLCHLGLVFGLEAPGGWLDHSNTSLGINTPVNGSPVCLEAWDPASAGPARFSLSLLLFFLPLAITAFCYVGCLRALARSGLTHRRKLRAAWVAGGALLTLLLCVGPYNASNVASFLYPNLGGSWRKLGLITGAWSVVLNPLVTGYLGRGPGLKTVCAARTQGGKSQK
T25608	DRUGINFO	D0M0WV	Fasiglifam hemihydrate	Phase 3
T25608	DRUGINFO	D0V1WQ	TAK-875	Phase 3
T25608	DRUGINFO	D01CEG	P-1736	Phase 2
T25608	DRUGINFO	D0U8QB	JTT-851	Phase 2
T25608	DRUGINFO	DT56YX	PBI-4050	Phase 2
T25608	DRUGINFO	D0EO2C	LY-2881835	Phase 1
T25608	DRUGINFO	D0FP9N	P11187	Phase 1
T25608	DRUGINFO	D6CZ0T	CPL207-280CA	Phase 1
T25608	DRUGINFO	DMDS20	LY2922470	Phase 1
T25608	DRUGINFO	DZLM72	SHR0534	Phase 1
T25608	DRUGINFO	D4M0GR	CNX-011-67	Preclinical
T25608	DRUGINFO	DDV09U	DS-1558	Preclinical
T25608	DRUGINFO	DRN30U	BMS-986118	Preclinical
T25608	DRUGINFO	D01CCG	TUG-424	Investigative
T25608	DRUGINFO	D03VMX	GW1100	Investigative
T25608	DRUGINFO	D08LVH	medica 16	Investigative
T25608	DRUGINFO	D08MLH	TUG-469	Investigative
T25608	DRUGINFO	D0O5UF	CNX-011	Investigative
T25608	DRUGINFO	D0Q7BG	AMG-837	Investigative
T25608	DRUGINFO	D0S0QY	TUG-770	Investigative
T25608	DRUGINFO	D0UH9E	PMID18477808CB 	Investigative
T25608	DRUGINFO	D08ZYC	GW9508	Investigative
T25608	DRUGINFO	D0C5SV	alpha-linolenic acid	Investigative

T02677	TARGETID	T02677
T02677	FORMERID	TTDC00273
T02677	UNIPROID	BIRC5_HUMAN
T02677	TARGNAME	Apoptosis inhibitor survivin (BIRC5)
T02677	GENENAME	BIRC5
T02677	TARGTYPE	Clinical trial
T02677	SYNONYMS	Survivin; IAP4; Baculoviral IAP repeat-containing protein 5; Apoptosis inhibitor 4; API4
T02677	FUNCTION	Component of a chromosome passage protein complex (CPC) which is essential for chromosome alignment and segregation during mitosis and cytokinesis. Acts as an important regulator of the localization of this complex; directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organization of the center spindle by associating with polymerized microtubules. Involved in the recruitment of CPC to centromeres during early mitosis via association with histone H3 phosphorylated at 'Thr-3' (H3pT3) during mitosis. The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules. May counteract a default induction of apoptosis in G2/M phase. The acetylated form represses STAT3 transactivation of target gene promoters. May play a role in neoplasia. Inhibitor of CASP3 and CASP7. Isoform 2 and isoform 3 do not appear to play vital roles in mitosis. Isoform 3 shows a marked reduction in its anti-apoptotic effects when compared with the displayed wild-type isoform. Multitasking protein that has dual roles in promoting cell proliferation and preventing apoptosis.
T02677	PDBSTRUC	4A0N; 4A0J; 4A0I; 3UIK; 3UIJ
T02677	BIOCLASS	Acyltransferase
T02677	SEQUENCE	MGAPTLPPAWQPFLKDHRISTFKNWPFLEGCACTPERMAEAGFIHCPTENEPDLAQCFFCFKELEGWEPDDDPIEEHKKHSSGCAFLSVKKQFEELTLGEFLKLDRERAKNKIAKETNNKKKEFEETAKKVRRAIEQLAAMD
T02677	DRUGINFO	D07TMR	ISIS 23722	Phase 3
T02677	DRUGINFO	D0KQ8W	SurVaxM	Phase 2
T02677	DRUGINFO	D02DVK	CV-9201	Phase 1/2
T02677	DRUGINFO	D01GQD	EZN-3042	Phase 1

T67894	TARGETID	T67894
T67894	FORMERID	TTDC00007
T67894	UNIPROID	TLR3_HUMAN
T67894	TARGNAME	Toll-like receptor 3 (TLR3)
T67894	GENENAME	TLR3
T67894	TARGTYPE	Clinical trial
T67894	SYNONYMS	CD283
T67894	FUNCTION	Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. Acts via the adapter TRIF/TICAM1, leading to NF-kappa-B activation, IRF3 nuclear translocation, cytokine secretion and the inflammatory response.
T67894	PDBSTRUC	5GS0; 3ULV; 3ULU; 2MKA; 2MK9
T67894	BIOCLASS	Toll-like receptor
T67894	SEQUENCE	MRQTLPCIYFWGGLLPFGMLCASSTTKCTVSHEVADCSHLKLTQVPDDLPTNITVLNLTHNQLRRLPAANFTRYSQLTSLDVGFNTISKLEPELCQKLPMLKVLNLQHNELSQLSDKTFAFCTNLTELHLMSNSIQKIKNNPFVKQKNLITLDLSHNGLSSTKLGTQVQLENLQELLLSNNKIQALKSEELDIFANSSLKKLELSSNQIKEFSPGCFHAIGRLFGLFLNNVQLGPSLTEKLCLELANTSIRNLSLSNSQLSTTSNTTFLGLKWTNLTMLDLSYNNLNVVGNDSFAWLPQLEYFFLEYNNIQHLFSHSLHGLFNVRYLNLKRSFTKQSISLASLPKIDDFSFQWLKCLEHLNMEDNDIPGIKSNMFTGLINLKYLSLSNSFTSLRTLTNETFVSLAHSPLHILNLTKNKISKIESDAFSWLGHLEVLDLGLNEIGQELTGQEWRGLENIFEIYLSYNKYLQLTRNSFALVPSLQRLMLRRVALKNVDSSPSPFQPLRNLTILDLSNNNIANINDDMLEGLEKLEILDLQHNNLARLWKHANPGGPIYFLKGLSHLHILNLESNGFDEIPVEVFKDLFELKIIDLGLNNLNTLPASVFNNQVSLKSLNLQKNLITSVEKKVFGPAFRNLTELDMRFNPFDCTCESIAWFVNWINETHTNIPELSSHYLCNTPPHYHGFPVRLFDTSSCKDSAPFELFFMINTSILLIFIFIVLLIHFEGWRISFYWNVSVHRVLGFKEIDRQTEQFEYAAYIIHAYKDKDWVWEHFSSMEKEDQSLKFCLEERDFEAGVFELEAIVNSIKRSRKIIFVITHHLLKDPLCKRFKVHHAVQQAIEQNLDSIILVFLEEIPDYKLNHALCLRRGMFKSHCILNWPVQKERIGAFRHKLQVALGSKNSVH
T67894	DRUGINFO	D08JIP	Rintatolimod	Phase 3
T67894	DRUGINFO	D0V8AG	Poly-ICLC	Phase 2
T67894	DRUGINFO	D09LPI	BCG65-E7	Discontinued in Phase 3
T67894	DRUGINFO	D07THJ	IPH-3102	Terminated
T67894	DRUGINFO	D0B6MQ	polyIC	Investigative
T67894	DRUGINFO	D0J7CD	Poly IC-poly arginine	Investigative
T67894	DRUGINFO	D0L8EO	Anti-TLR3 mabs	Investigative
T67894	DRUGINFO	D0O0BR	Poly-ICR	Investigative

T54132	TARGETID	T54132
T54132	FORMERID	TTDC00128
T54132	UNIPROID	KCNQ3_HUMAN
T54132	TARGNAME	Voltage-gated potassium channel Kv7.3 (KCNQ3)
T54132	GENENAME	KCNQ3
T54132	TARGTYPE	Clinical trial
T54132	SYNONYMS	Voltage-gated potassium channel subunit Kv7.3; Potassium channel alpha subunit KvLQT3; Potassium channel KQT-like 3; KQT-like 3; KCNQ3; K+ channel KCNQ3
T54132	FUNCTION	Probably important in the regulation of neuronal excitability. Associates with KCNQ2 or KCNQ5 to form a potassium channel with essentially identical properties to the channel underlying the native M-current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to synaptic inputs.
T54132	PDBSTRUC	5J03
T54132	BIOCLASS	Voltage-gated ion channel
T54132	SEQUENCE	MGLKARRAAGAAGGGGDGGGGGGGAANPAGGDAAAAGDEERKVGLAPGDVEQVTLALGAGADKDGTLLLEGGGRDEGQRRTPQGIGLLAKTPLSRPVKRNNAKYRRIQTLIYDALERPRGWALLYHALVFLIVLGCLILAVLTTFKEYETVSGDWLLLLETFAIFIFGAEFALRIWAAGCCCRYKGWRGRLKFARKPLCMLDIFVLIASVPVVAVGNQGNVLATSLRSLRFLQILRMLRMDRRGGTWKLLGSAICAHSKELITAWYIGFLTLILSSFLVYLVEKDVPEVDAQGEEMKEEFETYADALWWGLITLATIGYGDKTPKTWEGRLIAATFSLIGVSFFALPAGILGSGLALKVQEQHRQKHFEKRRKPAAELIQAAWRYYATNPNRIDLVATWRFYESVVSFPFFRKEQLEAASSQKLGLLDRVRLSNPRGSNTKGKLFTPLNVDAIEESPSKEPKPVGLNNKERFRTAFRMKAYAFWQSSEDAGTGDPMAEDRGYGNDFPIEDMIPTLKAAIRAVRILQFRLYKKKFKETLRPYDVKDVIEQYSAGHLDMLSRIKYLQTRIDMIFTPGPPSTPKHKKSQKGSAFTFPSQQSPRNEPYVARPSTSEIEDQSMMGKFVKVERQVQDMGKKLDFLVDMHMQHMERLQVQVTEYYPTKGTSSPAEAEKKEDNRYSDLKTIICNYSETGPPEPPYSFHQVTIDKVSPYGFFAHDPVNLPRGGPSSGKVQATPPSSATTYVERPTVLPILTLLDSRVSCHSQADLQGPYSDRISPRQRRSITRDSDTPLSLMSVNHEELERSPSGFSISQDRDDYVFGPNGGSSWMREKRYLAEGETDTDTDPFTPSGSMPLSSTGDGISDSVWTPSNKPI
T54132	DRUGINFO	D0X7GL	Retigabine	Approved
T54132	DRUGINFO	D08YHS	Linopirdine	Phase 3
T54132	DRUGINFO	D08OJF	ICA-105665	Phase 2
T54132	DRUGINFO	D0WW3O	XEN1101	Phase 1
T54132	DRUGINFO	D0E2FZ	ICA-69673	Preclinical
T54132	DRUGINFO	D08RJC	PD-32577	Investigative
T54132	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T16739	TARGETID	T16739
T16739	FORMERID	TTDI02104
T16739	UNIPROID	KDM1A_HUMAN
T16739	TARGNAME	Lysine-specific histone demethylase 1 (LSD)
T16739	GENENAME	KDM1A
T16739	TARGTYPE	Clinical trial
T16739	SYNONYMS	Lysine-specific histone demethylase 1A; LSD1; KIAA0601; KDM1; Flavin-containing amine oxidase domain-containing protein 2; BRAF35-HDAC complex protein BHC110; AOF2
T16739	FUNCTION	Histone demethylase that can demethylate both 'Lys-4' (H3K4me) and 'Lys-9' (H3K9me) of histone H3, thereby acting as a coactivator or a corepressor, depending on the context. Acts by oxidizing the substrate by FAD to generate the corresponding imine that is subsequently hydrolyzed. Acts as a corepressor by mediating demethylation of H3K4me, a specific tag for epigenetic transcriptional activation. Demethylates both mono- (H3K4me1) and di-methylated (H3K4me2) H3K4me. May play a role in the repression of neuronal genes. Alone, it is unable to demethylate H3K4me on nucleosomes and requires the presence of RCOR1/CoREST to achieve such activity. Also acts as a coactivator of androgen receptor (ANDR)-dependent transcription, by being recruited to ANDR target genes and mediating demethylation of H3K9me, a specific tag for epigenetic transcriptional repression. The presence of PRKCB in ANDR-containing complexes, which mediates phosphorylation of 'Thr-6' of histone H3 (H3T6ph), a specific tag that prevents demethylation H3K4me, prevents H3K4me demethylase activity of KDM1A. Demethylates di-methylated 'Lys-370' of p53/TP53 which prevents interaction of p53/TP53 with TP53BP1 and represses p53/TP53-mediated transcriptional activation. Demethylates and stabilizes the DNA methylase DNMT1. Required for gastrulation during embryogenesis. Component of a RCOR/GFI/KDM1A/HDAC complex that suppresses, via histone deacetylase (HDAC) recruitment, a number of genes implicated in multilineage blood cell development. Effector of SNAI1-mediated transcription repression of E-cadherin/CDH1, CDN7 and KRT8. Required for the maintenance of the silenced state of the SNAI1 target genes E-cadherin/CDH1 and CDN7.
T16739	PDBSTRUC	6NQU; 6NQM; 5YJB; 5X60; 5LHI
T16739	BIOCLASS	CH-NH(2) donor oxidoreductase
T16739	ECNUMBER	EC 1.-.-.-
T16739	SEQUENCE	MLSGKKAAAAAAAAAAAATGTEAGPGTAGGSENGSEVAAQPAGLSGPAEVGPGAVGERTPRKKEPPRASPPGGLAEPPGSAGPQAGPTVVPGSATPMETGIAETPEGRRTSRRKRAKVEYREMDESLANLSEDEYYSEEERNAKAEKEKKLPPPPPQAPPEEENESEPEEPSGVEGAAFQSRLPHDRMTSQEAACFPDIISGPQQTQKVFLFIRNRTLQLWLDNPKIQLTFEATLQQLEAPYNSDTVLVHRVHSYLERHGLINFGIYKRIKPLPTKKTGKVIIIGSGVSGLAAARQLQSFGMDVTLLEARDRVGGRVATFRKGNYVADLGAMVVTGLGGNPMAVVSKQVNMELAKIKQKCPLYEANGQAVPKEKDEMVEQEFNRLLEATSYLSHQLDFNVLNNKPVSLGQALEVVIQLQEKHVKDEQIEHWKKIVKTQEELKELLNKMVNLKEKIKELHQQYKEASEVKPPRDITAEFLVKSKHRDLTALCKEYDELAETQGKLEEKLQELEANPPSDVYLSSRDRQILDWHFANLEFANATPLSTLSLKHWDQDDDFEFTGSHLTVRNGYSCVPVALAEGLDIKLNTAVRQVRYTASGCEVIAVNTRSTSQTFIYKCDAVLCTLPLGVLKQQPPAVQFVPPLPEWKTSAVQRMGFGNLNKVVLCFDRVFWDPSVNLFGHVGSTTASRGELFLFWNLYKAPILLALVAGEAAGIMENISDDVIVGRCLAILKGIFGSSAVPQPKETVVSRWRADPWARGSYSYVAAGSSGNDYDLMAQPITPGPSIPGAPQPIPRLFFAGEHTIRNYPATVHGALLSGLREAGRIADQFLGAMYTLPRQATPGVPAQQSPSM
T16739	DRUGINFO	D03EOZ	IMG-7289	Phase 2
T16739	DRUGINFO	D5NAL9	Vafidemstat	Phase 2
T16739	DRUGINFO	DB5UA2	CC-90011	Phase 2
T16739	DRUGINFO	DL50ZE	ORY-2001	Phase 2
T16739	DRUGINFO	D0R7CD	INCB59872	Phase 1/2
T16739	DRUGINFO	D04GNG	CC-90011	Phase 1
T16739	DRUGINFO	D0I4ZN	GSK2879552	Phase 1
T16739	DRUGINFO	DCWT40	Seclidemstat	Phase 1
T16739	DRUGINFO	DI17KH	TAS-1440	Phase 1
T16739	DRUGINFO	D02YGX	PMID27019002-Compound-16	Patented
T16739	DRUGINFO	D05FVW	PMID27019002-Compound-41	Patented
T16739	DRUGINFO	D05HBM	Benzenamine derivative 2	Patented
T16739	DRUGINFO	D06XEU	PMID27019002-Compound-28a	Patented
T16739	DRUGINFO	D07IAO	Aryl cyclopropylamine derivative 5	Patented
T16739	DRUGINFO	D07LKA	Pyrimidine derivative 17	Patented
T16739	DRUGINFO	D08FVR	PMID27019002-Compound-31b	Patented
T16739	DRUGINFO	D08WMK	Benzenamine derivative 3	Patented
T16739	DRUGINFO	D0B6GK	Cyclopropylamine derivative 1	Patented
T16739	DRUGINFO	D0BE4Z	N6-cyclopropyllydine derivative 1	Patented
T16739	DRUGINFO	D0BG7B	Tarnylcypromine derivative 1	Patented
T16739	DRUGINFO	D0C0PK	Cyclopropylamine derivative 7	Patented
T16739	DRUGINFO	D0C1TH	Aryl cyclopropylamine derivative 4	Patented
T16739	DRUGINFO	D0D9CK	PMID27019002-Compound-45	Patented
T16739	DRUGINFO	D0DD4I	PMID27019002-Compound-13	Patented
T16739	DRUGINFO	D0DL5J	PMID27019002-Compound-49	Patented
T16739	DRUGINFO	D0F1CT	Cyclopropylamine derivative 4	Patented
T16739	DRUGINFO	D0GA7D	PMID27019002-Compound-42b	Patented
T16739	DRUGINFO	D0I9QC	PMID27019002-Compound-31a	Patented
T16739	DRUGINFO	D0J1HQ	PMID27019002-Compound-43c	Patented
T16739	DRUGINFO	D0JE6I	Aryl cyclopropylamine derivative 3	Patented
T16739	DRUGINFO	D0KR0I	Benzenamine derivative 4	Patented
T16739	DRUGINFO	D0KZ5T	Cyclopropylamine derivative 6	Patented
T16739	DRUGINFO	D0L0DT	Pyrimidine derivative 16	Patented
T16739	DRUGINFO	D0L4OH	PMID27019002-Compound-28	Patented
T16739	DRUGINFO	D0LK8A	Heteroaryl-cyclopropylamine derivative 2	Patented
T16739	DRUGINFO	D0LR6D	Cyclopropylamine derivative 5	Patented
T16739	DRUGINFO	D0MO5Y	PMID27019002-Compound-43b	Patented
T16739	DRUGINFO	D0N2QZ	Pyrimidine derivative 18	Patented
T16739	DRUGINFO	D0NJ6B	Cyclopropylamine derivative 3	Patented
T16739	DRUGINFO	D0O2WW	PMID27019002-Compound-20b	Patented
T16739	DRUGINFO	D0P4NF	PMID27019002-Compound-50	Patented
T16739	DRUGINFO	D0R7RY	Cyclopropylamine derivative 8	Patented
T16739	DRUGINFO	D0RC0G	PMID27019002-Compound-43a	Patented
T16739	DRUGINFO	D0U1DY	Benzenamine derivative 1	Patented
T16739	DRUGINFO	D0U4DT	PMID27019002-Compound-7	Patented
T16739	DRUGINFO	D0UG5Q	PMID27019002-Compound-42a	Patented
T16739	DRUGINFO	D0VB7F	PMID27019002-Compound-37a	Patented
T16739	DRUGINFO	D0W8XM	PMID27019002-Compound-44	Patented
T16739	DRUGINFO	D0YI0V	PMID27019002-Compound-21a	Patented
T16739	DRUGINFO	D0YX4R	PMID27019002-Compound-37b	Patented
T16739	DRUGINFO	D01CIK	Heteroaryl-cyclopropylamine derivative 4	Patented
T16739	DRUGINFO	D02CIX	Cyclopropylamine derivative 11	Patented
T16739	DRUGINFO	D02WXS	PMID25399762-Compound-Table 6-11	Patented
T16739	DRUGINFO	D03MPD	PMID27019002-Compound-20a	Patented
T16739	DRUGINFO	D04PWX	Cyclopropylamine derivative 9	Patented
T16739	DRUGINFO	D06KBT	PMID25399762-Compound-Table 6-13	Patented
T16739	DRUGINFO	D06VMN	Heteroaryl-cyclopropylamine derivative 3	Patented
T16739	DRUGINFO	D07DIJ	Cyclopropylamine derivative 13	Patented
T16739	DRUGINFO	D07MQD	PMID27019002-Compound-21b	Patented
T16739	DRUGINFO	D09OMM	PMID27019002-Compound-48	Patented
T16739	DRUGINFO	D0AI6J	PMID25399762-Compound-Table 6-10	Patented
T16739	DRUGINFO	D0E7SF	PMID25399762-Compound-Table 6-12	Patented
T16739	DRUGINFO	D0IO2A	PMID25399762-Compound-Table 6-9	Patented
T16739	DRUGINFO	D0PM2S	PMID25399762-Compound-Table 6-14	Patented
T16739	DRUGINFO	D0Q1EG	PMID25399762-Compound-Table 6-15	Patented
T16739	DRUGINFO	D0R2YA	Cyclopropylamine derivative 12	Patented
T16739	DRUGINFO	D0UE4K	PMID27019002-Compound-21c	Patented
T16739	DRUGINFO	D0W9VF	Cyclopropylamine derivative 10	Patented
T16739	DRUGINFO	D0WO5W	PMID27019002-Compound-47	Patented
T16739	DRUGINFO	D0WT1Z	PMID27019002-Compound-17	Patented
T16739	DRUGINFO	D0XH9M	N-(2-phenylcyclopropyl) amino acid derivative 2	Patented
T16739	DRUGINFO	D0Z7HE	PMID27019002-Compound-46	Patented
T16739	DRUGINFO	D04OEV	Cyclic peptide derivative 1	Patented
T16739	DRUGINFO	D07NTA	Heteroaryl-cyclopropylamine derivative 1	Patented
T16739	DRUGINFO	D08IOP	N-(2-phenylcyclopropyl) amino acid derivative 3	Patented
T16739	DRUGINFO	D0UL9U	N-(2-phenylcyclopropyl) amino acid derivative 1	Patented
T16739	DRUGINFO	D04OHC	Tarnylcypromine derivative 2	Patented
T16739	DRUGINFO	D0O7IH	Tarnylcypromine derivative 3	Patented
T16739	DRUGINFO	D0C8SX	OG-L002	Investigative
T16739	DRUGINFO	D0EV7U	GSK-LSD1	Investigative
T16739	DRUGINFO	D0L6TQ	NCL-1	Investigative

T17852	TARGETID	T17852
T17852	FORMERID	TTDI02148
T17852	UNIPROID	PDE9A_HUMAN
T17852	TARGNAME	Phosphodiesterase 9 (PDE9)
T17852	GENENAME	PDE9A
T17852	TARGTYPE	Clinical trial
T17852	SYNONYMS	High affinity cGMPspecific 3',5'cyclic phosphodiesterase 9A; High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A
T17852	FUNCTION	Highly specific: compared to other members of the cyclic nucleotide phosphodiesterase family, has the highest affinity and selectivity for cGMP. Specifically regulates natriuretic-peptide-dependent cGMP signaling in heart, acting as a regulator of cardiac hypertrophy in myocytes and muscle. Does not regulate nitric oxide-dependent cGMP in heart. Additional experiments are required to confirm whether its ability to hydrolyze natriuretic-peptide-dependent cGMP is specific to heart or is a general feature of the protein. In brain, involved in cognitive function, such as learning and long-term memory. Specifically hydrolyzes the second messenger cGMP, which is a key regulator of many important physiological processes.
T17852	PDBSTRUC	6A3N; 4Y8C; 4Y87; 4Y86; 4GH6
T17852	BIOCLASS	Phosphoric diester hydrolase
T17852	ECNUMBER	EC 3.1.4.35
T17852	SEQUENCE	MGSGSSSYRPKAIYLDIDGRIQKVIFSKYCNSSDIMDLFCIATGLPRNTTISLLTTDDAMVSIDPTMPANSERTPYKVRPVAIKQLSAGVEDKRTTSRGQSAERPLRDRRVVGLEQPRREGAFESGQVEPRPREPQGCYQEGQRIPPEREELIQSVLAQVAEQFSRAFKINELKAEVANHLAVLEKRVELEGLKVVEIEKCKSDIKKMREELAARSSRTNCPCKYSFLDNHKKLTPRRDVPTYPKYLLSPETIEALRKPTFDVWLWEPNEMLSCLEHMYHDLGLVRDFSINPVTLRRWLFCVHDNYRNNPFHNFRHCFCVAQMMYSMVWLCSLQEKFSQTDILILMTAAICHDLDHPGYNNTYQINARTELAVRYNDISPLENHHCAVAFQILAEPECNIFSNIPPDGFKQIRQGMITLILATDMARHAEIMDSFKEKMENFDYSNEEHMTLLKMILIKCCDISNEVRPMEVAEPWVDCLLEEYFMQSDREKSEGLPVAPFMDRDKVTKATAQIGFIKFVLIPMFETVTKLFPMVEEIMLQPLWESRDRYEELKRIDDAMKELQKKTDSLTSGATEKSRERSRDVKNSEGDCA
T17852	DRUGINFO	D0A9IY	PF-4447943	Phase 2
T17852	DRUGINFO	D0BT7R	ASP-4901	Phase 2
T17852	DRUGINFO	D0S0FD	E2027	Phase 2
T17852	DRUGINFO	D0W7UN	BI-409306	Phase 2
T17852	DRUGINFO	D1Z0IM	IMR-687	Phase 2
T17852	DRUGINFO	DNGT70	CRD-740	Phase 2
T17852	DRUGINFO	DSN1B6	TT-00920	Phase 1
T17852	DRUGINFO	D06NIT	PF-4181366	Investigative
T17852	DRUGINFO	D02VHD	SCH51866	Investigative

T01575	TARGETID	T01575
T01575	FORMERID	TTDI02173
T01575	UNIPROID	SGPL1_HUMAN
T01575	TARGNAME	Sphingosine-1-phosphate lyase 1 (SGPL1)
T01575	GENENAME	SGPL1
T01575	TARGTYPE	Clinical trial
T01575	SYNONYMS	hSPL; Sphingosine-1-phosphate aldolase; SPL 1; SP-lyase 1; S1PL; KIAA1252
T01575	FUNCTION	Elevates stress-induced ceramide production and apoptosis. Required for global lipid homeostasis in liver and cholesterol homeostasis in fibroblasts. Involved in the regulation of pro-inflammatory response and neutrophil trafficking. Modulates neuronal autophagy via phosphoethanolamine production which regulates accumulation of aggregate-prone proteins such as APP. Seems to play a role in establishing neuronal contact sites and axonal maintenance. Cleaves phosphorylated sphingoid bases (PSBs), such as sphingosine-1-phosphate, into fatty aldehydes and phosphoethanolamine.
T01575	PDBSTRUC	4Q6R
T01575	BIOCLASS	Carbon-carbon lyase
T01575	ECNUMBER	EC 4.1.2.27
T01575	SEQUENCE	MPSTDLLMLKAFEPYLEILEVYSTKAKNYVNGHCTKYEPWQLIAWSVVWTLLIVWGYEFVFQPESLWSRFKKKCFKLTRKMPIIGRKIQDKLNKTKDDISKNMSFLKVDKEYVKALPSQGLSSSAVLEKLKEYSSMDAFWQEGRASGTVYSGEEKLTELLVKAYGDFAWSNPLHPDIFPGLRKIEAEIVRIACSLFNGGPDSCGCVTSGGTESILMACKAYRDLAFEKGIKTPEIVAPQSAHAAFNKAASYFGMKIVRVPLTKMMEVDVRAMRRAISRNTAMLVCSTPQFPHGVIDPVPEVAKLAVKYKIPLHVDACLGGFLIVFMEKAGYPLEHPFDFRVKGVTSISADTHKYGYAPKGSSLVLYSDKKYRNYQFFVDTDWQGGIYASPTIAGSRPGGISAACWAALMHFGENGYVEATKQIIKTARFLKSELENIKGIFVFGNPQLSVIALGSRDFDIYRLSNLMTAKGWNLNQLQFPPSIHFCITLLHARKRVAIQFLKDIRESVTQIMKNPKAKTTGMGAIYGMAQTTVDRNMVAELSSVFLDSLYSTDTVTQGSQMNGSPKPH
T01575	DRUGINFO	D09ZWH	LX2931	Phase 2
T01575	DRUGINFO	D01FLN	LX-2932	Terminated
T01575	DRUGINFO	D0S5OU	PMID24809814C31	Investigative

T28713	TARGETID	T28713
T28713	FORMERID	TTDC00010
T28713	UNIPROID	CHK2_HUMAN
T28713	TARGNAME	Serine/threonine-protein kinase Chk2 (RAD53)
T28713	GENENAME	CHEK2
T28713	TARGTYPE	Clinical trial
T28713	SYNONYMS	hCds1; Hucds1; Checkpoint kinase 2; Cds1 homolog; Cds1; CHK2 checkpoint homolog; CHK2
T28713	FUNCTION	May also negatively regulate cell cycle progression during unperturbed cell cycles. Following activation, phosphorylates numerous effectors preferentially at the consensus sequence [L-X-R-X-X-S/T]. Regulates cell cycle checkpoint arrest through phosphorylation of CDC25A, CDC25B and CDC25C, inhibiting their activity. Inhibition of CDC25 phosphatase activity leads to increased inhibitory tyrosine phosphorylation of CDK-cyclin complexes and blocks cell cycle progression. May also phosphorylate NEK6 which is involved in G2/M cell cycle arrest. Regulates DNA repair through phosphorylation of BRCA2, enhancing the association of RAD51 with chromatin which promotes DNA repair by homologous recombination. Also stimulates the transcription of genes involved in DNA repair (including BRCA2) through the phosphorylation and activation of the transcription factor FOXM1. Regulates apoptosis through the phosphorylation of p53/TP53, MDM4 and PML. Phosphorylation of p53/TP53 at 'Ser-20' by CHEK2 may alleviate inhibition by MDM2, leading to accumulation of active p53/TP53. Phosphorylation of MDM4 may also reduce degradation of p53/TP53. Also controls the transcription of pro-apoptotic genes through phosphorylation of the transcription factor E2F1. Tumor suppressor, it may also have a DNA damage-independent function in mitotic spindle assembly by phosphorylating BRCA1. Its absence may be a cause of the chromosomal instability observed in some cancer cells. Promotes the CCAR2-SIRT1 association and is required for CCAR2-mediated SIRT1 inhibition. Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest, activation of DNA repair and apoptosis in response to the presence of DNA double-strand breaks.
T28713	PDBSTRUC	4BDK; 4BDJ; 4BDI; 4BDH; 4BDG
T28713	BIOCLASS	Kinase
T28713	ECNUMBER	EC 2.7.11.1
T28713	SEQUENCE	MSRESDVEAQQSHGSSACSQPHGSVTQSQGSSSQSQGISSSSTSTMPNSSQSSHSSSGTLSSLETVSTQELYSIPEDQEPEDQEPEEPTPAPWARLWALQDGFANLECVNDNYWFGRDKSCEYCFDEPLLKRTDKYRTYSKKHFRIFREVGPKNSYIAYIEDHSGNGTFVNTELVGKGKRRPLNNNSEIALSLSRNKVFVFFDLTVDDQSVYPKALRDEYIMSKTLGSGACGEVKLAFERKTCKKVAIKIISKRKFAIGSAREADPALNVETEIEILKKLNHPCIIKIKNFFDAEDYYIVLELMEGGELFDKVVGNKRLKEATCKLYFYQMLLAVQYLHENGIIHRDLKPENVLLSSQEEDCLIKITDFGHSKILGETSLMRTLCGTPTYLAPEVLVSVGTAGYNRAVDCWSLGVILFICLSGYPPFSEHRTQVSLKDQITSGKYNFIPEVWAEVSEKALDLVKKLLVVDPKARFTTEEALRHPWLQDEDMKRKFQDLLSEENESTALPQVLAQPSTSRKRPREGEAEGAETTKRPAVCAAVL
T28713	DRUGINFO	D00EPT	E7850	Phase 2
T28713	DRUGINFO	D0O6TG	PMID27410995-Compound-Figure3j	Patented
T28713	DRUGINFO	D05UGJ	XL844	Discontinued in Phase 1
T28713	DRUGINFO	D00MLE	2-(4-Phenoxy-phenyl)-1H-benzoimidazol-5-ylamine	Investigative
T28713	DRUGINFO	D02HWR	PV-1019	Investigative
T28713	DRUGINFO	D0D3AS	5-Nitro-2-(4-phenoxy-phenyl)-1H-benzoimidazole	Investigative
T28713	DRUGINFO	D0DH1H	CCT-241533	Investigative
T28713	DRUGINFO	D0EM1C	Chk2 inhibitor II	Investigative
T28713	DRUGINFO	D01WAI	DEBROMOHYMENIALDISINE	Investigative
T28713	DRUGINFO	D09AID	PMID22564207C25b	Investigative

T22977	TARGETID	T22977
T22977	FORMERID	TTDR00265
T22977	UNIPROID	SODC_HUMAN
T22977	TARGNAME	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
T22977	GENENAME	SOD1
T22977	TARGTYPE	Clinical trial
T22977	SYNONYMS	hSod1; Superoxide dismutase [Cu-Zn]; Superoxide dismutase 1; Superoxide dismutase
T22977	FUNCTION	Destroys radicals which are normally produced within the cells and which are toxic to biological systems.
T22977	PDBSTRUC	6FP6; 6FON; 6FOL; 6FOI; 6FLH
T22977	BIOCLASS	Superoxide dismutase/reductase
T22977	ECNUMBER	EC 1.15.1.1
T22977	SEQUENCE	MATKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAGCTSAGPHFNPLSRKHGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCIIGRTLVVHEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQ
T22977	DRUGINFO	D06WPM	Coprexa	Phase 3
T22977	DRUGINFO	D04GZS	Tempol	Phase 2
T22977	DRUGINFO	D05RTV	Superoxide dismutase	Phase 2
T22977	DRUGINFO	D09IUR	Midismase	Phase 2
T22977	DRUGINFO	D0D9NZ	Methoxyestradiol	Phase 2
T22977	DRUGINFO	D0T8MA	ATN-224	Phase 2
T22977	DRUGINFO	D0U6PJ	PC-SOD	Phase 2
T22977	DRUGINFO	D0HE9J	APN-201	Phase 1/2
T22977	DRUGINFO	D06VAQ	EUK-189	Phase 1
T22977	DRUGINFO	D0G1EH	AEOL-10150	Preclinical
T22977	DRUGINFO	D0N4SU	Pegorgotein	Terminated
T22977	DRUGINFO	D0U0PV	M-40401	Terminated
T22977	DRUGINFO	D0U1FZ	EUK-207	Terminated
T22977	DRUGINFO	D02TFB	EC-SOD	Investigative
T22977	DRUGINFO	D05SCQ	TDI-0079	Investigative
T22977	DRUGINFO	D0BT4P	TDI-0060	Investigative
T22977	DRUGINFO	D0LE6M	VLTS-582	Investigative
T22977	DRUGINFO	D0W7DP	TDI-0107	Investigative
T22977	DRUGINFO	D0F2ME	Acetate Ion	Investigative

T91696	TARGETID	T91696
T91696	FORMERID	TTDC00012
T91696	UNIPROID	FINC_HUMAN
T91696	TARGNAME	Fibronectin (FN1)
T91696	GENENAME	FN1
T91696	TARGTYPE	Clinical trial
T91696	SYNONYMS	FN; Cold-insoluble globulin; CIG
T91696	FUNCTION	Fibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin. Fibronectins are involved in cell adhesion, cell motility, opsonization, wound healing, and maintenance of cell shape. Involved in osteoblast compaction through the fibronectin fibrillogenesis cell-mediated matrix assembly process, essential for osteoblast mineralization. Participates in the regulation of type I collagen deposition by osteoblasts.
T91696	PDBSTRUC	6HNF; 5N48; 5N47; 5M0A; 5J7C
T91696	BIOCLASS	Fibronectin protein
T91696	SEQUENCE	MLRGPGPGLLLLAVQCLGTAVPSTGASKSKRQAQQMVQPQSPVAVSQSKPGCYDNGKHYQINQQWERTYLGNALVCTCYGGSRGFNCESKPEAEETCFDKYTGNTYRVGDTYERPKDSMIWDCTCIGAGRGRISCTIANRCHEGGQSYKIGDTWRRPHETGGYMLECVCLGNGKGEWTCKPIAEKCFDHAAGTSYVVGETWEKPYQGWMMVDCTCLGEGSGRITCTSRNRCNDQDTRTSYRIGDTWSKKDNRGNLLQCICTGNGRGEWKCERHTSVQTTSSGSGPFTDVRAAVYQPQPHPQPPPYGHCVTDSGVVYSVGMQWLKTQGNKQMLCTCLGNGVSCQETAVTQTYGGNSNGEPCVLPFTYNGRTFYSCTTEGRQDGHLWCSTTSNYEQDQKYSFCTDHTVLVQTRGGNSNGALCHFPFLYNNHNYTDCTSEGRRDNMKWCGTTQNYDADQKFGFCPMAAHEEICTTNEGVMYRIGDQWDKQHDMGHMMRCTCVGNGRGEWTCIAYSQLRDQCIVDDITYNVNDTFHKRHEEGHMLNCTCFGQGRGRWKCDPVDQCQDSETGTFYQIGDSWEKYVHGVRYQCYCYGRGIGEWHCQPLQTYPSSSGPVEVFITETPSQPNSHPIQWNAPQPSHISKYILRWRPKNSVGRWKEATIPGHLNSYTIKGLKPGVVYEGQLISIQQYGHQEVTRFDFTTTSTSTPVTSNTVTGETTPFSPLVATSESVTEITASSFVVSWVSASDTVSGFRVEYELSEEGDEPQYLDLPSTATSVNIPDLLPGRKYIVNVYQISEDGEQSLILSTSQTTAPDAPPDTTVDQVDDTSIVVRWSRPQAPITGYRIVYSPSVEGSSTELNLPETANSVTLSDLQPGVQYNITIYAVEENQESTPVVIQQETTGTPRSDTVPSPRDLQFVEVTDVKVTIMWTPPESAVTGYRVDVIPVNLPGEHGQRLPISRNTFAEVTGLSPGVTYYFKVFAVSHGRESKPLTAQQTTKLDAPTNLQFVNETDSTVLVRWTPPRAQITGYRLTVGLTRRGQPRQYNVGPSVSKYPLRNLQPASEYTVSLVAIKGNQESPKATGVFTTLQPGSSIPPYNTEVTETTIVITWTPAPRIGFKLGVRPSQGGEAPREVTSDSGSIVVSGLTPGVEYVYTIQVLRDGQERDAPIVNKVVTPLSPPTNLHLEANPDTGVLTVSWERSTTPDITGYRITTTPTNGQQGNSLEEVVHADQSSCTFDNLSPGLEYNVSVYTVKDDKESVPISDTIIPEVPQLTDLSFVDITDSSIGLRWTPLNSSTIIGYRITVVAAGEGIPIFEDFVDSSVGYYTVTGLEPGIDYDISVITLINGGESAPTTLTQQTAVPPPTDLRFTNIGPDTMRVTWAPPPSIDLTNFLVRYSPVKNEEDVAELSISPSDNAVVLTNLLPGTEYVVSVSSVYEQHESTPLRGRQKTGLDSPTGIDFSDITANSFTVHWIAPRATITGYRIRHHPEHFSGRPREDRVPHSRNSITLTNLTPGTEYVVSIVALNGREESPLLIGQQSTVSDVPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNSPVQEFTVPGSKSTATISGLKPGVDYTITVYAVTGRGDSPASSKPISINYRTEIDKPSQMQVTDVQDNSISVKWLPSSSPVTGYRVTTTPKNGPGPTKTKTAGPDQTEMTIEGLQPTVEYVVSVYAQNPSGESQPLVQTAVTNIDRPKGLAFTDVDVDSIKIAWESPQGQVSRYRVTYSSPEDGIHELFPAPDGEEDTAELQGLRPGSEYTVSVVALHDDMESQPLIGTQSTAIPAPTDLKFTQVTPTSLSAQWTPPNVQLTGYRVRVTPKEKTGPMKEINLAPDSSSVVVSGLMVATKYEVSVYALKDTLTSRPAQGVVTTLENVSPPRRARVTDATETTITISWRTKTETITGFQVDAVPANGQTPIQRTIKPDVRSYTITGLQPGTDYKIYLYTLNDNARSSPVVIDASTAIDAPSNLRFLATTPNSLLVSWQPPRARITGYIIKYEKPGSPPREVVPRPRPGVTEATITGLEPGTEYTIYVIALKNNQKSEPLIGRKKTDELPQLVTLPHPNLHGPEILDVPSTVQKTPFVTHPGYDTGNGIQLPGTSGQQPSVGQQMIFEEHGFRRTTPPTTATPIRHRPRPYPPNVGEEIQIGHIPREDVDYHLYPHGPGLNPNASTGQEALSQTTISWAPFQDTSEYIISCHPVGTDEEPLQFRVPGTSTSATLTGLTRGATYNVIVEALKDQQRHKVREEVVTVGNSVNEGLNQPTDDSCFDPYTVSHYAVGDEWERMSESGFKLLCQCLGFGSGHFRCDSSRWCHDNGVNYKIGEKWDRQGENGQMMSCTCLGNGKGEFKCDPHEATCYDDGKTYHVGEQWQKEYLGAICSCTCFGGQRGWRCDNCRRPGGEPSPEGTTGQSYNQYSQRYHQRTNTNVNCPIECFMPLDVQADREDSRE
T91696	DRUGINFO	D0Y7XG	Ocriplasmin	Approved
T91696	DRUGINFO	D0GZ3A	L19-TNF-alpha	Phase 2

T39321	TARGETID	T39321
T39321	FORMERID	TTDR00995
T39321	UNIPROID	G3P_HUMAN
T39321	TARGNAME	Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
T39321	GENENAME	GAPDH
T39321	TARGTYPE	Clinical trial
T39321	SYNONYMS	Peptidyl-cysteine S-nitrosylase GAPDH; OK/SW-cl.12; GAPD; D-glyceraldehyde-3-phosphate dehydrogenase; CDABP0047
T39321	FUNCTION	Participates in nuclear events including transcription, RNA transport, DNA replication and apoptosis. Nuclear functions are probably due to the nitrosylase activity that mediates cysteine S-nitrosylation of nuclear target proteins such as SIRT1, HDAC2 and PRKDC. Modulates the organization and assembly of the cytoskeleton. Facilitates the CHP1-dependent microtubule and membrane associations through its ability to stimulate the binding of CHP1 to microtubules. Glyceraldehyde-3-phosphate dehydrogenase is a key enzyme in glycolysis that catalyzes the first step of the pathway by converting D-glyceraldehyde 3-phosphate (G3P) into 3-phospho-D-glyceroyl phosphate. Component of the GAIT (gamma interferon-activated inhibitor of translation) complex which mediates interferon-gamma-induced transcript-selective translation inhibition in inflammation processes. Upon interferon-gamma treatment assembles into the GAIT complex which binds to stem loop-containing GAIT elements in the 3'-UTR of diverse inflammatory mRNAs (such as ceruplasmin) and suppresses their translation. Has both glyceraldehyde-3-phosphate dehydrogenase and nitrosylase activities, thereby playing a role in glycolysis and nuclear functions, respectively.
T39321	PDBSTRUC	6ADE; 4WNI; 4WNC; 3GPD; 2FEH
T39321	BIOCLASS	Aldehyde/oxo donor oxidoreductase
T39321	ECNUMBER	EC 1.2.1.12
T39321	SEQUENCE	MGKVKVGVNGFGRIGRLVTRAAFNSGKVDIVAINDPFIDLNYMVYMFQYDSTHGKFHGTVKAENGKLVINGNPITIFQERDPSKIKWGDAGAEYVVESTGVFTTMEKAGAHLQGGAKRVIISAPSADAPMFVMGVNHEKYDNSLKIISNASCTTNCLAPLAKVIHDNFGIVEGLMTTVHAITATQKTVDGPSGKLWRDGRGALQNIIPASTGAAKAVGKVIPELNGKLTGMAFRVPTANVSVVDLTCRLEKPAKYDDIKKVVKQASEGPLKGILGYTEHQVVSSDFNSDTHSSTFDAGAGIALNDHFVKLISWYDNEFGYSNRVVDLMAHMASKE
T39321	DRUGINFO	D06KSV	Omigapil	Phase 2
T39321	DRUGINFO	D0K6UK	Saframycin A	Investigative

T15739	TARGETID	T15739
T15739	FORMERID	TTDC00118
T15739	UNIPROID	P53_HUMAN
T15739	TARGNAME	Cellular tumor antigen p53 (TP53)
T15739	GENENAME	TP53
T15739	TARGTYPE	Clinical trial
T15739	SYNONYMS	Tumor suppressor p53; Phosphoprotein p53; P53; Antigen NY-CO-13
T15739	FUNCTION	Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER2. Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type.
T15739	PDBSTRUC	6GGF; 6GGE; 6GGD; 6GGC; 6GGB
T15739	SEQUENCE	MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD
T15739	DRUGINFO	D04FYL	Contusugene ladenovec	Phase 3
T15739	DRUGINFO	D0D5ZU	QPI-1002	Phase 3
T15739	DRUGINFO	DY4OZ6	Thymoquinone	Phase 2/3
T15739	DRUGINFO	D02EOH	SGT-53	Phase 2
T15739	DRUGINFO	D03XTY	APR-246	Phase 2
T15739	DRUGINFO	D0CO9B	Ad-p53	Phase 2
T15739	DRUGINFO	D0K7DV	Kevetrin	Phase 2
T15739	DRUGINFO	D0V2SP	INGN-225	Phase 2
T15739	DRUGINFO	D0V5JH	ALT-801	Phase 2
T15739	DRUGINFO	D04SXL	APG-115	Phase 2
T15739	DRUGINFO	D0KK4N	ISA-P53-01	Phase 1/2
T15739	DRUGINFO	D03YSQ	SAR-405838	Phase 1
T15739	DRUGINFO	D05CPS	Dendritic cell vaccine	Phase 1
T15739	DRUGINFO	D0G7YS	ONYX-015	Phase 1
T15739	DRUGINFO	D0G8CU	COTI-2	Phase 1
T15739	DRUGINFO	D0Q7AG	CGM097	Phase 1
T15739	DRUGINFO	D01KTG	HDM201	Phase 1
T15739	DRUGINFO	D05AHK	INGN-234	Discontinued in Phase 2
T15739	DRUGINFO	D02NYK	Pifithrin-alpha	Terminated
T15739	DRUGINFO	D0LG1K	TAR-1	Terminated
T15739	DRUGINFO	D08PLU	1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine	Investigative
T15739	DRUGINFO	D01QKK	NUTLIN-3	Investigative
T15739	DRUGINFO	D0F1SN	NU-8231	Investigative

T44282	TARGETID	T44282
T44282	FORMERID	TTDR01185
T44282	UNIPROID	ALDH2_HUMAN
T44282	TARGNAME	Mitochondrial aldehyde dehydrogenase (ALDH2)
T44282	GENENAME	ALDH2
T44282	TARGTYPE	Clinical trial
T44282	SYNONYMS	Aldehyde dehydrogenase, mitochondrial; ALDM; ALDHI; ALDH-E2; ALDH class 2
T44282	FUNCTION	Second enzyme of the major oxidative pathway of alcohol metabolism. Catalyzes the chemical transformation from acetaldehyde to acetic acid.  Additionally, functions as a protector against oxidative stress.
T44282	PDBSTRUC	5L13; 4KWG; 4KWF; 4FR8; 4FQF
T44282	BIOCLASS	Aldehyde/oxo donor oxidoreductase
T44282	ECNUMBER	EC 1.2.1.3
T44282	SEQUENCE	MLRAAARFGPRLGRRLLSAAATQAVPAPNQQPEVFCNQIFINNEWHDAVSRKTFPTVNPSTGEVICQVAEGDKEDVDKAVKAARAAFQLGSPWRRMDASHRGRLLNRLADLIERDRTYLAALETLDNGKPYVISYLVDLDMVLKCLRYYAGWADKYHGKTIPIDGDFFSYTRHEPVGVCGQIIPWNFPLLMQAWKLGPALATGNVVVMKVAEQTPLTALYVANLIKEAGFPPGVVNIVPGFGPTAGAAIASHEDVDKVAFTGSTEIGRVIQVAAGSSNLKRVTLELGGKSPNIIMSDADMDWAVEQAHFALFFNQGQCCCAGSRTFVQEDIYDEFVERSVARAKSRVVGNPFDSKTEQGPQVDETQFKKILGYINTGKQEGAKLLCGGGIAADRGYFIQPTVFGDVQDGMTIAKEEIFGPVMQILKFKTIEEVVGRANNSTYGLAAAVFTKDLDKANYLSQALQAGTVWVNCYDVFGAQSPFGGYKMSGSGRELGEYGLQAYTEVKTVTVKVPQKNS
T44282	DRUGINFO	D0D8SN	ALD-401	Phase 2
T44282	DRUGINFO	D00IXN	GS-6637	Phase 1
T44282	DRUGINFO	D09PSY	ANS-6637	Phase 1
T44282	DRUGINFO	D0BI7J	FP-045	Phase 1
T44282	DRUGINFO	D01WGJ	Daidzin	Terminated
T44282	DRUGINFO	D08MTZ	ISOFORMONENTIN	Investigative
T44282	DRUGINFO	D0A9RM	prunetin	Investigative
T44282	DRUGINFO	D0W4WP	CVT-10216	Investigative
T44282	DRUGINFO	D09CSB	crotylaldehyde	Investigative
T44282	DRUGINFO	D0R6JE	Nicotinamide-Adenine-Dinucleotide	Investigative

T15556	TARGETID	T15556
T15556	FORMERID	TTDR00556
T15556	UNIPROID	PAI1_HUMAN
T15556	TARGNAME	Endothelial plasminogen activator inhibitor (SERPINE1)
T15556	GENENAME	SERPINE1
T15556	TARGTYPE	Clinical trial
T15556	SYNONYMS	Serpin E1; Plasminogen activator inhibitor type 1; Plasminogen activator inhibitor 1; PLANH1; PAI1; PAI-1
T15556	FUNCTION	Inhibits TMPRSS7. Is a primary inhibitor of tissue-type plasminogen activator (PLAT) and urokinase-type plasminogen activator (PLAU). As PLAT inhibitor, it is required for fibrinolysis down-regulation and is responsible for the controlled degradation of blood clots. As PLAU inhibitor, it is involved in the regulation of cell adhesion and spreading. Acts as a regulator of cell migration, independently of its role as protease inhibitor. It is required for stimulation of keratinocyte migration during cutaneous injury repair. It is involved in cellular and replicative senescence. Plays a role in alveolar type 2 cells senescence in the lung. Is involved in the regulation of cementogenic differentiation of periodontal ligament stem cells, and regulates odontoblast differentiation and dentin formation during odontogenesis. Serine protease inhibitor.
T15556	PDBSTRUC	9PAI; 6I8S; 5ZLZ; 5BRR; 4IC0
T15556	BIOCLASS	Serpin protein
T15556	SEQUENCE	MQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPYGVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAIFVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAVDQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPDGHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPKFSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASSSTAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP
T15556	DRUGINFO	D05ZDJ	THR-18	Phase 2
T15556	DRUGINFO	D0XJ6C	DIAPLASININ	Phase 1
T15556	DRUGINFO	D0YK7C	XR-5118	Terminated
T15556	DRUGINFO	D05GSZ	AR-HO29953XX	Investigative
T15556	DRUGINFO	D05VKW	Sideroxylonal C	Investigative
T15556	DRUGINFO	D0U4LV	SIDEROXYLONAL B	Investigative
T15556	DRUGINFO	D0WX7S	SIDEROXYLONAL A	Investigative

T01851	TARGETID	T01851
T01851	FORMERID	TTDC00148
T01851	UNIPROID	ITB1_HUMAN
T01851	TARGNAME	Integrin beta-1 (ITGB1)
T01851	GENENAME	ITGB1
T01851	TARGTYPE	Clinical trial
T01851	SYNONYMS	VLA-4 subunit beta; MSK12; MDF2; Integrin VLA-4 beta subunit; Glycoprotein IIa; GPIIA; Fibronectin receptor subunit beta; Fibronectin receptor beta subunit; FNRB; CD29 antigen; CD29; Beta(1) integrin
T01851	FUNCTION	Integrins alpha-1/beta-1 and alpha-2/beta-2 recognize the proline-hydroxylated sequence G-F-P-G-E-R in collagen. Integrins alpha-2/beta-1, alpha-3/beta-1, alpha-4/beta-1, alpha-5/beta-1, alpha-8/beta-1, alpha-10/beta-1, alpha-11/beta-1 and alpha-V/beta-1 are receptors for fibronectin. Alpha-4/beta-1 recognizes one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. Integrin alpha-5/beta-1 is a receptor for fibrinogen. Integrin alpha-1/beta-1, alpha-2/beta-1, alpha-6/beta-1 and alpha-7/beta-1 are receptors for lamimin. Integrin alpha-6/beta-1 (ITGA6:ITGB1) is present in oocytes and is involved in sperm-egg fusion. Integrin alpha-4/beta-1 is a receptor for VCAM1. It recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha-9/beta-1 is a receptor for VCAM1, cytotactin and osteopontin. It recognizes the sequence A-E-I-D-G-I-E-L in cytotactin. Integrin alpha-3/beta-1 is a receptor for epiligrin, thrombospondin and CSPG4. Alpha-3/beta-1 may mediate with LGALS3 the stimulation by CSPG4 of endothelial cells migration. Integrin alpha-V/beta-1 is a receptor for vitronectin. Beta-1 integrins recognize the sequence R-G-D in a wide array of ligands. Isoform 2 interferes with isoform 1 resulting in a dominant negative effect on cell adhesion and migration (in vitro). When associated with alpha-7/beta-1 integrin, regulates cell adhesion and laminin matrix deposition. Involved in promoting endothelial cell motility and angiogenesis. Involved in osteoblast compaction through the fibronectin fibrillogenesis cell-mediated matrix assembly process and the formation of mineralized bone nodules. May be involved in up-regulation of the activity of kinases such as PKC via binding to KRT1. Together with KRT1 and RACK1, serves as a platform for SRC activation or inactivation. Plays a mechanistic adhesive role during telophase, required for the successful completion of cytokinesis. Integrin alpha-3/beta-1 provides a docking site for FAP (seprase) at invadopodia plasma membranes in a collagen-dependent manner and hence may participate in the adhesion, formation of invadopodia and matrix degradation processes, promoting cell invasion. ITGA4:ITGB1 binds to fractalkine (CX3CL1) and may act as its coreceptor in CX3CR1-dependent fractalkine signaling. ITGA4:ITGB1 and ITGA5:ITGB1 bind to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1. ITGA5:ITGB1 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1. ITGA5:ITGB1 is a receptor for IL1B and binding is essential for IL1B signaling. Integrins alpha-1/beta-1, alpha-2/beta-1, alpha-10/beta-1 and alpha-11/beta-1 are receptors for collagen.
T01851	PDBSTRUC	4WK4; 4WK2; 4WK0; 4WJK; 4DX9
T01851	BIOCLASS	Integrin
T01851	SEQUENCE	MNLQPIFWIGLISSVCCVFAQTDENRCLKANAKSCGECIQAGPNCGWCTNSTFLQEGMPTSARCDDLEALKKKGCPPDDIENPRGSKDIKKNKNVTNRSKGTAEKLKPEDITQIQPQQLVLRLRSGEPQTFTLKFKRAEDYPIDLYYLMDLSYSMKDDLENVKSLGTDLMNEMRRITSDFRIGFGSFVEKTVMPYISTTPAKLRNPCTSEQNCTSPFSYKNVLSLTNKGEVFNELVGKQRISGNLDSPEGGFDAIMQVAVCGSLIGWRNVTRLLVFSTDAGFHFAGDGKLGGIVLPNDGQCHLENNMYTMSHYYDYPSIAHLVQKLSENNIQTIFAVTEEFQPVYKELKNLIPKSAVGTLSANSSNVIQLIIDAYNSLSSEVILENGKLSEGVTISYKSYCKNGVNGTGENGRKCSNISIGDEVQFEISITSNKCPKKDSDSFKIRPLGFTEEVEVILQYICECECQSEGIPESPKCHEGNGTFECGACRCNEGRVGRHCECSTDEVNSEDMDAYCRKENSSEICSNNGECVCGQCVCRKRDNTNEIYSGKFCECDNFNCDRSNGLICGGNGVCKCRVCECNPNYTGSACDCSLDTSTCEASNGQICNGRGICECGVCKCTDPKFQGQTCEMCQTCLGVCAEHKECVQCRAFNKGEKKDTCTQECSYFNITKVESRDKLPQPVQPDPVSHCKEKDVDDCWFYFTYSVNGNNEVMVHVVENPECPTGPDIIPIVAGVVAGIVLIGLALLLIWKLLMIIHDRREFAKFEKEKMNAKWDTGENPIYKSAVTTVVNPKYEGK
T01851	DRUGINFO	D0H4GT	131I-radretumab	Phase 1/2
T01851	DRUGINFO	DB8MR6	OS2966	Phase 1
T01851	DRUGINFO	D0ZT4J	JSM 6427	Phase 1
T01851	DRUGINFO	D09XED	MK-0668	Investigative
T01851	DRUGINFO	D0R3CY	SB-265123	Investigative
T01851	DRUGINFO	D0B4JU	C(-GRGDfL-)	Investigative

T40276	TARGETID	T40276
T40276	FORMERID	TTDC00163
T40276	UNIPROID	KPCB_HUMAN
T40276	TARGNAME	Protein kinase C beta (PRKCB)
T40276	GENENAME	PRKCB
T40276	TARGTYPE	Clinical trial
T40276	SYNONYMS	Protein kinase C beta type; PRKCB1; PKCB; PKC-beta; PKC-B
T40276	FUNCTION	Plays a key role in B-cell activation by regulating BCR-induced NF-kappa-B activation. Mediates the activation of the canonical NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11/CARMA1 at 'Ser-559', 'Ser-644' and 'Ser-652'. Phosphorylation induces CARD11/CARMA1 association with lipid rafts and recruitment of the BCL10-MALT1 complex as well as MAP3K7/TAK1, which then activates IKK complex, resulting in nuclear translocation and activation of NFKB1. Plays a direct role in the negative feedback regulation of the BCR signaling, by down-modulating BTK function via direct phosphorylation of BTK at 'Ser-180', which results in the alteration of BTK plasma membrane localization and in turn inhibition of BTK activity. Involved in apoptosis following oxidative damage: in case of oxidative conditions, specifically phosphorylates 'Ser-36' of isoform p66Shc of SHC1, leading to mitochondrial accumulation of p66Shc, where p66Shc acts as a reactive oxygen species producer. Acts as a coactivator of androgen receptor (ANDR)-dependent transcription, by being recruited to ANDR target genes and specifically mediating phosphorylation of 'Thr-6' of histone H3 (H3T6ph), a specific tag for epigenetic transcriptional activation that prevents demethylation of histone H3 'Lys-4' (H3K4me) by LSD1/KDM1A. In insulin signaling, may function downstream of IRS1 in muscle cells and mediate insulin-dependent DNA synthesis through the RAF1-MAPK/ERK signaling cascade. May participate in the regulation of glucose transport in adipocytes by negatively modulating the insulin-stimulated translocation of the glucose transporter SLC2A4/GLUT4. Under high glucose in pancreatic beta-cells, is probably involved in the inhibition of the insulin gene transcription, via regulation of MYC expression. In endothelial cells, activation of PRKCB induces increased phosphorylation of RB1, increased VEGFA-induced cell proliferation, and inhibits PI3K/AKT-dependent nitric oxide synthase (NOS3/eNOS) regulation by insulin, which causes endothelial dysfunction. Also involved in triglyceride homeostasis. Phosphorylates ATF2 which promotes cooperation between ATF2 and JUN, activating transcription. Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase involved in various cellular processes such as regulation of the B-cell receptor (BCR) signalosome, oxidative stress-induced apoptosis, androgen receptor-dependent transcription regulation, insulin signaling and endothelial cells proliferation.
T40276	PDBSTRUC	2I0E
T40276	BIOCLASS	Kinase
T40276	ECNUMBER	EC 2.7.11.13
T40276	SEQUENCE	MADPAAGPPPSEGEESTVRFARKGALRQKNVHEVKNHKFTARFFKQPTFCSHCTDFIWGFGKQGFQCQVCCFVVHKRCHEFVTFSCPGADKGPASDDPRSKHKFKIHTYSSPTFCDHCGSLLYGLIHQGMKCDTCMMNVHKRCVMNVPSLCGTDHTERRGRIYIQAHIDRDVLIVLVRDAKNLVPMDPNGLSDPYVKLKLIPDPKSESKQKTKTIKCSLNPEWNETFRFQLKESDKDRRLSVEIWDWDLTSRNDFMGSLSFGISELQKASVDGWFKLLSQEEGEYFNVPVPPEGSEANEELRQKFERAKISQGTKVPEEKTTNTVSKFDNNGNRDRMKLTDFNFLMVLGKGSFGKVMLSERKGTDELYAVKILKKDVVIQDDDVECTMVEKRVLALPGKPPFLTQLHSCFQTMDRLYFVMEYVNGGDLMYHIQQVGRFKEPHAVFYAAEIAIGLFFLQSKGIIYRDLKLDNVMLDSEGHIKIADFGMCKENIWDGVTTKTFCGTPDYIAPEIIAYQPYGKSVDWWAFGVLLYEMLAGQAPFEGEDEDELFQSIMEHNVAYPKSMSKEAVAICKGLMTKHPGKRLGCGPEGERDIKEHAFFRYIDWEKLERKEIQPPYKPKARDKRDTSNFDKEFTRQPVELTPTDKLFIMNLDQNEFAGFSYTNPEFVINV
T40276	DRUGINFO	D0MV4W	RUBOXISTAURIN HYDROCHLORIDE	Phase 3
T40276	DRUGINFO	D0I6VU	Enzastaurin	Phase 3
T40276	DRUGINFO	D0W3LI	LY333531	Phase 2
T40276	DRUGINFO	D0F5HB	Sotrastaurin acetate	Phase 2
T40276	DRUGINFO	D98VPM	MS-553	Phase 1
T40276	DRUGINFO	D0E8UV	Linetastine	Discontinued in Phase 2
T40276	DRUGINFO	D0X0HN	LY-317644	Terminated
T40276	DRUGINFO	D0R5ZR	RO-320432	Terminated
T40276	DRUGINFO	D0R2TM	BALANOL	Terminated
T40276	DRUGINFO	D04TBJ	O-Phosphoethanolamine	Investigative
T40276	DRUGINFO	D0H7DQ	K00248	Investigative
T40276	DRUGINFO	D0B1SO	TANNIN	Investigative
T40276	DRUGINFO	D0Q3XB	PUNICAFOLIN	Investigative
T40276	DRUGINFO	D0X2DH	3-(1H-Indol-3-yl)-4-phenylamino-pyrrole-2,5-dione	Investigative
T40276	DRUGINFO	D04OHM	4-cyclopentyliden(4-hydroxyphenyl)methylphenol	Investigative
T40276	DRUGINFO	D0L1YA	(-)-Cercosporamide	Investigative
T40276	DRUGINFO	D06TLL	Go 6983	Investigative
T40276	DRUGINFO	D00TWA	[2,2':5',2'']Terthiophen-4-yl-methanol	Investigative
T40276	DRUGINFO	D02PUV	4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol	Investigative
T40276	DRUGINFO	D02QME	2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile	Investigative
T40276	DRUGINFO	D05LRV	[2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde	Investigative
T40276	DRUGINFO	D09TSC	Ro-32-0557	Investigative
T40276	DRUGINFO	D09XIE	3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile	Investigative
T40276	DRUGINFO	D0A8MN	3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile	Investigative
T40276	DRUGINFO	D0D3MR	[2,2':5',2'']Terthiophene-4-carbaldehyde	Investigative
T40276	DRUGINFO	D0Q3GQ	4-cycloheptyliden(4-hydroxyphenyl)methylphenol	Investigative
T40276	DRUGINFO	D0S9UK	2,3,3-Triphenyl-acrylonitrile	Investigative
T40276	DRUGINFO	D0T0UH	3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile	Investigative
T40276	DRUGINFO	D0V9SW	4-cyclohexyliden(4-hydroxyphenyl)methylphenol	Investigative
T40276	DRUGINFO	D04JNZ	PROSTRATIN	Investigative
T40276	DRUGINFO	D06ZCX	LY-326449	Investigative
T40276	DRUGINFO	D0L8HO	RO-316233	Investigative

T67103	TARGETID	T67103
T67103	FORMERID	TTDR00473
T67103	UNIPROID	ITAV_HUMAN
T67103	TARGNAME	Integrin alpha-V (ITGAV)
T67103	GENENAME	ITGAV
T67103	TARGTYPE	Clinical trial
T67103	SYNONYMS	Vitronectin receptor subunit alpha; Vitronectin receptor alpha subunit; Vitronectin receptor; VTNR; VNRA; MSK8; CD51 antigen; CD51
T67103	FUNCTION	The alpha-V (ITGAV) integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. They recognize the sequence R-G-D in a wide array of ligands. ITGAV:ITGB3 binds to fractalkine (CX3CL1) and may act as its coreceptor in CX3CR1-dependent fractalkine signaling. ITGAV:ITGB3 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling. ITGAV:ITGB3 binds to FGF1 and this binding is essential for FGF1 signaling. ITGAV:ITGB3 binds to FGF2 and this binding is essential for FGF2 signaling. ITGAV:ITGB3 binds to IGF1 and this binding is essential for IGF1 signaling. ITGAV:ITGB3 binds to IGF2 and this binding is essential for IGF2 signaling. ITGAV:ITGB3 binds to IL1B and this binding is essential for IL1B signaling. ITGAV:ITGB3 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1. ITGAV:ITGB3 and ITGAV:ITGB6 act as a receptor for fibrillin-1 (FBN1) and mediate R-G-D-dependent cell adhesion to FBN1. Integrin alpha-V/beta-6 or alpha-V/beta-8 (ITGAV:ITGB6 or ITGAV:ITGB8) mediates R-G-D-dependent release of transforming growth factor beta-1 (TGF-beta-1) from regulatory Latency-associated peptide (LAP), thereby playing a key role in TGF-beta-1 activation.
T67103	PDBSTRUC	6DJP; 6AVU; 6AVR; 6AVQ; 5NEU
T67103	BIOCLASS	Integrin
T67103	SEQUENCE	MAFPPRRRLRLGPRGLPLLLSGLLLPLCRAFNLDVDSPAEYSGPEGSYFGFAVDFFVPSASSRMFLLVGAPKANTTQPGIVEGGQVLKCDWSSTRRCQPIEFDATGNRDYAKDDPLEFKSHQWFGASVRSKQDKILACAPLYHWRTEMKQEREPVGTCFLQDGTKTVEYAPCRSQDIDADGQGFCQGGFSIDFTKADRVLLGGPGSFYWQGQLISDQVAEIVSKYDPNVYSIKYNNQLATRTAQAIFDDSYLGYSVAVGDFNGDGIDDFVSGVPRAARTLGMVYIYDGKNMSSLYNFTGEQMAAYFGFSVAATDINGDDYADVFIGAPLFMDRGSDGKLQEVGQVSVSLQRASGDFQTTKLNGFEVFARFGSAIAPLGDLDQDGFNDIAIAAPYGGEDKKGIVYIFNGRSTGLNAVPSQILEGQWAARSMPPSFGYSMKGATDIDKNGYPDLIVGAFGVDRAILYRARPVITVNAGLEVYPSILNQDNKTCSLPGTALKVSCFNVRFCLKADGKGVLPRKLNFQVELLLDKLKQKGAIRRALFLYSRSPSHSKNMTISRGGLMQCEELIAYLRDESEFRDKLTPITIFMEYRLDYRTAADTTGLQPILNQFTPANISRQAHILLDCGEDNVCKPKLEVSVDSDQKKIYIGDDNPLTLIVKAQNQGEGAYEAELIVSIPLQADFIGVVRNNEALARLSCAFKTENQTRQVVCDLGNPMKAGTQLLAGLRFSVHQQSEMDTSVKFDLQIQSSNLFDKVSPVVSHKVDLAVLAAVEIRGVSSPDHVFLPIPNWEHKENPETEEDVGPVVQHIYELRNNGPSSFSKAMLHLQWPYKYNNNTLLYILHYDIDGPMNCTSDMEINPLRIKISSLQTTEKNDTVAGQGERDHLITKRDLALSEGDIHTLGCGVAQCLKIVCQVGRLDRGKSAILYVKSLLWTETFMNKENQNHSYSLKSSASFNVIEFPYKNLPIEDITNSTLVTTNVTWGIQPAPMPVPVWVIILAVLAGLLLLAVLVFVMYRMGFFKRVRPPQEEQEREQLQPHENGEGNSET
T67103	DRUGINFO	D0F9QH	Abituzumab	Phase 2
T67103	DRUGINFO	D07HKV	IMGN-388	Phase 1
T67103	DRUGINFO	D0LT1S	SB-223245	Terminated
T67103	DRUGINFO	D06LUT	G(D-Pen)-G-H-R-G-D-L-R-C-A	Investigative
T67103	DRUGINFO	D06WNY	NAVPNLRGDLQVLAQKVART	Investigative
T67103	DRUGINFO	D07SFV	C[RGDf-(3S)-Carboxymorpholine]	Investigative
T67103	DRUGINFO	D0F7SE	C[RGDf-(3R)-Carboxymorpholine]	Investigative
T67103	DRUGINFO	D00YBU	C(RGDfF)	Investigative
T67103	DRUGINFO	D01AXA	Ac-Asp-Arg-Leu-Asp-Ser-OH	Investigative
T67103	DRUGINFO	D01BZH	C[-Arg-Gly-Asp-Acpca21-]	Investigative
T67103	DRUGINFO	D01MGI	C-[-Arg-Gly-Asp-Acpca32-]	Investigative
T67103	DRUGINFO	D03KLT	Cyclo-[-Arg-Gly-Asp-Amp22-]	Investigative
T67103	DRUGINFO	D03YLY	Cyclo-[-Arg-Gly-Asp-Amp21-]	Investigative
T67103	DRUGINFO	D04MCL	Cypate-[(RGD)2-NH2]2	Investigative
T67103	DRUGINFO	D04WVG	C[-Arg-Gly-Asp-Acpca35-]	Investigative
T67103	DRUGINFO	D05EWB	C[RGDf-(S)-alpha-TfmV]	Investigative
T67103	DRUGINFO	D05GXK	Cyclo-[-Arg-Gly-Asp-Amp26-]	Investigative
T67103	DRUGINFO	D05MJG	E[c(RGDyK)]2	Investigative
T67103	DRUGINFO	D05VEC	C-[-Arg-Gly-Asp-Acpca30-]	Investigative
T67103	DRUGINFO	D06JLN	C[-Arg-Gly-Asp-Acpca36-]	Investigative
T67103	DRUGINFO	D06LKH	Gly-Arg-Gly-Asp-Ser	Investigative
T67103	DRUGINFO	D07QJD	Cyclo-[-Arg-Gly-Asp-Amp25-]	Investigative
T67103	DRUGINFO	D07UOF	C(RGDfMeF)	Investigative
T67103	DRUGINFO	D08CFM	C[RGDf-(R)-alpha-TfmV]	Investigative
T67103	DRUGINFO	D08DSG	C(Arg-Gly-Asp-D-Phe-Val)	Investigative
T67103	DRUGINFO	D09PLA	C-[-Arg-Gly-Asp-Acpca31-]	Investigative
T67103	DRUGINFO	D0D4QZ	RGDechi	Investigative
T67103	DRUGINFO	D0G8JI	Cyclo(RGDfV) (control)	Investigative
T67103	DRUGINFO	D0H4EK	C[RGDf-(R)-N-Me-alpha-TfmF]	Investigative
T67103	DRUGINFO	D0H4MB	ISONIPECOTAMIDE	Investigative
T67103	DRUGINFO	D0I5BY	C[RGDf-(S)-alpha-TfmF]	Investigative
T67103	DRUGINFO	D0ID6U	CYCLORGDFV	Investigative
T67103	DRUGINFO	D0J6SP	Cyclo-[-Arg-Gly-Asp-Amp28-]	Investigative
T67103	DRUGINFO	D0K5DM	E[c(RGDyK)]2-PTX conjugate	Investigative
T67103	DRUGINFO	D0L2PQ	Cypate-[(RGD)3-NH2]1	Investigative
T67103	DRUGINFO	D0LF7W	C[-Arg-Gly-Asp-Acpca19-]	Investigative
T67103	DRUGINFO	D0LV6B	Gly-Arg-Gly-Asp-Ser-Pro-Lys	Investigative
T67103	DRUGINFO	D0M0BN	C[RGDf-(R)-alpha-TfmF]	Investigative
T67103	DRUGINFO	D0M6NQ	C[RGDf-(S)-N-Me-alpha-TfmF]	Investigative
T67103	DRUGINFO	D0N9NA	Cypate-[(RGD)4-NH2]2	Investigative
T67103	DRUGINFO	D0O6DN	C[-Arg-Gly-Asp-Acpca34-]	Investigative
T67103	DRUGINFO	D0O9FL	Cyclo-[-Arg-Gly-Asp-Amp24-]	Investigative
T67103	DRUGINFO	D0P4RB	Cypate-[(RGD)2-NH2]1	Investigative
T67103	DRUGINFO	D0R9AD	N-(3,5-dichlorophenyl)imidodicarbonimidic diamide	Investigative
T67103	DRUGINFO	D0R9GW	C[-Arg-Gly-Asp-Acpca22-]	Investigative
T67103	DRUGINFO	D0R9SJ	ST-1646	Investigative
T67103	DRUGINFO	D0T1II	Cyclo[RGDfK(cypate)]	Investigative
T67103	DRUGINFO	D0U0VF	Cyclo-[-Arg-Gly-Asp-Amp27-]	Investigative
T67103	DRUGINFO	D0U2NV	C[RGD-(R)-alpha-TfmfV]	Investigative
T67103	DRUGINFO	D0UE7H	C-[-Arg-Gly-Asp-Acpca33-]	Investigative
T67103	DRUGINFO	D0UO0Y	Cypate-[(RGD)3-NH2]2	Investigative
T67103	DRUGINFO	D0V0JC	C[RGD-(S)-alpha-TfmfV]	Investigative
T67103	DRUGINFO	D0W6CJ	C[-Arg-Gly-Asp-Acpca20-]	Investigative
T67103	DRUGINFO	D0WK2F	C[RGDf-(S,R)-alpha-Dfm-F]	Investigative
T67103	DRUGINFO	D0X4EE	AcDRGDS	Investigative
T67103	DRUGINFO	D0Y8UD	Cypate-[(RGD)4-NH2]1	Investigative
T67103	DRUGINFO	D0Z6WZ	Cyclo-[-Arg-Gly-Asp-Amp23-]	Investigative
T67103	DRUGINFO	D0R3CY	SB-265123	Investigative
T67103	DRUGINFO	D0B4JU	C(-GRGDfL-)	Investigative

T93509	TARGETID	T93509
T93509	FORMERID	TTDC00017
T93509	UNIPROID	CALCA_HUMAN
T93509	TARGNAME	Calcitonin gene-related peptide 1 (CALCA)
T93509	GENENAME	CALCA
T93509	TARGTYPE	Clinical trial
T93509	SYNONYMS	Calcitonin gene-related peptide I; CGRP-I; CALCA; CALC1; Alpha-type CGRP
T93509	FUNCTION	CGRP induces vasodilation. It dilates a variety of vessels including the coronary, cerebral and systemic vasculature. Its abundance in the CNS also points toward a neurotransmitter or neuromodulator role. It also elevates platelet cAMP.
T93509	PDBSTRUC	6E3Y; 1LS7
T93509	BIOCLASS	Cytotoxic amylin family
T93509	SEQUENCE	MGFQKFSPFLALSILVLLQAGSLHAAPFRSALESSPADPATLSEDEARLLLAALVQDYVQMKASELEQEQEREGSRIIAQKRACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGSKAFGRRRRDLQA
T93509	DRUGINFO	D04BUH	Cizolirtine	Phase 2
T93509	DRUGINFO	D02YXI	Ac-WVTH[hArg]LAGLLS[hArg]SGGVVRKNFVPTDVGPFAF-NH2	Investigative
T93509	DRUGINFO	D03VFP	Ac-WVEHRLKGELSRKGGVV[hArg]KNFVPTDVGPFAF-NH2	Investigative
T93509	DRUGINFO	D05LMD	VTHRLAGLLSRSGGVVKNNFVPTNVGSKAF-NH2	Investigative
T93509	DRUGINFO	D06JYM	Ac-WVTHQLAGLLSQSGGVVRKNFVPTDVGPFAF-NH2	Investigative
T93509	DRUGINFO	D08WZV	Ac-VTHRLAGLLSRSGGVVKNNFVPTDVGPFAF-NH2	Investigative
T93509	DRUGINFO	D09EJG	Ac-WVTHRLAGLLSRSGGVVRKNFVPTDVGPFAF-NH2	Investigative
T93509	DRUGINFO	D09WRS	Ac-WVTH[Cit]LAGLLSRSGGVVRKNFVPTDVGPFAF-NH2	Investigative
T93509	DRUGINFO	D0G7CO	Ac-WVTHRLAGLLS[Cit]SGGVVRKNFVPTDVGPFAF-NH2	Investigative
T93509	DRUGINFO	D0I2HH	Ac-WVTH[Cit]LAGLLS[Cit]SGGVVRKNFVPTDVGPFAF-NH2	Investigative
T93509	DRUGINFO	D0I2PK	Ac-VTHRLAGLLSRSGGVVRKNFVPTDVGPFAF-NH2	Investigative
T93509	DRUGINFO	D0U4BO	WVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF-NH2	Investigative
T93509	DRUGINFO	D0I2KW	FV-Aib-TDVGPFAF	Investigative

T36935	TARGETID	T36935
T36935	FORMERID	TTDR00503
T36935	UNIPROID	KLK3_HUMAN
T36935	TARGNAME	Prostate specific antigen (KLK3)
T36935	GENENAME	KLK3
T36935	TARGTYPE	Clinical trial
T36935	SYNONYMS	Seminin; Semenogelase; Prostate-specific antigen; PSA; P-30 antigen; Kallikrein-3; Gamma-seminoprotein; APS
T36935	FUNCTION	Hydrolyzes semenogelin-1 thus leading to the liquefaction of the seminal coagulum.
T36935	PDBSTRUC	3QUM; 2ZCL; 2ZCK; 2ZCH; 2PSA
T36935	BIOCLASS	Peptidase
T36935	ECNUMBER	EC 3.4.21.77
T36935	SEQUENCE	MWVPVVFLTLSVTWIGAAPLILSRIVGGWECEKHSQPWQVLVASRGRAVCGGVLVHPQWVLTAAHCIRNKSVILLGRHSLFHPEDTGQVFQVSHSFPHPLYDMSLLKNRFLRPGDDSSHDLMLLRLSEPAELTDAVKVMDLPTQEPALGTTCYASGWGSIEPEEFLTPKKLQCVDLHVISNDVCAQVHPQKVTKFMLCAGRWTGGKSTCSGDSGGPLVCNGVLQGITSWGSEPCALPERPSLYTKVVHYRKWIKDTIVANP
T36935	DRUGINFO	D08KGY	PRX-302	Phase 3
T36935	DRUGINFO	D0A3FZ	Rilimogene galvacirepvec	Phase 3
T36935	DRUGINFO	D0G2MR	ProstaVac	Phase 3
T36935	DRUGINFO	D0U3RV	Motexafin lutetium	Phase 3
T36935	DRUGINFO	D09SCP	ADXS-PSA	Phase 1/2
T36935	DRUGINFO	D08GFN	MVA-BN Breast	Phase 1
T36935	DRUGINFO	D04BPQ	PMID23692593C20	Investigative
T36935	DRUGINFO	D07NCC	VTT-201	Investigative
T36935	DRUGINFO	D0BK3Z	ProstaRex	Investigative
T36935	DRUGINFO	D0Z3AB	Anti-PSA mabs	Investigative

T41141	TARGETID	T41141
T41141	FORMERID	TTDR01031
T41141	UNIPROID	CATL1_HUMAN
T41141	TARGNAME	Cathepsin L (CTSL)
T41141	GENENAME	CTSL
T41141	TARGTYPE	Clinical trial
T41141	SYNONYMS	Major excreted protein; MEP; Cathepsin L1; CTSL1
T41141	FUNCTION	Important for the overall degradation of proteins in lysosomes.
T41141	PDBSTRUC	6F06; 6EZX; 6EZP; 5MQY; 5MAJ
T41141	BIOCLASS	Peptidase
T41141	ECNUMBER	EC 3.4.22.15
T41141	SEQUENCE	MNPTLILAAFCLGIASATLTFDHSLEAQWTKWKAMHNRLYGMNEEGWRRAVWEKNMKMIELHNQEYREGKHSFTMAMNAFGDMTSEEFRQVMNGFQNRKPRKGKVFQEPLFYEAPRSVDWREKGYVTPVKNQGQCGSCWAFSATGALEGQMFRKTGRLISLSEQNLVDCSGPQGNEGCNGGLMDYAFQYVQDNGGLDSEESYPYEATEESCKYNPKYSVANDTGFVDIPKQEKALMKAVATVGPISVAIDAGHESFLFYKEGIYFEPDCSSEDMDHGVLVVGYGFESTESDNNKYWLVKNSWGEEWGMGGYVKMAKDRRNHCGIASAASYPTV
T41141	DRUGINFO	D0X6QL	KGP94	Clinical trial
T41141	DRUGINFO	D0J0WG	PMID27998201-Compound-1	Patented
T41141	DRUGINFO	D0ZN3M	PMID27998201-Compound-19	Patented
T41141	DRUGINFO	D01MKD	Phenylalanine derivative 1	Patented
T41141	DRUGINFO	D0JD5W	PMID27998201-Compound-7	Patented
T41141	DRUGINFO	D0X1AF	PMID27998201-Compound-6	Patented
T41141	DRUGINFO	D06XTA	PMID27998201-Compound-17	Patented
T41141	DRUGINFO	D04VGR	PMID27998201-Compound-9	Patented
T41141	DRUGINFO	D06LLT	PMID25399719-Compound-17	Patented
T41141	DRUGINFO	D05OIU	PMID27998201-Compound-5	Patented
T41141	DRUGINFO	D06XCD	PMID27998201-Compound-12	Patented
T41141	DRUGINFO	DW24LQ	CLIK-148	Preclinical
T41141	DRUGINFO	DYU3I8	CLIK-181	Preclinical
T41141	DRUGINFO	DCZ16N	SD1002	Preclinical
T41141	DRUGINFO	DM69TL	Z-Phe-Ala-diazomethylketone	Preclinical
T41141	DRUGINFO	DSM03D	SD1003	Preclinical
T41141	DRUGINFO	D0Z0PR	L-006235-1	Preclinical
T41141	DRUGINFO	D00VAN	[(3-Bromophenyl)-m-tolyl-ketone]thiosemicarbazone	Investigative
T41141	DRUGINFO	D01CSE	Bis(3-bromophenyl)(5-hydroxy)thiosemicarbazone	Investigative
T41141	DRUGINFO	D01YTS	CAA0225	Investigative
T41141	DRUGINFO	D02RWL	BIPHENYL-4-YL-ACETALDEHYDE	Investigative
T41141	DRUGINFO	D08TWJ	Peptide alpha-keto-beta-aldehyde-based inhibitors	Investigative
T41141	DRUGINFO	D09NBP	(3-Bromobenzoylpyridine)thiosemicarbazone	Investigative
T41141	DRUGINFO	D0B4JS	1-(1,3-diphenylpropylidene)thiosemicarbazide	Investigative
T41141	DRUGINFO	D0J7OM	6-(benzylamino)-9-butyl-9H-purine-2-carbonitrile	Investigative
T41141	DRUGINFO	D0LL1F	[2-Phenylacetophenone]thiosemicarbazone	Investigative
T41141	DRUGINFO	D0M3AP	Bis(3-Fluorophenyl)-ketone]thiosemicarbazone	Investigative
T41141	DRUGINFO	D0MD6D	9-benzyl-6-(benzylamino)-9H-purine-2-carbonitrile	Investigative
T41141	DRUGINFO	D03JYN	1-(phenyl(p-tolyl)methylene)thiosemicarbazide	Investigative
T41141	DRUGINFO	D04DFX	Bis(3-bromophenyl)(4-hydroxy)thiosemicarbazone	Investigative
T41141	DRUGINFO	D0B2JC	[(3-Bromophenyl)-p-tolyl-ketone]thiosemicarbazone	Investigative
T41141	DRUGINFO	D0JF8D	N-(tert-butoxycarbonyl)-tyrosyl-glycine-nitrile	Investigative
T41141	DRUGINFO	D0T7QF	(S)-tert-butyl 1-oxohexan-2-ylcarbamate	Investigative
T41141	DRUGINFO	D01YNC	N-(tert-butoxycarbonyl)-isoleucyl-glycine-nitrile	Investigative
T41141	DRUGINFO	D06VIP	N-(tert-butoxycarbonyl)-valyl-glycine-nitrile	Investigative
T41141	DRUGINFO	D07FLB	N-(tert-butoxycarbonyl)-norleucyl-glycine-nitrile	Investigative
T41141	DRUGINFO	D07RSA	N-(4-phenylbenzoyl)-phenylalanyl-glycine-nitrile	Investigative
T41141	DRUGINFO	D09AHN	N-(tert-butoxycarbonyl)-leucyl-glycine-nitrile	Investigative
T41141	DRUGINFO	D0A8OV	N-acetyl-phenylalanyl-glycine-nitrile	Investigative
T41141	DRUGINFO	D0G8OD	N-(benzyloxycarbonyl)-leucyl-glycine-nitrile	Investigative
T41141	DRUGINFO	D0JN8Q	N-benzoyl-phenylalanyl-glycine-nitrile	Investigative
T41141	DRUGINFO	D0U0XG	N-(tert-butoxycarbonyl)-methionyl-glycine-nitrile	Investigative
T41141	DRUGINFO	D0VE0F	(S)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate	Investigative
T41141	DRUGINFO	D05AMX	Cysteinesulfonic Acid	Investigative
T41141	DRUGINFO	D0D0LD	L-873724	Investigative

T68163	TARGETID	T68163
T68163	FORMERID	TTDI02273
T68163	UNIPROID	LYN_HUMAN
T68163	TARGNAME	Tyrosine-protein kinase Lyn (JTK8)
T68163	GENENAME	LYN
T68163	TARGTYPE	Clinical trial
T68163	SYNONYMS	p56Lyn; p53Lyn; V-yes-1 Yamaguchi sarcoma viral related oncogene homolog; Lck/Yes-related novel protein tyrosine kinase
T68163	FUNCTION	Functions primarily as negative regulator, but can also function as activator, depending on the context. Required for the initiation of the B-cell response, but also for its down-regulation and termination. Plays an important role in the regulation of B-cell differentiation, proliferation, survival and apoptosis, and is important for immune self-tolerance. Acts downstream of several immune receptors, including the B-cell receptor, CD79A, CD79B, CD5, CD19, CD22, FCER1, FCGR2, FCGR1A, TLR2 and TLR4. Plays a role in the inflammatory response to bacterial lipopolysaccharide. Mediates the responses to cytokines and growth factors in hematopoietic progenitors, platelets, erythrocytes, and in mature myeloid cells, such as dendritic cells, neutrophils and eosinophils. Acts downstream of EPOR, KIT, MPL, the chemokine receptor CXCR4, as well as the receptors for IL3, IL5 and CSF2. Plays an important role in integrin signaling. Regulates cell proliferation, survival, differentiation, migration, adhesion, degranulation, and cytokine release. Down-regulates signaling pathways by phosphorylation of immunoreceptor tyrosine-based inhibitory motifs (ITIM), that then serve as binding sites for phosphatases, such as PTPN6/SHP-1, PTPN11/SHP-2 and INPP5D/SHIP-1, that modulate signaling by dephosphorylation of kinases and their substrates. Phosphorylates LIME1 in response to CD22 activation. Phosphorylates BTK, CBL, CD5, CD19, CD72, CD79A, CD79B, CSF2RB, DOK1, HCLS1, LILRB3/PIR-B, MS4A2/FCER1B, SYK and TEC. Promotes phosphorylation of SIRPA, PTPN6/SHP-1, PTPN11/SHP-2 and INPP5D/SHIP-1. Mediates phosphorylation of the BCR-ABL fusion protein. Required for rapid phosphorylation of FER in response to FCER1 activation. Mediates KIT phosphorylation. Acts as an effector of EPOR (erythropoietin receptor) in controlling KIT expression and may play a role in erythroid differentiation during the switch between proliferation and maturation. Depending on the context, activates or inhibits several signaling cascades. Regulates phosphatidylinositol 3-kinase activity and AKT1 activation. Regulates activation of the MAP kinase signaling cascade, including activation of MAP2K1/MEK1, MAPK1/ERK2, MAPK3/ERK1, MAPK8/JNK1 and MAPK9/JNK2. Mediates activation of STAT5A and/or STAT5B. Phosphorylates LPXN on 'Tyr-72'. Kinase activity facilitates TLR4-TLR6 heterodimerization and signal initiation. Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors and plays an important role in the regulation of innate and adaptive immune responses, hematopoiesis, responses to growth factors and cytokines, integrin signaling, but also responses to DNA damage and genotoxic agents.
T68163	PDBSTRUC	6NMW; 5XY1; 3A4O; 1WA7; 1W1F
T68163	BIOCLASS	Kinase
T68163	ECNUMBER	EC 2.7.10.2
T68163	SEQUENCE	MGCIKSKGKDSLSDDGVDLKTQPVRNTERTIYVRDPTSNKQQRPVPESQLLPGQRFQTKDPEEQGDIVVALYPYDGIHPDDLSFKKGEKMKVLEEHGEWWKAKSLLTKKEGFIPSNYVAKLNTLETEEWFFKDITRKDAERQLLAPGNSAGAFLIRESETLKGSFSLSVRDFDPVHGDVIKHYKIRSLDNGGYYISPRITFPCISDMIKHYQKQADGLCRRLEKACISPKPQKPWDKDAWEIPRESIKLVKRLGAGQFGEVWMGYYNNSTKVAVKTLKPGTMSVQAFLEEANLMKTLQHDKLVRLYAVVTREEPIYIITEYMAKGSLLDFLKSDEGGKVLLPKLIDFSAQIAEGMAYIERKNYIHRDLRAANVLVSESLMCKIADFGLARVIEDNEYTAREGAKFPIKWTAPEAINFGCFTIKSDVWSFGILLYEIVTYGKIPYPGRTNADVMTALSQGYRMPRVENCPDELYDIMKMCWKEKAEERPTFDYLQSVLDDFYTATEGQYQQQP
T68163	DRUGINFO	D0G0VV	Bafetinib	Phase 2
T68163	DRUGINFO	D0U3XL	JNJ-26483327	Phase 1
T68163	DRUGINFO	D0JZ2B	Alkynyl-substituted pyrimidinyl-pyrrole derivative 1	Patented
T68163	DRUGINFO	D04TLI	PMID17600705C23	Investigative
T68163	DRUGINFO	D0X7IC	NG-25	Investigative

T05409	TARGETID	T05409
T05409	FORMERID	TTDS00449
T05409	UNIPROID	NEP_HUMAN
T05409	TARGNAME	Neutral endopeptidase (MME)
T05409	GENENAME	MME
T05409	TARGTYPE	Clinical trial
T05409	SYNONYMS	Skin fibroblast elastase; SFE; Neutral endopeptidase 24.11; Neprilysin; NEP protein; Enkephalinase; EPN; Common acute lymphocytic leukemia antigen; CD10; CALLA; Atriopeptidase
T05409	FUNCTION	Biologically important in the destruction of opioid peptides such as Met- and Leu-enkephalins by cleavage of a Gly-Phe bond. Able to cleave angiotensin-1, angiotensin-2 and angiotensin 1-9. Involved in the degradation of atrial natriuretic factor (ANF). Displays UV-inducible elastase activity toward skin preelastic and elastic fibers. Thermolysin-like specificity, but is almost confined on acting on polypeptides of up to 30 amino acids.
T05409	PDBSTRUC	6GID; 5JMY; 4CTH; 2YB9; 2QPJ
T05409	BIOCLASS	Peptidase
T05409	ECNUMBER	EC 3.4.24.11
T05409	SEQUENCE	MGKSESQMDITDINTPKPKKKQRWTPLEISLSVLVLLLTIIAVTMIALYATYDDGICKSSDCIKSAARLIQNMDATTEPCTDFFKYACGGWLKRNVIPETSSRYGNFDILRDELEVVLKDVLQEPKTEDIVAVQKAKALYRSCINESAIDSRGGEPLLKLLPDIYGWPVATENWEQKYGASWTAEKAIAQLNSKYGKKVLINLFVGTDDKNSVNHVIHIDQPRLGLPSRDYYECTGIYKEACTAYVDFMISVARLIRQEERLPIDENQLALEMNKVMELEKEIANATAKPEDRNDPMLLYNKMTLAQIQNNFSLEINGKPFSWLNFTNEIMSTVNISITNEEDVVVYAPEYLTKLKPILTKYSARDLQNLMSWRFIMDLVSSLSRTYKESRNAFRKALYGTTSETATWRRCANYVNGNMENAVGRLYVEAAFAGESKHVVEDLIAQIREVFIQTLDDLTWMDAETKKRAEEKALAIKERIGYPDDIVSNDNKLNNEYLELNYKEDEYFENIIQNLKFSQSKQLKKLREKVDKDEWISGAAVVNAFYSSGRNQIVFPAGILQPPFFSAQQSNSLNYGGIGMVIGHEITHGFDDNGRNFNKDGDLVDWWTQQSASNFKEQSQCMVYQYGNFSWDLAGGQHLNGINTLGENIADNGGLGQAYRAYQNYIKKNGEEKLLPGLDLNHKQLFFLNFAQVWCGTYRPEYAVNSIKTDVHSPGNFRIIGTLQNSAEFSEAFHCRKNSYMNPEKKCRVW
T05409	DRUGINFO	D0LJ8C	LCZ696	Approved
T05409	DRUGINFO	D0WF7K	Candoxatril	Phase 3
T05409	DRUGINFO	D09JES	Sampatrilat	Phase 2
T05409	DRUGINFO	D01HDP	SLV 306	Phase 2
T05409	DRUGINFO	D03CPM	SLV-334	Phase 2
T05409	DRUGINFO	D0N1SH	VX-15	Phase 2
T05409	DRUGINFO	D00ERV	Gallopamil	Phase 2
T05409	DRUGINFO	D02HUY	Debio 0827	Phase 1
T05409	DRUGINFO	D04SKM	CART-10 cells	Phase 1
T05409	DRUGINFO	D06WTQ	TD-0714	Phase 1
T05409	DRUGINFO	D08HKK	CD10-CART	Phase 1
T05409	DRUGINFO	D0WY3J	Pfizer 4	Phase 1
T05409	DRUGINFO	D00CLC	SLV-338	Phase 1
T05409	DRUGINFO	D0C1AY	GW-796406	Phase 1
T05409	DRUGINFO	D0K6SM	Ilepatril	Discontinued in Phase 2/3
T05409	DRUGINFO	D01IPI	Gemopatrilat	Discontinued in Phase 2
T05409	DRUGINFO	D02HBW	SCH-32615	Discontinued in Phase 2
T05409	DRUGINFO	D09PYD	CGS-25462	Discontinued in Phase 2
T05409	DRUGINFO	D0H1GF	Sch-34826	Discontinued in Phase 2
T05409	DRUGINFO	D0L2IQ	Fasidotril	Discontinued in Phase 2
T05409	DRUGINFO	D0M0RN	SCH-42495	Discontinued in Phase 2
T05409	DRUGINFO	D0N5HN	M-100240	Discontinued in Phase 2
T05409	DRUGINFO	D04LAQ	Candoxatrilat	Discontinued in Phase 1
T05409	DRUGINFO	D02DLE	CGS-26303	Terminated
T05409	DRUGINFO	D06WBA	SQ-28603	Terminated
T05409	DRUGINFO	D0DS4P	CGS-26393	Terminated
T05409	DRUGINFO	D04MBS	BMS-182657	Terminated
T05409	DRUGINFO	D05UQD	Omapatrilat	Terminated
T05409	DRUGINFO	D0F9BX	GW-660511	Terminated
T05409	DRUGINFO	D0I5QZ	SQ-26332	Terminated
T05409	DRUGINFO	D0KR3X	CGS-30440	Terminated
T05409	DRUGINFO	D0K9YR	SCH-54470	Terminated
T05409	DRUGINFO	D02NQB	LBQ657	Investigative
T05409	DRUGINFO	D0DY1C	9-Mercaptomethyl-10-oxo-azecane-2-carboxylic acid	Investigative
T05409	DRUGINFO	D0K1MA	CGS-314447	Investigative
T05409	DRUGINFO	D0PB5Q	Thiorphan	Investigative
T05409	DRUGINFO	D04DHD	fasidotrilat	Investigative
T05409	DRUGINFO	D09GXF	RB-105	Investigative
T05409	DRUGINFO	D09NAJ	Phosphoramidon	Investigative
T05409	DRUGINFO	D09SZG	[2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala	Investigative
T05409	DRUGINFO	D0N4RO	PMID18078750C1b	Investigative

T29879	TARGETID	T29879
T29879	FORMERID	TTDC00020
T29879	UNIPROID	ITA5_HUMAN
T29879	TARGNAME	Integrin alpha-5 (ITGA5)
T29879	GENENAME	ITGA5
T29879	TARGTYPE	Clinical trial
T29879	SYNONYMS	VLA-5; Integrin alpha-F; Integrin alpha-5 light chain; Integrin alpha-5 heavy chain; Fibronectin receptor subunit alpha; FNRA; CD49e antigen; CD49e; CD49 antigen-like family member E
T29879	FUNCTION	It recognizes the sequence R-G-D in its ligands. ITGA5:ITGB1 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1. ITGA5:ITGB1 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1. ITGA5:ITGB1 is a receptor for IL1B and binding is essential for IL1B signaling. Integrin alpha-5/beta-1 (ITGA5:ITGB1) is a receptor for fibronectin and fibrinogen.
T29879	PDBSTRUC	4WK4; 4WK2; 4WK0; 4WJK; 3VI4
T29879	BIOCLASS	Integrin
T29879	SEQUENCE	MGSRTPESPLHAVQLRWGPRRRPPLLPLLLLLLPPPPRVGGFNLDAEAPAVLSGPPGSFFGFSVEFYRPGTDGVSVLVGAPKANTSQPGVLQGGAVYLCPWGASPTQCTPIEFDSKGSRLLESSLSSSEGEEPVEYKSLQWFGATVRAHGSSILACAPLYSWRTEKEPLSDPVGTCYLSTDNFTRILEYAPCRSDFSWAAGQGYCQGGFSAEFTKTGRVVLGGPGSYFWQGQILSATQEQIAESYYPEYLINLVQGQLQTRQASSIYDDSYLGYSVAVGEFSGDDTEDFVAGVPKGNLTYGYVTILNGSDIRSLYNFSGEQMASYFGYAVAATDVNGDGLDDLLVGAPLLMDRTPDGRPQEVGRVYVYLQHPAGIEPTPTLTLTGHDEFGRFGSSLTPLGDLDQDGYNDVAIGAPFGGETQQGVVFVFPGGPGGLGSKPSQVLQPLWAASHTPDFFGSALRGGRDLDGNGYPDLIVGSFGVDKAVVYRGRPIVSASASLTIFPAMFNPEERSCSLEGNPVACINLSFCLNASGKHVADSIGFTVELQLDWQKQKGGVRRALFLASRQATLTQTLLIQNGAREDCREMKIYLRNESEFRDKLSPIHIALNFSLDPQAPVDSHGLRPALHYQSKSRIEDKAQILLDCGEDNICVPDLQLEVFGEQNHVYLGDKNALNLTFHAQNVGEGGAYEAELRVTAPPEAEYSGLVRHPGNFSSLSCDYFAVNQSRLLVCDLGNPMKAGASLWGGLRFTVPHLRDTKKTIQFDFQILSKNLNNSQSDVVSFRLSVEAQAQVTLNGVSKPEAVLFPVSDWHPRDQPQKEEDLGPAVHHVYELINQGPSSISQGVLELSCPQALEGQQLLYVTRVTGLNCTTNHPINPKGLELDPEGSLHHQQKREAPSRSSASSGPQILKCPEAECFRLRCELGPLHQQESQSLQLHFRVWAKTFLQREHQPFSLQCEAVYKALKMPYRILPRQLPQKERQVATAVQWTKAEGSYGVPLWIIILAILFGLLLLGLLIYILYKLGFFKRSLPYGTAMEKAQLKPPATSDA
T29879	DRUGINFO	D0ZT4J	JSM 6427	Phase 1
T29879	DRUGINFO	D0F9QP	GW-559090	Discontinued in Phase 2
T29879	DRUGINFO	D01VSK	TR-14531	Discontinued in Phase 1
T29879	DRUGINFO	D03EIC	ZD-7349	Discontinued in Phase 1
T29879	DRUGINFO	D0I5PM	DW-908e	Discontinued in Phase 1
T29879	DRUGINFO	D0B4JU	C(-GRGDfL-)	Investigative

T21669	TARGETID	T21669
T21669	FORMERID	TTDI02088
T21669	UNIPROID	GSTP1_HUMAN
T21669	TARGNAME	Glutathione S-transferase P (GSTP1)
T21669	GENENAME	GSTP1
T21669	TARGTYPE	Clinical trial
T21669	SYNONYMS	GSTP11; GSTP1-1; GST3; GST classpi; GST class-pi; FAEES3
T21669	FUNCTION	Regulates negatively CDK5 activity via p25/p35 translocation to prevent neurodegeneration. Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.
T21669	PDBSTRUC	9GSS; 8GSS; 7GSS; 6GSS; 6AP9
T21669	BIOCLASS	Alkyl aryl transferase
T21669	ECNUMBER	EC 2.5.1.18
T21669	SEQUENCE	MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ
T21669	DRUGINFO	D0A9SA	Canfosfamide	Phase 3
T21669	DRUGINFO	D0F5VD	Ezatiostat	Phase 2

T25703	TARGETID	T25703
T25703	FORMERID	TTDC00134
T25703	UNIPROID	HMOX1_HUMAN
T25703	TARGNAME	Heme oxygenase 1 (HMOX1)
T25703	GENENAME	HMOX1
T25703	TARGTYPE	Clinical trial
T25703	SYNONYMS	HO1; HO-1; HO
T25703	FUNCTION	Heme oxygenase cleaves the heme ring at the alpha methene bridge to form biliverdin. Biliverdin is subsequently converted to bilirubin by biliverdin reductase. Under physiological conditions, the activity of heme oxygenase is highest in the spleen, where senescent erythrocytes are sequestrated and destroyed. Exhibits cytoprotective effects since excess of free heme sensitizes cells to undergo apoptosis.
T25703	PDBSTRUC	6EHA; 5BTQ; 4WD4; 3TGM; 3K4F
T25703	BIOCLASS	Paired donor oxygen oxidoreductase
T25703	ECNUMBER	EC 1.14.14.18
T25703	SEQUENCE	MERPQPDSMPQDLSEALKEATKEVHTQAENAEFMRNFQKGQVTRDGFKLVMASLYHIYVALEEEIERNKESPVFAPVYFPEELHRKAALEQDLAFWYGPRWQEVIPYTPAMQRYVKRLHEVGRTEPELLVAHAYTRYLGDLSGGQVLKKIAQKALDLPSSGEGLAFFTFPNIASATKFKQLYRSRMNSLEMTPAVRQRVIEEAKTAFLLNIQLFEELQELLTHDTKDQSPSRAPGLRQRASNKVQDSAPVETPRGKPPLNTRSQAPLLRWVLTLSFLVATVAVGLYAM
T25703	DRUGINFO	D02JAY	Stannsoporfin	Phase 2
T25703	DRUGINFO	D02AVZ	2-Phenylheme	Investigative
T25703	DRUGINFO	D06SCF	Biliverdine Ix Alpha	Investigative
T25703	DRUGINFO	D06UNX	Verdoheme	Investigative
T25703	DRUGINFO	D0HX0D	Tin protoporphyrin	Investigative
T25703	DRUGINFO	D0K1NM	1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone	Investigative
T25703	DRUGINFO	D0S8UN	12-Phenylheme	Investigative
T25703	DRUGINFO	D0W7LK	2-Propanol, Isopropanol	Investigative
T25703	DRUGINFO	D06EWG	Formic Acid	Investigative
T25703	DRUGINFO	D0UU1I	Heme	Investigative

T77594	TARGETID	T77594
T77594	FORMERID	TTDI02087
T77594	UNIPROID	BIP_HUMAN
T77594	TARGNAME	Endoplasmic reticulum chaperone BiP (HSPA5)
T77594	GENENAME	HSPA5
T77594	TARGTYPE	Clinical trial
T77594	SYNONYMS	Immunoglobulin heavy chainbinding protein; Immunoglobulin heavy chain-binding protein; Heat shock protein family A member 5; Heat shock protein 70 family protein 5; Heat shock 70 kDa protein 5; HSP70 family protein 5; GRP78; GRP-78; Endoplasmic reticulum lumenal Ca(2+)binding protein grp78; Binding-immunoglobulin protein; BiP; 78 kDa glucose-regulated protein
T77594	FUNCTION	Involved in the correct folding of proteins and degradation of misfolded proteins via its interaction with DNAJC10/ERdj5, probably to facilitate the release of DNAJC10/ERdj5 from its substrate. Acts as a key repressor of the ERN1/IRE1-mediated unfolded protein response (UPR). In the unstressed endoplasmic reticulum, recruited by DNAJB9/ERdj4 to the luminal region of ERN1/IRE1, leading to disrupt the dimerization of ERN1/IRE1, thereby inactivating ERN1/IRE1. Accumulation of misfolded protein in the endoplasmic reticulum causes release of HSPA5/BiP from ERN1/IRE1, allowing homodimerization and subsequent activation of ERN1/IRE1. Plays an auxiliary role in post-translational transport of small presecretory proteins across endoplasmic reticulum (ER). May function as an allosteric modulator for SEC61 channel-forming translocon complex, likely cooperating with SEC62 to enable the productive insertion of these precursors into SEC61 channel. Appears to specifically regulate translocation of precursors having inhibitory residues in their mature region that weaken channel gating. Endoplasmic reticulum chaperone that plays a key role in protein folding and quality control in the endoplasmic reticulum lumen.
T77594	PDBSTRUC	6DFO; 6DFM; 6CZ1; 6ASY; 5F2R
T77594	BIOCLASS	Acid anhydride hydrolase
T77594	ECNUMBER	EC 3.6.4.10
T77594	SEQUENCE	MKLSLVAAMLLLLSAARAEEEDKKEDVGTVVGIDLGTTYSCVGVFKNGRVEIIANDQGNRITPSYVAFTPEGERLIGDAAKNQLTSNPENTVFDAKRLIGRTWNDPSVQQDIKFLPFKVVEKKTKPYIQVDIGGGQTKTFAPEEISAMVLTKMKETAEAYLGKKVTHAVVTVPAYFNDAQRQATKDAGTIAGLNVMRIINEPTAAAIAYGLDKREGEKNILVFDLGGGTFDVSLLTIDNGVFEVVATNGDTHLGGEDFDQRVMEHFIKLYKKKTGKDVRKDNRAVQKLRREVEKAKRALSSQHQARIEIESFYEGEDFSETLTRAKFEELNMDLFRSTMKPVQKVLEDSDLKKSDIDEIVLVGGSTRIPKIQQLVKEFFNGKEPSRGINPDEAVAYGAAVQAGVLSGDQDTGDLVLLDVCPLTLGIETVGGVMTKLIPRNTVVPTKKSQIFSTASDNQPTVTIKVYEGERPLTKDNHLLGTFDLTGIPPAPRGVPQIEVTFEIDVNGILRVTAEDKGTGNKNKITITNDQNRLTPEEIERMVNDAEKFAEEDKKLKERIDTRNELESYAYSLKNQIGDKEKLGGKLSSEDKETMEKAVEEKIEWLESHQDADIEDFKAKKKELEEIVQPIISKLYGSAGPPPTGEEDTAEKDEL
T77594	DRUGINFO	D06PZC	SAM-6	Phase 1
T77594	DRUGINFO	D0Q4LG	IT-139	Phase 1
T77594	DRUGINFO	D08SIT	NKP-1339	Phase 1

T50594	TARGETID	T50594
T50594	FORMERID	TTDNC00498
T50594	UNIPROID	PIM1_HUMAN
T50594	TARGNAME	Serine/threonine-protein kinase pim-1 (PIM1)
T50594	GENENAME	PIM1
T50594	TARGTYPE	Clinical trial
T50594	SYNONYMS	Pim-1 proto-oncogene, serine/threonine kinase; PIM
T50594	FUNCTION	Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity. The stabilization of MYC exerted by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1. Phosphorylation of MAP3K5, an other proapoptotic protein, by PIM1, significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis. Stimulates cell cycle progression at the G1-S and G2-M transitions by phosphorylation of CDC25A and CDC25C. Phosphorylation of CDKN1A, a regulator of cell cycle progression at G1, results in the relocation of CDKN1A to the cytoplasm and enhanced CDKN1A protein stability. Promote cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression, CDKN1B, at both transcriptional and post-translational levels. Phosphorylation of CDKN1B,induces 14-3-3-proteins binding, nuclear export and proteasome-dependent degradation. May affect the structure or silencing of chromatin by phosphorylating HP1 gamma/CBX3. Acts also as a regulator of homing and migration of bone marrow cells involving functional interaction with the CXCL12-CXCR4 signaling axis. Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis.
T50594	PDBSTRUC	6QXK; 6NO9; 6MT0; 6BSK; 6AYD
T50594	BIOCLASS	Kinase
T50594	ECNUMBER	EC 2.7.11.1
T50594	SEQUENCE	MLLSKINSLAHLRAAPCNDLHATKLAPGKEKEPLESQYQVGPLLGSGGFGSVYSGIRVSDNLPVAIKHVEKDRISDWGELPNGTRVPMEVVLLKKVSSGFSGVIRLLDWFERPDSFVLILERPEPVQDLFDFITERGALQEELARSFFWQVLEAVRHCHNCGVLHRDIKDENILIDLNRGELKLIDFGSGALLKDTVYTDFDGTRVYSPPEWIRYHRYHGRSAAVWSLGILLYDMVCGDIPFEHDEEIIRGQVFFRQRVSSECQHLIRWCLALRPSDRPTFEEIQNHPWMQDVLLPQETAEIHLHSLSPGPSK
T50594	DRUGINFO	D0X8ID	SEL-24	Phase 1/2
T50594	DRUGINFO	D00YDN	CXR-1002	Phase 1
T50594	DRUGINFO	D00BFF	Benzothiazine derivative 1	Patented
T50594	DRUGINFO	D0Q1HF	NCGC00167772-01	Investigative
T50594	DRUGINFO	DAJ3D2	SMI-4a	Investigative
T50594	DRUGINFO	D06HVH	PMID22136433C20	Investigative
T50594	DRUGINFO	D06UKS	PMID21982499C14k	Investigative
T50594	DRUGINFO	D04IMY	leucettine L41	Investigative

T15334	TARGETID	T15334
T15334	FORMERID	TTDC00124
T15334	UNIPROID	CETP_HUMAN
T15334	TARGNAME	Cholesteryl ester transfer protein (CETP)
T15334	GENENAME	CETP
T15334	TARGTYPE	Clinical trial
T15334	SYNONYMS	Lipid transfer protein I; Cholesterol ester transfer protein
T15334	FUNCTION	Allows the net movement of cholesteryl ester from high density lipoproteins/HDL to triglyceride-rich very low density lipoproteins/VLDL, and the equimolar transport of triglyceride from VLDL to HDL. Regulates the reverse cholesterol transport, by which excess cholesterol is removed from peripheral tissues and returned to the liver for elimination. Involved in the transfer of neutral lipids, including cholesteryl ester and triglyceride, among lipoprotein particles.
T15334	PDBSTRUC	4F2A; 4EWS; 2OBD
T15334	BIOCLASS	Bactericidal permeability increasing protein
T15334	SEQUENCE	MLAATVLTLALLGNAHACSKGTSHEAGIVCRITKPALLVLNHETAKVIQTAFQRASYPDITGEKAMMLLGQVKYGLHNIQISHLSIASSQVELVEAKSIDVSIQNVSVVFKGTLKYGYTTAWWLGIDQSIDFEIDSAIDLQINTQLTCDSGRVRTDAPDCYLSFHKLLLHLQGEREPGWIKQLFTNFISFTLKLVLKGQICKEINVISNIMADFVQTRAASILSDGDIGVDISLTGDPVITASYLESHHKGHFIYKNVSEDLPLPTFSPTLLGDSRMLYFWFSERVFHSLAKVAFQDGRLMLSLMGDEFKAVLETWGFNTNQEIFQEVVGGFPSQAQVTVHCLKMPKISCQNKGVVVNSSVMVKFLFPRPDQQHSVAYTFEEDIVTTVQASYSKKKLFLSLLDFQITPKTVSNLTESSSESVQSFLQSMITAVGIPEVMSRLEVVFTALMNSKGVSLFDIINPEIITRDGFLLLQMDFGFPEHLLVDFLQSLS
T15334	DRUGINFO	D02XXN	Evacetrapib	Phase 3
T15334	DRUGINFO	D05SSC	Dalcetrapib	Phase 3
T15334	DRUGINFO	D07HLS	Anacetrapib	Phase 3
T15334	DRUGINFO	D04ZBU	JTT-302	Phase 2
T15334	DRUGINFO	D07UJA	DRL-17822	Phase 2
T15334	DRUGINFO	D0G7MM	TA-8995	Phase 2
T15334	DRUGINFO	D00JQE	BAY-60-5521	Phase 1
T15334	DRUGINFO	D07GDN	Torcetrapib	Discontinued in Phase 2
T15334	DRUGINFO	D0J4KC	CETi-1	Discontinued in Phase 2
T15334	DRUGINFO	D03MAD	CP-800569	Discontinued in Phase 1
T15334	DRUGINFO	D0B0UN	R7232	Discontinued in Phase 1
T15334	DRUGINFO	D0F8XI	DS-1442	Discontinued in Phase 1
T15334	DRUGINFO	D0K3GU	PF-3185043	Discontinued in Phase 1
T15334	DRUGINFO	D05QXT	BAY-38-1315	Preclinical
T15334	DRUGINFO	D04VCE	TETRAHYDROQUINOLINE A	Investigative
T15334	DRUGINFO	D04WPM	SC-795	Investigative
T15334	DRUGINFO	D05TQP	NSC-89508	Investigative
T15334	DRUGINFO	D0C9FK	TETRAHYDROQUINOLINE B	Investigative
T15334	DRUGINFO	D0M1TF	NSC-40331	Investigative

T11309	TARGETID	T11309
T11309	FORMERID	TTDR00451
T11309	UNIPROID	CCL2_HUMAN
T11309	TARGNAME	Monocyte chemotactic and activating factor (CCL2)
T11309	GENENAME	CCL2
T11309	TARGTYPE	Clinical trial
T11309	SYNONYMS	Small-inducible cytokine A2; SCYA2; Monocyte secretory protein JE; Monocyte chemotactic protein 1; Monocyte chemoattractant protein-1; Monocyte Chemoattractant Protein 1; MCP1; MCP-1; MCAF; HC11; C-C motif chemokine 2
T11309	FUNCTION	Signals through binding and activation of CCR2 and induces a strong chemotactic response and mobilization of intracellular calcium ions. Exhibits a chemotactic activity for monocytes and basophils but not neutrophils or eosinophils. May be involved in the recruitment of monocytes into the arterial wall during the disease process of atherosclerosis. Acts as a ligand for C-C chemokine receptor CCR2.
T11309	PDBSTRUC	4ZK9; 4R8I; 4DN4; 3IFD; 2NZ1
T11309	BIOCLASS	Cytokine: CC chemokine
T11309	SEQUENCE	MKVSAALLCLLLIAATFIPQGLAQPDAINAPVTCCYNFTNRKISVQRLASYRRITSSKCPKEAVIFKTIVAKEICADPKQKWVQDSMDHLDKQTQTPKT
T11309	DRUGINFO	D0XM4G	Bindarit	Phase 3
T11309	DRUGINFO	D06WUK	Carlumab	Phase 2
T11309	DRUGINFO	D09LKU	NOX-E36	Phase 2
T11309	DRUGINFO	D07HZP	CNTO888	Phase 1
T11309	DRUGINFO	D04MYO	ABN-912	Discontinued in Phase 1
T11309	DRUGINFO	D0V9ND	MCP-1	Preclinical
T11309	DRUGINFO	D0X4SI	RS-504393	Preclinical

T39977	TARGETID	T39977
T39977	FORMERID	TTDC00103
T39977	UNIPROID	MIF_HUMAN
T39977	TARGNAME	Macrophage migration inhibitory factor (MIF)
T39977	GENENAME	MIF
T39977	TARGTYPE	Clinical trial
T39977	SYNONYMS	Phenylpyruvate tautomerase; MMIF; L-dopachrome tautomerase; L-dopachrome isomerase; Glycosylation-inhibiting factor; GLIF; GIF
T39977	FUNCTION	Involved in the innate immune response to bacterial pathogens. The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense. Counteracts the anti-inflammatory activity of glucocorticoids. Has phenylpyruvate tautomerase and dopachrome tautomerase activity (in vitro), but the physiological substrate is not known. It is not clear whether the tautomerase activity has any physiological relevance, and whether it is important for cytokine activity. Pro-inflammatory cytokine.
T39977	PDBSTRUC	6FVH; 6FVE; 6CBH; 6CBG; 6CBF
T39977	BIOCLASS	Intramolecular oxidoreductase
T39977	ECNUMBER	EC 5.3.2.1
T39977	SEQUENCE	MPMFIVNTNVPRASVPDGFLSELTQQLAQATGKPPQYIAVHVVPDQLMAFGGSSEPCALCSLHSIGKIGGAQNRSYSKLLCGLLAERLRISPDRVYINYYDMNAANVGWNNSTFA
T39977	DRUGINFO	D0O7IZ	Anti-MIF antibodies	Phase 4
T39977	DRUGINFO	D0V9EN	3,4-Dihydroxycinnamic Acid	Phase 4
T39977	DRUGINFO	D04KKT	ISO-1	Phase 1
T39977	DRUGINFO	D0F3II	COR100140	Preclinical
T39977	DRUGINFO	D00YTS	AVP-13546	Investigative
T39977	DRUGINFO	D01SWJ	AVP-13748	Investigative
T39977	DRUGINFO	D0NN3G	4-HYDROXYBENZALDEHYDE O-(CYCLOHEXYLCARBONYL)OXIME	Investigative
T39977	DRUGINFO	D0W1JY	NAPQI	Investigative
T39977	DRUGINFO	D0A6HS	6-HYDROXY-1,3-BENZOTHIAZOLE-2-SULFONAMIDE	Investigative
T39977	DRUGINFO	D0G6RI	4-hydroxyphenylpyruvic acid	Investigative

T83797	TARGETID	T83797
T83797	FORMERID	TTDC00194
T83797	UNIPROID	HGF_HUMAN
T83797	TARGNAME	Hepatocyte growth factor (HGF)
T83797	GENENAME	HGF
T83797	TARGTYPE	Clinical trial
T83797	SYNONYMS	Scatter factor; SF; Hepatopoietin-A; Hepatopoeitin A; HPTA
T83797	FUNCTION	Activating ligand for the receptor tyrosine kinase MET by binding to it and promoting its dimerization. Potent mitogen for mature parenchymal hepatocyte cells, seems to be a hepatotrophic factor, and acts as a growth factor for a broad spectrum of tissues and cell types.
T83797	PDBSTRUC	5CT3; 5CT2; 5CT1; 5CSQ; 5CS9
T83797	BIOCLASS	Peptidase
T83797	SEQUENCE	MWVTKLLPALLLQHVLLHLLLLPIAIPYAEGQRKRRNTIHEFKKSAKTTLIKIDPALKIKTKKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDLYENKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEHSFLPSSYRGKDLQENYCRNPRGEEGGPWCFTSNPEVRYEVCDIPQCSEVECMTCNGESYRGLMDHTESGKICQRWDHQTPHRHKFLPERYPDKGFDDNYCRNPDGQPRPWCYTLDPHTRWEYCAIKTCADNTMNDTDVPLETTECIQGQGEGYRGTVNTIWNGIPCQRWDSQYPHEHDMTPENFKCKDLRENYCRNPDGSESPWCFTTDPNIRVGYCSQIPNCDMSHGQDCYRGNGKNYMGNLSQTRSGLTCSMWDKNMEDLHRHIFWEPDASKLNENYCRNPDDDAHGPWCYTGNPLIPWDYCPISRCEGDTTPTIVNLDHPVISCAKTKQLRVVNGIPTRTNIGWMVSLRYRNKHICGGSLIKESWVLTARQCFPSRDLKDYEAWLGIHDVHGRGDEKCKQVLNVSQLVYGPEGSDLVLMKLARPAVLDDFVSTIDLPNYGCTIPEKTSCSVYGWGYTGLINYDGLLRVAHLYIMGNEKCSQHHRGKVTLNESEICAGAEKIGSGPCEGDYGGPLVCEQHKMRMVLGVIVPGRGCAIPNRPGIFVRVAYYAKWIHKIILTYKVPQS
T83797	DRUGINFO	D0D4OS	VM-202	Phase 3
T83797	DRUGINFO	D5E2KR	ANG-3777	Phase 3
T83797	DRUGINFO	D9CI7V	Donaperminogene seltoplasmid	Phase 3
T83797	DRUGINFO	D03UBW	Ficlatuzumab	Phase 2
T83797	DRUGINFO	DNHW41	Collategene	Phase 2
T83797	DRUGINFO	D0ME7Q	MP0250	Phase 1/2
T83797	DRUGINFO	D0H9HT	TAK-701	Phase 1
T83797	DRUGINFO	D0P4KU	ABI-011	Phase 1
T83797	DRUGINFO	D07AOO	Rilotumumab	Discontinued in Phase 2
T83797	DRUGINFO	D06VYT	O2-Sulfo-Glucuronic Acid	Investigative
T83797	DRUGINFO	D0B0SV	N,O6-Disulfo-Glucosamine	Investigative

T19579	TARGETID	T19579
T19579	FORMERID	TTDC00026
T19579	UNIPROID	IL2RB_HUMAN
T19579	TARGNAME	Interleukin 2 receptor beta (IL2RB)
T19579	GENENAME	IL2RB
T19579	TARGTYPE	Clinical trial
T19579	SYNONYMS	P70-75; Interleukin-2 receptor subunit beta; Interleukin-15 receptor subunit beta; IL15RB; IL-2RB; IL-2R subunit beta; IL-2 receptor subunit beta; IL-2 receptor; High affinity IL-2 receptor subunit beta; CD122
T19579	FUNCTION	Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2. Probably in association with IL15RA, involved in the stimulation of neutrophil phagocytosis by IL15.
T19579	PDBSTRUC	6E8K; 5M5E; 4GS7; 3QAZ; 2ERJ
T19579	BIOCLASS	Cytokine receptor
T19579	SEQUENCE	MAAPALSWRLPLLILLLPLATSWASAAVNGTSQFTCFYNSRANISCVWSQDGALQDTSCQVHAWPDRRRWNQTCELLPVSQASWACNLILGAPDSQKLTTVDIVTLRVLCREGVRWRVMAIQDFKPFENLRLMAPISLQVVHVETHRCNISWEISQASHYFERHLEFEARTLSPGHTWEEAPLLTLKQKQEWICLETLTPDTQYEFQVRVKPLQGEFTTWSPWSQPLAFRTKPAALGKDTIPWLGHLLVGLSGAFGFIILVYLLINCRNTGPWLKKVLKCNTPDPSKFFSQLSSEHGGDVQKWLSSPFPSSSFSPGGLAPEISPLEVLERDKVTQLLLQQDKVPEPASLSSNHSLTSCFTNQGYFFFHLPDALEIEACQVYFTYDPYSEEDPDEGVAGAPTGSSPQPLQPLSGEDDAYCTFPSRDDLLLFSPSLLGGPSPPSTAPGGSGAGEERMPPSLQERVPRDWDPQPLGPPTPGVPDLVDFQPPPELVLREAGEEVPDAGPREGVSFPWSRPPGQGEFRALNARLPLNTDAYLSLQELQGQDPTHLV
T19579	DRUGINFO	D02QQE	NKTR 214	Phase 3
T19579	DRUGINFO	D5ISZ1	NKTR-214	Phase 3
T19579	DRUGINFO	D05YFL	AFTVac	Phase 2
T19579	DRUGINFO	D0U0RJ	Leukocyte interleukin	Phase 1
T19579	DRUGINFO	D06KWH	DAB-486-IL-2	Investigative

T72335	TARGETID	T72335
T72335	FORMERID	TTDR01027
T72335	UNIPROID	LEF_BACAN
T72335	TARGNAME	Bacterial Lethal factor (Bact lef)
T72335	GENENAME	Bact lef
T72335	TARGTYPE	Clinical trial
T72335	SYNONYMS	lef; Anthrax lethal toxin endopeptidase component; Anthrax lethal factor; ALF
T72335	FUNCTION	One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. LF is the lethal factor that, when associated with PA, causes death. LF is not toxic by itself. It is a protease that cleaves the N-terminal of most dual specificity mitogen-activated protein kinase kinases (MAPKKs or MAP2Ks) (except for MAP2K5). Cleavage invariably occurs within the N-terminal proline-rich region preceding the kinase domain, thus disrupting a sequence involved in directing specific protein-protein interactions necessary for the assembly of signaling complexes. There may be other cytosolic targets of LF involved in cytotoxicity. The proteasome may mediate a toxic process initiated by LF in the cell cytosol involving degradation of unidentified molecules that are essential for macrophage homeostasis. This is an early step in LeTx intoxication, but it is downstream of the cleavage by LF of MEK1 or other putative substrates.
T72335	PDBSTRUC	5D1U; 5D1T; 5D1S; 4XM8; 4XM7
T72335	BIOCLASS	Peptidase
T72335	ECNUMBER	EC 3.4.24.83
T72335	SEQUENCE	MNIKKEFIKVISMSCLVTAITLSGPVFIPLVQGAGGHGDVGMHVKEKEKNKDENKRKDEERNKTQEEHLKEIMKHIVKIEVKGEEAVKKEAAEKLLEKVPSDVLEMYKAIGGKIYIVDGDITKHISLEALSEDKKKIKDIYGKDALLHEHYVYAKEGYEPVLVIQSSEDYVENTEKALNVYYEIGKILSRDILSKINQPYQKFLDVLNTIKNASDSDGQDLLFTNQLKEHPTDFSVEFLEQNSNEVQEVFAKAFAYYIEPQHRDVLQLYAPEAFNYMDKFNEQEINLSLEELKDQRMLARYEKWEKIKQHYQHWSDSLSEEGRGLLKKLQIPIEPKKDDIIHSLSQEEKELLKRIQIDSSDFLSTEEKEFLKKLQIDIRDSLSEEEKELLNRIQVDSSNPLSEKEKEFLKKLKLDIQPYDINQRLQDTGGLIDSPSINLDVRKQYKRDIQNIDALLHQSIGSTLYNKIYLYENMNINNLTATLGADLVDSTDNTKINRGIFNEFKKNFKYSISSNYMIVDINERPALDNERLKWRIQLSPDTRAGYLENGKLILQRNIGLEIKDVQIIKQSEKEYIRIDAKVVPKSKIDTKIQEAQLNINQEWNKALGLPKYTKLITFNVHNRYASNIVESAYLILNEWKNNIQSDLIKKVTNYLVDGNGRFVFTDITLPNIAEQYTHQDEIYEQVHSKGLYVPESRSILLHGPSKGVELRNDSEGFIHEFGHAVDDYAGYLLDKNQSDLVTNSKKFIDIFKEEGSNLTSYGRTNEAEFFAEAFRLMHSTDHAERLKVQKNAPKTFQFINDQIKFIINS
T72335	DRUGINFO	D09SZY	IQ-DAA	Phase 1
T72335	DRUGINFO	D0T9HG	GM6001	Discontinued in Phase 2
T72335	DRUGINFO	D01MBG	N-(Sulfanylacetyl)Tyrosylprolylmethioninamide	Investigative
T72335	DRUGINFO	D01QWL	N-(3,4-dihydroxybenzyl)oleamide	Investigative
T72335	DRUGINFO	D03QAN	N,N'-Bis(4-Amino-2-Methylquinolin-6-Yl)Urea	Investigative
T72335	DRUGINFO	D0EL3A	N-hydroxy-4-(oleamidomethyl)benzamide	Investigative
T72335	DRUGINFO	D0M2KQ	N-(3,4,5-trihydroxyphenethyl)oleamide	Investigative
T72335	DRUGINFO	D0M4IF	N-oleoyl-dopamine	Investigative
T72335	DRUGINFO	D0MV0W	GNF-PF-600	Investigative
T72335	DRUGINFO	D0SU7B	N-hydroxy-4-(2-oleamidoethyl)benzamide	Investigative
T72335	DRUGINFO	D0X1JG	3-(2,5-dimethyl-1H-pyrrol-1-yl)benzoic acid	Investigative
T72335	DRUGINFO	D0J5VK	NSC-622445	Investigative
T72335	DRUGINFO	D0A4TC	MMI270	Investigative
T72335	DRUGINFO	D0TO6S	Bisindolylmaleimide-I	Investigative

T00938	TARGETID	T00938
T00938	FORMERID	TTDI02203
T00938	UNIPROID	TYRP1_HUMAN
T00938	TARGNAME	Melanoma antigen gp75 (TYRP1)
T00938	GENENAME	TYRP1
T00938	TARGTYPE	Clinical trial
T00938	SYNONYMS	Tyrosinaserelated protein 1; TYRP1; TRP; Glycoprotein 75; Catalase B; 5,6dihydroxyindole2carboxylic acid oxidase
T00938	FUNCTION	Oxidation of 5,6-dihydroxyindole-2-carboxylic acid (DHICA)into indole-5,6-quinone-2-carboxylic acid. May regulate or influence the type of melanin synthesized.
T00938	PDBSTRUC	5M8T; 5M8S; 5M8R; 5M8Q; 5M8P
T00938	BIOCLASS	Tyrosinase
T00938	ECNUMBER	EC 1.14.18.-
T00938	SEQUENCE	MSAPKLLSLGCIFFPLLLFQQARAQFPRQCATVEALRSGMCCPDLSPVSGPGTDRCGSSSGRGRCEAVTADSRPHSPQYPHDGRDDREVWPLRFFNRTCHCNGNFSGHNCGTCRPGWRGAACDQRVLIVRRNLLDLSKEEKNHFVRALDMAKRTTHPLFVIATRRSEEILGPDGNTPQFENISIYNYFVWTHYYSVKKTFLGVGQESFGEVDFSHEGPAFLTWHRYHLLRLEKDMQEMLQEPSFSLPYWNFATGKNVCDICTDDLMGSRSNFDSTLISPNSVFSQWRVVCDSLEDYDTLGTLCNSTEDGPIRRNPAGNVARPMVQRLPEPQDVAQCLEVGLFDTPPFYSNSTNSFRNTVEGYSDPTGKYDPAVRSLHNLAHLFLNGTGGQTHLSPNDPIFVLLHTFTDAVFDEWLRRYNADISTFPLENAPIGHNRQYNMVPFWPPVTNTEMFVTAPDNLGYTYEIQWPSREFSVPEIIAIAVVGALLLVALIFGTASYLIRARRSMDEANQPLLTDQYQCYAEEYEKLQNPNQSVV
T00938	DRUGINFO	D0TI3R	FLX-787	Phase 2
T00938	DRUGINFO	D05WQT	Flanvotumab	Phase 1

T04902	TARGETID	T04902
T04902	FORMERID	TTDR00505
T04902	UNIPROID	CAN2_HUMAN
T04902	TARGNAME	Calpain-2 (CAPN2)
T04902	GENENAME	CAPN2
T04902	TARGTYPE	Clinical trial
T04902	SYNONYMS	Millimolar-calpain; M-calpain; Calpain-2 large subunit; Calpain-2 catalytic subunit; Calpain large polypeptide L2; Calpain M-type; Calcium-activated neutral proteinase 2; Calcium-activated neutral proteinase; CANPL2; CANP 2; CANP
T04902	FUNCTION	Proteolytically cleaves MYOC at 'Arg-226'. Proteolytically cleaves CPEB3 following neuronal stimulation which abolishes CPEB3 translational repressor activity, leading to translation of CPEB3 target mRNAs. Calcium-regulated non-lysosomal thiol-protease which catalyzes limited proteolysis of substrates involved in cytoskeletal remodeling and signal transduction.
T04902	BIOCLASS	Peptidase
T04902	ECNUMBER	EC 3.4.22.53
T04902	SEQUENCE	MAGIAAKLAKDREAAEGLGSHDRAIKYLNQDYEALRNECLEAGTLFQDPSFPAIPSALGFKELGPYSSKTRGIEWKRPTEICADPQFIIGGATRTDICQGALGDCWLLAAIASLTLNEEILARVVPLNQSFQENYAGIFHFQFWQYGEWVEVVVDDRLPTKDGELLFVHSAEGSEFWSALLEKAYAKINGCYEALSGGATTEGFEDFTGGIAEWYELKKPPPNLFKIIQKALQKGSLLGCSIDITSAADSEAITFQKLVKGHAYSVTGAEEVESNGSLQKLIRIRNPWGEVEWTGRWNDNCPSWNTIDPEERERLTRRHEDGEFWMSFSDFLRHYSRLEICNLTPDTLTSDTYKKWKLTKMDGNWRRGSTAGGCRNYPNTFWMNPQYLIKLEEEDEDEEDGESGCTFLVGLIQKHRRRQRKMGEDMHTIGFGIYEVPEELSGQTNIHLSKNFFLTNRARERSDTFINLREVLNRFKLPPGEYILVPSTFEPNKDGDFCIRVFSEKKADYQAVDDEIEANLEEFDISEDDIDDGFRRLFAQLAGEDAEISAFELQTILRRVLAKRQDIKSDGFSIETCKIMVDMLDSDGSGKLGLKEFYILWTKIQKYQKIYREIDVDRSGTMNSYEMRKALEEAGFKMPCQLHQVIVARFADDQLIIDFDNFVRCLVRLETLFKIFKQLDPENTGTIELDLISWLCFSVL
T04902	DRUGINFO	D03NLQ	ABT-957	Phase 1
T04902	DRUGINFO	D03ZOR	Epoxysuccinate derivative 9	Patented
T04902	DRUGINFO	D05LZV	Epoxysuccinate derivative 4	Patented
T04902	DRUGINFO	D06JCF	Carboxamide derivative 7	Patented
T04902	DRUGINFO	D08CGI	Epoxysuccinate derivative 7	Patented
T04902	DRUGINFO	D09CGG	Carboxamide derivative 10	Patented
T04902	DRUGINFO	D0C4YX	Carboxamide derivative 11	Patented
T04902	DRUGINFO	D0CO2G	Carboxamide derivative 8	Patented
T04902	DRUGINFO	D0FG4C	Epoxysuccinate derivative 10	Patented
T04902	DRUGINFO	D0H0LO	Carboxamide derivative 6	Patented
T04902	DRUGINFO	D0HZ1Z	Epoxysuccinate derivative 2	Patented
T04902	DRUGINFO	D0IO8Y	Epoxysuccinate derivative 8	Patented
T04902	DRUGINFO	D0KA3L	Epoxysuccinate derivative 6	Patented
T04902	DRUGINFO	D0L3RN	Epoxysuccinate derivative 5	Patented
T04902	DRUGINFO	D0OI2F	Epoxysuccinate derivative 1	Patented
T04902	DRUGINFO	D0U2JU	5-azolone derivative 1	Patented
T04902	DRUGINFO	D0WS4U	Epoxysuccinate derivative 3	Patented
T04902	DRUGINFO	D0X9DL	Carboxamide derivative 9	Patented
T04902	DRUGINFO	D0XC2D	Carboxamide derivative 5	Patented
T04902	DRUGINFO	D06LLT	PMID25399719-Compound-17	Patented
T04902	DRUGINFO	D0QQ1J	BITHIONOL	Withdrawn from market
T04902	DRUGINFO	D0NJ1A	Aloxistatin	Discontinued in Phase 3
T04902	DRUGINFO	D00QHT	AK-295	Terminated
T04902	DRUGINFO	D06VTU	SJA-6017	Terminated
T04902	DRUGINFO	D0G5ZE	MDL-28170	Terminated
T04902	DRUGINFO	D00JPH	N-(1-Benzyl-2-oxo-ethyl)-benzamide	Investigative
T04902	DRUGINFO	D01HUQ	3-(1H-Pyrrol-3-yl)-propionamide	Investigative
T04902	DRUGINFO	D03GAN	A-558693	Investigative
T04902	DRUGINFO	D03UYO	PMID8831774C19	Investigative
T04902	DRUGINFO	D07ZYE	PMID20690647C4b	Investigative
T04902	DRUGINFO	D08TCW	Calpastatin	Investigative
T04902	DRUGINFO	D0G0HK	GNF-PF-4453	Investigative
T04902	DRUGINFO	D0L2AO	DIHYDROXANTHOHUMOL	Investigative
T04902	DRUGINFO	D0N6QM	(1-Benzyl-2-oxo-ethyl)-carbamic acid benzyl ester	Investigative
T04902	DRUGINFO	D0S9XO	mercaptoacrylate inhibitor of calpain 1	Investigative
T04902	DRUGINFO	D0T4FT	PMID20690647C5a	Investigative
T04902	DRUGINFO	D0W9ZV	AW-00430	Investigative

T82543	TARGETID	T82543
T82543	FORMERID	TTDC00301
T82543	UNIPROID	ACHB2_HUMAN
T82543	TARGNAME	Neuronal acetylcholine receptor beta-2 (CHRNB2)
T82543	GENENAME	CHRNB2
T82543	TARGTYPE	Clinical trial
T82543	SYNONYMS	Nicotinic acetylcholine receptor beta2; Nicotinic acetylcholine receptor beta 2-subunit protein; CHRNB2; Beta-2 nAChR; Alpha-4/beta-2 nicotinic receptor
T82543	FUNCTION	After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodiun ions.
T82543	PDBSTRUC	6CNK; 6CNJ; 5KXI; 2LM2; 2KSR
T82543	BIOCLASS	Neurotransmitter receptor
T82543	SEQUENCE	MARRCGPVALLLGFGLLRLCSGVWGTDTEERLVEHLLDPSRYNKLIRPATNGSELVTVQLMVSLAQLISVHEREQIMTTNVWLTQEWEDYRLTWKPEEFDNMKKVRLPSKHIWLPDVVLYNNADGMYEVSFYSNAVVSYDGSIFWLPPAIYKSACKIEVKHFPFDQQNCTMKFRSWTYDRTEIDLVLKSEVASLDDFTPSGEWDIVALPGRRNENPDDSTYVDITYDFIIRRKPLFYTINLIIPCVLITSLAILVFYLPSDCGEKMTLCISVLLALTVFLLLISKIVPPTSLDVPLVGKYLMFTMVLVTFSIVTSVCVLNVHHRSPTTHTMAPWVKVVFLEKLPALLFMQQPRHHCARQRLRLRRRQREREGAGALFFREAPGADSCTCFVNRASVQGLAGAFGAEPAPVAGPGRSGEPCGCGLREAVDGVRFIADHMRSEDDDQSVSEDWKYVAMVIDRLFLWIFVFVCVFGTIGMFLQPLFQNYTTTTFLHSDHSAPSSK
T82543	DRUGINFO	D08XPW	CYTISINE	Phase 3
T82543	DRUGINFO	D0D7YW	TC-5214	Phase 2
T82543	DRUGINFO	D07WJU	SUVN-911	Phase 1
T82543	DRUGINFO	D04HYP	ABT-594	Discontinued in Phase 2
T82543	DRUGINFO	D09ADT	ABT-418	Discontinued in Phase 2
T82543	DRUGINFO	D0F7FX	AZD-9684	Discontinued in Phase 2
T82543	DRUGINFO	D0C9KD	HOMOEPIBATIDINE	Terminated
T82543	DRUGINFO	D01OMG	NS9283	Investigative
T82543	DRUGINFO	D02BPT	[3H]nicotine	Investigative
T82543	DRUGINFO	D0V0AW	TC-2559	Investigative
T82543	DRUGINFO	D02LWF	GCCSHPACAGNNQHIC*	Investigative
T82543	DRUGINFO	D03FEV	N-methyl-2-(pyridin-3-yloxy)ethanamine	Investigative
T82543	DRUGINFO	D03SYO	N-methyl-4-(pyridin-3-yl)but-3-yn-1-amine	Investigative
T82543	DRUGINFO	D04HQP	N,N-dimethyl-4-(pyridin-3-yl)but-3-yn-1-amine	Investigative
T82543	DRUGINFO	D06KYM	N-methyl-N-(pyridin-3-ylmethyl)ethanamine	Investigative
T82543	DRUGINFO	D0A7HM	N,N-dimethyl-2-(pyridin-3-yloxy)ethanamine	Investigative
T82543	DRUGINFO	D0P9ED	CMI-489	Investigative
T82543	DRUGINFO	D0R8YJ	N-ethyl-N-methyl-4-(pyridin-3-yl)but-3-yn-1-amine	Investigative
T82543	DRUGINFO	D0U2HZ	6'-methylepibatidine	Investigative
T82543	DRUGINFO	D0UX5M	N,N-dimethyl(pyridin-3-yl)methanamine	Investigative
T82543	DRUGINFO	D0V2KB	Predicentrine methiodide	Investigative
T82543	DRUGINFO	D0V7HJ	3-[2-(N,N,N-trimethylammonium)ethoxy]pyridine	Investigative
T82543	DRUGINFO	D04MIG	LY2087101	Investigative
T82543	DRUGINFO	D0D4LF	NS1738	Investigative
T82543	DRUGINFO	D0DA1E	A-867744	Investigative
T82543	DRUGINFO	D0UH8F	GCCSNPVCHLEHSNLC*	Investigative
T82543	DRUGINFO	D0Y3DW	[3H]cytisine	Investigative
T82543	DRUGINFO	D0LH4L	BOLDINE	Investigative
T82543	DRUGINFO	D0R4RN	[125I]epibatidine	Investigative
T82543	DRUGINFO	D00QCP	(2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol	Investigative
T82543	DRUGINFO	D03YQY	(2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol	Investigative
T82543	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T16347	TARGETID	T16347
T16347	FORMERID	TTDI01934
T16347	UNIPROID	PTN1_HUMAN
T16347	TARGNAME	Protein-tyrosine phosphatase 1B (PTP1B)
T16347	GENENAME	PTPN1
T16347	TARGTYPE	Clinical trial
T16347	SYNONYMS	Tyrosine-protein phosphatase non-receptor type 1; PTP-1B
T16347	FUNCTION	Mediates dephosphorylation of EIF2AK3/PERK; inactivating the protein kinase activity of EIF2AK3/PERK. May play an important role in CKII- and p60c-src-induced signal transduction cascades. May regulate the EFNA5-EPHA3 signaling pathway which modulates cell reorganization and cell-cell repulsion. May also regulate the hepatocyte growth factor receptor signaling pathway through dephosphorylation of MET. Tyrosine-protein phosphatase which acts as a regulator of endoplasmic reticulum unfolded protein response.
T16347	PDBSTRUC	6CWV; 6CWU; 6BAI; 6B95; 6B90
T16347	BIOCLASS	Phosphoric monoester hydrolase
T16347	ECNUMBER	EC 3.1.3.48
T16347	SEQUENCE	MEMEKEFEQIDKSGSWAAIYQDIRHEASDFPCRVAKLPKNKNRNRYRDVSPFDHSRIKLHQEDNDYINASLIKMEEAQRSYILTQGPLPNTCGHFWEMVWEQKSRGVVMLNRVMEKGSLKCAQYWPQKEEKEMIFEDTNLKLTLISEDIKSYYTVRQLELENLTTQETREILHFHYTTWPDFGVPESPASFLNFLFKVRESGSLSPEHGPVVVHCSAGIGRSGTFCLADTCLLLMDKRKDPSSVDIKKVLLEMRKFRMGLIQTADQLRFSYLAVIEGAKFIMGDSSVQDQWKELSHEDLEPPPEHIPPPPRPPKRILEPHNGKCREFFPNHQWVKEETQEDKDCPIKEEKGSPLNAAPYGIESMSQDTEVRSRVVGGSLRGAQAASPAKGEPSLPEKDEDHALSYWKPFLVNMCVATVLTAGAYLCYRFLFNSNT
T16347	DRUGINFO	D0LI5N	IONIS-PTP1BRX	Phase 2
T16347	DRUGINFO	D00QUZ	TTP-814	Phase 1/2
T16347	DRUGINFO	D0O3QW	Trodusquemine	Phase 1
T16347	DRUGINFO	D0Y4MJ	KQ-791	Phase 1
T16347	DRUGINFO	D0DN1I	JTT-551	Terminated

T82028	TARGETID	T82028
T82028	FORMERID	TTDR00347
T82028	UNIPROID	SL9A1_HUMAN
T82028	TARGNAME	Sodium/hydrogen exchanger 1 (SLC9A1)
T82028	GENENAME	SLC9A1
T82028	TARGTYPE	Clinical trial
T82028	SYNONYMS	Solute carrier family 9 member 1; Na+/H+ antiporter, amiloride-sensitive; Na(+)Sodium/hydrogen exchanger 1/H(+) exchanger 1; Na(+)/H(+) exchanger 1; Na(+)/H(+) antiporter, amiloride-sensitive; NHE1; NHE-1; Myocardial Na+/H+ exchanger; APNH1; APNH
T82028	FUNCTION	Major proton extruding system driven by the inward sodium ion chemical gradient. Plays an important role in signal transduction. Involved in pH regulation to eliminate acids generated by active metabolism or to counter adverse environmental conditions.
T82028	PDBSTRUC	6BJF; 2YGG; 2MDF; 2L0E; 2KBV
T82028	BIOCLASS	Monovalent cation:proton antiporter-1
T82028	SEQUENCE	MVLRSGICGLSPHRIFPSLLVVVALVGLLPVLRSHGLQLSPTASTIRSSEPPRERSIGDVTTAPPEVTPESRPVNHSVTDHGMKPRKAFPVLGIDYTHVRTPFEISLWILLACLMKIGFHVIPTISSIVPESCLLIVVGLLVGGLIKGVGETPPFLQSDVFFLFLLPPIILDAGYFLPLRQFTENLGTILIFAVVGTLWNAFFLGGLMYAVCLVGGEQINNIGLLDNLLFGSIISAVDPVAVLAVFEEIHINELLHILVFGESLLNDAVTVVLYHLFEEFANYEHVGIVDIFLGFLSFFVVALGGVLVGVVYGVIAAFTSRFTSHIRVIEPLFVFLYSYMAYLSAELFHLSGIMALIASGVVMRPYVEANISHKSHTTIKYFLKMWSSVSETLIFIFLGVSTVAGSHHWNWTFVISTLLFCLIARVLGVLGLTWFINKFRIVKLTPKDQFIIAYGGLRGAIAFSLGYLLDKKHFPMCDLFLTAIITVIFFTVFVQGMTIRPLVDLLAVKKKQETKRSINEEIHTQFLDHLLTGIEDICGHYGHHHWKDKLNRFNKKYVKKCLIAGERSKEPQLIAFYHKMEMKQAIELVESGGMGKIPSAVSTVSMQNIHPKSLPSERILPALSKDKEEEIRKILRNNLQKTRQRLRSYNRHTLVADPYEEAWNQMLLRRQKARQLEQKINNYLTVPAHKLDSPTMSRARIGSDPLAYEPKEDLPVITIDPASPQSPESVDLVNEELKGKVLGLSRDPAKVAEEDEDDDGGIMMRSKETSSPGTDDVFTPAPSDSPSSQRIQRCLSDPGPHPEPGEGEPFFPKGQ
T82028	DRUGINFO	D0C8PI	Zoniporide hydrochloride	Phase 3
T82028	DRUGINFO	D0N8QQ	CARIPORIDE	Discontinued in Phase 2
T82028	DRUGINFO	D0V9RU	ENIPORIDE	Discontinued in Phase 2
T82028	DRUGINFO	D0K2CV	HOE-694	Terminated
T82028	DRUGINFO	D01RDB	N-[2-(1H-benzoimidazol-2-yl)-benzoyl]-guanidine	Investigative
T82028	DRUGINFO	D01ZIP	N-[5-(2-Ethyl-phenyl)-furan-2-carbonyl]-guanidine	Investigative
T82028	DRUGINFO	D06AKW	N-(5-m-Tolyl-furan-2-carbonyl)-guanidine	Investigative
T82028	DRUGINFO	D07WXS	Homoserine Lactone	Investigative
T82028	DRUGINFO	D08BDI	N-(5-o-Tolyl-furan-2-carbonyl)-guanidine	Investigative
T82028	DRUGINFO	D09ZSK	N-(5-Phenyl-furan-2-carbonyl)-guanidine	Investigative
T82028	DRUGINFO	D0D3OX	N-[5-(2-Nitro-phenyl)-furan-2-carbonyl]-guanidine	Investigative
T82028	DRUGINFO	D0NS9C	BIIB-513	Investigative
T82028	DRUGINFO	D0V5NZ	5'-(N-ethyl-N-isopropyl)amiloride	Investigative
T82028	DRUGINFO	D0Y4CC	N-[4-(1H-benzoimidazol-2-yl)-benzoyl]-guanidine	Investigative
T82028	DRUGINFO	D03AGV	N-(3-Methanesulfonyl-4-methyl-benzoyl)-guanidine	Investigative
T82028	DRUGINFO	D04OTF	N-(4-Chloro-3-methanesulfonyl-benzoyl)-guanidine	Investigative
T82028	DRUGINFO	D04UMY	N-(4-Cyano-3-methanesulfonyl-benzoyl)-guanidine	Investigative
T82028	DRUGINFO	D05CQR	N-(4-Bromo-3-methanesulfonyl-benzoyl)-guanidine	Investigative
T82028	DRUGINFO	D07DUW	N-(3-Methanesulfonyl-4-methoxy-benzoyl)-guanidine	Investigative
T82028	DRUGINFO	D0T1OG	N-(5-Methanesulfonyl-2-methyl-benzoyl)-guanidine	Investigative

T96627	TARGETID	T96627
T96627	FORMERID	TTDC00225
T96627	UNIPROID	CXCL2_HUMAN
T96627	TARGNAME	C-X-C motif chemokine 2 (CXCL2)
T96627	GENENAME	CXCL2
T96627	TARGTYPE	Clinical trial
T96627	SYNONYMS	SCYB2; Macrophage inflammatory protein 2-alpha; MIP2A; MIP2-alpha; Growth-regulated protein beta; Growth regulatedprotein beta; Gro-beta; GROB; GRO2
T96627	FUNCTION	Hematoregulatory chemokine, which, in vitro, suppresses hematopoietic progenitor cell proliferation. GRO-beta(5-73) shows a highly enhanced hematopoietic activity. Produced by activated monocytes and neutrophils and expressed at sites of inflammation.
T96627	PDBSTRUC	5OB5; 1QNK
T96627	BIOCLASS	Cytokine: CXC chemokine
T96627	SEQUENCE	MARATLSAAPSNPRLLRVALLLLLLVAASRRAAGAPLATELRCQCLQTLQGIHLKNIQSVKVKSPGPHCAQTEVIATLKNGQKACLNPASPMVKKIIEKMLKNGKSN
T96627	DRUGINFO	D09INF	Laquinamod	Phase 3

T86350	TARGETID	T86350
T86350	FORMERID	TTDR01265
T86350	UNIPROID	ERBB3_HUMAN
T86350	TARGNAME	Erbb3 tyrosine kinase receptor (Erbb-3)
T86350	GENENAME	ERBB3
T86350	TARGTYPE	Clinical trial
T86350	SYNONYMS	Tyrosine kinase-type cell surface receptor HER3; Receptor tyrosine-protein kinase erbB-3; Proto-oncogene-like protein c-ErbB-3; HER3; C-erbB3; C-erbB-3 protein
T86350	FUNCTION	Binds to neuregulin-1 (NRG1) and is activated by it; ligand-binding increases phosphorylation on tyrosine residues and promotes its association with the p85 subunit of phosphatidylinositol 3-kinase. May also be activated by CSPG5. Involved in the regulation of myeloid cell differentiation. Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins.
T86350	PDBSTRUC	5O7P; 5O4O; 5CUS; 4RIY; 4RIX
T86350	BIOCLASS	Kinase
T86350	ECNUMBER	EC 2.7.10.1
T86350	SEQUENCE	MRANDALQVLGLLFSLARGSEVGNSQAVCPGTLNGLSVTGDAENQYQTLYKLYERCEVVMGNLEIVLTGHNADLSFLQWIREVTGYVLVAMNEFSTLPLPNLRVVRGTQVYDGKFAIFVMLNYNTNSSHALRQLRLTQLTEILSGGVYIEKNDKLCHMDTIDWRDIVRDRDAEIVVKDNGRSCPPCHEVCKGRCWGPGSEDCQTLTKTICAPQCNGHCFGPNPNQCCHDECAGGCSGPQDTDCFACRHFNDSGACVPRCPQPLVYNKLTFQLEPNPHTKYQYGGVCVASCPHNFVVDQTSCVRACPPDKMEVDKNGLKMCEPCGGLCPKACEGTGSGSRFQTVDSSNIDGFVNCTKILGNLDFLITGLNGDPWHKIPALDPEKLNVFRTVREITGYLNIQSWPPHMHNFSVFSNLTTIGGRSLYNRGFSLLIMKNLNVTSLGFRSLKEISAGRIYISANRQLCYHHSLNWTKVLRGPTEERLDIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEPREFAHEAECFSCHPECQPMEGTATCNGSGSDTCAQCAHFRDGPHCVSSCPHGVLGAKGPIYKYPDVQNECRPCHENCTQGCKGPELQDCLGQTLVLIGKTHLTMALTVIAGLVVIFMMLGGTFLYWRGRRIQNKRAMRRYLERGESIEPLDPSEKANKVLARIFKETELRKLKVLGSGVFGTVHKGVWIPEGESIKIPVCIKVIEDKSGRQSFQAVTDHMLAIGSLDHAHIVRLLGLCPGSSLQLVTQYLPLGSLLDHVRQHRGALGPQLLLNWGVQIAKGMYYLEEHGMVHRNLAARNVLLKSPSQVQVADFGVADLLPPDDKQLLYSEAKTPIKWMALESIHFGKYTHQSDVWSYGVTVWELMTFGAEPYAGLRLAEVPDLLEKGERLAQPQICTIDVYMVMVKCWMIDENIRPTFKELANEFTRMARDPPRYLVIKRESGPGIAPGPEPHGLTNKKLEEVELEPELDLDLDLEAEEDNLATTTLGSALSLPVGTLNRPRGSQSLLSPSSGYMPMNQGNLGESCQESAVSGSSERCPRPVSLHPMPRGCLASESSEGHVTGSEAELQEKVSMCRSRSRSRSPRPRGDSAYHSQRHSLLTPVTPLSPPGLEEEDVNGYVMPDTHLKGTPSSREGTLSSVGLSSVLGTEEEDEDEEYEYMNRRRRHSPPHPPRPSSLEELGYEYMDVGSDLSASLGSTQSCPLHPVPIMPTAGTTPDEDYEYMNRQRDGGGPGGDYAAMGACPASEQGYEEMRAFQGPGHQAPHVHYARLKTLRSLEATDSAFDNPDYWHSRLFPKANAQRT
T86350	DRUGINFO	D06DOJ	Seribantumab	Phase 2
T86350	DRUGINFO	D06FUE	CDX-3379	Phase 2
T86350	DRUGINFO	D06SBL	MM-121	Phase 2
T86350	DRUGINFO	D08GIM	Elisidepsin	Phase 2
T86350	DRUGINFO	D09BZJ	MEHD-7945A	Phase 2
T86350	DRUGINFO	D1J4CI	Zenocutuzumab	Phase 2
T86350	DRUGINFO	D00BUO	MM-141	Phase 2
T86350	DRUGINFO	D05ECA	LJM716	Phase 1/2
T86350	DRUGINFO	D0T8CE	AMG888/U3-1287	Phase 1/2
T86350	DRUGINFO	D6SL3N	Zenocutuzomab	Phase 1/2
T86350	DRUGINFO	D0FF2G	Sym013	Phase 1/2
T86350	DRUGINFO	D00EQY	KTN3379	Phase 1
T86350	DRUGINFO	D04RHJ	RG7116	Phase 1
T86350	DRUGINFO	D0D4UT	GSK2849330	Phase 1
T86350	DRUGINFO	D0I4QA	Drug 2849330	Phase 1
T86350	DRUGINFO	D0N2QW	Patritumab	Phase 1
T86350	DRUGINFO	D0UK7B	REGN1400	Phase 1
T86350	DRUGINFO	D0Y5ED	AV-203	Phase 1
T86350	DRUGINFO	D01NAP	MM-151	Phase 1
T86350	DRUGINFO	D0JW2O	Anti-HER3/EGFR DAF	Phase 1
T86350	DRUGINFO	D0UL7L	Recombinant human Erbb3 fragment therapeutic tumor vaccine	Phase 1
T86350	DRUGINFO	D6JM8Z	SI-B001	Phase 1
T86350	DRUGINFO	D0F1OG	Soluble ErbB3 theragnostics	Investigative
T86350	DRUGINFO	D0T4ZW	MP-RM-1	Investigative
T86350	DRUGINFO	D0Q8GX	SYM-011	Investigative

T15882	TARGETID	T15882
T15882	FORMERID	TTDI02312
T15882	UNIPROID	PRTN3_HUMAN
T15882	TARGNAME	Leukocyte proteinase-3 (PRTN3)
T15882	GENENAME	PRTN3
T15882	TARGTYPE	Clinical trial
T15882	SYNONYMS	Wegener autoantigen; PR3; PR-3; P29; Neutrophil proteinase 4; NP4; NP-4; Myeloblastin; MBN; Leukocyte proteinase 3; CANCA antigen; C-ANCA antigen; AGP7
T15882	FUNCTION	By cleaving and activating receptor F2RL1/PAR-2, enhances endothelial cell barrier function and thus vascular integrity during neutrophil transendothelial migration. May play a role in neutrophil transendothelial migration, probably when associated with CD177. Serine protease that degrades elastin, fibronectin, laminin, vitronectin, and collagen types I, III, and IV (in vitro).
T15882	PDBSTRUC	1FUJ
T15882	BIOCLASS	Peptidase
T15882	ECNUMBER	EC 3.4.21.76
T15882	SEQUENCE	MAHRPPSPALASVLLALLLSGAARAAEIVGGHEAQPHSRPYMASLQMRGNPGSHFCGGTLIHPSFVLTAAHCLRDIPQRLVNVVLGAHNVRTQEPTQQHFSVAQVFLNNYDAENKLNDVLLIQLSSPANLSASVATVQLPQQDQPVPHGTQCLAMGWGRVGAHDPPAQVLQELNVTVVTFFCRPHNICTFVPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCATRLFPDFFTRVALYVDWIRSTLRRVEAKGRP
T15882	DRUGINFO	D05BPC	Tiprelestat	Phase 2
T15882	DRUGINFO	D0O8AY	Combined PR1/WT1 vaccine	Phase 2
T15882	DRUGINFO	D0C1NP	PMID22595175C4g	Investigative

T78356	TARGETID	T78356
T78356	FORMERID	TTDC00086
T78356	UNIPROID	THAS_HUMAN
T78356	TARGNAME	Thromboxane-A synthase (TBXAS1)
T78356	GENENAME	TBXAS1
T78356	TARGTYPE	Clinical trial
T78356	SYNONYMS	Thromboxane A2 synthase; TXS; TXA synthase; Cytochrome P450 5A1; CYP5A1; CYP5
T78356	FUNCTION	endoplasmic reticulum membrane, 12-hydroxyheptadecatrienoic acid synthase activity, thromboxane-A synthase activity, cyclooxygenase pathway, icosanoid metabolic process.
T78356	BIOCLASS	Intramolecular oxidoreductase
T78356	ECNUMBER	EC 5.3.99.5
T78356	SEQUENCE	MEALGFLKLEVNGPMVTVALSVALLALLKWYSTSAFSRLEKLGLRHPKPSPFIGNLTFFRQGFWESQMELRKLYGPLCGYYLGRRMFIVISEPDMIKQVLVENFSNFTNRMASGLEFKSVADSVLFLRDKRWEEVRGALMSAFSPEKLNEMVPLISQACDLLLAHLKRYAESGDAFDIQRCYCNYTTDVVASVAFGTPVDSWQAPEDPFVKHCKRFFEFCIPRPILVLLLSFPSIMVPLARILPNKNRDELNGFFNKLIRNVIALRDQQAAEERRRDFLQMVLDARHSASPMGVQDFDIVRDVFSSTGCKPNPSRQHQPSPMARPLTVDEIVGQAFIFLIAGYEIITNTLSFATYLLATNPDCQEKLLREVDVFKEKHMAPEFCSLEEGLPYLDMVIAETLRMYPPAFRFTREAAQDCEVLGQRIPAGAVLEMAVGALHHDPEHWPSPETFNPERFTAEARQQHRPFTYLPFGAGPRSCLGVRLGLLEVKLTLLHVLHKFRFQACPETQVPLQLESKSALGPKNGVYIKIVSR
T78356	DRUGINFO	D0T8LY	PYRIDINE	Phase 4
T78356	DRUGINFO	D06LFV	NM-702	Phase 3
T78356	DRUGINFO	D08PKI	EV-077	Phase 2
T78356	DRUGINFO	D0K9UK	E-6700	Phase 2
T78356	DRUGINFO	D0WH9U	FK-070	Phase 2
T78356	DRUGINFO	D07YEK	NV-52	Phase 1
T78356	DRUGINFO	D0RU7T	G-619	Phase 1
T78356	DRUGINFO	D0L0MO	Satigrel	Discontinued in Preregistration
T78356	DRUGINFO	D05DON	MILACAINIDE TARTRATE	Discontinued in Phase 2
T78356	DRUGINFO	D0K4UW	Imitrodast	Discontinued in Phase 2
T78356	DRUGINFO	D0V7GC	Rolafagrel	Discontinued in Phase 2
T78356	DRUGINFO	D0G5DK	ONO-1301	Preclinical
T78356	DRUGINFO	D04EEU	Dazoxiben	Terminated
T78356	DRUGINFO	D09QRO	CGS-13080	Terminated
T78356	DRUGINFO	D01JWT	2-(10-Imidazol-1-yl-decyl)-isoindole-1,3-dione	Investigative
T78356	DRUGINFO	D01NZS	2-(6-Imidazol-1-yl-hexyl)-isoindole-1,3-dione	Investigative
T78356	DRUGINFO	D01QOU	ONO-1581	Investigative
T78356	DRUGINFO	D05KVN	2-(8-Imidazol-1-yl-octyl)-isoindole-1,3-dione	Investigative
T78356	DRUGINFO	D09IQS	4-Methyl-pyridine	Investigative
T78356	DRUGINFO	D0F0KV	CV-6504.HCL	Investigative
T78356	DRUGINFO	D0K2SE	5-Imidazol-1-yl-5,6,7,8-tetrahydro-quinoline	Investigative
T78356	DRUGINFO	D08PKR	6-Imidazol-1-yl-isoquinoline	Investigative
T78356	DRUGINFO	D04ZGF	5-(2-Imidazol-1-yl-ethyl)-7,8-dihydro-quinoline	Investigative

T68290	TARGETID	T68290
T68290	FORMERID	TTDC00067
T68290	UNIPROID	CATS_HUMAN
T68290	TARGNAME	Cathepsin S (CTSS)
T68290	GENENAME	CTSS
T68290	TARGTYPE	Clinical trial
T68290	SYNONYMS	Cysteine protease cathepsin S
T68290	FUNCTION	Key protease responsible for the removal of the invariant chain from MHC class II molecules. The bond-specificity of this proteinase is in part similar to the specificities of cathepsin L. Thiol protease.
T68290	PDBSTRUC	5QCJ; 5QCI; 5QCH; 5QCG; 5QCF
T68290	BIOCLASS	Peptidase
T68290	ECNUMBER	EC 3.4.22.27
T68290	SEQUENCE	MKRLVCVLLVCSSAVAQLHKDPTLDHHWHLWKKTYGKQYKEKNEEAVRRLIWEKNLKFVMLHNLEHSMGMHSYDLGMNHLGDMTSEEVMSLMSSLRVPSQWQRNITYKSNPNRILPDSVDWREKGCVTEVKYQGSCGACWAFSAVGALEAQLKLKTGKLVSLSAQNLVDCSTEKYGNKGCNGGFMTTAFQYIIDNKGIDSDASYPYKAMDQKCQYDSKYRAATCSKYTELPYGREDVLKEAVANKGPVSVGVDARHPSFFLYRSGVYYEPSCTQNVNHGVLVVGYGDLNGKEYWLVKNSWGHNFGEEGYIRMARNKGNHCGIASFPSYPEI
T68290	DRUGINFO	D0DQ2D	RG7625	Phase 2
T68290	DRUGINFO	D01REJ	VBY- 891	Phase 1
T68290	DRUGINFO	D07ODC	VBY- 036	Phase 1
T68290	DRUGINFO	D07UKF	VBY-129	Phase 1
T68290	DRUGINFO	D08KIB	SAR-114137	Phase 1
T68290	DRUGINFO	D01MKD	Phenylalanine derivative 1	Patented
T68290	DRUGINFO	D0JD5W	PMID27998201-Compound-7	Patented
T68290	DRUGINFO	D0MR9V	PMID27998201-Compound-15	Patented
T68290	DRUGINFO	D0QM0D	Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1	Patented
T68290	DRUGINFO	D0X1AF	PMID27998201-Compound-6	Patented
T68290	DRUGINFO	D06XTA	PMID27998201-Compound-17	Patented
T68290	DRUGINFO	D04VGR	PMID27998201-Compound-9	Patented
T68290	DRUGINFO	D06LLT	PMID25399719-Compound-17	Patented
T68290	DRUGINFO	D05OIU	PMID27998201-Compound-5	Patented
T68290	DRUGINFO	D06XCD	PMID27998201-Compound-12	Patented
T68290	DRUGINFO	D0D3KG	RG-7236	Discontinued in Phase 1
T68290	DRUGINFO	DC9J1Y	RO5461111	Preclinical
T68290	DRUGINFO	D0Z0PR	L-006235-1	Preclinical
T68290	DRUGINFO	D0K0IW	CRA-028129	Terminated
T68290	DRUGINFO	D01IFO	6-(3-(trifluoromethyl)phenyl)picolinonitrile	Investigative
T68290	DRUGINFO	D01NCW	Cbz-Ile-Phe-Ala-LeuVSMe	Investigative
T68290	DRUGINFO	D02FPU	N-(1-oxobutan-2-yl)-3-(trifluoromethyl)benzamide	Investigative
T68290	DRUGINFO	D05MDE	Cbz-Ile-Pro-Ala-LeuVSMe	Investigative
T68290	DRUGINFO	D07SOQ	N-(2-naphthylsulfonyl)-glycyl-glycine-nitrile	Investigative
T68290	DRUGINFO	D08WDP	AM-3840	Investigative
T68290	DRUGINFO	D09GZQ	Ac-hPhe-Leu-Gly-LeuVSMe	Investigative
T68290	DRUGINFO	D09IMK	Cbz-Ile-t-ButylGln-Ala-LeuVSMe	Investigative
T68290	DRUGINFO	D0B3US	Cbz-Ile-MetO2-Ala-LeuVSMe	Investigative
T68290	DRUGINFO	D0G3PK	Fsn-0503	Investigative
T68290	DRUGINFO	D0J0HV	VBY- 285	Investigative
T68290	DRUGINFO	D0K0KT	Cbz-Glu(OtBu)-Ala-LeuVSMe	Investigative
T68290	DRUGINFO	D0M8WX	2-[(2',3',4'-TRIFLUOROBIPHENYL-2-YL)OXY]ETHANOL	Investigative
T68290	DRUGINFO	D0P5RJ	BF/PC-18	Investigative
T68290	DRUGINFO	D0RL4S	Cbz-Ile-hPhe-Ala-LeuVSMe	Investigative
T68290	DRUGINFO	D0V5LJ	JNJ-10329670	Investigative
T68290	DRUGINFO	D0Y8LO	Clik60	Investigative
T68290	DRUGINFO	D01JGB	4-cyclooctyl-6-propylpyrimidine-2-carbonitrile	Investigative
T68290	DRUGINFO	D04BGT	4-propyl-6-m-tolylpyrimidine-2-carbonitrile	Investigative
T68290	DRUGINFO	D05VEV	Ac-hPhe-Leu-Ala-LeuVSMe	Investigative
T68290	DRUGINFO	D05WZF	P2,P3 Ketoamide derivative	Investigative
T68290	DRUGINFO	D06NEB	Ac-hPhe-Leu-Phe-LeuVSMe	Investigative
T68290	DRUGINFO	D06WQP	PMID22686657C(R)-26	Investigative
T68290	DRUGINFO	D0A7ER	N-(tert-butoxycarbonyl)-norvalyl-glycine-nitrile	Investigative
T68290	DRUGINFO	D0I0MU	Cbz-Ile-Leu-Ala-LeuVSMe	Investigative
T68290	DRUGINFO	D0JF8D	N-(tert-butoxycarbonyl)-tyrosyl-glycine-nitrile	Investigative
T68290	DRUGINFO	D0QY3R	Cbz-Ile-t-ButylhomoGlu-Ala-LeuVSMe	Investigative
T68290	DRUGINFO	D0U4TY	4-cycloheptyl-6-propylpyrimidine-2-carbonitrile	Investigative
T68290	DRUGINFO	D01YNC	N-(tert-butoxycarbonyl)-isoleucyl-glycine-nitrile	Investigative
T68290	DRUGINFO	D06VIP	N-(tert-butoxycarbonyl)-valyl-glycine-nitrile	Investigative
T68290	DRUGINFO	D07FLB	N-(tert-butoxycarbonyl)-norleucyl-glycine-nitrile	Investigative
T68290	DRUGINFO	D07RSA	N-(4-phenylbenzoyl)-phenylalanyl-glycine-nitrile	Investigative
T68290	DRUGINFO	D09AHN	N-(tert-butoxycarbonyl)-leucyl-glycine-nitrile	Investigative
T68290	DRUGINFO	D0A8OV	N-acetyl-phenylalanyl-glycine-nitrile	Investigative
T68290	DRUGINFO	D0G8OD	N-(benzyloxycarbonyl)-leucyl-glycine-nitrile	Investigative
T68290	DRUGINFO	D0JN8Q	N-benzoyl-phenylalanyl-glycine-nitrile	Investigative
T68290	DRUGINFO	D0U0XG	N-(tert-butoxycarbonyl)-methionyl-glycine-nitrile	Investigative
T68290	DRUGINFO	D09FGQ	E-64	Investigative
T68290	DRUGINFO	D0D0LD	L-873724	Investigative
T68290	DRUGINFO	D0L9VP	GNF-PF-5434	Investigative
T68290	DRUGINFO	D0G6XS	Fucose	Investigative

T45758	TARGETID	T45758
T45758	FORMERID	TTDC00188
T45758	UNIPROID	TNR5_HUMAN
T45758	TARGNAME	CD40L receptor (CD40)
T45758	GENENAME	CD40
T45758	TARGTYPE	Clinical trial
T45758	SYNONYMS	Tumor necrosis factor receptor superfamily member 5; TNFRSF5; CDw40; Bp50; B-cell surfaceantigen CD40; B-cell surface antigen CD40
T45758	FUNCTION	Transduces TRAF6- and MAP3K8-mediated signals that activate ERK in macrophages and B cells, leading to induction of immunoglobulin secretion. Receptor for TNFSF5/CD40LG.
T45758	PDBSTRUC	6FAX; 5IHL; 5DMJ; 5DMI; 3QD6
T45758	BIOCLASS	Cytokine receptor
T45758	SEQUENCE	MVRLPLQCVLWGCLLTAVHPEPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTETECLPCGESEFLDTWNRETHCHQHKYCDPNLGLRVQQKGTSETDTICTCEEGWHCTSEACESCVLHRSCSPGFGVKQIATGVSDTICEPCPVGFFSNVSSAFEKCHPWTSCETKDLVVQQAGTNKTDVVCGPQDRLRALVVIPIIFGILFAILLVLVFIKKVAKKPTNKAPHPKQEPQEINFPDDLPGSNTAAPVQETLHGCQPVTQEDGKESRISVQERQ
T45758	DRUGINFO	D01ZLK	APX005M	Phase 2
T45758	DRUGINFO	D0G3TJ	ASKP-1240	Phase 2
T45758	DRUGINFO	D0SD6V	CFZ533	Phase 2
T45758	DRUGINFO	D3NSU0	KPL-404	Phase 2
T45758	DRUGINFO	D4B9KS	Iscalimab	Phase 2
T45758	DRUGINFO	D6WO5I	Frexalimab	Phase 2
T45758	DRUGINFO	DPDI65	Dazodalibep	Phase 2
T45758	DRUGINFO	DQ5YL2	AT-1501	Phase 2
T45758	DRUGINFO	D0C8NG	BI 655064	Phase 2
T45758	DRUGINFO	D01NZH	ABBV-323	Phase 1
T45758	DRUGINFO	D91DAH	RG6189	Phase 1
T45758	DRUGINFO	DE0TD1	CP-870,893	Phase 1
T45758	DRUGINFO	DKM7S3	CDX-1140	Phase 1
T45758	DRUGINFO	DNMF63	YH003	Phase 1
T45758	DRUGINFO	DTM8B0	NG-350A	Phase 1
T45758	DRUGINFO	DKUF26	SL-172154	Phase 1
T45758	DRUGINFO	DN28KM	GEN1042	Phase 1
T45758	DRUGINFO	D0L4BR	HuCD40L	Terminated
T45758	DRUGINFO	D0Y3XB	RhuCD40L	Terminated
T45758	DRUGINFO	D0A9BO	PG-120	Investigative
T45758	DRUGINFO	D0Q5GS	CD154	Investigative
T45758	DRUGINFO	D0SO4M	Human CD40 agonist ligand	Investigative
T45758	DRUGINFO	D0V3HC	Anti-CD40-XTEN	Investigative
T45758	DRUGINFO	DH0JW9	YH008	Investigative

T88304	TARGETID	T88304
T88304	FORMERID	TTDNC00597
T88304	UNIPROID	DNMT1_HUMAN
T88304	TARGNAME	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
T88304	GENENAME	DNMT1
T88304	TARGTYPE	Clinical trial
T88304	SYNONYMS	MCMT; M.HsaI; Dnmt1; DNMT; DNA methyltransferase HsaI; DNA MTase HsaI; DNA (cytosine5)methyltransferase 1; DNA (cytosine-5)-methyltransferase 1; CXXCtype zinc finger protein 9; CXXC9; CXXC-type zinc finger protein 9; AIM
T88304	FUNCTION	Preferentially methylates hemimethylated DNA. Associates with DNA replication sites in S phase maintaining the methylation pattern in the newly synthesized strand, that is essential for epigenetic inheritance. Associates with chromatin during G2 and M phases to maintain DNA methylation independently of replication. It is responsible for maintaining methylation patterns established in development. DNA methylation is coordinated with methylation of histones. Mediates transcriptional repression by direct binding to HDAC2. In association with DNMT3B and via the recruitment of CTCFL/BORIS, involved in activation of BAG1 gene expression by modulating dimethylation of promoter histone H3 at H3K4 and H3K9. Probably forms a corepressor complex required for activated KRAS-mediated promoter hypermethylation and transcriptional silencing of tumor suppressor genes (TSGs) or other tumor-related genes in colorectal cancer (CRC) cells. Also required to maintain a transcriptionally repressive state of genes in undifferentiated embryonic stem cells (ESCs). Associates at promoter regions of tumor suppressor genes (TSGs) leading to their gene silencing. Promotes tumor growth. Methylates CpG residues.
T88304	PDBSTRUC	5YDR; 5WVO; 4Z97; 4Z96; 4YOC
T88304	BIOCLASS	Methyltransferase
T88304	ECNUMBER	EC 2.1.1.37
T88304	SEQUENCE	MPARTAPARVPTLAVPAISLPDDVRRRLKDLERDSLTEKECVKEKLNLLHEFLQTEIKNQLCDLETKLRKEELSEEGYLAKVKSLLNKDLSLENGAHAYNREVNGRLENGNQARSEARRVGMADANSPPKPLSKPRTPRRSKSDGEAKPEPSPSPRITRKSTRQTTITSHFAKGPAKRKPQEESERAKSDESIKEEDKDQDEKRRRVTSRERVARPLPAEEPERAKSGTRTEKEEERDEKEEKRLRSQTKEPTPKQKLKEEPDREARAGVQADEDEDGDEKDEKKHRSQPKDLAAKRRPEEKEPEKVNPQISDEKDEDEKEEKRRKTTPKEPTEKKMARAKTVMNSKTHPPKCIQCGQYLDDPDLKYGQHPPDAVDEPQMLTNEKLSIFDANESGFESYEALPQHKLTCFSVYCKHGHLCPIDTGLIEKNIELFFSGSAKPIYDDDPSLEGGVNGKNLGPINEWWITGFDGGEKALIGFSTSFAEYILMDPSPEYAPIFGLMQEKIYISKIVVEFLQSNSDSTYEDLINKIETTVPPSGLNLNRFTEDSLLRHAQFVVEQVESYDEAGDSDEQPIFLTPCMRDLIKLAGVTLGQRRAQARRQTIRHSTREKDRGPTKATTTKLVYQIFDTFFAEQIEKDDREDKENAFKRRRCGVCEVCQQPECGKCKACKDMVKFGGSGRSKQACQERRCPNMAMKEADDDEEVDDNIPEMPSPKKMHQGKKKKQNKNRISWVGEAVKTDGKKSYYKKVCIDAETLEVGDCVSVIPDDSSKPLYLARVTALWEDSSNGQMFHAHWFCAGTDTVLGATSDPLELFLVDECEDMQLSYIHSKVKVIYKAPSENWAMEGGMDPESLLEGDDGKTYFYQLWYDQDYARFESPPKTQPTEDNKFKFCVSCARLAEMRQKEIPRVLEQLEDLDSRVLYYSATKNGILYRVGDGVYLPPEAFTFNIKLSSPVKRPRKEPVDEDLYPEHYRKYSDYIKGSNLDAPEPYRIGRIKEIFCPKKSNGRPNETDIKIRVNKFYRPENTHKSTPASYHADINLLYWSDEEAVVDFKAVQGRCTVEYGEDLPECVQVYSMGGPNRFYFLEAYNAKSKSFEDPPNHARSPGNKGKGKGKGKGKPKSQACEPSEPEIEIKLPKLRTLDVFSGCGGLSEGFHQAGISDTLWAIEMWDPAAQAFRLNNPGSTVFTEDCNILLKLVMAGETTNSRGQRLPQKGDVEMLCGGPPCQGFSGMNRFNSRTYSKFKNSLVVSFLSYCDYYRPRFFLLENVRNFVSFKRSMVLKLTLRCLVRMGYQCTFGVLQAGQYGVAQTRRRAIILAAAPGEKLPLFPEPLHVFAPRACQLSVVVDDKKFVSNITRLSSGPFRTITVRDTMSDLPEVRNGASALEISYNGEPQSWFQRQLRGAQYQPILRDHICKDMSALVAARMRHIPLAPGSDWRDLPNIEVRLSDGTMARKLRYTHHDRKNGRSSSGALRGVCSCVEAGKACDPAARQFNTLIPWCLPHTGNRHNHWAGLYGRLEWDGFFSTTVTNPEPMGKQGRVLHPEQHRVVSVRECARSQGFPDTYRLFGNILDKHRQVGNAVPPPLAKAIGLEIKLCMLAKARESASAKIKEEEAAKD
T88304	DRUGINFO	D0Q5KZ	SGI110	Phase 3
T88304	DRUGINFO	D0VZ4N	Guadecitabine	Phase 3
T88304	DRUGINFO	D09NTC	CC-486	Phase 3
T88304	DRUGINFO	D0A2BO	S-110	Phase 3
T88304	DRUGINFO	D04FDN	Palifosfamide	Phase 2
T88304	DRUGINFO	D0L7WS	RX-3117	Phase 2
T88304	DRUGINFO	D0T3AW	Antroquinonol	Phase 2
T88304	DRUGINFO	D5QR2M	GSK4172239	Phase 1
T88304	DRUGINFO	D01CGQ	PMID27376512-Compound-miR-155-5p	Patented
T88304	DRUGINFO	D04JIH	PMID27376512-Compound-Table1Example11	Patented
T88304	DRUGINFO	D05DSL	PMID27376512-Compound-Table1Example16	Patented
T88304	DRUGINFO	D09FMS	PMID27376512-Compound-Table1Example5	Patented
T88304	DRUGINFO	D0E7OA	PMID27376512-Compound-asCEBP-2HPE	Patented
T88304	DRUGINFO	D0G6ON	PMID27376512-Compound-asCEBP-1	Patented
T88304	DRUGINFO	D0K4YF	PMID27376512-Compound-Table1Example4	Patented
T88304	DRUGINFO	D0KE4E	PMID27376512-Compound-asCEBP-2	Patented
T88304	DRUGINFO	D0LK4R	PMID27376512-Compound-asCEBP-1HPE	Patented
T88304	DRUGINFO	D0RT6C	PMID27376512-Compound-Table1Example8	Patented
T88304	DRUGINFO	D0U5CK	PMID27376512-Compound-MTC-433	Patented
T88304	DRUGINFO	D0YK6K	PMID27376512-Compound-Table1Example30	Patented
T88304	DRUGINFO	D02WRM	PMID27376512-Compound-MTC-424	Patented
T88304	DRUGINFO	D0HA0J	PMID27376512-Compound-MTC-427	Patented
T88304	DRUGINFO	D0QY0N	PMID27376512-Compound-MTC-422 	Patented
T88304	DRUGINFO	D0W9VZ	PMID27376512-Compound-MTC-423	Patented
T88304	DRUGINFO	D03DTQ	PMX-700	Investigative
T88304	DRUGINFO	D0JV8Q	XB-05	Investigative
T88304	DRUGINFO	D0OT1S	CP-4200	Investigative

T23347	TARGETID	T23347
T23347	FORMERID	TTDC00234
T23347	UNIPROID	IL1R2_HUMAN
T23347	TARGNAME	Interleukin 1 receptor type 2 (IL1R2)
T23347	GENENAME	IL1R2
T23347	TARGTYPE	Clinical trial
T23347	SYNONYMS	Interleukin-1 receptor type II; Interleukin-1 receptor type 2; Interleukin-1 receptor beta; Interleukin 1 receptor type II; IL1RB; IL-1RT2; IL-1RT-2; IL-1R-beta; IL-1R-2; IL-1 type II receptor; CDw121b; CD121b; CD121 antigen-like family member B; Antigen CDw121b
T23347	FUNCTION	Reduces IL1B activities. Serves as a decoy receptor by competetive binding to IL1B and preventing its binding to IL1R1. Also modulates cellular response through non-signaling association with IL1RAP after binding to IL1B. IL1R2 (membrane and secreted forms) preferentially binds IL1B and poorly IL1A and IL1RN. The secreted IL1R2 recruits secreted IL1RAP with high affinity; this complex formation may be the dominant mechanism for neutralization of IL1B by secreted/soluble receptors. Non-signaling receptor for IL1A, IL1B and IL1RN.
T23347	PDBSTRUC	3O4O
T23347	BIOCLASS	Cytokine receptor
T23347	SEQUENCE	MLRLYVLVMGVSAFTLQPAAHTGAARSCRFRGRHYKREFRLEGEPVALRCPQVPYWLWASVSPRINLTWHKNDSARTVPGEEETRMWAQDGALWLLPALQEDSGTYVCTTRNASYCDKMSIELRVFENTDAFLPFISYPQILTLSTSGVLVCPDLSEFTRDKTDVKIQWYKDSLLLDKDNEKFLSVRGTTHLLVHDVALEDAGYYRCVLTFAHEGQQYNITRSIELRIKKKKEETIPVIISPLKTISASLGSRLTIPCKVFLGTGTPLTTMLWWTANDTHIESAYPGGRVTEGPRQEYSENNENYIEVPLIFDPVTREDLHMDFKCVVHNTLSFQTLRTTVKEASSTFSWGIVLAPLSLAFLVLGGIWMHRRCKHRTGKADGLTVLWPHHQDFQSYPK
T23347	DRUGINFO	D03FVR	GSK-1827771	Phase 1
T23347	DRUGINFO	D0W7VG	AMG 108	Discontinued in Phase 2
T23347	DRUGINFO	D0S7VN	MRL-953	Terminated
T23347	DRUGINFO	D04SVB	FR-133605	Terminated

T35194	TARGETID	T35194
T35194	FORMERID	TTDR00085
T35194	UNIPROID	DUS1_HUMAN
T35194	TARGNAME	Dual specificity protein phosphatase 1 (DUSP1)
T35194	GENENAME	DUSP1
T35194	TARGTYPE	Clinical trial
T35194	SYNONYMS	VH1; Protein-tyrosine phosphatase CL100; PTPN10; Mitogen-activated protein kinase phosphatase 1; MKP1; MKP-1; MAP kinase phosphatase-1; MAP kinase phosphatase 1; Dual specificity protein phosphatase hVH1; CL100
T35194	FUNCTION	Dual specificity phosphatase that dephosphorylates MAP kinase MAPK1/ERK2 on both 'Thr-183' and 'Tyr-185', regulating its activity during the meiotic cell cycle.
T35194	PDBSTRUC	6D67; 6D66; 6D65; 6APX
T35194	BIOCLASS	Phosphoric monoester hydrolase
T35194	ECNUMBER	EC 3.1.3.16
T35194	SEQUENCE	MVMEVGTLDAGGLRALLGERAAQCLLLDCRSFFAFNAGHIAGSVNVRFSTIVRRRAKGAMGLEHIVPNAELRGRLLAGAYHAVVLLDERSAALDGAKRDGTLALAAGALCREARAAQVFFLKGGYEAFSASCPELCSKQSTPMGLSLPLSTSVPDSAESGCSSCSTPLYDQGGPVEILPFLYLGSAYHASRKDMLDALGITALINVSANCPNHFEGHYQYKSIPVEDNHKADISSWFNEAIDFIDSIKNAGGRVFVHCQAGISRSATICLAYLMRTNRVKLDEAFEFVKQRRSIISPNFSFMGQLLQFESQVLAPHCSAEAGSPAMAVLDRGTSTTTVFNFPVSIPVHSTNSALSYLQSPITTSPSC
T35194	DRUGINFO	D0C0NH	Avastin+/-Tarceva	Phase 3
T35194	DRUGINFO	D01SLG	Okadaic acid	Investigative
T35194	DRUGINFO	D07FFL	ADOCIAQUINONE B	Investigative
T35194	DRUGINFO	D07REK	4-ethoxynaphthalene-1,2-dione	Investigative

T73756	TARGETID	T73756
T73756	FORMERID	TTDR01133
T73756	UNIPROID	EPHB2_HUMAN
T73756	TARGNAME	Ephrin type-B receptor 2 (EPHB2)
T73756	GENENAME	EPHB2
T73756	TARGTYPE	Clinical trial
T73756	SYNONYMS	hEK5; Tyrosine-protein kinase receptor EPH-3; Tyrosine-protein kinase TYRO5; TYRO5; Renal carcinoma antigen NY-REN-47; Receptor protein-tyrosine kinase HEK5; EphB2 receptor tyrosine kinase; EphB2; EPTH3; EPHT3; EPH-like kinase 5; EPH tyrosine kinase 3; ELK-related tyrosine kinase; EK5; Developmentally-regulated Eph-related tyrosine kinase; DRT
T73756	FUNCTION	The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Functions in axon guidance during development. Involved in the guidance of commissural axons, that form a major interhemispheric connection between the 2 temporal lobes of the cerebral cortex. Also involved in guidance of contralateral inner ear efferent growth cones at the midline and of retinal ganglion cell axons to the optic disk. In addition to axon guidance, also regulates dendritic spines development and maturation and stimulates the formation of excitatory synapses. Upon activation by EFNB1, abolishes the ARHGEF15-mediated negative regulation on excitatory synapse formation. Controls other aspects of development including angiogenesis, palate development and in inner ear development through regulation of endolymph production. Forward and reverse signaling through the EFNB2/EPHB2 complex regulate movement and adhesion of cells that tubularize the urethra and septate the cloaca. May function as a tumor suppressor. Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells.
T73756	PDBSTRUC	3ZFM; 2QBX; 1F0M; 1B4F
T73756	BIOCLASS	Kinase
T73756	ECNUMBER	EC 2.7.10.1
T73756	SEQUENCE	MALRRLGAALLLLPLLAAVEETLMDSTTATAELGWMVHPPSGWEEVSGYDENMNTIRTYQVCNVFESSQNNWLRTKFIRRRGAHRIHVEMKFSVRDCSSIPSVPGSCKETFNLYYYEADFDSATKTFPNWMENPWVKVDTIAADESFSQVDLGGRVMKINTEVRSFGPVSRSGFYLAFQDYGGCMSLIAVRVFYRKCPRIIQNGAIFQETLSGAESTSLVAARGSCIANAEEVDVPIKLYCNGDGEWLVPIGRCMCKAGFEAVENGTVCRGCPSGTFKANQGDEACTHCPINSRTTSEGATNCVCRNGYYRADLDPLDMPCTTIPSAPQAVISSVNETSLMLEWTPPRDSGGREDLVYNIICKSCGSGRGACTRCGDNVQYAPRQLGLTEPRIYISDLLAHTQYTFEIQAVNGVTDQSPFSPQFASVNITTNQAAPSAVSIMHQVSRTVDSITLSWSQPDQPNGVILDYELQYYEKELSEYNATAIKSPTNTVTVQGLKAGAIYVFQVRARTVAGYGRYSGKMYFQTMTEAEYQTSIQEKLPLIIGSSAAGLVFLIAVVVIAIVCNRRGFERADSEYTDKLQHYTSGHMTPGMKIYIDPFTYEDPNEAVREFAKEIDISCVKIEQVIGAGEFGEVCSGHLKLPGKREIFVAIKTLKSGYTEKQRRDFLSEASIMGQFDHPNVIHLEGVVTKSTPVMIITEFMENGSLDSFLRQNDGQFTVIQLVGMLRGIAAGMKYLADMNYVHRDLAARNILVNSNLVCKVSDFGLSRFLEDDTSDPTYTSALGGKIPIRWTAPEAIQYRKFTSASDVWSYGIVMWEVMSYGERPYWDMTNQDVINAIEQDYRLPPPMDCPSALHQLMLDCWQKDRNHRPKFGQIVNTLDKMIRNPNSLKAMAPLSSGINLPLLDRTIPDYTSFNTVDEWLEAIKMGQYKESFANAGFTSFDVVSQMMMEDILRVGVTLAGHQKKILNSIQVMRAQMNQIQSVEGQPLARRPRATGRTKRCQPRDVTKKTCNSNDGKKKGMGKKKTDPGRGREIQGIFFKEDSHKESNDCSCGG
T73756	DRUGINFO	DXWP72	SEphB4-HSA	Phase 2
T73756	DRUGINFO	D01IED	BVD-523	Phase 2
T73756	DRUGINFO	D0A1DG	KO-947	Phase 1
T73756	DRUGINFO	D0L1GD	MK-8353	Phase 1
T73756	DRUGINFO	D0H3IS	SNEWIQPRLPQH	Investigative
T73756	DRUGINFO	D05FXD	PMID19788238C66	Investigative
T73756	DRUGINFO	D00ICA	AMP-PNP	Investigative
T73756	DRUGINFO	D0X8BU	PMID23489211C20	Investigative

T98269	TARGETID	T98269
T98269	FORMERID	TTDR00434
T98269	UNIPROID	CASP1_HUMAN
T98269	TARGNAME	Caspase-1 (CASP1)
T98269	GENENAME	CASP1
T98269	TARGTYPE	Clinical trial
T98269	SYNONYMS	P45; Interleukin-1 beta-converting enzyme; Interleukin-1 beta converting enzyme; Interleukin-1 beta convertase; IL1BCE; IL1BC; IL-1BC; IL-1 beta-converting enzyme; IL-1 beta converting enzyme; ICE; CASP-1
T98269	FUNCTION	Important for defense against pathogens. Cleaves and activates sterol regulatory element binding proteins (SREBPs). Can also promote apoptosis. Upon inflammasome activation, during DNA virus infection but not RNA virus challenge, controls antiviral immunity through the cleavage of CGAS, rendering it inactive. Thiol protease that cleaves IL-1 beta between an Asp and an Ala, releasing the mature cytokine which is involved in a variety of inflammatory processes.
T98269	BIOCLASS	Peptidase
T98269	ECNUMBER	EC 3.4.22.36
T98269	SEQUENCE	MADKVLKEKRKLFIRSMGEGTINGLLDELLQTRVLNKEEMEKVKRENATVMDKTRALIDSVIPKGAQACQICITYICEEDSYLAGTLGLSADQTSGNYLNMQDSQGVLSSFPAPQAVQDNPAMPTSSGSEGNVKLCSLEEAQRIWKQKSAEIYPIMDKSSRTRLALIICNEEFDSIPRRTGAEVDITGMTMLLQNLGYSVDVKKNLTASDMTTELEAFAHRPEHKTSDSTFLVFMSHGIREGICGKKHSEQVPDILQLNAIFNMLNTKNCPSLKDKPKVIIIQACRGDSPGVVWFKDSVGVSGNLSLPTTEEFEDDAIKKAHIEKDFIAFCSSTPDNVSWRHPTMGSVFIGRLIEHMQEYACSCDVEEIFRKVRFSFEQPDGRAQMPTTERVTLTRCFYLFPGH
T98269	DRUGINFO	D0HK3N	Belnacasan	Phase 2
T98269	DRUGINFO	D0U6WQ	PRALNACASAN	Phase 2
T98269	DRUGINFO	D0Z2JF	Nivocasan	Phase 2
T98269	DRUGINFO	D0WP2R	AC-201	Phase 2
T98269	DRUGINFO	D04KIH	Ac-YVAD-FMK	Patented
T98269	DRUGINFO	D07AVV	Ac-YVAD-cmk	Patented
T98269	DRUGINFO	D0A3HF	VE-16084	Terminated
T98269	DRUGINFO	D0F9FA	L-709049	Terminated
T98269	DRUGINFO	D0K1CL	SDZ-224-015	Terminated
T98269	DRUGINFO	D0B3WF	YVAD	Investigative
T98269	DRUGINFO	D0P3XJ	Z-YVAD-CHO	Investigative
T98269	DRUGINFO	D0X8XO	Z-VAD-CHO	Investigative
T98269	DRUGINFO	D0YX4V	Z-YVAD-FMK	Investigative
T98269	DRUGINFO	D00YNW	M826	Investigative

T46365	TARGETID	T46365
T46365	FORMERID	TTDR00116
T46365	UNIPROID	MPIP2_HUMAN
T46365	TARGNAME	M-phase inducer phosphatase 2 (MPIP2)
T46365	GENENAME	CDC25B
T46365	TARGTYPE	Clinical trial
T46365	SYNONYMS	Dual specificity phosphatase Cdc25B; Cdc25B phosphatase; CDC25HU2
T46365	FUNCTION	Required for G2/M phases of the cell cycle progression and abscission during cytokinesis in a ECT2-dependent manner. Directly dephosphorylates CDK1 and stimulates its kinase activity. The three isoforms seem to have a different level of activity. Tyrosine protein phosphatase which functions as a dosage-dependent inducer of mitotic progression.
T46365	PDBSTRUC	4WH9; 4WH7; 3FQU; 3FQT; 2UZQ
T46365	BIOCLASS	Phosphoric monoester hydrolase
T46365	ECNUMBER	EC 3.1.3.48
T46365	SEQUENCE	MEVPQPEPAPGSALSPAGVCGGAQRPGHLPGLLLGSHGLLGSPVRAAASSPVTTLTQTMHDLAGLGSETPKSQVGTLLFRSRSRLTHLSLSRRASESSLSSESSESSDAGLCMDSPSPMDPHMAEQTFEQAIQAASRIIRNEQFAIRRFQSMPVRLLGHSPVLRNITNSQAPDGRRKSEAGSGAASSSGEDKENDGFVFKMPWKPTHPSSTHALAEWASRREAFAQRPSSAPDLMCLSPDRKMEVEELSPLALGRFSLTPAEGDTEEDDGFVDILESDLKDDDAVPPGMESLISAPLVKTLEKEEEKDLVMYSKCQRLFRSPSMPCSVIRPILKRLERPQDRDTPVQNKRRRSVTPPEEQQEAEEPKARVLRSKSLCHDEIENLLDSDHRELIGDYSKAFLLQTVDGKHQDLKYISPETMVALLTGKFSNIVDKFVIVDCRYPYEYEGGHIKTAVNLPLERDAESFLLKSPIAPCSLDKRVILIFHCEFSSERGPRMCRFIRERDRAVNDYPSLYYPEMYILKGGYKEFFPQHPNFCEPQDYRPMNHEAFKDELKTFRLKTRSWAGERSRRELCSRLQDQ
T46365	DRUGINFO	D0C0NH	Avastin+/-Tarceva	Phase 3
T46365	DRUGINFO	D06REJ	MX-7065	Terminated
T46365	DRUGINFO	D02UHP	6,7-dibromoquinoline-5,8-dione	Investigative
T46365	DRUGINFO	D0L5LN	ANTHRAQUINONE	Investigative
T46365	DRUGINFO	D0SI7S	5,6,7,8-tetrahydroanthracene-1,4-dione	Investigative
T46365	DRUGINFO	D07FFL	ADOCIAQUINONE B	Investigative
T46365	DRUGINFO	D07JRA	3-isopropyl-4-phenylnaphthalene-1,2-dione	Investigative
T46365	DRUGINFO	D07REK	4-ethoxynaphthalene-1,2-dione	Investigative
T46365	DRUGINFO	D09CZV	Methyl Mercury Ion	Investigative
T46365	DRUGINFO	D0J1KH	NSC-95397	Investigative
T46365	DRUGINFO	D0X5WD	3-isopropyl-4-(phenylamino)naphthalene-1,2-dione	Investigative
T46365	DRUGINFO	D08GWQ	3-isopropyl-4-(phenylthio)naphthalene-1,2-dione	Investigative
T46365	DRUGINFO	D0N7YT	4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione	Investigative
T46365	DRUGINFO	D05AMX	Cysteinesulfonic Acid	Investigative
T46365	DRUGINFO	D0V6UC	Cysteine Sulfenic Acid	Investigative
T46365	DRUGINFO	D0H1GU	Double Oxidized Cysteine	Investigative
T46365	DRUGINFO	D0Q5FV	2-Sulfhydryl-Ethanol	Investigative

T28226	TARGETID	T28226
T28226	FORMERID	TTDR00115
T28226	UNIPROID	GCH1_HUMAN
T28226	TARGNAME	GTP cyclohydrolase-I (GCH1)
T28226	GENENAME	GCH1
T28226	TARGTYPE	Clinical trial
T28226	SYNONYMS	Guanosine triphosphate cyclohydrolase I; GTP-CH-I; GTP cyclohydrolase I; GTP cyclohydrolase 1; GCH; DYT5
T28226	FUNCTION	May be involved in dopamine synthesis. May modify pain sensitivity and persistence. Isoform GCH-1 is the functional enzyme, the potential function of the enzymatically inactive isoforms remains unknown. Positively regulates nitric oxide synthesis in umbilical vein endothelial cells (HUVECs).
T28226	PDBSTRUC	1FB1
T28226	BIOCLASS	Carbon-nitrogen hydrolase
T28226	ECNUMBER	EC 3.5.4.16
T28226	SEQUENCE	MEKGPVRAPAEKPRGARCSNGFPERDPPRPGPSRPAEKPPRPEAKSAQPADGWKGERPRSEEDNELNLPNLAAAYSSILSSLGENPQRQGLLKTPWRAASAMQFFTKGYQETISDVLNDAIFDEDHDEMVIVKDIDMFSMCEHHLVPFVGKVHIGYLPNKQVLGLSKLARIVEIYSRRLQVQERLTKQIAVAITEALRPAGVGVVVEATHMCMVMRGVQKMNSKTVTSTMLGVFREDPKTREEFLTLIRS
T28226	DRUGINFO	D08NKJ	Guanine	Phase 3
T28226	DRUGINFO	D05ICS	ProSavin	Phase 1/2
T28226	DRUGINFO	D72UDH	OXB-102	Phase 1/2
T28226	DRUGINFO	D07FSW	8-hydroxyguanine	Investigative
T28226	DRUGINFO	D0EQ4T	Guanosine-5'-Triphosphate	Investigative
T28226	DRUGINFO	D0W7LK	2-Propanol, Isopropanol	Investigative

T73724	TARGETID	T73724
T73724	FORMERID	TTDR00164
T73724	UNIPROID	ACHB4_HUMAN
T73724	TARGNAME	Neuronal acetylcholine receptor beta-4 (CHRNB4)
T73724	GENENAME	CHRNB4
T73724	TARGTYPE	Clinical trial
T73724	SYNONYMS	CHRNB4; Beta-4 nAChR
T73724	FUNCTION	After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
T73724	PDBSTRUC	2ASG
T73724	BIOCLASS	Neurotransmitter receptor
T73724	SEQUENCE	MRRAPSLVLFFLVALCGRGNCRVANAEEKLMDDLLNKTRYNNLIRPATSSSQLISIKLQLSLAQLISVNEREQIMTTNVWLKQEWTDYRLTWNSSRYEGVNILRIPAKRIWLPDIVLYNNADGTYEVSVYTNLIVRSNGSVLWLPPAIYKSACKIEVKYFPFDQQNCTLKFRSWTYDHTEIDMVLMTPTASMDDFTPSGEWDIVALPGRRTVNPQDPSYVDVTYDFIIKRKPLFYTINLIIPCVLTTLLAILVFYLPSDCGEKMTLCISVLLALTFFLLLISKIVPPTSLDVPLIGKYLMFTMVLVTFSIVTSVCVLNVHHRSPSTHTMAPWVKRCFLHKLPTFLFMKRPGPDSSPARAFPPSKSCVTKPEATATSTSPSNFYGNSMYFVNPASAASKSPAGSTPVAIPRDFWLRSSGRFRQDVQEALEGVSFIAQHMKNDDEDQSVVEDWKYVAMVVDRLFLWVFMFVCVLGTVGLFLPPLFQTHAASEGPYAAQRD
T73724	DRUGINFO	D08XPW	CYTISINE	Phase 3
T73724	DRUGINFO	D00ECO	SIB-1553A	Discontinued in Phase 2
T73724	DRUGINFO	D0C9KD	HOMOEPIBATIDINE	Terminated
T73724	DRUGINFO	D00YDR	18-Methylaminocoronaridine	Investigative
T73724	DRUGINFO	D02FCS	15-nor-18-Methoxycornaridine	Investigative
T73724	DRUGINFO	D06CDG	2-Acetylaminoethyl 18-methoxycoronaridinate	Investigative
T73724	DRUGINFO	D0B6PX	N,N-Dimethylaminoethyl 18-methoxycoronaridinate	Investigative
T73724	DRUGINFO	D0F7XJ	2-Methoxyethyl 18-methoxycoronaridinate	Investigative
T73724	DRUGINFO	D0T2YP	2-Hydroxyethyl 18-methoxycoronaridinate	Investigative
T73724	DRUGINFO	D0U0LH	18-Dimethylaminocoronaridine	Investigative
T73724	DRUGINFO	D0VA5V	18-methoxycoronaridinate 2-Hydroxyethylamide	Investigative
T73724	DRUGINFO	D0WQ9A	18-methoxycoronaridinate 2-methoxyethylamide	Investigative
T73724	DRUGINFO	D0UH8F	GCCSNPVCHLEHSNLC*	Investigative
T73724	DRUGINFO	D00QCP	(2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol	Investigative
T73724	DRUGINFO	D03YQY	(2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol	Investigative

T86364	TARGETID	T86364
T86364	FORMERID	TTDC00204
T86364	UNIPROID	VIPR1_HUMAN
T86364	TARGNAME	Vasoactive intestinal polypeptide receptor 1 (VIPR1)
T86364	GENENAME	VIPR1
T86364	TARGTYPE	Clinical trial
T86364	SYNONYMS	Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide receptor-1; Vasoactive intestinal peptide receptor 1; VPAC1; VPAC-1; VIPR1; VIP-R-1; Pituitary adenylate cyclase activating polypeptide type II receptor; PACAP-R-2; PACAP type II receptor
T86364	FUNCTION	This is a receptor for vip. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. The affinity is vip = pacap-27 > pacap-38.
T86364	PDBSTRUC	5IB5; 5IB4; 5IB3; 5IB2; 5IB1
T86364	BIOCLASS	GPCR secretin
T86364	SEQUENCE	MRPPSPLPARWLCVLAGALAWALGPAGGQAARLQEECDYVQMIEVQHKQCLEEAQLENETIGCSKMWDNLTCWPATPRGQVVVLACPLIFKLFSSIQGRNVSRSCTDEGWTHLEPGPYPIACGLDDKAASLDEQQTMFYGSVKTGYTIGYGLSLATLLVATAILSLFRKLHCTRNYIHMHLFISFILRAAAVFIKDLALFDSGESDQCSEGSVGCKAAMVFFQYCVMANFFWLLVEGLYLYTLLAVSFFSERKYFWGYILIGWGVPSTFTMVWTIARIHFEDYGCWDTINSSLWWIIKGPILTSILVNFILFICIIRILLQKLRPPDIRKSDSSPYSRLARSTLLLIPLFGVHYIMFAFFPDNFKPEVKMVFELVVGSFQGFVVAILYCFLNGEVQAELRRKWRRWHLQGVLGWNPKYRHPSGGSNGATCSTQVSMLTRVSPGARRSSSFQAEVSLV
T86364	DRUGINFO	D0T4TN	Vasoactive intestinal peptide	Phase 2
T86364	DRUGINFO	D0B2MN	helodermin	Investigative
T86364	DRUGINFO	D0MC5J	PACAP-27	Investigative

T16016	TARGETID	T16016
T16016	FORMERID	TTDC00215
T16016	UNIPROID	CCR1_HUMAN
T16016	TARGNAME	C-C chemokine receptor type 1 (CCR1)
T16016	GENENAME	CCR1
T16016	TARGTYPE	Clinical trial
T16016	SYNONYMS	SCYAR1; RANTES-R; Macrophage inflammatory protein-1 alpha receptor; Macrophage inflammatory protein 1-alpha receptor; MIP-1alpha-R; LD78 receptor; HM145; Chemokine receptor CCR1; CMKR1; CMKBR1; CD191; CCR-1; CC-CKR-1; C-C CKR-1
T16016	FUNCTION	Binds to MIP-1-alpha, MIP-1-delta, RANTES, and MCP-3 and, less efficiently, to MIP-1-beta or MCP-1 and subsequently transduces a signal by increasing the intracellular calcium ions level. Responsible for affecting stem cell proliferation. Receptor for a C-C type chemokine.
T16016	PDBSTRUC	1Y5D
T16016	BIOCLASS	GPCR rhodopsin
T16016	SEQUENCE	METPNTTEDYDTTTEFDYGDATPCQKVNERAFGAQLLPPLYSLVFVIGLVGNILVVLVLVQYKRLKNMTSIYLLNLAISDLLFLFTLPFWIDYKLKDDWVFGDAMCKILSGFYYTGLYSEIFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIIIWALAILASMPGLYFSKTQWEFTHHTCSLHFPHESLREWKLFQALKLNLFGLVLPLLVMIICYTGIIKILLRRPNEKKSKAVRLIFVIMIIFFLFWTPYNLTILISVFQDFLFTHECEQSRHLDLAVQVTEVIAYTHCCVNPVIYAFVGERFRKYLRQLFHRRVAVHLVKWLPFLSVDRLERVSSTSPSTGEHELSAGF
T16016	DRUGINFO	D05VTN	CCX-354	Phase 2
T16016	DRUGINFO	D0UX2V	BMS-817399	Phase 2
T16016	DRUGINFO	D0Q2BB	AVE1701	Phase 1
T16016	DRUGINFO	D00PFW	AZD4818	Discontinued in Phase 2
T16016	DRUGINFO	D0KF6X	MLN3897	Discontinued in Phase 2
T16016	DRUGINFO	D00FOE	COSALANE	Terminated
T16016	DRUGINFO	D05XZF	BX 471	Investigative
T16016	DRUGINFO	D0X9MZ	Cosalane derivative	Investigative
T16016	DRUGINFO	D0F9QT	A-987306	Investigative

T35734	TARGETID	T35734
T35734	FORMERID	TTDR01203
T35734	UNIPROID	HYES_HUMAN
T35734	TARGNAME	Soluble epoxide hydrolase (EPHX2)
T35734	GENENAME	EPHX2
T35734	TARGTYPE	Clinical trial
T35734	SYNONYMS	Bifunctional epoxide hydrolase 2
T35734	FUNCTION	Bifunctional enzyme. The C-terminal domain has epoxide hydrolase activity and acts on epoxides (alkene oxides, oxiranes) and arene oxides. Plays a role in xenobiotic metabolism by degrading potentially toxic epoxides (By similarity). Also determines steady-state levels of physiological mediators. The N-terminal domain has lipid phosphatase activity, with the highest activity towards threo-9,10-phosphonooxy-hydroxy-octadecanoic acid, followed by erythro-9,10-phosphonooxy-hydroxy-octadecanoic acid, 12-phosphonooxy-octadec-9Z-enoic acid and 12-phosphonooxy-octadec-9E-enoic acid.
T35734	PDBSTRUC	6AUM; 5MWA; 5FP0; 5AM5; 5AM4
T35734	BIOCLASS	Ether bond hydrolase
T35734	SEQUENCE	MTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARNPPVVSKM
T35734	DRUGINFO	D0KL3U	AR9281	Phase 2
T35734	DRUGINFO	D0A8KQ	GSK2256294	Phase 1
T35734	DRUGINFO	D00CHD	13-n-Heptanamidotridec-8(Z)-enoic acid	Investigative
T35734	DRUGINFO	D00HAZ	N-(naphthalen-1-yl)benzo[d]isoxazol-3-amine	Investigative
T35734	DRUGINFO	D00RST	1-adamantan-1-yl-3-(6-propyloxyhexyl)urea	Investigative
T35734	DRUGINFO	D00VZE	N-adamantyl-N'-cyclohexylurea	Investigative
T35734	DRUGINFO	D01CGC	13-(N-Methyl-n-heptnamido)tridec-8(Z)-enoic acid	Investigative
T35734	DRUGINFO	D01DZF	N-(3,3-Diphenyl-propyl)-isonicotinamide	Investigative
T35734	DRUGINFO	D01JJV	1-Adamantan-1-yl-3-(3-hydroxy-phenyl)-urea	Investigative
T35734	DRUGINFO	D01NFH	1-Cyclohexyl-3-(1-propionylpiperidin-4-yl)urea	Investigative
T35734	DRUGINFO	D01OZF	1-(4-(3-morpholinopropoxy)phenyl)-3-phenylurea	Investigative
T35734	DRUGINFO	D02ATA	9-(3-n-Pentylureido)non-4-ynoic acid	Investigative
T35734	DRUGINFO	D02CKF	13-(3-n-Pentylureido)tridec-8-ynoic acid	Investigative
T35734	DRUGINFO	D02UJV	1-(3-(3-morpholinopropoxy)phenyl)-3-phenylurea	Investigative
T35734	DRUGINFO	D02YEE	N-benzyl-6-(3,3,3-trifluoropropoxy)nicotinamide	Investigative
T35734	DRUGINFO	D03CSL	13-(n-Pentylcarbamoyloxy)tridec-8(Z)-enoic acid	Investigative
T35734	DRUGINFO	D03IVU	Methyl 14-(3-n-butylureido)tetradec-8(Z)-enoate	Investigative
T35734	DRUGINFO	D04ARH	1-Octyl-3-(1-propionylpiperidin-4-yl)urea	Investigative
T35734	DRUGINFO	D04NJC	1-Adamantan-1-yl-3-(4-methoxy-phenyl)-urea	Investigative
T35734	DRUGINFO	D04PNC	2-Cyclohexyl-N-phenethyl-acetamide	Investigative
T35734	DRUGINFO	D05IKY	14-(n-Hexylamino)-14-oxotetradec-8(Z)-enoic acid	Investigative
T35734	DRUGINFO	D05MAT	1-adamantan-1-yl-3-(3-hydroxypropyl)urea	Investigative
T35734	DRUGINFO	D05MTA	1-adamantan-1-yl-3-(4-pentyloxycylclohexyl)urea	Investigative
T35734	DRUGINFO	D05NZH	Methyl 4-(3-cyclohexylureido)butanoate	Investigative
T35734	DRUGINFO	D06DZO	Dodecanoic acid adamantan-1-ylamide	Investigative
T35734	DRUGINFO	D06OFY	[4-(3-Adamantan-1-yl-ureido)-phenyl]-acetic acid	Investigative
T35734	DRUGINFO	D06RJQ	1-(3-Chloro-phenyl)-3-(4-hydroxy-decyl)-urea	Investigative
T35734	DRUGINFO	D07BJC	13-n-Heptanamidotridec-5-ynoic acid	Investigative
T35734	DRUGINFO	D07BQN	N-(3,3-Diphenyl-propyl)-2-pyridine-3-ylacetamide	Investigative
T35734	DRUGINFO	D07HSQ	1-adamantan-1-yl-3-((R)-1-phenyl-ethyl)-urea	Investigative
T35734	DRUGINFO	D07HWV	13-(5-n-Pentylfuran-2-yl)tridec-8(Z)-enoic acid	Investigative
T35734	DRUGINFO	D07MHZ	N-Cyclohexyl-N'-(Propyl)Phenyl Urea	Investigative
T35734	DRUGINFO	D07QNN	N-Cyclohexyl-2-phenyl-acetamide	Investigative
T35734	DRUGINFO	D07TOI	1-adamantan-1-yl-3-(4-pentyloxybutyl)urea	Investigative
T35734	DRUGINFO	D07UIO	13-(3-n-Pentylureido)tridec-8(E)-enoic acid	Investigative
T35734	DRUGINFO	D08AKP	13-(N-Isopropylheptanamido)tridec-8(Z)-enoic acid	Investigative
T35734	DRUGINFO	D08AZT	1-Adamantan-1-yl-3-(2-hydroxy-phenyl)-urea	Investigative
T35734	DRUGINFO	D08HUX	N-(3,3-diphenyl-propyl)-nicotinamide	Investigative
T35734	DRUGINFO	D08IBD	N-(3-Chloro-phenyl)-2-cyclohexyl-acetamide	Investigative
T35734	DRUGINFO	D08RFH	Cis-1-adamantan-1-yl-3-(4-methoxycyclohexyl)urea	Investigative
T35734	DRUGINFO	D08RPW	1-Cyclohexyl-3-phenethyl-urea	Investigative
T35734	DRUGINFO	D08TWI	12-(3-n-Hexylureido)dodec-8(Z)-enoic acid	Investigative
T35734	DRUGINFO	D08USX	N-(4,4-Diphenyl-butyl)-nicotinamide	Investigative
T35734	DRUGINFO	D08WHU	4-(3-Adamantan-1-yl-ureido)-benzoic acid	Investigative
T35734	DRUGINFO	D08XYV	9-(3-n-Pentylureido)non-4(Z)-enoic acid	Investigative
T35734	DRUGINFO	D08YJF	2-Cyclohexyl-N-phenyl-acetamide	Investigative
T35734	DRUGINFO	D09DPC	1-Adamantan-1-yl-3-(2-methoxy-phenyl)-urea	Investigative
T35734	DRUGINFO	D09FEC	1-Cyclohexyl-3-(4-methoxy-phenyl)-urea	Investigative
T35734	DRUGINFO	D09VSL	1-adamantan-1-yl-3-piperidin-4-ylmethyl-urea	Investigative
T35734	DRUGINFO	D09WQW	6-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}HEXANOIC ACID	Investigative
T35734	DRUGINFO	D0A4VS	1-adamantan-1-yl-3-[4-(4-fluorophenoxy)butyl]urea	Investigative
T35734	DRUGINFO	D0AT6Z	16-(3-Ethylureido)hexadec-11(Z)-enoic acid	Investigative
T35734	DRUGINFO	D0B0ES	1-(3-Chloro-phenyl)-3-cyclohexyl-urea	Investigative
T35734	DRUGINFO	D0B0MU	12-(3-n-Pentylureidooxy)dodec-8(Z)-enoic acid	Investigative
T35734	DRUGINFO	D0B3GP	6-amino-N-(2,4-dichlorobenzyl)nicotinamide	Investigative
T35734	DRUGINFO	D0B4CV	N-[(CYCLOHEXYLAMINO)CARBONYL]GLYCINE	Investigative
T35734	DRUGINFO	D0BI0Z	4,4-Diphenyl-N-(pyridin-3-yl)-butyramide	Investigative
T35734	DRUGINFO	D0C1EP	N-(biphenyl-3-yl)benzo[d]isoxazol-3-amine	Investigative
T35734	DRUGINFO	D0C5GW	1-Cyclohexyl-3-phenyl-urea	Investigative
T35734	DRUGINFO	D0C8HN	13-(3-n-Pentylthioureido)tridec-8(Z)-enoic Acid	Investigative
T35734	DRUGINFO	D0D0KT	N-(3-Phenyl-propyl)-nicotinamide	Investigative
T35734	DRUGINFO	D0D3GF	1-adamantan-1-yl-3-(1-butyl-piperidin-4-yl)-urea	Investigative
T35734	DRUGINFO	D0D7ID	N-Cyclohexyl-N'-Decylurea	Investigative
T35734	DRUGINFO	D0F3PF	1-adamantan-1-yl-3-(1-benzyl-piperidin-4-yl)-urea	Investigative
T35734	DRUGINFO	D0F3VZ	1-Cycloheptyl-3-(1-propionylpiperidin-4-yl)urea	Investigative
T35734	DRUGINFO	D0F5XQ	1-adamantan-1-yl-3-(4-hydroxybutyl)urea	Investigative
T35734	DRUGINFO	D0G8HM	N-Cyclohexyl-N'-(4-Iodophenyl)Urea	Investigative
T35734	DRUGINFO	D0I0YE	N-[3,3-Bis-(4-fluorophenyl)-propyl]-benzamide	Investigative
T35734	DRUGINFO	D0I4KB	1-(1-Propionylpiperidin-4-yl)-3-p-tolylurea	Investigative
T35734	DRUGINFO	D0IC8U	1-adamantan-1-yl-3-(1-propyl-piperidin-4-yl)-urea	Investigative
T35734	DRUGINFO	D0IM1Q	N-(biphenyl-4-yl)benzo[d]isoxazol-3-amine	Investigative
T35734	DRUGINFO	D0J0YB	1-adamantan-1-yl-3-(2-hydroxyethyl)urea	Investigative
T35734	DRUGINFO	D0J5KK	1-adamantan-1-yl-3-piperidin-4-yl-urea	Investigative
T35734	DRUGINFO	D0J7FK	Methyl 6-(3-cyclohexylureido)hexanoate	Investigative
T35734	DRUGINFO	D0K6GX	N-Cyclohexyl-4-phenyl-butyramide	Investigative
T35734	DRUGINFO	D0K6IW	N-[3,3-Bis-(4-fluorophenyl)-propyl]-nicotinamide	Investigative
T35734	DRUGINFO	D0K6OL	2-Cyclohexyl-N-(4-methoxy-phenyl)-acetamide	Investigative
T35734	DRUGINFO	D0M0KA	1-adamantan-1-yl-3-(5-butoxypentyl)urea	Investigative
T35734	DRUGINFO	D0N1SE	1-(1-Propionylpiperidin-4-yl)-3-m-tolylurea	Investigative
T35734	DRUGINFO	D0P3WB	6-amino-N-(3,3-diphenylpropyl)nicotinamide	Investigative
T35734	DRUGINFO	D0P8MM	1-(1-Propionylpiperidin-4-yl)-3-o-tolylurea	Investigative
T35734	DRUGINFO	D0Q8NE	1-Adamantan-1-yl-3-(4-hydroxy-phenyl)-urea	Investigative
T35734	DRUGINFO	D0R1YP	Trans,trans-1,3-bis-(4-hydroxycyclohexyl)urea	Investigative
T35734	DRUGINFO	D0R6CW	1-Phenyl-3-(1-propionylpiperidin-4-yl)urea	Investigative
T35734	DRUGINFO	D0RK4K	3-(3-Adamantan-1-yl-ureido)-benzoic acid	Investigative
T35734	DRUGINFO	D0RX9W	N,N'-dicyclohexyl-urea	Investigative
T35734	DRUGINFO	D0S0SH	12-(3-Adamantan-1-yl-ureido)-dodeca noic acid	Investigative
T35734	DRUGINFO	D0S3KS	N-Cyclohexyl-2-(4-methoxy-phenyl)-acetamide	Investigative
T35734	DRUGINFO	D0T9ZN	1-Adamantan-1-yl-3-(4-hydroxy-decyl)-urea	Investigative
T35734	DRUGINFO	D0TS7G	4-(3-cyclohexylureido)butanoic acid	Investigative
T35734	DRUGINFO	D0U0WU	13-(3-Pentyluredo)tridec-8(Z)-enoic acid	Investigative
T35734	DRUGINFO	D0U4KM	1-(1-Adamantyl)-3-(1-propionylpiperidin-4-yl)urea	Investigative
T35734	DRUGINFO	D0U6TM	2-Adamantan-1-yl-N-decyl-acetamide	Investigative
T35734	DRUGINFO	D0UJ9V	1-adamantan-1-yl-3-(5-hydroxypentyl)urea	Investigative
T35734	DRUGINFO	D0V8EQ	1-Adamantan-1-yl-3-(3-methoxy-phenyl)-urea	Investigative
T35734	DRUGINFO	D0VW6Y	1-adamantan-1-yl-3-(3-hexyloxypropyl)urea	Investigative
T35734	DRUGINFO	D0X0ZD	EXRD-4605	Investigative
T35734	DRUGINFO	D0X1EG	13-(3-n-Pentylureido)tridec-5(Z)-enoic acid	Investigative
T35734	DRUGINFO	D0X6ZY	Cis-1-adamantan-1-yl-3-(4-hydroxycyclohexyl)urea	Investigative
T35734	DRUGINFO	D0X7IM	1,3-DIPHENYLUREA	Investigative
T35734	DRUGINFO	D0XG0G	1-Adamantan-1-yl-3-decyl-urea	Investigative
T35734	DRUGINFO	D0XS3W	1-adamantan-1-yl-3-(1-ethyl-piperidin-4-yl)-urea	Investigative
T35734	DRUGINFO	D0YS1G	1-adamantan-1-yl-3-(2-heptyloxyethyl)urea	Investigative
T35734	DRUGINFO	D0Z0XL	N-(naphthalen-2-yl)benzo[d]isoxazol-3-amine	Investigative
T35734	DRUGINFO	D0Z6SS	1-Adamantan-1-yl-3-phenyl-urea	Investigative
T35734	DRUGINFO	D0Z8RL	1-adamantan-1-yl-3-(6-hydroxyhexyl)urea	Investigative

T18876	TARGETID	T18876
T18876	FORMERID	TTDC00151
T18876	UNIPROID	PE2R4_HUMAN
T18876	TARGNAME	Prostaglandin E2 receptor EP4 (PTGER4)
T18876	GENENAME	PTGER4
T18876	TARGTYPE	Clinical trial
T18876	SYNONYMS	Prostanoid EP4 receptor; Prostaglandin E2 receptor EP4 subtype; PTGER2; PGE2 receptor EP4 subtype; PGE receptor EP4 subtype
T18876	FUNCTION	Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. Has a relaxing effect on smooth muscle. May play an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function.
T18876	PDBSTRUC	5YWY; 5YHL
T18876	BIOCLASS	GPCR rhodopsin
T18876	SEQUENCE	MSTPGVNSSASLSPDRLNSPVTIPAVMFIFGVVGNLVAIVVLCKSRKEQKETTFYTLVCGLAVTDLLGTLLVSPVTIATYMKGQWPGGQPLCEYSTFILLFFSLSGLSIICAMSVERYLAINHAYFYSHYVDKRLAGLTLFAVYASNVLFCALPNMGLGSSRLQYPDTWCFIDWTTNVTAHAAYSYMYAGFSSFLILATVLCNVLVCGALLRMHRQFMRRTSLGTEQHHAAAAASVASRGHPAASPALPRLSDFRRRRSFRRIAGAEIQMVILLIATSLVVLICSIPLVVRVFVNQLYQPSLEREVSKNPDLQAIRIASVNPILDPWIYILLRKTVLSKAIEKIKCLFCRIGGSRRERSGQHCSDSQRTSSAMSGHSRSFISRELKEISSTSQTLLPDLSLPDLSENGLGGRNLLPGVPGMGLAQEDTTSLRTLRISETSDSSQGQDSESVLLVDEAGGSGRAGPAPKGSSLQVTFPSETLNLSEKCI
T18876	DRUGINFO	D00IQH	RQ-00000007 (oral)	Phase 2
T18876	DRUGINFO	D03YAS	ONO-AE1-437	Phase 2
T18876	DRUGINFO	D0HJ5H	BGC-20-1531	Phase 2
T18876	DRUGINFO	D0U7WF	16,16-dimethyl-PGE2	Phase 2
T18876	DRUGINFO	D1KES8	IK-007	Phase 1/2
T18876	DRUGINFO	D01SHJ	E7046	Phase 1
T18876	DRUGINFO	D02STG	ONO-4232	Phase 1
T18876	DRUGINFO	D03UHV	ONO-4578	Phase 1
T18876	DRUGINFO	D1G4EK	AN0025	Phase 1
T18876	DRUGINFO	D54FYW	TPST-1495	Phase 1
T18876	DRUGINFO	D00HTY	PGF2alpha	Clinical trial
T18876	DRUGINFO	D0W2OT	BUTAPROST	Patented
T18876	DRUGINFO	D0O4XW	ONO-4819	Discontinued in Phase 2
T18876	DRUGINFO	D01HCL	13,14-dihydro-PGE1	Investigative
T18876	DRUGINFO	D01WXZ	11-deoxy-PGE2	Investigative
T18876	DRUGINFO	D02MXT	MK-2894	Investigative
T18876	DRUGINFO	D03URI	GW 627368	Investigative
T18876	DRUGINFO	D07JMB	8-aza-11-deoxyprostaglandin E1	Investigative
T18876	DRUGINFO	D07UXB	1-OH-PGE1	Investigative
T18876	DRUGINFO	D08CEW	L902688	Investigative
T18876	DRUGINFO	D09TPW	PF-04475270	Investigative
T18876	DRUGINFO	D0D8DA	KAG-308	Investigative
T18876	DRUGINFO	D0F4QJ	CR-5790	Investigative
T18876	DRUGINFO	D0H5TU	RQ-00000008	Investigative
T18876	DRUGINFO	D0N1TQ	ER819762	Investigative
T18876	DRUGINFO	D0S2LO	TCS 2510	Investigative
T18876	DRUGINFO	D0Y6FA	CP734432	Investigative
T18876	DRUGINFO	D05MXO	19(R)-OH-PGE2	Investigative
T18876	DRUGINFO	D07WQV	AH23848	Investigative
T18876	DRUGINFO	D08KPK	ONO-AE3-240	Investigative
T18876	DRUGINFO	D0AK4K	ONO-AE3-208	Investigative
T18876	DRUGINFO	D0I0UI	ONO-AE2-227	Investigative
T18876	DRUGINFO	D02LXJ	3-(2-cinnamylphenyl)acrylic acid	Investigative
T18876	DRUGINFO	D02SAD	3-(2-(4-methoxycinnamyl)phenyl)acrylic acid	Investigative
T18876	DRUGINFO	D06VZS	ONO-AE1-329	Investigative
T18876	DRUGINFO	D0G5MT	11-deoxy-PGE1	Investigative
T18876	DRUGINFO	D0TA0L	FR-181157	Investigative
T18876	DRUGINFO	D0W4GQ	3-(2-((E)-3-phenylprop-1-enyl)phenyl)acrylic acid	Investigative
T18876	DRUGINFO	D0Z3XJ	3-(2-(naphthalen-2-ylmethyl)phenyl)acrylic acid	Investigative
T18876	DRUGINFO	D05SFA	cicaprost	Investigative
T18876	DRUGINFO	D08MNO	butaprost (free acid form)	Investigative
T18876	DRUGINFO	D0BN1U	M&B 28767	Investigative
T18876	DRUGINFO	D06KBO	PGD2	Investigative
T18876	DRUGINFO	D0W7RI	carbacyclin	Investigative
T18876	DRUGINFO	D03PLH	U46619	Investigative

T02546	TARGETID	T02546
T02546	FORMERID	TTDS00416
T02546	UNIPROID	SCN4A_HUMAN
T02546	TARGNAME	Voltage-gated sodium channel alpha Nav1.4 (SCN4A)
T02546	GENENAME	SCN4A
T02546	TARGTYPE	Clinical trial
T02546	SYNONYMS	Voltage-gated sodium channel subunit alpha Nav1.4; Sodium channel protein type IV subunit alpha; Sodium channel protein skeletal muscle subunit alpha; SkM1; SCN4A
T02546	FUNCTION	This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. This sodium channel may be present in both denervated and innervated skeletal muscle.
T02546	PDBSTRUC	6MC9; 6MBA; 6AGF
T02546	BIOCLASS	Voltage-gated ion channel
T02546	SEQUENCE	MARPSLCTLVPLGPECLRPFTRESLAAIEQRAVEEEARLQRNKQMEIEEPERKPRSDLEAGKNLPMIYGDPPPEVIGIPLEDLDPYYSNKKTFIVLNKGKAIFRFSATPALYLLSPFSVVRRGAIKVLIHALFSMFIMITILTNCVFMTMSDPPPWSKNVEYTFTGIYTFESLIKILARGFCVDDFTFLRDPWNWLDFSVIMMAYLTEFVDLGNISALRTFRVLRALKTITVIPGLKTIVGALIQSVKKLSDVMILTVFCLSVFALVGLQLFMGNLRQKCVRWPPPFNDTNTTWYSNDTWYGNDTWYGNEMWYGNDSWYANDTWNSHASWATNDTFDWDAYISDEGNFYFLEGSNDALLCGNSSDAGHCPEGYECIKTGRNPNYGYTSYDTFSWAFLALFRLMTQDYWENLFQLTLRAAGKTYMIFFVVIIFLGSFYLINLILAVVAMAYAEQNEATLAEDKEKEEEFQQMLEKFKKHQEELEKAKAAQALEGGEADGDPAHGKDCNGSLDTSQGEKGAPRQSSSGDSGISDAMEELEEAHQKCPPWWYKCAHKVLIWNCCAPWLKFKNIIHLIVMDPFVDLGITICIVLNTLFMAMEHYPMTEHFDNVLTVGNLVFTGIFTAEMVLKLIAMDPYEYFQQGWNIFDSIIVTLSLVELGLANVQGLSVLRSFRLLRVFKLAKSWPTLNMLIKIIGNSVGALGNLTLVLAIIVFIFAVVGMQLFGKSYKECVCKIALDCNLPRWHMHDFFHSFLIVFRILCGEWIETMWDCMEVAGQAMCLTVFLMVMVIGNLVVLNLFLALLLSSFSADSLAASDEDGEMNNLQIAIGRIKLGIGFAKAFLLGLLHGKILSPKDIMLSLGEADGAGEAGEAGETAPEDEKKEPPEEDLKKDNHILNHMGLADGPPSSLELDHLNFINNPYLTIQVPIASEESDLEMPTEEETDTFSEPEDSKKPPQPLYDGNSSVCSTADYKPPEEDPEEQAEENPEGEQPEECFTEACVQRWPCLYVDISQGRGKKWWTLRRACFKIVEHNWFETFIVFMILLSSGALAFEDIYIEQRRVIRTILEYADKVFTYIFIMEMLLKWVAYGFKVYFTNAWCWLDFLIVDVSIISLVANWLGYSELGPIKSLRTLRALRPLRALSRFEGMRVVVNALLGAIPSIMNVLLVCLIFWLIFSIMGVNLFAGKFYYCINTTTSERFDISEVNNKSECESLMHTGQVRWLNVKVNYDNVGLGYLSLLQVATFKGWMDIMYAAVDSREKEEQPQYEVNLYMYLYFVIFIIFGSFFTLNLFIGVIIDNFNQQKKKLGGKDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPQNKIQGMVYDLVTKQAFDITIMILICLNMVTMMVETDNQSQLKVDILYNINMIFIIIFTGECVLKMLALRQYYFTVGWNIFDFVVVILSIVGLALSDLIQKYFVSPTLFRVIRLARIGRVLRLIRGAKGIRTLLFALMMSLPALFNIGLLLFLVMFIYSIFGMSNFAYVKKESGIDDMFNFETFGNSIICLFEITTSAGWDGLLNPILNSGPPDCDPNLENPGTSVKGDCGNPSIGICFFCSYIIISFLIVVNMYIAIILENFNVATEESSEPLGEDDFEMFYETWEKFDPDATQFIAYSRLSDFVDTLQEPLRIAKPNKIKLITLDLPMVPGDKIHCLDILFALTKEVLGDSGEMDALKQTMEEKFMAANPSKVSYEPITTTLKRKHEEVCAIKIQRAYRRHLLQRSMKQASYMYRHSHDGSGDDAPEKEGLLANTMSKMYGHENGNSSSPSPEEKGEAGDAGPTMGLMPISPSDTAWPPAPPPGQTVRPGVKESLV
T02546	DRUGINFO	D0O9VW	Lanperisone	Phase 3
T02546	DRUGINFO	D0EC2K	SIPATRIGINE	Discontinued in Phase 2
T02546	DRUGINFO	D07EQF	V-102862	Discontinued in Phase 1
T02546	DRUGINFO	D01YPT	CCNCSSKWCRAHSRCC	Investigative
T02546	DRUGINFO	D05PRQ	CCACSSKWCRDHSRCC	Investigative
T02546	DRUGINFO	D06KAD	CCNCASKWCRDHSRCC	Investigative
T02546	DRUGINFO	D0H5QU	ZNCCNCSSKWCRDHSRCC	Investigative
T02546	DRUGINFO	D0KH1D	3-[4-(4-Fluoro-phenoxy)-phenyl]-1H-pyrazole	Investigative
T02546	DRUGINFO	D0M5VF	3-(4-Phenoxy-phenyl)-1H-pyrazole	Investigative
T02546	DRUGINFO	D0RO2K	CCNCSSKWCRDHARCC	Investigative
T02546	DRUGINFO	D0W5HA	XEP-018	Investigative
T02546	DRUGINFO	D0Y4AU	CCNCSAKWCRDHSRCC	Investigative
T02546	DRUGINFO	D0YA8J	grayanotoxin III	Investigative
T02546	DRUGINFO	D0Z5LN	ZRCCNCSSKWCRDHSRCC	Investigative
T02546	DRUGINFO	D0N0KO	CCNCSSKWCRDHSRCC	Investigative
T02546	DRUGINFO	D0B9UU	BW-202W92	Investigative
T02546	DRUGINFO	D0G9WE	batrachotoxin	Investigative
T02546	DRUGINFO	D0S4MN	veratridine	Investigative

T40785	TARGETID	T40785
T40785	FORMERID	TTDS00299
T40785	UNIPROID	FKS1_YEAST
T40785	TARGNAME	Fungal Papulacandin B resistance protein 1 (Fung FKS1)
T40785	GENENAME	Fung FKS1
T40785	TARGTYPE	Clinical trial
T40785	SYNONYMS	UDP-glucose-1,3-beta-D-glucan glucosyltransferase; Papulacandin B sensitivity protein 1 of Saccharomyces cerevisiae; Glucan synthase; FKS1 protein of Saccharomyces cerevisiae; FKS1; CWN53 protein of Saccharomyces cerevisiae; CND1 protein of Saccharomyces cerevisiae; Beta-1,3-glucan synthetase; Beta-1,3-glucan synthase; 1,3-beta-D-glucan-UDP glucosyltransferase of Saccharomyces cerevisiae; (1,3)-beta-D-glucan synthase
T40785	FUNCTION	Alternate catalytic subunit of the 1,3-beta-glucan synthase (GS). Synthesizes 1,3-beta-glucan, a major structural component of the yeast cell wall. Involved in cell wall synthesis, maintenance and cell wall remodeling.
T40785	BIOCLASS	Hexosyltransferase
T40785	ECNUMBER	EC 2.4.1.34
T40785	SEQUENCE	MNTDQQPYQGQTDYTQGPGNGQSQEQDYDQYGQPLYPSQADGYYDPNVAAGTEADMYGQQPPNESYDQDYTNGEYYGQPPNMAAQDGENFSDFSSYGPPGTPGYDSYGGQYTASQMSYGEPNSSGTSTPIYGNYDPNAIAMALPNEPYPAWTADSQSPVSIEQIEDIFIDLTNRLGFQRDSMRNMFDHFMVLLDSRSSRMSPDQALLSLHADYIGGDTANYKKWYFAAQLDMDDEIGFRNMSLGKLSRKARKAKKKNKKAMEEANPEDTEETLNKIEGDNSLEAADFRWKAKMNQLSPLERVRHIALYLLCWGEANQVRFTAECLCFIYKCALDYLDSPLCQQRQEPMPEGDFLNRVITPIYHFIRNQVYEIVDGRFVKRERDHNKIVGYDDLNQLFWYPEGIAKIVLEDGTKLIELPLEERYLRLGDVVWDDVFFKTYKETRTWLHLVTNFNRIWVMHISIFWMYFAYNSPTFYTHNYQQLVDNQPLAAYKWASCALGGTVASLIQIVATLCEWSFVPRKWAGAQHLSRRFWFLCIIFGINLGPIIFVFAYDKDTVYSTAAHVVAAVMFFVAVATIIFFSIMPLGGLFTSYMKKSTRRYVASQTFTAAFAPLHGLDRWMSYLVWVTVFAAKYSESYYFLVLSLRDPIRILSTTAMRCTGEYWWGAVLCKVQPKIVLGLVIATDFILFFLDTYLWYIIVNTIFSVGKSFYLGISILTPWRNIFTRLPKRIYSKILATTDMEIKYKPKVLISQVWNAIIISMYREHLLAIDHVQKLLYHQVPSEIEGKRTLRAPTFFVSQDDNNFETEFFPRDSEAERRISFFAQSLSTPIPEPLPVDNMPTFTVLTPHYAERILLSLREIIREDDQFSRVTLLEYLKQLHPVEWECFVKDTKILAEETAAYEGNENEAEKEDALKSQIDDLPFYCIGFKSAAPEYTLRTRIWASLRSQTLYRTISGFMNYSRAIKLLYRVENPEIVQMFGGNAEGLERELEKMARRKFKFLVSMQRLAKFKPHELENAEFLLRAYPDLQIAYLDEEPPLTEGEEPRIYSALIDGHCEILDNGRRRPKFRVQLSGNPILGDGKSDNQNHALIFYRGEYIQLIDANQDNYLEECLKIRSVLAEFEELNVEQVNPYAPGLRYEEQTTNHPVAIVGAREYIFSENSGVLGDVAAGKEQTFGTLFARTLSQIGGKLHYGHPDFINATFMTTRGGVSKAQKGLHLNEDIYAGMNAMLRGGRIKHCEYYQCGKGRDLGFGTILNFTTKIGAGMGEQMLSREYYYLGTQLPVDRFLTFYYAHPGFHLNNLFIQLSLQMFMLTLVNLSSLAHESIMCIYDRNKPKTDVLVPIGCYNFQPAVDWVRRYTLSIFIVFWIAFVPIVVQELIERGLWKATQRFFCHLLSLSPMFEVFAGQIYSSALLSDLAIGGARYISTGRGFATSRIPFSILYSRFAGSAIYMGARSMLMLLFGTVAHWQAPLLWFWASLSSLIFAPFVFNPHQFAWEDFFLDYRDYIRWLSRGNNQYHRNSWIGYVRMSRARITGFKRKLVGDESEKAAGDASRAHRTNLIMAEIIPCAIYAAGCFIAFTFINAQTGVKTTDDDRVNSVLRIIICTLAPIAVNLGVLFFCMGMSCCSGPLFGMCCKKTGSVMAGIAHGVAVIVHIAFFIVMWVLESFNFVRMLIGVVTCIQCQRLIFHCMTALMLTREFKNDHANTAFWTGKWYGKGMGYMAWTQPSRELTAKVIELSEFAADFVLGHVILICQLPLIIIPKIDKFHSIMLFWLKPSRQIRPPIYSLKQTRLRKRMVKKYCSLYFLVLAIFAGCIIGPAVASAKIHKHIGDSLDGVVHNLFQPINTTNNDTGSQMSTYQSHYYTHTPSLKTWSTIK
T40785	DRUGINFO	D0O2NQ	Eraxis/Vfend	Phase 3
T40785	DRUGINFO	D0V6VL	Cilofungin	Terminated
T40785	DRUGINFO	D09DNJ	L-692289	Investigative
T40785	DRUGINFO	D0C9KY	Pyridobenzimidazole	Investigative
T40785	DRUGINFO	D0E4OS	ACULEACIN A	Investigative

T32240	TARGETID	T32240
T32240	FORMERID	TTDC00251
T32240	UNIPROID	IL15_HUMAN
T32240	TARGNAME	Interleukin-15 (IL15)
T32240	GENENAME	IL15
T32240	TARGTYPE	Clinical trial
T32240	SYNONYMS	IL-15
T32240	FUNCTION	Stimulation by IL15 requires interaction of IL15 with components of the IL2 receptor, including IL2RB and probably IL2RG but not IL2RA. In neutrophils, stimulates phagocytosis probably by signaling through the IL15 receptor, composed of the subunits IL15RA, IL2RB and IL2RG, which results in kinase SYK activation. Cytokine that stimulates the proliferation of T-lymphocytes.
T32240	PDBSTRUC	4GS7; 2Z3R; 2Z3Q; 2XQB
T32240	BIOCLASS	Cytokine: interleukin
T32240	SEQUENCE	MRISKPHLRSISIQCYLCLLLNSHFLTEAGIHVFILGCFSAGLPKTEANWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS
T32240	DRUGINFO	D0A5EN	AMG-714	Phase 2
T32240	DRUGINFO	D53YZV	SAR445877	Phase 2
T32240	DRUGINFO	DE09IO	BNZ-1	Phase 2
T32240	DRUGINFO	DO6T4G	PF-07209960	Phase 1
T32240	DRUGINFO	DT7I5A	N-803	Phase 1

T52921	TARGETID	T52921
T52921	FORMERID	TTDR01247
T52921	UNIPROID	OPRX_HUMAN
T52921	TARGNAME	Nociceptin receptor (OPRL1)
T52921	GENENAME	OPRL1
T52921	TARGTYPE	Clinical trial
T52921	SYNONYMS	Orphanin FQ receptor; Opioid-receptor-like 1; Opioid receptor like-1 receptor; Opioid receptor 4; ORL-1 receptor; ORL-1; OPRL1; OP(4); Kappa-type 3 opioid receptor; KOR-3
T52921	FUNCTION	G-protein coupled opioid receptor that functions as receptor for the endogenous neuropeptide nociceptin. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling via G proteins mediates inhibition of adenylate cyclase activity and calcium channel activity. Arrestins modulate signaling via G proteins and mediate the activation of alternative signaling pathways that lead to the activation of MAP kinases. Plays a role in modulating nociception and the perception of pain. Plays a role in the regulation of locomotor activity by the neuropeptide nociceptin.
T52921	PDBSTRUC	5DHH; 5DHG; 4EA3
T52921	BIOCLASS	GPCR rhodopsin
T52921	SEQUENCE	MEPLFPAPFWEVIYGSHLQGNLSLLSPNHSLLPPHLLLNASHGAFLPLGLKVTIVGLYLAVCVGGLLGNCLVMYVILRHTKMKTATNIYIFNLALADTLVLLTLPFQGTDILLGFWPFGNALCKTVIAIDYYNMFTSTFTLTAMSVDRYVAICHPIRALDVRTSSKAQAVNVAIWALASVVGVPVAIMGSAQVEDEEIECLVEIPTPQDYWGPVFAICIFLFSFIVPVLVISVCYSLMIRRLRGVRLLSGSREKDRNLRRITRLVLVVVAVFVGCWTPVQVFVLAQGLGVQPSSETAVAILRFCTALGYVNSCLNPILYAFLDENFKACFRKFCCASALRRDVQVSDRVRSIAKDVALACKTSETVPRPA
T52921	DRUGINFO	D08FSD	SER-100	Phase 2
T52921	DRUGINFO	D0IA9E	BTRX-246040	Phase 2
T52921	DRUGINFO	D0Z9GM	LY-2940094	Phase 2
T52921	DRUGINFO	D0G2XE	PMX-53	Phase 2
T52921	DRUGINFO	D0W4YO	NOCICEPTIN	Phase 1
T52921	DRUGINFO	D08SNL	JTC-801	Discontinued in Phase 2
T52921	DRUGINFO	D00ACC	ND1251	Discontinued in Phase 1
T52921	DRUGINFO	D0M1YN	ATI-17000	Preclinical
T52921	DRUGINFO	D00BIE	Cyclo-[Asp6,Lys10]N/OFQ(1-13)NH2	Investigative
T52921	DRUGINFO	D00FLZ	CFGGFTGARKCARK	Investigative
T52921	DRUGINFO	D00HYL	F-G-G-F-T-G-A-R-K-S-MeA-R-K-L-A-N-Q-CONH2	Investigative
T52921	DRUGINFO	D00LVW	Ada-RYYRIK-NH2	Investigative
T52921	DRUGINFO	D01CFO	IsoVa-RYYRIK-NH2	Investigative
T52921	DRUGINFO	D01LZL	FGGFTGCRKSCRK	Investigative
T52921	DRUGINFO	D02IMK	FGGFTGARKSARKRKRK	Investigative
T52921	DRUGINFO	D02IWH	F-G-G-F-T-G-A-R-K-S-MeA-R-K-L-A-N-Q-COOH	Investigative
T52921	DRUGINFO	D02LMJ	FGGFTGARKCARKC	Investigative
T52921	DRUGINFO	D02NSY	Banyu Compound-24	Investigative
T52921	DRUGINFO	D02WBU	2,2-diMeBut-RYYRIK-NH2	Investigative
T52921	DRUGINFO	D02WKZ	F-G-G-F-T-G-MeA-R-K-S-A-R-K-L-A-N-Q-CONH2	Investigative
T52921	DRUGINFO	D03BVN	2-MePen-RYYRIK-NH2	Investigative
T52921	DRUGINFO	D04PUK	1-(3,3-diphenylpropyl)-4-phenylpiperidin-4-ol	Investigative
T52921	DRUGINFO	D04WRO	H-RYYRIK-NH2	Investigative
T52921	DRUGINFO	D05EUV	FGGFTGARKSARKRRNQ	Investigative
T52921	DRUGINFO	D05GXA	F-G-G-F-T-G-A-R-K-S-Aib-R-K-L-A-N-Q-COOH	Investigative
T52921	DRUGINFO	D05MUA	NOX 2149	Investigative
T52921	DRUGINFO	D05NHR	FGGFTGARKSARKKRNQ	Investigative
T52921	DRUGINFO	D05NIE	4-(2-(aminomethyl)phenyl)-1-benzylpiperidin-4-ol	Investigative
T52921	DRUGINFO	D05PJJ	NOX 2137a/b	Investigative
T52921	DRUGINFO	D05YMD	MeBut-RYYRIK-NH2	Investigative
T52921	DRUGINFO	D06RSR	Bz--RYYRIK-NH2	Investigative
T52921	DRUGINFO	D06ZTU	FGGFTGARKSARKLLNQ	Investigative
T52921	DRUGINFO	D07HWJ	FGGFTGARKSARKRKNQ	Investigative
T52921	DRUGINFO	D07HZU	FGGFTGARKSARKLVNQ	Investigative
T52921	DRUGINFO	D07KNS	FGGFTGARKSARKLKNQ	Investigative
T52921	DRUGINFO	D07TKE	4-phenyl-1-(3-phenylpropyl)piperidin-4-ol	Investigative
T52921	DRUGINFO	D07WQG	FGGFTGARKSARKLADE	Investigative
T52921	DRUGINFO	D07ZFH	FGGFTRKRKSARKLANQ	Investigative
T52921	DRUGINFO	D08BAW	Bu-RYYRIK-NH2	Investigative
T52921	DRUGINFO	D08NDP	Cyclo[Cys7,Cys10]N/OFQ(1-13)NH2	Investigative
T52921	DRUGINFO	D08RIW	F-G-G-F-T-G-Aib-R-K-S-A-R-K-L-A-N-Q-CONH2	Investigative
T52921	DRUGINFO	D08ZDP	1-benzhydryl-4-(4-butylphenyl)piperidin-4-ol	Investigative
T52921	DRUGINFO	D08ZIR	FGGFTGARKSARKLFNQ	Investigative
T52921	DRUGINFO	D08ZJR	FGGFTGARKSARKWKNQ	Investigative
T52921	DRUGINFO	D09POP	FGGFTGARKRKRKLANQ	Investigative
T52921	DRUGINFO	D09SUP	peptide III-BTD	Investigative
T52921	DRUGINFO	D09XZM	FGGFTCARKCARK	Investigative
T52921	DRUGINFO	D09ZTU	FGGFTGARKSARKWRNQ	Investigative
T52921	DRUGINFO	D0A8NZ	Cyclo[DAsp7,Lys10]N/OFQ(1-13)NH2	Investigative
T52921	DRUGINFO	D0A8ZS	EtBut-RYYRIK-NH2	Investigative
T52921	DRUGINFO	D0A9VZ	F-G-G-F-T-G-A-R-K-S-A-R-K-L-Aib-N-Q-COOH	Investigative
T52921	DRUGINFO	D0AC0A	SB-612111	Investigative
T52921	DRUGINFO	D0BH3Y	FGGFTGARKSARKLRNQ	Investigative
T52921	DRUGINFO	D0C1US	FGGFTGARKSARKLWNQ	Investigative
T52921	DRUGINFO	D0C9QV	F-G-G-F-T-G-MeA-R-K-S-A-R-K-L-A-N-Q-COOH	Investigative
T52921	DRUGINFO	D0CV7C	CFGGFTCARKSARK	Investigative
T52921	DRUGINFO	D0H7NY	FGGFTGARKSARKAANQ	Investigative
T52921	DRUGINFO	D0HK7B	FGGFTGARKSARKYANQ	Investigative
T52921	DRUGINFO	D0HN2M	UFP-112	Investigative
T52921	DRUGINFO	D0I3KG	FGGFTGARKSARKKWNQ	Investigative
T52921	DRUGINFO	D0J2RW	FGGFTGCRKSARKC	Investigative
T52921	DRUGINFO	D0J7DN	F-G-G-F-T-G-A-R-K-S-A-R-K-L-Aib-N-Q-CONH2	Investigative
T52921	DRUGINFO	D0K0CJ	F-G-G-F-T-G-Aib-R-K-S-A-R-K-L-A-N-Q-COOH	Investigative
T52921	DRUGINFO	D0K2NY	Va-RYYRIK-NH2	Investigative
T52921	DRUGINFO	D0K4XA	F-G-G-F-T-G-A-R-K-S-A-R-K-L-MeA-N-Q-COOH	Investigative
T52921	DRUGINFO	D0L1BS	PF-454583	Investigative
T52921	DRUGINFO	D0L3JC	FGGFTGARKSARKRANQ	Investigative
T52921	DRUGINFO	D0L5BC	FGGFTGARKSARKFANQ	Investigative
T52921	DRUGINFO	D0L8YY	SR-14136	Investigative
T52921	DRUGINFO	D0M7TP	Piv-RYYRIK-NH2	Investigative
T52921	DRUGINFO	D0N7ZF	FGGFTGARKSARKWANQ	Investigative
T52921	DRUGINFO	D0O3SJ	FGGFTGARKSARKLYNQ	Investigative
T52921	DRUGINFO	D0O6NZ	F-G-G-F-T-G-A-R-K-S-Aib-R-K-L-A-N-Q-CONH2	Investigative
T52921	DRUGINFO	D0PN2C	IsoBu-RYYRIK-NH2	Investigative
T52921	DRUGINFO	D0PR2Q	Pr-RYYRIK-NH2	Investigative
T52921	DRUGINFO	D0Q2PO	[Asp6,Lys10]N/OFQ(1-13)NH2	Investigative
T52921	DRUGINFO	D0R6GK	F-G-G-F-T-G-A-R-K-S-A-R-K-L-MeA-N-Q-CONH2	Investigative
T52921	DRUGINFO	D0R7FI	4-phenyl-1-(1-phenylpropan-2-yl)piperidin-4-ol	Investigative
T52921	DRUGINFO	D0R7IM	UFP-101	Investigative
T52921	DRUGINFO	D0RS4B	FGGFTGARKSARKVANQ	Investigative
T52921	DRUGINFO	D0SE9S	SCH-221510	Investigative
T52921	DRUGINFO	D0SG5A	FGGFTGARKSARKRWNQ	Investigative
T52921	DRUGINFO	D0SN6V	T-BuAc-RYYRIK-NH2	Investigative
T52921	DRUGINFO	D0T0GL	For-RYYRIK-NH2	Investigative
T52921	DRUGINFO	D0TJ7R	1-benzyl-4-phenylpiperidin-4-ol	Investigative
T52921	DRUGINFO	D0U6FM	Hex-RYYRIK-NH2	Investigative
T52921	DRUGINFO	D0U9QL	[Nphe(1)]-nociceptin (1-13)-NH(2)	Investigative
T52921	DRUGINFO	D0V6HE	FGGFTGARKSARKLARK	Investigative
T52921	DRUGINFO	D0VH3M	Cyclo[Cys6,Cys10]N/OFQ(1-13)NH2	Investigative
T52921	DRUGINFO	D0W7CF	Ac-RYYRIK-NH2	Investigative
T52921	DRUGINFO	D0X2MZ	Syn-1020	Investigative
T52921	DRUGINFO	D0Y0IE	FGGFTGARKSARKL	Investigative
T52921	DRUGINFO	D0Y2MR	F-G-G-F-T-G-Aib-R-K-S-Aib-R-K-L-A-N-Q-CONH2	Investigative
T52921	DRUGINFO	D0Y4EW	N/OFQ-(1-13)-NH2	Investigative
T52921	DRUGINFO	D0Y5AT	FGGFTGARKSARKKKNQ	Investigative
T52921	DRUGINFO	D0Y5MF	BND-001	Investigative
T52921	DRUGINFO	D0YM8F	[D-Asp7,Lys10]N/OFQ(1-13)NH2	Investigative
T52921	DRUGINFO	D0Z3HM	FGGFTGARKSARKKANQ	Investigative
T52921	DRUGINFO	D02TPK	Ac-RYYRIK-GGG-K-(NH2)-YRFB-GGGGG	Investigative
T52921	DRUGINFO	D09CTG	Ac-RYYRIK-K-(NH2)-YRFB	Investigative
T52921	DRUGINFO	D09KBQ	FLUPERAMIDE	Investigative
T52921	DRUGINFO	D0E3RQ	Ac-RYYRIK-GGG-K-(NH2)-YAFGYPS-GG	Investigative
T52921	DRUGINFO	D0F8AX	1-benzhydryl-4-cyclopropylpiperidin-4-ol	Investigative
T52921	DRUGINFO	D0Y2MT	Ac-RYYRIK-K-(NH2)-YAFGYPS	Investigative
T52921	DRUGINFO	D00XZH	1-benzhydryl-4-isopropylpiperidin-4-ol	Investigative
T52921	DRUGINFO	D01MUV	1-benzhydryl-4-tert-butylpiperidin-4-ol	Investigative
T52921	DRUGINFO	D05RII	3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole	Investigative
T52921	DRUGINFO	D06PVO	4-phenyl-1-(1-phenylpropyl)piperidin-4-ol	Investigative
T52921	DRUGINFO	D07FCB	4-phenyl-1-(1-phenylethyl)piperidin-4-ol	Investigative
T52921	DRUGINFO	D0D9BB	1-benzhydryl-4-(pyridin-2-yl)piperidin-4-ol	Investigative
T52921	DRUGINFO	D0IL9H	1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol	Investigative
T52921	DRUGINFO	D0S2OA	1-benzhydryl-4-(benzyloxy)-4-phenylpiperidine	Investigative
T52921	DRUGINFO	D0Y7KE	1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol	Investigative
T52921	DRUGINFO	D00YCW	4-phenyl-1-(1-phenylbutyl)piperidin-4-ol	Investigative
T52921	DRUGINFO	D01WMU	1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol	Investigative
T52921	DRUGINFO	D03PTV	1-benzhydryl-4-ethoxy-4-phenylpiperidine	Investigative
T52921	DRUGINFO	D03UJW	1-benzhydryl-4-butylpiperidin-4-ol	Investigative
T52921	DRUGINFO	D04ZQX	4-phenyl-1-(1-phenylheptyl)piperidin-4-ol	Investigative
T52921	DRUGINFO	D06MQG	1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol	Investigative
T52921	DRUGINFO	D06PHT	1-benzhydryl-4-phenylpiperidin-4-ol	Investigative
T52921	DRUGINFO	D07CIU	1-benzhydryl-4-p-tolylpiperidin-4-ol	Investigative
T52921	DRUGINFO	D07NMH	1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol	Investigative
T52921	DRUGINFO	D08DVV	1-benzhydryl-4-hexylpiperidin-4-ol	Investigative
T52921	DRUGINFO	D08QBU	1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol	Investigative
T52921	DRUGINFO	D08TFY	1-benzhydryl-4-cyclohexylpiperidin-4-ol	Investigative
T52921	DRUGINFO	D09BYD	1-benzhydryl-4-o-tolylpiperidin-4-ol	Investigative
T52921	DRUGINFO	D09FJY	4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol	Investigative
T52921	DRUGINFO	D09LRO	1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol	Investigative
T52921	DRUGINFO	D09VRT	1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol	Investigative
T52921	DRUGINFO	D0D0UP	1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol	Investigative
T52921	DRUGINFO	D0G4FA	1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol	Investigative
T52921	DRUGINFO	D0G7DF	4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol	Investigative
T52921	DRUGINFO	D0J5JO	1-benzhydryl-4-m-tolylpiperidin-4-ol	Investigative
T52921	DRUGINFO	D0JH5D	1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol	Investigative
T52921	DRUGINFO	D0O7JV	4-phenyl-1-(1-phenylhexyl)piperidin-4-ol	Investigative
T52921	DRUGINFO	D0P3FP	4-phenyl-1-(1-phenylpentyl)piperidin-4-ol	Investigative
T52921	DRUGINFO	D0Q9TQ	1-benzhydryl-4-methoxy-4-phenylpiperidine	Investigative
T52921	DRUGINFO	D0QH4A	1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol	Investigative
T52921	DRUGINFO	D0T4ZY	1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol	Investigative
T52921	DRUGINFO	D0T9KE	1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol	Investigative
T52921	DRUGINFO	D0W3VT	1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol	Investigative
T52921	DRUGINFO	D0X4SX	1-benzhydryl-4-phenyl-4-propoxypiperidine	Investigative
T52921	DRUGINFO	D0XX1Y	4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol	Investigative
T52921	DRUGINFO	D0Y5LJ	1-benzhydryl-4-(furan-2-yl)piperidin-4-ol	Investigative
T52921	DRUGINFO	D0ZE2W	1-benzhydryl-4-benzylpiperidin-4-ol	Investigative

T93515	TARGETID	T93515
T93515	FORMERID	TTDC00179
T93515	UNIPROID	P2RY2_HUMAN
T93515	TARGNAME	P2Y purinoceptor 2 (P2RY2)
T93515	GENENAME	P2RY2
T93515	TARGTYPE	Clinical trial
T93515	SYNONYMS	P2Y2; P2U1; P2U receptor; P2U purinoceptor 1; P2U nucleotide receptor; P2RY2; Adenosine P2Y2 receptor
T93515	FUNCTION	Receptor for ATP and UTP coupled to G-proteins thatactivate a phosphatidylinositol-calcium second messenger system. The affinity range is UTP = ATP > ATP-gamma-S >> 2-methylthio-ATP = ADP.
T93515	PDBSTRUC	1Z8E
T93515	BIOCLASS	GPCR rhodopsin
T93515	SEQUENCE	MAADLGPWNDTINGTWDGDELGYRCRFNEDFKYVLLPVSYGVVCVPGLCLNAVALYIFLCRLKTWNASTTYMFHLAVSDALYAASLPLLVYYYARGDHWPFSTVLCKLVRFLFYTNLYCSILFLTCISVHRCLGVLRPLRSLRWGRARYARRVAGAVWVLVLACQAPVLYFVTTSARGGRVTCHDTSAPELFSRFVAYSSVMLGLLFAVPFAVILVCYVLMARRLLKPAYGTSGGLPRAKRKSVRTIAVVLAVFALCFLPFHVTRTLYYSFRSLDLSCHTLNAINMAYKVTRPLASANSCLDPVLYFLAGQRLVRFARDAKPPTGPSPATPARRRLGLRRSDRTDMQRIEDVLGSSEDSRRTESTPAGSENTKDIRL
T93515	DRUGINFO	D0S6AE	Diquafosol	Phase 3
T93515	DRUGINFO	D07QQP	INS-37217	Phase 2
T93515	DRUGINFO	D0Z7FU	INS 316	Discontinued in Phase 3
T93515	DRUGINFO	D04IWB	2-thioUTP	Investigative
T93515	DRUGINFO	D06DBA	SB-416	Investigative
T93515	DRUGINFO	D09CLX	MDT-006	Investigative
T93515	DRUGINFO	D09SFJ	AR-C126313	Investigative
T93515	DRUGINFO	D0GF4I	4-thio-UTP	Investigative
T93515	DRUGINFO	D0P4GP	PSB1114	Investigative
T93515	DRUGINFO	D0Q1HE	MRS2698	Investigative
T93515	DRUGINFO	D0UC4G	PSB-716	Investigative
T93515	DRUGINFO	D0Y3WN	MRS2768	Investigative
T93515	DRUGINFO	D0Z4GJ	AR-C118925XX	Investigative
T93515	DRUGINFO	D02OAJ	UTPgammaS	Investigative
T93515	DRUGINFO	D08DXA	Acid blue 25	Investigative
T93515	DRUGINFO	D0P7RI	5BrUTP	Investigative
T93515	DRUGINFO	D06GQY	PSB-0963	Investigative
T93515	DRUGINFO	D0B0ZQ	RB 2	Investigative

T99347	TARGETID	T99347
T99347	FORMERID	TTDC00100
T99347	UNIPROID	GRM5_HUMAN
T99347	TARGNAME	Metabotropic glutamate receptor 5 (mGluR5)
T99347	GENENAME	GRM5
T99347	TARGTYPE	Clinical trial
T99347	SYNONYMS	MGLUR5; GPRC1E
T99347	FUNCTION	G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling activates a phosphatidylinositol-calcium second messenger system and generates a calcium-activated chloride current. Plays an important role in the regulation of synaptic plasticity and the modulation of the neural network activity.
T99347	PDBSTRUC	6N52; 6N51; 6N50; 6N4Y; 6N4X
T99347	BIOCLASS	GPCR glutamate
T99347	SEQUENCE	MVLLLILSVLLLKEDVRGSAQSSERRVVAHMPGDIIIGALFSVHHQPTVDKVHERKCGAVREQYGIQRVEAMLHTLERINSDPTLLPNITLGCEIRDSCWHSAVALEQSIEFIRDSLISSEEEEGLVRCVDGSSSSFRSKKPIVGVIGPGSSSVAIQVQNLLQLFNIPQIAYSATSMDLSDKTLFKYFMRVVPSDAQQARAMVDIVKRYNWTYVSAVHTEGNYGESGMEAFKDMSAKEGICIAHSYKIYSNAGEQSFDKLLKKLTSHLPKARVVACFCEGMTVRGLLMAMRRLGLAGEFLLLGSDGWADRYDVTDGYQREAVGGITIKLQSPDVKWFDDYYLKLRPETNHRNPWFQEFWQHRFQCRLEGFPQENSKYNKTCNSSLTLKTHHVQDSKMGFVINAIYSMAYGLHNMQMSLCPGYAGLCDAMKPIDGRKLLESLMKTNFTGVSGDTILFDENGDSPGRYEIMNFKEMGKDYFDYINVGSWDNGELKMDDDEVWSKKSNIIRSVCSEPCEKGQIKVIRKGEVSCCWTCTPCKENEYVFDEYTCKACQLGSWPTDDLTGCDLIPVQYLRWGDPEPIAAVVFACLGLLATLFVTVVFIIYRDTPVVKSSSRELCYIILAGICLGYLCTFCLIAKPKQIYCYLQRIGIGLSPAMSYSALVTKTNRIARILAGSKKKICTKKPRFMSACAQLVIAFILICIQLGIIVALFIMEPPDIMHDYPSIREVYLICNTTNLGVVTPLGYNGLLILSCTFYAFKTRNVPANFNEAKYIAFTMYTTCIIWLAFVPIYFGSNYKIITMCFSVSLSATVALGCMFVPKVYIILAKPERNVRSAFTTSTVVRMHVGDGKSSSAASRSSSLVNLWKRRGSSGETLRYKDRRLAQHKSEIECFTPKGSMGNGGRATMSSSNGKSVTWAQNEKSSRGQHLWQRLSIHINKKENPNQTAVIKPFPKSTESRGLGAGAGAGGSAGGVGATGGAGCAGAGPGGPESPDAGPKALYDVAEAEEHFPAPARPRSPSPISTLSHRAGSASRTDDDVPSLHSEPVARSSSSQGSLMEQISSVVTRFTANISELNSMMLSTAAPSPGVGAPLCSSYLIPKEIQLPTTMTTFAEIQPLPAIEVTGGAQPAAGAQAAGDAARESPAAGPEAAAAKPDLEELVALTPPSPFRDSVDSGSTTPNSPVSESALCIPSSPKYDTLIIRDYTQSSSSL
T99347	DRUGINFO	D0G5PF	AFQ056	Phase 2/3
T99347	DRUGINFO	D0I5TL	ADX-48621	Phase 2/3
T99347	DRUGINFO	D04QKU	RG-7090	Phase 2
T99347	DRUGINFO	D09YDQ	STX-107	Phase 2
T99347	DRUGINFO	D0P4WO	ADX10059	Phase 2
T99347	DRUGINFO	D0L1YM	McN3377	Phase 1/2
T99347	DRUGINFO	D09PYZ	MK-3328	Phase 1
T99347	DRUGINFO	D0I0JG	[3H]fenobam	Phase 1
T99347	DRUGINFO	D0L2GX	RG7342	Phase 1
T99347	DRUGINFO	D34YLZ	BMS-984923	Phase 1
T99347	DRUGINFO	DB7V3D	BMS‐984923	Phase 1
T99347	DRUGINFO	D01AFN	Pyrrolidine derivative 3	Patented
T99347	DRUGINFO	D01BSX	Ethynyl compound 7	Patented
T99347	DRUGINFO	D03ZXG	Imidazopyridine and triazolopyridine compound 1	Patented
T99347	DRUGINFO	D04IGZ	Pyrrolidine derivative 4	Patented
T99347	DRUGINFO	D05RUG	Ethynyl compound 6	Patented
T99347	DRUGINFO	D05VWD	Ethynyl compound 5	Patented
T99347	DRUGINFO	D06FVQ	Bicarboxylic and tricarboxylic ethynyl derivative 3	Patented
T99347	DRUGINFO	D06JFS	Pyrazolopyrimidine derivative 2	Patented
T99347	DRUGINFO	D07EFT	Ethynyl compound 3	Patented
T99347	DRUGINFO	D07JTE	Tetra-hydro-pyrazolopyrazine derivative 1	Patented
T99347	DRUGINFO	D07KER	Tetra-hydro-pyrazolopyrazine derivative 3	Patented
T99347	DRUGINFO	D08DMM	Imidazopyridine and triazolopyridine compound 3	Patented
T99347	DRUGINFO	D09CAM	Central azetidine derivative 1	Patented
T99347	DRUGINFO	D09QQS	Diazepinone derivative 1	Patented
T99347	DRUGINFO	D09UVF	Bicarboxylic and tricarboxylic ethynyl derivative 2	Patented
T99347	DRUGINFO	D09VNK	Heterocyclic derivative 2	Patented
T99347	DRUGINFO	D0A7NX	Pyrazolopyrimidine derivative 6	Patented
T99347	DRUGINFO	D0AK4X	Tetra-hydro-oxazolopyridine derivative 5	Patented
T99347	DRUGINFO	D0AZ6X	Pyridine derivative 16	Patented
T99347	DRUGINFO	D0B3CG	Pyrazolopyrimidine derivative 4	Patented
T99347	DRUGINFO	D0B4IU	Heterocyclic derivative 1	Patented
T99347	DRUGINFO	D0BS0K	Tetra-hydro-pyrazolopyrazine derivative 5	Patented
T99347	DRUGINFO	D0CI3E	Bicyclic heteroaryl carboxamide analog 1	Patented
T99347	DRUGINFO	D0CI9L	Pyridine derivative 13	Patented
T99347	DRUGINFO	D0D3GL	Tetra-hydro-pyrazolopyrazine derivative 2	Patented
T99347	DRUGINFO	D0DL7P	Diazepinone derivative 4	Patented
T99347	DRUGINFO	D0DR0S	Pyridine derivative 15	Patented
T99347	DRUGINFO	D0DZ0M	Pyrrolidine derivative 1	Patented
T99347	DRUGINFO	D0FS2X	PMID28067079-Compound-98	Patented
T99347	DRUGINFO	D0GS6T	6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analog 1	Patented
T99347	DRUGINFO	D0HG1W	2-(substituted ethynyl)quinoline derivative 4	Patented
T99347	DRUGINFO	D0IK9N	Ethynyl compound 1	Patented
T99347	DRUGINFO	D0J4QE	Diazepinone derivative 5	Patented
T99347	DRUGINFO	D0K4LQ	Pyrazolopyrimidine derivative 3	Patented
T99347	DRUGINFO	D0KG5I	N-alkylamide derivative 1	Patented
T99347	DRUGINFO	D0L7YW	Pyridine derivative 12	Patented
T99347	DRUGINFO	D0LI2I	Imidazopyridine and triazolopyridine compound 4	Patented
T99347	DRUGINFO	D0LU9X	Tetra-hydro-oxazolopyridine derivative 3	Patented
T99347	DRUGINFO	D0M3VE	Pyrazolopyrimidine derivative 5	Patented
T99347	DRUGINFO	D0M4KF	PMID28067079-Compound-97	Patented
T99347	DRUGINFO	D0M8IR	Heterocyclic derivative 3	Patented
T99347	DRUGINFO	D0MB0V	2-(substituted ethynyl)quinoline derivative 2	Patented
T99347	DRUGINFO	D0MI7K	Bicarboxylic and tricarboxylic ethynyl derivative 1	Patented
T99347	DRUGINFO	D0MM8M	Diazepinone derivative 2	Patented
T99347	DRUGINFO	D0N6HP	Bicyclic heteroaryl carboxamide analog 3	Patented
T99347	DRUGINFO	D0NJ9E	Imidazopyridine and triazolopyridine compound 2	Patented
T99347	DRUGINFO	D0O4KM	Ethynyl compound 4	Patented
T99347	DRUGINFO	D0OH5L	N-alkylamide derivative 2	Patented
T99347	DRUGINFO	D0PJ8X	2-(substituted ethynyl)quinoline derivative 1	Patented
T99347	DRUGINFO	D0Q1WV	Pyrrolidine derivative 5	Patented
T99347	DRUGINFO	D0Q4ST	Diazepinone derivative 3	Patented
T99347	DRUGINFO	D0QE8S	Bicyclic heteroaryl carboxamide analog 2	Patented
T99347	DRUGINFO	D0QM1D	Central azetidine derivative 2	Patented
T99347	DRUGINFO	D0RG9J	Pyrrolidine derivative 2	Patented
T99347	DRUGINFO	D0RU0W	Tetra-hydro-oxazolopyridine derivative 4	Patented
T99347	DRUGINFO	D0SZ5A	Pyrazolopyrimidine derivative 1	Patented
T99347	DRUGINFO	D0T9IR	6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analog 3	Patented
T99347	DRUGINFO	D0UX1S	PMID28067079-Compound-95	Patented
T99347	DRUGINFO	D0V2VM	Pyridine derivative 17	Patented
T99347	DRUGINFO	D0V3SA	Pyridine derivative 14	Patented
T99347	DRUGINFO	D0V5GR	Tetra-hydro-pyrazolopyrazine derivative 4	Patented
T99347	DRUGINFO	D0VI3F	Imidazo[1,2-a]pyridine derivative 1	Patented
T99347	DRUGINFO	D0VM5Z	Ethynyl compound 2	Patented
T99347	DRUGINFO	D0XB2W	6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analog 2	Patented
T99347	DRUGINFO	D0XQ4T	2-(substituted ethynyl)quinoline derivative 3	Patented
T99347	DRUGINFO	D0XX9N	Tetra-hydro-oxazolopyridine derivative 6	Patented
T99347	DRUGINFO	D0DL1O	Tetra-hydro-oxazolopyridine derivative 2	Patented
T99347	DRUGINFO	D0GQ2Z	Tetra-hydro-oxazolopyridine derivative 1	Patented
T99347	DRUGINFO	D06UDV	AZD2516	Discontinued in Phase 2
T99347	DRUGINFO	D09GPB	AZD2066	Discontinued in Phase 2
T99347	DRUGINFO	D04XMJ	LY525327	Terminated
T99347	DRUGINFO	D08XOT	LY467711	Terminated
T99347	DRUGINFO	D00EPM	VU0463841	Investigative
T99347	DRUGINFO	D00HIH	LSN2814617	Investigative
T99347	DRUGINFO	D00JUO	PMID21757343C30	Investigative
T99347	DRUGINFO	D00SAB	7-m-tolyl-1,6-naphthyridine	Investigative
T99347	DRUGINFO	D01AJZ	3-(4-Pyridin-2-yl-imidazol-1-yl)-benzonitrile	Investigative
T99347	DRUGINFO	D01ALS	2-methyl-4-(2-thienylethynyl)thiazole	Investigative
T99347	DRUGINFO	D01AMV	3-(6-fluoroquinazolin-4-ylamino)benzonitrile	Investigative
T99347	DRUGINFO	D01DPN	3-[(5-ethyl-2-methyl-4-thiazolyl)ethynyl]pyridine	Investigative
T99347	DRUGINFO	D01ECL	2-(2-Methyl-thiazol-4-ylethynyl)-pyridine	Investigative
T99347	DRUGINFO	D01FGW	6-bromo-N-(3-bromophenyl)quinazolin-4-amine	Investigative
T99347	DRUGINFO	D01FTP	2-methyl-7-m-tolylquinoline	Investigative
T99347	DRUGINFO	D01MAN	2-Benzoxy-5-(2-methylquinolin-7-yl)benzonitrile	Investigative
T99347	DRUGINFO	D01PTE	2-benzyloxy-7,8-dihydro-6H-quinolin-5-one	Investigative
T99347	DRUGINFO	D01SYO	4-(2-Methyl-thiazol-4-ylethynyl)-pyridine	Investigative
T99347	DRUGINFO	D01TQD	VU0424465	Investigative
T99347	DRUGINFO	D01UUH	4-(3-pyridylethynyl)-2-thiazolylamine	Investigative
T99347	DRUGINFO	D01VOJ	RTI-4229-982	Investigative
T99347	DRUGINFO	D01XMK	2-(3-(2-methylquinolin-7-yl)phenyl)acetonitrile	Investigative
T99347	DRUGINFO	D02BFK	4-(3-chlorophenylethynyl)-2-methylthiazole	Investigative
T99347	DRUGINFO	D02BNC	3-(1,8-naphthyridin-2-yl)benzonitrile	Investigative
T99347	DRUGINFO	D02CKM	N-(3-chlorophenyl)-3-cyano-5-fluorobenzamide	Investigative
T99347	DRUGINFO	D02DOP	3-(1-Pyridin-2-yl-1H-pyrazol-3-yl)-benzonitrile	Investigative
T99347	DRUGINFO	D02GLY	Br-5MPEPy	Investigative
T99347	DRUGINFO	D02KHF	2-Cyclohexylethynyl-pyridine	Investigative
T99347	DRUGINFO	D02MOV	6-bromo-N-(3-fluorophenyl)quinazolin-4-amine	Investigative
T99347	DRUGINFO	D02NHZ	7-(4-methoxyphenyl)-2-methylquinoline	Investigative
T99347	DRUGINFO	D02OHW	2-(3-chlorophenyl)-7-methyl-1,8-naphthyridine	Investigative
T99347	DRUGINFO	D02QEP	VU0361747	Investigative
T99347	DRUGINFO	D02QML	1-(3-(2-methylquinolin-7-yl)phenyl)ethanone	Investigative
T99347	DRUGINFO	D02QTE	ACDPP	Investigative
T99347	DRUGINFO	D02RZH	3-cyano-5-fluoro-N-(3-fluorophenyl)benzamide	Investigative
T99347	DRUGINFO	D02SSD	7-(2-methoxyphenyl)-2-methylquinoline	Investigative
T99347	DRUGINFO	D02VFF	VU0357121	Investigative
T99347	DRUGINFO	D02XFR	3-chloro-N-(4-methylthiazol-2-yl)benzamide	Investigative
T99347	DRUGINFO	D03CCP	2-ethynyl-4-(3-fluorophenylethynyl)thiazole	Investigative
T99347	DRUGINFO	D03FOM	2-(2-methylquinolin-7-yl)benzonitrile	Investigative
T99347	DRUGINFO	D03LCM	3-chloro-N-(6-chloropyridin-2-yl)benzamide	Investigative
T99347	DRUGINFO	D03NIO	5-[(2-methyl-4-thiazolyl)ethynyl]pyrimidine	Investigative
T99347	DRUGINFO	D03NYF	4-Biphenyl-4-ylethynyl-2-methyl-thiazole	Investigative
T99347	DRUGINFO	D03OLR	PMID23374867C24	Investigative
T99347	DRUGINFO	D03QRG	3-(3-methylphenylethynyl)-5-methyl[1,2,4]triazine	Investigative
T99347	DRUGINFO	D03TRO	GRN-529	Investigative
T99347	DRUGINFO	D03UZZ	3-cyano-N-(3-ethynylphenyl)-5-fluorobenzamide	Investigative
T99347	DRUGINFO	D03XHE	alloswitch-1	Investigative
T99347	DRUGINFO	D04BES	2-(4-(3-chlorophenyl)but-1-ynyl)-6-methylpyridine	Investigative
T99347	DRUGINFO	D04GPT	N-(3-acetamidophenyl)-3-chlorobenzamide	Investigative
T99347	DRUGINFO	D04IKS	7-(3-methoxyphenyl)-2-methyl-1,6-naphthyridine	Investigative
T99347	DRUGINFO	D04ILS	2-(3-chlorobenzyloxy)-6-chloroisonicotinonitrile	Investigative
T99347	DRUGINFO	D04PBZ	4-(3-methoxyphenylethynyl)-2-methylthiazole	Investigative
T99347	DRUGINFO	D04RVW	2-Phenyl-5-(2-methylthiazol-4ylethynyl)pyridine	Investigative
T99347	DRUGINFO	D04UDE	7-(4,6-dimethoxypyrimidin-2-yl)-2-methylquinoline	Investigative
T99347	DRUGINFO	D04WGR	5-(2-methylquinolin-7-yl)isophthalonitrile	Investigative
T99347	DRUGINFO	D04YTO	6-fluoro-N-m-tolylquinazolin-4-amine	Investigative
T99347	DRUGINFO	D04YXB	2-phenyl-1,8-naphthyridine	Investigative
T99347	DRUGINFO	D05AJJ	VU0240382	Investigative
T99347	DRUGINFO	D05BPM	3-cyano-5-fluoro-N-m-tolylbenzamide	Investigative
T99347	DRUGINFO	D05DDU	3-(2-methylquinolin-7-yl)phenol	Investigative
T99347	DRUGINFO	D05FCO	2-Cyclopent-1-enylethynyl-pyridine	Investigative
T99347	DRUGINFO	D05FEO	LSN2463359	Investigative
T99347	DRUGINFO	D05HUS	7-(3-fluorophenyl)-2-methylquinoline	Investigative
T99347	DRUGINFO	D05TFE	SIB-1757	Investigative
T99347	DRUGINFO	D05XNS	N-(6-methylpyridin-2-yl)biphenyl-3-carboxamide	Investigative
T99347	DRUGINFO	D06KVX	4-(2-methoxyphenylethynyl)-2-methylthiazole	Investigative
T99347	DRUGINFO	D06OMD	7-(4-methoxypyrimidin-2-yl)-2-methylquinoline	Investigative
T99347	DRUGINFO	D06PTC	2-methyl-6-(5-phenylpent-1-ynyl)pyridine	Investigative
T99347	DRUGINFO	D06SFA	3-(3,4-dimethylphenyl)-1,5-naphthyridine	Investigative
T99347	DRUGINFO	D06SXN	3-methoxy-5-(2-methylquinolin-7-yl)benzonitrile	Investigative
T99347	DRUGINFO	D06TCX	4-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide	Investigative
T99347	DRUGINFO	D06TMM	PTeB	Investigative
T99347	DRUGINFO	D06XFS	2-methyl-7-(pyridin-3-yl)quinoline	Investigative
T99347	DRUGINFO	D06YKH	2-bromo-4-(3-fluorophenylethynyl)thiazole	Investigative
T99347	DRUGINFO	D06ZBT	3-bromo-5-[(2-methyl-4-thiazolyl)ethynyl]pyridine	Investigative
T99347	DRUGINFO	D06ZSX	3-chloro-N-(3-isobutyramidophenyl)benzamide	Investigative
T99347	DRUGINFO	D07FVZ	CPPHA	Investigative
T99347	DRUGINFO	D07FXC	2-(3-(3-methoxyphenoxy)prop-1-ynyl)pyridine	Investigative
T99347	DRUGINFO	D07JLC	3-iodo-N-(6-methylpyridin-2-yl)benzamide	Investigative
T99347	DRUGINFO	D07KEV	5PAM523	Investigative
T99347	DRUGINFO	D07LMB	PMID20809633C29b	Investigative
T99347	DRUGINFO	D07QJQ	2-Methyl-4-phenylethynyl-thiazole	Investigative
T99347	DRUGINFO	D07RRA	2-[(2-methyl-4-thiazolyl)ethynyl]pyrazine	Investigative
T99347	DRUGINFO	D07XZP	N-(1,4-diphenyl-1H-pyrazol-5-yl)benzamide	Investigative
T99347	DRUGINFO	D08ADI	3-(3-(3-chlorobenzyloxy)-5-methylphenyl)pyridine	Investigative
T99347	DRUGINFO	D08FDI	3-(2-Pyridin-2-yl-2H-tetrazol-5-yl)-benzonitrile	Investigative
T99347	DRUGINFO	D08FEV	3-[(2-methyl-4-thiazolyl)ethynyl]benzamide	Investigative
T99347	DRUGINFO	D08KYB	2-(3,5-dimethoxyphenyl)-1,8-naphthyridine	Investigative
T99347	DRUGINFO	D08NJT	3-bromo-5-(2-methylquinolin-7-yl)benzonitrile	Investigative
T99347	DRUGINFO	D08NOP	2-methyl-7-m-tolyl-1,6-naphthyridine	Investigative
T99347	DRUGINFO	D08NQW	CHPG	Investigative
T99347	DRUGINFO	D08PDF	5-(phenylethynyl)pyrimidine	Investigative
T99347	DRUGINFO	D08RLS	2-m-tolyl-1,8-naphthyridine	Investigative
T99347	DRUGINFO	D08SSG	3-[(2,5-dimethyl-4-thiazolyl)ethynyl]pyridine	Investigative
T99347	DRUGINFO	D08SYN	3-cyano-N-(6-ethylpyridin-2-yl)-5-fluorobenzamide	Investigative
T99347	DRUGINFO	D08USC	7-bromo-N-(3-bromophenyl)isoquinolin-1-amine	Investigative
T99347	DRUGINFO	D09GMG	3-methoxy-N-(6-methylpyridin-2-yl)benzamide	Investigative
T99347	DRUGINFO	D09GYH	3-methyl-5-(2-methylquinolin-7-yl)benzonitrile	Investigative
T99347	DRUGINFO	D09HRX	VU-1545	Investigative
T99347	DRUGINFO	D09JHM	N-(3-chlorophenyl)-6-methoxyquinazolin-4-amine	Investigative
T99347	DRUGINFO	D09JXO	2-(3-bromophenyl)-7-methylpyrido[2,3-d]pyrimidine	Investigative
T99347	DRUGINFO	D09LDM	2-methyl-4-(m-tolylethynyl)thiazole	Investigative
T99347	DRUGINFO	D09PCZ	PMID16439120C20	Investigative
T99347	DRUGINFO	D09QUN	VU0404251	Investigative
T99347	DRUGINFO	D09RNK	5-Biphenyl-4-ylethynyl-pyrimidine	Investigative
T99347	DRUGINFO	D09RPR	SP203	Investigative
T99347	DRUGINFO	D09VPJ	2-(3,5-difluorophenyl)-7-methyl-1,8-naphthyridine	Investigative
T99347	DRUGINFO	D09WPX	VU0366058	Investigative
T99347	DRUGINFO	D0A0LE	3-(2-methylbenzo[d]thiazol-5-yl)benzonitrile	Investigative
T99347	DRUGINFO	D0A1WQ	VU0364289	Investigative
T99347	DRUGINFO	D0A2LP	2-methyl-7-m-tolyl-1,8-naphthyridine	Investigative
T99347	DRUGINFO	D0A5QP	N-(2-phenylimidazo[1,2-a]pyridin-3-yl)benzamide	Investigative
T99347	DRUGINFO	D0A8QA	2-Chloro-5-(2-methylquinolin-7-yl)nicotinonitrile	Investigative
T99347	DRUGINFO	D0AG1Q	PMID15686941C13	Investigative
T99347	DRUGINFO	D0B2GK	PMID17723296C18	Investigative
T99347	DRUGINFO	D0B2LP	PMID15482908C8	Investigative
T99347	DRUGINFO	D0B5OK	6-phenylethynyl-nicotinic acid methyl ester	Investigative
T99347	DRUGINFO	D0B9SS	7-(3-methoxyphenyl)-2-methylquinoline	Investigative
T99347	DRUGINFO	D0BO6C	N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide	Investigative
T99347	DRUGINFO	D0BU5N	3-chloro-5-(2-methylquinolin-7-yl)benzonitrile	Investigative
T99347	DRUGINFO	D0C0FH	2-Cyclohex-1-enylethynyl-pyridine	Investigative
T99347	DRUGINFO	D0C4OV	PMID14697765C16a	Investigative
T99347	DRUGINFO	D0C6BY	PMID23434029C41	Investigative
T99347	DRUGINFO	D0C6JG	2-methyl-6-(3-(phenylthio)prop-1-ynyl)pyridine	Investigative
T99347	DRUGINFO	D0C7TX	3-cyano-N-(6-methylpyridin-2-yl)benzamide	Investigative
T99347	DRUGINFO	D0C9FH	N-[4-(3-pyridylethynyl)-2-thiazolyl]acetamide	Investigative
T99347	DRUGINFO	D0CQ6I	3-[(2-methyl-4-thiazolyl)ethynyl]-5-vinylpyridine	Investigative
T99347	DRUGINFO	D0CT7P	2-(pyridin-2-yl)-4-(m-tolylthio)pyrimidine	Investigative
T99347	DRUGINFO	D0D1GI	3-(1-Pyridin-2-yl-1H-pyrrol-3-yl)-benzonitrile	Investigative
T99347	DRUGINFO	D0D2FB	2-(3-(benzyloxy)phenyl)isoindoline-1,3-dione	Investigative
T99347	DRUGINFO	D0D3FF	2-(phenylethynyl)pyrimidine	Investigative
T99347	DRUGINFO	D0D4AE	N-(3-(3-cyanobenzamido)phenyl)-2-methoxybenzamide	Investigative
T99347	DRUGINFO	D0D4HG	3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide	Investigative
T99347	DRUGINFO	D0D7DC	2-chloro-N-(3-(3-chlorobenzamido)phenyl)benzamide	Investigative
T99347	DRUGINFO	D0DX6U	PMID19931453C16m	Investigative
T99347	DRUGINFO	D0E3WH	2-methyl-6-(3-(p-tolyloxy)prop-1-ynyl)pyridine	Investigative
T99347	DRUGINFO	D0E8DM	3-(4-Pyridin-2-yl-pyrazol-1-yl)-benzonitrile	Investigative
T99347	DRUGINFO	D0E8IJ	3-hydroxy-5-(2-methylquinolin-7-yl)benzonitrile	Investigative
T99347	DRUGINFO	D0EB9H	3-ethoxy-5-(2-methylquinolin-7-yl)benzonitrile	Investigative
T99347	DRUGINFO	D0EK6F	5-methyl-3-phenylethynyl[1,2,4]triazine	Investigative
T99347	DRUGINFO	D0ET4S	BOMA	Investigative
T99347	DRUGINFO	D0EX7S	3-cyano-N-(1,4-diphenyl-1H-pyrazol-5-yl)benzamide	Investigative
T99347	DRUGINFO	D0F2KL	3-[(6-Methylpyridin-2-yl)ethynyl]benzonitrile	Investigative
T99347	DRUGINFO	D0F6EJ	PMID21927650C18	Investigative
T99347	DRUGINFO	D0F6YB	3-cyano-5-fluoro-N-phenylbenzamide	Investigative
T99347	DRUGINFO	D0F9QY	3,3'-difluorobenzaldazine	Investigative
T99347	DRUGINFO	D0FK3W	2-(3-bromophenyl)pyrido[2,3-d]pyrimidine	Investigative
T99347	DRUGINFO	D0G0OV	2-phenylethynyl-5,6,7,8-tetrahydro-quinoline	Investigative
T99347	DRUGINFO	D0G0WC	2-(3-bromophenyl)-7-methyl-1,8-naphthyridine	Investigative
T99347	DRUGINFO	D0GA4M	3-(1-Pyridin-2-yl-1H-pyrazol-4-yl)-benzonitrile	Investigative
T99347	DRUGINFO	D0H3DT	(3-(2-methylquinolin-7-yl)phenyl)methanol	Investigative
T99347	DRUGINFO	D0H3LE	7-methyl-2-phenylpyrido[2,3-d]pyrimidine	Investigative
T99347	DRUGINFO	D0I1TB	5-(2-Methylquinolin-7-yl)-2-phenylnicotinonitrile	Investigative
T99347	DRUGINFO	D0I2JX	3-isobutoxy-5-(2-methylquinolin-7-yl)benzonitrile	Investigative
T99347	DRUGINFO	D0I6KU	5-(2-m-tolylethynyl)pyrimidine	Investigative
T99347	DRUGINFO	D0I9NE	4-(2-(3-fluorophenyl)ethynyl)-2-methylthiazole	Investigative
T99347	DRUGINFO	D0J3NX	N-cyclopentyl-6-(2-phenylethynyl)nicotinamide	Investigative
T99347	DRUGINFO	D0J4HH	3-(5-Pyridin-2-yl-tetrazol-2-yl)-benzonitrile	Investigative
T99347	DRUGINFO	D0JG2W	4-(4-chlorophenylthio)-2-(pyridin-2-yl)pyrimidine	Investigative
T99347	DRUGINFO	D0JH2D	2-methyl-6-(4-phenylbut-1-ynyl)pyridine	Investigative
T99347	DRUGINFO	D0K0ZK	ADX-63365	Investigative
T99347	DRUGINFO	D0K7KM	3-Phenyl-1-(2-methylthiazol-4-ylethynyl)benzene	Investigative
T99347	DRUGINFO	D0L0KO	6-bromo-N-m-tolylquinazolin-4-amine	Investigative
T99347	DRUGINFO	D0L1PQ	3-(3-Pyridin-2-yl-pyrrol-1-yl)-benzonitrile	Investigative
T99347	DRUGINFO	D0L2KN	2-methyl-4-(3-thienylethynyl)thiazole	Investigative
T99347	DRUGINFO	D0L5FW	[3H]methoxy-PEPy	Investigative
T99347	DRUGINFO	D0L6PL	3-biphenyl-4-ylethynyl-5-methyl-[1,2,4]triazine	Investigative
T99347	DRUGINFO	D0L9FD	PMID21295468C47	Investigative
T99347	DRUGINFO	D0LO8S	3-methoxy-5-(1,6-naphthyridin-7-yl)benzonitrile	Investigative
T99347	DRUGINFO	D0LP7W	GSK-2210875	Investigative
T99347	DRUGINFO	D0M0LC	5-(2-(4-fluoro-3-methylphenyl)ethynyl)pyrimidine	Investigative
T99347	DRUGINFO	D0M1EI	5-(2-Methylquinolin-7-yl)-2-phenylbenzonitrile	Investigative
T99347	DRUGINFO	D0M2YQ	PMID15482906C10	Investigative
T99347	DRUGINFO	D0N2TP	2-(m-tolylethynyl)pyrimidine	Investigative
T99347	DRUGINFO	D0N5LF	3-(1,5-naphthyridin-3-yl)benzonitrile	Investigative
T99347	DRUGINFO	D0N6FJ	5-(2-(3,5-difluorophenyl)ethynyl)pyrimidine	Investigative
T99347	DRUGINFO	D0NB2G	PMID16439120C26	Investigative
T99347	DRUGINFO	D0NS9H	2-methyl-6-(4-phenylpent-1-ynyl)pyridine	Investigative
T99347	DRUGINFO	D0O4QX	2-ethoxy-5-(m-tolylethynyl)pyrimidine	Investigative
T99347	DRUGINFO	D0ON2A	5-(2-methylquinolin-7-yl)nicotinonitrile	Investigative
T99347	DRUGINFO	D0P0QI	VU0285683	Investigative
T99347	DRUGINFO	D0P0RY	3-[(2-methyl-4-thiazolyl)ethynyl]benzonitrile	Investigative
T99347	DRUGINFO	D0P2DV	4-(2-(4-fluorophenyl)ethynyl)-2-methylthiazole	Investigative
T99347	DRUGINFO	D0P2IJ	CPPZ	Investigative
T99347	DRUGINFO	D0P4TX	[14C]MTEP	Investigative
T99347	DRUGINFO	D0PI5D	7-methyl-2-m-tolylpyrido[2,3-d]pyrimidine	Investigative
T99347	DRUGINFO	D0PU1R	2-methyl-7-phenyl-1,8-naphthyridine	Investigative
T99347	DRUGINFO	D0Q3DI	3-methoxy-5-(1,5-naphthyridin-3-yl)benzonitrile	Investigative
T99347	DRUGINFO	D0Q6EE	3-(2-methylquinolin-7-yl)benzonitrile	Investigative
T99347	DRUGINFO	D0Q6VH	SIB-1893	Investigative
T99347	DRUGINFO	D0Q9CM	4-(3-bromophenoxy)-6-chloroquinazoline	Investigative
T99347	DRUGINFO	D0QE0D	5-((6-Methylpyridin-2-yl)ethynyl)nicotinonitrile	Investigative
T99347	DRUGINFO	D0QE3C	2-phenylethynyl-7,8-dihydro-6H-quinolin-5-one	Investigative
T99347	DRUGINFO	D0R0JE	3-(3-bromophenylethynyl)-5-methyl[1,2,4]triazine	Investigative
T99347	DRUGINFO	D0R0PU	7-(3-fluoro-5-methylphenyl)-1,6-naphthyridine	Investigative
T99347	DRUGINFO	D0R0UZ	3-fluoro-5-(1,6-naphthyridin-7-yl)benzonitrile	Investigative
T99347	DRUGINFO	D0R2CF	7-(3,5-dimethoxyphenyl)-1,6-naphthyridine	Investigative
T99347	DRUGINFO	D0R2OX	5-MPEP	Investigative
T99347	DRUGINFO	D0R7VW	4-(3-chlorophenylthio)-2-(pyridin-2-yl)pyrimidine	Investigative
T99347	DRUGINFO	D0RI6U	3-nitro-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide	Investigative
T99347	DRUGINFO	D0RJ5B	4-(3-bromophenylthio)-2-(pyridin-2-yl)pyrimidine	Investigative
T99347	DRUGINFO	D0S1CS	3-fluoro-5-(2-methylquinolin-7-yl)benzonitrile	Investigative
T99347	DRUGINFO	D0S1DD	3-chloro-N-(6-methylpyridin-2-yl)benzamide	Investigative
T99347	DRUGINFO	D0S7SE	[3H]methoxymethyl-MTEP	Investigative
T99347	DRUGINFO	D0SE2D	6-(4-chlorophenylamino)-N,N-diethylnicotinamide	Investigative
T99347	DRUGINFO	D0SE9M	PMID23434029C53	Investigative
T99347	DRUGINFO	D0ST3S	4-(3-fluorophenylethynyl)-2-thiazolylamine	Investigative
T99347	DRUGINFO	D0T2DC	3-cyano-N-(3-ethylphenyl)-5-fluorobenzamide	Investigative
T99347	DRUGINFO	D0T4QX	CTEP	Investigative
T99347	DRUGINFO	D0T4YQ	VU0092273	Investigative
T99347	DRUGINFO	D0T7BZ	7-(3-(methoxymethyl)phenyl)-2-methylquinoline	Investigative
T99347	DRUGINFO	D0T7SA	4-Biphenyl-2-ylethynyl-2-methyl-thiazole	Investigative
T99347	DRUGINFO	D0TW0I	(E)-3-[2-(2-methyl-4-thiazolyl)vinyl]pyridine	Investigative
T99347	DRUGINFO	D0U0UB	2-Methyl-4-o-tolylethynyl-thiazole	Investigative
T99347	DRUGINFO	D0U2GG	5-(3-chlorophenylethynyl)-5-methyl[1,2,4]triazine	Investigative
T99347	DRUGINFO	D0U7IO	N-(3-chlorophenyl)-6-fluoroquinazolin-4-amine	Investigative
T99347	DRUGINFO	D0UN6P	N-(3-chlorophenyl)-6-nitroquinazolin-4-amine	Investigative
T99347	DRUGINFO	D0UO6Q	2-methyl-7-phenylquinoline	Investigative
T99347	DRUGINFO	D0V4RO	3-(3-Pyridin-2-yl-pyrazol-1-yl)-benzonitrile	Investigative
T99347	DRUGINFO	D0V4TK	N-(6-methylpyridin-2-yl)-6-phenylnicotinamide	Investigative
T99347	DRUGINFO	D0V6TM	PMID14697765C11a	Investigative
T99347	DRUGINFO	D0V7KU	2-(3,5-dichlorophenyl)pyrido[2,3-d]pyrimidine	Investigative
T99347	DRUGINFO	D0V7TC	5-(2-(3-chlorophenyl)ethynyl)pyrimidine	Investigative
T99347	DRUGINFO	D0W1SX	3-bromo-N-(6-methylpyridin-2-yl)benzamide	Investigative
T99347	DRUGINFO	D0W5JE	4-(3,5-difluorophenylethynyl)-2-methylthiazole	Investigative
T99347	DRUGINFO	D0W6AC	PMID23357634C24d	Investigative
T99347	DRUGINFO	D0WJ8I	3-[(2-methyl-4-thiazolyl)ethynyl]phenol	Investigative
T99347	DRUGINFO	D0X3TO	PMID20598884C8	Investigative
T99347	DRUGINFO	D0X4UN	3-methyl-N-(6-methylpyridin-2-yl)benzamide	Investigative
T99347	DRUGINFO	D0X5SZ	PMID17189691C42	Investigative
T99347	DRUGINFO	D0X6EI	PMID17936624C36	Investigative
T99347	DRUGINFO	D0X8VQ	3-(7-methyl-1,8-naphthyridin-2-yl)benzonitrile	Investigative
T99347	DRUGINFO	D0XN4W	2-(3,4-dimethylphenyl)-1,8-naphthyridine	Investigative
T99347	DRUGINFO	D0XT4J	7-(3-chlorophenyl)-2-methylquinoline	Investigative
T99347	DRUGINFO	D0Y2GE	3-cyano-5-fluoro-N-(pyridin-2-yl)benzamide	Investigative
T99347	DRUGINFO	D0Y3PV	2-phenylethynyl-5,6,7,8-tetrahydro-quinolin-5-ol	Investigative
T99347	DRUGINFO	D0Y3UT	N-(6-methylpyridin-2-yl)-5-phenylpicolinamide	Investigative
T99347	DRUGINFO	D0Y3VE	3-m-tolyl-1,5-naphthyridine	Investigative
T99347	DRUGINFO	D0YZ8G	5-Chloro-2-(2-methylquinolin-7-yl)benzonitrile	Investigative
T99347	DRUGINFO	D0Z0JF	M-5MPEP	Investigative
T99347	DRUGINFO	D0Z0JU	(3-Ethoxy-pyridin-2-yl)-pyridin-2-yl-amine	Investigative
T99347	DRUGINFO	D0Z0LV	VU0360172	Investigative
T99347	DRUGINFO	D0Z0ZP	5-(2-(2,5-dimethylphenyl)ethynyl)pyrimidine	Investigative
T99347	DRUGINFO	D0Z1OC	3-cyano-N-(3-cyanophenyl)-5-fluorobenzamide	Investigative
T99347	DRUGINFO	D0Z1PY	4-(2-fluorophenylethynyl)-2-methylthiazole	Investigative
T99347	DRUGINFO	D0Z4KU	7-(4,6-dimethylpyrimidin-2-yl)-2-methylquinoline	Investigative
T99347	DRUGINFO	D0Z9QZ	2-Methyl-4-p-tolylethynyl-thiazole	Investigative
T99347	DRUGINFO	D0ZY8G	NCFP	Investigative
T99347	DRUGINFO	D01IUB	[3H]resolvin E1	Investigative
T99347	DRUGINFO	D01YEN	ibotenate	Investigative
T99347	DRUGINFO	D02FMR	6-bromo-N-(3-chlorophenyl)quinazolin-4-amine	Investigative
T99347	DRUGINFO	D03VAO	N-(3-bromophenyl)-6-fluoroquinazolin-4-amine	Investigative
T99347	DRUGINFO	D04ODF	LY-3390334	Investigative
T99347	DRUGINFO	D0B5RX	(E)-1-Adamantan-1-yl-3-quinolin-3-yl-propenone	Investigative
T99347	DRUGINFO	D0E7LU	3,5-DHPG	Investigative
T99347	DRUGINFO	D0J5SK	6-chloro-N-(3-chlorophenyl)quinazolin-4-amine	Investigative
T99347	DRUGINFO	D0L3RY	3-methoxy-N-(4-methylthiazol-2-yl)benzamide	Investigative
T99347	DRUGINFO	D0OH2P	(S)-(+)-CBPG	Investigative
T99347	DRUGINFO	D0P3XO	(S)-4CPG	Investigative
T99347	DRUGINFO	D0R6ZS	N-(3-bromophenyl)-6-chloroquinazolin-4-amine	Investigative
T99347	DRUGINFO	D0U5YT	(S)-3HPG	Investigative
T99347	DRUGINFO	D0IO8J	2-methyl-6-(phenylethynyl)pyridine	Investigative
T99347	DRUGINFO	D0S6DK	(S)-4C3HPG	Investigative
T99347	DRUGINFO	D0J8OW	(+)-MCPG	Investigative
T99347	DRUGINFO	D04DKM	(1S,3R)-ACPD	Investigative
T99347	DRUGINFO	D06DUE	[3H]quisqualate	Investigative
T99347	DRUGINFO	D0Z7CZ	L-CCG-I	Investigative

T89988	TARGETID	T89988
T89988	FORMERID	TTDC00122
T89988	UNIPROID	CCR2_HUMAN
T89988	TARGNAME	C-C chemokine receptor type 2 (CCR2)
T89988	GENENAME	CCR2
T89988	TARGTYPE	Clinical trial
T89988	SYNONYMS	Monocyte chemoattractant protein 1 receptor; MCP-1-R; Chemokine receptor CCR2B; CMKBR2; CD192; CCR-2; CC-CKR-2; C-C CKR-2
T89988	FUNCTION	Its binding with CCL2 on monocytes and macrophages mediates chemotaxis and migration induction through the activation of the PI3K cascade, the small G protein Rac and lamellipodium protrusion. Also acts as a receptor for the beta-defensin DEFB106A/DEFB106B. Regulates the expression of T-cell inflammatory cytokines and T-cell differentiation, promoting the differentiation of T-cells into T-helper 17 cells (Th17) during inflammation. Faciltates the export of mature thymocytes by enhancing directional movement of thymocytes to sphingosine-1-phosphate stimulation and up-regulation of S1P1R expression; signals through the JAK-STAT pathway to regulate FOXO1 activity leading to an increased expression of S1P1R. Plays an important role in mediating peripheral nerve injury-induced neuropathic pain. Increases NMDA-mediated synaptic transmission in both dopamine D1 and D2 receptor-containing neurons, which may be caused by MAPK/ERK-dependent phosphorylation of GRIN2B/NMDAR2B. Mediates the recruitment of macrophages and monocytes to the injury site following brain injury. Key functional receptor for CCL2 but can also bind CCL7 and CCL12.
T89988	PDBSTRUC	5T1A; 2MLQ; 2MLO; 1KP1; 1KAD
T89988	BIOCLASS	GPCR rhodopsin
T89988	SEQUENCE	MLSTSRSRFIRNTNESGEEVTTFFDYDYGAPCHKFDVKQIGAQLLPPLYSLVFIFGFVGNMLVVLILINCKKLKCLTDIYLLNLAISDLLFLITLPLWAHSAANEWVFGNAMCKLFTGLYHIGYFGGIFFIILLTIDRYLAIVHAVFALKARTVTFGVVTSVITWLVAVFASVPGIIFTKCQKEDSVYVCGPYFPRGWNNFHTIMRNILGLVLPLLIMVICYSGILKTLLRCRNEKKRHRAVRVIFTIMIVYFLFWTPYNIVILLNTFQEFFGLSNCESTSQLDQATQVTETLGMTHCCINPIIYAFVGEKFRSLFHIALGCRIAPLQKPVCGGPGVRPGKNVKVTTQGLLDGRGKGKSIGRAPEASLQDKEGA
T89988	DRUGINFO	D06IME	CCX-140	Phase 2
T89988	DRUGINFO	D0E5NY	AZD-2423	Phase 2
T89988	DRUGINFO	D0Q3PB	CCX872	Phase 2
T89988	DRUGINFO	D0TG9Q	MK-0812	Phase 2
T89988	DRUGINFO	D06KCU	MLN1202	Phase 2
T89988	DRUGINFO	D0B1SG	BMS-813160	Phase 2
T89988	DRUGINFO	D0YQ7U	Cenicriviroc	Phase 2
T89988	DRUGINFO	D0DT2S	TAK-202	Phase 1
T89988	DRUGINFO	D0U7PM	OPL-CCL2-LPM	Phase 1
T89988	DRUGINFO	D0VR7F	CNTX-6970	Phase 1
T89988	DRUGINFO	D0V0NL	Aminoguanidine	Phase 1
T89988	DRUGINFO	D07VXT	INCB8696	Discontinued in Phase 1
T89988	DRUGINFO	D0MT0A	CCX915	Discontinued in Phase 1
T89988	DRUGINFO	D0V9ND	MCP-1	Preclinical
T89988	DRUGINFO	D0X4SI	RS-504393	Preclinical
T89988	DRUGINFO	D07KIJ	INCB3344	Terminated
T89988	DRUGINFO	D0I9YI	AZD-6942	Terminated
T89988	DRUGINFO	D0Q2JS	SB-282241	Terminated
T89988	DRUGINFO	D00JXV	INCB-10820	Investigative
T89988	DRUGINFO	D00VYD	RS-136270	Investigative
T89988	DRUGINFO	D01KYM	(S)-3-(2',2'-Dimethyl-propionyl)amino-caprolactam	Investigative
T89988	DRUGINFO	D02XNT	BMS-A	Investigative
T89988	DRUGINFO	D07RPC	RAP-103	Investigative
T89988	DRUGINFO	D0C5XF	GSK-1344386B	Investigative
T89988	DRUGINFO	D0G1JJ	(S)-3-(1'-Adamantanecarbonyl)amino-caprolactam	Investigative
T89988	DRUGINFO	D0H5WL	NSC-651016	Investigative
T89988	DRUGINFO	D0J9QK	(R)-3-(1'-Adamantanecarbonyl)amino-caprolactam	Investigative
T89988	DRUGINFO	D0M8CJ	RS-102895	Investigative
T89988	DRUGINFO	D0RM7J	Teijin-lead_cmp_5	Investigative
T89988	DRUGINFO	D0W9OW	RAP-310	Investigative
T89988	DRUGINFO	D09PZD	viral macrophage inflammatory protein-II	Investigative

T05031	TARGETID	T05031
T05031	FORMERID	TTDI02297
T05031	UNIPROID	PK3CB_HUMAN
T05031	TARGNAME	PI3-kinase beta (PIK3CB)
T05031	GENENAME	PIK3CB
T05031	TARGTYPE	Clinical trial
T05031	SYNONYMS	p110beta; PtdIns3kinase subunit p110beta; PtdIns3kinase subunit beta; PtdIns-3-kinase subunit p110-beta; PtdIns-3-kinase subunit beta; Phosphatidylinositol 4,5bisphosphate 3kinase catalytic subunitbeta isoform; Phosphatidylinositol 4,5bisphosphate 3kinase 110 kDa catalyticsubunit beta; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit beta; PIK3C1; PI3kinase subunit beta; PI3Kbeta; PI3K-beta; PI3-kinase subunit beta
T05031	FUNCTION	Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns (Phosphatidylinositol), PtdIns4P (Phosphatidylinositol 4-phosphate) and PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Involved in the activation of AKT1 upon stimulation by G-protein coupled receptors (GPCRs) ligands such as CXCL12, sphingosine 1-phosphate, and lysophosphatidic acid. May also act downstream receptor tyrosine kinases. Required in different signaling pathways for stable platelet adhesion and aggregation. Plays a role in platelet activation signaling triggered by GPCRs, alpha-IIb/beta-3 integrins (ITGA2B/ ITGB3) and ITAM (immunoreceptor tyrosine-based activation motif)-bearing receptors such as GP6. Regulates the strength of adhesion of ITGA2B/ ITGB3 activated receptors necessary for the cellular transmission of contractile forces. Required for platelet aggregation induced by F2 (thrombin) and thromboxane A2 (TXA2). Has a role in cell survival. May have a role in cell migration. Involved in the early stage of autophagosome formation. Modulates the intracellular level of PtdIns3P (Phosphatidylinositol 3-phosphate) and activates PIK3C3 kinase activity. May act as a scaffold, independently of its lipid kinase activity to positively regulate autophagy. May have a role in insulin signaling as scaffolding protein in which the lipid kinase activity is not required. May have a kinase-independent function in regulating cell proliferation and in clathrin-mediated endocytosis. Mediator of oncogenic signal in cell lines lacking PTEN. The lipid kinase activity is necessary for its role in oncogenic transformation. Required for the growth of ERBB2 and RAS driven tumors.
T05031	BIOCLASS	Kinase
T05031	ECNUMBER	EC 2.7.1.153
T05031	SEQUENCE	MCFSFIMPPAMADILDIWAVDSQIASDGSIPVDFLLPTGIYIQLEVPREATISYIKQMLWKQVHNYPMFNLLMDIDSYMFACVNQTAVYEELEDETRRLCDVRPFLPVLKLVTRSCDPGEKLDSKIGVLIGKGLHEFDSLKDPEVNEFRRKMRKFSEEKILSLVGLSWMDWLKQTYPPEHEPSIPENLEDKLYGGKLIVAVHFENCQDVFSFQVSPNMNPIKVNELAIQKRLTIHGKEDEVSPYDYVLQVSGRVEYVFGDHPLIQFQYIRNCVMNRALPHFILVECCKIKKMYEQEMIAIEAAINRNSSNLPLPLPPKKTRIISHVWENNNPFQIVLVKGNKLNTEETVKVHVRAGLFHGTELLCKTIVSSEVSGKNDHIWNEPLEFDINICDLPRMARLCFAVYAVLDKVKTKKSTKTINPSKYQTIRKAGKVHYPVAWVNTMVFDFKGQLRTGDIILHSWSSFPDELEEMLNPMGTVQTNPYTENATALHVKFPENKKQPYYYPPFDKIIEKAAEIASSDSANVSSRGGKKFLPVLKEILDRDPLSQLCENEMDLIWTLRQDCREIFPQSLPKLLLSIKWNKLEDVAQLQALLQIWPKLPPREALELLDFNYPDQYVREYAVGCLRQMSDEELSQYLLQLVQVLKYEPFLDCALSRFLLERALGNRRIGQFLFWHLRSEVHIPAVSVQFGVILEAYCRGSVGHMKVLSKQVEALNKLKTLNSLIKLNAVKLNRAKGKEAMHTCLKQSAYREALSDLQSPLNPCVILSELYVEKCKYMDSKMKPLWLVYNNKVFGEDSVGVIFKNGDDLRQDMLTLQMLRLMDLLWKEAGLDLRMLPYGCLATGDRSGLIEVVSTSETIADIQLNSSNVAAAAAFNKDALLNWLKEYNSGDDLDRAIEEFTLSCAGYCVASYVLGIGDRHSDNIMVKKTGQLFHIDFGHILGNFKSKFGIKRERVPFILTYDFIHVIQQGKTGNTEKFGRFRQCCEDAYLILRRHGNLFITLFALMLTAGLPELTSVKDIQYLKDSLALGKSEEEALKQFKQKFDEALRESWTTKVNWMAHTVRKDYRS
T05031	DRUGINFO	D01QSO	Buparlisib	Phase 3
T05031	DRUGINFO	D0TU7B	PQR309	Phase 2
T05031	DRUGINFO	D05CBJ	PA-799	Phase 1/2
T05031	DRUGINFO	D0G3MN	GSK2636771	Phase 1
T05031	DRUGINFO	D0KJ2J	BAY 1082439	Phase 1
T05031	DRUGINFO	D03BHZ	AZD8186	Phase 1
T05031	DRUGINFO	D0D0QA	AZD6482	Terminated
T05031	DRUGINFO	D01SSI	PI-3065	Investigative
T05031	DRUGINFO	D06DNH	TGX-221	Investigative
T05031	DRUGINFO	D00HSJ	PIK-75	Investigative
T05031	DRUGINFO	D0R0TW	KU-0060648	Investigative
T05031	DRUGINFO	D03EHM	PP121	Investigative

T57943	TARGETID	T57943
T57943	FORMERID	TTDR00440
T57943	UNIPROID	CASP3_HUMAN
T57943	TARGNAME	Caspase-3 (CASP3)
T57943	GENENAME	CASP3
T57943	TARGTYPE	Clinical trial
T57943	SYNONYMS	Yama protein; SREBP cleavage activity 1; SCA-1; Protein Yama; Cysteine protease CPP32; Caspase 3; CPP32; CPP-32; CASP-3; Apopain
T57943	FUNCTION	At the onset of apoptosis it proteolytically cleaves poly(ADP-ribose) polymerase (PARP) at a '216-Asp-|-Gly-217' bond. Cleaves and activates sterol regulatory element binding proteins (SREBPs) between the basic helix-loop-helix leucine zipper domain and the membrane attachment domain. Cleaves and activates caspase-6, -7 and -9. Involved in the cleavage of huntingtin. Triggers cell adhesion in sympathetic neurons through RET cleavage. Involved in the activation cascade of caspases responsible for apoptosis execution.
T57943	BIOCLASS	Peptidase
T57943	ECNUMBER	EC 3.4.22.56
T57943	SEQUENCE	MENTENSVDSKSIKNLEPKIIHGSESMDSGISLDNSYKMDYPEMGLCIIINNKNFHKSTGMTSRSGTDVDAANLRETFRNLKYEVRNKNDLTREEIVELMRDVSKEDHSKRSSFVCVLLSHGEEGIIFGTNGPVDLKKITNFFRGDRCRSLTGKPKLFIIQACRGTELDCGIETDSGVDDDMACHKIPVEADFLYAYSTAPGYYSWRNSKDGSWFIQSLCAMLKQYADKLEFMHILTRVNRKVATEFESFSFDATFHAKKQIPCIVSMLTKELYFYH
T57943	DRUGINFO	D01YIF	PAC1	Phase 1
T57943	DRUGINFO	D01XMM	5-(piperidin-1-ylsulfonyl)indoline-2,3-dione	Investigative
T57943	DRUGINFO	D02DOK	SJ-8002	Investigative
T57943	DRUGINFO	D03JDL	AZ10417808	Investigative
T57943	DRUGINFO	D05GGE	2-phenethylisoquinoline-1,3,4-trione	Investigative
T57943	DRUGINFO	D09AED	2-benzylisoquinoline-1,3,4-trione	Investigative
T57943	DRUGINFO	D09GKA	2-(4-methoxy-benzyl)isoquinoline-1,3,4-trione	Investigative
T57943	DRUGINFO	D0B6VI	5-(azetidin-1-ylsulfonyl)indoline-2,3-dione	Investigative
T57943	DRUGINFO	D0B8HU	2-allylisoquinoline-1,3,4-trione	Investigative
T57943	DRUGINFO	D0D4RW	5-(azepan-1-ylsulfonyl)indoline-2,3-dione	Investigative
T57943	DRUGINFO	D0FZ7W	2-methylisoquinoline-1,3,4-trione	Investigative
T57943	DRUGINFO	D0L3PO	2-(4-fluoro-benzyl)isoquinoline-1,3,4-trione	Investigative
T57943	DRUGINFO	D0N5MU	5-(pyrrolidin-1-ylsulfonyl)indoline-2,3-dione	Investigative
T57943	DRUGINFO	D0P0XF	Ac-Asp-Glu-Val-Asp-CHO	Investigative
T57943	DRUGINFO	D0T5GV	PETCM	Investigative
T57943	DRUGINFO	D0L9AX	Ac-DEVD-CHO	Investigative
T57943	DRUGINFO	D0Y2TI	Glionitrin A	Investigative
T57943	DRUGINFO	D0V6DX	Isoquinoline-1,3,4(2H)-trione	Investigative
T57943	DRUGINFO	D00YNW	M826	Investigative

T96760	TARGETID	T96760
T96760	FORMERID	TTDI02078
T96760	UNIPROID	GDF5_HUMAN
T96760	TARGNAME	Growth/differentiation factor 5 (GDF-5)
T96760	GENENAME	GDF5
T96760	TARGTYPE	Clinical trial
T96760	SYNONYMS	Radotermin; Lipopolysaccharide-associated protein 4; LPS-associated protein 4; LAP-4; Cartilagederived morphogenetic protein 1; Cartilage-derived morphogenetic protein 1; CDMP1; CDMP-1; Bone morphogenetic protein 14; BMP14; BMP-14
T96760	FUNCTION	During cartilage development regulates differentiation of chondrogenic tissue through two pathways. Firstly, positively regulates differentiation of chondrogenic tissue through its binding of high affinity with BMPR1B and of less affinity with BMPR1A, leading to induction of SMAD1-SMAD5-SMAD8 complex phosphorylation and then SMAD protein signaling transduction. Secondly, negatively regulates chondrogenic differentiation through its interaction with NOG. Required to prevent excessive muscle loss upon denervation. This function requires SMAD4 and is mediated by phosphorylated SMAD1/5/8. Binds bacterial lipopolysaccharide (LPS) and mediates LPS-induced inflammatory response, including TNF secretion by monocytes. Growth factor involved in bone and cartilage formation.
T96760	PDBSTRUC	5HK5; 3QB4; 3EVS; 2BHK; 1WAQ
T96760	BIOCLASS	Growth factor
T96760	SEQUENCE	MRLPKLLTFLLWYLAWLDLEFICTVLGAPDLGQRPQGTRPGLAKAEAKERPPLARNVFRPGGHSYGGGATNANARAKGGTGQTGGLTQPKKDEPKKLPPRPGGPEPKPGHPPQTRQATARTVTPKGQLPGGKAPPKAGSVPSSFLLKKAREPGPPREPKEPFRPPPITPHEYMLSLYRTLSDADRKGGNSSVKLEAGLANTITSFIDKGQDDRGPVVRKQRYVFDISALEKDGLLGAELRILRKKPSDTAKPAAPGGGRAAQLKLSSCPSGRQPASLLDVRSVPGLDGSGWEVFDIWKLFRNFKNSAQLCLELEAWERGRAVDLRGLGFDRAARQVHEKALFLVFGRTKKRDLFFNEIKARSGQDDKTVYEYLFSQRRKRRAPLATRQGKRPSKNLKARCSRKALHVNFKDMGWDDWIIAPLEYEAFHCEGLCEFPLRSHLEPTNHAVIQTLMNSMDPESTPPTCCVPTRLSPISILFIDSANNVVYKQYEDMVVESCGCR
T96760	DRUGINFO	D0V4IQ	RhGDF-5	Phase 2

T85467	TARGETID	T85467
T85467	FORMERID	TTDC00037
T85467	UNIPROID	PE2R3_HUMAN
T85467	TARGNAME	Prostaglandin E2 receptor EP3 (PTGER3)
T85467	GENENAME	PTGER3
T85467	TARGTYPE	Clinical trial
T85467	SYNONYMS	Prostanoid EP3 receptor; Prostaglandin E2 receptor EP3 subtype; PGE2-R; PGE2 receptor EP3 subtype; PGE receptor, EP3 subtype; PGE receptor EP3 subtype
T85467	FUNCTION	The activity of this receptor can couple to both the inhibition of adenylate cyclase mediated by G(i) proteins, and to an elevation of intracellular calcium. Required for normal development of fever in response to pyrinogens, including IL1B, prostaglandin E2 and bacterial lipopolysaccharide (LPS). Required for normal potentiation of platelet aggregation by prostaglandin E2, and thus plays a role in the regulation of blood coagulation. Required for increased HCO3(-) secretion in the duodenum in response to mucosal acidification, and thereby contributes to the protection of the mucosa against acid-induced ulceration. Not required for normal kidney function, normal urine volume and osmolality. Receptor for prostaglandin E2 (PGE2).
T85467	PDBSTRUC	6M9T; 6AK3
T85467	BIOCLASS	GPCR rhodopsin
T85467	SEQUENCE	MKETRGYGGDAPFCTRLNHSYTGMWAPERSAEARGNLTRPPGSGEDCGSVSVAFPITMLLTGFVGNALAMLLVSRSYRRRESKRKKSFLLCIGWLALTDLVGQLLTTPVVIVVYLSKQRWEHIDPSGRLCTFFGLTMTVFGLSSLFIASAMAVERALAIRAPHWYASHMKTRATRAVLLGVWLAVLAFALLPVLGVGQYTVQWPGTWCFISTGRGGNGTSSSHNWGNLFFASAFAFLGLLALTVTFSCNLATIKALVSRCRAKATASQSSAQWGRITTETAIQLMGIMCVLSVCWSPLLIMMLKMIFNQTSVEHCKTHTEKQKECNFFLIAVRLASLNQILDPWVYLLLRKILLRKFCQIRYHTNNYASSSTSLPCQCSSTLMWSDHLER
T85467	DRUGINFO	D0V5QH	ONO-9054	Phase 2
T85467	DRUGINFO	D0U7WF	16,16-dimethyl-PGE2	Phase 2
T85467	DRUGINFO	D00HTY	PGF2alpha	Clinical trial
T85467	DRUGINFO	D0W2OT	BUTAPROST	Patented
T85467	DRUGINFO	D08QHS	DG041	Discontinued in Phase 2
T85467	DRUGINFO	D07RVP	GR-63799X	Discontinued in Phase 1
T85467	DRUGINFO	D07TWQ	ONO-AE5-599	Investigative
T85467	DRUGINFO	D07UDT	L-798,106	Investigative
T85467	DRUGINFO	D0K4VN	Molecule 21	Investigative
T85467	DRUGINFO	D0L8DV	SC46275	Investigative
T85467	DRUGINFO	D0VR8J	ONO-AP-324	Investigative
T85467	DRUGINFO	D0X6DO	L-826266	Investigative
T85467	DRUGINFO	D00GTU	STA2	Investigative
T85467	DRUGINFO	D08KPK	ONO-AE3-240	Investigative
T85467	DRUGINFO	D0AK4K	ONO-AE3-208	Investigative
T85467	DRUGINFO	D0CW4T	ONO-AE-248	Investigative
T85467	DRUGINFO	D0I0UI	ONO-AE2-227	Investigative
T85467	DRUGINFO	D0T2GA	ONO-8713	Investigative
T85467	DRUGINFO	D02LXJ	3-(2-cinnamylphenyl)acrylic acid	Investigative
T85467	DRUGINFO	D02SAD	3-(2-(4-methoxycinnamyl)phenyl)acrylic acid	Investigative
T85467	DRUGINFO	D02YIJ	isocarbacyclin	Investigative
T85467	DRUGINFO	D05TNX	fluprostenol	Investigative
T85467	DRUGINFO	D06VZS	ONO-AE1-329	Investigative
T85467	DRUGINFO	D0G5MT	11-deoxy-PGE1	Investigative
T85467	DRUGINFO	D0TA0L	FR-181157	Investigative
T85467	DRUGINFO	D0W4GQ	3-(2-((E)-3-phenylprop-1-enyl)phenyl)acrylic acid	Investigative
T85467	DRUGINFO	D0X2MQ	17-phenyl-omega-trinor-PGE2	Investigative
T85467	DRUGINFO	D0X5MA	I-BOP	Investigative
T85467	DRUGINFO	D0Z3XJ	3-(2-(naphthalen-2-ylmethyl)phenyl)acrylic acid	Investigative
T85467	DRUGINFO	D0J9PG	AH6809	Investigative
T85467	DRUGINFO	D05SFA	cicaprost	Investigative
T85467	DRUGINFO	D0O9ES	cloprostenol	Investigative
T85467	DRUGINFO	D08MNO	butaprost (free acid form)	Investigative
T85467	DRUGINFO	D0BN1U	M&B 28767	Investigative
T85467	DRUGINFO	D06KBO	PGD2	Investigative
T85467	DRUGINFO	D0W7RI	carbacyclin	Investigative
T85467	DRUGINFO	D03PLH	U46619	Investigative

T54582	TARGETID	T54582
T54582	FORMERID	TTDI02132
T54582	UNIPROID	NAMPT_HUMAN
T54582	TARGNAME	Nicotinamide phosphoribosyltransferase (NAMPT)
T54582	GENENAME	NAMPT
T54582	TARGTYPE	Clinical trial
T54582	SYNONYMS	Visfatin; PreBcell colonyenhancing factor 1; PreB cellenhancing factor; Pre-B-cell colony-enhancing factor 1; Pre-B cell-enhancing factor; PBEF1; PBEF; Nampt; NAmPRTase
T54582	FUNCTION	It is the rate limiting component in the mammalian NAD biosynthesis pathway. The secreted form behaves both as a cytokine with immunomodulating properties and an adipokine with anti-diabetic properties, it has no enzymatic activity, partly because of lack of activation by ATP, which has a low level in extracellular space and plasma. Plays a role in the modulation of circadian clock function. NAMPT-dependent oscillatory production of NAD regulates oscillation of clock target gene expression by releasing the core clock component: CLOCK-ARNTL/BMAL1 heterodimer from NAD-dependent SIRT1-mediated suppression. Catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, an intermediate in the biosynthesis of NAD.
T54582	PDBSTRUC	6B76; 6B75; 6AZJ; 6ATB; 6.00E+68
T54582	BIOCLASS	Glycosyltransferases
T54582	ECNUMBER	EC 2.4.2.12
T54582	SEQUENCE	MNPAAEAEFNILLATDSYKVTHYKQYPPNTSKVYSYFECREKKTENSKLRKVKYEETVFYGLQYILNKYLKGKVVTKEKIQEAKDVYKEHFQDDVFNEKGWNYILEKYDGHLPIEIKAVPEGFVIPRGNVLFTVENTDPECYWLTNWIETILVQSWYPITVATNSREQKKILAKYLLETSGNLDGLEYKLHDFGYRGVSSQETAGIGASAHLVNFKGTDTVAGLALIKKYYGTKDPVPGYSVPAAEHSTITAWGKDHEKDAFEHIVTQFSSVPVSVVSDSYDIYNACEKIWGEDLRHLIVSRSTQAPLIIRPDSGNPLDTVLKVLEILGKKFPVTENSKGYKLLPPYLRVIQGDGVDINTLQEIVEGMKQKMWSIENIAFGSGGGLLQKLTRDLLNCSFKCSYVVTNGLGINVFKDPVADPNKRSKKGRLSLHRTPAGNFVTLEEGKGDLEEYGQDLLHTVFKNGKVTKSYSFDEIRKNAQLNIELEAAHH
T54582	DRUGINFO	D0H9SX	Daporinad	Phase 2
T54582	DRUGINFO	D0Y1NC	CHS-828	Phase 1/2
T54582	DRUGINFO	D0V7YA	GMX1777	Phase 1
T54582	DRUGINFO	DN6MT7	OT-82	Phase 1

T78692	TARGETID	T78692
T78692	FORMERID	TTDS00150
T78692	UNIPROID	KCNJ5_HUMAN
T78692	TARGNAME	Inward rectifier potassium channel Kir3.4 (KCNJ5)
T78692	GENENAME	KCNJ5
T78692	TARGTYPE	Clinical trial
T78692	SYNONYMS	Potassium channel, inwardly rectifying, subfamily J, member 5; KCNJ5; KATP-1; KATP channel; Inward rectifier K+ channel Kir3.4; Heart KATP channel; GIRK4; Cardiac inward rectifier; CIR
T78692	FUNCTION	This potassium channel is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. Can be blocked by external barium.
T78692	BIOCLASS	Inward rectifier potassium channel
T78692	SEQUENCE	MAGDSRNAMNQDMEIGVTPWDPKKIPKQARDYVPIATDRTRLLAEGKKPRQRYMEKSGKCNVHHGNVQETYRYLSDLFTTLVDLKWRFNLLVFTMVYTVTWLFFGFIWWLIAYIRGDLDHVGDQEWIPCVENLSGFVSAFLFSIETETTIGYGFRVITEKCPEGIILLLVQAILGSIVNAFMVGCMFVKISQPKKRAETLMFSNNAVISMRDEKLCLMFRVGDLRNSHIVEASIRAKLIKSRQTKEGEFIPLNQTDINVGFDTGDDRLFLVSPLIISHEINQKSPFWEMSQAQLHQEEFEVVVILEGMVEATGMTCQARSSYMDTEVLWGHRFTPVLTLEKGFYEVDYNTFHDTYETNTPSCCAKELAEMKREGRLLQYLPSPPLLGGCAEAGLDAEAEQNEEDEPKGLGGSREARGSV
T78692	DRUGINFO	D09DHT	phorbol 12-myristate 13-acetate	Phase 2
T78692	DRUGINFO	D07ZAJ	PIP2	Investigative

T93105	TARGETID	T93105
T93105	FORMERID	TTDR00444
T93105	UNIPROID	PSN1_HUMAN
T93105	TARGNAME	Presenilin 1 (PSEN1)
T93105	GENENAME	PSEN1
T93105	TARGTYPE	Clinical trial
T93105	SYNONYMS	S182 protein; Protein S182; Presenilin-1; PSNL1; PS1; PS-1; AD3
T93105	FUNCTION	Requires the presence of the other members of the gamma-secretase complex for protease activity. Plays a role in Notch and Wnt signaling cascades and regulation of downstream processes via its role in processing key regulatory proteins, and by regulating cytosolic CTNNB1 levels. Stimulates cell-cell adhesion via its interaction with CDH1; this stabilizes the complexes between CDH1 (E-cadherin) and its interaction partners CTNNB1 (beta-catenin), CTNND1 and JUP (gamma-catenin). Under conditions of apoptosis or calcium influx, cleaves CDH1. This promotes the disassembly of the complexes between CDH1 and CTNND1, JUP and CTNNB1, increases the pool of cytoplasmic CTNNB1, and thereby negatively regulates Wnt signaling. Required for normal embryonic brain and skeleton development, and for normal angiogenesis. Mediates the proteolytic cleavage of EphB2/CTF1 into EphB2/CTF2. The holoprotein functions as a calcium-leak channel that allows the passive movement of calcium from endoplasmic reticulum to cytosol and is therefore involved in calcium homeostasis. Involved in the regulation of neurite outgrowth. Is a regulator of presynaptic facilitation, spike transmission and synaptic vesicles replenishment in a process that depends on gamma-secretase activity. It acts through the control of SYT7 presynaptic expression. Catalytic subunit of the gamma-secretase complex, an endoprotease complex that catalyzes the intramembrane cleavage of integral membrane proteins such as Notch receptors and APP (amyloid-beta precursor protein).
T93105	PDBSTRUC	6IYC; 6IDF; 5FN5; 5FN4; 5FN3
T93105	BIOCLASS	Peptidase
T93105	ECNUMBER	EC 3.4.23.-
T93105	SEQUENCE	MTELPAPLSYFQNAQMSEDNHLSNTVRSQNDNRERQEHNDRRSLGHPEPLSNGRPQGNSRQVVEQDEEEDEELTLKYGAKHVIMLFVPVTLCMVVVVATIKSVSFYTRKDGQLIYTPFTEDTETVGQRALHSILNAAIMISVIVVMTILLVVLYKYRCYKVIHAWLIISSLLLLFFFSFIYLGEVFKTYNVAVDYITVALLIWNFGVVGMISIHWKGPLRLQQAYLIMISALMALVFIKYLPEWTAWLILAVISVYDLVAVLCPKGPLRMLVETAQERNETLFPALIYSSTMVWLVNMAEGDPEAQRRVSKNSKYNAESTERESQDTVAENDDGGFSEEWEAQRDSHLGPHRSTPESRAAVQELSSSILAGEDPEERGVKLGLGDFIFYSVLVGKASATASGDWNTTIACFVAILIGLCLTLLLLAIFKKALPALPISITFGLVFYFATDYLVQPFMDQLAFHQFYI
T93105	DRUGINFO	D0G2IC	(S)-FLURBIPROFEN	Preregistration
T93105	DRUGINFO	D05FGR	R-flurbiprofen	Phase 2
T93105	DRUGINFO	D0K8LN	1-Chloro-4-(1-phenyl-cyclohexanesulfonyl)-benzene	Investigative
T93105	DRUGINFO	D00DFR	(5R,6S)-5,6-bis(benzyloxy)cyclohex-2-enone	Investigative
T93105	DRUGINFO	D04TWU	(5R,6S)-6-(benzyloxy)-5-methoxycyclohex-2-enone	Investigative
T93105	DRUGINFO	D06TPT	Drug 311951	Investigative
T93105	DRUGINFO	D09HAD	Drug 311383	Investigative
T93105	DRUGINFO	D0I8BA	1-benzoyl-2-benzyl-1,2-dihydropyridin-3(6H)-one	Investigative
T93105	DRUGINFO	D0M2LV	(2S,3R)-2-(benzyloxy)-3-methoxycyclohexanone	Investigative
T93105	DRUGINFO	D0V7YM	Drug 311952	Investigative
T93105	DRUGINFO	D0XQ2T	Drug 311440	Investigative

T16691	TARGETID	T16691
T16691	FORMERID	TTDC00185
T16691	UNIPROID	5HT6R_HUMAN
T16691	TARGNAME	5-HT 6 receptor (HTR6)
T16691	GENENAME	HTR6
T16691	TARGTYPE	Clinical trial
T16691	SYNONYMS	Serotonin receptor 6; 5-hydroxytryptamine receptor 6; 5-HT6 receptor; 5-HT6; 5-HT-6
T16691	FUNCTION	The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs. Controls pyramidal neurons migration during corticogenesis, through the regulation of CDK5 activity. Is an activator of TOR signaling. This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen.
T16691	BIOCLASS	GPCR rhodopsin
T16691	SEQUENCE	MVPEPGPTANSTPAWGAGPPSAPGGSGWVAAALCVVIALTAAANSLLIALICTQPALRNTSNFFLVSLFTSDLMVGLVVMPPAMLNALYGRWVLARGLCLLWTAFDVMCCSASILNLCLISLDRYLLILSPLRYKLRMTPLRALALVLGAWSLAALASFLPLLLGWHELGHARPPVPGQCRLLASLPFVLVASGLTFFLPSGAICFTYCRILLAARKQAVQVASLTTGMASQASETLQVPRTPRPGVESADSRRLATKHSRKALKASLTLGILLGMFFVTWLPFFVANIVQAVCDCISPGLFDVLTWLGYCNSTMNPIIYPLFMRDFKRALGRFLPCPRCPRERQASLASPSLRTSHSGPRPGLSLQQVLPLPLPPDSDSDSDAGSGGSSGLRLTAQLLLPGEATQDPPLPTRAAAAVNFFNIDPAEPELRPHPLGIPTN
T16691	DRUGINFO	D09IRN	LU AE58054	Phase 3
T16691	DRUGINFO	D0R9HI	SB-742457	Phase 3
T16691	DRUGINFO	D0WH4L	AVN 211	Phase 2/3
T16691	DRUGINFO	D01NDF	AVN 101	Phase 2
T16691	DRUGINFO	D07RQR	SYN-120	Phase 2
T16691	DRUGINFO	D0G1YA	PF-05212377	Phase 2
T16691	DRUGINFO	D0L8IO	AVN 322	Phase 2
T16691	DRUGINFO	D0V4ZQ	SAM-531	Phase 2
T16691	DRUGINFO	D0Z0GX	SUVN-502	Phase 2
T16691	DRUGINFO	D9I3WE	SYN120	Phase 2
T16691	DRUGINFO	D02KLD	BVT-74316	Phase 1
T16691	DRUGINFO	D03ZPX	PRX-07034	Phase 1
T16691	DRUGINFO	D08PIK	11C-GSK-215083	Phase 1
T16691	DRUGINFO	D0X9HF	ABT-354	Phase 1
T16691	DRUGINFO	DWD06K	AVN-322	Phase 1
T16691	DRUGINFO	D09BCJ	PMID30124346-Compound-34TABLE4	Patented
T16691	DRUGINFO	D0F4NB	PMID30124346-Compound-13TABLE4	Patented
T16691	DRUGINFO	D0J7EP	AVN 397	Discontinued in Phase 2
T16691	DRUGINFO	D04VTV	SYN-114	Discontinued in Phase 1
T16691	DRUGINFO	D06ZVC	WAY-181187	Discontinued in Phase 1
T16691	DRUGINFO	D00DZY	4-(2-benzenesulfonylphenyl)piperazine	Investigative
T16691	DRUGINFO	D00OCC	4-(3-benzenesulfonylphenyl)piperazine	Investigative
T16691	DRUGINFO	D00PBI	SUVN-501	Investigative
T16691	DRUGINFO	D01DCE	4-(Indan-1-ylsulfanyl)-phenylamine	Investigative
T16691	DRUGINFO	D01TYJ	4-(4,6-dinitro-1H-indol-1-ylsulfonyl)benzenamine	Investigative
T16691	DRUGINFO	D01ZMO	4-(3H-Inden-1-ylmethyl)-phenylamine	Investigative
T16691	DRUGINFO	D02JFD	SB399885	Investigative
T16691	DRUGINFO	D02LFU	1-Benzenesulfonyl-3-piperidin-3-yl-1H-indole	Investigative
T16691	DRUGINFO	D02SBM	6-(piperazin-1-yl)-3-tosyl-1H-indazole	Investigative
T16691	DRUGINFO	D02VHJ	2-(1-(phenylsulfonyl)-1H-indol-3-yl)ethanamine	Investigative
T16691	DRUGINFO	D05DAF	N-(3-aminophenyl)benzenesulfonamide	Investigative
T16691	DRUGINFO	D05HJP	4-Inden-(1E)-ylidenemethyl-phenylamine	Investigative
T16691	DRUGINFO	D05JPG	[2-(3-Benzyl-3H-inden-1-yl)-ethyl]-methyl-amine	Investigative
T16691	DRUGINFO	D05SAP	N-(3-(aminomethyl)phenyl)benzenesulfonamide	Investigative
T16691	DRUGINFO	D05XGR	SB-214111	Investigative
T16691	DRUGINFO	D06FXO	3-(phenylsulfonyl)-1-(piperidin-3-yl)-1H-indole	Investigative
T16691	DRUGINFO	D06PXY	alpha-ergocryptine	Investigative
T16691	DRUGINFO	D06QVB	4-(Naphthalene-1-sulfonyl)-phenylamine	Investigative
T16691	DRUGINFO	D07DCN	4-(3-benzenesulfonamidophenyl)piperazine	Investigative
T16691	DRUGINFO	D07LIE	2-(3-benzenesulfonyl)phenyl-1-aminoethane	Investigative
T16691	DRUGINFO	D08SMK	2-(1-tosyl-1H-indol-3-yl)ethanamine	Investigative
T16691	DRUGINFO	D09CHX	AMR-SIX-1	Investigative
T16691	DRUGINFO	D09LVG	4-(1H-Inden-1-ylmethyl)-phenylamine	Investigative
T16691	DRUGINFO	D09RXU	2-Benzyl-4-piperazin-1-yl-1H-benzimidazole	Investigative
T16691	DRUGINFO	D09VSK	4-(1H-Indol-3-ylmethyl)-phenylamine	Investigative
T16691	DRUGINFO	D0C4AE	3-(phenylsulfonyl)-1-(piperidin-4-yl)-1H-indole	Investigative
T16691	DRUGINFO	D0C8UV	4-(4-benzenesulfonylphenyl)piperazine	Investigative
T16691	DRUGINFO	D0CY6E	2-(4-(benzenesulfonyl)phenyl)-1-aminoethane	Investigative
T16691	DRUGINFO	D0D2XH	4-(4-methoxy-1H-indol-1-ylsulfonyl)benzenamine	Investigative
T16691	DRUGINFO	D0D6FC	N-(4-(2-aminoethyl)phenyl)benzenesulfonamide	Investigative
T16691	DRUGINFO	D0DE8K	lergotrile	Investigative
T16691	DRUGINFO	D0E0DR	N-(3-(2-aminoethyl)phenyl)benzenesulfonamide	Investigative
T16691	DRUGINFO	D0F6GP	5-(4-Methylpiperazin-1-yl)-3-tosyl-1H-indazole	Investigative
T16691	DRUGINFO	D0FV7K	4-((1H-indol-1-yl)methyl)benzenamine	Investigative
T16691	DRUGINFO	D0G6NV	4-(6-methoxy-1H-indol-1-ylsulfonyl)benzenamine	Investigative
T16691	DRUGINFO	D0G7QT	EMD-386088	Investigative
T16691	DRUGINFO	D0H0IZ	N-phenyl-3-(2-aminoethyl)benzenesulfonamide	Investigative
T16691	DRUGINFO	D0H5EP	1-Benzenesulfonyl-3-piperidin-4-yl-1H-indole	Investigative
T16691	DRUGINFO	D0H7PC	SB-357134	Investigative
T16691	DRUGINFO	D0J7EM	1-phenylthio-N,N-dimethyltryptamine	Investigative
T16691	DRUGINFO	D0J9MP	N-(3-(3-aminopropyl)phenyl)benzenesulfonamide	Investigative
T16691	DRUGINFO	D0JT3M	[2-(3-Benzyl-indol-1-yl)-ethyl]-dimethyl-amine	Investigative
T16691	DRUGINFO	D0K8PH	SUVN-504	Investigative
T16691	DRUGINFO	D0KD8D	[2-(3-Benzyl-3H-indol-1-yl)-ethyl]-dimethyl-amine	Investigative
T16691	DRUGINFO	D0L7PA	SB 258585	Investigative
T16691	DRUGINFO	D0LA4I	4-(Indane-1-sulfonyl)-phenylamine	Investigative
T16691	DRUGINFO	D0N7NK	E6801	Investigative
T16691	DRUGINFO	D0N8AO	4-(4-benzenesulfonamidophenyl)piperazine	Investigative
T16691	DRUGINFO	D0O3GQ	2-(3-phenylthio)phenyl)-1-aminoethane	Investigative
T16691	DRUGINFO	D0P8JA	Ro-04-6790	Investigative
T16691	DRUGINFO	D0PQ1U	2-(1-benzyl-1H-inden-3-yl)-N,N-dimethylethanamine	Investigative
T16691	DRUGINFO	D0Q7AF	E-6837	Investigative
T16691	DRUGINFO	D0R7VT	4-(1H-indol-1-ylsulfonyl)benzenamine	Investigative
T16691	DRUGINFO	D0S3UH	SUVN-507	Investigative
T16691	DRUGINFO	D0S4XR	1-(3-(benzyloxy)-2-methylphenyl)piperazine	Investigative
T16691	DRUGINFO	D0SJ6E	N,N-dimethyl-2-(1-tosyl-1H-indol-3-yl)ethanamine	Investigative
T16691	DRUGINFO	D0T7VZ	2-(1-benzyl-1H-indol-3-yl)-N,N-dimethylethanamine	Investigative
T16691	DRUGINFO	D0TG0I	1-(phenylsulfonyl)-4-(piperazin-1-yl)-1H-indole	Investigative
T16691	DRUGINFO	D0TX8W	4-(piperazin-1-yl)-1H-indole	Investigative
T16691	DRUGINFO	D0UB6O	[125I]SB-258585	Investigative
T16691	DRUGINFO	D0V2PB	[3H]Ro 63-0563	Investigative
T16691	DRUGINFO	D0V5AN	6-tosyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole	Investigative
T16691	DRUGINFO	D0VI0S	4-(piperazin-1-yl)-3-tosyl-1H-indazole	Investigative
T16691	DRUGINFO	D0W2HW	N,N-diethyl-2-(1H-indol-3-yl)ethanamine	Investigative
T16691	DRUGINFO	D0W2QN	2-Ethyl-5-methoxy-3-piperidin-4-yl-1H-indole	Investigative
T16691	DRUGINFO	D0X1IU	4-Indan-1-ylmethyl-phenylamine	Investigative
T16691	DRUGINFO	D0XJ6D	4-(3-Methyl-indole-1-sulfonyl)-phenylamine	Investigative
T16691	DRUGINFO	D0Y1LJ	2-(3-(phenylsulfonyl)-1H-indol-1-yl)ethanamine	Investigative
T16691	DRUGINFO	D0Y4WH	3-(phenylsulfonyl)-1-(pyrrolidin-3-yl)-1H-indole	Investigative
T16691	DRUGINFO	D0ZC9Q	[2-(3H-Indol-1-yl)-ethyl]-dimethyl-amine	Investigative
T16691	DRUGINFO	D00VRV	2-bromo-LSD	Investigative
T16691	DRUGINFO	D02YSX	DIMEBOLIN	Investigative
T16691	DRUGINFO	D09ULA	OPC 4392	Investigative
T16691	DRUGINFO	D0F8TG	fluperlapine	Investigative
T16691	DRUGINFO	D0J0KG	DM-1451	Investigative
T16691	DRUGINFO	D0T4PS	LY 165,163	Investigative
T16691	DRUGINFO	D03DLZ	2-(1H-indol-3-yl)-N,N-dimethylethanamine	Investigative
T16691	DRUGINFO	D04AQE	5-METHOXYTRYPTAMINE	Investigative
T16691	DRUGINFO	D0X6MT	METHIOTHEPIN	Investigative
T16691	DRUGINFO	D07HQZ	[3H]LSD	Investigative
T16691	DRUGINFO	D0C5XQ	5-MEO-DMT	Investigative
T16691	DRUGINFO	D08PJK	[3H]5-CT	Investigative
T16691	DRUGINFO	D0OG0R	WAY-208466	Investigative
T16691	DRUGINFO	D0P1XQ	SEL-73	Investigative
T16691	DRUGINFO	D0SP2J	bufotenine	Investigative
T16691	DRUGINFO	D0CK9K	EDMT	Investigative
T16691	DRUGINFO	D0V3XU	CHLOROPHENYLPIPERAZINE	Investigative
T16691	DRUGINFO	D06VPR	WAY-466	Investigative
T16691	DRUGINFO	D08BCF	QUIPAZINE	Investigative
T16691	DRUGINFO	D0C5GF	MPDT	Investigative
T16691	DRUGINFO	D0D3YN	OCTOCLOTHEPIN	Investigative
T16691	DRUGINFO	D0J6JT	m-chlorophenylpiperazine	Investigative
T16691	DRUGINFO	D0LG8A	1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine	Investigative
T16691	DRUGINFO	D0V4RP	1-(2-Methoxy-phenyl)-piperazine	Investigative
T16691	DRUGINFO	D00CRA	2-methyl-5-HT	Investigative
T16691	DRUGINFO	D05EQG	[3H]spiperone	Investigative
T16691	DRUGINFO	D08VGJ	5,6-dichloro-3,4-dihydroquinazolin-2-amine	Investigative
T16691	DRUGINFO	D09OYA	alpha-methyl-5-HT	Investigative
T16691	DRUGINFO	D03TDN	1-naphthylpiperazine	Investigative
T16691	DRUGINFO	D04TVG	BRL-15572	Investigative
T16691	DRUGINFO	D07LRJ	SB-271046	Investigative
T16691	DRUGINFO	D02UWB	5-CT	Investigative
T16691	DRUGINFO	D0V5HV	TFMPP	Investigative
T16691	DRUGINFO	D0F6CD	SEROTONIN	Investigative
T16691	DRUGINFO	D0L5MW	(+/-)-nantenine	Investigative

T75596	TARGETID	T75596
T75596	FORMERID	TTDR00721
T75596	UNIPROID	MAP2_HUMAN
T75596	TARGNAME	Methionine aminopeptidase 2 (METAP2)
T75596	GENENAME	METAP2
T75596	TARGTYPE	Clinical trial
T75596	SYNONYMS	Peptidase M 2; P67eIF2; P67; MetAP 2; METAP2; Initiation factor 2 associated 67 kDa glycoprotein; (MetAP)-2
T75596	FUNCTION	Cotranslationally removes the N-terminal methionine from nascent proteins. The N-terminal methionine is often cleaved when the second residue in the primary sequence is small and uncharged (Met-Ala-, Cys, Gly, Pro, Ser, Thr, or Val).
T75596	PDBSTRUC	6QEJ; 6QEI; 6QEH; 6QEG; 6QEF
T75596	BIOCLASS	Peptidase
T75596	ECNUMBER	EC 3.4.11.18
T75596	SEQUENCE	MAGVEEVAASGSHLNGDLDPDDREEGAASTAEEAAKKKRRKKKKSKGPSAAGEQEPDKESGASVDEVARQLERSALEDKERDEDDEDGDGDGDGATGKKKKKKKKKRGPKVQTDPPSVPICDLYPNGVFPKGQECEYPPTQDGRTAAWRTTSEEKKALDQASEEIWNDFREAAEAHRQVRKYVMSWIKPGMTMIEICEKLEDCSRKLIKENGLNAGLAFPTGCSLNNCAAHYTPNAGDTTVLQYDDICKIDFGTHISGRIIDCAFTVTFNPKYDTLLKAVKDATNTGIKCAGIDVRLCDVGEAIQEVMESYEVEIDGKTYQVKPIRNLNGHSIGQYRIHAGKTVPIVKGGEATRMEEGEVYAIETFGSTGKGVVHDDMECSHYMKNFDVGHVPIRLPRTKHLLNVINENFGTLAFCRRWLDRLGESKYLMALKNLCDLGIVDPYPPLCDIKGSYTAQFEHTILLRPTCKEVVSRGDDY
T75596	DRUGINFO	D0E4VQ	Beloranib	Phase 3
T75596	DRUGINFO	D0N0KW	D-Methionine	Phase 3
T75596	DRUGINFO	DA3GL5	ZGN-1061	Phase 2
T75596	DRUGINFO	D02SHI	M8891	Phase 1
T75596	DRUGINFO	D07DWC	SDX-7320	Phase 1
T75596	DRUGINFO	D0KR1N	PPI-2458	Phase 1
T75596	DRUGINFO	D09OAQ	TNP-470	Discontinued in Phase 2
T75596	DRUGINFO	D00MUJ	2-(phenylsulfonamido)-5-propylbenzoic acid	Investigative
T75596	DRUGINFO	D02ADV	5-p-Tolyl-1H-[1,2,3]triazole	Investigative
T75596	DRUGINFO	D02APY	A-357300	Investigative
T75596	DRUGINFO	D04MIY	5-chloro-2-(pyridin-2-yl)-1H-benzo[d]imidazole	Investigative
T75596	DRUGINFO	D04SLM	Ovalicin	Investigative
T75596	DRUGINFO	D05DCQ	3-anilino-5-benzylthio-1,2,4-triazole	Investigative
T75596	DRUGINFO	D05YKW	3,5,6,8-Tetramethyl-N-Methyl Phenanthrolinium	Investigative
T75596	DRUGINFO	D07CWJ	5-methyl-2-(phenylsulfonamido)benzoic acid	Investigative
T75596	DRUGINFO	D07PXR	5-fluoro-2-(pyridin-2-yl)-1H-benzo[d]imidazole	Investigative
T75596	DRUGINFO	D08AXA	2-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridine	Investigative
T75596	DRUGINFO	D08CFL	Fumagillin	Investigative
T75596	DRUGINFO	D09KTF	5-butyl-2-(phenylsulfonamido)benzoic acid	Investigative
T75596	DRUGINFO	D0B1LR	2-(thiazol-4-yl)-1H-benzo[d]imidazol-5-amine	Investigative
T75596	DRUGINFO	D0C0UB	5-methyl-2-(pyridin-2-yl)-1H-benzo[d]imidazole	Investigative
T75596	DRUGINFO	D0FO2B	OXYQUINOLINE	Investigative
T75596	DRUGINFO	D0I6RL	2-(phenylsulfonamido)-1-naphthoic acid	Investigative
T75596	DRUGINFO	D0K5UM	3,5-dimethyl-2-(phenylsulfonamido)benzoic acid	Investigative
T75596	DRUGINFO	D0K7PS	5-bromo-2-(4-chlorophenylsulfonamido)benzoic acid	Investigative
T75596	DRUGINFO	D0L4YF	2-(pyridin-2-yl)-1H-benzo[d]imidazole	Investigative
T75596	DRUGINFO	D0L6ZY	2-(pyridin-2-yl)-1H-benzo[d]imidazol-5-amine	Investigative
T75596	DRUGINFO	D0MT5K	XMT-1191	Investigative
T75596	DRUGINFO	D0R4KE	2-(4-fluorophenylsulfonamido)-1-naphthoic acid	Investigative
T75596	DRUGINFO	D0S5GM	5-ethyl-2-(phenylsulfonamido)benzoic acid	Investigative
T75596	DRUGINFO	D0Q7LD	2-Methyl-2-Propanol	Investigative

T58449	TARGETID	T58449
T58449	FORMERID	TTDC00094
T58449	UNIPROID	CDK7_HUMAN
T58449	TARGNAME	Cyclin-dependent kinase 7 (CDK7)
T58449	GENENAME	CDK7
T58449	TARGTYPE	Clinical trial
T58449	SYNONYMS	TFIIH basal transcription factor complex kinase subunit; Serine/threonine-protein kinase 1; P39 Mo15; MO15; Cell division protein kinase 7; CDKN7; CDK-activating kinase 1; CDK-activating kinase; CAK1; CAK; 39 kDa protein kinase
T58449	FUNCTION	Cyclin-dependent kinases (CDKs) are activated by the binding to a cyclin and mediate the progression through the cell cycle. Each different complex controls a specific transition between 2 subsequent phases in the cell cycle. Required for both activation and complex formation of CDK1/cyclin-B during G2-M transition, and for activation of CDK2/cyclins during G1-S transition (but not complex formation). CDK7 is the catalytic subunit of the CDK-activating kinase (CAK) complex. Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11. CAK activates the cyclin-associated kinases CDK1, CDK2, CDK4 and CDK6 by threonine phosphorylation, thus regulating cell cycle progression. CAK complexed to the core-TFIIH basal transcription factor activates RNA polymerase II by serine phosphorylation of the repetitive C-terminal domain (CTD) of its large subunit (POLR2A), allowing its escape from the promoter and elongation of the transcripts. Phosphorylation of POLR2A in complex with DNA promotes transcription initiation by triggering dissociation from DNA. Its expression and activity are constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 activation by phosphorylation, but is inactivated in turn by p53/TP53; this feedback loop may lead to an arrest of the cell cycle and of the transcription, helping in cell recovery, or to apoptosis. Required for DNA-bound peptides-mediated transcription and cellular growth inhibition. Serine/threonine kinase involved in cell cycle control and in RNA polymerase II-mediated RNA transcription.
T58449	PDBSTRUC	2HIC; 1UA2; 1PA8; 1LG3
T58449	BIOCLASS	Kinase
T58449	ECNUMBER	EC 2.7.11.22
T58449	SEQUENCE	MALDVKSRAKRYEKLDFLGEGQFATVYKARDKNTNQIVAIKKIKLGHRSEAKDGINRTALREIKLLQELSHPNIIGLLDAFGHKSNISLVFDFMETDLEVIIKDNSLVLTPSHIKAYMLMTLQGLEYLHQHWILHRDLKPNNLLLDENGVLKLADFGLAKSFGSPNRAYTHQVVTRWYRAPELLFGARMYGVGVDMWAVGCILAELLLRVPFLPGDSDLDQLTRIFETLGTPTEEQWPDMCSLPDYVTFKSFPGIPLHHIFSAAGDDLLDLIQGLFLFNPCARITATQALKMKYFSNRPGPTPGCQLPRPNCPVETLKEQSNPALAIKRKRTEALEQGGLPKKLIF
T58449	DRUGINFO	D05ADP	R-roscovitine	Phase 2
T58449	DRUGINFO	DV74BT	Samuraciclib	Phase 1/2
T58449	DRUGINFO	D09OHR	SY-1365	Phase 1
T58449	DRUGINFO	D0VIG4	LY3405105	Phase 1
T58449	DRUGINFO	DJ9WC4	SY-5609	Phase 1
T58449	DRUGINFO	D0S5RC	SNS-032	Phase 1
T58449	DRUGINFO	D5VMP4	BTX-A51	Phase 1
T58449	DRUGINFO	D0G2SI	Pyrazolo-triazine derivative 1	Patented
T58449	DRUGINFO	D0NA4O	PMID26161698-Compound-34	Patented
T58449	DRUGINFO	D0T6CM	Pyrazolo-triazine derivative 2	Patented
T58449	DRUGINFO	D07DUX	Roscovitine derivative 1	Patented
T58449	DRUGINFO	D0NY7M	Tricyclic benzimidazole derivative 1	Patented
T58449	DRUGINFO	D0M5DX	Oxazolyl methylthiothiazole derivative 1	Patented
T58449	DRUGINFO	D04FHB	R547	Discontinued in Phase 1
T58449	DRUGINFO	D00VBT	ZK 304709	Discontinued in Phase 1
T58449	DRUGINFO	D0LO5B	THZ1	Investigative
T58449	DRUGINFO	D06WUE	2,5-dichloro-N-p-tolylthiophene-3-sulfonamide	Investigative
T58449	DRUGINFO	D0J4ON	RGB-286147	Investigative
T58449	DRUGINFO	D02QAZ	PF-228	Investigative
T58449	DRUGINFO	D04WFN	NU6140	Investigative
T58449	DRUGINFO	D05BHG	Phosphonothreonine	Investigative

T28484	TARGETID	T28484
T28484	FORMERID	TTDC00143
T28484	UNIPROID	KIF11_HUMAN
T28484	TARGNAME	Kinesin-like protein KIF11 (KIF11)
T28484	GENENAME	KIF11
T28484	TARGTYPE	Clinical trial
T28484	SYNONYMS	Thyroid receptor interacting protein 5; TRIP5; Kinesin-related motor protein Eg5; Kinesin-like spindle protein HKSP; Kinesin-like protein 1; KIF11; Eg5
T28484	FUNCTION	Motor protein required for establishing a bipolar spindle. Blocking of KIF11 prevents centrosome migration and arrest cells in mitosis with monoastral microtubule arrays.
T28484	PDBSTRUC	6G6Z; 6G6Y; 5ZO9; 5ZO8; 5ZO7
T28484	BIOCLASS	Kinesin-like protein family
T28484	SEQUENCE	MASQPNSSAKKKEEKGKNIQVVVRCRPFNLAERKASAHSIVECDPVRKEVSVRTGGLADKSSRKTYTFDMVFGASTKQIDVYRSVVCPILDEVIMGYNCTIFAYGQTGTGKTFTMEGERSPNEEYTWEEDPLAGIIPRTLHQIFEKLTDNGTEFSVKVSLLEIYNEELFDLLNPSSDVSERLQMFDDPRNKRGVIIKGLEEITVHNKDEVYQILEKGAAKRTTAATLMNAYSSRSHSVFSVTIHMKETTIDGEELVKIGKLNLVDLAGSENIGRSGAVDKRAREAGNINQSLLTLGRVITALVERTPHVPYRESKLTRILQDSLGGRTRTSIIATISPASLNLEETLSTLEYAHRAKNILNKPEVNQKLTKKALIKEYTEEIERLKRDLAAAREKNGVYISEENFRVMSGKLTVQEEQIVELIEKIGAVEEELNRVTELFMDNKNELDQCKSDLQNKTQELETTQKHLQETKLQLVKEEYITSALESTEEKLHDAASKLLNTVEETTKDVSGLHSKLDRKKAVDQHNAEAQDIFGKNLNSLFNNMEELIKDGSSKQKAMLEVHKTLFGNLLSSSVSALDTITTVALGSLTSIPENVSTHVSQIFNMILKEQSLAAESKTVLQELINVLKTDLLSSLEMILSPTVVSILKINSQLKHIFKTSLTVADKIEDQKKELDGFLSILCNNLHELQENTICSLVESQKQCGNLTEDLKTIKQTHSQELCKLMNLWTERFCALEEKCENIQKPLSSVQENIQQKSKDIVNKMTFHSQKFCADSDGFSQELRNFNQEGTKLVEESVKHSDKLNGNLEKISQETEQRCESLNTRTVYFSEQWVSSLNEREQELHNLLEVVSQCCEASSSDITEKSDGRKAAHEKQHNIFLDQMTIDEDKLIAQNLELNETIKIGLTKLNCFLEQDLKLDIPTGTTPQRKSYLYPSTLVRTEPREHLLDQLKRKQPELLMMLNCSENNKEETIPDVDVEEAVLGQYTEEPLSQEPSVDAGVDCSSIGGVPFFQHKKSHGKDKENRGINTLERSKVEETTEHLVTKSRLPLRAQINL
T28484	DRUGINFO	D02AAO	AZD-4877	Phase 2
T28484	DRUGINFO	D04VWJ	ARRY-520	Phase 2
T28484	DRUGINFO	D0PW4N	Ispinesib	Phase 2
T28484	DRUGINFO	D0U4EU	SB-743921	Phase 2
T28484	DRUGINFO	D0W9SL	LY2523355	Phase 2
T28484	DRUGINFO	D07BKR	ARQ 621	Phase 1
T28484	DRUGINFO	D08OPX	4SC-205	Phase 1
T28484	DRUGINFO	D0V2YJ	MK-0731	Phase 1
T28484	DRUGINFO	D0ZK2G	Monastrol	Investigative

T70490	TARGETID	T70490
T70490	FORMERID	TTDR00571
T70490	UNIPROID	CATC_HUMAN
T70490	TARGNAME	Dipeptidyl peptidase I (CTSC)
T70490	GENENAME	CTSC
T70490	TARGTYPE	Clinical trial
T70490	SYNONYMS	Dipeptidyl transferase; Dipeptidyl peptidase 1; DPPI; DPP-I; Cysteine protease dipeptidyl peptidase I; Cathepsin J; Cathepsin C; CPPI
T70490	FUNCTION	Has dipeptidylpeptidase activity. Active against a broad range of dipeptide substrates composed of both polar and hydrophobic amino acids. Proline cannot occupy the P1 position and arginine cannot occupy the P2 position of the substrate. Can act as both an exopeptidase and endopeptidase. Activates serine proteases such as elastase, cathepsin G and granzymes A and B. Can also activate neuraminidase and factor XIII. Thiol protease.
T70490	PDBSTRUC	4OEM; 4OEL; 4CDF; 4CDE; 4CDD
T70490	BIOCLASS	Peptidase
T70490	ECNUMBER	EC 3.4.14.1
T70490	SEQUENCE	MGAGPSLLLAALLLLLSGDGAVRCDTPANCTYLDLLGTWVFQVGSSGSQRDVNCSVMGPQEKKVVVYLQKLDTAYDDLGNSGHFTIIYNQGFEIVLNDYKWFAFFKYKEEGSKVTTYCNETMTGWVHDVLGRNWACFTGKKVGTASENVYVNIAHLKNSQEKYSNRLYKYDHNFVKAINAIQKSWTATTYMEYETLTLGDMIRRSGGHSRKIPRPKPAPLTAEIQQKILHLPTSWDWRNVHGINFVSPVRNQASCGSCYSFASMGMLEARIRILTNNSQTPILSPQEVVSCSQYAQGCEGGFPYLIAGKYAQDFGLVEEACFPYTGTDSPCKMKEDCFRYYSSEYHYVGGFYGGCNEALMKLELVHHGPMAVAFEVYDDFLHYKKGIYHHTGLRDPFNPFELTNHAVLLVGYGTDSASGMDYWIVKNSWGTGWGENGYFRIRRGTDECAIESIAVAATPIPKL
T70490	DRUGINFO	D5H9TE	BI 1291583	Phase 2
T70490	DRUGINFO	D0V4XG	GSK2793660	Phase 1
T70490	DRUGINFO	D0IV5D	PMID3941405C3d	Investigative
T70490	DRUGINFO	D0U4TA	(S)-2-amino-N-(1-cyano-2-phenylethyl)acetamide	Investigative
T70490	DRUGINFO	D0L9VP	GNF-PF-5434	Investigative

T12646	TARGETID	T12646
T12646	FORMERID	TTDI02187
T12646	UNIPROID	TERA_HUMAN
T12646	TARGNAME	Valosin-containing protein p97 (VCP)
T12646	GENENAME	VCP
T12646	TARGTYPE	Clinical trial
T12646	SYNONYMS	Valosin-containing protein; Transitional endoplasmic reticulum ATPase; TER ATPase; 15S Mg(2+)-ATPase p97 subunit
T12646	FUNCTION	Involved in the formation of the transitional endoplasmic reticulum (tER). The transfer of membranes from the endoplasmic reticulum to the Golgi apparatus occurs via 50-70 nm transition vesicles which derive from part-rough, part-smooth transitional elements of the endoplasmic reticulum (tER). Vesicle budding from the tER is an ATP-dependent process. The ternary complex containing UFD1, VCP and NPLOC4 binds ubiquitinated proteins and is necessary for the export of misfolded proteins from the ER to the cytoplasm, where they are degraded by the proteasome. The NPLOC4-UFD1-VCP complex regulates spindle disassembly at the end of mitosis and is necessary for the formation of a closed nuclear envelope. Regulates E3 ubiquitin-protein ligase activity of RNF19A. Component of the VCP/p97-AMFR/gp78 complex that participates in the final step of the sterol-mediated ubiquitination and endoplasmic reticulum-associated degradation (ERAD) of HMGCR. Involved in endoplasmic reticulum stress-induced pre-emptive quality control, a mechanism that selectively attenuates the translocation of newly synthesized proteins into the endoplasmic reticulum and reroutes them to the cytosol for proteasomal degradation. Plays a role in the regulation of stress granules (SGs) clearance process upon arsenite-induced response. Also involved in DNA damage response: recruited to double-strand breaks (DSBs) sites in a RNF8- and RNF168-dependent manner and promotes the recruitment of TP53BP1 at DNA damage sites. Recruited to stalled replication forks by SPRTN: may act by mediating extraction of DNA polymerase eta (POLH) to prevent excessive translesion DNA synthesis and limit the incidence of mutations induced by DNA damage. Required for cytoplasmic retrotranslocation of stressed/damaged mitochondrial outer-membrane proteins and their subsequent proteasomal degradation. Essential for the maturation of ubiquitin-containing autophagosomes and the clearance of ubiquitinated protein by autophagy. Acts as a negative regulator of type I interferon production by interacting with DDX58/RIG-I: interaction takes place when DDX58/RIG-I is ubiquitinated via 'Lys-63'-linked ubiquitin on its CARD domains, leading to recruit RNF125 and promote ubiquitination and degradation of DDX58/RIG-I. May play a role in the ubiquitin-dependent sorting of membrane proteins to lysosomes where they undergo degradation. May more particularly play a role in caveolins sorting in cells. By controlling the steady-state expression of the IGF1R receptor, indirectly regulates the insulin-like growth factor receptor signaling pathway. Necessary for the fragmentation of Golgi stacks during mitosis and for their reassembly after mitosis.
T12646	PDBSTRUC	6MCK; 6G30; 6G2Z; 6G2Y; 6G2X
T12646	BIOCLASS	Acid anhydride hydrolase
T12646	ECNUMBER	EC 3.6.4.6
T12646	SEQUENCE	MASGADSKGDDLSTAILKQKNRPNRLIVDEAINEDNSVVSLSQPKMDELQLFRGDTVLLKGKKRREAVCIVLSDDTCSDEKIRMNRVVRNNLRVRLGDVISIQPCPDVKYGKRIHVLPIDDTVEGITGNLFEVYLKPYFLEAYRPIRKGDIFLVRGGMRAVEFKVVETDPSPYCIVAPDTVIHCEGEPIKREDEEESLNEVGYDDIGGCRKQLAQIKEMVELPLRHPALFKAIGVKPPRGILLYGPPGTGKTLIARAVANETGAFFFLINGPEIMSKLAGESESNLRKAFEEAEKNAPAIIFIDELDAIAPKREKTHGEVERRIVSQLLTLMDGLKQRAHVIVMAATNRPNSIDPALRRFGRFDREVDIGIPDATGRLEILQIHTKNMKLADDVDLEQVANETHGHVGADLAALCSEAALQAIRKKMDLIDLEDETIDAEVMNSLAVTMDDFRWALSQSNPSALRETVVEVPQVTWEDIGGLEDVKRELQELVQYPVEHPDKFLKFGMTPSKGVLFYGPPGCGKTLLAKAIANECQANFISIKGPELLTMWFGESEANVREIFDKARQAAPCVLFFDELDSIAKARGGNIGDGGGAADRVINQILTEMDGMSTKKNVFIIGATNRPDIIDPAILRPGRLDQLIYIPLPDEKSRVAILKANLRKSPVAKDVDLEFLAKMTNGFSGADLTEICQRACKLAIRESIESEIRRERERQTNPSAMEVEEDDPVPEIRRDHFEEAMRFARRSVSDNDIRKYEMFAQTLQQSRGFGSFRFPSGNQGGAGPSQGSGGGTGGSVYTEDNDDDLYG
T12646	DRUGINFO	D08OOJ	CB-5083	Phase 1
T12646	DRUGINFO	DFC0V4	CB-5339	Phase 1

T15610	TARGETID	T15610
T15610	FORMERID	TTDC00249
T15610	UNIPROID	PSA_HUMAN
T15610	TARGNAME	Puromycin-sensitive aminopeptidase (NPEPPS)
T15610	GENENAME	NPEPPS
T15610	TARGTYPE	Clinical trial
T15610	SYNONYMS	NPEPPS
T15610	FUNCTION	Aminopeptidase with broad substrate specificity for several peptides. Involved in proteolytic events essential for cell growth and viability. May act as regulator of neuropeptide activity. Plays a role in the antigen-processing pathway for MHC class I molecules. Involved in the N-terminal trimming of cytotoxic T-cell epitope precursors. Digests the poly-Q peptides found in many cellular proteins. Digests tau from normal brain moreefficiently than tau from Alzheimer disease brain.
T15610	BIOCLASS	Peptidase
T15610	ECNUMBER	EC 3.4.11.14
T15610	SEQUENCE	MWLAAAAPSLARRLLFLGPPPPPLLLLVFSRSSRRRLHSLGLAAMPEKRPFERLPADVSPINYSLCLKPDLLDFTFEGKLEAAAQVRQATNQIVMNCADIDIITASYAPEGDEEIHATGFNYQNEDEKVTLSFPSTLQTGTGTLKIDFVGELNDKMKGFYRSKYTTPSGEVRYAAVTQFEATDARRAFPCWDEPAIKATFDISLVVPKDRVALSNMNVIDRKPYPDDENLVEVKFARTPVMSTYLVAFVVGEYDFVETRSKDGVCVRVYTPVGKAEQGKFALEVAAKTLPFYKDYFNVPYPLPKIDLIAIADFAAGAMENWGLVTYRETALLIDPKNSCSSSRQWVALVVGHELAHQWFGNLVTMEWWTHLWLNEGFASWIEYLCVDHCFPEYDIWTQFVSADYTRAQELDALDNSHPIEVSVGHPSEVDEIFDAISYSKGASVIRMLHDYIGDKDFKKGMNMYLTKFQQKNAATEDLWESLENASGKPIAAVMNTWTKQMGFPLIYVEAEQVEDDRLLRLSQKKFCAGGSYVGEDCPQWMVPITISTSEDPNQAKLKILMDKPEMNVVLKNVKPDQWVKLNLGTVGFYRTQYSSAMLESLLPGIRDLSLPPVDRLGLQNDLFSLARAGIISTVEVLKVMEAFVNEPNYTVWSDLSCNLGILSTLLSHTDFYEEIQEFVKDVFSPIGERLGWDPKPGEGHLDALLRGLVLGKLGKAGHKATLEEARRRFKDHVEGKQILSADLRSPVYLTVLKHGDGTTLDIMLKLHKQADMQEEKNRIERVLGATLLPDLIQKVLTFALSEEVRPQDTVSVIGGVAGGSKHGRKAAWKFIKDNWEELYNRYQGGFLISRLIKLSVEGFAVDKMAGEVKAFFESHPAPSAERTIQQCCENILLNAAWLKRDAESIHQYLLQRKASPPTV
T15610	DRUGINFO	D0F2JS	CHR-2797	Phase 2
T15610	DRUGINFO	D0J0IY	ANTAQ	Investigative

T14143	TARGETID	T14143
T14143	FORMERID	TTDC00272
T14143	UNIPROID	TGFB2_HUMAN
T14143	TARGNAME	Transforming growth factor beta 2 (TGFB2)
T14143	GENENAME	TGFB2
T14143	TARGTYPE	Clinical trial
T14143	SYNONYMS	Transforming growth factor beta-2 proprotein; TGF-beta 2; Polyergin; Glioblastoma-derived T-cell suppressor factor; G-TSF; Cetermin; BSC-1 cell growth inhibitor
T14143	FUNCTION	Transforming growth factor beta-2 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains, which constitute the regulatory and active subunit of TGF-beta-2, respectively.
T14143	PDBSTRUC	5TY4; 5TX4; 4KXZ; 2TGI; 1TFG
T14143	BIOCLASS	Growth factor
T14143	SEQUENCE	MHYCVLSAFLILHLVTVALSLSTCSTLDMDQFMRKRIEAIRGQILSKLKLTSPPEDYPEPEEVPPEVISIYNSTRDLLQEKASRRAAACERERSDEEYYAKEVYKIDMPPFFPSENAIPPTFYRPYFRIVRFDVSAMEKNASNLVKAEFRVFRLQNPKARVPEQRIELYQILKSKDLTSPTQRYIDSKVVKTRAEGEWLSFDVTDAVHEWLHHKDRNLGFKISLHCPCCTFVPSNNYIIPNKSEELEARFAGIDGTSTYTSGDQKTIKSTRKKNSGKTPHLLLMLLPSYRLESQQTNRRKKRALDAAYCFRNVQDNCCLRPLYIDFKRDLGWKWIHEPKGYNANFCAGACPYLWSSDTQHSRVLSLYNTINPEASASPCCVSQDLEPLTILYYIGKTPKIEQLSNMIVKSCKCS
T14143	DRUGINFO	D08KSU	AP12009	Phase 3
T14143	DRUGINFO	D0PR9I	Lerdelimumab	Investigative

T81735	TARGETID	T81735
T81735	FORMERID	TTDR01142
T81735	UNIPROID	PRKDC_HUMAN
T81735	TARGNAME	DNA-dependent protein kinase catalytic (PRKDC)
T81735	GENENAME	PRKDC
T81735	TARGTYPE	Clinical trial
T81735	SYNONYMS	p460; HYRC1; HYRC; DNPK1; DNA-dependent protein kinase catalytic subunit; DNA-PKcs; DNA-PK catalytic subunit
T81735	FUNCTION	Serine/threonine-protein kinase that acts as a molecular sensor for DNA damage. Involved in DNA non-homologous end joining (NHEJ) required for double-strand break (DSB) repair and V(D)J recombination. Must be bound to DNA to express its catalytic properties. Promotes processing of hairpin DNA structures in V(D)J recombination by activation of the hairpin endonuclease artemis (DCLRE1C). The assembly of the DNA-PK complex at DNA ends is also required for the NHEJ ligation step. Required to protect and align broken ends of DNA. May also act as a scaffold protein to aid the localization of DNA repair proteins to the site of damage. Found at the ends of chromosomes, suggesting a further role in the maintenance of telomeric stability and the prevention of chromosomal end fusion. Also involved in modulation of transcription. Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX, thereby regulating DNA damage response mechanism. Phosphorylates DCLRE1C, c-Abl/ABL1, histone H1, HSPCA, c-jun/JUN, p53/TP53, PARP1, POU2F1, DHX9, FH, SRF, XRCC1, XRCC1, XRCC4, XRCC5, XRCC6, WRN, MYC and RFA2. Can phosphorylate C1D not only in the presence of linear DNA but also in the presence of supercoiled DNA. Ability to phosphorylate p53/TP53 in the presence of supercoiled DNA is dependent on C1D. Contributes to the determination of the circadian period length by antagonizing phosphorylation of CRY1 'Ser-588' and increasing CRY1 protein stability, most likely through an indirect mechanism (By similarity). Plays a role in the regulation of DNA virus-mediated innate immune response by assembling into the HDP-RNP complex, a complex that serves as a platform for IRF3 phosphorylation and subsequent innate immune response activation through the cGAS-STING pathway.
T81735	PDBSTRUC	5Y3R; 5W1R; 5LUQ
T81735	BIOCLASS	Kinase
T81735	ECNUMBER	EC 2.7.11.1
T81735	SEQUENCE	MAGSGAGVRCSLLRLQETLSAADRCGAALAGHQLIRGLGQECVLSSSPAVLALQTSLVFSRDFGLLVFVRKSLNSIEFRECREEILKFLCIFLEKMGQKIAPYSVEIKNTCTSVYTKDRAAKCKIPALDLLIKLLQTFRSSRLMDEFKIGELFSKFYGELALKKKIPDTVLEKVYELLGLLGEVHPSEMINNAENLFRAFLGELKTQMTSAVREPKLPVLAGCLKGLSSLLCNFTKSMEEDPQTSREIFNFVLKAIRPQIDLKRYAVPSAGLRLFALHASQFSTCLLDNYVSLFEVLLKWCAHTNVELKKAALSALESFLKQVSNMVAKNAEMHKNKLQYFMEQFYGIIRNVDSNNKELSIAIRGYGLFAGPCKVINAKDVDFMYVELIQRCKQMFLTQTDTGDDRVYQMPSFLQSVASVLLYLDTVPEVYTPVLEHLVVMQIDSFPQYSPKMQLVCCRAIVKVFLALAAKGPVLRNCISTVVHQGLIRICSKPVVLPKGPESESEDHRASGEVRTGKWKVPTYKDYVDLFRHLLSSDQMMDSILADEAFFSVNSSSESLNHLLYDEFVKSVLKIVEKLDLTLEIQTVGEQENGDEAPGVWMIPTSDPAANLHPAKPKDFSAFINLVEFCREILPEKQAEFFEPWVYSFSYELILQSTRLPLISGFYKLLSITVRNAKKIKYFEGVSPKSLKHSPEDPEKYSCFALFVKFGKEVAVKMKQYKDELLASCLTFLLSLPHNIIELDVRAYVPALQMAFKLGLSYTPLAEVGLNALEEWSIYIDRHVMQPYYKDILPCLDGYLKTSALSDETKNNWEVSALSRAAQKGFNKVVLKHLKKTKNLSSNEAISLEEIRIRVVQMLGSLGGQINKNLLTVTSSDEMMKSYVAWDREKRLSFAVPFREMKPVIFLDVFLPRVTELALTASDRQTKVAACELLHSMVMFMLGKATQMPEGGQGAPPMYQLYKRTFPVLLRLACDVDQVTRQLYEPLVMQLIHWFTNNKKFESQDTVALLEAILDGIVDPVDSTLRDFCGRCIREFLKWSIKQITPQQQEKSPVNTKSLFKRLYSLALHPNAFKRLGASLAFNNIYREFREEESLVEQFVFEALVIYMESLALAHADEKSLGTIQQCCDAIDHLCRIIEKKHVSLNKAKKRRLPRGFPPSASLCLLDLVKWLLAHCGRPQTECRHKSIELFYKFVPLLPGNRSPNLWLKDVLKEEGVSFLINTFEGGGCGQPSGILAQPTLLYLRGPFSLQATLCWLDLLLAALECYNTFIGERTVGALQVLGTEAQSSLLKAVAFFLESIAMHDIIAAEKCFGTGAAGNRTSPQEGERYNYSKCTVVVRIMEFTTTLLNTSPEGWKLLKKDLCNTHLMRVLVQTLCEPASIGFNIGDVQVMAHLPDVCVNLMKALKMSPYKDILETHLREKITAQSIEELCAVNLYGPDAQVDRSRLAAVVSACKQLHRAGLLHNILPSQSTDLHHSVGTELLSLVYKGIAPGDERQCLPSLDLSCKQLASGLLELAFAFGGLCERLVSLLLNPAVLSTASLGSSQGSVIHFSHGEYFYSLFSETINTELLKNLDLAVLELMQSSVDNTKMVSAVLNGMLDQSFRERANQKHQGLKLATTILQHWKKCDSWWAKDSPLETKMAVLALLAKILQIDSSVSFNTSHGSFPEVFTTYISLLADTKLDLHLKGQAVTLLPFFTSLTGGSLEELRRVLEQLIVAHFPMQSREFPPGTPRFNNYVDCMKKFLDALELSQSPMLLELMTEVLCREQQHVMEELFQSSFRRIARRGSCVTQVGLLESVYEMFRKDDPRLSFTRQSFVDRSLLTLLWHCSLDALREFFSTIVVDAIDVLKSRFTKLNESTFDTQITKKMGYYKILDVMYSRLPKDDVHAKESKINQVFHGSCITEGNELTKTLIKLCYDAFTENMAGENQLLERRRLYHCAAYNCAISVICCVFNELKFYQGFLFSEKPEKNLLIFENLIDLKRRYNFPVEVEVPMERKKKYIEIRKEAREAANGDSDGPSYMSSLSYLADSTLSEEMSQFDFSTGVQSYSYSSQDPRPATGRFRRREQRDPTVHDDVLELEMDELNRHECMAPLTALVKHMHRSLGPPQGEEDSVPRDLPSWMKFLHGKLGNPIVPLNIRLFLAKLVINTEEVFRPYAKHWLSPLLQLAASENNGGEGIHYMVVEIVATILSWTGLATPTGVPKDEVLANRLLNFLMKHVFHPKRAVFRHNLEIIKTLVECWKDCLSIPYRLIFEKFSGKDPNSKDNSVGIQLLGIVMANDLPPYDPQCGIQSSEYFQALVNNMSFVRYKEVYAAAAEVLGLILRYVMERKNILEESLCELVAKQLKQHQNTMEDKFIVCLNKVTKSFPPLADRFMNAVFFLLPKFHGVLKTLCLEVVLCRVEGMTELYFQLKSKDFVQVMRHRDDERQKVCLDIIYKMMPKLKPVELRELLNPVVEFVSHPSTTCREQMYNILMWIHDNYRDPESETDNDSQEIFKLAKDVLIQGLIDENPGLQLIIRNFWSHETRLPSNTLDRLLALNSLYSPKIEVHFLSLATNFLLEMTSMSPDYPNPMFEHPLSECEFQEYTIDSDWRFRSTVLTPMFVETQASQGTLQTRTQEGSLSARWPVAGQIRATQQQHDFTLTQTADGRSSFDWLTGSSTDPLVDHTSPSSDSLLFAHKRSERLQRAPLKSVGPDFGKKRLGLPGDEVDNKVKGAAGRTDLLRLRRRFMRDQEKLSLMYARKGVAEQKREKEIKSELKMKQDAQVVLYRSYRHGDLPDIQIKHSSLITPLQAVAQRDPIIAKQLFSSLFSGILKEMDKFKTLSEKNNITQKLLQDFNRFLNTTFSFFPPFVSCIQDISCQHAALLSLDPAAVSAGCLASLQQPVGIRLLEEALLRLLPAELPAKRVRGKARLPPDVLRWVELAKLYRSIGEYDVLRGIFTSEIGTKQITQSALLAEARSDYSEAAKQYDEALNKQDWVDGEPTEAEKDFWELASLDCYNHLAEWKSLEYCSTASIDSENPPDLNKIWSEPFYQETYLPYMIRSKLKLLLQGEADQSLLTFIDKAMHGELQKAILELHYSQELSLLYLLQDDVDRAKYYIQNGIQSFMQNYSSIDVLLHQSRLTKLQSVQALTEIQEFISFISKQGNLSSQVPLKRLLNTWTNRYPDAKMDPMNIWDDIITNRCFFLSKIEEKLTPLPEDNSMNVDQDGDPSDRMEVQEQEEDISSLIRSCKFSMKMKMIDSARKQNNFSLAMKLLKELHKESKTRDDWLVSWVQSYCRLSHCRSRSQGCSEQVLTVLKTVSLLDENNVSSYLSKNILAFRDQNILLGTTYRIIANALSSEPACLAEIEEDKARRILELSGSSSEDSEKVIAGLYQRAFQHLSEAVQAAEEEAQPPSWSCGPAAGVIDAYMTLADFCDQQLRKEEENASVIDSAELQAYPALVVEKMLKALKLNSNEARLKFPRLLQIIERYPEETLSLMTKEISSVPCWQFISWISHMVALLDKDQAVAVQHSVEEITDNYPQAIVYPFIISSESYSFKDTSTGHKNKEFVARIKSKLDQGGVIQDFINALDQLSNPELLFKDWSNDVRAELAKTPVNKKNIEKMYERMYAALGDPKAPGLGAFRRKFIQTFGKEFDKHFGKGGSKLLRMKLSDFNDITNMLLLKMNKDSKPPGNLKECSPWMSDFKVEFLRNELEIPGQYDGRGKPLPEYHVRIAGFDERVTVMASLRRPKRIIIRGHDEREHPFLVKGGEDLRQDQRVEQLFQVMNGILAQDSACSQRALQLRTYSVVPMTSRLGLIEWLENTVTLKDLLLNTMSQEEKAAYLSDPRAPPCEYKDWLTKMSGKHDVGAYMLMYKGANRTETVTSFRKRESKVPADLLKRAFVRMSTSPEAFLALRSHFASSHALICISHWILGIGDRHLNNFMVAMETGGVIGIDFGHAFGSATQFLPVPELMPFRLTRQFINLMLPMKETGLMYSIMVHALRAFRSDPGLLTNTMDVFVKEPSFDWKNFEQKMLKKGGSWIQEINVAEKNWYPRQKICYAKRKLAGANPAVITCDELLLGHEKAPAFRDYVAVARGSKDHNIRAQEPESGLSEETQVKCLMDQATDPNILGRTWEGWEPWM
T81735	DRUGINFO	D0H3UR	M3814	Phase 1/2
T81735	DRUGINFO	DPNT63	AZD7648	Phase 1/2
T81735	DRUGINFO	D02IKF	M9831	Phase 1
T81735	DRUGINFO	D00HXZ	2-morpholino-6-(thianthren-1-yl)-4H-chromen-4-one	Investigative
T81735	DRUGINFO	D00IRL	2-(4-methoxyphenyl)-6-morpholino-4H-pyran-4-one	Investigative
T81735	DRUGINFO	D00MCG	2-(1H-indol-5-yl)-6-morpholino-4H-pyran-4-one	Investigative
T81735	DRUGINFO	D00MXW	8-(2-acetylphenyl)-2-morpholin-4-ylchromen-4-one	Investigative
T81735	DRUGINFO	D00TUH	8-(4-acetylphenyl)-2-morpholin-4-ylchromen-4-one	Investigative
T81735	DRUGINFO	D01MXN	8-(1H-indol-5-yl)-2-morpholin-4-ylchromen-4-one	Investigative
T81735	DRUGINFO	D01SXB	3-(6-morpholino-4-oxo-4H-pyran-2-yl)benzaldehyde	Investigative
T81735	DRUGINFO	D01ZMP	2-morpholino-6-(thiophen-2-yl)-4H-pyran-4-one	Investigative
T81735	DRUGINFO	D02DDM	2-(2-methoxyphenyl)-6-morpholino-4H-pyran-4-one	Investigative
T81735	DRUGINFO	D02IDN	2-(4-Amino-phenyl)-benzo[h]chromen-4-one	Investigative
T81735	DRUGINFO	D02MPG	2-(4-chlorophenyl)-6-morpholino-4H-pyran-4-one	Investigative
T81735	DRUGINFO	D02PBS	7-benzoyloxy-2-(morpholin-4-yl)-chromen-4-one	Investigative
T81735	DRUGINFO	D02SMG	2-(furan-2-yl)-6-morpholino-4H-pyran-4-one	Investigative
T81735	DRUGINFO	D02TCZ	2-Thiomorpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one	Investigative
T81735	DRUGINFO	D03DGP	6-(2-acetylphenyl)-2-morpholin-4-ylchromen-4-one	Investigative
T81735	DRUGINFO	D03DJC	2-(2-aminophenyl)-6-morpholino-4H-pyran-4-one	Investigative
T81735	DRUGINFO	D03FTE	2-dibenzofuran-4-yl-6-morpholin-4-yl-pyran-4-one	Investigative
T81735	DRUGINFO	D03IQX	2-(2-Fluoro-phenyl)-benzo[h]chromen-4-one	Investigative
T81735	DRUGINFO	D03MDA	2-morpholin-4-yl-6-phenyl-4H-thiopyran-4-one	Investigative
T81735	DRUGINFO	D03QQH	AMA37	Investigative
T81735	DRUGINFO	D03TQO	6-(3-hydroxyphenyl)-2-morpholino-4H-chromen-4-one	Investigative
T81735	DRUGINFO	D04DQF	2-(3-acetylphenyl)-6-morpholino-4H-pyran-4-one	Investigative
T81735	DRUGINFO	D04ECT	4-Thiomorpholin-4-yl-benzo[g]chromen-2-one	Investigative
T81735	DRUGINFO	D04JGZ	2-morpholin-4-yl-8-styrylchromen-4-one	Investigative
T81735	DRUGINFO	D04NVK	ShRNA molecule silencing DNAPK radiosensitizer	Investigative
T81735	DRUGINFO	D04RAW	2-morpholin-4-yl-8-naphthalen-2-ylchromen-4-one	Investigative
T81735	DRUGINFO	D04SCD	6-Chloro-4-morpholin-4-yl-chromen-2-one	Investigative
T81735	DRUGINFO	D04XFN	7-phenyloxyethoxy-2-morpholin-4-yl-chromen-4-one	Investigative
T81735	DRUGINFO	D05SBJ	1-Morpholin-4-yl-benzo[f]chromen-3-one	Investigative
T81735	DRUGINFO	D05SGV	3-morpholino-1H-benzo[f]chromen-1-one	Investigative
T81735	DRUGINFO	D05USL	KU-55933	Investigative
T81735	DRUGINFO	D06BDY	6-Methoxy-4-morpholin-4-yl-chromen-2-one	Investigative
T81735	DRUGINFO	D06DAY	8-furan-2-yl-2-morpholin-4-ylchromen-4-one	Investigative
T81735	DRUGINFO	D06GNE	IC86621	Investigative
T81735	DRUGINFO	D06TGR	8-(3-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one	Investigative
T81735	DRUGINFO	D06WCT	7-phenylethoxy-2-morpholin-4-yl-chromen-4-one	Investigative
T81735	DRUGINFO	D07AXO	8-Methoxy-4-morpholin-4-yl-chromen-2-one	Investigative
T81735	DRUGINFO	D07NSR	4-Morpholin-4-yl-benzo[g]chromen-2-one	Investigative
T81735	DRUGINFO	D08BRZ	2-(4-fluorophenyl)-6-morpholino-4H-pyran-4-one	Investigative
T81735	DRUGINFO	D08WQW	2-biphenyl-4-yl-6-morpholin-4-yl-pyran-4-one	Investigative
T81735	DRUGINFO	D09TJK	3-(6-morpholino-4-oxo-4H-pyran-2-yl)benzonitrile	Investigative
T81735	DRUGINFO	D09YAL	6-tert-Butyl-2-morpholin-4-yl-4H-thiopyran-4-one	Investigative
T81735	DRUGINFO	D0AG8B	2-thiomorpholino-4H-benzo[h]chromen-4-one	Investigative
T81735	DRUGINFO	D0B0QS	2-[1,4]Oxazepan-4-yl-benzo[h]chromen-4-one	Investigative
T81735	DRUGINFO	D0B4CJ	2-Morpholin-4-yl-6-phenyl-chromen-4-one	Investigative
T81735	DRUGINFO	D0B9EZ	2-(piperidin-1-yl)-4H-benzo[h]chromen-4-one	Investigative
T81735	DRUGINFO	D0C3SJ	6-isopropyl-2-morpholin-4-yl-4H-thiopyran-4-one	Investigative
T81735	DRUGINFO	D0C8MK	2-morpholin-4-yl-8-phenoxathiin-4-ylchromen-4-one	Investigative
T81735	DRUGINFO	D0D9RN	7-hydroxy-2-(morpholin-4-yl)chromen-4-one	Investigative
T81735	DRUGINFO	D0F5BD	2-morpholinobenzo[h]quinolin-4(1H)-one	Investigative
T81735	DRUGINFO	D0F6ZC	8-Methyl-2-morpholin-4-yl-chromen-4-one	Investigative
T81735	DRUGINFO	D0F7ZK	2-morpholino-6-styryl-4H-pyran-4-one	Investigative
T81735	DRUGINFO	D0G4RG	4-Morpholin-4-yl-benzo[h]chromen-2-one	Investigative
T81735	DRUGINFO	D0H2BL	7-benzyloxy-2-(morpholin-4-yl)-chromen-4-one	Investigative
T81735	DRUGINFO	D0H9DB	8-biphenyl-2-yl-2-morpholin-4-ylchromen-4-one	Investigative
T81735	DRUGINFO	D0I1LR	2-morpholin-4-yl-8-thiophen-3-ylchromen-4-one	Investigative
T81735	DRUGINFO	D0I3IO	6-(4-fluorostyryl)-2-morpholino-4H-chromen-4-one	Investigative
T81735	DRUGINFO	D0J7BH	4-Morpholin-4-yl-chromen-2-one	Investigative
T81735	DRUGINFO	D0JB6H	6-Methyl-4-morpholin-4-yl-chromen-2-one	Investigative
T81735	DRUGINFO	D0JH9J	6-biphenyl-2-yl-2-morpholin-4-yl-chromen-4-one	Investigative
T81735	DRUGINFO	D0K3VK	4-(6-morpholino-4-oxo-4H-pyran-2-yl)benzonitrile	Investigative
T81735	DRUGINFO	D0K5VE	6-(4-chlorophenyl)-4-morpholino-2H-pyran-2-one	Investigative
T81735	DRUGINFO	D0K7LZ	8-dibenzofuran-4-yl-2-morpholin-4-ylchromen-4-one	Investigative
T81735	DRUGINFO	D0KG0Z	2-(3-Fluoro-phenyl)-benzo[h]chromen-4-one	Investigative
T81735	DRUGINFO	D0KH8S	3-(6-morpholino-4-oxo-4H-pyran-2-yl)benzoic acid	Investigative
T81735	DRUGINFO	D0L3TX	4-Piperidin-1-yl-chromen-2-one	Investigative
T81735	DRUGINFO	D0LC5C	6-(4-chlorophenyl)-2-morpholin-4-ylpyridin-4-ol	Investigative
T81735	DRUGINFO	D0M3RY	4-morpholino-6-phenyl-2H-pyran-2-one	Investigative
T81735	DRUGINFO	D0N2LW	8-Phenyl-2-thiomorpholin-4-yl-chromen-4-one	Investigative
T81735	DRUGINFO	D0N2XO	2-(3-methoxyphenyl)-6-morpholino-4H-pyran-4-one	Investigative
T81735	DRUGINFO	D0O3VF	2-morpholin-4-yl-8-thiophen-2-ylchromen-4-one	Investigative
T81735	DRUGINFO	D0O4KC	7-Methoxy-4-morpholin-4-yl-chromen-2-one	Investigative
T81735	DRUGINFO	D0O5BC	2-(benzofuran-2-yl)-6-morpholino-4H-pyran-4-one	Investigative
T81735	DRUGINFO	D0O9OB	7-propoxy-2-(morpholin-4-yl)-chromen-4-one	Investigative
T81735	DRUGINFO	D0P4MU	7-ethyloxyethoxy-2-morpholin-4-yl-chromen-4-one	Investigative
T81735	DRUGINFO	D0PO9X	2-morpholino-6-(naphthalen-1-yl)-4H-pyran-4-one	Investigative
T81735	DRUGINFO	D0Q4GJ	2-Pyridin-3-yl-benzo[h]chromen-4-one	Investigative
T81735	DRUGINFO	D0Q5FJ	8-Phenyl-2-piperidin-1-yl-chromen-4-one	Investigative
T81735	DRUGINFO	D0QB9L	2-morpholino-6-(naphthalen-2-yl)-4H-pyran-4-one	Investigative
T81735	DRUGINFO	D0R1BG	8-Methoxy-2-morpholin-4-yl-chromen-4-one	Investigative
T81735	DRUGINFO	D0R7HM	2-morpholino-6-phenyl-4H-pyran-4-one	Investigative
T81735	DRUGINFO	D0S5SG	2-morpholino-6-(thiophen-3-yl)-4H-pyran-4-one	Investigative
T81735	DRUGINFO	D0S7NM	8-(4-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one	Investigative
T81735	DRUGINFO	D0U4JL	6-(4-hydroxyphenyl)-2-morpholino-4H-chromen-4-one	Investigative
T81735	DRUGINFO	D0U7WU	2-morpholino-4H-benzo[g]chromen-4-one	Investigative
T81735	DRUGINFO	D0U9ZW	8-Methyl-4-morpholin-4-yl-chromen-2-one	Investigative
T81735	DRUGINFO	D0V0SD	2-Morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one	Investigative
T81735	DRUGINFO	D0V3XZ	8-(4-chlorophenyl)-2-morpholin-4-ylchromen-4-one	Investigative
T81735	DRUGINFO	D0V8VY	2-Pyrrolidin-1-yl-benzo[h]chromen-4-one	Investigative
T81735	DRUGINFO	D0W3QB	2-Morpholin-4-yl-benzo[h]chromene-4-thione	Investigative
T81735	DRUGINFO	D0XL6P	2-morpholino-6-(naphthalen-1-yl)-4H-chromen-4-one	Investigative
T81735	DRUGINFO	D0Y3OO	NU-7432	Investigative
T81735	DRUGINFO	D0Y7WU	6-(4-methoxyphenyl)-4-morpholino-2H-pyran-2-one	Investigative
T81735	DRUGINFO	D0Z3CC	2-morpholino-6-(quinolin-8-yl)-4H-pyran-4-one	Investigative
T81735	DRUGINFO	D0ZQ8Z	7-Methoxy-2-morpholin-4-yl-chromen-4-one	Investigative
T81735	DRUGINFO	D0I7GE	ALPHA-NAPHTHOFLAVONE	Investigative
T81735	DRUGINFO	D0T0BY	2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one	Investigative
T81735	DRUGINFO	D0X7TB	2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one	Investigative
T81735	DRUGINFO	D00HSJ	PIK-75	Investigative
T81735	DRUGINFO	D0R0TW	KU-0060648	Investigative
T81735	DRUGINFO	D07APP	LY-292223	Investigative
T81735	DRUGINFO	D0W1ST	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	Investigative
T81735	DRUGINFO	D03EHM	PP121	Investigative

T43721	TARGETID	T43721
T43721	FORMERID	TTDR01269
T43721	UNIPROID	DHI2_HUMAN
T43721	TARGNAME	Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2)
T43721	GENENAME	HSD11B2
T43721	TARGTYPE	Clinical trial
T43721	SYNONYMS	NAD-dependent 11-beta-hydroxysteroid dehydrogenase; HSD11B2; 11-beta-hydroxysteroid dehydrogenase type 2; 11-beta-HSD2; 11-DH2; 11 beta-hydroxysteroid dehydrogenase type 2; 11 beta-HSD2
T43721	FUNCTION	Catalyzes the conversion of cortisol to the inactive metabolite cortisone. modulates intracellular glucocorticoid levels, thus protecting the nonselective mineralocorticoid receptor from occupation by glucocorticoids.
T43721	BIOCLASS	Short-chain dehydrogenases reductase
T43721	ECNUMBER	EC 1.1.1.-
T43721	SEQUENCE	MERWPWPSGGAWLLVAARALLQLLRSDLRLGRPLLAALALLAALDWLCQRLLPPPAALAVLAAAGWIALSRLARPQRLPVATRAVLITGCDSGFGKETAKKLDSMGFTVLATVLELNSPGAIELRTCCSPRLRLLQMDLTKPGDISRVLEFTKAHTTSTGLWGLVNNAGHNEVVADAELSPVATFRSCMEVNFFGALELTKGLLPLLRSSRGRIVTVGSPAGDMPYPCLGAYGTSKAAVALLMDTFSCELLPWGVKVSIIQPGCFKTESVRNVGQWEKRKQLLLANLPQELLQAYGKDYIEHLHGQFLHSLRLAMSDLTPVVDAITDALLAARPRRRYYPGQGLGLMYFIHYYLPEGLRRRFLQAFFISHCLPRALQPGQPGTTPPQDAAQDPNLSPGPSPAVAR
T43721	DRUGINFO	D04ZNL	RG-7234	Phase 2
T43721	DRUGINFO	D03NPA	Ganoderic acid A	Investigative
T43721	DRUGINFO	D02XEX	3-acetyl-11-keto-beta-boswellic acid	Investigative
T43721	DRUGINFO	D09VYW	11-keto-beta-boswellicacid	Investigative
T43721	DRUGINFO	D0U8IF	[(125)I] RB129	Investigative

T36557	TARGETID	T36557
T36557	FORMERID	TTDC00069
T36557	UNIPROID	PPARD_HUMAN
T36557	TARGNAME	Peroxisome proliferator-activated receptor delta (PPARD)
T36557	GENENAME	PPARD
T36557	TARGTYPE	Clinical trial
T36557	SYNONYMS	Peroxisomeproliferator-activated receptor beta; Peroxisomeproliferator activated receptor beta/delta; Peroxisome proliferator-activated receptor beta; PPARdelta; PPARB; PPAR-delta; PPAR-beta; Nuclear receptor subfamily 1 group C member 2; Nuclear hormone receptor 1; NUCI; NUC1; NR1C2
T36557	FUNCTION	Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Has a preference for poly-unsaturated fatty acids, such as gamma-linoleic acid and eicosapentanoic acid. Once activated by a ligand, the receptor binds to promoter elements of target genes. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as transcription activator for the acyl-CoA oxidase gene. Decreases expression of NPC1L1 once activated by a ligand. Ligand-activated transcription factor.
T36557	PDBSTRUC	5ZXI; 5Y7X; 5XMX; 5U46; 5U45
T36557	BIOCLASS	Nuclear hormone receptor
T36557	SEQUENCE	MEQPQEEAPEVREEEEKEEVAEAEGAPELNGGPQHALPSSSYTDLSRSSSPPSLLDQLQMGCDGASCGSLNMECRVCGDKASGFHYGVHACEGCKGFFRRTIRMKLEYEKCERSCKIQKKNRNKCQYCRFQKCLALGMSHNAIRFGRMPEAEKRKLVAGLTANEGSQYNPQVADLKAFSKHIYNAYLKNFNMTKKKARSILTGKASHTAPFVIHDIETLWQAEKGLVWKQLVNGLPPYKEISVHVFYRCQCTTVETVRELTEFAKSIPSFSSLFLNDQVTLLKYGVHEAIFAMLASIVNKDGLLVANGSGFVTREFLRSLRKPFSDIIEPKFEFAVKFNALELDDSDLALFIAAIILCGDRPGLMNVPRVEAIQDTILRALEFHLQANHPDAQYLFPKLLQKMADLRQLVTEHAQMMQRIKKTETETSLHPLLQEIYKDMY
T36557	DRUGINFO	D0LW1Y	GFT-505	Phase 3
T36557	DRUGINFO	D03OSG	MBX-8025	Phase 2/3
T36557	DRUGINFO	D53BEH	T3D‐959	Phase 2
T36557	DRUGINFO	D0ZT8A	T3D-959	Phase 1/2
T36557	DRUGINFO	D01PVV	KD3010	Phase 1
T36557	DRUGINFO	D04NJS	SAR351034	Phase 1
T36557	DRUGINFO	D06KPR	CER-002	Phase 1
T36557	DRUGINFO	D0V0JN	PMID25416646-Compound-Figure5-C	Patented
T36557	DRUGINFO	D05HDX	GW-501516	Discontinued in Phase 4
T36557	DRUGINFO	D01JGG	Sodelglitazar	Discontinued in Phase 2
T36557	DRUGINFO	D09OHP	Indeglitazar	Discontinued in Phase 2
T36557	DRUGINFO	D0S6KX	GSK-677954	Discontinued in Phase 2
T36557	DRUGINFO	D06GFG	KD-3020	Preclinical
T36557	DRUGINFO	D0V0TT	CS-204	Terminated
T36557	DRUGINFO	D06VBQ	GSK-0660	Investigative
T36557	DRUGINFO	D07USR	SAVX-1	Investigative
T36557	DRUGINFO	D0K1TQ	GW0742X	Investigative
T36557	DRUGINFO	D0NM0G	GSK-3787	Investigative
T36557	DRUGINFO	D0V6DE	(11E)-OCTADEC-11-ENOIC ACID	Investigative
T36557	DRUGINFO	D0XR8Q	GW2433	Investigative
T36557	DRUGINFO	D0YK9T	L-165041	Investigative
T36557	DRUGINFO	D06IBV	Heptyl-Beta-D-Glucopyranoside	Investigative
T36557	DRUGINFO	D01ARG	DB-900	Investigative
T36557	DRUGINFO	D09JII	L-796449	Investigative
T36557	DRUGINFO	D0F0MP	L-165461	Investigative
T36557	DRUGINFO	D08QXD	L-783483	Investigative

T88285	TARGETID	T88285
T88285	FORMERID	TTDR01246
T88285	UNIPROID	LGUL_HUMAN
T88285	TARGNAME	Lactoylglutathione lyase (GLO1)
T88285	GENENAME	GLO1
T88285	TARGTYPE	Clinical trial
T88285	SYNONYMS	S-D-lactoylglutathione methylglyoxal lyase; Methylglyoxalase; Ketone-aldehyde mutase; Glyoxalase I; GlxI; Glx I; GLO1; Aldoketomutase
T88285	FUNCTION	Catalyzes the conversion of hemimercaptal, formed from methylglyoxal and glutathione, to S-lactoylglutathione. Involved in the regulation of TNF-induced transcriptional activity of NF- kappa-B. Required for normal osteoclastogenesis.
T88285	PDBSTRUC	3W0U; 3W0T; 3VW9; 1QIP; 1QIN
T88285	BIOCLASS	Carbon-sulfur lyases
T88285	ECNUMBER	EC 4.4.1.5
T88285	SEQUENCE	MAEPQPPSGGLTDEAALSCCSDADPSTKDFLLQQTMLRVKDPKKSLDFYTRVLGMTLIQKCDFPIMKFSLYFLAYEDKNDIPKEKDEKIAWALSRKATLELTHNWGTEDDETQSYHNGNSDPRGFGHIGIAVPDVYSACKRFEELGVKFVKKPDDGKMKGLAFIQDPDGYWIEILNPNKMATLM
T88285	DRUGINFO	D00YEV	BAICALEIN	Phase 2
T88285	DRUGINFO	D02ABO	NARINGENIN	Phase 1
T88285	DRUGINFO	D00XKH	S-(N-butyl-N-hydroxycarbamoyl)glutathione	Investigative
T88285	DRUGINFO	D01UKL	S-(N-heptyl-N-hydroxycarbamoyl)glutathione	Investigative
T88285	DRUGINFO	D03OXL	S-(N-propyl-N-hydroxycarbamoyl)glutathione	Investigative
T88285	DRUGINFO	D08DOY	S-(N-Hydroxy-N-Iodophenylcarbamoyl)Glutathione	Investigative
T88285	DRUGINFO	D0E3VR	S-(N-pentyl-N-hydroxycarbamoyl)glutathione	Investigative
T88285	DRUGINFO	D0FX3J	S-(N-methyl-N-hydroxycarbamoyl)glutathione	Investigative
T88285	DRUGINFO	D0I2AG	S-(N-4bromophenyl-N-hydroxycarbamoyl)glutathione	Investigative
T88285	DRUGINFO	D0I6JQ	S-(N-4chlorophenyl-N-hydroxycarbamoyl)glutathione	Investigative
T88285	DRUGINFO	D0I8PQ	S-(N-ethyl-N-hydroxycarbamoyl)glutathione	Investigative
T88285	DRUGINFO	D0K2UP	S-Benzyl-Glutathione	Investigative
T88285	DRUGINFO	D0O3DI	PELARGONIDIN CHLORIDE	Investigative
T88285	DRUGINFO	D0R3IN	S-p-bromobenzyl glutatione	Investigative
T88285	DRUGINFO	D0V3PG	CYANIDIN	Investigative
T88285	DRUGINFO	D0X7OS	S-P-Nitrobenzyloxycarbonylglutathione	Investigative
T88285	DRUGINFO	D0YI5C	S-(N-hexyl-N-hydroxycarbamoyl)glutathione	Investigative
T88285	DRUGINFO	D0Z9WS	S-(N-phenyl-N-hydroxycarbamoyl)glutathione	Investigative
T88285	DRUGINFO	D0G3TK	KAEMPFEROL	Investigative
T88285	DRUGINFO	D0Q5FV	2-Sulfhydryl-Ethanol	Investigative

T01973	TARGETID	T01973
T01973	FORMERID	TTDNC00418
T01973	UNIPROID	RON_HUMAN
T01973	TARGNAME	Macrophage-stimulating protein receptor (RON)
T01973	GENENAME	MST1R
T01973	TARGTYPE	Clinical trial
T01973	SYNONYMS	p185Ron; Proteintyrosine kinase 8; Macrophagestimulating protein receptor beta chain; Macrophagestimulating protein receptor; MST1R; MSP receptor; CDw136; CD136
T01973	FUNCTION	Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to MST1 ligand. Regulates many physiological processes including cell survival, migration and differentiation. Ligand binding at the cell surface induces autophosphorylation of RON on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1 or the adapter GAB1. Recruitment of these downstream effectors by RON leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. RON signaling activates the wound healing response by promoting epithelial cell migration, proliferation as well as survival at the wound site. Plays also a role in the innate immune response by regulating the migration and phagocytic activity of macrophages. Alternatively, RON can also promote signals such as cell migration and proliferation in response to growth factors other than MST1 ligand.
T01973	PDBSTRUC	4QT8; 4FWW; 3PLS
T01973	BIOCLASS	Kinase
T01973	ECNUMBER	EC 2.7.10.1
T01973	SEQUENCE	MELLPPLPQSFLLLLLLPAKPAAGEDWQCPRTPYAASRDFDVKYVVPSFSAGGLVQAMVTYEGDRNESAVFVAIRNRLHVLGPDLKSVQSLATGPAGDPGCQTCAACGPGPHGPPGDTDTKVLVLDPALPALVSCGSSLQGRCFLHDLEPQGTAVHLAAPACLFSAHHNRPDDCPDCVASPLGTRVTVVEQGQASYFYVASSLDAAVAASFSPRSVSIRRLKADASGFAPGFVALSVLPKHLVSYSIEYVHSFHTGAFVYFLTVQPASVTDDPSALHTRLARLSATEPELGDYRELVLDCRFAPKRRRRGAPEGGQPYPVLRVAHSAPVGAQLATELSIAEGQEVLFGVFVTGKDGGPGVGPNSVVCAFPIDLLDTLIDEGVERCCESPVHPGLRRGLDFFQSPSFCPNPPGLEALSPNTSCRHFPLLVSSSFSRVDLFNGLLGPVQVTALYVTRLDNVTVAHMGTMDGRILQVELVRSLNYLLYVSNFSLGDSGQPVQRDVSRLGDHLLFASGDQVFQVPIQGPGCRHFLTCGRCLRAWHFMGCGWCGNMCGQQKECPGSWQQDHCPPKLTEFHPHSGPLRGSTRLTLCGSNFYLHPSGLVPEGTHQVTVGQSPCRPLPKDSSKLRPVPRKDFVEEFECELEPLGTQAVGPTNVSLTVTNMPPGKHFRVDGTSVLRGFSFMEPVLIAVQPLFGPRAGGTCLTLEGQSLSVGTSRAVLVNGTECLLARVSEGQLLCATPPGATVASVPLSLQVGGAQVPGSWTFQYREDPVVLSISPNCGYINSHITICGQHLTSAWHLVLSFHDGLRAVESRCERQLPEQQLCRLPEYVVRDPQGWVAGNLSARGDGAAGFTLPGFRFLPPPHPPSANLVPLKPEEHAIKFEYIGLGAVADCVGINVTVGGESCQHEFRGDMVVCPLPPSLQLGQDGAPLQVCVDGECHILGRVVRPGPDGVPQSTLLGILLPLLLLVAALATALVFSYWWRRKQLVLPPNLNDLASLDQTAGATPLPILYSGSDYRSGLALPAIDGLDSTTCVHGASFSDSEDESCVPLLRKESIQLRDLDSALLAEVKDVLIPHERVVTHSDRVIGKGHFGVVYHGEYIDQAQNRIQCAIKSLSRITEMQQVEAFLREGLLMRGLNHPNVLALIGIMLPPEGLPHVLLPYMCHGDLLQFIRSPQRNPTVKDLISFGLQVARGMEYLAEQKFVHRDLAARNCMLDESFTVKVADFGLARDILDREYYSVQQHRHARLPVKWMALESLQTYRFTTKSDVWSFGVLLWELLTRGAPPYRHIDPFDLTHFLAQGRRLPQPEYCPDSLYQVMQQCWEADPAVRPTFRVLVGEVEQIVSALLGDHYVQLPATYMNLGPSTSHEMNVRPEQPQFSPMPGNVRRPRPLSEPPRPT
T01973	DRUGINFO	D00DRL	MK-2461	Phase 1/2
T01973	DRUGINFO	D07PWY	Anti-RON receptor mabs	Investigative
T01973	DRUGINFO	D0BG2L	ABC-7	Investigative

T15068	TARGETID	T15068
T15068	FORMERID	TTDR00669
T15068	UNIPROID	FAK1_HUMAN
T15068	TARGNAME	Focal adhesion kinase 1 (FAK)
T15068	GENENAME	PTK2
T15068	TARGTYPE	Clinical trial
T15068	SYNONYMS	pp125FAK; p125FAK; Protein-tyrosine kinase 2; Protein phosphatase 1 regulatory subunit 71; PPP1R71; Focal adhesion kinase-related nonkinase; FRNK; FAK1; FADK 1; FADK
T15068	FUNCTION	Required for early embryonic development and placenta development. Required for embryonic angiogenesis, normal cardiomyocyte migration and proliferation, and normal heart development. Regulates axon growth and neuronal cell migration, axon branching and synapse formation; required for normal development of the nervous system. Plays a role in osteogenesis and differentiation of osteoblasts. Functions in integrin signal transduction, but also in signaling downstream of numerous growth factor receptors, G-protein coupled receptors (GPCR), EPHA2, netrin receptors and LDL receptors. Forms multisubunit signaling complexes with SRC and SRC family members upon activation; this leads to the phosphorylation of additional tyrosine residues, creating binding sites for scaffold proteins, effectors and substrates. Regulates numerous signaling pathways. Promotes activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascade. Promotes activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling cascade. Promotes localized and transient activation of guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs), and thereby modulates the activity of Rho family GTPases. Signaling via CAS family members mediates activation of RAC1. Recruits the ubiquitin ligase MDM2 to P53/TP53 in the nucleus, and thereby regulates P53/TP53 activity, P53/TP53 ubiquitination and proteasomal degradation. Phosphorylates SRC; this increases SRC kinase activity. Phosphorylates ACTN1, ARHGEF7, GRB7, RET and WASL. Promotes phosphorylation of PXN and STAT1; most likely PXN and STAT1 are phosphorylated by a SRC family kinase that is recruited to autophosphorylated PTK2/FAK1, rather than by PTK2/FAK1 itself. Promotes phosphorylation of BCAR1; GIT2 and SHC1; this requires both SRC and PTK2/FAK1. Promotes phosphorylation of BMX and PIK3R1. Isoform 6 (FRNK) does not contain a kinase domain and inhibits PTK2/FAK1 phosphorylation and signaling. Its enhanced expression can attenuate the nuclear accumulation of LPXN and limit its ability to enhance serum response factor (SRF)-dependent gene transcription. Non-receptor protein-tyrosine kinase that plays an essential role in regulating cell migration, adhesion, spreading, reorganization of the actin cytoskeleton, formation and disassembly of focal adhesions and cell protrusions, cell cycle progression, cell proliferation and apoptosis.
T15068	PDBSTRUC	6I8Z; 4Q9S; 4NY0; 4KAO; 4KAB
T15068	BIOCLASS	Kinase
T15068	ECNUMBER	EC 2.7.10.2
T15068	SEQUENCE	MAAAYLDPNLNHTPNSSTKTHLGTGMERSPGAMERVLKVFHYFESNSEPTTWASIIRHGDATDVRGIIQKIVDSHKVKHVACYGFRLSHLRSEEVHWLHVDMGVSSVREKYELAHPPEEWKYELRIRYLPKGFLNQFTEDKPTLNFFYQQVKSDYMLEIADQVDQEIALKLGCLEIRRSYWEMRGNALEKKSNYEVLEKDVGLKRFFPKSLLDSVKAKTLRKLIQQTFRQFANLNREESILKFFEILSPVYRFDKECFKCALGSSWIISVELAIGPEEGISYLTDKGCNPTHLADFTQVQTIQYSNSEDKDRKGMLQLKIAGAPEPLTVTAPSLTIAENMADLIDGYCRLVNGTSQSFIIRPQKEGERALPSIPKLANSEKQGMRTHAVSVSETDDYAEIIDEEDTYTMPSTRDYEIQRERIELGRCIGEGQFGDVHQGIYMSPENPALAVAIKTCKNCTSDSVREKFLQEALTMRQFDHPHIVKLIGVITENPVWIIMELCTLGELRSFLQVRKYSLDLASLILYAYQLSTALAYLESKRFVHRDIAARNVLVSSNDCVKLGDFGLSRYMEDSTYYKASKGKLPIKWMAPESINFRRFTSASDVWMFGVCMWEILMHGVKPFQGVKNNDVIGRIENGERLPMPPNCPPTLYSLMTKCWAYDPSRRPRFTELKAQLSTILEEEKAQQEERMRMESRRQATVSWDSGGSDEAPPKPSRPGYPSPRSSEGFYPSPQHMVQTNHYQVSGYPGSHGITAMAGSIYPGQASLLDQTDSWNHRPQEIAMWQPNVEDSTVLDLRGIGQVLPTHLMEERLIRQQQEMEEDQRWLEKEERFLKPDVRLSRGSIDREDGSLQGPIGNQHIYQPVGKPDPAAPPKKPPRPGAPGHLGSLASLSSPADSYNEGVKLQPQEISPPPTANLDRSNDKVYENVTGLVKAVIEMSSKIQPAPPEEYVPMVKEVGLALRTLLATVDETIPLLPASTHREIEMAQKLLNSDLGELINKMKLAQQYVMTSLQQEYKKQMLTAAHALAVDAKNLLDVIDQARLKMLGQTRPH
T15068	DRUGINFO	D0Y1UO	VS-6063	Phase 2
T15068	DRUGINFO	D00KNI	BI-853520	Phase 1
T15068	DRUGINFO	D01SJT	PF-562271	Phase 1
T15068	DRUGINFO	D0A6VD	VS-4718	Phase 1
T15068	DRUGINFO	D0B9MR	GSK-2256098	Phase 1
T15068	DRUGINFO	D0N6NM	CEP-37440	Phase 1
T15068	DRUGINFO	D1EW3O	IN10018	Phase 1
T15068	DRUGINFO	D07XYI	1,2,4-triazolo[1,5a]pyridine derivative 1	Patented
T15068	DRUGINFO	D0AY0F	PMID23414845C30	Investigative
T15068	DRUGINFO	D02QAZ	PF-228	Investigative
T15068	DRUGINFO	D0M4SY	BMS-536924	Investigative

T13057	TARGETID	T13057
T13057	FORMERID	TTDR01263
T13057	UNIPROID	PTN11_HUMAN
T13057	TARGNAME	Protein-tyrosine phosphatase SHP-2 (PTPN11)
T13057	GENENAME	PTPN11
T13057	TARGTYPE	Clinical trial
T13057	SYNONYMS	Tyrosine-protein phosphatase non-receptor type 11; SHPTP2; SHP2; SHP-2; SH-PTP3; SH-PTP2; Protein-tyrosine phosphatase SHP2; Protein-tyrosine phosphatase 2C; Protein-tyrosine phosphatase 1D; PTP2C; PTP-2C; PTP-1D
T13057	FUNCTION	Positively regulates MAPK signal transduction pathway. Dephosphorylates GAB1, ARHGAP35 and EGFR. Dephosphorylates ROCK2 at 'Tyr-722' resulting in stimulatation of its RhoA binding activity. Dephosphorylates CDC73. Acts downstream of various receptor and cytoplasmic protein tyrosine kinases to participate in the signal transduction from the cell surface to the nucleus.
T13057	PDBSTRUC	6MDD; 6MDC; 6MDB; 6MDA; 6MD9
T13057	BIOCLASS	Phosphoric monoester hydrolase
T13057	ECNUMBER	EC 3.1.3.48
T13057	SEQUENCE	MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGHEYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR
T13057	DRUGINFO	D1LEU5	JAB-3312	Phase 1/2
T13057	DRUGINFO	D08IID	TNO155	Phase 1
T13057	DRUGINFO	D0AF1I	PF-07284892	Phase 1
T13057	DRUGINFO	D2CL0D	RG6433	Phase 1
T13057	DRUGINFO	DM16HS	JAB-3068	Phase 1
T13057	DRUGINFO	DN7M4T	BBP-398	Phase 1
T13057	DRUGINFO	DQ8F7A	A380	Phase 1
T13057	DRUGINFO	DS9R3G	SAR442720	Phase 1
T13057	DRUGINFO	DYQZ38	RLY-1971	Phase 1
T13057	DRUGINFO	D00MFW	NSC-87877	Patented
T13057	DRUGINFO	D0P7KP	Dodecane-Trimethylamine	Investigative

T31956	TARGETID	T31956
T31956	FORMERID	TTDR00531
T31956	UNIPROID	AMPE_HUMAN
T31956	TARGNAME	Glutamyl aminopeptidase (ENPEP)
T31956	GENENAME	ENPEP
T31956	TARGTYPE	Clinical trial
T31956	SYNONYMS	ENPEP; EAP; Differentiation antigen gp160; Aminopeptidase A; APA
T31956	FUNCTION	Appears to have a role in the catabolicpathway of the renin-angiotensin system. Probably plays a role in regulating growth and differentiation of early B-lineage cells.
T31956	PDBSTRUC	4KXD; 4KXC; 4KXB; 4KXA; 4KX9
T31956	BIOCLASS	Peptidase
T31956	ECNUMBER	EC 3.4.11.7
T31956	SEQUENCE	MNFAEREGSKRYCIQTKHVAILCAVVVGVGLIVGLAVGLTRSCDSSGDGGPGTAPAPSHLPSSTASPSGPPAQDQDICPASEDESGQWKNFRLPDFVNPVHYDLHVKPLLEEDTYTGTVSISINLSAPTRYLWLHLRETRITRLPELKRPSGDQVQVRRCFEYKKQEYVVVEAEEELTPSSGDGLYLLTMEFAGWLNGSLVGFYRTTYTENGQVKSIVATDHEPTDARKSFPCFDEPNKKATYTISITHPKEYGALSNMPVAKEESVDDKWTRTTFEKSVPMSTYLVCFAVHQFDSVKRISNSGKPLTIYVQPEQKHTAEYAANITKSVFDYFEEYFAMNYSLPKLDKIAIPDFGTGAMENWGLITYRETNLLYDPKESASSNQQRVATVVAHELVHQWFGNIVTMDWWEDLWLNEGFASFFEFLGVNHAETDWQMRDQMLLEDVLPVQEDDSLMSSHPIIVTVTTPDEITSVFDGISYSKGSSILRMLEDWIKPENFQKGCQMYLEKYQFKNAKTSDFWAALEEASRLPVKEVMDTWTRQMGYPVLNVNGVKNITQKRFLLDPRANPSQPPSDLGYTWNIPVKWTEDNITSSVLFNRSEKEGITLNSSNPSGNAFLKINPDHIGFYRVNYEVATWDSIATALSLNHKTFSSADRASLIDDAFALARAQLLDYKVALNLTKYLKREENFLPWQRVISAVTYIISMFEDDKELYPMIEEYFQGQVKPIADSLGWNDAGDHVTKLLRSSVLGFACKMGDREALNNASSLFEQWLNGTVSLPVNLRLLVYRYGMQNSGNEISWNYTLEQYQKTSLAQEKEKLLYGLASVKNVTLLSRYLDLLKDTNLIKTQDVFTVIRYISYNSYGKNMAWNWIQLNWDYLVNRYTLNNRNLGRIVTIAEPFNTELQLWQMESFFAKYPQAGAGEKPREQVLETVKNNIEWLKQHRNTIREWFFNLLESG
T31956	DRUGINFO	D0C1JV	QGC-001	Phase 2
T31956	DRUGINFO	D0B9ZE	PMID10602705C40	Investigative
T31956	DRUGINFO	D0IW6G	EC33	Investigative
T31956	DRUGINFO	D04QJY	KELATORPHAN	Investigative

T56510	TARGETID	T56510
T56510	FORMERID	TTDC00168
T56510	UNIPROID	B2CL1_HUMAN
T56510	TARGNAME	Apoptosis regulator Bcl-xL (BCL-xL)
T56510	GENENAME	BCL2L1
T56510	TARGTYPE	Clinical trial
T56510	SYNONYMS	Bcl2like protein 1; Bcl2L1; Bcl2-L-1; Bcl-XL; Bcl-2-like protein 1; BCLX; BCL2L; Apoptosis regulator Bcl-X
T56510	FUNCTION	Inhibits activation of caspases. Appears to regulate cell death by blocking the voltage-dependent anion channel (VDAC) by binding to it and preventing the release of the caspase activator, CYC1, from the mitochondrial membrane. Also acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis. Potent inhibitor of cell death.
T56510	PDBSTRUC	6IJQ; 6F46; 6DCO; 6DCN; 6BF2
T56510	BIOCLASS	B-cell lymphoma Bcl-2
T56510	SEQUENCE	MSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAINGNPSWHLADSPAVNGATGHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAYQSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEPWIQENGGWDTFVELYGNNAAAESRKGQERFNRWFLTGMTVAGVVLLGSLFSRK
T56510	DRUGINFO	D06ETI	ABT-263	Phase 3
T56510	DRUGINFO	D02OZK	Obatoclax	Phase 2
T56510	DRUGINFO	D4WN2M	APG-1252	Phase 1/2
T56510	DRUGINFO	DQ1P6X	AZD0466	Phase 1/2
T56510	DRUGINFO	D09XWR	PMID27744724-Compound-26	Patented
T56510	DRUGINFO	D0F9QC	PMID27744724-Compound-27	Patented
T56510	DRUGINFO	D0C2DV	Indole-based analog 2	Patented
T56510	DRUGINFO	D0IS8R	PMID27744724-Compound-10	Patented
T56510	DRUGINFO	D0J9FN	PMID27744724-Compound-21	Patented
T56510	DRUGINFO	D0MZ7I	Indole-based analog 3	Patented
T56510	DRUGINFO	D0TU3N	PMID27744724-Compound-18	Patented
T56510	DRUGINFO	D04IPX	WEHI-0103122	Investigative
T56510	DRUGINFO	D09FWK	E-003	Investigative
T56510	DRUGINFO	D0T3VP	4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID	Investigative
T56510	DRUGINFO	D2SJZ9	EAPB0203	Investigative

T14912	TARGETID	T14912
T14912	FORMERID	TTDC00048
T14912	UNIPROID	MCL1_HUMAN
T14912	TARGNAME	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
T14912	GENENAME	MCL1
T14912	TARGTYPE	Clinical trial
T14912	SYNONYMS	mcl1/EAT; Bcl2-L-3; Bcl-2-related protein EAT/mcl1; Bcl-2-like protein 3; BCL2L3
T14912	FUNCTION	Mediates its effects by interactions with a number of other regulators of apoptosis. Isoform 1 inhibits apoptosis. Isoform 2 promotes apoptosis. Involved in the regulation of apoptosis versus cell survival, and in the maintenance of viability but not of proliferation.
T14912	PDBSTRUC	6OVC; 6OQN; 6OQD; 6OQC; 6OQB
T14912	BIOCLASS	B-cell lymphoma Bcl-2
T14912	SEQUENCE	MFGLKRNAVIGLNLYCGGAGLGAGSGGATRPGGRLLATEKEASARREIGGGEAGAVIGGSAGASPPSTLTPDSRRVARPPPIGAEVPDVTATPARLLFFAPTRRAAPLEEMEAPAADAIMSPEEELDGYEPEPLGKRPAVLPLLELVGESGNNTSTDGSLPSTPPPAEEEEDELYRQSLEIISRYLREQATGAKDTKPMGRSGATSRKALETLRRVGDGVQRNHETAFQGMLRKLDIKNEDDVKSLSRVMIHVFSDGVTNWGRIVTLISFGAFVAKHLKTINQESCIEPLAESITDVLVRTKRDWLVKQRGWDGFVEFFHVEDLEGGIRNVLLAFAGVAGVGAGLAYLIR
T14912	DRUGINFO	D02OZK	Obatoclax	Phase 2
T14912	DRUGINFO	D06XCP	AZD5991	Phase 1
T14912	DRUGINFO	D0I5DP	AMG 176	Phase 1
T14912	DRUGINFO	D50CXM	PRT1419	Phase 1
T14912	DRUGINFO	D63QIY	ABBV-467	Phase 1
T14912	DRUGINFO	D7LC8N	MIK665	Phase 1
T14912	DRUGINFO	DBI81F	AMG 397	Phase 1
T14912	DRUGINFO	D00BEJ	PMID27744724-Compound-19	Patented
T14912	DRUGINFO	D03FZI	Biphenyl carboxylic acid derivative 1	Patented
T14912	DRUGINFO	D09SGU	Biphenyl carboxylic acid derivative 2	Patented
T14912	DRUGINFO	D0DG0F	PMID27744724-Compound-Fomula2	Patented
T14912	DRUGINFO	D0F8LE	Indole-based analog 1	Patented
T14912	DRUGINFO	D0H3NO	PMID27744724-Compound-4	Patented
T14912	DRUGINFO	D0I9PC	PMID27744724-Compound-13	Patented
T14912	DRUGINFO	D0IV8T	PMID27744724-Compound-5	Patented
T14912	DRUGINFO	D0JA5B	PMID27744724-Compound-3	Patented
T14912	DRUGINFO	D0JZ4W	PMID27744724-Compound-29	Patented
T14912	DRUGINFO	D0LO7X	PMID27744724-Compound-23	Patented
T14912	DRUGINFO	D0M6MP	PMID27744724-Compound-28	Patented
T14912	DRUGINFO	D0NT2S	PMID27744724-Compound-20	Patented
T14912	DRUGINFO	D0QE9E	PMID27744724-Compound-22	Patented
T14912	DRUGINFO	D0RJ1U	PMID27744724-Compound-6	Patented
T14912	DRUGINFO	D09XWR	PMID27744724-Compound-26	Patented
T14912	DRUGINFO	D0F9QC	PMID27744724-Compound-27	Patented
T14912	DRUGINFO	D0C2DV	Indole-based analog 2	Patented
T14912	DRUGINFO	D0IS8R	PMID27744724-Compound-10	Patented
T14912	DRUGINFO	D0J9FN	PMID27744724-Compound-21	Patented
T14912	DRUGINFO	D0MZ7I	Indole-based analog 3	Patented
T14912	DRUGINFO	D0TU3N	PMID27744724-Compound-18	Patented
T14912	DRUGINFO	D0QQ1J	BITHIONOL	Withdrawn from market
T14912	DRUGINFO	D00MEV	Sch-45752	Terminated
T14912	DRUGINFO	D0G3SZ	ALTENUSIN	Investigative
T14912	DRUGINFO	D0G5LZ	GNF-PF-1591	Investigative
T14912	DRUGINFO	D0GN5Z	SULFURETIN	Investigative
T14912	DRUGINFO	D0H7BH	GNF-PF-3955	Investigative
T14912	DRUGINFO	D0U4QZ	EU-517	Investigative
T14912	DRUGINFO	D05PTT	ROSMARINIC ACID	Investigative
T14912	DRUGINFO	D0IK4V	GNF-PF-5134	Investigative
T14912	DRUGINFO	D0WN7V	NSC-180246	Investigative
T14912	DRUGINFO	D0XU4Y	NSC-66209	Investigative
T14912	DRUGINFO	D00LHS	TW-37	Investigative
T14912	DRUGINFO	D0S6IW	QEDIIRNIARHLAQVGDSMDR	Investigative
T14912	DRUGINFO	D0NJ4H	MORIN	Investigative
T14912	DRUGINFO	D06HRX	AMENTOFLAVONE	Investigative

T55781	TARGETID	T55781
T55781	FORMERID	TTDI00012
T55781	UNIPROID	MERTK_HUMAN
T55781	TARGNAME	Tyrosine-protein kinase Mer (MERTK)
T55781	GENENAME	MERTK
T55781	TARGTYPE	Clinical trial
T55781	SYNONYMS	Receptor tyrosine kinase MerTK; Proto-oncogene c-Mer
T55781	FUNCTION	Regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells (efferocytosis). Ligand binding at the cell surface induces autophosphorylation of MERTK on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with GRB2 or PLCG2 and induces phosphorylation of MAPK1, MAPK2, FAK/PTK2 or RAC1. MERTK signaling plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment. Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis. Plays also an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1, which selectively induces production of suppressors of cytokine signaling SOCS1 and SOCS3. Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to several ligands including LGALS3, TUB, TULP1 or GAS6.
T55781	PDBSTRUC	5U6C; 5TD2; 5TC0; 5K0X; 5K0K
T55781	BIOCLASS	Kinase
T55781	ECNUMBER	EC 2.7.10.1
T55781	SEQUENCE	MGPAPLPLLLGLFLPALWRRAITEAREEAKPYPLFPGPFPGSLQTDHTPLLSLPHASGYQPALMFSPTQPGRPHTGNVAIPQVTSVESKPLPPLAFKHTVGHIILSEHKGVKFNCSISVPNIYQDTTISWWKDGKELLGAHHAITQFYPDDEVTAIIASFSITSVQRSDNGSYICKMKINNEEIVSDPIYIEVQGLPHFTKQPESMNVTRNTAFNLTCQAVGPPEPVNIFWVQNSSRVNEQPEKSPSVLTVPGLTEMAVFSCEAHNDKGLTVSKGVQINIKAIPSPPTEVSIRNSTAHSILISWVPGFDGYSPFRNCSIQVKEADPLSNGSVMIFNTSALPHLYQIKQLQALANYSIGVSCMNEIGWSAVSPWILASTTEGAPSVAPLNVTVFLNESSDNVDIRWMKPPTKQQDGELVGYRISHVWQSAGISKELLEEVGQNGSRARISVQVHNATCTVRIAAVTRGGVGPFSDPVKIFIPAHGWVDYAPSSTPAPGNADPVLIIFGCFCGFILIGLILYISLAIRKRVQETKFGNAFTEEDSELVVNYIAKKSFCRRAIELTLHSLGVSEELQNKLEDVVIDRNLLILGKILGEGEFGSVMEGNLKQEDGTSLKVAVKTMKLDNSSQREIEEFLSEAACMKDFSHPNVIRLLGVCIEMSSQGIPKPMVILPFMKYGDLHTYLLYSRLETGPKHIPLQTLLKFMVDIALGMEYLSNRNFLHRDLAARNCMLRDDMTVCVADFGLSKKIYSGDYYRQGRIAKMPVKWIAIESLADRVYTSKSDVWAFGVTMWEIATRGMTPYPGVQNHEMYDYLLHGHRLKQPEDCLDELYEIMYSCWRTDPLDRPTFSVLRLQLEKLLESLPDVRNQADVIYVNTQLLESSEGLAQGSTLAPLDLNIDPDSIIASCTPRAAISVVTAEVHDSKPHEGRYILNGGSEEWEDLTSAPSAAVTAEKNSVLPGERLVRNGVSWSHSSMLPLGSSLPDELLFADDSSEGSEVLM
T55781	DRUGINFO	DA1MG8	ONO-7475	Phase 1/2
T55781	DRUGINFO	D00DRL	MK-2461	Phase 1/2
T55781	DRUGINFO	D0VH4T	ONO-7475	Phase 1
T55781	DRUGINFO	D10LNV	MRX-2843	Phase 1
T55781	DRUGINFO	DP4KH3	PF-07265807	Phase 1
T55781	DRUGINFO	DQX83Z	INCB81776	Phase 1
T55781	DRUGINFO	D7HZ3T	RXDX-106	Phase 1
T55781	DRUGINFO	DCJX65	UNC2025	Investigative
T55781	DRUGINFO	DI81LW	UNC569	Investigative
T55781	DRUGINFO	D0N3XP	G749	Investigative
T55781	DRUGINFO	D09TFN	LDC1267	Investigative

T53764	TARGETID	T53764
T53764	FORMERID	TTDR01154
T53764	UNIPROID	SEPR_HUMAN
T53764	TARGNAME	Prolyl endopeptidase FAP (FAP)
T53764	GENENAME	FAP
T53764	TARGTYPE	Clinical trial
T53764	SYNONYMS	Integral membrane serine protease; Fibroblast activation protein alpha; FAP; Antiplasmin-cleaving enzyme; APCE; 170-kDa melanoma membrane-bound gelatinase
T53764	FUNCTION	Cell surface glycoprotein serine protease that participatesin extracellular matrix degradation and involved in many cellular processes including tissue remodeling, fibrosis, wound healing, inflammation and tumor growth. Both plasma membrane and soluble formsexhibit post-proline cleaving endopeptidase activity, with a marked preference for Ala/Ser-Gly-Pro-Ser/Asn/Ala consensus sequences, on substrate such as alpha-2-antiplasmin SERPINF2 and SPRY2 (PubMed:14751930, PubMed:16223769, PubMed:16480718, PubMed:16410248, PubMed:17381073, PubMed:18095711, PubMed:21288888, PubMed:24371721). Degrade also gelatin, heat-denatured type I collagen, but not native collagen type I and IV, vibronectin, tenascin, laminin, fibronectin, fibrin or casein (PubMed:9065413, PubMed:2172980, PubMed:7923219, PubMed:10347120, PubMed:10455171, PubMed:12376466, PubMed:16223769, PubMed:16651416, PubMed:18095711). Have also dipeptidyl peptidase activity, exhibiting the ability to hydrolyze the prolyl bond two residues from the N-terminus of synthetic dipeptide substrates provided that the penultimate residue is proline, with a preference for Ala-Pro, Ile-Pro, Gly-Pro, Arg-Pro and Pro-Pro (PubMed:10347120, PubMed:10593948, PubMed:16175601, PubMed:16223769, PubMed:16651416, PubMed:16410248, PubMed:17381073, PubMed:21314817, PubMed:24371721, PubMed:24717288). Natural neuropeptide hormones for dipeptidyl peptidase are the neuropeptide Y (NPY), peptide YY (PYY), substance P (TAC1) and brain natriuretic peptide 32 (NPPB) (PubMed:21314817). The plasma membrane form, in association with either DPP4, PLAUR or integrins, is involved in the pericellular proteolysis of the extracellular matrix (ECM), and hence promotes cell adhesion, migration and invasion through the ECM. Plays a role in tissue remodeling during development and wound healing. Participates in the cell invasiveness towards the ECM in malignant melanoma cancers. Enhances tumor growth progression by increasing angiogenesis, collagen fiber degradation and apoptosis and by reducing antitumor response of the immune system. Promotes glioma cell invasion through the brain parenchyma by degrading the proteoglycan brevican. Acts as a tumor suppressor in melanocytic cells through regulation of cell proliferation and survival in a serine protease activity-independent manner.
T53764	PDBSTRUC	1Z68
T53764	BIOCLASS	Peptidase
T53764	ECNUMBER	EC 3.4.21.26
T53764	SEQUENCE	MKTWVKIVFGVATSAVLALLVMCIVLRPSRVHNSEENTMRALTLKDILNGTFSYKTFFPNWISGQEYLHQSADNNIVLYNIETGQSYTILSNRTMKSVNASNYGLSPDRQFVYLESDYSKLWRYSYTATYYIYDLSNGEFVRGNELPRPIQYLCWSPVGSKLAYVYQNNIYLKQRPGDPPFQITFNGRENKIFNGIPDWVYEEEMLATKYALWWSPNGKFLAYAEFNDTDIPVIAYSYYGDEQYPRTINIPYPKAGAKNPVVRIFIIDTTYPAYVGPQEVPVPAMIASSDYYFSWLTWVTDERVCLQWLKRVQNVSVLSICDFREDWQTWDCPKTQEHIEESRTGWAGGFFVSTPVFSYDAISYYKIFSDKDGYKHIHYIKDTVENAIQITSGKWEAINIFRVTQDSLFYSSNEFEEYPGRRNIYRISIGSYPPSKKCVTCHLRKERCQYYTASFSDYAKYYALVCYGPGIPISTLHDGRTDQEIKILEENKELENALKNIQLPKEEIKKLEVDEITLWYKMILPPQFDRSKKYPLLIQVYGGPCSQSVRSVFAVNWISYLASKEGMVIALVDGRGTAFQGDKLLYAVYRKLGVYEVEDQITAVRKFIEMGFIDEKRIAIWGWSYGGYVSSLALASGTGLFKCGIAVAPVSSWEYYASVYTERFMGLPTKDDNLEHYKNSTVMARAEYFRNVDYLLIHGTADDNVHFQNSAQIAKALVNAQVDFQAMWYSDQNHGLSGLSTNHLYTHMTHFLKQCFSLSD
T53764	DRUGINFO	D0FQ2U	Talabostat	Phase 3
T53764	DRUGINFO	D0N7LA	BIBH 1	Phase 2
T53764	DRUGINFO	DVX3H0	Sibrotuzumab	Phase 2
T53764	DRUGINFO	D0V7GS	RG7461	Phase 1
T53764	DRUGINFO	DN2F9A	AMG 506	Phase 1
T53764	DRUGINFO	D1A8NU	NG-641	Phase 1
T53764	DRUGINFO	DO7HS1	FAP5-DM1	Preclinical
T53764	DRUGINFO	D7K0GP	PT630	Preclinical
T53764	DRUGINFO	D01HTS	MIP-1231	Investigative
T53764	DRUGINFO	D0A9WW	FE-999040	Investigative
T53764	DRUGINFO	D0M9SD	VA-119930	Investigative
T53764	DRUGINFO	D03DNV	ARI-3099	Investigative

T97196	TARGETID	T97196
T97196	FORMERID	TTDI03045
T97196	UNIPROID	ATM_HUMAN
T97196	TARGNAME	ATM serine/threonine kinase (ATM)
T97196	GENENAME	ATM
T97196	TARGTYPE	Clinical trial
T97196	SYNONYMS	Serine-protein kinase ATM; Ataxia telangiectasia mutated; A-T mutated
T97196	FUNCTION	Serine/threonine protein kinase which activates checkpoint signaling upon double strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing ultraviolet A light (UVA), thereby acting as a DNA damage sensor. Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX at double strand breaks (DSBs), thereby regulating DNA damage response mechanism. Also plays a role in pre-B cell allelic exclusion, a process leading to expression of a single immunoglobulin heavy chain allele to enforce clonality and monospecific recognition by the B-cell antigen receptor (BCR) expressed on individual B-lymphocytes. After the introduction of DNA breaks by the RAG complex on one immunoglobulin allele, acts by mediating a repositioning of the second allele to pericentromeric heterochromatin, preventing accessibility to the RAG complex and recombination of the second allele. Also involved in signal transduction and cell cycle control. May function as a tumor suppressor. Necessary for activation of ABL1 and SAPK. Phosphorylates DYRK2, CHEK2, p53/TP53, FANCD2, NFKBIA, BRCA1, CTIP, nibrin (NBN), TERF1, RAD9, UBQLN4 and DCLRE1C. May play a role in vesicle and/or protein transport. Could play a role in T-cell development, gonad and neurological function. Plays a role in replication-dependent histone mRNA degradation. Binds DNA ends. Phosphorylation of DYRK2 in nucleus in response to genotoxic stress prevents its MDM2-mediated ubiquitination and subsequent proteasome degradation. Phosphorylates ATF2 which stimulates its function in DNA damage response.
T97196	PDBSTRUC	6HKA; 5NP1; 5NP0
T97196	BIOCLASS	Kinase
T97196	ECNUMBER	EC 2.7.11.1
T97196	SEQUENCE	MSLVLNDLLICCRQLEHDRATERKKEVEKFKRLIRDPETIKHLDRHSDSKQGKYLNWDAVFRFLQKYIQKETECLRIAKPNVSASTQASRQKKMQEISSLVKYFIKCANRRAPRLKCQELLNYIMDTVKDSSNGAIYGADCSNILLKDILSVRKYWCEISQQQWLELFSVYFRLYLKPSQDVHRVLVARIIHAVTKGCCSQTDGLNSKFLDFFSKAIQCARQEKSSSGLNHILAALTIFLKTLAVNFRIRVCELGDEILPTLLYIWTQHRLNDSLKEVIIELFQLQIYIHHPKGAKTQEKGAYESTKWRSILYNLYDLLVNEISHIGSRGKYSSGFRNIAVKENLIELMADICHQVFNEDTRSLEISQSYTTTQRESSDYSVPCKRKKIELGWEVIKDHLQKSQNDFDLVPWLQIATQLISKYPASLPNCELSPLLMILSQLLPQQRHGERTPYVLRCLTEVALCQDKRSNLESSQKSDLLKLWNKIWCITFRGISSEQIQAENFGLLGAIIQGSLVEVDREFWKLFTGSACRPSCPAVCCLTLALTTSIVPGTVKMGIEQNMCEVNRSFSLKESIMKWLLFYQLEGDLENSTEVPPILHSNFPHLVLEKILVSLTMKNCKAAMNFFQSVPECEHHQKDKEELSFSEVEELFLQTTFDKMDFLTIVRECGIEKHQSSIGFSVHQNLKESLDRCLLGLSEQLLNNYSSEITNSETLVRCSRLLVGVLGCYCYMGVIAEEEAYKSELFQKAKSLMQCAGESITLFKNKTNEEFRIGSLRNMMQLCTRCLSNCTKKSPNKIASGFFLRLLTSKLMNDIADICKSLASFIKKPFDRGEVESMEDDTNGNLMEVEDQSSMNLFNDYPDSSVSDANEPGESQSTIGAINPLAEEYLSKQDLLFLDMLKFLCLCVTTAQTNTVSFRAADIRRKLLMLIDSSTLEPTKSLHLHMYLMLLKELPGEEYPLPMEDVLELLKPLSNVCSLYRRDQDVCKTILNHVLHVVKNLGQSNMDSENTRDAQGQFLTVIGAFWHLTKERKYIFSVRMALVNCLKTLLEADPYSKWAILNVMGKDFPVNEVFTQFLADNHHQVRMLAAESINRLFQDTKGDSSRLLKALPLKLQQTAFENAYLKAQEGMREMSHSAENPETLDEIYNRKSVLLTLIAVVLSCSPICEKQALFALCKSVKENGLEPHLVKKVLEKVSETFGYRRLEDFMASHLDYLVLEWLNLQDTEYNLSSFPFILLNYTNIEDFYRSCYKVLIPHLVIRSHFDEVKSIANQIQEDWKSLLTDCFPKILVNILPYFAYEGTRDSGMAQQRETATKVYDMLKSENLLGKQIDHLFISNLPEIVVELLMTLHEPANSSASQSTDLCDFSGDLDPAPNPPHFPSHVIKATFAYISNCHKTKLKSILEILSKSPDSYQKILLAICEQAAETNNVYKKHRILKIYHLFVSLLLKDIKSGLGGAWAFVLRDVIYTLIHYINQRPSCIMDVSLRSFSLCCDLLSQVCQTAVTYCKDALENHLHVIVGTLIPLVYEQVEVQKQVLDLLKYLVIDNKDNENLYITIKLLDPFPDHVVFKDLRITQQKIKYSRGPFSLLEEINHFLSVSVYDALPLTRLEGLKDLRRQLELHKDQMVDIMRASQDNPQDGIMVKLVVNLLQLSKMAINHTGEKEVLEAVGSCLGEVGPIDFSTIAIQHSKDASYTKALKLFEDKELQWTFIMLTYLNNTLVEDCVKVRSAAVTCLKNILATKTGHSFWEIYKMTTDPMLAYLQPFRTSRKKFLEVPRFDKENPFEGLDDINLWIPLSENHDIWIKTLTCAFLDSGGTKCEILQLLKPMCEVKTDFCQTVLPYLIHDILLQDTNESWRNLLSTHVQGFFTSCLRHFSQTSRSTTPANLDSESEHFFRCCLDKKSQRTMLAVVDYMRRQKRPSSGTIFNDAFWLDLNYLEVAKVAQSCAAHFTALLYAEIYADKKSMDDQEKRSLAFEEGSQSTTISSLSEKSKEETGISLQDLLLEIYRSIGEPDSLYGCGGGKMLQPITRLRTYEHEAMWGKALVTYDLETAIPSSTRQAGIIQALQNLGLCHILSVYLKGLDYENKDWCPELEELHYQAAWRNMQWDHCTSVSKEVEGTSYHESLYNALQSLRDREFSTFYESLKYARVKEVEEMCKRSLESVYSLYPTLSRLQAIGELESIGELFSRSVTHRQLSEVYIKWQKHSQLLKDSDFSFQEPIMALRTVILEILMEKEMDNSQRECIKDILTKHLVELSILARTFKNTQLPERAIFQIKQYNSVSCGVSEWQLEEAQVFWAKKEQSLALSILKQMIKKLDASCAANNPSLKLTYTECLRVCGNWLAETCLENPAVIMQTYLEKAVEVAGNYDGESSDELRNGKMKAFLSLARFSDTQYQRIENYMKSSEFENKQALLKRAKEEVGLLREHKIQTNRYTVKVQRELELDELALRALKEDRKRFLCKAVENYINCLLSGEEHDMWVFRLCSLWLENSGVSEVNGMMKRDGMKIPTYKFLPLMYQLAARMGTKMMGGLGFHEVLNNLISRISMDHPHHTLFIILALANANRDEFLTKPEVARRSRITKNVPKQSSQLDEDRTEAANRIICTIRSRRPQMVRSVEALCDAYIILANLDATQWKTQRKGINIPADQPITKLKNLEDVVVPTMEIKVDHTGEYGNLVTIQSFKAEFRLAGGVNLPKIIDCVGSDGKERRQLVKGRDDLRQDAVMQQVFQMCNTLLQRNTETRKRKLTICTYKVVPLSQRSGVLEWCTGTVPIGEFLVNNEDGAHKRYRPNDFSAFQCQKKMMEVQKKSFEEKYEVFMDVCQNFQPVFRYFCMEKFLDPAIWFEKRLAYTRSVATSSIVGYILGLGDRHVQNILINEQSAELVHIDLGVAFEQGKILPTPETVPFRLTRDIVDGMGITGVEGVFRRCCEKTMEVMRNSQETLLTIVEVLLYDPLFDWTMNPLKALYLQQRPEDETELHPTLNADDQECKRNLSDIDQSFNKVAERVLMRLQEKLKGVEEGTVLSVGGQVNLLIQQAIDPKNLSRLFPGWKAWV
T97196	DRUGINFO	D0L6XO	AZD1390	Phase 1
T97196	DRUGINFO	D0NW8C	M3541	Phase 1
T97196	DRUGINFO	D0XD4I	AZD0156	Phase 1
T97196	DRUGINFO	D02NUT	KU-60019	Clinical trial
T97196	DRUGINFO	D00PXO	CGK733	Investigative

T16308	TARGETID	T16308
T16308	FORMERID	TTDR00355
T16308	UNIPROID	PIN1_HUMAN
T16308	TARGNAME	Rotamase Pin1 (PIN1)
T16308	GENENAME	PIN1
T16308	TARGTYPE	Clinical trial
T16308	SYNONYMS	Prolyl isomerase Pin1; Peptidyl-prolyl cis-trans isomerase Pin1; Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1; Peptidyl prolyl cis/trans isomerase Pin1; PPIase Pin1
T16308	FUNCTION	By inducing conformational changes in a subset of phosphorylated proteins, acts as a molecular switch in multiple cellular processes (, Ref. 21). Displays a preference for acidic residues located N-terminally to the proline bond to be isomerized. Regulates mitosis presumably by interacting with NIMA and attenuating its mitosis-promoting activity. Down-regulates kinase activity of BTK. Can transactivate multiple oncogenes and induce centrosome amplification, chromosome instability and cell transformation. Required for the efficient dephosphorylation and recycling of RAF1 after mitogen activation. Binds and targets PML and BCL6 for degradation in a phosphorylation-dependent manner. Acts as a regulator of JNK cascade by binding to phosphorylated FBXW7, disrupting FBXW7 dimerization and promoting FBXW7 autoubiquitination and degradation: degradation of FBXW7 leads to subsequent stabilization of JUN. May facilitate the ubiquitination and proteasomal degradation of RBBP8/CtIP through CUL3/KLHL15 E3 ubiquitin-protein ligase complex, hence favors DNA double-strand repair through error-prone non-homologous end joining (NHEJ) over error-free, RBBP8-mediated homologous recombination (HR). Peptidyl-prolyl cis/trans isomerase (PPIase) that binds to and isomerizes specific phosphorylated Ser/Thr-Pro (pSer/Thr-Pro) motifs.
T16308	PDBSTRUC	6DUN; 5VTK; 5VTJ; 5VTI; 5UY9
T16308	BIOCLASS	Cis-trans-isomerase
T16308	ECNUMBER	EC 5.2.1.8
T16308	SEQUENCE	MADEEKLPPGWEKRMSRSSGRVYYFNHITNASQWERPSGNSSSGGKNGQGEPARVRCSHLLVKHSQSRRPSSWRQEKITRTKEEALELINGYIQKIKSGEEDFESLASQFSDCSSAKARGDLGAFSRGQMQKPFEDASFALRTGEMSGPVFTDSGIHIILRTE
T16308	DRUGINFO	D0C0NH	Avastin+/-Tarceva	Phase 3
T16308	DRUGINFO	D08MJE	(R,)-2-(2-naphthamido)-5-phenylpent-4-enoic acid	Investigative
T16308	DRUGINFO	D08TZA	(R)-2-(2-naphthamido)-3-p-tolylpropanoic acid	Investigative
T16308	DRUGINFO	D0E2AC	3,6,9,12,15,18-HEXAOXAICOSANE	Investigative
T16308	DRUGINFO	D0M9FC	(R)-3-(2-naphthamido)-4-m-tolylbutanoic acid	Investigative
T16308	DRUGINFO	D0N9NS	(R)-2-(2-naphthamido)-3-m-tolylpropanoic acid	Investigative
T16308	DRUGINFO	D0Q9YG	(R)-2-(2-naphthamido)-5-phenylpent-4-ynoic acid	Investigative
T16308	DRUGINFO	D0W4CN	Ac-Phe-D-Thr(PO3H2)-Pip-Nal-Gln-NH2	Investigative
T16308	DRUGINFO	D0W8MX	Ac-Phe-Thr(PO3H2)-Pip-Nal-Gln-NH2	Investigative
T16308	DRUGINFO	D0Y7PY	Ac-Bth-Thr(PO3H2)-Pip-Nal-Gln-NH2	Investigative
T16308	DRUGINFO	D0N0YX	Beta-(2-Naphthyl)-Alanine	Investigative

T06671	TARGETID	T06671
T06671	FORMERID	TTDC00221
T06671	UNIPROID	IL18_HUMAN
T06671	TARGNAME	Interleukin-18 (IL18)
T06671	GENENAME	IL18
T06671	TARGTYPE	Clinical trial
T06671	SYNONYMS	Interleukin-1 gamma; Interferon-gamma inducing factor; Interferon gamma-inducing factor; Iboctadekin; IL1F4; IL-18; IL-1 gamma; IGIF; IFN-gamma-inducing factor
T06671	FUNCTION	Upon binding to IL18R1 and IL18RAP, forms a signaling ternary complex which activates NF-kappa-B, triggering synthesis of inflammatory mediators. Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells and natural killer (NK) cells. A proinflammatory cytokine primarily involved in polarized T-helper 1 (Th1) cell and natural killer (NK) cell immune responses.
T06671	PDBSTRUC	4XFU; 4XFT; 4XFS; 4R6U; 4HJJ
T06671	BIOCLASS	Cytokine: interleukin
T06671	SEQUENCE	MAAEPVEDNCINFVAMKFIDNTLYFIAEDDENLESDYFGKLESKLSVIRNLNDQVLFIDQGNRPLFEDMTDSDCRDNAPRTIFIISMYKDSQPRGMAVTISVKCEKISTLSCENKIISFKEMNPPDNIKDTKSDIIFFQRSVPGHDNKMQFESSSYEGYFLACEKERDLFKLILKKEDELGDRSIMFTVQNED
T06671	DRUGINFO	DF6UP7	Tadekinig alfa	Phase 3
T06671	DRUGINFO	D06XDS	GSK-1070806	Phase 2
T06671	DRUGINFO	D05UCW	MEDI-2338	Phase 1
T06671	DRUGINFO	D0A8HN	Iboctadekin	Phase 1
T06671	DRUGINFO	D0F3PU	Iboctadekin + Doxil	Phase 1
T06671	DRUGINFO	D0J2VB	Iboctadekin + rituximab	Phase 1
T06671	DRUGINFO	D0I1BQ	IL-18BP	Discontinued in Phase 1

T62820	TARGETID	T62820
T62820	FORMERID	TTDR00321
T62820	UNIPROID	GRM2_HUMAN
T62820	TARGNAME	Metabotropic glutamate receptor 2 (mGluR2)
T62820	GENENAME	GRM2
T62820	TARGTYPE	Clinical trial
T62820	SYNONYMS	mGLUR2; Group II metabotropic glutamate receptor; Glutamate receptor mGLU2; GPRC1B
T62820	FUNCTION	Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. May mediate suppression of neurotransmission or may be involved in synaptogenesis or synaptic stabilization. G-protein coupled receptor for glutamate.
T62820	PDBSTRUC	5KZQ; 5KZN; 5CNJ; 5CNI; 4XAS
T62820	BIOCLASS	GPCR glutamate
T62820	SEQUENCE	MGSLLALLALLLLWGAVAEGPAKKVLTLEGDLVLGGLFPVHQKGGPAEDCGPVNEHRGIQRLEAMLFALDRINRDPHLLPGVRLGAHILDSCSKDTHALEQALDFVRASLSRGADGSRHICPDGSYATHGDAPTAITGVIGGSYSDVSIQVANLLRLFQIPQISYASTSAKLSDKSRYDYFARTVPPDFFQAKAMAEILRFFNWTYVSTVASEGDYGETGIEAFELEARARNICVATSEKVGRAMSRAAFEGVVRALLQKPSARVAVLFTRSEDARELLAASQRLNASFTWVASDGWGALESVVAGSEGAAEGAITIELASYPISDFASYFQSLDPWNNSRNPWFREFWEQRFRCSFRQRDCAAHSLRAVPFEQESKIMFVVNAVYAMAHALHNMHRALCPNTTRLCDAMRPVNGRRLYKDFVLNVKFDAPFRPADTHNEVRFDRFGDGIGRYNIFTYLRAGSGRYRYQKVGYWAEGLTLDTSLIPWASPSAGPLPASRCSEPCLQNEVKSVQPGEVCCWLCIPCQPYEYRLDEFTCADCGLGYWPNASLTGCFELPQEYIRWGDAWAVGPVTIACLGALATLFVLGVFVRHNATPVVKASGRELCYILLGGVFLCYCMTFIFIAKPSTAVCTLRRLGLGTAFSVCYSALLTKTNRIARIFGGAREGAQRPRFISPASQVAICLALISGQLLIVVAWLVVEAPGTGKETAPERREVVTLRCNHRDASMLGSLAYNVLLIALCTLYAFKTRKCPENFNEAKFIGFTMYTTCIIWLAFLPIFYVTSSDYRVQTTTMCVSVSLSGSVVLGCLFAPKLHIILFQPQKNVVSHRAPTSRFGSAAARASSSLGQGSGSQFVPTVCNGREVVDSTTSSL
T62820	DRUGINFO	D8GJ1E	JNJ-64281802	Phase 2
T62820	DRUGINFO	D08OTE	RO-4995819	Phase 2
T62820	DRUGINFO	D0N5CW	Oleoyl-estrone	Phase 2
T62820	DRUGINFO	DSK7I5	MP-101	Phase 2
T62820	DRUGINFO	D02XLI	LY-2979165	Phase 1
T62820	DRUGINFO	D07GVM	JNJ-42491293	Phase 1
T62820	DRUGINFO	D0TS8E	ADX71149	Phase 1
T62820	DRUGINFO	D09WZU	BCI-838	Phase 1
T62820	DRUGINFO	D0P0ZY	Pomaglumetad	Phase 1
T62820	DRUGINFO	D0T3DG	BCI-632	Phase 1
T62820	DRUGINFO	D01EVT	Ethinyl-pyrazole derivative 1	Patented
T62820	DRUGINFO	D02RRE	Pyrazole derivative 78	Patented
T62820	DRUGINFO	D03KYL	Quinoline derivative 4	Patented
T62820	DRUGINFO	D03PRA	Heteroaryl-pyrazole derivative 2	Patented
T62820	DRUGINFO	D04LRT	Quinoline derivative 9	Patented
T62820	DRUGINFO	D04VAE	PMID25435285-Compound-26	Patented
T62820	DRUGINFO	D05CBS	PMID25435285-Compound-37	Patented
T62820	DRUGINFO	D06NZY	PMID25435285-Compound-44	Patented
T62820	DRUGINFO	D08JPW	N-substituted pyrazole derivative 1	Patented
T62820	DRUGINFO	D08PHH	PMID25435285-Compound-45	Patented
T62820	DRUGINFO	D09JZA	Quinoline derivative 8	Patented
T62820	DRUGINFO	D09NRH	Quinoline derivative 5	Patented
T62820	DRUGINFO	D09OQZ	PMID25435285-Compound-49	Patented
T62820	DRUGINFO	D09WXH	PMID25435285-Compound-25	Patented
T62820	DRUGINFO	D0B6DN	Ethinyl-pyrazole derivative 3	Patented
T62820	DRUGINFO	D0BP6R	Ethinyl-pyrazole derivative 2	Patented
T62820	DRUGINFO	D0C2ZJ	Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 3	Patented
T62820	DRUGINFO	D0CZ6T	Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 2	Patented
T62820	DRUGINFO	D0E5QO	Quinoline derivative 7	Patented
T62820	DRUGINFO	D0H2BU	PMID25435285-Compound-53	Patented
T62820	DRUGINFO	D0H2LD	PMID25435285-Compound-43	Patented
T62820	DRUGINFO	D0HD8F	Pyrazole derivative 76	Patented
T62820	DRUGINFO	D0I6LO	PMID25435285-Compound-47	Patented
T62820	DRUGINFO	D0IL4Z	PMID25435285-Compound-38	Patented
T62820	DRUGINFO	D0IY8T	PMID25435285-Compound-46	Patented
T62820	DRUGINFO	D0K0ZX	Heteroaryl-pyrazole derivative 3	Patented
T62820	DRUGINFO	D0K1RU	Quinoline derivative 3	Patented
T62820	DRUGINFO	D0KZ6Q	PMID25435285-Compound-40	Patented
T62820	DRUGINFO	D0LI2E	Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 1	Patented
T62820	DRUGINFO	D0N0FA	PMID25435285-Compound-51	Patented
T62820	DRUGINFO	D0N1CC	PMID25435285-Compound-42	Patented
T62820	DRUGINFO	D0N9IA	Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 4	Patented
T62820	DRUGINFO	D0NE0W	Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 6	Patented
T62820	DRUGINFO	D0O6QC	Heteroaryl-pyrazole derivative 1	Patented
T62820	DRUGINFO	D0O9TL	PMID25435285-Compound-52	Patented
T62820	DRUGINFO	D0OT4O	Quinoline derivative 6	Patented
T62820	DRUGINFO	D0P7DA	PMID25435285-Compound-10	Patented
T62820	DRUGINFO	D0Q2FC	Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 5	Patented
T62820	DRUGINFO	D0QM1R	Pyrazole derivative 77	Patented
T62820	DRUGINFO	D0RX0M	PMID25435285-Compound-39	Patented
T62820	DRUGINFO	D0S5SK	Pyrazole derivative 79	Patented
T62820	DRUGINFO	D0V0BC	N-substituted pyrazole derivative 2	Patented
T62820	DRUGINFO	D0WP5S	N-substituted pyrazole derivative 3	Patented
T62820	DRUGINFO	D0Y5DN	PMID25435285-Compound-41	Patented
T62820	DRUGINFO	D0YZ7D	PMID25435285-Compound-50	Patented
T62820	DRUGINFO	D01VZE	PMID25435285-Compound-16	Patented
T62820	DRUGINFO	D0D4OW	PMID25435285-Compound-15	Patented
T62820	DRUGINFO	D0KV7D	PMID25435285-Compound-20	Patented
T62820	DRUGINFO	D0SF1E	PMID25435285-Compound-22	Patented
T62820	DRUGINFO	D0P4BQ	LY-544344	Discontinued in Phase 3
T62820	DRUGINFO	D08JNE	RG1578	Discontinued in Phase 2
T62820	DRUGINFO	D09RON	LY-2300559	Discontinued in Phase 2
T62820	DRUGINFO	D0U5CS	LY354740	Discontinued in Phase 2
T62820	DRUGINFO	D0Y3RY	R-1578	Discontinued in Phase 2
T62820	DRUGINFO	D07WSR	TS-032	Discontinued in Phase 1
T62820	DRUGINFO	D00HKQ	PMID22364337C48	Investigative
T62820	DRUGINFO	D01EAQ	[3H]2,2,2-TEMPS	Investigative
T62820	DRUGINFO	D01ETL	3-MPPTS	Investigative
T62820	DRUGINFO	D02DEF	JNJ-42153605	Investigative
T62820	DRUGINFO	D02HNQ	PMID21155570C14	Investigative
T62820	DRUGINFO	D03IES	cyPPTS	Investigative
T62820	DRUGINFO	D04GWD	[3H]JNJ-40068782	Investigative
T62820	DRUGINFO	D06SDD	MGS0028	Investigative
T62820	DRUGINFO	D07MHL	biphenylindanone A	Investigative
T62820	DRUGINFO	D07TBD	DT-2228	Investigative
T62820	DRUGINFO	D08BXD	4-MPPTS	Investigative
T62820	DRUGINFO	D08JKW	PMID20409708C34	Investigative
T62820	DRUGINFO	D08LEB	RO5488608	Investigative
T62820	DRUGINFO	D08OCG	PTBE	Investigative
T62820	DRUGINFO	D09RZQ	CBiPES	Investigative
T62820	DRUGINFO	D09UBS	Ro64-5229	Investigative
T62820	DRUGINFO	D0EK6P	(2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate	Investigative
T62820	DRUGINFO	D0ES5X	4-APPES	Investigative
T62820	DRUGINFO	D0I6WA	THIIC	Investigative
T62820	DRUGINFO	D0J2WN	PCCG-4	Investigative
T62820	DRUGINFO	D0N6HV	RO4988546	Investigative
T62820	DRUGINFO	D0SL4Q	GSK1331268	Investigative
T62820	DRUGINFO	D0Y1WV	DCG IV	Investigative
T62820	DRUGINFO	D01WKR	eGlu	Investigative
T62820	DRUGINFO	D06PAK	LY-389795	Investigative
T62820	DRUGINFO	D06UJA	MNI-136	Investigative
T62820	DRUGINFO	D07GRG	LY-379268	Investigative
T62820	DRUGINFO	D09YEQ	Ro4491533	Investigative
T62820	DRUGINFO	D0C3JX	MNI-137	Investigative
T62820	DRUGINFO	D0H3FH	MNI-135	Investigative
T62820	DRUGINFO	D0S6DK	(S)-4C3HPG	Investigative
T62820	DRUGINFO	D0N9UZ	[3H]LY341495	Investigative
T62820	DRUGINFO	D0O8AK	alpha-methylserine-O-phosphate	Investigative
T62820	DRUGINFO	D0J8OW	(+)-MCPG	Investigative
T62820	DRUGINFO	D04DKM	(1S,3R)-ACPD	Investigative
T62820	DRUGINFO	D06DUE	[3H]quisqualate	Investigative
T62820	DRUGINFO	D0Z7CZ	L-CCG-I	Investigative

T02719	TARGETID	T02719
T02719	FORMERID	TTDC00126
T02719	UNIPROID	GRM3_HUMAN
T02719	TARGNAME	Metabotropic glutamate receptor 3 (mGluR3)
T02719	GENENAME	GRM3
T02719	TARGTYPE	Clinical trial
T02719	SYNONYMS	mGLUR3; Group III metabotropic glutamate receptor; GPRC1C
T02719	FUNCTION	Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling inhibits adenylate cyclase activity. G-protein coupled receptor for glutamate.
T02719	PDBSTRUC	6B7H; 5CNM; 5CNK; 4XAR; 3SM9
T02719	BIOCLASS	GPCR glutamate
T02719	SEQUENCE	MKMLTRLQVLTLALFSKGFLLSLGDHNFLRREIKIEGDLVLGGLFPINEKGTGTEECGRINEDRGIQRLEAMLFAIDEINKDDYLLPGVKLGVHILDTCSRDTYALEQSLEFVRASLTKVDEAEYMCPDGSYAIQENIPLLIAGVIGGSYSSVSIQVANLLRLFQIPQISYASTSAKLSDKSRYDYFARTVPPDFYQAKAMAEILRFFNWTYVSTVASEGDYGETGIEAFEQEARLRNICIATAEKVGRSNIRKSYDSVIRELLQKPNARVVVLFMRSDDSRELIAAASRANASFTWVASDGWGAQESIIKGSEHVAYGAITLELASQPVRQFDRYFQSLNPYNNHRNPWFRDFWEQKFQCSLQNKRNHRRVCDKHLAIDSSNYEQESKIMFVVNAVYAMAHALHKMQRTLCPNTTKLCDAMKILDGKKLYKDYLLKINFTAPFNPNKDADSIVKFDTFGDGMGRYNVFNFQNVGGKYSYLKVGHWAETLSLDVNSIHWSRNSVPTSQCSDPCAPNEMKNMQPGDVCCWICIPCEPYEYLADEFTCMDCGSGQWPTADLTGCYDLPEDYIRWEDAWAIGPVTIACLGFMCTCMVVTVFIKHNNTPLVKASGRELCYILLFGVGLSYCMTFFFIAKPSPVICALRRLGLGSSFAICYSALLTKTNCIARIFDGVKNGAQRPKFISPSSQVFICLGLILVQIVMVSVWLILEAPGTRRYTLAEKRETVILKCNVKDSSMLISLTYDVILVILCTVYAFKTRKCPENFNEAKFIGFTMYTTCIIWLAFLPIFYVTSSDYRVQTTTMCISVSLSGFVVLGCLFAPKVHIILFQPQKNVVTHRLHLNRFSVSGTGTTYSQSSASTYVPTVCNGREVLDSTTSSL
T02719	DRUGINFO	D0B6RA	LY404039	Phase 3
T02719	DRUGINFO	D08OTE	RO-4995819	Phase 2
T02719	DRUGINFO	D0N5CW	Oleoyl-estrone	Phase 2
T02719	DRUGINFO	DSK7I5	MP-101	Phase 2
T02719	DRUGINFO	D09WZU	BCI-838	Phase 1
T02719	DRUGINFO	D0P0ZY	Pomaglumetad	Phase 1
T02719	DRUGINFO	D0T3DG	BCI-632	Phase 1
T02719	DRUGINFO	D01VZE	PMID25435285-Compound-16	Patented
T02719	DRUGINFO	D0D4OW	PMID25435285-Compound-15	Patented
T02719	DRUGINFO	D0KV7D	PMID25435285-Compound-20	Patented
T02719	DRUGINFO	D0SF1E	PMID25435285-Compound-22	Patented
T02719	DRUGINFO	D0P4BQ	LY-544344	Discontinued in Phase 3
T02719	DRUGINFO	D0U5CS	LY354740	Discontinued in Phase 2
T02719	DRUGINFO	D0Y3RY	R-1578	Discontinued in Phase 2
T02719	DRUGINFO	D02FCY	NAAG	Investigative
T02719	DRUGINFO	D0R0IB	VU0463597	Investigative
T02719	DRUGINFO	D01WKR	eGlu	Investigative
T02719	DRUGINFO	D06PAK	LY-389795	Investigative
T02719	DRUGINFO	D06UJA	MNI-136	Investigative
T02719	DRUGINFO	D07GRG	LY-379268	Investigative
T02719	DRUGINFO	D09YEQ	Ro4491533	Investigative
T02719	DRUGINFO	D0C3JX	MNI-137	Investigative
T02719	DRUGINFO	D0H3FH	MNI-135	Investigative
T02719	DRUGINFO	D0N9UZ	[3H]LY341495	Investigative
T02719	DRUGINFO	D0J8OW	(+)-MCPG	Investigative
T02719	DRUGINFO	D04DKM	(1S,3R)-ACPD	Investigative
T02719	DRUGINFO	D06DUE	[3H]quisqualate	Investigative
T02719	DRUGINFO	D0Z7CZ	L-CCG-I	Investigative

T44141	TARGETID	T44141
T44141	FORMERID	TTDC00247
T44141	UNIPROID	ANGP1_HUMAN
T44141	TARGNAME	Angiopoietin-1 (ANGPT1)
T44141	GENENAME	ANGPT1
T44141	TARGTYPE	Clinical trial
T44141	SYNONYMS	Angiopoietin1; ANGPT1; ANG1; ANG-1
T44141	FUNCTION	Binds and activates TEK/TIE2 receptor by inducing its dimerization and tyrosine phosphorylation. Plays an important role in the regulation of angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton, but also maintenance of vascular quiescence. Required for normal angiogenesis and heart development during embryogenesis. After birth, activates or inhibits angiogenesis, depending on the context. Inhibits angiogenesis and promotes vascular stability in quiescent vessels, where endothelial cells have tight contacts. In quiescent vessels, ANGPT1 oligomers recruit TEK to cell-cell contacts, forming complexes with TEK molecules from adjoining cells, and this leads to preferential activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascades. In migrating endothelial cells that lack cell-cell adhesions, ANGT1 recruits TEK to contacts with the extracellular matrix, leading to the formation of focal adhesion complexes, activation of PTK2/FAK and of the downstream kinases MAPK1/ERK2 and MAPK3/ERK1, and ultimately to the stimulation of sprouting angiogenesis. Mediates blood vessel maturation/stability. Implicated in endothelial developmental processes laterand distinct from that of VEGF. Appears to play a crucial role in mediating reciprocal interactions between the endothelium and surrounding matrix and mesenchyme.
T44141	PDBSTRUC	4K0V; 4JYO; 4EPU
T44141	BIOCLASS	Fibrinogen protein
T44141	SEQUENCE	MTVFLSFAFLAAILTHIGCSNQRRSPENSGRRYNRIQHGQCAYTFILPEHDGNCRESTTDQYNTNALQRDAPHVEPDFSSQKLQHLEHVMENYTQWLQKLENYIVENMKSEMAQIQQNAVQNHTATMLEIGTSLLSQTAEQTRKLTDVETQVLNQTSRLEIQLLENSLSTYKLEKQLLQQTNEILKIHEKNSLLEHKILEMEGKHKEELDTLKEEKENLQGLVTRQTYIIQELEKQLNRATTNNSVLQKQQLELMDTVHNLVNLCTKEGVLLKGGKREEEKPFRDCADVYQAGFNKSGIYTIYINNMPEPKKVFCNMDVNGGGWTVIQHREDGSLDFQRGWKEYKMGFGNPSGEYWLGNEFIFAITSQRQYMLRIELMDWEGNRAYSQYDRFHIGNEKQNYRLYLKGHTGTAGKQSSLILHGADFSTKDADNDNCMCKCALMLTGGWWFDACGPSNLNGMFYTAGQNHGKLNGIKWHYFKGPSYSLRSTTMMIRPLDF
T44141	DRUGINFO	D9NL3R	Trebananib	Phase 3
T44141	DRUGINFO	D0K8NR	AMG 386	Phase 3
T44141	DRUGINFO	D08UHV	AMG 780	Phase 1

T92521	TARGETID	T92521
T92521	FORMERID	TTDR00242
T92521	UNIPROID	CP1B1_HUMAN
T92521	TARGNAME	Cytochrome P450 1B1 (CYP1B1)
T92521	GENENAME	CYP1B1
T92521	TARGTYPE	Clinical trial
T92521	SYNONYMS	CYPIB1
T92521	FUNCTION	In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compounds to their activated forms, including polycyclic aromatic hydrocarbons. Promotes angiogenesis by removing cellular oxygenation products, thereby decreasing oxidative stress, release of antiangiogenic factor THBS2, then allowing endothelial cells migration, cell adhesion and capillary morphogenesis. These changes are concommitant with the endothelial nitric oxide synthase activity and nitric oxide synthesis. Plays an important role in the regulation of perivascular cell proliferation, migration, and survival through modulation of the intracellular oxidative state and NF-kappa-B expression and/or activity, during angiogenesis. Contributes to oxidative homeostasis and ultrastructural organization and function of trabecular meshwork tissue through modulation of POSTN expression. Cytochromes P450 are a group of heme-thiolate monooxygenases.
T92521	PDBSTRUC	6IQ5; 3PM0
T92521	BIOCLASS	Paired donor oxygen oxidoreductase
T92521	ECNUMBER	EC 1.14.14.-
T92521	SEQUENCE	MGTSLSPNDPWPLNPLSIQQTTLLLLLSVLATVHVGQRLLRQRRRQLRSAPPGPFAWPLIGNAAAVGQAAHLSFARLARRYGDVFQIRLGSCPIVVLNGERAIHQALVQQGSAFADRPAFASFRVVSGGRSMAFGHYSEHWKVQRRAAHSMMRNFFTRQPRSRQVLEGHVLSEARELVALLVRGSADGAFLDPRPLTVVAVANVMSAVCFGCRYSHDDPEFRELLSHNEEFGRTVGAGSLVDVMPWLQYFPNPVRTVFREFEQLNRNFSNFILDKFLRHCESLRPGAAPRDMMDAFILSAEKKAAGDSHGGGARLDLENVPATITDIFGASQDTLSTALQWLLLLFTRYPDVQTRVQAELDQVVGRDRLPCMGDQPNLPYVLAFLYEAMRFSSFVPVTIPHATTANTSVLGYHIPKDTVVFVNQWSVNHDPLKWPNPENFDPARFLDKDGLINKDLTSRVMIFSVGKRRCIGEELSKMQLFLFISILAHQCDFRANPNEPAKMNFSYGLTIKPKSFKVNVTLRESMELLDSAVQNLQAKETCQ
T92521	DRUGINFO	D0G5CS	PINOCEMBRIN	Phase 2
T92521	DRUGINFO	D02ABO	NARINGENIN	Phase 1
T92521	DRUGINFO	D00RFY	DIOSMETIN	Investigative
T92521	DRUGINFO	D01FJE	ISOSAKUTANETIN	Investigative
T92521	DRUGINFO	D04DYO	KAEMPFERIDE	Investigative
T92521	DRUGINFO	D06PZE	TAMARIXETIN	Investigative
T92521	DRUGINFO	D06VXW	3-[2-(3,5-Dimethoxy-phenyl)-vinyl]-furan	Investigative
T92521	DRUGINFO	D08AIJ	ERIODICTYOL	Investigative
T92521	DRUGINFO	D0CR8V	HOMOERIODICTYOL	Investigative
T92521	DRUGINFO	D0J9OG	N-(2,4-Dimethoxy-phenyl)-3,5-dimethoxy-benzamide	Investigative
T92521	DRUGINFO	D0T9IK	4-[2-(3,5-Dimethoxy-phenyl)-vinyl]-pyridine	Investigative
T92521	DRUGINFO	D0Z1AL	2-[2-(3,5-Dimethoxy-phenyl)-vinyl]-thiophene	Investigative
T92521	DRUGINFO	D01FGM	CHRYSOERIOL	Investigative
T92521	DRUGINFO	D07YDN	ISORHAMNETIN	Investigative
T92521	DRUGINFO	D0NS1S	ACACETIN	Investigative
T92521	DRUGINFO	D0O9NE	TRISMETHOXYRESVERATROL	Investigative
T92521	DRUGINFO	D0Y7HG	Galangin	Investigative
T92521	DRUGINFO	D01UYI	Chrysin	Investigative
T92521	DRUGINFO	D00RIX	APIGENIN	Investigative
T92521	DRUGINFO	D0G3TK	KAEMPFEROL	Investigative

T87686	TARGETID	T87686
T87686	FORMERID	TTDNC00492
T87686	UNIPROID	DOT1L_HUMAN
T87686	TARGNAME	Histone-lysine N-methyltransferase (HLNM)
T87686	GENENAME	DOT1L
T87686	TARGTYPE	Clinical trial
T87686	SYNONYMS	Lysine N-methyltransferase 4; KMT4; KIAA1814; Histone-lysine N-methyltransferase, H3 lysine-79 specific; Histone H3-K79 methyltransferase; H3-K79-HMTase; DOT1-like protein
T87686	FUNCTION	Histone methyltransferase. Methylates 'Lys-79' of histone H3. Nucleosomes are preferred as substrate compared to free histones. Binds to DNA.
T87686	PDBSTRUC	6O96; 6NQA; 6NOG; 6NN6; 6NJ9
T87686	BIOCLASS	Methyltransferase
T87686	ECNUMBER	EC 2.1.1.43
T87686	SEQUENCE	MGEKLELRLKSPVGAEPAVYPWPLPVYDKHHDAAHEIIETIRWVCEEIPDLKLAMENYVLIDYDTKSFESMQRLCDKYNRAIDSIHQLWKGTTQPMKLNTRPSTGLLRHILQQVYNHSVTDPEKLNNYEPFSPEVYGETSFDLVAQMIDEIKMTDDDLFVDLGSGVGQVVLQVAAATNCKHHYGVEKADIPAKYAETMDREFRKWMKWYGKKHAEYTLERGDFLSEEWRERIANTSVIFVNNFAFGPEVDHQLKERFANMKEGGRIVSSKPFAPLNFRINSRNLSDIGTIMRVVELSPLKGSVSWTGKPVSYYLHTIDRTILENYFSSLKNPKLREEQEAARRRQQRESKSNAATPTKGPEGKVAGPADAPMDSGAEEEKAGAATVKKPSPSKARKKKLNKKGRKMAGRKRGRPKKMNTANPERKPKKNQTALDALHAQTVSQTAASSPQDAYRSPHSPFYQLPPSVQRHSPNPLLVAPTPPALQKLLESFKIQYLQFLAYTKTPQYKASLQELLGQEKEKNAQLLGAAQQLLSHCQAQKEEIRRLFQQKLDELGVKALTYNDLIQAQKEISAHNQQLREQSEQLEQDNRALRGQSLQLLKARCEELQLDWATLSLEKLLKEKQALKSQISEKQRHCLELQISIVELEKSQRQQELLQLKSCVPPDDALSLHLRGKGALGRELEPDASRLHLELDCTKFSLPHLSSMSPELSMNGQAAGYELCGVLSRPSSKQNTPQYLASPLDQEVVPCTPSHVGRPRLEKLSGLAAPDYTRLSPAKIVLRRHLSQDHTVPGRPAASELHSRAEHTKENGLPYQSPSVPGSMKLSPQDPRPLSPGALQLAGEKSSEKGLRERAYGSSGELITSLPISIPLSTVQPNKLPVSIPLASVVLPSRAERARSTPSPVLQPRDPSSTLEKQIGANAHGAGSRSLALAPAGFSYAGSVAISGALAGSPASLTPGAEPATLDESSSSGSLFATVGSRSSTPQHPLLLAQPRNSLPASPAHQLSSSPRLGGAAQGPLPEASKGDLPSDSGFSDPESEAKRRIVFTITTGAGSAKQSPSSKHSPLTASARGDCVPSHGQDSRRRGRRKRASAGTPSLSAGVSPKRRALPSVAGLFTQPSGSPLNLNSMVSNINQPLEITAISSPETSLKSSPVPYQDHDQPPVLKKERPLSQTNGAHYSPLTSDEEPGSEDEPSSARIERKIATISLESKSPPKTLENGGGLAGRKPAPAGEPVNSSKWKSTFSPISDIGLAKSADSPLQASSALSQNSLFTFRPALEEPSADAKLAAHPRKGFPGSLSGADGLSPGTNPANGCTFGGGLAADLSLHSFSDGASLPHKGPEAAGLSSPLSFPSQRGKEGSDANPFLSKRQLDGLAGLKGEGSRGKEAGEGGLPLCGPTDKTPLLSGKAAKARDREVDLKNGHNLFISAAAVPPGSLLSGPGLAPAASSAGGAASSAQTHRSFLGPFPPGPQFALGPMSLQANLGSVAGSSVLQSLFSSVPAAAGLVHVSSAATRLTNSHAMGSFSGVAGGTVGGN
T87686	DRUGINFO	D0C6GK	EPZ-5676	Phase 1/2
T87686	DRUGINFO	D09ENZ	EPZ-004777	Investigative
T87686	DRUGINFO	D0L0DC	bromo-deaza-SAH	Investigative
T87686	DRUGINFO	D0S9SJ	SGC0946	Investigative

T92640	TARGETID	T92640
T92640	FORMERID	TTDR00580
T92640	UNIPROID	LPAR1_HUMAN
T92640	TARGNAME	Lysophosphatidic acid receptor 1 (LPAR1)
T92640	GENENAME	LPAR1
T92640	TARGTYPE	Clinical trial
T92640	SYNONYMS	Lysophosphatidic acid receptor Edg-2; LPA1; LPA-1; LPA receptor 1; EDG2; EDG 2 receptor
T92640	FUNCTION	Plays a role in the reorganization of the actin cytoskeleton, cell migration, differentiation and proliferation, and thereby contributes to the responses to tissue damage and infectious agents. Activates downstream signaling cascades via the G(i)/G(o), G(12)/G(13), and G(q) families of heteromeric G proteins. Signaling inhibits adenylyl cyclase activity and decreases cellular cAMP levels. Signaling triggers an increase of cytoplasmic Ca(2+) levels. Activates RALA; this leads to the activation of phospholipase C (PLC) and the formation of inositol 1,4,5-trisphosphate. Signaling mediates activation of down-stream MAP kinases. Contributes to the regulation of cell shape. Promotes Rho-dependent reorganization of the actin cytoskeleton in neuronal cells and neurite retraction. Promotes the activation of Rho and the formation of actin stress fibers. Promotes formation of lamellipodia at the leading edge of migrating cells via activation of RAC1. Through its function as lysophosphatidic acid receptor, plays a role in chemotaxis and cell migration, including responses to injury and wounding. Plays a role in triggering inflammation in response to bacterial lipopolysaccharide (LPS) via its interaction with CD14. Promotes cell proliferation in response to lysophosphatidic acid. Required for normal skeleton development. May play a role in osteoblast differentiation. Required for normal brain development. Required for normal proliferation, survival and maturation of newly formed neurons in the adult dentate gyrus. Plays a role in pain perception and in the initiation of neuropathic pain. Receptor for lysophosphatidic acid (LPA).
T92640	PDBSTRUC	4Z36; 4Z35; 4Z34
T92640	BIOCLASS	GPCR rhodopsin
T92640	SEQUENCE	MAAISTSIPVISQPQFTAMNEPQCFYNESIAFFYNRSGKHLATEWNTVSKLVMGLGITVCIFIMLANLLVMVAIYVNRRFHFPIYYLMANLAAADFFAGLAYFYLMFNTGPNTRRLTVSTWLLRQGLIDTSLTASVANLLAIAIERHITVFRMQLHTRMSNRRVVVVIVVIWTMAIVMGAIPSVGWNCICDIENCSNMAPLYSDSYLVFWAIFNLVTFVVMVVLYAHIFGYVRQRTMRMSRHSSGPRRNRDTMMSLLKTVVIVLGAFIICWTPGLVLLLLDVCCPQCDVLAYEKFFLLLAEFNSAMNPIIYSYRDKEMSATFRQILCCQRSENPTGPTEGSDRSASSLNHTILAGVHSNDHSVV
T92640	DRUGINFO	D0D6ZW	BMS-986020	Phase 2
T92640	DRUGINFO	DB53RG	BMS-986278	Phase 2
T92640	DRUGINFO	D07WCT	SAR-100842	Phase 2
T92640	DRUGINFO	DCW89Z	BMS-986337	Phase 1
T92640	DRUGINFO	D06XGC	BMS-986202	Preclinical
T92640	DRUGINFO	D02RYR	Phosphoric acid monodec-9-enyl ester	Investigative
T92640	DRUGINFO	D03HLU	Phosphoric acid mono-((E)-dec-4-enyl) ester	Investigative
T92640	DRUGINFO	D04BLL	Phosphoric acid mono-((E)-tetradec-11-enyl) ester	Investigative
T92640	DRUGINFO	D04CJG	Phosphoric acid monotetradecyl ester	Investigative
T92640	DRUGINFO	D06YTN	Decyl-phosphonic acid	Investigative
T92640	DRUGINFO	D07WLV	Phosphoric acid mono-((E)-dodec-9-enyl) ester	Investigative
T92640	DRUGINFO	D07YUV	Phosphoric acid mono-((E)-tetradec-9-enyl) ester	Investigative
T92640	DRUGINFO	D0BP3E	(1,1-Difluoro-pentadecyl)-phosphonic acid	Investigative
T92640	DRUGINFO	D0F2SQ	Thiophosphoric acid dec-9-enyl ester	Investigative
T92640	DRUGINFO	D0J2WC	ONO-9780307	Investigative
T92640	DRUGINFO	D0N3YN	ONO-3080573	Investigative
T92640	DRUGINFO	D0N4AG	Thiophosphoric acid (E)-tetradec-9-enyl ester	Investigative
T92640	DRUGINFO	D0OF2J	anti-BrP-LPA	Investigative
T92640	DRUGINFO	D0P7GR	Tetradecyl-phosphonic acid	Investigative
T92640	DRUGINFO	D0S8MS	ONO-9910539	Investigative
T92640	DRUGINFO	D0U5US	Dodecyl-phosphonic acid	Investigative
T92640	DRUGINFO	D0X7MB	syn-BrP-LPA	Investigative
T92640	DRUGINFO	D0XJ9P	Phosphoric acid monododecyl ester	Investigative
T92640	DRUGINFO	D0XY0Z	Thiophosphoric acid (E)-dodec-9-enyl ester	Investigative
T92640	DRUGINFO	D0Z2QV	Thiophosphoric acid decyl ester	Investigative
T92640	DRUGINFO	D06IXI	BrP-LPA	Investigative
T92640	DRUGINFO	D0S6CW	VPC32183	Investigative
T92640	DRUGINFO	D0X0OP	alkyl OMPT	Investigative
T92640	DRUGINFO	D0Z6DG	T13	Investigative
T92640	DRUGINFO	D04KQT	dodecyl-thiophosphate	Investigative
T92640	DRUGINFO	D0K3GQ	oleoyl-thiophosphate	Investigative
T92640	DRUGINFO	D0PI4H	VPC12249	Investigative
T92640	DRUGINFO	D0R8LB	NAEPA	Investigative
T92640	DRUGINFO	D02LXI	Ki16425	Investigative
T92640	DRUGINFO	D0G6XT	dioctanoylglycerol pyrophosphate	Investigative
T92640	DRUGINFO	D0R2VH	2-oleoyl-LPA	Investigative
T92640	DRUGINFO	D0X0UR	LPA	Investigative

T46871	TARGETID	T46871
T46871	FORMERID	TTDI02174
T46871	UNIPROID	SHIP1_HUMAN
T46871	TARGNAME	SH2 domain inositol 5'-phosphatase 1 (INPP5D)
T46871	GENENAME	INPP5D
T46871	TARGTYPE	Clinical trial
T46871	SYNONYMS	p150Ship; hp51CN; SIP145; SIP-145; SHIP1; SHIP-1; SHIP; SH2 domaincontaining inositol phosphatase 1; SH2 domaincontaining inositol 5'phosphatase 1; SH2 domain-containing inositol phosphatase 1; SH2 domain-containing inositol 5'-phosphatase 1; Phosphatidylinositol 3,4,5trisphosphate 5phosphatase 1; Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1; Inositol polyphosphate5phosphatase of 145 kDa; Inositol polyphosphate-5-phosphatase of 145 kDa
T46871	FUNCTION	Acts as a negative regulator of B-cell antigen receptor signaling. Mediates signaling from the FC-gamma-RIIB receptor (FCGR2B), playing a central role in terminating signal transduction from activating immune/hematopoietic cell receptor systems. Acts as a negative regulator of myeloid cell proliferation/survival and chemotaxis, mast cell degranulation, immune cells homeostasis, integrin alpha-IIb/beta-3 signaling in platelets and JNK signaling in B-cells. Regulates proliferation of osteoclast precursors, macrophage programming, phagocytosis and activation and is required for endotoxin tolerance. Involved in the control of cell-cell junctions, CD32a signaling in neutrophils and modulation of EGF-induced phospholipase C activity. Key regulator of neutrophil migration, by governing the formation of the leading edge and polarization required for chemotaxis. Modulates FCGR3/CD16-mediated cytotoxicity in NK cells. Mediates the activin/TGF-beta-induced apoptosis through its Smad-dependent expression. May also hydrolyze PtdIns(1,3,4,5)P4, and could thus affect the levels of the higher inositol polyphosphates like InsP6. Phosphatidylinositol (PtdIns) phosphatase that specifically hydrolyzes the 5-phosphate of phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3) to produce PtdIns(3,4)P2, thereby negatively regulating the PI3K (phosphoinositide 3-kinase) pathways.
T46871	PDBSTRUC	6IBD; 2YSX
T46871	BIOCLASS	Phosphoric monoester hydrolase
T46871	ECNUMBER	EC 3.1.3.86
T46871	SEQUENCE	MVPCWNHGNITRSKAEELLSRTGKDGSFLVRASESISRAYALCVLYRNCVYTYRILPNEDDKFTVQASEGVSMRFFTKLDQLIEFYKKENMGLVTHLQYPVPLEEEDTGDDPEEDTVESVVSPPELPPRNIPLTASSCEAKEVPFSNENPRATETSRPSLSETLFQRLQSMDTSGLPEEHLKAIQDYLSTQLAQDSEFVKTGSSSLPHLKKLTTLLCKELYGEVIRTLPSLESLQRLFDQQLSPGLRPRPQVPGEANPINMVSKLSQLTSLLSSIEDKVKALLHEGPESPHRPSLIPPVTFEVKAESLGIPQKMQLKVDVESGKLIIKKSKDGSEDKFYSHKKILQLIKSQKFLNKLVILVETEKEKILRKEYVFADSKKREGFCQLLQQMKNKHSEQPEPDMITIFIGTWNMGNAPPPKKITSWFLSKGQGKTRDDSADYIPHDIYVIGTQEDPLSEKEWLEILKHSLQEITSVTFKTVAIHTLWNIRIVVLAKPEHENRISHICTDNVKTGIANTLGNKGAVGVSFMFNGTSLGFVNSHLTSGSEKKLRRNQNYMNILRFLALGDKKLSPFNITHRFTHLFWFGDLNYRVDLPTWEAETIIQKIKQQQYADLLSHDQLLTERREQKVFLHFEEEEITFAPTYRFERLTRDKYAYTKQKATGMKYNLPSWCDRVLWKSYPLVHVVCQSYGSTSDIMTSDHSPVFATFEAGVTSQFVSKNGPGTVDSQGQIEFLRCYATLKTKSQTKFYLEFHSSCLESFVKSQEGENEEGSEGELVVKFGETLPKLKPIISDPEYLLDQHILISIKSSDSDESYGEGCIALRLEATETQLPIYTPLTHHGELTGHFQGEIKLQTSQGKTREKLYDFVKTERDESSGPKTLKSLTSHDPMKQWEVTSRAPPCSGSSITEIINPNYMGVGPFGPPMPLHVKQTLSPDQQPTAWSYDQPPKDSPLGPCRGESPPTPPGQPPISPKKFLPSTANRGLPPRTQESRPSDLGKNAGDTLPQEDLPLTKPEMFENPLYGSLSSFPKPAPRKDQESPKMPRKEPPPCPEPGILSPSIVLTKAQEADRGEGPGKQVPAPRLRSFTCSSSAEGRAAGGDKSQGKPKTPVSSQAPVPAKRPIKPSRSEINQQTPPTPTPRPPLPVKSPAVLHLQHSKGRDYRDNTELPHHGKHRPEEGPPGPLGRTAMQ
T46871	DRUGINFO	D02HDG	AQX-1125	Phase 2

T03755	TARGETID	T03755
T03755	FORMERID	TTDC00244
T03755	UNIPROID	B2CL2_HUMAN
T03755	TARGNAME	Apoptosis regulator Bcl-W (BCL-W)
T03755	GENENAME	BCL2L2
T03755	TARGTYPE	Clinical trial
T03755	SYNONYMS	KIAA0271; Bcl2-L-2; Bcl-2-like protein 2; BCLW
T03755	FUNCTION	Blocks dexamethasone-induced apoptosis. Mediates survival of postmitotic Sertoli cells by suppressing death-promoting activity of BAX. Promotes cell survival.
T03755	PDBSTRUC	4CIM; 2Y6W; 1ZY3; 1O0L; 1MK3
T03755	BIOCLASS	B-cell lymphoma Bcl-2
T03755	SEQUENCE	MATPASAPDTRALVADFVGYKLRQKGYVCGAGPGEGPAADPLHQAMRAAGDEFETRFRRTFSDLAAQLHVTPGSAQQRFTQVSDELFQGGPNWGRLVAFFVFGAALCAESVNKEMEPLVGQVQEWMVAYLETQLADWIHSSGGWAEFTALYGDGALEEARRLREGNWASVRTVLTGAVALGALVTVGAFFASK
T03755	DRUGINFO	D06ETI	ABT-263	Phase 3
T03755	DRUGINFO	D0TU3N	PMID27744724-Compound-18	Patented

T98022	TARGETID	T98022
T98022	FORMERID	TTDC00053
T98022	UNIPROID	CBPB2_HUMAN
T98022	TARGNAME	Carboxypeptidase B2 (CPB2)
T98022	GENENAME	CPB2
T98022	TARGTYPE	Clinical trial
T98022	SYNONYMS	Thrombin-activable fibrinolysis inhibitor; TAFI; Plasma carboxypeptidase B; Carboxypeptidase U; CPU; CPB2
T98022	FUNCTION	Cleaves C-terminal arginine or lysine residues from biologically active peptides such as kinins or anaphylatoxins in the circulation thereby regulating their activities. Down- regulates fibrinolysis by removing C-terminal lysine residues from fibrin that has already been partially degraded by plasmin.
T98022	PDBSTRUC	5HVH; 5HVG; 5HVF; 4P10; 3LMS
T98022	BIOCLASS	Peptidase
T98022	ECNUMBER	EC 3.4.17.20
T98022	SEQUENCE	MKLCSLAVLVPIVLFCEQHVFAFQSGQVLAALPRTSRQVQVLQNLTTTYEIVLWQPVTADLIVKKKQVHFFVNASDVDNVKAHLNVSGIPCSVLLADVEDLIQQQISNDTVSPRASASYYEQYHSLNEIYSWIEFITERHPDMLTKIHIGSSFEKYPLYVLKVSGKEQAAKNAIWIDCGIHAREWISPAFCLWFIGHITQFYGIIGQYTNLLRLVDFYVMPVVNVDGYDYSWKKNRMWRKNRSFYANNHCIGTDLNRNFASKHWCEEGASSSSCSETYCGLYPESEPEVKAVASFLRRNINQIKAYISMHSYSQHIVFPYSYTRSKSKDHEELSLVASEAVRAIEKISKNTRYTHGHGSETLYLAPGGGDDWIYDLGIKYSFTIELRDTGTYGFLLPERYIKPTCREAFAAVSKIAWHVIRNV
T98022	DRUGINFO	D01NXX	SAR-126119	Phase 1
T98022	DRUGINFO	D05WSP	UK-396082	Phase 1
T98022	DRUGINFO	D06RHC	DS-1040	Phase 1
T98022	DRUGINFO	D0V6JF	SAR-104772	Phase 1
T98022	DRUGINFO	D0F7FX	AZD-9684	Discontinued in Phase 2
T98022	DRUGINFO	D00DXB	3-mercapto-2-(piperidin-3-yl)propanoic acid	Investigative
T98022	DRUGINFO	D00GOD	6-Amino-2-(1H-imidazol-4-yl)-hexanoic acid	Investigative
T98022	DRUGINFO	D06TJC	3-mercapto-2-(piperidin-4-yl)propanoic acid	Investigative
T98022	DRUGINFO	D07RXJ	2-(4-benzoylpiperidine-1-carbonyl)benzoic acid	Investigative
T98022	DRUGINFO	D08SBS	DL-guanidinoethylmercaptosuccinic acid	Investigative
T98022	DRUGINFO	D0D2MV	2-(3-guanidinophenyl)-3-mercaptopropanoic acid	Investigative
T98022	DRUGINFO	D0JD9E	SQ-24798	Investigative
T98022	DRUGINFO	D0R2PW	2-(3-aminophenyl)-3-mercaptopropanoic acid	Investigative
T98022	DRUGINFO	D0R3KN	MN-462	Investigative
T98022	DRUGINFO	D0R7PE	(+/-)-5-amino-2-(mercaptomethyl)pentanoic acid	Investigative
T98022	DRUGINFO	D06LNX	DL-benzylsuccinic acid	Investigative
T98022	DRUGINFO	D0O3QJ	PMID19954973C4	Investigative
T98022	DRUGINFO	D0XA0N	PMID14640538C3	Investigative

T27889	TARGETID	T27889
T27889	FORMERID	TTDNC00602
T27889	UNIPROID	ACE2_HUMAN
T27889	TARGNAME	Angiotensin-converting enzyme 2 (ACE2)
T27889	GENENAME	ACE2
T27889	TARGTYPE	Clinical trial
T27889	SYNONYMS	Processed angiotensinconverting enzyme 2; Metalloprotease MPROT15; Angiotensinconverting enzyme homolog; Angiotensinconverting enzyme 2; ACErelated carboxypeptidase; ACEH; ACE2
T27889	FUNCTION	Carboxypeptidase which converts angiotensin I to angiotensin 1-9, a peptide of unknown function, and angiotensin II to angiotensin 1-7, a vasodilator. Also able to hydrolyze apelin- 13 and dynorphin-13 with high efficiency. May be an important regulator of heart function. In case of human coronaviruses SARS and HCoV-NL63 infections, serve as functional receptor for the spike glycoprotein of both coronaviruses.
T27889	PDBSTRUC	6CS2; 6ACK; 6ACJ; 6ACG; 3SCL
T27889	BIOCLASS	Peptidase
T27889	ECNUMBER	EC 3.4.17.23
T27889	SEQUENCE	MSSSSWLLLSLVAVTAAQSTIEEQAKTFLDKFNHEAEDLFYQSSLASWNYNTNITEENVQNMNNAGDKWSAFLKEQSTLAQMYPLQEIQNLTVKLQLQALQQNGSSVLSEDKSKRLNTILNTMSTIYSTGKVCNPDNPQECLLLEPGLNEIMANSLDYNERLWAWESWRSEVGKQLRPLYEEYVVLKNEMARANHYEDYGDYWRGDYEVNGVDGYDYSRGQLIEDVEHTFEEIKPLYEHLHAYVRAKLMNAYPSYISPIGCLPAHLLGDMWGRFWTNLYSLTVPFGQKPNIDVTDAMVDQAWDAQRIFKEAEKFFVSVGLPNMTQGFWENSMLTDPGNVQKAVCHPTAWDLGKGDFRILMCTKVTMDDFLTAHHEMGHIQYDMAYAAQPFLLRNGANEGFHEAVGEIMSLSAATPKHLKSIGLLSPDFQEDNETEINFLLKQALTIVGTLPFTYMLEKWRWMVFKGEIPKDQWMKKWWEMKREIVGVVEPVPHDETYCDPASLFHVSNDYSFIRYYTRTLYQFQFQEALCQAAKHEGPLHKCDISNSTEAGQKLFNMLRLGKSEPWTLALENVVGAKNMNVRPLLNYFEPLFTWLKDQNKNSFVGWSTDWSPYADQSIKVRISLKSALGDKAYEWNDNEMYLFRSSVAYAMRQYFLKVKNQMILFGEEDVRVANLKPRISFNFFVTAPKNVSDIIPRTEVEKAIRMSRSRINDAFRLNDNSLEFLGIQPTLGPPNQPPVSIWLIVFGVVMGVIVVGIVILIFTGIRDRKKKNKARSGENPYASIDISKGENNPGFQNTDDVQTSF
T27889	DRUGINFO	D0ET2T	GSK2586881	Phase 2
T27889	DRUGINFO	D08EYQ	ORE-1001	Phase 1/2
T27889	DRUGINFO	D0NQ0B	XNT	Investigative
T27889	DRUGINFO	D0P0MP	PMID18324760C28	Investigative

T26500	TARGETID	T26500
T26500	FORMERID	TTDR01193
T26500	UNIPROID	HRH4_HUMAN
T26500	TARGNAME	Histamine H4 receptor (H4R)
T26500	GENENAME	HRH4
T26500	TARGTYPE	Clinical trial
T26500	SYNONYMS	SP9144; Pfi-013; HH4R; H4 receptor; GPRv53; GPCR105; G protein-coupled receptor 105; AXOR35
T26500	FUNCTION	Displays a significant level of constitutive activity (spontaneous activity in the absence of agonist). The H4 subclass of histamine receptors could mediate the histamine signals in peripheral tissues.
T26500	BIOCLASS	GPCR rhodopsin
T26500	SEQUENCE	MPDTNSTINLSLSTRVTLAFFMSLVAFAIMLGNALVILAFVVDKNLRHRSSYFFLNLAISDFFVGVISIPLYIPHTLFEWDFGKEICVFWLTTDYLLCTASVYNIVLISYDRYLSVSNAVSYRTQHTGVLKIVTLMVAVWVLAFLVNGPMILVSESWKDEGSECEPGFFSEWYILAITSFLEFVIPVILVAYFNMNIYWSLWKRDHLSRCQSHPGLTAVSSNICGHSFRGRLSSRRSLSASTEVPASFHSERQRRKSSLMFSSRTKMNSNTIASKMGSFSQSDSVALHQREHVELLRARRLAKSLAILLGVFAVCWAPYSLFTIVLSFYSSATGPKSVWYRIAFWLQWFNSFVNPLLYPLCHKRFQKAFLKIFCIKKQPLPSQHSRSVSS
T26500	DRUGINFO	D02DTQ	PF-3893787	Phase 2
T26500	DRUGINFO	D04VBF	JNJ-38518168	Phase 2
T26500	DRUGINFO	D05GYL	UR-63325	Phase 2
T26500	DRUGINFO	D05FYA	Thioperamide	Terminated
T26500	DRUGINFO	D00XJR	JNJ-10191584	Investigative
T26500	DRUGINFO	D02SQF	4-methylhistamine	Investigative
T26500	DRUGINFO	D04EDO	improgan	Investigative
T26500	DRUGINFO	D05OIF	N-ethylhistamine	Investigative
T26500	DRUGINFO	D08BLM	9-benzyl-6-(4-methylpiperazin-1-yl)-9H-purine	Investigative
T26500	DRUGINFO	D08DOG	A-846714	Investigative
T26500	DRUGINFO	D09HUF	UR-60427	Investigative
T26500	DRUGINFO	D09UVB	HTMT	Investigative
T26500	DRUGINFO	D0E9SR	[3H]JNJ 7777120	Investigative
T26500	DRUGINFO	D0G3RZ	6-(4-Methylpiperazin-1-yl)-9H-purin-2-amine	Investigative
T26500	DRUGINFO	D0IF3N	N,N-dimethylhistamine	Investigative
T26500	DRUGINFO	D0MP8E	VUF 8430	Investigative
T26500	DRUGINFO	D0P8DW	A-943931	Investigative
T26500	DRUGINFO	D0QT2F	6-(4-methylpiperazin-1-yl)-9Hpurine	Investigative
T26500	DRUGINFO	D0TC5E	2-methylhistamine	Investigative
T26500	DRUGINFO	D0UK0F	6-(4-Methylpiperazin-1-yl)pyrimidine-2,4-diamine	Investigative
T26500	DRUGINFO	D02RAN	Imetit	Investigative
T26500	DRUGINFO	D03ECU	[125I]iodophenpropit	Investigative
T26500	DRUGINFO	D03SAM	(R)-alpha-methylhistamine	Investigative
T26500	DRUGINFO	D08ECP	N-[3H]alpha-methylhistamine	Investigative
T26500	DRUGINFO	D0A4XL	N-[3H]methylhistamine	Investigative
T26500	DRUGINFO	D0C8IB	(R)-3-(1H-imidazol-4-yl)propyl sec-butylcarbamate	Investigative
T26500	DRUGINFO	D0G6AQ	2-(3-bromophenyl)histamine	Investigative
T26500	DRUGINFO	D0H2KD	(1H-indol-2-yl)(piperazin-1-yl)methanone	Investigative
T26500	DRUGINFO	D0Q8BS	(S)-alpha-methylhistamine	Investigative
T26500	DRUGINFO	D0T6SC	N-methylhistamine	Investigative
T26500	DRUGINFO	D0T8OD	Clobenpropit	Investigative
T26500	DRUGINFO	D06RNM	burimamide	Investigative
T26500	DRUGINFO	D01JXM	2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole	Investigative
T26500	DRUGINFO	D0B4SF	impromidine	Investigative

T30563	TARGETID	T30563
T30563	FORMERID	TTDR00545
T30563	UNIPROID	LT4R2_HUMAN
T30563	TARGNAME	Leukotriene B4 receptor 2 (LTB4R2)
T30563	GENENAME	LTB4R2
T30563	TARGTYPE	Clinical trial
T30563	SYNONYMS	Seven transmembrane receptor BLTR2; Leukotriene B4 receptor BLT2; Leukotriene B(4) receptor BLT2; LTB4-R2; LTB4-R 2; LTB4 receptor JULF2; BLTR2; BLT2R
T30563	FUNCTION	Mediates chemotaxis of granulocytes and macrophages. The response is mediated via G-proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of affinities for the leukotrienes is LTB4 > 12-epi-LTB4 > LTB5 > LTB3. Low-affinity receptor for leukotrienes including leukotriene B4.
T30563	BIOCLASS	GPCR rhodopsin
T30563	SEQUENCE	MSVCYRPPGNETLLSWKTSRATGTAFLLLAALLGLPGNGFVVWSLAGWRPARGRPLAATLVLHLALADGAVLLLTPLFVAFLTRQAWPLGQAGCKAVYYVCALSMYASVLLTGLLSLQRCLAVTRPFLAPRLRSPALARRLLLAVWLAALLLAVPAAVYRHLWRDRVCQLCHPSPVHAAAHLSLETLTAFVLPFGLMLGCYSVTLARLRGARWGSGRHGARVGRLVSAIVLAFGLLWAPYHAVNLLQAVAALAPPEGALAKLGGAGQAARAGTTALAFFSSSVNPVLYVFTAGDLLPRAGPRFLTRLFEGSGEARGGGRSREGTMELRTTPQLKVVGQGRGNGDPGGGMEKDGPEWDL
T30563	DRUGINFO	D0O4NR	LTB4	Phase 2
T30563	DRUGINFO	D0S0WN	Biomed 101	Phase 1
T30563	DRUGINFO	D0Z0OT	ONO-4057	Discontinued in Phase 2
T30563	DRUGINFO	D0C0EO	CP-105696	Discontinued in Phase 1
T30563	DRUGINFO	D01XMO	LY-292728	Terminated
T30563	DRUGINFO	D0Y2IH	LY-255283	Terminated
T30563	DRUGINFO	D01CRJ	ZK-158252	Investigative
T30563	DRUGINFO	D07BYG	[3H]LTB4	Investigative
T30563	DRUGINFO	D0F7XM	12-epi LTB4	Investigative
T30563	DRUGINFO	D0I4FF	20-hydroxy-LTB4	Investigative
T30563	DRUGINFO	D0S0DT	CAY10583	Investigative
T30563	DRUGINFO	D0SK3A	BIIL 260	Investigative
T30563	DRUGINFO	D0SM3V	12-hydroxyheptadecatrienoic acid	Investigative
T30563	DRUGINFO	D0V3ZG	RO5101576	Investigative
T30563	DRUGINFO	D0Y2XY	12R-HETE	Investigative
T30563	DRUGINFO	D05HNB	LY-282210	Investigative
T30563	DRUGINFO	D06IGT	(3S,4R)-3-Benzyl-7-isopropyl-chroman-4-ol	Investigative
T30563	DRUGINFO	D0Z5QA	12S-HETE	Investigative

T86014	TARGETID	T86014
T86014	FORMERID	TTDI02179
T86014	UNIPROID	SPHK1_HUMAN
T86014	TARGNAME	Sphingosine kinase 1 (SPHK1)
T86014	GENENAME	SPHK1
T86014	TARGTYPE	Clinical trial
T86014	SYNONYMS	SPK 1; SPK; SPHK1; SK 1; Acetyltransferase SPHK1
T86014	FUNCTION	Acts on D-erythro-sphingosine and to a lesser extent sphinganine, but not other lipids, such as D,L-threo-dihydrosphingosine, N,N-dimethylsphingosine, diacylglycerol, ceramide, or phosphatidylinositol. In contrast to proapoptotic SPHK2, has a negative effect on intracellular ceramide levels, enhances cell growth and inhibits apoptosis. Involved in the regulation of inflammatory response and neuroinflammation. Via the product sphingosine 1-phosphate, stimulates TRAF2 E3 ubiquitin ligase activity, and promotes activation of NF-kappa-B in response to TNF signaling leading to IL17 secretion. In response to TNF and in parallel to NF-kappa-B activation, negatively regulates RANTES inducion through p38 MAPK signaling pathway. Involved in endocytic membrane trafficking induced by sphingosine, recruited to dilate endosomes, also plays a role on later stages of endosomal maturation and membrane fusion independently of its kinase activity. In Purkinje cells, seems to be also involved in the regulation of autophagosome-lysosome fusion upon VEGFA. Catalyzes the phosphorylation of sphingosine to form sphingosine 1-phosphate (SPP), a lipid mediator with both intra- and extracellular functions.
T86014	PDBSTRUC	4V24; 4L02; 3VZD; 3VZC; 3VZB
T86014	BIOCLASS	Kinase
T86014	ECNUMBER	EC 2.7.1.91
T86014	SEQUENCE	MDPAGGPRGVLPRPCRVLVLLNPRGGKGKALQLFRSHVQPLLAEAEISFTLMLTERRNHARELVRSEELGRWDALVVMSGDGLMHEVVNGLMERPDWETAIQKPLCSLPAGSGNALAASLNHYAGYEQVTNEDLLTNCTLLLCRRLLSPMNLLSLHTASGLRLFSVLSLAWGFIADVDLESEKYRRLGEMRFTLGTFLRLAALRTYRGRLAYLPVGRVGSKTPASPVVVQQGPVDAHLVPLEEPVPSHWTVVPDEDFVLVLALLHSHLGSEMFAAPMGRCAAGVMHLFYVRAGVSRAMLLRLFLAMEKGRHMEYECPYLVYVPVVAFRLEPKDGKGVFAVDGELMVSEAVQGQVHPNYFWMVSGCVEPPPSWKPQQMPPPEEPL
T86014	DRUGINFO	D03YOS	Phenoxodiol	Phase 1/2
T86014	DRUGINFO	D0HI1K	GSK618334	Phase 1
T86014	DRUGINFO	D02DLL	PMID27539678-Compound-6	Patented
T86014	DRUGINFO	D04VDD	Methylbenzenesulfonamide derivative 1	Patented
T86014	DRUGINFO	D07QBL	PMID27539678-Compound-12	Patented
T86014	DRUGINFO	D0DG7E	PMID27539678-Compound-10	Patented
T86014	DRUGINFO	D0G2TX	PMID27539678-Compound-16	Patented
T86014	DRUGINFO	D0H1BQ	PMID27539678-Compound-14	Patented
T86014	DRUGINFO	D0HM6Q	PMID27539678-Compound-13	Patented
T86014	DRUGINFO	D0QT5B	PMID27539678-Compound-11	Patented
T86014	DRUGINFO	D0RE9W	PMID27539678-Compound-7	Patented
T86014	DRUGINFO	D0TR9T	PMID27539678-Compound-17	Patented
T86014	DRUGINFO	D0VB2X	PMID27539678-Compound-9	Patented
T86014	DRUGINFO	D02YQJ	B-5354a	Terminated
T86014	DRUGINFO	D0O0JH	F-12509A	Terminated
T86014	DRUGINFO	D00YNY	VPC-94075	Investigative
T86014	DRUGINFO	D05SLY	SK1-I	Investigative
T86014	DRUGINFO	D08SND	PF-543	Investigative

T07279	TARGETID	T07279
T07279	FORMERID	TTDNR00746
T07279	UNIPROID	PIM2_HUMAN
T07279	TARGNAME	Serine/threonine-protein kinase pim-2 (PIM2)
T07279	GENENAME	PIM2
T07279	TARGTYPE	Clinical trial
T07279	SYNONYMS	Pim-2h; PIM2
T07279	FUNCTION	Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression, the regulation of cap-dependent protein translation and through survival signaling by phosphorylation of a pro-apoptotic protein, BAD. Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase transcriptional activity. The stabilization of MYC exerted by PIM2 might explain partly the strong synergism between these 2 oncogenes in tumorigenesis. Regulates cap-dependent protein translation in a mammalian target of rapamycin complex 1 (mTORC1)-independent manner and in parallel to the PI3K-Akt pathway. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti- apoptotic protein Bcl-X(L)/BCL2L1. Promotes cell survival in response to a variety of proliferative signals via positive regulation of the I-kappa-B kinase/NF-kappa-B cascade; this process requires phosphorylation of MAP3K8/COT. Isoform 1 is less active in this respect. Promotes growth factor-independent proliferation by phosphorylation of cell cycle factors such as CDKN1A and CDKN1B. Involved in the positive regulation of chondrocyte survival and autophagy in the epiphyseal growth plate.
T07279	PDBSTRUC	4X7Q; 2IWI
T07279	BIOCLASS	Kinase
T07279	ECNUMBER	EC 2.7.11.1
T07279	SEQUENCE	MLTKPLQGPPAPPGTPTPPPGGKDREAFEAEYRLGPLLGKGGFGTVFAGHRLTDRLQVAIKVIPRNRVLGWSPLSDSVTCPLEVALLWKVGAGGGHPGVIRLLDWFETQEGFMLVLERPLPAQDLFDYITEKGPLGEGPSRCFFGQVVAAIQHCHSRGVVHRDIKDENILIDLRRGCAKLIDFGSGALLHDEPYTDFDGTRVYSPPEWISRHQYHALPATVWSLGILLYDMVCGDIPFERDQEILEAELHFPAHVSPDCCALIRRCLAPKPSSRPSLEEILLDPWMQTPAEDVPLNPSKGGPAPLAWSLLP
T07279	DRUGINFO	D07EHV	LGH-447	Phase 1/2
T07279	DRUGINFO	D00IFR	AZD1208	Phase 1
T07279	DRUGINFO	D0V9MV	IDDBCP226234	Investigative
T07279	DRUGINFO	D06UKS	PMID21982499C14k	Investigative

T65501	TARGETID	T65501
T65501	FORMERID	TTDR01100
T65501	UNIPROID	DNM3B_HUMAN
T65501	TARGNAME	DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
T65501	GENENAME	DNMT3B
T65501	TARGTYPE	Clinical trial
T65501	SYNONYMS	M.HsaIIIB; Dnmt3b; DNA methyltransferase HsaIIIB; DNA methyltransferase 3B; DNA MTase HsaIIIB; DNA (cytosine-5)-methyltransferase 3B
T65501	FUNCTION	DNA methylation is coordinated with methylation of histones. May preferentially methylates nucleosomal DNA within the nucleosome core region. May function as transcriptional co-repressor by associating with CBX4 and independently of DNA methylation. Seems to be involved in gene silencing. In association with DNMT1 and via the recruitment of CTCFL/BORIS, involved in activation of BAG1 gene expression by modulating dimethylation of promoter histone H3 at H3K4 and H3K9. Isoforms 4 and 5 are probably not functional due to the deletion of two conserved methyltransferase motifs. Function as transcriptional corepressor by associating with ZHX1. Required for DUX4 silencing in somatic cells. Required for genome-wide de novo methylation and is essential for the establishment of DNA methylation patterns during development.
T65501	PDBSTRUC	5NVO; 5NV7; 5NV2; 5NV0; 5NRV
T65501	BIOCLASS	Methyltransferase
T65501	ECNUMBER	EC 2.1.1.37
T65501	SEQUENCE	MKGDTRHLNGEEDAGGREDSILVNGACSDQSSDSPPILEAIRTPEIRGRRSSSRLSKREVSSLLSYTQDLTGDGDGEDGDGSDTPVMPKLFRETRTRSESPAVRTRNNNSVSSRERHRPSPRSTRGRQGRNHVDESPVEFPATRSLRRRATASAGTPWPSPPSSYLTIDLTDDTEDTHGTPQSSSTPYARLAQDSQQGGMESPQVEADSGDGDSSEYQDGKEFGIGDLVWGKIKGFSWWPAMVVSWKATSKRQAMSGMRWVQWFGDGKFSEVSADKLVALGLFSQHFNLATFNKLVSYRKAMYHALEKARVRAGKTFPSSPGDSLEDQLKPMLEWAHGGFKPTGIEGLKPNNTQPVVNKSKVRRAGSRKLESRKYENKTRRRTADDSATSDYCPAPKRLKTNCYNNGKDRGDEDQSREQMASDVANNKSSLEDGCLSCGRKNPVSFHPLFEGGLCQTCRDRFLELFYMYDDDGYQSYCTVCCEGRELLLCSNTSCCRCFCVECLEVLVGTGTAAEAKLQEPWSCYMCLPQRCHGVLRRRKDWNVRLQAFFTSDTGLEYEAPKLYPAIPAARRRPIRVLSLFDGIATGYLVLKELGIKVGKYVASEVCEESIAVGTVKHEGNIKYVNDVRNITKKNIEEWGPFDLVIGGSPCNDLSNVNPARKGLYEGTGRLFFEFYHLLNYSRPKEGDDRPFFWMFENVVAMKVGDKRDISRFLECNPVMIDAIKVSAAHRARYFWGNLPGMNRPVIASKNDKLELQDCLEYNRIAKLKKVQTITTKSNSIKQGKNQLFPVVMNGKEDVLWCTELERIFGFPVHYTDVSNMGRGARQKLLGRSWSVPVIRHLFAPLKDYFACE
T65501	DRUGINFO	D07SDQ	Curcumin	Phase 3
T65501	DRUGINFO	D02WRM	PMID27376512-Compound-MTC-424	Patented
T65501	DRUGINFO	D0HA0J	PMID27376512-Compound-MTC-427	Patented
T65501	DRUGINFO	D0QY0N	PMID27376512-Compound-MTC-422 	Patented
T65501	DRUGINFO	D0W9VZ	PMID27376512-Compound-MTC-423	Patented
T65501	DRUGINFO	D01VNN	NSC-622444	Investigative
T65501	DRUGINFO	D03PWU	NSC-138419	Investigative
T65501	DRUGINFO	D06RGX	NSC-319745	Investigative
T65501	DRUGINFO	D06VVV	NSC-348926	Investigative
T65501	DRUGINFO	D07VWC	NSC-401077	Investigative
T65501	DRUGINFO	D08TGQ	S-tubercidinylhomocysteine	Investigative
T65501	DRUGINFO	D0A2ZH	NSC-106084	Investigative
T65501	DRUGINFO	D0C4NA	NSC-154957	Investigative
T65501	DRUGINFO	D0FN7C	NSC-54162	Investigative
T65501	DRUGINFO	D0G9NS	NSC-57893	Investigative
T65501	DRUGINFO	D0H1YK	NSC-56071	Investigative
T65501	DRUGINFO	D0I5JP	NSC-137546	Investigative
T65501	DRUGINFO	D0LS2U	NSC-623548	Investigative
T65501	DRUGINFO	D0MP7N	NSC-345763	Investigative
T65501	DRUGINFO	D0W5SZ	NSC-158324	Investigative
T65501	DRUGINFO	D09CLP	(L-)-S-adenosyl-L-homocysteine	Investigative
T65501	DRUGINFO	D0J5VK	NSC-622445	Investigative

T84133	TARGETID	T84133
T84133	FORMERID	TTDNC00456
T84133	UNIPROID	PDE10_HUMAN
T84133	TARGNAME	Phosphodiesterase 10A (PDE10)
T84133	GENENAME	PDE10A
T84133	TARGTYPE	Clinical trial
T84133	SYNONYMS	cAMP and cAMPinhibited cGMP 3',5'cyclic phosphodiesterase 10A; cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A
T84133	FUNCTION	Can hydrolyze both cAMP and cGMP, but has higher affinity for cAMP and is more efficient with cAMP as substrate. May play a critical role in regulating cAMP and cGMP levels in the striatum, a region of the brain that contributes to the control of movement and cognition. Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides.
T84133	PDBSTRUC	6MSC; 6MSA; 6IJI; 6IJH; 5ZNL
T84133	BIOCLASS	Phosphoric diester hydrolase
T84133	ECNUMBER	EC 3.1.4.17
T84133	SEQUENCE	MRIEERKSQHLTGLTDEKVKAYLSLHPQVLDEFVSESVSAETVEKWLKRKNNKSEDESAPKEVSRYQDTNMQGVVYELNSYIEQRLDTGGDNQLLLYELSSIIKIATKADGFALYFLGECNNSLCIFTPPGIKEGKPRLIPAGPITQGTTVSAYVAKSRKTLLVEDILGDERFPRGTGLESGTRIQSVLCLPIVTAIGDLIGILELYRHWGKEAFCLSHQEVATANLAWASVAIHQVQVCRGLAKQTELNDFLLDVSKTYFDNIVAIDSLLEHIMIYAKNLVNADRCALFQVDHKNKELYSDLFDIGEEKEGKPVFKKTKEIRFSIEKGIAGQVARTGEVLNIPDAYADPRFNREVDLYTGYTTRNILCMPIVSRGSVIGVVQMVNKISGSAFSKTDENNFKMFAVFCALALHCANMYHRIRHSECIYRVTMEKLSYHSICTSEEWQGLMQFTLPVRLCKEIELFHFDIGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVIGLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEETATWISSPSVAQKAAASED
T84133	DRUGINFO	D09UZL	TAK-063	Phase 2
T84133	DRUGINFO	D0OH2W	PF-02545920	Phase 2
T84133	DRUGINFO	D0U3QK	OMS824	Phase 2
T84133	DRUGINFO	DC29HL	Lu AF11167	Phase 2
T84133	DRUGINFO	DB82TO	Tofisopam	Phase 2
T84133	DRUGINFO	D09GPI	FRM-6308	Phase 1b
T84133	DRUGINFO	D0LB6D	RG7203	Phase 1
T84133	DRUGINFO	D0X0PP	AMG 579	Phase 1
T84133	DRUGINFO	DJ0P6A	PBF-999	Phase 1
T84133	DRUGINFO	D00YOY	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 2	Patented
T84133	DRUGINFO	D01ITP	Triazolo-pyridine derivative 5	Patented
T84133	DRUGINFO	D02PFP	PMID27321640-Compound-58	Patented
T84133	DRUGINFO	D05VBJ	Triazolo-pyridine derivative 4	Patented
T84133	DRUGINFO	D07EUB	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 3	Patented
T84133	DRUGINFO	D07NRP	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 4	Patented
T84133	DRUGINFO	D07ZTT	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 5	Patented
T84133	DRUGINFO	D09BDD	1,2,4-triazole [4,3-a]quinoxaline derivative 1	Patented
T84133	DRUGINFO	D09RWM	PMID27321640-Compound-59	Patented
T84133	DRUGINFO	D0A8EV	Triazolo-pyridine derivative 6	Patented
T84133	DRUGINFO	D0D0QT	Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 2	Patented
T84133	DRUGINFO	D0D4YR	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 1	Patented
T84133	DRUGINFO	D0FV3G	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 6	Patented
T84133	DRUGINFO	D0I5UY	Imidazo[5,1-c][1,2,4]benzotriazine derivative 2	Patented
T84133	DRUGINFO	D0J6KS	1,2,4-triazole [4,3-a]quinoxaline derivative 3	Patented
T84133	DRUGINFO	D0J8YF	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 8	Patented
T84133	DRUGINFO	D0JJ8K	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 7	Patented
T84133	DRUGINFO	D0L6AM	Imidazo[5,1-c][1,2,4]benzotriazine derivative 4	Patented
T84133	DRUGINFO	D0LI6Z	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 3	Patented
T84133	DRUGINFO	D0MK7X	Imidazo[5,1-c][1,2,4]benzotriazine derivative 3	Patented
T84133	DRUGINFO	D0PP8O	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 6	Patented
T84133	DRUGINFO	D0QE7X	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 4	Patented
T84133	DRUGINFO	D0QI8G	Imidazo[5,1-c][1,2,4]benzotriazine derivative 1	Patented
T84133	DRUGINFO	D0RI3W	1,2,4-triazole [4,3-a]quinoxaline derivative 2	Patented
T84133	DRUGINFO	D0SV1I	Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 3	Patented
T84133	DRUGINFO	D0U3KV	Triazolo-pyridine derivative 2	Patented
T84133	DRUGINFO	D0X2UO	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 5	Patented
T84133	DRUGINFO	D0Z4IA	Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 1	Patented
T84133	DRUGINFO	D0Z8VY	Triazolo-pyridine derivative 3	Patented
T84133	DRUGINFO	D01LSP	Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1	Patented
T84133	DRUGINFO	D0T8WU	Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2	Patented

T61722	TARGETID	T61722
T61722	FORMERID	TTDC00237
T61722	UNIPROID	PD2R2_HUMAN
T61722	TARGNAME	Prostaglandin D2 receptor 2 (PTGDR2)
T61722	GENENAME	PTGDR2
T61722	TARGTYPE	Clinical trial
T61722	SYNONYMS	PTGDR2; Chemoattractant receptor-homologous molecule expressed on Th2 cells; CD294
T61722	FUNCTION	Receptor for prostaglandin D2 (PGD2). Coupled to the G(i)-protein. Receptor activation may result in pertussis toxin- sensitive decreases in cAMP levels and Ca(2+) mobilization. PI3K signaling is also implicated in mediating PTGDR2 effects. PGD2 induced receptor internalization. CRTH2 internalization can be regulated by diverse kinases such as, PKC, PKA, ADRBK1/GRK2, GPRK5/GRK5 and GRK6. Receptoractivation is responsible, at least in part, in immune regulation and allergic/inflammation responses.
T61722	PDBSTRUC	6D27; 6D26
T61722	BIOCLASS	GPCR rhodopsin
T61722	SEQUENCE	MSANATLKPLCPILEQMSRLQSHSNTSIRYIDHAAVLLHGLASLLGLVENGVILFVVGCRMRQTVVTTWVLHLALSDLLASASLPFFTYFLAVGHSWELGTTFCKLHSSIFFLNMFASGFLLSAISLDRCLQVVRPVWAQNHRTVAAAHKVCLVLWALAVLNTVPYFVFRDTISRLDGRIMCYYNVLLLNPGPDRDATCNSRQVALAVSKFLLAFLVPLAIIASSHAAVSLRLQHRGRRRPGRFVRLVAAVVAAFALCWGPYHVFSLLEARAHANPGLRPLVWRGLPFVTSLAFFNSVANPVLYVLTCPDMLRKLRRSLRTVLESVLVDDSELGGAGSSRRRRTSSTARSASPLALCSRPEEPRGPARLLGWLLGSCAASPQTGPLNRALSSTSS
T61722	DRUGINFO	D0WL5V	LAROPIPRANT	Phase 4
T61722	DRUGINFO	DH7F9S	Fevipiprant	Phase 3
T61722	DRUGINFO	D0SP5V	Setipiprant	Phase 3
T61722	DRUGINFO	D0GC5H	Ramatroban	Phase 2/3
T61722	DRUGINFO	D02JND	ADC-3680	Phase 2
T61722	DRUGINFO	D05STL	ARRY-502	Phase 2
T61722	DRUGINFO	D0K1EG	QAV-680	Phase 2
T61722	DRUGINFO	D0RL4X	AP-761	Phase 2
T61722	DRUGINFO	D0T4SG	AZD1981	Phase 2
T61722	DRUGINFO	D0X7EG	OC-000459	Phase 2
T61722	DRUGINFO	DKP0T7	GB001	Phase 2
T61722	DRUGINFO	DVT3F8	BBI-5000	Phase 2
T61722	DRUGINFO	D0YB2Y	AMG 853	Phase 2
T61722	DRUGINFO	D06ESU	AM-461	Phase 1
T61722	DRUGINFO	D0I3TU	MK-7246	Phase 1
T61722	DRUGINFO	D0U1HN	AM-211	Phase 1
T61722	DRUGINFO	D00HTY	PGF2alpha	Clinical trial
T61722	DRUGINFO	D01NGT	RG-7185	Discontinued in Phase 1
T61722	DRUGINFO	D01RVS	AZD5985	Discontinued in Phase 1
T61722	DRUGINFO	D06XSG	AZD8075	Discontinued in Phase 1
T61722	DRUGINFO	D00GHK	13,14-dihydro-15-keto-PGD2	Investigative
T61722	DRUGINFO	D00GUE	2-(2-benzhydryl-4-phenylthiazol-5-yl)acetic acid	Investigative
T61722	DRUGINFO	D01AFV	2-(4-bromo-2-cyclohexylphenoxy)acetic acid	Investigative
T61722	DRUGINFO	D03ZPH	15-deoxy-Delta12,14-PGD2	Investigative
T61722	DRUGINFO	D05GWV	2-(4-cyano-2-cyclohexylphenoxy)acetic acid	Investigative
T61722	DRUGINFO	D05HPB	2-(2-cyclohexyl-4-methoxyphenoxy)acetic acid	Investigative
T61722	DRUGINFO	D07GCA	2-(4-chloro-2-cycloheptylphenoxy)acetic acid	Investigative
T61722	DRUGINFO	D08CLB	2-(2-cyclohexylphenoxy)acetic acid	Investigative
T61722	DRUGINFO	D08KZJ	CAY 10471	Investigative
T61722	DRUGINFO	D09ZSV	2-(4-bromo-2-formylphenoxy)acetic acid	Investigative
T61722	DRUGINFO	D0A0UL	15(S)-15-methyl-PGD2	Investigative
T61722	DRUGINFO	D0C0FU	Methyl 2-(4-chloro-2-cyclohexylphenoxy)acetate	Investigative
T61722	DRUGINFO	D0CS4I	15(R)-15-methyl-PGD2	Investigative
T61722	DRUGINFO	D0E0HT	2-(2-allyl-4-chlorophenoxy)acetic acid	Investigative
T61722	DRUGINFO	D0E3WT	2-(2,4-diphenylthiazol-5-yl)acetic acid	Investigative
T61722	DRUGINFO	D0H2SL	2-(4-bromo-2-tert-butylphenoxy)acetic acid	Investigative
T61722	DRUGINFO	D0HK3U	AM-156	Investigative
T61722	DRUGINFO	D0I8MN	2-(4-chloro-2-cyclopentylphenoxy)acetic acid	Investigative
T61722	DRUGINFO	D0J2PW	2-(2-formylphenoxy)acetic acid	Investigative
T61722	DRUGINFO	D0J5OX	3-(4-chloro-2-cyclohexylphenoxy)propanoic acid	Investigative
T61722	DRUGINFO	D0M2DJ	2-(2-acetyl-4-bromophenoxy)acetic acid	Investigative
T61722	DRUGINFO	D0Q0GY	IW-1221	Investigative
T61722	DRUGINFO	D0QE3V	L-888607	Investigative
T61722	DRUGINFO	D0QH5C	2-(4-chloro-2-cyclohexylphenoxy)acetic acid	Investigative
T61722	DRUGINFO	D0R1KE	2-(4-bromo-2-(hydroxymethyl)phenoxy)acetic acid	Investigative
T61722	DRUGINFO	D0S0BK	2-(2-cyclohexyl-4-methylphenoxy)acetic acid	Investigative
T61722	DRUGINFO	D0U3LA	2-(2-benzoyl-4-bromophenoxy)acetic acid	Investigative
T61722	DRUGINFO	D0U3YW	ADC-9971	Investigative
T61722	DRUGINFO	D0U5PC	4-(4-chloro-2-cyclohexylphenoxy)butanoic acid	Investigative
T61722	DRUGINFO	D0V4PZ	PGD3	Investigative
T61722	DRUGINFO	D0X4NG	13,14-dihydro-15-keto-PGF2alpha	Investigative
T61722	DRUGINFO	D0Y4UG	2-(2-cyclohexyl-4-fluorophenoxy)acetic acid	Investigative
T61722	DRUGINFO	D01RQK	15-deoxy-Delta12,14-PGJ2	Investigative
T61722	DRUGINFO	D0MS3D	Delta12-PGJ2	Investigative
T61722	DRUGINFO	D0WV5J	L-888,291	Investigative
T61722	DRUGINFO	D0Y6OX	PGJ2	Investigative
T61722	DRUGINFO	D06KBO	PGD2	Investigative
T61722	DRUGINFO	D03PLH	U46619	Investigative

T92463	TARGETID	T92463
T92463	FORMERID	TTDR01346
T92463	UNIPROID	RIPK2_HUMAN
T92463	TARGNAME	RIP2 messenger RNA (RIP2 mRNA)
T92463	GENENAME	RIPK2
T92463	TARGTYPE	Clinical trial
T92463	SYNONYMS	UNQ277/PRO314/PRO34092 (mRNA); Tyrosine-protein kinase RIPK2 (mRNA); Receptor-interacting serine/threonine-protein kinase 2 (mRNA); Receptor-interacting protein 2 (mRNA); RIP2 (mRNA); RIP-like-interacting CLARP kinase (mRNA); RIP-2 (mRNA); RICK (mRNA); CARDIAK (mRNA); CARD-containing interleukin-1 beta-converting enzyme-associated kinase (mRNA); CARD-containing IL-1 beta ICE-kinase (mRNA)
T92463	FUNCTION	Upon stimulation by bacterial peptidoglycans, NOD1 and NOD2 are activated, oligomerize and recruit RIPK2 through CARD-CARD domains. Contributes to the tyrosine phosphorylation of the guanine exchange factor ARHGEF2 through Src tyrosine kinase leading to NF-kappaB activation by NOD2. Once recruited, RIPK2 autophosphorylates and undergoes 'Lys-63'-linked polyubiquitination by E3 ubiquitin ligases XIAP, BIRC2 and BIRC3. The polyubiquitinated protein mediates the recruitment of MAP3K7/TAK1 to IKBKG/NEMO and induces 'Lys-63'-linked polyubiquitination of IKBKG/NEMO and subsequent activation of IKBKB/IKKB. In turn, NF-kappa-B is released from NF-kappa-B inhibitors and translocates into the nucleus where it activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. Plays also a role during engagement of the T-cell receptor (TCR) in promoting BCL10 phosphorylation and subsequent NF-kappa-B activation. Serine/threonine/tyrosine kinase that plays an essential role in modulation of innate and adaptive immune responses.
T92463	PDBSTRUC	6HMX; 6GGS; 6GFJ; 6FU5; 6ES0
T92463	BIOCLASS	mRNA target
T92463	ECNUMBER	EC 2.7.11.1
T92463	SEQUENCE	MNGEAICSALPTIPYHKLADLRYLSRGASGTVSSARHADWRVQVAVKHLHIHTPLLDSERKDVLREAEILHKARFSYILPILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYPDVAWPLRFRILHEIALGVNYLHNMTPPLLHHDLKTQNILLDNEFHVKIADFGLSKWRMMSLSQSRSSKSAPEGGTIIYMPPENYEPGQKSRASIKHDIYSYAVITWEVLSRKQPFEDVTNPLQIMYSVSQGHRPVINEESLPYDIPHRARMISLIESGWAQNPDERPSFLKCLIELEPVLRTFEEITFLEAVIQLKKTKLQSVSSAIHLCDKKKMELSLNIPVNHGPQEESCGSSQLHENSGSPETSRSLPAPQDNDFLSRKAQDCYFMKLHHCPGNHSWDSTISGSQRAAFCDHKTTPCSSAIINPLSTAGNSERLQPGIAQQWIQSKREDIVNQMTEACLNQSLDALLSRDLIMKEDYELVSTKPTRTSKVRQLLDTTDIQGEEFAKVIVQKLKDNKQMGLQPYPEILVVSRSPSLNLLQNKSM
T92463	DRUGINFO	D06CIJ	ISIS-CRP	Phase 1
T92463	DRUGINFO	D02AOC	ISIS 104258	Investigative
T92463	DRUGINFO	D05EHP	ISIS 104254	Investigative
T92463	DRUGINFO	D07RJW	ISIS 104211	Investigative
T92463	DRUGINFO	D0F8WV	ISIS 104257	Investigative
T92463	DRUGINFO	D0J1DV	ISIS 104256	Investigative
T92463	DRUGINFO	D0PE2Y	ISIS 104255	Investigative
T92463	DRUGINFO	D0Q0IN	ISIS 104253	Investigative
T92463	DRUGINFO	D0U2QT	Src kinase inhibitor I	Investigative
T92463	DRUGINFO	D0GT8N	NM-PP1	Investigative

T10482	TARGETID	T10482
T10482	FORMERID	TTDI02677
T10482	UNIPROID	FA12_HUMAN
T10482	TARGNAME	Factor XII messenger RNA (FA12 mRNA)
T10482	GENENAME	F12
T10482	TARGTYPE	Clinical trial
T10482	SYNONYMS	Hageman factor (mRNA); HAF (mRNA); Coagulation factor XII (mRNA)
T10482	FUNCTION	Prekallikrein is cleaved by factor XII to form kallikrein, which then cleaves factor XII first to alpha-factor XIIa and then trypsin cleaves it to beta-factor XIIa. Alpha-factor XIIa activates factor XI to factor XIa. Factor XII is a serum glycoprotein that participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin.
T10482	PDBSTRUC	6B77; 6B74; 4XE4; 4XDE; 4BDX
T10482	BIOCLASS	mRNA target
T10482	ECNUMBER	EC 3.4.21.38
T10482	SEQUENCE	MRALLLLGFLLVSLESTLSIPPWEAPKEHKYKAEEHTVVLTVTGEPCHFPFQYHRQLYHKCTHKGRPGPQPWCATTPNFDQDQRWGYCLEPKKVKDHCSKHSPCQKGGTCVNMPSGPHCLCPQHLTGNHCQKEKCFEPQLLRFFHKNEIWYRTEQAAVARCQCKGPDAHCQRLASQACRTNPCLHGGRCLEVEGHRLCHCPVGYTGAFCDVDTKASCYDGRGLSYRGLARTTLSGAPCQPWASEATYRNVTAEQARNWGLGGHAFCRNPDNDIRPWCFVLNRDRLSWEYCDLAQCQTPTQAAPPTPVSPRLHVPLMPAQPAPPKPQPTTRTPPQSQTPGALPAKREQPPSLTRNGPLSCGQRLRKSLSSMTRVVGGLVALRGAHPYIAALYWGHSFCAGSLIAPCWVLTAAHCLQDRPAPEDLTVVLGQERRNHSCEPCQTLAVRSYRLHEAFSPVSYQHDLALLRLQEDADGSCALLSPYVQPVCLPSGAARPSETTLCQVAGWGHQFEGAEEYASFLQEAQVPFLSLERCSAPDVHGSSILPGMLCAGFLEGGTDACQGDSGGPLVCEDQAAERRLTLQGIISWGSGCGDRNKPGVYTDVAYYLAWIREHTVS
T10482	DRUGINFO	D0R7EA	methyl 5-[(4-tert-butylbenzoyl)amino]-2H-1,2,4-triazole-3-carboxylate	Clinical trial

T15803	TARGETID	T15803
T15803	FORMERID	TTDC00330
T15803	UNIPROID	FA11_HUMAN
T15803	TARGNAME	Factor XI messenger RNA (F11 mRNA)
T15803	GENENAME	F11
T15803	TARGTYPE	Clinical trial
T15803	SYNONYMS	Plasma thromboplastin antecedent (mRNA); PTA (mRNA); FXI (mRNA); Coagulation factor XI (mRNA)
T15803	FUNCTION	Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX.
T15803	PDBSTRUC	6R8X; 6I58; 6C0S; 6AOD; 5WB6
T15803	BIOCLASS	mRNA target
T15803	ECNUMBER	EC 3.4.21.27
T15803	SEQUENCE	MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV
T15803	DRUGINFO	D0KY7S	ISIS-FXI	Phase 2
T15803	DRUGINFO	DB6XD8	BMS-986177	Phase 2
T15803	DRUGINFO	DD2C5E	IONIS-416858	Phase 2
T15803	DRUGINFO	D05TKW	alpha-ketothiazole analogue 36	Clinical trial
T15803	DRUGINFO	D0F7ZH	FXI-AS1	Investigative

T46521	TARGETID	T46521
T46521	FORMERID	TTDC00332
T46521	UNIPROID	ANDR_HUMAN
T46521	TARGNAME	Androgen receptor messenger RNA (AR mRNA)
T46521	GENENAME	AR
T46521	TARGTYPE	Clinical trial
T46521	SYNONYMS	Testosterone receptor (mRNA); Nuclear receptor subfamily 3 group C member 4 (mRNA); NR3C4 (mRNA); Dihydrotestosterone receptor (mRNA); DHTR (mRNA); Androgen receptor (mRNA)
T46521	FUNCTION	Transcription factor activity is modulated by bound coactivator and corepressor proteins like ZBTB7A that recruits NCOR1 and NCOR2 to the androgen response elements/ARE on target genes, negatively regulating androgen receptor signaling and androgen-induced cell proliferation. Transcription activation is also down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3. Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues.
T46521	PDBSTRUC	5VO4; 5V8Q; 5T8J; 5T8E; 5JJM
T46521	BIOCLASS	mRNA target
T46521	SEQUENCE	MEVQLGLGRVYPRPPSKTYRGAFQNLFQSVREVIQNPGPRHPEAASAAPPGASLLLLQQQQQQQQQQQQQQQQQQQQQQQETSPRQQQQQQGEDGSPQAHRRGPTGYLVLDEEQQPSQPQSALECHPERGCVPEPGAAVAASKGLPQQLPAPPDEDDSAAPSTLSLLGPTFPGLSSCSADLKDILSEASTMQLLQQQQQEAVSEGSSSGRAREASGAPTSSKDNYLGGTSTISDNAKELCKAVSVSMGLGVEALEHLSPGEQLRGDCMYAPLLGVPPAVRPTPCAPLAECKGSLLDDSAGKSTEDTAEYSPFKGGYTKGLEGESLGCSGSAAAGSSGTLELPSTLSLYKSGALDEAAAYQSRDYYNFPLALAGPPPPPPPPHPHARIKLENPLDYGSAWAAAAAQCRYGDLASLHGAGAAGPGSGSPSAAASSSWHTLFTAEEGQLYGPCGGGGGGGGGGGGGGGGGGGGGGGEAGAVAPYGYTRPPQGLAGQESDFTAPDVWYPGGMVSRVPYPSPTCVKSEMGPWMDSYSGPYGDMRLETARDHVLPIDYYFPPQKTCLICGDEASGCHYGALTCGSCKVFFKRAAEGKQKYLCASRNDCTIDKFRRKNCPSCRLRKCYEAGMTLGARKLKKLGNLKLQEEGEASSTTSPTEETTQKLTVSHIEGYECQPIFLNVLEAIEPGVVCAGHDNNQPDSFAALLSSLNELGERQLVHVVKWAKALPGFRNLHVDDQMAVIQYSWMGLMVFAMGWRSFTNVNSRMLYFAPDLVFNEYRMHKSRMYSQCVRMRHLSQEFGWLQITPQEFLCMKALLLFSIIPVDGLKNQKFFDELRMNYIKELDRIIACKRKNPTSCSRRFYQLTKLLDSVQPIARELHQFTFDLLIKSHMVSVDFPEMMAEIISVQVPKILSGKVKPIYFHTQ
T46521	DRUGINFO	D04DJN	Dihydrotestosterone	Phase 4
T46521	DRUGINFO	D0L3HU	BAY 86-5044	Phase 2
T46521	DRUGINFO	D0SD9Z	TRC-253	Phase 1/2
T46521	DRUGINFO	D3BZ0H	IONIS-AR-2.5Rx	Phase 1/2
T46521	DRUGINFO	D03POY	ISIS-AR	Phase 1
T46521	DRUGINFO	D09RND	EZN-4176	Phase 1
T46521	DRUGINFO	D0O4QB	EUGENOL	Patented
T46521	DRUGINFO	D0L5KF	RU-58841	Discontinued in Phase 1
T46521	DRUGINFO	D00BLY	4-(isopropylthio)-2-methoxybenzonitrile	Investigative
T46521	DRUGINFO	D00CDF	andarine	Investigative
T46521	DRUGINFO	D01THF	4-(mesitylthio)-2-methoxybenzonitrile	Investigative
T46521	DRUGINFO	D02CXU	3-methoxy-4-(m-tolyloxy)benzonitrile	Investigative
T46521	DRUGINFO	D02ZEE	2'-Hydroxy-3-methoxy-biphenyl-4-carbonitrile	Investigative
T46521	DRUGINFO	D03MQA	4-(cyclopropylmethylthio)-2-methoxybenzonitrile	Investigative
T46521	DRUGINFO	D03VQC	4-(isopentylthio)-2-methoxybenzonitrile	Investigative
T46521	DRUGINFO	D03WHD	6-amino-4-trifluoromethylquinolin-2(1H)-one	Investigative
T46521	DRUGINFO	D04KPW	2-methoxy-4-(m-tolyloxy)benzonitrile	Investigative
T46521	DRUGINFO	D04PLB	2-chloro-4-(o-tolyloxy)benzonitrile	Investigative
T46521	DRUGINFO	D04QAT	4-(p-tolyloxy)-2-(trifluoromethyl)benzonitrile	Investigative
T46521	DRUGINFO	D04USO	4-(mesityloxy)-2-(trifluoromethyl)benzonitrile	Investigative
T46521	DRUGINFO	D05FPU	4-(butylthio)-2-methoxybenzonitrile	Investigative
T46521	DRUGINFO	D06JPP	LG-121071	Investigative
T46521	DRUGINFO	D06PRV	3-chloro-4-(o-tolylthio)benzonitrile	Investigative
T46521	DRUGINFO	D06WNK	4-(2,6-dimethylphenylthio)-2-methoxybenzonitrile	Investigative
T46521	DRUGINFO	D06YKU	NSC-26745	Investigative
T46521	DRUGINFO	D06ZZM	3-chloro-4-(o-tolyloxy)benzonitrile	Investigative
T46521	DRUGINFO	D07GCR	4-(mesitylthio)-2-(trifluoromethyl)benzonitrile	Investigative
T46521	DRUGINFO	D07QFN	3-methoxy-4-(p-tolyloxy)benzonitrile	Investigative
T46521	DRUGINFO	D07TVI	PF-0998425	Investigative
T46521	DRUGINFO	D08DHC	4-(o-tolyloxy)-2-(trifluoromethyl)benzonitrile	Investigative
T46521	DRUGINFO	D08FZN	6-N-propyl -4-trifluoromethylquinolin-2(1H)-one	Investigative
T46521	DRUGINFO	D08FZR	2-methoxy-4-(2-methoxyphenylthio)benzonitrile	Investigative
T46521	DRUGINFO	D08RCS	2-methoxy-4-(propylthio)benzonitrile	Investigative
T46521	DRUGINFO	D09SJY	2-methoxy-4-(o-tolyloxy)benzonitrile	Investigative
T46521	DRUGINFO	D0B2JG	4-(m-tolyloxy)-2-(trifluoromethyl)benzonitrile	Investigative
T46521	DRUGINFO	D0BU5X	4-(cyclobutylmethylthio)-2-methoxybenzonitrile	Investigative
T46521	DRUGINFO	D0F5JY	BMS-564929	Investigative
T46521	DRUGINFO	D0FI1I	3-methoxy-4-(o-tolyloxy)benzonitrile	Investigative
T46521	DRUGINFO	D0G0XB	3,2'-bis-trifluoromethyl-biphenyl-4-carbonitrile	Investigative
T46521	DRUGINFO	D0G3IT	RU-56187	Investigative
T46521	DRUGINFO	D0I5YU	4-(propylthio)-2-(trifluoromethyl)benzonitrile	Investigative
T46521	DRUGINFO	D0L7OC	4-(butylthio)-2-(trifluoromethyl)benzonitrile	Investigative
T46521	DRUGINFO	D0M0RS	LGD-2226	Investigative
T46521	DRUGINFO	D0O0ZC	6-Hydroxyflavanone	Investigative
T46521	DRUGINFO	D0P0ZQ	4-(isopropylthio)-2-(trifluoromethyl)benzonitrile	Investigative
T46521	DRUGINFO	D0T7LR	2-methoxy-4-(p-tolyloxy)benzonitrile	Investigative
T46521	DRUGINFO	D0U9IR	4-(o-tolylthio)-2-(trifluoromethyl)benzonitrile	Investigative
T46521	DRUGINFO	D0V3UU	YM-175735	Investigative
T46521	DRUGINFO	D0V5HF	5-Methoxyflavone	Investigative
T46521	DRUGINFO	D0VE6A	4-(isopentylthio)-2-(trifluoromethyl)benzonitrile	Investigative
T46521	DRUGINFO	D02RQP	bisphenol A	Investigative
T46521	DRUGINFO	D06BLF	1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane	Investigative
T46521	DRUGINFO	D06VZE	[3H]mibolerone	Investigative
T46521	DRUGINFO	D07KWO	RU-43044	Investigative
T46521	DRUGINFO	D01ETZ	[3H]methyltrienolone	Investigative
T46521	DRUGINFO	D09OKK	LG-120838	Investigative
T46521	DRUGINFO	D0G5OV	WAY-255348	Investigative
T46521	DRUGINFO	D0XS0R	Epierenone	Investigative
T46521	DRUGINFO	D08KQM	LGD-5552	Investigative
T46521	DRUGINFO	D0GR5L	AL-43	Investigative
T46521	DRUGINFO	D0J7XZ	CP-409069	Investigative
T46521	DRUGINFO	D0L5IC	CP-394531	Investigative
T46521	DRUGINFO	D0S0RK	flavone	Investigative
T46521	DRUGINFO	D00RIX	APIGENIN	Investigative
T46521	DRUGINFO	D0G3TK	KAEMPFEROL	Investigative

T41515	TARGETID	T41515
T41515	FORMERID	TTDR01438
T41515	UNIPROID	FGFR4_HUMAN
T41515	TARGNAME	FGFR4 messenger RNA (FGFR4 mRNA)
T41515	GENENAME	FGFR4
T41515	TARGTYPE	Clinical trial
T41515	SYNONYMS	TKF (mRNA); JTK2 (mRNA); FGFR-4 (mRNA); CD334 (mRNA)
T41515	FUNCTION	Required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. Phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes SRC-dependent phosphorylation of the matrix protease MMP14 and its lysosomal degradation. FGFR4 signaling is down-regulated by receptor internalization and degradation; MMP14 promotes internalization and degradation of FGFR4. Mutations that lead to constitutive kinase activation or impair normal FGFR4 inactivation lead to aberrant signaling. Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis.
T41515	PDBSTRUC	6JPJ; 5XFJ; 5XFF; 5NWZ; 5NUD
T41515	BIOCLASS	mRNA target
T41515	ECNUMBER	EC 2.7.10.1
T41515	SEQUENCE	MRLLLALLGVLLSVPGPPVLSLEASEEVELEPCLAPSLEQQEQELTVALGQPVRLCCGRAERGGHWYKEGSRLAPAGRVRGWRGRLEIASFLPEDAGRYLCLARGSMIVLQNLTLITGDSLTSSNDDEDPKSHRDPSNRHSYPQQAPYWTHPQRMEKKLHAVPAGNTVKFRCPAAGNPTPTIRWLKDGQAFHGENRIGGIRLRHQHWSLVMESVVPSDRGTYTCLVENAVGSIRYNYLLDVLERSPHRPILQAGLPANTTAVVGSDVELLCKVYSDAQPHIQWLKHIVINGSSFGADGFPYVQVLKTADINSSEVEVLYLRNVSAEDAGEYTCLAGNSIGLSYQSAWLTVLPEEDPTWTAAAPEARYTDIILYASGSLALAVLLLLAGLYRGQALHGRHPRPPATVQKLSRFPLARQFSLESGSSGKSSSSLVRGVRLSSSGPALLAGLVSLDLPLDPLWEFPRDRLVLGKPLGEGCFGQVVRAEAFGMDPARPDQASTVAVKMLKDNASDKDLADLVSEMEVMKLIGRHKNIINLLGVCTQEGPLYVIVECAAKGNLREFLRARRPPGPDLSPDGPRSSEGPLSFPVLVSCAYQVARGMQYLESRKCIHRDLAARNVLVTEDNVMKIADFGLARGVHHIDYYKKTSNGRLPVKWMAPEALFDRVYTHQSDVWSFGILLWEIFTLGGSPYPGIPVEELFSLLREGHRMDRPPHCPPELYGLMRECWHAAPSQRPTFKQLVEALDKVLLAVSEEYLDLRLTFGPYSPSGGDASSTCSSSDSVFSHDPLPLGSSSFPFGSGVQT
T41515	DRUGINFO	D0SL8T	ISIS-FGFR4	Phase 2
T41515	DRUGINFO	D08EQD	FGF401	Phase 1/2
T41515	DRUGINFO	D0D6XT	H3B-6527	Phase 1
T41515	DRUGINFO	D0XZ1D	BLU-554	Phase 1
T41515	DRUGINFO	D0Z0KD	PD-0183812	Terminated
T41515	DRUGINFO	D09XIL	Ro-4396686	Investigative

T37952	TARGETID	T37952
T37952	FORMERID	TTDI02237
T37952	UNIPROID	KSYK_HUMAN
T37952	TARGNAME	SYK messenger RNA (SYK mRNA)
T37952	GENENAME	SYK
T37952	TARGTYPE	Clinical trial
T37952	SYNONYMS	p72-Syk (mRNA); Spleen tyrosine kinase (mRNA)
T37952	FUNCTION	Regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. Assembles into signaling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosine-phosphorylated ITAM domains. The association with the receptor can also be indirect and mediated by adapter proteins containing ITAM or partial hemITAM domains. The phosphorylation of the ITAM domains is generally mediated by SRC subfamily kinases upon engagement of the receptor. More rarely signal transduction via SYK could be ITAM-independent. Direct downstream effectors phosphorylated by SYK include VAV1, PLCG1, PI-3-kinase, LCP2 and BLNK. Initially identified as essential in B-cell receptor (BCR) signaling, it is necessary for the maturation of B-cells most probably at the pro-B to pre-B transition. Activated upon BCR engagement, it phosphorylates and activates BLNK an adapter linking the activated BCR to downstream signaling adapters and effectors. It also phosphorylates and activates PLCG1 and the PKC signaling pathway. It also phosphorylates BTK and regulates its activity in B-cell antigen receptor (BCR)-coupled signaling. In addition to its function downstream of BCR plays also a role in T-cell receptor signaling. Plays also a crucial role in the innate immune response to fungal, bacterial and viral pathogens. It is for instance activated by the membrane lectin CLEC7A. Upon stimulation by fungal proteins, CLEC7A together with SYK activates immune cells inducing the production of ROS. Also activates the inflammasome and NF-kappa-B-mediated transcription of chemokines and cytokines in presence of pathogens. Regulates neutrophil degranulation and phagocytosis through activation of the MAPK signaling cascade. Required for the stimulation of neutrophil phagocytosis by IL15. Also mediates the activation of dendritic cells by cell necrosis stimuli. Also involved in mast cells activation. Involved in interleukin-3/IL3-mediated signaling pathway in basophils. Also functions downstream of receptors mediating cell adhesion. Relays for instance, integrin-mediated neutrophils and macrophages activation and P-selectin receptor/SELPG-mediated recruitment of leukocytes to inflammatory loci. Plays also a role in non-immune processes. It is for instance involved in vascular development where it may regulate blood and lymphatic vascular separation. It is also required for osteoclast development and function. Functions in the activation of platelets by collagen, mediating PLCG2 phosphorylation and activation. May be coupled to the collagen receptor by the ITAM domain-containing FCER1G. Also activated by the membrane lectin CLEC1B that is required for activation of platelets by PDPN/podoplanin. Involved in platelet adhesion being activated by ITGB3 engaged by fibrinogen. Together with CEACAM20, enhances production of the cytokine CXCL8/IL-8 via the NFKB pathway and may thus have a role in the intestinal immune response. Non-receptor tyrosine kinase which mediates signal transduction downstream of a variety of transmembrane receptors including classical immunoreceptors like the B-cell receptor (BCR).
T37952	PDBSTRUC	6HM7; 6HM6; 5Y5U; 5Y5T; 5TT7
T37952	BIOCLASS	mRNA target
T37952	ECNUMBER	EC 2.7.10.2
T37952	SEQUENCE	MASSGMADSANHLPFFFGNITREEAEDYLVQGGMSDGLYLLRQSRNYLGGFALSVAHGRKAHHYTIERELNGTYAIAGGRTHASPADLCHYHSQESDGLVCLLKKPFNRPQGVQPKTGPFEDLKENLIREYVKQTWNLQGQALEQAIISQKPQLEKLIATTAHEKMPWFHGKISREESEQIVLIGSKTNGKFLIRARDNNGSYALCLLHEGKVLHYRIDKDKTGKLSIPEGKKFDTLWQLVEHYSYKADGLLRVLTVPCQKIGTQGNVNFGGRPQLPGSHPATWSAGGIISRIKSYSFPKPGHRKSSPAQGNRQESTVSFNPYEPELAPWAADKGPQREALPMDTEVYESPYADPEEIRPKEVYLDRKLLTLEDKELGSGNFGTVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAEANVMQQLDNPYIVRMIGICEAESWMLVMEMAELGPLNKYLQQNRHVKDKNIIELVHQVSMGMKYLEESNFVHRDLAARNVLLVTQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYAPECINYYKFSSKSDVWSFGVLMWEAFSYGQKPYRGMKGSEVTAMLEKGERMGCPAGCPREMYDLMNLCWTYDVENRPGFAAVELRLRNYYYDVVN
T37952	DRUGINFO	D0TG4S	ASN002	Phase 2

T87875	TARGETID	T87875
T87875	FORMERID	TTDC00286
T87875	UNIPROID	GLR_HUMAN
T87875	TARGNAME	Glucagon receptor messenger RNA (GCGR mRNA)
T87875	GENENAME	GCGR
T87875	TARGTYPE	Clinical trial
T87875	SYNONYMS	Glucagon receptor (mRNA); GLR (mRNA); GL-R (mRNA)
T87875	FUNCTION	Regulates the rate of hepatic glucose production by promoting glycogen hydrolysis and gluconeogenesis. Plays an important role in mediating the responses to fasting. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Promotes activation of adenylate cyclase. Besides, plays a role in signaling via a phosphatidylinositol-calcium second messenger system. G-protein coupled receptor for glucagon that plays a central role in the regulation of blood glucose levels and glucose homeostasis.
T87875	PDBSTRUC	5XEZ; 5EE7; 4LF3; 4L6R; 4ERS
T87875	BIOCLASS	mRNA target
T87875	SEQUENCE	MPPCQPQRPLLLLLLLLACQPQVPSAQVMDFLFEKWKLYGDQCHHNLSLLPPPTELVCNRTFDKYSCWPDTPANTTANISCPWYLPWHHKVQHRFVFKRCGPDGQWVRGPRGQPWRDASQCQMDGEEIEVQKEVAKMYSSFQVMYTVGYSLSLGALLLALAILGGLSKLHCTRNAIHANLFASFVLKASSVLVIDGLLRTRYSQKIGDDLSVSTWLSDGAVAGCRVAAVFMQYGIVANYCWLLVEGLYLHNLLGLATLPERSFFSLYLGIGWGAPMLFVVPWAVVKCLFENVQCWTSNDNMGFWWILRFPVFLAILINFFIFVRIVQLLVAKLRARQMHHTDYKFRLAKSTLTLIPLLGVHEVVFAFVTDEHAQGTLRSAKLFFDLFLSSFQGLLVAVLYCFLNKEVQSELRRRWHRWRLGKVLWEERNTSNHRASSSPGHGPPSKELQFGRGGGSQDSSAETPLAGGLPRLAESPF
T87875	DRUGINFO	D04WIF	ISIS-GCGR	Phase 2
T87875	DRUGINFO	DW7XC5	IONIS-GCGR-Rx	Phase 2
T87875	DRUGINFO	D05LTJ	ISIS 325568	Phase 1

T81892	TARGETID	T81892
T81892	FORMERID	TTDC00280
T81892	UNIPROID	XIAP_HUMAN
T81892	TARGNAME	XIAP messenger RNA (XIAP mRNA)
T81892	GENENAME	XIAP
T81892	TARGTYPE	Clinical trial
T81892	SYNONYMS	hILP (mRNA); hIAP3 (mRNA); hIAP-3 (mRNA); Xlinked IAP (mRNA); X-linked IAP (mRNA); RING-type E3 ubiquitin transferase XIAP (mRNA); Inhibitor of apoptosis protein 3 (mRNA); ILP (mRNA); IAPlike protein (mRNA); IAP3 (mRNA); IAP-like protein (mRNA); IAP-3 (mRNA); E3 ubiquitinprotein ligase XIAP (mRNA); E3 ubiquitin-protein ligase XIAP (mRNA); Baculoviral IAP repeatcontaining protein 4 (mRNA); Baculoviral IAP repeat-containing protein 4 (mRNA); BIRC4 (mRNA); API3 (mRNA)
T81892	FUNCTION	Acts as a direct caspase inhibitor. Directly bind to the active site pocket of CASP3 and CASP7 and obstructs substrate entry. Inactivates CASP9 by keeping it in a monomeric, inactive state. Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and the target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, CASP3, CASP7, CASP8, CASP9, MAP3K2/MEKK2, DIABLO/SMAC, AIFM1, CCS and BIRC5/survivin. Ubiquitinion of CCS leads to enhancement of its chaperone activity toward its physiologic target, SOD1, rather than proteasomal degradation. Ubiquitinion of MAP3K2/MEKK2 and AIFM1 does not lead to proteasomal degradation. Plays a role in copper homeostasis by ubiquitinationg COMMD1 and promoting its proteasomal degradation. Can also function as E3 ubiquitin-protein ligase of the NEDD8 conjugation pathway, targeting effector caspases for neddylation and inactivation. Regulates the BMP signaling pathway and the SMAD and MAP3K7/TAK1 dependent pathways leading to NF-kappa-B and JNK activation. Acts as an important regulator of innate immune signaling via regulation of Nodlike receptors (NLRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8. Acts as a positive regulator of Wnt signaling and ubiquitinates TLE1, TLE2, TLE3, TLE4 and AES. Ubiquitination of TLE3 results in inhibition of its interaction with TCF7L2/TCF4 thereby allowing efficient recruitment and binding of the transcriptional coactivator beta-catenin to TCF7L2/TCF4 that is required to initiate a Wnt-specific transcriptional program. Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, copper homeostasis, mitogenic kinase signaling, cell proliferation, as well as cell invasion and metastasis.
T81892	PDBSTRUC	6QCI; 6EY2; 5OQW; 5O6T; 5M6M
T81892	BIOCLASS	mRNA target
T81892	ECNUMBER	EC 2.3.2.27
T81892	SEQUENCE	MTFNSFEGSKTCVPADINKEEEFVEEFNRLKTFANFPSGSPVSASTLARAGFLYTGEGDTVRCFSCHAAVDRWQYGDSAVGRHRKVSPNCRFINGFYLENSATQSTNSGIQNGQYKVENYLGSRDHFALDRPSETHADYLLRTGQVVDISDTIYPRNPAMYSEEARLKSFQNWPDYAHLTPRELASAGLYYTGIGDQVQCFCCGGKLKNWEPCDRAWSEHRRHFPNCFFVLGRNLNIRSESDAVSSDRNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKCFHCGGGLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVRTTEKTPSLTRRIDDTIFQNPMVQEAIRMGFSFKDIKKIMEEKIQISGSNYKSLEVLVADLVNAQKDSMQDESSQTSLQKEISTEEQLRRLQEEKLCKICMDRNIAIVFVPCGHLVTCKQCAEAVDKCPMCYTVITFKQKIFMS
T81892	DRUGINFO	D01NUR	ASTX660	Phase 2
T81892	DRUGINFO	D0C1JP	AEG35156	Phase 1/2
T81892	DRUGINFO	D05HSW	EMBELIN	Terminated
T81892	DRUGINFO	D09BKS	ARPFAQK-FAM	Investigative
T81892	DRUGINFO	D0E7NV	AVPIAQKSEK-FAM	Investigative
T81892	DRUGINFO	D03KZH	SM-337	Investigative
T81892	DRUGINFO	D0BW7P	SM-131	Investigative
T81892	DRUGINFO	D0O4UQ	BV-6	Investigative
T81892	DRUGINFO	D0Q7TL	SM-122	Investigative
T81892	DRUGINFO	D0VK7M	AZD5582	Investigative

T81358	TARGETID	T81358
T81358	FORMERID	TTDI02039
T81358	UNIPROID	CDC7_HUMAN
T81358	TARGNAME	CDC7-related kinase (CDC7)
T81358	GENENAME	CDC7
T81358	TARGTYPE	Clinical trial
T81358	SYNONYMS	huCdc7; HsCdc7; Cell division cycle 7related protein kinase; Cell division cycle 7-related protein kinase; CDC7related kinase; CDC7L1
T81358	FUNCTION	Can phosphorylates MCM2 and MCM3. Seems to phosphorylate critical substrates that regulate the G1/S phase transition and/or DNA replication.
T81358	PDBSTRUC	5UWR; 5UWQ; 4F9C; 4F9B; 4F9A
T81358	BIOCLASS	Kinase
T81358	ECNUMBER	EC 2.7.11.1
T81358	SEQUENCE	MEASLGIQMDEPMAFSPQRDRFQAEGSLKKNEQNFKLAGVKKDIEKLYEAVPQLSNVFKIEDKIGEGTFSSVYLATAQLQVGPEEKIALKHLIPTSHPIRIAAELQCLTVAGGQDNVMGVKYCFRKNDHVVIAMPYLEHESFLDILNSLSFQEVREYMLNLFKALKRIHQFGIVHRDVKPSNFLYNRRLKKYALVDFGLAQGTHDTKIELLKFVQSEAQQERCSQNKSHIITGNKIPLSGPVPKELDQQSTTKASVKRPYTNAQIQIKQGKDGKEGSVGLSVQRSVFGERNFNIHSSISHESPAVKLMKQSKTVDVLSRKLATKKKAISTKVMNSAVMRKTASSCPASLTCDCYATDKVCSICLSRRQQVAPRAGTPGFRAPEVLTKCPNQTTAIDMWSAGVIFLSLLSGRYPFYKASDDLTALAQIMTIRGSRETIQAAKTFGKSILCSKEVPAQDLRKLCERLRGMDSSTPKLTSDIQGHASHQPAISEKTDHKASCLVQTPPGQYSGNSFKKGDSNSCEHCFDEYNTNLEGWNEVPDEAYDLLDKLLDLNPASRITAEEALLHPFFKDMSL
T81358	DRUGINFO	D03ISJ	BMS-863233	Phase 1/2
T81358	DRUGINFO	D0LL4Y	TAK-931	Phase 1
T81358	DRUGINFO	D0G6QW	PMID26161698-Compound-44	Patented
T81358	DRUGINFO	D03DZO	PHA-767491	Investigative
T81358	DRUGINFO	D0N3LC	PMID24793884C77	Investigative
T81358	DRUGINFO	D08HFG	PMID20873740C18	Investigative
T81358	DRUGINFO	D0RJ8J	PMID24793884C74	Investigative
T81358	DRUGINFO	D0T8NU	PMID19115845C89S	Investigative

T87749	TARGETID	T87749
T87749	FORMERID	TTDR00823
T87749	UNIPROID	GDF8_HUMAN
T87749	TARGNAME	Growth/differentiation factor 8 (GDF-8)
T87749	GENENAME	MSTN
T87749	TARGTYPE	Clinical trial
T87749	SYNONYMS	GDF8
T87749	FUNCTION	Acts specifically as a negative regulator of skeletal muscle growth.
T87749	PDBSTRUC	5NXS; 5NTU; 5F3H; 5F3B
T87749	BIOCLASS	Growth factor
T87749	SEQUENCE	MQKLQLCVYIYLFMLIVAGPVDLNENSEQKENVEKEGLCNACTWRQNTKSSRIEAIKIQILSKLRLETAPNISKDVIRQLLPKAPPLRELIDQYDVQRDDSSDGSLEDDDYHATTETIITMPTESDFLMQVDGKPKCCFFKFSSKIQYNKVVKAQLWIYLRPVETPTTVFVQILRLIKPMKDGTRYTGIRSLKLDMNPGTGIWQSIDVKTVLQNWLKQPESNLGIEIKALDENGHDLAVTFPGPGEDGLNPFLEVKVTDTPKRSRRDFGLDCDEHSTESRCCRYPLTVDFEAFGWDWIIAPKRYKANYCSGECEFVFLQKYPHTHLVHQANPRGSAGPCCTPTKMSPINMLYFNGKEQIIYGKIPAMVVDRCGCS
T87749	DRUGINFO	D00TUR	LY2495655	Phase 2
T87749	DRUGINFO	D00UFZ	AMG 745	Phase 2
T87749	DRUGINFO	D05KKP	PF-06252616	Phase 2
T87749	DRUGINFO	D09GIA	SAR391786	Phase 2
T87749	DRUGINFO	D0OK1N	Domagrozumab	Phase 2
T87749	DRUGINFO	D0T6EE	ACE-031	Phase 2
T87749	DRUGINFO	D0C6IQ	Stamulumab	Phase 1/2

T51407	TARGETID	T51407
T51407	FORMERID	TTDNR00671
T51407	UNIPROID	XPO1_HUMAN
T51407	TARGNAME	Exportin-1 (XPO1)
T51407	GENENAME	XPO1
T51407	TARGTYPE	Clinical trial
T51407	SYNONYMS	Exp1; Chromosome region maintenance 1 protein homolog; CRM1
T51407	FUNCTION	In the nucleus, in association with RANBP3, binds cooperatively to the NES on its target protein and to the GTPase RAN in its active GTP-bound form (Ran-GTP). Docking of this complex to the nuclear pore complex (NPC) is mediated through binding to nucleoporins. Upon transit of a nuclear export complex into the cytoplasm, disassembling of the complex and hydrolysis of Ran-GTP to Ran-GDP (induced by RANBP1 and RANGAP1, respectively) cause release of the cargo from the export receptor. The directionality of nuclear export is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus. Involved in U3 snoRNA transport from Cajal bodies to nucleoli. Binds to late precursor U3 snoRNA bearing a TMG cap. Mediates the nuclear export of cellular proteins (cargos) bearing a leucine-rich nuclear export signal (NES) and of RNAs.
T51407	PDBSTRUC	5DIS; 4BSN; 4BSM; 3GB8; 2L1L
T51407	BIOCLASS	Eukaryotic nuclear pore complex
T51407	SEQUENCE	MPAIMTMLADHAARQLLDFSQKLDINLLDNVVNCLYHGEGAQQRMAQEVLTHLKEHPDAWTRVDTILEFSQNMNTKYYGLQILENVIKTRWKILPRNQCEGIKKYVVGLIIKTSSDPTCVEKEKVYIGKLNMILVQILKQEWPKHWPTFISDIVGASRTSESLCQNNMVILKLLSEEVFDFSSGQITQVKSKHLKDSMCNEFSQIFQLCQFVMENSQNAPLVHATLETLLRFLNWIPLGYIFETKLISTLIYKFLNVPMFRNVSLKCLTEIAGVSVSQYEEQFVTLFTLTMMQLKQMLPLNTNIRLAYSNGKDDEQNFIQNLSLFLCTFLKEHDQLIEKRLNLRETLMEALHYMLLVSEVEETEIFKICLEYWNHLAAELYRESPFSTSASPLLSGSQHFDVPPRRQLYLPMLFKVRLLMVSRMAKPEEVLVVENDQGEVVREFMKDTDSINLYKNMRETLVYLTHLDYVDTERIMTEKLHNQVNGTEWSWKNLNTLCWAIGSISGAMHEEDEKRFLVTVIKDLLGLCEQKRGKDNKAIIASNIMYIVGQYPRFLRAHWKFLKTVVNKLFEFMHETHDGVQDMACDTFIKIAQKCRRHFVQVQVGEVMPFIDEILNNINTIICDLQPQQVHTFYEAVGYMIGAQTDQTVQEHLIEKYMLLPNQVWDSIIQQATKNVDILKDPETVKQLGSILKTNVRACKAVGHPFVIQLGRIYLDMLNVYKCLSENISAAIQANGEMVTKQPLIRSMRTVKRETLKLISGWVSRSNDPQMVAENFVPPLLDAVLIDYQRNVPAAREPEVLSTMAIIVNKLGGHITAEIPQIFDAVFECTLNMINKDFEEYPEHRTNFFLLLQAVNSHCFPAFLAIPPTQFKLVLDSIIWAFKHTMRNVADTGLQILFTLLQNVAQEEAAAQSFYQTYFCDILQHIFSVVTDTSHTAGLTMHASILAYMFNLVEEGKISTSLNPGNPVNNQIFLQEYVANLLKSAFPHLQDAQVKLFVTGLFSLNQDIPAFKEHLRDFLVQIKEFAGEDTSDLFLEEREIALRQADEEKHKRQMSVPGIFNPHEIPEEMCD
T51407	DRUGINFO	D00LNW	Selinexor	Phase 3
T51407	DRUGINFO	D0VI7R	Selinexor oral	Phase 2
T51407	DRUGINFO	D0JF6C	Eltanexor oral	Phase 1/2
T51407	DRUGINFO	D0SP6A	SL-801	Phase 1
T51407	DRUGINFO	D0Z8EJ	KOS-1815	Preclinical
T51407	DRUGINFO	D2U4RX	S109	Investigative
T51407	DRUGINFO	D3GD1L	Octahydrocurcumin	Investigative

T05090	TARGETID	T05090
T05090	FORMERID	TTDI01956
T05090	UNIPROID	HDAC3_HUMAN
T05090	TARGNAME	Histone deacetylase 3 (HDAC3)
T05090	GENENAME	HDAC3
T05090	TARGTYPE	Clinical trial
T05090	SYNONYMS	SMAP45; RPD32; RPD3-2; HD3
T05090	FUNCTION	Gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Participates in the BCL6 transcriptional repressor activity by deacetylating the H3 'Lys-27' (H3K27) on enhancer elements, antagonizing EP300 acetyltransferase activity and repressing proximal gene expression. Probably participates in the regulation of transcription through its binding to the zinc-finger transcription factor YY1; increases YY1 repression activity. Required to repress transcription of the POU1F1 transcription factor. Acts as a molecular chaperone for shuttling phosphorylated NR2C1 to PML bodies for sumoylation. Contributes, together with XBP1 isoform 1, to the activation of NFE2L2-mediated HMOX1 transcription factor gene expression in a PI(3)K/mTORC2/Akt-dependent signaling pathway leading to endothelial cell (EC) survival under disturbed flow/oxidative stress. Regulates both the transcriptional activation and repression phases of the circadian clock in a deacetylase activity-independent manner. During the activation phase, promotes the accumulation of ubiquitinated ARNTL/BMAL1 at the E-boxes and during the repression phase, blocks FBXL3-mediated CRY1/2 ubiquitination and promotes the interaction of CRY1 and ARNTL/BMAL1. The NCOR1-HDAC3 complex regulates the circadian expression of the core clock gene ARTNL/BMAL1 and the genes involved in lipid metabolism in the liver. Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4), and some other non-histone substrates.
T05090	PDBSTRUC	4A69
T05090	BIOCLASS	Carbon-nitrogen hydrolase
T05090	ECNUMBER	EC 3.5.1.98
T05090	SEQUENCE	MAKTVAYFYDPDVGNFHYGAGHPMKPHRLALTHSLVLHYGLYKKMIVFKPYQASQHDMCRFHSEDYIDFLQRVSPTNMQGFTKSLNAFNVGDDCPVFPGLFEFCSRYTGASLQGATQLNNKICDIAINWAGGLHHAKKFEASGFCYVNDIVIGILELLKYHPRVLYIDIDIHHGDGVQEAFYLTDRVMTVSFHKYGNYFFPGTGDMYEVGAESGRYYCLNVPLRDGIDDQSYKHLFQPVINQVVDFYQPTCIVLQCGADSLGCDRLGCFNLSIRGHGECVEYVKSFNIPLLVLGGGGYTVRNVARCWTYETSLLVEEAISEELPYSEYFEYFAPDFTLHPDVSTRIENQNSRQYLDQIRQTIFENLKMLNHAPSVQIHDVPADLLTYDRTDEADAEERGPEENYSRPEAPNEFYDGDHDNDKESDVEI
T05090	DRUGINFO	D06TKI	CHR-3996	Phase 1/2
T05090	DRUGINFO	D0UD9R	PMID29671355-Compound-57	Patented
T05090	DRUGINFO	D0XN2W	Diaryl amine derivative 4	Patented
T05090	DRUGINFO	D0C9NX	PMID29671355-Compound-59	Patented
T05090	DRUGINFO	D0OU0J	PMID29671355-Compound-55	Patented
T05090	DRUGINFO	D0EH2K	PMID29671355-Compound-11	Patented
T05090	DRUGINFO	D0Q1QY	PMID29671355-Compound-9	Patented
T05090	DRUGINFO	D0LN1T	PMID29671355-Compound-8	Patented
T05090	DRUGINFO	D0JB4S	PMID29671355-Compound-61	Patented
T05090	DRUGINFO	D0N2DK	PMID29671355-Compound-44	Patented
T05090	DRUGINFO	D0CH8Q	PMID29671355-Compound-56	Patented
T05090	DRUGINFO	D0M0RE	PMID29671355-Compound-67	Patented
T05090	DRUGINFO	D0DI9S	PMID29671355-Compound-31	Patented
T05090	DRUGINFO	D0LP1K	PMID29671355-Compound-21	Patented
T05090	DRUGINFO	D07WAT	PMID29671355-Compound-62	Patented
T05090	DRUGINFO	D0BP8I	PMID29671355-Compound-43	Patented
T05090	DRUGINFO	D0RA0D	PMID29671355-Compound-25	Patented
T05090	DRUGINFO	D00HXX	RGFP966	Investigative
T05090	DRUGINFO	D00VXM	droxinostat	Investigative

T20891	TARGETID	T20891
T20891	FORMERID	TTDR00273
T20891	UNIPROID	PDPK1_HUMAN
T20891	TARGNAME	Phosphoinositide dependent protein kinase-1 (PDPK1)
T20891	GENENAME	PDPK1
T20891	TARGTYPE	Clinical trial
T20891	SYNONYMS	PDK1; HPDK1; 3-phosphoinositide-dependent protein kinase 1; 3-Phosphoinositide-dependent kinase-1; 3'-phosphoinositide dependent kinase 1
T20891	FUNCTION	Its targets include: protein kinase B (PKB/AKT1, PKB/AKT2, PKB/AKT3), p70 ribosomal protein S6 kinase (RPS6KB1), p90 ribosomal protein S6 kinase (RPS6KA1, RPS6KA2 and RPS6KA3), cyclic AMP-dependent protein kinase (PRKACA), protein kinase C (PRKCD and PRKCZ), serum and glucocorticoid-inducible kinase (SGK1, SGK2 and SGK3), p21-activated kinase-1 (PAK1), protein kinase PKN (PKN1 and PKN2). Plays a central role in the transduction of signals from insulin by providing the activating phosphorylation to PKB/AKT1, thus propagating the signal to downstream targets controlling cell proliferation and survival, as well as glucose and amino acid uptake and storage. Negatively regulates the TGF-beta-induced signaling by: modulating the association of SMAD3 and SMAD7 with TGF-beta receptor, phosphorylating SMAD2, SMAD3, SMAD4 and SMAD7, preventing the nuclear translocation of SMAD3 and SMAD4 and the translocation of SMAD7 from the nucleus to the cytoplasm in response to TGF-beta. Activates PPARG transcriptional activity and promotes adipocyte differentiation. Activates the NF-kappa-B pathway via phosphorylation of IKKB. The tyrosine phosphorylated form is crucial for the regulation of focal adhesions by angiotensin II. Controls proliferation, survival, and growth of developing pancreatic cells. Participates in the regulation of Ca(2+) entry and Ca(2+)-activated K(+) channels of mast cells. Essential for the motility of vascular endothelial cells (ECs) and is involved in the regulation of their chemotaxis. Plays a critical role in cardiac homeostasis by serving as a dual effector for cell survival and beta-adrenergic response. Plays an important role during thymocyte development by regulating the expression of key nutrient receptors on the surface of pre-T cells and mediating Notch-induced cell growth and proliferative responses. Provides negative feedback inhibition to toll-like receptor-mediated NF-kappa-B activation in macrophages. Isoform 3 is catalytically inactive. Serine/threonine kinase which acts as a master kinase, phosphorylating and activating a subgroup of the AGC family of protein kinases.
T20891	PDBSTRUC	5MRD; 5LVP; 5LVO; 5LVN; 5LVM
T20891	BIOCLASS	Kinase
T20891	ECNUMBER	EC 2.7.11.1
T20891	SEQUENCE	MARTTSQLYDAVPIQSSVVLCSCPSPSMVRTQTESSTPPGIPGGSRQGPAMDGTAAEPRPGAGSLQHAQPPPQPRKKRPEDFKFGKILGEGSFSTVVLARELATSREYAIKILEKRHIIKENKVPYVTRERDVMSRLDHPFFVKLYFTFQDDEKLYFGLSYAKNGELLKYIRKIGSFDETCTRFYTAEIVSALEYLHGKGIIHRDLKPENILLNEDMHIQITDFGTAKVLSPESKQARANSFVGTAQYVSPELLTEKSACKSSDLWALGCIIYQLVAGLPPFRAGNEYLIFQKIIKLEYDFPEKFFPKARDLVEKLLVLDATKRLGCEEMEGYGPLKAHPFFESVTWENLHQQTPPKLTAYLPAMSEDDEDCYGNYDNLLSQFGCMQVSSSSSSHSLSASDTGLPQRSGSNIEQYIHDLDSNSFELDLQFSEDEKRLLLEKQAGGNPWHQFVENNLILKMGPVDKRKGLFARRRQLLLTEGPHLYYVDPVNKVLKGEIPWSQELRPEAKNFKTFFVHTPNRTYYLMDPSGNAHKWCRKIQEVWRQRYQSHPDAAVQ
T20891	DRUGINFO	D0C9JJ	AR-12	Phase 1
T20891	DRUGINFO	D09BXJ	PF-5177624	Investigative
T20891	DRUGINFO	D0EU1R	GSK-2334470	Investigative
T20891	DRUGINFO	D0M9QJ	PHT-427	Investigative
T20891	DRUGINFO	D0IX7Y	BX-912	Investigative
T20891	DRUGINFO	D0RG0Z	BX-795	Investigative
T20891	DRUGINFO	D0L2WP	PMID20005102C1	Investigative
T20891	DRUGINFO	D07PZQ	L-serine-O-phosphate	Investigative

T84634	TARGETID	T84634
T84634	FORMERID	TTDC00232
T84634	UNIPROID	CP26A_HUMAN
T84634	TARGNAME	Cytochrome P450 26 (CYP26A1)
T84634	GENENAME	CYP26A1
T84634	TARGTYPE	Clinical trial
T84634	SYNONYMS	Retinoic acid-metabolizing cytochrome; Retinoic acid inducible enzyme; Retinoic acid 4-hydroxylase; P450RAI; P450 retinoic acid-inactivating 1; HP450RAI; Cytochrome P450RAI; CYP26A1
T84634	FUNCTION	Plays a key role in retinoic acid metabolism. Acts on retinoids, including all-trans-retinoic acid (RA) and its stereoisomer 9-cis-RA. Capable of both 4-hydroxylation and 18- hydroxylation. Responsible for generation of several hydroxylated forms of RA, including 4-OH-RA, 4-oxo-RA and 18-OH-RA.
T84634	BIOCLASS	Paired donor oxygen oxidoreductase
T84634	ECNUMBER	EC 1.14.13.-
T84634	SEQUENCE	MGLPALLASALCTFVLPLLLFLAAIKLWDLYCVSGRDRSCALPLPPGTMGFPFFGETLQMVLQRRKFLQMKRRKYGFIYKTHLFGRPTVRVMGADNVRRILLGEHRLVSVHWPASVRTILGSGCLSNLHDSSHKQRKKVIMRAFSREALECYVPVITEEVGSSLEQWLSCGERGLLVYPEVKRLMFRIAMRILLGCEPQLAGDGDSEQQLVEAFEEMTRNLFSLPIDVPFSGLYRGMKARNLIHARIEQNIRAKICGLRASEAGQGCKDALQLLIEHSWERGERLDMQALKQSSTELLFGGHETTASAATSLITYLGLYPHVLQKVREELKSKGLLCKSNQDNKLDMEILEQLKYIGCVIKETLRLNPPVPGGFRVALKTFELNGYQIPKGWNVIYSICDTHDVAEIFTNKEEFNPDRFMLPHPEDASRFSFIPFGGGLRSCVGKEFAKILLKIFTVELARHCDWQLLNGPPTMKTSPTVYPVDNLPARFTHFHGEI
T84634	DRUGINFO	D08UGX	LIAROZOLE	Phase 2/3
T84634	DRUGINFO	D0AA6Z	Rambazole	Phase 2
T84634	DRUGINFO	D07VYX	4-((+/-)-(1H-imidazol-1-yl)-(E)-methylretinoate	Investigative
T84634	DRUGINFO	D0F8JO	4-((+/-)-(1H-imidazol-1-yl)-(E)-retinoic acid	Investigative

T62306	TARGETID	T62306
T62306	FORMERID	TTDC00155
T62306	UNIPROID	MTLR_HUMAN
T62306	TARGNAME	Motilin receptor (MLNR)
T62306	GENENAME	MLNR
T62306	TARGTYPE	Clinical trial
T62306	SYNONYMS	MLNR; Gprotein coupled receptor 38
T62306	FUNCTION	Receptor for motilin.
T62306	BIOCLASS	GPCR rhodopsin
T62306	SEQUENCE	MGSPWNGSDGPEGAREPPWPALPPCDERRCSPFPLGALVPVTAVCLCLFVVGVSGNVVTVMLIGRYRDMRTTTNLYLGSMAVSDLLILLGLPFDLYRLWRSRPWVFGPLLCRLSLYVGEGCTYATLLHMTALSVERYLAICRPLRARVLVTRRRVRALIAVLWAVALLSAGPFLFLVGVEQDPGISVVPGLNGTARIASSPLASSPPLWLSRAPPPSPPSGPETAEAAALFSRECRPSPAQLGALRVMLWVTTAYFFLPFLCLSILYGLIGRELWSSRRPLRGPAASGRERGHRQTVRVLLVVVLAFIICWLPFHVGRIIYINTEDSRMMYFSQYFNIVALQLFYLSASINPILYNLISKKYRAAAFKLLLARKSRPRGFHRSRDTAGEVAGDTGGDTVGYTETSANVKTMG
T62306	DRUGINFO	D05SGO	MOTILIN	Phase 4
T62306	DRUGINFO	D05UYQ	Camicinal	Phase 2
T62306	DRUGINFO	D0XH0K	Mitemcinal fumarate	Phase 2
T62306	DRUGINFO	D04UPW	RWJ-68023	Phase 1
T62306	DRUGINFO	D08WBJ	KOS-2187	Phase 1
T62306	DRUGINFO	D0T5FU	DS-3801	Phase 1
T62306	DRUGINFO	D0U9HM	GSK-1322888	Phase 1
T62306	DRUGINFO	D04JFT	KW-5139	Discontinued in Phase 2
T62306	DRUGINFO	D07SCN	KC-11458	Discontinued in Phase 2
T62306	DRUGINFO	D0ZY9U	SLV-305	Discontinued in Phase 2
T62306	DRUGINFO	D0E3BJ	SLV-311	Discontinued in Phase 1
T62306	DRUGINFO	D04LDK	TZP-202	Preclinical
T62306	DRUGINFO	D0U9OJ	GSK-326416	Preclinical
T62306	DRUGINFO	D02IUX	MA-2029	Investigative
T62306	DRUGINFO	D03FQP	ME4	Investigative
T62306	DRUGINFO	D03OCS	ME36	Investigative
T62306	DRUGINFO	D06ZDF	ME67	Investigative
T62306	DRUGINFO	D0D7LP	RQ-00201894	Investigative
T62306	DRUGINFO	D0F5QL	GM-109	Investigative
T62306	DRUGINFO	D0J2VQ	EM-523	Investigative
T62306	DRUGINFO	D0M6OV	KOS1326	Investigative
T62306	DRUGINFO	D0Q9IU	[Leu13]motilin (human)	Investigative
T62306	DRUGINFO	D0W6AQ	TZP-201	Investigative
T62306	DRUGINFO	D0Z7FY	CEM-301	Investigative

T73482	TARGETID	T73482
T73482	FORMERID	TTDC00153
T73482	UNIPROID	OX1R_HUMAN
T73482	TARGNAME	Orexin receptor type 1 (HCRTR1)
T73482	GENENAME	HCRTR1
T73482	TARGTYPE	Clinical trial
T73482	SYNONYMS	Ox1r; Ox1-R; Ox-1-R; Orexin-1 receptor; Hypocretin receptor type 1; HFGAN72 receptor; 7-transmembrane G-protein coupledneuropeptide receptor
T73482	FUNCTION	Triggers an increase in cytoplasmic Ca(2+) levels in response to orexin-A binding. Moderately selective excitatory receptor for orexin-A and, with a lower affinity, for orexin-B neuropeptide.
T73482	PDBSTRUC	4ZJC; 4ZJ8
T73482	BIOCLASS	GPCR rhodopsin
T73482	SEQUENCE	MEPSATPGAQMGVPPGSREPSPVPPDYEDEFLRYLWRDYLYPKQYEWVLIAAYVAVFVVALVGNTLVCLAVWRNHHMRTVTNYFIVNLSLADVLVTAICLPASLLVDITESWLFGHALCKVIPYLQAVSVSVAVLTLSFIALDRWYAICHPLLFKSTARRARGSILGIWAVSLAIMVPQAAVMECSSVLPELANRTRLFSVCDERWADDLYPKIYHSCFFIVTYLAPLGLMAMAYFQIFRKLWGRQIPGTTSALVRNWKRPSDQLGDLEQGLSGEPQPRARAFLAEVKQMRARRKTAKMLMVVLLVFALCYLPISVLNVLKRVFGMFRQASDREAVYACFTFSHWLVYANSAANPIIYNFLSGKFREQFKAAFSCCLPGLGPCGSLKAPSPRSSASHKSLSLQSRCSISKISEHVVLTSVTTVLP
T73482	DRUGINFO	D06CKX	SB-649868	Phase 2
T73482	DRUGINFO	D0WZC1	JNJ-61393215	Phase 2
T73482	DRUGINFO	D0YK9O	AZD4041	Phase 1
T73482	DRUGINFO	D00VEM	1,2-diamino cyclopentane-based derivative 25	Patented
T73482	DRUGINFO	D01NWU	1,2-diamino cyclopentane-based derivative 5	Patented
T73482	DRUGINFO	D02CCF	1,2-diamino cyclopentane-based derivative 20	Patented
T73482	DRUGINFO	D02LWJ	1,2-diamino cyclopentane-based derivative 15	Patented
T73482	DRUGINFO	D03JAZ	1,2-diamino cyclopentane-based derivative 13	Patented
T73482	DRUGINFO	D04DCO	1,2-diamino cyclopentane-based derivative 9	Patented
T73482	DRUGINFO	D04JLF	1,2-diamino cyclopentane-based derivative 8	Patented
T73482	DRUGINFO	D05PMY	1,2-diamino cyclopentane-based derivative 26	Patented
T73482	DRUGINFO	D05QWJ	1,2-diamino cyclopentane-based derivative 2	Patented
T73482	DRUGINFO	D05WDQ	1,2-diamino cyclopentane-based derivative 12	Patented
T73482	DRUGINFO	D06NRQ	1,2-diamino cyclopentane-based derivative 18	Patented
T73482	DRUGINFO	D06OTA	1,2-diamino cyclopentane-based derivative 29	Patented
T73482	DRUGINFO	D08KYM	1,2-diamino cyclopentane-based derivative 22	Patented
T73482	DRUGINFO	D08ZRN	1,2-diamino cyclopentane-based derivative 27	Patented
T73482	DRUGINFO	D09XLY	1,2-diamino cyclopentane-based derivative 31	Patented
T73482	DRUGINFO	D0AL3I	1,2-diamino cyclopentane-based derivative 16	Patented
T73482	DRUGINFO	D0C6GE	1,2-diamino cyclopentane-based derivative 21	Patented
T73482	DRUGINFO	D0CG0D	1,2-diamino cyclopentane-based derivative 33	Patented
T73482	DRUGINFO	D0DO4J	1,2-diamino cyclopentane-based derivative 11	Patented
T73482	DRUGINFO	D0EG3N	1,2-diamino cyclopentane-based derivative 34	Patented
T73482	DRUGINFO	D0FI1W	1,2-diamino cyclopentane-based derivative 10	Patented
T73482	DRUGINFO	D0J4YW	1,2-diamino cyclopentane-based derivative 24	Patented
T73482	DRUGINFO	D0L0YA	1,2-diamino cyclopentane-based derivative 19	Patented
T73482	DRUGINFO	D0NX4W	1,2-diamino cyclopentane-based derivative 14	Patented
T73482	DRUGINFO	D0P8AX	1,2-diamino cyclopentane-based derivative 23	Patented
T73482	DRUGINFO	D0S4UG	1,2-diamino cyclopentane-based derivative 32	Patented
T73482	DRUGINFO	D0U7VC	1,2-diamino cyclopentane-based derivative 7	Patented
T73482	DRUGINFO	D0U9WX	1,2-diamino cyclopentane-based derivative 30	Patented
T73482	DRUGINFO	D0VE3H	1,2-diamino cyclopentane-based derivative 17	Patented
T73482	DRUGINFO	D0VR1K	1,2-diamino cyclopentane-based derivative 3	Patented
T73482	DRUGINFO	D0WX1B	1,2-diamino cyclopentane-based derivative 1	Patented
T73482	DRUGINFO	D0YI3Z	1,2-diamino cyclopentane-based derivative 4	Patented
T73482	DRUGINFO	D0ZC1O	1,2-diamino cyclopentane-based derivative 6	Patented
T73482	DRUGINFO	D06BTF	Almorexant	Terminated
T73482	DRUGINFO	D0KP3K	SB-410220	Investigative
T73482	DRUGINFO	D08MXD	[3H]SB-674042	Investigative
T73482	DRUGINFO	D0J3PJ	SB-408124	Investigative
T73482	DRUGINFO	D0MY0E	orexin-B	Investigative
T73482	DRUGINFO	D0R4BT	PMID15261275C1	Investigative
T73482	DRUGINFO	D0UZ4J	SB-334867	Investigative

T82078	TARGETID	T82078
T82078	FORMERID	TTDR00813
T82078	UNIPROID	TLR2_HUMAN
T82078	TARGNAME	Toll-like receptor 2 (TLR2)
T82078	GENENAME	TLR2
T82078	TARGTYPE	Clinical trial
T82078	SYNONYMS	Toll/interleukin-1 receptor-like protein 4; TIL4; CD282
T82078	FUNCTION	Cooperates with TLR1 or TLR6 to mediate the innate immune response to bacterial lipoproteins or lipopeptides. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. May also activate immune cells and promote apoptosis in response to the lipid moiety of lipoproteins. Recognizes mycoplasmal macrophage-activating lipopeptide-2kD (MALP-2), soluble tuberculosis factor (STF), phenol-soluble modulin (PSM) and B. burgdorferi outer surface protein A lipoprotein (OspA-L) cooperatively with TLR6. Stimulation of monocytes in vitro with M. tuberculosis PstS1 induces p38 MAPK and ERK1/2 activation primarily via this receptor, but also partially via TLR4. MAPK activation in response to bacterial peptidoglycan also occurs via this receptor. Acts as a receptor for M. tuberculosis lipoproteins LprA, LprG, LpqH and PstS1, some lipoproteins are dependent on other coreceptors (TLR1, CD14 and/or CD36); the lipoproteins act as agonists to modulate antigen presenting cell functions in response to the pathogen. M. tuberculosis HSP70 (dnaK) but not HSP65 (groEL-2) acts via this protein to stimulate NF-kappa-B expression. Recognizes M. tuberculosis major T-antigen EsxA (ESAT-6) which inhibits downstream MYD88-dependent signaling (shown in mouse). Forms activation clusters composed of several receptors depending on the ligand, these clusters trigger signaling from the cell surface and subsequently are targeted to the Golgi in a lipid-raft dependent pathway. Forms the cluster TLR2:TLR6:CD14:CD36 in response to diacylated lipopeptides and TLR2:TLR1:CD14 in response to triacylated lipopeptides. Required for normal uptake of M. tuberculosis, a process that is inhibited by M. tuberculosis LppM. Cooperates with LY96 to mediate the innate immune response to bacterial lipoproteins and other microbial cell wall components.
T82078	PDBSTRUC	6NIG; 2Z80; 2Z7X; 1O77; 1FYX
T82078	BIOCLASS	Toll-like receptor
T82078	SEQUENCE	MPHTLWMVWVLGVIISLSKEESSNQASLSCDRNGICKGSSGSLNSIPSGLTEAVKSLDLSNNRITYISNSDLQRCVNLQALVLTSNGINTIEEDSFSSLGSLEHLDLSYNYLSNLSSSWFKPLSSLTFLNLLGNPYKTLGETSLFSHLTKLQILRVGNMDTFTKIQRKDFAGLTFLEELEIDASDLQSYEPKSLKSIQNVSHLILHMKQHILLLEIFVDVTSSVECLELRDTDLDTFHFSELSTGETNSLIKKFTFRNVKITDESLFQVMKLLNQISGLLELEFDDCTLNGVGNFRASDNDRVIDPGKVETLTIRRLHIPRFYLFYDLSTLYSLTERVKRITVENSKVFLVPCLLSQHLKSLEYLDLSENLMVEEYLKNSACEDAWPSLQTLILRQNHLASLEKTGETLLTLKNLTNIDISKNSFHSMPETCQWPEKMKYLNLSSTRIHSVTGCIPKTLEILDVSNNNLNLFSLNLPQLKELYISRNKLMTLPDASLLPMLLVLKISRNAITTFSKEQLDSFHTLKTLEAGGNNFICSCEFLSFTQEQQALAKVLIDWPANYLCDSPSHVRGQQVQDVRLSVSECHRTALVSGMCCALFLLILLTGVLCHRFHGLWYMKMMWAWLQAKRKPRKAPSRNICYDAFVSYSERDAYWVENLMVQELENFNPPFKLCLHKRDFIPGKWIIDNIIDSIEKSHKTVFVLSENFVKSEWCKYELDFSHFRLFDENNDAAILILLEPIEKKAIPQRFCKLRKIMNTKTYLEWPMDEAQREGFWVNLRAAIKS
T82078	DRUGINFO	D0V0JR	Cadi-05	Phase 3
T82078	DRUGINFO	D03ONZ	MCS-18	Phase 2
T82078	DRUGINFO	D0VI9P	OPN-305	Phase 2
T82078	DRUGINFO	D00UVU	Lipoteichoic acid	Phase 1/2
T82078	DRUGINFO	D0K3SM	MALP-2S	Phase 1/2
T82078	DRUGINFO	D09POQ	OM-174	Phase 1
T82078	DRUGINFO	D07CQJ	F-50040	Discontinued in Phase 1
T82078	DRUGINFO	D04UYT	CBLB-612	Investigative
T82078	DRUGINFO	D08TGY	S-(Dimethylarsenic)Cysteine	Investigative

T40556	TARGETID	T40556
T40556	FORMERID	TTDI02032
T40556	UNIPROID	BRD4_HUMAN
T40556	TARGNAME	Bromodomain-containing protein 4 (BRD4)
T40556	GENENAME	BRD4
T40556	TARGTYPE	Clinical trial
T40556	SYNONYMS	Protein HUNK1; HUNK1
T40556	FUNCTION	Chromatin reader protein that recognizes and binds acetylated histones and plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. Remains associated with acetylated chromatin throughout the entire cell cycle and provides epigenetic memory for postmitotic G1 gene transcription by preserving acetylated chromatin status and maintaining high-order chromatin structure. During interphase, plays a key role in regulating the transcription of signal-inducible genes by associating with the P-TEFb complex and recruiting it to promoters. Also recruits P-TEFb complex to distal enhancers, so called anti-pause enhancers in collaboration with JMJD6. BRD4 and JMJD6 are required to form the transcriptionally active P-TEFb complex by displacing negative regulators such as HEXIM1 and 7SKsnRNA complex from P-TEFb, thereby transforming it into an active form that can then phosphorylate the C-terminal domain (CTD) of RNA polymerase II. Promotes phosphorylation of 'Ser-2' of the C-terminal domain (CTD) of RNA polymerase II. According to a report, directly acts as an atypical protein kinase and mediates phosphorylation of 'Ser-2' of the C-terminal domain (CTD) of RNA polymerase II; these data however need additional evidences in vivo. In addition to acetylated histones, also recognizes and binds acetylated RELA, leading to further recruitment of the P-TEFb complex and subsequent activation of NF-kappa-B. Also acts as a regulator of p53/TP53-mediated transcription: following phosphorylation by CK2, recruited to p53/TP53 specific target promoters.
T40556	PDBSTRUC	6Q3Z; 6Q3Y; 6MNL; 6MAU; 6HDQ
T40556	BIOCLASS	Bromodomain
T40556	SEQUENCE	MSAESGPGTRLRNLPVMGDGLETSQMSTTQAQAQPQPANAASTNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEETEIMIVQAKGRGRGRKETGTAKPGVSTVPNTTQASTPPQTQTPQPNPPPVQATPHPFPAVTPDLIVQTPVMTVVPPQPLQTPPPVPPQPQPPPAPAPQPVQSHPPIIAATPQPVKTKKGVKRKADTTTPTTIDPIHEPPSLPPEPKTTKLGQRRESSRPVKPPKKDVPDSQQHPAPEKSSKVSEQLKCCSGILKEMFAKKHAAYAWPFYKPVDVEALGLHDYCDIIKHPMDMSTIKSKLEAREYRDAQEFGADVRLMFSNCYKYNPPDHEVVAMARKLQDVFEMRFAKMPDEPEEPVVAVSSPAVPPPTKVVAPPSSSDSSSDSSSDSDSSTDDSEEERAQRLAELQEQLKAVHEQLAALSQPQQNKPKKKEKDKKEKKKEKHKRKEEVEENKKSKAKEPPPKKTKKNNSSNSNVSKKEPAPMKSKPPPTYESEEEDKCKPMSYEEKRQLSLDINKLPGEKLGRVVHIIQSREPSLKNSNPDEIEIDFETLKPSTLRELERYVTSCLRKKRKPQAEKVDVIAGSSKMKGFSSSESESSSESSSSDSEDSETEMAPKSKKKGHPGREQKKHHHHHHQQMQQAPAPVPQQPPPPPQQPPPPPPPQQQQQPPPPPPPPSMPQQAAPAMKSSPPPFIATQVPVLEPQLPGSVFDPIGHFTQPILHLPQPELPPHLPQPPEHSTPPHLNQHAVVSPPALHNALPQQPSRPSNRAAALPPKPARPPAVSPALTQTPLLPQPPMAQPPQVLLEDEEPPAPPLTSMQMQLYLQQLQKVQPPTPLLPSVKVQSQPPPPLPPPPHPSVQQQLQQQPPPPPPPQPQPPPQQQHQPPPRPVHLQPMQFSTHIQQPPPPQGQQPPHPPPGQQPPPPQPAKPQQVIQHHHSPRHHKSDPYSTGHLREAPSPLMIHSPQMSQFQSLTHQSPPQQNVQPKKQELRAASVVQPQPLVVVKEEKIHSPIIRSEPFSPSLRPEPPKHPESIKAPVHLPQRPEMKPVDVGRPVIRPPEQNAPPPGAPDKDKQKQEPKTPVAPKKDLKIKNMGSWASLVQKHPTTPSSTAKSSSDSFEQFRRAAREKEEREKALKAQAEHAEKEKERLRQERMRSREDEDALEQARRAHEEARRRQEQQQQQRQEQQQQQQQQAAAVAAAATPQAQSSQPQSMLDQQRELARKREQERRRREAMAATIDMNFQSDLLSIFEENLF
T40556	DRUGINFO	D01LVE	CPI-0610	Phase 3
T40556	DRUGINFO	D07GHA	PLX2853	Phase 1/2
T40556	DRUGINFO	D0N7WW	RVX-208	Phase 1/2
T40556	DRUGINFO	D0P7FM	INCB57643	Phase 1/2
T40556	DRUGINFO	D02YNI	OTX-015	Phase 1/2
T40556	DRUGINFO	D0B5PK	TEN010	Phase 1
T40556	DRUGINFO	D0PH9I	AZD5153	Phase 1
T40556	DRUGINFO	D07OFM	GSK525762	Phase 1
T40556	DRUGINFO	D05ICT	ABBV-744	Phase 1
T40556	DRUGINFO	D0ZW4W	(+)-JQ1	Phase 1
T40556	DRUGINFO	D00MXR	PMID26924192-Compound-23	Patented
T40556	DRUGINFO	D04HTM	Aminocyclopentenone compound 1	Patented
T40556	DRUGINFO	D05LTB	Pyrazole and thiophene derivative 4	Patented
T40556	DRUGINFO	D07CSE	Benzothiazepine analog 12	Patented
T40556	DRUGINFO	D07IYX	PMID26924192-Compound-20	Patented
T40556	DRUGINFO	D08BCK	PMID26924192-Compound-24	Patented
T40556	DRUGINFO	D08JHQ	Aminocyclopentenone compound 2	Patented
T40556	DRUGINFO	D09FVR	Pyrrolo-pyrrolone derivative 3	Patented
T40556	DRUGINFO	D09QSH	Aminocyclopentenone compound 5	Patented
T40556	DRUGINFO	D0AU3O	Aminocyclopentenone compound 6	Patented
T40556	DRUGINFO	D0C9RQ	PMID26924192-Compound-22	Patented
T40556	DRUGINFO	D0CB8D	PMID26924192-Compound-31	Patented
T40556	DRUGINFO	D0EN4B	Pyrazole and thiophene derivative 2	Patented
T40556	DRUGINFO	D0FN6F	PMID26924192-Compound-25	Patented
T40556	DRUGINFO	D0HO8V	Pyrrolo-pyrrolone derivative 4	Patented
T40556	DRUGINFO	D0J4QG	Pyrazole and thiophene derivative 3	Patented
T40556	DRUGINFO	D0KF8C	Aminocyclopentenone compound 3	Patented
T40556	DRUGINFO	D0N6JZ	Aminocyclopentenone compound 4	Patented
T40556	DRUGINFO	D0PE1R	Pyrrolo-pyrrolone derivative 2	Patented
T40556	DRUGINFO	D0S5ID	Benzothiazepine analog 11	Patented
T40556	DRUGINFO	D0SQ0F	Pyrazole and thiophene derivative 1	Patented
T40556	DRUGINFO	D0XM8B	PMID26924192-Compound-21	Patented
T40556	DRUGINFO	D0XR9Y	Pyrrolo-pyrrolone derivative 5	Patented
T40556	DRUGINFO	D0Y7YC	Benzothiazepine analog 10	Patented
T40556	DRUGINFO	D0L7SK	PMID26924192-Compound-30	Patented
T40556	DRUGINFO	D0SB3H	PMID26924192-Compound-32	Patented
T40556	DRUGINFO	D0VB3P	PMID26924192-Compound-33	Patented
T40556	DRUGINFO	D0YM3G	Pyrrolo-pyrrolone derivative 1	Patented
T40556	DRUGINFO	D03NWT	PMID26924192-Compound-104	Patented
T40556	DRUGINFO	D03RPJ	PMID26924192-Compound-102	Patented
T40556	DRUGINFO	D05XXS	PMID26924192-Compound-103	Patented
T40556	DRUGINFO	D0NN4U	PMID26924192-Compound-105	Patented
T40556	DRUGINFO	D01DMN	XD1	Investigative
T40556	DRUGINFO	D01EVE	PMID25703523C7d	Investigative
T40556	DRUGINFO	D01YSN	isoxazole azepine compound 3	Investigative
T40556	DRUGINFO	D03LNF	PFI-1	Investigative
T40556	DRUGINFO	D09HBR	MS436	Investigative
T40556	DRUGINFO	D0C2JS	CPI-203	Investigative
T40556	DRUGINFO	D0M5DB	BzT-7	Investigative
T40556	DRUGINFO	D0O2RX	PMID23517011C9	Investigative
T40556	DRUGINFO	D0T3YY	MS417	Investigative
T40556	DRUGINFO	D03BTJ	PMID25408830C3	Investigative
T40556	DRUGINFO	D09ZPM	PMID25408830C1	Investigative
T40556	DRUGINFO	D0H3TC	PMID21851057C4d	Investigative
T40556	DRUGINFO	D0J6XI	PMID25408830C2	Investigative
T40556	DRUGINFO	D03LIP	GW841819X	Investigative
T40556	DRUGINFO	D0C2XT	PMID24000170C36	Investigative
T40556	DRUGINFO	D0Q2GK	PMID24000170C38	Investigative
T40556	DRUGINFO	D0WU1S	I-BET151	Investigative
T40556	DRUGINFO	D07FGY	XD14	Investigative

T56697	TARGETID	T56697
T56697	FORMERID	TTDNC00370
T56697	UNIPROID	DKK1_HUMAN
T56697	TARGNAME	Dickkopf-related protein 1 (DKK1)
T56697	GENENAME	DKK1
T56697	TARGTYPE	Clinical trial
T56697	SYNONYMS	hDkk1; hDkk-1; UNQ492/PRO1008; Dkk1; Dkk-1; Dickkopfrelated protein 1; Dickkopf1; Dickkopf-1
T56697	FUNCTION	DKKs play an important role in vertebrate development, where they locally inhibit Wnt regulated processes such as antero-posterior axial patterning, limb development, somitogenesis and eye formation. In the adult, Dkks are implicated in bone formation and bone disease, cancer and Alzheimer disease. Inhibits the pro-apoptotic function of KREMEN1 in a Wnt-independent manner, and has anti-apoptotic activity. Antagonizes canonical Wnt signaling by inhibiting LRP5/6 interaction with Wnt and by forming a ternary complex with the transmembrane protein KREMEN that promotes internalization of LRP5/6.
T56697	PDBSTRUC	5GJE; 5FWW; 3SOQ; 3S8V; 3S2K
T56697	BIOCLASS	Dickkopf protein
T56697	SEQUENCE	MMALGAAGATRVFVAMVAAALGGHPLLGVSATLNSVLNSNAIKNLPPPLGGAAGHPGSAVSAAPGILYPGGNKYQTIDNYQPYPCAEDEECGTDEYCASPTRGGDAGVQICLACRKRRKRCMRHAMCCPGNYCKNGICVSSDQNHFRGEIEETITESFGNDHSTLDGYSRRTTLSSKMYHTKGQEGSVCLRSSDCASGLCCARHFWSKICKPVLKEGQVCTKHRRKGSHGLEIFQRCYCGEGLSCRIQKDHHQASNSSRLHTCQRH
T56697	DRUGINFO	D62FLA	BHQ880	Phase 2
T56697	DRUGINFO	DMF73Z	DKN-01	Phase 2
T56697	DRUGINFO	D04OMR	PF-04840082	Phase 1

T23797	TARGETID	T23797
T23797	FORMERID	TTDI02101
T23797	UNIPROID	IL33_HUMAN
T23797	TARGNAME	Interleukin-33 (IL33)
T23797	GENENAME	IL33
T23797	TARGTYPE	Clinical trial
T23797	SYNONYMS	Nuclear factor from high endothelial venules; NFHEV; NF-HEV; Interleukin1 family member 11; Interleukin-1 family member 11; IL1F11; IL-33; IL-1F11; C9orf26
T23797	FUNCTION	Involved in the maturation of Th2 cells inducing the secretion of T-helper type 2-associated cytokines. Also involved in activation of mast cells, basophils, eosinophils and natural killer cells. Acts as a chemoattractant for Th2 cells, and may function as an "alarmin", that amplifies immune responses during tissue injury. Cytokine that binds to and signals through the IL1RL1/ST2 receptor which in turn activates NF-kappa-B and MAPK signaling pathways in target cells.
T23797	PDBSTRUC	4KC3; 2KLL
T23797	BIOCLASS	Cytokine: interleukin
T23797	SEQUENCE	MKPKMKYSTNKISTAKWKNTASKALCFKLGKSQQKAKEVCPMYFMKLRSGLMIKKEACYFRRETTKRPSLKTGRKHKRHLVLAACQQQSTVECFAFGISGVQKYTRALHDSSITGISPITEYLASLSTYNDQSITFALEDESYEIYVEDLKKDEKKDKVLLSYYESQHPSNESGDGVDGKMLMVTLSPTKDFWLHANNKEHSVELHKCEKPLPDQAFFVLHNMHSNCVSFECKTDPGVFIGVKDNHLALIKVDSSENLCTENILFKLSET
T23797	DRUGINFO	D0YFN1	Tozorakimab	Phase 3
T23797	DRUGINFO	D8U1EX	SAR440340	Phase 3
T23797	DRUGINFO	DOTF14	MEDI3506	Phase 3
T23797	DRUGINFO	DPT90B	Itepekimab	Phase 3
T23797	DRUGINFO	D07GDR	AMG 282	Phase 1
T23797	DRUGINFO	D1LP4B	PF-07264660	Phase 1

T29339	TARGETID	T29339
T29339	FORMERID	TTDI02051
T29339	UNIPROID	DDX58_HUMAN
T29339	TARGNAME	Retinoic acid-inducible gene-1 (RIG-1)
T29339	GENENAME	DDX58
T29339	TARGTYPE	Clinical trial
T29339	SYNONYMS	Retinoic acidinducible gene I protein; Retinoic acidinducible gene 1 protein; Retinoic acid-inducible gene I protein; Retinoic acid-inducible gene 1 protein; RLR1; RLR-1; RIGIlike receptor 1; RIGI; RIG1; RIG-I-like receptor 1; RIG-I; Probable ATPdependent RNA helicase DDX58; Probable ATP-dependent RNA helicase DDX58; DEAD box protein 58
T29339	FUNCTION	Its ligands include: 5'-triphosphorylated ssRNA and dsRNA and short dsRNA (<1 kb in length). In addition to the 5'-triphosphate moiety, blunt-end base pairing at the 5'-end of the RNA is very essential. Overhangs at the non-triphosphorylated end of the dsRNA RNA have no major impact on its activity. A 3'overhang at the 5'triphosphate end decreases and any 5'overhang at the 5' triphosphate end abolishes its activity. Upon ligand binding it associates with mitochondria antiviral signaling protein (MAVS/IPS1) which activates the IKK-related kinases: TBK1 and IKBKE which phosphorylate interferon regulatory factors: IRF3 and IRF7 which in turn activate transcription of antiviral immunological genes, including interferons (IFNs); IFN-alpha and IFN-beta. Detects both positive and negative strand RNA viruses including members of the families Paramyxoviridae: Human respiratory syncytial virus and measles virus (MeV), Rhabdoviridae: vesicular stomatitis virus (VSV), Orthomyxoviridae: influenza A and B virus, Flaviviridae: Japanese encephalitis virus (JEV), hepatitis C virus (HCV), dengue virus (DENV) and west Nile virus (WNV). It also detects rotavirus and reovirus. Also involved in antiviral signaling in response to viruses containing a dsDNA genome such as Epstein-Barr virus (EBV). Detects dsRNA produced from non-self dsDNA by RNA polymerase III, such as Epstein-Barr virus-encoded RNAs (EBERs). May play important roles in granulocyte production and differentiation, bacterial phagocytosis and in the regulation of cell migration. Innate immune receptor which acts as a cytoplasmic sensor of viral nucleic acids and plays a major role in sensing viral infection and in the activation of a cascade of antiviral responses including the induction of type I interferons and proinflammatory cytokines.
T29339	PDBSTRUC	6GPG; 5F9H; 5F9F; 5F98; 5E3H
T29339	BIOCLASS	Acid anhydride hydrolase
T29339	ECNUMBER	EC 3.6.4.13
T29339	SEQUENCE	MTTEQRRSLQAFQDYIRKTLDPTYILSYMAPWFREEEVQYIQAEKNNKGPMEAATLFLKFLLELQEEGWFRGFLDALDHAGYSGLYEAIESWDFKKIEKLEEYRLLLKRLQPEFKTRIIPTDIISDLSECLINQECEEILQICSTKGMMAGAEKLVECLLRSDKENWPKTLKLALEKERNKFSELWIVEKGIKDVETEDLEDKMETSDIQIFYQEDPECQNLSENSCPPSEVSDTNLYSPFKPRNYQLELALPAMKGKNTIICAPTGCGKTFVSLLICEHHLKKFPQGQKGKVVFFANQIPVYEQQKSVFSKYFERHGYRVTGISGATAENVPVEQIVENNDIIILTPQILVNNLKKGTIPSLSIFTLMIFDECHNTSKQHPYNMIMFNYLDQKLGGSSGPLPQVIGLTASVGVGDAKNTDEALDYICKLCASLDASVIATVKHNLEELEQVVYKPQKFFRKVESRISDKFKYIIAQLMRDTESLAKRICKDLENLSQIQNREFGTQKYEQWIVTVQKACMVFQMPDKDEESRICKALFLYTSHLRKYNDALIISEHARMKDALDYLKDFFSNVRAAGFDEIEQDLTQRFEEKLQELESVSRDPSNENPKLEDLCFILQEEYHLNPETITILFVKTRALVDALKNWIEGNPKLSFLKPGILTGRGKTNQNTGMTLPAQKCILDAFKASGDHNILIATSVADEGIDIAQCNLVILYEYVGNVIKMIQTRGRGRARGSKCFLLTSNAGVIEKEQINMYKEKMMNDSILRLQTWDEAVFREKILHIQTHEKFIRDSQEKPKPVPDKENKKLLCRKCKALACYTADVRVIEECHYTVLGDAFKECFVSRPHPKPKQFSSFEKRAKIFCARQNCSHDWGIHVKYKTFEIPVIKIESFVVEDIATGVQTLYSKWKDFHFEKIPFDPAEMSK
T29339	DRUGINFO	D04HQC	SB-9200	Phase 2
T29339	DRUGINFO	DFO5W3	MK-4621	Phase 1
T29339	DRUGINFO	DVU2H8	CV8102	Phase 1

T98293	TARGETID	T98293
T98293	FORMERID	TTDI02145
T98293	UNIPROID	PAK4_HUMAN
T98293	TARGNAME	PAK-4 protein kinase (PAK4)
T98293	GENENAME	PAK4
T98293	TARGTYPE	Clinical trial
T98293	SYNONYMS	p21-activated kinase 4; Serine/threonine-protein kinase PAK 4; PAK-4; KIAA1142
T98293	FUNCTION	Activation by various effectors including growth factor receptors or active CDC42 and RAC1 results in a conformational change and a subsequent autophosphorylation on several serine and/or threonine residues. Phosphorylates and inactivates the protein phosphatase SSH1, leading to increased inhibitory phosphorylation of the actin binding/depolymerizing factor cofilin. Decreased cofilin activity may lead to stabilization of actin filaments. Phosphorylates LIMK1, a kinase that also inhibits the activity of cofilin. Phosphorylates integrin beta5/ITGB5 and thus regulates cell motility. Phosphorylates ARHGEF2 and activates the downstream target RHOA that plays a role in the regulation of assembly of focal adhesions and actin stress fibers. Stimulates cell survival by phosphorylating the BCL2 antagonist of cell death BAD. Alternatively, inhibits apoptosis by preventing caspase-8 binding to death domain receptors in a kinase independent manner. Plays a role in cell-cycle progression by controlling levels of the cell-cycle regulatory protein CDKN1A and by phosphorylating RAN. Serine/threonine protein kinase that plays a role in a variety of different signaling pathways including cytoskeleton regulation, cell migration, growth, proliferation or cell survival.
T98293	PDBSTRUC	5ZJW; 5XVG; 5XVF; 5XVA; 5VEF
T98293	BIOCLASS	Kinase
T98293	ECNUMBER	EC 2.7.11.1
T98293	SEQUENCE	MFGKRKKRVEISAPSNFEHRVHTGFDQHEQKFTGLPRQWQSLIEESARRPKPLVDPACITSIQPGAPKTIVRGSKGAKDGALTLLLDEFENMSVTRSNSLRRDSPPPPARARQENGMPEEPATTARGGPGKAGSRGRFAGHSEAGGGSGDRRRAGPEKRPKSSREGSGGPQESSRDKRPLSGPDVGTPQPAGLASGAKLAAGRPFNTYPRADTDHPSRGAQGEPHDVAPNGPSAGGLAIPQSSSSSSRPPTRARGAPSPGVLGPHASEPQLAPPACTPAAPAVPGPPGPRSPQREPQRVSHEQFRAALQLVVDPGDPRSYLDNFIKIGEGSTGIVCIATVRSSGKLVAVKKMDLRKQQRRELLFNEVVIMRDYQHENVVEMYNSYLVGDELWVVMEFLEGGALTDIVTHTRMNEEQIAAVCLAVLQALSVLHAQGVIHRDIKSDSILLTHDGRVKLSDFGFCAQVSKEVPRRKSLVGTPYWMAPELISRLPYGPEVDIWSLGIMVIEMVDGEPPYFNEPPLKAMKMIRDNLPPRLKNLHKVSPSLKGFLDRLLVRDPAQRATAAELLKHPFLAKAGPPASIVPLMRQNRTR
T98293	DRUGINFO	D04ZQB	KPT-9274	Phase 1
T98293	DRUGINFO	D08MHM	PF-3758309	Phase 1

T66383	TARGETID	T66383
T66383	FORMERID	TTDC00326
T66383	UNIPROID	CFAD_HUMAN
T66383	TARGNAME	Complement factor D (CFD)
T66383	GENENAME	CFD
T66383	TARGTYPE	Clinical trial
T66383	SYNONYMS	Properdin factor D; PFD; DF; C3 convertase activator; Adipsin
T66383	FUNCTION	Factor D cleaves factor B when the latter is complexed with factor C3b, activating the C3bbb complex, which then becomes the C3 convertase of the alternate pathway. Its function is homologous to that of C1s in the classical pathway.
T66383	PDBSTRUC	6QMT; 6QMR; 6FUT; 6FUJ; 6FUI
T66383	BIOCLASS	Peptidase
T66383	ECNUMBER	EC 3.4.21.46
T66383	SEQUENCE	MHSWERLAVLVLLGAAACAAPPRGRILGGREAEAHARPYMASVQLNGAHLCGGVLVAEQWVLSAAHCLEDAADGKVQVLLGAHSLSQPEPSKRLYDVLRAVPHPDSQPDTIDHDLLLLQLSEKATLGPAVRPLPWQRVDRDVAPGTLCDVAGWGIVNHAGRRPDSLQHVLLPVLDRATCNRRTHHDGAITERLMCAESNRRDSCKGDSGGPLVCGGVLEGVVTSGSRVCGNRKKPGIYTRVASYAAWIDSVLA
T66383	DRUGINFO	DJ43UK	ALXN2040	Phase 3
T66383	DRUGINFO	DM7Z6Y	Lampalizumab	Phase 3
T66383	DRUGINFO	D0C9MA	ACH-4471	Phase 2
T66383	DRUGINFO	DZ9N5O	BCX-9930	Phase 2
T66383	DRUGINFO	D3LZ2F	Vemircopan	Phase 2
T66383	DRUGINFO	D3LZ2F	Vemircopan	Phase 2
T66383	DRUGINFO	D08ZDI	Anti-Factor D	Phase 1/2
T66383	DRUGINFO	DKI1A8	ALXN2080	Phase 1
T66383	DRUGINFO	D04MIN	example 373 [WO2012093101]	Investigative
T66383	DRUGINFO	D0P8LR	HC3-1496	Investigative

T35486	TARGETID	T35486
T35486	FORMERID	TTDI01767
T35486	UNIPROID	RASN_HUMAN
T35486	TARGNAME	GTPase NRas (NRAS)
T35486	GENENAME	NRAS
T35486	TARGTYPE	Clinical trial
T35486	SYNONYMS	Transforming protein N-Ras; HRAS1
T35486	FUNCTION	Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.
T35486	PDBSTRUC	5UHV; 3CON; 2N9C
T35486	BIOCLASS	Small GTPase
T35486	SEQUENCE	MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNSKSFADINLYREQIKRVKDSDDVPMVLVGNKCDLPTRTVDTKQAHELAKSYGIPFIETSAKTRQGVEDAFYTLVREIRQYRMKKLNSSDDGTQGCMGLPCVVM
T35486	DRUGINFO	D01LFC	Mutant ras vaccine	Phase 2
T35486	DRUGINFO	D0N4SF	GI-4000	Phase 2
T35486	DRUGINFO	D0VV6V	Reovirus	Phase 2
T35486	DRUGINFO	D00KTV	Salirasib	Phase 2
T35486	DRUGINFO	D0S2HO	Perillyl alcohol	Discontinued in Phase 2
T35486	DRUGINFO	D01SVG	KA-10X	Investigative
T35486	DRUGINFO	D03ZWR	APC-300	Investigative

T85670	TARGETID	T85670
T85670	FORMERID	TTDI02219
T85670	UNIPROID	NGF_HUMAN
T85670	TARGNAME	Nerve growth factor (NGF)
T85670	GENENAME	NGF
T85670	TARGTYPE	Clinical trial
T85670	SYNONYMS	NGFB; Beta-nerve growth factor; Beta-NGF
T85670	FUNCTION	Nerve growth factor is important for the development and maintenance of the sympathetic and sensory nervous systems. Extracellular ligand for the NTRK1 and NGFR receptors, activates cellular signaling cascades to regulate neuronal proliferation, differentiation and survival (Probable). The immature NGF precursor (proNGF) functions as ligand for the heterodimeric receptor formed by SORCS2 and NGFR, and activates cellular signaling cascades that lead to inactivation of RAC1 and/or RAC2, reorganization of the actin cytoskeleton and neuronal growth cone collapse. In contrast to mature NGF, the precursor form (proNGF) promotes neuronal apoptosis (in vitro) (By similarity). Inhibits metalloproteinase-dependent proteolysis of platelet glycoprotein VI. Binds lysophosphatidylinositol and lysophosphatidylserine between the two chains of the homodimer. The lipid-bound form promotes histamine relase from mast cells, contrary to the lipid-free form (By similarity).
T85670	PDBSTRUC	5JZ7; 4ZBN; 4EDX; 4EDW; 2IFG
T85670	BIOCLASS	Growth factor
T85670	SEQUENCE	MSMLFYTLITAFLIGIQAEPHSESNVPAGHTIPQAHWTKLQHSLDTALRRARSAPAAAIAARVAGQTRNITVDPRLFKKRRLRSPRVLFSTQPPREAADTQDLDFEVGGAAPFNRTHRSKRSSSHPIFHRGEFSVCDSVSVWVGDKTTATDIKGKEVMVLGEVNINNSVFKQYFFETKCRDPNPVDSGCRGIDSKHWNSYCTTTHTFVKALTMDGKQAAWRFIRIDTACVCVLSRKAVRRA
T85670	DRUGINFO	D00BVS	Tanezumab	Phase 3
T85670	DRUGINFO	D0AD4Z	Fasinumab	Phase 3
T85670	DRUGINFO	D0SB5K	SAR164877	Phase 2/3
T85670	DRUGINFO	D0MP1M	CERE-110	Phase 2
T85670	DRUGINFO	D0U9PV	CXB-909	Phase 1/2
T85670	DRUGINFO	D03APM	ABT-110	Phase 1
T85670	DRUGINFO	D0D0GH	NsG-0202	Phase 1
T85670	DRUGINFO	D0JA3Y	MEDI-578	Phase 1
T85670	DRUGINFO	D0A0MJ	Nerve growth factor	Terminated

T16128	TARGETID	T16128
T16128	FORMERID	TTDI02076
T16128	UNIPROID	GAST_HUMAN
T16128	TARGNAME	Gastrin (GAST)
T16128	GENENAME	GAST
T16128	TARGTYPE	Clinical trial
T16128	SYNONYMS	Gastrin6; GAST; G52; G34; G14
T16128	FUNCTION	Gastrin stimulates the stomach mucosa to produce and secrete hydrochloric acid and the pancreas to secrete its digestive enzymes. It also stimulates smooth muscle contraction and increases blood circulation and water secretion in the stomach and intestine.
T16128	PDBSTRUC	5WRJ
T16128	BIOCLASS	Gastrin cholecystokinin
T16128	SEQUENCE	MQRLCVYVLIFALALAAFSEASWKPRSQQPDAPLGTGANRDLELPWLEQQGPASHHRRQLGPQGPPHLVADPSKKQGPWLEEEEEAYGWMDFGRRSAEDEN
T16128	DRUGINFO	D0G8ZQ	G17DT	Phase 3

T85158	TARGETID	T85158
T85158	FORMERID	TTDC00327
T85158	UNIPROID	TNFB_HUMAN
T85158	TARGNAME	Lymphotoxin-alpha (LTA)
T85158	GENENAME	LTA
T85158	TARGTYPE	Clinical trial
T85158	SYNONYMS	Tumor necrosis factor ligand superfamily member 1; TNFSF1; TNFB; TNF-beta; LT-alpha
T85158	FUNCTION	In its heterotrimeric form with LTB binds to TNFRSF3/LTBR. Lymphotoxin is produced by lymphocytes and is cytotoxic for a wide range of tumor cells in vitro and in vivo. Cytokine that in its homotrimeric form binds to TNFRSF1A/TNFR1, TNFRSF1B/TNFBR and TNFRSF14/HVEM.
T85158	PDBSTRUC	4MXW; 4MXV; 1TNR
T85158	BIOCLASS	Cytokine: tumor necrosis factor
T85158	SEQUENCE	MTPPERLFLPRVCGTTLHLLLLGLLLVLLPGAQGLPGVGLTPSAAQTARQHPKMHLAHSTLKPAAHLIGDPSKQNSLLWRANTDRAFLQDGFSLSNNSLLVPTSGIYFVYSQVVFSGKAYSPKATSSPLYLAHEVQLFSSQYPFHVPLLSSQKMVYPGLQEPWLHSMYHGAAFQLTQGDQLSTHTDGIPHLVLSPSTVFFGAFAL
T85158	DRUGINFO	D0L1OC	Anti-LT alpha	Phase 2

T16340	TARGETID	T16340
T16340	FORMERID	TTDI01935
T16340	UNIPROID	IL1A_HUMAN
T16340	TARGNAME	Interleukin-1 alpha (IL1A)
T16340	GENENAME	IL1A
T16340	TARGTYPE	Clinical trial
T16340	SYNONYMS	IL1F1; IL-1 alpha; Hematopoietin-1
T16340	FUNCTION	Produced by activated macrophages, IL-1 stimulates thymocyte proliferation by inducing IL-2 release, B-cell maturation and proliferation, and fibroblast growth factor activity. IL-1 proteins are involved in the inflammatory response, being identified as endogenous pyrogens, and are reported to stimulate the release of prostaglandin and collagenase from synovial cells.
T16340	PDBSTRUC	5UC6; 2L5X; 2KKI; 2ILA; 1ITA
T16340	BIOCLASS	Cytokine: interleukin
T16340	SEQUENCE	MAKVPDMFEDLKNCYSENEEDSSSIDHLSLNQKSFYHVSYGPLHEGCMDQSVSLSISETSKTSKLTFKESMVVVATNGKVLKKRRLSLSQSITDDDLEAIANDSEEEIIKPRSAPFSFLSNVKYNFMRIIKYEFILNDALNQSIIRANDQYLTAAALHNLDEAVKFDMGAYKSSKDDAKITVILRISKTQLYVTAQDEDQPVLLKEMPEIPKTITGSETNLLFFWETHGTKNYFTSVAHPNLFIATKQDYWVCLAGGPPSITDFQILENQA
T16340	DRUGINFO	D09AYM	MABp1	Phase 3
T16340	DRUGINFO	D0YO4C	Xilonix	Phase 3
T16340	DRUGINFO	DCL35B	Bermekimab	Phase 2
T16340	DRUGINFO	DOVW19	Natrunix	Phase 2
T16340	DRUGINFO	D01WQQ	ABT-981	Phase 2
T16340	DRUGINFO	D0X2PQ	IX207-887	Discontinued in Phase 2
T16340	DRUGINFO	D03VFV	IL1aQb	Terminated
T16340	DRUGINFO	D0B4DB	Interleukin-1-alpha - Amgen/Roche	Investigative

T56545	TARGETID	T56545
T56545	FORMERID	TTDI02020
T56545	UNIPROID	APOA1_HUMAN
T56545	TARGNAME	Apolipoprotein A-I (APOA1)
T56545	GENENAME	APOA1
T56545	TARGTYPE	Clinical trial
T56545	SYNONYMS	Truncated apolipoprotein AI; Apolipoprotein A1; ApoAI; ApoA-I; Apo-AI
T56545	FUNCTION	As part of the SPAP complex, activates spermatozoa motility. Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT).
T56545	PDBSTRUC	6CM1; 6CLZ; 6CCX; 6CCH; 6CC9
T56545	BIOCLASS	Apolipoprotein
T56545	SEQUENCE	MKAAVLTLAVLFLTGSQARHFWQQDEPPQSPWDRVKDLATVYVDVLKDSGRDYVSQFEGSALGKQLNLKLLDNWDSVTSTFSKLREQLGPVTQEFWDNLEKETEGLRQEMSKDLEEVKAKVQPYLDDFQKKWQEEMELYRQKVEPLRAELQEGARQKLHELQEKLSPLGEEMRDRARAHVDALRTHLAPYSDELRQRLAARLEALKENGGARLAEYHAKATEHLSTLSEKAKPALEDLRQGLLPVLESFKVSFLSALEEYTKKLNTQ
T56545	DRUGINFO	D03AKH	CER-001	Phase 2
T56545	DRUGINFO	D0L8VA	CSL-112	Phase 2
T56545	DRUGINFO	D04PPK	CER-522	Phase 1
T56545	DRUGINFO	D0L1ZK	MDCO-216	Phase 1
T56545	DRUGINFO	D0I5QL	CRD-5	Discontinued in Phase 2
T56545	DRUGINFO	D03FPA	APP-018	Discontinued in Phase 1
T56545	DRUGINFO	D02TLD	AMT-050	Terminated
T56545	DRUGINFO	D05AON	LSI-518P	Terminated

T37742	TARGETID	T37742
T37742	FORMERID	TTDR00446
T37742	UNIPROID	SAMP_HUMAN
T37742	TARGNAME	Serum amyloid P-component (APCS)
T37742	GENENAME	APCS
T37742	TARGTYPE	Clinical trial
T37742	SYNONYMS	SAP; APCS; 9.5S alpha-1-glycoprotein
T37742	FUNCTION	Can interact with DNA and histones and may scavenge nuclear material released from damaged circulating cells. May also function as a calcium-dependent lectin.
T37742	PDBSTRUC	4AYU; 4AVV; 4AVT; 4AVS; 3KQR
T37742	BIOCLASS	Pentraxin family
T37742	SEQUENCE	MNKPLLWISVLTSLLEAFAHTDLSGKVFVFPRESVTDHVNLITPLEKPLQNFTLCFRAYSDLSRAYSLFSYNTQGRDNELLVYKERVGEYSLYIGRHKVTSKVIEKFPAPVHICVSWESSSGIAEFWINGTPLVKKGLRQGYFVEAQPKIVLGQEQDSYGGKFDRSQSFVGEIGDLYMWDSVLPPENILSAYQGTPLPANILDWQALNYEIRGYVIIKPLVWV
T37742	DRUGINFO	D19RKX	Zinpentraxin alfa	Phase 3
T37742	DRUGINFO	D05FBZ	CPHPC	Phase 1/2
T37742	DRUGINFO	D07LBQ	GSK2398852	Phase 1
T37742	DRUGINFO	D0AY1I	GSK-2315698	Phase 1

T30635	TARGETID	T30635
T30635	FORMERID	TTDR00498
T30635	UNIPROID	CXL10_HUMAN
T30635	TARGNAME	C-X-C motif chemokine 10 (CXCL10)
T30635	GENENAME	CXCL10
T30635	TARGTYPE	Clinical trial
T30635	SYNONYMS	Small-inducible cytokine B10; SCYB10; IP-10; INP10; Gamma-IP10; 10 kDa interferon gamma-induced protein
T30635	FUNCTION	Pro-inflammatory cytokine that is involved in a wide variety of processes such as chemotaxis, differentiation, and activation of peripheral immune cells, regulation of cell growth, apoptosis and modulation of angiostatic effects. Plays thereby an important role during viral infections by stimulating the activation and migration of immune cells to the infected sites (By similarity). Mechanistically, binding of CXCL10 to the CXCR3 receptor activates G protein-mediated signaling and results in downstream activation of phospholipase C-dependent pathway, an increase in intracellular calcium production and actin reorganization. In turn, recruitment of activated Th1 lymphocytes occurs at sites of inflammation. Activation of the CXCL10/CXCR3 axis plays also an important role in neurons in response to brain injury for activating microglia, the resident macrophage population of the central nervous system, and directing them to the lesion site. This recruitment is an essential element for neuronal reorganization (By similarity).
T30635	PDBSTRUC	1O80; 1O7Z; 1O7Y; 1LV9
T30635	BIOCLASS	Cytokine: CXC chemokine
T30635	SEQUENCE	MNQTAILICCLIFLTLSGIQGVPLSRTVRCTCISISNQPVNPRSLEKLEIIPASQFCPRVEIIATMKKKGEKRCLNPESKAIKNLLKAVSKERSKRSP
T30635	DRUGINFO	D00YWL	BMS-936557	Phase 2
T30635	DRUGINFO	D03VNB	NI-0801	Phase 2
T30635	DRUGINFO	D0C1UF	MDX-1100	Phase 2
T30635	DRUGINFO	D0L7LH	Anti-IP10	Phase 2
T30635	DRUGINFO	D0VE3U	JT02	Phase 2
T30635	DRUGINFO	D1A8NU	NG-641	Phase 1
T30635	DRUGINFO	D0F6OK	N-Methylleucine	Investigative

T67801	TARGETID	T67801
T67801	FORMERID	TTDR01148
T67801	UNIPROID	TRFL_HUMAN
T67801	TARGNAME	Lactotransferrin (LTF)
T67801	GENENAME	LTF
T67801	TARGTYPE	Clinical trial
T67801	SYNONYMS	Talalactoferrin; Lactoferrin; LF; Growth-inhibiting protein 12; GIG12
T67801	FUNCTION	Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate.
T67801	PDBSTRUC	2PMS; 2HD4; 2GMD; 2GMC; 2DP4
T67801	BIOCLASS	Transferrin
T67801	ECNUMBER	EC 3.4.21.-
T67801	SEQUENCE	MKLVFLVLLFLGALGLCLAGRRRSVQWCAVSQPEATKCFQWQRNMRKVRGPPVSCIKRDSPIQCIQAIAENRADAVTLDGGFIYEAGLAPYKLRPVAAEVYGTERQPRTHYYAVAVVKKGGSFQLNELQGLKSCHTGLRRTAGWNVPIGTLRPFLNWTGPPEPIEAAVARFFSASCVPGADKGQFPNLCRLCAGTGENKCAFSSQEPYFSYSGAFKCLRDGAGDVAFIRESTVFEDLSDEAERDEYELLCPDNTRKPVDKFKDCHLARVPSHAVVARSVNGKEDAIWNLLRQAQEKFGKDKSPKFQLFGSPSGQKDLLFKDSAIGFSRVPPRIDSGLYLGSGYFTAIQNLRKSEEEVAARRARVVWCAVGEQELRKCNQWSGLSEGSVTCSSASTTEDCIALVLKGEADAMSLDGGYVYTAGKCGLVPVLAENYKSQQSSDPDPNCVDRPVEGYLAVAVVRRSDTSLTWNSVKGKKSCHTAVDRTAGWNIPMGLLFNQTGSCKFDEYFSQSCAPGSDPRSNLCALCIGDEQGENKCVPNSNERYYGYTGAFRCLAENAGDVAFVKDVTVLQNTDGNNNEAWAKDLKLADFALLCLDGKRKPVTEARSCHLAMAPNHAVVSRMDKVERLKQVLLHQQAKFGRNGSDCPDKFCLFQSETKNLLFNDNTECLARLHGKTTYEKYLGPQYVAGITNLKKCSTSPLLEACEFLRK
T67801	DRUGINFO	D05UWI	Parecoxib	Phase 4
T67801	DRUGINFO	D0IM6O	Talactoferrin	Phase 3
T67801	DRUGINFO	D0D8EY	HLF 1-11	Phase 1/2
T67801	DRUGINFO	D0C0JT	Nimesulide	Terminated
T67801	DRUGINFO	D01XEY	Alpha-D-Fucose	Investigative
T67801	DRUGINFO	D03ZSY	Nitrilotriacetic Acid	Investigative
T67801	DRUGINFO	D0H6MC	3h-Indole-5,6-Diol	Investigative
T67801	DRUGINFO	D0N0UC	Lauric Acid	Investigative
T67801	DRUGINFO	D0G6XS	Fucose	Investigative
T67801	DRUGINFO	D07LUR	Alpha-D-Mannose	Investigative

T89873	TARGETID	T89873
T89873	FORMERID	TTDR01293
T89873	UNIPROID	FRIH_HUMAN
T89873	TARGNAME	Ferritin (FTH1)
T89873	GENENAME	FTH1
T89873	TARGTYPE	Clinical trial
T89873	SYNONYMS	PIG15; OK/SW-cl.84; Ferritin heavy chain; Ferritin H subunit; FTHL6; FTH; Cell proliferationinducing gene 15 protein; Cell proliferation-inducing gene 15 protein
T89873	FUNCTION	Important for iron homeostasis. Has ferroxidase activity. Iron is taken up in the ferrous form and deposited as ferric hydroxides after oxidation. Also plays a role in delivery of iron to cells. Mediates iron uptake in capsule cells of the developing kidney. Stores iron in a soluble, non-toxic, readily available form.
T89873	PDBSTRUC	6IPQ; 6IPP; 6IPO; 6IPC; 6H5I
T89873	BIOCLASS	Metal ion oxidoreductase
T89873	ECNUMBER	EC 1.16.3.1
T89873	SEQUENCE	MTTASTSQVRQNYHQDSEAAINRQINLELYASYVYLSMSYYFDRDDVALKNFAKYFLHQSHEEREHAEKLMKLQNQRGGRIFLQDIKKPDCDDWESGLNAMECALHLEKNVNQSLLELHKLATDKNDPHLCDFIETHYLNEQVKAIKELGDHVTNLRKMGAPESGLAEYLFDKHTLGDSDNES
T89873	DRUGINFO	D0D8KU	Ferritarg P	Phase 1/2

T01597	TARGETID	T01597
T01597	FORMERID	TTDI02035
T01597	UNIPROID	CATA_HUMAN
T01597	TARGNAME	Catalase (CAT)
T01597	GENENAME	CAT
T01597	TARGTYPE	Clinical trial
T01597	SYNONYMS	Human catalase
T01597	FUNCTION	Promotes growth of cells including T-cells, B-cells, myeloid leukemia cells, melanoma cells, mastocytoma cells and normal and transformed fibroblast cells. Occurs in almost all aerobically respiring organisms and serves to protect cells from the toxic effects of hydrogen peroxide.
T01597	PDBSTRUC	1QQW; 1F4J; 1DGH; 1DGG; 1DGF
T01597	BIOCLASS	Peroxide acceptor oxidoreductase
T01597	ECNUMBER	EC 1.11.1.6
T01597	SEQUENCE	MADSRDPASDQMQHWKEQRAAQKADVLTTGAGNPVGDKLNVITVGPRGPLLVQDVVFTDEMAHFDRERIPERVVHAKGAGAFGYFEVTHDITKYSKAKVFEHIGKKTPIAVRFSTVAGESGSADTVRDPRGFAVKFYTEDGNWDLVGNNTPIFFIRDPILFPSFIHSQKRNPQTHLKDPDMVWDFWSLRPESLHQVSFLFSDRGIPDGHRHMNGYGSHTFKLVNANGEAVYCKFHYKTDQGIKNLSVEDAARLSQEDPDYGIRDLFNAIATGKYPSWTFYIQVMTFNQAETFPFNPFDLTKVWPHKDYPLIPVGKLVLNRNPVNYFAEVEQIAFDPSNMPPGIEASPDKMLQGRLFAYPDTHRHRLGPNYLHIPVNCPYRARVANYQRDGPMCMQDNQGGAPNYYPNSFGAPEQQPSALEHSIQYSGEVRRFNTANDDNVTQVRAFYVNVLNEEQRKRLCENIAGHLKDAQIFIQKKAVKNFTEVHPDYGSHIQALLDKYNAEKPKNAIHTFVQSGSHLAAREKANL
T01597	DRUGINFO	D06VAQ	EUK-189	Phase 1

T23673	TARGETID	T23673
T23673	FORMERID	TTDI02287
T23673	UNIPROID	RAF1_HUMAN
T23673	TARGNAME	Proto-oncogene c-RAF (c-RAF)
T23673	GENENAME	RAF1
T23673	TARGTYPE	Clinical trial
T23673	SYNONYMS	cRaf; Raf-1; RAF proto-oncogene serine/threonine-protein kinase; RAF
T23673	FUNCTION	RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that comprises a sequential phosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and the extracellular signal-regulated kinases (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (on residues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylyl cyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation. Phosphorylates PPP1R12A resulting in inhibition of the phosphatase activity. Phosphorylates TNNT2/cardiac muscle troponin T. Can promote NF-kB activation and inhibit signal transducers involved in motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2), proliferation and angiogenesis (RB1). Can protect cells from apoptosis also by translocating to the mitochondria where it binds BCL2 and displaces BAD/Bcl2-antagonist of cell death. Regulates Rho signaling and migration, and is required for normal wound healing. Plays a role in the oncogenic transformation of epithelial cells via repression of the TJ protein, occludin (OCLN) by inducing the up-regulation of a transcriptional repressor SNAI2/SLUG, which induces down-regulation of OCLN. Restricts caspase activation in response to selected stimuli, notably Fas stimulation, pathogen-mediated macrophage apoptosis, and erythroid differentiation. Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation.
T23673	PDBSTRUC	4IHL; 4IEA; 4G3X; 4G0N; 4FJ3
T23673	BIOCLASS	Kinase
T23673	ECNUMBER	EC 2.7.11.1
T23673	SEQUENCE	MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYELMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF
T23673	DRUGINFO	D01WKE	Semapimod	Phase 2
T23673	DRUGINFO	DMYS25	BGB-3245	Phase 2
T23673	DRUGINFO	D0VS9E	GDC-5573	Phase 1
T23673	DRUGINFO	DU98JH	Belvarafenib	Phase 1

T89147	TARGETID	T89147
T89147	FORMERID	TTDI02177
T89147	UNIPROID	SODM_HUMAN
T89147	TARGNAME	Superoxide dismutase Mn (SOD Mn)
T89147	GENENAME	SOD2
T89147	TARGTYPE	Clinical trial
T89147	SYNONYMS	Superoxide dismutase [Mn], mitochondrial
T89147	FUNCTION	Destroys superoxide anion radicals which are normally produced within the cells and which are toxic to biological systems.
T89147	PDBSTRUC	5VF9; 5T30; 5GXO; 3C3T; 3C3S
T89147	BIOCLASS	Superoxide dismutase/reductase
T89147	ECNUMBER	EC 1.15.1.1
T89147	SEQUENCE	MLSRAVCGTSRQLAPVLGYLGSRQKHSLPDLPYDYGALEPHINAQIMQLHHSKHHAAYVNNLNVTEEKYQEALAKGDVTAQIALQPALKFNGGGHINHSIFWTNLSPNGGGEPKGELLEAIKRDFGSFDKFKEKLTAASVGVQGSGWGWLGFNKERGHLQIAACPNQDPLQGTTGLIPLLGIDVWEHAYYLQYKNVRPDYLKAIWNVINWENVTERYMACKK
T89147	DRUGINFO	D00OYQ	Imisopasem manganese	Phase 2

T05661	TARGETID	T05661
T05661	FORMERID	TTDI02111
T05661	UNIPROID	LCAT_HUMAN
T05661	TARGNAME	Lecithin-cholesterol acyltransferase (LCAT)
T05661	GENENAME	LCAT
T05661	TARGTYPE	Clinical trial
T05661	SYNONYMS	Phospholipidcholesterolacyltransferase; Phospholipid-cholesterol acyltransferase; Phosphatidylcholinesterol acyltransferase; Phosphatidylcholine-sterol acyltransferase
T05661	FUNCTION	Synthesized mainly in the liver and secreted into plasma where it converts cholesterol and phosphatidylcholines (lecithins) to cholesteryl esters and lysophosphatidylcholines on the surface of high and low density lipoproteins (HDLs and LDLs). The cholesterol ester is then transported back to the liver. Has a preference for plasma 16:0-18:2 or 18:O-18:2 phosphatidylcholines. Also produced in the brain by primary astrocytes, and esterifies free cholesterol on nascent APOE-containing lipoproteins secreted from glia and influences cerebral spinal fluid (CSF) APOE- and APOA1 levels. Together with APOE and the cholesterol transporter ABCA1, plays a key role in the maturation of glial-derived, nascent lipoproteins. Required for remodeling high-density lipoprotein particles into their spherical forms. Central enzyme in the extracellular metabolism of plasma lipoproteins.
T05661	PDBSTRUC	6MVD; 5TXF; 5BV7; 4XX1; 4XWG
T05661	BIOCLASS	Acyltransferase
T05661	ECNUMBER	EC 2.3.1.43
T05661	SEQUENCE	MGPPGSPWQWVTLLLGLLLPPAAPFWLLNVLFPPHTTPKAELSNHTRPVILVPGCLGNQLEAKLDKPDVVNWMCYRKTEDFFTIWLDLNMFLPLGVDCWIDNTRVVYNRSSGLVSNAPGVQIRVPGFGKTYSVEYLDSSKLAGYLHTLVQNLVNNGYVRDETVRAAPYDWRLEPGQQEEYYRKLAGLVEEMHAAYGKPVFLIGHSLGCLHLLYFLLRQPQAWKDRFIDGFISLGAPWGGSIKPMLVLASGDNQGIPIMSSIKLKEEQRITTTSPWMFPSRMAWPEDHVFISTPSFNYTGRDFQRFFADLHFEEGWYMWLQSRDLLAGLPAPGVEVYCLYGVGLPTPRTYIYDHGFPYTDPVGVLYEDGDDTVATRSTELCGLWQGRQPQPVHLLPLHGIQHLNMVFSNLTLEHINAILLGAYRQGPPASPTASPEPPPPE
T05661	DRUGINFO	D0T5YB	MEDI6012	Phase 2

T18639	TARGETID	T18639
T18639	FORMERID	TTDR00925
T18639	UNIPROID	FGF1_HUMAN
T18639	TARGNAME	Heparin-binding growth factor 1 (FGF1)
T18639	GENENAME	FGF1
T18639	TARGTYPE	Clinical trial
T18639	SYNONYMS	HBGF-1; Fibroblast growth factor 1; FGFA; FGF-1; Endothelial cell growth factor; ECGF-beta; ECGF; Beta-endothelial cell growth factor; Acidic fibroblast growth factor; AFGF
T18639	FUNCTION	Functions as potent mitogen in vitro. Acts as a ligand for FGFR1 and integrins. Binds to FGFR1 in the presence of heparin leading to FGFR1 dimerization and activation via sequential autophosphorylation on tyrosine residues which act as docking sites for interacting proteins, leading to the activation of several signaling cascades. Binds to integrin ITGAV:ITGB3. Its binding to integrin, subsequent ternary complex formation with integrin and FGFR1, and the recruitment of PTPN11 to the complex are essential for FGF1 signaling. Induces the phosphorylation and activation of FGFR1, FRS2, MAPK3/ERK1, MAPK1/ERK2 and AKT1. Can induce angiogenesis. Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration.
T18639	PDBSTRUC	4YOL; 4XKI; 4QO3; 4QC4; 4QBV
T18639	BIOCLASS	Growth factor
T18639	SEQUENCE	MAEGEITTFTALTEKFNLPPGNYKKPKLLYCSNGGHFLRILPDGTVDGTRDRSDQHIQLQLSAESVGEVYIKSTETGQYLAMDTDGLLYGSQTPNEECLFLERLEENHYNTYISKKHAEKNWFVGLKKNGSCKRGPRTHYGQKAILFLPLPVSSD
T18639	DRUGINFO	D06ANS	CVBT-141H	Phase 2
T18639	DRUGINFO	D01OSN	Riferminogene pecaplasmid	Discontinued in Phase 3
T18639	DRUGINFO	D07WQA	Naphthalene Trisulfonate	Investigative
T18639	DRUGINFO	D0I7FI	5-AMINO-NAPHTALENE-2-MONOSULFONATE	Investigative
T18639	DRUGINFO	D0P9RP	Sucrose Octasulfate	Investigative
T18639	DRUGINFO	D06VYT	O2-Sulfo-Glucuronic Acid	Investigative
T18639	DRUGINFO	D0B0SV	N,O6-Disulfo-Glucosamine	Investigative
T18639	DRUGINFO	D06EWG	Formic Acid	Investigative

T38431	TARGETID	T38431
T38431	FORMERID	TTDR00790
T38431	UNIPROID	S10A9_HUMAN
T38431	TARGNAME	Calgranulin B (S100A9)
T38431	GENENAME	S100A9
T38431	TARGTYPE	Clinical trial
T38431	SYNONYMS	S100 calcium-binding protein A9; Protein S100-A9; P14; Myeloid-related protein 14; Migration inhibitory factor-related protein 14; MRP14; MRP-14; Leukocyte L1 complex heavy chain; Calprotectin L1H subunit; Calgranulin-B; CAGB
T38431	FUNCTION	It can induce neutrophil chemotaxis, adhesion, can increase the bactericidal activity of neutrophils by promoting phagocytosis via activation of SYK, PI3K/AKT, and ERK1/2 and can induce degranulation of neutrophils by a MAPK-dependent mechanism. Predominantly found as calprotectin (S100A8/A9) which has a wide plethora of intra- and extracellular functions. The intracellular functions include: facilitating leukocyte arachidonic acid trafficking and metabolism, modulation of the tubulin-dependent cytoskeleton during migration of phagocytes and activation of the neutrophilic NADPH-oxidase. Activates NADPH-oxidase by facilitating the enzyme complex assembly at the cell membrane, transferring arachidonic acid, an essential cofactor, to the enzyme complex and S100A8 contributes to the enzyme assembly by directly binding to NCF2/P67PHOX. The extracellular functions involve proinflammatory, antimicrobial, oxidant-scavenging and apoptosis-inducing activities. Its proinflammatory activity includes recruitment of leukocytes, promotion of cytokine and chemokine production, and regulation of leukocyte adhesion and migration. Acts as an alarmin or a danger associated molecular pattern (DAMP) molecule and stimulates innate immune cells via binding to pattern recognition receptors such as Toll-like receptor 4 (TLR4) and receptor for advanced glycation endproducts (AGER). Binding to TLR4 and AGER activates the MAP-kinase and NF-kappa-B signaling pathways resulting in the amplification of the proinflammatory cascade. Has antimicrobial activity towards bacteria and fungi and exerts its antimicrobial activity probably via chelation of Zn(2+) which is essential for microbial growth. Can induce cell death via autophagy and apoptosis and this occurs through the cross-talk of mitochondria and lysosomes via reactive oxygen species (ROS) and the process involves BNIP3. Can regulate neutrophil number and apoptosis by an anti-apoptotic effect; regulates cell survival via ITGAM/ITGB and TLR4 and a signaling mechanism involving MEK-ERK. Its role as an oxidant scavenger has a protective role in preventing exaggerated tissue damage by scavenging oxidants. Can act as a potent amplifier of inflammation in autoimmunity as well as in cancer development and tumor spread. Has transnitrosylase activity; in oxidatively-modified low-densitity lipoprotein (LDL(ox))-induced S-nitrosylation of GAPDH on 'Cys-247' proposed to transfer the NO moiety from NOS2/iNOS to GAPDH via its own S-nitrosylated Cys-3. The iNOS-S100A8/A9 transnitrosylase complex is proposed to also direct selective inflammatory stimulus-dependent S-nitrosylation of multiple targets such as ANXA5, EZR, MSN and VIM by recognizing a [IL]-x-C-x-x-[DE] motif. S100A9 is a calcium- and zinc-binding protein which plays a prominent role in the regulation of inflammatory processes and immune response.
T38431	PDBSTRUC	6DS2; 5W1F; 5I8N; 4XJK; 4GGF
T38431	BIOCLASS	S100 calcium-binding protein
T38431	SEQUENCE	MTCKMSQLERNIETIINTFHQYSVKLGHPDTLNQGEFKELVRKDLQNFLKKENKNEKVIEHIMEDLDTNADKQLSFEEFIMLMARLTWASHEKMHEGDEGPGHHHKPGLGEGTP
T38431	DRUGINFO	D02JMU	Tasquinimod	Phase 3
T38431	DRUGINFO	D0G5SU	Paquinimod	Phase 2

T16601	TARGETID	T16601
T16601	FORMERID	TTDR00681
T16601	UNIPROID	CEAM5_HUMAN
T16601	TARGNAME	Carcinoembryonic antigen CEA (CD66e)
T16601	GENENAME	CEACAM5
T16601	TARGTYPE	Clinical trial
T16601	SYNONYMS	Meconium antigen 100; Carcinoembryonic antigen-related cell adhesion molecule 5; CEA; CD66e antigen
T16601	FUNCTION	Mediates homophilic and heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM6. Plays a role as an oncogene by promoting tumor progression; induces resistance to anoikis of colorectal carcinoma cells. Cell surface glycoprotein that plays a role in cell adhesion, intracellular signaling and tumor progression.
T16601	PDBSTRUC	2VER; 2QST; 2QSQ; 1.00E+07
T16601	BIOCLASS	Immunoglobulin
T16601	SEQUENCE	MESPSAPPHRWCIPWQRLLLTASLLTFWNPPTTAKLTIESTPFNVAEGKEVLLLVHNLPQHLFGYSWYKGERVDGNRQIIGYVIGTQQATPGPAYSGREIIYPNASLLIQNIIQNDTGFYTLHVIKSDLVNEEATGQFRVYPELPKPSISSNNSKPVEDKDAVAFTCEPETQDATYLWWVNNQSLPVSPRLQLSNGNRTLTLFNVTRNDTASYKCETQNPVSARRSDSVILNVLYGPDAPTISPLNTSYRSGENLNLSCHAASNPPAQYSWFVNGTFQQSTQELFIPNITVNNSGSYTCQAHNSDTGLNRTTVTTITVYAEPPKPFITSNNSNPVEDEDAVALTCEPEIQNTTYLWWVNNQSLPVSPRLQLSNDNRTLTLLSVTRNDVGPYECGIQNKLSVDHSDPVILNVLYGPDDPTISPSYTYYRPGVNLSLSCHAASNPPAQYSWLIDGNIQQHTQELFISNITEKNSGLYTCQANNSASGHSRTTVKTITVSAELPKPSISSNNSKPVEDKDAVAFTCEPEAQNTTYLWWVNGQSLPVSPRLQLSNGNRTLTLFNVTRNDARAYVCGIQNSVSANRSDPVTLDVLYGPDTPIISPPDSSYLSGANLNLSCHSASNPSPQYSWRINGIPQQHTQVLFIAKITPNNNGTYACFVSNLATGRNNSIVKSITVSASGTSPGLSAGATVGIMIGVLVGVALI
T16601	DRUGINFO	D05TBQ	SAR408701	Phase 3
T16601	DRUGINFO	D2D6NJ	Tusamitamab ravtansine	Phase 3
T16601	DRUGINFO	D02UKX	CAP1-6D	Phase 2
T16601	DRUGINFO	D0A3JJ	Pentacea	Phase 2
T16601	DRUGINFO	D0L7VC	GI-6207	Phase 2
T16601	DRUGINFO	D0O5XF	CeaVac	Phase 2
T16601	DRUGINFO	D0XP4A	Labetuzumab I-131	Phase 2
T16601	DRUGINFO	D03QMY	IDM-2101	Phase 2
T16601	DRUGINFO	D05ENG	AVX701	Phase 1/2
T16601	DRUGINFO	D0H5MS	CT84.66	Phase 1/2
T16601	DRUGINFO	D0T5DC	CAR-T cells targeting CEA	Phase 1/2
T16601	DRUGINFO	D1XI9E	BDC-1001	Phase 1/2
T16601	DRUGINFO	D00KDQ	Anti-CEA CAR-T cells	Phase 1
T16601	DRUGINFO	D08UVN	Anti-CEA CAR-T cells	Phase 1
T16601	DRUGINFO	D0L6HU	CAR-T Cells targeting CEA	Phase 1
T16601	DRUGINFO	D0M3GK	RG7813	Phase 1
T16601	DRUGINFO	D0P9UX	AMG 211	Phase 1
T16601	DRUGINFO	D0S1QN	Anti-CEA-CAR T	Phase 1
T16601	DRUGINFO	D0T5LQ	123-Iodine-labeled MFE-23	Phase 1
T16601	DRUGINFO	D0U1WP	MV-CEA	Phase 1
T16601	DRUGINFO	D0Z0EP	CIGB-M3	Phase 1
T16601	DRUGINFO	DR0M3F	CEA CAR-T	Phase 1
T16601	DRUGINFO	D7K5XP	NEO-201	Phase 1
T16601	DRUGINFO	D0S0DU	KSB-303	Discontinued in Phase 1/2
T16601	DRUGINFO	D00SJN	HLL1-Fab-A3B3	Investigative
T16601	DRUGINFO	D05GIO	ICT-037	Investigative

T67207	TARGETID	T67207
T67207	FORMERID	TTDI02068
T67207	UNIPROID	FCER2_HUMAN
T67207	TARGNAME	Lymphocyte IgE receptor (CD23)
T67207	GENENAME	FCER2
T67207	TARGTYPE	Clinical trial
T67207	SYNONYMS	Low affinity immunoglobulin epsilon Fc receptor soluble form; Low affinity immunoglobulin epsilon Fc receptor; Immunoglobulin Ebinding factor; FcepsilonRII; FCER2; Ctype lectin domain family 4 member J; CD23; BLAST2
T67207	FUNCTION	Low-affinity receptor for immunoglobulin E (IgE) and CR2/CD21. Has essential roles in the regulation of IgE production and in the differentiation of B-cells (it is a B-cell-specific antigen).
T67207	PDBSTRUC	5LGK; 4KI1; 4J6Q; 4J6P; 4J6N
T67207	BIOCLASS	Immunoglobulin
T67207	SEQUENCE	MEEGQYSEIEELPRRRCCRRGTQIVLLGLVTAALWAGLLTLLLLWHWDTTQSLKQLEERAARNVSQVSKNLESHHGDQMAQKSQSTQISQELEELRAEQQRLKSQDLELSWNLNGLQADLSSFKSQELNERNEASDLLERLREEVTKLRMELQVSSGFVCNTCPEKWINFQRKCYYFGKGTKQWVHARYACDDMEGQLVSIHSPEEQDFLTKHASHTGSWIGLRNLDLKGEFIWVDGSHVDYSNWAPGEPTSRSQGEDCVMMRGSGRWNDAFCDRKLGAWVCDRLATCTPPASEGSAESMGPDSRPDPDGRLPTPSAPLHS
T67207	DRUGINFO	D0M5JA	Lumiliximab	Phase 2

T49064	TARGETID	T49064
T49064	FORMERID	TTDS00429
T49064	UNIPROID	LIPG_HUMAN
T49064	TARGNAME	Gastric triacylglycerol lipase (LIPF)
T49064	GENENAME	LIPF
T49064	TARGTYPE	Clinical trial
T49064	SYNONYMS	Gastric lipase; GL
T49064	FUNCTION	An acidic lipase secreted by the gastric chief cells in the fundic mucosa in the stomach. Makes up 30% of lipid hydrolysis occurring during digestion in the human adult,
T49064	PDBSTRUC	1HLG
T49064	BIOCLASS	Carboxylic ester hydrolase
T49064	ECNUMBER	EC 3.1.1.3
T49064	SEQUENCE	MWLLLTMASLISVLGTTHGLFGKLHPGSPEVTMNISQMITYWGYPNEEYEVVTEDGYILEVNRIPYGKKNSGNTGQRPVVFLQHGLLASATNWISNLPNNSLAFILADAGYDVWLGNSRGNTWARRNLYYSPDSVEFWAFSFDEMAKYDLPATIDFIVKKTGQKQLHYVGHSQGTTIGFIAFSTNPSLAKRIKTFYALAPVATVKYTKSLINKLRFVPQSLFKFIFGDKIFYPHNFFDQFLATEVCSREMLNLLCSNALFIICGFDSKNFNTSRLDVYLSHNPAGTSVQNMFHWTQAVKSGKFQAYDWGSPVQNRMHYDQSQPPYYNVTAMNVPIAVWNGGKDLLADPQDVGLLLPKLPNLIYHKEIPFYNHLDFIWAMDAPQEVYNDIVSMISEDKK
T49064	DRUGINFO	D04NRB	Cetilistat	Phase 3
T49064	DRUGINFO	D09BWD	Undecyl-Phosphinic Acid Butyl Ester	Investigative
T49064	DRUGINFO	D02UVH	B-Octylglucoside	Investigative

T67416	TARGETID	T67416
T67416	FORMERID	TTDI01994
T67416	UNIPROID	SYEP_HUMAN
T67416	TARGNAME	Bifunctional aminoacyl-tRNA synthetase (EPRS)
T67416	GENENAME	EPRS
T67416	TARGTYPE	Clinical trial
T67416	SYNONYMS	QPRS; QARS; ProlinetRNA ligase; PIG32; GlutamatylprolyltRNA synthetase; Glutamatyl-prolyl-tRNA synthetase; GluRS; EPRS; Cell proliferationinducing gene 32 protein; Cell proliferation-inducing gene 32 protein; Bifunctional glutamate/prolinetRNA ligase; Bifunctional glutamate/proline--tRNA ligase; Bifunctional aminoacyltRNA synthetase
T67416	FUNCTION	The phosphorylation of EPRS, induced by interferon-gamma, dissociates the protein from the aminoacyl-tRNA synthetase multienzyme complex and recruits it to the GAIT complex that binds to stem loop-containing GAIT elements in the 3'-UTR of diverse inflammatory mRNAs (such as ceruplasmin), suppressing their translation. Interferon-gamma can therefore redirect, in specific cells, the EPRS function from protein synthesis to translation inhibition. Also functions as an effector of the mTORC1 signaling pathway by promoting, through SLC27A1, the uptake of long-chain fatty acid by adipocytes. Thereby, it also plays a role in fat metabolism and more indirectly influences lifespan. Multifunctional protein which is primarily part of the aminoacyl-tRNA synthetase multienzyme complex, also know as multisynthetase complex, that catalyzes the attachment of the cognate amino acid to the corresponding tRNA in a two-step reaction: the amino acid is first activated by ATP to form a covalent intermediate with AMP and is then transferred to the acceptor end of the cognate tRNA.
T67416	PDBSTRUC	5Y6L; 5VAD; 5V58; 5BMU; 5A5H
T67416	BIOCLASS	Carbon-oxygen ligase
T67416	SEQUENCE	MATLSLTVNSGDPPLGALLAVEHVKDDVSISVEEGKENILHVSENVIFTDVNSILRYLARVATTAGLYGSNLMEHTEIDHWLEFSATKLSSCDSFTSTINELNHCLSLRTYLVGNSLSLADLCVWATLKGNAAWQEQLKQKKAPVHVKRWFGFLEAQQAFQSVGTKWDVSTTKARVAPEKKQDVGKFVELPGAEMGKVTVRFPPEASGYLHIGHAKAALLNQHYQVNFKGKLIMRFDDTNPEKEKEDFEKVILEDVAMLHIKPDQFTYTSDHFETIMKYAEKLIQEGKAYVDDTPAEQMKAEREQRIDSKHRKNPIEKNLQMWEEMKKGSQFGQSCCLRAKIDMSSNNGCMRDPTLYRCKIQPHPRTGNKYNVYPTYDFACPIVDSIEGVTHALRTTEYHDRDEQFYWIIEALGIRKPYIWEYSRLNLNNTVLSKRKLTWFVNEGLVDGWDDPRFPTVRGVLRRGMTVEGLKQFIAAQGSSRSVVNMEWDKIWAFNKKVIDPVAPRYVALLKKEVIPVNVPEAQEEMKEVAKHPKNPEVGLKPVWYSPKVFIEGADAETFSEGEMVTFINWGNLNITKIHKNADGKIISLDAKLNLENKDYKKTTKVTWLAETTHALPIPVICVTYEHLITKPVLGKDEDFKQYVNKNSKHEELMLGDPCLKDLKKGDIIQLQRRGFFICDQPYEPVSPYSCKEAPCVLIYIPDGHTKEMPTSGSKEKTKVEATKNETSAPFKERPTPSLNNNCTTSEDSLVLYNRVAVQGDVVRELKAKKAPKEDVDAAVKQLLSLKAEYKEKTGQEYKPGNPPAEIGQNISSNSSASILESKSLYDEVAAQGEVVRKLKAEKSPKAKINEAVECLLSLKAQYKEKTGKEYIPGQPPLSQSSDSSPTRNSEPAGLETPEAKVLFDKVASQGEVVRKLKTEKAPKDQVDIAVQELLQLKAQYKSLIGVEYKPVSATGAEDKDKKKKEKENKSEKQNKPQKQNDGQRKDPSKNQGGGLSSSGAGEGQGPKKQTRLGLEAKKEENLADWYSQVITKSEMIEYHDISGCYILRPWAYAIWEAIKDFFDAEIKKLGVENCYFPMFVSQSALEKEKTHVADFAPEVAWVTRSGKTELAEPIAIRPTSETVMYPAYAKWVQSHRDLPIKLNQWCNVVRWEFKHPQPFLRTREFLWQEGHSAFATMEEAAEEVLQILDLYAQVYEELLAIPVVKGRKTEKEKFAGGDYTTTIEAFISASGRAIQGGTSHHLGQNFSKMFEIVFEDPKIPGEKQFAYQNSWGLTTRTIGVMTMVHGDNMGLVLPPRVACVQVVIIPCGITNALSEEDKEALIAKCNDYRRRLLSVNIRVRADLRDNYSPGWKFNHWELKGVPIRLEVGPRDMKSCQFVAVRRDTGEKLTVAENEAETKLQAILEDIQVTLFTRASEDLKTHMVVANTMEDFQKILDSGKIVQIPFCGEIDCEDWIKKTTARDQDLEPGAPSMGAKSLCIPFKPLCELQPGAKCVCGKNPAKYYTLFGRSY
T67416	DRUGINFO	D0U3KP	HT-100	Phase 2

T47466	TARGETID	T47466
T47466	FORMERID	TTDI02359
T47466	UNIPROID	HEM3_HUMAN
T47466	TARGNAME	Porphobilinogen deaminase (HMBS)
T47466	GENENAME	HMBS
T47466	TARGTYPE	Clinical trial
T47466	SYNONYMS	Preuroporphyrinogen synthase; PBGD; Hydroxymethylbilane synthase; HMBS
T47466	FUNCTION	Tetrapolymerization of the monopyrrole PBG into the hydroxymethylbilane pre-uroporphyrinogen in several discrete steps.
T47466	PDBSTRUC	5M7F; 5M6R; 3EQ1; 3ECR
T47466	BIOCLASS	Alkyl aryl transferase
T47466	ECNUMBER	EC 2.5.1.61
T47466	SEQUENCE	MSGNGNAAATAEENSPKMRVIRVGTRKSQLARIQTDSVVATLKASYPGLQFEIIAMSTTGDKILDTALSKIGEKSLFTKELEHALEKNEVDLVVHSLKDLPTVLPPGFTIGAICKRENPHDAVVFHPKFVGKTLETLPEKSVVGTSSLRRAAQLQRKFPHLEFRSIRGNLNTRLRKLDEQQEFSAIILATAGLQRMGWHNRVGQILHPEECMYAVGQGALGVEVRAKDQDILDLVGVLHDPETLLRCIAERAFLRHLEGGCSVPVAVHTAMKDGQLYLTGGVWSLDGSDSIQETMQATIHVPAQHEDGPEDDPQLVGITARNIPRGPQLAAQNLGISLANLLLSKGAKNILDVARQLNDAH
T47466	DRUGINFO	D0C9IS	P-9808	Phase 2

T52671	TARGETID	T52671
T52671	FORMERID	TTDR00831
T52671	UNIPROID	APOA_HUMAN
T52671	TARGNAME	Apolipoprotein(a) (LPA)
T52671	GENENAME	LPA
T52671	TARGTYPE	Clinical trial
T52671	SYNONYMS	Lp(a); Lipoprotein(a); LPA; Apo(a)
T52671	FUNCTION	Apo(a) is the main constituent of lipoprotein(a) (Lp(a)). It has serine proteinase activity and is able of autoproteolysis. Inhibits tissue-type plasminogen activator 1. Lp(a) may be a ligand for megalin/Gp 330.
T52671	PDBSTRUC	4KIV; 4BVW; 4BVV; 4BVD; 4BVC
T52671	BIOCLASS	Apolipoprotein
T52671	ECNUMBER	EC 3.4.21.-
T52671	SEQUENCE	MEHKEVVLLLLLFLKSAAPEQSHVVQDCYHGDGQSYRGTYSTTVTGRTCQAWSSMTPHQHNRTTENYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDPVAAPYCYTRDPSVRWEYCNLTQCSDAEGTAVAPPTITPIPSLEAPSEQAPTEQRPGVQECYHGNGQSYQGTYFITVTGRTCQAWSSMTPHSHSRTPAYYPNAGLIKNYCRNPDPVAAPWCYTTDPSVRWEYCNLTRCSDAEWTAFVPPNVILAPSLEAFFEQALTEETPGVQDCYYHYGQSYRGTYSTTVTGRTCQAWSSMTPHQHSRTPENYPNAGLTRNYCRNPDAEIRPWCYTMDPSVRWEYCNLTQCLVTESSVLATLTVVPDPSTEASSEEAPTEQSPGVQDCYHGDGQSYRGSFSTTVTGRTCQSWSSMTPHWHQRTTEYYPNGGLTRNYCRNPDAEISPWCYTMDPNVRWEYCNLTQCPVTESSVLATSTAVSEQAPTEQSPTVQDCYHGDGQSYRGSFSTTVTGRTCQSWSSMTPHWHQRTTEYYPNGGLTRNYCRNPDAEIRPWCYTMDPSVRWEYCNLTQCPVMESTLLTTPTVVPVPSTELPSEEAPTENSTGVQDCYRGDGQSYRGTLSTTITGRTCQSWSSMTPHWHRRIPLYYPNAGLTRNYCRNPDAEIRPWCYTMDPSVRWEYCNLTRCPVTESSVLTTPTVAPVPSTEAPSEQAPPEKSPVVQDCYHGDGRSYRGISSTTVTGRTCQSWSSMIPHWHQRTPENYPNAGLTENYCRNPDSGKQPWCYTTDPCVRWEYCNLTQCSETESGVLETPTVVPVPSMEAHSEAAPTEQTPVVRQCYHGNGQSYRGTFSTTVTGRTCQSWSSMTPHRHQRTPENYPNDGLTMNYCRNPDADTGPWCFTMDPSIRWEYCNLTRCSDTEGTVVAPPTVIQVPSLGPPSEQDCMFGNGKGYRGKKATTVTGTPCQEWAAQEPHRHSTFIPGTNKWAGLEKNYCRNPDGDINGPWCYTMNPRKLFDYCDIPLCASSSFDCGKPQVEPKKCPGSIVGGCVAHPHSWPWQVSLRTRFGKHFCGGTLISPEWVLTAAHCLKKSSRPSSYKVILGAHQEVNLESHVQEIEVSRLFLEPTQADIALLKLSRPAVITDKVMPACLPSPDYMVTARTECYITGWGETQGTFGTGLLKEAQLLVIENEVCNHYKYICAEHLARGTDSCQGDSGGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYARVSRFVTWIEGMMRNN
T52671	DRUGINFO	DTG28Y	LY3473329	Phase 2
T52671	DRUGINFO	D02XAC	MG-1102	Phase 1

T94094	TARGETID	T94094
T94094	FORMERID	TTDR00064
T94094	UNIPROID	DPOL_HCMVA
T94094	TARGNAME	Cytomegalovirus DNA polymerase (CMV UL54)
T94094	GENENAME	CMV UL54
T94094	TARGTYPE	Clinical trial
T94094	SYNONYMS	UL54; DNA polymerase of Human herpesvirus 5
T94094	FUNCTION	Replicates viral genomic DNA in the late phase of lytic infection, producing long concatemeric DNA. The replication complex is composed of six viral proteins: the DNA polymerase, processivity factor, primase, primase-associated factor, helicase, and ssDNA-binding protein.
T94094	PDBSTRUC	1YYP
T94094	BIOCLASS	DNA polymerase type-B family
T94094	ECNUMBER	EC 2.7.7.7
T94094	SEQUENCE	MFFNPYLSGGVTGGAVAGGRRQRSQPGSAQGSGKRPPQKQFLQIVPRGVMFDGQTGLIKHKTGRLPLMFYREIKHLLSHDMVWPCPWRETLVGRVVGPIRFHTYDQTDAVLFFDSPENVSPRYRQHLVPSGNVLRFFGATEHGYSICVNVFGQRSYFYCEYSDTDRLREVIASVGELVPEPRTPYAVSVTPATKTSIYGYGTRPVPDLQCVSISNWTMARKIGEYLLEQGFPVYEVRVDPLTRLVIDRRITTFGWCSVNRYDWRQQGRASTCDIEVDCDVSDLVAVPDDSSWPRYRCLSFDIECMSGEGGFPCAEKSDDIVIQISCVCYETGGNTAVDQGIPNGNDGRGCTSEGVIFGHSGLHLFTIGTCGQVGPDVDVYEFPSEYELLLGFMLFFQRYAPAFVTGYNINSFDLKYILTRLEYLYKVDSQRFCKLPTAQGGRFFLHSPAVGFKRQYAAAFPSASHNNPASTAATKVYIAGSVVIDMYPVCMAKTNSPNYKLNTMAELYLRQRKDDLSYKDIPRCFVANAEGRAQVGRYCLQDAVLVRDLFNTINFHYEAGAIARLAKIPLRRVIFDGQQIRIYTSLLDECACRDFILPNHYSKGTTVPETNSVAVSPNAAIISTAAVPGDAGSVAAMFQMSPPLQSAPSSQDGVSPGSGSNSSSSVGVFSVGSGSSGGVGVSNDNHGAGGTAAVSYQGATVFEPEVGYYNDPVAVFDFASLYPSIIMAHNLCYSTLLVPGGEYPVDPADVYSVTLENGVTHRFVRASVRVSVLSELLNKWVSQRRAVRECMRECQDPVRRMLLDKEQMALKVTCNAFYGFTGVVNGMMPCLPIAASITRIGRDMLERTARFIKDNFSEPCFLHNFFNQEDYVVGTREGDSEESSALPEGLETSSGGSNERRVEARVIYGDTDSVFVRFRGLTPQALVARGPSLAHYVTACLFVEPVKLEFEKVFVSLMMICKKRYIGKVEGASGLSMKGVDLVRKTACEFVKGVTRDVLSLLFEDREVSEAAVRLSRLSLDEVKKYGVPRGFWRILRRLVQARDDLYLHRVRVEDLVLSSVLSKDISLYRQSNLPHIAVIKRLAARSEELPSVGDRVFYVLTAPGVRTAPQGSSDNGDSVTAGVVSRSDAIDGTDDDADGGGVEESNRRGGEPAKKRARKPPSAVCNYEVAEDPSYVREHGVPIHADKYFEQVLKAVTNVLSPVFPGGETARKDKFLHMVLPRRLHLEPAFLPYSVKAHECC
T94094	DRUGINFO	D0H1OL	Guanosine	Phase 1
T94094	DRUGINFO	D04AWP	Guanosine-5'-Monophosphate	Investigative

T74937	TARGETID	T74937
T74937	FORMERID	TTDI02054
T74937	UNIPROID	DOPO_HUMAN
T74937	TARGNAME	Dopamine beta hydroxylase (DBH)
T74937	GENENAME	DBH
T74937	TARGTYPE	Clinical trial
T74937	SYNONYMS	Soluble dopamine betahydroxylase; Dopamine betamonooxygenase; Dopamine betahydroxylase; Dopamine beta-monooxygenase; Dopamine beta-hydroxylase
T74937	FUNCTION	Conversion of dopamine to noradrenaline.
T74937	PDBSTRUC	4ZEL
T74937	BIOCLASS	Paired donor oxygen oxidoreductase
T74937	ECNUMBER	EC 1.14.17.1
T74937	SEQUENCE	MPALSRWASLPGPSMREAAFMYSTAVAIFLVILVAALQGSAPRESPLPYHIPLDPEGSLELSWNVSYTQEAIHFQLLVRRLKAGVLFGMSDRGELENADLVVLWTDGDTAYFADAWSDQKGQIHLDPQQDYQLLQVQRTPEGLTLLFKRPFGTCDPKDYLIEDGTVHLVYGILEEPFRSLEAINGSGLQMGLQRVQLLKPNIPEPELPSDACTMEVQAPNIQIPSQETTYWCYIKELPKGFSRHHIIKYEPIVTKGNEALVHHMEVFQCAPEMDSVPHFSGPCDSKMKPDRLNYCRHVLAAWALGAKAFYYPEEAGLAFGGPGSSRYLRLEVHYHNPLVIEGRNDSSGIRLYYTAKLRRFNAGIMELGLVYTPVMAIPPRETAFILTGYCTDKCTQLALPPSGIHIFASQLHTHLTGRKVVTVLVRDGREWEIVNQDNHYSPHFQEIRMLKKVVSVHPGDVLITSCTYNTEDRELATVGGFGILEEMCVNYVHYYPQTQLELCKSAVDAGFLQKYFHLINRFNNEDVCTCPQASVSQQFTSVPWNSFNRDVLKALYSFAPISMHCNKSSAVRFQGEWNLQPLPKVISTLEEPTPQCPTSQGRSPAGPTVVSIGGGKG
T74937	DRUGINFO	D0H5HZ	Etamicastat	Phase 2
T74937	DRUGINFO	D0N5YD	Nepicastat oral	Phase 2

T33990	TARGETID	T33990
T33990	FORMERID	TTDC00263
T33990	UNIPROID	CSF1_HUMAN
T33990	TARGNAME	Macrophage colony-stimulating factor 1 (CSF1)
T33990	GENENAME	CSF1
T33990	TARGTYPE	Clinical trial
T33990	SYNONYMS	Processed macrophagecolony-stimulating factor 1; MCSF; M-CSF; Lanimostim; CSF-1
T33990	FUNCTION	Promotes the release of proinflammatory chemokines, and thereby plays an important role in innate immunity and in inflammatory processes. Plays an important role in the regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone development. Required for normal male and female fertility. Promotes reorganization of the actin cytoskeleton, regulates formation of membrane ruffles, cell adhesion and cell migration. Plays a role in lipoprotein clearance. Cytokine that plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes.
T33990	PDBSTRUC	5LXF; 4WRM; 4WRL; 4FA8; 4ADF
T33990	SEQUENCE	MTAPGAAGRCPPTTWLGSLLLLVCLLASRSITEEVSEYCSHMIGSGHLQSLQRLIDSQMETSCQITFEFVDQEQLKDPVCYLKKAFLLVQDIMEDTMRFRDNTPNAIAIVQLQELSLRLKSCFTKDYEEHDKACVRTFYETPLQLLEKVKNVFNETKNLLDKDWNIFSKNCNNSFAECSSQDVVTKPDCNCLYPKAIPSSDPASVSPHQPLAPSMAPVAGLTWEDSEGTEGSSLLPGEQPLHTVDPGSAKQRPPRSTCQSFEPPETPVVKDSTIGGSPQPRPSVGAFNPGMEDILDSAMGTNWVPEEASGEASEIPVPQGTELSPSRPGGGSMQTEPARPSNFLSASSPLPASAKGQQPADVTGTALPRVGPVRPTGQDWNHTPQKTDHPSALLRDPPEPGSPRISSLRPQGLSNPSTLSAQPQLSRSHSSGSVLPLGELEGRRSTRDRRSPAEPEGGPASEGAARPLPRFNSVPLTDTGHERQSEGSFSPQLQESVFHLLVPSVILVLLAVGGLLFYRWRRRSHQEPQRADSPLEQPEGSPLTQDDRQVELPV
T33990	DRUGINFO	D06NQH	RG7155	Phase 2
T33990	DRUGINFO	D00MJI	Emactuzumab	Phase 1
T33990	DRUGINFO	D0PL8D	PLX73086	Phase 1
T33990	DRUGINFO	D18QIB	MSC110	Phase 1

T37154	TARGETID	T37154
T37154	FORMERID	TTDNC00448
T37154	UNIPROID	PPGB_HUMAN
T37154	TARGNAME	Cathepsin A (CTSA)
T37154	GENENAME	CTSA
T37154	TARGTYPE	Clinical trial
T37154	SYNONYMS	Protective protein for betagalactosidase; Protective protein cathepsin A; PPCA; Lysosomal protective protein 20 kDa chain; Lysosomal protective protein; Carboxypeptidase L; Carboxypeptidase C; CTSA
T37154	FUNCTION	Protective protein appears to be essential for both the activity of beta-galactosidase and neuraminidase, it associates with these enzymes and exerts a protective function necessary for their stability and activity. This protein is also a carboxypeptidase and can deamidate tachykinins.
T37154	PDBSTRUC	4MWT; 4MWS; 4CIB; 4CIA; 4CI9
T37154	BIOCLASS	Peptidase
T37154	ECNUMBER	EC 3.4.16.5
T37154	SEQUENCE	MIRAAPPPLFLLLLLLLLLVSWASRGEAAPDQDEIQRLPGLAKQPSFRQYSGYLKGSGSKHLHYWFVESQKDPENSPVVLWLNGGPGCSSLDGLLTEHGPFLVQPDGVTLEYNPYSWNLIANVLYLESPAGVGFSYSDDKFYATNDTEVAQSNFEALQDFFRLFPEYKNNKLFLTGESYAGIYIPTLAVLVMQDPSMNLQGLAVGNGLSSYEQNDNSLVYFAYYHGLLGNRLWSSLQTHCCSQNKCNFYDNKDLECVTNLQEVARIVGNSGLNIYNLYAPCAGGVPSHFRYEKDTVVVQDLGNIFTRLPLKRMWHQALLRSGDKVRMDPPCTNTTAASTYLNNPYVRKALNIPEQLPQWDMCNFLVNLQYRRLYRSMNSQYLKLLSSQKYQILLYNGDVDMACNFMGDEWFVDSLNQKMEVQRRPWLVKYGDSGEQIAGFVKEFSHIAFLTIKGAGHMVPTDKPLAAFTMFSRFLNKQPY
T37154	DRUGINFO	D01CIB	SAR164653	Phase 1
T37154	DRUGINFO	D01QJT	example 166  (WO2014154727)	Investigative
T37154	DRUGINFO	D0I9PF	PMID22861813C8a	Investigative

T11283	TARGETID	T11283
T11283	FORMERID	TTDR00663
T11283	UNIPROID	CH60_HUMAN
T11283	TARGNAME	Mitochondrial matrix protein P1 (HSPD1)
T11283	GENENAME	HSPD1
T11283	TARGTYPE	Clinical trial
T11283	SYNONYMS	P60 lymphocyte protein; HuCHA60; Hsp60; Heat shock protein 60; HSP-60; Chaperonin 60; CPN60; 60 kDa heat shock protein, mitochondrial; 60 kDa chaperonin
T11283	FUNCTION	Together with Hsp10, facilitates the correct folding of imported proteins. May also prevent misfolding and promote the refolding and proper assembly of unfolded polypeptides generated under stress conditions in the mitochondrial matrix. The functional units of these chaperonins consist of heptameric rings of the large subunit Hsp60, which function as a back-to-back double ring. In a cyclic reaction, Hsp60 ring complexes bind one unfolded substrate protein per ring, followed by the binding of ATP and association with 2 heptameric rings of the co-chaperonin Hsp10. This leads to sequestration of the substrate protein in the inner cavity of Hsp60 where, for a certain period of time, it can fold undisturbed by other cell components. Synchronous hydrolysis of ATP in all Hsp60 subunits results in the dissociation of the chaperonin rings and the release of ADP and the folded substrate protein. Chaperonin implicated in mitochondrial protein import and macromolecular assembly.
T11283	PDBSTRUC	4PJ1
T11283	BIOCLASS	Chaperonin ATPase
T11283	ECNUMBER	EC 5.6.1.7
T11283	SEQUENCE	MLRLPTVFRQMRPVSRVLAPHLTRAYAKDVKFGADARALMLQGVDLLADAVAVTMGPKGRTVIIEQSWGSPKVTKDGVTVAKSIDLKDKYKNIGAKLVQDVANNTNEEAGDGTTTATVLARSIAKEGFEKISKGANPVEIRRGVMLAVDAVIAELKKQSKPVTTPEEIAQVATISANGDKEIGNIISDAMKKVGRKGVITVKDGKTLNDELEIIEGMKFDRGYISPYFINTSKGQKCEFQDAYVLLSEKKISSIQSIVPALEIANAHRKPLVIIAEDVDGEALSTLVLNRLKVGLQVVAVKAPGFGDNRKNQLKDMAIATGGAVFGEEGLTLNLEDVQPHDLGKVGEVIVTKDDAMLLKGKGDKAQIEKRIQEIIEQLDVTTSEYEKEKLNERLAKLSDGVAVLKVGGTSDVEVNEKKDRVTDALNATRAAVEEGIVLGGGCALLRCIPALDSLTPANEDQKIGIEIIKRTLKIPAMTIAKNAGVEGSLIVEKIMQSSSEVGYDAMAGDFVNMVEKGIIDPTKVVRTALLDAAGVASLLTTAEVVVTEIPKEEKDPGMGAMGGMGGGMGGGMF
T11283	DRUGINFO	D0G6TL	DiaPep-277	Phase 3

T17048	TARGETID	T17048
T17048	FORMERID	TTDI01972
T17048	UNIPROID	TOP2A_HUMAN
T17048	TARGNAME	DNA topoisomerase II alpha (TOP2A)
T17048	GENENAME	TOP2A
T17048	TARGTYPE	Clinical trial
T17048	SYNONYMS	DNA topoisomerase II, alpha isozyme; DNA topoisomerase 2alpha; DNA topoisomerase 2-alpha
T17048	FUNCTION	Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segregation of daughter chromosomes. May play a role in regulating the period length of ARNTL/BMAL1 transcriptional oscillation. Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands.
T17048	PDBSTRUC	5NNE; 5GWK; 4R1F; 4FM9; 1ZXN
T17048	BIOCLASS	Topoisomerase
T17048	ECNUMBER	EC 5.6.2.3
T17048	SEQUENCE	MEVSPLQPVNENMQVNKIKKNEDAKKRLSVERIYQKKTQLEHILLRPDTYIGSVELVTQQMWVYDEDVGINYREVTFVPGLYKIFDEILVNAADNKQRDPKMSCIRVTIDPENNLISIWNNGKGIPVVEHKVEKMYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKLCNIFSTKFTVETASREYKKMFKQTWMDNMGRAGEMELKPFNGEDYTCITFQPDLSKFKMQSLDKDIVALMVRRAYDIAGSTKDVKVFLNGNKLPVKGFRSYVDMYLKDKLDETGNSLKVIHEQVNHRWEVCLTMSEKGFQQISFVNSIATSKGGRHVDYVADQIVTKLVDVVKKKNKGGVAVKAHQVKNHMWIFVNALIENPTFDSQTKENMTLQPKSFGSTCQLSEKFIKAAIGCGIVESILNWVKFKAQVQLNKKCSAVKHNRIKGIPKLDDANDAGGRNSTECTLILTEGDSAKTLAVSGLGVVGRDKYGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYKKNYEDEDSLKTLRYGKIMIMTDQDQDGSHIKGLLINFIHHNWPSLLRHRFLEEFITPIVKVSKNKQEMAFYSLPEFEEWKSSTPNHKKWKVKYYKGLGTSTSKEAKEYFADMKRHRIQFKYSGPEDDAAISLAFSKKQIDDRKEWLTNFMEDRRQRKLLGLPEDYLYGQTTTYLTYNDFINKELILFSNSDNERSIPSMVDGLKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSSYHHGEMSLMMTIINLAQNFVGSNNLNLLQPIGQFGTRLHGGKDSASPRYIFTMLSSLARLLFPPKDDHTLKFLYDDNQRVEPEWYIPIIPMVLINGAEGIGTGWSCKIPNFDVREIVNNIRRLMDGEEPLPMLPSYKNFKGTIEELAPNQYVISGEVAILNSTTIEISELPVRTWTQTYKEQVLEPMLNGTEKTPPLITDYREYHTDTTVKFVVKMTEEKLAEAERVGLHKVFKLQTSLTCNSMVLFDHVGCLKKYDTVLDILRDFFELRLKYYGLRKEWLLGMLGAESAKLNNQARFILEKIDGKIIIENKPKKELIKVLIQRGYDSDPVKAWKEAQQKVPDEEENEESDNEKETEKSDSVTDSGPTFNYLLDMPLWYLTKEKKDELCRLRNEKEQELDTLKRKSPSDLWKEDLATFIEELEAVEAKEKQDEQVGLPGKGGKAKGKKTQMAEVLPSPRGQRVIPRITIEMKAEAEKKNKKKIKNENTEGSPQEDGVELEGLKQRLEKKQKREPGTKTKKQTTLAFKPIKKGKKRNPWSDSESDRSSDESNFDVPPRETEPRRAATKTKFTMDLDSDEDFSDFDEKTDDEDFVPSDASPPKTKTSPKLSNKELKPQKSVVSDLEADDVKGSVPLSSSPPATHFPDETEITNPVPKKNVTVKKTAAKSQSSTSTTGAKKRAAPKGTKRDPALNSGVSQKPDPAKTKNRRKRKPSTSDDSDSNFEKIVSKAVTSKKSKGESDDFHMDFDSAVAPRAKSVRAKKPIKYLEESDEDDLF
T17048	DRUGINFO	D01ZMS	PK1	Phase 2
T17048	DRUGINFO	DE53JQ	Camsirubicin	Phase 2
T17048	DRUGINFO	DCT2Q3	Annamycin	Phase 1/2
T17048	DRUGINFO	DGZ38L	NK314	Investigative

T12909	TARGETID	T12909
T12909	FORMERID	TTDI02053
T12909	UNIPROID	DMD_HUMAN
T12909	TARGNAME	Dystrophin (DMD)
T12909	GENENAME	DMD
T12909	TARGTYPE	Clinical trial
T12909	SYNONYMS	Dystrophin
T12909	FUNCTION	Anchors the extracellular matrix to the cytoskeleton via F-actin. Ligand for dystroglycan. Component of the dystrophin-associated glycoprotein complex which accumulates at the neuromuscular junction (NMJ) and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma. Also implicated in signaling events and synaptic transmission.
T12909	PDBSTRUC	3UUN; 1EG4; 1EG3; 1DXX
T12909	BIOCLASS	Dystrophin protein
T12909	SEQUENCE	MLWWEEVEDCYEREDVQKKTFTKWVNAQFSKFGKQHIENLFSDLQDGRRLLDLLEGLTGQKLPKEKGSTRVHALNNVNKALRVLQNNNVDLVNIGSTDIVDGNHKLTLGLIWNIILHWQVKNVMKNIMAGLQQTNSEKILLSWVRQSTRNYPQVNVINFTTSWSDGLALNALIHSHRPDLFDWNSVVCQQSATQRLEHAFNIARYQLGIEKLLDPEDVDTTYPDKKSILMYITSLFQVLPQQVSIEAIQEVEMLPRPPKVTKEEHFQLHHQMHYSQQITVSLAQGYERTSSPKPRFKSYAYTQAAYVTTSDPTRSPFPSQHLEAPEDKSFGSSLMESEVNLDRYQTALEEVLSWLLSAEDTLQAQGEISNDVEVVKDQFHTHEGYMMDLTAHQGRVGNILQLGSKLIGTGKLSEDEETEVQEQMNLLNSRWECLRVASMEKQSNLHRVLMDLQNQKLKELNDWLTKTEERTRKMEEEPLGPDLEDLKRQVQQHKVLQEDLEQEQVRVNSLTHMVVVVDESSGDHATAALEEQLKVLGDRWANICRWTEDRWVLLQDILLKWQRLTEEQCLFSAWLSEKEDAVNKIHTTGFKDQNEMLSSLQKLAVLKADLEKKKQSMGKLYSLKQDLLSTLKNKSVTQKTEAWLDNFARCWDNLVQKLEKSTAQISQAVTTTQPSLTQTTVMETVTTVTTREQILVKHAQEELPPPPPQKKRQITVDSEIRKRLDVDITELHSWITRSEAVLQSPEFAIFRKEGNFSDLKEKVNAIEREKAEKFRKLQDASRSAQALVEQMVNEGVNADSIKQASEQLNSRWIEFCQLLSERLNWLEYQNNIIAFYNQLQQLEQMTTTAENWLKIQPTTPSEPTAIKSQLKICKDEVNRLSDLQPQIERLKIQSIALKEKGQGPMFLDADFVAFTNHFKQVFSDVQAREKELQTIFDTLPPMRYQETMSAIRTWVQQSETKLSIPQLSVTDYEIMEQRLGELQALQSSLQEQQSGLYYLSTTVKEMSKKAPSEISRKYQSEFEEIEGRWKKLSSQLVEHCQKLEEQMNKLRKIQNHIQTLKKWMAEVDVFLKEEWPALGDSEILKKQLKQCRLLVSDIQTIQPSLNSVNEGGQKIKNEAEPEFASRLETELKELNTQWDHMCQQVYARKEALKGGLEKTVSLQKDLSEMHEWMTQAEEEYLERDFEYKTPDELQKAVEEMKRAKEEAQQKEAKVKLLTESVNSVIAQAPPVAQEALKKELETLTTNYQWLCTRLNGKCKTLEEVWACWHELLSYLEKANKWLNEVEFKLKTTENIPGGAEEISEVLDSLENLMRHSEDNPNQIRILAQTLTDGGVMDELINEELETFNSRWRELHEEAVRRQKLLEQSIQSAQETEKSLHLIQESLTFIDKQLAAYIADKVDAAQMPQEAQKIQSDLTSHEISLEEMKKHNQGKEAAQRVLSQIDVAQKKLQDVSMKFRLFQKPANFEQRLQESKMILDEVKMHLPALETKSVEQEVVQSQLNHCVNLYKSLSEVKSEVEMVIKTGRQIVQKKQTENPKELDERVTALKLHYNELGAKVTERKQQLEKCLKLSRKMRKEMNVLTEWLAATDMELTKRSAVEGMPSNLDSEVAWGKATQKEIEKQKVHLKSITEVGEALKTVLGKKETLVEDKLSLLNSNWIAVTSRAEEWLNLLLEYQKHMETFDQNVDHITKWIIQADTLLDESEKKKPQQKEDVLKRLKAELNDIRPKVDSTRDQAANLMANRGDHCRKLVEPQISELNHRFAAISHRIKTGKASIPLKELEQFNSDIQKLLEPLEAEIQQGVNLKEEDFNKDMNEDNEGTVKELLQRGDNLQQRITDERKREEIKIKQQLLQTKHNALKDLRSQRRKKALEISHQWYQYKRQADDLLKCLDDIEKKLASLPEPRDERKIKEIDRELQKKKEELNAVRRQAEGLSEDGAAMAVEPTQIQLSKRWREIESKFAQFRRLNFAQIHTVREETMMVMTEDMPLEISYVPSTYLTEITHVSQALLEVEQLLNAPDLCAKDFEDLFKQEESLKNIKDSLQQSSGRIDIIHSKKTAALQSATPVERVKLQEALSQLDFQWEKVNKMYKDRQGRFDRSVEKWRRFHYDIKIFNQWLTEAEQFLRKTQIPENWEHAKYKWYLKELQDGIGQRQTVVRTLNATGEEIIQQSSKTDASILQEKLGSLNLRWQEVCKQLSDRKKRLEEQKNILSEFQRDLNEFVLWLEEADNIASIPLEPGKEQQLKEKLEQVKLLVEELPLRQGILKQLNETGGPVLVSAPISPEEQDKLENKLKQTNLQWIKVSRALPEKQGEIEAQIKDLGQLEKKLEDLEEQLNHLLLWLSPIRNQLEIYNQPNQEGPFDVKETEIAVQAKQPDVEEILSKGQHLYKEKPATQPVKRKLEDLSSEWKAVNRLLQELRAKQPDLAPGLTTIGASPTQTVTLVTQPVVTKETAISKLEMPSSLMLEVPALADFNRAWTELTDWLSLLDQVIKSQRVMVGDLEDINEMIIKQKATMQDLEQRRPQLEELITAAQNLKNKTSNQEARTIITDRIERIQNQWDEVQEHLQNRRQQLNEMLKDSTQWLEAKEEAEQVLGQARAKLESWKEGPYTVDAIQKKITETKQLAKDLRQWQTNVDVANDLALKLLRDYSADDTRKVHMITENINASWRSIHKRVSEREAALEETHRLLQQFPLDLEKFLAWLTEAETTANVLQDATRKERLLEDSKGVKELMKQWQDLQGEIEAHTDVYHNLDENSQKILRSLEGSDDAVLLQRRLDNMNFKWSELRKKSLNIRSHLEASSDQWKRLHLSLQELLVWLQLKDDELSRQAPIGGDFPAVQKQNDVHRAFKRELKTKEPVIMSTLETVRIFLTEQPLEGLEKLYQEPRELPPEERAQNVTRLLRKQAEEVNTEWEKLNLHSADWQRKIDETLERLQELQEATDELDLKLRQAEVIKGSWQPVGDLLIDSLQDHLEKVKALRGEIAPLKENVSHVNDLARQLTTLGIQLSPYNLSTLEDLNTRWKLLQVAVEDRVRQLHEAHRDFGPASQHFLSTSVQGPWERAISPNKVPYYINHETQTTCWDHPKMTELYQSLADLNNVRFSAYRTAMKLRRLQKALCLDLLSLSAACDALDQHNLKQNDQPMDILQIINCLTTIYDRLEQEHNNLVNVPLCVDMCLNWLLNVYDTGRTGRIRVLSFKTGIISLCKAHLEDKYRYLFKQVASSTGFCDQRRLGLLLHDSIQIPRQLGEVASFGGSNIEPSVRSCFQFANNKPEIEAALFLDWMRLEPQSMVWLPVLHRVAAAETAKHQAKCNICKECPIIGFRYRSLKHFNYDICQSCFFSGRVAKGHKMHYPMVEYCTPTTSGEDVRDFAKVLKNKFRTKRYFAKHPRMGYLPVQTVLEGDNMETPVTLINFWPVDSAPASSPQLSHDDTHSRIEHYASRLAEMENSNGSYLNDSISPNESIDDEHLLIQHYCQSLNQDSPLSQPRSPAQILISLESEERGELERILADLEEENRNLQAEYDRLKQQHEHKGLSPLPSPPEMMPTSPQSPRDAELIAEAKLLRQHKGRLEARMQILEDHNKQLESQLHRLRQLLEQPQAEAKVNGTTVSSPSTSLQRSDSSQPMLLRVVGSQTSDSMGEEDLLSPPQDTSTGLEEVMEQLNNSFPSSRGRNTPGKPMREDTM
T12909	DRUGINFO	D34VAB	Fordadistrogene movaparvovec	Phase 3
T12909	DRUGINFO	D06SZU	WVE-210201	Phase 2/3
T12909	DRUGINFO	D9M8FK	SRP-9001	Phase 2
T12909	DRUGINFO	D05EHS	MyoDys	Phase 1
T12909	DRUGINFO	D08DTD	Biostrophin	Phase 1

T35232	TARGETID	T35232
T35232	FORMERID	TTDNC00584
T35232	UNIPROID	IL7_HUMAN
T35232	TARGNAME	Interleukin-7 (IL7)
T35232	GENENAME	IL7
T35232	TARGTYPE	Clinical trial
T35232	SYNONYMS	Interleukin7; IL-7
T35232	FUNCTION	It is important for proliferation during certain stages of B-cell maturation. Hematopoietic growth factor capable of stimulating the proliferation of lymphoid progenitors.
T35232	PDBSTRUC	3DI3; 3DI2; 1IL7
T35232	BIOCLASS	Cytokine: interleukin
T35232	SEQUENCE	MFHVSFRYIFGLPPLILVLLPVASSDCDIEGKDGKQYESVLMVSIDQLLDSMKEIGSNCLNNEFNFFKRHICDANKEGMFLFRAARKLRQFLKMNSTGDFDLHLLKVSEGTTILLNCTGQVKGRKPAALGEAQPTKSLEENKSLKEQKKLNDLCFLKRLLQEIKTCWNKILMGTKEH
T35232	DRUGINFO	D00SYV	GSK2618960	Phase 1
T35232	DRUGINFO	DPI9N4	GSK3888130?	Phase 1
T35232	DRUGINFO	D1FUQ2	ASP9801	Phase 1

T54771	TARGETID	T54771
T54771	FORMERID	TTDC00260
T54771	UNIPROID	SC5A1_HUMAN
T54771	TARGNAME	Sodium/glucose cotransporter 1 (SGLT1)
T54771	GENENAME	SLC5A1
T54771	TARGTYPE	Clinical trial
T54771	SYNONYMS	Solute carrier family 5 member 1; Na(+)/glucose cotransporter 1; NAGT; High affinity sodium-glucose cotransporter
T54771	FUNCTION	Efficient substrate transport in mammalian kidney is provided by the concerted action of a low affinity high capacity and a high affinity low capacity Na(+)/glucose cotransporter arranged in series along kidney proximal tubules. Actively transports glucose into cells by Na(+) cotransport with a Na(+) to glucose coupling ratio of 2:1.
T54771	BIOCLASS	Solute:sodium symporter
T54771	SEQUENCE	MDSSTWSPKTTAVTRPVETHELIRNAADISIIVIYFVVVMAVGLWAMFSTNRGTVGGFFLAGRSMVWWPIGASLFASNIGSGHFVGLAGTGAASGIAIGGFEWNALVLVVVLGWLFVPIYIKAGVVTMPEYLRKRFGGQRIQVYLSLLSLLLYIFTKISADIFSGAIFINLALGLNLYLAIFLLLAITALYTITGGLAAVIYTDTLQTVIMLVGSLILTGFAFHEVGGYDAFMEKYMKAIPTIVSDGNTTFQEKCYTPRADSFHIFRDPLTGDLPWPGFIFGMSILTLWYWCTDQVIVQRCLSAKNMSHVKGGCILCGYLKLMPMFIMVMPGMISRILYTEKIACVVPSECEKYCGTKVGCTNIAYPTLVVELMPNGLRGLMLSVMLASLMSSLTSIFNSASTLFTMDIYAKVRKRASEKELMIAGRLFILVLIGISIAWVPIVQSAQSGQLFDYIQSITSYLGPPIAAVFLLAIFWKRVNEPGAFWGLILGLLIGISRMITEFAYGTGSCMEPSNCPTIICGVHYLYFAIILFAISFITIVVISLLTKPIPDVHLYRLCWSLRNSKEERIDLDAEEENIQEGPKETIEIETQVPEKKKGIFRRAYDLFCGLEQHGAPKMTEEEEKAMKMKMTDTSEKPLWRTVLNVNGIILVTVAVFCHAYFA
T54771	DRUGINFO	D0X2UI	LIK-066	Phase 2
T54771	DRUGINFO	D6KEW7	YG1699	Phase 2
T54771	DRUGINFO	D09GLS	GSK1614235	Phase 1
T54771	DRUGINFO	D5T7QW	LX2761	Phase 1
T54771	DRUGINFO	D0D2WX	1614235 + 2330672	Phase 1
T54771	DRUGINFO	D0X1YF	T-1095	Discontinued in Phase 2
T54771	DRUGINFO	D06GXT	Acerogenin A	Investigative
T54771	DRUGINFO	D06WAL	Phlorizin	Investigative
T54771	DRUGINFO	D0H6DA	QCP	Investigative
T54771	DRUGINFO	D0K6SV	QSPac	Investigative
T54771	DRUGINFO	D0Q2YH	QCPac	Investigative
T54771	DRUGINFO	D0V7CD	QNEQCPQVSac	Investigative
T54771	DRUGINFO	D00HFT	10-methoxy-N(1)-methylburnamine-17-O-veratrate	Investigative
T54771	DRUGINFO	D01DIQ	Alstiphyllanine F	Investigative
T54771	DRUGINFO	D03VSQ	Kushenol N	Investigative
T54771	DRUGINFO	D05AZW	Alstiphyllanine E	Investigative
T54771	DRUGINFO	D0I2FC	Burnamine-17-O-3',4',5'-trimethoxybenzoate	Investigative
T54771	DRUGINFO	D0L8OJ	Alstiphyllanine D	Investigative
T54771	DRUGINFO	D0M8EH	O-spiroketal glucoside	Investigative
T54771	DRUGINFO	D0S1MI	ACEROGENIN B	Investigative
T54771	DRUGINFO	D0VE0Q	Sophoraflavanone G	Investigative
T54771	DRUGINFO	D0X1TN	sergliflozin	Investigative
T54771	DRUGINFO	D01PNM	KURARINONE	Investigative
T54771	DRUGINFO	D06GUJ	KURAIDIN	Investigative

T60526	TARGETID	T60526
T60526	FORMERID	TTDR00722
T60526	UNIPROID	LYAM1_HUMAN
T60526	TARGNAME	L-selectin (SELL)
T60526	GENENAME	SELL
T60526	TARGTYPE	Clinical trial
T60526	SYNONYMS	TQ1; SELL; Lymph node homing receptor; Leukocyte-endothelial cell adhesion molecule 1; Leukocyte surface antigen Leu-8; Leukocyte adhesion molecule-1; LECAM1; LAM-1; Gp90-MEL; CD62L
T60526	FUNCTION	Cell surface adhesion protein. Mediates the adherence of lymphocytes to endothelial cells of high endothelial venules in peripheral lymph nodes. Promotes initial tethering and rolling of leukocytes in endothelia.
T60526	PDBSTRUC	5VC1; 3CFW; 2LGF; 1KJB
T60526	SEQUENCE	MIFPWKCQSTQRDLWNIFKLWGWTMLCCDFLAHHGTDCWTYHYSEKPMNWQRARRFCRDNYTDLVAIQNKAEIEYLEKTLPFSRSYYWIGIRKIGGIWTWVGTNKSLTEEAENWGDGEPNNKKNKEDCVEIYIKRNKDAGKWNDDACHKLKAALCYTASCQPWSCSGHGECVEIINNYTCNCDVGYYGPQCQFVIQCEPLEAPELGTMDCTHPLGNFSFSSQCAFSCSEGTNLTGIEETTCGPFGNWSSPEPTCQVIQCEPLSAPDLGIMNCSHPLASFSFTSACTFICSEGTELIGKKKTICESSGIWSNPSPICQKLDKSFSMIKEGDYNPLFIPVAVMVTAFSGLAFIIWLARRLKKGKKSKRSMNDPY
T60526	DRUGINFO	D0N4EO	GMI-1070	Phase 3
T60526	DRUGINFO	D00YEV	BAICALEIN	Phase 2
T60526	DRUGINFO	D0Z0HS	Hu Dreg 55	Terminated
T60526	DRUGINFO	D0R7MJ	PURPUROGALLIN	Terminated
T60526	DRUGINFO	D03HTZ	LD201t1	Investigative
T60526	DRUGINFO	D0E9NT	2,3,4-trihydroxybenzoic acid	Investigative

T81311	TARGETID	T81311
T81311	FORMERID	TTDI01987
T81311	UNIPROID	ENPL_HUMAN
T81311	TARGNAME	Endoplasmin (HSP90B1)
T81311	GENENAME	HSP90B1
T81311	TARGTYPE	Clinical trial
T81311	SYNONYMS	gp96 homolog; Tumor rejection antigen 1; TRA1; Heat shock protein 90 kDa beta member 1; GRP94; GRP-94; 94 kDa glucoseregulated protein; 94 kDa glucose-regulated protein
T81311	FUNCTION	When associated with CNPY3, required for proper folding of Toll-like receptors. Functions in endoplasmic reticulum associated degradation (ERAD). Has ATPase activity. Molecular chaperone that functions in the processing and transport of secreted proteins.
T81311	PDBSTRUC	4NH9
T81311	BIOCLASS	Heat shock protein
T81311	SEQUENCE	MRALWVLGLCCVLLTFGSVRADDEVDVDGTVEEDLGKSREGSRTDDEVVQREEEAIQLDGLNASQIRELREKSEKFAFQAEVNRMMKLIINSLYKNKEIFLRELISNASDALDKIRLISLTDENALSGNEELTVKIKCDKEKNLLHVTDTGVGMTREELVKNLGTIAKSGTSEFLNKMTEAQEDGQSTSELIGQFGVGFYSAFLVADKVIVTSKHNNDTQHIWESDSNEFSVIADPRGNTLGRGTTITLVLKEEASDYLELDTIKNLVKKYSQFINFPIYVWSSKTETVEEPMEEEEAAKEEKEESDDEAAVEEEEEEKKPKTKKVEKTVWDWELMNDIKPIWQRPSKEVEEDEYKAFYKSFSKESDDPMAYIHFTAEGEVTFKSILFVPTSAPRGLFDEYGSKKSDYIKLYVRRVFITDDFHDMMPKYLNFVKGVVDSDDLPLNVSRETLQQHKLLKVIRKKLVRKTLDMIKKIADDKYNDTFWKEFGTNIKLGVIEDHSNRTRLAKLLRFQSSHHPTDITSLDQYVERMKEKQDKIYFMAGSSRKEAESSPFVERLLKKGYEVIYLTEPVDEYCIQALPEFDGKRFQNVAKEGVKFDESEKTKESREAVEKEFEPLLNWMKDKALKDKIEKAVVSQRLTESPCALVASQYGWSGNMERIMKAQAYQTGKDISTNYYASQKKTFEINPRHPLIRDMLRRIKEDEDDKTVLDLAVVLFETATLRSGYLLPDTKAYGDRIERMLRLSLNIDPDAKVEEEPEEEPEETAEDTTEDTEQDEDEEMDVGTDEEEETAKESTAEKDEL
T81311	DRUGINFO	D0F3EO	HS-110	Phase 2

T33124	TARGETID	T33124
T33124	FORMERID	TTDI02364
T33124	UNIPROID	OXDA_HUMAN
T33124	TARGNAME	D-amino acid oxidase (DAO)
T33124	GENENAME	DAO
T33124	TARGTYPE	Clinical trial
T33124	SYNONYMS	Daminoacid oxidase; DAMOX; DAAO
T33124	FUNCTION	Regulates the level of the neuromodulator D-serine in the brain. Has high activity towards D-DOPA and contributes to dopamine synthesis. Could act as a detoxifying agent which removes D-amino acids accumulated during aging. Acts on a variety of D-amino acids with a preference for those having small hydrophobic side chains followed by those bearing polar, aromatic, and basic groups. Does not act on acidic amino acids.
T33124	PDBSTRUC	5ZJA; 5ZJ9; 4QFD; 4QFC; 3ZNQ
T33124	BIOCLASS	CH-NH(2) donor oxidoreductase
T33124	ECNUMBER	EC 1.4.3.3
T33124	SEQUENCE	MRVVVIGAGVIGLSTALCIHERYHSVLQPLDIKVYADRFTPLTTTDVAAGLWQPYLSDPNNPQEADWSQQTFDYLLSHVHSPNAENLGLFLISGYNLFHEAIPDPSWKDTVLGFRKLTPRELDMFPDYGYGWFHTSLILEGKNYLQWLTERLTERGVKFFQRKVESFEEVAREGADVIVNCTGVWAGALQRDPLLQPGRGQIMKVDAPWMKHFILTHDPERGIYNSPYIIPGTQTVTLGGIFQLGNWSELNNIQDHNTIWEGCCRLEPTLKNARIIGERTGFRPVRPQIRLEREQLRTGPSNTEVIHNYGHGGYGLTIHWGCALEAAKLFGRILEEKKLSRMPPSHL
T33124	DRUGINFO	D03RXS	TAK-831	Phase 2
T33124	DRUGINFO	DT45OV	TAK-831	Phase 2
T33124	DRUGINFO	D0XW4W	SEP-227900	Terminated

T67079	TARGETID	T67079
T67079	FORMERID	TTDC00186
T67079	UNIPROID	IL9_HUMAN
T67079	TARGNAME	Interleukin-9 (IL9)
T67079	GENENAME	IL9
T67079	TARGTYPE	Clinical trial
T67079	SYNONYMS	T-cell growth factor P40; P40 cytokine; IL-9; Cytokine P40
T67079	FUNCTION	Supports IL-2 independent and IL-4 independent growth of helper T-cells.
T67079	BIOCLASS	Cytokine: interleukin
T67079	SEQUENCE	MLLAMVLTSALLLCSVAGQGCPTLAGILDINFLINKMQEDPASKCHCSANVTSCLCLGIPSDNCTRPCFSERLSQMTNTTMQTRYPLIFSRVKKSVEVLKNNKCPYFSCEQPCNQTTAGNALTFLKSLLEIFQKEKMRGMRGKI
T67079	DRUGINFO	D0FI5C	MEDI-528	Phase 2
T67079	DRUGINFO	DE09IO	BNZ-1	Phase 2

T70518	TARGETID	T70518
T70518	FORMERID	TTDI02232
T70518	UNIPROID	CBR1_HUMAN
T70518	TARGNAME	S-nitrosoglutathione reductase (CBR1)
T70518	GENENAME	CBR1
T70518	TARGTYPE	Clinical trial
T70518	SYNONYMS	ProstaglandinE(2) 9reductase; Prostaglandin 9ketoreductase; NADPHdependent carbonyl reductase 1; Carbonyl reductase [NADPH] 1; CBR1; 15hydroxyprostaglandin dehydrogenase [NADP(+)]
T70518	FUNCTION	NADPH-dependent reductase with broad substratespecificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E2 to prostaglandin F2-alpha. Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S-nitrosoglutathione.
T70518	PDBSTRUC	4Z3D; 3BHM; 3BHJ; 3BHI; 2PFG
T70518	BIOCLASS	Short-chain dehydrogenases reductase
T70518	ECNUMBER	EC 1.1.1.184
T70518	SEQUENCE	MSSGIHVALVTGGNKGIGLAIVRDLCRLFSGDVVLTARDVTRGQAAVQQLQAEGLSPRFHQLDIDDLQSIRALRDFLRKEYGGLDVLVNNAGIAFKVADPTPFHIQAEVTMKTNFFGTRDVCTELLPLIKPQGRVVNVSSIMSVRALKSCSPELQQKFRSETITEEELVGLMNKFVEDTKKGVHQKEGWPSSAYGVTKIGVTVLSRIHARKLSEQRKGDKILLNACCPGWVRTDMAGPKATKSPEEGAETPVYLALLPPDAEGPHGQFVSEKRVEQW
T70518	DRUGINFO	D09LPV	N6022	Phase 2

T72835	TARGETID	T72835
T72835	FORMERID	TTDC00098
T72835	UNIPROID	LYAM2_HUMAN
T72835	TARGNAME	E-selectin (SELE)
T72835	GENENAME	SELE
T72835	TARGTYPE	Clinical trial
T72835	SYNONYMS	Leukocyte-endothelial cell adhesion molecule 2; LECAM2; Endothelial leukocyte adhesion molecule 1; ELAM1; ELAM-1; CD62E antigen; CD62E; CD62 antigen-like family member E
T72835	FUNCTION	Mediates in the adhesion of blood neutrophils in cytokine-activated endothelium through interaction with SELPLG/PSGL1. May have a role in capillary morphogenesis. Cell-surface glycoprotein having a role in immunoadhesion.
T72835	PDBSTRUC	6EYK; 6EYJ; 6EYI; 4CSY; 4C16
T72835	SEQUENCE	MIASQFLSALTLVLLIKESGAWSYNTSTEAMTYDEASAYCQQRYTHLVAIQNKEEIEYLNSILSYSPSYYWIGIRKVNNVWVWVGTQKPLTEEAKNWAPGEPNNRQKDEDCVEIYIKREKDVGMWNDERCSKKKLALCYTAACTNTSCSGHGECVETINNYTCKCDPGFSGLKCEQIVNCTALESPEHGSLVCSHPLGNFSYNSSCSISCDRGYLPSSMETMQCMSSGEWSAPIPACNVVECDAVTNPANGFVECFQNPGSFPWNTTCTFDCEEGFELMGAQSLQCTSSGNWDNEKPTCKAVTCRAVRQPQNGSVRCSHSPAGEFTFKSSCNFTCEEGFMLQGPAQVECTTQGQWTQQIPVCEAFQCTALSNPERGYMNCLPSASGSFRYGSSCEFSCEQGFVLKGSKRLQCGPTGEWDNEKPTCEAVRCDAVHQPPKGLVRCAHSPIGEFTYKSSCAFSCEEGFELHGSTQLECTSQGQWTEEVPSCQVVKCSSLAVPGKINMSCSGEPVFGTVCKFACPEGWTLNGSAARTCGATGHWSGLLPTCEAPTESNIPLVAGLSAAGLSLLTLAPFLLWLRKCLRKAKKFVPASSCQSLESDGSYQKPSYIL
T72835	DRUGINFO	D03PWD	GMI-1271	Phase 3
T72835	DRUGINFO	D0N4EO	GMI-1070	Phase 3
T72835	DRUGINFO	D0B7LK	CY-1503	Phase 2/3
T72835	DRUGINFO	D02AUB	Bimosiamose	Phase 2a
T72835	DRUGINFO	D2SRG1	PF-07209326	Phase 1
T72835	DRUGINFO	DBDW09	GMI-1359	Phase 1
T72835	DRUGINFO	D0L3XV	SMART anti-E/P selectin	Discontinued in Phase 1
T72835	DRUGINFO	D0RR4T	GI-270384X	Terminated
T72835	DRUGINFO	D08RYE	Efomycine M	Investigative
T72835	DRUGINFO	D0U7DO	1na	Investigative
T72835	DRUGINFO	D08WQM	O-Sialic Acid	Investigative
T72835	DRUGINFO	D0G6XS	Fucose	Investigative

T15377	TARGETID	T15377
T15377	FORMERID	TTDR00513
T15377	UNIPROID	AT2A2_HUMAN
T15377	TARGNAME	Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (ATP2A2)
T15377	GENENAME	ATP2A2
T15377	TARGTYPE	Clinical trial
T15377	SYNONYMS	SR Ca(2+)Sarcoplasmic/endoplasmic reticulum calcium ATPase 2-ATPase 2; SR Ca(2+)-ATPase 2; SR Ca(2+)-ATPase; SR Ca(2+) pump; SERCA2; Endoplasmic reticulum class 1/2 Ca(2+) ATPase; Cardiacsarcoplasmic reticulum calcium ATPase; CardiacCa2+ ATPase (SERCA2a); Calciumpump 2; Calcium-transporting ATPase sarcoplasmic reticulum type, slow twitch skeletal muscle isoform; Calcium pump 2; ATP2B
T15377	FUNCTION	Isoform 2 is involved in the regulation of the contraction/relaxation cycle. Acts as a regulator of TNFSF11-mediated Ca(2+) signaling pathways via its interaction with TMEM64 which is critical for the TNFSF11-induced CREB1 activation and mitochondrial ROS generation necessary for proper osteoclast generation. Association between TMEM64 and SERCA2 in the ER leads to cytosolic Ca (2+) spiking for activation of NFATC1 and production of mitochondrial ROS, thereby triggering Ca (2+) signaling cascades that promote osteoclast differentiation and activation. This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the translocation of calcium from the cytosol to the sarcoplasmic reticulum lumen.
T15377	PDBSTRUC	6JJU; 5ZTF
T15377	BIOCLASS	Cation transporting ATPase
T15377	ECNUMBER	EC 7.2.2.10
T15377	SEQUENCE	MENAHTKTVEEVLGHFGVNESTGLSLEQVKKLKERWGSNELPAEEGKTLLELVIEQFEDLLVRILLLAACISFVLAWFEEGEETITAFVEPFVILLILVANAIVGVWQERNAENAIEALKEYEPEMGKVYRQDRKSVQRIKAKDIVPGDIVEIAVGDKVPADIRLTSIKSTTLRVDQSILTGESVSVIKHTDPVPDPRAVNQDKKNMLFSGTNIAAGKAMGVVVATGVNTEIGKIRDEMVATEQERTPLQQKLDEFGEQLSKVISLICIAVWIINIGHFNDPVHGGSWIRGAIYYFKIAVALAVAAIPEGLPAVITTCLALGTRRMAKKNAIVRSLPSVETLGCTSVICSDKTGTLTTNQMSVCRMFILDRVEGDTCSLNEFTITGSTYAPIGEVHKDDKPVNCHQYDGLVELATICALCNDSALDYNEAKGVYEKVGEATETALTCLVEKMNVFDTELKGLSKIERANACNSVIKQLMKKEFTLEFSRDRKSMSVYCTPNKPSRTSMSKMFVKGAPEGVIDRCTHIRVGSTKVPMTSGVKQKIMSVIREWGSGSDTLRCLALATHDNPLRREEMHLEDSANFIKYETNLTFVGCVGMLDPPRIEVASSVKLCRQAGIRVIMITGDNKGTAVAICRRIGIFGQDEDVTSKAFTGREFDELNPSAQRDACLNARCFARVEPSHKSKIVEFLQSFDEITAMTGDGVNDAPALKKAEIGIAMGSGTAVAKTASEMVLADDNFSTIVAAVEEGRAIYNNMKQFIRYLISSNVGEVVCIFLTAALGFPEALIPVQLLWVNLVTDGLPATALGFNPPDLDIMNKPPRNPKEPLISGWLFFRYLAIGCYVGAATVGAAAWWFIAADGGPRVSFYQLSHFLQCKEDNPDFEGVDCAIFESPYPMTMALSVLVTIEMCNALNSLSENQSLLRMPPWENIWLVGSICLSMSLHFLILYVEPLPLIFQITPLNVTQWLMVLKISLPVILMDETLKFVARNYLEPGKECVQPATKSCSFSACTDGISWPFVLLIMPLVIWVYSTDTNFSDMFWS
T15377	DRUGINFO	D01NXF	Mydicar	Phase 2
T15377	DRUGINFO	D00ERV	Gallopamil	Phase 2

T85025	TARGETID	T85025
T85025	FORMERID	TTDC00136
T85025	UNIPROID	IL7RA_HUMAN
T85025	TARGNAME	Interleukin 7 receptor alpha (IL7R)
T85025	GENENAME	IL7R
T85025	TARGTYPE	Clinical trial
T85025	SYNONYMS	Interleukin-7 receptor subunit alpha; IL-7RA; IL-7R-alpha; IL-7R subunit alpha; IL-7R alpha chain; IL-7 receptor subunit alpha; CDw127; CD127 antigen; CD127
T85025	FUNCTION	Acts as a receptor for thymic stromal lymphopoietin (TSLP). Receptor for interleukin-7.
T85025	PDBSTRUC	5J11; 3UP1; 3DI3; 3DI2
T85025	BIOCLASS	Cytokine receptor
T85025	SEQUENCE	MTILGTTFGMVFSLLQVVSGESGYAQNGDLEDAELDDYSFSCYSQLEVNGSQHSLTCAFEDPDVNITNLEFEICGALVEVKCLNFRKLQEIYFIETKKFLLIGKSNICVKVGEKSLTCKKIDLTTIVKPEAPFDLSVVYREGANDFVVTFNTSHLQKKYVKVLMHDVAYRQEKDENKWTHVNLSSTKLTLLQRKLQPAAMYEIKVRSIPDHYFKGFWSEWSPSYYFRTPEINNSSGEMDPILLTISILSFFSVALLVILACVLWKKRIKPIVWPSLPDHKKTLEHLCKKPRKNLNVSFNPESFLDCQIHRVDDIQARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTMSSFYQNQ
T85025	DRUGINFO	D08GVP	ADX-914	Phase 2
T85025	DRUGINFO	D0P1CE	CYT 99007	Phase 2
T85025	DRUGINFO	D0Q7IX	PF-06342674	Phase 1

T55293	TARGETID	T55293
T55293	FORMERID	TTDR00276
T55293	UNIPROID	ITA2_HUMAN
T55293	TARGNAME	Integrin alpha-2 (ITGA2)
T55293	GENENAME	ITGA2
T55293	TARGTYPE	Clinical trial
T55293	SYNONYMS	VLA-2 subunit alpha; VLA-2 alphachain; VLA-2; Platelet membrane glycoprotein Ia; Platelet glycoprotein Ia/IIa; Glycoprotein Ia-IIa; GPIa/IIa; GPIa; Collagen receptor; CD49b; CD49 antigen-like family member B; Adhesive platelet receptor alpha1 beta2
T55293	FUNCTION	It recognizes the proline-hydroxylated sequence G-F-P-G-E-R in collagen. It is responsible for adhesion of platelets and other cells to collagens, modulation of collagen and collagenase gene expression, force generation and organization of newly synthesized extracellular matrix. Integrin alpha-2/beta-1 is a receptor for laminin, collagen, collagen C-propeptides, fibronectin and E-cadherin.
T55293	PDBSTRUC	6NDH; 6NDG; 6NDF; 6NDE; 6NDD
T55293	BIOCLASS	Integrin
T55293	SEQUENCE	MGPERTGAAPLPLLLVLALSQGILNCCLAYNVGLPEAKIFSGPSSEQFGYAVQQFINPKGNWLLVGSPWSGFPENRMGDVYKCPVDLSTATCEKLNLQTSTSIPNVTEMKTNMSLGLILTRNMGTGGFLTCGPLWAQQCGNQYYTTGVCSDISPDFQLSASFSPATQPCPSLIDVVVVCDESNSIYPWDAVKNFLEKFVQGLDIGPTKTQVGLIQYANNPRVVFNLNTYKTKEEMIVATSQTSQYGGDLTNTFGAIQYARKYAYSAASGGRRSATKVMVVVTDGESHDGSMLKAVIDQCNHDNILRFGIAVLGYLNRNALDTKNLIKEIKAIASIPTERYFFNVSDEAALLEKAGTLGEQIFSIEGTVQGGDNFQMEMSQVGFSADYSSQNDILMLGAVGAFGWSGTIVQKTSHGHLIFPKQAFDQILQDRNHSSYLGYSVAAISTGESTHFVAGAPRANYTGQIVLYSVNENGNITVIQAHRGDQIGSYFGSVLCSVDVDKDTITDVLLVGAPMYMSDLKKEEGRVYLFTIKKGILGQHQFLEGPEGIENTRFGSAIAALSDINMDGFNDVIVGSPLENQNSGAVYIYNGHQGTIRTKYSQKILGSDGAFRSHLQYFGRSLDGYGDLNGDSITDVSIGAFGQVVQLWSQSIADVAIEASFTPEKITLVNKNAQIILKLCFSAKFRPTKQNNQVAIVYNITLDADGFSSRVTSRGLFKENNERCLQKNMVVNQAQSCPEHIIYIQEPSDVVNSLDLRVDISLENPGTSPALEAYSETAKVFSIPFHKDCGEDGLCISDLVLDVRQIPAAQEQPFIVSNQNKRLTFSVTLKNKRESAYNTGIVVDFSENLFFASFSLPVDGTEVTCQVAASQKSVACDVGYPALKREQQVTFTINFDFNLQNLQNQASLSFQALSESQEENKADNLVNLKIPLLYDAEIHLTRSTNINFYEISSDGNVPSIVHSFEDVGPKFIFSLKVTTGSVPVSMATVIIHIPQYTKEKNPLMYLTGVQTDKAGDISCNADINPLKIGQTSSSVSFKSENFRHTKELNCRTASCSNVTCWLKDVHMKGEYFVNVTTRIWNGTFASSTFQTVQLTAAAEINTYNPEIYVIEDNTVTIPLMIMKPDEKAEVPTGVIIGSIIAGILLLLALVAILWKLGFFKRKYEKMTKNPDEIDETTELSS
T55293	DRUGINFO	D02BQE	E7820	Phase 2
T55293	DRUGINFO	D08PYJ	MAGGIEMYCIN	Investigative
T55293	DRUGINFO	D01ZJF	3-(3-(carbamoyl)benzamido)propanoic acid	Investigative
T55293	DRUGINFO	D0G7QJ	3-(3-(benzamido)-5-nitrobenzamido)propanoic acid	Investigative
T55293	DRUGINFO	D0TP8S	3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid	Investigative

T78915	TARGETID	T78915
T78915	FORMERID	TTDI01969
T78915	UNIPROID	TPH1_HUMAN
T78915	TARGNAME	Tryptophan 5-hydroxylase 1 (TPH1)
T78915	GENENAME	TPH1
T78915	TARGTYPE	Clinical trial
T78915	SYNONYMS	Tryptophan 5-monooxygenase 1; TRPH; TPRH
T78915	FUNCTION	Responsible for addition of the -HO group (hydroxylation) to the 5 position to form the amino acid 5-hydroxytryptophan (5-HTP), which is the initial and rate-limiting step in the synthesis of the neurotransmitter serotonin.
T78915	PDBSTRUC	5TPG; 5L01; 5J6D; 3HFB; 3HF8
T78915	BIOCLASS	Paired donor oxygen oxidoreductase
T78915	ECNUMBER	EC 1.14.16.4
T78915	SEQUENCE	MIEDNKENKDHSLERGRASLIFSLKNEVGGLIKALKIFQEKHVNLLHIESRKSKRRNSEFEIFVDCDINREQLNDIFHLLKSHTNVLSVNLPDNFTLKEDGMETVPWFPKKISDLDHCANRVLMYGSELDADHPGFKDNVYRKRRKYFADLAMNYKHGDPIPKVEFTEEEIKTWGTVFQELNKLYPTHACREYLKNLPLLSKYCGYREDNIPQLEDVSNFLKERTGFSIRPVAGYLSPRDFLSGLAFRVFHCTQYVRHSSDPFYTPEPDTCHELLGHVPLLAEPSFAQFSQEIGLASLGASEEAVQKLATCYFFTVEFGLCKQDGQLRVFGAGLLSSISELKHALSGHAKVKPFDPKITCKQECLITTFQDVYFVSESFEDAKEKMREFTKTIKRPFGVKYNPYTRSIQILKDTKSITSAMNELQHDLDVVSDALAKVSRKPSI
T78915	DRUGINFO	D09OWK	AGN-2979	Phase 2
T78915	DRUGINFO	D0VS3W	KAR5585	Phase 1
T78915	DRUGINFO	D0U9QD	6-fluorotryptophan	Investigative
T78915	DRUGINFO	D0F2GG	fenclonine	Investigative
T78915	DRUGINFO	D0IT5D	alpha-propyldopacetamide	Investigative

T70101	TARGETID	T70101
T70101	FORMERID	TTDR00956
T70101	UNIPROID	PYRG1_HUMAN
T70101	TARGNAME	CTP synthase (CTPS1)
T70101	GENENAME	CTPS1
T70101	TARGTYPE	Clinical trial
T70101	SYNONYMS	Uridine triphosphate aminase; UTP:ammonia ligase (ADP-forming); UTP--ammonia ligase; Cytidine triphosphate synthetase; Cytidine 5'-triphosphate synthetase; CTPS1; CTP synthetase
T70101	FUNCTION	This enzyme is involved in the de novo synthesis of CTP, a precursor of DNA, RNA and phospholipids. Catalyzes the ATP- dependent amination of UTP to CTP with either L-glutamine or ammonia as a source of nitrogen. This enzyme and its product, CTP, play a crucial role in the proliferation of activated lymphocytes and therefore in immunity.
T70101	PDBSTRUC	5U03; 2VO1
T70101	BIOCLASS	Carbon-nitrogen ligase
T70101	ECNUMBER	EC 6.3.4.2
T70101	SEQUENCE	MKYILVTGGVISGIGKGIIASSVGTILKSCGLHVTSIKIDPYINIDAGTFSPYEHGEVFVLDDGGEVDLDLGNYERFLDIRLTKDNNLTTGKIYQYVINKERKGDYLGKTVQVVPHITDAIQEWVMRQALIPVDEDGLEPQVCVIELGGTVGDIESMPFIEAFRQFQFKVKRENFCNIHVSLVPQPSSTGEQKTKPTQNSVRELRGLGLSPDLVVCRCSNPLDTSVKEKISMFCHVEPEQVICVHDVSSIYRVPLLLEEQGVVDYFLRRLDLPIERQPRKMLMKWKEMADRYDRLLETCSIALVGKYTKFSDSYASVIKALEHSALAINHKLEIKYIDSADLEPITSQEEPVRYHEAWQKLCSAHGVLVPGGFGVRGTEGKIQAIAWARNQKKPFLGVCLGMQLAVVEFSRNVLGWQDANSTEFDPTTSHPVVVDMPEHNPGQMGGTMRLGKRRTLFQTKNSVMRKLYGDADYLEERHRHRFEVNPVWKKCLEEQGLKFVGQDVEGERMEIVELEDHPFFVGVQYHPEFLSRPIKPSPPYFGLLLASVGRLSHYLQKGCRLSPRDTYSDRSGSSSPDSEITELKFPSINHD
T70101	DRUGINFO	D0VW0I	Cyclopentenylcytosine	Phase 1
T70101	DRUGINFO	D02JUT	Acivicin	Discontinued in Phase 3
T70101	DRUGINFO	D08XAW	Cyclopentylcytosine	Investigative
T70101	DRUGINFO	D0B3MG	Carbodine	Investigative
T70101	DRUGINFO	D0GK2Q	Cylopentenyl cytosine	Investigative
T70101	DRUGINFO	D06GOK	2-Methyl-2,4-Pentanediol	Investigative

T70309	TARGETID	T70309
T70309	FORMERID	TTDR01182
T70309	UNIPROID	S5A1_HUMAN
T70309	TARGNAME	Steroid 5-alpha-reductase 1 (SRD5A1)
T70309	GENENAME	SRD5A1
T70309	TARGTYPE	Clinical trial
T70309	SYNONYMS	SRD5A1; SR type 1; 5-alpha reductase 1
T70309	FUNCTION	Converts testosterone into 5-alpha-dihydrotestosterone and progesterone or corticosterone into their corresponding 5- alpha-3-oxosteroids. It plays a central role in sexual differentiation and androgen physiology.
T70309	BIOCLASS	CH-CH donor oxidoreductase
T70309	ECNUMBER	EC 1.3.1.22
T70309	SEQUENCE	MATATGVAEERLLAALAYLQCAVGCAVFARNRQTNSVYGRHALPSHRLRVPARAAWVVQELPSLALPLYQYASESAPRLRSAPNCILLAMFLVHYGHRCLIYPFLMRGGKPMPLLACTMAIMFCTCNGYLQSRYLSHCAVYADDWVTDPRFLIGFGLWLTGMLINIHSDHILRNLRKPGDTGYKIPRGGLFEYVTAANYFGEIMEWCGYALASWSVQGAAFAFFTFCFLSGRAKEHHEWYLRKFEEYPKFRKIIIPFLF
T70309	DRUGINFO	D01CJY	FR-146687	Phase 2
T70309	DRUGINFO	D0C1SI	MK-386	Discontinued in Phase 2
T70309	DRUGINFO	D0P9EL	AS-601811	Discontinued in Phase 1
T70309	DRUGINFO	D0Z9UB	Bexlosteride	Terminated
T70309	DRUGINFO	D00IFJ	1,2,5,6-tetrahydro pyrido[1,2-a]quinolin-3-one	Investigative
T70309	DRUGINFO	D02ZRX	1-Methyl-5-phenyl-piperidin-2-one	Investigative
T70309	DRUGINFO	D07KDB	4-Methyl-5,6-dihydro-pyrido[1,2-a]quinolin-3-one	Investigative
T70309	DRUGINFO	D08SPJ	3,4,5,6-Tetrahydrobenzo[c]quinolizin-3-(4aH)-one	Investigative
T70309	DRUGINFO	D09KZA	1-Methyl-5-(4-phenylazo-phenyl)-piperidin-2-one	Investigative
T70309	DRUGINFO	D0H7NB	5-(4-Chloro-phenyl)-1-methyl-piperidine-2-thione	Investigative
T70309	DRUGINFO	D0JH9F	5-(4-Chloro-phenyl)-1-methyl-piperidin-2-one	Investigative
T70309	DRUGINFO	D0M7OP	LY-266111	Investigative
T70309	DRUGINFO	D01AUS	4-[4-benzyloxy)benzoyl]benzoic acid	Investigative
T70309	DRUGINFO	D04AED	4-[4-(benzhydryloxy)benzoyl]benzoic acid	Investigative
T70309	DRUGINFO	D05XPT	(3-methyl-4-(4-phenoxybenzoyl)phenyl)acetic acid	Investigative
T70309	DRUGINFO	D07BHS	(3-fluoro-4-(4-phenoxybenzoyl)phenyl)acetic acid	Investigative
T70309	DRUGINFO	D07BQG	{4-[4-(4-bromophenoxy)benzoyl]phenyl}acetic acid	Investigative
T70309	DRUGINFO	D0Q4GH	(E)-3-(4-(4-phenoxybenzoyl)phenyl)acrylic acid	Investigative
T70309	DRUGINFO	D0VR9L	4,4'-dihydroxyoctafluoroazobenzene	Investigative
T70309	DRUGINFO	D0W6HB	4-(4-phenoxybenzoyl)benzoic acid	Investigative
T70309	DRUGINFO	D07OAC	GP515	Investigative
T70309	DRUGINFO	D07ZNR	2,3,5,6-Tetrafluoro-4-pentafluorophenylazo-phenol	Investigative

T13017	TARGETID	T13017
T13017	FORMERID	TTDI02170
T13017	UNIPROID	SDC1_HUMAN
T13017	TARGNAME	Syndecan-1 (SDC1)
T13017	GENENAME	SDC1
T13017	TARGTYPE	Clinical trial
T13017	SYNONYMS	SYND1; SDC; CD138
T13017	FUNCTION	Regulates exosome biogenesis in concert with SDCBP and PDCD6IP. Cell surface proteoglycan that bears both heparan sulfate and chondroitin sulfate and that links the cytoskeleton to the interstitial matrix.
T13017	PDBSTRUC	6EJE; 4GVD; 4GVC
T13017	BIOCLASS	Peptide translocating syndecan
T13017	SEQUENCE	MRRAALWLWLCALALSLQPALPQIVATNLPPEDQDGSGDDSDNFSGSGAGALQDITLSQQTPSTWKDTQLLTAIPTSPEPTGLEATAASTSTLPAGEGPKEGEAVVLPEVEPGLTAREQEATPRPRETTQLPTTHLASTTTATTAQEPATSHPHRDMQPGHHETSTPAGPSQADLHTPHTEDGGPSATERAAEDGASSQLPAAEGSGEQDFTFETSGENTAVVAVEPDRRNQSPVDQGATGASQGLLDRKEVLGGVIAGGLVGLIFAVCLVGFMLYRMKKKDEGSYSLEEPKQANGGAYQKPTKQEEFYA
T13017	DRUGINFO	D04PUI	BT-062	Phase 2
T13017	DRUGINFO	D05CTQ	CD138 CAR T cells	Phase 1/2
T13017	DRUGINFO	D0M3RI	CART-138 cells	Phase 1/2
T13017	DRUGINFO	D0Y4MA	CART-138 cells	Phase 1/2
T13017	DRUGINFO	D09ZDY	CAR138 T Cells	Phase 1
T13017	DRUGINFO	D0T6NG	CAR-T cells targeting CD138	Clinical trial

T59056	TARGETID	T59056
T59056	FORMERID	TTDNC00572
T59056	UNIPROID	C11B2_HUMAN
T59056	TARGNAME	Aldosterone synthase (CYP11B2)
T59056	GENENAME	CYP11B2
T59056	TARGTYPE	Clinical trial
T59056	SYNONYMS	Steroid 18hydroxylase; Cytochrome P450C18; Cytochrome P450Aldo; Cytochrome P450 11B2, mitochondrial; CYPXIB2; CYP11B2; Aldosteronesynthesizing enzyme; ALDOS
T59056	FUNCTION	Preferentially catalyzes the conversion of 11- deoxycorticosterone to aldosterone via corticosterone and 18- hydroxycorticosterone.
T59056	PDBSTRUC	4ZGX; 4FDH; 4DVQ
T59056	BIOCLASS	Paired donor oxygen oxidoreductase
T59056	ECNUMBER	EC 1.14.15.4
T59056	SEQUENCE	MALRAKAEVCVAAPWLSLQRARALGTRAARAPRTVLPFEAMPQHPGNRWLRLLQIWREQGYEHLHLEMHQTFQELGPIFRYNLGGPRMVCVMLPEDVEKLQQVDSLHPCRMILEPWVAYRQHRGHKCGVFLLNGPEWRFNRLRLNPDVLSPKAVQRFLPMVDAVARDFSQALKKKVLQNARGSLTLDVQPSIFHYTIEASNLALFGERLGLVGHSPSSASLNFLHALEVMFKSTVQLMFMPRSLSRWISPKVWKEHFEAWDCIFQYGDNCIQKIYQELAFNRPQHYTGIVAELLLKAELSLEAIKANSMELTAGSVDTTAFPLLMTLFELARNPDVQQILRQESLAAAASISEHPQKATTELPLLRAALKETLRLYPVGLFLERVVSSDLVLQNYHIPAGTLVQVFLYSLGRNAALFPRPERYNPQRWLDIRGSGRNFHHVPFGFGMRQCLGRRLAEAEMLLLLHHVLKHFLVETLTQEDIKMVYSFILRPGTSPLLTFRAIN
T59056	DRUGINFO	D8FHG5	Baxdrostat	Phase 2
T59056	DRUGINFO	DKO16W	MLS-101	Phase 2

T86552	TARGETID	T86552
T86552	FORMERID	TTDNC00502
T86552	UNIPROID	TNR1A_HUMAN
T86552	TARGNAME	Tumor necrosis factor receptor type I (TNF-R1)
T86552	GENENAME	TNFRSF1A
T86552	TARGTYPE	Clinical trial
T86552	SYNONYMS	p60; p55; Tumor necrosis factor-binding protein 1; Tumor necrosis factor receptor superfamily member 1A; Tumor necrosis factor receptor 1; TNFR1; TNFR-I; TNFAR; TNF-RI; TBPI; CD120a
T86552	FUNCTION	The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes to the induction of non-cytocidal TNF effects including anti-viral state and activation of the acid sphingomyelinase. Receptor for TNFSF2/TNF-alpha and homotrimeric TNFSF1/lymphotoxin-alpha.
T86552	PDBSTRUC	1TNR; 1NCF; 1ICH; 1FT4; 1EXT
T86552	BIOCLASS	Cytokine receptor
T86552	SEQUENCE	MGLSTVPDLLLPLVLLELLVGIYPSGVIGLVPHLGDREKRDSVCPQGKYIHPQNNSICCTKCHKGTYLYNDCPGPGQDTDCRECESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTVCGCRKNQYRHYWSENLFQCFNCSLCLNGTVHLSCQEKQNTVCTCHAGFFLRENECVSCSNCKKSLECTKLCLPQIENVKGTEDSGTTVLLPLVIFFGLCLLSLLFIGLMYRYQRWKSKLYSIVCGKSTPEKEGELEGTTTKPLAPNPSFSPTPGFTPTLGFSPVPSSTFTSSSTYTPGDCPNFAAPRREVAPPYQGADPILATALASDPIPNPLQKWEDSAHKPQSLDTDDPATLYAVVENVPPLRWKEFVRRLGLSDHEIDRLELQNGRCLREAQYSMLATWRRRTPRREATLELLGRVLRDMDLLGCLEDIEEALCGPAALPPAPSLLR
T86552	DRUGINFO	D0S4LV	VB-111	Phase 3
T86552	DRUGINFO	D07LMO	Drug 2862277	Phase 2
T86552	DRUGINFO	D08ENB	GSK1995057	Phase 1
T86552	DRUGINFO	D03HIG	AVX-470	Phase 1
T86552	DRUGINFO	D0R4OD	Anti-IFN gamma	Terminated
T86552	DRUGINFO	D03IMU	TNFR1 NAM	Investigative
T86552	DRUGINFO	D08TQK	NM-9405	Investigative
T86552	DRUGINFO	D0B6WV	TNFmab	Investigative
T86552	DRUGINFO	D0G9XS	ADS-0101	Investigative
T86552	DRUGINFO	D0P4WI	Recombinant human TNF receptor	Investigative
T86552	DRUGINFO	D0U4QQ	TNFcept	Investigative
T86552	DRUGINFO	D0W0BN	NM-2014	Investigative
T86552	DRUGINFO	D0W7FG	ALF-421	Investigative
T86552	DRUGINFO	D0X8SM	Anti-TNF human mabs	Investigative

T29960	TARGETID	T29960
T29960	FORMERID	TTDR00688
T29960	UNIPROID	WT1_HUMAN
T29960	TARGNAME	Wilms tumor protein (WT1)
T29960	GENENAME	WT1
T29960	TARGTYPE	Clinical trial
T29960	SYNONYMS	Wilms' tumour 1 protein; WT33; WT1 protein
T29960	FUNCTION	Recognizes and binds to the DNA sequence 5'-GCG(T/G)GGGCG-3'. Regulates the expression of numerous target genes, including EPO. Plays an essential role for development of the urogenital system. It has a tumor suppressor as well as an oncogenic role in tumor formation. Function may be isoform-specific: isoforms lacking the KTS motif may act as transcription factors. Isoforms containing the KTS motif may bind mRNA and play a role in mRNA metabolism or splicing. Isoform 1 has lower affinity for DNA, and can bind RNA. Transcription factor that plays an important role in cellular development and cell survival.
T29960	PDBSTRUC	6BLW; 6B0R; 6B0Q; 6B0P; 6B0O
T29960	BIOCLASS	EGR C2H2-type zinc-finger
T29960	SEQUENCE	MGSDVRDLNALLPAVPSLGGGGGCALPVSGAAQWAPVLDFAPPGASAYGSLGGPAPPPAPPPPPPPPPHSFIKQEPSWGGAEPHEEQCLSAFTVHFSGQFTGTAGACRYGPFGPPPPSQASSGQARMFPNAPYLPSCLESQPAIRNQGYSTVTFDGTPSYGHTPSHHAAQFPNHSFKHEDPMGQQGSLGEQQYSVPPPVYGCHTPTDSCTGSQALLLRTPYSSDNLYQMTSQLECMTWNQMNLGATLKGVAAGSSSSVKWTEGQSNHSTGYESDNHTTPILCGAQYRIHTHGVFRGIQDVRRVPGVAPTLVRSASETSEKRPFMCAYPGCNKRYFKLSHLQMHSRKHTGEKPYQCDFKDCERRFSRSDQLKRHQRRHTGVKPFQCKTCQRKFSRSDHLKTHTRTHTGKTSEKPFSCRWPSCQKKFARSDELVRHHNMHQRNMTKLQLAL
T29960	DRUGINFO	D00QXB	WT1 peptide vaccine	Phase 2
T29960	DRUGINFO	D02MLO	WT1-targeted autologous dendritic cell vaccine	Phase 2
T29960	DRUGINFO	D0RG8Z	FPI-01	Phase 2
T29960	DRUGINFO	D0O8AY	Combined PR1/WT1 vaccine	Phase 2
T29960	DRUGINFO	D01MYJ	WT-4869	Phase 1/2
T29960	DRUGINFO	D02JEW	GSK-2130579A	Phase 1
T29960	DRUGINFO	D0P2ZY	INNO-305	Phase 1

T39677	TARGETID	T39677
T39677	FORMERID	TTDR00692
T39677	UNIPROID	CEL_HUMAN
T39677	TARGNAME	Bile-salt-activated lipase (CEL)
T39677	GENENAME	CEL
T39677	TARGTYPE	Clinical trial
T39677	SYNONYMS	Pancreatic lysophospholipase; Pancreatic cholesterol esterase; Cholesterol esterase; Carboxyl ester lipase; CEL; Bile-salt-stimulated lipase; BSSL; BAL
T39677	FUNCTION	Catalyzes fat and vitamin absorption. Acts in concert with pancreatic lipase and colipase for the complete digestion of dietary triglycerides.
T39677	PDBSTRUC	6H1A; 6H19; 6H18; 6H0V; 6H0T
T39677	BIOCLASS	Carboxylic ester hydrolase
T39677	ECNUMBER	EC 3.1.1.13
T39677	SEQUENCE	MGRLQLVVLGLTCCWAVASAAKLGAVYTEGGFVEGVNKKLGLLGDSVDIFKGIPFAAPTKALENPQPHPGWQGTLKAKNFKKRCLQATITQDSTYGDEDCLYLNIWVPQGRKQVSRDLPVMIWIYGGAFLMGSGHGANFLNNYLYDGEEIATRGNVIVVTFNYRVGPLGFLSTGDANLPGNYGLRDQHMAIAWVKRNIAAFGGDPNNITLFGESAGGASVSLQTLSPYNKGLIRRAISQSGVALSPWVIQKNPLFWAKKVAEKVGCPVGDAARMAQCLKVTDPRALTLAYKVPLAGLEYPMLHYVGFVPVIDGDFIPADPINLYANAADIDYIAGTNNMDGHIFASIDMPAINKGNKKVTEEDFYKLVSEFTITKGLRGAKTTFDVYTESWAQDPSQENKKKTVVDFETDVLFLVPTEIALAQHRANAKSAKTYAYLFSHPSRMPVYPKWVGADHADDIQYVFGKPFATPTGYRPQDRTVSKAMIAYWTNFAKTGDPNMGDSAVPTHWEPYTTENSGYLEITKKMGSSSMKRSLRTNFLRYWTLTYLALPTVTDQEATPVPPTGDSEATPVPPTGDSETAPVPPTGDSGAPPVPPTGDSGAPPVPPTGDSGAPPVPPTGDSGAPPVPPTGDSGAPPVPPTGDSGAPPVPPTGDSGAPPVPPTGDSGAPPVPPTGDAGPPPVPPTGDSGAPPVPPTGDSGAPPVTPTGDSETAPVPPTGDSGAPPVPPTGDSEAAPVPPTDDSKEAQMPAVIRF
T39677	DRUGINFO	D04MZR	Bucelipase alfa	Phase 3
T39677	DRUGINFO	D09NTG	Taurocholic Acid	Phase 1/2
T39677	DRUGINFO	D0GH1C	CVT-1	Terminated
T39677	DRUGINFO	D0D2RR	TgBSSL	Investigative
T39677	DRUGINFO	D06GTS	PMID24556381C10l	Investigative
T39677	DRUGINFO	D0T9WZ	PMID24556381C10f	Investigative

T56308	TARGETID	T56308
T56308	FORMERID	TTDR00519
T56308	UNIPROID	IL11_HUMAN
T56308	TARGNAME	Interleukin-11 (IL11)
T56308	GENENAME	IL11
T56308	TARGTYPE	Clinical trial
T56308	SYNONYMS	Oprelvekin; IL-11; Adipogenesis inhibitory factor; AGIF
T56308	FUNCTION	Promotes the proliferation of hepatocytes in response to liver damage. Binding to its receptor formed by IL6ST and either IL11RA1 or IL11RA2 activates a signaling cascade that promotes cell proliferation. Signaling leads to the activation of intracellular protein kinases and the phosphorylation of STAT3. Cytokine that stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production.
T56308	PDBSTRUC	4MHL
T56308	BIOCLASS	Cytokine: interleukin
T56308	SEQUENCE	MNCVCRLVLVVLSLWPDTAVAPGPPPGPPRVSPDPRAELDSTVLLTRSLLADTRQLAAQLRDKFPADGDHNLDSLPTLAMSAGALGALQLPGVLTRLRADLLSYLRHVQWLRRAGGSSLKTLEPELGTLQARLDRLLRRLQLLMSRLALPQPPPDPPAPPLAPPSSAWGGIRAAHAILGGLHLTLDWAVRGLLLLKTRL
T56308	DRUGINFO	D05XKW	VM-501	Phase 3

T52790	TARGETID	T52790
T52790	FORMERID	TTDC00090
T52790	UNIPROID	NK2R_HUMAN
T52790	TARGNAME	Substance-K receptor (TACR2)
T52790	GENENAME	TACR2
T52790	TARGTYPE	Clinical trial
T52790	SYNONYMS	Tachykinin receptor 2; Tachykinin neurokinin 2 receptor; TACR2; SKR; Neurokinin A receptor; NK-2R; NK-2 receptor
T52790	FUNCTION	This is a receptor for the tachykinin neuropeptide substance K (neurokinin A). It is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of affinity of this receptor to tachykinins is: substance K > neuromedin-K > substance P.
T52790	BIOCLASS	GPCR rhodopsin
T52790	SEQUENCE	MGTCDIVTEANISSGPESNTTGITAFSMPSWQLALWATAYLALVLVAVTGNAIVIWIILAHRRMRTVTNYFIVNLALADLCMAAFNAAFNFVYASHNIWYFGRAFCYFQNLFPITAMFVSIYSMTAIAADRYMAIVHPFQPRLSAPSTKAVIAGIWLVALALASPQCFYSTVTMDQGATKCVVAWPEDSGGKTLLLYHLVVIALIYFLPLAVMFVAYSVIGLTLWRRAVPGHQAHGANLRHLQAMKKFVKTMVLVVLTFAICWLPYHLYFILGSFQEDIYCHKFIQQVYLALFWLAMSSTMYNPIIYCCLNHRFRSGFRLAFRCCPWVTPTKEDKLELTPTTSLSTRVNRCHTKETLFMAGDTAPSEATSGEAGRPQDGSGLWFGYGLLAPTKTHVEI
T52790	DRUGINFO	D0XS4X	Ibodutant	Phase 3
T52790	DRUGINFO	D0AA6Z	Rambazole	Phase 2
T52790	DRUGINFO	D0G2XE	PMX-53	Phase 2
T52790	DRUGINFO	D0S6JV	Nepadutant	Phase 1/2
T52790	DRUGINFO	D05WJQ	Saredutant	Discontinued in Phase 3
T52790	DRUGINFO	D02FIJ	FK-224	Discontinued in Phase 2
T52790	DRUGINFO	D0C9FF	DNK-333	Discontinued in Phase 2
T52790	DRUGINFO	D03ZKE	CS-003	Discontinued in Phase 2
T52790	DRUGINFO	D0Y4GJ	AVE-5883	Discontinued in Phase 1/2
T52790	DRUGINFO	D08WVA	UK-224671	Discontinued in Phase 1
T52790	DRUGINFO	D0E9EE	SR 144190	Discontinued in Phase 1
T52790	DRUGINFO	D02NMG	SLV-332	Preclinical
T52790	DRUGINFO	D02YWV	GR-159897	Terminated
T52790	DRUGINFO	D04RCG	MEN-10627	Terminated
T52790	DRUGINFO	D09KLO	AZD-5106	Terminated
T52790	DRUGINFO	D0IW0Y	MEN-10207	Terminated
T52790	DRUGINFO	D0J3QU	ZD-7944	Terminated
T52790	DRUGINFO	D0S1RT	UK-290795	Terminated
T52790	DRUGINFO	D08ZBV	L-732138	Terminated
T52790	DRUGINFO	D05DYX	ZM 253270	Investigative
T52790	DRUGINFO	D07CVE	R396	Investigative
T52790	DRUGINFO	D08SGF	GR100679	Investigative
T52790	DRUGINFO	D0KX3C	ZM-274773	Investigative
T52790	DRUGINFO	D0N1PH	YM49598	Investigative
T52790	DRUGINFO	D0RR7X	GR94800	Investigative
T52790	DRUGINFO	D0U4WP	YM44781	Investigative
T52790	DRUGINFO	D0ZJ6Y	YM44778	Investigative
T52790	DRUGINFO	D0Z6TG	ZD-6021	Investigative
T52790	DRUGINFO	D00HAJ	Hoo-Phe-Orn-Pro-hle-Pff-Phe-NH2	Investigative
T52790	DRUGINFO	D01NPA	neurokinin A	Investigative
T52790	DRUGINFO	D07JAN	SCH 206272	Investigative
T52790	DRUGINFO	D0C7LY	WAY-207024	Investigative
T52790	DRUGINFO	D0F9QT	A-987306	Investigative
T52790	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T76914	TARGETID	T76914
T76914	FORMERID	TTDR00903
T76914	UNIPROID	KCNA3_HUMAN
T76914	TARGNAME	Voltage-gated potassium channel Kv1.3 (KCNA3)
T76914	GENENAME	KCNA3
T76914	TARGTYPE	Clinical trial
T76914	SYNONYMS	Voltage-gated potassium channel subunit Kv1.3; Voltage-gated Kv1.3 K(+) channel; Voltage-gated K(+) channel Kv1.3; Potassium channel Kv1.3; KCNA3; HuKIII; HPCN3; HLK3; HGK5
T76914	FUNCTION	Mediates the voltage-dependent potassium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a potassium-selective channel through which potassium ions may pass in accordance with their electrochemical gradient.
T76914	PDBSTRUC	4BGC
T76914	BIOCLASS	Voltage-gated ion channel
T76914	SEQUENCE	MDERLSLLRSPPPPSARHRAHPPQRPASSGGAHTLVNHGYAEPAAGRELPPDMTVVPGDHLLEPEVADGGGAPPQGGCGGGGCDRYEPLPPSLPAAGEQDCCGERVVINISGLRFETQLKTLCQFPETLLGDPKRRMRYFDPLRNEYFFDRNRPSFDAILYYYQSGGRIRRPVNVPIDIFSEEIRFYQLGEEAMEKFREDEGFLREEERPLPRRDFQRQVWLLFEYPESSGPARGIAIVSVLVILISIVIFCLETLPEFRDEKDYPASTSQDSFEAAGNSTSGSRAGASSFSDPFFVVETLCIIWFSFELLVRFFACPSKATFSRNIMNLIDIVAIIPYFITLGTELAERQGNGQQAMSLAILRVIRLVRVFRIFKLSRHSKGLQILGQTLKASMRELGLLIFFLFIGVILFSSAVYFAEADDPTSGFSSIPDAFWWAVVTMTTVGYGDMHPVTIGGKIVGSLCAIAGVLTIALPVPVIVSNFNYFYHRETEGEEQSQYMHVGSCQHLSSSAEELRKARSNSTLSKSEYMVIEEGGMNHSAFPQTPFKTGNSTATCTTNNNPNSCVNIKKIFTDV
T76914	DRUGINFO	D01XEO	Debio-0824	Phase 1b/2a
T76914	DRUGINFO	D0OK4O	Dalazatide	Phase 1b/2a
T76914	DRUGINFO	D0G1VS	UK-78282	Terminated
T76914	DRUGINFO	D04UVC	2-Methoxy-N-(3-methyl-2-phenyl-butyl)-benzamide	Investigative
T76914	DRUGINFO	D05CDC	correolide	Investigative
T76914	DRUGINFO	D0CI6E	Correloid	Investigative
T76914	DRUGINFO	D0E9MC	CP-339818	Investigative
T76914	DRUGINFO	D0H1EI	5-(4-Phenylbutoxy)psoralen	Investigative
T76914	DRUGINFO	D0L0FC	[1-Benzyl-1H-quinolin-(4E)-ylidene]-hexyl-amine	Investigative
T76914	DRUGINFO	D0S8CL	1-Benzyl-7-chloro-4-hexyloxy-quinolinium	Investigative
T76914	DRUGINFO	D0R9CF	4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one	Investigative
T76914	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T89918	TARGETID	T89918
T89918	FORMERID	TTDR01240
T89918	UNIPROID	PUR2_HUMAN
T89918	TARGNAME	Glycinamide ribonucleotide formyltransferase (GART)
T89918	GENENAME	GART
T89918	TARGTYPE	Clinical trial
T89918	SYNONYMS	Trifunctional purine biosynthetic protein adenosine-3; PRGS; PGFT
T89918	FUNCTION	A trifunctional polypeptide. Has Phosphoribosylamineglycine ligase, Phosphoribosylglycinamide formyltransferase, AIR synthetase (FGAM cyclase) activity which is required for de novo purine biosynthesis.
T89918	PDBSTRUC	5J9F; 4ZZ3; 4ZZ2; 4ZZ1; 4ZZ0
T89918	BIOCLASS	Carbon-nitrogen ligase
T89918	SEQUENCE	MAARVLIIGSGGREHTLAWKLAQSHHVKQVLVAPGNAGTACSEKISNTAISISDHTALAQFCKEKKIEFVVVGPEAPLAAGIVGNLRSAGVQCFGPTAEAAQLESSKRFAKEFMDRHGIPTAQWKAFTKPEEACSFILSADFPALVVKASGLAAGKGVIVAKSKEEACKAVQEIMQEKAFGAAGETIVIEELLDGEEVSCLCFTDGKTVAPMPPAQDHKRLLEGDGGPNTGGMGAYCPAPQVSNDLLLKIKDTVLQRTVDGMQQEGTPYTGILYAGIMLTKNGPKVLEFNCRFGDPECQVILPLLKSDLYEVIQSTLDGLLCTSLPVWLENHTALTVVMASKGYPGDYTKGVEITGFPEAQALGLEVFHAGTALKNGKVVTHGGRVLAVTAIRENLISALEEAKKGLAAIKFEGAIYRKDVGFRAIAFLQQPRSLTYKESGVDIAAGNMLVKKIQPLAKATSRSGCKVDLGGFAGLFDLKAAGFKDPLLASGTDGVGTKLKIAQLCNKHDTIGQDLVAMCVNDILAQGAEPLFFLDYFSCGKLDLSVTEAVVAGIAKACGKAGCALLGGETAEMPDMYPPGEYDLAGFAVGAMERDQKLPHLERITEGDVVVGIASSGLHSNGFSLVRKIVAKSSLQYSSPAPDGCGDQTLGDLLLTPTRIYSHSLLPVLRSGHVKAFAHITGGGLLENIPRVLPEKLGVDLDAQTWRIPRVFSWLQQEGHLSEEEMARTFNCGVGAVLVVSKEQTEQILRDIQQHKEEAWVIGSVVARAEGSPRVKVKNLIESMQINGSVLKNGSLTNHFSFEKKKARVAVLISGTGSNLQALIDSTREPNSSAQIDIVISNKAAVAGLDKAERAGIPTRVINHKLYKNRVEFDSAIDLVLEEFSIDIVCLAGFMRILSGPFVQKWNGKMLNIHPSLLPSFKGSNAHEQALETGVTVTGCTVHFVAEDVDAGQIILQEAVPVKRGDTVATLSERVKLAEHKIFPAALQLVASGTVQLGENGKICWVKEE
T89918	DRUGINFO	D0J9IH	PELITREXOL	Phase 2
T89918	DRUGINFO	D0IZ1A	LY309887	Phase 1
T89918	DRUGINFO	D00UUG	10-Formyl-5,8,10-Trideazafolic Acid	Investigative
T89918	DRUGINFO	D07DGI	Glycinamide Ribonucleotide	Investigative
T89918	DRUGINFO	D0E0CV	(10r)-10-Formyl-5,8,10-Trideazafolic Acid	Investigative
T89918	DRUGINFO	D0F2WA	10-trifluoroacetyl-DDACTHF	Investigative
T89918	DRUGINFO	D0R7LQ	Dideazaacyclotetrahydrofolic acid	Investigative
T89918	DRUGINFO	D0XU7N	10-CF3C(OH)2-DDACTHF	Investigative
T89918	DRUGINFO	D0Z9QC	Dideazafolate	Investigative

T09092	TARGETID	T09092
T09092	FORMERID	TTDR00138
T09092	UNIPROID	IL10_HUMAN
T09092	TARGNAME	Interleukin-10 (IL10)
T09092	GENENAME	IL10
T09092	TARGTYPE	Clinical trial
T09092	SYNONYMS	IL-10; Cytokine synthesis inhibitory factor; CSIF
T09092	FUNCTION	Mechanistically, IL10 binds to its heterotetrameric receptor comprising IL10RA and IL10RB leading to JAK1 and STAT2-mediated phosphorylation of STAT3. In turn, STAT3 translocates to the nucleus where it drives expression of anti-inflammatory mediators. Targets antigen-presenting cells (APCs) such as macrophages and monocytes and inhibits their release of pro-inflammatory cytokines including granulocyte-macrophage colony-stimulating factor /GM-CSF, granulocyte colony-stimulating factor/G-CSF, IL-1 alpha, IL-1 beta, IL-6, IL-8 and TNF-alpha. Interferes also with antigen presentation by reducing the expression of MHC-class II and co-stimulatory molecules, thereby inhibiting their ability to induce T cell activation. In addition, controls the inflammatory response of macrophages by reprogramming essential metabolic pathways including mTOR signaling. Major immune regulatory cytokine that acts on many cells of the immune system where it has profound anti-inflammatory functions, limiting excessive tissue disruption caused by inflammation.
T09092	PDBSTRUC	2ILK; 2H24; 1Y6K; 1LK3; 1J7V
T09092	BIOCLASS	Cytokine: interleukin
T09092	SEQUENCE	MHSSALLCCLVLLTGVRASPGQGTQSENSCTHFPGNLPNMLRDLRDAFSRVKTFFQMKDQLDNLLLKESLLEDFKGYLGCQALSEMIQFYLEEVMPQAENQDPDIKAHVNSLGENLKTLRLRLRRCHRFLPCENKSKAVEQVKNAFNKLQEKGIYKAMSEFDIFINYIEAYMTMKIRN
T09092	DRUGINFO	D03MYX	AM0010	Phase 3
T09092	DRUGINFO	D0O5ZB	Ilodecakin	Phase 2
T09092	DRUGINFO	D0T4KG	F-8-IL-10 fusion protein	Phase 2
T09092	DRUGINFO	DPC0T8	XT-150	Phase 2
T09092	DRUGINFO	DL6EZ5	AG019	Phase 1/2
T09092	DRUGINFO	D05TZJ	Ankinara	Investigative

T90989	TARGETID	T90989
T90989	FORMERID	TTDNC00621
T90989	UNIPROID	FGFR4_HUMAN
T90989	TARGNAME	Fibroblast growth factor receptor 4 (FGFR4)
T90989	GENENAME	FGFR4
T90989	TARGTYPE	Clinical trial
T90989	SYNONYMS	TKF; JTK2; FGFR-4; CD334
T90989	FUNCTION	Required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. Phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes SRC-dependent phosphorylation of the matrix protease MMP14 and its lysosomal degradation. FGFR4 signaling is down-regulated by receptor internalization and degradation; MMP14 promotes internalization and degradation of FGFR4. Mutations that lead to constitutive kinase activation or impair normal FGFR4 inactivation lead to aberrant signaling. Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis.
T90989	PDBSTRUC	6JPJ; 5XFJ; 5XFF; 5NWZ; 5NUD
T90989	BIOCLASS	Kinase
T90989	ECNUMBER	EC 2.7.10.1
T90989	SEQUENCE	MRLLLALLGVLLSVPGPPVLSLEASEEVELEPCLAPSLEQQEQELTVALGQPVRLCCGRAERGGHWYKEGSRLAPAGRVRGWRGRLEIASFLPEDAGRYLCLARGSMIVLQNLTLITGDSLTSSNDDEDPKSHRDPSNRHSYPQQAPYWTHPQRMEKKLHAVPAGNTVKFRCPAAGNPTPTIRWLKDGQAFHGENRIGGIRLRHQHWSLVMESVVPSDRGTYTCLVENAVGSIRYNYLLDVLERSPHRPILQAGLPANTTAVVGSDVELLCKVYSDAQPHIQWLKHIVINGSSFGADGFPYVQVLKTADINSSEVEVLYLRNVSAEDAGEYTCLAGNSIGLSYQSAWLTVLPEEDPTWTAAAPEARYTDIILYASGSLALAVLLLLAGLYRGQALHGRHPRPPATVQKLSRFPLARQFSLESGSSGKSSSSLVRGVRLSSSGPALLAGLVSLDLPLDPLWEFPRDRLVLGKPLGEGCFGQVVRAEAFGMDPARPDQASTVAVKMLKDNASDKDLADLVSEMEVMKLIGRHKNIINLLGVCTQEGPLYVIVECAAKGNLREFLRARRPPGPDLSPDGPRSSEGPLSFPVLVSCAYQVARGMQYLESRKCIHRDLAARNVLVTEDNVMKIADFGLARGVHHIDYYKKTSNGRLPVKWMAPEALFDRVYTHQSDVWSFGILLWEIFTLGGSPYPGIPVEELFSLLREGHRMDRPPHCPPELYGLMRECWHAAPSQRPTFKQLVEALDKVLLAVSEEYLDLRLTFGPYSPSGGDASSTCSSSDSVFSHDPLPLGSSSFPFGSGVQT
T90989	DRUGINFO	D0BE8H	INCB62079	Phase 1/2
T90989	DRUGINFO	D08HZN	ABC-4	Investigative
T90989	DRUGINFO	D0R6OM	ACTB-1003	Investigative

T55860	TARGETID	T55860
T55860	FORMERID	TTDI02194
T55860	UNIPROID	TNFL4_HUMAN
T55860	TARGNAME	TAX transcriptionally-activated glycoprotein 1 (OX40)
T55860	GENENAME	TNFSF4
T55860	TARGTYPE	Clinical trial
T55860	SYNONYMS	Tumor necrosis factor ligand superfamily member 4; TNFSF4; OX40L; Glycoprotein Gp34; CD252
T55860	FUNCTION	Cytokine that binds to TNFRSF4. Co-stimulates T-cell proliferation and cytokine production.
T55860	PDBSTRUC	2HEV
T55860	BIOCLASS	Cytokine: tumor necrosis factor
T55860	SEQUENCE	MERVQPLEENVGNAARPRFERNKLLLVASVIQGLGLLLCFTYICLHFSALQVSHRYPRIQSIKVQFTEYKKEKGFILTSQKEDEIMKVQNNSVIINCDGFYLISLKGYFSQEVNISLHYQKDEEPLFQLKKVRSVNSLMVASLTYKDKVYLNVTTDNTSLDDFHVNGGELILIHQNPGEFCVL
T55860	DRUGINFO	D0K8NR	AMG 386	Phase 3
T55860	DRUGINFO	D03UZP	RG7888	Phase 2
T55860	DRUGINFO	DN2OL8	Amlitelimab	Phase 2
T55860	DRUGINFO	D02UBC	MEDI6383	Phase 1
T55860	DRUGINFO	D70SHJ	mRNA-2416	Phase 1
T55860	DRUGINFO	D31CPE	SAR442970	Phase 1
T55860	DRUGINFO	DC5A9Q	mRNA-2752	Phase 1

T12355	TARGETID	T12355
T12355	FORMERID	TTDR00397
T12355	UNIPROID	CCND1_HUMAN
T12355	TARGNAME	G1/S-specific cyclin-D1 (CCND1)
T12355	GENENAME	CCND1
T12355	TARGTYPE	Clinical trial
T12355	SYNONYMS	PRAD1 oncogene; PRAD1; Cyclin D1; BCL1; BCL-1 oncogene; BCL-1; B-cell lymphoma 1 protein
T12355	FUNCTION	Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex, cyclin D1/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex. Exhibits transcriptional corepressor activity with INSM1 on the NEUROD1 and INS promoters in a cell cycle-independent manner. Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition.
T12355	PDBSTRUC	5VZU; 2W9Z; 2W9F; 2W99; 2W96
T12355	SEQUENCE	MEHQLLCCEVETIRRAYPDANLLNDRVLRAMLKAEETCAPSVSYFKCVQKEVLPSMRKIVATWMLEVCEEQKCEEEVFPLAMNYLDRFLSLEPVKKSRLQLLGATCMFVASKMKETIPLTAEKLCIYTDNSIRPEELLQMELLLVNKLKWNLAAMTPHDFIEHFLSKMPEAEENKQIIRKHAQTFVALCATDVKFISNPPSMVAAGSVVAAVQGLNLRSPNNFLSYYRLTRFLSRVIKCDPDCLRACQEQIEALLESSLRQAQQNMDPKAAEEEEEEEEEVDLACTPTDVRDVDI
T12355	DRUGINFO	D06ETI	ABT-263	Phase 3
T12355	DRUGINFO	D0T0KT	Briciclib	Phase 1
T12355	DRUGINFO	D02JEZ	7-hydroxycoumarin	Investigative
T12355	DRUGINFO	D06AOY	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	Investigative
T12355	DRUGINFO	D00NYT	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	Investigative
T12355	DRUGINFO	D0C3WY	3,4-diphenyl-1H-pyrrole-2,5-dione	Investigative
T12355	DRUGINFO	D0EK0G	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	Investigative
T12355	DRUGINFO	D0A5RM	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	Investigative

T86399	TARGETID	T86399
T86399	FORMERID	TTDI02030
T86399	UNIPROID	BRD2_HUMAN
T86399	TARGNAME	Bromodomain-containing protein 2 (BRD2)
T86399	GENENAME	BRD2
T86399	TARGTYPE	Clinical trial
T86399	SYNONYMS	Really interesting new gene 3 protein; RING3; O27.1.1; KIAA9001
T86399	FUNCTION	Binds hyperacetylated chromatin and plays a role in the regulation of transcription, probably by chromatin remodeling. Regulates transcription of the CCND1 gene. Plays a role in nucleosome assembly. May play a role in spermatogenesis or folliculogenesis.
T86399	PDBSTRUC	6MOA; 6MO9; 6MO8; 6MO7; 6FFG
T86399	BIOCLASS	Bromodomain
T86399	SEQUENCE	MLQNVTPHNKLPGEGNAGLLGLGPEAAAPGKRIRKPSLLYEGFESPTMASVPALQLTPANPPPPEVSNPKKPGRVTNQLQYLHKVVMKALWKHQFAWPFRQPVDAVKLGLPDYHKIIKQPMDMGTIKRRLENNYYWAASECMQDFNTMFTNCYIYNKPTDDIVLMAQTLEKIFLQKVASMPQEEQELVVTIPKNSHKKGAKLAALQGSVTSAHQVPAVSSVSHTALYTPPPEIPTTVLNIPHPSVISSPLLKSLHSAGPPLLAVTAAPPAQPLAKKKGVKRKADTTTPTPTAILAPGSPASPPGSLEPKAARLPPMRRESGRPIKPPRKDLPDSQQQHQSSKKGKLSEQLKHCNGILKELLSKKHAAYAWPFYKPVDASALGLHDYHDIIKHPMDLSTVKRKMENRDYRDAQEFAADVRLMFSNCYKYNPPDHDVVAMARKLQDVFEFRYAKMPDEPLEPGPLPVSTAMPPGLAKSSSESSSEESSSESSSEEEEEEDEEDEEEEESESSDSEEERAHRLAELQEQLRAVHEQLAALSQGPISKPKRKREKKEKKKKRKAEKHRGRAGADEDDKGPRAPRPPQPKKSKKASGSGGGSAALGPSGFGPSGGSGTKLPKKATKTAPPALPTGYDSEEEEESRPMSYDEKRQLSLDINKLPGEKLGRVVHIIQAREPSLRDSNPEEIEIDFETLKPSTLRELERYVLSCLRKKPRKPYTIKKPVGKTKEELALEKKRELEKRLQDVSGQLNSTKKPPKKANEKTESSSAQQVAVSRLSASSSSSDSSSSSSSSSSSDTSDSDSG
T86399	DRUGINFO	D02YNI	OTX-015	Phase 1/2
T86399	DRUGINFO	D05ICT	ABBV-744	Phase 1
T86399	DRUGINFO	D0AE6Y	PMID26924192-Compound-106	Patented
T86399	DRUGINFO	D0YM3G	Pyrrolo-pyrrolone derivative 1	Patented
T86399	DRUGINFO	D03NWT	PMID26924192-Compound-104	Patented
T86399	DRUGINFO	D03RPJ	PMID26924192-Compound-102	Patented
T86399	DRUGINFO	D05XXS	PMID26924192-Compound-103	Patented
T86399	DRUGINFO	D0NN4U	PMID26924192-Compound-105	Patented
T86399	DRUGINFO	D08SEK	ET bromodomain inhibitor	Investigative
T86399	DRUGINFO	D09QOB	ME bromodomain inhibitor	Investigative
T86399	DRUGINFO	D0T3AT	BIC1	Investigative
T86399	DRUGINFO	D0H3TC	PMID21851057C4d	Investigative
T86399	DRUGINFO	D03LIP	GW841819X	Investigative
T86399	DRUGINFO	D0C2XT	PMID24000170C36	Investigative
T86399	DRUGINFO	D0Q2GK	PMID24000170C38	Investigative
T86399	DRUGINFO	D0WU1S	I-BET151	Investigative
T86399	DRUGINFO	D07FGY	XD14	Investigative

T14592	TARGETID	T14592
T14592	FORMERID	TTDI02199
T14592	UNIPROID	TNR6_HUMAN
T14592	TARGNAME	Apoptosis mediating surface antigen FAS (FAS)
T14592	GENENAME	FAS
T14592	TARGTYPE	Clinical trial
T14592	SYNONYMS	Tumor necrosis factor receptor superfamily member 6; TNFRSF6; FASLG receptor; FAS1; CD95; Apoptosis-mediating surface antigen FAS; Apo-1 antigen; APT1
T14592	FUNCTION	The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. FAS-mediated apoptosis may have a role in the induction of peripheral tolerance, in the antigen-stimulated suicide of mature T-cells, or both. The secreted isoforms 2 to 6 block apoptosis (in vitro). Receptor for TNFSF6/FASLG.
T14592	PDBSTRUC	3TJE; 3THM; 3EZQ; 3EWT; 2NA7
T14592	BIOCLASS	Cytokine receptor
T14592	SEQUENCE	MLGIWTLLPLVLTSVARLSSKSVNAQVTDINSKGLELRKTVTTVETQNLEGLHHDGQFCHKPCPPGERKARDCTVNGDEPDCVPCQEGKEYTDKAHFSSKCRRCRLCDEGHGLEVEINCTRTQNTKCRCKPNFFCNSTVCEHCDPCTKCEHGIIKECTLTSNTKCKEEGSRSNLGWLCLLLLPIPLIVWVKRKEVQKTCRKHRKENQGSHESPTLNPETVAINLSDVDLSKYITTIAGVMTLSQVKGFVRKNGVNEAKIDEIKNDNVQDTAEQKVQLLRNWHQLHGKKEAYDTLIKDLKKANLCTLAEKIQTIILKDITSDSENSNFRNEIQSLV
T14592	DRUGINFO	D0S4LV	VB-111	Phase 3
T14592	DRUGINFO	D07PRH	DE-098	Phase 2
T14592	DRUGINFO	D0N4JI	APG-101	Phase 2
T14592	DRUGINFO	D0Q6SF	APO-010	Phase 1
T14592	DRUGINFO	D0N1DG	F61F12	Investigative
T14592	DRUGINFO	D0QA7X	APG-103	Investigative
T14592	DRUGINFO	DAQ31P	2-aminophenoxazine-3-one	Investigative

T89213	TARGETID	T89213
T89213	FORMERID	TTDC00193
T89213	UNIPROID	NPY1R_HUMAN
T89213	TARGNAME	Neuropeptide Y receptor type 1 (NPY1R)
T89213	GENENAME	NPY1R
T89213	TARGTYPE	Clinical trial
T89213	SYNONYMS	Neuropeptide Y-Y1 receptor; Neuropeptide Y receptor Y1; Neuropeptide Y Y(1) receptor; NPY1R; NPY1-R
T89213	FUNCTION	Receptor for neuropeptide Y and peptide YY. The rank order of affinity of this receptor for pancreatic polypeptides is NPY > [Pro-34] PYY, PYY and [Leu-31, Pro-34] NPY > NPY (2-36) > [Ile-31, Gln-34] PP and PYY (3-36) > PP > NPY free acid.
T89213	PDBSTRUC	5ZBQ; 2IIL; 2F1U
T89213	BIOCLASS	GPCR rhodopsin
T89213	SEQUENCE	MNSTLFSQVENHSVHSNFSEKNAQLLAFENDDCHLPLAMIFTLALAYGAVIILGVSGNLALIIIILKQKEMRNVTNILIVNLSFSDLLVAIMCLPFTFVYTLMDHWVFGEAMCKLNPFVQCVSITVSIFSLVLIAVERHQLIINPRGWRPNNRHAYVGIAVIWVLAVASSLPFLIYQVMTDEPFQNVTLDAYKDKYVCFDQFPSDSHRLSYTTLLLVLQYFGPLCFIFICYFKIYIRLKRRNNMMDKMRDNKYRSSETKRINIMLLSIVVAFAVCWLPLTIFNTVFDWNHQIIATCNHNLLFLLCHLTAMISTCVNPIFYGFLNKNFQRDLQFFFNFCDFRSRDDDYETIAMSTMHTDVSKTSLKQASPVAFKKINNNDDNEKI
T89213	DRUGINFO	D0I1KQ	NEUROPEPTIDE-Y	Phase 2
T89213	DRUGINFO	D03GAY	H-409/22	Discontinued in Phase 2
T89213	DRUGINFO	D0Q3UL	PD-160170	Preclinical
T89213	DRUGINFO	D0R2CI	GI-264879A	Preclinical
T89213	DRUGINFO	D04QXG	SR 120819A	Terminated
T89213	DRUGINFO	D0V2GT	BIBP 3226	Terminated
T89213	DRUGINFO	D01MBR	BMS-245782	Investigative
T89213	DRUGINFO	D06HXC	NPY-1 antagonist	Investigative
T89213	DRUGINFO	D08VVZ	J-104870	Investigative
T89213	DRUGINFO	D0F1IS	BMS-189323	Investigative
T89213	DRUGINFO	D0SD8Q	BMS-193885	Investigative
T89213	DRUGINFO	D0U5TK	BIBO3304	Investigative
T89213	DRUGINFO	D02MKP	AcPYY(22-36)	Investigative
T89213	DRUGINFO	D07BCH	[Cys-Trp-Arg-Nva-Arg-Tyr-NH2]2	Investigative
T89213	DRUGINFO	D07DJT	LRHYLNLLTRQRY-NH2	Investigative
T89213	DRUGINFO	D08ROQ	S-25585	Investigative
T89213	DRUGINFO	D0H8KI	[125I]GR231118	Investigative
T89213	DRUGINFO	D0NY7A	S-19528	Investigative
T89213	DRUGINFO	D0P9KP	PYY(22-36)	Investigative
T89213	DRUGINFO	D00OLA	H-[Trp-Arg-Nva-Arg-Tyr]3-NH2	Investigative
T89213	DRUGINFO	D07OOG	Sub[-Trp-Arg-Nva-Arg-Tyr-NH2]2	Investigative
T89213	DRUGINFO	D08YWE	Pim[-Trp-Arg-Nva-Arg-Tyr-NH2]2	Investigative
T89213	DRUGINFO	D0G4HT	Sub[-Tyr-Arg-Leu-Arg-Tyr-NH2]2	Investigative
T89213	DRUGINFO	D0J9VA	H-[Trp-Arg-Nva-Arg-Tyr]2-NH2	Investigative
T89213	DRUGINFO	D0V0HM	Adp[-Trp-Arg-Nva-Arg-Tyr-NH2]2	Investigative
T89213	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T83192	TARGETID	T83192
T83192	FORMERID	TTDR00032
T83192	UNIPROID	CNTF_HUMAN
T83192	TARGNAME	Ciliary neurotrophic factor (CNTF)
T83192	GENENAME	CNTF
T83192	TARGTYPE	Clinical trial
T83192	SYNONYMS	CNTF
T83192	FUNCTION	CNTF is a survival factor for various neuronal cell types. Seems to prevent the degeneration of motor axons after axotomy.
T83192	PDBSTRUC	1CNT
T83192	BIOCLASS	Ciliary neurotrophic factor
T83192	SEQUENCE	MAFTEHSPLTPHRRDLCSRSIWLARKIRSDLTALTESYVKHQGLNKNINLDSADGMPVASTDQWSELTEAERLQENLQAYRTFHVLLARLLEDQQVHFTPTEGDFHQAIHTLLLQVAAFAYQIEELMILLEYKIPRNEADGMPINVGDGGLFEKKLWGLKVLQELSQWTVRSIHDLRFISSHQTGIPARGSHYIANNKKM
T83192	DRUGINFO	D07GWZ	NT-501 CNTF	Phase 1/2

T61033	TARGETID	T61033
T61033	FORMERID	TTDC00257
T61033	UNIPROID	CNTFR_HUMAN
T61033	TARGNAME	Ciliary neurotrophic factor receptor alpha (CNTFR)
T61033	GENENAME	CNTFR
T61033	TARGTYPE	Clinical trial
T61033	SYNONYMS	Ciliary neurotrophic factor receptor subunit alpha; CNTFR-alpha; CNTFR alpha; CNTF receptor subunit alpha
T61033	FUNCTION	The alpha subunit provides the receptor specificity. Binds to CNTF.
T61033	PDBSTRUC	1UC6
T61033	BIOCLASS	Cytokine receptor
T61033	SEQUENCE	MAAPVPWACCAVLAAAAAVVYAQRHSPQEAPHVQYERLGSDVTLPCGTANWDAAVTWRVNGTDLAPDLLNGSQLVLHGLELGHSGLYACFHRDSWHLRHQVLLHVGLPPREPVLSCRSNTYPKGFYCSWHLPTPTYIPNTFNVTVLHGSKIMVCEKDPALKNRCHIRYMHLFSTIKYKVSISVSNALGHNATAITFDEFTIVKPDPPENVVARPVPSNPRRLEVTWQTPSTWPDPESFPLKFFLRYRPLILDQWQHVELSDGTAHTITDAYAGKEYIIQVAAKDNEIGTWSDWSVAAHATPWTEEPRHLTTEAQAAETTTSTTSSLAPPPTTKICDPGELGSGGGPSAPFLVSVPITLALAAAAATASSLLI
T61033	DRUGINFO	D0A7WO	NT-501	Phase 2/3
T61033	DRUGINFO	D0C2HI	PegCNTF	Phase 1

T23276	TARGETID	T23276
T23276	FORMERID	TTDR00373
T23276	UNIPROID	MK03_HUMAN
T23276	TARGNAME	Extracellular signal-regulated kinase 1 (ERK1)
T23276	GENENAME	MAPK3
T23276	TARGTYPE	Clinical trial
T23276	SYNONYMS	PRKM3; P44-MAPK; P44-ERK1; P44 Mitogen-activated protein kinase; Mitogen-activated protein kinase 3; Microtubule-associated protein-2 kinase; Microtubule-associated protein 2 kinase; MAPK 3; MAP kinase isoform p44; MAP kinase 3; Insulin-stimulated MAP2 kinase; ERT2; ERK-1
T23276	FUNCTION	MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signaling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, cytoskeletal rearrangements. The MAPK/ERK cascade plays also a role in initiation and regulation of meiosis, mitosis, and postmitotic functions in differentiated cells by phosphorylating a number of transcription factors. About 160 substrates have already been discovered for ERKs. Many of these substrates are localized in the nucleus, and seem to participate in the regulation of transcription upon stimulation. However, other substrates are found in the cytosol as well as in other cellular organelles, and those are responsible for processes such as translation, mitosis and apoptosis. Moreover, the MAPK/ERK cascade is also involved in the regulation of the endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC); as well as in the fragmentation of the Golgi apparatus during mitosis. The substrates include transcription factors (such as ATF2, BCL6, ELK1, ERF, FOS, HSF4 or SPZ1), cytoskeletal elements (such as CANX, CTTN, GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1), regulators of apoptosis (such as BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG), regulators of translation (such as EIF4EBP1) and a variety of other signaling-related molecules (like ARHGEF2, FRS2 or GRB10). Protein kinases (such as RAF1, RPS6KA1/RSK1, RPS6KA3/RSK2, RPS6KA2/RSK3, RPS6KA6/RSK4, SYK, MKNK1/MNK1, MKNK2/MNK2, RPS6KA5/MSK1, RPS6KA4/MSK2, MAPKAPK3 or MAPKAPK5) and phosphatases (such as DUSP1, DUSP4, DUSP6 or DUSP16) are other substrates which enable the propagation the MAPK/ERK signal to additional cytosolic and nuclear targets, thereby extending the specificity of the cascade. Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway.
T23276	PDBSTRUC	6GES; 4QTB; 2ZOQ
T23276	BIOCLASS	Kinase
T23276	ECNUMBER	EC 2.7.11.24
T23276	SEQUENCE	MAAAAAQGGGGGEPRRTEGVGPGVPGEVEMVKGQPFDVGPRYTQLQYIGEGAYGMVSSAYDHVRKTRVAIKKISPFEHQTYCQRTLREIQILLRFRHENVIGIRDILRASTLEAMRDVYIVQDLMETDLYKLLKSQQLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLINTTCDLKICDFGLARIADPEHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINMKARNYLQSLPSKTKVAWAKLFPKSDSKALDLLDRMLTFNPNKRITVEEALAHPYLEQYYDPTDEPVAEEPFTFAMELDDLPKERLKELIFQETARFQPGVLEAP
T23276	DRUGINFO	D01IED	BVD-523	Phase 2
T23276	DRUGINFO	D1KIY9	HH2710	Phase 1/2
T23276	DRUGINFO	DM1FD5	ASTX029	Phase 1/2
T23276	DRUGINFO	D0D2XQ	ASN007	Phase 1
T23276	DRUGINFO	D08KNG	VAN-10-4-eluting stent	Phase 1
T23276	DRUGINFO	D0Q4IX	GDC-0994	Phase 1
T23276	DRUGINFO	DBU16T	JSI-1187	Phase 1
T23276	DRUGINFO	DOJ6D9	COR-D	Preclinical
T23276	DRUGINFO	D02TYK	6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine	Investigative

T13348	TARGETID	T13348
T13348	FORMERID	TTDR00967
T13348	UNIPROID	APEX1_HUMAN
T13348	TARGNAME	AP endonuclease 1 (APEX1)
T13348	GENENAME	APEX1
T13348	TARGTYPE	Clinical trial
T13348	SYNONYMS	Redox factor-1; REF1; REF-1; HAP1; DNA-(apurinic or apyrimidinic site) lyase; Apurinic-apyrimidinic endonuclease 1; APX; APEX nuclease; APEX; APEN; APE1; APE-1; APE
T13348	FUNCTION	Multifunctional protein that plays a central role in the cellular response to oxidative stress. The two major activities of APEX1 are DNA repair and redox regulation of transcriptional factors. Functions as a apurinic/apyrimidinic (AP) endodeoxyribonuclease in the DNA base excision repair (BER) pathway of DNA lesions induced by oxidative and alkylating agents. Initiates repair of AP sites in DNA by catalyzing hydrolytic incision of the phosphodiester backbone immediately adjacent to the damage, generating a single-strand break with 5'-deoxyribose phosphate and 3'-hydroxyl ends. Does also incise at AP sites in the DNA strand of DNA/RNA hybrids, single-stranded DNA regions of R-loop structures, and single-stranded RNA molecules. Has a 3'-5' exoribonuclease activity on mismatched deoxyribonucleotides at the 3' termini of nicked or gapped DNA molecules during short-patch BER. Possesses a DNA 3' phosphodiesterase activity capable of removing lesions (such as phosphoglycolate) blocking the 3' side of DNA strand breaks. May also play a role in the epigenetic regulation of gene expression by participating in DNA demethylation. Acts as a loading factor for POLB onto non-incised AP sites in DNA and stimulates the 5'-terminal deoxyribose 5'-phosphate (dRp) excision activity of POLB. Plays a role in the protection from granzymes-mediated cellular repair leading to cell death. Also involved in the DNA cleavage step of class switch recombination (CSR). On the other hand, APEX1 also exerts reversible nuclear redox activity to regulate DNA binding affinity and transcriptional activity of transcriptional factors by controlling the redox status of their DNA-binding domain, such as the FOS/JUN AP-1 complex after exposure to IR. Involved in calcium-dependent down-regulation of parathyroid hormone (PTH) expression by binding to negative calcium response elements (nCaREs). Together with HNRNPL or the dimer XRCC5/XRCC6, associates with nCaRE, acting as an activator of transcriptional repression. Stimulates the YBX1-mediated MDR1 promoter activity, when acetylated at Lys-6 and Lys-7, leading to drug resistance. Acts also as an endoribonuclease involved in the control of single-stranded RNA metabolism. Plays a role in regulating MYC mRNA turnover by preferentially cleaving in between UA and CA dinucleotides of the MYC coding region determinant (CRD). In association with NMD1, plays a role in the rRNA quality control process during cell cycle progression. Associates, together with YBX1, on the MDR1 promoter. Together with NPM1, associates with rRNA. Binds DNA and RNA.
T13348	PDBSTRUC	6MKO; 6MKM; 6MKK; 6MK3; 6BOW
T13348	BIOCLASS	Alpha-carbonic anhydrase
T13348	ECNUMBER	EC 3.1.-.-
T13348	SEQUENCE	MPKRGKKGAVAEDGDELRTEPEAKKSKTAAKKNDKEAAGEGPALYEDPPDQKTSPSGKPATLKICSWNVDGLRAWIKKKGLDWVKEEAPDILCLQETKCSENKLPAELQELPGLSHQYWSAPSDKEGYSGVGLLSRQCPLKVSYGIGDEEHDQEGRVIVAEFDSFVLVTAYVPNAGRGLVRLEYRQRWDEAFRKFLKGLASRKPLVLCGDLNVAHEEIDLRNPKGNKKNAGFTPQERQGFGELLQAVPLADSFRHLYPNTPYAYTFWTYMMNARSKNVGWRLDYFLLSHSLLPALCDSKIRSKALGSDHCPITLYLAL
T13348	DRUGINFO	D9YG4P	APX3330	Phase 2
T13348	DRUGINFO	D0U8XW	APX-3330	Phase 1
T13348	DRUGINFO	D06BFH	5-fluoro-1H-indole-2-carboxylic acid	Investigative
T13348	DRUGINFO	D07DZS	1,3-bis(1,3-benzothiazol-2-ylthio)acetone	Investigative
T13348	DRUGINFO	D0A3SQ	3-benzofuran-2-yl-2-benzothiazol-2-yl-3-oxo-propanenitrile	Investigative

T57278	TARGETID	T57278
T57278	FORMERID	TTDR01214
T57278	UNIPROID	EPHA2_HUMAN
T57278	TARGNAME	Ephrin type-A receptor 2 (EPHA2)
T57278	GENENAME	EPHA2
T57278	TARGTYPE	Clinical trial
T57278	SYNONYMS	Tyrosine-protein kinase receptor ECK; Epithelial cell kinase; EphA2receptor; ECK
T57278	FUNCTION	The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Activated by the ligand ephrin-A1/EFNA1 regulates migration, integrin-mediated adhesion, proliferation and differentiation of cells. Regulates cell adhesion and differentiation through DSG1/desmoglein-1 and inhibition of the ERK1/ERK2 (MAPK3/MAPK1, respectively) signaling pathway. May also participate in UV radiation-induced apoptosis and have a ligand-independent stimulatory effect on chemotactic cell migration. During development, may function in distinctive aspects of pattern formation and subsequently in development of several fetal tissues. Involved for instance in angiogenesis, in early hindbrain development and epithelial proliferation and branching morphogenesis during mammary gland development. Engaged by the ligand ephrin-A5/EFNA5 may regulate lens fiber cells shape and interactions and be important for lens transparency development and maintenance. With ephrin-A2/EFNA2 may play a role in bone remodeling through regulation of osteoclastogenesis and osteoblastogenesis. Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells.
T57278	PDBSTRUC	6NKP; 6NK2; 6NK1; 6NK0; 6NJZ
T57278	BIOCLASS	Kinase
T57278	ECNUMBER	EC 2.7.10.1
T57278	SEQUENCE	MELQAARACFALLWGCALAAAAAAQGKEVVLLDFAAAGGELGWLTHPYGKGWDLMQNIMNDMPIYMYSVCNVMSGDQDNWLRTNWVYRGEAERIFIELKFTVRDCNSFPGGASSCKETFNLYYAESDLDYGTNFQKRLFTKIDTIAPDEITVSSDFEARHVKLNVEERSVGPLTRKGFYLAFQDIGACVALLSVRVYYKKCPELLQGLAHFPETIAGSDAPSLATVAGTCVDHAVVPPGGEEPRMHCAVDGEWLVPIGQCLCQAGYEKVEDACQACSPGFFKFEASESPCLECPEHTLPSPEGATSCECEEGFFRAPQDPASMPCTRPPSAPHYLTAVGMGAKVELRWTPPQDSGGREDIVYSVTCEQCWPESGECGPCEASVRYSEPPHGLTRTSVTVSDLEPHMNYTFTVEARNGVSGLVTSRSFRTASVSINQTEPPKVRLEGRSTTSLSVSWSIPPPQQSRVWKYEVTYRKKGDSNSYNVRRTEGFSVTLDDLAPDTTYLVQVQALTQEGQGAGSKVHEFQTLSPEGSGNLAVIGGVAVGVVLLLVLAGVGFFIHRRRKNQRARQSPEDVYFSKSEQLKPLKTYVDPHTYEDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSGSEGVPFRTVSEWLESIKMQQYTEHFMAAGYTAIEKVVQMTNDDIKRIGVRLPGHQKRIAYSLLGLKDQVNTVGIPI
T57278	DRUGINFO	D05OHY	CAR-T cells targeting EphA2	Phase 1/2
T57278	DRUGINFO	DS5C0K	BT5528	Phase 1/2
T57278	DRUGINFO	D03YBJ	DS-8895	Phase 1
T57278	DRUGINFO	D0B8MS	MEDI-547	Phase 1
T57278	DRUGINFO	D0W8HP	MEDI-543	Preclinical
T57278	DRUGINFO	D02BXJ	PMID21561767C8h	Investigative
T57278	DRUGINFO	D05FXD	PMID19788238C66	Investigative
T57278	DRUGINFO	D00ICA	AMP-PNP	Investigative
T57278	DRUGINFO	D0X8BU	PMID23489211C20	Investigative

T28413	TARGETID	T28413
T28413	FORMERID	TTDI02061
T28413	UNIPROID	EPHA3_HUMAN
T28413	TARGNAME	Ephrin type-A receptor 3 (EPHA3)
T28413	GENENAME	EPHA3
T28413	TARGTYPE	Clinical trial
T28413	SYNONYMS	hEK4; Tyrosineprotein kinase receptor ETK1; Tyrosineprotein kinase TYRO4; Tyrosine-protein kinase receptor ETK1; Tyrosine-protein kinase TYRO4; TYRO4; Human embryo kinase; HEK; Ephrin typeA receptor 3; Ephlike tyrosine kinase 1; Eph-like tyrosine kinase 1; ETK1; ETK protein; EPHlike kinase 4; EPH-like kinase 4; EK4
T28413	FUNCTION	The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Highly promiscuous for ephrin-A ligands it binds preferentially EFNA5. Upon activation by EFNA5 regulates cell-cell adhesion, cytoskeletal organization and cell migration. Plays a role in cardiac cells migration and differentiation and regulates the formation of the atrioventricular canal and septum during development probably through activation by EFNA1. Involved in the retinotectal mapping of neurons. May also control the segregation but not the guidance of motor and sensory axons during neuromuscular circuit development. Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells.
T28413	PDBSTRUC	4TWO; 4TWN; 4P5Z; 4P5Q; 4P4C
T28413	BIOCLASS	Kinase
T28413	ECNUMBER	EC 2.7.10.1
T28413	SEQUENCE	MDCQLSILLLLSCSVLDSFGELIPQPSNEVNLLDSKTIQGELGWISYPSHGWEEISGVDEHYTPIRTYQVCNVMDHSQNNWLRTNWVPRNSAQKIYVELKFTLRDCNSIPLVLGTCKETFNLYYMESDDDHGVKFREHQFTKIDTIAADESFTQMDLGDRILKLNTEIREVGPVNKKGFYLAFQDVGACVALVSVRVYFKKCPFTVKNLAMFPDTVPMDSQSLVEVRGSCVNNSKEEDPPRMYCSTEGEWLVPIGKCSCNAGYEERGFMCQACRPGFYKALDGNMKCAKCPPHSSTQEDGSMNCRCENNYFRADKDPPSMACTRPPSSPRNVISNINETSVILDWSWPLDTGGRKDVTFNIICKKCGWNIKQCEPCSPNVRFLPRQFGLTNTTVTVTDLLAHTNYTFEIDAVNGVSELSSPPRQFAAVSITTNQAAPSPVLTIKKDRTSRNSISLSWQEPEHPNGIILDYEVKYYEKQEQETSYTILRARGTNVTISSLKPDTIYVFQIRARTAAGYGTNSRKFEFETSPDSFSISGESSQVVMIAISAAVAIILLTVVIYVLIGRFCGYKSKHGADEKRLHFGNGHLKLPGLRTYVDPHTYEDPTQAVHEFAKELDATNISIDKVVGAGEFGEVCSGRLKLPSKKEISVAIKTLKVGYTEKQRRDFLGEASIMGQFDHPNIIRLEGVVTKSKPVMIVTEYMENGSLDSFLRKHDAQFTVIQLVGMLRGIASGMKYLSDMGYVHRDLAARNILINSNLVCKVSDFGLSRVLEDDPEAAYTTRGGKIPIRWTSPEAIAYRKFTSASDVWSYGIVLWEVMSYGERPYWEMSNQDVIKAVDEGYRLPPPMDCPAALYQLMLDCWQKDRNNRPKFEQIVSILDKLIRNPGSLKIITSAAARPSNLLLDQSNVDITTFRTTGDWLNGVWTAHCKEIFTGVEYSSCDTIAKISTDDMKKVGVTVVGPQKKIISSIKALETQSKNGPVPV
T28413	DRUGINFO	D08NZG	Ifabotuzumab	Phase 2
T28413	DRUGINFO	D0FJ9W	KB-004	Phase 1/2
T28413	DRUGINFO	D02BXJ	PMID21561767C8h	Investigative
T28413	DRUGINFO	D05FXD	PMID19788238C66	Investigative
T28413	DRUGINFO	D0X8BU	PMID23489211C20	Investigative

T14755	TARGETID	T14755
T14755	FORMERID	TTDR00284
T14755	UNIPROID	CD40L_HUMAN
T14755	TARGNAME	TNF related activation protein (CD40LG)
T14755	GENENAME	CD40LG
T14755	TARGTYPE	Clinical trial
T14755	SYNONYMS	Tumor necrosis factor ligand superfamily member 5; TRAP; TNFSF5; TNF-related activation protein; T-cell antigen Gp39; T cell antigen Gp39; CD40L; CD40-L; CD40 ligand; CD154 antigen; CD154
T14755	FUNCTION	Costimulates T-cell proliferation and cytokine production. Its cross-linking on T-cells generates a costimulatory signal which enhances the production of IL4 and IL10 in conjunction with the TCR/CD3 ligation and CD28 costimulation. Induces the activation of NF-kappa-B and kinases MAPK8 and PAK2 in T-cells. Induces tyrosine phosphorylation of isoform 3 of CD28. Mediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL4. Involved in immunoglobulin class switching. Cytokine that binds to CD40/TNFRSF5.
T14755	PDBSTRUC	6BRB; 3QD6; 3LKJ; 1I9R; 1ALY
T14755	BIOCLASS	Cytokine: tumor necrosis factor
T14755	SEQUENCE	MIETYNQTSPRSAATGLPISMKIFMYLLTVFLITQMIGSALFAVYLHRRLDKIEDERNLHEDFVFMKTIQRCNTGERSLSLLNCEEIKSQFEGFVKDIMLNKEETKKENSFEMQKGDQNPQIAAHVISEASSKTTSVLQWAEKGYYTMSNNLVTLENGKQLTVKRQGLYYIYAQVTFCSNREASSQAPFIASLCLKSPGRFERILLRAANTHSSAKPCGQQSIHLGGVFELQPGASVFVNVTDPSQVSHGTGFTSFGLLKL
T14755	DRUGINFO	D03BBU	Lucatumumab	Phase 2
T14755	DRUGINFO	D05CFV	Dapirolizumab pegol	Phase 2
T14755	DRUGINFO	D05KAC	PG-102	Phase 2
T14755	DRUGINFO	D0HD8X	ISF35	Phase 2
T14755	DRUGINFO	D05RRU	IL-2/CD40L-expressing leukemia vaccine	Phase 2
T14755	DRUGINFO	D0C8NG	BI 655064	Phase 2
T14755	DRUGINFO	D02KAW	CDP-7657	Phase 1
T14755	DRUGINFO	D06HNO	MEDI4920	Phase 1
T14755	DRUGINFO	D07WTH	UltraCD40L	Phase 1
T14755	DRUGINFO	D0L6SS	BPX-101	Phase 1
T14755	DRUGINFO	D0M4BB	Chi Lob 7/4	Phase 1
T14755	DRUGINFO	D0QD4A	ABBV-428	Phase 1
T14755	DRUGINFO	D0A2NH	IDEC-131	Discontinued in Phase 1
T14755	DRUGINFO	D0PU8Z	Dacetuzumab	Terminated
T14755	DRUGINFO	D0W5ZU	Antova	Terminated
T14755	DRUGINFO	D04PFD	TriMixDC	Investigative

T99816	TARGETID	T99816
T99816	FORMERID	TTDC00230
T99816	UNIPROID	GRPR_HUMAN
T99816	TARGNAME	Gastrin-releasing peptide receptor (GRPR)
T99816	GENENAME	GRPR
T99816	TARGTYPE	Clinical trial
T99816	SYNONYMS	GRPR; GRP-preferring bombesin receptor; GRP-R; Bombesin/gastrin-releasing peptide receptor
T99816	FUNCTION	Receptor for gastrin-releasing peptide (GRP). Signals via association with G proteins that activate a phosphatidylinositol-calcium second messenger system, resulting in Akt phosphorylation. Contributes to the regulation of food intake. Contributes to the perception of prurient stimuli and transmission of itch signals in the spinal cord that promote scratching behavior, but does not play a role in the perception of pain. Contributes primarily to nonhistaminergic itch sensation. Contributes to long-term fear memory, but not normal spatial memory.
T99816	BIOCLASS	GPCR rhodopsin
T99816	SEQUENCE	MALNDCFLLNLEVDHFMHCNISSHSADLPVNDDWSHPGILYVIPAVYGVIILIGLIGNITLIKIFCTVKSMRNVPNLFISSLALGDLLLLITCAPVDASRYLADRWLFGRIGCKLIPFIQLTSVGVSVFTLTALSADRYKAIVRPMDIQASHALMKICLKAAFIWIISMLLAIPEAVFSDLHPFHEESTNQTFISCAPYPHSNELHPKIHSMASFLVFYVIPLSIISVYYYFIAKNLIQSAYNLPVEGNIHVKKQIESRKRLAKTVLVFVGLFAFCWLPNHVIYLYRSYHYSEVDTSMLHFVTSICARLLAFTNSCVNPFALYLLSKSFRKQFNTQLLCCQPGLIIRSHSTGRSTTCMTSLKSTNPSVATFSLINGNICHERYV
T99816	DRUGINFO	D03CDK	ASP-7147	Phase 2
T99816	DRUGINFO	D0AC8W	RC-3095	Phase 2
T99816	DRUGINFO	DD25UM	177Lu-labelled NeoBOMB1	Phase 2
T99816	DRUGINFO	D0ZVM5	177-Lu-NeoB	Phase 1/2
T99816	DRUGINFO	D02TMO	177Lu-AMBA	Phase 1
T99816	DRUGINFO	D0Q8DM	BIM-26226	Discontinued in Phase 1
T99816	DRUGINFO	D01VUY	[N40,Pro1,Tyr4,Nle 14]BB	Investigative
T99816	DRUGINFO	D03DSG	Ac-His-Trp-Ala-Val-D-Ala-His-Leu-Met-NH2	Investigative
T99816	DRUGINFO	D06JUN	[Tyr4]Bombesin	Investigative
T99816	DRUGINFO	D07GGP	JMV 1693	Investigative
T99816	DRUGINFO	D07OAR	(CH3)CCO-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2	Investigative
T99816	DRUGINFO	D07ZUI	Ac-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2	Investigative
T99816	DRUGINFO	D08LCD	JMV 1803	Investigative
T99816	DRUGINFO	D0D2ET	JMV 1813	Investigative
T99816	DRUGINFO	D0FY6N	[N40,Pro1,Tyr4]BB	Investigative
T99816	DRUGINFO	D0H6TE	JMV 1802	Investigative
T99816	DRUGINFO	D0HN2U	JMV 1535	Investigative
T99816	DRUGINFO	D0LC2O	Ac-His-Trp-Ala-Val-Ala-His-Leu-Met-NH2	Investigative
T99816	DRUGINFO	D0MH6P	[(N4-Bzdig)0,Nle14]BB(7-14)	Investigative
T99816	DRUGINFO	D0N1XQ	JMV 1719	Investigative
T99816	DRUGINFO	D0N9MH	JMV 1799	Investigative
T99816	DRUGINFO	D0W1BY	(D)Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH2	Investigative
T99816	DRUGINFO	D0W2EP	JMV 1801	Investigative
T99816	DRUGINFO	D59BZJ	177Lu-labelled RM2	Investigative
T99816	DRUGINFO	D01PWM	kuwanon H	Investigative
T99816	DRUGINFO	D02QOD	bombesin	Investigative
T99816	DRUGINFO	D07IAK	PD 168368	Investigative
T99816	DRUGINFO	D08RQW	MK-5046	Investigative
T99816	DRUGINFO	D09FOQ	bantag-1	Investigative
T99816	DRUGINFO	D0E1EC	ranatensin	Investigative
T99816	DRUGINFO	D0I5CS	PD 176252	Investigative
T99816	DRUGINFO	D0R8TG	[(N4-Bzdig)0]BB(7-14)	Investigative
T99816	DRUGINFO	D0S3XL	neuromedin B	Investigative

T02728	TARGETID	T02728
T02728	FORMERID	TTDC00144
T02728	UNIPROID	NTR1_HUMAN
T02728	TARGNAME	Neurotensin receptor type 1 (NTSR1)
T02728	GENENAME	NTSR1
T02728	TARGTYPE	Clinical trial
T02728	SYNONYMS	NTSR1; NTRH; NTR1; NTR subtype 1; NT-R1; NT-R-1; High-affinity levocabastine-insensitive neurotensin receptor
T02728	FUNCTION	G-protein coupled receptor for the tridecapeptide neurotensin (NTS). Signaling is effected via G proteins that activate a phosphatidylinositol-calcium second messenger system. Signaling leads to the activation of downstream MAP kinases and protects cells against apoptosis.
T02728	PDBSTRUC	2LYW
T02728	BIOCLASS	GPCR rhodopsin
T02728	SEQUENCE	MRLNSSAPGTPGTPAADPFQRAQAGLEEALLAPGFGNASGNASERVLAAPSSELDVNTDIYSKVLVTAVYLALFVVGTVGNTVTAFTLARKKSLQSLQSTVHYHLGSLALSDLLTLLLAMPVELYNFIWVHHPWAFGDAGCRGYYFLRDACTYATALNVASLSVERYLAICHPFKAKTLMSRSRTKKFISAIWLASALLAVPMLFTMGEQNRSADGQHAGGLVCTPTIHTATVKVVIQVNTFMSFIFPMVVISVLNTIIANKLTVMVRQAAEQGQVCTVGGEHSTFSMAIEPGRVQALRHGVRVLRAVVIAFVVCWLPYHVRRLMFCYISDEQWTPFLYDFYHYFYMVTNALFYVSSTINPILYNLVSANFRHIFLATLACLCPVWRRRRKRPAFSRKADSVSSNHTLSSNATRETLY
T02728	DRUGINFO	D0G0TS	Meclinertant	Phase 2/3
T02728	DRUGINFO	D03XUQ	ABS-212	Terminated
T02728	DRUGINFO	D08ZIH	CGX-1160	Terminated
T02728	DRUGINFO	D02WCJ	Neurotensin(8-13)	Investigative
T02728	DRUGINFO	D04LEF	JMV449	Investigative
T02728	DRUGINFO	D05HYV	SR48527	Investigative
T02728	DRUGINFO	D06ECM	HBN-2	Investigative
T02728	DRUGINFO	D0A3DE	[3H]meclinertant	Investigative
T02728	DRUGINFO	D0B4SQ	H-Arg-Arg-Pro-Tyr-Ile-Aac-OH	Investigative
T02728	DRUGINFO	D0H7EB	H-Arg-Arg-Pro-Tyr-N-Me-Ile-Leu-OH	Investigative
T02728	DRUGINFO	D0H8AI	NEUROTENSIN	Investigative
T02728	DRUGINFO	D0N4RF	Demotensin 3	Investigative
T02728	DRUGINFO	D0OJ7S	SR142948A	Investigative
T02728	DRUGINFO	D0OT9G	H-Arg-Arg-Pro-Tyr-Ile-N-Me-Leu-OH	Investigative
T02728	DRUGINFO	D0P5VL	Demotensin 1	Investigative
T02728	DRUGINFO	D0S9PC	H-Arg-N-Me-Arg-Pro-Tyr-Ile-Leu-OH	Investigative
T02728	DRUGINFO	D0V4HB	Demotensin 2	Investigative
T02728	DRUGINFO	D0W2KG	NT-69-L	Investigative
T02728	DRUGINFO	D0W9II	EISAI-1	Investigative
T02728	DRUGINFO	D0X3RW	Demotensin 4	Investigative
T02728	DRUGINFO	D09RSL	JMV458	Investigative
T02728	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T97008	TARGETID	T97008
T97008	UNIPROID	METK2_HUMAN
T97008	TARGNAME	S-adenosylmethionine synthase type-2 (MAT2A)
T97008	GENENAME	MAT2A
T97008	TARGTYPE	Clinical trial
T97008	SYNONYMS	Methionine adenosyltransferase II; Methionine adenosyltransferase 2; MAT-II; MAT 2; AdoMet synthase 2
T97008	FUNCTION	Catalyzes the formation of S-adenosylmethionine from methionine and ATP. The reaction comprises two steps that are both catalyzed by the same enzyme: formation of S-adenosylmethionine (AdoMet) and triphosphate, and subsequent hydrolysis of the triphosphate.
T97008	PDBSTRUC	6G6R; 6FWB; 6FCD; 6FCB; 6FBP
T97008	BIOCLASS	AdoMet synthase family
T97008	ECNUMBER	EC 2.5.1.6
T97008	SEQUENCE	MNGQLNGFHEAFIEEGTFLFTSESVGEGHPDKICDQISDAVLDAHLQQDPDAKVACETVAKTGMILLAGEITSRAAVDYQKVVREAVKHIGYDDSSKGFDYKTCNVLVALEQQSPDIAQGVHLDRNEEDIGAGDQGLMFGYATDETEECMPLTIVLAHKLNAKLAELRRNGTLPWLRPDSKTQVTVQYMQDRGAVLPIRVHTIVISVQHDEEVCLDEMRDALKEKVIKAVVPAKYLDEDTIYHLQPSGRFVIGGPQGDAGLTGRKIIVDTYGGWGAHGGGAFSGKDYTKVDRSAAYAARWVAKSLVKGGLCRRVLVQVSYAIGVSHPLSISIFHYGTSQKSERELLEIVKKNFDLRPGVIVRDLDLKKPIYQRTAAYGHFGRDSFPWEVPKKLKY
T97008	DRUGINFO	D0C2BP	AG-270	Phase 1
T97008	DRUGINFO	DN62IU	AG-270	Phase 1

T62974	TARGETID	T62974
T62974	FORMERID	TTDC00034
T62974	UNIPROID	SSR4_HUMAN
T62974	TARGNAME	Somatostatin receptor type 4 (SSTR4)
T62974	GENENAME	SSTR4
T62974	TARGTYPE	Clinical trial
T62974	SYNONYMS	SSTR4; SS4R
T62974	FUNCTION	Receptor for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibits adenylyl cyclase. It is functionally coupled not only to inhibition of adenylate cyclase, but also to activation of both arachidonate release and mitogen-activated protein (MAP) kinase cascade. Mediates antiproliferative action of somatostatin in tumor cells.
T62974	BIOCLASS	GPCR rhodopsin
T62974	SEQUENCE	MSAPSTLPPGGEEGLGTAWPSAANASSAPAEAEEAVAGPGDARAAGMVAIQCIYALVCLVGLVGNALVIFVILRYAKMKTATNIYLLNLAVADELFMLSVPFVASSAALRHWPFGSVLCRAVLSVDGLNMFTSVFCLTVLSVDRYVAVVHPLRAATYRRPSVAKLINLGVWLASLLVTLPIAIFADTRPARGGQAVACNLQWPHPAWSAVFVVYTFLLGFLLPVLAIGLCYLLIVGKMRAVALRAGWQQRRRSEKKITRLVLMVVVVFVLCWMPFYVVQLLNLFVTSLDATVNHVSLILSYANSCANPILYGFLSDNFRRFFQRVLCLRCCLLEGAGGAEEEPLDYYATALKSKGGAGCMCPPLPCQQEALQPEPGRKRIPLTRTTTF
T62974	DRUGINFO	D06JFI	ODT-8	Phase 3
T62974	DRUGINFO	DXE53Z	LY3556050	Phase 2
T62974	DRUGINFO	D0M5VV	177Lu-DOTATATE	Phase 2
T62974	DRUGINFO	D0U0CF	CNTX-0290	Phase 1
T62974	DRUGINFO	D05EKM	FR-121196	Terminated
T62974	DRUGINFO	D04QBM	L-803,087	Investigative
T62974	DRUGINFO	D05CEM	NNC269100	Investigative
T62974	DRUGINFO	D06AVM	beta3-tetrapeptide	Investigative
T62974	DRUGINFO	D07FYX	Pyz7-D-Trp8-SRIF	Investigative
T62974	DRUGINFO	D0S0AK	D-Trp8-SRIF-14	Investigative
T62974	DRUGINFO	D03DRL	Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Thr12]SRIF	Investigative
T62974	DRUGINFO	D09EIG	Pyz6-D-Trp8-SRIF	Investigative
T62974	DRUGINFO	D09LHN	Des-AA1,2,5-[IAmp9,Tyr11]-SRIF	Investigative
T62974	DRUGINFO	D0A1XX	Des-AA1,5-[Tyr2,D-Trp8,(NalphaMe)IAmp9]Cbm-SRIF	Investigative
T62974	DRUGINFO	D0GN3M	Ala11-SRIF-14-amide	Investigative
T62974	DRUGINFO	D0H0DC	Des-AA1,2,4,5,10,12,13-[D-Trp8]SRIF	Investigative
T62974	DRUGINFO	D0K9TS	Pyz11-D-Trp8-SRIF	Investigative
T62974	DRUGINFO	D0R0OX	Des-AA1,5-[Tyr2,D-Trp8,(NalphaMe)IAmp9]SRIF	Investigative
T62974	DRUGINFO	D0WG0O	Des-AA1,2,4,5,6,12,13-[D-Trp8]SRIF	Investigative
T62974	DRUGINFO	D0Y1PT	Ala6-SRIF-14-amide	Investigative
T62974	DRUGINFO	D02NJV	Des-AA1,2,5,12,13-[D-Trp8,IAmp9]SRIF	Investigative
T62974	DRUGINFO	D0W0AF	Des-AA1,2,5-[D-Trp8,(NalphaMe)IAmp9]SRIF	Investigative
T62974	DRUGINFO	D02OJQ	Des-AA1,2,5-[D-Trp8,Tyr11]SRIF	Investigative
T62974	DRUGINFO	D04ORV	Des-AA1,2,5,12,13-[D-Trp8]SRIF	Investigative
T62974	DRUGINFO	D06WCI	SRIF-28	Investigative
T62974	DRUGINFO	D06WYG	99mTc-MIP-1407	Investigative
T62974	DRUGINFO	D09DAC	Des-AA1,2,4,12,13-[D-Trp8]SRIF	Investigative
T62974	DRUGINFO	D0B5AZ	Cytotoxin Peptide Conjugate	Investigative
T62974	DRUGINFO	D0C5RH	Des-AA1,2,4,13-[D-Trp8]SRIF	Investigative
T62974	DRUGINFO	D0H4WH	Des-AA5-[D-Trp8]SRIF	Investigative
T62974	DRUGINFO	D0J5OY	Des-AA1,2,4,5-[D-Trp8]SRIF	Investigative
T62974	DRUGINFO	D0P3WF	CGP 23996	Investigative
T62974	DRUGINFO	D0R7OD	SRIF-14	Investigative
T62974	DRUGINFO	D0Z3LZ	Des-AA1,2,4,5,13-[D-Trp8]-SRIF	Investigative
T62974	DRUGINFO	D0T5RO	SOMATOSTATIN	Investigative

T79027	TARGETID	T79027
T79027	FORMERID	TTDI02040
T79027	UNIPROID	CDD_HUMAN
T79027	TARGNAME	Cytidine deaminase (CDA)
T79027	GENENAME	CDA
T79027	TARGTYPE	Clinical trial
T79027	SYNONYMS	Cytidine aminohydrolase; CDA
T79027	FUNCTION	This enzyme scavenges exogenous and endogenous cytidine and 2'-deoxycytidine for UMP synthesis.
T79027	PDBSTRUC	1MQ0
T79027	BIOCLASS	Carbon-nitrogen hydrolase
T79027	ECNUMBER	EC 3.5.4.5
T79027	SEQUENCE	MAQKRPACTLKPECVQQLLVCSQEAKKSAYCPYSHFPVGAALLTQEGRIFKGCNIENACYPLGICAERTAIQKAVSEGYKDFRAIAIASDMQDDFISPCGACRQVMREFGTNWPVYMTKPDGTYIVMTVQELLPSSFGPEDLQKTQ
T79027	DRUGINFO	D0I5OR	Tetrahydrouridine	Phase 2

T74977	TARGETID	T74977
T74977	FORMERID	TTDR01110
T74977	UNIPROID	TTK_HUMAN
T74977	TARGNAME	Dual specificity protein kinase TTK (MPS1)
T74977	GENENAME	TTK
T74977	TARGTYPE	Clinical trial
T74977	SYNONYMS	Tyrosine threonine kinase; Phosphotyrosine picked threonine-protein kinase; PYT; MPS1L1
T74977	FUNCTION	Probably associated with cell proliferation. Essential for chromosome alignment by enhancing AURKB activity (via direct CDCA8 phosphorylation) at the centromere, and for the mitotic checkpoint. Phosphorylates proteins on serine, threonine, and tyrosine.
T74977	PDBSTRUC	6N6O; 6H3K; 6GVJ; 6B4W; 5O91
T74977	BIOCLASS	Kinase
T74977	ECNUMBER	EC 2.7.12.1
T74977	SEQUENCE	MESEDLSGRELTIDSIMNKVRDIKNKFKNEDLTDELSLNKISADTTDNSGTVNQIMMMANNPEDWLSLLLKLEKNSVPLSDALLNKLIGRYSQAIEALPPDKYGQNESFARIQVRFAELKAIQEPDDARDYFQMARANCKKFAFVHISFAQFELSQGNVKKSKQLLQKAVERGAVPLEMLEIALRNLNLQKKQLLSEEEKKNLSASTVLTAQESFSGSLGHLQNRNNSCDSRGQTTKARFLYGENMPPQDAEIGYRNSLRQTNKTKQSCPFGRVPVNLLNSPDCDVKTDDSVVPCFMKRQTSRSECRDLVVPGSKPSGNDSCELRNLKSVQNSHFKEPLVSDEKSSELIITDSITLKNKTESSLLAKLEETKEYQEPEVPESNQKQWQSKRKSECINQNPAASSNHWQIPELARKVNTEQKHTTFEQPVFSVSKQSPPISTSKWFDPKSICKTPSSNTLDDYMSCFRTPVVKNDFPPACQLSTPYGQPACFQQQQHQILATPLQNLQVLASSSANECISVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMECGNIDLNSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHPVNQMAKGTTEEMKYVLGQLVGLNSPNSILKAAKTLYEHYSGGESHNSSSSKTFEKKRGKK
T74977	DRUGINFO	D0HY9S	BOS172722	Phase 1
T74977	DRUGINFO	D0J6RV	BAY1161909	Phase 1
T74977	DRUGINFO	D81YNE	CFI-402257	Phase 1
T74977	DRUGINFO	D06GGI	Tricyclic isoxazoloquinazoline derivative 2	Patented
T74977	DRUGINFO	D0JC8E	Tricyclic isoxazoloquinazoline derivative 4	Patented
T74977	DRUGINFO	D0WK2S	Tricyclic isoxazoloquinazoline derivative 3	Patented
T74977	DRUGINFO	D0J5FK	GNE-7915	Investigative
T74977	DRUGINFO	D02PVB	2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One	Investigative

T79062	TARGETID	T79062
T79062	FORMERID	TTDR00157
T79062	UNIPROID	5HT7R_HUMAN
T79062	TARGNAME	5-HT 7 receptor (HTR7)
T79062	GENENAME	HTR7
T79062	TARGTYPE	Clinical trial
T79062	SYNONYMS	Serotonin receptor 7; 5HT7; 5-hydroxytryptamine receptor 7; 5-HT7 receptor; 5-HT7; 5-HT-X; 5-HT-7
T79062	FUNCTION	The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen.
T79062	BIOCLASS	GPCR rhodopsin
T79062	SEQUENCE	MMDVNSSGRPDLYGHLRSFLLPEVGRGLPDLSPDGGADPVAGSWAPHLLSEVTASPAPTWDAPPDNASGCGEQINYGRVEKVVIGSILTLITLLTIAGNCLVVISVCFVKKLRQPSNYLIVSLALADLSVAVAVMPFVSVTDLIGGKWIFGHFFCNVFIAMDVMCCTASIMTLCVISIDRYLGITRPLTYPVRQNGKCMAKMILSVWLLSASITLPPLFGWAQNVNDDKVCLISQDFGYTIYSTAVAFYIPMSVMLFMYYQIYKAARKSAAKHKFPGFPRVEPDSVIALNGIVKLQKEVEECANLSRLLKHERKNISIFKREQKAATTLGIIVGAFTVCWLPFFLLSTARPFICGTSCSCIPLWVERTFLWLGYANSLINPFIYAFFNRDLRTTYRSLLQCQYRNINRKLSAAGMHEALKLAERPERPEFVLRACTRRVLLRPEKRPPVSVWVLQSPDHHNWLADKMLTTVEKKVMIHD
T79062	DRUGINFO	D0T8KA	JNJ-18038683	Phase 2
T79062	DRUGINFO	DM04QU	AVN-101	Phase 2
T79062	DRUGINFO	D05XEA	RP5063	Phase 2
T79062	DRUGINFO	D06NOF	ATI-9242	Phase 1
T79062	DRUGINFO	D0E6KF	Carbamide derivative 2	Patented
T79062	DRUGINFO	D0F0XC	4-oxadiazole derivative 1	Patented
T79062	DRUGINFO	D09BCJ	PMID30124346-Compound-34TABLE4	Patented
T79062	DRUGINFO	D0F4NB	PMID30124346-Compound-13TABLE4	Patented
T79062	DRUGINFO	D0YP7L	SB-269970	Terminated
T79062	DRUGINFO	D00PEU	pirenperone	Investigative
T79062	DRUGINFO	D01KVG	DR-4004	Investigative
T79062	DRUGINFO	D02HZG	2-(2-Bromophenoxy)-N,N-dimethylethanamine	Investigative
T79062	DRUGINFO	D03NBX	P-hydroxyphenethyl trans-ferulate	Investigative
T79062	DRUGINFO	D03TSY	E55888	Investigative
T79062	DRUGINFO	D04GBL	2-(1-o-tolyl-1H-pyrrol-3-yl)ethanamine	Investigative
T79062	DRUGINFO	D07JRV	2-(Biphenyl-2-ylthio)-N,N-dimethylethanamine	Investigative
T79062	DRUGINFO	D07JTZ	UCM-5600	Investigative
T79062	DRUGINFO	D08CKM	SB-258741	Investigative
T79062	DRUGINFO	D09ROW	IMPERATORIN	Investigative
T79062	DRUGINFO	D0B4LD	(2-biphenyl-3-yl-ethyl)-dimethyl-amine	Investigative
T79062	DRUGINFO	D0B9TN	2-(2-Bromophenylthio)-N,N-dimethylethanamine	Investigative
T79062	DRUGINFO	D0BG5H	SB 269970-A	Investigative
T79062	DRUGINFO	D0HE4S	Disulergine	Investigative
T79062	DRUGINFO	D0K0HU	N,N-dimethyl-2-(2'-methylbiphenyl-3-yl)ethanamine	Investigative
T79062	DRUGINFO	D0LT5D	(R)-8-phenyl-N,N-dipropylchroman-3-amine	Investigative
T79062	DRUGINFO	D0U8RZ	2-[1-(2-Chloro-phenyl)-1H-pyrrol-2-yl]-ethylamine	Investigative
T79062	DRUGINFO	D0X7SD	2-(Biphenyl-2-yloxy)-N,N-dimethylethanamine	Investigative
T79062	DRUGINFO	D0X9YS	AS-19	Investigative
T79062	DRUGINFO	D00VRV	2-bromo-LSD	Investigative
T79062	DRUGINFO	D03AHJ	Elaidoylamide	Investigative
T79062	DRUGINFO	D09ULA	OPC 4392	Investigative
T79062	DRUGINFO	D09WIL	SB-656104	Investigative
T79062	DRUGINFO	D0F8TG	fluperlapine	Investigative
T79062	DRUGINFO	D0H9QG	SB-258719	Investigative
T79062	DRUGINFO	D0I0ML	2-(2'-methyl-biphenyl-3-yl)-ethylamine	Investigative
T79062	DRUGINFO	D0J0KG	DM-1451	Investigative
T79062	DRUGINFO	D0M7AU	N-methyl-Pip-F-homoF-vinyl sulfonyl phenyl (N-methyl-Pip-F-hF-VS phi)	Investigative
T79062	DRUGINFO	D0UI3L	dihydroergocryptine	Investigative
T79062	DRUGINFO	D00GSD	LP-211	Investigative
T79062	DRUGINFO	D0X6MT	METHIOTHEPIN	Investigative
T79062	DRUGINFO	D03ZHB	5-chloro-4-ethyl-3,4-dihydroquinazolin-2-amine	Investigative
T79062	DRUGINFO	D07HQZ	[3H]LSD	Investigative
T79062	DRUGINFO	D0BW9V	[125I]LSD	Investigative
T79062	DRUGINFO	D0D3PZ	dipropyl-5-CT	Investigative
T79062	DRUGINFO	D0G7NW	cyamemazine	Investigative
T79062	DRUGINFO	D0K5NZ	MESULERGINE	Investigative
T79062	DRUGINFO	D0N8BJ	[3H]5-HT	Investigative
T79062	DRUGINFO	D0X4PH	LP-44	Investigative
T79062	DRUGINFO	D0Z1OF	LP-12	Investigative
T79062	DRUGINFO	D04TPO	5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine	Investigative
T79062	DRUGINFO	D08PJK	[3H]5-CT	Investigative
T79062	DRUGINFO	D08UOX	FALCARINDIOL	Investigative
T79062	DRUGINFO	D0OG0R	WAY-208466	Investigative
T79062	DRUGINFO	D0P1XQ	SEL-73	Investigative
T79062	DRUGINFO	D0SP2J	bufotenine	Investigative
T79062	DRUGINFO	D0XX2U	8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine	Investigative
T79062	DRUGINFO	D0CK9K	EDMT	Investigative
T79062	DRUGINFO	D06VPR	WAY-466	Investigative
T79062	DRUGINFO	D0C5GF	MPDT	Investigative
T79062	DRUGINFO	D0J6JT	m-chlorophenylpiperazine	Investigative
T79062	DRUGINFO	D0LG8A	1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine	Investigative
T79062	DRUGINFO	D0V4RP	1-(2-Methoxy-phenyl)-piperazine	Investigative
T79062	DRUGINFO	D0Y9TL	5-chloro-3,4-dihydroquinazolin-2-amine	Investigative
T79062	DRUGINFO	D05EQG	[3H]spiperone	Investigative
T79062	DRUGINFO	D08VGJ	5,6-dichloro-3,4-dihydroquinazolin-2-amine	Investigative
T79062	DRUGINFO	D03TDN	1-naphthylpiperazine	Investigative
T79062	DRUGINFO	D07LRJ	SB-271046	Investigative
T79062	DRUGINFO	D02UWB	5-CT	Investigative
T79062	DRUGINFO	D0V5HV	TFMPP	Investigative
T79062	DRUGINFO	D0F6CD	SEROTONIN	Investigative
T79062	DRUGINFO	D0L5MW	(+/-)-nantenine	Investigative
T79062	DRUGINFO	D0T2RY	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	Investigative

T35040	TARGETID	T35040
T35040	FORMERID	TTDNR00648
T35040	UNIPROID	BASI_HUMAN
T35040	TARGNAME	Basigin (BSG)
T35040	GENENAME	BSG
T35040	TARGTYPE	Clinical trial
T35040	SYNONYMS	UNQ6505/PRO21383; Tumor cell-derived collagenase stimulatory factor; TCSF; OK blood group antigen; Leukocyte activation antigen M6; Extracellular matrix metalloproteinase inducer; EMMPRIN; 5F7
T35040	FUNCTION	Plays pivotal roles in spermatogenesis, embryo implantation, neural network formation and tumor progression. Stimulates adjacent fibroblasts to produce matrix metalloproteinases (MMPS). Seems to be a receptor for oligomannosidic glycans. In vitro, promotes outgrowth of astrocytic processes. Plays an important role in targeting the monocarboxylate transporters SLC16A1, SLC16A3, SLC16A8, SLC16A11 and SLC16A12 to the plasma membrane.
T35040	PDBSTRUC	5XF0; 5X0T; 4U0Q; 3QR2; 3QQN
T35040	BIOCLASS	Basigin protein
T35040	SEQUENCE	MAAALFVLLGFALLGTHGASGAAGFVQAPLSQQRWVGGSVELHCEAVGSPVPEIQWWFEGQGPNDTCSQLWDGARLDRVHIHATYHQHAASTISIDTLVEEDTGTYECRASNDPDRNHLTRAPRVKWVRAQAVVLVLEPGTVFTTVEDLGSKILLTCSLNDSATEVTGHRWLKGGVVLKEDALPGQKTEFKVDSDDQWGEYSCVFLPEPMGTANIQLHGPPRVKAVKSSEHINEGETAMLVCKSESVPPVTDWAWYKITDSEDKALMNGSESRFFVSSSQGRSELHIENLNMEADPGQYRCNGTSSKGSDQAIITLRVRSHLAALWPFLGIVAEVLVLVTIIFIYEKRRKPEDVLDDDDAGSAPLKSSGQHQNDKGKNVRQRNSS
T35040	DRUGINFO	D03RDQ	Gavilimomab	Phase 2/3
T35040	DRUGINFO	D0E5BW	[131I]-Metuximab	Phase 2

T55260	TARGETID	T55260
T55260	UNIPROID	PPM1A_HUMAN
T55260	TARGNAME	Protein phosphatase 1A (PPM1A)
T55260	GENENAME	PPM1A
T55260	TARGTYPE	Clinical trial
T55260	SYNONYMS	Protein phosphatase IA; Protein phosphatase 2C isoform alpha; PP2C-alpha
T55260	FUNCTION	Enzyme with a broad specificity. Negatively regulates TGF-beta signaling through dephosphorylating SMAD2 and SMAD3, resulting in their dissociation from SMAD4, nuclear export of the SMADs and termination of the TGF-beta-mediated signaling. Dephosphorylates PRKAA1 and PRKAA2. Plays an important role in the termination of TNF-alpha-mediated NF-kappa-B activation through dephosphorylating and inactivating IKBKB/IKKB.
T55260	PDBSTRUC	6B67; 4RAG; 4RAF; 4RA2; 3FXO
T55260	BIOCLASS	PP2C family
T55260	ECNUMBER	EC 3.1.3.16
T55260	SEQUENCE	MGAFLDKPKMEKHNAQGQGNGLRYGLSSMQGWRVEMEDAHTAVIGLPSGLESWSFFAVYDGHAGSQVAKYCCEHLLDHITNNQDFKGSAGAPSVENVKNGIRTGFLEIDEHMRVMSEKKHGADRSGSTAVGVLISPQHTYFINCGDSRGLLCRNRKVHFFTQDHKPSNPLEKERIQNAGGSVMIQRVNGSLAVSRALGDFDYKCVHGKGPTEQLVSPEPEVHDIERSEEDDQFIILACDGIWDVMGNEELCDFVRSRLEVTDDLEKVCNEVVDTCLYKGSRDNMSVILICFPNAPKVSPEAVKKEAELDKYLECRVEEIIKKQGEGVPDLVHVMRTLASENIPSLPPGGELASKRNVIEAVYNRLNPYKNDDTDSTSTDDMW
T55260	DRUGINFO	D01HZQ	VP-102	Phase 3

T50699	TARGETID	T50699
T50699	FORMERID	TTDI02198
T50699	UNIPROID	TNR3_HUMAN
T50699	TARGNAME	Lymphotoxin beta receptor (LTBR)
T50699	GENENAME	LTBR
T50699	TARGTYPE	Clinical trial
T50699	SYNONYMS	Tumor necrosis factor receptor type III; Tumor necrosis factor receptor superfamily member 3; Tumor necrosis factor receptor 2-related protein; Tumor necrosis factor C receptor; TNFRSF3; TNFR3; TNFR-III; TNFCR; TNF-RIII; Lymphotoxin-beta receptor; D12S370
T50699	FUNCTION	Promotes apoptosis via TRAF3 and TRAF5. May play a role in the development of lymphoid organs. Receptor for the heterotrimeric lymphotoxin containing LTA and LTB, and for TNFS14/LIGHT.
T50699	PDBSTRUC	4MXW; 1RF3
T50699	BIOCLASS	Cytokine receptor
T50699	SEQUENCE	MLLPWATSAPGLAWGPLVLGLFGLLAASQPQAVPPYASENQTCRDQEKEYYEPQHRICCSRCPPGTYVSAKCSRIRDTVCATCAENSYNEHWNYLTICQLCRPCDPVMGLEEIAPCTSKRKTQCRCQPGMFCAAWALECTHCELLSDCPPGTEAELKDEVGKGNNHCVPCKAGHFQNTSSPSARCQPHTRCENQGLVEAAPGTAQSDTTCKNPLEPLPPEMSGTMLMLAVLLPLAFFLLLATVFSCIWKSHPSLCRKLGSLLKRRPQGEGPNPVAGSWEPPKAHPYFPDLVQPLLPISGDVSPVSTGLPAAPVLEAGVPQQQSPLDLTREPQLEPGEQSQVAHGTNGIHVTGGSMTITGNIYIYNGPVLGGPPGPGDLPATPEPPYPIPEEGDPGPPGLSTPHQEDGKAWHLAETEHCGATPSNRGPRNQFITHD
T50699	DRUGINFO	D08XVR	Baminercept	Phase 2
T50699	DRUGINFO	D09XRQ	HCBE-11	Phase 1

T36959	TARGETID	T36959
T36959	FORMERID	TTDC00338
T36959	UNIPROID	ACVL1_HUMAN
T36959	TARGNAME	Activin receptor-like kinase-1 (ACVRL1)
T36959	GENENAME	ACVRL1
T36959	TARGTYPE	Clinical trial
T36959	SYNONYMS	Serine/threonine-protein kinase receptor R3; SKR3; Activin receptor-like kinase 1; ALK-1; ACVRLK1; ACVRL1
T36959	FUNCTION	Type I receptor for TGF-beta family ligands BMP9/GDF2 and BMP10 and important regulator of normal blood vessel development. On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. May bindactivin as well.
T36959	PDBSTRUC	4FAO; 3MY0; 2LCR
T36959	BIOCLASS	Kinase
T36959	ECNUMBER	EC 2.7.11.30
T36959	SEQUENCE	MTLGSPRKGLLMLLMALVTQGDPVKPSRGPLVTCTCESPHCKGPTCRGAWCTVVLVREEGRHPQEHRGCGNLHRELCRGRPTEFVNHYCCDSHLCNHNVSLVLEATQPPSEQPGTDGQLALILGPVLALLALVALGVLGLWHVRRRQEKQRGLHSELGESSLILKASEQGDSMLGDLLDSDCTTGSGSGLPFLVQRTVARQVALVECVGKGRYGEVWRGLWHGESVAVKIFSSRDEQSWFRETEIYNTVLLRHDNILGFIASDMTSRNSSTQLWLITHYHEHGSLYDFLQRQTLEPHLALRLAVSAACGLAHLHVEIFGTQGKPAIAHRDFKSRNVLVKSNLQCCIADLGLAVMHSQGSDYLDIGNNPRVGTKRYMAPEVLDEQIRTDCFESYKWTDIWAFGLVLWEIARRTIVNGIVEDYRPPFYDVVPNDPSFEDMKKVVCVDQQTPTIPNRLAADPVLSGLAQMMRECWYPNPSARLTALRIKKTLQKISNSPEKPKVIQ
T36959	DRUGINFO	D08JBL	PF-03446962	Phase 2
T36959	DRUGINFO	D0RF7O	ML347	Investigative
T36959	DRUGINFO	D06CMG	LDN-214117	Investigative
T36959	DRUGINFO	D05NEC	PMID23639540C13r	Investigative
T36959	DRUGINFO	D0F2MP	PMID23639540C13d	Investigative
T36959	DRUGINFO	D0PP6Y	PMID23639540C13a	Investigative

T49989	TARGETID	T49989
T49989	FORMERID	TTDI02190
T49989	UNIPROID	TGFR2_HUMAN
T49989	TARGNAME	TGF-beta receptor type II (TGFBR2)
T49989	GENENAME	TGFBR2
T49989	TARGTYPE	Clinical trial
T49989	SYNONYMS	Transforminggrowth factor-beta receptor type II; Transforming growth factor-beta receptor type II; TbetaR-II; TGFR-2; TGF-beta type II receptor; TGF-beta receptor type-2
T49989	FUNCTION	Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFRB1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3.
T49989	PDBSTRUC	5TY4; 5TX4; 5QIN; 5E8Y; 5E8V
T49989	BIOCLASS	Kinase
T49989	ECNUMBER	EC 2.7.11.30
T49989	SEQUENCE	MGRGLLRGLWPLHIVLWTRIASTIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLLVIFQVTGISLLPPLGVAISVIIIFYCYRVNRQQKLSSTWETGKTRKLMEFSEHCAIILEDDRSDISSTCANNINHNTELLPIELDTLVGKGRFAEVYKAKLKQNTSEQFETVAVKIFPYEEYASWKTEKDIFSDINLKHENILQFLTAEERKTELGKQYWLITAFHAKGNLQEYLTRHVISWEDLRKLGSSLARGIAHLHSDHTPCGRPKMPIVHRDLKSSNILVKNDLTCCLCDFGLSLRLDPTLSVDDLANSGQVGTARYMAPEVLESRMNLENVESFKQTDVYSMALVLWEMTSRCNAVGEVKDYEPPFGSKVREHPCVESMKDNVLRDRGRPEIPSFWLNHQGIQMVCETLTECWDHDPEARLTAQCVAERFSELEHLDRLSGRSCSEEKIPEDGSLNTTK
T49989	DRUGINFO	D0P7KU	TGF-BR2 mab	Phase 1
T49989	DRUGINFO	D06KKN	LY2109761	Investigative
T49989	DRUGINFO	D06BDC	PMID16539403C15b	Investigative
T49989	DRUGINFO	D0F2MP	PMID23639540C13d	Investigative
T49989	DRUGINFO	D0PP6Y	PMID23639540C13a	Investigative

T03644	TARGETID	T03644
T03644	FORMERID	TTDI02186
T03644	UNIPROID	SYUA_HUMAN
T03644	TARGNAME	Synuclein alpha (SNCA)
T03644	GENENAME	SNCA
T03644	TARGTYPE	Clinical trial
T03644	SYNONYMS	PARK1; Non-A4 component of amyloid precursor; Non-A beta component of AD amyloid; NACP; Alpha-synuclein
T03644	FUNCTION	Neuronal protein that plays several roles in synaptic activity such as regulation of synaptic vesicle trafficking and subsequent neurotransmitter release. Participates as a monomer in synaptic vesicle exocytosis by enhancing vesicle priming, fusion and dilation of exocytotic fusion pores. Mechanistically, acts by increasing local Ca(2+) release from microdomains which is essential for the enhancement of ATP-induced exocytosis. Acts also as a molecular chaperone in its multimeric membrane-bound state, assisting in the folding of synaptic fusion components called SNAREs (Soluble NSF Attachment Protein REceptors) at presynaptic plasma membrane in conjunction with cysteine string protein-alpha/DNAJC5. This chaperone activity is important to sustain normal SNARE-complex assembly during aging. Plays also a role in the regulation of the dopamine neurotransmission by associating with the dopamine transporter (DAT1) and thereby modulating its activity.
T03644	PDBSTRUC	6H6B; 6FLT; 6CU8; 6CU7; 6CT7
T03644	BIOCLASS	Synuclein
T03644	SEQUENCE	MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVHGVATVAEKTKEQVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA
T03644	DRUGINFO	D05AEE	RG7935	Phase 2
T03644	DRUGINFO	D0TU9W	BIIB054	Phase 2
T03644	DRUGINFO	D4N2JV	PRX002	Phase 2
T03644	DRUGINFO	DA85YQ	TAK-341	Phase 2
T03644	DRUGINFO	D01UYA	MEDI1341	Phase 1
T03644	DRUGINFO	D05VAE	Posiphen R-phenserine	Phase 1
T03644	DRUGINFO	D7G1JR	UCB7853	Phase 1
T03644	DRUGINFO	DIW37N	NPT200-11	Phase 1
T03644	DRUGINFO	DS8V3L	Anle138b	Phase 1
T03644	DRUGINFO	D10KTZ	SAR446159	Phase 1

T06182	TARGETID	T06182
T06182	FORMERID	TTDI02208
T06182	UNIPROID	VIPR2_HUMAN
T06182	TARGNAME	Helodermin-preferring VIP receptor (VIPR2)
T06182	GENENAME	VIPR2
T06182	TARGTYPE	Clinical trial
T06182	SYNONYMS	Vasoactive intestinal polypeptide receptor 2; VPAC2; VIPR2; VIP-R-2; Pituitary adenylate cyclase-activating polypeptide typeIII receptor; PACAP-R3; PACAP-R-3; PACAP type III receptor
T06182	FUNCTION	This is a receptor for VIP as well as PACAP-38 and -27,the activity of this receptor is mediated by G proteins which activate adenylyl cyclase. Can be coupled to phospholipase C.
T06182	PDBSTRUC	2X57
T06182	BIOCLASS	GPCR secretin
T06182	SEQUENCE	MRTLLPPALLTCWLLAPVNSIHPECRFHLEIQEEETKCAELLRSQTEKHKACSGVWDNITCWRPANVGETVTVPCPKVFSNFYSKAGNISKNCTSDGWSETFPDFVDACGYSDPEDESKITFYILVKAIYTLGYSVSLMSLATGSIILCLFRKLHCTRNYIHLNLFLSFILRAISVLVKDDVLYSSSGTLHCPDQPSSWVGCKLSLVFLQYCIMANFFWLLVEGLYLHTLLVAMLPPRRCFLAYLLIGWGLPTVCIGAWTAARLYLEDTGCWDTNDHSVPWWVIRIPILISIIVNFVLFISIIRILLQKLTSPDVGGNDQSQYKRLAKSTLLLIPLFGVHYMVFAVFPISISSKYQILFELCLGSFQGLVVAVLYCFLNSEVQCELKRKWRSRCPTPSASRDYRVCGSSFSRNGSEGALQFHRGSRAQSFLQTETSVI
T06182	DRUGINFO	D0G9JQ	PB1046	Phase 2
T06182	DRUGINFO	D0S7UQ	RG-7103	Phase 1
T06182	DRUGINFO	D03BFX	PB-1120	Investigative
T06182	DRUGINFO	D0B2MN	helodermin	Investigative
T06182	DRUGINFO	D0MC5J	PACAP-27	Investigative

T42854	TARGETID	T42854
T42854	FORMERID	TTDI02338
T42854	UNIPROID	MAGA1_HUMAN
T42854	TARGNAME	Melanoma-associated antigen 1 (MAGEA1)
T42854	GENENAME	MAGEA1
T42854	TARGTYPE	Clinical trial
T42854	SYNONYMS	Melanomaassociated antigen 1; MAGE1A; MAGE1 antigen; MAGE1; MAGE-1 antigen; Cancer/testis antigen 1.1; CT1.1; Antigen MZ2E; Antigen MZ2-E
T42854	FUNCTION	May inhibit notch intracellular domain (NICD) transactivation. May play a role in embryonal development and tumor transformation or aspects of tumor progression. Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes. May be involved in transcriptional regulation through interaction with SNW1 and recruiting histone deactelyase HDAC1.
T42854	PDBSTRUC	3BO8; 1W72
T42854	BIOCLASS	Melanoma associated antigen
T42854	SEQUENCE	MSLEQRSLHCKPEEALEAQQEALGLVCVQAATSSSSPLVLGTLEEVPTAGSTDPPQSPQGASAFPTTINFTRQRQPSEGSSSREEEGPSTSCILESLFRAVITKKVADLVGFLLLKYRAREPVTKAEMLESVIKNYKHCFPEIFGKASESLQLVFGIDVKEADPTGHSYVLVTCLGLSYDGLLGDNQIMPKTGFLIIVLVMIAMEGGHAPEEEIWEELSVMEVYDGREHSAYGEPRKLLTQDLVQEKYLEYRQVPDSDPARYEFLWGPRALAETSYVKVLEYVIKVSARVRFFFPSLREAALREEEEGV
T42854	DRUGINFO	D0NA4J	CAR-T cells targeting MAGE-A1	Phase 1/2
T42854	DRUGINFO	D0C1EO	Melanoma vaccine (ALVAC)	Discontinued in Phase 2

T92124	TARGETID	T92124
T92124	FORMERID	TTDC00219
T92124	UNIPROID	TNR4_HUMAN
T92124	TARGNAME	OX40L receptor (CD134)
T92124	GENENAME	TNFRSF4
T92124	TARGTYPE	Clinical trial
T92124	SYNONYMS	Tumor necrosis factor receptor superfamily member 4; TXGP1L; TAX transcriptionally-activated glycoprotein 1 receptor; CD134; ACT35 antigen
T92124	FUNCTION	Receptor for TNFSF4/OX40L/GP34. Is a costimulatory molecule implicated in long-term T-cell immunity.
T92124	PDBSTRUC	2HEY; 2HEV; 1D0A
T92124	SEQUENCE	MCVGARRLGRGPCAALLLLGLGLSTVTGLHCVGDTYPSNDRCCHECRPGNGMVSRCSRSQNTVCRPCGPGFYNDVVSSKPCKPCTWCNLRSGSERKQLCTATQDTVCRCRAGTQPLDSYKPGVDCAPCPPGHFSPGDNQACKPWTNCTLAGKHTLQPASNSSDAICEDRDPPATQPQETQGPPARPITVQPTEAWPRTSQGPSTRPVEVPGGRAVAAILGLGLVLGLLGPLAILLALYLLRRDQRLPPDAHKPPGGGSFRTPIQEEQADAHSTLAKI
T92124	DRUGINFO	D03AKW	Rocatinlimab	Phase 3
T92124	DRUGINFO	D03DUI	GBR 830	Phase 2
T92124	DRUGINFO	D0E5WX	PF-04518600	Phase 2
T92124	DRUGINFO	DVCN93	INCAGN01949	Phase 2
T92124	DRUGINFO	D03SXI	INCAGN1949	Phase 1/2
T92124	DRUGINFO	D0YG4P	Anti-OX40 mab	Phase 1
T92124	DRUGINFO	D0ZO5K	MEDI0562	Phase 1
T92124	DRUGINFO	DBZ87Q	BGB-A445	Phase 1
T92124	DRUGINFO	DF6BU4	YH002	Phase 1
T92124	DRUGINFO	D0U0EC	TRemelimumab + MEDI0562	Phase 1
T92124	DRUGINFO	D9SL1N	TAK-252	Phase 1
T92124	DRUGINFO	DZ7EG5	YH006	Investigative

T71928	TARGETID	T71928
T71928	FORMERID	TTDI02105
T71928	UNIPROID	KI2L1_HUMAN
T71928	TARGNAME	MHC class I NK cell receptor 2DL1 (CD158A)
T71928	GENENAME	KIR2DL1
T71928	TARGTYPE	Clinical trial
T71928	SYNONYMS	p58.1 MHC class-I-specific NK receptor; p58 natural killer cell receptor clones CL-42/47.11; p58 NK receptor CL-42/47.11; Natural killer-associated transcript 1; NKAT1; NKAT-1; Killer cell immunoglobulin-like receptor 2DL1; CD158A; CD158 antigen-like family member A
T71928	FUNCTION	Receptor on natural killer (NK) cells for some HLA-C alleles such as w4 and w6. Inhibits the activity of NK cells thus preventing cell lysis.
T71928	PDBSTRUC	1NKR; 1IM9
T71928	BIOCLASS	Immunoglobulin
T71928	SEQUENCE	MSLLVVSMACVGFFLLQGAWPHEGVHRKPSLLAHPGPLVKSEETVILQCWSDVMFEHFLLHREGMFNDTLRLIGEHHDGVSKANFSISRMTQDLAGTYRCYGSVTHSPYQVSAPSDPLDIVIIGLYEKPSLSAQPGPTVLAGENVTLSCSSRSSYDMYHLSREGEAHERRLPAGPKVNGTFQADFPLGPATHGGTYRCFGSFHDSPYEWSKSSDPLLVSVTGNPSNSWPSPTEPSSKTGNPRHLHILIGTSVVIILFILLFFLLHRWCSNKKNAAVMDQESAGNRTANSEDSDEQDPQEVTYTQLNHCVFTQRKITRPSQRPKTPPTDIIVYTELPNAESRSKVVSCP
T71928	DRUGINFO	D00RYU	IPH-2102	Phase 2
T71928	DRUGINFO	D08XPN	mab 1-7F9	Phase 2
T71928	DRUGINFO	D04IXD	IPH-2101	Phase 2

T54902	TARGETID	T54902
T54902	FORMERID	TTDI02106
T54902	UNIPROID	KI2L2_HUMAN
T54902	TARGNAME	MHC class I NK cell receptor 2DL2 (CD158b1)
T54902	GENENAME	KIR2DL2
T54902	TARGTYPE	Clinical trial
T54902	SYNONYMS	p58 natural killer cell receptor clone CL-43; p58 NK receptor CL-43; Natural killer-associated transcript 6; NKAT6; NKAT-6; Killer cell immunoglobulin-like receptor 2DL2; CD158B1; CD158 antigen-like family member B1
T54902	FUNCTION	Receptor on natural killer (NK) cells for HLA-Cw1, 3, 7, and 8 allotypes. Inhibits the activity of NK cells thus preventing cell lysis.
T54902	PDBSTRUC	2DLI; 2DL2; 1EFX
T54902	BIOCLASS	Immunoglobulin
T54902	SEQUENCE	MSLMVVSMACVGFFLLQGAWPHEGVHRKPSLLAHPGRLVKSEETVILQCWSDVRFEHFLLHREGKFKDTLHLIGEHHDGVSKANFSIGPMMQDLAGTYRCYGSVTHSPYQLSAPSDPLDIVITGLYEKPSLSAQPGPTVLAGESVTLSCSSRSSYDMYHLSREGEAHECRFSAGPKVNGTFQADFPLGPATHGGTYRCFGSFRDSPYEWSNSSDPLLVSVIGNPSNSWPSPTEPSSKTGNPRHLHILIGTSVVIILFILLFFLLHRWCSNKKNAAVMDQESAGNRTANSEDSDEQDPQEVTYTQLNHCVFTQRKITRPSQRPKTPPTDIIVYAELPNAESRSKVVSCP
T54902	DRUGINFO	D00RYU	IPH-2102	Phase 2
T54902	DRUGINFO	D08XPN	mab 1-7F9	Phase 2
T54902	DRUGINFO	D04IXD	IPH-2101	Phase 2

T53472	TARGETID	T53472
T53472	FORMERID	TTDI02107
T53472	UNIPROID	KI2L3_HUMAN
T53472	TARGNAME	MHC class I NK cell receptor 2DL3 (CD158b2)
T53472	GENENAME	KIR2DL3
T53472	TARGTYPE	Clinical trial
T53472	SYNONYMS	p58.2 MHC class-I-specific NK receptor; p58 natural killer cell receptor clone CL-6; p58 NK receptor CL-6; Natural killer-associated transcript 2; NKAT2b; NKAT2a; NKAT2; NKAT-2; Killer inhibitory receptor cl 2-3; Killer cell immunoglobulin-like receptor 2DL3; KIRCL23; KIR-023GB; CD158B2; CD158 antigen-like family member B2
T53472	FUNCTION	Receptor on natural killer (NK) cells for HLA-C alleles (HLA-Cw1, HLA-Cw3 and HLA-Cw7). Inhibits the activity of NK cells thus preventing cell lysis.
T53472	PDBSTRUC	1B6U
T53472	BIOCLASS	Immunoglobulin
T53472	SEQUENCE	MSLMVVSMVCVGFFLLQGAWPHEGVHRKPSLLAHPGPLVKSEETVILQCWSDVRFQHFLLHREGKFKDTLHLIGEHHDGVSKANFSIGPMMQDLAGTYRCYGSVTHSPYQLSAPSDPLDIVITGLYEKPSLSAQPGPTVLAGESVTLSCSSRSSYDMYHLSREGEAHERRFSAGPKVNGTFQADFPLGPATHGGTYRCFGSFRDSPYEWSNSSDPLLVSVTGNPSNSWPSPTEPSSETGNPRHLHVLIGTSVVIILFILLLFFLLHRWCCNKKNAVVMDQEPAGNRTVNREDSDEQDPQEVTYAQLNHCVFTQRKITRPSQRPKTPPTDIIVYTELPNAEP
T53472	DRUGINFO	D00RYU	IPH-2102	Phase 2
T53472	DRUGINFO	D08XPN	mab 1-7F9	Phase 2
T53472	DRUGINFO	D04IXD	IPH-2101	Phase 2

T58589	TARGETID	T58589
T58589	FORMERID	TTDR00405
T58589	UNIPROID	BKRB1_HUMAN
T58589	TARGNAME	B1 bradykinin receptor (BDKRB1)
T58589	GENENAME	BDKRB1
T58589	TARGTYPE	Clinical trial
T58589	SYNONYMS	BRADYB1; BK-1 receptor; B1R
T58589	FUNCTION	This is a receptor for bradykinin. Could be a factor in chronic pain and inflammation.
T58589	BIOCLASS	GPCR rhodopsin
T58589	SEQUENCE	MASSWPPLELQSSNQSQLFPQNATACDNAPEAWDLLHRVLPTFIISICFFGLLGNLFVLLVFLLPRRQLNVAEIYLANLAASDLVFVLGLPFWAENIWNQFNWPFGALLCRVINGVIKANLFISIFLVVAISQDRYRVLVHPMASRRQQRRRQARVTCVLIWVVGGLLSIPTFLLRSIQAVPDLNITACILLLPHEAWHFARIVELNILGFLLPLAAIVFFNYHILASLRTREEVSRTRCGGRKDSKTTALILTLVVAFLVCWAPYHFFAFLEFLFQVQAVRGCFWEDFIDLGLQLANFFAFTNSSLNPVIYVFVGRLFRTKVWELYKQCTPKSLAPISSSHRKEIFQLFWRN
T58589	DRUGINFO	D03UVL	SSR-240612	Phase 2
T58589	DRUGINFO	D06BHG	Safotibant	Phase 2
T58589	DRUGINFO	D0R9HE	BI 113823	Phase 1
T58589	DRUGINFO	D01FAA	Ac-Lys-[Leu(8)]-des-Arg(9)-BK	Investigative
T58589	DRUGINFO	D04KFR	NVP-SAA164	Investigative
T58589	DRUGINFO	D05TZN	Des-Arg10-Kallidin	Investigative
T58589	DRUGINFO	D0V0LY	Des-Arg10-Leu9-Kallidin	Investigative
T58589	DRUGINFO	D00FAE	H-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1638)	Investigative
T58589	DRUGINFO	D02DGP	H-Lys-Arg-Pro-Hyp-Gly-Thi-Ser-D-BT-OH(JMV1669)	Investigative
T58589	DRUGINFO	D04KWH	Des-Arg(9)-[Leu(8)]-BK	Investigative
T58589	DRUGINFO	D0C3KW	H-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1645)	Investigative
T58589	DRUGINFO	D0N2GM	JMV1431	Investigative

T72120	TARGETID	T72120
T72120	FORMERID	TTDI02205
T72120	UNIPROID	UTRO_HUMAN
T72120	TARGNAME	Utrophin (UTRN)
T72120	GENENAME	UTRN
T72120	TARGTYPE	Clinical trial
T72120	SYNONYMS	Dystrophin-related protein 1; DRP1; DRP-1; DMDL
T72120	FUNCTION	May play a role in anchoring the cytoskeleton to the plasma membrane.
T72120	PDBSTRUC	1QAG; 1BHD
T72120	BIOCLASS	Zinc-finger
T72120	SEQUENCE	MAKYGEHEASPDNGQNEFSDIIKSRSDEHNDVQKKTFTKWINARFSKSGKPPINDMFTDLKDGRKLLDLLEGLTGTSLPKERGSTRVHALNNVNRVLQVLHQNNVELVNIGGTDIVDGNHKLTLGLLWSIILHWQVKDVMKDVMSDLQQTNSEKILLSWVRQTTRPYSQVNVLNFTTSWTDGLAFNAVLHRHKPDLFSWDKVVKMSPIERLEHAFSKAQTYLGIEKLLDPEDVAVQLPDKKSIIMYLTSLFEVLPQQVTIDAIREVETLPRKYKKECEEEAINIQSTAPEEEHESPRAETPSTVTEVDMDLDSYQIALEEVLTWLLSAEDTFQEQDDISDDVEEVKDQFATHEAFMMELTAHQSSVGSVLQAGNQLITQGTLSDEEEFEIQEQMTLLNARWEALRVESMDRQSRLHDVLMELQKKQLQQLSAWLTLTEERIQKMETCPLDDDVKSLQKLLEEHKSLQSDLEAEQVKVNSLTHMVVIVDENSGESATAILEDQLQKLGERWTAVCRWTEERWNRLQEINILWQELLEEQCLLKAWLTEKEEALNKVQTSNFKDQKELSVSVRRLAILKEDMEMKRQTLDQLSEIGQDVGQLLDNSKASKKINSDSEELTQRWDSLVQRLEDSSNQVTQAVAKLGMSQIPQKDLLETVRVREQAITKKSKQELPPPPPPKKRQIHVDIEAKKKFDAISAELLNWILKWKTAIQTTEIKEYMKMQDTSEMKKKLKALEKEQRERIPRADELNQTGQILVEQMGKEGLPTEEIKNVLEKVSSEWKNVSQHLEDLERKIQLQEDINAYFKQLDELEKVIKTKEEWVKHTSISESSRQSLPSLKDSCQRELTNLLGLHPKIEMARASCSALMSQPSAPDFVQRGFDSFLGRYQAVQEAVEDRQQHLENELKGQPGHAYLETLKTLKDVLNDSENKAQVSLNVLNDLAKVEKALQEKKTLDEILENQKPALHKLAEETKALEKNVHPDVEKLYKQEFDDVQGKWNKLKVLVSKDLHLLEEIALTLRAFEADSTVIEKWMDGVKDFLMKQQAAQGDDAGLQRQLDQCSAFVNEIETIESSLKNMKEIETNLRSGPVAGIKTWVQTRLGDYQTQLEKLSKEIATQKSRLSESQEKAANLKKDLAEMQEWMTQAEEEYLERDFEYKSPEELESAVEEMKRAKEDVLQKEVRVKILKDNIKLLAAKVPSGGQELTSELNVVLENYQLLCNRIRGKCHTLEEVWSCWIELLHYLDLETTWLNTLEERMKSTEVLPEKTDAVNEALESLESVLRHPADNRTQIRELGQTLIDGGILDDIISEKLEAFNSRYEDLSHLAESKQISLEKQLQVLRETDQMLQVLQESLGELDKQLTTYLTDRIDAFQVPQEAQKIQAEISAHELTLEELRRNMRSQPLTSPESRTARGGSQMDVLQRKLREVSTKFQLFQKPANFEQRMLDCKRVLDGVKAELHVLDVKDVDPDVIQTHLDKCMKLYKTLSEVKLEVETVIKTGRHIVQKQQTDNPKGMDEQLTSLKVLYNDLGAQVTEGKQDLERASQLARKMKKEAASLSEWLSATETELVQKSTSEGLLGDLDTEISWAKNVLKDLEKRKADLNTITESSAALQNLIEGSEPILEERLCVLNAGWSRVRTWTEDWCNTLMNHQNQLEIFDGNVAHISTWLYQAEALLDEIEKKPTSKQEEIVKRLVSELDDANLQVENVRDQALILMNARGSSSRELVEPKLAELNRNFEKVSQHIKSAKLLIAQEPLYQCLVTTETFETGVPFSDLEKLENDIENMLKFVEKHLESSDEDEKMDEESAQIEEVLQRGEEMLHQPMEDNKKEKIRLQLLLLHTRYNKIKAIPIQQRKMGQLASGIRSSLLPTDYLVEINKILLCMDDVELSLNVPELNTAIYEDFSFQEDSLKNIKDQLDKLGEQIAVIHEKQPDVILEASGPEAIQIRDTLTQLNAKWDRINRMYSDRKGCFDRAMEEWRQFHCDLNDLTQWITEAEELLVDTCAPGGSLDLEKARIHQQELEVGISSHQPSFAALNRTGDGIVQKLSQADGSFLKEKLAGLNQRWDAIVAEVKDRQPRLKGESKQVMKYRHQLDEIICWLTKAEHAMQKRSTTELGENLQELRDLTQEMEVHAEKLKWLNRTELEMLSDKSLSLPERDKISESLRTVNMTWNKICREVPTTLKECIQEPSSVSQTRIAAHPNVQKVVLVSSASDIPVQSHRTSEISIPADLDKTITELADWLVLIDQMLKSNIVTVGDVEEINKTVSRMKITKADLEQRHPQLDYVFTLAQNLKNKASSSDMRTAITEKLERVKNQWDGTQHGVELRQQQLEDMIIDSLQWDDHREETEELMRKYEARLYILQQARRDPLTKQISDNQILLQELGPGDGIVMAFDNVLQKLLEEYGSDDTRNVKETTEYLKTSWINLKQSIADRQNALEAEWRTVQASRRDLENFLKWIQEAETTVNVLVDASHRENALQDSILARELKQQMQDIQAEIDAHNDIFKSIDGNRQKMVKALGNSEEATMLQHRLDDMNQRWNDLKAKSASIRAHLEASAEKWNRLLMSLEELIKWLNMKDEELKKQMPIGGDVPALQLQYDHCKALRRELKEKEYSVLNAVDQARVFLADQPIEAPEEPRRNLQSKTELTPEERAQKIAKAMRKQSSEVKEKWESLNAVTSNWQKQVDKALEKLRDLQGAMDDLDADMKEAESVRNGWKPVGDLLIDSLQDHIEKIMAFREEIAPINFKVKTVNDLSSQLSPLDLHPSLKMSRQLDDLNMRWKLLQVSVDDRLKQLQEAHRDFGPSSQHFLSTSVQLPWQRSISHNKVPYYINHQTQTTCWDHPKMTELFQSLADLNNVRFSAYRTAIKIRRLQKALCLDLLELSTTNEIFKQHKLNQNDQLLSVPDVINCLTTTYDGLEQMHKDLVNVPLCVDMCLNWLLNVYDTGRTGKIRVQSLKIGLMSLSKGLLEEKYRYLFKEVAGPTEMCDQRQLGLLLHDAIQIPRQLGEVAAFGGSNIEPSVRSCFQQNNNKPEISVKEFIDWMHLEPQSMVWLPVLHRVAAAETAKHQAKCNICKECPIVGFRYRSLKHFNYDVCQSCFFSGRTAKGHKLHYPMVEYCIPTTSGEDVRDFTKVLKNKFRSKKYFAKHPRLGYLPVQTVLEGDNLETPITLISMWPEHYDPSQSPQLFHDDTHSRIEQYATRLAQMERTNGSFLTDSSSTTGSVEDEHALIQQYCQTLGGESPVSQPQSPAQILKSVEREERGELERIIADLEEEQRNLQVEYEQLKDQHLRRGLPVGSPPESIISPHHTSEDSELIAEAKLLRQHKGRLEARMQILEDHNKQLESQLHRLRQLLEQPESDSRINGVSPWASPQHSALSYSLDPDASGPQFHQAAGEDLLAPPHDTSTDLTEVMEQIHSTFPSCCPNVPSRPQAM
T72120	DRUGINFO	D0Y7YD	SMT-C1100	Phase 2

T14834	TARGETID	T14834
T14834	FORMERID	TTDR00443
T14834	UNIPROID	PA24A_HUMAN
T14834	TARGNAME	Cytosolic phospholipase A2 (GIVA cPLA2)
T14834	GENENAME	PLA2G4A
T14834	TARGTYPE	Clinical trial
T14834	SYNONYMS	Phospholipase A2 group IVA; PLA2G4; CPLA2
T14834	FUNCTION	Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory response. Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid.
T14834	PDBSTRUC	1RLW; 1CJY; 1BCI
T14834	BIOCLASS	Carboxylic ester hydrolase
T14834	SEQUENCE	MSFIDPYQHIIVEHQYSHKFTVVVLRATKVTKGAFGDMLDTPDPYVELFISTTPDSRKRTRHFNNDINPVWNETFEFILDPNQENVLEITLMDANYVMDETLGTATFTVSSMKVGEKKEVPFIFNQVTEMVLEMSLEVCSCPDLRFSMALCDQEKTFRQQRKEHIRESMKKLLGPKNSEGLHSARDVPVVAILGSGGGFRAMVGFSGVMKALYESGILDCATYVAGLSGSTWYMSTLYSHPDFPEKGPEEINEELMKNVSHNPLLLLTPQKVKRYVESLWKKKSSGQPVTFTDIFGMLIGETLIHNRMNTTLSSLKEKVNTAQCPLPLFTCLHVKPDVSELMFADWVEFSPYEIGMAKYGTFMAPDLFGSKFFMGTVVKKYEENPLHFLMGVWGSAFSILFNRVLGVSGSQSRGSTMEEELENITTKHIVSNDSSDSDDESHEPKGTENEDAGSDYQSDNQASWIHRMIMALVSDSALFNTREGRAGKVHNFMLGLNLNTSYPLSPLSDFATQDSFDDDELDAAVADPDEFERIYEPLDVKSKKIHVVDSGLTFNLPYPLILRPQRGVDLIISFDFSARPSDSSPPFKELLLAEKWAKMNKLPFPKIDPYVFDREGLKECYVFKPKNPDMEKDCPTIIHFVLANINFRKYRAPGVPRETEEEKEIADFDIFDDPESPFSTFNFQYPNQAFKRLHDLMHFNTLNNIDVIKEAMVESIEYRRQNPSRCSVSLSNVEARRFFNKEFLSKPKA
T14834	DRUGINFO	D02XBN	ZPL521	Phase 1/2
T14834	DRUGINFO	D0E1WY	EFIPLADIB	Terminated
T14834	DRUGINFO	D00GQP	AX-006	Investigative
T14834	DRUGINFO	D01GZV	N-(4-Ethoxybutyl)-2-oxohexadecanamide	Investigative
T14834	DRUGINFO	D02GTZ	[3,4''']biflavone	Investigative
T14834	DRUGINFO	D03DIV	1,1,1-Trifluoro-6-(naphthalen-2-yl)hexan-2-one	Investigative
T14834	DRUGINFO	D03FQJ	1,1,1,3-Tetrafluoro-7-phenylheptan-2-one	Investigative
T14834	DRUGINFO	D03NYE	4-(2-oxohexadecanamido)butanoic acid	Investigative
T14834	DRUGINFO	D05BTF	Tert-Butyl 5-(2-oxohexadecanamido)pentanoate	Investigative
T14834	DRUGINFO	D05GUD	AX-048	Investigative
T14834	DRUGINFO	D05LWK	[6,4''']biflavone	Investigative
T14834	DRUGINFO	D05MUN	1,1,1,2,2-Pentafluoro-9-phenyl-nonan-3-one	Investigative
T14834	DRUGINFO	D05TGU	1,1,1,3-Tetrafluoro-6-phenylhexan-2-one	Investigative
T14834	DRUGINFO	D05TZP	Tert-Butyl 3-(2-oxo-8-phenyloctanamido)propanoate	Investigative
T14834	DRUGINFO	D06OXA	Tert-Butyl 3-(2-oxohexadecanamido)propanoate	Investigative
T14834	DRUGINFO	D06XFP	1,1,1-Trifluoro-6-(4-hexyloxy-phenyl)-hexan-2-one	Investigative
T14834	DRUGINFO	D07QSM	Methyl 2-(2-oxohexadecanamido)acetate	Investigative
T14834	DRUGINFO	D07TCK	Tert-Butyl 2-(2-oxohexadecanamido)acetate	Investigative
T14834	DRUGINFO	D07VJT	[6,3''']biflavone	Investigative
T14834	DRUGINFO	D08SIJ	1,1,1-Trifluoro-4-(4-hexyloxy-phenyl)-butan-2-one	Investigative
T14834	DRUGINFO	D09CVD	1,1,1,3-Tetrafluoro-heptadecan-2-one	Investigative
T14834	DRUGINFO	D09ZUX	1,1,1,2,2,4-hexafluoro-7-phenylheptan-3-one	Investigative
T14834	DRUGINFO	D0B2RW	(S)-Ethyl 6-(2-oxohexadecanamido)decanoate	Investigative
T14834	DRUGINFO	D0D2SE	(Z)-1,1,1,2,2,3,3-heptafluorohenicos-12-en-4-one	Investigative
T14834	DRUGINFO	D0F4WJ	6-(4-Decyloxy-phenyl)-1,1,1-trifluoro-hexan-2-one	Investigative
T14834	DRUGINFO	D0F7IW	1,1,1-Trifluoro-5-(4-octylphenoxy)pentan-2-one	Investigative
T14834	DRUGINFO	D0F9PM	WAY-196025	Investigative
T14834	DRUGINFO	D0K0HD	Ethyl 2-(2-oxohexadecanamido)acetate	Investigative
T14834	DRUGINFO	D0K2PI	(S)-Methyl 4-(2-oxohexadecanamido)octanoate	Investigative
T14834	DRUGINFO	D0L6GV	[4',4''']-biflavone	Investigative
T14834	DRUGINFO	D0ND4N	Allyl 4-(2-oxohexadecanamido)butanoate	Investigative
T14834	DRUGINFO	D0P5UW	ECOPLADIB	Investigative
T14834	DRUGINFO	D0P9CN	1,1,1,2,2,3,3,5-octafluoro-8-phenyloctan-4-one	Investigative
T14834	DRUGINFO	D0PP8T	Methyl 2-(2-oxo-8-phenyloctanamido)acetate	Investigative
T14834	DRUGINFO	D0Q1LD	Ethyl 4-(2-oxohexadecanamido)benzoate	Investigative
T14834	DRUGINFO	D0R3AA	1,1,1-trifluoroheptadecan-2-one	Investigative
T14834	DRUGINFO	D0U1YU	(S)-tert-Butyl 4-(2-oxohexadecanamido)pentanoate	Investigative
T14834	DRUGINFO	D0U2GX	4-(4-Decyloxy-phenyl)-1,1,1-trifluoro-butan-2-one	Investigative
T14834	DRUGINFO	D0U2QY	1,1,1,2,2-Pentafluoro-8-phenyl-octan-3-one	Investigative
T14834	DRUGINFO	D0UV2N	1,1,1,2,2,3,3-heptafluoro-8-phenyloctan-4-ol	Investigative
T14834	DRUGINFO	D0V6QA	Methyl arachidonyl fluorophosphonate	Investigative
T14834	DRUGINFO	D08YHD	1,1,1-Trifluoro-7-phenylheptan-2-one	Investigative
T14834	DRUGINFO	D0J8TY	ARACHIDONYL TRIFLUOROMETHYLKETONE	Investigative
T14834	DRUGINFO	D0N1CK	1,1,1-Trifluoro-8-phenyl-octan-2-one	Investigative
T14834	DRUGINFO	D0W4VM	AR-C70484XX	Investigative
T14834	DRUGINFO	D0Y2BD	1-Imidazol-1-yl-3-(4-octylphenoxy)propan-2-one	Investigative

T70201	TARGETID	T70201
T70201	FORMERID	TTDI02081
T70201	UNIPROID	GLIP1_HUMAN
T70201	TARGNAME	Glioma pathogenesis-related protein 1 (GLIPR1)
T70201	GENENAME	GLIPR1
T70201	TARGTYPE	Clinical trial
T70201	SYNONYMS	RTVP1; Protein RTVP-1; GliPR 1; GLIPR
T70201	FUNCTION	Similarity to both the pathogenesis-related protein (PR) superfamily and the cysteine-rich secretory protein (CRISP) family
T70201	PDBSTRUC	3Q2U; 3Q2R
T70201	BIOCLASS	Cysteine-rich secretory protein
T70201	SEQUENCE	MRVTLATIAWMVSFVSNYSHTANILPDIENEDFIKDCVRIHNKFRSEVKPTASDMLYMTWDPALAQIAKAWASNCQFSHNTRLKPPHKLHPNFTSLGENIWTGSVPIFSVSSAITNWYDEIQDYDFKTRICKKVCGHYTQVVWADSYKVGCAVQFCPKVSGFDALSNGAHFICNYGPGGNYPTWPYKRGATCSACPNNDKCLDNLCVNRQRDQVKRYYSVVYPGWPIYPRNRYTSLFLIVNSVILILSVIITILVQHKYPNLVLLD
T70201	DRUGINFO	D09RZH	AdRTVP-1	Phase 1

T69685	TARGETID	T69685
T69685	FORMERID	TTDC00227
T69685	UNIPROID	SC6A9_HUMAN
T69685	TARGNAME	Glycine transporter GlyT-1 (SLC6A9)
T69685	GENENAME	SLC6A9
T69685	TARGTYPE	Clinical trial
T69685	SYNONYMS	Solute carrier family 6 member 9; Sodium- and chloride-dependent glycine transporter 1; Glycine type-1 transporter; Glycine transporter type 1; GlyT1; GlyT-1
T69685	FUNCTION	May play a role in regulation of glycine levels in NMDA receptor-mediated neurotransmission. Terminates the action of glycine by its high affinity sodium-dependent reuptake into presynaptic terminals.
T69685	BIOCLASS	Neurotransmitter:sodium symporter
T69685	SEQUENCE	MSGGDTRAAIARPRMAAAHGPVAPSSPEQVTLLPVQRSFFLPPFSGATPSTSLAESVLKVWHGAYNSGLLPQLMAQHSLAMAQNGAVPSEATKRDQNLKRGNWGNQIEFVLTSVGYAVGLGNVWRFPYLCYRNGGGAFMFPYFIMLIFCGIPLFFMELSFGQFASQGCLGVWRISPMFKGVGYGMMVVSTYIGIYYNVVICIAFYYFFSSMTHVLPWAYCNNPWNTHDCAGVLDASNLTNGSRPAALPSNLSHLLNHSLQRTSPSEEYWRLYVLKLSDDIGNFGEVRLPLLGCLGVSWLVVFLCLIRGVKSSGKVVYFTATFPYVVLTILFVRGVTLEGAFDGIMYYLTPQWDKILEAKVWGDAASQIFYSLGCAWGGLITMASYNKFHNNCYRDSVIISITNCATSVYAGFVIFSILGFMANHLGVDVSRVADHGPGLAFVAYPEALTLLPISPLWSLLFFFMLILLGLGTQFCLLETLVTAIVDEVGNEWILQKKTYVTLGVAVAGFLLGIPLTSQAGIYWLLLMDNYAASFSLVVISCIMCVAIMYIYGHRNYFQDIQMMLGFPPPLFFQICWRFVSPAIIFFILVFTVIQYQPITYNHYQYPGWAVAIGFLMALSSVLCIPLYAMFRLCRTDGDTLLQRLKNATKPSRDWGPALLEHRTGRYAPTIAPSPEDGFEVQPLHPDKAQIPIVGSNGSSRLQDSRI
T69685	DRUGINFO	D0B6IZ	R1678	Phase 3
T69685	DRUGINFO	D76PDV	BI 425809	Phase 3
T69685	DRUGINFO	DJOU19	Iclepertin	Phase 3
T69685	DRUGINFO	D04NIZ	AMG 747	Phase 2
T69685	DRUGINFO	D0LT0U	ORG-25935	Phase 2
T69685	DRUGINFO	D0O0BM	PF-3463275	Phase 2
T69685	DRUGINFO	D02XSL	GlyT1 PET radiotracers	Phase 1
T69685	DRUGINFO	D05WWJ	ALX-5407	Phase 1
T69685	DRUGINFO	D0F4NP	JNJ-17305600	Phase 1
T69685	DRUGINFO	D0R8HY	DCCCyB	Phase 1
T69685	DRUGINFO	D0Y3AZ	MK-2637	Phase 1
T69685	DRUGINFO	D00JEC	PMID29338548-Compound-24	Patented
T69685	DRUGINFO	D01IJO	PMID29338548-Compound-25	Patented
T69685	DRUGINFO	D02TZT	PMID29338548-Compound-17	Patented
T69685	DRUGINFO	D03PQS	PMID29338548-Compound-38	Patented
T69685	DRUGINFO	D06BUG	PMID29338548-Compound-41	Patented
T69685	DRUGINFO	D06OSE	PMID29338548-Compound-39	Patented
T69685	DRUGINFO	D07GSH	PMID29338548-Compound-31	Patented
T69685	DRUGINFO	D08GXR	PMID29338548-Compound-18	Patented
T69685	DRUGINFO	D08UQK	PMID29338548-Compound-29	Patented
T69685	DRUGINFO	D0B5NJ	PMID29338548-Compound-46	Patented
T69685	DRUGINFO	D0E2VI	PMID29338548-Compound-36	Patented
T69685	DRUGINFO	D0EF0P	PMID29338548-Compound-23	Patented
T69685	DRUGINFO	D0EV6V	PMID29338548-Compound-15	Patented
T69685	DRUGINFO	D0FG2H	PMID29338548-Compound-26	Patented
T69685	DRUGINFO	D0GX8J	PMID29338548-Compound-34	Patented
T69685	DRUGINFO	D0H2KL	PMID29338548-Compound-13	Patented
T69685	DRUGINFO	D0H5VO	PMID29338548-Compound-27	Patented
T69685	DRUGINFO	D0H5WE	PMID29338548-Compound-30	Patented
T69685	DRUGINFO	D0I7AJ	PMID29338548-Compound-14	Patented
T69685	DRUGINFO	D0K6CM	PMID29338548-Compound-16	Patented
T69685	DRUGINFO	D0M6PI	PMID29338548-Compound-44	Patented
T69685	DRUGINFO	D0MT4C	PMID29338548-Compound-48	Patented
T69685	DRUGINFO	D0S6BG	PMID29338548-Compound-20	Patented
T69685	DRUGINFO	D0T1BE	PMID29338548-Compound-33	Patented
T69685	DRUGINFO	D0T2QP	PMID29338548-Compound-22	Patented
T69685	DRUGINFO	D0V5KY	PMID29338548-Compound-45	Patented
T69685	DRUGINFO	D0W2YK	PMID29338548-Compound-40	Patented
T69685	DRUGINFO	D0W7FS	PMID29338548-Compound-21	Patented
T69685	DRUGINFO	D0WT3F	PMID29338548-Compound-37	Patented
T69685	DRUGINFO	D0X1ZA	PMID29338548-Compound-28	Patented
T69685	DRUGINFO	D0XG8H	PMID29338548-Compound-49	Patented
T69685	DRUGINFO	D0XS1I	PMID29338548-Compound-47	Patented
T69685	DRUGINFO	D0Y9FA	PMID29338548-Compound-19	Patented
T69685	DRUGINFO	D0WY2L	GSK1018921	Discontinued in Phase 1
T69685	DRUGINFO	D06SBS	SSR-504734	Preclinical
T69685	DRUGINFO	D07PNC	Organon	Preclinical
T69685	DRUGINFO	D0I6JG	Organon-3	Preclinical
T69685	DRUGINFO	D0O5ZT	Organon-2	Preclinical
T69685	DRUGINFO	D0U1HP	Org-24461	Preclinical
T69685	DRUGINFO	D0Y9KR	SSR-103800	Preclinical
T69685	DRUGINFO	D00CFU	RO-4840700	Investigative
T69685	DRUGINFO	D07IYZ	[3H](R)-NPTS	Investigative
T69685	DRUGINFO	D07PKH	GSK931145	Investigative
T69685	DRUGINFO	D08AYM	[3H]NFPS	Investigative
T69685	DRUGINFO	D09FDV	[35S]ACPPB	Investigative
T69685	DRUGINFO	D0GI5V	[3H]N-methyl-SSR504734	Investigative
T69685	DRUGINFO	D0H7RV	[3H]SB-733993	Investigative
T69685	DRUGINFO	D0I5ZO	AS-1522489-00	Investigative
T69685	DRUGINFO	D0O8LR	[3H]GSK931145	Investigative
T69685	DRUGINFO	D0U1CN	LY2365109	Investigative

T21307	TARGETID	T21307
T21307	FORMERID	TTDI02119
T21307	UNIPROID	MAPK2_HUMAN
T21307	TARGNAME	MAPK-activated protein kinase 2 (MAPKAPK2)
T21307	GENENAME	MAPKAPK2
T21307	TARGTYPE	Clinical trial
T21307	SYNONYMS	MK2; MK-2; MAPKactivated protein kinase 2; MAPKAPK-2; MAPKAP-K2; MAPKAP kinase 2; MAP kinaseactivated protein kinase 2; MAP kinase-activated protein kinase 2
T21307	FUNCTION	Following stress, it is phosphorylated and activated by MAP kinase p38-alpha/MAPK14, leading to phosphorylation of substrates. Phosphorylates serine in the peptide sequence, Hyd-X-R-X(2)-S, where Hyd is a large hydrophobic residue. Phosphorylates ALOX5, CDC25B, CDC25C, CEP131, ELAVL1, HNRNPA0, HSP27/HSPB1, KRT18, KRT20, LIMK1, LSP1, PABPC1, PARN, PDE4A, RCSD1, RPS6KA3, TAB3 and TTP/ZFP36. Phosphorylates HSF1; leading to the interaction with HSP90 proteins and inhibiting HSF1 homotrimerization, DNA-binding and transactivation activities. Mediates phosphorylation of HSP27/HSPB1 in response to stress, leading to the dissociation of HSP27/HSPB1 from large small heat-shock protein (sHsps) oligomers and impairment of their chaperone activities and ability to protect against oxidative stress effectively. Involved in inflammatory response by regulating tumor necrosis factor (TNF) and IL6 production post-transcriptionally: acts by phosphorylating AU-rich elements (AREs)-binding proteins ELAVL1, HNRNPA0, PABPC1 and TTP/ZFP36, leading to the regulation of the stability and translation of TNF and IL6 mRNAs. Phosphorylation of TTP/ZFP36, a major post-transcriptional regulator of TNF, promotes its binding to 14-3-3 proteins and reduces its ARE mRNA affinity, leading to inhibition of dependent degradation of ARE-containing transcripts. Phosphorylates CEP131 in response to cellular stress induced by ultraviolet irradiation which promotes binding of CEP131 to 14-3-3 proteins and inhibits formation of novel centriolar satellites. Also involved in late G2/M checkpoint following DNA damage through a process of post-transcriptional mRNA stabilization: following DNA damage, relocalizes from nucleus to cytoplasm and phosphorylates HNRNPA0 and PARN, leading to stabilization of GADD45A mRNA. Involved in toll-like receptor signaling pathway (TLR) in dendritic cells: required for acute TLR-induced macropinocytosis by phosphorylating and activating RPS6KA3. Stress-activated serine/threonine-protein kinase involved in cytokine production, endocytosis, reorganization of the cytoskeleton, cell migration, cell cycle control, chromatin remodeling, DNA damage response and transcriptional regulation.
T21307	PDBSTRUC	4TYH; 3WI6; 3R30; 3R2Y; 3R2B
T21307	BIOCLASS	Kinase
T21307	ECNUMBER	EC 2.7.11.1
T21307	SEQUENCE	MLSNSQGQSPPVPFPAPAPPPQPPTPALPHPPAQPPPPPPQQFPQFHVKSGLQIKKNAIIDDYKVTSQVLGLGINGKVLQIFNKRTQEKFALKMLQDCPKARREVELHWRASQCPHIVRIVDVYENLYAGRKCLLIVMECLDGGELFSRIQDRGDQAFTEREASEIMKSIGEAIQYLHSINIAHRDVKPENLLYTSKRPNAILKLTDFGFAKETTSHNSLTTPCYTPYYVAPEVLGPEKYDKSCDMWSLGVIMYILLCGYPPFYSNHGLAISPGMKTRIRMGQYEFPNPEWSEVSEEVKMLIRNLLKTEPTQRMTITEFMNHPWIMQSTKVPQTPLHTSRVLKEDKERWEDVKEEMTSALATMRVDYEQIKIKKIEDASNPLLLKRRKKARALEAAALAH
T21307	DRUGINFO	DQ15ZM	Zunsemetinib	Phase 2
T21307	DRUGINFO	D02NNN	CBP-501	Phase 1/2
T21307	DRUGINFO	D0S7NS	MMI-0100	Phase 1
T21307	DRUGINFO	D06QBJ	PF-3644022	Investigative
T21307	DRUGINFO	D0O7UT	CMPD1	Investigative
T21307	DRUGINFO	D0EW9J	PMID17480064C16	Investigative
T21307	DRUGINFO	D01YWE	PMID19364658C33	Investigative

T10670	TARGETID	T10670
T10670	FORMERID	TTDC00040
T10670	UNIPROID	NPY2R_HUMAN
T10670	TARGNAME	Neuropeptide Y receptor type 2 (NPY2R)
T10670	GENENAME	NPY2R
T10670	TARGTYPE	Clinical trial
T10670	SYNONYMS	Y2 receptor; NPY2R; NPY2-R; NPY-Y2 receptor
T10670	FUNCTION	Receptor for neuropeptide Y andpeptide YY. The rank order of affinity of this receptor for pancreatic polypeptides is PYY > NPY > PYY (3-36) > NPY (2-36) > [Ile-31, Gln-34] PP > [Leu- 31, Pro-34] NPY > PP, [Pro-34] PYY and NPY free acid.
T10670	PDBSTRUC	2IK3
T10670	BIOCLASS	GPCR rhodopsin
T10670	SEQUENCE	MGPIGAEADENQTVEEMKVEQYGPQTTPRGELVPDPEPELIDSTKLIEVQVVLILAYCSIILLGVIGNSLVIHVVIKFKSMRTVTNFFIANLAVADLLVNTLCLPFTLTYTLMGEWKMGPVLCHLVPYAQGLAVQVSTITLTVIALDRHRCIVYHLESKISKRISFLIIGLAWGISALLASPLAIFREYSLIEIIPDFEIVACTEKWPGEEKSIYGTVYSLSSLLILYVLPLGIISFSYTRIWSKLKNHVSPGAANDHYHQRRQKTTKMLVCVVVVFAVSWLPLHAFQLAVDIDSQVLDLKEYKLIFTVFHIIAMCSTFANPLLYGWMNSNYRKAFLSAFRCEQRLDAIHSEVSVTFKAKKNLEVRKNSGPNDSFTEATNV
T10670	DRUGINFO	D0I1KQ	NEUROPEPTIDE-Y	Phase 2
T10670	DRUGINFO	D0S2LQ	PYY3-36	Discontinued in Phase 2
T10670	DRUGINFO	D07SWU	TM30338	Discontinued in Phase 2
T10670	DRUGINFO	D03WMK	AC-162352	Discontinued in Phase 1
T10670	DRUGINFO	D08MCT	BMS-192548	Preclinical
T10670	DRUGINFO	DV7JX1	CIN-110	Preclinical
T10670	DRUGINFO	D02WBY	JNJ-5207787	Investigative
T10670	DRUGINFO	D06ERA	AcNPY(25-36)	Investigative
T10670	DRUGINFO	D06GFZ	BIIE0246	Investigative
T10670	DRUGINFO	D08ZRC	AcPYY(25-36)	Investigative
T10670	DRUGINFO	D0J1KG	PD-4048	Investigative
T10670	DRUGINFO	D0Q2IU	AcPYY(26-36)	Investigative
T10670	DRUGINFO	D0RF9B	PYY(25-36)	Investigative
T10670	DRUGINFO	D0U1HE	PEGylated PYY-3-36	Investigative
T10670	DRUGINFO	D02MKP	AcPYY(22-36)	Investigative
T10670	DRUGINFO	D07DJT	LRHYLNLLTRQRY-NH2	Investigative
T10670	DRUGINFO	D0P9KP	PYY(22-36)	Investigative
T10670	DRUGINFO	D00OLA	H-[Trp-Arg-Nva-Arg-Tyr]3-NH2	Investigative
T10670	DRUGINFO	D07OOG	Sub[-Trp-Arg-Nva-Arg-Tyr-NH2]2	Investigative
T10670	DRUGINFO	D08YWE	Pim[-Trp-Arg-Nva-Arg-Tyr-NH2]2	Investigative
T10670	DRUGINFO	D0G4HT	Sub[-Tyr-Arg-Leu-Arg-Tyr-NH2]2	Investigative
T10670	DRUGINFO	D0J9VA	H-[Trp-Arg-Nva-Arg-Tyr]2-NH2	Investigative
T10670	DRUGINFO	D0V0HM	Adp[-Trp-Arg-Nva-Arg-Tyr-NH2]2	Investigative

T99204	TARGETID	T99204
T99204	FORMERID	TTDR00445
T99204	UNIPROID	PSN2_HUMAN
T99204	TARGNAME	Presenilin 2 (PSEN2)
T99204	GENENAME	PSEN2
T99204	TARGTYPE	Clinical trial
T99204	SYNONYMS	STM2; STM-2; Presenilin-2; PSNL2; PS-2; E5-1; AD5; AD4; AD3LP
T99204	FUNCTION	Requires the other members of the gamma-secretase complex to have a protease activity. May play a role in intracellular signaling and gene expression or in linking chromatin to the nuclear membrane. May function in the cytoplasmic partitioning of proteins. The holoprotein functions as a calcium-leak channel that allows the passive movement of calcium from endoplasmic reticulum to cytosol and is involved in calcium homeostasis. Is a regulator of mitochondrion-endoplasmic reticulum membrane tethering and modulates calcium ions shuttling between ER and mitochondria. Probable catalytic subunit of the gamma-secretase complex, an endoprotease complex that catalyzes the intramembrane cleavage of integral membrane proteins such as Notch receptors and APP (amyloid-beta precursor protein).
T99204	BIOCLASS	Peptidase
T99204	ECNUMBER	EC 3.4.23.-
T99204	SEQUENCE	MLTFMASDSEEEVCDERTSLMSAESPTPRSCQEGRQGPEDGENTAQWRSQENEEDGEEDPDRYVCSGVPGRPPGLEEELTLKYGAKHVIMLFVPVTLCMIVVVATIKSVRFYTEKNGQLIYTPFTEDTPSVGQRLLNSVLNTLIMISVIVVMTIFLVVLYKYRCYKFIHGWLIMSSLMLLFLFTYIYLGEVLKTYNVAMDYPTLLLTVWNFGAVGMVCIHWKGPLVLQQAYLIMISALMALVFIKYLPEWSAWVILGAISVYDLVAVLCPKGPLRMLVETAQERNEPIFPALIYSSAMVWTVGMAKLDPSSQGALQLPYDPEMEEDSYDSFGEPSYPEVFEPPLTGYPGEELEEEEERGVKLGLGDFIFYSVLVGKAAATGSGDWNTTLACFVAILIGLCLTLLLLAVFKKALPALPISITFGLIFYFSTDNLVRPFMDTLASHQLYI
T99204	DRUGINFO	D0G2IC	(S)-FLURBIPROFEN	Preregistration
T99204	DRUGINFO	D05FGR	R-flurbiprofen	Phase 2
T99204	DRUGINFO	D0K8LN	1-Chloro-4-(1-phenyl-cyclohexanesulfonyl)-benzene	Investigative
T99204	DRUGINFO	D00DFR	(5R,6S)-5,6-bis(benzyloxy)cyclohex-2-enone	Investigative
T99204	DRUGINFO	D04TWU	(5R,6S)-6-(benzyloxy)-5-methoxycyclohex-2-enone	Investigative
T99204	DRUGINFO	D06TPT	Drug 311951	Investigative
T99204	DRUGINFO	D09HAD	Drug 311383	Investigative
T99204	DRUGINFO	D0I8BA	1-benzoyl-2-benzyl-1,2-dihydropyridin-3(6H)-one	Investigative
T99204	DRUGINFO	D0M2LV	(2S,3R)-2-(benzyloxy)-3-methoxycyclohexanone	Investigative
T99204	DRUGINFO	D0V7YM	Drug 311952	Investigative
T99204	DRUGINFO	D0XQ2T	Drug 311440	Investigative

T27944	TARGETID	T27944
T27944	FORMERID	TTDC00043
T27944	UNIPROID	NPY4R_HUMAN
T27944	TARGNAME	Neuropeptide Y receptor type 4 (NPY4R)
T27944	GENENAME	NPY4R
T27944	TARGTYPE	Clinical trial
T27944	SYNONYMS	Pancreatic polypeptide receptor 1; PPYR1; NPY4R; NPY4-R
T27944	FUNCTION	Receptor for neuropeptide Y and peptide YY. The rank order of affinity of this receptor for pancreatic polypeptides is PP, PP (2-36) and [Ile-31, Gln-34] PP > [Pro-34] PYY > PYY and [Leu-31, Pro-34] NPY > NPY > PYY (3-36) and NPY (2-36) > PP (13- 36) > PP (31-36) > NPY free acid.
T27944	PDBSTRUC	2IK5
T27944	BIOCLASS	GPCR rhodopsin
T27944	SEQUENCE	MNTSHLLALLLPKSPQGENRSKPLGTPYNFSEHCQDSVDVMVFIVTSYSIETVVGVLGNLCLMCVTVRQKEKANVTNLLIANLAFSDFLMCLLCQPLTAVYTIMDYWIFGETLCKMSAFIQCMSVTVSILSLVLVALERHQLIINPTGWKPSISQAYLGIVLIWVIACVLSLPFLANSILENVFHKNHSKALEFLADKVVCTESWPLAHHRTIYTTFLLLFQYCLPLGFILVCYARIYRRLQRQGRVFHKGTYSLRAGHMKQVNVVLVVMVVAFAVLWLPLHVFNSLEDWHHEAIPICHGNLIFLVCHLLAMASTCVNPFIYGFLNTNFKKEIKALVLTCQQSAPLEESEHLPLSTVHTEVSKGSLRLSGRSNPI
T27944	DRUGINFO	D0B7QP	TM30339	Discontinued in Phase 2
T27944	DRUGINFO	D07SWU	TM30338	Discontinued in Phase 2
T27944	DRUGINFO	D0CE5S	PD-4074	Investigative
T27944	DRUGINFO	D07BCH	[Cys-Trp-Arg-Nva-Arg-Tyr-NH2]2	Investigative
T27944	DRUGINFO	D0H8KI	[125I]GR231118	Investigative
T27944	DRUGINFO	D00OLA	H-[Trp-Arg-Nva-Arg-Tyr]3-NH2	Investigative
T27944	DRUGINFO	D07OOG	Sub[-Trp-Arg-Nva-Arg-Tyr-NH2]2	Investigative
T27944	DRUGINFO	D08YWE	Pim[-Trp-Arg-Nva-Arg-Tyr-NH2]2	Investigative
T27944	DRUGINFO	D0G4HT	Sub[-Tyr-Arg-Leu-Arg-Tyr-NH2]2	Investigative
T27944	DRUGINFO	D0J9VA	H-[Trp-Arg-Nva-Arg-Tyr]2-NH2	Investigative
T27944	DRUGINFO	D0V0HM	Adp[-Trp-Arg-Nva-Arg-Tyr-NH2]2	Investigative

T46084	TARGETID	T46084
T46084	FORMERID	TTDI02193
T46084	UNIPROID	TNF10_HUMAN
T46084	TARGNAME	TNF related apoptosis inducing ligand (TNFSF10)
T46084	GENENAME	TNFSF10
T46084	TARGTYPE	Clinical trial
T46084	SYNONYMS	Tumor necrosis factor ligand superfamily member 10; TRAIL; TNF-related apoptosis-inducing ligand; Protein TRAIL; CD253; Apo-2L; Apo-2 ligand; APO2L
T46084	FUNCTION	Induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis. Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG.
T46084	PDBSTRUC	5CIR; 4N90; 1DU3; 1DG6; 1D4V
T46084	BIOCLASS	Cytokine: tumor necrosis factor
T46084	SEQUENCE	MAMMEVQGGPSLGQTCVLIVIFTVLLQSLCVAVTYVYFTNELKQMQDKYSKSGIACFLKEDDSYWDPNDEESMNSPCWQVKWQLRQLVRKMILRTSEETISTVQEKQQNISPLVRERGPQRVAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHSFLSNLHLRNGELVIHEKGFYYIYSQTYFRFQEEIKENTKNDKQMVQYIYKYTSYPDPILLMKSARNSCWSKDAEYGLYSIYQGGIFELKENDRIFVSVTNEHLIDMDHEASFFGAFLVG
T46084	DRUGINFO	D0K1LJ	Ad5-TRAIL	Phase 1
T46084	DRUGINFO	D0V3ZX	DA-3607	Phase 1
T46084	DRUGINFO	DCD1M8	ABBV-621	Phase 1
T46084	DRUGINFO	D0C0JT	Nimesulide	Terminated

T97873	TARGETID	T97873
T97873	FORMERID	TTDNC00667
T97873	UNIPROID	CCR9_HUMAN
T97873	TARGNAME	C-C chemokine receptor type 9 (CCR9)
T97873	GENENAME	CCR9
T97873	TARGTYPE	Clinical trial
T97873	SYNONYMS	Gprotein coupled receptor 28; GPR96; GPR28; GPR-9-6; G-protein coupled receptor 28; CDw199; CCR-9; CCCKR9; CC-CKR-9; CC chemokine receptor type 9; CC CKR9; C-C CKR-9
T97873	FUNCTION	Subsequently transduces a signal by increasing the intracellular calcium ions level. Receptor for chemokine SCYA25/TECK.
T97873	PDBSTRUC	5LWE
T97873	BIOCLASS	GPCR rhodopsin
T97873	SEQUENCE	MTPTDFTSPIPNMADDYGSESTSSMEDYVNFNFTDFYCEKNNVRQFASHFLPPLYWLVFIVGALGNSLVILVYWYCTRVKTMTDMFLLNLAIADLLFLVTLPFWAIAAADQWKFQTFMCKVVNSMYKMNFYSCVLLIMCISVDRYIAIAQAMRAHTWREKRLLYSKMVCFTIWVLAAALCIPEILYSQIKEESGIAICTMVYPSDESTKLKSAVLTLKVILGFFLPFVVMACCYTIIIHTLIQAKKSSKHKALKVTITVLTVFVLSQFPYNCILLVQTIDAYAMFISNCAVSTNIDICFQVTQTIAFFHSCLNPVLYVFVGERFRRDLVKTLKNLGCISQAQWVSFTRREGSLKLSSMLLETTSGALSL
T97873	DRUGINFO	D0K3UQ	Vercirnon	Phase 3
T97873	DRUGINFO	D00YXU	CCX-025	Phase 1
T97873	DRUGINFO	D03DHM	CCX507	Phase 1
T97873	DRUGINFO	D0Q4CX	MLN-3126	Phase 1

T64645	TARGETID	T64645
T64645	FORMERID	TTDI02180
T64645	UNIPROID	SPHM_HUMAN
T64645	TARGNAME	N-sulphoglucosamine sulphohydrolase (SGSH)
T64645	GENENAME	SGSH
T64645	TARGTYPE	Clinical trial
T64645	SYNONYMS	Sulphamidase; Sulfoglucosamine sulfamidase; HSS
T64645	FUNCTION	Catalyzes a step in lysosomal heparan sulfate degradation.
T64645	PDBSTRUC	4MIV; 4MHX
T64645	BIOCLASS	Sulfur-nitrogen hydrolase
T64645	ECNUMBER	EC 3.10.1.1
T64645	SEQUENCE	MSCPVPACCALLLVLGLCRARPRNALLLLADDGGFESGAYNNSAIATPHLDALARRSLLFRNAFTSVSSCSPSRASLLTGLPQHQNGMYGLHQDVHHFNSFDKVRSLPLLLSQAGVRTGIIGKKHVGPETVYPFDFAYTEENGSVLQVGRNITRIKLLVRKFLQTQDDRPFFLYVAFHDPHRCGHSQPQYGTFCEKFGNGESGMGRIPDWTPQAYDPLDVLVPYFVPNTPAARADLAAQYTTVGRMDQGVGLVLQELRDAGVLNDTLVIFTSDNGIPFPSGRTNLYWPGTAEPLLVSSPEHPKRWGQVSEAYVSLLDLTPTILDWFSIPYPSYAIFGSKTIHLTGRSLLPALEAEPLWATVFGSQSHHEVTMSYPMRSVQHRHFRLVHNLNFKMPFPIDQDFYVSPTFQDLLNRTTAGQPTGWYKDLRHYYYRARWELYDRSRDPHETQNLATDPRFAQLLEMLRDQLAKWQWETHDPWVCAPDGVLEEKLSPQCQPLHNEL
T64645	DRUGINFO	D5DAR1	LYS-SAF302	Phase 2/3
T64645	DRUGINFO	D0Q5BK	HGT-1410	Phase 2
T64645	DRUGINFO	D3W5TL	ABO-102	Phase 1/2
T64645	DRUGINFO	DQ62VF	SOBI003	Phase 1/2

T96685	TARGETID	T96685
T96685	UNIPROID	HXK2_HUMAN
T96685	TARGNAME	Hexokinase-2 (HK2)
T96685	GENENAME	HK2
T96685	TARGTYPE	Clinical trial
T96685	SYNONYMS	Muscle form hexokinase; Hexokinase type II; HK II
T96685	FUNCTION	cytosol, membrane, mitochondrial outer membrane, fructokinase activity, glucokinase activity, hexokinase activity, mannokinase activity, apoptotic mitochondrial changes, canonical glycolysis, cellular glucose homeostasis.
T96685	PDBSTRUC	5HG1; 5HFU; 5HEX; 2NZT
T96685	BIOCLASS	Hexokinase family
T96685	ECNUMBER	EC 2.7.1.1
T96685	SEQUENCE	MIASHLLAYFFTELNHDQVQKVDQYLYHMRLSDETLLEISKRFRKEMEKGLGATTHPTAAVKMLPTFVRSTPDGTEHGEFLALDLGGTNFRVLWVKVTDNGLQKVEMENQIYAIPEDIMRGSGTQLFDHIAECLANFMDKLQIKDKKLPLGFTFSFPCHQTKLDESFLVSWTKGFKSSGVEGRDVVALIRKAIQRRGDFDIDIVAVVNDTVGTMMTCGYDDHNCEIGLIVGTGSNACYMEEMRHIDMVEGDEGRMCINMEWGAFGDDGSLNDIRTEFDQEIDMGSLNPGKQLFEKMISGMYMGELVRLILVKMAKEELLFGGKLSPELLNTGRFETKDISDIEGEKDGIRKAREVLMRLGLDPTQEDCVATHRICQIVSTRSASLCAATLAAVLQRIKENKGEERLRSTIGVDGSVYKKHPHFAKRLHKTVRRLVPGCDVRFLRSEDGSGKGAAMVTAVAYRLADQHRARQKTLEHLQLSHDQLLEVKRRMKVEMERGLSKETHASAPVKMLPTYVCATPDGTEKGDFLALDLGGTNFRVLLVRVRNGKWGGVEMHNKIYAIPQEVMHGTGDELFDHIVQCIADFLEYMGMKGVSLPLGFTFSFPCQQNSLDESILLKWTKGFKASGCEGEDVVTLLKEAIHRREEFDLDVVAVVNDTVGTMMTCGFEDPHCEVGLIVGTGSNACYMEEMRNVELVEGEEGRMCVNMEWGAFGDNGCLDDFRTEFDVAVDELSLNPGKQRFEKMISGMYLGEIVRNILIDFTKRGLLFRGRISERLKTRGIFETKFLSQIESDCLALLQVRAILQHLGLESTCDDSIIVKEVCTVVARRAAQLCGAGMAAVVDRIRENRGLDALKVTVGVDGTLYKLHPHFAKVMHETVKDLAPKCDVSFLQSEDGSGKGAALITAVACRIREAGQR
T96685	DRUGINFO	D06QBX	VDA-1102	Phase 2

T35063	TARGETID	T35063
T35063	FORMERID	TTDNC00413
T35063	UNIPROID	GEM_HUMAN
T35063	TARGNAME	RAS-like protein KIR (GEM)
T35063	GENENAME	GEM
T35063	TARGTYPE	Clinical trial
T35063	SYNONYMS	RASlike protein KIR; GTPbinding protein GEM; GTPbinding mitogeninduced Tcell protein
T35063	FUNCTION	Could be a regulatory protein, possibly participating in receptor-mediated signal transduction at the plasma membrane. Has guanine nucleotide-binding activity but undetectable intrinsic GTPase activity.
T35063	PDBSTRUC	2HT6; 2G3Y; 2CJW
T35063	BIOCLASS	Small GTPase superfamily
T35063	SEQUENCE	MTLNNVTMRQGTVGMQPQQQRWSIPADGRHLMVQKEPHQYSHRNRHSATPEDHCRRSWSSDSTDSVISSESGNTYYRVVLIGEQGVGKSTLANIFAGVHDSMDSDCEVLGEDTYERTLMVDGESATIILLDMWENKGENEWLHDHCMQVGDAYLIVYSITDRASFEKASELRIQLRRARQTEDIPIILVGNKSDLVRCREVSVSEGRACAVVFDCKFIETSAAVQHNVKELFEGIVRQVRLRRDSKEKNERRLAYQKRKESMPRKARRFWGKIVAKNNKNMAFKLKSKSCHDLSVL
T35063	DRUGINFO	D0I7PU	Lirilumab	Phase 2

T13714	TARGETID	T13714
T13714	FORMERID	TTDR00421
T13714	UNIPROID	NR1H2_HUMAN
T13714	TARGNAME	Oxysterols receptor LXR-beta (NR1H2)
T13714	GENENAME	NR1H2
T13714	TARGTYPE	Clinical trial
T13714	SYNONYMS	Ubiquitously-expressed nuclear receptor; Nuclear receptor subfamily 1 group H member 2; Nuclear receptor NER; Nuclear orphan receptor LXR-beta; NER; Liver X receptor beta; LXRbeta; LXRB
T13714	FUNCTION	Binds preferentially to double-stranded oligonucleotide direct repeats having the consensus half-site sequence 5'-AGGTCA-3' and 4-nt spacing (DR-4). Regulates cholesterol uptake through MYLIP-dependent ubiquitination of LDLR, VLDLR and LRP8; DLDLR and LRP8. Interplays functionally with RORA for the regulation of genes involved in liver metabolism. Plays an anti-inflammatory role during the hepatic acute phase response by acting as a corepressor: inhibits the hepatic acute phase response by preventing dissociation of the N-Cor corepressor complex. Nuclear receptor that exhibits a ligand-dependent transcriptional activation activity.
T13714	PDBSTRUC	5KYJ; 5KYA; 5JY3; 5I4V; 5HJP
T13714	BIOCLASS	Nuclear hormone receptor
T13714	SEQUENCE	MSSPTTSSLDTPLPGNGPPQPGAPSSSPTVKEEGPEPWPGGPDPDVPGTDEASSACSTDWVIPDPEEEPERKRKKGPAPKMLGHELCRVCGDKASGFHYNVLSCEGCKGFFRRSVVRGGARRYACRGGGTCQMDAFMRRKCQQCRLRKCKEAGMREQCVLSEEQIRKKKIRKQQQESQSQSQSPVGPQGSSSSASGPGASPGGSEAGSQGSGEGEGVQLTAAQELMIQQLVAAQLQCNKRSFSDQPKVTPWPLGADPQSRDARQQRFAHFTELAIISVQEIVDFAKQVPGFLQLGREDQIALLKASTIEIMLLETARRYNHETECITFLKDFTYSKDDFHRAGLQVEFINPIFEFSRAMRRLGLDDAEYALLIAINIFSADRPNVQEPGRVEALQQPYVEALLSYTRIKRPQDQLRFPRMLMKLVSLRTLSSVHSEQVFALRLQDKKLPPLLSEIWDVHE
T13714	DRUGINFO	D01XMC	VTB-38543	Phase 2
T13714	DRUGINFO	D08LFT	Benzenesulfonyl	Investigative
T13714	DRUGINFO	D00DLU	GSK-9772	Investigative
T13714	DRUGINFO	D00HVP	Riccardin C	Investigative
T13714	DRUGINFO	D01HDD	2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione	Investigative
T13714	DRUGINFO	D03YUL	AZ12260493	Investigative
T13714	DRUGINFO	D06VRA	4,17-dehydroxyriccardin C	Investigative
T13714	DRUGINFO	D08URT	24(S)-hydroxycholesterol	Investigative
T13714	DRUGINFO	D09UND	12,17-dehydroxyriccardin C	Investigative
T13714	DRUGINFO	D0A1WR	SR9238	Investigative
T13714	DRUGINFO	D0C2CY	WAY-254011	Investigative
T13714	DRUGINFO	D0C6QI	acetyl-podocarpic dimer	Investigative
T13714	DRUGINFO	D0HA0U	12-dehydroxyriccardin C	Investigative
T13714	DRUGINFO	D0IZ9O	4-dehydroxyriccardin C	Investigative
T13714	DRUGINFO	D0PL4F	GW-3965	Investigative
T13714	DRUGINFO	D0Q2RP	24(S), 25-epoxycholesterol	Investigative
T13714	DRUGINFO	D0R8LN	N-{4-[2-(3-Methoxyphenyl)ethyl]phenyl}phthalimide	Investigative
T13714	DRUGINFO	D0Z3TJ	GSK2033	Investigative
T13714	DRUGINFO	D0Z8LE	17-dehydroxyriccardin C	Investigative
T13714	DRUGINFO	D0Z8RH	2-Benzyl-3-phenyl-7-(trifluoromethyl)-2H-indazole	Investigative
T13714	DRUGINFO	D01RNA	desmosterol	Investigative
T13714	DRUGINFO	D0H2YM	27-hydroxycholesterol	Investigative
T13714	DRUGINFO	D0K4GK	22R-hydroxycholesterol	Investigative
T13714	DRUGINFO	D08QXD	L-783483	Investigative
T13714	DRUGINFO	D0V4RZ	WAY-214950	Investigative
T13714	DRUGINFO	D0W7LK	2-Propanol, Isopropanol	Investigative

T93903	TARGETID	T93903
T93903	FORMERID	TTDR01006
T93903	UNIPROID	CASP9_HUMAN
T93903	TARGNAME	Caspase-9 (CASP9)
T93903	GENENAME	CASP9
T93903	TARGTYPE	Clinical trial
T93903	SYNONYMS	MCH6; ICE-like apoptotic protease 6; ICE-LAP6; CASP-9; Apoptotic protease-activating factor 3; Apoptotic protease activating factor 3; Apoptotic protease Mch-6; APAF-3
T93903	FUNCTION	Binding of caspase-9 to Apaf-1 leads to activation of the protease which then cleaves and activates caspase-3. Promotes DNA damage-induced apoptosis in a ABL1/c-Abl-dependent manner. Proteolytically cleaves poly(ADP-ribose) polymerase (PARP). Involved in the activation cascade of caspases responsible for apoptosis execution.
T93903	PDBSTRUC	5WVE; 5WVC; 5JUY; 4RHW; 3YGS
T93903	BIOCLASS	Peptidase
T93903	ECNUMBER	EC 3.4.22.62
T93903	SEQUENCE	MDEADRRLLRRCRLRLVEELQVDQLWDALLSRELFRPHMIEDIQRAGSGSRRDQARQLIIDLETRGSQALPLFISCLEDTGQDMLASFLRTNRQAAKLSKPTLENLTPVVLRPEIRKPEVLRPETPRPVDIGSGGFGDVGALESLRGNADLAYILSMEPCGHCLIINNVNFCRESGLRTRTGSNIDCEKLRRRFSSLHFMVEVKGDLTAKKMVLALLELAQQDHGALDCCVVVILSHGCQASHLQFPGAVYGTDGCPVSVEKIVNIFNGTSCPSLGGKPKLFFIQACGGEQKDHGFEVASTSPEDESPGSNPEPDATPFQEGLRTFDQLDAISSLPTPSDIFVSYSTFPGFVSWRDPKSGSWYVETLDDIFEQWAHSEDLQSLLLRVANAVSVKGIYKQMPGCFNFLRKKLFFKTS
T93903	DRUGINFO	D0J3SU	isatin sulfonamide 34	Clinical trial
T93903	DRUGINFO	D08BFI	Z-LEHD-fmk	Investigative
T93903	DRUGINFO	D0U1DU	NVX-207	Investigative
T93903	DRUGINFO	D0Y2TI	Glionitrin A	Investigative

T17140	TARGETID	T17140
T17140	FORMERID	TTDR00278
T17140	UNIPROID	P2RX3_HUMAN
T17140	TARGNAME	P2X purinoceptor 3 (P2RX3)
T17140	GENENAME	P2RX3
T17140	TARGTYPE	Clinical trial
T17140	SYNONYMS	P2X3 receptor; P2X3; P2RX3; ATP-gated ion channel P2X(3)
T17140	FUNCTION	Receptor for ATP that acts as a ligand-gated ionchannel.
T17140	PDBSTRUC	5YVE; 5SVT; 5SVS; 5SVR; 5SVQ
T17140	BIOCLASS	ATP-gated P2X receptor cation channel
T17140	SEQUENCE	MNCISDFFTYETTKSVVVKSWTIGIINRVVQLLIISYFVGWVFLHEKAYQVRDTAIESSVVTKVKGSGLYANRVMDVSDYVTPPQGTSVFVIITKMIVTENQMQGFCPESEEKYRCVSDSQCGPERLPGGGILTGRCVNYSSVLRTCEIQGWCPTEVDTVETPIMMEAENFTIFIKNSIRFPLFNFEKGNLLPNLTARDMKTCRFHPDKDPFCPILRVGDVVKFAGQDFAKLARTGGVLGIKIGWVCDLDKAWDQCIPKYSFTRLDSVSEKSSVSPGYNFRFAKYYKMENGSEYRTLLKAFGIRFDVLVYGNAGKFNIIPTIISSVAAFTSVGVGTVLCDIILLNFLKGADQYKAKKFEEVNETTLKIAALTNPVYPSDQTTAEKQSTDSGAFSIGH
T17140	DRUGINFO	D0PL3N	Gefapixant	Phase 3
T17140	DRUGINFO	D01VRQ	BAY-1902607	Phase 2
T17140	DRUGINFO	D3X1TS	BAY 1902607	Phase 1/2
T17140	DRUGINFO	D0K4RU	AF-130	Phase 1
T17140	DRUGINFO	D0NF1D	BAY-1817080	Phase 1
T17140	DRUGINFO	DF0PI8	BAY 1817080	Phase 1
T17140	DRUGINFO	D02RXA	LVAYPWT	Investigative
T17140	DRUGINFO	D04TGU	MK-3901	Investigative
T17140	DRUGINFO	D05RRF	Cyclic LVVYPWT	Investigative
T17140	DRUGINFO	D0B1KT	AF353	Investigative
T17140	DRUGINFO	D0G8NI	RO3	Investigative
T17140	DRUGINFO	D0M8HU	LAVYPWT	Investigative
T17140	DRUGINFO	D0TR4N	LVVAPWT	Investigative
T17140	DRUGINFO	D0Z0QD	LVVYPWT	Investigative
T17140	DRUGINFO	D0Z1DQ	[3H]A317491	Investigative
T17140	DRUGINFO	D0Z6UE	AVVYPWT	Investigative
T17140	DRUGINFO	D01VVM	TNP-ATP	Investigative
T17140	DRUGINFO	D05BFC	ISOPPADS	Investigative
T17140	DRUGINFO	D06HDW	BzATP	Investigative

T79031	TARGETID	T79031
T79031	UNIPROID	BACE1_HUMAN
T79031	TARGNAME	Beta-secretase 1 (BACE1)
T79031	GENENAME	BACE1
T79031	TARGTYPE	Clinical trial
T79031	SYNONYMS	Membrane-associated aspartic protease 2; Memapsin-2; KIAA1149; Beta-site amyloid precursor protein cleaving enzyme 1; Beta-site APP cleaving enzyme 1; BACE; Aspartyl protease 2; Asp 2; ASP2
T79031	FUNCTION	Cleaves at the N-terminus of the A-beta peptide sequence, between residues 671 and 672 of APP, leads to the generation and extracellular release of beta-cleaved soluble APP, and a corresponding cell-associated C-terminal fragment which is later released by gamma-secretase. Cleaves APP with much more catalytic efficiency than for the wild-type. Responsible for the proteolytic processing of the amyloid precursor protein (APP).
T79031	PDBSTRUC	6FGY; 6EQM; 6EJ3; 6EJ2; 6DMI
T79031	BIOCLASS	Peptidase
T79031	ECNUMBER	EC 3.4.23.46
T79031	SEQUENCE	MAQALPWLLLWMGAGVLPAHGTQHGIRLPLRSGLGGAPLGLRLPRETDEEPEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDESTLMTIAYVMAAICALFMLPLCLMVCQWRCLRCLRQQHDDFADDISLLK
T79031	DRUGINFO	D08MHD	E-2609	Phase 3
T79031	DRUGINFO	D0R4KK	verubecestat	Phase 3
T79031	DRUGINFO	D0H4YD	AMG520	Phase 2/3

T40491	TARGETID	T40491
T40491	FORMERID	TTDI00641
T40491	UNIPROID	PP2AA_HUMAN
T40491	TARGNAME	Serine/threonine PP2A-alpha (PPP2CA)
T40491	GENENAME	PPP2CA
T40491	TARGTYPE	Clinical trial
T40491	SYNONYMS	Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform; Replication protein C; RP-C; PP2A-alpha
T40491	FUNCTION	PP2A can modulate the activity of phosphorylase B kinase casein kinase 2, mitogen-stimulated S6 kinase, and MAP-2 kinase. Cooperates with SGO2 to protect centromeric cohesin from separase-mediated cleavage in oocytes specifically during meiosis I. Can dephosphorylate SV40 large T antigen and p53/TP53. Activates RAF1 by dephosphorylating it at 'Ser-259'. PP2A is the major phosphatase for microtubule-associated proteins (MAPs).
T40491	PDBSTRUC	5W0W; 4LAC; 4IYP; 4I5N; 4I5L
T40491	BIOCLASS	Phosphoric monoester hydrolase
T40491	ECNUMBER	EC 3.1.3.16
T40491	SEQUENCE	MDEKVFTKELDQWIEQLNECKQLSESQVKSLCEKAKEILTKESNVQEVRCPVTVCGDVHGQFHDLMELFRIGGKSPDTNYLFMGDYVDRGYYSVETVTLLVALKVRYRERITILRGNHESRQITQVYGFYDECLRKYGNANVWKYFTDLFDYLPLTALVDGQIFCLHGGLSPSIDTLDHIRALDRLQEVPHEGPMCDLLWSDPDDRGGWGISPRGAGYTFGQDISETFNHANGLTLVSRAHQLVMEGYNWCHDRNVVTIFSAPNYCYRCGNQAAIMELDDTLKYSFLQFDPAPRRGEPHVTRRTPDYFL
T40491	DRUGINFO	D01HZQ	VP-102	Phase 3
T40491	DRUGINFO	D02RNR	LB-100	Phase 2

T02228	TARGETID	T02228
T02228	FORMERID	TTDS00084
T02228	UNIPROID	PARC_STRPN
T02228	TARGNAME	Streptococcus Topoisomerase IV A (Stre-coc parC)
T02228	GENENAME	Stre-coc parC
T02228	TARGTYPE	Clinical trial
T02228	SYNONYMS	parC of Streptococcus pneumoniae serotype 4; DNA topoisomerase IV of Streptococcus pneumoniae serotype 4
T02228	FUNCTION	Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
T02228	PDBSTRUC	4Z53; 4Z4Q; 4Z3O; 4KPF; 4KPE
T02228	BIOCLASS	Topoisomerase GyrA ParC
T02228	ECNUMBER	EC 5.6.2.3
T02228	SEQUENCE	MSNIQNMSLEDIMGERFGRYSKYIIQDRALPDIRDGLKPVQRRILYSMNKDSNTFDKSYRKSAKSVGNIMGNFHPHGDSSIYDAMVRMSQNWKNREILVEMHGNNGSMDGDPPAAMRYTEARLSEIAGYLLQDIEKKTVPFAWNFDDTEKEPTVLPAAFPNLLVNGSTGISAGYATDIPPHNLAEVIDAAVYMIDHPTAKIDKLMEFLPGPDFPTGAIIQGRDEIKKAYETGKGRVVVRSKTEIEKLKGGKEQIVIIEIPYEINKANLVKKIDDVRVNNKVAGIAEVRDESDRDGLRIAIELKKDANTELVLNYLFKYTDLQINYNFNMVAIDNFTPRQVGIVPILSSYIAHRREVILARSRFDKEKAEKRLHIVEGLIRVISILDEVIALIRASENKADAKENLKVSYDFTEEQAEAIVTLQLYRLTNTDVVVLQEEEAELREKIAMLAAIIGDERTMYNLMKKELREVKKKFATPRLSSLEDTAKAIEIDTASLIAEEDTYVSVTKAGYIKRTSPRSFAASTLEEIGKRDDDRLIFVQSAKTTQHLLMFTSLGNVIYRPIHELADIRWKDIGEHLSQTITNFETNEEILYVEVLDQFDDATTYFAVTRLGQIKRVERKEFTPWRTYRSKSVKYAKLKDDTDQIVAVAPIKLDDVVLVSQNGYALRFNIEEVPVVGAKAAGVKAMNLKEDDVLQSGFICNTSSFYLLTQRGSLKRVSIEEILATSRAKRGLQVLRELKNKPHRVFLAGAVAEQGFVGDFFSTEVDVNDQTLLVQSNKGTIYESRLQDLNLSERTSNGSFISDTISDEEVFDAYLQEVVTEDK
T02228	DRUGINFO	D07DTM	Cetraxal Otic	Phase 3
T02228	DRUGINFO	D0PC5N	Premafloxacin	Investigative
T02228	DRUGINFO	D0V6EY	Pumiliotoxin 251D	Investigative

T04507	TARGETID	T04507
T04507	FORMERID	TTDR00806
T04507	UNIPROID	DLG4_HUMAN
T04507	TARGNAME	Presynaptic density protein 95 (DLG4)
T04507	GENENAME	DLG4
T04507	TARGTYPE	Clinical trial
T04507	SYNONYMS	Synapse-associated protein 90; SAP90; SAP-90; Postsynaptic density-95; Postsynaptic density protein 95; PSD95; PSD-95; Disks large homolog 4; Discs, large homolog 4
T04507	FUNCTION	Required for synaptic plasticity associated with NMDA receptor signaling. Overexpression or depletion of DLG4 changes the ratio of excitatory to inhibitory synapses in hippocampal neurons. May reduce the amplitude of ASIC3 acid-evoked currents by retaining the channel intracellularly. May regulate the intracellular trafficking of ADR1B. Also regulates AMPA-type glutamate receptor (AMPAR) immobilization at postsynaptic density keeping the channels in an activated state in the presence of glutamate and preventing synaptic depression. Interacts with the cytoplasmic tail of NMDA receptor subunits and shaker-type potassium channels.
T04507	PDBSTRUC	6QJN; 6QJL; 6QJK; 6QJJ; 6QJI
T04507	BIOCLASS	Ezrin/radixin/moesin-binding phosphoprotein 50
T04507	SEQUENCE	MDCLCIVTTKKYRYQDEDTPPLEHSPAHLPNQANSPPVIVNTDTLEAPGYELQVNGTEGEMEYEEITLERGNSGLGFSIAGGTDNPHIGDDPSIFITKIIPGGAAAQDGRLRVNDSILFVNEVDVREVTHSAAVEALKEAGSIVRLYVMRRKPPAEKVMEIKLIKGPKGLGFSIAGGVGNQHIPGDNSIYVTKIIEGGAAHKDGRLQIGDKILAVNSVGLEDVMHEDAVAALKNTYDVVYLKVAKPSNAYLSDSYAPPDITTSYSQHLDNEISHSSYLGTDYPTAMTPTSPRRYSPVAKDLLGEEDIPREPRRIVIHRGSTGLGFNIVGGEDGEGIFISFILAGGPADLSGELRKGDQILSVNGVDLRNASHEQAAIALKNAGQTVTIIAQYKPEEYSRFEAKIHDLREQLMNSSLGSGTASLRSNPKRGFYIRALFDYDKTKDCGFLSQALSFRFGDVLHVIDASDEEWWQARRVHSDSETDDIGFIPSKRRVERREWSRLKAKDWGSSSGSQGREDSVLSYETVTQMEVHYARPIIILGPTKDRANDDLLSEFPDKFGSCVPHTTRPKREYEIDGRDYHFVSSREKMEKDIQAHKFIEAGQYNSHLYGTSVQSVREVAEQGKHCILDVSANAVRRLQAAHLHPIAIFIRPRSLENVLEINKRITEEQARKAFDRATKLEQEFTECFSAIVEGDSFEEIYHKVKRVIEDLSGPYIWVPARERL
T04507	DRUGINFO	D01JLO	Tat-NR2B9c	Phase 3
T04507	DRUGINFO	D00SOE	KSG-YEKLSSIESDV	Investigative
T04507	DRUGINFO	D00YVJ	N-(3,4-Difluorophenyl)propyl-ETAV	Investigative
T04507	DRUGINFO	D03HYZ	N-Propyl-ETAV	Investigative
T04507	DRUGINFO	D03LMH	N-Phenylethyl-ETAV	Investigative
T04507	DRUGINFO	D04HQL	N-Cyclohexylmethyl-ETAV	Investigative
T04507	DRUGINFO	D06DWW	FETAV	Investigative
T04507	DRUGINFO	D07FJR	N-Butyl-ETAV	Investigative
T04507	DRUGINFO	D08DUM	N-Methyl-ETAV	Investigative
T04507	DRUGINFO	D08FDY	YGRKKRRQRRR-KLSSIESDV	Investigative
T04507	DRUGINFO	D09QIC	N-Phenylpropyl-ETAV	Investigative
T04507	DRUGINFO	D09WVP	N-Benzyl-ETAV	Investigative
T04507	DRUGINFO	D0EV3O	N-Ethyl-ETAV	Investigative
T04507	DRUGINFO	D0H4NR	N-(3,4-Dichlorophenyl)propyl-ETAV	Investigative
T04507	DRUGINFO	D0SU5M	N-Cyclohexylethyl-ETAV	Investigative
T04507	DRUGINFO	D0T2HN	N-(Naphthalene-2-yl)ethyl-ETAV	Investigative
T04507	DRUGINFO	D0UJ6V	KSG-LDTKNYKQTSV	Investigative
T04507	DRUGINFO	D04AWP	Guanosine-5'-Monophosphate	Investigative
T04507	DRUGINFO	D06GOK	2-Methyl-2,4-Pentanediol	Investigative

T36806	TARGETID	T36806
T36806	FORMERID	TTDR00732
T36806	UNIPROID	ARGI2_HUMAN
T36806	TARGNAME	Kidney-type arginase (ARG2)
T36806	GENENAME	ARG2
T36806	TARGTYPE	Clinical trial
T36806	SYNONYMS	Non-hepatic arginase; Human penile arginase; Arginase II; ARG2
T36806	FUNCTION	May play a role in the regulation of extra-urea cycle arginine metabolism and also in down-regulation of nitric oxide synthesis. Extrahepatic arginase functions to regulate L-arginine bioavailability to NO synthase. Since NO synthase is found in the penile corpus cavernosum smooth muscle, the clitoral corpus cavernosum and the vagina, arginase II plays a role in both male and female sexual arousal. It is therefore a potential target for the treatment of male and female sexual arousal disorders.
T36806	PDBSTRUC	4IXV; 4IXU; 4IE3; 4IE2; 4I06
T36806	BIOCLASS	Carbon-nitrogen hydrolase
T36806	ECNUMBER	EC 3.5.3.1
T36806	SEQUENCE	MSLRGSLSRLLQTRVHSILKKSVHSVAVIGAPFSQGQKRKGVEHGPAAIREAGLMKRLSSLGCHLKDFGDLSFTPVPKDDLYNNLIVNPRSVGLANQELAEVVSRAVSDGYSCVTLGGDHSLAIGTISGHARHCPDLCVVWVDAHADINTPLTTSSGNLHGQPVSFLLRELQDKVPQLPGFSWIKPCISSASIVYIGLRDVDPPEHFILKNYDIQYFSMRDIDRLGIQKVMERTFDLLIGKRQRPIHLSFDIDAFDPTLAPATGTPVVGGLTYREGMYIAEEIHNTGLLSALDLVEVNPQLATSEEEAKTTANLAVDVIASSFGQTREGGHIVYDQLPTPSSPDESENQARVRI
T36806	DRUGINFO	D09ZIC	N-hydroxy-nor-L-arginine	Investigative
T36806	DRUGINFO	D0A8ZM	S-(2-boronoethyl)-L-cysteine	Investigative

T22995	TARGETID	T22995
T22995	FORMERID	TTDI02090
T22995	UNIPROID	HEPC_HUMAN
T22995	TARGNAME	Hepcidin (HAMP)
T22995	GENENAME	HAMP
T22995	TARGTYPE	Clinical trial
T22995	SYNONYMS	Putative liver tumor regressor; PLTR; Liverexpressed antimicrobial peptide 1; LEAP1; Hepcidin20; Hepc25; Hepc20; HAMP
T22995	FUNCTION	Has strong antimicrobial activity against E.coli ML35P N.cinereaand weaker against S.epidermidis, S.aureus and group b streptococcus bacteria. Active against the fungus C.albicans. No activity against P.aeruginosa (PubMed:11113131, PubMed:11034317).
T22995	PDBSTRUC	4QAE; 3H0T; 2KEF; 1M4F; 1M4E
T22995	BIOCLASS	Hepcidin family
T22995	SEQUENCE	MALSSQIWAACLLLLLLLASLTSGSVFPQQTGQLAELQPQDRAGARASWMPMFQRRRRRDTHFPICIFCCGCCHRSKCGMCCKT
T22995	DRUGINFO	D02CAF	NOX-H94	Phase 2
T22995	DRUGINFO	DQ3AM0	PTG-300	Phase 2
T22995	DRUGINFO	DXM30Y	LJPC-401	Phase 2
T22995	DRUGINFO	D0V4YW	Hepcidin mab	Phase 1
T22995	DRUGINFO	DAOT46	LY2787106	Phase 1
T22995	DRUGINFO	DY7IP9	12B9m	Preclinical

T16769	TARGETID	T16769
T16769	FORMERID	TTDI02333
T16769	UNIPROID	XIAP_HUMAN
T16769	TARGNAME	X-linked inhibitor of apoptosis protein (XIAP)
T16769	GENENAME	XIAP
T16769	TARGTYPE	Clinical trial
T16769	SYNONYMS	hILP; hIAP3; hIAP-3; Xlinked IAP; X-linked IAP; RING-type E3 ubiquitin transferase XIAP; Inhibitor of apoptosis protein 3; ILP; IAPlike protein; IAP3; IAP-like protein; IAP-3; E3 ubiquitinprotein ligase XIAP; E3 ubiquitin-protein ligase XIAP; Baculoviral IAP repeatcontaining protein 4; Baculoviral IAP repeat-containing protein 4; BIRC4; API3
T16769	FUNCTION	Acts as a direct caspase inhibitor. Directly bind to the active site pocket of CASP3 and CASP7 and obstructs substrate entry. Inactivates CASP9 by keeping it in a monomeric, inactive state. Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and the target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, CASP3, CASP7, CASP8, CASP9, MAP3K2/MEKK2, DIABLO/SMAC, AIFM1, CCS and BIRC5/survivin. Ubiquitinion of CCS leads to enhancement of its chaperone activity toward its physiologic target, SOD1, rather than proteasomal degradation. Ubiquitinion of MAP3K2/MEKK2 and AIFM1 does not lead to proteasomal degradation. Plays a role in copper homeostasis by ubiquitinationg COMMD1 and promoting its proteasomal degradation. Can also function as E3 ubiquitin-protein ligase of the NEDD8 conjugation pathway, targeting effector caspases for neddylation and inactivation. Regulates the BMP signaling pathway and the SMAD and MAP3K7/TAK1 dependent pathways leading to NF-kappa-B and JNK activation. Acts as an important regulator of innate immune signaling via regulation of Nodlike receptors (NLRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8. Acts as a positive regulator of Wnt signaling and ubiquitinates TLE1, TLE2, TLE3, TLE4 and AES. Ubiquitination of TLE3 results in inhibition of its interaction with TCF7L2/TCF4 thereby allowing efficient recruitment and binding of the transcriptional coactivator beta-catenin to TCF7L2/TCF4 that is required to initiate a Wnt-specific transcriptional program. Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, copper homeostasis, mitogenic kinase signaling, cell proliferation, as well as cell invasion and metastasis.
T16769	PDBSTRUC	6QCI; 6EY2; 5OQW; 5O6T; 5M6M
T16769	BIOCLASS	Acyltransferase
T16769	ECNUMBER	EC 2.3.2.27
T16769	SEQUENCE	MTFNSFEGSKTCVPADINKEEEFVEEFNRLKTFANFPSGSPVSASTLARAGFLYTGEGDTVRCFSCHAAVDRWQYGDSAVGRHRKVSPNCRFINGFYLENSATQSTNSGIQNGQYKVENYLGSRDHFALDRPSETHADYLLRTGQVVDISDTIYPRNPAMYSEEARLKSFQNWPDYAHLTPRELASAGLYYTGIGDQVQCFCCGGKLKNWEPCDRAWSEHRRHFPNCFFVLGRNLNIRSESDAVSSDRNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKCFHCGGGLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVRTTEKTPSLTRRIDDTIFQNPMVQEAIRMGFSFKDIKKIMEEKIQISGSNYKSLEVLVADLVNAQKDSMQDESSQTSLQKEISTEEQLRRLQEEKLCKICMDRNIAIVFVPCGHLVTCKQCAEAVDKCPMCYTVITFKQKIFMS
T16769	DRUGINFO	D03MXK	AT-406	Phase 3
T16769	DRUGINFO	D0E8NP	Birinapant	Phase 2
T16769	DRUGINFO	D03YOS	Phenoxodiol	Phase 1/2
T16769	DRUGINFO	D02AMG	HGS-1029	Phase 1
T16769	DRUGINFO	D07CLV	GDC-0152	Phase 1
T16769	DRUGINFO	D0NP8P	APG-1387	Phase 1
T16769	DRUGINFO	D00VXV	PMID25980951-Compound-40	Patented
T16769	DRUGINFO	D01JEH	PMID25980951-Compound-29	Patented
T16769	DRUGINFO	D03JHD	PMID25980951-Compound-15	Patented
T16769	DRUGINFO	D03TQU	PMID25980951-Compound-31	Patented
T16769	DRUGINFO	D08UPQ	PMID25980951-Compound-30	Patented
T16769	DRUGINFO	D0EZ9G	PMID25980951-Compound-14	Patented
T16769	DRUGINFO	D0G9CR	PMID25980951-Compound-39	Patented
T16769	DRUGINFO	D0K2PK	PMID25980951-Compound-33	Patented
T16769	DRUGINFO	D0NB0V	PMID25980951-Compound-28	Patented
T16769	DRUGINFO	D0P9PZ	PMID25980951-Compound-10	Patented
T16769	DRUGINFO	D0PF7S	PMID25980951-Compound-11	Patented
T16769	DRUGINFO	D0Q1XF	PMID25980951-Compound-32	Patented
T16769	DRUGINFO	D0S0XT	PMID25980951-Compound-26	Patented
T16769	DRUGINFO	D0U5TX	PMID25980951-Compound-13	Patented
T16769	DRUGINFO	D0UT1G	PMID25980951-Compound-12	Patented
T16769	DRUGINFO	D0UU7G	PMID25980951-Compound-45	Patented
T16769	DRUGINFO	D02UOD	PMID25980951-Compound-3	Patented
T16769	DRUGINFO	D02ZHC	PMID25980951-Compound-4	Patented
T16769	DRUGINFO	D03DQW	PMID25980951-Compound-21	Patented
T16769	DRUGINFO	D03PTG	PMID25980951-Compound-42	Patented
T16769	DRUGINFO	D03VPP	PMID25980951-Compound-22	Patented
T16769	DRUGINFO	D07FRU	PMID25980951-Compound-37	Patented
T16769	DRUGINFO	D0AC8H	PMID25980951-Compound-36	Patented
T16769	DRUGINFO	D0CV9K	PMID25980951-Compound-20	Patented
T16769	DRUGINFO	D0GF3P	PMID25980951-Compound-38	Patented
T16769	DRUGINFO	D0ID3R	PMID25980951-Compound-5	Patented
T16769	DRUGINFO	D0M3BY	PMID25980951-Compound-41	Patented
T16769	DRUGINFO	D0MH4B	PMID25980951-Compound-19	Patented
T16769	DRUGINFO	D0O8ZD	PMID25980951-Compound-7	Patented
T16769	DRUGINFO	D09VAX	PMID25980951-Compound-6	Patented
T16769	DRUGINFO	D0B6KC	PMID25980951-Compound-27	Patented
T16769	DRUGINFO	D0HY5Q	PMID25980951-Compound-43	Patented
T16769	DRUGINFO	D0R3YM	PMID25980951-Compound-1	Patented
T16769	DRUGINFO	D0YN1X	PMID25980951-Compound-44	Patented

T24793	TARGETID	T24793
T24793	FORMERID	TTDR00620
T24793	UNIPROID	CAC1D_HUMAN
T24793	TARGNAME	Voltage-gated calcium channel alpha Cav1.3 (CACNA1D)
T24793	GENENAME	CACNA1D
T24793	TARGTYPE	Clinical trial
T24793	SYNONYMS	Voltage-gated calcium channel alpha subunit Cav1.3; Voltage-gated L-type Ca2+ channel alpha1D; Calcium channel, L type, alpha-1 polypeptide, isoform 2; CACNA1D
T24793	FUNCTION	Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group. They are blocked by dihydropyridines (DHP), phenylalkylamines, benzothiazepines, and by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to omega-conotoxin- GVIA (omega-CTx-GVIA) and omega-agatoxin-IVA (omega-Aga-IVA).
T24793	PDBSTRUC	3LV3
T24793	BIOCLASS	Voltage-gated ion channel
T24793	SEQUENCE	MMMMMMMKKMQHQRQQQADHANEANYARGTRLPLSGEGPTSQPNSSKQTVLSWQAAIDAARQAKAAQTMSTSAPPPVGSLSQRKRQQYAKSKKQGNSSNSRPARALFCLSLNNPIRRACISIVEWKPFDIFILLAIFANCVALAIYIPFPEDDSNSTNHNLEKVEYAFLIIFTVETFLKIIAYGLLLHPNAYVRNGWNLLDFVIVIVGLFSVILEQLTKETEGGNHSSGKSGGFDVKALRAFRVLRPLRLVSGVPSLQVVLNSIIKAMVPLLHIALLVLFVIIIYAIIGLELFIGKMHKTCFFADSDIVAEEDPAPCAFSGNGRQCTANGTECRSGWVGPNGGITNFDNFAFAMLTVFQCITMEGWTDVLYWMNDAMGFELPWVYFVSLVIFGSFFVLNLVLGVLSGEFSKEREKAKARGDFQKLREKQQLEEDLKGYLDWITQAEDIDPENEEEGGEEGKRNTSMPTSETESVNTENVSGEGENRGCCGSLCQAISKSKLSRRWRRWNRFNRRRCRAAVKSVTFYWLVIVLVFLNTLTISSEHYNQPDWLTQIQDIANKVLLALFTCEMLVKMYSLGLQAYFVSLFNRFDCFVVCGGITETILVELEIMSPLGISVFRCVRLLRIFKVTRHWTSLSNLVASLLNSMKSIASLLLLLFLFIIIFSLLGMQLFGGKFNFDETQTKRSTFDNFPQALLTVFQILTGEDWNAVMYDGIMAYGGPSSSGMIVCIYFIILFICGNYILLNVFLAIAVDNLADAESLNTAQKEEAEEKERKKIARKESLENKKNNKPEVNQIANSDNKVTIDDYREEDEDKDPYPPCDVPVGEEEEEEEEDEPEVPAGPRPRRISELNMKEKIAPIPEGSAFFILSKTNPIRVGCHKLINHHIFTNLILVFIMLSSAALAAEDPIRSHSFRNTILGYFDYAFTAIFTVEILLKMTTFGAFLHKGAFCRNYFNLLDMLVVGVSLVSFGIQSSAISVVKILRVLRVLRPLRAINRAKGLKHVVQCVFVAIRTIGNIMIVTTLLQFMFACIGVQLFKGKFYRCTDEAKSNPEECRGLFILYKDGDVDSPVVRERIWQNSDFNFDNVLSAMMALFTVSTFEGWPALLYKAIDSNGENIGPIYNHRVEISIFFIIYIIIVAFFMMNIFVGFVIVTFQEQGEKEYKNCELDKNQRQCVEYALKARPLRRYIPKNPYQYKFWYVVNSSPFEYMMFVLIMLNTLCLAMQHYEQSKMFNDAMDILNMVFTGVFTVEMVLKVIAFKPKGYFSDAWNTFDSLIVIGSIIDVALSEADPTESENVPVPTATPGNSEESNRISITFFRLFRVMRLVKLLSRGEGIRTLLWTFIKSFQALPYVALLIAMLFFIYAVIGMQMFGKVAMRDNNQINRNNNFQTFPQAVLLLFRCATGEAWQEIMLACLPGKLCDPESDYNPGEEYTCGSNFAIVYFISFYMLCAFLIINLFVAVIMDNFDYLTRDWSILGPHHLDEFKRIWSEYDPEAKGRIKHLDVVTLLRRIQPPLGFGKLCPHRVACKRLVAMNMPLNSDGTVMFNATLFALVRTALKIKTEGNLEQANEELRAVIKKIWKKTSMKLLDQVVPPAGDDEVTVGKFYATFLIQDYFRKFKKRKEQGLVGKYPAKNTTIALQAGLRTLHDIGPEIRRAISCDLQDDEPEETKREEEDDVFKRNGALLGNHVNHVNSDRRDSLQQTNTTHRPLHVQRPSIPPASDTEKPLFPPAGNSVCHNHHNHNSIGKQVPTSTNANLNNANMSKAAHGKRPSIGNLEHVSENGHHSSHKHDREPQRRSSVKRTRYYETYIRSDSGDEQLPTICREDPEIHGYFRDPHCLGEQEYFSSEECYEDDSSPTWSRQNYGYYSRYPGRNIDSERPRGYHHPQGFLEDDDSPVCYDSRRSPRRRLLPPTPASHRRSSFNFECLRRQSSQEEVPSSPIFPHRTALPLHLMQQQIMAVAGLDSSKAQKYSPSHSTRSWATPPATPPYRDWTPCYTPLIQVEQSEALDQVNGSLPSLHRSSWYTDEPDISYRTFTPASLTVPSSFRNKNSDKQRSADSLVEAVLISEGLGRYARDPKFVSATKHEIADACDLTIDEMESAASTLLNGNVRPRANGDVGPLSHRQDYELQDFGPGYSDEEPDPGRDEEDLADEMICITTL
T24793	DRUGINFO	D06GRK	ARC029	Phase 3
T24793	DRUGINFO	D0EC2K	SIPATRIGINE	Discontinued in Phase 2
T24793	DRUGINFO	D00JMZ	CGS-27830	Terminated
T24793	DRUGINFO	D0QQ7N	TH-9229	Terminated
T24793	DRUGINFO	D06HRY	SNAP-5089	Terminated
T24793	DRUGINFO	D07FEO	N,N'-Di-acenaphthen-5-yl-guanidine	Investigative
T24793	DRUGINFO	D0D6PC	azidopine	Investigative
T24793	DRUGINFO	D04UDT	MEBUDIPINE	Investigative
T24793	DRUGINFO	D0I9VY	CV-4093	Investigative
T24793	DRUGINFO	D0S3YP	[3H](+)-isradipine	Investigative
T24793	DRUGINFO	D02RIH	(-)-(S)-BayK8644	Investigative
T24793	DRUGINFO	D09YTH	CPU-228	Investigative
T24793	DRUGINFO	D08RJC	PD-32577	Investigative

T91435	TARGETID	T91435
T91435	UNIPROID	ROR2_HUMAN
T91435	TARGNAME	Neurotrophic tyrosine kinase ROR2 (ROR2)
T91435	GENENAME	ROR2
T91435	TARGTYPE	Clinical trial
T91435	SYNONYMS	receptor tyrosine kinase like orphan receptor 2; neurotrophic tyrosine kinase, receptor-related 2; Tyrosine-protein kinase transmembrane receptor ROR2; NTRKR2; BDB1; BDB
T91435	FUNCTION	It seems to be required for cartilage and growth plate development. Phosphorylates YWHAB, leading to induction of osteogenesis and bone formation. In contrast, has also been shown to have very little tyrosine kinase activity in vitro. May act as a receptor for wnt ligand WNT5A which may result in the inhibition of WNT3A-mediated signaling. Tyrosine-protein kinase receptor which may be involved in the early formation of the chondrocytes.
T91435	PDBSTRUC	4GT4; 3ZZW
T91435	BIOCLASS	Kinase
T91435	ECNUMBER	EC 2.7.10.1
T91435	SEQUENCE	MARGSALPRRPLLCIPAVWAAAALLLSVSRTSGEVEVLDPNDPLGPLDGQDGPIPTLKGYFLNFLEPVNNITIVQGQTAILHCKVAGNPPPNVRWLKNDAPVVQEPRRIIIRKTEYGSRLRIQDLDTTDTGYYQCVATNGMKTITATGVLFVRLGPTHSPNHNFQDDYHEDGFCQPYRGIACARFIGNRTIYVDSLQMQGEIENRITAAFTMIGTSTHLSDQCSQFAIPSFCHFVFPLCDARSRTPKPRELCRDECEVLESDLCRQEYTIARSNPLILMRLQLPKCEALPMPESPDAANCMRIGIPAERLGRYHQCYNGSGMDYRGTASTTKSGHQCQPWALQHPHSHHLSSTDFPELGGGHAYCRNPGGQMEGPWCFTQNKNVRMELCDVPSCSPRDSSKMGILYILVPSIAIPLVIACLFFLVCMCRNKQKASASTPQRRQLMASPSQDMEMPLINQHKQAKLKEISLSAVRFMEELGEDRFGKVYKGHLFGPAPGEQTQAVAIKTLKDKAEGPLREEFRHEAMLRARLQHPNVVCLLGVVTKDQPLSMIFSYCSHGDLHEFLVMRSPHSDVGSTDDDRTVKSALEPPDFVHLVAQIAAGMEYLSSHHVVHKDLATRNVLVYDKLNVKISDLGLFREVYAADYYKLLGNSLLPIRWMAPEAIMYGKFSIDSDIWSYGVVLWEVFSYGLQPYCGYSNQDVVEMIRNRQVLPCPDDCPAWVYALMIECWNEFPSRRPRFKDIHSRLRAWGNLSNYNSSAQTSGASNTTQTSSLSTSPVSNVSNARYVGPKQKAPPFPQPQFIPMKGQIRPMVPPPQLYVPVNGYQPVPAYGAYLPNFYPVQIPMQMAPQQVPPQMVPKPSSHHSGSGSTSTGYVTTAPSNTSMADRAALLSEGADDTQNAPEDGAQSTVQEAEEEEEGSVPETELLGDCDTLQVDEAQVQLEA
T91435	DRUGINFO	D82BZH	Ozuriftamab vedotin	Phase 2
T91435	DRUGINFO	D0C2PH	CCT301-59 (targeting ROR2)	Phase 1/2
T91435	DRUGINFO	D0RA9C	CCT301-38 (targeting ROR2)	Phase 1/2

T61581	TARGETID	T61581
T61581	FORMERID	TTDS00424
T61581	UNIPROID	GCYB1_HUMAN
T61581	TARGNAME	Guanylate cyclase soluble beta-1 (GUCY1B1)
T61581	GENENAME	GUCY1B1
T61581	TARGTYPE	Clinical trial
T61581	SYNONYMS	Soluble guanylate cyclase small subunit; Guanylate cyclase soluble subunit beta-3; Guanylate cyclase soluble subunit beta-1; GUCY1B3; GUCSB3; GUC1B3; GCS-beta-3; GCS-beta-1
T61581	FUNCTION	Mediates responses to nitric oxide (NO) by catalyzing the biosynthesis of the signaling molecule cGMP.
T61581	PDBSTRUC	5MNW; 4NI2; 3UVJ; 2WZ1
T61581	BIOCLASS	Phosphorus-oxygen lyase
T61581	ECNUMBER	EC 4.6.1.2
T61581	SEQUENCE	MYGFVNHALELLVIRNYGPEVWEDIKKEAQLDEEGQFLVRIIYDDSKTYDLVAAASKVLNLNAGEILQMFGKMFFVFCQESGYDTILRVLGSNVREFLQNLDALHDHLATIYPGMRAPSFRCTDAEKGKGLILHYYSEREGLQDIVIGIIKTVAQQIHGTEIDMKVIQQRNEECDHTQFLIEEKESKEEDFYEDLDRFEENGTQESRISPYTFCKAFPFHIIFDRDLVVTQCGNAIYRVLPQLQPGNCSLLSVFSLVRPHIDISFHGILSHINTVFVLRSKEGLLDVEKLECEDELTGTEISCLRLKGQMIYLPEADSILFLCSPSVMNLDDLTRRGLYLSDIPLHDATRDLVLLGEQFREEYKLTQELEILTDRLQLTLRALEDEKKKTDTLLYSVLPPSVANELRHKRPVPAKRYDNVTILFSGIVGFNAFCSKHASGEGAMKIVNLLNDLYTRFDTLTDSRKNPFVYKVETVGDKYMTVSGLPEPCIHHARSICHLALDMMEIAGQVQVDGESVQITIGIHTGEVVTGVIGQRMPRYCLFGNTVNLTSRTETTGEKGKINVSEYTYRCLMSPENSDPQFHLEHRGPVSMKGKKEPMQVWFLSRKNTGTEETKQDDD
T61581	DRUGINFO	D08YVP	Vericigiuat	Phase 2
T61581	DRUGINFO	D0ZT0G	Cinaciguat	Phase 2
T61581	DRUGINFO	D00TLD	RIG-200	Discontinued in Phase 1

T22128	TARGETID	T22128
T22128	FORMERID	TTDI02320
T22128	UNIPROID	DCE2_HUMAN
T22128	TARGNAME	Glutamate decarboxylase 2 (GAD2)
T22128	GENENAME	GAD2
T22128	TARGTYPE	Clinical trial
T22128	SYNONYMS	Glutamate decarboxylase 65 kDa isoform; GAD65; GAD2; 65 kDa glutamic acid decarboxylase
T22128	FUNCTION	Catalyzes the production of GABA.
T22128	PDBSTRUC	2OKK; 1ES0
T22128	BIOCLASS	Carbon-carbon lyase
T22128	ECNUMBER	EC 4.1.1.15
T22128	SEQUENCE	MASPGSGFWSFGSEDGSGDSENPGTARAWCQVAQKFTGGIGNKLCALLYGDAEKPAESGGSQPPRAAARKAACACDQKPCSCSKVDVNYAFLHATDLLPACDGERPTLAFLQDVMNILLQYVVKSFDRSTKVIDFHYPNELLQEYNWELADQPQNLEEILMHCQTTLKYAIKTGHPRYFNQLSTGLDMVGLAADWLTSTANTNMFTYEIAPVFVLLEYVTLKKMREIIGWPGGSGDGIFSPGGAISNMYAMMIARFKMFPEVKEKGMAALPRLIAFTSEHSHFSLKKGAAALGIGTDSVILIKCDERGKMIPSDLERRILEAKQKGFVPFLVSATAGTTVYGAFDPLLAVADICKKYKIWMHVDAAWGGGLLMSRKHKWKLSGVERANSVTWNPHKMMGVPLQCSALLVREEGLMQNCNQMHASYLFQQDKHYDLSYDTGDKALQCGRHVDVFKLWLMWRAKGTTGFEAHVDKCLELAEYLYNIIKNREGYEMVFDGKPQHTNVCFWYIPPSLRTLEDNEERMSRLSKVAPVIKARMMEYGTTMVSYQPLGDKVNFFRMVISNPAATHQDIDFLIEEIERLGQDL
T22128	DRUGINFO	D01KNA	Diamyd	Phase 3
T22128	DRUGINFO	D09OTM	s-allylglycine	Investigative

T92458	TARGETID	T92458
T92458	FORMERID	TTDI02046
T92458	UNIPROID	CP24A_HUMAN
T92458	TARGNAME	Cytochrome P450 24 (CYP24A1)
T92458	GENENAME	CYP24A1
T92458	TARGTYPE	Clinical trial
T92458	SYNONYMS	Vitamin D(3) 24hydroxylase; Cytochrome P450CC24; CYP24A1; 24OHase; 1,25dihydroxyvitamin D(3) 24hydroxylase, mitochondrial
T92458	FUNCTION	Has a role in maintaining calcium homeostasis. Catalyzes the NADPH-dependent 24-hydroxylation of calcidiol (25- hydroxyvitamin D(3)) and calcitriol (1-alpha,25-dihydroxyvitamin D(3)). The enzyme can perform up to 6 rounds of hydroxylation of calcitriol leading to calcitroic acid. It also shows 23- hydroxylating activity leading to 1-alpha,25-dihydroxyvitamin D(3)-26,23-lactone as end product.
T92458	BIOCLASS	Paired donor oxygen oxidoreductase
T92458	ECNUMBER	EC 1.14.15.16
T92458	SEQUENCE	MSSPISKSRSLAAFLQQLRSPRQPPRLVTSTAYTSPQPREVPVCPLTAGGETQNAAALPGPTSWPLLGSLLQILWKGGLKKQHDTLVEYHKKYGKIFRMKLGSFESVHLGSPCLLEALYRTESAYPQRLEIKPWKAYRDYRKEGYGLLILEGEDWQRVRSAFQKKLMKPGEVMKLDNKINEVLADFMGRIDELCDERGHVEDLYSELNKWSFESICLVLYEKRFGLLQKNAGDEAVNFIMAIKTMMSTFGRMMVTPVELHKSLNTKVWQDHTLAWDTIFKSVKACIDNRLEKYSQQPSADFLCDIYHQNRLSKKELYAAVTELQLAAVETTANSLMWILYNLSRNPQVQQKLLKEIQSVLPENQVPRAEDLRNMPYLKACLKESMRLTPSVPFTTRTLDKATVLGEYALPKGTVLMLNTQVLGSSEDNFEDSSQFRPERWLQEKEKINPFAHLPFGVGKRMCIGRRLAELQLHLALCWIVRKYDIQATDNEPVEMLHSGTLVPSRELPIAFCQR
T92458	DRUGINFO	D00DYK	Lunacalcipol	Phase 2

T91761	TARGETID	T91761
T91761	FORMERID	TTDR00858
T91761	UNIPROID	ITK_HUMAN
T91761	TARGNAME	T-cell-specific kinase (ITK)
T91761	GENENAME	ITK
T91761	TARGTYPE	Clinical trial
T91761	SYNONYMS	Tyrosine kinase ITK; Inducible T cell kinase; EMT
T91761	FUNCTION	Regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells. When antigen presenting cells (APC) activate T-cell receptor (TCR), a series of phosphorylation lead to the recruitment of ITK to the cell membrane, in the vicinity of the stimulated TCR receptor, where it is phosphorylated by LCK. Phosphorylation leads to ITK autophosphorylation and full activation. Once activated, phosphorylates PLCG1, leading to the activation of this lipase and subsequent cleavage of its substrates. In turn, the endoplasmic reticulum releases calcium in the cytoplasm and the nuclear activator of activated T-cells (NFAT) translocates into the nucleus to perform its transcriptional duty. Phosphorylates 2 essential adapter proteins: the linker for activation of T-cells/LAT protein and LCP2. Then, a large number of signaling molecules such as VAV1 are recruited and ultimately lead to lymphokine production, T-cell proliferation and differentiation. Phosphorylates TBX21 at 'Tyr-530' and mediates its interaction with GATA3. Tyrosine kinase that plays an essential role in regulation of the adaptive immune response.
T91761	PDBSTRUC	4RFM; 4QD6; 4PQN; 4PPC; 4PPB
T91761	BIOCLASS	Kinase
T91761	ECNUMBER	EC 2.7.10.2
T91761	SEQUENCE	MNNFILLEEQLIKKSQQKRRTSPSNFKVRFFVLTKASLAYFEDRHGKKRTLKGSIELSRIKCVEIVKSDISIPCHYKYPFQVVHDNYLLYVFAPDRESRQRWVLALKEETRNNNSLVPKYHPNFWMDGKWRCCSQLEKLATGCAQYDPTKNASKKPLPPTPEDNRRPLWEPEETVVIALYDYQTNDPQELALRRNEEYCLLDSSEIHWWRVQDRNGHEGYVPSSYLVEKSPNNLETYEWYNKSISRDKAEKLLLDTGKEGAFMVRDSRTAGTYTVSVFTKAVVSENNPCIKHYHIKETNDNPKRYYVAEKYVFDSIPLLINYHQHNGGGLVTRLRYPVCFGRQKAPVTAGLRYGKWVIDPSELTFVQEIGSGQFGLVHLGYWLNKDKVAIKTIREGAMSEEDFIEEAEVMMKLSHPKLVQLYGVCLEQAPICLVFEFMEHGCLSDYLRTQRGLFAAETLLGMCLDVCEGMAYLEEACVIHRDLAARNCLVGENQVIKVSDFGMTRFVLDDQYTSSTGTKFPVKWASPEVFSFSRYSSKSDVWSFGVLMWEVFSEGKIPYENRSNSEVVEDISTGFRLYKPRLASTHVYQIMNHCWKERPEDRPAFSRLLRQLAEIAESGL
T91761	DRUGINFO	D01EJJ	JTE-051	Phase 2
T91761	DRUGINFO	D1YZ5O	CPI-818	Phase 1
T91761	DRUGINFO	D02IET	PMID27774824-Compound-Figure3Example7	Patented
T91761	DRUGINFO	D09PIS	Pyrazolo[4,3-c]pyridine derivative 2	Patented
T91761	DRUGINFO	D04PEI	BMS-509744	Investigative
T91761	DRUGINFO	D05RPN	BMS-488516	Investigative

T06031	TARGETID	T06031
T06031	FORMERID	TTDNC00348
T06031	UNIPROID	M3K1_HUMAN
T06031	TARGNAME	MAPK/ERK kinase kinase 1 (MAP3K1)
T06031	GENENAME	MAP3K1
T06031	TARGTYPE	Clinical trial
T06031	SYNONYMS	Mitogenactivated protein kinase kinase kinase 1; Mitogen-activated protein kinase kinase kinase 1; MEKK1; MEKK 1; MEKK; MEK kinase 1; MAPKKK1
T06031	FUNCTION	Activates the ERK and JNK kinase pathways by phosphorylation of MAP2K1 and MAP2K4. May phosphorylate the MAPK8/JNK1 kinase. Activates CHUK and IKBKB, the central protein kinases of the NF-kappa-B pathway. Component of a protein kinase signal transduction cascade.
T06031	BIOCLASS	Kinase
T06031	ECNUMBER	EC 2.7.11.25
T06031	SEQUENCE	MAAAAGNRASSSGFPGARATSPEAGGGGGALKASSAPAAAAGLLREAGSGGRERADWRRRQLRKVRSVELDQLPEQPLFLAASPPASSTSPSPEPADAAGSGTGFQPVAVPPPHGAASRGGAHLTESVAAPDSGASSPAAAEPGEKRAPAAEPSPAAAPAGREMENKETLKGLHKMDDRPEERMIREKLKATCMPAWKHEWLERRNRRGPVVVKPIPVKGDGSEMNHLAAESPGEVQASAASPASKGRRSPSPGNSPSGRTVKSESPGVRRKRVSPVPFQSGRITPPRRAPSPDGFSPYSPEETNRRVNKVMRARLYLLQQIGPNSFLIGGDSPDNKYRVFIGPQNCSCARGTFCIHLLFVMLRVFQLEPSDPMLWRKTLKNFEVESLFQKYHSRRSSRIKAPSRNTIQKFVSRMSNSHTLSSSSTSTSSSENSIKDEEEQMCPICLLGMLDEESLTVCEDGCRNKLHHHCMSIWAEECRRNREPLICPLCRSKWRSHDFYSHELSSPVDSPSSLRAAQQQTVQQQPLAGSRRNQESNFNLTHYGTQQIPPAYKDLAEPWIQVFGMELVGCLFSRNWNVREMALRRLSHDVSGALLLANGESTGNSGGSSGSSPSGGATSGSSQTSISGDVVEACCSVLSMVCADPVYKVYVAALKTLRAMLVYTPCHSLAERIKLQRLLQPVVDTILVKCADANSRTSQLSISTLLELCKGQAGELAVGREILKAGSIGIGGVDYVLNCILGNQTESNNWQELLGRLCLIDRLLLEFPAEFYPHIVSTDVSQAEPVEIRYKKLLSLLTFALQSIDNSHSMVGKLSRRIYLSSARMVTTVPHVFSKLLEMLSVSSSTHFTRMRRRLMAIADEVEIAEAIQLGVEDTLDGQQDSFLQASVPNNYLETTENSSPECTVHLEKTGKGLCATKLSASSEDISERLASISVGPSSSTTTTTTTTEQPKPMVQTKGRPHSQCLNSSPLSHHSQLMFPALSTPSSSTPSVPAGTATDVSKHRLQGFIPCRIPSASPQTQRKFSLQFHRNCPENKDSDKLSPVFTQSRPLPSSNIHRPKPSRPTPGNTSKQGDPSKNSMTLDLNSSSKCDDSFGCSSNSSNAVIPSDETVFTPVEEKCRLDVNTELNSSIEDLLEASMPSSDTTVTFKSEVAVLSPEKAENDDTYKDDVNHNQKCKEKMEAEEEEALAIAMAMSASQDALPIVPQLQVENGEDIIIIQQDTPETLPGHTKAKQPYREDTEWLKGQQIGLGAFSSCYQAQDVGTGTLMAVKQVTYVRNTSSEQEEVVEALREEIRMMSHLNHPNIIRMLGATCEKSNYNLFIEWMAGGSVAHLLSKYGAFKESVVINYTEQLLRGLSYLHENQIIHRDVKGANLLIDSTGQRLRIADFGAAARLASKGTGAGEFQGQLLGTIAFMAPEVLRGQQYGRSCDVWSVGCAIIEMACAKPPWNAEKHSNHLALIFKIASATTAPSIPSHLSPGLRDVALRCLELQPQDRPPSRELLKHPVFRTTW
T06031	DRUGINFO	D0C7LR	LLZ16406	Investigative
T06031	DRUGINFO	D0C1OZ	Ro092210	Investigative
T06031	DRUGINFO	D0GD8Y	U0126	Investigative
T06031	DRUGINFO	D0B9BU	CI-1040	Investigative

T68782	TARGETID	T68782
T68782	FORMERID	TTDR00802
T68782	UNIPROID	PD2R_HUMAN
T68782	TARGNAME	Prostaglandin D2 receptor (PTGDR)
T68782	GENENAME	PTGDR
T68782	TARGTYPE	Clinical trial
T68782	SYNONYMS	Prostanoid DP receptor; PGD2 receptor; PGD receptor
T68782	FUNCTION	The activity of this receptor is mainly mediated by G(s) proteins that stimulate adenylate cyclase, resulting in an elevation of intracellular cAMP. A mobilization of calcium is also observed, but without formation of inositol 1,4,5-trisphosphate. Receptor for prostaglandin D2 (PGD2).
T68782	BIOCLASS	GPCR rhodopsin
T68782	SEQUENCE	MKSPFYRCQNTTSVEKGNSAVMGGVLFSTGLLGNLLALGLLARSGLGWCSRRPLRPLPSVFYMLVCGLTVTDLLGKCLLSPVVLAAYAQNRSLRVLAPALDNSLCQAFAFFMSFFGLSSTLQLLAMALECWLSLGHPFFYRRHITLRLGALVAPVVSAFSLAFCALPFMGFGKFVQYCPGTWCFIQMVHEEGSLSVLGYSVLYSSLMALLVLATVLCNLGAMRNLYAMHRRLQRHPRSCTRDCAEPRADGREASPQPLEELDHLLLLALMTVLFTMCSLPVIYRAYYGAFKDVKEKNRTSEEAEDLRALRFLSVISIVDPWIFIIFRSPVFRIFFHKIFIRPLRYRSRCSNSTNMESSL
T68782	DRUGINFO	D0WL5V	LAROPIPRANT	Phase 4
T68782	DRUGINFO	D06XDI	QAW-039	Phase 3
T68782	DRUGINFO	D0SP5V	Setipiprant	Phase 3
T68782	DRUGINFO	D04NWU	ONO-4053	Phase 2
T68782	DRUGINFO	D06GNF	TS-022	Phase 2
T68782	DRUGINFO	D0B9DM	S-555739	Phase 2
T68782	DRUGINFO	D0N4ZX	MK-1029	Phase 2
T68782	DRUGINFO	D0YB2Y	AMG 853	Phase 2
T68782	DRUGINFO	D0AR7L	SAR-389644	Phase 1
T68782	DRUGINFO	D0NU6Y	192C86	Phase 1
T68782	DRUGINFO	DGV5Z3	MK-1092	Phase 1
T68782	DRUGINFO	D00HTY	PGF2alpha	Clinical trial
T68782	DRUGINFO	D03GYK	Laropiprant+niacin	Discontinued in Phase 3
T68782	DRUGINFO	D0K0VH	S-5751	Discontinued in Phase 2
T68782	DRUGINFO	D05PQF	ONO-4127	Discontinued in Phase 1
T68782	DRUGINFO	D07OEY	ZK-118182	Terminated
T68782	DRUGINFO	D01TRN	ONO-AE3-237	Investigative
T68782	DRUGINFO	D02LQA	TTH 03-001	Investigative
T68782	DRUGINFO	D03AGD	BWA868C	Investigative
T68782	DRUGINFO	D06HPV	DIASTEREOMER 2	Investigative
T68782	DRUGINFO	D08DFY	SQ-27986	Investigative
T68782	DRUGINFO	D0H5FY	RS 93520	Investigative
T68782	DRUGINFO	D0R2KL	L-644,698	Investigative
T68782	DRUGINFO	D0R9CC	BW 245C	Investigative
T68782	DRUGINFO	D00QTX	ZK110841	Investigative
T68782	DRUGINFO	D01RQK	15-deoxy-Delta12,14-PGJ2	Investigative
T68782	DRUGINFO	D0MS3D	Delta12-PGJ2	Investigative
T68782	DRUGINFO	D0WV5J	L-888,291	Investigative
T68782	DRUGINFO	D0Y6OX	PGJ2	Investigative
T68782	DRUGINFO	D0J9PG	AH6809	Investigative
T68782	DRUGINFO	D0O9ES	cloprostenol	Investigative
T68782	DRUGINFO	D08MNO	butaprost (free acid form)	Investigative
T68782	DRUGINFO	D06KBO	PGD2	Investigative
T68782	DRUGINFO	D0W7RI	carbacyclin	Investigative
T68782	DRUGINFO	D03PLH	U46619	Investigative

T11011	TARGETID	T11011
T11011	FORMERID	TTDC00074
T11011	UNIPROID	CRFR2_HUMAN
T11011	TARGNAME	Corticotropin-releasing factor receptor 2 (CRHR2)
T11011	GENENAME	CRHR2
T11011	TARGTYPE	Clinical trial
T11011	SYNONYMS	Corticotropin-releasinghormone receptor 2; CRHR2; CRH2 receptor; CRH-R 2; CRF2; CRF-R 2
T11011	FUNCTION	This is a receptor for corticotropin releasing factor. Shows high-affinity crf binding. Also binds to urocortin i, ii and iii. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.
T11011	PDBSTRUC	3N96; 3N95; 3N93
T11011	BIOCLASS	GPCR secretin
T11011	SEQUENCE	MDAALLHSLLEANCSLALAEELLLDGWGPPLDPEGPYSYCNTTLDQIGTCWPRSAAGALVERPCPEYFNGVKYNTTRNAYRECLENGTWASKINYSQCEPILDDKQRKYDLHYRIALVVNYLGHCVSVAALVAAFLLFLALRSIRCLRNVIHWNLITTFILRNVMWFLLQLVDHEVHESNEVWCRCITTIFNYFVVTNFFWMFVEGCYLHTAIVMTYSTERLRKCLFLFIGWCIPFPIIVAWAIGKLYYENEQCWFGKEPGDLVDYIYQGPIILVLLINFVFLFNIVRILMTKLRASTTSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDLSQIMFIYFNSFLQSFQGFFVSVFYCFFNGEVRSAVRKRWHRWQDHHSLRVPMARAMSIPTSPTRISFHSIKQTAAV
T11011	DRUGINFO	D0W2HG	Urocortin 2	Phase 2
T11011	DRUGINFO	DYSA16	RT-400	Phase 2
T11011	DRUGINFO	D07QWW	NBI-34041	Phase 1
T11011	DRUGINFO	D01TGH	PF-572778	Terminated
T11011	DRUGINFO	D07NWC	SC-241	Terminated
T11011	DRUGINFO	D0L5RY	astressin	Investigative

T22655	TARGETID	T22655
T22655	FORMERID	TTDC00248
T22655	UNIPROID	MADCA_HUMAN
T22655	TARGNAME	Mucosal addressin cell adhesion molecule 1 (MADCAM1)
T22655	GENENAME	MADCAM1
T22655	TARGTYPE	Clinical trial
T22655	SYNONYMS	hMAdCAM-1; MAdCAM-1; MADCAM1
T22655	FUNCTION	Cell adhesion leukocyte receptor expressed by mucosal venules, helps to direct lymphocyte traffic into mucosal tissues including the Peyer patches and the intestinal lamina propria. It can bind both integrin alpha-4/beta-7 and L-selectin, regulating both the passage and retention of leukocytes. Isoform 2, lacking the mucin-like domain, may be specialized in supporting integrin alpha-4/beta-7-dependent adhesion strengthening, independent of L- selectin binding.
T22655	PDBSTRUC	4HD9; 4HCR; 4HC1; 4HBQ; 1GSM
T22655	SEQUENCE	MDFGLALLLAGLLGLLLGQSLQVKPLQVEPPEPVVAVALGASRQLTCRLACADRGASVQWRGLDTSLGAVQSDTGRSVLTVRNASLSAAGTRVCVGSCGGRTFQHTVQLLVYAFPDQLTVSPAALVPGDPEVACTAHKVTPVDPNALSFSLLVGGQELEGAQALGPEVQEEEEEPQGDEDVLFRVTERWRLPPLGTPVPPALYCQATMRLPGLELSHRQAIPVLHSPTSPEPPDTTSPESPDTTSPESPDTTSQEPPDTTSPEPPDKTSPEPAPQQGSTHTPRSPGSTRTRRPEISQAGPTQGEVIPTGSSKPAGDQLPAALWTSSAVLGLLLLALPTYHLWKRCRHLAEDDTHPPASLRLLPQVSAWAGLRGTGQVGISPS
T22655	DRUGINFO	D02QWK	SHP647	Phase 3
T22655	DRUGINFO	D00QKI	SCH-527123	Phase 2

T35173	TARGETID	T35173
T35173	FORMERID	TTDI02026
T35173	UNIPROID	BIRC3_HUMAN
T35173	TARGNAME	Cellular inhibitor of apoptosis 2 (BIRC3)
T35173	GENENAME	BIRC3
T35173	TARGTYPE	Clinical trial
T35173	SYNONYMS	hIAP1; hIAP-1; TNFR2TRAFsignaling complex protein 1; TNFR2-TRAF-signaling complex protein 1; RNF49; RING-type E3 ubiquitin transferase BIRC3; RING finger protein 49; MIHC; Inhibitor of apoptosis protein 1; IAP1; IAP homolog C; CIAP2; C-IAP2; Baculoviral IAP repeatcontaining protein3; Baculoviral IAP repeat-containing protein 3; Apoptosis inhibitor 2; API2
T35173	FUNCTION	Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and regulates both canonical and non-canonical NF-kappa-B signaling by acting in opposite directions: acts as a positive regulator of the canonical pathway and suppresses constitutive activation of non-canonical NF-kappa-B signaling. The target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4, CASP3, CASP7, CASP8, IKBKE, TRAF1, and BCL10. Acts as an important regulator of innate immune signaling via regulation of Toll-like receptors (TLRs), Nodlike receptors (NLRs) and RIG-I like receptors (RLRs), collectively referred to as pattern recognition receptors (PRRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8. Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, mitogenic kinase signaling and cell proliferation, as well as cell invasion and metastasis.
T35173	PDBSTRUC	3M0D; 3M0A; 3EB6; 3EB5; 2UVL
T35173	BIOCLASS	Acyltransferase
T35173	ECNUMBER	EC 2.3.2.27
T35173	SEQUENCE	MNIVENSIFLSNLMKSANTFELKYDLSCELYRMSTYSTFPAGVPVSERSLARAGFYYTGVNDKVKCFCCGLMLDNWKRGDSPTEKHKKLYPSCRFVQSLNSVNNLEATSQPTFPSSVTNSTHSLLPGTENSGYFRGSYSNSPSNPVNSRANQDFSALMRSSYHCAMNNENARLLTFQTWPLTFLSPTDLAKAGFYYIGPGDRVACFACGGKLSNWEPKDNAMSEHLRHFPKCPFIENQLQDTSRYTVSNLSMQTHAARFKTFFNWPSSVLVNPEQLASAGFYYVGNSDDVKCFCCDGGLRCWESGDDPWVQHAKWFPRCEYLIRIKGQEFIRQVQASYPHLLEQLLSTSDSPGDENAESSIIHFEPGEDHSEDAIMMNTPVINAAVEMGFSRSLVKQTVQRKILATGENYRLVNDLVLDLLNAEDEIREEERERATEEKESNDLLLIRKNRMALFQHLTCVIPILDSLLTAGIINEQEHDVIKQKTQTSLQARELIDTILVKGNIAATVFRNSLQEAEAVLYEHLFVQQDIKYIPTEDVSDLPVEEQLRRLQEERTCKVCMDKEVSIVFIPCGHLVVCKDCAPSLRKCPICRSTIKGTVRTFLS
T35173	DRUGINFO	D03MXK	AT-406	Phase 3
T35173	DRUGINFO	D0B6KC	PMID25980951-Compound-27	Patented
T35173	DRUGINFO	D0HY5Q	PMID25980951-Compound-43	Patented
T35173	DRUGINFO	D0R3YM	PMID25980951-Compound-1	Patented
T35173	DRUGINFO	D0YN1X	PMID25980951-Compound-44	Patented
T35173	DRUGINFO	D0VK7M	AZD5582	Investigative

T84780	TARGETID	T84780
T84780	FORMERID	TTDI02025
T84780	UNIPROID	BIRC2_HUMAN
T84780	TARGNAME	Cellular inhibitor of apoptosis 1 (BIRC2)
T84780	GENENAME	BIRC2
T84780	TARGTYPE	Clinical trial
T84780	SYNONYMS	hIAP2; hIAP-2; TNFR2TRAFsignaling complex protein 2; TNFR2-TRAF-signaling complex protein 2; RNF48; RING-type E3 ubiquitin transferase BIRC2; RING finger protein 48; MIHB; Inhibitor of apoptosis protein 2; IAP2; IAP homolog B; CIAP1; C-IAP1; Baculoviral IAP repeatcontaining protein 2; Baculoviral IAP repeat-containing protein 2; API1
T84780	FUNCTION	Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and regulates both canonical and non-canonical NF-kappa-B signaling by acting in opposite directions: acts as a positive regulator of the canonical pathway and suppresses constitutive activation of non-canonical NF-kappa-B signaling. The target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4, CASP3, CASP7, CASP8, TRAF2, DIABLO/SMAC, MAP3K14/NIK, MAP3K5/ASK1, IKBKG/NEMO, IKBKE and MXD1/MAD1. Can also function as an E3 ubiquitin-protein ligase of the NEDD8 conjugation pathway, targeting effector caspases for neddylation and inactivation. Acts as an important regulator of innate immune signaling via regulation of Toll-like receptors (TLRs), Nodlike receptors (NLRs) and RIG-I like receptors (RLRs), collectively referred to as pattern recognition receptors (PRRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8. Can stimulate the transcriptional activity of E2F1. Plays a role in the modulation of the cell cycle. Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, mitogenic kinase signaling, and cell proliferation, as well as cell invasion and metastasis.
T84780	PDBSTRUC	6HPR; 6EXW; 5M6N; 4MU7; 4MTI
T84780	BIOCLASS	Acyltransferase
T84780	ECNUMBER	EC 2.3.2.27
T84780	SEQUENCE	MHKTASQRLFPGPSYQNIKSIMEDSTILSDWTNSNKQKMKYDFSCELYRMSTYSTFPAGVPVSERSLARAGFYYTGVNDKVKCFCCGLMLDNWKLGDSPIQKHKQLYPSCSFIQNLVSASLGSTSKNTSPMRNSFAHSLSPTLEHSSLFSGSYSSLSPNPLNSRAVEDISSSRTNPYSYAMSTEEARFLTYHMWPLTFLSPSELARAGFYYIGPGDRVACFACGGKLSNWEPKDDAMSEHRRHFPNCPFLENSLETLRFSISNLSMQTHAARMRTFMYWPSSVPVQPEQLASAGFYYVGRNDDVKCFCCDGGLRCWESGDDPWVEHAKWFPRCEFLIRMKGQEFVDEIQGRYPHLLEQLLSTSDTTGEENADPPIIHFGPGESSSEDAVMMNTPVVKSALEMGFNRDLVKQTVQSKILTTGENYKTVNDIVSALLNAEDEKREEEKEKQAEEMASDDLSLIRKNRMALFQQLTCVLPILDNLLKANVINKQEHDIIKQKTQIPLQARELIDTILVKGNAAANIFKNCLKEIDSTLYKNLFVDKNMKYIPTEDVSGLSLEEQLRRLQEERTCKVCMDKEVSVVFIPCGHLVVCQECAPSLRKCPICRGIIKGTVRTFLS
T84780	DRUGINFO	D03MXK	AT-406	Phase 3
T84780	DRUGINFO	D0E8NP	Birinapant	Phase 2
T84780	DRUGINFO	D05HBW	PMID25980951-Compound-18	Patented
T84780	DRUGINFO	D08XOV	PMID25980951-Compound-16	Patented
T84780	DRUGINFO	D0F4GT	PMID25980951-Compound-17	Patented
T84780	DRUGINFO	D02UOD	PMID25980951-Compound-3	Patented
T84780	DRUGINFO	D02ZHC	PMID25980951-Compound-4	Patented
T84780	DRUGINFO	D03DQW	PMID25980951-Compound-21	Patented
T84780	DRUGINFO	D03PTG	PMID25980951-Compound-42	Patented
T84780	DRUGINFO	D03VPP	PMID25980951-Compound-22	Patented
T84780	DRUGINFO	D07FRU	PMID25980951-Compound-37	Patented
T84780	DRUGINFO	D0AC8H	PMID25980951-Compound-36	Patented
T84780	DRUGINFO	D0CV9K	PMID25980951-Compound-20	Patented
T84780	DRUGINFO	D0GF3P	PMID25980951-Compound-38	Patented
T84780	DRUGINFO	D0ID3R	PMID25980951-Compound-5	Patented
T84780	DRUGINFO	D0M3BY	PMID25980951-Compound-41	Patented
T84780	DRUGINFO	D0MH4B	PMID25980951-Compound-19	Patented
T84780	DRUGINFO	D0O8ZD	PMID25980951-Compound-7	Patented
T84780	DRUGINFO	D09VAX	PMID25980951-Compound-6	Patented
T84780	DRUGINFO	D0B6KC	PMID25980951-Compound-27	Patented
T84780	DRUGINFO	D0HY5Q	PMID25980951-Compound-43	Patented
T84780	DRUGINFO	D0R3YM	PMID25980951-Compound-1	Patented
T84780	DRUGINFO	D0YN1X	PMID25980951-Compound-44	Patented
T84780	DRUGINFO	D0O4UQ	BV-6	Investigative
T84780	DRUGINFO	D2SJZ9	EAPB0203	Investigative
T84780	DRUGINFO	D0VK7M	AZD5582	Investigative

T97155	TARGETID	T97155
T97155	FORMERID	TTDI02023
T97155	UNIPROID	ATR_HUMAN
T97155	TARGNAME	Serine/threonine-protein kinase ATR (FRP1)
T97155	GENENAME	ATR
T97155	TARGTYPE	Clinical trial
T97155	SYNONYMS	FRAP-related protein 1; Ataxia telangiectasia and Rad3-related protein
T97155	FUNCTION	Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates BRCA1, CHEK1, MCM2, RAD17, RPA2, SMC1 and p53/TP53, which collectively inhibit DNA replication and mitosis and promote DNA repair, recombination and apoptosis. Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX at sites of DNA damage, thereby regulating DNA damage response mechanism. Required for FANCD2 ubiquitination. Critical for maintenance of fragile site stability and efficient regulation of centrosome duplication. Serine/threonine protein kinase which activates checkpoint signaling upon genotoxic stresses such as ionizing radiation (IR), ultraviolet light (UV), or DNA replication stalling, thereby acting as a DNA damage sensor.
T97155	PDBSTRUC	5YZ0
T97155	BIOCLASS	Kinase
T97155	ECNUMBER	EC 2.7.11.1
T97155	SEQUENCE	MGEHGLELASMIPALRELGSATPEEYNTVVQKPRQILCQFIDRILTDVNVVAVELVKKTDSQPTSVMLLDFIQHIMKSSPLMFVNVSGSHEAKGSCIEFSNWIITRLLRIAATPSCHLLHKKICEVICSLLFLFKSKSPAIFGVLTKELLQLFEDLVYLHRRNVMGHAVEWPVVMSRFLSQLDEHMGYLQSAPLQLMSMQNLEFIEVTLLMVLTRIIAIVFFRRQELLLWQIGCVLLEYGSPKIKSLAISFLTELFQLGGLPAQPASTFFSSFLELLKHLVEMDTDQLKLYEEPLSKLIKTLFPFEAEAYRNIEPVYLNMLLEKLCVMFEDGVLMRLKSDLLKAALCHLLQYFLKFVPAGYESALQVRKVYVRNICKALLDVLGIEVDAEYLLGPLYAALKMESMEIIEEIQCQTQQENLSSNSDGISPKRRRLSSSLNPSKRAPKQTEEIKHVDMNQKSILWSALKQKAESLQISLEYSGLKNPVIEMLEGIAVVLQLTALCTVHCSHQNMNCRTFKDCQHKSKKKPSVVITWMSLDFYTKVLKSCRSLLESVQKLDLEATIDKVVKIYDALIYMQVNSSFEDHILEDLCGMLSLPWIYSHSDDGCLKLTTFAANLLTLSCRISDSYSPQAQSRCVFLLTLFPRRIFLEWRTAVYNWALQSSHEVIRASCVSGFFILLQQQNSCNRVPKILIDKVKDDSDIVKKEFASILGQLVCTLHGMFYLTSSLTEPFSEHGHVDLFCRNLKATSQHECSSSQLKASVCKPFLFLLKKKIPSPVKLAFIDNLHHLCKHLDFREDETDVKAVLGTLLNLMEDPDKDVRVAFSGNIKHILESLDSEDGFIKELFVLRMKEAYTHAQISRNNELKDTLILTTGDIGRAAKGDLVPFALLHLLHCLLSKSASVSGAAYTEIRALVAAKSVKLQSFFSQYKKPICQFLVESLHSSQMTALPNTPCQNADVRKQDVAHQREMALNTLSEIANVFDFPDLNRFLTRTLQVLLPDLAAKASPAASALIRTLGKQLNVNRREILINNFKYIFSHLVCSCSKDELERALHYLKNETEIELGSLLRQDFQGLHNELLLRIGEHYQQVFNGLSILASFASSDDPYQGPRDIISPELMADYLQPKLLGILAFFNMQLLSSSVGIEDKKMALNSLMSLMKLMGPKHVSSVRVKMMTTLRTGLRFKDDFPELCCRAWDCFVRCLDHACLGSLLSHVIVALLPLIHIQPKETAAIFHYLIIENRDAVQDFLHEIYFLPDHPELKKIKAVLQEYRKETSESTDLQTTLQLSMKAIQHENVDVRIHALTSLKETLYKNQEKLIKYATDSETVEPIISQLVTVLLKGCQDANSQARLLCGECLGELGAIDPGRLDFSTTETQGKDFTFVTGVEDSSFAYGLLMELTRAYLAYADNSRAQDSAAYAIQELLSIYDCREMETNGPGHQLWRRFPEHVREILEPHLNTRYKSSQKSTDWSGVKKPIYLSKLGSNFAEWSASWAGYLITKVRHDLASKIFTCCSIMMKHDFKVTIYLLPHILVYVLLGCNQEDQQEVYAEIMAVLKHDDQHTINTQDIASDLCQLSTQTVFSMLDHLTQWARHKFQALKAEKCPHSKSNRNKVDSMVSTVDYEDYQSVTRFLDLIPQDTLAVASFRSKAYTRAVMHFESFITEKKQNIQEHLGFLQKLYAAMHEPDGVAGVSAIRKAEPSLKEQILEHESLGLLRDATACYDRAIQLEPDQIIHYHGVVKSMLGLGQLSTVITQVNGVHANRSEWTDELNTYRVEAAWKLSQWDLVENYLAADGKSTTWSVRLGQLLLSAKKRDITAFYDSLKLVRAEQIVPLSAASFERGSYQRGYEYIVRLHMLCELEHSIKPLFQHSPGDSSQEDSLNWVARLEMTQNSYRAKEPILALRRALLSLNKRPDYNEMVGECWLQSARVARKAGHHQTAYNALLNAGESRLAELYVERAKWLWSKGDVHQALIVLQKGVELCFPENETPPEGKNMLIHGRAMLLVGRFMEETANFESNAIMKKYKDVTACLPEWEDGHFYLAKYYDKLMPMVTDNKMEKQGDLIRYIVLHFGRSLQYGNQFIYQSMPRMLTLWLDYGTKAYEWEKAGRSDRVQMRNDLGKINKVITEHTNYLAPYQFLTAFSQLISRICHSHDEVFVVLMEIIAKVFLAYPQQAMWMMTAVSKSSYPMRVNRCKEILNKAIHMKKSLEKFVGDATRLTDKLLELCNKPVDGSSSTLSMSTHFKMLKKLVEEATFSEILIPLQSVMIPTLPSILGTHANHASHEPFPGHWAYIAGFDDMVEILASLQKPKKISLKGSDGKFYIMMCKPKDDLRKDCRLMEFNSLINKCLRKDAESRRRELHIRTYAVIPLNDECGIIEWVNNTAGLRPILTKLYKEKGVYMTGKELRQCMLPKSAALSEKLKVFREFLLPRHPPIFHEWFLRTFPDPTSWYSSRSAYCRSTAVMSMVGYILGLGDRHGENILFDSLTGECVHVDFNCLFNKGETFEVPEIVPFRLTHNMVNGMGPMGTEGLFRRACEVTMRLMRDQREPLMSVLKTFLHDPLVEWSKPVKGHSKAPLNETGEVVNEKAKTHVLDIEQRLQGVIKTRNRVTGLPLSIEGHVHYLIQEATDENLLCQMYLGWTPYM
T97155	DRUGINFO	D0H9DA	AZD6738	Phase 2
T97155	DRUGINFO	DAD65R	RP-3500	Phase 1/2
T97155	DRUGINFO	DDSW97	Camonsertib	Phase 1/2
T97155	DRUGINFO	D03BYM	BAY1895344	Phase 1
T97155	DRUGINFO	D06DMQ	VX-970	Phase 1
T97155	DRUGINFO	D0IE9L	M4344	Phase 1
T97155	DRUGINFO	D3OWG9	M1774	Phase 1
T97155	DRUGINFO	D02TSN	AZ20	Investigative
T97155	DRUGINFO	D0G0BJ	VE-821	Investigative
T97155	DRUGINFO	D00PXO	CGK733	Investigative

T73694	TARGETID	T73694
T73694	FORMERID	TTDR00884
T73694	UNIPROID	PTK6_HUMAN
T73694	TARGNAME	Tyrosine-protein kinase BRK (PTK6)
T73694	GENENAME	PTK6
T73694	TARGTYPE	Clinical trial
T73694	SYNONYMS	Protein-tyrosine kinase 6; Breast tumor kinase; BRK
T73694	FUNCTION	Non-receptor tyrosine-protein kinase implicated in the regulation of a variety of signaling pathways that control the differentiation and maintenance of normal epithelia, as well as tumor growth. Function seems to be context dependent and differ depending on cell type, as well as its intracellular localization. A number of potential nuclear and cytoplasmic substrates have been identified. These include the RNA-binding proteins: KHDRBS1/SAM68, KHDRBS2/SLM1, KHDRBS3/SLM2 and SFPQ/PSF; transcription factors: STAT3 and STAT5A/B and a variety of signaling molecules: ARHGAP35/p190RhoGAP, PXN/paxillin, BTK/ATK, STAP2/BKS. Associates also with a variety of proteins that are likely upstream of PTK6 in various signaling pathways, or for which PTK6 may play an adapter-like role. These proteins include ADAM15, EGFR, ERBB2, ERBB3 and IRS4. In normal or non-tumorigenic tissues, PTK6 promotes cellular differentiation and apoptosis. In tumors PTK6 contributes to cancer progression by sensitizing cells to mitogenic signals and enhancing proliferation, anchorage-independent survival and migration/invasion. Association with EGFR, ERBB2, ERBB3 may contribute to mammary tumor development and growth through enhancement of EGF-induced signaling via BTK/AKT and PI3 kinase. Contributes to migration and proliferation by contributing to EGF-mediated phosphorylation of ARHGAP35/p190RhoGAP, which promotes association with RASA1/p120RasGAP, inactivating RhoA while activating RAS. EGF stimulation resulted in phosphorylation of PNX/Paxillin by PTK6 and activation of RAC1 via CRK/CrKII, thereby promoting migration and invasion. PTK6 activates STAT3 and STAT5B to promote proliferation. Nuclear PTK6 may be important for regulating growth in normal epithelia, while cytoplasmic PTK6 might activate oncogenic signaling pathways.
T73694	PDBSTRUC	6CZ4; 6CZ3; 6CZ2; 5H2U; 5DA3
T73694	BIOCLASS	Kinase
T73694	ECNUMBER	EC 2.7.10.2
T73694	SEQUENCE	MVSRDQAHLGPKYVGLWDFKSRTDEELSFRAGDVFHVARKEEQWWWATLLDEAGGAVAQGYVPHNYLAERETVESEPWFFGCISRSEAVRRLQAEGNATGAFLIRVSEKPSADYVLSVRDTQAVRHYKIWRRAGGRLHLNEAVSFLSLPELVNYHRAQSLSHGLRLAAPCRKHEPEPLPHWDDWERPREEFTLCRKLGSGYFGEVFEGLWKDRVQVAIKVISRDNLLHQQMLQSEIQAMKKLRHKHILALYAVVSVGDPVYIITELMAKGSLLELLRDSDEKVLPVSELLDIAWQVAEGMCYLESQNYIHRDLAARNILVGENTLCKVGDFGLARLIKEDVYLSHDHNIPYKWTAPEALSRGHYSTKSDVWSFGILLHEMFSRGQVPYPGMSNHEAFLRVDAGYRMPCPLECPPSVHKLMLTCWCRDPEQRPCFKALRERLSSFTSYENPT
T73694	DRUGINFO	D06CIJ	ISIS-CRP	Phase 1
T73694	DRUGINFO	D0IZ8M	PMID21855335C19a	Investigative

T40459	TARGETID	T40459
T40459	FORMERID	TTDR00677
T40459	UNIPROID	I13R2_HUMAN
T40459	TARGNAME	Interleukin 13 receptor alpha-2 (IL13RA2)
T40459	GENENAME	IL13RA2
T40459	TARGTYPE	Clinical trial
T40459	SYNONYMS	Interleukin-13-binding protein; Interleukin-13 receptor subunit alpha-2; Interleukin-13 binding protein; IL-13RA2; IL-13R-alpha-2; IL-13R subunit alpha-2; IL-13R alpha-2 chain; IL-13 receptor subunit alpha-2; CD213a2
T40459	FUNCTION	Binds as a monomer with high affinity to interleukin-13 (IL13), but not to interleukin-4 (IL4).
T40459	PDBSTRUC	3LB6
T40459	BIOCLASS	Cytokine receptor
T40459	SEQUENCE	MAFVCLAIGCLYTFLISTTFGCTSSSDTEIKVNPPQDFEIVDPGYLGYLYLQWQPPLSLDHFKECTVEYELKYRNIGSETWKTIITKNLHYKDGFDLNKGIEAKIHTLLPWQCTNGSEVQSSWAETTYWISPQGIPETKVQDMDCVYYNWQYLLCSWKPGIGVLLDTNYNLFYWYEGLDHALQCVDYIKADGQNIGCRFPYLEASDYKDFYICVNGSSENKPIRSSYFTFQLQNIVKPLPPVYLTFTRESSCEIKLKWSIPLGPIPARCFDYEIEIREDDTTLVTATVENETYTLKTTNETRQLCFVVRSKVNIYCSDDGIWSEWSDKQCWEGEDLSKKTLLRFWLPFGFILILVIFVTGLLLRKPNTYPKMIPEFFCDT
T40459	DRUGINFO	D0M1RD	ICT-107	Phase 3
T40459	DRUGINFO	D0N3WN	ABT-308	Phase 2
T40459	DRUGINFO	D0YN9Y	MB-101	Phase 1

T42048	TARGETID	T42048
T42048	FORMERID	TTDI02031
T42048	UNIPROID	BRD3_HUMAN
T42048	TARGNAME	Bromodomain-containing protein 3 (BRD3)
T42048	GENENAME	BRD3
T42048	TARGTYPE	Clinical trial
T42048	SYNONYMS	RING3like protein; RING3L; RING3-like protein; KIAA0043
T42048	FUNCTION	Regulates transcription by promoting the binding of the transcription factor GATA1 to its targets. Chromatin reader that recognizes and binds hyperacetylated chromatin and plays a role in the regulation of transcription, probably by chromatin remodeling and interaction with transcription factors.
T42048	PDBSTRUC	6I7A; 6I68; 6I5P; 6I41; 6BGH
T42048	BIOCLASS	Bromodomain
T42048	SEQUENCE	MSTATTVAPAGIPATPGPVNPPPPEVSNPSKPGRKTNQLQYMQNVVVKTLWKHQFAWPFYQPVDAIKLNLPDYHKIIKNPMDMGTIKKRLENNYYWSASECMQDFNTMFTNCYIYNKPTDDIVLMAQALEKIFLQKVAQMPQEEVELLPPAPKGKGRKPAAGAQSAGTQQVAAVSSVSPATPFQSVPPTVSQTPVIAATPVPTITANVTSVPVPPAAAPPPPATPIVPVVPPTPPVVKKKGVKRKADTTTPTTSAITASRSESPPPLSDPKQAKVVARRESGGRPIKPPKKDLEDGEVPQHAGKKGKLSEHLRYCDSILREMLSKKHAAYAWPFYKPVDAEALELHDYHDIIKHPMDLSTVKRKMDGREYPDAQGFAADVRLMFSNCYKYNPPDHEVVAMARKLQDVFEMRFAKMPDEPVEAPALPAPAAPMVSKGAESSRSSEESSSDSGSSDSEEERATRLAELQEQLKAVHEQLAALSQAPVNKPKKKKEKKEKEKKKKDKEKEKEKHKVKAEEEKKAKVAPPAKQAQQKKAPAKKANSTTTAGRQLKKGGKQASASYDSEEEEEGLPMSYDEKRQLSLDINRLPGEKLGRVVHIIQSREPSLRDSNPDEIEIDFETLKPTTLRELERYVKSCLQKKQRKPFSASGKKQAAKSKEELAQEKKKELEKRLQDVSGQLSSSKKPARKEKPGSAPSGGPSRLSSSSSSESGSSSSSGSSSDSSDSE
T42048	DRUGINFO	D05ICT	ABBV-744	Phase 1
T42048	DRUGINFO	D0YM3G	Pyrrolo-pyrrolone derivative 1	Patented
T42048	DRUGINFO	D03NWT	PMID26924192-Compound-104	Patented
T42048	DRUGINFO	D03RPJ	PMID26924192-Compound-102	Patented
T42048	DRUGINFO	D05XXS	PMID26924192-Compound-103	Patented
T42048	DRUGINFO	D0NN4U	PMID26924192-Compound-105	Patented
T42048	DRUGINFO	D03LIP	GW841819X	Investigative
T42048	DRUGINFO	D0C2XT	PMID24000170C36	Investigative
T42048	DRUGINFO	D0Q2GK	PMID24000170C38	Investigative
T42048	DRUGINFO	D0WU1S	I-BET151	Investigative
T42048	DRUGINFO	D07FGY	XD14	Investigative

T90782	TARGETID	T90782
T90782	FORMERID	TTDR00731
T90782	UNIPROID	P2RY6_HUMAN
T90782	TARGNAME	P2Y purinoceptor 6 (P2RY6)
T90782	GENENAME	P2RY6
T90782	TARGTYPE	Clinical trial
T90782	SYNONYMS	P2Y6; P2RY6; Adenosine P2Y6 receptor
T90782	FUNCTION	Receptor for extracellular UDP > UTP > ATP. The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system.
T90782	PDBSTRUC	2B6R
T90782	BIOCLASS	GPCR rhodopsin
T90782	SEQUENCE	MEWDNGTGQALGLPPTTCVYRENFKQLLLPPVYSAVLAAGLPLNICVITQICTSRRALTRTAVYTLNLALADLLYACSLPLLIYNYAQGDHWPFGDFACRLVRFLFYANLHGSILFLTCISFQRYLGICHPLAPWHKRGGRRAAWLVCVAVWLAVTTQCLPTAIFAATGIQRNRTVCYDLSPPALATHYMPYGMALTVIGFLLPFAALLACYCLLACRLCRQDGPAEPVAQERRGKAARMAVVVAAAFAISFLPFHITKTAYLAVRSTPGVPCTVLEAFAAAYKGTRPFASANSVLDPILFYFTQKKFRRRPHELLQKLTAKWQRQGR
T90782	DRUGINFO	D0D4HO	GC021109	Phase 1
T90782	DRUGINFO	D0Z7FU	INS 316	Discontinued in Phase 3
T90782	DRUGINFO	D03WBX	MRS2782	Investigative
T90782	DRUGINFO	D03YRN	MRS2578	Investigative
T90782	DRUGINFO	D08VPN	UDP-beta-S	Investigative
T90782	DRUGINFO	D09RGZ	Up3U	Investigative
T90782	DRUGINFO	D0C5FN	Rp-5-OMe-UDPalphaB	Investigative
T90782	DRUGINFO	D0J4MU	MRS2957	Investigative
T90782	DRUGINFO	D0P6KN	INS48823	Investigative
T90782	DRUGINFO	D0Q2OK	MRS2693	Investigative
T90782	DRUGINFO	D0T4WF	3-phenacyl-UDP	Investigative
T90782	DRUGINFO	D0V4FT	MRS2567	Investigative
T90782	DRUGINFO	D0DZ1K	PSB-0952	Investigative
T90782	DRUGINFO	D0P7RI	5BrUTP	Investigative
T90782	DRUGINFO	D0B0ZQ	RB 2	Investigative
T90782	DRUGINFO	D0U1OJ	2MeSATP	Investigative
T90782	DRUGINFO	D05NWF	adenosine diphosphate	Investigative

T07400	TARGETID	T07400
T07400	FORMERID	TTDR00745
T07400	UNIPROID	RAGE_HUMAN
T07400	TARGNAME	Advanced glycosylation end product receptor (AGER)
T07400	GENENAME	AGER
T07400	TARGTYPE	Clinical trial
T07400	SYNONYMS	Receptor foradvanced glycosylation end products; RAGESEC; RAGE; AGER
T07400	FUNCTION	Mediates interactions of advanced glycosylation end products (age). These are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. Receptor for amyloid beta peptide.
T07400	PDBSTRUC	5D7F; 4YBH; 4XYN; 4P2Y; 4OI8
T07400	BIOCLASS	Immunoglobulin
T07400	SEQUENCE	MAAGTAVGAWVLVLSLWGAVVGAQNITARIGEPLVLKCKGAPKKPPQRLEWKLNTGRTEAWKVLSPQGGGPWDSVARVLPNGSLFLPAVGIQDEGIFRCQAMNRNGKETKSNYRVRVYQIPGKPEIVDSASELTAGVPNKVGTCVSEGSYPAGTLSWHLDGKPLVPNEKGVSVKEQTRRHPETGLFTLQSELMVTPARGGDPRPTFSCSFSPGLPRHRALRTAPIQPRVWEPVPLEEVQLVVEPEGGAVAPGGTVTLTCEVPAQPSPQIHWMKDGVPLPLPPSPVLILPEIGPQDQGTYSCVATHSSHGPQESRAVSISIIEPGEEGPTAGSVGGSGLGTLALALGILGGLGTAALLIGVILWQRRQRRGEERKAPENQEEEEERAELNQSEEPEAGESSTGGP
T07400	DRUGINFO	D02YPU	Pyridoxamine	Phase 3
T07400	DRUGINFO	D0MW7B	PF-4494700	Phase 3
T07400	DRUGINFO	D07JLM	Alagebrium chloride	Phase 2/3
T07400	DRUGINFO	D0PU9C	TTP-448	Phase 2
T07400	DRUGINFO	D0I0YS	TTP-4000	Phase 1
T07400	DRUGINFO	D07QVY	DBT-066	Investigative

T25317	TARGETID	T25317
T25317	FORMERID	TTDI02057
T25317	UNIPROID	EBP_HUMAN
T25317	TARGNAME	Cholestenol delta-isomerase (EBP)
T25317	GENENAME	EBP
T25317	TARGTYPE	Clinical trial
T25317	SYNONYMS	Emopamilbinding protein; EBP; Delta(8)Delta(7) sterol isomerase; D8D7 sterol isomerase; 3betahydroxysteroidDelta(8),Delta(7)isomerase
T25317	FUNCTION	Catalyzes the conversion of Delta(8)-sterols to their corresponding Delta(7)-isomers.
T25317	BIOCLASS	Intramolecular oxidoreductases
T25317	ECNUMBER	EC 5.3.3.5
T25317	SEQUENCE	MTTNAGPLHPYWPQHLRLDNFVPNDRPTWHILAGLFSVTGVLVVTTWLLSGRAAVVPLGTWRRLSLCWFAVCGFIHLVIEGWFVLYYEDLLGDQAFLSQLWKEYAKGDSRYILGDNFTVCMETITACLWGPLSLWVVIAFLRQHPLRFILQLVVSVGQIYGDVLYFLTEHRDGFQHGELGHPLYFWFYFVFMNALWLVLPGVLVLDAVKHLTHAQSTLDAKATKAKSKKN
T25317	DRUGINFO	D0D4JI	SR-31747	Phase 2

T59626	TARGETID	T59626
T59626	FORMERID	TTDC00129
T59626	UNIPROID	LT4R1_HUMAN
T59626	TARGNAME	Leukotriene B4 receptor 1 (LTB4R)
T59626	GENENAME	LTB4R
T59626	TARGTYPE	Clinical trial
T59626	SYNONYMS	P2Y7; P2Y purinoceptor 7; P2RY7; Leukotriene B(4) receptor BLT1; LTB4-R1; LTB4-R 1; LTB4-R; GPR16; G-protein coupled receptor 16; Chemoattractant receptor-like 1; CMKRL1; BLTR; BLT1; BLT
T59626	FUNCTION	The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. May be the cardiac P2Y receptor involved in the regulation of cardiac muscle contraction through modulation of L-type calcium currents. Is a receptor for leukotriene B4, a potent chemoattractant involved in inflammation and immune response. Receptor for extracellular ATP > UTP and ADP.
T59626	BIOCLASS	GPCR rhodopsin
T59626	SEQUENCE	MNTTSSAAPPSLGVEFISLLAIILLSVALAVGLPGNSFVVWSILKRMQKRSVTALMVLNLALADLAVLLTAPFFLHFLAQGTWSFGLAGCRLCHYVCGVSMYASVLLITAMSLDRSLAVARPFVSQKLRTKAMARRVLAGIWVLSFLLATPVLAYRTVVPWKTNMSLCFPRYPSEGHRAFHLIFEAVTGFLLPFLAVVASYSDIGRRLQARRFRRSRRTGRLVVLIILTFAAFWLPYHVVNLAEAGRALAGQAAGLGLVGKRLSLARNVLIALAFLSSSVNPVLYACAGGGLLRSAGVGFVAKLLEGTGSEASSTRRGGSLGQTARSGPAALEPGPSESLTASSPLKLNELN
T59626	DRUGINFO	D0QG2D	Amelubant	Phase 2
T59626	DRUGINFO	D0O4NR	LTB4	Phase 2
T59626	DRUGINFO	D0S0WN	Biomed 101	Phase 1
T59626	DRUGINFO	D00GNK	LY293111	Discontinued in Phase 2
T59626	DRUGINFO	D0B6JV	SB-201993	Discontinued in Phase 2
T59626	DRUGINFO	D0KV4Z	CI-949	Discontinued in Phase 2
T59626	DRUGINFO	D0MM2K	CP-195543	Discontinued in Phase 2
T59626	DRUGINFO	D0N0PU	LTB 019	Discontinued in Phase 2
T59626	DRUGINFO	D0U9JL	LY-223982	Discontinued in Phase 2
T59626	DRUGINFO	D0C0EO	CP-105696	Discontinued in Phase 1
T59626	DRUGINFO	D0P9KL	TAK-683	Discontinued in Phase 1
T59626	DRUGINFO	D04AWZ	SB-201146	Terminated
T59626	DRUGINFO	D04JJE	RP-66153	Terminated
T59626	DRUGINFO	D05LYL	SC-51146	Terminated
T59626	DRUGINFO	D09LQP	RG-14893	Terminated
T59626	DRUGINFO	D0A5ZJ	DW-1350	Terminated
T59626	DRUGINFO	D0G7SP	SB-209247	Terminated
T59626	DRUGINFO	D0J3NJ	RP-69698	Terminated
T59626	DRUGINFO	D0NK8D	SC-53228	Terminated
T59626	DRUGINFO	D0OP7B	LY-210073	Terminated
T59626	DRUGINFO	D0Z1TF	Ro-25-4094	Terminated
T59626	DRUGINFO	D01XMO	LY-292728	Terminated
T59626	DRUGINFO	D05BBQ	RP-66364	Terminated
T59626	DRUGINFO	D0Y2IH	LY-255283	Terminated
T59626	DRUGINFO	D00HYO	Leucettamidine	Investigative
T59626	DRUGINFO	D06IJI	SC-52073	Investigative
T59626	DRUGINFO	D07EGC	SC-50073	Investigative
T59626	DRUGINFO	D09QJS	SC-53229	Investigative
T59626	DRUGINFO	D0C2GW	SC-52569	Investigative
T59626	DRUGINFO	D0F4EL	LEUCETTAMINE A	Investigative
T59626	DRUGINFO	D0H6YL	(LTB4-(Csa)4)2-Glu-H Conjugate	Investigative
T59626	DRUGINFO	D0L8VT	DTPA Conjugate	Investigative
T59626	DRUGINFO	D0R9ED	SC-50676	Investigative
T59626	DRUGINFO	D0T1IK	HYNIC Analogue	Investigative
T59626	DRUGINFO	D0ZB8S	SC-50135	Investigative
T59626	DRUGINFO	D05HNB	LY-282210	Investigative
T59626	DRUGINFO	D06IGT	(3S,4R)-3-Benzyl-7-isopropyl-chroman-4-ol	Investigative

T97141	TARGETID	T97141
T97141	FORMERID	TTDR00794
T97141	UNIPROID	MYLK_HUMAN
T97141	TARGNAME	Myosin light kinase (MYLK)
T97141	GENENAME	MYLK
T97141	TARGTYPE	Clinical trial
T97141	SYNONYMS	smMLCK; Telokin; Myosin light chain kinase, smooth muscle; MYLK1; MLCK210; MLCK1; MLCK; Kinase-related protein; KRP; Endothelial cell (EC) MLCK isoform; EC mlck; 210,000 molecular weight myosin light chain kinase
T97141	FUNCTION	Regulates actin-myosin interaction through a non-kinase activity. Phosphorylates PTK2B/PYK2 and myosin light-chains. Involved in the inflammatory response (e. g. apoptosis, vascular permeability, leukocyte diapedesis), cell motility and morphology, airway hyperreactivity and other activities relevant to asthma. Required for tonic airway smooth muscle contraction that is necessary for physiological and asthmatic airway resistance. Necessary for gastrointestinal motility. Implicated in the regulation of endothelial as well as vascular permeability, probably via the regulation of cytoskeletal rearrangements. In the nervous system it has been shown to control the growth initiation of astrocytic processes in culture and to participate in transmitter release at synapses formed between cultured sympathetic ganglion cells. Critical participant in signaling sequences that result in fibroblast apoptosis. Plays a role in the regulation of epithelial cell survival. Required for epithelial wound healing, especially during actomyosin ring contraction during purse-string wound closure. Mediates RhoA-dependent membrane blebbing. Triggers TRPC5 channel activity in a calcium-dependent signaling, by inducing its subcellular localization at the plasma membrane. Promotes cell migration (including tumor cells) and tumor metastasis. PTK2B/PYK2 activation by phosphorylation mediates ITGB2 activation and is thus essential to trigger neutrophil transmigration during acute lung injury (ALI). May regulate optic nerve head astrocyte migration. Probably involved in mitotic cytoskeletal regulation. Regulates tight junction probably by modulating ZO-1 exchange in the perijunctional actomyosin ring. Mediates burn-induced microvascular barrier injury; triggers endothelial contraction in the development of microvascular hyperpermeability by phosphorylating MLC. Essential for intestinal barrier dysfunction. Mediates Giardia spp. -mediated reduced epithelial barrier function during giardiasis intestinal infection via reorganization of cytoskeletal F-actin and tight junctional ZO-1. Necessary for hypotonicity-induced Ca(2+) entry and subsequent activation of volume-sensitive organic osmolyte/anion channels (VSOAC) in cervical cancer cells. Responsible for high proliferative ability of breast cancer cells through anti-apoptosis. Calcium/calmodulin-dependent myosin light chain kinase implicated in smooth muscle contraction via phosphorylation of myosin light chains (MLC).
T97141	PDBSTRUC	6C6M; 5JTH; 5JQA; 2YR3; 2K0F
T97141	BIOCLASS	Kinase
T97141	ECNUMBER	EC 2.7.11.18
T97141	SEQUENCE	MGDVKLVASSHISKTSLSVDPSRVDSMPLTEAPAFILPPRNLCIKEGATAKFEGRVRGYPEPQVTWHRNGQPITSGGRFLLDCGIRGTFSLVIHAVHEEDRGKYTCEATNGSGARQVTVELTVEGSFAKQLGQPVVSKTLGDRFSAPAVETRPSIWGECPPKFATKLGRVVVKEGQMGRFSCKITGRPQPQVTWLKGNVPLQPSARVSVSEKNGMQVLEIHGVNQDDVGVYTCLVVNGSGKASMSAELSIQGLDSANRSFVRETKATNSDVRKEVTNVISKESKLDSLEAAAKSKNCSSPQRGGSPPWAANSQPQPPRESKLESCKDSPRTAPQTPVLQKTSSSITLQAARVQPEPRAPGLGVLSPSGEERKRPAPPRPATFPTRQPGLGSQDVVSKAANRRIPMEGQRDSAFPKFESKPQSQEVKENQTVKFRCEVSGIPKPEVAWFLEGTPVRRQEGSIEVYEDAGSHYLCLLKARTRDSGTYSCTASNAQGQLSCSWTLQVERLAVMEVAPSFSSVLKDCAVIEGQDFVLQCSVRGTPVPRITWLLNGQPIQYARSTCEAGVAELHIQDALPEDHGTYTCLAENALGQVSCSAWVTVHEKKSSRKSEYLLPVAPSKPTAPIFLQGLSDLKVMDGSQVTMTVQVSGNPPPEVIWLHNGNEIQESEDFHFEQRGTQHSLCIQEVFPEDTGTYTCEAWNSAGEVRTQAVLTVQEPHDGTQPWFISKPRSVTASLGQSVLISCAIAGDPFPTVHWLRDGKALCKDTGHFEVLQNEDVFTLVLKKVQPWHAGQYEILLKNRVGECSCQVSLMLQNSSARALPRGREPASCEDLCGGGVGADGGGSDRYGSLRPGWPARGQGWLEEEDGEDVRGVLKRRVETRQHTEEAIRQQEVEQLDFRDLLGKKVSTKTLSEDDLKEIPAEQMDFRANLQRQVKPKTVSEEERKVHSPQQVDFRSVLAKKGTSKTPVPEKVPPPKPATPDFRSVLGGKKKLPAENGSSSAETLNAKAVESSKPLSNAQPSGPLKPVGNAKPAETLKPMGNAKPAETLKPMGNAKPDENLKSASKEELKKDVKNDVNCKRGHAGTTDNEKRSESQGTAPAFKQKLQDVHVAEGKKLLLQCQVSSDPPATIIWTLNGKTLKTTKFIILSQEGSLCSVSIEKALPEDRGLYKCVAKNDAGQAECSCQVTVDDAPASENTKAPEMKSRRPKSSLPPVLGTESDATVKKKPAPKTPPKAAMPPQIIQFPEDQKVRAGESVELFGKVTGTQPITCTWMKFRKQIQESEHMKVENSENGSKLTILAARQEHCGCYTLLVENKLGSRQAQVNLTVVDKPDPPAGTPCASDIRSSSLTLSWYGSSYDGGSAVQSYSIEIWDSANKTWKELATCRSTSFNVQDLLPDHEYKFRVRAINVYGTSEPSQESELTTVGEKPEEPKDEVEVSDDDEKEPEVDYRTVTINTEQKVSDFYDIEERLGSGKFGQVFRLVEKKTRKVWAGKFFKAYSAKEKENIRQEISIMNCLHHPKLVQCVDAFEEKANIVMVLEIVSGGELFERIIDEDFELTERECIKYMRQISEGVEYIHKQGIVHLDLKPENIMCVNKTGTRIKLIDFGLARRLENAGSLKVLFGTPEFVAPEVINYEPIGYATDMWSIGVICYILVSGLSPFMGDNDNETLANVTSATWDFDDEAFDEISDDAKDFISNLLKKDMKNRLDCTQCLQHPWLMKDTKNMEAKKLSKDRMKKYMARRKWQKTGNAVRAIGRLSSMAMISGLSGRKSSTGSPTSPLNAEKLESEEDVSQAFLEAVAEEKPHVKPYFSKTIRDLEVVEGSAARFDCKIEGYPDPEVVWFKDDQSIRESRHFQIDYDEDGNCSLIISDVCGDDDAKYTCKAVNSLGEATCTAELIVETMEEGEGEGEEEEE
T97141	DRUGINFO	D0L8MO	ME-3407	Phase 2
T97141	DRUGINFO	D03CPB	RKI-1447	Investigative

T46245	TARGETID	T46245
T46245	FORMERID	TTDI02156
T46245	UNIPROID	QPCT_HUMAN
T46245	TARGNAME	Glutaminyl cyclase (QPCT)
T46245	GENENAME	QPCT
T46245	TARGTYPE	Clinical trial
T46245	SYNONYMS	sQC; QPCT; QC; Glutamyl cyclase; GlutaminyltRNA cyclotransferase; Glutaminylpeptide cyclotransferase; EC
T46245	FUNCTION	Responsible for the biosynthesis of pyroglutamyl peptides. Has a bias against acidic and tryptophan residues adjacent to the N-terminal glutaminyl residue and a lack of importance of chain length after the second residue. Also catalyzes N-terminal pyroglutamate formation. In vitro, catalyzes pyroglutamate formation of N-terminally truncated form of APP amyloid-beta peptides [Glu-3]-beta-amyloid. May be involved in the N-terminal pyroglutamate formation of several amyloid-related plaque-forming peptides.
T46245	PDBSTRUC	6GBX; 4YWY; 4YU9; 3SI0; 3PBE
T46245	BIOCLASS	Acyltransferase
T46245	ECNUMBER	EC 2.3.2.5
T46245	SEQUENCE	MAGGRHRRVVGTLHLLLLVAALPWASRGVSPSASAWPEEKNYHQPAILNSSALRQIAEGTSISEMWQNDLQPLLIERYPGSPGSYAARQHIMQRIQRLQADWVLEIDTFLSQTPYGYRSFSNIISTLNPTAKRHLVLACHYDSKYFSHWNNRVFVGATDSAVPCAMMLELARALDKKLLSLKTVSDSKPDLSLQLIFFDGEEAFLHWSPQDSLYGSRHLAAKMASTPHPPGARGTSQLHGMDLLVLLDLIGAPNPTFPNFFPNSARWFERLQAIEHELHELGLLKDHSLEGRYFQNYSYGGVIQDDHIPFLRRGVPVLHLIPSPFPEVWHTMDDNEENLDESTIDNLNKILQVFVLEYLHL
T46245	DRUGINFO	D0UD4Y	PQ-912	Phase 2
T46245	DRUGINFO	D00JHN	PBD150	Investigative

T32972	TARGETID	T32972
T32972	UNIPROID	CP51A_HUMAN
T32972	TARGNAME	Lanosterol 14-alpha demethylase (CYP51A1)
T32972	GENENAME	CYP51A1
T32972	TARGTYPE	Clinical trial
T32972	SYNONYMS	Cytochrome P450LI; Cytochrome P45014DM; Cytochrome P450-14DM; Cytochrome P450 51A1
T32972	FUNCTION	Catalyzes C14-demethylation of lanosterol; it transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol.
T32972	PDBSTRUC	4UHL; 4UHI; 3LD6; 3JUV; 3JUS
T32972	BIOCLASS	Cytochrome P450 family
T32972	ECNUMBER	EC 1.14.14.154
T32972	SEQUENCE	MLLLGLLQAGGSVLGQAMEKVTGGNLLSMLLIACAFTLSLVYLIRLAAGHLVQLPAGVKSPPYIFSPIPFLGHAIAFGKSPIEFLENAYEKYGPVFSFTMVGKTFTYLLGSDAAALLFNSKNEDLNAEDVYSRLTTPVFGKGVAYDVPNPVFLEQKKMLKSGLNIAHFKQHVSIIEKETKEYFESWGESGEKNVFEALSELIILTASHCLHGKEIRSQLNEKVAQLYADLDGGFSHAAWLLPGWLPLPSFRRRDRAHREIKDIFYKAIQKRRQSQEKIDDILQTLLDATYKDGRPLTDDEVAGMLIGLLLAGQHTSSTTSAWMGFFLARDKTLQKKCYLEQKTVCGENLPPLTYDQLKDLNLLDRCIKETLRLRPPIMIMMRMARTPQTVAGYTIPPGHQVCVSPTVNQRLKDSWVERLDFNPDRYLQDNPASGEKFAYVPFGAGRHRCIGENFAYVQIKTIWSTMLRLYEFDLIDGYFPTVNYTTMIHTPENPVIRYKRRSK
T32972	DRUGINFO	D0UA9J	VT-1129	Phase 2

T90985	TARGETID	T90985
T90985	FORMERID	TTDI02033
T90985	UNIPROID	BRDT_HUMAN
T90985	TARGNAME	Bromodomain testis-specific protein (BRDT)
T90985	GENENAME	BRDT
T90985	TARGTYPE	Clinical trial
T90985	SYNONYMS	Cancer/testis antigen 9; CT9
T90985	FUNCTION	Required in late pachytene spermatocytes: plays a role in meiotic and post-meiotic cells by binding to acetylated histones at the promoter of specific meiotic and post-meiotic genes, facilitating their activation at the appropriate time. In the post-meiotic phase of spermatogenesis, binds to hyperacetylated histones and participates in their general removal from DNA. Also recognizes and binds a subset of butyrylated histones: able to bind histone H4 butyrylated at 'Lys-8' (H4K8ac), while it is not able to bind H4 butyrylated at 'Lys-5' (H4K5ac). Also acts as a component of the splicing machinery in pachytene spermatocytes and round spermatids and participates in 3'-UTR truncation of specific mRNAs in post-meiotic spermatids. Required for chromocenter organization, a structure comprised of peri-centromeric heterochromatin. Testis-specific chromatin protein that specifically binds histone H4 acetylated at 'Lys-5' and 'Lys-8' (H4K5ac and H4K8ac, respectively) and plays a key role in spermatogenesis.
T90985	PDBSTRUC	5VBR; 5VBQ; 4KCX; 4FLP; 2RFJ
T90985	BIOCLASS	Bromodomain
T90985	SEQUENCE	MSLPSRQTAIIVNPPPPEYINTKKNGRLTNQLQYLQKVVLKDLWKHSFSWPFQRPVDAVKLQLPDYYTIIKNPMDLNTIKKRLENKYYAKASECIEDFNTMFSNCYLYNKPGDDIVLMAQALEKLFMQKLSQMPQEEQVVGVKERIKKGTQQNIAVSSAKEKSSPSATEKVFKQQEIPSVFPKTSISPLNVVQGASVNSSSQTAAQVTKGVKRKADTTTPATSAVKASSEFSPTFTEKSVALPPIKENMPKNVLPDSQQQYNVVKTVKVTEQLRHCSEILKEMLAKKHFSYAWPFYNPVDVNALGLHNYYDVVKNPMDLGTIKEKMDNQEYKDAYKFAADVRLMFMNCYKYNPPDHEVVTMARMLQDVFETHFSKIPIEPVESMPLCYIKTDITETTGRENTNEASSEGNSSDDSEDERVKRLAKLQEQLKAVHQQLQVLSQVPFRKLNKKKEKSKKEKKKEKVNNSNENPRKMCEQMRLKEKSKRNQPKKRKQQFIGLKSEDEDNAKPMNYDEKRQLSLNINKLPGDKLGRVVHIIQSREPSLSNSNPDEIEIDFETLKASTLRELEKYVSACLRKRPLKPPAKKIMMSKEELHSQKKQELEKRLLDVNNQLNSRKRQTKSDKTQPSKAVENVSRLSESSSSSSSSSESESSSSDLSSSDSSDSESEMFPKFTEVKPNDSPSKENVKKMKNECIPPEGRTGVTQIGYCVQDTTSANTTLVHQTTPSHVMPPNHHQLAFNYQELEHLQTVKNISPLQILPPSGDSEQLSNGITVMHPSGDSDTTMLESECQAPVQKDIKIKNADSWKSLGKPVKPSGVMKSSDELFNQFRKAAIEKEVKARTQELIRKHLEQNTKELKASQENQRDLGNGLTVESFSNKIQNKCSGEEQKEHQQSSEAQDKSKLWLLKDRDLARQKEQERRRREAMVGTIDMTLQSDIMTMFENNFD
T90985	DRUGINFO	D0ZW4W	(+)-JQ1	Phase 1
T90985	DRUGINFO	D03NWT	PMID26924192-Compound-104	Patented
T90985	DRUGINFO	D03RPJ	PMID26924192-Compound-102	Patented
T90985	DRUGINFO	D05XXS	PMID26924192-Compound-103	Patented
T90985	DRUGINFO	D0NN4U	PMID26924192-Compound-105	Patented
T90985	DRUGINFO	D07FGY	XD14	Investigative

T78381	TARGETID	T78381
T78381	FORMERID	TTDI02296
T78381	UNIPROID	IFNL1_HUMAN
T78381	TARGNAME	Interleukin-29 (IL29)
T78381	GENENAME	IFNL1
T78381	TARGTYPE	Clinical trial
T78381	SYNONYMS	ZCYTO21; Interleukin29; Interferon lambda1; Interferon lambda-1; IL-29; IFNlambda1; IFN-lambda-1; Cytokine Zcyto21
T78381	FUNCTION	Plays a critical role in the antiviral host defense, predominantly in the epithelial tissues. Acts as a ligand for the heterodimeric class II cytokine receptor composed of IL10RB and IFNLR1, and receptor engagement leads to the activation of the JAK/STAT signaling pathway resulting in the expression of IFN-stimulated genes (ISG), which mediate the antiviral state. Has a restricted receptor distribution and therefore restricted targets: is primarily active in epithelial cells and this cell type-selective action is because of the epithelial cell-specific expression of its receptor IFNLR1. Exerts an immunomodulatory effect by up-regulating MHC class I antigen expression. Cytokine with antiviral, antitumour and immunomodulatory activities.
T78381	PDBSTRUC	3OG6; 3OG4
T78381	BIOCLASS	Cytokine: interleukin
T78381	SEQUENCE	MAAAWTVVLVTLVLGLAVAGPVPTSKPTTTGKGCHIGRFKSLSPQELASFKKARDALEESLKLKNWSCSSPVFPGNWDLRLLQVRERPVALEAELALTLKVLEAAAGPALEDVLDQPLHTLHHILSQLQACIQPQPTAGPRPRGRLHHWLHRLQEAPKKESAGCLEASVTFNLFRLLTRDLKYVADGNLCLRTSTHPEST
T78381	DRUGINFO	D0T6IN	Peginterferon lambda-1a	Phase 3
T78381	DRUGINFO	D0D1XW	PEG-Interferon lambda (IL-29)	Phase 1

T58496	TARGETID	T58496
T58496	FORMERID	TTDR01258
T58496	UNIPROID	TRPV3_HUMAN
T58496	TARGNAME	Transient receptor potential cation channel V3 (TRPV3)
T58496	GENENAME	TRPV3
T58496	TARGTYPE	Clinical trial
T58496	SYNONYMS	Vanilloid receptor-like 3; VRL-3; TrpV3
T58496	FUNCTION	Putative receptor-activated non-selective calcium permeant cation channel. It is activated by innocuous (warm) temperatures and shows an increased response at noxious temperatures greater than 39 degrees Celsius. Activation exhibits an outward rectification. May associate with TRPV1 and may modulate its activity. Is a negative regulator of hair growth and cycling: TRPV3-coupled signaling suppresses keratinocyte proliferation in hair follicles and induces apoptosis and premature hair follicle regression (catagen).
T58496	PDBSTRUC	6OT5; 6OT2; 6MHX; 6MHW; 6MHV
T58496	BIOCLASS	Transient receptor potential catioin channel
T58496	SEQUENCE	MKAHPKEMVPLMGKRVAAPSGNPAILPEKRPAEITPTKKSAHFFLEIEGFEPNPTVAKTSPPVFSKPMDSNIRQCISGNCDDMDSPQSPQDDVTETPSNPNSPSAQLAKEEQRRKKRRLKKRIFAAVSEGCVEELVELLVELQELCRRRHDEDVPDFLMHKLTASDTGKTCLMKALLNINPNTKEIVRILLAFAEENDILGRFINAEYTEEAYEGQTALNIAIERRQGDIAALLIAAGADVNAHAKGAFFNPKYQHEGFYFGETPLALAACTNQPEIVQLLMEHEQTDITSRDSRGNNILHALVTVAEDFKTQNDFVKRMYDMILLRSGNWELETTRNNDGLTPLQLAAKMGKAEILKYILSREIKEKRLRSLSRKFTDWAYGPVSSSLYDLTNVDTTTDNSVLEITVYNTNIDNRHEMLTLEPLHTLLHMKWKKFAKHMFFLSFCFYFFYNITLTLVSYYRPREEEAIPHPLALTHKMGWLQLLGRMFVLIWAMCISVKEGIAIFLLRPSDLQSILSDAWFHFVFFIQAVLVILSVFLYLFAYKEYLACLVLAMALGWANMLYYTRGFQSMGMYSVMIQKVILHDVLKFLFVYIVFLLGFGVALASLIEKCPKDNKDCSSYGSFSDAVLELFKLTIGLGDLNIQQNSKYPILFLFLLITYVILTFVLLLNMLIALMGETVENVSKESERIWRLQRARTILEFEKMLPEWLRSRFRMGELCKVAEDDFRLCLRINEVKWTEWKTHVSFLNEDPGPVRRTDFNKIQDSSRNNSKTTLNAFEEVEEFPETSV
T58496	DRUGINFO	D03SLK	SAR292833	Phase 2
T58496	DRUGINFO	D01BDJ	diphenyltetrahydrofuran	Investigative
T58496	DRUGINFO	D03EYA	carveol	Investigative
T58496	DRUGINFO	D07GOR	dihydrocarveol	Investigative
T58496	DRUGINFO	D0D8PZ	tetrahydrocannabivarin	Investigative
T58496	DRUGINFO	D0F0BB	6-tert-butyl-m-cresol	Investigative
T58496	DRUGINFO	D0H0EP	EDP-18	Investigative
T58496	DRUGINFO	D0JW1C	incensole acetate	Investigative
T58496	DRUGINFO	D0P8RH	borneol	Investigative
T58496	DRUGINFO	D00VWN	citral	Investigative
T58496	DRUGINFO	D05PYO	aspirin-triggered resolvin D1	Investigative
T58496	DRUGINFO	D07JDC	carvacrol	Investigative
T58496	DRUGINFO	D0PJ3M	cinnamaldehyde	Investigative
T58496	DRUGINFO	D03TWR	diphenylboronic anhydride	Investigative
T58496	DRUGINFO	D00HCI	2-APB	Investigative

T86273	TARGETID	T86273
T86273	FORMERID	TTDR01440
T86273	UNIPROID	GPBAR_HUMAN
T86273	TARGNAME	G-protein coupled bile acid receptor 1 (GPBAR1)
T86273	GENENAME	GPBAR1
T86273	TARGTYPE	Clinical trial
T86273	SYNONYMS	hGPCR19; hBG37; TGR5; Membrane-type receptor for bile acids; M-BAR; G-protein coupled receptor GPCR19; BG37
T86273	FUNCTION	Bile acid-binding induces its internalization, activation of extracellular signal-regulated kinase and intracellular cAMP production. May be involved in the suppression of macrophage functions by bile acids. Receptor for bile acid.
T86273	BIOCLASS	GPCR rhodopsin
T86273	SEQUENCE	MTPNSTGEVPSPIPKGALGLSLALASLIITANLLLALGIAWDRRLRSPPAGCFFLSLLLAGLLTGLALPTLPGLWNQSRRGYWSCLLVYLAPNFSFLSLLANLLLVHGERYMAVLRPLQPPGSIRLALLLTWAGPLLFASLPALGWNHWTPGANCSSQAIFPAPYLYLEVYGLLLPAVGAAAFLSVRVLATAHRQLQDICRLERAVCRDEPSALARALTWRQARAQAGAMLLFGLCWGPYVATLLLSVLAYEQRPPLGPGTLLSLLSLGSASAAAVPVAMGLGDQRYTAPWRAAAQRCLQGLWGRASRDSPGPSIAYHPSSQSSVDLDLN
T86273	DRUGINFO	D03BZN	Sodium taurocholate	Phase 1/2
T86273	DRUGINFO	D08LIB	PMID29649907-Compound-INT767	Patented
T86273	DRUGINFO	D0AA3P	PMID29649907-Compound-8	Patented
T86273	DRUGINFO	D09ODU	XL475	Preclinical
T86273	DRUGINFO	DNZ96J	INT-767	Preclinical
T86273	DRUGINFO	D0B7AH	INT-777	Investigative
T86273	DRUGINFO	D0MZ9Q	Bile acid	Investigative

T03634	TARGETID	T03634
T03634	FORMERID	TTDNC00387
T03634	UNIPROID	CBP_HUMAN
T03634	TARGNAME	CREB-binding protein (CREBBP)
T03634	GENENAME	CREBBP
T03634	TARGTYPE	Clinical trial
T03634	SYNONYMS	CREBbinding protein; CBP
T03634	FUNCTION	Acetylates non-histone proteins, like NCOA3 and FOXO1. Binds specifically to phosphorylated CREB and enhances its transcriptional activity toward cAMP-responsive genes. Acts as a coactivator of ALX1. Acts as a circadian transcriptional coactivator which enhances the activity of the circadian transcriptional activators: NPAS2-ARNTL/BMAL1 and CLOCK-ARNTL/BMAL1 heterodimers. Acetylates PCNA; acetylation promotes removal of chromatin-bound PCNA and its degradation during nucleotide excision repair (NER). Functions as a transcriptional coactivator for SMAD4 in the TGF-beta signaling pathway. Acetylates histones, giving a specific tag for transcriptional activation.
T03634	PDBSTRUC	6FRF; 6FR0; 6FQU; 6FQT; 6FQO
T03634	BIOCLASS	Acyltransferase
T03634	ECNUMBER	EC 2.3.1.48
T03634	SEQUENCE	MAENLLDGPPNPKRAKLSSPGFSANDSTDFGSLFDLENDLPDELIPNGGELGLLNSGNLVPDAASKHKQLSELLRGGSGSSINPGIGNVSASSPVQQGLGGQAQGQPNSANMASLSAMGKSPLSQGDSSAPSLPKQAASTSGPTPAASQALNPQAQKQVGLATSSPATSQTGPGICMNANFNQTHPGLLNSNSGHSLINQASQGQAQVMNGSLGAAGRGRGAGMPYPTPAMQGASSSVLAETLTQVSPQMTGHAGLNTAQAGGMAKMGITGNTSPFGQPFSQAGGQPMGATGVNPQLASKQSMVNSLPTFPTDIKNTSVTNVPNMSQMQTSVGIVPTQAIATGPTADPEKRKLIQQQLVLLLHAHKCQRREQANGEVRACSLPHCRTMKNVLNHMTHCQAGKACQVAHCASSRQIISHWKNCTRHDCPVCLPLKNASDKRNQQTILGSPASGIQNTIGSVGTGQQNATSLSNPNPIDPSSMQRAYAALGLPYMNQPQTQLQPQVPGQQPAQPQTHQQMRTLNPLGNNPMNIPAGGITTDQQPPNLISESALPTSLGATNPLMNDGSNSGNIGTLSTIPTAAPPSSTGVRKGWHEHVTQDLRSHLVHKLVQAIFPTPDPAALKDRRMENLVAYAKKVEGDMYESANSRDEYYHLLAEKIYKIQKELEEKRRSRLHKQGILGNQPALPAPGAQPPVIPQAQPVRPPNGPLSLPVNRMQVSQGMNSFNPMSLGNVQLPQAPMGPRAASPMNHSVQMNSMGSVPGMAISPSRMPQPPNMMGAHTNNMMAQAPAQSQFLPQNQFPSSSGAMSVGMGQPPAQTGVSQGQVPGAALPNPLNMLGPQASQLPCPPVTQSPLHPTPPPASTAAGMPSLQHTTPPGMTPPQPAAPTQPSTPVSSSGQTPTPTPGSVPSATQTQSTPTVQAAAQAQVTPQPQTPVQPPSVATPQSSQQQPTPVHAQPPGTPLSQAAASIDNRVPTPSSVASAETNSQQPGPDVPVLEMKTETQAEDTEPDPGESKGEPRSEMMEEDLQGASQVKEETDIAEQKSEPMEVDEKKPEVKVEVKEEEESSSNGTASQSTSPSQPRKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLGYCCGRKYEFSPQTLCCYGKQLCTIPRDAAYYSYQNRYHFCEKCFTEIQGENVTLGDDPSQPQTTISKDQFEKKKNDTLDPEPFVDCKECGRKMHQICVLHYDIIWPSGFVCDNCLKKTGRPRKENKFSAKRLQTTRLGNHLEDRVNKFLRRQNHPEAGEVFVRVVASSDKTVEVKPGMKSRFVDSGEMSESFPYRTKALFAFEEIDGVDVCFFGMHVQEYGSDCPPPNTRRVYISYLDSIHFFRPRCLRTAVYHEILIGYLEYVKKLGYVTGHIWACPPSEGDDYIFHCHPPDQKIPKPKRLQEWYKKMLDKAFAERIIHDYKDIFKQATEDRLTSAKELPYFEGDFWPNVLEESIKELEQEEEERKKEESTAASETTEGSQGDSKNAKKKNNKKTNKNKSSISRANKKKPSMPNVSNDLSQKLYATMEKHKEVFFVIHLHAGPVINTLPPIVDPDPLLSCDLMDGRDAFLTLARDKHWEFSSLRRSKWSTLCMLVELHTQGQDRFVYTCNECKHHVETRWHCTVCEDYDLCINCYNTKSHAHKMVKWGLGLDDEGSSQGEPQSKSPQESRRLSIQRCIQSLVHACQCRNANCSLPSCQKMKRVVQHTKGCKRKTNGGCPVCKQLIALCCYHAKHCQENKCPVPFCLNIKHKLRQQQIQHRLQQAQLMRRRMATMNTRNVPQQSLPSPTSAPPGTPTQQPSTPQTPQPPAQPQPSPVSMSPAGFPSVARTQPPTTVSTGKPTSQVPAPPPPAQPPPAAVEAARQIEREAQQQQHLYRVNINNSMPPGRTGMGTPGSQMAPVSLNVPRPNQVSGPVMPSMPPGQWQQAPLPQQQPMPGLPRPVISMQAQAAVAGPRMPSVQPPRSISPSALQDLLRTLKSPSSPQQQQQVLNILKSNPQLMAAFIKQRTAKYVANQPGMQPQPGLQSQPGMQPQPGMHQQPSLQNLNAMQAGVPRPGVPPQQQAMGGLNPQGQALNIMNPGHNPNMASMNPQYREMLRRQLLQQQQQQQQQQQQQQQQQQGSAGMAGGMAGHGQFQQPQGPGGYPPAMQQQQRMQQHLPLQGSSMGQMAAQMGQLGQMGQPGLGADSTPNIQQALQQRILQQQQMKQQIGSPGQPNPMSPQQHMLSGQPQASHLPGQQIATSLSNQVRSPAPVQSPRPQSQPPHSSPSPRIQPQPSPHHVSPQTGSPHPGLAVTMASSIDQGHLGNPEQSAMLPQLNTPSRSALSSELSLVGDTTGDTLEKFVEGL
T03634	DRUGINFO	D0Q0ZY	PRI-724	Phase 1/2
T03634	DRUGINFO	D0DA5M	C 82	Phase 1/2
T03634	DRUGINFO	DIY4C2	CCS1477	Phase 1/2
T03634	DRUGINFO	DT8IL6	FT-7051	Phase 1
T03634	DRUGINFO	D0O9WQ	Pyrrolo-pyrrolone derivative 6	Patented
T03634	DRUGINFO	D00DXI	ischemin	Investigative
T03634	DRUGINFO	D03XXT	SGC-CBP30	Investigative
T03634	DRUGINFO	D0J3JI	I-CBP112	Investigative

T64074	TARGETID	T64074
T64074	FORMERID	TTDC00341
T64074	UNIPROID	DCPS_HUMAN
T64074	TARGNAME	Scavenger decapping enzyme DcpS (DCPS)
T64074	GENENAME	DCPS
T64074	TARGTYPE	Clinical trial
T64074	SYNONYMS	Scavenger mRNA-decapping enzyme DcpS; Histidine triad protein member5; Hint-related 7meGMP-directed hydrolase; HINT-5; DCS-1; DCPS
T64074	FUNCTION	Decapping scavenger enzyme that catalyzes the cleavage of a residual cap structure following the degradation of mRNAs by the 3'->5' exosome-mediated mRNA decay pathway. Hydrolyzes cap analog structures like 7-methylguanosine nucleoside triphosphate (m7GpppG) with up to 10 nucleotide substrates (small capped oligoribonucleotides) and specifically releases 5'-phosphorylated RNA fragments and 7-methylguanosine monophosphate (m7GMP). Cleaves cap analog structures like tri-methyl guanosine nucleoside triphosphate (m3(2,2,7)GpppG) with very poor efficiency. Does not hydrolyze unmethylated cap analog (GpppG) and shows no decapping activity on intact m7GpppG-capped mRNA molecules longer than 25 nucleotides. Does not hydrolyze 7-methylguanosine diphosphate (m7GDP) to m7GMP (PubMed:22985415). May also play a role in the 5'->3 mRNA decay pathway; m7GDP, the downstream product released by the 5'->3' mRNA mediated decapping activity, may be also converted by DCPS to m7GMP (PubMed:14523240). Binds to m7GpppG and strongly to m7GDP. Plays a role in first intron splicing of pre- mRNAs. Inhibits activation-induced cell death.
T64074	PDBSTRUC	5OSY; 4QEB; 4QDV; 4QDE; 3BLA
T64074	BIOCLASS	Acid anhydrides hydrolase
T64074	ECNUMBER	EC 3.6.1.59
T64074	SEQUENCE	MADAAPQLGKRKRELDVEEAHAASTEEKEAGVGNGTCAPVRLPFSGFRLQKVLRESARDKIIFLHGKVNEASGDGDGEDAVVILEKTPFQVEQVAQLLTGSPELQLQFSNDIYSTYHLFPPRQLNDVKTTVVYPATEKHLQKYLRQDLRLIRETGDDYRNITLPHLESQSLSIQWVYNILDKKAEADRIVFENPDPSDGFVLIPDLKWNQQQLDDLYLIAICHRRGIRSLRDLTPEHLPLLRNILHQGQEAILQRYRMKGDHLRVYLHYLPSYYHLHVHFTALGFEAPGSGVERAHLLAEVIENLECDPRHYQQRTLTFALRADDPLLKLLQEAQQS
T64074	DRUGINFO	D0KV6C	RG3039	Phase 1

T05643	TARGETID	T05643
T05643	FORMERID	TTDI02113
T05643	UNIPROID	LIGO1_HUMAN
T05643	TARGNAME	Leucine-rich repeat neuronal protein 1 (LINGO1)
T05643	GENENAME	LINGO1
T05643	TARGTYPE	Clinical trial
T05643	SYNONYMS	Leucinerich repeat neuronal protein 6A; Leucinerich repeat and immunoglobulinlike domaincontaining nogo receptorinteracting protein 1; Leucinerich repeat and immunoglobulin domaincontaining protein 1; LINGO1
T05643	FUNCTION	Functional component of the Nogo receptor signaling complex (RTN4R/NGFR) in RhoA activation responsible for some inhibition of axonal regeneration by myelin-associated factors. Is also an important negative regulator of oligodentrocyte differentiation and axonal myelination. Acts in conjunction with RTN4 and RTN4R in regulating neuronal precursor cell motility during cortical development. {ECO:0000250}.
T05643	PDBSTRUC	4OQT; 2ID5
T05643	BIOCLASS	Immunoglobulin
T05643	SEQUENCE	MQVSKRMLAGGVRSMPSPLLACWQPILLLVLGSVLSGSATGCPPRCECSAQDRAVLCHRKRFVAVPEGIPTETRLLDLGKNRIKTLNQDEFASFPHLEELELNENIVSAVEPGAFNNLFNLRTLGLRSNRLKLIPLGVFTGLSNLTKLDISENKIVILLDYMFQDLYNLKSLEVGDNDLVYISHRAFSGLNSLEQLTLEKCNLTSIPTEALSHLHGLIVLRLRHLNINAIRDYSFKRLYRLKVLEISHWPYLDTMTPNCLYGLNLTSLSITHCNLTAVPYLAVRHLVYLRFLNLSYNPISTIEGSMLHELLRLQEIQLVGGQLAVVEPYAFRGLNYLRVLNVSGNQLTTLEESVFHSVGNLETLILDSNPLACDCRLLWVFRRRWRLNFNRQQPTCATPEFVQGKEFKDFPDVLLPNYFTCRRARIRDRKAQQVFVDEGHTVQFVCRADGDPPPAILWLSPRKHLVSAKSNGRLTVFPDGTLEVRYAQVQDNGTYLCIAANAGGNDSMPAHLHVRSYSPDWPHQPNKTFAFISNQPGEGEANSTRATVPFPFDIKTLIIATTMGFISFLGVVLFCLVLLFLWSRGKGNTKHNIEIEYVPRKSDAGISSADAPRKFNMKMI
T05643	DRUGINFO	D07DSN	BIIB 033	Phase 2

T76093	TARGETID	T76093
T76093	FORMERID	TTDNC00420
T76093	UNIPROID	HBEGF_HUMAN
T76093	TARGNAME	Proheparin-binding EGF-like growth factor (HBEGF)
T76093	GENENAME	HBEGF
T76093	TARGTYPE	Clinical trial
T76093	SYNONYMS	Proheparinbinding EGFlike growth factor; Heparinbinding EGFlike growth factor; Heparin-binding EGF-like growth factor; HEGFL; HB-EGF; Diphtheria toxin receptor; DTS; DTR; DT-R
T76093	FUNCTION	Required for normal cardiac valve formation and normal heart function. Promotes smooth muscle cell proliferation. May be involved in macrophage-mediated cellular proliferation. It is mitogenic for fibroblasts, but not endothelial cells. It is able to bind EGF receptor/EGFR with higher affinity than EGF itself and is a far more potent mitogen for smooth muscle cells than EGF. Also acts as a diphtheria toxin receptor. Growth factor that mediates its effects via EGFR, ERBB2 and ERBB4.
T76093	PDBSTRUC	2M8S; 1XDT
T76093	BIOCLASS	Growth factor
T76093	SEQUENCE	MKLLPSVVLKLFLAAVLSALVTGESLERLRRGLAAGTSNPDPPTVSTDQLLPLGGGRDRKVRDLQEADLDLLRVTLSSKPQALATPNKEEHGKRKKKGKGLGKKRDPCLRKYKDFCIHGECKYVKELRAPSCICHPGYHGERCHGLSLPVENRLYTYDHTTILAVVAVVLSSVCLLVIVGLLMFRYHRRGGYDVENEEKVKLGMTNSH
T76093	DRUGINFO	D06ZXF	U3-1565	Phase 1
T76093	DRUGINFO	D0S4KJ	KHK-2866	Phase 1
T76093	DRUGINFO	DM5PA2	ASP0598	Phase 1

T32973	TARGETID	T32973
T32973	FORMERID	TTDI02612
T32973	UNIPROID	LGMN_HUMAN
T32973	TARGNAME	Legumain (LGMN)
T32973	GENENAME	LGMN
T32973	TARGTYPE	Clinical trial
T32973	SYNONYMS	Protease, cysteine 1; PRSC1; Asparaginyl endopeptidase
T32973	FUNCTION	Can also cleave aspartyl bonds slowly, especially under acidic conditions. Required for normal lysosomal protein degradation in renal proximal tubules. Required for normal degradation of internalized EGFR. Plays a role in the regulation of cell proliferation via its role in EGFR degradation. May be involved in the processing of proteins for MHC class II antigen presentation in the lysosomal/endosomal system. Has a strict specificity for hydrolysis of asparaginyl bonds.
T32973	PDBSTRUC	5LUB; 5LUA; 5LU9; 5LU8; 4N6O
T32973	BIOCLASS	Peptidase
T32973	ECNUMBER	EC 3.4.22.34
T32973	SEQUENCE	MVWKVAVFLSVALGIGAVPIDDPEDGGKHWVVIVAGSNGWYNYRHQADACHAYQIIHRNGIPDEQIVVMMYDDIAYSEDNPTPGIVINRPNGTDVYQGVPKDYTGEDVTPQNFLAVLRGDAEAVKGIGSGKVLKSGPQDHVFIYFTDHGSTGILVFPNEDLHVKDLNETIHYMYKHKMYRKMVFYIEACESGSMMNHLPDNINVYATTAANPRESSYACYYDEKRSTYLGDWYSVNWMEDSDVEDLTKETLHKQYHLVKSHTNTSHVMQYGNKTISTMKVMQFQGMKRKASSPVPLPPVTHLDLTPSPDVPLTIMKRKLMNTNDLEESRQLTEEIQRHLDARHLIEKSVRKIVSLLAASEAEVEQLLSERAPLTGHSCYPEALLHFRTHCFNWHSPTYEYALRHLYVLVNLCEKPYPLHRIKLSMDHVCLGHY
T32973	DRUGINFO	D0PV4H	Legumain-cleavable doxorubicin prodrugs	Phase 2/3
T32973	DRUGINFO	D0W6HI	PMID24775305C7u	Investigative

T63414	TARGETID	T63414
T63414	FORMERID	TTDC00218
T63414	UNIPROID	P2RX7_HUMAN
T63414	TARGNAME	P2X purinoceptor 7 (P2RX7)
T63414	GENENAME	P2RX7
T63414	TARGTYPE	Clinical trial
T63414	SYNONYMS	Purinergic receptor 7; P2Z receptor; P2X7; Adenosine P2X7 receptor; ATP receptor
T63414	FUNCTION	Responsible for ATP-dependent lysis of macrophages through the formation of membrane pores permeable to large molecules. Could function in both fast synaptic transmission and the ATP-mediated lysis of antigen-presenting cells. In the absence of its natural ligand, ATP, functions as a scavenger receptor in the recognition and engulfment of apoptotic cells. Receptor for ATP that acts as a ligand-gated ion channel.
T63414	BIOCLASS	ATP-gated P2X receptor cation channel
T63414	SEQUENCE	MPACCSCSDVFQYETNKVTRIQSMNYGTIKWFFHVIIFSYVCFALVSDKLYQRKEPVISSVHTKVKGIAEVKEEIVENGVKKLVHSVFDTADYTFPLQGNSFFVMTNFLKTEGQEQRLCPEYPTRRTLCSSDRGCKKGWMDPQSKGIQTGRCVVYEGNQKTCEVSAWCPIEAVEEAPRPALLNSAENFTVLIKNNIDFPGHNYTTRNILPGLNITCTFHKTQNPQCPIFRLGDIFRETGDNFSDVAIQGGIMGIEIYWDCNLDRWFHHCRPKYSFRRLDDKTTNVSLYPGYNFRYAKYYKENNVEKRTLIKVFGIRFDILVFGTGGKFDIIQLVVYIGSTLSYFGLAAVFIDFLIDTYSSNCCRSHIYPWCKCCQPCVVNEYYYRKKCESIVEPKPTLKYVSFVDESHIRMVNQQLLGRSLQDVKGQEVPRPAMDFTDLSRLPLALHDTPPIPGQPEEIQLLRKEATPRSRDSPVWCQCGSCLPSQLPESHRCLEELCCRKKPGACITTSELFRKLVLSRHVLQFLLLYQEPLLALDVDSTNSRLRHCAYRCYATWRFGSQDMADFAILPSCCRWRIRKEFPKSEGQYSGFKSPY
T63414	DRUGINFO	D0F4JK	CE-224535	Phase 2/3
T63414	DRUGINFO	D0CS2C	AZD9056	Phase 2
T63414	DRUGINFO	DX5T4D	LY3857210	Phase 2
T63414	DRUGINFO	D02AIZ	BIL010t	Phase 1/2
T63414	DRUGINFO	D01TLV	EVT 401	Phase 1
T63414	DRUGINFO	D02XAS	SGM-1019	Phase 1
T63414	DRUGINFO	D0I7BU	GSK1482160	Phase 1
T63414	DRUGINFO	D0OQ1A	JNJ-55308942	Phase 1
T63414	DRUGINFO	D0VI4N	JNJ-54175446	Phase 1
T63414	DRUGINFO	D07QTG	JNJ-479655	Clinical trial
T63414	DRUGINFO	D00PVH	Triazole derivative 2	Patented
T63414	DRUGINFO	D04QLC	Benzamide derivative 13	Patented
T63414	DRUGINFO	D04SHK	Isothiazolidine derivative 1	Patented
T63414	DRUGINFO	D05KRX	Quinoline derivative 10	Patented
T63414	DRUGINFO	D06MSZ	PMID27724045-Compound-19	Patented
T63414	DRUGINFO	D07EBW	PMID27724045-Compound-17	Patented
T63414	DRUGINFO	D07VLC	Fluorophenyl-substituted heterocyclic amide analog 1	Patented
T63414	DRUGINFO	D08OKB	Bicyclic heteroaryl amide derivative 2	Patented
T63414	DRUGINFO	D08PQU	PMID27724045-Compound-33	Patented
T63414	DRUGINFO	D08SFW	PMID27724045-Compound-15	Patented
T63414	DRUGINFO	D09REZ	PMID27724045-Compound-14	Patented
T63414	DRUGINFO	D0AI1I	Fused triazoloamino-phenyl analog 1	Patented
T63414	DRUGINFO	D0C9WD	Thiazole-fused cycloalkyl carboxamide derivative 1	Patented
T63414	DRUGINFO	D0EY5F	Isoindole 1,3-dione analog 1	Patented
T63414	DRUGINFO	D0FR8L	Chlorobenzamide derivative 2	Patented
T63414	DRUGINFO	D0GQ6D	Aminobenzoxazole analog 1	Patented
T63414	DRUGINFO	D0L8QD	Pyridazinone derivative 1	Patented
T63414	DRUGINFO	D0N2TV	Benzamide derivative 12	Patented
T63414	DRUGINFO	D0N4RJ	Triazolo-pyrazinone derivative 1	Patented
T63414	DRUGINFO	D0NG6O	Piperidinone derivative 1	Patented
T63414	DRUGINFO	D0O8DL	Dihydroisoquinoline carboxamide analog 1	Patented
T63414	DRUGINFO	D0OG3Z	Bicyclic heteroaryl amide derivative 3	Patented
T63414	DRUGINFO	D0PI1X	Bicyclic heteroaryl amide derivative 1	Patented
T63414	DRUGINFO	D0QC5O	Piperazine derivative 6	Patented
T63414	DRUGINFO	D0R4IT	Heterocyclic-fused piperazine derivative 1	Patented
T63414	DRUGINFO	D0RG4J	Chlorobenzamide derivative 1	Patented
T63414	DRUGINFO	D0S9HE	PMID27724045-Compound-29	Patented
T63414	DRUGINFO	D0T1JN	Thiazole derivative 5	Patented
T63414	DRUGINFO	D0UC8I	Tetrazole derivative 1	Patented
T63414	DRUGINFO	D0WI9M	Imidazolidine derivative 1	Patented
T63414	DRUGINFO	D0ZY5M	Indole carboxamide derivative 1	Patented
T63414	DRUGINFO	D01EBW	Quinoline derivative 12	Patented
T63414	DRUGINFO	D0B7KM	Quinoline derivative 13	Patented
T63414	DRUGINFO	D0L2KM	Quinoline derivative 11	Patented
T63414	DRUGINFO	D00REB	AZ11657312 (salt free)	Investigative
T63414	DRUGINFO	D02EFX	AZ11645373	Investigative
T63414	DRUGINFO	D02TNK	STYLISSADINE B	Investigative
T63414	DRUGINFO	D03HJZ	AZ-11657312	Investigative
T63414	DRUGINFO	D05DLI	STYLISSADINE A	Investigative
T63414	DRUGINFO	D05QLT	A438079	Investigative
T63414	DRUGINFO	D0M0XC	A839977	Investigative
T63414	DRUGINFO	D0N1ST	AFC-5128	Investigative
T63414	DRUGINFO	D0Q1PO	A804598	Investigative
T63414	DRUGINFO	D0U5ML	A-740003	Investigative
T63414	DRUGINFO	D05BFC	ISOPPADS	Investigative
T63414	DRUGINFO	D0T9ZL	chelerythrine	Investigative
T63414	DRUGINFO	D06KHR	decavanadate	Investigative
T63414	DRUGINFO	D0N6ES	KN-62	Investigative

T97589	TARGETID	T97589
T97589	FORMERID	TTDR00968
T97589	UNIPROID	M3K5_HUMAN
T97589	TARGNAME	Apoptosis signal-regulating kinase 1 (MAP3K5)
T97589	GENENAME	MAP3K5
T97589	TARGTYPE	Clinical trial
T97589	SYNONYMS	Mitogen-activated protein kinase kinase kinase 5; MEKK5; MEKK 5; MEK kinase 5; MAPKKK5; MAPK/ERK kinase kinase 5; ASK1; ASK-1
T97589	FUNCTION	Plays an important role in the cascades of cellular responses evoked by changes in the environment. Mediates signaling for determination of cell fate such as differentiation and survival. Plays a crucial role in the apoptosis signal transduction pathway through mitochondria-dependent caspase activation. MAP3K5/ASK1 is required for the innate immune response, which is essential for host defense against a wide range of pathogens. Mediates signal transduction of various stressors like oxidative stress as well as by receptor-mediated inflammatory signals, such as the tumor necrosis factor (TNF) or lipopolysaccharide (LPS). Once activated, acts as an upstream activator of the MKK/JNK signal transduction cascade and the p38 MAPK signal transduction cascade through the phosphorylation and activation of several MAP kinase kinases like MAP2K4/SEK1, MAP2K3/MKK3, MAP2K6/MKK6 and MAP2K7/MKK7. These MAP2Ks in turn activate p38 MAPKs and c-jun N-terminal kinases (JNKs). Both p38 MAPK and JNKs control the transcription factors activator protein-1 (AP-1). Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway.
T97589	PDBSTRUC	6EJL; 6E2O; 6E2N; 6E2M; 5VIO
T97589	BIOCLASS	Kinase
T97589	ECNUMBER	EC 2.7.11.25
T97589	SEQUENCE	MSTEADEGITFSVPPFAPSGFCTIPEGGICRRGGAAAVGEGEEHQLPPPPPGSFWNVESAAAPGIGCPAATSSSSATRGRGSSVGGGSRRTTVAYVINEASQGQLVVAESEALQSLREACETVGATLETLHFGKLDFGETTVLDRFYNADIAVVEMSDAFRQPSLFYHLGVRESFSMANNIILYCDTNSDSLQSLKEIICQKNTMCTGNYTFVPYMITPHNKVYCCDSSFMKGLTELMQPNFELLLGPICLPLVDRFIQLLKVAQASSSQYFRESILNDIRKARNLYTGKELAAELARIRQRVDNIEVLTADIVINLLLSYRDIQDYDSIVKLVETLEKLPTFDLASHHHVKFHYAFALNRRNLPGDRAKALDIMIPMVQSEGQVASDMYCLVGRIYKDMFLDSNFTDTESRDHGASWFKKAFESEPTLQSGINYAVLLLAAGHQFESSFELRKVGVKLSSLLGKKGNLEKLQSYWEVGFFLGASVLANDHMRVIQASEKLFKLKTPAWYLKSIVETILIYKHFVKLTTEQPVAKQELVDFWMDFLVEATKTDVTVVRFPVLILEPTKIYQPSYLSINNEVEEKTISIWHVLPDDKKGIHEWNFSASSVRGVSISKFEERCCFLYVLHNSDDFQIYFCTELHCKKFFEMVNTITEEKGRSTEEGDCESDLLEYDYEYDENGDRVVLGKGTYGIVYAGRDLSNQVRIAIKEIPERDSRYSQPLHEEIALHKHLKHKNIVQYLGSFSENGFIKIFMEQVPGGSLSALLRSKWGPLKDNEQTIGFYTKQILEGLKYLHDNQIVHRDIKGDNVLINTYSGVLKISDFGTSKRLAGINPCTETFTGTLQYMAPEIIDKGPRGYGKAADIWSLGCTIIEMATGKPPFYELGEPQAAMFKVGMFKVHPEIPESMSAEAKAFILKCFEPDPDKRACANDLLVDEFLKVSSKKKKTQPKLSALSAGSNEYLRSISLPVPVLVEDTSSSSEYGSVSPDTELKVDPFSFKTRAKSCGERDVKGIRTLFLGIPDENFEDHSAPPSPEEKDSGFFMLRKDSERRATLHRILTEDQDKIVRNLMESLAQGAEEPKLKWEHITTLIASLREFVRSTDRKIIATTLSKLKLELDFDSHGISQVQVVLFGFQDAVNKVLRNHNIKPHWMFALDSIIRKAVQTAITILVPELRPHFSLASESDTADQEDLDVEDDHEEQPSNQTVRRPQAVIEDAVATSGVSTLSSTVSHDSQSAHRSLNVQLGRMKIETNRLLEELVRKEKELQALLHRAIEEKDQEIKHLKLKSQPIEIPELPVFHLNSSGTNTEDSELTDWLRVNGADEDTISRFLAEDYTLLDVLYYVTRDDLKCLRLRGGMLCTLWKAIIDFRNKQT
T97589	DRUGINFO	D0D0OT	GS-4977	Phase 2
T97589	DRUGINFO	D0RN3S	GS-4997	Phase 2
T97589	DRUGINFO	D0F0XZ	MSC2032964A	Investigative
T97589	DRUGINFO	D0Q0YV	PMID23147077C10	Investigative

T18664	TARGETID	T18664
T18664	FORMERID	TTDI02646
T18664	UNIPROID	MGLL_HUMAN
T18664	TARGNAME	Monoglyceride lipase (MAGL)
T18664	GENENAME	MGLL
T18664	TARGTYPE	Clinical trial
T18664	SYNONYMS	Monoacylglycerol lipase; MGL; Lysophospholipaselike; Lysophospholipase-like; Lysophospholipase homolog; HUK5; HU-K5
T18664	FUNCTION	Hydrolyzes the endocannabinoid 2-arachidonoylglycerol, and thereby contributes to the regulation of endocannabinoid signaling, nociperception and perception of pain. Regulates the levels of fatty acids that serve as signaling molecules and promote cancer cell migration, invasion and tumor growth. Converts monoacylglycerides to free fatty acids and glycerol.
T18664	PDBSTRUC	6BQ0; 6AX1; 5ZUN; 4UUQ; 3PE6
T18664	BIOCLASS	Carboxylic ester hydrolase
T18664	ECNUMBER	EC 3.1.1.23
T18664	SEQUENCE	MPEESSPRRTPQSIPYQDLPHLVNADGQYLFCRYWKPTGTPKALIFVSHGAGEHSGRYEELARMLMGLDLLVFAHDHVGHGQSEGERMVVSDFHVFVRDVLQHVDSMQKDYPGLPVFLLGHSMGGAIAILTAAERPGHFAGMVLISPLVLANPESATTFKVLAAKVLNLVLPNLSLGPIDSSVLSRNKTEVDIYNSDPLICRAGLKVCFGIQLLNAVSRVERALPKLTVPFLLLQGSADRLCDSKGAYLLMELAKSQDKTLKIYEGAYHVLHKELPEVTNSVFHEINMWVSQRTATAGTASPP
T18664	DRUGINFO	D0CW8S	ABX-1431	Phase 1
T18664	DRUGINFO	D00KFI	Azetidinyl-piperazine derivative 3	Patented
T18664	DRUGINFO	D00PFS	Azetidinyl-piperidine derivative 1	Patented
T18664	DRUGINFO	D00VBP	PMID29053063-Compound-7f	Patented
T18664	DRUGINFO	D03HHN	PMID29053063-Compound-7b	Patented
T18664	DRUGINFO	D03LKM	PMID29053063-Compound-7a	Patented
T18664	DRUGINFO	D04ZEX	Pyrazole derivative 85	Patented
T18664	DRUGINFO	D05SWA	Azetidinyl-piperidine derivative 3	Patented
T18664	DRUGINFO	D07YWE	PMID29053063-Compound-5	Patented
T18664	DRUGINFO	D08EMW	Carbamate derivative 15	Patented
T18664	DRUGINFO	D09LAD	Piperazine carbamic compound 3	Patented
T18664	DRUGINFO	D0B5BT	Azetidinyl-piperazine derivative 1	Patented
T18664	DRUGINFO	D0C5SQ	Carbamate derivative 13	Patented
T18664	DRUGINFO	D0D2YG	PMID29053063-Compound-7d	Patented
T18664	DRUGINFO	D0FK7E	Carbamate derivative 14	Patented
T18664	DRUGINFO	D0G9NQ	PMID29053063-Compound-17	Patented
T18664	DRUGINFO	D0J0UC	Azetidine-benzoxazin-3(4H)-one derivative 1	Patented
T18664	DRUGINFO	D0NK4T	Carbamate derivative 12	Patented
T18664	DRUGINFO	D0OK3K	Azetidinyl-piperazine derivative 2	Patented
T18664	DRUGINFO	D0Q4OB	Carbamate derivative 11	Patented
T18664	DRUGINFO	D0S9MR	Azetidine-benzoxazin-3(4H)-one derivative 2	Patented
T18664	DRUGINFO	D0TT7U	PMID29053063-Compound-7c	Patented
T18664	DRUGINFO	D0TW7K	PMID29053063-Compound-7e	Patented
T18664	DRUGINFO	D0UW6S	PMID29053063-Compound-4	Patented
T18664	DRUGINFO	D0VS7X	Azetidine-benzoxazin-3(4H)-one derivative 3	Patented
T18664	DRUGINFO	D0VY7R	Azetidinyl-piperidine derivative 2	Patented
T18664	DRUGINFO	D00IPI	Carbamide derivative 24	Patented
T18664	DRUGINFO	D00TVG	Piperazine carbamic compound 4	Patented
T18664	DRUGINFO	D02ZUW	Carbamide derivative 26	Patented
T18664	DRUGINFO	D05DBG	Carbamate derivative 16	Patented
T18664	DRUGINFO	D08SMT	Carbamate derivative 17	Patented
T18664	DRUGINFO	D09RGE	Carbamide derivative 25	Patented
T18664	DRUGINFO	D0L6XG	Carbamate derivative 9	Patented
T18664	DRUGINFO	D0S2JF	Pyrazole derivative 83	Patented
T18664	DRUGINFO	D0TU6D	PMID29053063-Compound-11c	Patented
T18664	DRUGINFO	D0V7PO	PMID29053063-Compound-14	Patented
T18664	DRUGINFO	D0Y7LM	Carbamate derivative 10	Patented
T18664	DRUGINFO	D0YM0G	Pyrazole derivative 84	Patented
T18664	DRUGINFO	D0Z7FL	Piperazine carbamic compound 5	Patented
T18664	DRUGINFO	D0GT0I	PMID29053063-Compound-11d	Patented
T18664	DRUGINFO	D0J6TA	Piperazine carbamic compound 1	Patented
T18664	DRUGINFO	D0LC5Y	Piperazine carbamic compound 2	Patented
T18664	DRUGINFO	D0LL0X	Pyrazole derivative 82	Patented
T18664	DRUGINFO	D0O9DS	Pyrazole derivative 81	Patented
T18664	DRUGINFO	D0TL1G	PMID29053063-Compound-15	Patented
T18664	DRUGINFO	D0X9GC	Pyrazole derivative 80	Patented
T18664	DRUGINFO	D0G0MZ	JZL184	Investigative

T09572	TARGETID	T09572
T09572	FORMERID	TTDC00133
T09572	UNIPROID	MCHR1_HUMAN
T09572	TARGNAME	Melanin-concentrating hormone receptor 1 (MCHR1)
T09572	GENENAME	MCHR1
T09572	TARGTYPE	Clinical trial
T09572	SYNONYMS	Somatostatinreceptor-like protein; Somatostatin receptor-like protein; SLC1; SLC-1; Melanin-concentrating hormone receptor subtype 1; MCHR-1; MCHR; MCH1R; MCH-R1; MCH-1R; MCH(1) receptor; MCH receptor1; MCH receptor 1; GPR24; G-protein coupled receptor 24; G protein coupled receptor 24
T09572	FUNCTION	Receptor for melanin-concentrating hormone, coupled to both G proteins that inhibit adenylyl cyclase and G proteins that activate phosphoinositide hydrolysis.
T09572	BIOCLASS	GPCR rhodopsin
T09572	SEQUENCE	MSVGAMKKGVGRAVGLGGGSGCQATEEDPLPNCGACAPGQGGRRWRLPQPAWVEGSSARLWEQATGTGWMDLEASLLPTGPNASNTSDGPDNLTSAGSPPRTGSISYINIIMPSVFGTICLLGIIGNSTVIFAVVKKSKLHWCNNVPDIFIINLSVVDLLFLLGMPFMIHQLMGNGVWHFGETMCTLITAMDANSQFTSTYILTAMAIDRYLATVHPISSTKFRKPSVATLVICLLWALSFISITPVWLYARLIPFPGGAVGCGIRLPNPDTDLYWFTLYQFFLAFALPFVVITAAYVRILQRMTSSVAPASQRSIRLRTKRVTRTAIAICLVFFVCWAPYYVLQLTQLSISRPTLTFVYLYNAAISLGYANSCLNPFVYIVLCETFRKRLVLSVKPAAQGQLRAVSNAQTADEERTESKGT
T09572	DRUGINFO	D01KMW	BMS-830216	Phase 1
T09572	DRUGINFO	D0A3CL	AZD1979	Phase 1
T09572	DRUGINFO	D00HQJ	PMID25522065-Compound-27	Patented
T09572	DRUGINFO	D00RUE	PMID25522065-Compound-29	Patented
T09572	DRUGINFO	D01RQE	PMID25522065-Compound-34	Patented
T09572	DRUGINFO	D01SYN	PMID25522065-Compound-39	Patented
T09572	DRUGINFO	D02MTQ	PMID25522065-Compound-40	Patented
T09572	DRUGINFO	D03JJW	PMID25522065-Compound-11	Patented
T09572	DRUGINFO	D03KWP	PMID25522065-Compound-50	Patented
T09572	DRUGINFO	D03TCR	PMID25522065-Compound-12	Patented
T09572	DRUGINFO	D04NIU	PMID25522065-Compound-2	Patented
T09572	DRUGINFO	D07MJJ	PMID25522065-Compound-8	Patented
T09572	DRUGINFO	D08JKR	PMID25522065-Compound-9	Patented
T09572	DRUGINFO	D08JMZ	PMID25522065-Compound-5	Patented
T09572	DRUGINFO	D09CER	PMID25522065-Compound-44	Patented
T09572	DRUGINFO	D09UGQ	PMID25522065-Compound-36	Patented
T09572	DRUGINFO	D0A2NT	PMID25522065-Compound-46	Patented
T09572	DRUGINFO	D0BQ7K	PMID25522065-Compound-33	Patented
T09572	DRUGINFO	D0C5RD	PMID25522065-Compound-31	Patented
T09572	DRUGINFO	D0CC6Q	PMID25522065-Compound-3	Patented
T09572	DRUGINFO	D0CV5F	PMID25522065-Compound-18	Patented
T09572	DRUGINFO	D0DB8G	PMID25522065-Compound-47	Patented
T09572	DRUGINFO	D0DN8Z	PMID25522065-Compound-21	Patented
T09572	DRUGINFO	D0FQ4W	PMID25522065-Compound-13	Patented
T09572	DRUGINFO	D0GH0Z	PMID25522065-Compound-41	Patented
T09572	DRUGINFO	D0GN5K	PMID25522065-Compound-23	Patented
T09572	DRUGINFO	D0HH1O	PMID25522065-Compound-14	Patented
T09572	DRUGINFO	D0I6YT	PMID25522065-Compound-42	Patented
T09572	DRUGINFO	D0I9BT	PMID25522065-Compound-4	Patented
T09572	DRUGINFO	D0J6MM	PMID25522065-Compound-37	Patented
T09572	DRUGINFO	D0JY4C	PMID25522065-Compound-19	Patented
T09572	DRUGINFO	D0KF0X	PMID25522065-Compound-10	Patented
T09572	DRUGINFO	D0KJ9U	PMID25522065-Compound-28	Patented
T09572	DRUGINFO	D0L2EQ	PMID25522065-Compound-7	Patented
T09572	DRUGINFO	D0L3ZZ	PMID25522065-Compound-16	Patented
T09572	DRUGINFO	D0M8KC	PMID25522065-Compound-48	Patented
T09572	DRUGINFO	D0M9JM	PMID25522065-Compound-17	Patented
T09572	DRUGINFO	D0MT7T	PMID25522065-Compound-49	Patented
T09572	DRUGINFO	D0N8CI	PMID25522065-Compound-15	Patented
T09572	DRUGINFO	D0Q1NA	PMID25522065-Compound-51	Patented
T09572	DRUGINFO	D0R0YB	PMID25522065-Compound-6	Patented
T09572	DRUGINFO	D0RX2U	PMID25522065-Compound-25	Patented
T09572	DRUGINFO	D0S2ED	PMID25522065-Compound-35	Patented
T09572	DRUGINFO	D0S6DD	PMID25522065-Compound-38	Patented
T09572	DRUGINFO	D0T6UX	PMID25522065-Compound-24	Patented
T09572	DRUGINFO	D0TK2N	PMID25522065-Compound-45	Patented
T09572	DRUGINFO	D0TK3S	PMID25522065-Compound-43	Patented
T09572	DRUGINFO	D0TY8S	PMID25522065-Compound-22	Patented
T09572	DRUGINFO	D0TZ6J	PMID25522065-Compound-26	Patented
T09572	DRUGINFO	D0V3OD	PMID25522065-Compound-32	Patented
T09572	DRUGINFO	D0V8FC	PMID25522065-Compound-30	Patented
T09572	DRUGINFO	D0Y0RS	PMID25522065-Compound-20	Patented
T09572	DRUGINFO	D0N1AS	NGD-4715	Discontinued in Phase 1
T09572	DRUGINFO	D0X4MC	AMG 076	Discontinued in Phase 1
T09572	DRUGINFO	D0U0YR	SNAP-7941	Preclinical
T09572	DRUGINFO	D0K6NS	T-226293	Preclinical
T09572	DRUGINFO	D0TV4N	T-226296	Preclinical
T09572	DRUGINFO	D05SUA	A-798	Terminated
T09572	DRUGINFO	D05VGS	ALB-127158(a)	Terminated
T09572	DRUGINFO	D00MSU	8-(2-Cyclopropyl-ethoxy)-quinolin-2-ylamine	Investigative
T09572	DRUGINFO	D01OYC	8-sec-Butoxy-quinolin-2-ylamine	Investigative
T09572	DRUGINFO	D01OZL	8-(2-Methyl-butoxy)-quinolin-2-ylamine	Investigative
T09572	DRUGINFO	D01PFN	8-Cyclobutylmethoxy-quinolin-2-ylamine	Investigative
T09572	DRUGINFO	D02FQG	pyrrolidine MCHR1 antagonist 1	Investigative
T09572	DRUGINFO	D02QXF	8-(1-Methyl-butoxy)-quinolin-2-ylamine	Investigative
T09572	DRUGINFO	D03BIQ	ADS-102891	Investigative
T09572	DRUGINFO	D03CDM	8-(2-Ethoxy-1-methyl-ethoxy)-quinolin-2-ylamine	Investigative
T09572	DRUGINFO	D03FJK	8-(1,3,3-Trimethyl-butoxy)-quinolin-2-ylamine	Investigative
T09572	DRUGINFO	D03FNQ	ADS-103214	Investigative
T09572	DRUGINFO	D03SEC	8-Butoxy-quinolin-2-ylamine	Investigative
T09572	DRUGINFO	D04OOK	Phenyl-N,N-bis(tosylmethyl)methanamine	Investigative
T09572	DRUGINFO	D05CYD	C3	Investigative
T09572	DRUGINFO	D05HFC	8-(1,2-Dimethyl-propoxy)-quinolin-2-ylamine	Investigative
T09572	DRUGINFO	D05MEW	N-(1-benzylpiperidin-4-yl)-3,5-dimethoxybenzamide	Investigative
T09572	DRUGINFO	D05QTT	tetralin_urea analogue (7o)	Investigative
T09572	DRUGINFO	D05TVU	A-224940	Investigative
T09572	DRUGINFO	D05UZY	7-fluorochromone-2-carboxamide	Investigative
T09572	DRUGINFO	D06KLQ	GNF-PF-1550	Investigative
T09572	DRUGINFO	D07EPU	ADS-103254	Investigative
T09572	DRUGINFO	D07HQP	8-Pentyloxy-quinolin-2-ylamine	Investigative
T09572	DRUGINFO	D07IUE	8-Cyclopentylmethoxy-quinolin-2-ylamine	Investigative
T09572	DRUGINFO	D07WFH	2-phenyl-N,N-bis(o-tolylthiomethyl)ethanamine	Investigative
T09572	DRUGINFO	D07XEA	8-Cycloheptyloxy-quinolin-2-ylamine	Investigative
T09572	DRUGINFO	D08OQO	8-Isopropoxy-quinolin-2-ylamine	Investigative
T09572	DRUGINFO	D08SOE	PMID17125263C17	Investigative
T09572	DRUGINFO	D09RGM	N,N-bis(tosylmethyl)hexan-1-amine	Investigative
T09572	DRUGINFO	D0AT3U	N-(4-amino-2-propylquinolin-6-yl)cinnamamide	Investigative
T09572	DRUGINFO	D0AT5N	4-arylphthalazin-1(2H)-3,4-Di-F	Investigative
T09572	DRUGINFO	D0AU6T	8-(3-Methoxy-3-methyl-butoxy)-quinolin-2-ylamine	Investigative
T09572	DRUGINFO	D0C5RQ	SB-568849	Investigative
T09572	DRUGINFO	D0C7ED	PMID22490048C(R)-10h	Investigative
T09572	DRUGINFO	D0C9DP	ADS-103168	Investigative
T09572	DRUGINFO	D0D7EK	TPI-1361-17	Investigative
T09572	DRUGINFO	D0ES2Y	8-(2-Methyl-cyclohexyloxy)-quinolin-2-ylamine	Investigative
T09572	DRUGINFO	D0F3VX	8-(2-Methoxy-1-methyl-ethoxy)-quinolin-2-ylamine	Investigative
T09572	DRUGINFO	D0G6DS	8-Hexyloxy-quinolin-2-ylamine	Investigative
T09572	DRUGINFO	D0I7FK	8-(3-Methyl-cyclohexyloxy)-quinolin-2-ylamine	Investigative
T09572	DRUGINFO	D0J7MM	ADS-103316	Investigative
T09572	DRUGINFO	D0K5JA	8-Cyclohexyloxy-quinolin-2-ylamine	Investigative
T09572	DRUGINFO	D0K5QJ	ADS-103294	Investigative
T09572	DRUGINFO	D0K5XL	ADS-103293	Investigative
T09572	DRUGINFO	D0L4WB	8-(4-Methyl-cyclohexyloxy)-quinolin-2-ylamine	Investigative
T09572	DRUGINFO	D0LJ4Q	8-Propoxy-quinolin-2-ylamine	Investigative
T09572	DRUGINFO	D0M3HZ	AZ13483342	Investigative
T09572	DRUGINFO	D0N1YW	GNF-PF-2322	Investigative
T09572	DRUGINFO	D0P4CQ	8-(2-Ethyl-1-methyl-butoxy)-quinolin-2-ylamine	Investigative
T09572	DRUGINFO	D0P5QW	MQ1	Investigative
T09572	DRUGINFO	D0PX3G	[3H]SNAP-7941	Investigative
T09572	DRUGINFO	D0S7IJ	8-(3-Methyl-cyclopentyloxy)-quinolin-2-ylamine	Investigative
T09572	DRUGINFO	D0U1OX	8-(3,3-Dimethyl-butoxy)-quinolin-2-ylamine	Investigative
T09572	DRUGINFO	D0V2IR	8-(1-Ethyl-propoxy)-quinolin-2-ylamine	Investigative
T09572	DRUGINFO	D0V9KF	8-(3,3,3-trifluoropropoxy)quinolin-2-amine	Investigative
T09572	DRUGINFO	D0W7ZM	8-(3-Methyl-butoxy)-quinolin-2-ylamine	Investigative
T09572	DRUGINFO	D00AWM	GW803430	Investigative
T09572	DRUGINFO	D01BTF	melanin-concentrating hormone	Investigative
T09572	DRUGINFO	D01NOZ	ADS-103274	Investigative
T09572	DRUGINFO	D0V5ZP	ATC0065	Investigative
T09572	DRUGINFO	D0D2PL	8-Methoxy-quinolin-2-ylamine	Investigative
T09572	DRUGINFO	D0K0KR	AR-129330	Investigative
T09572	DRUGINFO	D0N6OL	ADS-103253	Investigative

T97136	TARGETID	T97136
T97136	UNIPROID	MKNK1_HUMAN
T97136	TARGNAME	MAPK signal-integrating kinase 1 (MKNK1)
T97136	GENENAME	MKNK1
T97136	TARGTYPE	Clinical trial
T97136	SYNONYMS	Mnk1; MAP kinase signal-integrating kinase 1
T97136	FUNCTION	May play a role in the response to environmental stress and cytokines. Appears to regulate translation by phosphorylating EIF4E, thus increasing the affinity of this protein for the 7-methylguanosine-containing mRNA cap.
T97136	PDBSTRUC	5WVD; 2Y9Q; 2HW6
T97136	BIOCLASS	Protein kinase superfamily. CAMK Ser/Thr protein kinase family
T97136	ECNUMBER	EC 2.7.11.1
T97136	SEQUENCE	MVSSQKLEKPIEMGSSEPLPIADGDRRRKKKRRGRATDSLPGKFEDMYKLTSELLGEGAYAKVQGAVSLQNGKEYAVKIIEKQAGHSRSRVFREVETLYQCQGNKNILELIEFFEDDTRFYLVFEKLQGGSILAHIQKQKHFNEREASRVVRDVAAALDFLHTKDKVSLCHLGWSAMAPSGLTAAPTSLGSSDPPTSASQVAGTTGIAHRDLKPENILCESPEKVSPVKICDFDLGSGMKLNNSCTPITTPELTTPCGSAEYMAPEVVEVFTDQATFYDKRCDLWSLGVVLYIMLSGYPPFVGHCGADCGWDRGEVCRVCQNKLFESIQEGKYEFPDKDWAHISSEAKDLISKLLVRDAKQRLSAAQVLQHPWVQGQAPEKGLPTPQVLQRNSSTMDLTLFAAEAIALNRQLSQHEENELAEEPEALADGLCSMKLSPPCKSRLARRRALAQAGRGEDRSPPTAL
T97136	DRUGINFO	D07XOV	EFT508	Phase 2

T44682	TARGETID	T44682
T44682	FORMERID	TTDI02341
T44682	UNIPROID	IL22_HUMAN
T44682	TARGNAME	Interleukin-22 (IL22)
T44682	GENENAME	IL22
T44682	TARGTYPE	Clinical trial
T44682	SYNONYMS	ZCYTO18; UNQ3099/PRO10096; Interleukin22; ILTIF; IL10related Tcellderivedinducible factor; IL-TIF; IL-22; IL-10-related T-cell-derived-inducible factor; Cytokine Zcyto18
T44682	FUNCTION	Cytokine that contributes to the inflammatory response in vivo.
T44682	PDBSTRUC	3Q1S; 3G9V; 3DLQ; 3DGC; 1YKB
T44682	BIOCLASS	Cytokine: interleukin
T44682	SEQUENCE	MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLAKEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVPFLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI
T44682	DRUGINFO	D01AIN	Fezakinumab	Phase 2
T44682	DRUGINFO	D0G5BL	RG7880	Phase 2
T44682	DRUGINFO	DL2HO7	F-652	Phase 2
T44682	DRUGINFO	D0A9GI	ILV-095	Phase 1

T36467	TARGETID	T36467
T36467	FORMERID	TTDI02014
T36467	UNIPROID	AICDA_HUMAN
T36467	TARGNAME	Cytosine deaminase (AICDA)
T36467	GENENAME	AICDA
T36467	TARGTYPE	Clinical trial
T36467	SYNONYMS	Activationinduced cytidine deaminase; AICDA
T36467	FUNCTION	Single-stranded DNA-specific cytidine deaminase. Involved in somatic hypermutation, gene conversion, and class- switch recombination in B-lymphocytes. Required for several crucial steps of B-cell terminal differentiation necessary for efficient antibody responses. May also play a role in the epigenetic regulation of gene expression by participating in DNA demethylation.
T36467	PDBSTRUC	5W1C; 5W0Z; 5W0U; 5W0R; 5JJ4
T36467	BIOCLASS	Carbon-nitrogen hydrolase
T36467	ECNUMBER	EC 3.5.4.38
T36467	SEQUENCE	MDSLLMNRRKFLYQFKNVRWAKGRRETYLCYVVKRRDSATSFSLDFGYLRNKNGCHVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVADFLRGNPNLSLRIFTARLYFCEDRKAEPEGLRRLHRAGVQIAIMTFKDYFYCWNTFVENHERTFKAWEGLHENSVRLSRQLRRILLPLYEVDDLRDAFRTLGL
T36467	DRUGINFO	D0H2YY	JX-929	Phase 1

T08133	TARGETID	T08133
T08133	FORMERID	TTDR00350
T08133	UNIPROID	TRPV6_HUMAN
T08133	TARGNAME	Transient receptor potential cation channel V6 (TRPV6)
T08133	GENENAME	TRPV6
T08133	TARGTYPE	Clinical trial
T08133	SYNONYMS	Transient receptor potential cation channel subfamily V, member 6; TRPV6; HTRP8; ECaC2; Calcium transport protein CaT1; Calcium channel CAT1
T08133	FUNCTION	Calcium selective cation channel probably involved in Ca(2+) uptake in various tissues, including Ca(2+) reabsorption in intestine. The channel is activated by low internal calcium level, probably including intracellular calcium store depletion, and the current exhibits an inward rectification. Inactivation includes both, a rapid Ca(2+)-dependent and a slower Ca(2+)-calmodulin- dependent mechanism, the lattermay be regulated by phosphorylation. In vitro, is slowly inhibited by Mg(2+) in a voltage-independent manner. Heteromeric assembly with TRPV5 seems to modify channel properties. TRPV5-TRPV6 heteromultimeric concatemers exhibit voltage-dependent gating.
T08133	PDBSTRUC	6E2F; 6D7T; 6D7S; 6BOA; 6BO9
T08133	BIOCLASS	Transient receptor potential catioin channel
T08133	SEQUENCE	MGPLQGDGGPALGGADVAPRLSPVRVWPRPQAPKEPALHPMGLSLPKEKGLILCLWSKFCRWFQRRESWAQSRDEQNLLQQKRIWESPLLLAAKDNDVQALNKLLKYEDCKVHQRGAMGETALHIAALYDNLEAAMVLMEAAPELVFEPMTSELYEGQTALHIAVVNQNMNLVRALLARRASVSARATGTAFRRSPCNLIYFGEHPLSFAACVNSEEIVRLLIEHGADIRAQDSLGNTVLHILILQPNKTFACQMYNLLLSYDRHGDHLQPLDLVPNHQGLTPFKLAGVEGNTVMFQHLMQKRKHTQWTYGPLTSTLYDLTEIDSSGDEQSLLELIITTKKREARQILDQTPVKELVSLKWKRYGRPYFCMLGAIYLLYIICFTMCCIYRPLKPRTNNRTSPRDNTLLQQKLLQEAYMTPKDDIRLVGELVTVIGAIIILLVEVPDIFRMGVTRFFGQTILGGPFHVLIITYAFMVLVTMVMRLISASGEVVPMSFALVLGWCNVMYFARGFQMLGPFTIMIQKMIFGDLMRFCWLMAVVILGFASAFYIIFQTEDPEELGHFYDYPMALFSTFELFLTIIDGPANYNVDLPFMYSITYAAFAIIATLLMLNLLIAMMGDTHWRVAHERDELWRAQIVATTVMLERKLPRCLWPRSGICGREYGLGDRWFLRVEDRQDLNRQRIQRYAQAFHTRGSEDLDKDSVEKLELGCPFSPHLSLPMPSVSRSTSRSSANWERLRQGTLRRDLRGIINRGLEDGESWEYQI
T08133	DRUGINFO	D06UWF	SOR-C13	Phase 1
T08133	DRUGINFO	D00HCI	2-APB	Investigative

T64213	TARGETID	T64213
T64213	FORMERID	TTDR01160
T64213	UNIPROID	TRPV4_HUMAN
T64213	TARGNAME	Transient receptor potential cation channel V4 (TRPV4)
T64213	GENENAME	TRPV4
T64213	TARGTYPE	Clinical trial
T64213	SYNONYMS	Vanilloid receptor-related osmotically-activated channel; Vanilloid receptor-like protein 2; Vanilloid receptor-like channel 2; VROAC; VRL2; VRL-2; VR-OAC; TrpV4; Transient receptor potential protein 12; Transient receptor potential cation channel subfamily V member 4; TRP12; Osm-9-like TRP channel 4; OTRPC4
T64213	FUNCTION	Non-selective calcium permeant cation channel involved in osmotic sensitivity and mechanosensitivity. Activation by exposure to hypotonicity within the physiological range exhibits an outward rectification. Also activated by heat, low pH, citrate and phorbol esters. Increase of intracellular Ca(2+) potentiates currents. Channel activity seems to be regulated by a calmodulin-dependent mechanism with a negative feedback mechanism. Promotes cell-cell junction formation in skin keratinocytes and plays an important role in the formation and/or maintenance of functional intercellular barriers (By similarity). Acts as a regulator of intracellular Ca(2+) in synoviocytes. Plays an obligatory role as a molecular component in the nonselective cation channel activation induced by 4-alpha-phorbol 12,13-didecanoate and hypotonic stimulation in synoviocytes and also regulates production of IL-8. Together with PKD2, forms mechano- and thermosensitive channels in cilium. Negatively regulates expression of PPARGC1A, UCP1, oxidative metabolism and respiration in adipocytes (By similarity). Regulates expression of chemokines and cytokines related to proinflammatory pathway in adipocytes (By similarity). Together with AQP5, controls regulatory volume decrease in salivary epithelial cells (By similarity). Required for normal development and maintenance of bone and cartilage.
T64213	PDBSTRUC	4DX2; 4DX1
T64213	BIOCLASS	Transient receptor potential catioin channel
T64213	SEQUENCE	MADSSEGPRAGPGEVAELPGDESGTPGGEAFPLSSLANLFEGEDGSLSPSPADASRPAGPGDGRPNLRMKFQGAFRKGVPNPIDLLESTLYESSVVPGPKKAPMDSLFDYGTYRHHSSDNKRWRKKIIEKQPQSPKAPAPQPPPILKVFNRPILFDIVSRGSTADLDGLLPFLLTHKKRLTDEEFREPSTGKTCLPKALLNLSNGRNDTIPVLLDIAERTGNMREFINSPFRDIYYRGQTALHIAIERRCKHYVELLVAQGADVHAQARGRFFQPKDEGGYFYFGELPLSLAACTNQPHIVNYLTENPHKKADMRRQDSRGNTVLHALVAIADNTRENTKFVTKMYDLLLLKCARLFPDSNLEAVLNNDGLSPLMMAAKTGKIGIFQHIIRREVTDEDTRHLSRKFKDWAYGPVYSSLYDLSSLDTCGEEASVLEILVYNSKIENRHEMLAVEPINELLRDKWRKFGAVSFYINVVSYLCAMVIFTLTAYYQPLEGTPPYPYRTTVDYLRLAGEVITLFTGVLFFFTNIKDLFMKKCPGVNSLFIDGSFQLLYFIYSVLVIVSAALYLAGIEAYLAVMVFALVLGWMNALYFTRGLKLTGTYSIMIQKILFKDLFRFLLVYLLFMIGYASALVSLLNPCANMKVCNEDQTNCTVPTYPSCRDSETFSTFLLDLFKLTIGMGDLEMLSSTKYPVVFIILLVTYIILTFVLLLNMLIALMGETVGQVSKESKHIWKLQWATTILDIERSFPVFLRKAFRSGEMVTVGKSSDGTPDRRWCFRVDEVNWSHWNQNLGIINEDPGKNETYQYYGFSHTVGRLRRDRWSSVVPRVVELNKNSNPDEVVVPLDSMGNPRCDGHQQGYPRKWRTDDAPL
T64213	DRUGINFO	D07HSR	GSK2798745	Phase 2
T64213	DRUGINFO	D09DHT	phorbol 12-myristate 13-acetate	Phase 2
T64213	DRUGINFO	D02UVR	bisandrographolide	Investigative
T64213	DRUGINFO	D03HJW	GSK1016790A	Investigative
T64213	DRUGINFO	D03LVL	GSK2193874	Investigative
T64213	DRUGINFO	D03OLU	RN1734	Investigative
T64213	DRUGINFO	D09OHS	4alpha-PDD	Investigative
T64213	DRUGINFO	D0A5LY	RN1747	Investigative
T64213	DRUGINFO	D0B1QM	HC067047	Investigative
T64213	DRUGINFO	D0D5BI	5,6-epoxyeicosatrienoic acid	Investigative
T64213	DRUGINFO	D0J1SX	4alpha-PDH	Investigative
T64213	DRUGINFO	D0N2QH	5'-iodoresiniferatoxin	Investigative
T64213	DRUGINFO	D00ESG	4-Pyridin-2-yl-piperazine-1-carboxylic acid amide	Investigative
T64213	DRUGINFO	D03KQG	Pyrrolidin-1-yl-thiourea	Investigative
T64213	DRUGINFO	D0G8BN	CAPSAZEPINE	Investigative
T64213	DRUGINFO	D0X7AM	SC-0030	Investigative
T64213	DRUGINFO	D02RTS	citric acid	Investigative

T51223	TARGETID	T51223
T51223	FORMERID	TTDNC00371
T51223	UNIPROID	IL21_HUMAN
T51223	TARGNAME	Interleukin-21 (IL21)
T51223	GENENAME	IL21
T51223	TARGTYPE	Clinical trial
T51223	SYNONYMS	Za11; Interleukin21; IL-21
T51223	FUNCTION	May promote the transition between innate and adaptive immunity. Induces the production of IgG(1) and IgG(3) in B-cells. May play a role in proliferation and maturation of natural killer (NK) cells in synergy with IL15. May regulate proliferation of mature B- and T-cells in response to activating stimuli. In synergy with IL15 and IL18 stimulates interferon gamma production in T-cells and NK cells. During T-cell mediated immune response may inhibit dendritic cells (DC) activation and maturation. Cytokine with immunoregulatory activity.
T51223	PDBSTRUC	3TGX; 2OQP
T51223	BIOCLASS	Cytokine: interleukin
T51223	SEQUENCE	MRSSPGNMERIVICLMVIFLGTLVHKSSSQGQDRHMIRMRQLIDIVDQLKNYVNDLVPEFLPAPEDVETNCEWSAFSCFQKAQLKSANTGNNERIINVSIKKLKRKPPSTNAGRRQKHRLTCPSCDSYEKKPPKEFLERFKSLLQKMIHQHLSSRTHGSEDS
T51223	DRUGINFO	D07JWO	IL-21	Phase 2
T51223	DRUGINFO	D05ZSX	NN-8828	Phase 1

T99160	TARGETID	T99160
T99160	UNIPROID	MKNK2_HUMAN
T99160	TARGNAME	MAP kinase signal-integrating kinase 2 (MKNK2)
T99160	GENENAME	MKNK2
T99160	TARGTYPE	Clinical trial
T99160	SYNONYMS	Mnk2; MAPK signal-integrating kinase 2
T99160	FUNCTION	Serine/threonine-protein kinase that phosphorylates SFPQ/PSF, HNRNPA1 and EIF4E. May play a role in the response to environmental stress and cytokines. Appears to regulate translation by phosphorylating EIF4E, thus increasing the affinity of this protein for the 7-methylguanosine-containing mRNA cap. Required for mediating PP2A-inhibition-induced EIF4E phosphorylation. Triggers EIF4E shuttling from cytoplasm to nucleus. Isoform 1 displays a high basal kinase activity, but isoform 2 exhibits a very low kinase activity. Acts as a mediator of the suppressive effects of IFNgamma on hematopoiesis. Negative regulator for signals that control generation of arsenic trioxide As(2)O(3)-dependent apoptosis and anti-leukemic responses. Involved in anti-apoptotic signaling in response to serum withdrawal.
T99160	PDBSTRUC	6CKI; 6CK6; 6CK3; 6CJY; 6CJW
T99160	BIOCLASS	Protein kinase superfamily. CAMK Ser/Thr protein kinase family
T99160	ECNUMBER	EC 2.7.11.1
T99160	SEQUENCE	MVQKKPAELQGFHRSFKGQNPFELAFSLDQPDHGDSDFGLQCSARPDMPASQPIDIPDAKKRGKKKKRGRATDSFSGRFEDVYQLQEDVLGEGAHARVQTCINLITSQEYAVKIIEKQPGHIRSRVFREVEMLYQCQGHRNVLELIEFFEEEDRFYLVFEKMRGGSILSHIHKRRHFNELEASVVVQDVASALDFLHNKGIAHRDLKPENILCEHPNQVSPVKICDFDLGSGIKLNGDCSPISTPELLTPCGSAEYMAPEVVEAFSEEASIYDKRCDLWSLGVILYILLSGYPPFVGRCGSDCGWDRGEACPACQNMLFESIQEGKYEFPDKDWAHISCAAKDLISKLLVRDAKQRLSAAQVLQHPWVQGCAPENTLPTPMVLQRNSCAKDLTSFAAEAIAMNRQLAQHDEDLAEEEAAGQGQPVLVRATSRCLQLSPPSQSKLAQRRQRASLSSAPVVLVGDHA
T99160	DRUGINFO	D07XOV	EFT508	Phase 2

T86264	TARGETID	T86264
T86264	FORMERID	TTDNC00532
T86264	UNIPROID	S40A1_HUMAN
T86264	TARGNAME	Solute carrier family 40 member 1 (SLC40A1)
T86264	GENENAME	SLC40A1
T86264	TARGTYPE	Clinical trial
T86264	SYNONYMS	SLC11A3; MSTP079; IREG1; Ferroportin-1; FPN1
T86264	FUNCTION	Mediates iron efflux in the presence of a ferroxidase (hephaestin and/or ceruloplasmin). May be involved in iron export from duodenal epithelial cell and also in transfer of iron between maternal and fetal circulation.
T86264	BIOCLASS	Ferroportin protein
T86264	SEQUENCE	MTRAGDHNRQRGCCGSLADYLTSAKFLLYLGHSLSTWGDRMWHFAVSVFLVELYGNSLLLTAVYGLVVAGSVLVLGAIIGDWVDKNARLKVAQTSLVVQNVSVILCGIILMMVFLHKHELLTMYHGWVLTSCYILIITIANIANLASTATAITIQRDWIVVVAGEDRSKLANMNATIRRIDQLTNILAPMAVGQIMTFGSPVIGCGFISGWNLVSMCVEYVLLWKVYQKTPALAVKAGLKEEETELKQLNLHKDTEPKPLEGTHLMGVKDSNIHELEHEQEPTCASQMAEPFRTFRDGWVSYYNQPVFLAGMGLAFLYMTVLGFDCITTGYAYTQGLSGSILSILMGASAITGIMGTVAFTWLRRKCGLVRTGLISGLAQLSCLILCVISVFMPGSPLDLSVSPFEDIRSRFIQGESITPTKIPEITTEIYMSNGSNSANIVPETSPESVPIISVSLLFAGVIAARIGLWSFDLTVTQLLQENVIESERGIINGVQNSMNYLLDLLHFIMVILAPNPEAFGLLVLISVSFVAMGHIMYFRFAQNTLGNKLFACGPDAKEVRKENQANTSVV
T86264	DRUGINFO	D0IN8Z	LY2928057	Phase 2
T86264	DRUGINFO	D07SQT	Ferroportin mab	Phase 1
T86264	DRUGINFO	D5W7BG	M012	Phase 1

T28717	TARGETID	T28717
T28717	FORMERID	TTDI02196
T28717	UNIPROID	TNR12_HUMAN
T28717	TARGNAME	TNF superfamily receptor 12A (TNFRSF12A)
T28717	GENENAME	TNFRSF12A
T28717	TARGTYPE	Clinical trial
T28717	SYNONYMS	TweakR; Tweak-receptor; Tumor necrosis factor receptor superfamily member 12A; Fibroblast growth factor-inducible immediate-early response protein 14; FN14; FGF-inducible 14; CD266
T28717	FUNCTION	Weak inducer of apoptosis in some cell types. Promotes angiogenesis and the proliferation of endothelial cells. May modulate cellular adhesion to matrix proteins. Receptor for TNFSF12/TWEAK.
T28717	PDBSTRUC	2RPJ; 2KMZ; 2EQP
T28717	BIOCLASS	Cytokine receptor
T28717	SEQUENCE	MARGSLRRLLRLLVLGLWLALLRSVAGEQAPGTAPCSRGSSWSADLDKCMDCASCRARPHSDFCLGCAAAPPAPFRLLWPILGGALSLTFVLGLLSGFLVWRRCRRREKFTTPIEETGGEGCPAVALIQ
T28717	DRUGINFO	D07UKJ	Enavatuzumab	Phase 1

T91451	TARGETID	T91451
T91451	UNIPROID	UBE2T_HUMAN
T91451	TARGNAME	E2 ubiquitin-conjugating enzyme T (UBE2T)
T91451	GENENAME	UBE2T
T91451	TARGTYPE	Clinical trial
T91451	SYNONYMS	Ubiquitin-protein ligase T; Ubiquitin carrier protein T; Cell proliferation-inducing gene 50 protein
T91451	FUNCTION	Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. Catalyzes monoubiquitination. Involved in mitomycin-C (MMC)-induced DNA repair. Acts as a specific E2 ubiquitin-conjugating enzyme for the Fanconi anemia complex by associating with E3 ubiquitin-protein ligase FANCL and catalyzing monoubiquitination of FANCD2, a key step in the DNA damage pathway (PubMed:16916645, PubMed:17938197, PubMed:19111657, PubMed:19589784, PubMed:28437106). Also mediates monoubiquitination of FANCL and FANCI (PubMed:16916645, PubMed:17938197, PubMed:19111657, PubMed:19589784). May contribute to ubiquitination and degradation of BRCA1 (PubMed:19887602). In vitro able to promote polyubiquitination using all 7 ubiquitin Lys residues, but may prefer 'Lys-11'-, 'Lys-27'-, 'Lys-48'- and 'Lys-63'-linked polyubiquitination (PubMed:20061386).
T91451	PDBSTRUC	5OJJ; 5NGZ; 4CCG; 1YH2
T91451	BIOCLASS	Ubiquitin-conjugating enzyme family
T91451	ECNUMBER	EC 2.3.2.23
T91451	SEQUENCE	MQRASRLKRELHMLATEPPPGITCWQDKDQMDDLRAQILGGANTPYEKGVFKLEVIIPERYPFEPPQIRFLTPIYHPNIDSAGRICLDVLKLPPKGAWRPSLNIATVLTSIQLLMSEPNPDDPLMADISSEFKYNKPAFLKNARQWTEKHARQKQKADEEEMLDNLPEAGDSRVHNSTQKRKASQLVGIEKKFHPDV
T91451	DRUGINFO	D0W3RW	MK-2206	Phase 2

T11451	TARGETID	T11451
T11451	FORMERID	TTDC00107
T11451	UNIPROID	TLR9_HUMAN
T11451	TARGNAME	Toll-like receptor 9 (TLR9)
T11451	GENENAME	TLR9
T11451	TARGTYPE	Clinical trial
T11451	SYNONYMS	UNQ5798/PRO19605; TLR-9; CD289
T11451	FUNCTION	Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR9 is a nucleotide-sensing TLR which is activated by unmethylated cytidine-phosphate-guanosine (CpG) dinucleotides. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Controls lymphocyte response to Helicobacter infection. Upon CpG stimulation, induces B-cell proliferation, activation, survival and antibody production.
T11451	BIOCLASS	Toll-like receptor
T11451	SEQUENCE	MGFCRSALHPLSLLVQAIMLAMTLALGTLPAFLPCELQPHGLVNCNWLFLKSVPHFSMAAPRGNVTSLSLSSNRIHHLHDSDFAHLPSLRHLNLKWNCPPVGLSPMHFPCHMTIEPSTFLAVPTLEELNLSYNNIMTVPALPKSLISLSLSHTNILMLDSASLAGLHALRFLFMDGNCYYKNPCRQALEVAPGALLGLGNLTHLSLKYNNLTVVPRNLPSSLEYLLLSYNRIVKLAPEDLANLTALRVLDVGGNCRRCDHAPNPCMECPRHFPQLHPDTFSHLSRLEGLVLKDSSLSWLNASWFRGLGNLRVLDLSENFLYKCITKTKAFQGLTQLRKLNLSFNYQKRVSFAHLSLAPSFGSLVALKELDMHGIFFRSLDETTLRPLARLPMLQTLRLQMNFINQAQLGIFRAFPGLRYVDLSDNRISGASELTATMGEADGGEKVWLQPGDLAPAPVDTPSSEDFRPNCSTLNFTLDLSRNNLVTVQPEMFAQLSHLQCLRLSHNCISQAVNGSQFLPLTGLQVLDLSHNKLDLYHEHSFTELPRLEALDLSYNSQPFGMQGVGHNFSFVAHLRTLRHLSLAHNNIHSQVSQQLCSTSLRALDFSGNALGHMWAEGDLYLHFFQGLSGLIWLDLSQNRLHTLLPQTLRNLPKSLQVLRLRDNYLAFFKWWSLHFLPKLEVLDLAGNQLKALTNGSLPAGTRLRRLDVSCNSISFVAPGFFSKAKELRELNLSANALKTVDHSWFGPLASALQILDVSANPLHCACGAAFMDFLLEVQAAVPGLPSRVKCGSPGQLQGLSIFAQDLRLCLDEALSWDCFALSLLAVALGLGVPMLHHLCGWDLWYCFHLCLAWLPWRGRQSGRDEDALPYDAFVVFDKTQSAVADWVYNELRGQLEECRGRWALRLCLEERDWLPGKTLFENLWASVYGSRKTLFVLAHTDRVSGLLRASFLLAQQRLLEDRKDVVVLVILSPDGRRSRYVRLRQRLCRQSVLLWPHQPSGQRSFWAQLGMALTRDNHHFYNRNFCQGPTAE
T11451	DRUGINFO	D08RJM	SD-101	Phase 3
T11451	DRUGINFO	D0F7YW	MGN-1703	Phase 3
T11451	DRUGINFO	D0FM5M	IMO-2125	Phase 3
T11451	DRUGINFO	D6YD0X	Tilsotolimod	Phase 3
T11451	DRUGINFO	D0V0JR	Cadi-05	Phase 3
T11451	DRUGINFO	D02GIA	BL-7040	Phase 2
T11451	DRUGINFO	D09CEJ	CYT003	Phase 2
T11451	DRUGINFO	D0C6ZS	CpG-10101	Phase 2
T11451	DRUGINFO	D0D4LP	JVRS-100	Phase 2
T11451	DRUGINFO	D0GR5X	Tolamba	Phase 2
T11451	DRUGINFO	D0W6HO	IMO-2055	Phase 2
T11451	DRUGINFO	DY46GM	Lefitolimod	Phase 2
T11451	DRUGINFO	D01UHA	MIS-416	Phase 2
T11451	DRUGINFO	D08OXU	IMO-3100	Phase 2
T11451	DRUGINFO	D0C3VQ	Zadaxin/lamivudine	Phase 2
T11451	DRUGINFO	D00CQL	N-8295	Phase 1
T11451	DRUGINFO	D01SPJ	Litenimod	Phase 1
T11451	DRUGINFO	D02AWQ	AZD1419	Phase 1
T11451	DRUGINFO	D04CXX	GNKG-168	Phase 1
T11451	DRUGINFO	D05ZLY	AST-008	Phase 1
T11451	DRUGINFO	D0R8RO	SAR-21609	Phase 1
T11451	DRUGINFO	D0U8LD	MGN-1706	Phase 1
T11451	DRUGINFO	D0X8VX	DV281	Phase 1
T11451	DRUGINFO	D7T5AN	CMP-001	Phase 1
T11451	DRUGINFO	DBU13L	Cavrotolimod	Phase 1
T11451	DRUGINFO	D00CGX	DV-1179	Phase 1
T11451	DRUGINFO	D0G1TY	CPG 52364	Phase 1
T11451	DRUGINFO	D03GAI	IR-103	Discontinued in Phase 3
T11451	DRUGINFO	D0D5FQ	Agatolimod	Discontinued in Phase 2
T11451	DRUGINFO	D0H4XV	IM0-8400	Discontinued in Phase 1/2
T11451	DRUGINFO	D02ZWR	IMO-2134	Preclinical
T11451	DRUGINFO	D0B6WN	AVE0675	Terminated
T11451	DRUGINFO	D0Q2UW	DIMS-9054	Investigative
T11451	DRUGINFO	DT6N0O	ODN-2088	Investigative
T11451	DRUGINFO	DX45IW	COV08-0064	Investigative

T48703	TARGETID	T48703
T48703	FORMERID	TTDC00056
T48703	UNIPROID	TLR8_HUMAN
T48703	TARGNAME	Toll-like receptor 8 (TLR8)
T48703	GENENAME	TLR8
T48703	TARGTYPE	Clinical trial
T48703	SYNONYMS	UNQ249/PRO286; CD288 antigen; CD288
T48703	FUNCTION	Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.
T48703	PDBSTRUC	5Z15; 5Z14; 5WYZ; 5WYX; 5HDH
T48703	BIOCLASS	Toll-like receptor
T48703	SEQUENCE	MENMFLQSSMLTCIFLLISGSCELCAEENFSRSYPCDEKKQNDSVIAECSNRRLQEVPQTVGKYVTELDLSDNFITHITNESFQGLQNLTKINLNHNPNVQHQNGNPGIQSNGLNITDGAFLNLKNLRELLLEDNQLPQIPSGLPESLTELSLIQNNIYNITKEGISRLINLKNLYLAWNCYFNKVCEKTNIEDGVFETLTNLELLSLSFNSLSHVPPKLPSSLRKLFLSNTQIKYISEEDFKGLINLTLLDLSGNCPRCFNAPFPCVPCDGGASINIDRFAFQNLTQLRYLNLSSTSLRKINAAWFKNMPHLKVLDLEFNYLVGEIASGAFLTMLPRLEILDLSFNYIKGSYPQHINISRNFSKLLSLRALHLRGYVFQELREDDFQPLMQLPNLSTINLGINFIKQIDFKLFQNFSNLEIIYLSENRISPLVKDTRQSYANSSSFQRHIRKRRSTDFEFDPHSNFYHFTRPLIKPQCAAYGKALDLSLNSIFFIGPNQFENLPDIACLNLSANSNAQVLSGTEFSAIPHVKYLDLTNNRLDFDNASALTELSDLEVLDLSYNSHYFRIAGVTHHLEFIQNFTNLKVLNLSHNNIYTLTDKYNLESKSLVELVFSGNRLDILWNDDDNRYISIFKGLKNLTRLDLSLNRLKHIPNEAFLNLPASLTELHINDNMLKFFNWTLLQQFPRLELLDLRGNKLLFLTDSLSDFTSSLRTLLLSHNRISHLPSGFLSEVSSLKHLDLSSNLLKTINKSALETKTTTKLSMLELHGNPFECTCDIGDFRRWMDEHLNVKIPRLVDVICASPGDQRGKSIVSLELTTCVSDVTAVILFFFTFFITTMVMLAALAHHLFYWDVWFIYNVCLAKVKGYRSLSTSQTFYDAYISYDTKDASVTDWVINELRYHLEESRDKNVLLCLEERDWDPGLAIIDNLMQSINQSKKTVFVLTKKYAKSWNFKTAFYLALQRLMDENMDVIIFILLEPVLQHSQYLRLRQRICKSSILQWPDNPKAEGLFWQTLRNVVLTENDSRYNNMYVDSIKQY
T48703	DRUGINFO	DOV7J4	Selgantolimod	Phase 2
T48703	DRUGINFO	D0C8KF	Resiquimod	Phase 2
T48703	DRUGINFO	DW0ZV1	Afimetoran	Phase 2
T48703	DRUGINFO	D8JN5H	NKTR-262	Phase 1/2
T48703	DRUGINFO	D05ASV	VTX-1463	Phase 1
T48703	DRUGINFO	D98FBH	DN1508052	Phase 1
T48703	DRUGINFO	DC3I7P	GSK5251738	Phase 1
T48703	DRUGINFO	D0L8HB	MEDI9197	Phase 1
T48703	DRUGINFO	DUA7P2	SBT6050	Phase 1
T48703	DRUGINFO	D0G1TY	CPG 52364	Phase 1
T48703	DRUGINFO	DVU2H8	CV8102	Phase 1
T48703	DRUGINFO	D0H3JF	VTX-2337	Discontinued in Phase 2
T48703	DRUGINFO	D0H4XV	IM0-8400	Discontinued in Phase 1/2
T48703	DRUGINFO	D01DSB	VTX-744	Investigative
T48703	DRUGINFO	D0UI0B	VTX-763	Investigative
T48703	DRUGINFO	D5S7JL	ODN-1411	Investigative

T31989	TARGETID	T31989
T31989	FORMERID	TTDC00058
T31989	UNIPROID	SPHK2_HUMAN
T31989	TARGNAME	Sphingosine kinase 2 (SPHK2)
T31989	GENENAME	SPHK2
T31989	TARGTYPE	Clinical trial
T31989	SYNONYMS	SPK 2; SK 2
T31989	FUNCTION	Acts on D-erythro-dihydrosphingosine, D-erythro-sphingosine and L-threo-dihydrosphingosine. Binds phosphoinositides. Catalyzes the phosphorylation of sphingosine to form sphingosine 1-phosphate (SPP), a lipid mediator with both intra- and extracellular functions.
T31989	BIOCLASS	Kinase
T31989	ECNUMBER	EC 2.7.1.91
T31989	SEQUENCE	MNGHLEAEEQQDQRPDQELTGSWGHGPRSTLVRAKAMAPPPPPLAASTPLLHGEFGSYPARGPRFALTLTSQALHIQRLRPKPEARPRGGLVPLAEVSGCCTLRSRSPSDSAAYFCIYTYPRGRRGARRRATRTFRADGAATYEENRAEAQRWATALTCLLRGLPLPGDGEITPDLLPRPPRLLLLVNPFGGRGLAWQWCKNHVLPMISEAGLSFNLIQTERQNHARELVQGLSLSEWDGIVTVSGDGLLHEVLNGLLDRPDWEEAVKMPVGILPCGSGNALAGAVNQHGGFEPALGLDLLLNCSLLLCRGGGHPLDLLSVTLASGSRCFSFLSVAWGFVSDVDIQSERFRALGSARFTLGTVLGLATLHTYRGRLSYLPATVEPASPTPAHSLPRAKSELTLTPDPAPPMAHSPLHRSVSDLPLPLPQPALASPGSPEPLPILSLNGGGPELAGDWGGAGDAPLSPDPLLSSPPGSPKAALHSPVSEGAPVIPPSSGLPLPTPDARVGASTCGPPDHLLPPLGTPLPPDWVTLEGDFVLMLAISPSHLGADLVAAPHARFDDGLVHLCWVRSGISRAALLRLFLAMERGSHFSLGCPQLGYAAARAFRLEPLTPRGVLTVDGEQVEYGPLQAQMHPGIGTLLTGPPGCPGREP
T31989	DRUGINFO	D0X6BX	ABC294640	Phase 3
T31989	DRUGINFO	D01UUZ	(R)-2-amino-4-hydroxy-N-(4-octylphenyl)butanamide	Investigative
T31989	DRUGINFO	D01XSX	(S)-2-amino-6-hydroxy-N-(4-octylphenyl)hexanamide	Investigative
T31989	DRUGINFO	D0E3LA	(R)-2-amino-3-(4-octylphenylamino)propan-1-ol	Investigative
T31989	DRUGINFO	D0H2LN	ROMe	Investigative
T31989	DRUGINFO	D0M9DT	DIMETHYLSPINGOSINE	Investigative
T31989	DRUGINFO	D0TC4I	(S)-2-amino-4-hydroxy-N-(4-octylphenyl)butanamide	Investigative

T42928	TARGETID	T42928
T42928	FORMERID	TTDI02071
T42928	UNIPROID	FGF21_HUMAN
T42928	TARGNAME	Fibroblast growth factor-21 (FGF21)
T42928	GENENAME	FGF21
T42928	TARGTYPE	Clinical trial
T42928	SYNONYMS	UNQ3115/PRO10196; Fibroblast growth factor 21; FGF-21
T42928	FUNCTION	Activity requires the presence of KLB. Stimulates glucose uptake in differentiated adipocytes via the induction of glucose transporter SLC2A1/GLUT1 expression (but not SLC2A4/GLUT4 expression).
T42928	PDBSTRUC	5VAQ
T42928	BIOCLASS	Growth factor
T42928	SEQUENCE	MDSDETGFEHSGLWVSVLAGLLLGACQAHPIPDSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIREDGTVGGAADQSPESLLQLKALKPGVIQILGVKTSRFLCQRPDGALYGSLHFDPEACSFRELLLEDGYNVYQSEAHGLPLHLPGNKSPHRDPAPRGPARFLPLPGLPPALPEPPGILAPQPPDVGSSDPLSMVGPSQGRSPSYAS
T42928	DRUGINFO	DZ2B3I	Pegozafermin	Phase 3
T42928	DRUGINFO	D0PO0T	BMS-986036	Phase 2
T42928	DRUGINFO	D0WK6V	PF-05231023	Phase 1
T42928	DRUGINFO	D03OCG	FGF-21	Discontinued in Phase 1/2

T55398	TARGETID	T55398
T55398	FORMERID	TTDR00045
T55398	UNIPROID	IRAK4_HUMAN
T55398	TARGNAME	Renal carcinoma antigen NY-REN-64 (IRAK-4)
T55398	GENENAME	IRAK4
T55398	TARGTYPE	Clinical trial
T55398	SYNONYMS	Interleukin-1 receptor-associated kinase 4; IRAK-4
T55398	FUNCTION	Serine/threonine-protein kinase that plays a critical role in initiating innate immune response against foreign pathogens. Involved in Toll-like receptor (TLR) and IL-1R signaling pathways. Is rapidly recruited by MYD88 to the receptor-signaling complex upon TLR activation to form the Myddosome together with IRAK2. Phosphorylates initially IRAK1, thus stimulating the kinase activity and intensive autophosphorylation of IRAK1. Phosphorylates E3 ubiquitin ligases Pellino proteins (PELI1, PELI2 and PELI3) to promote pellino-mediated polyubiquitination of IRAK1. Then, the ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. In turn, MAP3K7/TAK1 activates IKKs (CHUK/IKKA and IKBKB/IKKB) leading to NF-kappa-B nuclear translocation and activation. Alternatively, phosphorylates TIRAP to promote its ubiquitination and subsequent degradation. Phosphorylates NCF1 and regulates NADPH oxidase activation after LPS stimulation suggesting a similar mechanism during microbial infections.
T55398	PDBSTRUC	6O9D; 6O95; 6O94; 6O8U; 6N8G
T55398	BIOCLASS	Kinase
T55398	ECNUMBER	EC 2.7.11.1
T55398	SEQUENCE	MNKPITPSTYVRCLNVGLIRKLSDFIDPQEGWKKLAVAIKKPSGDDRYNQFHIRRFEALLQTGKSPTSELLFDWGTTNCTVGDLVDLLIQNEFFAPASLLLPDAVPKTANTLPSKEAITVQQKQMPFCDKDRTLMTPVQNLEQSYMPPDSSSPENKSLEVSDTRFHSFSFYELKNVTNNFDERPISVGGNKMGEGGFGVVYKGYVNNTTVAVKKLAAMVDITTEELKQQFDQEIKVMAKCQHENLVELLGFSSDGDDLCLVYVYMPNGSLLDRLSCLDGTPPLSWHMRCKIAQGAANGINFLHENHHIHRDIKSANILLDEAFTAKISDFGLARASEKFAQTVMTSRIVGTTAYMAPEALRGEITPKSDIYSFGVVLLEIITGLPAVDEHREPQLLLDIKEEIEDEEKTIEDYIDKKMNDADSTSVEAMYSVASQCLHEKKNKRPDIKKVQQLLQEMTAS
T55398	DRUGINFO	D5XVM6	Zabedosertib	Phase 2
T55398	DRUGINFO	DF1T2W	GS-5718	Phase 2
T55398	DRUGINFO	D0AY8A	CA-4948	Phase 1
T55398	DRUGINFO	D0CW9M	SAR444656	Phase 1
T55398	DRUGINFO	D0QQ7I	BAY1834845	Phase 1
T55398	DRUGINFO	D7MYO0	AZD6793	Phase 1
T55398	DRUGINFO	D00WDA	Indazole amide derivative 2	Patented
T55398	DRUGINFO	D04UIH	Amidopyrazole derivative 1	Patented
T55398	DRUGINFO	D0A2BX	Amidopyrazole derivative 3	Patented
T55398	DRUGINFO	D0DC8B	Indazole amide derivative 1	Patented
T55398	DRUGINFO	D0DK0R	Macrolactam derivative 3	Patented
T55398	DRUGINFO	D0G3NC	Amidopyrazole derivative 2	Patented
T55398	DRUGINFO	D0GA8C	Macrolactam derivative 1	Patented
T55398	DRUGINFO	D0L7OR	Diaminopyridine analog 5	Patented
T55398	DRUGINFO	D0N4ZM	Amidopyrazole derivative 6	Patented
T55398	DRUGINFO	D0N5WE	Macrolactam derivative 2	Patented
T55398	DRUGINFO	D0Q7ZF	Macrolactam derivative 4	Patented
T55398	DRUGINFO	D0S1DI	Diaminopyridine analog 4	Patented
T55398	DRUGINFO	D0TV9G	Amidopyrazole derivative 4	Patented
T55398	DRUGINFO	D0VD3P	Amidopyrazole derivative 5	Patented
T55398	DRUGINFO	D0W3TL	Fused benzoheterocycle amide derivative 2	Patented
T55398	DRUGINFO	D0YF6E	Fused benzoheterocycle amide derivative 1	Patented
T55398	DRUGINFO	D0YJ1O	Pyrazole N-1 aryl and heteroaryl derivative 1	Patented
T55398	DRUGINFO	D0E5AT	Pyrazolopyrimidine and thienopyrimidine amide derivative 1	Patented
T55398	DRUGINFO	D0F2NW	Pyrazolopyrimidine and thienopyrimidine amide derivative 2	Patented
T55398	DRUGINFO	D0NT8U	Indazoletriazolephenyl derivative 1	Patented
T55398	DRUGINFO	D0O6GQ	Indazoletriazolephenyl derivative 2	Patented
T55398	DRUGINFO	D00DSG	PF-05313261	Investigative
T55398	DRUGINFO	D04CFM	ND-2158	Investigative
T55398	DRUGINFO	D09JUD	IRAK4 inhibitor 4b	Investigative
T55398	DRUGINFO	D0J8VR	IRAK4 inhibitor rac-45	Investigative
T55398	DRUGINFO	D0Y2ZC	ND-2110	Investigative
T55398	DRUGINFO	D04ZIV	WO2012007375C1	Investigative
T55398	DRUGINFO	D0I2FZ	IRAK-1/4 inhibitor	Investigative
T55398	DRUGINFO	D0T2NE	WO2012007375C7 	Investigative

T22583	TARGETID	T22583
T22583	FORMERID	TTDC00158
T22583	UNIPROID	SC5A4_HUMAN
T22583	TARGNAME	Sodium/glucose cotransporter 2 (SLC5A4)
T22583	GENENAME	SLC5A4
T22583	TARGTYPE	Clinical trial
T22583	SYNONYMS	Sodium/glucose cotransporter 4; SLC5A4
T22583	FUNCTION	Sodium-dependent glucose transporter.
T22583	BIOCLASS	Solute:sodium symporter
T22583	SEQUENCE	MASTVSPSTIAETPEPPPLSDHIRNAADISVIVIYFLVVMAVGLWAMLKTNRGTIGGFFLAGRDMAWWPMGASLFASNIGSNHYVGLAGTGAASGVATVTFEWTSSVMLLILGWIFVPIYIKSGVMTMPEYLKKRFGGERLQVYLSILSLFICVVLLISADIFAGAIFIKLALGLDLYLAIFILLAMTAVYTTTGGLASVIYTDTLQTIIMLIGSFILMGFAFNEVGGYESFTEKYVNATPSVVEGDNLTISASCYTPRADSFHIFRDAVTGDIPWPGIIFGMPITALWYWCTNQVIVQRCLCGKDMSHVKAACIMCAYLKLLPMFLMVMPGMISRILYTDMVACVVPSECVKHCGVDVGCTNYAYPTMVLELMPQGLRGLMLSVMLASLMSSLTSIFNSASTLFTIDLYTKMRKQASEKELLIAGRIFVLLLTVVSIVWVPLVQVSQNGQLIHYTESISSYLGPPIAAVFVLAIFCKRVNEQGAFWGLMVGLAMGLIRMITEFAYGTGSCLAPSNCPKIICGVHYLYFSIVLFFGSMLVTLGISLLTKPIPDVHLYRLCWVLRNSTEERIDIDAEEKSQEETDDGVEEDYPEKSRGCLKKAYDLFCGLQKGPKLTKEEEEALSKKLTDTSERPSWRTIVNINAILLLAVVVFIHGYYA
T22583	DRUGINFO	D04WQT	RG7201	Phase 3
T22583	DRUGINFO	D09XMX	SaxaDapa FDC	Phase 3
T22583	DRUGINFO	D0I5ZM	Remogli ozin-etabonate	Phase 2
T22583	DRUGINFO	D0V4MB	Remogliflozin etabonate	Phase 2
T22583	DRUGINFO	D0U9TM	Ponalrestat	Discontinued in Phase 3

T94482	TARGETID	T94482
T94482	FORMERID	TTDR00855
T94482	UNIPROID	IL20_HUMAN
T94482	TARGNAME	Interleukin-20 (IL20)
T94482	GENENAME	IL20
T94482	TARGTYPE	Clinical trial
T94482	SYNONYMS	ZCYTO10; UNQ852/PRO1801; IL-20; Four alpha helix cytokine ZCYTO10; Cytokine Zcyto10
T94482	FUNCTION	Angiogenic and proliferative activities are antagonized by IL10. May act through STAT3. Proinflammatory and angiogenic cytokine that may be involved in epidermal function and psoriasis.
T94482	PDBSTRUC	4DOH
T94482	BIOCLASS	Cytokine: interleukin
T94482	SEQUENCE	MKASSLAFSLLSAAFYLLWTPSTGLKTLNLGSCVIATNLQEIRNGFSEIRGSVQAKDGNIDIRILRRTESLQDTKPANRCCLLRHLLRLYLDRVFKNYQTPDHYTLRKISSLANSFLTIKKDLRLCHAHMTCHCGEEAMKKYSQILSHFEKLEPQAAVVKALGELDILLQWMEETE
T94482	DRUGINFO	D00LGA	NN-8226	Phase 2

T91286	TARGETID	T91286
T91286	FORMERID	TTDNC00499
T91286	UNIPROID	STEA1_HUMAN
T91286	TARGNAME	Metalloreductase STEAP1 (STEAP1)
T91286	GENENAME	STEAP1
T91286	TARGTYPE	Clinical trial
T91286	SYNONYMS	Sixtransmembrane epithelial antigen of prostate 1; STEAP1
T91286	FUNCTION	Metalloreductase that has the ability to reduce both Fe(3+) to Fe(2+) and Cu(2+) to Cu(1+). Uses NAD(+) as acceptor.
T91286	BIOCLASS	Metal ion oxidoreductase
T91286	ECNUMBER	EC 1.16.1.-
T91286	SEQUENCE	MESRKDITNQEELWKMKPRRNLEEDDYLHKDTGETSMLKRPVLLHLHQTAHADEFDCPSELQHTQELFPQWHLPIKIAAIIASLTFLYTLLREVIHPLATSHQQYFYKIPILVINKVLPMVSITLLALVYLPGVIAAIVQLHNGTKYKKFPHWLDKWMLTRKQFGLLSFFFAVLHAIYSLSYPMRRSYRYKLLNWAYQQVQQNKEDAWIEHDVWRMEIYVSLGIVGLAILALLAVTSIPSVSDSLTWREFHYIQSKLGIVSLLLGTIHALIFAWNKWIDIKQFVWYTPPTFMIAVFLPIVVLIFKSILFLPCLRKKILKIRHGWEDVTKINKTEICSQL
T91286	DRUGINFO	D0O6YE	RG7450	Phase 1
T91286	DRUGINFO	DAX06Q	AMG 509	Phase 1

T49072	TARGETID	T49072
T49072	FORMERID	TTDR00562
T49072	UNIPROID	UR2R_HUMAN
T49072	TARGNAME	Urotensin II receptor (UTS2R)
T49072	GENENAME	UTS2R
T49072	TARGTYPE	Clinical trial
T49072	SYNONYMS	Urotensin-II receptor GPR14; UTS2R; UR-II-R; G protein coupled receptor 14
T49072	FUNCTION	High affinity receptor for urotensin-2 and urotensin-2B. The activity of this receptor is mediated by a G-protein that activate a phosphatidylinositol-calcium second messenger system.
T49072	BIOCLASS	GPCR rhodopsin
T49072	SEQUENCE	MALTPESPSSFPGLAATGSSVPEPPGGPNATLNSSWASPTEPSSLEDLVATGTIGTLLSAMGVVGVVGNAYTLVVTCRSLRAVASMYVYVVNLALADLLYLLSIPFIVATYVTKEWHFGDVGCRVLFGLDFLTMHASIFTLTVMSSERYAAVLRPLDTVQRPKGYRKLLALGTWLLALLLTLPVMLAMRLVRRGPKSLCLPAWGPRAHRAYLTLLFATSIAGPGLLIGLLYARLARAYRRSQRASFKRARRPGARALRLVLGIVLLFWACFLPFWLWQLLAQYHQAPLAPRTARIVNYLTTCLTYGNSCANPFLYTLLTRNYRDHLRGRVRGPGSGGGRGPVPSLQPRARFQRCSGRSLSSCSPQPTDSLVLAPAAPARPAPEGPRAPA
T49072	DRUGINFO	D04LWT	GSK1440115	Phase 1
T49072	DRUGINFO	D0PQ8T	SB-436811	Phase 1
T49072	DRUGINFO	D08FGX	PALOSURAN	Discontinued in Phase 2
T49072	DRUGINFO	D04LSH	SAR101099	Discontinued in Phase 1
T49072	DRUGINFO	D00CLB	SB-328872	Investigative
T49072	DRUGINFO	D03AHQ	Ac-[CFWKFC]-NH2	Investigative
T49072	DRUGINFO	D03JLK	Ac-FWKY-NH2	Investigative
T49072	DRUGINFO	D03NCB	Ac-[CFWkYC]-NH2	Investigative
T49072	DRUGINFO	D04UHT	urotensin II-related peptide	Investigative
T49072	DRUGINFO	D05WON	SB-611812	Investigative
T49072	DRUGINFO	D07JDU	SB-706375	Investigative
T49072	DRUGINFO	D0J7HS	AGTAD[CFWKYC]V	Investigative
T49072	DRUGINFO	D0M1BF	S6716	Investigative
T49072	DRUGINFO	D0M9ZX	FL104	Investigative
T49072	DRUGINFO	D0P1HC	Ac-WKY-NH2	Investigative
T49072	DRUGINFO	D0R8GW	AC-7954	Investigative
T49072	DRUGINFO	D0T0RI	JNJ-28318706	Investigative
T49072	DRUGINFO	D0YY3T	Ac-SFWKYS-NH2	Investigative
T49072	DRUGINFO	D03SAV	ICI-199441	Investigative

T42065	TARGETID	T42065
T42065	FORMERID	TTDI02080
T42065	UNIPROID	GLCNE_HUMAN
T42065	TARGNAME	N-acetylmannosamine kinase (GNE)
T42065	GENENAME	GNE
T42065	TARGTYPE	Clinical trial
T42065	SYNONYMS	UDPGlcNAc2epimerase/ManAc kinase; GNE; Bifunctional UDPNacetylglucosamine 2epimerase/Nacetylmannosamine kinase
T42065	FUNCTION	Regulates and initiates biosynthesis of N- acetylneuraminic acid (NeuAc), a precursor of sialic acids. Plays an essential role in early development. Required for normal sialylation in hematopoietic cells. Sialylation is implicated in cell adhesion, signal transduction, tumorigenicity and metastatic behavior of malignant cells. {ECO:0000250, ECO:0000269|PubMed:10334995}.
T42065	PDBSTRUC	4ZHT; 3EO3; 2YI1; 2YHY; 2YHW
T42065	BIOCLASS	Kinase
T42065	SEQUENCE	MEKNGNNRKLRVCVATCNRADYSKLAPIMFGIKTEPEFFELDVVVLGSHLIDDYGNTYRMIEQDDFDINTRLHTIVRGEDEAAMVESVGLALVKLPDVLNRLKPDIMIVHGDRFDALALATSAALMNIRILHIEGGEVSGTIDDSIRHAITKLAHYHVCCTRSAEQHLISMCEDHDRILLAGCPSYDKLLSAKNKDYMSIIRMWLGDDVKSKDYIVALQHPVTTDIKHSIKMFELTLDALISFNKRTLVLFPNIDAGSKEMVRVMRKKGIEHHPNFRAVKHVPFDQFIQLVAHAGCMIGNSSCGVREVGAFGTPVINLGTRQIGRETGENVLHVRDADTQDKILQALHLQFGKQYPCSKIYGDGNAVPRILKFLKSIDLQEPLQKKFCFPPVKENISQDIDHILETLSALAVDLGGTNLRVAIVSMKGEIVKKYTQFNPKTYEERINLILQMCVEAAAEAVKLNCRILGVGISTGGRVNPREGIVLHSTKLIQEWNSVDLRTPLSDTLHLPVWVDNDGNCAALAERKFGQGKGLENFVTLITGTGIGGGIIHQHELIHGSSFCAAELGHLVVSLDGPDCSCGSHGCIEAYASGMALQREAKKLHDEDLLLVEGMSVPKDEAVGALHLIQAAKLGNAKAQSILRTAGTALGLGVVNILHTMNPSLVILSGVLASHYIHIVKDVIRQQALSSVQDVDVVVSDLVDPALLGAASMVLDYTTRRIY
T42065	DRUGINFO	D0KX8B	GNE Lipoplex	Phase 1

T76508	TARGETID	T76508
T76508	FORMERID	TTDR00337
T76508	UNIPROID	M3K2_HUMAN
T76508	TARGNAME	MAPK/ERK kinase kinase 2 (MAP3K2)
T76508	GENENAME	MAP3K2
T76508	TARGTYPE	Clinical trial
T76508	SYNONYMS	Mitogen-activated protein kinase kinase kinase 2; MEKK2; MEKK 2; MEK kinase 2; MAPKKK2
T76508	FUNCTION	Regulates the JNK and ERK5 pathways by phosphorylating and activating MAP2K5 and MAP2K7. Plays a role in caveolae kiss-and-run dynamics. Component of a protein kinase signal transduction cascade.
T76508	PDBSTRUC	5HQ8; 5EX0; 2NPT; 2CU1
T76508	BIOCLASS	Kinase
T76508	ECNUMBER	EC 2.7.11.25
T76508	SEQUENCE	MDDQQALNSIMQDLAVLHKASRPALSLQETRKAKSSSPKKQNDVRVKFEHRGEKRILQFPRPVKLEDLRSKAKIAFGQSMDLHYTNNELVIPLTTQDDLDKAVELLDRSIHMKSLKILLVINGSTQATNLEPLPSLEDLDNTVFGAERKKRLSIIGPTSRDRSSPPPGYIPDELHQVARNGSFTSINSEGEFIPESMDQMLDPLSLSSPENSGSGSCPSLDSPLDGESYPKSRMPRAQSYPDNHQEFSDYDNPIFEKFGKGGTYPRRYHVSYHHQEYNDGRKTFPRARRTQGTSLRSPVSFSPTDHSLSTSSGSSIFTPEYDDSRIRRRGSDIDNPTLTVMDISPPSRSPRAPTNWRLGKLLGQGAFGRVYLCYDVDTGRELAVKQVQFDPDSPETSKEVNALECEIQLLKNLLHERIVQYYGCLRDPQEKTLSIFMEYMPGGSIKDQLKAYGALTENVTRKYTRQILEGVHYLHSNMIVHRDIKGANILRDSTGNVKLGDFGASKRLQTICLSGTGMKSVTGTPYWMSPEVISGEGYGRKADIWSVACTVVEMLTEKPPWAEFEAMAAIFKIATQPTNPKLPPHVSDYTRDFLKRIFVEAKLRPSADELLRHMFVHYH
T76508	DRUGINFO	D04BCG	LLZ16407	Investigative
T76508	DRUGINFO	D0C1OZ	Ro092210	Investigative
T76508	DRUGINFO	D0GD8Y	U0126	Investigative
T76508	DRUGINFO	D07ADX	URMC-099	Investigative
T76508	DRUGINFO	D0B9BU	CI-1040	Investigative

T33641	TARGETID	T33641
T33641	FORMERID	TTDI02047
T33641	UNIPROID	CP46A_HUMAN
T33641	TARGNAME	Cholesterol 24-hydroxylase (CYP46A1)
T33641	GENENAME	CYP46A1
T33641	TARGTYPE	Clinical trial
T33641	SYNONYMS	Cytochrome P450 46A1; CYP46; Cholesterol 24S-hydroxylase; Cholesterol 24-monooxygenase; CH24H
T33641	FUNCTION	Primarily catalyzes the hydroxylation (with S stereochemistry) at C-24 of cholesterol side chain, triggering cholesterol diffusion out of neurons and its further degradation. By promoting constant cholesterol elimination in neurons, may activate the mevalonate pathway and coordinate the synthesis of new cholesterol and nonsterol isoprenoids involved in synaptic activity and learning. Further hydroxylates cholesterol derivatives and hormone steroids on both the ring and side chain of these molecules, converting them into active oxysterols involved in lipid signaling and biosynthesis. Acts as an epoxidase converting cholesta-5,24-dien-3beta-ol/desmosterol into (24S),25-epoxycholesterol, an abundant lipid ligand of nuclear NR1H2 and NR1H3 receptors shown to promote neurogenesis in developing brain. May also catalyze the oxidative metabolism of xenobiotics, such as clotrimazole. P450 monooxygenase that plays a major role in cholesterol homeostasis in the brain.
T33641	PDBSTRUC	4J14; 4FIA; 4ENH; 3MDV; 3MDT
T33641	BIOCLASS	Paired donor oxygen oxidoreductase
T33641	ECNUMBER	EC 1.14.14.25
T33641	SEQUENCE	MSPGLLLLGSAVLLAFGLCCTFVHRARSRYEHIPGPPRPSFLLGHLPCFWKKDEVGGRVLQDVFLDWAKKYGPVVRVNVFHKTSVIVTSPESVKKFLMSTKYNKDSKMYRALQTVFGERLFGQGLVSECNYERWHKQRRVIDLAFSRSSLVSLMETFNEKAEQLVEILEAKADGQTPVSMQDMLTYTAMDILAKAAFGMETSMLLGAQKPLSQAVKLMLEGITASRNTLAKFLPGKRKQLREVRESIRFLRQVGRDWVQRRREALKRGEEVPADILTQILKAEEGAQDDEGLLDNFVTFFIAGHETSANHLAFTVMELSRQPEIVARLQAEVDEVIGSKRYLDFEDLGRLQYLSQVLKESLRLYPPAWGTFRLLEEETLIDGVRVPGNTPLLFSTYVMGRMDTYFEDPLTFNPDRFGPGAPKPRFTYFPFSLGHRSCIGQQFAQMEVKVVMAKLLQRLEFRLVPGQRFGLQEQATLKPLDPVLCTLRPRGWQPAPPPPPC
T33641	DRUGINFO	D06EHX	TAK-935	Phase 2
T33641	DRUGINFO	D01EEY	PMID25514969-Compound-Figure3	Patented
T33641	DRUGINFO	D05TMN	PMID25514969-Compound-8	Patented
T33641	DRUGINFO	D08HYS	PMID25514969-Compound-10	Patented
T33641	DRUGINFO	D09RTV	PMID25514969-Compound-9	Patented
T33641	DRUGINFO	D0L5NZ	PMID25514969-Compound-Figure2-3	Patented
T33641	DRUGINFO	D0LW9K	PMID25514969-Compound-11	Patented
T33641	DRUGINFO	D0M4XO	PMID25514969-Compound-Figure2-4	Patented
T33641	DRUGINFO	D0RY9R	PMID25514969-Compound-13	Patented
T33641	DRUGINFO	D0SQ4B	PMID25514969-Compound-12	Patented
T33641	DRUGINFO	D0XJ3S	PMID25514969-Compound-Figure2-2	Patented

T41560	TARGETID	T41560
T41560	FORMERID	TTDI02249
T41560	UNIPROID	EGFR_HUMAN
T41560	TARGNAME	EGFR messenger RNA (EGFR mRNA)
T41560	GENENAME	EGFR
T41560	TARGTYPE	Clinical trial
T41560	SYNONYMS	Receptor tyrosine-protein kinase erbB-1 (mRNA); Proto-oncogene c-ErbB-1 (mRNA); HER1 (mRNA); Epidermal growth factor receptor (mRNA); ERBB1 (mRNA); ERBB (mRNA); EGFR (mRNA)
T41560	FUNCTION	Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin. Plays a role in enhancing learning and memory performance.
T41560	PDBSTRUC	6D8E; 6B3S; 6ARU; 5ZWJ; 5YU9
T41560	BIOCLASS	mRNA target
T41560	ECNUMBER	EC 2.7.10.1
T41560	SEQUENCE	MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALAVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDFQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRVAPQSSEFIGA
T41560	DRUGINFO	D0FV3K	AC0010	Phase 3
T41560	DRUGINFO	D06VFF	EGFR antisense DNA	Phase 1/2
T41560	DRUGINFO	D09BZS	CK-101	Phase 1/2
T41560	DRUGINFO	D0M8YM	Pyrotinib	Phase 1

T85651	TARGETID	T85651
T85651	FORMERID	TTDI02268
T85651	UNIPROID	MYC_HUMAN
T85651	TARGNAME	Myc messenger RNA (MYC mRNA)
T85651	GENENAME	MYC
T85651	TARGTYPE	Clinical trial
T85651	SYNONYMS	bHLHe39 (mRNA); Transcription factor p64 (mRNA); Proto-oncogene c-Myc (mRNA); Myc proto-oncogene protein (mRNA); Class E basic helix-loop-helix protein 39 (mRNA); C-myc oncogene (mRNA); C-myc (mRNA)
T85651	FUNCTION	Activates the transcription of growth-related genes. Binds to the VEGFA promoter, promoting VEGFA production and subsequent sprouting angiogenesis. Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'.
T85651	PDBSTRUC	6G6L; 6G6K; 6G6J; 6C4U; 5I50
T85651	BIOCLASS	mRNA target
T85651	SEQUENCE	MPLNVSFTNRNYDLDYDSVQPYFYCDEEENFYQQQQQSELQPPAPSEDIWKKFELLPTPPLSPSRRSGLCSPSYVAVTPFSLRGDNDGGGGSFSTADQLEMVTELLGGDMVNQSFICDPDDETFIKNIIIQDCMWSGFSAAAKLVSEKLASYQAARKDSGSPNPARGHSVCSTSSLYLQDLSAAASECIDPSVVFPYPLNDSSSPKSCASQDSSAFSPSSDSLLSSTESSPQGSPEPLVLHEETPPTTSSDSEEEQEDEEEIDVVSVEKRQAPGKRSESGSPSAGGHSKPPHSPLVLKRCHVSTHQHNYAAPPSTRKDYPAAKRVKLDSVRVLRQISNNRKCTSPRSSDTEENVKRRTHNVLERQRRNELKRSFFALRDQIPELENNEKAPKVVILKKATAYILSVQAEEQKLISEEDLLRKRREQLKHKLEQLRNSCA
T85651	DRUGINFO	D01VDI	AVI-5126	Phase 2
T85651	DRUGINFO	D0M4MG	Resten-NG	Phase 2

T52953	TARGETID	T52953
T52953	FORMERID	TTDC00216
T52953	UNIPROID	CRP_HUMAN
T52953	TARGNAME	CRP messenger RNA (CRP mRNA)
T52953	GENENAME	CRP
T52953	TARGTYPE	Clinical trial
T52953	SYNONYMS	PTX1 (mRNA); C-reactive protein (mRNA)
T52953	FUNCTION	Can interact with DNA and histones and may scavenge nuclear material released from damaged circulating cells. Displays several functions associated with host defense: it promotes agglutination, bacterial capsular swelling, phagocytosis and complement fixation through its calcium-dependent binding to phosphorylcholine.
T52953	PDBSTRUC	3PVO; 3PVN; 3L2Y; 1LJ7; 1GNH
T52953	BIOCLASS	mRNA target
T52953	SEQUENCE	MEKLLCFLVLTSLSHAFGQTDMSRKAFVFPKESDTSYVSLKAPLTKPLKAFTVCLHFYTELSSTRGYSIFSYATKRQDNEILIFWSKDIGYSFTVGGSEILFEVPEVTVAPVHICTSWESASGIVEFWVDGKPRVRKSLKKGYTVGAEASIILGQEQDSFGGNFEGSQSLVGDIGNVNMWDFVLSPDEINTIYLGGPFSPNVLNWRALKYEVQGEVFTKPQLWP
T52953	DRUGINFO	D0H1TG	ISIS-CRPRx	Phase 2
T52953	DRUGINFO	D06CIJ	ISIS-CRP	Phase 1
T52953	DRUGINFO	D01EPD	ISIS 133726	Investigative
T52953	DRUGINFO	D02OHL	ISIS 133712	Investigative
T52953	DRUGINFO	D06TJI	ISIS 140180	Investigative
T52953	DRUGINFO	D08XCL	ISIS 330031	Investigative
T52953	DRUGINFO	D0C9FX	ISIS 330012	Investigative
T52953	DRUGINFO	D0Q4HW	ISIS 329956	Investigative
T52953	DRUGINFO	D0Q4JF	Phosphocholine	Investigative

T87939	TARGETID	T87939
T87939	FORMERID	TTDI02261
T87939	UNIPROID	KLKB1_HUMAN
T87939	TARGNAME	Plasma kallikrein messenger RNA (KLKB1 mRNA)
T87939	GENENAME	KLKB1
T87939	TARGTYPE	Clinical trial
T87939	SYNONYMS	Plasma prekallikrein (mRNA); Plasma kallikrein light chain (mRNA); Plasma kallikrein heavy chain (mRNA); PKK (mRNA); Kininogenin (mRNA); KLK3 (mRNA); Fletcher factor (mRNA)
T87939	FUNCTION	It activates, in a reciprocal reaction, factor XII after its binding to a negatively charged surface. It also releases bradykinin from HMW kininogen and may also play a role in the renin-angiotensin system by converting prorenin into renin. The enzyme cleaves Lys-Arg and Arg-Ser bonds.
T87939	PDBSTRUC	6O1S; 6O1G; 6I44; 5TJX; 5F8Z
T87939	BIOCLASS	mRNA target
T87939	ECNUMBER	EC 3.4.21.34
T87939	SEQUENCE	MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA
T87939	DRUGINFO	D0HL1X	ISIS-PKK	Phase 3
T87939	DRUGINFO	DR0B6F	Donidalorsen	Phase 3

T52316	TARGETID	T52316
T52316	FORMERID	TTDR00129
T52316	UNIPROID	RAF1_HUMAN
T52316	TARGNAME	Raf messenger RNA (Raf mRNA)
T52316	GENENAME	RAF1
T52316	TARGTYPE	Clinical trial
T52316	SYNONYMS	cRaf (mRNA); Raf-1 (mRNA); RAF proto-oncogene serine/threonine-protein kinase (mRNA); RAF (mRNA)
T52316	FUNCTION	RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that comprises a sequential phosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and the extracellular signal-regulated kinases (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (on residues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylyl cyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation. Phosphorylates PPP1R12A resulting in inhibition of the phosphatase activity. Phosphorylates TNNT2/cardiac muscle troponin T. Can promote NF-kB activation and inhibit signal transducers involved in motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2), proliferation and angiogenesis (RB1). Can protect cells from apoptosis also by translocating to the mitochondria where it binds BCL2 and displaces BAD/Bcl2-antagonist of cell death. Regulates Rho signaling and migration, and is required for normal wound healing. Plays a role in the oncogenic transformation of epithelial cells via repression of the TJ protein, occludin (OCLN) by inducing the up-regulation of a transcriptional repressor SNAI2/SLUG, which induces down-regulation of OCLN. Restricts caspase activation in response to selected stimuli, notably Fas stimulation, pathogen-mediated macrophage apoptosis, and erythroid differentiation. Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation.
T52316	PDBSTRUC	4IHL; 4IEA; 4G3X; 4G0N; 4FJ3
T52316	BIOCLASS	mRNA target
T52316	ECNUMBER	EC 2.7.11.1
T52316	SEQUENCE	MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYELMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF
T52316	DRUGINFO	D07IEU	MLN2480	Phase 2
T52316	DRUGINFO	D0T4QA	LXH254	Phase 1
T52316	DRUGINFO	D0W2BK	ICo-007	Phase 1
T52316	DRUGINFO	D0W9QI	LErafAON	Phase 1
T52316	DRUGINFO	D02DXC	SPN-803	Phase 1
T52316	DRUGINFO	D06EFW	RG7304	Phase 1
T52316	DRUGINFO	D01KEF	ISIS 10707	Investigative
T52316	DRUGINFO	D01LYK	ISIS 9058	Investigative
T52316	DRUGINFO	D05UPS	5-(4-hydroxy-2,6-dimethylstyryl)nicotinic acid	Investigative
T52316	DRUGINFO	D07JHY	ISIS 7853	Investigative
T52316	DRUGINFO	D07QVR	ISIS 7855	Investigative
T52316	DRUGINFO	D07XKC	ISIS 7851	Investigative
T52316	DRUGINFO	D08KOD	ISIS 15770	Investigative
T52316	DRUGINFO	D09IOO	ISIS 11061	Investigative
T52316	DRUGINFO	D0E7WU	ISIS 7848	Investigative
T52316	DRUGINFO	D0K5WH	ISIS 6717	Investigative
T52316	DRUGINFO	D0LG0E	ISIS 6720	Investigative
T52316	DRUGINFO	D0OV7O	ISIS 6729	Investigative
T52316	DRUGINFO	D0Q1UM	ISIS 7849	Investigative
T52316	DRUGINFO	D0QN6U	L-790070	Investigative
T52316	DRUGINFO	D0R9BP	ISIS 7847	Investigative
T52316	DRUGINFO	D02TYK	6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine	Investigative
T52316	DRUGINFO	D06YMT	PLX-ORI3	Investigative
T52316	DRUGINFO	D0BH7S	6-Benzylsulfanyl-9H-purine	Investigative
T52316	DRUGINFO	D0Z5TQ	GW-5074	Investigative
T52316	DRUGINFO	D00NWF	ZM-336372	Investigative
T52316	DRUGINFO	D01WAI	DEBROMOHYMENIALDISINE	Investigative

T82051	TARGETID	T82051
T82051	FORMERID	TTDI02325
T82051	UNIPROID	P53_HUMAN
T82051	TARGNAME	P53 messenger RNA (TP53 mRNA)
T82051	GENENAME	TP53
T82051	TARGTYPE	Clinical trial
T82051	SYNONYMS	Tumor suppressor p53 (mRNA); Phosphoprotein p53 (mRNA); P53 (mRNA); Antigen NY-CO-13 (mRNA)
T82051	FUNCTION	Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER2. Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type.
T82051	PDBSTRUC	6GGF; 6GGE; 6GGD; 6GGC; 6GGB
T82051	BIOCLASS	mRNA target
T82051	SEQUENCE	MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD
T82051	DRUGINFO	D02CKH	OPI-1002	Phase 2
T82051	DRUGINFO	D0K4VW	Cenersen	Phase 2
T82051	DRUGINFO	D0T8EL	AHL	Investigative

T24555	TARGETID	T24555
T24555	FORMERID	TTDI02256
T24555	UNIPROID	ADRB2_HUMAN
T24555	TARGNAME	ADRB2 messenger RNA (ADRB2 mRNA)
T24555	GENENAME	ADRB2
T24555	TARGTYPE	Clinical trial
T24555	SYNONYMS	Beta-2 adrenoreceptor (mRNA); Beta-2 adrenoceptor (mRNA); Beta-2 adrenergic receptor (mRNA); B2AR (mRNA); ADRB2R (mRNA)
T24555	FUNCTION	The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine. Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins.
T24555	PDBSTRUC	6MXT; 5X7D; 5JQH; 5D6L; 5D5B
T24555	BIOCLASS	mRNA target
T24555	SEQUENCE	MGQPGNGSAFLLAPNGSHAPDHDVTQERDEVWVVGMGIVMSLIVLAIVFGNVLVITAIAKFERLQTVTNYFITSLACADLVMGLAVVPFGAAHILMKMWTFGNFWCEFWTSIDVLCVTASIETLCVIAVDRYFAITSPFKYQSLLTKNKARVIILMVWIVSGLTSFLPIQMHWYRATHQEAINCYANETCCDFFTNQAYAIASSIVSFYVPLVIMVFVYSRVFQEAKRQLQKIDKSEGRFHVQNLSQVEQDGRTGHGLRRSSKFCLKEHKALKTLGIIMGTFTLCWLPFFIVNIVHVIQDNLIRKEVYILLNWIGYVNSGFNPLIYCRSPDFRIAFQELLCLRRSSLKAYGNGYSSNGNTGEQSGYHVEQEKENKLLCEDLPGTEDFVGHQGTVPSDNIDSQGRNCSTNDSLL
T24555	DRUGINFO	D0Q8LL	SYL-040012	Phase 2
T24555	DRUGINFO	D4RD0C	Bamosiran	Phase 2

T38810	TARGETID	T38810
T38810	FORMERID	TTDI02266
T38810	UNIPROID	APOA_HUMAN
T38810	TARGNAME	Apolipoprotein A messenger RNA (LPA mRNA)
T38810	GENENAME	LPA
T38810	TARGTYPE	Clinical trial
T38810	SYNONYMS	Lp(a) (mRNA); Apolipoprotein(a) (mRNA); Apo(a) (mRNA)
T38810	FUNCTION	It has serine proteinase activity and is able of autoproteolysis. Inhibits tissue-type plasminogen activator 1. Lp(a) may be a ligand for megalin/Gp 330. Apo(a) is the main constituent of lipoprotein(a) (Lp(a)).
T38810	PDBSTRUC	4KIV; 4BVW; 4BVV; 4BVD; 4BVC
T38810	BIOCLASS	mRNA target
T38810	ECNUMBER	EC 3.4.21.-
T38810	SEQUENCE	MEHKEVVLLLLLFLKSAAPEQSHVVQDCYHGDGQSYRGTYSTTVTGRTCQAWSSMTPHQHNRTTENYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDPVAAPYCYTRDPSVRWEYCNLTQCSDAEGTAVAPPTITPIPSLEAPSEQAPTEQRPGVQECYHGNGQSYQGTYFITVTGRTCQAWSSMTPHSHSRTPAYYPNAGLIKNYCRNPDPVAAPWCYTTDPSVRWEYCNLTRCSDAEWTAFVPPNVILAPSLEAFFEQALTEETPGVQDCYYHYGQSYRGTYSTTVTGRTCQAWSSMTPHQHSRTPENYPNAGLTRNYCRNPDAEIRPWCYTMDPSVRWEYCNLTQCLVTESSVLATLTVVPDPSTEASSEEAPTEQSPGVQDCYHGDGQSYRGSFSTTVTGRTCQSWSSMTPHWHQRTTEYYPNGGLTRNYCRNPDAEISPWCYTMDPNVRWEYCNLTQCPVTESSVLATSTAVSEQAPTEQSPTVQDCYHGDGQSYRGSFSTTVTGRTCQSWSSMTPHWHQRTTEYYPNGGLTRNYCRNPDAEIRPWCYTMDPSVRWEYCNLTQCPVMESTLLTTPTVVPVPSTELPSEEAPTENSTGVQDCYRGDGQSYRGTLSTTITGRTCQSWSSMTPHWHRRIPLYYPNAGLTRNYCRNPDAEIRPWCYTMDPSVRWEYCNLTRCPVTESSVLTTPTVAPVPSTEAPSEQAPPEKSPVVQDCYHGDGRSYRGISSTTVTGRTCQSWSSMIPHWHQRTPENYPNAGLTENYCRNPDSGKQPWCYTTDPCVRWEYCNLTQCSETESGVLETPTVVPVPSMEAHSEAAPTEQTPVVRQCYHGNGQSYRGTFSTTVTGRTCQSWSSMTPHRHQRTPENYPNDGLTMNYCRNPDADTGPWCFTMDPSIRWEYCNLTRCSDTEGTVVAPPTVIQVPSLGPPSEQDCMFGNGKGYRGKKATTVTGTPCQEWAAQEPHRHSTFIPGTNKWAGLEKNYCRNPDGDINGPWCYTMNPRKLFDYCDIPLCASSSFDCGKPQVEPKKCPGSIVGGCVAHPHSWPWQVSLRTRFGKHFCGGTLISPEWVLTAAHCLKKSSRPSSYKVILGAHQEVNLESHVQEIEVSRLFLEPTQADIALLKLSRPAVITDKVMPACLPSPDYMVTARTECYITGWGETQGTFGTGLLKEAQLLVIENEVCNHYKYICAEHLARGTDSCQGDSGGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYARVSRFVTWIEGMMRNN
T38810	DRUGINFO	DKN63V	Pelacarsen	Phase 3
T38810	DRUGINFO	D0Y0KY	ISIS-APO(a)	Phase 2
T38810	DRUGINFO	D2SDM0	SLN360	Phase 2
T38810	DRUGINFO	D81AQG	AMG 890	Phase 2
T38810	DRUGINFO	DT2N8D	LY3819469	Phase 2

T90391	TARGETID	T90391
T90391	FORMERID	TTDI02262
T90391	UNIPROID	CP3A4_HUMAN
T90391	TARGNAME	CYP3A4 messenger RNA (CYP3A4 mRNA)
T90391	GENENAME	CYP3A4
T90391	TARGTYPE	Clinical trial
T90391	SYNONYMS	Taurochenodeoxycholate 6-alpha-hydroxylase (mRNA); Quinine 3-monooxygenase (mRNA); P450-PCN1 (mRNA); Nifedipine oxidase (mRNA); NF-25 (mRNA); HLp (mRNA); Cytochrome P450-PCN1 (mRNA); Cytochrome P450 NF-25 (mRNA); Cytochrome P450 HLp (mRNA); Cytochrome P450 3A4 (mRNA); Cytochrome P450 3A3 (mRNA); CYPIIIA4 (mRNA); CYPIIIA3 (mRNA); CYP3A3 (mRNA); Albendazole sulfoxidase (mRNA); Albendazole monooxygenase (sulfoxide-forming) (mRNA); 1,8-cineole 2-exo-monooxygenase (mRNA)
T90391	FUNCTION	In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e. g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide. Catalyzes 4-beta-hydroxylation of cholesterol. May catalyze 25-hydroxylation of cholesterol in vitro. Catalyzes sulfoxidation of the anthelmintics albendazole and fenbendazole. Cytochromes P450 are a group of heme-thiolate monooxygenases.
T90391	PDBSTRUC	6BDM; 6BDK; 6BDI; 6BDH; 6BD8
T90391	BIOCLASS	mRNA target
T90391	ECNUMBER	EC 1.14.14.-
T90391	SEQUENCE	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMFDMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISIAEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYSMDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICVFPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSIIFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVVNETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFSKKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLGGLLQPEKPVVLKVESRDGTVSGA
T90391	DRUGINFO	D0J6FE	AVI-4557	Phase 2

T99740	TARGETID	T99740
T99740	FORMERID	TTDC00022
T99740	UNIPROID	MYB_HUMAN
T99740	TARGNAME	Myb messenger RNA (MYB mRNA)
T99740	GENENAME	MYB
T99740	TARGTYPE	Clinical trial
T99740	SYNONYMS	Transcriptional activator Myb (mRNA); Proto-oncogene c-Myb (mRNA)
T99740	FUNCTION	Plays an important role in the control of proliferation and differentiation of hematopoietic progenitor cells. Transcriptional activator; DNA-binding protein that specifically recognize the sequence 5'-YAAC[GT]G-3'.
T99740	BIOCLASS	mRNA target
T99740	SEQUENCE	MARRPRHSIYSSDEDDEDFEMCDHDYDGLLPKSGKRHLGKTRWTREEDEKLKKLVEQNGTDDWKVIANYLPNRTDVQCQHRWQKVLNPELIKGPWTKEEDQRVIELVQKYGPKRWSVIAKHLKGRIGKQCRERWHNHLNPEVKKTSWTEEEDRIIYQAHKRLGNRWAEIAKLLPGRTDNAIKNHWNSTMRRKVEQEGYLQESSKASQPAVATSFQKNSHLMGFAQAPPTAQLPATGQPTVNNDYSYYHISEAQNVSSHVPYPVALHVNIVNVPQPAAAAIQRHYNDEDPEKEKRIKELELLLMSTENELKGQQVLPTQNHTCSYPGWHSTTIADHTRPHGDSAPVSCLGEHHSTPSLPADPGSLPEESASPARCMIVHQGTILDNVKNLLEFAETLQFIDSFLNTSSNHENSDLEMPSLTSTPLIGHKLTVTTPFHRDQTVKTQKENTVFRTPAIKRSILESSPRTPTPFKHALAAQEIKYGPLKMLPQTPSHLVEDLQDVIKQESDESGIVAEFQENGPPLLKKIKQEVESPTDKSGNFFCSHHWEGDSLNTQLFTQTSPVADAPNILTSSVLMAPASEDEDNVLKAFTVPKNRSLASPLQPCSSTWEPASCGKMEEQMTSSSQARKYVNAFSARTLVM
T99740	DRUGINFO	D01MZJ	LR3001	Phase 2

T88430	TARGETID	T88430
T88430	FORMERID	TTDR01370
T88430	UNIPROID	ARAF_HUMAN
T88430	TARGNAME	A-Raf messenger RNA (ARAF mRNA)
T88430	GENENAME	ARAF
T88430	TARGTYPE	Clinical trial
T88430	SYNONYMS	Serine/threonine-protein kinase A-Raf (mRNA); Proto-oncogene Pks (mRNA); Proto-oncogene A-Raf-1 (mRNA); Proto-oncogene A-Raf (mRNA); PKS2 (mRNA); PKS (mRNA); ARAF1 (mRNA)
T88430	FUNCTION	May also regulate the TOR signaling cascade. Involved in the transduction of mitogenic signals from the cell membrane to the nucleus.
T88430	PDBSTRUC	2MSE; 1WXM
T88430	BIOCLASS	mRNA target
T88430	ECNUMBER	EC 2.7.11.1
T88430	SEQUENCE	MEPPRGPPANGAEPSRAVGTVKVYLPNKQRTVVTVRDGMSVYDSLDKALKVRGLNQDCCVVYRLIKGRKTVTAWDTAIAPLDGEELIVEVLEDVPLTMHNFVRKTFFSLAFCDFCLKFLFHGFRCQTCGYKFHQHCSSKVPTVCVDMSTNRQQFYHSVQDLSGGSRQHEAPSNRPLNELLTPQGPSPRTQHCDPEHFPFPAPANAPLQRIRSTSTPNVHMVSTTAPMDSNLIQLTGQSFSTDAAGSRGGSDGTPRGSPSPASVSSGRKSPHSKSPAEQRERKSLADDKKKVKNLGYRDSGYYWEVPPSEVQLLKRIGTGSFGTVFRGRWHGDVAVKVLKVSQPTAEQAQAFKNEMQVLRKTRHVNILLFMGFMTRPGFAIITQWCEGSSLYHHLHVADTRFDMVQLIDVARQTAQGMDYLHAKNIIHRDLKSNNIFLHEGLTVKIGDFGLATVKTRWSGAQPLEQPSGSVLWMAAEVIRMQDPNPYSFQSDVYAYGVVLYELMTGSLPYSHIGCRDQIIFMVGRGYLSPDLSKISSNCPKAMRRLLSDCLKFQREERPLFPQILATIELLQRSLPKIERSASEPSLHRTQADELPACLLSAARLVP
T88430	DRUGINFO	D06EFW	RG7304	Phase 1
T88430	DRUGINFO	D00DRY	ISIS 9065	Investigative
T88430	DRUGINFO	D00QGF	ISIS 9063	Investigative
T88430	DRUGINFO	D01UOK	ISIS 10228	Investigative
T88430	DRUGINFO	D03NLG	ISIS 9064	Investigative
T88430	DRUGINFO	D04SUV	ISIS 9061	Investigative
T88430	DRUGINFO	D04ZIA	ISIS 9071	Investigative
T88430	DRUGINFO	D07XNO	ISIS 9060	Investigative
T88430	DRUGINFO	D08AHE	ISIS 9070	Investigative
T88430	DRUGINFO	D0F4GU	ISIS 9069	Investigative
T88430	DRUGINFO	D0GG2F	ISIS 9067	Investigative
T88430	DRUGINFO	D0R4QE	ISIS 9062	Investigative
T88430	DRUGINFO	D0T3BZ	ISIS 9068	Investigative
T88430	DRUGINFO	D0V2BG	ISIS 9066	Investigative

T47387	TARGETID	T47387
T47387	FORMERID	TTDI02260
T47387	UNIPROID	BCL2_HUMAN
T47387	TARGNAME	BCL-2 messenger RNA (BCL2 mRNA)
T47387	GENENAME	BCL2
T47387	TARGTYPE	Clinical trial
T47387	SYNONYMS	Bcl-2 (mRNA); Apoptosis regulator Bcl-2 (mRNA)
T47387	FUNCTION	Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1). May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release. Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells.
T47387	PDBSTRUC	6GL8; 5VAY; 5VAX; 5VAU; 5JSN
T47387	BIOCLASS	mRNA target
T47387	SEQUENCE	MAHAGRTGYDNREIVMKYIHYKLSQRGYEWDAGDVGAAPPGAAPAPGIFSSQPGHTPHPAASRDPVARTSPLQTPAAPGAAAGPALSPVPPVVHLTLRQAGDDFSRRYRRDFAEMSSQLHLTPFTARGRFATVVEELFRDGVNWGRIVAFFEFGGVMCVESVNREMSPLVDNIALWMTEYLNRHLHTWIQDNGGWDAFVELYGPSMRPLFDFSWLSLKTLLSLALVGACITLGAYLGHK
T47387	DRUGINFO	D07ACL	PNT-2258	Phase 2
T47387	DRUGINFO	D00GAM	Beclanorsen	Phase 1/2
T47387	DRUGINFO	DBPV74	BP1002	Phase 1
T47387	DRUGINFO	D00DDR	G3139 + Thalidomide	Investigative
T47387	DRUGINFO	D05IAN	G3139 + Irinotecan	Investigative
T47387	DRUGINFO	D0B0HK	G3139 + G-CSF	Investigative
T47387	DRUGINFO	D0LM3T	G3139 + Fludarabine	Investigative
T47387	DRUGINFO	D0Q5NZ	BP-100-1.02	Investigative
T47387	DRUGINFO	D0S1FM	G3139 + Paclitaxel	Investigative
T47387	DRUGINFO	D0W8ZE	G3139 + Dexamethasone	Investigative
T47387	DRUGINFO	D0XU1I	G3139 + Dacarbazine	Investigative
T47387	DRUGINFO	D0XU9F	G3139 + cytarabine (ARA-C)	Investigative

T95899	TARGETID	T95899
T95899	FORMERID	TTDC00142
T95899	UNIPROID	CLUS_HUMAN
T95899	TARGNAME	Clusterin messenger RNA (Clusterin mRNA)
T95899	GENENAME	CLU
T95899	TARGTYPE	Clinical trial
T95899	SYNONYMS	Testosteronerepressed prostate message 2 (mRNA); Testosterone-repressed prostate message 2 (mRNA); TRPM-2 (mRNA); NA1/NA2 (mRNA); Ku70binding protein 1 (mRNA); Ku70-binding protein 1 (mRNA); KUB1 (mRNA); Complementassociated protein SP40,40 (mRNA); Complement-associated protein SP-40,40 (mRNA); Complement cytolysis inhibitor (mRNA); Clusterin alpha chain (mRNA); Clusterin (mRNA); CLI (mRNA); Apolipoprotein J (mRNA); ApoJ (mRNA); Apo-J (mRNA); Agingassociated gene 4 protein (mRNA); Aging-associated gene 4 protein (mRNA); AAG4 (mRNA)
T95899	FUNCTION	Prevents stress-induced aggregation of blood plasma proteins. Inhibits formation of amyloid fibrils by APP, APOC2, B2M, CALCA, CSN3, SNCA and aggregation-prone LYZ variants (in vitro). Does not require ATP. Maintains partially unfolded proteins in a state appropriate for subsequent refolding by other chaperones, such as HSPA8/HSC70. Does not refold proteins by itself. Binding to cell surface receptors triggers internalization of the chaperone-client complex and subsequent lysosomal or proteasomal degradation. Secreted isoform 1 protects cells against apoptosis and against cytolysis by complement. Intracellular isoforms interact with ubiquitin and SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complexes and promote the ubiquitination and subsequent proteasomal degradation of target proteins. Promotes proteasomal degradation of COMMD1 and IKBKB. Modulates NF-kappa-B transcriptional activity. Nuclear isoforms promote apoptosis. Mitochondrial isoforms suppress BAX-dependent release of cytochrome c into the cytoplasm and inhibit apoptosis. Plays a role in the regulation of cell proliferation. Isoform 1 functions as extracellular chaperone that prevents aggregation of nonnative proteins.
T95899	BIOCLASS	mRNA target
T95899	SEQUENCE	MMKTLLLFVGLLLTWESGQVLGDQTVSDNELQEMSNQGSKYVNKEIQNAVNGVKQIKTLIEKTNEERKTLLSNLEEAKKKKEDALNETRESETKLKELPGVCNETMMALWEECKPCLKQTCMKFYARVCRSGSGLVGRQLEEFLNQSSPFYFWMNGDRIDSLLENDRQQTHMLDVMQDHFSRASSIIDELFQDRFFTREPQDTYHYLPFSLPHRRPHFFFPKSRIVRSLMPFSPYEPLNFHAMFQPFLEMIHEAQQAMDIHFHSPAFQHPPTEFIREGDDDRTVCREIRHNSTGCLRMKDQCDKCREILSVDCSTNNPSQAKLRRELDESLQVAERLTRKYNELLKSYQWKMLNTSSLLEQLNEQFNWVSRLANLTQGEDQYYLRVTTVASHTSDSDVPSGVTEVVVKLFDSDPITVTVPVEVSRKNPKFMETVAEKALQEYRKKHREE
T95899	DRUGINFO	D0K3XS	Custirsen	Phase 3

T88847	TARGETID	T88847
T88847	FORMERID	TTDI02300
T88847	UNIPROID	DMD_HUMAN
T88847	TARGNAME	Dystrophin messenger RNA (DMD mRNA)
T88847	GENENAME	DMD
T88847	TARGTYPE	Clinical trial
T88847	SYNONYMS	Dystrophin mRNA
T88847	FUNCTION	Anchors the extracellular matrix to the cytoskeleton via F-actin. Ligand for dystroglycan. Component of the dystrophin-associated glycoprotein complex which accumulates at the neuromuscular junction (NMJ) and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma. Also implicated in signaling events and synaptic transmission.
T88847	PDBSTRUC	3UUN; 1EG4; 1EG3; 1DXX
T88847	BIOCLASS	mRNA target
T88847	SEQUENCE	MLWWEEVEDCYEREDVQKKTFTKWVNAQFSKFGKQHIENLFSDLQDGRRLLDLLEGLTGQKLPKEKGSTRVHALNNVNKALRVLQNNNVDLVNIGSTDIVDGNHKLTLGLIWNIILHWQVKNVMKNIMAGLQQTNSEKILLSWVRQSTRNYPQVNVINFTTSWSDGLALNALIHSHRPDLFDWNSVVCQQSATQRLEHAFNIARYQLGIEKLLDPEDVDTTYPDKKSILMYITSLFQVLPQQVSIEAIQEVEMLPRPPKVTKEEHFQLHHQMHYSQQITVSLAQGYERTSSPKPRFKSYAYTQAAYVTTSDPTRSPFPSQHLEAPEDKSFGSSLMESEVNLDRYQTALEEVLSWLLSAEDTLQAQGEISNDVEVVKDQFHTHEGYMMDLTAHQGRVGNILQLGSKLIGTGKLSEDEETEVQEQMNLLNSRWECLRVASMEKQSNLHRVLMDLQNQKLKELNDWLTKTEERTRKMEEEPLGPDLEDLKRQVQQHKVLQEDLEQEQVRVNSLTHMVVVVDESSGDHATAALEEQLKVLGDRWANICRWTEDRWVLLQDILLKWQRLTEEQCLFSAWLSEKEDAVNKIHTTGFKDQNEMLSSLQKLAVLKADLEKKKQSMGKLYSLKQDLLSTLKNKSVTQKTEAWLDNFARCWDNLVQKLEKSTAQISQAVTTTQPSLTQTTVMETVTTVTTREQILVKHAQEELPPPPPQKKRQITVDSEIRKRLDVDITELHSWITRSEAVLQSPEFAIFRKEGNFSDLKEKVNAIEREKAEKFRKLQDASRSAQALVEQMVNEGVNADSIKQASEQLNSRWIEFCQLLSERLNWLEYQNNIIAFYNQLQQLEQMTTTAENWLKIQPTTPSEPTAIKSQLKICKDEVNRLSDLQPQIERLKIQSIALKEKGQGPMFLDADFVAFTNHFKQVFSDVQAREKELQTIFDTLPPMRYQETMSAIRTWVQQSETKLSIPQLSVTDYEIMEQRLGELQALQSSLQEQQSGLYYLSTTVKEMSKKAPSEISRKYQSEFEEIEGRWKKLSSQLVEHCQKLEEQMNKLRKIQNHIQTLKKWMAEVDVFLKEEWPALGDSEILKKQLKQCRLLVSDIQTIQPSLNSVNEGGQKIKNEAEPEFASRLETELKELNTQWDHMCQQVYARKEALKGGLEKTVSLQKDLSEMHEWMTQAEEEYLERDFEYKTPDELQKAVEEMKRAKEEAQQKEAKVKLLTESVNSVIAQAPPVAQEALKKELETLTTNYQWLCTRLNGKCKTLEEVWACWHELLSYLEKANKWLNEVEFKLKTTENIPGGAEEISEVLDSLENLMRHSEDNPNQIRILAQTLTDGGVMDELINEELETFNSRWRELHEEAVRRQKLLEQSIQSAQETEKSLHLIQESLTFIDKQLAAYIADKVDAAQMPQEAQKIQSDLTSHEISLEEMKKHNQGKEAAQRVLSQIDVAQKKLQDVSMKFRLFQKPANFEQRLQESKMILDEVKMHLPALETKSVEQEVVQSQLNHCVNLYKSLSEVKSEVEMVIKTGRQIVQKKQTENPKELDERVTALKLHYNELGAKVTERKQQLEKCLKLSRKMRKEMNVLTEWLAATDMELTKRSAVEGMPSNLDSEVAWGKATQKEIEKQKVHLKSITEVGEALKTVLGKKETLVEDKLSLLNSNWIAVTSRAEEWLNLLLEYQKHMETFDQNVDHITKWIIQADTLLDESEKKKPQQKEDVLKRLKAELNDIRPKVDSTRDQAANLMANRGDHCRKLVEPQISELNHRFAAISHRIKTGKASIPLKELEQFNSDIQKLLEPLEAEIQQGVNLKEEDFNKDMNEDNEGTVKELLQRGDNLQQRITDERKREEIKIKQQLLQTKHNALKDLRSQRRKKALEISHQWYQYKRQADDLLKCLDDIEKKLASLPEPRDERKIKEIDRELQKKKEELNAVRRQAEGLSEDGAAMAVEPTQIQLSKRWREIESKFAQFRRLNFAQIHTVREETMMVMTEDMPLEISYVPSTYLTEITHVSQALLEVEQLLNAPDLCAKDFEDLFKQEESLKNIKDSLQQSSGRIDIIHSKKTAALQSATPVERVKLQEALSQLDFQWEKVNKMYKDRQGRFDRSVEKWRRFHYDIKIFNQWLTEAEQFLRKTQIPENWEHAKYKWYLKELQDGIGQRQTVVRTLNATGEEIIQQSSKTDASILQEKLGSLNLRWQEVCKQLSDRKKRLEEQKNILSEFQRDLNEFVLWLEEADNIASIPLEPGKEQQLKEKLEQVKLLVEELPLRQGILKQLNETGGPVLVSAPISPEEQDKLENKLKQTNLQWIKVSRALPEKQGEIEAQIKDLGQLEKKLEDLEEQLNHLLLWLSPIRNQLEIYNQPNQEGPFDVKETEIAVQAKQPDVEEILSKGQHLYKEKPATQPVKRKLEDLSSEWKAVNRLLQELRAKQPDLAPGLTTIGASPTQTVTLVTQPVVTKETAISKLEMPSSLMLEVPALADFNRAWTELTDWLSLLDQVIKSQRVMVGDLEDINEMIIKQKATMQDLEQRRPQLEELITAAQNLKNKTSNQEARTIITDRIERIQNQWDEVQEHLQNRRQQLNEMLKDSTQWLEAKEEAEQVLGQARAKLESWKEGPYTVDAIQKKITETKQLAKDLRQWQTNVDVANDLALKLLRDYSADDTRKVHMITENINASWRSIHKRVSEREAALEETHRLLQQFPLDLEKFLAWLTEAETTANVLQDATRKERLLEDSKGVKELMKQWQDLQGEIEAHTDVYHNLDENSQKILRSLEGSDDAVLLQRRLDNMNFKWSELRKKSLNIRSHLEASSDQWKRLHLSLQELLVWLQLKDDELSRQAPIGGDFPAVQKQNDVHRAFKRELKTKEPVIMSTLETVRIFLTEQPLEGLEKLYQEPRELPPEERAQNVTRLLRKQAEEVNTEWEKLNLHSADWQRKIDETLERLQELQEATDELDLKLRQAEVIKGSWQPVGDLLIDSLQDHLEKVKALRGEIAPLKENVSHVNDLARQLTTLGIQLSPYNLSTLEDLNTRWKLLQVAVEDRVRQLHEAHRDFGPASQHFLSTSVQGPWERAISPNKVPYYINHETQTTCWDHPKMTELYQSLADLNNVRFSAYRTAMKLRRLQKALCLDLLSLSAACDALDQHNLKQNDQPMDILQIINCLTTIYDRLEQEHNNLVNVPLCVDMCLNWLLNVYDTGRTGRIRVLSFKTGIISLCKAHLEDKYRYLFKQVASSTGFCDQRRLGLLLHDSIQIPRQLGEVASFGGSNIEPSVRSCFQFANNKPEIEAALFLDWMRLEPQSMVWLPVLHRVAAAETAKHQAKCNICKECPIIGFRYRSLKHFNYDICQSCFFSGRVAKGHKMHYPMVEYCTPTTSGEDVRDFAKVLKNKFRTKRYFAKHPRMGYLPVQTVLEGDNMETPVTLINFWPVDSAPASSPQLSHDDTHSRIEHYASRLAEMENSNGSYLNDSISPNESIDDEHLLIQHYCQSLNQDSPLSQPRSPAQILISLESEERGELERILADLEEENRNLQAEYDRLKQQHEHKGLSPLPSPPEMMPTSPQSPRDAELIAEAKLLRQHKGRLEARMQILEDHNKQLESQLHRLRQLLEQPQAEAKVNGTTVSSPSTSLQRSDSSQPMLLRVVGSQTSDSMGEEDLLSPPQDTSTGLEEVMEQLNNSFPSSRGRNTPGKPMREDTM
T88847	DRUGINFO	D04AIV	Eteplirsen	Approved
T88847	DRUGINFO	D0PE2L	GSK2402968	Phase 3
T88847	DRUGINFO	D0X4DB	Drisapersen	Phase 3
T88847	DRUGINFO	D4OZC7	Suvodirsen	Phase 2/3
T88847	DRUGINFO	D05DFV	PRO-044	Phase 2

T78892	TARGETID	T78892
T78892	FORMERID	TTDR01371
T78892	UNIPROID	ITA4_HUMAN
T78892	TARGNAME	ITGA4 messenger RNA (ITGA4 mRNA)
T78892	GENENAME	ITGA4
T78892	TARGTYPE	Clinical trial
T78892	SYNONYMS	VLA4 subunit alpha (mRNA); VLA-4 subunit alpha (mRNA); Integrin alphaIV (mRNA); Integrin alpha4 (mRNA); Integrin alpha-IV (mRNA); Integrin alpha-4 (mRNA); CD49d (mRNA); CD49 antigenlike family member D (mRNA); CD49 antigen-like family member D (mRNA)
T78892	FUNCTION	Integrins alpha-4/beta-1 (VLA-4) and alpha-4/beta-7 are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1. Integrin alpha-4/beta-1 recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha-4/beta-7 is also a receptor for MADCAM1. It recognizes the sequence L-D-T in MADCAM1. On activated endothelial cells integrin VLA-4 triggers homotypic aggregation for most VLA-4-positive leukocyte cell lines. It may also participate in cytolytic T-cell interactions with target cells. ITGA4:ITGB1 binds to fractalkine (CX3CL1) and may act as its coreceptor in CX3CR1-dependent fractalkine signaling. ITGA4:ITGB1 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1.
T78892	PDBSTRUC	5FPI; 5C7Z; 4HKC; 3V4V; 3V4P
T78892	BIOCLASS	mRNA target
T78892	SEQUENCE	MAWEARREPGPRRAAVRETVMLLLCLGVPTGRPYNVDTESALLYQGPHNTLFGYSVVLHSHGANRWLLVGAPTANWLANASVINPGAIYRCRIGKNPGQTCEQLQLGSPNGEPCGKTCLEERDNQWLGVTLSRQPGENGSIVTCGHRWKNIFYIKNENKLPTGGCYGVPPDLRTELSKRIAPCYQDYVKKFGENFASCQAGISSFYTKDLIVMGAPGSSYWTGSLFVYNITTNKYKAFLDKQNQVKFGSYLGYSVGAGHFRSQHTTEVVGGAPQHEQIGKAYIFSIDEKELNILHEMKGKKLGSYFGASVCAVDLNADGFSDLLVGAPMQSTIREEGRVFVYINSGSGAVMNAMETNLVGSDKYAARFGESIVNLGDIDNDGFEDVAIGAPQEDDLQGAIYIYNGRADGISSTFSQRIEGLQISKSLSMFGQSISGQIDADNNGYVDVAVGAFRSDSAVLLRTRPVVIVDASLSHPESVNRTKFDCVENGWPSVCIDLTLCFSYKGKEVPGYIVLFYNMSLDVNRKAESPPRFYFSSNGTSDVITGSIQVSSREANCRTHQAFMRKDVRDILTPIQIEAAYHLGPHVISKRSTEEFPPLQPILQQKKEKDIMKKTINFARFCAHENCSADLQVSAKIGFLKPHENKTYLAVGSMKTLMLNVSLFNAGDDAYETTLHVKLPVGLYFIKILELEEKQINCEVTDNSGVVQLDCSIGYIYVDHLSRIDISFLLDVSSLSRAEEDLSITVHATCENEEEMDNLKHSRVTVAIPLKYEVKLTVHGFVNPTSFVYGSNDENEPETCMVEKMNLTFHVINTGNSMAPNVSVEIMVPNSFSPQTDKLFNILDVQTTTGECHFENYQRVCALEQQKSAMQTLKGIVRFLSKTDKRLLYCIKADPHCLNFLCNFGKMESGKEASVHIQLEGRPSILEMDETSALKFEIRATGFPEPNPRVIELNKDENVAHVLLEGLHHQRPKRYFTIVIISSSLLLGLIVLLLISYVMWKAGFFKRQYKSILQEENRRDSWSYINSKSNDD
T78892	DRUGINFO	D0E6SQ	ATL1102	Phase 2
T78892	DRUGINFO	D07FJI	ISIS 24477	Investigative
T78892	DRUGINFO	D07NMV	ISIS 24448	Investigative
T78892	DRUGINFO	D08PJN	ISIS 24453	Investigative
T78892	DRUGINFO	D0CW7X	ISIS 24475	Investigative
T78892	DRUGINFO	D0R6UO	ISIS 24454	Investigative
T78892	DRUGINFO	D09XED	MK-0668	Investigative

T88714	TARGETID	T88714
T88714	FORMERID	TTDR00342
T88714	UNIPROID	AA1R_HUMAN
T88714	TARGNAME	ADORA1 messenger RNA (ADORA1 mRNA)
T88714	GENENAME	ADORA1
T88714	TARGTYPE	Clinical trial
T88714	SYNONYMS	Adenosine receptor A1 (mRNA); A(1) adenosine receptor (mRNA)
T88714	FUNCTION	The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. Receptor for adenosine.
T88714	PDBSTRUC	6D9H; 5UEN; 5N2S
T88714	BIOCLASS	mRNA target
T88714	SEQUENCE	MPPSISAFQAAYIGIEVLIALVSVPGNVLVIWAVKVNQALRDATFCFIVSLAVADVAVGALVIPLAILINIGPQTYFHTCLMVACPVLILTQSSILALLAIAVDRYLRVKIPLRYKMVVTPRRAAVAIAGCWILSFVVGLTPMFGWNNLSAVERAWAANGSMGEPVIKCEFEKVISMEYMVYFNFFVWVLPPLLLMVLIYLEVFYLIRKQLNKKVSASSGDPQKYYGKELKIAKSLALILFLFALSWLPLHILNCITLFCPSCHKPSILTYIAIFLTHGNSAMNPIVYAFRIQKFRVTFLKIWNDHFRCQPAPPIDEDLPEERPDD
T88714	DRUGINFO	D0UD1Y	Neladenoson bialanate	Phase 2
T88714	DRUGINFO	D0QH0B	EPI-2010	Discontinued in Phase 2

T63986	TARGETID	T63986
T63986	FORMERID	TTDC00339
T63986	UNIPROID	KIF11_HUMAN
T63986	TARGNAME	Kinesin spindle messenger RNA (KIF11 mRNA)
T63986	GENENAME	KIF11
T63986	TARGTYPE	Clinical trial
T63986	SYNONYMS	Thyroid receptor-interacting protein 5 (mRNA); TRIP5 (mRNA); TRIP-5 (mRNA); TR-interacting protein 5 (mRNA); Kinesin-related motor protein Eg5 (mRNA); Kinesin-like spindle protein HKSP (mRNA); Kinesin-like protein KIF11 (mRNA); Kinesin-like protein 1 (mRNA); KNSL1 (mRNA); EG5 (mRNA)
T63986	FUNCTION	Required in non-mitotic cells for transport of secretory proteins from the Golgi complex to the cell surface. Motor protein required for establishing a bipolar spindle during mitosis.
T63986	PDBSTRUC	6G6Z; 6G6Y; 5ZO9; 5ZO8; 5ZO7
T63986	BIOCLASS	mRNA target
T63986	SEQUENCE	MASQPNSSAKKKEEKGKNIQVVVRCRPFNLAERKASAHSIVECDPVRKEVSVRTGGLADKSSRKTYTFDMVFGASTKQIDVYRSVVCPILDEVIMGYNCTIFAYGQTGTGKTFTMEGERSPNEEYTWEEDPLAGIIPRTLHQIFEKLTDNGTEFSVKVSLLEIYNEELFDLLNPSSDVSERLQMFDDPRNKRGVIIKGLEEITVHNKDEVYQILEKGAAKRTTAATLMNAYSSRSHSVFSVTIHMKETTIDGEELVKIGKLNLVDLAGSENIGRSGAVDKRAREAGNINQSLLTLGRVITALVERTPHVPYRESKLTRILQDSLGGRTRTSIIATISPASLNLEETLSTLEYAHRAKNILNKPEVNQKLTKKALIKEYTEEIERLKRDLAAAREKNGVYISEENFRVMSGKLTVQEEQIVELIEKIGAVEEELNRVTELFMDNKNELDQCKSDLQNKTQELETTQKHLQETKLQLVKEEYITSALESTEEKLHDAASKLLNTVEETTKDVSGLHSKLDRKKAVDQHNAEAQDIFGKNLNSLFNNMEELIKDGSSKQKAMLEVHKTLFGNLLSSSVSALDTITTVALGSLTSIPENVSTHVSQIFNMILKEQSLAAESKTVLQELINVLKTDLLSSLEMILSPTVVSILKINSQLKHIFKTSLTVADKIEDQKKELDGFLSILCNNLHELQENTICSLVESQKQCGNLTEDLKTIKQTHSQELCKLMNLWTERFCALEEKCENIQKPLSSVQENIQQKSKDIVNKMTFHSQKFCADSDGFSQELRNFNQEGTKLVEESVKHSDKLNGNLEKISQETEQRCESLNTRTVYFSEQWVSSLNEREQELHNLLEVVSQCCEASSSDITEKSDGRKAAHEKQHNIFLDQMTIDEDKLIAQNLELNETIKIGLTKLNCFLEQDLKLDIPTGTTPQRKSYLYPSTLVRTEPREHLLDQLKRKQPELLMMLNCSENNKEETIPDVDVEEAVLGQYTEEPLSQEPSVDAGVDCSSIGGVPFFQHKKSHGKDKENRGINTLERSKVEETTEHLVTKSRLPLRAQINL
T63986	DRUGINFO	D08JMI	ALN-VSP	Phase 1
T63986	DRUGINFO	D0Q5QC	EMD-534085	Phase 1
T63986	DRUGINFO	D00HFV	N-[4'-(trifluoromethyl)-4-biphenylyl]thiourea	Investigative
T63986	DRUGINFO	D00OZN	N-[3'-(trifluoromethyl)-4-biphenylyl]urea	Investigative
T63986	DRUGINFO	D00PRE	4'-(trifluoromethyl)-4-biphenylsulfonamide	Investigative
T63986	DRUGINFO	D00WOE	N-(4'-chloro-4-biphenylyl)methanesulfonamide	Investigative
T63986	DRUGINFO	D00YYQ	ISIS 183881	Investigative
T63986	DRUGINFO	D01DVS	ISIS 183911	Investigative
T63986	DRUGINFO	D01ESV	4'-(trifluoromethyl)-4-biphenylyl carbamate	Investigative
T63986	DRUGINFO	D02DAU	ISIS 183910	Investigative
T63986	DRUGINFO	D02HMN	2-(difluoromethyl)-9H-carbazole	Investigative
T63986	DRUGINFO	D02LDY	N-[4-(1,3-benzodioxol-5-yl)phenyl]sulfamide	Investigative
T63986	DRUGINFO	D02SDD	ISIS 183882	Investigative
T63986	DRUGINFO	D02SGH	Methyl 7-tert-butyl-9H-carbazole-3-carboxylate	Investigative
T63986	DRUGINFO	D03ZHM	ISIS 183912	Investigative
T63986	DRUGINFO	D05MQU	N-{4'-[(trifluoromethyl)sulfonyl]-4-biphenyl}urea	Investigative
T63986	DRUGINFO	D05OMR	Methyl 9H-carbazole-2-carboxylate	Investigative
T63986	DRUGINFO	D06HLH	2-tert-butyl-7-(trifluoromethyl)-9H-carbazole	Investigative
T63986	DRUGINFO	D08FXD	2-isopropyl-9H-carbazole	Investigative
T63986	DRUGINFO	D08MYP	ISIS 183897	Investigative
T63986	DRUGINFO	D08RMK	N-(4'-methyl-4-biphenylyl)urea	Investigative
T63986	DRUGINFO	D09DGA	11H-benzo[a]carbazole	Investigative
T63986	DRUGINFO	D09FZW	2-(trifluoromethoxy)-9H-carbazole	Investigative
T63986	DRUGINFO	D09KFR	(S)-dimethylenastron	Investigative
T63986	DRUGINFO	D09MSF	2-tert-butyl-9H-carbazole	Investigative
T63986	DRUGINFO	D09MXK	3-(trifluoromethyl)-9H-carbazole	Investigative
T63986	DRUGINFO	D09PLT	3-tert-butyl-9H-carbazole	Investigative
T63986	DRUGINFO	D0A9IB	Methyl[4'-(trifluoromethyl)-4-biphenylyl]amine	Investigative
T63986	DRUGINFO	D0AV3M	N-(4'-isopropyl-4-biphenylyl)urea	Investigative
T63986	DRUGINFO	D0D3FV	1-tert-butyl-9H-carbazole	Investigative
T63986	DRUGINFO	D0E2KC	4'-(trifluoromethyl)-4-biphenylyl sulfamate	Investigative
T63986	DRUGINFO	D0EC0B	6-fluoro-2-methyl-9H-carbazole	Investigative
T63986	DRUGINFO	D0G1DW	N-[4'-(trifluoromethyl)-4-biphenylyl]sulfamide	Investigative
T63986	DRUGINFO	D0H3OP	2-ethyl-9H-carbazole	Investigative
T63986	DRUGINFO	D0H7ZS	N-[4'-(ethylsulfonyl)-3-fluoro-4-biphenylyl]urea	Investigative
T63986	DRUGINFO	D0J9UC	N-[4'-(trifluoromethyl)-4-biphenylyl]urea	Investigative
T63986	DRUGINFO	D0JN0N	N-{4'-[(trifluoromethyl)thio]-4-biphenyl}urea	Investigative
T63986	DRUGINFO	D0K7HV	N-(4'-t-butyl-4-biphenylyl)urea	Investigative
T63986	DRUGINFO	D0M3VA	SB-731489	Investigative
T63986	DRUGINFO	D0M3ZV	9H-carbazole-3-carbaldehyde	Investigative
T63986	DRUGINFO	D0M7KF	1-(7-methyl-9H-carbazol-3-yl)ethanone	Investigative
T63986	DRUGINFO	D0MW5Z	2-methyl-6-(trifluoromethyl)-9H-carbazole	Investigative
T63986	DRUGINFO	D0MZ8E	ISIS 183901	Investigative
T63986	DRUGINFO	D0N5OD	4-(trifluoromethyl)biphenyl	Investigative
T63986	DRUGINFO	D0N8FU	2-tert-butoxy-9H-carbazole	Investigative
T63986	DRUGINFO	D0NJ8L	N-(4'-bromo-3,3'-difluoro-4-biphenylyl)urea	Investigative
T63986	DRUGINFO	D0O5SA	Adociasulfate-2	Investigative
T63986	DRUGINFO	D0OF6C	2-(trifluoromethyl)-9H-carbazole	Investigative
T63986	DRUGINFO	D0OS3L	1-(trifluoromethyl)-9H-carbazole	Investigative
T63986	DRUGINFO	D0P9ZN	3-methyl-6-(trifluoromethyl)-9H-carbazole	Investigative
T63986	DRUGINFO	D0RO7K	2-methyl-9H-carbazole	Investigative
T63986	DRUGINFO	D0T6MF	7-tert-butyl-9H-carbazole-3-carboxylic acid	Investigative
T63986	DRUGINFO	D0TN1F	4'-trifluoromethyl-biphenyl-4-ylamine	Investigative
T63986	DRUGINFO	D0TR0R	9H-carbazole-2-carbaldehyde	Investigative
T63986	DRUGINFO	D0U2HN	ISIS 183883	Investigative
T63986	DRUGINFO	D0V6CM	2,3,4,11-tetrahydro-1H-benzo[a]carbazole	Investigative
T63986	DRUGINFO	D0W4GY	4'-(trifluoromethyl)-4-biphenylol	Investigative
T63986	DRUGINFO	D0Y6IQ	9-methyl-2-(trifluoromethyl)-9H-carbazole	Investigative
T63986	DRUGINFO	D0YE2Z	(S)-enastron	Investigative

T59273	TARGETID	T59273
T59273	FORMERID	TTDI02239
T59273	UNIPROID	PLK1_HUMAN
T59273	TARGNAME	PLK1 messenger RNA (PLK1 mRNA)
T59273	GENENAME	PLK1
T59273	TARGTYPE	Clinical trial
T59273	SYNONYMS	Serine/threonine-protein kinase PLK1 (mRNA); Serine/threonine-protein kinase 13 (mRNA); Serine-threonine protein kinase 13 (mRNA); STPK13 (mRNA); Plk1 (mRNA); PLK-1 (mRNA); PLK (mRNA); Mitoticserine-threonine kinase polo-like kinase 1 (mRNA)
T59273	FUNCTION	Polo-like kinase proteins acts by binding and phosphorylating proteins are that already phosphorylated on a specific motif recognized by the POLO box domains. Phosphorylates BORA, BUB1B/BUBR1, CCNB1, CDC25C, CEP55, ECT2, ERCC6L, FBXO5/EMI1, FOXM1, KIF20A/MKLP2, CENPU, NEDD1, NINL, NPM1, NUDC, PKMYT1/MYT1, KIZ, PPP1R12A/MYPT1, PRC1, RACGAP1/CYK4, SGO1, STAG2/SA2, TEX14, TOPORS, p73/TP73, TPT1, WEE1 and HNRNPU. Plays a key role in centrosome functions and the assembly of bipolar spindles by phosphorylating KIZ, NEDD1 and NINL. NEDD1 phosphorylation promotes subsequent targeting of the gamma-tubulin ring complex (gTuRC) to the centrosome, an important step for spindle formation. Phosphorylation of NINL component of the centrosome leads to NINL dissociation from other centrosomal proteins. Involved in mitosis exit and cytokinesis by phosphorylating CEP55, ECT2, KIF20A/MKLP2, CENPU, PRC1 and RACGAP1. Recruited at the central spindle by phosphorylating and docking PRC1 and KIF20A/MKLP2; creates its own docking sites on PRC1 and KIF20A/MKLP2 by mediating phosphorylation of sites subsequently recognized by the POLO box domains. Phosphorylates RACGAP1, thereby creating a docking site for the Rho GTP exchange factor ECT2 that is essential for the cleavage furrow formation. Promotes the central spindle recruitment of ECT2. Plays a central role in G2/M transition of mitotic cell cycle by phosphorylating CCNB1, CDC25C, FOXM1, CENPU, PKMYT1/MYT1, PPP1R12A/MYPT1 and WEE1. Part of a regulatory circuit that promotes the activation of CDK1 by phosphorylating the positive regulator CDC25C and inhibiting the negative regulators WEE1 and PKMYT1/MYT1. Also acts by mediating phosphorylation of cyclin-B1 (CCNB1) on centrosomes in prophase. Phosphorylates FOXM1, a key mitotic transcription regulator, leading to enhance FOXM1 transcriptional activity. Involved in kinetochore functions and sister chromatid cohesion by phosphorylating BUB1B/BUBR1, FBXO5/EMI1 and STAG2/SA2. PLK1 is high on non-attached kinetochores suggesting a role of PLK1 in kinetochore attachment or in spindle assembly checkpoint (SAC) regulation. Required for kinetochore localization of BUB1B. Regulates the dissociation of cohesin from chromosomes by phosphorylating cohesin subunits such as STAG2/SA2. Phosphorylates SGO1: required for spindle pole localization of isoform 3 of SGO1 and plays a role in regulating its centriole cohesion function. Mediates phosphorylation of FBXO5/EMI1, a negative regulator of the APC/C complex during prophase, leading to FBXO5/EMI1 ubiquitination and degradation by the proteasome. Acts as a negative regulator of p53 family members: phosphorylates TOPORS, leading to inhibit the sumoylation of p53/TP53 and simultaneously enhance the ubiquitination and subsequent degradation of p53/TP53. Phosphorylates the transactivation domain of the transcription factor p73/TP73, leading to inhibit p73/TP73-mediated transcriptional activation and pro-apoptotic functions. Phosphorylates BORA, and thereby promotes the degradation of BORA. Contributes to the regulation of AURKA function. Also required for recovery after DNA damage checkpoint and entry into mitosis. Phosphorylates MISP, leading to stabilization of cortical and astral microtubule attachments required for proper spindle positioning. Together with MEIKIN, acts as a regulator of kinetochore function during meiosis I: required both for mono-orientation of kinetochores on sister chromosomes and protection of centromeric cohesin from separase-mediated cleavage. Phosphorylates CEP68 and is required for its degradation. Regulates nuclear envelope breakdown during prophase by phosphorylating DCTN1 resulting in its localization in the nuclear envelope. Phosphorylates the heat shock transcription factor HSF1, promoting HSF1 nuclear translocation upon heat shock. Phosphorylates HSF1 also in the early mitotic period; this phosphorylation regulates HSF1 localization to the spindle pole, the recruitment of the SCF(BTRC) ubiquitin ligase complex induicing HSF1 degradation, and hence mitotic progression. Regulates mitotic progression by phosphorylating RIOK2. Serine/threonine-protein kinase that performs several important functions throughout M phase of the cell cycle, including the regulation of centrosome maturation and spindle assembly, the removal of cohesins from chromosome arms, the inactivation of anaphase-promoting complex/cyclosome (APC/C) inhibitors, and the regulation of mitotic exit and cytokinesis.
T59273	PDBSTRUC	6AX4; 5TA8; 5TA6; 5NN2; 5NN1
T59273	BIOCLASS	mRNA target
T59273	ECNUMBER	EC 2.7.11.21
T59273	SEQUENCE	MSAAVTAGKLARAPADPGKAGVPGVAAPGAPAAAPPAKEIPEVLVDPRSRRRYVRGRFLGKGGFAKCFEISDADTKEVFAGKIVPKSLLLKPHQREKMSMEISIHRSLAHQHVVGFHGFFEDNDFVFVVLELCRRRSLLELHKRRKALTEPEARYYLRQIVLGCQYLHRNRVIHRDLKLGNLFLNEDLEVKIGDFGLATKVEYDGERKKTLCGTPNYIAPEVLSKKGHSFEVDVWSIGCIMYTLLVGKPPFETSCLKETYLRIKKNEYSIPKHINPVAASLIQKMLQTDPTARPTINELLNDEFFTSGYIPARLPITCLTIPPRFSIAPSSLDPSNRKPLTVLNKGLENPLPERPREKEEPVVRETGEVVDCHLSDMLQQLHSVNASKPSERGLVRQEEAEDPACIPIFWVSKWVDYSDKYGLGYQLCDNSVGVLFNDSTRLILYNDGDSLQYIERDGTESYLTVSSHPNSLMKKITLLKYFRNYMSEHLLKAGANITPREGDELARLPYLRTWFRTRSAIILHLSNGSVQINFFQDHTKLILCPLMAAVTYIDEKRDFRTYRLSLLEEYGCCKELASRLRYARTMVDKLLSSRSASNRLKAS
T59273	DRUGINFO	D06WNQ	TKM-PLK1	Phase 1/2

T44771	TARGETID	T44771
T44771	FORMERID	TTDI02306
T44771	UNIPROID	TGFB2_HUMAN
T44771	TARGNAME	TGF beta-2 messenger RNA (TGFB2 mRNA)
T44771	GENENAME	TGFB2
T44771	TARGTYPE	Clinical trial
T44771	SYNONYMS	Transforming growth factor beta-2 proprotein (mRNA); TGF-beta 2 (mRNA); Polyergin (mRNA); Glioblastoma-derived T-cell suppressor factor (mRNA); G-TSF (mRNA); Cetermin (mRNA); BSC-1 cell growth inhibitor (mRNA)
T44771	FUNCTION	Transforming growth factor beta-2 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains, which constitute the regulatory and active subunit of TGF-beta-2, respectively.
T44771	PDBSTRUC	5TY4; 5TX4; 4KXZ; 2TGI; 1TFG
T44771	BIOCLASS	mRNA target
T44771	SEQUENCE	MHYCVLSAFLILHLVTVALSLSTCSTLDMDQFMRKRIEAIRGQILSKLKLTSPPEDYPEPEEVPPEVISIYNSTRDLLQEKASRRAAACERERSDEEYYAKEVYKIDMPPFFPSENAIPPTFYRPYFRIVRFDVSAMEKNASNLVKAEFRVFRLQNPKARVPEQRIELYQILKSKDLTSPTQRYIDSKVVKTRAEGEWLSFDVTDAVHEWLHHKDRNLGFKISLHCPCCTFVPSNNYIIPNKSEELEARFAGIDGTSTYTSGDQKTIKSTRKKNSGKTPHLLLMLLPSYRLESQQTNRRKKRALDAAYCFRNVQDNCCLRPLYIDFKRDLGWKWIHEPKGYNANFCAGACPYLWSSDTQHSRVLSLYNTINPEASASPCCVSQDLEPLTILYYIGKTPKIEQLSNMIVKSCKCS
T44771	DRUGINFO	D03OTH	Belagenpumatucel-L	Phase 3
T44771	DRUGINFO	DO5H6K	OT-101	Phase 2/3
T44771	DRUGINFO	D0N5AY	Ranagengliotucel-T	Discontinued in Phase 3

T30926	TARGETID	T30926
T30926	FORMERID	TTDI02247
T30926	UNIPROID	GRB2_HUMAN
T30926	TARGNAME	GRB2 messenger RNA (GRB2 mRNA)
T30926	GENENAME	GRB2
T30926	TARGTYPE	Clinical trial
T30926	SYNONYMS	SH2/SH3 adapter GRB2 (mRNA); Protein Ash (mRNA); Growth factor receptor-bound protein 2 (mRNA); Adapter protein GRB2 (mRNA); ASH (mRNA)
T30926	FUNCTION	Adapter protein that provides a critical link between cell surface growth factor receptors and the Ras signaling pathway.
T30926	PDBSTRUC	5CDW; 4P9Z; 4P9V; 3WA4; 3S8O
T30926	BIOCLASS	mRNA target
T30926	SEQUENCE	MEAIAKYDFKATADDELSFKRGDILKVLNEECDQNWYKAELNGKDGFIPKNYIEMKPHPWFFGKIPRAKAEEMLSKQRHDGAFLIRESESAPGDFSLSVKFGNDVQHFKVLRDGAGKYFLWVVKFNSLNELVDYHRSTSVSRNQQIFLRDIEQVPQQPTYVQALFDFDPQEDGELGFRRGDFIHVMDNSDPNWWKGACHGQTGMFPRNYVTPVNRNV
T30926	DRUGINFO	D0L3KA	BP-100-1-01	Phase 2

T00238	TARGETID	T00238
T00238	FORMERID	TTDI02298
T00238	UNIPROID	NFKB2_HUMAN
T00238	TARGNAME	NFKB messenger RNA (NFKB mRNA)
T00238	GENENAME	NFKB2
T00238	TARGTYPE	Clinical trial
T00238	SYNONYMS	Oncogene Lyt-10 (mRNA); Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (mRNA); Nuclear factor NF-kappa-Bp52 subunit (mRNA); Nuclear factor NF-kappa-B p100 subunit (mRNA); Lyt10 (mRNA); Lymphocyte translocation chromosome 10 protein (mRNA); Lymphocyte translocation chromosome 10 (mRNA); H2TF1 (mRNA); DNA-binding factor KBF2 (mRNA)
T00238	FUNCTION	NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65. In concert with RELB, regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer. NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis.
T00238	PDBSTRUC	5ZMC; 4OT9; 3DO7; 2D96; 1A3Q
T00238	BIOCLASS	mRNA target
T00238	SEQUENCE	MESCYNPGLDGIIEYDDFKLNSSIVEPKEPAPETADGPYLVIVEQPKQRGFRFRYGCEGPSHGGLPGASSEKGRKTYPTVKICNYEGPAKIEVDLVTHSDPPRAHAHSLVGKQCSELGICAVSVGPKDMTAQFNNLGVLHVTKKNMMGTMIQKLQRQRLRSRPQGLTEAEQRELEQEAKELKKVMDLSIVRLRFSAFLRASDGSFSLPLKPVISQPIHDSKSPGASNLKISRMDKTAGSVRGGDEVYLLCDKVQKDDIEVRFYEDDENGWQAFGDFSPTDVHKQYAIVFRTPPYHKMKIERPVTVFLQLKRKRGGDVSDSKQFTYYPLVEDKEEVQRKRRKALPTFSQPFGGGSHMGGGSGGAAGGYGGAGGGGSLGFFPSSLAYSPYQSGAGPMGCYPGGGGGAQMAATVPSRDSGEEAAEPSAPSRTPQCEPQAPEMLQRAREYNARLFGLAQRSARALLDYGVTADARALLAGQRHLLTAQDENGDTPLHLAIIHGQTSVIEQIVYVIHHAQDLGVVNLTNHLHQTPLHLAVITGQTSVVSFLLRVGADPALLDRHGDSAMHLALRAGAGAPELLRALLQSGAPAVPQLLHMPDFEGLYPVHLAVRARSPECLDLLVDSGAEVEATERQGGRTALHLATEMEELGLVTHLVTKLRANVNARTFAGNTPLHLAAGLGYPTLTRLLLKAGADIHAENEEPLCPLPSPPTSDSDSDSEGPEKDTRSSFRGHTPLDLTCSTKVKTLLLNAAQNTMEPPLTPPSPAGPGLSLGDTALQNLEQLLDGPEAQGSWAELAERLGLRSLVDTYRQTTSPSGSLLRSYELAGGDLAGLLEALSDMGLEEGVRLLRGPETRDKLPSTAEVKEDSAYGSQSVEQEAEKLGPPPEPPGGLCHGHPQPQVH
T00238	DRUGINFO	D0U1HX	DIMS-0150	Phase 3

T51748	TARGETID	T51748
T51748	FORMERID	TTDR01416
T51748	UNIPROID	HIF1A_HUMAN
T51748	TARGNAME	HIF1-alpha messenger RNA (HIF1A mRNA)
T51748	GENENAME	HIF1A
T51748	TARGTYPE	Clinical trial
T51748	SYNONYMS	bHLHe78 (mRNA); Transcription factor HIF-1 (mRNA); PASD8 (mRNA); PAS domain-containing protein 8 (mRNA); Member of PAS protein 1 (mRNA); MOP1 (mRNA); Hypoxia-inducible transcription factor (HIF)-1 (mRNA); Hypoxia-inducible factor 1-alpha (mRNA); Hypoxia-inducible factor 1 (mRNA); Hypoxia inducible factor 1 (mRNA); HIF1-alpha (mRNA); HIF1 alpha (mRNA); HIF-1alpha (mRNA); HIF-1-alpha (mRNA); HIF-1 alpha (mRNA); Class E basic helix-loop-helix protein 78 (mRNA); Basic-helix-loop-helix-PAS protein MOP1 (mRNA); ARNT-interacting protein (mRNA); ARNT interacting protein (mRNA)
T51748	FUNCTION	Under hypoxic conditions, activates the transcription of over 40 genes, including erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor, HILPDA, and other genes whose protein products increase oxygen delivery or facilitate metabolic adaptation to hypoxia. Plays an essential role in embryonic vascularization, tumor angiogenesis and pathophysiology of ischemic disease. Heterodimerizes with ARNT; heterodimer binds to core DNA sequence 5'-TACGTG-3' within the hypoxia response element (HRE) of target gene promoters. Activation requires recruitment of transcriptional coactivators such as CREBBP and EP300. Activity is enhanced by interaction with both, NCOA1 or NCOA2. Interaction with redox regulatory protein APEX seems to activate CTAD and potentiates activation by NCOA1 and CREBBP. Involved in the axonal distribution and transport of mitochondria in neurons during hypoxia. Functions as a master transcriptional regulator of the adaptive response to hypoxia.
T51748	PDBSTRUC	6GMR; 6GFX; 5LAS; 5LA9; 5L9V
T51748	BIOCLASS	mRNA target
T51748	SEQUENCE	MEGAGGANDKKKISSERRKEKSRDAARSRRSKESEVFYELAHQLPLPHNVSSHLDKASVMRLTISYLRVRKLLDAGDLDIEDDMKAQMNCFYLKALDGFVMVLTDDGDMIYISDNVNKYMGLTQFELTGHSVFDFTHPCDHEEMREMLTHRNGLVKKGKEQNTQRSFFLRMKCTLTSRGRTMNIKSATWKVLHCTGHIHVYDTNSNQPQCGYKKPPMTCLVLICEPIPHPSNIEIPLDSKTFLSRHSLDMKFSYCDERITELMGYEPEELLGRSIYEYYHALDSDHLTKTHHDMFTKGQVTTGQYRMLAKRGGYVWVETQATVIYNTKNSQPQCIVCVNYVVSGIIQHDLIFSLQQTECVLKPVESSDMKMTQLFTKVESEDTSSLFDKLKKEPDALTLLAPAAGDTIISLDFGSNDTETDDQQLEEVPLYNDVMLPSPNEKLQNINLAMSPLPTAETPKPLRSSADPALNQEVALKLEPNPESLELSFTMPQIQDQTPSPSDGSTRQSSPEPNSPSEYCFYVDSDMVNEFKLELVEKLFAEDTEAKNPFSTQDTDLDLEMLAPYIPMDDDFQLRSFDQLSPLESSSASPESASPQSTVTVFQQTQIQEPTANATTTTATTDELKTVTKDRMEDIKILIASPSPTHIHKETTSATSSPYRDTQSRTASPNRAGKGVIEQTEKSHPRSPNVLSVALSQRTTVPEEELNPKILALQNAQRKRKMEHDGSLFQAVGIGTLLQQPDDHAATTSLSWKRVKGCKSSEQNGMEQKTIILIPSDLACRLLGQSMDESGLPQLTSYDCEVNAPIQGSRNLLQGEELLRALDQVN
T51748	DRUGINFO	D0C9PZ	PT2385	Phase 2
T51748	DRUGINFO	D00JHE	ISIS 298697	Investigative
T51748	DRUGINFO	D01DDQ	ISIS 298744	Investigative
T51748	DRUGINFO	D01ZCK	ISIS 298746	Investigative
T51748	DRUGINFO	D07GVC	ISIS 298745	Investigative
T51748	DRUGINFO	D09DCJ	ISIS 298743	Investigative
T51748	DRUGINFO	D0B5LQ	ISIS 298702	Investigative
T51748	DRUGINFO	D0C2IG	ISIS 298700	Investigative
T51748	DRUGINFO	D0G9BP	ISIS 175510	Investigative
T51748	DRUGINFO	D0L5ME	ISIS 298699	Investigative
T51748	DRUGINFO	D0L9KW	ISIS 298712	Investigative
T51748	DRUGINFO	D0SN5O	ISIS 298711	Investigative
T51748	DRUGINFO	D0X8GB	ISIS 298701	Investigative
T51748	DRUGINFO	D00REK	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	Investigative

T37245	TARGETID	T37245
T37245	FORMERID	TTDC00241
T37245	UNIPROID	DDIT4_HUMAN
T37245	TARGNAME	RTP801 messenger RNA (RTP801 mRNA)
T37245	GENENAME	DDIT4
T37245	TARGTYPE	Clinical trial
T37245	SYNONYMS	RTP801 (mRNA); REDD1 (mRNA); REDD-1 (mRNA); Protein regulated in development and DNA damage response 1 (mRNA); HIF-1 responsive protein RTP801 (mRNA); DNA damage-inducible transcript 4 protein (mRNA)
T37245	FUNCTION	Inhibition of mTORC1 is mediated by a pathway that involves DDIT4/REDD1, AKT1, the TSC1-TSC2 complex and the GTPase RHEB. Plays an important role in responses to cellular energy levels and cellular stress, including responses to hypoxia and DNA damage. Regulates p53/TP53-mediated apoptosis in response to DNA damage via its effect on mTORC1 activity. Its role in the response to hypoxia depends on the cell type; it mediates mTORC1 inhibition in fibroblasts and thymocytes, but not in hepatocytes. Required for mTORC1-mediated defense against viral protein synthesis and virus replication. Inhibits neuronal differentiation and neurite outgrowth mediated by NGF via its effect on mTORC1 activity. Required for normal neuron migration during embryonic brain development. Plays a role in neuronal cell death. Regulates cell growth, proliferation and survival via inhibition of the activity of the mammalian target of rapamycin complex 1 (mTORC1).
T37245	PDBSTRUC	3LQ9
T37245	BIOCLASS	mRNA target
T37245	SEQUENCE	MPSLWDRFSSSSTSSSPSSLPRTPTPDRPPRSAWGSATREEGFDRSTSLESSDCESLDSSNSGFGPEEDTAYLDGVSLPDFELLSDPEDEHLCANLMQLLQESLAQARLGSRRPARLLMPSQLVSQVGKELLRLAYSEPCGLRGALLDVCVEQGKSCHSVGQLALDPSLVPTFQLTLVLRLDSRLWPKIQGLFSSANSPFLPGFSQSLTLSTGFRVIKKKLYSSEQLLIEEC
T37245	DRUGINFO	D0NN5H	PF-4523655	Phase 2

T07448	TARGETID	T07448
T07448	FORMERID	TTDI02484
T07448	UNIPROID	MASP2_HUMAN
T07448	TARGNAME	Mannan-binding lectin serine protease-2 (MASP2)
T07448	GENENAME	MASP2
T07448	TARGTYPE	Clinical trial
T07448	SYNONYMS	Mannosebinding proteinassociated serine protease 2; Mannanbinding lectin serine protease 2 B chain; Mannanbinding lectin serine protease 2; MBLassociated serine protease 2; MASP2
T07448	FUNCTION	Serum protease that plays an important role in the activation of the complement system via mannose-binding lectin. After activation by auto-catalytic cleavage it cleaves C2 and C4, leading to their activation and to the formation of C3 convertase. {ECO:0000269|PubMed:10946292}.
T07448	PDBSTRUC	5JPM; 4FXG; 3TVJ; 1ZJK; 1SZB
T07448	BIOCLASS	Peptidase
T07448	ECNUMBER	EC 3.4.21.104
T07448	SEQUENCE	MRLLTLLGLLCGSVATPLGPKWPEPVFGRLASPGFPGEYANDQERRWTLTAPPGYRLRLYFTHFDLELSHLCEYDFVKLSSGAKVLATLCGQESTDTERAPGKDTFYSLGSSLDITFRSDYSNEKPFTGFEAFYAAEDIDECQVAPGEAPTCDHHCHNHLGGFYCSCRAGYVLHRNKRTCSALCSGQVFTQRSGELSSPEYPRPYPKLSSCTYSISLEEGFSVILDFVESFDVETHPETLCPYDFLKIQTDREEHGPFCGKTLPHRIETKSNTVTITFVTDESGDHTGWKIHYTSTAQPCPYPMAPPNGHVSPVQAKYILKDSFSIFCETGYELLQGHLPLKSFTAVCQKDGSWDRPMPACSIVDCGPPDDLPSGRVEYITGPGVTTYKAVIQYSCEETFYTMKVNDGKYVCEADGFWTSSKGEKSLPVCEPVCGLSARTTGGRIYGGQKAKPGDFPWQVLILGGTTAAGALLYDNWVLTAAHAVYEQKHDASALDIRMGTLKRLSPHYTQAWSEAVFIHEGYTHDAGFDNDIALIKLNNKVVINSNITPICLPRKEAESFMRTDDIGTASGWGLTQRGFLARNLMYVDIPIVDHQKCTAAYEKPPYPRGSVTANMLCAGLESGGKDSCRGDSGGALVFLDSETERWFVGGIVSWGSMNCGEAGQYGVYTKVINYIPWIENIISDF
T07448	DRUGINFO	D0QU0H	OMS721	Phase 3
T07448	DRUGINFO	DTB64R	Narsoplimab	Phase 3

T52937	TARGETID	T52937
T52937	FORMERID	TTDR00096
T52937	UNIPROID	AGRP_HUMAN
T52937	TARGNAME	Agouti-related protein (AGRP)
T52937	GENENAME	AGRP
T52937	TARGTYPE	Clinical trial
T52937	SYNONYMS	Agouti-related peptide; Agouti related protein; AGRP
T52937	FUNCTION	Plays a role in weight homeostasis. Involved in the control of feeding behavior through the central melanocortin system. Acts as alpha melanocyte-stimulating hormone antagonist by inhibiting cAMP production mediated by stimulation of melanocortin receptors within the hypothalamus and adrenal gland. Has very low activity with MC5R. Is an inverse agonist for MC3R and MC4R being able to suppress their constitutive activity. It promotes MC3R and MC4R endocytosis in an arrestin-dependent manner.
T52937	PDBSTRUC	2IQV; 1MR0; 1HYK
T52937	BIOCLASS	Agouti protein
T52937	SEQUENCE	MLTAAVLSCALLLALPATRGAQMGLAPMEGIRRPDQALLPELPGLGLRAPLKKTTAEQAEEDLLQEAQALAEVLDLQDREPRSSRRCVRLHESCLGQQVPCCDPCATCYCRFFNAFCYCRKLGTAMNPCSRT
T52937	DRUGINFO	D0PX8I	TTP435	Phase 2

T76285	TARGETID	T76285
T76285	UNIPROID	ENPP3_HUMAN
T76285	TARGNAME	Phosphodiesterase I beta (ENPP3)
T76285	GENENAME	ENPP3
T76285	TARGTYPE	Clinical trial
T76285	SYNONYMS	Phosphodiesterase I/nucleotide pyrophosphatase 3; PDNP3; PD-Ibeta; NPP3; Ectonucleotide pyrophosphatase/phosphodiesterase family member 3; E-NPP 3; CD203c
T76285	FUNCTION	Limits mast cell and basophil responses during inflammation and during the chronic phases of allergic responses by eliminating the extracellular ATP that functions as signaling molecule and activates basophils and mast cells and induces the release of inflammatory cytokines. Metabolizes extracellular ATP in the lumen of the small intestine, and thereby prevents ATP-induced apoptosis of intestinal plasmacytoid dendritic cells. Has also alkaline phosphodiesterase activity. Hydrolase that metabolizes extracellular nucleotides, including ATP, GTP, UTP and CTP.
T76285	PDBSTRUC	6C02; 6C01
T76285	BIOCLASS	Phosphoric diester hydrolase
T76285	SEQUENCE	MESTLTLATEQPVKKNTLKKYKIACIVLLALLVIMSLGLGLGLGLRKLEKQGSCRKKCFDASFRGLENCRCDVACKDRGDCCWDFEDTCVESTRIWMCNKFRCGETRLEASLCSCSDDCLQRKDCCADYKSVCQGETSWLEENCDTAQQSQCPEGFDLPPVILFSMDGFRAEYLYTWDTLMPNINKLKTCGIHSKYMRAMYPTKTFPNHYTIVTGLYPESHGIIDNNMYDVNLNKNFSLSSKEQNNPAWWHGQPMWLTAMYQGLKAATYFWPGSEVAINGSFPSIYMPYNGSVPFEERISTLLKWLDLPKAERPRFYTMYFEEPDSSGHAGGPVSARVIKALQVVDHAFGMLMEGLKQRNLHNCVNIILLADHGMDQTYCNKMEYMTDYFPRINFFYMYEGPAPRIRAHNIPHDFFSFNSEEIVRNLSCRKPDQHFKPYLTPDLPKRLHYAKNVRIDKVHLFVDQQWLAVRSKSNTNCGGGNHGYNNEFRSMEAIFLAHGPSFKEKTEVEPFENIEVYNLMCDLLRIQPAPNNGTHGSLNHLLKVPFYEPSHAEEVSKFSVCGFANPLPTESLDCFCPHLQNSTQLEQVNQMLNLTQEEITATVKVNLPFGRPRVLQKNVDHCLLYHREYVSGFGKAMRMPMWSSYTVPQLGDTSPLPPTVPDCLRADVRVPPSESQKCSFYLADKNITHGFLYPPASNRTSDSQYDALITSNLVPMYEEFRKMWDYFHSVLLIKHATERNGVNVVSGPIFDYNYDGHFDAPDEITKHLANTDVPIPTHYFVVLTSCKNKSHTPENCPGWLDVLPFIIPHRPTNVESCPEGKPEALWVEERFTAHIARVRDVELLTGLDFYQDKVQPVSEILQLKTYLPTFETTI
T76285	DRUGINFO	D0XT5Q	AGS-16C3F	Phase 2

T82665	TARGETID	T82665
T82665	FORMERID	TTDI03486
T82665	UNIPROID	ANM5_HUMAN
T82665	TARGNAME	Protein arginine methyltransferase 5 (PRMT5)
T82665	GENENAME	PRMT5
T82665	TARGTYPE	Clinical trial
T82665	SYNONYMS	Shk1 kinase-binding protein 1 homolog; SKB1Hs; SKB1 homolog; SKB1; Protein arginine N-methyltransferase 5; Jak-binding protein 1; JBP1; IBP72; Histone-arginine N-methyltransferase PRMT5; HRMT1L5; 72 kDa ICln-binding protein
T82665	FUNCTION	Specifically mediates the symmetrical dimethylation of arginine residues in the small nuclear ribonucleoproteins Sm D1 (SNRPD1) and Sm D3 (SNRPD3); such methylation being required for the assembly and biogenesis of snRNP core particles. Methylates SUPT5H and may regulate its transcriptional elongation properties. Mono- and dimethylates arginine residues of myelin basic protein (MBP) in vitro. May play a role in cytokine-activated transduction pathways. Negatively regulates cyclin E1 promoter activity and cellular proliferation. Methylates histone H2A and H4 'Arg-3' during germ cell development. Methylates histone H3 'Arg-8', which may repress transcription. Methylates the Piwi proteins (PIWIL1, PIWIL2 and PIWIL4), methylation of Piwi proteins being required for the interaction with Tudor domain-containing proteins and subsequent localization to the meiotic nuage. Methylates RPS10. Attenuates EGF signaling through the MAPK1/MAPK3 pathway acting at 2 levels. First, monomethylates EGFR; this enhances EGFR 'Tyr-1197' phosphorylation and PTPN6 recruitment, eventually leading to reduced SOS1 phosphorylation. Second, methylates RAF1 and probably BRAF, hence destabilizing these 2 signaling proteins and reducing their catalytic activity. Required for induction of E-selectin and VCAM-1, on the endothelial cells surface at sites of inflammation. Methylates HOXA9. Methylates and regulates SRGAP2 which is involved in cell migration and differentiation. Acts as a transcriptional corepressor in CRY1-mediated repression of the core circadian component PER1 by regulating the H4R3 dimethylation at the PER1 promoter. Methylates GM130/GOLGA2, regulating Golgi ribbon formation. Methylates H4R3 in genes involved in glioblastomagenesis in a CHTOP- and/or TET1-dependent manner. Symmetrically methylates POLR2A, a modification that allows the recruitment to POLR2A of proteins including SMN1/SMN2 and SETX. This is required for resolving RNA-DNA hybrids created by RNA polymerase II, that form R-loop in transcription terminal regions, an important step in proper transcription termination. Along with LYAR, binds the promoter of gamma-globin HBG1/HBG2 and represses its expression. Symmetrically methylates NCL. Methylates TP53; methylation might possibly affect TP53 target gene specificity. Arginine methyltransferase that can both catalyze the formation of omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA), with a preference for the formation of MMA.
T82665	PDBSTRUC	6CKC; 5FA5; 5EMM; 5EML; 5EMK
T82665	BIOCLASS	Methyltransferase
T82665	ECNUMBER	EC 2.1.1.320
T82665	SEQUENCE	MAAMAVGGAGGSRVSSGRDLNCVPEIADTLGAVAKQGFDFLCMPVFHPRFKREFIQEPAKNRPGPQTRSDLLLSGRDWNTLIVGKLSPWIRPDSKVEKIRRNSEAAMLQELNFGAYLGLPAFLLPLNQEDNTNLARVLTNHIHTGHHSSMFWMRVPLVAPEDLRDDIIENAPTTHTEEYSGEEKTWMWWHNFRTLCDYSKRIAVALEIGADLPSNHVIDRWLGEPIKAAILPTSIFLTNKKGFPVLSKMHQRLIFRLLKLEVQFIITGTNHHSEKEFCSYLQYLEYLSQNRPPPNAYELFAKGYEDYLQSPLQPLMDNLESQTYEVFEKDPIKYSQYQQAIYKCLLDRVPEEEKDTNVQVLMVLGAGRGPLVNASLRAAKQADRRIKLYAVEKNPNAVVTLENWQFEEWGSQVTVVSSDMREWVAPEKADIIVSELLGSFADNELSPECLDGAQHFLKDDGVSIPGEYTSFLAPISSSKLYNEVRACREKDRDPEAQFEMPYVVRLHNFHQLSAPQPCFTFSHPNRDPMIDNNRYCTLEFPVEVNTVLHGFAGYFETVLYQDITLSIRPETHSPGMFSWFPILFPIKQPITVREGQTICVRFWRCSNSKKVWYEWAVTAPVCSAIHNPTGRSYTIGL
T82665	DRUGINFO	D0CR7L	GSK3326595	Phase 2
T82665	DRUGINFO	D7I3JM	AMG 193	Phase 2
T82665	DRUGINFO	D1SL2W	PRT811	Phase 1
T82665	DRUGINFO	DC6UG5	PRT543	Phase 1
T82665	DRUGINFO	DFZ0V3	JNJ-64619178	Phase 1
T82665	DRUGINFO	DM1VE5	PF-06939999	Phase 1
T82665	DRUGINFO	D04NZF	cmp5	Investigative
T82665	DRUGINFO	D05XQD	EPZ015666	Investigative
T82665	DRUGINFO	D00QZA	DS-437	Investigative

T79157	TARGETID	T79157
T79157	FORMERID	TTDI02062
T79157	UNIPROID	EREG_HUMAN
T79157	TARGNAME	Epiregulin (EREG)
T79157	GENENAME	EREG
T79157	TARGTYPE	Clinical trial
T79157	SYNONYMS	l=Epiregulin; Proepiregulin; EPR
T79157	FUNCTION	Stimulates EGFR and ERBB4 tyrosine phosphorylation. Contributes to inflammation, wound healing, tissue repair, and oocyte maturation by regulating angiogenesis and vascular remodeling and by stimulating cell proliferation. Ligand of the EGF receptor/EGFR and ERBB4.
T79157	PDBSTRUC	5WB7; 5E8D; 1K37; 1K36
T79157	BIOCLASS	Growth factor
T79157	SEQUENCE	MTAGRRMEMLCAGRVPALLLCLGFHLLQAVLSTTVIPSCIPGESSDNCTALVQTEDNPRVAQVSITKCSSDMNGYCLHGQCIYLVDMSQNYCRCEVGYTGVRCEHFFLTVHQPLSKEYVALTVILIILFLITVVGSTYYFCRWYRNRKSKEPKKEYERVTSGDPELPQV
T79157	DRUGINFO	D08EIK	LY3016859	Phase 1/2

T94695	TARGETID	T94695
T94695	UNIPROID	SMAD7_HUMAN
T94695	TARGNAME	Mothers against decapentaplegic homolog 7 (SMAD7)
T94695	GENENAME	SMAD7
T94695	TARGTYPE	Clinical trial
T94695	SYNONYMS	hSMAD7; Smad7; SMAD family member 7; SMAD 7; Mothers against decapentaplegic homolog 8; Mothers against DPP homolog 8; MAD homolog 8
T94695	FUNCTION	Antagonist of signaling by TGF-beta (transforming growth factor) type 1 receptor superfamily members; has been shown to inhibit TGF-beta (Transforming growth factor) and activin signaling by associating with their receptors thus preventing SMAD2 access. Functions as an adapter to recruit SMURF2 to the TGF-beta receptor complex. Also acts by recruiting the PPP1R15A-PP1 complex to TGFBR1, which promotes its dephosphorylation. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator.
T94695	PDBSTRUC	2LTZ; 2LTY; 2LTX; 2LTW; 2LTV
T94695	BIOCLASS	Dwarfin/SMAD family
T94695	SEQUENCE	MFRTKRSALVRRLWRSRAPGGEDEEEGAGGGGGGGELRGEGATDSRAHGAGGGGPGRAGCCLGKAVRGAKGHHHPHPPAAGAGAAGGAEADLKALTHSVLKKLKERQLELLLQAVESRGGTRTACLLLPGRLDCRLGPGAPAGAQPAQPPSSYSLPLLLCKVFRWPDLRHSSEVKRLCCCESYGKINPELVCCNPHHLSRLCELESPPPPYSRYPMDFLKPTADCPDAVPSSAETGGTNYLAPGGLSDSQLLLEPGDRSHWCVVAYWEEKTRVGRLYCVQEPSLDIFYDLPQGNGFCLGQLNSDNKSQLVQKVRSKIGCGIQLTREVDGVWVYNRSSYPIFIKSATLDNPDSRTLLVHKVFPGFSIKAFDYEKAYSLQRPNDHEFMQQPWTGFTVQISFVKGWGQCYTRQFISSCPCWLEVIFNSR
T94695	DRUGINFO	D09FKY	GED-0301	Phase 3

T36741	TARGETID	T36741
T36741	UNIPROID	MDM4_HUMAN
T36741	TARGNAME	p53-binding protein Mdm4 (MDM4)
T36741	GENENAME	MDM4
T36741	TARGTYPE	Clinical trial
T36741	SYNONYMS	Protein Mdmx; Mdm2-like p53-binding protein; Double minute 4 protein
T36741	FUNCTION	Inhibits p53/TP53- and TP73/p73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. Inhibits degradation of MDM2. Can reverse MDM2-targeted degradation of TP53 while maintaining suppression of TP53 transactivation and apoptotic functions.
T36741	PDBSTRUC	6Q9Y; 6Q9W; 6Q9U; 6Q9S; 6Q9Q
T36741	BIOCLASS	MDM2/MDM4 family
T36741	SEQUENCE	MTSFSTSAQCSTSDSACRISPGQINQVRPKLPLLKILHAAGAQGEMFTVKEVMHYLGQYIMVKQLYDQQEQHMVYCGGDLLGELLGRQSFSVKDPSPLYDMLRKNLVTLATATTDAAQTLALAQDHSMDIPSQDQLKQSAEESSTSRKRTTEDDIPTLPTSEHKCIHSREDEDLIENLAQDETSRLDLGFEEWDVAGLPWWFLGNLRSNYTPRSNGSTDLQTNQDVGTAIVSDTTDDLWFLNESVSEQLGVGIKVEAADTEQTSEEVGKVSDKKVIEVGKNDDLEDSKSLSDDTDVEVTSEDEWQCTECKKFNSPSKRYCFRCWALRKDWYSDCSKLTHSLSTSDITAIPEKENEGNDVPDCRRTISAPVVRPKDAYIKKENSKLFDPCNSVEFLDLAHSSESQETISSMGEQLDNLSEQRTDTENMEDCQNLLKPCSLCEKRPRDGNIIHGRTGHLVTCFHCARRLKKAGASCPICKKEIQLVIKVFIA
T36741	DRUGINFO	D07UKT	ALRN-6924	Phase 2
T36741	DRUGINFO	DPBE75	NSC-207895	Preclinical

T19567	TARGETID	T19567
T19567	FORMERID	TTDI02633
T19567	UNIPROID	OGA_HUMAN
T19567	TARGNAME	Beta-N-acetylhexosaminidase (OGA)
T19567	GENENAME	MGEA5
T19567	TARGTYPE	Clinical trial
T19567	SYNONYMS	OGA; Nuclear cytoplasmic OGlcNAcase and acetyltransferase; Meningiomaexpressed antigen 5; MGEA5; Histone acetyltransferase; Bifunctional protein NCOAT
T19567	FUNCTION	Isoform 3: Cleaves GlcNAc but not GalNAc from O- glycosylated proteins. Can use p-nitrophenyl-beta-GlcNAc as substrate but not p-nitrophenyl-beta-GalNAc or p-nitrophenyl- alpha-GlcNAc (in vitro), but has about six times lower specific activity than isoform1. {ECO:0000269|PubMed:20673219}.
T19567	PDBSTRUC	6HKI; 5VVX; 5VVV; 5VVU; 5VVT
T19567	BIOCLASS	Glycosylase
T19567	ECNUMBER	EC 3.2.1.169
T19567	SEQUENCE	MVQKESQATLEERESELSSNPAASAGASLEPPAAPAPGEDNPAGAGGAAVAGAAGGARRFLCGVVEGFYGRPWVMEQRKELFRRLQKWELNTYLYAPKDDYKHRMFWREMYSVEEAEQLMTLISAAREYEIEFIYAISPGLDITFSNPKEVSTLKRKLDQVSQFGCRSFALLFDDIDHNMCAADKEVFSSFAHAQVSITNEIYQYLGEPETFLFCPTEYCGTFCYPNVSQSPYLRTVGEKLLPGIEVLWTGPKVVSKEIPVESIEEVSKIIKRAPVIWDNIHANDYDQKRLFLGPYKGRSTELIPRLKGVLTNPNCEFEANYVAIHTLATWYKSNMNGVRKDVVMTDSEDSTVSIQIKLENEGSDEDIETDVLYSPQMALKLALTEWLQEFGVPHQYSSRQVAHSGAKASVVDGTPLVAAPSLNATTVVTTVYQEPIMSQGAALSGEPTTLTKEEEKKQPDEEPMDMVVEKQEETDHKNDNQILSEIVEAKMAEELKPMDTDKESIAESKSPEMSMQEDCISDIAPMQTDEQTNKEQFVPGPNEKPLYTAEPVTLEDLQLLADLFYLPYEHGPKGAQMLREFQWLRANSSVVSVNCKGKDSEKIEEWRSRAAKFEEMCGLVMGMFTRLSNCANRTILYDMYSYVWDIKSIMSMVKSFVQWLGCRSHSSAQFLIGDQEPWAFRGGLAGEFQRLLPIDGANDLFFQPPPLTPTSKVYTIRPYFPKDEASVYKICREMYDDGVGLPFQSQPDLIGDKLVGGLLSLSLDYCFVLEDEDGICGYALGTVDVTPFIKKCKISWIPFMQEKYTKPNGDKELSEAEKIMLSFHEEQEVLPETFLANFPSLIKMDIHKKVTDPSVAKSMMACLLSSLKANGSRGAFCEVRPDDKRILEFYSKLGCFEIAKMEGFPKDVVILGRSL
T19567	DRUGINFO	DVY0C6	LY3372689	Phase 2
T19567	DRUGINFO	D03HDL	MK 8719	Phase 1
T19567	DRUGINFO	D2KV0F	BIIB113	Phase 1
T19567	DRUGINFO	DP6Y5N	MK-8719	Phase 1
T19567	DRUGINFO	DS70NZ	ASN51	Phase 1

T43718	TARGETID	T43718
T43718	FORMERID	TTDI02191
T43718	UNIPROID	TLR5_HUMAN
T43718	TARGNAME	Toll-like receptor 5 (TLR5)
T43718	GENENAME	TLR5
T43718	TARGTYPE	Clinical trial
T43718	SYNONYMS	Toll/interleukin-1 receptor-like protein 3; TIL3
T43718	FUNCTION	Recognizes small molecular motifs named pathogen-associated molecular pattern (PAMPs) expressed by pathogens and microbe-associated molecular patterns (MAMPs) usually expressed by resident microbiota. Upon ligand binding such as bacterial flagellins, recruits intracellular adapter proteins MYD88 and TRIF leading to NF-kappa-B activation, cytokine secretion and induction of the inflammatory response. Plays thereby an important role in the relationship between the intestinal epithelium and enteric microbes and contributes to the gut microbiota composition throughout life. Pattern recognition receptor (PRR) located on the cell surface that participates in the activation of innate immunity and inflammatory response.
T43718	PDBSTRUC	3J0A; 1P95
T43718	BIOCLASS	Toll-like receptor
T43718	SEQUENCE	MGDHLDLLLGVVLMAGPVFGIPSCSFDGRIAFYRFCNLTQVPQVLNTTERLLLSFNYIRTVTASSFPFLEQLQLLELGSQYTPLTIDKEAFRNLPNLRILDLGSSKIYFLHPDAFQGLFHLFELRLYFCGLSDAVLKDGYFRNLKALTRLDLSKNQIRSLYLHPSFGKLNSLKSIDFSSNQIFLVCEHELEPLQGKTLSFFSLAANSLYSRVSVDWGKCMNPFRNMVLEILDVSGNGWTVDITGNFSNAISKSQAFSLILAHHIMGAGFGFHNIKDPDQNTFAGLARSSVRHLDLSHGFVFSLNSRVFETLKDLKVLNLAYNKINKIADEAFYGLDNLQVLNLSYNLLGELYSSNFYGLPKVAYIDLQKNHIAIIQDQTFKFLEKLQTLDLRDNALTTIHFIPSIPDIFLSGNKLVTLPKINLTANLIHLSENRLENLDILYFLLRVPHLQILILNQNRFSSCSGDQTPSENPSLEQLFLGENMLQLAWETELCWDVFEGLSHLQVLYLNHNYLNSLPPGVFSHLTALRGLSLNSNRLTVLSHNDLPANLEILDISRNQLLAPNPDVFVSLSVLDITHNKFICECELSTFINWLNHTNVTIAGPPADIYCVYPDSFSGVSLFSLSTEGCDEEEVLKSLKFSLFIVCTVTLTLFLMTILTVTKFRGFCFICYKTAQRLVFKDHPQGTEPDMYKYDAYLCFSSKDFTWVQNALLKHLDTQYSDQNRFNLCFEERDFVPGENRIANIQDAIWNSRKIVCLVSRHFLRDGWCLEAFSYAQGRCLSDLNSALIMVVVGSLSQYQLMKHQSIRGFVQKQQYLRWPEDFQDVGWFLHKLSQQILKKEKEKKKDNNIPLQTVATIS
T43718	DRUGINFO	D0V4TV	CBLB-502	Phase 2
T43718	DRUGINFO	D0WZ3G	Entolimod	Phase 1
T43718	DRUGINFO	DP2X4C	STAT-600	Phase 1

T39797	TARGETID	T39797
T39797	FORMERID	TTDI02075
T39797	UNIPROID	FZD7_HUMAN
T39797	TARGNAME	Frizzled-7 receptor (FZD7)
T39797	GENENAME	FZD7
T39797	TARGTYPE	Clinical trial
T39797	SYNONYMS	hFz7; FzE3; Fz7; Fz-7; Frizzled7; Frizzled-7
T39797	FUNCTION	Most of frizzled receptors are coupled to the beta-catenin canonical signaling pathway, which leads to the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes. A second signaling pathway involving PKC and calcium fluxes has been seen for some family members, but it is not yet clear if it represents a distinct pathway or if it can be integrated in the canonical pathway, as PKC seems to be required for Wnt-mediated inactivation of GSK-3 kinase. Both pathways seem to involve interactions with G-proteins. May be involved in transduction and intercellular transmission of polarity information during tissue morphogenesis and/or in differentiated tissues. Receptor for Wnt proteins.
T39797	PDBSTRUC	6O3B; 6O3A; 6NE4; 6NE2; 5WBS
T39797	BIOCLASS	GPCR frizzled
T39797	SEQUENCE	MRDPGAAAPLSSLGLCALVLALLGALSAGAGAQPYHGEKGISVPDHGFCQPISIPLCTDIAYNQTILPNLLGHTNQEDAGLEVHQFYPLVKVQCSPELRFFLCSMYAPVCTVLDQAIPPCRSLCERARQGCEALMNKFGFQWPERLRCENFPVHGAGEICVGQNTSDGSGGPGGGPTAYPTAPYLPDLPFTALPPGASDGRGRPAFPFSCPRQLKVPPYLGYRFLGERDCGAPCEPGRANGLMYFKEEERRFARLWVGVWSVLCCASTLFTVLTYLVDMRRFSYPERPIIFLSGCYFMVAVAHVAGFLLEDRAVCVERFSDDGYRTVAQGTKKEGCTILFMVLYFFGMASSIWWVILSLTWFLAAGMKWGHEAIEANSQYFHLAAWAVPAVKTITILAMGQVDGDLLSGVCYVGLSSVDALRGFVLAPLFVYLFIGTSFLLAGFVSLFRIRTIMKHDGTKTEKLEKLMVRIGVFSVLYTVPATIVLACYFYEQAFREHWERTWLLQTCKSYAVPCPPGHFPPMSPDFTVFMIKYLMTMIVGITTGFWIWSGKTLQSWRRFYHRLSHSSKGETAV
T39797	DRUGINFO	D00GPY	OMP-18R5	Phase 1

T88569	TARGETID	T88569
T88569	UNIPROID	IDHC_HUMAN
T88569	TARGNAME	Mutated oxalosuccinate decarboxylase (mIDH1)
T88569	GENENAME	IDH1
T88569	TARGTYPE	Clinical trial
T88569	SYNONYMS	PICD (mutated); Oxalosuccinate decarboxylase (mutated); NADP(+)-specific ICDH (mutated); Isocitrate dehydrogenase [NADP] cytoplasmic (mutated); IDP (mutated); IDH (mutated); Cytosolic NADP-isocitrate dehydrogenase (mutated)
T88569	FUNCTION	Catalyses the NADPH-dependent reduction of alpha-ketoglutarate to R(-)-2-hydroxyglutarate (2HG).
T88569	PDBSTRUC	6BL2; 6BL1; 6BL0; 6BKZ; 6BKY
T88569	BIOCLASS	Short-chain dehydrogenases reductase
T88569	ECNUMBER	EC 1.1.1.42
T88569	SEQUENCE	MSKKISGGSVVEMQGDEMTRIIWELIKEKLIFPYVELDLHSYDLGIENRDATNDQVTKDAAEAIKKHNVGVKCATITPDEKRVEEFKLKQMWKSPNGTIRNILGGTVFREAIICKNIPRLVSGWVKPIIIGRHAYGDQYRATDFVVPGPGKVEITYTPSDGTQKVTYLVHNFEEGGGVAMGMYNQDKSIEDFAHSSFQMALSKGWPLYLSTKNTILKKYDGRFKDIFQEIYDKQYKSQFEAQKIWYEHRLIDDMVAQAMKSEGGFIWACKNYDGDVQSDSVAQGYGSLGMMTSVLVCPDGKTVEAEAAHGTVTRHYRMYQKGQETSTNPIASIFAWTRGLAHRAKLDNNKELAFFANALEEVSIETIEAGFMTKDLAACIKGLPNVQRSDYLNTFEFMDKLGENLKIKLAQAKL
T88569	DRUGINFO	D0C6RM	BAY1436032	Phase 1

T14676	TARGETID	T14676
T14676	FORMERID	TTDNC00650
T14676	UNIPROID	TNF13_HUMAN
T14676	TARGNAME	A proliferation-inducing ligand (APRIL)
T14676	GENENAME	TNFSF13
T14676	TARGTYPE	Clinical trial
T14676	SYNONYMS	ZTNF2; UNQ383/PRO715; Tumor necrosis factor ligand superfamily member 13; TRDL-1; TNF-related death ligand 1; TNF- and APOL-related leukocyte expressed ligand 2; TALL2; TALL-2; CD256
T14676	FUNCTION	Plays a role in the regulation of tumor cell growth. May be involved in monocyte/macrophage-mediated immunological processes. Cytokine that binds to TNFRSF13B/TACI and to TNFRSF17/BCMA.
T14676	PDBSTRUC	4ZCH
T14676	BIOCLASS	Cytokine: tumor necrosis factor
T14676	SEQUENCE	MPASSPFLLAPKGPPGNMGGPVREPALSVALWLSWGAALGAVACAMALLTQQTELQSLRREVSRLQGTGGPSQNGEGYPWQSLPEQSSDALEAWENGERSRKRRAVLTQKQKKQHSVLHLVPINATSKDDSDVTEVMWQPALRRGRGLQAQGYGVRIQDAGVYLLYSQVLFQDVTFTMGQVVSREGQGRQETLFRCIRSMPSHPDRAYNSCYSAGVFHLHQGDILSVIIPRARAKLNLSPHGTFLGFVKL
T14676	DRUGINFO	D04YWM	Atacicept	Phase 3

T99732	TARGETID	T99732
T99732	FORMERID	TTDI02070
T99732	UNIPROID	FGF18_HUMAN
T99732	TARGNAME	Fibroblast growth factor-18 (FGF18)
T99732	GENENAME	FGF18
T99732	TARGTYPE	Clinical trial
T99732	SYNONYMS	zFGF5; Fibroblast growth factor 18; FGF18
T99732	FUNCTION	Plays an important role in the regulation of cell proliferation, cell differentiation and cell migration. Required for normal ossification and bone development. Stimulates hepatic and intestinal proliferation.
T99732	PDBSTRUC	4CJM
T99732	BIOCLASS	Growth factor
T99732	SEQUENCE	MYSAPSACTCLCLHFLLLCFQVQVLVAEENVDFRIHVENQTRARDDVSRKQLRLYQLYSRTSGKHIQVLGRRISARGEDGDKYAQLLVETDTFGSQVRIKGKETEFYLCMNRKGKLVGKPDGTSKECVFIEKVLENNYTALMSAKYSGWYVGFTKKGRPRKGPKTRENQQDVHFMKRYPKGQPELQKPFKYTTVTKRSRRIRPTHPA
T99732	DRUGINFO	D04GKP	AS-902330	Phase 2

T64969	TARGETID	T64969
T64969	FORMERID	TTDR00576
T64969	UNIPROID	EGFR_HUMAN
T64969	TARGNAME	Epidermal growth factor receptor variant III (EGFR vIII)
T64969	GENENAME	EGFR
T64969	TARGTYPE	Clinical trial
T64969	SYNONYMS	ERBB1 variant III; ERBB variant III
T64969	FUNCTION	Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin. Plays a role in enhancing learning and memory performance (By similarity).
T64969	PDBSTRUC	6D8E; 6B3S; 6ARU; 5ZWJ; 5YU9
T64969	BIOCLASS	Kinase
T64969	ECNUMBER	EC 2.7.10.1
T64969	SEQUENCE	MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALAVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDFQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRVAPQSSEFIGA
T64969	DRUGINFO	D08RJY	Anti-EGFRvIII CAR transduced PBL	Phase 1/2
T64969	DRUGINFO	D0LU4N	EGFRvIII CAR	Phase 1/2
T64969	DRUGINFO	D0Q4EJ	Anti-EGFR V III CAR-T cells	Phase 1/2
T64969	DRUGINFO	D01LWE	EGFRvIII CAR T cells	Phase 1
T64969	DRUGINFO	D03CMZ	CAR-T cells targeting EGFRviii	Phase 1
T64969	DRUGINFO	D09OSC	Anti-EGFRvIII CAR T cells	Phase 1
T64969	DRUGINFO	D0B5PV	CART-EGFRvIII T cells	Phase 1
T64969	DRUGINFO	D0PT2M	EGFRvIII-CARs	Phase 1
T64969	DRUGINFO	D0ZQ6N	CAR-T Cells targeting EGFRvIII	Phase 1
T64969	DRUGINFO	DF8X5N	RG6156	Phase 1
T64969	DRUGINFO	DOJ6E8	AMG 596	Phase 1
T64969	DRUGINFO	DR4ND6	D2C7	Phase 1

T48598	TARGETID	T48598
T48598	FORMERID	TTDNC00549
T48598	UNIPROID	RASK_HUMAN
T48598	TARGNAME	GTPase KRas (KRAS)
T48598	GENENAME	KRAS
T48598	TARGTYPE	Clinical trial
T48598	SYNONYMS	c-Ki-ras; c-K-ras; RASK2; Ki-Ras; KRAS2; K-Ras 2
T48598	FUNCTION	Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. Plays an important role in the regulation of cell proliferation. Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner.
T48598	PDBSTRUC	6N2K; 6N2J; 6H47; 6H46; 6GQY
T48598	BIOCLASS	Small GTPase
T48598	SEQUENCE	MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM
T48598	DRUGINFO	D0DT5H	AZD4785	Phase 1
T48598	DRUGINFO	DR4K0V	BI 1701963	Phase 1

T87350	TARGETID	T87350
T87350	FORMERID	TTDI02317
T87350	UNIPROID	PDGFB_HUMAN
T87350	TARGNAME	Platelet-derived growth factor B (PDGFB)
T87350	GENENAME	PDGFB
T87350	TARGTYPE	Clinical trial
T87350	SYNONYMS	SIS; Protooncogene cSis; Proto-oncogene c-Sis; Plateletderived growth factor subunit B; Plateletderived growth factor beta polypeptide; Plateletderived growth factor B chain; Platelet-derived growth factor subunit B; Platelet-derived growth factor beta polypeptide; Platelet-derived growth factor B chain; PDGF2; PDGF-2; PDGF subunit B; Becaplermin
T87350	FUNCTION	Potent mitogen for cells of mesenchymal origin. Required for normal proliferation and recruitment of pericytes and vascular smooth muscle cells in the central nervous system, skin, lung, heart and placenta. Required for normal blood vessel development, and for normal development of kidney glomeruli. Plays an important role in wound healing. Signaling is modulated by the formation of heterodimers with PDGFA. Growth factor that plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis.
T87350	PDBSTRUC	4QCI; 4HQX; 4HQU; 3MJG; 1PDG
T87350	BIOCLASS	Growth factor
T87350	SEQUENCE	MNRCWALFLSLCCYLRLVSAEGDPIPEELYEMLSDHSIRSFDDLQRLLHGDPGEEDGAELDLNMTRSHSGGELESLARGRRSLGSLTIAEPAMIAECKTRTEVFEISRRLIDRTNANFLVWPPCVEVQRCSGCCNNRNVQCRPTQVQLRPVQVRKIEIVRKKPIFKKATVTLEDHLACKCETVAAARPVTRSPGGSQEQRAKTPQTRVTIRTVRVRRPPKGKHRKFKHTHDKTALKETLGA
T87350	DRUGINFO	D04BVN	PDGF-BB	Phase 3
T87350	DRUGINFO	D01GSE	E-10030	Phase 2
T87350	DRUGINFO	D0A6WA	GAM-501	Phase 2
T87350	DRUGINFO	D0W0GE	CR-002	Phase 1

T00033	TARGETID	T00033
T00033	FORMERID	TTDR00181
T00033	UNIPROID	TGFA_HUMAN
T00033	TARGNAME	Transforming growth factor alpha (TGFA)
T00033	GENENAME	TGFA
T00033	TARGTYPE	Clinical trial
T00033	SYNONYMS	TGF-alpha (40-89); TGF type 1 (40-89); Protransforming growth factor alpha (40-89); ETGF (40-89); EGF-like TGF (40-89)
T00033	FUNCTION	TGF alpha is a mitogenic polypeptide that is able to bind to the EGF receptor/EGFR and to act synergistically with TGF beta to promote anchorage-independent cell proliferation in soft agar.
T00033	PDBSTRUC	5KN5; 4TGF; 3TGF; 3.00E+50; 2TGF
T00033	BIOCLASS	Growth factor
T00033	SEQUENCE	MVPSAGQLALFALGIVLAACQALENSTSPLSADPPVAAAVVSHFNDCPDSHTQFCFHGTCRFLVQEDKPACVCHSGYVGARCEHADLLAVVAASQKKQAITALVVVSIVALAVLIITCVLIHCCQVRKHCEWCRALICRHEKPSALLKGRTACCHSETVV
T00033	DRUGINFO	D08EIK	LY3016859	Phase 1/2

T10092	TARGETID	T10092
T10092	FORMERID	TTDR00006
T10092	UNIPROID	FSHB_HUMAN
T10092	TARGNAME	Follicle stimulating hormone (FSHB)
T10092	GENENAME	FSHB
T10092	TARGTYPE	Clinical trial
T10092	SYNONYMS	Follitropin subunit beta; Follitropin beta chain; Follicle-stimulating hormone beta subunit; FSH-beta; FSH-B
T10092	FUNCTION	Together with the alpha chain CGA constitutes follitropin, the follicle-stimulating hormone, and provides its biological specificity to the hormone heterodimer. Binds FSHR, a G protein-coupled receptor, on target cells to activate downstream signaling pathways. Follitropin is involved in follicle development and spermatogenesis in reproductive organs.
T10092	PDBSTRUC	4MQW; 4AY9; 1XWD; 1FL7
T10092	BIOCLASS	Hormone
T10092	SEQUENCE	MKTLQFFFLFCCWKAICCNSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYETVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE
T10092	DRUGINFO	D0KM1B	Follicle stimulating hormone	Phase 2
T10092	DRUGINFO	D08OHK	AKP-501	Phase 1

T19784	TARGETID	T19784
T19784	FORMERID	TTDR01048
T19784	UNIPROID	SOMA_HUMAN
T19784	TARGNAME	Somatotropin (GH1)
T19784	GENENAME	GH1
T19784	TARGTYPE	Clinical trial
T19784	SYNONYMS	Pituitary growth hormone; Growth hormone 1; Growth hormone; GH-N; GH
T19784	FUNCTION	Plays an important role in growth control. Its major role in stimulating body growth is to stimulate the liver and other tissues to secrete IGF-1. It stimulates both the differentiation and proliferation of myoblasts. It also stimulates amino acid uptake and protein synthesis in muscle and other tissues.
T19784	PDBSTRUC	3HHR; 1KF9; 1HWH; 1HWG; 1HUW
T19784	BIOCLASS	Somatotropin/prolactin
T19784	SEQUENCE	MATGSRTSLLLAFGLLCLPWLQEGSAFPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF
T19784	DRUGINFO	D0H8MH	HGH-CTP	Phase 3
T19784	DRUGINFO	D0XN5L	Albutropin	Phase 3
T19784	DRUGINFO	D0Y7VP	VRS-317	Phase 3
T19784	DRUGINFO	D0C9SW	Somatropin intranasal rhGH	Phase 2
T19784	DRUGINFO	D00HZA	YPEG-Somatropin	Phase 1
T19784	DRUGINFO	D01LFA	ARX-201	Discontinued in Phase 2

T44919	TARGETID	T44919
T44919	UNIPROID	GLUC_HUMAN
T44919	TARGNAME	Glucagon (GCG)
T44919	GENENAME	GCG
T44919	TARGTYPE	Clinical trial
T44919	SYNONYMS	GRPP; GLP2; GLP1; GLP-1
T44919	FUNCTION	Glucagon plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes.
T44919	PDBSTRUC	6EDS; 5YQZ; 5VAI; 5OTX; 5OTW
T44919	BIOCLASS	Glucagon
T44919	SEQUENCE	MKSIYFVAGLFVMLVQGSWQRSLQDTEEKSRSFSASQADPLSDPDQMNEDKRHSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAKRHDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRGRRDFPEEVAIVEELGRRHADGSFSDEMNTILDNLAARDFINWLIQTKITDRK
T44919	DRUGINFO	D09PCL	JNJ-64565111	Phase 2
T44919	DRUGINFO	D0MO0J	MEDI0382	Phase 2
T44919	DRUGINFO	DC5NS1	PT320	Phase 2
T44919	DRUGINFO	D03MSV	PB-1023	Phase 2
T44919	DRUGINFO	D04CQK	MK-8521	Phase 2
T44919	DRUGINFO	D02URD	SAR425899	Phase 1
T44919	DRUGINFO	D0FW0B	ZP2929	Phase 1

T35303	TARGETID	T35303
T35303	FORMERID	TTDI02211
T35303	UNIPROID	PAHO_HUMAN
T35303	TARGNAME	Pancreatic hormone (PH)
T35303	GENENAME	PPY
T35303	TARGTYPE	Clinical trial
T35303	SYNONYMS	Pancreatic prohormone; Pancreatic polypeptide; Pancreatic icosapeptide; PPY; PP; PI; PH; Obinepitide
T35303	FUNCTION	The physiological role for the icosapeptide has notyet been elucidated.
T35303	PDBSTRUC	1TZ5; 1TZ4
T35303	BIOCLASS	Neuropeptide Y
T35303	SEQUENCE	APLEPVYPGDNATPEQMAQYAADLRRYINMLTRPRY
T35303	DRUGINFO	D0DG9F	PP-1420	Phase 1/2

T07958	TARGETID	T07958
T07958	FORMERID	TTDI01917
T07958	UNIPROID	EPO_HUMAN
T07958	TARGNAME	Erythropoietin (EPO)
T07958	GENENAME	EPO
T07958	TARGTYPE	Clinical trial
T07958	SYNONYMS	Epoetin
T07958	FUNCTION	Binds to EPOR leading to EPOR dimerization and JAK2 activation thereby activating specific downstream effectors, including STAT1 and STAT3. Hormone involved in the regulation of erythrocyte proliferation and differentiation and the maintenance of a physiological level of circulating erythrocyte mass.
T07958	PDBSTRUC	1EER; 1CN4; 1BUY
T07958	SEQUENCE	MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMEVGQQAVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDR
T07958	DRUGINFO	D0E1LB	MK-2578	Phase 2
T07958	DRUGINFO	DO0GJ1	LKA651	Phase 2
T07958	DRUGINFO	D00ANG	Erythropoietin-transfected autologous cell therapy	Phase 1/2
T07958	DRUGINFO	D04UTH	Long-acting erythropoietin conjugate	Phase 1
T07958	DRUGINFO	D0KV1I	GC-1113	Phase 1
T07958	DRUGINFO	D0Q9WN	FC EPO	Discontinued in Phase 1
T07958	DRUGINFO	D0OL4S	GLY-515n	Terminated

T47415	TARGETID	T47415
T47415	FORMERID	TTDI02337
T47415	UNIPROID	1B07_HUMAN
T47415	TARGNAME	HLA class I antigen B-7 (HLA-B)
T47415	GENENAME	HLA-B
T47415	TARGTYPE	Clinical trial
T47415	SYNONYMS	MHC class I antigen B*7; HLAB; HLA class I histocompatibility antigen, B7 alpha chain; HLA class I histocompatibility antigen, B-7 alpha chain
T47415	FUNCTION	Involved in the presentation of foreign antigens to the immune system.
T47415	PDBSTRUC	6AVG; 6AVF; 6AT5; 5WMP; 5WMO
T47415	BIOCLASS	MHC class I
T47415	SEQUENCE	MLVMAPRTVLLLLSAALALTETWAGSHSMRYFYTSVSRPGRGEPRFISVGYVDDTQFVRFDSDAASPREEPRAPWIEQEGPEYWDRNTQIYKAQAQTDRESLRNLRGYYNQSEAGSHTLQSMYGCDVGPDGRLLRGHDQYAYDGKDYIALNEDLRSWTAADTAAQITQRKWEAAREAEQRRAYLEGECVEWLRRYLENGKDKLERADPPKTHVTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDRTFQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWEPSSQSTVPIVGIVAGLAVLAVVVIGAVVAAVMCRRKSSGGKGGSYSQAACSDSAQGSDVSLTA
T47415	DRUGINFO	D0Y9YN	Velimogene aliplasmid	Phase 3

T00419	TARGETID	T00419
T00419	FORMERID	TTDI02195
T00419	UNIPROID	TNNC2_HUMAN
T00419	TARGNAME	Fast skeletal muscle troponin complex (TNNC2)
T00419	GENENAME	TNNC2
T00419	TARGTYPE	Clinical trial
T00419	SYNONYMS	fTnT; Troponin T, fast skeletal muscle; Troponin I, fast-twitch isoform; Troponin I, fast skeletal muscle; Troponin C, skeletal muscle; TnTf; TNNT3; TNNI2; TNNC2; Fast skeletal muscle troponin T; Beta-TnTF
T00419	FUNCTION	Troponin I is the inhibitory subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity.
T00419	BIOCLASS	Troponin
T00419	SEQUENCE	MTDQQAEARSYLSEEMIAEFKAAFDMFDADGGGDISVKELGTVMRMLGQTPTKEELDAIIEEVDEDGSGTIDFEEFLVMMVRQMKEDAKGKSEEELAECFRIFDRNADGYIDPEELAEIFRASGEHVTDEEIESLMKDGDKNNDGRIDFDEFLKMMEGVQ
T00419	DRUGINFO	D07EBF	CK-2017357	Phase 3
T00419	DRUGINFO	D07ZUZ	CK-2127107	Phase 2

T21689	TARGETID	T21689
T21689	FORMERID	TTDR00411
T21689	UNIPROID	APOE_HUMAN
T21689	TARGNAME	Apolipoprotein E (APOE)
T21689	GENENAME	APOE
T21689	TARGTYPE	Clinical trial
T21689	SYNONYMS	ApoE; Apo-E
T21689	FUNCTION	APOE is a core component of plasma lipoproteins and is involved in their production, conversion and clearance. Apoliproteins are amphipathic molecules that interact both with lipids of the lipoprotein particle core and the aqueous environment of the plasma. As such, APOE associates with chylomicrons, chylomicron remnants, very low density lipoproteins (VLDL) and intermediate density lipoproteins (IDL) but shows a preferential binding to high-density lipoproteins (HDL). It also binds a wide range of cellular receptors including the LDL receptor/LDLR, the LDL receptor-related proteins LRP1, LRP2 and LRP8 and the very low-density lipoprotein receptor/VLDLR that mediate the cellular uptake of the APOE-containing lipoprotein particles. Finally, APOE has also a heparin-binding activity and binds heparan-sulfate proteoglycans on the surface of cells, a property that supports the capture and the receptor-mediated uptake of APOE-containing lipoproteins by cells. A main function of APOE is to mediate lipoprotein clearance through the uptake of chylomicrons, VLDLs, and HDLs by hepatocytes. APOE is also involved in the biosynthesis by the liver of VLDLs as well as their uptake by peripheral tissues ensuring the delivery of triglycerides and energy storage in muscle, heart and adipose tissues. By participating to the lipoprotein-mediated distribution of lipids among tissues, APOE plays a critical role in plasma and tissues lipid homeostasis. APOE is also involved in two steps of reverse cholesterol transport, the HDLs-mediated transport of cholesterol from peripheral tissues to the liver, and thereby plays an important role in cholesterol homeostasis. First, it is functionally associated with ABCA1 in the biogenesis of HDLs in tissues. Second, it is enriched in circulating HDLs and mediates their uptake by hepatocytes. APOE also plays an important role in lipid transport in the central nervous system, regulating neuron survival and sprouting. APOE in also involved in innate and adaptive immune responses, controlling for instance the survival of myeloid-derived suppressor cells. APOE, may also play a role in transcription regulation through a receptor-dependent and cholesterol-independent mechanism, that activates MAP3K12 and a non-canonical MAPK signal transduction pathway that results in enhanced AP-1-mediated transcription of APP. APOE is an apolipoprotein, a protein associating with lipid particles, that mainly functions in lipoprotein-mediated lipid transport between organs via the plasma and interstitial fluids.
T21689	PDBSTRUC	6NCO; 6NCN; 2L7B; 2KNY; 2KC3
T21689	BIOCLASS	Apolipoprotein
T21689	SEQUENCE	MKVLWAALLVTFLAGCQAKVEQAVETEPEPELRQQTEWQSGQRWELALGRFWDYLRWVQTLSEQVQEELLSSQVTQELRALMDETMKELKAYKSELEEQLTPVAEETRARLSKELQAAQARLGADMEDVCGRLVQYRGEVQAMLGQSTEELRVRLASHLRKLRKRLLRDADDLQKRLAVYQAGAREGAERGLSAIRERLGPLVEQGRVRAATVGSLAGQPLQERAQAWGERLRARMEEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH
T21689	DRUGINFO	D07ADU	AEM-28	Phase 2
T21689	DRUGINFO	D0V6OZ	CN-105	Phase 2
T21689	DRUGINFO	D6UEI3	LX1001	Phase 1/2
T21689	DRUGINFO	D02ADJ	Apolipoprotein E	Terminated

T31518	TARGETID	T31518
T31518	FORMERID	TTDNC00616
T31518	UNIPROID	APOC3_HUMAN
T31518	TARGNAME	Apolipoprotein C-III (ApoCIII)
T31518	GENENAME	APOC3
T31518	TARGTYPE	Clinical trial
T31518	SYNONYMS	Apolipoprotein CIII; Apolipoprotein C3; ApoC-III; Apo-CIII
T31518	FUNCTION	Plays a multifaceted role in triglyceride homeostasis. Intracellularly, promotes hepatic very low density lipoprotein 1 (VLDL1) assembly and secretion; extracellularly, attenuates hydrolysis and clearance of triglyceride-rich lipoproteins (TRLs). Impairs the lipolysis of TRLs by inhibiting lipoprotein lipase and the hepatic uptake of TRLs by remnant receptors. Formed of several curved helices connected via semiflexible hinges, so that it can wrap tightly around the curved micelle surface and easily adapt to the different diameters of its natural binding partners. Component of triglyceride-rich very low density lipoproteins (VLDL) and high density lipoproteins (HDL) in plasma.
T31518	PDBSTRUC	2JQ3
T31518	BIOCLASS	Apolipoprotein
T31518	SEQUENCE	MQPRVLLVVALLALLASARASEAEDASLLSFMQGYMKHATKTAKDALSSVQESQVAQQARGWVTDGFSSLKDYWSTVKDKFSEFWDLDPEVRPTSAVAA

T54761	TARGETID	T54761
T54761	FORMERID	TTDI02324
T54761	UNIPROID	MBP_HUMAN
T54761	TARGNAME	Myelin basic protein (MBP)
T54761	GENENAME	MBP
T54761	TARGTYPE	Clinical trial
T54761	SYNONYMS	Myelin membrane encephalitogenic protein; Myelin A1 protein
T54761	FUNCTION	The classic group of MBP isoforms (isoform 4-isoform 14) are with PLP the most abundant protein components of the myelin membrane in the CNS. They have a role in both its formation and stabilization. The smaller isoforms might have an important role in remyelination of denuded axons in multiple sclerosis. The non-classic group of MBP isoforms (isoform 1-isoform 3/Golli-MBPs) may preferentially have a role in the early developing brain long before myelination, maybe as components of transcriptional complexes, and may also be involved in signaling pathways in T-cells and neural cells. Differential splicing events combined with optional post-translational modifications give a wide spectrum of isomers, with each of them potentially having a specialized function. Induces T-cell proliferation.
T54761	PDBSTRUC	1ZGL; 1YMM; 1QCL; 1K2D; 1HQR
T54761	SEQUENCE	MGNHAGKRELNAEKASTNSETNRGESEKKRNLGELSRTTSEDNEVFGEADANQNNGTSSQDTAVTDSKRTADPKNAWQDAHPADPGSRPHLIRLFSRDAPGREDNTFKDRPSESDELQTIQEDSAATSESLDVMASQKRPSQRHGSKYLATASTMDHARHGFLPRHRDTGILDSIGRFFGGDRGAPKRGSGKDSHHPARTAHYGSLPQKSHGRTQDENPVVHFFKNIVTPRTPPPSQGKGRGLSLSRFSWGAEGQRPGFGYGGRASDYKSAHKGFKGVDAQGTLSKIFKLGGRDSRSGSPMARR
T54761	DRUGINFO	D05QKO	NBI-5788	Phase 2
T54761	DRUGINFO	D0C5FQ	BHT-3009	Phase 2

T10828	TARGETID	T10828
T10828	FORMERID	TTDR00679
T10828	UNIPROID	FETA_HUMAN
T10828	TARGNAME	Alpha-fetoprotein (AFP)
T10828	GENENAME	AFP
T10828	TARGTYPE	Clinical trial
T10828	SYNONYMS	Alpha-fetoglobulin; Alpha-1-fetoprotein; AFP
T10828	FUNCTION	Binds copper, nickel, and fatty acids as well as, and bilirubin less well than, serum albumin. Only a small percentage (less than 2%) of the human AFP shows estrogen-binding properties.
T10828	PDBSTRUC	3MRK
T10828	BIOCLASS	Serum albumin family
T10828	SEQUENCE	MKWVESIFLIFLLNFTESRTLHRNEYGIASILDSYQCTAEISLADLATIFFAQFVQEATYKEVSKMVKDALTAIEKPTGDEQSSGCLENQLPAFLEELCHEKEILEKYGHSDCCSQSEEGRHNCFLAHKKPTPASIPLFQVPEPVTSCEAYEEDRETFMNKFIYEIARRHPFLYAPTILLWAARYDKIIPSCCKAENAVECFQTKAATVTKELRESSLLNQHACAVMKNFGTRTFQAITVTKLSQKFTKVNFTEIQKLVLDVAHVHEHCCRGDVLDCLQDGEKIMSYICSQQDTLSNKITECCKLTTLERGQCIIHAENDEKPEGLSPNLNRFLGDRDFNQFSSGEKNIFLASFVHEYSRRHPQLAVSVILRVAKGYQELLEKCFQTENPLECQDKGEEELQKYIQESQALAKRSCGLFQKLGEYYLQNAFLVAYTKKAPQLTSSELMAITRKMAATAATCCQLSEDKLLACGEGAADIIIGHLCIRHEMTPVNPGVGQCCTSSYANRRPCFSSLVVDETYVPPAFSDDKFIFHKDLCQAQGVALQTMKQEFLINLVKQKPQITEEQLEAVIADFSGLLEKCCQGQEQEVCFAEEGQKLISKTRAALGV
T10828	DRUGINFO	D05RQY	MM-093	Phase 2
T10828	DRUGINFO	D4K2OF	ET140202	Phase 1

T02617	TARGETID	T02617
T02617	FORMERID	TTDI02373
T02617	UNIPROID	TRFE_HUMAN
T02617	TARGNAME	Transferrin (TF)
T02617	GENENAME	TF
T02617	TARGTYPE	Clinical trial
T02617	SYNONYMS	Siderophilin; Serotransferrin; PRO1400; Beta-1 metal-binding globulin
T02617	FUNCTION	It is responsible for the transport of iron from sites of absorption and heme degradation to those of storage and utilization. Serum transferrin may also have a further role in stimulating cell proliferation. Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate.
T02617	PDBSTRUC	6D05; 6D04; 6D03; 6CTC; 5Y6K
T02617	BIOCLASS	Transferrin
T02617	SEQUENCE	MRLAVGALLVCAVLGLCLAVPDKTVRWCAVSEHEATKCQSFRDHMKSVIPSDGPSVACVKKASYLDCIRAIAANEADAVTLDAGLVYDAYLAPNNLKPVVAEFYGSKEDPQTFYYAVAVVKKDSGFQMNQLRGKKSCHTGLGRSAGWNIPIGLLYCDLPEPRKPLEKAVANFFSGSCAPCADGTDFPQLCQLCPGCGCSTLNQYFGYSGAFKCLKDGAGDVAFVKHSTIFENLANKADRDQYELLCLDNTRKPVDEYKDCHLAQVPSHTVVARSMGGKEDLIWELLNQAQEHFGKDKSKEFQLFSSPHGKDLLFKDSAHGFLKVPPRMDAKMYLGYEYVTAIRNLREGTCPEAPTDECKPVKWCALSHHERLKCDEWSVNSVGKIECVSAETTEDCIAKIMNGEADAMSLDGGFVYIAGKCGLVPVLAENYNKSDNCEDTPEAGYFAIAVVKKSASDLTWDNLKGKKSCHTAVGRTAGWNIPMGLLYNKINHCRFDEFFSEGCAPGSKKDSSLCKLCMGSGLNLCEPNNKEGYYGYTGAFRCLVEKGDVAFVKHQTVPQNTGGKNPDPWAKNLNEKDYELLCLDGTRKPVEEYANCHLARAPNHAVVTRKDKEACVHKILRQQQHLFGSNVTDCSGNFCLFRSETKDLLFRDDTVCLAKLHDRNTYEKYLGEEYVKAVGNLRKCSTSSLLEACTFRRP
T02617	DRUGINFO	D0A1GR	CALAA-01	Phase 1
T02617	DRUGINFO	D0QB8Q	EP-2167	Preclinical

T53811	TARGETID	T53811
T53811	FORMERID	TTDI02206
T53811	UNIPROID	VE6_HPV16
T53811	TARGNAME	Human papillomavirus protein E6 (HPV E6)
T53811	GENENAME	HPV E6
T53811	TARGTYPE	Clinical trial
T53811	SYNONYMS	Protein E6; E6
T53811	FUNCTION	Plays a major role in the induction and maintenance of cellular transformation. Acts mainly as an oncoprotein by stimulating the destruction of many host cell key regulatory proteins. E6 associates with host E6-AP ubiquitin-protein ligase, and inactivates tumor suppressors TP53 and TP73 by targeting them to the 26S proteasome for degradation. In turn, DNA damage and chromosomal instabilities increase and lead to cell proliferation and cancer development. The complex E6/E6P targets several other substrates to degradation via the proteasome including host NFX1- 91, a repressor of human telomerase reverse transcriptase (hTERT). The resulting increased expression of hTERT prevents the shortening of telomere length leading to cell immortalization. Other cellular targets including Bak, Fas-associated death domain- containing protein (FADD) and procaspase 8, are degraded by E6/E6AP causing inhibition of apoptosis. E6 also inhibits immune response by interacting with host IRF3 and TYK2. These interactions prevent IRF3 transcriptional activities and inhibit TYK2-mediated JAK-STAT activation by interferon alpha resulting in inhibition of the interferon signaling pathway.
T53811	PDBSTRUC	6HKS; 4XR8; 4JOP; 4GIZ; 2LJZ
T53811	BIOCLASS	Papillomaviridae E protein
T53811	SEQUENCE	MHQKRTAMFQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVYDFAFRDLCIVYRDGNPYAVCDKCLKFYSKISEYRHYCYSLYGTTLEQQYNKPLCDLLIRCINCQKPLCPEEKQRHLDKKQRFHNIRGRWTGRCMSCCRSSRTRRETQL
T53811	DRUGINFO	D00PMB	VGX-3100	Phase 3
T53811	DRUGINFO	D0P9QW	Tipapkinogene sovacivec	Phase 2

T83793	TARGETID	T83793
T83793	FORMERID	TTDR00778
T83793	UNIPROID	NEF_HV1A2
T83793	TARGNAME	Human immunodeficiency virus Negative factor (HIV nef)
T83793	GENENAME	HIV nef
T83793	TARGTYPE	Clinical trial
T83793	SYNONYMS	nef; Nef protein; F-protein; 3'ORF; 27 kDa protein
T83793	FUNCTION	Extracellular Nef protein targets CD4(+) T-lymphocytes for apoptosis by interacting with CXCR4 surface receptors.
T83793	PDBSTRUC	6B72; 5XOV; 4U5W; 4U1N; 4U1M
T83793	BIOCLASS	Lentivirus primate group Nef
T83793	SEQUENCE	MGGKWSKRSMGGWSAIRERMRRAEPRAEPAADGVGAVSRDLEKHGAITSSNTAATNADCAWLEAQEEEEVGFPVRPQVPLRPMTYKAALDISHFLKEKGGLEGLIWSQRRQEILDLWIYHTQGYFPDWQNYTPGPGIRYPLTFGWCFKLVPVEPEKVEEANEGENNSLLHPMSLHGMEDAEKEVLVWRFDSKLAFHHMARELHPEYYKDC
T83793	DRUGINFO	D0R0SP	LIPO-5	Phase 2
T83793	DRUGINFO	D05GBH	F4co vaccine	Phase 2
T83793	DRUGINFO	D0W9IH	Ad35-GRIN	Phase 1/2
T83793	DRUGINFO	D09ZKB	Ad35-GRIN/ENV	Phase 1
T83793	DRUGINFO	D02ESK	GSK-732461	Discontinued in Phase 2
T83793	DRUGINFO	D08OBF	MYRISTIC ACID	Investigative

T46040	TARGETID	T46040
T46040	FORMERID	TTDI01964
T46040	UNIPROID	FA11_HUMAN
T46040	TARGNAME	Coagulation factor XI (F11)
T46040	GENENAME	F11
T46040	TARGTYPE	Clinical trial
T46040	SYNONYMS	Plasma thromboplastin antecedent; PTA; FXI
T46040	FUNCTION	Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX.
T46040	PDBSTRUC	6R8X; 6I58; 6C0S; 6AOD; 5WB6
T46040	BIOCLASS	Peptidase
T46040	ECNUMBER	EC 3.4.21.27
T46040	SEQUENCE	MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV
T46040	DRUGINFO	DHJ64U	A186	IND submitted
T46040	DRUGINFO	D2HD0V	Asundexian	Phase 3
T46040	DRUGINFO	D9DWC6	Abelacimab	Phase 2
T46040	DRUGINFO	DZD7W6	MK-2060	Phase 2
T46040	DRUGINFO	D07LPT	EP-7041	Phase 1
T46040	DRUGINFO	D4P8YO	AB023	Phase 1
T46040	DRUGINFO	DU6SH2	A336	Phase 1

T91894	TARGETID	T91894
T91894	FORMERID	TTDI02313
T91894	UNIPROID	MAS_HUMAN
T91894	TARGNAME	Proto-oncogene Mas (MAS)
T91894	GENENAME	MAS1
T91894	TARGTYPE	Clinical trial
T91894	SYNONYMS	MGRA; MAS1 proto-oncogene, G protein-coupled receptor
T91894	FUNCTION	Acts specifically as a functional antagonist of AGTR1 (angiotensin-2 type 1 receptor), although it up-regulates AGTR1 receptor levels. Positive regulation of AGTR1 levels occurs through activation of the G-proteins GNA11 and GNAQ, and stimulation of the protein kinase C signaling cascade. The antagonist effect on AGTR1 function is probably due to AGTR1 being physically altered by MAS1. Receptor for angiotensin 1-7.
T91894	BIOCLASS	GPCR rhodopsin
T91894	SEQUENCE	MDGSNVTSFVVEEPTNISTGRNASVGNAHRQIPIVHWVIMSISPVGFVENGILLWFLCFRMRRNPFTVYITHLSIADISLLFCIFILSIDYALDYELSSGHYYTIVTLSVTFLFGYNTGLYLLTAISVERCLSVLYPIWYRCHRPKYQSALVCALLWALSCLVTTMEYVMCIDREEESHSRNDCRAVIIFIAILSFLVFTPLMLVSSTILVVKIRKNTWASHSSKLYIVIMVTIIIFLIFAMPMRLLYLLYYEYWSTFGNLHHISLLFSTINSSANPFIYFFVGSSKKKRFKESLKVVLTRAFKDEMQPRRQKDNCNTVTVETVV
T91894	DRUGINFO	D01TEA	DSC-127	Phase 3
T91894	DRUGINFO	D0MH8O	Angiotensin-(1-7)	Phase 3
T91894	DRUGINFO	D02VJX	AVE 0991	Investigative
T91894	DRUGINFO	D03QFD	AR234960	Investigative
T91894	DRUGINFO	D0Z2FF	AR244555	Investigative

T86918	TARGETID	T86918
T86918	FORMERID	TTDS00397
T86918	UNIPROID	AMYP_HUMAN
T86918	TARGNAME	Pancreatic alpha-amylase (AMY2A)
T86918	GENENAME	AMY2A
T86918	TARGTYPE	Clinical trial
T86918	SYNONYMS	PA; 1,4-alpha-D-glucan glucanohydrolase
T86918	FUNCTION	Hydrolyses alpha bonds of large, alpha-linked polysaccharides, such as starch and glycogen, yielding glucose and maltose.
T86918	PDBSTRUC	5VA9; 5U3A; 5TD4; 5KEZ; 5EMY
T86918	BIOCLASS	Glycosylase
T86918	ECNUMBER	EC 3.2.1.1
T86918	SEQUENCE	MKFFLLLFTIGFCWAQYSPNTQQGRTSIVHLFEWRWVDIALECERYLAPKGFGGVQVSPPNENVAIYNPFRPWWERYQPVSYKLCTRSGNEDEFRNMVTRCNNVGVRIYVDAVINHMCGNAVSAGTSSTCGSYFNPGSRDFPAVPYSGWDFNDGKCKTGSGDIENYNDATQVRDCRLTGLLDLALEKDYVRSKIAEYMNHLIDIGVAGFRLDASKHMWPGDIKAILDKLHNLNSNWFPAGSKPFIYQEVIDLGGEPIKSSDYFGNGRVTEFKYGAKLGTVIRKWNGEKMSYLKNWGEGWGFVPSDRALVFVDNHDNQRGHGAGGASILTFWDARLYKMAVGFMLAHPYGFTRVMSSYRWPRQFQNGNDVNDWVGPPNNNGVIKEVTINPDTTCGNDWVCEHRWRQIRNMVIFRNVVDGQPFTNWYDNGSNQVAFGRGNRGFIVFNNDDWSFSLTLQTGLPAGTYCDVISGDKINGNCTGIKIYVSDDGKAHFSISNSAEDPFIAIHAESKL
T86918	DRUGINFO	D0A5DJ	Pancrecarb	NDA filed
T86918	DRUGINFO	D0T9LR	Liprotamase	Phase 3
T86918	DRUGINFO	D03AHW	Acarbose Derived Hexasaccharide	Investigative
T86918	DRUGINFO	D06PCE	Maltosyl-Alpha (1,4)-D-Gluconhydroximo-1,5-Lactam	Investigative
T86918	DRUGINFO	D07WIB	Hydroxycitric acid	Investigative
T86918	DRUGINFO	D09WFG	Alpha-acarviosinyl-(1-->9)-3-alpha-D-glucopyranosylpropen	Investigative
T86918	DRUGINFO	D0A5MA	Alpha-acarviosinyl-(1-->7)-3-alpha-D-glucopyranosylpropen	Investigative
T86918	DRUGINFO	D0P8YV	5-Hydroxymethyl-Chonduritol	Investigative
T86918	DRUGINFO	D0Y9RY	4,6-Dideoxy-4-Amino-Alpha-D-Glucose	Investigative
T86918	DRUGINFO	D09CXQ	Acanthus ilicifolius Linn	Investigative
T86918	DRUGINFO	D0E0VN	6-Deoxy-Alpha-D-Glucose	Investigative
T86918	DRUGINFO	D0U7QA	Pyroglutamic Acid	Investigative
T86918	DRUGINFO	D07ONX	Beta-D-Glucose	Investigative

T96476	TARGETID	T96476
T96476	FORMERID	TTDI02129
T96476	UNIPROID	MSP1_PLAFW
T96476	TARGNAME	Plasmodium Merozoite surface protein 1 (Malaria MSP-1)
T96476	GENENAME	Malaria MSP-1
T96476	TARGTYPE	Clinical trial
T96476	SYNONYMS	p195; PMMSA; Merozoite surface protein 1; Merozoite surface antigens
T96476	FUNCTION	MSP-1 complex targets spectrin, a complex on the internal surface of the cell membrane of a red blood cell. The majority of the MSP-1 complex is shed upon entry into the red blood cell, but a small portion of the C-terminus, called MSP-119, is conserved.
T96476	PDBSTRUC	2MUE; 2MU7; 2FLG; 1CEJ
T96476	BIOCLASS	Merozoite surface protein
T96476	SEQUENCE	MKIIFFLCSFLFFIINTQCVTHESYQELVKKLEALEDAVLTGYSLFQKEKMVLNEGTSGTAVTTSTPGSKGSVASGGSGGSVASGGSVASGGSVASGGSVASGGSGNSRRTNPSDNSSDSDAKSYADLKHRVRNYLLTIKELKYPQLFDLTNHMLTLCDNIHGFKYLIDGYEEINELLYKLNFYFDLLRAKLNDVCANDYCQIPFNLKIRANELDVLKKLVFGYRKPLDNIKDNVGKMEDYIKKNKKTIENINELIEESKKTIDKNKNATKEEEKKKLYQAQYDLSIYNKQLEEAHNLISVLEKRIDTLKKNENIKELLDKINEIKNPPPANSGNTPNTLLDKNKKIEEHEKEIKEIAKTIKFNIDSLFTDPLELEYYLREKNKNIDISAKVETKESTEPNEYPNGVTYPLSYNDINNALNELNSFGDLINPFDYTKEPSKNIYTDNERKKFINEIKEKIKIEKKKIESDKKSYEDRSKSLNDITKEYEKLLNEIYDSKFNNNIDLTNFEKMMGKRYSYKVEKLTHHNTFASYENSKHNLEKLTKALKYMEDYSLRNIVVEKELKYYKNLISKIENEIETLVENIKKDEEQLFEKKITKDENKPDEKILEVSDIVKVQVQKVLLMNKIDELKKTQLILKNVELKHNIHVPNSYKQENKQEPYYLIVLKKEIDKLKVFMPKVESLINEEKKNIKTEGQSDNSEPSTEGEITGQATTKPGQQAGSALEGDSVQAQAQEQKQAQPPVPVPVPEAKAQVPTPPAPVNNKTENVSKLDYLEKLYEFLNTSYICHKYILVSHSTMNEKILKQYKITKEEESKLSSCDPLDLLFNIQNNIPVMYSMFDSLNNSLSQLFMEIYEKEMVCNLYKLKDNDKIKNLLEEAKKVSTSVKTLSSSSMQPLSLTPQDKPEVSANDDTSHSTNLNNSLKLFENILSLGKNKNIYQELIGQKSSENFYEKILKDSDTFYNESFTNFVKSKADDINSLNDESKRKKLEEDINKLKKTLQLSFDLYNKYKLKLERLFDKKKTVGKYKMQIKKLTLLKEQLESKLNSLNNPKHVLQNFSVFFNKKKEAEIAETENTLENTKILLKHYKGLVKYYNGESSPLKTLSEESIQTEDNYASLENFKVLSKLEGKLKDNLNLEKKKLSYLSSGLHHLIAELKEVIKNKNYTGNSPSENNTDVNNALESYKKFLPEGTDVATVVSESGSDTLEQSQPKKPASTHVGAESNTITTSQNVDDEVDDVIIVPIFGESEEDYDDLGQVVTGEAVTPSVIDNILSKIENEYEVLYLKPLAGVYRSLKKQLENNVMTFNVNVKDILNSRFNKRENFKNVLESDLIPYKDLTSSNYVVKDPYKFLNKEKRDKFLSSYNYIKDSIDTDINFANDVLGYYKILSEKYKSDLDSIKKYINDKQGENEKYLPFLNNIETLYKTVNDKIDLFVIHLEAKVLNYTYEKSNVEVKIKELNYLKTIQDKLADFKKNNNFVGIADLSTDYNHNNLLTKFLSTGMVFENLAKTVLSNLLDGNLQGMLNISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPTCNENNGGCDADAKCTEEDSGSNGKKITCECTKPDSYPLFDGIFCSSSNFLGISFLLILMLILYSFI
T96476	DRUGINFO	D0B1TT	AdCh63-MSP1	Phase 1/2

T66120	TARGETID	T66120
T66120	FORMERID	TTDR00676
T66120	UNIPROID	KDSB_ECOLI
T66120	TARGNAME	Bacterial Deoxy-manno-octulosonate cytidylyltransferase (Bact kdsB)
T66120	GENENAME	Bact kdsB
T66120	TARGTYPE	Clinical trial
T66120	SYNONYMS	kdsB; CMP-KDO synthetase; CMP-2-keto-3-deoxyoctulosonic acid synthetase; CKS; 3-deoxy-D-manno-octulosonate cytidylytransferase
T66120	FUNCTION	Activates KDO (a required 8-carbon sugar) for incorporation into bacterial lipopolysaccharide in Gram-negative bacteria.
T66120	PDBSTRUC	3K8E; 3K8D; 1VH1
T66120	BIOCLASS	Kinase
T66120	ECNUMBER	EC 2.7.7.38
T66120	SEQUENCE	MSFVVIIPARYASTRLPGKPLVDINGKPMIVHVLERARESGAERIIVATDHEDVARAVEAAGGEVCMTRADHQSGTERLAEVVEKCAFSDDTVIVNVQGDEPMIPATIIRQVADNLAQRQVGMATLAVPIHNAEEAFNPNAVKVVLDAEGYALYFSRATIPWDRDRFAEGLETVGDNFLRHLGIYGYRAGFIRRYVNWQPSPLEHIEMLEQLRVLWYGEKIHVAVAQEVPGTGVDTPEDLERVRAEMR
T66120	DRUGINFO	D03ZKM	UX-001	Phase 3
T66120	DRUGINFO	D0G7CG	Cmp-2-Keto-3-Deoxy-Octulosonic Acid	Investigative
T66120	DRUGINFO	D07XZT	Cytidine-5'-Diphosphate	Investigative
T66120	DRUGINFO	D0S2QZ	Cytidine-5'-Monophosphate	Investigative

T11005	TARGETID	T11005
T11005	FORMERID	TTDI02097
T11005	UNIPROID	IFNW1_HUMAN
T11005	TARGNAME	Interferon-omega (IFNW1)
T11005	GENENAME	IFNW1
T11005	TARGTYPE	Clinical trial
T11005	SYNONYMS	Interferon omega1; Interferon omega-1; Interferon alphaII1; Interferon alpha-II-1
T11005	FUNCTION	extracellular space, cytokine activity, cytokine receptor binding, type I interferon receptor binding, adaptive immune response, B cell differentiation, B cell proliferation, cell cycle arrest, cytokine-mediated signaling pathway, humoral immune response.
T11005	PDBSTRUC	3SE4
T11005	BIOCLASS	Cytokine: interferon
T11005	SEQUENCE	MALLFPLLAALVMTSYSPVGSLGCDLPQNHGLLSRNTLVLLHQMRRISPFLCLKDRRDFRFPQEMVKGSQLQKAHVMSVLHEMLQQIFSLFHTERSSAAWNMTLLDQLHTGLHQQLQHLETCLLQVVGEGESAGAISSPALTLRRYFQGIRVYLKEKKYSDCAWEVVRMEIMKSLFLSTNMQERLRSKDRDLGSS
T11005	DRUGINFO	D0Z0TU	ITCA-638	Phase 2

T00239	TARGETID	T00239
T00239	FORMERID	TTDR00086
T00239	UNIPROID	IL4_HUMAN
T00239	TARGNAME	Interleukin-4 (IL4)
T00239	GENENAME	IL4
T00239	TARGTYPE	Clinical trial
T00239	SYNONYMS	Pitrakinra; Lymphocyte stimulatory factor 1; IL-4; Binetrakin; BSF-1; B-cell stimulatory factor 1
T00239	FUNCTION	It is a costimulator of DNA-synthesis. It induces the expression of class II MHC molecules on resting B-cells. It enhances both secretion and cell surface expression of IgE and IgG1. It also regulates the expression of the low affinity Fc receptor for IgE (CD23) on both lymphocytes and monocytes. Positively regulates IL31RA expression in macrophages. Stimulates autophagy in dendritic cells by interfering with mTORC1 signaling and through the induction of RUFY4. Participates in at least several B-cell activation processes as well as of other cell types.
T00239	PDBSTRUC	5FHX; 4YDY; 3QB7; 3BPN; 3BPL
T00239	BIOCLASS	Cytokine: interleukin
T00239	SEQUENCE	MGLTSQLLPPLFFLLACAGNFVHGHKCDITLQEIIKTLNSLTEQKTLCTELTVTDIFAASKNTTEKETFCRAATVLRQFYSHHEKDTRCLGATAQQFHRHKQLIRFLKRLDRNLWGLAGLNSCPVKEANQSTLENFLERLKTIMREKYSKCSS
T00239	DRUGINFO	DP2UR8	Dexpramipexole	Phase 3
T00239	DRUGINFO	D0I9DN	IL-4R	Phase 2
T00239	DRUGINFO	D0NO1L	Pascolizumab	Phase 2
T00239	DRUGINFO	D00KQN	PEGylated pitrakinra	Phase 2
T00239	DRUGINFO	D04WMR	Tepoxalin	Phase 2
T00239	DRUGINFO	DF5R7E	Romilkimab	Phase 2
T00239	DRUGINFO	D0O4SH	SAR-156597	Phase 2
T00239	DRUGINFO	D1LP4B	PF-07264660	Phase 1
T00239	DRUGINFO	DIWU14	PF-07275315	Phase 1

T44862	TARGETID	T44862
T44862	FORMERID	TTDI02329
T44862	UNIPROID	PP65_HCMVA
T44862	TARGNAME	Cytomegalovirus 65kDa phosphoprotein (HCV UL83)
T44862	GENENAME	HCV UL83
T44862	TARGTYPE	Clinical trial
T44862	SYNONYMS	pp65; UL83; Tegument protein UL83; Phosphoprotein UL83; 65 kDa phosphoprotein; 65 kDa matrix phosphoprotein
T44862	FUNCTION	Counteracts thehost antiviral immune response when activated and phosphorylated, by preventing IRF3 from entering the nucleus. Also participates in the transactivation of viral major immediate-early genes by the recruitment of host IFI16 to the promoters pf these genes.
T44862	PDBSTRUC	3GSO; 2X4T; 2X4R
T44862	BIOCLASS	Herpesviridae pp65
T44862	SEQUENCE	MESRGRRCPEMISVLGPISGHVLKAVFSRGDTPVLPHETRLLQTGIHVRVSQPSLILVSQYTPDSTPCHRGDNQLQVQHTYFTGSEVENVSVNVHNPTGRSICPSQEPMSIYVYALPLKMLNIPSINVHHYPSAAERKHRHLPVADAVIHASGKQMWQARLTVSGLAWTRQQNQWKEPDVYYTSAFVFPTKDVALRHVVCAHELVCSMENTRATKMQVIGDQYVKVYLESFCEDVPSGKLFMHVTLGSDVEEDLTMTRNPQPFMRPHERNGFTVLCPKNMIIKPGKISHIMLDVAFTSHEHFGLLCPKSIPGLSISGNLLMNGQQIFLEVQAIRETVELRQYDPVAALFFFDIDLLLQRGPQYSEHPTFTSQYRIQGKLEYRHTWDRHDEGAAQGDDDVWTSGSDSDEELVTTERKTPRVTGGGAMAGASTSAGRKRKSASSATACTSGVMTRGRLKAESTVAPEEDTDEDSDNEIHNPAVFTWPPWQAGILARNLVPMVATVQGQNLKYQEFFWDANDIYRIFAELEGVWQPAAQPKRRRHRQDALPGPCIASTPKKHRG
T44862	DRUGINFO	D0V0VR	CMVpp65-A0201	Phase 2

T67363	TARGETID	T67363
T67363	FORMERID	TTDI01789
T67363	UNIPROID	ITAV_HUMAN-ITB3_HUMAN
T67363	TARGNAME	Integrin alpha-V/beta-3 (ITGAV/B3)
T67363	GENENAME	ITGAV-ITGB3
T67363	TARGTYPE	Clinical trial
T67363	SYNONYMS	Integrin alphaVbeta3; Integrin alpha-v beta-3; Integrin alpha V beta 3; Alpha(v)beta(3) Integrin; Alpha v beta 3 integrin
T67363	FUNCTION	Receptor for phagocytosis on macrophages or dendritic cells. In cancer and other diseases, its role in angiogenesis is directly responsible to providing blood supply to problematic overgrowths.
T67363	BIOCLASS	Integrin
T67363	SEQUENCE	MRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLGSPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRPDDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFGAFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSRNRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCHVGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLSMDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDTVSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGTFECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFGKITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLLCSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRYCRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDILVVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTFTNITYRGTMAFPPRRRLRLGPRGLPLLLSGLLLPLCRAFNLDVDSPAEYSGPEGSYFGFAVDFFVPSASSRMFLLVGAPKANTTQPGIVEGGQVLKCDWSSTRRCQPIEFDATGNRDYAKDDPLEFKSHQWFGASVRSKQDKILACAPLYHWRTEMKQEREPVGTCFLQDGTKTVEYAPCRSQDIDADGQGFCQGGFSIDFTKADRVLLGGPGSFYWQGQLISDQVAEIVSKYDPNVYSIKYNNQLATRTAQAIFDDSYLGYSVAVGDFNGDGIDDFVSGVPRAARTLGMVYIYDGKNMSSLYNFTGEQMAAYFGFSVAATDINGDDYADVFIGAPLFMDRGSDGKLQEVGQVSVSLQRASGDFQTTKLNGFEVFARFGSAIAPLGDLDQDGFNDIAIAAPYGGEDKKGIVYIFNGRSTGLNAVPSQILEGQWAARSMPPSFGYSMKGATDIDKNGYPDLIVGAFGVDRAILYRARPVITVNAGLEVYPSILNQDNKTCSLPGTALKVSCFNVRFCLKADGKGVLPRKLNFQVELLLDKLKQKGAIRRALFLYSRSPSHSKNMTISRGGLMQCEELIAYLRDESEFRDKLTPITIFMEYRLDYRTAADTTGLQPILNQFTPANISRQAHILLDCGEDNVCKPKLEVSVDSDQKKIYIGDDNPLTLIVKAQNQGEGAYEAELIVSIPLQADFIGVVRNNEALARLSCAFKTENQTRQVVCDLGNPMKAGTQLLAGLRFSVHQQSEMDTSVKFDLQIQSSNLFDKVSPVVSHKVDLAVLAAVEIRGVSSPDHVFLPIPNWEHKENPETEEDVGPVVQHIYELRNNGPSSFSKAMLHLQWPYKYNNNTLLYILHYDIDGPMNCTSDMEINPLRIKISSLQTTEKNDTVAGQGERDHLITKRDLALSEGDIHTLGCGVAQCLKIVCQVGRLDRGKSAILYVKSLLWTETFMNKENQNHSYSLKSSASFNVIEFPYKNLPIEDITNSTLVTTNVTWGIQPAPMPVPVWVIILAVLAGLLLLAVLVFVMYRMGFFKRVRPPQEEQEREQLQPHENGEGNSET
T67363	DRUGINFO	D09ZXO	Cilengitide	Phase 3
T67363	DRUGINFO	D09WCN	Intetumumab	Phase 2
T67363	DRUGINFO	D0D7DU	VLTS-589	Phase 2
T67363	DRUGINFO	D0X4IH	Fluciclatide F-18	Phase 2
T67363	DRUGINFO	D00QVT	ATN-161	Phase 2
T67363	DRUGINFO	D0TT6L	SF0166	Phase 1/2
T67363	DRUGINFO	D08XBF	AMEP	Phase 1
T67363	DRUGINFO	D04HLE	Vitaxin	Discontinued in Phase 2
T67363	DRUGINFO	D0B9SR	SB-273005	Discontinued in Phase 1
T67363	DRUGINFO	D02VIP	SB-267268	Discontinued in Phase 1
T67363	DRUGINFO	D04YEY	PS-388023	Terminated
T67363	DRUGINFO	D02DGT	IS20I	Investigative
T67363	DRUGINFO	D02SZF	18F-SMIBR-K5	Investigative

T15167	TARGETID	T15167
T15167	FORMERID	TTDI01960
T15167	UNIPROID	CO1A2_HUMAN
T15167	TARGNAME	Collagen I (COL1A2)
T15167	GENENAME	COL1A2
T15167	TARGTYPE	Clinical trial
T15167	SYNONYMS	Collagen alpha-2(I) chain; Alpha-2 type I collagen
T15167	FUNCTION	Type I collagen is a member of group I collagen (fibrillar forming collagen).
T15167	PDBSTRUC	5CVA; 5CTI; 5CTD
T15167	SEQUENCE	MLSFVDTRTLLLLAVTLCLATCQSLQEETVRKGPAGDRGPRGERGPPGPPGRDGEDGPTGPPGPPGPPGPPGLGGNFAAQYDGKGVGLGPGPMGLMGPRGPPGAAGAPGPQGFQGPAGEPGEPGQTGPAGARGPAGPPGKAGEDGHPGKPGRPGERGVVGPQGARGFPGTPGLPGFKGIRGHNGLDGLKGQPGAPGVKGEPGAPGENGTPGQTGARGLPGERGRVGAPGPAGARGSDGSVGPVGPAGPIGSAGPPGFPGAPGPKGEIGAVGNAGPAGPAGPRGEVGLPGLSGPVGPPGNPGANGLTGAKGAAGLPGVAGAPGLPGPRGIPGPVGAAGATGARGLVGEPGPAGSKGESGNKGEPGSAGPQGPPGPSGEEGKRGPNGEAGSAGPPGPPGLRGSPGSRGLPGADGRAGVMGPPGSRGASGPAGVRGPNGDAGRPGEPGLMGPRGLPGSPGNIGPAGKEGPVGLPGIDGRPGPIGPAGARGEPGNIGFPGPKGPTGDPGKNGDKGHAGLAGARGAPGPDGNNGAQGPPGPQGVQGGKGEQGPPGPPGFQGLPGPSGPAGEVGKPGERGLHGEFGLPGPAGPRGERGPPGESGAAGPTGPIGSRGPSGPPGPDGNKGEPGVVGAVGTAGPSGPSGLPGERGAAGIPGGKGEKGEPGLRGEIGNPGRDGARGAPGAVGAPGPAGATGDRGEAGAAGPAGPAGPRGSPGERGEVGPAGPNGFAGPAGAAGQPGAKGERGAKGPKGENGVVGPTGPVGAAGPAGPNGPPGPAGSRGDGGPPGMTGFPGAAGRTGPPGPSGISGPPGPPGPAGKEGLRGPRGDQGPVGRTGEVGAVGPPGFAGEKGPSGEAGTAGPPGTPGPQGLLGAPGILGLPGSRGERGLPGVAGAVGEPGPLGIAGPPGARGPPGAVGSPGVNGAPGEAGRDGNPGNDGPPGRDGQPGHKGERGYPGNIGPVGAAGAPGPHGPVGPAGKHGNRGETGPSGPVGPAGAVGPRGPSGPQGIRGDKGEPGEKGPRGLPGLKGHNGLQGLPGIAGHHGDQGAPGSVGPAGPRGPAGPSGPAGKDGRTGHPGTVGPAGIRGPQGHQGPAGPPGPPGPPGPPGVSGGGYDFGYDGDFYRADQPRSAPSLRPKDYEVDATLKSLNNQIETLLTPEGSRKNPARTCRDLRLSHPEWSSGYYWIDPNQGCTMDAIKVYCDFSTGETCIRAQPENIPAKNWYRSSKDKKHVWLGETINAGSQFEYNVEGVTSKEMATQLAFMRLLANYASQNITYHCKNSIAYMDEETGNLKKAVILQGSNDVELVAEGNSRFTYTVLVDGCSKKTNEWGKTIIEYKTNKPSRLPFLDIAPLDIGGADQEFFVDIGPVCFK
T15167	DRUGINFO	D02CFV	Solubilized type 1 native bovine collagen	Phase 2

T78114	TARGETID	T78114
T78114	FORMERID	TTDI02050
T78114	UNIPROID	DAF_HUMAN
T78114	TARGNAME	Complement decay-accelerating factor (CD55)
T78114	GENENAME	CD55
T78114	TARGTYPE	Clinical trial
T78114	SYNONYMS	DAF; Complement decayaccelerating factor; CR
T78114	FUNCTION	Interaction of daf with cell-associated C4b and C3b polypeptides interferes with their ability to catalyze the conversion of C2 and factor B to enzymatically active C2a and Bb and thereby prevents the formation of C4b2a and C3bBb, the amplification convertases of the complement cascade. Inhibits complement activation by destabilizing and preventing the formation of C3 and C5 convertases, which prevents complement damage. This protein recognizes C4b and C3b fragments that condense with cell-surface hydroxyl or amino groups when nascent C4b and C3b are locally generated during C4 and c3 activation.
T78114	PDBSTRUC	6ILK; 6ILJ; 5FOA; 3J24; 3IYP
T78114	SEQUENCE	MTVARPSVPAALPLLGELPRLLLLVLLCLPAVWGDCGLPPDVPNAQPALEGRTSFPEDTVITYKCEESFVKIPGEKDSVICLKGSQWSDIEEFCNRSCEVPTRLNSASLKQPYITQNYFPVGTVVEYECRPGYRREPSLSPKLTCLQNLKWSTAVEFCKKKSCPNPGEIRNGQIDVPGGILFGATISFSCNTGYKLFGSTSSFCLISGSSVQWSDPLPECREIYCPAPPQIDNGIIQGERDHYGYRQSVTYACNKGFTMIGEHSIYCTVNNDEGEWSGPPPECRGKSLTSKVPPTVQKPTTVNVPTTEVSPTSQKTTTKTTTPNAQATRSTPVSRTTKHFHETTPNKGSGTTSGTTRLLSGHTCFTLTGLLGTLVTMGLLT
T78114	DRUGINFO	D0C4BL	Coxsackievirus A21	Phase 2
T78114	DRUGINFO	D00UOQ	PAT-SC1	Phase 1/2
T78114	DRUGINFO	D02WLS	Onyvax-105	Phase 1/2

T46263	TARGETID	T46263
T46263	FORMERID	TTDI02011
T46263	UNIPROID	4F2_HUMAN
T46263	TARGNAME	Lymphocyte activation antigen 4F2 (SLC3A2)
T46263	GENENAME	SLC3A2
T46263	TARGTYPE	Clinical trial
T46263	SYNONYMS	SLC3A2; Lymphocyte activation antigen 4F2 large subunit; CD98; 4F2hc; 4F2 heavy chain antigen; 4F2 cellsurface antigen heavy chain
T46263	FUNCTION	Required for the function of light chain amino-acid transporters. Involved in sodium-independent, high-affinity transport of large neutral amino acids such as phenylalanine, tyrosine, leucine, arginine and tryptophan. Involved in guiding and targeting of LAT1 and LAT2 to the plasma membrane. When associated with SLC7A6 or SLC7A7 acts as an arginine/glutamine exchanger, following an antiport mechanism for amino acid transport, influencing arginine release in exchange for extracellular amino acids. Plays a role in nitric oxide synthesis in human umbilical vein endothelial cells (HUVECs) via transport of L-arginine. Required for normal and neoplastic cell growth. When associated with SLC7A5/LAT1, is also involved in the transport of L-DOPA across the blood-brain barrier, and that of thyroid hormones triiodothyronine (T3) and thyroxine (T4) across the cell membrane in tissues such as placenta. Involved in the uptake of methylmercury (MeHg) when administered as the L-cysteine or D,L-homocysteine complexes, and hence plays a role in metal ion homeostasis and toxicity. When associated with SLC7A5 or SLC7A8, involved in the cellular activity of small molecular weight nitrosothiols, via the stereoselective transport of L- nitrosocysteine (L-CNSO) across the transmembrane. Together with ICAM1, regulates the transport activity LAT2 in polarized intestinal cells, by generating and delivering intracellular signals. Whenassociated with SLC7A5, plays an important role in transporting L-leucine from the circulating blood to the retina across the inner blood-retinal barrier.
T46263	PDBSTRUC	6IRT; 6IRS; 2DH3; 2DH2
T46263	SEQUENCE	MELQPPEASIAVVSIPRQLPGSHSEAGVQGLSAGDDSELGSHCVAQTGLELLASGDPLPSASQNAEMIETGSDCVTQAGLQLLASSDPPALASKNAEVTGTMSQDTEVDMKEVELNELEPEKQPMNAASGAAMSLAGAEKNGLVKIKVAEDEAEAAAAAKFTGLSKEELLKVAGSPGWVRTRWALLLLFWLGWLGMLAGAVVIIVRAPRCRELPAQKWWHTGALYRIGDLQAFQGHGAGNLAGLKGRLDYLSSLKVKGLVLGPIHKNQKDDVAQTDLLQIDPNFGSKEDFDSLLQSAKKKSIRVILDLTPNYRGENSWFSTQVDTVATKVKDALEFWLQAGVDGFQVRDIENLKDASSFLAEWQNITKGFSEDRLLIAGTNSSDLQQILSLLESNKDLLLTSSYLSDSGSTGEHTKSLVTQYLNATGNRWCSWSLSQARLLTSFLPAQLLRLYQLMLFTLPGTPVFSYGDEIGLDAAALPGQPMEAPVMLWDESSFPDIPGAVSANMTVKGQSEDPGSLLSLFRRLSDQRSKERSLLHGDFHAFSAGPGLFSYIRHWDQNERFLVVLNFGDVGLSAGLQASDLPASASLPAKADLLLSTQPGREEGSPLELERLKLEPHEGLLLRFPYAA
T46263	DRUGINFO	D0OQ5R	IGN523	Phase 1

T96623	TARGETID	T96623
T96623	UNIPROID	HS90B_HUMAN
T96623	TARGNAME	Heat shock protein 90 beta (HSP90B)
T96623	GENENAME	HSP90AB1
T96623	TARGTYPE	Clinical trial
T96623	SYNONYMS	Heat shock 84 kDa; HSP84; HSP 84
T96623	FUNCTION	Molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved for instance in cell cycle control and signal transduction. Undergoes a functional cycle that is linked to its ATPase activity. This cycle probably induces conformational changes in the client proteins, thereby causing their activation. Interacts dynamically with various co-chaperones that modulate its substrate recognition, ATPase cycle and chaperone function (PubMed:16478993, PubMed:19696785). Engages with a range of client protein classes via its interaction with various co-chaperone proteins or complexes, that act as adapters, simultaneously able to interact with the specific client and the central chaperone itself. Recruitment of ATP and co-chaperone followed by client protein forms a functional chaperone. After the completion of the chaperoning process, properly folded client protein and co-chaperone leave HSP90 in an ADP-bound partially open conformation and finally, ADP is released from HSP90 which acquires an open conformation for the next cycle (PubMed:27295069, PubMed:26991466). Apart from its chaperone activity, it also plays a role in the regulation of the transcription machinery. HSP90 and its co-chaperones modulate transcription at least at three different levels. In the first place, they alter the steady-state levels of certain transcription factors in response to various physiological cues. Second, they modulate the activity of certain epigenetic modifiers, such as histone deacetylases or DNA methyl transferases, and thereby respond to the change in the environment. Third, they participate in the eviction of histones from the promoter region of certain genes and thereby turn on gene expression (PubMed:25973397). Antagonizes STUB1-mediated inhibition of TGF-beta signaling via inhibition of STUB1-mediated SMAD3 ubiquitination and degradation (PubMed:24613385). Promotes cell differentiation by chaperoning BIRC2 and thereby protecting from auto-ubiquitination and degradation by the proteasomal machinery (PubMed:18239673). Main chaperone that is involved in the phosphorylation/activation of the STAT1 by chaperoning both JAK2 and PRKCE under heat shock and in turn, activates its own transcription (PubMed:20353823).
T96623	PDBSTRUC	5UCJ; 5UCI; 5UCH; 5UC4; 5FWP
T96623	BIOCLASS	Heat shock protein
T96623	SEQUENCE	MPEEVHHGEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNASDALDKIRYESLTDPSKLDSGKELKIDIIPNPQERTLTLVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVVVITKHNDDEQYAWESSAGGSFTVRADHGEPIGRGTKVILHLKEDQTEYLEERRVKEVVKKHSQFIGYPITLYLEKEREKEISDDEAEEEKGEKEEEDKDDEEKPKIEDVGSDEEDDSGKDKKKKTKKIKEKYIDQEELNKTKPIWTRNPDDITQEEYGEFYKSLTNDWEDHLAVKHFSVEGQLEFRALLFIPRRAPFDLFENKKKKNNIKLYVRRVFIMDSCDELIPEYLNFIRGVVDSEDLPLNISREMLQQSKILKVIRKNIVKKCLELFSELAEDKENYKKFYEAFSKNLKLGIHEDSTNRRRLSELLRYHTSQSGDEMTSLSEYVSRMKETQKSIYYITGESKEQVANSAFVERVRKRGFEVVYMTEPIDEYCVQQLKEFDGKSLVSVTKEGLELPEDEEEKKKMEESKAKFENLCKLMKEILDKKVEKVTISNRLVSSPCCIVTSTYGWTANMERIMKAQALRDNSTMGYMMAKKHLEINPDHPIVETLRQKAEADKNDKAVKDLVVLLFETALLSSGFSLEDPQTHSNRIYRMIKLGLGIDEDEVAAEEPNAAVPDEIPPLEGDEDASRMEEVD
T96623	DRUGINFO	D07MPL	SNX-5422	Phase 1/2
T96623	DRUGINFO	D01FYA	PU-H71	Phase 1
T96623	DRUGINFO	D0F3NF	TAS-116	Phase 1

T23212	TARGETID	T23212
T23212	FORMERID	TTDR00283
T23212	UNIPROID	CD14_HUMAN
T23212	TARGNAME	Monocyte differentiation antigen CD14 (CD14)
T23212	GENENAME	CD14
T23212	TARGTYPE	Clinical trial
T23212	SYNONYMS	Myeloid cell-specific leucine-rich glycoprotein
T23212	FUNCTION	In concert with LBP, binds to monomeric lipopolysaccharide and delivers it to the LY96/TLR4 complex, thereby mediating the innate immune response to bacterial lipopolysaccharide (LPS). Acts via MyD88, TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Acts as a coreceptor for TLR2:TLR6 heterodimer in response to diacylated lipopeptides and for TLR2:TLR1 heterodimer in response to triacylated lipopeptides, these clusters trigger signaling from the cell surface and subsequently are targeted to the Golgi in a lipid-raft dependent pathway. Binds electronegative LDL (LDL(-)) and mediates the cytokine release induced by LDL(-). Coreceptor for bacterial lipopolysaccharide.
T23212	PDBSTRUC	4GLP
T23212	SEQUENCE	MERASCLLLLLLPLVHVSATTPEPCELDDEDFRCVCNFSEPQPDWSEAFQCVSAVEVEIHAGGLNLEPFLKRVDADADPRQYADTVKALRVRRLTVGAAQVPAQLLVGALRVLAYSRLKELTLEDLKITGTMPPLPLEATGLALSSLRLRNVSWATGRSWLAELQQWLKPGLKVLSIAQAHSPAFSCEQVRAFPALTSLDLSDNPGLGERGLMAALCPHKFPAIQNLALRNTGMETPTGVCAALAAAGVQPHSLDLSHNSLRATVNPSAPRCMWSSALNSLNLSFAGLEQVPKGLPAKLRVLDLSCNRLNRAPQPDELPEVDNLTLDGNPFLVPGTALPHEGSMNSGVVPACARSTLSVGVSGTLVLLQGARGFA
T23212	DRUGINFO	D0UB5A	IC14	Phase 2

T88806	TARGETID	T88806
T88806	FORMERID	TTDI01790
T88806	UNIPROID	ITA5_HUMAN-ITB1_HUMAN
T88806	TARGNAME	Integrin alpha-5/beta-1 (ITGA5/B1)
T88806	GENENAME	ITGA5-ITGB1
T88806	TARGTYPE	Clinical trial
T88806	SYNONYMS	alpha(5)beta(1) integrin; Alpha 5 beta 1 integrin
T88806	FUNCTION	binds to matrix macromolecules and proteinases and thereby stimulates angiogenesis. The interaction of VLA-5 with fibronectin plays an important role in regulating inflammatory cytokine production by human articular chondrocytes.
T88806	BIOCLASS	Integrin
T88806	SEQUENCE	MNLQPIFWIGLISSVCCVFAQTDENRCLKANAKSCGECIQAGPNCGWCTNSTFLQEGMPTSARCDDLEALKKKGCPPDDIENPRGSKDIKKNKNVTNRSKGTAEKLKPEDITQIQPQQLVLRLRSGEPQTFTLKFKRAEDYPIDLYYLMDLSYSMKDDLENVKSLGTDLMNEMRRITSDFRIGFGSFVEKTVMPYISTTPAKLRNPCTSEQNCTSPFSYKNVLSLTNKGEVFNELVGKQRISGNLDSPEGGFDAIMQVAVCGSLIGWRNVTRLLVFSTDAGFHFAGDGKLGGIVLPNDGQCHLENNMYTMSHYYDYPSIAHLVQKLSENNIQTIFAVTEEFQPVYKELKNLIPKSAVGTLSANSSNVIQLIIDAYNSLSSEVILENGKLSEGVTISYKSYCKNGVNGTGENGRKCSNISIGDEVQFEISITSNKCPKKDSDSFKIRPLGFTEEVEVILQYICECECQSEGIPESPKCHEGNGTFECGACRCNEGRVGRHCECSTDEVNSEDMDAYCRKENSSEICSNNGECVCGQCVCRKRDNTNEIYSGKFCECDNFNCDRSNGLICGGNGVCKCRVCECNPNYTGSACDCSLDTSTCEASNGQICNGRGICECGVCKCTDPKFQGQTCEMCQTCLGVCAEHKECVQCRAFNKGEKKDTCTQECSYFNITKVESRDKLPQPVQPDPVSHCKEKDVDDCWFYFTYSVNGNNEVMVHVVENPECPTGPDIIPIVAGVVAGIVLIGLALLLIWKLLMIIHDRREFAKFEKEKMNAKWDTGENPIYKSAVTTVVNPKYEGKMGSRTPESPLHAVQLRWGPRRRPPLLPLLLLLLPPPPRVGGFNLDAEAPAVLSGPPGSFFGFSVEFYRPGTDGVSVLVGAPKANTSQPGVLQGGAVYLCPWGASPTQCTPIEFDSKGSRLLESSLSSSEGEEPVEYKSLQWFGATVRAHGSSILACAPLYSWRTEKEPLSDPVGTCYLSTDNFTRILEYAPCRSDFSWAAGQGYCQGGFSAEFTKTGRVVLGGPGSYFWQGQILSATQEQIAESYYPEYLINLVQGQLQTRQASSIYDDSYLGYSVAVGEFSGDDTEDFVAGVPKGNLTYGYVTILNGSDIRSLYNFSGEQMASYFGYAVAATDVNGDGLDDLLVGAPLLMDRTPDGRPQEVGRVYVYLQHPAGIEPTPTLTLTGHDEFGRFGSSLTPLGDLDQDGYNDVAIGAPFGGETQQGVVFVFPGGPGGLGSKPSQVLQPLWAASHTPDFFGSALRGGRDLDGNGYPDLIVGSFGVDKAVVYRGRPIVSASASLTIFPAMFNPEERSCSLEGNPVACINLSFCLNASGKHVADSIGFTVELQLDWQKQKGGVRRALFLASRQATLTQTLLIQNGAREDCREMKIYLRNESEFRDKLSPIHIALNFSLDPQAPVDSHGLRPALHYQSKSRIEDKAQILLDCGEDNICVPDLQLEVFGEQNHVYLGDKNALNLTFHAQNVGEGGAYEAELRVTAPPEAEYSGLVRHPGNFSSLSCDYFAVNQSRLLVCDLGNPMKAGASLWGGLRFTVPHLRDTKKTIQFDFQILSKNLNNSQSDVVSFRLSVEAQAQVTLNGVSKPEAVLFPVSDWHPRDQPQKEEDLGPAVHHVYELINQGPSSISQGVLELSCPQALEGQQLLYVTRVTGLNCTTNHPINPKGLELDPEGSLHHQQKREAPSRSSASSGPQILKCPEAECFRLRCELGPLHQQESQSLQLHFRVWAKTFLQREHQPFSLQCEAVYKALKMPYRILPRQLPQKERQVATAVQWTKAEGSYGVPLWIIILAILFGLLLLGLLIYILYKLGFFKRSLPYGTAMEKAQLKPPATSDA
T88806	DRUGINFO	D06PVA	Volociximab	Phase 2
T88806	DRUGINFO	D00QVT	ATN-161	Phase 2
T88806	DRUGINFO	D08XBF	AMEP	Phase 1
T88806	DRUGINFO	D0ZV0R	F-200	Terminated

T72195	TARGETID	T72195
T72195	FORMERID	TTDI02019
T72195	UNIPROID	ANXA5_HUMAN
T72195	TARGNAME	Annexin A5 (ANXA5)
T72195	GENENAME	ANXA5
T72195	TARGTYPE	Clinical trial
T72195	SYNONYMS	Vascular anticoagulantalpha; Vascular anticoagulant-alpha; VACalpha; VAC-alpha; Thromboplastin inhibitor; Placental anticoagulant protein I; Placental anticoagulant protein 4; PP4; PAPI; PAP-I; Lipocortin V; Endonexin II; ENX2; Calphobindin I; CBPI; CBP-I; Annexin5; Annexin-5; Annexin V; Anchorin CII; ANX5
T72195	FUNCTION	This protein is an anticoagulant protein that acts as an indirect inhibitor of the thromboplastin-specific complex, which is involved in the blood coagulation cascade.
T72195	PDBSTRUC	2XO3; 2XO2; 1SAV; 1HVG; 1HVF
T72195	BIOCLASS	Annexin protein
T72195	SEQUENCE	MAQVLRGTVTDFPGFDERADAETLRKAMKGLGTDEESILTLLTSRSNAQRQEISAAFKTLFGRDLLDDLKSELTGKFEKLIVALMKPSRLYDAYELKHALKGAGTNEKVLTEIIASRTPEELRAIKQVYEEEYGSSLEDDVVGDTSGYYQRMLVVLLQANRDPDAGIDEAQVEQDAQALFQAGELKWGTDEEKFITIFGTRSVSHLRKVFDKYMTISGFQIEETIDRETSGNLEQLLLAVVKSIRSIPAYLAETLYYAMKGAGTDDHTLIRVMVSRSEIDLFNIRKEFRKNFATSLYSMIKGDTSGDYKKALLLLCGEDD
T72195	DRUGINFO	D07FQL	Diannexin	Phase 2

T41820	TARGETID	T41820
T41820	FORMERID	TTDI02185
T41820	UNIPROID	SYIC_YEAST
T41820	TARGNAME	Fungal Isoleucyl t-RNA synthetase (Fung ILS1)
T41820	GENENAME	Fung ILS1
T41820	TARGTYPE	Clinical trial
T41820	SYNONYMS	Fung Isoleucyl-tRNA synthetase; Fung Isoleucine--tRNA ligase, cytoplasmic; Fung IleRS
T41820	FUNCTION	Has aminoacyl-tRNA editing and isoleucine-tRNA ligase activity.
T41820	BIOCLASS	Carbon-oxygen ligase
T41820	ECNUMBER	EC 6.1.1.5
T41820	SEQUENCE	MSESNAHFSFPKEEEKVLSLWDEIDAFHTSLELTKDKPEFSFFDGPPFATGTPHYGHILASTIKDIVPRYATMTGHHVERRFGWDTHGVPIEHIIDKKLGITGKDDVFKYGLENYNNECRSIVMTYASDWRKTIGRLGRWIDFDNDYKTMYPSFMESTWWAFKQLHEKGQVYRGFKVMPYSTGLTTPLSNFEAQQNYKDVNDPAVTIGFNVIGQEKTQLVAWTTTPWTLPSNLSLCVNADFEYVKIYDETRDRYFILLESLIKTLYKKPKNEKYKIVEKIKGSDLVGLKYEPLFPYFAEQFHETAFRVISDDYVTSDSGTGIVHNAPAFGEEDNAACLKNGVISEDSVLPNAIDDLGRFTKDVPDFEGVYVKDADKLIIKYLTNTGNLLLASQIRHSYPFCWRSDTPLLYRSVPAWFVRVKNIVPQMLDSVMKSHWVPNTIKEKRFANWIANARDWNVSRNRYWGTPIPLWVSDDFEEVVCVGSIKELEELTGVRNITDLHRDVIDKLTIPSKQGKGDLKRIEEVFDCWFESGSMPYASQHYPFENTEKFDERVPANFISEGLDQTRGWFYTLAVLGTHLFGSVPYKNVIVSGIVLAADGRKMSKSLKNYPDPSIVLNKYGADALRLYLINSPVLKAESLKFKEEGVKEVVSKVLLPWWNSFKFLDGQIALLKKMSNIDFQYDDSVKSDNVMDRWILASMQSLVQFIHEEMGQYKLYTVVPKLLNFIDELTNWYIRFNRRRLKGENGVEDCLKALNSLFDALFTFVRAMAPFTPFLSESIYLRLKEYIPEAVLAKYGKDGRSVHFLSYPVVKKEYFDEAIETAVSRMQSVIDLGRNIREKKTISLKTPLKTLVILHSDESYLKDVEALKNYIIEELNVRDVVITSDEAKYGVEYKAVADWPVLGKKLKKDAKKVKDALPSVTSEQVREYLESGKLEVAGIELVKGDLNAIRGLPESAVQAGQETRTDQDVLIIMDTNIYSELKSEGLARELVNRIQKLRKKCGLEATDDVLVEYELVKDTIDFEAIVKEHFDMLSKTCRSDIAKYDGSKTDPIGDEEQSINDTIFKLKVFKL
T41820	DRUGINFO	D09XUY	Icofungipen	Phase 2
T41820	DRUGINFO	D0F1AX	CB-102930	Terminated

T83391	TARGETID	T83391
T83391	FORMERID	TTDC00152
T83391	UNIPROID	F16P1_HUMAN; F16P2_HUMAN
T83391	TARGNAME	Fructose-1,6-bisphosphatase (FBP)
T83391	GENENAME	FBP1; FBP2
T83391	TARGTYPE	Clinical trial
T83391	SYNONYMS	FBPase; D-fructose-1,6-bisphosphate 1-phosphohydrolase
T83391	FUNCTION	Catalyzes the hydrolysis of fructose 1,6-bisphosphate to fructose 6-phosphate in the presence of divalent cations, acting as a rate-limiting enzyme in gluconeogenesis. Plays a role in regulating glucose sensing and insulin secretion of pancreatic beta-cells. Appears to modulate glycerol gluconeogenesis in liver. Important regulator of appetite and adiposity; increased expression of the protein in liver after nutrient excess increases circulating satiety hormones and reduces appetite-stimulating neuropeptides and thus seems to provide a feedback mechanism to limit weight gain.
T83391	BIOCLASS	Phosphoric monoester hydrolase
T83391	SEQUENCE	MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGIAGSTNVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNIDCLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVNCFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYARDFDPAVTEYIQRKKFPPDNSAPYGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGSPDDVLEFLKVYEKHSAQ
T83391	DRUGINFO	D0G2ZL	Managlinat dialanetil	Phase 2
T83391	DRUGINFO	D0KU4M	MB07803	Phase 2
T83391	DRUGINFO	D00XCL	1-(4-aminophenylsulfonyl)-3-(2-mercaptoethyl)urea	Investigative
T83391	DRUGINFO	D0C2YL	2,5-Anhydroglucitol-1,6-Biphosphate	Investigative
T83391	DRUGINFO	D0H3IJ	Fructose-6-Phosphate	Investigative
T83391	DRUGINFO	D0H6WG	1-(2-mercaptoethyl)-3-(m-tolylsulfonyl)urea	Investigative
T83391	DRUGINFO	D0J3EJ	4-(4-(4-Nitrophenyl)thiazol-2-ylamino)phenol	Investigative
T83391	DRUGINFO	D0L8EN	3-(4-(4-Hydroxyphenyl)thiazol-2-ylamino)phenol	Investigative
T83391	DRUGINFO	D0T5OW	2-(4-(4-Hydroxyphenyl)thiazol-2-ylamino)phenol	Investigative
T83391	DRUGINFO	D0X6YR	N-(5-chlorobenzo[d]oxazol-2-yl)benzenesulfonamide	Investigative
T83391	DRUGINFO	D01KOI	4-(2-amino-1,3-thiazol-4-yl)phenol	Investigative
T83391	DRUGINFO	D03GBO	4,6-Dichloro-1H-indole-2-carboxylic acid	Investigative

T04321	TARGETID	T04321
T04321	FORMERID	TTDI02092
T04321	UNIPROID	HLA_STAAU
T04321	TARGNAME	Staphylococcus Alpha-hemolysin (Stap-coc hly)
T04321	GENENAME	Stap-coc hly
T04321	TARGTYPE	Clinical trial
T04321	SYNONYMS	hla; Alpha-toxin; Alpha-hemolysin; Alpha-HL
T04321	FUNCTION	Alpha-toxin binds to the membrane of eukaryotic cells (particularly red blood cells, RBC) forming pores, resulting in hemolysis, with the release of low-molecular weight molecules leading to eventual osmotic RBC lysis. Human RBCs bind much less alpha-toxin than do rabbit RBCs. Heptamer oligomerization and pore formation is required for lytic activity.
T04321	PDBSTRUC	7AHL; 4YHD; 4IDJ; 3M4E; 3M4D
T04321	BIOCLASS	Alpha-hemolysin channel-forming toxin
T04321	SEQUENCE	MKTRIVSSVTTTLLLGSILMNPVAGAADSDINIKTGTTDIGSNTTVKTGDLVTYDKENGMHKKVFYSFIDDKNHNKKLLVIRTKGTIAGQYRVYSEEGANKSGLAWPSAFKVQLQLPDNEVAQISDYYPRNSIDTKEYMSTLTYGFNGNVTGDDTGKIGGLIGANVSIGHTLKYVQPDFKTILESPTDKKVGWKVIFNNMVNQNWGPYDRDSWNPVYGNQLFMKTRNGSMKAADNFLDPNKASSLLSSGFSPDFATVITMDRKASKQQTNIDVIYERVRDDYQLHWTSTNWKGTNTKDKWTDRSSERYKIDWEKEEMTN
T04321	DRUGINFO	D0VP9E	Cyrtominetin	Phase 3
T04321	DRUGINFO	DN8F1Z	AR-301	Phase 3
T04321	DRUGINFO	D0Q9XE	MEDI4893	Phase 2b
T04321	DRUGINFO	D0Z2NJ	ASN100	Phase 2

T49639	TARGETID	T49639
T49639	FORMERID	TTDR00169
T49639	UNIPROID	HS71A_HUMAN; HS71B_HUMAN
T49639	TARGNAME	Heat shock protein 70 (HSP70)
T49639	GENENAME	HSPA1A; HSPA1B
T49639	TARGTYPE	Clinical trial
T49639	SYNONYMS	Heat shock 70 kDa protein; HSP72; HSP70
T49639	FUNCTION	In unstressed cells, is present in a HSP90-containing multichaperone complex that maintains it in a non-DNA-binding inactivated monomeric form. Upon exposure to heat and other stress stimuli, undergoes homotrimerization and activates HSP gene transcription through binding to site-specific heat shock elements (HSEs) present in the promoter regions of HSP genes. Activation is reversible, and during the attenuation and recovery phase period of the HSR, returns to its unactivated form. Binds to inverted 5'-NGAAN-3' pentamer DNA sequences. Binds to chromatin at heat shock gene promoters. Plays also several other functions independently of its transcriptional activity. Involved in the repression of Ras-induced transcriptional activation of the c-fos gene in heat-stressed cells. Positively regulates pre-mRNA 3'-end processing and polyadenylation of HSP70 mRNA upon heat-stressed cells in a symplekin (SYMPK)-dependent manner. Plays a role in nuclear export of stress-induced HSP70 mRNA. Plays a role in the regulation of mitotic progression. Plays also a role as a negative regulator of non-homologous end joining (NHEJ) repair activity in a DNA damage-dependent manner. Involved in stress-induced cancer cell proliferation in a IER5-dependent manner. Function as a stress-inducible and DNA-binding transcription factor that plays a central role in the transcriptional activation of the heat shock response (HSR), leading to the expression of a large class of molecular chaperones heat shock proteins (HSPs) that protect cells from cellular insults' damage.
T49639	BIOCLASS	Heat shock protein
T49639	SEQUENCE	MAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVINDGDKPKVQVSYKGETKAFYPEEISSMVLTKMKEIAEAYLGYPVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTAAAIAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLVNHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSSSTQASLEIDSLFEGIDFYTSITRARFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPKVQKLLQDFFNGRDLNKSINPDEAVAYGAAVQAAILMGDKSENVQDLLLLDVAPLSLGLETAGGVMTALIKRNSTIPTKQTQIFTTYSDNQPGVLIQVYEGERAMTKDNNLLGRFELSGIPPAPRGVPQIEVTFDIDANGILNVTATDKSTGKANKITITNDKGRLSKEEIERMVQEAEKYKAEDEVQRERVSAKNALESYAFNMKSAVEDEGLKGKISEADKKKVLDKCQEVISWLDANTLAEKDEFEHKRKELEQVCNPIISGLYQGAGGPGPGGFGAQGPKGGSGSGPTIEEVD
T49639	DRUGINFO	D06KIJ	AG-858	Phase 2
T49639	DRUGINFO	D09POH	AEG-33773	Phase 2
T49639	DRUGINFO	D05BSG	Enkastim-ev	Phase 1
T49639	DRUGINFO	D05UFJ	Minnelide 001	Phase 1
T49639	DRUGINFO	D09VWI	BRX-005	Phase 1
T49639	DRUGINFO	D0GR1Y	Minnelide	Phase 1
T49639	DRUGINFO	D0I7MG	AG-707	Phase 1
T49639	DRUGINFO	D0VZ1C	H-103	Phase 1
T49639	DRUGINFO	D0U1SI	Bimoclomol	Discontinued in Phase 2
T49639	DRUGINFO	D0I3EI	NK-1001	Discontinued in Phase 2
T49639	DRUGINFO	D0ZW2F	NSC-119910	Investigative
T49639	DRUGINFO	D0GP7D	NSC-119911	Investigative
T49639	DRUGINFO	D0Z5LU	NSC-119913	Investigative
T49639	DRUGINFO	D0A1CM	ELLAGIC ACID	Investigative

T06575	TARGETID	T06575
T06575	FORMERID	TTDR00707
T06575	UNIPROID	CGB3_HUMAN
T06575	TARGNAME	Choriogonadotropin beta (CG-beta)
T06575	GENENAME	CGB3
T06575	TARGTYPE	Clinical trial
T06575	SYNONYMS	Chorionic gonadotropin beta subunit; Chorionic gonadotrophin beta subunit; CG-beta
T06575	FUNCTION	Stimulates the ovaries to synthesize the steroids that are essential for the maintenance of pregnancy.
T06575	PDBSTRUC	1XUL; 1QFW; 1HRP; 1HCN
T06575	BIOCLASS	Hormone
T06575	SEQUENCE	MEMFQGLLLLLLLSMGGTWASKEPLRPRCRPINATLAVEKEGCPVCITVNTTICAGYCPTMTRVLQGVLPALPQVVCNYRDVRFESIRLPGCPRGVNPVVSYAVALSCQCALCRRSTTDCGGPKDHPLTCDDPRFQDSSSSKAPPPSLPSPSRLPGPSDTPILPQ
T06575	DRUGINFO	D04REV	CDX-1307	Phase 2

T24127	TARGETID	T24127
T24127	FORMERID	TTDR00943
T24127	UNIPROID	PYY_HUMAN
T24127	TARGNAME	Peptide tyrosine tyrosine PYY (PYY)
T24127	GENENAME	PYY
T24127	TARGTYPE	Clinical trial
T24127	SYNONYMS	PYY-II
T24127	FUNCTION	This gut peptide inhibits exocrine pancreatic secretion, has a vasoconstrictory action and inhibitis jejunal and colonic mobility.
T24127	PDBSTRUC	2NA5; 2L60; 2DF0; 2DEZ
T24127	BIOCLASS	NPY family
T24127	SEQUENCE	IKPEAPREDASPEELNRYYASLRHYLNLVTRQRY
T24127	DRUGINFO	D08CJM	Peptide YY 3-36	Phase 2

T97765	TARGETID	T97765
T97765	FORMERID	TTDR00921
T97765	UNIPROID	CCL3_HUMAN
T97765	TARGNAME	Macrophage inflammatory protein 1-alpha (CCL3)
T97765	GENENAME	CCL3
T97765	TARGTYPE	Clinical trial
T97765	SYNONYMS	Tonsillar lymphocyte LD78 alpha protein; Small-inducible cytokine A3; SIS-beta; SCYA3; PAT 464.1; Macrophage Inflammatory Protein-1alpha Nuclear Protein; MNP; MIP1A; MIP-1-alpha; G0S19-1 protein; G0S19-1; G0/G1 switch regulatory protein 19-1; C-C motif chemokine 3
T97765	FUNCTION	Binds to CCR1, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant MIP-1-alpha induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). Monokine with inflammatory and chemokinetic properties.
T97765	PDBSTRUC	5D65; 5COR; 4ZKB; 4RA8; 3KBX
T97765	BIOCLASS	Cytokine: CC chemokine
T97765	SEQUENCE	MQVSTAALAVLLCTMALCNQFSASLAADTPTACCFSYTSRQIPQNFIADYFETSSQCSKPGVIFLTKRSRQVCADPSEEWVQKYVSDLELSA
T97765	DRUGINFO	D02PMT	Nagrestipen	Phase 1

T85616	TARGETID	T85616
T85616	FORMERID	TTDC00075
T85616	UNIPROID	THIO_HUMAN
T85616	TARGNAME	Thioredoxin (TXN)
T85616	GENENAME	TXN
T85616	TARGTYPE	Clinical trial
T85616	SYNONYMS	Trx; TRX1; TRDX; Surface-associated sulphydryl protein; Surface associated sulphydryl protein; SASP; ATL-derived factor; ADF
T85616	FUNCTION	Plays a role in the reversible S-nitrosylation of cysteine residues in target proteins, and thereby contributes to the response to intracellular nitric oxide. Nitrosylates the active site Cys of CASP3 in response to nitric oxide (NO), and thereby inhibits caspase-3 activity. Induces the FOS/JUN AP-1 DNA-binding activity in ionizing radiation (IR) cells through its oxidation/reduction status and stimulates AP-1 transcriptional activity. Participates in various redox reactions through the reversible oxidation of its active center dithiol to a disulfide and catalyzes dithiol-disulfide exchange reactions.
T85616	PDBSTRUC	5DQY; 4TRX; 4PUF; 4POM; 4POL
T85616	SEQUENCE	MVKQIESKTAFQEALDAAGDKLVVVDFSATWCGPCKMIKPFFHSLSEKYSNVIFLEVDVDDCQDVASECEVKCMPTFQFFKKGQKVGEFSGANKEKLEATINELV
T85616	DRUGINFO	D04JTD	PX-12	Phase 2
T85616	DRUGINFO	D09TVP	Cacodylate Ion	Investigative
T85616	DRUGINFO	D0F2ME	Acetate Ion	Investigative

T22978	TARGETID	T22978
T22978	FORMERID	TTDI02189
T22978	UNIPROID	TGFB3_HUMAN
T22978	TARGNAME	Transforming growth factor beta 3 (TGFB3)
T22978	GENENAME	TGFB3
T22978	TARGTYPE	Clinical trial
T22978	SYNONYMS	Transforming growth factor beta-3 proprotein; Transforming growth factor beta-3; TGF-beta-3; Latency-associated peptide
T22978	FUNCTION	Transforming growth factor beta-3 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-3 (TGF-beta-3) chains, which constitute the regulatory and active subunit of TGF-beta-3, respectively.
T22978	PDBSTRUC	4UM9; 3EO1; 2PJY; 1TGK; 1TGJ
T22978	BIOCLASS	Growth factor
T22978	SEQUENCE	MKMHLQRALVVLALLNFATVSLSLSTCTTLDFGHIKKKRVEAIRGQILSKLRLTSPPEPTVMTHVPYQVLALYNSTRELLEEMHGEREEGCTQENTESEYYAKEIHKFDMIQGLAEHNELAVCPKGITSKVFRFNVSSVEKNRTNLFRAEFRVLRVPNPSSKRNEQRIELFQILRPDEHIAKQRYIGGKNLPTRGTAEWLSFDVTDTVREWLLRRESNLGLEISIHCPCHTFQPNGDILENIHEVMEIKFKGVDNEDDHGRGDLGRLKKQKDHHNPHLILMMIPPHRLDNPGQGGQRKKRALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYYANFCSGPCPYLRSADTTHSTVLGLYNTLNPEASASPCCVPQDLEPLTILYYVGRTPKVEQLSNMVVKSCKCS
T22978	DRUGINFO	D0P9YQ	Avotermin	Phase 3

T45593	TARGETID	T45593
T45593	FORMERID	TTDI01945
T45593	UNIPROID	TAU_HUMAN
T45593	TARGNAME	Microtubule-associated protein tau (MAPT)
T45593	GENENAME	MAPT
T45593	TARGTYPE	Clinical trial
T45593	SYNONYMS	tau; Paired helical filamenttau; Paired helical filament-tau; Neurofibrillary tangle protein; MTBT1; MAPTL
T45593	FUNCTION	The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization. Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity.
T45593	PDBSTRUC	6QJQ; 6QJP; 6QJM; 6QJH; 6NWQ
T45593	SEQUENCE	MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQEPESGKVVQEGFLREPGPPGLSHQLMSGMPGAPLLPEGPREATRQPSGTGPEDTEGGRHAPELLKHQLLGDLHQEGPPLKGAGGKERPGSKEEVDEDRDVDESSPQDSPPSKASPAQDGRPPQTAAREATSIPGFPAEGAIPLPVDFLSKVSTEIPASEPDGPSVGRAKGQDAPLEFTFHVEITPNVQKEQAHSEEHLGRAAFPGAPGEGPEARGPSLGEDTKEADLPEPSEKQPAAAPRGKPVSRVPQLKARMVSKSKDGTGSDDKKAKTSTRSSAKTLKNRPCLSPKHPTPGSSDPLIQPSSPAVCPEPPSSPKYVSSVTSRTGSSGAKEMKLKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGL
T45593	DRUGINFO	D0V1FF	Davunetide	Phase 3
T45593	DRUGINFO	D5FSV8	TRx0237	Phase 3
T45593	DRUGINFO	D05XDZ	LMT-X	Phase 3
T45593	DRUGINFO	DQ02VJ	E2814	Phase 2/3
T45593	DRUGINFO	DQ02VJ	E2814	Phase 2/3
T45593	DRUGINFO	D00GXL	PBT-2	Phase 2
T45593	DRUGINFO	D01EJG	RG6100	Phase 2
T45593	DRUGINFO	D02IJA	Tau-binding PET tracer	Phase 2
T45593	DRUGINFO	D0I8FS	BIIB092	Phase 2
T45593	DRUGINFO	DJH56Z	JNJ‐63733657	Phase 2
T45593	DRUGINFO	D96UBZ	Semorinemab	Phase 2
T45593	DRUGINFO	DK6BL5	Bepranemab	Phase 2
T45593	DRUGINFO	DK6BL5	Bepranemab	Phase 2
T45593	DRUGINFO	D02DZK	LY3303560	Phase 1
T45593	DRUGINFO	D0P8YJ	PTI-80	Phase 1
T45593	DRUGINFO	DMSL68	PRX-005	Phase 1
T45593	DRUGINFO	DO31MK	APNmAb005	Phase 1
T45593	DRUGINFO	DFM7X6	BEY2153	Phase 1
T45593	DRUGINFO	DPU26Z	Lu AF87908	Phase 1
T45593	DRUGINFO	DPU26Z	Lu AF87908	Phase 1
T45593	DRUGINFO	D03LGX	NI-105	Investigative
T45593	DRUGINFO	D0D2GZ	AL-408	Investigative
T45593	DRUGINFO	D0T9PL	BLV-0703	Investigative

T78890	TARGETID	T78890
T78890	FORMERID	TTDI02330
T78890	UNIPROID	TFPI1_HUMAN
T78890	TARGNAME	Tissue factor pathway inhibitor (TFPI)
T78890	GENENAME	TFPI
T78890	TARGTYPE	Clinical trial
T78890	SYNONYMS	TFPI1; Lipoprotein-associated coagulation inhibitor; LACI; Extrinsic pathway inhibitor; EPI
T78890	FUNCTION	It possesses an antithrombotic action and also the ability to associate with lipoproteins in plasma. Inhibits factor X (X(a)) directly and, in a Xa-dependent way, inhibits VIIa/tissue factor activity, presumably by forming a quaternary Xa/LACI/VIIa/TF complex.
T78890	PDBSTRUC	6BX8; 5NMV; 4DTG; 4BQD; 1TFX
T78890	SEQUENCE	MIYTMKKVHALWASVCLLLNLAPAPLNADSEEDEEHTIITDTELPPLKLMHSFCAFKADDGPCKAIMKRFFFNIFTRQCEEFIYGGCEGNQNRFESLEECKKMCTRDNANRIIKTTLQQEKPDFCFLEEDPGICRGYITRYFYNNQTKQCERFKYGGCLGNMNNFETLEECKNICEDGPNGFQVDNYGTQLNAVNNSLTPQSTKVPSLFEFHGPSWCLTPADRGLCRANENRFYYNSVIGKCRPFKYSGCGGNENNFTSKQECLRACKKGFIQRISKGGLIKTKRKRKKQRVKIAYEEIFVKNM
T78890	DRUGINFO	D0B7VK	Tifacogin	Phase 3
T78890	DRUGINFO	D19OMU	PF-06741086	Phase 3
T78890	DRUGINFO	D2FE7T	Concizumab	Phase 3
T78890	DRUGINFO	D0U0XL	NN-7415	Phase 1
T78890	DRUGINFO	D0X4ZV	BAX-499	Phase 1

T59550	TARGETID	T59550
T59550	FORMERID	TTDI02126
T59550	UNIPROID	MPRI_HUMAN
T59550	TARGNAME	CI Man-6-P receptor (IGF2R)
T59550	GENENAME	IGF2R
T59550	TARGTYPE	Clinical trial
T59550	SYNONYMS	MPRI; MPR 300; M6PR; M6P/IGF2R; M6P/IGF2 receptor; Insulinlike growth factor II receptor; Insulinlike growth factor 2 receptor; Insulin-like growth factor II receptor; Insulin-like growth factor 2 receptor; IGFII receptor; IGF-II receptor; Cationindependent mannose6phosphate receptor; Cation-independent mannose-6-phosphate receptor; CIMPR; CI-MPR; CD222; 300 kDa mannose 6phosphate receptor; 300 kDa mannose 6-phosphate receptor
T59550	FUNCTION	Lysosomal enzymes bearing phosphomannosyl residues bind specifically to mannose-6-phosphate receptors in the Golgi apparatus and the resulting receptor-ligand complex is transported to an acidic prelyosomal compartment where the low pH mediates the dissociation of the complex. This receptor also binds IGF2. Acts as a positive regulator of T-cell coactivation, by binding DPP4. Transport of phosphorylated lysosomal enzymes from the Golgi complex and the cell surface to lysosomes.
T59550	PDBSTRUC	5IEI; 2V5P; 2V5O; 2V5N; 2M6T
T59550	BIOCLASS	Mannose 6-phosphate receptor
T59550	SEQUENCE	MGAAAGRSPHLGPAPARRPQRSLLLLQLLLLVAAPGSTQAQAAPFPELCSYTWEAVDTKNNVLYKINICGSVDIVQCGPSSAVCMHDLKTRTYHSVGDSVLRSATRSLLEFNTTVSCDQQGTNHRVQSSIAFLCGKTLGTPEFVTATECVHYFEWRTTAACKKDIFKANKEVPCYVFDEELRKHDLNPLIKLSGAYLVDDSDPDTSLFINVCRDIDTLRDPGSQLRACPPGTAACLVRGHQAFDVGQPRDGLKLVRKDRLVLSYVREEAGKLDFCDGHSPAVTITFVCPSERREGTIPKLTAKSNCRYEIEWITEYACHRDYLESKTCSLSGEQQDVSIDLTPLAQSGGSSYISDGKEYLFYLNVCGETEIQFCNKKQAAVCQVKKSDTSQVKAAGRYHNQTLRYSDGDLTLIYFGGDECSSGFQRMSVINFECNKTAGNDGKGTPVFTGEVDCTYFFTWDTEYACVKEKEDLLCGATDGKKRYDLSALVRHAEPEQNWEAVDGSQTETEKKHFFINICHRVLQEGKARGCPEDAAVCAVDKNGSKNLGKFISSPMKEKGNIQLSYSDGDDCGHGKKIKTNITLVCKPGDLESAPVLRTSGEGGCFYEFEWHTAAACVLSKTEGENCTVFDSQAGFSFDLSPLTKKNGAYKVETKKYDFYINVCGPVSVSPCQPDSGACQVAKSDEKTWNLGLSNAKLSYYDGMIQLNYRGGTPYNNERHTPRATLITFLCDRDAGVGFPEYQEEDNSTYNFRWYTSYACPEEPLECVVTDPSTLEQYDLSSLAKSEGGLGGNWYAMDNSGEHVTWRKYYINVCRPLNPVPGCNRYASACQMKYEKDQGSFTEVVSISNLGMAKTGPVVEDSGSLLLEYVNGSACTTSDGRQTTYTTRIHLVCSRGRLNSHPIFSLNWECVVSFLWNTEAACPIQTTTDTDQACSIRDPNSGFVFNLNPLNSSQGYNVSGIGKIFMFNVCGTMPVCGTILGKPASGCEAETQTEELKNWKPARPVGIEKSLQLSTEGFITLTYKGPLSAKGTADAFIVRFVCNDDVYSGPLKFLHQDIDSGQGIRNTYFEFETALACVPSPVDCQVTDLAGNEYDLTGLSTVRKPWTAVDTSVDGRKRTFYLSVCNPLPYIPGCQGSAVGSCLVSEGNSWNLGVVQMSPQAAANGSLSIMYVNGDKCGNQRFSTRITFECAQISGSPAFQLQDGCEYVFIWRTVEACPVVRVEGDNCEVKDPRHGNLYDLKPLGLNDTIVSAGEYTYYFRVCGKLSSDVCPTSDKSKVVSSCQEKREPQGFHKVAGLLTQKLTYENGLLKMNFTGGDTCHKVYQRSTAIFFYCDRGTQRPVFLKETSDCSYLFEWRTQYACPPFDLTECSFKDGAGNSFDLSSLSRYSDNWEAITGTGDPEHYLINVCKSLAPQAGTEPCPPEAAACLLGGSKPVNLGRVRDGPQWRDGIIVLKYVDGDLCPDGIRKKSTTIRFTCSESQVNSRPMFISAVEDCEYTFAWPTATACPMKSNEHDDCQVTNPSTGHLFDLSSLSGRAGFTAAYSEKGLVYMSICGENENCPPGVGACFGQTRISVGKANKRLRYVDQVLQLVYKDGSPCPSKSGLSYKSVISFVCRPEARPTNRPMLISLDKQTCTLFFSWHTPLACEQATECSVRNGSSIVDLSPLIHRTGGYEAYDESEDDASDTNPDFYINICQPLNPMHGVPCPAGAAVCKVPIDGPPIDIGRVAGPPILNPIANEIYLNFESSTPCLADKHFNYTSLIAFHCKRGVSMGTPKLLRTSECDFVFEWETPVVCPDEVRMDGCTLTDEQLLYSFNLSSLSTSTFKVTRDSRTYSVGVCTFAVGPEQGGCKDGGVCLLSGTKGASFGRLQSMKLDYRHQDEAVVLSYVNGDRCPPETDDGVPCVFPFIFNGKSYEECIIESRAKLWCSTTADYDRDHEWGFCRHSNSYRTSSIIFKCDEDEDIGRPQVFSEVRGCDVTFEWKTKVVCPPKKLECKFVQKHKTYDLRLLSSLTGSWSLVHNGVSYYINLCQKIYKGPLGCSERASICRRTTTGDVQVLGLVHTQKLGVIGDKVVVTYSKGYPCGGNKTASSVIELTCTKTVGRPAFKRFDIDSCTYYFSWDSRAACAVKPQEVQMVNGTITNPINGKSFSLGDIYFKLFRASGDMRTNGDNYLYEIQLSSITSSRNPACSGANICQVKPNDQHFSRKVGTSDKTKYYLQDGDLDVVFASSSKCGKDKTKSVSSTIFFHCDPLVEDGIPEFSHETADCQYLFSWYTSAVCPLGVGFDSENPGDDGQMHKGLSERSQAVGAVLSLLLVALTCCLLALLLYKKERRETVISKLTTCCRRSSNVSYKYSKVNKEEETDENETEWLMEEIQLPPPRQGKEGQENGHITTKSVKALSSLHGDDQDSEDEVLTIPEVKVHSGRGAGAESSHPVRNAQSNALQEREDDRVGLVRGEKARKGKSSSAQQKTVSSTKLVSFHDDSDEDLLHI
T59550	DRUGINFO	D00WHL	Juvidex	Phase 2
T59550	DRUGINFO	D00VFH	PXS-25	Phase 1
T59550	DRUGINFO	D0H3YC	EP-128504	Preclinical

T68383	TARGETID	T68383
T68383	FORMERID	TTDI01983
T68383	UNIPROID	BMP2_HUMAN
T68383	TARGNAME	Bone morphogenetic protein 2 (BMP2)
T68383	GENENAME	BMP2
T68383	TARGTYPE	Clinical trial
T68383	SYNONYMS	Bone morphogenetic protein 2A; BMP2A; BMP-2A; BMP-2
T68383	FUNCTION	Stimulates the differentiation of myoblasts into osteoblasts via the EIF2AK3-EIF2A- ATF4 pathway. BMP2 activation of EIF2AK3 stimulates phosphorylation of EIF2A which leads to increased expression of ATF4 which plays a central role in osteoblast differentiation. In addition stimulates TMEM119, which upregulates the expression of ATF4. Induces cartilage and bone formation.
T68383	PDBSTRUC	6OMN; 4UI2; 4UI1; 4UI0; 4UHZ
T68383	BIOCLASS	Growth factor
T68383	SEQUENCE	MVAGTRCLLALLLPQVLLGGAAGLVPELGRRKFAAASSGRPSSQPSDEVLSEFELRLLSMFGLKQRPTPSRDAVVPPYMLDLYRRHSGQPGSPAPDHRLERAASRANTVRSFHHEESLEELPETSGKTTRRFFFNLSSIPTEEFITSAELQVFREQMQDALGNNSSFHHRINIYEIIKPATANSKFPVTRLLDTRLVNQNASRWESFDVTPAVMRWTAQGHANHGFVVEVAHLEEKQGVSKRHVRISRSLHQDEHSWSQIRPLLVTFGHDGKGHPLHKREKRQAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR
T68383	DRUGINFO	D03HDV	DWP-431	Phase 3

T07507	TARGETID	T07507
T07507	FORMERID	TTDI02131
T07507	UNIPROID	MYH7_HUMAN
T07507	TARGNAME	Myosin-7 (MYH7)
T07507	GENENAME	MYH7
T07507	TARGTYPE	Clinical trial
T07507	SYNONYMS	Myosin heavy chain, cardiac muscle beta isoform; Myosin heavy chain slow isoform; Myosin heavy chain 7; MyHCslow; MyHCbeta; MYH7
T07507	FUNCTION	Muscle contraction.
T07507	PDBSTRUC	5WME; 5WLZ; 5WLQ; 5WJB; 5WJ7
T07507	BIOCLASS	TRAFAC class myosin-kinesin ATPase
T07507	SEQUENCE	MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAKIVSREGGKVTAETEYGKTVTVKEDQVMQQNPPKFDKIEDMAMLTFLHEPAVLYNLKDRYGSWMIYTYSGLFCVTVNPYKWLPVYTPEVVAAYRGKKRSEAPPHIFSISDNAYQYMLTDRENQSILITGESGAGKTVNTKRVIQYFAVIAAIGDRSKKDQSPGKGTLEDQIIQANPALEAFGNAKTVRNDNSSRFGKFIRIHFGATGKLASADIETYLLEKSRVIFQLKAERDYHIFYQILSNKKPELLDMLLITNNPYDYAFISQGETTVASIDDAEELMATDNAFDVLGFTSEEKNSMYKLTGAIMHFGNMKFKLKQREEQAEPDGTEEADKSAYLMGLNSADLLKGLCHPRVKVGNEYVTKGQNVQQVIYATGALAKAVYERMFNWMVTRINATLETKQPRQYFIGVLDIAGFEIFDFNSFEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLQACIDLIEKPMGIMSILEEECMFPKATDMTFKAKLFDNHLGKSANFQKPRNIKGKPEAHFSLIHYAGIVDYNIIGWLQKNKDPLNETVVGLYQKSSLKLLSTLFANYAGADAPIEKGKGKAKKGSSFQTVSALHRENLNKLMTNLRSTHPHFVRCIIPNETKSPGVMDNPLVMHQLRCNGVLEGIRICRKGFPNRILYGDFRQRYRILNPAAIPEGQFIDSRKGAEKLLSSLDIDHNQYKFGHTKVFFKAGLLGLLEEMRDERLSRIITRIQAQSRGVLARMEYKKLLERRDSLLVIQWNIRAFMGVKNWPWMKLYFKIKPLLKSAEREKEMASMKEEFTRLKEALEKSEARRKELEEKMVSLLQEKNDLQLQVQAEQDNLADAEERCDQLIKNKIQLEAKVKEMNERLEDEEEMNAELTAKKRKLEDECSELKRDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDEIIAKLTKEKKALQEAHQQALDDLQAEEDKVNTLTKAKVKLEQQVDDLEGSLEQEKKVRMDLERAKRKLEGDLKLTQESIMDLENDKQQLDERLKKKDFELNALNARIEDEQALGSQLQKKLKELQARIEELEEELEAERTARAKVEKLRSDLSRELEEISERLEEAGGATSVQIEMNKKREAEFQKMRRDLEEATLQHEATAAALRKKHADSVAELGEQIDNLQRVKQKLEKEKSEFKLELDDVTSNMEQIIKAKANLEKMCRTLEDQMNEHRSKAEETQRSVNDLTSQRAKLQTENGELSRQLDEKEALISQLTRGKLTYTQQLEDLKRQLEEEVKAKNALAHALQSARHDCDLLREQYEEETEAKAELQRVLSKANSEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQEAEEAVEAVNAKCSSLEKTKHRLQNEIEDLMVDVERSNAAAAALDKKQRNFDKILAEWKQKYEESQSELESSQKEARSLSTELFKLKNAYEESLEHLETFKRENKNLQEEISDLTEQLGSSGKTIHELEKVRKQLEAEKMELQSALEEAEASLEHEEGKILRAQLEFNQIKAEIERKLAEKDEEMEQAKRNHLRVVDSLQTSLDAETRSRNEALRVKKKMEGDLNEMEIQLSHANRMAAEAQKQVKSLQSLLKDTQIQLDDAVRANDDLKENIAIVERRNNLLQAELEELRAVVEQTERSRKLAEQELIETSERVQLLHSQNTSLINQKKKMDADLSQLQTEVEEAVQECRNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTIKDLQHRLDEAEQIALKGGKKQLQKLEARVRELENELEAEQKRNAESVKGMRKSERRIKELTYQTEEDRKNLLRLQDLVDKLQLKVKAYKRQAEEAEEQANTNLSKFRKVQHELDEAEERADIAESQVNKLRAKSRDIGTKGLNEE
T07507	DRUGINFO	D0YO5Z	UshStat	Phase 1/2

T16263	TARGETID	T16263
T16263	FORMERID	TTDI02037
T16263	UNIPROID	CCL5_HUMAN
T16263	TARGNAME	T-cell-specific protein RANTES (CCL5)
T16263	GENENAME	CCL5
T16263	TARGTYPE	Clinical trial
T16263	SYNONYMS	Tcellspecific protein RANTES; TCP228; T cellspecific protein P228; T cell-specific protein P228; Smallinducible cytokine A5; Small-inducible cytokine A5; SISdelta; SIS-delta; SCYA5; RANTES(468); Eosinophil chemotactic cytokine; EoCP; D17S136E; CC motif chemokine 5; C-C motif chemokine 5
T16263	FUNCTION	Causes the release of histamine from basophils and activates eosinophils. May activate several chemokine receptors including CCR1, CCR3, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant RANTES protein induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form RANTES(3-68) acts as a natural chemotaxis inhibitor and is a more potent inhibitor of HIV-1-infection. The second processed form RANTES(4-68) exhibits reduced chemotactic and HIV-suppressive activity compared with RANTES(1-68) and RANTES(3-68) and is generated by an unidentified enzyme associated with monocytes and neutrophils. May also be an agonist of the G protein-coupled receptor GPR75, stimulating inositol trisphosphate production and calcium mobilization through its activation. Together with GPR75, may play a role in neuron survival through activation of a downstream signaling pathway involving the PI3, Akt and MAP kinases. By activating GPR75 may also play a role in insulin secretion by islet cells. Chemoattractant for blood monocytes, memory T-helper cells and eosinophils.
T16263	PDBSTRUC	6FGP; 6C6D; 5UIW; 5L2U; 5DNF
T16263	BIOCLASS	Cytokine: CC chemokine
T16263	SEQUENCE	MKVSAAALAVILIATALCAPASASPYSSDTTPCCFAYIARPLPRAHIKEYFYTSGKCSNPAVVFVTRKNRQVCANPEKKWVREYINSLEMS
T16263	DRUGINFO	D02MVA	NI-0701	Phase 1

T86130	TARGETID	T86130
T86130	FORMERID	TTDI01797
T86130	UNIPROID	ITA4_HUMAN-ITB1_HUMAN
T86130	TARGNAME	Integrin alpha-4/beta-1 (ITGA4/B1)
T86130	GENENAME	ITGA4-ITGB1
T86130	TARGTYPE	Clinical trial
T86130	SYNONYMS	alpha(4)beta(1) integrin; Alpha 4 beta 1 integrin
T86130	FUNCTION	Integrins alpha-4/beta-1 (VLA-4) and alpha-4/beta-7 are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1. Integrin alpha- 4/beta-1 recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha- 4/beta-7 is also a receptor for MADCAM1. It recognizes the sequence L-D-T in MADCAM1. On activated endothelial cells integrin VLA-4 triggers homotypic aggregation for most VLA-4-positive leukocyte cell lines. It may also participate in cytolytic T-cell interactions with target cells.
T86130	BIOCLASS	Integrin
T86130	SEQUENCE	MNLQPIFWIGLISSVCCVFAQTDENRCLKANAKSCGECIQAGPNCGWCTNSTFLQEGMPTSARCDDLEALKKKGCPPDDIENPRGSKDIKKNKNVTNRSKGTAEKLKPEDITQIQPQQLVLRLRSGEPQTFTLKFKRAEDYPIDLYYLMDLSYSMKDDLENVKSLGTDLMNEMRRITSDFRIGFGSFVEKTVMPYISTTPAKLRNPCTSEQNCTSPFSYKNVLSLTNKGEVFNELVGKQRISGNLDSPEGGFDAIMQVAVCGSLIGWRNVTRLLVFSTDAGFHFAGDGKLGGIVLPNDGQCHLENNMYTMSHYYDYPSIAHLVQKLSENNIQTIFAVTEEFQPVYKELKNLIPKSAVGTLSANSSNVIQLIIDAYNSLSSEVILENGKLSEGVTISYKSYCKNGVNGTGENGRKCSNISIGDEVQFEISITSNKCPKKDSDSFKIRPLGFTEEVEVILQYICECECQSEGIPESPKCHEGNGTFECGACRCNEGRVGRHCECSTDEVNSEDMDAYCRKENSSEICSNNGECVCGQCVCRKRDNTNEIYSGKFCECDNFNCDRSNGLICGGNGVCKCRVCECNPNYTGSACDCSLDTSTCEASNGQICNGRGICECGVCKCTDPKFQGQTCEMCQTCLGVCAEHKECVQCRAFNKGEKKDTCTQECSYFNITKVESRDKLPQPVQPDPVSHCKEKDVDDCWFYFTYSVNGNNEVMVHVVENPECPTGPDIIPIVAGVVAGIVLIGLALLLIWKLLMIIHDRREFAKFEKEKMNAKWDTGENPIYKSAVTTVVNPKYEGKMAWEARREPGPRRAAVRETVMLLLCLGVPTGRPYNVDTESALLYQGPHNTLFGYSVVLHSHGANRWLLVGAPTANWLANASVINPGAIYRCRIGKNPGQTCEQLQLGSPNGEPCGKTCLEERDNQWLGVTLSRQPGENGSIVTCGHRWKNIFYIKNENKLPTGGCYGVPPDLRTELSKRIAPCYQDYVKKFGENFASCQAGISSFYTKDLIVMGAPGSSYWTGSLFVYNITTNKYKAFLDKQNQVKFGSYLGYSVGAGHFRSQHTTEVVGGAPQHEQIGKAYIFSIDEKELNILHEMKGKKLGSYFGASVCAVDLNADGFSDLLVGAPMQSTIREEGRVFVYINSGSGAVMNAMETNLVGSDKYAARFGESIVNLGDIDNDGFEDVAIGAPQEDDLQGAIYIYNGRADGISSTFSQRIEGLQISKSLSMFGQSISGQIDADNNGYVDVAVGAFRSDSAVLLRTRPVVIVDASLSHPESVNRTKFDCVENGWPSVCIDLTLCFSYKGKEVPGYIVLFYNMSLDVNRKAESPPRFYFSSNGTSDVITGSIQVSSREANCRTHQAFMRKDVRDILTPIQIEAAYHLGPHVISKRSTEEFPPLQPILQQKKEKDIMKKTINFARFCAHENCSADLQVSAKIGFLKPHENKTYLAVGSMKTLMLNVSLFNAGDDAYETTLHVKLPVGLYFIKILELEEKQINCEVTDNSGVVQLDCSIGYIYVDHLSRIDISFLLDVSSLSRAEEDLSITVHATCENEEEMDNLKHSRVTVAIPLKYEVKLTVHGFVNPTSFVYGSNDENEPETCMVEKMNLTFHVINTGNSMAPNVSVEIMVPNSFSPQTDKLFNILDVQTTTGECHFENYQRVCALEQQKSAMQTLKGIVRFLSKTDKRLLYCIKADPHCLNFLCNFGKMESGKEASVHIQLEGRPSILEMDETSALKFEIRATGFPEPNPRVIELNKDENVAHVLLEGLHHQRPKRYFTIVIISSSLLLGLIVLLLISYVMWKAGFFKRQYKSILQEENRRDSWSYINSKSNDD
T86130	DRUGINFO	D0M1WU	AJM-300	Phase 3
T86130	DRUGINFO	D04YJN	R411	Phase 2
T86130	DRUGINFO	D08MJO	CDP323	Phase 2
T86130	DRUGINFO	D0H8FY	Firategrast	Phase 2
T86130	DRUGINFO	D0A2KH	TRK-170	Phase 2
T86130	DRUGINFO	D0L3DC	HMR-1031	Phase 1
T86130	DRUGINFO	D9XS2Y	BIIB107	Phase 1
T86130	DRUGINFO	D02WII	TR-14035	Discontinued in Phase 1
T86130	DRUGINFO	D0A1GJ	CY-9652	Terminated
T86130	DRUGINFO	D08XWS	TCS2314	Investigative

T61729	TARGETID	T61729
T61729	FORMERID	TTDI01991
T61729	UNIPROID	P4HA1_HUMAN
T61729	TARGNAME	Prolyl 4-hydroxylasesubunit alpha-1 (P4HA1)
T61729	GENENAME	P4HA1
T61729	TARGTYPE	Clinical trial
T61729	SYNONYMS	Prolyl 4-hydroxylase subunit alpha-1; Procollagenproline,2oxoglutarate4dioxygenase subunit alpha1; Procollagen-proline,2-oxoglutarate-4-dioxygenase subunit alpha-1; P4HA; 4PH alpha1; 4-PH alpha-1
T61729	FUNCTION	Catalyzes the post-translational formation of 4-hydroxyproline in -Xaa-Pro-Gly- sequences in collagens and other proteins.
T61729	PDBSTRUC	4BTB; 4BTA; 4BT9; 4BT8; 2YQ8
T61729	BIOCLASS	Paired donor oxygen oxidoreductase
T61729	ECNUMBER	EC 1.14.11.2
T61729	SEQUENCE	MIWYILIIGILLPQSLAHPGFFTSIGQMTDLIHTEKDLVTSLKDYIKAEEDKLEQIKKWAEKLDRLTSTATKDPEGFVGHPVNAFKLMKRLNTEWSELENLVLKDMSDGFISNLTIQRQYFPNDEDQVGAAKALLRLQDTYNLDTDTISKGNLPGVKHKSFLTAEDCFELGKVAYTEADYYHTELWMEQALRQLDEGEISTIDKVSVLDYLSYAVYQQGDLDKALLLTKKLLELDPEHQRANGNLKYFEYIMAKEKDVNKSASDDQSDQKTTPKKKGVAVDYLPERQKYEMLCRGEGIKMTPRRQKKLFCRYHDGNRNPKFILAPAKQEDEWDKPRIIRFHDIISDAEIEIVKDLAKPRLRRATISNPITGDLETVHYRISKSAWLSGYENPVVSRINMRIQDLTGLDVSTAEELQVANYGVGGQYEPHFDFARKDEPDAFKELGTGNRIATWLFYMSDVSAGGATVFPEVGASVWPKKGTAVFWYNLFASGEGDYSTRHAACPVLVGNKWVSNKWLHERGQEFRRPCTLSELE
T61729	DRUGINFO	D01NCH	Lufironil	Phase 2
T61729	DRUGINFO	D0P2BD	SAFIRONIL	Phase 1

T65889	TARGETID	T65889
T65889	FORMERID	TTDI02110
T65889	UNIPROID	KPYM_HUMAN
T65889	TARGNAME	Pyruvate kinase M2 (PKM)
T65889	GENENAME	PKM
T65889	TARGTYPE	Clinical trial
T65889	SYNONYMS	p58; Tumor M2-PK; Thyroid hormone-binding protein 1; THBP1; Pyruvate kinase muscle isozyme; Pyruvate kinase isozymes M1/M2; Pyruvate kinase PKM; Pyruvate kinase 2/3; PKM2; PK3; PK2; Opa-interacting protein 3; OIP3; OIP-3; Cytosolic thyroid hormone-binding protein; CTHBP
T65889	FUNCTION	Stimulates POU5F1-mediated transcriptional activation. Plays a general role in caspase independent cell death of tumor cells. The ratio between the highly active tetrameric form and nearly inactive dimeric form determines whether glucose carbons are channeled to biosynthetic processes or used for glycolytic ATP production. The transition between the 2 forms contributes to the control of glycolysis and is important for tumor cell proliferation and survival. Promotes in a STAT1-dependent manner, the expression of the immune checkpoint protein CD274 in ARNTL/BMAL1-deficient macrophages. Glycolytic enzyme that catalyzes the transfer of a phosphoryl group from phosphoenolpyruvate (PEP) to ADP, generating ATP.
T65889	PDBSTRUC	6GG6; 6GG5; 6GG4; 6B6U; 5X1W
T65889	BIOCLASS	Kinase
T65889	ECNUMBER	EC 2.7.1.40
T65889	SEQUENCE	MSKPHSEAGTAFIQTQQLHAAMADTFLEHMCRLDIDSPPITARNTGIICTIGPASRSVETLKEMIKSGMNVARLNFSHGTHEYHAETIKNVRTATESFASDPILYRPVAVALDTKGPEIRTGLIKGSGTAEVELKKGATLKITLDNAYMEKCDENILWLDYKNICKVVEVGSKIYVDDGLISLQVKQKGADFLVTEVENGGSLGSKKGVNLPGAAVDLPAVSEKDIQDLKFGVEQDVDMVFASFIRKASDVHEVRKVLGEKGKNIKIISKIENHEGVRRFDEILEASDGIMVARGDLGIEIPAEKVFLAQKMMIGRCNRAGKPVICATQMLESMIKKPRPTRAEGSDVANAVLDGADCIMLSGETAKGDYPLEAVRMQHLIAREAEAAIYHLQLFEELRRLAPITSDPTEATAVGAVEASFKCCSGAIIVLTKSGRSAHQVARYRPRAPIIAVTRNPQTARQAHLYRGIFPVLCKDPVQEAWAEDVDLRVNFAMNVGKARGFFKKGDVVIVLTGWRPGSGFTNTMRVVPVP
T65889	DRUGINFO	D09EFC	CAP-232	Phase 2a
T65889	DRUGINFO	DLN0P8	TP-1454	Phase 1

T67658	TARGETID	T67658
T67658	FORMERID	TTDR00776
T67658	UNIPROID	GLUT4_HUMAN
T67658	TARGNAME	Glucose transporter type 4 (SLC2A4)
T67658	GENENAME	SLC2A4
T67658	TARGTYPE	Clinical trial
T67658	SYNONYMS	Solute carrier family 2, facilitated glucose transporter member 4; Glut4 protein; Glucose transporter type 4, insulin-responsive; GLUT4; GLUT-4
T67658	FUNCTION	Insulin-regulated facilitative glucose transporter.
T67658	BIOCLASS	Major facilitator
T67658	SEQUENCE	MPSGFQQIGSEDGEPPQQRVTGTLVLAVFSAVLGSLQFGYNIGVINAPQKVIEQSYNETWLGRQGPEGPSSIPPGTLTTLWALSVAIFSVGGMISSFLIGIISQWLGRKRAMLVNNVLAVLGGSLMGLANAAASYEMLILGRFLIGAYSGLTSGLVPMYVGEIAPTHLRGALGTLNQLAIVIGILIAQVLGLESLLGTASLWPLLLGLTVLPALLQLVLLPFCPESPRYLYIIQNLEGPARKSLKRLTGWADVSGVLAELKDEKRKLERERPLSLLQLLGSRTHRQPLIIAVVLQLSQQLSGINAVFYYSTSIFETAGVGQPAYATIGAGVVNTVFTLVSVLLVERAGRRTLHLLGLAGMCGCAILMTVALLLLERVPAMSYVSIVAIFGFVAFFEIGPGPIPWFIVAELFSQGPRPAAMAVAGFSNWTSNFIIGMGFQYVAEAMGPYVFLLFAVLLLGFFIFTFLRVPETRGRTFDQISAAFHRTPSLLEQEVKPSTELEYLGPDEND
T67658	DRUGINFO	D03UZC	DS-1150b	Phase 1

T93283	TARGETID	T93283
T93283	UNIPROID	PPAP_HUMAN
T93283	TARGNAME	Prostatic acid phosphatase (ACPP)
T93283	GENENAME	ACPP
T93283	TARGTYPE	Clinical trial
T93283	SYNONYMS	Thiamine monophosphatase; TMPase; PAP
T93283	FUNCTION	A non-specific tyrosine phosphatase that dephosphorylates a diverse number of substrates under acidic conditions (pH 4-6) including alkyl, aryl, and acyl orthophosphate monoesters and phosphorylated proteins. Has lipid phosphatase activity and inactivates lysophosphatidic acid in seminal plasma.
T93283	PDBSTRUC	3PPD; 2MG0; 2L79; 2L77; 2L3H
T93283	ECNUMBER	EC 3.1.3.2
T93283	SEQUENCE	MRAAPLLLARAASLSLGFLFLLFFWLDRSVLAKELKFVTLVFRHGDRSPIDTFPTDPIKESSWPQGFGQLTQLGMEQHYELGEYIRKRYRKFLNESYKHEQVYIRSTDVDRTLMSAMTNLAALFPPEGVSIWNPILLWQPIPVHTVPLSEDQLLYLPFRNCPRFQELESETLKSEEFQKRLHPYKDFIATLGKLSGLHGQDLFGIWSKVYDPLYCESVHNFTLPSWATEDTMTKLRELSELSLLSLYGIHKQKEKSRLQGGVLVNEILNHMKRATQIPSYKKLIMYSAHDTTVSGLQMALDVYNGLLPPYASCHLTELYFEKGEYFVEMYYRNETQHEPYPLMLPGCSPSCPLERFAELVGPVIPQDWSTECMTTNSHQGTEDSTD
T93283	DRUGINFO	D09PGG	MVI-816	Phase 2

T18779	TARGETID	T18779
T18779	FORMERID	TTDR00730
T18779	UNIPROID	MUC1_HUMAN
T18779	TARGNAME	Mucin-1 (MUC1)
T18779	GENENAME	MUC1
T18779	TARGTYPE	Clinical trial
T18779	SYNONYMS	Tumour-associated antigen mucin 1; Tumor-associated mucin; Tumor-associated epithelial membraneantigen; Tumor-associated epithelial membrane antigen; Polymorphic epithelial mucin; Peanut-reactive urinary mucin; PUM; PEMT; PEM; MUC-1; Krebs von den Lungen-6; KL-6; H23AG; Episialin; EMA; Carcinoma-associated mucin; Cancer antigen 15-3; CD227 antigen; CD227; CA 15-3; Breast carcinoma-associated antigen DF3
T18779	FUNCTION	Can act both as an adhesion and an anti-adhesion protein. May provide a protective layer on epithelial cells against bacterial and enzyme attack. The alpha subunit has cell adhesive properties.
T18779	PDBSTRUC	6FZR; 6FZQ; 5T78; 5T6P; 2FO4
T18779	SEQUENCE	MTPGTQSPFFLLLLLTVLTVVTGSGHASSTPGGEKETSATQRSSVPSSTEKNAVSMTSSVLSSHSPGSGSSTTQGQDVTLAPATEPASGSAATWGQDVTSVPVTRPALGSTTPPAHDVTSAPDNKPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDNRPALGSTAPPVHNVTSASGSASGSASTLVHNGTSARATTTPASKSTPFSIPSHHSDTPTTLASHSTKTDASSTHHSSVPPLTSSNHSTSPQLSTGVSFFFLSFHISNLQFNSSLEDPSTDYYQELQRDISEMFLQIYKQGGFLGLSNIKFRPGSVVVQLTLAFREGTINVHDVETQFNQYKTEAASRYNLTISDVSVSDVPFPFSAQSGAGVPGWGIALLVLVCVLVALAIVYLIALAVCQCRRKNYGQLDIFPARDTYHPMSEYPTYHTHGRYVPPSSTDRSPYEKVSAGNGGSSLSYTNPAVAATSANL
T18779	DRUGINFO	D0V2KR	Yttrium (90Y) clivatuzumab tetraxetan	Phase 3
T18779	DRUGINFO	D0ZW3R	TG-4010	Phase 2/3
T18779	DRUGINFO	D01YGD	ICO-25	Phase 2
T18779	DRUGINFO	D02HKC	MUC1-Poly-ICLC	Phase 2
T18779	DRUGINFO	D04VOE	AS-1402	Phase 2
T18779	DRUGINFO	D05BPD	Emepepimut-S	Phase 2
T18779	DRUGINFO	D07OAD	GO-203-2c	Phase 2
T18779	DRUGINFO	D0G5YR	SAR-566658	Phase 2
T18779	DRUGINFO	D0T1KL	Pankomab-GEX	Phase 2
T18779	DRUGINFO	D04UFI	ImMucin	Phase 1/2
T18779	DRUGINFO	D04WHM	G0-203-2c	Phase 1/2
T18779	DRUGINFO	D05CSS	CAR-T cells targeting MucI	Phase 1/2
T18779	DRUGINFO	D08WII	Anti-MUC1 CAR T Cells	Phase 1/2
T18779	DRUGINFO	D09KWN	Anti-MUC1 CAR-T cells	Phase 1/2
T18779	DRUGINFO	D0AI7H	Anti-MUC1 CAR T Cells	Phase 1/2
T18779	DRUGINFO	D0C9MJ	Anti-MUC1 CAR-T cells	Phase 1/2
T18779	DRUGINFO	D0IN7R	MUC-1 CART cell immunotherapy	Phase 1/2
T18779	DRUGINFO	D0IQ3E	Muc1-specific gene-engineered T cells	Phase 1/2
T18779	DRUGINFO	D0M5JC	BrevaRex	Phase 1/2
T18779	DRUGINFO	D0R1BA	CAR-T cells targeting Muc1	Phase 1/2
T18779	DRUGINFO	D04CYD	ONT-10	Phase 1
T18779	DRUGINFO	D06URX	CAR-T Cells targeting MUCI	Phase 1
T18779	DRUGINFO	D0DJ8S	CART-Muc1 cells	Phase 1
T18779	DRUGINFO	D0H2CF	Anti-MUC1 mab	Phase 1
T18779	DRUGINFO	D0NU9N	CAR-T cells targeting MUC1	Phase 1
T18779	DRUGINFO	D0O0RG	MUC-1 dendritic cancer vaccine	Phase 1
T18779	DRUGINFO	DKGB36	TnMUC-1 CAR-T cell therapy	Phase 1
T18779	DRUGINFO	DRZ1J4	HuMNC2-CAR44 T cells	Phase 1
T18779	DRUGINFO	D0JW9E	CAR-T cells targeting Mucl	Preclinical
T18779	DRUGINFO	D0GF2L	TG-1031	Investigative

T26226	TARGETID	T26226
T26226	FORMERID	TTDC00333
T26226	UNIPROID	PRLR_HUMAN
T26226	TARGNAME	Prolactin receptor (PRLR)
T26226	GENENAME	PRLR
T26226	TARGTYPE	Clinical trial
T26226	SYNONYMS	PRL-R
T26226	FUNCTION	Acts as a prosurvival factor for spermatozoa by inhibiting sperm capacitation through suppression of SRC kinase activation and stimulation of AKT. Isoform 4 is unable to transduce prolactin signaling. Isoform 6 is unable to transduce prolactin signaling. This is a receptor for the anterior pituitary hormone prolactin (PRL).
T26226	PDBSTRUC	4I18; 3NCF; 3NCE; 3NCC; 3NCB
T26226	BIOCLASS	Cytokine receptor
T26226	SEQUENCE	MKENVASATVFTLLLFLNTCLLNGQLPPGKPEIFKCRSPNKETFTCWWRPGTDGGLPTNYSLTYHREGETLMHECPDYITGGPNSCHFGKQYTSMWRTYIMMVNATNQMGSSFSDELYVDVTYIVQPDPPLELAVEVKQPEDRKPYLWIKWSPPTLIDLKTGWFTLLYEIRLKPEKAAEWEIHFAGQQTEFKILSLHPGQKYLVQVRCKPDHGYWSAWSPATFIQIPSDFTMNDTTVWISVAVLSAVICLIIVWAVALKGYSMVTCIFPPVPGPKIKGFDAHLLEKGKSEELLSALGCQDFPPTSDYEDLLVEYLEVDDSEDQHLMSVHSKEHPSQGMKPTYLDPDTDSGRGSCDSPSLLSEKCEEPQANPSTFYDPEVIEKPENPETTHTWDPQCISMEGKIPYFHAGGSKCSTWPLPQPSQHNPRSSYHNITDVCELAVGPAGAPATLLNEAGKDALKSSQTIKSREEGKATQQREVESFHSETDQDTPWLLPQEKTPFGSAKPLDYVEIHKVNKDGALSLLPKQRENSGKPKKPGTPENNKEYAKVSGVMDNNILVLVPDPHAKNVACFEESAKEAPPSLEQNQAEKALANFTATSSKCRLQLGGLDYLDPACFTHSFH
T26226	DRUGINFO	D0V6AH	Endostatin	Phase 2
T26226	DRUGINFO	D0F1ZB	LFA-102	Phase 1
T26226	DRUGINFO	D0J1OG	Prolanta	Phase 1

T12409	TARGETID	T12409
T12409	FORMERID	TTDR00753
T12409	UNIPROID	GLMS_ECOLI
T12409	TARGNAME	Bacterial Glucosamine-6-phosphate synthase (Bact glmS)
T12409	GENENAME	Bact glmS
T12409	TARGTYPE	Clinical trial
T12409	SYNONYMS	glmS; L-glutamine-D-fructose-6-phosphate amidotransferase; Hexosephosphate aminotransferase; Glucosamine--fructose-6-phosphate aminotransferase; GFAT; D-fructose-6-phosphate amidotransferase
T12409	FUNCTION	Catalyzesthe first step in hexosamine metabolism, converting fructose-6P into glucosamine-6P using glutamine as a nitrogen source.
T12409	PDBSTRUC	4AMV; 3OOJ; 2VF5; 2VF4; 2J6H
T12409	BIOCLASS	Transaminase
T12409	ECNUMBER	EC 2.6.1.16
T12409	SEQUENCE	MCGIVGAIAQRDVAEILLEGLRRLEYRGYDSAGLAVVDAEGHMTRLRRLGKVQMLAQAAEEHPLHGGTGIAHTRWATHGEPSEVNAHPHVSEHIVVVHNGIIENHEPLREELKARGYTFVSETDTEVIAHLVNWELKQGGTLREAVLRAIPQLRGAYGTVIMDSRHPDTLLAARSGSPLVIGLGMGENFIASDQLALLPVTRRFIFLEEGDIAEITRRSVNIFDKTGAEVKRQDIESNLQYDAGDKGIYRHYMQKEIYEQPNAIKNTLTGRISHGQVDLSELGPNADELLSKVEHIQILACGTSYNSGMVSRYWFESLAGIPCDVEIASEFRYRKSAVRRNSLMITLSQSGETADTLAGLRLSKELGYLGSLAICNVPGSSLVRESDLALMTNAGTEIGVASTKAFTTQLTVLLMLVAKLSRLKGLDASIEHDIVHGLQALPSRIEQMLSQDKRIEALAEDFSDKHHALFLGRGDQYPIALEGALKLKEISYIHAEAYAAGELKHGPLALIDADMPVIVVAPNNELLEKLKSNIEEVRARGGQLYVFADQDAGFVSSDNMHIIEMPHVEEVIAPIFYTVPLQLLAYHVALIKGTDVDQPRNLAKSVTVE
T12409	DRUGINFO	D05TIS	Glucose-6-Phosphate	Phase 1
T12409	DRUGINFO	D0G9LM	Glutamine Hydroxamate	Investigative
T12409	DRUGINFO	D0O1LW	2-Deoxy-2-Amino Glucitol-6-Phosphate	Investigative
T12409	DRUGINFO	D0Y8PY	Glucosamine 6-Phosphate	Investigative
T12409	DRUGINFO	D01AWD	Alpha-D-Glucose-6-Phosphate	Investigative
T12409	DRUGINFO	D07KZA	2-(N-Morpholino)-Ethanesulfonic Acid	Investigative
T12409	DRUGINFO	D06GOK	2-Methyl-2,4-Pentanediol	Investigative
T12409	DRUGINFO	D0F2ME	Acetate Ion	Investigative

T95371	TARGETID	T95371
T95371	FORMERID	TTDNC00373
T95371	UNIPROID	INAR1_HUMAN
T95371	TARGNAME	Interferon alpha/beta receptor 1 (IFNAR1)
T95371	GENENAME	IFNAR1
T95371	TARGTYPE	Clinical trial
T95371	SYNONYMS	Type I interferon receptor 1; IFNalpha/beta receptor 1; IFNR1; IFNAR; IFN-alpha/beta receptor 1; IFN-R-1; Cytokine receptor family 2 member 1; Cytokine receptor classII member 1; Cytokine receptor class-II member 1; CRF21; CRF2-1
T95371	FUNCTION	Functions in general as heterodimer with IFNAR2. Type I interferon binding activates the JAK-STAT signaling cascade, and triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and the IFNR alpha- and beta-subunits themselves. Can form an active IFNB1 receptor by itself and activate a signaling cascade that does not involve activation of the JAK-STAT pathway. Component of the receptor for type I interferons, including interferons alpha, IFNB1 and IFNW1.
T95371	PDBSTRUC	4PO6; 3SE4; 3SE3; 3S98
T95371	BIOCLASS	Cytokine receptor
T95371	SEQUENCE	MMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVTFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSFTPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERIENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQNQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQKGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTPVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSVFSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDEYFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSNEDESESKTSEELQQDFV
T95371	DRUGINFO	D02VBL	EMZ701	Phase 2
T95371	DRUGINFO	D06TME	MEDI-546	Phase 2
T95371	DRUGINFO	D0B3RL	R-IFN-1a	Phase 2
T95371	DRUGINFO	D0C3VQ	Zadaxin/lamivudine	Phase 2
T95371	DRUGINFO	D05ODU	Belerofon	Phase 1
T95371	DRUGINFO	D00LXD	Omega interferon	Discontinued in Phase 2
T95371	DRUGINFO	D0F0MU	BLX-883	Discontinued in Phase 1
T95371	DRUGINFO	D04TXB	Ceplene/Peg-Intron/Rebetol	Investigative

T97353	TARGETID	T97353
T97353	FORMERID	TTDI01786
T97353	UNIPROID	ITA2_HUMAN-ITB1_HUMAN
T97353	TARGNAME	Integrin alpha-2/beta-1 (ITGA2/B1)
T97353	GENENAME	ITGA2-ITGB1
T97353	TARGTYPE	Clinical trial
T97353	SYNONYMS	alpha(2)beta(1) integrin; Integrin alpha(2)beta(1); Alpha 2 beta 1 integrin
T97353	FUNCTION	Integrin alpha-2/beta-1 isa receptor for laminin, collagen, collagen C-propeptides, fibronectin and E-cadherin. It recognizes the proline-hydroxylated sequence G-F-P-G-E-R in collagen. It is responsible for adhesion of platelets and other cells to collagens, modulation of collagen and collagenase gene expression, force generation and organization of newly synthesized extracellular matrix.
T97353	BIOCLASS	Integrin
T97353	SEQUENCE	MNLQPIFWIGLISSVCCVFAQTDENRCLKANAKSCGECIQAGPNCGWCTNSTFLQEGMPTSARCDDLEALKKKGCPPDDIENPRGSKDIKKNKNVTNRSKGTAEKLKPEDITQIQPQQLVLRLRSGEPQTFTLKFKRAEDYPIDLYYLMDLSYSMKDDLENVKSLGTDLMNEMRRITSDFRIGFGSFVEKTVMPYISTTPAKLRNPCTSEQNCTSPFSYKNVLSLTNKGEVFNELVGKQRISGNLDSPEGGFDAIMQVAVCGSLIGWRNVTRLLVFSTDAGFHFAGDGKLGGIVLPNDGQCHLENNMYTMSHYYDYPSIAHLVQKLSENNIQTIFAVTEEFQPVYKELKNLIPKSAVGTLSANSSNVIQLIIDAYNSLSSEVILENGKLSEGVTISYKSYCKNGVNGTGENGRKCSNISIGDEVQFEISITSNKCPKKDSDSFKIRPLGFTEEVEVILQYICECECQSEGIPESPKCHEGNGTFECGACRCNEGRVGRHCECSTDEVNSEDMDAYCRKENSSEICSNNGECVCGQCVCRKRDNTNEIYSGKFCECDNFNCDRSNGLICGGNGVCKCRVCECNPNYTGSACDCSLDTSTCEASNGQICNGRGICECGVCKCTDPKFQGQTCEMCQTCLGVCAEHKECVQCRAFNKGEKKDTCTQECSYFNITKVESRDKLPQPVQPDPVSHCKEKDVDDCWFYFTYSVNGNNEVMVHVVENPECPTGPDIIPIVAGVVAGIVLIGLALLLIWKLLMIIHDRREFAKFEKEKMNAKWDTGENPIYKSAVTTVVNPKYEGKMGPERTGAAPLPLLLVLALSQGILNCCLAYNVGLPEAKIFSGPSSEQFGYAVQQFINPKGNWLLVGSPWSGFPENRMGDVYKCPVDLSTATCEKLNLQTSTSIPNVTEMKTNMSLGLILTRNMGTGGFLTCGPLWAQQCGNQYYTTGVCSDISPDFQLSASFSPATQPCPSLIDVVVVCDESNSIYPWDAVKNFLEKFVQGLDIGPTKTQVGLIQYANNPRVVFNLNTYKTKEEMIVATSQTSQYGGDLTNTFGAIQYARKYAYSAASGGRRSATKVMVVVTDGESHDGSMLKAVIDQCNHDNILRFGIAVLGYLNRNALDTKNLIKEIKAIASIPTERYFFNVSDEAALLEKAGTLGEQIFSIEGTVQGGDNFQMEMSQVGFSADYSSQNDILMLGAVGAFGWSGTIVQKTSHGHLIFPKQAFDQILQDRNHSSYLGYSVAAISTGESTHFVAGAPRANYTGQIVLYSVNENGNITVIQAHRGDQIGSYFGSVLCSVDVDKDTITDVLLVGAPMYMSDLKKEEGRVYLFTIKKGILGQHQFLEGPEGIENTRFGSAIAALSDINMDGFNDVIVGSPLENQNSGAVYIYNGHQGTIRTKYSQKILGSDGAFRSHLQYFGRSLDGYGDLNGDSITDVSIGAFGQVVQLWSQSIADVAIEASFTPEKITLVNKNAQIILKLCFSAKFRPTKQNNQVAIVYNITLDADGFSSRVTSRGLFKENNERCLQKNMVVNQAQSCPEHIIYIQEPSDVVNSLDLRVDISLENPGTSPALEAYSETAKVFSIPFHKDCGEDGLCISDLVLDVRQIPAAQEQPFIVSNQNKRLTFSVTLKNKRESAYNTGIVVDFSENLFFASFSLPVDGTEVTCQVAASQKSVACDVGYPALKREQQVTFTINFDFNLQNLQNQASLSFQALSESQEENKADNLVNLKIPLLYDAEIHLTRSTNINFYEISSDGNVPSIVHSFEDVGPKFIFSLKVTTGSVPVSMATVIIHIPQYTKEKNPLMYLTGVQTDKAGDISCNADINPLKIGQTSSSVSFKSENFRHTKELNCRTASCSNVTCWLKDVHMKGEYFVNVTTRIWNGTFASSTFQTVQLTAAAEINTYNPEIYVIEDNTVTIPLMIMKPDEKAEVPTGVIIGSIIAGILLLLALVAILWKLGFFKRKYEKMTKNPDEIDETTELSS
T97353	DRUGINFO	D0KN0I	Valetizumab	Phase 2
T97353	DRUGINFO	D0R9IH	SAR-339658	Phase 2
T97353	DRUGINFO	D0X9UA	Vatelizumab	Phase 2
T97353	DRUGINFO	D05CGH	Evatak	Investigative
T97353	DRUGINFO	D0XF7N	TCI15	Investigative

T44479	TARGETID	T44479
T44479	FORMERID	TTDR00293
T44479	UNIPROID	CXA1_HUMAN
T44479	TARGNAME	Gap junction alpha-1 protein (GJA1)
T44479	GENENAME	GJA1
T44479	TARGTYPE	Clinical trial
T44479	SYNONYMS	Gap junction 43 kDa heart protein; GJAL; Cx43; Connexin-43; Connexin 43
T44479	FUNCTION	A gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell. May play a critical role in the physiology of hearing by participating in the recycling of potassium to the cochlear endolymph. Negative regulator of bladder functional capacity: acts by enhancing intercellular electrical and chemical transmission, thus sensitizing bladder muscles to cholinergic neural stimuli and causing them to contract. May play a role in cell growth inhibition through the regulation of NOV expression and localization. Plays an essential role in gap junction communication in the ventricles. Gap junction protein that acts as a regulator of bladder capacity.
T44479	PDBSTRUC	2LL2
T44479	BIOCLASS	Gap junction-forming connexin
T44479	SEQUENCE	MGDWSALGKLLDKVQAYSTAGGKVWLSVLFIFRILLLGTAVESAWGDEQSAFRCNTQQPGCENVCYDKSFPISHVRFWVLQIIFVSVPTLLYLAHVFYVMRKEEKLNKKEEELKVAQTDGVNVDMHLKQIEIKKFKYGIEEHGKVKMRGGLLRTYIISILFKSIFEVAFLLIQWYIYGFSLSAVYTCKRDPCPHQVDCFLSRPTEKTIFIIFMLVVSLVSLALNIIELFYVFFKGVKDRVKGKSDPYHATSGALSPAKDCGSQKYAYFNGCSSPTAPLSPMSPPGYKLVTGDRNNSSCRNYNKQASEQNWANYSAEQNRMGQAGSTISNSHAQPFDFPDDNQNSKKLAAGHELQPLAIVDQRPSSRASSRASSRPRPDDLEI
T44479	DRUGINFO	D01NWV	Granexin gel	Phase 3
T44479	DRUGINFO	D04WBT	Act1	Phase 3
T44479	DRUGINFO	DZEF27	HCB1019	Phase 2
T44479	DRUGINFO	DXAI94	ALMB-0168	Phase 1/2
T44479	DRUGINFO	DJR71Z	ALMB-0166	Phase 1
T44479	DRUGINFO	D00VJY	octanol	Investigative

T51499	TARGETID	T51499
T51499	FORMERID	TTDI02169
T51499	UNIPROID	SAP3_HUMAN
T51499	TARGNAME	Ganglioside GM2 activator (GM2A)
T51499	GENENAME	GM2A
T51499	TARGTYPE	Clinical trial
T51499	SYNONYMS	Sphingolipid activator protein 3; SAP3; Ganglioside GM2 activator isoform short; GM2AP; GM2A; Cerebroside sulfate activator protein
T51499	FUNCTION	The large binding pocket can accommodate severalsingle chain phospholipids and fatty acids, GM2A also exhibits some calcium-independent phospholipase activity. Binds gangliosides and stimulates ganglioside GM2 degradation. It stimulates only the breakdown of ganglioside GM2 and glycolipid GA2 by beta-hexosaminidase A. It extracts single GM2 molecules from membranes and presents them in soluble form to beta- hexosaminidase A forcleavage of N-acetyl-D-galactosamine and conversion to GM3.
T51499	PDBSTRUC	2AG9; 2AG4; 2AG2; 2AF9; 1TJJ
T51499	SEQUENCE	MQSLMQAPLLIALGLLLAAPAQAHLKKPSQLSSFSWDNCDEGKDPAVIRSLTLEPDPIIVPGNVTLSVMGSTSVPLSSPLKVDLVLEKEVAGLWIKIPCTDYIGSCTFEHFCDVLDMLIPTGEPCPEPLRTYGLPCHCPFKEGTYSLPKSEFVVPDLELPSWLTTGNYRIESVLSSSGKRLGCIKIAASLKGI
T51499	DRUGINFO	D0N6TD	BIW-8962	Phase 1/2

T48457	TARGETID	T48457
T48457	FORMERID	TTDR00734
T48457	UNIPROID	CR1_HUMAN
T48457	TARGNAME	Complement receptor type 1 (CR1)
T48457	GENENAME	CR1
T48457	TARGTYPE	Clinical trial
T48457	SYNONYMS	CR1; CD35 antigen; C3b/C4b receptor
T48457	FUNCTION	Mediates cellular binding of particles and immunecomplexes that have activated complement.
T48457	PDBSTRUC	5FO9; 2Q7Z; 2MCZ; 2MCY; 1PPQ
T48457	BIOCLASS	Receptor of complement activation
T48457	SEQUENCE	MGASSPRSPEPVGPPAPGLPFCCGGSLLAVVVLLALPVAWGQCNAPEWLPFARPTNLTDEFEFPIGTYLNYECRPGYSGRPFSIICLKNSVWTGAKDRCRRKSCRNPPDPVNGMVHVIKGIQFGSQIKYSCTKGYRLIGSSSATCIISGDTVIWDNETPICDRIPCGLPPTITNGDFISTNRENFHYGSVVTYRCNPGSGGRKVFELVGEPSIYCTSNDDQVGIWSGPAPQCIIPNKCTPPNVENGILVSDNRSLFSLNEVVEFRCQPGFVMKGPRRVKCQALNKWEPELPSCSRVCQPPPDVLHAERTQRDKDNFSPGQEVFYSCEPGYDLRGAASMRCTPQGDWSPAAPTCEVKSCDDFMGQLLNGRVLFPVNLQLGAKVDFVCDEGFQLKGSSASYCVLAGMESLWNSSVPVCEQIFCPSPPVIPNGRHTGKPLEVFPFGKTVNYTCDPHPDRGTSFDLIGESTIRCTSDPQGNGVWSSPAPRCGILGHCQAPDHFLFAKLKTQTNASDFPIGTSLKYECRPEYYGRPFSITCLDNLVWSSPKDVCKRKSCKTPPDPVNGMVHVITDIQVGSRINYSCTTGHRLIGHSSAECILSGNAAHWSTKPPICQRIPCGLPPTIANGDFISTNRENFHYGSVVTYRCNPGSGGRKVFELVGEPSIYCTSNDDQVGIWSGPAPQCIIPNKCTPPNVENGILVSDNRSLFSLNEVVEFRCQPGFVMKGPRRVKCQALNKWEPELPSCSRVCQPPPDVLHAERTQRDKDNFSPGQEVFYSCEPGYDLRGAASMRCTPQGDWSPAAPTCEVKSCDDFMGQLLNGRVLFPVNLQLGAKVDFVCDEGFQLKGSSASYCVLAGMESLWNSSVPVCEQIFCPSPPVIPNGRHTGKPLEVFPFGKAVNYTCDPHPDRGTSFDLIGESTIRCTSDPQGNGVWSSPAPRCGILGHCQAPDHFLFAKLKTQTNASDFPIGTSLKYECRPEYYGRPFSITCLDNLVWSSPKDVCKRKSCKTPPDPVNGMVHVITDIQVGSRINYSCTTGHRLIGHSSAECILSGNTAHWSTKPPICQRIPCGLPPTIANGDFISTNRENFHYGSVVTYRCNLGSRGRKVFELVGEPSIYCTSNDDQVGIWSGPAPQCIIPNKCTPPNVENGILVSDNRSLFSLNEVVEFRCQPGFVMKGPRRVKCQALNKWEPELPSCSRVCQPPPEILHGEHTPSHQDNFSPGQEVFYSCEPGYDLRGAASLHCTPQGDWSPEAPRCAVKSCDDFLGQLPHGRVLFPLNLQLGAKVSFVCDEGFRLKGSSVSHCVLVGMRSLWNNSVPVCEHIFCPNPPAILNGRHTGTPSGDIPYGKEISYTCDPHPDRGMTFNLIGESTIRCTSDPHGNGVWSSPAPRCELSVRAGHCKTPEQFPFASPTIPINDFEFPVGTSLNYECRPGYFGKMFSISCLENLVWSSVEDNCRRKSCGPPPEPFNGMVHINTDTQFGSTVNYSCNEGFRLIGSPSTTCLVSGNNVTWDKKAPICEIISCEPPPTISNGDFYSNNRTSFHNGTVVTYQCHTGPDGEQLFELVGERSIYCTSKDDQVGVWSSPPPRCISTNKCTAPEVENAIRVPGNRSFFSLTEIIRFRCQPGFVMVGSHTVQCQTNGRWGPKLPHCSRVCQPPPEILHGEHTLSHQDNFSPGQEVFYSCEPSYDLRGAASLHCTPQGDWSPEAPRCTVKSCDDFLGQLPHGRVLLPLNLQLGAKVSFVCDEGFRLKGRSASHCVLAGMKALWNSSVPVCEQIFCPNPPAILNGRHTGTPFGDIPYGKEISYACDTHPDRGMTFNLIGESSIRCTSDPQGNGVWSSPAPRCELSVPAACPHPPKIQNGHYIGGHVSLYLPGMTISYICDPGYLLVGKGFIFCTDQGIWSQLDHYCKEVNCSFPLFMNGISKELEMKKVYHYGDYVTLKCEDGYTLEGSPWSQCQADDRWDPPLAKCTSRTHDALIVGTLSGTIFFILLIIFLSWIILKHRKGNNAHENPKEVAIHLHSQGGSSVHPRTLQTNEENSRVLP
T48457	DRUGINFO	D0T4NV	CDX-1135	Phase 1

T72038	TARGETID	T72038
T72038	FORMERID	TTDR00804
T72038	UNIPROID	LEG3_HUMAN
T72038	TARGNAME	Galectin-3 (LGALS3)
T72038	GENENAME	LGALS3
T72038	TARGTYPE	Clinical trial
T72038	SYNONYMS	Mac-2 antigen; MAC2; Lectin L-29; Laminin-binding protein; L-31; IgE-binding protein; Galactoside-binding protein; Galactose-specific lectin 3; Gal-3; GALBP; Carbohydrate-binding protein 35; Carbohydrate binding protein 35; CBP 35; Beta-galactoside-binding protein LGALS3; 35 kDa lectin
T72038	FUNCTION	May mediate with the alpha-3, beta-1 integrin the stimulation by CSPG4 of endothelial cells migration. Together with DMBT1, required for terminal differentiation of columnar epithelial cells during early embryogenesis. In the nucleus: acts as a pre-mRNA splicing factor. Involved in acute inflammatory responses including neutrophil activation and adhesion, chemoattraction of monocytes macrophages, opsonization of apoptotic neutrophils, and activation of mast cells. Together with TRIM16, coordinates the recognition of membrane damage with mobilization of the core autophagy regulators ATG16L1 and BECN1 in response to damaged endomembranes. Galactose-specific lectin which binds IgE.
T72038	PDBSTRUC	6QGF; 6QGE; 6I78; 6I77; 6I76
T72038	SEQUENCE	MADNFSLHDALSGSGNPNPQGWPGAWGNQPAGAGGYPGASYPGAYPGQAPPGAYPGQAPPGAYPGAPGAYPGAPAPGVYPGPPSGPGAYPSSGQPSATGAYPATGPYGAPAGPLIVPYNLPLPGGVVPRMLITILGTVKPNANRIALDFQRGNDVAFHFNPRFNENNRRVIVCNTKLDNNWGREERQSVFPFESGKPFKIQVLVEPDHFKVAVNDAHLLQYNHRVKKLNEISKLGISGDIDLTSASYTMI
T72038	DRUGINFO	D06BKH	GR-MD-02	Phase 2
T72038	DRUGINFO	DU5G2B	GB0139	Phase 2
T72038	DRUGINFO	DU5G2B	GB0139	Phase 2
T72038	DRUGINFO	D03CDB	PFFFFF	Investigative
T72038	DRUGINFO	D0HB9G	2,3,5,6-Tetrafluoro-4-Methoxy-Benzamide	Investigative

T07045	TARGETID	T07045
T07045	FORMERID	TTDI02210
T07045	UNIPROID	PACA_HUMAN
T07045	TARGNAME	Pituitary adenylate cyclase-activating 38 (PACAP-38)
T07045	GENENAME	ADCYAP1
T07045	TARGTYPE	Clinical trial
T07045	SYNONYMS	Pituitary adenylate cyclase-activating polypeptide; PACAP38; PACAP27; PACAP-38; PACAP-27; PACAP; ADCYAP1
T07045	FUNCTION	Binding to its receptor activates G proteins and stimulates adenylate cyclase in pituitary cells. Promotes neuron projection development through the RAPGEF2/Rap1/B-Raf/ERK pathway.
T07045	PDBSTRUC	2JOD; 2D2P; 1GEA
T07045	BIOCLASS	Glucagon
T07045	SEQUENCE	HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK
T07045	DRUGINFO	D00EGU	PACAP38	Phase 1

T16868	TARGETID	T16868
T16868	FORMERID	TTDC00137
T16868	UNIPROID	CADH2_HUMAN
T16868	TARGNAME	Neural cadherin (CDH2)
T16868	GENENAME	CDH2
T16868	TARGTYPE	Clinical trial
T16868	SYNONYMS	NCAD; N-cadherin; Cadherin-2; CDw325; CDHN; CD325
T16868	FUNCTION	Cadherins may thus contribute to the sorting of heterogeneous cell types. Acts as a regulator of neural stem cells quiescence by mediating anchorage of neural stem cells to ependymocytes in the adult subependymal zone: upon cleavage by MMP24, CDH2-mediated anchorage is affected, leading to modulate neural stem cell quiescence. CDH2 may be involved in neuronal recognition mechanism. In hippocampal neurons, may regulate dendritic spine density. Calcium-dependent cell adhesion protein; preferentially mediates homotypic cell-cell adhesion by dimerization with a CDH2 chain from another cell.
T16868	BIOCLASS	Cadherin protein
T16868	SEQUENCE	MCRIAGALRTLLPLLAALLQASVEASGEIALCKTGFPEDVYSAVLSKDVHEGQPLLNVKFSNCNGKRKVQYESSEPADFKVDEDGMVYAVRSFPLSSEHAKFLIYAQDKETQEKWQVAVKLSLKPTLTEESVKESAEVEEIVFPRQFSKHSGHLQRQKRDWVIPPINLPENSRGPFPQELVRIRSDRDKNLSLRYSVTGPGADQPPTGIFIINPISGQLSVTKPLDREQIARFHLRAHAVDINGNQVENPIDIVINVIDMNDNRPEFLHQVWNGTVPEGSKPGTYVMTVTAIDADDPNALNGMLRYRIVSQAPSTPSPNMFTINNETGDIITVAAGLDREKVQQYTLIIQATDMEGNPTYGLSNTATAVITVTDVNDNPPEFTAMTFYGEVPENRVDIIVANLTVTDKDQPHTPAWNAVYRISGGDPTGRFAIQTDPNSNDGLVTVVKPIDFETNRMFVLTVAAENQVPLAKGIQHPPQSTATVSVTVIDVNENPYFAPNPKIIRQEEGLHAGTMLTTFTAQDPDRYMQQNIRYTKLSDPANWLKIDPVNGQITTIAVLDRESPNVKNNIYNATFLASDNGIPPMSGTGTLQIYLLDINDNAPQVLPQEAETCETPDPNSINITALDYDIDPNAGPFAFDLPLSPVTIKRNWTITRLNGDFAQLNLKIKFLEAGIYEVPIIITDSGNPPKSNISILRVKVCQCDSNGDCTDVDRIVGAGLGTGAIIAILLCIIILLILVLMFVVWMKRRDKERQAKQLLIDPEDDVRDNILKYDEEGGGEEDQDYDLSQLQQPDTVEPDAIKPVGIRRMDERPIHAEPQYPVRSAAPHPGDIGDFINEGLKAADNDPTAPPYDSLLVFDYEGSGSTAGSLSSLNSSSSGGEQDYDYLNDWGPRFKKLADMYGGGDD
T16868	DRUGINFO	D0KK9E	Exherin	Phase 2

T06475	TARGETID	T06475
T06475	FORMERID	TTDR00575
T06475	UNIPROID	NUCL_HUMAN
T06475	TARGNAME	Nucleolin (NCL)
T06475	GENENAME	NCL
T06475	TARGTYPE	Clinical trial
T06475	SYNONYMS	Protein C23
T06475	FUNCTION	It is found associated with intranucleolar chromatin and pre-ribosomal particles. It induces chromatin decondensation by binding to histone H1. It is thought to play a role in pre-rRNA transcription and ribosome assembly. May play a role in the process of transcriptional elongation. Binds RNA oligonucleotides with 5'-UUAGGG-3' repeats more tightly than the telomeric single-stranded DNA 5'-TTAGGG-3' repeats. Nucleolin is the major nucleolar protein of growing eukaryotic cells.
T06475	PDBSTRUC	2KRR; 2FC9; 2FC8
T06475	SEQUENCE	MVKLAKAGKNQGDPKKMAPPPKEVEEDSEDEEMSEDEEDDSSGEEVVIPQKKGKKAAATSAKKVVVSPTKKVAVATPAKKAAVTPGKKAAATPAKKTVTPAKAVTTPGKKGATPGKALVATPGKKGAAIPAKGAKNGKNAKKEDSDEEEDDDSEEDEEDDEDEDEDEDEIEPAAMKAAAAAPASEDEDDEDDEDDEDDDDDEEDDSEEEAMETTPAKGKKAAKVVPVKAKNVAEDEDEEEDDEDEDDDDDEDDEDDDDEDDEEEEEEEEEEPVKEAPGKRKKEMAKQKAAPEAKKQKVEGTEPTTAFNLFVGNLNFNKSAPELKTGISDVFAKNDLAVVDVRIGMTRKFGYVDFESAEDLEKALELTGLKVFGNEIKLEKPKGKDSKKERDARTLLAKNLPYKVTQDELKEVFEDAAEIRLVSKDGKSKGIAYIEFKTEADAEKTFEEKQGTEIDGRSISLYYTGEKGQNQDYRGGKNSTWSGESKTLVLSNLSYSATEETLQEVFEKATFIKVPQNQNGKSKGYAFIEFASFEDAKEALNSCNKREIEGRAIRLELQGPRGSPNARSQPSKTLFVKGLSEDTTEETLKESFDGSVRARIVTDRETGSSKGFGFVDFNSEEDAKAAKEAMEDGEIDGNKVTLDWAKPKGEGGFGGRGGGRGGFGGRGGGRGGRGGFGGRGRGGFGGRGGFRGGRGGGGDHKPQGKKTKFE
T06475	DRUGINFO	D06XBN	ACT-GRO-777	Phase 2
T06475	DRUGINFO	D09ENR	Itarnafloxin	Phase 2
T06475	DRUGINFO	D0Z1OR	IPP-204106	Phase 1/2

T40192	TARGETID	T40192
T40192	FORMERID	TTDI01966
T40192	UNIPROID	NFKB1_HUMAN
T40192	TARGNAME	DNA-binding factor KBF1 (p105)
T40192	GENENAME	NFKB1
T40192	TARGTYPE	Clinical trial
T40192	SYNONYMS	Nuclear factor of kappa light polypeptide gene enhancer in Bcells 1; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1; Nuclear factor NFkappaB p50 subunit; Nuclear factor NFkappaB p105 subunit; Nuclear factor NF-kappa-B p105 subunit; EBP1; EBP-1; DNAbinding factor KBF1
T40192	FUNCTION	NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105. NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis.
T40192	PDBSTRUC	3GUT; 2O61; 2DBF; 1SVC; 1NFI
T40192	SEQUENCE	MAEDDPYLGRPEQMFHLDPSLTHTIFNPEVFQPQMALPTDGPYLQILEQPKQRGFRFRYVCEGPSHGGLPGASSEKNKKSYPQVKICNYVGPAKVIVQLVTNGKNIHLHAHSLVGKHCEDGICTVTAGPKDMVVGFANLGILHVTKKKVFETLEARMTEACIRGYNPGLLVHPDLAYLQAEGGGDRQLGDREKELIRQAALQQTKEMDLSVVRLMFTAFLPDSTGSFTRRLEPVVSDAIYDSKAPNASNLKIVRMDRTAGCVTGGEEIYLLCDKVQKDDIQIRFYEEEENGGVWEGFGDFSPTDVHRQFAIVFKTPKYKDINITKPASVFVQLRRKSDLETSEPKPFLYYPEIKDKEEVQRKRQKLMPNFSDSFGGGSGAGAGGGGMFGSGGGGGGTGSTGPGYSFPHYGFPTYGGITFHPGTTKSNAGMKHGTMDTESKKDPEGCDKSDDKNTVNLFGKVIETTEQDQEPSEATVGNGEVTLTYATGTKEESAGVQDNLFLEKAMQLAKRHANALFDYAVTGDVKMLLAVQRHLTAVQDENGDSVLHLAIIHLHSQLVRDLLEVTSGLISDDIINMRNDLYQTPLHLAVITKQEDVVEDLLRAGADLSLLDRLGNSVLHLAAKEGHDKVLSILLKHKKAALLLDHPNGDGLNAIHLAMMSNSLPCLLLLVAAGADVNAQEQKSGRTALHLAVEHDNISLAGCLLLEGDAHVDSTTYDGTTPLHIAAGRGSTRLAALLKAAGADPLVENFEPLYDLDDSWENAGEDEGVVPGTTPLDMATSWQVFDILNGKPYEPEFTSDDLLAQGDMKQLAEDVKLQLYKLLEIPDPDKNWATLAQKLGLGILNNAFRLSPAPSKTLMDNYEVSGGTVRELVEALRQMGYTEAIEVIQAASSPVKTTSQAHSLPLSPASTRQQIDELRDSDSVCDSGVETSFRKLSFTESLTSGASLLTLNKMPHDYGQEGPLEGKI
T40192	DRUGINFO	D0V3LM	P54	Phase 2
T40192	DRUGINFO	D06TZZ	CAT 1004	Phase 2

T37808	TARGETID	T37808
T37808	FORMERID	TTDC00029
T37808	UNIPROID	ANPRB_HUMAN
T37808	TARGNAME	Atrial natriuretic peptide receptor B (NPR2)
T37808	GENENAME	NPR2
T37808	TARGTYPE	Clinical trial
T37808	SYNONYMS	NPR-B; Guanylate cyclase B; GC-B; Atrial natriuretic peptide receptor type B; Atrial natriuretic peptide receptor 2; ANPRB; ANPR-B; ANP-B
T37808	FUNCTION	Receptor for the C-type natriuretic peptide NPPC/CNP hormone. Has guanylate cyclase activity upon binding of its ligand. May play a role in the regulation of skeletal growth.
T37808	BIOCLASS	Phosphorus-oxygen lyase
T37808	ECNUMBER	EC 4.6.1.2
T37808	SEQUENCE	MALPSLLLLVAALAGGVRPPGARNLTLAVVLPEHNLSYAWAWPRVGPAVALAVEALGRALPVDLRFVSSELEGACSEYLAPLSAVDLKLYHDPDLLLGPGCVYPAASVARFASHWRLPLLTAGAVASGFSAKNDHYRTLVRTGPSAPKLGEFVVTLHGHFNWTARAALLYLDARTDDRPHYFTIEGVFEALQGSNLSVQHQVYAREPGGPEQATHFIRANGRIVYICGPLEMLHEILLQAQRENLTNGDYVFFYLDVFGESLRAGPTRATGRPWQDNRTREQAQALREAFQTVLVITYREPPNPEYQEFQNRLLIRAREDFGVELGPSLMNLIAGCFYDGILLYAEVLNETIQEGGTREDGLRIVEKMQGRRYHGVTGLVVMDKNNDRETDFVLWAMGDLDSGDFQPAAHYSGAEKQIWWTGRPIPWVKGAPPSDNPPCAFDLDDPSCDKTPLSTLAIVALGTGITFIMFGVSSFLIFRKLMLEKELASMLWRIRWEELQFGNSERYHKGAGSRLTLSLRGSSYGSLMTAHGKYQIFANTGHFKGNVVAIKHVNKKRIELTRQVLFELKHMRDVQFNHLTRFIGACIDPPNICIVTEYCPRGSLQDILENDSINLDWMFRYSLINDLVKGMAFLHNSIISSHGSLKSSNCVVDSRFVLKITDYGLASFRSTAEPDDSHALYAKKLWTAPELLSGNPLPTTGMQKADVYSFGIILQEIALRSGPFYLEGLDLSPKEIVQKVRNGQRPYFRPSIDRTQLNEELVLLMERCWAQDPAERPDFGQIKGFIRRFNKEGGTSILDNLLLRMEQYANNLEKLVEERTQAYLEEKRKAEALLYQILPHSVAEQLKRGETVQAEAFDSVTIYFSDIVGFTALSAESTPMQVVTLLNDLYTCFDAIIDNFDVYKVETIGDAYMVVSGLPGRNGQRHAPEIARMALALLDAVSSFRIRHRPHDQLRLRIGVHTGPVCAGVVGLKMPRYCLFGDTVNTASRMESNGQALKIHVSSTTKDALDELGCFQLELRGDVEMKGKGKMRTYWLLGERKGPPGLL

T03556	TARGETID	T03556
T03556	FORMERID	TTDR00268
T03556	UNIPROID	HNF1A_HUMAN
T03556	TARGNAME	Hepatocyte nuclear factor 1-alpha (HNF1A)
T03556	GENENAME	HNF1A
T03556	TARGTYPE	Clinical trial
T03556	SYNONYMS	Transcription factor-1; Transcription factor 1; TCF1; TCF-1; Liver-specific transcription factor LF-B1; Liver specific transcription factor LF-B1; LFB1; HNF-1A; HNF-1-alpha; HNF-1 alpha
T03556	FUNCTION	Binds to the inverted palindrome 5'-GTTAATNATTAAC-3'. Activates the transcription of CYP1A2, CYP2E1 and CYP3A11. Transcriptional activator that regulates the tissue specific expression of multiple genes, especially in pancreatic islet cells and in liver.
T03556	PDBSTRUC	2GYP; 1IC8
T03556	SEQUENCE	MVSKLSQLQTELLAALLESGLSKEALIQALGEPGPYLLAGEGPLDKGESCGGGRGELAELPNGLGETRGSEDETDDDGEDFTPPILKELENLSPEEAAHQKAVVETLLQEDPWRVAKMVKSYLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAALYTWYVRKQREVAQQFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFRHKLAMDTYSGPPPGPGPGPALPAHSSPGLPPPALSPSKVHGVRYGQPATSETAEVPSSSGGPLVTVSTPLHQVSPTGLEPSHSLLSTEAKLVSAAGGPLPPVSTLTALHSLEQTSPGLNQQPQNLIMASLPGVMTIGPGEPASLGPTFTNTGASTLVIGLASTQAQSVPVINSMGSSLTTLQPVQFSQPLHPSYQQPLMPPVQSHVTQSPFMATMAQLQSPHALYSHKPEVAQYTHTGLLPQTMLITDTTNLSALASLTPTKQVFTSDTEASSESGLHTPASQATTLHVPSQDPAGIQHLQPAHRLSASPTVSSSSLVLYQSSDSSNGQSHLLPSNHSVIETFISTQMASSSQ
T03556	DRUGINFO	D00EFT	Norleucine	Phase 1/2

T87831	TARGETID	T87831
T87831	FORMERID	TTDR00011
T87831	UNIPROID	FPR1_HUMAN
T87831	TARGNAME	N-formyl peptide receptor (FPR1)
T87831	GENENAME	FPR1
T87831	TARGTYPE	Clinical trial
T87831	SYNONYMS	N-formylpeptide chemoattractant receptor; FPR1; FPR
T87831	FUNCTION	High affinity receptor for N-formyl-methionyl peptides (fMLP), which are powerful neutrophil chemotactic factors (PubMed:2161213, PubMed:2176894, PubMed:10514456, PubMed:15153520). Binding of fMLP to the receptor stimulates intracellular calcium mobilization and superoxide anion release (PubMed:2161213, PubMed:1712023, PubMed:15153520). This response is mediated via a G-protein that activates a phosphatidylinositol- calcium second messenger system(PubMed:1712023, PubMed:10514456).
T87831	BIOCLASS	GPCR rhodopsin
T87831	SEQUENCE	METNSSLPTNISGGTPAVSAGYLFLDIITYLVFAVTFVLGVLGNGLVIWVAGFRMTHTVTTISYLNLAVADFCFTSTLPFFMVRKAMGGHWPFGWFLCKFVFTIVDINLFGSVFLIALIALDRCVCVLHPVWTQNHRTVSLAKKVIIGPWVMALLLTLPVIIRVTTVPGKTGTVACTFNFSPWTNDPKERINVAVAMLTVRGIIRFIIGFSAPMSIVAVSYGLIATKIHKQGLIKSSRPLRVLSFVAAAFFLCWSPYQVVALIATVRIRELLQGMYKEIGIAVDVTSALAFFNSCLNPMLYVFMGQDFRERLIHALPASLERALTEDSTQTSDTATNSTLPSAEVELQAK
T87831	DRUGINFO	D03BQP	Rebamipide	Phase 3
T87831	DRUGINFO	D00OMW	group E 1682-2106	Investigative
T87831	DRUGINFO	D00XGW	BVT173187	Investigative
T87831	DRUGINFO	D01VFQ	CGEN-855	Investigative
T87831	DRUGINFO	D01VLV	AG-11/03	Investigative
T87831	DRUGINFO	D05UWQ	methionine benzimidazole 6	Investigative
T87831	DRUGINFO	D09DAP	AG-09/1	Investigative
T87831	DRUGINFO	D0G5DH	diamide 7	Investigative
T87831	DRUGINFO	D0M9RF	3570-0208	Investigative
T87831	DRUGINFO	D0Q8TJ	AG-14	Investigative
T87831	DRUGINFO	D01EOQ	PMID22607879CR-(-)-5f	Investigative
T87831	DRUGINFO	D0M0YH	fMet-Leu-Phe	Investigative
T87831	DRUGINFO	D0WB8E	pyrazolone, 1	Investigative

T99397	TARGETID	T99397
T99397	UNIPROID	VDAC1_HUMAN
T99397	TARGNAME	Voltage-dependent anion-selective channel 1 (VDAC1)
T99397	GENENAME	VDAC1
T99397	TARGTYPE	Clinical trial
T99397	SYNONYMS	Porin 31HM; Porin 31HL; Plasmalemmal porin; Outer mitochondrial membrane protein porin 1
T99397	FUNCTION	Forms a channel through the mitochondrial outer membrane and also the plasma membrane. The channel at the outer mitochondrial membrane allows diffusion of small hydrophilic molecules; in the plasma membrane it is involved in cell volume regulation and apoptosis. It adopts an open conformation at low or zero membrane potential and a closed conformation at potentials above 30-40 mV. The open state has a weak anion selectivity whereas the closed state is cation-selective (PubMed:11845315, PubMed:18755977, PubMed:20230784, PubMed:8420959). May participate in the formation of the permeability transition pore complex (PTPC) responsible for the release of mitochondrial products that triggers apoptosis (PubMed:15033708, PubMed:25296756).
T99397	PDBSTRUC	6G73; 6G6U; 5XDO; 5XDN; 5JDP
T99397	BIOCLASS	Eukaryotic mitochondrial porin
T99397	SEQUENCE	MAVPPTYADLGKSARDVFTKGYGFGLIKLDLKTKSENGLEFTSSGSANTETTKVTGSLETKYRWTEYGLTFTEKWNTDNTLGTEITVEDQLARGLKLTFDSSFSPNTGKKNAKIKTGYKREHINLGCDMDFDIAGPSIRGALVLGYEGWLAGYQMNFETAKSRVTQSNFAVGYKTDEFQLHTNVNDGTEFGGSIYQKVNKKLETAVNLAWTAGNSNTRFGIAAKYQIDPDACFSAKVNNSSLIGLGYTQTLKPGIKLTLSALLDGKNVNAGGHKLGLGLEFQA
T99397	DRUGINFO	D06QBX	VDA-1102	Phase 2

T83905	TARGETID	T83905
T83905	FORMERID	TTDI02034
T83905	UNIPROID	CADH3_HUMAN
T83905	TARGNAME	Placental cadherin (CDH3)
T83905	GENENAME	CDH3
T83905	TARGTYPE	Clinical trial
T83905	SYNONYMS	Pcadherin; P-cadherin; Cadherin-3; CDHP
T83905	FUNCTION	Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types.
T83905	PDBSTRUC	5JYM; 5JYL; 4ZMZ; 4ZMY; 4ZMX
T83905	BIOCLASS	Cadherin protein
T83905	SEQUENCE	MGLPRGPLASLLLLQVCWLQCAASEPCRAVFREAEVTLEAGGAEQEPGQALGKVFMGCPGQEPALFSTDNDDFTVRNGETVQERRSLKERNPLKIFPSKRILRRHKRDWVVAPISVPENGKGPFPQRLNQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGTISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILDANDNAPMFDPQKYEAHVPENAVGHEVQRLTVTDLDAPNSPAWRATYLIMGGDDGDHFTITTHPESNQGILTTRKGLDFEAKNQHTLYVEVTNEAPFVLKLPTSTATIVVHVEDVNEAPVFVPPSKVVEVQEGIPTGEPVCVYTAEDPDKENQKISYRILRDPAGWLAMDPDSGQVTAVGTLDREDEQFVRNNIYEVMVLAMDNGSPPTTGTGTLLLTLIDVNDHGPVPEPRQITICNQSPVRQVLNITDKDLSPHTSPFQAQLTDDSDIYWTAEVNEEGDTVVLSLKKFLKQDTYDVHLSLSDHGNKEQLTVIRATVCDCHGHVETCPGPWKGGFILPVLGAVLALLFLLLVLLLLVRKKRKIKEPLLLPEDDTRDNVFYYGEEGGGEEDQDYDITQLHRGLEARPEVVLRNDVAPTIIPTPMYRPRPANPDEIGNFIIENLKAANTDPTAPPYDTLLVFDYEGSGSDAASLSSLTSSASDQDQDYDYLNEWGSRFKKLADMYGGGEDD
T83905	DRUGINFO	D0P9KD	PF-3732010	Phase 1
T83905	DRUGINFO	D0Y0HC	PF-06671008	Phase 1

T57034	TARGETID	T57034
T57034	FORMERID	TTDI02155
T57034	UNIPROID	PTPRB_HUMAN
T57034	TARGNAME	Protein tyrosine phosphatase beta (PTPRB)
T57034	GENENAME	PTPRB
T57034	TARGTYPE	Clinical trial
T57034	SYNONYMS	Vascular endothelial protein tyrosine phosphatase; VE-PTP; Receptor-type tyrosine-protein phosphatase beta; R-PTP-beta; PTPRB
T57034	FUNCTION	Plays an important role in blood vessel remodeling and angiogenesis. Not necessary for the initial formation of blood vessels, but is essential for their maintenance and remodeling. Can induce dephosphorylation of TEK/TIE2, CDH5/VE-cadherin and KDR/VEGFR-2. Regulates angiopoietin-TIE2 signaling in endothelial cells. Acts as a negative regulator of TIE2, and controls TIE2 driven endothelial cell proliferation, which in turn affects blood vessel remodeling during embryonic development and determines blood vessel size during perinatal growth. Essential for the maintenance of endothelial cell contact integrity and for the adhesive function of VE-cadherin in endothelial cells and this requires the presence of plakoglobin.
T57034	PDBSTRUC	2I5X; 2I4H; 2I4G; 2I4E; 2I3U
T57034	BIOCLASS	Phosphoric monoester hydrolase
T57034	ECNUMBER	EC 3.1.3.48
T57034	SEQUENCE	MLSHGAGLALWITLSLLQTGLAEPERCNFTLAESKASSHSVSIQWRILGSPCNFSLIYSSDTLGAALCPTFRIDNTTYGCNLQDLQAGTIYNFRIISLDEERTVVLQTDPLPPARFGVSKEKTTSTSLHVWWTPSSGKVTSYEVQLFDENNQKIQGVQIQESTSWNEYTFFNLTAGSKYNIAITAVSGGKRSFSVYTNGSTVPSPVKDIGISTKANSLLISWSHGSGNVERYRLMLMDKGILVHGGVVDKHATSYAFHGLTPGYLYNLTVMTEAAGLQNYRWKLVRTAPMEVSNLKVTNDGSLTSLKVKWQRPPGNVDSYNITLSHKGTIKESRVLAPWITETHFKELVPGRLYQVTVSCVSGELSAQKMAVGRTFPDKVANLEANNNGRMRSLVVSWSPPAGDWEQYRILLFNDSVVLLNITVGKEETQYVMDDTGLVPGRQYEVEVIVESGNLKNSERCQGRTVPLAVLQLRVKHANETSLSIMWQTPVAEWEKYIISLADRDLLLIHKSLSKDAKEFTFTDLVPGRKYMATVTSISGDLKNSSSVKGRTVPAQVTDLHVANQGMTSSLFTNWTQAQGDVEFYQVLLIHENVVIKNESISSETSRYSFHSLKSGSLYSVVVTTVSGGISSRQVVVEGRTVPSSVSGVTVNNSGRNDYLSVSWLLAPGDVDNYEVTLSHDGKVVQSLVIAKSVRECSFSSLTPGRLYTVTITTRSGKYENHSFSQERTVPDKVQGVSVSNSARSDYLRVSWVHATGDFDHYEVTIKNKNNFIQTKSIPKSENECVFVQLVPGRLYSVTVTTKSGQYEANEQGNGRTIPEPVKDLTLRNRSTEDLHVTWSGANGDVDQYEIQLLFNDMKVFPPFHLVNTATEYRFTSLTPGRQYKILVLTISGDVQQSAFIEGFTVPSAVKNIHISPNGATDSLTVNWTPGGGDVDSYTVSAFRHSQKVDSQTIPKHVFEHTFHRLEAGEQYQIMIASVSGSLKNQINVVGRTVPASVQGVIADNAYSSYSLIVSWQKAAGVAERYDILLLTENGILLRNTSEPATTKQHKFEDLTPGKKYKIQILTVSGGLFSKEAQTEGRTVPAAVTDLRITENSTRHLSFRWTASEGELSWYNIFLYNPDGNLQERAQVDPLVQSFSFQNLLQGRMYKMVIVTHSGELSNESFIFGRTVPASVSHLRGSNRNTTDSLWFNWSPASGDFDFYELILYNPNGTKKENWKDKDLTEWRFQGLVPGRKYVLWVVTHSGDLSNKVTAESRTAPSPPSLMSFADIANTSLAITWKGPPDWTDYNDFELQWLPRDALTVFNPYNNRKSEGRIVYGLRPGRSYQFNVKTVSGDSWKTYSKPIFGSVRTKPDKIQNLHCRPQNSTAIACSWIPPDSDFDGYSIECRKMDTQEVEFSRKLEKEKSLLNIMMLVPHKRYLVSIKVQSAGMTSEVVEDSTITMIDRPPPPPPHIRVNEKDVLISKSSINFTVNCSWFSDTNGAVKYFTVVVREADGSDELKPEQQHPLPSYLEYRHNASIRVYQTNYFASKCAENPNSNSKSFNIKLGAEMESLGGKCDPTQQKFCDGPLKPHTAYRISIRAFTQLFDEDLKEFTKPLYSDTFFSLPITTESEPLFGAIEGVSAGLFLIGMLVAVVALLICRQKVSHGRERPSARLSIRRDRPLSVHLNLGQKGNRKTSCPIKINQFEGHFMKLQADSNYLLSKEYEELKDVGRNQSCDIALLPENRGKNRYNNILPYDATRVKLSNVDDDPCSDYINASYIPGNNFRREYIVTQGPLPGTKDDFWKMVWEQNVHNIVMVTQCVEKGRVKCDHYWPADQDSLYYGDLILQMLSESVLPEWTIREFKICGEEQLDAHRLIRHFHYTVWPDHGVPETTQSLIQFVRTVRDYINRSPGAGPTVVHCSAGVGRTGTFIALDRILQQLDSKDSVDIYGAVHDLRLHRVHMVQTECQYVYLHQCVRDVLRARKLRSEQENPLFPIYENVNPEYHRDPVYSRH
T57034	DRUGINFO	D08VIS	AKB-9778	Phase 2

T93122	TARGETID	T93122
T93122	FORMERID	TTDNC00645
T93122	UNIPROID	BDNF_HUMAN
T93122	TARGNAME	Brain-derived neurotrophic factor (BDNF)
T93122	GENENAME	BDNF
T93122	TARGTYPE	Clinical trial
T93122	SYNONYMS	Brainderived neurotrophic factor; Abrineurin
T93122	FUNCTION	Participates in axonal growth, pathfinding and in the modulation of dendritic growth and morphology. Major regulator of synaptic transmission and plasticity at adult synapses in many regions of the CNS. The versatility of BDNF is emphasized by its contribution to a range of adaptive neuronal responses including long-term potentiation (LTP), long-term depression (LTD), certain forms of short-term synaptic plasticity, as well as homeostatic regulation of intrinsic neuronal excitability. During development, promotes the survival and differentiation of selected neuronal populations of the peripheral and central nervous systems.
T93122	PDBSTRUC	1BND; 1B8M
T93122	BIOCLASS	Growth factor
T93122	SEQUENCE	MTILFLTMVISYFGCMKAAPMKEANIRGQGGLAYPGVRTHGTLESVNGPKAGSRGLTSLADTFEHVIEELLDEDQKVRPNEENNKDADLYTSRVMLSSQVPLEPPLLFLLEEYKNYLDAANMSMRVRRHSDPARRGELSVCDSISEWVTAADKKTAVDMSGGTVTVLEKVPVSKGQLKQYFYETKCNPMGYTKEGCRGIDKRHWNSQCRTTQSYVRALTMDSKKRIGWRFIRIDTSCVCTLTIKRGR
T93122	DRUGINFO	D0M2TG	PYM-50028	Phase 2

T86254	TARGETID	T86254
T86254	FORMERID	TTDR00683
T86254	UNIPROID	TENA_HUMAN
T86254	TARGNAME	Tenascin (TNC)
T86254	GENENAME	TNC
T86254	TARGTYPE	Clinical trial
T86254	SYNONYMS	Tenascin-C; TN-C; TN; Neuronectin; Myotendinous antigen; Miotendinous antigen; JI; Hexabrachion; HXB; Glioma-associated-extracellular matrix antigen; GP 150-225; GMEM; Cytotactin
T86254	FUNCTION	Promotes neurite outgrowth from cortical neurons grown on a monolayer of astrocytes. Ligand for integrins alpha-8/beta-1, alpha-9/beta-1, alpha-V/beta-3 and alpha-V/beta-6. In tumors, stimulates angiogenesis by elongation, migration and sprouting of endothelial cells. Extracellular matrix protein implicated in guidance of migrating neurons as well as axons during development, synaptic plasticity as well as neuronal regeneration.
T86254	PDBSTRUC	6QNV; 6BRB; 2RBL; 2RB8; 1TEN
T86254	SEQUENCE	MGAMTQLLAGVFLAFLALATEGGVLKKVIRHKRQSGVNATLPEENQPVVFNHVYNIKLPVGSQCSVDLESASGEKDLAPPSEPSESFQEHTVDGENQIVFTHRINIPRRACGCAAAPDVKELLSRLEELENLVSSLREQCTAGAGCCLQPATGRLDTRPFCSGRGNFSTEGCGCVCEPGWKGPNCSEPECPGNCHLRGRCIDGQCICDDGFTGEDCSQLACPSDCNDQGKCVNGVCICFEGYAGADCSREICPVPCSEEHGTCVDGLCVCHDGFAGDDCNKPLCLNNCYNRGRCVENECVCDEGFTGEDCSELICPNDCFDRGRCINGTCYCEEGFTGEDCGKPTCPHACHTQGRCEEGQCVCDEGFAGVDCSEKRCPADCHNRGRCVDGRCECDDGFTGADCGELKCPNGCSGHGRCVNGQCVCDEGYTGEDCSQLRCPNDCHSRGRCVEGKCVCEQGFKGYDCSDMSCPNDCHQHGRCVNGMCVCDDGYTGEDCRDRQCPRDCSNRGLCVDGQCVCEDGFTGPDCAELSCPNDCHGQGRCVNGQCVCHEGFMGKDCKEQRCPSDCHGQGRCVDGQCICHEGFTGLDCGQHSCPSDCNNLGQCVSGRCICNEGYSGEDCSEVSPPKDLVVTEVTEETVNLAWDNEMRVTEYLVVYTPTHEGGLEMQFRVPGDQTSTIIQELEPGVEYFIRVFAILENKKSIPVSARVATYLPAPEGLKFKSIKETSVEVEWDPLDIAFETWEIIFRNMNKEDEGEITKSLRRPETSYRQTGLAPGQEYEISLHIVKNNTRGPGLKRVTTTRLDAPSQIEVKDVTDTTALITWFKPLAEIDGIELTYGIKDVPGDRTTIDLTEDENQYSIGNLKPDTEYEVSLISRRGDMSSNPAKETFTTGLDAPRNLRRVSQTDNSITLEWRNGKAAIDSYRIKYAPISGGDHAEVDVPKSQQATTKTTLTGLRPGTEYGIGVSAVKEDKESNPATINAATELDTPKDLQVSETAETSLTLLWKTPLAKFDRYRLNYSLPTGQWVGVQLPRNTTSYVLRGLEPGQEYNVLLTAEKGRHKSKPARVKASTEQAPELENLTVTEVGWDGLRLNWTAADQAYEHFIIQVQEANKVEAARNLTVPGSLRAVDIPGLKAATPYTVSIYGVIQGYRTPVLSAEASTGETPNLGEVVVAEVGWDALKLNWTAPEGAYEYFFIQVQEADTVEAAQNLTVPGGLRSTDLPGLKAATHYTITIRGVTQDFSTTPLSVEVLTEEVPDMGNLTVTEVSWDALRLNWTTPDGTYDQFTIQVQEADQVEEAHNLTVPGSLRSMEIPGLRAGTPYTVTLHGEVRGHSTRPLAVEVVTEDLPQLGDLAVSEVGWDGLRLNWTAADNAYEHFVIQVQEVNKVEAAQNLTLPGSLRAVDIPGLEAATPYRVSIYGVIRGYRTPVLSAEASTAKEPEIGNLNVSDITPESFNLSWMATDGIFETFTIEIIDSNRLLETVEYNISGAERTAHISGLPPSTDFIVYLSGLAPSIRTKTISATATTEALPLLENLTISDINPYGFTVSWMASENAFDSFLVTVVDSGKLLDPQEFTLSGTQRKLELRGLITGIGYEVMVSGFTQGHQTKPLRAEIVTEAEPEVDNLLVSDATPDGFRLSWTADEGVFDNFVLKIRDTKKQSEPLEITLLAPERTRDITGLREATEYEIELYGISKGRRSQTVSAIATTAMGSPKEVIFSDITENSATVSWRAPTAQVESFRITYVPITGGTPSMVTVDGTKTQTRLVKLIPGVEYLVSIIAMKGFEESEPVSGSFTTALDGPSGLVTANITDSEALARWQPAIATVDSYVISYTGEKVPEITRTVSGNTVEYALTDLEPATEYTLRIFAEKGPQKSSTITAKFTTDLDSPRDLTATEVQSETALLTWRPPRASVTGYLLVYESVDGTVKEVIVGPDTTSYSLADLSPSTHYTAKIQALNGPLRSNMIQTIFTTIGLLYPFPKDCSQAMLNGDTTSGLYTIYLNGDKAEALEVFCDMTSDGGGWIVFLRRKNGRENFYQNWKAYAAGFGDRREEFWLGLDNLNKITAQGQYELRVDLRDHGETAFAVYDKFSVGDAKTRYKLKVEGYSGTAGDSMAYHNGRSFSTFDKDTDSAITNCALSYKGAFWYRNCHRVNLMGRYGDNNHSQGVNWFHWKGHEHSIQFAEMKLRPSNFRNLEGRRKRA
T86254	DRUGINFO	D0F1ZI	F-16-IL-2 fusion protein	Phase 2
T86254	DRUGINFO	D0G1IG	F-16-131I	Phase 1/2
T86254	DRUGINFO	D06JAL	8H9	Phase 1
T86254	DRUGINFO	D07ZKK	131I-81C6	Terminated

T85554	TARGETID	T85554
T85554	FORMERID	TTDNC00484
T85554	UNIPROID	CD27_HUMAN
T85554	TARGNAME	T-cell activation antigen CD27 (CD27)
T85554	GENENAME	CD27
T85554	TARGTYPE	Clinical trial
T85554	SYNONYMS	Tumor necrosis factor receptor superfamily member 7; Tcell activation antigen CD27; TNFRSF7; T14; CD27L receptor; CD27 antigen
T85554	FUNCTION	May play a role in survival of activated T-cells. May play a role in apoptosis through association with SIVA1. Receptor for CD70/CD27L.
T85554	PDBSTRUC	5TLK; 5TLJ; 5TL5
T85554	BIOCLASS	Cytokine receptor
T85554	SEQUENCE	MARPHPWWLCVLGTLVGLSATPAPKSCPERHYWAQGKLCCQMCEPGTFLVKDCDQHRKAAQCDPCIPGVSFSPDHHTRPHCESCRHCNSGLLVRNCTITANAECACRNGWQCRDKECTECDPLPNPSLTARSSQALSPHPQPTHLPYVSEMLEARTAGHMQTLADFRQLPARTLSTHWPPQRSLCSSDFIRILVIFSGMFLVFTLAGALFLHQRRKYRSNKGESPVEPAEPCHYSCPREEEGSTIPIQEDYRKPEPACSP
T85554	DRUGINFO	D0KV3M	Varlilumab	Phase 2
T85554	DRUGINFO	D09RLQ	CDX-1127	Phase 1
T85554	DRUGINFO	D28MNU	CDX-527	Phase 1

T47366	TARGETID	T47366
T47366	FORMERID	TTDNC00625
T47366	UNIPROID	AVR2A_HUMAN
T47366	TARGNAME	Activin receptor type IIA (ACVR2A)
T47366	GENENAME	ACVR2A
T47366	TARGTYPE	Clinical trial
T47366	SYNONYMS	Activin receptor type2A; Activin receptor type-2A; ACVR2; ACTRIIA; ACTR-IIA
T47366	FUNCTION	Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for activin A, activin B and inhibin A. Mediates induction of adipogenesis by GDF6. On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases.
T47366	PDBSTRUC	5NH3; 4ASX; 3SOC; 3Q4T
T47366	BIOCLASS	Kinase
T47366	ECNUMBER	EC 2.7.11.30
T47366	SEQUENCE	MGAAAKLAFAVFLISCSSGAILGRSETQECLFFNANWEKDRTNQTGVEPCYGDKDKRRHCFATWKNISGSIEIVKQGCWLDDINCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTSNPVTPKPPYYNILLYSLVPLMLIAGIVICAFWVYRHHKMAYPPVLVPTQDPGPPPPSPLLGLKPLQLLEVKARGRFGCVWKAQLLNEYVAVKIFPIQDKQSWQNEYEVYSLPGMKHENILQFIGAEKRGTSVDVDLWLITAFHEKGSLSDFLKANVVSWNELCHIAETMARGLAYLHEDIPGLKDGHKPAISHRDIKSKNVLLKNNLTACIADFGLALKFEAGKSAGDTHGQVGTRRYMAPEVLEGAINFQRDAFLRIDMYAMGLVLWELASRCTAADGPVDEYMLPFEEEIGQHPSLEDMQEVVVHKKKRPVLRDYWQKHAGMAMLCETIEECWDHDAEARLSAGCVGERITQMQRLTNIITTEDIVTVVTMVTNVDFPPKESSL
T47366	DRUGINFO	D0S5FF	BYM338	Phase 3

T68887	TARGETID	T68887
T68887	FORMERID	TTDI01778
T68887	UNIPROID	NMBR_HUMAN; GRPR_HUMAN; BRS3_HUMAN
T68887	TARGNAME	Bombesin receptor (BS)
T68887	GENENAME	NMBR; GRPR; BRS3
T68887	TARGTYPE	Clinical trial
T68887	SYNONYMS	BB
T68887	FUNCTION	Bombesin receptor activity. G protein-coupled receptor activity. Receptor for neuromedin-B. G protein-coupled receptor signaling pathway. Phospholipase C-activating G protein-coupled receptor signaling pathway.
T68887	BIOCLASS	GPCR rhodopsin
T68887	SEQUENCE	MPSKSLSNLSVTTGANESGSVPEGWERDFLPASDGTTTELVIRCVIPSLYLLIITVGLLGNIMLVKIFITNSAMRSVPNIFISNLAAGDLLLLLTCVPVDASRYFFDEWMFGKVGCKLIPVIQLTSVGVSVFTLTALSADRYRAIVNPMDMQTSGALLRTCVKAMGIWVVSVLLAVPEAVFSEVARISSLDNSSFTACIPYPQTDELHPKIHSVLIFLVYFLIPLAIISIYYYHIAKTLIKSAHNLPGEYNEHTKKQMETRKRLAKIVLVFVGCFIFCWFPNHILYMYRSFNYNEIDPSLGHMIVTLVARVLSFGNSCVNPFALYLLSESFRRHFNSQLCCGRKSYQERGTSYLLSSSAVRMTSLKSNAKNMVTNSVLLNGHSMKQEMAL
T68887	DRUGINFO	D08EEO	Demobesin	Phase 1
T68887	DRUGINFO	D0A4UW	BAY-86-7548	Phase 1
T68887	DRUGINFO	D02TPY	bag-1	Investigative
T68887	DRUGINFO	D03JFB	PMID12723954C21b	Investigative
T68887	DRUGINFO	D03TEJ	PD 165929	Investigative
T68887	DRUGINFO	D0A0DS	[3H]bag-2	Investigative
T68887	DRUGINFO	D0A1FE	PMID25497965C17c	Investigative
T68887	DRUGINFO	D0D5IV	PMID24412111C9f	Investigative
T68887	DRUGINFO	D0H4LP	PMID24412111C9g	Investigative
T68887	DRUGINFO	D0PP7U	phenylacetyl-Ala,DTrp-phenthylamide	Investigative
T68887	DRUGINFO	D0RF6M	ML-18	Investigative
T68887	DRUGINFO	D0T9VC	PMID24900283C8a	Investigative
T68887	DRUGINFO	D0U4ZS	PMID20167483C22e	Investigative
T68887	DRUGINFO	D01PWM	kuwanon H	Investigative
T68887	DRUGINFO	D02QOD	bombesin	Investigative
T68887	DRUGINFO	D07IAK	PD 168368	Investigative
T68887	DRUGINFO	D08RQW	MK-5046	Investigative
T68887	DRUGINFO	D09FOQ	bantag-1	Investigative
T68887	DRUGINFO	D0E1EC	ranatensin	Investigative
T68887	DRUGINFO	D0I5CS	PD 176252	Investigative
T68887	DRUGINFO	D0R8TG	[(N4-Bzdig)0]BB(7-14)	Investigative
T68887	DRUGINFO	D0S3XL	neuromedin B	Investigative

T50444	TARGETID	T50444
T50444	FORMERID	TTDC00213
T50444	UNIPROID	CTGF_HUMAN
T50444	TARGNAME	Connective tissue growth factor (CTGF)
T50444	GENENAME	CTGF
T50444	TARGTYPE	Clinical trial
T50444	SYNONYMS	Long; Insulin-like growth factor-binding protein 8; IGFBP8; IGFBP-8; IGF-binding protein 8; IBP-8; Hypertrophic chondrocyte-specific protein 24; HCS24; CCN2; CCN family member 2
T50444	FUNCTION	Promotes proliferation and differentiation of chondrocytes. Mediates heparin- and divalent cation-dependent cell adhesion in many cell types including fibroblasts, myofibroblasts, endothelial and epithelial cells. Enhances fibroblast growth factor-induced DNA synthesis. Major connective tissue mitoattractant secreted by vascular endothelial cells.
T50444	SEQUENCE	MTAASMGPVRVAFVVLLALCSRPAVGQNCSGPCRCPDEPAPRCPAGVSLVLDGCGCCRVCAKQLGELCTERDPCDPHKGLFCHFGSPANRKIGVCTAKDGAPCIFGGTVYRSGESFQSSCKYQCTCLDGAVGCMPLCSMDVRLPSPDCPFPRRVKLPGKCCEEWVCDEPKDQTVVGPALAAYRLEDTFGPDPTMIRANCLVQTTEWSACSKTCGMGISTRVTNDNASCRLEKQSRLCMVRPCEADLEENIKKGKKCIRTPKISKPIKFELSGCTSMKTYRAKFCGVCTDGRCCTPHRTTTLPVEFKCPDGEVMKKNMMFIKTCACHYNCPGDNDIFESLYYRKMYGDMA
T50444	DRUGINFO	D01FQR	Ocaperidone	Phase 2

T03573	TARGETID	T03573
T03573	FORMERID	TTDNC00464
T03573	UNIPROID	FCG2B_HUMAN
T03573	TARGNAME	Immunoglobulin gamma Fc receptor IIB (FCGR2B)
T03573	GENENAME	FCGR2B
T03573	TARGTYPE	Clinical trial
T03573	SYNONYMS	Low affinity immunoglobulin gamma Fc region receptor II-b; IgG Fc receptor II-b; FcRII-b; Fc-gamma-RIIb; Fc-gamma RII-b; FCG2B; CDw32 B; CD32 B
T03573	FUNCTION	Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis.
T03573	PDBSTRUC	5OCC; 3WJJ; 2FCB
T03573	BIOCLASS	Immunoglobulin
T03573	SEQUENCE	MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWINVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPNFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAAVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDALEEPDDQNRI
T03573	DRUGINFO	D00NXT	Xmab 5871	Phase 2
T03573	DRUGINFO	DD4H6V	BI 1206	Phase 1/2
T03573	DRUGINFO	D0QO6N	MGD010	Phase 1

T44589	TARGETID	T44589
T44589	FORMERID	TTDI01800
T44589	UNIPROID	IL3RB_HUMAN
T44589	TARGNAME	Interleukin 3 receptor (CSF2RB)
T44589	GENENAME	CSF2RB
T44589	TARGTYPE	Clinical trial
T44589	SYNONYMS	IL5RB; IL3RB; IL-5R; GM-CSF/IL-3/IL-5 receptor common beta subunit; Cytokine receptor common subunit beta; CDw131; CD131
T44589	FUNCTION	High affinity receptor for interleukin-3, interleukin-5 and granulocyte-macrophage colony-stimulating factor.
T44589	PDBSTRUC	5DWU; 4NKQ; 2NA9; 2NA8; 2GYS
T44589	BIOCLASS	Cytokine receptor
T44589	SEQUENCE	MVLAQGLLSMALLALCWERSLAGAEETIPLQTLRCYNDYTSHITCRWADTQDAQRLVNVTLIRRVNEDLLEPVSCDLSDDMPWSACPHPRCVPRRCVIPCQSFVVTDVDYFSFQPDRPLGTRLTVTLTQHVQPPEPRDLQISTDQDHFLLTWSVALGSPQSHWLSPGDLEFEVVYKRLQDSWEDAAILLSNTSQATLGPEHLMPSSTYVARVRTRLAPGSRLSGRPSKWSPEVCWDSQPGDEAQPQNLECFFDGAAVLSCSWEVRKEVASSVSFGLFYKPSPDAGEEECSPVLREGLGSLHTRHHCQIPVPDPATHGQYIVSVQPRRAEKHIKSSVNIQMAPPSLNVTKDGDSYSLRWETMKMRYEHIDHTFEIQYRKDTATWKDSKTETLQNAHSMALPALEPSTRYWARVRVRTSRTGYNGIWSEWSEARSWDTESVLPMWVLALIVIFLTIAVLLALRFCGIYGYRLRRKWEEKIPNPSKSHLFQNGSAELWPPGSMSAFTSGSPPHQGPWGSRFPELEGVFPVGFGDSEVSPLTIEDPKHVCDPPSGPDTTPAASDLPTEQPPSPQPGPPAASHTPEKQASSFDFNGPYLGPPHSRSLPDILGQPEPPQEGGSQKSPPPGSLEYLCLPAGGQVQLVPLAQAMGPGQAVEVERRPSQGAAGSPSLESGGGPAPPALGPRVGGQDQKDSPVAIPMSSGDTEDPGVASGYVSSADLVFTPNSGASSVSLVPSLGLPSDQTPSLCPGLASGPPGAPGPVKSGFEGYVELPPIEGRSPRSPRNNPVPPEAKSPVLNPGERPADVSPTSPQPEGLLVLQQVGDYCFLPGLGPGPLSLRSKPSSPGPGPEIKNLDQAFQVKKPPGQAVPQVPVIQLFKALKQQDYLSLPPWEVNKPGEVC
T44589	DRUGINFO	D00GFV	Leridistim	Phase 2
T44589	DRUGINFO	D02RPP	TPI ASM8	Phase 2
T44589	DRUGINFO	D08MKR	DT388IL-3	Phase 1/2
T44589	DRUGINFO	D0Z2ZY	SL-401	Phase 1/2
T44589	DRUGINFO	D0JF9Z	CSL-362	Phase 1

T67805	TARGETID	T67805
T67805	FORMERID	TTDC00337
T67805	UNIPROID	CD70_HUMAN
T67805	TARGNAME	CD70 antigen (CD27-L)
T67805	GENENAME	CD70
T67805	TARGTYPE	Clinical trial
T67805	SYNONYMS	Tumor necrosis factor ligandsuperfamily member 7; Tumor necrosis factor ligand superfamily member 7; TNFSF7; CD27LG; CD27L; CD27 ligand
T67805	FUNCTION	Plays a role in T-cell activation. Induces the proliferation of costimulated T-cells and enhances the generation of cytolytic T-cells. Cytokine that binds to CD27.
T67805	BIOCLASS	Cytokine: tumor necrosis factor
T67805	SEQUENCE	MPEEGSGCSVRRRPYGCVLRAALVPLVAGLVICLVVCIQRFAQAQQQLPLESLGWDVAELQLNHTGPQQDPRLYWQGGPALGRSFLHGPELDKGQLRIHRDGIYMVHIQVTLAICSSTTASRHHPTTLAVGICSPASRSISLLRLSFHQGCTIASQRLTPLARGDTLCTNLTGTLLPSRNTDETFFGVQWVRP
T67805	DRUGINFO	D6Q5MG	JNJ-74494550	Phase 2
T67805	DRUGINFO	D02YRD	4SCAR19 and 4SCAR70	Phase 1/2
T67805	DRUGINFO	D03KLF	MDX-1203	Phase 1
T67805	DRUGINFO	D03KVW	MDX-1411	Phase 1
T67805	DRUGINFO	D06FHQ	BMS-936561	Phase 1
T67805	DRUGINFO	D09PQP	SGN-70	Phase 1
T67805	DRUGINFO	D0E2ZX	SGN-CD70A	Phase 1
T67805	DRUGINFO	D0JO9M	Anti-hCD70 CAR transduced PBL	Phase 1
T67805	DRUGINFO	D0NC1Q	AMG 172	Phase 1
T67805	DRUGINFO	D6H9TE	SEA-CD70	Phase 1
T67805	DRUGINFO	DVIY25	CTX130	Phase 1
T67805	DRUGINFO	D08WTE	Vorsetuzumab mafodotin	Discontinued in Phase 1
T67805	DRUGINFO	D04PFD	TriMixDC	Investigative

T39054	TARGETID	T39054
T39054	FORMERID	TTDI02587
T39054	UNIPROID	DUT_HUMAN
T39054	TARGNAME	dUTP pyrophosphatase (DUT)
T39054	GENENAME	DUT
T39054	TARGTYPE	Clinical trial
T39054	SYNONYMS	Deoxyuridine 5' triphosphate nucleotidohydrolase, mitochondrial; DUT
T39054	FUNCTION	This enzyme is involved in nucleotide metabolism: it produces dUMP, the immediate precursor of thymidine nucleotides and it decreases the intracellular concentration of dUTP so that uracil cannot be incorporated into DNA. {ECO:0000269|PubMed:8805593}.
T39054	PDBSTRUC	5H4J; 4MZ6; 4MZ5; 3EHW; 3ARN
T39054	BIOCLASS	Acid anhydrides hydrolase
T39054	ECNUMBER	EC 3.6.1.23
T39054	SEQUENCE	MTPLCPRPALCYHFLTSLLRSAMQNARGARQRAEAAVLSGPGPPLGRAAQHGIPRPLSSAGRLSQGCRGASTVGAAGWKGELPKAGGSPAPGPETPAISPSKRARPAEVGGMQLRFARLSEHATAPTRGSARAAGYDLYSAYDYTIPPMEKAVVKTDIQIALPSGCYGRVAPRSGLAAKHFIDVGAGVIDEDYRGNVGVVLFNFGKEKFEVKKGDRIAQLICERIFYPEIEEVQALDDTERGSGGFGSTGKN
T39054	DRUGINFO	D0Z6KF	TAS-114	Phase 2

T15497	TARGETID	T15497
T15497	FORMERID	TTDR00673
T15497	UNIPROID	PE2R1_HUMAN
T15497	TARGNAME	Prostaglandin E2 receptor EP1 (PTGER1)
T15497	GENENAME	PTGER1
T15497	TARGTYPE	Clinical trial
T15497	SYNONYMS	Prostanoid EP1 receptor; Prostaglandin E2 receptor EP1 subtype; PGE2 receptor EP1 subtype; PGE receptor, EP1 subtype; PGE receptor EP1 subtype; EP1 receptor
T15497	FUNCTION	The activity of this receptor is mediated by G(q) proteins which activate a phosphatidylinositol-calcium second messenger system. May play a role as an important modulator of renal function. Implicated the smooth muscle contractile response to PGE2 in various tissues. Receptor for prostaglandin E2 (PGE2).
T15497	BIOCLASS	GPCR rhodopsin
T15497	SEQUENCE	MSPCGPLNLSLAGEATTCAAPWVPNTSAVPPSGASPALPIFSMTLGAVSNLLALALLAQAAGRLRRRRSAATFLLFVASLLATDLAGHVIPGALVLRLYTAGRAPAGGACHFLGGCMVFFGLCPLLLGCGMAVERCVGVTRPLLHAARVSVARARLALAAVAAVALAVALLPLARVGRYELQYPGTWCFIGLGPPGGWRQALLAGLFASLGLVALLAALVCNTLSGLALLRARWRRRSRRPPPASGPDSRRRWGAHGPRSASASSASSIASASTFFGGSRSSGSARRARAHDVEMVGQLVGIMVVSCICWSPMLVLVALAVGGWSSTSLQRPLFLAVRLASWNQILDPWVYILLRQAVLRQLLRLLPPRAGAKGGPAGLGLTPSAWEASSLRSSRHSGLSHF
T15497	DRUGINFO	D0D7UD	AS-013	Phase 3
T15497	DRUGINFO	D00HTY	PGF2alpha	Clinical trial
T15497	DRUGINFO	D0W2OT	BUTAPROST	Patented
T15497	DRUGINFO	D0T2TK	ZD6416	Discontinued in Phase 2
T15497	DRUGINFO	D0K6DG	ONO-8130	Terminated
T15497	DRUGINFO	D0X2OV	ONO-8711	Terminated
T15497	DRUGINFO	D02IVR	ONO-DI-004	Investigative
T15497	DRUGINFO	D04IIT	ZM 325802	Investigative
T15497	DRUGINFO	D0OA8M	SC-19220	Investigative
T15497	DRUGINFO	D0R2TW	GW848687X	Investigative
T15497	DRUGINFO	D0S6NE	MF266-1	Investigative
T15497	DRUGINFO	D0V9QT	SC-51322	Investigative
T15497	DRUGINFO	D00QTX	ZK110841	Investigative
T15497	DRUGINFO	D0T2GA	ONO-8713	Investigative
T15497	DRUGINFO	D0X2MQ	17-phenyl-omega-trinor-PGE2	Investigative
T15497	DRUGINFO	D0J9PG	AH6809	Investigative
T15497	DRUGINFO	D05SFA	cicaprost	Investigative
T15497	DRUGINFO	D0O9ES	cloprostenol	Investigative
T15497	DRUGINFO	D0BN1U	M&B 28767	Investigative
T15497	DRUGINFO	D06KBO	PGD2	Investigative
T15497	DRUGINFO	D0W7RI	carbacyclin	Investigative
T15497	DRUGINFO	D03PLH	U46619	Investigative

T54447	TARGETID	T54447
T54447	FORMERID	TTDC00252
T54447	UNIPROID	PEDF_HUMAN
T54447	TARGNAME	Pigment epithelium-derived factor (SERPINF1)
T54447	GENENAME	SERPINF1
T54447	TARGTYPE	Clinical trial
T54447	SYNONYMS	Serpin-F1; SERPINF1; PEDF; EPC-1
T54447	FUNCTION	Neurotrophic protein; induces extensive neuronal differentiation in retinoblastoma cells. Potent inhibitor of angiogenesis. As it does not undergo the S (stressed) to R (relaxed) conformationaltransition characteristic of active serpins, it exhibits no serine protease inhibitory activity.
T54447	PDBSTRUC	1IMV
T54447	BIOCLASS	Serpin protein
T54447	SEQUENCE	MQALVLLLCIGALLGHSSCQNPASPPEEGSPDPDSTGALVEEEDPFFKVPVNKLAAAVSNFGYDLYRVRSSTSPTTNVLLSPLSVATALSALSLGAEQRTESIIHRALYYDLISSPDIHGTYKELLDTVTAPQKNLKSASRIVFEKKLRIKSSFVAPLEKSYGTRPRVLTGNPRLDLQEINNWVQAQMKGKLARSTKEIPDEISILLLGVAHFKGQWVTKFDSRKTSLEDFYLDEERTVRVPMMSDPKAVLRYGLDSDLSCKIAQLPLTGSMSIIFFLPLKVTQNLTLIEESLTSEFIHDIDRELKTVQAVLTVPKLKLSYEGEVTKSLQEMKLQSLFDSPDFSKITGKPIKLTQVEHRAGFEWNEDGAGTTPSPGLQPAHLTFPLDYHLNQPFIFVLRDTDTGALLFIGKILDPRGP
T54447	DRUGINFO	D0G3GF	AdPEDR	Phase 2
T54447	DRUGINFO	D0PF8B	PEDF gene therapy	Phase 1

T99909	TARGETID	T99909
T99909	FORMERID	TTDI02086
T99909	UNIPROID	GRP75_HUMAN
T99909	TARGNAME	Mortalin (HSPA9)
T99909	GENENAME	HSPA9
T99909	TARGTYPE	Clinical trial
T99909	SYNONYMS	mt-HSP70; Stress-70 protein, mitochondrial; Peptide-binding protein 74; PBP74; MOT; Heat shock 70 kDa protein 9; HSPA9B; GRP75; GRP-75; 75 kDa glucose-regulated protein
T99909	FUNCTION	Interacts with and stabilizes ISC cluster assembly proteins FXN, NFU1, NFS1 and ISCU. Regulates erythropoiesis via stabilization of ISC assembly. May play a role in the control of cell proliferation and cellular aging. Chaperone protein which plays an important role in mitochondrial iron-sulfur cluster (ISC) biogenesis.
T99909	PDBSTRUC	6NHK; 4KBO; 3N8E
T99909	BIOCLASS	Heat shock protein
T99909	SEQUENCE	MISASRAAAARLVGAAASRGPTAARHQDSWNGLSHEAFRLVSRRDYASEAIKGAVVGIDLGTTNSCVAVMEGKQAKVLENAEGARTTPSVVAFTADGERLVGMPAKRQAVTNPNNTFYATKRLIGRRYDDPEVQKDIKNVPFKIVRASNGDAWVEAHGKLYSPSQIGAFVLMKMKETAENYLGHTAKNAVITVPAYFNDSQRQATKDAGQISGLNVLRVINEPTAAALAYGLDKSEDKVIAVYDLGGGTFDISILEIQKGVFEVKSTNGDTFLGGEDFDQALLRHIVKEFKRETGVDLTKDNMALQRVREAAEKAKCELSSSVQTDINLPYLTMDSSGPKHLNMKLTRAQFEGIVTDLIRRTIAPCQKAMQDAEVSKSDIGEVILVGGMTRMPKVQQTVQDLFGRAPSKAVNPDEAVAIGAAIQGGVLAGDVTDVLLLDVTPLSLGIETLGGVFTKLINRNTTIPTKKSQVFSTAADGQTQVEIKVCQGEREMAGDNKLLGQFTLIGIPPAPRGVPQIEVTFDIDANGIVHVSAKDKGTGREQQIVIQSSGGLSKDDIENMVKNAEKYAEEDRRKKERVEAVNMAEGIIHDTETKMEEFKDQLPADECNKLKEEISKMRELLARKDSETGENIRQAASSLQQASLKLFEMAYKKMASEREGSGSSGTGEQKEDQKEEKQ
T99909	DRUGINFO	D0X9HB	MKT-077	Phase 2

T79160	TARGETID	T79160
T79160	FORMERID	TTDI02527
T79160	UNIPROID	GDNF_HUMAN
T79160	TARGNAME	Glial cell line-derived neurotrophic factor (GDNF)
T79160	GENENAME	GDNF
T79160	TARGTYPE	Clinical trial
T79160	SYNONYMS	hGDNF; Glial cell linederived neurotrophic factor; Astrocytederived trophic factor; Astrocyte-derived trophic factor; ATF
T79160	FUNCTION	Neurotrophic factor that enhances survival and morphological differentiation of dopaminergic neurons and increases their high-affinity dopamine uptake.
T79160	PDBSTRUC	4UX8; 3FUB; 2V5E
T79160	BIOCLASS	Growth factor
T79160	SEQUENCE	MKLWDVVAVCLVLLHTASAFPLPAGKRPPEAPAEDRSLGRRRAPFALSSDSNMPEDYPDQFDDVMDFIQATIKRLKRSPDKQMAVLPRRERNRQAAAANPENSRGKGRRGQRGKNRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYDKILKNLSRNRRLVSDKVGQACCRPIAFDDDLSFLDDNLVYHILRKHSAKRCGCI
T79160	DRUGINFO	D0IN9G	Liatermin	Phase 1/2

T99379	TARGETID	T99379
T99379	UNIPROID	TPO_HUMAN
T99379	TARGNAME	Thrombopoietin (THPO)
T99379	GENENAME	THPO
T99379	TARGTYPE	Clinical trial
T99379	SYNONYMS	Myeloproliferative leukemia virus oncogene ligand; Megakaryocyte growth and development factor; Megakaryocyte colony-stimulating factor; ML; MGDF; C-mpl ligand
T99379	FUNCTION	Lineage-specific cytokine affecting the proliferation and maturation of megakaryocytes from their committed progenitor cells. It acts at a late stage of megakaryocyte development. It may be the major physiological regulator of circulating platelets.
T99379	PDBSTRUC	1V7N; 1V7M
T99379	BIOCLASS	EPO/TPO family
T99379	SEQUENCE	MELTELLLVVMLLLTARLTLSSPAPPACDLRVLSKLLRDSHVLHSRLSQCPEVHPLPTPVLLPAVDFSLGEWKTQMEETKAQDILGAVTLLLEGVMAARGQLGPTCLSSLLGQLSGQVRLLLGALQSLLGTQLPPQGRTTAHKDPNAIFLSFQHLLRGKVRFLMLVGGSTLCVRRAPPTTAVPSRTSLVLTLNELPNRTSGLLETNFTASARTTGSGLLKWQQGFRAKIPGLLNQTSRSLDQIPGYLNRIHELLNGTRGLFPGPSRRTLGAPDISSGTSDTGSLPPNLQPGYSPSPTHPPTGQYTLFPLPPTLPTPVVQLHPLLPDPSAPTPTPTSPLLNTSYTHSQNLSQEG
T99379	DRUGINFO	D14VOX	A157	IND submitted
T99379	DRUGINFO	D04KVA	BVI-007	Phase 1

T96894	TARGETID	T96894
T96894	FORMERID	TTDI02361
T96894	UNIPROID	LIFR_HUMAN
T96894	TARGNAME	Leukemia inhibitory factor receptor (LIFR)
T96894	GENENAME	LIFR
T96894	TARGTYPE	Clinical trial
T96894	SYNONYMS	LIF-R; LIF receptor; CD118
T96894	FUNCTION	May have a common pathway with IL6ST. The soluble form inhibits the biological activity of LIF by blocking its binding to receptors on target cells. Signal-transducing molecule.
T96894	PDBSTRUC	3E0G
T96894	BIOCLASS	Cytokine receptor
T96894	SEQUENCE	MMDIYVCLKRPSWMVDNKRMRTASNFQWLLSTFILLYLMNQVNSQKKGAPHDLKCVTNNLQVWNCSWKAPSGTGRGTDYEVCIENRSRSCYQLEKTSIKIPALSHGDYEITINSLHDFGSSTSKFTLNEQNVSLIPDTPEILNLSADFSTSTLYLKWNDRGSVFPHRSNVIWEIKVLRKESMELVKLVTHNTTLNGKDTLHHWSWASDMPLECAIHFVEIRCYIDNLHFSGLEEWSDWSPVKNISWIPDSQTKVFPQDKVILVGSDITFCCVSQEKVLSALIGHTNCPLIHLDGENVAIKIRNISVSASSGTNVVFTTEDNIFGTVIFAGYPPDTPQQLNCETHDLKEIICSWNPGRVTALVGPRATSYTLVESFSGKYVRLKRAEAPTNESYQLLFQMLPNQEIYNFTLNAHNPLGRSQSTILVNITEKVYPHTPTSFKVKDINSTAVKLSWHLPGNFAKINFLCEIEIKKSNSVQEQRNVTIKGVENSSYLVALDKLNPYTLYTFRIRCSTETFWKWSKWSNKKQHLTTEASPSKGPDTWREWSSDGKNLIIYWKPLPINEANGKILSYNVSCSSDEETQSLSEIPDPQHKAEIRLDKNDYIISVVAKNSVGSSPPSKIASMEIPNDDLKIEQVVGMGKGILLTWHYDPNMTCDYVIKWCNSSRSEPCLMDWRKVPSNSTETVIESDEFRPGIRYNFFLYGCRNQGYQLLRSMIGYIEELAPIVAPNFTVEDTSADSILVKWEDIPVEELRGFLRGYLFYFGKGERDTSKMRVLESGRSDIKVKNITDISQKTLRIADLQGKTSYHLVLRAYTDGGVGPEKSMYVVTKENSVGLIIAILIPVAVAVIVGVVTSILCYRKREWIKETFYPDIPNPENCKALQFQKSVCEGSSALKTLEMNPCTPNNVEVLETRSAFPKIEDTEIISPVAERPEDRSDAEPENHVVVSYCPPIIEEEIPNPAADEAGGTAQVIYIDVQSMYQPQAKPEEEQENDPVGGAGYKPQMHLPINSTVEDIAAEEDLDKTAGYRPQANVNTWNLVSPDSPRSIDSNSEIVSFGSPCSINSRQFLIPPKDEDSPKSNGGGWSFTNFFQNKPND
T96894	DRUGINFO	D0L1FN	Emfilermin	Phase 1/2

T34596	TARGETID	T34596
T34596	FORMERID	TTDR00178
T34596	UNIPROID	GYRA_HAEIN
T34596	TARGNAME	Haemophilus influenzae DNA gyrase A (Hae-influ gyrA)
T34596	GENENAME	Hae-influ gyrA
T34596	TARGTYPE	Clinical trial
T34596	SYNONYMS	GyrA; DNA gyrase subunit A of Haemophilus influenzae
T34596	FUNCTION	DNA gyrasenegatively supercoils closed circular double- stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings.
T34596	BIOCLASS	ATP-hydrolyzing DNA topoisomerase
T34596	ECNUMBER	EC 5.6.2.3
T34596	SEQUENCE	MTDSIQSSITPVNIEEELKSSYLDYAMSVIVGRALPDVRDGLKPVHRRVLFSMDREGNTANKKYVKSARVVGDVIGKYHPHGDSAVYDTIVRMAQPFSLRYMLVDGQGNFGSIDGDAPAAMRYTEVRMQKITQALLTDLDKETVNFSPNYDGELMIPDVLPTRIPALLANGSSGIAVGMATNIPPHNLNEVLNGCLAYIDKNEITIDELMQHIPGPDFPTAALINGRKGIEEAYRTGRGKVYVRARATVETNEKGREQIIVSELPYQVNKAKLVEKIAELIREKKIEGISNITDLSNKEGIRIEIDIKRDAVGEVVLNHLYSLTQMQVTFGINMVALDHGQPRLFNLKEIIEAFVLHRREVVTRRSIFELRKARERTHILEGLAVARSNIDEMIAIIRNSKNREEAATSISSRSWTLHSDIINLLDASARPDELEENLGIQGEQYYLSPAQVNAILELRLHRLTGIAFEEVIKEYEELLVKIADLLHILSSAERLMEVIREELEEVKAQFGDDRLTEITAASGDIDLEDLIAQEDVVVTLSHEGYVKYQPLTDYEAQRRGGKGKSATKMKEEDFIEKLLVANTHDTILCFSSRGRLYWLKVYQLPQASRGARGRPIVNILPLQENERITAILPVSAYEEDKFVVMATAGGIVKKIALTEFSRPRSNGIIALNLRDEDELIGVDITDGSNEIMLFSSQGRVVRFAENAVRAMGRLATGVRGIKLALTNDISDDESAVEIEDISDDNAEASLDLNIDKVVSLVVPKGEGAILTATQNGYGKRTQLSEYPTKSRNTKGVISIKVSERNGKVVAATQVEETDQIMLITDAGTLVRTRVSEVSIVGRNTQGVRLIRTADDEHVVSLERVCDADEDDSLEESSSEE
T34596	DRUGINFO	D07DTM	Cetraxal Otic	Phase 3
T34596	DRUGINFO	D05LOY	ACH-702	Investigative

T07394	TARGETID	T07394
T07394	FORMERID	TTDNC00415
T07394	UNIPROID	NOTC1_HUMAN
T07394	TARGNAME	Notch-1 receptor (NOTCH1)
T07394	GENENAME	NOTCH1
T07394	TARGTYPE	Clinical trial
T07394	SYNONYMS	hN1; Translocationassociated notch protein TAN1; Translocation-associated notch protein TAN-1; TAN1; Notch 1 intracellular domain; Notch 1; Neurogenic locus notch homolog protein 1; NICD
T07394	FUNCTION	Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs. Involved in angiogenesis; negatively regulates endothelial cell proliferation and migration and angiogenic sprouting. Involved in the maturation of both CD4(+) and CD8(+) cells in the thymus. Important for follicular differentiation and possibly cell fate selection within the follicle. During cerebellar development, functions as a receptor for neuronal DNER and is involved in the differentiation of Bergmann glia. Represses neuronal and myogenic differentiation. May play an essential role in postimplantation development, probably in some aspect of cell specification and/or differentiation. May be involved in mesoderm development, somite formation and neurogenesis. May enhance HIF1A function by sequestering HIF1AN away from HIF1A. Required for the THBS4 function in regulating protective astrogenesis from the subventricular zone (SVZ) niche after injury. Involved in determination of left/right symmetry by modulating the balance between motile and immotile (sensory) cilia at the left-right organiser (LRO). Functions as a receptor for membrane-bound ligands Jagged-1 (JAG1), Jagged-2 (JAG2) and Delta-1 (DLL1) to regulate cell-fate determination.
T07394	PDBSTRUC	6IDF; 5UB5; 5L0R; 5KZO; 5FMA
T07394	BIOCLASS	Notch protein
T07394	SEQUENCE	MPPLLAPLLCLALLPALAARGPRCSQPGETCLNGGKCEAANGTEACVCGGAFVGPRCQDPNPCLSTPCKNAGTCHVVDRRGVADYACSCALGFSGPLCLTPLDNACLTNPCRNGGTCDLLTLTEYKCRCPPGWSGKSCQQADPCASNPCANGGQCLPFEASYICHCPPSFHGPTCRQDVNECGQKPGLCRHGGTCHNEVGSYRCVCRATHTGPNCERPYVPCSPSPCQNGGTCRPTGDVTHECACLPGFTGQNCEENIDDCPGNNCKNGGACVDGVNTYNCRCPPEWTGQYCTEDVDECQLMPNACQNGGTCHNTHGGYNCVCVNGWTGEDCSENIDDCASAACFHGATCHDRVASFYCECPHGRTGLLCHLNDACISNPCNEGSNCDTNPVNGKAICTCPSGYTGPACSQDVDECSLGANPCEHAGKCINTLGSFECQCLQGYTGPRCEIDVNECVSNPCQNDATCLDQIGEFQCICMPGYEGVHCEVNTDECASSPCLHNGRCLDKINEFQCECPTGFTGHLCQYDVDECASTPCKNGAKCLDGPNTYTCVCTEGYTGTHCEVDIDECDPDPCHYGSCKDGVATFTCLCRPGYTGHHCETNINECSSQPCRHGGTCQDRDNAYLCFCLKGTTGPNCEINLDDCASSPCDSGTCLDKIDGYECACEPGYTGSMCNINIDECAGNPCHNGGTCEDGINGFTCRCPEGYHDPTCLSEVNECNSNPCVHGACRDSLNGYKCDCDPGWSGTNCDINNNECESNPCVNGGTCKDMTSGYVCTCREGFSGPNCQTNINECASNPCLNQGTCIDDVAGYKCNCLLPYTGATCEVVLAPCAPSPCRNGGECRQSEDYESFSCVCPTGWQGQTCEVDINECVLSPCRHGASCQNTHGGYRCHCQAGYSGRNCETDIDDCRPNPCHNGGSCTDGINTAFCDCLPGFRGTFCEEDINECASDPCRNGANCTDCVDSYTCTCPAGFSGIHCENNTPDCTESSCFNGGTCVDGINSFTCLCPPGFTGSYCQHDVNECDSQPCLHGGTCQDGCGSYRCTCPQGYTGPNCQNLVHWCDSSPCKNGGKCWQTHTQYRCECPSGWTGLYCDVPSVSCEVAAQRQGVDVARLCQHGGLCVDAGNTHHCRCQAGYTGSYCEDLVDECSPSPCQNGATCTDYLGGYSCKCVAGYHGVNCSEEIDECLSHPCQNGGTCLDLPNTYKCSCPRGTQGVHCEINVDDCNPPVDPVSRSPKCFNNGTCVDQVGGYSCTCPPGFVGERCEGDVNECLSNPCDARGTQNCVQRVNDFHCECRAGHTGRRCESVINGCKGKPCKNGGTCAVASNTARGFICKCPAGFEGATCENDARTCGSLRCLNGGTCISGPRSPTCLCLGPFTGPECQFPASSPCLGGNPCYNQGTCEPTSESPFYRCLCPAKFNGLLCHILDYSFGGGAGRDIPPPLIEEACELPECQEDAGNKVCSLQCNNHACGWDGGDCSLNFNDPWKNCTQSLQCWKYFSDGHCDSQCNSAGCLFDGFDCQRAEGQCNPLYDQYCKDHFSDGHCDQGCNSAECEWDGLDCAEHVPERLAAGTLVVVVLMPPEQLRNSSFHFLRELSRVLHTNVVFKRDAHGQQMIFPYYGREEELRKHPIKRAAEGWAAPDALLGQVKASLLPGGSEGGRRRRELDPMDVRGSIVYLEIDNRQCVQASSQCFQSATDVAAFLGALASLGSLNIPYKIEAVQSETVEPPPPAQLHFMYVAAAAFVLLFFVGCGVLLSRKRRRQHGQLWFPEGFKVSEASKKKRREPLGEDSVGLKPLKNASDGALMDDNQNEWGDEDLETKKFRFEEPVVLPDLDDQTDHRQWTQQHLDAADLRMSAMAPTPPQGEVDADCMDVNVRGPDGFTPLMIASCSGGGLETGNSEEEEDAPAVISDFIYQGASLHNQTDRTGETALHLAARYSRSDAAKRLLEASADANIQDNMGRTPLHAAVSADAQGVFQILIRNRATDLDARMHDGTTPLILAARLAVEGMLEDLINSHADVNAVDDLGKSALHWAAAVNNVDAAVVLLKNGANKDMQNNREETPLFLAAREGSYETAKVLLDHFANRDITDHMDRLPRDIAQERMHHDIVRLLDEYNLVRSPQLHGAPLGGTPTLSPPLCSPNGYLGSLKPGVQGKKVRKPSSKGLACGSKEAKDLKARRKKSQDGKGCLLDSSGMLSPVDSLESPHGYLSDVASPPLLPSPFQQSPSVPLNHLPGMPDTHLGIGHLNVAAKPEMAALGGGGRLAFETGPPRLSHLPVASGTSTVLGSSSGGALNFTVGGSTSLNGQCEWLSRLQSGMVPNQYNPLRGSVAPGPLSTQAPSLQHGMVGPLHSSLAASALSQMMSYQGLPSTRLATQPHLVQTQQVQPQNLQMQQQNLQPANIQQQQSLQPPPPPPQPHLGVSSAASGHLGRSFLSGEPSQADVQPLGPSSLAVHTILPQESPALPTSLPSSLVPPVTAAQFLTPPSQHSYSSPVDNTPSHQLQVPEHPFLTPSPESPDQWSSSSPHSNVSDWSEGVSSPPTSMQSQIARIPEAFK
T07394	DRUGINFO	D08WOW	LY3039478	Phase 1/2
T07394	DRUGINFO	D0X3YY	OMP-52M51	Phase 1

T98494	TARGETID	T98494
T98494	FORMERID	TTDI01803
T98494	UNIPROID	GALR1_HUMAN; GALR2_HUMAN; GALR3_HUMAN
T98494	TARGNAME	Galanin receptor (GAL-R)
T98494	GENENAME	GALR1; GALR2; GALR3
T98494	TARGTYPE	Clinical trial
T98494	SYNONYMS	GALR; GALNR; GAL-R
T98494	FUNCTION	Receptor for the hormone galanin. Receptor for the hormone spexin-1.
T98494	BIOCLASS	GPCR rhodopsin
T98494	SEQUENCE	MELAVGNLSEGNASWPEPPAPEPGPLFGIGVENFVTLVVFGLIFALGVLGNSLVITVLARSKPGKPRSTTNLFILNLSIADLAYLLFCIPFQATVYALPTWVLGAFICKFIHYFFTVSMLVSIFTLAAMSVDRYVAIVHSRRSSSLRVSRNALLGVGCIWALSIAMASPVAYHQGLFHPRASNQTFCWEQWPDPRHKKAYVVCTFVFGYLLPLLLICFCYAKVLNHLHKKLKNMSKKSEASKKKTAQTVLVVVVVFGISWLPHHIIHLWAEFGVFPLTPASFLFRITAHCLAYSNSSVNPIIYAFLSENFRKAYKQVFKCHIRKDSHLSDTKESKSRIDTPPSTNCTHV
T98494	DRUGINFO	D04AHY	HT-2157	Phase 1/2
T98494	DRUGINFO	D08FGR	galmic	Investigative
T98494	DRUGINFO	D09QPH	Sch 202596	Investigative
T98494	DRUGINFO	D0A1QQ	GalR3ant	Investigative
T98494	DRUGINFO	D0E7BU	CYM2503	Investigative
T98494	DRUGINFO	D0H0HM	(E)-3-(4-chlorophenylimino)indolin-2-one	Investigative
T98494	DRUGINFO	D0HH3R	SNAP 398299	Investigative
T98494	DRUGINFO	D0R9KF	(E)-3-(2,3-dichlorophenylimino)indolin-2-one	Investigative
T98494	DRUGINFO	D0XR0L	2,3-dihydro-1,4-dithiin-1,1,4,4-tetroxide	Investigative
T98494	DRUGINFO	D0Z8CP	dithiipin-1,1,4,4-tetroxide analogue 7	Investigative

T04773	TARGETID	T04773
T04773	FORMERID	TTDR00808
T04773	UNIPROID	SDF1_HUMAN
T04773	TARGNAME	Stromal cell-derived factor 1 (CXCL12)
T04773	GENENAME	CXCL12
T04773	TARGTYPE	Clinical trial
T04773	SYNONYMS	hSDF-1; SDF1B; SDF1A; SDF1; SDF-1; Pre-B cell growth-stimulating factor; Pre-B cell growth stimulating factor; PBSF; Intercrine reduced in hepatomas; IRH; HIRH; C-X-C motif chemokine 12
T04773	FUNCTION	Activates the C-X-C chemokine receptor CXCR4 to induce a rapid and transient rise in the level of intracellular calcium ions and chemotaxis. SDF-1-beta(3-72) and SDF-1-alpha(3-67) show a reduced chemotactic activity. Binding to cell surface proteoglycans seems to inhibit formation of SDF-1-alpha(3-67) and thus to preserve activity on local sites. Also binds to atypical chemokine receptor ACKR3, which activates the beta-arrestin pathway and acts as a scavenger receptor for SDF-1. Binds to the allosteric site (site 2) of integrins and activates integrins ITGAV:ITGB3, ITGA4:ITGB1 and ITGA5:ITGB1 in a CXCR4-independent manner. Acts as a positive regulator of monocyte migration and a negative regulator of monocyte adhesion via the LYN kinase. Stimulates migration of monocytes and T-lymphocytes through its receptors, CXCR4 and ACKR3, and decreases monocyte adherence to surfaces coated with ICAM-1, a ligand for beta-2 integrins. SDF1A/CXCR4 signaling axis inhibits beta-2 integrin LFA-1 mediated adhesion of monocytes to ICAM-1 through LYN kinase. Inhibits CXCR4-mediated infection by T-cell line-adapted HIV-1. Plays a protective role after myocardial infarction. Induces down-regulation and internalization of ACKR3 expressed in various cells. Has several critical functions during embryonic development; required for B-cell lymphopoiesis, myelopoiesis in bone marrow and heart ventricular septum formation. Stimulates the proliferation of bone marrow-derived B-cell progenitors in the presence of IL7 as well as growth of stromal cell-dependent pre-B-cells. Chemoattractant active on T-lymphocytes and monocytes but not neutrophils.
T04773	PDBSTRUC	4UAI; 4LMQ; 3HP3; 3GV3; 2SDF
T04773	BIOCLASS	Cytokine: CXC chemokine
T04773	SEQUENCE	MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQEYLEKALNKRFKM
T04773	DRUGINFO	D0DR4W	MyoCell SDF-1	Phase 3
T04773	DRUGINFO	D5VRX2	Dociparstat sodium	Phase 3
T04773	DRUGINFO	D07YLO	SDF-1	Phase 2
T04773	DRUGINFO	D0D8MG	NOX-A12	Phase 1
T04773	DRUGINFO	D0K6NW	REC-02	Phase 1

T22032	TARGETID	T22032
T22032	FORMERID	TTDC00041
T22032	UNIPROID	PTH2R_HUMAN
T22032	TARGNAME	Parathyroid hormone receptor (PTH2R)
T22032	GENENAME	PTH2R
T22032	TARGTYPE	Clinical trial
T22032	SYNONYMS	PTHR2; PTH2R; PTH2 receptor
T22032	FUNCTION	This is a specific receptor for parathyroid hormone. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. PTH2R may be responsible for PTH effects in a number of physiological systems. It may play asignificant role in pancreatic function. PTH2R presence in neurons indicates that it may function as a neurotransmitter receptor.
T22032	BIOCLASS	GPCR secretin
T22032	SEQUENCE	MAGLGASLHVWGWLMLGSCLLARAQLDSDGTITIEEQIVLVLKAKVQCELNITAQLQEGEGNCFPEWDGLICWPRGTVGKISAVPCPPYIYDFNHKGVAFRHCNPNGTWDFMHSLNKTWANYSDCLRFLQPDISIGKQEFFERLYVMYTVGYSISFGSLAVAILIIGYFRRLHCTRNYIHMHLFVSFMLRATSIFVKDRVVHAHIGVKELESLIMQDDPQNSIEATSVDKSQYIGCKIAVVMFIYFLATNYYWILVEGLYLHNLIFVAFFSDTKYLWGFILIGWGFPAAFVAAWAVARATLADARCWELSAGDIKWIYQAPILAAIGLNFILFLNTVRVLATKIWETNAVGHDTRKQYRKLAKSTLVLVLVFGVHYIVFVCLPHSFTGLGWEIRMHCELFFNSFQGFFVSIIYCYCNGEVQAEVKKMWSRWNLSVDWKRTPPCGSRRCGSVLTTVTHSTSSQSQVAASTRMVLISGKAAKIASRQPDSHITLPGYVWSNSEQDCLPHSFHEETKEDSGRQGDDILMEKPSRPMESNPDTEGCQGETEDVL
T22032	DRUGINFO	D0S2BU	BA-058	Phase 3
T22032	DRUGINFO	D0F5WX	GSK768974	Phase 2
T22032	DRUGINFO	D0R7IU	NPSP-795	Phase 2
T22032	DRUGINFO	D0X2EM	UNI-PH (1-34)	Phase 2
T22032	DRUGINFO	D0H2DS	PTH(7-34) liposomal cream	Phase 1
T22032	DRUGINFO	D0BB1T	Semparatide	Discontinued in Phase 2
T22032	DRUGINFO	D00MCA	BB-PTH 1-84	Investigative
T22032	DRUGINFO	D0A3SX	PTHr pepducins	Investigative
T22032	DRUGINFO	D0B0IU	Hemoparatide	Investigative
T22032	DRUGINFO	D0G3BK	ZP-2307	Investigative
T22032	DRUGINFO	D0Z4GF	SDZ-PTS-893	Investigative

T51425	TARGETID	T51425
T51425	FORMERID	TTDNC00385
T51425	UNIPROID	VEGFC_HUMAN
T51425	TARGNAME	Vascular endothelial growth factor C (VEGFC)
T51425	GENENAME	VEGFC
T51425	TARGTYPE	Clinical trial
T51425	SYNONYMS	Vascular endothelial growth factor-related protein; VRP; VEGF-C; Flt4-L; Flt4 ligand
T51425	FUNCTION	May function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates KDR/VEGFR2 and FLT4/VEGFR3 receptors. Growth factor active in angiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels.
T51425	PDBSTRUC	4BSK; 2X1X; 2X1W
T51425	BIOCLASS	Growth factor
T51425	SEQUENCE	MHLLGFFSVACSLLAAALLPGPREAPAAAAAFESGLDLSDAEPDAGEATAYASKDLEEQLRSVSSVDELMTVLYPEYWKMYKCQLRKGGWQHNREQANLNSRTEETIKFAAAHYNTEILKSIDNEWRKTQCMPREVCIDVGKEFGVATNTFFKPPCVSVYRCGGCCNSEGLQCMNTSTSYLSKTLFEITVPLSQGPKPVTISFANHTSCRCMSKLDVYRQVHSIIRRSLPATLPQCQAANKTCPTNYMWNNHICRCLAQEDFMFSSDAGDDSTDGFHDICGPNKELDEETCQCVCRAGLRPASCGPHKELDRNSCQCVCKNKLFPSQCGANREFDENTCQCVCKRTCPRNQPLNPGKCACECTESPQKCLLKGKKFHHQTCSCYRRPCTNRQKACEPGFSYSEEVCRCVPSYWKRPQMS
T51425	DRUGINFO	DNA7I1	OPT-302	Phase 2
T51425	DRUGINFO	D0GP0H	VGX-100	Phase 1

T97740	TARGETID	T97740
T97740	UNIPROID	PPT1_HUMAN
T97740	TARGNAME	Palmitoyl-protein thioesterase 1 (PPT1)
T97740	GENENAME	PPT1
T97740	TARGTYPE	Clinical trial
T97740	SYNONYMS	Palmitoyl-protein hydrolase 1; PPT-1; PPT; CLN1
T97740	FUNCTION	Prefers acyl chain lengths of 14 to 18 carbons. Removes thioester-linked fatty acyl groups such as palmitate from modified cysteine residues in proteins or peptides during lysosomal degradation.
T97740	PDBSTRUC	3GRO
T97740	BIOCLASS	Palmitoyl thioesterase
T97740	ECNUMBER	EC 3.1.2.22
T97740	SEQUENCE	MASPGCLWLLAVALLPWTCASRALQHLDPPAPLPLVIWHGMGDSCCNPLSMGAIKKMVEKKIPGIYVLSLEIGKTLMEDVENSFFLNVNSQVTTVCQALAKDPKLQQGYNAMGFSQGGQFLRAVAQRCPSPPMINLISVGGQHQGVFGLPRCPGESSHICDFIRKTLNAGAYSKVVQERLVQAEYWHDPIKEDVYRNHSIFLADINQERGINESYKKNLMALKKFVMVKFLNDSIVDPVDSEWFGFYRSGQAKETIPLQETSLYTQDRLGLKEMDNAGQLVFLATEGDHLQLSEEWFYAHIIPFLG
T97740	DRUGINFO	D07QJK	Plitidepsin	Phase 3
T97740	DRUGINFO	D7KQ6N	TSHA-118	Phase 1/2

T72252	TARGETID	T72252
T72252	FORMERID	TTDI03090
T72252	UNIPROID	CASP7_HUMAN
T72252	TARGNAME	Caspase-7 (CASP7)
T72252	GENENAME	CASP7
T72252	TARGTYPE	Clinical trial
T72252	SYNONYMS	MCH3; ICE-like apoptotic protease 3; ICE-LAP3; CMH-1; CASP-7; Apoptotic protease Mch-3
T72252	FUNCTION	Cleaves and activates sterol regulatory element binding proteins (SREBPs). Proteolytically cleaves poly(ADP-ribose) polymerase (PARP) at a '216-Asp-|-Gly-217' bond. Overexpression promotes programmed cell death. Involved in the activation cascade of caspases responsible for apoptosis execution.
T72252	PDBSTRUC	5V6Z; 5V6U; 5K20; 5IC6; 4ZVU
T72252	BIOCLASS	Peptidase
T72252	ECNUMBER	EC 3.4.22.60
T72252	SEQUENCE	MADDQGCIEEQGVEDSANEDSVDAKPDRSSFVPSLFSKKKKNVTMRSIKTTRDRVPTYQYNMNFEKLGKCIIINNKNFDKVTGMGVRNGTDKDAEALFKCFRSLGFDVIVYNDCSCAKMQDLLKKASEEDHTNAACFACILLSHGEENVIYGKDGVTPIKDLTAHFRGDRCKTLLEKPKLFFIQACRGTELDDGIQADSGPINDTDANPRYKIPVEADFLFAYSTVPGYYSWRSPGRGSWFVQALCSILEEHGKDLEIMQILTRVNDRVARHFESQSDDPHFHEKKQIPCVVSMLTKELYFSQ
T72252	DRUGINFO	D0J3SU	isatin sulfonamide 34	Clinical trial
T72252	DRUGINFO	D00YNW	M826	Investigative

T30940	TARGETID	T30940
T30940	FORMERID	TTDI02043
T30940	UNIPROID	CH10_HUMAN
T30940	TARGNAME	Mitochondrial 10kDa heat shock protein (HSPE1)
T30940	GENENAME	HSPE1
T30940	TARGTYPE	Clinical trial
T30940	SYNONYMS	Hsp10; Earlypregnancy factor; Early-pregnancy factor; EPF; Chaperonin 10; CPN10; 10 kDa heat shock protein, mitochondrial; 10 kDa chaperonin
T30940	FUNCTION	Together with Hsp60, facilitates the correct folding of imported proteins. May also prevent misfolding and promote the refolding and proper assembly of unfolded polypeptides generated under stress conditions in the mitochondrial matrix. The functional units of these chaperonins consist of heptameric rings of the large subunit Hsp60, which function as a back-to-back double ring. In a cyclic reaction, Hsp60 ring complexes bind one unfolded substrate protein per ring, followed by the binding of ATP and association with 2 heptameric rings of the co-chaperonin Hsp10. This leads to sequestration of the substrate protein in the inner cavity of Hsp60 where, for a certain period of time, it can fold undisturbed by other cell components. Synchronous hydrolysis of ATP in all Hsp60 subunits results in the dissociation of the chaperonin rings and the release of ADP and the folded substrate protein. Co-chaperonin implicated in mitochondrial protein import and macromolecular assembly.
T30940	PDBSTRUC	4PJ1
T30940	BIOCLASS	Heat shock protein
T30940	SEQUENCE	MAGQAFRKFLPLFDRVLVERSAAETVTKGGIMLPEKSQGKVLQATVVAVGSGSKGKGGEIQPVSVKVGDKVLLPEYGGTKVVLDDKDYFLFRDGDILGKYVD
T30940	DRUGINFO	D0FN4K	XToll	Phase 1/2

T58093	TARGETID	T58093
T58093	FORMERID	TTDR00267
T58093	UNIPROID	DEF_STAAU
T58093	TARGNAME	Staphylococcus Peptide deformylase (Stap-coc def)
T58093	GENENAME	Stap-coc def
T58093	TARGTYPE	Clinical trial
T58093	SYNONYMS	def; Stap-coc Polypeptide deformylase
T58093	FUNCTION	Removes the formyl group from the N-terminal Met of newly synthesized proteins. Requires at least a dipeptide for an efficient rate of reaction. N-terminal L-methionine is a prerequisite for activity but the enzyme has broad specificity at other positions.
T58093	PDBSTRUC	2AI9; 1Q1Y; 1LQW; 1LMH; 1LM4
T58093	BIOCLASS	Carbon-nitrogen hydrolase
T58093	SEQUENCE	MLTMKDIIRDGHPTLRQKAAELELPLTKEEKETLIAMREFLVNSQDEEIAKRYGLRSGVGLAAPQINISKRMIAVLIPDDGSGKSYDYMLVNPKIVSHSVQEAYLPTGEGCLSVDDNVAGLVHRHNRITIKAKDIEGNDIQLRLKGYPAIVFQHEIDHLNGVMFYDHIDKNHPLQPHTDAVEV
T58093	DRUGINFO	D0S7BQ	GSK1322322	Phase 2
T58093	DRUGINFO	D0T2IQ	Actinonin	Terminated
T58093	DRUGINFO	D02XIF	HYDROXY[3-(6-METHYLPYRIDIN-2-YL)PROPYL]FORMAMIDE	Investigative
T58093	DRUGINFO	D02ZLE	2-(3-BENZOYLPHENOXY)ETHYL(HYDROXY)FORMAMIDE	Investigative
T58093	DRUGINFO	D05JBZ	[HYDROXY(3-PHENYLPROPYL)AMINO]METHANOL	Investigative
T58093	DRUGINFO	D0B4SJ	VRC3375	Investigative
T58093	DRUGINFO	D0H7FP	N-alkyl urea hydroxamic acids	Investigative
T58093	DRUGINFO	D0N8YA	Bb-3497	Investigative
T58093	DRUGINFO	D0Q8WN	N-(2-Acetamido)Iminodiacetic Acid	Investigative
T58093	DRUGINFO	D0VM0T	NVP-PDF386	Investigative
T58093	DRUGINFO	D0E8JM	3-Sulfinoalanine	Investigative
T58093	DRUGINFO	D05AMX	Cysteinesulfonic Acid	Investigative
T58093	DRUGINFO	D0H1GU	Double Oxidized Cysteine	Investigative
T58093	DRUGINFO	D06EWG	Formic Acid	Investigative

T31825	TARGETID	T31825
T31825	FORMERID	TTDI01041
T31825	UNIPROID	HBB_HUMAN
T31825	TARGNAME	Hemoglobin subunit beta (HBB)
T31825	GENENAME	HBB
T31825	TARGTYPE	Clinical trial
T31825	SYNONYMS	LVVhemorphin7; Hemoglobin beta chain; Betaglobin; Beta-globin
T31825	FUNCTION	Involved in oxygen transport from the lung to the various peripheral tissues.
T31825	PDBSTRUC	6NBD; 6NBC; 6HBW; 6HAL; 6FQF
T31825	BIOCLASS	Pore-forming globin
T31825	SEQUENCE	MVHLTPEEKSAVTALWGKVNVDEVGGEALGRLLVVYPWTQRFFESFGDLSTPDAVMGNPKVKAHGKKVLGAFSDGLAHLDNLKGTFATLSELHCDKLHVDPENFRLLGNVLVCVLAHHFGKEFTPPVQAAYQKVVAGVANALAHKYH
T31825	DRUGINFO	D0C9LQ	LentiGlobin	Phase 3
T31825	DRUGINFO	D1RMS5	OTL-300	Phase 1/2
T31825	DRUGINFO	DSEP59	PF-07059013	Phase 1

T49327	TARGETID	T49327
T49327	FORMERID	TTDI02222
T49327	UNIPROID	ABCA4_HUMAN
T49327	TARGNAME	ATP-binding cassette transporter A4 (ABCA4)
T49327	GENENAME	ABCA4
T49327	TARGTYPE	Clinical trial
T49327	SYNONYMS	Stargardt disease protein; RmP; Retinal-specific ATP-binding cassette transporter; RIM protein; RIM ABC transporter; ATP-binding cassette sub-family A member 4; ABCA4
T49327	FUNCTION	In the visualcycle, acts as an inward-directed retinoid flipase, retinoid substrates imported by ABCA4 from the extracellular or intradiscal (rod) membrane surfaces to the cytoplasmic membrane surface are all-trans-retinaldehyde (ATR) and N-retinyl-phosphatidyl-ethanolamine (NR-PE). Once transported to the cytoplasmic surface, ATR is reduced to vitamin A by trans- retinol dehydrogenase (tRDH) and then transferred to the retinal pigment epithelium (RPE) where it is converted to 11-cis-retinal. May play a role in photoresponse, removing ATR/NR-PE from the extracellular photoreceptor surfaces during bleach recovery.
T49327	BIOCLASS	ABC transporter
T49327	ECNUMBER	EC 7.6.2.1
T49327	SEQUENCE	MGFVRQIQLLLWKNWTLRKRQKIRFVVELVWPLSLFLVLIWLRNANPLYSHHECHFPNKAMPSAGMLPWLQGIFCNVNNPCFQSPTPGESPGIVSNYNNSILARVYRDFQELLMNAPESQHLGRIWTELHILSQFMDTLRTHPERIAGRGIRIRDILKDEETLTLFLIKNIGLSDSVVYLLINSQVRPEQFAHGVPDLALKDIACSEALLERFIIFSQRRGAKTVRYALCSLSQGTLQWIEDTLYANVDFFKLFRVLPTLLDSRSQGINLRSWGGILSDMSPRIQEFIHRPSMQDLLWVTRPLMQNGGPETFTKLMGILSDLLCGYPEGGGSRVLSFNWYEDNNYKAFLGIDSTRKDPIYSYDRRTTSFCNALIQSLESNPLTKIAWRAAKPLLMGKILYTPDSPAARRILKNANSTFEELEHVRKLVKAWEEVGPQIWYFFDNSTQMNMIRDTLGNPTVKDFLNRQLGEEGITAEAILNFLYKGPRESQADDMANFDWRDIFNITDRTLRLVNQYLECLVLDKFESYNDETQLTQRALSLLEENMFWAGVVFPDMYPWTSSLPPHVKYKIRMDIDVVEKTNKIKDRYWDSGPRADPVEDFRYIWGGFAYLQDMVEQGITRSQVQAEAPVGIYLQQMPYPCFVDDSFMIILNRCFPIFMVLAWIYSVSMTVKSIVLEKELRLKETLKNQGVSNAVIWCTWFLDSFSIMSMSIFLLTIFIMHGRILHYSDPFILFLFLLAFSTATIMLCFLLSTFFSKASLAAACSGVIYFTLYLPHILCFAWQDRMTAELKKAVSLLSPVAFGFGTEYLVRFEEQGLGLQWSNIGNSPTEGDEFSFLLSMQMMLLDAAVYGLLAWYLDQVFPGDYGTPLPWYFLLQESYWLGGEGCSTREERALEKTEPLTEETEDPEHPEGIHDSFFEREHPGWVPGVCVKNLVKIFEPCGRPAVDRLNITFYENQITAFLGHNGAGKTTTLSILTGLLPPTSGTVLVGGRDIETSLDAVRQSLGMCPQHNILFHHLTVAEHMLFYAQLKGKSQEEAQLEMEAMLEDTGLHHKRNEEAQDLSGGMQRKLSVAIAFVGDAKVVILDEPTSGVDPYSRRSIWDLLLKYRSGRTIIMSTHHMDEADLLGDRIAIIAQGRLYCSGTPLFLKNCFGTGLYLTLVRKMKNIQSQRKGSEGTCSCSSKGFSTTCPAHVDDLTPEQVLDGDVNELMDVVLHHVPEAKLVECIGQELIFLLPNKNFKHRAYASLFRELEETLADLGLSSFGISDTPLEEIFLKVTEDSDSGPLFAGGAQQKRENVNPRHPCLGPREKAGQTPQDSNVCSPGAPAAHPEGQPPPEPECPGPQLNTGTQLVLQHVQALLVKRFQHTIRSHKDFLAQIVLPATFVFLALMLSIVIPPFGEYPALTLHPWIYGQQYTFFSMDEPGSEQFTVLADVLLNKPGFGNRCLKEGWLPEYPCGNSTPWKTPSVSPNITQLFQKQKWTQVNPSPSCRCSTREKLTMLPECPEGAGGLPPPQRTQRSTEILQDLTDRNISDFLVKTYPALIRSSLKSKFWVNEQRYGGISIGGKLPVVPITGEALVGFLSDLGRIMNVSGGPITREASKEIPDFLKHLETEDNIKVWFNNKGWHALVSFLNVAHNAILRASLPKDRSPEEYGITVISQPLNLTKEQLSEITVLTTSVDAVVAICVIFSMSFVPASFVLYLIQERVNKSKHLQFISGVSPTTYWVTNFLWDIMNYSVSAGLVVGIFIGFQKKAYTSPENLPALVALLLLYGWAVIPMMYPASFLFDVPSTAYVALSCANLFIGINSSAITFILELFENNRTLLRFNAVLRKLLIVFPHFCLGRGLIDLALSQAVTDVYARFGEEHSANPFHWDLIGKNLFAMVVEGVVYFLLTLLVQRHFFLSQWIAEPTKEPIVDEDDDVAEERQRIITGGNKTDILRLHELTKIYPGTSSPAVDRLCVGVRPGECFGLLGVNGAGKTTTFKMLTGDTTVTSGDATVAGKSILTNISEVHQNMGYCPQFDAIDELLTGREHLYLYARLRGVPAEEIEKVANWSIKSLGLTVYADCLAGTYSGGNKRKLSTAIALIGCPPLVLLDEPTTGMDPQARRMLWNVIVSIIREGRAVVLTSHSMEECEALCTRLAIMVKGAFRCMGTIQHLKSKFGDGYIVTMKIKSPKDDLLPDLNPVEQFFQGNFPGSVQRERHYNMLQFQVSSSSLARIFQLLLSHKDSLLIEEYSVTQTTLDQVFVNFAKQQTESHDLPLHPRAAGASRQAQD
T49327	DRUGINFO	D0F6SY	StarGen	Phase 1/2

T55936	TARGETID	T55936
T55936	FORMERID	TTDR00622
T55936	UNIPROID	PSS_MYCTU
T55936	TARGNAME	Mycobacterium CDP-diacylglycerol-inositol phosphatidyltransferase (MycB pssA)
T55936	GENENAME	MycB pssA
T55936	TARGTYPE	Clinical trial
T55936	SYNONYMS	pssA; PtdIns synthase; Phosphatidylinositol synthase; PI synthase
T55936	FUNCTION	Catalyzes the biosynthesis of phosphatidylinositol (ptdins) as well as ptdins:inositol exchange reaction. May thus act to reduce an excessive cellular ptdins content. The exchange activity is due to the reverse reaction of ptdins synthase.
T55936	BIOCLASS	Kinase
T55936	ECNUMBER	EC 2.7.8.8
T55936	SEQUENCE	MIGKPRGRRGVNLQILPSAMTVLSICAGLTAIKFALEHQPKAAMALIAAAAILDGLDGRVARILDAQSRMGAEIDSLADAVNFGVTPALVLYVSMLSKWPVGWVVVLLYAVCVVLRLARYNALQDDGTQPAYAHEFFVGMPAPAGAVSMIGLLALKMQFGEGWWTSGWFLSFWVTGTSILLVSGIPMKKMHAVSVPPNYAAALLAVLAICAAAAVLAPYLLIWVIIIAYMCHIPFAVRSQRWLAQHPEVWDDKPKQRRAVRRASRRAHPYRPSMARLGLRKPGRRL
T55936	DRUGINFO	D03SHD	Myo-inositol	Phase 2
T55936	DRUGINFO	D04DWJ	Zn2+	Investigative

T74203	TARGETID	T74203
T74203	FORMERID	TTDI02230
T74203	UNIPROID	A85A_MYCTU
T74203	TARGNAME	Mycobacterium Antigen complex 85A (MycB fbpA)
T74203	GENENAME	MycB fbpA
T74203	TARGTYPE	Clinical trial
T74203	SYNONYMS	Fibronectinbinding protein A; Fbps A; Diacylglycerol acyltransferase/mycolyltransferase Ag85A; Antigen 85 complex A; Ag85A; AcylCoA:diacylglycerol acyltransferase; 85A
T74203	FUNCTION	The antigen 85 proteins (FbpA, FbpB, FbpC) are responsible for the high affinity of mycobacteria for fibronectin, a large adhesive glycoprotein, which facilitates the attachment of M.tuberculosis to murine alveolar macrophages (AMs). They also help to maintain the integrity of the cell wall by catalyzing the transfer of mycolic acids to cell wall arabinogalactan, and through the synthesis of alpha,alpha-trehalose dimycolate (TDM, cord factor). They catalyze the transfer of a mycoloyl residue from one molecule of alpha,alpha-trehalose monomycolate (TMM) to another TMM, leading to the formation of TDM. FbpA mediates triacylglycerol (TAG) formation with long-chain acyl-CoA as the acyl donor and 1,2-dipalmitoyl-sn-glycerol (1,2-dipalmitin) as the acyl acceptor. It has a preference for C26:0-CoAover C18:1-CoA.
T74203	PDBSTRUC	1SFR
T74203	BIOCLASS	Acyltransferase
T74203	SEQUENCE	MQLVDRVRGAVTGMSRRLVVGAVGAALVSGLVGAVGGTATAGAFSRPGLPVEYLQVPSPSMGRDIKVQFQSGGANSPALYLLDGLRAQDDFSGWDINTPAFEWYDQSGLSVVMPVGGQSSFYSDWYQPACGKAGCQTYKWETFLTSELPGWLQANRHVKPTGSAVVGLSMAASSALTLAIYHPQQFVYAGAMSGLLDPSQAMGPTLIGLAMGDAGGYKASDMWGPKEDPAWQRNDPLLNVGKLIANNTRVWVYCGNGKPSDLGGNNLPAKFLEGFVRTSNIKFQDAYNAGGGHNGVFDFPDSGTHSWEYWGAQLNAMKPDLQRALGATPNTGPAPQGA
T74203	DRUGINFO	D07GMF	MVA-85A	Phase 2

T22956	TARGETID	T22956
T22956	FORMERID	TTDI02041
T22956	UNIPROID	CDK3_HUMAN
T22956	TARGNAME	Cyclin-dependent kinase 3 (CDK3)
T22956	GENENAME	CDK3
T22956	TARGTYPE	Clinical trial
T22956	SYNONYMS	Cyclindependent kinase 3; Cell division protein kinase 3; CDKN3
T22956	FUNCTION	Interacts with CCNC/cyclin-C during interphase. Phosphorylates histone H1, ATF1, RB1 and CABLES1. ATF1 phosphorylation triggers ATF1 transactivation and transcriptional activities, and promotes cell proliferation and transformation. CDK3/cyclin-C mediated RB1 phosphorylation is required for G0-G1 transition. Promotes G1-S transition probably by contributing to the activation of E2F1, E2F2 and E2F3 in a RB1-independent manner. Serine/threonine-protein kinase that plays a critical role in the control of the eukaryotic cell cycle; involved in G0-G1 and G1-S cell cycle transitions.
T22956	PDBSTRUC	1LFN
T22956	BIOCLASS	Kinase
T22956	ECNUMBER	EC 2.7.11.22
T22956	SEQUENCE	MDMFQKVEKIGEGTYGVVYKAKNRETGQLVALKKIRLDLEMEGVPSTAIREISLLKELKHPNIVRLLDVVHNERKLYLVFEFLSQDLKKYMDSTPGSELPLHLIKSYLFQLLQGVSFCHSHRVIHRDLKPQNLLINELGAIKLADFGLARAFGVPLRTYTHEVVTLWYRAPEILLGSKFYTTAVDIWSIGCIFAEMVTRKALFPGDSEIDQLFRIFRMLGTPSEDTWPGVTQLPDYKGSFPKWTRKGLEEIVPNLEPEGRDLLMQLLQYDPSQRITAKTALAHPYFSSPEPSPAARQYVLQRFRH
T22956	DRUGINFO	D03DKV	RGB-286638	Phase 1
T22956	DRUGINFO	D0FQ6V	PMID26161698-Compound-17	Patented
T22956	DRUGINFO	D0LK4L	Nitrogen mustard derivative 1	Patented
T22956	DRUGINFO	D0M5DX	Oxazolyl methylthiothiazole derivative 1	Patented

T87871	TARGETID	T87871
T87871	FORMERID	TTDI01510
T87871	UNIPROID	ROR1_HUMAN
T87871	TARGNAME	Neurotrophic tyrosine kinase ROR1 (ROR1)
T87871	GENENAME	ROR1
T87871	TARGTYPE	Clinical trial
T87871	SYNONYMS	receptor tyrosine kinase-like orphan receptor 1; receptor tyrosine kinase like orphan receptor 1; neurotrophic tyrosine kinase, receptor-related 1; dJ537F10.1; Tyrosine-protein kinase transmembrane receptor ROR1; NTRKR1; Inactive tyrosine-protein kinase transmembrane receptor ROR1
T87871	FUNCTION	Receptor for ligand WNT5A which activate downstream NFkB signaling pathway and may result in the inhibition of WNT3A-mediated signaling. In inner ear, crucial for spiral ganglion neurons to innervate auditory hair cells. Has very low kinase activity in vitro and is unlikely to function as a tyrosine kinase in vivo.
T87871	PDBSTRUC	6BAN; 6BA5; 5Z55
T87871	BIOCLASS	Kinase
T87871	SEQUENCE	MHRPRRRGTRPPLLALLAALLLAARGAAAQETELSVSAELVPTSSWNISSELNKDSYLTLDEPMNNITTSLGQTAELHCKVSGNPPPTIRWFKNDAPVVQEPRRLSFRSTIYGSRLRIRNLDTTDTGYFQCVATNGKEVVSSTGVLFVKFGPPPTASPGYSDEYEEDGFCQPYRGIACARFIGNRTVYMESLHMQGEIENQITAAFTMIGTSSHLSDKCSQFAIPSLCHYAFPYCDETSSVPKPRDLCRDECEILENVLCQTEYIFARSNPMILMRLKLPNCEDLPQPESPEAANCIRIGIPMADPINKNHKCYNSTGVDYRGTVSVTKSGRQCQPWNSQYPHTHTFTALRFPELNGGHSYCRNPGNQKEAPWCFTLDENFKSDLCDIPACDSKDSKEKNKMEILYILVPSVAIPLAIALLFFFICVCRNNQKSSSAPVQRQPKHVRGQNVEMSMLNAYKPKSKAKELPLSAVRFMEELGECAFGKIYKGHLYLPGMDHAQLVAIKTLKDYNNPQQWTEFQQEASLMAELHHPNIVCLLGAVTQEQPVCMLFEYINQGDLHEFLIMRSPHSDVGCSSDEDGTVKSSLDHGDFLHIAIQIAAGMEYLSSHFFVHKDLAARNILIGEQLHVKISDLGLSREIYSADYYRVQSKSLLPIRWMPPEAIMYGKFSSDSDIWSFGVVLWEIFSFGLQPYYGFSNQEVIEMVRKRQLLPCSEDCPPRMYSLMTECWNEIPSRRPRFKDIHVRLRSWEGLSSHTSSTTPSGGNATTQTTSLSASPVSNLSNPRYPNYMFPSQGITPQGQIAGFIGPPIPQNQRFIPINGYPIPPGYAAFPAAHYQPTGPPRVIQHCPPPKSRSPSSASGSTSTGHVTSLPSSGSNQEANIPLLPHMSIPNHPGGMGITVFGNKSQKPYKIDSKQASLLGDANIHGHTESMISAEL
T87871	DRUGINFO	D3YJZ7	Zilovertamab vedotin	Phase 2/3
T87871	DRUGINFO	D0P7PY	Cirmtuzumab	Phase 2
T87871	DRUGINFO	D1CG5M	VLS-101	Phase 2
T87871	DRUGINFO	D8P1KS	Zilovertamab	Phase 2
T87871	DRUGINFO	D79HBK	NBE-002	Phase 1/2
T87871	DRUGINFO	D0L5KK	ROR1R-CAR-T Cell	Phase 1
T87871	DRUGINFO	D0Q8ML	ROR1 CAR-specific Autologous T-Lymphocytes	Phase 1

T60636	TARGETID	T60636
T60636	UNIPROID	ODO1_HUMAN
T60636	TARGNAME	Alpha-ketoglutarate dehydrogenase (OGDH)
T60636	GENENAME	OGDH
T60636	TARGTYPE	Clinical trial
T60636	SYNONYMS	OGDC-E1; 2-oxoglutarate dehydrogenase, mitochondrial; 2-oxoglutarate dehydrogenase complex component E1
T60636	FUNCTION	The 2-oxoglutarate dehydrogenase complex catalyzes the overall conversion of 2-oxoglutarate to succinyl-CoA and CO(2). The 2-oxoglutarate dehydrogenase complex is mainly active in the mitochondrion. A fraction of the 2-oxoglutarate dehydrogenase complex also localizes in the nucleus and is required for lysine succinylation of histones: associates with KAT2A on chromatin and provides succinyl-CoA to histone succinyltransferase KAT2A. 2-oxoglutarate dehydrogenase (E1) component of the 2-oxoglutarate dehydrogenase complex, which mediates the decarboxylation of alpha-ketoglutarate.
T60636	PDBSTRUC	3ERY
T60636	BIOCLASS	Aldehyde/oxo donor oxidoreductase
T60636	ECNUMBER	EC 1.2.4.2
T60636	SEQUENCE	MFHLRTCAAKLRPLTASQTVKTFSQNRPAAARTFQQIRCYSAPVAAEPFLSGTSSNYVEEMYCAWLENPKSVHKSWDIFFRNTNAGAPPGTAYQSPLPLSRGSLAAVAHAQSLVEAQPNVDKLVEDHLAVQSLIRAYQIRGHHVAQLDPLGILDADLDSSVPADIISSTDKLGFYGLDESDLDKVFHLPTTTFIGGQESALPLREIIRRLEMAYCQHIGVEFMFINDLEQCQWIRQKFETPGIMQFTNEEKRTLLARLVRSTRFEEFLQRKWSSEKRFGLEGCEVLIPALKTIIDKSSENGVDYVIMGMPHRGRLNVLANVIRKELEQIFCQFDSKLEAADEGSGDVKYHLGMYHRRINRVTDRNITLSLVANPSHLEAADPVVMGKTKAEQFYCGDTEGKKVMSILLHGDAAFAGQGIVYETFHLSDLPSYTTHGTVHVVVNNQIGFTTDPRMARSSPYPTDVARVVNAPIFHVNSDDPEAVMYVCKVAAEWRSTFHKDVVVDLVCYRRNGHNEMDEPMFTQPLMYKQIRKQKPVLQKYAELLVSQGVVNQPEYEEEISKYDKICEEAFARSKDEKILHIKHWLDSPWPGFFTLDGQPRSMSCPSTGLTEDILTHIGNVASSVPVENFTIHGGLSRILKTRGEMVKNRTVDWALAEYMAFGSLLKEGIHIRLSGQDVERGTFSHRHHVLHDQNVDKRTCIPMNHLWPNQAPYTVCNSSLSEYGVLGFELGFAMASPNALVLWEAQFGDFHNTAQCIIDQFICPGQAKWVRQNGIVLLLPHGMEGMGPEHSSARPERFLQMCNDDPDVLPDLKEANFDINQLYDCNWVVVNCSTPGNFFHVLRRQILLPFRKPLIIFTPKSLLRHPEARSSFDEMLPGTHFQRVIPEDGPAAQNPENVKRLLFCTGKVYYDLTRERKARDMVGQVAITRIEQLSPFPFDLLLKEVQKYPNAELAWCQEEHKNQGYYDYVKPRLRTTISRAKPVWYAGRDPAAAPATGNKKTHLTELQRLLDTAFDLDVFKNFS
T60636	DRUGINFO	D07NVI	CPI-613	Phase 3

T89065	TARGETID	T89065
T89065	FORMERID	TTDR01222
T89065	UNIPROID	PLOD1_HUMAN
T89065	TARGNAME	Lysyl hydroxylase 1 (PLOD1)
T89065	GENENAME	PLOD1
T89065	TARGTYPE	Clinical trial
T89065	SYNONYMS	Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1; Peptidyllysine, 2-oxoglutarate:oxygen 5-oxidoreductase; PLOD; Lysyl hydroxylase; LLH; LH1; LH
T89065	FUNCTION	Forms hydroxylysine residues in -Xaa-Lys-Gly- sequences in collagens. These hydroxylysines serve as sites of attachment for carbohydrate units and are essential for the stability of the intermolecular collagen cross-links. Part of a complex composed of PLOD1, P3H3 and P3H4 that catalyzes hydroxylation of lysine residues in collagen alpha chains and is required for normal assembly and cross-linkling of collagen fibrils.
T89065	BIOCLASS	Paired donor oxygen oxidoreductase
T89065	ECNUMBER	EC 1.14.11.4
T89065	SEQUENCE	MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQFFNYKIQALGLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFADSYDVLFASGPRELLKKFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKRFLGSGGFIGYAPNLSKLVAEWEGQDSDSDQLFYTKIFLDPEKREQINITLDHRCRIFQNLDGALDEVVLKFEMGHVRARNLAYDTLPVLIHGNGPTKLQLNYLGNYIPRFWTFETGCTVCDEGLRSLKGIGDEALPTVLVGVFIEQPTPFVSLFFQRLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVKLVGPEVRMANADARNMGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQNKNVIAPLMTRHGRLWSNFWGALSADGYYARSEDYVDIVQGRRVGVWNVPYISNIYLIKGSALRGELQSSDLFHHSKLDPDMAFCANIRQQDVFMFLTNRHTLGHLLSLDSYRTTHLHNDLWEVFSNPEDWKEKYIHQNYTKALAGKLVETPCPDVYWFPIFTEVACDELVEEMEHFGQWSLGNNKDNRIQGGYENVPTIDIHMNQIGFEREWHKFLLEYIAPMTEKLYPGYYTRAQFDLAFVVRYKPDEQPSLMPHHDASTFTINIALNRVGVDYEGGGCRFLRYNCSIRAPRKGWTLMHPGRLTHYHEGLPTTRGTRYIAVSFVDP

T88656	TARGETID	T88656
T88656	FORMERID	TTDI02134
T88656	UNIPROID	NOTC2_HUMAN
T88656	TARGNAME	Notch-2 receptor (NOTCH2)
T88656	GENENAME	NOTCH2
T88656	TARGTYPE	Clinical trial
T88656	SYNONYMS	hN2; Notch 2 intracellular domain; Notch 2; Neurogenic locus notch homolog protein 2
T88656	FUNCTION	Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs. Involved in bone remodeling and homeostasis. In collaboration with RELA/p65 enhances NFATc1 promoter activity and positively regulates RANKL-induced osteoclast differentiation. Positively regulates self-renewal of liver cancer cells. Functions as a receptor for membrane-bound ligands Jagged-1 (JAG1), Jagged-2 (JAG2) and Delta-1 (DLL1) to regulate cell-fate determination.
T88656	PDBSTRUC	5MWB; 2OO4
T88656	BIOCLASS	Notch protein
T88656	SEQUENCE	MPALRPALLWALLALWLCCAAPAHALQCRDGYEPCVNEGMCVTYHNGTGYCKCPEGFLGEYCQHRDPCEKNRCQNGGTCVAQAMLGKATCRCASGFTGEDCQYSTSHPCFVSRPCLNGGTCHMLSRDTYECTCQVGFTGKECQWTDACLSHPCANGSTCTTVANQFSCKCLTGFTGQKCETDVNECDIPGHCQHGGTCLNLPGSYQCQCPQGFTGQYCDSLYVPCAPSPCVNGGTCRQTGDFTFECNCLPGFEGSTCERNIDDCPNHRCQNGGVCVDGVNTYNCRCPPQWTGQFCTEDVDECLLQPNACQNGGTCANRNGGYGCVCVNGWSGDDCSENIDDCAFASCTPGSTCIDRVASFSCMCPEGKAGLLCHLDDACISNPCHKGALCDTNPLNGQYICTCPQGYKGADCTEDVDECAMANSNPCEHAGKCVNTDGAFHCECLKGYAGPRCEMDINECHSDPCQNDATCLDKIGGFTCLCMPGFKGVHCELEINECQSNPCVNNGQCVDKVNRFQCLCPPGFTGPVCQIDIDDCSSTPCLNGAKCIDHPNGYECQCATGFTGVLCEENIDNCDPDPCHHGQCQDGIDSYTCICNPGYMGAICSDQIDECYSSPCLNDGRCIDLVNGYQCNCQPGTSGVNCEINFDDCASNPCIHGICMDGINRYSCVCSPGFTGQRCNIDIDECASNPCRKGATCINGVNGFRCICPEGPHHPSCYSQVNECLSNPCIHGNCTGGLSGYKCLCDAGWVGINCEVDKNECLSNPCQNGGTCDNLVNGYRCTCKKGFKGYNCQVNIDECASNPCLNQGTCFDDISGYTCHCVLPYTGKNCQTVLAPCSPNPCENAAVCKESPNFESYTCLCAPGWQGQRCTIDIDECISKPCMNHGLCHNTQGSYMCECPPGFSGMDCEEDIDDCLANPCQNGGSCMDGVNTFSCLCLPGFTGDKCQTDMNECLSEPCKNGGTCSDYVNSYTCKCQAGFDGVHCENNINECTESSCFNGGTCVDGINSFSCLCPVGFTGSFCLHEINECSSHPCLNEGTCVDGLGTYRCSCPLGYTGKNCQTLVNLCSRSPCKNKGTCVQKKAESQCLCPSGWAGAYCDVPNVSCDIAASRRGVLVEHLCQHSGVCINAGNTHYCQCPLGYTGSYCEEQLDECASNPCQHGATCSDFIGGYRCECVPGYQGVNCEYEVDECQNQPCQNGGTCIDLVNHFKCSCPPGTRGLLCEENIDDCARGPHCLNGGQCMDRIGGYSCRCLPGFAGERCEGDINECLSNPCSSEGSLDCIQLTNDYLCVCRSAFTGRHCETFVDVCPQMPCLNGGTCAVASNMPDGFICRCPPGFSGARCQSSCGQVKCRKGEQCVHTASGPRCFCPSPRDCESGCASSPCQHGGSCHPQRQPPYYSCQCAPPFSGSRCELYTAPPSTPPATCLSQYCADKARDGVCDEACNSHACQWDGGDCSLTMENPWANCSSPLPCWDYINNQCDELCNTVECLFDNFECQGNSKTCKYDKYCADHFKDNHCDQGCNSEECGWDGLDCAADQPENLAEGTLVIVVLMPPEQLLQDARSFLRALGTLLHTNLRIKRDSQGELMVYPYYGEKSAAMKKQRMTRRSLPGEQEQEVAGSKVFLEIDNRQCVQDSDHCFKNTDAAAALLASHAIQGTLSYPLVSVVSESLTPERTQLLYLLAVAVVIILFIILLGVIMAKRKRKHGSLWLPEGFTLRRDASNHKRREPVGQDAVGLKNLSVQVSEANLIGTGTSEHWVDDEGPQPKKVKAEDEALLSEEDDPIDRRPWTQQHLEAADIRRTPSLALTPPQAEQEVDVLDVNVRGPDGCTPLMLASLRGGSSDLSDEDEDAEDSSANIITDLVYQGASLQAQTDRTGEMALHLAARYSRADAAKRLLDAGADANAQDNMGRCPLHAAVAADAQGVFQILIRNRVTDLDARMNDGTTPLILAARLAVEGMVAELINCQADVNAVDDHGKSALHWAAAVNNVEATLLLLKNGANRDMQDNKEETPLFLAAREGSYEAAKILLDHFANRDITDHMDRLPRDVARDRMHHDIVRLLDEYNVTPSPPGTVLTSALSPVICGPNRSFLSLKHTPMGKKSRRPSAKSTMPTSLPNLAKEAKDAKGSRRKKSLSEKVQLSESSVTLSPVDSLESPHTYVSDTTSSPMITSPGILQASPNPMLATAAPPAPVHAQHALSFSNLHEMQPLAHGASTVLPSVSQLLSHHHIVSPGSGSAGSLSRLHPVPVPADWMNRMEVNETQYNEMFGMVLAPAEGTHPGIAPQSRPPEGKHITTPREPLPPIVTFQLIPKGSIAQPAGAPQPQSTCPPAVAGPLPTMYQIPEMARLPSVAFPTAMMPQQDGQVAQTILPAYHPFPASVGKYPTPPSQHSYASSNAAERTPSHSGHLQGEHPYLTPSPESPDQWSSSSPHSASDWSDVTTSPTPGGAGGGQRGPGTHMSEPPHNNMQVYA
T88656	DRUGINFO	D01QLP	Tarextumab	Phase 2

T93923	TARGETID	T93923
T93923	FORMERID	TTDNC00406
T93923	UNIPROID	TNR9_HUMAN
T93923	TARGNAME	Co-stimulatory molecule 4-1BB (CD137)
T93923	GENENAME	TNFRSF9
T93923	TARGTYPE	Clinical trial
T93923	SYNONYMS	Tumor necrosis factor receptor superfamily member 9; T-cell antigen ILA; T-cell antigen 4-1BB homolog; ILA; CDw137; 4-1BB ligand receptor
T93923	FUNCTION	Possibly active during T cell activation. Receptor for TNFSF9/4-1BBL.
T93923	PDBSTRUC	6MI2; 6MHR; 6MGP; 6CU0; 6CPR
T93923	BIOCLASS	Cytokine receptor
T93923	SEQUENCE	MGNSCYNIVATLLLVLNFERTRSLQDPCSNCPAGTFCDNNRNQICSPCPPNSFSSAGGQRTCDICRQCKGVFRTRKECSSTSNAECDCTPGFHCLGAGCSMCEQDCKQGQELTKKGCKDCCFGTFNDQKRGICRPWTNCSLDGKSVLVNGTKERDVVCGPSPADLSPGASSVTPPAPAREPGHSPQIISFFLALTSTALLFLLFFLTLRFSVVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL
T93923	DRUGINFO	D02ZMB	Urelumab	Phase 2
T93923	DRUGINFO	D06NAG	Anti-CD137	Phase 2
T93923	DRUGINFO	D03LUF	CD137 CAR-T Cell	Phase 1/2
T93923	DRUGINFO	DB91HQ	ADG106	Phase 1/2
T93923	DRUGINFO	D0Q5GK	MG7-CART	Phase 1/2
T93923	DRUGINFO	DUVH60	NM21-1480	Phase 1/2
T93923	DRUGINFO	D01ZLR	PF-05082566	Phase 1
T93923	DRUGINFO	D4BC6I	RG7827	Phase 1
T93923	DRUGINFO	D4HDR2	LVGN6051	Phase 1
T93923	DRUGINFO	D9DN5J	RG6076	Phase 1
T93923	DRUGINFO	DK6S3G	CTX-471	Phase 1
T93923	DRUGINFO	DL9ZT4	Utomilumab	Phase 1
T93923	DRUGINFO	DOA3J0	AGEN2373	Phase 1
T93923	DRUGINFO	D0JY0M	CD28 and CD137 CAR-T Cells	Phase 1
T93923	DRUGINFO	D2QY0Z	MCLA-145	Phase 1
T93923	DRUGINFO	D3HBJ1	GEN1046	Phase 1
T93923	DRUGINFO	DA1X5W	INBRX-105	Phase 1
T93923	DRUGINFO	DN28KM	GEN1042	Phase 1
T93923	DRUGINFO	DN2F9A	AMG 506	Phase 1
T93923	DRUGINFO	D2L9MD	RG6524	Phase 1
T93923	DRUGINFO	D07RXX	HG-1051	Investigative

T93450	TARGETID	T93450
T93450	FORMERID	TTDI02335
T93450	UNIPROID	IL24_HUMAN
T93450	TARGNAME	Interleukin-24 (IL24)
T93450	GENENAME	IL24
T93450	TARGTYPE	Clinical trial
T93450	SYNONYMS	Suppression of tumorigenicity 16 protein; ST16; Melanoma differentiationassociated gene 7 protein; Melanoma differentiation-associated gene 7 protein; MDA7; MDA-7; Interleukin24; IL-24
T93450	FUNCTION	Has antiproliferative properties on melanoma cells and may contribute to terminal cell differentiation.
T93450	PDBSTRUC	6GG1; 6DF3
T93450	BIOCLASS	Cytokine: interleukin
T93450	SEQUENCE	MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSGAQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQNVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANNFVLIVSQLQPSQENEMFSIRDSAHRRFLLFRRAFKQLDVEAALTKALGEVDILLTWMQKFYKL
T93450	DRUGINFO	D02FTV	INGN-241	Phase 2

T38875	TARGETID	T38875
T38875	FORMERID	TTDS00209
T38875	UNIPROID	AAPK1_HUMAN; AAKB1_HUMAN; AAKG1_HUMAN
T38875	TARGNAME	AMP-activated protein kinase (AMPK)
T38875	GENENAME	PRKAA1; PRKAB1; PRKAG1
T38875	TARGTYPE	Clinical trial
T38875	SYNONYMS	AMPK; 5'-AMP-activated protein kinase
T38875	FUNCTION	Catalytic subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism. In response to reduction of intracellular ATP levels, AMPK activates energy-producing pathways and inhibits energy-consuming processes: inhibits protein, carbohydrate and lipid biosynthesis, as well as cell growth and proliferation. AMPK acts via direct phosphorylation of metabolic enzymes, and by longer-term effects via phosphorylation of transcription regulators. Also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton; probably by indirectly activating myosin. Regulates lipid synthesis by phosphorylating and inactivating lipid metabolic enzymes such as ACACA, ACACB, GYS1, HMGCR and LIPE; regulates fatty acid and cholesterol synthesis by phosphorylating acetyl-CoA carboxylase (ACACA and ACACB) and hormone-sensitive lipase (LIPE) enzymes, respectively. Regulates insulin-signaling and glycolysis by phosphorylating IRS1, PFKFB2 and PFKFB3. AMPK stimulates glucose uptake in muscle by increasing the translocation of the glucose transporter SLC2A4/GLUT4 to the plasma membrane, possibly by mediating phosphorylation of TBC1D4/AS160. Regulates transcription and chromatin structure by phosphorylating transcription regulators involved in energy metabolism such as CRTC2/TORC2, FOXO3, histone H2B, HDAC5, MEF2C, MLXIPL/ChREBP, EP300, HNF4A, p53/TP53, SREBF1, SREBF2 and PPARGC1A. Acts as a key regulator of glucose homeostasis in liver by phosphorylating CRTC2/TORC2, leading to CRTC2/TORC2 sequestration in the cytoplasm. In response to stress, phosphorylates 'Ser-36' of histone H2B (H2BS36ph), leading to promote transcription. Acts as a key regulator of cell growth and proliferation by phosphorylating TSC2, RPTOR and ATG1/ULK1: in response to nutrient limitation, negatively regulates the mTORC1 complex by phosphorylating RPTOR component of the mTORC1 complex and by phosphorylating and activating TSC2. In response to nutrient limitation, promotes autophagy by phosphorylating and activating ATG1/ULK1. AMPK also acts as a regulator of circadian rhythm by mediating phosphorylation of CRY1, leading to destabilize it. May regulate the Wnt signaling pathway by phosphorylating CTNNB1, leading to stabilize it. Also has tau-protein kinase activity: in response to amyloid beta A4 protein (APP) exposure, activated by CAMKK2, leading to phosphorylation of MAPT/TAU; however the relevance of such data remains unclear in vivo. Also phosphorylates CFTR, EEF2K, KLC1, NOS3 and SLC12A1.
T38875	BIOCLASS	Kinase
T38875	SEQUENCE	MRRLSSWRKMATAEKQKHDGRVKIGHYILGDTLGVGTFGKVKVGKHELTGHKVAVKILNRQKIRSLDVVGKIRREIQNLKLFRHPHIIKLYQVISTPSDIFMVMEYVSGGELFDYICKNGRLDEKESRRLFQQILSGVDYCHRHMVVHRDLKPENVLLDAHMNAKIADFGLSNMMSDGEFLRTSCGSPNYAAPEVISGRLYAGPEVDIWSSGVILYALLCGTLPFDDDHVPTLFKKICDGIFYTPQYLNPSVISLLKHMLQVDPMKRATIKDIREHEWFKQDLPKYLFPEDPSYSSTMIDDEALKEVCEKFECSEEEVLSCLYNRNHQDPLAVAYHLIIDNRRIMNEAKDFYLATSPPDSFLDDHHLTRPHPERVPFLVAETPRARHTLDELNPQKSKHQGVRKAKWHLGIRSQSRPNDIMAEVCRAIKQLDYEWKVVNPYYLRVRRKNPVTSTYSKMSLQLYQVDSRTYLLDFRSIDDEITEAKSGTATPQRSGSVSNYRSCQRSDSDAEAQGKSSEVSLTSSVTSLDSSPVDLTPRPGSHTIEFFEMCANLIKILAQ
T38875	DRUGINFO	D0R3MT	Acadesine	Phase 3
T38875	DRUGINFO	D03JCA	MB-11055	Phase 2
T38875	DRUGINFO	D08PMB	Imeglimin	Phase 2
T38875	DRUGINFO	D67AKN	PXL-770	Phase 2
T38875	DRUGINFO	DD3IE7	ENERGI-F701	Phase 2
T38875	DRUGINFO	DL9F3C	O-304	Phase 2
T38875	DRUGINFO	D0Q5DT	IM156	Phase 1
T38875	DRUGINFO	D07XPE	Phenformin	Withdrawn from market
T38875	DRUGINFO	D01UVU	4-(3-bromopyrazolo[1,5-a]pyrimidin-6-yl)phenol	Investigative
T38875	DRUGINFO	D0C1OJ	Debio-0930	Investigative
T38875	DRUGINFO	D0C3GW	TG-1022	Investigative
T38875	DRUGINFO	D0Y0BK	Dorsomorphin	Investigative
T38875	DRUGINFO	DCVO04	OSU-53	Investigative
T38875	DRUGINFO	D0CE3R	SU 6656	Investigative
T38875	DRUGINFO	D0PP6Y	PMID23639540C13a	Investigative
T38875	DRUGINFO	D0O1YH	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	Investigative

T48429	TARGETID	T48429
T48429	FORMERID	TTDI02093
T48429	UNIPROID	I15RA_HUMAN
T48429	TARGNAME	Interleukin 15 receptor alpha (IL15RA)
T48429	GENENAME	IL15RA
T48429	TARGTYPE	Clinical trial
T48429	SYNONYMS	sIL15Ralpha; sIL15RA; sIL15 receptor subunit alpha; Soluble interleukin15 receptor subunit alpha; Interleukin-15 receptor subunit alpha; IL15Ralpha; IL15 receptor subunit alpha; IL-15RA; IL-15R-alpha; IL-15 receptor subunit alpha; CD215
T48429	FUNCTION	Can signal both in cis and trans where IL15R from one subset of cells presents IL15 to neighboring IL2RG-expressing cells. In neutrophils, binds and activates kinase SYK in response to IL15 stimulation. In neutrophils, required for IL15-induced phagocytosis in a SYK-dependent manner. Expression of different isoforms may alter or interfere with signal transduction. High-affinity receptor for interleukin-15.
T48429	PDBSTRUC	4GS7; 2Z3R; 2Z3Q; 2ERS
T48429	BIOCLASS	Cytokine receptor
T48429	SEQUENCE	MAPRRARGCRTLGLPALLLLLLLRPPATRGITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRDPALVHQRPAPPSTVTTAGVTPQPESLSPSGKEPAASSPSSNNTAATTAAIVPGSQLMPSKSPSTGTTEISSHESSHGTPSQTTAKNWELTASASHQPPGVYPQGHSDTTVAISTSTVLLCGLSAVSLLACYLKSRQTPPLASVEMEAMEALPVTWGTSSRDEDLENCSHHL
T48429	DRUGINFO	D0FD7H	ALT-803	Phase 2
T48429	DRUGINFO	D2YN1W	NKTR-255	Phase 1/2

T87108	TARGETID	T87108
T87108	FORMERID	TTDNC00477
T87108	UNIPROID	MSLN_HUMAN
T87108	TARGNAME	Mesothelin (MSLN)
T87108	GENENAME	MSLN
T87108	TARGTYPE	Clinical trial
T87108	SYNONYMS	Prepromegakaryocytepotentiating factor; Pre-pro-megakaryocyte-potentiating factor; Mesothelin, cleaved form; MPF; CAK1 antigen
T87108	FUNCTION	Membrane-anchored forms may play a role in cellular adhesion.
T87108	PDBSTRUC	4F3F
T87108	SEQUENCE	MALPTARPLLGSCGTPALGSLLFLLFSLGWVQPSRTLAGETGQEAAPLDGVLANPPNISSLSPRQLLGFPCAEVSGLSTERVRELAVALAQKNVKLSTEQLRCLAHRLSEPPEDLDALPLDLLLFLNPDAFSGPQACTRFFSRITKANVDLLPRGAPERQRLLPAALACWGVRGSLLSEADVRALGGLACDLPGRFVAESAEVLLPRLVSCPGPLDQDQQEAARAALQGGGPPYGPPSTWSVSTMDALRGLLPVLGQPIIRSIPQGIVAAWRQRSSRDPSWRQPERTILRPRFRREVEKTACPSGKKAREIDESLIFYKKWELEACVDAALLATQMDRVNAIPFTYEQLDVLKHKLDELYPQGYPESVIQHLGYLFLKMSPEDIRKWNVTSLETLKALLEVNKGHEMSPQAPRRPLPQVATLIDRFVKGRGQLDKDTLDTLTAFYPGYLCSLSPEELSSVPPSSIWAVRPQDLDTCDPRQLDVLYPKARLAFQNMNGSEYFVKIQSFLGGAPTEDLKALSQQNVSMDLATFMKLRTDAVLPLTVAEVQKLLGPHVEGLKAEERHRPVRDWILRQRQDDLDTLGLGLQGGIPNGYLVLDLSMQEALSGTPCLLGPGPVLTVLALLLASTLA
T87108	DRUGINFO	D02WSB	CRS-207	Phase 2
T87108	DRUGINFO	D0R6MJ	MORAb-009	Phase 2
T87108	DRUGINFO	D00YXG	Anti-mesothelin CAR transduced PBL	Phase 1/2
T87108	DRUGINFO	D05FUP	CAR-T cells targeting Mesothelin	Phase 1/2
T87108	DRUGINFO	D0BE6M	Anti-Mesothelin CAR-T cells	Phase 1/2
T87108	DRUGINFO	D0HW1L	HPN536	Phase 1/2
T87108	DRUGINFO	D0KC2S	CAR-T cells targeting mesothelin	Phase 1/2
T87108	DRUGINFO	DJA64B	TC-510	Phase 1/2
T87108	DRUGINFO	DX6O9V	TC-210	Phase 1/2
T87108	DRUGINFO	D03OIO	Anti-Mesothelin CAR-T cells	Phase 1
T87108	DRUGINFO	D07YPB	Hu-CART meso cells	Phase 1
T87108	DRUGINFO	D09YXN	CAR-T cells targeting Mesothelin	Phase 1
T87108	DRUGINFO	D0CA3M	Anti-meso-CAR T cells	Phase 1
T87108	DRUGINFO	D0D2LE	Meso-CART	Phase 1
T87108	DRUGINFO	D0EB0Y	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1	Phase 1
T87108	DRUGINFO	D0G4GY	Anti-meso-CAR vector transduced T cells	Phase 1
T87108	DRUGINFO	D0L7OJ	CAR-T Cells targeting Mesothelin	Phase 1
T87108	DRUGINFO	D0O2XK	Mesothelin-targeted T cells	Phase 1
T87108	DRUGINFO	D0P2GA	CART-meso cells	Phase 1
T87108	DRUGINFO	D0P5MG	BAY 94-9343	Phase 1
T87108	DRUGINFO	D0PT5D	Anti-mesothelin CAR T Cells	Phase 1
T87108	DRUGINFO	D0S9FI	ICasp9M28z T cell	Phase 1
T87108	DRUGINFO	D0V7QW	RG7882	Phase 1
T87108	DRUGINFO	D0ZF9J	HuCART-meso cells	Phase 1
T87108	DRUGINFO	D8EIB7	MCY-M11	Phase 1
T87108	DRUGINFO	DF9S1L	ATA2271	Phase 1
T87108	DRUGINFO	DJ25DI	227Th-labelled MSLN-TTC	Phase 1
T87108	DRUGINFO	D0MD8S	CARTmeso/19	Phase 1
T87108	DRUGINFO	D0V5DD	CART-meso-19 T cells	Phase 1
T87108	DRUGINFO	D04WZL	CART-meso cells	Clinical trial
T87108	DRUGINFO	D09YUK	SS1(dsFv)-PE38	Discontinued in Phase 1
T87108	DRUGINFO	D8AI0N	ATA3271	Preclinical

T99340	TARGETID	T99340
T99340	FORMERID	TTDI03510
T99340	UNIPROID	RIPK1_HUMAN
T99340	TARGNAME	Receptor-interacting protein 1 (RIPK1)
T99340	GENENAME	RIPK1
T99340	TARGTYPE	Clinical trial
T99340	SYNONYMS	Receptor-interacting serine/threonine-protein kinase 1; RIP1; RIP-1; RIP; Cell death protein RIP
T99340	FUNCTION	Upon activation of TNFR1 by the TNF-alpha family cytokines, TRADD and TRAF2 are recruited to the receptor. Phosphorylates DAB2IP at 'Ser-728' in a TNF-alpha-dependent manner, and thereby activates the MAP3K5-JNK apoptotic cascade. Ubiquitination by TRAF2 via 'Lys-63'-link chains acts as a critical enhancer of communication with downstream signal transducers in the mitogen-activated protein kinase pathway and the NF-kappa-B pathway, which in turn mediate downstream events including the activation of genes encoding inflammatory molecules. Polyubiquitinated protein binds to IKBKG/NEMO, the regulatory subunit of the IKK complex, a critical event for NF-kappa-B activation. Interaction with other cellular RHIM-containing adapters initiates gene activation and cell death. RIPK1 and RIPK3 association, in particular, forms a necrosis-inducing complex. Serine-threonine kinase which transduces inflammatory and cell-death signals (programmed necrosis) following death receptors ligation, activation of pathogen recognition receptors (PRRs), and DNA damage.
T99340	PDBSTRUC	6R5F; 6OCQ; 6NW2; 6HHO; 6C4D
T99340	BIOCLASS	Kinase
T99340	ECNUMBER	EC 2.7.11.1
T99340	SEQUENCE	MQPDMSLNVIKMKSSDFLESAELDSGGFGKVSLCFHRTQGLMIMKTVYKGPNCIEHNEALLEEAKMMNRLRHSRVVKLLGVIIEEGKYSLVMEYMEKGNLMHVLKAEMSTPLSVKGRIILEIIEGMCYLHGKGVIHKDLKPENILVDNDFHIKIADLGLASFKMWSKLNNEEHNELREVDGTAKKNGGTLYYMAPEHLNDVNAKPTEKSDVYSFAVVLWAIFANKEPYENAICEQQLIMCIKSGNRPDVDDITEYCPREIISLMKLCWEANPEARPTFPGIEEKFRPFYLSQLEESVEEDVKSLKKEYSNENAVVKRMQSLQLDCVAVPSSRSNSATEQPGSLHSSQGLGMGPVEESWFAPSLEHPQEENEPSLQSKLQDEANYHLYGSRMDRQTKQQPRQNVAYNREEERRRRVSHDPFAQQRPYENFQNTEGKGTAYSSAASHGNAVHQPSGLTSQPQVLYQNNGLYSSHGFGTRPLDPGTAGPRVWYRPIPSHMPSLHNIPVPETNYLGNTPTMPFSSLPPTDESIKYTIYNSTGIQIGAYNYMEIGGTSSSLLDSTNTNFKEEPAAKYQAIFDNTTSLTDKHLDPIRENLGKHWKNCARKLGFTQSQIDEIDHDYERDGLKEKVYQMLQKWVMREGIKGATVGKLAQALHQCSRIDLLSSLIYVSQN
T99340	DRUGINFO	D0LQ3L	GSK2982772	Phase 2
T99340	DRUGINFO	D8GVM1	SAR443820	Phase 2
T99340	DRUGINFO	DC1AV3	DNL758	Phase 2
T99340	DRUGINFO	DWM2Y5	Eclitasertib	Phase 2
T99340	DRUGINFO	D0Z7BX	GSK3145095	Phase 1/2
T99340	DRUGINFO	D9FT0A	R552	Phase 1
T99340	DRUGINFO	DGH83L	DNL747	Phase 1
T99340	DRUGINFO	DHD2S9	DNL104	Phase 1
T99340	DRUGINFO	D0AY2N	Tricyclic compound 10	Patented
T99340	DRUGINFO	D0LF0B	Tricyclic compound 8	Patented
T99340	DRUGINFO	D0M7WS	Tricyclic compound 9	Patented
T99340	DRUGINFO	DW0D7G	GNE684	Preclinical
T99340	DRUGINFO	D0K8YD	PMID24900635C21	Investigative
T99340	DRUGINFO	D1N2BO	GSK'963	Investigative
T99340	DRUGINFO	DEV97R	PK68	Investigative
T99340	DRUGINFO	DF5C2I	RIPA-56	Investigative

T96892	TARGETID	T96892
T96892	UNIPROID	MELK_HUMAN
T96892	TARGNAME	Maternal embryonic leucine zipper kinase (MELK)
T96892	GENENAME	MELK
T96892	TARGTYPE	Clinical trial
T96892	SYNONYMS	Protein kinase PK38; Protein kinase Eg3
T96892	FUNCTION	Serine/threonine-protein kinase involved in various processes such as cell cycle regulation, self-renewal of stem cells, apoptosis and splicing regulation. Has a broad substrate specificity; phosphorylates BCL2L14, CDC25B, MAP3K5/ASK1 and ZNF622. Acts as an activator of apoptosis by phosphorylating and activating MAP3K5/ASK1. Acts as a regulator of cell cycle, notably by mediating phosphorylation of CDC25B, promoting localization of CDC25B to the centrosome and the spindle poles during mitosis. Plays a key role in cell proliferation and carcinogenesis. Required for proliferation of embryonic and postnatal multipotent neural progenitors. Phosphorylates and inhibits BCL2L14, possibly leading to affect mammary carcinogenesis by mediating inhibition of the pro-apoptotic function of BCL2L14. Also involved in the inhibition of spliceosome assembly during mitosis by phosphorylating ZNF622, thereby contributing to its redirection to the nucleus. May also play a role in primitive hematopoiesis.
T96892	PDBSTRUC	5TX3; 5TWZ; 5TWY; 5TWU; 5TWL
T96892	BIOCLASS	Protein kinase superfamily. CAMK Ser/Thr protein kinase family
T96892	ECNUMBER	EC 2.7.11.1
T96892	SEQUENCE	MKDYDELLKYYELHETIGTGGFAKVKLACHILTGEMVAIKIMDKNTLGSDLPRIKTEIEALKNLRHQHICQLYHVLETANKIFMVLEYCPGGELFDYIISQDRLSEEETRVVFRQIVSAVAYVHSQGYAHRDLKPENLLFDEYHKLKLIDFGLCAKPKGNKDYHLQTCCGSLAYAAPELIQGKSYLGSEADVWSMGILLYVLMCGFLPFDDDNVMALYKKIMRGKYDVPKWLSPSSILLLQQMLQVDPKKRISMKNLLNHPWIMQDYNYPVEWQSKNPFIHLDDDCVTELSVHHRNNRQTMEDLISLWQYDHLTATYLLLLAKKARGKPVRLRLSSFSCGQASATPFTDIKSNNWSLEDVTASDKNYVAGLIDYDWCEDDLSTGAATPRTSQFTKYWTESNGVESKSLTPALCRTPANKLKNKENVYTPKSAVKNEEYFMFPEPKTPVNKNQHKREILTTPNRYTTPSKARNQCLKETPIKIPVNSTGTDKLMTGVISPERRCRSVELDLNQAHMEETPKRKGAKVFGSLERGLDKVITVLTRSKRKGSARDGPRRLKLHYNVTTTRLVNPDQLLNEIMSILPKKHVDFVQKGYTLKCQTQSDFGKVTMQFELEVCQLQKPDVVGIRRQRLKGDAWVYKRLVEDILSSCKV
T96892	DRUGINFO	D08FIX	OTSSP167	Phase 1

T85523	TARGETID	T85523
T85523	FORMERID	TTDNC00586
T85523	UNIPROID	MYPC3_HUMAN
T85523	TARGNAME	Cardiac myosin (MYBPC3)
T85523	GENENAME	MYBPC3
T85523	TARGTYPE	Clinical trial
T85523	SYNONYMS	Myosinbinding protein C, cardiactype; Myosin-binding protein C, cardiac-type; Cprotein, cardiac muscle isoform; Cardiac MyBPC; Cardiac MyBP-C; C-protein, cardiac muscle isoform
T85523	FUNCTION	In vitro it binds MHC, F-actin and native thin filaments, and modifies the activity of actin-activated myosin ATPase. It may modulate muscle contraction or may play a more structural role. Thick filament-associated protein located in the crossbridge region of vertebrate striated muscle a bands.
T85523	PDBSTRUC	6G2T; 6CXJ; 6CXI; 5K6P; 3CX2
T85523	BIOCLASS	Immunoglobulin
T85523	SEQUENCE	MPEPGKKPVSAFSKKPRSVEVAAGSPAVFEAETERAGVKVRWQRGGSDISASNKYGLATEGTRHTLTVREVGPADQGSYAVIAGSSKVKFDLKVIEAEKAEPMLAPAPAPAEATGAPGEAPAPAAELGESAPSPKGSSSAALNGPTPGAPDDPIGLFVMRPQDGEVTVGGSITFSARVAGASLLKPPVVKWFKGKWVDLSSKVGQHLQLHDSYDRASKVYLFELHITDAQPAFTGSYRCEVSTKDKFDCSNFNLTVHEAMGTGDLDLLSAFRRTSLAGGGRRISDSHEDTGILDFSSLLKKRDSFRTPRDSKLEAPAEEDVWEILRQAPPSEYERIAFQYGVTDLRGMLKRLKGMRRDEKKSTAFQKKLEPAYQVSKGHKIRLTVELADHDAEVKWLKNGQEIQMSGSKYIFESIGAKRTLTISQCSLADDAAYQCVVGGEKCSTELFVKEPPVLITRPLEDQLVMVGQRVEFECEVSEEGAQVKWLKDGVELTREETFKYRFKKDGQRHHLIINEAMLEDAGHYALCTSGGQALAELIVQEKKLEVYQSIADLMVGAKDQAVFKCEVSDENVRGVWLKNGKELVPDSRIKVSHIGRVHKLTIDDVTPADEADYSFVPEGFACNLSAKLHFMEVKIDFVPRQEPPKIHLDCPGRIPDTIVVVAGNKLRLDVPISGDPAPTVIWQKAITQGNKAPARPAPDAPEDTGDSDEWVFDKKLLCETEGRVRVETTKDRSIFTVEGAEKEDEGVYTVTVKNPVGEDQVNLTVKVIDVPDAPAAPKISNVGEDSCTVQWEPPAYDGGQPILGYILERKKKKSYRWMRLNFDLIQELSHEARRMIEGVVYEMRVYAVNAIGMSRPSPASQPFMPIGPPSEPTHLAVEDVSDTTVSLKWRPPERVGAGGLDGYSVEYCPEGCSEWVAALQGLTEHTSILVKDLPTGARLLFRVRAHNMAGPGAPVTTTEPVTVQEILQRPRLQLPRHLRQTIQKKVGEPVNLLIPFQGKPRPQVTWTKEGQPLAGEEVSIRNSPTDTILFIRAARRVHSGTYQVTVRIENMEDKATLVLQVVDKPSPPQDLRVTDAWGLNVALEWKPPQDVGNTELWGYTVQKADKKTMEWFTVLEHYRRTHCVVPELIIGNGYYFRVFSQNMVGFSDRAATTKEPVFIPRPGITYEPPNYKALDFSEAPSFTQPLVNRSVIAGYTAMLCCAVRGSPKPKISWFKNGLDLGEDARFRMFSKQGVLTLEIRKPCPFDGGIYVCRATNLQGEARCECRLEVRVPQ
T85523	DRUGINFO	D0YL8U	Omecamtiv mecarbil	Phase 3
T85523	DRUGINFO	D6SY9X	Aficamten	Phase 3

T17502	TARGETID	T17502
T17502	FORMERID	TTDI02295
T17502	UNIPROID	RPE65_HUMAN
T17502	TARGNAME	Retinal pigment epithelium protein (RPE65)
T17502	GENENAME	RPE65
T17502	TARGTYPE	Clinical trial
T17502	SYNONYMS	Retinol isomerase; Retinoid isomerohydrolase; Retinal pigment epithelium-specific 65 kDa protein; Meso-zeaxanthin isomerase; Lutein isomerase; All-trans-retinyl-palmitate hydrolase
T17502	FUNCTION	Critical isomerohydrolase in the retinoid cycle involved in regeneration of 11-cis-retinal, the chromophore of rod and cone opsins. Catalyzes the cleavage and isomerization of all-trans-retinyl fatty acid esters to 11-cis-retinol which is further oxidized by 11-cis retinol dehydrogenase to 11-cis-retinal for use as visual chromophore. Essential for the production of 11-cis retinal for both rod and cone photoreceptors. Also capable of catalyzing the isomerization of lutein to meso-zeaxanthin an eye-specific carotenoid. The soluble form binds vitamin A (all-trans-retinol), making it available for LRAT processing to all-trans-retinyl ester. The membrane form, palmitoylated by LRAT, binds all-trans-retinyl esters, making them available for IMH (isomerohydrolase) processing to all-cis-retinol. The soluble form is regenerated by transferring its palmitoyl groups onto 11-cis-retinol, a reaction catalyzed by LRAT (By similarity).
T17502	BIOCLASS	Carboxylic ester hydrolase
T17502	ECNUMBER	EC 3.1.1.64
T17502	SEQUENCE	MSIQVEHPAGGYKKLFETVEELSSPLTAHVTGRIPLWLTGSLLRCGPGLFEVGSEPFYHLFDGQALLHKFDFKEGHVTYHRRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFSYFRGVEVTDNALVNVYPVGEDYYACTETNFITKINPETLETIKQVDLCNYVSVNGATAHPHIENDGTVYNIGNCFGKNFSIAYNIVKIPPLQADKEDPISKSEIVVQFPCSDRFKPSYVHSFGLTPNYIVFVETPVKINLFKFLSSWSLWGANYMDCFESNETMGVWLHIADKKRKKYLNNKYRTSPFNLFHHINTYEDNGFLIVDLCCWKGFEFVYNYLYLANLRENWEEVKKNARKAPQPEVRRYVLPLNIDKADTGKNLVTLPNTTATAILCSDETIWLEPEVLFSGPRQAFEFPQINYQKYCGKPYTYAYGLGLNHFVPDRLCKLNVKTKETWVWQEPDSYPSEPIFVSHPDALEEDDGVVLSVVVSPGAGQKPAYLLILNAKDLSEVARAEVEINIPVTFHGLFKKS
T17502	DRUGINFO	D01SRB	AAV2-hRPE65v2	Phase 3
T17502	DRUGINFO	D0GP1O	Emixustat	Phase 2/3
T17502	DRUGINFO	D04FSD	TgAAG76	Phase 1/2
T17502	DRUGINFO	D0DX1F	Leber's congenital amaurosis gene therapy	Phase 1/2
T17502	DRUGINFO	DDX95P	AAV-RPE65	Phase 1/2

T94977	TARGETID	T94977
T94977	FORMERID	TTDNR00652
T94977	UNIPROID	CTF1_HUMAN
T94977	TARGNAME	Cardiotrophin-1 (CTF1)
T94977	GENENAME	CTF1
T94977	TARGTYPE	Clinical trial
T94977	SYNONYMS	CTF1; CT-1
T94977	FUNCTION	Induces cardiac myocyte hypertrophy in vitro. Binds to and activates the ILST/gp130 receptor.
T94977	BIOCLASS	Cytokine: interleukin
T94977	SEQUENCE	MSRREGSLEDPQTDSSVSLLPHLEAKIRQTHSLAHLLTKYAEQLLQEYVQLQGDPFGLPSFSPPRLPVAGLSAPAPSHAGLPVHERLRLDAAALAALPPLLDAVCRRQAELNPRAPRLLRRLEDAARQARALGAAVEALLAALGAANRGPRAEPPAATASAASATGVFPAKVLGLRVCGLYREWLSRTEGDLGQLLPGGSA
T94977	DRUGINFO	D06IEX	Cardiotrophin-1	Phase 1

T55610	TARGETID	T55610
T55610	FORMERID	TTDC00101
T55610	UNIPROID	HIF1A_HUMAN
T55610	TARGNAME	Hypoxia-inducible factor 1 alpha (HIF-1A)
T55610	GENENAME	HIF1A
T55610	TARGTYPE	Clinical trial
T55610	SYNONYMS	bHLHe78; Transcription factor HIF-1; PASD8; PAS domain-containing protein 8; Member of PAS protein 1; MOP1; Hypoxia-inducible transcription factor (HIF)-1; Hypoxia-inducible factor 1-alpha; Hypoxia-inducible factor 1 A; Hypoxia inducible factor 1; HIF1-alpha; HIF1 alpha; HIF-1alpha; HIF-1-alpha; HIF-1 alpha; Class E basic helix-loop-helix protein 78; Basic-helix-loop-helix-PAS protein MOP1; ARNT-interacting protein; ARNT interacting protein
T55610	FUNCTION	Under hypoxic conditions, activates the transcription of over 40 genes, including erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor, HILPDA, and other genes whose protein products increase oxygen delivery or facilitate metabolic adaptation to hypoxia. Plays an essential role in embryonic vascularization, tumor angiogenesis and pathophysiology of ischemic disease. Heterodimerizes with ARNT; heterodimer binds to core DNA sequence 5'-TACGTG-3' within the hypoxia response element (HRE) of target gene promoters. Activation requires recruitment of transcriptional coactivators such as CREBBP and EP300. Activity is enhanced by interaction with both, NCOA1 or NCOA2. Interaction with redox regulatory protein APEX seems to activate CTAD and potentiates activation by NCOA1 and CREBBP. Involved in the axonal distribution and transport of mitochondria in neurons during hypoxia. Functions as a master transcriptional regulator of the adaptive response to hypoxia.
T55610	PDBSTRUC	6GMR; 6GFX; 5LAS; 5LA9; 5L9V
T55610	SEQUENCE	MEGAGGANDKKKISSERRKEKSRDAARSRRSKESEVFYELAHQLPLPHNVSSHLDKASVMRLTISYLRVRKLLDAGDLDIEDDMKAQMNCFYLKALDGFVMVLTDDGDMIYISDNVNKYMGLTQFELTGHSVFDFTHPCDHEEMREMLTHRNGLVKKGKEQNTQRSFFLRMKCTLTSRGRTMNIKSATWKVLHCTGHIHVYDTNSNQPQCGYKKPPMTCLVLICEPIPHPSNIEIPLDSKTFLSRHSLDMKFSYCDERITELMGYEPEELLGRSIYEYYHALDSDHLTKTHHDMFTKGQVTTGQYRMLAKRGGYVWVETQATVIYNTKNSQPQCIVCVNYVVSGIIQHDLIFSLQQTECVLKPVESSDMKMTQLFTKVESEDTSSLFDKLKKEPDALTLLAPAAGDTIISLDFGSNDTETDDQQLEEVPLYNDVMLPSPNEKLQNINLAMSPLPTAETPKPLRSSADPALNQEVALKLEPNPESLELSFTMPQIQDQTPSPSDGSTRQSSPEPNSPSEYCFYVDSDMVNEFKLELVEKLFAEDTEAKNPFSTQDTDLDLEMLAPYIPMDDDFQLRSFDQLSPLESSSASPESASPQSTVTVFQQTQIQEPTANATTTTATTDELKTVTKDRMEDIKILIASPSPTHIHKETTSATSSPYRDTQSRTASPNRAGKGVIEQTEKSHPRSPNVLSVALSQRTTVPEEELNPKILALQNAQRKRKMEHDGSLFQAVGIGTLLQQPDDHAATTSLSWKRVKGCKSSEQNGMEQKTIILIPSDLACRLLGQSMDESGLPQLTSYDCEVNAPIQGSRNLLQGEELLRALDQVN
T55610	DRUGINFO	D0B0AX	HIF-1alpha	Phase 4
T55610	DRUGINFO	D06PEW	IT-101	Phase 3
T55610	DRUGINFO	D06NYA	2-Methoxyestradiol	Phase 2
T55610	DRUGINFO	D06ZVO	PX-478	Phase 1
T55610	DRUGINFO	D0NF5J	EZN-2968	Phase 1
T55610	DRUGINFO	D0Y5QD	ENMD-1198	Phase 1
T55610	DRUGINFO	D0Q2SE	Pyrrolidine carboxamide derivative 1	Patented

T23787	TARGETID	T23787
T23787	FORMERID	TTDI02065
T23787	UNIPROID	F263_HUMAN
T23787	TARGNAME	Renal carcinoma antigen NY-REN-56 (PFKFB3)
T23787	GENENAME	PFKFB3
T23787	TARGTYPE	Clinical trial
T23787	SYNONYMS	iPFK2; Renal carcinoma antigen NYREN56; PFKFB3; Fructose2,6bisphosphatase; 6phosphofructo2kinase/fructose2,6bisphosphatase 3; 6PF2K/Fru2,6P2ase brain/placentatype isozyme; 6PF2K/Fru2,6P2ase 3
T23787	FUNCTION	Synthesis and degradation of fructose 2,6-bisphosphate.
T23787	PDBSTRUC	6IC0; 6IBZ; 6IBY; 6IBX; 6HVJ
T23787	BIOCLASS	Kinase
T23787	SEQUENCE	MPLELTQSRVQKIWVPVDHRPSLPRSCGPKLTNSPTVIVMVGLPARGKTYISKKLTRYLNWIGVPTKVFNVGEYRREAVKQYSSYNFFRPDNEEAMKVRKQCALAALRDVKSYLAKEGGQIAVFDATNTTRERRHMILHFAKENDFKAFFIESVCDDPTVVASNIMEVKISSPDYKDCNSAEAMDDFMKRISCYEASYQPLDPDKCDRDLSLIKVIDVGRRFLVNRVQDHIQSRIVYYLMNIHVQPRTIYLCRHGENEHNLQGRIGGDSGLSSRGKKFASALSKFVEEQNLKDLRVWTSQLKSTIQTAEALRLPYEQWKALNEIDAGVCEELTYEEIRDTYPEEYALREQDKYYYRYPTGESYQDLVQRLEPVIMELERQENVLVICHQAVLRCLLAYFLDKSAEEMPYLKCPLHTVLKLTPVAYGCRVESIYLNVESVCTHRERSEDAKKGPNPLMRRNSVTPLASPEPTKKPRINSFEEHVASTSAALPSCLPPEVPTQLPGQNMKGSRSSADSSRKH
T23787	DRUGINFO	D0W0VR	PFK-158	Phase 1
T23787	DRUGINFO	D4RMB0	3PO	Investigative

T23036	TARGETID	T23036
T23036	FORMERID	TTDI02067
T23036	UNIPROID	FABI_STAA8
T23036	TARGNAME	Staphylococcus Enoyl ACP reductase (Stap-coc fabI)
T23036	GENENAME	Stap-coc fabI
T23036	TARGTYPE	Clinical trial
T23036	SYNONYMS	NADPHdependent enoylACP reductase; Enoyl[acylcarrierprotein] reductase [NADPH] FabI
T23036	FUNCTION	Catalyzes the reduction of a carbon-carbon double bond in an enoyl moiety that is covalently linked to an acyl carrier protein (ACP). It has a preference for a long chain (C12) substrate compared to the shorter (C4) acyl group. Involved in the elongation cycle of fatty acid which are used in the lipid metabolism.
T23036	BIOCLASS	Short-chain dehydrogenases reductase
T23036	SEQUENCE	MLNLENKTYVIMGIANKRSIAFGVAKVLDQLGAKLVFTYRKERSRKELEKLLEQLNQPEAHLYQIDVQSDEEVINGFEQIGKDVGNIDGVYHSIAFANMEDLRGRFSETSREGFLLAQDISSYSLTIVAHEAKKLMPEGGSIVATTYLGGEFAVQNYNVMGVAKASLEANVKYLALDLGPDNIRVNAISASPIRTLSAKGVGGFNTILKEIEERAPLKRNVDQVEVGKTAAYLLSDLSSGVTGENIHVDSGFHAIK
T23036	DRUGINFO	D00HYK	AFN-1252	Phase 2
T23036	DRUGINFO	D05PIX	CG-400549	Phase 2
T23036	DRUGINFO	D0D8UM	Afabicin	Phase 2
T23036	DRUGINFO	D00KJO	MUT-056399	Preclinical

T32764	TARGETID	T32764
T32764	UNIPROID	AAK1_HUMAN
T32764	TARGNAME	Adaptor-associated kinase 1 (AAK1)
T32764	GENENAME	AAK1
T32764	TARGTYPE	Clinical trial
T32764	SYNONYMS	Adaptor-associated kinase 1
T32764	FUNCTION	Regulates clathrin-mediated endocytosis by phosphorylating the AP2M1/mu2 subunit of the adaptor protein complex 2 (AP-2) which ensures high affinity binding of AP-2 to cargo membrane proteins during the initial stages of endocytosis. Isoform 1 and isoform 2 display similar levels of kinase activity towards AP2M1. Regulates phosphorylation of other AP-2 subunits as well as AP-2 localization and AP-2-mediated internalization of ligand complexes. Phosphorylates NUMB and regulates its cellular localization, promoting NUMB localization to endosomes. Binds to and stabilizes the activated form of NOTCH1, increases its localization in endosomes and regulates its transcriptional activity.
T32764	PDBSTRUC	5TE0; 5L4Q; 4WSQ
T32764	BIOCLASS	Kinase
T32764	ECNUMBER	EC 2.7.11.1
T32764	SEQUENCE	MKKFFDSRREQGGSGLGSGSSGGGGSTSGLGSGYIGRVFGIGRQQVTVDEVLAEGGFAIVFLVRTSNGMKCALKRMFVNNEHDLQVCKREIQIMRDLSGHKNIVGYIDSSINNVSSGDVWEVLILMDFCRGGQVVNLMNQRLQTGFTENEVLQIFCDTCEAVARLHQCKTPIIHRDLKVENILLHDRGHYVLCDFGSATNKFQNPQTEGVNAVEDEIKKYTTLSYRAPEMVNLYSGKIITTKADIWALGCLLYKLCYFTLPFGESQVAICDGNFTIPDNSRYSQDMHCLIRYMLEPDPDKRPDIYQVSYFSFKLLKKECPIPNVQNSPIPAKLPEPVKASEAAAKKTQPKARLTDPIPTTETSIAPRQRPKAGQTQPNPGILPIQPALTPRKRATVQPPPQAAGSSNQPGLLASVPQPKPQAPPSQPLPQTQAKQPQAPPTPQQTPSTQAQGLPAQAQATPQHQQQLFLKQQQQQQQPPPAQQQPAGTFYQQQQAQTQQFQAVHPATQKPAIAQFPVVSQGGSQQQLMQNFYQQQQQQQQQQQQQQLATALHQQQLMTQQAALQQKPTMAAGQQPQPQPAAAPQPAPAQEPAIQAPVRQQPKVQTTPPPAVQGQKVGSLTPPSSPKTQRAGHRRILSDVTHSAVFGVPASKSTQLLQAAAAEASLNKSKSATTTPSGSPRTSQQNVYNPSEGSTWNPFDDDNFSKLTAEELLNKDFAKLGEGKHPEKLGGSAESLIPGFQSTQGDAFATTSFSAGTAEKRKGGQTVDSGLPLLSVSDPFIPLQVPDAPEKLIEGLKSPDTSLLLPDLLPMTDPFGSTSDAVIEKADVAVESLIPGLEPPVPQRLPSQTESVTSNRTDSLTGEDSLLDCSLLSNPTTDLLEEFAPTAISAPVHKAAEDSNLISGFDVPEGSDKVAEDEFDPIPVLITKNPQGGHSRNSSGSSESSLPNLARSLLLVDQLIDL
T32764	DRUGINFO	D05IQI	LX9211	Phase 1

T91023	TARGETID	T91023
T91023	FORMERID	TTDI02163
T91023	UNIPROID	RSPO1_HUMAN
T91023	TARGNAME	Roof plate-specific spondin-1 (RSPO1)
T91023	GENENAME	RSPO1
T91023	TARGTYPE	Clinical trial
T91023	SYNONYMS	hRspo1; R-spondin-1
T91023	FUNCTION	Upon binding to LGR4-6 (LGR4, LGR5 or LGR6), LGR4-6 associate with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signaling pathway to increase expression of target genes. Also regulates the canonical Wnt/beta-catenin-dependent pathway and non-canonical Wnt signaling by acting as an inhibitor of ZNRF3, an important regulator of the Wnt signaling pathway. Acts as a ligand for frizzled FZD8 and LRP6. May negatively regulate the TGF-beta pathway. Has a essential roles in ovary determination. Regulates Wnt signaling by antagonizing DKK1/KREM1-mediated internalization of LRP6 through an interaction with KREM1. Activator of the canonical Wnt signaling pathway by acting as a ligand for LGR4-6 receptors.
T91023	PDBSTRUC	4QXF; 4LI2; 4KT1; 4KNG; 4CDK
T91023	SEQUENCE	MRLGLCVVALVLSWTHLTISSRGIKGKRQRRISAEGSQACAKGCELCSEVNGCLKCSPKLFILLERNDIRQVGVCLPSCPPGYFDARNPDMNKCIKCKIEHCEACFSHNFCTKCKEGLYLHKGRCYPACPEGSSAANGTMECSSPAQCEMSEWSPWGPCSKKQQLCGFRRGSEERTRRVLHAPVGDHAACSDTKETRRCTVRRVPCPEGQKRRKGGQGRRENANRNLARKESKEAGAGSRRRKGQQQQQQQGTVGPLTSAGPA
T91023	DRUGINFO	D08JVS	NU-206	Phase 1

T56362	TARGETID	T56362
T56362	FORMERID	TTDC00340
T56362	UNIPROID	CTL4_HUMAN
T56362	TARGNAME	Choline transporter-like protein 4 (SLC44A4)
T56362	GENENAME	SLC44A4
T56362	TARGTYPE	Clinical trial
T56362	SYNONYMS	hTPPT1; Thiamine pyrophosphate transporter 1; Solute carrier family 44 member 4; NG22; CTL4; C6orf29
T56362	FUNCTION	Choline transporter that plays a role in the choline-acetylcholine system and is required to the efferent innervation of hair cells in the olivocochlear bundle for the maintenance of physiological function of outer hair cells and the protection of hair cells from acoustic injury (By similarity). Also described as a thiamine pyrophosphate transporter in colon, may mediate the absorption of microbiota-generated thiamine pyrophosphate and contribute to host thiamine (vitamin B1) homeostasis.
T56362	BIOCLASS	Choline transporter-like
T56362	SEQUENCE	MGGKQRDEDDEAYGKPVKYDPSFRGPIKNRSCTDVICCVLFLLFILGYIVVGIVAWLYGDPRQVLYPRNSTGAYCGMGENKDKPYLLYFNIFSCILSSNIISVAENGLQCPTPQVCVSSCPEDPWTVGKNEFSQTVGEVFYTKNRNFCLPGVPWNMTVITSLQQELCPSFLLPSAPALGRCFPWTNVTPPALPGITNDTTIQQGISGLIDSLNARDISVKIFEDFAQSWYWILVALGVALVLSLLFILLLRLVAGPLVLVLILGVLGVLAYGIYYCWEEYRVLRDKGASISQLGFTTNLSAYQSVQETWLAALIVLAVLEAILLLMLIFLRQRIRIAIALLKEASKAVGQMMSTMFYPLVTFVLLLICIAYWAMTALYLATSGQPQYVLWASNISSPGCEKVPINTSCNPTAHLVNSSCPGLMCVFQGYSSKGLIQRSVFNLQIYGVLGLFWTLNWVLALGQCVLAGAFASFYWAFHKPQDIPTFPLISAFIRTLRYHTGSLAFGALILTLVQIARVILEYIDHKLRGVQNPVARCIMCCFKCCLWCLEKFIKFLNRNAYIMIAIYGKNFCVSAKNAFMLLMRNIVRVVVLDKVTDLLLFFGKLLVVGGVGVLSFFFFSGRIPGLGKDFKSPHLNYYWLPIMTSILGAYVIASGFFSVFGMCVDTLFLCFLEDLERNNGSLDRPYYMSKSLLKILGKKNEAPPDNKKRKK
T56362	DRUGINFO	D0BC6M	ASG-5ME	Phase 1

T08123	TARGETID	T08123
T08123	FORMERID	TTDI03347
T08123	UNIPROID	LRRK2_HUMAN
T08123	TARGNAME	Leucine-rich repeat kinase 2 (LRRK2)
T08123	GENENAME	LRRK2
T08123	TARGTYPE	Clinical trial
T08123	SYNONYMS	PARK8; Leucine-rich repeat serine/threonine-protein kinase 2; Dardarin
T08123	FUNCTION	Positively regulates autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway. The process involves activation of nicotinic acid adenine dinucleotide phosphate (NAADP) receptors, increase in lysosomal pH, and calcium release from lysosomes. Together with RAB29, plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner. Regulates neuronal process morphology in the intact central nervous system (CNS). Plays a role in synaptic vesicle trafficking. Phosphorylates PRDX3. Has GTPase activity. May play a role in the phosphorylation of proteins central to Parkinson disease. Plays an important role in recuiting SEC16A to endoplasmic reticulum exit sites (ERES) and in regulating ER to Golgi vesicle-mediated transport and ERES organization.
T08123	PDBSTRUC	6DLP; 6DLO; 5MYC; 5MY9; 3D6T
T08123	BIOCLASS	Kinase
T08123	ECNUMBER	EC 2.7.11.1
T08123	SEQUENCE	MASGSCQGCEEDEETLKKLIVRLNNVQEGKQIETLVQILEDLLVFTYSERASKLFQGKNIHVPLLIVLDSYMRVASVQQVGWSLLCKLIEVCPGTMQSLMGPQDVGNDWEVLGVHQLILKMLTVHNASVNLSVIGLKTLDLLLTSGKITLLILDEESDIFMLIFDAMHSFPANDEVQKLGCKALHVLFERVSEEQLTEFVENKDYMILLSALTNFKDEEEIVLHVLHCLHSLAIPCNNVEVLMSGNVRCYNIVVEAMKAFPMSERIQEVSCCLLHRLTLGNFFNILVLNEVHEFVVKAVQQYPENAALQISALSCLALLTETIFLNQDLEEKNENQENDDEGEEDKLFWLEACYKALTWHRKNKHVQEAACWALNNLLMYQNSLHEKIGDEDGHFPAHREVMLSMLMHSSSKEVFQASANALSTLLEQNVNFRKILLSKGIHLNVLELMQKHIHSPEVAESGCKMLNHLFEGSNTSLDIMAAVVPKILTVMKRHETSLPVQLEALRAILHFIVPGMPEESREDTEFHHKLNMVKKQCFKNDIHKLVLAALNRFIGNPGIQKCGLKVISSIVHFPDALEMLSLEGAMDSVLHTLQMYPDDQEIQCLGLSLIGYLITKKNVFIGTGHLLAKILVSSLYRFKDVAEIQTKGFQTILAILKLSASFSKLLVHHSFDLVIFHQMSSNIMEQKDQQFLNLCCKCFAKVAMDDYLKNVMLERACDQNNSIMVECLLLLGADANQAKEGSSLICQVCEKESSPKLVELLLNSGSREQDVRKALTISIGKGDSQIISLLLRRLALDVANNSICLGGFCIGKVEPSWLGPLFPDKTSNLRKQTNIASTLARMVIRYQMKSAVEEGTASGSDGNFSEDVLSKFDEWTFIPDSSMDSVFAQSDDLDSEGSEGSFLVKKKSNSISVGEFYRDAVLQRCSPNLQRHSNSLGPIFDHEDLLKRKRKILSSDDSLRSSKLQSHMRHSDSISSLASEREYITSLDLSANELRDIDALSQKCCISVHLEHLEKLELHQNALTSFPQQLCETLKSLTHLDLHSNKFTSFPSYLLKMSCIANLDVSRNDIGPSVVLDPTVKCPTLKQFNLSYNQLSFVPENLTDVVEKLEQLILEGNKISGICSPLRLKELKILNLSKNHISSLSENFLEACPKVESFSARMNFLAAMPFLPPSMTILKLSQNKFSCIPEAILNLPHLRSLDMSSNDIQYLPGPAHWKSLNLRELLFSHNQISILDLSEKAYLWSRVEKLHLSHNKLKEIPPEIGCLENLTSLDVSYNLELRSFPNEMGKLSKIWDLPLDELHLNFDFKHIGCKAKDIIRFLQQRLKKAVPYNRMKLMIVGNTGSGKTTLLQQLMKTKKSDLGMQSATVGIDVKDWPIQIRDKRKRDLVLNVWDFAGREEFYSTHPHFMTQRALYLAVYDLSKGQAEVDAMKPWLFNIKARASSSPVILVGTHLDVSDEKQRKACMSKITKELLNKRGFPAIRDYHFVNATEESDALAKLRKTIINESLNFKIRDQLVVGQLIPDCYVELEKIILSERKNVPIEFPVIDRKRLLQLVRENQLQLDENELPHAVHFLNESGVLLHFQDPALQLSDLYFVEPKWLCKIMAQILTVKVEGCPKHPKGIISRRDVEKFLSKKRKFPKNYMSQYFKLLEKFQIALPIGEEYLLVPSSLSDHRPVIELPHCENSEIIIRLYEMPYFPMGFWSRLINRLLEISPYMLSGRERALRPNRMYWRQGIYLNWSPEAYCLVGSEVLDNHPESFLKITVPSCRKGCILLGQVVDHIDSLMEEWFPGLLEIDICGEGETLLKKWALYSFNDGEEHQKILLDDLMKKAEEGDLLVNPDQPRLTIPISQIAPDLILADLPRNIMLNNDELEFEQAPEFLLGDGSFGSVYRAAYEGEEVAVKIFNKHTSLRLLRQELVVLCHLHHPSLISLLAAGIRPRMLVMELASKGSLDRLLQQDKASLTRTLQHRIALHVADGLRYLHSAMIIYRDLKPHNVLLFTLYPNAAIIAKIADYGIAQYCCRMGIKTSEGTPGFRAPEVARGNVIYNQQADVYSFGLLLYDILTTGGRIVEGLKFPNEFDELEIQGKLPDPVKEYGCAPWPMVEKLIKQCLKENPQERPTSAQVFDILNSAELVCLTRRILLPKNVIVECMVATHHNSRNASIWLGCGHTDRGQLSFLDLNTEGYTSEEVADSRILCLALVHLPVEKESWIVSGTQSGTLLVINTEDGKKRHTLEKMTDSVTCLYCNSFSKQSKQKNFLLVGTADGKLAIFEDKTVKLKGAAPLKILNIGNVSTPLMCLSESTNSTERNVMWGGCGTKIFSFSNDFTIQKLIETRTSQLFSYAAFSDSNIITVVVDTALYIAKQNSPVVEVWDKKTEKLCGLIDCVHFLREVMVKENKESKHKMSYSGRVKTLCLQKNTALWIGTGGGHILLLDLSTRRLIRVIYNFCNSVRVMMTAQLGSLKNVMLVLGYNRKNTEGTQKQKEIQSCLTVWDINLPHEVQNLEKHIEVRKELAEKMRRTSVE
T08123	DRUGINFO	D03YBQ	DNL151	Phase 1
T08123	DRUGINFO	D0K6UV	DNL201	Phase 1
T08123	DRUGINFO	D2AO6J	BIIB094	Phase 1
T08123	DRUGINFO	D01EIT	Pyrrolo-pyrimidine derivative 8	Patented
T08123	DRUGINFO	D01PFZ	Pyridopyrimidinone derivative 2	Patented
T08123	DRUGINFO	D01YHY	PMID28117607-Compound-20	Patented
T08123	DRUGINFO	D02YTB	Pyrrolo-pyrimidine derivative 9	Patented
T08123	DRUGINFO	D03GDC	Pyrrolo-pyridine derivative 1	Patented
T08123	DRUGINFO	D03HNU	Hydrazide derivative 5	Patented
T08123	DRUGINFO	D04WND	Pyridopyrimidinone derivative 1	Patented
T08123	DRUGINFO	D06FIH	Azaindazole derivative 1	Patented
T08123	DRUGINFO	D07FFA	PMID28117607-Compound-7	Patented
T08123	DRUGINFO	D07SEG	Oxindole derivative 2	Patented
T08123	DRUGINFO	D08VBG	PMID28117607-Compound-5	Patented
T08123	DRUGINFO	D0C5HR	Pyrrolo-pyrimidine derivative 10	Patented
T08123	DRUGINFO	D0DP6U	Azaindazole derivative 3	Patented
T08123	DRUGINFO	D0GJ4G	Pyrrolo-pyrimidine derivative 1	Patented
T08123	DRUGINFO	D0HY0H	Hydrazide derivative 4	Patented
T08123	DRUGINFO	D0M5BR	PMID28117607-Compound-21	Patented
T08123	DRUGINFO	D0NO4O	Azaindazole derivative 2	Patented
T08123	DRUGINFO	D0O8AP	PMID28117607-Compound-4	Patented
T08123	DRUGINFO	D0PY1G	Hydrazide derivative 3	Patented
T08123	DRUGINFO	D0Q6VL	Pyrrolo-pyridazine derivative 1	Patented
T08123	DRUGINFO	D0S4IB	Pyridopyrimidinone derivative 3	Patented
T08123	DRUGINFO	D0V8XG	PMID28117607-Compound-6	Patented
T08123	DRUGINFO	D0X8LX	Aminopyridine derivative 2	Patented
T08123	DRUGINFO	D0XY1J	Pyrrolo-pyrimidine derivative 11	Patented
T08123	DRUGINFO	D0ZW5B	Azaindazole derivative 4	Patented
T08123	DRUGINFO	D00FKF	Pyrrolo-pyridine derivative 2	Patented
T08123	DRUGINFO	D00GWE	Bidentate ligands of Markush derivative 2	Patented
T08123	DRUGINFO	D08WVK	Oxindole derivative 3	Patented
T08123	DRUGINFO	D0D6DN	Aminopyridine derivative 3	Patented
T08123	DRUGINFO	D0FS9X	Fused thiophene derivative 1	Patented
T08123	DRUGINFO	D0QK7K	Oxindole derivative 4	Patented
T08123	DRUGINFO	D0SV0D	Bidentate ligands of Markush derivative 1	Patented
T08123	DRUGINFO	D01OXV	GNE-9605	Investigative
T08123	DRUGINFO	D01XYD	HMS3229G13	Investigative
T08123	DRUGINFO	D0B6KT	PF-06454589	Investigative
T08123	DRUGINFO	D0WK9R	PF-06447475	Investigative
T08123	DRUGINFO	D0J5FK	GNE-7915	Investigative
T08123	DRUGINFO	D07ADX	URMC-099	Investigative

T00484	TARGETID	T00484
T00484	FORMERID	TTDI02336
T00484	UNIPROID	IL23R_HUMAN
T00484	TARGNAME	Interleukin 23 receptor (IL23R)
T00484	GENENAME	IL23R
T00484	TARGTYPE	Clinical trial
T00484	SYNONYMS	Interleukin-23 receptor; IL23 receptor; IL-23R; IL-23 receptor
T00484	FUNCTION	Binds IL23 and mediates T-cells, NK cells and possibly certain macrophage/myeloid cells stimulation probably through activation of the Jak-Stat signaling cascade. IL23 functions in innate and adaptive immunity and may participate in acute response to infection in peripheral tissues. IL23 may be responsible for autoimmune inflammatory diseases and be important for tumorigenesis. Associates with IL12RB1 to form the interleukin-23 receptor.
T00484	PDBSTRUC	5MZV
T00484	BIOCLASS	Cytokine receptor
T00484	SEQUENCE	MNQVTIQWDAVIALYILFSWCHGGITNINCSGHIWVEPATIFKMGMNISIYCQAAIKNCQPRKLHFYKNGIKERFQITRINKTTARLWYKNFLEPHASMYCTAECPKHFQETLICGKDISSGYPPDIPDEVTCVIYEYSGNMTCTWNAGKLTYIDTKYVVHVKSLETEEEQQYLTSSYINISTDSLQGGKKYLVWVQAANALGMEESKQLQIHLDDIVIPSAAVISRAETINATVPKTIIYWDSQTTIEKVSCEMRYKATTNQTWNVKEFDTNFTYVQQSEFYLEPNIKYVFQVRCQETGKRYWQPWSSLFFHKTPETVPQVTSKAFQHDTWNSGLTVASISTGHLTSDNRGDIGLLLGMIVFAVMLSILSLIGIFNRSFRTGIKRRILLLIPKWLYEDIPNMKNSNVVKMLQENSELMNNNSSEQVLYVDPMITEIKEIFIPEHKPTDYKKENTGPLETRDYPQNSLFDNTTVVYIPDLNTGYKPQISNFLPEGSHLSNNNEITSLTLKPPVDSLDSGNNPRLQKHPNFAFSVSSVNSLSNTIFLGELSLILNQGECSSPDIQNSVEEETTMLLENDSPSETIPEQTLLPDEFVSCLGIVNEELPSINTYFPQNILESHFNRISLLEK
T00484	DRUGINFO	D06ARV	Anti-IL-23	Phase 3
T00484	DRUGINFO	D0G0AQ	ADC-1012	Investigative
T00484	DRUGINFO	D0Y0WW	FM-303	Investigative
T00484	DRUGINFO	D0YZ1J	APG-2305	Investigative

T45612	TARGETID	T45612
T45612	FORMERID	TTDNC00398
T45612	UNIPROID	CD276_HUMAN
T45612	TARGNAME	B7 homolog 3 (CD276)
T45612	GENENAME	CD276
T45612	TARGTYPE	Clinical trial
T45612	SYNONYMS	UNQ309/PRO352; PSEC0249; Costimulatory molecule; CD276 antigen; B7H3; B7-H3; 4IgB7H3; 4Ig-B7-H3
T45612	FUNCTION	May play a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. May be involved in the development of acute and chronic transplant rejection and in the regulation of lymphocytic activity at mucosal surfaces. Could also play a key role in providing the placenta and fetus with a suitable immunological environment throughout pregnancy. Both isoform 1 and isoform 2 appear to be redundant in their ability to modulate CD4 T-cell responses. Isoform 2 is shown to enhance the induction of cytotoxic T-cells and selectively stimulates interferon gamma production in the presence of T-cell receptor signaling. May participate in the regulation of T-cell-mediated immune response.
T45612	BIOCLASS	Immunoglobulin
T45612	SEQUENCE	MLRRRGSPGMGVHVGAALGALWFCLTGALEVQVPEDPVVALVGTDATLCCSFSPEPGFSLAQLNLIWQLTDTKQLVHSFAEGQDQGSAYANRTALFPDLLAQGNASLRLQRVRVADEGSFTCFVSIRDFGSAAVSLQVAAPYSKPSMTLEPNKDLRPGDTVTITCSSYQGYPEAEVFWQDGQGVPLTGNVTTSQMANEQGLFDVHSILRVVLGANGTYSCLVRNPVLQQDAHSSVTITPQRSPTGAVEVQVPEDPVVALVGTDATLRCSFSPEPGFSLAQLNLIWQLTDTKQLVHSFTEGRDQGSAYANRTALFPDLLAQGNASLRLQRVRVADEGSFTCFVSIRDFGSAAVSLQVAAPYSKPSMTLEPNKDLRPGDTVTITCSSYRGYPEAEVFWQDGQGVPLTGNVTTSQMANEQGLFDVHSVLRVVLGANGTYSCLVRNPVLQQDAHGSVTITGQPMTFPPEALWVTVGLSVCLIALLVALAFVCWRKIKQSCEEENAGAEDQDGEGEGSKTALQPLKHSDSKEDDGQEIA
T45612	DRUGINFO	D08BZZ	Omburtamab I-131	Phase 2/3
T45612	DRUGINFO	DKJ93L	131 I-omburtamab	Phase 2/3
T45612	DRUGINFO	DUBW95	Omburtamab	Phase 2/3
T45612	DRUGINFO	D0S1WV	Enoblituzumab	Phase 2
T45612	DRUGINFO	DHN9I5	TAK-280	Phase 2
T45612	DRUGINFO	D0BI3K	Omburtamab I-124	Phase 1/2
T45612	DRUGINFO	DDP74J	MGC018	Phase 1/2
T45612	DRUGINFO	DT8R1L	DS-7300	Phase 1/2
T45612	DRUGINFO	D05FHZ	MGD009	Phase 1
T45612	DRUGINFO	D06UOU	MGA271	Phase 1
T45612	DRUGINFO	D0J7QC	124I-8H9	Phase 1

T45968	TARGETID	T45968
T45968	UNIPROID	RNF43_HUMAN
T45968	TARGNAME	RING finger protein 43 (RNF43)
T45968	GENENAME	RNF43
T45968	TARGTYPE	Clinical trial
T45968	SYNONYMS	RING-type E3 ubiquitin transferase RNF43; E3 ubiquitin-protein ligase RNF43
T45968	FUNCTION	E3 ubiquitin-protein ligase that acts as a negative regulator of the Wnt signaling pathway by mediating the ubiquitination, endocytosis and subsequent degradation of Wnt receptor complex components Frizzled. Acts on both canonical and non-canonical Wnt signaling pathway. Along with RSPO2 and ZNRF3, constitutes a master switch that governs limb specification (By similarity).
T45968	PDBSTRUC	4KNG
T45968	ECNUMBER	EC 2.3.2.27
T45968	SEQUENCE	MSGGHQLQLAALWPWLLMATLQAGFGRTGLVLAAAVESERSAEQKAIIRVIPLKMDPTGKLNLTLEGVFAGVAEITPAEGKLMQSHPLYLCNASDDDNLEPGFISIVKLESPRRAPRPCLSLASKARMAGERGASAVLFDITEDRAAAEQLQQPLGLTWPVVLIWGNDAEKLMEFVYKNQKAHVRIELKEPPAWPDYDVWILMTVVGTIFVIILASVLRIRCRPRHSRPDPLQQRTAWAISQLATRRYQASCRQARGEWPDSGSSCSSAPVCAICLEEFSEGQELRVISCLHEFHRNCVDPWLHQHRTCPLCMFNITEGDSFSQSLGPSRSYQEPGRRLHLIRQHPGHAHYHLPAAYLLGPSRSAVARPPRPGPFLPSQEPGMGPRHHRFPRAAHPRAPGEQQRLAGAQHPYAQGWGLSHLQSTSQHPAACPVPLRRARPPDSSGSGESYCTERSGYLADGPASDSSSGPCHGSSSDSVVNCTDISLQGVHGSSSTFCSSLSSDFDPLVYCSPKGDPQRVDMQPSVTSRPRSLDSVVPTGETQVSSHVHYHRHRHHHYKKRFQWHGRKPGPETGVPQSRPPIPRTQPQPEPPSPDQQVTRSNSAAPSGRLSNPQCPRALPEPAPGPVDASSICPSTSSLFNLQKSSLSARHPQRKRRGGPSEPTPGSRPQDATVHPACQIFPHYTPSVAYPWSPEAHPLICGPPGLDKRLLPETPGPCYSNSQPVWLCLTPRQPLEPHPPGEGPSEWSSDTAEGRPCPYPHCQVLSAQPGSEEELEELCEQAV
T45968	DRUGINFO	D01EXL	RNF43-721	Phase 2

T15855	TARGETID	T15855
T15855	FORMERID	TTDI03156
T15855	UNIPROID	DPP8_HUMAN
T15855	TARGNAME	Dipeptidyl peptidase 8 (DPP-8)
T15855	GENENAME	DPP8
T15855	TARGTYPE	Clinical trial
T15855	SYNONYMS	Prolyl dipeptidase DPP8; MSTP141; MSTP135; MSTP097; Dipeptidyl peptidase VIII; Dipeptidyl peptidase IV-related protein 1; DPRP1; DPRP-1; DPP VIII; DP8
T15855	FUNCTION	Dipeptidyl peptidase that cleaves off N-terminal dipeptides from proteins having a Pro or Ala residue at position 2.
T15855	PDBSTRUC	6EOT; 6EOS; 6EOP; 6EOO
T15855	BIOCLASS	Peptidase
T15855	ECNUMBER	EC 3.4.14.5
T15855	SEQUENCE	MWKRSEQMKIKSGKCNMAAAMETEQLGVEIFETADCEENIESQDRPKLEPFYVERYSWSQLKKLLADTRKYHGYMMAKAPHDFMFVKRNDPDGPHSDRIYYLAMSGENRENTLFYSEIPKTINRAAVLMLSWKPLLDLFQATLDYGMYSREEELLRERKRIGTVGIASYDYHQGSGTFLFQAGSGIYHVKDGGPQGFTQQPLRPNLVETSCPNIRMDPKLCPADPDWIAFIHSNDIWISNIVTREERRLTYVHNELANMEEDARSAGVATFVLQEEFDRYSGYWWCPKAETTPSGGKILRILYEENDESEVEIIHVTSPMLETRRADSFRYPKTGTANPKVTFKMSEIMIDAEGRIIDVIDKELIQPFEILFEGVEYIARAGWTPEGKYAWSILLDRSQTRLQIVLISPELFIPVEDDVMERQRLIESVPDSVTPLIIYEETTDIWINIHDIFHVFPQSHEEEIEFIFASECKTGFRHLYKITSILKESKYKRSSGGLPAPSDFKCPIKEEIAITSGEWEVLGRHGSNIQVDEVRRLVYFEGTKDSPLEHHLYVVSYVNPGEVTRLTDRGYSHSCCISQHCDFFISKYSNQKNPHCVSLYKLSSPEDDPTCKTKEFWATILDSAGPLPDYTPPEIFSFESTTGFTLYGMLYKPHDLQPGKKYPTVLFIYGGPQVQLVNNRFKGVKYFRLNTLASLGYVVVVIDNRGSCHRGLKFEGAFKYKMGQIEIDDQVEGLQYLASRYDFIDLDRVGIHGWSYGGYLSLMALMQRSDIFRVAIAGAPVTLWIFYDTGYTERYMGHPDQNEQGYYLGSVAMQAEKFPSEPNRLLLLHGFLDENVHFAHTSILLSFLVRAGKPYDLQIYPQERHSIRVPESGEHYELHLLHYLQENLGSRIAALKVI
T15855	DRUGINFO	D0FQ2U	Talabostat	Phase 3
T15855	DRUGINFO	D1PBC7	BXCL701	Phase 1/2
T15855	DRUGINFO	D06HJX	Thiomorpholine derivative 1	Patented
T15855	DRUGINFO	D0D4BP	Thiomorpholine derivative 2	Patented
T15855	DRUGINFO	D02RDY	PMID15664838C18	Investigative
T15855	DRUGINFO	D0CP1J	1G244	Investigative
T15855	DRUGINFO	D08NMS	PMID20684603C24dd	Investigative

T66252	TARGETID	T66252
T66252	FORMERID	TTDI03157
T66252	UNIPROID	DPP9_HUMAN
T66252	TARGNAME	Dipeptidyl peptidase 9 (DPP-9)
T66252	GENENAME	DPP9
T66252	TARGTYPE	Clinical trial
T66252	SYNONYMS	Dipeptidyl peptidase-like protein 9; Dipeptidyl peptidase IX; Dipeptidyl peptidase IV-related protein 2; DPRP2; DPRP-2; DPP IX; DPLP9; DP9
T66252	FUNCTION	Dipeptidyl peptidase that cleaves off N-terminal dipeptides from proteins having a Pro or Ala residue at position 2.
T66252	PDBSTRUC	6EOR; 6EOQ
T66252	BIOCLASS	Peptidase
T66252	ECNUMBER	EC 3.4.14.5
T66252	SEQUENCE	MATTGTPTADRGDAAATDDPAARFQVQKHSWDGLRSIIHGSRKYSGLIVNKAPHDFQFVQKTDESGPHSHRLYYLGMPYGSRENSLLYSEIPKKVRKEALLLLSWKQMLDHFQATPHHGVYSREEELLRERKRLGVFGITSYDFHSESGLFLFQASNSLFHCRDGGKNGFMVSPMKPLEIKTQCSGPRMDPKICPADPAFFSFINNSDLWVANIETGEERRLTFCHQGLSNVLDDPKSAGVATFVIQEEFDRFTGYWWCPTASWEGSEGLKTLRILYEEVDESEVEVIHVPSPALEERKTDSYRYPRTGSKNPKIALKLAEFQTDSQGKIVSTQEKELVQPFSSLFPKVEYIARAGWTRDGKYAWAMFLDRPQQWLQLVLLPPALFIPSTENEEQRLASARAVPRNVQPYVVYEEVTNVWINVHDIFYPFPQSEGEDELCFLRANECKTGFCHLYKVTAVLKSQGYDWSEPFSPGEDEFKCPIKEEIALTSGEWEVLARHGSKIWVNEETKLVYFQGTKDTPLEHHLYVVSYEAAGEIVRLTTPGFSHSCSMSQNFDMFVSHYSSVSTPPCVHVYKLSGPDDDPLHKQPRFWASMMEAASCPPDYVPPEIFHFHTRSDVRLYGMIYKPHALQPGKKHPTVLFVYGGPQVQLVNNSFKGIKYLRLNTLASLGYAVVVIDGRGSCQRGLRFEGALKNQMGQVEIEDQVEGLQFVAEKYGFIDLSRVAIHGWSYGGFLSLMGLIHKPQVFKVAIAGAPVTVWMAYDTGYTERYMDVPENNQHGYEAGSVALHVEKLPNEPNRLLILHGFLDENVHFFHTNFLVSQLIRAGKPYQLQIYPNERHSIRCPESGEHYEVTLLHFLQEYL
T66252	DRUGINFO	D0FQ2U	Talabostat	Phase 3
T66252	DRUGINFO	D1PBC7	BXCL701	Phase 1/2
T66252	DRUGINFO	D06HJX	Thiomorpholine derivative 1	Patented
T66252	DRUGINFO	D0D4BP	Thiomorpholine derivative 2	Patented
T66252	DRUGINFO	D0CP1J	1G244	Investigative
T66252	DRUGINFO	D08NMS	PMID20684603C24dd	Investigative

T67063	TARGETID	T67063
T67063	FORMERID	TTDI01980
T67063	UNIPROID	KCMB4_HUMAN
T67063	TARGNAME	Charybdotoxin receptor beta-4 (BKbeta4)
T67063	GENENAME	KCNMB4
T67063	TARGTYPE	Clinical trial
T67063	SYNONYMS	KCNMB4; Calcium activated potassium KCNMA1 (maxiK) channel
T67063	FUNCTION	Regulatory subunit of the calcium activated potassium KCNMA1 (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel diversity. Increases the apparent Ca(2+)/voltage sensitivity of the KCNMA1 channel. It also modifies KCNMA1 channel kinetics and alters its pharmacological properties. It slows down the activation and the deactivation kinetics of the channel. Acts as a negative regulator of smooth muscle contraction by enhancing the calcium sensitivity to KCNMA1. Its presence is also a requirement for internal binding of the KCNMA1 channel opener dehydrosoyasaponin I (DHS-1) triterpene glycoside and for external binding of the agonist hormone 17-beta-estradiol (E2). Increases the binding activity of charybdotoxin (CTX) toxin to KCNMA1 peptide blocker by increasing the CTX association rate and decreasing the dissociation rate.
T67063	PDBSTRUC	5Y7L
T67063	SEQUENCE	MAKLRVAYEYTEAEDKSIRLGLFLIISGVVSLFIFGFCWLSPALQDLQATEANCTVLSVQQIGEVFECTFTCGADCRGTSQYPCVQVYVNNSESNSRALLHSDEHQLLTNPKCSYIPPCKRENQKNLESVMNWQQYWKDEIGSQPFTCYFNQHQRPDDVLLHRTHDEIVLLHCFLWPLVTFVVGVLIVVLTICAKSLAVKAEAMKKRKFS
T67063	DRUGINFO	D08PMW	BMS-223131	Phase 2
T67063	DRUGINFO	D09BVL	NS-1619	Terminated
T67063	DRUGINFO	D0D1GV	CNS-1237	Terminated
T67063	DRUGINFO	D0YS9J	slotoxin	Investigative
T67063	DRUGINFO	D0V4WT	paxilline	Investigative
T67063	DRUGINFO	D0O2TC	iberiotoxin	Investigative
T67063	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T99338	TARGETID	T99338
T99338	UNIPROID	STING_HUMAN
T99338	TARGNAME	Stimulator of interferon genes protein (TMEM173)
T99338	GENENAME	TMEM173
T99338	TARGTYPE	Clinical trial
T99338	SYNONYMS	Mediator of IRF3 activation; Endoplasmic reticulum interferon stimulator; ERIS
T99338	FUNCTION	Facilitator of innate immune signaling that acts as a sensor of cytosolic DNA from bacteria and viruses and promotes the production of type I interferon (IFN-alpha and IFN-beta). Innate immune response is triggered in response to non-CpG double-stranded DNA from viruses and bacteria delivered to the cytoplasm. Acts by recognizing and binding cyclic di-GMP (c-di-GMP), a second messenger produced by bacteria, and cyclic GMP-AMP (cGAMP), a messenger produced in response to DNA virus in the cytosol: upon binding of c-di-GMP or cGAMP, autoinhibition is alleviated and TMEM173/STING is able to activate both NF-kappa-B and IRF3 transcription pathways to induce expression of type I interferon and exert a potent anti-viral state. May be involved in translocon function, the translocon possibly being able to influence the induction of type I interferons. May be involved in transduction of apoptotic signals via its association with the major histocompatibility complex class II (MHC-II). Mediates death signaling via activation of the extracellular signal-regulated kinase (ERK) pathway. Essential for the induction of IFN-beta in response to human herpes simplex virus 1 (HHV-1) infection. Exhibits 2',3' phosphodiester linkage-specific ligand recognition. Can bind both 2'-3' linked cGAMP and 3'-3' linked cGAMP but is preferentially activated by 2'-3' linked cGAMP (PubMed:26300263).
T99338	PDBSTRUC	6O8C; 6O8B; 6NT5; 6MXE; 6MX3
T99338	BIOCLASS	TMEM173 family
T99338	SEQUENCE	MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELRHIHSRYRGSYWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKGNFNVAHGLAWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDHAGIKDRVYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPESQNNCRLIAYQEPADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFS
T99338	DRUGINFO	D0N6VS	ADU-S100	Phase 2
T99338	DRUGINFO	DCIX20	ADU- S100	Phase 2
T99338	DRUGINFO	DQ4OU8	MK-1454	Phase 2
T99338	DRUGINFO	DC37YW	IMSA101	Phase 1/2
T99338	DRUGINFO	D2KOX5	BMS-986301	Phase 1
T99338	DRUGINFO	D4JU8H	MK-2118	Phase 1
T99338	DRUGINFO	D7AT3H	XMT-2056	Phase 1
T99338	DRUGINFO	D9ICV2	TAK-500	Phase 1
T99338	DRUGINFO	DA79HM	SB 11285	Phase 1
T99338	DRUGINFO	DO7D1L	E7766	Phase 1
T99338	DRUGINFO	DQ6J0W	GSK3745417	Phase 1
T99338	DRUGINFO	DTV17S	A296	Phase 1
T99338	DRUGINFO	DTYQ45	TAK-676	Phase 1
T99338	DRUGINFO	DUA7N4	SNX281	Phase 1
T99338	DRUGINFO	DUR0F6	SYNB1891	Phase 1
T99338	DRUGINFO	D7CI5F	C-178	Investigative
T99338	DRUGINFO	DP2F6W	C-176	Investigative

T50823	TARGETID	T50823
T50823	FORMERID	TTDI02171
T50823	UNIPROID	SEM4D_HUMAN
T50823	TARGNAME	Semaphorin-4D (SEMA4D)
T50823	GENENAME	SEMA4D
T50823	TARGTYPE	Clinical trial
T50823	SYNONYMS	SEMAJ; GR3; CD100; C9orf164; BB18; A8
T50823	FUNCTION	Regulates GABAergic synapse development. Promotes the development of inhibitory synapses in a PLXNB1-dependent manner. Modulates the complexity and arborization of developing neurites in hippocampal neurons by activating PLXNB1 and interaction with PLXNB1 mediates activation of RHOA. Promotes the migration of cerebellar granule cells. Plays a role in the immune system; induces B-cells to aggregate and improves their viability (in vitro). Induces endothelial cell migration through the activation of PTK2B/PYK2, SRC, and the phosphatidylinositol 3-kinase-AKT pathway. Cell surface receptor for PLXNB1 and PLXNB2 that plays an important role in cell-cell signaling.
T50823	PDBSTRUC	3OL2; 1OLZ
T50823	SEQUENCE	MRMCTPIRGLLMALAVMFGTAMAFAPIPRITWEHREVHLVQFHEPDIYNYSALLLSEDKDTLYIGAREAVFAVNALNISEKQHEVYWKVSEDKKAKCAEKGKSKQTECLNYIRVLQPLSATSLYVCGTNAFQPACDHLNLTSFKFLGKNEDGKGRCPFDPAHSYTSVMVDGELYSGTSYNFLGSEPIISRNSSHSPLRTEYAIPWLNEPSFVFADVIRKSPDSPDGEDDRVYFFFTEVSVEYEFVFRVLIPRIARVCKGDQGGLRTLQKKWTSFLKARLICSRPDSGLVFNVLRDVFVLRSPGLKVPVFYALFTPQLNNVGLSAVCAYNLSTAEEVFSHGKYMQSTTVEQSHTKWVRYNGPVPKPRPGACIDSEARAANYTSSLNLPDKTLQFVKDHPLMDDSVTPIDNRPRLIKKDVNYTQIVVDRTQALDGTVYDVMFVSTDRGALHKAISLEHAVHIIEETQLFQDFEPVQTLLLSSKKGNRFVYAGSNSGVVQAPLAFCGKHGTCEDCVLARDPYCAWSPPTATCVALHQTESPSRGLIQEMSGDASVCPDKSKGSYRQHFFKHGGTAELKCSQKSNLARVFWKFQNGVLKAESPKYGLMGRKNLLIFNLSEGDSGVYQCLSEERVKNKTVFQVVAKHVLEVKVVPKPVVAPTLSVVQTEGSRIATKVLVASTQGSSPPTPAVQATSSGAITLPPKPAPTGTSCEPKIVINTVPQLHSEKTMYLKSSDNRLLMSLFLFFFVLFLCLFFYNCYKGYLPRQCLKFRSALLIGKKKPKSDFCDREQSLKETLVEPGSFSQQNGEHPKPALDTGYETEQDTITSKVPTDREDSQRIDDLSARDKPFDVKCELKFADSDADGD
T50823	DRUGINFO	D0N1SH	VX-15	Phase 2
T50823	DRUGINFO	DG1ED2	Pepinemab	Phase 1/2

T61317	TARGETID	T61317
T61317	FORMERID	TTDR00657
T61317	UNIPROID	Q965D6_PLAFA
T61317	TARGNAME	Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG)
T61317	GENENAME	Malaria fabG
T61317	TARGTYPE	Clinical trial
T61317	SYNONYMS	3-oxoacyl-acyl-carrier protein reductase
T61317	FUNCTION	Participates in fatty acid biosynthesis and polyunsaturated fatty acid biosynthesis. Catalyzes the NADPH-dependent reduction of beta-ketoacyl-ACP substrates to beta-hydroxyacyl-ACP products, the first reductive step in the elongation cycle of fatty acid biosynthesis.
T61317	BIOCLASS	Short-chain dehydrogenases reductase
T61317	ECNUMBER	EC 1.1.1.100
T61317	SEQUENCE	MSVLHRFYLFFLFTKFFHCYKISYVLKNAKLAPNHAIKNINSLNLLSENKKENYYYCGENKVALVTGAGRGIGREIAKMLAKSVSHVICISRTQKSCDSVVDEIKSFGYESSGYAGDVSKKEEISEVINKILTEHKNVDILVSNAGITRDNLFLRMKNDEWEDVLRTNLNSLFYITQPISKRMINNRYGRIINISSIVGLTGNVGQANYSSSKAGVIGFTKSLAKELASRNITVNAIAPGFISSDMTDKISEQIKKNIISNIPAGRMGTPEEVANLACFLSSDKSGYINGRVFVIDGGLSP
T61317	DRUGINFO	D0U2BH	Epigallocatechin gallate	Phase 3
T61317	DRUGINFO	D03DWG	NADPH	Investigative
T61317	DRUGINFO	D07YDN	ISORHAMNETIN	Investigative
T61317	DRUGINFO	D05HRK	2-Hexadecynoic acid	Investigative
T61317	DRUGINFO	D07KXK	GALLOCATECHIN GALLATE	Investigative
T61317	DRUGINFO	D01UYI	Chrysin	Investigative
T61317	DRUGINFO	D0MF5Y	3,7,3',4'-TETRAHYDROXYFLAVONE	Investigative
T61317	DRUGINFO	D0RB1V	(-)-CATECHINGALLATE	Investigative
T61317	DRUGINFO	D0NJ4H	MORIN	Investigative
T61317	DRUGINFO	D0G3TK	KAEMPFEROL	Investigative

T99313	TARGETID	T99313
T99313	UNIPROID	RGMA_HUMAN
T99313	TARGNAME	Repulsive guidance molecule A (RGMA)
T99313	GENENAME	RGMA
T99313	TARGTYPE	Clinical trial
T99313	SYNONYMS	RGM domain family member A
T99313	FUNCTION	Member of the repulsive guidance molecule (RGM) family that performs several functions in the developing and adult nervous system. Regulates cephalic neural tube closure, inhibits neurite outgrowth and cortical neuron branching, and the formation of mature synapses. Binding to its receptor NEO1/neogenin induces activation of RHOA-ROCK1/Rho-kinase signaling pathway through UNC5B-ARHGEF12/LARG-PTK2/FAK1 cascade, leading to collapse of the neuronal growth cone and neurite outgrowth inhibition. Furthermore, RGMA binding to NEO1/neogenin leads to HRAS inactivation by influencing HRAS-PTK2/FAK1-AKT1 pathway. It also functions as a bone morphogenetic protein (BMP) coreceptor that may signal through SMAD1, SMAD5, and SMAD8.
T99313	PDBSTRUC	4UHY
T99313	BIOCLASS	Repulsive guidance molecule (RGM) family
T99313	SEQUENCE	MQPPRERLVVTGRAGWMGMGRGAGRSALGFWPTLAFLLCSFPAATSPCKILKCNSEFWSATSGSHAPASDDTPEFCAALRSYALCTRRTARTCRGDLAYHSAVHGIEDLMSQHNCSKDGPTSQPRLRTLPPAGDSQERSDSPEICHYEKSFHKHSATPNYTHCGLFGDPHLRTFTDRFQTCKVQGAWPLIDNNYLNVQVTNTPVLPGSAATATSKLTIIFKNFQECVDQKVYQAEMDELPAAFVDGSKNGGDKHGANSLKITEKVSGQHVEIQAKYIGTTIVVRQVGRYLTFAVRMPEEVVNAVEDWDSQGLYLCLRGCPLNQQIDFQAFHTNAEGTGARRLAAASPAPTAPETFPYETAVAKCKEKLPVEDLYYQACVFDLLTTGDVNFTLAAYYALEDVKMLHSNKDKLHLYDRTRDLPGRAAAGLPLAPRPLLGALVPLLALLPVFC
T99313	DRUGINFO	D0DV8Z	Elezanumab	Phase 2

T30790	TARGETID	T30790
T30790	FORMERID	TTDC00342
T30790	UNIPROID	CRCM1_HUMAN
T30790	TARGNAME	Calcium-release activated calcium channel (CRACM)
T30790	GENENAME	ORAI1
T30790	TARGTYPE	Clinical trial
T30790	SYNONYMS	Transmembrane protein 142A; TMEM142A; Protein orai-1; Calcium release-activated calcium channel protein 1; CRACM1
T30790	FUNCTION	CRAC channels are the main pathway for Ca(2+) influx in T-cells and promote the immune response to pathogens by activating the transcription factor NFAT. Ca(2+) release-activated Ca(2+) (CRAC) channel subunit which mediates Ca(2+) influx following depletion of intracellular Ca(2+) stores and channel activation by the Ca(2+) sensor, STIM1.
T30790	PDBSTRUC	4EHQ; 2MAK
T30790	SEQUENCE	MHPEPAPPPSRSSPELPPSGGSTTSGSRRSRRRSGDGEPPGAPPPPPSAVTYPDWIGQSYSEVMSLNEHSMQALSWRKLYLSRAKLKASSRTSALLSGFAMVAMVEVQLDADHDYPPGLLIAFSACTTVLVAVHLFALMISTCILPNIEAVSNVHNLNSVKESPHERMHRHIELAWAFSTVIGTLLFLAEVVLLCWVKFLPLKKQPGQPRPTSKPPASGAAANVSTSGITPGQAAAIASTTIMVPFGLIFIVFAVHFYRSLVSHKTDRQFQELNELAEFARLQDQLDHRGDHPLTPGSHYA
T30790	DRUGINFO	D09MJJ	RP4010	Phase 1

T83687	TARGETID	T83687
T83687	FORMERID	TTDR00936
T83687	UNIPROID	TR13C_HUMAN
T83687	TARGNAME	B-cell-activating factor receptor (TNFRSF13C)
T83687	GENENAME	TNFRSF13C
T83687	TARGTYPE	Clinical trial
T83687	SYNONYMS	Tumor necrosis factor receptor superfamily member 13C; CD268; BR3; BLyS receptor 3; BAFFR; BAFF-R; BAFF receptor; B cell-activating factor receptor
T83687	FUNCTION	Promotes the survival of mature B-cells and the B-cell response. B-cell receptor specific for TNFSF13B/TALL1/BAFF/BLyS.
T83687	PDBSTRUC	4V46; 3V56; 2HFG; 1OSX; 1OQE
T83687	BIOCLASS	Cytokine receptor
T83687	SEQUENCE	MRRGPRSLRGRDAPAPTPCVPAECFDLLVRHCVACGLLRTPRPKPAGASSPAPRTALQPQESVGAGAGEAALPLPGLLFGAPALLGLALVLALVLVGLVSWRRRQRRLRGASSAEAPDGDKDAPEPLDKVIILSPGISDATAPAWPPPGEDPGTTPPGHSVPVPATELGSTELVTTKTAGPEQQ
T83687	DRUGINFO	D09SQM	VAY736	Phase 2

T60330	TARGETID	T60330
T60330	FORMERID	TTDR01261
T60330	UNIPROID	P2RX4_HUMAN
T60330	TARGNAME	P2X purinoceptor 4 (P2RX4)
T60330	GENENAME	P2RX4
T60330	TARGTYPE	Clinical trial
T60330	SYNONYMS	P2X4; P2RX4
T60330	FUNCTION	Receptor for ATP that acts as a ligand gated ion channel. This receptor is insensitive to the antagonists PPADS and suramin.
T60330	BIOCLASS	ATP-gated P2X receptor cation channel
T60330	SEQUENCE	MAGCCAALAAFLFEYDTPRIVLIRSRKVGLMNRAVQLLILAYVIGWVFVWEKGYQETDSVVSSVTTKVKGVAVTNTSKLGFRIWDVADYVIPAQEENSLFVMTNVILTMNQTQGLCPEIPDATTVCKSDASCTAGSAGTHSNGVSTGRCVAFNGSVKTCEVAAWCPVEDDTHVPQPAFLKAAENFTLLVKNNIWYPKFNFSKRNILPNITTTYLKSCIYDAKTDPFCPIFRLGKIVENAGHSFQDMAVEGGIMGIQVNWDCNLDRAASLCLPRYSFRRLDTRDVEHNVSPGYNFRFAKYYRDLAGNEQRTLIKAYGIRFDIIVFGKAGKFDIIPTMINIGSGLALLGMATVLCDIIVLYCMKKRLYYREKKYKYVEDYEQGLASELDQ
T60330	DRUGINFO	D0U0KJ	MRS-2160	Investigative

T01283	TARGETID	T01283
T01283	FORMERID	TTDI02200
T01283	UNIPROID	TS101_HUMAN
T01283	TARGNAME	Tumor susceptibility gene protein 101 (TSG101)
T01283	GENENAME	TSG101
T01283	TARGTYPE	Clinical trial
T01283	SYNONYMS	Tumor susceptibility gene 101 protein; ESCRT-I complex subunit TSG101
T01283	FUNCTION	Binds to ubiquitinated cargo proteins and is required for the sorting of endocytic ubiquitinated cargos into multivesicular bodies (MVBs). Mediates the association between the ESCRT-0 and ESCRT-I complex. Required for completion of cytokinesis; the function requires CEP55. May be involved in cell growth and differentiation. Acts as a negative growth regulator. Involved in the budding of many viruses through an interaction with viral proteins that contain a late-budding motif P-[ST]-A-P. This interaction is essential for viral particle budding of numerous retroviruses. Required for the exosomal release of SDCBP, CD63 and syndecan. It may also play a role in the extracellular release of microvesicles that differ from the exosomes. Component of the ESCRT-I complex, a regulator of vesicular trafficking process.
T01283	PDBSTRUC	5VKG; 4ZNY; 4YC1; 4EJE; 3P9H
T01283	BIOCLASS	Ubiquitin-conjugating enzyme
T01283	SEQUENCE	MAVSESQLKKMVSKYKYRDLTVRETVNVITLYKDLKPVLDSYVFNDGSSRELMNLTGTIPVPYRGNTYNIPICLWLLDTYPYNPPICFVKPTSSMTIKTGKHVDANGKIYLPYLHEWKHPQSDLLGLIQVMIVVFGDEPPVFSRPISASYPPYQATGPPNTSYMPGMPGGISPYPSGYPPNPSGYPGCPYPPGGPYPATTSSQYPSQPPVTTVGPSRDGTISEDTIRASLISAVSDKLRWRMKEEMDRAQAELNALKRTEEDLKKGHQKLEEMVTRLDQEVAEVDKNIELLKKKDEELSSALEKMENQSENNDIDEVIIPTAPLYKQILNLYAEENAIEDTIFYLGEALRRGVIDLDVFLKHVRLLSRKQFQLRALMQKARKTAGLSDLY
T01283	DRUGINFO	D03RCB	FGI-101-1A6	Phase 1

T27198	TARGETID	T27198
T27198	FORMERID	TTDR01063
T27198	UNIPROID	SYM_STRP1
T27198	TARGNAME	Streptococcus Methionyl-tRNA synthetase (Stre-coc metG)
T27198	GENENAME	Stre-coc metG
T27198	TARGTYPE	Clinical trial
T27198	SYNONYMS	metG; Methionyl-transferribonucleic acid synthetase; Methionyl-transferribonucleate synthetase; Methionyl-transferRNA synthetase; Methionyl t-RNA synthetase; Methionine-tRNA ligase; Methionine--tRNA ligase; Methionine translase; MetRS; MRS
T27198	FUNCTION	Is required not only for elongation of protein synthesis but also for the initiation of all mRNA translation through initiator tRNA(fMet) aminoacylation.
T27198	BIOCLASS	Carbon-oxygen ligase
T27198	ECNUMBER	EC 6.1.1.10
T27198	SEQUENCE	MKKPFYITTPIYYPSGKLHIGSAYTTIACDVLARYKRLMGHEVFYLTGLDEHGQKIQTKAKEAGITPQTYVDNMAKDVKALWQLLDISYDTFIRTTDDYHEEVVAAVFEKLLAQDDIYLGEYSGWYSVSDEEFFTESQLKEVFRDEDGQVIGGIAPSGHEVEWVSEESYFLRLSKYDDRLVAFFKERPDFIQPDGRMNEMVKNFIEPGLEDLAVSRTTFTWGVPVPSDPKHVVYVWIDALLNYATALGYRQANHANFDKFWNGTVFHMVGKDILRFHSIYWPILLMMLDLPMPDRLIAHGWFVMKDGKMSKSKGNVVYPEMLVERFGLDPLRYYLMRSLPVGSDGTFTPEDYVGRINYELANDLGNLLNRTVAMINKYFDGTVPAYVDNGTAFDADLSQLIDAQLADYHKHMEAVDYPRALEAVWTIIARTNKYIDETAPWVLAKEDGDKAQLASVMAHLAASLRLVAHVIQPFMMETSAAIMAQLGLEPVSDLSTLALADFPANTKVVAKGTPIFPRLDMEAEIDYIKAQMGDSSAISQEKEWVPEEVALKSEKDVITFETFDAVEIRVAEVKEVSKVEGSEKLLRFRVDAGDGQDRQILSGIAKFYPNEQELVGKKLQIVANLKPRKMMKKYISQGMILSAEHGDQLTVLTVDSSVPNGSIIG
T27198	DRUGINFO	D01GXL	REP8839	Phase 1
T27198	DRUGINFO	D07YXL	Difluoromethionine	Investigative
T27198	DRUGINFO	D0V2YR	5'-O-[(L-Methionyl)-Sulphamoyl]Adenosine	Investigative
T27198	DRUGINFO	D0Z2KB	Methionine Phosphonate	Investigative

T21434	TARGETID	T21434
T21434	FORMERID	TTDC00242
T21434	UNIPROID	ACH10_HUMAN
T21434	TARGNAME	Neuronal acetylcholine receptor alpha-10 (CHRNA10)
T21434	GENENAME	CHRNA10
T21434	TARGTYPE	Clinical trial
T21434	SYNONYMS	Nicotinic acetylcholine receptor subunit alpha 10; NACHR alpha 10; CHRNA10
T21434	FUNCTION	Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding may induce an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes thecell membrane. In the ear, this may lead to a reduction in basilar membrane motion, altering the activity of auditory nerve fibers and reducing the range of dynamic hearing. This may protect against acoustic trauma.
T21434	BIOCLASS	Neurotransmitter receptor
T21434	SEQUENCE	MGLRSHHLSLGLLLLFLLPAECLGAEGRLALKLFRDLFANYTSALRPVADTDQTLNVTLEVTLSQIIDMDERNQVLTLYLWIRQEWTDAYLRWDPNAYGGLDAIRIPSSLVWRPDIVLYNKADAQPPGSASTNVVLRHDGAVRWDAPAITRSSCRVDVAAFPFDAQHCGLTFGSWTHGGHQLDVRPRGAAASLADFVENVEWRVLGMPARRRVLTYGCCSEPYPDVTFTLLLRRRAAAYVCNLLLPCVLISLLAPLAFHLPADSGEKVSLGVTVLLALTVFQLLLAESMPPAESVPLIGKYYMATMTMVTFSTALTILIMNLHYCGPSVRPVPAWARALLLGHLARGLCVRERGEPCGQSRPPELSPSPQSPEGGAGPPAGPCHEPRCLCRQEALLHHVATIANTFRSHRAAQRCHEDWKRLARVMDRFFLAIFFSMALVMSLLVLVQAL
T21434	DRUGINFO	D00WPT	ACV-1	Phase 1
T21434	DRUGINFO	D09VJI	[3H]methyllycaconitine	Investigative

T50089	TARGETID	T50089
T50089	FORMERID	TTDI02167
T50089	UNIPROID	S1PR5_HUMAN
T50089	TARGNAME	Sphingosine-1-phosphate receptor 5 (S1PR5)
T50089	GENENAME	S1PR5
T50089	TARGTYPE	Clinical trial
T50089	SYNONYMS	Sphingosine 1-phosphate receptor Edg-8; S1PR5; S1P5; S1P receptor Edg-8; S1P receptor 5; Endothelial differentiation G-protein-coupled receptor 8
T50089	FUNCTION	Receptor for the lysosphingolipid sphingosine 1- phosphate (S1P). S1P is a bioactive lysophospholipid that elicits diverse physiological effect on most types of cells and tissues. Is coupled to both the G(i/0)alpha and G(12) subclass of heteromeric G-proteins. May play a regulatory role in the transformation of radial glial cells into astrocytes and may affect proliferative activity of these cells.
T50089	BIOCLASS	GPCR rhodopsin
T50089	SEQUENCE	MESGLLRPAPVSEVIVLHYNYTGKLRGARYQPGAGLRADAVVCLAVCAFIVLENLAVLLVLGRHPRFHAPMFLLLGSLTLSDLLAGAAYAANILLSGPLTLKLSPALWFAREGGVFVALTASVLSLLAIALERSLTMARRGPAPVSSRGRTLAMAAAAWGVSLLLGLLPALGWNCLGRLDACSTVLPLYAKAYVLFCVLAFVGILAAICALYARIYCQVRANARRLPARPGTAGTTSTRARRKPRSLALLRTLSVVLLAFVACWGPLFLLLLLDVACPARTCPVLLQADPFLGLAMANSLLNPIIYTLTNRDLRHALLRLVCCGRHSCGRDPSGSQQSASAAEASGGLRRCLPPGLDGSFSGSERSSPQRDGLDTSGSTGSPGAPTAARTLVSEPAAD
T50089	DRUGINFO	D0Q0JI	ASP-4058	Phase 1
T50089	DRUGINFO	D06GFH	VPC44116	Investigative
T50089	DRUGINFO	D05KEE	AFD(R)	Investigative
T50089	DRUGINFO	D06DYN	FTY720-phosphate	Investigative
T50089	DRUGINFO	D0W1ZW	VPC03090-P	Investigative
T50089	DRUGINFO	D03BRM	AUY954	Investigative

T86271	TARGETID	T86271
T86271	FORMERID	TTDI03308
T86271	UNIPROID	KCNN2_HUMAN
T86271	TARGNAME	Calcium-activated potassium channel KCa2.2 (KCNN2)
T86271	GENENAME	KCNN2
T86271	TARGTYPE	Clinical trial
T86271	SYNONYMS	Small conductance calcium-activated potassium channel protein 2; SKCa2; SKCa 2; SK2; KCa2.2
T86271	FUNCTION	Forms a voltage-independent potassium channel activated by intracellular calcium. Activation is followed by membrane hyperpolarization. Thought to regulate neuronal excitability by contributing to the slow component of synaptic afterhyperpolarization. The channel is blocked by apamin.
T86271	PDBSTRUC	6ALE; 5WC5; 5WBX; 5V02
T86271	BIOCLASS	Voltage-gated ion channel
T86271	SEQUENCE	MSSCRYNGGVMRPLSNLSASRRNLHEMDSEAQPLQPPASVGGGGGASSPSAAAAAAAAVSSSAPEIVVSKPEHNNSNNLALYGTGGGGSTGGGGGGGGSGHGSSSGTKSSKKKNQNIGYKLGHRRALFEKRKRLSDYALIFGMFGIVVMVIETELSWGAYDKASLYSLALKCLISLSTIILLGLIIVYHAREIQLFMVDNGADDWRIAMTYERIFFICLEILVCAIHPIPGNYTFTWTARLAFSYAPSTTTADVDIILSIPMFLRLYLIARVMLLHSKLFTDASSRSIGALNKINFNTRFVMKTLMTICPGTVLLVFSISLWIIAAWTVRACERYHDQQDVTSNFLGAMWLISITFLSIGYGDMVPNTYCGKGVCLLTGIMGAGCTALVVAVVARKLELTKAEKHVHNFMMDTQLTKRVKNAAANVLRETWLIYKNTKLVKKIDHAKVRKHQRKFLQAIHQLRSVKMEQRKLNDQANTLVDLAKTQNIMYDMISDLNERSEDFEKRIVTLETKLETLIGSIHALPGLISQTIRQQQRDFIEAQMESYDKHVTYNAERSRSSSRRRRSSSTAPPTSSESS
T86271	DRUGINFO	D0I2FI	dequalinium	Clinical trial
T86271	DRUGINFO	D0N0LB	zoxazolamine	Terminated
T86271	DRUGINFO	D00DIF	CyPPA	Investigative
T86271	DRUGINFO	D00WMV	UCL1684	Investigative
T86271	DRUGINFO	D0I6MA	DC-EBIO	Investigative
T86271	DRUGINFO	D0N1HE	UCL1848	Investigative
T86271	DRUGINFO	D0VK9Y	apamin	Investigative
T86271	DRUGINFO	D0T0AG	EBIO	Investigative
T86271	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T19334	TARGETID	T19334
T19334	FORMERID	TTDI02099
T19334	UNIPROID	IL21R_HUMAN
T19334	TARGNAME	Interleukin 21 receptor (IL21R)
T19334	GENENAME	IL21R
T19334	TARGTYPE	Clinical trial
T19334	SYNONYMS	UNQ3121/PRO10273; Novel interleukin receptor; NILR; Interleukin-21 receptor; IL21 receptor; IL-21R; IL-21 receptor; CD360
T19334	FUNCTION	This is a receptor for interleukin-21.
T19334	PDBSTRUC	4NZD; 3TGX
T19334	BIOCLASS	Cytokine receptor
T19334	SEQUENCE	MPRGWAAPLLLLLLQGGWGCPDLVCYTDYLQTVICILEMWNLHPSTLTLTWQDQYEELKDEATSCSLHRSAHNATHATYTCHMDVFHFMADDIFSVNITDQSGNYSQECGSFLLAESIKPAPPFNVTVTFSGQYNISWRSDYEDPAFYMLKGKLQYELQYRNRGDPWAVSPRRKLISVDSRSVSLLPLEFRKDSSYELQVRAGPMPGSSYQGTWSEWSDPVIFQTQSEELKEGWNPHLLLLLLLVIVFIPAFWSLKTHPLWRLWKKIWAVPSPERFFMPLYKGCSGDFKKWVGAPFTGSSLELGPWSPEVPSTLEVYSCHPPRSPAKRLQLTELQEPAELVESDGVPKPSFWPTAQNSGGSAYSEERDRPYGLVSIDTVTVLDAEGPCTWPCSCEDDGYPALDLDAGLEPSPGLEDPLLDAGTTVLSCGCVSAGSPGLGGPLGSLLDRLKPPLADGEDWAGGLPWGGRSPGGVSESEAGSPLAGLDMDTFDSGFVGSDCSSPVECDFTSPGDEGPPRSYLRQWVVIPPPLSSPGPQAS
T19334	DRUGINFO	D07KTA	Ab-01	Phase 2
T19334	DRUGINFO	D0M4MH	ATR-107	Phase 1
T19334	DRUGINFO	DHQ9S3	AMG 256	Phase 1

T60514	TARGETID	T60514
T60514	FORMERID	TTDI02085
T60514	UNIPROID	GPVI_HUMAN
T60514	TARGNAME	Platelet glycoprotein VI (GP6)
T60514	GENENAME	GP6
T60514	TARGTYPE	Clinical trial
T60514	SYNONYMS	Glycoprotein 6; GPVI
T60514	FUNCTION	Collagen receptor involved in collagen-induced platelet adhesion and activation. Plays a key role in platelet procoagulant activity and subsequent thrombin and fibrin formation. This procoagulant function may contribute to arterial and venous thrombus formation. The signaling pathway involves the FcR gamma-chain, the Src kinases (likely FYN or LYN) and SYK, the adapter protein LAT and leads to the activation of PLCG2.
T60514	PDBSTRUC	5OU9; 5OU8; 5OU7; 2GI7
T60514	SEQUENCE	MSPSPTALFCLGLCLGRVPAQSGPLPKPSLQALPSSLVPLEKPVTLRCQGPPGVDLYRLEKLSSSRYQDQAVLFIPAMKRSLAGRYRCSYQNGSLWSLPSDQLELVATGVFAKPSLSAQPGPAVSSGGDVTLQCQTRYGFDQFALYKEGDPAPYKNPERWYRASFPIITVTAAHSGTYRCYSFSSRDPYLWSAPSDPLELVVTGTSVTPSRLPTEPPSPVAEFSEATAELTVSFTNEVFTTETSRSITASPKESDSPAGPARQYYTKGNLVRICLGAVILIILAGFLAEDWHSRRKRLRHRGRAVQRPLPPLPPLPLTRKSNGGQDGGRQDVHSRGLCS
T60514	DRUGINFO	D03BAC	Revacept	Phase 2
T60514	DRUGINFO	DPG5T9	ACT017	Phase 1/2

T29741	TARGETID	T29741
T29741	FORMERID	TTDI02136
T29741	UNIPROID	NOX4_HUMAN
T29741	TARGNAME	NADPH oxidase 4 (NOX4)
T29741	GENENAME	NOX4
T29741	TARGTYPE	Clinical trial
T29741	SYNONYMS	Renal NAD(P)Hoxidase; Renal NAD(P)H-oxidase; RENOX; Kidney superoxideproducing NADPH oxidase; Kidney superoxide-producing NADPH oxidase; Kidney oxidase1; Kidney oxidase-1; KOX1; KOX-1
T29741	FUNCTION	Regulates signaling cascades probably through phosphatases inhibition. May function as an oxygen sensor regulating the KCNK3/TASK-1 potassium channel and HIF1A activity. May regulate insulin signaling cascade. May play a role in apoptosis, bone resorption and lipolysaccharide-mediated activation of NFKB. May produce superoxide in the nucleus and play a role in regulating gene expression upon cell stimulation. Isoform 3 is not functional. Isoform 5 and isoform 6 display reduced activity. Constitutive NADPH oxidase which generates superoxide intracellularly upon formation of a complex with CYBA/p22phox.
T29741	BIOCLASS	NADH/NADPH oxidoreductase
T29741	ECNUMBER	EC 1.6.3.-
T29741	SEQUENCE	MAVSWRSWLANEGVKHLCLFIWLSMNVLLFWKTFLLYNQGPEYHYLHQMLGLGLCLSRASASVLNLNCSLILLPMCRTLLAYLRGSQKVPSRRTRRLLDKSRTFHITCGVTICIFSGVHVAAHLVNALNFSVNYSEDFVELNAARYRDEDPRKLLFTTVPGLTGVCMVVVLFLMITASTYAIRVSNYDIFWYTHNLFFVFYMLLTLHVSGGLLKYQTNLDTHPPGCISLNRTSSQNISLPEYFSEHFHEPFPEGFSKPAEFTQHKFVKICMEEPRFQANFPQTWLWISGPLCLYCAERLYRYIRSNKPVTIISVMSHPSDVMEIRMVKENFKARPGQYITLHCPSVSALENHPFTLTMCPTETKATFGVHLKIVGDWTERFRDLLLPPSSQDSEILPFIQSRNYPKLYIDGPFGSPFEESLNYEVSLCVAGGIGVTPFASILNTLLDDWKPYKLRRLYFIWVCRDIQSFRWFADLLCMLHNKFWQENRPDYVNIQLYLSQTDGIQKIIGEKYHALNSRLFIGRPRWKLLFDEIAKYNRGKTVGVFCCGPNSLSKTLHKLSNQNNSYGTRFEYNKESFS
T29741	DRUGINFO	D04XVU	GKT-137831	Phase 2

T74238	TARGETID	T74238
T74238	FORMERID	TTDI01916
T74238	UNIPROID	CLTR2_HUMAN
T74238	TARGNAME	Leukotriene CysLT2 receptor (CYSLTR2)
T74238	GENENAME	CYSLTR2
T74238	TARGTYPE	Clinical trial
T74238	SYNONYMS	hGPCR21; PSEC0146; HPN321; Gprotein coupled receptor HG57; Gprotein coupled receptor GPCR21; G-protein coupled receptor HG57; G-protein coupled receptor GPCR21; Cysteinyl leukotriene receptor 2; CysLTR2; CYSLT2R; CYSLT2
T74238	FUNCTION	The response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system. Stimulation by BAY u9773, a partial agonist, induces specific contractions of pulmonary veins and might also have an indirect role in the relaxation of the pulmonary vascular endothelium. The rank order of affinities for the leukotrienes is LTC4 = LTD4 >> LTE4. Receptor for cysteinyl leukotrienes.
T74238	BIOCLASS	GPCR rhodopsin
T74238	SEQUENCE	MERKFMSLQPSISVSEMEPNGTFSNNNSRNCTIENFKREFFPIVYLIIFFWGVLGNGLSIYVFLQPYKKSTSVNVFMLNLAISDLLFISTLPFRADYYLRGSNWIFGDLACRIMSYSLYVNMYSSIYFLTVLSVVRFLAMVHPFRLLHVTSIRSAWILCGIIWILIMASSIMLLDSGSEQNGSVTSCLELNLYKIAKLQTMNYIALVVGCLLPFFTLSICYLLIIRVLLKVEVPESGLRVSHRKALTTIIITLIIFFLCFLPYHTLRTVHLTTWKVGLCKDRLHKALVITLALAAANACFNPLLYYFAGENFKDRLKSALRKGHPQKAKTKCVFPVSVWLRKETRV
T74238	DRUGINFO	D0GY0O	BAY-X-7195	Phase 2
T74238	DRUGINFO	D0B6EU	AS-35	Discontinued in Phase 2
T74238	DRUGINFO	D0F4IG	DS-4574	Discontinued in Phase 2
T74238	DRUGINFO	D0G8UG	Sulukast	Discontinued in Phase 2
T74238	DRUGINFO	D09ZVR	MDL-43291	Terminated
T74238	DRUGINFO	D0D0XX	LY-290154	Terminated
T74238	DRUGINFO	D0ZE5V	FPL-55712	Terminated
T74238	DRUGINFO	D0J7UI	ICI-198615	Terminated
T74238	DRUGINFO	D06AYN	HAMI3379	Investigative
T74238	DRUGINFO	D0LK5P	[3H]LTC4	Investigative
T74238	DRUGINFO	D03VGR	N-methyl LTC4	Investigative
T74238	DRUGINFO	D04CZQ	CGP-57698	Investigative
T74238	DRUGINFO	D05CNT	BAYu9773	Investigative
T74238	DRUGINFO	D09JQU	BayCysLT2	Investigative
T74238	DRUGINFO	D0G7OZ	pobilukast	Investigative
T74238	DRUGINFO	D03YBH	LTD4	Investigative
T74238	DRUGINFO	D0EW6H	LTC4	Investigative
T74238	DRUGINFO	D0C0KJ	LTE4	Investigative

T89054	TARGETID	T89054
T89054	FORMERID	TTDR00113
T89054	UNIPROID	PURA_PLAFA
T89054	TARGNAME	Plasmodium Adenylosuccinate synthetase (Malaria Adss)
T89054	GENENAME	Malaria Adss
T89054	TARGTYPE	Clinical trial
T89054	SYNONYMS	IMP--aspartate ligase; Adenylosuccinate synthase; AdSS; AMPSase
T89054	FUNCTION	Plays an important role in the salvage pathway for purine nucleotide biosynthesis. Catalyzes the first committed step in the biosynthesis of AMP from IMP.
T89054	PDBSTRUC	1P9B
T89054	BIOCLASS	Carbon-nitrogen ligase
T89054	ECNUMBER	EC 6.3.4.4
T89054	SEQUENCE	MNIFDHQIKNVDKGNVVAILGAQWGDEGKGKIIDMLSEYSDITCRFNGGANAGHTISVNDKKYALHLLPCGVLYDNNISVLGNGMVIHVKSLMEEIESVGGKLLDRLYLSNKAHILFDIHQIIDSIQETKKLKEGKQIGTTKRGIGPCYSTKASRIGIRLGTLKNFENFKNMYSKLIDHLMDLYNITEYDKEKELNLFYNYHIKLRDRIVDVISFMNTNLENNKKVLIEGANAAMLDIDFGTYPYVTSSCTTVGGVFSGLGIHHKKLNLVVGVVKSYLTRVGCGPFLTELNNDVGQYLREKGHEYGTTTKRPRRCGWLDIPMLLYVKCINSIDMINLTKLDVLSGLEEILLCVNFKNKKTGELLEKGCYPVEEEISEEYEPVYEKFSGWKEDISTCNEFDELPENAKKYILAIEKYLKTPIVWIGVGPNRKNMIVKKNFNLN
T89054	DRUGINFO	D00HWD	(Carboxyhydroxyamino)Ethanoic Acid	Investigative
T89054	DRUGINFO	D03RLJ	(C8-R)-Hydantocidin 5'-Phosphate	Investigative
T89054	DRUGINFO	D0M5WP	(C8-S)-Hydantocidin 5'-Phosphate	Investigative
T89054	DRUGINFO	D0T6XN	6-O-Phosphoryl Inosine Monophosphate	Investigative
T89054	DRUGINFO	D0VW5G	Hydantocidin-5'-Monophosphate	Investigative
T89054	DRUGINFO	D05EHM	6-Cl-IMP	Investigative
T89054	DRUGINFO	D0R4PI	Diphosphate	Investigative
T89054	DRUGINFO	D0H2YT	Inosinic Acid	Investigative
T89054	DRUGINFO	D0C7LS	Guanosine-5'-Diphosphate	Investigative
T89054	DRUGINFO	D0Q5FV	2-Sulfhydryl-Ethanol	Investigative

T40010	TARGETID	T40010
T40010	FORMERID	TTDC00238
T40010	UNIPROID	EGFL7_HUMAN
T40010	TARGNAME	Epidermal growth factor-like protein 7 (EGFL7)
T40010	GENENAME	EGFL7
T40010	TARGTYPE	Clinical trial
T40010	SYNONYMS	ZNEU1; Vascular endothelial statin; VE-statin; UNQ187/PRO1449; NOTCH4-like protein; Multiple epidermal growth factor-like domains protein 7; Multiple epidermal growth factor-like domain protein 7; Multiple EGF-like domains protein 7; Multiple EGF-like domain protein 7; MEGF7; EGF-like protein 7
T40010	FUNCTION	Inhibits platelet-derived growth factor (PDGF)-BB-induced smooth muscle cell migration and promotes endothelial cell adhesion to the extracellular matrix and angiogenesis. Regulates vascular tubulogenesis in vivo.
T40010	BIOCLASS	Growth factor
T40010	SEQUENCE	MRGSQEVLLMWLLVLAVGGTEHAYRPGRRVCAVRAHGDPVSESFVQRVYQPFLTTCDGHRACSTYRTIYRTAYRRSPGLAPARPRYACCPGWKRTSGLPGACGAAICQPPCRNGGSCVQPGRCRCPAGWRGDTCQSDVDECSARRGGCPQRCVNTAGSYWCQCWEGHSLSADGTLCVPKGGPPRVAPNPTGVDSAMKEEVQRLQSRVDLLEEKLQLVLAPLHSLASQALEHGLPDPGSLLVHSFQQLGRIDSLSEQISFLEEQLGSCSCKKDS
T40010	DRUGINFO	D01LES	MEGF0444A	Phase 2
T40010	DRUGINFO	D08QTK	Anti-EGFL7	Phase 1
T40010	DRUGINFO	D01AFG	RG7414	Discontinued in Phase 2

T45287	TARGETID	T45287
T45287	FORMERID	TTDI03026
T45287	UNIPROID	DNPEP_HUMAN
T45287	TARGNAME	Aspartyl aminopeptidase (DNPEP)
T45287	GENENAME	DNPEP
T45287	TARGTYPE	Clinical trial
T45287	SYNONYMS	DAP; ASPEP
T45287	FUNCTION	Likely to play an important role in intracellular protein and peptide metabolism. Aminopeptidase with specificity towards an acidic amino acid at the N-terminus.
T45287	PDBSTRUC	4DYO
T45287	BIOCLASS	Peptidase
T45287	ECNUMBER	EC 3.4.11.21
T45287	SEQUENCE	MSGHSPTRGAMQVAMNGKARKEAVQTAAKELLKFVNRSPSPFHAVAECRNRLLQAGFSELKETEKWNIKPESKYFMTRNSSTIIAFAVGGQYVPGNGFSLIGAHTDSPCLRVKRRSRRSQVGFQQVGVETYGGGIWSTWFDRDLTLAGRVIVKCPTSGRLEQQLVHVERPILRIPHLAIHLQRNINENFGPNTEMHLVPILATAIQEELEKGTPEPGPLNAVDERHHSVLMSLLCAHLGLSPKDIVEMELCLADTQPAVLGGAYDEFIFAPRLDNLHSCFCALQALIDSCAGPGSLATEPHVRMVTLYDNEEVGSESAQGAQSLLTELVLRRISASCQHPTAFEEAIPKSFMISADMAHAVHPNYLDKHEENHRPLFHKGPVIKVNSKQRYASNAVSEALIREVANKVKVPLQDLMVRNDTPCGTTIGPILASRLGLRVLDLGSPQLAMHSIREMACTTGVLQTLTLFKGFFELFPSLSHNLLVD
T45287	DRUGINFO	D0C1JV	QGC-001	Phase 2
T45287	DRUGINFO	D0A7GO	PMID1738140C9	Investigative

T44684	TARGETID	T44684
T44684	FORMERID	TTDI02135
T44684	UNIPROID	NOTC3_HUMAN
T44684	TARGNAME	Notch-3 receptor (NOTCH3)
T44684	GENENAME	NOTCH3
T44684	TARGTYPE	Clinical trial
T44684	SYNONYMS	Notch 3 intracellular domain; Notch 3; Neurogenic locus notch homolog protein 3
T44684	FUNCTION	Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs. Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination.
T44684	PDBSTRUC	5CZX; 5CZV; 4ZLP
T44684	BIOCLASS	Notch protein
T44684	SEQUENCE	MGPGARGRRRRRRPMSPPPPPPPVRALPLLLLLAGPGAAAPPCLDGSPCANGGRCTQLPSREAACLCPPGWVGERCQLEDPCHSGPCAGRGVCQSSVVAGTARFSCRCPRGFRGPDCSLPDPCLSSPCAHGARCSVGPDGRFLCSCPPGYQGRSCRSDVDECRVGEPCRHGGTCLNTPGSFRCQCPAGYTGPLCENPAVPCAPSPCRNGGTCRQSGDLTYDCACLPGFEGQNCEVNVDDCPGHRCLNGGTCVDGVNTYNCQCPPEWTGQFCTEDVDECQLQPNACHNGGTCFNTLGGHSCVCVNGWTGESCSQNIDDCATAVCFHGATCHDRVASFYCACPMGKTGLLCHLDDACVSNPCHEDAICDTNPVNGRAICTCPPGFTGGACDQDVDECSIGANPCEHLGRCVNTQGSFLCQCGRGYTGPRCETDVNECLSGPCRNQATCLDRIGQFTCICMAGFTGTYCEVDIDECQSSPCVNGGVCKDRVNGFSCTCPSGFSGSTCQLDVDECASTPCRNGAKCVDQPDGYECRCAEGFEGTLCDRNVDDCSPDPCHHGRCVDGIASFSCACAPGYTGTRCESQVDECRSQPCRHGGKCLDLVDKYLCRCPSGTTGVNCEVNIDDCASNPCTFGVCRDGINRYDCVCQPGFTGPLCNVEINECASSPCGEGGSCVDGENGFRCLCPPGSLPPLCLPPSHPCAHEPCSHGICYDAPGGFRCVCEPGWSGPRCSQSLARDACESQPCRAGGTCSSDGMGFHCTCPPGVQGRQCELLSPCTPNPCEHGGRCESAPGQLPVCSCPQGWQGPRCQQDVDECAGPAPCGPHGICTNLAGSFSCTCHGGYTGPSCDQDINDCDPNPCLNGGSCQDGVGSFSCSCLPGFAGPRCARDVDECLSNPCGPGTCTDHVASFTCTCPPGYGGFHCEQDLPDCSPSSCFNGGTCVDGVNSFSCLCRPGYTGAHCQHEADPCLSRPCLHGGVCSAAHPGFRCTCLESFTGPQCQTLVDWCSRQPCQNGGRCVQTGAYCLCPPGWSGRLCDIRSLPCREAAAQIGVRLEQLCQAGGQCVDEDSSHYCVCPEGRTGSHCEQEVDPCLAQPCQHGGTCRGYMGGYMCECLPGYNGDNCEDDVDECASQPCQHGGSCIDLVARYLCSCPPGTLGVLCEINEDDCGPGPPLDSGPRCLHNGTCVDLVGGFRCTCPPGYTGLRCEADINECRSGACHAAHTRDCLQDPGGGFRCLCHAGFSGPRCQTVLSPCESQPCQHGGQCRPSPGPGGGLTFTCHCAQPFWGPRCERVARSCRELQCPVGVPCQQTPRGPRCACPPGLSGPSCRSFPGSPPGASNASCAAAPCLHGGSCRPAPLAPFFRCACAQGWTGPRCEAPAAAPEVSEEPRCPRAACQAKRGDQRCDRECNSPGCGWDGGDCSLSVGDPWRQCEALQCWRLFNNSRCDPACSSPACLYDNFDCHAGGRERTCNPVYEKYCADHFADGRCDQGCNTEECGWDGLDCASEVPALLARGVLVLTVLLPPEELLRSSADFLQRLSAILRTSLRFRLDAHGQAMVFPYHRPSPGSEPRARRELAPEVIGSVVMLEIDNRLCLQSPENDHCFPDAQSAADYLGALSAVERLDFPYPLRDVRGEPLEPPEPSVPLLPLLVAGAVLLLVILVLGVMVARRKREHSTLWFPEGFSLHKDVASGHKGRREPVGQDALGMKNMAKGESLMGEVATDWMDTECPEAKRLKVEEPGMGAEEAVDCRQWTQHHLVAADIRVAPAMALTPPQGDADADGMDVNVRGPDGFTPLMLASFCGGALEPMPTEEDEADDTSASIISDLICQGAQLGARTDRTGETALHLAARYARADAAKRLLDAGADTNAQDHSGRTPLHTAVTADAQGVFQILIRNRSTDLDARMADGSTALILAARLAVEGMVEELIASHADVNAVDELGKSALHWAAAVNNVEATLALLKNGANKDMQDSKEETPLFLAAREGSYEAAKLLLDHFANREITDHLDRLPRDVAQERLHQDIVRLLDQPSGPRSPPGPHGLGPLLCPPGAFLPGLKAAQSGSKKSRRPPGKAGLGPQGPRGRGKKLTLACPGPLADSSVTLSPVDSLDSPRPFGGPPASPGGFPLEGPYAAATATAVSLAQLGGPGRAGLGRQPPGGCVLSLGLLNPVAVPLDWARLPPPAPPGPSFLLPLAPGPQLLNPGTPVSPQERPPPYLAVPGHGEEYPAAGAHSSPPKARFLRVPSEHPYLTPSPESPEHWASPSPPSLSDWSESTPSPATATGAMATTTGALPAQPLPLSVPSSLAQAQTQLGPQPEVTPKRQVLA
T44684	DRUGINFO	D01QLP	Tarextumab	Phase 2

T18299	TARGETID	T18299
T18299	FORMERID	TTDI02008
T18299	UNIPROID	KCC2A_HUMAN; KCC2B_HUMAN; KCC2D_HUMAN; KCC2G_HUMAN
T18299	TARGNAME	CaM-kinase II (CAMK2)
T18299	GENENAME	CAMK2A; CAMK2B; CAMK2D; CAMK2G
T18299	TARGTYPE	Clinical trial
T18299	SYNONYMS	Calcium/calmodulin-dependent protein kinase type II; CaMK-II; CaM kinase II; CAMK
T18299	FUNCTION	CaM-kinase II (CAMK2) is a prominent kinase in the central nervous system that may function in long-term potentiation and neurotransmitter release. Member of the NMDAR signaling complex in excitatory synapses it may regulate NMDAR-dependent potentiation of the AMPAR and synaptic plasticity.
T18299	BIOCLASS	Kinase
T18299	SEQUENCE	MATITCTRFTEEYQLFEELGKGAFSVVRRCVKVLAGQEYAAKIINTKKLSARDHQKLEREARICRLLKHPNIVRLHDSISEEGHHYLIFDLVTGGELFEDIVAREYYSEADASHCIQQILEAVLHCHQMGVVHRDLKPENLLLASKLKGAAVKLADFGLAIEVEGEQQAWFGFAGTPGYLSPEVLRKDPYGKPVDLWACGVILYILLVGYPPFWDEDQHRLYQQIKAGAYDFPSPEWDTVTPEAKDLINKMLTINPSKRITAAEALKHPWISHRSTVASCMHRQETVDCLKKFNARRKLKGAILTTMLATRNFSGGKSGGNKKSDGVKESSESTNTTIEDEDTKVRKQEIIKVTEQLIEAISNGDFESYTKMCDPGMTAFEPEALGNLVEGLDFHRFYFENLWSRNSKPVHTTILNPHIHLMGDESACIAYIRITQYLDAGGIPRTAQSEETRVWHRRDGKWQIVHFHRSGAPSVLPH
T18299	DRUGINFO	D06PHH	Rimacalib	Phase 2
T18299	DRUGINFO	D01EPO	ABIO 09-01	Investigative
T18299	DRUGINFO	D0D7HR	PMID18337095C27	Investigative
T18299	DRUGINFO	D0FH9J	PMID18334293C15b	Investigative
T18299	DRUGINFO	D0XT3Z	KN-93	Investigative

T64774	TARGETID	T64774
T64774	FORMERID	TTDC00061
T64774	UNIPROID	VDAC3_HUMAN
T64774	TARGNAME	Voltage-dependent anion-selective channel 3 (VDAC3)
T64774	GENENAME	VDAC3
T64774	TARGTYPE	Clinical trial
T64774	SYNONYMS	hVDAC3; VDAC3; VDAC-3; Outer mitochondrial membrane protein porin 3
T64774	FUNCTION	Forms a channel through the mitochondrial outer membrane that allows diffusion of small hydrophilic molecules.
T64774	BIOCLASS	Eukaryotic mitochondrial porin
T64774	SEQUENCE	MCNTPTYCDLGKAAKDVFNKGYGFGMVKIDLKTKSCSGVEFSTSGHAYTDTGKASGNLETKYKVCNYGLTFTQKWNTDNTLGTEISWENKLAEGLKLTLDTIFVPNTGKKSGKLKASYKRDCFSVGSNVDIDFSGPTIYGWAVLAFEGWLAGYQMSFDTAKSKLSQNNFALGYKAADFQLHTHVNDGTEFGGSIYQKVNEKIETSINLAWTAGSNNTRFGIAAKYMLDCRTSLSAKVNNASLIGLGYTQTLRPGVKLTLSALIDGKNFSAGGHKVGLGFELEA
T64774	DRUGINFO	D0P0EI	PRLX93936	Phase 1/2

T52037	TARGETID	T52037
T52037	FORMERID	TTDI02192
T52037	UNIPROID	TLR6_HUMAN
T52037	TARGNAME	Toll-like receptor 6 (TLR6)
T52037	GENENAME	TLR6
T52037	TARGTYPE	Clinical trial
T52037	SYNONYMS	CD286
T52037	FUNCTION	Specifically recognizes diacylated and, to a lesser extent, triacylated lipopeptides. In response to diacylated lipopeptides, forms the activation cluster TLR2:TLR6:CD14:CD36, this cluster triggers signaling from the cell surface and subsequently is targeted to the Golgi in a lipid-raft dependent pathway. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Recognizes mycoplasmal macrophage-activating lipopeptide-2kD (MALP-2), soluble tuberculosis factor (STF), phenol-soluble modulin (PSM) and B. burgdorferi outer surface protein A lipoprotein (OspA-L) cooperatively with TLR2. In complex with TLR4, promotes sterile inflammation in monocytes/macrophages in response to oxidized low-density lipoprotein (oxLDL) or amyloid-beta 42. In this context, the initial signal is provided by oxLDL- or amyloid-beta 42-binding to CD36. This event induces the formation of a heterodimer of TLR4 and TLR6, which is rapidly internalized and triggers inflammatory response, leading to the NF-kappa-B-dependent production of CXCL1, CXCL2 and CCL9 cytokines, via MYD88 signaling pathway, and CCL5 cytokine, via TICAM1 signaling pathway, as well as IL1B secretion. Participates in the innate immune response to Gram-positive bacteria and fungi.
T52037	PDBSTRUC	4OM7
T52037	BIOCLASS	Toll-like receptor
T52037	SEQUENCE	MTKDKEPIVKSFHFVCLMIIIVGTRIQFSDGNEFAVDKSKRGLIHVPKDLPLKTKVLDMSQNYIAELQVSDMSFLSELTVLRLSHNRIQLLDLSVFKFNQDLEYLDLSHNQLQKISCHPIVSFRHLDLSFNDFKALPICKEFGNLSQLNFLGLSAMKLQKLDLLPIAHLHLSYILLDLRNYYIKENETESLQILNAKTLHLVFHPTSLFAIQVNISVNTLGCLQLTNIKLNDDNCQVFIKFLSELTRGSTLLNFTLNHIETTWKCLVRVFQFLWPKPVEYLNIYNLTIIESIREEDFTYSKTTLKALTIEHITNQVFLFSQTALYTVFSEMNIMMLTISDTPFIHMLCPHAPSTFKFLNFTQNVFTDSIFEKCSTLVKLETLILQKNGLKDLFKVGLMTKDMPSLEILDVSWNSLESGRHKENCTWVESIVVLNLSSNMLTDSVFRCLPPRIKVLDLHSNKIKSVPKQVVKLEALQELNVAFNSLTDLPGCGSFSSLSVLIIDHNSVSHPSADFFQSCQKMRSIKAGDNPFQCTCELREFVKNIDQVSSEVLEGWPDSYKCDYPESYRGSPLKDFHMSELSCNITLLIVTIGATMLVLAVTVTSLCIYLDLPWYLRMVCQWTQTRRRARNIPLEELQRNLQFHAFISYSEHDSAWVKSELVPYLEKEDIQICLHERNFVPGKSIVENIINCIEKSYKSIFVLSPNFVQSEWCHYELYFAHHNLFHEGSNNLILILLEPIPQNSIPNKYHKLKALMTQRTYLQWPKEKSKRGLFWANIRAAFNMKLTLVTENNDVKS
T52037	DRUGINFO	D0K3SM	MALP-2S	Phase 1/2

T95998	TARGETID	T95998
T95998	FORMERID	TTDR00172
T95998	UNIPROID	PCY1B_HUMAN
T95998	TARGNAME	Cholinephosphate cytidylyltransferase (PCYT1B)
T95998	GENENAME	PCYT1B
T95998	TARGTYPE	Clinical trial
T95998	SYNONYMS	Phosphorylcholine transferase; PCYT1B; CTP:phosphocholine cytidylyltransferase; CT; CCT
T95998	FUNCTION	Controls phosphatidylcholine synthesis.
T95998	BIOCLASS	Nucleotidyltransferase
T95998	ECNUMBER	EC 2.7.7.15
T95998	SEQUENCE	MPVVTTDAESETGIPKSLSNEPPSETMEEIEHTCPQPRLTLTAPAPFADETNCQCQAPHEKLTIAQARLGTPADRPVRVYADGIFDLFHSGHARALMQAKTLFPNSYLLVGVCSDDLTHKFKGFTVMNEAERYEALRHCRYVDEVIRDAPWTLTPEFLEKHKIDFVAHDDIPYSSAGSDDVYKHIKEAGMFVPTQRTEGISTSDIITRIVRDYDVYARRNLQRGYTAKELNVSFINEKRYRFQNQVDKMKEKVKNVEERSKEFVNRVEEKSHDLIQKWEEKSREFIGNFLELFGPDGAWKQMFQERSSRMLQALSPKQSPVSSPTRSRSPSRSPSPTFSWLPLKTSPPSSPKAASASISSMSEGDEDEK
T95998	DRUGINFO	D0V0DI	CT-2584	Phase 3
T95998	DRUGINFO	D0L0YG	Sphingosine	Phase 1
T95998	DRUGINFO	D02DLW	Cholesterol	Investigative

T15344	TARGETID	T15344
T15344	FORMERID	TTDI02197
T15344	UNIPROID	TNR18_HUMAN
T15344	TARGNAME	Activation-inducible TNFR family receptor (TNFRSF18)
T15344	GENENAME	TNFRSF18
T15344	TARGTYPE	Clinical trial
T15344	SYNONYMS	UNQ319/PRO364; Tumor necrosis factor receptor superfamily member 18; Glucocorticoid-induced TNFR-related protein; GITR; CD357; AITR
T15344	FUNCTION	Seems to be involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death. Mediated NF-kappa-B activation via the TRAF2/NIK pathway. Receptor for TNFSF18.
T15344	BIOCLASS	Cytokine receptor
T15344	SEQUENCE	MAQHGAMGAFRALCGLALLCALSLGQRPTGGPGCGPGRLLLGTGTDARCCRVHTTRCCRDYPGEECCSEWDCMCVQPEFHCGDPCCTTCRHHPCPPGQGVQSQGKFSFGFQCIDCASGTFSGGHEGHCKPWTDCTQFGFLTVFPGNKTHNAVCVPGSPPAEPLGWLTVVLLAVAACVLLLTSAQLGLHIWQLRSQCMWPRETQLLLEVPPSTEDARSCQFPEEERGERSAEEKGRLGDLWV
T15344	DRUGINFO	DOI7H2	INCAGN01876	Phase 2
T15344	DRUGINFO	D06CJN	INCAGN1876	Phase 1/2
T15344	DRUGINFO	D0J1MO	TRX-518	Phase 1/2
T15344	DRUGINFO	D0Y2XZ	MK-4166	Phase 1
T15344	DRUGINFO	D8CFX3	REGN6569	Phase 1
T15344	DRUGINFO	DG17UJ	AMG 228	Phase 1
T15344	DRUGINFO	DJ6NE2	TRX518	Phase 1
T15344	DRUGINFO	DYSI03	ASP1951	Phase 1

T93661	TARGETID	T93661
T93661	FORMERID	TTDR01343
T93661	UNIPROID	SMAD7_HUMAN
T93661	TARGNAME	Smad7 messenger RNA (Smad7 mRNA)
T93661	GENENAME	SMAD7
T93661	TARGTYPE	Clinical trial
T93661	SYNONYMS	hSMAD7 (mRNA); Smad7 (mRNA); SMAD family member 7 (mRNA); SMAD 7 (mRNA); Mothers against decapentaplegic homolog 8 (mRNA); Mothers against decapentaplegic homolog 7 (mRNA); Mothers against DPP homolog 8 (mRNA); Mothers against DPP homolog 7 (mRNA); MADH8 (mRNA); MADH7 (mRNA); MAD homolog 8 (mRNA); MAD homolog 7 (mRNA)
T93661	FUNCTION	Functions as an adapter to recruit SMURF2 to the TGF-beta receptor complex. Also acts by recruiting the PPP1R15A-PP1 complex to TGFBR1, which promotes its dephosphorylation. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator. Antagonist of signaling by TGF-beta (transforming growth factor) type 1 receptor superfamily members; has been shown to inhibit TGF-beta (Transforming growth factor) and activin signaling by associating with their receptors thus preventing SMAD2 access.
T93661	PDBSTRUC	2LTZ; 2LTY; 2LTX; 2LTW; 2LTV
T93661	BIOCLASS	mRNA target
T93661	SEQUENCE	MFRTKRSALVRRLWRSRAPGGEDEEEGAGGGGGGGELRGEGATDSRAHGAGGGGPGRAGCCLGKAVRGAKGHHHPHPPAAGAGAAGGAEADLKALTHSVLKKLKERQLELLLQAVESRGGTRTACLLLPGRLDCRLGPGAPAGAQPAQPPSSYSLPLLLCKVFRWPDLRHSSEVKRLCCCESYGKINPELVCCNPHHLSRLCELESPPPPYSRYPMDFLKPTADCPDAVPSSAETGGTNYLAPGGLSDSQLLLEPGDRSHWCVVAYWEEKTRVGRLYCVQEPSLDIFYDLPQGNGFCLGQLNSDNKSQLVQKVRSKIGCGIQLTREVDGVWVYNRSSYPIFIKSATLDNPDSRTLLVHKVFPGFSIKAFDYEKAYSLQRPNDHEFMQQPWTGFTVQISFVKGWGQCYTRQFISSCPCWLEVIFNSR
T93661	DRUGINFO	D09FKY	GED-0301	Phase 3
T93661	DRUGINFO	D01VBU	ISIS 28466	Investigative
T93661	DRUGINFO	D03BSQ	ISIS 28477	Investigative
T93661	DRUGINFO	D0AL2R	ISIS 28465	Investigative
T93661	DRUGINFO	D0E0WX	ISIS 28472	Investigative

T95515	TARGETID	T95515
T95515	FORMERID	TTDI02270
T95515	UNIPROID	K2C6A_HUMAN
T95515	TARGNAME	Keratin 6A messenger RNA (KRT6A mRNA)
T95515	GENENAME	KRT6A
T95515	TARGTYPE	Clinical trial
T95515	SYNONYMS	Type-II keratin Kb6 (mRNA); Keratin-6A (mRNA); Keratin, type II cytoskeletal 6A (mRNA); KRT6D (mRNA); K6A (mRNA); Hom s 5 (mRNA); Cytokeratin-6D (mRNA); Cytokeratin-6A (mRNA); CK-6D (mRNA); CK-6A (mRNA)
T95515	FUNCTION	Involved in the activation of follicular keratinocytes after wounding, while it does not play a major role in keratinocyte proliferation or migration. Participates in the regulation of epithelial migration by inhibiting the activity of SRC during wound repair. Epidermis-specific type I keratin involved in wound healing.
T95515	PDBSTRUC	5KI0
T95515	BIOCLASS	mRNA target
T95515	SEQUENCE	MASTSTTIRSHSSSRRGFSANSARLPGVSRSGFSSVSVSRSRGSGGLGGACGGAGFGSRSLYGLGGSKRISIGGGSCAISGGYGSRAGGSYGFGGAGSGFGFGGGAGIGFGLGGGAGLAGGFGGPGFPVCPPGGIQEVTVNQSLLTPLNLQIDPTIQRVRAEEREQIKTLNNKFASFIDKVRFLEQQNKVLETKWTLLQEQGTKTVRQNLEPLFEQYINNLRRQLDSIVGERGRLDSELRGMQDLVEDFKNKYEDEINKRTAAENEFVTLKKDVDAAYMNKVELQAKADTLTDEINFLRALYDAELSQMQTHISDTSVVLSMDNNRNLDLDSIIAEVKAQYEEIAQRSRAEAESWYQTKYEELQVTAGRHGDDLRNTKQEIAEINRMIQRLRSEIDHVKKQCANLQAAIADAEQRGEMALKDAKNKLEGLEDALQKAKQDLARLLKEYQELMNVKLALDVEIATYRKLLEGEECRLNGEGVGQVNISVVQSTVSSGYGGASGVGSGLGLGGGSSYSYGSGLGVGGGFSSSSGRAIGGGLSSVGGGSSTIKYTTTSSSSRKSYKH
T95515	DRUGINFO	D06ECI	TD-101	Phase 2

T87259	TARGETID	T87259
T87259	FORMERID	TTDC00282
T87259	UNIPROID	ITAV_HUMAN
T87259	TARGNAME	ITGAV messenger RNA (ITGAV mRNA)
T87259	GENENAME	ITGAV
T87259	TARGTYPE	Clinical trial
T87259	SYNONYMS	Vitronectin receptor subunit alpha (mRNA); Vitronectin receptor alpha subunit (mRNA); Vitronectin receptor (mRNA); VTNR (mRNA); VNRA (mRNA); MSK8 (mRNA); CD51 antigen (mRNA); CD51 (mRNA)
T87259	FUNCTION	The alpha-V (ITGAV) integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. They recognize the sequence R-G-D in a wide array of ligands. ITGAV:ITGB3 binds to fractalkine (CX3CL1) and may act as its coreceptor in CX3CR1-dependent fractalkine signaling. ITGAV:ITGB3 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling. ITGAV:ITGB3 binds to FGF1 and this binding is essential for FGF1 signaling. ITGAV:ITGB3 binds to FGF2 and this binding is essential for FGF2 signaling. ITGAV:ITGB3 binds to IGF1 and this binding is essential for IGF1 signaling. ITGAV:ITGB3 binds to IGF2 and this binding is essential for IGF2 signaling. ITGAV:ITGB3 binds to IL1B and this binding is essential for IL1B signaling. ITGAV:ITGB3 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1. ITGAV:ITGB3 and ITGAV:ITGB6 act as a receptor for fibrillin-1 (FBN1) and mediate R-G-D-dependent cell adhesion to FBN1. Integrin alpha-V/beta-6 or alpha-V/beta-8 (ITGAV:ITGB6 or ITGAV:ITGB8) mediates R-G-D-dependent release of transforming growth factor beta-1 (TGF-beta-1) from regulatory Latency-associated peptide (LAP), thereby playing a key role in TGF-beta-1 activation.
T87259	PDBSTRUC	6DJP; 6AVU; 6AVR; 6AVQ; 5NEU
T87259	BIOCLASS	mRNA target
T87259	SEQUENCE	MAFPPRRRLRLGPRGLPLLLSGLLLPLCRAFNLDVDSPAEYSGPEGSYFGFAVDFFVPSASSRMFLLVGAPKANTTQPGIVEGGQVLKCDWSSTRRCQPIEFDATGNRDYAKDDPLEFKSHQWFGASVRSKQDKILACAPLYHWRTEMKQEREPVGTCFLQDGTKTVEYAPCRSQDIDADGQGFCQGGFSIDFTKADRVLLGGPGSFYWQGQLISDQVAEIVSKYDPNVYSIKYNNQLATRTAQAIFDDSYLGYSVAVGDFNGDGIDDFVSGVPRAARTLGMVYIYDGKNMSSLYNFTGEQMAAYFGFSVAATDINGDDYADVFIGAPLFMDRGSDGKLQEVGQVSVSLQRASGDFQTTKLNGFEVFARFGSAIAPLGDLDQDGFNDIAIAAPYGGEDKKGIVYIFNGRSTGLNAVPSQILEGQWAARSMPPSFGYSMKGATDIDKNGYPDLIVGAFGVDRAILYRARPVITVNAGLEVYPSILNQDNKTCSLPGTALKVSCFNVRFCLKADGKGVLPRKLNFQVELLLDKLKQKGAIRRALFLYSRSPSHSKNMTISRGGLMQCEELIAYLRDESEFRDKLTPITIFMEYRLDYRTAADTTGLQPILNQFTPANISRQAHILLDCGEDNVCKPKLEVSVDSDQKKIYIGDDNPLTLIVKAQNQGEGAYEAELIVSIPLQADFIGVVRNNEALARLSCAFKTENQTRQVVCDLGNPMKAGTQLLAGLRFSVHQQSEMDTSVKFDLQIQSSNLFDKVSPVVSHKVDLAVLAAVEIRGVSSPDHVFLPIPNWEHKENPETEEDVGPVVQHIYELRNNGPSSFSKAMLHLQWPYKYNNNTLLYILHYDIDGPMNCTSDMEINPLRIKISSLQTTEKNDTVAGQGERDHLITKRDLALSEGDIHTLGCGVAQCLKIVCQVGRLDRGKSAILYVKSLLWTETFMNKENQNHSYSLKSSASFNVIEFPYKNLPIEDITNSTLVTTNVTWGIQPAPMPVPVWVIILAVLAGLLLLAVLVFVMYRMGFFKRVRPPQEEQEREQLQPHENGEGNSET
T87259	DRUGINFO	D03TPI	TV-1102	Phase 2

T15494	TARGETID	T15494
T15494	FORMERID	TTDC00345
T15494	UNIPROID	GHR_HUMAN
T15494	TARGNAME	GHR messenger RNA (GHR mRNA)
T15494	GENENAME	GHR
T15494	TARGTYPE	Clinical trial
T15494	SYNONYMS	Somatotropin receptor (mRNA); Serum bindingprotein (mRNA); Growth hormone receptor (mRNA); GH receptor (mRNA)
T15494	FUNCTION	On ligand binding, couples to the JAK2/STAT5 pathway. Receptor for pituitary gland growth hormone involved in regulating postnatal body growth.
T15494	PDBSTRUC	5OHD; 5OEK; 3HHR; 2AEW; 1KF9
T15494	BIOCLASS	mRNA target
T15494	SEQUENCE	MDLWQLLLTLALAGSSDAFSGSEATAAILSRAPWSLQSVNPGLKTNSSKEPKFTKCRSPERETFSCHWTDEVHHGTKNLGPIQLFYTRRNTQEWTQEWKECPDYVSAGENSCYFNSSFTSIWIPYCIKLTSNGGTVDEKCFSVDEIVQPDPPIALNWTLLNVSLTGIHADIQVRWEAPRNADIQKGWMVLEYELQYKEVNETKWKMMDPILTTSVPVYSLKVDKEYEVRVRSKQRNSGNYGEFSEVLYVTLPQMSQFTCEEDFYFPWLLIIIFGIFGLTVMLFVFLFSKQQRIKMLILPPVPVPKIKGIDPDLLKEGKLEEVNTILAIHDSYKPEFHSDDSWVEFIELDIDEPDEKTEESDTDRLLSSDHEKSHSNLGVKDGDSGRTSCCEPDILETDFNANDIHEGTSEVAQPQRLKGEADLLCLDQKNQNNSPYHDACPATQQPSVIQAEKNKPQPLPTEGAESTHQAAHIQLSNPSSLSNIDFYAQVSDITPAGSVVLSPGQKNKAGMSQCDMHPEMVSLCQENFLMDNAYFCEADAKKCIPVAPHIKVESHIQPSLNQEDIYITTESLTTAAGRPGTGEHVPGSEMPVPDYTSIHIVQSPQGLILNATALPLPDKEFLSSCGYVSTDQLNKIMP
T15494	DRUGINFO	D0W3BC	ATL1103	Phase 1

T86803	TARGETID	T86803
T86803	FORMERID	TTDR01387
T86803	UNIPROID	STAT3_HUMAN
T86803	TARGNAME	STAT3 messenger RNA (STAT3 mRNA)
T86803	GENENAME	STAT3
T86803	TARGTYPE	Clinical trial
T86803	SYNONYMS	Transcription factor STAT3 (mRNA); Stat3 (mRNA); Signal transducer and activator of transcription 3 (mRNA); Acute-phase response factor (mRNA); APRF (mRNA)
T86803	FUNCTION	Once activated, recruits coactivators, such as NCOA1 or MED1, to the promoter region of the target gene. May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4. Binds to the interleukin-6 (IL-6)-responsive elements identified in the promoters of various acute-phase protein genes. Activated by IL31 through IL31RA. Acts as a regulator of inflammatory response by regulating differentiation of naive CD4(+) T-cells into T-helper Th17 or regulatory T-cells (Treg): deacetylation and oxidation of lysine residues by LOXL3, leads to disrupt STAT3 dimerization and inhibit its transcription activity. Involved in cell cycle regulation by inducing the expression of key genes for the progression from G1 to S phase, such as CCND1. Mediates the effects of LEP on melanocortin production, body energy homeostasis and lactation. May play an apoptotic role by transctivating BIRC5 expression under LEP activation. Cytoplasmic STAT3 represses macroautophagy by inhibiting EIF2AK2/PKR activity. Plays a crucial role in basal beta cell functions, such as regulation of insulin secretion. Signal transducer and transcription activator that mediates cellular responses to interleukins, KITLG/SCF, LEP and other growth factors.
T86803	PDBSTRUC	5U5S; 5AX3
T86803	BIOCLASS	mRNA target
T86803	SEQUENCE	MAQWNQLQQLDTRYLEQLHQLYSDSFPMELRQFLAPWIESQDWAYAASKESHATLVFHNLLGEIDQQYSRFLQESNVLYQHNLRRIKQFLQSRYLEKPMEIARIVARCLWEESRLLQTAATAAQQGGQANHPTAAVVTEKQQMLEQHLQDVRKRVQDLEQKMKVVENLQDDFDFNYKTLKSQGDMQDLNGNNQSVTRQKMQQLEQMLTALDQMRRSIVSELAGLLSAMEYVQKTLTDEELADWKRRQQIACIGGPPNICLDRLENWITSLAESQLQTRQQIKKLEELQQKVSYKGDPIVQHRPMLEERIVELFRNLMKSAFVVERQPCMPMHPDRPLVIKTGVQFTTKVRLLVKFPELNYQLKIKVCIDKDSGDVAALRGSRKFNILGTNTKVMNMEESNNGSLSAEFKHLTLREQRCGNGGRANCDASLIVTEELHLITFETEVYHQGLKIDLETHSLPVVVISNICQMPNAWASILWYNMLTNNPKNVNFFTKPPIGTWDQVAEVLSWQFSSTTKRGLSIEQLTTLAEKLLGPGVNYSGCQITWAKFCKENMAGKGFSFWVWLDNIIDLVKKYILALWNEGYIMGFISKERERAILSTKPPGTFLLRFSESSKEGGVTFTWVEKDISGKTQIQSVEPYTKQQLNNMSFAEIIMGYKIMDATNILVSPLVYLYPDIPKEEAFGKYCRPESQEHPEADPGSAAPYLKTKFICVTPTTCSNTIDLPMSPRTLDSLMQFGNNGEGAEPSAGGQFESLTFDMELTSECATSPM
T86803	DRUGINFO	D0B4MK	ISIS-STAT3	Phase 1/2
T86803	DRUGINFO	D09CLC	C188-9	Phase 1
T86803	DRUGINFO	D03MRO	ISIS 113187	Investigative
T86803	DRUGINFO	D07XRC	ISIS 113176	Investigative
T86803	DRUGINFO	D09YBP	ISIS 113209	Investigative
T86803	DRUGINFO	D0E3ZU	ISIS 113210	Investigative
T86803	DRUGINFO	D0O3DZ	ISIS 17148	Investigative
T86803	DRUGINFO	D0W2FY	ISIS 17152	Investigative

T81103	TARGETID	T81103
T81103	FORMERID	TTDI02255
T81103	UNIPROID	CASP2_HUMAN
T81103	TARGNAME	Caspase 2 messenger RNA (CASP2 mRNA)
T81103	GENENAME	CASP2
T81103	TARGTYPE	Clinical trial
T81103	SYNONYMS	Protease ICH1 (mRNA); Protease ICH-1 (mRNA); Neural precursor cell expressed developmentally downregulated protein 2 (mRNA); Neural precursor cell expressed developmentally down-regulated protein 2 (mRNA); NEDD2 (mRNA); NEDD-2 (mRNA); ICH1 (mRNA); Caspase2 subunit p12 (mRNA); CASP-2 (mRNA)
T81103	FUNCTION	Might function by either activating some proteins required for cell death or inactivating proteins necessary for cell survival. Associates with PIDD1 and CRADD to form the PIDDosome, a complex that activates CASP2 and triggers apoptosis in response to genotoxic stress. Involved in the activation cascade of caspases responsible for apoptosis execution.
T81103	BIOCLASS	mRNA target
T81103	ECNUMBER	EC 3.4.22.55
T81103	SEQUENCE	MAAPSAGSWSTFQHKELMAADRGRRILGVCGMHPHHQETLKKNRVVLAKQLLLSELLEHLLEKDIITLEMRELIQAKVGSFSQNVELLNLLPKRGPQAFDAFCEALRETKQGHLEDMLLTTLSGLQHVLPPLSCDYDLSLPFPVCESCPLYKKLRLSTDTVEHSLDNKDGPVCLQVKPCTPEFYQTHFQLAYRLQSRPRGLALVLSNVHFTGEKELEFRSGGDVDHSTLVTLFKLLGYDVHVLCDQTAQEMQEKLQNFAQLPAHRVTDSCIVALLSHGVEGAIYGVDGKLLQLQEVFQLFDNANCPSLQNKPKMFFIQACRGDETDRGVDQQDGKNHAGSPGCEESDAGKEKLPKMRLPTRSDMICGYACLKGTAAMRNTKRGSWYIEALAQVFSERACDMHVADMLVKVNALIKDREGYAPGTEFHRCKEMSEYCSTLCRHLYLFPGHPPT
T81103	DRUGINFO	D06ZFV	QPI-1007	Phase 3

T85228	TARGETID	T85228
T85228	FORMERID	TTDI02253
T85228	UNIPROID	CCR3_HUMAN
T85228	TARGNAME	CCR3 messenger RNA (CCR3 mRNA)
T85228	GENENAME	CCR3
T85228	TARGTYPE	Clinical trial
T85228	SYNONYMS	Eosinophil eotaxin receptor (mRNA); Chemokine receptor CCR3 (mRNA); CMKBR3 (mRNA); CKR3 (mRNA); CD193 (mRNA); CCR-3 (mRNA); CC-CKR-3 (mRNA); C-C chemokine receptor type 3 (mRNA); C-C CKR-3 (mRNA)
T85228	FUNCTION	Binds to eotaxin, eotaxin-3, MCP-3, MCP-4, RANTES and MIP-1 delta. Subsequently transduces a signal by increasing the intracellular calcium ions level. Alternative coreceptor with CD4 for HIV-1 infection. Receptor for a C-C type chemokine.
T85228	BIOCLASS	mRNA target
T85228	SEQUENCE	MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILIKYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSEIFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEETLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRLIFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSHCCMNPVIYAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF
T85228	DRUGINFO	D0L3IL	ASM8	Phase 2
T85228	DRUGINFO	D01JZV	banyu (I)	Investigative
T85228	DRUGINFO	D02BJB	RO116-9132/238	Investigative
T85228	DRUGINFO	D05QAD	RO320-2947/001	Investigative
T85228	DRUGINFO	D0B0NO	RO116-4875/608	Investigative
T85228	DRUGINFO	D0JA5D	RO330-0802/001	Investigative

T68766	TARGETID	T68766
T68766	FORMERID	TTDI02257
T68766	UNIPROID	DMPK_HUMAN
T68766	TARGNAME	DMPK messenger RNA (DMPK mRNA)
T68766	GENENAME	DMPK
T68766	TARGTYPE	Clinical trial
T68766	SYNONYMS	Myotonin-protein kinase (mRNA); Myotonic dystrophy protein kinase (mRNA); MT-PK (mRNA); MDPK (mRNA); DMPK (mRNA); DMK (mRNA); DM1PK (mRNA); DM1 protein kinase (mRNA); DM-kinase (mRNA)
T68766	FUNCTION	May play a role in myocyte differentiation and survival by regulating the integrity of the nuclear envelope and the expression of muscle-specific genes. May also phosphorylate PPP1R12A and inhibit the myosin phosphatase activity to regulate myosin phosphorylation. Also critical to the modulation of cardiac contractility and to the maintenance of proper cardiac conduction activity probably through the regulation of cellular calcium homeostasis. Phosphorylates PLN, a regulator of calcium pumps and may regulate sarcoplasmic reticulum calcium uptake in myocytes. May also phosphorylate FXYD1/PLM which is able to induce chloride currents. May also play a role in synaptic plasticity. Non-receptor serine/threonine protein kinase which is necessary for the maintenance of skeletal muscle structure and function.
T68766	PDBSTRUC	2VD5; 1WT6
T68766	BIOCLASS	mRNA target
T68766	ECNUMBER	EC 2.7.11.1
T68766	SEQUENCE	MSAEVRLRRLQQLVLDPGFLGLEPLLDLLLGVHQELGASELAQDKYVADFLQWAEPIVVRLKEVRLQRDDFEILKVIGRGAFSEVAVVKMKQTGQVYAMKIMNKWDMLKRGEVSCFREERDVLVNGDRRWITQLHFAFQDENYLYLVMEYYVGGDLLTLLSKFGERIPAEMARFYLAEIVMAIDSVHRLGYVHRDIKPDNILLDRCGHIRLADFGSCLKLRADGTVRSLVAVGTPDYLSPEILQAVGGGPGTGSYGPECDWWALGVFAYEMFYGQTPFYADSTAETYGKIVHYKEHLSLPLVDEGVPEEARDFIQRLLCPPETRLGRGGAGDFRTHPFFFGLDWDGLRDSVPPFTPDFEGATDTCNFDLVEDGLTAMVSGGGETLSDIREGAPLGVHLPFVGYSYSCMALRDSEVPGPTPMELEAEQLLEPHVQAPSLEPSVSPQDETAEVAVPAAVPAAEAEAEVTLRELQEALEEEVLTRQSLSREMEAIRTDNQNFASQLREAEARNRDLEAHVRQLQERMELLQAEGATAVTGVPSPRATDPPSHLDGPPAVAVGQCPLVGPGPMHRRHLLLPARVPRPGLSEALSLLLFAVVLSRAAALGCIGLVAHAGQLTAVWRRPGAARAP
T68766	DRUGINFO	D0X9WC	ISIS-DMPK	Phase 1/2
T68766	DRUGINFO	D0N7HT	PRO-135	Investigative
T68766	DRUGINFO	D0P4MA	2-MOE phosphorothioate gapmers	Investigative
T68766	DRUGINFO	D03CPB	RKI-1447	Investigative

T80011	TARGETID	T80011
T80011	FORMERID	TTDR01411
T80011	UNIPROID	4EBP2_HUMAN
T80011	TARGNAME	eIF4E-BP2 messenger RNA (eIF4E-BP2 mRNA)
T80011	GENENAME	EIF4EBP2
T80011	TARGTYPE	Clinical trial
T80011	SYNONYMS	eIF4E-binding protein 2 (mRNA); Eukaryotic translation initiation factor 4E-binding protein 2 (mRNA); 4E-BP2 (mRNA)
T80011	FUNCTION	Regulates EIF4E activity by preventing its assembly into the eIF4F complex: hypophosphorylated form of EIF4EBP2 competes with EIF4G1/EIF4G3 and strongly binds to EIF4E, leading to repress translation. In contrast, hyperphosphorylated form dissociates from EIF4E, allowing interaction between EIF4G1/EIF4G3 and EIF4E, leading to initiation of translation. EIF4EBP2 is enriched in brain and acts as a regulator of synapse activity and neuronal stem cell renewal via its ability to repress translation initiation. Mediates the regulation of protein translation by hormones, growth factors and other stimuli that signal through the MAP kinase and mTORC1 pathways. Repressor of translation initiation involved in synaptic plasticity, learning and memory formation.
T80011	PDBSTRUC	3AM7; 2MX4
T80011	BIOCLASS	mRNA target
T80011	SEQUENCE	MSSSAGSGHQPSQSRAIPTRTVAISDAAQLPHDYCTTPGGTLFSTTPGGTRIIYDRKFLLDRRNSPMAQTPPCHLPNIPGVTSPGTLIEDSKVEVNNLNNLNNHDRKHAVGDDAQFEMDI
T80011	DRUGINFO	D08HQI	ISIS-EIF4E	Phase 2
T80011	DRUGINFO	D0FI9M	ISIS 232828	Investigative
T80011	DRUGINFO	D0QE7H	ISIS 347577	Investigative
T80011	DRUGINFO	D0W3RV	ISIS 347573	Investigative

T37298	TARGETID	T37298
T37298	FORMERID	TTDI02265
T37298	UNIPROID	MYCBP_HUMAN
T37298	TARGNAME	MYCBP messenger RNA (MYCBP mRNA)
T37298	GENENAME	MYCBP
T37298	TARGTYPE	Clinical trial
T37298	SYNONYMS	c-Myc-binding protein (mRNA); Associate of Myc 1 (mRNA); AMY1 (mRNA); AMY-1 (mRNA)
T37298	FUNCTION	Stimulates the activation of E box-dependent transcription by MYC. May control the transcriptional activity of MYC.
T37298	PDBSTRUC	2YY0
T37298	BIOCLASS	mRNA target
T37298	SEQUENCE	MAHYKAADSKREQFRRYLEKSGVLDTLTKVLVALYEEPEKPNSALDFLKHHLGAATPENPEIELLRLELAEMKEKYEAIVEENKKLKAKLAQYEPPQEEKRAE
T37298	DRUGINFO	D02OZT	DCR-MYC	Phase 1/2

T41003	TARGETID	T41003
T41003	FORMERID	TTDR01423
T41003	UNIPROID	EPAS1_HUMAN
T41003	TARGNAME	HIF2-alpha messenger RNA (EPAS1 mRNA)
T41003	GENENAME	EPAS1
T41003	TARGTYPE	Clinical trial
T41003	SYNONYMS	PASD2 mRNA; PAS domain-containing protein 2 mRNA; Member of PAS protein 2 mRNA; MOP2 mRNA; Hypoxia-inducible factor 2-alpha mRNA; HLF mRNA; HIF2A mRNA; HIF2-alpha mRNA; HIF-2-alpha mRNA; HIF-1-alpha-like factor mRNA; Endothelial PAS domain-containing protein 1 mRNA; EPAS-1 mRNA; Class E basic helix-loop-helix protein 73 mRNA; Basic-helix-loop-helix-PAS protein MOP2 mRNA; BHLHE73 mRNA
T41003	FUNCTION	Transcription factor involved in the induction of oxygen regulated genes. Heterodimerizes with ARNT; heterodimer binds to core DNA sequence 5'-TACGTG-3' within the hypoxia response element (HRE) of target gene promoters (By similarity). Regulates the vascular endothelial growth factor (VEGF) expression and seems to be implicated in the development of blood vessels and the tubular system of lung. May also play a role in the formation of the endothelium that gives rise to the blood brain barrier. Potent activator of the Tie-2 tyrosine kinase expression. Activation requires recruitment of transcriptional coactivators such as CREBBP and probably EP300. Interaction with redox regulatory protein APEX seems to activate CTAD (By similarity).
T41003	PDBSTRUC	6D0C; 6D0B; 6D09; 6CZW; 6BVB
T41003	BIOCLASS	mRNA target
T41003	SEQUENCE	MTADKEKKRSSSERRKEKSRDAARCRRSKETEVFYELAHELPLPHSVSSHLDKASIMRLAISFLRTHKLLSSVCSENESEAEADQQMDNLYLKALEGFIAVVTQDGDMIFLSENISKFMGLTQVELTGHSIFDFTHPCDHEEIRENLSLKNGSGFGKKSKDMSTERDFFMRMKCTVTNRGRTVNLKSATWKVLHCTGQVKVYNNCPPHNSLCGYKEPLLSCLIIMCEPIQHPSHMDIPLDSKTFLSRHSMDMKFTYCDDRITELIGYHPEELLGRSAYEFYHALDSENMTKSHQNLCTKGQVVSGQYRMLAKHGGYVWLETQGTVIYNPRNLQPQCIMCVNYVLSEIEKNDVVFSMDQTESLFKPHLMAMNSIFDSSGKGAVSEKSNFLFTKLKEEPEELAQLAPTPGDAIISLDFGNQNFEESSAYGKAILPPSQPWATELRSHSTQSEAGSLPAFTVPQAAAPGSTTPSATSSSSSCSTPNSPEDYYTSLDNDLKIEVIEKLFAMDTEAKDQCSTQTDFNELDLETLAPYIPMDGEDFQLSPICPEERLLAENPQSTPQHCFSAMTNIFQPLAPVAPHSPFLLDKFQQQLESKKTEPEHRPMSSIFFDAGSKASLPPCCGQASTPLSSMGGRSNTQWPPDPPLHFGPTKWAVGDQRTEFLGAAPLGPPVSPPHVSTFKTRSAKGFGARGPDVLSPAMVALSNKLKLKRQLEYEEQAFQDLSGGDPPGGSTSHLMWKRMKNLRGGSCPLMPDKPLSANVPNDKFTQNPMRGLGHPLRHLPLPQPPSAISPGENSKSRFPPQCYATQYQDYSLSSAHKVSGMASRLLGPSFESYLLPELTRYDCEVNVPVLGSSTLLQGGDLLRALDQAT
T41003	DRUGINFO	D0C9PZ	PT2385	Phase 2
T41003	DRUGINFO	DE8V1R	ARO-HIF2	Phase 1
T41003	DRUGINFO	D04PSH	ISIS 222041	Investigative
T41003	DRUGINFO	D05THV	ISIS 222035	Investigative
T41003	DRUGINFO	D06NHW	ISIS 222039	Investigative
T41003	DRUGINFO	D06YSI	ISIS 222001	Investigative
T41003	DRUGINFO	D0K2GT	ISIS 222043	Investigative

T88697	TARGETID	T88697
T88697	FORMERID	TTDI02240
T88697	UNIPROID	ANGL3_HUMAN
T88697	TARGNAME	ANGPTL3 messenger RNA (ANGPTL3 mRNA)
T88697	GENENAME	ANGPTL3
T88697	TARGTYPE	Clinical trial
T88697	SYNONYMS	UNQ153/PRO179 (mRNA); Angiopoietin-related protein 3 (mRNA); Angiopoietin-like protein 3 (mRNA); Angiopoietin-5 (mRNA); ANGPT5 (mRNA); ANG-5 (mRNA)
T88697	FUNCTION	Proposed to play a role in the trafficking of energy substrates to either storage or oxidative tissues in response to food intake. Has a stimulatory effect on plasma triglycerides (TG), which is achieved by suppressing plasma TG clearance via inhibition of LPL activity. The inhibition of LPL activity appears to be an indirect mechanism involving recruitment of proprotein convertases PCSK6 and FURIN to LPL leading to cleavage and dissociation of LPL from the cell surface; the function does not require ANGPTL3 proteolytic cleavage but seems to be mediated by the N-terminal domain, and is not inhibited by GPIHBP1. Can inhibit endothelial lipase, causing increased plasma levels of high density lipoprotein (HDL) cholesterol and phospholipids. Can bind to adipocytes to activate lipolysis, releasing free fatty acids and glycerol. Suppresses LPL specifically in oxidative tissues which is required to route very low density lipoprotein (VLDL)-TG to white adipose tissue (WAT) for storage in response to food; the function may involve cooperation with circulating, liver-derived ANGPTL8 and ANGPTL4 expression in WAT. Contributes to lower plasma levels of low density lipoprotein (LDL)-cholesterol by a mechanism that is independent of the canonical pathway implicating APOE and LDLR. May stimulate hypothalamic LPL activity. Acts in part as a hepatokine that is involved in regulation of lipid and glucose metabolism.
T88697	PDBSTRUC	6EUA
T88697	BIOCLASS	mRNA target
T88697	SEQUENCE	MFTIKLLLFIVPLVISSRIDQDNSSFDSLSPEPKSRFAMLDDVKILANGLLQLGHGLKDFVHKTKGQINDIFQKLNIFDQSFYDLSLQTSEIKEEEKELRRTTYKLQVKNEEVKNMSLELNSKLESLLEEKILLQQKVKYLEEQLTNLIQNQPETPEHPEVTSLKTFVEKQDNSIKDLLQTVEDQYKQLNQQHSQIKEIENQLRRTSIQEPTEISLSSKPRAPRTTPFLQLNEIRNVKHDGIPAECTTIYNRGEHTSGMYAIRPSNSQVFHVYCDVISGSPWTLIQHRIDGSQNFNETWENYKYGFGRLDGEFWLGLEKIYSIVKQSNYVLRIELEDWKDNKHYIEYSFYLGNHETNYTLHLVAITGNVPNAIPENKDLVFSTWDHKAKGHFNCPEGYSGGWWWHDECGENNLNGKYNKPRAKSKPERRRGLSWKSQNGRLYSIKSTKMLIHPTDSESFE
T88697	DRUGINFO	D0RK1O	ARO-ANG3	Phase 2
T88697	DRUGINFO	DDU2Y0	Vupanorsen	Phase 2
T88697	DRUGINFO	D0T3RR	ISIS-ANGPTL3	Phase 1

T10383	TARGETID	T10383
T10383	FORMERID	TTDI03468
T10383	UNIPROID	PLD2_HUMAN
T10383	TARGNAME	Phospholipase D2 (PLD2)
T10383	GENENAME	PLD2
T10383	TARGTYPE	Clinical trial
T10383	SYNONYMS	hPLD2; Phosphatidylcholine-hydrolyzing phospholipase D2; PLD1C; PLD 2; Choline phosphatase 2
T10383	FUNCTION	May have a role in signal-induced cytoskeletal regulation and/or endocytosis.
T10383	BIOCLASS	Phosphoric diester hydrolase
T10383	ECNUMBER	EC 3.1.4.4
T10383	SEQUENCE	MTATPESLFPTGDELDSSQLQMESDEVDTLKEGEDPADRMHPFLAIYELQSLKVHPLVFAPGVPVTAQVVGTERYTSGSKVGTCTLYSVRLTHGDFSWTTKKKYRHFQELHRDLLRHKVLMSLLPLARFAVAYSPARDAGNREMPSLPRAGPEGSTRHAASKQKYLENYLNRLLTMSFYRNYHAMTEFLEVSQLSFIPDLGRKGLEGMIRKRSGGHRVPGLTCCGRDQVCYRWSKRWLVVKDSFLLYMCLETGAISFVQLFDPGFEVQVGKRSTEARHGVRIDTSHRSLILKCSSYRQARWWAQEITELAQGPGRDFLQLHRHDSYAPPRPGTLARWFVNGAGYFAAVADAILRAQEEIFITDWWLSPEVYLKRPAHSDDWRLDIMLKRKAEEGVRVSILLFKEVELALGINSGYSKRALMLLHPNIKVMRHPDQVTLWAHHEKLLVVDQVVAFLGGLDLAYGRWDDLHYRLTDLGDSSESAASQPPTPRPDSPATPDLSHNQFFWLGKDYSNLITKDWVQLDRPFEDFIDRETTPRMPWRDVGVVVHGLPARDLARHFIQRWNFTKTTKAKYKTPTYPYLLPKSTSTANQLPFTLPGGQCTTVQVLRSVDRWSAGTLENSILNAYLHTIRESQHFLYIENQFFISCSDGRTVLNKVGDEIVDRILKAHKQGWCYRVYVLLPLLPGFEGDISTGGGNSIQAILHFTYRTLCRGEYSILHRLKAAMGTAWRDYISICGLRTHGELGGHPVSELIYIHSKVLIADDRTVIIGSANINDRSLLGKRDSELAVLIEDTETEPSLMNGAEYQAGRFALSLRKHCFGVILGANTRPDLDLRDPICDDFFQLWQDMAESNANIYEQIFRCLPSNATRSLRTLREYVAVEPLATVSPPLARSELTQVQGHLVHFPLKFLEDESLLPPLGSKEGMIPLEVWT
T10383	DRUGINFO	D03JRG	VU0364739	Clinical trial
T10383	DRUGINFO	D07ZAJ	PIP2	Investigative

T54093	TARGETID	T54093
T54093	FORMERID	TTDI02029
T54093	UNIPROID	TBXT_HUMAN
T54093	TARGNAME	T-box transcription factor T (TBXT)
T54093	GENENAME	T
T54093	TARGTYPE	Clinical trial
T54093	SYNONYMS	T; Protein T
T54093	FUNCTION	Involved in the transcriptional regulation of genes required for mesoderm formation and differentiation. Binds to a palindromic site (called T site) and activates gene transcription when bound to such a site.
T54093	PDBSTRUC	6F59; 6F58
T54093	SEQUENCE	MSSPGTESAGKSLQYRVDHLLSAVENELQAGSEKGDPTERELRVGLEESELWLRFKELTNEMIVTKNGRRMFPVLKVNVSGLDPNAMYSFLLDFVAADNHRWKYVNGEWVPGGKPEPQAPSCVYIHPDSPNFGAHWMKAPVSFSKVKLTNKLNGGGQIMLNSLHKYEPRIHIVRVGGPQRMITSHCFPETQFIAVTAYQNEEITALKIKYNPFAKAFLDAKERSDHKEMMEEPGDSQQPGYSQWGWLLPGTSTLCPPANPHPQFGGALSLPSTHSCDRYPTLRSHRSSPYPSPYAHRNNSPTYSDNSPACLSMLQSHDNWSSLGMPAHPSMLPVSHNASPPTSSSQYPSLWSVSNGAVTPGSQAAAVSNGLGAQFFRGSPAHYTPLTHPVSAPSSSGSPLYEGAAAATDIVDSQYDAAAQGRLIASWTPVSPPSM
T54093	DRUGINFO	D0S9WW	GI-6301	Phase 2

T28213	TARGETID	T28213
T28213	FORMERID	TTDI02069
T28213	UNIPROID	FFAR2_HUMAN
T28213	TARGNAME	Free fatty acid receptor 2 (FFAR2)
T28213	GENENAME	FFAR2
T28213	TARGTYPE	Clinical trial
T28213	SYNONYMS	Gprotein coupled receptor 43; FFAR2
T28213	FUNCTION	G protein-coupled receptor that is activated by a major product of dietary fiber digestion, the short chain fatty acids (SCFAs), and that plays a role in the regulation of whole-body energy homeostasis and in intestinal immunity. In omnivorous mammals, the short chain fatty acids acetate, propionate and butyrate are produced primarily by the gut microbiome that metabolizes dietary fibers. SCFAs serve as a source of energy but also act as signaling molecules. That G protein-coupled receptor is probably coupled to the pertussis toxin-sensitive, G(i/o)-alpha family of G proteins but also to the Gq family (PubMed:12496283, PubMed:12711604, PubMed:23589301). Its activation results in the formation of inositol 1,4,5-trisphosphate, the mobilization of intracellular calcium, the phosphorylation of the MAPK3/ERK1 and MAPK1/ERK2 kinases and the inhibition of intracellular cAMP accumulation. May play a role in glucose homeostasis by regulating the secretion of GLP-1, in response to short-chain fatty acids accumulating in the intestine. May also regulate the production of LEP/Leptin, a hormone acting on the central nervous system to inhibit food intake. Finally, may also regulate whole-body energy homeostasis through adipogenesis regulating both differentiation and lipid storage of adipocytes. In parallel to its role in energy homeostasis, may also mediate the activation of the inflammatory and immune responses by SCFA in the intestine, regulating the rapid production of chemokines and cytokines. May also play a role in the resolution of the inflammatory response and control chemotaxis in neutrophils. In addition to SCFAs, may also be activated by the extracellular lectin FCN1 in a process leading to activation of monocytes and inducing the secretion of interleukin- 8/IL-8 in response to the presence of microbes (PubMed:21037097). Among SCFAs, the fatty acids containing less than 6 carbons, the most potent activators are probably acetate, propionate and butyrate (PubMed:12496283, PubMed:12711604). Exhibits a SCFA- independent constitutive G protein-coupled receptor activity (PubMed:23066016).
T28213	BIOCLASS	GPCR rhodopsin
T28213	SEQUENCE	MLPDWKSSLILMAYIIIFLTGLPANLLALRAFVGRIRQPQPAPVHILLLSLTLADLLLLLLLPFKIIEAASNFRWYLPKVVCALTSFGFYSSIYCSTWLLAGISIERYLGVAFPVQYKLSRRPLYGVIAALVAWVMSFGHCTIVIIVQYLNTTEQVRSGNEITCYENFTDNQLDVVLPVRLELCLVLFFIPMAVTIFCYWRFVWIMLSQPLVGAQRRRRAVGLAVVTLLNFLVCFGPYNVSHLVGYHQRKSPWWRSIAVVFSSLNASLDPLLFYFSSSVVRRAFGRGLQVLRNQGSSLLGRRGKDTAEGTNEDRGVGQGEGMPSSDFTTE
T28213	DRUGINFO	D0TA4A	GLPG0974	Phase 2
T28213	DRUGINFO	D0W7AE	HL-018	Phase 1
T28213	DRUGINFO	D01THG	trans-2-methylcrotonic acid	Investigative
T28213	DRUGINFO	D07ITP	AMG7703	Investigative
T28213	DRUGINFO	D09JXR	PMID23589301C1	Investigative
T28213	DRUGINFO	D0L4UV	CATPB	Investigative
T28213	DRUGINFO	D05UBB	(S)-4-CMTB	Investigative
T28213	DRUGINFO	D06ZVB	isobutyric acid	Investigative
T28213	DRUGINFO	D07FPQ	1-methylcyclopropanecarboxylic acid	Investigative
T28213	DRUGINFO	D0V6IE	pentanoic acid	Investigative

T42724	TARGETID	T42724
T42724	FORMERID	TTDI03310
T42724	UNIPROID	KCNN4_HUMAN
T42724	TARGNAME	Calcium-activated potassium channel KCa3.1 (KCNN4)
T42724	GENENAME	KCNN4
T42724	TARGTYPE	Clinical trial
T42724	SYNONYMS	SKCa4; SKCa 4; SK4; Putative Gardos channel; KCa4; KCa3.1; Intermediate conductance calcium-activated potassium channel protein 4; IKCa1; IK1
T42724	FUNCTION	Activation is followed by membrane hyperpolarization which promotes calcium influx. Required for maximal calcium influx and proliferation during the reactivation of naive T-cells. Plays a role in the late stages of EGF-induced macropinocytosis. Forms a voltage-independent potassium channel that is activated by intracellular calcium.
T42724	PDBSTRUC	6D42; 6CNO; 6CNN; 6CNM
T42724	BIOCLASS	Voltage-gated ion channel
T42724	SEQUENCE	MGGDLVLGLGALRRRKRLLEQEKSLAGWALVLAGTGIGLMVLHAEMLWFGGCSWALYLFLVKCTISISTFLLLCLIVAFHAKEVQLFMTDNGLRDWRVALTGRQAAQIVLELVVCGLHPAPVRGPPCVQDLGAPLTSPQPWPGFLGQGEALLSLAMLLRLYLVPRAVLLRSGVLLNASYRSIGALNQVRFRHWFVAKLYMNTHPGRLLLGLTLGLWLTTAWVLSVAERQAVNATGHLSDTLWLIPITFLTIGYGDVVPGTMWGKIVCLCTGVMGVCCTALLVAVVARKLEFNKAEKHVHNFMMDIQYTKEMKESAARVLQEAWMFYKHTRRKESHAARRHQRKLLAAINAFRQVRLKHRKLREQVNSMVDISKMHMILYDLQQNLSSSHRALEKQIDTLAGKLDALTELLSTALGPRQLPEPSQQSK
T42724	DRUGINFO	DF0R5I	ASP0819	Phase 2
T42724	DRUGINFO	D00BUR	ICA-17043	Phase 2
T42724	DRUGINFO	D05PHX	SKA-121	Investigative
T42724	DRUGINFO	D0M7LA	PMID15603962Crac-16	Investigative
T42724	DRUGINFO	D0UL7R	SKA-31	Investigative
T42724	DRUGINFO	D05RLR	1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole	Investigative
T42724	DRUGINFO	D0I6MA	DC-EBIO	Investigative
T42724	DRUGINFO	D0T0AG	EBIO	Investigative

T46524	TARGETID	T46524
T46524	UNIPROID	TNF12_HUMAN
T46524	TARGNAME	TNF-related weak inducer of apoptosis (TWEAK)
T46524	GENENAME	TNFSF12
T46524	TARGTYPE	Clinical trial
T46524	SYNONYMS	Tumor necrosis factor ligand superfamily member 12; TWEAK; DR3LG; APO3L; APO3 ligand
T46524	FUNCTION	Binds to FN14 and possibly also to TNRFSF12/APO3. Weak inducer of apoptosis in some cell types. Mediates NF-kappa-B activation. Promotes angiogenesis and the proliferation of endothelial cells. Also involved in induction of inflammatory cytokines. Promotes IL8 secretion.
T46524	PDBSTRUC	4HT1
T46524	BIOCLASS	Cytokine: tumor necrosis factor
T46524	SEQUENCE	MAARRSQRRRGRRGEPGTALLVPLALGLGLALACLGLLLAVVSLGSRASLSAQEPAQEELVAEEDQDPSELNPQTEESQDPAPFLNRLVRPRRSAPKGRKTRARRAIAAHYEVHPRPGQDGAQAGVDGTVSGWEEARINSSSPLRYNRQIGEFIVTRAGLYYLYCQVHFDEGKAVYLKLDLLVDGVLALRCLEEFSATAASSLGPQLRLCQVSGLLALRPGSSLRIRTLPWAHLKAAPFLTYFGLFQVH
T46524	DRUGINFO	D08YHB	BIIB 023	Phase 2
T46524	DRUGINFO	D0F3ZG	RO-5458640	Phase 1

T74381	TARGETID	T74381
T74381	FORMERID	TTDNR00651
T74381	UNIPROID	MAGC1_HUMAN
T74381	TARGNAME	Cancer/testis antigen MAGE-C1/CT7 (MAGEC1)
T74381	GENENAME	MAGEC1
T74381	TARGTYPE	Clinical trial
T74381	SYNONYMS	Melanoma-associated antigen C1; MAGE-C1 antigen; Cancer/testis antigen 7.1; CT7.1
T74381	FUNCTION	Tumor antigen.
T74381	BIOCLASS	Melanoma associated antigen family
T74381	SEQUENCE	MGDKDMPTAGMPSLLQSSSESPQSCPEGEDSQSPLQIPQSSPESDDTLYPLQSPQSRSEGEDSSDPLQRPPEGKDSQSPLQIPQSSPEGDDTQSPLQNSQSSPEGKDSLSPLEISQSPPEGEDVQSPLQNPASSFFSSALLSIFQSSPESTQSPFEGFPQSVLQIPVSAASSSTLVSIFQSSPESTQSPFEGFPQSPLQIPVSRSFSSTLLSIFQSSPERTQSTFEGFAQSPLQIPVSPSSSSTLLSLFQSFSERTQSTFEGFAQSSLQIPVSPSFSSTLVSLFQSSPERTQSTFEGFPQSPLQIPVSSSSSSTLLSLFQSSPERTHSTFEGFPQSLLQIPMTSSFSSTLLSIFQSSPESAQSTFEGFPQSPLQIPGSPSFSSTLLSLFQSSPERTHSTFEGFPQSPLQIPMTSSFSSTLLSILQSSPESAQSAFEGFPQSPLQIPVSSSFSYTLLSLFQSSPERTHSTFEGFPQSPLQIPVSSSSSSSTLLSLFQSSPECTQSTFEGFPQSPLQIPQSPPEGENTHSPLQIVPSLPEWEDSLSPHYFPQSPPQGEDSLSPHYFPQSPPQGEDSLSPHYFPQSPQGEDSLSPHYFPQSPPQGEDSMSPLYFPQSPLQGEEFQSSLQSPVSICSSSTPSSLPQSFPESSQSPPEGPVQSPLHSPQSPPEGMHSQSPLQSPESAPEGEDSLSPLQIPQSPLEGEDSLSSLHFPQSPPEWEDSLSPLHFPQFPPQGEDFQSSLQSPVSICSSSTSLSLPQSFPESPQSPPEGPAQSPLQRPVSSFFSYTLASLLQSSHESPQSPPEGPAQSPLQSPVSSFPSSTSSSLSQSSPVSSFPSSTSSSLSKSSPESPLQSPVISFSSSTSLSPFSEESSSPVDEYTSSSDTLLESDSLTDSESLIESEPLFTYTLDEKVDELARFLLLKYQVKQPITKAEMLTNVISRYTGYFPVIFRKAREFIEILFGISLREVDPDDSYVFVNTLDLTSEGCLSDEQGMSQNRLLILILSIIFIKGTYASEEVIWDVLSGIGVRAGREHFAFGEPRELLTKVWVQEHYLEYREVPNSSPPRYEFLWGPRAHSEVIKRKVVEFLAMLKNTVPITFPSSYKDALKDVEERAQAIIDTTDDSTATESASSSVMSPSFSSE
T74381	DRUGINFO	D02DVK	CV-9201	Phase 1/2

T16144	TARGETID	T16144
T16144	FORMERID	TTDNC00463
T16144	UNIPROID	ICOSL_HUMAN
T16144	TARGNAME	B7-related protein 1 (B7RP1)
T16144	GENENAME	ICOSLG
T16144	TARGTYPE	Clinical trial
T16144	SYNONYMS	KIAA0653; ICOSL; ICOS ligand; CD275; B7related protein 1; B7like protein Gl50; B7RP-1; B7H2; B7-like protein Gl50; B7-H2; B7 homolog 2
T16144	FUNCTION	Acts as a costimulatory signal for T-cell proliferation and cytokine secretion; induces also B-cell proliferation and differentiation into plasma cells. Could play an important role in mediating local tissue responses to inflammatory conditions, as well as in modulating the secondary immune response by co-stimulating memory T-cell function. Ligand for the T-cell-specific cell surface receptor ICOS.
T16144	BIOCLASS	Immunoglobulin
T16144	SEQUENCE	MRLGSPGLLFLLFSSLRADTQEKEVRAMVGSDVELSCACPEGSRFDLNDVYVYWQTSESKTVVTYHIPQNSSLENVDSRYRNRALMSPAGMLRGDFSLRLFNVTPQDEQKFHCLVLSQSLGFQEVLSVEVTLHVAANFSVPVVSAPHSPSQDELTFTCTSINGYPRPNVYWINKTDNSLLDQALQNDTVFLNMRGLYDVVSVLRIARTPSVNIGCCIENVLLQQNLTVGSQTGNDIGERDKITENPVSTGEKNAATWSILAVLCLLVVVAVAIGWVCRDRCLQHSYAGAWAVSPETELTGHV
T16144	DRUGINFO	D0V0UH	AMG 557	Phase 2
T16144	DRUGINFO	DV2CR7	AMG 570	Phase 2

T83376	TARGETID	T83376
T83376	FORMERID	TTDI02202
T83376	UNIPROID	TUSC2_HUMAN
T83376	TARGNAME	Tumor suppressor candidate 2 (TUSC2)
T83376	GENENAME	TUSC2
T83376	TARGTYPE	Clinical trial
T83376	SYNONYMS	PDGFA-associated protein 2; PDAP2; LGCC; Fusion 1 protein; Fus-1 protein; FUS1; C3orf11
T83376	FUNCTION	May function as a tumor suppressor, inhibiting colony formation, causing G1 arrest and ultimately inducing apoptosis in homozygous 3p21. 3 120-kb region-deficient cells.
T83376	SEQUENCE	MGASGSKARGLWPFASAAGGGGSEAAGAEQALVRPRGRAVPPFVFTRRGSMFYDEDGDLAHEFYEETIVTKNGQKRAKLRRVHKNLIPQGIVKLDHPRIHVDFPVILYEV
T83376	DRUGINFO	D03YJW	Fus-1 tumor suppressor gene therapy	Phase 1/2
T83376	DRUGINFO	D04YIA	CNVN-202	Phase 1/2
T83376	DRUGINFO	DVD0E9	Quaratusugene ozeplasmid	Phase 1/2

T86734	TARGETID	T86734
T86734	FORMERID	TTDI02002
T86734	UNIPROID	GLSK_HUMAN; GLSL_HUMAN
T86734	TARGNAME	Glutaminase (GLS)
T86734	GENENAME	GLS; GLS2
T86734	TARGTYPE	Clinical trial
T86734	SYNONYMS	L-glutamine amidohydrolase; Glutaminase, mitochondrial; GLS
T86734	FUNCTION	Plays a role in maintaining acid-base homeostasis. Regulates the levels of the neurotransmitter glutamate in the brain. Isoform 2 lacks catalytic activity. Catalyzes the first reaction in the primary pathway for the renal catabolism of glutamine.
T86734	BIOCLASS	Carbon-nitrogen hydrolase
T86734	SEQUENCE	MMRLRGSGMLRDLLLRSPAGVSATLRRAQPLVTLCRRPRGGGRPAAGPAAAARLHPWWGGGGWPAEPLARGLSSSPSEILQELGKGSTHPQPGVSPPAAPAAPGPKDGPGETDAFGNSEGKELVASGENKIKQGLLPSLEDLLFYTIAEGQEKIPVHKFITALKSTGLRTSDPRLKECMDMLRLTLQTTSDGVMLDKDLFKKCVQSNIVLLTQAFRRKFVIPDFMSFTSHIDELYESAKKQSGGKVADYIPQLAKFSPDLWGVSVCTVDGQRHSTGDTKVPFCLQSCVKPLKYAIAVNDLGTEYVHRYVGKEPSGLRFNKLFLNEDDKPHNPMVNAGAIVVTSLIKQGVNNAEKFDYVMQFLNKMAGNEYVGFSNATFQSERESGDRNFAIGYYLKEKKCFPEGTDMVGILDFYFQLCSIEVTCESASVMAATLANGGFCPITGERVLSPEAVRNTLSLMHSCGMYDFSGQFAFHVGLPAKSGVAGGILLVVPNVMGMMCWSPPLDKMGNSVKGIHFCHDLVSLCNFHNYDNLRHFAKKLDPRREGGDQRVKSVINLLFAAYTGDVSALRRFALSAMDMEQRDYDSRTALHVAAAEGHVEVVKFLLEACKVNPFPKDRWNNTPMDEALHFGHHDVFKILQEYQVQYTPQGDSDNGKENQTVHKNLDGLL
T86734	DRUGINFO	D01PBW	CB-839	Phase 2
T86734	DRUGINFO	D00KII	PMID30273516-Compound-39	Patented
T86734	DRUGINFO	D01RUI	PMID30273516-Compound-13	Patented
T86734	DRUGINFO	D02IVA	PMID30273516-Compound-22a	Patented
T86734	DRUGINFO	D05CXZ	PMID30273516-Compound-37	Patented
T86734	DRUGINFO	D05TBZ	PMID30273516-Compound-12	Patented
T86734	DRUGINFO	D07IQM	PMID30273516-Compound-38	Patented
T86734	DRUGINFO	D07KON	PMID30273516-Compound-22b	Patented
T86734	DRUGINFO	D0G4YI	PMID30273516-Compound-1	Patented
T86734	DRUGINFO	D0KN6L	PMID30273516-Compound-15	Patented
T86734	DRUGINFO	D0KP4J	PMID30273516-Compound-41	Patented
T86734	DRUGINFO	D0P0ES	PMID30273516-Compound-40	Patented
T86734	DRUGINFO	D0YE0P	PMID30273516-Compound-14	Patented

T17710	TARGETID	T17710
T17710	FORMERID	TTDI02310
T17710	UNIPROID	HPT_HUMAN
T17710	TARGNAME	Haptoglobin (HP)
T17710	GENENAME	HP
T17710	TARGTYPE	Clinical trial
T17710	SYNONYMS	Haptoglobin beta chain; HP
T17710	FUNCTION	Uncleaved haptoglogin, also known as zonulin, plays a role in intestinal permeability, allowing intercellular tight junction disassembly, and controlling the equilibrium between tolerance and immunity to non-self antigens. {ECO:0000269|PubMed:21248165}.
T17710	PDBSTRUC	5HU6; 4X0L; 4WJG
T17710	BIOCLASS	Peptidase
T17710	SEQUENCE	MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRYQCKNYYKLRTEGDGVYTLNDKKQWINKAVGDKLPECEADDGCPKPPEIAHGYVEHSVRYQCKNYYKLRTEGDGVYTLNNEKQWINKAVGDKLPECEAVCGKPKNPANPVQRILGGHLDAKGSFPWQAKMVSHHNLTTGATLINEQWLLTTAKNLFLNHSENATAKDIAPTLTLYVGKKQLVEIEKVVLHPNYSQVDIGLIKLKQKVSVNERVMPICLPSKDYAEVGRVGYVSGWGRNANFKFTDHLKYVMLPVADQDQCIRHYEGSTVPEKKTPKSPVGVQPILNEHTFCAGMSKYQEDTCYGDAGSAFAVHDLEEDTWYATGILSFDKSCAVAEYGVYVKVTSIQDWVQKTIAEN
T17710	DRUGINFO	D00GZY	AT1001	Phase 3

T67364	TARGETID	T67364
T67364	FORMERID	TTDI01955
T67364	UNIPROID	STRP_STREQ
T67364	TARGNAME	Streptococcus Streptokinase (Stre-coc skc)
T67364	GENENAME	Stre-coc skc
T67364	TARGTYPE	Clinical trial
T67364	SYNONYMS	skc; Streptokinase C
T67364	FUNCTION	This protein is not a protease, but it activates plasminogen by complexing with it. As a potential virulence factor, it is thought to prevent the formation of effective fibrin barriers around the site of infection, thereby contributing to the invasiveness of the cells.
T67364	PDBSTRUC	1QQR; 1L4Z; 1L4D; 1BML
T67364	BIOCLASS	Staphylokinase streptokinase
T67364	SEQUENCE	MKNYLSFGMFALLFALTFGTVNSVQAIAGPEWLLDRPSVNNSQLVVSVAGTVEGTNQDISLKFFEIDLTSRPAHGGKTEQGLSPKSKPFATDSGAMSHKLEKADLLKAIQEQLIANVHSNDDYFEVIDFASDATITDRNGKVYFADKDGSVTLPTQPVQEFLLSGHVRVRPYKEKPIQNQAKSVDVEYTVQFTPLNPDDDFRPGLKDTKLLKTLAIGDTITSQELLAQAQSILNKNHPGYTIYERDSSIVTHDNDIFRTILPMDQEFTYRVKNREQAYRINKKSGLNEEINNTDLISEKYYVLKKGEKPYDPFDRSHLKLFTIKYVDVDTNELLKSEQLLTASERNLDFRDLYDPRDKAKLLYNNLDAFGIMDYTLTGKVEDNHDDTNRIITVYMGKRPEGENASYHLAYDKDRYTEEEREVYSYLRYTGTPIPDNPNDK
T67364	DRUGINFO	D0Y6DO	Streptokinase rectal suppository	Phase 3
T67364	DRUGINFO	D0X9PA	Heberkinasa	Investigative

T30731	TARGETID	T30731
T30731	FORMERID	TTDR00406
T30731	UNIPROID	KNG1_HUMAN
T30731	TARGNAME	Kininogen (KNG1)
T30731	GENENAME	KNG1
T30731	TARGTYPE	Clinical trial
T30731	SYNONYMS	KNG1; Bradykinin
T30731	FUNCTION	Kininogens are inhibitors of thiol proteases; hmw-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor xi next to factor xii; hmw-kininogen inhibits the thrombin-and plasmin- induced process.
T30731	PDBSTRUC	6F3Y; 6F3X; 6F3W; 6F3V; 6F27
T30731	SEQUENCE	MKLITILFLCSRLLLSLTQESQSEEIDCNDKDLFKAVDAALKKYNSQNQSNNQFVLYRITEATKTVGSDTFYSFKYEIKEGDCPVQSGKTWQDCEYKDAAKAATGECTATVGKRSSTKFSVATQTCQITPAEGPVVTAQYDCLGCVHPISTQSPDLEPILRHGIQYFNNNTQHSSLFMLNEVKRAQRQVVAGLNFRITYSIVQTNCSKENFLFLTPDCKSLWNGDTGECTDNAYIDIQLRIASFSQNCDIYPGKDFVQPPTKICVGCPRDIPTNSPELEETLTHTITKLNAENNATFYFKIDNVKKARVQVVAGKKYFIDFVARETTCSKESNEELTESCETKKLGQSLDCNAEVYVVPWEKKIYPTVNCQPLGMISLMKRPPGFSPFRSSRIGEIKEETTVSPPHTSMAPAQDEERDSGKEQGHTRRHDWGHEKQRKHNLGHGHKHERDQGHGHQRGHGLGHGHEQQHGLGHGHKFKLDDDLEHQGGHVLDHGHKHKHGHGHGKHKNKGKKNGKHNGWKTEHLASSSEDSTTPSAQTQEKTEGPTPIPSLAKPGVTVTFSDFQDSDLIATMMPPISPAPIQSDDDWIPDIQIDPNGLSFNPISDFPDTTSPKCPGRPWKSVSEINPTTQMKESYYFDLTDGLS
T30731	DRUGINFO	D0V4HO	Avoralstat	Phase 2/3
T30731	DRUGINFO	D05NMK	CU201 (B9870)	Investigative

T08156	TARGETID	T08156
T08156	FORMERID	TTDI02096
T08156	UNIPROID	IFNA5_HUMAN
T08156	TARGNAME	Interferon-alpha 5 (IFNA5)
T08156	GENENAME	IFNA5
T08156	TARGTYPE	Clinical trial
T08156	SYNONYMS	LeIF G; Interferon alphaG; Interferon alpha61; Interferon alpha5; Interferon alpha-G; Interferon alpha-61; Interferon alpha-5; IFNalpha5; IFN-alpha-5
T08156	FUNCTION	Interferon stimulates the production of two enzymes: a protein kinase and an oligoadenylate synthetase. Produced by macrophages, IFN-alpha have antiviral activities.
T08156	BIOCLASS	Cytokine: interferon
T08156	SEQUENCE	MALPFVLLMALVVLNCKSICSLGCDLPQTHSLSNRRTLMIMAQMGRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSATWDETLLDKFYTELYQQLNDLEACMMQEVGVEDTPLMNVDSILTVRKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSANLQERLRRKE
T08156	DRUGINFO	D0E1FP	Interferon alpha 5	Phase 1/2
T08156	DRUGINFO	D0F2WN	NAHE-001	Phase 1/2

T49146	TARGETID	T49146
T49146	FORMERID	TTDI01649
T49146	UNIPROID	DRA_HUMAN; 2B1F_HUMAN; DRB3_HUMAN; DRB4_HUMAN; DRB5_HUMAN
T49146	TARGNAME	MHC class II antigen DR (HLA-DR)
T49146	GENENAME	HLA-DRA; HLA-DRB1; HLA-DRB3; HLA-DRB4; HLA-DRB5
T49146	TARGTYPE	Clinical trial
T49146	SYNONYMS	HLA class II histocompatibility antigen
T49146	FUNCTION	Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of thiscomplex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class IImolecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DMand MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.
T49146	BIOCLASS	MHC class II
T49146	SEQUENCE	MAISGVPVLGFFIIAVLMSAQESWAIKEEHVIIQAEFYLNPDQSGEFMFDFDGDEIFHVDMAKKETVWRLEEFGRFASFEAQGALANIAVDKANLEIMTKRSNYTPITNVPPEVTVLTNSPVELREPNVLICFIDKFTPPVVNVTWLRNGKPVTTGVSETVFLPREDHLFRKFHYLPFLPSTEDVYDCRVEHWGLDEPLLKHWEFDAPSPLPETTENVVCALGLTVGLVGIIIGTIFIIKGVRKSNAAERRGPL
T49146	DRUGINFO	D0W6WC	Apolizumab	Phase 2
T49146	DRUGINFO	D0G7SM	AEA-35p	Phase 1
T49146	DRUGINFO	D0P5PD	IMMU-114	Phase 1

T85072	TARGETID	T85072
T85072	FORMERID	TTDI02207
T85072	UNIPROID	VE7_HPV16
T85072	TARGNAME	Human papillomavirus protein E7 (HPV E7)
T85072	GENENAME	HPV E7
T85072	TARGTYPE	Clinical trial
T85072	SYNONYMS	Protein E7; E7
T85072	FUNCTION	E7 protein has both transforming and trans-activating activities. Disrupts the function of host retinoblastoma protein RB1/pRb, which is a key regulator of the cell cycle. Induces the disassembly of the E2F1 transcription factors from RB1, with subsequent transcriptional activation of E2F1-regulated S-phase genes. Inactivation of the ability of RB1 to arrest the cell cycle is critical for cellular transformation, uncontrolled cellular growth and proliferation induced by viral infection. Stimulation of progression from G1 to S phase allows the virus to efficiently use the cellular DNA replicating machinery to achieve viral genome replication. Interferes with histone deacetylation mediated by HDAC1 and HDAC2, leading to activation of transcription.
T85072	PDBSTRUC	6APN; 4YOZ
T85072	BIOCLASS	Papillomaviridae E protein
T85072	SEQUENCE	MHGDTPTLHEYMLDLQPETTDLYCYEQLNDSSEEEDEIDGPAGQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIRTLEDLLMGTLGIVCPICSQKP
T85072	DRUGINFO	D00PMB	VGX-3100	Phase 3
T85072	DRUGINFO	D04FFM	ADXS-HPV	Phase 2
T85072	DRUGINFO	D0P9QW	Tipapkinogene sovacivec	Phase 2
T85072	DRUGINFO	D0M2YX	CIGB-228	Phase 1
T85072	DRUGINFO	DHMO41	KITE-439	Phase 1

T53640	TARGETID	T53640
T53640	FORMERID	TTDI01988
T53640	UNIPROID	HBSAG_HBVA3
T53640	TARGNAME	Hepatitis B virus Large envelope protein (HBV S)
T53640	GENENAME	HBV S
T53640	TARGTYPE	Clinical trial
T53640	SYNONYMS	Major surface antigen; Large surface protein; Large envelope protein; Large S protein; LHB; L-HBsAg; L glycoprotein
T53640	FUNCTION	The large envelope protein exists in two topological conformations, one which is termed 'external' or Le-HBsAg and the other 'internal' or Li-HBsAg. In its external conformation the protein attaches the virus to cell receptors and thereby initiating infection. This interaction determines the species specificity and liver tropism. This attachment induces virion internalization predominantly through caveolin-mediated endocytosis. The large envelope protein also assures fusion between virion membrane and endosomal membrane. In its internal conformation the protein plays a role in virion morphogenesis and mediates the contact with the nucleocapsid like a matrix protein.
T53640	BIOCLASS	Orthohepadnavirus major surface antigen
T53640	SEQUENCE	MGGWSSKPRKGMGTNLSVPNPLGFFPDHQLDPAFGANSNNPDWDFNPVKDDWPAANQVGVGAFGPRLTPPHGGILGWSPQAQGILTTVSTIPPPASTNRQSGRQPTPISPPLRDSHPQAMQWNSTAFHQTLQDPRVRGLYLPAGGSSSGTVNPAPNIASHISSISARTGDPVTNMENITSGFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGSPVCLGQNSQSPTSNHSPTSCPPICPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSTTTSTGPCKTCTTPAQGNSMFPSCCCTKPTDGNCTCIPIPSSWAFAKYLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSAIWMMWYWGPSLYSIVSPFIPLLPIFFCLWVYI
T53640	DRUGINFO	D07FND	Nabi-HB	Approved
T53640	DRUGINFO	D0U4SM	NASVAC	Phase 3

T13409	TARGETID	T13409
T13409	FORMERID	TTDI02209
T13409	UNIPROID	POL_HV1B1
T13409	TARGNAME	Human immunodeficiency virus Matrix p17 (HIV MA)
T13409	GENENAME	HIV MA
T13409	TARGTYPE	Clinical trial
T13409	SYNONYMS	gag
T13409	FUNCTION	p6-gag: Plays a role in budding of the assembled particle by interacting with the host class E VPS proteins TSG101 and PDCD6IP/AIP1.
T13409	PDBSTRUC	6OE3; 6HAK; 6ELI; 6DUH; 6DUG
T13409	SEQUENCE	GARASVLSGGELDRWEKIRLRPGGKKKYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQTGSEELRSLYNTVATLYCVHQRIEIKDTKEALDKIEEEQNKSKKKAQQAAADTGHSSQVSQNY
T13409	DRUGINFO	D05GBH	F4co vaccine	Phase 2

T88360	TARGETID	T88360
T88360	FORMERID	TTDI02133
T88360	UNIPROID	NCAP_HRSVA
T88360	TARGNAME	Respiratory syncytial virus protein N (RSV N)
T88360	GENENAME	RSV N
T88360	TARGTYPE	Clinical trial
T88360	SYNONYMS	RSV Protein N; RSV Nucleoprotein; RSV Nucleocapsid protein; N
T88360	FUNCTION	Encapsidates the genome, protecting it from nucleases. The nucleocapsid (NC) has a helical structure. The encapsidated genomic RNA is termed the NC and serves as template for transcription and replication. During replication, encapsidation by protein N is coupled to RNA synthesis and all replicative products are resistant to nucleases.
T88360	PDBSTRUC	4UCE; 4UCD; 4UCC; 4UCB; 4UCA
T88360	BIOCLASS	Paramyxoviruses nucleocapsid
T88360	SEQUENCE	MALSKVKLNDTLNKDQLLSSSKYTIQRSTGDSIDTPNYDVQKHINKLCGMLLITEDANHKFTGLIGMLYAMSRLGREDTIKILRDAGYHVKANGVDVTTHRQDINGKEMKFEVLTLASLTTEIQINIEIESRKSYKKMLKEMGEVAPEYRHDSPDCGMIILCIAALVITKLAAGDRSGLTAVIRRANNVLKNEMKRYKGLLPKDIANSFYEVFEKHPHFIDVFVHFGIAQSSTRGGSRVEGIFAGLFMNAYGAGQVMLRWGVLAKSVKNIMLGHASVQAEMEQVVEVYEYAQKLGGEAGFYHILNNPKASLLSLTQFPHFSSVVLGNAAGLGIMGEYRGTPRNQDLYDAAKAYAEQLKENGVINYSVLDLTAEELEAIKHQLNPKDNDVEL
T88360	DRUGINFO	D09KNG	RSV-604	Phase 2
T88360	DRUGINFO	DA08WU	EDP-938	Phase 2

T06869	TARGETID	T06869
T06869	FORMERID	TTDR01216
T06869	UNIPROID	PDGFA_HUMAN
T06869	TARGNAME	Platelet-derived growth factor A (PDGFA)
T06869	GENENAME	PDGFA
T06869	TARGTYPE	Clinical trial
T06869	SYNONYMS	Platelet-derived growth factor subunit A; Platelet-derived growth factor alpha polypeptide; Platelet-derived growth factor A chain; Platelet derived growth factor; PDGF1; PDGF-1; PDGF subunit A; PDGF; C-SIS oncogene
T06869	FUNCTION	Potent mitogen for cells of mesenchymal origin. Required for normal lung alveolar septum formation during embryogenesis, normal development of the gastrointestinal tract, normal development of Leydig cells and spermatogenesis. Required for normal oligodendrocyte development and normal myelination in the spinal cord and cerebellum. Plays an important role in wound healing. Signaling is modulated by the formation of heterodimers with PDGFB. Growth factor that plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis.
T06869	PDBSTRUC	3MJK
T06869	BIOCLASS	Growth factor
T06869	SEQUENCE	MRTLACLLLLGCGYLAHVLAEEAEIPREVIERLARSQIHSIRDLQRLLEIDSVGSEDSLDTSLRAHGVHATKHVPEKRPLPIRRKRSIEEAVPAVCKTRTVIYEIPRSQVDPTSANFLIWPPCVEVKRCTGCCNTSSVKCQPSRVHHRSVKVAKVEYVRKKPKLKEVQVRLEEHLECACATTSLNPDYREEDTGRPRESGKKRKRKRLKPT
T06869	DRUGINFO	D07PVB	Squalamine	Phase 3

T07533	TARGETID	T07533
T07533	FORMERID	TTDC00331
T07533	UNIPROID	APOB_HUMAN
T07533	TARGNAME	Apolipoprotein B-100 (APOB)
T07533	GENENAME	APOB
T07533	TARGTYPE	Clinical trial
T07533	SYNONYMS	Apolipoprotein B48; Apo B48; Apo B100; Apo B-100
T07533	FUNCTION	Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor. Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100).
T07533	BIOCLASS	Apolipoprotein
T07533	SEQUENCE	MDPPRPALLALLALPALLLLLLAGARAEEEMLENVSLVCPKDATRFKHLRKYTYNYEAESSSGVPGTADSRSATRINCKVELEVPQLCSFILKTSQCTLKEVYGFNPEGKALLKKTKNSEEFAAAMSRYELKLAIPEGKQVFLYPEKDEPTYILNIKRGIISALLVPPETEEAKQVLFLDTVYGNCSTHFTVKTRKGNVATEISTERDLGQCDRFKPIRTGISPLALIKGMTRPLSTLISSSQSCQYTLDAKRKHVAEAICKEQHLFLPFSYKNKYGMVAQVTQTLKLEDTPKINSRFFGEGTKKMGLAFESTKSTSPPKQAEAVLKTLQELKKLTISEQNIQRANLFNKLVTELRGLSDEAVTSLLPQLIEVSSPITLQALVQCGQPQCSTHILQWLKRVHANPLLIDVVTYLVALIPEPSAQQLREIFNMARDQRSRATLYALSHAVNNYHKTNPTGTQELLDIANYLMEQIQDDCTGDEDYTYLILRVIGNMGQTMEQLTPELKSSILKCVQSTKPSLMIQKAAIQALRKMEPKDKDQEVLLQTFLDDASPGDKRLAAYLMLMRSPSQADINKIVQILPWEQNEQVKNFVASHIANILNSEELDIQDLKKLVKEALKESQLPTVMDFRKFSRNYQLYKSVSLPSLDPASAKIEGNLIFDPNNYLPKESMLKTTLTAFGFASADLIEIGLEGKGFEPTLEALFGKQGFFPDSVNKALYWVNGQVPDGVSKVLVDHFGYTKDDKHEQDMVNGIMLSVEKLIKDLKSKEVPEARAYLRILGEELGFASLHDLQLLGKLLLMGARTLQGIPQMIGEVIRKGSKNDFFLHYIFMENAFELPTGAGLQLQISSSGVIAPGAKAGVKLEVANMQAELVAKPSVSVEFVTNMGIIIPDFARSGVQMNTNFFHESGLEAHVALKAGKLKFIIPSPKRPVKLLSGGNTLHLVSTTKTEVIPPLIENRQSWSVCKQVFPGLNYCTSGAYSNASSTDSASYYPLTGDTRLELELRPTGEIEQYSVSATYELQREDRALVDTLKFVTQAEGAKQTEATMTFKYNRQSMTLSSEVQIPDFDVDLGTILRVNDESTEGKTSYRLTLDIQNKKITEVALMGHLSCDTKEERKIKGVISIPRLQAEARSEILAHWSPAKLLLQMDSSATAYGSTVSKRVAWHYDEEKIEFEWNTGTNVDTKKMTSNFPVDLSDYPKSLHMYANRLLDHRVPQTDMTFRHVGSKLIVAMSSWLQKASGSLPYTQTLQDHLNSLKEFNLQNMGLPDFHIPENLFLKSDGRVKYTLNKNSLKIEIPLPFGGKSSRDLKMLETVRTPALHFKSVGFHLPSREFQVPTFTIPKLYQLQVPLLGVLDLSTNVYSNLYNWSASYSGGNTSTDHFSLRARYHMKADSVVDLLSYNVQGSGETTYDHKNTFTLSYDGSLRHKFLDSNIKFSHVEKLGNNPVSKGLLIFDASSSWGPQMSASVHLDSKKKQHLFVKEVKIDGQFRVSSFYAKGTYGLSCQRDPNTGRLNGESNLRFNSSYLQGTNQITGRYEDGTLSLTSTSDLQSGIIKNTASLKYENYELTLKSDTNGKYKNFATSNKMDMTFSKQNALLRSEYQADYESLRFFSLLSGSLNSHGLELNADILGTDKINSGAHKATLRIGQDGISTSATTNLKCSLLVLENELNAELGLSGASMKLTTNGRFREHNAKFSLDGKAALTELSLGSAYQAMILGVDSKNIFNFKVSQEGLKLSNDMMGSYAEMKFDHTNSLNIAGLSLDFSSKLDNIYSSDKFYKQTVNLQLQPYSLVTTLNSDLKYNALDLTNNGKLRLEPLKLHVAGNLKGAYQNNEIKHIYAISSAALSASYKADTVAKVQGVEFSHRLNTDIAGLASAIDMSTNYNSDSLHFSNVFRSVMAPFTMTIDAHTNGNGKLALWGEHTGQLYSKFLLKAEPLAFTFSHDYKGSTSHHLVSRKSISAALEHKVSALLTPAEQTGTWKLKTQFNNNEYSQDLDAYNTKDKIGVELTGRTLADLTLLDSPIKVPLLLSEPINIIDALEMRDAVEKPQEFTIVAFVKYDKNQDVHSINLPFFETLQEYFERNRQTIIVVLENVQRNLKHINIDQFVRKYRAALGKLPQQANDYLNSFNWERQVSHAKEKLTALTKKYRITENDIQIALDDAKINFNEKLSQLQTYMIQFDQYIKDSYDLHDLKIAIANIIDEIIEKLKSLDEHYHIRVNLVKTIHDLHLFIENIDFNKSGSSTASWIQNVDTKYQIRIQIQEKLQQLKRHIQNIDIQHLAGKLKQHIEAIDVRVLLDQLGTTISFERINDILEHVKHFVINLIGDFEVAEKINAFRAKVHELIERYEVDQQIQVLMDKLVELAHQYKLKETIQKLSNVLQQVKIKDYFEKLVGFIDDAVKKLNELSFKTFIEDVNKFLDMLIKKLKSFDYHQFVDETNDKIREVTQRLNGEIQALELPQKAEALKLFLEETKATVAVYLESLQDTKITLIINWLQEALSSASLAHMKAKFRETLEDTRDRMYQMDIQQELQRYLSLVGQVYSTLVTYISDWWTLAAKNLTDFAEQYSIQDWAKRMKALVEQGFTVPEIKTILGTMPAFEVSLQALQKATFQTPDFIVPLTDLRIPSVQINFKDLKNIKIPSRFSTPEFTILNTFHIPSFTIDFVEMKVKIIRTIDQMLNSELQWPVPDIYLRDLKVEDIPLARITLPDFRLPEIAIPEFIIPTLNLNDFQVPDLHIPEFQLPHISHTIEVPTFGKLYSILKIQSPLFTLDANADIGNGTTSANEAGIAASITAKGESKLEVLNFDFQANAQLSNPKINPLALKESVKFSSKYLRTEHGSEMLFFGNAIEGKSNTVASLHTEKNTLELSNGVIVKINNQLTLDSNTKYFHKLNIPKLDFSSQADLRNEIKTLLKAGHIAWTSSGKGSWKWACPRFSDEGTHESQISFTIEGPLTSFGLSNKINSKHLRVNQNLVYESGSLNFSKLEIQSQVDSQHVGHSVLTAKGMALFGEGKAEFTGRHDAHLNGKVIGTLKNSLFFSAQPFEITASTNNEGNLKVRFPLRLTGKIDFLNNYALFLSPSAQQASWQVSARFNQYKYNQNFSAGNNENIMEAHVGINGEANLDFLNIPLTIPEMRLPYTIITTPPLKDFSLWEKTGLKEFLKTTKQSFDLSVKAQYKKNKHRHSITNPLAVLCEFISQSIKSFDRHFEKNRNNALDFVTKSYNETKIKFDKYKAEKSHDELPRTFQIPGYTVPVVNVEVSPFTIEMSAFGYVFPKAVSMPSFSILGSDVRVPSYTLILPSLELPVLHVPRNLKLSLPDFKELCTISHIFIPAMGNITYDFSFKSSVITLNTNAELFNQSDIVAHLLSSSSSVIDALQYKLEGTTRLTRKRGLKLATALSLSNKFVEGSHNSTVSLTTKNMEVSVATTTKAQIPILRMNFKQELNGNTKSKPTVSSSMEFKYDFNSSMLYSTAKGAVDHKLSLESLTSYFSIESSTKGDVKGSVLSREYSGTIASEANTYLNSKSTRSSVKLQGTSKIDDIWNLEVKENFAGEATLQRIYSLWEHSTKNHLQLEGLFFTNGEHTSKATLELSPWQMSALVQVHASQPSSFHDFPDLGQEVALNANTKNQKIRWKNEVRIHSGSFQSQVELSNDQEKAHLDIAGSLEGHLRFLKNIILPVYDKSLWDFLKLDVTTSIGRRQHLRVSTAFVYTKNPNGYSFSIPVKVLADKFIIPGLKLNDLNSVLVMPTFHVPFTDLQVPSCKLDFREIQIYKKLRTSSFALNLPTLPEVKFPEVDVLTKYSQPEDSLIPFFEITVPESQLTVSQFTLPKSVSDGIAALDLNAVANKIADFELPTIIVPEQTIEIPSIKFSVPAGIVIPSFQALTARFEVDSPVYNATWSASLKNKADYVETVLDSTCSSTVQFLEYELNVLGTHKIEDGTLASKTKGTFAHRDFSAEYEEDGKYEGLQEWEGKAHLNIKSPAFTDLHLRYQKDKKGISTSAASPAVGTVGMDMDEDDDFSKWNFYYSPQSSPDKKLTIFKTELRVRESDEETQIKVNWEEEAASGLLTSLKDNVPKATGVLYDYVNKYHWEHTGLTLREVSSKLRRNLQNNAEWVYQGAIRQIDDIDVRFQKAASGTTGTYQEWKDKAQNLYQELLTQEGQASFQGLKDNVFDGLVRVTQEFHMKVKHLIDSLIDFLNFPRFQFPGKPGIYTREELCTMFIREVGTVLSQVYSKVHNGSEILFSYFQDLVITLPFELRKHKLIDVISMYRELLKDLSKEAQEVFKAIQSLKTTEVLRNLQDLLQFIFQLIEDNIKQLKEMKFTYLINYIQDEINTIFSDYIPYVFKLLKENLCLNLHKFNEFIQNELQEASQELQQIHQYIMALREEYFDPSIVGWTVKYYELEEKIVSLIKNLLVALKDFHSEYIVSASNFTSQLSSQVEQFLHRNIQEYLSILTDPDGKGKEKIAELSATAQEIIKSQAIATKKIISDYHQQFRYKLQDFSDQLSDYYEKFIAESKRLIDLSIQNYHTFLIYITELLKKLQSTTVMNPYMKLAPGELTIIL
T07533	DRUGINFO	D0X1IL	SPC4955	Phase 1

T38159	TARGETID	T38159
T38159	FORMERID	TTDI02188
T38159	UNIPROID	TFF1_HUMAN
T38159	TARGNAME	Trefoil factor-1 (TFF1)
T38159	GENENAME	TFF1
T38159	TARGTYPE	Clinical trial
T38159	SYNONYMS	hP1.A; Trefoil factor 1; Protein pS2; Polypeptide P1.A; PS2; PNR-2; Breast cancer estrogen-inducible protein; BCEI
T38159	FUNCTION	May inhibit the growth of calcium oxalate crystals in urine. Stabilizer of the mucous gel overlying the gastrointestinal mucosa that provides a physical barrier against various noxious agents.
T38159	PDBSTRUC	1PS2; 1HI7
T38159	SEQUENCE	MATMENKVICALVLVSMLALGTLAEAQTETCTVAPRERQNCGFPGVTPSQCANKGCCFDDTVRGVPWCFYPNTIDVPPEEECEF
T38159	DRUGINFO	D0IJ0F	AG-013	Phase 2/3

T08231	TARGETID	T08231
T08231	FORMERID	TTDI02091
T08231	UNIPROID	HG2A_HUMAN
T08231	TARGNAME	HLA-DR antigens-associated invariant (CD74)
T08231	GENENAME	CD74
T08231	TARGTYPE	Clinical trial
T08231	SYNONYMS	Ii; Ia antigenassociated invariant chain; Ia antigen-associated invariant chain; HLADR antigensassociated invariant chain; HLA-DR antigens-associated invariant chain; HLA class II histocompatibility antigen gamma chain; DHLAG
T08231	FUNCTION	Serves as cell surface receptor for the cytokine MIF. Plays a critical role in MHC class II antigen processing by stabilizing peptide-free class II alpha/beta heterodimers in a complex soon after their synthesis and directing transport of the complex from the endoplasmic reticulum to the endosomal/lysosomal system where the antigen processing and binding of antigenic peptides to MHC class II takes place.
T08231	PDBSTRUC	5KSV; 5KSU; 4X5W; 4AH2; 4AEN
T08231	SEQUENCE	MHRRRSRSCREDQKPVMDDQRDLISNNEQLPMLGRRPGAPESKCSRGALYTGFSILVTLLLAGQATTAYFLYQQQGRLDKLTVTSQNLQLENLRMKLPKPPKPVSKMRMATPLLMQALPMGALPQGPMQNATKYGNMTEDHVMHLLQNADPLKVYPPLKGSFPENLRHLKNTMETIDWKVFESWMHHWLLFEMSRHSLEQKPTDAPPKVLTKCQEEVSHIPAVHPGSFRPKCDENGNYLPLQCYGSIGYCWCVFPNGTEVPNTRSRGHHNCSESLELEDPSSGLGVTKQDLGPVPM
T08231	DRUGINFO	D08SIF	Milatuzumab	Phase 1/2

T87206	TARGETID	T87206
T87206	FORMERID	TTDI02165
T87206	UNIPROID	S100B_HUMAN
T87206	TARGNAME	S100 calcium-binding protein B (S100B)
T87206	GENENAME	S100B
T87206	TARGTYPE	Clinical trial
T87206	SYNONYMS	S-100 protein subunit beta; S-100 protein beta chain; Protein S100-B
T87206	FUNCTION	Physiological concentrations of potassium ion antagonize the binding of both divalent cations, especially affecting high-affinity calcium-binding sites. Binds to and initiates the activation of STK38 by releasing autoinhibitory intramolecular interactions within the kinase. Interaction with AGER after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling. Could assist ATAD3A cytoplasmic processing, preventing aggregation and favoring mitochondrial localization. May mediate calcium-dependent regulation on many physiological processes by interacting with other proteins, such as TPR-containing proteins, and modulating their activity. Weakly binds calcium but binds zinc very tightly-distinct binding sites with different affinities exist for both ions on each monomer.
T87206	PDBSTRUC	5D7F; 5CSN; 5CSJ; 5CSI; 5CSF
T87206	BIOCLASS	S100 calcium-binding protein
T87206	SEQUENCE	MSELEKAMVALIDVFHQYSGREGDKHKLKKSELKELINNELSHFLEEIKEQEVVDKVMETLDNDGDGECDFQEFMAFVAMVTTACHEFFEHE
T87206	DRUGINFO	D00GZW	ONO-2506	Phase 2/3

T93627	TARGETID	T93627
T93627	FORMERID	TTDI01920
T93627	UNIPROID	GAG_HV1H2
T93627	TARGNAME	Human immunodeficiency virus GAG protein (HIV gag)
T93627	GENENAME	HIV gag
T93627	TARGTYPE	Clinical trial
T93627	SYNONYMS	Pr55Gag; Gag polyprotein
T93627	FUNCTION	Gag polyprotein: Mediates, with Gag-Pol polyprotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi).
T93627	PDBSTRUC	6CQR; 6CQQ; 6CQN; 6CQL; 6CQJ
T93627	SEQUENCE	MGARASVLSGGELDRWEKIRLRPGGKKKYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQTGSEELRSLYNTVATLYCVHQRIEIKDTKEALDKIEEEQNKSKKKAQQAAADTGHSNQVSQNYPIVQNIQGQMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAAEWDRVHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKARVLAEAMSQVTNSATIMMQRGNFRNQRKIVKCFNCGKEGHTARNCRAPRKKGCWKCGKEGHQMKDCTERQANFLGKIWPSYKGRPGNFLQSRPEPTAPPEESFRSGVETTTPPQKQEPIDKELYPLTSLRSLFGNDPSSQ
T93627	DRUGINFO	D04MPB	Bevirimat	Phase 2
T93627	DRUGINFO	D0R0SP	LIPO-5	Phase 2
T93627	DRUGINFO	D0W9IH	Ad35-GRIN	Phase 1/2
T93627	DRUGINFO	D07LCY	RVSVIN HIV-1 gag vaccine	Phase 1
T93627	DRUGINFO	D0W1MU	TBC-M4	Phase 1
T93627	DRUGINFO	D09ZKB	Ad35-GRIN/ENV	Phase 1
T93627	DRUGINFO	D02ESK	GSK-732461	Discontinued in Phase 2
T93627	DRUGINFO	D08LDV	PA-1050040	Discontinued in Phase 1
T93627	DRUGINFO	D0AP4O	Gem 92	Discontinued in Phase 1
T93627	DRUGINFO	D0F8TS	MPC-9055	Discontinued in Phase 1
T93627	DRUGINFO	D03PCJ	MPI-461359	Terminated

T39921	TARGETID	T39921
T39921	FORMERID	TTDR01151
T39921	UNIPROID	HSPB1_HUMAN
T39921	TARGNAME	Heat shock protein 20 (HSP20)
T39921	GENENAME	HSPB1
T39921	TARGTYPE	Clinical trial
T39921	SYNONYMS	Stress-responsive protein 27; SRP27; HspB1; Heat shock protein beta-1; Heat shock 27 kDa protein; HSP28; HSP27; HSP 27; Estrogen-regulated 24 kDa protein; 28 kDa heat shock protein
T39921	FUNCTION	Small heat shock protein which functions as a molecular chaperone probably maintaining denatured proteins in a folding-competent state. Plays a role in stress resistance and actin organization. Through its molecular chaperone activity may regulate numerous biological processes including the phosphorylation and the axonal transport of neurofilament proteins.
T39921	PDBSTRUC	4MJH; 3Q9Q; 3Q9P; 2N3J
T39921	BIOCLASS	Heat shock protein
T39921	SEQUENCE	MTERRVPFSLLRGPSWDPFRDWYPHSRLFDQAFGLPRLPEEWSQWLGGSSWPGYVRPLPPAAIESPAVAAPAYSRALSRQLSSGVSEIRHTADRWRVSLDVNHFAPDELTVKTKDGVVEITGKHEERQDEHGYISRCFTRKYTLPPGVDPTQVSSSLSPEGTLTVEAPMPKLATQSNEITIPVTFESRAQLGGPEAAKSDETAAK
T39921	DRUGINFO	D09IGR	AZX-100	Phase 2

T40909	TARGETID	T40909
T40909	FORMERID	TTDI01645
T40909	UNIPROID	POLG_HRV2
T40909	TARGNAME	Rhinovirus Protease 3C (HRV P3C)
T40909	GENENAME	HRV P3C
T40909	TARGTYPE	Clinical trial
T40909	SYNONYMS	Rhinovirus P3C
T40909	FUNCTION	Capsid protein VP1: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host VLDLR to provide virion attachment to target host cells. This attachment induces virion internalization. Tyrosine kinases are probably involved in the entry process. After binding to its receptor, the capsid undergoes conformational changes. Capsid protein VP1 N-terminus (that contains an amphipathic alpha-helix) and capsid protein VP4 are externalized. Together, they shape a pore in the host membrane through which viral genome is translocated to host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).
T40909	PDBSTRUC	6FFS; 6FFN; 5FX6; 5FX5; 4L3B
T40909	ECNUMBER	EC 3.4.22.28
T40909	SEQUENCE	MSLIKHNSCVITTENGKFTGLGVYDRFVVVPTHADPGKEIQVDGITTKVIDSYDLYNKNGIKLEITVLKLDRNEKFRDIRRYIPNNEDDYPNCNLALLANQPEPTIINVGDVVSYGNILLSGNQTARMLKYSYPTKSGYCGGVLYKIGQVLGIHVGGNGRDGFSAMLLRSYFTDVQGQITLS
T40909	DRUGINFO	D0S0SE	Rupintrivir	Phase 2

T11947	TARGETID	T11947
T11947	FORMERID	TTDI01939
T11947	UNIPROID	F13B_HUMAN
T11947	TARGNAME	Coagulation factor XIII (F13B)
T11947	GENENAME	F13B
T11947	TARGTYPE	Clinical trial
T11947	SYNONYMS	F13B
T11947	FUNCTION	Factor XIII is activated by thrombin and calcium ion to a transglutaminase that catalyzes the formation of gamma-glutamyl- epsilon-lysine cross-links between fibrin chains, thus stabilizing the fibrin clot. Also cross-link alpha-2-plasmin inhibitor, or fibronectin, to the alpha chains of fibrin.
T11947	BIOCLASS	Acyltransferase
T11947	SEQUENCE	MRLKNLTFIIILIISGELYAEEKPCGFPHVENGRIAQYYYTFKSFYFPMSIDKKLSFFCLAGYTTESGRQEEQTTCTTEGWSPEPRCFKKCTKPDLSNGYISDVKLLYKIQENMRYGCASGYKTTGGKDEEVVQCLSDGWSSQPTCRKEHETCLAPELYNGNYSTTQKTFKVKDKVQYECATGYYTAGGKKTEEVECLTYGWSLTPKCTKLKCSSLRLIENGYFHPVKQTYEEGDVVQFFCHENYYLSGSDLIQCYNFGWYPESPVCEGRRNRCPPPPLPINSKIQTHSTTYRHGEIVHIECELNFEIHGSAEIRCEDGKWTEPPKCIEGQEKVACEEPPFIENGAANLHSKIYYNGDKVTYACKSGYLLHGSNEITCNRGKWTLPPECVENNENCKHPPVVMNGAVADGILASYATGSSVEYRCNEYYLLRGSKISRCEQGKWSSPPVCLEPCTVNVDYMNRNNIEMKWKYEGKVLHGDLIDFVCKQGYDLSPLTPLSELSVQCNRGEVKYPLCTRKESKGMCTSPPLIKHGVIISSTVDTYENGSSVEYRCFDHHFLEGSREAYCLDGMWTTPPLCLEPCTLSFTEMEKNNLLLKWDFDNRPHILHGEYIEFICRGDTYPAELYITGSILRMQCDRGQLKYPRCIPRQSTLSYQEPLRT
T11947	DRUGINFO	D0V2OL	NN1841	Phase 3
T11947	DRUGINFO	D0X3GA	NN8717	Phase 3
T11947	DRUGINFO	D0QF6E	Tridegin	Terminated

T82958	TARGETID	T82958
T82958	FORMERID	TTDI02077
T82958	UNIPROID	GB_HCMVA
T82958	TARGNAME	Cytomegalovirus Glycoprotein B (CMV gB)
T82958	GENENAME	CMV gB
T82958	TARGTYPE	Clinical trial
T82958	SYNONYMS	gB; Envelope glycoprotein B
T82958	FUNCTION	Viral ligand for CD209/DC-SIGN. This interaction allows capture of viral particles by dendritic (DCs) cells and subsequent virus transmission to permissive cells. DCs are professional antigen presenting cells, critical for host immunity by inducing specific immune responses against a broad variety of pathogens. They act as sentinels in various tissues where they entrap pathogens and convey them to local lymphoid tissue or lymph node for establishment of immunity. CMV subverts the migration properties of dendritic cells to gain access to target organs or susceptible cells.
T82958	PDBSTRUC	5CXF
T82958	BIOCLASS	Hepacivirus polyprotein
T82958	SEQUENCE	MESRIWCLVVCVNLCIVCLGAAVSSSSTSHATSSTHNGSHTSRTTSAQTRSVYSQHVTSSEAVSHRANETIYNTTLKYGDVVGVNTTKYPYRVCSMAQGTDLIRFERNIICTSMKPINEDLDEGIMVVYKRNIVAHTFKVRVYQKVLTFRRSYAYIYTTYLLGSNTEYVAPPMWEIHHINKFAQCYSSYSRVIGGTVFVAYHRDSYENKTMQLIPDDYSNTHSTRYVTVKDQWHSRGSTWLYRETCNLNCMLTITTARSKYPYHFFATSTGDVVYISPFYNGTNRNASYFGENADKFFIFPNYTIVSDFGRPNAAPETHRLVAFLERADSVISWDIQDEKNVTCQLTFWEASERTIRSEAEDSYHFSSAKMTATFLSKKQEVNMSDSALDCVRDEAINKLQQIFNTSYNQTYEKYGNVSVFETSGGLVVFWQGIKQKSLVELERLANRSSLNITHRTRRSTSDNNTTHLSSMESVHNLVYAQLQFTYDTLRGYINRALAQIAEAWCVDQRRTLEVFKELSKINPSAILSAIYNKPIAARFMGDVLGLASCVTINQTSVKVLRDMNVKESPGRCYSRPVVIFNFANSSYVQYGQLGEDNEILLGNHRTEECQLPSLKIFIAGNSAYEYVDYLFKRMIDLSSISTVDSMIALDIDPLENTDFRVLELYSQKELRSSNVFDLEEIMREFNSYKQRVKYVEDKVVDPLPPYLKGLDDLMSGLGAAGKAVGVAIGAVGGAVASVVEGVATFLKNPFGAFTIILVAIAVVIITYLIYTRQRRLCTQPLQNLFPYLVSADGTTVTSGSTKDTSLQAPPSYEESVYNSGRKGPGPPSSDASTAAPPYTNEQAYQMLLALARLDAEQRAQQNGTDSLDGQTGTQDKGQKPNLLDRLRHRKNGYRHLKDSDEEENV
T82958	DRUGINFO	D0V6KU	CMV glycoprotein B subunit vaccine	Phase 1

T02532	TARGETID	T02532
T02532	FORMERID	TTDS00368
T02532	UNIPROID	CD2_HUMAN
T02532	TARGNAME	T-cell surface antigen CD2 (CD2)
T02532	GENENAME	CD2
T02532	TARGTYPE	Clinical trial
T02532	SYNONYMS	T-cell surface antigen T11/Leu-5; SRBC; Rosette receptor; LFA-3 receptor; LFA-2; Erythrocyte receptor
T02532	FUNCTION	CD2 is implicated in the triggering of T-cells, the cytoplasmic domain is implicated in the signaling function. CD2 interacts with lymphocyte function-associated antigen CD58 (LFA-3) and CD48/BCM1 to mediate adhesion between T-cells and other cell types.
T02532	PDBSTRUC	2J7I; 2J6O; 1QA9; 1L2Z; 1HNF
T02532	SEQUENCE	MSFPCKFVASFLLIFNVSSKGAVSKEITNALETWGALGQDINLDIPSFQMSDDIDDIKWEKTSDKKKIAQFRKEKETFKEKDTYKLFKNGTLKIKHLKTDDQDIYKVSIYDTKGKNVLEKIFDLKIQERVSKPKISWTCINTTLTCEVMNGTDPELNLYQDGKHLKLSQRVITHKWTTSLSAKFKCTAGNKVSKESSVEPVSCPEKGLDIYLIIGICGGGSLLMVFVALLVFYITKRKKQRSRRNDEELETRAHRVATEERGRKPHQIPASTPQNPATSQHPPPPPGHRSQAPSHRPPPPGHRVQHQPQKRPPAPSGTQVHQQKGPPLPRPRVQPKPPHGAAENSLSPSSN
T02532	DRUGINFO	D0A7NB	Siplizumab	Phase 2
T02532	DRUGINFO	D06FTK	Cyclo(1,12)PenIYDTKGKNVLC-OH	Investigative
T02532	DRUGINFO	D0D6MO	Pen(Acm)AQFRKEKETFC(Acm)-OH	Investigative
T02532	DRUGINFO	D0GC3E	Cyclo(1,11)H-ESIYDPGDDIK-OH	Investigative
T02532	DRUGINFO	D0GD1A	Cyclo(1,10)H-EIYDPGDDIK-OH	Investigative
T02532	DRUGINFO	D0TL3X	Cyclo(1,10)EIYDPGDDIK	Investigative
T02532	DRUGINFO	D07LUR	Alpha-D-Mannose	Investigative

T45591	TARGETID	T45591
T45591	FORMERID	TTDI02137
T45591	UNIPROID	NPM_HUMAN
T45591	TARGNAME	Nucleophosmin (NPM1)
T45591	GENENAME	NPM1
T45591	TARGTYPE	Clinical trial
T45591	SYNONYMS	Numatrin; Nucleolar protein NO38; Nucleolar phosphoprotein B23; NPM
T45591	FUNCTION	Binds ribosome presumably to drive ribosome nuclear export. Associated with nucleolar ribonucleoprotein structures and bind single-stranded nucleic acids. Acts as a chaperonin for the core histones H3, H2B and H4. Stimulates APEX1 endonuclease activity on apurinic/apyrimidinic (AP) double-stranded DNA but inhibits APEX1 endonuclease activity on AP single-stranded RNA. May exert a control of APEX1 endonuclease activity within nucleoli devoted to repair AP on rDNA and the removal of oxidized rRNA molecules. In concert with BRCA2, regulates centrosome duplication. Regulates centriole duplication: phosphorylation by PLK2 is able to trigger centriole replication. Negatively regulates the activation of EIF2AK2/PKR and suppresses apoptosis through inhibition of EIF2AK2/PKR autophosphorylation. Antagonizes the inhibitory effect of ATF5 on cell proliferation and relieves ATF5-induced G2/M blockade. In complex with MYC enhances the transcription of MYC target genes. Involved in diverse cellular processes such as ribosome biogenesis, centrosome duplication, protein chaperoning, histone assembly, cell proliferation, and regulation of tumor suppressors p53/TP53 and ARF.
T45591	PDBSTRUC	5EHD; 2VXD; 2P1B; 2LLH
T45591	SEQUENCE	MEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDELHIVEAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVAVEEDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDDDDFDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTPKGPSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL
T45591	DRUGINFO	D0Z1OR	IPP-204106	Phase 1/2

T32780	TARGETID	T32780
T32780	UNIPROID	ASGR1_HUMAN
T32780	TARGNAME	Asialoglycoprotein receptor 1 (ASGR1)
T32780	GENENAME	ASGR1
T32780	TARGTYPE	Clinical trial
T32780	SYNONYMS	Hepatic lectin H1; HL-1; C-type lectin domain family 4 member H1
T32780	FUNCTION	Mediates the endocytosis of plasma glycoproteins to which the terminal sialic acid residue on their complex carbohydrate moieties has been removed. The receptor recognizes terminal galactose and N-acetylgalactosamine units. After ligand binding to the receptor, the resulting complex is internalized and transported to a sorting organelle, where receptor and ligand are disassociated. The receptor then returns to the cell membrane surface.
T32780	PDBSTRUC	5JQ1; 5JPV; 1DV8
T32780	SEQUENCE	MTKEYQDLQHLDNEESDHHQLRKGPPPPQPLLQRLCSGPRLLLLSLGLSLLLLVVVCVIGSQNSQLQEELRGLRETFSNFTASTEAQVKGLSTQGGNVGRKMKSLESQLEKQQKDLSEDHSSLLLHVKQFVSDLRSLSCQMAALQGNGSERTCCPVNWVEHERSCYWFSRSGKAWADADNYCRLEDAHLVVVTSWEEQKFVQHHIGPVNTWMGLHDQNGPWKWVDGTDYETGFKNWRPEQPDDWYGHGLGGGEDCAHFTDDGRWNDDVCQRPYRWVCETELDKASQEPPLL
T32780	DRUGINFO	D09ZFJ	AMG 529	Phase 1

T17427	TARGETID	T17427
T17427	FORMERID	TTDI02083
T17427	UNIPROID	GP1BA_HUMAN
T17427	TARGNAME	Platelet glycoprotein Ib alpha (CD42b)
T17427	GENENAME	GP1BA
T17427	TARGTYPE	Clinical trial
T17427	SYNONYMS	Platelet glycoprotein Ib alpha chain; Glycoprotein Ibalpha; Glycocalicin; GPIbalpha; GPIbA; GPIb-alpha; GPIb alpha; GP-Ib alpha; Antigen CD42balpha; Antigen CD42b-alpha
T17427	FUNCTION	GP-Ib, a surface membrane protein of platelets, participates in the formation of platelet plugs by binding to the A1 domain of vWF, which is already bound to the subendothelium.
T17427	PDBSTRUC	4YR6; 4MGX; 4CH8; 4CH2; 4C2B
T17427	SEQUENCE	MPLLLLLLLLPSPLHPHPICEVSKVASHLEVNCDKRNLTALPPDLPKDTTILHLSENLLYTFSLATLMPYTRLTQLNLDRCELTKLQVDGTLPVLGTLDLSHNQLQSLPLLGQTLPALTVLDVSFNRLTSLPLGALRGLGELQELYLKGNELKTLPPGLLTPTPKLEKLSLANNNLTELPAGLLNGLENLDTLLLQENSLYTIPKGFFGSHLLPFAFLHGNPWLCNCEILYFRRWLQDNAENVYVWKQGVDVKAMTSNVASVQCDNSDKFPVYKYPGKGCPTLGDEGDTDLYDYYPEEDTEGDKVRATRTVVKFPTKAHTTPWGLFYSWSTASLDSQMPSSLHPTQESTKEQTTFPPRWTPNFTLHMESITFSKTPKSTTEPTPSPTTSEPVPEPAPNMTTLEPTPSPTTPEPTSEPAPSPTTPEPTSEPAPSPTTPEPTSEPAPSPTTPEPTPIPTIATSPTILVSATSLITPKSTFLTTTKPVSLLESTKKTIPELDQPPKLRGVLQGHLESSRNDPFLHPDFCCLLPLGFYVLGLFWLLFASVVLILLLSWVGHVKPQALDSGQGAALTTATQTTHLELQRGRQVTVPRAWLLFLRGSLPTFRSSLFLWVRPNGRVGPLVAGRRPSALSQGRGQDLLSTVSIRYSGHSL
T17427	DRUGINFO	D02TDV	ZK-001	Phase 1/2
T17427	DRUGINFO	D05HFU	TGX-6B4	Preclinical

T30784	TARGETID	T30784
T30784	FORMERID	TTDI02201
T30784	UNIPROID	TSP1_HUMAN
T30784	TARGNAME	Thrombospondin-1 (THBS1)
T30784	GENENAME	THBS1
T30784	TARGTYPE	Clinical trial
T30784	SYNONYMS	TSP1; TSP; Glycoprotein G
T30784	FUNCTION	Binds heparin. May play a role in dentinogenesis and/or maintenance of dentin and dental pulp. Ligand for CD36 mediating antiangiogenic properties. Plays a role in ER stress response, via its interaction with the activating transcription factor 6 alpha (ATF6) which produces adaptive ER stress response factors. Adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions.
T30784	PDBSTRUC	5FOE; 3R6B; 2OUJ; 2OUH; 2ES3
T30784	SEQUENCE	MGLAWGLGVLFLMHVCGTNRIPESGGDNSVFDIFELTGAARKGSGRRLVKGPDPSSPAFRIEDANLIPPVPDDKFQDLVDAVRAEKGFLLLASLRQMKKTRGTLLALERKDHSGQVFSVVSNGKAGTLDLSLTVQGKQHVVSVEEALLATGQWKSITLFVQEDRAQLYIDCEKMENAELDVPIQSVFTRDLASIARLRIAKGGVNDNFQGVLQNVRFVFGTTPEDILRNKGCSSSTSVLLTLDNNVVNGSSPAIRTNYIGHKTKDLQAICGISCDELSSMVLELRGLRTIVTTLQDSIRKVTEENKELANELRRPPLCYHNGVQYRNNEEWTVDSCTECHCQNSVTICKKVSCPIMPCSNATVPDGECCPRCWPSDSADDGWSPWSEWTSCSTSCGNGIQQRGRSCDSLNNRCEGSSVQTRTCHIQECDKRFKQDGGWSHWSPWSSCSVTCGDGVITRIRLCNSPSPQMNGKPCEGEARETKACKKDACPINGGWGPWSPWDICSVTCGGGVQKRSRLCNNPTPQFGGKDCVGDVTENQICNKQDCPIDGCLSNPCFAGVKCTSYPDGSWKCGACPPGYSGNGIQCTDVDECKEVPDACFNHNGEHRCENTDPGYNCLPCPPRFTGSQPFGQGVEHATANKQVCKPRNPCTDGTHDCNKNAKCNYLGHYSDPMYRCECKPGYAGNGIICGEDTDLDGWPNENLVCVANATYHCKKDNCPNLPNSGQEDYDKDGIGDACDDDDDNDKIPDDRDNCPFHYNPAQYDYDRDDVGDRCDNCPYNHNPDQADTDNNGEGDACAADIDGDGILNERDNCQYVYNVDQRDTDMDGVGDQCDNCPLEHNPDQLDSDSDRIGDTCDNNQDIDEDGHQNNLDNCPYVPNANQADHDKDGKGDACDHDDDNDGIPDDKDNCRLVPNPDQKDSDGDGRGDACKDDFDHDSVPDIDDICPENVDISETDFRRFQMIPLDPKGTSQNDPNWVVRHQGKELVQTVNCDPGLAVGYDEFNAVDFSGTFFINTERDDDYAGFVFGYQSSSRFYVVMWKQVTQSYWDTNPTRAQGYSGLSVKVVNSTTGPGEHLRNALWHTGNTPGQVRTLWHDPRHIGWKDFTAYRWRLSHRPKTGFIRVVMYEGKKIMADSGPIYDKTYAGGRLGLFVFSQEMVFFSDLKYECRDP
T30784	DRUGINFO	D0G4MB	ABT-510	Phase 2
T30784	DRUGINFO	D0S0KP	CVX-045	Phase 2

T07374	TARGETID	T07374
T07374	FORMERID	TTDI02128
T07374	UNIPROID	MSMB_HUMAN
T07374	TARGNAME	Beta-microseminoprotein (MSMB)
T07374	GENENAME	MSMB
T07374	TARGTYPE	Clinical trial
T07374	SYNONYMS	Seminal plasma beta-inhibin; Prostate secretory protein of 94 amino acids; Prostate secreted seminal plasma protein; PSP94; PSP-94; PRSP; PN44; Immunoglobulin-binding factor; IGBF
T07374	FUNCTION	A member of the immunoglobulin binding factor family. May have a role as an autocrine paracrine factor in uterine, breast and other female reproductive tissues. Inhibits growth of cancer cells in an experimental model of prostate cancer, though this property is cell line specific.
T07374	PDBSTRUC	3IX0; 2IZ3
T07374	SEQUENCE	MNVLLGSVVIFATFVTLCNASCYFIPNEGVPGDSTRKCMDLKGNKHPINSEWQTDNCETCTCYETEISCCTLVSTPVGYDKDNCQRIFKKEDCKYIVVEKKDPKKTCSVSEWII
T07374	DRUGINFO	D0UN1S	Tigapotide	Phase 1

T71086	TARGETID	T71086
T71086	FORMERID	TTDI02042
T71086	UNIPROID	CFAH_HUMAN
T71086	TARGNAME	Complement factor H (CFH)
T71086	GENENAME	CFH
T71086	TARGTYPE	Clinical trial
T71086	SYNONYMS	HF2; HF1; HF; H factor 1
T71086	FUNCTION	Glycoprotein that plays an essential role in maintaining a well-balanced immune response by modulating complement activation. Acts as a soluble inhibitor of complement, where its binding to self markers such as glycan structures prevents complement activation and amplification on cell surfaces. Accelerates the decay of the complement alternative pathway (AP) C3 convertase C3bBb, thus preventing local formation of more C3b, the central player of the complement amplification loop. As a cofactor of the serine protease factor I, CFH also regulates proteolytic degradation of already-deposited C3b. In addition, mediates several cellular responses through interaction with specific receptors. For example, interacts with CR3/ITGAM receptor and thereby mediates the adhesion of human neutrophils to different pathogens. In turn, these pathogens are phagocytosed and destroyed.
T71086	PDBSTRUC	6ATG; 5WTB; 5O35; 5O32; 5NBQ
T71086	SEQUENCE	MRLLAKIICLMLWAICVAEDCNELPPRRNTEILTGSWSDQTYPEGTQAIYKCRPGYRSLGNVIMVCRKGEWVALNPLRKCQKRPCGHPGDTPFGTFTLTGGNVFEYGVKAVYTCNEGYQLLGEINYRECDTDGWTNDIPICEVVKCLPVTAPENGKIVSSAMEPDREYHFGQAVRFVCNSGYKIEGDEEMHCSDDGFWSKEKPKCVEISCKSPDVINGSPISQKIIYKENERFQYKCNMGYEYSERGDAVCTESGWRPLPSCEEKSCDNPYIPNGDYSPLRIKHRTGDEITYQCRNGFYPATRGNTAKCTSTGWIPAPRCTLKPCDYPDIKHGGLYHENMRRPYFPVAVGKYYSYYCDEHFETPSGSYWDHIHCTQDGWSPAVPCLRKCYFPYLENGYNQNYGRKFVQGKSIDVACHPGYALPKAQTTVTCMENGWSPTPRCIRVKTCSKSSIDIENGFISESQYTYALKEKAKYQCKLGYVTADGETSGSITCGKDGWSAQPTCIKSCDIPVFMNARTKNDFTWFKLNDTLDYECHDGYESNTGSTTGSIVCGYNGWSDLPICYERECELPKIDVHLVPDRKKDQYKVGEVLKFSCKPGFTIVGPNSVQCYHFGLSPDLPICKEQVQSCGPPPELLNGNVKEKTKEEYGHSEVVEYYCNPRFLMKGPNKIQCVDGEWTTLPVCIVEESTCGDIPELEHGWAQLSSPPYYYGDSVEFNCSESFTMIGHRSITCIHGVWTQLPQCVAIDKLKKCKSSNLIILEEHLKNKKEFDHNSNIRYRCRGKEGWIHTVCINGRWDPEVNCSMAQIQLCPPPPQIPNSHNMTTTLNYRDGEKVSVLCQENYLIQEGEEITCKDGRWQSIPLCVEKIPCSQPPQIEHGTINSSRSSQESYAHGTKLSYTCEGGFRISEENETTCYMGKWSSPPQCEGLPCKSPPEISHGVVAHMSDSYQYGEEVTYKCFEGFGIDGPAIAKCLGEKWSHPPSCIKTDCLSLPSFENAIPMGEKKDVYKAGEQVTYTCATYYKMDGASNVTCINSRWTGRPTCRDTSCVNPPTVQNAYIVSRQMSKYPSGERVRYQCRSPYEMFGDEEVMCLNGNWTEPPQCKDSTGKCGPPPPIDNGDITSFPLSVYAPASSVEYQCQNLYQLEGNKRITCRNGQWSEPPKCLHPCVISREIMENYNIALRWTAKQKLYSRTGESVEFVCKRGYRLSSRSHTLRTTCWDGKLEYPTCAKR
T71086	DRUGINFO	D00BZJ	Trumenba	Approved
T71086	DRUGINFO	DH2S8X	GT103	Phase 1
T71086	DRUGINFO	D01XQQ	TT-30	Phase 1

T59001	TARGETID	T59001
T59001	UNIPROID	FCG3A_HUMAN
T59001	TARGNAME	Immunoglobulin gamma Fc receptor IIIA (FCGR3A)
T59001	GENENAME	FCGR3A
T59001	TARGTYPE	Clinical trial
T59001	SYNONYMS	FCGR3A
T59001	FUNCTION	Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis.
T59001	PDBSTRUC	5YC5; 5XJF; 5XJE; 5VU0; 5MN2
T59001	BIOCLASS	Immunoglobulin
T59001	SEQUENCE	MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQWFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKEEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKNVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDWKDHKFKWRKDPQDK
T59001	DRUGINFO	DZM2L1	AFM13	Phase 2
T59001	DRUGINFO	DK8QG3	AFM24	Phase 1/2
T59001	DRUGINFO	DC3Y7O	RG6296	Phase 1

T18972	TARGETID	T18972
T18972	FORMERID	TTDNC00504
T18972	UNIPROID	CD3G_HUMAN
T18972	TARGNAME	T-cell surface glycoprotein CD3 gamma (CD3G)
T18972	GENENAME	CD3G
T18972	TARGTYPE	Clinical trial
T18972	SYNONYMS	T3G; T-cell surface glycoprotein CD3 gamma chain; T-cell receptor T3 gamma chain; CD3g
T18972	FUNCTION	When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain. Upon TCR engagement, these motifs become phosphorylated by Src family protein tyrosine kinases LCK and FYN, resulting in the activation of downstream signaling pathways. In addition to this role of signal transduction in T-cell activation, CD3G plays an essential role in the dynamic regulation of TCR expression at the cell surface. Indeed, constitutive TCR cycling is dependent on the di-leucine-based (diL) receptor-sorting motif present in CD3G. Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response.
T18972	PDBSTRUC	1SY6
T18972	SEQUENCE	MEQGKGLAVLILAIILLQGTLAQSIKGNHLVKVYDYQEDGSVLLTCDAEAKNITWFKDGKMIGFLTEDKKKWNLGSNAKDPRGMYQCKGSQNKSKPLQVYYRMCQNCIELNAATISGFLFAEIVSIFVLAVGVYFIAGQDGVRQSRASDKQTLLPNDQLYQPLKDREDDQYSHLQGNQLRRN
T18972	DRUGINFO	D0O2JI	Ertumaxomab	Phase 2
T18972	DRUGINFO	D00PEN	MGD007	Phase 1/2
T18972	DRUGINFO	D0PY3L	MEDI-565	Phase 1
T18972	DRUGINFO	D00YOV	MT-110	Phase 1
T18972	DRUGINFO	D04UWG	Autologous T-cell therapy	Phase 1

T02702	TARGETID	T02702
T02702	UNIPROID	DYR_ECOLI
T02702	TARGNAME	Bacterial Dihydrofolate reductase (Bact DHFR)
T02702	GENENAME	Bact DHFR
T02702	TARGTYPE	Clinical trial
T02702	SYNONYMS	Bact Dihydrofolate reductase
T02702	FUNCTION	Key enzyme in folate metabolism. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis.
T02702	PDBSTRUC	7DFR; 6MTH; 6MT8; 6MR9; 6DFR
T02702	ECNUMBER	EC 1.5.1.3
T02702	SEQUENCE	MISLIAALAVDRVIGMENAMPWNLPADLAWFKRNTLNKPVIMGRHTWESIGRPLPGRKNIILSSQPGTDDRVTWVKSVDEAIAACGDVPEIMVIGGGRVYEQFLPKAQKLYLTHIDAEVEGDTHFPDYEPDDWESVFSEFHDADAQNSHSYCFEILERR
T02702	DRUGINFO	D04LBC	Iclaprim	Phase 3
T02702	DRUGINFO	D03ICO	AR-709	Terminated
T02702	DRUGINFO	D05AHQ	Epiroprim	Terminated
T02702	DRUGINFO	D0FC5T	DIAVERIDINE	Terminated

T62187	TARGETID	T62187
T62187	FORMERID	TTDR00326
T62187	UNIPROID	HEPA_HHV11
T62187	TARGNAME	Herpes simplex virus Helicase-primase (HSV UL8)
T62187	GENENAME	HSV UL8
T62187	TARGTYPE	Clinical trial
T62187	SYNONYMS	Primase-associated factor; HEPA; DNA helicase/primase complex-associated protein
T62187	FUNCTION	Component of the helicase/primase complex. Unwinds the DNA at the replication forks and generates single-stranded DNA for both leading and lagging strand synthesis. The primase synthesizes short RNA primers on the lagging strand that the polymerase presumably elongates using dNTPs. The primase-associated factor has no known catalytic activity in the complex and may serve to facilitate the formation of the replisome by directly interacting with the origin-binding protein and the polymerase.
T62187	BIOCLASS	Acid anhydrides hydrolase
T62187	SEQUENCE	MDTADIVWVEESVSAITLYAVWLPPRAREYFHALVYFVCRNAAGEGRARFAEVSVTATELRDFYGSADVSVQAVVAAARAATTPAASPLEPLENPTLWRALYACVLAALERQTGPVALFAPLRIGSDPRTGLVVKVERASWGPPAAPRAALLVAEANIDIDPMALAARVAEHPDARLAWARLAAIRDTPQCASAASLTVNITTGTALFAREYQTLAFPPIKKEGAFGDLVEVCEVGLRPRGHPQRVTARVLLPRDYDYFVSAGEKFSAPALVALFRQWHTTVHAAPGALAPVFAFLGPEFEVRGGPVPYFAVLGFPGWPTFTVPATAESARDLVRGAAAAYAALLGAWPAVGARVVLPPRAWPGVASAAAGCLLPAVREAVARWHPATKIIQLLDPPAAVGPVWTARFCFPGLRAQLLAALADLGGSGLADPHGRTGLARLDALVVAAPSEPWAGAVLERLVPDTCNACPALRQLLGGVMAAVCLQIEETASSVKFAVCGGDGGAFWGVFNVDPQDADAASGVIEDARRAIETAVGAVLRANAVRLRHPLCLALEGVYTHAVAWSQAGVWFWNSRDNTDHLGGFPLRGPAYTTAAGVVRDTLRRVLGLTTACVPEEDALTARGLMEDACDRLILDAFNKRLDAEYWSVRVSPFEASDPLPPTAFRGGALLDAEHYWRRVVRVCPGGGESVGVPVDLYPRPLVLPPVDCAHHLREILREIELVFTGVLAGVWGEGGKFVYPFDDKMSFLFA
T62187	DRUGINFO	D07PXQ	ASP-2151	Phase 3
T62187	DRUGINFO	D05ZXZ	BAY 57-1293	Phase 2

T46616	TARGETID	T46616
T46616	FORMERID	TTDI01999
T46616	UNIPROID	BXA1_CLOBO
T46616	TARGNAME	Bacterial Botulinum toxin A (Bact botA)
T46616	GENENAME	Bact botA
T46616	TARGTYPE	Clinical trial
T46616	SYNONYMS	botA
T46616	FUNCTION	Inhibits acetylcholine release. The botulinum toxin binds with high affinity to peripheral neuronal presynaptic membrane to the secretory vesicle protein SV2. It binds directly to the largest luminal loop of SV2A, SV2B and SV2C. It is then internalized by receptor-mediated endocytosis. The C-terminus of the heavy chain (H) is responsible for the adherence of the toxin to the cell surface while the N-terminus mediates transport of the light chain from the endocytic vesicle to the cytosol. After translocation, the light chain (L) hydrolyzes the 197-Gln-|-Arg- 198 bond in SNAP-25, thereby blocking neurotransmitter release. Inhibition of acetylcholine release results in flaccid paralysis, with frequent heart or respiratory failure.
T46616	PDBSTRUC	6MHJ; 6DKK; 5VGX; 5VGV; 5V8U
T46616	BIOCLASS	Peptidase
T46616	SEQUENCE	MPFVNKQFNYKDPVNGVDIAYIKIPNVGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVRGIITSKTKSLDKGYNKALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLSTFTEYIKNIINTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNNEYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTITNNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELNEKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPRGSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQAGVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAKLVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL
T46616	DRUGINFO	D00UWY	RT-001	Phase 2
T46616	DRUGINFO	D0RD1I	XOMA-3AB	Phase 1

T97111	TARGETID	T97111
T97111	FORMERID	TTDNC00540
T97111	UNIPROID	CD37_HUMAN
T97111	TARGNAME	Leukocyte antigen CD37 (CD37)
T97111	GENENAME	CD37
T97111	TARGTYPE	Clinical trial
T97111	SYNONYMS	Tspan26; Tspan-26; Tetraspanin26; Tetraspanin-26
T97111	FUNCTION	extracellular exosome, immunological synapse, integral component of plasma membrane, membrane, cell surface receptor signaling pathway.
T97111	BIOCLASS	Tetraspanin
T97111	SEQUENCE	MSAQESCLSLIKYFLFVFNLFFFVLGSLIFCFGIWILIDKTSFVSFVGLAFVPLQIWSKVLAISGIFTMGIALLGCVGALKELRCLLGLYFGMLLLLFATQITLGILISTQRAQLERSLRDVVEKTIQKYGTNPEETAAEESWDYVQFQLRCCGWHYPQDWFQVLILRGNGSEAHRVPCSCYNLSATNDSTILDKVILPQLSRLGHLARSRHSADICAVPAESHIYREGCAQGLQKWLHNNLISIVGICLGVGLLELGFMTLSIFLCRNLDHVYNRLARYR
T97111	DRUGINFO	D08JGB	Otlertuzumab	Phase 2
T97111	DRUGINFO	D09WKM	BI-836826	Phase 2
T97111	DRUGINFO	D0C0LO	IMGN529	Phase 2
T97111	DRUGINFO	D2R0UM	Naratuximab emtansine	Phase 2
T97111	DRUGINFO	D0T7QC	TRU-016	Phase 1/2
T97111	DRUGINFO	D1W2DS	GEN3009	Phase 1/2
T97111	DRUGINFO	DI9ZQ6	212Pb-labelled aCD37	Preclinical

T21782	TARGETID	T21782
T21782	FORMERID	TTDI00605
T21782	UNIPROID	PCNA_HUMAN
T21782	TARGNAME	Proliferating cell nuclear antigen (PCNA)
T21782	GENENAME	PCNA
T21782	TARGTYPE	Clinical trial
T21782	SYNONYMS	Cyclin
T21782	FUNCTION	Induces a robust stimulatory effect on the 3'-5' exonuclease and 3'-phosphodiesterase, but not apurinic-apyrimidinic (AP) endonuclease, APEX2 activities. Has to be loaded onto DNA in order to be able to stimulate APEX2. Plays a key role in DNA damage response (DDR) by being conveniently positioned at the replication fork to coordinate DNA replication with DNA repair and DNA damage tolerance pathways. Acts as a loading platform to recruit DDR proteins that allow completion of DNA replication after DNA damage and promote postreplication repair: Monoubiquitinated PCNA leads to recruitment of translesion (TLS) polymerases, while 'Lys-63'-linked polyubiquitination of PCNA is involved in error-free pathway and employs recombination mechanisms to synthesize across the lesion. Auxiliary protein of DNA polymerase delta and is involved in the control of eukaryotic DNA replication by increasing the polymerase's processibility during elongation of the leading strand.
T21782	PDBSTRUC	6QCG; 6QC0; 6HVO; 6GWS; 6GIS
T21782	SEQUENCE	MFEARLVQGSILKKVLEALKDLINEACWDISSSGVNLQSMDSSHVSLVQLTLRSEGFDTYRCDRNLAMGVNLTSMSKILKCAGNEDIITLRAEDNADTLALVFEAPNQEKVSDYEMKLMDLDVEQLGIPEQEYSCVVKMPSGEFARICRDLSHIGDAVVISCAKDGVKFSASGELGNGNIKLSQTSNVDKEEEAVTIEMNEPVQLTFALRYLNFFTKATPLSSTVTLSMSADVPLVVEYKIADMGHLKYYLAPKIEDEEGS
T21782	DRUGINFO	D02PQB	ATX-101	Phase 3
T21782	DRUGINFO	D04XEO	ChelASE	Discontinued in Phase 1

T33636	TARGETID	T33636
T33636	FORMERID	TTDI02114
T33636	UNIPROID	LMP2_EBVB9
T33636	TARGNAME	Epstein-Barr virus Latent membrane protein 2 (EBV LMP2)
T33636	GENENAME	EBV LMP2
T33636	TARGTYPE	Clinical trial
T33636	SYNONYMS	Terminal protein; Latent membrane protein 2
T33636	FUNCTION	Isoform LMP2B may be a negative regulator of isoform LMP2A.
T33636	PDBSTRUC	5GSD; 5GRD; 3REW; 3BVN; 2JO9
T33636	BIOCLASS	Herpesviridae LMP-2
T33636	SEQUENCE	MGSLEMVPMGAGPPSPGGDPDGYDGGNNSQYPSASGSSGNTPTPPNDEERESNEEPPPPYEDPYWGNGDRHSDYQPLGTQDQSLYLGLQHDGNDGLPPPPYSPRDDSSQHIYEEAGRGSMNPVCLPVIVAPYLFWLAAIAASCFTASVSTVVTATGLALSLLLLAAVASSYAAAQRKLLTPVTVLTAVVTFFAICLTWRIEDPPFNSLLFALLAAAGGLQGIYVLVMLVLLILAYRRRWRRLTVCGGIMFLACVLVLIVDAVLQLSPLLGAVTVVSMTLLLLAFVLWLSSPGGLGTLGAALLTLAAALALLASLILGTLNLTTMFLLMLLWTLVVLLICSSCSSCPLSKILLARLFLYALALLLLASALIAGGSILQTNFKSLSSTEFIPNLFCMLLLIVAGILFILAILTEWGSGNRTYGPVFMCLGGLLTMVAGAVWLTVMSNTLLSAWILTAGFLIFLIGFALFGVIRCCRYCCYYCLTLESEERPPTPYRNTV
T33636	DRUGINFO	D0Z6RW	LMP-1/LMP-2 CTLs	Phase 1
T33636	DRUGINFO	D0Q8PF	Ad5f35-LMPd1-2-transduced autologous dendritic cells	Investigative

T47864	TARGETID	T47864
T47864	FORMERID	TTDR01155
T47864	UNIPROID	TDGF1_HUMAN
T47864	TARGNAME	Teratocarcinoma-derived growth factor 1 (TDGF1)
T47864	GENENAME	TDGF1
T47864	TARGTYPE	Clinical trial
T47864	SYNONYMS	TDGF1; Epidermal growth factor-like cripto protein CR1; Cripto-1 growth factor; Cripto; CRGF
T47864	FUNCTION	Could play a role in the determination of the epiblastic cells that subsequently give rise to the mesoderm.
T47864	BIOCLASS	Growth factor
T47864	SEQUENCE	MDCRKMARFSYSVIWIMAISKVFELGLVAGLGHQEFARPSRGYLAFRDDSIWPQEEPAIRPRSSQRVPPMGIQHSKELNRTCCLNGGTCMLGSFCACPPSFYGRNCEHDVRKENCGSVPHDTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSARTTTFMLVGICLSIQSYY
T47864	DRUGINFO	D08IRG	BIIB 015	Phase 1

T86323	TARGETID	T86323
T86323	UNIPROID	NCAM1_HUMAN
T86323	TARGNAME	Neural cell adhesion molecule 1 (NCAM1)
T86323	GENENAME	NCAM1
T86323	TARGTYPE	Clinical trial
T86323	SYNONYMS	NCAM-1; NCAM; N-CAM-1; MSK39; CD56
T86323	FUNCTION	This protein is a cell adhesion molecule involved in neuron-neuron adhesion, neurite fasciculation, outgrowth of neurites, etc.
T86323	PDBSTRUC	5LKN; 5AEA; 3MTR; 2VKX; 2VKW
T86323	SEQUENCE	MLQTKDLIWTLFFLGTAVSLQVDIVPSQGEISVGESKFFLCQVAGDAKDKDISWFSPNGEKLTPNQQRISVVWNDDSSSTLTIYNANIDDAGIYKCVVTGEDGSESEATVNVKIFQKLMFKNAPTPQEFREGEDAVIVCDVVSSLPPTIIWKHKGRDVILKKDVRFIVLSNNYLQIRGIKKTDEGTYRCEGRILARGEINFKDIQVIVNVPPTIQARQNIVNATANLGQSVTLVCDAEGFPEPTMSWTKDGEQIEQEEDDEKYIFSDDSSQLTIKKVDKNDEAEYICIAENKAGEQDATIHLKVFAKPKITYVENQTAMELEEQVTLTCEASGDPIPSITWRTSTRNISSEEKASWTRPEKQETLDGHMVVRSHARVSSLTLKSIQYTDAGEYICTASNTIGQDSQSMYLEVQYAPKLQGPVAVYTWEGNQVNITCEVFAYPSATISWFRDGQLLPSSNYSNIKIYNTPSASYLEVTPDSENDFGNYNCTAVNRIGQESLEFILVQADTPSSPSIDQVEPYSSTAQVQFDEPEATGGVPILKYKAEWRAVGEEVWHSKWYDAKEASMEGIVTIVGLKPETTYAVRLAALNGKGLGEISAASEFKTQPVQGEPSAPKLEGQMGEDGNSIKVNLIKQDDGGSPIRHYLVRYRALSSEWKPEIRLPSGSDHVMLKSLDWNAEYEVYVVAENQQGKSKAAHFVFRTSAQPTAIPANGSPTSGLSTGAIVGILIVIFVLLLVVVDITCYFLNKCGLFMCIAVNLCGKAGPGAKGKDMEEGKAAFSKDESKEPIVEVRTEEERTPNHDGGKHTEPNETTPLTEPEKGPVEAKPECQETETKPAPAEVKTVPNDATQTKENESKA
T86323	DRUGINFO	D03HML	CD56-specific gene-engineered T cells	Phase 1/2
T86323	DRUGINFO	D0U1GP	CD56 CAR T cells	Phase 1/2
T86323	DRUGINFO	D0YH5L	CART-56 cells	Phase 1
T86323	DRUGINFO	D0V6WW	CAR-T cells targeting CD56	Clinical trial

T19556	TARGETID	T19556
T19556	FORMERID	TTDR00458
T19556	UNIPROID	ONCM_HUMAN
T19556	TARGNAME	Oncostatin-M (OSM)
T19556	GENENAME	OSM
T19556	TARGTYPE	Clinical trial
T19556	SYNONYMS	OSM
T19556	FUNCTION	Growth regulator. Inhibits the proliferation of a number of tumor cell lines. Stimulates proliferation of AIDS-KS cells. It regulates cytokine production, including IL-6, G-CSF and GM-CSF from endothelial cells. Uses both type I OSM receptor (heterodimers composed of LIPR and IL6ST) and type II OSM receptor (heterodimers composed of OSMR and IL6ST). Involved in the maturation of fetal hepatocytes, thereby promoting liver development and regeneration.
T19556	PDBSTRUC	1EVS
T19556	SEQUENCE	MGVLLTQRTLLSLVLALLFPSMASMAAIGSCSKEYRVLLGQLQKQTDLMQDTSRLLDPYIRIQGLDVPKLREHCRERPGAFPSEETLRGLGRRGFLQTLNATLGCVLHRLADLEQRLPKAQDLERSGLNIEDLEKLQMARPNILGLRNNIYCMAQLLDNSDTAEPTKAGRGASQPPTPTPASDAFQRKLEGCRFLHGYHRFMHSVGRVFSKWGESPNRSRRHSPHQALRKGVRRTRPSRKGKRLMTRGQLPR
T19556	DRUGINFO	D0D3TQ	GSK2330811	Phase 2
T19556	DRUGINFO	D04VCF	ADR58	Investigative

T93121	TARGETID	T93121
T93121	UNIPROID	ETS2_HUMAN
T93121	TARGNAME	Protein C-ets-2 (ETS2)
T93121	GENENAME	ETS2
T93121	TARGTYPE	Clinical trial
T93121	SYNONYMS	ETS2IT1; ETS proto-oncogene 2, transcription factor
T93121	FUNCTION	Binds specifically the DNA GGAA/T core motif (Ets-binding site or EBS) in gene promoters and stimulates transcription. Transcription factor activating transcription.
T93121	PDBSTRUC	4MHV; 4BQA
T93121	BIOCLASS	E26 transformation-specific ETS
T93121	SEQUENCE	MNDFGIKNMDQVAPVANSYRGTLKRQPAFDTFDGSLFAVFPSLNEEQTLQEVPTGLDSISHDSANCELPLLTPCSKAVMSQALKATFSGFKKEQRRLGIPKNPWLWSEQQVCQWLLWATNEFSLVNVNLQRFGMNGQMLCNLGKERFLELAPDFVGDILWEHLEQMIKENQEKTEDQYEENSHLTSVPHWINSNTLGFGTEQAPYGMQTQNYPKGGLLDSMCPASTPSVLSSEQEFQMFPKSRLSSVSVTYCSVSQDFPGSNLNLLTNNSGTPKDHDSPENGADSFESSDSLLQSWNSQSSLLDVQRVPSFESFEDDCSQSLCLNKPTMSFKDYIQERSDPVEQGKPVIPAAVLAGFTGSGPIQLWQFLLELLSDKSCQSFISWTGDGWEFKLADPDEVARRWGKRKNKPKMNYEKLSRGLRYYYDKNIIHKTSGKRYVYRFVCDLQNLLGFTPEELHAILGVQPDTED
T93121	DRUGINFO	D0HU0A	TK216	Phase 1

T78319	TARGETID	T78319
T78319	FORMERID	TTDR00525
T78319	UNIPROID	CD44_HUMAN
T78319	TARGNAME	Extracellular matrix receptor III (CD44)
T78319	GENENAME	CD44
T78319	TARGTYPE	Clinical trial
T78319	SYNONYMS	Phagocytic glycoprotein I; Phagocytic glycoprotein 1; PGP-I; PGP-1; MIC4; MDU3; MDU2; LHR; Hyaluronate receptor; Hermes antigen; Heparan sulfate proteoglycan; HUTCH-I; GP90 lymphocyte homing/adhesion receptor; Extracellular matrix receptor-III; Epican; ECMR-III; CDw44; CD44 antigen
T78319	FUNCTION	Participates thereby in a wide variety of cellular functions including the activation, recirculation and homing of T-lymphocytes, hematopoiesis, inflammation and response to bacterial infection. Engages, through its ectodomain, extracellular matrix components such as hyaluronan/HA, collagen, growth factors, cytokines or proteases and serves as a platform for signal transduction by assembling, via its cytoplasmic domain, protein complexes containing receptor kinases and membrane proteases. Such effectors include PKN2, the RhoGTPases RAC1 and RHOA, Rho-kinases and phospholipase C that coordinate signaling pathways promoting calcium mobilization and actin-mediated cytoskeleton reorganization essential for cell migration and adhesion. Cell-surface receptor that plays a role in cell-cell interactions, cell adhesion and migration, helping them to sense and respond to changes in the tissue microenvironment.
T78319	PDBSTRUC	4PZ4; 4PZ3; 2I83; 1UUH; 1POZ
T78319	SEQUENCE	MDKFWWHAAWGLCLVPLSLAQIDLNITCRFAGVFHVEKNGRYSISRTEAADLCKAFNSTLPTMAQMEKALSIGFETCRYGFIEGHVVIPRIHPNSICAANNTGVYILTSNTSQYDTYCFNASAPPEEDCTSVTDLPNAFDGPITITIVNRDGTRYVQKGEYRTNPEDIYPSNPTDDDVSSGSSSERSSTSGGYIFYTFSTVHPIPDEDSPWITDSTDRIPATTLMSTSATATETATKRQETWDWFSWLFLPSESKNHLHTTTQMAGTSSNTISAGWEPNEENEDERDRHLSFSGSGIDDDEDFISSTISTTPRAFDHTKQNQDWTQWNPSHSNPEVLLQTTTRMTDVDRNGTTAYEGNWNPEAHPPLIHHEHHEEEETPHSTSTIQATPSSTTEETATQKEQWFGNRWHEGYRQTPKEDSHSTTGTAAASAHTSHPMQGRTTPSPEDSSWTDFFNPISHPMGRGHQAGRRMDMDSSHSITLQPTANPNTGLVEDLDRTGPLSMTTQQSNSQSFSTSHEGLEEDKDHPTTSTLTSSNRNDVTGGRRDPNHSEGSTTLLEGYTSHYPHTKESRTFIPVTSAKTGSFGVTAVTVGDSNSNVNRSLSGDQDTFHPSGGSHTTHGSESDGHSHGSQEGGANTTSGPIRTPQIPEWLIILASLLALALILAVCIAVNSRRRCGQKKKLVINSGNGAVEDRKPSGLNGEASKSQEMVHLVNKESSETPDQFMTADETRNLQNVDMKIGV
T78319	DRUGINFO	D0CT7M	A-6	Phase 2
T78319	DRUGINFO	D2C0DY	SPL-108	Phase 2
T78319	DRUGINFO	D05OXZ	BIWA 4	Phase 1
T78319	DRUGINFO	D0R6EQ	Bivatuzumab mertansine	Terminated

T68230	TARGETID	T68230
T68230	FORMERID	TTDI01812
T68230	UNIPROID	TOXA_CLODI
T68230	TARGNAME	Clostridium difficile Toxin A (CD toxA)
T68230	GENENAME	CD toxA
T68230	TARGTYPE	Clinical trial
T68230	SYNONYMS	Toxin A
T68230	FUNCTION	Only after the enteral delivery of the enterotoxin A may the characteristic disease called pseudomembranous colitis be induced.
T68230	PDBSTRUC	5UQL; 5UQK; 5UMI; 4R04; 4DMW
T68230	ECNUMBER	EC 3.4.22.-
T68230	SEQUENCE	MSLISKEELIKLAYSIRPRENEYKTILTNLDEYNKLTTNNNENKYLQLKKLNESIDVFMNKYKTSSRNRALSNLKKDILKEVILIKNSNTSPVEKNLHFVWIGGEVSDIALEYIKQWADINAEYNIKLWYDSEAFLVNTLKKAIVESSTTEALQLLEEEIQNPQFDNMKFYKKRMEFIYDRQKRFINYYKSQINKPTVPTIDDIIKSHLVSEYNRDETVLESYRTNSLRKINSNHGIDIRANSLFTEQELLNIYSQELLNRGNLAAASDIVRLLALKNFGGVYLDVDMLPGIHSDLFKTISRPSSIGLDRWEMIKLEAIMKYKKYINNYTSENFDKLDQQLKDNFKLIIESKSEKSEIFSKLENLNVSDLEIKIAFALGSVINQALISKQGSYLTNLVIEQVKNRYQFLNQHLNPAIESDNNFTDTTKIFHDSLFNSATAENSMFLTKIAPYLQVGFMPEARSTISLSGPGAYASAYYDFINLQENTIEKTLKASDLIEFKFPENNLSQLTEQEINSLWSFDQASAKYQFEKYVRDYTGGSLSEDNGVDFNKNTALDKNYLLNNKIPSNNVEEAGSKNYVHYIIQLQGDDISYEATCNLFSKNPKNSIIIQRNMNESAKSYFLSDDGESILELNKYRIPERLKNKEKVKVTFIGHGKDEFNTSEFARLSVDSLSNEISSFLDTIKLDISPKNVEVNLLGCNMFSYDFNVEETYPGKLLLSIMDKITSTLPDVNKNSITIGANQYEVRINSEGRKELLAHSGKWINKEEAIMSDLSSKEYIFFDSIDNKLKAKSKNIPGLASISEDIKTLLLDASVSPDTKFILNNLKLNIESSIGDYIYYEKLEPVKNIIHNSIDDLIDEFNLLENVSDELYELKKLNNLDEKYLISFEDISKNNSTYSVRFINKSNGESVYVETEKEIFSKYSEHITKEISTIKNSIITDVNGNLLDNIQLDHTSQVNTLNAAFFIQSLIDYSSNKDVLNDLSTSVKVQLYAQLFSTGLNTIYDSIQLVNLISNAVNDTINVLPTITEGIPIVSTILDGINLGAAIKELLDEHDPLLKKELEAKVGVLAINMSLSIAATVASIVGIGAEVTIFLLPIAGISAGIPSLVNNELILHDKATSVVNYFNHLSESKKYGPLKTEDDKILVPIDDLVISEIDFNNNSIKLGTCNILAMEGGSGHTVTGNIDHFFSSPSISSHIPSLSIYSAIGIETENLDFSKKIMMLPNAPSRVFWWETGAVPGLRSLENDGTRLLDSIRDLYPGKFYWRFYAFFDYAITTLKPVYEDTNIKIKLDKDTRNFIMPTITTNEIRNKLSYSFDGAGGTYSLLLSSYPISTNINLSKDDLWIFNIDNEVREISIENGTIKKGKLIKDVLSKIDINKNKLIIGNQTIDFSGDIDNKDRYIFLTCELDDKISLIIEINLVAKSYSLLLSGDKNYLISNLSNTIEKINTLGLDSKNIAYNYTDESNNKYFGAISKTSQKSIIHYKKDSKNILEFYNDSTLEFNSKDFIAEDINVFMKDDINTITGKYYVDNNTDKSIDFSISLVSKNQVKVNGLYLNESVYSSYLDFVKNSDGHHNTSNFMNLFLDNISFWKLFGFENINFVIDKYFTLVGKTNLGYVEFICDNNKNIDIYFGEWKTSSSKSTIFSGNGRNVVVEPIYNPDTGEDISTSLDFSYEPLYGIDRYINKVLIAPDLYTSLININTNYYSNEYYPEIIVLNPNTFHKKVNINLDSSSFEYKWSTEGSDFILVRYLEESNKKILQKIRIKGILSNTQSFNKMSIDFKDIKKLSLGYIMSNFKSFNSENELDRDHLGFKIIDNKTYYYDEDSKLVKGLININNSLFYFDPIEFNLVTGWQTINGKKYYFDINTGAALTSYKIINGKHFYFNNDGVMQLGVFKGPDGFEYFAPANTQNNNIEGQAIVYQSKFLTLNGKKYYFDNNSKAVTGWRIINNEKYYFNPNNAIAAVGLQVIDNNKYYFNPDTAIISKGWQTVNGSRYYFDTDTAIAFNGYKTIDGKHFYFDSDCVVKIGVFSTSNGFEYFAPANTYNNNIEGQAIVYQSKFLTLNGKKYYFDNNSKAVTGLQTIDSKKYYFNTNTAEAATGWQTIDGKKYYFNTNTAEAATGWQTIDGKKYYFNTNTAIASTGYTIINGKHFYFNTDGIMQIGVFKGPNGFEYFAPANTDANNIEGQAILYQNEFLTLNGKKYYFGSDSKAVTGWRIINNKKYYFNPNNAIAAIHLCTINNDKYYFSYDGILQNGYITIERNNFYFDANNESKMVTGVFKGPNGFEYFAPANTHNNNIEGQAIVYQNKFLTLNGKKYYFDNDSKAVTGWQTIDGKKYYFNLNTAEAATGWQTIDGKKYYFNLNTAEAATGWQTIDGKKYYFNTNTFIASTGYTSINGKHFYFNTDGIMQIGVFKGPNGFEYFAPANTDANNIEGQAILYQNKFLTLNGKKYYFGSDSKAVTGLRTIDGKKYYFNTNTAVAVTGWQTINGKKYYFNTNTSIASTGYTIISGKHFYFNTDGIMQIGVFKGPDGFEYFAPANTDANNIEGQAIRYQNRFLYLHDNIYYFGNNSKAATGWVTIDGNRYYFEPNTAMGANGYKTIDNKNFYFRNGLPQIGVFKGSNGFEYFAPANTDANNIEGQAIRYQNRFLHLLGKIYYFGNNSKAVTGWQTINGKVYYFMPDTAMAAAGGLFEIDGVIYFFGVDGVKAPGIYG
T68230	DRUGINFO	D06IBG	MK-3415A	Phase 3

T47863	TARGETID	T47863
T47863	FORMERID	TTDR00765
T47863	UNIPROID	EPCAM_HUMAN
T47863	TARGNAME	Tumor-associated calcium signal transducer 1 (EPCAM)
T47863	GENENAME	EPCAM
T47863	TARGTYPE	Clinical trial
T47863	SYNONYMS	hEGP314; TROP1; TACSTD1; Major gastrointestinal tumor-associated protein GA733-2; MIC18; M4S1; M1S2; KSA; KS 1/4 antigen; Gastrointestinal carcinoma antigen GA733; GA733-2; Epithelial glycoprotein 314; Epithelial glycoprotein; Epithelial cell surface antigen; Epithelial cell adhesion molecule; Ep-CAM; EGP314; EGP; Cell surface glycoprotein Trop-1; CD326; Adenocarcinoma-associated antigen
T47863	FUNCTION	Plays a role in embryonic stem cells proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E. May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection.
T47863	PDBSTRUC	6I07; 4MZV
T47863	SEQUENCE	MAPPQVLAFGLLLAAATATFAAAQEECVCENYKLAVNCFVNNNRQCQCTSVGAQNTVICSKLAAKCLVMKAEMNGSKLGRRAKPEGALQNNDGLYDPDCDESGLFKAKQCNGTSMCWCVNTAGVRRTDKDTEITCSERVRTYWIIIELKHKAREKPYDSKSLRTALQKEITTRYQLDPKFITSILYENNVITIDLVQNSSQKTQNDVDIADVAYYFEKDVKGESLFHSKKMDLTVNGEQLDLDPGQTLIYYVDEKAPEFSMQGLKAGVIAVIVVVVIAVVAGIVVLVISRKKRMAKYEKAEIKEMGEMHRELNA
T47863	DRUGINFO	DRP4Q9	Vicineum	Phase 3
T47863	DRUGINFO	D0Q3IS	VB4-845	Phase 2/3
T47863	DRUGINFO	D08QYW	CAR-T Cells targeting EpCAM	Phase 1/2
T47863	DRUGINFO	D01TNK	CAR-T cells targeting EpCAM	Phase 1
T47863	DRUGINFO	D04RNG	CAR-T cells recognizing EpCAM	Phase 1
T47863	DRUGINFO	D05DOY	ING-1	Phase 1
T47863	DRUGINFO	D0C6ID	Citatuzumab bogatox	Phase 1
T47863	DRUGINFO	D7FPZ4	A-337	Phase 1
T47863	DRUGINFO	D00YOV	MT-110	Phase 1
T47863	DRUGINFO	D0T8DD	EPCAM-targeted CAR-T cells	Clinical trial
T47863	DRUGINFO	D0J9KC	IGN-101	Discontinued in Phase 2

T50584	TARGETID	T50584
T50584	FORMERID	TTDI02028
T50584	UNIPROID	BPI_HUMAN
T50584	TARGNAME	Protein bactericidal permeability-increasing (BPI)
T50584	GENENAME	BPI
T50584	TARGTYPE	Clinical trial
T50584	SYNONYMS	CAP 57; BPI
T50584	FUNCTION	The cytotoxic action of BPI is limited to many species of Gram-negative bacteria; this specificity may be explained by a strong affinity of the very basic N-terminal half for the negatively charged lipopolysaccharides that are unique to the Gram-negative bacterial outer envelope. Has antibacterial activity against the Gram-nagative bacterium P.aeruginosa, this activity is inhibited by LPS from P.aeruginosa. {ECO:0000269|PubMed:1937776, ECO:0000269|PubMed:2722846}.
T50584	PDBSTRUC	1EWF; 1BP1
T50584	BIOCLASS	Bactericidal permeability increasing protein
T50584	SEQUENCE	MRENMARGPCNAPRWASLMVLVAIGTAVTAAVNPGVVVRISQKGLDYASQQGTAALQKELKRIKIPDYSDSFKIKHLGKGHYSFYSMDIREFQLPSSQISMVPNVGLKFSISNANIKISGKWKAQKRFLKMSGNFDLSIEGMSISADLKLGSNPTSGKPTITCSSCSSHINSVHVHISKSKVGWLIQLFHKKIESALRNKMNSQVCEKVTNSVSSELQPYFQTLPVMTKIDSVAGINYGLVAPPATTAETLDVQMKGEFYSENHHNPPPFAPPVMEFPAAHDRMVYLGLSDYFFNTAGLVYQEAGVLKMTLRDDMIPKESKFRLTTKFFGTFLPEVAKKFPNMKIQIHVSASTPPHLSVQPTGLTFYPAVDVQAFAVLPNSSLASLFLIGMHTTGSMEVSAESNRLVGELKLDRLLLELKHSNIGPFPVELLQDIMNYIVPILVLPRVNEKLQKGFPLPTPARVQLYNVVLQPHQNFLLFGADVVYK
T50584	DRUGINFO	D0UF8E	XOMA-629	Phase 2

T92963	TARGETID	T92963
T92963	FORMERID	TTDI01819
T92963	UNIPROID	ANPRC_HUMAN
T92963	TARGNAME	Natriuretic peptide receptor (NPR3)
T92963	GENENAME	NPR3
T92963	TARGTYPE	Clinical trial
T92963	SYNONYMS	NPR3
T92963	FUNCTION	Receptor for the atrial natriuretic peptide NPPA/ANP and the brain natriuretic peptide NPPB/BNP which are potent vasoactive hormones playing a key role in cardiovascular homeostasis. Has guanylate cyclase activity upon binding of the ligand.
T92963	PDBSTRUC	1YK1; 1YK0; 1JDP; 1JDN
T92963	BIOCLASS	Phosphorus-oxygen lyase
T92963	SEQUENCE	MPSLLVLTFSPCVLLGWALLAGGTGGGGVGGGGGGAGIGGGRQEREALPPQKIEVLVLLPQDDSYLFSLTRVRPAIEYALRSVEGNGTGRRLLPPGTRFQVAYEDSDCGNRALFSLVDRVAAARGAKPDLILGPVCEYAAAPVARLASHWDLPMLSAGALAAGFQHKDSEYSHLTRVAPAYAKMGEMMLALFRHHHWSRAALVYSDDKLERNCYFTLEGVHEVFQEEGLHTSIYSFDETKDLDLEDIVRNIQASERVVIMCASSDTIRSIMLVAHRHGMTSGDYAFFNIELFNSSSYGDGSWKRGDKHDFEAKQAYSSLQTVTLLRTVKPEFEKFSMEVKSSVEKQGLNMEDYVNMFVEGFHDAILLYVLALHEVLRAGYSKKDGGKIIQQTWNRTFEGIAGQVSIDANGDRYGDFSVIAMTDVEAGTQEVIGDYFGKEGRFEMRPNVKYPWGPLKLRIDENRIVEHTNSSPCKSSGGLEESAVTGIVVGALLGAGLLMAFYFFRKKYRITIERRTQQEESNLGKHRELREDSIRSHFSVA
T92963	DRUGINFO	D0SZ5G	ANX-042	Phase 1
T92963	DRUGINFO	D05ODA	AP811	Investigative
T92963	DRUGINFO	D09CFD	M372049	Investigative

T22350	TARGETID	T22350
T22350	FORMERID	TTDR00642
T22350	UNIPROID	EGLN_HUMAN
T22350	TARGNAME	Endoglin CD105 (ENG)
T22350	GENENAME	ENG
T22350	TARGTYPE	Clinical trial
T22350	SYNONYMS	Endoglin; END; CD105
T22350	FUNCTION	Vascular endothelium glycoprotein that plays an important role in the regulation of angiogenesis. Required for normal structure and integrity of adult vasculature. Regulates the migration of vascular endothelial cells. Required for normal extraembryonic angiogenesis and for embryonic heart development (By similarity). May regulate endothelial cell shape changes in response to blood flow, which drive vascular remodeling and establishment of normal vascular morphology during angiogenesis (By similarity). May play a critical role in the binding of endothelial cells to integrins and/or other RGD receptors. Acts as TGF-beta coreceptor and is involved in the TGF-beta/BMP signaling cascade that ultimately leads to the activation of SMAD transcription factors. Required for GDF2/BMP9 signaling through SMAD1 in endothelial cells and modulates TGFB1 signaling through SMAD3.
T22350	PDBSTRUC	5I04; 5HZW; 5HZV
T22350	SEQUENCE	MDRGTLPLAVALLLASCSLSPTSLAETVHCDLQPVGPERGEVTYTTSQVSKGCVAQAPNAILEVHVLFLEFPTGPSQLELTLQASKQNGTWPREVLLVLSVNSSVFLHLQALGIPLHLAYNSSLVTFQEPPGVNTTELPSFPKTQILEWAAERGPITSAAELNDPQSILLRLGQAQGSLSFCMLEASQDMGRTLEWRPRTPALVRGCHLEGVAGHKEAHILRVLPGHSAGPRTVTVKVELSCAPGDLDAVLILQGPPYVSWLIDANHNMQIWTTGEYSFKIFPEKNIRGFKLPDTPQGLLGEARMLNASIVASFVELPLASIVSLHASSCGGRLQTSPAPIQTTPPKDTCSPELLMSLIQTKCADDAMTLVLKKELVAHLKCTITGLTFWDPSCEAEDRGDKFVLRSAYSSCGMQVSASMISNEAVVNILSSSSPQRKKVHCLNMDSLSFQLGLYLSPHFLQASNTIEPGQQSFVQVRVSPSVSEFLLQLDSCHLDLGPEGGTVELIQGRAAKGNCVSLLSPSPEGDPRFSFLLHFYTVPIPKTGTLSCTVALRPKTGSQDQEVHRTVFMRLNIISPDLSGCTSKGLVLPAVLGITFGAFLIGALLTAALWYIYSHTRSPSKREPVVAVAAPASSESSSTNHSIGSTQSTPCSTSSMA
T22350	DRUGINFO	D00YQI	TRC105	Phase 3
T22350	DRUGINFO	DQ8K3R	ENV-105	Phase 1

T27918	TARGETID	T27918
T27918	UNIPROID	DDX5_HUMAN
T27918	TARGNAME	ATP-dependent RNA helicase DDX5 (DDX5)
T27918	GENENAME	DDX5
T27918	TARGTYPE	Clinical trial
T27918	SYNONYMS	RNA helicase p68; Probable ATP-dependent RNA helicase DDX5; HLR1; HELR; G17P1; DEAD box protein 5
T27918	FUNCTION	Binds to the tau pre-mRNA in the stem-loop region downstream of exon 10. The rate of ATP hydrolysis is highly stimulated by single-stranded RNA. Involved in transcriptional regulation; the function is independent of the RNA helicase activity. Transcriptional coactivator for androgen receptor AR but probably not ESR1. Synergizes with DDX17 and SRA1 RNA to activate MYOD1 transcriptional activity and involved in skeletal muscle differentiation. Transcriptional coactivator for p53/TP53 and involved in p53/TP53 transcriptional response to DNA damage and p53/TP53-dependent apoptosis. Transcriptional coactivator for RUNX2 and involved in regulation of osteoblast differentiation. Acts as transcriptional repressor in a promoter-specific manner; the function probably involves association with histone deacetylases, such as HDAC1. As component of a large PER complex is involved in the inhibition of 3' transcriptional termination of circadian target genes such as PER1 and NR1D1 and the control of the circadian rhythms. Involved in the alternative regulation of pre-mRNA splicing; its RNA helicase activity is necessary for increasing tau exon 10 inclusion and occurs in a RBM4-dependent manner.
T27918	PDBSTRUC	4A4D; 3FE2
T27918	ECNUMBER	EC 3.6.4.13
T27918	SEQUENCE	MSGYSSDRDRGRDRGFGAPRFGGSRAGPLSGKKFGNPGEKLVKKKWNLDELPKFEKNFYQEHPDLARRTAQEVETYRRSKEITVRGHNCPKPVLNFYEANFPANVMDVIARQNFTEPTAIQAQGWPVALSGLDMVGVAQTGSGKTLSYLLPAIVHINHQPFLERGDGPICLVLAPTRELAQQVQQVAAEYCRACRLKSTCIYGGAPKGPQIRDLERGVEICIATPGRLIDFLECGKTNLRRTTYLVLDEADRMLDMGFEPQIRKIVDQIRPDRQTLMWSATWPKEVRQLAEDFLKDYIHINIGALELSANHNILQIVDVCHDVEKDEKLIRLMEEIMSEKENKTIVFVETKRRCDELTRKMRRDGWPAMGIHGDKSQQERDWVLNEFKHGKAPILIATDVASRGLDVEDVKFVINYDYPNSSEDYIHRIGRTARSTKTGTAYTFFTPNNIKQVSDLISVLREANQAINPKLLQLVEDRGSGRSRGRGGMKDDRRDRYSAGKRGGFNTFRDRENYDRGYSSLLKRDFGAKTQNGVYSAANYTNGSFGSNFVSAGIQTSFRTGNPTGTYQNGYDSTQQYGSNVPNMHNGMNQQAYAYPATAAAPMIGYPMPTGYSQ
T27918	DRUGINFO	D0S1TI	RX-5902	Phase 2

T93061	TARGETID	T93061
T93061	UNIPROID	DDX5_HUMAN
T93061	TARGNAME	Phosphorylated p68 RNA helicase (pDDX5)
T93061	GENENAME	DDX5
T93061	TARGTYPE	Clinical trial
T93061	SYNONYMS	RNA helicase p68 (phosphorylated); Probable ATP-dependent RNA helicase DDX5 (phosphorylated); HLR1 (phosphorylated); HELR (phosphorylated); G17P1 (phosphorylated); DEAD box protein 5 (phosphorylated)
T93061	FUNCTION	Involved in the alternative regulation of pre-mRNA splicing; its RNA helicase activity is necessary for increasing tau exon 10 inclusion and occurs in a RBM4-dependent manner. Binds to the tau pre-mRNA in the stem-loop region downstream of exon 10. The rate of ATP hydrolysis is highly stimulated by single-stranded RNA. Involved in transcriptional regulation; the function is independent of the RNA helicase activity. Transcriptional coactivator for androgen receptor AR but probably not ESR1. Synergizes with DDX17 and SRA1 RNA to activate MYOD1 transcriptional activity and involved in skeletal muscle differentiation. Transcriptional coactivator for p53/TP53 and involved in p53/TP53 transcriptional response to DNA damage and p53/TP53-dependent apoptosis. Transcriptional coactivator for RUNX2 and involved in regulation of osteoblast differentiation. Acts as transcriptional repressor in a promoter-specific manner; the function probably involves association with histone deacetylases, such as HDAC1. As component of a large PER complex is involved in the inhibition of 3' transcriptional termination of circadian target genes such as PER1 and NR1D1 and the control of the circadian rhythms.
T93061	PDBSTRUC	4A4D; 3FE2
T93061	ECNUMBER	EC 3.6.4.13
T93061	SEQUENCE	MSGYSSDRDRGRDRGFGAPRFGGSRAGPLSGKKFGNPGEKLVKKKWNLDELPKFEKNFYQEHPDLARRTAQEVETYRRSKEITVRGHNCPKPVLNFYEANFPANVMDVIARQNFTEPTAIQAQGWPVALSGLDMVGVAQTGSGKTLSYLLPAIVHINHQPFLERGDGPICLVLAPTRELAQQVQQVAAEYCRACRLKSTCIYGGAPKGPQIRDLERGVEICIATPGRLIDFLECGKTNLRRTTYLVLDEADRMLDMGFEPQIRKIVDQIRPDRQTLMWSATWPKEVRQLAEDFLKDYIHINIGALELSANHNILQIVDVCHDVEKDEKLIRLMEEIMSEKENKTIVFVETKRRCDELTRKMRRDGWPAMGIHGDKSQQERDWVLNEFKHGKAPILIATDVASRGLDVEDVKFVINYDYPNSSEDYIHRIGRTARSTKTGTAYTFFTPNNIKQVSDLISVLREANQAINPKLLQLVEDRGSGRSRGRGGMKDDRRDRYSAGKRGGFNTFRDRENYDRGYSSLLKRDFGAKTQNGVYSAANYTNGSFGSNFVSAGIQTSFRTGNPTGTYQNGYDSTQQYGSNVPNMHNGMNQQAYAYPATAAAPMIGYPMPTGYSQ
T93061	DRUGINFO	D0S1TI	RX-5902	Phase 2

T32348	TARGETID	T32348
T32348	FORMERID	TTDI02059
T32348	UNIPROID	EGR1_HUMAN
T32348	TARGNAME	Early growth response protein 1 (EGR-1)
T32348	GENENAME	EGR1
T32348	TARGTYPE	Clinical trial
T32348	SYNONYMS	Zinc finger protein Krox24; Zinc finger protein Krox-24; Zinc finger protein 225; ZNF225; Transcription factor Zif268; Transcription factor ETR103; Nerve growth factorinduced protein A; Nerve growth factor-induced protein A; NGFIA; NGFI-A; KROX24; AT225
T32348	FUNCTION	Recognizes and binds to the DNA sequence 5'-GCG(T/G)GGGCG-3'(EGR-site) in the promoter region of target genes. Binds double-stranded target DNA, irrespective of the cytosine methylation status. Regulates the transcription of numerous target genes, and thereby plays an important role in regulating the response to growth factors, DNA damage, and ischemia. Plays a role in the regulation of cell survival, proliferation and cell death. Activates expression of p53/TP53 and TGFB1, and thereby helps prevent tumor formation. Required for normal progress through mitosis and normal proliferation of hepatocytes after partial hepatectomy. Mediates responses to ischemia and hypoxia; regulates the expression of proteins such as IL1B and CXCL2 that are involved in inflammatory processes and development of tissue damage after ischemia. Regulates biosynthesis of luteinizing hormone (LHB) in the pituitary. Regulates the amplitude of the expression rhythms of clock genes: ARNTL/BMAL1, PER2 and NR1D1 in the liver via the activation of PER1 (clock repressor) transcription. Regulates the rhythmic expression of core-clock gene ARNTL/BMAL1 in the suprachiasmatic nucleus (SCN). Transcriptional regulator.
T32348	PDBSTRUC	5N14; 4X9J; 4R2D; 4R2C; 4R2A
T32348	BIOCLASS	EGR C2H2-type zinc-finger
T32348	SEQUENCE	MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDELTRHIRIHTGQKPFQCRICMRNFSRSDHLTTHIRTHTGEKPFACDICGRKFARSDERKRHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC
T32348	DRUGINFO	D01OIR	AYX-1	Phase 2

T18059	TARGETID	T18059
T18059	FORMERID	TTDNC00676
T18059	UNIPROID	CR2_HUMAN
T18059	TARGNAME	Complement receptor type 2 (CD21)
T18059	GENENAME	CR2
T18059	TARGTYPE	Clinical trial
T18059	SYNONYMS	EpsteinBarr virus receptor; Epstein-Barr virus receptor; EBV receptor; Cr2; Complement C3d receptor; C3DR
T18059	FUNCTION	Participates in B lymphocytes activation. Receptor for complement C3, for the Epstein-Barr virus on human B-cells and T-cells and for HNRNPU.
T18059	PDBSTRUC	3OED; 2GSX; 2ATY; 1W2S; 1W2R
T18059	SEQUENCE	MGAAGLLGVFLALVAPGVLGISCGSPPPILNGRISYYSTPIAVGTVIRYSCSGTFRLIGEKSLLCITKDKVDGTWDKPAPKCEYFNKYSSCPEPIVPGGYKIRGSTPYRHGDSVTFACKTNFSMNGNKSVWCQANNMWGPTRLPTCVSVFPLECPALPMIHNGHHTSENVGSIAPGLSVTYSCESGYLLVGEKIINCLSSGKWSAVPPTCEEARCKSLGRFPNGKVKEPPILRVGVTANFFCDEGYRLQGPPSSRCVIAGQGVAWTKMPVCEEIFCPSPPPILNGRHIGNSLANVSYGSIVTYTCDPDPEEGVNFILIGESTLRCTVDSQKTGTWSGPAPRCELSTSAVQCPHPQILRGRMVSGQKDRYTYNDTVIFACMFGFTLKGSKQIRCNAQGTWEPSAPVCEKECQAPPNILNGQKEDRHMVRFDPGTSIKYSCNPGYVLVGEESIQCTSEGVWTPPVPQCKVAACEATGRQLLTKPQHQFVRPDVNSSCGEGYKLSGSVYQECQGTIPWFMEIRLCKEITCPPPPVIYNGAHTGSSLEDFPYGTTVTYTCNPGPERGVEFSLIGESTIRCTSNDQERGTWSGPAPLCKLSLLAVQCSHVHIANGYKISGKEAPYFYNDTVTFKCYSGFTLKGSSQIRCKADNTWDPEIPVCEKETCQHVRQSLQELPAGSRVELVNTSCQDGYQLTGHAYQMCQDAENGIWFKKIPLCKVIHCHPPPVIVNGKHTGMMAENFLYGNEVSYECDQGFYLLGEKKLQCRSDSKGHGSWSGPSPQCLRSPPVTRCPNPEVKHGYKLNKTHSAYSHNDIVYVDCNPGFIMNGSRVIRCHTDNTWVPGVPTCIKKAFIGCPPPPKTPNGNHTGGNIARFSPGMSILYSCDQGYLLVGEALLLCTHEGTWSQPAPHCKEVNCSSPADMDGIQKGLEPRKMYQYGAVVTLECEDGYMLEGSPQSQCQSDHQWNPPLAVCRSRSLAPVLCGIAAGLILLTFLIVITLYVISKHRARNYYTDTSQKEAFHLEAREVYSVDPYNPAS
T18059	DRUGINFO	D01XQQ	TT-30	Phase 1

T95286	TARGETID	T95286
T95286	FORMERID	TTDR01066
T95286	UNIPROID	MAG_HUMAN
T95286	TARGNAME	Myelin-associated glycoprotein (MAG)
T95286	GENENAME	MAG
T95286	TARGTYPE	Clinical trial
T95286	SYNONYMS	MAG
T95286	FUNCTION	Adhesion molecule in postnatal neural development that mediates sialic-acid dependent cell-cell interactions between neuronal and myelinating cells. Preferentially binds to alpha-2,3- linked sialic acid.
T95286	BIOCLASS	Immunoglobulin
T95286	SEQUENCE	MIFLTALPLFWIMISASRGGHWGAWMPSSISAFEGTCVSIPCRFDFPDELRPAVVHGVWYFNSPYPKNYPPVVFKSRTQVVHESFQGRSRLLGDLGLRNCTLLLSNVSPELGGKYYFRGDLGGYNQYTFSEHSVLDIVNTPNIVVPPEVVAGTEVEVSCMVPDNCPELRPELSWLGHEGLGEPAVLGRLREDEGTWVQVSLLHFVPTREANGHRLGCQASFPNTTLQFEGYASMDVKYPPVIVEMNSSVEAIEGSHVSLLCGADSNPPPLLTWMRDGTVLREAVAESLLLELEEVTPAEDGVYACLAENAYGQDNRTVGLSVMYAPWKPTVNGTMVAVEGETVSILCSTQSNPDPILTIFKEKQILSTVIYESELQLELPAVSPEDDGEYWCVAENQYGQRATAFNLSVEFAPVLLLESHCAAARDTVQCLCVVKSNPEPSVAFELPSRNVTVNESEREFVYSERSGLVLTSILTLRGQAQAPPRVICTARNLYGAKSLELPFQGAHRLMWAKIGPVGAVVAFAILIAIVCYITQTRRKKNVTESPSFSAGDNPPVLFSSDFRISGAPEKYESERRLGSERRLLGLRGEPPELDLSYSHSDLGKRPTKDSYTLTEELAEYAEIRVK
T95286	DRUGINFO	D0JP8D	GSK249320	Phase 2

T00750	TARGETID	T00750
T00750	FORMERID	TTDI02074
T00750	UNIPROID	FUT3_HUMAN
T00750	TARGNAME	Galactoside 3(4)-L-fucosyltransferase (FUT3)
T00750	GENENAME	FUT3
T00750	TARGTYPE	Clinical trial
T00750	SYNONYMS	Lewis FT; Fucosyltransferase III; Fucosyltransferase 3; FucTIII; FUT3; Blood group Lewis alpha4fucosyltransferase
T00750	FUNCTION	May catalyze alpha-1,3and alpha-1,4 glycosidic linkages involved in the expression of Vim-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination; Lewis-positive(Le(+)) individuals have an active enzyme while Lewis-negative (Le(-)) individuals have an inactive enzyme. Also acts on the corresponding 1,4-galactosyl derivative, forming 1,3-L-fucosyl links.
T00750	BIOCLASS	Hexosyltransferase
T00750	ECNUMBER	EC 2.4.1.65
T00750	SEQUENCE	MDPLGAAKPQWPWRRCLAALLFQLLVAVCFFSYLRVSRDDATGSPRAPSGSSRQDTTPTRPTLLILLWTWPFHIPVALSRCSEMVPGTADCHITADRKVYPQADTVIVHHWDIMSNPKSRLPPSPRPQGQRWIWFNLEPPPNCQHLEALDRYFNLTMSYRSDSDIFTPYGWLEPWSGQPAHPPLNLSAKTELVAWAVSNWKPDSARVRYYQSLQAHLKVDVYGRSHKPLPKGTMMETLSRYKFYLAFENSLHPDYITEKLWRNALEAWAVPVVLGPSRSNYERFLPPDAFIHVDDFQSPKDLARYLQELDKDHARYLSYFRWRETLRPRSFSWALDFCKACWKLQQESRYQTVRSIAAWFT
T00750	DRUGINFO	D0I3OS	Rebmab-100	Phase 2

T66161	TARGETID	T66161
T66161	FORMERID	TTDR00385
T66161	UNIPROID	FLNA_HUMAN
T66161	TARGNAME	Filamin A (FLNA)
T66161	GENENAME	FLNA
T66161	TARGTYPE	Clinical trial
T66161	SYNONYMS	Nonmuscle filamin; Non-muscle filamin; Filamin-A; Filamin-1; Filamin 1; FLN1; FLN-A; FLN; Endothelial actin-binding protein; Endothelial actin cytoskeleton; Alpha-filamin; Actin-binding protein 280; ABP-280
T66161	FUNCTION	Anchors various transmembrane proteins to the actin cytoskeleton and serves as a scaffold for a wide range of cytoplasmic signaling proteins. Interaction with FLNA may allow neuroblast migration from the ventricular zone into the cortical plate. Tethers cell surface-localized furin, modulates its rate of internalization and directs its intracellular trafficking. Involved in ciliogenesis. Plays a role in cell-cell contacts and adherens junctions during the development of blood vessels, heart and brain organs. Plays a role in platelets morphology through interaction with SYK that regulates ITAM- and ITAM-like-containing receptor signaling, resulting in by platelet cytoskeleton organization maintenance. Promotes orthogonal branching of actin filaments and links actin filaments to membrane glycoproteins.
T66161	PDBSTRUC	6EW1; 6D8C; 5XR1; 4P3W; 4M9P
T66161	BIOCLASS	Dystrophin protein
T66161	SEQUENCE	MSSSHSRAGQSAAGAAPGGGVDTRDAEMPATEKDLAEDAPWKKIQQNTFTRWCNEHLKCVSKRIANLQTDLSDGLRLIALLEVLSQKKMHRKHNQRPTFRQMQLENVSVALEFLDRESIKLVSIDSKAIVDGNLKLILGLIWTLILHYSISMPMWDEEEDEEAKKQTPKQRLLGWIQNKLPQLPITNFSRDWQSGRALGALVDSCAPGLCPDWDSWDASKPVTNAREAMQQADDWLGIPQVITPEEIVDPNVDEHSVMTYLSQFPKAKLKPGAPLRPKLNPKKARAYGPGIEPTGNMVKKRAEFTVETRSAGQGEVLVYVEDPAGHQEEAKVTANNDKNRTFSVWYVPEVTGTHKVTVLFAGQHIAKSPFEVYVDKSQGDASKVTAQGPGLEPSGNIANKTTYFEIFTAGAGTGEVEVVIQDPMGQKGTVEPQLEARGDSTYRCSYQPTMEGVHTVHVTFAGVPIPRSPYTVTVGQACNPSACRAVGRGLQPKGVRVKETADFKVYTKGAGSGELKVTVKGPKGEERVKQKDLGDGVYGFEYYPMVPGTYIVTITWGGQNIGRSPFEVKVGTECGNQKVRAWGPGLEGGVVGKSADFVVEAIGDDVGTLGFSVEGPSQAKIECDDKGDGSCDVRYWPQEAGEYAVHVLCNSEDIRLSPFMADIRDAPQDFHPDRVKARGPGLEKTGVAVNKPAEFTVDAKHGGKAPLRVQVQDNEGCPVEALVKDNGNGTYSCSYVPRKPVKHTAMVSWGGVSIPNSPFRVNVGAGSHPNKVKVYGPGVAKTGLKAHEPTYFTVDCAEAGQGDVSIGIKCAPGVVGPAEADIDFDIIRNDNDTFTVKYTPRGAGSYTIMVLFADQATPTSPIRVKVEPSHDASKVKAEGPGLSRTGVELGKPTHFTVNAKAAGKGKLDVQFSGLTKGDAVRDVDIIDHHDNTYTVKYTPVQQGPVGVNVTYGGDPIPKSPFSVAVSPSLDLSKIKVSGLGEKVDVGKDQEFTVKSKGAGGQGKVASKIVGPSGAAVPCKVEPGLGADNSVVRFLPREEGPYEVEVTYDGVPVPGSPFPLEAVAPTKPSKVKAFGPGLQGGSAGSPARFTIDTKGAGTGGLGLTVEGPCEAQLECLDNGDGTCSVSYVPTEPGDYNINILFADTHIPGSPFKAHVVPCFDASKVKCSGPGLERATAGEVGQFQVDCSSAGSAELTIEICSEAGLPAEVYIQDHGDGTHTITYIPLCPGAYTVTIKYGGQPVPNFPSKLQVEPAVDTSGVQCYGPGIEGQGVFREATTEFSVDARALTQTGGPHVKARVANPSGNLTETYVQDRGDGMYKVEYTPYEEGLHSVDVTYDGSPVPSSPFQVPVTEGCDPSRVRVHGPGIQSGTTNKPNKFTVETRGAGTGGLGLAVEGPSEAKMSCMDNKDGSCSVEYIPYEAGTYSLNVTYGGHQVPGSPFKVPVHDVTDASKVKCSGPGLSPGMVRANLPQSFQVDTSKAGVAPLQVKVQGPKGLVEPVDVVDNADGTQTVNYVPSREGPYSISVLYGDEEVPRSPFKVKVLPTHDASKVKASGPGLNTTGVPASLPVEFTIDAKDAGEGLLAVQITDPEGKPKKTHIQDNHDGTYTVAYVPDVTGRYTILIKYGGDEIPFSPYRVRAVPTGDASKCTVTVSIGGHGLGAGIGPTIQIGEETVITVDTKAAGKGKVTCTVCTPDGSEVDVDVVENEDGTFDIFYTAPQPGKYVICVRFGGEHVPNSPFQVTALAGDQPSVQPPLRSQQLAPQYTYAQGGQQTWAPERPLVGVNGLDVTSLRPFDLVIPFTIKKGEITGEVRMPSGKVAQPTITDNKDGTVTVRYAPSEAGLHEMDIRYDNMHIPGSPLQFYVDYVNCGHVTAYGPGLTHGVVNKPATFTVNTKDAGEGGLSLAIEGPSKAEISCTDNQDGTCSVSYLPVLPGDYSILVKYNEQHVPGSPFTARVTGDDSMRMSHLKVGSAADIPINISETDLSLLTATVVPPSGREEPCLLKRLRNGHVGISFVPKETGEHLVHVKKNGQHVASSPIPVVISQSEIGDASRVRVSGQGLHEGHTFEPAEFIIDTRDAGYGGLSLSIEGPSKVDINTEDLEDGTCRVTYCPTEPGNYIINIKFADQHVPGSPFSVKVTGEGRVKESITRRRRAPSVANVGSHCDLSLKIPEISIQDMTAQVTSPSGKTHEAEIVEGENHTYCIRFVPAEMGTHTVSVKYKGQHVPGSPFQFTVGPLGEGGAHKVRAGGPGLERAEAGVPAEFSIWTREAGAGGLAIAVEGPSKAEISFEDRKDGSCGVAYVVQEPGDYEVSVKFNEEHIPDSPFVVPVASPSGDARRLTVSSLQESGLKVNQPASFAVSLNGAKGAIDAKVHSPSGALEECYVTEIDQDKYAVRFIPRENGVYLIDVKFNGTHIPGSPFKIRVGEPGHGGDPGLVSAYGAGLEGGVTGNPAEFVVNTSNAGAGALSVTIDGPSKVKMDCQECPEGYRVTYTPMAPGSYLISIKYGGPYHIGGSPFKAKVTGPRLVSNHSLHETSSVFVDSLTKATCAPQHGAPGPGPADASKVVAKGLGLSKAYVGQKSSFTVDCSKAGNNMLLVGVHGPRTPCEEILVKHVGSRLYSVSYLLKDKGEYTLVVKWGDEHIPGSPYRVVVP
T66161	DRUGINFO	D6ETD2	PTI-125	Phase 2
T66161	DRUGINFO	D0X2HJ	PTI-125	Phase 1

T72042	TARGETID	T72042
T72042	UNIPROID	PUR2_HUMAN
T72042	TARGNAME	GAR transformylase (GART)
T72042	GENENAME	GART
T72042	TARGTYPE	Clinical trial
T72042	SYNONYMS	Phosphoribosylglycinamide formyltransferase; 5'-phosphoribosylglycinamide transformylase; GART
T72042	FUNCTION	A folate-dependent enzyme, essential  for the de novo purine synthesis pathway.
T72042	PDBSTRUC	5J9F; 4ZZ3; 4ZZ2; 4ZZ1; 4ZZ0
T72042	ECNUMBER	EC 2.1.2.2
T72042	SEQUENCE	VAVLISGTGSNLQALIDSTREPNSSAQIDIVISNKAAVAGLDKAERAGIPTRVINHKLYKNRVEFDSAIDLVLEEFSIDIVCLAGFMRILSGPFVQKWNGKMLNIHPSLLPSFKGSNAHEQALETGVTVTGCTVHFVAEDVDAGQIILQEAVPVKRGDTVATLSERVKLAEHKIFPAALQLVASGTVQLGENGKICWVKEE
T72042	DRUGINFO	D0A8LP	AG2034	Phase 1
T72042	DRUGINFO	D06YIB	DDATHF	Investigative

T21291	TARGETID	T21291
T21291	FORMERID	TTDI02017
T21291	UNIPROID	AMA1_PLAFF
T21291	TARGNAME	Plasmodium Apical membrane protein (Malaria AMA-1)
T21291	GENENAME	Malaria AMA-1
T21291	TARGTYPE	Clinical trial
T21291	SYNONYMS	Merozoite surface antigen; Apical membrane antigen 1; AMA1; AMA-1
T21291	FUNCTION	Involved in parasite invasion of erythrocytes.
T21291	PDBSTRUC	2Q8B; 2Q8A; 1YXE
T21291	BIOCLASS	Apicomplexan parasites AMA1
T21291	SEQUENCE	MRKLYCVLLLSAFEFTYMINFGRGQNYWEHPYQKSDVYHPINEHREHPKEYQYPLHQEHTYQQEDSGEDENTLQHAYPIDHEGAEPAPQEQNLFSSIEIVERSNYMGNPWTEYMAKYDIEEVHGSGIRVDLGEDAEVAGTQYRLPSGKCPVFGKGIIIENSNTTFLTPVATGNQYLKDGGFAFPPTEPLMSPMTLDEMRHFYKDNKYVKNLDELTLCSRHAGNMIPDNDKNSNYKYPAVYDDKDKKCHILYIAAQENNGPRYCNKDESKRNSMFCFRPAKDISFQNYTYLSKNVVDNWEKVCPRKNLQNAKFGLWVDGNCEDIPHVNEFSAIDLFECNKLVFELSASDQPKQYEQHLTDYEKIKEGFKNKNASMIKSAFLPTGAFKADRYKSHGKGYNWGNYNTETQKCEIFNVKPTCLINNSSYIATTALSHPIEVEHNFPCSLYKNEIMKEIERESKRIKLNDNDDEGNKKIIAPRIFISDDKDSLKCPCDPEIVSNSTCNFFVCKCVERRAEVTSNNEVVVKEEYKDEYADIPEHKPTYDKMKIIIASSAAVAVLATILMVYLYKRKGNAEKYDKMDEPQHYGKSNSRNDEMLDPEASFWGEEKRASHTTPVLMEKPYY
T21291	DRUGINFO	D02CLV	AdCh63 AMA1	Phase 1/2
T21291	DRUGINFO	D03KHQ	DNA-Ad	Phase 1/2
T21291	DRUGINFO	D0H9OT	PfAMA-1	Phase 1

T87689	TARGETID	T87689
T87689	FORMERID	TTDI02018
T87689	UNIPROID	ANFC_HUMAN
T87689	TARGNAME	C-type natriuretic peptide (NPPC)
T87689	GENENAME	NPPC
T87689	TARGTYPE	Clinical trial
T87689	SYNONYMS	NPPC; Ctype natriuretic peptide; CNP53
T87689	FUNCTION	Hormone which plays a role in endochondral ossification through regulation of cartilaginous growth plate chondrocytes proliferation and differentiation. May also be vasoactive and natriuretic. Specifically binds and stimulates the cGMP production of the NPR2 receptor. Binds the clearance receptor NPR3.
T87689	PDBSTRUC	1JDP
T87689	BIOCLASS	C-type natriuretic peptide
T87689	SEQUENCE	MHLSQLLACALLLTLLSLRPSEAKPGAPPKVPRTPPAEELAEPQAAGGGQKKGDKAPGGGGANLKGDRSRLLRDLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC

T88729	TARGETID	T88729
T88729	FORMERID	TTDR00082
T88729	UNIPROID	UCP1_HUMAN
T88729	TARGNAME	Mitochondrial uncoupling protein 1 (UCP1)
T88729	GENENAME	UCP1
T88729	TARGTYPE	Clinical trial
T88729	SYNONYMS	UCP 1; UCP; Thermogenin; Solute carrier family 25 member 7; SLC25A7; Mitochondrial brown fat uncoupling protein 1
T88729	FUNCTION	Functions as a long-chain fatty acid/LCFA and proton symporter, simultaneously transporting one LCFA and one proton through the inner mitochondrial membrane. However, LCFAs remaining associated with the transporter via their hydrophobic tails, it results in an apparent transport of protons activated by LCFAs. Thereby, dissipates the mitochondrial proton gradient and converts the energy of substrate oxydation into heat instead of ATP. Regulates the production of reactive oxygen species/ROS by mitochondria. Mitochondrial protein responsible for thermogenic respiration, a specialized capacity of brown adipose tissue and beige fat that participates to non-shivering adaptive thermogenesis to temperature and diet variations and more generally to the regulation of energy balance.
T88729	BIOCLASS	Mitochondrial carrier
T88729	SEQUENCE	MGGLTASDVHPTLGVQLFSAGIAACLADVITFPLDTAKVRLQVQGECPTSSVIRYKGVLGTITAVVKTEGRMKLYSGLPAGLQRQISSASLRIGLYDTVQEFLTAGKETAPSLGSKILAGLTTGGVAVFIGQPTEVVKVRLQAQSHLHGIKPRYTGTYNAYRIIATTEGLTGLWKGTTPNLMRSVIINCTELVTYDLMKEAFVKNNILADDVPCHLVSALIAGFCATAMSSPVDVVKTRFINSPPGQYKSVPNCAMKVFTNEGPTAFFKGLVPSFLRLGSWNVIMFVCFEQLKRELSKSRQTMDCAT
T88729	DRUGINFO	D07WHS	CL-316,243	Phase 2
T88729	DRUGINFO	D02CFE	NC-2100	Investigative

T04911	TARGETID	T04911
T04911	FORMERID	TTDI02214
T04911	UNIPROID	POLG_HCV1
T04911	TARGNAME	Hepatitis C virus Non-structural 4B (HCV NS4B)
T04911	GENENAME	HCV NS4B
T04911	TARGTYPE	Clinical trial
T04911	SYNONYMS	HCV p27
T04911	FUNCTION	Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity).
T04911	PDBSTRUC	3SU4; 3RC5; 3RC4; 3QGI; 3QGH
T04911	BIOCLASS	Hepacivirus polyprotein
T04911	SEQUENCE	SQHLPYIEQGMMLAEQFKQKALGLLQTASRQAEVIAPAVQTNWQKLETFWAKHMWNFISGIQYLAGLSTLPGNPAIASLMAFTAAVTSPLTTSQTLLFNILGGWVAAQLAAPGAATAFVGAGLAGAAIGSVGLGKVLIDILAGYGAGVAGALVAFKIMSGEVPSTEDLVNLLPAILSPGALVVGVVCAAILRRHVGPGEGAVQWMNRLIAFASRGNHVSPTHYVPESDAAARVTAILSSLTVTQLLRRLHQWISSECTTPC
T04911	DRUGINFO	D06XDJ	Clemizole	Phase 1

T15783	TARGETID	T15783
T15783	FORMERID	TTDNC00520
T15783	UNIPROID	NKG2A_HUMAN
T15783	TARGNAME	NKG2-A/B-activating NK receptor (NKG2A)
T15783	GENENAME	KLRC1
T15783	TARGTYPE	Clinical trial
T15783	SYNONYMS	NKG2A/NKG2B type II integral membrane protein; NKG2A/Bactivating NK receptor; NK cell receptor A; KLRC1; CD159a; CD159 antigenlike family member A
T15783	FUNCTION	Plays a role as a receptor for the recognition of MHC class I HLA-E molecules by NK cells and some cytotoxic T-cells.
T15783	PDBSTRUC	3CII; 3CDG; 3BDW; 2YU7; 2RMX
T15783	SEQUENCE	MDNQGVIYSDLNLPPNPKRQQRKPKGNKNSILATEQEITYAELNLQKASQDFQGNDKTYHCKDLPSAPEKLIVGILGIICLILMASVVTIVVIPSTLIQRHNNSSLNTRTQKARHCGHCPEEWITYSNSCYYIGKERRTWEESLLACTSKNSSLLSIDNEEEMKFLSIISPSSWIGVFRNSSHHPWVTMNGLAFKHEIKDSDNAELNCAVLQVNRLKSAQCGSSIIYHCKHKL
T15783	DRUGINFO	D07YNM	NN8765	Phase 2
T15783	DRUGINFO	D0RI6Q	Monalizumab	Phase 1/2
T15783	DRUGINFO	D6XS7L	BMS-986315	Phase 1/2
T15783	DRUGINFO	DNUS02	IM1240	Preclinical

T49736	TARGETID	T49736
T49736	FORMERID	TTDI02302
T49736	UNIPROID	CD6_HUMAN
T49736	TARGNAME	T-cell differentiation antigen CD6 (TP120)
T49736	GENENAME	CD6
T49736	TARGTYPE	Clinical trial
T49736	SYNONYMS	T12
T49736	FUNCTION	Contributes to signaling cascades triggered by activation of the TCR/CD3 complex. Functions as costimulatory molecule; promotes T-cell activation and proliferation. Contributes to the formation and maturation of the immunological synapse. Functions as calcium-dependent pattern receptor that binds and aggregates both Gram-positive and Gram-negative bacteria. Binds both lipopolysaccharide (LPS) from Gram-negative bacteria and lipoteichoic acid from Gram-positive bacteria. LPS binding leads to the activation of signaling cascades and down-stream MAP kinases. Mediates activation of the inflammatory response and the secretion of pro-inflammatory cytokines in response to LPS. Cell adhesion molecule that mediates cell-cell contacts and regulates T-cell responses via its interaction with ALCAM/CD166.
T49736	PDBSTRUC	5A2E
T49736	SEQUENCE	MWLFFGITGLLTAALSGHPSPAPPDQLNTSSAESELWEPGERLPVRLTNGSSSCSGTVEVRLEASWEPACGALWDSRAAEAVCRALGCGGAEAASQLAPPTPELPPPPAAGNTSVAANATLAGAPALLCSGAEWRLCEVVEHACRSDGRRARVTCAENRALRLVDGGGACAGRVEMLEHGEWGSVCDDTWDLEDAHVVCRQLGCGWAVQALPGLHFTPGRGPIHRDQVNCSGAEAYLWDCPGLPGQHYCGHKEDAGAVCSEHQSWRLTGGADRCEGQVEVHFRGVWNTVCDSEWYPSEAKVLCQSLGCGTAVERPKGLPHSLSGRMYYSCNGEELTLSNCSWRFNNSNLCSQSLAARVLCSASRSLHNLSTPEVPASVQTVTIESSVTVKIENKESRELMLLIPSIVLGILLLGSLIFIAFILLRIKGKYALPVMVNHQHLPTTIPAGSNSYQPVPITIPKEVFMLPIQVQAPPPEDSDSGSDSDYEHYDFSAQPPVALTTFYNSQRHRVTDEEVQQSRFQMPPLEEGLEELHASHIPTANPGHCITDPPSLGPQYHPRSNSESSTSSGEDYCNSPKSKLPPWNPQVFSSERSSFLEQPPNLELAGTQPAFSAGPPADDSSSTSSGEWYQNFQPPPQPPSEEQFGCPGSPSPQPDSTDNDDYDDISAA
T49736	DRUGINFO	D06QSN	Itolizumab	Phase 3

T54347	TARGETID	T54347
T54347	FORMERID	TTDI02044
T54347	UNIPROID	CHS3_CANAX
T54347	TARGNAME	Candida Chitin synthase 3 (Candi CHS3)
T54347	GENENAME	Candi CHS3
T54347	TARGTYPE	Clinical trial
T54347	SYNONYMS	ClassIV chitin synthase3; ChitinUDP acetylglucosaminyl transferase 3; Chitin synthase 3; CHS3
T54347	FUNCTION	Formation and repair ofthe disk-shaped septum in yeast and the cross walls of the hyphal phase.
T54347	BIOCLASS	Hexosyltransferase
T54347	ECNUMBER	EC 2.4.1.16
T54347	SEQUENCE	MSNFRDSSSPRRGYSEFDPESGEGLGRKKSLIRPERSRMDESHPRFHYTQVANQESNHIKVQPSSTGVDPRKSNELSTSRSHLSNYATPPHQEEEEDEGIPLMDIHNASPNVSSDQNNDLKGGREVYGLNDEINDYGSSPKKNQVISSSRPMNNEKPAKPKHDIYFWKVYCYAITFWAPAPLLKLFGLPTKDRQFAWREKIGLISCILYVGAFVAYLTFGFTKTVCSSQVVRTQINHVNGGYLIINGRAYDLTSSQHPKAAGIQAGSNVLYPPMNAGGKDASFLFQNVNGNCKGLIKPRDNCSIPYDGDELAWYMPCRLFNQDGSTKPNNTFAYYKGWACHTSETARDAYYKLKVNGDVYFTWDDVKNSSRNLVVYSGNVLDLDLINWIETDDVTYPELFDKLRDDETYRGLDISLVLTNSEERQAARCLTEIIKVGSIDTDTIGCIASKVVLYMSLVFILSVVVVKFIMACWFKWVTSRKQGATMYDSKAWAKRNREIEDWVDHDHGIGAEVKTVPVKARANYKAAKTNRQSVFHRAQKLSLGPNADLSQYYDNPNALSKTFKYTTMSTQAALLGRNGYGKRGNNANKSVSGGFNGRQSNLYLTDQGSSTDLLNRPVSSYNPFDSMGDDSIVINGLSPDIIHPDVVPQPPVEYQPFGYPLAHTINLVTCYSEDEEGIRITLDSIATTDYPNSHKLILVICDGIIKGSGNDETTPDIVLDMMSDLTVPRDEVEAYSYVAVAQGSKRHNMAKVYAGFYKYNDETVPPEKQQRIPMITIVKCGTPEEASAPKPGNRGKRDSQIILMSFLQKVVFDERMTSLEYEMLQSIWRITGLMAEFYEIVLMVDADTKVFPDSLTHMVAEMVKDPTIMGLCGETKISNKAQTWVTAIQVFEYYISHHQAKAFESIFGGVTCLPGCFCMYRIKAPKGSDGYWVPILANPDIVERYSDNVVDTLHRKNLLLLGEDRYLSSLMLRTFPTRKQVFVPKAACKTVVPDKFKVLLSQRRRWINSTVHNLFELVLVKDLCGTFCFSMQFVIFIELIGTLVLPAAITFTIYVIIVAIVSKPTPVMSLVLLAVIFGLPGCLIVITVSSLSYLVYFVIYLFALPIWNFVLPSYAYWKFDDFSWGETRTVAGGDKGDHSAVEGKFDSSKIAMKRWREWERERRSTENRKQQQQQQLTNNSSNNLAVPGAAWDPSNTGGNLIDDLSQGSSSGSS
T54347	DRUGINFO	D0SN1T	Nikkomycin Z	Phase 1/2

T80020	TARGETID	T80020
T80020	UNIPROID	L1CAM_HUMAN
T80020	TARGNAME	Neural cell adhesion molecule L1 (L1CAM)
T80020	GENENAME	L1CAM
T80020	TARGTYPE	Clinical trial
T80020	SYNONYMS	SPG1; S10; NCAM-L1; N-CAML1; N-CAM-L1; MIC5; MASA; L1 cell adhesion molecule; HSAS1; HSAS; CD171; CAML1
T80020	FUNCTION	During brain development, critical in multiple processes, including neuronal migration, axonal growth and fasciculation, and synaptogenesis. In the mature brain, plays a role in the dynamics of neuronal structure and function, including synaptic plasticity. Neural cell adhesion molecule involved in the dynamics of cell adhesion and in the generation of transmembrane signals at tyrosine kinase receptors.
T80020	BIOCLASS	Immunoglobulin
T80020	SEQUENCE	MVVALRYVWPLLLCSPCLLIQIPEEYEGHHVMEPPVITEQSPRRLVVFPTDDISLKCEASGKPEVQFRWTRDGVHFKPKEELGVTVYQSPHSGSFTITGNNSNFAQRFQGIYRCFASNKLGTAMSHEIRLMAEGAPKWPKETVKPVEVEEGESVVLPCNPPPSAEPLRIYWMNSKILHIKQDERVTMGQNGNLYFANVLTSDNHSDYICHAHFPGTRTIIQKEPIDLRVKATNSMIDRKPRLLFPTNSSSHLVALQGQPLVLECIAEGFPTPTIKWLRPSGPMPADRVTYQNHNKTLQLLKVGEEDDGEYRCLAENSLGSARHAYYVTVEAAPYWLHKPQSHLYGPGETARLDCQVQGRPQPEVTWRINGIPVEELAKDQKYRIQRGALILSNVQPSDTMVTQCEARNRHGLLLANAYIYVVQLPAKILTADNQTYMAVQGSTAYLLCKAFGAPVPSVQWLDEDGTTVLQDERFFPYANGTLGIRDLQANDTGRYFCLAANDQNNVTIMANLKVKDATQITQGPRSTIEKKGSRVTFTCQASFDPSLQPSITWRGDGRDLQELGDSDKYFIEDGRLVIHSLDYSDQGNYSCVASTELDVVESRAQLLVVGSPGPVPRLVLSDLHLLTQSQVRVSWSPAEDHNAPIEKYDIEFEDKEMAPEKWYSLGKVPGNQTSTTLKLSPYVHYTFRVTAINKYGPGEPSPVSETVVTPEAAPEKNPVDVKGEGNETTNMVITWKPLRWMDWNAPQVQYRVQWRPQGTRGPWQEQIVSDPFLVVSNTSTFVPYEIKVQAVNSQGKGPEPQVTIGYSGEDYPQAIPELEGIEILNSSAVLVKWRPVDLAQVKGHLRGYNVTYWREGSQRKHSKRHIHKDHVVVPANTTSVILSGLRPYSSYHLEVQAFNGRGSGPASEFTFSTPEGVPGHPEALHLECQSNTSLLLRWQPPLSHNGVLTGYVLSYHPLDEGGKGQLSFNLRDPELRTHNLTDLSPHLRYRFQLQATTKEGPGEAIVREGGTMALSGISDFGNISATAGENYSVVSWVPKEGQCNFRFHILFKALGEEKGGASLSPQYVSYNQSSYTQWDLQPDTDYEIHLFKERMFRHQMAVKTNGTGRVRLPPAGFATEGWFIGFVSAIILLLLVLLILCFIKRSKGGKYSVKDKEDTQVDSEARPMKDETFGEYRSLESDNEEKAFGSSQPSLNGDIKPLGSDDSLADYGGSVDVQFNEDGSFIGQYSGKKEKEAAGGNDSSGATSPINPAVALE
T80020	DRUGINFO	D05KFH	CD171 specific CAR T cells expressing EGFRt	Phase 1
T80020	DRUGINFO	D0M9TO	JCAR023	Phase 1

T95302	TARGETID	T95302
T95302	FORMERID	TTDI02123
T95302	UNIPROID	MC5R_HUMAN
T95302	TARGNAME	Melanocortin receptor 5 (MC5R)
T95302	GENENAME	MC5R
T95302	TARGTYPE	Clinical trial
T95302	SYNONYMS	MC5-R; MC2; MC-2
T95302	FUNCTION	The activity of this receptor is mediated by G proteins which activate adenylate cyclase. This receptor is a possible mediator of the immunomodulation properties of melanocortins. Receptor for MSH (alpha, beta and gamma) and ACTH.
T95302	BIOCLASS	GPCR rhodopsin
T95302	SEQUENCE	MNSSFHLHFLDLNLNATEGNLSGPNVKNKSSPCEDMGIAVEVFLTLGVISLLENILVIGAIVKNKNLHSPMYFFVCSLAVADMLVSMSSAWETITIYLLNNKHLVIADAFVRHIDNVFDSMICISVVASMCSLLAIAVDRYVTIFYALRYHHIMTARRSGAIIAGIWAFCTGCGIVFILYSESTYVILCLISMFFAMLFLLVSLYIHMFLLARTHVKRIAALPGASSARQRTSMQGAVTVTMLLGVFTVCWAPFFLHLTLMLSCPQNLYCSRFMSHFNMYLILIMCNSVMDPLIYAFRSQEMRKTFKEIICCRGFRIACSFPRRD
T95302	DRUGINFO	D08ZCC	MTC-896	Phase 2
T95302	DRUGINFO	D0O6NA	JNJ-10229570	Phase 2
T95302	DRUGINFO	D0YB7F	MT-II	Investigative

T75788	TARGETID	T75788
T75788	FORMERID	TTDI01940
T75788	UNIPROID	COIA1_HUMAN
T75788	TARGNAME	Endostatin (COL18A1)
T75788	GENENAME	COL18A1
T75788	TARGTYPE	Clinical trial
T75788	SYNONYMS	Collagen alpha1(XVIII) chain; Collagen alpha-1(XVIII) chain
T75788	FUNCTION	Probably plays a major role in determining the retinal structure as well as in the closure of the neural tube.
T75788	PDBSTRUC	3HSH; 3HON; 1BNL
T75788	SEQUENCE	MAPYPCGCHILLLLFCCLAAARANLLNLNWLWFNNEDTSHAATTIPEPQGPLPVQPTADTTTHVTPRNGSTEPATAPGSPEPPSELLEDGQDTPTSAESPDAPEENIAGVGAEILNVAKGIRSFVQLWNDTVPTESLARAETLVLETPVGPLALAGPSSTPQENGTTLWPSRGIPSSPGAHTTEAGTLPAPTPSPPSLGRPWAPLTGPSVPPPSSGRASLSSLLGGAPPWGSLQDPDSQGLSPAAAAPSQQLQRPDVRLRTPLLHPLVMGSLGKHAAPSAFSSGLPGALSQVAVTTLTRDSGAWVSHVANSVGPGLANNSALLGADPEAPAGRCLPLPPSLPVCGHLGISRFWLPNHLHHESGEQVRAGARAWGGLLQTHCHPFLAWFFCLLLVPPCGSVPPPAPPPCCQFCEALQDACWSRLGGGRLPVACASLPTQEDGYCVLIGPAAERISEEVGLLQLLGDPPPQQVTQTDDPDVGLAYVFGPDANSGQVARYHFPSLFFRDFSLLFHIRPATEGPGVLFAITDSAQAMVLLGVKLSGVQDGHQDISLLYTEPGAGQTHTAASFRLPAFVGQWTHLALSVAGGFVALYVDCEEFQRMPLARSSRGLELEPGAGLFVAQAGGADPDKFQGVIAELKVRRDPQVSPMHCLDEEGDDSDGASGDSGSGLGDARELLREETGAALKPRLPAPPPVTTPPLAGGSSTEDSRSEEVEEQTTVASLGAQTLPGSDSVSTWDGSVRTPGGRVKEGGLKGQKGEPGVPGPPGRAGPPGSPCLPGPPGLPCPVSPLGPAGPALQTVPGPQGPPGPPGRDGTPGRDGEPGDPGEDGKPGDTGPQGFPGTPGDVGPKGDKGDPGVGERGPPGPQGPPGPPGPSFRHDKLTFIDMEGSGFGGDLEALRGPRGFPGPPGPPGVPGLPGEPGRFGVNSSDVPGPAGLPGVPGREGPPGFPGLPGPPGPPGREGPPGRTGQKGSLGEAGAPGHKGSKGAPGPAGARGESGLAGAPGPAGPPGPPGPPGPPGPGLPAGFDDMEGSGGPFWSTARSADGPQGPPGLPGLKGDPGVPGLPGAKGEVGADGVPGFPGLPGREGIAGPQGPKGDRGSRGEKGDPGKDGVGQPGLPGPPGPPGPVVYVSEQDGSVLSVPGPEGRPGFAGFPGPAGPKGNLGSKGERGSPGPKGEKGEPGSIFSPDGGALGPAQKGAKGEPGFRGPPGPYGRPGYKGEIGFPGRPGRPGMNGLKGEKGEPGDASLGFGMRGMPGPPGPPGPPGPPGTPVYDSNVFAESSRPGPPGLPGNQGPPGPKGAKGEVGPPGPPGQFPFDFLQLEAEMKGEKGDRGDAGQKGERGEPGGGGFFGSSLPGPPGPPGPPGPRGYPGIPGPKGESIRGQPGPPGPQGPPGIGYEGRQGPPGPPGPPGPPSFPGPHRQTISVPGPPGPPGPPGPPGTMGASSGVRLWATRQAMLGQVHEVPEGWLIFVAEQEELYVRVQNGFRKVQLEARTPLPRGTDNEVAALQPPVVQLHDSNPYPRREHPHPTARPWRADDILASPPRLPEPQPYPGAPHHSSYVHLRPARPTSPPAHSHRDFQPVLHLVALNSPLSGGMRGIRGADFQCFQQARAVGLAGTFRAFLSSRLQDLYSIVRRADRAAVPIVNLKDELLFPSWEALFSGSEGPLKPGARIFSFDGKDVLRHPTWPQKSVWHGSDPNGRRLTESYCETWRTEAPSATGQASSLLGGRLLGQSAASCHHAYIVLCIENSFMTASK
T75788	DRUGINFO	D0RD0Y	RetinoStat	Phase 2
T75788	DRUGINFO	D0O6ZH	Endo-CD	Investigative

T81695	TARGETID	T81695
T81695	FORMERID	TTDI02143
T81695	UNIPROID	OX2G_HUMAN
T81695	TARGNAME	Membrane glycoprotein OX2 (CD200)
T81695	GENENAME	CD200
T81695	TARGTYPE	Clinical trial
T81695	SYNONYMS	OX2 membrane glycoprotein; OX-2 membrane glycoprotein; My033; MOX2; MOX1
T81695	FUNCTION	May regulate myeloid cell activity in a variety of tissues. Costimulates T-cell proliferation.
T81695	BIOCLASS	Immunoglobulin
T81695	SEQUENCE	MERLVIRMPFSHLSTYSLVWVMAAVVLCTAQVQVVTQDEREQLYTPASLKCSLQNAQEALIVTWQKKKAVSPENMVTFSENHGVVIQPAYKDKINITQLGLQNSTITFWNITLEDEGCYMCLFNTFGFGKISGTACLTVYVQPIVSLHYKFSEDHLNITCSATARPAPMVFWKVPRSGIENSTVTLSHPNGTTSVTSILHIKDPKNQVGKEVICQVLHLGTVTDFKQTVNKGYWFSVPLLLSIVSLVILLVLISILLYWKRHRNQDRGELSQGVQKMT
T81695	DRUGINFO	D0OY9L	ALXN6000	Phase 2

T83585	TARGETID	T83585
T83585	FORMERID	TTDI02221
T83585	UNIPROID	WASP_HUMAN
T83585	TARGNAME	Wiskott-Aldrich syndrome protein (WAS)
T83585	GENENAME	WAS
T83585	TARGTYPE	Clinical trial
T83585	SYNONYMS	WASp; IMD2
T83585	FUNCTION	Important for efficient actin polymerization. Possible regulator of lymphocyte and platelet function. Mediates actin filament reorganization and the formation of actin pedestals upon infection by pathogenic bacteria. In addition to its role in the cytoplasmic cytoskeleton, also promotes actin polymerization in the nucleus, thereby regulating gene transcription and repair of damaged DNA. Promotes homologous recombination (HR) repair in response to DNA damage by promoting nuclear actin polymerization, leading to drive motility of double-strand breaks (DSBs). Effector protein for Rho-type GTPases that regulates actin filament reorganization via its interaction with the Arp2/3 complex.
T83585	PDBSTRUC	2OT0; 2K42; 2A3Z; 1T84; 1EJ5
T83585	SEQUENCE	MSGGPMGGRPGGRGAPAVQQNIPSTLLQDHENQRLFEMLGRKCLTLATAVVQLYLALPPGAEHWTKEHCGAVCFVKDNPQKSYFIRLYGLQAGRLLWEQELYSQLVYSTPTPFFHTFAGDDCQAGLNFADEDEAQAFRALVQEKIQKRNQRQSGDRRQLPPPPTPANEERRGGLPPLPLHPGGDQGGPPVGPLSLGLATVDIQNPDITSSRYRGLPAPGPSPADKKRSGKKKISKADIGAPSGFKHVSHVGWDPQNGFDVNNLDPDLRSLFSRAGISEAQLTDAETSKLIYDFIEDQGGLEAVRQEMRRQEPLPPPPPPSRGGNQLPRPPIVGGNKGRSGPLPPVPLGIAPPPPTPRGPPPPGRGGPPPPPPPATGRSGPLPPPPPGAGGPPMPPPPPPPPPPPSSGNGPAPPPLPPALVPAGGLAPGGGRGALLDQIRQGIQLNKTPGAPESSALQPPPQSSEGLVGALMHVMQKRSRAIHSSDEGEDQAGDEDEDDEWDD
T83585	DRUGINFO	DY2WH5	OTL-103	Phase 3
T83585	DRUGINFO	D01QQC	Hematopoietic stem cell gene therapy	Phase 1/2
T83585	DRUGINFO	D0V4VQ	WASP gene therapy	Phase 1/2

T51693	TARGETID	T51693
T51693	FORMERID	TTDR00750
T51693	UNIPROID	MAGA3_HUMAN
T51693	TARGNAME	Melanoma-associated antigen 3 (MAGEA3)
T51693	GENENAME	MAGEA3
T51693	TARGTYPE	Clinical trial
T51693	SYNONYMS	Melanoma associated antigen-A3; Melanoma antigen 3; MAGE3; MAGE-A3 antigen; MAGE-A3; MAGE-3 antigen; Cancer/testis antigen 1.3; CT1.3; Antigen MZ2-D
T51693	FUNCTION	May enhance ubiquitin ligase activity of TRIM28 and stimulate p53/TP53 ubiquitination by TRIM28. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex. May play a role in embryonal development and tumor transformation or aspects of tumor progression. In vitro promotes cell viability in melanoma cell lines. Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes. Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases.
T51693	PDBSTRUC	5BRZ; 4V0P; 1QEW
T51693	BIOCLASS	Melanoma associated antigen
T51693	SEQUENCE	MPLEQRSQHCKPEEGLEARGEALGLVGAQAPATEEQEAASSSSTLVEVTLGEVPAAESPDPPQSPQGASSLPTTMNYPLWSQSYEDSSNQEEEGPSTFPDLESEFQAALSRKVAELVHFLLLKYRAREPVTKAEMLGSVVGNWQYFFPVIFSKASSSLQLVFGIELMEVDPIGHLYIFATCLGLSYDGLLGDNQIMPKAGLLIIVLAIIAREGDCAPEEKIWEELSVLEVFEGREDSILGDPKKLLTQHFVQENYLEYRQVPGSDPACYEFLWGPRALVETSYVKVLHHMVKISGGPHISYPPLHEWVLREGEE
T51693	DRUGINFO	D02XYA	Astuprotimut-R	Phase 3
T51693	DRUGINFO	D08DUF	GL-0817	Phase 2
T51693	DRUGINFO	D03QMY	IDM-2101	Phase 2
T51693	DRUGINFO	D00DSV	Polynoma-1	Phase 2
T51693	DRUGINFO	DN46RL	KITE-718	Phase 1
T51693	DRUGINFO	D0C1EO	Melanoma vaccine (ALVAC)	Discontinued in Phase 2

T12097	TARGETID	T12097
T12097	FORMERID	TTDR00773
T12097	UNIPROID	MAGA4_HUMAN
T12097	TARGNAME	Melanoma-associated antigen 4 (MAGEA4)
T12097	GENENAME	MAGEA4
T12097	TARGTYPE	Clinical trial
T12097	SYNONYMS	MAGE4; MAGE-X2 antigen; MAGE-X2; MAGE-41 antigen; MAGE-41; MAGE-4 protein; MAGE-4 antigen; Cancer/testis antigen 1.4; CT1.4
T12097	FUNCTION	Not known, though may play a role in embryonal development and tumor transformation or aspects of tumor progression.
T12097	PDBSTRUC	2WA0; 1I4F
T12097	BIOCLASS	Melanoma associated antigen
T12097	SEQUENCE	MSSEQKSQHCKPEEGVEAQEEALGLVGAQAPTTEEQEAAVSSSSPLVPGTLEEVPAAESAGPPQSPQGASALPTTISFTCWRQPNEGSSSQEEEGPSTSPDAESLFREALSNKVDELAHFLLRKYRAKELVTKAEMLERVIKNYKRCFPVIFGKASESLKMIFGIDVKEVDPASNTYTLVTCLGLSYDGLLGNNQIFPKTGLLIIVLGTIAMEGDSASEEEIWEELGVMGVYDGREHTVYGEPRKLLTQDWVQENYLEYRQVPGSNPARYEFLWGPRALAETSYVKVLEHVVRVNARVRIAYPSLREAALLEEEEGV
T12097	DRUGINFO	D2YT5I	ADP-A2M4	Phase 2
T12097	DRUGINFO	DFY5L8	Afamitresgene autoleucel	Phase 2
T12097	DRUGINFO	D0XZ2S	CAR-T cells targeting MAGE-A4	Phase 1/2

T77515	TARGETID	T77515
T77515	UNIPROID	KI2S2_HUMAN
T77515	TARGNAME	MHC class I NK cell receptor 2DS2 (CD158j)
T77515	GENENAME	KIR2DS2
T77515	TARGTYPE	Clinical trial
T77515	SYNONYMS	p58 natural killer cell receptor clone CL-49; p58 NK receptor CL-49; Natural killer-associated transcript 5; NKAT5; NKAT-5; NK receptor 183 ActI; MHC class I NK cell receptor; Killer cell immunoglobulin-like receptor 2DS2; CD158J; CD158 antigen-like family member J
T77515	FUNCTION	Receptor on natural killer (NK) cells for HLA-C alleles. Does not inhibit the activity of NK cells.
T77515	PDBSTRUC	4N8V; 1M4K
T77515	BIOCLASS	Immunoglobulin
T77515	SEQUENCE	MSLMVVSMACVGFFLLQGAWPHEGVHRKPSLLAHPGPLVKSEETVILQCWSDVRFEHFLLHREGKYKDTLHLIGEHHDGVSKANFSIGPMMQDLAGTYRCYGSVTHSPYQLSAPSDPLDIVITGLYEKPSLSAQPGPTVLAGESVTLSCSSRSSYDMYHLSREGEAHERRFSAGPKVNGTFQADFPLGPATHGGTYRCFGSFRDSPYEWSNSSDPLLVSVTGNPSNSWPSPTEPSSKTGNPRHLHVLIGTSVVKIPFTILLFFLLHRWCSNKKNAAVMDQEPAGNRTVNSEDSDEQDHQEVSYA
T77515	DRUGINFO	D04IXD	IPH-2101	Phase 2

T92281	TARGETID	T92281
T92281	FORMERID	TTDI02139
T92281	UNIPROID	NPTX2_HUMAN
T92281	TARGNAME	Neuronal pentraxin-2 (NPTX2)
T92281	GENENAME	NPTX2
T92281	TARGTYPE	Clinical trial
T92281	SYNONYMS	Neuronal pentraxin II; NPTX2; NPII; NP2
T92281	FUNCTION	Likely to play role in the modification of cellular properties that underlie long-term plasticity. Binds to agar matrix in a calcium-dependent manner.
T92281	BIOCLASS	Pentaxin family
T92281	SEQUENCE	MLALLAASVALAVAAGAQDSPAPGSRFVCTALPPEAVHAGCPLPAMPMQGGAQSPEEELRAAVLQLRETVVQQKETLGAQREAIRELTGKLARCEGLAGGKARGAGATGKDTMGDLPRDPGHVVEQLSRSLQTLKDRLESLEHQLRANVSNAGLPGDFREVLQQRLGELERQLLRKVAELEDEKSLLHNETSAHRQKTESTLNALLQRVTELERGNSAFKSPDAFKVSLPLRTNYLYGKIKKTLPELYAFTICLWLRSSASPGIGTPFSYAVPGQANEIVLIEWGNNPIELLINDKVAQLPLFVSDGKWHHICVTWTTRDGMWEAFQDGEKLGTGENLAPWHPIKPGGVLILGQEQDTVGGRFDATQAFVGELSQFNIWDRVLRAQEIVNIANCSTNMPGNIIPWVDNNVDVFGGASKWPVETCEERLLDL
T92281	DRUGINFO	D09EDA	PRM-151	Phase 2

T81386	TARGETID	T81386
T81386	FORMERID	TTDI02000
T81386	UNIPROID	CDK9_HUMAN-CCNT1_HUMAN
T81386	TARGNAME	Positive transcription elongation factor b (P-TEFb)
T81386	GENENAME	CDK9-CCNT1
T81386	TARGTYPE	Clinical trial
T81386	SYNONYMS	P-TEFb
T81386	FUNCTION	The elongin BC complex seems to be involved as an adapter protein in the proteasomal degradation of target proteins via different E3 ubiquitin ligase complexes, including the von Hippel-Lindau ubiquitination complex CBC(VHL). By binding to BC- box motifs it seems to link target recruitment subunits, like VHL and members of the SOCS box family, to Cullin/RBX1 modules that activate E2 ubiquitination enzymes.
T81386	BIOCLASS	S-phase kinase-associated protein
T81386	SEQUENCE	MEGERKNNNKRWYFTREQLENSPSRRFGVDPDKELSYRQQAANLLQDMGQRLNVSQLTINTAIVYMHRFYMIQSFTQFPGNSVAPAALFLAAKVEEQPKKLEHVIKVAHTCLHPQESLPDTRSEAYLQQVQDLVILESIILQTLGFELTIDHPHTHVVKCTQLVRASKDLAQTSYFMATNSLHLTTFSLQYTPPVVACVCIHLACKWSNWEIPVSTDGKHWWEYVDATVTLELLDELTHEFLQILEKTPNRLKRIWNWRACEAAKKTKADDRGTDEKTSEQTILNMISQSSSDTTIAGLMSMSTSTTSAVPSLPVSEESSSNLTSVEMLPGKRWLSSQPSFKLEPTQGHRTSENLALTGVDHSLPQDGSNAFISQKQNSKSVPSAKVSLKEYRAKHAEELAAQKRQLENMEANVKSQYAYAAQNLLSHHDSHSSVILKMPIEGSENPERPFLEKADKTALKMRIPVAGGDKAASSKPEEIKMRIKVHAAADKHNSVEDSVTKSREHKEKHKTHPSNHHHHHNHHSHKHSHSQLPVGTGNKRPGDPKHSSQTSNLAHKTYSLSSSFSSSSSTRKRGPSEETGGAVFDHPAKIAKSTKSSSLNFSFPSLPTMGQMPGHSSDTSGLSFSQPSCKTRVPHSKLDKGPTGANGHNTTQTIDYQDTVNMLHSLLSAQGVQPTQPTAFEFVRPYSDYLNPRSGGISSRSGNTDKPRPPPLPSEPPPPLPPLPKMAKQYDSVECPFCDEVSKYEKLAKIGQGTFGEVFKARHRKTGQKVALKKVLMENEKEGFPITALREIKILQLLKHENVVNLIEICRTKASPYNRCKGSIYLVFDFCEHDLAGLLSNVLVKFTLSEIKRVMQMLLNGLYYIHRNKILHRDMKAANVLITRDGVLKLADFGLARAFSLAKNSQPNRYTNRVVTLWYRPPELLLGERDYGPPIDLWGAGCIMAEMWTRSPIMQGNTEQHQLALISQLCGSITPEVWPNVDNYELYEKLELVKGQKRKVKDRLKAYVRDPYALDLIDKLLVLDPAQRIDSDDALNHDFFWSDPMPSDLKGMLSTHLTSMFEYLAPPRRKGSQITQQSTNQSRNPATTNQTEFERVF
T81386	DRUGINFO	D06HMN	BAY1251152	Phase 1
T81386	DRUGINFO	D06PSU	BAY1143572	Phase 1

T25307	TARGETID	T25307
T25307	FORMERID	TTDI03508
T25307	UNIPROID	RORG_HUMAN
T25307	TARGNAME	Nuclear receptor ROR-gamma (RORG)
T25307	GENENAME	RORC
T25307	TARGTYPE	Clinical trial
T25307	SYNONYMS	Retinoid-related orphan receptor-gamma; RZRG; RORG; RAR-related orphan receptor C; Nuclear receptor subfamily 1 group F member 3; Nuclear receptor RZR-gamma; NR1F3
T25307	FUNCTION	Nuclear receptor that binds DNA as a monomer to ROR response elements (RORE) containing a single core motif half-site 5'-AGGTCA-3' preceded by a short A-T-rich sequence. Key regulator of cellular differentiation, immunity, peripheral circadian rhythm as well as lipid, steroid, xenobiotics and glucose metabolism. Considered to have intrinsic transcriptional activity, have some natural ligands like oxysterols that act as agonists (25-hydroxycholesterol) or inverse agonists (7-oxygenated sterols), enhancing or repressing the transcriptional activity, respectively. Recruits distinct combinations of cofactors to target gene regulatory regions to modulate their transcriptional expression, depending on the tissue, time and promoter contexts. Regulates the circadian expression of clock genes such as CRY1, ARNTL/BMAL1 and NR1D1 in peripheral tissues and in a tissue-selective manner. Competes with NR1D1 for binding to their shared DNA response element on some clock genes such as ARNTL/BMAL1, CRY1 and NR1D1 itself, resulting in NR1D1-mediated repression or RORC-mediated activation of the expression, leading to the circadian pattern of clock genes expression. Therefore influences the period length and stability of the clock. Involved in the regulation of the rhythmic expression of genes involved in glucose and lipid metabolism, including PLIN2 and AVPR1A. Negative regulator of adipocyte differentiation through the regulation of early phase genes expression, such as MMP3. Controls adipogenesis as well as adipocyte size and modulates insulin sensitivity in obesity. In liver, has specific and redundant functions with RORA as positive or negative modulator of expression of genes encoding phase I and Phase II proteins involved in the metabolism of lipids, steroids and xenobiotics, such as SULT1E1. Also plays also a role in the regulation of hepatocyte glucose metabolism through the regulation of G6PC and PCK1. Regulates the rhythmic expression of PROX1 and promotes its nuclear localization. Plays an indispensable role in the induction of IFN-gamma dependent anti-mycobacterial systemic immunity.
T25307	PDBSTRUC	6O98; 6NAD; 6J1L; 6IVX; 6G07
T25307	BIOCLASS	Nuclear hormone receptor
T25307	SEQUENCE	MDRAPQRQHRASRELLAAKKTHTSQIEVIPCKICGDKSSGIHYGVITCEGCKGFFRRSQRCNAAYSCTRQQNCPIDRTSRNRCQHCRLQKCLALGMSRDAVKFGRMSKKQRDSLHAEVQKQLQQRQQQQQEPVVKTPPAGAQGADTLTYTLGLPDGQLPLGSSPDLPEASACPPGLLKASGSGPSYSNNLAKAGLNGASCHLEYSPERGKAEGRESFYSTGSQLTPDRCGLRFEEHRHPGLGELGQGPDSYGSPSFRSTPEAPYASLTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLCKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQHLHPIVVQAAFPPLYKELFSTETESPVGLSK
T25307	DRUGINFO	D0BF4Z	GSK2981278	Phase 2
T25307	DRUGINFO	D0T7YE	LYC-55716	Phase 2
T25307	DRUGINFO	D0VB4X	VTP-43742	Phase 2
T25307	DRUGINFO	D0X1ST	ESR0114	Phase 1/2
T25307	DRUGINFO	D00BLS	AZD0284	Phase 1
T25307	DRUGINFO	D0A0ZW	ARN-6039	Phase 1
T25307	DRUGINFO	D0D7CH	TAK-828	Phase 1
T25307	DRUGINFO	D0FY4J	BBI-6000	Phase 1
T25307	DRUGINFO	D0K9YJ	JNJ-3534	Phase 1
T25307	DRUGINFO	D0W2RI	JTE-451	Phase 1
T25307	DRUGINFO	D92KUQ	ARN-6039	Phase 1
T25307	DRUGINFO	D4PG6A	Nobiletin	Preclinical
T25307	DRUGINFO	D8VH5Q	ML209	Preclinical
T25307	DRUGINFO	DE7BZ4	SR2211	Preclinical
T25307	DRUGINFO	DW5R6Y	SR1555	Preclinical
T25307	DRUGINFO	D9D6QN	SR1078	Preclinical
T25307	DRUGINFO	D06OVX	25-hydroxycholesterol	Investigative

T25726	TARGETID	T25726
T25726	FORMERID	TTDI02084
T25726	UNIPROID	GPC3_HUMAN
T25726	TARGNAME	Glypican-3 (GPC3)
T25726	GENENAME	GPC3
T25726	TARGTYPE	Clinical trial
T25726	SYNONYMS	Secreted glypican3; OCI5; MXR7; Intestinal protein OCI5; Intestinal protein OCI-5; GTR22; GTR2-2
T25726	FUNCTION	Negatively regulates the hedgehog signaling pathway when attached via the GPI-anchor to the cell surface by competing with the hedgehog receptor PTC1 for binding to hedgehog proteins. Binding to the hedgehog protein SHH triggers internalization of the complex by endocytosis and its subsequent lysosomal degradation. Positively regulates the canonical Wnt signaling pathway by binding to the Wnt receptor Frizzled and stimulating the binding of the Frizzled receptor to Wnt ligands. Positively regulates the non-canonical Wnt signaling pathway. Binds to CD81 which decreases the availability of free CD81 for binding to the transcriptional repressor HHEX, resulting in nuclear translocation of HHEX and transcriptional repression. Inhibits the dipeptidyl peptidase activity of DPP4. Plays a role in limb patterning and skeletal development by controlling the cellular response to BMP4. Modulates the effects of growth factors BMP2, BMP7 and FGF7 on renal branching morphogenesis. Required for coronary vascular development. Plays a role in regulating cell movements during gastrulation. Cell surface proteoglycan that bears heparan sulfate.
T25726	SEQUENCE	MAGTVRTACLVVAMLLSLDFPGQAQPPPPPPDATCHQVRSFFQRLQPGLKWVPETPVPGSDLQVCLPKGPTCCSRKMEEKYQLTARLNMEQLLQSASMELKFLIIQNAAVFQEAFEIVVRHAKNYTNAMFKNNYPSLTPQAFEFVGEFFTDVSLYILGSDINVDDMVNELFDSLFPVIYTQLMNPGLPDSALDINECLRGARRDLKVFGNFPKLIMTQVSKSLQVTRIFLQALNLGIEVINTTDHLKFSKDCGRMLTRMWYCSYCQGLMMVKPCGGYCNVVMQGCMAGVVEIDKYWREYILSLEELVNGMYRIYDMENVLLGLFSTIHDSIQYVQKNAGKLTTTIGKLCAHSQQRQYRSAYYPEDLFIDKKVLKVAHVEHEETLSSRRRELIQKLKSFISFYSALPGYICSHSPVAENDTLCWNGQELVERYSQKAARNGMKNQFNLHELKMKGPEPVVSQIIDKLKHINQLLRTMSMPKGRVLDKNLDEEGFESGDCGDDEDECIGGSGDGMIKVKNQLRFLAELAYDLDVDDAPGNSQQATPKDNEISTFHNLGNVHSPLKLLTSMAISVVCFFFLVH
T25726	DRUGINFO	D02ONR	RG7686	Phase 2
T25726	DRUGINFO	D05HZJ	GPC-3298306	Phase 2
T25726	DRUGINFO	D0P0BY	Codrituzumab	Phase 2
T25726	DRUGINFO	D17HKT	GC33	Phase 2
T25726	DRUGINFO	DF6Z3C	SAR444200	Phase 2
T25726	DRUGINFO	D04CKC	GPC3-CART cells	Phase 1/2
T25726	DRUGINFO	D0FY5E	TAI-GPC3-CART cells	Phase 1/2
T25726	DRUGINFO	D0J2IN	CAR-T cells targeting GPC3	Phase 1/2
T25726	DRUGINFO	D0N0OV	Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs	Phase 1/2
T25726	DRUGINFO	D0WN2Y	CAR-T cells targeting Glypican-3 (GPC3)	Phase 1/2
T25726	DRUGINFO	D08UNC	GPC3 targeting CAR-T cells	Phase 1
T25726	DRUGINFO	D0GD9E	GAP T cells	Phase 1
T25726	DRUGINFO	D0H4UP	CAR-GPC3 T Cells	Phase 1
T25726	DRUGINFO	D0IK5R	ERY974	Phase 1
T25726	DRUGINFO	D0IQ4V	Anti-GPC3 CAR T	Phase 1
T25726	DRUGINFO	D0MA2E	GLYCAR T cells	Phase 1
T25726	DRUGINFO	D2MZF8	TAK-102	Phase 1
T25726	DRUGINFO	D09RPP	CAR-GPC3 T cell	Clinical trial
T25726	DRUGINFO	D0P1BM	CAR-GPC3 T cells	Clinical trial

T16888	TARGETID	T16888
T16888	FORMERID	TTDI02036
T16888	UNIPROID	CCL11_HUMAN
T16888	TARGNAME	Small-inducible cytokine A11 (CCL11)
T16888	GENENAME	CCL11
T16888	TARGTYPE	Clinical trial
T16888	SYNONYMS	Smallinducible cytokine A11; SCYA11; Eotaxin; Eosinophil chemotactic protein; CC motif chemokine 11; C-C motif chemokine 11
T16888	FUNCTION	Binds to CCR3. In response to the presence of allergens, this protein directly promotes the accumulation of eosinophils, a prominent feature of allergic inflammatory reactions.
T16888	PDBSTRUC	2MPM; 2EOT; 1EOT
T16888	BIOCLASS	Cytokine: CC chemokine
T16888	SEQUENCE	MKVSAALLWLLLIAAAFSPQGLAGPASVPTTCCFNLANRKIPLQRLESYRRITSGKCPQKAVIFKTKLAKDICADPKKKWVQDSMKYLDQKSPTPKP
T16888	DRUGINFO	D0V9LY	Bertilimumab	Phase 2

T76396	TARGETID	T76396
T76396	FORMERID	TTDR00229
T76396	UNIPROID	PGTB1_HUMAN
T76396	TARGNAME	Geranylgeranyl transferase I (GGTase-I)
T76396	GENENAME	PGGT1B
T76396	TARGTYPE	Clinical trial
T76396	SYNONYMS	Type I protein geranyl-geranyltransferase subunit beta; Type I protein geranyl-geranyltransferase beta subunit of Saccharomyces cerevisiae; RAS proteins geranylgeranyltransferase beta subunit; PGGT; Geranylgeranyl transferase type-1 subunit beta; Geranylgeranyl transferase type I subunit beta; GGTase-I-beta of Saccharomyces cerevisiae; GGTase-I-beta; CDC43
T76396	FUNCTION	Catalyzes the transfer of a geranyl-geranyl moiety from geranyl-geranyl pyrophosphate to a cysteine at the fourth position from the C-terminus of proteins having the C-terminal sequence Cys-aliphatic-aliphatic-X. Known substrates include RAC1, RAC2, RAP1A and RAP1B.
T76396	BIOCLASS	Alkyl aryl transferase
T76396	ECNUMBER	EC 2.5.1.59
T76396	SEQUENCE	MAATEDERLAGSGEGERLDFLRDRHVRFFQRCLQVLPERYSSLETSRLTIAFFALSGLDMLDSLDVVNKDDIIEWIYSLQVLPTEDRSNLNRCGFRGSSYLGIPFNPSKAPGTAHPYDSGHIAMTYTGLSCLVILGDDLSRVNKEACLAGLRALQLEDGSFCAVPEGSENDMRFVYCASCICYMLNNWSGMDMKKAITYIRRSMSYDNGLAQGAGLESHGGSTFCGIASLCLMGKLEEVFSEKELNRIKRWCIMRQQNGYHGRPNKPVDTCYSFWVGATLKLLKIFQYTNFEKNRNYILSTQDRLVGGFAKWPDSHPDALHAYFGICGLSLMEESGICKVHPALNVSTRTSERLLDLHQSWKTKDSKQCSENVHIST
T76396	DRUGINFO	D0Q5VW	L-778123	Phase 1
T76396	DRUGINFO	D0D0WF	GGTI-298	Terminated
T76396	DRUGINFO	D03OLA	L-745631	Terminated
T76396	DRUGINFO	D0DD8I	J-109,390	Investigative
T76396	DRUGINFO	D0Q5WB	L-269,289	Investigative
T76396	DRUGINFO	D0T2SJ	A-313326	Investigative
T76396	DRUGINFO	D06DSE	PD-83176	Investigative

T84560	TARGETID	T84560
T84560	FORMERID	TTDR00083
T84560	UNIPROID	UCP2_HUMAN
T84560	TARGNAME	Mitochondrial uncoupling protein 2 (UCP2)
T84560	GENENAME	UCP2
T84560	TARGTYPE	Clinical trial
T84560	SYNONYMS	UCPH; UCP 2; Solute carrier family 25 member 8; SLC25A8
T84560	FUNCTION	UCP are mitochondrial transporter proteins that create proton leaks across the inner mitochondrial membrane, thus uncoupling oxidative phosphorylation from ATP synthesis. As a result, energy is dissipated in the form of heat.
T84560	BIOCLASS	Mitochondrial carrier
T84560	SEQUENCE	MVGFKATDVPPTATVKFLGAGTAACIADLITFPLDTAKVRLQIQGESQGPVRATASAQYRGVMGTILTMVRTEGPRSLYNGLVAGLQRQMSFASVRIGLYDSVKQFYTKGSEHASIGSRLLAGSTTGALAVAVAQPTDVVKVRFQAQARAGGGRRYQSTVNAYKTIAREEGFRGLWKGTSPNVARNAIVNCAELVTYDLIKDALLKANLMTDDLPCHFTSAFGAGFCTTVIASPVDVVKTRYMNSALGQYSSAGHCALTMLQKEGPRAFYKGFMPSFLRLGSWNVVMFVTYEQLKRALMAACTSREAPF
T84560	DRUGINFO	D07WHS	CL-316,243	Phase 2
T84560	DRUGINFO	D02CFE	NC-2100	Investigative

T69146	TARGETID	T69146
T69146	FORMERID	TTDR00084
T69146	UNIPROID	UCP3_HUMAN
T69146	TARGNAME	Mitochondrial uncoupling protein 3 (UCP3)
T69146	GENENAME	UCP3
T69146	TARGTYPE	Clinical trial
T69146	SYNONYMS	UCP 3; Solute carrier family 25 member 9; SLC25A9
T69146	FUNCTION	UCP are mitochondrial transporter proteins that create proton leaks across the inner mitochondrial membrane, thus uncoupling oxidative phosphorylation. As a result, energy is dissipated in the form of heat. May play a role in the modulation of tissue respiratory control. Participates in thermogenesis and energy balance.
T69146	BIOCLASS	Mitochondrial carrier
T69146	SEQUENCE	MVGLKPSDVPPTMAVKFLGAGTAACFADLVTFPLDTAKVRLQIQGENQAVQTARLVQYRGVLGTILTMVRTEGPCSPYNGLVAGLQRQMSFASIRIGLYDSVKQVYTPKGADNSSLTTRILAGCTTGAMAVTCAQPTDVVKVRFQASIHLGPSRSDRKYSGTMDAYRTIAREEGVRGLWKGTLPNIMRNAIVNCAEVVTYDILKEKLLDYHLLTDNFPCHFVSAFGAGFCATVVASPVDVVKTRYMNSPPGQYFSPLDCMIKMVAQEGPTAFYKGFTPSFLRLGSWNVVMFVTYEQLKRALMKVQMLRESPF
T69146	DRUGINFO	D07WHS	CL-316,243	Phase 2

T31818	TARGETID	T31818
T31818	FORMERID	TTDNC00372
T31818	UNIPROID	ITA1_HUMAN
T31818	TARGNAME	Integrin alpha-1 (VLA-1)
T31818	GENENAME	ITGA1
T31818	TARGTYPE	Clinical trial
T31818	SYNONYMS	Laminin and collagen receptor; Integrin alpha1; ITGA1; CD49a; CD49 antigenlike family member A
T31818	FUNCTION	Integrin alpha-1/beta-1 is a receptor for laminin and collagen. It recognizes the proline-hydroxylated sequence G-F-P-G- E-R in collagen. Involved in anchorage-dependent, negative regulation of EGF-stimulated cell growth.
T31818	PDBSTRUC	5HGJ; 4A0Q; 2M32; 2L8S; 1QCY
T31818	BIOCLASS	Integrin
T31818	SEQUENCE	MAPRPRARPGVAVACCWLLTVVLRCCVSFNVDVKNSMTFSGPVEDMFGYTVQQYENEEGKWVLIGSPLVGQPKNRTGDVYKCPVGRGESLPCVKLDLPVNTSIPNVTEVKENMTFGSTLVTNPNGGFLACGPLYAYRCGHLHYTTGICSDVSPTFQVVNSIAPVQECSTQLDIVIVLDGSNSIYPWDSVTAFLNDLLERMDIGPKQTQVGIVQYGENVTHEFNLNKYSSTEEVLVAAKKIVQRGGRQTMTALGIDTARKEAFTEARGARRGVKKVMVIVTDGESHDNHRLKKVIQDCEDENIQRFSIAILGSYNRGNLSTEKFVEEIKSIASEPTEKHFFNVSDELALVTIVKTLGERIFALEATADQSAASFEMEMSQTGFSAHYSQDWVMLGAVGAYDWNGTVVMQKASQIIIPRNTTFNVESTKKNEPLASYLGYTVNSATASSGDVLYIAGQPRYNHTGQVIIYRMEDGNIKILQTLSGEQIGSYFGSILTTTDIDKDSNTDILLVGAPMYMGTEKEEQGKVYVYALNQTRFEYQMSLEPIKQTCCSSRQHNSCTTENKNEPCGARFGTAIAAVKDLNLDGFNDIVIGAPLEDDHGGAVYIYHGSGKTIRKEYAQRIPSGGDGKTLKFFGQSIHGEMDLNGDGLTDVTIGGLGGAALFWSRDVAVVKVTMNFEPNKVNIQKKNCHMEGKETVCINATVCFDVKLKSKEDTIYEADLQYRVTLDSLRQISRSFFSGTQERKVQRNITVRKSECTKHSFYMLDKHDFQDSVRITLDFNLTDPENGPVLDDSLPNSVHEYIPFAKDCGNKEKCISDLSLHVATTEKDLLIVRSQNDKFNVSLTVKNTKDSAYNTRTIVHYSPNLVFSGIEAIQKDSCESNHNITCKVGYPFLRRGEMVTFKILFQFNTSYLMENVTIYLSATSDSEEPPETLSDNVVNISIPVKYEVGLQFYSSASEYHISIAANETVPEVINSTEDIGNEINIFYLIRKSGSFPMPELKLSISFPNMTSNGYPVLYPTGLSSSENANCRPHIFEDPFSINSGKKMTTSTDHLKRGTILDCNTCKFATITCNLTSSDISQVNVSLILWKPTFIKSYFSSLNLTIRGELRSENASLVLSSSNQKRELAIQISKDGLPGRVPLWVILLSAFAGLLLLMLLILALWKIGFFKRPLKKKMEK
T31818	DRUGINFO	D0B5VA	SAN-300	Phase 2

T65883	TARGETID	T65883
T65883	FORMERID	TTDI02045
T65883	UNIPROID	CLD18_HUMAN
T65883	TARGNAME	Claudin-18 (CLDN18)
T65883	GENENAME	CLDN18
T65883	TARGTYPE	Clinical trial
T65883	SYNONYMS	UNQ778/PRO1572; Claudin18
T65883	FUNCTION	Plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity.
T65883	SEQUENCE	MSTTTCQVVAFLLSILGLAGCIAATGMDMWSTQDLYDNPVTSVFQYEGLWRSCVRQSSGFTECRPYFTILGLPAMLQAVRALMIVGIVLGAIGLLVSIFALKCIRIGSMEDSAKANMTLTSGIMFIVSGLCAIAGVSVFANMLVTNFWMSTANMYTGMGGMVQTVQTRYTFGAALFVGWVAGGLTLIGGVMMCIACRGLAPEETNYKAVSYHASGHSVAYKPGGFKASTGFGSNTKNKKIYDGGARTEDEVQSYPSKHDYV
T65883	DRUGINFO	D0B3ZC	Claudiximab	Phase 3
T65883	DRUGINFO	D4HQ1F	Zolbetuximab	Phase 3
T65883	DRUGINFO	D5R8YF	RC118	Phase 1/2
T65883	DRUGINFO	DJ6AW5	CT-041	Phase 1/2
T65883	DRUGINFO	D56AJO	SKB315	Phase 1
T65883	DRUGINFO	DYCI37	TST001	Phase 1
T65883	DRUGINFO	DEDP81	AMG 910	Phase 1
T65883	DRUGINFO	DTQL30	ASP2138	Phase 1
T65883	DRUGINFO	D06CWZ	CAR-CLD18 T cell	Clinical trial
T65883	DRUGINFO	D5E1QZ	BNT212	Preclinical

T04894	TARGETID	T04894
T04894	FORMERID	TTDI00043
T04894	UNIPROID	CCL20_HUMAN
T04894	TARGNAME	Liver and activation-regulated chemokine (CCL20)
T04894	GENENAME	CCL20
T04894	TARGTYPE	Clinical trial
T04894	SYNONYMS	Smallinducible cytokine A20; Small-inducible cytokine A20; SCYA20; Macrophage inflammatory protein 3 alpha; MIP3alpha; MIP3A; MIP-3-alpha; Liver and activationregulated chemokine; LARC; CCL20(270); CC motif chemokine 20; CC chemokine LARC; C-C motif chemokine 20; Betachemokine exodus1; Beta-chemokine exodus-1
T04894	FUNCTION	Signals through binding and activation of CCR6 and induces a strong chemotactic response and mobilization of intracellular calcium ions. The ligand-receptor pair CCL20-CCR6 is responsible for the chemotaxis of dendritic cells (DC), effector/memory T-cells and B-cells and plays an important role at skin and mucosal surfaces under homeostatic and inflammatory conditions, as well as in pathology, including cancer and various autoimmune diseases. CCL20 acts as a chemotactic factor that attracts lymphocytes and, slightly, neutrophils, but not monocytes. Involved in the recruitment of both the proinflammatory IL17 producing helper T-cells (Th17) and the regulatory T-cells (Treg) to sites of inflammation. Required for optimal migration of thymic natural regulatory T cells (nTregs) and DN1 early thymocyte progenitor cells. C-terminal processed forms have been shown to be equally chemotactically active for leukocytes. Positively regulates sperm motility and chemotaxis via its binding to CCR6 which triggers Ca2+ mobilization in the sperm which is important for its motility. Inhibits proliferation of myeloid progenitors in colony formation assays. May be involved in formation and function of the mucosal lymphoid tissues by attracting lymphocytes and dendritic cells towards epithelial cells. Possesses antibacterial activity towards E. coli ATCC 25922 and S. aureus ATCC 29213. Acts as a ligand for C-C chemokine receptor CCR6.
T04894	PDBSTRUC	5UR7; 2JYO; 2HCI; 1M8A
T04894	BIOCLASS	Cytokine: CC chemokine
T04894	SEQUENCE	MCCTKSLLLAALMSVLLLHLCGESEAASNFDCCLGYTDRILHPKFIVGFTRQLANEGCDINAIIFHTKKKLSVCANPKQTWVKYIVRLLSKKVKNM
T04894	DRUGINFO	D0T3VF	GSK3050002	Phase 1

T07247	TARGETID	T07247
T07247	FORMERID	TTDR00803
T07247	UNIPROID	S10AC_HUMAN
T07247	TARGNAME	Calgranulin D (S100A12)
T07247	GENENAME	S100A12
T07247	TARGTYPE	Clinical trial
T07247	SYNONYMS	S100 calcium-binding protein A12; Protein S100-A12; P6; Neutrophil S100 protein; Migration inhibitory factor-related protein 6; MRP-6; Extracellular newly identified RAGE-binding protein; EN-RAGE; Calgranulin-C; Calcium-binding protein in amniotic fluid 1; CGRP; CAGC; CAAF1
T07247	FUNCTION	Its proinflammatory activity involves recruitment of leukocytes, promotion of cytokine and chemokine production, and regulation of leukocyte adhesion and migration. Acts as an alarmin or a danger associated molecular pattern (DAMP) molecule and stimulates innate immune cells via binding to receptor for advanced glycation endproducts (AGER). Binding to AGER activates the MAP-kinase and NF-kappa-B signaling pathways leading to production of proinflammatory cytokines and up-regulation of cell adhesion molecules ICAM1 and VCAM1. Acts as a monocyte and mast cell chemoattractant. Can stimulate mast cell degranulation and activation which generates chemokines, histamine and cytokines inducing further leukocyte recruitment to the sites of inflammation. Can inhibit the activity of matrix metalloproteinases; MMP2, MMP3 and MMP9 by chelating Zn(2+) from their active sites. Possesses filariacidal and filariastatic activity. Calcitermin possesses antifungal activity against C. albicans and is also active against E. coli and P. aeruginosa but not L. monocytogenes and S. aureus. S100A12 is a calcium-, zinc- and copper-binding protein which plays a prominent role in the regulation of inflammatory processes and immune response.
T07247	PDBSTRUC	2WCF; 2WCE; 2WCB; 2WC8; 2M9G
T07247	BIOCLASS	S100 calcium-binding protein
T07247	SEQUENCE	MTKLEEHLEGIVNIFHQYSVRKGHFDTLSKGELKQLLTKELANTIKNIKDKAVIDEIFQGLDANQDEQVDFQEFISLVAIALKAAHYHTHKE

T27826	TARGETID	T27826
T27826	FORMERID	TTDI02181
T27826	UNIPROID	SPTB2_HUMAN
T27826	TARGNAME	Spectrin non-erythroid beta chain 1 (SPTBN1)
T27826	GENENAME	SPTBN1
T27826	TARGTYPE	Clinical trial
T27826	SYNONYMS	Spectrin, non-erythroid beta chain 1; Spectrin beta chain, non-erythrocytic 1; SPTB2; Fodrin beta chain; Beta-II spectrin
T27826	FUNCTION	Fodrin, which seems to be involved in secretion, interacts with calmodulin in a calcium-dependent manner and is thus candidate for the calcium-dependent movement of the cytoskeleton at the membrane.
T27826	PDBSTRUC	3EDV; 1BKR; 1AA2
T27826	SEQUENCE	MTTTVATDYDNIEIQQQYSDVNNRWDVDDWDNENSSARLFERSRIKALADEREAVQKKTFTKWVNSHLARVSCRITDLYTDLRDGRMLIKLLEVLSGERLPKPTKGRMRIHCLENVDKALQFLKEQRVHLENMGSHDIVDGNHRLTLGLIWTIILRFQIQDISVETEDNKEKKSAKDALLLWCQMKTAGYPNVNIHNFTTSWRDGMAFNALIHKHRPDLIDFDKLKKSNAHYNLQNAFNLAEQHLGLTKLLDPEDISVDHPDEKSIITYVVTYYHYFSKMKALAVEGKRIGKVLDNAIETEKMIEKYESLASDLLEWIEQTIIILNNRKFANSLVGVQQQLQAFNTYRTVEKPPKFTEKGNLEVLLFTIQSKMRANNQKVYMPREGKLISDINKAWERLEKAEHERELALRNELIRQEKLEQLARRFDRKAAMRETWLSENQRLVSQDNFGFDLPAVEAATKKHEAIETDIAAYEERVQAVVAVARELEAENYHDIKRITARKDNVIRLWEYLLELLRARRQRLEMNLGLQKIFQEMLYIMDWMDEMKVLVLSQDYGKHLLGVEDLLQKHTLVEADIGIQAERVRGVNASAQKFATDGEGYKPCDPQVIRDRVAHMEFCYQELCQLAAERRARLEESRRLWKFFWEMAEEEGWIREKEKILSSDDYGKDLTSVMRLLSKHRAFEDEMSGRSGHFEQAIKEGEDMIAEEHFGSEKIRERIIYIREQWANLEQLSAIRKKRLEEASLLHQFQADADDIDAWMLDILKIVSSSDVGHDEYSTQSLVKKHKDVAEEIANYRPTLDTLHEQASALPQEHAESPDVRGRLSGIEERYKEVAELTRLRKQALQDTLALYKMFSEADACELWIDEKEQWLNNMQIPEKLEDLEVIQHRFESLEPEMNNQASRVAVVNQIARQLMHSGHPSEKEIKAQQDKLNTRWSQFRELVDRKKDALLSALSIQNYHLECNETKSWIREKTKVIESTQDLGNDLAGVMALQRKLTGMERDLVAIEAKLSDLQKEAEKLESEHPDQAQAILSRLAEISDVWEEMKTTLKNREASLGEASKLQQFLRDLDDFQSWLSRTQTAIASEDMPNTLTEAEKLLTQHENIKNEIDNYEEDYQKMRDMGEMVTQGQTDAQYMFLRQRLQALDTGWNELHKMWENRQNLLSQSHAYQQFLRDTKQAEAFLNNQEYVLAHTEMPTTLEGAEAAIKKQEDFMTTMDANEEKINAVVETGRRLVSDGNINSDRIQEKVDSIDDRHRKNRETASELLMRLKDNRDLQKFLQDCQELSLWINEKMLTAQDMSYDEARNLHSKWLKHQAFMAELASNKEWLDKIEKEGMQLISEKPETEAVVKEKLTGLHKMWEVLESTTQTKAQRLFDANKAELFTQSCADLDKWLHGLESQIQSDDYGKDLTSVNILLKKQQMLENQMEVRKKEIEELQSQAQALSQEGKSTDEVDSKRLTVQTKFMELLEPLNERKHNLLASKEIHQFNRDVEDEILWVGERMPLATSTDHGHNLQTVQLLIKKNQTLQKEIQGHQPRIDDIFERSQNIVTDSSSLSAEAIRQRLADLKQLWGLLIEETEKRHRRLEEAHRAQQYYFDAAEAEAWMSEQELYMMSEEKAKDEQSAVSMLKKHQILEQAVEDYAETVHQLSKTSRALVADSHPESERISMRQSKVDKLYAGLKDLAEERRGKLDERHRLFQLNREVDDLEQWIAEREVVAGSHELGQDYEHVTMLQERFREFARDTGNIGQERVDTVNHLADELINSGHSDAATIAEWKDGLNEAWADLLELIDTRTQILAASYELHKFYHDAKEIFGRIQDKHKKLPEELGRDQNTVETLQRMHTTFEHDIQALGTQVRQLQEDAARLQAAYAGDKADDIQKRENEVLEAWKSLLDACESRRVRLVDTGDKFRFFSMVRDLMLWMEDVIRQIEAQEKPRDVSSVELLMNNHQGIKAEIDARNDSFTTCIELGKSLLARKHYASEEIKEKLLQLTEKRKEMIDKWEDRWEWLRLILEVHQFSRDASVAEAWLLGQEPYLSSREIGQSVDEVEKLIKRHEAFEKSAATWDERFSALERLTTLELLEVRRQQEEEERKRRPPSPEPSTKVSEEAESQQQWDTSKGEQVSQNGLPAEQGSPRMAETVDTSEMVNGATEQRTSSKESSPIPSPTSDRKAKTALPAQSAATLPARTQETPSAQMEGFLNRKHEWEAHNKKASSRSWHNVYCVINNQEMGFYKDAKTAASGIPYHSEVPVSLKEAVCEVALDYKKKKHVFKLRLNDGNEYLFQAKDDEEMNTWIQAISSAISSDKHEVSASTQSTPASSRAQTLPTSVVTITSESSPGKREKDKEKDKEKRFSLFGKKK
T27826	DRUGINFO	D01QKZ	ABT-413	Phase 1

T57059	TARGETID	T57059
T57059	FORMERID	TTDNC00411
T57059	UNIPROID	E2F1_HUMAN
T57059	TARGNAME	E2F transcription factor 1 (E2F1)
T57059	GENENAME	E2F1
T57059	TARGTYPE	Clinical trial
T57059	SYNONYMS	pRB-binding protein E2F-1; Transcription factor E2F1; Retinoblastoma-binding protein 3; Retinoblastoma-associated protein 1; RBBP3; RBBP-3; RBAP-1; PBR3; E2F-1
T57059	FUNCTION	The DRTF1/E2F complex functions in the control of cell-cycle progression from G1 to S phase. E2F1 binds preferentially RB1 in a cell-cycle dependent manner. It can mediate both cell proliferation and TP53/p53-dependent apoptosis. Blocks adipocyte differentiation by binding to specific promoters repressing CEBPA binding to its target gene promoters. Positively regulates transcription of RRP1B. Transcription activator that binds DNA cooperatively with DP proteins through the E2 recognition site, 5'-TTTC[CG]CGC-3' found in the promoter region of a number of genes whose products are involved in cell cycle regulation or in DNA replication.
T57059	PDBSTRUC	6G0P; 5M9O; 5M9N; 2AZE; 1O9K
T57059	SEQUENCE	MALAGAPAGGPCAPALEALLGAGALRLLDSSQIVIISAAQDASAPPAPTGPAAPAAGPCDPDLLLFATPQAPRPTPSAPRPALGRPPVKRRLDLETDHQYLAESSGPARGRGRHPGKGVKSPGEKSRYETSLNLTTKRFLELLSHSADGVVDLNWAAEVLKVQKRRIYDITNVLEGIQLIAKKSKNHIQWLGSHTTVGVGGRLEGLTQDLRQLQESEQQLDHLMNICTTQLRLLSEDTDSQRLAYVTCQDLRSIADPAEQMVMVIKAPPETQLQAVDSSENFQISLKSKQGPIDVFLCPEETVGGISPGKTPSQEVTSEEENRATDSATIVSPPPSSPPSSLTTDPSQSLLSLEQEPLLSRMGSLRAPVDEDRLSPLVAADSLLEHVREDFSGLLPEEFISLSPPHEALDYHFGLEEGEGIRDLFDCDFGDLTPLDF
T57059	DRUGINFO	D00SIA	ARQ-171	Phase 1

T30356	TARGETID	T30356
T30356	FORMERID	TTDI01992
T30356	UNIPROID	RHD_HUMAN
T30356	TARGNAME	Blood group Rh(D) polypeptide (RHD)
T30356	GENENAME	RHD
T30356	TARGTYPE	Clinical trial
T30356	SYNONYMS	Rhesus D antigen; RhPII; Rh polypeptide 2; RHXIII; RHD; CD240D
T30356	FUNCTION	May be part of an oligomeric complex which is likely to have a transport or channel function in the erythrocyte membrane.
T30356	BIOCLASS	Ammonia transporter channel
T30356	SEQUENCE	MSSKYPRSVRRCLPLWALTLEAALILLFYFFTHYDASLEDQKGLVASYQVGQDLTVMAAIGLGFLTSSFRRHSWSSVAFNLFMLALGVQWAILLDGFLSQFPSGKVVITLFSIRLATMSALSVLISVDAVLGKVNLAQLVVMVLVEVTALGNLRMVISNIFNTDYHMNMMHIYVFAAYFGLSVAWCLPKPLPEGTEDKDQTATIPSLSAMLGALFLWMFWPSFNSALLRSPIERKNAVFNTYYAVAVSVVTAISGSSLAHPQGKISKTYVHSAVLAGGVAVGTSCHLIPSPWLAMVLGLVAGLISVGGAKYLPGCCNRVLGIPHSSIMGYNFSLLGLLGEIIYIVLLVLDTVGAGNGMIGFQVLLSIGELSLAIVIALMSGLLTGLLLNLKIWKAPHEAKYFDDQVFWKFPHLAVGF
T30356	DRUGINFO	D01ADL	Roledumab	Phase 2/3
T30356	DRUGINFO	D06UPS	Rozrolimupab	Discontinued in Phase 2

T65198	TARGETID	T65198
T65198	FORMERID	TTDR00668
T65198	UNIPROID	NRG1_HUMAN
T65198	TARGNAME	Pro-neuregulin-1 (Pro-NRG1)
T65198	GENENAME	NRG1
T65198	TARGTYPE	Clinical trial
T65198	SYNONYMS	SMDF  (20-241); Pro-neuregulin-1, membrane-bound isoform  (20-241); NDF  (20-241); Heregulin  (20-241); HRGA  (20-241); HGL  (20-241); GGF  (20-241)
T65198	FUNCTION	Concomitantly recruits ERBB1 and ERBB2 coreceptors, resulting in ligand-stimulated tyrosine phosphorylation and activation of the ERBB receptors. The multiple isoforms perform diverse functions such as inducing growth and differentiation of epithelial, glial, neuronal, and skeletal muscle cells; inducing expression of acetylcholine receptor in synaptic vesicles during the formation of the neuromuscular junction; stimulating lobuloalveolar budding and milk production in the mammary gland and inducing differentiation of mammary tumor cells; stimulating Schwann cell proliferation; implication in the development of the myocardium such as trabeculation of the developing heart. Isoform 10 may play a role in motor and sensory neuron development. Binds to ERBB4. Binds to ERBB3. Acts as a ligand for integrins and binds (via EGF domain) to integrins ITGAV:ITGB3 or ITGA6:ITGB4. Its binding to integrins and subsequent ternary complex formation with integrins and ERRB3 are essential for NRG1-ERBB signaling. Induces the phosphorylation and activation of MAPK3/ERK1, MAPK1/ERK2 and AKT1. Ligand-dependent ERBB4 endocytosis is essential for the NRG1-mediated activation of these kinases in neurons. Direct ligand for ERBB3 and ERBB4 tyrosine kinase receptors.
T65198	PDBSTRUC	3U7U; 1HRF; 1HRE; 1HAF; 1HAE
T65198	SEQUENCE	MSERKEGRGKGKGKKKERGSGKKPESAAGSQSPALPPRLKEMKSQESAAGSKLVLRCETSSEYSSLRFKWFKNGNELNRKNKPQNIKIQKKPGKSELRINKASLADSGEYMCKVISKLGNDSASANITIVESNEIITGMPASTEGAYVSSESPIRISVSTEGANTSSSTSTSTTGTSHLVKCAEKEKTFCVNGGECFMVKDLSNPSRYLCKCQPGFTGARCTENVPMKVQNQEKAEELYQKRVLTITGICIALLVVGIMCVVAYCKTKKQRKKLHDRLRQSLRSERNNMMNIANGPHHPNPPPENVQLVNQYVSKNVISSEHIVEREAETSFSTSHYTSTAHHSTTVTQTPSHSWSNGHTESILSESHSVIVMSSVENSRHSSPTGGPRGRLNGTGGPRECNSFLRHARETPDSYRDSPHSERYVSAMTTPARMSPVDFHTPSSPKSPPSEMSPPVSSMTVSMPSMAVSPFMEEERPLLLVTPPRLREKKFDHHPQQFSSFHHNPAHDSNSLPASPLRIVEDEEYETTQEYEPAQEPVKKLANSRRAKRTKPNGHIANRLEVDSNTSSQSSNSESETEDERVGEDTPFLGIQNPLAASLEATPAFRLADSRTNPAGRFSTQEEIQARLSSVIANQDPIAV
T65198	DRUGINFO	D00ZPR	Neucardin	Phase 3
T65198	DRUGINFO	D08WNO	GGF	Phase 1b
T65198	DRUGINFO	D0H0YZ	GGF-2	Phase 1

T92030	TARGETID	T92030
T92030	FORMERID	TTDNC00443
T92030	UNIPROID	REG3A_HUMAN
T92030	TARGNAME	Regenerating human pro-islet peptide (REG3A)
T92030	GENENAME	REG3A
T92030	TARGTYPE	Clinical trial
T92030	SYNONYMS	Regenerating islet-derived protein III-alpha; Regenerating islet-derived protein 3-alpha 15 kDa form; Regenerating islet-derived protein 3-alpha; Reg III-alpha; REG3A; REG-3-alpha; Pancreatitis-associated protein 1; Human proislet peptide; Hepatointestinal pancreatic protein; HIP/PAP
T92030	FUNCTION	Bactericidal C-type lectin which acts exclusively against Gram-positive bacteria and mediates bacterial killing by binding to surface-exposed carbohydrate moieties of peptidoglycan. Regulates keratinocyte proliferation and differentiation after skin injury via activation of EXTL3-PI3K-AKT signaling pathway.
T92030	PDBSTRUC	4MTH; 2GO0; 1UV0
T92030	SEQUENCE	MLPPMALPSVSWMLLSCLMLLSQVQGEEPQRELPSARIRCPKGSKAYGSHCYALFLSPKSWTDADLACQKRPSGNLVSVLSGAEGSFVSSLVKSIGNSYSYVWIGLHDPTQGTEPNGEGWEWSSSDVMNYFAWERNPSTISSPGHCASLSRSTAFLRWKDYNCNVRLPYVCKFTD
T92030	DRUGINFO	D01FBS	ALF-5755	Phase 2
T92030	DRUGINFO	D0ZF8F	HIP-2B	Phase 1

T97766	TARGETID	T97766
T97766	FORMERID	TTDI02423
T97766	UNIPROID	CD47_HUMAN
T97766	TARGNAME	Leukocyte surface antigen CD47 (CD47)
T97766	GENENAME	CD47
T97766	TARGTYPE	Clinical trial
T97766	SYNONYMS	Protein MER6; MER6; Integrinassociated protein; Integrin-associated protein; IAP; Antigenic surface determinant protein OA3
T97766	FUNCTION	Plays an important role in memory formation and synaptic plasticity in the hippocampus. Receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. May play a role in membrane transport and/or integrin dependent signal transduction. May prevent premature elimination of red blood cells. May be involved in membrane permeability changes induced following virus infection. Has a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins.
T97766	PDBSTRUC	5TZU; 5TZT; 5TZ2; 5IWL; 4KJY
T97766	BIOCLASS	Osteoclast fusion complex
T97766	SEQUENCE	MWPLVAALLLGSACCGSAQLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEVYVKWKFKGRDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELTREGETIIELKYRVVSWFSPNENILIVIFPIFAILLFWGQFGIKTLKYRSGGMDEKTIALLVAGLVITVIVIVGAILFVPGEYSLKNATGLGLIVTSTGILILLHYYVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACIPMHGPLLISGLSILALAQLLGLVYMKFVASNQKTIQPPRKAVEEPLNAFKESKGMMNDE
T97766	DRUGINFO	D09JYL	Hu5F9-G4	Phase 3
T97766	DRUGINFO	DRP8H0	Evorpacept	Phase 2/3
T97766	DRUGINFO	D6SJ0B	PF-07901801	Phase 2
T97766	DRUGINFO	D0J7UL	ALX148	Phase 1/2
T97766	DRUGINFO	D1WB6Z	DSP-107	Phase 1/2
T97766	DRUGINFO	DA4W1I	AO-176	Phase 1/2
T97766	DRUGINFO	D01CUO	TTI-621	Phase 1
T97766	DRUGINFO	D5FCP1	TTI-622	Phase 1
T97766	DRUGINFO	D5V2HR	IBI188	Phase 1
T97766	DRUGINFO	DEUC70	TJC4	Phase 1
T97766	DRUGINFO	DI8WC4	CC-90002	Phase 1
T97766	DRUGINFO	DTHR46	IMC-002	Phase 1
T97766	DRUGINFO	DY7D9A	ZL-1201	Phase 1
T97766	DRUGINFO	D1A7OP	PF-07257876	Phase 1
T97766	DRUGINFO	D8UNG2	TG-1801	Phase 1
T97766	DRUGINFO	DKUF26	SL-172154	Phase 1

T88322	TARGETID	T88322
T88322	FORMERID	TTDI02183
T88322	UNIPROID	SSRP1_HUMAN
T88322	TARGNAME	Facilitates chromatin transcription complex (FACT)
T88322	GENENAME	SSRP1
T88322	TARGTYPE	Clinical trial
T88322	SYNONYMS	hSSRP1; T160; Structure-specific recognition protein 1; Recombination signal sequence recognition protein 1; Facilitates chromatin transcription complex subunit SSRP1; Facilitates chromatin transcription complex 80 kDa subunit; FACTp80; FACT80; FACT complex subunit SSRP1; FACT 80 kDa subunit; Chromatin-specific transcription elongation factor 80 kDa subunit
T88322	FUNCTION	The FACT complex is involved in multiple processes that require DNA as a template such as mRNA elongation, DNA replication and DNA repair. During transcription elongation the FACT complex acts as a histone chaperone that both destabilizes and restores nucleosomal structure. It facilitates the passage of RNA polymerase II and transcription by promoting the dissociation of one histone H2A-H2B dimer from the nucleosome, then subsequently promotes the reestablishment of the nucleosome following the passage of RNA polymerase II. The FACT complex is probably also involved in phosphorylation of 'Ser-392' of p53/TP53 via its association with CK2 (casein kinase II). Binds specifically to double-stranded DNA and at low levels to DNA modified by the antitumor agent cisplatin. May potentiate cisplatin-induced cell death by blocking replication and repair of modified DNA. Also acts as a transcriptional coactivator for p63/TP63. Component of the FACT complex, a general chromatin factor that acts to reorganize nucleosomes.
T88322	PDBSTRUC	5VWE; 5UMS; 5UMR; 4IFS
T88322	SEQUENCE	MAETLEFNDVYQEVKGSMNDGRLRLSRQGIIFKNSKTGKVDNIQAGELTEGIWRRVALGHGLKLLTKNGHVYKYDGFRESEFEKLSDFFKTHYRLELMEKDLCVKGWNWGTVKFGGQLLSFDIGDQPVFEIPLSNVSQCTTGKNEVTLEFHQNDDAEVSLMEVRFYVPPTQEDGVDPVEAFAQNVLSKADVIQATGDAICIFRELQCLTPRGRYDIRIYPTFLHLHGKTFDYKIPYTTVLRLFLLPHKDQRQMFFVISLDPPIKQGQTRYHFLILLFSKDEDISLTLNMNEEEVEKRFEGRLTKNMSGSLYEMVSRVMKALVNRKITVPGNFQGHSGAQCITCSYKASSGLLYPLERGFIYVHKPPVHIRFDEISFVNFARGTTTTRSFDFEIETKQGTQYTFSSIEREEYGKLFDFVNAKKLNIKNRGLKEGMNPSYDEYADSDEDQHDAYLERMKEEGKIREENANDSSDDSGEETDESFNPGEEEEDVAEEFDSNASASSSSNEGDSDRDEKKRKQLKKAKMAKDRKSRKKPVEVKKGKDPNAPKRPMSAYMLWLNASREKIKSDHPGISITDLSKKAGEIWKGMSKEKKEEWDRKAEDARRDYEKAMKEYEGGRGESSKRDKSKKKKKVKVKMEKKSTPSRGSSSKSSSRQLSESFKSKEFVSSDESSSGENKSKKKRRRSEDSEEEELASTPPSSEDSASGSDE
T88322	DRUGINFO	D0C8ES	CBL0102	Phase 1/2
T88322	DRUGINFO	D0Z0XM	CBL0137	Phase 1

T68517	TARGETID	T68517
T68517	FORMERID	TTDNR00685
T68517	UNIPROID	HSPB3_HUMAN
T68517	TARGNAME	Heat shock protein 27 (HSP27)
T68517	GENENAME	HSPB3
T68517	TARGTYPE	Clinical trial
T68517	SYNONYMS	Protein 3; HspB3; Heat shock protein beta3; Heat shock 17 kDa protein; HSP 17
T68517	FUNCTION	Inhibitor of actin polymerization.
T68517	PDBSTRUC	6F2R
T68517	BIOCLASS	Heat shock protein
T68517	SEQUENCE	MAKIILRHLIEIPVRYQEEFEARGLEDCRLDHALYALPGPTIVDLRKTRAAQSPPVDSAAETPPREGKSHFQILLDVVQFLPEDIIIQTFEGWLLIKAQHGTRMDEHGFISRSFTRQYKLPDGVEIKDLSAVLCHDGILVVEVKDPVGTK
T68517	DRUGINFO	D0AX1N	OGX-427	Phase 2
T68517	DRUGINFO	D0I3EI	NK-1001	Discontinued in Phase 2

T25739	TARGETID	T25739
T25739	FORMERID	TTDI02168
T25739	UNIPROID	S39A6_HUMAN
T25739	TARGNAME	Solute carrier family 39 member 6 (SLC39A6)
T25739	GENENAME	SLC39A6
T25739	TARGTYPE	Clinical trial
T25739	SYNONYMS	Zrt- and Irt-like protein 6; ZIP-6; SLC39A6; Estrogen-regulated protein LIV-1
T25739	FUNCTION	May act as a zinc-influx transporter.
T25739	SEQUENCE	MARKLSVILILTFALSVTNPLHELKAAAFPQTTEKISPNWESGINVDLAISTRQYHLQQLFYRYGENNSLSVEGFRKLLQNIGIDKIKRIHIHHDHDHHSDHEHHSDHERHSDHEHHSEHEHHSDHDHHSHHNHAASGKNKRKALCPDHDSDSSGKDPRNSQGKGAHRPEHASGRRNVKDSVSASEVTSTVYNTVSEGTHFLETIETPRPGKLFPKDVSSSTPPSVTSKSRVSRLAGRKTNESVSEPRKGFMYSRNTNENPQECFNASKLLTSHGMGIQVPLNATEFNYLCPAIINQIDARSCLIHTSEKKAEIPPKTYSLQIAWVGGFIAISIISFLSLLGVILVPLMNRVFFKFLLSFLVALAVGTLSGDAFLHLLPHSHASHHHSHSHEEPAMEMKRGPLFSHLSSQNIEESAYFDSTWKGLTALGGLYFMFLVEHVLTLIKQFKDKKKKNQKKPENDDDVEIKKQLSKYESQLSTNEEKVDTDDRTEGYLRADSQEPSHFDSQQPAVLEEEEVMIAHAHPQEVYNEYVPRGCKNKCHSHFHDTLGQSDDLIHHHHDYHHILHHHHHQNHHPHSHSQRYSREELKDAGVATLAWMVIMGDGLHNFSDGLAIGAAFTEGLSSGLSTSVAVFCHELPHELGDFAVLLKAGMTVKQAVLYNALSAMLAYLGMATGIFIGHYAENVSMWIFALTAGLFMYVALVDMVPEMLHNDASDHGCSRWGYFFLQNAGMLLGFGIMLLISIFEHKIVFRINF
T25739	DRUGINFO	DS6B1L	SGN-LIV1A	Phase 2
T25739	DRUGINFO	D06JBV	SGN LIV1A	Phase 1

T09058	TARGETID	T09058
T09058	FORMERID	TTDR00714
T09058	UNIPROID	TPBG_HUMAN
T09058	TARGNAME	Oncotrophoblast glycoprotein 5T4 (TPBG)
T09058	GENENAME	TPBG
T09058	TARGTYPE	Clinical trial
T09058	SYNONYMS	Trophoblast glycoprotein; TPBG
T09058	FUNCTION	May function as an inhibitor of Wnt/beta-catenin signaling by indirectly interacting with LRP6 and blocking Wnt3a- dependent LRP6 internalization.
T09058	PDBSTRUC	4CNM; 4CNC
T09058	SEQUENCE	MPGGCSRGPAAGDGRLRLARLALVLLGWVSSSSPTSSASSFSSSAPFLASAVSAQPPLPDQCPALCECSEAARTVKCVNRNLTEVPTDLPAYVRNLFLTGNQLAVLPAGAFARRPPLAELAALNLSGSRLDEVRAGAFEHLPSLRQLDLSHNPLADLSPFAFSGSNASVSAPSPLVELILNHIVPPEDERQNRSFEGMVVAALLAGRALQGLRRLELASNHFLYLPRDVLAQLPSLRHLDLSNNSLVSLTYVSFRNLTHLESLHLEDNALKVLHNGTLAELQGLPHIRVFLDNNPWVCDCHMADMVTWLKETEVVQGKDRLTCAYPEKMRNRVLLELNSADLDCDPILPPSLQTSYVFLGIVLALIGAIFLLVLYLNRKGIKKWMHNIRDACRDHMEGYHYRYEINADPRLTNLSSNSDV
T09058	DRUGINFO	D0L1OT	TroVax	Phase 3
T09058	DRUGINFO	D0T8HR	Naptumomab estafenatox	Phase 2/3
T09058	DRUGINFO	D02DVK	CV-9201	Phase 1/2
T09058	DRUGINFO	D03JZC	PF-06263507	Phase 1
T09058	DRUGINFO	DQ15HJ	GEN1044	Phase 1
T09058	DRUGINFO	DNUS02	IM1240	Preclinical
T09058	DRUGINFO	D0W5NP	Anatumomab mafenatox	Terminated

T21865	TARGETID	T21865
T21865	FORMERID	TTDR01112
T21865	UNIPROID	SELPL_HUMAN
T21865	TARGNAME	P-selectin glycoprotein ligand 1 (SELPLG)
T21865	GENENAME	SELPLG
T21865	TARGTYPE	Clinical trial
T21865	SYNONYMS	Selectin P ligand; SPSGL-1; SELPLG; PSGL-1; P-selectin glycoprotein ligand-1; CD162 antigen
T21865	FUNCTION	A SLe(x)-type proteoglycan, which through high affinity, calcium-dependent interactions with E-, P- and L-selectins, mediates rapid rolling of leukocytes over vascular surfaces during the initial steps in inflammation. Critical for the initial leukocyte capture.
T21865	PDBSTRUC	1G1S
T21865	SEQUENCE	MPLQLLLLLILLGPGNSLQLWDTWADEAEKALGPLLARDRRQATEYEYLDYDFLPETEPPEMLRNSTDTTPLTGPGTPESTTVEPAARRSTGLDAGGAVTELTTELANMGNLSTDSAAMEIQTTQPAATEAQTTQPVPTEAQTTPLAATEAQTTRLTATEAQTTPLAATEAQTTPPAATEAQTTQPTGLEAQTTAPAAMEAQTTAPAAMEAQTTPPAAMEAQTTQTTAMEAQTTAPEATEAQTTQPTATEAQTTPLAAMEALSTEPSATEALSMEPTTKRGLFIPFSVSSVTHKGIPMAASNLSVNYPVGAPDHISVKQCLLAILILALVATIFFVCTVVLAVRLSRKGHMYPVRNYSPTEMVCISSLLPDGGEGPSATANGGLSKAKSPGLTPEPREDREGDDLTLHSFLP
T21865	DRUGINFO	D02YIP	AbGn-168	Phase 2
T21865	DRUGINFO	D0I6IQ	Neihulizumab	Phase 2
T21865	DRUGINFO	D0M7VE	RO-4905417	Phase 2
T21865	DRUGINFO	DFTV08	SelK2	Phase 2

T61518	TARGETID	T61518
T61518	UNIPROID	MELK_HUMAN
T61518	TARGNAME	Tyrosine-protein kinase MELK (MELK)
T61518	GENENAME	MELK
T61518	TARGTYPE	Clinical trial
T61518	SYNONYMS	pEg3 kinase; hPK38; hMELK; MELK
T61518	FUNCTION	Serine/threonine-protein kinase involved in various processes such as cell cycle regulation, self-renewal of stem cells, apoptosis and splicing regulation. Has a broad substrate specificity; phosphorylates BCL2L14, CDC25B, MAP3K5/ASK1 andZNF622. Acts as an activator of apoptosis by phosphorylating and activating MAP3K5/ASK1. Acts as a regulator of cell cycle, notably by mediating phosphorylation of CDC25B, promoting localization of CDC25B to the centrosome and the spindle poles during mitosis. Plays a key role in cell proliferation and carcinogenesis. Required for proliferation of embryonic and postnatal multipotent neural progenitors. Phosphorylates and inhibits BCL2L14, possibly leading to affect mammary carcinogenesis by mediating inhibition of the pro-apoptotic function of BCL2L14. Also involved in the inhibition of spliceosome assembly during mitosis by phosphorylating ZNF622, thereby contributing to its redirection to the nucleus. May also play a role in primitive hematopoiesis. {ECO:0000269|PubMed:11802789, ECO:0000269|PubMed:12400006, ECO:0000269|PubMed:14699119, ECO:0000269|PubMed:15908796, ECO:0000269|PubMed:16216881, ECO:0000269|PubMed:17280616}.
T61518	PDBSTRUC	5TX3; 5TWZ; 5TWY; 5TWU; 5TWL
T61518	ECNUMBER	EC 2.7.11.1
T61518	SEQUENCE	MKDYDELLKYYELHETIGTGGFAKVKLACHILTGEMVAIKIMDKNTLGSDLPRIKTEIEALKNLRHQHICQLYHVLETANKIFMVLEYCPGGELFDYIISQDRLSEEETRVVFRQIVSAVAYVHSQGYAHRDLKPENLLFDEYHKLKLIDFGLCAKPKGNKDYHLQTCCGSLAYAAPELIQGKSYLGSEADVWSMGILLYVLMCGFLPFDDDNVMALYKKIMRGKYDVPKWLSPSSILLLQQMLQVDPKKRISMKNLLNHPWIMQDYNYPVEWQSKNPFIHLDDDCVTELSVHHRNNRQTMEDLISLWQYDHLTATYLLLLAKKARGKPVRLRLSSFSCGQASATPFTDIKSNNWSLEDVTASDKNYVAGLIDYDWCEDDLSTGAATPRTSQFTKYWTESNGVESKSLTPALCRTPANKLKNKENVYTPKSAVKNEEYFMFPEPKTPVNKNQHKREILTTPNRYTTPSKARNQCLKETPIKIPVNSTGTDKLMTGVISPERRCRSVELDLNQAHMEETPKRKGAKVFGSLERGLDKVITVLTRSKRKGSARDGPRRLKLHYNVTTTRLVNPDQLLNEIMSILPKKHVDFVQKGYTLKCQTQSDFGKVTMQFELEVCQLQKPDVVGIRRQRLKGDAWVYKRLVEDILSSCKV
T61518	DRUGINFO	D08FIX	OTSSP167	Phase 1

T93995	TARGETID	T93995
T93995	UNIPROID	NEDD8_HUMAN
T93995	TARGNAME	Ubiquitin-like protein Nedd8 (NEDD8)
T93995	GENENAME	NEDD8
T93995	TARGTYPE	Clinical trial
T93995	SYNONYMS	Neural precursor cell expressed developmentally down-regulated protein 8; Neddylin; NEDD-8
T93995	FUNCTION	Ubiquitin-like protein which plays an important role in cell cycle control and embryogenesis. Covalent attachment to its substrates requires prior activation by the E1 complex UBE1C-APPBP1 and linkage to the E2 enzyme UBE2M. Attachment of NEDD8 to cullins activates their associated E3 ubiquitin ligase activity, and thus promotes polyubiquitination and proteasomal degradation of cyclins and other regulatory proteins.
T93995	PDBSTRUC	4P5O; 4HCP; 4FBJ; 4F8C; 3GZN
T93995	BIOCLASS	Ubiquitin family
T93995	SEQUENCE	MLIKVKTLTGKEIEIDIEPTDKVERIKERVEEKEGIPPQQQRLIYSGKQMNDEKTAADYKILGGSVLHLVLALRGGGGLRQ
T93995	DRUGINFO	D0ZD2M	MLN4924	Phase 3

T75256	TARGETID	T75256
T75256	FORMERID	TTDI02120
T75256	UNIPROID	MAR1_HUMAN
T75256	TARGNAME	MART-1 melanoma antigen (MLANA)
T75256	GENENAME	MLANA
T75256	TARGTYPE	Clinical trial
T75256	SYNONYMS	Protein MelanA; Melanoma antigen recognized by Tcells 1; MLANA; MART1; Antigen SK29AA; Antigen LB39AA
T75256	FUNCTION	Involved in melanosome biogenesis by ensuring the stability of GPR143. Plays a vital role in the expression, stability, trafficking, and processing of melanocyte protein PMEL, which is critical to the formation of stage II melanosomes.
T75256	PDBSTRUC	6DKP; 6D78; 5NQK; 5NHT; 5E9D
T75256	SEQUENCE	MPREDAHFIYGYPKKGHGHSYTTAEEAAGIGILTVILGVLLLIGCWYCRRRNGYRALMDKSLHVGTQCALTRRCPQEGFDHRDSKVSLQEKNCEPVVPNAPPAYEKLSAEQSPPPYSP
T75256	DRUGINFO	D0P5TG	Multi-epitope peptide melanoma vaccine	Phase 3
T75256	DRUGINFO	D0U9MJ	Melanoma vaccine	Phase 3
T75256	DRUGINFO	D0J7MQ	MKC-1106-MT	Phase 2
T75256	DRUGINFO	D00DSV	Polynoma-1	Phase 2
T75256	DRUGINFO	D0C1EO	Melanoma vaccine (ALVAC)	Discontinued in Phase 2
T75256	DRUGINFO	D07CQJ	F-50040	Discontinued in Phase 1

T99532	TARGETID	T99532
T99532	FORMERID	TTDI02010
T99532	UNIPROID	2B1A_HUMAN
T99532	TARGNAME	HLA class II antigen DR10 (HLA-DRB1)
T99532	GENENAME	HLA-DRB1
T99532	TARGTYPE	Clinical trial
T99532	SYNONYMS	MHC class II antigen DRB1*10; HLADRB1; HLA class II histocompatibility antigen, DRB110 beta chain; DRw10
T99532	FUNCTION	Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route; where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules; and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments; exogenous antigens must compete withthose derived from endogenous components. Autophagy is also a source of endogenous peptides; autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs; other cells of the gastrointestinal tract; such as epithelial cells; express MHC class II molecules and CD74 and act as APCs; which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen; three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs; CD74 undergoes a sequential degradation by various proteases; including CTSS and CTSL; leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells; the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules; increased acidification produces increased proteolysis and efficient peptide loading.
T99532	BIOCLASS	MHC class II
T99532	SEQUENCE	MVCLKLPGGSCMTALTVTLMVLSSPLALSGDTRPRFLWQPKRECHFFNGTERVRFLDRYFYNQEESVRFDSDVGEFRAVTELGRPDAEYWNSQKDILEQARAAVDTYCRHNYGVVESFTVQRRVQPKVTVYPSKTQPLQHHNLLVCSVSGFYPGSIEVRWFLNGQEEKAGMVSTGLIQNGDWTFQTLVMLETVPRSGEVYTCQVEHPSVTSPLTVEWRARSESAQSKMLSGVGGFVLGLLFLGAGLFIYFRNQKGHSGLQPTGFLS

T40874	TARGETID	T40874
T40874	UNIPROID	TIGIT_HUMAN
T40874	TARGNAME	V-set and immunoglobulin domain-containing protein 9 (TIGIT)
T40874	GENENAME	TIGIT
T40874	TARGTYPE	Clinical trial
T40874	SYNONYMS	VSTM3; VSIG9; V-set and transmembrane domain-containing protein 3; T-cell immunoreceptor with Ig and ITIM domains
T40874	FUNCTION	Binds with high affinity to the poliovirus receptor (PVR) which causes increased secretion of IL10 and decreased secretion of IL12B and suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells.
T40874	PDBSTRUC	5V52; 3UDW; 3UCR; 3RQ3; 3Q0H
T40874	SEQUENCE	MRWCLLLIWAQGLRQAPLASGMMTGTIETTGNISAEKGGSIILQCHLSSTTAQVTQVNWEQQDQLLAICNADLGWHISPSFKDRVAPGPGLGLTLQSLTVNDTGEYFCIYHTYPDGTYTGRIFLEVLESSVAEHGARFQIPLLGAMAATLVVICTAVIVVVALTRKKKALRIHSVEGDLRRKSAGQEEWSPSAPSPPGSCVQAEAAPAGLCGEQRGEDCAELHDYFNVLSYRSLGNCSFFTETG
T40874	DRUGINFO	DFYL51	Ociperlimab	Phase 3
T40874	DRUGINFO	DT1FS0	AB154	Phase 3
T40874	DRUGINFO	DQ72BV	GSK4428859	Phase 2
T40874	DRUGINFO	D4RMC9	Rilvegostomig	Phase 1/2
T40874	DRUGINFO	D0U9OC	ASP8374	Phase 1
T40874	DRUGINFO	D1AVT5	SEA-TGT	Phase 1
T40874	DRUGINFO	D9LA6Q	COM902	Phase 1
T40874	DRUGINFO	DA8MK6	M6223	Phase 1

T17248	TARGETID	T17248
T17248	FORMERID	TTDS00347
T17248	UNIPROID	FUS_MEASC
T17248	TARGNAME	Measles virus Fusion glycoprotein (MeV F)
T17248	GENENAME	MeV F
T17248	TARGTYPE	Clinical trial
T17248	SYNONYMS	Measles virus fusion protein; MV fusion protein; Fusion protein
T17248	FUNCTION	Class I viral fusion protein. Under the current model, the protein has at least 3 conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During viral and plasma cell membrane fusion,the heptad repeat (HR) regions assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C- terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and plasma cell membranes. Directs fusion of viral and cellular membranes leading to delivery of the nucleocapsid into the cytoplasm. This fusion is pH independent and occurs directly at the outer cell membrane. The trimer of F1-F2 (F protein) probably interacts with HN at the virion surface. Upon HN binding to its cellular receptor, the hydrophobic fusion peptide is unmasked and interacts with the cellular membrane, inducing the fusion between cell and virion membranes. Later in infection, F proteins expressed at the plasma membrane of infected cells could mediate fusion with adjacent cells to form syncytia, a cytopathic effect that could lead to tissue necrosis.
T17248	PDBSTRUC	5YZD; 5YZC; 5YXW
T17248	BIOCLASS	Paramyxoviruses fusion glycoprotein
T17248	SEQUENCE	MGLKVNVSAIFMAVLLTLQTPTGQIHWGNLSKIGVVGIGSASYKVMTRSSHQSLVIKLMPNITLLNNCTRVEIAEYRRLLRTVLEPIRDALNAMTQNIRPVQSVASSRRHKRFAGVVLAGAALGVATAAQITAGIALHQSMLNSQAIDNLRASLETTNQAIEAIRQAGQEMILAVQGVQDYINNELIPSMNQLSCDLIGQKLGLKLLRYYTEILSLFGPSLRDPISAEISIQALSYALGGDINKVLEKLGYSGGDLLGILESRGIKARITHVDTESYFIVLSIAYPTLSEIKGVIVHRLEGVSYNIGSQEWYTTVPKYVATQGYLISNFDESSCTFMPEGTVCSQNALYPMSPLLQECLRGSTKSCARTLVSGSFGNRFILSQGNLIANCASILCKCYTTGTIINQDPDKILTYIAADHCPVVEVNGVTIQVGSRRYPDAVYLHRIDLGPPISLERLDVGTNLGNAIAKLEDAKELLESSDQILRSMKGLSSTSIVYILIAVCLGGLIGIPALICCCRGRCNKKGEQVGMSRPGLKPDLTGTSKSYVRSL
T17248	DRUGINFO	D06KCU	MLN1202	Phase 2
T17248	DRUGINFO	D0VT1S	TTP889	Phase 2
T17248	DRUGINFO	D02MZD	AMG 876	Phase 1
T17248	DRUGINFO	D0NN7L	AC 165198	Phase 1

T84885	TARGETID	T84885
T84885	FORMERID	TTDI02332
T84885	UNIPROID	CAPSD_NVN68
T84885	TARGNAME	Picornavirus Capsid protein VP1 (PicVir VP1)
T84885	GENENAME	PicVir VP1
T84885	TARGTYPE	Clinical trial
T84885	SYNONYMS	p30; Soluble capsid protein; ORF2; Capsid protein VP1; CP of Norwalk virus
T84885	FUNCTION	Soluble capsid protein may play arole in viral immunoevasion.
T84885	PDBSTRUC	6H72; 6H71; 6H70; 6H6Z; 6H6Y
T84885	BIOCLASS	Caliciviridae capsid protein
T84885	SEQUENCE	MMMASKDATSSVDGASGAGQLVPEVNASDPLAMDPVAGSSTAVATAGQVNPIDPWIINNFVQAPQGEFTISPNNTPGDVLFDLSLGPHLNPFLLHLSQMYNGWVGNMRVRIMLAGNAFTAGKIIVSCIPPGFGSHNLTIAQATLFPHVIADVRTLDPIEVPLEDVRNVLFHNNDRNQQTMRLVCMLYTPLRTGGGTGDSFVVAGRVMTCPSPDFNFLFLVPPTVEQKTRPFTLPNLPLSSLSNSRAPLPISSMGISPDNVQSVQFQNGRCTLDGRLVGTTPVSLSHVAKIRGTSNGTVINLTELDGTPFHPFEGPAPIGFPDLGGCDWHINMTQFGHSSQTQYDVDTTPDTFVPHLGSIQANGIGSGNYVGVLSWISPPSHPSGSQVDLWKIPNYGSSITEATHLAPSVYPPGFGEVLVFFMSKMPGPGAYNLPCLLPQEYISHLASEQAPTVGEAALLHYVDPDTGRNLGEFKAYPDGFLTCVPNGASSGPQQLPINGVFVFVSWVSRFYQLKPVGTASSARGRLGLRR
T84885	DRUGINFO	D0W1US	PLECONARIL	Phase 2

T14110	TARGETID	T14110
T14110	FORMERID	TTDNR00650
T14110	UNIPROID	KLOTB_HUMAN
T14110	TARGNAME	Beta-klotho (KLB)
T14110	GENENAME	KLB
T14110	TARGTYPE	Clinical trial
T14110	SYNONYMS	Klotho beta-like protein; BetaKlotho; BKL
T14110	FUNCTION	Probably inactive as a glycosidase. Increases the ability of FGFR1 and FGFR4 to bind FGF21. Contributes to the transcriptional repression of cholesterol 7-alpha-hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid synthesis.
T14110	PDBSTRUC	6NFJ; 5WI9; 5VAQ; 5VAN; 5VAK
T14110	BIOCLASS	Glycosylase
T14110	SEQUENCE	MKPGCAAGSPGNEWIFFSTDEITTRYRNTMSNGGLQRSVILSALILLRAVTGFSGDGRAIWSKNPNFTPVNESQLFLYDTFPKNFFWGIGTGALQVEGSWKKDGKGPSIWDHFIHTHLKNVSSTNGSSDSYIFLEKDLSALDFIGVSFYQFSISWPRLFPDGIVTVANAKGLQYYSTLLDALVLRNIEPIVTLYHWDLPLALQEKYGGWKNDTIIDIFNDYATYCFQMFGDRVKYWITIHNPYLVAWHGYGTGMHAPGEKGNLAAVYTVGHNLIKAHSKVWHNYNTHFRPHQKGWLSITLGSHWIEPNRSENTMDIFKCQQSMVSVLGWFANPIHGDGDYPEGMRKKLFSVLPIFSEAEKHEMRGTADFFAFSFGPNNFKPLNTMAKMGQNVSLNLREALNWIKLEYNNPRILIAENGWFTDSRVKTEDTTAIYMMKNFLSQVLQAIRLDEIRVFGYTAWSLLDGFEWQDAYTIRRGLFYVDFNSKQKERKPKSSAHYYKQIIRENGFSLKESTPDVQGQFPCDFSWGVTESVLKPESVASSPQFSDPHLYVWNATGNRLLHRVEGVRLKTRPAQCTDFVNIKKQLEMLARMKVTHYRFALDWASVLPTGNLSAVNRQALRYYRCVVSEGLKLGISAMVTLYYPTHAHLGLPEPLLHADGWLNPSTAEAFQAYAGLCFQELGDLVKLWITINEPNRLSDIYNRSGNDTYGAAHNLLVAHALAWRLYDRQFRPSQRGAVSLSLHADWAEPANPYADSHWRAAERFLQFEIAWFAEPLFKTGDYPAAMREYIASKHRRGLSSSALPRLTEAERRLLKGTVDFCALNHFTTRFVMHEQLAGSRYDSDRDIQFLQDITRLSSPTRLAVIPWGVRKLLRWVRRNYGDMDIYITASGIDDQALEDDRLRKYYLGKYLQEVLKAYLIDKVRIKGYYAFKLAEEKSKPRFGFFTSDFKAKSSIQFYNKVISSRGFPFENSSSRCSQTQENTECTVCLFLVQKKPLIFLGCCFFSTLVLLLSIAIFQRQKRRKFWKAKNLQHIPLKKGKRVVS
T14110	DRUGINFO	DR8CM0	MK-3655	Phase 2
T14110	DRUGINFO	D0DJ0S	NGM313	Phase 1

T94255	TARGETID	T94255
T94255	FORMERID	TTDI03595
T94255	UNIPROID	TRPM4_HUMAN
T94255	TARGNAME	Long transient receptor potential channel 4 (TRPM4)
T94255	GENENAME	TRPM4
T94255	TARGTYPE	Clinical trial
T94255	SYNONYMS	hTRPM4; Transient receptor potential cation channel subfamily M member 4; Melastatin-4; LTrpC4; LTrpC-4; Calcium-activated non-selective cation channel 1
T94255	FUNCTION	Calcium-activated non selective (CAN) cation channel that mediates membrane depolarization. While it is activated by increase in intracellular Ca(2+), it is impermeable to it. Mediates transport of monovalent cations (Na(+) > K(+) > Cs(+) > Li(+)), leading to depolarize the membrane. It thereby plays a central role in cadiomyocytes, neurons from entorhinal cortex, dorsal root and vomeronasal neurons, endocrine pancreas cells, kidney epithelial cells, cochlea hair cells etc. Participates in T-cell activation by modulating Ca(2+) oscillations after T lymphocyte activation, which is required for NFAT-dependent IL2 production. Involved in myogenic constriction of cerebral arteries. Controls insulin secretion in pancreatic beta-cells. May also be involved in pacemaking or could cause irregular electrical activity under conditions of Ca(2+) overload. Affects T-helper 1 (Th1) and T-helper 2 (Th2) cell motility and cytokine production through differential regulation of calcium signaling and NFATC1 localization. Enhances cell proliferation through up-regulation of the beta-catenin signaling pathway.
T94255	PDBSTRUC	6BWI; 6BQV; 6BQR; 5WP6
T94255	BIOCLASS	Transient receptor potential catioin channel
T94255	SEQUENCE	MVVPEKEQSWIPKIFKKKTCTTFIVDSTDPGGTLCQCGRPRTAHPAVAMEDAFGAAVVTVWDSDAHTTEKPTDAYGELDFTGAGRKHSNFLRLSDRTDPAAVYSLVTRTWGFRAPNLVVSVLGGSGGPVLQTWLQDLLRRGLVRAAQSTGAWIVTGGLHTGIGRHVGVAVRDHQMASTGGTKVVAMGVAPWGVVRNRDTLINPKGSFPARYRWRGDPEDGVQFPLDYNYSAFFLVDDGTHGCLGGENRFRLRLESYISQQKTGVGGTGIDIPVLLLLIDGDEKMLTRIENATQAQLPCLLVAGSGGAADCLAETLEDTLAPGSGGARQGEARDRIRRFFPKGDLEVLQAQVERIMTRKELLTVYSSEDGSEEFETIVLKALVKACGSSEASAYLDELRLAVAWNRVDIAQSELFRGDIQWRSFHLEASLMDALLNDRPEFVRLLISHGLSLGHFLTPMRLAQLYSAAPSNSLIRNLLDQASHSAGTKAPALKGGAAELRPPDVGHVLRMLLGKMCAPRYPSGGAWDPHPGQGFGESMYLLSDKATSPLSLDAGLGQAPWSDLLLWALLLNRAQMAMYFWEMGSNAVSSALGACLLLRVMARLEPDAEEAARRKDLAFKFEGMGVDLFGECYRSSEVRAARLLLRRCPLWGDATCLQLAMQADARAFFAQDGVQSLLTQKWWGDMASTTPIWALVLAFFCPPLIYTRLITFRKSEEEPTREELEFDMDSVINGEGPVGTADPAEKTPLGVPRQSGRPGCCGGRCGGRRCLRRWFHFWGAPVTIFMGNVVSYLLFLLLFSRVLLVDFQPAPPGSLELLLYFWAFTLLCEELRQGLSGGGGSLASGGPGPGHASLSQRLRLYLADSWNQCDLVALTCFLLGVGCRLTPGLYHLGRTVLCIDFMVFTVRLLHIFTVNKQLGPKIVIVSKMMKDVFFFLFFLGVWLVAYGVATEGLLRPRDSDFPSILRRVFYRPYLQIFGQIPQEDMDVALMEHSNCSSEPGFWAHPPGAQAGTCVSQYANWLVVLLLVIFLLVANILLVNLLIAMFSYTFGKVQGNSDLYWKAQRYRLIREFHSRPALAPPFIVISHLRLLLRQLCRRPRSPQPSSPALEHFRVYLSKEAERKLLTWESVHKENFLLARARDKRESDSERLKRTSQKVDLALKQLGHIREYEQRLKVLEREVQQCSRVLGWVAEALSRSALLPPGGPPPPDLPGSKD
T94255	DRUGINFO	D0G2MU	9-phenanthrol	Investigative
T94255	DRUGINFO	D0JV2P	BTP2	Investigative
T94255	DRUGINFO	D05NWF	adenosine diphosphate	Investigative
T94255	DRUGINFO	D06KHR	decavanadate	Investigative
T94255	DRUGINFO	D07ZAJ	PIP2	Investigative
T94255	DRUGINFO	D00ICA	AMP-PNP	Investigative

T76233	TARGETID	T76233
T76233	FORMERID	TTDNR00686
T76233	UNIPROID	HAVR2_HUMAN
T76233	TARGNAME	Hepatitis A virus cellular receptor 2 (TIM3)
T76233	GENENAME	Hepatitis A virus HAVCR2
T76233	TARGTYPE	Clinical trial
T76233	SYNONYMS	TIMD3; TIMD-3; TIM3; TIM-3; T-cell membrane protein 3; T-cell immunoglobulin mucin receptor 3; T-cell immunoglobulin and mucin domain-containing protein 3; HAVcr-2; HAVCR2; CD366
T76233	FUNCTION	Generally accepted to have an inhibiting function. Reports on stimulating functions suggest that the activity may be influenced by the cellular context and/or the respective ligand. Regulates macrophage activation. Inhibits T-helper type 1 lymphocyte (Th1)-mediated auto- and alloimmune responses and promotes immunological tolerance. In CD8+ cells attenuates TCR-induced signaling, specifically by blocking NF-kappaB and NFAT promoter activities resulting in the loss of IL-2 secretion. The function may implicate its association with LCK proposed to impair phosphorylation of TCR subunits, and/or LGALS9-dependent recruitment of PTPRC to the immunological synapse. In contrast, shown to activate TCR-induced signaling in T-cells probably implicating ZAP70, LCP2, LCK and FYN. Expressed on Treg cells can inhibit Th17 cell responses. Receptor for LGALS9. Binding to LGALS9 is believed to result in suppression of T-cell responses; the resulting apoptosis of antigen-specific cells may implicate HAVCR2 phosphorylation and disruption of its association with BAG6. Binding to LGALS9 is proposed to be involved in innate immune response to intracellular pathogens. Expressed on Th1 cells interacts with LGALS9 expressed on Mycobacterium tuberculosis-infected macrophages to stimulate antibactericidal activity including IL-1 beta secretion and to restrict intracellular bacterial growth. However, the function as receptor for LGALS9 has been challenged. Also reported to enhance CD8+ T-cell responses to an acute infection such as by Listeria monocytogenes. Receptor for phosphatidylserine (PtSer); PtSer-binding is calcium-dependent. May recognize PtSer on apoptotic cells leading to their phagocytosis. Mediates the engulfment of apoptotic cells by dendritic cells. Expressed on T-cells, promotes conjugation but not engulfment of apoptotic cells. Expressed on dendritic cells (DCs) positively regulates innate immune response and in synergy with Toll-like receptors promotes secretion of TNF-alpha. In tumor-imfiltrating DCs suppresses nucleic acid-mediated innate immune repsonse by interaction with HMGB1 and interfering with nucleic acid-sensing and trafficking of nucleid acids to endosomes. Expressed on natural killer (NK) cells acts as a coreceptor to enhance IFN-gamma production in response to LGALS9. In contrast, shown to suppress NK cell-mediated cytotoxicity. Negatively regulates NK cell function in LPS-induced endotoxic shock. Cell surface receptor implicated in modulating innate and adaptive immune responses.
T76233	PDBSTRUC	6DHB; 5F71; 5DZL
T76233	BIOCLASS	Immunoglobulin
T76233	SEQUENCE	MFSHLPFDCVLLLLLLLLTRSSEVEYRAEVGQNAYLPCFYTPAAPGNLVPVCWGKGACPVFECGNVVLRTDERDVNYWTSRYWLNGDFRKGDVSLTIENVTLADSGIYCCRIQIPGIMNDEKFNLKLVIKPAKVTPAPTRQRDFTAAFPRMLTTRGHGPAETQTLGSLPDINLTQISTLANELRDSRLANDLRDSGATIRIGIYIGAGICAGLALALIFGALIFKWYSHSKEKIQNLSLISLANLPPSGLANAVAEGIRSEENIYTIEENVYEVEEPNEYYCYVSSRQQPSQPLGCRFAMP
T76233	DRUGINFO	D0AE6Q	MBG453	Phase 3
T76233	DRUGINFO	DW7J9D	TB006	Phase 2
T76233	DRUGINFO	DZW53X	GSK4069889	Phase 2
T76233	DRUGINFO	DNI7E3	AZD7789	Phase 2
T76233	DRUGINFO	DQM48O	RO7121661	Phase 2
T76233	DRUGINFO	D7UIZ1	BGB-A425	Phase 1/2
T76233	DRUGINFO	D09YXT	LY3321367	Phase 1
T76233	DRUGINFO	DEU8O6	Sym023	Phase 1
T76233	DRUGINFO	DVA36E	INCAGN2390	Phase 1
T76233	DRUGINFO	DC8HR6	LY3415244	Phase 1

T05938	TARGETID	T05938
T05938	FORMERID	TTDI02319
T05938	UNIPROID	MUC16_HUMAN
T05938	TARGNAME	Ovarian carcinoma antigen CA125 (MUC16)
T05938	GENENAME	MUC16
T05938	TARGTYPE	Clinical trial
T05938	SYNONYMS	Ovarian cancerrelated tumor marker CA125; Mucin16; MUC16; CA125
T05938	FUNCTION	Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces.
T05938	BIOCLASS	Mucin
T05938	SEQUENCE	MLKPSGLPGSSSPTRSLMTGSRSTKATPEMDSGLTGATLSPKTSTGAIVVTEHTLPFTSPDKTLASPTSSVVGRTTQSLGVMSSALPESTSRGMTHSEQRTSPSLSPQVNGTPSRNYPATSMVSGLSSPRTRTSSTEGNFTKEASTYTLTVETTSGPVTEKYTVPTETSTTEGDSTETPWDTRYIPVKITSPMKTFADSTASKENAPVSMTPAETTVTDSHTPGRTNPSFGTLYSSFLDLSPKGTPNSRGETSLELILSTTGYPFSSPEPGSAGHSRISTSAPLSSSASVLDNKISETSIFSGQSLTSPLSPGVPEARASTMPNSAIPFSMTLSNAETSAERVRSTISSLGTPSISTKQTAETILTFHAFAETMDIPSTHIAKTLASEWLGSPGTLGGTSTSALTTTSPSTTLVSEETNTHHSTSGKETEGTLNTSMTPLETSAPGEESEMTATLVPTLGFTTLDSKIRSPSQVSSSHPTRELRTTGSTSGRQSSSTAAHGSSDILRATTSSTSKASSWTSESTAQQFSEPQHTQWVETSPSMKTERPPASTSVAAPITTSVPSVVSGFTTLKTSSTKGIWLEETSADTLIGESTAGPTTHQFAVPTGISMTGGSSTRGSQGTTHLLTRATASSETSADLTLATNGVPVSVSPAVSKTAAGSSPPGGTKPSYTMVSSVIPETSSLQSSAFREGTSLGLTPLNTRHPFSSPEPDSAGHTKISTSIPLLSSASVLEDKVSATSTFSHHKATSSITTGTPEISTKTKPSSAVLSSMTLSNAATSPERVRNATSPLTHPSPSGEETAGSVLTLSTSAETTDSPNIHPTGTLTSESSESPSTLSLPSVSGVKTTFSSSTPSTHLFTSGEETEETSNPSVSQPETSVSRVRTTLASTSVPTPVFPTMDTWPTRSAQFSSSHLVSELRATSSTSVTNSTGSALPKISHLTGTATMSQTNRDTFNDSAAPQSTTWPETSPRFKTGLPSATTTVSTSATSLSATVMVSKFTSPATSSMEATSIREPSTTILTTETTNGPGSMAVASTNIPIGKGYITEGRLDTSHLPIGTTASSETSMDFTMAKESVSMSVSPSQSMDAAGSSTPGRTSQFVDTFSDDVYHLTSREITIPRDGTSSALTPQMTATHPPSPDPGSARSTWLGILSSSPSSPTPKVTMSSTFSTQRVTTSMIMDTVETSRWNMPNLPSTTSLTPSNIPTSGAIGKSTLVPLDTPSPATSLEASEGGLPTLSTYPESTNTPSIHLGAHASSESPSTIKLTMASVVKPGSYTPLTFPSIETHIHVSTARMAYSSGSSPEMTAPGETNTGSTWDPTTYITTTDPKDTSSAQVSTPHSVRTLRTTENHPKTESATPAAYSGSPKISSSPNLTSPATKAWTITDTTEHSTQLHYTKLAEKSSGFETQSAPGPVSVVIPTSPTIGSSTLELTSDVPGEPLVLAPSEQTTITLPMATWLSTSLTEEMASTDLDISSPSSPMSTFAIFPPMSTPSHELSKSEADTSAIRNTDSTTLDQHLGIRSLGRTGDLTTVPITPLTTTWTSVIEHSTQAQDTLSATMSPTHVTQSLKDQTSIPASASPSHLTEVYPELGTQGRSSSEATTFWKPSTDTLSREIETGPTNIQSTPPMDNTTTGSSSSGVTLGIAHLPIGTSSPAETSTNMALERRSSTATVSMAGTMGLLVTSAPGRSISQSLGRVSSVLSESTTEGVTDSSKGSSPRLNTQGNTALSSSLEPSYAEGSQMSTSIPLTSSPTTPDVEFIGGSTFWTKEVTTVMTSDISKSSARTESSSATLMSTALGSTENTGKEKLRTASMDLPSPTPSMEVTPWISLTLSNAPNTTDSLDLSHGVHTSSAGTLATDRSLNTGVTRASRLENGSDTSSKSLSMGNSTHTSMTYTEKSEVSSSIHPRPETSAPGAETTLTSTPGNRAISLTLPFSSIPVEEVISTGITSGPDINSAPMTHSPITPPTIVWTSTGTIEQSTQPLHAVSSEKVSVQTQSTPYVNSVAVSASPTHENSVSSGSSTSSPYSSASLESLDSTISRRNAITSWLWDLTTSLPTTTWPSTSLSEALSSGHSGVSNPSSTTTEFPLFSAASTSAAKQRNPETETHGPQNTAASTLNTDASSVTGLSETPVGASISSEVPLPMAITSRSDVSGLTSESTANPSLGTASSAGTKLTRTISLPTSESLVSFRMNKDPWTVSIPLGSHPTTNTETSIPVNSAGPPGLSTVASDVIDTPSDGAESIPTVSFSPSPDTEVTTISHFPEKTTHSFRTISSLTHELTSRVTPIPGDWMSSAMSTKPTGASPSITLGERRTITSAAPTTSPIVLTASFTETSTVSLDNETTVKTSDILDARKTNELPSDSSSSSDLINTSIASSTMDVTKTASISPTSISGMTASSSPSLFSSDRPQVPTSTTETNTATSPSVSSNTYSLDGGSNVGGTPSTLPPFTITHPVETSSALLAWSRPVRTFSTMVSTDTASGENPTSSNSVVTSVPAPGTWTSVGSTTDLPAMGFLKTSPAGEAHSLLASTIEPATAFTPHLSAAVVTGSSATSEASLLTTSESKAIHSSPQTPTTPTSGANWETSATPESLLVVTETSDTTLTSKILVTDTILFSTVSTPPSKFPSTGTLSGASFPTLLPDTPAIPLTATEPTSSLATSFDSTPLVTIASDSLGTVPETTLTMSETSNGDALVLKTVSNPDRSIPGITIQGVTESPLHPSSTSPSKIVAPRNTTYEGSITVALSTLPAGTTGSLVFSQSSENSETTALVDSSAGLERASVMPLTTGSQGMASSGGIRSGSTHSTGTKTFSSLPLTMNPGEVTAMSEITTNRLTATQSTAPKGIPVKPTSAESGLLTPVSASSSPSKAFASLTTAPPTWGIPQSTLTFEFSEVPSLDTKSASLPTPGQSLNTIPDSDASTASSSLSKSPEKNPRARMMTSTKAISASSFQSTGFTETPEGSASPSMAGHEPRVPTSGTGDPRYASESMSYPDPSKASSAMTSTSLASKLTTLFSTGQAARSGSSSSPISLSTEKETSFLSPTASTSRKTSLFLGPSMARQPNILVHLQTSALTLSPTSTLNMSQEEPPELTSSQTIAEEEGTTAETQTLTFTPSETPTSLLPVSSPTEPTARRKSSPETWASSISVPAKTSLVETTDGTLVTTIKMSSQAAQGNSTWPAPAEETGSSPAGTSPGSPEMSTTLKIMSSKEPSISPEIRSTVRNSPWKTPETTVPMETTVEPVTLQSTALGSGSTSISHLPTGTTSPTKSPTENMLATERVSLSPSPPEAWTNLYSGTPGGTRQSLATMSSVSLESPTARSITGTGQQSSPELVSKTTGMEFSMWHGSTGGTTGDTHVSLSTSSNILEDPVTSPNSVSSLTDKSKHKTETWVSTTAIPSTVLNNKIMAAEQQTSRSVDEAYSSTSSWSDQTSGSDITLGASPDVTNTLYITSTAQTTSLVSLPSGDQGITSLTNPSGGKTSSASSVTSPSIGLETLRANVSAVKSDIAPTAGHLSQTSSPAEVSILDVTTAPTPGISTTITTMGTNSISTTTPNPEVGMSTMDSTPATERRTTSTEHPSTWSSTAASDSWTVTDMTSNLKVARSPGTISTMHTTSFLASSTELDSMSTPHGRITVIGTSLVTPSSDASAVKTETSTSERTLSPSDTTASTPISTFSRVQRMSISVPDILSTSWTPSSTEAEDVPVSMVSTDHASTKTDPNTPLSTFLFDSLSTLDWDTGRSLSSATATTSAPQGATTPQELTLETMISPATSQLPFSIGHITSAVTPAAMARSSGVTFSRPDPTSKKAEQTSTQLPTTTSAHPGQVPRSAATTLDVIPHTAKTPDATFQRQGQTALTTEARATSDSWNEKEKSTPSAPWITEMMNSVSEDTIKEVTSSSSVLRTLNTLDINLESGTTSSPSWKSSPYERIAPSESTTDKEAIHPSTNTVETTGWVTSSEHASHSTIPAHSASSKLTSPVVTTSTREQAIVSMSTTTWPESTRARTEPNSFLTIELRDVSPYMDTSSTTQTSIISSPGSTAITKGPRTEITSSKRISSSFLAQSMRSSDSPSEAITRLSNFPAMTESGGMILAMQTSPPGATSLSAPTLDTSATASWTGTPLATTQRFTYSEKTTLFSKGPEDTSQPSPPSVEETSSSSSLVPIHATTSPSNILLTSQGHSPSSTPPVTSVFLSETSGLGKTTDMSRISLEPGTSLPPNLSSTAGEALSTYEASRDTKAIHHSADTAVTNMEATSSEYSPIPGHTKPSKATSPLVTSHIMGDITSSTSVFGSSETTEIETVSSVNQGLQERSTSQVASSATETSTVITHVSSGDATTHVTKTQATFSSGTSISSPHQFITSTNTFTDVSTNPSTSLIMTESSGVTITTQTGPTGAATQGPYLLDTSTMPYLTETPLAVTPDFMQSEKTTLISKGPKDVSWTSPPSVAETSYPSSLTPFLVTTIPPATSTLQGQHTSSPVSATSVLTSGLVKTTDMLNTSMEPVTNSPQNLNNPSNEILATLAATTDIETIHPSINKAVTNMGTASSAHVLHSTLPVSSEPSTATSPMVPASSMGDALASISIPGSETTDIEGEPTSSLTAGRKENSTLQEMNSTTESNIILSNVSVGAITEATKMEVPSFDATFIPTPAQSTKFPDIFSVASSRLSNSPPMTISTHMTTTQTGSSGATSKIPLALDTSTLETSAGTPSVVTEGFAHSKITTAMNNDVKDVSQTNPPFQDEASSPSSQAPVLVTTLPSSVAFTPQWHSTSSPVSMSSVLTSSLVKTAGKVDTSLETVTSSPQSMSNTLDDISVTSAATTDIETTHPSINTVVTNVGTTGSAFESHSTVSAYPEPSKVTSPNVTTSTMEDTTISRSIPKSSKTTRTETETTSSLTPKLRETSISQEITSSTETSTVPYKELTGATTEVSRTDVTSSSSTSFPGPDQSTVSLDISTETNTRLSTSPIMTESAEITITTQTGPHGATSQDTFTMDPSNTTPQAGIHSAMTHGFSQLDVTTLMSRIPQDVSWTSPPSVDKTSSPSSFLSSPAMTTPSLISSTLPEDKLSSPMTSLLTSGLVKITDILRTRLEPVTSSLPNFSSTSDKILATSKDSKDTKEIFPSINTEETNVKANNSGHESHSPALADSETPKATTQMVITTTVGDPAPSTSMPVHGSSETTNIKREPTYFLTPRLRETSTSQESSFPTDTSFLLSKVPTGTITEVSSTGVNSSSKISTPDHDKSTVPPDTFTGEIPRVFTSSIKTKSAEMTITTQASPPESASHSTLPLDTSTTLSQGGTHSTVTQGFPYSEVTTLMGMGPGNVSWMTTPPVEETSSVSSLMSSPAMTSPSPVSSTSPQSIPSSPLPVTALPTSVLVTTTDVLGTTSPESVTSSPPNLSSITHERPATYKDTAHTEAAMHHSTNTAVTNVGTSGSGHKSQSSVLADSETSKATPLMSTTSTLGDTSVSTSTPNISQTNQIQTEPTASLSPRLRESSTSEKTSSTTETNTAFSYVPTGAITQASRTEISSSRTSISDLDRPTIAPDISTGMITRLFTSPIMTKSAEMTVTTQTTTPGATSQGILPWDTSTTLFQGGTHSTVSQGFPHSEITTLRSRTPGDVSWMTTPPVEETSSGFSLMSPSMTSPSPVSSTSPESIPSSPLPVTALLTSVLVTTTNVLGTTSPEPVTSSPPNLSSPTQERLTTYKDTAHTEAMHASMHTNTAVANVGTSISGHESQSSVPADSHTSKATSPMGITFAMGDTSVSTSTPAFFETRIQTESTSSLIPGLRDTRTSEEINTVTETSTVLSEVPTTTTTEVSRTEVITSSRTTISGPDHSKMSPYISTETITRLSTFPFVTGSTEMAITNQTGPIGTISQATLTLDTSSTASWEGTHSPVTQRFPHSEETTTMSRSTKGVSWQSPPSVEETSSPSSPVPLPAITSHSSLYSAVSGSSPTSALPVTSLLTSGRRKTIDMLDTHSELVTSSLPSASSFSGEILTSEASTNTETIHFSENTAETNMGTTNSMHKLHSSVSIHSQPSGHTPPKVTGSMMEDAIVSTSTPGSPETKNVDRDSTSPLTPELKEDSTALVMNSTTESNTVFSSVSLDAATEVSRAEVTYYDPTFMPASAQSTKSPDISPEASSSHSNSPPLTISTHKTIATQTGPSGVTSLGQLTLDTSTIATSAGTPSARTQDFVDSETTSVMNNDLNDVLKTSPFSAEEANSLSSQAPLLVTTSPSPVTSTLQEHSTSSLVSVTSVPTPTLAKITDMDTNLEPVTRSPQNLRNTLATSEATTDTHTMHPSINTAVANVGTTSSPNEFYFTVSPDSDPYKATSAVVITSTSGDSIVSTSMPRSSAMKKIESETTFSLIFRLRETSTSQKIGSSSDTSTVFDKAFTAATTEVSRTELTSSSRTSIQGTEKPTMSPDTSTRSVTMLSTFAGLTKSEERTIATQTGPHRATSQGTLTWDTSITTSQAGTHSAMTHGFSQLDLSTLTSRVPEYISGTSPPSVEKTSSSSSLLSLPAITSPSPVPTTLPESRPSSPVHLTSLPTSGLVKTTDMLASVASLPPNLGSTSHKIPTTSEDIKDTEKMYPSTNIAVTNVGTTTSEKESYSSVPAYSEPPKVTSPMVTSFNIRDTIVSTSMPGSSEITRIEMESTFSLAHGLKGTSTSQDPIVSTEKSAVLHKLTTGATETSRTEVASSRRTSIPGPDHSTESPDISTEVIPSLPISLGITESSNMTIITRTGPPLGSTSQGTFTLDTPTTSSRAGTHSMATQEFPHSEMTTVMNKDPEILSWTIPPSIEKTSFSSSLMPSPAMTSPPVSSTLPKTIHTTPSPMTSLLTPSLVMTTDTLGTSPEPTTSSPPNLSSTSHEILTTDEDTTAIEAMHPSTSTAATNVETTSSGHGSQSSVLADSEKTKATAPMDTTSTMGHTTVSTSMSVSSETTKIKRESTYSLTPGLRETSISQNASFSTDTSIVLSEVPTGTTAEVSRTEVTSSGRTSIPGPSQSTVLPEISTRTMTRLFASPTMTESAEMTIPTQTGPSGSTSQDTLTLDTSTTKSQAKTHSTLTQRFPHSEMTTLMSRGPGDMSWQSSPSLENPSSLPSLLSLPATTSPPPISSTLPVTISSSPLPVTSLLTSSPVTTTDMLHTSPELVTSSPPKLSHTSDERLTTGKDTTNTEAVHPSTNTAASNVEIPSSGHESPSSALADSETSKATSPMFITSTQEDTTVAISTPHFLETSRIQKESISSLSPKLRETGSSVETSSAIETSAVLSEVSIGATTEISRTEVTSSSRTSISGSAESTMLPEISTTRKIIKFPTSPILAESSEMTIKTQTSPPGSTSESTFTLDTSTTPSLVITHSTMTQRLPHSEITTLVSRGAGDVPRPSSLPVEETSPPSSQLSLSAMISPSPVSSTLPASSHSSSASVTSLLTPGQVKTTEVLDASAEPETSSPPSLSSTSVEILATSEVTTDTEKIHPFSNTAVTKVGTSSSGHESPSSVLPDSETTKATSAMGTISIMGDTSVSTLTPALSNTRKIQSEPASSLTTRLRETSTSEETSLATEANTVLSKVSTGATTEVSRTEAISFSRTSMSGPEQSTMSQDISIGTIPRISASSVLTESAKMTITTQTGPSESTLESTLNLNTATTPSWVETHSIVIQGFPHPEMTTSMGRGPGGVSWPSPPFVKETSPPSSPLSLPAVTSPHPVSTTFLAHIPPSPLPVTSLLTSGPATTTDILGTSTEPGTSSSSSLSTTSHERLTTYKDTAHTEAVHPSTNTGGTNVATTSSGYKSQSSVLADSSPMCTTSTMGDTSVLTSTPAFLETRRIQTELASSLTPGLRESSGSEGTSSGTKMSTVLSKVPTGATTEISKEDVTSIPGPAQSTISPDISTRTVSWFSTSPVMTESAEITMNTHTSPLGATTQGTSTLDTSSTTSLTMTHSTISQGFSHSQMSTLMRRGPEDVSWMSPPLLEKTRPSFSLMSSPATTSPSPVSSTLPESISSSPLPVTSLLTSGLAKTTDMLHKSSEPVTNSPANLSSTSVEILATSEVTTDTEKTHPSSNRTVTDVGTSSSGHESTSFVLADSQTSKVTSPMVITSTMEDTSVSTSTPGFFETSRIQTEPTSSLTLGLRKTSSSEGTSLATEMSTVLSGVPTGATAEVSRTEVTSSSRTSISGFAQLTVSPETSTETITRLPTSSIMTESAEMMIKTQTDPPGSTPESTHTVDISTTPNWVETHSTVTQRFSHSEMTTLVSRSPGDMLWPSQSSVEETSSASSLLSLPATTSPSPVSSTLVEDFPSASLPVTSLLNPGLVITTDRMGISREPGTSSTSNLSSTSHERLTTLEDTVDTEDMQPSTHTAVTNVRTSISGHESQSSVLSDSETPKATSPMGTTYTMGETSVSISTSDFFETSRIQIEPTSSLTSGLRETSSSERISSATEGSTVLSEVPSGATTEVSRTEVISSRGTSMSGPDQFTISPDISTEAITRLSTSPIMTESAESAITIETGSPGATSEGTLTLDTSTTTFWSGTHSTASPGFSHSEMTTLMSRTPGDVPWPSLPSVEEASSVSSSLSSPAMTSTSFFSTLPESISSSPHPVTALLTLGPVKTTDMLRTSSEPETSSPPNLSSTSAEILATSEVTKDREKIHPSSNTPVVNVGTVIYKHLSPSSVLADLVTTKPTSPMATTSTLGNTSVSTSTPAFPETMMTQPTSSLTSGLREISTSQETSSATERSASLSGMPTGATTKVSRTEALSLGRTSTPGPAQSTISPEISTETITRISTPLTTTGSAEMTITPKTGHSGASSQGTFTLDTSSRASWPGTHSAATHRSPHSGMTTPMSRGPEDVSWPSRPSVEKTSPPSSLVSLSAVTSPSPLYSTPSESSHSSPLRVTSLFTPVMMKTTDMLDTSLEPVTTSPPSMNITSDESLATSKATMETEAIQLSENTAVTQMGTISARQEFYSSYPGLPEPSKVTSPVVTSSTIKDIVSTTIPASSEITRIEMESTSTLTPTPRETSTSQEIHSATKPSTVPYKALTSATIEDSMTQVMSSSRGPSPDQSTMSQDISTEVITRLSTSPIKTESTEMTITTQTGSPGATSRGTLTLDTSTTFMSGTHSTASQGFSHSQMTALMSRTPGDVPWLSHPSVEEASSASFSLSSPVMTSSSPVSSTLPDSIHSSSLPVTSLLTSGLVKTTELLGTSSEPETSSPPNLSSTSAEILAITEVTTDTEKLEMTNVVTSGYTHESPSSVLADSVTTKATSSMGITYPTGDTNVLTSTPAFSDTSRIQTKSKLSLTPGLMETSISEETSSATEKSTVLSSVPTGATTEVSRTEAISSSRTSIPGPAQSTMSSDTSMETITRISTPLTRKESTDMAITPKTGPSGATSQGTFTLDSSSTASWPGTHSATTQRFPQSVVTTPMSRGPEDVSWPSPLSVEKNSPPSSLVSSSSVTSPSPLYSTPSGSSHSSPVPVTSLFTSIMMKATDMLDASLEPETTSAPNMNITSDESLAASKATTETEAIHVFENTAASHVETTSATEELYSSSPGFSEPTKVISPVVTSSSIRDNMVSTTMPGSSGITRIEIESMSSLTPGLRETRTSQDITSSTETSTVLYKMPSGATPEVSRTEVMPSSRTSIPGPAQSTMSLDISDEVVTRLSTSPIMTESAEITITTQTGYSLATSQVTLPLGTSMTFLSGTHSTMSQGLSHSEMTNLMSRGPESLSWTSPRFVETTRSSSSLTSLPLTTSLSPVSSTLLDSSPSSPLPVTSLILPGLVKTTEVLDTSSEPKTSSSPNLSSTSVEIPATSEIMTDTEKIHPSSNTAVAKVRTSSSVHESHSSVLADSETTITIPSMGITSAVDDTTVFTSNPAFSETRRIPTEPTFSLTPGFRETSTSEETTSITETSAVLYGVPTSATTEVSMTEIMSSNRIHIPDSDQSTMSPDIITEVITRLSSSSMMSESTQMTITTQKSSPGATAQSTLTLATTTAPLARTHSTVPPRFLHSEMTTLMSRSPENPSWKSSLFVEKTSSSSSLLSLPVTTSPSVSSTLPQSIPSSSFSVTSLLTPGMVKTTDTSTEPGTSLSPNLSGTSVEILAASEVTTDTEKIHPSSSMAVTNVGTTSSGHELYSSVSIHSEPSKATYPVGTPSSMAETSISTSMPANFETTGFEAEPFSHLTSGFRKTNMSLDTSSVTPTNTPSSPGSTHLLQSSKTDFTSSAKTSSPDWPPASQYTEIPVDIITPFNASPSITESTGITSFPESRFTMSVTESTHHLSTDLLPSAETISTGTVMPSLSEAMTSFATTGVPRAISGSGSPFSRTESGPGDATLSTIAESLPSSTPVPFSSSTFTTTDSSTIPALHEITSSSATPYRVDTSLGTESSTTEGRLVMVSTLDTSSQPGRTSSSPILDTRMTESVELGTVTSAYQVPSLSTRLTRTDGIMEHITKIPNEAAHRGTIRPVKGPQTSTSPASPKGLHTGGTKRMETTTTALKTTTTALKTTSRATLTTSVYTPTLGTLTPLNASMQMASTIPTEMMITTPYVFPDVPETTSSLATSLGAETSTALPRTTPSVFNRESETTASLVSRSGAERSPVIQTLDVSSSEPDTTASWVIHPAETIPTVSKTTPNFFHSELDTVSSTATSHGADVSSAIPTNISPSELDALTPLVTISGTDTSTTFPTLTKSPHETETRTTWLTHPAETSSTIPRTIPNFSHHESDATPSIATSPGAETSSAIPIMTVSPGAEDLVTSQVTSSGTDRNMTIPTLTLSPGEPKTIASLVTHPEAQTSSAIPTSTISPAVSRLVTSMVTSLAAKTSTTNRALTNSPGEPATTVSLVTHPAQTSPTVPWTTSIFFHSKSDTTPSMTTSHGAESSSAVPTPTVSTEVPGVVTPLVTSSRAVISTTIPILTLSPGEPETTPSMATSHGEEASSAIPTPTVSPGVPGVVTSLVTSSRAVTSTTIPILTFSLGEPETTPSMATSHGTEAGSAVPTVLPEVPGMVTSLVASSRAVTSTTLPTLTLSPGEPETTPSMATSHGAEASSTVPTVSPEVPGVVTSLVTSSSGVNSTSIPTLILSPGELETTPSMATSHGAEASSAVPTPTVSPGVSGVVTPLVTSSRAVTSTTIPILTLSSSEPETTPSMATSHGVEASSAVLTVSPEVPGMVTSLVTSSRAVTSTTIPTLTISSDEPETTTSLVTHSEAKMISAIPTLAVSPTVQGLVTSLVTSSGSETSAFSNLTVASSQPETIDSWVAHPGTEASSVVPTLTVSTGEPFTNISLVTHPAESSSTLPRTTSRFSHSELDTMPSTVTSPEAESSSAISTTISPGIPGVLTSLVTSSGRDISATFPTVPESPHESEATASWVTHPAVTSTTVPRTTPNYSHSEPDTTPSIATSPGAEATSDFPTITVSPDVPDMVTSQVTSSGTDTSITIPTLTLSSGEPETTTSFITYSETHTSSAIPTLPVSPGASKMLTSLVISSGTDSTTTFPTLTETPYEPETTAIQLIHPAETNTMVPRTTPKFSHSKSDTTLPVAITSPGPEASSAVSTTTISPDMSDLVTSLVPSSGTDTSTTFPTLSETPYEPETTATWLTHPAETSTTVSGTIPNFSHRGSDTAPSMVTSPGVDTRSGVPTTTIPPSIPGVVTSQVTSSATDTSTAIPTLTPSPGEPETTASSATHPGTQTGFTVPIRTVPSSEPDTMASWVTHPPQTSTPVSRTTSSFSHSSPDATPVMATSPRTEASSAVLTTISPGAPEMVTSQITSSGAATSTTVPTLTHSPGMPETTALLSTHPRTETSKTFPASTVFPQVSETTASLTIRPGAETSTALPTQTTSSLFTLLVTGTSRVDLSPTASPGVSAKTAPLSTHPGTETSTMIPTSTLSLGLLETTGLLATSSSAETSTSTLTLTVSPAVSGLSSASITTDKPQTVTSWNTETSPSVTSVGPPEFSRTVTGTTMTLIPSEMPTPPKTSHGEGVSPTTILRTTMVEATNLATTGSSPTVAKTTTTFNTLAGSLFTPLTTPGMSTLASESVTSRTSYNHRSWISTTSSYNRRYWTPATSTPVTSTFSPGISTSSIPSSTAATVPFMVPFTLNFTITNLQYEEDMRHPGSRKFNATERELQGLLKPLFRNSSLEYLYSGCRLASLRPEKDSSATAVDAICTHRPDPEDLGLDRERLYWELSNLTNGIQELGPYTLDRNSLYVNGFTHRSSMPTTSTPGTSTVDVGTSGTPSSSPSPTTAGPLLMPFTLNFTITNLQYEEDMRRTGSRKFNTMESVLQGLLKPLFKNTSVGPLYSGCRLTLLRPEKDGAATGVDAICTHRLDPKSPGLNREQLYWELSKLTNDIEELGPYTLDRNSLYVNGFTHQSSVSTTSTPGTSTVDLRTSGTPSSLSSPTIMAAGPLLVPFTLNFTITNLQYGEDMGHPGSRKFNTTERVLQGLLGPIFKNTSVGPLYSGCRLTSLRSEKDGAATGVDAICIHHLDPKSPGLNRERLYWELSQLTNGIKELGPYTLDRNSLYVNGFTHRTSVPTSSTPGTSTVDLGTSGTPFSLPSPATAGPLLVLFTLNFTITNLKYEEDMHRPGSRKFNTTERVLQTLLGPMFKNTSVGLLYSGCRLTLLRSEKDGAATGVDAICTHRLDPKSPGVDREQLYWELSQLTNGIKELGPYTLDRNSLYVNGFTHWIPVPTSSTPGTSTVDLGSGTPSSLPSPTTAGPLLVPFTLNFTITNLKYEEDMHCPGSRKFNTTERVLQSLLGPMFKNTSVGPLYSGCRLTLLRSEKDGAATGVDAICTHRLDPKSPGVDREQLYWELSQLTNGIKELGPYTLDRNSLYVNGFTHQTSAPNTSTPGTSTVDLGTSGTPSSLPSPTSAGPLLVPFTLNFTITNLQYEEDMHHPGSRKFNTTERVLQGLLGPMFKNTSVGLLYSGCRLTLLRPEKNGAATGMDAICSHRLDPKSPGLNREQLYWELSQLTHGIKELGPYTLDRNSLYVNGFTHRSSVAPTSTPGTSTVDLGTSGTPSSLPSPTTAVPLLVPFTLNFTITNLQYGEDMRHPGSRKFNTTERVLQGLLGPLFKNSSVGPLYSGCRLISLRSEKDGAATGVDAICTHHLNPQSPGLDREQLYWQLSQMTNGIKELGPYTLDRNSLYVNGFTHRSSGLTTSTPWTSTVDLGTSGTPSPVPSPTTTGPLLVPFTLNFTITNLQYEENMGHPGSRKFNITESVLQGLLKPLFKSTSVGPLYSGCRLTLLRPEKDGVATRVDAICTHRPDPKIPGLDRQQLYWELSQLTHSITELGPYTLDRDSLYVNGFTQRSSVPTTSTPGTFTVQPETSETPSSLPGPTATGPVLLPFTLNFTITNLQYEEDMRRPGSRKFNTTERVLQGLLMPLFKNTSVSSLYSGCRLTLLRPEKDGAATRVDAVCTHRPDPKSPGLDRERLYWKLSQLTHGITELGPYTLDRHSLYVNGFTHQSSMTTTRTPDTSTMHLATSRTPASLSGPMTASPLLVLFTINFTITNLRYEENMHHPGSRKFNTTERVLQGLLRPVFKNTSVGPLYSGCRLTLLRPKKDGAATKVDAICTYRPDPKSPGLDREQLYWELSQLTHSITELGPYTLDRDSLYVNGFTQRSSVPTTSIPGTPTVDLGTSGTPVSKPGPSAASPLLVLFTLNFTITNLRYEENMQHPGSRKFNTTERVLQGLLRSLFKSTSVGPLYSGCRLTLLRPEKDGTATGVDAICTHHPDPKSPRLDREQLYWELSQLTHNITELGPYALDNDSLFVNGFTHRSSVSTTSTPGTPTVYLGASKTPASIFGPSAASHLLILFTLNFTITNLRYEENMWPGSRKFNTTERVLQGLLRPLFKNTSVGPLYSGCRLTLLRPEKDGEATGVDAICTHRPDPTGPGLDREQLYLELSQLTHSITELGPYTLDRDSLYVNGFTHRSSVPTTSTGVVSEEPFTLNFTINNLRYMADMGQPGSLKFNITDNVMQHLLSPLFQRSSLGARYTGCRVIALRSVKNGAETRVDLLCTYLQPLSGPGLPIKQVFHELSQQTHGITRLGPYSLDKDSLYLNGYNEPGPDEPPTTPKPATTFLPPLSEATTAMGYHLKTLTLNFTISNLQYSPDMGKGSATFNSTEGVLQHLLRPLFQKSSMGPFYLGCQLISLRPEKDGAATGVDTTCTYHPDPVGPGLDIQQLYWELSQLTHGVTQLGFYVLDRDSLFINGYAPQNLSIRGEYQINFHIVNWNLSNPDPTSSEYITLLRDIQDKVTTLYKGSQLHDTFRFCLVTNLTMDSVLVTVKALFSSNLDPSLVEQVFLDKTLNASFHWLGSTYQLVDIHVTEMESSVYQPTSSSSTQHFYLNFTITNLPYSQDKAQPGTTNYQRNKRNIEDALNQLFRNSSIKSYFSDCQVSTFRSVPNRHHTGVDSLCNFSPLARRVDRVAIYEEFLRMTRNGTQLQNFTLDRSSVLVDGYSPNRNEPLTGNSDLPFWAVILIGLAGLLGVITCLICGVLVTTRRRKKEGEYNVQQQCPGYYQSHLDLEDLQ
T05938	DRUGINFO	D07HUW	Oregovomab	Phase 3
T05938	DRUGINFO	D00KGB	Abagovomab	Phase 2/3
T05938	DRUGINFO	D0LA9K	REGN4018	Phase 1/2
T05938	DRUGINFO	DT1R9E	REGN5668	Phase 1/2
T05938	DRUGINFO	D04ZIZ	DMUC-5754A	Phase 1
T05938	DRUGINFO	D0I0FA	JCAR020	Phase 1
T05938	DRUGINFO	D12AIV	PRGN-3005	Phase 1
T05938	DRUGINFO	D0G9ZJ	RG7458	Discontinued in Phase 1

T17986	TARGETID	T17986
T17986	FORMERID	TTDI03173
T17986	UNIPROID	EZH1_HUMAN
T17986	TARGNAME	Enhancer of zeste homolog 1 (EZH1)
T17986	GENENAME	EZH1
T17986	TARGTYPE	Clinical trial
T17986	SYNONYMS	KIAA0388; Histone-lysine N-methyltransferase EZH1; ENX-2
T17986	FUNCTION	Catalytic subunit of the PRC2/EED-EZH1 complex, which methylates 'Lys-27' of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. Required for embryonic stem cell derivation and self-renewal, suggesting that it is involved in safeguarding embryonic stem cell identity. Compared to EZH2-containing complexes, it is less abundant in embryonic stem cells, has weak methyltransferase activity and plays a less critical role in forming H3K27me3, which is required for embryonic stem cell identity and proper differentiation. Polycomb group (PcG) protein.
T17986	BIOCLASS	Methyltransferase
T17986	ECNUMBER	EC 2.1.1.43
T17986	SEQUENCE	MEIPNPPTSKCITYWKRKVKSEYMRLRQLKRLQANMGAKALYVANFAKVQEKTQILNEEWKKLRVQPVQSMKPVSGHPFLKKCTIESIFPGFASQHMLMRSLNTVALVPIMYSWSPLQQNFMVEDETVLCNIPYMGDEVKEEDETFIEELINNYDGKVHGEEEMIPGSVLISDAVFLELVDALNQYSDEEEEGHNDTSDGKQDDSKEDLPVTRKRKRHAIEGNKKSSKKQFPNDMIFSAIASMFPENGVPDDMKERYRELTEMSDPNALPPQCTPNIDGPNAKSVQREQSLHSFHTLFCRRCFKYDCFLHPFHATPNVYKRKNKEIKIEPEPCGTDCFLLLEGAKEYAMLHNPRSKCSGRRRRRHHIVSASCSNASASAVAETKEGDSDRDTGNDWASSSSEANSRCQTPTKQKASPAPPQLCVVEAPSEPVEWTGAEESLFRVFHGTYFNNFCSIARLLGTKTCKQVFQFAVKESLILKLPTDELMNPSQKKKRKHRLWAAHCRKIQLKKDNSSTQVYNYQPCDHPDRPCDSTCPCIMTQNFCEKFCQCNPDCQNRFPGCRCKTQCNTKQCPCYLAVRECDPDLCLTCGASEHWDCKVVSCKNCSIQRGLKKHLLLAPSDVAGWGTFIKESVQKNEFISEYCGELISQDEADRRGKVYDKYMSSFLFNLNNDFVVDATRKGNKIRFANHSVNPNCYAKVVMVNGDHRIGIFAKRAIQAGEELFFDYRYSQADALKYVGIERETDVL
T17986	DRUGINFO	DNM79H	DS-3201b	Phase 2
T17986	DRUGINFO	D0LG8T	DS-3201	Phase 1
T17986	DRUGINFO	D6EU7R	HH2853	Phase 1
T17986	DRUGINFO	D02TVQ	GSK343	Investigative

T07063	TARGETID	T07063
T07063	FORMERID	TTDR01001
T07063	UNIPROID	SC5A5_HUMAN
T07063	TARGNAME	Sodium/iodide cotransporter (SLC5A5)
T07063	GENENAME	SLC5A5
T07063	TARGTYPE	Clinical trial
T07063	SYNONYMS	Solute carrier family 5 member 5; Sodium/iodide symporter; Sodium-iodide symporter; Na+/I-symporter; Na(+)/I(-) symporter; Na(+)/I(-) cotransporter; NIS
T07063	FUNCTION	Mediates iodide uptake in the thyroid gland.
T07063	BIOCLASS	Solute:sodium symporter
T07063	SEQUENCE	MEAVETGERPTFGAWDYGVFALMLLVSTGIGLWVGLARGGQRSAEDFFTGGRRLAALPVGLSLSASFMSAVQVLGVPSEAYRYGLKFLWMCLGQLLNSVLTALLFMPVFYRLGLTSTYEYLEMRFSRAVRLCGTLQYIVATMLYTGIVIYAPALILNQVTGLDIWASLLSTGIICTFYTAVGGMKAVVWTDVFQVVVMLSGFWVVLARGVMLVGGPRQVLTLAQNHSRINLMDFNPDPRSRYTFWTFVVGGTLVWLSMYGVNQAQVQRYVACRTEKQAKLALLINQVGLFLIVSSAACCGIVMFVFYTDCDPLLLGRISAPDQYMPLLVLDIFEDLPGVPGLFLACAYSGTLSTASTSINAMAAVTVEDLIKPRLRSLAPRKLVIISKGLSLIYGSACLTVAALSSLLGGGVLQGSFTVMGVISGPLLGAFILGMFLPACNTPGVLAGLGAGLALSLWVALGATLYPPSEQTMRVLPSSAARCVALSVNASGLLDPALLPANDSSRAPSSGMDASRPALADSFYAISYLYYGALGTLTTVLCGALISCLTGPTKRSTLAPGLLWWDLARQTASVAPKEEVAILDDNLVKGPEELPTGNKKPPGFLPTNEDRLFFLGQKELEGAGSWTPCVGHDGGRDQQETNL
T07063	DRUGINFO	D0G8DV	Ad5CMV-NIS	Phase 1

T01943	TARGETID	T01943
T01943	UNIPROID	Q965D7_PLAFA
T01943	TARGNAME	Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ)
T01943	GENENAME	Malaria FabZ
T01943	TARGTYPE	Clinical trial
T01943	SYNONYMS	fabZ; Fatty acid synthesis protein; Beta-hydroxyacyl-ACP dehydratase; 17 kDa actomyosin component; (3R)-hydroxymyristoyl-[acyl-carrier-protein] dehydratase; (3R)-hydroxymyristoyl-ACP dehydrase
T01943	FUNCTION	Involved in unsaturated fatty acids biosynthesis. Catalyzes the dehydration of short chain beta-hydroxyacyl-ACPs and long chain saturated and unsaturated beta-hydroxyacyl-ACPs.
T01943	PDBSTRUC	3AZB; 3AZA; 3AZ9; 3AZ8; 2OKI
T01943	SEQUENCE	MRFLIIHIAVIVLPFVLMIDVKRENSFFLRHSPKRLYKKADYNNMYDKIIKKQQNRIYDVSSQINQDNINGQNISFNLTFPNYDTSIDIEDIKKILPHRYPFLLVDKVIYMQPNKTIIGLKQVSTNEPFFNGHFPQKQIMPGVLQIEALAQLAGILCLKSDDSQKNNLFLFAGVDGVRWKKPVLPGDTLTMQANLISFKSSLGIAKLSGVGYVNGKVVINISEMTFALSK
T01943	DRUGINFO	D0U2BH	Epigallocatechin gallate	Phase 3
T01943	DRUGINFO	D05HRK	2-Hexadecynoic acid	Investigative
T01943	DRUGINFO	D07KXK	GALLOCATECHIN GALLATE	Investigative
T01943	DRUGINFO	D0MF5Y	3,7,3',4'-TETRAHYDROXYFLAVONE	Investigative
T01943	DRUGINFO	D0RB1V	(-)-CATECHINGALLATE	Investigative
T01943	DRUGINFO	D0S9YX	biochanin A	Investigative
T01943	DRUGINFO	D0NJ4H	MORIN	Investigative

T49453	TARGETID	T49453
T49453	FORMERID	TTDI01779
T49453	UNIPROID	NOTC4_HUMAN
T49453	TARGNAME	Notch-4 receptor (NOTCH4)
T49453	GENENAME	NOTCH4
T49453	TARGTYPE	Clinical trial
T49453	SYNONYMS	hNotch4; Notch 4; Neurogenic locus notch homolog protein 4; INT3
T49453	FUNCTION	Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs. May regulate branching morphogenesis in the developing vascular system. Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination.
T49453	BIOCLASS	Notch protein
T49453	SEQUENCE	MQPPSLLLLLLLLLLLCVSVVRPRGLLCGSFPEPCANGGTCLSLSLGQGTCQCAPGFLGETCQFPDPCQNAQLCQNGGSCQALLPAPLGLPSSPSPLTPSFLCTCLPGFTGERCQAKLEDPCPPSFCSKRGRCHIQASGRPQCSCMPGWTGEQCQLRDFCSANPCVNGGVCLATYPQIQCHCPPGFEGHACERDVNECFQDPGPCPKGTSCHNTLGSFQCLCPVGQEGPRCELRAGPCPPRGCSNGGTCQLMPEKDSTFHLCLCPPGFIGPDCEVNPDNCVSHQCQNGGTCQDGLDTYTCLCPETWTGWDCSEDVDECETQGPPHCRNGGTCQNSAGSFHCVCVSGWGGTSCEENLDDCIAATCAPGSTCIDRVGSFSCLCPPGRTGLLCHLEDMCLSQPCHGDAQCSTNPLTGSTLCLCQPGYSGPTCHQDLDECLMAQQGPSPCEHGGSCLNTPGSFNCLCPPGYTGSRCEADHNECLSQPCHPGSTCLDLLATFHCLCPPGLEGQLCEVETNECASAPCLNHADCHDLLNGFQCICLPGFSGTRCEEDIDECRSSPCANGGQCQDQPGAFHCKCLPGFEGPRCQTEVDECLSDPCPVGASCLDLPGAFFCLCPSGFTGQLCEVPLCAPNLCQPKQICKDQKDKANCLCPDGSPGCAPPEDNCTCHHGHCQRSSCVCDVGWTGPECEAELGGCISAPCAHGGTCYPQPSGYNCTCPTGYTGPTCSEEMTACHSGPCLNGGSCNPSPGGYYCTCPPSHTGPQCQTSTDYCVSAPCFNGGTCVNRPGTFSCLCAMGFQGPRCEGKLRPSCADSPCRNRATCQDSPQGPRCLCPTGYTGGSCQTLMDLCAQKPCPRNSHCLQTGPSFHCLCLQGWTGPLCNLPLSSCQKAALSQGIDVSSLCHNGGLCVDSGPSYFCHCPPGFQGSLCQDHVNPCESRPCQNGATCMAQPSGYLCQCAPGYDGQNCSKELDACQSQPCHNHGTCTPKPGGFHCACPPGFVGLRCEGDVDECLDQPCHPTGTAACHSLANAFYCQCLPGHTGQWCEVEIDPCHSQPCFHGGTCEATAGSPLGFICHCPKGFEGPTCSHRAPSCGFHHCHHGGLCLPSPKPGFPPRCACLSGYGGPDCLTPPAPKGCGPPSPCLYNGSCSETTGLGGPGFRCSCPHSSPGPRCQKPGAKGCEGRSGDGACDAGCSGPGGNWDGGDCSLGVPDPWKGCPSHSRCWLLFRDGQCHPQCDSEECLFDGYDCETPPACTPAYDQYCHDHFHNGHCEKGCNTAECGWDGGDCRPEDGDPEWGPSLALLVVLSPPALDQQLFALARVLSLTLRVGLWVRKDRDGRDMVYPYPGARAEEKLGGTRDPTYQERAAPQTQPLGKETDSLSAGFVVVMGVDLSRCGPDHPASRCPWDPGLLLRFLAAMAAVGALEPLLPGPLLAVHPHAGTAPPANQLPWPVLCSPVAGVILLALGALLVLQLIRRRRREHGALWLPPGFTRRPRTQSAPHRRRPPLGEDSIGLKALKPKAEVDEDGVVMCSGPEEGEEVGQAEETGPPSTCQLWSLSGGCGALPQAAMLTPPQESEMEAPDLDTRGPDGVTPLMSAVCCGEVQSGTFQGAWLGCPEPWEPLLDGGACPQAHTVGTGETPLHLAARFSRPTAARRLLEAGANPNQPDRAGRTPLHAAVAADAREVCQLLLRSRQTAVDARTEDGTTPLMLAARLAVEDLVEELIAAQADVGARDKWGKTALHWAAAVNNARAARSLLQAGADKDAQDNREQTPLFLAAREGAVEVAQLLLGLGAARELRDQAGLAPADVAHQRNHWDLLTLLEGAGPPEARHKATPGREAGPFPRARTVSVSVPPHGGGALPRCRTLSAGAGPRGGGACLQARTWSVDLAARGGGAYSHCRSLSGVGAGGGPTPRGRRFSAGMRGPRPNPAIMRGRYGVAAGRGGRVSTDDWPCDWVALGACGSASNIPIPPPCLTPSPERGSPQLDCGPPALQEMPINQGGEGKK
T49453	DRUGINFO	D08WOW	LY3039478	Phase 1/2

T57001	TARGETID	T57001
T57001	FORMERID	TTDR00892
T57001	UNIPROID	GPA33_HUMAN
T57001	TARGNAME	Cell surface A33 antigen (GPA33)
T57001	GENENAME	GPA33
T57001	TARGTYPE	Clinical trial
T57001	SYNONYMS	GPA33; A33 cognate antigen; A33 antigen
T57001	FUNCTION	May play a role in cell-cell recognition and signaling.
T57001	BIOCLASS	Immunoglobulin
T57001	SEQUENCE	MVGKMWPVLWTLCAVRVTVDAISVETPQDVLRASQGKSVTLPCTYHTSTSSREGLIQWDKLLLTHTERVVIWPFSNKNYIHGELYKNRVSISNNAEQSDASITIDQLTMADNGTYECSVSLMSDLEGNTKSRVRLLVLVPPSKPECGIEGETIIGNNIQLTCQSKEGSPTPQYSWKRYNILNQEQPLAQPASGQPVSLKNISTDTSGYYICTSSNEEGTQFCNITVAVRSPSMNVALYVGIAVGVVAALIIIGIIIYCCCCRGKDDNTEDKEDARPNREAYEEPPEQLRELSREREEEDDYRQEEQRSTGRESPDHLDQ
T57001	DRUGINFO	D07GNO	KRN-330	Phase 1/2
T57001	DRUGINFO	D00PEN	MGD007	Phase 1/2
T57001	DRUGINFO	D08IDB	HuA33	Phase 1
T57001	DRUGINFO	D0LY0C	Radiolabelled-huA33	Phase 1

T54519	TARGETID	T54519
T54519	FORMERID	TTDI01929
T54519	UNIPROID	Q9BMI9_SCHMA
T54519	TARGNAME	Schistosoma Purine nucleoside phosphorylase (sch PNP)
T54519	GENENAME	sch PNP
T54519	TARGTYPE	Clinical trial
T54519	SYNONYMS	sch Purine nucleoside phosphorylase; sch Inosine-guanosine phosphorylase
T54519	FUNCTION	The purine nucleoside phosphorylases catalyze the phosphorolytic breakdown of the N-glycosidic bond in the beta-(deoxy)ribonucleoside molecules, with the formation of the corresponding free purine bases and pentose-1-phosphate.
T54519	PDBSTRUC	3IEX; 3FNQ; 3FB1; 3FAZ; 3F8W
T54519	ECNUMBER	EC 2.4.2.1
T54519	SEQUENCE	MHESVTANIENVKKVAHHIQKLTSIVPEIGIICGSGLGKLADGVKDKITIPYTKIPNFPQTSVVGHSGNLIFGTLSGRKVVVMQGRFHMYEGYSNDTVALPIRVMKLLGVKILMVSNAAGGLNRSLKLGDFVILKDHIYLPGLGLNNILVGPNQEAFGTRFPALSNAYDRDLRKLAVQVAEENGFGNLVHQGVYVMNGGPCYETPAECTMLLNMGCDVVGMSTIPEVVIARHCGIQVFAVSLVTNISVLDVESDLKPNHEEVLATGAQRAELMQSWFEKIIEKLPKD
T54519	DRUGINFO	D01OOQ	FP-253-GDEPT	Phase 1

T79162	TARGETID	T79162
T79162	UNIPROID	RSPO3_HUMAN
T79162	TARGNAME	R-spondin-3 (RSPO3)
T79162	GENENAME	RSPO3
T79162	TARGTYPE	Clinical trial
T79162	SYNONYMS	hRspo3; hPWTSR; Thrombospondin type-1 domain-containing protein 2; Roof plate-specific spondin-3; Protein with TSP type-1 repeat
T79162	FUNCTION	Activator of the canonical Wnt signaling pathway by acting as a ligand for LGR4-6 receptors, which acts as a key regulator of angiogenesis. Upon binding to LGR4-6 (LGR4, LGR5 or LGR6), LGR4-6 associate with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signaling pathway to increase expression of target genes. Also regulates the canonical Wnt/beta-catenin-dependent pathway and non-canonical Wnt signaling by acting as an inhibitor of ZNRF3, an important regulator of the Wnt signaling pathway. Acts as a ligand for frizzled FZD8 and LRP6. May negatively regulate the TGF-beta pathway. Acts as a key regulator of angiogenesis by controlling vascular stability and pruning: acts by activating the non-canonical Wnt signaling pathway in endothelial cells. Can also amplify Wnt signaling pathway independently of LGR4-6 receptors, possibly by acting as a direct antagonistic ligand to RNF43 and ZNRF3.
T79162	BIOCLASS	R-spondin family
T79162	SEQUENCE	MHLRLISWLFIILNFMEYIGSQNASRGRRQRRMHPNVSQGCQGGCATCSDYNGCLSCKPRLFFALERIGMKQIGVCLSSCPSGYYGTRYPDINKCTKCKADCDTCFNKNFCTKCKSGFYLHLGKCLDNCPEGLEANNHTMECVSIVHCEVSEWNPWSPCTKKGKTCGFKRGTETRVREIIQHPSAKGNLCPPTNETRKCTVQRKKCQKGERGKKGRERKRKKPNKGESKEAIPDSKSLESSKEIPEQRENKQQQKKRKVQDKQKSVSVSTVH
T79162	DRUGINFO	D0J3TI	Rosmantuzumab	Phase 1
T79162	DRUGINFO	DPIR35	OMP-131R10	Phase 1

T79747	TARGETID	T79747
T79747	FORMERID	TTDI02152
T79747	UNIPROID	PORCN_HUMAN
T79747	TARGNAME	Protein-serine O-palmitoleoyltransferase porcupine (PORCN)
T79747	GENENAME	PORCN
T79747	TARGTYPE	Clinical trial
T79747	SYNONYMS	Protein-cysteine N-palmitoyltransferase porcupine; Protein MG61; PORCN
T79747	FUNCTION	protein-cysteine N-palmitoyltransferase that modulates the processingof Wnt proteins by mediating serine palmitoylation of Wnt family members.
T79747	BIOCLASS	Acyltransferase
T79747	ECNUMBER	EC 2.3.1.250
T79747	SEQUENCE	MATFSRQEFFQQLLQGCLLPTAQQGLDQIWLLLAICLACRLLWRLGLPSYLKHASTVAGGFFSLYHFFQLHMVWVVLLSLLCYLVLFLCRHSSHRGVFLSVTILIYLLMGEMHMVDTVTWHKMRGAQMIVAMKAVSLGFDLDRGEVGTVPSPVEFMGYLYFVGTIVFGPWISFHSYLQAVQGRPLSCRWLQKVARSLALALLCLVLSTCVGPYLFPYFIPLNGDRLLRNKKRKARGTMVRWLRAYESAVSFHFSNYFVGFLSEATATLAGAGFTEEKDHLEWDLTVSKPLNVELPRSMVEVVTSWNLPMSYWLNNYVFKNALRLGTFSAVLVTYAASALLHGFSFHLAAVLLSLAFITYVEHVLRKRLARILSACVLSKRCPPDCSHQHRLGLGVRALNLLFGALAIFHLAYLGSLFDVDVDDTTEEQGYGMAYTVHKWSELSWASHWVTFGCWIFYRLIG
T79747	DRUGINFO	D05FKU	ETC-1922159	Phase 1
T79747	DRUGINFO	D0J5HR	LGK974	Phase 1
T79747	DRUGINFO	DYA4W9	RXC006	Phase 1

T62241	TARGETID	T62241
T62241	FORMERID	TTDI01796
T62241	UNIPROID	IL25_HUMAN
T62241	TARGNAME	Interleukin-25 (IL25)
T62241	GENENAME	IL25
T62241	TARGTYPE	Clinical trial
T62241	SYNONYMS	UNQ3120/PRO10272; Interleukin-17E; IL17E; IL-25; IL-17E
T62241	FUNCTION	Proinflammatory cytokine favoring Th2-type immune responses. Induces activation of NF-kappa-B and stimulates production of the proinflammatory chemokine IL-8.
T62241	BIOCLASS	Cytokine: interleukin
T62241	SEQUENCE	MRERPRLGEDSSLISLFLQVVAFLAMVMGTHTYSHWPSCCPSKGQDTSEELLRWSTVPVPPLEPARPNRHPESCRASEDGPLNSRAISPWRYELDRDLNRLPQDLYHARCLCPHCVSLQTGSHMDPRGNSELLYHNQTVFYRRPCHGEKGTHKGYCLERRLYRVSLACVCVRPRVMG
T62241	DRUGINFO	D0B5UH	ALX-0761	Phase 1

T84397	TARGETID	T84397
T84397	FORMERID	TTDI00967
T84397	UNIPROID	TBB1_HUMAN
T84397	TARGNAME	Tubulin beta-1 chain (TUBB1)
T84397	GENENAME	TUBB1
T84397	TARGTYPE	Clinical trial
T84397	SYNONYMS	TUBB1
T84397	FUNCTION	Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
T84397	BIOCLASS	Tubulin family
T84397	SEQUENCE	MREIVHIQIGQCGNQIGAKFWEMIGEEHGIDLAGSDRGASALQLERISVYYNEAYGRKYVPRAVLVDLEPGTMDSIRSSKLGALFQPDSFVHGNSGAGNNWAKGHYTEGAELIENVLEVVRHESESCDCLQGFQIVHSLGGGTGSGMGTLLMNKIREEYPDRIMNSFSVMPSPKVSDTVVEPYNAVLSIHQLIENADACFCIDNEALYDICFRTLKLTTPTYGDLNHLVSLTMSGITTSLRFPGQLNADLRKLAVNMVPFPRLHFFMPGFAPLTAQGSQQYRALSVAELTQQMFDARNTMAACDLRRGRYLTVACIFRGKMSTKEVDQQLLSVQTRNSSCFVEWIPNNVKVAVCDIPPRGLSMAATFIGNNTAIQEIFNRVSEHFSAMFKRKAFVHWYTSEGMDINEFGEAENNIHDLVSEYQQFQDAKAVLEEDEEVTEEAEMEPEDKGH
T84397	DRUGINFO	D0K8LB	PI-88/Taxotere	Phase 2
T84397	DRUGINFO	D03UDW	AI-850	Phase 1
T84397	DRUGINFO	D05CHN	Irofulven/Taxotere	Phase 1
T84397	DRUGINFO	D01WYV	Angiostatin/paclitaxel/carboplatin	Investigative

T73696	TARGETID	T73696
T73696	FORMERID	TTDI02307
T73696	UNIPROID	RXFP1_HUMAN
T73696	TARGNAME	Relaxin receptor 1 (RXFP1)
T73696	GENENAME	RXFP1
T73696	TARGTYPE	Clinical trial
T73696	SYNONYMS	Relaxin family peptide receptor 1; RXFP1; Leucine-rich repeat-containing G-protein coupled receptor 7
T73696	FUNCTION	Receptor for relaxins. The activity of this receptor is mediated by G proteins leading to stimulation of adenylate cyclase and an increase of cAMP. Binding of the ligand may also activate a tyrosine kinase pathway that inhibits the activity of a phosphodiesterase that degrades cAMP.
T73696	PDBSTRUC	2M7P; 2JM4
T73696	BIOCLASS	GPCR rhodopsin
T73696	SEQUENCE	MTSGSVFFYILIFGKYFSHGGGQDVKCSLGYFPCGNITKCLPQLLHCNGVDDCGNQADEDNCGDNNGWSLQFDKYFASYYKMTSQYPFEAETPECLVGSVPVQCLCQGLELDCDETNLRAVPSVSSNVTAMSLQWNLIRKLPPDCFKNYHDLQKLYLQNNKITSISIYAFRGLNSLTKLYLSHNRITFLKPGVFEDLHRLEWLIIEDNHLSRISPPTFYGLNSLILLVLMNNVLTRLPDKPLCQHMPRLHWLDLEGNHIHNLRNLTFISCSNLTVLVMRKNKINHLNENTFAPLQKLDELDLGSNKIENLPPLIFKDLKELSQLNLSYNPIQKIQANQFDYLVKLKSLSLEGIEISNIQQRMFRPLMNLSHIYFKKFQYCGYAPHVRSCKPNTDGISSLENLLASIIQRVFVWVVSAVTCFGNIFVICMRPYIRSENKLYAMSIISLCCADCLMGIYLFVIGGFDLKFRGEYNKHAQLWMESTHCQLVGSLAILSTEVSVLLLTFLTLEKYICIVYPFRCVRPGKCRTITVLILIWITGFIVAFIPLSNKEFFKNYYGTNGVCFPLHSEDTESIGAQIYSVAIFLGINLAAFIIIVFSYGSMFYSVHQSAITATEIRNQVKKEMILAKRFFFIVFTDALCWIPIFVVKFLSLLQVEIPGTITSWVVIFILPINSALNPILYTLTTRPFKEMIHRFWYNYRQRKSMDSKGQKTYAPSFIWVEMWPLQEMPPELMKPDLFTYPCEMSLISQSTRLNSYS
T73696	DRUGINFO	D0T3FN	RLX030	Approval submitted
T73696	DRUGINFO	D0CI3Z	AZD5462	Phase 1
T73696	DRUGINFO	D01WWO	ML290	Investigative

T23050	TARGETID	T23050
T23050	UNIPROID	LPTD_PSEAE
T23050	TARGNAME	Pseudomonas LPS-assembly protein LptD (Pseudo lptD)
T23050	GENENAME	Pseudo lptD
T23050	TARGTYPE	Clinical trial
T23050	SYNONYMS	ostA; Pseudo imp
T23050	FUNCTION	Together with LptE, is involved in the assembly of lipopolysaccharide (LPS) at the surface of the outer membrane.
T23050	PDBSTRUC	5IVA
T23050	BIOCLASS	LptD family
T23050	SEQUENCE	MAVKSLVFRRKFPLLVTGSLLALQPVAALTVQAADQFDCKVSATGGWDCSPLQNANANLPPRPAHTATSVSTAAAGSSVSGSGGETVEAEPTQRLVTESGGRALKSRSADYSHLDWIPREKLTAAQLAEIGPYCGGSYIEPVRPGMDDGAPSDESPTYVSAKASRYEQEKQIATLAGDVVLRQGSMQVEGDEANLHQLENRGELVGNVKLRDKGMLVVGDHAQVQLDNGEAQVDNAEYVIHKAHARGSALYAKRSENAIIMLKDGTYTRCEPSSNAWTLKGNNVKLNPATGFGTATNATLRVKDFPVFYTPYIYFPIDDRRQSGFLPPSFSSTSDTGFTLVTPYYFNLAPNYDATLYPRYMAKRGMMLEGEFRYLTHSSEGIVNAAYLNDKDDHREGFPDYSKDRWLYGLKNTTGLDSRWLAEVDYTRISDPYYFQDLDTDLGVGSTTYVNQRGTLTYRGDTFTGRLNAQAYQLATTTDVTPYDRLPQITFDGFLPYNPGGMQFTYGTEFVRFDRDLDENIYFNDDGSIRGKRPDASLQGLARATGDRMHLEPGMSLPMTRSWGYVTPTLKYLYTKYDLDLDSQGKTDLNKRDESFDSNQDRSLPLVKVDSGLYFDRDTTFAGTPFRQTLEPRAMYLYVPYKDQDSLPVFDTSEPSFSYDSLWRENRFTGKDRIGDANQLSLGVTSRFIEENGFERASISAGQIYYFRDRRVQLPGLTEKDLKRLNLDPSGLDNDSWRSPYAFAGQYRFNRDWRINSDFNWNPNTSRTESGSAIFHYQPEVDPGKVVNVGYRYRADARRFDSSRGTFRYGNENDIIKQHDFSVIWPLVPQWSVLARWQYDYNKNRTLEAFGGFEYDSCCWKLRLINRYWLDVDDDAFLVQSEKADRGIFLQIVLKGLGGIVGNKTEMFLDKGIQGYRQREDQAM
T23050	DRUGINFO	D00IVF	Murepavadin	Phase 3

T70062	TARGETID	T70062
T70062	FORMERID	TTDI02164
T70062	UNIPROID	RTN4_HUMAN
T70062	TARGNAME	Reticulon-4 (RTN4)
T70062	GENENAME	RTN4
T70062	TARGTYPE	Clinical trial
T70062	SYNONYMS	SP1507; My043
T70062	FUNCTION	Required to induce the formation and stabilization of endoplasmic reticulum (ER) tubules. They regulate membrane morphogenesis in the ER by promoting tubular ER production. They influence nuclear envelope expansion, nuclear pore complex formation and proper localization of inner nuclear membrane proteins. However each isoform have specific functions mainly depending on their tissue expression specificities.
T70062	PDBSTRUC	2JV5; 2G31
T70062	SEQUENCE	MEDLDQSPLVSSSDSPPRPQPAFKYQFVREPEDEEEEEEEEEEDEDEDLEELEVLERKPAAGLSAAPVPTAPAAGAPLMDFGNDFVPPAPRGPLPAAPPVAPERQPSWDPSPVSSTVPAPSPLSAAAVSPSKLPEDDEPPARPPPPPPASVSPQAEPVWTPPAPAPAAPPSTPAAPKRRGSSGSVDETLFALPAASEPVIRSSAENMDLKEQPGNTISAGQEDFPSVLLETAASLPSLSPLSAASFKEHEYLGNLSTVLPTEGTLQENVSEASKEVSEKAKTLLIDRDLTEFSELEYSEMGSSFSVSPKAESAVIVANPREEIIVKNKDEEEKLVSNNILHNQQELPTALTKLVKEDEVVSSEKAKDSFNEKRVAVEAPMREEYADFKPFERVWEVKDSKEDSDMLAAGGKIESNLESKVDKKCFADSLEQTNHEKDSESSNDDTSFPSTPEGIKDRSGAYITCAPFNPAATESIATNIFPLLGDPTSENKTDEKKIEEKKAQIVTEKNTSTKTSNPFLVAAQDSETDYVTTDNLTKVTEEVVANMPEGLTPDLVQEACESELNEVTGTKIAYETKMDLVQTSEVMQESLYPAAQLCPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASVIQPSSSPLEASSVNYESIKHEPENPPPYEEAMSVSLKKVSGIKEEIKEPENINAALQETEAPYISIACDLIKETKLSAEPAPDFSDYSEMAKVEQPVPDHSELVEDSSPDSEPVDLFSDDSIPDVPQKQDETVMLVKESLTETSFESMIEYENKEKLSALPPEGGKPYLESFKLSLDNTKDTLLPDEVSTLSKKEKIPLQMEELSTAVYSNDDLFISKEAQIRETETFSDSSPIEIIDEFPTLISSKTDSFSKLAREYTDLEVSHKSEIANAPDGAGSLPCTELPHDLSLKNIQPKVEEKISFSDDFSKNGSATSKVLLLPPDVSALATQAEIESIVKPKVLVKEAEKKLPSDTEKEDRSPSAIFSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLKRKAE
T70062	DRUGINFO	D0M0WM	ATI-355	Phase 1

T55273	TARGETID	T55273
T55273	FORMERID	TTDNC00397
T55273	UNIPROID	DLL4_HUMAN
T55273	TARGNAME	Delta-like protein 4 (DLL4)
T55273	GENENAME	DLL4
T55273	TARGTYPE	Clinical trial
T55273	SYNONYMS	UNQ1895/PRO4341; Drosophila Delta homolog 4; Deltalike protein 4; Delta4
T55273	FUNCTION	Activates NOTCH1 and NOTCH4. Involved in angiogenesis; negatively regulates endothelial cell proliferation and migration and angiogenic sprouting. Essential for retinal progenitor proliferation. Required for suppressing rod fates in late retinal progenitors as well as for proper generation of other retinal cell types. During spinal cord neurogenesis, inhibits V2a interneuron fate. Involved in the Notch signaling pathway as Notch ligand.
T55273	PDBSTRUC	5MVX
T55273	SEQUENCE	MAAASRSASGWALLLLVALWQQRAAGSGVFQLQLQEFINERGVLASGRPCEPGCRTFFRVCLKHFQAVVSPGPCTFGTVSTPVLGTNSFAVRDDSSGGGRNPLQLPFNFTWPGTFSLIIEAWHAPGDDLRPEALPPDALISKIAIQGSLAVGQNWLLDEQTSTLTRLRYSYRVICSDNYYGDNCSRLCKKRNDHFGHYVCQPDGNLSCLPGWTGEYCQQPICLSGCHEQNGYCSKPAECLCRPGWQGRLCNECIPHNGCRHGTCSTPWQCTCDEGWGGLFCDQDLNYCTHHSPCKNGATCSNSGQRSYTCTCRPGYTGVDCELELSECDSNPCRNGGSCKDQEDGYHCLCPPGYYGLHCEHSTLSCADSPCFNGGSCRERNQGANYACECPPNFTGSNCEKKVDRCTSNPCANGGQCLNRGPSRMCRCRPGFTGTYCELHVSDCARNPCAHGGTCHDLENGLMCTCPAGFSGRRCEVRTSIDACASSPCFNRATCYTDLSTDTFVCNCPYGFVGSRCEFPVGLPPSFPWVAVSLGVGLAVLLVLLGMVAVAVRQLRLRRPDDGSREAMNNLSDFQKDNLIPAAQLKNTNQKKELEVDCGLDKSNCGKQQNHTLDYNLAPGPLGRGTMPGKFPHSDKSLGEKAPLRLHSEKPECRISAICSPRDSMYQSVCLISEERNECVIATEV
T55273	DRUGINFO	DMEV15	Dilpacimab	Phase 2
T55273	DRUGINFO	D06VCC	REGN-421	Phase 1
T55273	DRUGINFO	D0GS9X	OMP-21M18	Phase 1
T55273	DRUGINFO	D00IVN	Navicixizumab	Phase 1
T55273	DRUGINFO	D0PP6A	ABT-165	Phase 1
T55273	DRUGINFO	DIPY14	NOV1501	Phase 1

T57718	TARGETID	T57718
T57718	FORMERID	TTDI02217
T57718	UNIPROID	MAGC2_HUMAN
T57718	TARGNAME	Melanoma-associated antigen C2 (MAGEC2)
T57718	GENENAME	MAGEC2
T57718	TARGTYPE	Clinical trial
T57718	SYNONYMS	MAGEE1 antigen; MAGEE1; MAGEC2 antigen; MAGE-E1 antigen; MAGE-C2 antigen; Hepatocellular carcinomaassociated antigen 587; Hepatocellular carcinoma-associated antigen 587; HCA587; Cancer/testis antigen 10; CT10
T57718	FUNCTION	In vitro enhances ubiquitin ligase activity of TRIM28 and stimulates p53/TP53 ubiquitination in presence of Ubl-conjugating enzyme UBE2H leading to p53/TP53 degradation. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzymes (E2) at the E3:substrate complex. Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases.
T57718	BIOCLASS	Melanoma associated antigen
T57718	SEQUENCE	MPPVPGVPFRNVDNDSPTSVELEDWVDAQHPTDEEEEEASSASSTLYLVFSPSSFSTSSSLILGGPEEEEVPSGVIPNLTESIPSSPPQGPPQGPSQSPLSSCCSSFSWSSFSEESSSQKGEDTGTCQGLPDSESSFTYTLDEKVAELVEFLLLKYEAEEPVTEAEMLMIVIKYKDYFPVILKRAREFMELLFGLALIEVGPDHFCVFANTVGLTDEGSDDEGMPENSLLIIILSVIFIKGNCASEEVIWEVLNAVGVYAGREHFVYGEPRELLTKVWVQGHYLEYREVPHSSPPYYEFLWGPRAHSESIKKKVLEFLAKLNNTVPSSFPSWYKDALKDVEERVQATIDTADDATVMASESLSVMSSNVSFSE
T57718	DRUGINFO	D02DVK	CV-9201	Phase 1/2

T96916	TARGETID	T96916
T96916	UNIPROID	DKK3_HUMAN
T96916	TARGNAME	Dickkopf-related protein 3 (DKK3)
T96916	GENENAME	DKK3
T96916	TARGTYPE	Clinical trial
T96916	SYNONYMS	hDkk-3; UNQ258/PRO295; REIC; Dkk-3; Dickkopf-3
T96916	FUNCTION	DKKs play an important role in vertebrate development, where they locally inhibit Wnt regulated processes such as antero-posterior axial patterning, limb development, somitogenesis and eye formation. In the adult, Dkks are implicated in bone formation and bone disease, cancer and Alzheimer disease. Antagonizes canonical Wnt signaling by inhibiting LRP5/6 interaction with Wnt and by forming a ternary complex with the transmembrane protein KREMEN that promotes internalization of LRP5/6.
T96916	BIOCLASS	Dickkopf protein
T96916	SEQUENCE	MQRLGATLLCLLLAAAVPTAPAPAPTATSAPVKPGPALSYPQEEATLNEMFREVEELMEDTQHKLRSAVEEMEAEEAAAKASSEVNLANLPPSYHNETNTDTKVGNNTIHVHREIHKITNNQTGQMVFSETVITSVGDEEGRRSHECIIDEDCGPSMYCQFASFQYTCQPCRGQRMLCTRDSECCGDQLCVWGHCTKMATRGSNGTICDNQRDCQPGLCCAFQRGLLFPVCTPLPVEGELCHDPASRLLDLITWELEPDGALDRCPCASGLLCQPHSHSLVYVCKPTFVGSRDQDGEILLPREVPDEYEVGSFMEEVRQELEDLERSLTEEMALREPAAAAAALLGGEEI
T96916	DRUGINFO	D0D2XA	REIC gene therapy	Phase 1/2

T06850	TARGETID	T06850
T06850	FORMERID	TTDR00583
T06850	UNIPROID	GHRL_HUMAN
T06850	TARGNAME	Ghrelin (GHRL)
T06850	GENENAME	GHRL
T06850	TARGTYPE	Clinical trial
T06850	SYNONYMS	UNQ524/PRO1066; Motilin-related peptide; M46 protein; Growth hormone secretagogue; Growth hormone releasing peptide; Gastric peptide ghrelin; GHRL
T06850	FUNCTION	Specific ligand for the growth hormone secretagogue receptor type 1 (ghsr) inducing the release of growth hormone from the pituitary. Has an appetite-stimulating effect, induces adiposity and stimulates gastric acid secretion.Involved in growth regulation.
T06850	PDBSTRUC	1P7X
T06850	SEQUENCE	MPSPGTVCSLLLLGMLWLDLAMAGSSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPEDGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK
T06850	DRUGINFO	D01TDY	Unacylated ghrelin	Phase 1

T95923	TARGETID	T95923
T95923	FORMERID	TTDI02116
T95923	UNIPROID	LPAR3_HUMAN
T95923	TARGNAME	Lysophosphatidate-3 receptor (LPAR3)
T95923	GENENAME	LPAR3
T95923	TARGTYPE	Clinical trial
T95923	SYNONYMS	Lysophosphatidic acid receptor Edg7; Lysophosphatidic acid receptor 3; LPAR3; LPA3; LPA receptor 3
T95923	FUNCTION	Receptor for lysophosphatidic acid (LPA), a mediator of diverse cellular activities. May play a role in the development of ovarian cancer. Seems to be coupled to the G(i)/G(o) and G(q) families of heteromeric G proteins.
T95923	BIOCLASS	GPCR rhodopsin
T95923	SEQUENCE	MNECHYDKHMDFFYNRSNTDTVDDWTGTKLVIVLCVGTFFCLFIFFSNSLVIAAVIKNRKFHFPFYYLLANLAAADFFAGIAYVFLMFNTGPVSKTLTVNRWFLRQGLLDSSLTASLTNLLVIAVERHMSIMRMRVHSNLTKKRVTLLILLVWAIAIFMGAVPTLGWNCLCNISACSSLAPIYSRSYLVFWTVSNLMAFLIMVVVYLRIYVYVKRKTNVLSPHTSGSISRRRTPMKLMKTVMTVLGAFVVCWTPGLVVLLLDGLNCRQCGVQHVKRWFLLLALLNSVVNPIIYSYKDEDMYGTMKKMICCFSQENPERRPSRIPSTVLSRSDTGSQYIEDSISQGAVCNKSTS
T95923	DRUGINFO	D07WCT	SAR-100842	Phase 2
T95923	DRUGINFO	D0D5OY	alpha-fluoromethylenephosphonate	Investigative
T95923	DRUGINFO	D0H6DZ	OMPT	Investigative
T95923	DRUGINFO	D0SH0M	PMID19800804C12	Investigative
T95923	DRUGINFO	D0FZ6A	dodecylphosphate	Investigative
T95923	DRUGINFO	D0S6CW	VPC32183	Investigative
T95923	DRUGINFO	D0X0OP	alkyl OMPT	Investigative
T95923	DRUGINFO	D0Z6DG	T13	Investigative
T95923	DRUGINFO	D04KQT	dodecyl-thiophosphate	Investigative
T95923	DRUGINFO	D0K3GQ	oleoyl-thiophosphate	Investigative
T95923	DRUGINFO	D0PI4H	VPC12249	Investigative
T95923	DRUGINFO	D0R8LB	NAEPA	Investigative
T95923	DRUGINFO	D02LXI	Ki16425	Investigative
T95923	DRUGINFO	D0G6XT	dioctanoylglycerol pyrophosphate	Investigative
T95923	DRUGINFO	D0R2VH	2-oleoyl-LPA	Investigative
T95923	DRUGINFO	D0X0UR	LPA	Investigative

T27611	TARGETID	T27611
T27611	FORMERID	TTDI02218
T27611	UNIPROID	GDF2_HUMAN
T27611	TARGNAME	Growth/differentiation factor 2 (GDF2)
T27611	GENENAME	GDF2
T27611	TARGTYPE	Clinical trial
T27611	SYNONYMS	GDF2; Bone morphogenetic protein 9; BMP9
T27611	FUNCTION	Potent circulating inhibitor of angiogenesis. Couldbe involved in bone formation. Signals through the type I activin receptor ACVRL1 but not other Alks. Signaling through SMAD1 in endothelial cells requires TGF-beta coreceptor endoglin/ENG.
T27611	PDBSTRUC	5I05; 5HZW; 4YCI; 4YCG; 4MPL
T27611	BIOCLASS	Growth factor
T27611	SEQUENCE	MCPGALWVALPLLSLLAGSLQGKPLQSWGRGSAGGNAHSPLGVPGGGLPEHTFNLKMFLENVKVDFLRSLNLSGVPSQDKTRVEPPQYMIDLYNRYTSDKSTTPASNIVRSFSMEDAISITATEDFPFQKHILLFNISIPRHEQITRAELRLYVSCQNHVDPSHDLKGSVVIYDVLDGTDAWDSATETKTFLVSQDIQDEGWETLEVSSAVKRWVRSDSTKSKNKLEVTVESHRKGCDTLDISVPPGSRNLPFFVVFSNDHSSGTKETRLELREMISHEQESVLKKLSKDGSTEAGESSHEEDTDGHVAAGSTLARRKRSAGAGSHCQKTSLRVNFEDIGWDSWIIAPKEYEAYECKGGCFFPLADDVTPTKHAIVQTLVHLKFPTKVGKACCVPTKLSPISVLYKDDMGVPTLKYHYEGMSVAECGCR
T27611	DRUGINFO	D0N9PL	ACE-041	Phase 1

T00156	TARGETID	T00156
T00156	FORMERID	TTDI02490
T00156	UNIPROID	TRPC5_HUMAN
T00156	TARGNAME	Short transient receptor potential channel 5 (TRPC5)
T00156	GENENAME	TRPC5
T00156	TARGTYPE	Clinical trial
T00156	SYNONYMS	hTRP5; hTRP-5; TrpC5; Transient receptor protein 5; TRP-5
T00156	FUNCTION	Thought to form a receptor-activated non-selective calcium permeant cation channel. Probably is operated by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases or G-protein coupled receptors. Has also been shown to be calcium-selective. May also be activated by intracellular calcium store depletion.
T00156	BIOCLASS	Transient receptor potential catioin channel
T00156	SEQUENCE	MAQLYYKKVNYSPYRDRIPLQIVRAETELSAEEKAFLNAVEKGDYATVKQALQEAEIYYNVNINCMDPLGRSALLIAIENENLEIMELLLNHSVYVGDALLYAIRKEVVGAVELLLSYRRPSGEKQVPTLMMDTQFSEFTPDITPIMLAAHTNNYEIIKLLVQKRVTIPRPHQIRCNCVECVSSSEVDSLRHSRSRLNIYKALASPSLIALSSEDPILTAFRLGWELKELSKVENEFKAEYEELSQQCKLFAKDLLDQARSSRELEIILNHRDDHSEELDPQKYHDLAKLKVAIKYHQKEFVAQPNCQQLLATLWYDGFPGWRRKHWVVKLLTCMTIGFLFPMLSIAYLISPRSNLGLFIKKPFIKFICHTASYLTFLFMLLLASQHIVRTDLHVQGPPPTVVEWMILPWVLGFIWGEIKEMWDGGFTEYIHDWWNLMDFAMNSLYLATISLKIVAYVKYNGSRPREEWEMWHPTLIAEALFAISNILSSLRLISLFTANSHLGPLQISLGRMLLDILKFLFIYCLVLLAFANGLNQLYFYYETRAIDEPNNCKGIRCEKQNNAFSTLFETLQSLFWSVFGLLNLYVTNVKARHEFTEFVGATMFGTYNVISLVVLLNMLIAMMNNSYQLIADHADIEWKFARTKLWMSYFDEGGTLPPPFNIIPSPKSFLYLGNWFNNTFCPKRDPDGRRRRRNLRSFTERNADSLIQNQHYQEVIRNLVKRYVAAMIRNSKTHEGLTEENFKELKQDISSFRYEVLDLLGNRKHPRSFSTSSTELSQRDDNNDGSGGARAKSKSVSFNLGCKKKTCHGPPLIRTMPRSSGAQGKSKAESSSKRSFMGPSLKKLGLLFSKFNGHMSEPSSEPMYTISDGIVQQHCMWQDIRYSQMEKGKAEACSQSEINLSEVELGEVQGAAQSSECPLACSSSLHCASSICSSNSKLLDSSEDVFETWGEACDLLMHKWGDGQEEQVTTRL
T00156	DRUGINFO	D1IFS2	GFB-887	Phase 2
T00156	DRUGINFO	DD1ZV6	BI 1358894	Phase 2
T00156	DRUGINFO	D09YUL	bromoenol lactone	Investigative
T00156	DRUGINFO	D0G8FT	ML204	Investigative
T00156	DRUGINFO	D0M6VZ	(-)-englerin A	Investigative
T00156	DRUGINFO	D0F4FK	KB-R7943	Investigative
T00156	DRUGINFO	D0JV2P	BTP2	Investigative
T00156	DRUGINFO	D0KT5E	lysophosphatidylcholine	Investigative
T00156	DRUGINFO	D0SY2M	daidzein	Investigative
T00156	DRUGINFO	D00HCI	2-APB	Investigative

T58741	TARGETID	T58741
T58741	FORMERID	TTDI02461
T58741	UNIPROID	SCN8A_HUMAN
T58741	TARGNAME	Voltage-gated sodium channel alpha Nav1.6 (SCN8A)
T58741	GENENAME	SCN8A
T58741	TARGTYPE	Clinical trial
T58741	SYNONYMS	Voltage-gated sodium channel subunit alpha Nav1.6; Sodium channel protein type VIII subunit alpha; Sodium channel protein type 8 subunit alpha; SCN8A
T58741	FUNCTION	Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. In macrophages and melanoma cells, isoform 5 may participate in the control of podosome and invadopodia formation.
T58741	BIOCLASS	Voltage-gated ion channel
T58741	SEQUENCE	MAARLLAPPGPDSFKPFTPESLANIERRIAESKLKKPPKADGSHREDDEDSKPKPNSDLEAGKSLPFIYGDIPQGLVAVPLEDFDPYYLTQKTFVVLNRGKTLFRFSATPALYILSPFNLIRRIAIKILIHSVFSMIIMCTILTNCVFMTFSNPPDWSKNVEYTFTGIYTFESLVKIIARGFCIDGFTFLRDPWNWLDFSVIMMAYITEFVNLGNVSALRTFRVLRALKTISVIPGLKTIVGALIQSVKKLSDVMILTVFCLSVFALIGLQLFMGNLRNKCVVWPINFNESYLENGTKGFDWEEYINNKTNFYTVPGMLEPLLCGNSSDAGQCPEGYQCMKAGRNPNYGYTSFDTFSWAFLALFRLMTQDYWENLYQLTLRAAGKTYMIFFVLVIFVGSFYLVNLILAVVAMAYEEQNQATLEEAEQKEAEFKAMLEQLKKQQEEAQAAAMATSAGTVSEDAIEEEGEEGGGSPRSSSEISKLSSKSAKERRNRRKKRKQKELSEGEEKGDPEKVFKSESEDGMRRKAFRLPDNRIGRKFSIMNQSLLSIPGSPFLSRHNSKSSIFSFRGPGRFRDPGSENEFADDEHSTVEESEGRRDSLFIPIRARERRSSYSGYSGYSQGSRSSRIFPSLRRSVKRNSTVDCNGVVSLIGGPGSHIGGRLLPEATTEVEIKKKGPGSLLVSMDQLASYGRKDRINSIMSVVTNTLVEELEESQRKCPPCWYKFANTFLIWECHPYWIKLKEIVNLIVMDPFVDLAITICIVLNTLFMAMEHHPMTPQFEHVLAVGNLVFTGIFTAEMFLKLIAMDPYYYFQEGWNIFDGFIVSLSLMELSLADVEGLSVLRSFRLLRVFKLAKSWPTLNMLIKIIGNSVGALGNLTLVLAIIVFIFAVVGMQLFGKSYKECVCKINQDCELPRWHMHDFFHSFLIVFRVLCGEWIETMWDCMEVAGQAMCLIVFMMVMVIGNLVVLNLFLALLLSSFSADNLAATDDDGEMNNLQISVIRIKKGVAWTKLKVHAFMQAHFKQREADEVKPLDELYEKKANCIANHTGADIHRNGDFQKNGNGTTSGIGSSVEKYIIDEDHMSFINNPNLTVRVPIAVGESDFENLNTEDVSSESDPEGSKDKLDDTSSSEGSTIDIKPEVEEVPVEQPEEYLDPDACFTEGCVQRFKCCQVNIEEGLGKSWWILRKTCFLIVEHNWFETFIIFMILLSSGALAFEDIYIEQRKTIRTILEYADKVFTYIFILEMLLKWTAYGFVKFFTNAWCWLDFLIVAVSLVSLIANALGYSELGAIKSLRTLRALRPLRALSRFEGMRVVVNALVGAIPSIMNVLLVCLIFWLIFSIMGVNLFAGKYHYCFNETSEIRFEIEDVNNKTECEKLMEGNNTEIRWKNVKINFDNVGAGYLALLQVATFKGWMDIMYAAVDSRKPDEQPKYEDNIYMYIYFVIFIIFGSFFTLNLFIGVIIDNFNQQKKKFGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPLNKIQGIVFDFVTQQAFDIVIMMLICLNMVTMMVETDTQSKQMENILYWINLVFVIFFTCECVLKMFALRHYYFTIGWNIFDFVVVILSIVGMFLADIIEKYFVSPTLFRVIRLARIGRILRLIKGAKGIRTLLFALMMSLPALFNIGLLLFLVMFIFSIFGMSNFAYVKHEAGIDDMFNFETFGNSMICLFQITTSAGWDGLLLPILNRPPDCSLDKEHPGSGFKGDCGNPSVGIFFFVSYIIISFLIVVNMYIAIILENFSVATEESADPLSEDDFETFYEIWEKFDPDATQFIEYCKLADFADALEHPLRVPKPNTIELIAMDLPMVSGDRIHCLDILFAFTKRVLGDSGELDILRQQMEERFVASNPSKVSYEPITTTLRRKQEEVSAVVLQRAYRGHLARRGFICKKTTSNKLENGGTHREKKESTPSTASLPSYDSVTKPEKEKQQRAEEGRRERAKRQKEVRESKC
T58741	DRUGINFO	DMT4U6	NBI-921352	Phase 2
T58741	DRUGINFO	D01QTJ	XEN901	Phase 1
T58741	DRUGINFO	D0R0JN	PRAX-330	Phase 1
T58741	DRUGINFO	D04HXU	4,9-anhydro-tetrodotoxin	Investigative
T58741	DRUGINFO	D0G9WE	batrachotoxin	Investigative
T58741	DRUGINFO	D0S4MN	veratridine	Investigative

T02469	TARGETID	T02469
T02469	UNIPROID	FYV1_HUMAN
T02469	TARGNAME	Phosphatidylinositol-3-phosphate 5-kinase (PIP5K3)
T02469	GENENAME	PIKFYVE
T02469	TARGTYPE	Clinical trial
T02469	SYNONYMS	Type III PIP kinase; Phosphatidylinositol 3-phosphate 5-kinase type III; PIPkin-III; PIKfyve; FYVE finger-containing phosphoinositide kinase
T02469	FUNCTION	The PI(3,5)P2 regulatory complex regulates both the synthesis and turnover of phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2). Catalyzes the phosphorylation of phosphatidylinositol 3-phosphate on the fifth hydroxyl of the myo-inositol ring, to form phosphatidylinositol 3,5-bisphosphate. Required for endocytic-vacuolar pathway and nuclear migration. Plays a role in the biogenesis of endosome carrier vesicles (ECV)/ multivesicular bodies (MVB) transport intermediates from early endosomes.
T02469	ECNUMBER	EC 2.7.1.150
T02469	SEQUENCE	MATDDKTSPTLDSANDLPRSPTSPSHLTHFKPLTPDQDEPPFKSAYSSFVNLFRFNKERAEGGQGEQQPLSGSWTSPQLPSRTQSVRSPTPYKKQLNEELQRRSSALDTRRKAEPTFGGHDPRTAVQLRSLSTVLKRLKEIMEGKSQDSDLKQYWMPDSQCKECYDCSEKFTTFRRRHHCRLCGQIFCSRCCNQEIPGKFMGYTGDLRACTYCRKIALSYAHSTDSNSIGEDLNALSDSACSVSVLDPSEPRTPVGSRKASRNIFLEDDLAWQSLIHPDSSNTPLSTRLVSVQEDAGKSPARNRSASITNLSLDRSGSPMVPSYETSVSPQANRTYVRTETTEDERKILLDSVQLKDLWKKICHHSSGMEFQDHRYWLRTHPNCIVGKELVNWLIRNGHIATRAQAIAIGQAMVDGRWLDCVSHHDQLFRDEYALYRPLQSTEFSETPSPDSDSVNSVEGHSEPSWFKDIKFDDSDTEQIAEEGDDNLANSASPSKRTSVSSFQSTVDSDSAASISLNVELDNVNFHIKKPSKYPHVPPHPADQKEYLISDTGGQQLSISDAFIKESLFNRRVEEKSKELPFTPLGWHHNNLELLREENGEKQAMERLLSANHNHMMALLQQLLHSDSLSSSWRDIIVSLVCQVVQTVRPDVKNQDDDMDIRQFVHIKKIPGGKKFDSVVVNGFVCTKNIAHKKMSSCIKNPKILLLKCSIEYLYREETKFTCIDPIVLQEREFLKNYVQRIVDVRPTLVLVEKTVSRIAQDMLLEHGITLVINVKSQVLERISRMTQGDLVMSMDQLLTKPHLGTCHKFYMQIFQLPNEQTKTLMFFEGCPQHLGCTIKLRGGSDYELARVKEILIFMICVAYHSQLEISFLMDEFAMPPTLMQNPSFHSLIEGRGHEGAVQEQYGGGSIPWDPDIPPESLPCDDSSLLELRIVFEKGEQENKNLPQAVASVKHQEHSTTACPAGLPCAFFAPVPESLLPLPVDDQQDALGSEQPETLQQTVVLQDPKSQIRAFRDPLQDDTGLYVTEEVTSSEDKRKTYSLAFKQELKDVILCISPVITFREPFLLTEKGMRCSTRDYFAEQVYWSPLLNKEFKEMENRRKKQLLRDLSGLQGMNGSIQAKSIQVLPSHELVSTRIAEHLGDSQSLGRMLADYRARGGRIQPKNSDPFAHSKDASSTSSGQSGSKNEGDEERGLILSDAVWSTKVDCLNPINHQRLCVLFSSSSAQSSNAPSACVSPWIVTMEFYGKNDLTLGIFLERYCFRPSYQCPSMFCDTPMVHHIRRFVHGQGCVQIILKELDSPVPGYQHTILTYSWCRICKQVTPVVALSNESWSMSFAKYLELRFYGHQYTRRANAEPCGHSIHHDYHQYFSYNQMVASFSYSPIRLLEVCVPLPKIFIKRQAPLKVSLLQDLKDFFQKVSQVYVAIDERLASLKTDTFSKTREEKMEDIFAQKEMEEGEFKNWIEKMQARLMSSSVDTPQQLQSVFESLIAKKQSLCEVLQAWNNRLQDLFQQEKGRKRPSVPPSPGRLRQGEESKISAMDASPRNISPGLQNGEKEDRFLTTLSSQSSTSSTHLQLPTPPEVMSEQSVGGPPELDTASSSEDVFDGHLLGSTDSQVKEKSTMKAIFANLLPGNSYNPIPFPFDPDKHYLMYEHERVPIAVCEKEPSSIIAFALSCKEYRNALEELSKATQWNSAEEGLPTNSTSDSRPKSSSPIRLPEMSGGQTNRTTETEPQPTKKASGMLSFFRGTAGKSPDLSSQKRETLRGADSAYYQVGQTGKEGTENQGVEPQDEVDGGDTQKKQLINPHVELQFSDANAKFYCRLYYAGEFHKMREVILDSSEEDFIRSLSHSSPWQARGGKSGAAFYATEDDRFILKQMPRLEVQSFLDFAPHYFNYITNAVQQKRPTALAKILGVYRIGYKNSQNNTEKKLDLLVMENLFYGRKMAQVFDLKGSLRNRNVKTDTGKESCDVVLLDENLLKMVRDNPLYIRSHSKAVLRTSIHSDSHFLSSHLIIDYSLLVGRDDTSNELVVGIIDYIRTFTWDKKLEMVVKSTGILGGQGKMPTVVSPELYRTRFCEAMDKYFLMVPDHWTGLGLNC
T02469	DRUGINFO	D03SUQ	Apilimod dimesylate	Phase 2
T02469	DRUGINFO	D0JW6R	LAM-002	Phase 2
T02469	DRUGINFO	DPN2R7	YM-201636	Preclinical

T25637	TARGETID	T25637
T25637	FORMERID	TTDI02115
T25637	UNIPROID	LOXL2_HUMAN
T25637	TARGNAME	Lysyl oxidase homolog 2 (LOXL2)
T25637	GENENAME	LOXL2
T25637	TARGTYPE	Clinical trial
T25637	SYNONYMS	Lysyl oxidaserelated protein WS914; Lysyl oxidaserelated protein 2; Lysyl oxidaselike protein 2; LOXL2
T25637	FUNCTION	Mediates the post-translational oxidative deamination of lysine residues on target proteins leading to the formation of deaminated lysine (allysine). When secreted in extracellular matrix, promotes cross-linking of extracellular matrix proteins by mediating oxidative deamination of peptidyl lysine residues in precursors to fibrous collagen and elastin. Acts as a regulator of sprouting angiogenesis, probably via collagen IV scaffolding. When nuclear, acts as a transcription corepressor and specifically mediates deamination of trimethylated 'Lys-4' of histone H3 (H3K4me3), a specific tag for epigenetic transcriptional activation. Involved in epithelial to mesenchymal transition (EMT) via interaction with SNAI1 and participates in repression of E- cadherin, probably by mediating deamination of histone H3. Also involved in E-cadherin repression following hypoxia, a hallmark of epithelial to mesenchymal transition believed to amplify tumor aggressiveness, suggesting that it may play a role in tumor progression. Acts as a regulator of chondrocyte differentiation, probably by regulating expression of factors that control chondrocyte differentiation.
T25637	PDBSTRUC	5ZE3
T25637	ECNUMBER	EC 1.4.3.13
T25637	SEQUENCE	MERPLCSHLCSCLAMLALLSPLSLAQYDSWPHYPEYFQQPAPEYHQPQAPANVAKIQLRLAGQKRKHSEGRVEVYYDGQWGTVCDDDFSIHAAHVVCRELGYVEAKSWTASSSYGKGEGPIWLDNLHCTGNEATLAACTSNGWGVTDCKHTEDVGVVCSDKRIPGFKFDNSLINQIENLNIQVEDIRIRAILSTYRKRTPVMEGYVEVKEGKTWKQICDKHWTAKNSRVVCGMFGFPGERTYNTKVYKMFASRRKQRYWPFSMDCTGTEAHISSCKLGPQVSLDPMKNVTCENGLPAVVSCVPGQVFSPDGPSRFRKAYKPEQPLVRLRGGAYIGEGRVEVLKNGEWGTVCDDKWDLVSASVVCRELGFGSAKEAVTGSRLGQGIGPIHLNEIQCTGNEKSIIDCKFNAESQGCNHEEDAGVRCNTPAMGLQKKLRLNGGRNPYEGRVEVLVERNGSLVWGMVCGQNWGIVEAMVVCRQLGLGFASNAFQETWYWHGDVNSNKVVMSGVKCSGTELSLAHCRHDGEDVACPQGGVQYGAGVACSETAPDLVLNAEMVQQTTYLEDRPMFMLQCAMEENCLSASAAQTDPTTGYRRLLRFSSQIHNNGQSDFRPKNGRHAWIWHDCHRHYHSMEVFTHYDLLNLNGTKVAEGHKASFCLEDTECEGDIQKNYECANFGDQGITMGCWDMYRHDIDCQWVDITDVPPGDYLFQVVINPNFEVAESDYSNNIMKCRSRYDGHRIWMYNCHIGGSFSEETEKKFEHFSGLLNNQLSPQ
T25637	DRUGINFO	D09NCU	GS-6624	Phase 2
T25637	DRUGINFO	D7ZXE5	Beta-aminopropionitrile	Preclinical

T01280	TARGETID	T01280
T01280	FORMERID	TTDI03051
T01280	UNIPROID	BACE2_HUMAN
T01280	TARGNAME	Beta-site APP-cleaving enzyme 2 (BACE2)
T01280	GENENAME	BACE2
T01280	TARGTYPE	Clinical trial
T01280	SYNONYMS	Theta-secretase; Membrane-associated aspartic protease 1; Memapsin-1; Down region aspartic protease; DRAP; Beta-site amyloid precursor protein cleaving enzyme 2; Beta-site APP cleaving enzyme 2; Beta-secretase 2; Aspartyl protease 1; Aspartic-like protease 56 kDa; Asp 1; ASP21; ASP1; ALP56; AEPLC
T01280	FUNCTION	Responsible for the proteolytic processing of the amyloid precursor protein (APP). Cleaves APP, between residues 690 and 691, leading to the generation and extracellular release of beta-cleaved soluble APP, and a corresponding cell-associated C-terminal fragment which is later released by gamma-secretase. It has also been shown that it can cleave APP between residues 671 and 672. Responsible also for the proteolytic processing of CLTRN in pancreatic beta cells.
T01280	PDBSTRUC	4BFB; 4BEL; 3ZLQ; 3ZL7; 3ZKX
T01280	ECNUMBER	EC 3.4.23.45
T01280	SEQUENCE	MGALARALLLPLLAQWLLRAAPELAPAPFTLPLRVAAATNRVVAPTPGPGTPAERHADGLALALEPALASPAGAANFLAMVDNLQGDSGRGYYLEMLIGTPPQKLQILVDTGSSNFAVAGTPHSYIDTYFDTERSSTYRSKGFDVTVKYTQGSWTGFVGEDLVTIPKGFNTSFLVNIATIFESENFFLPGIKWNGILGLAYATLAKPSSSLETFFDSLVTQANIPNVFSMQMCGAGLPVAGSGTNGGSLVLGGIEPSLYKGDIWYTPIKEEWYYQIEILKLEIGGQSLNLDCREYNADKAIVDSGTTLLRLPQKVFDAVVEAVARASLIPEFSDGFWTGSQLACWTNSETPWSYFPKISIYLRDENSSRSFRITILPQLYIQPMMGAGLNYECYRFGISPSTNALVIGATVMEGFYVIFDRAQKRVGFAASPCAEIAGAAVSEISGPFSTEDVASNCVPAQSLSEPILWIVSYALMSVCGAILLVLIVLLLLPFRCQRRPRDPEVVNDESSLVRHRWK
T01280	DRUGINFO	D0O7HP	example 98 (WO2011020806)	Clinical trial
T01280	DRUGINFO	D07IXP	example 20 (WO2010128058)	Investigative
T01280	DRUGINFO	D09OCY	example 41 (WO2012028563)	Investigative
T01280	DRUGINFO	D0HO1O	2ewy	Investigative
T01280	DRUGINFO	D0Z4JT	example 92 (WO2012095521)	Investigative
T01280	DRUGINFO	D00SDQ	PMID21907142CJ	Investigative
T01280	DRUGINFO	D0O0GW	example 2 (WO2013004676)	Investigative

T62705	TARGETID	T62705
T62705	FORMERID	TTDR01123
T62705	UNIPROID	ICOS_HUMAN
T62705	TARGNAME	Inducible T-cell costimulator (ICOS)
T62705	GENENAME	ICOS
T62705	TARGTYPE	Clinical trial
T62705	SYNONYMS	Inducible costimulator; Inducible T-cell co-stimulator; Inducible COSTIMULATOR precursor; CD278; Activation-inducible lymphocyte immunomediatory molecule; AILIM
T62705	FUNCTION	Essential both for efficient interaction between T and B-cells and for normal antibody responses to T-cell dependent antigens. Does not up-regulate the production of interleukin-2, but superinduces the synthesis of interleukin-10. Prevents the apoptosis of pre-activated T-cells. Plays a critical role in CD40-mediated class switching of immunoglobin isotypes. Enhances all basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines, up-regulation of molecules that mediate cell-cell interaction, and effective help for antibody secretion by B-cells.
T62705	BIOCLASS	Immunoglobulin
T62705	SEQUENCE	MKSGLWYFFLFCLRIKVLTGEINGSANYEMFIFHNGGVQILCKYPDIVQQFKMQLLKGGQILCDLTKTKGSGNTVSIKSLKFCHSQLSNNSVSFFLYNLDHSHANYYFCNLSIFDPPPFKVTLTGGYLHIYESQLCCQLKFWLPIGCAAFVVVCILGCILICWLTKKKYSSSVHDPNGEYMFMRAVNTAKKSRLTDVTL
T62705	DRUGINFO	D0EL5Q	JTX-2011	Phase 2
T62705	DRUGINFO	DALG29	KY1044	Phase 1/2
T62705	DRUGINFO	D0E6NH	MEDI-570	Phase 1
T62705	DRUGINFO	D8FJ9K	XmAb23104	Phase 1

T60568	TARGETID	T60568
T60568	FORMERID	TTDC00274
T60568	UNIPROID	TAT_HV1H2
T60568	TARGNAME	Human immunodeficiency virus Tat messenger RNA (HIV tat mRNA)
T60568	GENENAME	HIV tat mRNA
T60568	TARGTYPE	Clinical trial
T60568	SYNONYMS	tat (mRNA); Transactivating regulatory protein (mRNA); Protein Tat (mRNA)
T60568	FUNCTION	Acts as a sequence-specific molecular adapter, directing components of the cellular transcription machinery to the viral RNA to promote processive transcription elongation by the RNA polymerase II (RNA pol II) complex, thereby increasing the level of full-length transcripts. In the absence of Tat, the RNA Pol II generates short or non-processive transcripts that terminate at approximately 60 bp from the initiation site. Tat associates with the CCNT1/cyclin-T1 component of the P-TEFb complex (CDK9 and CCNT1), which promotes RNA chain elongation. This binding increases Tat's affinity for a hairpin structure at the 5'-end of all nascent viral mRNAs referred to as the transactivation responsive RNA element (TAR RNA) and allows Tat/P-TEFb complex to bind cooperatively to TAR RNA. The CDK9 component of P-TEFb and other Tat-activated kinases hyperphosphorylate the C-terminus of RNA Pol II that becomes stabilized and much more processive. Other factors such as HTATSF1/Tat-SF1, SUPT5H/SPT5, and HTATIP2 are also important for Tat's function. Besides its effect on RNA Pol II processivity, Tat induces chromatin remodeling of proviral genes by recruiting the histone acetyltransferases (HATs) CREBBP, EP300 and PCAF to the chromatin. This also contributes to the increase in proviral transcription rate, especially when the provirus integrates in transcriptionally silent region of the host genome. To ensure maximal activation of the LTR, Tat mediates nuclear translocation of NF-kappa-B by interacting with host RELA. Through its interaction with host TBP, Tat may also modulate transcription initiation. Tat can reactivate a latently infected cell by penetrating in it and transactivating its LTR promoter. In the cytoplasm, Tat is thought to act as a translational activator of HIV-1 mRNAs. Nuclear transcriptional activator of viral gene expression, that is essential for viral transcription from the LTR promoter and replication.
T60568	PDBSTRUC	6MCF; 6MCE; 5V61; 4OR5; 3MIA
T60568	BIOCLASS	mRNA target
T60568	SEQUENCE	MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKALGISYGRKKRRQRRRAHQNSQTHQASLSKQPTSQPRGDPTGPKE
T60568	DRUGINFO	D0JZ8X	HGTV43	Phase 2

T62739	TARGETID	T62739
T62739	FORMERID	TTDI02269
T62739	UNIPROID	STMN1_HUMAN
T62739	TARGNAME	STMN1 messenger RNA (STMN1 mRNA)
T62739	GENENAME	STMN1
T62739	TARGTYPE	Clinical trial
T62739	SYNONYMS	pp19 (mRNA); pp17 (mRNA); Stathmin (mRNA); Protein Pr22 (mRNA); Prosolin (mRNA); Phosphoprotein p19 (mRNA); Op18 (mRNA); Oncoprotein 18 (mRNA); Metablastin (mRNA); Leukemia-associated phosphoprotein p18 (mRNA); LAP18 (mRNA); C1orf215 (mRNA)
T62739	FUNCTION	Prevents assembly and promotes disassembly of microtubules. Phosphorylation at Ser-16 may be required for axon formation during neurogenesis. Involved in the control of the learned and innate fear. Involved in the regulation of the microtubule (MT) filament system by destabilizing microtubules.
T62739	BIOCLASS	mRNA target
T62739	SEQUENCE	MASSDIQVKELEKRASGQAFELILSPRSKESVPEFPLSPPKKKDLSLEEIQKKLEAAEERRKSHEAEVLKQLAEKREHEKEVLQKAIEENNNFSKMAEEKLTHKMEANKENREAQMAAKLERLREKDKHIEEVRKNKESKDPADETEAD
T62739	DRUGINFO	DSE59Z	pbi-shRNA STMN1	Phase 1

T16605	TARGETID	T16605
T16605	FORMERID	TTDI02267
T16605	UNIPROID	NCAP_MABVM
T16605	TARGNAME	Marburg virus NP messenger RNA (MV NP mRNA)
T16605	GENENAME	MV NP mRNA
T16605	TARGTYPE	Clinical trial
T16605	SYNONYMS	Protein N (mRNA); Nucleoprotein (mRNA); Nucleocapsid protein (mRNA)
T16605	FUNCTION	The encapsidated genomic RNA is termed the nucleocapsid and serves as template for transcription and replication. During replication, encapsidation by NP is coupled to RNA synthesis and all replicative products are resistant to nucleases. Encapsidates the genome, protecting it from nucleases.
T16605	PDBSTRUC	6APP; 5T3W; 4W2Q; 4W2O
T16605	BIOCLASS	mRNA target
T16605	SEQUENCE	MDLHSLLELGTKPTAPHVRNKKVILFDTNHQVSICNQIIDAINSGIDLGDLLEGGLLTLCVEHYYNSDKDKFNTSPVAKYLRDAGYEFDVIKNADATRFLDVSPNEPHYSPLILALKTLESTESQRGRIGLFLSFCSLFLPKLVVGDRASIEKALRQVTVHQEQGIVTYPNHWLTTGHMKVIFGILRSSFILKFVLIHQGVNLVTGHDAYDSIISNSVGQTRFSGLLIVKTVLEFILQKTDSGVTLHPLVRTSKVKNEVASFKQALSNLARHGEYAPFARVLNLSGINNLEHGLYPQLSAIALGVATAHGSTLAGVNVGEQYQQLREAAHDAEVKLQRRHEHQEIQAIAEDDEERKILEQFHLQKTEITHSQTLAVLSQKREKLARLAAEIENNIVEDQGFKQSQNRVSQSFLNDPTPVEVTVQARPMNRPTALPPPVDDKIEHESTEDSSSSSSFVDLNDPFALLNEDEDTLDDSVMIPGTTSREFQGIPEPPRQSQDLNNSQGKQEDESTNRIKKQFLRYQELPPVQEDDESEYTTDSQESIDQPGSDNEQGVDLPPPPLYAQEKRQDPIQHPAANPQDPFGSIGDVNGDILEPIRSPSSPSAPQEDTRMREAYELSPDFTNDEDNQQNWPQRVVTKKGRTFLYPNDLLQTNPPESLITALVEEYQNPVSAKELQADWPDMSFDERRHVAMNL
T16605	DRUGINFO	D07CXM	AVI-7288	Phase 1

T00039	TARGETID	T00039
T00039	FORMERID	TTDC00335
T00039	UNIPROID	CTGF_HUMAN
T00039	TARGNAME	CTGF messenger RNA (CTGF mRNA)
T00039	GENENAME	CTGF
T00039	TARGTYPE	Clinical trial
T00039	SYNONYMS	Long (mRNA); Insulin-like growth factor-binding protein 8 (mRNA); IGFBP8 (mRNA); IGFBP-8 (mRNA); IGF-binding protein 8 (mRNA); IBP-8 (mRNA); Hypertrophic chondrocyte-specific protein 24 (mRNA); HCS24 (mRNA); Connective tissue growth factor (mRNA); CCN2 (mRNA); CCN family member 2 (mRNA)
T00039	FUNCTION	Promotes proliferation and differentiation of chondrocytes. Mediates heparin- and divalent cation-dependent cell adhesion in many cell types including fibroblasts, myofibroblasts, endothelial and epithelial cells. Enhances fibroblast growth factor-induced DNA synthesis. Major connective tissue mitoattractant secreted by vascular endothelial cells.
T00039	BIOCLASS	mRNA target
T00039	SEQUENCE	MTAASMGPVRVAFVVLLALCSRPAVGQNCSGPCRCPDEPAPRCPAGVSLVLDGCGCCRVCAKQLGELCTERDPCDPHKGLFCHFGSPANRKIGVCTAKDGAPCIFGGTVYRSGESFQSSCKYQCTCLDGAVGCMPLCSMDVRLPSPDCPFPRRVKLPGKCCEEWVCDEPKDQTVVGPALAAYRLEDTFGPDPTMIRANCLVQTTEWSACSKTCGMGISTRVTNDNASCRLEKQSRLCMVRPCEADLEENIKKGKKCIRTPKISKPIKFELSGCTSMKTYRAKFCGVCTDGRCCTPHRTTTLPVEFKCPDGEVMKKNMMFIKTCACHYNCPGDNDIFESLYYRKMYGDMA
T00039	DRUGINFO	D0R3LQ	EXC 001	Phase 2

T97752	TARGETID	T97752
T97752	FORMERID	TTDI02246
T97752	UNIPROID	VP24_EBOSU
T97752	TARGNAME	Ebola virus VP24 messenger RNA (EV VP24 mRNA)
T97752	GENENAME	EV VP24 mRNA
T97752	TARGTYPE	Clinical trial
T97752	SYNONYMS	rVP24 (mRNA); VP24 (mRNA); Reston VP24 (mRNA); Membrane-associated protein VP24 (mRNA)
T97752	FUNCTION	Blocks the IFN-induced nuclear accumulation of host phosphorylated STAT1, by interacting with the STAT1-binding region of host importin alpha-1/KPNA1 protein, thereby inhibiting the latter. Without the activity of this protein, activated STAT1 would not enter the nucleus and be unable to activate IFN-induced genes. Plays a role in assembly of viral nucleocapsid and virion budding. May act as a minor matrix protein that plays a role in assembly of viral nucleocapsid and virion budding. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways.
T97752	PDBSTRUC	3VNF; 3VNE
T97752	BIOCLASS	mRNA target
T97752	SEQUENCE	MAKATGRYNLVTPKRELEQGVVFSDLCNFLVTPTVQGWKVYWAGLEFDVNQKGITLLNRLKVNDFAPAWAMTRNLFPHLFKNQQSEVQTPIWALRVILAAGILDQLMDHSLIEPLSGALNLIADWLLTTSTNHFNMRTQRVKDQLSMRMLSLIRSNIINFINKLETLHVVNYKGLLSSVEIGTPSYAIIITRTNMGYLVEVQEPDKSAMDIRHPGPVKFSLLHESTLKPVATPKPSSITSLIMEFNSSLAI
T97752	DRUGINFO	D09ELC	AVI-7537	Phase 1
T97752	DRUGINFO	D04LIH	AVI-6002	Phase 1
T97752	DRUGINFO	D0CB6N	AVI-6003	Phase 1

T12059	TARGETID	T12059
T12059	FORMERID	TTDI02293
T12059	UNIPROID	MA2B1_HUMAN; MA2B2_HUMAN; MA2C1_HUMAN
T12059	TARGNAME	Alpha-mannosidase (MANA)
T12059	GENENAME	MAN2B1; MAN2B2; MAN2C1
T12059	TARGTYPE	Clinical trial
T12059	SYNONYMS	Mannosidase alpha class 2
T12059	FUNCTION	Necessary for the catabolism of N-linked carbohydrates released during glycoprotein turnover. Cleaves all known types of alpha-mannosidic linkages.
T12059	BIOCLASS	Glycosylase
T12059	SEQUENCE	MGAYARASGVCARGCLDSAGPWTMSRALRPPLPPLCFFLLLLAAAGARAGGYETCPTVQPNMLNVHLLPHTHDDVGWLKTVDQYFYGIKNDIQHAGVQYILDSVISALLADPTRRFIYVEIAFFSRWWHQQTNATQEVVRDLVRQGRLEFANGGWVMNDEAATHYGAIVDQMTLGLRFLEDTFGNDGRPRVAWHIDPFGHSREQASLFAQMGFDGFFFGRLDYQDKWVRMQKLEMEQVWRASTSLKPPTADLFTGVLPNGYNPPRNLCWDVLCVDQPLVEDPRSPEYNAKELVDYFLNVATAQGRYYRTNHTVMTMGSDFQYENANMWFKNLDKLIRLVNAQQAKGSSVHVLYSTPACYLWELNKANLTWSVKHDDFFPYADGPHQFWTGYFSSRPALKRYERLSYNFLQVCNQLEALVGLAANVGPYGSGDSAPLNEAMAVLQHHDAVSGTSRQHVANDYARQLAAGWGPCEVLLSNALARLRGFKDHFTFCQQLNISICPLSQTAARFQVIVYNPLGRKVNWMVRLPVSEGVFVVKDPNGRTVPSDVVIFPSSDSQAHPPELLFSASLPALGFSTYSVAQVPRWKPQARAPQPIPRRSWSPALTIENEHIRATFDPDTGLLMEIMNMNQQLLLPVRQTFFWYNASIGDNESDQASGAYIFRPNQQKPLPVSRWAQIHLVKTPLVQEVHQNFSAWCSQVVRLYPGQRHLELEWSVGPIPVGDTWGKEVISRFDTPLETKGRFYTDSNGREILERRRDYRPTWKLNQTEPVAGNYYPVNTRIYITDGNMQLTVLTDRSQGGSSLRDGSLELMVHRRLLKDDGRGVSEPLMENGSGAWVRGRHLVLLDTAQAAAAGHRLLAEQEVLAPQVVLAPGGGAAYNLGAPPRTQFSGLRRDLPPSVHLLTLASWGPEMVLLRLEHQFAVGEDSGRNLSAPVTLNLRDLFSTFTITRLQETTLVANQLREAASRLKWTTNTGPTPHQTPYQLDPANITLEPMEIRTFLASVQWKEVDG
T12059	DRUGINFO	D06SVC	M-0011	Phase 3

T15795	TARGETID	T15795
T15795	UNIPROID	KCNK3_HUMAN
T15795	TARGNAME	TWIK-related acid-sensitive potassium channel 1 (TASK1)
T15795	GENENAME	KCNK3
T15795	TARGTYPE	Clinical trial
T15795	SYNONYMS	Two pore potassium channel KT3.1; Two pore K(+) channel KT3.1; TWIK-related acid-sensitive K(+) channel 1; Acid-sensitive potassium channel protein TASK-1
T15795	FUNCTION	pH-dependent, voltage-insensitive, background potassium channel protein. Rectification direction results from potassium ion concentration on either side of the membrane. Acts as an outward rectifier when external potassium concentration is low. When external potassium concentration is high, current is inward.
T15795	SEQUENCE	MKRQNVRTLALIVCTFTYLLVGAAVFDALESEPELIERQRLELRQQELRARYNLSQGGYEELERVVLRLKPHKAGVQWRFAGSFYFAITVITTIGYGHAAPSTDGGKVFCMFYALLGIPLTLVMFQSLGERINTLVRYLLHRAKKGLGMRRADVSMANMVLIGFFSCISTLCIGAAAFSHYEHWTFFQAYYYCFITLTTIGFGDYVALQKDQALQTQPQYVAFSFVYILTGLTVIGAFLNLVVLRFMTMNAEDEKRDAEHRALLTRNGQAGGGGGGGSAHTTDTASSTAAAGGGGFRNVYAEVLHFQSMCSCLWYKSREKLQYSIPMIIPRDLSTSDTCVEQSHSSPGGGGRYSDTPSRRCLCSGAPRSAISSVSTGLHSLSTFRGLMKRRSSV
T15795	DRUGINFO	D0E7XM	BAY-2253651	Phase 2
T15795	DRUGINFO	D85NEG	BAY 2253651	Phase 2

T80024	TARGETID	T80024
T80024	FORMERID	TTDI01235
T80024	UNIPROID	GDF8_HUMAN
T80024	TARGNAME	Myostatin (MSTN)
T80024	GENENAME	MSTN
T80024	TARGTYPE	Clinical trial
T80024	SYNONYMS	GDF-8
T80024	FUNCTION	Acts specifically as a negative regulator of skeletal muscle growth.
T80024	PDBSTRUC	5NXS; 5NTU; 5F3H; 5F3B
T80024	SEQUENCE	MQKLQLCVYIYLFMLIVAGPVDLNENSEQKENVEKEGLCNACTWRQNTKSSRIEAIKIQILSKLRLETAPNISKDVIRQLLPKAPPLRELIDQYDVQRDDSSDGSLEDDDYHATTETIITMPTESDFLMQVDGKPKCCFFKFSSKIQYNKVVKAQLWIYLRPVETPTTVFVQILRLIKPMKDGTRYTGIRSLKLDMNPGTGIWQSIDVKTVLQNWLKQPESNLGIEIKALDENGHDLAVTFPGPGEDGLNPFLEVKVTDTPKRSRRDFGLDCDEHSTESRCCRYPLTVDFEAFGWDWIIAPKRYKANYCSGECEFVFLQKYPHTHLVHQANPRGSAGPCCTPTKMSPINMLYFNGKEQIIYGKIPAMVVDRCGCS
T80024	DRUGINFO	DN5J9R	SRK-015	Phase 2
T80024	DRUGINFO	D0T5QC	AAV1-FS344	Phase 1/2

T99394	TARGETID	T99394
T99394	FORMERID	TTDR00935
T99394	UNIPROID	TR13B_HUMAN
T99394	TARGNAME	Transmembrane activator and CAML interactor (TNFRSF13B)
T99394	GENENAME	TNFRSF13B
T99394	TARGTYPE	Clinical trial
T99394	SYNONYMS	Tumor necrosis factor receptor superfamily member 13B; TACI; CD267
T99394	FUNCTION	Mediates calcineurin-dependent activation of NF-AT, as well as activation of NF-kappa-B and AP-1. Involved in the stimulation of B- and T-cell function and the regulation of humoral immunity. Receptor for TNFSF13/APRIL and TNFSF13B/TALL1/BAFF/BLYS that binds both ligands with similar high affinity.
T99394	PDBSTRUC	1XUT; 1XU1
T99394	SEQUENCE	MSGLGRSRRGGRSRVDQEERFPQGLWTGVAMRSCPEEQYWDPLLGTCMSCKTICNHQSQRTCAAFCRSLSCRKEQGKFYDHLLRDCISCASICGQHPKQCAYFCENKLRSPVNLPPELRRQRSGEVENNSDNSGRYQGLEHRGSEASPALPGLKLSADQVALVYSTLGLCLCAVLCCFLVAVACFLKKRGDPCSCQPRSRPRQSPAKSSQDHAMEAGSPVSTSPEPVETCSFCFPECRAPTQESAVTPGTPDPTCAGRWGCHTRTTVLQPCPHIPDSGLGIVCVPAQEGGPGA
T99394	DRUGINFO	D0B8UW	AUTO2	Phase 1/2

T81916	TARGETID	T81916
T81916	FORMERID	TTDI02109
T81916	UNIPROID	KLF4_HUMAN
T81916	TARGNAME	Kruppel like factor 4 (KLF4)
T81916	GENENAME	KLF4
T81916	TARGTYPE	Clinical trial
T81916	SYNONYMS	Krueppellike factor 4; Krueppel-like factor 4; Gutenriched krueppellike factor; Gut-enriched krueppel-like factor; GKLF; Epithelial zinc finger protein EZF; EZF
T81916	FUNCTION	Binds the 5'-CACCC-3' core sequence. Binds to the promoter region of its own gene and can activate its own transcription. Regulates the expression of key transcription factors during embryonic development. Plays an important role in maintaining embryonic stem cells, and in preventing their differentiation. Required for establishing the barrier function of the skin and for postnatal maturation and maintenance of the ocular surface. Involved in the differentiation of epithelial cells and may also function in skeletal and kidney development. Contributes to the down-regulation of p53/TP53 transcription. Transcription factor; can act both as activator and as repressor.
T81916	SEQUENCE	MRQPPGESDMAVSDALLPSFSTFASGPAGREKTLRQAGAPNNRWREELSHMKRLPPVLPGRPYDLAAATVATDLESGGAGAACGGSNLAPLPRRETEEFNDLLDLDFILSNSLTHPPESVAATVSSSASASSSSSPSSSGPASAPSTCSFTYPIRAGNDPGVAPGGTGGGLLYGRESAPPPTAPFNLADINDVSPSGGFVAELLRPELDPVYIPPQQPQPPGGGLMGKFVLKASLSAPGSEYGSPSVISVSKGSPDGSHPVVVAPYNGGPPRTCPKIKQEAVSSCTHLGAGPPLSNGHRPAAHDFPLGRQLPSRTTPTLGLEEVLSSRDCHPALPLPPGFHPHPGPNYPSFLPDQMQPQVPPLHYQGQSRGFVARAGEPCVCWPHFGTHGMMLTPPSSPLELMPPGSCMPEEPKPKRGRRSWPRKRTATHTCDYAGCGKTYTKSSHLKAHLRTHTGEKPYHCDWDGCGWKFARSDELTRHYRKHTGHRPFQCQKCDRAFSRSDHLALHMKRHF
T81916	DRUGINFO	D07TRP	APTO-253	Phase 1

T37434	TARGETID	T37434
T37434	FORMERID	TTDI02154
T37434	UNIPROID	PROM1_HUMAN
T37434	TARGNAME	Prominin-1 (PROM1)
T37434	GENENAME	PROM1
T37434	TARGTYPE	Clinical trial
T37434	SYNONYMS	Promininlike protein 1; Prominin1; Prominin-like protein 1; PROML1; MSTP061; CD133; Antigen AC133
T37434	FUNCTION	Binds cholesterol in cholesterol-containing plasma membrane microdomains and may play a role in the organization of the apical plasma membrane in epithelial cells. During early retinal development acts as a key regulator of disk morphogenesis. Involved in regulation of MAPK and Akt signaling pathways. In neuroblastoma cells suppresses cell differentiation such as neurite outgrowth in a RET-dependent manner. May play a role in cell differentiation, proliferation and apoptosis.
T37434	SEQUENCE	MALVLGSLLLLGLCGNSFSGGQPSSTDAPKAWNYELPATNYETQDSHKAGPIGILFELVHIFLYVVQPRDFPEDTLRKFLQKAYESKIDYDKPETVILGLKIVYYEAGIILCCVLGLLFIILMPLVGYFFCMCRCCNKCGGEMHQRQKENGPFLRKCFAISLLVICIIISIGIFYGFVANHQVRTRIKRSRKLADSNFKDLRTLLNETPEQIKYILAQYNTTKDKAFTDLNSINSVLGGGILDRLRPNIIPVLDEIKSMATAIKETKEALENMNSTLKSLHQQSTQLSSSLTSVKTSLRSSLNDPLCLVHPSSETCNSIRLSLSQLNSNPELRQLPPVDAELDNVNNVLRTDLDGLVQQGYQSLNDIPDRVQRQTTTVVAGIKRVLNSIGSDIDNVTQRLPIQDILSAFSVYVNNTESYIHRNLPTLEEYDSYWWLGGLVICSLLTLIVIFYYLGLLCGVCGYDRHATPTTRGCVSNTGGVFLMVGVGLSFLFCWILMIIVVLTFVFGANVEKLICEPYTSKELFRVLDTPYLLNEDWEYYLSGKLFNKSKMKLTFEQVYSDCKKNRGTYGTLHLQNSFNISEHLNINEHTGSISSELESLKVNLNIFLLGAAGRKNLQDFAACGIDRMNYDSYLAQTGKSPAGVNLLSFAYDLEAKANSLPPGNLRNSLKRDAQTIKTIHQQRVLPIEQSLSTLYQSVKILQRTGNGLLERVTRILASLDFAQNFITNNTSSVIIEETKKYGRTIIGYFEHYLQWIEFSISEKVASCKPVATALDTAVDVFLCSYIIDPLNLFWFGIGKATVFLLPALIFAVKLAKYYRRMDSEDVYDDVETIPMKNMENGNNGYHKDHVYGIHNPVMTSPSQH
T37434	DRUGINFO	D09HRH	Anti-CD133-CAR vector-transduced T cells	Phase 1
T37434	DRUGINFO	D09NBH	ICT-121	Phase 1
T37434	DRUGINFO	D04JSI	CAR-T cells targeting CD133	Preclinical

T92042	TARGETID	T92042
T92042	UNIPROID	GFRA3_HUMAN
T92042	TARGNAME	GDNF receptor alpha-3 (GFRA3)
T92042	GENENAME	GFRA3
T92042	TARGTYPE	Clinical trial
T92042	SYNONYMS	UNQ339/PRO538/PRO3664; GFR-alpha-3; GDNFR-alpha-3; GDNF family receptor alpha-3
T92042	FUNCTION	Mediates the artemin-induced autophosphorylation and activation of the RET receptor tyrosine kinase. Receptor for the glial cell line-derived neurotrophic factor, ARTN (artemin).
T92042	PDBSTRUC	2GH0
T92042	SEQUENCE	MVRPLNPRPLPPVVLMLLLLLPPSPLPLAAGDPLPTESRLMNSCLQARRKCQADPTCSAAYHHLDSCTSSISTPLPSEEPSVPADCLEAAQQLRNSSLIGCMCHRRMKNQVACLDIYWTVHRARSLGNYELDVSPYEDTVTSKPWKMNLSKLNMLKPDSDLCLKFAMLCTLNDKCDRLRKAYGEACSGPHCQRHVCLRQLLTFFEKAAEPHAQGLLLCPCAPNDRGCGERRRNTIAPNCALPPVAPNCLELRRLCFSDPLCRSRLVDFQTHCHPMDILGTCATEQSRCLRAYLGLIGTAMTPNFVSNVNTSVALSCTCRGSGNLQEECEMLEGFFSHNPCLTEAIAAKMRFHSQLFSQDWPHPTFAVMAHQNENPAVRPQPWVPSLFSCTLPLILLLSLW
T92042	DRUGINFO	D08ZXQ	Neublastin	Phase 2

T44916	TARGETID	T44916
T44916	UNIPROID	EED_HUMAN
T44916	TARGNAME	Embryonic ectoderm development protein (EED)
T44916	GENENAME	EED
T44916	TARGTYPE	Clinical trial
T44916	SYNONYMS	hEED; WD protein associating with integrin cytoplasmic tails 1; WAIT-1
T44916	FUNCTION	Polycomb group (PcG) protein. Component of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' and 'Lys-27' of histone H3, leading to transcriptional repression of the affected target gene. Also recognizes 'Lys-26' trimethylated histone H1 with the effect of inhibiting PRC2 complex methyltransferase activity on nucleosomal histone H3 'Lys-27', whereas H3 'Lys-27' recognition has the opposite effect, enabling the propagation of this repressive mark. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1 and CDKN2A.
T44916	PDBSTRUC	6C24; 6C23; 6B3W; 5WUK; 5WP3
T44916	SEQUENCE	MSEREVSTAPAGTDMPAAKKQKLSSDENSNPDLSGDENDDAVSIESGTNTERPDTPTNTPNAPGRKSWGKGKWKSKKCKYSFKCVNSLKEDHNQPLFGVQFNWHSKEGDPLVFATVGSNRVTLYECHSQGEIRLLQSYVDADADENFYTCAWTYDSNTSHPLLAVAGSRGIIRIINPITMQCIKHYVGHGNAINELKFHPRDPNLLLSVSKDHALRLWNIQTDTLVAIFGGVEGHRDEVLSADYDLLGEKIMSCGMDHSLKLWRINSKRMMNAIKESYDYNPNKTNRPFISQKIHFPDFSTRDIHRNYVDCVRWLGDLILSKSCENAIVCWKPGKMEDDIDKIKPSESNVTILGRFDYSQCDIWYMRFSMDFWQKMLALGNQVGKLYVWDLEVEDPHKAKCTTLTHHKCGAAIRQTSFSRDSSILIAVCDDASIWRWDRLR
T44916	DRUGINFO	D0UO0C	MAK683	Phase 1/2
T44916	DRUGINFO	DPS29T	ORIC-944	Phase 1
T44916	DRUGINFO	DQ0V7Y	A-395	Investigative

T03046	TARGETID	T03046
T03046	FORMERID	TTDI01322
T03046	UNIPROID	RASK_HUMAN
T03046	TARGNAME	Mutated KRAS (mKRAS)
T03046	GENENAME	KRAS
T03046	TARGTYPE	Clinical trial
T03046	SYNONYMS	c-Ki-ras (mutated); c-K-ras (mutated); RASK2 (mutated); Ki-Ras (mutated); KRAS2 (mutated); K-Ras 2 (mutated); GTPase KRas (mutated)
T03046	FUNCTION	Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. Plays an important role in the regulation of cell proliferation. Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner.
T03046	PDBSTRUC	6N2K; 6N2J; 6H47; 6H46; 6GQY
T03046	SEQUENCE	MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM
T03046	DRUGINFO	D0KK9V	GI-4000 + gemcitabine	Phase 2

T90572	TARGETID	T90572
T90572	FORMERID	TTDR00252
T90572	UNIPROID	IGF2_HUMAN
T90572	TARGNAME	Insulin-like growth factor-II (IGF2)
T90572	GENENAME	IGF2
T90572	TARGTYPE	Clinical trial
T90572	SYNONYMS	T3M-11-derived growth factor; Somatomedin-A; Somatomedin A; PP1446; Insulin-like growth factor II; Insulin-like growth factor 2; IGF-II
T90572	FUNCTION	Major fetal growth hormone in mammals. Plays a key role in regulating fetoplacental development. IGF-II is influenced by placental lactogen. Also involved in tissue differentiation. Positively regulates myogenic transcription factor MYOD1 function by facilitating the recruitment of transcriptional coactivators, thereby controlling muscle terminal differentiation. In adults, involved in glucose metabolism in adipose tissue, skeletal muscle and liver. Acts as a ligand for integrin which is required for IGF2 signaling. The insulin-like growth factors possess growth-promoting activity.
T90572	PDBSTRUC	5L3N; 5L3M; 5L3L; 3KR3; 3E4Z
T90572	SEQUENCE	MGIPMGKSMLVLLTFLAFASCCIAAYRPSETLCGGELVDTLQFVCGDRGFYFSRPASRVSRRSRGIVEECCFRSCDLALLETYCATPAKSERDVSTPPTVLPDNFPRYPVGKFFQYDTWKQSTQRLRRGLPALLRARRGHVLAKELEAFREAKRHRPLIALPTQDPAHGGAPPEMASNRK
T90572	DRUGINFO	D09TQY	Dusigitumab	Phase 2
T90572	DRUGINFO	D04DNB	Xentuzumab	Phase 2

T20978	TARGETID	T20978
T20978	FORMERID	TTDI01957
T20978	UNIPROID	CD8A_HUMAN; CD8B_HUMAN
T20978	TARGNAME	T-cell surface glycoprotein CD8 (CD8)
T20978	GENENAME	CD8A; CD8B
T20978	TARGTYPE	Clinical trial
T20978	SYNONYMS	T-lymphocyte differentiation antigen T8/Leu-2; CD8
T20978	FUNCTION	Identifies cytotoxic/suppressor T-cells that interact with MHC class I bearing targets. CD8 is thought to play a role in the process of T-cell mediated killing. CD8 alpha chains binds to class I MHC molecules alpha-3 domains.
T20978	SEQUENCE	MALPVTALLLPLALLLHAARPSQFRVSPLDRTWNLGETVELKCQVLLSNPTSGCSWLFQPRGAAASPTFLLYLSQNKPKAAEGLDTQRFSGKRLGDTFVLTLSDFRRENEGYYFCSALSNSIMYFSHFVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRRRVCKCPRPVVKSGDKPSLSARYV
T20978	DRUGINFO	D0C8AL	Fluoropeptide vaccine	Phase 2
T20978	DRUGINFO	D0U6BQ	Anti-VEGFR2 CD8 cell therapy	Phase 1/2
T20978	DRUGINFO	D0T7LV	LIPO-4	Phase 1

T99557	TARGETID	T99557
T99557	UNIPROID	TRBC1_HUMAN
T99557	TARGNAME	T-cell receptor beta constant 1 (TRBC1)
T99557	GENENAME	TRBC1
T99557	TARGTYPE	Clinical trial
T99557	SYNONYMS	TCRBC1; BV05S1J2.2
T99557	FUNCTION	Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens. Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn, ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation. The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity. Constant region of T cell receptor (TR) alpha chain.
T99557	PDBSTRUC	4ZDH; 4X6D; 4X6C; 4X6B; 4PRP
T99557	SEQUENCE	DLNKVFPPEVAVFEPSEAEISHTQKATLVCLATGFFPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSVSYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDF
T99557	DRUGINFO	D01MDX	TRBC1	Phase 1/2

T97036	TARGETID	T97036
T97036	FORMERID	TTDI00662
T97036	UNIPROID	FETUA_HUMAN
T97036	TARGNAME	Connecting peptide (C-peptide)
T97036	GENENAME	AHSG
T97036	TARGTYPE	Clinical trial
T97036	SYNONYMS	Fetuin-A; Alpha-2-Z-globulin; Alpha-2-HS-glycoprotein chainB; Alpha-2-HS-glycoprotein (301-340); AHSG
T97036	FUNCTION	Promotes endocytosis, possesses opsonic properties and influences the mineral phase of bone. Shows affinity for calcium and barium ions.
T97036	BIOCLASS	Fetuin family
T97036	SEQUENCE	LAAPPGHQLHRAHYDLRHTFMGVVSLGSPSGEVSHPRKTR
T97036	DRUGINFO	D0N3BB	CBX-129801	Phase 2

T15107	TARGETID	T15107
T15107	FORMERID	TTDI02213
T15107	UNIPROID	POL_HV1B1
T15107	TARGNAME	Human immunodeficiency virus Nucleocapsid p7 (HIV p7)
T15107	GENENAME	HIV p7
T15107	TARGTYPE	Clinical trial
T15107	SYNONYMS	HIV NC
T15107	FUNCTION	Gag-Pol polyprotein: Mediates, with Gag polyprotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi). Gag-Pol polyprotein may regulate its own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, the polyprotein would promote translation, whereas at high concentration, the polyprotein would encapsidate genomic RNA and then shut off translation.
T15107	PDBSTRUC	6OE3; 6HAK; 6ELI; 6DUH; 6DUG
T15107	SEQUENCE	MQRGNFRNQRKMVKCFNCGKEGHTARNCRAPRKKGCWKCGKEGHQMKDCTERQAN
T15107	DRUGINFO	D0A0SK	HPH-116	Phase 2

T57654	TARGETID	T57654
T57654	FORMERID	TTDI01738
T57654	UNIPROID	PB2_I34A1
T57654	TARGNAME	Influenza Polymerase basic protein 2 (Influ PB2)
T57654	GENENAME	Influ PB2
T57654	TARGTYPE	Clinical trial
T57654	SYNONYMS	RNA-directed RNA polymerase subunit P3; Polymerase basic protein 2
T57654	FUNCTION	Plays an essential role in transcription initiation and cap-stealing mechanism, in which cellular capped pre-mRNAs are used to generate primers for viral transcription. Recognizes and binds the 7-methylguanosine-containing cap of the target pre-RNA which is subsequently cleaved after 10-13 nucleotides by the viral protein PA. Plays a role in the initiation of the viral genome replication and modulates the activity of the ribonucleoprotein (RNP) complex. In addition, participates in the inhibition of type I interferon induction through interaction with and inhibition of the host mitochondrial antiviral signaling protein MAVS.
T57654	PDBSTRUC	4U6O; 4J2R; 4ENF; 3WI1; 3WI0
T57654	SEQUENCE	MERIKELRNLMSQSRTREILTKTTVDHMAIIKKYTSGRQEKNPALRMKWMMAMKYPITADKRITEMIPERNEQGQTLWSKMNDAGSDRVMVSPLAVTWWNRNGPITNTVHYPKIYKTYFERVERLKHGTFGPVHFRNQVKIRRRVDINPGHADLSAKEAQDVIMEVVFPNEVGARILTSESQLTITKEKKEELQDCKISPLMVAYMLERELVRKTRFLPVAGGTSSVYIEVLHLTQGTCWEQMYTPGGEVRNDDVDQSLIIAARNIVRRAAVSADPLASLLEMCHSTQIGGIRMVDILRQNPTEEQAVDICKAAMGLRISSSFSFGGFTFKRTSGSSVKREEEVLTGNLQTLKIRVHEGYEEFTMVGRRATAILRKATRRLIQLIVSGRDEQSIAEAIIVAMVFSQEDCMIKAVRGDLNFVNRANQRLNPMHQLLRHFQKDAKVLFQNWGVEPIDNVMGMIGILPDMTPSIEMSMRGVRISKMGVDEYSSTERVVVSIDRFLRIRDQRGNVLLSPEEVSETQGTEKLTITYSSSMMWEINGPESVLVNTYQWIIRNWETVKIQWSQNPTMLYNKMEFEPFQSLVPKAIRGQYSGFVRTLFQQMRDVLGTFDTAQIIKLLPFAAAPPKQSRMQFSSFTVNVRGSGMRILVRGNSPVFNYNKATKRLTVLGKDAGTLTEDPDEGTAGVESAVLRGFLILGKEDKRYGPALSINELSNLAKGEKANVLIGQGDVVLVMKRKRDSSILTDSQTATKRIRMAIN
T57654	DRUGINFO	D08DHN	VX-787	Phase 3

T02591	TARGETID	T02591
T02591	FORMERID	TTDI01959
T02591	UNIPROID	ENV_HV1H2
T02591	TARGNAME	Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env)
T02591	GENENAME	HIV env
T02591	TARGTYPE	Clinical trial
T02591	SYNONYMS	Envelope glycoprotein gp160; Env polyprotein
T02591	FUNCTION	Envelope glycoprotein gp160: Oligomerizes in the host endoplasmic reticulum into predominantly trimers. In a second time, gp160 transits in the host Golgi, where glycosylation is completed. The precursor is then proteolytically cleaved in the trans-Golgi and thereby activated by cellular furin or furin-like proteases to produce gp120 and gp41.
T02591	PDBSTRUC	6DLN; 6DE7; 6BXQ; 6BXP; 6B9K
T02591	SEQUENCE	MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVVLVNVTENFNMWKNDMVEQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTNTNSSSGRMIMEKGEIKNCSFNISTSIRGKVQKEYAFFYKLDIIPIDNDTTSYKLTSCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSVNFTDNAKTIIVQLNTSVEINCTRPNNNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKLREQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNSTWSTEGSNNTEGSDTITLPCRIKQIINMWQKVGKAMYAPPISGQIRCSSNITGLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTKAKRRVVQREKRAVGIGALFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLEQIWNHTTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNWLWYIKLFIMIVGGLVGLRIVFAVLSIVNRVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDRDRSIRLVNGSLALIWDDLRSLCLFSYHRLRDLLLIVTRIVELLGRRGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEVVQGACRAIRHIPRRIRQGLERILL
T02591	DRUGINFO	D0G7LC	PENNVAX-6	Phase 1
T02591	DRUGINFO	D0OX1Y	Ad5-ENVA-48	Phase 1
T02591	DRUGINFO	D0W1MU	TBC-M4	Phase 1
T02591	DRUGINFO	DRI97M	MGD014	Phase 1
T02591	DRUGINFO	D09ZKB	Ad35-GRIN/ENV	Phase 1
T02591	DRUGINFO	D0A9JW	GPG	Discontinued in Phase 1/2

T00420	TARGETID	T00420
T00420	FORMERID	TTDI02157
T00420	UNIPROID	REV_HV1H2
T00420	TARGNAME	Human immunodeficiency virus Rev protein (HIV rev)
T00420	GENENAME	HIV rev
T00420	TARGTYPE	Clinical trial
T00420	SYNONYMS	rev; Regulator of expression of viral proteins; Anti-repression transactivator; ART/TRS
T00420	FUNCTION	Escorts unspliced or incompletely spliced viral pre- mRNAs (late transcripts) out of the nucleus of infected cells. These pre-mRNAs carry a recognition sequence called Rev responsive element (RRE) located in the env gene, that is not present in fully spliced viral mRNAs (early transcripts). This function is essential since most viral proteins are translated from unspliced or partially spliced pre-mRNAs which cannot exit the nucleus by the pathway used by fully processed cellular mRNAs. Rev itself is translated from a fully spliced mRNA that readily exits the nucleus. Rev's nuclear localization signal (NLS) bindsdirectly to KPNB1/Importin beta-1 without previous binding to KPNA1/Importin alpha-1. KPNB1 binds to the GDP bound form of RAN (Ran-GDP) and targets Rev to the nucleus. In the nucleus, the conversionfrom Ran-GDP to Ran-GTP dissociates Rev from KPNB1 and allows Rev's binding to the RRE in viral pre-mRNAs. Rev multimerization on the RRE via cooperative assembly exposes its nuclear export signal (NES) to the surface. Rev can then form a complex with XPO1/CRM1 and Ran-GTP, leading to nuclear export of the complex. Conversion from Ran-GTP to Ran-GDP mediates dissociation of the Rev/RRE/XPO1/RAN complex, so that Rev can return to the nucleus for a subsequent round of export. Beside KPNB1, also seems to interact with TNPO1/Transportin-1, RANBP5/IPO5 and IPO7/RANBP7 for nuclear import. The nucleoporin-like HRB/RIP is an essential cofactor that probably indirectly interacts with Rev to release HIV RNAs from the perinuclear region to the cytoplasm. Interacts with DDX1; the interaction is necessary for proper subcellular localization of this protein.
T00420	SEQUENCE	MAGRSGDSDEELIRTVRLIKLLYQSNPPPNPEGTRQARRNRRRRWRERQRQIHSISERILGTYLGRSAEPVPLQLPPLERLTLDCNEDCGTSGTQGVGSPQILVESPTVLESGTKE
T00420	DRUGINFO	D0N2GQ	ATI-0917	Phase 1
T00420	DRUGINFO	D09ZKB	Ad35-GRIN/ENV	Phase 1

T60930	TARGETID	T60930
T60930	FORMERID	TTDI02228
T60930	UNIPROID	IGF1_HUMAN
T60930	TARGNAME	Insulin-like growth factor-I (IGF1)
T60930	GENENAME	IGF1
T60930	TARGTYPE	Clinical trial
T60930	SYNONYMS	SomatomedinC; Somatomedin-C; Mechano growth factor; Insulin-like growth factor I; IGFI; IGF-I
T60930	FUNCTION	May be a physiological regulator of [1-14C]-2-deoxy-D-glucose (2DG) transport and glycogen synthesis in osteoblasts. Stimulates glucose transport in bone-derived osteoblastic (PyMS) cells and is effective at much lower concentrations than insulin, not only regarding glycogen and DNA synthesis but also with regard to enhancing glucose uptake. May play a role in synapse maturation. Ca(2+)-dependent exocytosis of IGF1 is required for sensory perception of smell in the olfactory bulb. Acts as a ligand for IGF1R. Binds to the alpha subunit of IGF1R, leading to the activation of the intrinsic tyrosine kinase activity which autophosphorylates tyrosine residues in the beta subunit thus initiatiating a cascade of down-stream signaling events leading to activation of the PI3K-AKT/PKB and the Ras-MAPK pathways. Binds to integrins ITGAV:ITGB3 and ITGA6:ITGB4. Its binding to integrins and subsequent ternary complex formation with integrins and IGFR1 are essential for IGF1 signaling. Induces the phosphorylation and activation of IGFR1, MAPK3/ERK1, MAPK1/ERK2 and AKT1. The insulin-like growth factors, isolated from plasma, are structurally and functionally related to insulin but have a much higher growth-promoting activity.
T60930	PDBSTRUC	6FF3; 5U8Q; 4XSS; 3LRI; 3GF1
T60930	SEQUENCE	MGKISSLPTQLFKCCFCDFLKVKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSARSVRAQRHTDMPKTQKYQPPSTNKNTKSQRRKGWPKTHPGGEQKEGTEASLQIRGKKKEQRREIGSRNAECRGKKGK
T60930	DRUGINFO	D04DNB	Xentuzumab	Phase 2
T60930	DRUGINFO	D0F2IM	MEDI-573	Phase 1
T60930	DRUGINFO	D0X4KN	BI-836845	Phase 1

T45151	TARGETID	T45151
T45151	FORMERID	TTDI01754
T45151	UNIPROID	PAI1_HUMAN; PAI2_HUMAN; IPSP_HUMAN
T45151	TARGNAME	Plasminogen activator inhibitor (PAI)
T45151	GENENAME	SERPINE1; SERPINB2; SERPINA5
T45151	TARGTYPE	Clinical trial
T45151	SYNONYMS	Serpin; PAI
T45151	FUNCTION	Serine protease inhibitor. This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation offibrinolysis.
T45151	SEQUENCE	MQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPYGVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAIFVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAVDQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPDGHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPKFSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASSSTAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP
T45151	DRUGINFO	D0JI2E	Aleplasinin	Phase 1
T45151	DRUGINFO	D07MWY	XR-1853	Terminated
T45151	DRUGINFO	D08EIX	T-686	Terminated
T45151	DRUGINFO	D0J9JQ	XR-5082	Terminated
T45151	DRUGINFO	D0Z0KE	BX-044	Terminated

T71141	TARGETID	T71141
T71141	FORMERID	TTDI01813
T71141	UNIPROID	ITAV_HUMAN-ITB6_HUMAN
T71141	TARGNAME	Integrin alpha-V/beta-6 (ITGAV/B6)
T71141	GENENAME	ITGAV-ITGB6
T71141	TARGTYPE	Clinical trial
T71141	SYNONYMS	alpha(V)beta(6) integrin; Alpha V beta 6 integrin
T71141	FUNCTION	It is expressed exclusively on subsets of epithelial cells, especially during development, after injury or inflammation, or on many carcinomas.
T71141	BIOCLASS	Integrin
T71141	SEQUENCE	MGIELLCLFFLFLGRNDHVQGGCALGGAETCEDCLLIGPQCAWCAQENFTHPSGVGERCDTPANLLAKGCQLNFIENPVSQVEILKNKPLSVGRQKNSSDIVQIAPQSLILKLRPGGAQTLQVHVRQTEDYPVDLYYLMDLSASMDDDLNTIKELGSRLSKEMSKLTSNFRLGFGSFVEKPVSPFVKTTPEEIANPCSSIPYFCLPTFGFKHILPLTNDAERFNEIVKNQKISANIDTPEGGFDAIMQAAVCKEKIGWRNDSLHLLVFVSDADSHFGMDSKLAGIVIPNDGLCHLDSKNEYSMSTVLEYPTIGQLIDKLVQNNVLLIFAVTQEQVHLYENYAKLIPGATVGLLQKDSGNILQLIISAYEELRSEVELEVLGDTEGLNLSFTAICNNGTLFQHQKKCSHMKVGDTASFSVTVNIPHCERRSRHIIIKPVGLGDALELLVSPECNCDCQKEVEVNSSKCHHGNGSFQCGVCACHPGHMGPRCECGEDMLSTDSCKEAPDHPSCSGRGDCYCGQCICHLSPYGNIYGPYCQCDNFSCVRHKGLLCGGNGDCDCGECVCRSGWTGEYCNCTTSTDSCVSEDGVLCSGRGDCVCGKCVCTNPGASGPTCERCPTCGDPCNSKRSCIECHLSAAGQAREECVDKCKLAGATISEEEDFSKDGSVSCSLQGENECLITFLITTDNEGKTIIHSINEKDCPKPPNIPMIMLGVSLAILLIGVVLLCIWKLLVSFHDRKEVAKFEAERSKAKWQTGTNPLYRGSTSTFKNVTYKHREKQKVDLSTDCMAFPPRRRLRLGPRGLPLLLSGLLLPLCRAFNLDVDSPAEYSGPEGSYFGFAVDFFVPSASSRMFLLVGAPKANTTQPGIVEGGQVLKCDWSSTRRCQPIEFDATGNRDYAKDDPLEFKSHQWFGASVRSKQDKILACAPLYHWRTEMKQEREPVGTCFLQDGTKTVEYAPCRSQDIDADGQGFCQGGFSIDFTKADRVLLGGPGSFYWQGQLISDQVAEIVSKYDPNVYSIKYNNQLATRTAQAIFDDSYLGYSVAVGDFNGDGIDDFVSGVPRAARTLGMVYIYDGKNMSSLYNFTGEQMAAYFGFSVAATDINGDDYADVFIGAPLFMDRGSDGKLQEVGQVSVSLQRASGDFQTTKLNGFEVFARFGSAIAPLGDLDQDGFNDIAIAAPYGGEDKKGIVYIFNGRSTGLNAVPSQILEGQWAARSMPPSFGYSMKGATDIDKNGYPDLIVGAFGVDRAILYRARPVITVNAGLEVYPSILNQDNKTCSLPGTALKVSCFNVRFCLKADGKGVLPRKLNFQVELLLDKLKQKGAIRRALFLYSRSPSHSKNMTISRGGLMQCEELIAYLRDESEFRDKLTPITIFMEYRLDYRTAADTTGLQPILNQFTPANISRQAHILLDCGEDNVCKPKLEVSVDSDQKKIYIGDDNPLTLIVKAQNQGEGAYEAELIVSIPLQADFIGVVRNNEALARLSCAFKTENQTRQVVCDLGNPMKAGTQLLAGLRFSVHQQSEMDTSVKFDLQIQSSNLFDKVSPVVSHKVDLAVLAAVEIRGVSSPDHVFLPIPNWEHKENPETEEDVGPVVQHIYELRNNGPSSFSKAMLHLQWPYKYNNNTLLYILHYDIDGPMNCTSDMEINPLRIKISSLQTTEKNDTVAGQGERDHLITKRDLALSEGDIHTLGCGVAQCLKIVCQVGRLDRGKSAILYVKSLLWTETFMNKENQNHSYSLKSSASFNVIEFPYKNLPIEDITNSTLVTTNVTWGIQPAPMPVPVWVIILAVLAGLLLLAVLVFVMYRMGFFKRVRPPQEEQEREQLQPHENGEGNSET
T71141	DRUGINFO	D0WL4D	STX-100	Phase 2
T71141	DRUGINFO	D3MG8W	PLN-74809	Phase 2
T71141	DRUGINFO	D0ALN1	CWHM-12	Preclinical

T61544	TARGETID	T61544
T61544	FORMERID	TTDI02178
T61544	UNIPROID	SP1_HUMAN
T61544	TARGNAME	Transcription factor Sp1 (SP1)
T61544	GENENAME	SP1
T61544	TARGTYPE	Clinical trial
T61544	SYNONYMS	TSFP1
T61544	FUNCTION	Transcription factor that can activate or repress transcription in response to physiological and pathological stimuli. Binds with high affinity to GC-rich motifs and regulates the expression of a large number of genes involved in a variety of processes such as cell growth, apoptosis, differentiation and immune responses. Highly regulated by post-translational modifications (phosphorylations, sumoylation, proteolytic cleavage, glycosylation and acetylation). Binds also the PDGFR-alpha G-box promoter. May have a role in modulating the cellular response to DNA damage. Implicated in chromatin remodeling. Plays an essential role in the regulation of FE65 gene expression. In complex with ATF7IP, maintains telomerase activity in cancer cells by inducing TERT and TERC gene expression. Isoform 3 is a stronger activator of transcription than isoform 1. Positively regulates the transcription of the core clock component ARNTL/BMAL1. Plays a role in the recruitment of SMARCA4/BRG1 on the c-FOS promoter. Plays a role in protecting cells against oxidative stress following brain injury by regulating the expression of RNF112 (By similarity).
T61544	PDBSTRUC	1VA3; 1VA2; 1VA1; 1SP2; 1SP1
T61544	SEQUENCE	MSDQDHSMDEMTAVVKIEKGVGGNNGGNGNGGGAFSQARSSSTGSSSSTGGGGQESQPSPLALLAATCSRIESPNENSNNSQGPSQSGGTGELDLTATQLSQGANGWQIISSSSGATPTSKEQSGSSTNGSNGSESSKNRTVSGGQYVVAAAPNLQNQQVLTGLPGVMPNIQYQVIPQFQTVDGQQLQFAATGAQVQQDGSGQIQIIPGANQQIITNRGSGGNIIAAMPNLLQQAVPLQGLANNVLSGQTQYVTNVPVALNGNITLLPVNSVSAATLTPSSQAVTISSSGSQESGSQPVTSGTTISSASLVSSQASSSSFFTNANSYSTTTTTSNMGIMNFTTSGSSGTNSQGQTPQRVSGLQGSDALNIQQNQTSGGSLQAGQQKEGEQNQQTQQQQILIQPQLVQGGQALQALQAAPLSGQTFTTQAISQETLQNLQLQAVPNSGPIIIRTPTVGPNGQVSWQTLQLQNLQVQNPQAQTITLAPMQGVSLGQTSSSNTTLTPIASAASIPAGTVTVNAAQLSSMPGLQTINLSALGTSGIQVHPIQGLPLAIANAPGDHGAQLGLHGAGGDGIHDDTAGGEEGENSPDAQPQAGRRTRREACTCPYCKDSEGRGSGDPGKKKQHICHIQGCGKVYGKTSHLRAHLRWHTGERPFMCTWSYCGKRFTRSDELQRHKRTHTGEKKFACPECPKRFMRSDHLSKHIKTHQNKKGGPGVALSVGTLPLDSGAGSEGSGTATPSALITTNMVAMEAICPEGIARLANSGINVMQVADLQSINISGNGF
T61544	DRUGINFO	D00UDP	Terameprocol	Phase 2

T96837	TARGETID	T96837
T96837	UNIPROID	IGG1_HUMAN
T96837	TARGNAME	Immunoglobulin gamma-1 heavy NIE (NIE)
T96837	GENENAME	NIE
T96837	TARGTYPE	Clinical trial
T96837	SYNONYMS	Immunoglobulin gamma-1 heavy chain NIE
T96837	FUNCTION	Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170).
T96837	PDBSTRUC	6OGE; 6N35; 6N32; 6N2X; 6MUB
T96837	SEQUENCE	QVQLVQSGGGVVQPGRSLRLSCAASGFTFSRYTIHWVRQAPGKGLEWVAVMSYNGNNKHYADSVNGRFTISRNDSKNTLYLNMNSLRPEDTAVYYCARIRDTAMFFAHWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
T96837	DRUGINFO	D0B0VD	MORAb-022	Phase 1

T02779	TARGETID	T02779
T02779	FORMERID	TTDI01538
T02779	UNIPROID	DMD_HUMAN
T02779	TARGNAME	Dystrophin nonsense mutant (DMD)
T02779	GENENAME	DMD
T02779	TARGTYPE	Clinical trial
T02779	SYNONYMS	MRX85 nonsense mutant; DXS272 nonsense mutant; DXS270 nonsense mutant; DXS269 nonsense mutant; DXS268 nonsense mutant; DXS239 nonsense mutant; DXS230 nonsense mutant; DXS206 nonsense mutant; DXS164 nonsense mutant; DXS142 nonsense mutant; CMD3B nonsense mutant; BMD nonsense mutant
T02779	FUNCTION	Ligand for dystroglycan. Component of the dystrophin-associated glycoprotein complex which accumulates at the neuromuscular junction (NMJ) and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma. Also implicated in signaling events and synaptic transmission. Anchors the extracellular matrix to the cytoskeleton via F-actin.
T02779	PDBSTRUC	3UUN; 1EG4; 1EG3; 1DXX
T02779	SEQUENCE	MLWWEEVEDCYEREDVQKKTFTKWVNAQFSKFGKQHIENLFSDLQDGRRLLDLLEGLTGQKLPKEKGSTRVHALNNVNKALRVLQNNNVDLVNIGSTDIVDGNHKLTLGLIWNIILHWQVKNVMKNIMAGLQQTNSEKILLSWVRQSTRNYPQVNVINFTTSWSDGLALNALIHSHRPDLFDWNSVVCQQSATQRLEHAFNIARYQLGIEKLLDPEDVDTTYPDKKSILMYITSLFQVLPQQVSIEAIQEVEMLPRPPKVTKEEHFQLHHQMHYSQQITVSLAQGYERTSSPKPRFKSYAYTQAAYVTTSDPTRSPFPSQHLEAPEDKSFGSSLMESEVNLDRYQTALEEVLSWLLSAEDTLQAQGEISNDVEVVKDQFHTHEGYMMDLTAHQGRVGNILQLGSKLIGTGKLSEDEETEVQEQMNLLNSRWECLRVASMEKQSNLHRVLMDLQNQKLKELNDWLTKTEERTRKMEEEPLGPDLEDLKRQVQQHKVLQEDLEQEQVRVNSLTHMVVVVDESSGDHATAALEEQLKVLGDRWANICRWTEDRWVLLQDILLKWQRLTEEQCLFSAWLSEKEDAVNKIHTTGFKDQNEMLSSLQKLAVLKADLEKKKQSMGKLYSLKQDLLSTLKNKSVTQKTEAWLDNFARCWDNLVQKLEKSTAQISQAVTTTQPSLTQTTVMETVTTVTTREQILVKHAQEELPPPPPQKKRQITVDSEIRKRLDVDITELHSWITRSEAVLQSPEFAIFRKEGNFSDLKEKVNAIEREKAEKFRKLQDASRSAQALVEQMVNEGVNADSIKQASEQLNSRWIEFCQLLSERLNWLEYQNNIIAFYNQLQQLEQMTTTAENWLKIQPTTPSEPTAIKSQLKICKDEVNRLSDLQPQIERLKIQSIALKEKGQGPMFLDADFVAFTNHFKQVFSDVQAREKELQTIFDTLPPMRYQETMSAIRTWVQQSETKLSIPQLSVTDYEIMEQRLGELQALQSSLQEQQSGLYYLSTTVKEMSKKAPSEISRKYQSEFEEIEGRWKKLSSQLVEHCQKLEEQMNKLRKIQNHIQTLKKWMAEVDVFLKEEWPALGDSEILKKQLKQCRLLVSDIQTIQPSLNSVNEGGQKIKNEAEPEFASRLETELKELNTQWDHMCQQVYARKEALKGGLEKTVSLQKDLSEMHEWMTQAEEEYLERDFEYKTPDELQKAVEEMKRAKEEAQQKEAKVKLLTESVNSVIAQAPPVAQEALKKELETLTTNYQWLCTRLNGKCKTLEEVWACWHELLSYLEKANKWLNEVEFKLKTTENIPGGAEEISEVLDSLENLMRHSEDNPNQIRILAQTLTDGGVMDELINEELETFNSRWRELHEEAVRRQKLLEQSIQSAQETEKSLHLIQESLTFIDKQLAAYIADKVDAAQMPQEAQKIQSDLTSHEISLEEMKKHNQGKEAAQRVLSQIDVAQKKLQDVSMKFRLFQKPANFEQRLQESKMILDEVKMHLPALETKSVEQEVVQSQLNHCVNLYKSLSEVKSEVEMVIKTGRQIVQKKQTENPKELDERVTALKLHYNELGAKVTERKQQLEKCLKLSRKMRKEMNVLTEWLAATDMELTKRSAVEGMPSNLDSEVAWGKATQKEIEKQKVHLKSITEVGEALKTVLGKKETLVEDKLSLLNSNWIAVTSRAEEWLNLLLEYQKHMETFDQNVDHITKWIIQADTLLDESEKKKPQQKEDVLKRLKAELNDIRPKVDSTRDQAANLMANRGDHCRKLVEPQISELNHRFAAISHRIKTGKASIPLKELEQFNSDIQKLLEPLEAEIQQGVNLKEEDFNKDMNEDNEGTVKELLQRGDNLQQRITDERKREEIKIKQQLLQTKHNALKDLRSQRRKKALEISHQWYQYKRQADDLLKCLDDIEKKLASLPEPRDERKIKEIDRELQKKKEELNAVRRQAEGLSEDGAAMAVEPTQIQLSKRWREIESKFAQFRRLNFAQIHTVREETMMVMTEDMPLEISYVPSTYLTEITHVSQALLEVEQLLNAPDLCAKDFEDLFKQEESLKNIKDSLQQSSGRIDIIHSKKTAALQSATPVERVKLQEALSQLDFQWEKVNKMYKDRQGRFDRSVEKWRRFHYDIKIFNQWLTEAEQFLRKTQIPENWEHAKYKWYLKELQDGIGQRQTVVRTLNATGEEIIQQSSKTDASILQEKLGSLNLRWQEVCKQLSDRKKRLEEQKNILSEFQRDLNEFVLWLEEADNIASIPLEPGKEQQLKEKLEQVKLLVEELPLRQGILKQLNETGGPVLVSAPISPEEQDKLENKLKQTNLQWIKVSRALPEKQGEIEAQIKDLGQLEKKLEDLEEQLNHLLLWLSPIRNQLEIYNQPNQEGPFDVKETEIAVQAKQPDVEEILSKGQHLYKEKPATQPVKRKLEDLSSEWKAVNRLLQELRAKQPDLAPGLTTIGASPTQTVTLVTQPVVTKETAISKLEMPSSLMLEVPALADFNRAWTELTDWLSLLDQVIKSQRVMVGDLEDINEMIIKQKATMQDLEQRRPQLEELITAAQNLKNKTSNQEARTIITDRIERIQNQWDEVQEHLQNRRQQLNEMLKDSTQWLEAKEEAEQVLGQARAKLESWKEGPYTVDAIQKKITETKQLAKDLRQWQTNVDVANDLALKLLRDYSADDTRKVHMITENINASWRSIHKRVSEREAALEETHRLLQQFPLDLEKFLAWLTEAETTANVLQDATRKERLLEDSKGVKELMKQWQDLQGEIEAHTDVYHNLDENSQKILRSLEGSDDAVLLQRRLDNMNFKWSELRKKSLNIRSHLEASSDQWKRLHLSLQELLVWLQLKDDELSRQAPIGGDFPAVQKQNDVHRAFKRELKTKEPVIMSTLETVRIFLTEQPLEGLEKLYQEPRELPPEERAQNVTRLLRKQAEEVNTEWEKLNLHSADWQRKIDETLERLQELQEATDELDLKLRQAEVIKGSWQPVGDLLIDSLQDHLEKVKALRGEIAPLKENVSHVNDLARQLTTLGIQLSPYNLSTLEDLNTRWKLLQVAVEDRVRQLHEAHRDFGPASQHFLSTSVQGPWERAISPNKVPYYINHETQTTCWDHPKMTELYQSLADLNNVRFSAYRTAMKLRRLQKALCLDLLSLSAACDALDQHNLKQNDQPMDILQIINCLTTIYDRLEQEHNNLVNVPLCVDMCLNWLLNVYDTGRTGRIRVLSFKTGIISLCKAHLEDKYRYLFKQVASSTGFCDQRRLGLLLHDSIQIPRQLGEVASFGGSNIEPSVRSCFQFANNKPEIEAALFLDWMRLEPQSMVWLPVLHRVAAAETAKHQAKCNICKECPIIGFRYRSLKHFNYDICQSCFFSGRVAKGHKMHYPMVEYCTPTTSGEDVRDFAKVLKNKFRTKRYFAKHPRMGYLPVQTVLEGDNMETPVTLINFWPVDSAPASSPQLSHDDTHSRIEHYASRLAEMENSNGSYLNDSISPNESIDDEHLLIQHYCQSLNQDSPLSQPRSPAQILISLESEERGELERILADLEEENRNLQAEYDRLKQQHEHKGLSPLPSPPEMMPTSPQSPRDAELIAEAKLLRQHKGRLEARMQILEDHNKQLESQLHRLRQLLEQPQAEAKVNGTTVSSPSTSLQRSDSSQPMLLRVVGSQTSDSMGEEDLLSPPQDTSTGLEEVMEQLNNSFPSSRGRNTPGKPMREDTM
T02779	DRUGINFO	D09IRQ	Ataluren	Phase 3

T70532	TARGETID	T70532
T70532	FORMERID	TTDI00106
T70532	UNIPROID	NCK1_HUMAN
T70532	TARGNAME	NCK adaptor protein 1 (NCK1)
T70532	GENENAME	NCK1
T70532	TARGTYPE	Clinical trial
T70532	SYNONYMS	SH2/SH3 adaptor protein NCKalpha; SH2/SH3 adaptor protein NCK-alpha; Nck1; Nck-1; NCK; Cytoplasmic protein NCK1
T70532	FUNCTION	Maintains low levels of EIF2S1 phosphorylation by promoting its dephosphorylation by PP1. Plays a role in the DNA damage response, not in the detection of the damage by ATM/ATR, but for efficient activation of downstream effectors, such as that of CHEK2. Plays a role in ELK1-dependent transcriptional activation in response to activated Ras signaling. Modulates the activation of EIF2AK2/PKR by dsRNA. May play a role in cell adhesion and migration through interaction with ephrin receptors. Adapter protein which associates with tyrosine-phosphorylated growth factor receptors, such as KDR and PDGFRB, or their cellular substrates.
T70532	PDBSTRUC	2JW4; 2JS2; 2JS0; 2CUB; 2CI9
T70532	SEQUENCE	MAEEVVVVAKFDYVAQQEQELDIKKNERLWLLDDSKSWWRVRNSMNKTGFVPSNYVERKNSARKASIVKNLKDTLGIGKVKRKPSVPDSASPADDSFVDPGERLYDLNMPAYVKFNYMAEREDELSLIKGTKVIVMEKCSDGWWRGSYNGQVGWFPSNYVTEEGDSPLGDHVGSLSEKLAAVVNNLNTGQVLHVVQALYPFSSSNDEELNFEKGDVMDVIEKPENDPEWWKCRKINGMVGLVPKNYVTVMQNNPLTSGLEPSPPQCDYIRPSLTGKFAGNPWYYGKVTRHQAEMALNERGHEGDFLIRDSESSPNDFSVSLKAQGKNKHFKVQLKETVYCIGQRKFSTMEELVEHYKKAPIFTSEQGEKLYLVKHLS
T70532	DRUGINFO	D00JDJ	AX-024	Phase 1

T08884	TARGETID	T08884
T08884	FORMERID	TTDI01713
T08884	UNIPROID	TRAP_PLAFA
T08884	TARGNAME	Plasmodium Thrombospondin relate anonymous protein (Plasm TRAP)
T08884	GENENAME	Plasm TRAP
T08884	TARGTYPE	Clinical trial
T08884	SYNONYMS	Thrombospondin-related anonymous protein
T08884	FUNCTION	A type 1 membrane protein that possesses multiple adhesive domains in its extracellular region. Essential for sporozoite motility and for liver cell invasion. 
T08884	PDBSTRUC	2BBX
T08884	SEQUENCE	MNHLGNVKYLVIVFLIFFDLFLVNGRDVQNNIVDEIKYSEEVCNDQVDLYLLMDCSGSIRRHNWVNHAVPLAMKLIQQLNLNDNAIHLYVNVFSNNAKEIIRLHSDASKNKEKALIIIRSLLSTNLPYGRTNLTDALLQVRKHLNDRINRENANQLVVILTDGIPDSIQDSLKESRKLSDRGVKIAVFGIGQGINVAFNRFLVGCHPSDGKCNLYADSAWENVKNVIGPFMKAVCVEVEKTASCGVWDEWSPCSVTCGKGTRSRKREILHEGCTSEIQEQCEEERCPPKWEPLDVPDEPEDDQPRPRGDNSSVQKPEENIIDNNPQEPSPNPEEGKDENPNGFDLDENPENPPNPDIPEQKPNIPEDSEKEVPSDVPKNPEDDREENFDIPKKPENKHDNQNNLPNDKSDRNIPYSPLPPKVLDNERKQSDPQSQDNNGNRHVPNSEDRETRPHGRNNENRSYNRKYNDTPKHPEREEHEKPDNNKKKGESDNKYKIAGGIAGGLALLACAGLAYKFVVPGAATPYAGEPAPFDETLGEEDKDLDEPEQFRLPEENEWN
T08884	DRUGINFO	D0K4OF	PlaMavax	Phase 2

T58920	TARGETID	T58920
T58920	UNIPROID	TRH_HUMAN
T58920	TARGNAME	Thyrotropin-releasing hormone (TRH)
T58920	GENENAME	TRH
T58920	TARGTYPE	Clinical trial
T58920	SYNONYMS	Prothyroliberin; Pro-thyrotropin-releasing hormone; Pro-TRH
T58920	FUNCTION	As a component of the hypothalamic-pituitary-thyroid axis, it controls the secretion of thyroid-stimulating hormone (TSH) and is involved in thyroid hormone synthesis regulation. It also operates as modulator of hair growth. It promotes hair-shaft elongation, prolongs the hair cycle growth phase (anagen) and antagonizes its termination (catagen) by TGFB2. It stimulates proliferation and inhibits apoptosis of hair matrix keratinocytes.
T58920	SEQUENCE	MPGPWLLLALALTLNLTGVPGGRAQPEAAQQEAVTAAEHPGLDDFLRQVERLLFLRENIQRLQGDQGEHSASQIFQSDWLSKRQHPGKREEEEEEGVEEEEEEEGGAVGPHKRQHPGRREDEASWSVDVTQHKRQHPGRRSPWLAYAVPKRQHPGRRLADPKAQRSWEEEEEEEEREEDLMPEKRQHPGKRALGGPCGPQGAYGQAGLLLGLLDDLSRSQGAEEKRQHPGRRAAWVREPLEE
T58920	DRUGINFO	D01WWD	KPS-0373	Phase 3
T58920	DRUGINFO	D01JOJ	RX-77368	Discontinued in Phase 2

T19852	TARGETID	T19852
T19852	UNIPROID	FGF7_HUMAN
T19852	TARGNAME	Keratinocyte growth factor (FGF7)
T19852	GENENAME	FGF7
T19852	TARGTYPE	Clinical trial
T19852	SYNONYMS	KGF; Heparin-binding growth factor 7; HBGF-7; Fibroblast growth factor 7; FGF-7
T19852	FUNCTION	Required for normal branching morphogenesis. Growth factor active on keratinocytes. Possible major paracrine effector of normal epithelial cell proliferation. Plays an important role in the regulation of embryonic development, cell proliferation and cell differentiation.
T19852	BIOCLASS	Growth factor
T19852	SEQUENCE	MHKWILTWILPTLLYRSCFHIICLVGTISLACNDMTPEQMATNVNCSSPERHTRSYDYMEGGDIRVRRLFCRTQWYLRIDKRGKVKGTQEMKNNYNIMEIRTVAVGIVAIKGVESEFYLAMNKEGKLYAKKECNEDCNFKELILENHYNTYASAKWTHNGGEMFVALNQKGIPVRGKKTKKEQKTAHFLPMAIT
T19852	DRUGINFO	D0WA1R	Keratinocyte growth factor	Phase 1

T37876	TARGETID	T37876
T37876	FORMERID	TTDI01627
T37876	UNIPROID	POLG_HRV1A
T37876	TARGNAME	Rhinovirus Capsid protein (HRV VP)
T37876	GENENAME	HRV VP
T37876	TARGTYPE	Clinical trial
T37876	SYNONYMS	Rhinovirus Virion protein
T37876	FUNCTION	Capsid protein VP1: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host cell receptor to provide virion attachment to target host cells. This attachment induces virion internalization. Tyrosine kinases are probably involved in the entry process. After binding to its receptor, the capsid undergoes conformational changes. Capsid protein VP1 N-terminus (that contains an amphipathic alpha-helix) and capsid protein VP4 are externalized. Together, they shape a pore in the host membrane through which viral genome is translocated to host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).
T37876	PDBSTRUC	2HWF; 2HWE; 2HWD; 1R1A; 1AYN
T37876	SEQUENCE	GAQVSRQNVGTHSTQNSVSNGSSLNYFNINYFKDAASSGASRLDFSQDPSKFTDPVKDVLEKGIPTLQSPSVEACGYSDRIMQITRGDSTITSQDVANAVVGYGVWPHYLTPQDATAIDKPTQPDTSSNRFYTLESKHWNGSSKGWWWKLPDALKDMGIFGENMYYHFLGRSGYTVHVQCNASKFHQGTLLVAMIPEHQLASAKHGSVTAGYKLTHPGEAGRDVSQERDASLRQPSDDSWLNFDGTLLGNLLIFPHQFINLRSNNSATLIVPYVNAVPMDSMLRHNNWSLVIIPISPLRSETTSSNIVPITVSISPMCAEFSGARAKNIKQGLPVYITPGSGQFMTTDDMQSPCALPWYHPTKEISIPGEVKNLIEMCQVDTLIPVNNVGNNVGNVSMYTVQLGNQTGMAQKVFSIKVDITSQPLATTLIGEIASYYTHWTGSLRFSFMFCGTANTTLKLLLAYTPPGIDEPTTRKDAMLGTHVVWDVGLQSTISLVVPWVSASHFRLTADNKYSMAGYITCWYQTNLVVPPSTPQTADMLCFVSACKDFCLRMARDTDLHIQSGPIEQNPVENYIDEVLNEVLVVPNIKESHHTTSNSAPLLDAAETGHTSNVQPEDAIETRYVITSQTRDEMSIESFLGRSGCVHISRIKVDYTDYNGQDINFTKWKITLQEMAQIRRKFELFTYVRFDSEITLVPCIAGRGDDIGHIVMQYMYVPPGAPIPSKRNDFSWQSGTNMSIFWQHGQPFPRFSLPFLSIASAYYMFYDGYDGDNTSSKYGSVVTNDMGTICSRIVTEKQKHSVVITTHIYHKAKHTKAWCPRPPRAVPYTHSHVTNYMPETGDVTTAIVRRNTITTA
T37876	DRUGINFO	D0FZ1W	BTA-798	Phase 2
T37876	DRUGINFO	D02GVH	PIRODAVIR	Discontinued in Phase 2

T97759	TARGETID	T97759
T97759	FORMERID	TTDI02215
T97759	UNIPROID	POLG_HCV1
T97759	TARGNAME	Hepatitis C virus Envelope glycoprotein E2 (HCV NS1)
T97759	GENENAME	HCV NS1
T97759	TARGTYPE	Clinical trial
T97759	SYNONYMS	Hepacivirus polyprotein
T97759	FUNCTION	NS5B is an RNA-dependent RNA polymerase that plays an essential role in the virus replication.
T97759	PDBSTRUC	3SU4; 3RC5; 3RC4; 3QGI; 3QGH
T97759	SEQUENCE	ETHVTGGSAGHTVSGFVSLLAPGAKQNVQLINTNGSWHLNSTALNCNDSLNTGWLAGLFYHHKFNSSGCPERLASCRPLTDFDQGWGPISYANGSGPDQRPYCWHYPPKPCGIVPAKSVCGPVYCFTPSPVVVGTTDRSGAPTYSWGENDTDVFVLNNTRPPLGNWFGCTWMNSTGFTKVCGAPPCVIGGAGNNTLHCPTDCFRKHPDATYSRCGSGPWITPRCLVDYPYRLWHYPCTINYTIFKIRMYVGGVEHRLEAACNWTRGERCDLEDRDRSELSPLLLTTTQWQVLPCSFTTLPALSTGLIHLHQNIVDVQYLYGVGSSIASWAIKWEYVVLLFLLLADARVCSCLWMMLLISQAEA
T97759	DRUGINFO	D0T3QU	MBL-HCV1	Phase 2
T97759	DRUGINFO	D0MU1F	XTL-6865	Phase 1
T97759	DRUGINFO	D0CY2Z	HuMax-HepC	Terminated

T34997	TARGETID	T34997
T34997	UNIPROID	POLG_HCV1
T34997	TARGNAME	Hepatitis C virus Serine protease NS4A (HCV NS4A)
T34997	GENENAME	HCV NS4A
T34997	TARGTYPE	Clinical trial
T34997	SYNONYMS	HCV p8
T34997	FUNCTION	Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity).
T34997	PDBSTRUC	3SU4; 3RC5; 3RC4; 3QGI; 3QGH
T34997	SEQUENCE	STWVLVGGVLAALAAYCLSTGCVVIVGRVVLSGKPAIIPDREVLYREFDEMEECSQHLPYIEQGMMLAEQFKQKALGLLQTASRQAEVIAPAVQTNWQKLETFWAKHMWNFISGIQYLAGLSTLPGNPAIASLMAFTAAVTSPLTTSQTLLFNILGGWVAAQLAAPGAATAFVGAGLAGAAIGSVGLGKVLIDILAGYGAGVAGALVAFKIMSGEVPSTEDLVNLLPAILSPGALVVGVVCAAILRRHVGPGEGAVQWMNRLIAFASRGNHVSPTHYVPESDAAARVTAILSSLTVTQLLRRLHQWISSECTTPC
T34997	DRUGINFO	D04ZQO	TG-2349	Phase 2
T34997	DRUGINFO	D02BAW	MK-6325	Phase 1
T34997	DRUGINFO	D07OBJ	PHX-1766	Phase 1
T34997	DRUGINFO	D09VTB	IDX-320	Discontinued in Phase 1/2
T34997	DRUGINFO	D0S7LN	GS-9132	Discontinued in Phase 1/2

T35289	TARGETID	T35289
T35289	FORMERID	TTDI02343
T35289	UNIPROID	NKG2D_HUMAN
T35289	TARGNAME	NKG2 D activating NK receptor (KLRK1)
T35289	GENENAME	KLRK1
T35289	TARGTYPE	Clinical trial
T35289	SYNONYMS	NKG2Dactivating NK receptor; NKG2D type II integral membrane protein; NKG2D; NKG2-D-activating NK receptor; NKG2-D type II integral membrane protein; NK cell receptor D; Killer cell lectinlike receptor subfamily K member 1; Killer cell lectin-like receptor subfamily K member 1; D12S2489E; CD314
T35289	FUNCTION	Provides both stimulatory and costimulatory innate immune responses on activated killer (NK) cells, leading to cytotoxic activity. Acts as a costimulatory receptor for T-cell receptor (TCR) in CD8(+) T-cell-mediated adaptive immune responses by amplifying T-cell activation. Stimulates perforin-mediated elimination of ligand-expressing tumor cells. Signaling involves calcium influx, culminating in the expression of TNF-alpha. Participates in NK cell-mediated bone marrow graft rejection. May play a regulatory role in differentiation and survival of NK cells. Binds to ligands belonging to various subfamilies of MHC class I-related glycoproteins including MICA, MICB, RAET1E, RAET1G, RAET1L/ULBP6, ULBP1, ULBP2, ULBP3 (ULBP2>ULBP1>ULBP3) and ULBP4. Function as an activating and costimulatory receptor involved in immunosurveillance upon binding to various cellular stress-inducible ligands displayed at the surface of autologous tumor cells and virus-infected cells.
T35289	PDBSTRUC	4S0U; 4PDC; 1MPU; 1KCG; 1HYR
T35289	SEQUENCE	MGWIRGRRSRHSWEMSEFHNYNLDLKKSDFSTRWQKQRCPVVKSKCRENASPFFFCCFIAVAMGIRFIIMVAIWSAVFLNSLFNQEVQIPLTESYCGPCPKNWICYKNNCYQFFDESKNWYESQASCMSQNASLLKVYSKEDQDLLKLVKSYHWMGLVHIPTNGSWQWEDGSILSPNLLTIIEMQKGDCALYASSFKGYIENCSTPNTYICMQRTV
T35289	DRUGINFO	D06JUE	NN8555	Phase 2
T35289	DRUGINFO	D08YHE	NKR-2 CAR-T Cells	Phase 1
T35289	DRUGINFO	D0FB4W	CYAD-101	Phase 1
T35289	DRUGINFO	D0NC9M	CM-CS1 T-cell	Phase 1
T35289	DRUGINFO	D0QR2K	NKR-2 cells	Phase 1

T66426	TARGETID	T66426
T66426	FORMERID	TTDI02038
T66426	UNIPROID	CD34_HUMAN
T66426	TARGNAME	Hematopoietic progenitor cell antigen CD34 (CD34)
T66426	GENENAME	CD34
T66426	TARGTYPE	Clinical trial
T66426	SYNONYMS	CD34 molecule
T66426	FUNCTION	Could act as a scaffold for the attachment of lineage specific glycans, allowing stem cells to bind to lectins expressed by stromal cells or other marrow components. Presents carbohydrate ligands to selectins. Possible adhesion molecule with a role in early hematopoiesis by mediating the attachment of stem cells to the bone marrow extracellular matrix or directly to stromal cells.
T66426	SEQUENCE	MLVRRGARAGPRMPRGWTALCLLSLLPSGFMSLDNNGTATPELPTQGTFSNVSTNVSYQETTTPSTLGSTSLHPVSQHGNEATTNITETTVKFTSTSVITSVYGNTNSSVQSQTSVISTVFTTPANVSTPETTLKPSLSPGNVSDLSTTSTSLATSPTKPYTSSSPILSDIKAEIKCSGIREVKLTQGICLEQNKTSSCAEFKKDRGEGLARVLCGEEQADADAGAQVCSLLLAQSEVRPQCLLLVLANRTEISSKLQLMKKHQSDLKKLGILDFTEQDVASHQSYSQKTLIALVTSGALLAVLGITGYFLMNRRSWSPTGERLGEDPYYTENGGGQGYSSGPGTSPEAQGKASVNRGAQENGTGQATSRNGHSARQHVVADTEL
T66426	DRUGINFO	D08GVB	AMR-001	Phase 2
T66426	DRUGINFO	D0NY1Y	CART-34 cells	Phase 1
T66426	DRUGINFO	D08ABX	CAR-T cells targeting CD34	Preclinical

T05351	TARGETID	T05351
T05351	FORMERID	TTDI02121
T05351	UNIPROID	MARCS_HUMAN
T05351	TARGNAME	Myristoylated alanine-rich C-kinase substrate (MARCKS)
T05351	GENENAME	MARCKS
T05351	TARGTYPE	Clinical trial
T05351	SYNONYMS	Protein kinase C substrate, 80 kDa protein, light chain; PRKCSL; PKCSL; Myristoylated alaninerich Ckinase substrate; MACS; 80KL protein; 80K-L protein
T05351	FUNCTION	MARCKS is the most prominent cellular substrate for protein kinase C. This protein binds calmodulin, actin, and synapsin. MARCKS is a filamentous (F) actin cross-linking protein.
T05351	SEQUENCE	MGAQFSKTAAKGEAAAERPGEAAVASSPSKANGQENGHVKVNGDASPAAAESGAKEELQANGSAPAADKEEPAAAGSGAASPSAAEKGEPAAAAAPEAGASPVEKEAPAEGEAAEPGSPTAAEGEAASAASSTSSPKAEDGATPSPSNETPKKKKKRFSFKKSFKLSGFSFKKNKKEAGEGGEAEAPAAEGGKDEAAGGAAAAAAEAGAASGEQAAAPGEEAAAGEEGAAGGDPQEAKPQEAAVAPEKPPASDETKAAEEPSKVEEKKAEEAGASAAACEAPSAAGPGAPPEQEAAPAEEPAAAAASSACAAPSQEAQPECSPEAPPAEAAE
T05351	DRUGINFO	D0C3XD	BIO-11006	Phase 2
T05351	DRUGINFO	DQM0X1	BIO-11006	Phase 2

T62753	TARGETID	T62753
T62753	FORMERID	TTDI01285
T62753	UNIPROID	AKT1_HUMAN; AKT2_HUMAN; AKT3_HUMAN
T62753	TARGNAME	Phosphorylated protein kinase B (pAKT)
T62753	GENENAME	AKT1; AKT2; AKT3
T62753	TARGTYPE	Clinical trial
T62753	SYNONYMS	RAC-serine/threonine-protein kinase; RAC-PK; Protein kinase B; Protein kinase Akt; PKB
T62753	FUNCTION	AKT kinases are 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3), and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. Phosphorylation of PTPN1 at 'Ser-50' negatively modulates its phosphatase activity preventing dephosphorylation of the insulin receptor and the attenuation of insulin signaling. Phosphorylation of TBC1D4 triggers the binding of this effector to inhibitory 14-3-3 proteins, which is required for insulin-stimulated glucose transport. AKT regulates also the storage of glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity. Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven. AKT regulates also cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related kinase). Phosphorylation of 'Ser-83' decreases MAP3K5 kinase activity stimulated by oxidative stress and thereby prevents apoptosis. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT is involved in the phosphorylation of members of the FOXO factors (Forkhead family of transcription factors), leading to binding of 14-3-3 proteins and cytoplasmic localization. In particular, FOXO1 is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 and FOXO4 are phosphorylated on equivalent sites. AKT has an important role in the regulation of NF-kappa-B-dependent gene transcription and positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein). The phosphorylation of CREB1 induces the binding of accessory proteins that are necessary for the transcription of pro-survival genes such as BCL2 and MCL1. AKT phosphorylates 'Ser-454' on ATP citrate lyase (ACLY), thereby potentially regulating ACLY activity and fatty acid synthesis. Activates the 3B isoform of cyclic nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', resulting in reduced cyclic AMP levels and inhibition of lipolysis. Phosphorylates PIKFYVE on 'Ser-318', which results in increased PI(3)P-5 activity. The Rho GTPase-activating protein DLC1 is another substrate and its phosphorylation is implicated in the regulation cell proliferation and cell growth. AKT plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). AKT mediates the antiapoptotic effects of IGF-I. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. May be involved in the regulation of the placental development. Phosphorylates STK4/MST1 at 'Thr-120' and 'Thr-387' leading to inhibition of its: kinase activity, nuclear translocation, autophosphorylation and ability to phosphorylate FOXO3. Phosphorylates STK3/MST2 at 'Thr-117' and 'Thr-384' leading to inhibition of its: cleavage, kinase activity, autophosphorylation at Thr-180, binding to RASSF1 and nuclear translocation. Phosphorylates SRPK2 and enhances its kinase activity towards SRSF2 and ACIN1 and promotes its nuclear translocation. Phosphorylates RAF1 at 'Ser-259' and negatively regulates its activity. Phosphorylation of BAD stimulates its pro-apoptotic activity. Phosphorylates KAT6A at 'Thr-369' and this phosphorylation inhibits the interaction of KAT6A with PML and negatively regulates its acetylation activity towards p53/TP53.
T62753	BIOCLASS	Kinase
T62753	SEQUENCE	MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA
T62753	DRUGINFO	D0F5VX	MNX-100	Phase 2

T09528	TARGETID	T09528
T09528	FORMERID	TTDR00287
T09528	UNIPROID	CXCR5_HUMAN
T09528	TARGNAME	C-X-C chemokine receptor type 5 (CXCR5)
T09528	GENENAME	CXCR5
T09528	TARGTYPE	Clinical trial
T09528	SYNONYMS	Monocyte-derived receptor15; Monocyte-derived receptor 15; MDR15; MDR-15; Chemokine receptor CXCR5; CXCR-5; CXC-R5; CD185; Burkitt'S lymphoma receptor 1; Burkitt lymphoma receptor 1; BLR1
T09528	FUNCTION	Involved in B-cell migration into B-cell follicles of spleen and Peyer patches but not into those of mesenteric or peripheral lymph nodes. May have a regulatory function in Burkitt lymphoma (BL) lymphomagenesis and/or B-cell differentiation. Cytokine receptor that binds to B-lymphocyte chemoattractant (BLC).
T09528	BIOCLASS	GPCR rhodopsin
T09528	SEQUENCE	MNYPLTLEMDLENLEDLFWELDRLDNYNDTSLVENHLCPATEGPLMASFKAVFVPVAYSLIFLLGVIGNVLVLVILERHRQTRSSTETFLFHLAVADLLLVFILPFAVAEGSVGWVLGTFLCKTVIALHKVNFYCSSLLLACIAVDRYLAIVHAVHAYRHRRLLSIHITCGTIWLVGFLLALPEILFAKVSQGHHNNSLPRCTFSQENQAETHAWFTSRFLYHVAGFLLPMLVMGWCYVGVVHRLRQAQRRPQRQKAVRVAILVTSIFFLCWSPYHIVIFLDTLARLKAVDNTCKLNGSLPVAITMCEFLGLAHCCLNPMLYTFAGVKFRSDLSRLLTKLGCTGPASLCQLFPSWRRSSLSESENATSLTTF
T09528	DRUGINFO	D2W0LG	PF-06835375	Phase 2
T09528	DRUGINFO	D0T6RG	SAR113244	Phase 1
T09528	DRUGINFO	D82DGN	JT08	Preclinical

T65783	TARGETID	T65783
T65783	FORMERID	TTDR01277
T65783	UNIPROID	APJ_HUMAN
T65783	TARGNAME	Apelin receptor (APLNR)
T65783	GENENAME	APLNR
T65783	TARGTYPE	Clinical trial
T65783	SYNONYMS	G-protein coupled receptor HG11; G-protein coupled receptor APJ; Angiotensin receptor-like 1; APJ; AGTRL1
T65783	FUNCTION	Receptor for apelin receptor early endogenous ligand (APELA) and apelin (APLN) hormones coupled to G proteins that inhibit adenylate cyclase activity. Plays a key role in early development such as gastrulation, blood vessels formation and heart morphogenesis by acting as a receptor for APELA hormone (By similarity). May promote angioblast migration toward the embryonic midline, i.e. the position of the future vessel formation, during vasculogenesis (By similarity). Promotes sinus venosus (SV)-derived endothelial cells migration into the developing heart to promote coronary blood vessel development (By similarity). Plays also a role in various processes in adults such as regulation of blood vessel formation, blood pressure, heart contractility and heart failure.
T65783	PDBSTRUC	5VBL; 2LOW; 2LOV; 2LOU; 2LOT
T65783	SEQUENCE	MEEGGDFDNYYGADNQSECEYTDWKSSGALIPAIYMLVFLLGTTGNGLVLWTVFRSSREKRRSADIFIASLAVADLTFVVTLPLWATYTYRDYDWPFGTFFCKLSSYLIFVNMYASVFCLTGLSFDRYLAIVRPVANARLRLRVSGAVATAVLWVLAALLAMPVMVLRTTGDLENTTKVQCYMDYSMVATVSSEWAWEVGLGVSSTTVGFVVPFTIMLTCYFFIAQTIAGHFRKERIEGLRKRRRLLSIIVVLVVTFALCWMPYHLVKTLYMLGSLLHWPCDFDLFLMNIFPYCTCISYVNSCLNPFLYAFFDPRFRQACTSMLCCGQSRCAGTSHSSSGEKSASYSSGHSQGPGPNMGKGGEQMHEKSIPYSQETLVVD
T65783	DRUGINFO	D0QX9K	AMG 986	Phase 1
T65783	DRUGINFO	D00QYH	apelin-13	Investigative
T65783	DRUGINFO	D05NXX	ML221	Investigative
T65783	DRUGINFO	D0I8TR	ML233	Investigative
T65783	DRUGINFO	D0J6UH	E339-3D6	Investigative

T92185	TARGETID	T92185
T92185	FORMERID	TTDI03440
T92185	UNIPROID	PACR_HUMAN
T92185	TARGNAME	PACAP type I receptor (PAC1R)
T92185	GENENAME	ADCYAP1R1
T92185	TARGTYPE	Clinical trial
T92185	SYNONYMS	Pituitary adenylate cyclase-activating polypeptide type I receptor; PACAP-R1; PACAP-R-1
T92185	FUNCTION	This is a receptor for PACAP-27 and PACAP-38. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. May regulate the release of adrenocorticotropin, luteinizing hormone, growth hormone, prolactin, epinephrine, and catecholamine. May play a role in spermatogenesis and sperm motility. Causes smooth muscle relaxation and secretion in the gastrointestinal tract.
T92185	PDBSTRUC	3N94; 2JOD
T92185	SEQUENCE	MAGVVHVSLAALLLLPMAPAMHSDCIFKKEQAMCLEKIQRANELMGFNDSSPGCPGMWDNITCWKPAHVGEMVLVSCPELFRIFNPDQVWETETIGESDFGDSNSLDLSDMGVVSRNCTEDGWSEPFPHYFDACGFDEYESETGDQDYYYLSVKALYTVGYSTSLVTLTTAMVILCRFRKLHCTRNFIHMNLFVSFMLRAISVFIKDWILYAEQDSNHCFISTVECKAVMVFFHYCVVSNYFWLFIEGLYLFTLLVETFFPERRYFYWYTIIGWGTPTVCVTVWATLRLYFDDTGCWDMNDSTALWWVIKGPVVGSIMVNFVLFIGIIVILVQKLQSPDMGGNESSIYLRLARSTLLLIPLFGIHYTVFAFSPENVSKRERLVFELGLGSFQGFVVAVLYCFLNGEVQAEIKRKWRSWKVNRYFAVDFKHRHPSLASSGVNGGTQLSILSKSSSQIRMSGLPADNLAT
T92185	DRUGINFO	D0CO2W	AMG 301	Phase 2
T92185	DRUGINFO	D0MC5J	PACAP-27	Investigative

T28217	TARGETID	T28217
T28217	FORMERID	TTDI02397
T28217	UNIPROID	KI3L2_HUMAN
T28217	TARGNAME	MHC class I NK cell receptor 3DL2 (CD158k)
T28217	GENENAME	KIR3DL2
T28217	TARGTYPE	Clinical trial
T28217	SYNONYMS	p70 natural killer cell receptor clone CL5; p70 NK receptor CL5; Natural killerassociated transcript 4; NKAT4; KIR3DL2; CD158k; CD158 antigenlike family member K
T28217	FUNCTION	Receptor on natural killer (NK) cells for HLA-A alleles. Inhibits the activity of NK cells thus preventing cell lysis.
T28217	BIOCLASS	Immunoglobulin
T28217	SEQUENCE	MSLTVVSMACVGFFLLQGAWPLMGGQDKPFLSARPSTVVPRGGHVALQCHYRRGFNNFMLYKEDRSHVPIFHGRIFQESFIMGPVTPAHAGTYRCRGSRPHSLTGWSAPSNPLVIMVTGNHRKPSLLAHPGPLLKSGETVILQCWSDVMFEHFFLHREGISEDPSRLVGQIHDGVSKANFSIGPLMPVLAGTYRCYGSVPHSPYQLSAPSDPLDIVITGLYEKPSLSAQPGPTVQAGENVTLSCSSWSSYDIYHLSREGEAHERRLRAVPKVNRTFQADFPLGPATHGGTYRCFGSFRALPCVWSNSSDPLLVSVTGNPSSSWPSPTEPSSKSGICRHLHVLIGTSVVIFLFILLLFFLLYRWCSNKKNAAVMDQEPAGDRTVNRQDSDEQDPQEVTYAQLDHCVFIQRKISRPSQRPKTPLTDTSVYTELPNAEPRSKVVSCPRAPQSGLEGVF
T28217	DRUGINFO	D0GO4T	IPH4102	Phase 2

T85421	TARGETID	T85421
T85421	FORMERID	TTDR00289
T85421	UNIPROID	MK08_HUMAN; MK09_HUMAN; MK10_HUMAN
T85421	TARGNAME	Jun N terminal kinase (JNK)
T85421	GENENAME	MAPK8; MAPK9; MAPK10
T85421	TARGTYPE	Clinical trial
T85421	SYNONYMS	c-Jun N-terminal kinase; Stress-activated protein kinase JNK; SAPK1; PRKM; MAP kinase; JNK
T85421	FUNCTION	Associates with scaffold proteins JNK interacting proteins as well as their upstream kinases JNKK1 and JNKK2 following their activation. Modifies the activity of numerous proteins that reside at the mitochondria or act in the nucleus. Downstream molecules that are activated by JNK include c-Jun, ATF2, ELK1, SMAD4, p53 and HSF1. Involved in apoptosis, neurodegeneration, cell differentiation and proliferation, inflammatory conditions and cytokine production mediated by AP-1 (activation protein 1) such as RANTES, IL-8 and GM-CSF.
T85421	BIOCLASS	Kinase
T85421	SEQUENCE	MSRSKRDNNFYSVEIGDSTFTVLKRYQNLKPIGSGAQGIVCAAYDAILERNVAIKKLSRPFQNQTHAKRAYRELVLMKCVNHKNIIGLLNVFTPQKSLEEFQDVYIVMELMDANLCQVIQMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTAGTSFMMTPYVVTRYYRAPEVILGMGYKENVDLWSVGCIMGEMVCHKILFPGRDYIDQWNKVIEQLGTPCPEFMKKLQPTVRTYVENRPKYAGYSFEKLFPDVLFPADSEHNKLKASQARDLLSKMLVIDASKRISVDEALQHPYINVWYDPSEAEAPPPKIPDKQLDEREHTIEEWKELIYKEVMDLEERTKNGVIRGQPSPLGAAVINGSQHPSSSSSVNDVSSMSTDPTLASDTDSSLEAAAGPLGCCR
T85421	DRUGINFO	D0N7WG	AM-111	Phase 3
T85421	DRUGINFO	D04UUD	CC-401	Phase 2
T85421	DRUGINFO	D0X4MN	CC-930	Phase 2
T85421	DRUGINFO	D08LRV	BGP-15	Phase 2
T85421	DRUGINFO	D03MTX	PMID25991433-Compound-O1	Patented
T85421	DRUGINFO	D0V7UQ	PMID25991433-Compound-Q1	Patented
T85421	DRUGINFO	D02PVB	2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One	Investigative

T38200	TARGETID	T38200
T38200	FORMERID	TTDR01163
T38200	UNIPROID	S6A11_HUMAN
T38200	TARGNAME	GABA transporter-3 (SLC6A11)
T38200	GENENAME	SLC6A11
T38200	TARGTYPE	Clinical trial
T38200	SYNONYMS	Solute carrier family 6 member 11; Sodium- and chloride-dependent GABA transporter 3; GAT3; GAT-3; GABT3
T38200	FUNCTION	Terminates the action of GABA by its high affinity sodium-dependent reuptake into presynaptic terminals.
T38200	SEQUENCE	MTAEKALPLGNGKAAEEARESEAPGGGCSSGGAAPARHPRVKRDKAVHERGHWNNKVEFVLSVAGEIIGLGNVWRFPYLCYKNGGGAFLIPYVVFFICCGIPVFFLETALGQFTSEGGITCWRKVCPLFEGIGYATQVIEAHLNVYYIIILAWAIFYLSNCFTTELPWATCGHEWNTENCVEFQKLNVSNYSHVSLQNATSPVMEFWEHRVLAISDGIEHIGNLRWELALCLLAAWTICYFCIWKGTKSTGKVVYVTATFPYIMLLILLIRGVTLPGASEGIKFYLYPDLSRLSDPQVWVDAGTQIFFSYAICLGCLTALGSYNNYNNNCYRDCIMLCCLNSGTSFVAGFAIFSVLGFMAYEQGVPIAEVAESGPGLAFIAYPKAVTMMPLSPLWATLFFMMLIFLGLDSQFVCVESLVTAVVDMYPKVFRRGYRRELLILALSVISYFLGLVMLTEGGMYIFQLFDSYAASGMCLLFVAIFECICIGWVYGSNRFYDNIEDMIGYRPPSLIKWCWMIMTPGICAGIFIFFLIKYKPLKYNNIYTYPAWGYGIGWLMALSSMLCIPLWICITVWKTEGTLPEKLQKLTTPSTDLKMRGKLGVSPRMVTVNDCDAKLKSDGTIAAITEKETHF
T38200	DRUGINFO	D0C9XA	GSK683699	Phase 2
T38200	DRUGINFO	D0W8SX	Beta-Alanine	Investigative
T38200	DRUGINFO	D0ER1G	4-Hydroxy-piperidine-3-carboxylic acid	Investigative
T38200	DRUGINFO	D09TTI	2,4-Diamino-butyric acid(GABA)	Investigative
T38200	DRUGINFO	D0RF2M	NIPECOTIC ACID	Investigative

T82277	TARGETID	T82277
T82277	FORMERID	TTDNC00483
T82277	UNIPROID	CTG1B_HUMAN
T82277	TARGNAME	Cancer/testis antigen 1 (NY-ESO-1)
T82277	GENENAME	CTAG1A
T82277	TARGTYPE	Clinical trial
T82277	SYNONYMS	LAGE2B; LAGE2A; LAGE2; LAGE-2; L antigen family member 2; ESO1; Cancer/testis antigen 6.1; CTAG1B; CTAG1; CTAG; CT6.1; Autoimmunogenic cancer/testis antigen NYESO1; Autoimmunogenic cancer/testis antigen NY-ESO-1
T82277	FUNCTION	Immunogenic protein. Its aberrant re-expression is induced by molecular mechanisms including: DNA demethylation, histone post-translational modification, and microRNA-mediated regulation. The effect of DNA demethylation is evident by the capability of demethylating agents, like 5-aza-2-deoxycytidine, to induce the re-expression of NY-ESO-1 in tumour cells but not in normal epithelial cells.
T82277	PDBSTRUC	6AVG; 6AVF; 6AT5; 3KLA; 3HAE
T82277	SEQUENCE	MQAEGRGTGGSTGDADGPGGPGIPDGPGGNAGGPGEAGATGGRGPRGAGAARASGPGGGAPRGPHGGAASGLNGCCRCGARGPESRLLEFYLAMPFATPMEAELARRSLAQDAPPLPVPGVLLKEFTVSGNILTIRLTAADHRQLQLSISSCLQQLSLLMWITQCFLPVFLAQPPSGQRR
T82277	DRUGINFO	D09TCY	CDX-1401	Phase 2
T82277	DRUGINFO	D0LJ2S	Anti-NY-ESO-1 CAR-T cells	Phase 1/2
T82277	DRUGINFO	D02DVK	CV-9201	Phase 1/2
T82277	DRUGINFO	D09XOF	NY-ESO-1 vaccine	Phase 1
T82277	DRUGINFO	D0IA5O	GSK-2241658A	Phase 1
T82277	DRUGINFO	DHS3X7	GSK3901961	Phase 1
T82277	DRUGINFO	DS39MT	GSK3845097	Phase 1
T82277	DRUGINFO	D0C1EO	Melanoma vaccine (ALVAC)	Discontinued in Phase 2

T82913	TARGETID	T82913
T82913	FORMERID	TTDR00359
T82913	UNIPROID	EF1A_PLAFK
T82913	TARGNAME	Plasmodium Elongation factor 1-alpha 1 (Malaria MEF-1)
T82913	GENENAME	Malaria MEF-1
T82913	TARGTYPE	Clinical trial
T82913	SYNONYMS	MEF-1; Elongation factor Tu of Plasmodium falciparum; Elongation factor 1 A-1; EF-Tu; EF-1-alpha-1 of Plasmodium falciparum; EEF1A-1
T82913	FUNCTION	This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis.
T82913	BIOCLASS	Acid anhydrides hydrolase
T82913	SEQUENCE	MGKEKTHINLVVIGHVDSGKSTTTGHIIYKLGGIDRRTIEKFEKESAEMGKGSFKYAWVLDKLKAERERGITIDIALWKFETPRYFFTVIDAPGHKDFIKNMITGTSQADVALLVVPADVGGFDGAFSKEGQTKEHVLLAFTLGVKQIVVGVNKMDTVKYSEDRYEEIKKEVKDYLKKVGYQADKVDFIPISGFEGDNLIEKSDKTPWYKGRTLIEALDTMQPPKRPYDKPLRIPLQGVYKIGGIGTVPVGRVETGILKAGMVLNFAPSAVVSECKSVEMHKEVLEEARPGDNIGFNVKNVSVKEIKRGYVASDTKNEPAKGCSKFTAQVIILNHPGEIKNGYTPLLDCHTSHISCKFLNIDSKIDKRSGKVVEENPKAIKSGDSALVSLEPKKPMVVETFTEYPPLGRFAIRDMRQTIAVGIINQLKRKNLGAVTAKAPAKK
T82913	DRUGINFO	D0Y3XA	Ge2270a	Phase 1
T82913	DRUGINFO	D05CNB	Amythiamicin	Investigative
T82913	DRUGINFO	D0C7LS	Guanosine-5'-Diphosphate	Investigative

T08014	TARGETID	T08014
T08014	FORMERID	TTDI02548
T08014	UNIPROID	TADBP_HUMAN
T08014	TARGNAME	TAR DNA binding protein 43 (TARDBP)
T08014	GENENAME	TARDBP
T08014	TARGTYPE	Clinical trial
T08014	SYNONYMS	TDP43; TDP-43; TAR DNA-binding protein 43
T08014	FUNCTION	RNA-binding protein that is involved in various steps of RNA biogenesis and processing. Preferentially binds, via its two RNA recognition motifs RRM1 and RRM2, to GU-repeats on RNA molecules predominantly localized within long introns and in the 3'UTR of mRNAs. In turn, regulates the splicing of many non-coding and protein-coding RNAs including proteins involved in neuronal survival, as well as mRNAs that encode proteins relevant for neurodegenerative diseases. Plays a role in maintaining mitochondrial homeostasis by regulating the processing of mitochondrial transcripts. Regulates also mRNA stability by recruiting CNOT7/CAF1 deadenylase on mRNA 3'UTR leading to poly(A) tail deadenylation and thus shortening. In response to oxidative insult, associates with stalled ribosomes localized to stress granules (SGs) and contributes to cell survival. Participates also in the normal skeletal muscle formation and regeneration, forming cytoplasmic myo-granules and binding mRNAs that encode sarcomeric proteins. Plays a role in the maintenance of the circadian clock periodicity via stabilization of the CRY1 and CRY2 proteins in a FBXL3-dependent manner.
T08014	PDBSTRUC	6CFH; 6CF4; 6B1G; 5X4F; 5WKD
T08014	SEQUENCE	MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGILHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDLKEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNSKQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGM
T08014	DRUGINFO	D05XDZ	LMT-X	Phase 3
T08014	DRUGINFO	DVX18N	PP-007	Phase 1

T68525	TARGETID	T68525
T68525	UNIPROID	PTK7_HUMAN
T68525	TARGNAME	Inactive tyrosine-protein kinase 7 (PTK7)
T68525	GENENAME	PTK7
T68525	TARGTYPE	Clinical trial
T68525	SYNONYMS	Tyrosine-protein kinase-like 7; Pseudo tyrosine kinase receptor 7; Protein-tyrosine kinase 7; Colon carcinoma kinase 4; CCK-4
T68525	FUNCTION	Inactive tyrosine kinase involved in Wnt signaling pathway. Component of both the non-canonical (also known as the Wnt/planar cell polarity signaling) and the canonical Wnt signaling pathway. Functions in cell adhesion, cell migration, cell polarity, proliferation, actin cytoskeleton reorganization and apoptosis. Has a role in embryogenesis, epithelial tissue organization and angiogenesis.
T68525	BIOCLASS	Protein kinase superfamily. Tyr protein kinase family. Insulin receptor subfamily
T68525	SEQUENCE	MGAARGSPARPRRLPLLSVLLLPLLGGTQTAIVFIKQPSSQDALQGRRALLRCEVEAPGPVHVYWLLDGAPVQDTERRFAQGSSLSFAAVDRLQDSGTFQCVARDDVTGEEARSANASFNIKWIEAGPVVLKHPASEAEIQPQTQVTLRCHIDGHPRPTYQWFRDGTPLSDGQSNHTVSSKERNLTLRPAGPEHSGLYSCCAHSAFGQACSSQNFTLSIADESFARVVLAPQDVVVARYEEAMFHCQFSAQPPPSLQWLFEDETPITNRSRPPHLRRATVFANGSLLLTQVRPRNAGIYRCIGQGQRGPPIILEATLHLAEIEDMPLFEPRVFTAGSEERVTCLPPKGLPEPSVWWEHAGVRLPTHGRVYQKGHELVLANIAESDAGVYTCHAANLAGQRRQDVNITVATVPSWLKKPQDSQLEEGKPGYLDCLTQATPKPTVVWYRNQMLISEDSRFEVFKNGTLRINSVEVYDGTWYRCMSSTPAGSIEAQARVQVLEKLKFTPPPQPQQCMEFDKEATVPCSATGREKPTIKWERADGSSLPEWVTDNAGTLHFARVTRDDAGNYTCIASNGPQGQIRAHVQLTVAVFITFKVEPERTTVYQGHTALLQCEAQGDPKPLIQWKGKDRILDPTKLGPRMHIFQNGSLVIHDVAPEDSGRYTCIAGNSCNIKHTEAPLYVVDKPVPEESEGPGSPPPYKMIQTIGLSVGAAVAYIIAVLGLMFYCKKRCKAKRLQKQPEGEEPEMECLNGGPLQNGQPSAEIQEEVALTSLGSGPAATNKRHSTSDKMHFPRSSLQPITTLGKSEFGEVFLAKAQGLEEGVAETLVLVKSLQSKDEQQQLDFRRELEMFGKLNHANVVRLLGLCREAEPHYMVLEYVDLGDLKQFLRISKSKDEKLKSQPLSTKQKVALCTQVALGMEHLSNNRFVHKDLAARNCLVSAQRQVKVSALGLSKDVYNSEYYHFRQAWVPLRWMSPEAILEGDFSTKSDVWAFGVLMWEVFTHGEMPHGGQADDEVLADLQAGKARLPQPEGCPSKLYRLMQRCWALSPKDRPSFSEIASALGDSTVDSKP
T68525	DRUGINFO	D0AD3V	PF-06647020	Phase 1

T29736	TARGETID	T29736
T29736	FORMERID	TTDR01057
T29736	UNIPROID	LAMB3_HUMAN
T29736	TARGNAME	Laminin beta-3 chain (LAMB3)
T29736	GENENAME	LAMB3
T29736	TARGTYPE	Clinical trial
T29736	SYNONYMS	Nicein subunit beta; Laminin5beta3; Laminin-5 subunit beta; Laminin subunit beta-3; Laminin B1k chain; Laminin 5 beta 3; LAMNB1; Kalinin subunit beta; Kalinin B1 chain; Epiligrin subunit bata
T29736	FUNCTION	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components.
T29736	SEQUENCE	MRPFFLLCFALPGLLHAQQACSRGACYPPVGDLLVGRTRFLRASSTCGLTKPETYCTQYGEWQMKCCKCDSRQPHNYYSHRVENVASSSGPMRWWQSQNDVNPVSLQLDLDRRFQLQEVMMEFQGPMPAGMLIERSSDFGKTWRVYQYLAADCTSTFPRVRQGRPQSWQDVRCQSLPQRPNARLNGGKVQLNLMDLVSGIPATQSQKIQEVGEITNLRVNFTRLAPVPQRGYHPPSAYYAVSQLRLQGSCFCHGHADRCAPKPGASAGPSTAVQVHDVCVCQHNTAGPNCERCAPFYNNRPWRPAEGQDAHECQRCDCNGHSETCHFDPAVFAASQGAYGGVCDNCRDHTEGKNCERCQLHYFRNRRPGASIQETCISCECDPDGAVPGAPCDPVTGQCVCKEHVQGERCDLCKPGFTGLTYANPQGCHRCDCNILGSRRDMPCDEESGRCLCLPNVVGPKCDQCAPYHWKLASGQGCEPCACDPHNSLSPQCNQFTGQCPCREGFGGLMCSAAAIRQCPDRTYGDVATGCRACDCDFRGTEGPGCDKASGRCLCRPGLTGPRCDQCQRGYCNRYPVCVACHPCFQTYDADLREQALRFGRLRNATASLWSGPGLEDRGLASRILDAKSKIEQIRAVLSSPAVTEQEVAQVASAILSLRRTLQGLQLDLPLEEETLSLPRDLESLDRSFNGLLTMYQRKREQFEKISSADPSGAFRMLSTAYEQSAQAAQQVSDSSRLLDQLRDSRREAERLVRQAGGGGGTGSPKLVALRLEMSSLPDLTPTFNKLCGNSRQMACTPISCPGELCPQDNGTACGSRCRGVLPRAGGAFLMAGQVAEQLRGFNAQLQRTRQMIRAAEESASQIQSSAQRLETQVSASRSQMEEDVRRTRLLIQQVRDFLTDPDTDAATIQEVSEAVLALWLPTDSATVLQKMNEIQAIAARLPNVDLVLSQTKQDIARARRLQAEAEEARSRAHAVEGQVEDVVGNLRQGTVALQEAQDTMQGTSRSLRLIQDRVAEVQQVLRPAEKLVTSMTKQLGDFWTRMEELRHQARQQGAEAVQAQQLAEGASEQALSAQEGFERIKQKYAELKDRLGQSSMLGEQGARIQSVKTEAEELFGETMEMMDRMKDMELELLRGSQAIMLRSADLTGLEKRVEQIRDHINGRVLYYATCK
T29736	DRUGINFO	D09PFR	LAMB3-transduced autologous epidermal stem cells	Phase 1

T32720	TARGETID	T32720
T32720	UNIPROID	KI2S1_HUMAN
T32720	TARGNAME	MHC class I NK cell receptor 2DS1 (CD158h)
T32720	GENENAME	KIR2DS1
T32720	TARGTYPE	Clinical trial
T32720	SYNONYMS	MHC class I NK cell receptor Eb6 ActI; Killer cell immunoglobulin-like receptor 2DS1; CD158h; CD158 antigen-like family member H
T32720	FUNCTION	Receptor on natural killer (NK) cells for some HLA-C alleles such as w6. Does not inhibit the activity of NK cells.
T32720	BIOCLASS	Immunoglobulin
T32720	SEQUENCE	MSLTVVSMACVGFFLLQGAWPHEGVHRKPSLLAHPGRLVKSEETVILQCWSDVMFEHFLLHREGMFNDTLRLIGEHHDGVSKANFSISRMKQDLAGTYRCYGSVTHSPYQLSAPSDPLDIVIIGLYEKPSLSAQPGPTVLAGENVTLSCSSRSSYDMYHLSREGEAHERRLPAGTKVNGTFQANFPLGPATHGGTYRCFGSFRDSPYEWSKSSDPLLVSVTGNPSNSWPSPTEPSSETGNPRHLHVLIGTSVVKIPFTILLFFLLHRWCSDKKNAAVMDQEPAGNRTVNSEDSDEQDHQEVSYA
T32720	DRUGINFO	D04IXD	IPH-2101	Phase 2

T18872	TARGETID	T18872
T18872	FORMERID	TTDR01010
T18872	UNIPROID	KISS1_HUMAN
T18872	TARGNAME	Metastasis-suppressor KiSS-1 (KISS1)
T18872	GENENAME	KISS1
T18872	TARGTYPE	Clinical trial
T18872	SYNONYMS	KiSS-1; KISS1
T18872	FUNCTION	Metastasis suppressor protein in malignant melanomas and in some breast cancers. May regulate events downstream of cell- matrix adhesion, perhaps involving cytoskeletal reorganization. Generates a C-terminally amidated peptide, metastin which functions as the endogenous ligand of the G-protein coupled receptor GPR54. Activation of the receptor inhibits cell proliferation and cell migration, key characteristics of tumor metastasis. Kp-10 is a decapeptide derived from the primary translation product, isolated in conditioned medium of first trimester trophoblast. Kp-10, but not other kisspeptins, increased intracellular Ca(2+) levels in isolated first trimester trophoblasts. Kp-10 is a paracrine/endocrine regulator in fine- tuning trophoblast invasion generated by the trophoblast itself. The receptor is also essential for normal gonadotropin-released hormone physiology and for puberty. The hypothalamic KiSS1/GPR54 system is a pivotal factor in central regulation of the gonadotropic axis at puberty and in adulthood.
T18872	SEQUENCE	MNSLVSWQLLLFLCATHFGEPLEKVASVGNSRPTGQQLESLGLLAPGEQSLPCTERKPAATARLSRRGTSLSPPPESSGSPQQPGLSAPHSRQIPAPQGAVLVQREKDLPNYNWNSFGLRFGKREAAPGNHGRSAGRG
T18872	DRUGINFO	D04GEI	TAK-448	Phase 2

T27736	TARGETID	T27736
T27736	FORMERID	TTDI02146
T27736	UNIPROID	PDCD2_HUMAN
T27736	TARGNAME	Programmed cell death protein 2 (PD-2)
T27736	GENENAME	PDCD2
T27736	TARGTYPE	Clinical trial
T27736	SYNONYMS	Zinc finger protein Rp8; Zinc finger protein Rp-8; Zinc finger MYND domaincontaining protein 7; Zinc finger MYND domain-containing protein 7; ZMYND7; RP8
T27736	FUNCTION	May play an important role in cell death and/or in regulation of cell proliferation. May be a DNA-binding protein with a regulatory function.
T27736	SEQUENCE	MAAAGARPVELGFAESAPAWRLRSEQFPSKVGGRPAWLGAAGLPGPQALACELCGRPLSFLLQVYAPLPGRPDAFHRCIFLFCCREQPCCAGLRVFRNQLPRKNDFYSYEPPSENPPPETGESVCLQLKSGAHLCRVCGCLGPKTCSRCHKAYYCSKEHQTLDWRLGHKQACAQPDHLDHIIPDHNFLFPEFEIVIETEDEIMPEVVEKEDYSEIIGSMGEALEEELDSMAKHESREDKIFQKFKTQIALEPEQILRYGRGIAPIWISGENIPQEKDIPDCPCGAKRILEFQVMPQLLNYLKADRLGKSIDWGILAVFTCAESCSLGTGYTEEFVWKQDVTDTP
T27736	DRUGINFO	D07BNG	RHIgM12B7	Phase 1

T84584	TARGETID	T84584
T84584	FORMERID	TTDI02220
T84584	UNIPROID	SGCA_HUMAN
T84584	TARGNAME	Sarcoglycan alpha (SGCA)
T84584	GENENAME	SGCA
T84584	TARGTYPE	Clinical trial
T84584	SYNONYMS	SGCA; Dystroglycan2; Alphasarcoglycan; AlphaSG; Adhalin; 50DAG; 50 kDa dystrophinassociated glycoprotein
T84584	FUNCTION	Component of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix.
T84584	BIOCLASS	Sarcoglycan
T84584	SEQUENCE	MAETLFWTPLLVVLLAGLGDTEAQQTTLHPLVGRVFVHTLDHETFLSLPEHVAVPPAVHITYHAHLQGHPDLPRWLRYTQRSPHHPGFLYGSATPEDRGLQVIEVTAYNRDSFDTTRQRLVLEIGDPEGPLLPYQAEFLVRSHDAEEVLPSTPASRFLSALGGLWEPGELQLLNVTSALDRGGRVPLPIEGRKEGVYIKVGSASPFSTCLKMVASPDSHARCAQGQPPLLSCYDTLAPHFRVDWCNVTLVDKSVPEPADEVPTPGDGILEHDPFFCPPTEAPDRDFLVDALVTLLVPLLVALLLTLLLAYVMCCRREGRLKRDLATSDIQMVHHCTIHGNTEELRQMAASREVPRPLSTLPMFNVHTGERLPPRVDSAQVPLILDQH
T84584	DRUGINFO	DUIA46	SRP-9004	Phase 1/2
T84584	DRUGINFO	D05HID	rAAV1.tMCK.human-alpha-sarcoglycan	Phase 1

T66903	TARGETID	T66903
T66903	FORMERID	TTDR00829
T66903	UNIPROID	FSCN1_HUMAN
T66903	TARGNAME	Fascin (FSCN1)
T66903	GENENAME	FSCN1
T66903	TARGTYPE	Clinical trial
T66903	SYNONYMS	Singed-like protein; SNL; HSN; FAN1; 55 kDa actin-bundling protein; 55 kDa actin bundling protein
T66903	FUNCTION	Plays a role in the organization of actin filament bundles and the formation of microspikes, membrane ruffles, and stress fibers. Important for the formation of a diverse set of cell protrusions, such as filopodia, and for cell motility and migration. Organizes filamentous actin into bundles with a minimum of 4. 1:1 actin/fascin ratio.
T66903	PDBSTRUC	6I18; 6I17; 6I16; 6I15; 6I14
T66903	SEQUENCE	MTANGTAEAVQIQFGLINCGNKYLTAEAFGFKVNASASSLKKKQIWTLEQPPDEAGSAAVCLRSHLGRYLAADKDGNVTCEREVPGPDCRFLIVAHDDGRWSLQSEAHRRYFGGTEDRLSCFAQTVSPAEKWSVHIAMHPQVNIYSVTRKRYAHLSARPADEIAVDRDVPWGVDSLITLAFQDQRYSVQTADHRFLRHDGRLVARPEPATGYTLEFRSGKVAFRDCEGRYLAPSGPSGTLKAGKATKVGKDELFALEQSCAQVVLQAANERNVSTRQGMDLSANQDEETDQETFQLEIDRDTKKCAFRTHTGKYWTLTATGGVQSTASSKNASCYFDIEWRDRRITLRASNGKFVTSKKNGQLAASVETAGDSELFLMKLINRPIIVFRGEHGFIGCRKVTGTLDANRSSYDVFQLEFNDGAYNIKDSTGKYWTVGSDSAVTSSGDTPVDFFFEFCDYNKVAIKVGGRYLKGDHAGVLKASAETVDPASLWEY
T66903	DRUGINFO	D0C2NT	NP-G2-044	Phase 1

T64526	TARGETID	T64526
T64526	FORMERID	TTDI01711
T64526	UNIPROID	CLFA_STAA8
T64526	TARGNAME	Staphylococcus Clumping factor A (Stap-coc ClfA)
T64526	GENENAME	Stap-coc ClfA
T64526	TARGTYPE	Clinical trial
T64526	SYNONYMS	Fibrinogen-binding protein A; Fibrinogen receptor A; Clumping factor A
T64526	FUNCTION	Cell surface-associated protein implicated in virulence. Promotes bacterial attachment exclusively to the gamma-chain of human fibrinogen. Induces formation of bacterial clumps, which diminish the ability of group IIA phospholipase A2 to cause bacterial phospholipid hydrolysis and killing. Significantly decreases macrophage phagocytosis possibly thanks to the clumps, clumped bacteria being too large to be phagocytosed. Dominant factor responsible for human platelet aggregation, which may be an important mechanism for initiating infective endocarditis. Enhances spleen cell proliferative response in vitro, contributing significantly to the immunostimulatory activity of S.aureus.
T64526	PDBSTRUC	2VR3
T64526	SEQUENCE	MNMKKKEKHAIRKKSIGVASVLVGTLIGFGLLSSKEADASENSVTQSDSASNESKSNDSSSVSAAPKTDDTNVSDTKTSSNTNNGETSVAQNPAQQETTQSSSTNATTEETPVTGEATTTTTNQANTPATTQSSNTNAEELVNQTSNETTSNDTNTVSSVNSPQNSTNAENVSTTQDTSTEATPSNNESAPQSTDASNKDVVNQAVNTSAPRMRAFSLAAVAADAPVAGTDITNQLTNVTVGIDSGTTVYPHQAGYVKLNYGFSVPNSAVKGDTFKITVPKELNLNGVTSTAKVPPIMAGDQVLANGVIDSDGNVIYTFTDYVNTKDDVKATLTMPAYIDPENVKKTGNVTLATGIGSTTANKTVLVDYEKYGKFYNLSIKGTIDQIDKTNNTYRQTIYVNPSGDNVIAPVLTGNLKPNTDSNALIDQQNTSIKVYKVDNAADLSESYFVNPENFEDVTNSVNITFPNPNQYKVEFNTPDDQITTPYIVVVNGHIDPNSKGDLALRSTLYGYNSNIIWRSMSWDNEVAFNNGSGSGDGIDKPVVPEQPDEPGEIEPIPEDSDSDPGSDSGSDSNSDSGSDSGSDSTSDSGSDSASDSDSASDSDSASDSDSASDSDSASDSDSDNDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSASDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSESDSDSDSDSDSDSDSDSDSDSDSASDSDSGSDSDSSSDSDSESDSNSDSESVSNNNVVPPNSPKNGTNASNKNEAKDSKEPLPDTGSEDEANTSLIWGLLASIGSLLLFRRKKENKDKK
T64526	DRUGINFO	D01DXI	PF-06290510	Phase 2

T24626	TARGETID	T24626
T24626	UNIPROID	LPXC_HAEI8
T24626	TARGNAME	Haemophilus influenzae Acetylglucosamine deacetylase (Hae-influ lpxC)
T24626	GENENAME	Hae-influ lpxC
T24626	TARGTYPE	Clinical trial
T24626	SYNONYMS	UDP-3-O-acyl-N-acetylglucosamine deacetylase; UDP-3-O-[R-3-hydroxymyristoyl]-N-acetylglucosamine deacetylase; Hae-influ UDP-3-O-acyl-GlcNAc deacetylase
T24626	FUNCTION	Catalyzes the hydrolysis of UDP-3-O-myristoyl-N-acetylglucosamine to form UDP-3-O-myristoylglucosamine and acetate, the committed step in lipid A biosynthesis.
T24626	ECNUMBER	EC 3.5.1.108
T24626	SEQUENCE	MIKQRTLKQSIKVTGVGLHSGNKVTLTLRPAMPNTGVVYYRTDLNPAVAFPADPNSVRDTMLCTALINDQGVRISTVEHLNAALAGLGIDNIIIEVDAPEIPIMDGSASPFIYLLLDAGIEEQNAAKKFIRIKEYVRVEDGDKWAEFKPYNGFRLDFTIDFDHPAIGKDVRNYEMNFSAQAFVHQISRARTFGFMKDIEYLQSQGLALGGSLDNAIVLDDYRILNEDGLRFKDELVRHKMLDAIGDLYMAGYNIIGDFKAYKSGHGLNNKLLRAVLANQEAWEFVTFEDKEQVPQGYVAPAQVLI
T24626	DRUGINFO	D08FKL	ACHN-975	Phase 1

T45674	TARGETID	T45674
T45674	UNIPROID	SGMR2_HUMAN
T45674	TARGNAME	Sigma intracellular receptor 2 (TMEM97)
T45674	GENENAME	TMEM97
T45674	TARGTYPE	Clinical trial
T45674	SYNONYMS	Transmembrane protein 97; Sigma2 receptor; Sigma-2 receptor; Meningioma-associated protein 30; MAC30
T45674	FUNCTION	Intracellular orphan receptor that binds numerous drugs and which is highly expressed in various proliferating cancer cells. Corresponds to the sigma-2 receptor, which is thought to play important role in regulating cell survival, morphology and differentiation. Under investigation for its potential diagnostic and therapeutic uses. May play a role as a regulator of cellular cholesterol homeostasis. May function as sterol isomerase. May alter the activity of some cytochrome P450 proteins.
T45674	BIOCLASS	TMEM97/sigma-2 receptor
T45674	SEQUENCE	MGAPATRRCVEWLLGLYFLSHIPITLFMDLQAVLPRELYPVEFRNLLKWYAKEFKDPLLQEPPAWFKSFLFCELVFQLPFFPIATYAFLKGSCKWIRTPAIIYSVHTMTTLIPILSTFLFEDFSKASGFKGQRPETLHERLTLVSVYAPYLLIPFILLIFMLRSPYYKYEEKRKKK
T45674	DRUGINFO	D0L7TA	MIN-101	Phase 3
T45674	DRUGINFO	D0FX8N	CT1812	Phase 2
T45674	DRUGINFO	D01IVR	Piperazinyl methyl quinazolinone derivative 2	Patented
T45674	DRUGINFO	D02ZGY	PMID30185082-Compound-53	Patented
T45674	DRUGINFO	D03DNE	Benzamide derivative 3	Patented
T45674	DRUGINFO	D04BSD	Piperazinyl norbenzomorphane compound 1	Patented
T45674	DRUGINFO	D04OPJ	Bicyclo-heptan-2-amine derivative 1	Patented
T45674	DRUGINFO	D04PDM	Benzamide derivative 2	Patented
T45674	DRUGINFO	D04WKL	Piperazinyl methyl quinazolinone derivative 3	Patented
T45674	DRUGINFO	D05MST	PMID30185082-Compound-27	Patented
T45674	DRUGINFO	D06HRI	PMID28051882-Compound-XI	Patented
T45674	DRUGINFO	D0A1DV	PMID30185082-Compound-28	Patented
T45674	DRUGINFO	D0AT9E	Piperazinyl methyl quinazolinone derivative 1	Patented
T45674	DRUGINFO	D0BI1O	PMID28051882-Compound-Figure9	Patented
T45674	DRUGINFO	D0CK6M	Fused aryl carbocycle derivative 3	Patented
T45674	DRUGINFO	D0DZ5H	PMID30185082-Compound-54	Patented
T45674	DRUGINFO	D0E3OT	PMID30185082-Compound-14	Patented
T45674	DRUGINFO	D0E9CV	Benzamide derivative 4	Patented
T45674	DRUGINFO	D0FH5K	N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl-phenylcarbamate analog 2	Patented
T45674	DRUGINFO	D0FU2M	Bicyclo-heptan-2-amine derivative 3	Patented
T45674	DRUGINFO	D0HY9M	Fused aryl carbocycle derivative 4	Patented
T45674	DRUGINFO	D0K7CD	Fused aryl carbocycle derivative 8	Patented
T45674	DRUGINFO	D0LN2J	Fused aryl carbocycle derivative 2	Patented
T45674	DRUGINFO	D0LP3P	PMID30185082-Compound-55	Patented
T45674	DRUGINFO	D0LV1G	Piperazinyl norbenzomorphane compound 4	Patented
T45674	DRUGINFO	D0M4BI	Benzamide derivative 1	Patented
T45674	DRUGINFO	D0M5LL	PMID30185082-Compound-56	Patented
T45674	DRUGINFO	D0N5JQ	PMID30185082-Compound-63	Patented
T45674	DRUGINFO	D0N6JH	N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl-phenylcarbamate analog 3	Patented
T45674	DRUGINFO	D0OZ1P	Fused aryl carbocycle derivative 9	Patented
T45674	DRUGINFO	D0PF9X	Bicyclo-heptan-2-amine derivative 2	Patented
T45674	DRUGINFO	D0R1QI	Aryl azepine derivative 2	Patented
T45674	DRUGINFO	D0U6OY	Piperazinyl norbenzomorphane compound 2	Patented
T45674	DRUGINFO	D0V4KJ	N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl-phenylcarbamate analog 1	Patented
T45674	DRUGINFO	D0VC0P	Piperazinyl norbenzomorphane compound 3	Patented
T45674	DRUGINFO	D0VE8R	Fused aryl carbocycle derivative 1	Patented
T45674	DRUGINFO	D0WE5J	Aryl azepine derivative 1	Patented
T45674	DRUGINFO	D0Y2NR	Bicyclo-heptan-2-amine derivative 4	Patented
T45674	DRUGINFO	D03MKY	Benzamide derivative 9	Patented
T45674	DRUGINFO	D05YFF	Benzamide derivative 10	Patented
T45674	DRUGINFO	D0DW1D	PMID30185082-Compound-57	Patented
T45674	DRUGINFO	D0EO9Z	PMID28051882-Compound-XIV	Patented
T45674	DRUGINFO	D0H2SE	Benzamide derivative 8	Patented
T45674	DRUGINFO	D0J9SL	Piperazine derivative 7	Patented
T45674	DRUGINFO	D0RS2J	Benzamide derivative 7	Patented
T45674	DRUGINFO	D0SG9W	PMID30185082-Compound-64	Patented
T45674	DRUGINFO	D0T5SO	Piperidine derivative 6	Patented
T45674	DRUGINFO	D0W3TS	Benzamide derivative 11	Patented
T45674	DRUGINFO	D0X9RA	Piperidine derivative 5	Patented
T45674	DRUGINFO	D02NPB	Isoindoline derivative 5	Patented
T45674	DRUGINFO	D06FNA	Isoindoline derivative 3	Patented
T45674	DRUGINFO	D0EK3Z	Isoindoline derivative 4	Patented
T45674	DRUGINFO	D0F8XU	Isoindoline derivative 2	Patented
T45674	DRUGINFO	D0S3ON	Isoindoline derivative 1	Patented
T45674	DRUGINFO	D0M6OW	ANAVEX 1007	Preclinical
T45674	DRUGINFO	D0X7BG	SM 21	Investigative
T45674	DRUGINFO	D02WJT	1,3-ditolylguanidine	Investigative

T02262	TARGETID	T02262
T02262	FORMERID	TTDI03324
T02262	UNIPROID	KCNT1_HUMAN
T02262	TARGNAME	Calcium-activated potassium channel KCa4.1 (KCNT1)
T02262	GENENAME	KCNT1
T02262	TARGTYPE	Clinical trial
T02262	SYNONYMS	Potassium channel subfamily T member 1; KIAA1422; KCa4.1
T02262	FUNCTION	Outwardly rectifying potassium channel subunit that may coassemble with other Slo-type channel subunits. Activated by high intracellular sodium or chloride levels. Activated upon stimulation of G-protein coupled receptors, such as CHRM1 and GRIA1. May be regulated by calcium in the absence of sodium ions (in vitro) (By similarity).
T02262	BIOCLASS	Voltage-gated ion channel
T02262	SEQUENCE	MARAKLPRSPSEGKAGPGGAPAGAAAPEEPHGLSPLLPARGGGSVGSDVGQRLPVEDFSLDSSLSQVQVEFYVNENTFKERLKLFFIKNQRSSLRIRLFNFSLKLLTCLLYIVRVLLDDPALGIGCWGCPKQNYSFNDSSSEINWAPILWVERKMTLWAIQVIVAIISFLETMLLIYLSYKGNIWEQIFRVSFVLEMINTLPFIITIFWPPLRNLFIPVFLNCWLAKHALENMINDFHRAILRTQSAMFNQVLILFCTLLCLVFTGTCGIQHLERAGENLSLLTSFYFCIVTFSTVGYGDVTPKIWPSQLLVVIMICVALVVLPLQFEELVYLWMERQKSGGNYSRHRAQTEKHVVLCVSSLKIDLLMDFLNEFYAHPRLQDYYVVILCPTEMDVQVRRVLQIPLWSQRVIYLQGSALKDQDLMRAKMDNGEACFILSSRNEVDRTAADHQTILRAWAVKDFAPNCPLYVQILKPENKFHVKFADHVVCEEECKYAMLALNCICPATSTLITLLVHTSRGQEGQESPEQWQRMYGRCSGNEVYHIRMGDSKFFREYEGKSFTYAAFHAHKKYGVCLIGLKREDNKSILLNPGPRHILAASDTCFYINITKEENSAFIFKQEEKRKKRAFSGQGLHEGPARLPVHSIIASMGTVAMDLQGTEHRPTQSGGGGGGSKLALPTENGSGSRRPSIAPVLELADSSALLPCDLLSDQSEDEVTPSDDEGLSVVEYVKGYPPNSPYIGSSPTLCHLLPVKAPFCCLRLDKGCKHNSYEDAKAYGFKNKLIIVSAETAGNGLYNFIVPLRAYYRSRKELNPIVLLLDNKPDHHFLEAICCFPMVYYMEGSVDNLDSLLQCGIIYADNLVVVDKESTMSAEEDYMADAKTIVNVQTMFRLFPSLSITTELTHPSNMRFMQFRAKDSYSLALSKLEKRERENGSNLAFMFRLPFAAGRVFSISMLDTLLYQSFVKDYMITITRLLLGLDTTPGSGYLCAMKITEGDLWIRTYGRLFQKLCSSSAEIPIGIYRTESHVFSTSESQISVNVEDCEDTREVKGPWGSRAGTGGSSQGRHTGGGDPAEHPLLRRKSLQWARRLSRKAPKQAGRAAAAEWISQQRLSLYRRSERQELSELVKNRMKHLGLPTTGYEDVANLTASDVMNRVNLGYLQDEMNDHQNTLSYVLINPPPDTRLEPSDIVYLIRSDPLAHVASSSQSRKSSCSHKLSSCNPETRDETQL
T02262	DRUGINFO	D09DHT	phorbol 12-myristate 13-acetate	Phase 2
T02262	DRUGINFO	D0O2TC	iberiotoxin	Investigative
T02262	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T11701	TARGETID	T11701
T11701	FORMERID	TTDI02100
T11701	UNIPROID	IL31_HUMAN
T11701	TARGNAME	Interleukin-31 (IL31)
T11701	GENENAME	IL31
T11701	TARGTYPE	Clinical trial
T11701	SYNONYMS	Interleukin31; IL-31
T11701	FUNCTION	May function in skin immunity. Enhances myeloid progenitor cell survival in vitro. Induces RETNLA and serum amyloid A protein expression in macrophages. Activates STAT3 and possibly STAT1 and STAT5 through the IL31 heterodimeric receptor composed of IL31RA and OSMR.
T11701	BIOCLASS	Cytokine: interleukin
T11701	SEQUENCE	MASHSGPSTSVLFLFCCLGGWLASHTLPVRLLRPSDDVQKIVEELQSLSKMLLKDVEEEKGVLVSQNYTLPCLSPDAQPPNNIHSPAIRAYLKTIRQLDNKSVIDEIIEHLDKLIFQDAPETNISVPTDTHECKRFILTISQQFSECMDLALKSLTSGAQQATT
T11701	DRUGINFO	D09KEW	KPL-716	Phase 1

T76855	TARGETID	T76855
T76855	FORMERID	TTDI02058
T76855	UNIPROID	EFTU_STAAS
T76855	TARGNAME	Staphylococcus Elongation factor Tu (Stap-coc tuf)
T76855	GENENAME	Stap-coc tuf
T76855	TARGTYPE	Clinical trial
T76855	SYNONYMS	tuf; Elongation factor Tu of Staphylococcus aureus; EFTu
T76855	FUNCTION	This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis.
T76855	BIOCLASS	TRAFAC class translation factor GTPase
T76855	SEQUENCE	MAKEKFDRSKEHANIGTIGHVDHGKTTLTAAIATVLAKNGDSVAQSYDMIDNAPEEKERGITINTSHIEYQTDKRHYAHVDCPGHADYVKNMITGAAQMDGGILVVSAADGPMPQTREHILLSRNVGVPALVVFLNKVDMVDDEELLELVEMEVRDLLSEYDFPGDDVPVIAGSALKALEGDAQYEEKILELMEAVDTYIPTPERDSDKPFMMPVEDVFSITGRGTVATGRVERGQIKVGEEVEIIGLHDTSKTTVTGVEMFRKLLDYAEAGDNIGALLRGVAREDVQRGQVLAAPGSITPHTEFKAEVYVLSKDEGGRHTPFFSNYRPQFYFRTTDVTGVVHLPEGTEMVMPGDNVEMTVELIAPIAIEDGTRFSIREGGRTVGSGVVTEIIK
T76855	DRUGINFO	D0Z1UB	NAI-acne	Phase 2
T76855	DRUGINFO	D0S4XZ	GE-1170A	Phase 1

T31600	TARGETID	T31600
T31600	UNIPROID	PKN3_HUMAN
T31600	TARGNAME	Protein kinase N3 (PKN3)
T31600	GENENAME	PKN3
T31600	TARGTYPE	Clinical trial
T31600	SYNONYMS	Serine/threonine-protein kinase N3; Protein-kinase C-related kinase 3; Protein kinase PKN-beta; PKNBETA
T31600	FUNCTION	Contributes to invasiveness in malignant prostate cancer.
T31600	ECNUMBER	EC 2.7.11.13
T31600	SEQUENCE	MEEGAPRQPGPSQWPPEDEKEVIRRAIQKELKIKEGVENLRRVATDRRHLGHVQQLLRSSNRRLEQLHGELRELHARILLPGPGPGPAEPVASGPRPWAEQLRARHLEALRRQLHVELKVKQGAENMTHTCASGTPKERKLLAAAQQMLRDSQLKVALLRMKISSLEASGSPEPGPELLAEELQHRLHVEAAVAEGAKNVVKLLSSRRTQDRKALAEAQAQLQESSQKLDLLRLALEQLLEQLPPAHPLRSRVTRELRAAVPGYPQPSGTPVKPTALTGTLQVRLLGCEQLLTAVPGRSPAAALASSPSEGWLRTKAKHQRGRGELASEVLAVLKVDNRVVGQTGWGQVAEQSWDQTFVIPLERARELEIGVHWRDWRQLCGVAFLRLEDFLDNACHQLSLSLVPQGLLFAQVTFCDPVIERRPRLQRQERIFSKRRGQDFLRASQMNLGMAAWGRLVMNLLPPCSSPSTISPPKGCPRTPTTLREASDPATPSNFLPKKTPLGEEMTPPPKPPRLYLPQEPTSEETPRTKRPHMEPRTRRGPSPPASPTRKPPRLQDFRCLAVLGRGHFGKVLLVQFKGTGKYYAIKALKKQEVLSRDEIESLYCEKRILEAVGCTGHPFLLSLLACFQTSSHACFVTEFVPGGDLMMQIHEDVFPEPQARFYVACVVLGLQFLHEKKIIYRDLKLDNLLLDAQGFLKIADFGLCKEGIGFGDRTSTFCGTPEFLAPEVLTQEAYTRAVDWWGLGVLLYEMLVGECPFPGDTEEEVFDCIVNMDAPYPGFLSVQGLEFIQKLLQKCPEKRLGAGEQDAEEIKVQPFFRTTNWQALLARTIQPPFVPTLCGPADLRYFEGEFTGLPPALTPPAPHSLLTARQQAAFRDFDFVSERFLEP
T31600	DRUGINFO	D09TGT	Atu-027	Phase 1

T78318	TARGETID	T78318
T78318	FORMERID	TTDI03325
T78318	UNIPROID	KCNT2_HUMAN
T78318	TARGNAME	Calcium-activated potassium channel KCa4.2 (KCNT2)
T78318	GENENAME	KCNT2
T78318	TARGTYPE	Clinical trial
T78318	SYNONYMS	Sodium and chloride-activated ATP-sensitive potassium channel Slo2.1; Sequence like an intermediate conductance potassium channel subunit; SLICK; Potassium channel subfamily T member 2
T78318	FUNCTION	Outward rectifying potassium channel. Produces rapidly activating outward rectifier K(+) currents. Activated by high intracellular sodium and chloride levels. Channel activity is inhibited by ATP and by inhalation anesthetics, such as isoflurane (By similarity). Inhibited upon stimulation of G-protein coupled receptors, such as CHRM1 and GRM1.
T78318	BIOCLASS	Voltage-gated ion channel
T78318	SEQUENCE	MVDLESEVPPLPPRYRFRDLLLGDQGWQNDDRVQVEFYMNENTFKERLKLFFIKNQRSSLRIRLFNFSLKLLSCLLYIIRVLLENPSQGNEWSHIFWVNRSLPLWGLQVSVALISLFETILLGYLSYKGNIWEQILRIPFILEIINAVPFIISIFWPSLRNLFVPVFLNCWLAKHALENMINDLHRAIQRTQSAMFNQVLILISTLLCLIFTCICGIQHLERIGKKLNLFDSLYFCIVTFSTVGFGDVTPETWSSKLFVVAMICVALVVLPIQFEQLAYLWMERQKSGGNYSRHRAQTEKHVVLCVSSLKIDLLMDFLNEFYAHPRLQDYYVVILCPTEMDVQVRRVLQIPMWSQRVIYLQGSALKDQDLLRAKMDDAEACFILSSRCEVDRTSSDHQTILRAWAVKDFAPNCPLYVQILKPENKFHIKFADHVVCEEEFKYAMLALNCICPATSTLITLLVHTSRGQEGQQSPEQWQKMYGRCSGNEVYHIVLEESTFFAEYEGKSFTYASFHAHKKFGVCLIGVRREDNKNILLNPGPRYIMNSTDICFYINITKEENSAFKNQDQQRKSNVSRSFYHGPSRLPVHSIIASMGTVAIDLQDTSCRSASGPTLSLPTEGSKEIRRPSIAPVLEVADTSSIQTCDLLSDQSEDETTPDEEMSSNLEYAKGYPPYSPYIGSSPTFCHLLHEKVPFCCLRLDKSCQHNYYEDAKAYGFKNKLIIVAAETAGNGLYNFIVPLRAYYRPKKELNPIVLLLDNPPDMHFLDAICWFPMVYYMVGSIDNLDDLLRCGVTFAANMVVVDKESTMSAEEDYMADAKTIVNVQTLFRLFSSLSIITELTHPANMRFMQFRAKDCYSLALSKLEKKERERGSNLAFMFRLPFAAGRVFSISMLDTLLYQSFVKDYMISITRLLLGLDTTPGSGFLCSMKITADDLWIRTYARLYQKLCSSTGDVPIGIYRTESQKLTTSESQISISVEEWEDTKDSKEQGHHRSNHRNSTSSDQSDHPLLRRKSMQWARRLSRKGPKHSGKTAEKITQQRLNLYRRSERQELAELVKNRMKHLGLSTVGYDEMNDHQSTLSYILINPSPDTRIELNDVVYLIRPDPLAYLPNSEPSRRNSICNVTGQDSREETQL
T78318	DRUGINFO	D09DHT	phorbol 12-myristate 13-acetate	Phase 2
T78318	DRUGINFO	D0O2TC	iberiotoxin	Investigative
T78318	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T42521	TARGETID	T42521
T42521	UNIPROID	Q7DJJ2_ECOLX
T42521	TARGNAME	Bacterial Shiga toxin 2 subunit B (Bact stxII)
T42521	GENENAME	Bact stxII
T42521	TARGTYPE	Clinical trial
T42521	SYNONYMS	Stx2B protein; Stx2B; Stx2 holotoxin subunit B; Stx2 holotoxin B subunit; Shiga-like toxin type II B subunit; Shiga toxin subunit B; Shiga toxin 2v subunit A; Shiga toxin 2B; Shiga toxin 2, subunit B; Shiga toxin 2 B subunit
T42521	FUNCTION	Shiga toxin, one of the most potent bacterial toxins known. Binds to the cellular receptor, globotriaosylceramide, Gb3, found primarily on endothelial cells.
T42521	PDBSTRUC	4M1U
T42521	SEQUENCE	MKKMFMAVLFALVSVNAMAADCAKGKIEFSKYNEDDTFTVKVDGKEYWTSRWNLQPLLQSAQLTGMTVTIKSSTCESGSGFAEVQFNND
T42521	DRUGINFO	D07YPW	Shigamabs	Phase 3

T68967	TARGETID	T68967
T68967	FORMERID	TTDI02006
T68967	UNIPROID	SMS1_HUMAN; SMS2_HUMAN
T68967	TARGNAME	Sphingomyelin synthase (SMS)
T68967	GENENAME	SGMS1; SGMS2
T68967	TARGTYPE	Clinical trial
T68967	SYNONYMS	SMS; Phosphatidylcholine:ceramide cholinephosphotransferase
T68967	FUNCTION	Sphingomyelin synthases synthesize the sphingolipid, sphingomyelin, through transfer of the phosphatidyl head group, phosphatidylcholine, on to the primary hydroxyl of ceramide. The reaction is bidirectional depending on the respective levels of the sphingolipid and ceramide. Golgi apparatus SMS1 directly and specifically recognizes the choline head group on the substrate, requiring two fatty chains on the choline-P donor molecule inorder to be recognized efficiently as a substrate. Major form in macrophages. Required for cell growth in certain cell types such as HeLa cells. Suppresses BAX-mediated apoptosis and also prevents cell death in response to stimuli such as hydrogen peroxide, osmotic stress, elevated temperature and exogenously supplied sphingolipids. May protect against cell death by reversing the stress-inducibleincrease in levels of proapoptotic ceramide.
T68967	BIOCLASS	Sphingomyelin synthase
T68967	SEQUENCE	MKEVVYWSPKKVADWLLENAMPEYCEPLEHFTGQDLINLTQEDFKKPPLCRVSSDNGQRLLDMIETLKMEHHLEAHKNGHANGHLNIGVDIPTPDGSFSIKIKPNGMPNGYRKEMIKIPMPELERSQYPMEWGKTFLAFLYALSCFVLTTVMISVVHERVPPKEVQPPLPDTFFDHFNRVQWAFSICEINGMILVGLWLIQWLLLKYKSIISRRFFCIVGTLYLYRCITMYVTTLPVPGMHFNCSPKLFGDWEAQLRRIMKLIAGGGLSITGSHNMCGDYLYSGHTVMLTLTYLFIKEYSPRRLWWYHWICWLLSVVGIFCILLAHDHYTVDVVVAYYITTRLFWWYHTMANQQVLKEASQMNLLARVWWYRPFQYFEKNVQGIVPRSYHWPFPWPVVHLSRQVKYSRLVNDT
T68967	DRUGINFO	D02DWK	2-hydroxyoleic acid	Phase 1/2

T84614	TARGETID	T84614
T84614	UNIPROID	IL31R_HUMAN
T84614	TARGNAME	Interleukin 31 receptor (IL31R)
T84614	GENENAME	IL31RA
T84614	TARGTYPE	Clinical trial
T84614	SYNONYMS	hGLM-R; ZcytoR17; UNQ6368/PRO21073/PRO21384; Interleukin-31 receptor subunit alpha; IL-31RA; IL-31R-alpha; IL-31R subunit alpha; IL-31R; IL-31 receptor subunit alpha; Gp130-like receptor; Gp130-like monocyte receptor; GPL; GLM-R; Cytokine receptor-like 3; CRL3
T84614	FUNCTION	May function in skin immunity. Mediates IL31-induced itch, probably in a manner dependent on cation channels TRPA1 and TRPV1. Positively regulates numbers and cycling status of immature subsets of myeloid progenitor cells in bone marrow in vivo and enhances myeloid progenitor cell survival in vitro. Associates with OSMR to form the interleukin-31 receptor which activates STAT3 and to a lower extent STAT1 and STAT5.
T84614	BIOCLASS	Cytokine receptor
T84614	SEQUENCE	MMWTWALWMLPSLCKFSLAALPAKPENISCVYYYRKNLTCTWSPGKETSYTQYTVKRTYAFGEKHDNCTTNSSTSENRASCSFFLPRITIPDNYTIEVEAENGDGVIKSHMTYWRLENIAKTEPPKIFRVKPVLGIKRMIQIEWIKPELAPVSSDLKYTLRFRTVNSTSWMEVNFAKNRKDKNQTYNLTGLQPFTEYVIALRCAVKESKFWSDWSQEKMGMTEEEAPCGLELWRVLKPAEADGRRPVRLLWKKARGAPVLEKTLGYNIWYYPESNTNLTETMNTTNQQLELHLGGESFWVSMISYNSLGKSPVATLRIPAIQEKSFQCIEVMQACVAEDQLVVKWQSSALDVNTWMIEWFPDVDSEPTTLSWESVSQATNWTIQQDKLKPFWCYNISVYPMLHDKVGEPYSIQAYAKEGVPSEGPETKVENIGVKTVTITWKEIPKSERKGIICNYTIFYQAEGGKGFSKTVNSSILQYGLESLKRKTSYIVQVMASTSAGGTNGTSINFKTLSFSVFEIILITSLIGGGLLILIILTVAYGLKKPNKLTHLCWPTVPNPAESSIATWHGDDFKDKLNLKESDDSVNTEDRILKPCSTPSDKLVIDKLVVNFGNVLQEIFTDEARTGQENNLGGEKNGYVTCPFRPDCPLGKSFEELPVSPEIPPRKSQYLRSRMPEGTRPEAKEQLLFSGQSLVPDHLCEEGAPNPYLKNSVTAREFLVSEKLPEHTKGEV
T84614	DRUGINFO	D0B2IR	Nemolizumab	Phase 3

T77990	TARGETID	T77990
T77990	FORMERID	TTDI02103
T77990	UNIPROID	ISDB_STAAW
T77990	TARGNAME	Staphylococcus Iron-regulated surface determinant B (Stap-coc isdB)
T77990	GENENAME	Stap-coc isdB
T77990	TARGTYPE	Clinical trial
T77990	SYNONYMS	isdB; Staphylococcus aureus surface protein J; Staphylococcal ironregulated protein H; Ironregulated surface determinant protein B; Furregulated protein B
T77990	FUNCTION	Seems to function as the primary receptor for hemoglobin since its inactivation inhibits the ability of S.aureus to bind hemoglobin. Binds hemoglobin in a dose-dependent way. Required for S.aureus growth using hemoglobin as the sole iron source. Also required for virulence. IsdA and/or IsdB promote resistance to hydrogen peroxide and killing by neutrophils.
T77990	PDBSTRUC	2MOQ
T77990	SEQUENCE	MNKQQKEFKSFYSIRKSSLGVASVAISTLLLLMSNGEAQAAAEETGGTNTEAQPKTEAVASPTTTSEKAPETKPVANAVSVSNKEVEAPTSETKEAKEVKEVKAPKETKEVKPAAKATNNTYPILNQELREAIKNPAIKDKDHSAPNSRPIDFEMKKKDGTQQFYHYASSVKPARVIFTDSKPEIELGLQSGQFWRKFEVYEGDKKLPIKLVSYDTVKDYAYIRFSVSNGTKAVKIVSSTHFNNKEEKYDYTLMEFAQPIYNSADKFKTEEDYKAEKLLAPYKKAKTLERQVYELNKIQDKLPEKLKAEYKKKLEDTKKALDEQVKSAITEFQNVQPTNEKMTDLQDTKYVVYESVENNESMMDTFVKHPIKTGMLNGKKYMVMETTNDDYWKDFMVEGQRVRTISKDAKNNTRTIIFPYVEGKTLYDAIVKVHVKTIDYDGQYHVRIVDKEAFTKANTDKSNKKEQQDNSAKKEATPATPSKPTPSPVEKESQKQDSQKDDNKQLPSVEKENDASSESGKDKTPATKPTKGEVESSSTTPTKVVSTTQNVAKPTTASSKTTKDVVQTSAGSSEAKDSAPLQKANIKNTNDGHTQSQNNKNTQENKAKSLPQTGEESNKDMTLPLMALLALSSIVAFVLPRKRKN
T77990	DRUGINFO	D0SQ8R	V-710	Phase 2/3

T11911	TARGETID	T11911
T11911	FORMERID	TTDI03307
T11911	UNIPROID	KCNN1_HUMAN
T11911	TARGNAME	Calcium-activated potassium channel KCa2.1 (KCNN1)
T11911	GENENAME	KCNN1
T11911	TARGTYPE	Clinical trial
T11911	SYNONYMS	Small conductance calcium-activated potassium channel protein 1; SKCa1; SKCa 1; SK1; SK; KCa2.1
T11911	FUNCTION	Forms a voltage-independent potassium channel activated by intracellular calcium. Activation is followed by membrane hyperpolarization. Thought to regulate neuronal excitability by contributing to the slow component of synaptic afterhyperpolarization. The channel is blocked by apamin (By similarity).
T11911	BIOCLASS	Voltage-gated ion channel
T11911	SEQUENCE	MNSHSYNGSVGRPLGSGPGALGRDPPDPEAGHPPQPPHSPGLQVVVAKSEPARPSPGSPRGQPQDQDDDEDDEEDEAGRQRASGKPSNVGHRLGHRRALFEKRKRLSDYALIFGMFGIVVMVTETELSWGVYTKESLYSFALKCLISLSTAILLGLVVLYHAREIQLFMVDNGADDWRIAMTCERVFLISLELAVCAIHPVPGHYRFTWTARLAFTYAPSVAEADVDVLLSIPMFLRLYLLGRVMLLHSKIFTDASSRSIGALNKITFNTRFVMKTLMTICPGTVLLVFSISSWIIAAWTVRVCERYHDKQEVTSNFLGAMWLISITFLSIGYGDMVPHTYCGKGVCLLTGIMGAGCTALVVAVVARKLELTKAEKHVHNFMMDTQLTKRVKNAAANVLRETWLIYKHTRLVKKPDQARVRKHQRKFLQAIHQAQKLRSVKIEQGKLNDQANTLTDLAKTQTVMYDLVSELHAQHEELEARLATLESRLDALGASLQALPGLIAQAIRPPPPPLPPRPGPGPQDQAARSSPCRWTPVAPSDCG
T11911	DRUGINFO	D0I2FI	dequalinium	Clinical trial
T11911	DRUGINFO	D00WMV	UCL1684	Investigative
T11911	DRUGINFO	D0N1HE	UCL1848	Investigative
T11911	DRUGINFO	D0VK9Y	apamin	Investigative
T11911	DRUGINFO	D0T0AG	EBIO	Investigative
T11911	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T08499	TARGETID	T08499
T08499	FORMERID	TTDI03405
T08499	UNIPROID	NLRP3_HUMAN
T08499	TARGNAME	Caterpiller protein 1.1 (NLRP3)
T08499	GENENAME	NLRP3
T08499	TARGTYPE	Clinical trial
T08499	SYNONYMS	PYRIN-containing APAF1-like protein 1; PYPAF1; NALP3; NACHT, LRR and PYD domains-containing protein 3; Cryopyrin; Cold-induced autoinflammatory syndrome 1 protein; CLR1.1; CIAS1; C1orf7; Angiotensin/vasopressin receptor AII/AVP-like
T08499	FUNCTION	In response to pathogens and other damage-associated signals, initiates the formation of the inflammasome polymeric complex, made of NLRP3, PYCARD and CASP1 (and possibly CASP4 and CASP5). Recruitment of proCASP1 to the inflammasome promotes its activation and CASP1-catalyzed IL1B and IL18 maturation and secretion in the extracellular milieu. Activation of NLRP3 inflammasome is also required for HMGB1 secretion. The active cytokines and HMGB1 stimulate inflammatory responses. Inflammasomes can also induce pyroptosis, an inflammatory form of programmed cell death. Under resting conditions, NLRP3 is autoinhibited. NLRP3 activation stimuli include extracellular ATP, reactive oxygen species, K(+) efflux, crystals of monosodium urate or cholesterol, amyloid-beta fibers, environmental or industrial particles and nanoparticles, cytosolic dsRNA, etc. However, it is unclear what constitutes the direct NLRP3 activator. Activation in presence of cytosolic dsRNA is mediated by DHX33. Independently of inflammasome activation, regulates the differentiation of T helper 2 (Th2) cells and has a role in Th2 cell-dependent asthma and tumor growth. During Th2 differentiation, required for optimal IRF4 binding to IL4 promoter and for IRF4-dependent IL4 transcription. Binds to the consensus DNA sequence 5'-GRRGGNRGAG-3'. May also participate in the transcription of IL5, IL13, GATA3, CCR3, CCR4 and MAF. As the sensor component of the NLRP3 inflammasome, plays a crucial role in innate immunity and inflammation.
T08499	PDBSTRUC	3QF2; 2NAQ
T08499	SEQUENCE	MKMASTRCKLARYLEDLEDVDLKKFKMHLEDYPPQKGCIPLPRGQTEKADHVDLATLMIDFNGEEKAWAMAVWIFAAINRRDLYEKAKRDEPKWGSDNARVSNPTVICQEDSIEEEWMGLLEYLSRISICKMKKDYRKKYRKYVRSRFQCIEDRNARLGESVSLNKRYTRLRLIKEHRSQQEREQELLAIGKTKTCESPVSPIKMELLFDPDDEHSEPVHTVVFQGAAGIGKTILARKMMLDWASGTLYQDRFDYLFYIHCREVSLVTQRSLGDLIMSCCPDPNPPIHKIVRKPSRILFLMDGFDELQGAFDEHIGPLCTDWQKAERGDILLSSLIRKKLLPEASLLITTRPVALEKLQHLLDHPRHVEILGFSEAKRKEYFFKYFSDEAQARAAFSLIQENEVLFTMCFIPLVCWIVCTGLKQQMESGKSLAQTSKTTTAVYVFFLSSLLQPRGGSQEHGLCAHLWGLCSLAADGIWNQKILFEESDLRNHGLQKADVSAFLRMNLFQKEVDCEKFYSFIHMTFQEFFAAMYYLLEEEKEGRTNVPGSRLKLPSRDVTVLLENYGKFEKGYLIFVVRFLFGLVNQERTSYLEKKLSCKISQQIRLELLKWIEVKAKAKKLQIQPSQLELFYCLYEMQEEDFVQRAMDYFPKIEINLSTRMDHMVSSFCIENCHRVESLSLGFLHNMPKEEEEEEKEGRHLDMVQCVLPSSSHAACSHGLVNSHLTSSFCRGLFSVLSTSQSLTELDLSDNSLGDPGMRVLCETLQHPGCNIRRLWLGRCGLSHECCFDISLVLSSNQKLVELDLSDNALGDFGIRLLCVGLKHLLCNLKKLWLVSCCLTSACCQDLASVLSTSHSLTRLYVGENALGDSGVAILCEKAKNPQCNLQKLGLVNSGLTSVCCSALSSVLSTNQNLTHLYLRGNTLGDKGIKLLCEGLLHPDCKLQVLELDNCNLTSHCCWDLSTLLTSSQSLRKLSLGNNDLGDLGVMMFCEVLKQQSCLLQNLGLSEMYFNYETKSALETLQEEKPELTVVFEPSW
T08499	DRUGINFO	D0TH5H	Dapansutrile	Phase 2
T08499	DRUGINFO	D75LNO	BMS-986299	Phase 1
T08499	DRUGINFO	D7KRB9	Selnoflast	Phase 1
T08499	DRUGINFO	D09FGL	MCC950	Investigative

T27861	TARGETID	T27861
T27861	FORMERID	TTDI01546
T27861	UNIPROID	CRBN_HUMAN
T27861	TARGNAME	Protein cereblon (CRBN)
T27861	GENENAME	CRBN
T27861	TARGTYPE	Clinical trial
T27861	SYNONYMS	Protein cereblon
T27861	FUNCTION	Substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as MEIS2. Normal degradation of key regulatory proteins is required for normal limb outgrowth and expression of the fibroblast growth factor FGF8. May play a role in memory and learning by regulating the assembly and neuronal surface expression of large-conductance calcium-activated potassium channels in brain regions involved in memory and learning via its interaction with KCNT1. Binding of pomalidomide and other thalidomide-related drugs changes the substrate specificity of the human protein, leading to decreased degradation of MEIS2 and other target proteins and increased degradation of MYC, IRF4, IKZF1 and IKZF3.
T27861	PDBSTRUC	6H0G; 6H0F; 6BOY; 6BNB; 6BN9
T27861	SEQUENCE	MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTSLCCKQCQETEITTKNEIFSLSLCGPMAAYVNPHGYVHETLTVYKACNLNLIGRPSTEHSWFPGYAWTVAQCKICASHIGWKFTATKKDMSPQKFWGLTRSALLPTIPDTEDEISPDKVILCL
T27861	DRUGINFO	D01XVX	CC-220	Phase 2
T27861	DRUGINFO	D03QZJ	CC-122	Phase 1

T85544	TARGETID	T85544
T85544	FORMERID	TTDNC00529
T85544	UNIPROID	SIN1_HUMAN
T85544	TARGNAME	Target of rapamycin complex 2 MAPKAP1 (MTORC2)
T85544	GENENAME	MAPKAP1
T85544	TARGTYPE	Clinical trial
T85544	SYNONYMS	mSIN1; Target of rapamycin complex 2 subunit MAPKAP1; TORC2 subunit MAPKAP1; Stress-activated map kinase-interacting protein 1; SIN1; SAPK-interacting protein 1; Mitogen-activated protein kinase 2-associated protein 1; MIP1
T85544	FUNCTION	mTORC2 is activated by growth factors, but, in contrast to mTORC1, seems to be nutrient-insensitive. mTORC2 seems to function upstream of Rho GTPases to regulate the actin cytoskeleton, probably by activating one or more Rho-type guanine nucleotide exchange factors. mTORC2 promotes the serum-induced formation of stress-fibers or F-actin. mTORC2 plays a critical role in AKT1 'Ser-473' phosphorylation, which may facilitate the phosphorylation of the activation loop of AKT1 on 'Thr-308' by PDK1 which is a prerequisite for full activation. mTORC2 regulates the phosphorylation of SGK1 at 'Ser-422'. mTORC2 also modulates the phosphorylation of PRKCA on 'Ser-657'. Within mTORC2, MAPKAP1 is required for complex formation and mTORC2 kinase activity. MAPKAP1 inhibits MAP3K2 by preventing its dimerization and autophosphorylation. Inhibits HRAS and KRAS signaling. Enhances osmotic stress-induced phosphorylation of ATF2 and ATF2-mediated transcription. Involved in ciliogenesis, regulates cilia length through its interaction with CCDC28B independently of mTORC2 complex. Subunit of mTORC2, which regulates cell growth and survival in response to hormonal signals.
T85544	PDBSTRUC	5ZCS; 3VOQ
T85544	SEQUENCE	MAFLDNPTIILAHIRQSHVTSDDTGMCEMVLIDHDVDLEKIHPPSMPGDSGSEIQGSNGETQGYVYAQSVDITSSWDFGIRRRSNTAQRLERLRKERQNQIKCKNIQWKERNSKQSAQELKSLFEKKSLKEKPPISGKQSILSVRLEQCPLQLNNPFNEYSKFDGKGHVGTTATKKIDVYLPLHSSQDRLLPMTVVTMASARVQDLIGLICWQYTSEGREPKLNDNVSAYCLHIAEDDGEVDTDFPPLDSNEPIHKFGFSTLALVEKYSSPGLTSKESLFVRINAAHGFSLIQVDNTKVTMKEILLKAVKRRKGSQKVSGPQYRLEKQSEPNVAVDLDSTLESQSAWEFCLVRENSSRADGVFEEDSQIDIATVQDMLSSHHYKSFKVSMIHRLRFTTDVQLGISGDKVEIDPVTNQKASTKFWIKQKPISIDSDLLCACDLAEEKSPSHAIFKLTYLSNHDYKHLYFESDAATVNEIVLKVNYILESRASTARADYFAQKQRKLNRRTSFSFQKEKKSGQQ
T85544	DRUGINFO	D0Z2UQ	AZD2014	Phase 2
T85544	DRUGINFO	D03IXK	ME-344	Phase 1/2
T85544	DRUGINFO	DP17AI	Palomid-529	Phase 1
T85544	DRUGINFO	D0U3DP	VS-5584	Phase 1

T77190	TARGETID	T77190
T77190	FORMERID	TTDI02175
T77190	UNIPROID	SLIK6_HUMAN
T77190	TARGNAME	SLIT and NTRK-like family member 6 (SLITRK6)
T77190	GENENAME	SLITRK6
T77190	TARGTYPE	Clinical trial
T77190	SYNONYMS	SLITRK6; SLIT and NTRK-like protein 6
T77190	FUNCTION	Regulator of neurite outgrowth required for normal hearing and vision.
T77190	SEQUENCE	MKLWIHLFYSSLLACISLHSQTPVLSSRGSCDSLCNCEEKDGTMLINCEAKGIKMVSEISVPPSRPFQLSLLNNGLTMLHTNDFSGLTNAISIHLGFNNIADIEIGAFNGLGLLKQLHINHNSLEILKEDTFHGLENLEFLQADNNFITVIEPSAFSKLNRLKVLILNDNAIESLPPNIFRFVPLTHLDLRGNQLQTLPYVGFLEHIGRILDLQLEDNKWACNCDLLQLKTWLENMPPQSIIGDVVCNSPPFFKGSILSRLKKESICPTPPVYEEHEDPSGSLHLAATSSINDSRMSTKTTSILKLPTKAPGLIPYITKPSTQLPGPYCPIPCNCKVLSPSGLLIHCQERNIESLSDLRPPPQNPRKLILAGNIIHSLMKSDLVEYFTLEMLHLGNNRIEVLEEGSFMNLTRLQKLYLNGNHLTKLSKGMFLGLHNLEYLYLEYNAIKEILPGTFNPMPKLKVLYLNNNLLQVLPPHIFSGVPLTKVNLKTNQFTHLPVSNILDDLDLLTQIDLEDNPWDCSCDLVGLQQWIQKLSKNTVTDDILCTSPGHLDKKELKALNSEILCPGLVNNPSMPTQTSYLMVTTPATTTNTADTILRSLTDAVPLSVLILGLLIMFITIVFCAAGIVVLVLHRRRRYKKKQVDEQMRDNSPVHLQYSMYGHKTTHHTTERPSASLYEQHMVSPMVHVYRSPSFGPKHLEEEEERNEKEGSDAKHLQRSLLEQENHSPLTGSNMKYKTTNQSTEFLSFQDASSLYRNILEKERELQQLGITEYLRKNIAQLQPDMEAHYPGAHEELKLMETLMYSRPRKVLVEQTKNEYFELKANLHAEPDYLEVLEQQT
T77190	DRUGINFO	D0UM4S	ASG-15ME	Phase 1

T99704	TARGETID	T99704
T99704	UNIPROID	VISTA_HUMAN
T99704	TARGNAME	V-set immunoregulatory receptor (VSIR)
T99704	GENENAME	VSIR
T99704	TARGTYPE	Clinical trial
T99704	SYNONYMS	VISTA; V-set domain-containing immunoregulatory receptor; Stress-induced secreted protein-1; Sisp-1; SISP1; Platelet receptor Gi24; C10orf54
T99704	FUNCTION	Immunoregulatory receptor which inhibits the T-cell response (PubMed:24691993). May promote differentiation of embryonic stem cells, by inhibiting BMP4 signaling. May stimulate MMP14-mediated MMP2 activation (PubMed:20666777).
T99704	SEQUENCE	MGVPTALEAGSWRWGSLLFALFLAASLGPVAAFKVATPYSLYVCPEGQNVTLTCRLLGPVDKGHDVTFYKTWYRSSRGEVQTCSERRPIRNLTFQDLHLHHGGHQAANTSHDLAQRHGLESASDHHGNFSITMRNLTLLDSGLYCCLVVEIRHHHSEHRVHGAMELQVQTGKDAPSNCVVYPSSSQDSENITAAALATGACIVGILCLPLILLLVYKQRQAASNRRAQELVRMDSNIQGIENPGFEASPPAQGIPEAKVRHPLSYVAQRQPSESGRHLLSEPSTPLSPPGPGDVFFPSLDPVPDSPNFEVI
T99704	DRUGINFO	D0PE3Z	JNJ-61610588	Phase 1
T99704	DRUGINFO	DXF93J	CI-8993	Phase 1
T99704	DRUGINFO	D09PPU	CA-170	Phase 1

T75643	TARGETID	T75643
T75643	FORMERID	TTDI01990
T75643	UNIPROID	NOD2_HUMAN
T75643	TARGNAME	Pattern recognition receptor NOD2 (NOD2)
T75643	GENENAME	NOD2
T75643	TARGTYPE	Clinical trial
T75643	SYNONYMS	Nucleotidebinding oligomerization domaincontaining protein 2; Nucleotide-binding oligomerization domain-containing protein 2; Inflammatory bowel disease protein 1; IBD1; Caspase recruitment domaincontaining protein 15; Caspase recruitment domain-containing protein 15; CARD15
T75643	FUNCTION	Upon stimulation by muramyl dipeptide (MDP), a fragment of bacterial peptidoglycan, binds the proximal adapter receptor-interacting RIPK2, which recruits ubiquitin ligases as XIAP, BIRC2, BIRC3, INAVA and the LUBAC complex, triggering activation of MAP kinases and activation of NF-kappa-B signaling. This in turn leads to the transcriptional activation of hundreds of genes involved in immune response. Required for MDP-induced NLRP1-dependent CASP1 activation and IL1B release in macrophages. Component of an autophagy-mediated antibacterial pathway together with ATG16L1. Plays also a role in sensing single-stranded RNA (ssRNA) from viruses. Interacts with mitochondrial antiviral signaling/MAVS, leading to activation of interferon regulatory factor-3/IRF3 and expression of type I interferon. Involved in gastrointestinal immunity.
T75643	SEQUENCE	MGEEGGSASHDEEERASVLLGHSPGCEMCSQEAFQAQRSQLVELLVSGSLEGFESVLDWLLSWEVLSWEDYEGFHLLGQPLSHLARRLLDTVWNKGTWACQKLIAAAQEAQADSQSPKLHGCWDPHSLHPARDLQSHRPAIVRRLHSHVENMLDLAWERGFVSQYECDEIRLPIFTPSQRARRLLDLATVKANGLAAFLLQHVQELPVPLALPLEAATCKKYMAKLRTTVSAQSRFLSTYDGAETLCLEDIYTENVLEVWADVGMAGPPQKSPATLGLEELFSTPGHLNDDADTVLVVGEAGSGKSTLLQRLHLLWAAGQDFQEFLFVFPFSCRQLQCMAKPLSVRTLLFEHCCWPDVGQEDIFQLLLDHPDRVLLTFDGFDEFKFRFTDRERHCSPTDPTSVQTLLFNLLQGNLLKNARKVVTSRPAAVSAFLRKYIRTEFNLKGFSEQGIELYLRKRHHEPGVADRLIRLLQETSALHGLCHLPVFSWMVSKCHQELLLQEGGSPKTTTDMYLLILQHFLLHATPPDSASQGLGPSLLRGRLPTLLHLGRLALWGLGMCCYVFSAQQLQAAQVSPDDISLGFLVRAKGVVPGSTAPLEFLHITFQCFFAAFYLALSADVPPALLRHLFNCGRPGNSPMARLLPTMCIQASEGKDSSVAALLQKAEPHNLQITAAFLAGLLSREHWGLLAECQTSEKALLRRQACARWCLARSLRKHFHSIPPAAPGEAKSVHAMPGFIWLIRSLYEMQEERLARKAARGLNVGHLKLTFCSVGPTECAALAFVLQHLRRPVALQLDYNSVGDIGVEQLLPCLGVCKALYLRDNNISDRGICKLIECALHCEQLQKLALFNNKLTDGCAHSMAKLLACRQNFLALRLGNNYITAAGAQVLAEGLRGNTSLQFLGFWGNRVGDEGAQALAEALGDHQSLRWLSLVGNNIGSVGAQALALMLAKNVMLEELCLEENHLQDEGVCSLAEGLKKNSSLKILKLSNNCITYLGAEALLQALERNDTILEVWLRGNTFSLEEVDKLGCRDTRLLL
T75643	DRUGINFO	D01UHA	MIS-416	Phase 2
T75643	DRUGINFO	D04HQC	SB-9200	Phase 2
T75643	DRUGINFO	D05UGC	muramyl dipeptide	Investigative

T86748	TARGETID	T86748
T86748	FORMERID	TTDNC00350
T86748	UNIPROID	CD248_HUMAN
T86748	TARGNAME	Endosialin (CD248)
T86748	GENENAME	CD248
T86748	TARGTYPE	Clinical trial
T86748	SYNONYMS	Tumor endothelial marker 1; Tumor Endothelial Marker 1 (TEM-1); TEM1; CD164L1
T86748	FUNCTION	May play a role in tumor angiogenesis.
T86748	SEQUENCE	MLLRLLLAWAAAGPTLGQDPWAAEPRAACGPSSCYALFPRRRTFLEAWRACRELGGDLATPRTPEEAQRVDSLVGAGPASRLLWIGLQRQARQCQLQRPLRGFTWTTGDQDTAFTNWAQPASGGPCPAQRCVALEASGEHRWLEGSCTLAVDGYLCQFGFEGACPALQDEAGQAGPAVYTTPFHLVSTEFEWLPFGSVAAVQCQAGRGASLLCVKQPEGGVGWSRAGPLCLGTGCSPDNGGCEHECVEEVDGHVSCRCTEGFRLAADGRSCEDPCAQAPCEQQCEPGGPQGYSCHCRLGFRPAEDDPHRCVDTDECQIAGVCQQMCVNYVGGFECYCSEGHELEADGISCSPAGAMGAQASQDLGDELLDDGEDEEDEDEAWKAFNGGWTEMPGILWMEPTQPPDFALAYRPSFPEDREPQIPYPEPTWPPPLSAPRVPYHSSVLSVTRPVVVSATHPTLPSAHQPPVIPATHPALSRDHQIPVIAANYPDLPSAYQPGILSVSHSAQPPAHQPPMISTKYPELFPAHQSPMFPDTRVAGTQTTTHLPGIPPNHAPLVTTLGAQLPPQAPDALVLRTQATQLPIIPTAQPSLTTTSRSPVSPAHQISVPAATQPAALPTLLPSQSPTNQTSPISPTHPHSKAPQIPREDGPSPKLALWLPSPAPTAAPTALGEAGLAEHSQRDDRWLLVALLVPTCVFLVVLLALGIVYCTRCGPHAPNKRITDCYRWVIHAGSKSPTEPMPPRGSLTGVQTCRTSV
T86748	DRUGINFO	D02RKG	MORAb-004	Phase 2
T86748	DRUGINFO	D0FK9H	Ontuxizumab	Phase 2

T42882	TARGETID	T42882
T42882	FORMERID	TTDI01243
T42882	UNIPROID	Q9I1N2_PSEAE
T42882	TARGNAME	Pseudomonas Psl exopolysaccharide (Pseudo pslG)
T42882	GENENAME	Pseudo pslG
T42882	TARGTYPE	Clinical trial
T42882	SYNONYMS	PslG
T42882	FUNCTION	A extracellular matrix component of P. aeruginosa biofilms. A galactose-rich and mannose-rich exopolysaccharide.
T42882	PDBSTRUC	5BXA; 5BX9; 4ZN2
T42882	SEQUENCE	MARKGLYLGGSALLLAVVLLLVFWGRPADAEIQVLKAPRAVVWKDFLGVNAQFLWFSPERYNKQIDRLQDLGLEWVRLDLHWDRLETAEDQYQLASLDQLVKDLEARQLKSVFYLVGSARFITTAPFYSPFQDQYPPRDPEVFARRMAMLSQRYPSVAAWQVWNEPNLIGFWRPKADPEGYAKLLQASTIALRMVDPEKPVVSAGMAFFSEMPDGRTMFDALGHLGVESLGTIATYHPYTQLPEGNYPWNLDFVSHANQINRALRNAGVPAIWSTEWGWSAYKGPKELQDIIGVEGQADYVLRRLALMSALDYDRIFLFTLSDLDQRASVRDRDYGLLDLDANPKPVYLALQRFLKVTGPKLRPADPPVTEDLPDGSFSIGWTREDGRNVWLFWSARGGNVRLPKLKEATLHDPLSGKVTPLSGSDGLEVPVKSSLQMLVWE
T42882	DRUGINFO	D05IYA	MEDI3902	Phase 2

T31329	TARGETID	T31329
T31329	FORMERID	TTDI01928
T31329	UNIPROID	Q9NJG8_LEIDO
T31329	TARGNAME	Leishmania DNA topoisomerase I (Leishm TOP1)
T31329	GENENAME	Leishm TOP1
T31329	TARGTYPE	Clinical trial
T31329	SYNONYMS	Leishm DNA topoisomerase I; DNA topoisomerase 1
T31329	FUNCTION	Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a single-strand break via transesterification at the specific target site 5'-[CT]CCTTp site in duplex DNA. The scissile phosphodiester is attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-(3'-phosphotyrosyl)-enzyme intermediate and the expulsion of a 5'-OH DNA strand. The free DNA strand then undergoes passage around the unbroken strand thus removing DNA supercoils. Finally, in the religation step, the DNA 5'-OH attacks the covalent intermediate to expel the active-site tyrosine and restore the DNA phosphodiester backbone.
T31329	ECNUMBER	EC 5.6.2.2
T31329	SEQUENCE	MPLPGGGTEVLKGITLLTQHHGLKPVQPMSFCYLSFLNRHTHEHHLRLHCCRPHAYARAHPCTCLIDFPLTSYPISQQCAPRLLPLPRQPPLSSQPAEAPSQIGTKDGLLLFRVSNRPQWVFCVCVCVRACPSFPLPRSCDFNRRGAVSPLSSPPRRAPVCCWRFFFHSCSFFFLVLYLLSAPYFCSLWARCANEEDKQNKLRIKQHETKKETPFRVCGGDCPSCCVGLSSHLFFPRWRLLVPPLPYTLDSNNSIFCVFHLFIYFLVCLFVSLAPSTYPFVPLCQLRTLHLYEPRPHIGTPLRCFCCHRDSIRRIMKVENSKMGVKREQSHSNEDEEINEEDLNWWEQENLRIAMKGERRWETLAHNGVLFPPEYEPHGIPIFYDGREFKMTPEEEEVATMFAVMKEHDYYRMEVFRRNFFESWREILDKRQHPIRRLELCDFEPIYQWHLVQREKKLSRTKEEKKAIKEKQDAEAEPYRYCVWDGRREQVANFRVEPPGLFRGRGKHPLMGKLKVRVQPEDITINIGETAEVPVPPAGHKWAAVQHDHTVTWLAMWRDSVAGNMKYVMLAPSSSVKGQSDMVKFEKARKLKDKVDDIRASYMEDFKSNDLHVAQRAVAMYIDRLALRVGNEKGEDEADTVGCCSLRVEHIQLMPDNIVRFDFLGKDSIRYQNDVAVLPEVYALLQRFTRRKSPGMDIFDQLNPTQLNDHLKSFMDGLSAKVFRTYNASITLDRWFKEKPVDPKWSTADKLAYFNKANTEVAILCNHQKSVSKNFKLQMMQLTTKSEYTRKTIELLEKAEVTAKKKSVEEAAKEFLEEQDRMQREWLESYGTEEQKKEFEEIVAKRAAPRVRSEKKKSTSGAKKAESASGKKRAAKKKKSAKKGGKMLSKKAASKSSKKAPKKLKEEDEDDVPLVSVAAKTKKTAGVKRQRANKVVSDDDDVPLAALRV
T31329	DRUGINFO	D09BBW	Sodium stibogluconate	Phase 2

T83561	TARGETID	T83561
T83561	FORMERID	TTDR01171
T83561	UNIPROID	DDIT4_HUMAN
T83561	TARGNAME	HIF-1 responsive protein RTP801 (DDIT4)
T83561	GENENAME	DDIT4
T83561	TARGTYPE	Clinical trial
T83561	SYNONYMS	RTP801; REDD1; REDD-1; Protein regulated in development and DNA damage response 1; DNA damage-inducible transcript 4 protein
T83561	FUNCTION	Regulates cell growth, proliferation and survival via inhibition of the activity of the mammalian target of rapamycin complex 1 (mTORC1). Inhibition of mTORC1 is mediated by a pathway that involves DDIT4/REDD1, AKT1, the TSC1-TSC2 complex and the GTPase RHEB. Plays an important role in responses to cellular energy levels and cellular stress, including responses to hypoxia and DNA damage. Regulates p53/TP53-mediated apoptosis in response to DNA damage via its effect on mTORC1 activity. Its role in the response to hypoxia depends on the cell type; it mediates mTORC1 inhibition in fibroblasts and thymocytes, but not in hepatocytes (By similarity). Required for mTORC1-mediated defense against viral protein synthesis and virus replication (By similarity). Inhibits neuronal differentiation and neurite outgrowth mediated by NGF via its effect on mTORC1 activity. Required for normal neuron migration during embryonic brain development. Plays a role in neuronal cell death.
T83561	PDBSTRUC	3LQ9
T83561	SEQUENCE	MPSLWDRFSSSSTSSSPSSLPRTPTPDRPPRSAWGSATREEGFDRSTSLESSDCESLDSSNSGFGPEEDTAYLDGVSLPDFELLSDPEDEHLCANLMQLLQESLAQARLGSRRPARLLMPSQLVSQVGKELLRLAYSEPCGLRGALLDVCVEQGKSCHSVGQLALDPSLVPTFQLTLVLRLDSRLWPKIQGLFSSANSPFLPGFSQSLTLSTGFRVIKKKLYSSEQLLIEEC
T83561	DRUGINFO	D01VVL	PF-04523655	Phase 2

T75716	TARGETID	T75716
T75716	UNIPROID	DLL3_HUMAN
T75716	TARGNAME	Delta-like protein 3 (DLL3)
T75716	GENENAME	DLL3
T75716	TARGTYPE	Clinical trial
T75716	SYNONYMS	pudgy; pu; delta like canonical Notch ligand 3; SCDO1; Drosophila Delta homolog 3; Delta3
T75716	FUNCTION	May be required to divert neurons along a specific differentiation pathway. Plays a role in the formation of somite boundaries during segmentation of the paraxial mesoderm. Inhibits primary neurogenesis.
T75716	SEQUENCE	MVSPRMSGLLSQTVILALIFLPQTRPAGVFELQIHSFGPGPGPGAPRSPCSARLPCRLFFRVCLKPGLSEEAAESPCALGAALSARGPVYTEQPGAPAPDLPLPDGLLQVPFRDAWPGTFSFIIETWREELGDQIGGPAWSLLARVAGRRRLAAGGPWARDIQRAGAWELRFSYRARCEPPAVGTACTRLCRPRSAPSRCGPGLRPCAPLEDECEAPLVCRAGCSPEHGFCEQPGECRCLEGWTGPLCTVPVSTSSCLSPRGPSSATTGCLVPGPGPCDGNPCANGGSCSETPRSFECTCPRGFYGLRCEVSGVTCADGPCFNGGLCVGGADPDSAYICHCPPGFQGSNCEKRVDRCSLQPCRNGGLCLDLGHALRCRCRAGFAGPRCEHDLDDCAGRACANGGTCVEGGGAHRCSCALGFGGRDCRERADPCAARPCAHGGRCYAHFSGLVCACAPGYMGARCEFPVHPDGASALPAAPPGLRPGDPQRYLLPPALGLLVAAGVAGAALLLVHVRRRGHSQDAGSRLLAGTPEPSVHALPDALNNLRTQEGSGDGPSSSVDWNRPEDVDPQGIYVISAPSIYAREVATPLFPPLHTGRAGQRQHLLFPYPSSILSVK
T75716	DRUGINFO	D06WOF	Rova-T	Phase 3
T75716	DRUGINFO	DRH03S	Tarlatamab	Phase 2
T75716	DRUGINFO	DM14CQ	HPN328	Phase 1/2
T75716	DRUGINFO	D9FGB3	AMG 119	Phase 1
T75716	DRUGINFO	D7IA0N	AMG 757	Phase 1
T75716	DRUGINFO	D2L9MD	RG6524	Phase 1

T13741	TARGETID	T13741
T13741	FORMERID	TTDI02229
T13741	UNIPROID	OGFR_HUMAN
T13741	TARGNAME	Opioid receptor zeta (OGFR)
T13741	GENENAME	OGFR
T13741	TARGTYPE	Clinical trial
T13741	SYNONYMS	Zetatype opioid receptor; Zeta-type opioid receptor; Protein 760; Protein 7-60; Opioid growth factor receptor; OGFr
T13741	FUNCTION	Seems to be involved in growth regulation. Receptor for opioid growth factor (OGF), also known as Met-enkephalin.
T13741	BIOCLASS	GPCR rhodopsin
T13741	SEQUENCE	MDDPDCDSTWEEDEEDAEDAEDEDCEDGEAAGARDADAGDEDEESEEPRAARPSSFQSRMTGSRNWRATRDMCRYRHNYPDLVERDCNGDTPNLSFYRNEIRFLPNGCFIEDILQNWTDNYDLLEDNHSYIQWLFPLREPGVNWHAKPLTLREVEVFKSSQEIQERLVRAYELMLGFYGIRLEDRGTGTVGRAQNYQKRFQNLNWRSHNNLRITRILKSLGELGLEHFQAPLVRFFLEETLVRRELPGVRQSALDYFMFAVRCRHQRRQLVHFAWEHFRPRCKFVWGPQDKLRRFKPSSLPHPLEGSRKVEEEGSPGDPDHEASTQGRTCGPEHSKGGGRVDEGPQPRSVEPQDAGPLERSQGDEAGGHGEDRPEPLSPKESKKRKLELSRREQPPTEPGPQSASEVEKIALNLEGCALSQGSLRTGTQEVGGQDPGEAVQPCRQPLGARVADKVRKRRKVDEGAGDSAAVASGGAQTLALAGSPAPSGHPKAGHSENGVEEDTEGRTGPKEGTPGSPSETPGPSPAGPAGDEPAESPSETPGPRPAGPAGDEPAESPSETPGPRPAGPAGDEPAESPSETPGPSPAGPTRDEPAESPSETPGPRPAGPAGDEPAESPSETPGPRPAGPAGDEPAESPSETPGPSPAGPTRDEPAKAGEAAELQDAEVESSAKSGKP
T13741	DRUGINFO	D0J5UK	IRT-102	Phase 2
T13741	DRUGINFO	D08KYN	INNO-105	Phase 1

T82391	TARGETID	T82391
T82391	FORMERID	TTDI02301
T82391	UNIPROID	NDUAD_HUMAN
T82391	TARGNAME	Mitochondrial complex I (NDUFA13)
T82391	GENENAME	NDUFA13
T82391	TARGTYPE	Clinical trial
T82391	SYNONYMS	NADH-ubiquinone oxidoreductase B16.6 subunit; NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13; Gene associated with retinoic and interferon-induced mortality 19 protein; Gene associated with retinoic and IFN-induced mortality 19 protein; GRIM19; GRIM-19; Complex I-B16.6; Cell death regulatory protein GRIM-19; CI-B16.6; CGI-39; CDA016
T82391	FUNCTION	Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone. Involved in the interferon/all-trans-retinoic acid (IFN/RA) induced cell death. This apoptotic activity is inhibited by interaction with viral IRF1. Prevents the transactivation of STAT3 target genes. May play a role in CARD15-mediated innate mucosal responses and serve to regulate intestinal epithelial cell responses to microbes. Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis.
T82391	PDBSTRUC	5XTI; 5XTH; 5XTD; 5XTC; 5XTB
T82391	SEQUENCE	MAASKVKQDMPPPGGYGPIDYKRNLPRRGLSGYSMLAIGIGTLIYGHWSIMKWNRERRRLQIEDFEARIALLPLLQAETDRRTLQMLRENLEEEAIIMKDVPDWKVGESVFHTTRWVPPLIGELYGLRTTEEALHASHGFMWYT
T82391	DRUGINFO	D0U1VZ	Flurpiridaz F 18	Phase 3

T91558	TARGETID	T91558
T91558	FORMERID	TTDI03591
T91558	UNIPROID	TRPC4_HUMAN
T91558	TARGNAME	Short transient receptor potential channel 4 (TRPC4)
T91558	GENENAME	TRPC4
T91558	TARGTYPE	Clinical trial
T91558	SYNONYMS	hTrp4; hTrp-4; TrpC4; Trp-related protein 4
T91558	FUNCTION	Form a receptor-activated non-selective calcium permeant cation channel. Acts as a cell-cell contact-dependent endothelial calcium entry channel. Probably operated by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases or G-protein coupled receptors. Mediates cation entry, with an enhanced permeability to barium over calcium. May also be activated by intracellular calcium store depletion.
T91558	BIOCLASS	Transient receptor potential catioin channel
T91558	SEQUENCE	MAQFYYKRNVNAPYRDRIPLRIVRAESELSPSEKAYLNAVEKGDYASVKKSLEEAEIYFKININCIDPLGRTALLIAIENENLELIELLLSFNVYVGDALLHAIRKEVVGAVELLLNHKKPSGEKQVPPILLDKQFSEFTPDITPIILAAHTNNYEIIKLLVQKGVSVPRPHEVRCNCVECVSSSDVDSLRHSRSRLNIYKALASPSLIALSSEDPFLTAFQLSWELQELSKVENEFKSEYEELSRQCKQFAKDLLDQTRSSRELEIILNYRDDNSLIEEQSGNDLARLKLAIKYRQKEFVAQPNCQQLLASRWYDEFPGWRRRHWAVKMVTCFIIGLLFPVFSVCYLIAPKSPLGLFIRKPFIKFICHTASYLTFLFLLLLASQHIDRSDLNRQGPPPTIVEWMILPWVLGFIWGEIKQMWDGGLQDYIHDWWNLMDFVMNSLYLATISLKIVAFVKYSALNPRESWDMWHPTLVAEALFAIANIFSSLRLISLFTANSHLGPLQISLGRMLLDILKFLFIYCLVLLAFANGLNQLYFYYEETKGLTCKGIRCEKQNNAFSTLFETLQSLFWSIFGLINLYVTNVKAQHEFTEFVGATMFGTYNVISLVVLLNMLIAMMNNSYQLIADHADIEWKFARTKLWMSYFEEGGTLPTPFNVIPSPKSLWYLIKWIWTHLCKKKMRRKPESFGTIGRRAADNLRRHHQYQEVMRNLVKRYVAAMIRDAKTEEGLTEENFKELKQDISSFRFEVLGLLRGSKLSTIQSANASKESSNSADSDEKSDSEGNSKDKKKNFSLFDLTTLIHPRSAAIASERHNISNGSALVVQEPPREKQRKVNFVTDIKNFGLFHRRSKQNAAEQNANQIFSVSEEVARQQAAGPLERNIQLESRGLASRGDLSIPGLSEQCVLVDHRERNTDTLGLQVGKRVCPFKSEKVVVEDTVPIIPKEKHAKEEDSSIDYDLNLPDTVTHEDYVTTRL
T91558	DRUGINFO	DD1ZV6	BI 1358894	Phase 2
T91558	DRUGINFO	D0G8FT	ML204	Investigative
T91558	DRUGINFO	D0M6VZ	(-)-englerin A	Investigative
T91558	DRUGINFO	D00HCI	2-APB	Investigative

T04388	TARGETID	T04388
T04388	FORMERID	TTDI03309
T04388	UNIPROID	KCNN3_HUMAN
T04388	TARGNAME	Calcium-activated potassium channel KCa2.3 (KCNN3)
T04388	GENENAME	KCNN3
T04388	TARGTYPE	Clinical trial
T04388	SYNONYMS	Small conductance calcium-activated potassium channel protein 3; SKCa3; SKCa 3; SK3; KCa2.3; K3
T04388	FUNCTION	Forms a voltage-independent potassium channel activated by intracellular calcium. Activation is followed by membrane hyperpolarization. Thought to regulate neuronal excitability by contributing to the slow component of synaptic afterhyperpolarization. The channel is blocked by apamin.
T04388	BIOCLASS	Voltage-gated ion channel
T04388	SEQUENCE	MDTSGHFHDSGVGDLDEDPKCPCPSSGDEQQQQQQQQQQQQPPPPAPPAAPQQPLGPSLQPQPPQLQQQQQQQQQQQQQQPPHPLSQLAQLQSQPVHPGLLHSSPTAFRAPPSSNSTAILHPSSRQGSQLNLNDHLLGHSPSSTATSGPGGGSRHRQASPLVHRRDSNPFTEIAMSSCKYSGGVMKPLSRLSASRRNLIEAETEGQPLQLFSPSNPPEIVISSREDNHAHQTLLHHPNATHNHQHAGTTASSTTFPKANKRKNQNIGYKLGHRRALFEKRKRLSDYALIFGMFGIVVMVIETELSWGLYSKDSMFSLALKCLISLSTIILLGLIIAYHTREVQLFVIDNGADDWRIAMTYERILYISLEMLVCAIHPIPGEYKFFWTARLAFSYTPSRAEADVDIILSIPMFLRLYLIARVMLLHSKLFTDASSRSIGALNKINFNTRFVMKTLMTICPGTVLLVFSISLWIIAAWTVRVCERYHDQQDVTSNFLGAMWLISITFLSIGYGDMVPHTYCGKGVCLLTGIMGAGCTALVVAVVARKLELTKAEKHVHNFMMDTQLTKRIKNAAANVLRETWLIYKHTKLLKKIDHAKVRKHQRKFLQAIHQLRSVKMEQRKLSDQANTLVDLSKMQNVMYDLITELNDRSEDLEKQIGSLESKLEHLTASFNSLPLLIADTLRQQQQQLLSAIIEARGVSVAVGTTHTPISDSPIGVSSTSFPTPYTSSSSC
T04388	DRUGINFO	D0I2FI	dequalinium	Clinical trial
T04388	DRUGINFO	D00DIF	CyPPA	Investigative
T04388	DRUGINFO	D00WMV	UCL1684	Investigative
T04388	DRUGINFO	D0I6MA	DC-EBIO	Investigative
T04388	DRUGINFO	D0N1HE	UCL1848	Investigative
T04388	DRUGINFO	D0VK9Y	apamin	Investigative
T04388	DRUGINFO	D0T0AG	EBIO	Investigative
T04388	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T19368	TARGETID	T19368
T19368	FORMERID	TTDI03354
T19368	UNIPROID	LIPE_HUMAN
T19368	TARGNAME	Endothelial lipase (LIPG)
T19368	GENENAME	LIPG
T19368	TARGTYPE	Clinical trial
T19368	SYNONYMS	Endothelial cell-derived lipase; EL; EDL
T19368	FUNCTION	Has phospholipase and triglyceride lipase activities. Hydrolyzes high density lipoproteins (HDL) more efficiently than other lipoproteins. Binds heparin.
T19368	ECNUMBER	EC 3.1.1.3
T19368	SEQUENCE	MSNSVPLLCFWSLCYCFAAGSPVPFGPEGRLEDKLHKPKATQTEVKPSVRFNLRTSKDPEHEGCYLSVGHSQPLEDCSFNMTAKTFFIIHGWTMSGIFENWLHKLVSALHTREKDANVVVVDWLPLAHQLYTDAVNNTRVVGHSIARMLDWLQEKDDFSLGNVHLIGYSLGAHVAGYAGNFVKGTVGRITGLDPAGPMFEGADIHKRLSPDDADFVDVLHTYTRSFGLSIGIQMPVGHIDIYPNGGDFQPGCGLNDVLGSIAYGTITEVVKCEHERAVHLFVDSLVNQDKPSFAFQCTDSNRFKKGICLSCRKNRCNSIGYNAKKMRNKRNSKMYLKTRAGMPFRVYHYQMKIHVFSYKNMGEIEPTFYVTLYGTNADSQTLPLEIVERIEQNATNTFLVYTEEDLGDLLKIQLTWEGASQSWYNLWKEFRSYLSQPRNPGRELNIRRIRVKSGETQRKLTFCTEDPENTSISPGRELWFRKCRDGWRMKNETSPTVELP
T19368	DRUGINFO	D0D4VK	REG-101	Phase 2
T19368	DRUGINFO	D02NHW	GSK-264220A	Clinical trial

T61547	TARGETID	T61547
T61547	FORMERID	TTDI01711
T61547	UNIPROID	W8TNQ9_STAAU
T61547	TARGNAME	Staphylococcus Manganese transporter C (Stap-coc MntC)
T61547	GENENAME	Stap-coc MntC
T61547	TARGTYPE	Clinical trial
T61547	SYNONYMS	Metal ABC transporter substrate-binding protein; Manganese ABC transporter substrate-binding protein; Manganese ABC transporter substrate-binding lipoprotein; ABC transporter substrate-binding protein; ABC superfamily ATP binding cassette transporter, binding protein
T61547	FUNCTION	A component of Mnt comples, conserved across the staphylococcal species group. Expressed on the cell surface of S. aureus in biofilms generated in in vivo models of infection.
T61547	PDBSTRUC	5HDQ
T61547	SEQUENCE	MKKLVPLLLALLLLVAACGTGGKQSSDKSNGKLKVVTTNSILYDMAKNVGGDNVDIHSIVPVGQDPHEYEVKPKDIKKLTDADVILYNGLNLETGNGWFEKALEQAGKSLKDKKVIAVSKDVKPIYLNGEEGNKDKQDPHAWLSLDNGIKYVKTIQQTFIDNDKKHKADYEKQGNKYIAQLEKLNNDSKDKFNDIPKEQRAMITSEGAFKYFSKQYGITPGYIWEINTEKQGTPEQMRQAIEFVKKHKLKHLLVETSVDKKAMESLSEETKKDIFGEVYTDSIGKEGTKGDSYYKMMKSNIETVHGSMK
T61547	DRUGINFO	D01DXI	PF-06290510	Phase 2

T57364	TARGETID	T57364
T57364	FORMERID	TTDC00274
T57364	UNIPROID	REV_HV1H2
T57364	TARGNAME	Human immunodeficiency virus Rev messenger RNA (HIV rev mRNA)
T57364	GENENAME	HIV rev mRNA
T57364	TARGTYPE	Clinical trial
T57364	SYNONYMS	rev (mRNA); Regulator of expression of viral proteins (mRNA); Protein Rev (mRNA); Anti-repression transactivator (mRNA); ART/TRS (mRNA)
T57364	FUNCTION	These pre-mRNAs carry a recognition sequence called Rev responsive element (RRE) located in the env gene, that is not present in fully spliced viral mRNAs (early transcripts). This function is essential since most viral proteins are translated from unspliced or partially spliced pre-mRNAs which cannot exit the nucleus by the pathway used by fully processed cellular mRNAs. Rev itself is translated from a fully spliced mRNA that readily exits the nucleus. Rev's nuclear localization signal (NLS) binds directly to KPNB1/Importin beta-1 without previous binding to KPNA1/Importin alpha-1. KPNB1 binds to the GDP bound form of RAN (Ran-GDP) and targets Rev to the nucleus. In the nucleus, the conversion from Ran-GDP to Ran-GTP dissociates Rev from KPNB1 and allows Rev's binding to the RRE in viral pre-mRNAs. Rev multimerization on the RRE via cooperative assembly exposes its nuclear export signal (NES) to the surface. Rev can then form a complex with XPO1/CRM1 and Ran-GTP, leading to nuclear export of the complex. Conversion from Ran-GTP to Ran-GDP mediates dissociation of the Rev/RRE/XPO1/RAN complex, so that Rev can return to the nucleus for a subsequent round of export. Beside KPNB1, also seems to interact with TNPO1/Transportin-1, RANBP5/IPO5 and IPO7/RANBP7 for nuclear import. The nucleoporin-like HRB/RIP is an essential cofactor that probably indirectly interacts with Rev to release HIV RNAs from the perinuclear region to the cytoplasm. Escorts unspliced or incompletely spliced viral pre-mRNAs (late transcripts) out of the nucleus of infected cells.
T57364	BIOCLASS	mRNA target
T57364	SEQUENCE	MAGRSGDSDEELIRTVRLIKLLYQSNPPPNPEGTRQARRNRRRRWRERQRQIHSISERILGTYLGRSAEPVPLQLPPLERLTLDCNEDCGTSGTQGVGSPQILVESPTVLESGTKE
T57364	DRUGINFO	D0JZ8X	HGTV43	Phase 2

T09037	TARGETID	T09037
T09037	FORMERID	TTDI02242
T09037	UNIPROID	VP35_EBOSU
T09037	TARGNAME	Ebola virus VP35 messenger RNA (EV VP35 mRNA)
T09037	GENENAME	EV VP35 mRNA
T09037	TARGTYPE	Clinical trial
T09037	SYNONYMS	VP35 (mRNA); Polymerase cofactor VP35 (mRNA)
T09037	FUNCTION	Prevents establishment of cellular antiviral state by blocking virus-induced phosphorylation and activation of interferon regulatory factor 3 (IRF3), a transcription factor critical for the induction of interferons alpha and beta. This blockage is produced through the interaction with and inhibition host IKBKE and TBK1 producing a strong inhibition of the phosphorylation and activation of IRF3. Also inhibits the antiviral effect mediated by the interferon-induced, double-stranded RNA-activated protein kinase EIF2AK2/PKR. Acts as a polymerase cofactor in the RNA polymerase transcription and replication complex.
T09037	BIOCLASS	mRNA target
T09037	SEQUENCE	MQQDRTYRHHGPEVSGWFSEQLMTGKIPLTEVFVDVENKPSPAPITIISKNPKTTRKSDKQVQTDDASSLLTEEVKAAINSVISAVRRQTNAIESLEGRVTTLEASLKPVQDMAKTISSLNRSCAEMVAKYDLLVMTTGRATATAAATEAYWNEHGQAPPGPSLYEDDAIKAKLKDPNGKVPESVKQAYINLDSTSALNEENFGRPYISAKDLKEIIYDHLPGFGTAFHQLVQVICKIGKDNNILDIIHAEFQASLAEGDSPQCALIQITKRIPAFQDASPPIVHIKSRGDIPKACQKSLRPVPPSPKIDRGWVCIFQFQDGKALGLKI
T09037	DRUGINFO	D04LIH	AVI-6002	Phase 1
T09037	DRUGINFO	D0CB6N	AVI-6003	Phase 1

T01110	TARGETID	T01110
T01110	FORMERID	TTDNC00521
T01110	UNIPROID	E9PEK4_HUMAN
T01110	TARGNAME	Colony stimulating factor-1 receptor (CSF-1R)
T01110	GENENAME	CSF1R
T01110	TARGTYPE	Clinical trial
T01110	SYNONYMS	Macrophage colony-stimulating factor 1 receptor
T01110	FUNCTION	A cytokine which controls the production, differentiation, and function of macrophages.
T01110	SEQUENCE	MGPGVLLLLLVATAWHGQGIPVIEPSVPELVVKPGATVTLRCVGNGSVEWDGPPSPHWTLYSDGSSSILSTNNATFQNTGTYRCTEPGDPLGGSAAIHLYVKDPARPWNVLAQEVVVFEDQDALLPCLLTDPVLEAGVSLVRVRGRPLMRHTNYSFSPWHGFTIHRAKFIQSQDYQCSALMGGRKVMSISIRLKVQKVIPGPPALTLVPAELVRIRGEAAQIVCSASSVDVNFDVFLQHNNTKLAIPQQSDFHNNRYQKVLTLNLDQVDFQHAGNYSCVASNVQGKHSTSMFFRVVESAYLNLSSEQNLIQEVTVGEGLNLKVMVEAYPGLQGFNWTYLGPFSDHQPEPKLANATTKDTYRHTFTLSLPRLKPSEAGRYSFLARNPGGWRALTFELTLRYPPEVSVIWTFINGSGTLLCAASGYPQPNVTWLQCSGHTDRCDEAQVLQVWDDPYPEVLSQEPFHKVTVQSLLTVETLEHNQTYECRAHNSVGSGSWAFIPISAGAHTHPPDEFLFTPVVVACMSIMALLLLLLLLLLYKYKQKPKYQVRWKIIESYEGNSYTFIDPTQLPYNEKWEFPRNNLQFGKTLGAGAFGKVVEATAFGLGKEDAVLKVAVKMLKSTAHADEKEALMSELKIMSHLGQHENIVNLLGACTHGGTVASPARVWTPMWR
T01110	DRUGINFO	D04EAT	MCS-110	Phase 2
T01110	DRUGINFO	D0C5JQ	JNJ-40346527	Phase 2
T01110	DRUGINFO	D0S1UZ	PD-360324	Phase 2
T01110	DRUGINFO	D05JAA	ARRY-382	Phase 2
T01110	DRUGINFO	D06NQH	RG7155	Phase 2
T01110	DRUGINFO	D08ZQI	FPA-008	Phase 1/2
T01110	DRUGINFO	D0CN7I	IMC-CS4	Phase 1
T01110	DRUGINFO	D0I8DX	AMG 820	Phase 1

T22415	TARGETID	T22415
T22415	FORMERID	TTDI02142
T22415	UNIPROID	O30527_PSEAI
T22415	TARGNAME	Pseudomonas PcrV protein type III (Pseudo pcrV)
T22415	GENENAME	Pseudo pcrV
T22415	TARGTYPE	Clinical trial
T22415	SYNONYMS	Type III secretion protein PcrV; Pseudo Virulence-associated V antigen; Pseudo Low calcium response locus protein V; PcrV
T22415	FUNCTION	Essential for cytotoxicity. Found both within the bacterial cytoplasm and localized extracellularly.
T22415	SEQUENCE	MEVRNLNAARELFLDELLAASAAPASAEQEELLALLRSERIVLAHAGQPLSEAQVLKALAWLLAANPSAPPGQGLEVLREVLQARRQPGAQWDLREFLVSAYFSLHGRLDEDVIGVYKDVLQTQDGKRKALLDELKALTAELKVYSVIQSQINAALSAKQGIRIDAGGIDLVDPTLYGYAVGDPRWKDSPEYALLSNLDTFSGKLSIKDFLSGSPKQSGELKGLSDEYPFEKDNNPVGNFATTVSDRSRPLNDKVNEKTTLLNDTSSRYNSAVEALNRFIQKYDSVLRDILSAI
T22415	DRUGINFO	DI6G5U	KB001A	Phase 2
T22415	DRUGINFO	D05IYA	MEDI3902	Phase 2

T23953	TARGETID	T23953
T23953	FORMERID	TTDR00392
T23953	UNIPROID	PSCA_HUMAN
T23953	TARGNAME	Prostate stem cell antigen (PSCA)
T23953	GENENAME	PSCA
T23953	TARGTYPE	Clinical trial
T23953	SYNONYMS	UNQ206/PRO232
T23953	FUNCTION	Has a cell-proliferation inhibition activity in vitro. May be involved in the regulation of cell proliferation.
T23953	SEQUENCE	MAGLALQPGTALLCYSCKAQVSNEDCLQVENCTQLGEQCWTARIRAVGLLTVISKGCSLNCVDDSQDYYVGKKNITCCDTDLCNASGAHALQPAAAILALLPALGLLLWGPGQL
T23953	DRUGINFO	D0G7ZT	Anti-PSCA mab	Phase 2
T23953	DRUGINFO	D0TY6U	BPX-601	Phase 1/2
T23953	DRUGINFO	D02MYI	CAR-T Cells targeting PSCA	Phase 1
T23953	DRUGINFO	D0MG3Z	CAR-T cells targeting PSCA	Phase 1
T23953	DRUGINFO	D1L7DE	GEM3PSCA	Phase 1
T23953	DRUGINFO	DD4XR3	MB-105	Phase 1

T02258	TARGETID	T02258
T02258	FORMERID	TTDI01628
T02258	UNIPROID	DPOLQ_HUMAN; DPOLN_HUMAN; DPOLB_HUMAN; DPOG2_HUMAN; DPOG1_HUMAN; DPOE2_HUMAN; DPOD4_HUMAN; DPOD1_HUMAN
T02258	TARGNAME	DNA-dependent DNA polymerase (DPOL)
T02258	GENENAME	POLQ; POLN; POLB; POLG2; POLG; POLE2; POLD4; ;POLD1
T02258	TARGTYPE	Clinical trial
T02258	SYNONYMS	DNA polymerase
T02258	FUNCTION	Has 5'-deoxyribose-5-phosphate lyase (dRP lyase) activity that removes the 5' sugar phosphate and also acts as a DNA polymerase that adds one nucleotide to the 3' end of the arising single-nucleotide gap. Repair polymerase that plays a key role in base-excision repair. Conducts 'gap-filling' DNA synthesis in a stepwise distributive fashion rather than in a processive fashion as for other DNA polymerases.
T02258	SEQUENCE	MNLLRRSGKRRRSESGSDSFSGSGGDSSASPQFLSGSVLSPPPGLGRCLKAAAAGECKPTVPDYERDKLLLANWGLPKAVLEKYHSFGVKKMFEWQAECLLLGQVLEGKNLVYSAPTSAGKTLVAELLILKRVLEMRKKALFILPFVSVAKEKKYYLQSLFQEVGIKVDGYMGSTSPSRHFSSLDIAVCTIERANGLINRLIEENKMDLLGMVVVDELHMLGDSHRGYLLELLLTKICYITRKSASCQADLASSLSNAVQIVGMSATLPNLELVASWLNAELYHTDFRPVPLLESVKVGNSIYDSSMKLVREFEPMLQVKGDEDHVVSLCYETICDNHSVLLFCPSKKWCEKLADIIAREFYNLHHQAEGLVKPSECPPVILEQKELLEVMDQLRRLPSGLDSVLQKTVPWGVAFHHAGLTFEERDIIEGAFRQGLIRVLAATSTLSSGVNLPARRVIIRTPIFGGRPLDILTYKQMVGRAGRKGVDTVGESILICKNSEKSKGIALLQGSLKPVRSCLQRREGEEVTGSMIRAILEIIVGGVASTSQDMHTYAACTFLAASMKEGKQGIQRNQESVQLGAIEACVMWLLENEFIQSTEASDGTEGKVYHPTHLGSATLSSSLSPADTLDIFADLQRAMKGFVLENDLHILYLVTPMFEDWTTIDWYRFFCLWEKLPTSMKRVAELVGVEEGFLARCVKGKVVARTERQHRQMAIHKRFFTSLVLLDLISEVPLREINQKYGCNRGQIQSLQQSAAVYAGMITVFSNRLGWHNMELLLSQFQKRLTFGIQRELCDLVRVSLLNAQRARVLYASGFHTVADLARANIVEVEVILKNAVPFKSARKAVDEEEEAVEERRNMRTIWVTGRKGLTEREAAALIVEEARMILQQDLVEMGVQWNPCALLHSSTCSLTHSESEVKEHTFISQTKSSYKKLTSKNKSNTIFSDSYIKHSPNIVQDLNKSREHTSSFNCNFQNGNQEHQTCSIFRARKRASLDINKEKPGASQNEGKTSDKKVVQTFSQKTKKAPLNFNSEKMSRSFRSWKRRKHLKRSRDSSPLKDSGACRIHLQGQTLSNPSLCEDPFTLDEKKTEFRNSGPFAKNVSLSGKEKDNKTSFPLQIKQNCSWNITLTNDNFVEHIVTGSQSKNVTCQATSVVSEKGRGVAVEAEKINEVLIQNGSKNQNVYMKHHDIHPINQYLRKQSHEQTSTITKQKNIIERQMPCEAVSSYINRDSNVTINCERIKLNTEENKPSHFQALGDDISRTVIPSEVLPSAGAFSKSEGQHENFLNISRLQEKTGTYTTNKTKNNHVSDLGLVLCDFEDSFYLDTQSEKIIQQMATENAKLGAKDTNLAAGIMQKSLVQQNSMNSFQKECHIPFPAEQHPLGATKIDHLDLKTVGTMKQSSDSHGVDILTPESPIFHSPILLEENGLFLKKNEVSVTDSQLNSFLQGYQTQETVKPVILLIPQKRTPTGVEGECLPVPETSLNMSDSLLFDSFSDDYLVKEQLPDMQMKEPLPSEVTSNHFSDSLCLQEDLIKKSNVNENQDTHQQLTCSNDESIIFSEMDSVQMVEALDNVDIFPVQEKNHTVVSPRALELSDPVLDEHHQGDQDGGDQDERAEKSKLTGTRQNHSFIWSGASFDLSPGLQRILDKVSSPLENEKLKSMTINFSSLNRKNTELNEEQEVISNLETKQVQGISFSSNNEVKSKIEMLENNANHDETSSLLPRKESNIVDDNGLIPPTPIPTSASKLTFPGILETPVNPWKTNNVLQPGESYLFGSPSDIKNHDLSPGSRNGFKDNSPISDTSFSLQLSQDGLQLTPASSSSESLSIIDVASDQNLFQTFIKEWRCKKRFSISLACEKIRSLTSSKTATIGSRFKQASSPQEIPIRDDGFPIKGCDDTLVVGLAVCWGGRDAYYFSLQKEQKHSEISASLVPPSLDPSLTLKDRMWYLQSCLRKESDKECSVVIYDFIQSYKILLLSCGISLEQSYEDPKVACWLLDPDSQEPTLHSIVTSFLPHELPLLEGMETSQGIQSLGLNAGSEHSGRYRASVESILIFNSMNQLNSLLQKENLQDVFRKVEMPSQYCLALLELNGIGFSTAECESQKHIMQAKLDAIETQAYQLAGHSFSFTSSDDIAEVLFLELKLPPNREMKNQGSKKTLGSTRRGIDNGRKLRLGRQFSTSKDVLNKLKALHPLPGLILEWRRITNAITKVVFPLQREKCLNPFLGMERIYPVSQSHTATGRITFTEPNIQNVPRDFEIKMPTLVGESPPSQAVGKGLLPMGRGKYKKGFSVNPRCQAQMEERAADRGMPFSISMRHAFVPFPGGSILAADYSQLELRILAHLSHDRRLIQVLNTGADVFRSIAAEWKMIEPESVGDDLRQQAKQICYGIIYGMGAKSLGEQMGIKENDAACYIDSFKSRYTGINQFMTETVKNCKRDGFVQTILGRRRYLPGIKDNNPYRKAHAERQAINTIVQGSAADIVKIATVNIQKQLETFHSTFKSHGHREGMLQSDQTGLSRKRKLQGMFCPIRGGFFILQLHDELLYEVAEEDVVQVAQIVKNEMESAVKLSVKLKVKVKIGASWGELKDFDV
T02258	DRUGINFO	D0W5NW	CMX-001	Phase 3
T02258	DRUGINFO	DE8S2F	DFP-14927	Phase 1

T57560	TARGETID	T57560
T57560	FORMERID	TTDR00093
T57560	UNIPROID	PBPA_ECOLI; PBPB_ECOLI; PBPC_ECOLI
T57560	TARGNAME	Bacterial Penicillin binding protein 1 (Bact pbp)
T57560	GENENAME	Bact mrcA; Bact mrcB; Bact pbpC
T57560	TARGTYPE	Clinical trial
T57560	SYNONYMS	Penicillin-binding protein 1; PBP1; PBP-1; Bact pon
T57560	FUNCTION	Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan strands) and a penicillin-sensitive transpeptidase C-terminal domain (cross-linking of the peptide subunits).
T57560	SEQUENCE	MKFVKYFLILAVCCILLGAGSIYGLYRYIEPQLPDVATLKDVRLQIPMQIYSADGELIAQYGEKRRIPVTLDQIPPEMVKAFIATEDSRFYEHHGVDPVGIFRAASVALFSGHASQGASTITQQLARNFFLSPERTLMRKIKEVFLAIRIEQLLTKDEILELYLNKIYLGYRAYGVGAAAQVYFGKTVDQLTLNEMAVIAGLPKAPSTFNPLYSMDRAVARRNVVLSRMLDEGYITQQQFDQTRTEAINANYHAPEIAFSAPYLSEMVRQEMYNRYGESAYEDGYRIYTTITRKVQQAAQQAVRNNVLDYDMRHGYRGPANVLWKVGESAWDNNKITDTLKALPTYGPLLPAAVTSANPQQATAMLADGSTVALSMEGVRWARPYRSDTQQGPTPRKVTDVLQTGQQIWVRQVGDAWWLAQVPEVNSALVSINPQNGAVMALVGGFDFNQSKFNRATQALRQVGSNIKPFLYTAAMDKGLTLASMLNDVPISRWDASAGSDWQPKNSPPQYAGPIRLRQGLGQSKNVVMVRAMRAMGVDYAAEYLQRFGFPAQNIVHTESLALGSASFTPMQVARGYAVMANGGFLVDPWFISKIENDQGGVIFEAKPKVACPECDIPVIYGDTQKSNVLENNDVEDVAISREQQNVSVPMPQLEQANQALVAKTGAQEYAPHVINTPLAFLIKSALNTNIFGEPGWQGTGWRAGRDLQRRDIGGKTGTTNSSKDAWFSGYGPGVVTSVWIGFDDHRRNLGHTTASGAIKDQISGYEGGAKSAQPAWDAYMKAVLEGVPEQPLTPPPGIVTVNIDRSTGQLANGGNSREEYFIEGTQPTQQAVHEVGTTIIDNGEAQELF
T57560	DRUGINFO	D00QAR	Benzylpenicillin	Phase 3

T29144	TARGETID	T29144
T29144	UNIPROID	ARGI1_HUMAN; ARGI2_HUMAN
T29144	TARGNAME	Arginase (ARG)
T29144	GENENAME	ARG1; ARG2
T29144	TARGTYPE	Clinical trial
T29144	SYNONYMS	L-arginase; Canavanase; Arginine transamidinase; Arginine amidinase
T29144	FUNCTION	Arginase I functions in the urea cycle, and is located primarily in the cytoplasm of hepatocytes (liver cells); Arginase II, implicated in the regulation of intracellular arginine/ornithine levels is located in mitochondria of several tissues in the body, with most abundance in the kidney and prostate.
T29144	SEQUENCE	MSAKSRTIGIIGAPFSKGQPRGGVEEGPTVLRKAGLLEKLKEQECDVKDYGDLPFADIPNDSPFQIVKNPRSVGKASEQLAGKVAEVKKNGRISLVLGGDHSLAIGSISGHARVHPDLGVIWVDAHTDINTPLTTTSGNLHGQPVSFLLKELKGKIPDVPGFSWVTPCISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRLGIGKVMEETLSYLLGRKKRPIHLSFDVDGLDPSFTPATGTPVVGGLTYREGLYITEEIYKTGLLSGLDIMEVNPSLGKTPEEVTRTVNTAVAITLACFGLAREGNHKPIDYLNPPK
T29144	DRUGINFO	D06XAT	BCT-100	Phase 1/2
T29144	DRUGINFO	D0XI3E	INCB01158	Phase 1/2

T17514	TARGETID	T17514
T17514	FORMERID	TTDR01275
T17514	UNIPROID	INHBA_HUMAN; INHBB_HUMAN; INHBC_HUMAN; INHBE_HUMAN
T17514	TARGNAME	Activin (ACT)
T17514	GENENAME	INHBA; INHBB; INHBC; INHBE
T17514	TARGTYPE	Clinical trial
T17514	SYNONYMS	Inhibin beta; Activin beta
T17514	FUNCTION	Inhibins and activins inhibit and activate, respectively, the secretion of follitropin by the pituitary gland. Inhibins/activins are involved in regulating a number of diverse functions such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell development and maturation, erythroid differentiation, insulin secretion, nerve cell survival, embryonic axial development or bone growth, depending on their subunit composition. Inhibins appear to oppose the functions of activins.
T17514	SEQUENCE	MPLLWLRGFLLASCWIIVRSSPTPGSEGHSAAPDCPSCALAALPKDVPNSQPEMVEAVKKHILNMLHLKKRPDVTQPVPKAALLNAIRKLHVGKVGENGYVEIEDDIGRRAEMNELMEQTSEIITFAESGTARKTLHFEISKEGSDLSVVERAEVWLFLKVPKANRTRTKVTIRLFQQQKHPQGSLDTGEEAEEVGLKGERSELLLSEKVVDARKSTWHVFPVSSSIQRLLDQGKSSLDVRIACEQCQESGASLVLLGKKKKKEEEGEGKKKGGGEGGAGADEEKEQSHRPFLMLQARQSEDHPHRRRRRGLECDGKVNICCKKQFFVSFKDIGWNDWIIAPSGYHANYCEGECPSHIAGTSGSSLSFHSTVINHYRMRGHSPFANLKSCCVPTKLRPMSMLYYDDGQNIIKKDIQNMIVEECGCS
T17514	DRUGINFO	D0X6DC	STM 434	Phase 1

T66266	TARGETID	T66266
T66266	UNIPROID	CD7_HUMAN
T66266	TARGNAME	T-cell antigen CD7 (CD7)
T66266	GENENAME	CD7
T66266	TARGTYPE	Clinical trial
T66266	SYNONYMS	Tp40; TP41; T-cell surface antigen Leu-9; T-cell leukemia antigen; LEU-9; GP40; CD7 molecule
T66266	FUNCTION	Not yet known.
T66266	SEQUENCE	MAGPPRLLLLPLLLALARGLPGALAAQEVQQSPHCTTVPVGASVNITCSTSGGLRGIYLRQLGPQPQDIIYYEDGVVPTTDRRFRGRIDFSGSQDNLTITMHRLQLSDTGTYTCQAITEVNVYGSGTLVLVTEEQSQGWHRCSDAPPRASALPAPPTGSALPDPQTASALPDPPAASALPAALAVISFLLGLGLGVACVLARTQIKKLCSWRDKNSAACVVYEDMSHSRCNTLSSPNQYQ
T66266	DRUGINFO	D09ICH	CD7.CAR/28zeta CAR T cells	Phase 1
T66266	DRUGINFO	D09SBE	Anti-CD7 CAR-T cells	Phase 1

T64987	TARGETID	T64987
T64987	FORMERID	TTDR00919
T64987	UNIPROID	LMP1_EBVG
T64987	TARGNAME	Epstein-Barr virus Latent membrane protein 1 (EBV LMP1)
T64987	GENENAME	EBV LMP1
T64987	TARGTYPE	Clinical trial
T64987	SYNONYMS	Protein p63; P63; Latent membrane protein 1; LMP1; LMP-1; BNLF1
T64987	FUNCTION	Functions as a constitutively active tumor necrosis factor receptor that induces the activation of several signaling pathways, including those of the NF-kappa-B family. LMP1 signaling leads to up-regulation of antiapoptotic proteins and provide growth signals in latently infected cells. Interacts with host UBE2I and subsequently affects the sumoylation state of several cellular proteins. For example, induces the sumoylation of host IRF7 thereby limiting its transcriptional activity and modulating the activation of innate immune responses. Acts as a CD40 functional homolog to prevent apoptosis of infected B-lymphocytes and drive their proliferation.
T64987	SEQUENCE	MERDLERGPPGPPRPPLGPPLSSSIGLALLLLLLALLFWLYIVLSNWTGGALLVLYSFALMLIIIILIIFIFRRDLLCPLGGLGLLLLMVTLLLIALWNLHGQALYLGIVLFIFGCLLVLGLWIYFLEILWRLGATIWQLLAFILAFFLAIILLIIALYLQQNWWTLLVDLLWLLLFMAILIWMYFHGPRHTDEHHHDDSLPHPQQATDDSSHESDSNSNEGRHHLLVSGAGDGPPLCSQNLGAPGGGPDNGPQDPDNTDDNGPQDPDNTDDNGNTDDNGPQDPDNTDDNGPHDPLPHNPSDSAGNDGGPPNLTEEVENKGGDRGPPSMTDGGGGDPHLPTLLLGTSGSGGDDDDPHGPVQLSYYD
T64987	DRUGINFO	D0RJ2V	LMP1-CAR-T cells	Phase 1/2
T64987	DRUGINFO	D0Z6RW	LMP-1/LMP-2 CTLs	Phase 1
T64987	DRUGINFO	D0Q8PF	Ad5f35-LMPd1-2-transduced autologous dendritic cells	Investigative

T51883	TARGETID	T51883
T51883	UNIPROID	ARAF_HUMAN; BRAF_HUMAN; RAF1_HUMAN
T51883	TARGNAME	Serine/threonine-protein kinase Raf (RAF)
T51883	GENENAME	ARAF; BRAF; RAF1
T51883	TARGTYPE	Clinical trial
T51883	SYNONYMS	Proto-oncogene Raf
T51883	FUNCTION	Participate in the RAS-RAF-MEK-ERK signal transduction cascade, also referred to as the mitogen-activated protein kinase (MAPK) cascade. Activation of RAF kinases requires interaction with RAS-GTPases.
T51883	SEQUENCE	MEPPRGPPANGAEPSRAVGTVKVYLPNKQRTVVTVRDGMSVYDSLDKALKVRGLNQDCCVVYRLIKGRKTVTAWDTAIAPLDGEELIVEVLEDVPLTMHNFVRKTFFSLAFCDFCLKFLFHGFRCQTCGYKFHQHCSSKVPTVCVDMSTNRQQFYHSVQDLSGGSRQHEAPSNRPLNELLTPQGPSPRTQHCDPEHFPFPAPANAPLQRIRSTSTPNVHMVSTTAPMDSNLIQLTGQSFSTDAAGSRGGSDGTPRGSPSPASVSSGRKSPHSKSPAEQRERKSLADDKKKVKNLGYRDSGYYWEVPPSEVQLLKRIGTGSFGTVFRGRWHGDVAVKVLKVSQPTAEQAQAFKNEMQVLRKTRHVNILLFMGFMTRPGFAIITQWCEGSSLYHHLHVADTRFDMVQLIDVARQTAQGMDYLHAKNIIHRDLKSNNIFLHEGLTVKIGDFGLATVKTRWSGAQPLEQPSGSVLWMAAEVIRMQDPNPYSFQSDVYAYGVVLYELMTGSLPYSHIGCRDQIIFMVGRGYLSPDLSKISSNCPKAMRRLLSDCLKFQREERPLFPQILATIELLQRSLPKIERSASEPSLHRTQADELPACLLSAARLVP
T51883	DRUGINFO	D0M6BD	RO-5126766	Phase 2
T51883	DRUGINFO	D07IEU	MLN2480	Phase 2
T51883	DRUGINFO	D04AHQ	LY3009120	Phase 1

T90286	TARGETID	T90286
T90286	UNIPROID	FGFR3_HUMAN-TACC3_HUMAN
T90286	TARGNAME	Fusion protein FGFR3-TACC3 (FGFR3-TACC3)
T90286	GENENAME	FGFR3-TACC3
T90286	TARGTYPE	Clinical trial
T90286	SYNONYMS	FGFR3-TACC3 gene fusion; FGFR3-TACC3
T90286	FUNCTION	An oncogenic function in respiratory epithelium.
T90286	SEQUENCE	MSLQVLNDKNVSNEKNTENCDFLFSPPEVTGRSSVLRVSQKENVPPKNLAKAMKVTFQTPLRDPQTHRILSPSMASKLEAPFTQDDTLGLENSHPVWTQKENQQLIKEVDAKTTHGILQKPVEADTDLLGDASPAFGSGSSSESGPGALADLDCSSSSQSPGSSENQMVSPGKVSGSPEQAVEENLSSYSLDRRVTPASETLEDPCRTESQHKAETPHGAEEECKAETPHGAEEECRHGGVCAPAAVATSPPGAIPKEACGGAPLQGLPGEALGCPAGVGTPVPADGTQTLTCAHTSAPESTAPTNHLVAGRAMTLSPQEEVAAGQMASSSRSGPVKLEFDVSDGATSKRAPPPRRLGERSGLKPPLRKAAVRQQKAPQEVEEDDGRSGAGEDPPMPASRGSYHLDWDKMDDPNFIPFGGDTKSGCSEAQPPESPETRLGQPAAEQLHAGPATEEPGPCLSQQLHSASAEDTPVVQLAAETPTAESKERALNSASTSLPTSCPGSEPVPTHQQGQPALELKEESFRDPAEVLGTGAEVDYLEQFGTSSFKESALRKQSLYLKFDPLLRDSPGRPVPVATETSSMHGANETPSGRPREAKLVEFDFLGALDIPVPGPPPGVPAPGGPPLSTGPIVDLLQYSQKDLDAVVKATQEENRELRSRCEELHGKNLELGKIMDRFEEVVYQAMEEVQKQKELSKAEIQKVLKEKDQLTTDLNSMEKSFSDLFKRFEKQKEVIEGYRKNEESLKKCVEDYLARITQEGQRYQALKAHAEEKLQLANEEIAQVRSKAQAEALALQASLRKEQMRIQSLEKTVEQKTKENEELTRICDDLISKMEKIMGAPACALALCVAVAIVAGASSESLGTEQRVVGRAAEVPGPEPGQQEQLVFGSGDAVELSCPPPGGGPMGPTVWVKDGTGLVPSERVLVGPQRLQVLNASHEDSGAYSCRQRLTQRVLCHFSVRVTDAPSSGDDEDGEDEAEDTGVDTGAPYWTRPERMDKKLLAVPAANTVRFRCPAAGNPTPSISWLKNGREFRGEHRIGGIKLRHQQWSLVMESVVPSDRGNYTCVVENKFGSIRQTYTLDVLERSPHRPILQAGLPANQTAVLGSDVEFHCKVYSDAQPHIQWLKHVEVNGSKVGPDGTPYVTVLKTAGANTTDKELEVLSLHNVTFEDAGEYTCLAGNSIGFSHHSAWLVVLPAEEELVEADEAGSVYAGILSYGVGFFLFILVVAAVTLCRLRSPPKKGLGSPTVHKISRFPLKRQVSLESNASMSSNTPLVRIARLSSGEGPTLANVSELELPADPKWELSRARLTLGKPLGEGCFGQVVMAEAIGIDKDRAAKPVTVAVKMLKDDATDKDLSDLVSEMEMMKMIGKHKNIINLLGACTQGGPLYVLVEYAAKGNLREFLRARRPPGLDYSFDTCKPPEEQLTFKDLVSCAYQVARGMEYLASQKCIHRDLAARNVLVTEDNVMKIADFGLARDVHNLDYYKKTTNGRLPVKWMAPEALFDRVYTHQSDVWSFGVLLWEIFTLGGSPYPGIPVEELFKLLKEGHRMDKPANCTHDLYMIMRECWHAAPSQRPTFKQLVEDLDRVLTVTSTDEYLDLSAPFEQYSPGGQDTPSSSSSGDDSVFAHDLLPPAPPSSGGSRT
T90286	DRUGINFO	D0VF6E	PD173074	Investigative

T93798	TARGETID	T93798
T93798	FORMERID	TTDI03120
T93798	UNIPROID	CNGA1_HUMAN
T93798	TARGNAME	Cyclic nucleotide-gated channel alpha-1 (CNGA1)
T93798	GENENAME	CNGA1
T93798	TARGTYPE	Clinical trial
T93798	SYNONYMS	cGMP-gated cation channel alpha-1; Rod photoreceptor cGMP-gated channel subunit alpha; Cyclic nucleotide-gated channel, photoreceptor; Cyclic nucleotide-gated cation channel 1; CNG1; CNG-1; CNG channel alpha-1; CNCG1; CNCG
T93798	FUNCTION	Visual signal transduction is mediated by a G-protein coupled cascade using cGMP as second messenger. This protein can be activated by cyclic GMP which leads to an opening of the cation channel and thereby causing a depolarization of rod photoreceptors.
T93798	SEQUENCE	MKLSMKNNIINTQQSFVTMPNVIVPDIEKEIRRMENGACSSFSEDDDSASTSEESENENPHARGSFSYKSLRKGGPSQREQYLPGAIALFNVNNSSNKDQEPEEKKKKKKEKKSKSDDKNENKNDPEKKKKKKDKEKKKKEEKSKDKKEEEKKEVVVIDPSGNTYYNWLFCITLPVMYNWTMVIARACFDELQSDYLEYWLILDYVSDIVYLIDMFVRTRTGYLEQGLLVKEELKLINKYKSNLQFKLDVLSLIPTDLLYFKLGWNYPEIRLNRLLRFSRMFEFFQRTETRTNYPNIFRISNLVMYIVIIIHWNACVFYSISKAIGFGNDTWVYPDINDPEFGRLARKYVYSLYWSTLTLTTIGETPPPVRDSEYVFVVVDFLIGVLIFATIVGNIGSMISNMNAARAEFQARIDAIKQYMHFRNVSKDMEKRVIKWFDYLWTNKKTVDEKEVLKYLPDKLRAEIAINVHLDTLKKVRIFADCEAGLLVELVLKLQPQVYSPGDYICKKGDIGREMYIIKEGKLAVVADDGVTQFVVLSDGSYFGEISILNIKGSKAGNRRTANIKSIGYSDLFCLSKDDLMEALTEYPDAKTMLEEKGKQILMKDGLLDLNIANAGSDPKDLEEKVTRMEGSVDLLQTRFARILAEYESMQQKLKQRLTKVEKFLKPLIDTEFSSIEGPGAESGPIDST
T93798	DRUGINFO	D0I2FI	dequalinium	Clinical trial
T93798	DRUGINFO	D02NGU	H-8	Investigative
T93798	DRUGINFO	D00YNI	L-(cis)-diltiazem	Investigative

T54606	TARGETID	T54606
T54606	UNIPROID	LUKF_STAAU
T54606	TARGNAME	Staphylococcus Five leukocidin toxins (Stap-coc lukF)
T54606	GENENAME	Stap-coc lukF
T54606	TARGTYPE	Clinical trial
T54606	SYNONYMS	lukF
T54606	FUNCTION	Leukocidin causes cytotoxic changes in polymorphonuclear leukocytes. Gamma-hemolysin causes hemolysis in red blood cells.
T54606	SEQUENCE	MKMNKLVKSSVATSMALLLLSGTANAEGKITPVSVKKVDDKVTLYKTTATADSDKFKISQILTFNFIKDKSYDKDTLVLKATGNINSGFVKPNPNDYDFSKLYWGAKYNVSISSQSNDSVNAVDYAPKNQNEEFQVQNTLGYTFGGDISISNGLSGGLNGNTAFSETINYKQESYRTLSRNTNYKNVGWGVEAHKIMNGWGPYGRDSFHPTYGNELFLAGRQSSAYAGQNFIAQHQMPLLSRSNFNPEFLSVLSHRQDRAKKSKITVTYQREMDLYQIRWNGFYWAGANYKNFKTRTFKSTYEIDWENHKVKLLDTKETENNK
T54606	DRUGINFO	D0Z2NJ	ASN100	Phase 2

T14463	TARGETID	T14463
T14463	UNIPROID	SOAT1_HUMAN; SOAT2_HUMAN
T14463	TARGNAME	Sterol O-acyltransferase (SOAT)
T14463	GENENAME	SOAT1; SOAT2
T14463	TARGTYPE	Clinical trial
T14463	SYNONYMS	Cholesterol acyltransferase; Acyl-coenzyme A:cholesterol acyltransferase; ACAT; ACACT
T14463	FUNCTION	Catalyzes the formation of fatty acid-cholesterol esters, which are less soluble in membranes than cholesterol. Plays a role in lipoprotein assembly and dietary cholesterol absorption. In addition to its acyltransferase activity, it may act as a ligase. May provide cholesteryl esters for lipoprotein secretion from hepatocytes and intestinal mucosa.
T14463	SEQUENCE	MVGEEKMSLRNRLSKSRENPEEDEDQRNPAKESLETPSNGRIDIKQLIAKKIKLTAEAEELKPFFMKEVGSHFDDFVTNLIEKSASLDNGGCALTTFSVLEGEKNNHRAKDLRAPPEQGKIFIARRSLLDELLEVDHIRTIYHMFIALLILFILSTLVVDYIDEGRLVLEFSLLSYAFGKFPTVVWTWWIMFLSTFSVPYFLFQHWATGYSKSSHPLIRSLFHGFLFMIFQIGVLGFGPTYVVLAYTLPPASRFIIIFEQIRFVMKAHSFVRENVPRVLNSAKEKSSTVPIPTVNQYLYFLFAPTLIYRDSYPRNPTVRWGYVAMKFAQVFGCFFYVYYIFERLCAPLFRNIKQEPFSARVLVLCVFNSILPGVLILFLTFFAFLHCWLNAFAEMLRFGDRMFYKDWWNSTSYSNYYRTWNVVVHDWLYYYAYKDFLWFFSKRFKSAAMLAVFAVSAVVHEYALAVCLSFFYPVLFVLFMFFGMAFNFIVNDSRKKPIWNVLMWTSLFLGNGVLLCFYSQEWYARQHCPLKNPTFLDYVRPRSWTCRYVF
T14463	DRUGINFO	D0MB2Z	ATR-101	Phase 1

T58772	TARGETID	T58772
T58772	FORMERID	TTDNC00528
T58772	UNIPROID	MTOR_HUMAN-RPTOR_HUMAN-LST8_HUMAN-AKTS1_HUMAN-DPTOR_HUMAN
T58772	TARGNAME	Mammalian target of rapamycin complex 1 (mTORC1)
T58772	GENENAME	MTOR-RPTORA-MLST8-KT1S1-DEPTOR
T58772	TARGTYPE	Clinical trial
T58772	SYNONYMS	mTORC1; Mechanistic target of rapamycin complex 1
T58772	FUNCTION	Functions as a nutrient/energy/redox sensor and controls protein synthesis. Activate translation of proteins. Invovled in autophagy, lysosomal damage and reactive oxygen species.
T58772	SEQUENCE	MNTSPGTVGSDPVILATAGYDHTVRFWQAHSGICTRTVQHQDSQVNALEVTPDRSMIAAAGYQHIRMYDLNSNNPNPIISYDGVNKNIASVGFHEDGRWMYTGGEDCTARIWDLRSRNLQCQRIFQVNAPINCVCLHPNQAELIVGDQSGAIHIWDLKTDHNEQLIPEPEVSITSAHIDPDASYMAAVNSTGNCYVWNLTGGIGDEVTQLIPKTKIPAHTRYALQCRFSPDSTLLATCSADQTCKIWRTSNFSLMTELSIKSGNPGESSRGWMWGCAFSGDSQYIVTASSDNLARLWCVETGEIKREYGGHQKAVVCLAFNDSVLGMLGTGPAAATTAATTSSNVSVLQQFASGLKSRNEETRAKAAKELQHYVTMELREMSQEESTRFYDQLNHHIFELVSSSDANERKGGILAIASLIGVEGGNATRIGRFANYLRNLLPSNDPVVMEMASKAIGRLAMAGDTFTAEYVEFEVKRALEWLGADRNEGRRHAAVLVLRELAISVPTFFFQQVQPFFDNIFVAVWDPKQAIREGAVAALRACLILTTQREPKEMQKPQWYRHTFEEAEKGFDETLAKEKGMNRDDRIHGALLILNELVRISSMEGERLREEMEEITQQQLVHDKYCKDLMGFGTKPRHITPFTSFQAVQPQQSNALVGLLGYSSHQGLMGFGTSPSPAKSTLVESRCCRDLMEEKFDQVCQWVLKCRNSKNSLIQMTILNLLPRLAAFRPSAFTDTQYLQDTMNHVLSCVKKEKERTAAFQALGLLSVAVRSEFKVYLPRVLDIIRAALPPKDFAHKRQKAMQVDATVFTCISMLARAMGPGIQQDIKELLEPMLAVGLSPALTAVLYDLSRQIPQLKKDIQDGLLKMLSLVLMHKPLRHPGMPKGLAHQLASPGLTTLPEASDVGSITLALRTLGSFEFEGHSLTQFVRHCADHFLNSEHKEIRMEAARTCSRLLTPSIHLISGHAHVVSQTAVQVVADVLSKLLVVGITDPDPDIRYCVLASLDERFDAHLAQAENLQALFVALNDQVFEIRELAICTVGRLSSMNPAFVMPFLRKMLIQILTELEHSGIGRIKEQSARMLGHLVSNAPRLIRPYMEPILKALILKLKDPDPDPNPGVINNVLATIGELAQVSGLEMRKWVDELFIIIMDMLQDSSLLAKRQVALWTLGQLVASTGYVVEPYRKYPTLLEVLLNFLKTEQNQGTRREAIRVLGLLGALDPYKHKVNIGMIDQSRDASAVSLSESKSSQDSSDYSTSEMLVNMGNLPLDEFYPAVSMVALMRIFRDQSLSHHHTMVVQAITFIFKSLGLKCVQFLPQVMPTFLNVIRVCDGAIREFLFQQLGMLVSFVKSHIRPYMDEIVTLMREFWVMNTSIQSTIILLIEQIVVALGGEFKLYLPQLIPHMLRVFMHDNSPGRIVSIKLLAAIQLFGANLDDYLHLLLPPIVKLFDAPEAPLPSRKAALETVDRLTESLDFTDYASRIIHPIVRTLDQSPELRSTAMDTLSSLVFQLGKKYQIFIPMVNKVLVRHRINHQRYDVLICRIVKGYTLADEEEDPLIYQHRMLRSGQGDALASGPVETGPMKKLHVSTINLQKAWGAARRVSKDDWLEWLRRLSLELLKDSSSPSLRSCWALAQAYNPMARDLFNAAFVSCWSELNEDQQDELIRSIELALTSQDIAEVTQTLLNLAEFMEHSDKGPLPLRDDNGIVLLGERAAKCRAYAKALHYKELEFQKGPTPAILESLISINNKLQQPEAAAGVLEYAMKHFGELEIQATWYEKLHEWEDALVAYDKKMDTNKDDPELMLGRMRCLEALGEWGQLHQQCCEKWTLVNDETQAKMARMAAAAAWGLGQWDSMEEYTCMIPRDTHDGAFYRAVLALHQDLFSLAQQCIDKARDLLDAELTAMAGESYSRAYGAMVSCHMLSELEEVIQYKLVPERREIIRQIWWERLQGCQRIVEDWQKILMVRSLVVSPHEDMRTWLKYASLCGKSGRLALAHKTLVLLLGVDPSRQLDHPLPTVHPQVTYAYMKNMWKSARKIDAFQHMQHFVQTMQQQAQHAIATEDQQHKQELHKLMARCFLKLGEWQLNLQGINESTIPKVLQYYSAATEHDRSWYKAWHAWAVMNFEAVLHYKHQNQARDEKKKLRHASGANITNATTAATTAATATTTASTEGSNSESEAESTENSPTPSPLQKKVTEDLSKTLLMYTVPAVQGFFRSISLSRGNNLQDTLRVLTLWFDYGHWPDVNEALVEGVKAIQIDTWLQVIPQLIARIDTPRPLVGRLIHQLLTDIGRYHPQALIYPLTVASKSTTTARHNAANKILKNMCEHSNTLVQQAMMVSEELIRVAILWHEMWHEGLEEASRLYFGERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFRRISKQLPQLTSLELQYVSPKLLMCRDLELAVPGTYDPNQPIIRIQSIAPSLQVITSKQRPRKLTLMGSNGHEFVFLLKGHEDLRQDERVMQLFGLVNTLLANDPTSLRKNLSIQRYAVIPLSTNSGLIGWVPHCDTLHALIRDYREKKKILLNIEHRIMLRMAPDYDHLTLMQKVEVFEHAVNNTAGDDLAKLLWLKSPSSEVWFDRRTNYTRSLAVMSMVGYILGLGDRHPSNLMLDRLSGKILHIDFGDCFEVAMTREKFPEKIPFRLTRMLTNAMEVTGLDGNYRITCHTVMEVLREHKDSVMAVLEAFVYDPLLNWRLMDTNTKGNKRSRTRTDSYSAGQSVEILDGVELGEPAHKKTGTTVPESIHSFIGDGLVKPEALNKKAIQIINRVRDKLTGRDFSHDDTLDVPTQVELLIKQATSHENLCQCYIGWCPFWMESEMLQSPLLGLGEEDEADLTDWNLPLAFMKKRHCEKIEGSKSLAQSWRMKDRMKTVSVALVLCLNVGVDPPDVVKTTPCARLECWIDPLSMGPQKALETIGANLQKQYENWQPRARYKQSLDPTVDEVKKLCTSLRRNAKEERVLFHYNGHGVPRPTVNGEVWVFNKNYTQYIPLSIYDLQTWMGSPSIFVYDCSNAGLIVKSFKQFALQREQELEVAAINPNHPLAQMPLPPSMKNCIQLAACEATELLPMIPDLPADLFTSCLTTPIKIALRWFCMQKCVSLVPGVTLDLIEKIPGRLNDRRTPLGELNWIFTAITDTIAWNVLPRDLFQKLFRQDLLVASLFRNFLLAERIMRSYNCTPVSSPRLPPTYMHAMWQAWDLAVDICLSQLPTIIEEGTAFRHSPFFAEQLTAFQVWLTMGVENRNPPEQLPIVLQVLLSQVHRLRALDLLGRFLDLGPWAVSLALSVGIFPYVLKLLQSSARELRPLLVFIWAKILAVDSSCQADLVKDNGHKYFLSVLADPYMPAEHRTMTAFILAVIVNSYHTGQEACLQGNLIAICLEQLNDPHPLLRQWVAICLGRIWQNFDSARWCGVRDSAHEKLYSLLSDPIPEVRCAAVFALGTFVGNSAERTDHSTTIDHNVAMMLAQLVSDGSPMVRKELVVALSHLVVQYESNFCTVALQFIEEEKNYALPSPATTEGGSLTPVRDSPCTPRLRSVSSYGNIRAVATARSLNKSLQNLSLTEESGGAVAFSPGNLSTSSSASSTLGSPENEEHILSFETIDKMRRASSYSSLNSLIGVSFNSVYTQIWRVLLHLAADPYPEVSDVAMKVLNSIAYKATVNARPQRVLDTSSLTQSAPASPTNKGVHIHQAGGSPPASSTSSSSLTNDVAKQPVSRDLPSGRPGTTGPAGAQYTPHSHQFPRTRKMFDKGPEQTADDADDAAGHKSFISATVQTGFCDWSARYFAQPVMKIPEEHDLESQIRKEREWRFLRNSRVRRQAQQVIQKGITRLDDQIFLNRNPGVPSVVKFHPFTPCIAVADKDSICFWDWEKGEKLDYFHNGNPRYTRVTAMEYLNGQDCSLLLTATDDGAIRVWKNFADLEKNPEMVTAWQGLSDMLPTTRGAGMVVDWEQETGLLMSSGDVRIVRIWDTDREMKVQDIPTGADSCVTSLSCDSHRSLIVAGLGDGSIRVYDRRMALSECRVMTYREHTAWVVKASLQKRPDGHIVSVSVNGDVRIFDPRMPESVNVLQIVKGLTALDIHPQADLIACGSVNQFTAIYNSSGELINNIKYYDGFMGQRVGAISCLAFHPHWPHLAVGSNDYYISVYSVEKRVRMEEGGSTGSAGSDSSTSGSGGAQQRELERMAEVLVTGEQLRLRLHEEKVIKDRRHHLKTYPNCFVAKELIDWLIEHKEASDRETAIKLMQKLADRGIIHHVCDEHKEFKDVKLFYRFRKDDGTFPLDNEVKAFMRGQRLYEKLMSPENTLLQPREEEGVKYERTFMASEFLDWLVQEGEATTRKEAEQLCHRLMEHGIIQHVSNKHPFVDSNLLYQFRMNFRRRRRLMELLNEKSPSSQETHDSPFCLRKQSHDNRKSTSFMSVSPSKEIKIVSAVRRSSMSSCGSSGYFSSSPTLSSSPPVLCNPKSVLKRPVTSEELLTPGAPYARKTFTIVGDAVGWGFVVRGSKPCHIQAVDPSGPAAAAGMKVCQFVVSVNGLNVLHVDYRTVSNLILTGPRTIVMEVMEELECMASGRPEELWEAVVGAAERFRARTGTELVLLTAAPPPPPRPGPCAYAAHGRGALAEAARRCLHDIALAHRAATAARPPAPPPAPQPPSPTPSPPRPTLAREDNEEDEDEPTETETSGEQLGISDNGGLFVMDEDATLQDLPPFCESDPESTDDGSLSEETPAGPPTCSVPPASALPTQQYAKSLPVSVPVWGFKEKRTEARSSDEENGPPSSPDLDRIAASMRALVLREAEDTQVFGDLPRPRLNTSDFQKLKRKY
T58772	DRUGINFO	D0NO0K	RBT-101	Phase 3
T58772	DRUGINFO	D0Z2UQ	AZD2014	Phase 2
T58772	DRUGINFO	D03IXK	ME-344	Phase 1/2
T58772	DRUGINFO	DAT0U5	NV-5138	Phase 1
T58772	DRUGINFO	DP17AI	Palomid-529	Phase 1
T58772	DRUGINFO	D0U3DP	VS-5584	Phase 1

T00890	TARGETID	T00890
T00890	FORMERID	TTDI03253
T00890	UNIPROID	HCAR3_HUMAN
T00890	TARGNAME	Hydroxycarboxylic acid receptor 3 (HCAR3)
T00890	GENENAME	HCAR3
T00890	TARGTYPE	Clinical trial
T00890	SYNONYMS	Nicotinic acid receptor 2; Niacin receptor 2; NIACR2; HM74B; HCA3; GPR109B; G-protein coupled receptor HM74B; G-protein coupled receptor HM74; G-protein coupled receptor 109B
T00890	FUNCTION	Receptor for 3-OH-octanoid acid mediates a negative feedback regulation of adipocyte lipolysis to counteract prolipolytic influences under conditions of physiological or pathological increases in beta-oxidation rates. Acts as a low affinity receptor for nicotinic acid. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet.
T00890	SEQUENCE	MNRHHLQDHFLEIDKKNCCVFRDDFIAKVLPPVLGLEFIFGLLGNGLALWIFCFHLKSWKSSRIFLFNLAVADFLLIICLPFVMDYYVRRSDWKFGDIPCRLVLFMFAMNRQGSIIFLTVVAVDRYFRVVHPHHALNKISNWTAAIISCLLWGITVGLTVHLLKKKLLIQNGTANVCISFSICHTFRWHEAMFLLEFFLPLGIILFCSARIIWSLRQRQMDRHAKIKRAITFIMVVAIVFVICFLPSVVVRIHIFWLLHTSGTQNCEVYRSVDLAFFITLSFTYMNSMLDPVVYYFSSPSFPNFFSTLINRCLQRKITGEPDNNRSTSVELTGDPNKTRGAPEALIANSGEPWSPSYLGPTSNNHSKKGHCHQEPASLEKQLGCCIE
T00890	DRUGINFO	D01VMZ	ARI-3037MO	Phase 2
T00890	DRUGINFO	D0V0WE	NIA-114	Clinical trial
T00890	DRUGINFO	D00FTQ	3-hydroxyoctanoic acid	Investigative
T00890	DRUGINFO	D02GRY	PMID17358052C5b	Investigative
T00890	DRUGINFO	D08CBB	D-tryptophan	Investigative
T00890	DRUGINFO	D09DXN	D-kynurenine	Investigative
T00890	DRUGINFO	D0J7LY	5-methyl-5-(5-methylthiophen-3-yl)-4-oxo-4,5-dihydrofuran-2-carboxylic acid	Investigative
T00890	DRUGINFO	D0K3LQ	4-(n-propyl)amino-3-nitrobenzoic acid	Investigative
T00890	DRUGINFO	D0Q3QI	2-hydroxyoctanoic acid	Investigative
T00890	DRUGINFO	D0T2KY	PMID19524438C6o	Investigative
T00890	DRUGINFO	D0VE9G	IBC 293	Investigative

T28385	TARGETID	T28385
T28385	FORMERID	TTDI02352
T28385	UNIPROID	CAD11_HUMAN
T28385	TARGNAME	Osteoblast cadherin (CDH11)
T28385	GENENAME	CDH11
T28385	TARGTYPE	Clinical trial
T28385	SYNONYMS	OSF4; OSF-4; OBcadherin; OB-cadherin; Cadherin-11
T28385	FUNCTION	Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types.
T28385	SEQUENCE	MKENYCLQAALVCLGMLCHSHAFAPERRGHLRPSFHGHHEKGKEGQVLQRSKRGWVWNQFFVIEEYTGPDPVLVGRLHSDIDSGDGNIKYILSGEGAGTIFVIDDKSGNIHATKTLDREERAQYTLMAQAVDRDTNRPLEPPSEFIVKVQDINDNPPEFLHETYHANVPERSNVGTSVIQVTASDADDPTYGNSAKLVYSILEGQPYFSVEAQTGIIRTALPNMDREAKEEYHVVIQAKDMGGHMGGLSGTTKVTITLTDVNDNPPKFPQSVYQMSVSEAAVPGEEVGRVKAKDPDIGENGLVTYNIVDGDGMESFEITTDYETQEGVIKLKKPVDFETKRAYSLKVEAANVHIDPKFISNGPFKDTVTVKISVEDADEPPMFLAPSYIHEVQENAAAGTVVGRVHAKDPDAANSPIRYSIDRHTDLDRFFTINPEDGFIKTTKPLDREETAWLNITVFAAEIHNRHQEAKVPVAIRVLDVNDNAPKFAAPYEGFICESDQTKPLSNQPIVTISADDKDDTANGPRFIFSLPPEIIHNPNFTVRDNRDNTAGVYARRGGFSRQKQDLYLLPIVISDGGIPPMSSTNTLTIKVCGCDVNGALLSCNAEAYILNAGLSTGALIAILACIVILLVIVVLFVTLRRQKKEPLIVFEEEDVRENIITYDDEGGGEEDTEAFDIATLQNPDGINGFIPRKDIKPEYQYMPRPGLRPAPNSVDVDDFINTRIQEADNDPTAPPYDSIQIYGYEGRGSVAGSLSSLESATTDSDLDYDYLQNWGPRFKKLADLYGSKDTFDDDS
T28385	DRUGINFO	D0X8RS	RG6125	Phase 1

T16738	TARGETID	T16738
T16738	FORMERID	TTDNR00732
T16738	UNIPROID	DLK1_HUMAN
T16738	TARGNAME	Protein delta homolog 1 (DLK1)
T16738	GENENAME	DLK1
T16738	TARGTYPE	Clinical trial
T16738	SYNONYMS	pG2; DLK-1
T16738	FUNCTION	May have a role in neuroendocrine differentiation.
T16738	SEQUENCE	MTATEALLRVLLLLLAFGHSTYGAECFPACNPQNGFCEDDNVCRCQPGWQGPLCDQCVTSPGCLHGLCGEPGQCICTDGWDGELCDRDVRACSSAPCANNRTCVSLDDGLYECSCAPGYSGKDCQKKDGPCVINGSPCQHGGTCVDDEGRASHASCLCPPGFSGNFCEIVANSCTPNPCENDGVCTDIGGDFRCRCPAGFIDKTCSRPVTNCASSPCQNGGTCLQHTQVSYECLCKPEFTGLTCVKKRALSPQQVTRLPSGYGLAYRLTPGVHELPVQQPEHRILKVSMKELNKKTPLLTEGQAICFTILGVLTSLVVLGTVGIVFLNKCETWVSNLRYNHMLRKKKNLLLQYNSGEDLAVNIIFPEKIDMTTFSKEAGDEEI
T16738	DRUGINFO	D0Y1FU	GDC0134	Phase 1

T61683	TARGETID	T61683
T61683	FORMERID	TTDI01686
T61683	UNIPROID	XIAP_HUMAN; BIRC2_HUMAN; BIRC3_HUMAN; BIRC1_HUMAN; BIRC7_HUMAN; BIRC5_HUMAN
T61683	TARGNAME	Inhibitor of apoptosis protein (hIAP)
T61683	GENENAME	XIAP; BIRC2; BIRC3; NAIP; BIRC5; BIRC7
T61683	TARGTYPE	Clinical trial
T61683	SYNONYMS	Baculoviral IAP repeat-containing protein
T61683	FUNCTION	A class of key apoptosis regulators. Influences a multitude of other cellular processes, such as ubiquitin (Ub) dependent signaling events that regulate activation of nuclear factor B (NFB), which in turn drive the expression of genes important for inflammation, immunity, cell migration and cell survival. Modulates signaling events that promote the activation of cell motility kinases and metastasis11 and they regulate mitogenic kinase signaling, proliferation and mitosis. 
T61683	SEQUENCE	MTFNSFEGSKTCVPADINKEEEFVEEFNRLKTFANFPSGSPVSASTLARAGFLYTGEGDTVRCFSCHAAVDRWQYGDSAVGRHRKVSPNCRFINGFYLENSATQSTNSGIQNGQYKVENYLGSRDHFALDRPSETHADYLLRTGQVVDISDTIYPRNPAMYSEEARLKSFQNWPDYAHLTPRELASAGLYYTGIGDQVQCFCCGGKLKNWEPCDRAWSEHRRHFPNCFFVLGRNLNIRSESDAVSSDRNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKCFHCGGGLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVRTTEKTPSLTRRIDDTIFQNPMVQEAIRMGFSFKDIKKIMEEKIQISGSNYKSLEVLVADLVNAQKDSMQDESSQTSLQKEISTEEQLRRLQEEKLCKICMDRNIAIVFVPCGHLVTCKQCAEAVDKCPMCYTVITFKQKIFMS
T61683	DRUGINFO	D03MXK	AT-406	Phase 3
T61683	DRUGINFO	D09MIN	LCL161	Phase 2
T61683	DRUGINFO	D0NP8P	APG-1387	Phase 1

T86992	TARGETID	T86992
T86992	FORMERID	TTDNC00457
T86992	UNIPROID	PPE42_MYCTU-ESXV_MYCTU-ESXW_MYCTU-Y1813_MYCTU
T86992	TARGNAME	Mycobacterium Fusion protein Rv2608-Rv3619-Rv3620-Rv1813 (MycB antigens)
T86992	GENENAME	MycB antigens
T86992	TARGTYPE	Clinical trial
T86992	SYNONYMS	Mycobacterium Fusion protein PPE42-esxV-esxW-MTY16F9.01
T86992	FUNCTION	Invovled in immune response.
T86992	SEQUENCE	MTSRFMTDPHAMRDMAGRFEVHAQTVEDEARRMWASAQNISGAGWSGMAEATSLDTMTQMNQAFRNIVNMLHGVRDGLVRDANNYEQQEQASQQILSSMTINYQFGDVDAHGAMIRAQAGSLEAEHQAIISDVLTASDFWGGAGSAACQGFITQLGRNFQVIYEQANAHGQKVQAAGNNMAQTDSAVGSSWAMNFAVLPPEVNSARIFAGAGLGPMLAAASAWDGLAEELHAAAGSFASVTTGLAGDAWHGPASLAMTRAASPYVGWLNTAAGQAAQAAGQARLAASAFEATLAATVSPAMVAANRTRLASLVAANLLGQNAPAIAAAEAEYEQIWAQDVAAMFGYHSAASAVATQLAPIQEGLQQQLQNVLAQLASGNLGSGNVGVGNIGNDNIGNANIGFGNRGDANIGIGNIGDRNLGIGNTGNWNIGIGITGNGQIGFGKPANPDVLVVGNGGPGVTALVMGGTDSLLPLPNIPLLEYAARFITPVHPGYTATFLETPSQFFPFTGLNSLTYDVSVAQGVTNLHTAIMAQLAAGNEVVVFGTSQSATIATFEMRYLQSLPAHLRPGLDELSFTLTGNPNRPDGGILTRFGFSIPQLGFTLSGATPADAYPTVDYAFQYDGVNDFPKYPLNVFATANAIAGILFLHSGLIALPPDLASGVVQPVSSPDVLTTYILLPSQDLPLLVPLRAIPLLGNPLADLIQPDLRVLVELGYDRTAHQDVPSPFGLFPDVDWAEVAADLQQGAVQGVNDALSGLGLPPPWQPALPRLFMITNLRRRTAMAAAGLGAALGLGILLVPTVDAHLANGSMSEVMMSEIAGLPIPPIIHYGAIAYAPSGASGKAWHQRTPARAEQVALEKCGDKTCKVVSRFTRCGAVAYNGSKYQGGTGLTRRAAEDDAVNRLEGGRIVNWACN
T86992	DRUGINFO	D01KQW	ID-93/GLA-SE	Phase 2

T03410	TARGETID	T03410
T03410	FORMERID	TTDI02125
T03410	UNIPROID	MMPL3_MYCTU
T03410	TARGNAME	Mycobacterium Membrane protein mmpL3 (MycB mmpL3)
T03410	GENENAME	MycB mmpL3
T03410	TARGTYPE	Clinical trial
T03410	SYNONYMS	Trehalose monomycolate exporter MmpL3; TMM exporter MmpL3
T03410	FUNCTION	Transports trehalose monomycolate (TMM) across the inner membrane. Could also be part of a heme-iron acquisition system.
T03410	SEQUENCE	MFAWWGRTVYRYRFIVIGVMVALCLGGGVFGLSLGKHVTQSGFYDDGSQSVQASVLGDQVYGRDRSGHIVAIFQAPAGKTVDDPAWSKKVVDELNRFQQDHPDQVLGWAGYLRASQATGMATADKKYTFVSIPLKGDDDDTILNNYKAIAPDLQRLDGGTVKLAGLQPVAEALTGTIATDQRRMEVLALPLVAVVLFFVFGGVIAAGLPVMVGGLCIAGALGIMRFLAIFGPVHYFAQPVVSLIGLGIAIDYGLFIVSRFREEIAEGYDTETAVRRTVITAGRTVTFSAVLIVASAIGLLLFPQGFLKSLTYATIASVMLSAILSITVLPACLGILGKHVDALGVRTLFRVPFLANWKISAAYLNWLADRLQRTKTREEVEAGFWGKLVNRVMKRPVLFAAPIVIIMILLIIPVGKLSLGGISEKYLPPTNSVRQAQEEFDKLFPGYRTNPLTLVIQTSNHQPVTDAQIADIRSKAMAIGGFIEPDNDPANMWQERAYAVGASKDPSVRVLQNGLINPADASKKLTELRAITPPKGITVLVGGTPALELDSIHGLFAKMPLMVVILLTTTIVLMFLAFGSVVLPIKATLMSALTLGSTMGILTWIFVDGHFSKWLNFTPTPLTAPVIGLIIALVFGLSTDYEVFLVSRMVEARERGMSTQEAIRIGTAATGRIITAAALIVAVVAGAFVFSDLVMMKYLAFGLMAALLLDATVVRMFLVPSVMKLLGDDCWWAPRWARRLQTRIGLGEIHLPDERKRPVSNGRPARPPVTAGLVAARAAGDPRPPHDPTHPLAESPRPARSSPASSPELTPALEATAAPAAPSGASTTRMQIGSSTEPPTTRLAAAGRSVQSPASTPPPTPTPPSAPSAGQTRAMPLAANRSTDAAGDPAEPTAALPIIRSDGDDSEAATEQLNARGTSDKTRQRRRGGGALSAQDLLRREGRL
T03410	DRUGINFO	D0K8DI	SQ-109	Phase 2
T03410	DRUGINFO	D0D4VH	BM-212	Phase 1

T01447	TARGETID	T01447
T01447	UNIPROID	ULA1_HUMAN; UBA3_HUMAN
T01447	TARGNAME	NEDD8-activating enzyme (NAE)
T01447	GENENAME	NAE1; UBA3
T01447	TARGTYPE	Clinical trial
T01447	SYNONYMS	NEDD8-activating enzyme E1
T01447	FUNCTION	Subunit of the dimeric UBA3-NAE1 E1 enzyme. E1 activates NEDD8 by first adenylating its C-terminal glycine residue with ATP, thereafter linking this residue to the side chain of the catalytic cysteine, yielding a NEDD8-UBA3 thioester and free AMP. E1 finally transfers NEDD8 to the catalytic cysteine of UBE2M. Necessary for cell cycle progression.
T01447	SEQUENCE	MAQLGKLLKEQKYDRQLRLWGDHGQEALESAHVCLINATATGTEILKNLVLPGIGSFTIIDGNQVSGEDAGNNFFLQRSSIGKNRAEAAMEFLQELNSDVSGSFVEESPENLLDNDPSFFCRFTVVVATQLPESTSLRLADVLWNSQIPLLICRTYGLVGYMRIIIKEHPVIESHPDNALEDLRLDKPFPELREHFQSYDLDHMEKKDHSHTPWIVIIAKYLAQWYSETNGRIPKTYKEKEDFRDLIRQGILKNENGAPEDEENFEEAIKNVNTALNTTQIPSSIEDIFNDDRCINITKQTPSFWILARALKEFVAKEGQGNLPVRGTIPDMIADSGKYIKLQNVYREKAKKDAAAVGNHVAKLLQSIGQAPESISEKELKLLCSNSAFLRVVRCRSLAEEYGLDTINKDEIISSMDNPDNEIVLYLMLRAVDRFHKQQGRYPGVSNYQVEEDIGKLKSCLTGFLQEYGLSVMVKDDYVHEFCRYGAAEPHTIAAFLGGAAAQEVIKIITKQFVIFNNTYIYSGMSQTSATFQL
T01447	DRUGINFO	D0ZD2M	MLN4924	Phase 3

T85581	TARGETID	T85581
T85581	FORMERID	TTDI01811
T85581	UNIPROID	S12A1_HUMAN; S12A2_HUMAN
T85581	TARGNAME	Na-K-Cl cotransporter (NKCC)
T85581	GENENAME	SLC12A1; SLC12A2
T85581	TARGTYPE	Clinical trial
T85581	SYNONYMS	Solute carrier family 12; Na-K-Cl symporter; NKCC; Bumetanide-sensitive sodium-(potassium)-chloride cotransporter
T85581	FUNCTION	Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
T85581	SEQUENCE	MSLNNSSNVFLDSVPSNTNRFQVSVINENHESSAAADDNTDPPHYEETSFGDEAQKRLRISFRPGNQECYDNFLQSGETAKTDASFHAYDSHTNTYYLQTFGHNTMDAVPKIEYYRNTGSISGPKVNRPSLLEIHEQLAKNVAVTPSSADRVANGDGIPGDEQAENKEDDQAGVVKFGWVKGVLVRCMLNIWGVMLFIRLSWIVGEAGIGLGVLIILLSTMVTSITGLSTSAIATNGFVRGGGAYYLISRSLGPEFGGSIGLIFAFANAVAVAMYVVGFAETVVDLLKESDSMMVDPTNDIRIIGSITVVILLGISVAGMEWEAKAQVILLVILLIAIANFFIGTVIPSNNEKKSRGFFNYQASIFAENFGPRFTKGEGFFSVFAIFFPAATGILAGANISGDLEDPQDAIPRGTMLAIFITTVAYLGVAICVGACVVRDATGNMNDTIISGMNCNGSAACGLGYDFSRCRHEPCQYGLMNNFQVMSMVSGFGPLITAGIFSATLSSALASLVSAPKVFQALCKDNIYKALQFFAKGYGKNNEPLRGYILTFLIAMAFILIAELNTIAPIISNFFLASYALINFSCFHASYAKSPGWRPAYGIYNMWVSLFGAVLCCAVMFVINWWAAVITYVIEFFLYVYVTCKKPDVNWGSSTQALSYVSALDNALELTTVEDHVKNFRPQCIVLTGGPMTRPALLDITHAFTKNSGLCICCEVFVGPRKLCVKEMNSGMAKKQAWLIKNKIKAFYAAVAADCFRDGVRSLLQASGLGRMKPNTLVIGYKKNWRKAPLTEIENYVGIIHDAFDFEIGVVIVRISQGFDISQVLQVQEELERLEQERLALEATIKDNECEEESGGIRGLFKKAGKLNITKTTPKKDGSINTSQSMHVGEFNQKLVEASTQFKKKQEKGTIDVWWLFDDGGLTLLIPYILTLRKKWKDCKLRIYVGGKINRIEEEKIVMASLLSKFRIKFADIHIIGDINIRPNKESWKVFEEMIEPYRLHESCKDLTTAEKLKRETPWKITDAELEAVKEKSYRQVRLNELLQEHSRAANLIVLSLPVARKGSISDLLYMAWLEILTKNLPPVLLVRGNHKNVLTFYS
T85581	DRUGINFO	D0D1ZS	CLP-1001	Phase 2

T84591	TARGETID	T84591
T84591	UNIPROID	EI2BA_HUMAN; EI2BB_HUMAN
T84591	TARGNAME	Guanine nucleotide exchange factor (GNEF)
T84591	GENENAME	EIF2B1; EIF2B2
T84591	TARGTYPE	Clinical trial
T84591	SYNONYMS	eIF-2B GDP-GTP exchange factor; Translation initiation factor eIF-2B; EIF2B
T84591	FUNCTION	Catalyzes the exchange of eukaryotic initiation factor 2-bound GDP for GTP.
T84591	SEQUENCE	MDDKELIEYFKSQMKEDPDMASAVAAIRTLLEFLKRDKGETIQGLRANLTSAIETLCGVDSSVAVSSGGELFLRFISLASLEYSDYSKCKKIMIERGELFLRRISLSRNKIADLCHTFIKDGATILTHAYSRVVLRVLEAAVAAKKRFSVYVTESQPDLSGKKMAKALCHLNVPVTVVLDAAVGYIMEKADLVIVGAEGVVENGGIINKIGTNQMAVCAKAQNKPFYVVAESFKFVRLFPLNQQDVPDKFKYKADTLKVAQTGQDLKEEHPWVDYTAPSLITLLFTDLGVLTPSAVSDELIKLYL
T84591	DRUGINFO	D0ZE1O	Plinabulin	Phase 3

T34204	TARGETID	T34204
T34204	FORMERID	TTDI03121
T34204	UNIPROID	CNGA2_HUMAN
T34204	TARGNAME	Cyclic nucleotide-gated channel alpha-2 (CNGA2)
T34204	GENENAME	CNGA2
T34204	TARGTYPE	Clinical trial
T34204	SYNONYMS	Cyclic nucleotide-gated olfactory channel; Cyclic nucleotide-gated cation channel 2; CNG2; CNG-2; CNG channel alpha-2; CNCG2; CNCA1; CNCA
T34204	FUNCTION	Odorant signal transduction is probably mediated by a G-protein coupled cascade using cAMP as second messenger. The olfactory channel can be shown to be activated by cyclic nucleotides which leads to a depolarization of olfactory sensory neurons.
T34204	SEQUENCE	MTEKTNGVKSSPANNHNHHAPPAIKANGKDDHRTSSRPHSAADDDTSSELQRLADVDAPQQGRSGFRRIVRLVGIIREWANKNFREEEPRPDSFLERFRGPELQTVTTQEGDGKGDKDGEDKGTKKKFELFVLDPAGDWYYCWLFVIAMPVLYNWCLLVARACFSDLQKGYYLVWLVLDYVSDVVYIADLFIRLRTGFLEQGLLVKDTKKLRDNYIHTLQFKLDVASIIPTDLIYFAVDIHSPEVRFNRLLHFARMFEFFDRTETRTNYPNIFRISNLVLYILVIIHWNACIYYAISKSIGFGVDTWVYPNITDPEYGYLAREYIYCLYWSTLTLTTIGETPPPVKDEEYLFVIFDFLIGVLIFATIVGNVGSMISNMNATRAEFQAKIDAVKHYMQFRKVSKGMEAKVIRWFDYLWTNKKTVDEREILKNLPAKLRAEIAINVHLSTLKKVRIFHDCEAGLLVELVLKLRPQVFSPGDYICRKGDIGKEMYIIKEGKLAVVADDGVTQYALLSAGSCFGEISILNIKGSKMGNRRTANIRSLGYSDLFCLSKDDLMEAVTEYPDAKKVLEERGREILMKEGLLDENEVATSMEVDVQEKLGQLETNMETLYTRFGRLLAEYTGAQQKLKQRITVLETKMKQNNEDDYLSDGMNSPELAAADEP
T34204	DRUGINFO	D0I2FI	dequalinium	Clinical trial
T34204	DRUGINFO	D05SOU	all-trans-retinal	Investigative
T34204	DRUGINFO	D0S3UR	PIP3	Investigative
T34204	DRUGINFO	D00YNI	L-(cis)-diltiazem	Investigative

T71205	TARGETID	T71205
T71205	UNIPROID	CL12A_HUMAN
T71205	TARGNAME	Myeloid inhibitory C-type lectin-like receptor (CD371)
T71205	GENENAME	CLEC12A
T71205	TARGTYPE	Clinical trial
T71205	SYNONYMS	MICL; Dendritic cell-associated lectin 2; DCAL2; DCAL-2; CLL1; CLL-1; C-type lectin-like molecule 1; C-type lectin domain family 12 member A
T71205	FUNCTION	Cell surface receptor that modulates signaling cascades and mediates tyrosine phosphorylation of target MAP kinases.
T71205	SEQUENCE	MSEEVTYADLQFQNSSEMEKIPEIGKFGEKAPPAPSHVWRPAALFLTLLCLLLLIGLGVLASMFHVTLKIEMKKMNKLQNISEELQRNISLQLMSNMNISNKIRNLSTTLQTIATKLCRELYSKEQEHKCKPCPRRWIWHKDSCYFLSDDVQTWQESKMACAAQNASLLKINNKNALEFIKSQSRSYDYWLGLSPEEDSTRGMRVDNIINSSAWVIRNAPDLNNMYCGYINRLYVQYYHCTYKKRMICEKMANPVQLGSTYFREA
T71205	DRUGINFO	D0RF4J	CLL1 CAR-T Cell	Phase 2/3
T71205	DRUGINFO	D04GGG	CD123/CLL1 CAR-T Cells	Phase 2/3
T71205	DRUGINFO	D00QWK	CLL1-specific gene-engineered T cells	Phase 1/2
T71205	DRUGINFO	D0DO8E	CAR-T cells targeting CLL1	Phase 1/2
T71205	DRUGINFO	D4UQ2B	KITE-222	Phase 1
T71205	DRUGINFO	DW01LJ	CLT030	Phase 1
T71205	DRUGINFO	D2Q3VY	Tepoditamab	Phase 1
T71205	DRUGINFO	D5T9GZ	CLL1-CD33 cCART cell therapy	Phase 1
T71205	DRUGINFO	DIW58H	UCART-CLL1	Preclinical

T84439	TARGETID	T84439
T84439	FORMERID	TTDI03232
T84439	UNIPROID	GP139_HUMAN
T84439	TARGNAME	G-protein-coupled receptor PGR3 (GPR139)
T84439	GENENAME	GPR139
T84439	TARGTYPE	Clinical trial
T84439	SYNONYMS	Probable G-protein coupled receptor 139; PGR3; GPRG1; G(q)-coupled orphan receptor GPRg1
T84439	FUNCTION	Orphan receptor. Seems to act through a G(q/11)-mediated pathway.
T84439	SEQUENCE	MEHTHAHLAANSSLSWWSPGSACGLGFVPVVYYSLLLCLGLPANILTVIILSQLVARRQKSSYNYLLALAAADILVLFFIVFVDFLLEDFILNMQMPQVPDKIIEVLEFSSIHTSIWITVPLTIDRYIAVCHPLKYHTVSYPARTRKVIVSVYITCFLTSIPYYWWPNIWTEDYISTSVHHVLIWIHCFTVYLVPCSIFFILNSIIVYKLRRKSNFRLRGYSTGKTTAILFTITSIFATLWAPRIIMILYHLYGAPIQNRWLVHIMSDIANMLALLNTAINFFLYCFISKRFRTMAAATLKAFFKCQKQPVQFYTNHNFSITSSPWISPANSHCIKMLVYQYDKNGKPIKVSP
T84439	DRUGINFO	D01GTC	TAK-041	Phase 1
T84439	DRUGINFO	D04ZMM	PMID24900311C1a	Investigative

T98196	TARGETID	T98196
T98196	FORMERID	TTDI01314
T98196	UNIPROID	MOCS1_HUMAN
T98196	TARGNAME	Cyclic pyranopterin monophosphate synthase (MOCS1)
T98196	GENENAME	MOCS1
T98196	TARGTYPE	Clinical trial
T98196	SYNONYMS	Molybdenum cofactor synthesis-step 1 protein A-B (414-636); Molybdenum cofactor biosynthesis protein 1 (414-636); MOCS1 (414-636); MIG11 (414-636); Cell migration-inducing gene 11 protein (414-636)
T98196	FUNCTION	MOCS1A catalyzes the cyclization of GTP to (8S)-3',8-cyclo-7,8-dihydroguanosine 5'-triphosphate and MOCS1B catalyzes the subsequent conversion of (8S)-3',8-cyclo-7,8-dihydroguanosine 5'-triphosphate to cPMP. Isoform MOCS1A and isoform MOCS1B probably form a complex that catalyzes the conversion of 5'-GTP to cyclic pyranopterin monophosphate (cPMP).
T98196	SEQUENCE	MAARPLSRMLRRLLRSSARSCSSGAPVTQPCPGESARAASEEVSRRRQFLREHAAPFSAFLTDSFGRQHSYLRISLTEKCNLRCQYCMPEEGVPLTPKANLLTTEEILTLARLFVKEGIDKIRLTGGEPLIRPDVVDIVAQLQRLEGLRTIGVTTNGINLARLLPQLQKAGLSAINISLDTLVPAKFEFIVRRKGFHKVMEGIHKAIELGYNPVKVNCVVMRGLNEDELLDFAALTEGLPLDVRFIEYMPFDGNKWNFKKMVSYKEMLDTVRQQWPELEKVPEEESSTAKAFKIPGFQGQISFITSMSEHFCGTCNRLRITADGNLKVCLFGNSEVSLRDHLRAGASEQELLRIIGAAVGRKKRQHAGMFSISQMKNRPMILIELFLMFPNSPPANPSIFSWDPLHVQGLRPRMSFSSQVATLWKGCRVPQTPPLAQQRLGSGSFQRHYTSRADSDANSKCLSPGSWASAAPSGPQLTSEQLTHVDSEGRAAMVDVGRKPDTERVAVASAVVLLGPVAFKLVQQNQLKKGDALVVAQLAGVQAAKVTSQLIPLCHHVALSHIQVQLELDSTRHAVKIQASCRARGPTGVEMEALTSAAVAALTLYDMCKAVSRDIVLEEIKLISKTGGQRGDFHRA
T98196	DRUGINFO	D01AKK	ALXN1101	Phase 2/3

T66093	TARGETID	T66093
T66093	FORMERID	TTDI02264
T66093	TARGNAME	Hepatitis C virus microRNA miR-122 (HCV MIR122)
T66093	TARGTYPE	Clinical trial
T66093	BIOCLASS	Non-coding RNA target
T66093	DRUGINFO	D0O6DE	RG-101	Phase 2
T66093	DRUGINFO	D0SQ2K	Miravirsen	Phase 2

T88483	TARGETID	T88483
T88483	TARGNAME	microRNA hsa-miR-155 (MIR155)
T88483	TARGTYPE	Clinical trial
T88483	BIOCLASS	Non-coding RNA target
T88483	DRUGINFO	D0P9XM	Cobomarsen	Phase 2
T88483	DRUGINFO	D08WZQ	MRG-201	Phase 2

T51803	TARGETID	T51803
T51803	FORMERID	TTDI02263
T51803	TARGNAME	microRNA hsa-miR-34 (MIR34)
T51803	TARGTYPE	Clinical trial
T51803	BIOCLASS	Non-coding RNA target
T51803	DRUGINFO	D08SJY	MRX34	Phase 1

T71164	TARGETID	T71164
T71164	FORMERID	TTDI01230
T71164	TARGNAME	Ganglioside GD2 (GD2)
T71164	TARGTYPE	Clinical trial
T71164	SYNONYMS	Ganglioside G2; GD2
T71164	DRUGINFO	D06EVZ	Anti-GD2 CART	Phase 2
T71164	DRUGINFO	D0R4UA	Hu3F8 mAb	Phase 2
T71164	DRUGINFO	DG5K6D	APN301	Phase 2
T71164	DRUGINFO	DI57MF	Nivatrotamab	Phase 2
T71164	DRUGINFO	D01YCF	4SCAR-GD2	Phase 1/2
T71164	DRUGINFO	D06TWS	CAR-T cells targeting CD2	Phase 1/2
T71164	DRUGINFO	D0E1ST	CAR-T cells targeting GD2	Phase 1/2
T71164	DRUGINFO	D0MA4F	GD2-CART01	Phase 1/2
T71164	DRUGINFO	D0S4GT	CAR-T cells targeting GD2	Phase 1/2
T71164	DRUGINFO	D01SFN	IC9-GD2-CD28-OX40	Phase 1
T71164	DRUGINFO	D04UNY	Anti-GD2 T-cells (1RG-CART)	Phase 1
T71164	DRUGINFO	D09DND	Anti-GD2-CAR engineered T cells	Phase 1
T71164	DRUGINFO	D0DA1U	C7R-GD2.CART cells	Phase 1
T71164	DRUGINFO	D0H0LK	IC9.GD2.CAR.IL-15 T-cells	Phase 1
T71164	DRUGINFO	D0Q5QV	MVT-5873	Phase 1
T71164	DRUGINFO	D0QB7N	GD2 T cells	Phase 1
T71164	DRUGINFO	D7AFK9	KUR-501	Phase 1
T71164	DRUGINFO	D0RI8E	GD2-targeted CAR-T cells	Clinical trial

T72737	TARGETID	T72737
T72737	FORMERID	TTDI01277
T72737	TARGNAME	Cytomegalovirus Deoxyribonucleic acid (CMV DNA)
T72737	TARGTYPE	Clinical trial
T72737	DRUGINFO	D0S4WA	ASP0113	Phase 3

T99566	TARGETID	T99566
T99566	FORMERID	TTDI01220
T99566	TARGNAME	Free radical (FRD)
T99566	TARGTYPE	Clinical trial
T99566	DRUGINFO	D0F3WG	Disufenton sodium	Phase 3
T99566	DRUGINFO	D0X8TS	RRx-001	Phase 3
T99566	DRUGINFO	D03ZDX	SM-88	Phase 2/3

T01822	TARGETID	T01822
T01822	FORMERID	TTDI01208
T01822	TARGNAME	Haematin (HA)
T01822	TARGTYPE	Clinical trial
T01822	DRUGINFO	D0I6YM	Ferroquine	Phase 2

T74034	TARGETID	T74034
T74034	FORMERID	TTDI01225
T74034	TARGNAME	Hepatitis C virus Deoxyribonucleic acid (HCV DNA)
T74034	TARGTYPE	Clinical trial
T74034	DRUGINFO	D0V5LG	ChronVac-C hepatitis C DNA vaccine	Phase 1/2

T48470	TARGETID	T48470
T48470	FORMERID	TTDI01237
T48470	TARGNAME	Hormone unspecific (HOM)
T48470	TARGTYPE	Clinical trial
T48470	DRUGINFO	D03KJU	NV-04	Phase 1
T48470	DRUGINFO	D0ZB2E	NV-07a	Investigative

T29525	TARGETID	T29525
T29525	FORMERID	TTDI01153
T29525	TARGNAME	Human immunodeficiency virus Deoxyribonucleic acid (HIV DNA)
T29525	TARGTYPE	Clinical trial
T29525	DRUGINFO	D09ZSY	CI-1012	Phase 2
T29525	DRUGINFO	D05UJF	PBSVax	Phase 1

T88479	TARGETID	T88479
T88479	TARGNAME	Malondialdehyde (MDA)
T88479	TARGTYPE	Clinical trial
T88479	DRUGINFO	D0ZG3S	Reproxalap	Phase 3

T91450	TARGETID	T91450
T91450	FORMERID	TTDI01998
T91450	TARGNAME	Poly-N-acetyl glucosamine (PNAG)
T91450	TARGTYPE	Clinical trial
T91450	DRUGINFO	D00MTG	SAR279356	Phase 2

T59955	TARGETID	T59955
T59955	FORMERID	TTDI01183
T59955	TARGNAME	Progesterone (PG)
T59955	TARGTYPE	Clinical trial
T59955	DRUGINFO	D0L3HU	BAY 86-5044	Phase 2
T59955	DRUGINFO	D0C5KG	ORG-33628	Discontinued in Phase 2

T25698	TARGETID	T25698
T25698	TARGNAME	Pseudomonas Lipopolysaccharide (Pseudo LPS)
T25698	TARGTYPE	Clinical trial
T25698	DRUGINFO	D03PSP	Panobacumab	Phase 2

T22295	TARGETID	T22295
T22295	FORMERID	TTDI01711
T22295	TARGNAME	Staphylococcus Capsular polysaccharide CP5 (Stap-coc CP5)
T22295	TARGTYPE	Clinical trial
T22295	DRUGINFO	D01DXI	PF-06290510	Phase 2

T67058	TARGETID	T67058
T67058	FORMERID	TTDI01711
T67058	TARGNAME	Staphylococcus Capsular polysaccharide CP8 (Stap-coc CP8)
T67058	TARGTYPE	Clinical trial
T67058	DRUGINFO	D01DXI	PF-06290510	Phase 2

T26327	TARGETID	T26327
T26327	FORMERID	TTDI01185
T26327	TARGNAME	Superoxide anion (SPA)
T26327	TARGTYPE	Clinical trial
T26327	DRUGINFO	D0F4RX	OPC-14117	Phase 1

T28887	TARGETID	T28887
T28887	FORMERID	TTDR01337
T28887	UNIPROID	HDAC8_HUMAN
T28887	TARGNAME	Histone deacetylase 8 (HDAC8)
T28887	GENENAME	HDAC8
T28887	TARGTYPE	Clinical trial
T28887	SYNONYMS	Histone deacetylase-8; HDACL1; HD8; CDA07
T28887	FUNCTION	Gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Also involved in the deacetylation of cohesin complex protein SMC3 regulating release of cohesin complexes from chromatin. May play a role in smooth muscle cell contractility. Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4).
T28887	PDBSTRUC	6HSK; 5VI6; 5THV; 5THU; 5THT
T28887	BIOCLASS	Carbon-nitrogen hydrolase
T28887	ECNUMBER	EC 3.5.1.98
T28887	SEQUENCE	MEEPEEPADSGQSLVPVYIYSPEYVSMCDSLAKIPKRASMVHSLIEAYALHKQMRIVKPKVASMEEMATFHTDAYLQHLQKVSQEGDDDHPDSIEYGLGYDCPATEGIFDYAAAIGGATITAAQCLIDGMCKVAINWSGGWHHAKKDEASGFCYLNDAVLGILRLRRKFERILYVDLDLHHGDGVEDAFSFTSKVMTVSLHKFSPGFFPGTGDVSDVGLGKGRYYSVNVPIQDGIQDEKYYQICESVLKEVYQAFNPKAVVLQLGADTIAGDPMCSFNMTPVGIGKCLKYILQWQLATLILGGGGYNLANTARCWTYLTGVILGKTLSSEIPDHEFFTAYGPDYVLEITPSCRPDRNEPHRIQQILNYIKGNLKHVV
T28887	DRUGINFO	D0SOG8	NBM-BMX	Phase 1
T28887	DRUGINFO	D04UGJ	PMID29671355-Compound-37	Patented
T28887	DRUGINFO	D04JWR	PMID29671355-Compound-36	Patented
T28887	DRUGINFO	D0GD6R	PMID29671355-Compound-68b	Patented
T28887	DRUGINFO	D0ZG5X	PMID29671355-Compound-13	Patented
T28887	DRUGINFO	D0JB4S	PMID29671355-Compound-61	Patented
T28887	DRUGINFO	D00HXJ	PMID29671355-Compound-23	Patented
T28887	DRUGINFO	D0N2DK	PMID29671355-Compound-44	Patented
T28887	DRUGINFO	D0CH8Q	PMID29671355-Compound-56	Patented
T28887	DRUGINFO	D0M0RE	PMID29671355-Compound-67	Patented
T28887	DRUGINFO	D0DI9S	PMID29671355-Compound-31	Patented
T28887	DRUGINFO	D0LP1K	PMID29671355-Compound-21	Patented
T28887	DRUGINFO	D07WAT	PMID29671355-Compound-62	Patented
T28887	DRUGINFO	D0BP8I	PMID29671355-Compound-43	Patented
T28887	DRUGINFO	D0RA0D	PMID29671355-Compound-25	Patented
T28887	DRUGINFO	D00DQZ	S-2,9-dioxo-9-(phenylamino)nonyl ethanethioate	Investigative
T28887	DRUGINFO	D01BCK	N-hydroxy-1-naphthamide	Investigative
T28887	DRUGINFO	D05PTL	NMB-T-BMX-OS01	Investigative
T28887	DRUGINFO	D09LVY	9-mercapto-8-oxo-N-phenylnonanamide	Investigative
T28887	DRUGINFO	D0P3SU	N-hydroxy-3-phenoxybenzamide	Investigative
T28887	DRUGINFO	D0Q5MC	PCI-34051	Investigative
T28887	DRUGINFO	D0R2HF	6-(2-mercaptoacetamido)-N-phenylhexanamide	Investigative
T28887	DRUGINFO	D0V1HA	N-hydroxy-3-(naphthalen-1-yl)acrylamide	Investigative
T28887	DRUGINFO	D03HNC	N-hydroxy-4-(naphthalen-1-yl)benzamide	Investigative
T28887	DRUGINFO	D06THS	Desclasinose Azithromycinarylalkyl Hydroxamate	Investigative
T28887	DRUGINFO	D0D7KH	Azithromycin-N-benzyltriazolyloctahydroxamic Acid	Investigative
T28887	DRUGINFO	D0H3RO	Azithromycin-N-benzyltriazolylnonahydroxamic Acid	Investigative
T28887	DRUGINFO	D0I5XM	Azithromycin-N-benzyltriazolylhexahydroxamic Acid	Investigative
T28887	DRUGINFO	D0L7HP	NILTUBACIN	Investigative
T28887	DRUGINFO	D0P9CQ	Azithromycinarylalkylhydroxamic Acid	Investigative
T28887	DRUGINFO	D00VXM	droxinostat	Investigative
T28887	DRUGINFO	D02NWS	4-Phenylbutyrohydroxamic acid	Investigative
T28887	DRUGINFO	D01YBR	ST-3050	Investigative
T28887	DRUGINFO	D07YZZ	Octanedioic acid bis-hydroxyamide	Investigative
T28887	DRUGINFO	D0N9AK	ST-2986	Investigative
T28887	DRUGINFO	D00KFF	9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide	Investigative
T28887	DRUGINFO	D00SEE	7-Mercapto-heptanoic acid phenylamide	Investigative
T28887	DRUGINFO	D00ZSD	6-benzenesulfinylhexanoic acid hydroxamide	Investigative
T28887	DRUGINFO	D01MFV	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	Investigative
T28887	DRUGINFO	D01XWZ	7-Mercapto-heptanoic acid biphenyl-4-ylamide	Investigative
T28887	DRUGINFO	D01XXN	N-Hydroxy-4-phenylacetylamino-benzamide	Investigative
T28887	DRUGINFO	D02MQM	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	Investigative
T28887	DRUGINFO	D02UTC	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	Investigative
T28887	DRUGINFO	D02WZK	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	Investigative
T28887	DRUGINFO	D04GGW	Octanedioic acid hydroxyamide pyridin-4-ylamide	Investigative
T28887	DRUGINFO	D04HSS	N-(6-Mercapto-hexyl)-benzamide	Investigative
T28887	DRUGINFO	D04NSP	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	Investigative
T28887	DRUGINFO	D04ZDI	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	Investigative
T28887	DRUGINFO	D05AHZ	6-benzenesulfonylhexanoic acid hydroxamide	Investigative
T28887	DRUGINFO	D05FEJ	9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one	Investigative
T28887	DRUGINFO	D05GVY	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	Investigative
T28887	DRUGINFO	D05LLX	4-Butyrylamino-N-hydroxy-benzamide	Investigative
T28887	DRUGINFO	D05VFP	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	Investigative
T28887	DRUGINFO	D05XAN	7-Mercapto-heptanoic acid biphenyl-3-ylamide	Investigative
T28887	DRUGINFO	D06IQB	5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione	Investigative
T28887	DRUGINFO	D06VBN	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	Investigative
T28887	DRUGINFO	D06XNP	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	Investigative
T28887	DRUGINFO	D07FJU	7-Mercapto-heptanoic acid pyridin-3-ylamide	Investigative
T28887	DRUGINFO	D09YBN	6-Phenoxy-hexane-1-thiol	Investigative
T28887	DRUGINFO	D09ZNU	4-Benzoylamino-N-hydroxy-benzamide	Investigative
T28887	DRUGINFO	D0A5LS	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	Investigative
T28887	DRUGINFO	D0AX7B	8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one	Investigative
T28887	DRUGINFO	D0B2ZJ	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	Investigative
T28887	DRUGINFO	D0B3ZM	6-Mercapto-hexanoic acid phenylamide	Investigative
T28887	DRUGINFO	D0C0VP	Cyclostellettamine derivative	Investigative
T28887	DRUGINFO	D0C2KD	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	Investigative
T28887	DRUGINFO	D0D2KE	5-Mercapto-pentanoic acid phenylamide	Investigative
T28887	DRUGINFO	D0E8KR	Octanedioic acid hydroxyamide pyridin-2-ylamide	Investigative
T28887	DRUGINFO	D0F0KS	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	Investigative
T28887	DRUGINFO	D0H1FZ	2-(methylsulfonylthio)ethyl 2-propylpentanoate	Investigative
T28887	DRUGINFO	D0KE3I	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	Investigative
T28887	DRUGINFO	D0QO0L	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	Investigative
T28887	DRUGINFO	D0R4BS	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	Investigative
T28887	DRUGINFO	D0R5VG	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	Investigative
T28887	DRUGINFO	D0RU1X	8-Oxo-8-phenyl-octanoic acid	Investigative
T28887	DRUGINFO	D0S7WQ	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	Investigative
T28887	DRUGINFO	D0S9JF	6-phenylsulfanylhexanoic acid hydroxamide	Investigative
T28887	DRUGINFO	D0T0SK	ST-2987	Investigative
T28887	DRUGINFO	D0T4IY	7-Mercapto-heptanoic acid quinolin-3-ylamide	Investigative
T28887	DRUGINFO	D0V2ZO	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	Investigative
T28887	DRUGINFO	D0XZ9Q	8-Mercapto-octanoic acid phenylamide	Investigative
T28887	DRUGINFO	D0YY9M	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	Investigative
T28887	DRUGINFO	D0Z3BM	7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one	Investigative
T28887	DRUGINFO	D0Z5KX	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	Investigative
T28887	DRUGINFO	D0Z7YS	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	Investigative
T28887	DRUGINFO	D0N0TS	PSAMMAPLIN A	Investigative

T05387	TARGETID	T05387
T05387	FORMERID	TTDC00120
T05387	UNIPROID	TGM2_HUMAN
T05387	TARGNAME	Tissue transglutaminase (TG2)
T05387	GENENAME	TGM2
T05387	TARGTYPE	Clinical trial
T05387	SYNONYMS	Transglutaminase-2; Transglutaminase H; Transglutaminase C; Transglutaminase 2; Tranglutaminase 2; TTg; TGase-H; TGase-2; TGase H; TGase C; TGC; TG(C)Protein-glutamine gamma-glutamyltransferase; TG(C); Protein-glutamine gamma-glutamyltransferase 2
T05387	FUNCTION	Catalyzes the cross-linking of proteins and the conjugation of polyamines to proteins.
T05387	PDBSTRUC	6A8P; 4PYG; 3S3S; 3S3P; 3S3J
T05387	BIOCLASS	Acyltransferase
T05387	ECNUMBER	EC 2.3.2.13
T05387	SEQUENCE	MAEELVLERCDLELETNGRDHHTADLCREKLVVRRGQPFWLTLHFEGRNYEASVDSLTFSVVTGPAPSQEAGTKARFPLRDAVEEGDWTATVVDQQDCTLSLQLTTPANAPIGLYRLSLEASTGYQGSSFVLGHFILLFNAWCPADAVYLDSEEERQEYVLTQQGFIYQGSAKFIKNIPWNFGQFEDGILDICLILLDVNPKFLKNAGRDCSRRSSPVYVGRVVSGMVNCNDDQGVLLGRWDNNYGDGVSPMSWIGSVDILRRWKNHGCQRVKYGQCWVFAAVACTVLRCLGIPTRVVTNYNSAHDQNSNLLIEYFRNEFGEIQGDKSEMIWNFHCWVESWMTRPDLQPGYEGWQALDPTPQEKSEGTYCCGPVPVRAIKEGDLSTKYDAPFVFAEVNADVVDWIQQDDGSVHKSINRSLIVGLKISTKSVGRDEREDITHTYKYPEGSSEEREAFTRANHLNKLAEKEETGMAMRIRVGQSMNMGSDFDVFAHITNNTAEEYVCRLLLCARTVSYNGILGPECGTKYLLNLNLEPFSEKSVPLCILYEKYRDCLTESNLIKVRALLVEPVINSYLLAERDLYLENPEIKIRILGEPKQKRKLVAEVSLQNPLPVALEGCTFTVEGAGLTEEQKTVEIPDPVEAGEEVKVRMDLLPLHMGLHKLVVNFESDKLKAVKGFRNVIIGPA
T05387	DRUGINFO	DB2V8K	ZED1227	Phase 2
T05387	DRUGINFO	D00SAH	PMID26560530-Compound-54	Patented
T05387	DRUGINFO	D01CCT	Triazole derivative 1	Patented
T05387	DRUGINFO	D01EKS	Acyl piperidine derivative 3	Patented
T05387	DRUGINFO	D02LBZ	PMID26560530-Compound-14	Patented
T05387	DRUGINFO	D02OXG	PMID26560530-Compound-1	Patented
T05387	DRUGINFO	D02XDG	PMID26560530-Compound-3	Patented
T05387	DRUGINFO	D03JCI	PMID26560530-Compound-11	Patented
T05387	DRUGINFO	D04LLK	Chloroacetyl ester derivative 1	Patented
T05387	DRUGINFO	D04MQZ	PMID26560530-Compound-7	Patented
T05387	DRUGINFO	D05ZTV	Dipeptide analog 2	Patented
T05387	DRUGINFO	D06TXR	PMID26560530-Compound-16	Patented
T05387	DRUGINFO	D06YBF	Acyl piperidine derivative 2	Patented
T05387	DRUGINFO	D08QGR	PMID26560530-Compound-34	Patented
T05387	DRUGINFO	D08UFW	PMID26560530-Compound-48	Patented
T05387	DRUGINFO	D0A9OC	PMID26560530-Compound-4	Patented
T05387	DRUGINFO	D0C2QU	PMID26560530-Compound-25	Patented
T05387	DRUGINFO	D0CL1D	Dihydroisoxazole derivative 2	Patented
T05387	DRUGINFO	D0DK4I	PMID26560530-Compound-24	Patented
T05387	DRUGINFO	D0EA3E	PMID26560530-Compound-26	Patented
T05387	DRUGINFO	D0EZ6C	PMID26560530-Compound-27	Patented
T05387	DRUGINFO	D0G0EG	PMID26560530-Compound-15	Patented
T05387	DRUGINFO	D0G3QD	Chalcone derivative 5	Patented
T05387	DRUGINFO	D0GR1X	Pyrazolodiazepine derivative 1	Patented
T05387	DRUGINFO	D0H2DL	PMID26560530-Compound-50	Patented
T05387	DRUGINFO	D0H4PF	Dipeptide analog 3	Patented
T05387	DRUGINFO	D0IE9E	PMID26560530-Compound-6	Patented
T05387	DRUGINFO	D0IQ8I	PMID26560530-Compound-23	Patented
T05387	DRUGINFO	D0J4IP	PMID26560530-Compound-31	Patented
T05387	DRUGINFO	D0K6SZ	Dipeptide analog 4	Patented
T05387	DRUGINFO	D0KZ6T	PMID26560530-Compound-47	Patented
T05387	DRUGINFO	D0L7MP	3-acylidene-2-oxoindole derivative 2	Patented
T05387	DRUGINFO	D0LO0I	PMID26560530-Compound-18	Patented
T05387	DRUGINFO	D0MA2H	PMID26560530-Compound-2	Patented
T05387	DRUGINFO	D0MF2V	PMID26560530-Compound-33	Patented
T05387	DRUGINFO	D0NB4O	PMID26560530-Compound-12	Patented
T05387	DRUGINFO	D0NX1O	PMID26560530-Compound-17	Patented
T05387	DRUGINFO	D0O6LL	PMID26560530-Compound-8	Patented
T05387	DRUGINFO	D0O9JZ	PMID26560530-Compound-49	Patented
T05387	DRUGINFO	D0PM3J	Dihydroisoxazole derivative 1	Patented
T05387	DRUGINFO	D0QR0U	PMID26560530-Compound-35	Patented
T05387	DRUGINFO	D0QX6W	Benzotriazole derivative 1	Patented
T05387	DRUGINFO	D0RX6D	3-acylidene-2-oxoindole derivative 1	Patented
T05387	DRUGINFO	D0S4YD	Peptide analog 52	Patented
T05387	DRUGINFO	D0U6CU	Sulfonamide derivative 9	Patented
T05387	DRUGINFO	D0UR1H	Peptide analog 54	Patented
T05387	DRUGINFO	D0VC9V	2-alkyloxy-3-phenylethynyl-4a,5-dihydropyrido[2,3-b]pyrazine derivative 1	Patented
T05387	DRUGINFO	D0W5ND	Azachalcone derivative 1	Patented
T05387	DRUGINFO	D0Y3YK	PMID26560530-Compound-5	Patented
T05387	DRUGINFO	D0Y6TX	PMID26560530-Compound-32	Patented
T05387	DRUGINFO	D0Y7FK	Peptide analog 53	Patented
T05387	DRUGINFO	D0YP7A	Isothiocyanate derivative 1	Patented
T05387	DRUGINFO	D0Z1VM	PMID26560530-Compound-46	Patented
T05387	DRUGINFO	D0KK6L	PMID26560530-Compound-13	Patented
T05387	DRUGINFO	D1Y6RQ	NTU281	Preclinical
T05387	DRUGINFO	D0C7LS	Guanosine-5'-Diphosphate	Investigative

T44818	TARGETID	T44818
T44818	UNIPROID	T23O_HUMAN
T44818	TARGNAME	Tryptophan 2,3-dioxygenase (TDO)
T44818	GENENAME	TDO2
T44818	TARGTYPE	Clinical trial
T44818	SYNONYMS	Tryptophanase; Tryptophan pyrrolase; Tryptophan oxygenase; Tryptamin 2,3-dioxygenase; TRPO; TO
T44818	FUNCTION	Catalyzes the oxidative cleavage of the indole moiety. Heme-dependent dioxygenase that catalyzes the oxidative cleavage of the L-tryptophan (L-Trp) pyrrole ring and converts L-tryptophan to N-formyl-L-kynurenine.
T44818	PDBSTRUC	6A4I; 5TIA; 5TI9; 4PW8
T44818	BIOCLASS	Oxygenase
T44818	ECNUMBER	EC 1.13.11.11
T44818	SEQUENCE	MSGCPFLGNNFGYTFKKLPVEGSEEDKSQTGVNRASKGGLIYGNYLHLEKVLNAQELQSETKGNKIHDEHLFIITHQAYELWFKQILWELDSVREIFQNGHVRDERNMLKVVSRMHRVSVILKLLVQQFSILETMTALDFNDFREYLSPASGFQSLQFRLLENKIGVLQNMRVPYNRRHYRDNFKGEENELLLKSEQEKTLLELVEAWLERTPGLEPHGFNFWGKLEKNITRGLEEEFIRIQAKEESEEKEEQVAEFQKQKEVLLSLFDEKRHEHLLSKGERRLSYRALQGALMIYFYREEPRFQVPFQLLTSLMDIDSLMTKWRYNHVCMVHRMLGSKAGTGGSSGYHYLRSTVSDRYKVFVDLFNLSTYLIPRHWIPKMNPTIHKFLYTAEYCDSSYFSSDESD
T44818	DRUGINFO	D9S7XO	DN1406131	Phase 1
T44818	DRUGINFO	DB53NH	HTI-1090	Phase 1
T44818	DRUGINFO	D0E8XV	2,3-diamino-benzo[b]thiophene derivative 3	Patented
T44818	DRUGINFO	D0F4MN	PMID29473428-Compound-76	Patented
T44818	DRUGINFO	D0JB1V	Indazole derivative 3	Patented
T44818	DRUGINFO	D04BZI	2,3-diamino-benzo[b]thiophene derivative 4	Patented
T44818	DRUGINFO	D04MIQ	PMID27172114-Compound-30	Patented
T44818	DRUGINFO	D05TIP	2,3-diamino-benzo[b]thiophene derivative 2	Patented
T44818	DRUGINFO	D05ZGX	2,3-diamino-benzo[b]thiophene derivative 8	Patented
T44818	DRUGINFO	D0F4VD	2,3-diamino-benzo[b]thiophene derivative 7	Patented
T44818	DRUGINFO	D0FF6H	2,3-diamino-benzo[b]thiophene derivative 6	Patented
T44818	DRUGINFO	D0HV0Y	2,3-diamino-benzo[b]thiophene derivative 5	Patented
T44818	DRUGINFO	D0RA7I	2,3-diamino-benzo[b]thiophene derivative 1	Patented
T44818	DRUGINFO	D83YSR	680C91	Preclinical
T44818	DRUGINFO	D9Y2KA	4-(4-fluoropyrazol-1-yl)-1,2-oxazol-5-amine	Preclinical
T44818	DRUGINFO	DZ8UP4	LM10	Preclinical
T44818	DRUGINFO	D9P8LE	RG70099	Preclinical
T44818	DRUGINFO	DZK24C	EPL-1410	Preclinical

T10822	TARGETID	T10822
T10822	FORMERID	TTDR00298
T10822	UNIPROID	CDK8_HUMAN
T10822	TARGNAME	Cyclin-dependent kinase 8 (CDK8)
T10822	GENENAME	CDK8
T10822	TARGTYPE	Clinical trial
T10822	SYNONYMS	Protein kinase K35; Mediator of RNA polymerase II transcription subunit CDK8; Mediator complex subunit CDK8; Cell division protein kinase 8
T10822	FUNCTION	Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors. Phosphorylates the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNAp II), which may inhibit the formation of a transcription initiation complex. Phosphorylates CCNH leading to down-regulation of the TFIIH complex and transcriptional repression. Recruited through interaction with MAML1 to hyperphosphorylate the intracellular domain of NOTCH, leading to its degradation. Component of the Mediator complex, a coactivator involved in regulated gene transcription of nearly all RNA polymerase II-dependent genes.
T10822	PDBSTRUC	5XS2; 5XQX; 5IDP; 5IDN; 5ICP
T10822	BIOCLASS	Kinase
T10822	ECNUMBER	EC 2.7.11.22
T10822	SEQUENCE	MDYDFKVKLSSERERVEDLFEYEGCKVGRGTYGHVYKAKRKDGKDDKDYALKQIEGTGISMSACREIALLRELKHPNVISLQKVFLSHADRKVWLLFDYAEHDLWHIIKFHRASKANKKPVQLPRGMVKSLLYQILDGIHYLHANWVLHRDLKPANILVMGEGPERGRVKIADMGFARLFNSPLKPLADLDPVVVTFWYRAPELLLGARHYTKAIDIWAIGCIFAELLTSEPIFHCRQEDIKTSNPYHHDQLDRIFNVMGFPADKDWEDIKKMPEHSTLMKDFRRNTYTNCSLIKYMEKHKVKPDSKAFHLLQKLLTMDPIKRITSEQAMQDPYFLEDPLPTSDVFAGCQIPYPKREFLTEEEPDDKGDKKNQQQQQGNNHTNGTGHPGNQDSSHTQGPPLKKVRVVPPTTTSGGLIMTSDYQRSNPHAAYPNPGPSTSQPQSSMGYSATSQQPPQYSHQTHRY
T10822	DRUGINFO	DOJG79	SEL120	Phase 1
T10822	DRUGINFO	D03OIA	Macrocycle derivative 14	Patented
T10822	DRUGINFO	D0NY7M	Tricyclic benzimidazole derivative 1	Patented
T10822	DRUGINFO	D70HIN	CCT251545	Preclinical
T10822	DRUGINFO	D03ALC	Oxindole 16 (compound 3)	Investigative
T10822	DRUGINFO	D0VC0I	Oxindole 94	Investigative

T58298	TARGETID	T58298
T58298	FORMERID	TTDR00537
T58298	UNIPROID	ENTP1_HUMAN
T58298	TARGNAME	Ectonucleoside triphosphate diphosphohydrolase 1 (CD39)
T58298	GENENAME	ENTPD1
T58298	TARGTYPE	Clinical trial
T58298	SYNONYMS	NTPDase1; NTPDase 1; Lymphoid cell activation antigen; Ecto-nucleotidase CD-39; Ecto-apyrase; Ecto-ATPase 1; Ecto-ATPDase 1; Ecto-ATP diphosphohydrolase 1; Ecto-ATP diphosphohydrolase; CD39 antigen; ATPDase
T58298	FUNCTION	Could also be implicated in the prevention of platelet aggregation by hydrolyzing platelet-activating ADP to AMP. Hydrolyzes ATP and ADP equally well. In the nervous system, could hydrolyze ATP and other nucleotides to regulate purinergic neurotransmission.
T58298	BIOCLASS	Acid anhydride hydrolase
T58298	ECNUMBER	EC 3.6.1.5
T58298	SEQUENCE	MEDTKESNVKTFCSKNILAILGFSSIIAVIALLAVGLTQNKALPENVKYGIVLDAGSSHTSLYIYKWPAEKENDTGVVHQVEECRVKGPGISKFVQKVNEIGIYLTDCMERAREVIPRSQHQETPVYLGATAGMRLLRMESEELADRVLDVVERSLSNYPFDFQGARIITGQEEGAYGWITINYLLGKFSQKTRWFSIVPYETNNQETFGALDLGGASTQVTFVPQNQTIESPDNALQFRLYGKDYNVYTHSFLCYGKDQALWQKLAKDIQVASNEILRDPCFHPGYKKVVNVSDLYKTPCTKRFEMTLPFQQFEIQGIGNYQQCHQSILELFNTSYCPYSQCAFNGIFLPPLQGDFGAFSAFYFVMKFLNLTSEKVSQEKVTEMMKKFCAQPWEEIKTSYAGVKEKYLSEYCFSGTYILSLLLQGYHFTADSWEHIHFIGKIQGSDAGWTLGYMLNLTNMIPAEQPLSTPLSHSTYVFLMVLFSLVLFTVAIIGLLIFHKPSYFWKDMV
T58298	DRUGINFO	D87PWZ	IPH5201	Phase 1
T58298	DRUGINFO	D9M0KJ	SRF617	Phase 1
T58298	DRUGINFO	DCMG03	TTX-030	Phase 1
T58298	DRUGINFO	D0R2UZ	PSB-6426	Investigative
T58298	DRUGINFO	D06GQY	PSB-0963	Investigative

T63512	TARGETID	T63512
T63512	UNIPROID	ENPP2_HUMAN
T63512	TARGNAME	Extracellular lysophospholipase D (E-NPP2)
T63512	GENENAME	ENPP2
T63512	TARGTYPE	Clinical trial
T63512	SYNONYMS	LysoPLD; Ectonucleotide pyrophosphatase/phosphodiesterase family member 2; E-NPP 2; Autotaxin; ATX
T63512	FUNCTION	Hydrolyzes lysophospholipids to produce the signaling molecule lysophosphatidic acid (LPA) in extracellular fluids. Major substrate is lysophosphatidylcholine. Also can act on sphingosylphosphorylcholine producing sphingosine-1-phosphate, a modulator of cell motility. Can hydrolyze, in vitro, bis-pNPP, to some extent pNP-TMP, and barely ATP. Involved in several motility-related processes such as angiogenesis and neurite outgrowth. Acts as an angiogenic factor by stimulating migration of smooth muscle cells and microtubule formation. Stimulates migration of melanoma cells, probably via a pertussis toxin-sensitive G protein. May have a role in induction of parturition. Possible involvement in cell proliferation and adipose tissue development (Probable). Tumor cell motility-stimulating factor.
T63512	PDBSTRUC	5MHP; 5M7M; 5KXA; 4ZGA; 4ZG9
T63512	BIOCLASS	Phosphoric diester hydrolase
T63512	ECNUMBER	EC 3.1.4.39
T63512	SEQUENCE	MARRSSFQSCQIISLFTFAVGVNICLGFTAHRIKRAEGWEEGPPTVLSDSPWTNISGSCKGRCFELQEAGPPDCRCDNLCKSYTSCCHDFDELCLKTARGWECTKDRCGEVRNEENACHCSEDCLARGDCCTNYQVVCKGESHWVDDDCEEIKAAECPAGFVRPPLIIFSVDGFRASYMKKGSKVMPNIEKLRSCGTHSPYMRPVYPTKTFPNLYTLATGLYPESHGIVGNSMYDPVFDATFHLRGREKFNHRWWGGQPLWITATKQGVKAGTFFWSVVIPHERRILTILQWLTLPDHERPSVYAFYSEQPDFSGHKYGPFGPEMTNPLREIDKIVGQLMDGLKQLKLHRCVNVIFVGDHGMEDVTCDRTEFLSNYLTNVDDITLVPGTLGRIRSKFSNNAKYDPKAIIANLTCKKPDQHFKPYLKQHLPKRLHYANNRRIEDIHLLVERRWHVARKPLDVYKKPSGKCFFQGDHGFDNKVNSMQTVFVGYGSTFKYKTKVPPFENIELYNVMCDLLGLKPAPNNGTHGSLNHLLRTNTFRPTMPEEVTRPNYPGIMYLQSDFDLGCTCDDKVEPKNKLDELNKRLHTKGSTEERHLLYGRPAVLYRTRYDILYHTDFESGYSEIFLMPLWTSYTVSKQAEVSSVPDHLTSCVRPDVRVSPSFSQNCLAYKNDKQMSYGFLFPPYLSSSPEAKYDAFLVTNMVPMYPAFKRVWNYFQRVLVKKYASERNGVNVISGPIFDYDYDGLHDTEDKIKQYVEGSSIPVPTHYYSIITSCLDFTQPADKCDGPLSVSSFILPHRPDNEESCNSSEDESKWVEELMKMHTARVRDIEHLTSLDFFRKTSRSYPEILTLKTYLHTYESEI
T63512	DRUGINFO	DN9V3S	Cudetaxestat	Phase 2
T63512	DRUGINFO	D00LWY	PMID28447479-Compound-24	Patented
T63512	DRUGINFO	D00PJE	Tetra-hydro-carboline derivative 2	Patented
T63512	DRUGINFO	D02BGU	Pyrido/pyrrolo-fused pyrimidine derivative 1	Patented
T63512	DRUGINFO	D02FWT	PMID28447479-Compound-14	Patented
T63512	DRUGINFO	D03RAU	Pyrimidinone derivative 5	Patented
T63512	DRUGINFO	D04TUG	Heteroaromatic ring derivative 3	Patented
T63512	DRUGINFO	D06ZAE	Pyrazolo[3,4-c]pyridine derivative 1	Patented
T63512	DRUGINFO	D07JTJ	Pyrazole derivative 87	Patented
T63512	DRUGINFO	D07UNH	Pyridine and pyrimidine derivative 1	Patented
T63512	DRUGINFO	D09IKN	Imidazopyrimidinone derivative 1	Patented
T63512	DRUGINFO	D0B7KP	PMID28447479-Compound-21	Patented
T63512	DRUGINFO	D0E3ED	Octahydro-pyrrolo[3,4-c]-pyrrole derivative 1	Patented
T63512	DRUGINFO	D0F1FD	Complex heterocyclic compound 1	Patented
T63512	DRUGINFO	D0F7NL	PMID28447479-Compound-20	Patented
T63512	DRUGINFO	D0FM6Y	PMID28447479-Compound-22	Patented
T63512	DRUGINFO	D0FN8Y	Heteroaromatic ring derivative 4	Patented
T63512	DRUGINFO	D0FO4C	Dihydropyrido pyrimidine derivative 1	Patented
T63512	DRUGINFO	D0GA6X	PMID28447479-Compound-4	Patented
T63512	DRUGINFO	D0J5GC	Heteroaromatic ring derivative 1	Patented
T63512	DRUGINFO	D0NG8Q	Heteroaromatic ring derivative 2	Patented
T63512	DRUGINFO	D0PI2I	PMID28447479-Compound-26	Patented
T63512	DRUGINFO	D0RB6K	Tetra-hydro-carboline derivative 1	Patented
T63512	DRUGINFO	D0S8EH	PMID28447479-Compound-11	Patented
T63512	DRUGINFO	D0U8BD	PMID28447479-Compound-23	Patented
T63512	DRUGINFO	D0WD8Z	Piperazine derivative 8	Patented
T63512	DRUGINFO	D0WL5E	PMID28447479-Compound-27	Patented
T63512	DRUGINFO	D0WX7F	PMID28447479-Compound-10	Patented

T15776	TARGETID	T15776
T15776	UNIPROID	PDK1_HUMAN
T15776	TARGNAME	Pyruvate dehydrogenase kinase 1 (PDHK1)
T15776	GENENAME	PDK1
T15776	TARGTYPE	Clinical trial
T15776	SYNONYMS	Pyruvate dehydrogenase kinase isoform 1; Pyruvate dehydrogenase (acetyl-transferring) kinase isozyme 1, mitochondrial; PDHK1; PDH kinase 1
T15776	FUNCTION	Kinase that plays a key role in regulation of glucose and fatty acid metabolism and homeostasis via phosphorylation of the pyruvate dehydrogenase subunits PDHA1 and PDHA2. This inhibits pyruvate dehydrogenase activity, and thereby regulates metabolite flux through the tricarboxylic acid cycle, down-regulates aerobic respiration and inhibits the formation of acetyl-coenzyme A from pyruvate. Plays an important role in cellular responses to hypoxia and is important for cell proliferation under hypoxia. Protects cells against apoptosis in response to hypoxia and oxidative stress.
T15776	PDBSTRUC	2Q8H; 2Q8G; 2Q8F
T15776	BIOCLASS	Kinase
T15776	ECNUMBER	EC 2.7.11.2
T15776	SEQUENCE	MRLARLLRGAALAGPGPGLRAAGFSRSFSSDSGSSPASERGVPGQVDFYARFSPSPLSMKQFLDFGSVNACEKTSFMFLRQELPVRLANIMKEISLLPDNLLRTPSVQLVQSWYIQSLQELLDFKDKSAEDAKAIYDFTDTVIRIRNRHNDVIPTMAQGVIEYKESFGVDPVTSQNVQYFLDRFYMSRISIRMLLNQHSLLFGGKGKGSPSHRKHIGSINPNCNVLEVIKDGYENARRLCDLYYINSPELELEELNAKSPGQPIQVVYVPSHLYHMVFELFKNAMRATMEHHANRGVYPPIQVHVTLGNEDLTVKMSDRGGGVPLRKIDRLFNYMYSTAPRPRVETSRAVPLAGFGYGLPISRLYAQYFQGDLKLYSLEGYGTDAVIYIKALSTDSIERLPVYNKAAWKHYNTNHEADDWCVPSREPKDMTTFRSA
T15776	DRUGINFO	D7I9JH	Dichloroacetate	Phase 4
T15776	DRUGINFO	D00LMA	Heteroaryl-carboxamide derivative 4	Patented
T15776	DRUGINFO	D00MLJ	Pyrazole derivative 61	Patented
T15776	DRUGINFO	D00SVK	PMID25684022-Compound-WO2011137219 37(4-6)	Patented
T15776	DRUGINFO	D00ZXR	Heteroaryl-carboxamide derivative 3	Patented
T15776	DRUGINFO	D02MMG	Pyrimidine derivative 3	Patented
T15776	DRUGINFO	D02USE	Heterocyclic derivative 15	Patented
T15776	DRUGINFO	D03GFZ	Thieno[3,2-c]pyridine-7-carboxamide derivative 2	Patented
T15776	DRUGINFO	D03WFI	Heteroaryl-carboxamide derivative 9	Patented
T15776	DRUGINFO	D04BBA	Thiazole carboxamide derivative 24	Patented
T15776	DRUGINFO	D04BBT	Heterocyclic derivative 12	Patented
T15776	DRUGINFO	D04EDM	PMID25684022-Compound-US20120277229 41(1.3)	Patented
T15776	DRUGINFO	D04MHV	Heterocyclic derivative 17	Patented
T15776	DRUGINFO	D04QRX	Thiazole carboxamide derivative 27	Patented
T15776	DRUGINFO	D04UHW	PMID25684022-Compound-WO2008079988	Patented
T15776	DRUGINFO	D05GMT	Pyridinone carboxamide derivative 1	Patented
T15776	DRUGINFO	D05OTD	Heterocyclic derivative 4	Patented
T15776	DRUGINFO	D06BSG	Thieno[3,2-c]pyridine-7-carboxamide derivative 1	Patented
T15776	DRUGINFO	D06LCB	Thiazole carboxamide derivative 9	Patented
T15776	DRUGINFO	D06LLS	PMID25684022-Compound-WO2009153313	Patented
T15776	DRUGINFO	D06LSZ	PMID25684022-Compound-US20120277229 40(1.2)	Patented
T15776	DRUGINFO	D06PTW	Thiazole carboxamide derivative 12	Patented
T15776	DRUGINFO	D06RGW	PMID25684022-Compound-WO2004087707	Patented
T15776	DRUGINFO	D06WAN	Benzimidazole and imidazopyridine derivative 1	Patented
T15776	DRUGINFO	D06WXJ	Thiazole carboxamide derivative 14	Patented
T15776	DRUGINFO	D07FMW	PMID25684022-Compound-US20130053382 38(5-7)	Patented
T15776	DRUGINFO	D07HOA	Heterocyclic derivative 9	Patented
T15776	DRUGINFO	D07IQE	Heterocyclic derivative 10	Patented
T15776	DRUGINFO	D07MSB	Thiazole carboxamide derivative 11	Patented
T15776	DRUGINFO	D07XBA	PMID25684022-Compound-US20130053382 36(3-5)	Patented
T15776	DRUGINFO	D07ZKE	PMID25684022-Compound-US20120277229 45(1.5)	Patented
T15776	DRUGINFO	D07ZMG	Thiazole carboxamide derivative 29	Patented
T15776	DRUGINFO	D08EGT	PMID25684022-Compound-WO2008005457	Patented
T15776	DRUGINFO	D08SNT	Heteroaryl-carboxamide derivative 2	Patented
T15776	DRUGINFO	D08YPQ	Thiazole carboxamide derivative 7	Patented
T15776	DRUGINFO	D09BNP	Heterocyclic derivative 11	Patented
T15776	DRUGINFO	D09FQP	PMID25684022-Compound-US20120277229 39(1.1)	Patented
T15776	DRUGINFO	D0AM2D	Heterocyclic derivative 8	Patented
T15776	DRUGINFO	D0B2GM	Thiazole carboxamide derivative 20	Patented
T15776	DRUGINFO	D0B8OB	PMID25684022-Compound-WO2011137219 36(3-5)	Patented
T15776	DRUGINFO	D0C6VX	PMID25684022-Compound-WO2010127754	Patented
T15776	DRUGINFO	D0CK8H	Indazole derivative 1	Patented
T15776	DRUGINFO	D0CQ1M	Heterocyclic-carboxamide derivative 2	Patented
T15776	DRUGINFO	D0D0ML	Heterocyclic derivative 6	Patented
T15776	DRUGINFO	D0D5YE	Imidazo quinoline derivative 1	Patented
T15776	DRUGINFO	D0D8PF	Thiazole carboxamide derivative 16	Patented
T15776	DRUGINFO	D0DC2P	PMID25684022-Compound-WO2012135799 42(1.4)	Patented
T15776	DRUGINFO	D0DM2G	Bis-indolylmaleimide derivative 1	Patented
T15776	DRUGINFO	D0DO6K	Thiazole carboxamide derivative 23	Patented
T15776	DRUGINFO	D0EH9Z	Heterocyclic derivative 14	Patented
T15776	DRUGINFO	D0FJ4A	Thiazole carboxamide derivative 18	Patented
T15776	DRUGINFO	D0FW3M	Heterocyclic derivative 18	Patented
T15776	DRUGINFO	D0GE6F	Thiazole carboxamide derivative 17	Patented
T15776	DRUGINFO	D0GH9W	Heteroaryl-carboxamide derivative 6	Patented
T15776	DRUGINFO	D0GY8G	Thiazole carboxamide derivative 19	Patented
T15776	DRUGINFO	D0H6AF	Thiazole carboxamide derivative 4	Patented
T15776	DRUGINFO	D0H7SO	Heteroaryl-carboxamide derivative 1	Patented
T15776	DRUGINFO	D0HI8X	Heterocyclic derivative 13	Patented
T15776	DRUGINFO	D0HP8K	Thiazole carboxamide derivative 2	Patented
T15776	DRUGINFO	D0I1YQ	Pyrazolopyridines and imidazopyridine derivative 1	Patented
T15776	DRUGINFO	D0I5KI	Dibenzo [c,f]-[2,7]naphthyridine derivative 1	Patented
T15776	DRUGINFO	D0IO2X	PMID25684022-Compound-WO2011137219 38(5-7)	Patented
T15776	DRUGINFO	D0IR8B	Benzonaphthyridine derivative 2	Patented
T15776	DRUGINFO	D0J9DI	Heterocyclic derivative 5	Patented
T15776	DRUGINFO	D0JR0F	Thiazole carboxamide derivative 25	Patented
T15776	DRUGINFO	D0K8XT	Thiazole carboxamide derivative 10	Patented
T15776	DRUGINFO	D0KN7T	Thiazole carboxamide derivative 22	Patented
T15776	DRUGINFO	D0MG4D	Heteroaryl-carboxamide derivative 5	Patented
T15776	DRUGINFO	D0MI3E	PMID25684022-Compound-WO2008107444	Patented
T15776	DRUGINFO	D0MW7L	Heteroaryl-carboxamide derivative 7	Patented
T15776	DRUGINFO	D0P0WF	PMID25684022-Compound-WO2011137219 35(1-11)	Patented
T15776	DRUGINFO	D0P1VT	Pyrimidinone derivative 1	Patented
T15776	DRUGINFO	D0P6PT	Thiazole carboxamide derivative 21	Patented
T15776	DRUGINFO	D0PD2I	Thiazole carboxamide derivative 8	Patented
T15776	DRUGINFO	D0PJ7M	1,2-dihydroindazolo[4,3-bc][1,5]benzoxazepine derivative 1	Patented
T15776	DRUGINFO	D0Q6RC	Thiazole carboxamide derivative 1	Patented
T15776	DRUGINFO	D0Q8JK	Thiazole carboxamide derivative 15	Patented
T15776	DRUGINFO	D0QV1E	Thiazole carboxamide derivative 28	Patented
T15776	DRUGINFO	D0R0SJ	PMID25684022-Compound-WO2012135799 43(1.5)	Patented
T15776	DRUGINFO	D0R3VG	Thiazole carboxamide derivative 3	Patented
T15776	DRUGINFO	D0RE3R	PMID25684022-Compound-US20120277229 44(1.4)	Patented
T15776	DRUGINFO	D0RH6G	Heterocyclic derivative 16	Patented
T15776	DRUGINFO	D0RP4U	PMID25684022-Compound-WO2006015124	Patented
T15776	DRUGINFO	D0RY6M	Heterocyclic-carboxamide derivative 1	Patented
T15776	DRUGINFO	D0SB4A	PMID25684022-Compound-US20130053382 35(1-11)	Patented
T15776	DRUGINFO	D0TB2H	Heteroaryl-carboxamide derivative 10	Patented
T15776	DRUGINFO	D0U3IS	Benzonaphthyridine derivative 1	Patented
T15776	DRUGINFO	D0U5HB	Thiazole carboxamide derivative 5	Patented
T15776	DRUGINFO	D0U7LW	Thiazole carboxamide derivative 26	Patented
T15776	DRUGINFO	D0W3JC	Heterocyclic derivative 7	Patented
T15776	DRUGINFO	D0WT9J	Heteroaryl-carboxamide derivative 8	Patented
T15776	DRUGINFO	D0WX4H	Heterocyclic derivative 19	Patented
T15776	DRUGINFO	D0Y0RG	PMID25684022-Compound-US20130053382 37(4-6)	Patented
T15776	DRUGINFO	D0YD1Q	PMID25684022-Compound-EP20041486488	Patented
T15776	DRUGINFO	D0Z3HW	Thiazole carboxamide derivative 30	Patented
T15776	DRUGINFO	D0Z5HL	Thiazole carboxamide derivative 6	Patented
T15776	DRUGINFO	D0ZE5U	Indolinone derivative 1	Patented
T15776	DRUGINFO	D0ZG0K	Thiazole carboxamide derivative 13	Patented
T15776	DRUGINFO	D0ZV9P	Pyrido[4,3-d]pyrimidin-5(6H)-one derivative 1	Patented

T40812	TARGETID	T40812
T40812	UNIPROID	PARP2_HUMAN
T40812	TARGNAME	Poly [ADP-ribose] polymerase 2 (PARP2)
T40812	GENENAME	PARP2
T40812	TARGTYPE	Clinical trial
T40812	SYNONYMS	pADPRT-2; hPARP-2; Protein poly-ADP-ribosyltransferase PARP2; Poly[ADP-ribose] synthase 2; PARP-2; NAD(+) ADP-ribosyltransferase 2; DNA ADP-ribosyltransferase PARP2; ARTD2; ADPRTL2; ADPRT2; ADPRT-2; ADP-ribosyltransferase diphtheria toxin-like 2
T40812	FUNCTION	Mainly mediates glutamate and aspartate ADP-ribosylation of target proteins: the ADP-D-ribosyl group of NAD(+) is transferred to the acceptor carboxyl group of glutamate and aspartate residues and further ADP-ribosyl groups are transferred to the 2'-position of the terminal adenosine moiety, building up a polymer with an average chain length of 20-30 units. ADP-ribosylation follows DNA damage and appears as an obligatory step in a detection/signaling pathway leading to the reparation of DNA strand breaks. Also mediates serine ADP-ribosylation of target proteins following interaction with HPF1; HPF1 conferring serine specificity. In addition to proteins, also able to ADP-ribosylate DNA: preferentially acts on 5'-terminal phosphates at DNA strand breaks termini in nicked duplex. Poly-ADP-ribosyltransferase that mediates poly-ADP-ribosylation of proteins and plays a key role in DNA repair.
T40812	PDBSTRUC	6F5F; 6F5B; 6F1K; 5DSY; 5D5K
T40812	BIOCLASS	Glycosyltransferases
T40812	ECNUMBER	EC 2.4.2.30
T40812	SEQUENCE	MAARRRRSTGGGRARALNESKRVNNGNTAPEDSSPAKKTRRCQRQESKKMPVAGGKANKDRTEDKQDGMPGRSWASKRVSESVKALLLKGKAPVDPECTAKVGKAHVYCEGNDVYDVMLNQTNLQFNNNKYYLIQLLEDDAQRNFSVWMRWGRVGKMGQHSLVACSGNLNKAKEIFQKKFLDKTKNNWEDREKFEKVPGKYDMLQMDYATNTQDEEETKKEESLKSPLKPESQLDLRVQELIKLICNVQAMEEMMMEMKYNTKKAPLGKLTVAQIKAGYQSLKKIEDCIRAGQHGRALMEACNEFYTRIPHDFGLRTPPLIRTQKELSEKIQLLEALGDIEIAIKLVKTELQSPEHPLDQHYRNLHCALRPLDHESYEFKVISQYLQSTHAPTHSDYTMTLLDLFEVEKDGEKEAFREDLHNRMLLWHGSRMSNWVGILSHGLRIAPPEAPITGYMFGKGIYFADMSSKSANYCFASRLKNTGLLLLSEVALGQCNELLEANPKAEGLLQGKHSTKGLGKMAPSSAHFVTLNGSTVPLGPASDTGILNPDGYTLNYNEYIVYNPNQVRMRYLLKVQFNFLQLW
T40812	DRUGINFO	D0F5TD	PMID27841036-Compound-37	Phase 2
T40812	DRUGINFO	DP48WE	Stenoparib	Phase 2
T40812	DRUGINFO	D8TE4F	AMXI 5001	Phase 1/2
T40812	DRUGINFO	D0P3YA	Dihydrodiazepinocarbazolone derivative 1	Patented
T40812	DRUGINFO	D0Z8IR	Tetra-cyclic pyridophthalazinone derivative 1	Patented
T40812	DRUGINFO	D0TD8R	3-phenyl isoquinolin-1(2H) derivative 1	Patented

T50973	TARGETID	T50973
T50973	FORMERID	TTDI02605
T50973	UNIPROID	KMO_HUMAN
T50973	TARGNAME	Kynurenine 3-hydroxylase (KMO)
T50973	GENENAME	KMO
T50973	TARGTYPE	Clinical trial
T50973	SYNONYMS	Kynurenine 3monooxygenase; Kynurenine 3-monooxygenase
T50973	FUNCTION	Required for synthesis of quinolinic acid, a neurotoxic NMDA receptor antagonist and potential endogenous inhibitor of NMDA receptor signaling in axonal targeting, synaptogenesis and apoptosis during brain development. Quinolinic acid may also affect NMDA receptor signaling in pancreatic beta cells, osteoblasts, myocardial cells, and the gastrointestinal tract. Catalyzes the hydroxylation of L-kynurenine (L-Kyn) to form 3-hydroxy-L-kynurenine (L-3OHKyn).
T50973	PDBSTRUC	5X68
T50973	BIOCLASS	Paired donor oxygen oxidoreductase
T50973	ECNUMBER	EC 1.14.13.9
T50973	SEQUENCE	MDSSVIQRKKVAVIGGGLVGSLQACFLAKRNFQIDVYEAREDTRVATFTRGRSINLALSHRGRQALKAVGLEDQIVSQGIPMRARMIHSLSGKKSAIPYGTKSQYILSVSRENLNKDLLTAAEKYPNVKMHFNHRLLKCNPEEGMITVLGSDKVPKDVTCDLIVGCDGAYSTVRSHLMKKPRFDYSQQYIPHGYMELTIPPKNGDYAMEPNYLHIWPRNTFMMIALPNMNKSFTCTLFMPFEEFEKLLTSNDVVDFFQKYFPDAIPLIGEKLLVQDFFLLPAQPMISVKCSSFHFKSHCVLLGDAAHAIVPFFGQGMNAGFEDCLVFDELMDKFSNDLSLCLPVFSRLRIPDDHAISDLSMYNYIEMRAHVNSSWFIFQKNMERFLHAIMPSTFIPLYTMVTFSRIRYHEAVQRWHWQKKVINKGLFFLGSLIAISSTYLLIHYMSPRSFLRLRRPWNWIAHFRNTTCFPAKAVDSLEQISNLISR
T50973	DRUGINFO	DGV8K5	GSK065	Phase 1
T50973	DRUGINFO	D00XMF	Isoxazoles and isoxazoline derivative 2	Patented
T50973	DRUGINFO	D01TDT	Aryl pyrimidine derivative 7	Patented
T50973	DRUGINFO	D03EYJ	Isoxazoles and isoxazoline derivative 1	Patented
T50973	DRUGINFO	D03ROY	Aryl pyrimidine derivative 2	Patented
T50973	DRUGINFO	D04BYB	Cyclopropane 1-carboxylic acid derivative 6	Patented
T50973	DRUGINFO	D06EDH	PMID27172114-Compound-47	Patented
T50973	DRUGINFO	D06KFU	Isoxazoles and isoxazoline derivative 4	Patented
T50973	DRUGINFO	D0BU9N	Cyclopropane 1-carboxylic acid derivative 2	Patented
T50973	DRUGINFO	D0DB7W	Cyclopropane 1-carboxylic acid derivative 9	Patented
T50973	DRUGINFO	D0FW5Q	Cyclopropane 1-carboxylic acid derivative 10	Patented
T50973	DRUGINFO	D0G6DW	Cyclopropane 1-carboxylic acid derivative 3	Patented
T50973	DRUGINFO	D0JZ9L	Cyclopropane 1-carboxylic acid derivative 4	Patented
T50973	DRUGINFO	D0LM5V	Benzene sulfonamide derivative 5	Patented
T50973	DRUGINFO	D0MV3E	Aryl pyrimidine derivative 4	Patented
T50973	DRUGINFO	D0N9WZ	Benzene sulfonamide derivative 6	Patented
T50973	DRUGINFO	D0O8MJ	Cyclopropane 1-carboxylic acid derivative 7	Patented
T50973	DRUGINFO	D0O9IS	Cyclopropane 1-carboxylic acid derivative 8	Patented
T50973	DRUGINFO	D0OM6D	Pyrimidine benzenesulfonamide derivative 3	Patented
T50973	DRUGINFO	D0P1BE	Benzene sulfonamide derivative 3	Patented
T50973	DRUGINFO	D0PI7V	Cyclopropane 1-carboxylic acid derivative 1	Patented
T50973	DRUGINFO	D0Q7NM	Isoxazoles and isoxazoline derivative 5	Patented
T50973	DRUGINFO	D0R3JM	Benzene sulfonamide derivative 7	Patented
T50973	DRUGINFO	D0R5HG	Pyrimidine benzenesulfonamide derivative 2	Patented
T50973	DRUGINFO	D0S0DL	Benzene sulfonamide derivative 2	Patented
T50973	DRUGINFO	D0T8AS	Pyrimidine benzenesulfonamide derivative 1	Patented
T50973	DRUGINFO	D0TK3W	Isoxazoles and isoxazoline derivative 3	Patented
T50973	DRUGINFO	D0UF8Z	Aryl pyrimidine derivative 9	Patented
T50973	DRUGINFO	D0UJ8Z	Cyclopropane 1-carboxylic acid derivative 5	Patented
T50973	DRUGINFO	D0VI4S	Benzene sulfonamide derivative 4	Patented
T50973	DRUGINFO	D0WL1Z	Isoxazoles and isoxazoline derivative 6	Patented
T50973	DRUGINFO	D0X5OC	PMID27172114-Compound-49	Patented
T50973	DRUGINFO	D0XR0Z	Aryl pyrimidine derivative 6	Patented
T50973	DRUGINFO	D0Z2JJ	Aryl pyrimidine derivative 5	Patented
T50973	DRUGINFO	D0ZB9T	Aryl pyrimidine derivative 3	Patented
T50973	DRUGINFO	D0ZL9P	Benzene sulfonamide derivative 1	Patented
T50973	DRUGINFO	D0ZY4T	Aryl pyrimidine derivative 8	Patented
T50973	DRUGINFO	DF1S3A	GSK180	Preclinical
T50973	DRUGINFO	DJ7Z5W	Ro 61-8048	Preclinical
T50973	DRUGINFO	DP3J2W	UPF-648	Preclinical
T50973	DRUGINFO	DV8A1L	CHDI-340246	Preclinical
T50973	DRUGINFO	DY0HV9	GSK366	Preclinical

T39231	TARGETID	T39231
T39231	UNIPROID	TNKS1_HUMAN
T39231	TARGNAME	Tankyrase-1 (TNKS-1)
T39231	GENENAME	TNKS
T39231	TARGTYPE	Clinical trial
T39231	SYNONYMS	Tankyrase I; TRF1-interacting ankyrin-related ADP-ribose polymerase; TNKS1; TINF1; TIN1; TANK1; Protein poly-ADP-ribosyltransferase tankyrase-1; Poly [ADP-ribose] polymerase tankyrase-1; Poly [ADP-ribose] polymerase 5A; PARPL; PARP5A; ARTD5; ADP-ribosyltransferase diphtheria toxin-like 5
T39231	FUNCTION	Acts as an activator of the Wnt signaling pathway by mediating poly-ADP-ribosylation (PARsylation) of AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex: poly-ADP-ribosylated target proteins are recognized by RNF146, which mediates their ubiquitination and subsequent degradation. Also mediates PARsylation of BLZF1 and CASC3, followed by recruitment of RNF146 and subsequent ubiquitination. Mediates PARsylation of TERF1, thereby contributing to the regulation of telomere length. Involved in centrosome maturation during prometaphase by mediating PARsylation of HEPACAM2/MIKI. May also regulate vesicle trafficking and modulate the subcellular distribution of SLC2A4/GLUT4-vesicles. May be involved in spindle pole assembly through PARsylation of NUMA1. Stimulates 26S proteasome activity. Poly-ADP-ribosyltransferase involved in various processes such as Wnt signaling pathway, telomere length and vesicle trafficking.
T39231	PDBSTRUC	5KNI; 5JU5; 5JTI; 5JHQ; 5GP7
T39231	BIOCLASS	Glycosyltransferases
T39231	ECNUMBER	EC 2.4.2.30
T39231	SEQUENCE	MAASRRSQHHHHHHQQQLQPAPGASAPPPPPPPPLSPGLAPGTTPASPTASGLAPFASPRHGLALPEGDGSRDPPDRPRSPDPVDGTSCCSTTSTICTVAAAPVVPAVSTSSAAGVAPNPAGSGSNNSPSSSSSPTSSSSSSPSSPGSSLAESPEAAGVSSTAPLGPGAAGPGTGVPAVSGALRELLEACRNGDVSRVKRLVDAANVNAKDMAGRKSSPLHFAAGFGRKDVVEHLLQMGANVHARDDGGLIPLHNACSFGHAEVVSLLLCQGADPNARDNWNYTPLHEAAIKGKIDVCIVLLQHGADPNIRNTDGKSALDLADPSAKAVLTGEYKKDELLEAARSGNEEKLMALLTPLNVNCHASDGRKSTPLHLAAGYNRVRIVQLLLQHGADVHAKDKGGLVPLHNACSYGHYEVTELLLKHGACVNAMDLWQFTPLHEAASKNRVEVCSLLLSHGADPTLVNCHGKSAVDMAPTPELRERLTYEFKGHSLLQAAREADLAKVKKTLALEIINFKQPQSHETALHCAVASLHPKRKQVTELLLRKGANVNEKNKDFMTPLHVAAERAHNDVMEVLHKHGAKMNALDTLGQTALHRAALAGHLQTCRLLLSYGSDPSIISLQGFTAAQMGNEAVQQILSESTPIRTSDVDYRLLEASKAGDLETVKQLCSSQNVNCRDLEGRHSTPLHFAAGYNRVSVVEYLLHHGADVHAKDKGGLVPLHNACSYGHYEVAELLVRHGASVNVADLWKFTPLHEAAAKGKYEICKLLLKHGADPTKKNRDGNTPLDLVKEGDTDIQDLLRGDAALLDAAKKGCLARVQKLCTPENINCRDTQGRNSTPLHLAAGYNNLEVAEYLLEHGADVNAQDKGGLIPLHNAASYGHVDIAALLIKYNTCVNATDKWAFTPLHEAAQKGRTQLCALLLAHGADPTMKNQEGQTPLDLATADDIRALLIDAMPPEALPTCFKPQATVVSASLISPASTPSCLSAASSIDNLTGPLAELAVGGASNAGDGAAGTERKEGEVAGLDMNISQFLKSLGLEHLRDIFETEQITLDVLADMGHEELKEIGINAYGHRHKLIKGVERLLGGQQGTNPYLTFHCVNQGTILLDLAPEDKEYQSVEEEMQSTIREHRDGGNAGGIFNRYNVIRIQKVVNKKLRERFCHRQKEVSEENHNHHNERMLFHGSPFINAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPTHKDRSCYICHRQMLFCRVTLGKSFLQFSTMKMAHAPPGHHSVIGRPSVNGLAYAEYVIYRGEQAYPEYLITYQIMKPEAPSQTATAAEQKT
T39231	DRUGINFO	D0F5TD	PMID27841036-Compound-37	Phase 2
T39231	DRUGINFO	DP48WE	Stenoparib	Phase 2

T77350	TARGETID	T77350
T77350	FORMERID	TTDI03483
T77350	UNIPROID	PSB8_HUMAN
T77350	TARGNAME	Proteasome beta-8 (PS beta-8)
T77350	GENENAME	PSMB8
T77350	TARGTYPE	Clinical trial
T77350	SYNONYMS	Y2; Really interesting new gene 10 protein; RING10; Proteasome subunit beta-5i; Proteasome subunit beta type-8; Proteasome component C13; PSMB5i; Multicatalytic endopeptidase complex subunit C13; Macropain subunit C13; Low molecular mass protein 7; LMP7
T77350	FUNCTION	The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. Replacement of PSMB5 by PSMB8 increases the capacity of the immunoproteasome to cleave model peptides after hydrophobic and basic residues. Acts as a major component of interferon gamma-induced sensitivity. Plays a key role in apoptosis via the degradation of the apoptotic inhibitor MCL1. May be involved in the inflammatory response pathway. In cancer cells, substitution of isoform 1 (E2) by isoform 2 (E1) results in immunoproteasome deficiency. Required for the differentiation of preadipocytes into adipocytes. The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH.
T77350	PDBSTRUC	6AVO; 5M2B; 5LTT; 5L5V; 5L5U
T77350	BIOCLASS	Peptidase
T77350	ECNUMBER	EC 3.4.25.1
T77350	SEQUENCE	MALLDVCGAPRGQRPESALPVAGSGRRSDPGHYSFSMRSPELALPRGMQPTEFFQSLGGDGERNVQIEMAHGTTTLAFKFQHGVIAAVDSRASAGSYISALRVNKVIEINPYLLGTMSGCAADCQYWERLLAKECRLYYLRNGERISVSAASKLLSNMMCQYRGMGLSMGSMICGWDKKGPGLYYVDEHGTRLSGNMFSTGSGNTYAYGVMDSGYRPNLSPEEAYDLGRRAIAYATHRDSYSGGVVNMYHMKEDGWVKVESTDVSDLLHQYREANQ
T77350	DRUGINFO	D7X8AQ	M3258	Phase 1
T77350	DRUGINFO	D02KPK	PMID29865878-Compound-58	Patented
T77350	DRUGINFO	D04HMP	PMID29865878-Compound-61	Patented
T77350	DRUGINFO	D0E5WC	PMID29865878-Compound-59	Patented
T77350	DRUGINFO	D0GI4S	PMID29865878-Compound-64	Patented
T77350	DRUGINFO	D0J6LT	PMID29865878-Compound-57	Patented
T77350	DRUGINFO	D0RK3U	PMID29865878-Compound-63	Patented
T77350	DRUGINFO	D0RY9I	PMID29865878-Compound-62	Patented
T77350	DRUGINFO	D02SYR	Peptide analog 27	Patented
T77350	DRUGINFO	D03JMZ	Peptide analog 28	Patented
T77350	DRUGINFO	D05MVF	Peptide analog 34	Patented
T77350	DRUGINFO	D06OXO	Peptide analog 33	Patented
T77350	DRUGINFO	D07SSU	Peptide analog 31	Patented
T77350	DRUGINFO	D08HPR	PMID29865878-Compound-44	Patented
T77350	DRUGINFO	D09WUW	PMID29865878-Compound-43	Patented
T77350	DRUGINFO	D0AR6B	Peptide analog 13	Patented
T77350	DRUGINFO	D0B0GG	Dipeptide analog 1	Patented
T77350	DRUGINFO	D0DK3R	Peptide analog 25	Patented
T77350	DRUGINFO	D0E6ED	Peptide analog 11	Patented
T77350	DRUGINFO	D0L1TT	Peptide analog 17	Patented
T77350	DRUGINFO	D0P8VL	PMID29865878-Compound-8	Patented
T77350	DRUGINFO	D0Q0XN	Peptide analog 19	Patented
T77350	DRUGINFO	D01VMN	PMID29865878-Compound-53	Patented
T77350	DRUGINFO	D03CMD	PMID29865878-Compound-55	Patented
T77350	DRUGINFO	D0C2MH	PMID29865878-Compound-46	Patented
T77350	DRUGINFO	D0K0GJ	PMID29865878-Compound-48	Patented
T77350	DRUGINFO	D0NE8M	PMID29865878-Compound-51	Patented
T77350	DRUGINFO	D0TU5R	PMID29865878-Compound-49	Patented
T77350	DRUGINFO	D01OOO	Peptide analog 41	Patented
T77350	DRUGINFO	D02PJI	Peptide analog 21	Patented
T77350	DRUGINFO	D0T1YB	Peptide analog 23	Patented
T77350	DRUGINFO	D0K7CX	HT1042	Investigative

T62841	TARGETID	T62841
T62841	FORMERID	TTDR00109
T62841	UNIPROID	PAR2_HUMAN
T62841	TARGNAME	Proteinase activated receptor 2 (PAR2)
T62841	GENENAME	F2RL1
T62841	TARGTYPE	Clinical trial
T62841	SYNONYMS	Thrombin receptor-like 1; Proteinase-activated receptor-2; Proteinase-activated receptor 2; Protease activated receptor 2; PAR-2; GPR11; G-protein coupled receptor 11; Coagulation factor II receptor-like 1
T62841	FUNCTION	Its function is mediated through the activation of several signaling pathways including phospholipase C (PLC), intracellular calcium, mitogen-activated protein kinase (MAPK), I-kappaB kinase/NF-kappaB and Rho. Can also be transactivated by cleaved F2R/PAR1. Involved in modulation of inflammatory responses and regulation of innate and adaptive immunity, and acts as a sensor for proteolytic enzymes generated during infection. Generally is promoting inflammation. Can signal synergistically with TLR4 and probably TLR2 in inflammatory responses and modulates TLR3 signaling. Has a protective role in establishing the endothelial barrier; the activity involves coagulation factor X. Regulates endothelial cell barrier integrity during neutrophil extravasation, probably following proteolytic cleavage by PRTN3. Proposed to have a bronchoprotective role in airway epithelium, but also shown to compromise the airway epithelial barrier by interrupting E-cadherin adhesion. Involved in the regulation of vascular tone; activation results in hypotension presumably mediated by vasodilation. Associates with a subset of G proteins alpha subunits such as GNAQ, GNA11, GNA14, GNA12 and GNA13, but probably not with G(o) alpha, G(i) subunit alpha-1 and G(i) subunit alpha-2. However, according to can signal through G(i) subunit alpha. Believed to be a class B receptor which internalizes as a complex with arrestin and traffic with it to endosomal vesicles, presumably as desensitized receptor, for extended periods of time. Mediates inhibition of TNF-alpha stimulated JNK phosphorylation via coupling to GNAQ and GNA11; the function involves dissociation of RIPK1 and TRADD from TNFR1. Mediates phosphorylation of nuclear factor NF-kappa-B RELA subunit at 'Ser-536'; the function involves IKBKB and is predominantly independent of G proteins. Involved in cellular migration. Involved in cytoskeletal rearrangement and chemotaxis through beta-arrestin-promoted scaffolds; the function is independent of GNAQ and GNA11 and involves promotion of cofilin dephosphorylation and actin filament severing. Induces redistribution of COPS5 from the plasma membrane to the cytosol and activation of the JNK cascade is mediated by COPS5. Involved in the recruitment of leukocytes to the sites of inflammation and is the major PAR receptor capable of modulating eosinophil function such as proinflammatory cytokine secretion, superoxide production and degranulation. During inflammation promotes dendritic cell maturation, trafficking to the lymph nodes and subsequent T-cell activation. Involved in antimicrobial response of innate immnune cells; activation enhances phagocytosis of Gram-positive and killing of Gram-negative bacteria. Acts synergistically with interferon-gamma in enhancing antiviral responses. Implicated in a number of acute and chronic inflammatory diseases such as of the joints, lungs, brain, gastrointestinal tract, periodontium, skin, and vascular systems, and in autoimmune disorders. Receptor for trypsin and trypsin-like enzymes coupled to G proteins.
T62841	PDBSTRUC	5NJ6; 5NDZ; 5NDD
T62841	BIOCLASS	GPCR rhodopsin
T62841	SEQUENCE	MRSPSAAWLLGAAILLAASLSCSGTIQGTNRSSKGRSLIGKVDGTSHVTGKGVTVETVFSVDEFSASVLTGKLTTVFLPIVYTIVFVVGLPSNGMALWVFLFRTKKKHPAVIYMANLALADLLSVIWFPLKIAYHIHGNNWIYGEALCNVLIGFFYGNMYCSILFMTCLSVQRYWVIVNPMGHSRKKANIAIGISLAIWLLILLVTIPLYVVKQTIFIPALNITTCHDVLPEQLLVGDMFNYFLSLAIGVFLFPAFLTASAYVLMIRMLRSSAMDENSEKKRKRAIKLIVTVLAMYLICFTPSNLLLVVHYFLIKSQGQSHVYALYIVALCLSTLNSCIDPFVYYFVSHDFRDHAKNALLCRSVRTVKQMQVSLTSKKHSRKSSSYSSSSTTVKTSY
T62841	DRUGINFO	DBNJ30	MEDI0618	Phase 1
T62841	DRUGINFO	D02SJB	Imidazopyridazine derivative 8	Patented
T62841	DRUGINFO	D04GIJ	Piperazine urea derivative 4	Patented
T62841	DRUGINFO	D04YKO	Piperidine derivative 2	Patented
T62841	DRUGINFO	D05VXK	Benzimidazole derivative 10	Patented
T62841	DRUGINFO	D06XWQ	Benzothiazine-carboxamide compound 2	Patented
T62841	DRUGINFO	D07AXK	Peptide analog 71	Patented
T62841	DRUGINFO	D07HJT	Amidine compound 3	Patented
T62841	DRUGINFO	D07OVM	Benzothiazine-carboxamide compound 4	Patented
T62841	DRUGINFO	D08ZEM	Quinazoline derivative 11	Patented
T62841	DRUGINFO	D09EIX	PMID26936077-Compound-13	Patented
T62841	DRUGINFO	D0AK6L	Amidine compound 4	Patented
T62841	DRUGINFO	D0CM5P	Quinazoline derivative 10	Patented
T62841	DRUGINFO	D0D2PU	Peptidomimetic analog 6	Patented
T62841	DRUGINFO	D0EC3H	Quinazoline derivative 12	Patented
T62841	DRUGINFO	D0G2EP	Amidine compound 6	Patented
T62841	DRUGINFO	D0G7KY	Imidazopyridazine derivative 5	Patented
T62841	DRUGINFO	D0H1JS	Piperazine urea derivative 3	Patented
T62841	DRUGINFO	D0H4SE	Benzothiazine-carboxamide compound 6	Patented
T62841	DRUGINFO	D0I2RS	PMID26936077-Compound-34	Patented
T62841	DRUGINFO	D0JT0B	Amidine compound 5	Patented
T62841	DRUGINFO	D0K9QH	Benzothiazine-carboxamide compound 3	Patented
T62841	DRUGINFO	D0LT5Y	Piperazine derivative 5	Patented
T62841	DRUGINFO	D0N3AF	Imidazopyridazine derivative 7	Patented
T62841	DRUGINFO	D0P2BJ	Quinazoline derivative 13	Patented
T62841	DRUGINFO	D0P7UB	Benzothiazine-carboxamide compound 1	Patented
T62841	DRUGINFO	D0Q8MQ	Benzothiazine-carboxamide compound 5	Patented
T62841	DRUGINFO	D0S6SJ	Piperidine derivative 3	Patented
T62841	DRUGINFO	D0T6SP	Benzimidazole derivative 9	Patented
T62841	DRUGINFO	D0UD6X	Imidazopyridazine derivative 3	Patented
T62841	DRUGINFO	D0UN9X	Imidazopyridazine derivative 4	Patented
T62841	DRUGINFO	D0VN2U	Amidine compound 1	Patented
T62841	DRUGINFO	D0W9AB	Imidazopyridazine derivative 6	Patented
T62841	DRUGINFO	D0WH1K	Amidine compound 2	Patented
T62841	DRUGINFO	D0Y9UV	Peptide analog 72	Patented
T62841	DRUGINFO	D0Z4SW	Benzimidazole derivative 8	Patented
T62841	DRUGINFO	D07ZNP	GB110	Investigative
T62841	DRUGINFO	D0A5GJ	GB88	Investigative
T62841	DRUGINFO	D0G7FS	ASKH95	Investigative

T12091	TARGETID	T12091
T12091	FORMERID	TTDI03010
T12091	UNIPROID	ACVR1_HUMAN
T12091	TARGNAME	Activin receptor-like kinase 2 (ALK-2)
T12091	GENENAME	ACVR1
T12091	TARGTYPE	Clinical trial
T12091	SYNONYMS	TSR-I; TGF-B superfamily receptor type I; Serine/threonine-protein kinase receptor R1; SKR1; Activin receptor type-1; Activin receptor type I; ACVRLK2; ACTR-I
T12091	FUNCTION	Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for activin. May be involved for left-right pattern formation during embryogenesis. On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases.
T12091	PDBSTRUC	6GIP; 6GIN; 6GI6; 6EIX; 6ACR
T12091	BIOCLASS	Kinase
T12091	ECNUMBER	EC 2.7.11.30
T12091	SEQUENCE	MVDGVMILPVLIMIALPSPSMEDEKPKVNPKLYMCVCEGLSCGNEDHCEGQQCFSSLSINDGFHVYQKGCFQVYEQGKMTCKTPPSPGQAVECCQGDWCNRNITAQLPTKGKSFPGTQNFHLEVGLIILSVVFAVCLLACLLGVALRKFKRRNQERLNPRDVEYGTIEGLITTNVGDSTLADLLDHSCTSGSGSGLPFLVQRTVARQITLLECVGKGRYGEVWRGSWQGENVAVKIFSSRDEKSWFRETELYNTVMLRHENILGFIASDMTSRHSSTQLWLITHYHEMGSLYDYLQLTTLDTVSCLRIVLSIASGLAHLHIEIFGTQGKPAIAHRDLKSKNILVKKNGQCCIADLGLAVMHSQSTNQLDVGNNPRVGTKRYMAPEVLDETIQVDCFDSYKRVDIWAFGLVLWEVARRMVSNGIVEDYKPPFYDVVPNDPSFEDMRKVVCVDQQRPNIPNRWFSDPTLTSLAKLMKECWYQNPSARLTALRIKKTLTKIDNSLDKLKTDC
T12091	DRUGINFO	D50OLM	INCB00928	Phase 2
T12091	DRUGINFO	DNI28K	TP-0184	Phase 1
T12091	DRUGINFO	D0A8BV	PMID27774822-Compound-Figure10Compound12	Patented
T12091	DRUGINFO	D0AE0M	PMID27774822-Compound-Figure10Compound4	Patented
T12091	DRUGINFO	D0RF7O	ML347	Investigative
T12091	DRUGINFO	D06CMG	LDN-214117	Investigative
T12091	DRUGINFO	D05NEC	PMID23639540C13r	Investigative
T12091	DRUGINFO	D0F2MP	PMID23639540C13d	Investigative
T12091	DRUGINFO	D0PP6Y	PMID23639540C13a	Investigative

T38087	TARGETID	T38087
T38087	UNIPROID	TNKS2_HUMAN
T38087	TARGNAME	Tankyrase-2 (TNKS-2)
T38087	GENENAME	TNKS2
T38087	TARGTYPE	Clinical trial
T38087	SYNONYMS	Tankyrase-related protein; Tankyrase-like protein; Tankyrase II; TRF1-interacting ankyrin-related ADP-ribose polymerase 2; TNKL; TANK2; Protein poly-ADP-ribosyltransferase tankyrase-2; Poly [ADP-ribose] polymerase tankyrase-2; Poly [ADP-ribose] polymerase 5B; PARP5B; ARTD6; ADP-ribosyltransferase diphtheria toxin-like 6
T38087	FUNCTION	Acts as an activator of the Wnt signaling pathway by mediating poly-ADP-ribosylation of AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex: poly-ADP-ribosylated target proteins are recognized by RNF146, which mediates their ubiquitination and subsequent degradation. Also mediates poly-ADP-ribosylation of BLZF1 and CASC3, followed by recruitment of RNF146 and subsequent ubiquitination. Mediates poly-ADP-ribosylation of TERF1, thereby contributing to the regulation of telomere length. Stimulates 26S proteasome activity. Poly-ADP-ribosyltransferase involved in various processes such as Wnt signaling pathway, telomere length and vesicle trafficking.
T38087	PDBSTRUC	5OWT; 5OWS; 5NUT; 5NSP; 5NOB
T38087	BIOCLASS	Glycosyltransferases
T38087	ECNUMBER	EC 2.4.2.30
T38087	SEQUENCE	MSGRRCAGGGAACASAAAEAVEPAARELFEACRNGDVERVKRLVTPEKVNSRDTAGRKSTPLHFAAGFGRKDVVEYLLQNGANVQARDDGGLIPLHNACSFGHAEVVNLLLRHGADPNARDNWNYTPLHEAAIKGKIDVCIVLLQHGAEPTIRNTDGRTALDLADPSAKAVLTGEYKKDELLESARSGNEEKMMALLTPLNVNCHASDGRKSTPLHLAAGYNRVKIVQLLLQHGADVHAKDKGDLVPLHNACSYGHYEVTELLVKHGACVNAMDLWQFTPLHEAASKNRVEVCSLLLSYGADPTLLNCHNKSAIDLAPTPQLKERLAYEFKGHSLLQAAREADVTRIKKHLSLEMVNFKHPQTHETALHCAAASPYPKRKQICELLLRKGANINEKTKEFLTPLHVASEKAHNDVVEVVVKHEAKVNALDNLGQTSLHRAAYCGHLQTCRLLLSYGCDPNIISLQGFTALQMGNENVQQLLQEGISLGNSEADRQLLEAAKAGDVETVKKLCTVQSVNCRDIEGRQSTPLHFAAGYNRVSVVEYLLQHGADVHAKDKGGLVPLHNACSYGHYEVAELLVKHGAVVNVADLWKFTPLHEAAAKGKYEICKLLLQHGADPTKKNRDGNTPLDLVKDGDTDIQDLLRGDAALLDAAKKGCLARVKKLSSPDNVNCRDTQGRHSTPLHLAAGYNNLEVAEYLLQHGADVNAQDKGGLIPLHNAASYGHVDVAALLIKYNACVNATDKWAFTPLHEAAQKGRTQLCALLLAHGADPTLKNQEGQTPLDLVSADDVSALLTAAMPPSALPSCYKPQVLNGVRSPGATADALSSGPSSPSSLSAASSLDNLSGSFSELSSVVSSSGTEGASSLEKKEVPGVDFSITQFVRNLGLEHLMDIFEREQITLDVLVEMGHKELKEIGINAYGHRHKLIKGVERLISGQQGLNPYLTLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAMKMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEGMVDG
T38087	DRUGINFO	D0F5TD	PMID27841036-Compound-37	Phase 2
T38087	DRUGINFO	DP48WE	Stenoparib	Phase 2

T13176	TARGETID	T13176
T13176	FORMERID	TTDI03189
T13176	UNIPROID	E2AK3_HUMAN
T13176	TARGNAME	PRKR-like endoplasmic reticulum kinase (PERK)
T13176	GENENAME	EIF2AK3
T13176	TARGTYPE	Clinical trial
T13176	SYNONYMS	PEK
T13176	FUNCTION	Converts phosphorylated eIF-2-alpha/EIF2S1 either in a global protein synthesis inhibitor, leading to a reduced overall utilization of amino acids, or to a translation initiation activator of specific mRNAs, such as the transcriptional activator ATF4, and hence allowing ATF4-mediated reprogramming of amino acid biosynthetic gene expression to alleviate nutrient depletion. Serves as a critical effector of unfolded protein response (UPR)-induced G1 growth arrest due to the loss of cyclin-D1 (CCND1). Involved in control of mitochondrial morphology and function. Metabolic-stress sensing protein kinase that phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (eIF-2-alpha/EIF2S1) on 'Ser-52' during the unfolded protein response (UPR) and in response to low amino acid availability.
T13176	PDBSTRUC	5SV7; 4YZS; 4X7O; 4X7N; 4X7L
T13176	BIOCLASS	Kinase
T13176	ECNUMBER	EC 2.7.11.1
T13176	SEQUENCE	MERAISPGLLVRALLLLLLLLGLAARTVAAGRARGLPAPTAEAAFGLGAAAAPTSATRVPAAGAVAAAEVTVEDAEALPAAAGEQEPRGPEPDDETELRPRGRSLVIISTLDGRIAALDPENHGKKQWDLDVGSGSLVSSSLSKPEVFGNKMIIPSLDGALFQWDQDRESMETVPFTVESLLESSYKFGDDVVLVGGKSLTTYGLSAYSGKVRYICSALGCRQWDSDEMEQEEDILLLQRTQKTVRAVGPRSGNEKWNFSVGHFELRYIPDMETRAGFIESTFKPNENTEESKIISDVEEQEAAIMDIVIKVSVADWKVMAFSKKGGHLEWEYQFCTPIASAWLLKDGKVIPISLFDDTSYTSNDDVLEDEEDIVEAARGATENSVYLGMYRGQLYLQSSVRISEKFPSSPKALESVTNENAIIPLPTIKWKPLIHSPSRTPVLVGSDEFDKCLSNDKFSHEEYSNGALSILQYPYDNGYYLPYYKRERNKRSTQITVRFLDNPHYNKNIRKKDPVLLLHWWKEIVATILFCIIATTFIVRRLFHPHPHRQRKESETQCQTENKYDSVSGEANDSSWNDIKNSGYISRYLTDFEPIQCLGRGGFGVVFEAKNKVDDCNYAIKRIRLPNRELAREKVMREVKALAKLEHPGIVRYFNAWLEAPPEKWQEKMDEIWLKDESTDWPLSSPSPMDAPSVKIRRMDPFATKEHIEIIAPSPQRSRSFSVGISCDQTSSSESQFSPLEFSGMDHEDISESVDAAYNLQDSCLTDCDVEDGTMDGNDEGHSFELCPSEASPYVRSRERTSSSIVFEDSGCDNASSKEEPKTNRLHIGNHCANKLTAFKPTSSKSSSEATLSISPPRPTTLSLDLTKNTTEKLQPSSPKVYLYIQMQLCRKENLKDWMNGRCTIEERERSVCLHIFLQIAEAVEFLHSKGLMHRDLKPSNIFFTMDDVVKVGDFGLVTAMDQDEEEQTVLTPMPAYARHTGQVGTKLYMSPEQIHGNSYSHKVDIFSLGLILFELLYPFSTQMERVRTLTDVRNLKFPPLFTQKYPCEYVMVQDMLSPSPMERPEAINIIENAVFEDLDFPGKTVLRQRSRSLSSSGTKHSRQSNNSHSPLPSN
T13176	DRUGINFO	DJQ96R	HC-5404	Phase 1
T13176	DRUGINFO	D04AMY	Phenylpyrrolidinone derivative 3	Patented
T13176	DRUGINFO	D06PIO	Indoline derivative 6	Patented
T13176	DRUGINFO	D08HTR	Tricyclic isoxazoloquinazoline derivative 1	Patented
T13176	DRUGINFO	D08JII	Phenylpyrrolidinone derivative 1	Patented
T13176	DRUGINFO	D0D4FR	Phenylpyrrolidinone derivative 5	Patented
T13176	DRUGINFO	D0DY3E	Indoline derivative 3	Patented
T13176	DRUGINFO	D0G5EI	Indoline derivative 11	Patented
T13176	DRUGINFO	D0H1WN	Indoline derivative 8	Patented
T13176	DRUGINFO	D0KH5D	Indoline derivative 2	Patented
T13176	DRUGINFO	D0NA2Q	Indoline derivative 9	Patented
T13176	DRUGINFO	D0RX8U	Indoline derivative 10	Patented
T13176	DRUGINFO	D0U8IL	Phenylpyrrolidinone derivative 2	Patented
T13176	DRUGINFO	D0YF7Q	Indoline derivative 7	Patented
T13176	DRUGINFO	D0Z5NP	Phenylpyrrolidinone derivative 4	Patented
T13176	DRUGINFO	D06GGI	Tricyclic isoxazoloquinazoline derivative 2	Patented
T13176	DRUGINFO	D0JC8E	Tricyclic isoxazoloquinazoline derivative 4	Patented
T13176	DRUGINFO	D0WK2S	Tricyclic isoxazoloquinazoline derivative 3	Patented
T13176	DRUGINFO	D0N4LR	GSK2606414	Investigative

T80886	TARGETID	T80886
T80886	UNIPROID	BACH1_HUMAN
T80886	TARGNAME	Transcription regulator protein BACH1 (Bach1)
T80886	GENENAME	BACH1
T80886	TARGTYPE	Clinical trial
T80886	SYNONYMS	HA2303; BTB and CNC homolog 1
T80886	FUNCTION	Binds to NF-E2 DNA binding sites. Play important roles in coordinating transcription activation and repression by MAFK. Together with MAF, represses the transcription of genes under the control of the NFE2L2 oxidative stress pathway. Transcriptional regulator that acts as repressor or activator, depending on the context.
T80886	PDBSTRUC	2IHC
T80886	BIOCLASS	Basic leucine zipper bZIP
T80886	SEQUENCE	MSLSENSVFAYESSVHSTNVLLSLNDQRKKDVLCDVTIFVEGQRFRAHRSVLAACSSYFHSRIVGQADGELNITLPEEVTVKGFEPLIQFAYTAKLILSKENVDEVCKCVEFLSVHNIEESCFQFLKFKFLDSTADQQECPRKKCFSSHCQKTDLKLSLLDQRDLETDEVEEFLENKNVQTPQCKLRRYQGNAKASPPLQDSASQTYESMCLEKDAALALPSLCPKYRKFQKAFGTDRVRTGESSVKDIHASVQPNERSENECLGGVPECRDLQVMLKCDESKLAMEPEETKKDPASQCPTEKSEVTPFPHNSSIDPHGLYSLSLLHTYDQYGDLNFAGMQNTTVLTEKPLSGTDVQEKTFGESQDLPLKSDLGTREDSSVASSDRSSVEREVAEHLAKGFWSDICSTDTPCQMQLSPAVAKDGSEQISQKRSECPWLGIRISESPEPGQRTFTTLSSVNCPFISTLSTEGCSSNLEIGNDDYVSEPQQEPCPYACVISLGDDSETDTEGDSESCSAREQECEVKLPFNAQRIISLSRNDFQSLLKMHKLTPEQLDCIHDIRRRSKNRIAAQRCRKRKLDCIQNLESEIEKLQSEKESLLKERDHILSTLGETKQNLTGLCQKVCKEAALSQEQIQILAKYSAADCPLSFLISEKDKSTPDGELALPSIFSLSDRPPAVLPPCARGNSEPGYARGQESQQMSTATSEQAGPAEQCRQSGGISDFCQQMTDKCTTDE
T80886	DRUGINFO	DPIE08	ASP8731	Phase 1

T46526	TARGETID	T46526
T46526	UNIPROID	FIMH_ECOLI
T46526	TARGNAME	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
T46526	GENENAME	Bact FimH
T46526	TARGTYPE	Clinical trial
T46526	SYNONYMS	fimH; b4320; Type 1 fimbrin D-mannose specific adhesin; Protein FimH; JW4283
T46526	FUNCTION	Adhesin responsible for the binding to D-mannose. It is laterally positioned at intervals in the structure of the type 1 fimbriae. In order to integrate FimH in the fimbriae FimF and FimG are needed. Involved in regulation of length and mediation of adhesion of type 1 fimbriae (but not necessary for the production of fimbriae).
T46526	PDBSTRUC	6GTY; 6GTX; 6G2S; 6G2R; 6.00E+15
T46526	SEQUENCE	MKRVITLFAVLLMGWSVNAWSFACKTANGTAIPIGGGSANVYVNLAPVVNVGQNLVVDLSTQIFCHNDYPETITDYVTLQRGSAYGGVLSNFSGTVKYSGSSYPFPTTSETPRVVYNSRTDKPWPVALYLTPVSSAGGVAIKAGSLIAVLILRQTNNYNSDDFQFVWNIYANNDVVVPTGGCDVSARDVTVTLPDYPGSVPIPLTVYCAKSQNLGYYLSGTTADAGNSIFTNTASFSPAQGVGVQLTRNGTIIPANNTVSLGAVGTSAVSLGLTANYARTGGQVTAGNVQSIIGVTFVYQ
T46526	DRUGINFO	D72HXF	EB8018	Phase 2
T46526	DRUGINFO	D7PFL1	GSK3882347	Phase 1
T46526	DRUGINFO	D7PFL1	GSK3882347	Phase 1
T46526	DRUGINFO	D00COH	Biaryl mannoside derivative 24	Patented
T46526	DRUGINFO	D00KKD	PMID26651364-Compound-5	Patented
T46526	DRUGINFO	D00RDO	PMID26651364-Compound-116	Patented
T46526	DRUGINFO	D00RQW	Biaryl mannoside derivative 8	Patented
T46526	DRUGINFO	D00XEM	Beta-cyclodextrin conjugate derivative 3	Patented
T46526	DRUGINFO	D00XKE	PMID26651364-Compound-109	Patented
T46526	DRUGINFO	D01CND	PMID26651364-Compound-114	Patented
T46526	DRUGINFO	D01PBX	Biphenyl mannoside derivative 6	Patented
T46526	DRUGINFO	D01RHK	PMID26651364-Compound-5d	Patented
T46526	DRUGINFO	D01ZKE	Biaryl mannoside derivative 21	Patented
T46526	DRUGINFO	D02AAD	Biaryl mannoside derivative 31	Patented
T46526	DRUGINFO	D02DFJ	Biaryl mannoside derivative 10	Patented
T46526	DRUGINFO	D02HPF	Biaryl mannoside derivative 9	Patented
T46526	DRUGINFO	D02NDP	PMID26651364-Compound-7a	Patented
T46526	DRUGINFO	D02UDO	PMID26651364-Compound-9d	Patented
T46526	DRUGINFO	D02WWT	Aryl mannoside derivative 19	Patented
T46526	DRUGINFO	D02XNH	C-linked disaccharide biphenyl mannoside derivative 6	Patented
T46526	DRUGINFO	D02ZYV	Biaryl mannoside derivative 15	Patented
T46526	DRUGINFO	D03CTH	Biphenyl mannoside derivative 10	Patented
T46526	DRUGINFO	D03HHG	PMID26651364-Compound-121	Patented
T46526	DRUGINFO	D03ITZ	Aryl mannoside derivative 4	Patented
T46526	DRUGINFO	D03JFJ	PMID26651364-Compound-108	Patented
T46526	DRUGINFO	D03KAV	Biphenyl mannoside derivative 12	Patented
T46526	DRUGINFO	D03RXE	Biphenyl mannoside derivative 3	Patented
T46526	DRUGINFO	D03WJB	Biphenyl mannoside derivative 25	Patented
T46526	DRUGINFO	D03WXM	C-linked disaccharide biphenyl mannoside derivative 4	Patented
T46526	DRUGINFO	D04NXG	PMID26651364-Compound-128	Patented
T46526	DRUGINFO	D04PKX	PMID26651364-Compound-125	Patented
T46526	DRUGINFO	D05AZE	Biphenyl mannoside derivative 30	Patented
T46526	DRUGINFO	D05BTL	PMID26651364-Compound-126c	Patented
T46526	DRUGINFO	D05BUD	Mannoside derivative 10	Patented
T46526	DRUGINFO	D05CBP	PMID26651364-Compound-9a	Patented
T46526	DRUGINFO	D05HKC	PMID26651364-Compound-123	Patented
T46526	DRUGINFO	D05JAS	Biphenyl mannoside derivative 5	Patented
T46526	DRUGINFO	D05OMO	PMID26651364-Compound-11b	Patented
T46526	DRUGINFO	D05WWX	Biphenyl mannoside derivative 14	Patented
T46526	DRUGINFO	D05XGH	PMID26651364-Compound-6e	Patented
T46526	DRUGINFO	D05ZHZ	PMID26651364-Compound-5e	Patented
T46526	DRUGINFO	D06PNN	Biaryl mannoside derivative 26	Patented
T46526	DRUGINFO	D06SWT	Aryl mannoside derivative 5	Patented
T46526	DRUGINFO	D07GAN	Biaryl mannoside derivative 12	Patented
T46526	DRUGINFO	D07HOP	Alkyl mannoside derivative 9	Patented
T46526	DRUGINFO	D07KCA	Aryl mannoside derivative 22	Patented
T46526	DRUGINFO	D07POS	Alkyl mannoside derivative 12	Patented
T46526	DRUGINFO	D07PVX	Aryl mannoside derivative 21	Patented
T46526	DRUGINFO	D07QAH	Biaryl mannoside derivative 17	Patented
T46526	DRUGINFO	D07RAA	PMID26651364-Compound-119	Patented
T46526	DRUGINFO	D07RQA	Alkyl mannoside derivative 8	Patented
T46526	DRUGINFO	D08BLZ	Aryl mannoside derivative 23	Patented
T46526	DRUGINFO	D08BNB	Biaryl mannoside derivative 5	Patented
T46526	DRUGINFO	D08OXD	Mannoside derivative 8	Patented
T46526	DRUGINFO	D08WZC	PMID26651364-Compound-48	Patented
T46526	DRUGINFO	D09BGB	Aryl mannoside derivative 1	Patented
T46526	DRUGINFO	D09EIQ	Biaryl mannoside derivative 18	Patented
T46526	DRUGINFO	D09EXQ	PMID26651364-Compound-8a	Patented
T46526	DRUGINFO	D09JDV	PMID26651364-Compound-5a	Patented
T46526	DRUGINFO	D09LWP	PMID26651364-Compound-105	Patented
T46526	DRUGINFO	D09LWZ	Mannoside derivative 7	Patented
T46526	DRUGINFO	D09SLI	Aryl mannoside derivative 13	Patented
T46526	DRUGINFO	D09TKY	Biaryl mannoside derivative 7	Patented
T46526	DRUGINFO	D09ZCA	Biphenyl mannoside derivative 24	Patented
T46526	DRUGINFO	D0A3PP	Biphenyl mannoside derivative 4	Patented
T46526	DRUGINFO	D0A8GW	PMID26651364-Compound-9e	Patented
T46526	DRUGINFO	D0A8RV	Biaryl mannoside derivative 4	Patented
T46526	DRUGINFO	D0AK2Y	PMID26651364-Compound-7b	Patented
T46526	DRUGINFO	D0AM0A	Aryl mannoside derivative 15	Patented
T46526	DRUGINFO	D0AY0H	PMID26651364-Compound-10c	Patented
T46526	DRUGINFO	D0B1HT	Biaryl mannoside derivative 20	Patented
T46526	DRUGINFO	D0B3CU	C-linked disaccharide biphenyl mannoside derivative 5	Patented
T46526	DRUGINFO	D0B8RU	Aryl mannoside derivative 14	Patented
T46526	DRUGINFO	D0B9LM	PMID26651364-Compound-8b	Patented
T46526	DRUGINFO	D0BR9C	Biphenyl mannoside derivative 2	Patented
T46526	DRUGINFO	D0BS3E	Biphenyl mannoside derivative 21	Patented
T46526	DRUGINFO	D0C8EB	PMID26651364-Compound-45	Patented
T46526	DRUGINFO	D0CD7Q	Beta-cyclodextrin conjugate derivative 4	Patented
T46526	DRUGINFO	D0CN6Q	PMID26651364-Compound-5c	Patented
T46526	DRUGINFO	D0CN7A	PMID26651364-Compound-7c	Patented
T46526	DRUGINFO	D0CR8J	Biphenyl mannoside derivative 26	Patented
T46526	DRUGINFO	D0D2QE	PMID26651364-Compound-117b	Patented
T46526	DRUGINFO	D0D6HS	Mannoside derivative 12	Patented
T46526	DRUGINFO	D0D6OM	Alkyl mannoside derivative 7	Patented
T46526	DRUGINFO	D0D9MV	Aryl mannoside derivative 17	Patented
T46526	DRUGINFO	D0DH0Y	Aryl mannoside derivative 12	Patented
T46526	DRUGINFO	D0DI1T	Biaryl mannoside derivative 16	Patented
T46526	DRUGINFO	D0DI6U	Alkyl mannoside derivative 10	Patented
T46526	DRUGINFO	D0DW7A	PMID26651364-Compound-6b	Patented
T46526	DRUGINFO	D0E1GC	PMID26651364-Compound-5g	Patented
T46526	DRUGINFO	D0E3DS	Alkyl mannoside derivative 11	Patented
T46526	DRUGINFO	D0E9GD	Biphenyl mannoside derivative 15	Patented
T46526	DRUGINFO	D0EA9Y	Biaryl mannoside derivative 14	Patented
T46526	DRUGINFO	D0ET9M	Biaryl mannoside derivative 30	Patented
T46526	DRUGINFO	D0F6TN	Mannoside derivative 6	Patented
T46526	DRUGINFO	D0FI3Q	Biaryl mannoside derivative 13	Patented
T46526	DRUGINFO	D0FL3H	PMID26651364-Compound-6a	Patented
T46526	DRUGINFO	D0FS9V	PMID26651364-Compound-120	Patented
T46526	DRUGINFO	D0FT4P	Aryl mannoside derivative 3	Patented
T46526	DRUGINFO	D0G9KS	Aryl mannoside derivative 2	Patented
T46526	DRUGINFO	D0GB6Y	PMID26651364-Compound-10a	Patented
T46526	DRUGINFO	D0GM6O	Biphenyl mannoside derivative 9	Patented
T46526	DRUGINFO	D0GP7L	PMID26651364-Compound-115	Patented
T46526	DRUGINFO	D0GR3C	Biphenyl mannoside derivative 22	Patented
T46526	DRUGINFO	D0GV9F	Biaryl mannoside derivative 2	Patented
T46526	DRUGINFO	D0H1BZ	Biaryl mannoside derivative 19	Patented
T46526	DRUGINFO	D0H4CL	C-linked disaccharide biphenyl mannoside derivative 1	Patented
T46526	DRUGINFO	D0H7UR	Mannoside derivative 11	Patented
T46526	DRUGINFO	D0HE3B	Biphenyl mannoside derivative 18	Patented
T46526	DRUGINFO	D0I2MR	PMID26651364-Compound-9f	Patented
T46526	DRUGINFO	D0IB8D	PMID26651364-Compound-117a	Patented
T46526	DRUGINFO	D0IF4J	PMID26651364-Compound-110	Patented
T46526	DRUGINFO	D0J0LC	PMID26651364-Compound-4	Patented
T46526	DRUGINFO	D0J8HJ	PMID26651364-Compound-127	Patented
T46526	DRUGINFO	D0K2AA	Biaryl mannoside derivative 11	Patented
T46526	DRUGINFO	D0K3DA	PMID26651364-Compound-112	Patented
T46526	DRUGINFO	D0K7TE	Biaryl mannoside derivative 27	Patented
T46526	DRUGINFO	D0KE8Q	PMID26651364-Compound-46	Patented
T46526	DRUGINFO	D0KG5U	PMID26651364-Compound-9b	Patented
T46526	DRUGINFO	D0KX1A	Aryl mannoside derivative 6	Patented
T46526	DRUGINFO	D0L1PO	Alkyl mannoside derivative 4	Patented
T46526	DRUGINFO	D0L2QZ	Biphenyl mannoside derivative 27	Patented
T46526	DRUGINFO	D0L3JL	Aryl mannoside derivative 8	Patented
T46526	DRUGINFO	D0L5OP	PMID26651364-Compound-6c	Patented
T46526	DRUGINFO	D0LZ1W	PMID26651364-Compound-122	Patented
T46526	DRUGINFO	D0M7XB	Beta-cyclodextrin conjugate derivative 1	Patented
T46526	DRUGINFO	D0MO0Z	Alkyl mannoside derivative 5	Patented
T46526	DRUGINFO	D0MZ8J	PMID26651364-Compound-10d	Patented
T46526	DRUGINFO	D0N2AI	Biphenyl mannoside derivative 19	Patented
T46526	DRUGINFO	D0N4TO	Biphenyl mannoside derivative 11	Patented
T46526	DRUGINFO	D0N4WW	PMID26651364-Compound-106	Patented
T46526	DRUGINFO	D0NB5P	Biphenyl mannoside derivative 8	Patented
T46526	DRUGINFO	D0O4TC	PMID26651364-Compound-10b	Patented
T46526	DRUGINFO	D0O8EX	PMID26651364-Compound-8c	Patented
T46526	DRUGINFO	D0OQ2R	Mannoside derivative 1	Patented
T46526	DRUGINFO	D0OW1V	Biaryl mannoside derivative 25	Patented
T46526	DRUGINFO	D0OW6O	PMID26651364-Compound-11c	Patented
T46526	DRUGINFO	D0P3SL	PMID26651364-Compound-8d	Patented
T46526	DRUGINFO	D0Q0XC	PMID26651364-Compound-9c	Patented
T46526	DRUGINFO	D0Q1SX	PMID26651364-Compound-7e	Patented
T46526	DRUGINFO	D0Q7QK	Mannoside derivative 13	Patented
T46526	DRUGINFO	D0QL0X	Biaryl mannoside derivative 23	Patented
T46526	DRUGINFO	D0QM2O	PMID26651364-Compound-5f	Patented
T46526	DRUGINFO	D0QQ5W	Beta-cyclodextrin conjugate derivative 2	Patented
T46526	DRUGINFO	D0QU6N	PMID26651364-Compound-47	Patented
T46526	DRUGINFO	D0R1GD	Aryl mannoside derivative 16	Patented
T46526	DRUGINFO	D0R1SQ	Biaryl mannoside derivative 1	Patented
T46526	DRUGINFO	D0R2GA	Biaryl mannoside derivative 29	Patented
T46526	DRUGINFO	D0R6FO	Aryl mannoside derivative 10	Patented
T46526	DRUGINFO	D0R7YN	Mannoside derivative 3	Patented
T46526	DRUGINFO	D0RE0F	Biphenyl mannoside derivative 13	Patented
T46526	DRUGINFO	D0RG1Z	Biaryl mannoside derivative 22	Patented
T46526	DRUGINFO	D0RZ5E	Biphenyl mannoside derivative 17	Patented
T46526	DRUGINFO	D0SD4Q	Aryl mannoside derivative 11	Patented
T46526	DRUGINFO	D0SE7V	Alkyl mannoside derivative 3	Patented
T46526	DRUGINFO	D0SR8I	PMID26651364-Compound-124	Patented
T46526	DRUGINFO	D0SU0E	Biphenyl mannoside derivative 1	Patented
T46526	DRUGINFO	D0T6NX	Biphenyl mannoside derivative 29	Patented
T46526	DRUGINFO	D0T7VN	Aryl mannoside derivative 20	Patented
T46526	DRUGINFO	D0TP8T	PMID26651364-Compound-113	Patented
T46526	DRUGINFO	D0TY1Q	Mannoside derivative 9	Patented
T46526	DRUGINFO	D0UB8U	Alkyl mannoside derivative 6	Patented
T46526	DRUGINFO	D0UE3F	Biphenyl mannoside derivative 28	Patented
T46526	DRUGINFO	D0UG9S	Biphenyl mannoside derivative 7	Patented
T46526	DRUGINFO	D0UK1S	PMID26651364-Compound-126a	Patented
T46526	DRUGINFO	D0US5I	C-linked disaccharide biphenyl mannoside derivative 2	Patented
T46526	DRUGINFO	D0UZ2S	PMID26651364-Compound-6d	Patented
T46526	DRUGINFO	D0VA1D	Alkyl mannoside derivative 1	Patented
T46526	DRUGINFO	D0VB4T	Aryl mannoside derivative 9	Patented
T46526	DRUGINFO	D0VF5B	PMID26651364-Compound-107	Patented
T46526	DRUGINFO	D0VG0F	Biphenyl mannoside derivative 23	Patented
T46526	DRUGINFO	D0W1SE	PMID26651364-Compound-5b	Patented
T46526	DRUGINFO	D0W7VE	Biphenyl mannoside derivative 20	Patented
T46526	DRUGINFO	D0WO2I	PMID26651364-Compound-111	Patented
T46526	DRUGINFO	D0WO6C	PMID26651364-Compound-49	Patented
T46526	DRUGINFO	D0WV9J	Beta-cyclodextrin conjugate derivative 5	Patented
T46526	DRUGINFO	D0WW9B	Aryl mannoside derivative 18	Patented
T46526	DRUGINFO	D0X4TV	PMID26651364-Compound-118	Patented
T46526	DRUGINFO	D0X7HN	PMID26651364-Compound-50	Patented
T46526	DRUGINFO	D0X8AB	Mannoside derivative 4	Patented
T46526	DRUGINFO	D0XH4K	C-linked disaccharide biphenyl mannoside derivative 3	Patented
T46526	DRUGINFO	D0XP5X	Mannoside derivative 5	Patented
T46526	DRUGINFO	D0XR1C	Biaryl mannoside derivative 28	Patented
T46526	DRUGINFO	D0Y0SI	Aryl mannoside derivative 7	Patented
T46526	DRUGINFO	D0Y3UB	PMID26651364-Compound-7d	Patented
T46526	DRUGINFO	D0YX4L	PMID26651364-Compound-126b	Patented
T46526	DRUGINFO	D0Z1YF	Biphenyl mannoside derivative 16	Patented
T46526	DRUGINFO	D0Z1ZA	Mannoside derivative 2	Patented
T46526	DRUGINFO	D0Z6PF	Alkyl mannoside derivative 2	Patented
T46526	DRUGINFO	D0ZD6N	Biaryl mannoside derivative 3	Patented
T46526	DRUGINFO	D0ZR2O	Biaryl mannoside derivative 6	Patented
T46526	DRUGINFO	DV19IS	mAb926	Preclinical

T22496	TARGETID	T22496
T22496	FORMERID	TTDI02645
T22496	UNIPROID	HD_HUMAN
T22496	TARGNAME	Huntingtin (HTT)
T22496	GENENAME	HTT
T22496	TARGTYPE	Clinical trial
T22496	SYNONYMS	IT15; Huntington disease protein; HD protein; HD
T22496	FUNCTION	May play a role in microtubule-mediated transport or vesicle function.
T22496	PDBSTRUC	6N8C; 6EZ8; 4RAV; 4FED; 4FEC
T22496	SEQUENCE	MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQPPPPPPPPPPPQLPQPPPQAQPLLPQPQPPPPPPPPPPGPAVAEEPLHRPKKELSATKKDRVNHCLTICENIVAQSVRNSPEFQKLLGIAMELFLLCSDDAESDVRMVADECLNKVIKALMDSNLPRLQLELYKEIKKNGAPRSLRAALWRFAELAHLVRPQKCRPYLVNLLPCLTRTSKRPEESVQETLAAAVPKIMASFGNFANDNEIKVLLKAFIANLKSSSPTIRRTAAGSAVSICQHSRRTQYFYSWLLNVLLGLLVPVEDEHSTLLILGVLLTLRYLVPLLQQQVKDTSLKGSFGVTRKEMEVSPSAEQLVQVYELTLHHTQHQDHNVVTGALELLQQLFRTPPPELLQTLTAVGGIGQLTAAKEESGGRSRSGSIVELIAGGGSSCSPVLSRKQKGKVLLGEEEALEDDSESRSDVSSSALTASVKDEISGELAASSGVSTPGSAGHDIITEQPRSQHTLQADSVDLASCDLTSSATDGDEEDILSHSSSQVSAVPSDPAMDLNDGTQASSPISDSSQTTTEGPDSAVTPSDSSEIVLDGTDNQYLGLQIGQPQDEDEEATGILPDEASEAFRNSSMALQQAHLLKNMSHCRQPSDSSVDKFVLRDEATEPGDQENKPCRIKGDIGQSTDDDSAPLVHCVRLLSASFLLTGGKNVLVPDRDVRVSVKALALSCVGAAVALHPESFFSKLYKVPLDTTEYPEEQYVSDILNYIDHGDPQVRGATAILCGTLICSILSRSRFHVGDWMGTIRTLTGNTFSLADCIPLLRKTLKDESSVTCKLACTAVRNCVMSLCSSSYSELGLQLIIDVLTLRNSSYWLVRTELLETLAEIDFRLVSFLEAKAENLHRGAHHYTGLLKLQERVLNNVVIHLLGDEDPRVRHVAAASLIRLVPKLFYKCDQGQADPVVAVARDQSSVYLKLLMHETQPPSHFSVSTITRIYRGYNLLPSITDVTMENNLSRVIAAVSHELITSTTRALTFGCCEALCLLSTAFPVCIWSLGWHCGVPPLSASDESRKSCTVGMATMILTLLSSAWFPLDLSAHQDALILAGNLLAASAPKSLRSSWASEEEANPAATKQEEVWPALGDRALVPMVEQLFSHLLKVINICAHVLDDVAPGPAIKAALPSLTNPPSLSPIRRKGKEKEPGEQASVPLSPKKGSEASAASRQSDTSGPVTTSKSSSLGSFYHLPSYLKLHDVLKATHANYKVTLDLQNSTEKFGGFLRSALDVLSQILELATLQDIGKCVEEILGYLKSCFSREPMMATVCVQQLLKTLFGTNLASQFDGLSSNPSKSQGRAQRLGSSSVRPGLYHYCFMAPYTHFTQALADASLRNMVQAEQENDTSGWFDVLQKVSTQLKTNLTSVTKNRADKNAIHNHIRLFEPLVIKALKQYTTTTCVQLQKQVLDLLAQLVQLRVNYCLLDSDQVFIGFVLKQFEYIEVGQFRESEAIIPNIFFFLVLLSYERYHSKQIIGIPKIIQLCDGIMASGRKAVTHAIPALQPIVHDLFVLRGTNKADAGKELETQKEVVVSMLLRLIQYHQVLEMFILVLQQCHKENEDKWKRLSRQIADIILPMLAKQQMHIDSHEALGVLNTLFEILAPSSLRPVDMLLRSMFVTPNTMASVSTVQLWISGILAILRVLISQSTEDIVLSRIQELSFSPYLISCTVINRLRDGDSTSTLEEHSEGKQIKNLPEETFSRFLLQLVGILLEDIVTKQLKVEMSEQQHTFYCQELGTLLMCLIHIFKSGMFRRITAAATRLFRSDGCGGSFYTLDSLNLRARSMITTHPALVLLWCQILLLVNHTDYRWWAEVQQTPKRHSLSSTKLLSPQMSGEEEDSDLAAKLGMCNREIVRRGALILFCDYVCQNLHDSEHLTWLIVNHIQDLISLSHEPPVQDFISAVHRNSAASGLFIQAIQSRCENLSTPTMLKKTLQCLEGIHLSQSGAVLTLYVDRLLCTPFRVLARMVDILACRRVEMLLAANLQSSMAQLPMEELNRIQEYLQSSGLAQRHQRLYSLLDRFRLSTMQDSLSPSPPVSSHPLDGDGHVSLETVSPDKDWYVHLVKSQCWTRSDSALLEGAELVNRIPAEDMNAFMMNSEFNLSLLAPCLSLGMSEISGGQKSALFEAAREVTLARVSGTVQQLPAVHHVFQPELPAEPAAYWSKLNDLFGDAALYQSLPTLARALAQYLVVVSKLPSHLHLPPEKEKDIVKFVVATLEALSWHLIHEQIPLSLDLQAGLDCCCLALQLPGLWSVVSSTEFVTHACSLIYCVHFILEAVAVQPGEQLLSPERRTNTPKAISEEEEEVDPNTQNPKYITAACEMVAEMVESLQSVLALGHKRNSGVPAFLTPLLRNIIISLARLPLVNSYTRVPPLVWKLGWSPKPGGDFGTAFPEIPVEFLQEKEVFKEFIYRINTLGWTSRTQFEETWATLLGVLVTQPLVMEQEESPPEEDTERTQINVLAVQAITSLVLSAMTVPVAGNPAVSCLEQQPRNKPLKALDTRFGRKLSIIRGIVEQEIQAMVSKRENIATHHLYQAWDPVPSLSPATTGALISHEKLLLQINPERELGSMSYKLGQVSIHSVWLGNSITPLREEEWDEEEEEEADAPAPSSPPTSPVNSRKHRAGVDIHSCSQFLLELYSRWILPSSSARRTPAILISEVVRSLLVVSDLFTERNQFELMYVTLTELRRVHPSEDEILAQYLVPATCKAAAVLGMDKAVAEPVSRLLESTLRSSHLPSRVGALHGVLYVLECDLLDDTAKQLIPVISDYLLSNLKGIAHCVNIHSQQHVLVMCATAFYLIENYPLDVGPEFSASIIQMCGVMLSGSEESTPSIIYHCALRGLERLLLSEQLSRLDAESLVKLSVDRVNVHSPHRAMAALGLMLTCMYTGKEKVSPGRTSDPNPAAPDSESVIVAMERVSVLFDRIRKGFPCEARVVARILPQFLDDFFPPQDIMNKVIGEFLSNQQPYPQFMATVVYKVFQTLHSTGQSSMVRDWVMLSLSNFTQRAPVAMATWSLSCFFVSASTSPWVAAILPHVISRMGKLEQVDVNLFCLVATDFYRHQIEEELDRRAFQSVLEVVAAPGSPYHRLLTCLRNVHKVTTC
T22496	DRUGINFO	DMOV12	Tominersen	Phase 3
T22496	DRUGINFO	D09ROP	AMT-130	Phase 1/2

T83198	TARGETID	T83198
T83198	UNIPROID	KEAP1_HUMAN
T83198	TARGNAME	Cysteines of Keap1 (KEAP1 Cysteines)
T83198	GENENAME	KEAP1
T83198	TARGTYPE	Clinical trial
T83198	SYNONYMS	Kelch-like protein 19-Cysteines; Kelch-like ECH-associated protein 1-Cysteines; KLHL19-Cysteines; KIAA0132-Cysteines; INrf2-Cysteines; Cytosolic inhibitor of Nrf2-Cysteines
T83198	FUNCTION	Retains NFE2L2/NRF2 and may also retain BPTF in the cytosol. Targets PGAM5 for ubiquitination and degradation by the proteasome. Acts as a substrate adapter protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1 and targets NFE2L2/NRF2 for ubiquitination and degradation by the proteasome, thus resulting in the suppression of its transcriptional activity and the repression of antioxidant response element-mediated detoxifying enzyme gene expression.
T83198	PDBSTRUC	6FMQ; 6FMP; 6FFM; 5X54; 5WIY
T83198	SEQUENCE	MQPDPRPSGAGACCRFLPLQSQCPEGAGDAVMYASTECKAEVTPSQHGNRTFSYTLEDHTKQAFGIMNELRLSQQLCDVTLQVKYQDAPAAQFMAHKVVLASSSPVFKAMFTNGLREQGMEVVSIEGIHPKVMERLIEFAYTASISMGEKCVLHVMNGAVMYQIDSVVRACSDFLVQQLDPSNAIGIANFAEQIGCVELHQRAREYIYMHFGEVAKQEEFFNLSHCQLVTLISRDDLNVRCESEVFHACINWVKYDCEQRRFYVQALLRAVRCHSLTPNFLQMQLQKCEILQSDSRCKDYLVKIFEELTLHKPTQVMPCRAPKVGRLIYTAGGYFRQSLSYLEAYNPSDGTWLRLADLQVPRSGLAGCVVGGLLYAVGGRNNSPDGNTDSSALDCYNPMTNQWSPCAPMSVPRNRIGVGVIDGHIYAVGGSHGCIHHNSVERYEPERDEWHLVAPMLTRRIGVGVAVLNRLLYAVGGFDGTNRLNSAECYYPERNEWRMITAMNTIRSGAGVCVLHNCIYAAGGYDGQDQLNSVERYDVETETWTFVAPMKHRRSALGITVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRMTSGRSGVGVAVTMEPCRKQIDQQNCTC
T83198	DRUGINFO	DF1JO7	CXA10	Phase 2
T83198	DRUGINFO	D01GTU	PMID28454500-Compound-8	Patented
T83198	DRUGINFO	D01MZI	Pyrazino[2,1-a]isoquinolin derivative 4	Patented
T83198	DRUGINFO	D01PKZ	PMID28454500-Compound-36	Patented
T83198	DRUGINFO	D02SPI	Chalcone derivative 4	Patented
T83198	DRUGINFO	D02YNU	2-hydroxybenzamide derivative 1	Patented
T83198	DRUGINFO	D04ILM	Vinyl sulfone derivative 1	Patented
T83198	DRUGINFO	D06LEF	Pyrazino[2,1-a]isoquinolin derivative 2	Patented
T83198	DRUGINFO	D09FZF	Diterpenoid derivative 1	Patented
T83198	DRUGINFO	D0AJ2T	PMID28454500-Compound-13	Patented
T83198	DRUGINFO	D0AX4Q	PMID28454500-Compound-12	Patented
T83198	DRUGINFO	D0AZ8T	Pyrazino[2,1-a]isoquinolin derivative 1	Patented
T83198	DRUGINFO	D0C1PB	PMID28454500-Compound-41	Patented
T83198	DRUGINFO	D0EO3S	Chalcone derivative 2	Patented
T83198	DRUGINFO	D0FH6P	PMID28454500-Compound-34	Patented
T83198	DRUGINFO	D0FM3Q	PMID28454500-Compound-33	Patented
T83198	DRUGINFO	D0G1LS	Chalcone derivative 3	Patented
T83198	DRUGINFO	D0G4EK	PMID28454500-Compound-50	Patented
T83198	DRUGINFO	D0JH8Z	PMID28454500-Compound-3	Patented
T83198	DRUGINFO	D0KX0J	Pyridyl compound 1	Patented
T83198	DRUGINFO	D0L1JQ	PMID28454500-Compound-32	Patented
T83198	DRUGINFO	D0MQ3X	PMID28454500-Compound-40	Patented
T83198	DRUGINFO	D0MX0Q	PMID28454500-Compound-35	Patented
T83198	DRUGINFO	D0N1VC	PMID28454500-Compound-49	Patented
T83198	DRUGINFO	D0N9GH	PMID28454500-Compound-9	Patented
T83198	DRUGINFO	D0Q9QQ	Diterpenoid derivative 2	Patented
T83198	DRUGINFO	D0RM4V	PMID28454500-Compound-11	Patented
T83198	DRUGINFO	D0SA1N	PMID28454500-Compound-37	Patented
T83198	DRUGINFO	D0U9TR	Chalcone derivative 1	Patented
T83198	DRUGINFO	D0VA2G	Pyrazino[2,1-a]isoquinolin derivative 3	Patented
T83198	DRUGINFO	D0VW9H	2-hydroxybenzamide derivative 2	Patented
T83198	DRUGINFO	D0WN1Y	PMID28454500-Compound-10	Patented
T83198	DRUGINFO	D0XL2V	Trepenoid derivative 1	Patented
T83198	DRUGINFO	D46EBX	VCB101	Preclinical
T83198	DRUGINFO	DG07UD	VCB102	Preclinical

T68001	TARGETID	T68001
T68001	UNIPROID	BTLA_HUMAN
T68001	TARGNAME	B- and T-lymphocyte attenuator (BTLA)
T68001	GENENAME	BTLA
T68001	TARGTYPE	Clinical trial
T68001	SYNONYMS	CD272; B- and T-lymphocyte-associated protein
T68001	FUNCTION	May interact in cis (on the same cell) or in trans (on other cells) with TNFRSF14. In cis interactions, appears to play an immune regulatory role inhibiting in trans interactions in naive T cells to maintain a resting state. In trans interactions, can predominate during adaptive immune response to provide survival signals to effector T cells. Inhibitory receptor on lymphocytes that negatively regulates antigen receptor signaling via PTPN6/SHP-1 and PTPN11/SHP-2.
T68001	PDBSTRUC	2AW2
T68001	SEQUENCE	MKTLPAMLGTGKLFWVFFLIPYLDIWNIHGKESCDVQLYIKRQSEHSILAGDPFELECPVKYCANRPHVTWCKLNGTTCVKLEDRQTSWKEEKNISFFILHFEPVLPNDNGSYRCSANFQSNLIESHSTTLYVTDVKSASERPSKDEMASRPWLLYRLLPLGGLPLLITTCFCLFCCLRRHQGKQNELSDTAGREINLVDAHLKSEQTEASTRQNSQVLLSETGIYDNDPDLCFRMQEGSEVYSNPCLEENKPGIVYASLNHSVIGPNSRLARNVKEAPTEYASICVRS
T68001	DRUGINFO	D1O4MP	LY3361237	Phase 2
T68001	DRUGINFO	D0GMN2	JS004	Phase 1

T10513	TARGETID	T10513
T10513	FORMERID	TTDR01170
T10513	UNIPROID	ITB2_HUMAN
T10513	TARGNAME	Integrin beta-2 (ITGB2)
T10513	GENENAME	ITGB2
T10513	TARGTYPE	Clinical trial
T10513	SYNONYMS	MFI7; Integrin alpha-M/beta-2; Complement receptor C3 subunit beta; Cell surface adhesion glycoproteins LFA-1/CR3/p150,95 subunit beta; CD18
T10513	FUNCTION	Integrin ITGAL/ITGB2 is also a receptor for the secreted form of ubiquitin-like protein ISG15; the interaction is mediated by ITGAL. Integrins ITGAM/ITGB2 and ITGAX/ITGB2 are receptors for the iC3b fragment of the third complement component and for fibrinogen. Integrin ITGAX/ITGB2 recognizes the sequence G-P-R in fibrinogen alpha-chain. Integrin ITGAM/ITGB2 recognizes P1 and P2 peptides of fibrinogen gamma chain. Integrin ITGAM/ITGB2 is also a receptor for factor X. Integrin ITGAD/ITGB2 is a receptor for ICAM3 and VCAM1. Contributes to natural killer cell cytotoxicity. Involved in leukocyte adhesion and transmigration of leukocytes including T-cells and neutrophils. Triggers neutrophil transmigration during lung injury through PTK2B/PYK2-mediated activation. Integrin ITGAL/ITGB2 in association with ICAM3, contributes to apoptotic neutrophil phagocytosis by macrophages. In association with alpha subunit ITGAM/CD11b, required for CD177-PRTN3-mediated activation of TNF primed neutrophils. Integrin ITGAL/ITGB2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4.
T10513	PDBSTRUC	5ZAZ; 5XR1; 5ES4; 5E6X; 5E6W
T10513	BIOCLASS	Integrin
T10513	SEQUENCE	MLGLRPPLLALVGLLSLGCVLSQECTKFKVSSCRECIESGPGCTWCQKLNFTGPGDPDSIRCDTRPQLLMRGCAADDIMDPTSLAETQEDHNGGQKQLSPQKVTLYLRPGQAAAFNVTFRRAKGYPIDLYYLMDLSYSMLDDLRNVKKLGGDLLRALNEITESGRIGFGSFVDKTVLPFVNTHPDKLRNPCPNKEKECQPPFAFRHVLKLTNNSNQFQTEVGKQLISGNLDAPEGGLDAMMQVAACPEEIGWRNVTRLLVFATDDGFHFAGDGKLGAILTPNDGRCHLEDNLYKRSNEFDYPSVGQLAHKLAENNIQPIFAVTSRMVKTYEKLTEIIPKSAVGELSEDSSNVVQLIKNAYNKLSSRVFLDHNALPDTLKVTYDSFCSNGVTHRNQPRGDCDGVQINVPITFQVKVTATECIQEQSFVIRALGFTDIVTVQVLPQCECRCRDQSRDRSLCHGKGFLECGICRCDTGYIGKNCECQTQGRSSQELEGSCRKDNNSIICSGLGDCVCGQCLCHTSDVPGKLIYGQYCECDTINCERYNGQVCGGPGRGLCFCGKCRCHPGFEGSACQCERTTEGCLNPRRVECSGRGRCRCNVCECHSGYQLPLCQECPGCPSPCGKYISCAECLKFEKGPFGKNCSAACPGLQLSNNPVKGRTCKERDSEGCWVAYTLEQQDGMDRYLIYVDESRECVAGPNIAAIVGGTVAGIVLIGILLLVIWKALIHLSDLREYRRFEKEKLKSQWNNDNPLFKSATTTVMNPKFAES
T10513	DRUGINFO	DQ0I4N	RP-L201	Phase 1/2
T10513	DRUGINFO	D04ZWH	UK-279,276	Discontinued in Phase 2
T10513	DRUGINFO	D0GT8W	BMS-587101	Discontinued in Phase 2
T10513	DRUGINFO	D07NYF	MLN-2201	Discontinued in Phase 1
T10513	DRUGINFO	D07XCA	A-286982	Investigative

T93062	TARGETID	T93062
T93062	FORMERID	TTDC00030
T93062	UNIPROID	MDR3_HUMAN
T93062	TARGNAME	Multidrug resistance protein 3 (ABCB4)
T93062	GENENAME	ABCB4
T93062	TARGTYPE	Clinical trial
T93062	SYNONYMS	PGY3; MDR3; ATP-binding cassette sub-family B member 4; ABCB4
T93062	FUNCTION	Mediates ATP-dependent export of organic anions and drugs from the cytoplasm. Hydrolyzes ATP with low efficiency. Not capable of conferring drug resistance. Mediates the translocation of phosphatidylcholine across the canalicular membrane of the hepatocyte.
T93062	BIOCLASS	Acid anhydrides hydrolase
T93062	ECNUMBER	EC 7.6.2.1
T93062	SEQUENCE	MDLEAAKNGTAWRPTSAEGDFELGISSKQKRKKTKTVKMIGVLTLFRYSDWQDKLFMSLGTIMAIAHGSGLPLMMIVFGEMTDKFVDTAGNFSFPVNFSLSLLNPGKILEEEMTRYAYYYSGLGAGVLVAAYIQVSFWTLAAGRQIRKIRQKFFHAILRQEIGWFDINDTTELNTRLTDDISKISEGIGDKVGMFFQAVATFFAGFIVGFIRGWKLTLVIMAISPILGLSAAVWAKILSAFSDKELAAYAKAGAVAEEALGAIRTVIAFGGQNKELERYQKHLENAKEIGIKKAISANISMGIAFLLIYASYALAFWYGSTLVISKEYTIGNAMTVFFSILIGAFSVGQAAPCIDAFANARGAAYVIFDIIDNNPKIDSFSERGHKPDSIKGNLEFNDVHFSYPSRANVKILKGLNLKVQSGQTVALVGSSGCGKSTTVQLIQRLYDPDEGTINIDGQDIRNFNVNYLREIIGVVSQEPVLFSTTIAENICYGRGNVTMDEIKKAVKEANAYEFIMKLPQKFDTLVGERGAQLSGGQKQRIAIARALVRNPKILLLDEATSALDTESEAEVQAALDKAREGRTTIVIAHRLSTVRNADVIAGFEDGVIVEQGSHSELMKKEGVYFKLVNMQTSGSQIQSEEFELNDEKAATRMAPNGWKSRLFRHSTQKNLKNSQMCQKSLDVETDGLEANVPPVSFLKVLKLNKTEWPYFVVGTVCAIANGGLQPAFSVIFSEIIAIFGPGDDAVKQQKCNIFSLIFLFLGIISFFTFFLQGFTFGKAGEILTRRLRSMAFKAMLRQDMSWFDDHKNSTGALSTRLATDAAQVQGATGTRLALIAQNIANLGTGIIISFIYGWQLTLLLLAVVPIIAVSGIVEMKLLAGNAKRDKKELEAAGKIATEAIENIRTVVSLTQERKFESMYVEKLYGPYRNSVQKAHIYGITFSISQAFMYFSYAGCFRFGAYLIVNGHMRFRDVILVFSAIVFGAVALGHASSFAPDYAKAKLSAAHLFMLFERQPLIDSYSEEGLKPDKFEGNITFNEVVFNYPTRANVPVLQGLSLEVKKGQTLALVGSSGCGKSTVVQLLERFYDPLAGTVFVDFGFQLLDGQEAKKLNVQWLRAQLGIVSQEPILFDCSIAENIAYGDNSRVVSQDEIVSAAKAANIHPFIETLPHKYETRVGDKGTQLSGGQKQRIAIARALIRQPQILLLDEATSALDTESEKVVQEALDKAREGRTCIVIAHRLSTIQNADLIVVFQNGRVKEHGTHQQLLAQKGIYFSMVSVQAGTQNL
T93062	DRUGINFO	D9UGX7	Encequidar	Phase 2
T93062	DRUGINFO	D0H0EM	Dofequidar fumarate	Discontinued in Phase 3
T93062	DRUGINFO	D06DCL	LY335979	Discontinued in Phase 3
T93062	DRUGINFO	D0A5MI	LANIQUIDAR	Discontinued in Phase 2
T93062	DRUGINFO	D0B1MJ	Dexniguldipine	Discontinued in Phase 2

T20575	TARGETID	T20575
T20575	FORMERID	TTDR00763
T20575	UNIPROID	CCR8_HUMAN
T20575	TARGNAME	C-C chemokine receptor type 8 (CCR8)
T20575	GENENAME	CCR8
T20575	TARGTYPE	Clinical trial
T20575	SYNONYMS	TER1; GPRCY6; GPR-CY6; Chemokine receptor-like 1; Chemokine receptor CCR8; CMKBRL2; CMKBR8; CKRL1; CKR-L1; CDw198; CCR-8; CC-chemokine receptor CHEMR1; CC-CKR-8; CC chemokine receptor CHEMR1; C-C CKR-8
T20575	FUNCTION	May regulate monocyte chemotaxis and thymic cell line apoptosis. Alternative coreceptor with CD4 for HIV-1 infection. Receptor for the chemokine CCL1/SCYA1/I-309.
T20575	BIOCLASS	GPCR rhodopsin
T20575	SEQUENCE	MDYTLDLSVTTVTDYYYPDIFSSPCDAELIQTNGKLLLAVFYCLLFVFSLLGNSLVILVLVVCKKLRSITDVYLLNLALSDLLFVFSFPFQTYYLLDQWVFGTVMCKVVSGFYYIGFYSSMFFITLMSVDRYLAVVHAVYALKVRTIRMGTTLCLAVWLTAIMATIPLLVFYQVASEDGVLQCYSFYNQQTLKWKIFTNFKMNILGLLIPFTIFMFCYIKILHQLKRCQNHNKTKAIRLVLIVVIASLLFWVPFNVVLFLTSLHSMHILDGCSISQQLTYATHVTEIISFTHCCVNPVIYAFVGEKFKKHLSEIFQKSCSQIFNYLGRQMPRESCEKSSSCQQHSSRSSSVDYIL
T20575	DRUGINFO	DRAL63	GS-1811	Phase 1
T20575	DRUGINFO	D04HZX	CCX-832	Discontinued in Phase 1
T20575	DRUGINFO	D03DTZ	ZK 756326	Investigative
T20575	DRUGINFO	D0K5QW	I-309	Investigative
T20575	DRUGINFO	D0K8BZ	N-(4-phenylsulfamoyl-naphthalen-1-yl)-benzamide	Investigative
T20575	DRUGINFO	D0M1AE	N-{4-[(benzylamino)sulfonyl]-1-naphthyl}benzamide	Investigative
T20575	DRUGINFO	D09PZD	viral macrophage inflammatory protein-II	Investigative

T63803	TARGETID	T63803
T63803	FORMERID	TTDR01251
T63803	UNIPROID	VEGFD_HUMAN
T63803	TARGNAME	Vascular endothelial growth factor D (VEGFD)
T63803	GENENAME	VEGFD
T63803	TARGTYPE	Clinical trial
T63803	SYNONYMS	c-Fos-induced growth factor; VEGFD; VEGF-D; FIGF
T63803	FUNCTION	Growth factor active in angiogenesis, lymphangiogenesis and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in the formationof the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates VEGFR-2 (KDR/FLK1) and VEGFR-3 (FLT4) receptors.
T63803	PDBSTRUC	2XV7
T63803	BIOCLASS	Growth factor
T63803	SEQUENCE	MYREWVVVNVFMMLYVQLVQGSSNEHGPVKRSSQSTLERSEQQIRAASSLEELLRITHSEDWKLWRCRLRLKSFTSMDSRSASHRSTRFAATFYDIETLKVIDEEWQRTQCSPRETCVEVASELGKSTNTFFKPPCVNVFRCGGCCNEESLICMNTSTSYISKQLFEISVPLTSVPELVPVKVANHTGCKCLPTAPRHPYSIIRRSIQIPEEDRCSHSKKLCPIDMLWDSNKCKCVLQEENPLAGTEDHSHLQEPALCGPHMMFDEDRCECVCKTPCPKDLIQHPKNCSCFECKESLETCCQKHKLFHPDTCSCEDRCPFHTRPCASGKTACAKHCRFPKEKRAAQGPHSRKNP
T63803	DRUGINFO	DNA7I1	OPT-302	Phase 2
T63803	DRUGINFO	D01RLU	EG-016	Discontinued in Phase 1/2
T63803	DRUGINFO	D0H3HB	EG-011	Discontinued in Phase 1/2

T49630	TARGETID	T49630
T49630	FORMERID	TTDR00861
T49630	UNIPROID	OLR1_HUMAN
T49630	TARGNAME	Lectin-like oxidized LDL receptor (OLR1)
T49630	GENENAME	OLR1
T49630	TARGTYPE	Clinical trial
T49630	SYNONYMS	hLOX-1; Oxidized low-density lipoprotein receptor 1; Oxidized low-density lipoprotein receptor; Oxidised low density lipoprotein (Lectin-like) receptor 1; Ox-LDL receptor 1; Lectin-type oxidized LDL receptor 1; Lectin-type oxidized LDL receptor; Lectin-like oxidized low-density lipoprotein receptor-1; Lectin-like oxidized LDL receptor-1; Lectin-like oxidized LDL receptor 1; Lectin-like oxLDL receptor 1; LOX1; LOX-1; CLEC8A; C-type lectin domain family 8 member A
T49630	FUNCTION	OxLDL is a marker of atherosclerosis that induces vascular endothelial cell activation and dysfunction, resulting in pro-inflammatory responses, pro-oxidative conditions and apoptosis. Its association with oxLDL induces the activation of NF-kappa-B through an increased production of intracellular reactive oxygen and a variety of pro-atherogenic cellular responses including a reduction of nitric oxide (NO) release, monocyte adhesion and apoptosis. In addition to binding oxLDL, it acts as a receptor for the HSP70 protein involved in antigen cross-presentation to naive T-cells in dendritic cells, thereby participating in cell-mediated antigen cross-presentation. Also involved in inflammatory process, by acting as a leukocyte-adhesion molecule at the vascular interface in endotoxin-induced inflammation. Also acts as a receptor for advanced glycation end (AGE) products, activated platelets, monocytes, apoptotic cells and both Gram-negative and Gram-positive bacteria. Receptor that mediates the recognition, internalization and degradation of oxidatively modified low density lipoprotein (oxLDL) by vascular endothelial cells.
T49630	PDBSTRUC	3VLG; 1YXK; 1YXJ; 1YPU; 1YPQ
T49630	SEQUENCE	MTFDDLKIQTVKDQPDEKSNGKKAKGLQFLYSPWWCLAAATLGVLCLGLVVTIMVLGMQLSQVSDLLTQEQANLTHQKKKLEGQISARQQAEEASQESENELKEMIETLARKLNEKSKEQMELHHQNLNLQETLKRVANCSAPCPQDWIWHGENCYLFSSGSFNWEKSQEKCLSLDAKLLKINSTADLDFIQQAISYSSFPFWMGLSRRNPSYPWLWEDGSPLMPHLFRVRGAVSQTYPSGTCAYIQRGAVYAENCILAAFSICQKKANLRAQ
T49630	DRUGINFO	DFG87U	MEDI6570	Phase 2
T49630	DRUGINFO	D0MH1R	RG7418	Discontinued in Phase 1

T30834	TARGETID	T30834
T30834	FORMERID	TTDI01947
T30834	UNIPROID	CALCR_HUMAN-RAMP1_HUMAN/RAMP2_HUMAN/RAMP3_HUMAN
T30834	TARGNAME	Amylin receptor (IAPPR)
T30834	GENENAME	CALCR-RAMP1/RAMP2/RAMP3
T30834	TARGTYPE	Clinical trial
T30834	SYNONYMS	Complex of Calcitonin receptor and Receptor activity-modifying protein
T30834	FUNCTION	Transports the calcitonin gene-related peptide type 1 receptor (CALCRL) to the plasma membrane. Acts as a receptor for calcitonin-gene-related peptide (CGRP) together with CALCRL.
T30834	SEQUENCE	MRFTFTSRCLALFLLLNHPTPILPAFSNQTYPTIEPKPFLYVVGRKKMMDAQYKCYDRMQQLPAYQGEGPYCNRTWDGWLCWDDTPAGVLSYQFCPDYFPDFDPSEKVTKYCDEKGVWFKHPENNRTWSNYTMCNAFTPEKLKNAYVLYYLAIVGHSLSIFTLVISLGIFVFFRSLGCQRVTLHKNMFLTYILNSMIIIIHLVEVVPNGELVRRDPVSCKILHFFHQYMMACNYFWMLCEGIYLHTLIVVAVFTEKQRLRWYYLLGWGFPLVPTTIHAITRAVYFNDNCWLSVETHLLYIIHGPVMAALVVNFFFLLNIVRVLVTKMRETHEAESHMYLKAVKATMILVPLLGIQFVVFPWRPSNKMLGKIYDYVMHSLIHFQGFFVATIYCFCNNEVQTTVKRQWAQFKIQWNQRWGRRPSNRSARAAAAAAEAGDIPIYICHQEPRNEPANNQGEESAEIIPLNIIEQESSAMARALCRLPRRGLWLLLAHHLFMTTACQEANYGALLRELCLTQFQVDMEAVGETLWCDWGRTIRSYRELADCTWHMAEKLGCFWPNAEVDRFFLAVHGRYFRSCPISGRAVRDPPGSILYPFIVVPITVTLLVTALVVWQSKRTEGIV
T30834	DRUGINFO	DW3J9N	DACRA 089	Phase 1
T30834	DRUGINFO	D0H4TC	Davalintide	Discontinued in Phase 2
T30834	DRUGINFO	D00RXR	AC-253	Discontinued in Phase 1
T30834	DRUGINFO	D0Q9NJ	AC-625	Discontinued in Phase 1
T30834	DRUGINFO	D00PZH	AC-187	Terminated

T00523	TARGETID	T00523
T00523	FORMERID	TTDI01558
T00523	UNIPROID	GTR9_HUMAN
T00523	TARGNAME	Glucose transporter type 9 (GLUT9)
T00523	GENENAME	SLC2A9
T00523	TARGTYPE	Clinical trial
T00523	SYNONYMS	Urate transporter; Solute carrier family 2, facilitated glucose transporter member 9; GLUT9; GLUT-9
T00523	FUNCTION	Urate transporter, which may play a role in the urate reabsorption by proximal tubules. Does not transport glucose, fructose or galactose.
T00523	SEQUENCE	MARKQNRNSKELGLVPLTDDTSHAGPPGPGRALLECDHLRSGVPGGRRRKDWSCSLLVASLAGAFGSSFLYGYNLSVVNAPTPYIKAFYNESWERRHGRPIDPDTLTLLWSVTVSIFAIGGLVGTLIVKMIGKVLGRKHTLLANNGFAISAALLMACSLQAGAFEMLIVGRFIMGIDGGVALSVLPMYLSEISPKEIRGSLGQVTAIFICIGVFTGQLLGLPELLGKESTWPYLFGVIVVPAVVQLLSLPFLPDSPRYLLLEKHNEARAVKAFQTFLGKADVSQEVEEVLAESRVQRSIRLVSVLELLRAPYVRWQVVTVIVTMACYQLCGLNAIWFYTNSIFGKAGIPPAKIPYVTLSTGGIETLAAVFSGLVIEHLGRRPLLIGGFGLMGLFFGTLTITLTLQDHAPWVPYLSIVGILAIIASFCSGPGGIPFILTGEFFQQSQRPAAFIIAGTVNWLSNFAVGLLFPFIQKSLDTYCFLVFATICITGAIYLYFVLPETKNRTYAEISQAFSKRNKAYPPEEKIDSAVTDGKINGRP
T00523	DRUGINFO	D89BQK	SAP-001	Phase 2
T00523	DRUGINFO	D05RZI	AA-193	Discontinued in Phase 2

T51843	TARGETID	T51843
T51843	FORMERID	TTDC00001
T51843	UNIPROID	POLG_HCVJA
T51843	TARGNAME	Virus RNA-dependent RNA polymerase (Viru RdRP)
T51843	GENENAME	Viru RdRP
T51843	TARGTYPE	Clinical trial
T51843	SYNONYMS	HCV NS5B; HCV p68
T51843	FUNCTION	Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity).
T51843	PDBSTRUC	4KTC; 4JMY; 4I33; 4I32; 4I31
T51843	BIOCLASS	Kinase
T51843	ECNUMBER	EC 2.7.7.48
T51843	SEQUENCE	SMSYTWTGALITPCAAEESKLPINPLSNSLLRHHSMVYSTTSRSASLRQKKVTFDRLQVLDDHYRDVLKEMKAKASTVKARLLSIEEACKLTPPHSAKSKFGYGAKDVRSLSSRAVNHIRSVWEDLLEDTETPIDTTIMAKNEVFCVQPEKGGRKPARLIVFPDLGVRVCEKMALYDVVSTLPQAVMGPSYGFQYSPGQRVEFLVNTWKSKKCPMGFSYDTRCFDSTVTENDIRTEESIYQCCDLAPEARQAIRSLTERLYVGGPLTNSKGQNCGYRRCRASGVLTTSCGNTLTCYLKATAACRAAKLQDCTMLVNGDDLVVICESAGTQEDAAALRAFTEAMTRYSAPPGDPPQPEYDLELITSCSSNVSVAHDASGKRVYYLTRDPTTPLARAAWETVRHTPVNSWLGNIIMYAPTLWARMILMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPQIIERLHGLSAFSLHSYSPGEINRVASCLRKLGVPPLRVWRHRARSVRAKLLSQGGRAATCGKYLFNWAVKTKLKLTPIPAASQLDLSGWFVAGYNGGDIYHSLSRARPRWFMLCLLLLSVGVGIYLLPNR
T51843	DRUGINFO	D5AV3Q	AT-527	Phase 2
T51843	DRUGINFO	D05TSP	Thiadiazolo[2,3-a]pyrimidine	Investigative
T51843	DRUGINFO	D09VHW	T-1105	Investigative
T51843	DRUGINFO	D0B0PW	Pyrimidinyl acylthiourea	Investigative
T51843	DRUGINFO	D0C0WE	FdG	Investigative
T51843	DRUGINFO	D0ZU6O	T-1106	Investigative
T51843	DRUGINFO	D0EQ4T	Guanosine-5'-Triphosphate	Investigative
T51843	DRUGINFO	D0A1DU	Pyrophosphate 2-	Investigative

T49755	TARGETID	T49755
T49755	FORMERID	TTDNR00702
T49755	UNIPROID	LRP6_HUMAN
T49755	TARGNAME	LDL receptor related protein-6 (LRP-6)
T49755	GENENAME	LRP6
T49755	TARGTYPE	Clinical trial
T49755	SYNONYMS	Low-density lipoprotein receptor-related protein 6
T49755	FUNCTION	Cell-surface coreceptor of Wnt/beta-catenin signaling, which plays a pivotal role in bone formation. The Wnt-induced Fzd/LRP6 coreceptor complex recruits DVL1 polymers to the plasma membrane which, in turn, recruits the AXIN1/GSK3B-complex to the cell surface promoting the formation of signalsomes and inhibiting AXIN1/GSK3-mediated phosphorylation and destruction of beta-catenin. Required for posterior patterning of the epiblast during gastrulation. Component of the Wnt-Fzd-LRP5-LRP6 complex that triggers beta-catenin signaling through inducing aggregation of receptor-ligand complexes into ribosome-sized signalsomes.
T49755	PDBSTRUC	6H16; 6H15; 5GJE; 5FWW; 5AIR
T49755	BIOCLASS	Low density lipoprotein receptor
T49755	SEQUENCE	MGAVLRSLLACSFCVLLRAAPLLLYANRRDLRLVDATNGKENATIVVGGLEDAAAVDFVFSHGLIYWSDVSEEAIKRTEFNKTESVQNVVVSGLLSPDGLACDWLGEKLYWTDSETNRIEVSNLDGSLRKVLFWQELDQPRAIALDPSSGFMYWTDWGEVPKIERAGMDGSSRFIIINSEIYWPNGLTLDYEEQKLYWADAKLNFIHKSNLDGTNRQAVVKGSLPHPFALTLFEDILYWTDWSTHSILACNKYTGEGLREIHSDIFSPMDIHAFSQQRQPNATNPCGIDNGGCSHLCLMSPVKPFYQCACPTGVKLLENGKTCKDGATELLLLARRTDLRRISLDTPDFTDIVLQLEDIRHAIAIDYDPVEGYIYWTDDEVRAIRRSFIDGSGSQFVVTAQIAHPDGIAVDWVARNLYWTDTGTDRIEVTRLNGTMRKILISEDLEEPRAIVLDPMVGYMYWTDWGEIPKIERAALDGSDRVVLVNTSLGWPNGLALDYDEGKIYWGDAKTDKIEVMNTDGTGRRVLVEDKIPHIFGFTLLGDYVYWTDWQRRSIERVHKRSAEREVIIDQLPDLMGLKATNVHRVIGSNPCAEENGGCSHLCLYRPQGLRCACPIGFELISDMKTCIVPEAFLLFSRRADIRRISLETNNNNVAIPLTGVKEASALDFDVTDNRIYWTDISLKTISRAFMNGSALEHVVEFGLDYPEGMAVDWLGKNLYWADTGTNRIEVSKLDGQHRQVLVWKDLDSPRALALDPAEGFMYWTEWGGKPKIDRAAMDGSERTTLVPNVGRANGLTIDYAKRRLYWTDLDTNLIESSNMLGLNREVIADDLPHPFGLTQYQDYIYWTDWSRRSIERANKTSGQNRTIIQGHLDYVMDILVFHSSRQSGWNECASSNGHCSHLCLAVPVGGFVCGCPAHYSLNADNRTCSAPTTFLLFSQKSAINRMVIDEQQSPDIILPIHSLRNVRAIDYDPLDKQLYWIDSRQNMIRKAQEDGSQGFTVVVSSVPSQNLEIQPYDLSIDIYSRYIYWTCEATNVINVTRLDGRSVGVVLKGEQDRPRAVVVNPEKGYMYFTNLQERSPKIERAALDGTEREVLFFSGLSKPIALALDSRLGKLFWADSDLRRIESSDLSGANRIVLEDSNILQPVGLTVFENWLYWIDKQQQMIEKIDMTGREGRTKVQARIAQLSDIHAVKELNLQEYRQHPCAQDNGGCSHICLVKGDGTTRCSCPMHLVLLQDELSCGEPPTCSPQQFTCFTGEIDCIPVAWRCDGFTECEDHSDELNCPVCSESQFQCASGQCIDGALRCNGDANCQDKSDEKNCEVLCLIDQFRCANGQCIGKHKKCDHNVDCSDKSDELDCYPTEEPAPQATNTVGSVIGVIVTIFVSGTVYFICQRMLCPRMKGDGETMTNDYVVHGPASVPLGYVPHPSSLSGSLPGMSRGKSMISSLSIMGGSSGPPYDRAHVTGASSSSSSSTKGTYFPAILNPPPSPATERSHYTMEFGYSSNSPSTHRSYSYRPYSYRHFAPPTTPCSTDVCDSDYAPSRRMTSVATAKGYTSDLNYDSEPVPPPPTPRSQYLSAEENYESCPPSPYTERSYSHHLYPPPPSPCTDSS
T49755	DRUGINFO	DTB43H	BI 905677	Phase 1

T11453	TARGETID	T11453
T11453	FORMERID	TTDR00432
T11453	UNIPROID	GIP_HUMAN
T11453	TARGNAME	Gastric inhibitory polypeptide (GIP)
T11453	GENENAME	GIP
T11453	TARGTYPE	Clinical trial
T11453	SYNONYMS	Glucose-dependent insulinotropic polypeptide; GIP
T11453	FUNCTION	Potent stimulator of insulin secretion and relatively poor inhibitor of gastric acid secretion.
T11453	PDBSTRUC	2QKH; 2OBU; 2L71; 2L70; 2B4N
T11453	BIOCLASS	Glucagon
T11453	SEQUENCE	MVATKTFALLLLSLFLAVGLGEKKEGHFSALPSLPVGSHAKVSSPQPRGPRYAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQREARALELASQANRKEEEAVEPQSSPAKNPSDEDLLRDLLIQELLACLLDQTNLCRLRSR
T11453	DRUGINFO	DVB59Y	LY3493269	Phase 1

T81503	TARGETID	T81503
T81503	FORMERID	TTDR00228
T81503	UNIPROID	GYRB_ECOLI
T81503	TARGNAME	Bacterial DNA gyrase B (Bact gyrB)
T81503	GENENAME	Bact gyrB
T81503	TARGTYPE	Clinical trial
T81503	SYNONYMS	gyrB; DNA gyrase subunit B
T81503	FUNCTION	DNA gyrase negatively supercoils closed circular double- stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings.
T81503	PDBSTRUC	6ENG; 5Z9Q; 5Z9N; 5Z9M; 5Z9L
T81503	BIOCLASS	ATP-hydrolyzing DNA topoisomerase
T81503	ECNUMBER	EC 5.6.2.3
T81503	SEQUENCE	MSNSYDSSSIKVLKGLDAVRKRPGMYIGDTDDGTGLHHMVFEVVDNAIDEALAGHCKEIIVTIHADNSVSVQDDGRGIPTGIHPEEGVSAAEVIMTVLHAGGKFDDNSYKVSGGLHGVGVSVVNALSQKLELVIQREGKIHRQIYEHGVPQAPLAVTGETEKTGTMVRFWPSLETFTNVTEFEYEILAKRLRELSFLNSGVSIRLRDKRDGKEDHFHYEGGIKAFVEYLNKNKTPIHPNIFYFSTEKDGIGVEVALQWNDGFQENIYCFTNNIPQRDGGTHLAGFRAAMTRTLNAYMDKEGYSKKAKVSATGDDAREGLIAVVSVKVPDPKFSSQTKDKLVSSEVKSAVEQQMNELLAEYLLENPTDAKIVVGKIIDAARAREAARRAREMTRRKGALDLAGLPGKLADCQERDPALSELYLVEGDSAGGSAKQGRNRKNQAILPLKGKILNVEKARFDKMLSSQEVATLITALGCGIGRDEYNPDKLRYHSIIIMTDADVDGSHIRTLLLTFFYRQMPEIVERGHVYIAQPPLYKVKKGKQEQYIKDDEAMDQYQISIALDGATLHTNASAPALAGEALEKLVSEYNATQKMINRMERRYPKAMLKELIYQPTLTEADLSDEQTVTRWVNALVSELNDKEQHGSQWKFDVHTNAEQNLFEPIVRVRTHGVDTDYPLDHEFITGGEYRRICTLGEKLRGLLEEDAFIERGERRQPVASFEQALDWLVKESRRGLSIQRYKGLGEMNPEQLWETTMDPESRRMLRVTVKDAIAADQLFTTLMGDAVEPRRAFIEENALKAANIDI
T81503	DRUGINFO	DURD59	SPR720	Phase 1/2
T81503	DRUGINFO	D00DXV	BAY 50-7952	Investigative
T81503	DRUGINFO	D0X3FT	Coumermycin	Investigative

T85309	TARGETID	T85309
T85309	FORMERID	TTDR00526
T85309	UNIPROID	CBS_HUMAN
T85309	TARGNAME	Cystathionine beta-synthase (CBS)
T85309	GENENAME	CBS
T85309	TARGTYPE	Clinical trial
T85309	SYNONYMS	Serine sulfhydrase; Beta-thionase
T85309	FUNCTION	Hydro-lyase catalyzing the first step of the transsulfuration pathway, where the hydroxyl group of L-serine is displaced by L-homocysteine in a beta-replacement reaction to form L-cystathionine, the precursor of L-cysteine. This catabolic route allows the elimination of L-methionine and the toxic metabolite L-homocysteine. Also involved in the production of hydrogen sulfide, a gasotransmitter with signaling and cytoprotective effects on neurons.
T85309	PDBSTRUC	5MMS; 4UUU; 4PCU; 4L3V; 4L28
T85309	BIOCLASS	Alpha-carbonic anhydrase
T85309	ECNUMBER	EC 4.2.1.22
T85309	SEQUENCE	MPSETPQAEVGPTGCPHRSGPHSAKGSLEKGSPEDKEAKEPLWIRPDAPSRCTWQLGRPASESPHHHTAPAKSPKILPDILKKIGDTPMVRINKIGKKFGLKCELLAKCEFFNAGGSVKDRISLRMIEDAERDGTLKPGDTIIEPTSGNTGIGLALAAAVRGYRCIIVMPEKMSSEKVDVLRALGAEIVRTPTNARFDSPESHVGVAWRLKNEIPNSHILDQYRNASNPLAHYDTTADEILQQCDGKLDMLVASVGTGGTITGIARKLKEKCPGCRIIGVDPEGSILAEPEELNQTEQTTYEVEGIGYDFIPTVLDRTVVDKWFKSNDEEAFTFARMLIAQEGLLCGGSAGSTVAVAVKAAQELQEGQRCVVILPDSVRNYMTKFLSDRWMLQKGFLKEEDLTEKKPWWWHLRVQELGLSAPLTVLPTITCGHTIEILREKGFDQAPVVDEAGVILGMVTLGNMLSSLLAGKVQPSDQVGKVIYKQFKQIRLTDTLGRLSHILEMDHFALVVHEQIQYHSTGKSSQRQMVFGVVTAIDLLNFVAAQERDQK
T85309	DRUGINFO	D87TMY	OT-58	Phase 1/2
T85309	DRUGINFO	D01BTV	aminooxyacetic acid	Investigative
T85309	DRUGINFO	D0UU1I	Heme	Investigative

T66538	TARGETID	T66538
T66538	FORMERID	TTDI01971
T66538	UNIPROID	KCMA1_HUMAN
T66538	TARGNAME	Calcium-activated potassium channel KCa1.1 (KCNMA1)
T66538	GENENAME	KCNMA1
T66538	TARGTYPE	Clinical trial
T66538	SYNONYMS	hSlo; Slowpoke homolog; Slo1; Slo-alpha; Slo homolog; SLO; MaxiK; Maxi K channel; KCa1.1; KCNMA; K(VCA)alpha; Calcium-activated potassium channel, subfamily M subunit alpha-1; Calcium-activated potassium channel subunit alpha-1; BKCA alpha; BK channel
T66538	FUNCTION	Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activation dampens the excitatory events that elevate the cytosolic Ca(2+) concentration and/or depolarize the cell membrane. It therefore contributes to repolarization of the membrane potential. Plays a key role in controlling excitability in a number of systems, such as regulation of the contraction of smooth muscle, the tuning of hair cells in the cochlea, regulation of transmitter release, and innate immunity. In smooth muscles, its activation by high level of Ca(2+), caused by ryanodine receptors in the sarcoplasmic reticulum, regulates the membrane potential. In cochlea cells, its number and kinetic properties partly determine the characteristic frequency of each hair cell and thereby helps to establish a tonotopic map. Kinetics of KCNMA1 channels are determined by alternative splicing, phosphorylation status and its combination with modulating beta subunits. Highly sensitive to both iberiotoxin (IbTx) and charybdotoxin (CTX).
T66538	PDBSTRUC	3NAF; 3MT5; 2K44
T66538	BIOCLASS	Voltage-gated ion channel
T66538	SEQUENCE	MANGGGGGGGSSGGGGGGGGSSLRMSSNIHANHLSLDASSSSSSSSSSSSSSSSSSSSSSVHEPKMDALIIPVTMEVPCDSRGQRMWWAFLASSMVTFFGGLFIILLWRTLKYLWTVCCHCGGKTKEAQKINNGSSQADGTLKPVDEKEEAVAAEVGWMTSVKDWAGVMISAQTLTGRVLVVLVFALSIGALVIYFIDSSNPIESCQNFYKDFTLQIDMAFNVFFLLYFGLRFIAANDKLWFWLEVNSVVDFFTVPPVFVSVYLNRSWLGLRFLRALRLIQFSEILQFLNILKTSNSIKLVNLLSIFISTWLTAAGFIHLVENSGDPWENFQNNQALTYWECVYLLMVTMSTVGYGDVYAKTTLGRLFMVFFILGGLAMFASYVPEIIELIGNRKKYGGSYSAVSGRKHIVVCGHITLESVSNFLKDFLHKDRDDVNVEIVFLHNISPNLELEALFKRHFTQVEFYQGSVLNPHDLARVKIESADACLILANKYCADPDAEDASNIMRVISIKNYHPKIRIITQMLQYHNKAHLLNIPSWNWKEGDDAICLAELKLGFIAQSCLAQGLSTMLANLFSMRSFIKIEEDTWQKYYLEGVSNEMYTEYLSSAFVGLSFPTVCELCFVKLKLLMIAIEYKSANRESRILINPGNHLKIQEGTLGFFIASDAKEVKRAFFYCKACHDDITDPKRIKKCGCKRPKMSIYKRMRRACCFDCGRSERDCSCMSGRVRGNVDTLERAFPLSSVSVNDCSTSFRAFEDEQPSTLSPKKKQRNGGMRNSPNTSPKLMRHDPLLIPGNDQIDNMDSNVKKYDSTGMFHWCAPKEIEKVILTRSEAAMTVLSGHVVVCIFGDVSSALIGLRNLVMPLRASNFHYHELKHIVFVGSIEYLKREWETLHNFPKVSILPGTPLSRADLRAVNINLCDMCVILSANQNNIDDTSLQDKECILASLNIKSMQFDDSIGVLQANSQGFTPPGMDRSSPDNSPVHGMLRQPSITTGVNIPIITELVNDTNVQFLDQDDDDDPDTELYLTQPFACGTAFAVSVLDSLMSATYFNDNILTLIRTLVTGGATPELEALIAEENALRGGYSTPQTLANRDRCRVAQLALLDGPFADLGDGGCYGDLFCKALKTYNMLCFGIYRLRDAHLSTPSQCTKRYVITNPPYEFELVPTDLIFCLMQFDHNAGQSRASLSHSSHSSQSSSKKSSSVHSIPSTANRQNRPKSRESRDKQKYVQEERL
T66538	DRUGINFO	D0VZ9S	CROMOGLYCATE LISETIL HYDROCHLORIDE	Phase 2
T66538	DRUGINFO	DMVJ21	URO-902	Phase 2

T22976	TARGETID	T22976
T22976	FORMERID	TTDR00783
T22976	UNIPROID	KITM_HUMAN
T22976	TARGNAME	Thymidine kinase 2 (Mt-TK2)
T22976	GENENAME	dnk
T22976	TARGTYPE	Clinical trial
T22976	SYNONYMS	dnk; Multispecific deoxynucleoside kinase; Dm-Dnk; Deoxyribonucleoside kinase
T22976	FUNCTION	Deoxyribonucleoside kinase that has a broad specificity phosphorylating thymidine, deoxyadenosine, deoxycytidine and deoxyguanosine. Specificity is higher for pyrimidine nucleosides. Several anti-viral and anti-cancer nucleoside analogs are also efficiently phosphorylated.
T22976	BIOCLASS	Kinase
T22976	ECNUMBER	EC 2.7.1.21
T22976	SEQUENCE	MLLWPLRGWAARALRCFGPGSRGSPASGPGPRRVQRRAWPPDKEQEKEKKSVICVEGNIASGKTTCLEFFSNATDVEVLTEPVSKWRNVRGHNPLGLMYHDASRWGLTLQTYVQLTMLDRHTRPQVSSVRLMERSIHSARYIFVENLYRSGKMPEVDYVVLSEWFDWILRNMDVSVDLIVYLRTNPETCYQRLKKRCREEEKVIPLEYLEAIHHLHEEWLIKGSLFPMAAPVLVIEADHHMERMLELFEQNRDRILTPENRKHCP
T22976	DRUGINFO	DI4SM3	MT-1621	Phase 3
T22976	DRUGINFO	D00KWL	1-[5-(triphenylmethoxy)pentyl]thymine	Investigative
T22976	DRUGINFO	D02CCD	1-[6-(triphenylmethoxy)hexyl]thymine	Investigative
T22976	DRUGINFO	D0I6UV	1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine	Investigative

T14231	TARGETID	T14231
T14231	FORMERID	TTDR00417
T14231	UNIPROID	LGR5_HUMAN
T14231	TARGNAME	Leucine-rich repeat-containing GPCR 5 (LGR5)
T14231	GENENAME	LGR5
T14231	TARGTYPE	Clinical trial
T14231	SYNONYMS	Orphan G protein-coupled receptor HG38; Leucine-rich repeat-containing G-protein coupled receptor 5; Gpr49; GPR67; G-protein coupled receptor HG38; G-protein coupled receptor 67; G-protein coupled receptor 49; G protein-coupled receptor 49
T14231	FUNCTION	Upon binding to R-spondins (RSPO1, RSPO2, RSPO3 or RSPO4), associates with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signaling pathway to increase expression of target genes. In contrast to classical G-protein coupled receptors, does not activate heterotrimeric G-proteins to transduce the signal. Involved in the development and/or maintenance of the adult intestinal stem cells during postembryonic development. Receptor for R-spondins that potentiates the canonical Wnt signaling pathway and acts as a stem cell marker of the intestinal epithelium and the hair follicle.
T14231	PDBSTRUC	4UFS; 4UFR; 4KNG; 4BSU; 4BST
T14231	BIOCLASS	GPCR rhodopsin
T14231	SEQUENCE	MDTSRLGVLLSLPVLLQLATGGSSPRSGVLLRGCPTHCHCEPDGRMLLRVDCSDLGLSELPSNLSVFTSYLDLSMNNISQLLPNPLPSLRFLEELRLAGNALTYIPKGAFTGLYSLKVLMLQNNQLRHVPTEALQNLRSLQSLRLDANHISYVPPSCFSGLHSLRHLWLDDNALTEIPVQAFRSLSALQAMTLALNKIHHIPDYAFGNLSSLVVLHLHNNRIHSLGKKCFDGLHSLETLDLNYNNLDEFPTAIRTLSNLKELGFHSNNIRSIPEKAFVGNPSLITIHFYDNPIQFVGRSAFQHLPELRTLTLNGASQITEFPDLTGTANLESLTLTGAQISSLPQTVCNQLPNLQVLDLSYNLLEDLPSFSVCQKLQKIDLRHNEIYEIKVDTFQQLLSLRSLNLAWNKIAIIHPNAFSTLPSLIKLDLSSNLLSSFPITGLHGLTHLKLTGNHALQSLISSENFPELKVIEMPYAYQCCAFGVCENAYKISNQWNKGDNSSMDDLHKKDAGMFQAQDERDLEDFLLDFEEDLKALHSVQCSPSPGPFKPCEHLLDGWLIRIGVWTIAVLALTCNALVTSTVFRSPLYISPIKLLIGVIAAVNMLTGVSSAVLAGVDAFTFGSFARHGAWWENGVGCHVIGFLSIFASESSVFLLTLAALERGFSVKYSAKFETKAPFSSLKVIILLCALLALTMAAVPLLGGSKYGASPLCLPLPFGEPSTMGYMVALILLNSLCFLMMTIAYTKLYCNLDKGDLENIWDCSMVKHIALLLFTNCILNCPVAFLSFSSLINLTFISPEVIKFILLVVVPLPACLNPLLYILFNPHFKEDLVSLRKQTYVWTRSKHPSLMSINSDDVEKQSCDSTQALVTFTSSSITYDLPPSSVPSPAYPVTESCHLSSVAFVPCL
T14231	DRUGINFO	DD6AZ5	BNC-101	Phase 1
T14231	DRUGINFO	DV8I4Q	MCLA-158	Phase 1
T14231	DRUGINFO	D2ZI3H	BNC-102	Preclinical
T14231	DRUGINFO	D0X1YZ	KM-4056	Investigative

T93325	TARGETID	T93325
T93325	UNIPROID	SF3B1_HUMAN
T93325	TARGNAME	Spliceosome-associated protein 155 (SF3B1)
T93325	GENENAME	SF3B1
T93325	TARGTYPE	Clinical trial
T93325	SYNONYMS	Splicing factor 3B subunit 1; SF3b155; SAP155; SAP 155; Pre-mRNA-splicing factor SF3b 155 kDa subunit
T93325	FUNCTION	Involved in pre-mRNA splicing as a component of the splicing factor SF3B complex. SF3B complex is required for 'A' complex assembly formed by the stable binding of U2 snRNP to the branchpoint sequence (BPS) in pre-mRNA. Sequence independent binding of SF3A/SF3B complex upstream of the branch site is essential, it may anchor U2 snRNP to the pre-mRNA. May also be involved in the assembly of the 'E' complex. Belongs also to the minor U12-dependent spliceosome, which is involved in the splicing of rare class of nuclear pre-mRNA intron.
T93325	PDBSTRUC	6QX9; 6N3E; 6FF7; 6FF4; 6EN4
T93325	BIOCLASS	SF3B1 family
T93325	SEQUENCE	MAKIAKTHEDIEAQIREIQGKKAALDEAQGVGLDSTGYYDQEIYGGSDSRFAGYVTSIAATELEDDDDDYSSSTSLLGQKKPGYHAPVALLNDIPQSTEQYDPFAEHRPPKIADREDEYKKHRRTMIISPERLDPFADGGKTPDPKMNARTYMDVMREQHLTKEEREIRQQLAEKAKAGELKVVNGAAASQPPSKRKRRWDQTADQTPGATPKKLSSWDQAETPGHTPSLRWDETPGRAKGSETPGATPGSKIWDPTPSHTPAGAATPGRGDTPGHATPGHGGATSSARKNRWDETPKTERDTPGHGSGWAETPRTDRGGDSIGETPTPGASKRKSRWDETPASQMGGSTPVLTPGKTPIGTPAMNMATPTPGHIMSMTPEQLQAWRWEREIDERNRPLSDEELDAMFPEGYKVLPPPAGYVPIRTPARKLTATPTPLGGMTGFHMQTEDRTMKSVNDQPSGNLPFLKPDDIQYFDKLLVDVDESTLSPEEQKERKIMKLLLKIKNGTPPMRKAALRQITDKAREFGAGPLFNQILPLLMSPTLEDQERHLLVKVIDRILYKLDDLVRPYVHKILVVIEPLLIDEDYYARVEGREIISNLAKAAGLATMISTMRPDIDNMDEYVRNTTARAFAVVASALGIPSLLPFLKAVCKSKKSWQARHTGIKIVQQIAILMGCAILPHLRSLVEIIEHGLVDEQQKVRTISALAIAALAEAATPYGIESFDSVLKPLWKGIRQHRGKGLAAFLKAIGYLIPLMDAEYANYYTREVMLILIREFQSPDEEMKKIVLKVVKQCCGTDGVEANYIKTEILPPFFKHFWQHRMALDRRNYRQLVDTTVELANKVGAAEIISRIVDDLKDEAEQYRKMVMETIEKIMGNLGAADIDHKLEEQLIDGILYAFQEQTTEDSVMLNGFGTVVNALGKRVKPYLPQICGTVLWRLNNKSAKVRQQAADLISRTAVVMKTCQEEKLMGHLGVVLYEYLGEEYPEVLGSILGALKAIVNVIGMHKMTPPIKDLLPRLTPILKNRHEKVQENCIDLVGRIADRGAEYVSAREWMRICFELLELLKAHKKAIRRATVNTFGYIAKAIGPHDVLATLLNNLKVQERQNRVCTTVAIAIVAETCSPFTVLPALMNEYRVPELNVQNGVLKSLSFLFEYIGEMGKDYIYAVTPLLEDALMDRDLVHRQTASAVVQHMSLGVYGFGCEDSLNHLLNYVWPNVFETSPHVIQAVMGALEGLRVAIGPCRMLQYCLQGLFHPARKVRDVYWKIYNSIYIGSQDALIAHYPRIYNDDKNTYIRYELDYIL

T47888	TARGETID	T47888
T47888	FORMERID	TTDI02522
T47888	UNIPROID	S1PR2_HUMAN
T47888	TARGNAME	Sphingosine-1-phosphate receptor 2 (S1PR2)
T47888	GENENAME	S1PR2
T47888	TARGTYPE	Clinical trial
T47888	SYNONYMS	Sphingosine 1-phosphate receptor Edg-5; S1PR2; S1P2; S1P receptor Edg-5; S1P receptor 2; Endothelial differentiation G-protein coupled receptor 5
T47888	FUNCTION	Receptor for the lysosphingolipid sphingosine 1- phosphate (S1P). S1P is a bioactive lysophospholipid that elicits diverse physiological effect on most types of cells and tissues. When expressed in rat HTC4 hepatoma cells, is capable of mediating S1P-induced cell proliferation and suppression of apoptosis.
T47888	PDBSTRUC	1ZTI
T47888	BIOCLASS	GPCR rhodopsin
T47888	SEQUENCE	MGSLYSEYLNPNKVQEHYNYTKETLETQETTSRQVASAFIVILCCAIVVENLLVLIAVARNSKFHSAMYLFLGNLAASDLLAGVAFVANTLLSGSVTLRLTPVQWFAREGSAFITLSASVFSLLAIAIERHVAIAKVKLYGSDKSCRMLLLIGASWLISLVLGGLPILGWNCLGHLEACSTVLPLYAKHYVLCVVTIFSIILLAIVALYVRIYCVVRSSHADMAAPQTLALLKTVTIVLGVFIVCWLPAFSILLLDYACPVHSCPILYKAHYFFAVSTLNSLLNPVIYTWRSRDLRREVLRPLQCWRPGVGVQGRRRGGTPGHHLLPLRSSSSLERGMHMPTSPTFLEGNTVV
T47888	DRUGINFO	D2E4CG	Amiselimod	Phase 2
T47888	DRUGINFO	D0C4AW	US8975409, Example 13	Patented
T47888	DRUGINFO	D0J5YV	SCHEMBL15295829	Patented
T47888	DRUGINFO	D0K4BI	Jte 013	Patented
T47888	DRUGINFO	D0PW0R	US8975409, Example 9(3)	Patented
T47888	DRUGINFO	D0QU9I	Unii-R228S06soh	Patented
T47888	DRUGINFO	D0T8FV	US8975409, Comparative compound B	Patented
T47888	DRUGINFO	D03BRM	AUY954	Investigative

T98397	TARGETID	T98397
T98397	FORMERID	TTDI00964
T98397	UNIPROID	TYSY_HUMAN
T98397	TARGNAME	Thymidylate synthase (TYMS)
T98397	GENENAME	TYMS
T98397	TARGTYPE	Clinical trial
T98397	SYNONYMS	TSase; TS
T98397	FUNCTION	Contributes to the de novo mitochondrial thymidylate biosynthesis pathway.
T98397	PDBSTRUC	6R2E; 6QYQ; 6QXH; 6QXG; 5X69
T98397	BIOCLASS	Methyltransferase
T98397	ECNUMBER	EC 2.1.1.45
T98397	SEQUENCE	MPVAGSELPRRPLPPAAQERDAEPRPPHGELQYLGQIQHILRCGVRKDDRTGTGTLSVFGMQARYSLRDEFPLLTTKRVFWKGVLEELLWFIKGSTNAKELSSKGVKIWDANGSRDFLDSLGFSTREEGDLGPVYGFQWRHFGAEYRDMESDYSGQGVDQLQRVIDTIKTNPDDRRIIMCAWNPRDLPLMALPPCHALCQFYVVNSELSCQLYQRSGDMGLGVPFNIASYALLTYMIAHITGLKPGDFIHTLGDAHIYLNHIEPLKIQLQREPRPFPKLRILRKVEKIDDFKAEDFQIEGYNPHPTIKMEMAV
T98397	DRUGINFO	D04FYZ	Plevitrexed (R)-isomer	Phase 2
T98397	DRUGINFO	DQ9B8C	NUC-3373	Phase 1
T98397	DRUGINFO	D0Q0EB	ICI-198583	Investigative

T13075	TARGETID	T13075
T13075	FORMERID	TTDI03079
T13075	UNIPROID	KC1A_HUMAN
T13075	TARGNAME	Casein kinase I alpha (CSNK1A1)
T13075	GENENAME	CSNK1A1
T13075	TARGTYPE	Clinical trial
T13075	SYNONYMS	Casein kinase I isoform alpha; CKI-alpha; CK1
T13075	FUNCTION	It can phosphorylate a large number of proteins. Participates in Wnt signaling. Phosphorylates CTNNB1 at 'Ser-45'. May phosphorylate PER1 and PER2. May play a role in segregating chromosomes during mitosis. May play a role in keratin cytoskeleton disassembly and thereby, it may regulate epithelial cell migration. Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates.
T13075	PDBSTRUC	6GZD; 5FQD
T13075	BIOCLASS	Kinase
T13075	ECNUMBER	EC 2.7.11.1
T13075	SEQUENCE	MASSSGSKAEFIVGGKYKLVRKIGSGSFGDIYLAINITNGEEVAVKLESQKARHPQLLYESKLYKILQGGVGIPHIRWYGQEKDYNVLVMDLLGPSLEDLFNFCSRRFTMKTVLMLADQMISRIEYVHTKNFIHRDIKPDNFLMGIGRHCNKLFLIDFGLAKKYRDNRTRQHIPYREDKNLTGTARYASINAHLGIEQSRRDDMESLGYVLMYFNRTSLPWQGLKAATKKQKYEKISEKKMSTPVEVLCKGFPAEFAMYLNYCRGLRFEEAPDYMYLRQLFRILFRTLNHQYDYTFDWTMLKQKAAQQAASSSGQGQQAQTPTGKQTDKTKSNMKGF
T13075	DRUGINFO	D5VMP4	BTX-A51	Phase 1
T13075	DRUGINFO	D0MN6V	US9096594, 3	Patented
T13075	DRUGINFO	D00JGL	D-4476	Preclinical
T13075	DRUGINFO	D0UN8H	IC261	Preclinical
T13075	DRUGINFO	D0H4VB	PMID24900428C14	Investigative

T25956	TARGETID	T25956
T25956	FORMERID	TTDI02489
T25956	UNIPROID	EP300_HUMAN
T25956	TARGNAME	Histone acetyltransferase p300 (EP300)
T25956	GENENAME	EP300
T25956	TARGTYPE	Clinical trial
T25956	SYNONYMS	p300 HAT; Protein propionyltransferase p300; P300; Histone crotonyltransferase p300; Histone butyryltransferase p300; E1Aassociated protein p300; E1A-associated protein p300
T25956	FUNCTION	Acetylates all four core histones in nucleosomes. Histone acetylation gives an epigenetic tag for transcriptional activation. Mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein. Mediates acetylation of histone H3 at 'Lys-122' (H3K122ac), a modification that localizes at the surface of the histone octamer and stimulates transcription, possibly by promoting nucleosome instability. Mediates acetylation of histone H3 at 'Lys-27' (H3K27ac). Also functions as acetyltransferase for non-histone targets, such as ALX1, HDAC1, PRMT1 or SIRT2. Acetylates 'Lys-131' of ALX1 and acts as its coactivator. Acetylates SIRT2 and is proposed to indirectly increase the transcriptional activity of TP53 through acetylation and subsequent attenuation of SIRT2 deacetylase function. Acetylates HDAC1 leading to its inactivation and modulation of transcription. Acts as a TFAP2A-mediated transcriptional coactivator in presence of CITED2. Plays a role as a coactivator of NEUROD1-dependent transcription of the secretin and p21 genes and controls terminal differentiation of cells in the intestinal epithelium. Promotes cardiac myocyte enlargement. Can also mediate transcriptional repression. Acetylates FOXO1 and enhances its transcriptional activity. Acetylates BCL6 wich disrupts its ability to recruit histone deacetylases and hinders its transcriptional repressor activity. Participates in CLOCK or NPAS2-regulated rhythmic gene transcription; exhibits a circadian association with CLOCK or NPAS2, correlating with increase in PER1/2 mRNA and histone H3 acetylation on the PER1/2 promoter. Acetylates MTA1 at 'Lys-626' which is essential for its transcriptional coactivator activity. Acetylates XBP1 isoform 2; acetylation increases protein stability of XBP1 isoform 2 and enhances its transcriptional activity. Acetylates PCNA; acetylation promotes removal of chromatin-bound PCNA and its degradation during nucleotide excision repair (NER). Acetylates MEF2D. Acetylates and stabilizes ZBTB7B protein by antagonizing ubiquitin conjugation and degragation, this mechanism may be involved in CD4/CD8 lineage differentiation. In addition to protein acetyltransferase, can use different acyl-CoA substrates, such as (2E)-butenoyl-CoA (crotonyl-CoA), butanoyl-CoA (butyryl-CoA) or propanoyl-CoA (propionyl-CoA), and is able to mediate protein crotonylation, butyrylation or propionylation, respectively. Acts as a histone crotonyltransferase; crotonylation marks active promoters and enhancers and confers resistance to transcriptional repressors. Histone crotonyltransferase activity is dependent on the concentration of (2E)-butenoyl-CoA (crotonyl-CoA) substrate and such activity is weak when (E)-but-2-enoyl-CoA (crotonyl-CoA) concentration is low. Also acts as a histone butyryltransferase; butyrylation marks active promoters. Functions as a transcriptional coactivator for SMAD4 in the TGF-beta signaling pathway. Acetylates PCK1 and promotes PCK1 anaplerotic activity. Functions as histone acetyltransferase and regulates transcription via chromatin remodeling.
T25956	PDBSTRUC	6GYT; 6GYR; 6FGS; 6FGN; 6DS6
T25956	BIOCLASS	Acyltransferase
T25956	ECNUMBER	EC 2.3.1.48
T25956	SEQUENCE	MAENVVEPGPPSAKRPKLSSPALSASASDGTDFGSLFDLEHDLPDELINSTELGLTNGGDINQLQTSLGMVQDAASKHKQLSELLRSGSSPNLNMGVGGPGQVMASQAQQSSPGLGLINSMVKSPMTQAGLTSPNMGMGTSGPNQGPTQSTGMMNSPVNQPAMGMNTGMNAGMNPGMLAAGNGQGIMPNQVMNGSIGAGRGRQNMQYPNPGMGSAGNLLTEPLQQGSPQMGGQTGLRGPQPLKMGMMNNPNPYGSPYTQNPGQQIGASGLGLQIQTKTVLSNNLSPFAMDKKAVPGGGMPNMGQQPAPQVQQPGLVTPVAQGMGSGAHTADPEKRKLIQQQLVLLLHAHKCQRREQANGEVRQCNLPHCRTMKNVLNHMTHCQSGKSCQVAHCASSRQIISHWKNCTRHDCPVCLPLKNAGDKRNQQPILTGAPVGLGNPSSLGVGQQSAPNLSTVSQIDPSSIERAYAALGLPYQVNQMPTQPQVQAKNQQNQQPGQSPQGMRPMSNMSASPMGVNGGVGVQTPSLLSDSMLHSAINSQNPMMSENASVPSLGPMPTAAQPSTTGIRKQWHEDITQDLRNHLVHKLVQAIFPTPDPAALKDRRMENLVAYARKVEGDMYESANNRAEYYHLLAEKIYKIQKELEEKRRTRLQKQNMLPNAAGMVPVSMNPGPNMGQPQPGMTSNGPLPDPSMIRGSVPNQMMPRITPQSGLNQFGQMSMAQPPIVPRQTPPLQHHGQLAQPGALNPPMGYGPRMQQPSNQGQFLPQTQFPSQGMNVTNIPLAPSSGQAPVSQAQMSSSSCPVNSPIMPPGSQGSHIHCPQLPQPALHQNSPSPVPSRTPTPHHTPPSIGAQQPPATTIPAPVPTPPAMPPGPQSQALHPPPRQTPTPPTTQLPQQVQPSLPAAPSADQPQQQPRSQQSTAASVPTPTAPLLPPQPATPLSQPAVSIEGQVSNPPSTSSTEVNSQAIAEKQPSQEVKMEAKMEVDQPEPADTQPEDISESKVEDCKMESTETEERSTELKTEIKEEEDQPSTSATQSSPAPGQSKKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKSPMDLSTIKRKLDTGQYQEPWQYVDDIWLMFNNAWLYNRKTSRVYKYCSKLSEVFEQEIDPVMQSLGYCCGRKLEFSPQTLCCYGKQLCTIPRDATYYSYQNRYHFCEKCFNEIQGESVSLGDDPSQPQTTINKEQFSKRKNDTLDPELFVECTECGRKMHQICVLHHEIIWPAGFVCDGCLKKSARTRKENKFSAKRLPSTRLGTFLENRVNDFLRRQNHPESGEVTVRVVHASDKTVEVKPGMKARFVDSGEMAESFPYRTKALFAFEEIDGVDLCFFGMHVQEYGSDCPPPNQRRVYISYLDSVHFFRPKCLRTAVYHEILIGYLEYVKKLGYTTGHIWACPPSEGDDYIFHCHPPDQKIPKPKRLQEWYKKMLDKAVSERIVHDYKDIFKQATEDRLTSAKELPYFEGDFWPNVLEESIKELEQEEEERKREENTSNESTDVTKGDSKNAKKKNNKKTSKNKSSLSRGNKKKPGMPNVSNDLSQKLYATMEKHKEVFFVIRLIAGPAANSLPPIVDPDPLIPCDLMDGRDAFLTLARDKHLEFSSLRRAQWSTMCMLVELHTQSQDRFVYTCNECKHHVETRWHCTVCEDYDLCITCYNTKNHDHKMEKLGLGLDDESNNQQAAATQSPGDSRRLSIQRCIQSLVHACQCRNANCSLPSCQKMKRVVQHTKGCKRKTNGGCPICKQLIALCCYHAKHCQENKCPVPFCLNIKQKLRQQQLQHRLQQAQMLRRRMASMQRTGVVGQQQGLPSPTPATPTTPTGQQPTTPQTPQPTSQPQPTPPNSMPPYLPRTQAAGPVSQGKAAGQVTPPTPPQTAQPPLPGPPPAAVEMAMQIQRAAETQRQMAHVQIFQRPIQHQMPPMTPMAPMGMNPPPMTRGPSGHLEPGMGPTGMQQQPPWSQGGLPQPQQLQSGMPRPAMMSVAQHGQPLNMAPQPGLGQVGISPLKPGTVSQQALQNLLRTLRSPSSPLQQQQVLSILHANPQLLAAFIKQRAAKYANSNPQPIPGQPGMPQGQPGLQPPTMPGQQGVHSNPAMQNMNPMQAGVQRAGLPQQQPQQQLQPPMGGMSPQAQQMNMNHNTMPSQFRDILRRQQMMQQQQQQGAGPGIGPGMANHNQFQQPQGVGYPPQQQQRMQHHMQQMQQGNMGQIGQLPQALGAEAGASLQAYQQRLLQQQMGSPVQPNPMSPQQHMLPNQAQSPHLQGQQIPNSLSNQVRSPQPVPSPRPQSQPPHSSPSPRMQPQPSPHHVSPQTSSPHPGLVAAQANPMEQGHFASPDQNSMLSQLASNPGMANLHGASATDLGLSTDNSDLNSNLSQSTLDIH
T25956	DRUGINFO	DIY4C2	CCS1477	Phase 1/2
T25956	DRUGINFO	DT8IL6	FT-7051	Phase 1

T00749	TARGETID	T00749
T00749	FORMERID	TTDNR00707
T00749	UNIPROID	M4K1_HUMAN
T00749	TARGNAME	MEK kinase kinase 1 (MAP4K1)
T00749	GENENAME	MAP4K1
T00749	TARGTYPE	Clinical trial
T00749	SYNONYMS	Mitogen-activated protein kinase kinase kinase kinase 1; MEKKK 1; MAPK/ERK kinase kinase kinase 1; Hematopoietic progenitor kinase; HPK1
T00749	FUNCTION	Appears to act upstream of the JUN N-terminal pathway. May play a role in hematopoietic lineage decisions and growth regulation. Able to autophosphorylate. Serine/threonine-protein kinase, which may play a role in the response to environmental stress.
T00749	PDBSTRUC	6NG0; 6NFZ; 6NFY; 6CQF; 6CQE
T00749	BIOCLASS	Kinase
T00749	ECNUMBER	EC 2.7.11.1
T00749	SEQUENCE	MDVVDPDIFNRDPRDHYDLLQRLGGGTYGEVFKARDKVSGDLVALKMVKMEPDDDVSTLQKEILILKTCRHANIVAYHGSYLWLQKLWICMEFCGAGSLQDIYQVTGSLSELQISYVCREVLQGLAYLHSQKKIHRDIKGANILINDAGEVRLADFGISAQIGATLARRLSFIGTPYWMAPEVAAVALKGGYNELCDIWSLGITAIELAELQPPLFDVHPLRVLFLMTKSGYQPPRLKEKGKWSAAFHNFIKVTLTKSPKKRPSATKMLSHQLVSQPGLNRGLILDLLDKLKNPGKGPSIGDIEDEEPELPPAIPRRIRSTHRSSSLGIPDADCCRRHMEFRKLRGMETRPPANTARLQPPRDLRSSSPRKQLSESSDDDYDDVDIPTPAEDTPPPLPPKPKFRSPSDEGPGSMGDDGQLSPGVLVRCASGPPPNSPRPGPPPSTSSPHLTAHSEPSLWNPPSRELDKPPLLPPKKEKMKRKGCALLVKLFNGCPLRIHSTAAWTHPSTKDQHLLLGAEEGIFILNRNDQEATLEMLFPSRTTWVYSINNVLMSLSGKTPHLYSHSILGLLERKETRAGNPIAHISPHRLLARKNMVSTKIQDTKGCRACCVAEGASSGGPFLCGALETSVVLLQWYQPMNKFLLVRQVLFPLPTPLSVFALLTGPGSELPAVCIGVSPGRPGKSVLFHTVRFGALSCWLGEMSTEHRGPVQVTQVEEDMVMVLMDGSVKLVTPEGSPVRGLRTPEIPMTEAVEAVAMVGGQLQAFWKHGVQVWALGSDQLLQELRDPTLTFRLLGSPRLECSGTISPHCNLLLPGSSNSPASASRVAGITGL
T00749	DRUGINFO	DXK49H	CFI-402411	Phase 1/2
T00749	DRUGINFO	D8MS6C	BGB-15025	Phase 1
T00749	DRUGINFO	DV3J1P	PF-07265028	Phase 1

T50445	TARGETID	T50445
T50445	FORMERID	TTDR01381
T50445	UNIPROID	TNR5_HUMAN
T50445	TARGNAME	CD40 messenger RNA (CD40 mRNA)
T50445	GENENAME	CD40
T50445	TARGTYPE	Clinical trial
T50445	SYNONYMS	Tumor necrosis factor receptor superfamily member 5 (mRNA); TNFRSF5 (mRNA); CDw40 (mRNA); CD40L receptor (mRNA); Bp50 (mRNA); B-cell surfaceantigen CD40 (mRNA); B-cell surface antigen CD40 (mRNA)
T50445	FUNCTION	Transduces TRAF6- and MAP3K8-mediated signals that activate ERK in macrophages and B cells, leading to induction of immunoglobulin secretion. Receptor for TNFSF5/CD40LG.
T50445	PDBSTRUC	6FAX; 5IHL; 5DMJ; 5DMI; 3QD6
T50445	BIOCLASS	mRNA target
T50445	SEQUENCE	MVRLPLQCVLWGCLLTAVHPEPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTETECLPCGESEFLDTWNRETHCHQHKYCDPNLGLRVQQKGTSETDTICTCEEGWHCTSEACESCVLHRSCSPGFGVKQIATGVSDTICEPCPVGFFSNVSSAFEKCHPWTSCETKDLVVQQAGTNKTDVVCGPQDRLRALVVIPIIFGILFAILLVLVFIKKVAKKPTNKAPHPKQEPQEINFPDDLPGSNTAAPVQETLHGCQPVTQEDGKESRISVQERQ
T50445	DRUGINFO	D1BT2M	NJA-730	Phase 1
T50445	DRUGINFO	D02NEY	ISIS 19213	Investigative
T50445	DRUGINFO	D05LSD	ISIS 19211	Investigative
T50445	DRUGINFO	D07UKR	ISIS 19220	Investigative
T50445	DRUGINFO	D08IOW	ISIS 19219	Investigative
T50445	DRUGINFO	D09KVB	ISIS 19221	Investigative
T50445	DRUGINFO	D0F8KX	ISIS 19218	Investigative
T50445	DRUGINFO	D0U6HC	ISIS 19217	Investigative
T50445	DRUGINFO	D0Z9NS	ISIS 19212	Investigative

T48881	TARGETID	T48881
T48881	FORMERID	TTDI02564
T48881	UNIPROID	TNF14_HUMAN
T48881	TARGNAME	Herpes virus entry mediator ligand (CD258)
T48881	GENENAME	TNFSF14
T48881	TARGTYPE	Clinical trial
T48881	SYNONYMS	UNQ391/PRO726; Tumor necrosis factor ligand superfamily member 14, soluble form; Tumor necrosis factor ligand superfamily member 14; LIGHT; Herpesvirus entry mediator ligand; HVEML; HVEM-L
T48881	FUNCTION	Binding to the decoy receptor TNFRSF6B modulates its effects. Acts as a ligand for TNFRSF14/HVEM. Upon binding to TNFRSF14/HVEM, delivers costimulatory signals to T cells, leading to T cell proliferation and IFNG production. Cytokine that binds to TNFRSF3/LTBR.
T48881	PDBSTRUC	4RSU; 4KGQ; 4KGG; 4KG8; 4J6G
T48881	BIOCLASS	Cytokine: tumor necrosis factor
T48881	SEQUENCE	MEESVVRPSVFVVDGQTDIPFTRLGRSHRRQSCSVARVGLGLLLLLMGAGLAVQGWFLLQLHWRLGEMVTRLPDGPAGSWEQLIQERRSHEVNPAAHLTGANSSLTGSGGPLLWETQLGLAFLRGLSYHDGALVVTKAGYYYIYSKVQLGGVGCPLGLASTITHGLYKRTPRYPEELELLVSQQSPCGRATSSSRVWWDSSFLGGVVHLEAGEKVVVRVLDERLVRLRDGTRSYFGAFMV
T48881	DRUGINFO	DBU4N1	AVTX-002	Phase 2

T73708	TARGETID	T73708
T73708	FORMERID	TTDI02494
T73708	UNIPROID	NRP2_HUMAN
T73708	TARGNAME	Neuropilin-2 (NRP2)
T73708	GENENAME	NRP2
T73708	TARGTYPE	Clinical trial
T73708	SYNONYMS	Vascular endothelial cell growth factor 165 receptor 2; VEGF165R2; Neuropilin2
T73708	FUNCTION	High affinity receptor for semaphorins 3C, 3F, VEGF-165 and VEGF-145 isoforms of VEGF, and the PLGF-2 isoform of PGF.
T73708	PDBSTRUC	6GH8; 5DQ0; 5DN2; 4QDS; 4QDR
T73708	BIOCLASS	Neuropilin and tolloid-like
T73708	SEQUENCE	MDMFPLTWVFLALYFSRHQVRGQPDPPCGGRLNSKDAGYITSPGYPQDYPSHQNCEWIVYAPEPNQKIVLNFNPHFEIEKHDCKYDFIEIRDGDSESADLLGKHCGNIAPPTIISSGSMLYIKFTSDYARQGAGFSLRYEIFKTGSEDCSKNFTSPNGTIESPGFPEKYPHNLDCTFTILAKPKMEIILQFLIFDLEHDPLQVGEGDCKYDWLDIWDGIPHVGPLIGKYCGTKTPSELRSSTGILSLTFHTDMAVAKDGFSARYYLVHQEPLENFQCNVPLGMESGRIANEQISASSTYSDGRWTPQQSRLHGDDNGWTPNLDSNKEYLQVDLRFLTMLTAIATQGAISRETQNGYYVKSYKLEVSTNGEDWMVYRHGKNHKVFQANNDATEVVLNKLHAPLLTRFVRIRPQTWHSGIALRLELFGCRVTDAPCSNMLGMLSGLIADSQISASSTQEYLWSPSAARLVSSRSGWFPRIPQAQPGEEWLQVDLGTPKTVKGVIIQGARGGDSITAVEARAFVRKFKVSYSLNGKDWEYIQDPRTQQPKLFEGNMHYDTPDIRRFDPIPAQYVRVYPERWSPAGIGMRLEVLGCDWTDSKPTVETLGPTVKSEETTTPYPTEEEATECGENCSFEDDKDLQLPSGFNCNFDFLEEPCGWMYDHAKWLRTTWASSSSPNDRTFPDDRNFLRLQSDSQREGQYARLISPPVHLPRSPVCMEFQYQATGGRGVALQVVREASQESKLLWVIREDQGGEWKHGRIILPSYDMEYQIVFEGVIGKGRSGEIAIDDIRISTDVPLENCMEPISAFAGENFKVDIPEIHEREGYEDEIDDEYEVDWSNSSSATSGSGAPSTDKEKSWLYTLDPILITIIAMSSLGVLLGATCAGLLLYCTCSYSGLSSRSCTTLENYNFELYDGLKHKVKMNHQKCCSEA
T73708	DRUGINFO	DN2W9I	ATYR1923	Phase 3

T01003	TARGETID	T01003
T01003	FORMERID	TTDI03172
T01003	UNIPROID	ERN1_HUMAN
T01003	TARGNAME	Endoplasmic reticulum to nucleus signaling 1 (ERN1)
T01003	GENENAME	ERN1
T01003	TARGTYPE	Clinical trial
T01003	SYNONYMS	Serine/threonine-protein kinase/endoribonuclease IRE1; Ire1-alpha; IRE1a; IRE1; Inositol-requiring protein 1; hIRE1p; Endoplasmic reticulum-to-nucleus signaling 1
T01003	FUNCTION	In unstressed cells, the endoplasmic reticulum luminal domain is maintained in its inactive monomeric state by binding to the endoplasmic reticulum chaperone HSPA5/BiP. Accumulation of misfolded protein in the endoplasmic reticulum causes release of HSPA5/BiP, allowing the luminal domain to homodimerize, promoting autophosphorylation of the kinase domain and subsequent activation of the endoribonuclease activity. The endoribonuclease activity is specific for XBP1 mRNA and excises 26 nucleotides from XBP1 mRNA. The resulting spliced transcript of XBP1 encodes a transcriptional activator protein that up-regulates expression of UPR target genes. Acts as an upstream signal for ER stress-induced GORASP2-mediated unconventional (ER/Golgi-independent) trafficking of CFTR to cell membrane by modulating the expression and localization of SEC16A. Serine/threonine-protein kinase and endoribonuclease that acts as a key sensor for the endoplasmic reticulum unfolded protein response (UPR).
T01003	PDBSTRUC	6HX1; 6HV0; 5HGI; 4Z7H; 4Z7G
T01003	BIOCLASS	Kinase
T01003	SEQUENCE	MPARRLLLLLTLLLPGLGIFGSTSTVTLPETLLFVSTLDGSLHAVSKRTGSIKWTLKEDPVLQVPTHVEEPAFLPDPNDGSLYTLGSKNNEGLTKLPFTIPELVQASPCRSSDGILYMGKKQDIWYVIDLLTGEKQQTLSSAFADSLCPSTSLLYLGRTEYTITMYDTKTRELRWNATYFDYAASLPEDDVDYKMSHFVSNGDGLVVTVDSESGDVLWIQNYASPVVAFYVWQREGLRKVMHINVAVETLRYLTFMSGEVGRITKWKYPFPKETEAKSKLTPTLYVGKYSTSLYASPSMVHEGVAVVPRGSTLPLLEGPQTDGVTIGDKGECVITPSTDVKFDPGLKSKNKLNYLRNYWLLIGHHETPLSASTKMLERFPNNLPKHRENVIPADSEKKSFEEVINLVDQTSENAPTTVSRDVEEKPAHAPARPEAPVDSMLKDMATIILSTFLLIGWVAFIITYPLSMHQQQQLQHQQFQKELEKIQLLQQQQQQLPFHPPGDTAQDGELLDTSGPYSESSGTSSPSTSPRASNHSLCSGSSASKAGSSPSLEQDDGDEETSVVIVGKISFCPKDVLGHGAEGTIVYRGMFDNRDVAVKRILPECFSFADREVQLLRESDEHPNVIRYFCTEKDRQFQYIAIELCAATLQEYVEQKDFAHLGLEPITLLQQTTSGLAHLHSLNIVHRDLKPHNILISMPNAHGKIKAMISDFGLCKKLAVGRHSFSRRSGVPGTEGWIAPEMLSEDCKENPTYTVDIFSAGCVFYYVISEGSHPFGKSLQRQANILLGACSLDCLHPEKHEDVIARELIEKMIAMDPQKRPSAKHVLKHPFFWSLEKQLQFFQDVSDRIEKESLDGPIVKQLERGGRAVVKMDWRENITVPLQTDLRKFRTYKGGSVRDLLRAMRNKKHHYRELPAEVRETLGSLPDDFVCYFTSRFPHLLAHTYRAMELCSHERLFQPYYFHEPPEPQPPVTPDAL
T01003	DRUGINFO	DK3QD9	ORIN1001	Phase 1/2
T01003	DRUGINFO	D00OUG	US9040714, 7	Patented
T01003	DRUGINFO	D01UPA	T8361	Patented
T01003	DRUGINFO	D0AV6X	US8614253, 29-1	Patented
T01003	DRUGINFO	D0DV4H	US8614253, 32-5	Patented
T01003	DRUGINFO	D0GK1K	US8614253, 29-19	Patented
T01003	DRUGINFO	D0KF0D	879325-11-8	Patented
T01003	DRUGINFO	D0M2TO	AC1LE05K	Patented
T01003	DRUGINFO	D0TA9C	US8614253, 32-4	Patented
T01003	DRUGINFO	D0VP7R	BB 0223767	Patented
T01003	DRUGINFO	D0XX5N	US9241942, 32-12	Patented
T01003	DRUGINFO	D0ZP0G	US9040714, 155	Patented
T01003	DRUGINFO	D0E3CB	PMID24749861C34	Investigative
T01003	DRUGINFO	D1BCW8	APY29	Investigative

T34601	TARGETID	T34601
T34601	FORMERID	TTDI02407
T34601	UNIPROID	DYSF_HUMAN
T34601	TARGNAME	Dysferlin (DYSF)
T34601	GENENAME	DYSF
T34601	TARGTYPE	Clinical trial
T34601	SYNONYMS	Fer1like protein 1; Dystrophyassociated fer1like protein; DYSF
T34601	FUNCTION	Key calcium ion sensor involved in the Ca(2+)-triggered synaptic vesicle-plasma membrane fusion. Plays a role in the sarcolemma repair mechanism of both skeletal muscle and cardiomyocytes that permits rapid resealing of membranes disrupted by mechanical stress.{ECO:0000250}.
T34601	PDBSTRUC	4IQH; 4IHB; 4CAI; 4CAH
T34601	BIOCLASS	Synaptosomal vesicle fusion pore
T34601	SEQUENCE	MLRVFILYAENVHTPDTDISDAYCSAVFAGVKKRTKVIKNSVNPVWNEGFEWDLKGIPLDQGSELHVVVKDHETMGRNRFLGEAKVPLREVLATPSLSASFNAPLLDTKKQPTGASLVLQVSYTPLPGAVPLFPPPTPLEPSPTLPDLDVVADTGGEEDTEDQGLTGDEAEPFLDQSGGPGAPTTPRKLPSRPPPHYPGIKRKRSAPTSRKLLSDKPQDFQIRVQVIEGRQLPGVNIKPVVKVTAAGQTKRTRIHKGNSPLFNETLFFNLFDSPGELFDEPIFITVVDSRSLRTDALLGEFRMDVGTIYREPRHAYLRKWLLLSDPDDFSAGARGYLKTSLCVLGPGDEAPLERKDPSEDKEDIESNLLRPTGVALRGAHFCLKVFRAEDLPQMDDAVMDNVKQIFGFESNKKNLVDPFVEVSFAGKMLCSKILEKTANPQWNQNITLPAMFPSMCEKMRIRIIDWDRLTHNDIVATTYLSMSKISAPGGEIEEEPAGAVKPSKASDLDDYLGFLPTFGPCYINLYGSPREFTGFPDPYTELNTGKGEGVAYRGRLLLSLETKLVEHSEQKVEDLPADDILRVEKYLRRRKYSLFAAFYSATMLQDVDDAIQFEVSIGNYGNKFDMTCLPLASTTQYSRAVFDGCHYYYLPWGNVKPVVVLSSYWEDISHRIETQNQLLGIADRLEAGLEQVHLALKAQCSTEDVDSLVAQLTDELIAGCSQPLGDIHETPSATHLDQYLYQLRTHHLSQITEAALALKLGHSELPAALEQAEDWLLRLRALAEEPQNSLPDIVIWMLQGDKRVAYQRVPAHQVLFSRRGANYCGKNCGKLQTIFLKYPMEKVPGARMPVQIRVKLWFGLSVDEKEFNQFAEGKLSVFAETYENETKLALVGNWGTTGLTYPKFSDVTGKIKLPKDSFRPSAGWTWAGDWFVCPEKTLLHDMDAGHLSFVEEVFENQTRLPGGQWIYMSDNYTDVNGEKVLPKDDIECPLGWKWEDEEWSTDLNRAVDEQGWEYSITIPPERKPKHWVPAEKMYYTHRRRRWVRLRRRDLSQMEALKRHRQAEAEGEGWEYASLFGWKFHLEYRKTDAFRRRRWRRRMEPLEKTGPAAVFALEGALGGVMDDKSEDSMSVSTLSFGVNRPTISCIFDYGNRYHLRCYMYQARDLAAMDKDSFSDPYAIVSFLHQSQKTVVVKNTLNPTWDQTLIFYEIEIFGEPATVAEQPPSIVVELYDHDTYGADEFMGRCICQPSLERMPRLAWFPLTRGSQPSGELLASFELIQREKPAIHHIPGFEVQETSRILDESEDTDLPYPPPQREANIYMVPQNIKPALQRTAIEILAWGLRNMKSYQLANISSPSLVVECGGQTVQSCVIRNLRKNPNFDICTLFMEVMLPREELYCPPITVKVIDNRQFGRRPVVGQCTIRSLESFLCDPYSAESPSPQGGPDDVSLLSPGEDVLIDIDDKEPLIPIQEEEFIDWWSKFFASIGEREKCGSYLEKDFDTLKVYDTQLENVEAFEGLSDFCNTFKLYRGKTQEETEDPSVIGEFKGLFKIYPLPEDPAIPMPPRQFHQLAAQGPQECLVRIYIVRAFGLQPKDPNGKCDPYIKISIGKKSVSDQDNYIPCTLEPVFGKMFELTCTLPLEKDLKITLYDYDLLSKDEKIGETVVDLENRLLSKFGARCGLPQTYCVSGPNQWRDQLRPSQLLHLFCQQHRVKAPVYRTDRVMFQDKEYSIEEIEAGRIPNPHLGPVEERLALHVLQQQGLVPEHVESRPLYSPLQPDIEQGKLQMWVDLFPKALGRPGPPFNITPRRARRFFLRCIIWNTRDVILDDLSLTGEKMSDIYVKGWMIGFEEHKQKTDVHYRSLGGEGNFNWRFIFPFDYLPAEQVCTIAKKDAFWRLDKTESKIPARVVFQIWDNDKFSFDDFLGSLQLDLNRMPKPAKTAKKCSLDQLDDAFHPEWFVSLFEQKTVKGWWPCVAEEGEKKILAGKLEMTLEIVAESEHEERPAGQGRDEPNMNPKLEDPRRPDTSFLWFTSPYKTMKFILWRRFRWAIILFIILFILLLFLAIFIYAFPNYAAMKLVKPFS
T34601	DRUGINFO	DMD0H5	SRP-6004	Phase 1

T35212	TARGETID	T35212
T35212	FORMERID	TTDI02565
T35212	UNIPROID	TNF15_HUMAN
T35212	TARGNAME	Vascular endothelial cell growth inhibitor (TNFSF15)
T35212	GENENAME	TNFSF15
T35212	TARGTYPE	Clinical trial
T35212	SYNONYMS	Tumor necrosis factor ligand superfamily member 15, secreted form; Tumor necrosis factor ligand superfamily member 15; TNFSF15; TNF ligand-related molecule 1
T35212	FUNCTION	Receptor for TNFRSF25 and TNFRSF6B. Mediates activation of NF-kappa-B. Inhibits vascular endothelial growth and angiogenesis (in vitro). Promotes activation of caspases and apoptosis.
T35212	PDBSTRUC	3MI8; 3K51; 2RJL; 2RJK; 2RE9
T35212	BIOCLASS	Cytokine: tumor necrosis factor
T35212	SEQUENCE	MAEDLGLSFGETASVEMLPEHGSCRPKARSSSARWALTCCLVLLPFLAGLTTYLLVSQLRAQGEACVQFQALKGQEFAPSHQQVYAPLRADGDKPRAHLTVVRQTPTQHFKNQFPALHWEHELGLAFTKNRMNYTNKFLLIPESGDYFIYSQVTFRGMTSECSEIRQAGRPNKPDSITVVITKVTDSYPEPTQLLMGTKSVCEVGSNWFQPIYLGAMFSLQEGDKLMVNVSDISLVDYTKEDKTFFGAFLL
T35212	DRUGINFO	D61PGU	PRA023	Phase 2
T35212	DRUGINFO	D82MSU	TEV-48574	Phase 2
T35212	DRUGINFO	DMA7E5	PF-07261271	Phase 1

T55703	TARGETID	T55703
T55703	FORMERID	TTDI02366
T55703	UNIPROID	RET4_HUMAN
T55703	TARGNAME	Plasma retinol-binding protein (RBP4)
T55703	GENENAME	RBP4
T55703	TARGTYPE	Clinical trial
T55703	SYNONYMS	Retinol-binding protein 4; RBP4; RBP; Plasma retinol-binding protein(1-176); PRBP
T55703	FUNCTION	Delivers retinol from the liver stores to the peripheral tissues. In plasma, the RBP-retinol complex interacts with transthyretin, this prevents its loss by filtration through the kidney glomeruli.
T55703	PDBSTRUC	5NUB; 5NUA; 5NU9; 5NU8; 5NU7
T55703	BIOCLASS	Calycin family
T55703	SEQUENCE	MKWVWALLLLAALGSGRAERDCRVSSFRVKENFDKARFSGTWYAMAKKDPEGLFLQDNIVAEFSVDETGQMSATAKGRVRLLNNWDVCADMVGTFTDTEDPAKFKMKYWGVASFLQKGNDDHWIVDTDYDTYAVQYSCRLLNLDGTCADSYSFVFSRDPNGLPPEAQKIVRQRQEELCLARQYRLIVHNGYCDGRSERNLL
T55703	DRUGINFO	DCD0M4	Tinlarebant	Phase 3
T55703	DRUGINFO	D01KKC	A1-10436	Patented
T55703	DRUGINFO	D02TPQ	US9434727, 93	Patented
T55703	DRUGINFO	D04BAA	US9434727, 153	Patented
T55703	DRUGINFO	D05AIC	US9434727, 40	Patented
T55703	DRUGINFO	D08PYU	US8586571, 12	Patented
T55703	DRUGINFO	D0D5AI	A1-10438	Patented
T55703	DRUGINFO	D0I1LE	US8586571, 36	Patented
T55703	DRUGINFO	D0IV0E	US8853215, 3	Patented
T55703	DRUGINFO	D0J9YV	US8586571, 6	Patented
T55703	DRUGINFO	D0K0IZ	US9434727, 120	Patented
T55703	DRUGINFO	D0YU9U	US9434727, 63	Patented

T33976	TARGETID	T33976
T33976	FORMERID	TTDR01147
T33976	UNIPROID	TFR1_HUMAN
T33976	TARGNAME	Transferrin receptor protein 1 (TFRC)
T33976	GENENAME	TFRC
T33976	TARGTYPE	Clinical trial
T33976	SYNONYMS	Trfr; TfR1; TfR; TR protein; T9; P90; CD71 antigen; CD71
T33976	FUNCTION	Endosomal acidification leads to iron release. The apotransferrin-receptor complex is then recycled to the cell surface with a return to neutral pH and the concomitant loss of affinity of apotransferrin for its receptor. Transferrin receptor is necessary for development of erythrocytes and the nervous system. A second ligand, the heditary hemochromatosis protein HFE, competes for binding with transferrin for an overlapping C-terminal binding site. Positively regulates T and B cell proliferation through iron uptake. Cellular uptake of iron occurs via receptor-mediated endocytosis of ligand-occupied transferrin receptor into specialized endosomes.
T33976	PDBSTRUC	6H5I; 6GSR; 6D05; 6D04; 6D03
T33976	BIOCLASS	Peptidase
T33976	SEQUENCE	MMDQARSAFSNLFGGEPLSYTRFSLARQVDGDNSHVEMKLAVDEEENADNNTKANVTKPKRCSGSICYGTIAVIVFFLIGFMIGYLGYCKGVEPKTECERLAGTESPVREEPGEDFPAARRLYWDDLKRKLSEKLDSTDFTGTIKLLNENSYVPREAGSQKDENLALYVENQFREFKLSKVWRDQHFVKIQVKDSAQNSVIIVDKNGRLVYLVENPGGYVAYSKAATVTGKLVHANFGTKKDFEDLYTPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVNAELSFFGHAHLGTGDPYTPGFPSFNHTQFPPSRSSGLPNIPVQTISRAAAEKLFGNMEGDCPSDWKTDSTCRMVTSESKNVKLTVSNVLKEIKILNIFGVIKGFVEPDHYVVVGAQRDAWGPGAAKSGVGTALLLKLAQMFSDMVLKDGFQPSRSIIFASWSAGDFGSVGATEWLEGYLSSLHLKAFTYINLDKAVLGTSNFKVSASPLLYTLIEKTMQNVKHPVTGQFLYQDSNWASKVEKLTLDNAAFPFLAYSGIPAVSFCFCEDTDYPYLGTTMDTYKELIERIPELNKVARAAAEVAGQFVIKLTHDVELNLDYERYNSQLLSFVRDLNQYRADIKEMGLSLQWLYSARGDFFRATSRLTTDFGNAEKTDRFVMKKLNDRVMRVEYHFLSPYVSPKESPFRHVFWGSGSHTLPALLENLKLRKQNNGAFNETLFRNQLALATWTIQGAANALSGDVWDIDNEF
T33976	DRUGINFO	DZ1F3N	CX2029	Phase 1/2
T33976	DRUGINFO	D58AMF	ABBV-CX-2029	Phase 1

T95616	TARGETID	T95616
T95616	FORMERID	TTDR00699
T95616	UNIPROID	ITAM_HUMAN
T95616	TARGNAME	Integrin alpha-M (ITGAM)
T95616	GENENAME	ITGAM
T95616	TARGTYPE	Clinical trial
T95616	SYNONYMS	Neutrophil adherence receptor; Leukocyte adhesion receptor MO1; Cell surface glycoprotein Mac-1; Cell surface glycoprotein MAC-1 subunit alpha; Cell surface glycoprotein MAC-1 alpha subunit; CR3A; CR-3 alpha chain; CD11b; CD11 antigen-like family member B
T95616	FUNCTION	It is identical with CR-3, the receptor for the iC3b fragment of the third complement component. It probably recognizes the R-G-D peptide in C3b. Integrin ITGAM/ITGB2 is also a receptor for fibrinogen, factor X and ICAM1. It recognizes P1 and P2 peptides of fibrinogen gamma chain. Regulates neutrophil migration. In association with beta subunit ITGB2/CD18, required for CD177-PRTN3-mediated activation of TNF primed neutrophils. May regulate phagocytosis-induced apoptosis in extravasated neutrophils. May play a role in mast cell development. Required with TYROBP/DAP12 in microglia to control production of microglial superoxide ions which promote the neuronal apoptosis that occurs during brain development. Integrin ITGAM/ITGB2 is implicated in various adhesive interactions of monocytes, macrophages and granulocytes as well as in mediating the uptake of complement-coated particles and pathogens.
T95616	PDBSTRUC	4XW2; 4M76; 3QA3; 3Q3G; 2LKJ
T95616	BIOCLASS	Integrin
T95616	SEQUENCE	MALRVLLLTALTLCHGFNLDTENAMTFQENARGFGQSVVQLQGSRVVVGAPQEIVAANQRGSLYQCDYSTGSCEPIRLQVPVEAVNMSLGLSLAATTSPPQLLACGPTVHQTCSENTYVKGLCFLFGSNLRQQPQKFPEALRGCPQEDSDIAFLIDGSGSIIPHDFRRMKEFVSTVMEQLKKSKTLFSLMQYSEEFRIHFTFKEFQNNPNPRSLVKPITQLLGRTHTATGIRKVVRELFNITNGARKNAFKILVVITDGEKFGDPLGYEDVIPEADREGVIRYVIGVGDAFRSEKSRQELNTIASKPPRDHVFQVNNFEALKTIQNQLREKIFAIEGTQTGSSSSFEHEMSQEGFSAAITSNGPLLSTVGSYDWAGGVFLYTSKEKSTFINMTRVDSDMNDAYLGYAAAIILRNRVQSLVLGAPRYQHIGLVAMFRQNTGMWESNANVKGTQIGAYFGASLCSVDVDSNGSTDLVLIGAPHYYEQTRGGQVSVCPLPRGRARWQCDAVLYGEQGQPWGRFGAALTVLGDVNGDKLTDVAIGAPGEEDNRGAVYLFHGTSGSGISPSHSQRIAGSKLSPRLQYFGQSLSGGQDLTMDGLVDLTVGAQGHVLLLRSQPVLRVKAIMEFNPREVARNVFECNDQVVKGKEAGEVRVCLHVQKSTRDRLREGQIQSVVTYDLALDSGRPHSRAVFNETKNSTRRQTQVLGLTQTCETLKLQLPNCIEDPVSPIVLRLNFSLVGTPLSAFGNLRPVLAEDAQRLFTALFPFEKNCGNDNICQDDLSITFSFMSLDCLVVGGPREFNVTVTVRNDGEDSYRTQVTFFFPLDLSYRKVSTLQNQRSQRSWRLACESASSTEVSGALKSTSCSINHPIFPENSEVTFNITFDVDSKASLGNKLLLKANVTSENNMPRTNKTEFQLELPVKYAVYMVVTSHGVSTKYLNFTASENTSRVMQHQYQVSNLGQRSLPISLVFLVPVRLNQTVIWDRPQVTFSENLSSTCHTKERLPSHSDFLAELRKAPVVNCSIAVCQRIQCDIPFFGIQEEFNATLKGNLSFDWYIKTSHNHLLIVSTAEILFNDSVFTLLPGQGAFVRSQTETKVEPFEVPNPLPLIVGSSVGGLLLLALITAALYKLGFFKRQYKDMMSEGGPPGAEPQ
T95616	DRUGINFO	DZ5K6F	GB1275	Phase 1/2

T73134	TARGETID	T73134
T73134	UNIPROID	BGAL_HUMAN
T73134	TARGNAME	Beta-galactosidase (GLB1)
T73134	GENENAME	GLB1
T73134	TARGTYPE	Clinical trial
T73134	SYNONYMS	Lactase; Elastin receptor 1; ELNR1; Acid beta-galactosidase
T73134	FUNCTION	Isoform 1: Cleaves beta-linked terminal galactosyl residues from gangliosides, glycoproteins, and glycosaminoglycans.
T73134	PDBSTRUC	3WF4; 3WF3; 3WF2; 3WF1; 3WF0
T73134	ECNUMBER	EC 3.2.1.23
T73134	SEQUENCE	MPGFLVRILPLLLVLLLLGPTRGLRNATQRMFEIDYSRDSFLKDGQPFRYISGSIHYSRVPRFYWKDRLLKMKMAGLNAIQTYVPWNFHEPWPGQYQFSEDHDVEYFLRLAHELGLLVILRPGPYICAEWEMGGLPAWLLEKESILLRSSDPDYLAAVDKWLGVLLPKMKPLLYQNGGPVITVQVENEYGSYFACDFDYLRFLQKRFRHHLGDDVVLFTTDGAHKTFLKCGALQGLYTTVDFGTGSNITDAFLSQRKCEPKGPLINSEFYTGWLDHWGQPHSTIKTEAVASSLYDILARGASVNLYMFIGGTNFAYWNGANSPYAAQPTSYDYDAPLSEAGDLTEKYFALRNIIQKFEKVPEGPIPPSTPKFAYGKVTLEKLKTVGAALDILCPSGPIKSLYPLTFIQVKQHYGFVLYRTTLPQDCSNPAPLSSPLNGVHDRAYVAVDGIPQGVLERNNVITLNITGKAGATLDLLVENMGRVNYGAYINDFKGLVSNLTLSSNILTDWTIFPLDTEDAVRSHLGGWGHRDSGHHDEAWAHNSSNYTLPAFYMGNFSIPSGIPDLPQDTFIQFPGWTKGQVWINGFNLGRYWPARGPQLTLFVPQHILMTSAPNTITVLELEWAPCSSDDPELCAVTFVDRPVIGSSVTYDHPSKPVEKRLMPPPPQKNKDSWLDHV
T73134	DRUGINFO	D93JPW	PBGM01	Phase 1/2
T73134	DRUGINFO	DN4O0S	AXO-AAV-GM1	Phase 1/2
T73134	DRUGINFO	DY8D2C	LYS-GM-101	Phase 1/2
T73134	DRUGINFO	D2DLN9	5N,6S-(N'-butyliminomethylidene)-6-thio-1-deoxygalactonojirimycin	Preclinical
T73134	DRUGINFO	DBJ5Z0	N-Octyl-4-epi-beta-valienamine	Preclinical

T64597	TARGETID	T64597
T64597	FORMERID	TTDNR00693
T64597	UNIPROID	ITB8_HUMAN
T64597	TARGNAME	Integrin beta-8 (ITGB8)
T64597	GENENAME	ITGB8
T64597	TARGTYPE	Clinical trial
T64597	SYNONYMS	Integrin subunit beta 8
T64597	FUNCTION	It recognizes the sequence R-G-D in its ligands. Integrin alpha-V:beta-6 (ITGAV:ITGB6) mediates R-G-D-dependent release of transforming growth factor beta-1 (TGF-beta-1) from regulatory Latency-associated peptide (LAP), thereby playing a key role in TGF-beta-1 activation on the surface of activated regulatory T-cells (Tregs). Required during vasculogenesis. Integrin alpha-V:beta-8 (ITGAV:ITGB8) is a receptor for fibronectin.
T64597	PDBSTRUC	6DJP
T64597	BIOCLASS	Integrin
T64597	SEQUENCE	MCGSALAFFTAAFVCLQNDRRGPASFLWAAWVFSLVLGLGQGEDNRCASSNAASCARCLALGPECGWCVQEDFISGGSRSERCDIVSNLISKGCSVDSIEYPSVHVIIPTENEINTQVTPGEVSIQLRPGAEANFMLKVHPLKKYPVDLYYLVDVSASMHNNIEKLNSVGNDLSRKMAFFSRDFRLGFGSYVDKTVSPYISIHPERIHNQCSDYNLDCMPPHGYIHVLSLTENITEFEKAVHRQKISGNIDTPEGGFDAMLQAAVCESHIGWRKEAKRLLLVMTDQTSHLALDSKLAGIVVPNDGNCHLKNNVYVKSTTMEHPSLGQLSEKLIDNNINVIFAVQGKQFHWYKDLLPLLPGTIAGEIESKAANLNNLVVEAYQKLISEVKVQVENQVQGIYFNITAICPDGSRKPGMEGCRNVTSNDEVLFNVTVTMKKCDVTGGKNYAIIKPIGFNETAKIHIHRNCSCQCEDNRGPKGKCVDETFLDSKCFQCDENKCHFDEDQFSSESCKSHKDQPVCSGRGVCVCGKCSCHKIKLGKVYGKYCEKDDFSCPYHHGNLCAGHGECEAGRCQCFSGWEGDRCQCPSAAAQHCVNSKGQVCSGRGTCVCGRCECTDPRSIGRFCEHCPTCYTACKENWNCMQCLHPHNLSQAILDQCKTSCALMEQQHYVDQTSECFSSPSYLRIFFIIFIVTFLIGLLKVLIIRQVILQWNSNKIKSSSDYRVSASKKDKLILQSVCTRAVTYRREKPEEIKMDISKLNAHETFRCNF
T64597	DRUGINFO	D37AYZ	MEDI8367	Phase 1
T64597	DRUGINFO	D04KXV	US10035778, Example 16	Patented
T64597	DRUGINFO	D0QG9P	US10035778, Example 1	Patented
T64597	DRUGINFO	D0UB5E	US10035778, Example 12	Patented

T44057	TARGETID	T44057
T44057	FORMERID	TTDI03034
T44057	UNIPROID	AQP1_HUMAN
T44057	TARGNAME	Aquaporin-1 (AQP1)
T44057	GENENAME	AQP1
T44057	TARGTYPE	Clinical trial
T44057	SYNONYMS	Water channel protein for red blood cells and kidney proximal tubule; Urine water channel; CHIP28; Aquaporin-CHIP; AQP-1
T44057	FUNCTION	Forms a water-specific channel that provides the plasma membranes of red cells and kidney proximal tubules with high permeability to water, thereby permitting water to move in the direction of an osmotic gradient.
T44057	PDBSTRUC	4CSK; 1IH5; 1H6I; 1FQY
T44057	BIOCLASS	Major intrinsic protein
T44057	SEQUENCE	MASEFKKKLFWRAVVAEFLATTLFVFISIGSALGFKYPVGNNQTAVQDNVKVSLAFGLSIATLAQSVGHISGAHLNPAVTLGLLLSCQISIFRALMYIIAQCVGAIVATAILSGITSSLTGNSLGRNDLADGVNSGQGLGIEIIGTLQLVLCVLATTDRRRRDLGGSAPLAIGLSVALGHLLAIDYTGCGINPARSFGSAVITHNFSNHWIFWVGPFIGGALAVLIYDFILAPRSSDLTDRVKVWTSGQVEEYDLDADDINSRVEMKPK
T44057	DRUGINFO	D4IWF1	AAV-AQP1	Phase 1/2
T44057	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T74066	TARGETID	T74066
T74066	FORMERID	TTDI02553
T74066	UNIPROID	BMI1_HUMAN
T74066	TARGNAME	Polycomb complex protein BMI-1 (BMI1)
T74066	GENENAME	BMI1
T74066	TARGTYPE	Clinical trial
T74066	SYNONYMS	RNF51; RING finger protein 51; Polycomb group RING finger protein 4; PCGF4
T74066	FUNCTION	PcG PRC1 complex acts via chromatin remodeling and modification of histones; it mediates monoubiquitination of histone H2A 'Lys-119', rendering chromatin heritably changed in its expressibility. The complex composed of RNF2, UB2D3 and BMI1 binds nucleosomes, and has activity only with nucleosomal histone H2A. In the PRC1-like complex, regulates the E3 ubiquitin-protein ligase activity of RNF2/RING2. Component of a Polycomb group (PcG) multiprotein PRC1-like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development.
T74066	PDBSTRUC	5FR6; 4R8P; 3RPG; 2NA1; 2H0D
T74066	BIOCLASS	Zinc-finger
T74066	SEQUENCE	MHRTTRIKITELNPHLMCVLCGGYFIDATTIIECLHSFCKTCIVRYLETSKYCPICDVQVHKTRPLLNIRSDKTLQDIVYKLVPGLFKNEMKRRRDFYAAHPSADAANGSNEDRGEVADEDKRIITDDEIISLSIEFFDQNRLDRKVNKDKEKSKEEVNDKRYLRCPAAMTVMHLRKFLRSKMDIPNTFQIDVMYEEEPLKDYYTLMDIAYIYTWRRNGPLPLKYRVRPTCKRMKISHQRDGLTNAGELESDSGSDKANSPAGGIPSTSSCLPSPSTPVQSPHPQFPHISSTMNGTSNSPSGNHQSSFANRPRKSSVNGSSATSSG
T74066	DRUGINFO	DUH2E6	Unesbulin	Phase 2/3

T20629	TARGETID	T20629
T20629	FORMERID	TTDR00834
T20629	UNIPROID	ADML_HUMAN
T20629	TARGNAME	Adrenomedullin (ADM)
T20629	GENENAME	ADM
T20629	TARGTYPE	Clinical trial
T20629	SYNONYMS	AM; ADM
T20629	FUNCTION	AM and PAMP are potent hypotensive and vasodilatator agents. Numerous actions have been reported most related to the physiologic control of fluid and electrolyte homeostasis. In the kidney, am is diuretic and natriuretic, and both am and pamp inhibit aldosterone secretion by direct adrenal actions. In pituitary gland, both peptides at physiologically relevant doses inhibit basal ACTH secretion. Both peptides appear to act in brain and pituitary gland to facilitate the loss of plasma volume, actions which complement their hypotensive effects in blood vessels.
T20629	PDBSTRUC	5V6Y; 4RWF; 2L7S; 2FLY
T20629	BIOCLASS	Adrenomedullin
T20629	SEQUENCE	MKLVSVALMYLGSLAFLGADTARLDVASEFRKKWNKWALSRGKRELRMSSSYPTGLADVKAGPAQTLIRPQDMKGASRSPEDSSPDAARIRVKRYRQSMNNFQGLRSFGCRFGTCTVQKLAHQIYQFTDKDKDNVAPRSKISPQGYGRRRRRSLPEAGPGRTLVSSKPQAHGAPAPPSGSAPHFL
T20629	DRUGINFO	DK8BS7	BAY1097761	Phase 2

T85221	TARGETID	T85221
T85221	FORMERID	TTDR00474
T85221	UNIPROID	G6PC_HUMAN
T85221	TARGNAME	Glucose-6-phosphatase (G6PC)
T85221	GENENAME	G6PC
T85221	TARGTYPE	Clinical trial
T85221	SYNONYMS	Glucose-6-phosphatase alpha; G6Pase-alpha; G6Pase; G6PT; G-6-Pase
T85221	FUNCTION	Forms with the glucose-6-phosphate transporter (SLC37A4/G6PT) the complex responsible for glucose production through glycogenolysis and gluconeogenesis. Hence, it is the key enzyme in homeostatic regulation of blood glucose levels. Hydrolyzes glucose-6-phosphate to glucose in the endoplasmic reticulum.
T85221	BIOCLASS	Phosphoric monoester hydrolase
T85221	ECNUMBER	EC 3.1.3.9
T85221	SEQUENCE	MEEGMNVLHDFGIQSTHYLQVNYQDSQDWFILVSVIADLRNAFYVLFPIWFHLQEAVGIKLLWVAVIGDWLNLVFKWILFGQRPYWWVLDTDYYSNTSVPLIKQFPVTCETGPGSPSGHAMGTAGVYYVMVTSTLSIFQGKIKPTYRFRCLNVILWLGFWAVQLNVCLSRIYLAAHFPHQVVAGVLSGIAVAETFSHIHSIYNASLKKYFLITFFLFSFAIGFYLLLKGLGVDLLWTLEKAQRWCEQPEWVHIDTTPFASLLKNLGTLFGLGLALNSSMYRESCKGKLSKWLPFRLSSIVASLVLLHVFDSLKPPSQVELVFYVLSFCKSAVVPLASVSVIPYCLAQVLGQPHKKSL
T85221	DRUGINFO	D5WAG1	DTX401	Phase 1

T44513	TARGETID	T44513
T44513	FORMERID	TTDR01128
T44513	UNIPROID	CEAM6_HUMAN
T44513	TARGNAME	Normal cross-reacting antigen (CD66c)
T44513	GENENAME	CEACAM6
T44513	TARGTYPE	Clinical trial
T44513	SYNONYMS	Nonspecific crossreacting antigen; Non-specific crossreacting antigen; NCA; Carcinoembryonic antigen-related cell adhesion molecule 6; CD66c antigen
T44513	FUNCTION	Intercellular adhesion occurs in a calcium- and fibronectin-independent manner. Mediates homophilic and heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM5 and CEACAM8. Heterophilic interaction with CEACAM8 occurs in activated neutrophils. Plays a role in neutrophil adhesion to cytokine-activated endothelial cells. Plays a role as an oncogene by promoting tumor progression; positively regulates cell migration, cell adhesion to endothelial cells and cell invasion. Also involved in the metastatic cascade process by inducing gain resistance to anoikis of pancreatic adenocarcinoma and colorectal carcinoma cells. Cell surface glycoprotein that plays a role in cell adhesion and tumor progression.
T44513	PDBSTRUC	4YIQ; 4Y8A; 4WTZ; 4WHC
T44513	BIOCLASS	Immunoglobulin
T44513	SEQUENCE	MGPPSAPPCRLHVPWKEVLLTASLLTFWNPPTTAKLTIESTPFNVAEGKEVLLLAHNLPQNRIGYSWYKGERVDGNSLIVGYVIGTQQATPGPAYSGRETIYPNASLLIQNVTQNDTGFYTLQVIKSDLVNEEATGQFHVYPELPKPSISSNNSNPVEDKDAVAFTCEPEVQNTTYLWWVNGQSLPVSPRLQLSNGNMTLTLLSVKRNDAGSYECEIQNPASANRSDPVTLNVLYGPDGPTISPSKANYRPGENLNLSCHAASNPPAQYSWFINGTFQQSTQELFIPNITVNNSGSYMCQAHNSATGLNRTTVTMITVSGSAPVLSAVATVGITIGVLARVALI
T44513	DRUGINFO	D5T1RN	BAY 1834942	Phase 1

T00852	TARGETID	T00852
T00852	FORMERID	TTDI01377
T00852	UNIPROID	M3K8_HUMAN
T00852	TARGNAME	Serine/threonine-protein kinase cot (COT)
T00852	GENENAME	MAP3K8
T00852	TARGTYPE	Clinical trial
T00852	SYNONYMS	Tumor progression locus 2; TPL-2; Proto-oncogene c-Cot; Mitogen-activated protein kinase kinase kinase 8; ESTF; Cancer Osaka thyroid oncogene; COT
T00852	FUNCTION	Required for lipopolysaccharide (LPS)-induced, TLR4-mediated activation of the MAPK/ERK pathway in macrophages, thus being critical for production of the proinflammatory cytokine TNF-alpha (TNF) during immune responses. Involved in the regulation of T-helper cell differentiation and IFNG expression in T-cells. Involved in mediating host resistance to bacterial infection through negative regulation of type I interferon (IFN) production. In vitro, activates MAPK/ERK pathway in response to IL1 in an IRAK1-independent manner, leading to up-regulation of IL8 and CCL4. Transduces CD40 and TNFRSF1A signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production. May also play a role in the transduction of TNF signals that activate JNK and NF-kappa-B in some cell types. In adipocytes, activates MAPK/ERK pathway in an IKBKB-dependent manner in response to IL1B and TNF, but not insulin, leading to induction of lipolysis. Plays a role in the cell cycle. Isoform 1 shows some transforming activity, although it is much weaker than that of the activated oncogenic variant.
T00852	PDBSTRUC	5IU2; 4Y85; 4Y83
T00852	ECNUMBER	EC 2.7.11.25
T00852	SEQUENCE	MEYMSTGSDNKEEIDLLIKHLNVSDVIDIMENLYASEEPAVYEPSLMTMCQDSNQNDERSKSLLLSGQEVPWLSSVRYGTVEDLLAFANHISNTAKHFYGQRPQESGILLNMVITPQNGRYQIDSDVLLIPWKLTYRNIGSDFIPRGAFGKVYLAQDIKTKKRMACKLIPVDQFKPSDVEIQACFRHENIAELYGAVLWGETVHLFMEAGEGGSVLEKLESCGPMREFEIIWVTKHVLKGLDFLHSKKVIHHDIKPSNIVFMSTKAVLVDFGLSVQMTEDVYFPKDLRGTEIYMSPEVILCRGHSTKADIYSLGATLIHMQTGTPPWVKRYPRSAYPSYLYIIHKQAPPLEDIADDCSPGMRELIEASLERNPNHRPRAADLLKHEALNPPREDQPRCQSLDSALLERKRLLSRKELELPENIADSSCTGSTEESEMLKRQRSLYIDLGALAGYFNLVRGPPTLEYG
T00852	DRUGINFO	D1BA7Z	GS-5290	Phase 1

T72024	TARGETID	T72024
T72024	FORMERID	TTDI02614
T72024	UNIPROID	GALC_HUMAN
T72024	TARGNAME	Galactocerebrosidase (GALC)
T72024	GENENAME	GALC
T72024	TARGTYPE	Clinical trial
T72024	SYNONYMS	Galactosylceramide betagalactosidase; Galactosylceramide beta-galactosidase; Galactosylceramidase; Galactocerebroside betagalactosidase; Galactocerebroside beta-galactosidase; GALCERase
T72024	FUNCTION	Enzyme with very low activity responsible for the lysosomal catabolism of galactosylceramide, a major lipid in myelin, kidney and epithelial cells of small intestine and colon. Hydrolyzes the galactose ester bonds of galactosylceramide, galactosylsphingosine, lactosylceramide, and monogalactosyldiglyceride.
T72024	BIOCLASS	Glycosylase
T72024	ECNUMBER	EC 3.2.1.46
T72024	SEQUENCE	MAEWLLSASWQRRAKAMTAAAGSAGRAAVPLLLCALLAPGGAYVLDDSDGLGREFDGIGAVSGGGATSRLLVNYPEPYRSQILDYLFKPNFGASLHILKVEIGGDGQTTDGTEPSHMHYALDENYFRGYEWWLMKEAKKRNPNITLIGLPWSFPGWLGKGFDWPYVNLQLTAYYVVTWIVGAKRYHDLDIDYIGIWNERSYNANYIKILRKMLNYQGLQRVKIIASDNLWESISASMLLDAELFKVVDVIGAHYPGTHSAKDAKLTGKKLWSSEDFSTLNSDMGAGCWGRILNQNYINGYMTSTIAWNLVASYYEQLPYGRCGLMTAQEPWSGHYVVESPVWVSAHTTQFTQPGWYYLKTVGHLEKGGSYVALTDGLGNLTIIIETMSHKHSKCIRPFLPYFNVSQQFATFVLKGSFSEIPELQVWYTKLGKTSERFLFKQLDSLWLLDSDGSFTLSLHEDELFTLTTLTTGRKGSYPLPPKSQPFPSTYKDDFNVDYPFFSEAPNFADQTGVFEYFTNIEDPGEHHFTLRQVLNQRPITWAADASNTISIIGDYNWTNLTIKCDVYIETPDTGGVFIAGRVNKGGILIRSARGIFFWIFANGSYRVTGDLAGWIIYALGRVEVTAKKWYTLTLTIKGHFTSGMLNDKSLWTDIPVNFPKNGWAAIGTHSFEFAQFDNFLVEATR
T72024	DRUGINFO	D0LJ4H	PBKR03	Phase 1/2
T72024	DRUGINFO	D62OSE	FBX-101	Phase 1/2

T59554	TARGETID	T59554
T59554	FORMERID	TTDI01430
T59554	UNIPROID	DPRE1_MYCTU
T59554	TARGNAME	Mycobacterium Decaprenylphosphoryl-beta-D-ribose oxidase (McyB dprE1)
T59554	GENENAME	McyB dprE1
T59554	TARGTYPE	Clinical trial
T59554	SYNONYMS	FAD-dependent decaprenylphosphoryl-beta-D-ribofuranose 2-oxidase; Decaprenylphosphoryl-beta-D-ribose oxidase; Decaprenylphosphoryl-beta-D-ribose 2-epimerase flavoprotein subunit; Decaprenylphosphoryl-beta-D-ribofuranose 2'-oxidase; Decaprenylphosphoryl-beta-D-ribofuranose 2'-epimerase subunit DprE1; Decaprenylphospho-beta-D-ribofuranose 2-dehydrogenase; Decaprenyl-phosphoribose 2'-epimerase subunit 1
T59554	FUNCTION	Component of the DprE1-DprE2 complex that catalyzes the 2-step epimerization of decaprenyl-phospho-ribose (DPR) to decaprenyl-phospho-arabinose (DPA), a key precursor that serves as the arabinose donor required for the synthesis of cell-wall arabinans. DprE1 catalyzes the first step of epimerization, namely FAD-dependent oxidation of the C2' hydroxyl of DPR to yield the keto intermediate decaprenyl-phospho-2'-keto-D-arabinose (DPX). The intermediate DPX is then transferred to DprE2 subunit of the epimerase complex, most probably through a 'substrate channel' at the interface of DprE1-DprE2 complex. Can also use farnesyl-phosphoryl-beta-D-ribofuranose (FPR) as substrate in vitro. Appears to be essential for the growth and survival of M.tuberculosis.
T59554	PDBSTRUC	6HFW; 6HFV; 6HF3; 6HF0; 6HEZ
T59554	ECNUMBER	EC 1.1.98.3
T59554	SEQUENCE	MLSVGATTTATRLTGWGRTAPSVANVLRTPDAEMIVKAVARVAESGGGRGAIARGLGRSYGDNAQNGGGLVIDMTPLNTIHSIDADTKLVDIDAGVNLDQLMKAALPFGLWVPVLPGTRQVTVGGAIACDIHGKNHHSAGSFGNHVRSMDLLTADGEIRHLTPTGEDAELFWATVGGNGLTGIIMRATIEMTPTSTAYFIADGDVTASLDETIALHSDGSEARYTYSSAWFDAISAPPKLGRAAVSRGRLATVEQLPAKLRSEPLKFDAPQLLTLPDVFPNGLANKYTFGPIGELWYRKSGTYRGKVQNLTQFYHPLDMFGEWNRAYGPAGFLQYQFVIPTEAVDEFKKIIGVIQASGHYSFLNVFKLFGPRNQAPLSFPIPGWNICVDFPIKDGLGKFVSELDRRVLEFGGRLYTAKDSRTTAETFHAMYPRVDEWISVRRKVDPLRVFASDMARRLELL
T59554	DRUGINFO	DCYV91	TBA-7371	Phase 2
T59554	DRUGINFO	DVK21S	BTZ-043	Phase 2
T59554	DRUGINFO	D8AF1M	OPC-167832	Phase 1/2
T59554	DRUGINFO	DTO06Y	Macozinone	Phase 1

T94880	TARGETID	T94880
T94880	FORMERID	TTDI03607
T94880	UNIPROID	TYRO3_HUMAN
T94880	TARGNAME	TYRO3 tyrosine kinase receptor (TYRO3)
T94880	GENENAME	TYRO3
T94880	TARGTYPE	Clinical trial
T94880	SYNONYMS	Tyrosine-protein kinase receptor TYRO3; Tyrosine-protein kinase TIF; Tyrosine-protein kinase SKY; Tyrosine-protein kinase RSE; Tyrosine-protein kinase DTK; Tyrosine-protein kinase BYK; TIF; SKY; RSE; DTK; BYK
T94880	FUNCTION	Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to several ligands including TULP1 or GAS6. Regulates many physiological processes including cell survival, migration and differentiation. Ligand binding at the cell surface induces dimerization and autophosphorylation of TYRO3 on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with PIK3R1 and thereby enhances PI3-kinase activity. Activates the AKT survival pathway, including nuclear translocation of NF-kappa-B and up-regulation of transcription of NF-kappa-B-regulated genes. TYRO3 signaling plays a role in various processes such as neuron protection from excitotoxic injury, platelet aggregation and cytoskeleton reorganization. Plays also an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1, which selectively induces production of suppressors of cytokine signaling SOCS1 and SOCS3.
T94880	PDBSTRUC	1RHF
T94880	ECNUMBER	EC 2.7.10.1
T94880	SEQUENCE	MALRRSMGRPGLPPLPLPPPPRLGLLLAALASLLLPESAAAGLKLMGAPVKLTVSQGQPVKLNCSVEGMEEPDIQWVKDGAVVQNLDQLYIPVSEQHWIGFLSLKSVERSDAGRYWCQVEDGGETEISQPVWLTVEGVPFFTVEPKDLAVPPNAPFQLSCEAVGPPEPVTIVWWRGTTKIGGPAPSPSVLNVTGVTQSTMFSCEAHNLKGLASSRTATVHLQALPAAPFNITVTKLSSSNASVAWMPGADGRALLQSCTVQVTQAPGGWEVLAVVVPVPPFTCLLRDLVPATNYSLRVRCANALGPSPYADWVPFQTKGLAPASAPQNLHAIRTDSGLILEWEEVIPEAPLEGPLGPYKLSWVQDNGTQDELTVEGTRANLTGWDPQKDLIVRVCVSNAVGCGPWSQPLVVSSHDRAGQQGPPHSRTSWVPVVLGVLTALVTAAALALILLRKRRKETRFGQAFDSVMARGEPAVHFRAARSFNRERPERIEATLDSLGISDELKEKLEDVLIPEQQFTLGRMLGKGEFGSVREAQLKQEDGSFVKVAVKMLKADIIASSDIEEFLREAACMKEFDHPHVAKLVGVSLRSRAKGRLPIPMVILPFMKHGDLHAFLLASRIGENPFNLPLQTLIRFMVDIACGMEYLSSRNFIHRDLAARNCMLAEDMTVCVADFGLSRKIYSGDYYRQGCASKLPVKWLALESLADNLYTVQSDVWAFGVTMWEIMTRGQTPYAGIENAEIYNYLIGGNRLKQPPECMEDVYDLMYQCWSADPKQRPSFTCLRMELENILGQLSVLSASQDPLYINIERAEEPTAGGSLELPGRDQPYSGAGDGSGMGAVGGTPSDCRYILTPGGLAEQPGQAEHQPESPLNETQRLLLLQQGLLPHSSC
T94880	DRUGINFO	D7HZ3T	RXDX-106	Phase 1
T94880	DRUGINFO	D03RHV	BDBM50444058	Patented
T94880	DRUGINFO	D08OEW	BDBM50444062	Patented
T94880	DRUGINFO	D0E0YY	KRDULPYOVRWKMA-UHFFFAOYSA-N	Patented
T94880	DRUGINFO	D0M9TR	BDBM50444059	Patented
T94880	DRUGINFO	D0N8QO	US10053465, 8	Patented
T94880	DRUGINFO	D0X7WG	US10053465, 12	Patented
T94880	DRUGINFO	D0ZY9S	US10053465, 5	Patented
T94880	DRUGINFO	D09TFN	LDC1267	Investigative

T63083	TARGETID	T63083
T63083	FORMERID	TTDR00922
T63083	UNIPROID	RAD51_HUMAN
T63083	TARGNAME	DNA repair protein RAD51 homolog 1 (RAD51)
T63083	GENENAME	RAD51
T63083	TARGTYPE	Clinical trial
T63083	SYNONYMS	hRAD51; RECA; RAD51A; RAD51 homolog A; HsRAD51
T63083	FUNCTION	Plays an important role in homologous strand exchange, a key step in DNA repair through homologous recombination (HR). Binds to single and double-stranded DNA and exhibits DNA-dependent ATPase activity. Catalyzes the recognition of homology and strand exchange between homologous DNA partners to form a joint molecule between a processed DNA break and the repair template. Binds to single-stranded DNA in an ATP-dependent manner to form nucleoprotein filaments which are essential for the homology search and strand exchange. Part of a PALB2-scaffolded HR complex containing BRCA2 and RAD51C and which is thought to play a role in DNA repair by HR. Plays a role in regulating mitochondrial DNA copy number under conditions of oxidative stress in the presence of RAD51C and XRCC3. Also involved in interstrand cross-link repair.
T63083	PDBSTRUC	5NWL; 5NP7; 5JZC; 5H1C; 5H1B
T63083	SEQUENCE	MAMQMQLEANADTSVEEESFGPQPISRLEQCGINANDVKKLEEAGFHTVEAVAYAPKKELINIKGISEAKADKILAEAAKLVPMGFTTATEFHQRRSEIIQITTGSKELDKLLQGGIETGSITEMFGEFRTGKTQICHTLAVTCQLPIDRGGGEGKAMYIDTEGTFRPERLLAVAERYGLSGSDVLDNVAYARAFNTDHQTQLLYQASAMMVESRYALLIVDSATALYRTDYSGRGELSARQMHLARFLRMLLRLADEFGVAVVITNQVVAQVDGAAMFAADPKKPIGGNIIAHASTTRLYLRKGRGETRICKIYDSPCLPEAEAMFAINADGVGDAKD
T63083	DRUGINFO	DR5VQ1	CYT-0851	Phase 1/2
T63083	DRUGINFO	D00ICA	AMP-PNP	Investigative

T73404	TARGETID	T73404
T73404	FORMERID	TTDI02500
T73404	UNIPROID	CD166_HUMAN
T73404	TARGNAME	Activated leukocyte cell adhesionmolecule (ALCAM)
T73404	GENENAME	ALCAM
T73404	TARGTYPE	Clinical trial
T73404	SYNONYMS	MEMD; CD166 antigen; CD166; Activated leukocyte cell adhesion molecule
T73404	FUNCTION	Promotes T-cell activation and proliferation via its interactions with CD6. Contributes to the formation and maturation of the immunological synapse via its interactions with CD6. Mediates homotypic interactions with cells that express ALCAM. Required for normal hematopoietic stem cell engraftment in the bone marrow. Mediates attachment of dendritic cells onto endothelial cells via homotypic interaction. Inhibits endothelial cell migration and promotes endothelial tube formation via homotypic interactions. Required for normal organization of the lymph vessel network. Required for normal hematopoietic stem cell engraftment in the bone marrow. Plays a role in hematopoiesis; required for normal numbers of hematopoietic stem cells in bone marrow. Promotes in vitro osteoblast proliferation and differentiation. Promotes neurite extension, axon growth and axon guidance; axons grow preferentially on surfaces that contain ALCAM. Mediates outgrowth and pathfinding for retinal ganglion cell axons. Cell adhesion molecule that mediates both heterotypic cell-cell contacts via its interaction with CD6, as well as homotypic cell-cell contacts.
T73404	PDBSTRUC	5A2F; 1KJC
T73404	BIOCLASS	Basigin protein
T73404	SEQUENCE	MESKGASSCRLLFCLLISATVFRPGLGWYTVNSAYGDTIIIPCRLDVPQNLMFGKWKYEKPDGSPVFIAFRSSTKKSVQYDDVPEYKDRLNLSENYTLSISNARISDEKRFVCMLVTEDNVFEAPTIVKVFKQPSKPEIVSKALFLETEQLKKLGDCISEDSYPDGNITWYRNGKVLHPLEGAVVIIFKKEMDPVTQLYTMTSTLEYKTTKADIQMPFTCSVTYYGPSGQKTIHSEQAVFDIYYPTEQVTIQVLPPKNAIKEGDNITLKCLGNGNPPPEEFLFYLPGQPEGIRSSNTYTLTDVRRNATGDYKCSLIDKKSMIASTAITVHYLDLSLNPSGEVTRQIGDALPVSCTISASRNATVVWMKDNIRLRSSPSFSSLHYQDAGNYVCETALQEVEGLKKRESLTLIVEGKPQIKMTKKTDPSGLSKTIICHVEGFPKPAIQWTITGSGSVINQTEESPYINGRYYSKIIISPEENVTLTCTAENQLERTVNSLNVSAISIPEHDEADEISDENREKVNDQAKLIVGIVVGLLLAALVAGVVYWLYMKKSKTASKHVNKDLGNMEENKKLEENNHKTEA
T73404	DRUGINFO	D1PC9J	CX2009	Phase 2

T35423	TARGETID	T35423
T35423	FORMERID	TTDI02638
T35423	UNIPROID	VTCN1_HUMAN
T35423	TARGNAME	Immune costimulatory protein B7H4 (VTCN1)
T35423	GENENAME	VTCN1
T35423	TARGTYPE	Clinical trial
T35423	SYNONYMS	VTCN1; V-set domain-containing T-cell activation inhibitor 1; T-cell costimulatory molecule B7x; Protein B7S1; B7h.5
T35423	FUNCTION	Negatively regulates T-cell-mediated immune response byinhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. When expressed on the cell surface of tumor macrophages, plays an important role, together with regulatory T-cells (Treg), in the suppression of tumor- associated antigen-specific T-cell immunity. Involved in promoting epithelial cell transformation.
T35423	PDBSTRUC	4GOS
T35423	BIOCLASS	Immunoglobulin
T35423	SEQUENCE	MASLGQILFWSIISIIIILAGAIALIIGFGISGRHSITVTTVASAGNIGEDGILSCTFEPDIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNVQLTDAGTYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVVWASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKVTESEIKRRSHLQLLNSKASLCVSSFFAISWALLPLSPYLMLK
T35423	DRUGINFO	DD10IZ	AZD8205	Phase 2
T35423	DRUGINFO	D7WMF3	PF-07260437	Phase 1

T26900	TARGETID	T26900
T26900	FORMERID	TTDI03226
T26900	UNIPROID	DCE1_HUMAN
T26900	TARGNAME	Glutamic acid decarboxylase 1 (GAD1)
T26900	GENENAME	GAD1
T26900	TARGTYPE	Clinical trial
T26900	SYNONYMS	Glutamate decarboxylase 67 kDa isoform; Glutamate decarboxylase 1; GAD67; GAD-67; GAD; 67 kDa glutamic acid decarboxylase
T26900	FUNCTION	Catalyzes the production of GABA.
T26900	PDBSTRUC	3VP6; 2OKJ
T26900	ECNUMBER	EC 4.1.1.15
T26900	SEQUENCE	MASSTPSSSATSSNAGADPNTTNLRPTTYDTWCGVAHGCTRKLGLKICGFLQRTNSLEEKSRLVSAFKERQSSKNLLSCENSDRDARFRRTETDFSNLFARDLLPAKNGEEQTVQFLLEVVDILLNYVRKTFDRSTKVLDFHHPHQLLEGMEGFNLELSDHPESLEQILVDCRDTLKYGVRTGHPRFFNQLSTGLDIIGLAGEWLTSTANTNMFTYEIAPVFVLMEQITLKKMREIVGWSSKDGDGIFSPGGAISNMYSIMAARYKYFPEVKTKGMAAVPKLVLFTSEQSHYSIKKAGAALGFGTDNVILIKCNERGKIIPADFEAKILEAKQKGYVPFYVNATAGTTVYGAFDPIQEIADICEKYNLWLHVDAAWGGGLLMSRKHRHKLNGIERANSVTWNPHKMMGVLLQCSAILVKEKGILQGCNQMCAGYLFQPDKQYDVSYDTGDKAIQCGRHVDIFKFWLMWKAKGTVGFENQINKCLELAEYLYAKIKNREEFEMVFNGEPEHTNVCFWYIPQSLRGVPDSPQRREKLHKVAPKIKALMMESGTTMVGYQPQGDKANFFRMVISNPAATQSDIDFLIEEIERLGQDL
T26900	DRUGINFO	D6CS1B	AAV-GAD	Phase 2
T26900	DRUGINFO	D09OTM	s-allylglycine	Investigative

T16808	TARGETID	T16808
T16808	FORMERID	TTDI03484
T16808	UNIPROID	ANM1_HUMAN
T16808	TARGNAME	Protein arginine methyltransferase 1 (PRMT1)
T16808	GENENAME	PRMT1
T16808	TARGTYPE	Clinical trial
T16808	SYNONYMS	Protein arginine N-methyltransferase 1; Interferon receptor 1-bound protein 4; IR1B4; Histone-arginine N-methyltransferase PRMT1; HRMT1L2; HMT2
T16808	FUNCTION	Constitutes the main enzyme that mediates monomethylation and asymmetric dimethylation of histone H4 'Arg-4' (H4R3me1 and H4R3me2a, respectively), a specific tag for epigenetic transcriptional activation. May be involved in the regulation of TAF15 transcriptional activity, act as an activator of estrogen receptor (ER)-mediated transactivation, play a key role in neurite outgrowth and act as a negative regulator of megakaryocytic differentiation, by modulating p38 MAPK pathway. Methylates RBM15, promoting ubiquitination and degradation of RBM15. Methylates FOXO1 and retains it in the nucleus increasing its transcriptional activity. Methylates CHTOP and this methylation is critical for its 5-hydroxymethylcytosine (5hmC)-binding activity. Methylates H4R3 in genes involved in glioblastomagenesis in a CHTOP- and/or TET1-dependent manner. Arginine methyltransferase that methylates (mono and asymmetric dimethylation) the guanidino nitrogens of arginyl residues present in proteins such as ESR1, histone H2, H3 and H4, ILF3, HNRNPA1, HNRNPD, NFATC2IP, SUPT5H, TAF15, EWS, HABP4 and SERBP1.
T16808	BIOCLASS	Methyltransferase
T16808	ECNUMBER	EC 2.1.1.319
T16808	SEQUENCE	MAAAEAANCIMENFVATLANGMSLQPPLEEVSCGQAESSEKPNAEDMTSKDYYFDSYAHFGIHEEMLKDEVRTLTYRNSMFHNRHLFKDKVVLDVGSGTGILCMFAAKAGARKVIGIECSSISDYAVKIVKANKLDHVVTIIKGKVEEVELPVEKVDIIISEWMGYCLFYESMLNTVLYARDKWLAPDGLIFPDRATLYVTAIEDRQYKDYKIHWWENVYGFDMSCIKDVAIKEPLVDVVDPKQLVTNACLIKEVDIYTVKVEDLTFTSPFCLQVKRNDYVHALVAYFNIEFTRCHKRTGFSTSPESPYTHWKQTVFYMEDYLTVKTGEEIFGTIGMRPNAKNNRDLDFTIDLDFKGQLCELSCSTDYRMR
T16808	DRUGINFO	DHYZ53	GSK3368715	Phase 1
T16808	DRUGINFO	D05UWW	RM65	Investigative
T16808	DRUGINFO	D09AFM	AMI-1	Investigative

T33245	TARGETID	T33245
T33245	FORMERID	TTDI01723
T33245	UNIPROID	GDF15_HUMAN
T33245	TARGNAME	Growth/differentiation factor 15 (GDF15)
T33245	GENENAME	GDF15
T33245	TARGTYPE	Clinical trial
T33245	SYNONYMS	Prostate differentiation factor; Placental bone morphogenetic protein; Placental TGF-beta; NSAID-regulated gene 1 protein; NSAID-activated gene 1 protein; NRG-1; NAG-1; Macrophage inhibitory cytokine 1; MIC1; MIC-1; GDF-15
T33245	FUNCTION	Regulates food intake, energy expenditure and body weight in response to metabolic and toxin-induced stresses. Binds to its receptor, GFRAL, and activates GFRAL-expressing neurons localized in the area postrema and nucleus tractus solitarius of the brainstem. It then triggers the activation of neurons localized within the parabrachial nucleus and central amygdala, which contitutes part of the 'emergency circuit' that shapes feeding responses to stressful conditions. On hepatocytes, inhibits growth hormone signaling (By similarity).
T33245	PDBSTRUC	5VZ4; 5VZ3; 5VT2
T33245	BIOCLASS	Growth factor
T33245	SEQUENCE	MPGQELRTVNGSQMLLVLLVLSWLPHGGALSLAEASRASFPGPSELHSEDSRFRELRKRYEDLLTRLRANQSWEDSNTDLVPAPAVRILTPEVRLGSGGHLHLRISRAALPEGLPEASRLHRALFRLSPTASRSWDVTRPLRRQLSLARPQAPALHLRLSPPPSQSDQLLAESSSARPQLELHLRPQAARGRRRARARNGDHCPLGPGRCCRLHTVRASLEDLGWADWVLSPREVQVTMCIGACPSQFRAANMHAQIKTSLHRLKPDTVPAPCCVPASYNPMVLIQKTDTGVSLQTYDDLLAKDCHCI
T33245	DRUGINFO	D97BHT	Ponsegromab	Phase 2
T33245	DRUGINFO	D2OEG6	CIN-109	Phase 1
T33245	DRUGINFO	D7FL3H	CIN-209	Preclinical

T30495	TARGETID	T30495
T30495	FORMERID	TTDR01323
T30495	UNIPROID	SIK2_HUMAN
T30495	TARGNAME	Salt-inducible kinase 2 (SIK2)
T30495	GENENAME	SIK2
T30495	TARGTYPE	Clinical trial
T30495	SYNONYMS	Serine/threonine-protein kinase SNF1-like kinase 2; Serine/threonine-protein kinase SIK2; SNF1LK2; SIK-2; Qin-induced kinase; QIK; KIAA0781
T30495	FUNCTION	Phosphorylates 'Ser-794' of IRS1 in insulin-stimulated adipocytes, potentially modulating the efficiency of insulin signal transduction. Inhibits CREB activity by phosphorylating and repressing TORCs, the CREB-specific coactivators.
T30495	ECNUMBER	EC 2.7.11.1
T30495	SEQUENCE	MVMADGPRHLQRGPVRVGFYDIEGTLGKGNFAVVKLGRHRITKTEVAIKIIDKSQLDAVNLEKIYREVQIMKMLDHPHIIKLYQVMETKSMLYLVTEYAKNGEIFDYLANHGRLNESEARRKFWQILSAVDYCHGRKIVHRDLKAENLLLDNNMNIKIADFGFGNFFKSGELLATWCGSPPYAAPEVFEGQQYEGPQLDIWSMGVVLYVLVCGALPFDGPTLPILRQRVLEGRFRIPYFMSEDCEHLIRRMLVLDPSKRLTIAQIKEHKWMLIEVPVQRPVLYPQEQENEPSIGEFNEQVLRLMHSLGIDQQKTIESLQNKSYNHFAAIYFLLVERLKSHRSSFPVEQRLDGRQRRPSTIAEQTVAKAQTVGLPVTMHSPNMRLLRSALLPQASNVEAFSFPASGCQAEAAFMEEECVDTPKVNGCLLDPVPPVLVRKGCQSLPSNMMETSIDEGLETEGEAEEDPAHAFEAFQSTRSGQRRHTLSEVTNQLVVMPGAGKIFSMNDSPSLDSVDSEYDMGSVQRDLNFLEDNPSLKDIMLANQPSPRMTSPFISLRPTNPAMQALSSQKREVHNRSPVSFREGRRASDTSLTQGIVAFRQHLQNLARTKGILELNKVQLLYEQIGPEADPNLAPAAPQLQDLASSCPQEEVSQQQESVSTLPASVHPQLSPRQSLETQYLQHRLQKPSLLSKAQNTCQLYCKEPPRSLEQQLQEHRLQQKRLFLQKQSQLQAYFNQMQIAESSYPQPSQQLPLPRQETPPPSQQAPPFSLTQPLSPVLEPSSEQMQYSPFLSQYQEMQLQPLPSTSGPRAAPPLPTQLQQQQPPPPPPPPPPRQPGAAPAPLQFSYQTCELPSAASPAPDYPTPCQYPVDGAQQSDLTGPDCPRSPGLQEAPSSYDPLALSELPGLFDCEMLDAVDPQHNGYVLVN
T30495	DRUGINFO	D40NQW	GRN-300	Phase 1
T30495	DRUGINFO	D03YVB	HG-9-91-01	Investigative

T53669	TARGETID	T53669
T53669	FORMERID	TTDI02048
T53669	UNIPROID	CRLF2_HUMAN
T53669	TARGNAME	Thymic stromal lymphoprotein receptor (CRLF2)
T53669	GENENAME	CRLF2
T53669	TARGTYPE	Clinical trial
T53669	SYNONYMS	Thymic stromal lymphopoietin protein receptor; TSLP receptor; ILXR; Cytokine receptorlike factor 2; Cytokine receptorlike 2; CRLF2
T53669	FUNCTION	Receptor for thymic stromal lymphopoietin (TSLP). Forms a functional complex with TSLP and IL7R which is capable of stimulating cell proliferation through activation of STAT3 and STAT5. Also activates JAK2. Implicated in the development of the hematopoietic system.
T53669	PDBSTRUC	5J12; 5J11
T53669	BIOCLASS	Cytokine receptor
T53669	SEQUENCE	MGRLVLLWGAAVFLLGGWMALGQGGAAEGVQIQIIYFNLETVQVTWNASKYSRTNLTFHYRFNGDEAYDQCTNYLLQEGHTSGCLLDAEQRDDILYFSIRNGTHPVFTASRWMVYYLKPSSPKHVRFSWHQDAVTVTCSDLSYGDLLYEVQYRSPFDTEWQSKQENTCNVTIEGLDAEKCYSFWVRVKAMEDVYGPDTYPSDWSEVTCWQRGEIRDACAETPTPPKPKLSKFILISSLAILLMVSLLLLSLWKLWRVKKFLIPSVPDPKSIFPGLFEIHQGNFQEWITDTQNVAHLHKMAGAEQESGPEEPLVVQLAKTEAESPRMLDPQTEEKEASGGSLQLPHQPLQGGDVVTIGGFTFVMNDRSYVAL
T53669	DRUGINFO	D7EJI9	UPB-101	Phase 1

T02974	TARGETID	T02974
T02974	FORMERID	TTDI02609
T02974	UNIPROID	IL1AP_HUMAN
T02974	TARGNAME	Interleukin 1 receptor accessory protein (IL1RAP)
T02974	GENENAME	IL1RAP
T02974	TARGTYPE	Clinical trial
T02974	SYNONYMS	Interleukin1 receptor 3; Interleukin-1 receptor accessory protein; Interleukin-1 receptor 3; IL1RAcP; IL1R3; IL1 receptor accessory protein; IL-1RAcP; IL-1R3; IL-1R-3; IL-1 receptor accessory protein; C3orf13
T02974	FUNCTION	Coreceptor with IL1R1 in the IL-1 signaling system. Associates with IL1R1 bound to IL1B to form the high affinity interleukin-1 receptor complex which mediates interleukin-1-dependent activation of NF-kappa-B and other pathways. Signaling involves the recruitment of adapter molecules such as TOLLIP, MYD88, and IRAK1 or IRAK2 via the respective TIR domains of the receptor/coreceptor subunits. Recruits TOLLIP to the signaling complex. Does not bind to interleukin-1 alone; binding of IL1RN to IL1R1, prevents its association with IL1R1 to form a signaling complex. The cellular response is modulated through a non-signaling association with the membrane IL1R2 decoy receptor. Coreceptor for IL1RL1 in the IL-33 signaling system. Can bidirectionally induce pre- and postsynaptic differentiation of neurons by trans-synaptically binding to PTPRD. May play a role in IL1B-mediated costimulation of IFNG production from T-helper 1 (Th1) cells. Coreceptor for IL1RL2 in the IL-36 signaling system.
T02974	PDBSTRUC	4DEP; 3O4O
T02974	BIOCLASS	Cytokine receptor
T02974	SEQUENCE	MTLLWCVVSLYFYGILQSDASERCDDWGLDTMRQIQVFEDEPARIKCPLFEHFLKFNYSTAHSAGLTLIWYWTRQDRDLEEPINFRLPENRISKEKDVLWFRPTLLNDTGNYTCMLRNTTYCSKVAFPLEVVQKDSCFNSPMKLPVHKLYIEYGIQRITCPNVDGYFPSSVKPTITWYMGCYKIQNFNNVIPEGMNLSFLIALISNNGNYTCVVTYPENGRTFHLTRTLTVKVVGSPKNAVPPVIHSPNDHVVYEKEPGEELLIPCTVYFSFLMDSRNEVWWTIDGKKPDDITIDVTINESISHSRTEDETRTQILSIKKVTSEDLKRSYVCHARSAKGEVAKAAKVKQKVPAPRYTVELACGFGATVLLVVILIVVYHVYWLEMVLFYRAHFGTDETILDGKEYDIYVSYARNAEEEEFVLLTLRGVLENEFGYKLCIFDRDSLPGGIVTDETLSFIQKSRRLLVVLSPNYVLQGTQALLELKAGLENMASRGNINVILVQYKAVKETKVKELKRAKTVLTVIKWKGEKSKYPQGRFWKQLQVAMPVKKSPRRSSSDEQGLSYSSLKNV
T02974	DRUGINFO	DB5UO0	CAN04	Phase 1

T12541	TARGETID	T12541
T12541	FORMERID	TTDI03461
T12541	UNIPROID	PI4KB_HUMAN
T12541	TARGNAME	Phosphatidylinositol-4-kinase beta (PI4KB)
T12541	GENENAME	PI4KB
T12541	TARGTYPE	Clinical trial
T12541	SYNONYMS	PtdIns 4-kinase beta; Phosphatidylinositol 4-kinase beta; PIK4CB; PI4Kbeta; PI4K92; PI4K-beta; NPIK
T12541	FUNCTION	Phosphorylates phosphatidylinositol (PI) in the first committed step in the production of the second messenger inositol-1,4,5,-trisphosphate (PIP). May regulate Golgi disintegration/reorganization during mitosis, possibly via its phosphorylation. Involved in Golgi-to-plasma membrane trafficking (By similarity).
T12541	PDBSTRUC	6GL3; 5NAS; 5LX2; 5FBW; 5FBV
T12541	ECNUMBER	EC 2.7.1.67
T12541	SEQUENCE	MGDTVVEPAPLKPTSEPTSGPPGNNGGSLLSVITEGVGELSVIDPEVAQKACQEVLEKVKLLHGGVAVSSRGTPLELVNGDGVDSEIRCLDDPPAQIREEEDEMGAAVASGTAKGARRRRQNNSAKQSWLLRLFESKLFDISMAISYLYNSKEPGVQAYIGNRLFCFRNEDVDFYLPQLLNMYIHMDEDVGDAIKPYIVHRCRQSINFSLQCALLLGAYSSDMHISTQRHSRGTKLRKLILSDELKPAHRKRELPSLSPAPDTGLSPSKRTHQRSKSDATASISLSSNLKRTASNPKVENEDEELSSSTESIDNSFSSPVRLAPEREFIKSLMAIGKRLATLPTKEQKTQRLISELSLLNHKLPARVWLPTAGFDHHVVRVPHTQAVVLNSKDKAPYLIYVEVLECENFDTTSVPARIPENRIRSTRSVENLPECGITHEQRAGSFSTVPNYDNDDEAWSVDDIGELQVELPEVHTNSCDNISQFSVDSITSQESKEPVFIAAGDIRRRLSEQLAHTPTAFKRDPEDPSAVALKEPWQEKVRRIREGSPYGHLPNWRLLSVIVKCGDDLRQELLAFQVLKQLQSIWEQERVPLWIKPYKILVISADSGMIEPVVNAVSIHQVKKQSQLSLLDYFLQEHGSYTTEAFLSAQRNFVQSCAGYCLVCYLLQVKDRHNGNILLDAEGHIIHIDFGFILSSSPRNLGFETSAFKLTTEFVDVMGGLDGDMFNYYKMLMLQGLIAARKHMDKVVQIVEIMQQGSQLPCFHGSSTIRNLKERFHMSMTEEQLQLLVEQMVDGSMRSITTKLYDGFQYLTNGIM
T12541	DRUGINFO	D5KX2H	GSK3923868	Phase 1
T12541	DRUGINFO	D5KX2H	GSK3923868	Phase 1
T12541	DRUGINFO	D0S5YV	PIK-93	Investigative

T23359	TARGETID	T23359
T23359	FORMERID	TTDR01098
T23359	UNIPROID	A4_HUMAN
T23359	TARGNAME	APP messenger RNA (APP mRNA)
T23359	GENENAME	APP
T23359	TARGTYPE	Clinical trial
T23359	SYNONYMS	Vascular beta-amyloid (mRNA); Protease nexin-II (mRNA); PreA4 (mRNA); PN-II (mRNA); Cerebral vascular amyloidpeptide (mRNA); Cerebral vascular amyloid peptide (mRNA); CVAP (mRNA); Beta-amyloid peptide (mRNA); Amyloid-beta precursor protein (mRNA); Amyloid-beta A4 protein (mRNA); Amyloid precursor protein (mRNA); Amyloid beta precursor protein (mRNA); Alzheimer's disease amyloid protein (mRNA); Alzheimer disease amyloid protein (mRNA); APPI (mRNA); AD1 (mRNA); ABPP (mRNA); A4 (mRNA)
T23359	FUNCTION	Interaction between APP molecules on neighboring cells promotes synaptogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(O) and JIP. Inhibits G(o) alpha ATPase activity. Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1. Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Provides Cu(2+) ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1. Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis.
T23359	PDBSTRUC	6IYC; 6GFI; 6CO3; 5W3P; 5VZY
T23359	BIOCLASS	mRNA target
T23359	SEQUENCE	MLPGLALLLLAAWTARALEVPTDGNAGLLAEPQIAMFCGRLNMHMNVQNGKWDSDPSGTKTCIDTKEGILQYCQEVYPELQITNVVEANQPVTIQNWCKRGRKQCKTHPHFVIPYRCLVGEFVSDALLVPDKCKFLHQERMDVCETHLHWHTVAKETCSEKSTNLHDYGMLLPCGIDKFRGVEFVCCPLAEESDNVDSADAEEDDSDVWWGGADTDYADGSEDKVVEVAEEEEVAEVEEEEADDDEDDEDGDEVEEEAEEPYEEATERTTSIATTTTTTTESVEEVVREVCSEQAETGPCRAMISRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAMSQSLLKTTQEPLARDPVKLPTTAASTPDAVDKYLETPGDENEHAHFQKAKERLEAKHRERMSQVMREWEEAERQAKNLPKADKKAVIQHFQEKVESLEQEAANERQQLVETHMARVEAMLNDRRRLALENYITALQAVPPRPRHVFNMLKKYVRAEQKDRQHTLKHFEHVRMVDPKKAAQIRSQVMTHLRVIYERMNQSLSLLYNVPAVAEEIQDEVDELLQKEQNYSDDVLANMISEPRISYGNDALMPSLTETKTTVELLPVNGEFSLDDLQPWHSFGADSVPANTENEVEPVDARPAADRGLTTRPGSGLTNIKTEEISEVKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVITLVMLKKKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN
T23359	DRUGINFO	D8W0NQ	ALN-APP	Phase 1

T27816	TARGETID	T27816
T27816	FORMERID	TTDI02663
T27816	UNIPROID	SYUA_HUMAN
T27816	TARGNAME	SNCA messenger RNA (SNCA mRNA)
T27816	GENENAME	SNCA
T27816	TARGTYPE	Clinical trial
T27816	SYNONYMS	PARK1 (mRNA); NonA4 component of amyloid precursor (mRNA); NonA beta component of AD amyloid (mRNA); Non-A4 component of amyloid precursor (mRNA); Non-A beta component of AD amyloid (mRNA); NACP (mRNA)
T27816	FUNCTION	Participates as a monomer in synaptic vesicle exocytosis by enhancing vesicle priming, fusion and dilation of exocytotic fusion pores. Mechanistically, acts by increasing local Ca(2+) release from microdomains which is essential for the enhancement of ATP-induced exocytosis. Acts also as a molecular chaperone in its multimeric membrane-bound state, assisting in the folding of synaptic fusion components called SNAREs (Soluble NSF Attachment Protein REceptors) at presynaptic plasma membrane in conjunction with cysteine string protein-alpha/DNAJC5. This chaperone activity is important to sustain normal SNARE-complex assembly during aging. Plays also a role in the regulation of the dopamine neurotransmission by associating with the dopamine transporter (DAT1) and thereby modulating its activity. Neuronal protein that plays several roles in synaptic activity such as regulation of synaptic vesicle trafficking and subsequent neurotransmitter release.
T27816	PDBSTRUC	6H6B; 6FLT; 6CU8; 6CU7; 6CT7
T27816	BIOCLASS	mRNA target
T27816	SEQUENCE	MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVHGVATVAEKTKEQVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA
T27816	DRUGINFO	D23VYO	ION464	Phase 1

T95695	TARGETID	T95695
T95695	FORMERID	TTDI02294
T95695	UNIPROID	SMN_HUMAN
T95695	TARGNAME	SMN1 messenger RNA (SMN1 mRNA)
T95695	GENENAME	SMN1
T95695	TARGTYPE	Clinical trial
T95695	SYNONYMS	Survival motor neuron protein mRNA; SMNT mRNA; SMNC mRNA; SMN mRNA; Gemin-1 mRNA; Component of gems 1 mRNA
T95695	FUNCTION	The SMN complex plays a catalyst role in the assembly of small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome. Thereby, plays an important role in the splicing of cellular pre-mRNAs. Most spliceosomal snRNPs contain a common set of Sm proteins SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG that assemble in a heptameric protein ring on the Sm site of the small nuclear RNA to form the core snRNP. In the cytosol, the Sm proteins SNRPD1, SNRPD2, SNRPE, SNRPF and SNRPG are trapped in an inactive 6S pICln-Sm complex by the chaperone CLNS1A that controls the assembly of the core snRNP. Dissociation by the SMN complex of CLNS1A from the trapped Sm proteins and their transfer to an SMN-Sm complex triggers the assembly of core snRNPs and their transport to the nucleus. Ensures the correct splicing of U12 intron-containing genes that may be important for normal motor and proprioceptive neurons development. Also required for resolving RNA-DNA hybrids created by RNA polymerase II, that form R-loop in transcription terminal regions, an important step in proper transcription termination. May also play a role in the metabolism of small nucleolar ribonucleoprotein (snoRNPs).
T95695	PDBSTRUC	5XJU; 5XJT; 5XJS; 5XJR; 5XJQ
T95695	BIOCLASS	mRNA target
T95695	SEQUENCE	MAMSSGGSGGGVPEQEDSVLFRRGTGQSDDSDIWDDTALIKAYDKAVASFKHALKNGDICETSGKPKTTPKRKPAKKNKSQKKNTAASLQQWKVGDKCSAIWSEDGCIYPATIASIDFKRETCVVVYTGYGNREEQNLSDLLSPICEVANNIEQNAQENENESQVSTDESENSRSPGNKSDNIKPKSAPWNSFLPPPPPMPGPRLGPGKPGLKFNGPPPPPPPPPPHLLSCWLPPFPSGPPIIPPPPPICPDSLDDADALGSMLISWYMSGYHTGYYMGFRQNQKEGRCSHSLN
T95695	DRUGINFO	D05MZI	nusinersen	Approved
T95695	DRUGINFO	DUWB31	BIIB115	Phase 1

T54031	TARGETID	T54031
T54031	FORMERID	TTDI02588
T54031	UNIPROID	XLRS1_HUMAN
T54031	TARGNAME	Retinoschisin (RS1)
T54031	GENENAME	RS1
T54031	TARGTYPE	Clinical trial
T54031	SYNONYMS	X-linked juvenile retinoschisis protein; RS1
T54031	FUNCTION	May be active in cell adhesion processes during retinal development.
T54031	PDBSTRUC	5N6W; 3JD6
T54031	SEQUENCE	MSRKIEGFLLLLLFGYEATLGLSSTEDEGEDPWYQKACKCDCQGGPNALWSAGATSLDCIPECPYHKPLGFESGEVTPDQITCSNPEQYVGWYSSWTANKARLNSQGFGCAWLSKFQDSSQWLQIDLKEIKVISGILTQGRCDIDEWMTKYSVQYRTDERLNWIYYKDQTGNNRVFYGNSDRTSTVQNLLRPPIISRFIRLIPLGWHVRIAIRMELLECVSKCA
T54031	DRUGINFO	D1U4BC	BIIB-087	Phase 1/2

T80002	TARGETID	T80002
T80002	FORMERID	TTDI02117
T80002	UNIPROID	LY75_HUMAN
T80002	TARGNAME	Lymphocyte antigen 75 (LY75)
T80002	GENENAME	LY75
T80002	TARGTYPE	Clinical trial
T80002	SYNONYMS	gp200MR6; Ly75; DEC205; Ctype lectin domain family 13 member B; CD205
T80002	FUNCTION	Acts as an endocytic receptor to direct captured antigens from the extracellular space to a specialized antigen- processing compartment. Causes reduced proliferation of B-lymphocytes.
T80002	BIOCLASS	C-type lectin
T80002	SEQUENCE	MRTGWATPRRPAGLLMLLFWFFDLAEPSGRAANDPFTIVHGNTGKCIKPVYGWIVADDCDETEDKLWKWVSQHRLFHLHSQKCLGLDITKSVNELRMFSCDSSAMLWWKCEHHSLYGAARYRLALKDGHGTAISNASDVWKKGGSEESLCDQPYHEIYTRDGNSYGRPCEFPFLIDGTWHHDCILDEDHSGPWCATTLNYEYDRKWGICLKPENGCEDNWEKNEQFGSCYQFNTQTALSWKEAYVSCQNQGADLLSINSAAELTYLKEKEGIAKIFWIGLNQLYSARGWEWSDHKPLNFLNWDPDRPSAPTIGGSSCARMDAESGLWQSFSCEAQLPYVCRKPLNNTVELTDVWTYSDTRCDAGWLPNNGFCYLLVNESNSWDKAHAKCKAFSSDLISIHSLADVEVVVTKLHNEDIKEEVWIGLKNINIPTLFQWSDGTEVTLTYWDENEPNVPYNKTPNCVSYLGELGQWKVQSCEEKLKYVCKRKGEKLNDASSDKMCPPDEGWKRHGETCYKIYEDEVPFGTNCNLTITSRFEQEYLNDLMKKYDKSLRKYFWTGLRDVDSCGEYNWATVGGRRRAVTFSNWNFLEPASPGGCVAMSTGKSVGKWEVKDCRSFKALSICKKMSGPLGPEEASPKPDDPCPEGWQSFPASLSCYKVFHAERIVRKRNWEEAERFCQALGAHLSSFSHVDEIKEFLHFLTDQFSGQHWLWIGLNKRSPDLQGSWQWSDRTPVSTIIMPNEFQQDYDIRDCAAVKVFHRPWRRGWHFYDDREFIYLRPFACDTKLEWVCQIPKGRTPKTPDWYNPDRAGIHGPPLIIEGSEYWFVADLHLNYEEAVLYCASNHSFLATITSFVGLKAIKNKIANISGDGQKWWIRISEWPIDDHFTYSRYPWHRFPVTFGEECLYMSAKTWLIDLGKPTDCSTKLPFICEKYNVSSLEKYSPDSAAKVQCSEQWIPFQNKCFLKIKPVSLTFSQASDTCHSYGGTLPSVLSQIEQDFITSLLPDMEATLWIGLRWTAYEKINKWTDNRELTYSNFHPLLVSGRLRIPENFFEEESRYHCALILNLQKSPFTGTWNFTSCSERHFVSLCQKYSEVKSRQTLQNASETVKYLNNLYKIIPKTLTWHSAKRECLKSNMQLVSITDPYQQAFLSVQALLHNSSLWIGLFSQDDELNFGWSDGKRLHFSRWAETNGQLEDCVVLDTDGFWKTVDCNDNQPGAICYYSGNETEKEVKPVDSVKCPSPVLNTPWIPFQNCCYNFIITKNRHMATTQDEVHTKCQKLNPKSHILSIRDEKENNFVLEQLLYFNYMASWVMLGITYRNKSLMWFDKTPLSYTHWRAGRPTIKNEKFLAGLSTDGFWDIQTFKVIEEAVYFHQHSILACKIEMVDYKEEYNTTLPQFMPYEDGIYSVIQKKVTWYEALNMCSQSGGHLASVHNQNGQLFLEDIVKRDGFPLWVGLSSHDGSESSFEWSDGSTFDYIPWKGQTSPGNCVLLDPKGTWKHEKCNSVKDGAICYKPTKSKKLSRLTYSSRCPAAKENGSRWIQYKGHCYKSDQALHSFSEAKKLCSKHDHSATIVSIKDEDENKFVSRLMRENNNITMRVWLGLSQHSVDQSWSWLDGSEVTFVKWENKSKSGVGRCSMLIASNETWKKVECEHGFGRVVCKVPLGPDYTAIAIIVATLSILVLMGGLIWFLFQRHRLHLAGFSSVRYAQGVNEDEIMLPSFHD
T80002	DRUGINFO	D8DJX0	OBT076	Phase 1

T40490	TARGETID	T40490
T40490	FORMERID	TTDI01424
T40490	UNIPROID	NCTR1_HUMAN
T40490	TARGNAME	Natural cytotoxic triggering receptor 1 (NCR1)
T40490	GENENAME	NCR1
T40490	TARGTYPE	Clinical trial
T40490	SYNONYMS	hNKp46; Natural killer cell p46-related protein; Natural cytotoxicity triggering receptor 1; NKp46; NK-p46; NK cell-activating receptor; Lymphocyte antigen 94 homolog; LY94; CD335
T40490	FUNCTION	Cytotoxicity-activating receptor that may contribute to the increased efficiency of activated natural killer (NK) cells to mediate tumor cell lysis.
T40490	PDBSTRUC	1P6F; 1OLL
T40490	SEQUENCE	MSSTLPALLCVGLCLSQRISAQQQTLPKPFIWAEPHFMVPKEKQVTICCQGNYGAVEYQLHFEGSLFAVDRPKPPERINKVKFYIPDMNSRMAGQYSCIYRVGELWSEPSNLLDLVVTEMYDTPTLSVHPGPEVISGEKVTFYCRLDTATSMFLLLKEGRSSHVQRGYGKVQAEFPLGPVTTAHRGTYRCFGSYNNHAWSFPSEPVKLLVTGDIENTSLAPEDPTFPADTWGTYLLTTETGLQKDHALWDHTAQNLLRMGLAFLVLVALVWFLVEDWLSRKRTRERASRASTWEGRRRLNTQTL
T40490	DRUGINFO	DMKG40	SAR443579	Phase 1

T98798	TARGETID	T98798
T98798	FORMERID	TTDI02138
T98798	UNIPROID	NPT2B_HUMAN
T98798	TARGNAME	Sodium/phosphate cotransporter 2B (SLC34A2)
T98798	GENENAME	SLC34A2
T98798	TARGTYPE	Clinical trial
T98798	SYNONYMS	Solute carrier family 34 member 2; Sodium-phosphate transport protein 2B; Sodium-dependent phosphate transport protein 2B; NaPi3b; NaPi-2b; Na(+)/Pi cotransporter 2B; Na(+)-dependent phosphate cotransporter 2B
T98798	FUNCTION	It may be the main phosphate transport protein in the intestinal brush border membrane. May have a role in the synthesis of surfactant in lungs' alveoli. May be involved in actively transporting phosphate into cells via Na(+) cotransport.
T98798	BIOCLASS	Phosphate:sodium symporter
T98798	SEQUENCE	MAPWPELGDAQPNPDKYLEGAAGQQPTAPDKSKETNKTDNTEAPVTKIELLPSYSTATLIDEPTEVDDPWNLPTLQDSGIKWSERDTKGKILCFFQGIGRLILLLGFLYFFVCSLDILSSAFQLVGGKMAGQFFSNSSIMSNPLLGLVIGVLVTVLVQSSSTSTSIVVSMVSSSLLTVRAAIPIIMGANIGTSITNTIVALMQVGDRSEFRRAFAGATVHDFFNWLSVLVLLPVEVATHYLEIITQLIVESFHFKNGEDAPDLLKVITKPFTKLIVQLDKKVISQIAMNDEKAKNKSLVKIWCKTFTNKTQINVTVPSTANCTSPSLCWTDGIQNWTMKNVTYKENIAKCQHIFVNFHLPDLAVGTILLILSLLVLCGCLIMIVKILGSVLKGQVATVIKKTINTDFPFPFAWLTGYLAILVGAGMTFIVQSSSVFTSALTPLIGIGVITIERAYPLTLGSNIGTTTTAILAALASPGNALRSSLQIALCHFFFNISGILLWYPIPFTRLPIRMAKGLGNISAKYRWFAVFYLIIFFFLIPLTVFGLSLAGWRVLVGVGVPVVFIIILVLCLRLLQSRCPRVLPKKLQNWNFLPLWMRSLKPWDAVVSKFTGCFQMRCCCCCRVCCRACCLLCDCPKCCRCSKCCEDLEEAQEGQDVPVKAPETFDNITISREAQGEVPASDSKTECTAL
T98798	DRUGINFO	D0QFD2	Upifitamab rilsodotin	Phase 3
T98798	DRUGINFO	DDL79K	XMT-1592	Phase 1/2

T56269	TARGETID	T56269
T56269	FORMERID	TTDR01025
T56269	UNIPROID	IAPP_HUMAN
T56269	TARGNAME	Islet amyloid polypeptide (IAPP)
T56269	GENENAME	IAPP
T56269	TARGTYPE	Clinical trial
T56269	SYNONYMS	Insulinoma amyloid peptide; IAPP; Diabetes-associated peptide; Amylin
T56269	FUNCTION	Selectively inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle, while not affecting adipocyte glucose metabolism.
T56269	PDBSTRUC	5MGQ; 5KO0; 5KNZ; 5K5G; 3HGZ
T56269	SEQUENCE	MGILKLQVFLIVLSVALNHLKATPIESHQVEKRKCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTYGKRNAVEVLKREPLNYLPL
T56269	DRUGINFO	D93YJK	LY 3541105	Phase 1

T78552	TARGETID	T78552
T78552	FORMERID	TTDI02529
T78552	UNIPROID	CD59_HUMAN
T78552	TARGNAME	Membrane inhibitor of reactive lysis (CD59)
T78552	GENENAME	CD59
T78552	TARGTYPE	Clinical trial
T78552	SYNONYMS	Protectin; Membrane attack complex inhibition factor; MSK21; MIRL; MIN3; MIN2; MIN1; MIC11; MEM43 antigen; MACinhibitory protein; MACIP; MACIF; MAC-inhibitory protein; MAC-IP; HRF20; HRF-20; CD59 glycoprotein; 20 kDa homologous restriction factor; 1F5 antigen
T78552	FUNCTION	Acts by binding to the C8 and/or C9 complements of the assembling MAC, thereby preventing incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore. This inhibitor appears to be species-specific. Involved in signal transduction for T-cell activation complexed to a protein tyrosine kinase. Potent inhibitor of the complement membrane attack complex (MAC) action.
T78552	PDBSTRUC	5IMY; 5IMT; 4BIK; 2UX2; 2UWR
T78552	SEQUENCE	MGIQGGSVLFGLLLVLAVFCHSGHSLQCYNCPNPTADCKTAVNCSSDFDACLITKAGLQVYNKCWKFEHCNFNDVTTRLRENELTYYCCKKDLCNFNEQLENGGTSLSEKTVLLLVTPFLAAAWSLHP
T78552	DRUGINFO	DEI4U0	HMR59	Phase 2

T29774	TARGETID	T29774
T29774	FORMERID	TTDR00422
T29774	UNIPROID	LIF_HUMAN
T29774	TARGNAME	Leukemia inhibitory factor (LIF)
T29774	GENENAME	LIF
T29774	TARGTYPE	Clinical trial
T29774	SYNONYMS	Melanoma-derived LPL inhibitor; MLPLI; HILDA; Emfilermin; Differentiation-stimulating factor; D factor
T29774	FUNCTION	Its activities include the induction of hematopoietic differentiation in normal and myeloid leukemia cells, the induction of neuronal cell differentiation, and the stimulation of acute-phase protein synthesis in hepatocytes. LIF has the capacity to induce terminal differentiation in leukemic cells.
T29774	PDBSTRUC	2Q7N; 1PVH; 1EMR
T29774	SEQUENCE	MKVLAAGVVPLLLVLHWKHGAGSPLPITPVNATCAIRHPCHNNLMNQIRSQLAQLNGSANALFILYYTAQGEPFPNNLDKLCGPNVTDFPPFHANGTEKAKLVELYRIVVYLGTSLGNITRDQKILNPSALSLHSKLNATADILRGLLSNVLCRLCSKYHVGHVDVTYGPDTSGKDVFQKKKLGCQLLGKYKQIIAVLAQAF
T29774	DRUGINFO	DX5T9B	MSC-1	Phase 1

T21395	TARGETID	T21395
T21395	FORMERID	TTDI02362
T21395	UNIPROID	MCP_HUMAN
T21395	TARGNAME	Membrane cofactor protein (CD46)
T21395	GENENAME	CD46
T21395	TARGTYPE	Clinical trial
T21395	SYNONYMS	Trophoblast leukocyte common antigen; TLX; MIC10; MCP
T21395	FUNCTION	May be involved in the fusion of the spermatozoa with the oocyte during fertilization. Also acts as a costimulatory factor for T-cells which induces the differentiation of CD4+ into T-regulatory 1 cells. T-regulatory 1 cells suppress immune responses by secreting interleukin-10, and therefore are thought to prevent autoimmunity. Acts as a cofactor for complement factor I, a serine protease which protects autologous cells against complement-mediated injury by cleaving C3b and C4b deposited on host tissue.
T21395	PDBSTRUC	5FO8; 3O8E; 3L89; 3INB; 2O39
T21395	SEQUENCE	MEPPGRRECPFPSWRFPGLLLAAMVLLLYSFSDACEEPPTFEAMELIGKPKPYYEIGERVDYKCKKGYFYIPPLATHTICDRNHTWLPVSDDACYRETCPYIRDPLNGQAVPANGTYEFGYQMHFICNEGYYLIGEEILYCELKGSVAIWSGKPPICEKVLCTPPPKIKNGKHTFSEVEVFEYLDAVTYSCDPAPGPDPFSLIGESTIYCGDNSVWSRAAPECKVVKCRFPVVENGKQISGFGKKFYYKATVMFECDKGFYLDGSDTIVCDSNSTWDPPVPKCLKVLPPSSTKPPALSHSVSTSSTTKSPASSASGPRPTYKPPVSNYPGYPKPEEGILDSLDVWVIAVIVIAIVVGVAVICVVPYRYLQRRKKKGTYLTDETHREVKFTSL
T21395	DRUGINFO	D48ZBO	FOR46	Phase 1

T33455	TARGETID	T33455
T33455	FORMERID	TTDR00449
T33455	UNIPROID	IBP3_HUMAN
T33455	TARGNAME	Insulin-like growth factor-binding protein 3 (IGFBP3)
T33455	GENENAME	IGFBP3
T33455	TARGTYPE	Clinical trial
T33455	SYNONYMS	IGFBP-3; IGF-binding protein 3; IBP3; IBP-3
T33455	FUNCTION	IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. Also exhibits IGF-independent antiproliferative and apoptotic effects mediated by its receptor TMEM219/IGFBP-3R.
T33455	BIOCLASS	Insulin-like growth factor binding
T33455	SEQUENCE	MQRARPTLWAAALTLLVLLRGPPVARAGASSAGLGPVVRCEPCDARALAQCAPPPAVCAELVREPGCGCCLTCALSEGQPCGIYTERCGSGLRCQPSPDEARPLQALLDGRGLCVNASAVSRLRAYLLPAPPAPGNASESEEDRSAGSVESPSVSSTHRVSDPKFHPLHSKIIIIKKGHAKDSQRYKVDYESQSTDTQNFSSESKRETEYGPCRREMEDTLNHLKFLNVLSPRGVHIPNCDKKGFYKKKQCRPSKGRKRGFCWCVDKYGQPLPGYTTKGKEDVHCYSMQSK
T33455	DRUGINFO	D2GV9Q	Salvianolic acid B	Phase 2

T08029	TARGETID	T08029
T08029	FORMERID	TTDI02375
T08029	UNIPROID	PROP_HUMAN
T08029	TARGNAME	Complement factor P (CFP)
T08029	GENENAME	CFP
T08029	TARGTYPE	Clinical trial
T08029	SYNONYMS	Properdin; CFP
T08029	FUNCTION	A positive regulator of the alternate pathway of complement. It binds to and stabilizes the C3- and C5-convertase enzyme complexes.
T08029	PDBSTRUC	1W0S; 1W0R
T08029	SEQUENCE	MITEGAQAPRLLLPPLLLLLTLPATGSDPVLCFTQYEESSGKCKGLLGGGVSVEDCCLNTAFAYQKRSGGLCQPCRSPRWSLWSTWAPCSVTCSEGSQLRYRRCVGWNGQCSGKVAPGTLEWQLQACEDQQCCPEMGGWSGWGPWEPCSVTCSKGTRTRRRACNHPAPKCGGHCPGQAQESEACDTQQVCPTHGAWATWGPWTPCSASCHGGPHEPKETRSRKCSAPEPSQKPPGKPCPGLAYEQRRCTGLPPCPVAGGWGPWGPVSPCPVTCGLGQTMEQRTCNHPVPQHGGPFCAGDATRTHICNTAVPCPVDGEWDSWGEWSPCIRRNMKSISCQEIPGQQSRGRTCRGRKFDGHRCAGQQQDIRHCYSIQHCPLKGSWSEWSTWGLCMPPCGPNPTRARQRLCTPLLPKYPPTVSMVEGQGEKNVTFWGRPLPRCEELQGQKLVVEEKRPCLHVPACKDPEEEEL
T08029	DRUGINFO	D4LJO9	CLG561	Phase 2
T08029	DRUGINFO	DVYW59	ALXN1820	Phase 2

T45182	TARGETID	T45182
T45182	FORMERID	TTDI01434
T45182	UNIPROID	GRN_HUMAN
T45182	TARGNAME	Progranulin (PGRN)
T45182	GENENAME	GRN
T45182	TARGTYPE	Clinical trial
T45182	SYNONYMS	Proepithelin; PGRN; PEPI; PCDGF; PC cell-derived growth factor; Granulin precursor; Glycoprotein of 88 Kda; Glycoprotein 88; GP88; Epithelin precursor; Acrogranin
T45182	FUNCTION	Secreted proteins that act as key regulator of lysosomal function and as a growth factor involved in inflammation, wound healing and cell proliferation. Functions as regulator of proteins trafficking to lysosome and activity of lysosomal enzymes. Facilitates also the acidification of lysosomes, causing degradation of mature CTSD by CTSB. In addition, functions as wound-related growth factor that acts directly on dermal fibroblasts and endothelial cells to promote division, migration and the formation of capillary-like tubule structure (By similarity). Also promotes epithelial cell proliferation by blocking TNF-mediated neutrophil activation preventing release of oxidants and proteases. Moreover, modulates inflammation in neuron by preserving neuron survival, axonal outgrowth and neuronal integrity.
T45182	PDBSTRUC	2JYV; 2JYU; 2JYT; 2JYE; 1G26
T45182	SEQUENCE	MWTLVSWVALTAGLVAGTRCPDGQFCPVACCLDPGGASYSCCRPLLDKWPTTLSRHLGGPCQVDAHCSAGHSCIFTVSGTSSCCPFPEAVACGDGHHCCPRGFHCSADGRSCFQRSGNNSVGAIQCPDSQFECPDFSTCCVMVDGSWGCCPMPQASCCEDRVHCCPHGAFCDLVHTRCITPTGTHPLAKKLPAQRTNRAVALSSSVMCPDARSRCPDGSTCCELPSGKYGCCPMPNATCCSDHLHCCPQDTVCDLIQSKCLSKENATTDLLTKLPAHTVGDVKCDMEVSCPDGYTCCRLQSGAWGCCPFTQAVCCEDHIHCCPAGFTCDTQKGTCEQGPHQVPWMEKAPAHLSLPDPQALKRDVPCDNVSSCPSSDTCCQLTSGEWGCCPIPEAVCCSDHQHCCPQGYTCVAEGQCQRGSEIVAGLEKMPARRASLSHPRDIGCDQHTSCPVGQTCCPSLGGSWACCQLPHAVCCEDRQHCCPAGYTCNVKARSCEKEVVSAQPATFLARSPHVGVKDVECGEGHFCHDNQTCCRDNRQGWACCPYRQGVCCADRRHCCPAGFRCAARGTKCLRREAPRWDAPLRDPALRQLL
T45182	DRUGINFO	D2AG4O	DNL593	Phase 1/2
T45182	DRUGINFO	D5C4YE	PR-006	Phase 1/2
T45182	DRUGINFO	D8FX9H	PBFT02	Phase 1/2

T84981	TARGETID	T84981
T84981	FORMERID	TTDI02506
T84981	UNIPROID	CCR7_HUMAN
T84981	TARGNAME	C-C chemokine receptor type 7 (CCR7)
T84981	GENENAME	CCR7
T84981	TARGTYPE	Clinical trial
T84981	SYNONYMS	MIP3 beta receptor; MIP-3 beta receptor; EpsteinBarr virusinduced Gprotein coupled receptor 1; Epstein-Barr virus-induced G-protein coupled receptor 1; EVI1; EBVinduced Gprotein coupled receptor 1; EBV-induced G-protein coupled receptor 1; EBI1; CMKBR7; CDw197; CD197; CCR-7; CCCKR7; CC-CKR-7; CC chemokine receptor type 7; CC CKR7; C-C CKR-7; BLR2
T84981	FUNCTION	Probable mediator of EBV effects on B-lymphocytes or of normal lymphocyte functions. Receptor for the MIP-3-beta chemokine.
T84981	BIOCLASS	GPCR rhodopsin
T84981	SEQUENCE	MDLGKPMKSVLVVALLVIFQVCLCQDEVTDDYIGDNTTVDYTLFESLCSKKDVRNFKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNLAVADILFLLTLPFWAYSAAKSWVFGVHFCKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYSDLQRSSSEQAMRCSLITEHVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITSSTCELSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSP
T84981	DRUGINFO	DQVR30	JBH492	Phase 1
T84981	DRUGINFO	DSYN57	CAP-100	Clinical trial

T81281	TARGETID	T81281
T81281	FORMERID	TTDI02403
T81281	UNIPROID	DSG3_HUMAN
T81281	TARGNAME	Desmoglein-3 (DSG3)
T81281	GENENAME	DSG3
T81281	TARGTYPE	Clinical trial
T81281	SYNONYMS	PVA; DSG3; Cadherin family member 6; 130 kDa pemphigus vulgaris antigen
T81281	FUNCTION	Component of intercellular desmosome junctions. Involved in the interaction of plaque proteins and intermediate filaments mediating cell-cell adhesion.
T81281	PDBSTRUC	5EQX
T81281	SEQUENCE	MMGLFPRTTGALAIFVVVILVHGELRIETKGQYDEEEMTMQQAKRRQKREWVKFAKPCREGEDNSKRNPIAKITSDYQATQKITYRISGVGIDQPPFGIFVVDKNTGDINITAIVDREETPSFLITCRALNAQGLDVEKPLILTVKILDINDNPPVFSQQIFMGEIEENSASNSLVMILNATDADEPNHLNSKIAFKIVSQEPAGTPMFLLSRNTGEVRTLTNSLDREQASSYRLVVSGADKDGEGLSTQCECNIKVKDVNDNFPMFRDSQYSARIEENILSSELLRFQVTDLDEEYTDNWLAVYFFTSGNEGNWFEIQTDPRTNEGILKVVKALDYEQLQSVKLSIAVKNKAEFHQSVISRYRVQSTPVTIQVINVREGIAFRPASKTFTVQKGISSKKLVDYILGTYQAIDEDTNKAASNVKYVMGRNDGGYLMIDSKTAEIKFVKNMNRDSTFIVNKTITAEVLAIDEYTGKTSTGTVYVRVPDFNDNCPTAVLEKDAVCSSSPSVVVSARTLNNRYTGPYTFALEDQPVKLPAVWSITTLNATSALLRAQEQIPPGVYHISLVLTDSQNNRCEMPRSLTLEVCQCDNRGICGTSYPTTSPGTRYGRPHSGRLGPAAIGLLLLGLLLLLLAPLLLLTCDCGAGSTGGVTGGFIPVPDGSEGTIHQWGIEGAHPEDKEITNICVPPVTANGADFMESSEVCTNTYARGTAVEGTSGMEMTTKLGAATESGGAAGFATGTVSGAASGFGAATGVGICSSGQSGTMRTRHSTGGTNKDYADGAISMNFLDSYFSQKAFACAEEDDGQEANDCLLIYDNEGADATGSPVGSVGCCSFIADDLDDSFLDSLGPKFKKLAEISLGVDGEGKEVQPPSKDSGYGIESCGHPIEVQQTGFVKCQTLSGSQGASALSTSGSVQPAVSIPDPLQHGNYLVTETYSASGSLVQPSTAGFDPLLTQNVIVTERVICPISSVPGNLAGPTQLRGSHTMLCTEDPCSRLI
T81281	DRUGINFO	DE1XF0	DSG3-CAART	Phase 1

T15510	TARGETID	T15510
T15510	FORMERID	TTDI02453
T15510	UNIPROID	IRS1_HUMAN
T15510	TARGNAME	Insulin receptor substrate-1 (IRS1)
T15510	GENENAME	IRS1
T15510	TARGTYPE	Clinical trial
T15510	SYNONYMS	Insulin receptor substrate 1; IRS-1
T15510	FUNCTION	When phosphorylated by the insulin receptor binds specifically to various cellular proteins containing SH2 domains such as phosphatidylinositol 3-kinase p85 subunit or GRB2. Activates phosphatidylinositol 3-kinase when bound to the regulatory p85 subunit. May mediate the control of various cellular processes by insulin.
T15510	PDBSTRUC	6BNT; 5U1M; 2Z8C; 1QQG; 1K3A
T15510	SEQUENCE	MASPPESDGFSDVRKVGYLRKPKSMHKRFFVLRAASEAGGPARLEYYENEKKWRHKSSAPKRSIPLESCFNINKRADSKNKHLVALYTRDEHFAIAADSEAEQDSWYQALLQLHNRAKGHHDGAAALGAGGGGGSCSGSSGLGEAGEDLSYGDVPPGPAFKEVWQVILKPKGLGQTKNLIGIYRLCLTSKTISFVKLNSEAAAVVLQLMNIRRCGHSENFFFIEVGRSAVTGPGEFWMQVDDSVVAQNMHETILEAMRAMSDEFRPRSKSQSSSNCSNPISVPLRRHHLNNPPPSQVGLTRRSRTESITATSPASMVGGKPGSFRVRASSDGEGTMSRPASVDGSPVSPSTNRTHAHRHRGSARLHPPLNHSRSIPMPASRCSPSATSPVSLSSSSTSGHGSTSDCLFPRRSSASVSGSPSDGGFISSDEYGSSPCDFRSSFRSVTPDSLGHTPPARGEEELSNYICMGGKGPSTLTAPNGHYILSRGGNGHRCTPGTGLGTSPALAGDEAASAADLDNRFRKRTHSAGTSPTITHQKTPSQSSVASIEEYTEMMPAYPPGGGSGGRLPGHRHSAFVPTRSYPEEGLEMHPLERRGGHHRPDSSTLHTDDGYMPMSPGVAPVPSGRKGSGDYMPMSPKSVSAPQQIINPIRRHPQRVDPNGYMMMSPSGGCSPDIGGGPSSSSSSSNAVPSGTSYGKLWTNGVGGHHSHVLPHPKPPVESSGGKLLPCTGDYMNMSPVGDSNTSSPSDCYYGPEDPQHKPVLSYYSLPRSFKHTQRPGEPEEGARHQHLRLSTSSGRLLYAATADDSSSSTSSDSLGGGYCGARLEPSLPHPHHQVLQPHLPRKVDTAAQTNSRLARPTRLSLGDPKASTLPRAREQQQQQQPLLHPPEPKSPGEYVNIEFGSDQSGYLSGPVAFHSSPSVRCPSQLQPAPREEETGTEEYMKMDLGPGRRAAWQESTGVEMGRLGPAPPGAASICRPTRAVPSSRGDYMTMQMSCPRQSYVDTSPAAPVSYADMRTGIAAEEVSLPRATMAAASSSSAASASPTGPQGAAELAAHSSLLGGPQGPGGMSAFTRVNLSPNRNQSAKVIRADPQGCRRRHSSETFSSTPSATRVGNTVPFGAGAAVGGGGGSSSSSEDVKRHSSASFENVWLRPGELGGAPKEPAKLCGAAGGLENGLNYIDLDLVKDFKQCPQECTPEPQPPPPPPPHQPLGSGESSSTRRSSEDLSAYASISFQKQPEDRQ
T15510	DRUGINFO	DUI59O	NT219	Phase 1/2

T82075	TARGETID	T82075
T82075	FORMERID	TTDR00969
T82075	UNIPROID	FTSZ_WOLSP
T82075	TARGNAME	Bacterial Celldivision protein FtsZ (Bact ftsZ)
T82075	GENENAME	Bact ftsZ
T82075	TARGTYPE	Clinical trial
T82075	SYNONYMS	FtsZprotein; FtsZ
T82075	FUNCTION	Essential cell division protein that forms a contractile ring structure (Z ring) at the future cell division site. The regulation of the ring assembly controls the timing and the location of cell division. One of the functions of the FtsZ ring is to recruit other cell division proteins to the septum to produce a new cell wall between the dividing cells. Binds GTP and shows GTPase activity.
T82075	BIOCLASS	Peptidase
T82075	SEQUENCE	MSIDLSLPELPILHPRITVVGVGGAGGNAVNNMIQSNLQGVNFVVANTDAQALEKSLCDKKIQLGINLTKGLGAGALPDVGKGAAEESIDEIMEHIKDSHMLFITAGMGGGTGTGAAPVIAKAAREARAAVKDRAPKEKKILTVGVVTKPFGFEGVRRMPIAELGLEELQKYVDTLIVIPNQNLFRIANEKTTFSDAFKLADNVLHIGIRGVTDLMVMPGLINLDFADIETVMSEMGKAMIGTGEAEGEDRAISAAEAAISNPLLDNVSMKGAQGILINITGGGDMTLFEVDAAANRVREEVDENANIIFGATFDQAMEGRVRVSVLATGIDGRNNKSETSPISQSEDSEKEKFKWPYSQSESTQDKTLETKPAEQVSEGAKWGSNIYDIPAYLRRKK
T82075	DRUGINFO	DVY5D9	TXA709	Phase 1
T82075	DRUGINFO	D0H2TZ	Phosphomethylphosphonic Acid Guanylate Ester	Investigative
T82075	DRUGINFO	D0Q5XD	5'-Guanosine-Diphosphate-Monothiophosphate	Investigative
T82075	DRUGINFO	D0C7LS	Guanosine-5'-Diphosphate	Investigative

T59686	TARGETID	T59686
T59686	FORMERID	TTDI00041
T59686	UNIPROID	MECP2_HUMAN
T59686	TARGNAME	Methyl cpg binding protein 2 (MECP2)
T59686	GENENAME	MECP2
T59686	TARGTYPE	Clinical trial
T59686	SYNONYMS	MethylCpGbinding protein 2; Methyl-CpG-binding protein 2; MeCp2 protein; MeCp2; MeCp-2 protein
T59686	FUNCTION	It can bind specifically to a single methyl-CpG pair. It is not influenced by sequences flanking the methyl-CpGs. Mediates transcriptional repression through interaction with histone deacetylase and the corepressor SIN3A. Binds both 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC)-containing DNA, with a preference for 5-methylcytosine (5mC). Chromosomal protein that binds to methylated DNA.
T59686	PDBSTRUC	6OGK; 6OGJ; 6C1Y; 5BT2; 3C2I
T59686	SEQUENCE	MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS
T59686	DRUGINFO	DE94CW	AVXS-201	Phase 1

T42974	TARGETID	T42974
T42974	FORMERID	TTDR01221
T42974	UNIPROID	GAS6_HUMAN
T42974	TARGNAME	AXL receptor tyrosine kinase ligand (GAS6)
T42974	GENENAME	GAS6
T42974	TARGTYPE	Clinical trial
T42974	SYNONYMS	Growth arrest-specific protein 6; GAS-6; AXLLG
T42974	FUNCTION	Ligand for tyrosine-protein kinase receptors AXL, TYRO3 and MER whose signaling is implicated in cell growth and survival, cell adhesion and cell migration. GAS6/AXL signaling plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses.
T42974	PDBSTRUC	5VXZ; 4RA0; 2C5D; 1H30
T42974	SEQUENCE	MAPSLSPGPAALRRAPQLLLLLLAAECALAALLPAREATQFLRPRQRRAFQVFEEAKQGHLERECVEELCSREEAREVFENDPETDYFYPRYLDCINKYGSPYTKNSGFATCVQNLPDQCTPNPCDRKGTQACQDLMGNFFCLCKAGWGGRLCDKDVNECSQENGGCLQICHNKPGSFHCSCHSGFELSSDGRTCQDIDECADSEACGEARCKNLPGSYSCLCDEGFAYSSQEKACRDVDECLQGRCEQVCVNSPGSYTCHCDGRGGLKLSQDMDTCEDILPCVPFSVAKSVKSLYLGRMFSGTPVIRLRFKRLQPTRLVAEFDFRTFDPEGILLFAGGHQDSTWIVLALRAGRLELQLRYNGVGRVTSSGPVINHGMWQTISVEELARNLVIKVNRDAVMKIAVAGDLFQPERGLYHLNLTVGGIPFHEKDLVQPINPRLDGCMRSWNWLNGEDTTIQETVKVNTRMQCFSVTERGSFYPGSGFAFYSLDYMRTPLDVGTESTWEVEVVAHIRPAADTGVLFALWAPDLRAVPLSVALVDYHSTKKLKKQLVVLAVEHTALALMEIKVCDGQEHVVTVSLRDGEATLEVDGTRGQSEVSAAQLQERLAVLERHLRSPVLTFAGGLPDVPVTSAPVTAFYRGCMTLEVNRRLLDLDEAAYKHSDITAHSCPPVEPAAA
T42974	DRUGINFO	DDRX30	Batiraxcept	Phase 3
T42974	DRUGINFO	D8PE7D	AVB-500	Phase 2

T78510	TARGETID	T78510
T78510	FORMERID	TTDI03122
T78510	UNIPROID	CNGA3_HUMAN
T78510	TARGNAME	Cyclic nucleotide-gated channel alpha-3 (CNGA3)
T78510	GENENAME	CNGA3
T78510	TARGTYPE	Clinical trial
T78510	SYNONYMS	Cyclic nucleotide-gated cation channel alpha-3; Cone photoreceptor cGMP-gated channel subunit alpha; CNG3; CNG-3; CNG channel alpha-3; CNCG3
T78510	FUNCTION	Visual signal transduction is mediated by a G-protein coupled cascade using cGMP as second messenger. This protein can be activated by cyclic GMP which leads to an opening of the cation channel and thereby causing a depolarization of cone photoreceptors. Induced a flickering channel gating, weakened the outward rectification in the presence of extracellular calcium, increased sensitivity for L-cis diltiazem and enhanced the cAMP efficacy of the channel when coexpressed with CNGB3 (By similarity). Essential for the generation of light-evoked electrical responses in the red-, green- and blue sensitive cones.
T78510	PDBSTRUC	3SWY
T78510	SEQUENCE	MAKINTQYSHPSRTHLKVKTSDRDLNRAENGLSRAHSSSEETSSVLQPGIAMETRGLADSGQGSFTGQGIARLSRLIFLLRRWAARHVHHQDQGPDSFPDRFRGAELKEVSSQESNAQANVGSQEPADRGRSAWPLAKCNTNTSNNTEEEKKTKKKDAIVVDPSSNLYYRWLTAIALPVFYNWYLLICRACFDELQSEYLMLWLVLDYSADVLYVLDVLVRARTGFLEQGLMVSDTNRLWQHYKTTTQFKLDVLSLVPTDLAYLKVGTNYPEVRFNRLLKFSRLFEFFDRTETRTNYPNMFRIGNLVLYILIIIHWNACIYFAISKFIGFGTDSWVYPNISIPEHGRLSRKYIYSLYWSTLTLTTIGETPPPVKDEEYLFVVVDFLVGVLIFATIVGNVGSMISNMNASRAEFQAKIDSIKQYMQFRKVTKDLETRVIRWFDYLWANKKTVDEKEVLKSLPDKLKAEIAINVHLDTLKKVRIFQDCEAGLLVELVLKLRPTVFSPGDYICKKGDIGKEMYIINEGKLAVVADDGVTQFVVLSDGSYFGEISILNIKGSKSGNRRTANIRSIGYSDLFCLSKDDLMEALTEYPEAKKALEEKGRQILMKDNLIDEELARAGADPKDLEEKVEQLGSSLDTLQTRFARLLAEYNATQMKMKQRLSQLESQVKGGGDKPLADGEVPGDATKTEDKQQ
T78510	DRUGINFO	D3M6SN	ACHM-CNGA3	Phase 1/2
T78510	DRUGINFO	DM90BJ	AAV-CNGA3	Phase 1/2
T78510	DRUGINFO	D00YNI	L-(cis)-diltiazem	Investigative

T85507	TARGETID	T85507
T85507	FORMERID	TTDI00182
T85507	UNIPROID	SIG15_HUMAN
T85507	TARGNAME	Sialic acid-binding immunoglobulin-like lectin 15 (SIGLEC15)
T85507	GENENAME	SIGLEC15
T85507	TARGTYPE	Clinical trial
T85507	SYNONYMS	Siglec-15; SIGLEC15; CD33 antigen-like 3
T85507	FUNCTION	Binds sialylated glycoproteins.
T85507	BIOCLASS	Immunoglobulin
T85507	SEQUENCE	MEKSIWLLACLAWVLPTGSFVRTKIDTTENLLNTEVHSSPAQRWSMQVPPEVSAEAGDAAVLPCTFTHPHRHYDGPLTAIWRAGEPYAGPQVFRCAAARGSELCQTALSLHGRFRLLGNPRRNDLSLRVERLALADDRRYFCRVEFAGDVHDRYESRHGVRLHVTAAPRIVNISVLPSPAHAFRALCTAEGEPPPALAWSGPALGNSLAAVRSPREGHGHLVTAELPALTHDGRYTCTAANSLGRSEASVYLFRFHGASGASTVALLLGALGFKALLLLGVLAARAARRRPEHLDTPDTPPRSQAQESNYENLSQMNPRSPPATMCSP
T85507	DRUGINFO	D9UZ5Q	NC318	Phase 2

T41171	TARGETID	T41171
T41171	FORMERID	TTDI02628
T41171	UNIPROID	IL17D_HUMAN
T41171	TARGNAME	Interleukin-27 (IL27)
T41171	GENENAME	IL17D
T41171	TARGTYPE	Clinical trial
T41171	SYNONYMS	UNQ3096/PRO21175; Interleukin27; Interleukin17D; Interleukin-17D; IL-27; IL-17D
T41171	FUNCTION	Induces expression of IL6, CXCL8/IL8, and CSF2/GM-CSF from endothelial cells.
T41171	BIOCLASS	Cytokine: interleukin
T41171	SEQUENCE	MLVAGFLLALPPSWAAGAPRAGRRPARPRGCADRPEELLEQLYGRLAAGVLSAFHHTLQLGPREQARNASCPAGGRPADRRFRPPTNLRSVSPWAYRISYDPARYPRYLPEAYCLCRGCLTGLFGEEDVRFRSAPVYMPTVVLRRTPACAGGRSVYTEAYVTIPVGCTCVPEPEKDADSINSSIDKQGAKLLLGPNDAPAGP
T41171	DRUGINFO	DLY89F	SRF388	Phase 1

T00496	TARGETID	T00496
T00496	FORMERID	TTDR01316
T00496	UNIPROID	PAWR_HUMAN
T00496	TARGNAME	Prostate apoptosis response-4 (PAWR)
T00496	GENENAME	PAWR
T00496	TARGTYPE	Clinical trial
T00496	SYNONYMS	Prostate apoptosis response 4 protein; PRKC apoptosis WT1 regulator protein; PAR4
T00496	FUNCTION	Pro-apoptopic protein capable of selectively inducing apoptosis in cancer cells, sensitizing the cells to diverse apoptotic stimuli and causing regression of tumors in animal models. Induces apoptosis in certain cancer cells by activation of the Fas prodeath pathway and coparallel inhibition of NF-kappa-B transcriptional activity. Inhibits the transcriptional activation and augments the transcriptional repression mediated by WT1. Down-regulates the anti-apoptotic protein BCL2 via its interaction with WT1. Seems also to be a transcriptional repressor by itself. May be directly involved in regulating the amyloid precursor protein (APP) cleavage activity of BACE1.
T00496	PDBSTRUC	2JK9
T00496	SEQUENCE	MATGGYRTSSGLGGSTTDFLEEWKAKREKMRAKQNPPGPAPPGGGSSDAAGKPPAGALGTPAAAAANELNNNLPGGAPAAPAVPGPGGVNCAVGSAMLTRAAPGPRRSEDEPPAASASAAPPPQRDEEEPDGVPEKGKSSGPSARKGKGQIEKRKLREKRRSTGVVNIPAAECLDEYEDDEAGQKERKREDAITQQNTIQNEAVNLLDPGSSYLLQEPPRTVSGRYKSTTSVSEEDVSSRYSRTDRSGFPRYNRDANVSGTLVSSSTLEKKIEDLEKEVVRERQENLRLVRLMQDKEEMIGKLKEEIDLLNRDLDDIEDENEQLKQENKTLLKVVGQLTR
T00496	DRUGINFO	D3AIE0	BMS-986141	Phase 2
T00496	DRUGINFO	DUM25X	BMS-986120	Phase 1

T32227	TARGETID	T32227
T32227	FORMERID	TTDI02530
T32227	UNIPROID	CNGB3_HUMAN
T32227	TARGNAME	Cyclic nucleotide-gated channel beta-3 (CNGB3)
T32227	GENENAME	CNGB3
T32227	TARGTYPE	Clinical trial
T32227	SYNONYMS	Cyclic nucleotidegated channel beta3; Cyclic nucleotidegated cation channel modulatory subunit; Cyclic nucleotidegated cation channel beta3; Cyclic nucleotide-gated cation channel modulatory subunit; Cyclic nucleotide-gated cation channel beta-3; Cone photoreceptor cGMPgated channel subunit beta; Cone photoreceptor cGMP-gated channel subunit beta; CNG channel beta3; CNG channel beta-3
T32227	FUNCTION	Visual signal transduction is mediated by a G-protein coupled cascade using cGMP as second messenger. This protein can be activated by cGMP which leads to an opening of the cation channel and thereby causing a depolarization of rod photoreceptors. Induced a flickering channel gating, weakened the outward rectification in the presence of extracellular calcium, increased sensitivity for L-cis diltiazem and enhanced the cAMP efficiency of the channel when coexpressed with CNGA3 (By similarity). Essential for the generation of light-evoked electrical responses in the red-, green- and blue sensitive cones.
T32227	SEQUENCE	MFKSLTKVNKVKPIGENNENEQSSRRNEEGSHPSNQSQQTTAQEENKGEEKSLKTKSTPVTSEEPHTNIQDKLSKKNSSGDLTTNPDPQNAAEPTGTVPEQKEMDPGKEGPNSPQNKPPAAPVINEYADAQLHNLVKRMRQRTALYKKKLVEGDLSSPEASPQTAKPTAVPPVKESDDKPTEHYYRLLWFKVKKMPLTEYLKRIKLPNSIDSYTDRLYLLWLLLVTLAYNWNCCFIPLRLVFPYQTADNIHYWLIADIICDIIYLYDMLFIQPRLQFVRGGDIIVDSNELRKHYRTSTKFQLDVASIIPFDICYLFFGFNPMFRANRMLKYTSFFEFNHHLESIMDKAYIYRVIRTTGYLLFILHINACVYYWASNYEGIGTTRWVYDGEGNEYLRCYYWAVRTLITIGGLPEPQTLFEIVFQLLNFFSGVFVFSSLIGQMRDVIGAATANQNYFRACMDDTIAYMNNYSIPKLVQKRVRTWYEYTWDSQRMLDESDLLKTLPTTVQLALAIDVNFSIISKVDLFKGCDTQMIYDMLLRLKSVLYLPGDFVCKKGEIGKEMYIIKHGEVQVLGGPDGTKVLVTLKAGSVFGEISLLAAGGGNRRTANVVAHGFANLLTLDKKTLQEILVHYPDSERILMKKARVLLKQKAKTAEATPPRKDLALLFPPKEETPKLFKTLLGGTGKASLARLLKLKREQAAQKKENSEGGEEEGKENEDKQKENEDKQKENEDKGKENEDKDKGREPEEKPLDRPECTASPIAVEEEPHSVRRTVLPRGTSRQSLIISMAPSAEGGEEVLTIEVKEKAKQ
T32227	DRUGINFO	D56WJV	AAV-CNGB3	Phase 1/2
T32227	DRUGINFO	DYRC18	ACHM-CNGB3	Phase 1/2
T32227	DRUGINFO	D00YNI	L-(cis)-diltiazem	Investigative

T45086	TARGETID	T45086
T45086	FORMERID	TTDI01447
T45086	UNIPROID	TREM2_HUMAN
T45086	TARGNAME	Triggering receptor expressed on monocytes 2 (TREM2)
T45086	GENENAME	TREM2
T45086	TARGTYPE	Clinical trial
T45086	SYNONYMS	Triggering receptor expressed on myeloid cells 2; TREM-2
T45086	FUNCTION	Forms a receptor signaling complex with TYROBP which mediates signaling and cell activation following ligand binding. Acts as a receptor for amyloid-beta protein 42, a cleavage product of the amyloid-beta precursor protein APP, and mediates its uptake and degradation by microglia. Binding to amyloid-beta 42 mediates microglial activation, proliferation, migration, apoptosis and expression of pro-inflammatory cytokines, such as IL6R and CCL3, and the anti-inflammatory cytokine ARG1 (By similarity). Acts as a receptor for lipoprotein particles such as LDL, VLDL, and HDL and for apolipoproteins such as APOA1, APOA2, APOB, APOE, APOE2, APOE3, APOE4, and CLU and enhances their uptake in microglia. Binds phospholipids (preferably anionic lipids) such as phosphatidylserine, phosphatidylethanolamine, phosphatidylglycerol and sphingomyelin. Regulates microglial proliferation by acting as an upstream regulator of the Wnt/beta-catenin signaling cascade (By similarity). Required for microglial phagocytosis of apoptotic neurons. Also required for microglial activation and phagocytosis of myelin debris after neuronal injury and of neuronal synapses during synapse elimination in the developing brain (By similarity). Regulates microglial chemotaxis and process outgrowth, and also the microglial response to oxidative stress and lipopolysaccharide (By similarity). It suppresses PI3K and NF-kappa-B signaling in response to lipopolysaccharide; thus promoting phagocytosis, suppressing pro-inflammatory cytokine and nitric oxide production, inhibiting apoptosis and increasing expression of IL10 and TGFB (By similarity). During oxidative stress, it promotes anti-apoptotic NF-kappa-B signaling and ERK signaling (By similarity). Plays a role in microglial MTOR activation and metabolism (By similarity). Regulates age-related changes in microglial numbers. Triggers activation of the immune responses in macrophages and dendritic cells. Mediates cytokine-induced formation of multinucleated giant cells which are formed by the fusion of macrophages (By similarity). In dendritic cells, it mediates up-regulation of chemokine receptor CCR7 and dendritic cell maturation and survival. Involved in the positive regulation of osteoclast differentiation.
T45086	PDBSTRUC	6B8O; 5UD8; 5UD7; 5ELI
T45086	SEQUENCE	MEPLRLLILLFVTELSGAHNTTVFQGVAGQSLQVSCPYDSMKHWGRRKAWCRQLGEKGPCQRVVSTHNLWLLSFLRRWNGSTAITDDTLGGTLTITLRNLQPHDAGLYQCQSLHGSEADTLRKVLVEVLADPLDHRDAGDLWFPGESESFEDAHVEHSISRSLLEGEIPFPPTSILLLLACIFLIKILAASALWAAAWHGQKPGTHPPSELDCGHDPGYQLQTLPGLRDT
T45086	DRUGINFO	DYT9B4	AL002	Phase 2
T45086	DRUGINFO	DN48GC	DNL919	Phase 1

T11615	TARGETID	T11615
T11615	FORMERID	TTDR01200
T11615	UNIPROID	XCT_HUMAN
T11615	TARGNAME	Cystine/glutamate transporter (SLC7A11)
T11615	GENENAME	SLC7A11
T11615	TARGTYPE	Clinical trial
T11615	SYNONYMS	XCT; X(c)-cystine transporter; X(c)- plasma membrane cystine transporter; Solute carrier family 7 member 11; Calcium channel blocker resistance protein CCBR1; Amino acid transport system xc-; Amino acid transport system XCT
T11615	FUNCTION	Sodium-independent, high-affinity exchange of anionic amino acids with high specificity for anionic form of cystine and glutamate.
T11615	BIOCLASS	Amino acid-polyamine-organocation
T11615	SEQUENCE	MVRKPVVSTISKGGYLQGNVNGRLPSLGNKEPPGQEKVQLKRKVTLLRGVSIIIGTIIGAGIFISPKGVLQNTGSVGMSLTIWTVCGVLSLFGALSYAELGTTIKKSGGHYTYILEVFGPLPAFVRVWVELLIIRPAATAVISLAFGRYILEPFFIQCEIPELAIKLITAVGITVVMVLNSMSVSWSARIQIFLTFCKLTAILIIIVPGVMQLIKGQTQNFKDAFSGRDSSITRLPLAFYYGMYAYAGWFYLNFVTEEVENPEKTIPLAICISMAIVTIGYVLTNVAYFTTINAEELLLSNAVAVTFSERLLGNFSLAVPIFVALSCFGSMNGGVFAVSRLFYVASREGHLPEILSMIHVRKHTPLPAVIVLHPLTMIMLFSGDLDSLLNFLSFARWLFIGLAVAGLIYLRYKCPDMHRPFKVPLFIPALFSFTCLFMVALSLYSDPFSTGIGFVITLTGVPAYYLFIIWDKKPRWFRIMSEKITRTLQIILEVVPEEDKL
T11615	DRUGINFO	D1KO3P	SXC-2023	Phase 2

T81830	TARGETID	T81830
T81830	FORMERID	TTDI03546
T81830	UNIPROID	SIK3_HUMAN
T81830	TARGNAME	SIK family kinase 3 (SIK3)
T81830	GENENAME	SIK3
T81830	TARGTYPE	Clinical trial
T81830	SYNONYMS	Serine/threonine-protein kinase SIK3; Serine/threonine-protein kinase QSK; Salt-inducible kinase 3; SIK-3; KIAA0999
T81830	FUNCTION	Positive regulator of mTOR signaling that functions by triggering the degradation of DEPTOR, an mTOR inhibitor. Involved in the dynamic regulation of mTOR signaling in chondrocyte differentiation during skeletogenesis. Negatively regulates cAMP signaling pathway possibly by acting on CRTC2/TORC2 and CRTC3/TORC3 (Probable). Prevents HDAC4 translocation to the nucleus (By similarity).
T81830	ECNUMBER	EC 2.7.11.1
T81830	SEQUENCE	MAAAAASGAGGAAGAGTGGAGPAGRLLPPPAPGSPAAPAAVSPAAGQPRPPAPASRGPMPARIGYYEIDRTIGKGNFAVVKRATHLVTKAKVAIKIIDKTQLDEENLKKIFREVQIMKMLCHPHIIRLYQVMETERMIYLVTEYASGGEIFDHLVAHGRMAEKEARRKFKQIVTAVYFCHCRNIVHRDLKAENLLLDANLNIKIADFGFSNLFTPGQLLKTWCGSPPYAAPELFEGKEYDGPKVDIWSLGVVLYVLVCGALPFDGSTLQNLRARVLSGKFRIPFFMSTECEHLIRHMLVLDPNKRLSMEQICKHKWMKLGDADPNFDRLIAECQQLKEERQVDPLNEDVLLAMEDMGLDKEQTLQSLRSDAYDHYSAIYSLLCDRHKRHKTLRLGALPSMPRALAFQAPVNIQAEQAGTAMNISVPQVQLINPENQIVEPDGTLNLDSDEGEEPSPEALVRYLSMRRHTVGVADPRTEVMEDLQKLLPGFPGVNPQAPFLQVAPNVNFMHNLLPMQNLQPTGQLEYKEQSLLQPPTLQLLNGMGPLGRRASDGGANIQLHAQQLLKRPRGPSPLVTMTPAVPAVTPVDEESSDGEPDQEAVQSSTYKDSNTLHLPTERFSPVRRFSDGAASIQAFKAHLEKMGNNSSIKQLQQECEQLQKMYGGQIDERTLEKTQQQHMLYQQEQHHQILQQQIQDSICPPQPSPPLQAACENQPALLTHQLQRLRIQPSSPPPNHPNNHLFRQPSNSPPPMSSAMIQPHGAASSSQFQGLPSRSAIFQQQPENCSSPPNVALTCLGMQQPAQSQQVTIQVQEPVDMLSNMPGTAAGSSGRGISISPSAGQMQMQHRTNLMATLSYGHRPLSKQLSADSAEAHSLNVNRFSPANYDQAHLHPHLFSDQSRGSPSSYSPSTGVGFSPTQALKVPPLDQFPTFPPSAHQQPPHYTTSALQQALLSPTPPDYTRHQQVPHILQGLLSPRHSLTGHSDIRLPPTEFAQLIKRQQQQRQQQQQQQQQQEYQELFRHMNQGDAGSLAPSLGGQSMTERQALSYQNADSYHHHTSPQHLLQIRAQECVSQASSPTPPHGYAHQPALMHSESMEEDCSCEGAKDGFQDSKSSSTLTKGCHDSPLLLSTGGPGDPESLLGTVSHAQELGIHPYGHQPTAAFSKNKVPSREPVIGNCMDRSSPGQAVELPDHNGLGYPARPSVHEHHRPRALQRHHTIQNSDDAYVQLDNLPGMSLVAGKALSSARMSDAVLSQSSLMGSQQFQDGENEECGASLGGHEHPDLSDGSQHLNSSCYPSTCITDILLSYKHPEVSFSMEQAGV
T81830	DRUGINFO	D40NQW	GRN-300	Phase 1
T81830	DRUGINFO	D03YVB	HG-9-91-01	Investigative

T66540	TARGETID	T66540
T66540	FORMERID	TTDI02664
T66540	UNIPROID	TRPV1_HUMAN
T66540	TARGNAME	TRPV1 messenger RNA (TRPV1 mRNA)
T66540	GENENAME	TRPV1
T66540	TARGTYPE	Clinical trial
T66540	SYNONYMS	Vanilloid receptor 1 (mRNA); VR1 (mRNA); TrpV1 (mRNA); Transient receptor potential cation channel subfamily V member 1 (mRNA); Osm-9-like TRP channel 1 (mRNA); OTRPC1 (mRNA); Capsaicin receptor (mRNA)
T66540	FUNCTION	Seems to mediate proton influx and may be involved in intracellular acidosis in nociceptive neurons. Involved in mediation of inflammatory pain and hyperalgesia. Sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL. Activation by vanilloids, like capsaicin, and temperatures higher than 42 degrees Celsius, exhibits a time- and Ca(2+)-dependent outward rectification, followed by a long-lasting refractory state. Mild extracellular acidic pH (6. 5) potentiates channel activation by noxious heat and vanilloids, whereas acidic conditions (pH <6) directly activate the channel. Can be activated by endogenous compounds, including 12-hydroperoxytetraenoic acid and bradykinin. Acts as ionotropic endocannabinoid receptor with central neuromodulatory effects. Triggers a form of long-term depression (TRPV1-LTD) mediated by the endocannabinoid anandamine in the hippocampus and nucleus accumbens by affecting AMPA receptors endocytosis. Ligand-activated non-selective calcium permeant cation channel involved in detection of noxious chemical and thermal stimuli.
T66540	BIOCLASS	mRNA target
T66540	SEQUENCE	MKKWSSTDLGAAADPLQKDTCPDPLDGDPNSRPPPAKPQLSTAKSRTRLFGKGDSEEAFPVDCPHEEGELDSCPTITVSPVITIQRPGDGPTGARLLSQDSVAASTEKTLRLYDRRSIFEAVAQNNCQDLESLLLFLQKSKKHLTDNEFKDPETGKTCLLKAMLNLHDGQNTTIPLLLEIARQTDSLKELVNASYTDSYYKGQTALHIAIERRNMALVTLLVENGADVQAAAHGDFFKKTKGRPGFYFGELPLSLAACTNQLGIVKFLLQNSWQTADISARDSVGNTVLHALVEVADNTADNTKFVTSMYNEILMLGAKLHPTLKLEELTNKKGMTPLALAAGTGKIGVLAYILQREIQEPECRHLSRKFTEWAYGPVHSSLYDLSCIDTCEKNSVLEVIAYSSSETPNRHDMLLVEPLNRLLQDKWDRFVKRIFYFNFLVYCLYMIIFTMAAYYRPVDGLPPFKMEKTGDYFRVTGEILSVLGGVYFFFRGIQYFLQRRPSMKTLFVDSYSEMLFFLQSLFMLATVVLYFSHLKEYVASMVFSLALGWTNMLYYTRGFQQMGIYAVMIEKMILRDLCRFMFVYIVFLFGFSTAVVTLIEDGKNDSLPSESTSHRWRGPACRPPDSSYNSLYSTCLELFKFTIGMGDLEFTENYDFKAVFIILLLAYVILTYILLLNMLIALMGETVNKIAQESKNIWKLQRAITILDTEKSFLKCMRKAFRSGKLLQVGYTPDGKDDYRWCFRVDEVNWTTWNTNVGIINEDPGNCEGVKRTLSFSLRSSRVSGRHWKNFALVPLLREASARDRQSAQPEEVYLRQFSGSLKPEDAEVFKSPAASGEK
T66540	DRUGINFO	DRA84P	Tivanisiran	Phase 3

T03189	TARGETID	T03189
T03189	FORMERID	TTDI02153
T03189	UNIPROID	PRAME_HUMAN
T03189	TARGNAME	Tumor expressed melanoma antigen (PRAME)
T03189	GENENAME	PRAME
T03189	TARGTYPE	Clinical trial
T03189	SYNONYMS	Preferentially expressed antigen of melanoma; Opa-interacting protein 4; OIP-4; Melanoma antigen preferentially expressed in tumors; MAPE
T03189	FUNCTION	Functions as a transcriptional repressor, inhibiting the signaling of retinoic acid through the retinoic acid receptors RARA, RARB and RARG. Prevents retinoic acid-induced cell proliferation arrest, differentiation and apoptosis.
T03189	SEQUENCE	MERRRLWGSIQSRYISMSVWTSPRRLVELAGQSLLKDEALAIAALELLPRELFPPLFMAAFDGRHSQTLKAMVQAWPFTCLPLGVLMKGQHLHLETFKAVLDGLDVLLAQEVRPRRWKLQVLDLRKNSHQDFWTVWSGNRASLYSFPEPEAAQPMTKKRKVDGLSTEAEQPFIPVEVLVDLFLKEGACDELFSYLIEKVKRKKNVLRLCCKKLKIFAMPMQDIKMILKMVQLDSIEDLEVTCTWKLPTLAKFSPYLGQMINLRRLLLSHIHASSYISPEKEEQYIAQFTSQFLSLQCLQALYVDSLFFLRGRLDQLLRHVMNPLETLSITNCRLSEGDVMHLSQSPSVSQLSVLSLSGVMLTDVSPEPLQALLERASATLQDLVFDECGITDDQLLALLPSLSHCSQLTTLSFYGNSISISALQSLLQHLIGLSNLTHVLYPVPLESYEDIHGTLHLERLAYLHARLRELLCELGRPSMVWLSANPCPHCGDRTFYDPEPILCPCFMPN
T03189	DRUGINFO	D0X8TK	IMC-F106C	Phase 1/2
T03189	DRUGINFO	D0V6MX	IMA 203	Phase 1

T96876	TARGETID	T96876
T96876	FORMERID	TTDI02479
T96876	UNIPROID	CO7A1_HUMAN
T96876	TARGNAME	Collagen VII (COL7A1)
T96876	GENENAME	COL7A1
T96876	TARGTYPE	Clinical trial
T96876	SYNONYMS	Longchain collagen; Long-chain collagen; LC collagen; Collagen alpha1(VII) chain; Collagen alpha-1(VII) chain
T96876	FUNCTION	Stratified squamous epithelial basement membrane protein that forms anchoring fibrils which may contribute to epithelial basement membrane organization and adherence by interacting with extracellular matrix (ECM) proteins such as type IV collagen.
T96876	SEQUENCE	MTLRLLVAALCAGILAEAPRVRAQHRERVTCTRLYAADIVFLLDGSSSIGRSNFREVRSFLEGLVLPFSGAASAQGVRFATVQYSDDPRTEFGLDALGSGGDVIRAIRELSYKGGNTRTGAAILHVADHVFLPQLARPGVPKVCILITDGKSQDLVDTAAQRLKGQGVKLFAVGIKNADPEELKRVASQPTSDFFFFVNDFSILRTLLPLVSRRVCTTAGGVPVTRPPDDSTSAPRDLVLSEPSSQSLRVQWTAASGPVTGYKVQYTPLTGLGQPLPSERQEVNVPAGETSVRLRGLRPLTEYQVTVIALYANSIGEAVSGTARTTALEGPELTIQNTTAHSLLVAWRSVPGATGYRVTWRVLSGGPTQQQELGPGQGSVLLRDLEPGTDYEVTVSTLFGRSVGPATSLMARTDASVEQTLRPVILGPTSILLSWNLVPEARGYRLEWRRETGLEPPQKVVLPSDVTRYQLDGLQPGTEYRLTLYTLLEGHEVATPATVVPTGPELPVSPVTDLQATELPGQRVRVSWSPVPGATQYRIIVRSTQGVERTLVLPGSQTAFDLDDVQAGLSYTVRVSARVGPREGSASVLTVRREPETPLAVPGLRVVVSDATRVRVAWGPVPGASGFRISWSTGSGPESSQTLPPDSTATDITGLQPGTTYQVAVSVLRGREEGPAAVIVARTDPLGPVRTVHVTQASSSSVTITWTRVPGATGYRVSWHSAHGPEKSQLVSGEATVAELDGLEPDTEYTVHVRAHVAGVDGPPASVVVRTAPEPVGRVSRLQILNASSDVLRITWVGVTGATAYRLAWGRSEGGPMRHQILPGNTDSAEIRGLEGGVSYSVRVTALVGDREGTPVSIVVTTPPEAPPALGTLHVVQRGEHSLRLRWEPVPRAQGFLLHWQPEGGQEQSRVLGPELSSYHLDGLEPATQYRVRLSVLGPAGEGPSAEVTARTESPRVPSIELRVVDTSIDSVTLAWTPVSRASSYILSWRPLRGPGQEVPGSPQTLPGISSSQRVTGLEPGVSYIFSLTPVLDGVRGPEASVTQTPVCPRGLADVVFLPHATQDNAHRAEATRRVLERLVLALGPLGPQAVQVGLLSYSHRPSPLFPLNGSHDLGIILQRIRDMPYMDPSGNNLGTAVVTAHRYMLAPDAPGRRQHVPGVMVLLVDEPLRGDIFSPIREAQASGLNVVMLGMAGADPEQLRRLAPGMDSVQTFFAVDDGPSLDQAVSGLATALCQASFTTQPRPEPCPVYCPKGQKGEPGEMGLRGQVGPPGDPGLPGRTGAPGPQGPPGSATAKGERGFPGADGRPGSPGRAGNPGTPGAPGLKGSPGLPGPRGDPGERGPRGPKGEPGAPGQVIGGEGPGLPGRKGDPGPSGPPGPRGPLGDPGPRGPPGLPGTAMKGDKGDRGERGPPGPGEGGIAPGEPGLPGLPGSPGPQGPVGPPGKKGEKGDSEDGAPGLPGQPGSPGEQGPRGPPGAIGPKGDRGFPGPLGEAGEKGERGPPGPAGSRGLPGVAGRPGAKGPEGPPGPTGRQGEKGEPGRPGDPAVVGPAVAGPKGEKGDVGPAGPRGATGVQGERGPPGLVLPGDPGPKGDPGDRGPIGLTGRAGPPGDSGPPGEKGDPGRPGPPGPVGPRGRDGEVGEKGDEGPPGDPGLPGKAGERGLRGAPGVRGPVGEKGDQGDPGEDGRNGSPGSSGPKGDRGEPGPPGPPGRLVDTGPGAREKGEPGDRGQEGPRGPKGDPGLPGAPGERGIEGFRGPPGPQGDPGVRGPAGEKGDRGPPGLDGRSGLDGKPGAAGPSGPNGAAGKAGDPGRDGLPGLRGEQGLPGPSGPPGLPGKPGEDGKPGLNGKNGEPGDPGEDGRKGEKGDSGASGREGRDGPKGERGAPGILGPQGPPGLPGPVGPPGQGFPGVPGGTGPKGDRGETGSKGEQGLPGERGLRGEPGSVPNVDRLLETAGIKASALREIVETWDESSGSFLPVPERRRGPKGDSGEQGPPGKEGPIGFPGERGLKGDRGDPGPQGPPGLALGERGPPGPSGLAGEPGKPGIPGLPGRAGGVGEAGRPGERGERGEKGERGEQGRDGPPGLPGTPGPPGPPGPKVSVDEPGPGLSGEQGPPGLKGAKGEPGSNGDQGPKGDRGVPGIKGDRGEPGPRGQDGNPGLPGERGMAGPEGKPGLQGPRGPPGPVGGHGDPGPPGAPGLAGPAGPQGPSGLKGEPGETGPPGRGLTGPTGAVGLPGPPGPSGLVGPQGSPGLPGQVGETGKPGAPGRDGASGKDGDRGSPGVPGSPGLPGPVGPKGEPGPTGAPGQAVVGLPGAKGEKGAPGGLAGDLVGEPGAKGDRGLPGPRGEKGEAGRAGEPGDPGEDGQKGAPGPKGFKGDPGVGVPGSPGPPGPPGVKGDLGLPGLPGAPGVVGFPGQTGPRGEMGQPGPSGERGLAGPPGREGIPGPLGPPGPPGSVGPPGASGLKGDKGDPGVGLPGPRGERGEPGIRGEDGRPGQEGPRGLTGPPGSRGERGEKGDVGSAGLKGDKGDSAVILGPPGPRGAKGDMGERGPRGLDGDKGPRGDNGDPGDKGSKGEPGDKGSAGLPGLRGLLGPQGQPGAAGIPGDPGSPGKDGVPGIRGEKGDVGFMGPRGLKGERGVKGACGLDGEKGDKGEAGPPGRPGLAGHKGEMGEPGVPGQSGAPGKEGLIGPKGDRGFDGQPGPKGDQGEKGERGTPGIGGFPGPSGNDGSAGPPGPPGSVGPRGPEGLQGQKGERGPPGERVVGAPGVPGAPGERGEQGRPGPAGPRGEKGEAALTEDDIRGFVRQEMSQHCACQGQFIASGSRPLPSYAADTAGSQLHAVPVLRVSHAEEEERVPPEDDEYSEYSEYSVEEYQDPEAPWDSDDPCSLPLDEGSCTAYTLRWYHRAVTGSTEACHPFVYGGCGGNANRFGTREACERRCPPRVVQSQGTGTAQD
T96876	DRUGINFO	D8CW9E	Beremagene geperpavec	Phase 3

T80912	TARGETID	T80912
T80912	FORMERID	TTDNR00766
T80912	UNIPROID	VPP3_HUMAN
T80912	TARGNAME	T-cell immune regulator 1 (TCIRG1)
T80912	GENENAME	TCIRG1
T80912	TARGTYPE	Clinical trial
T80912	SYNONYMS	Vacuolar proton translocating ATPase 116 kDa subunit a isoform 3; V-ATPase 116 kDa isoform a3; TIRC7; TCIRG1; T-cell immune response cDNA7 protein; Osteoclastic proton pump 116 kDa subunit; OC116; OC-116 kDa
T80912	FUNCTION	Part of the proton channel of V-ATPases. Seems to be directly involved in T-cell activation.
T80912	SEQUENCE	MGSMFRSEEVALVQLFLPTAAAYTCVSRLGELGLVEFRDLNASVSAFQRRFVVDVRRCEELEKTFTFLQEEVRRAGLVLPPPKGRLPAPPPRDLLRIQEETERLAQELRDVRGNQQALRAQLHQLQLHAAVLRQGHEPQLAAAHTDGASERTPLLQAPGGPHQDLRVNFVAGAVEPHKAPALERLLWRACRGFLIASFRELEQPLEHPVTGEPATWMTFLISYWGEQIGQKIRKITDCFHCHVFPFLQQEEARLGALQQLQQQSQELQEVLGETERFLSQVLGRVLQLLPPGQVQVHKMKAVYLALNQCSVSTTHKCLIAEAWCSVRDLPALQEALRDSSMEEGVSAVAHRIPCRDMPPTLIRTNRFTASFQGIVDAYGVGRYQEVNPAPYTIITFPFLFAVMFGDVGHGLLMFLFALAMVLAENRPAVKAAQNEIWQTFFRGRYLLLLMGLFSIYTGFIYNECFSRATSIFPSGWSVAAMANQSGWSDAFLAQHTMLTLDPNVTGVFLGPYPFGIDPIWSLAANHLSFLNSFKMKMSVILGVVHMAFGVVLGVFNHVHFGQRHRLLLETLPELTFLLGLFGYLVFLVIYKWLCVWAARAASAPSILIHFINMFLFSHSPSNRLLYPRQEVVQATLVVLALAMVPILLLGTPLHLLHRHRRRLRRRPADRQEENKAGLLDLPDASVNGWSSDEEKAGGLDDEEEAELVPSEVLMHQAIHTIEFCLGCVSNTASYLRLWALSLAHAQLSEVLWAMVMRIGLGLGREVGVAAVVLVPIFAAFAVMTVAILLVMEGLSAFLHALRLHWVEFQNKFYSGTGYKLSPFTFAATDD
T80912	DRUGINFO	DFP0R6	RP-L401	Phase 1

T20017	TARGETID	T20017
T20017	FORMERID	TTDNC00392
T20017	UNIPROID	CRTC1_HUMAN
T20017	TARGNAME	CREB-regulated transcription coactivator 1 (TORC1)
T20017	GENENAME	CRTC1
T20017	TARGTYPE	Clinical trial
T20017	SYNONYMS	WAMTP1; Transducer of regulated cAMP response elementbinding protein 1; Transducer of regulated cAMP response element-binding protein 1; Transducer of CREB protein 1; TORC1; TORC-1; Mucoepidermoid carcinoma translocated protein 1; MECT1; KIAA0616; CREBregulated transcription coactivator 1
T20017	FUNCTION	Acts as a coactivator, in the SIK/TORC signaling pathway, being active when dephosphorylated and acts independently of CREB1 'Ser-133' phosphorylation. Enhances the interaction of CREB1 with TAF4. Regulates the expression of specific CREB-activated genes such as the steroidogenic gene, StAR. Potent coactivator of PGC1alpha and inducer of mitochondrial biogenesis in muscle cells. In the hippocampus, involved in late-phase long-term potentiation (L-LTP) maintenance at the Schaffer collateral-CA1 synapses. May be required for dendritic growth of developing cortical neurons. In concert with SIK1, regulates the light-induced entrainment of the circadian clock. In response to light stimulus, coactivates the CREB-mediated transcription of PER1 which plays an important role in the photic entrainment of the circadian clock. Transcriptional coactivator for CREB1 which activates transcription through both consensus and variant cAMP response element (CRE) sites.
T20017	SEQUENCE	MATSNNPRKFSEKIALHNQKQAEETAAFEEVMKDLSLTRAARLQLQKSQYLQLGPSRGQYYGGSLPNVNQIGSGTMDLPFQTPFQSSGLDTSRTTRHHGLVDRVYRERGRLGSPHRRPLSVDKHGRQADSCPYGTMYLSPPADTSWRRTNSDSALHQSTMTPTQPESFSSGSQDVHQKRVLLLTVPGMEETTSEADKNLSKQAWDTKKTGSRPKSCEVPGINIFPSADQENTTALIPATHNTGGSLPDLTNIHFPSPLPTPLDPEEPTFPALSSSSSTGNLAANLTHLGIGGAGQGMSTPGSSPQHRPAGVSPLSLSTEARRQQASPTLSPLSPITQAVAMDALSLEQQLPYAFFTQAGSQQPPPQPQPPPPPPPASQQPPPPPPPQAPVRLPPGGPLLPSASLTRGPQPPPLAVTVPSSLPQSPPENPGQPSMGIDIASAPALQQYRTSAGSPANQSPTSPVSNQGFSPGSSPQHTSTLGSVFGDAYYEQQMAARQANALSHQLEQFNMMENAISSSSLYSPGSTLNYSQAAMMGLTGSHGSLPDSQQLGYASHSGIPNIILTVTGESPPSLSKELTSSLAGVGDVSFDSDSQFPLDELKIDPLTLDGLHMLNDPDMVLADPATEDTFRMDRL
T20017	DRUGINFO	DFY58O	RTB101	Phase 3

T98091	TARGETID	T98091
T98091	FORMERID	TTDI03248
T98091	UNIPROID	GPR84_HUMAN
T98091	TARGNAME	Inflammation-related GPCR EX33 (GPR84)
T98091	GENENAME	GPR84
T98091	TARGTYPE	Clinical trial
T98091	SYNONYMS	Inflammation-related G-protein coupled receptor EX33; G-protein coupled receptor 84; EX33
T98091	FUNCTION	Receptor for medium-chain free fatty acid (FFA) with carbon chain lengths of C9 to C14. Capric acid (C10:0), undecanoic acid (C11:0) and lauric acid (C12:0) are the most potent agonists. Not activated by short-chain and long-chain saturated and unsaturated FFAs. Activation by medium-chain free fatty acid is coupled to a pertussis toxin sensitive G(i/o) protein pathway. May have important roles in processes from fatty acid metabolism to regulation of the immune system.
T98091	SEQUENCE	MWNSSDANFSCYHESVLGYRYVAVSWGVVVAVTGTVGNVLTLLALAIQPKLRTRFNLLIANLTLADLLYCTLLQPFSVDTYLHLHWRTGATFCRVFGLLLFASNSVSILTLCLIALGRYLLIAHPKLFPQVFSAKGIVLALVSTWVVGVASFAPLWPIYILVPVVCTCSFDRIRGRPYTTILMGIYFVLGLSSVGIFYCLIHRQVKRAAQALDQYKLRQASIHSNHVARTDEAMPGRFQELDSRLASGGPSEGISSEPVSAATTQTLEGDSSEVGDQINSKRAKQMAEKSPPEASAKAQPIKGARRAPDSSSEFGKVTRMCFAVFLCFALSYIPFLLLNILDARVQAPRVVHMLAANLTWLNGCINPVLYAAMNRQFRQAYGSILKRGPRSFHRLH
T98091	DRUGINFO	DT56YX	PBI-4050	Phase 2
T98091	DRUGINFO	DZLM72	SHR0534	Phase 1
T98091	DRUGINFO	D03GHN	3-hydroxy capric acid	Investigative
T98091	DRUGINFO	D0E1UA	2-hydroxy capric acid	Investigative
T98091	DRUGINFO	D0R1MM	6-n-octylaminouracil	Investigative
T98091	DRUGINFO	D0T2CG	3-hydroxylauric acid	Investigative
T98091	DRUGINFO	D0T4BP	2-hydroxylauric acid	Investigative
T98091	DRUGINFO	D0X0PF	undecanoic acid	Investigative

T41202	TARGETID	T41202
T41202	FORMERID	TTDI00186
T41202	TARGNAME	microRNA hsa-miR-29b (MIR29b)
T41202	TARGTYPE	Clinical trial
T41202	BIOCLASS	Non-coding RNA target
T41202	DRUGINFO	DC7UF3	Remlarsen	Phase 2

T73992	TARGETID	T73992
T73992	FORMERID	TTDC00092
T73992	TARGNAME	Beta-secretase (BACE)
T73992	TARGTYPE	Clinical trial
T73992	SYNONYMS	Transmembrane aspartic protease; Beta-site amyloid precursor protein cleaving enzyme; Beta-site AbetaPP-cleaving enzyme; BACE1
T73992	FUNCTION	Responsible for the proteolytic processing of the amyloid precursor protein (app). Cleaves at the amino terminus of the a-beta peptide sequence, between residues 671 and 672 of app, leads to the generation and extracellular release of beta-cleaved soluble liquid.
T73992	BIOCLASS	Peptidase
T73992	DRUGINFO	D0G2IC	(S)-FLURBIPROFEN	Preregistration
T73992	DRUGINFO	D0Y0EP	Lanabecestat	Phase 3
T73992	DRUGINFO	D08MHD	E-2609	Phase 3
T73992	DRUGINFO	D0R4KK	verubecestat	Phase 3
T73992	DRUGINFO	D01AYX	AZD3293	Phase 2/3
T73992	DRUGINFO	D0T2FP	JNJ-54861911	Phase 2/3
T73992	DRUGINFO	D0F8GK	LY2886721	Phase 2
T73992	DRUGINFO	D0XD5N	LY3202626	Phase 2
T73992	DRUGINFO	D05FGR	R-flurbiprofen	Phase 2
T73992	DRUGINFO	D04OSA	AZD-3839	Phase 1
T73992	DRUGINFO	D04VZS	CTS-21166	Phase 1
T73992	DRUGINFO	D08TVI	HPP-854	Phase 1
T73992	DRUGINFO	D0N1BF	LY-2811376	Phase 1
T73992	DRUGINFO	D0O8UB	RG7129	Phase 1
T73992	DRUGINFO	D00XKB	AZ-4217	Clinical trial
T73992	DRUGINFO	D0CG8S	oxazine 89	Clinical trial
T73992	DRUGINFO	D0H6AG	PMID23981898C11d 	Clinical trial
T73992	DRUGINFO	D0Q6NN	TAK-070	Clinical trial
T73992	DRUGINFO	D0T7BV	PMID22911925C2	Clinical trial
T73992	DRUGINFO	D0E3SX	SCH-1359113	Preclinical
T73992	DRUGINFO	D0K3WN	DNP-004089	Terminated
T73992	DRUGINFO	D00CYX	Glu-Leu-Asp-Leu-(CHOH-CH2)-Ala-Ala-Glu-Phe	Investigative
T73992	DRUGINFO	D00LZS	KMI-538	Investigative
T73992	DRUGINFO	D02WYE	4-(2-aminoethyl)-2-cyclohexylphenol	Investigative
T73992	DRUGINFO	D03VQF	(2S)-2'-methoxy kurarinone	Investigative
T73992	DRUGINFO	D04RSC	OM00-3	Investigative
T73992	DRUGINFO	D06MYZ	N-(1-benzylpiperidin-4-yl)-4-sulfanylbutanamide	Investigative
T73992	DRUGINFO	D06ZJQ	KMI-172	Investigative
T73992	DRUGINFO	D07EWF	PMID23412139C16	Investigative
T73992	DRUGINFO	D08ALW	MMI-175	Investigative
T73992	DRUGINFO	D08HZD	N~3~-(3-PYRIDIN-3-YLBENZYL)PYRIDINE-2,3-DIAMINE	Investigative
T73992	DRUGINFO	D08MZY	Eckol	Investigative
T73992	DRUGINFO	D08UYP	DIECKOL	Investigative
T73992	DRUGINFO	D09SOY	5,5-Diphenyl-2-iminohydantoin	Investigative
T73992	DRUGINFO	D0A0RO	N~3~-BENZYLPYRIDINE-2,3-DIAMINE	Investigative
T73992	DRUGINFO	D0D4FV	LEACHIANONE A	Investigative
T73992	DRUGINFO	D0H0SE	TRIPHLOROETHOL A	Investigative
T73992	DRUGINFO	D0I8KC	6-[2-(1H-INDOL-6-YL)ETHYL]PYRIDIN-2-AMINE	Investigative
T73992	DRUGINFO	D0K5OZ	AZ3971	Investigative
T73992	DRUGINFO	D0L7AT	7-Phloroethol	Investigative
T73992	DRUGINFO	D0M4IR	KMI-494	Investigative
T73992	DRUGINFO	D0M4ND	4-(2-aminoethyl)-2-ethylphenol	Investigative
T73992	DRUGINFO	D0O0FA	KUSHENOL A	Investigative
T73992	DRUGINFO	D0PR9E	KMI-596	Investigative
T73992	DRUGINFO	D0Q5XM	GSK-188909	Investigative
T73992	DRUGINFO	D0S0BN	PHLOROFUCOFUROECKOL A	Investigative
T73992	DRUGINFO	D0V4PB	4-(4-FLUOROBENZYL)PIPERIDINE	Investigative
T73992	DRUGINFO	D0WA9S	DIOXINODEHYDROECKOL	Investigative
T73992	DRUGINFO	D00SDQ	PMID21907142CJ	Investigative
T73992	DRUGINFO	D02LCH	GRL-7234	Investigative
T73992	DRUGINFO	D0H3EJ	Carbocyclic Peptidomimetic	Investigative
T73992	DRUGINFO	D0O0GW	example 2 (WO2013004676)	Investigative
T73992	DRUGINFO	D0S1MC	AP-2243	Investigative
T73992	DRUGINFO	D01PNM	KURARINONE	Investigative
T73992	DRUGINFO	D0M4IE	Bis-7-tacrine	Investigative
T73992	DRUGINFO	D0RB1V	(-)-CATECHINGALLATE	Investigative

T92138	TARGETID	T92138
T92138	FORMERID	TTDC00315
T92138	TARGNAME	Phosphodiesterase (PDE)
T92138	TARGTYPE	Clinical trial
T92138	SYNONYMS	Human phosphodiesterase
T92138	FUNCTION	Participates in processes of transmission and amplification of the visual signal. cGMP-PDEs are the effector molecules in G-protein-mediated phototransduction in vertebrate rods and cones.
T92138	BIOCLASS	Phosphoric diester hydrolase
T92138	DRUGINFO	D0A8KX	M-518101	Phase 3
T92138	DRUGINFO	D06LFV	NM-702	Phase 3
T92138	DRUGINFO	D08FOX	Piroximone	Discontinued in Phase 3
T92138	DRUGINFO	D0B2OL	AA-2379	Discontinued in Phase 2
T92138	DRUGINFO	D0C1TJ	HN-10200	Discontinued in Phase 2
T92138	DRUGINFO	D0X1EX	TIBENELAST	Discontinued in Phase 2
T92138	DRUGINFO	D04ONP	ALBIFYLLINE	Discontinued in Phase 1
T92138	DRUGINFO	D05VLN	Isomazole	Terminated
T92138	DRUGINFO	D0E1ZE	BBB-022	Terminated
T92138	DRUGINFO	D0J0MK	JTT-608	Terminated
T92138	DRUGINFO	D00MEV	Sch-45752	Terminated
T92138	DRUGINFO	D09TDK	DPN-205-734	Investigative

T86192	TARGETID	T86192
T86192	FORMERID	TTDI01791
T86192	TARGNAME	Voltage-gated potassium channel Kv7 (KCNQ)
T86192	TARGTYPE	Clinical trial
T86192	SYNONYMS	Voltage-gated potassium channel subunit Kv7; Potassium voltage-gated channel subfamily KQT; Kv7; KVLQT; KQT-like; IKs producing slow voltage-gated potassium channel subunit alpha KvLQT; IKs producing slow voltage-gated potassium channel alpha subunit KvLQT
T86192	BIOCLASS	Voltage-gated ion channel
T86192	DRUGINFO	D0X7GL	Retigabine	Approved
T86192	DRUGINFO	D0SD9V	Flupirtine	Phase 2
T86192	DRUGINFO	D0D7MJ	CNSB-001	Phase 2
T86192	DRUGINFO	D0W7IR	DMP-543	Discontinued in Phase 2

T67747	TARGETID	T67747
T67747	FORMERID	TTDI02258
T67747	TARGNAME	NF-kappa-B messenger RNA (NFKB mRNA)
T67747	TARGTYPE	Clinical trial
T67747	SYNONYMS	mRNA of NF-kappaB; NF-kappaB mRNA
T67747	FUNCTION	NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65,RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.
T67747	BIOCLASS	mRNA target

T90768	TARGETID	T90768
T90768	FORMERID	TTDC00274
T90768	TARGNAME	Human immunodeficiency virus Trans-activation response element (HIV TAR RNA element)
T90768	TARGTYPE	Clinical trial
T90768	SYNONYMS	HIV TAR element
T90768	BIOCLASS	mRNA target
T90768	DRUGINFO	D0JZ8X	HGTV43	Phase 2

T75251	TARGETID	T75251
T75251	FORMERID	TTDI01923
T75251	TARGNAME	Tubulin receptor (TUBR)
T75251	TARGTYPE	Clinical trial
T75251	SYNONYMS	Tubulin protein
T75251	FUNCTION	Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
T75251	DRUGINFO	D00YBZ	OC-10X	Phase 1

T25537	TARGETID	T25537
T25537	FORMERID	TTDI01585
T25537	TARGNAME	Mitogen-activated protein kinase (MAPK)
T25537	TARGTYPE	Clinical trial
T25537	SYNONYMS	MAPK; Extracellular signal-regulated kinase; ERK
T25537	BIOCLASS	Kinase
T25537	DRUGINFO	D0C4GX	GBL-310	Phase 2
T25537	DRUGINFO	D0TA8O	LTT462	Phase 1
T25537	DRUGINFO	DQ5YV2	PF-07799544	Phase 1
T25537	DRUGINFO	D01FTR	PMID25991433-Compound-C3	Patented
T25537	DRUGINFO	D04JVY	PMID25991433-Compound-J6	Patented
T25537	DRUGINFO	D09EWC	PMID25991433-Compound-L	Patented
T25537	DRUGINFO	D0CS9R	PMID25991433-Compound-B1	Patented
T25537	DRUGINFO	D0GX7W	PMID25991433-Compound-P3	Patented
T25537	DRUGINFO	D0J8PJ	PMID25991433-Compound-B3	Patented
T25537	DRUGINFO	D0O2EF	PMID25991433-Compound-Q2	Patented
T25537	DRUGINFO	D0PG5N	PMID25991433-Compound-J1	Patented
T25537	DRUGINFO	D0QK6D	PMID25991433-Compound-C2	Patented
T25537	DRUGINFO	D0UY9Y	PMID25991433-Compound-P2	Patented
T25537	DRUGINFO	D0W7MG	PMID25991433-Compound-F1	Patented
T25537	DRUGINFO	D0X7OF	PMID25991433-Compound-N2	Patented
T25537	DRUGINFO	D0Y4KU	PMID25991433-Compound-B2	Patented
T25537	DRUGINFO	D00GWE	Bidentate ligands of Markush derivative 2	Patented
T25537	DRUGINFO	D0SV0D	Bidentate ligands of Markush derivative 1	Patented
T25537	DRUGINFO	D0V7UQ	PMID25991433-Compound-Q1	Patented
T25537	DRUGINFO	D08OJQ	PMID25991433-Compound-L2	Patented
T25537	DRUGINFO	D0G7LB	PMID25991433-Compound-L3	Patented
T25537	DRUGINFO	D0GD8Y	U0126	Investigative

T45597	TARGETID	T45597
T45597	TARGNAME	Ribosomal protein S6 kinase (S6K)
T45597	TARGTYPE	Clinical trial
T45597	SYNONYMS	Ribosomal s6 kinase
T45597	BIOCLASS	Kinase
T45597	DRUGINFO	D0VO5S	LY-2584702	Phase 1
T45597	DRUGINFO	D00DXH	LYS-6KAKT1	Phase 1
T45597	DRUGINFO	D0Q0PO	LY2780301	Phase 1
T45597	DRUGINFO	D0X2JM	XL418	Phase 1
T45597	DRUGINFO	D0M0AK	PMID27410995-Compound-Figure3k	Patented

T58998	TARGETID	T58998
T58998	FORMERID	TTDNC00380
T58998	TARGNAME	Bromodomain and extraterminal domain protein (BET)
T58998	TARGTYPE	Clinical trial
T58998	SYNONYMS	Bromodomain and Extra Terminal protein
T58998	DRUGINFO	D01LVE	CPI-0610	Phase 3
T58998	DRUGINFO	D8VJT5	ZEN-3694	Phase 2
T58998	DRUGINFO	D06ILL	BMS-986158	Phase 1/2
T58998	DRUGINFO	D4Y0IM	INCB054329	Phase 1/2
T58998	DRUGINFO	D7FJQ3	INCB057643	Phase 1/2
T58998	DRUGINFO	DA91HS	ODM-207	Phase 1/2
T58998	DRUGINFO	D02YNI	OTX-015	Phase 1/2
T58998	DRUGINFO	D03JLR	PLX51107	Phase 1
T58998	DRUGINFO	D06QBV	BI 894999	Phase 1
T58998	DRUGINFO	D08KSV	RG6146	Phase 1
T58998	DRUGINFO	D0M2TS	Mivebresib	Phase 1
T58998	DRUGINFO	D0N8RA	GS-5829	Phase 1
T58998	DRUGINFO	D0TM0Y	FT-1101	Phase 1
T58998	DRUGINFO	D0UL2X	CC-90010	Phase 1
T58998	DRUGINFO	D15ZUR	RO6870810	Phase 1
T58998	DRUGINFO	D3TW6X	ZEN003694	Phase 1
T58998	DRUGINFO	DIX61C	CC-90010	Phase 1
T58998	DRUGINFO	DM2Y8T	GSK2820151	Phase 1
T58998	DRUGINFO	DRK7Q1	BAY 1238097	Phase 1
T58998	DRUGINFO	DV1R0X	CC-95775	Phase 1
T58998	DRUGINFO	D07OFM	GSK525762	Phase 1
T58998	DRUGINFO	D0ZW4W	(+)-JQ1	Phase 1
T58998	DRUGINFO	D04WNN	PMID26924192-Compound-53	Patented
T58998	DRUGINFO	D05GPL	Isoxazole-based bicyclic compound 4	Patented
T58998	DRUGINFO	D05PZG	Tetra-hydro-quinoline derivative 4	Patented
T58998	DRUGINFO	D08IZA	Isoxazole-based bicyclic compound 17	Patented
T58998	DRUGINFO	D09ENS	Quinazolinone derivative 3	Patented
T58998	DRUGINFO	D0A4RP	Isoxazole-based bicyclic compound 19	Patented
T58998	DRUGINFO	D0B8GA	Isoxazole-based bicyclic compound 5	Patented
T58998	DRUGINFO	D0BH7X	Isoxazole-based bicyclic compound 6	Patented
T58998	DRUGINFO	D0C1HS	Dihydropyrido pyrazinone compound 1	Patented
T58998	DRUGINFO	D0CY3L	Isoxazole-based bicyclic compound 8	Patented
T58998	DRUGINFO	D0CY9X	Isoxazole-based bicyclic compound 7	Patented
T58998	DRUGINFO	D0E4UV	PMID26924192-Compound-51	Patented
T58998	DRUGINFO	D0FC0Z	Isoxazole-based bicyclic compound 13	Patented
T58998	DRUGINFO	D0FY9K	Quinazolinone derivative 4	Patented
T58998	DRUGINFO	D0G5UR	PMID26924192-Compound-52	Patented
T58998	DRUGINFO	D0G8IM	Isoxazole-based bicyclic compound 9	Patented
T58998	DRUGINFO	D0HB3F	Pyrimido-indole derivative 1	Patented
T58998	DRUGINFO	D0I6HB	Quinazolinone derivative 5	Patented
T58998	DRUGINFO	D0JR5G	PMID26924192-Compound-50	Patented
T58998	DRUGINFO	D0KG1T	Pyrimido-indole derivative 2	Patented
T58998	DRUGINFO	D0OJ1R	PMID26924192-Compound-57	Patented
T58998	DRUGINFO	D0ON7G	Isoxazole-based bicyclic compound 3	Patented
T58998	DRUGINFO	D0P5SF	Pyrimido-indole derivative 3	Patented
T58998	DRUGINFO	D0P8PE	Isoxazole-based bicyclic compound 14	Patented
T58998	DRUGINFO	D0PK4M	Isoxazole-based bicyclic compound 18	Patented
T58998	DRUGINFO	D0QA4O	Isoxazole-based bicyclic compound 10	Patented
T58998	DRUGINFO	D0R6KH	PMID26924192-Compound-56	Patented
T58998	DRUGINFO	D0R8CR	PMID26924192-Compound-54	Patented
T58998	DRUGINFO	D0SG9F	Isoxazole-based bicyclic compound 1	Patented
T58998	DRUGINFO	D0SV2S	Tetra-hydro-quinoline derivative 3	Patented
T58998	DRUGINFO	D0T8DH	Isoxazole-based bicyclic compound 15	Patented
T58998	DRUGINFO	D0T9ZO	PMID26924192-Compound-55	Patented
T58998	DRUGINFO	D0TF2N	Isoxazole-based bicyclic compound 16	Patented
T58998	DRUGINFO	D0U5BE	Tetra-hydro-quinoline derivative 2	Patented
T58998	DRUGINFO	D0UU2U	Isoxazole-based bicyclic compound 11	Patented
T58998	DRUGINFO	D0W3NX	Isoxazole-based bicyclic compound 12	Patented
T58998	DRUGINFO	D0WM3Y	Isoxazole-based bicyclic compound 2	Patented

T85574	TARGETID	T85574
T85574	FORMERID	TTDI01751
T85574	TARGNAME	Angiotensin II receptor (AGTR)
T85574	TARGTYPE	Clinical trial
T85574	FUNCTION	Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol- calcium second messenger system.
T85574	DRUGINFO	D0I7BD	CYT-006-AngQb	Phase 2
T85574	DRUGINFO	D0HJ7I	DA-727	Phase 1
T85574	DRUGINFO	D00NTW	BIBR-363	Discontinued in Phase 2
T85574	DRUGINFO	D03OKG	FK-739	Discontinued in Phase 2
T85574	DRUGINFO	D05EEJ	ETRX-101	Discontinued in Phase 2
T85574	DRUGINFO	D0CE6T	Elisartan potassium	Discontinued in Phase 2
T85574	DRUGINFO	D0F2HA	ICI-D-8731	Discontinued in Phase 2
T85574	DRUGINFO	D0M7PS	E-4177	Discontinued in Phase 2
T85574	DRUGINFO	D00BIY	CGP-48369	Discontinued in Phase 1
T85574	DRUGINFO	D0L3EW	ICI-D-6888	Discontinued in Phase 1
T85574	DRUGINFO	D0N1EW	DuP-532	Discontinued in Phase 1
T85574	DRUGINFO	D00FWB	L-163017	Terminated
T85574	DRUGINFO	D00MSP	FR-149581	Terminated
T85574	DRUGINFO	D02ABS	BMS-180560	Terminated
T85574	DRUGINFO	D02ZKB	WAY-126227	Terminated
T85574	DRUGINFO	D04FXE	KW-3433	Terminated
T85574	DRUGINFO	D07GQA	ZD-7155	Terminated
T85574	DRUGINFO	D07LEW	BIBS-39	Terminated
T85574	DRUGINFO	D08VTA	EXP-6803	Terminated
T85574	DRUGINFO	D0A8HL	DMP-811	Terminated
T85574	DRUGINFO	D0F0TW	SL-910102	Terminated
T85574	DRUGINFO	D0N5CT	BIBS-222	Terminated
T85574	DRUGINFO	D0O0QG	SC-51316	Terminated
T85574	DRUGINFO	D0O0RK	A-81282	Terminated
T85574	DRUGINFO	D0T5SG	ME-3221	Terminated
T85574	DRUGINFO	D0XI9O	RWJ-46458	Terminated
T85574	DRUGINFO	D0Y8PH	CI-996	Terminated
T85574	DRUGINFO	D06MUI	A-81988	Terminated
T85574	DRUGINFO	D0XG0Z	A-82186	Investigative

T95241	TARGETID	T95241
T95241	FORMERID	TTDNR00751
T95241	TARGNAME	Calcium-activated potassium channel KCa2 (KCNN)
T95241	TARGTYPE	Clinical trial
T95241	FUNCTION	Forms a voltage-independent potassium channel activated by intracellular calcium. Activation is followed by membrane hyperpolarization. Thought to regulate neuronal excitability by contributing to the slow component of synaptic afterhyperpolarization. The channel is blockedby apamin.
T95241	BIOCLASS	Voltage-gated ion channel
T95241	DRUGINFO	D08ANJ	AP-30663	Phase 1/2
T95241	DRUGINFO	D0FI1L	CAD-1883	Phase 1/2
T95241	DRUGINFO	D0WM8D	CAD-1833	Phase 1

T67022	TARGETID	T67022
T67022	FORMERID	TTDR00960
T67022	TARGNAME	Caspase (CASP)
T67022	TARGTYPE	Clinical trial
T67022	BIOCLASS	Peptidase
T67022	DRUGINFO	D09BTK	NCX-1000	Phase 2
T67022	DRUGINFO	D2D9CN	Z-VAD-fmk	Preclinical
T67022	DRUGINFO	DM16YT	VX-166	Preclinical
T67022	DRUGINFO	D0J1WJ	ALS-769	Terminated
T67022	DRUGINFO	D0O7HF	IDN-1965	Investigative
T67022	DRUGINFO	D0L9AX	Ac-DEVD-CHO	Investigative
T67022	DRUGINFO	DAQ31P	2-aminophenoxazine-3-one	Investigative
T67022	DRUGINFO	D0V6DX	Isoquinoline-1,3,4(2H)-trione	Investigative

T95488	TARGETID	T95488
T95488	FORMERID	TTDC00300
T95488	TARGNAME	Interleukin-1 (IL1)
T95488	TARGTYPE	Clinical trial
T95488	SYNONYMS	IL-1
T95488	DRUGINFO	D00IUD	K-832	Phase 2

T10445	TARGETID	T10445
T10445	FORMERID	TTDS00064
T10445	TARGNAME	Lipase unspecific (LIP)
T10445	TARGTYPE	Clinical trial
T10445	BIOCLASS	Ester hydrolase
T10445	DRUGINFO	D01CGX	ApoC-III	Phase 3
T10445	DRUGINFO	D0Y1VZ	GT-389255	Discontinued in Phase 2
T10445	DRUGINFO	D05JYE	Butylphosphonate	Investigative

T45457	TARGETID	T45457
T45457	FORMERID	TTDR00057
T45457	TARGNAME	Melanocortin receptor (MCR)
T45457	TARGTYPE	Clinical trial
T45457	SYNONYMS	Melanocortin receptor
T45457	DRUGINFO	D0B2SW	ASP-3291	Phase 2
T45457	DRUGINFO	D09LXL	Ac-His-DPhe(pBr)-Arg-Trp-NH2	Investigative
T45457	DRUGINFO	D0G3GE	Ac-His-DPhe(3,4-diCl)-Arg-Trp-NH2	Investigative
T45457	DRUGINFO	D0J0DK	Ac-His-DNal(2)-Arg-Trp-NH2	Investigative
T45457	DRUGINFO	D0O6WF	Ac-His-DPhe(pCF3)-Arg-Trp-NH2	Investigative
T45457	DRUGINFO	D0V1JT	Ac-His-DPhe(pI)-Arg-Trp-NH2	Investigative
T45457	DRUGINFO	D01VMU	C[CO-(CH2)3-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2	Investigative
T45457	DRUGINFO	D0B9NH	C[Nle-Glu-D-Phe-Arg-Trp-Glu]-NH2	Investigative
T45457	DRUGINFO	D00NOG	MK-11	Investigative
T45457	DRUGINFO	D00TSX	C[Nle-His-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T45457	DRUGINFO	D01HTX	C[Nle-Nle-D-Phe-Arg-Trp-Glu]-NH2	Investigative
T45457	DRUGINFO	D02MPZ	C[Nle-His-D-Phe-Arg-Trp-Glu]-NH2	Investigative
T45457	DRUGINFO	D04YZZ	C[CO-(CH2)3-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2	Investigative
T45457	DRUGINFO	D05WNC	C[Nle-Glu-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T45457	DRUGINFO	D07UXW	C[Nle-Asp-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T45457	DRUGINFO	D08DND	C[CO-(CH2)2-CO-Nle-D-Phe-Arg-Trp-Lys]-NH2	Investigative
T45457	DRUGINFO	D09UUC	MK-10	Investigative
T45457	DRUGINFO	D0M4EF	C[Nle-Val-D-Phe-Arg-Trp-Glu]-NH2	Investigative
T45457	DRUGINFO	D0P4GI	C[Nle-Pro-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T45457	DRUGINFO	D0VD7R	C[Nle-Pro-D-Phe-Arg-Trp-Glu]-NH2	Investigative
T45457	DRUGINFO	D0W1SM	C[Nle-Gln-D-Phe-Arg-Trp-Glu]-NH2	Investigative
T45457	DRUGINFO	D0XQ5U	C[CO-2,3-pyrazine-CO-D-Nal(2)-Arg-Trp-Lys]-NH2	Investigative
T45457	DRUGINFO	D02JVA	C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T45457	DRUGINFO	D03AZC	Ac-YRMEHdFRWG-NH2	Investigative
T45457	DRUGINFO	D05LLI	C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T45457	DRUGINFO	D06RTP	C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T45457	DRUGINFO	D07SFD	C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2	Investigative
T45457	DRUGINFO	D07TBR	Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2	Investigative
T45457	DRUGINFO	D09PDT	C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2	Investigative
T45457	DRUGINFO	D0AU4C	AEKKDEGPYRMEHFRWGSPPKD	Investigative
T45457	DRUGINFO	D0B4OL	Ac-YRMEHdFRWGSPPKD-NH2	Investigative
T45457	DRUGINFO	D0CK0K	Ac-Nle-c[Asp-His-DNal(2')-Pro-Trp-Lys]-NH2	Investigative
T45457	DRUGINFO	D0I8SJ	NDP-SYSMEHFRWGKPVG	Investigative
T45457	DRUGINFO	D0ID5M	GPYRMEHFRWGSPPKD-NH2	Investigative
T45457	DRUGINFO	D0L1MJ	C[Nle-Nle-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T45457	DRUGINFO	D0R0BY	Ac-YR[CEH(pCl-dF)RWC]-NH2	Investigative
T45457	DRUGINFO	D0WG8P	Ac-YR[CEH(pF-dF)RWC]-NH2	Investigative
T45457	DRUGINFO	D0WI8M	C[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2	Investigative
T45457	DRUGINFO	D0X1YL	Ac-YRC(Me)*EHdFRWC(Me)NH2	Investigative
T45457	DRUGINFO	D0YB7F	MT-II	Investigative

T32137	TARGETID	T32137
T32137	FORMERID	TTDNC00395
T32137	TARGNAME	NADPH oxidase (NOX)
T32137	TARGTYPE	Clinical trial
T32137	FUNCTION	NOH-1S is a voltage-gated proton channel that mediates the H(+) currents of resting phagocytes and other tissues. It participates in the regulation of cellular pH and is blocked by zinc. NOH-1L is a pyridine nucleotide-dependent oxidoreductase that generates superoxide and might conduct H(+) ions as part of its electron transport mechanism, whereas NOH-1S does not contain an electron transport chain.
T32137	DRUGINFO	D04XVU	GKT-137831	Phase 2
T32137	DRUGINFO	D0F9WF	SINOMENINE	Discontinued in Phase 2

T47165	TARGETID	T47165
T47165	FORMERID	TTDI02005
T47165	TARGNAME	Neural cell adhesion molecule (NCAM)
T47165	TARGTYPE	Clinical trial
T47165	BIOCLASS	Immunoglobulin
T47165	DRUGINFO	D09THN	IMGN901	Phase 2
T47165	DRUGINFO	D06EXI	FGLL	Phase 1
T47165	DRUGINFO	D0NP8B	ERIC-1	Terminated

T88318	TARGETID	T88318
T88318	FORMERID	TTDC00181
T88318	TARGNAME	Protein kinase C (PRKC)
T88318	TARGTYPE	Clinical trial
T88318	BIOCLASS	Kinase
T88318	DRUGINFO	D0M3BB	Synthetic hypericin	Phase 3
T88318	DRUGINFO	D00DPP	CYCLOPLATAM	Phase 2
T88318	DRUGINFO	D0LA1R	AEB07	Phase 2
T88318	DRUGINFO	D0O3XU	HO/03/03	Phase 2
T88318	DRUGINFO	DD8L0V	Bryostatin-1	Phase 2
T88318	DRUGINFO	D08VAR	APH-0812	Phase 2
T88318	DRUGINFO	D0R7HL	LXS196	Phase 1/2
T88318	DRUGINFO	D07CAQ	SAFINGOL	Phase 1
T88318	DRUGINFO	D0B2NF	AEB701	Phase 1
T88318	DRUGINFO	D07HYR	GCC-1290K	Phase 1
T88318	DRUGINFO	D00YSJ	Tecadenoson	Discontinued in Phase 3
T88318	DRUGINFO	D0R1JI	Rottlerin	Preclinical
T88318	DRUGINFO	D06AHQ	Ro-31-8830	Terminated
T88318	DRUGINFO	D0S6XD	Calphostin C	Terminated
T88318	DRUGINFO	D0E3TC	Staurosporine	Investigative
T88318	DRUGINFO	D08JPU	G6976	Investigative
T88318	DRUGINFO	D0TO6S	Bisindolylmaleimide-I	Investigative

T09227	TARGETID	T09227
T09227	FORMERID	TTDR00845
T09227	TARGNAME	Protein tyrosine phosphatase (PTP)
T09227	TARGTYPE	Clinical trial
T09227	SYNONYMS	PTPase; PTPN
T09227	BIOCLASS	Phosphoric monoester hydrolase
T09227	DRUGINFO	D05XLO	INCB13739	Phase 2a
T09227	DRUGINFO	D0I1QJ	KP-100	Phase 1/2
T09227	DRUGINFO	D0J0KC	Pervanadate	Investigative
T09227	DRUGINFO	D0X9TG	Diamide	Investigative

T93145	TARGETID	T93145
T93145	TARGNAME	Pyruvate dehydrogenase kinase (PDHK)
T93145	TARGTYPE	Clinical trial
T93145	SYNONYMS	PDH kinase
T93145	BIOCLASS	Kinase
T93145	DRUGINFO	D0E3EO	JTT-251	Phase 2
T93145	DRUGINFO	D52MXY	JTT-861	Phase 1

T74073	TARGETID	T74073
T74073	FORMERID	TTDI01794
T74073	TARGNAME	Serine/threonine-protein kinase pim (PIM)
T74073	TARGTYPE	Clinical trial
T74073	FUNCTION	Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity. The stabilization of MYC exerted by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis. Mediates survival signaling throughphosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl- X(L)/BCL2L1. Phosphorylation of MAP3K5, an other proapoptotic protein, by PIM1, significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis. Stimulates cell cycle progression at the G1-S and G2-M transitions by phosphorylation of CDC25A and CDC25C. Phosphorylation of CDKN1A, a regulator of cell cycle progression at G1, results in the relocation of CDKN1A to the cytoplasm and enhanced CDKN1A proteinstability. Promote cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression, CDKN1B, at both transcriptional and post- translational levels. Phosphorylation of CDKN1B,induces 14-3-3- proteins binding, nuclear export and proteasome-dependent degradation. May affect the structure or silencing of chromatin by phosphorylating HP1 gamma/CBX3. Actsalso as a regulator of homing and migration of bone marrow cells involving functional interaction with the CXCL12-CXCR4 signaling axis.
T74073	BIOCLASS	Kinase
T74073	DRUGINFO	D06FQU	INCB53914	Phase 1/2
T74073	DRUGINFO	D0V2ZC	SEL24	Phase 1/2
T74073	DRUGINFO	D01QNR	PIM447	Phase 1
T74073	DRUGINFO	D7Z1CR	TP-3654	Phase 1

T72478	TARGETID	T72478
T72478	FORMERID	TTDR00490
T72478	TARGNAME	Sodium/calcium exchanger (SLC)
T72478	TARGTYPE	Clinical trial
T72478	SYNONYMS	NaCaX; Na(+)/Ca(2+) exchanger; Mitochondrial sodium-calcium exchanger
T72478	DRUGINFO	D06FOL	CALDARET HYDRATE	Phase 2
T72478	DRUGINFO	D0IK1U	SEA-0400	Investigative

T34624	TARGETID	T34624
T34624	FORMERID	TTDR00365
T34624	TARGNAME	Stress-activated protein kinase (p38)
T34624	TARGTYPE	Clinical trial
T34624	SYNONYMS	p38) Stress-activated protein kinase; P38 MAPK; P38 MAP kinase; Mitogen-activated protein kinase p38
T34624	BIOCLASS	Kinase
T34624	DRUGINFO	DL14SU	PF-07265803	Phase 3
T34624	DRUGINFO	D04SPJ	AZD7624	Phase 2
T34624	DRUGINFO	D06GUA	GSK2269557	Phase 2
T34624	DRUGINFO	D0O6ZO	TAK-715	Phase 2
T34624	DRUGINFO	D38LQO	MW150	Phase 2
T34624	DRUGINFO	D02LBK	ARRY-797	Phase 2
T34624	DRUGINFO	D0Q0AP	BMS-582949	Phase 2
T34624	DRUGINFO	D08WYH	LY-2228820	Phase 1/2
T34624	DRUGINFO	DG2EK3	PUR1800	Phase 1
T34624	DRUGINFO	D02LCI	TA-5493	Discontinued in Phase 1
T34624	DRUGINFO	D03KWN	AZD-6703	Discontinued in Phase 1
T34624	DRUGINFO	D08CQE	AVE-9940	Discontinued in Phase 1
T34624	DRUGINFO	D0W3AX	SB-281832	Discontinued in Phase 1
T34624	DRUGINFO	D0ML0L	ARRY-614	Discontinued in Phase 1
T34624	DRUGINFO	D02MVG	AMG-548	Terminated

T83059	TARGETID	T83059
T83059	FORMERID	TTDI01798
T83059	TARGNAME	Tankyrase (TNKS)
T83059	TARGTYPE	Clinical trial
T83059	FUNCTION	Poly-ADP-ribosyltransferase involved in various processes such as Wnt signaling pathway, telomere length and vesicle trafficking. Acts as an activator of the Wnt signaling pathway by mediating poly-ADP-ribosylation (PARsylation) of AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex: poly-ADP-ribosylated target proteins are recognized by RNF146, which mediates their ubiquitination and subsequent degradation. Also mediates PARsylation of BLZF1 and CASC3, followed by recruitment of RNF146 and subsequent ubiquitination. Mediates PARsylation of TERF1, thereby contributing to the regulation of telomere length. Involved in centrosome maturation during prometaphase by mediating PARsylation of HEPACAM2/MIKI. May also regulate vesicle trafficking and modulate the subcellular distribution of SLC2A4/GLUT4-vesicles. May be involved in spindle pole assembly through PARsylation of NUMA1. Stimulates 26S proteasome activity.
T83059	BIOCLASS	Glycosyltransferases
T83059	DRUGINFO	D0D9IQ	BGB-290	Phase 2
T83059	DRUGINFO	D0SZ9R	2X-121	Phase 2
T83059	DRUGINFO	D5P3SI	STP1002	Phase 1

T06011	TARGETID	T06011
T06011	FORMERID	TTDC00203
T06011	TARGNAME	Transforming growth factor beta (TGFB)
T06011	TARGTYPE	Clinical trial
T06011	SYNONYMS	TGF-beta
T06011	DRUGINFO	D07VHU	NIS793	Phase 2
T06011	DRUGINFO	D32PZT	LY2382770	Phase 2
T06011	DRUGINFO	DB35WK	Fresolimumab	Phase 2
T06011	DRUGINFO	D0MR0B	TEW-7197	Phase 2
T06011	DRUGINFO	D5J3BL	Bintrafusp alfa	Phase 2
T06011	DRUGINFO	D05FPZ	M7824	Phase 2
T06011	DRUGINFO	D0F7GX	ACE-011	Phase 1
T06011	DRUGINFO	D1ONZ8	AVID200	Phase 1
T06011	DRUGINFO	DIBP49	RG6440	Phase 1
T06011	DRUGINFO	D0U7XJ	BCA101	Phase 1
T06011	DRUGINFO	DG6V7E	GS-1423	Phase 1
T06011	DRUGINFO	DD9NG5	SHP-627	Preclinical

T52258	TARGETID	T52258
T52258	FORMERID	TTDI01242
T52258	TARGNAME	Hepatitis B virus messenger RNA (HBV mRNA)
T52258	TARGTYPE	Clinical trial
T52258	SYNONYMS	mRNA of HBV protein
T52258	BIOCLASS	mRNA target
T52258	DRUGINFO	D08NDA	ISIS-HBV	Phase 2
T52258	DRUGINFO	DO9B3Y	AB-729	Phase 2
T52258	DRUGINFO	DWS5G1	ARO-HBV	Phase 1/2

T41963	TARGETID	T41963
T41963	FORMERID	TTDR00939
T41963	TARGNAME	Toll-like receptor (TLR)
T41963	TARGTYPE	Clinical trial
T41963	SYNONYMS	Toll-like receptor
T41963	DRUGINFO	D03VPM	DPV-001	Phase 2
T41963	DRUGINFO	D08SIC	BDB001	Phase 2
T41963	DRUGINFO	D0I0XF	IMO-8400	Phase 2
T41963	DRUGINFO	D0UF8M	IMO-9200	Phase 1
T41963	DRUGINFO	D06IVC	PMID30280939-Compound-WO2009082440	Patented
T41963	DRUGINFO	D07NEI	PMID30280939-Compound-US20179642901	Patented
T41963	DRUGINFO	D08TOM	PMID30280939-Compound-WO2015150568	Patented
T41963	DRUGINFO	D0AF4V	PMID30280939-Compound-WO200606195	Patented
T41963	DRUGINFO	D0BW2B	PMID30280939-Compound-WO2005070959	Patented
T41963	DRUGINFO	D0H9SD	PMID30280939-Compound-WO2013148426	Patented
T41963	DRUGINFO	D0HK3A	PMID30280939-Compound-WO2013148427	Patented
T41963	DRUGINFO	D0IH8R	PMID30280939-Compound-WO2008009652	Patented
T41963	DRUGINFO	D0K4CX	PMID30280939-Compound-WO2015035128	Patented
T41963	DRUGINFO	D0P8VT	PMID30280939-Compound-US20170128558	Patented
T41963	DRUGINFO	D0QW0C	PMID30280939-Compound-WO2013119856	Patented
T41963	DRUGINFO	D0T8XY	PMID30280939-Compound-WO2015091734	Patented
T41963	DRUGINFO	D06PKS	ONO-4007	Discontinued in Phase 2

T70508	TARGETID	T70508
T70508	FORMERID	TTDNC00434
T70508	TARGNAME	Cyclin-dependent kinase (CDK)
T70508	TARGTYPE	Clinical trial
T70508	SYNONYMS	Cyclin dependent kinase
T70508	DRUGINFO	D0LF1U	Flavopiridol	Phase 2
T70508	DRUGINFO	D05ADP	R-roscovitine	Phase 2
T70508	DRUGINFO	D0P0KN	TG02	Phase 1/2
T70508	DRUGINFO	D0V2LL	PF-06873600	Phase 1
T70508	DRUGINFO	D01UAL	Purine derivative 4	Patented
T70508	DRUGINFO	D0BU1L	Indole-based analog 12	Patented
T70508	DRUGINFO	D0U4ZO	PMID26161698-Compound-10	Patented
T70508	DRUGINFO	D0G6QW	PMID26161698-Compound-44	Patented
T70508	DRUGINFO	D01MNK	BS-194	Investigative

T70888	TARGETID	T70888
T70888	TARGNAME	TNF receptor (TNFR)
T70888	TARGTYPE	Clinical trial
T70888	SYNONYMS	TNFR
T70888	DRUGINFO	D09KIG	ETX201	Phase 1
T70888	DRUGINFO	D0H6CA	Lenercept	Discontinued in Phase 3
T70888	DRUGINFO	D01EYM	BB-2275	Terminated

T03513	TARGETID	T03513
T03513	TARGNAME	Dopamine receptor (DR)
T03513	TARGTYPE	Clinical trial
T03513	SYNONYMS	Human dopamine receptor
T03513	DRUGINFO	D81KMY	Neupro	Phase 4
T03513	DRUGINFO	D0T5VD	EVK-001	Phase 3
T03513	DRUGINFO	DP7GK8	ABBV-951	Phase 3
T03513	DRUGINFO	D07XQS	ONC201	Phase 2
T03513	DRUGINFO	D0J4AZ	L-piperazino-3-phenyl-indane derivative 1	Patented

T93430	TARGETID	T93430
T93430	FORMERID	TTDI01708
T93430	TARGNAME	ATP-binding cassette transporter (ABCA)
T93430	TARGTYPE	Clinical trial
T93430	BIOCLASS	ABC transporter
T93430	DRUGINFO	D06RIM	LIM-0705	Phase 2

T61484	TARGETID	T61484
T61484	FORMERID	TTDI01946
T61484	TARGNAME	Chymotrypsin (CTR)
T61484	TARGTYPE	Clinical trial
T61484	BIOCLASS	Peptidase
T61484	DRUGINFO	D0A5DJ	Pancrecarb	NDA filed
T61484	DRUGINFO	D0Q9HM	CM-AT	Phase 3
T61484	DRUGINFO	D0T9LR	Liprotamase	Phase 3
T61484	DRUGINFO	D08SMN	POP-1	Investigative
T61484	DRUGINFO	D0JR9V	JBP-1	Investigative

T20474	TARGETID	T20474
T20474	FORMERID	TTDR00142
T20474	TARGNAME	DNA topoisomerase (TOP)
T20474	TARGTYPE	Clinical trial
T20474	DRUGINFO	D02CZK	Karenitecin	Phase 3
T20474	DRUGINFO	D09XUY	Icofungipen	Phase 2
T20474	DRUGINFO	D02GNX	N*4*-Benzyl-6-chloro-pyrimidine-2,4-diamine	Investigative
T20474	DRUGINFO	D07ZFN	5-Bromo-6-p-tolylamino-1H-pyrimidine-2,4-dione	Investigative
T20474	DRUGINFO	D0A6LX	6-Benzylamino-1H-pyrimidine-2,4-dione	Investigative
T20474	DRUGINFO	D0AW7G	6-(3-Bromo-phenylamino)-1H-pyrimidine-2,4-dione	Investigative
T20474	DRUGINFO	D0C1VA	6-(Indan-5-ylamino)-1H-pyrimidine-2,4-dione	Investigative
T20474	DRUGINFO	D0D0DV	6-Benzylamino-5-bromo-1H-pyrimidine-2,4-dione	Investigative
T20474	DRUGINFO	D0G2RY	2-Amino-6-(indan-5-ylamino)-3H-pyrimidin-4-one	Investigative
T20474	DRUGINFO	D0KN0K	6-Benzylamino-5-iodo-1H-pyrimidine-2,4-dione	Investigative
T20474	DRUGINFO	D0M9JU	6-(Naphthalen-2-ylamino)-1H-pyrimidine-2,4-dione	Investigative
T20474	DRUGINFO	D0NW9G	3-(9-Acridinylamino)-5-(hydroxymethyl)aniline (AHMA)	Investigative
T20474	DRUGINFO	D0QH5P	6-(3-Iodo-phenylamino)-1H-pyrimidine-2,4-dione	Investigative
T20474	DRUGINFO	D0X6LS	6-p-Tolylamino-1H-pyrimidine-2,4-dione	Investigative
T20474	DRUGINFO	D0H6VK	6-(3-Ethyl-phenylamino)-1H-pyrimidine-2,4-dione	Investigative
T20474	DRUGINFO	D0L8BN	TOPOSTATIN	Investigative

T68315	TARGETID	T68315
T68315	FORMERID	TTDR01207
T68315	TARGNAME	Endothelin receptor (EDNR)
T68315	TARGTYPE	Clinical trial
T68315	SYNONYMS	Human endothelin receptor
T68315	DRUGINFO	D0H2RJ	Clazosentan	Phase 3
T68315	DRUGINFO	D0QG1B	Aprocitentan	Phase 2
T68315	DRUGINFO	D0P0DT	TAK-044	Discontinued in Phase 2
T68315	DRUGINFO	D0J5HU	Ro-46-2005	Terminated

T70071	TARGETID	T70071
T70071	FORMERID	TTDR00416
T70071	TARGNAME	Endothelin-converting enzyme (ECE)
T70071	TARGTYPE	Clinical trial
T70071	SYNONYMS	Endothelin converting enzyme
T70071	DRUGINFO	D01HDP	SLV 306	Phase 2
T70071	DRUGINFO	D03CPM	SLV-334	Phase 2
T70071	DRUGINFO	D00CLC	SLV-338	Phase 1
T70071	DRUGINFO	D08GQK	WS-75624B	Terminated
T70071	DRUGINFO	D0M3JI	SM-19712	Terminated
T70071	DRUGINFO	D09NAJ	Phosphoramidon	Investigative

T84472	TARGETID	T84472
T84472	TARGNAME	Geranylgeranyl transferase (GGTase)
T84472	TARGTYPE	Clinical trial
T84472	SYNONYMS	Geranylgeranyltransferase
T84472	DRUGINFO	D0NX0S	PTX-100	Phase 1

T03963	TARGETID	T03963
T03963	FORMERID	TTDI01291
T03963	TARGNAME	Heat shock protein 90 (HSP90)
T03963	TARGTYPE	Clinical trial
T03963	BIOCLASS	Heat shock protein
T03963	DRUGINFO	D0N9AD	RNS-60	Phase 2
T03963	DRUGINFO	D1FH8R	ADX-1612	Phase 1
T03963	DRUGINFO	D20IMG	LAM-003	Phase 1
T03963	DRUGINFO	DWOY01	RTA 901	Phase 1

T37308	TARGETID	T37308
T37308	FORMERID	TTDS00132
T37308	TARGNAME	Immunoglobulin E (IgE)
T37308	TARGTYPE	Clinical trial
T37308	SYNONYMS	IgE
T37308	DRUGINFO	DS4U1W	Ligelizumab	Phase 3
T37308	DRUGINFO	D01LSB	MEMP1972A	Phase 2
T37308	DRUGINFO	D0JQ4S	Xmab-7195	Phase 1
T37308	DRUGINFO	D0K2HU	PF-06444752	Phase 1
T37308	DRUGINFO	D0O5CV	MEDI4212	Phase 1
T37308	DRUGINFO	D0P9YP	AVP-13358	Phase 1
T37308	DRUGINFO	D01IYQ	TAK-201	Discontinued in Phase 2
T37308	DRUGINFO	D0C3TE	TEI-9874	Terminated
T37308	DRUGINFO	D0X7YC	IGE-026	Terminated
T37308	DRUGINFO	D03ILU	D17.4	Investigative
T37308	DRUGINFO	D0T7XO	IGEL1.2	Investigative

T73671	TARGETID	T73671
T73671	FORMERID	TTDI01664
T73671	TARGNAME	Interferon (IFN)
T73671	TARGTYPE	Clinical trial
T73671	SYNONYMS	Interferon protein
T73671	DRUGINFO	D0G1RM	Interferon	Phase 2

T59735	TARGETID	T59735
T59735	FORMERID	TTDI01567
T59735	TARGNAME	Interferon receptor (IFNR)
T59735	TARGTYPE	Clinical trial
T59735	SYNONYMS	Interferon receptor
T59735	DRUGINFO	D05DQR	HDV-interferon	Phase 2
T59735	DRUGINFO	D0O4NJ	Z-100	Phase 1
T59735	DRUGINFO	D07RPR	Bropirimine	Discontinued in Phase 3
T59735	DRUGINFO	D0M9FT	Omniferon	Terminated

T83103	TARGETID	T83103
T83103	FORMERID	TTDI01712
T83103	TARGNAME	Interleukin (IL)
T83103	TARGTYPE	Clinical trial
T83103	SYNONYMS	Interleukin
T83103	DRUGINFO	D06NXG	PF-04236921	Phase 2

T29649	TARGETID	T29649
T29649	FORMERID	TTDI01555
T29649	TARGNAME	Leukotriene receptor (LTR)
T29649	TARGTYPE	Clinical trial
T29649	SYNONYMS	Human leukotriene receptor
T29649	DRUGINFO	D00MHP	SR-2640	Phase 2
T29649	DRUGINFO	D08ZKJ	Ontazolast	Phase 2
T29649	DRUGINFO	D0S2UR	PIRODOMAST	Phase 2
T29649	DRUGINFO	D0MA0F	WF-11605	Phase 1
T29649	DRUGINFO	D00AKY	SK&F-S-106203	Discontinued in Phase 2
T29649	DRUGINFO	D0E6UD	FK-664	Discontinued in Phase 2
T29649	DRUGINFO	D00WWU	SMP-028	Discontinued in Phase 1
T29649	DRUGINFO	D02ANJ	NZ-107	Discontinued in Phase 1
T29649	DRUGINFO	D0GB3A	ABT-080	Discontinued in Phase 1
T29649	DRUGINFO	D0Y3RN	BAY-Y-1015	Discontinued in Phase 1
T29649	DRUGINFO	D05JQF	Tipredane	Terminated
T29649	DRUGINFO	D0J7UI	ICI-198615	Terminated
T29649	DRUGINFO	D0C7LA	MAR--99	Investigative

T71167	TARGETID	T71167
T71167	TARGNAME	Oxysterols receptor LXR (NR1H)
T71167	TARGTYPE	Clinical trial
T71167	BIOCLASS	Nuclear hormone receptor
T71167	DRUGINFO	D0CT5O	ALX-101	Phase 2
T71167	DRUGINFO	D0YZ1Q	RGX-104	Phase 1/2
T71167	DRUGINFO	D00QWU	BMS-779788	Phase 1
T71167	DRUGINFO	D0GY1Y	CS-8080	Phase 1
T71167	DRUGINFO	D0H4DR	BMS-852927	Phase 1
T71167	DRUGINFO	D0L0DZ	XL-041	Phase 1
T71167	DRUGINFO	D0O5XJ	XL652/XL014	Phase 1
T71167	DRUGINFO	D0R4EN	LXR 623	Phase 1
T71167	DRUGINFO	D0B5FC	T0901317	Investigative

T77534	TARGETID	T77534
T77534	FORMERID	TTDI01761
T77534	TARGNAME	Phospholipase C (PLC)
T77534	TARGTYPE	Clinical trial
T77534	BIOCLASS	Phosphoric diester hydrolase
T77534	DRUGINFO	D0J7ML	D-20133	Phase 1
T77534	DRUGINFO	D01NNL	Phosphonate	Terminated

T78874	TARGETID	T78874
T78874	FORMERID	TTDR01081
T78874	TARGNAME	Protein kinase (PK)
T78874	TARGTYPE	Clinical trial
T78874	BIOCLASS	Kinase
T78874	DRUGINFO	D05BLN	MGCD516	Phase 2/3
T78874	DRUGINFO	D0A5HC	RV-568	Phase 2
T78874	DRUGINFO	D06EGV	LY2801653	Phase 2
T78874	DRUGINFO	D08FDX	MGCD265	Phase 2
T78874	DRUGINFO	D0S7HM	ENMD-2076	Phase 2
T78874	DRUGINFO	D09XZL	LX-7101	Phase 1/2
T78874	DRUGINFO	D0P0KN	TG02	Phase 1/2
T78874	DRUGINFO	D0Z8LA	Cyclocreatine	Discontinued in Phase 1

T31458	TARGETID	T31458
T31458	FORMERID	TTDI01313
T31458	TARGNAME	Pyruvate kinase (PK)
T31458	TARGTYPE	Clinical trial
T31458	BIOCLASS	Kinase
T31458	DRUGINFO	D5U4MY	Etavopivat	Phase 2/3
T31458	DRUGINFO	D08WHX	AGS-348	Phase 1

T95289	TARGETID	T95289
T95289	TARGNAME	Retinoic acid receptor RXR (RXR)
T95289	TARGTYPE	Clinical trial
T95289	SYNONYMS	RXR
T95289	DRUGINFO	D09DJC	IRX4204	Phase 1
T95289	DRUGINFO	D0T3DO	IRX-5183	Phase 1

T93092	TARGETID	T93092
T93092	TARGNAME	Serine/threonine PP2A (PP2A)
T93092	TARGTYPE	Clinical trial
T93092	SYNONYMS	PP2A
T93092	DRUGINFO	D02RNR	LB-100	Phase 2

T54378	TARGETID	T54378
T54378	FORMERID	TTDI01827
T54378	TARGNAME	TRAIL receptor (TRAIL-R)
T54378	TARGTYPE	Clinical trial
T54378	FUNCTION	Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADDrecruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF- kappa-B.

T45083	TARGETID	T45083
T45083	FORMERID	TTDI01792
T45083	TARGNAME	Tryptophan 5-hydroxylase (TPH)
T45083	TARGTYPE	Clinical trial
T45083	BIOCLASS	Paired donor oxygen oxidoreductase
T45083	DRUGINFO	D0H9WR	LX-1031	Phase 2

T97701	TARGETID	T97701
T97701	TARGNAME	Voltage-gated T-type calcium channel (T-CaC)
T97701	TARGTYPE	Clinical trial
T97701	BIOCLASS	Voltage-gated ion channel
T97701	DRUGINFO	D0A0YQ	CX-8998	Phase 2

T66514	TARGETID	T66514
T66514	FORMERID	TTDI01677
T66514	TARGNAME	Carbohydrate antigen Lewis-Y (Lewis-Y)
T66514	TARGTYPE	Clinical trial
T66514	SYNONYMS	Lewis-Y carbohydrate antigen; Lewis-Y
T66514	DRUGINFO	D04RDW	CAR-T cells targeting Lewis-Y	Phase 1
T66514	DRUGINFO	D08QJD	IGN-311	Terminated

T15867	TARGETID	T15867
T15867	TARGNAME	Gastric carcinoma-associated antigen MG7 (MG7)
T15867	TARGTYPE	Clinical trial
T15867	SYNONYMS	MG7-Ag
T15867	DRUGINFO	D0Q5GK	MG7-CART	Phase 1/2

T31299	TARGETID	T31299
T31299	TARGNAME	HLA-A02/AFP complex (HLA-A02/AFP)
T31299	TARGTYPE	Clinical trial
T31299	SYNONYMS	HLA-A2/AFP complex
T31299	DRUGINFO	D09TGO	Autologous ET1402L1-CART cells	Phase 1

T60628	TARGETID	T60628
T60628	FORMERID	TTDI02098
T60628	TARGNAME	Kappa myeloma antigen (KMA)
T60628	TARGTYPE	Clinical trial
T60628	BIOCLASS	Kappa myeloma antigen
T60628	DRUGINFO	D0G6EB	MDX-1097	Phase 2

T39031	TARGETID	T39031
T39031	FORMERID	TTDI02144
T39031	TARGNAME	Tumor antigen NGcGM3 (NGcGM3)
T39031	TARGTYPE	Clinical trial
T39031	SYNONYMS	Tumor antigen N-glycolyl-GM3
T39031	DRUGINFO	D08ECW	Racotumomab	Phase 2

T02598	TARGETID	T02598
T02598	FORMERID	TTDI01310
T02598	TARGNAME	Leukocyte (WBC)
T02598	TARGTYPE	Clinical trial
T02598	SYNONYMS	Human leukocyte
T02598	DRUGINFO	D01KGP	IPL 550,260	Phase 1

T01232	TARGETID	T01232
T01232	FORMERID	TTDI01328
T01232	TARGNAME	T-cells (T-cells)
T01232	TARGTYPE	Clinical trial
T01232	SYNONYMS	T cells
T01232	DRUGINFO	D0O0QB	ATG-Fresenius S	Phase 3
T01232	DRUGINFO	D04BOK	DiabeCell	Phase 2
T01232	DRUGINFO	D0JH5K	TVI-Kidney-1	Phase 2
T01232	DRUGINFO	D0WK1M	Baltaleucel-T	Phase 2
T01232	DRUGINFO	D0X6EM	T2c-001	Phase 2
T01232	DRUGINFO	D06LYI	BPX-501	Phase 1/2
T01232	DRUGINFO	D0M1DG	RTL-1000	Phase 1
T01232	DRUGINFO	D00JDJ	AX-024	Phase 1

T45516	TARGETID	T45516
T45516	FORMERID	TTDI01178
T45516	TARGNAME	Cyclin D1 synthesis (CCND1 synthesis)
T45516	TARGTYPE	Clinical trial
T45516	SYNONYMS	Cyclin D1 biosynthesis
T45516	DRUGINFO	D0KW3Z	GORALATIDE	Phase 2

T22608	TARGETID	T22608
T22608	FORMERID	TTDI01843
T22608	TARGNAME	TNF alpha production (TNFA produ)
T22608	TARGTYPE	Clinical trial
T22608	SYNONYMS	Tumor necrosis factor alpha production
T22608	DRUGINFO	D00ICD	SH-529	Phase 2

T29075	TARGETID	T29075
T29075	TARGNAME	TNF-alpha signaling pathway (TNFA pathway)
T29075	TARGTYPE	Clinical trial
T29075	BIOCLASS	Viral DNA polymerase
T29075	DRUGINFO	D05UJS	ADVAX	Phase 1

T65054	TARGETID	T65054
T65054	FORMERID	TTDR00658
T65054	TARGNAME	Actin (ACT)
T65054	TARGTYPE	Clinical trial
T65054	DRUGINFO	D0P6JD	RGN-259	Phase 2

T08743	TARGETID	T08743
T08743	FORMERID	TTDI01635
T08743	TARGNAME	Aminopeptidase (AMP)
T08743	TARGTYPE	Clinical trial
T08743	DRUGINFO	D0F2JS	CHR-2797	Phase 2

T49571	TARGETID	T49571
T49571	FORMERID	TTDI01614
T49571	TARGNAME	Aminotransferase (AT)
T49571	TARGTYPE	Clinical trial
T49571	DRUGINFO	D00AKV	F-351	Phase 2

T04389	TARGETID	T04389
T04389	FORMERID	TTDI01568
T04389	TARGNAME	ATP phosphatase (ATPase)
T04389	TARGTYPE	Clinical trial
T04389	DRUGINFO	D07KIE	LYC-30937	Phase 2
T04389	DRUGINFO	D09PGM	BY-1949	Discontinued in Phase 2
T04389	DRUGINFO	D0IX7G	FR-76830	Terminated

T84894	TARGETID	T84894
T84894	FORMERID	TTDI03085
T84894	TARGNAME	Casein kinase II (CSNK2)
T84894	TARGTYPE	Clinical trial
T84894	DRUGINFO	D0IQ1V	CIGB-300	Phase 3
T84894	DRUGINFO	D09JEJ	CX-4945	Phase 2
T84894	DRUGINFO	D06KDU	Tetrabromocinnamic acid	Investigative

T68039	TARGETID	T68039
T68039	FORMERID	TTDI01581
T68039	TARGNAME	Cell adhesion molecule (CADM)
T68039	TARGTYPE	Clinical trial
T68039	DRUGINFO	D0L0DA	PRX003	Phase 1
T68039	DRUGINFO	D0G7YG	ABX-MA1	Discontinued in Phase 1
T68039	DRUGINFO	D05GBZ	ABS-205	Terminated
T68039	DRUGINFO	D0J1RH	CY-1748	Terminated
T68039	DRUGINFO	D0JS4E	ICM-3	Terminated
T68039	DRUGINFO	D0T2DL	GM-7050	Terminated
T68039	DRUGINFO	D0U3OY	Rovelizumab	Terminated
T68039	DRUGINFO	D0Z3AK	NPC-17923	Terminated

T78383	TARGETID	T78383
T78383	FORMERID	TTDI01721
T78383	TARGNAME	Chemosensory receptor (CheR)
T78383	TARGTYPE	Clinical trial
T78383	DRUGINFO	D0F7IG	PH10 nasal spray	Phase 2

T51209	TARGETID	T51209
T51209	FORMERID	TTDI01275
T51209	TARGNAME	Clostridium difficile Toxin (CD tox)
T51209	TARGTYPE	Clinical trial

T87946	TARGETID	T87946
T87946	FORMERID	TTDI01559
T87946	TARGNAME	Cytokine receptor unspecific (CRF)
T87946	TARGTYPE	Clinical trial
T87946	DRUGINFO	D03YKQ	AD-452	Phase 2
T87946	DRUGINFO	D0KS6F	IRX-2	Phase 2
T87946	DRUGINFO	D0E6FO	JTE-607	Discontinued in Phase 2
T87946	DRUGINFO	D0Y8IS	VP-025	Discontinued in Phase 1
T87946	DRUGINFO	D02WEL	VG-106	Terminated

T93703	TARGETID	T93703
T93703	FORMERID	TTDR00437
T93703	TARGNAME	Cytokine unspecific (CYK)
T93703	TARGTYPE	Clinical trial
T93703	DRUGINFO	D0V4XL	BMEC-1217B	Phase 1
T93703	DRUGINFO	D0W6YR	PF-06817024	Phase 1

T64376	TARGETID	T64376
T64376	FORMERID	TTDI01740
T64376	TARGNAME	Fibroblast growth factor (FGF)
T64376	TARGTYPE	Clinical trial
T64376	DRUGINFO	D07WTG	Recombinant acidic fibroblast growth factor	Phase 3
T64376	DRUGINFO	D0P0LT	GSK3052230	Phase 1

T27106	TARGETID	T27106
T27106	FORMERID	TTDI01175
T27106	TARGNAME	FK506-binding protein (FKBP)
T27106	TARGTYPE	Clinical trial
T27106	DRUGINFO	D0SL8J	Ascrolimus	Phase 2
T27106	DRUGINFO	D0VT2C	FK-505	Phase 2
T27106	DRUGINFO	D0F6TV	Timcodar dimesilate	Phase 1/2
T27106	DRUGINFO	D0ML9K	T-506	Discontinued in Phase 2

T96747	TARGETID	T96747
T96747	FORMERID	TTDI01706
T96747	TARGNAME	Galactosyltransferase (GALT)
T96747	TARGTYPE	Clinical trial
T96747	DRUGINFO	D00HSK	Algenpantucel-L	Phase 3

T06320	TARGETID	T06320
T06320	FORMERID	TTDI01239
T06320	TARGNAME	Galectin (LGALS)
T06320	TARGTYPE	Clinical trial
T06320	DRUGINFO	D0JW0V	GCS-100	Phase 2

T87742	TARGETID	T87742
T87742	FORMERID	TTDI01602
T87742	TARGNAME	Gap junction protein (GJP)
T87742	TARGTYPE	Clinical trial
T87742	DRUGINFO	D0C4QN	ROTIGAPTIDE	Phase 2
T87742	DRUGINFO	D0KQ0C	Danegaptide	Phase 2

T67310	TARGETID	T67310
T67310	FORMERID	TTDI01582
T67310	TARGNAME	Glutamate receptor ionotropic (GRI)
T67310	TARGTYPE	Clinical trial
T67310	DRUGINFO	D02QZR	LY-545694	Phase 2
T67310	DRUGINFO	D0A2IK	NPS-846	Terminated

T93368	TARGETID	T93368
T93368	FORMERID	TTDI01638
T93368	TARGNAME	Haemophilus influenzae Outer membrane protein (Hae-influ OMP)
T93368	TARGTYPE	Clinical trial

T55643	TARGETID	T55643
T55643	FORMERID	TTDI01415
T55643	TARGNAME	Heat shock protein (HSP)
T55643	TARGTYPE	Clinical trial
T55643	DRUGINFO	D0F2PD	Arimoclomol	Phase 2/3
T55643	DRUGINFO	D08QYS	Heat shock protein vaccine	Phase 2

T38763	TARGETID	T38763
T38763	FORMERID	TTDI01630
T38763	TARGNAME	Hepatitis C virus Non-structural 5 (HCV NS5)
T38763	TARGTYPE	Clinical trial
T38763	DRUGINFO	D0SY7H	IDX-184	Phase 1/2

T49689	TARGETID	T49689
T49689	FORMERID	TTDI01731
T49689	TARGNAME	Immunoglobulin G1k (IgG1k)
T49689	TARGTYPE	Clinical trial
T49689	DRUGINFO	D0D5LX	NKTT-120	Phase 1

T55012	TARGETID	T55012
T55012	FORMERID	TTDI01612
T55012	TARGNAME	Ion channel unspecific (IC)
T55012	TARGTYPE	Clinical trial
T55012	DRUGINFO	D01WLB	Lu-AA39959	Phase 2
T55012	DRUGINFO	D04TGF	AZD-2927	Phase 2
T55012	DRUGINFO	D0N1TH	ATI-2042	Phase 2
T55012	DRUGINFO	D06VPE	Lu-AA38466	Discontinued in Phase 1
T55012	DRUGINFO	D0F7LE	AZD-0902	Terminated

T10339	TARGETID	T10339
T10339	FORMERID	TTDI01597
T10339	TARGNAME	Lipoxygenase (ALOX)
T10339	TARGTYPE	Clinical trial
T10339	DRUGINFO	D0B6VN	TZI-41078	Phase 2
T10339	DRUGINFO	D0G6PG	CPA-926	Discontinued in Phase 2
T10339	DRUGINFO	D0T8VV	FLM-5011	Discontinued in Phase 1

T11069	TARGETID	T11069
T11069	FORMERID	TTDI01593
T11069	TARGNAME	Lyase unspecific (LYA)
T11069	TARGTYPE	Clinical trial
T11069	DRUGINFO	D0D2LF	YM-116	Phase 1

T28481	TARGETID	T28481
T28481	FORMERID	TTDI01626
T28481	TARGNAME	Lysosphingolipid receptor (LSPR)
T28481	TARGTYPE	Clinical trial
T28481	DRUGINFO	D0UR4K	Cenerimod	Phase 2

T88537	TARGETID	T88537
T88537	TARGNAME	Mitochondrial protein unspecific (MP)
T88537	TARGTYPE	Clinical trial
T88537	DRUGINFO	D00SWQ	Mitoglitazone	Phase 2
T88537	DRUGINFO	D05TPI	EPICATECHIN	Phase 1/2

T80452	TARGETID	T80452
T80452	FORMERID	TTDI01556
T80452	TARGNAME	Mucin (MUC)
T80452	TARGTYPE	Clinical trial
T80452	DRUGINFO	D02HRD	KLS-0611	Phase 2
T80452	DRUGINFO	D0D6ZK	15(S)-hydroxyeicosatetraenoic acid (ophthalmic, dry eye), Alcon	Discontinued in Phase 3

T47891	TARGETID	T47891
T47891	FORMERID	TTDI01718
T47891	TARGNAME	Natural killer cell receptor (NKCR)
T47891	TARGTYPE	Clinical trial
T47891	DRUGINFO	D0U4SM	NASVAC	Phase 3

T29815	TARGETID	T29815
T29815	FORMERID	TTDI01704
T29815	TARGNAME	Neoplasm antigen (NA)
T29815	TARGTYPE	Clinical trial
T29815	DRUGINFO	D0T2FC	NPC-1C	Phase 2

T14056	TARGETID	T14056
T14056	TARGNAME	Netrin (NET)
T14056	TARGTYPE	Clinical trial
T14056	DRUGINFO	D0U1MO	CERE-120	Phase 2

T37405	TARGETID	T37405
T37405	FORMERID	TTDI01631
T37405	TARGNAME	Neuropeptide receptor (NPR)
T37405	TARGTYPE	Clinical trial

T21351	TARGETID	T21351
T21351	FORMERID	TTDI01600
T21351	TARGNAME	Nuclear receptor unspecific (NR)
T21351	TARGTYPE	Clinical trial
T21351	DRUGINFO	D0H9YO	FLUASTERONE	Phase 2

T02221	TARGETID	T02221
T02221	FORMERID	TTDI01665
T02221	TARGNAME	Nucleoside DNA polymerase (DPOL)
T02221	TARGTYPE	Clinical trial

T13910	TARGETID	T13910
T13910	FORMERID	TTDI01705
T13910	TARGNAME	Phosphofructokinase 2 (PFK2)
T13910	TARGTYPE	Clinical trial
T13910	DRUGINFO	D0N4VN	INGAP peptide	Phase 2

T28746	TARGETID	T28746
T28746	FORMERID	TTDNS00552
T28746	TARGNAME	Protein kinase unspecific (PK)
T28746	TARGTYPE	Clinical trial
T28746	DRUGINFO	D0Q0AP	BMS-582949	Phase 2

T93026	TARGETID	T93026
T93026	TARGNAME	Quinone reductase (NQO)
T93026	TARGTYPE	Clinical trial
T93026	DRUGINFO	D09XJF	EPI 589	Phase 2

T09937	TARGETID	T09937
T09937	FORMERID	TTDI01650
T09937	TARGNAME	Receptor unspecific (Rec)
T09937	TARGTYPE	Clinical trial
T09937	DRUGINFO	D04XBU	ATL-104	Phase 2
T09937	DRUGINFO	D0UK1Q	Prosaptide TX14(A)	Phase 2
T09937	DRUGINFO	D06ZHN	Lactermin	Phase 1
T09937	DRUGINFO	D0F9TL	BT-063	Phase 1
T09937	DRUGINFO	D0N7ML	PV-707	Discontinued in Phase 2
T09937	DRUGINFO	D0YB6P	YP-004	Terminated

T40663	TARGETID	T40663
T40663	FORMERID	TTDI01653
T40663	TARGNAME	Regulatory protein unspecific (RGP)
T40663	TARGTYPE	Clinical trial
T40663	DRUGINFO	D0OH8W	Visilizumab	Phase 3
T40663	DRUGINFO	D0R8LV	NI-0401	Phase 1/2
T40663	DRUGINFO	D06ZZL	MEDI-500	Terminated

T50461	TARGETID	T50461
T50461	FORMERID	TTDI01632
T50461	TARGNAME	Ribonuclease (RNase)
T50461	TARGTYPE	Clinical trial
T50461	DRUGINFO	D0B8ZR	NTO-1151	Phase 2
T50461	DRUGINFO	D0I8QJ	Ranpirnase	Phase 2
T50461	DRUGINFO	D06FZH	MazF gene therapy	Phase 1
T50461	DRUGINFO	D0W1YM	AS-1406	Terminated

T11164	TARGETID	T11164
T11164	TARGNAME	Secretory phospholipase A2 (sPLA2)
T11164	TARGTYPE	Clinical trial
T11164	DRUGINFO	D07KFB	Varespladib methyl	Phase 3

T95379	TARGETID	T95379
T95379	TARGNAME	Selectin (SEL)
T95379	TARGTYPE	Clinical trial
T95379	DRUGINFO	D0N4EO	GMI-1070	Phase 3

T97553	TARGETID	T97553
T97553	TARGNAME	Serine/threonine-protein kinase (STK)
T97553	TARGTYPE	Clinical trial
T97553	DRUGINFO	D0L9XF	BBI503	Phase 2

T26220	TARGETID	T26220
T26220	TARGNAME	Somatostatin receptor (SSTR)
T26220	TARGTYPE	Clinical trial
T26220	DRUGINFO	D02ZHW	177Lu-DOTA-octreotate	Phase 3
T26220	DRUGINFO	DQP87H	177-Lu-oxodotreotide	Phase 3
T26220	DRUGINFO	D08YNI	Somatoprim	Phase 2
T26220	DRUGINFO	D0J8PI	Edotreotide	Phase 2
T26220	DRUGINFO	D0O3TC	FK-962	Phase 2
T26220	DRUGINFO	D0M5VV	177Lu-DOTATATE	Phase 2
T26220	DRUGINFO	DP85ES	177Lu-labelled DOTA-JR11	Phase 1/2
T26220	DRUGINFO	D0OV2F	212Pb-labelled DOTAMTATE	Phase 1
T26220	DRUGINFO	DDV8H5	AlphaMedix	Phase 1
T26220	DRUGINFO	D00RMD	FK-960	Discontinued in Phase 2
T26220	DRUGINFO	D09JXL	SEGLITIDE	Discontinued in Phase 2
T26220	DRUGINFO	D0M4LW	BIM-23268	Discontinued in Phase 2
T26220	DRUGINFO	D0WS8K	Ilatreotide	Investigative

T82494	TARGETID	T82494
T82494	FORMERID	TTDI01634
T82494	TARGNAME	T-cell receptor (TCR)
T82494	TARGTYPE	Clinical trial
T82494	DRUGINFO	D0T3CH	RGI-2001	Phase 2
T82494	DRUGINFO	D0Z1CZ	IR502	Phase 2
T82494	DRUGINFO	DF6Z3C	SAR444200	Phase 2
T82494	DRUGINFO	D07AKD	TOL-101	Phase 1/2
T82494	DRUGINFO	D0L1CO	MAGE-A10 TCR	Phase 1/2
T82494	DRUGINFO	D0TN1N	NY-ESO-TCR	Phase 1/2
T82494	DRUGINFO	D0M1MN	AFP TCR	Phase 1
T82494	DRUGINFO	D0ZA1K	BPX-701	Phase 1

T20059	TARGETID	T20059
T20059	TARGNAME	TGF-beta receptor (TGFBR)
T20059	TARGTYPE	Clinical trial
T20059	DRUGINFO	D0P0TA	GC-1008	Phase 1

T43760	TARGETID	T43760
T43760	FORMERID	TTDR00272
T43760	TARGNAME	Thyroid hormone receptor (THR)
T43760	TARGTYPE	Clinical trial
T43760	DRUGINFO	D01QXY	B7-2/GM-CSF	Phase 1
T43760	DRUGINFO	D0V1GK	KB-5359	Terminated
T43760	DRUGINFO	D09WBM	GC-14	Investigative
T43760	DRUGINFO	D0A5XG	NH-3	Investigative
T43760	DRUGINFO	D0E2IR	NH-4	Investigative
T43760	DRUGINFO	D0R2QS	Neplanocin A	Investigative

T70227	TARGETID	T70227
T70227	FORMERID	TTDI01619
T70227	TARGNAME	Transcription factor unspecific (TF)
T70227	TARGTYPE	Clinical trial
T70227	DRUGINFO	D0CN8U	PF-06763809	Phase 1

T21701	TARGETID	T21701
T21701	FORMERID	TTDI01405
T21701	TARGNAME	Transforming protein Rho (RHO)
T21701	TARGTYPE	Clinical trial
T21701	DRUGINFO	D0O9EQ	VX-210	Phase 2/3

T49578	TARGETID	T49578
T49578	FORMERID	TTDI01350
T49578	TARGNAME	Transient receptor potential channel (TRP channel)
T49578	TARGTYPE	Clinical trial
T49578	DRUGINFO	D0TI3R	FLX-787	Phase 2
T49578	DRUGINFO	D0D6MC	HC-030031	Investigative

T00100	TARGETID	T00100
T00100	FORMERID	TTDI01666
T00100	TARGNAME	Ubiquitin-activating enzyme (UBA)
T00100	TARGTYPE	Clinical trial
T00100	DRUGINFO	D0T4PA	TAK-243	Phase 1
T00100	DRUGINFO	D0Z0FA	MLN7243	Phase 1

T96299	TARGETID	T96299
T96299	FORMERID	TTDI01553
T96299	TARGNAME	Wnt protein (WNT)
T96299	TARGTYPE	Clinical trial
T96299	DRUGINFO	D0Z6AM	Ipafricept	Phase 1
T96299	DRUGINFO	D02LUP	RN-1005	Terminated

T15639	TARGETID	T15639
T15639	FORMERID	TTDI01657
T15639	TARGNAME	Zinc finger protein (ZNF)
T15639	TARGTYPE	Clinical trial
T15639	DRUGINFO	D01PHK	PCL-016	Phase 2

T64721	TARGETID	T64721
T64721	FORMERID	TTDI01636
T64721	TARGNAME	Cancer stemness kinase (CSK)
T64721	TARGTYPE	Clinical trial
T64721	DRUGINFO	D0L9XF	BBI503	Phase 2

T30383	TARGETID	T30383
T30383	FORMERID	TTDNC00508
T30383	TARGNAME	Endogenous gut peptide (EGP)
T30383	TARGTYPE	Clinical trial
T30383	DRUGINFO	D09AGG	GSK2890457	Phase 2

T96257	TARGETID	T96257
T96257	FORMERID	TTDI01246
T96257	TARGNAME	Haemophilus influenzae CRM197 (Hae-influ CRM197)
T96257	TARGTYPE	Clinical trial
T96257	DRUGINFO	D09RMZ	HibTITER	Phase 2
T96257	DRUGINFO	D0R0GK	NU300	Phase 2

T94493	TARGETID	T94493
T94493	FORMERID	TTDI01651
T94493	TARGNAME	Human immunodeficiency virus Adenovector Ad35 (HIV Ad35)
T94493	TARGTYPE	Clinical trial
T94493	DRUGINFO	D0H5KA	VRC-HIVDNA016-00-VP	Phase 2

T22778	TARGETID	T22778
T22778	FORMERID	TTDI01596
T22778	TARGNAME	Intracellular nitroreductase (INR)
T22778	TARGTYPE	Clinical trial
T22778	DRUGINFO	D0Z3LC	SR-4554	Phase 1

T79422	TARGETID	T79422
T79422	FORMERID	TTDC00323
T79422	TARGNAME	M1-prime segment of membrane-expressed IgE (M1 IgE)
T79422	TARGTYPE	Clinical trial
T79422	DRUGINFO	D04CWS	Anti-M1 prime	Phase 2

T61052	TARGETID	T61052
T61052	FORMERID	TTDI01289
T61052	TARGNAME	Neuroepithelial receptor (NR)
T61052	TARGTYPE	Clinical trial
T61052	DRUGINFO	D04FQD	PH-80	Phase 3

T33275	TARGETID	T33275
T33275	FORMERID	TTDI01683
T33275	TARGNAME	Tuftsin receptor (TR)
T33275	TARGTYPE	Clinical trial
T33275	DRUGINFO	D00QOJ	99mTc-RP-128	Phase 2

T19829	TARGETID	T19829
T19829	FORMERID	TTDI01236
T19829	TARGNAME	Helper-inducer T-lymphocyte (HITL)
T19829	TARGTYPE	Clinical trial

T33629	TARGETID	T33629
T33629	FORMERID	TTDI01830
T33629	TARGNAME	Prostate cance cell (PCC)
T33629	TARGTYPE	Clinical trial
T33629	DRUGINFO	D0N3IA	HE3235	Phase 2

T58184	TARGETID	T58184
T58184	FORMERID	TTDI01700
T58184	TARGNAME	Ribosome (hRBS)
T58184	TARGTYPE	Clinical trial
T58184	DRUGINFO	D18ATS	ELX-02	Phase 2
T58184	DRUGINFO	D01NSM	TST-10088	Phase 1

T07601	TARGETID	T07601
T07601	FORMERID	TTDR00122
T07601	UNIPROID	CAMLG_HUMAN
T07601	TARGNAME	Calcium signal-modulating cyclophilin ligand (CAML)
T07601	GENENAME	CAMLG; CAML
T07601	TARGTYPE	Clinical trial
T07601	SYNONYMS	cyclophilin
T07601	FUNCTION	Likely involved in the mobilization of calcium as a result of the TCR/CD3 complex interaction. Binds to cyclophilin B.
T07601	SEQUENCE	MESMAVATDGGERPGVPAGSGLSASQRRAELRRRKLLMNSEQRINRIMGFHRPGSGAEEESQTKSKQQDSDKLNSLSVPSVSKRVVLGDSVSTGTTDQQGGVAEVKGTQLGDKLDSFIKPPECSSDVNLELRQRNRGDLTADSVQRGSRHGLEQYLSRFEEAMKLRKQLISEKPSQEDGNTTEEFDSFRIFRLVGCALLALGVRAFVCKYLSIFAPFLTLQLAYMGLYKYFPKSEKKIKTTVLTAALLLSGIPAEVINRSMDTYSKMGEVFTDLCVYFFTFIFCHELLDYWGSEVP
T07601	DRUGINFO	D0CE0O	Alisporivir	Phase 3
T07601	DRUGINFO	D02EEJ	SCY-635	Phase 2
T07601	DRUGINFO	D0TP7T	SCY-641	Preclinical
T07601	DRUGINFO	D00CEG	D-43787	Terminated

T74437	TARGETID	T74437
T74437	FORMERID	TTDI01566
T74437	TARGNAME	Actin polymerization (Actin poly)
T74437	TARGTYPE	Clinical trial
T74437	DRUGINFO	D0DJ4A	Preverex	Phase 2

T62166	TARGETID	T62166
T62166	FORMERID	TTDI01147
T62166	TARGNAME	Adenine synthesis (Adeni synth)
T62166	TARGTYPE	Clinical trial
T62166	DRUGINFO	D02ELS	L-alanosine	Phase 2

T45196	TARGETID	T45196
T45196	FORMERID	TTDNC00541
T45196	TARGNAME	Angiogenesis (AGG)
T45196	TARGTYPE	Clinical trial
T45196	DRUGINFO	D00VUN	TRX-818	Phase 1
T45196	DRUGINFO	D0P4KU	ABI-011	Phase 1

T40160	TARGETID	T40160
T40160	FORMERID	TTDI01196
T40160	TARGNAME	Aryl hydrocarbon receptor signaling pathway (AhR pathway)
T40160	TARGTYPE	Clinical trial
T40160	DRUGINFO	D09HFS	AFP464	Phase 2

T52534	TARGETID	T52534
T52534	FORMERID	TTDI01188
T52534	TARGNAME	Bacterial Protein synthesis (Bact PROS)
T52534	TARGTYPE	Clinical trial
T52534	DRUGINFO	D00WZK	BC-3781 intravenous	Phase 2
T52534	DRUGINFO	D0BW4W	Sutezolid	Phase 2
T52534	DRUGINFO	D0W5PN	Radezolid	Phase 2

T76310	TARGETID	T76310
T76310	FORMERID	TTDI01160
T76310	TARGNAME	Calcium release (Ca rele)
T76310	TARGTYPE	Clinical trial
T76310	DRUGINFO	D01ASM	NPC-15199	Phase 2

T44008	TARGETID	T44008
T44008	FORMERID	TTDI01166
T44008	TARGNAME	cAMP formation (cAMP form)
T44008	TARGTYPE	Clinical trial
T44008	DRUGINFO	D0Z3RF	UCB-11056	Phase 2

T01358	TARGETID	T01358
T01358	FORMERID	TTDI01280
T01358	TARGNAME	Cell cycle (CC)
T01358	TARGTYPE	Clinical trial
T01358	DRUGINFO	D08KPA	BZL-101	Phase 2

T87237	TARGETID	T87237
T87237	FORMERID	TTDI01238
T87237	TARGNAME	Cell differentiation (CD)
T87237	TARGTYPE	Clinical trial
T87237	DRUGINFO	D02BVW	FF-10501-01	Phase 1/2

T59870	TARGETID	T59870
T59870	FORMERID	TTDNC00554
T59870	TARGNAME	Cholesterol absorption (Chole absorp)
T59870	TARGTYPE	Clinical trial
T59870	DRUGINFO	D02UMF	KT6-971	Phase 2
T59870	DRUGINFO	D0O6RK	MD-0727	Phase 2
T59870	DRUGINFO	D04IME	SCH-48461	Discontinued in Phase 2
T59870	DRUGINFO	D0T1YN	Tiqueside	Discontinued in Phase 2

T67233	TARGETID	T67233
T67233	FORMERID	TTDI01609
T67233	TARGNAME	Cholesterol uptake (Chole uptake)
T67233	TARGTYPE	Clinical trial
T67233	DRUGINFO	D0F4ZN	PAMAQUESIDE	Phase 3

T46658	TARGETID	T46658
T46658	FORMERID	TTDI01259
T46658	TARGNAME	Eosinophil/lymphocyte-rich accumulation (ELR accum)
T46658	TARGTYPE	Clinical trial
T46658	DRUGINFO	D0Q9IY	PNU-142731A	Phase 2

T49040	TARGETID	T49040
T49040	FORMERID	TTDI01254
T49040	TARGNAME	Glucose metabolism (Glucose metab)
T49040	TARGTYPE	Clinical trial
T49040	DRUGINFO	D01JMX	INS-1	Phase 2

T30208	TARGETID	T30208
T30208	FORMERID	TTDI01264
T30208	TARGNAME	Growth hormone secretion (GH secr)
T30208	TARGTYPE	Clinical trial
T30208	DRUGINFO	D0X9GE	CIGB-500	Phase 1

T93485	TARGETID	T93485
T93485	FORMERID	TTDI01174
T93485	TARGNAME	Hepatitis B virus Reverse transcriptase priming/DNA synthesis (HBV RTP/DS)
T93485	TARGTYPE	Clinical trial
T93485	DRUGINFO	D0QK5C	ALAMIFOVIR	Phase 1/2

T43902	TARGETID	T43902
T43902	FORMERID	TTDI01169
T43902	TARGNAME	Histamine release (His rele)
T43902	TARGTYPE	Clinical trial
T43902	DRUGINFO	D07TAS	CI-959	Phase 1
T43902	DRUGINFO	D09ZPX	HSR-6071	Discontinued in Phase 1

T10249	TARGETID	T10249
T10249	FORMERID	TTDI01162
T10249	TARGNAME	Histamine/peptide leukotriene release (His/p-LT rele)
T10249	TARGTYPE	Clinical trial
T10249	DRUGINFO	D09YDO	Quinotolast	Phase 3

T99907	TARGETID	T99907
T99907	FORMERID	TTDI01240
T99907	TARGNAME	Human immunodeficiency virus Maturation (HIV Mat)
T99907	TARGTYPE	Clinical trial
T99907	DRUGINFO	D0I2VW	GSK2838232	Phase 2
T99907	DRUGINFO	D0K5TE	BMS-955176	Phase 2
T99907	DRUGINFO	DB2U3O	GSK3640254	Phase 2

T83335	TARGETID	T83335
T83335	FORMERID	TTDI01295
T83335	TARGNAME	Human immunodeficiency virus Transmission (HIV Tran)
T83335	TARGTYPE	Clinical trial
T83335	DRUGINFO	D0ER8I	Ushercell	Phase 3

T33917	TARGETID	T33917
T33917	FORMERID	TTDI01209
T33917	TARGNAME	Hydroxy radical elimination (HYRE)
T33917	TARGTYPE	Clinical trial
T33917	DRUGINFO	D07ZMQ	HD-003	Phase 2

T07861	TARGETID	T07861
T07861	FORMERID	TTDI01156
T07861	TARGNAME	IL-1 synthesis/release (IL-1 synth/rele)
T07861	TARGTYPE	Clinical trial
T07861	DRUGINFO	D00NVO	Flezelastine	Phase 2

T21312	TARGETID	T21312
T21312	FORMERID	TTDI01554
T21312	TARGNAME	Immune checkpoint (ICH)
T21312	TARGTYPE	Clinical trial
T21312	DRUGINFO	D01HQU	AK107	Phase 1
T21312	DRUGINFO	D06MHZ	NLG919	Phase 1

T53684	TARGETID	T53684
T53684	FORMERID	TTDI01292
T53684	TARGNAME	Inflammation pathogenesis (IP)
T53684	TARGTYPE	Clinical trial
T53684	DRUGINFO	D0G6DF	HMPL-004	Phase 3

T71479	TARGETID	T71479
T71479	FORMERID	TTDI01221
T71479	TARGNAME	JAK-STAT signaling pathway (JAK-STAT pathway)
T71479	TARGTYPE	Clinical trial
T71479	DRUGINFO	D0IV4C	WP-1066	Phase 1/2
T71479	DRUGINFO	D0C3AA	CKD-712	Phase 1
T71479	DRUGINFO	D07PTU	Imidazo[4,5-c]pyridine derivative 1	Patented
T71479	DRUGINFO	D09ALF	Aminotriazolopyridine derivative 1	Patented
T71479	DRUGINFO	D0VJ1R	Imidazo[4,5-c]pyridine derivative 2	Patented
T71479	DRUGINFO	D0YR8S	PMID27774824-Compound-Figure11Example1up	Patented

T45596	TARGETID	T45596
T45596	FORMERID	TTDI01542
T45596	TARGNAME	JNK signaling pathway (JNK pathway)
T45596	TARGTYPE	Clinical trial
T45596	DRUGINFO	D0B5RO	REN-1654	Phase 2

T08383	TARGETID	T08383
T08383	FORMERID	TTDI01149
T08383	TARGNAME	Ketogenesis (KG)
T08383	TARGTYPE	Clinical trial
T08383	DRUGINFO	D01IHR	AC-1202	Phase 2

T27770	TARGETID	T27770
T27770	FORMERID	TTDI01297
T27770	TARGNAME	Late inward sodium current (LISC)
T27770	TARGTYPE	Clinical trial
T27770	DRUGINFO	D0A4UC	GS-6615	Phase 3

T15784	TARGETID	T15784
T15784	FORMERID	TTDI01215
T15784	TARGNAME	Lipid peroxidation (LPO)
T15784	TARGTYPE	Clinical trial
T15784	DRUGINFO	D04GKL	RAXOFELAST	Phase 2
T15784	DRUGINFO	D0E8HA	T-817MA	Phase 2
T15784	DRUGINFO	D0G6ES	TAK-218	Discontinued in Phase 2
T15784	DRUGINFO	D0R0OC	U-104067F	Discontinued in Phase 1
T15784	DRUGINFO	D0Q5II	G009	Investigative

T39554	TARGETID	T39554
T39554	FORMERID	TTDI01541
T39554	TARGNAME	MAPK/ERK signaling pathway (MAPK pathway)
T39554	TARGTYPE	Clinical trial
T39554	DRUGINFO	D0B5RO	REN-1654	Phase 2

T36846	TARGETID	T36846
T36846	FORMERID	TTDI01204
T36846	TARGNAME	Mitochondrial function (MF)
T36846	TARGTYPE	Clinical trial
T36846	DRUGINFO	D01WZG	Creatine ALS-08	Phase 3

T09347	TARGETID	T09347
T09347	FORMERID	TTDI01176
T09347	TARGNAME	Neurotransmitter release (NT rele)
T09347	TARGTYPE	Clinical trial
T09347	DRUGINFO	D0N9KZ	TN-871	Phase 2

T74402	TARGETID	T74402
T74402	FORMERID	TTDI01274
T74402	TARGNAME	NF-kappa-B-p38 signaling pathway (NFKB-p38 pathway)
T74402	TARGTYPE	Clinical trial
T74402	DRUGINFO	D03QEB	VGX-1027	Phase 1

T65731	TARGETID	T65731
T65731	FORMERID	TTDI01311
T65731	TARGNAME	Nitric oxide elimination (NOE)
T65731	TARGTYPE	Clinical trial
T65731	DRUGINFO	D07ELT	NOX-700	Phase 1

T36658	TARGETID	T36658
T36658	FORMERID	TTDI01201
T36658	TARGNAME	Oxidative stress (OS)
T36658	TARGTYPE	Clinical trial
T36658	DRUGINFO	D0E7AS	SUN-N8075	Phase 1
T36658	DRUGINFO	D0L8OE	AC3056	Discontinued in Phase 1

T04079	TARGETID	T04079
T04079	FORMERID	TTDI01187
T04079	TARGNAME	Plasmodial phospholipid metabolism (PPP metab)
T04079	TARGTYPE	Clinical trial
T04079	DRUGINFO	D02ETY	SAR97276	Phase 2
T04079	DRUGINFO	D0R3XI	CDRI-97/78	Phase 1

T65667	TARGETID	T65667
T65667	FORMERID	TTDI01598
T65667	TARGNAME	PMN apoptosis and chemotaxis (PMNAC)
T65667	TARGTYPE	Clinical trial
T65667	DRUGINFO	D07ANO	Synthetic neutrophil inhibitor peptide	Phase 1

T77158	TARGETID	T77158
T77158	FORMERID	TTDI01308
T77158	TARGNAME	Protein synthesis (hPRO synth)
T77158	TARGTYPE	Clinical trial
T77158	DRUGINFO	D0BE0Z	Contezolid acefosamil	Phase 2
T77158	DRUGINFO	D0I2GS	Contezolid	Phase 2
T77158	DRUGINFO	D36JFT	ARV-1801	Phase 2
T77158	DRUGINFO	D0T4OT	Zilascorb (2H)	Discontinued in Phase 2

T32456	TARGETID	T32456
T32456	FORMERID	TTDI01186
T32456	TARGNAME	Second phase insulin secretion (SPI secr)
T32456	TARGTYPE	Clinical trial
T32456	DRUGINFO	D0X1VJ	AGI-1067	Phase 3

T21617	TARGETID	T21617
T21617	FORMERID	TTDI01551
T21617	TARGNAME	Signal transduction unspecific (ST)
T21617	TARGTYPE	Clinical trial
T21617	DRUGINFO	D0W5LC	Forigerimod	Phase 3
T21617	DRUGINFO	D0J8AE	OMN-54	Phase 1

T98015	TARGETID	T98015
T98015	FORMERID	TTDI01562
T98015	TARGNAME	Sodium/potassium transport (Na/K trans)
T98015	TARGTYPE	Clinical trial
T98015	DRUGINFO	D05ZHA	Alilusem	Phase 3

T08769	TARGETID	T08769
T08769	FORMERID	TTDI01327
T08769	TARGNAME	STAT3-Beta-catenin pathway (SBC pathway)
T08769	TARGTYPE	Clinical trial

T80518	TARGETID	T80518
T80518	TARGNAME	Synaptic transmission (ST)
T80518	TARGTYPE	Clinical trial
T80518	DRUGINFO	D00YAH	E2730	Phase 1

T58902	TARGETID	T58902
T58902	FORMERID	TTDI01298
T58902	TARGNAME	Tau protein aggregation (TauA)
T58902	TARGTYPE	Clinical trial
T58902	DRUGINFO	D05XDZ	LMT-X	Phase 3

T49833	TARGETID	T49833
T49833	FORMERID	TTDI01290
T49833	TARGNAME	TNF/IL-10 release (TNF/IL10 rele)
T49833	TARGTYPE	Clinical trial
T49833	DRUGINFO	D05DZA	PUR-0110	Phase 2

T72182	TARGETID	T72182
T72182	FORMERID	TTDI01155
T72182	TARGNAME	TNF-alpha/IL-1 beta production (TNFA/IL1B produ)
T72182	TARGTYPE	Clinical trial
T72182	DRUGINFO	D0MY7X	Esonarimod	Phase 3

T60136	TARGETID	T60136
T60136	FORMERID	TTDI01316
T60136	TARGNAME	Trigeminal ganglion stimulation-induced response (TGSR)
T60136	TARGTYPE	Clinical trial
T60136	DRUGINFO	D05TLP	Carabersat	Phase 2

T08441	TARGETID	T08441
T08441	FORMERID	TTDI01234
T08441	TARGNAME	Viral Maturation (VM)
T08441	TARGTYPE	Clinical trial
T08441	DRUGINFO	D0C5OK	Drug 2838232	Phase 1

T97725	TARGETID	T97725
T97725	TARGNAME	Virus Replication (Viru Repli)
T97725	TARGTYPE	Clinical trial
T97725	DRUGINFO	D0UU4B	CLS006	Phase 3
T97725	DRUGINFO	D06ZPX	BTL-TML-001	Phase 2
T97725	DRUGINFO	D09BXF	CLS003	Phase 2

T72437	TARGETID	T72437
T72437	FORMERID	TTDI01320
T72437	TARGNAME	VWF-dependent platelet-collagen conversion (VDDPCC)
T72437	TARGTYPE	Clinical trial
T72437	DRUGINFO	D05BBB	Saratin	Phase 2

T54379	TARGETID	T54379
T54379	FORMERID	TTDNC00429
T54379	TARGNAME	Wnt signaling pathway (Wnt pathway)
T54379	TARGTYPE	Clinical trial
T54379	DRUGINFO	D0I9AC	SM04554	Phase 2/3
T54379	DRUGINFO	D05ZIS	SM-04690	Phase 2
T54379	DRUGINFO	D07AYI	CWP232291	Phase 1/2
T54379	DRUGINFO	D09YPJ	SM08502	Phase 1
T54379	DRUGINFO	D0P5XM	SM04755	Phase 1

T01011	TARGETID	T01011
T01011	TARGNAME	Aurora kinase (AURK)
T01011	TARGTYPE	Clinical trial
T01011	SYNONYMS	Serine/threonine kinase
T01011	DRUGINFO	DXD69J	AZD2811	Phase 2
T01011	DRUGINFO	D0LR2Y	Diamidothiazole derivative 1	Patented

T19947	TARGETID	T19947
T19947	TARGNAME	Immunoproteasome complex (IP)
T19947	TARGTYPE	Clinical trial
T19947	SYNONYMS	i-proteasome complex
T19947	DRUGINFO	DME75T	KZR-616	Phase 2
T19947	DRUGINFO	D01NCJ	Peptide analog 10	Patented
T19947	DRUGINFO	D01OBB	Peptide analog 40	Patented
T19947	DRUGINFO	D01VHD	PMID29865878-Compound-41	Patented
T19947	DRUGINFO	D03JWM	PMID29865878-Compound-38	Patented
T19947	DRUGINFO	D04HPR	Peptide analog 30	Patented
T19947	DRUGINFO	D06GDM	Peptide analog 16	Patented
T19947	DRUGINFO	D06SJU	Peptide analog 26	Patented
T19947	DRUGINFO	D08RXZ	Peptide analog 24	Patented
T19947	DRUGINFO	D09EGD	PMID29865878-Compound-54	Patented
T19947	DRUGINFO	D0A0VU	PMID29865878-Compound-56	Patented
T19947	DRUGINFO	D0B0VK	Peptide analog 32	Patented
T19947	DRUGINFO	D0C4JQ	Peptide analog 43	Patented
T19947	DRUGINFO	D0D2PS	PMID29865878-Compound-52	Patented
T19947	DRUGINFO	D0DU4H	Peptide analog 12	Patented
T19947	DRUGINFO	D0FJ8E	Peptide analog 18	Patented
T19947	DRUGINFO	D0HM4V	PMID29865878-Compound-50	Patented
T19947	DRUGINFO	D0HV3N	PMID29865878-Compound-60	Patented
T19947	DRUGINFO	D0JI5X	PMID29865878-Compound-42	Patented
T19947	DRUGINFO	D0JK0Y	Peptide analog 35	Patented
T19947	DRUGINFO	D0NO3H	Peptide analog 42	Patented
T19947	DRUGINFO	D0O9YJ	PMID29865878-Compound-47	Patented
T19947	DRUGINFO	D0P9YR	Peptide analog 29	Patented
T19947	DRUGINFO	D0R5FU	Peptide analog 9	Patented
T19947	DRUGINFO	D0RF5E	PMID29865878-Compound-39	Patented
T19947	DRUGINFO	D0UZ4S	Peptide analog 22	Patented
T19947	DRUGINFO	D0WF1F	PMID29865878-Compound-45	Patented
T19947	DRUGINFO	D0WJ3T	Peptide analog 15	Patented
T19947	DRUGINFO	D0X4HJ	Peptide analog 20	Patented
T19947	DRUGINFO	D0ZH3O	PMID29865878-Compound-40	Patented

T04977	TARGETID	T04977
T04977	FORMERID	TTDI01684
T04977	TARGNAME	Oxalate absorption (Oxalate absor)
T04977	TARGTYPE	Clinical trial
T04977	DRUGINFO	D1TED8	Reloxaliase	Phase 3
T04977	DRUGINFO	D0N9SJ	ALTU-237	Discontinued in Phase 1

T38143	TARGETID	T38143
T38143	FORMERID	TTDR01029
T38143	TARGNAME	Phosphodiesterase 5 (PDE5)
T38143	TARGTYPE	Clinical trial
T38143	SYNONYMS	Phosphosdiesterase-5; PDE5; PDE-V; PDE-5
T38143	BIOCLASS	Phosphoric diester hydrolase
T38143	DRUGINFO	D1OM8E	AR1001	Phase 3
T38143	DRUGINFO	D1OM8E	AR1001	Phase 3

T60348	TARGETID	T60348
T60348	FORMERID	TTDI01788
T60348	TARGNAME	Voltage-dependent anion channel (VDAC)
T60348	TARGTYPE	Clinical trial
T60348	FUNCTION	Forms a channel through the mitochondrial outer membrane that allows diffusion of small hydrophilic molecules.
T60348	BIOCLASS	Eukaryotic mitochondrial porin
T60348	DRUGINFO	DK6P5A	VDA-1102	Phase 2

T63551	TARGETID	T63551
T63551	FORMERID	TTDNC00629
T63551	TARGNAME	Integrin (ITG)
T63551	TARGTYPE	Clinical trial
T63551	SYNONYMS	Integrin protein
T63551	DRUGINFO	DS6OV9	THR-687	Phase 1

T18204	TARGETID	T18204
T18204	FORMERID	TTDI01734
T18204	TARGNAME	Alpha-secretase (ASE)
T18204	TARGTYPE	Clinical trial
T18204	DRUGINFO	DH6G1L	APH-1105	Phase 2
T18204	DRUGINFO	DM95PZ	ID1201	Phase 2
T18204	DRUGINFO	DNH51Q	APH-1104	Phase 1

T01674	TARGETID	T01674
T01674	UNIPROID	CE290_HUMAN
T01674	TARGNAME	CEP290 messenger RNA (CEP290 mRNA)
T01674	GENENAME	CEP290
T01674	TARGTYPE	Clinical trial
T01674	SYNONYMS	Cep290; Bardet-Biedl syndrome 14 protein; Cancer/testis antigen 87; CT87; Nephrocystin-6; Tumor antigen se2-2
T01674	FUNCTION	Involved in early and late steps in cilia formation. Its association with CCP110 is required for inhibition of primary cilia formation by CCP110. May play a role in early ciliogenesis in the disappearance of centriolar satellites and in the transition of primary ciliar vesicles (PCVs) to capped ciliary vesicles (CCVs). Required for the centrosomal recruitment of RAB8A and for the targeting of centriole satellite proteins to centrosomes such as of PCM1. Required for the correct localization of ciliary and phototransduction proteins in retinal photoreceptor cells; may play a role in ciliary transport processes (By similarity). Required for efficient recruitment of RAB8A to primary cilium. In the ciliary transition zone is part of the tectonic-like complex which is required for tissue-specific ciliogenesis and may regulate ciliary membrane composition (By similarity). Involved in regulation of the BBSome complex integrity, specifically for presence of BBS2, BBS5 and BBS8/TTC8 in the complex, and in ciliary targeting of selected BBSome cargos. May play a role in controlling entry of the BBSome complex to cilia possibly implicating IQCB1/NPHP5. Activates ATF4-mediated transcription.
T01674	BIOCLASS	mRNA target
T01674	SEQUENCE	MPPNINWKEIMKVDPDDLPRQEELADNLLISLSKVEVNELKSEKQENVIHLFRITQSLMKMKAQEVELALEEVEKAGEEQAKFENQLKTKVMKLENELEMAQQSAGGRDTRFLRNEICQLEKQLEQKDRELEDMEKELEKEKKVNEQLALRNEEAENENSKLRRENKRLKKKNEQLCQDIIDYQKQIDSQKETLLSRRGEDSDYRSQLSKKNYELIQYLDEIQTLTEANEKIEVQNQEMRKNLEESVQEMEKMTDEYNRMKAIVHQTDNVIDQLKKENDHYQLQVQELTDLLKSKNEEDDPIMVAVNAKVEEWKLILSSKDDEIIEYQQMLHNLREKLKNAQLDADKSNVMALQQGIQERDSQIKMLTEQVEQYTKEMEKNTCIIEDLKNELQRNKGASTLSQQTHMKIQSTLDILKEKTKEAERTAELAEADAREKDKELVEALKRLKDYESGVYGLEDAVVEIKNCKNQIKIRDREIEILTKEINKLELKISDFLDENEALRERVGLEPKTMIDLTEFRNSKHLKQQQYRAENQILLKEIESLEEERLDLKKKIRQMAQERGKRSATSGLTTEDLNLTENISQGDRISERKLDLLSLKNMSEAQSKNEFLSRELIEKERDLERSRTVIAKFQNKLKELVEENKQLEEGMKEILQAIKEMQKDPDVKGGETSLIIPSLERLVNAIESKNAEGIFDASLHLKAQVDQLTGRNEELRQELRESRKEAINYSQQLAKANLKIDHLEKETSLLRQSEGSNVVFKGIDLPDGIAPSSASIINSQNEYLIHLLQELENKEKKLKNLEDSLEDYNRKFAVIRHQQSLLYKEYLSEKETWKTESKTIKEEKRKLEDQVQQDAIKVKEYNNLLNALQMDSDEMKKILAENSRKITVLQVNEKSLIRQYTTLVELERQLRKENEKQKNELLSMEAEVCEKIGCLQRFKEMAIFKIAALQKVVDNSVSLSELELANKQYNELTAKYRDILQKDNMLVQRTSNLEHLECENISLKEQVESINKELEITKEKLHTIEQAWEQETKLGNESSMDKAKKSITNSDIVSISKKITMLEMKELNERQRAEHCQKMYEHLRTSLKQMEERNFELETKFAELTKINLDAQKVEQMLRDELADSVSKAVSDADRQRILELEKNEMELKVEVSKLREISDIARRQVEILNAQQQSRDKEVESLRMQLLDYQAQSDEKSLIAKLHQHNVSLQLSEATALGKLESITSKLQKMEAYNLRLEQKLDEKEQALYYARLEGRNRAKHLRQTIQSLRRQFSGALPLAQQEKFSKTMIQLQNDKLKIMQEMKNSQQEHRNMENKTLEMELKLKGLEELISTLKDTKGAQKVINWHMKIEELRLQELKLNRELVKDKEEIKYLNNIISEYERTISSLEEEIVQQNKFHEERQMAWDQREVDLERQLDIFDRQQNEILNAAQKFEEATGSIPDPSLPLPNQLEIALRKIKENIRIILETRATCKSLEEKLKEKESALRLAEQNILSRDKVINELRLRLPATAEREKLIAELGRKEMEPKSHHTLKIAHQTIANMQARLNQKEEVLKKYQRLLEKAREEQREIVKKHEEDLHILHHRLELQADSSLNKFKQTAWDLMKQSPTPVPTNKHFIRLAEMEQTVAEQDDSLSSLLVKLKKVSQDLERQREITELKVKEFENIKLQLQENHEDEVKKVKAEVEDLKYLLDQSQKESQCLKSELQAQKEANSRAPTTTMRNLVERLKSQLALKEKQQKALSRALLELRAEMTAAAEERIISATSQKEAHLNVQQIVDRHTRELKTQVEDLNENLLKLKEALKTSKNRENSLTDNLNDLNNELQKKQKAYNKILREKEEIDQENDELKRQIKRLTSGLQGKPLTDNKQSLIEELQRKVKKLENQLEGKVEEVDLKPMKEKNAKEELIRWEEGKKWQAKIEGIRNKLKEKEGEVFTLTKQLNTLKDLFAKADKEKLTLQRKLKTTGMTVDQVLGIRALESEKELEELKKRNLDLENDILYMRAHQALPRDSVVEDLHLQNRYLQEKLHALEKQFSKDTYSKPSISGIESDDHCQREQELQKENLKLSSENIELKFQLEQANKDLPRLKNQVRDLKEMCEFLKKEKAEVQRKLGHVRGSGRSGKTIPELEKTIGLMKKVVEKVQRENEQLKKASGILTSEKMANIEQENEKLKAELEKLKAHLGHQLSMHYESKTKGTEKIIAENERLRKELKKETDAAEKLRIAKNNLEILNEKMTVQLEETGKRLQFAESRGPQLEGADSKSWKSIVVTRMYETKLKELETDIAKKNQSITDLKQLVKEATEREQKVNKYNEDLEQQIKILKHVPEGAETEQGLKRELQVLRLANHQLDKEKAELIHQIEANKDQSGAESTIPDADQLKEKIKDLETQLKMSDLEKQHLKEEIKKLKKELENFDPSFFEEIEDLKYNYKEEVKKNILLEEKVKKLSEQLGVELTSPVAASEEFEDEEESPVNFPIY
T01674	DRUGINFO	DS14FO	Sepofarsen	Phase 2/3

T02584	TARGETID	T02584
T02584	UNIPROID	SYL_MYCTU
T02584	TARGNAME	Mycobacterium Leucine-tRNA ligase (MycB leuS)
T02584	GENENAME	MycB leuS
T02584	TARGTYPE	Clinical trial
T02584	SYNONYMS	Leucyl-tRNA synthetase; LeuRS
T02584	ECNUMBER	EC 6.1.1.4
T02584	SEQUENCE	MTESPTAGPGGVPRADDADSDVPRYRYTAELAARLERTWQENWARLGTFNVPNPVGSLAPPDGAAVPDDKLFVQDMFPYPSGEGLHVGHPLGYIATDVYARYFRMVGRNVLHALGFDAFGLPAEQYAVQTGTHPRTRTEANVVNFRRQLGRLGFGHDSRRSFSTTDVDFYRWTQWIFLQIYNAWFDTTANKARPISELVAEFESGARCLDGGRDWAKLTAGERADVIDEYRLVYRADSLVNWCPGLGTVLANEEVTADGRSDRGNFPVFRKRLRQWMMRITAYADRLLDDLDVLDWPEQVKTMQRNWIGRSTGAVALFSARAASDDGFEVDIEVFTTRPDTLFGATYLVLAPEHDLVDELVAASWPAGVNPLWTYGGGTPGEAIAAYRRAIAAKSDLERQESREKTGVFLGSYAINPANGEPVPIFIADYVLAGYGTGAIMAVPGHDQRDWDFARAFGLPIVEVIAGGNISESAYTGDGILVNSDYLNGMSVPAAKRAIVDRLESAGRGRARIEFKLRDWLFARQRYWGEPFPIVYDSDGRPHALDEAALPVELPDVPDYSPVLFDPDDADSEPSPPLAKATEWVHVDLDLGDGLKPYSRDTNVMPQWAGSSWYELRYTDPHNSERFCAKENEAYWMGPRPAEHGPDDPGGVDLYVGGAEHAVLHLLYSRFWHKVLYDLGHVSSREPYRRLVNQGYIQAYAYTDARGSYVPAEQVIERGDRFVYPGPDGEVEVFQEFGKIGKSLKNSVSPDEICDAYGADTLRVYEMSMGPLEASRPWATKDVVGAYRFLQRVWRLVVDEHTGETRVADGVELDIDTLRALHRTIVGVSEDFAALRNNTATAKLIEYTNHLTKKHRDAVPRAAVEPLVQMLAPLAPHIAEELWLRLGNTTSLAHGPFPKADAAYLVDETVEYPVQVNGKVRGRVVVAADTDEETLKAAVLTDEKVQAFLAGATPRKVIVVAGRLVNLVI
T02584	DRUGINFO	DUSB35	GSK3036656	Phase 2

T03485	TARGETID	T03485
T03485	UNIPROID	CFAB_HUMAN
T03485	TARGNAME	CFB messenger RNA (CFB mRNA)
T03485	GENENAME	CFB
T03485	TARGTYPE	Clinical trial
T03485	SYNONYMS	C3/C5 convertase; Glycine-rich beta glycoprotein; GBG; PBF2; Properdin factor B
T03485	FUNCTION	Factor B which is part of the alternate pathway of the complement system is cleaved by factor D into 2 fragments: Ba and Bb. Bb, a serine protease, then combines with complement factor 3b to generate the C3 or C5 convertase. It has also been implicated in proliferation and differentiation of preactivated B-lymphocytes, rapid spreading of peripheral blood monocytes, stimulation of lymphocyte blastogenesis and lysis of erythrocytes. Ba inhibits the proliferation of preactivated B-lymphocytes.
T03485	BIOCLASS	mRNA target
T03485	ECNUMBER	EC 3.4.21.47
T03485	SEQUENCE	MGSNLSPQLCLMPFILGLLSGGVTTTPWSLARPQGSCSLEGVEIKGGSFRLLQEGQALEYVCPSGFYPYPVQTRTCRSTGSWSTLKTQDQKTVRKAECRAIHCPRPHDFENGEYWPRSPYYNVSDEISFHCYDGYTLRGSANRTCQVNGRWSGQTAICDNGAGYCSNPGIPIGTRKVGSQYRLEDSVTYHCSRGLTLRGSQRRTCQEGGSWSGTEPSCQDSFMYDTPQEVAEAFLSSLTETIEGVDAEDGHGPGEQQKRKIVLDPSGSMNIYLVLDGSDSIGASNFTGAKKCLVNLIEKVASYGVKPRYGLVTYATYPKIWVKVSEADSSNADWVTKQLNEINYEDHKLKSGTNTKKALQAVYSMMSWPDDVPPEGWNRTRHVIILMTDGLHNMGGDPITVIDEIRDLLYIGKDRKNPREDYLDVYVFGVGPLVNQVNINALASKKDNEQHVFKVKDMENLEDVFYQMIDESQSLSLCGMVWEHRKGTDYHKQPWQAKISVIRPSKGHESCMGAVVSEYFVLTAAHCFTVDDKEHSIKVSVGGEKRDLEIEVVLFHPNYNINGKKEAGIPEFYDYDVALIKLKNKLKYGQTIRPICLPCTEGTTRALRLPPTTTCQQQKEELLPAQDIKALFVSEEEKKLTRKEVYIKNGDKKGSCERDAQYAPGYDKVKDISEVVTPRFLCTGGVSPYADPNTCRGDSGGPLIVHKRSRFIQVGVISWGVVDVCKNQKRQKQVPAHARDFHINLFQVLPWLKEKLQDEDLGFL
T03485	DRUGINFO	DQ2Y7L	IONIS-FB-LRx	Phase 2

T03672	TARGETID	T03672
T03672	UNIPROID	ADAM9_HUMAN
T03672	TARGNAME	Cellular disintegrin-related protein (ADAM9)
T03672	GENENAME	ADAM9
T03672	TARGTYPE	Clinical trial
T03672	SYNONYMS	ADAM 9; Cellular disintegrin-related protein; Meltrin-gamma; Metalloprotease/disintegrin/cysteine-rich protein 9; Myeloma cell metalloproteinase
T03672	FUNCTION	Cleaves and releases a number of molecules with important roles in tumorigenesis and angiogenesis, such as TEK, KDR, EPHB4, CD40, VCAM1 and CDH5. May mediate cell-cell, cell-matrix interactions and regulate the motility of cells via interactions with integrins.
T03672	ECNUMBER	EC 3.4.24.-
T03672	SEQUENCE	MGSGARFPSGTLRVRWLLLLGLVGPVLGAARPGFQQTSHLSSYEIITPWRLTRERREAPRPYSKQVSYVIQAEGKEHIIHLERNKDLLPEDFVVYTYNKEGTLITDHPNIQNHCHYRGYVEGVHNSSIALSDCFGLRGLLHLENASYGIEPLQNSSHFEHIIYRMDDVYKEPLKCGVSNKDIEKETAKDEEEEPPSMTQLLRRRRAVLPQTRYVELFIVVDKERYDMMGRNQTAVREEMILLANYLDSMYIMLNIRIVLVGLEIWTNGNLINIVGGAGDVLGNFVQWREKFLITRRRHDSAQLVLKKGFGGTAGMAFVGTVCSRSHAGGINVFGQITVETFASIVAHELGHNLGMNHDDGRDCSCGAKSCIMNSGASGSRNFSSCSAEDFEKLTLNKGGNCLLNIPKPDEAYSAPSCGNKLVDAGEECDCGTPKECELDPCCEGSTCKLKSFAECAYGDCCKDCRFLPGGTLCRGKTSECDVPEYCNGSSQFCQPDVFIQNGYPCQNNKAYCYNGMCQYYDAQCQVIFGSKAKAAPKDCFIEVNSKGDRFGNCGFSGNEYKKCATGNALCGKLQCENVQEIPVFGIVPAIIQTPSRGTKCWGVDFQLGSDVPDPGMVNEGTKCGAGKICRNFQCVDASVLNYDCDVQKKCHGHGVCNSNKNCHCENGWAPPNCETKGYGGSVDSGPTYNEMNTALRDGLLVFFFLIVPLIVCAIFIFIKRDQLWRSYFRKKRSQTYESDGKNQANPSRQPGSVPRHVSPVTPPREVPIYANRFAVPTYAAKQPQQFPSRPPPPQPKVSSQGNLIPARPAPAPPLYSSLT
T03672	DRUGINFO	DA4O8C	IMGC936	Phase 1

T06128	TARGETID	T06128
T06128	UNIPROID	IRS2_HUMAN
T06128	TARGNAME	Insulin receptor substrate 2 (IRS2)
T06128	GENENAME	IRS2
T06128	TARGTYPE	Clinical trial
T06128	SYNONYMS	IRS-2
T06128	FUNCTION	May mediate the control of various cellular processes by insulin.
T06128	SEQUENCE	MASPPRHGPPGPASGDGPNLNNNNNNNNHSVRKCGYLRKQKHGHKRFFVLRGPGAGGDEATAGGGSAPQPPRLEYYESEKKWRSKAGAPKRVIALDCCLNINKRADAKHKYLIALYTKDEYFAVAAENEQEQEGWYRALTDLVSEGRAAAGDAPPAAAPAASCSASLPGALGGSAGAAGAEDSYGLVAPATAAYREVWQVNLKPKGLGQSKNLTGVYRLCLSARTIGFVKLNCEQPSVTLQLMNIRRCGHSDSFFFIEVGRSAVTGPGELWMQADDSVVAQNIHETILEAMKALKELFEFRPRSKSQSSGSSATHPISVPGARRHHHLVNLPPSQTGLVRRSRTDSLAATPPAAKCSSCRVRTASEGDGGAAAGAAAAGARPVSVAGSPLSPGPVRAPLSRSHTLSGGCGGRGSKVALLPAGGALQHSRSMSMPVAHSPPAATSPGSLSSSSGHGSGSYPPPPGPHPPLPHPLHHGPGQRPSSGSASASGSPSDPGFMSLDEYGSSPGDLRAFCSHRSNTPESIAETPPARDGGGGGEFYGYMTMDRPLSHCGRSYRRVSGDAAQDLDRGLRKRTYSLTTPARQRPVPQPSSASLDEYTLMRATFSGSAGRLCPSCPASSPKVAYHPYPEDYGDIEIGSHRSSSSNLGADDGYMPMTPGAALAGSGSGSCRSDDYMPMSPASVSAPKQILQPRAAAAAAAAVPSAGPAGPAPTSAAGRTFPASGGGYKASSPAESSPEDSGYMRMWCGSKLSMEHADGKLLPNGDYLNVSPSDAVTTGTPPDFFSAALHPGGEPLRGVPGCCYSSLPRSYKAPYTCGGDSDQYVLMSSPVGRILEEERLEPQATPGPSQAASAFGAGPTQPPHPVVPSPVRPSGGRPEGFLGQRGRAVRPTRLSLEGLPSLPSMHEYPLPPEPKSPGEYINIDFGEPGARLSPPAPPLLASAASSSSLLSASSPASSLGSGTPGTSSDSRQRSPLSDYMNLDFSSPKSPKPGAPSGHPVGSLDGLLSPEASSPYPPLPPRPSASPSSSLQPPPPPPAPGELYRLPPASAVATAQGPGAASSLSSDTGDNGDYTEMAFGVAATPPQPIAAPPKPEAARVASPTSGVKRLSLMEQVSGVEAFLQASQPPDPHRGAKVIRADPQGGRRRHSSETFSSTTTVTPVSPSFAHNPKRHNSASVENVSLRKSSEGGVGVGPGGGDEPPTSPRQLQPAPPLAPQGRPWTPGQPGGLVGCPGSGGSPMRRETSAGFQNGLNYIAIDVREEPGLPPQPQPPPPPLPQPGDKSSWGRTRSLGGLISAVGVGSTGGGCGGPGPGALPPANTYASIDFLSHHLKEATIVKE
T06128	DRUGINFO	DUI59O	NT219	Phase 1/2

T06958	TARGETID	T06958
T06958	UNIPROID	DPOLB_HUMAN
T06958	TARGNAME	DNA polymerase beta (POLB)
T06958	GENENAME	POLB
T06958	TARGTYPE	Clinical trial
T06958	FUNCTION	Repair polymerase that plays a key role in base-excision repair. Has 5'-deoxyribose-5-phosphate lyase (dRP lyase) activity that removes the 5' sugar phosphate and also acts as a DNA polymerase that adds one nucleotide to the 3' end of the arising single-nucleotide gap. Conducts 'gap-filling' DNA synthesis in a stepwise distributive fashion rather than in a processive fashion as for other DNA polymerases.
T06958	ECNUMBER	EC 2.7.7.7
T06958	SEQUENCE	MSKRKAPQETLNGGITDMLTELANFEKNVSQAIHKYNAYRKAASVIAKYPHKIKSGAEAKKLPGVGTKIAEKIDEFLATGKLRKLEKIRQDDTSSSINFLTRVSGIGPSAARKFVDEGIKTLEDLRKNEDKLNHHQRIGLKYFGDFEKRIPREEMLQMQDIVLNEVKKVDSEYIATVCGSFRRGAESSGDMDVLLTHPSFTSESTKQPKLLHQVVEQLQKVHFITDTLSKGETKFMGVCQLPSKNDEKEYPHRRIDIRLIPKDQYYCGVLYFTGSDIFNKNMRAHALEKGFTINEYTIRPLGVTGVAGEPLPVDSEKDIFDYIQWKYREPKDRSE
T06958	DRUGINFO	DL30JC	FF-10502	Phase 1/2

T07816	TARGETID	T07816
T07816	UNIPROID	Q4QH56_LEIMA; Q4Q1Q9_LEIMA
T07816	TARGNAME	Leishmania major Proteasome (Leishm Proteasome)
T07816	TARGTYPE	Clinical trial
T07816	DRUGINFO	DA6C8N	LXE408	Phase 2

T07893	TARGETID	T07893
T07893	TARGNAME	Polyamine transport (Poly trans)
T07893	TARGTYPE	Clinical trial
T07893	DRUGINFO	DRL76S	AMXT1501	Phase 1

T07931	TARGETID	T07931
T07931	UNIPROID	LIRB2_HUMAN
T07931	TARGNAME	Leukocyte immunoglobulin-like receptor B2 (LILRB2)
T07931	GENENAME	LILRB2
T07931	TARGTYPE	Clinical trial
T07931	SYNONYMS	LIR-2; Leukocyte immunoglobulin-like receptor 2; CD85 antigen-like family member D; Immunoglobulin-like transcript 4; ILT-4; Monocyte/macrophage immunoglobulin-like receptor 10; MIR-10; DE   AltName: CD_antigen=CD85d
T07931	FUNCTION	Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles. Involved in the down-regulation of the immune response and the development of tolerance. Recognizes HLA-G in complex with B2M/beta-2 microglobulin and a nonamer self-peptide (peptide-bound HLA-G-B2M) triggering differentiation of type 1 regulatory T cells and myeloid-derived suppressor cells, both of which actively maintain maternal-fetal tolerance. Competes with CD8A for binding to class I MHC antigens. Inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.
T07931	SEQUENCE	MTPIVTVLICLGLSLGPRTHVQTGTIPKPTLWAEPDSVITQGSPVTLSCQGSLEAQEYRLYREKKSASWITRIRPELVKNGQFHIPSITWEHTGRYGCQYYSRARWSELSDPLVLVMTGAYPKPTLSAQPSPVVTSGGRVTLQCESQVAFGGFILCKEGEEEHPQCLNSQPHARGSSRAIFSVGPVSPNRRWSHRCYGYDLNSPYVWSSPSDLLELLVPGVSKKPSLSVQPGPVVAPGESLTLQCVSDVGYDRFVLYKEGERDLRQLPGRQPQAGLSQANFTLGPVSRSYGGQYRCYGAHNLSSECSAPSDPLDILITGQIRGTPFISVQPGPTVASGENVTLLCQSWRQFHTFLLTKAGAADAPLRLRSIHEYPKYQAEFPMSPVTSAHAGTYRCYGSLNSDPYLLSHPSEPLELVVSGPSMGSSPPPTGPISTPAGPEDQPLTPTGSDPQSGLGRHLGVVIGILVAVVLLLLLLLLLFLILRHRRQGKHWTSTQRKADFQHPAGAVGPEPTDRGLQWRSSPAADAQEENLYAAVKDTQPEDGVEMDTRAAASEAPQDVTYAQLHSLTLRRKATEPPPSQEREPPAEPSIYATLAIH
T07931	DRUGINFO	DE61WB	NGM707	Phase 2
T07931	DRUGINFO	DK4I9R	MK-4830	Phase 1

T08139	TARGETID	T08139
T08139	UNIPROID	FANCA_HUMAN
T08139	TARGNAME	Fanconi anemia group A protein (FANCA)
T08139	GENENAME	FANCA
T08139	TARGTYPE	Clinical trial
T08139	SYNONYMS	Protein FACA
T08139	FUNCTION	DNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. May be involved in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability.
T08139	SEQUENCE	MSDSWVPNSASGQDPGGRRRAWAELLAGRVKREKYNPERAQKLKESAVRLLRSHQDLNALLLEVEGPLCKKLSLSKVIDCDSSEAYANHSSSFIGSALQDQASRLGVPVGILSAGMVASSVGQICTAPAETSHPVLLTVEQRKKLSSLLEFAQYLLAHSMFSRLSFCQELWKIQSSLLLEAVWHLHVQGIVSLQELLESHPDMHAVGSWLFRNLCCLCEQMEASCQHADVARAMLSDFVQMFVLRGFQKNSDLRRTVEPEKMPQVTVDVLQRMLIFALDALAAGVQEESSTHKIVRCWFGVFSGHTLGSVISTDPLKRFFSHTLTQILTHSPVLKASDAVQMQREWSFARTHPLLTSLYRRLFVMLSAEELVGHLQEVLETQEVHWQRVLSFVSALVVCFPEAQQLLEDWVARLMAQAFESCQLDSMVTAFLVVRQAALEGPSAFLSYADWFKASFGSTRGYHGCSKKALVFLFTFLSELVPFESPRYLQVHILHPPLVPGKYRSLLTDYISLAKTRLADLKVSIENMGLYEDLSSAGDITEPHSQALQDVEKAIMVFEHTGNIPVTVMEASIFRRPYYVSHFLPALLTPRVLPKVPDSRVAFIESLKRADKIPPSLYSTYCQACSAAEEKPEDAALGVRAEPNSAEEPLGQLTAALGELRASMTDPSQRDVISAQVAVISERLRAVLGHNEDDSSVEISKIQLSINTPRLEPREHMAVDLLLTSFCQNLMAASSVAPPERQGPWAALFVRTMCGRVLPAVLTRLCQLLRHQGPSLSAPHVLGLAALAVHLGESRSALPEVDVGPPAPGAGLPVPALFDSLLTCRTRDSLFFCLKFCTAAISYSLCKFSSQSRDTLCSCLSPGLIKKFQFLMFRLFSEARQPLSEEDVASLSWRPLHLPSADWQRAALSLWTHRTFREVLKEEDVHLTYQDWLHLELEIQPEADALSDTERQDFHQWAIHEHFLPESSASGGCDGDLQAACTILVNALMDFHQSSRSYDHSENSDLVFGGRTGNEDIISRLQEMVADLELQQDLIVPLGHTPSQEHFLFEIFRRRLQALTSGWSVAASLQRQRELLMYKRILLRLPSSVLCGSSFQAEQPITARCEQFFHLVNSEMRNFCSHGGALTQDITAHFFRGLLNACLRSRDPSLMVDFILAKCQTKCPLILTSALVWWPSLEPVLLCRWRRHCQSPLPRELQKLQEGRQFASDFLSPEAASPAPNPDWLSAAALHFAIQQVREENIRKQLKKLDCEREELLVFLFFFSLMGLLSSHLTSNSTTDLPKAFHVCAAILECLEKRKISWLALFQLTESDLRLGRLLLRVAPDQHTRLLPFAFYSLLSYFHEDAAIREEAFLHVAVDMYLKLVQLFVAGDTSTVSPPAGRSLELKGQGNPVELITKARLFLLQLIPRCPKKSFSHVAELLADRGDCDPEVSAALQSRQQAAPDADLSQEPHLF
T08139	DRUGINFO	DL7HD5	RP-L102	Phase 2

T08326	TARGETID	T08326
T08326	UNIPROID	CDK12_HUMAN
T08326	TARGNAME	Cyclin-dependent kinase 12 (CDK12)
T08326	GENENAME	CDK12
T08326	TARGTYPE	Clinical trial
T08326	SYNONYMS	Cdc2-related kinase, arginine/serine-rich; CrkRS; Cell division cycle 2-related protein kinase 7; CDC2-related protein kinase 7; Cell division protein kinase 12; hCDK12
T08326	FUNCTION	Cyclin-dependent kinase that phosphorylates the C-terminal domain (CTD) of the large subunit of RNA polymerase II (POLR2A), thereby acting as a key regulator of transcription elongation. Regulates the expression of genes involved in DNA repair and is required for the maintenance of genomic stability. Preferentially phosphorylates 'Ser-5' in CTD repeats that are already phosphorylated at 'Ser-7', but can also phosphorylate 'Ser-2'. Required for RNA splicing, possibly by phosphorylating SRSF1/SF2. Involved in regulation of MAP kinase activity, possibly leading to affect the response to estrogen inhibitors.
T08326	BIOCLASS	Kinase
T08326	ECNUMBER	EC 2.7.11.22
T08326	SEQUENCE	MPNSERHGGKKDGSGGASGTLQPSSGGGSSNSRERHRLVSKHKRHKSKHSKDMGLVTPEAASLGTVIKPLVEYDDISSDSDTFSDDMAFKLDRRENDERRGSDRSDRLHKHRHHQHRRSRDLLKAKQTEKEKSQEVSSKSGSMKDRISGSSKRSNEETDDYGKAQVAKSSSKESRSSKLHKEKTRKERELKSGHKDRSKSHRKRETPKSYKTVDSPKRRSRSPHRKWSDSSKQDDSPSGASYGQDYDLSPSRSHTSSNYDSYKKSPGSTSRRQSVSPPYKEPSAYQSSTRSPSPYSRRQRSVSPYSRRRSSSYERSGSYSGRSPSPYGRRRSSSPFLSKRSLSRSPLPSRKSMKSRSRSPAYSRHSSSHSKKKRSSSRSRHSSISPVRLPLNSSLGAELSRKKKERAAAAAAAKMDGKESKGSPVFLPRKENSSVEAKDSGLESKKLPRSVKLEKSAPDTELVNVTHLNTEVKNSSDTGKVKLDENSEKHLVKDLKAQGTRDSKPIALKEEIVTPKETETSEKETPPPLPTIASPPPPLPTTTPPPQTPPLPPLPPIPALPQQPPLPPSQPAFSQVPASSTSTLPPSTHSKTSAVSSQANSQPPVQVSVKTQVSVTAAIPHLKTSTLPPLPLPPLLPGDDDMDSPKETLPSKPVKKEKEQRTRHLLTDLPLPPELPGGDLSPPDSPEPKAITPPQQPYKKRPKICCPRYGERRQTESDWGKRCVDKFDIIGIIGEGTYGQVYKAKDKDTGELVALKKVRLDNEKEGFPITAIREIKILRQLIHRSVVNMKEIVTDKQDALDFKKDKGAFYLVFEYMDHDLMGLLESGLVHFSEDHIKSFMKQLMEGLEYCHKKNFLHRDIKCSNILLNNSGQIKLADFGLARLYNSEESRPYTNKVITLWYRPPELLLGEERYTPAIDVWSCGCILGELFTKKPIFQANLELAQLELISRLCGSPCPAVWPDVIKLPYFNTMKPKKQYRRRLREEFSFIPSAALDLLDHMLTLDPSKRCTAEQTLQSDFLKDVELSKMAPPDLPHWQDCHELWSKKRRRQRQSGVVVEEPPPSKTSRKETTSGTSTEPVKNSSPAPPQPAPGKVESGAGDAIGLADITQQLNQSELAVLLNLLQSQTDLSIPQMAQLLNIHSNPEMQQQLEALNQSISALTEATSQQQDSETMAPEESLKEAPSAPVILPSAEQTTLEASSTPADMQNILAVLLSQLMKTQEPAGSLEENNSDKNSGPQGPRRTPTMPQEEAAACPPHILPPEKRPPEPPGPPPPPPPPPLVEGDLSSAPQELNPAVTAALLQLLSQPEAEPPGHLPHEHQALRPMEYSTRPRPNRTYGNTDGPETGFSAIDTDERNSGPALTESLVQTLVKNRTFSGSLSHLGESSSYQGTGSVQFPGDQDLRFARVPLALHPVVGQPFLKAEGSSNSVVHAETKLQNYGELGPGTTGASSSGAGLHWGGPTQSSAYGKLYRGPTRVPPRGGRGRGVPY
T08326	DRUGINFO	DN9IC4	GSK3186899	Phase 1
T08326	DRUGINFO	D7RK2M	THZ531	Investigative

T09483	TARGETID	T09483
T09483	UNIPROID	EGR1_HUMAN
T09483	TARGNAME	EGR1 messenger RNA (EGR1 mRNA)
T09483	GENENAME	EGR1
T09483	TARGTYPE	Clinical trial
T09483	SYNONYMS	EGR-1; AT225; Nerve growth factor-induced protein A; NGFI-A; Transcription factor ETR103; Transcription factor Zif268; Zinc finger protein 225; Zinc finger protein Krox-24
T09483	FUNCTION	Transcriptional regulator. Recognizes and binds to the DNA sequence 5'-GCG(T/G)GGGCG-3'(EGR-site) in the promoter region of target genes (By similarity). Binds double-stranded target DNA, irrespective of the cytosine methylation status. Regulates the transcription of numerous target genes, and thereby plays an important role in regulating the response to growth factors, DNA damage, and ischemia. Plays a role in the regulation of cell survival, proliferation and cell death. Activates expression of p53/TP53 and TGFB1, and thereby helps prevent tumor formation. Required for normal progress through mitosis and normal proliferation of hepatocytes after partial hepatectomy. Mediates responses to ischemia and hypoxia; regulates the expression of proteins such as IL1B and CXCL2 that are involved in inflammatory processes and development of tissue damage after ischemia. Regulates biosynthesis of luteinizing hormone (LHB) in the pituitary (By similarity). Regulates the amplitude of the expression rhythms of clock genes: ARNTL/BMAL1, PER2 and NR1D1 in the liver via the activation of PER1 (clock repressor) transcription. Regulates the rhythmic expression of core-clock gene ARNTL/BMAL1 in the suprachiasmatic nucleus (SCN) (By similarity).
T09483	BIOCLASS	mRNA target
T09483	SEQUENCE	MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDELTRHIRIHTGQKPFQCRICMRNFSRSDHLTTHIRTHTGEKPFACDICGRKFARSDERKRHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC
T09483	DRUGINFO	DG9QY7	Brivoligide	Phase 2

T10592	TARGETID	T10592
T10592	UNIPROID	DYN2_HUMAN
T10592	TARGNAME	DNM2 messenger RNA (DNM2 mRNA)
T10592	GENENAME	DNM2
T10592	TARGTYPE	Clinical trial
T10592	FUNCTION	Microtubule-associated force-producing protein involved in producing microtubule bundles and able to bind and hydrolyze GTP. Plays a role in the regulation of neuron morphology, axon growth and formation of neuronal growth cones (By similarity). Plays an important role in vesicular trafficking processes, in particular endocytosis. Involved in cytokinesis. Regulates maturation of apoptotic cell corpse-containing phagosomes by recruiting PIK3C3 to the phagosome membrane (By similarity).
T10592	BIOCLASS	mRNA target
T10592	ECNUMBER	EC 3.6.5.5
T10592	SEQUENCE	MGNRGMEELIPLVNKLQDAFSSIGQSCHLDLPQIAVVGGQSAGKSSVLENFVGRDFLPRGSGIVTRRPLILQLIFSKTEHAEFLHCKSKKFTDFDEVRQEIEAETDRVTGTNKGISPVPINLRVYSPHVLNLTLIDLPGITKVPVGDQPPDIEYQIKDMILQFISRESSLILAVTPANMDLANSDALKLAKEVDPQGLRTIGVITKLDLMDEGTDARDVLENKLLPLRRGYIGVVNRSQKDIEGKKDIRAALAAERKFFLSHPAYRHMADRMGTPHLQKTLNQQLTNHIRESLPALRSKLQSQLLSLEKEVEEYKNFRPDDPTRKTKALLQMVQQFGVDFEKRIEGSGDQVDTLELSGGARINRIFHERFPFELVKMEFDEKDLRREISYAIKNIHGVRTGLFTPDLAFEAIVKKQVVKLKEPCLKCVDLVIQELINTVRQCTSKLSSYPRLREETERIVTTYIREREGRTKDQILLLIDIEQSYINTNHEDFIGFANAQQRSTQLNKKRAIPNQGEILVIRRGWLTINNISLMKGGSKEYWFVLTAESLSWYKDEEEKEKKYMLPLDNLKIRDVEKGFMSNKHVFAIFNTEQRNVYKDLRQIELACDSQEDVDSWKASFLRAGVYPEKDQAENEDGAQENTFSMDPQLERQVETIRNLVDSYVAIINKSIRDLMPKTIMHLMINNTKAFIHHELLAYLYSSADQSSLMEESADQAQRRDDMLRMYHALKEALNIIGDISTSTVSTPVPPPVDDTWLQSASSHSPTPQRRPVSSIHPPGRPPAVRGPTPGPPLIPVPVGAAASFSAPPIPSRPGPQSVFANSDLFPAPPQIPSRPVRIPPGIPPGVPSRRPPAAPSRPTIIRPAEPSLLD
T10592	DRUGINFO	DLCB65	IONIS-DNM2-2.5Rx	Phase 2
T10592	DRUGINFO	D1ZAW4	DYN101	Phase 1/2

T10762	TARGETID	T10762
T10762	UNIPROID	BMP6_HUMAN
T10762	TARGNAME	Bone morphogenetic protein 6 (BMP6)
T10762	GENENAME	BMP6
T10762	TARGTYPE	Clinical trial
T10762	SYNONYMS	BMP-6; VG-1-related protein; VG-1-R; VGR-1
T10762	FUNCTION	Induces cartilage and bone formation.
T10762	SEQUENCE	MPGLGRRAQWLCWWWGLLCSCCGPPPLRPPLPAAAAAAAGGQLLGDGGSPGRTEQPPPSPQSSSGFLYRRLKTQEKREMQKEILSVLGLPHRPRPLHGLQQPQPPALRQQEEQQQQQQLPRGEPPPGRLKSAPLFMLDLYNALSADNDEDGASEGERQQSWPHEAASSSQRRQPPPGAAHPLNRKSLLAPGSGSGGASPLTSAQDSAFLNDADMVMSFVNLVEYDKEFSPRQRHHKEFKFNLSQIPEGEVVTAAEFRIYKDCVMGSFKNQTFLISIYQVLQEHQHRDSDLFLLDTRVVWASEEGWLEFDITATSNLWVVTPQHNMGLQLSVVTRDGVHVHPRAAGLVGRDGPYDKQPFMVAFFKVSEVHVRTTRSASSRRRQQSRNRSTQSQDVARVSSASDYNSSELKTACRKHELYVSFQDLGWQDWIIAPKGYAANYCDGECSFPLNAHMNATNHAIVQTLVHLMNPEYVPKPCCAPTKLNAISVLYFDDNSNVILKKYRNMVVRACGCH
T10762	DRUGINFO	DNV17I	LY3113593	Phase 2

T13209	TARGETID	T13209
T13209	UNIPROID	AVR2A_HUMAN; AVR2B_HUMAN
T13209	TARGNAME	Activin receptor type II (ACVR2)
T13209	TARGTYPE	Clinical trial
T13209	DRUGINFO	DW43DG	Bimagrumab	Phase 2

T13568	TARGETID	T13568
T13568	TARGNAME	Methamphetamine (Meth)
T13568	TARGTYPE	Clinical trial
T13568	DRUGINFO	D6FNV9	IXT-m200	Phase 2

T14037	TARGETID	T14037
T14037	UNIPROID	AKT1_HUMAN; AKT2_HUMAN; AKT3_HUMAN
T14037	TARGNAME	RAC serine/threonine-protein kinase (AKT)
T14037	TARGTYPE	Clinical trial
T14037	DRUGINFO	DRI23U	ARQ-751	Phase 1

T15894	TARGETID	T15894
T15894	UNIPROID	CUL4A_HUMAN/CUL4B_HUMAN-DDB1_HUMAN-CRBN_HUMAN
T15894	TARGNAME	Cerebron E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase)
T15894	GENENAME	CUL4A/CUL4B-DDB1-CRBN
T15894	TARGTYPE	Clinical trial
T15894	DRUGINFO	DB8J2U	KPG-818	Phase 1
T15894	DRUGINFO	DN3B5E	KPG-121	Phase 1

T16087	TARGETID	T16087
T16087	UNIPROID	TMPS6_HUMAN
T16087	TARGNAME	TMPRSS6 messenger RNA (TMPRSS6 mRNA)
T16087	GENENAME	TMPRSS6
T16087	TARGTYPE	Clinical trial
T16087	SYNONYMS	Matriptase-2
T16087	FUNCTION	Serine protease which hydrolyzes a range of proteins including type I collagen, fibronectin and fibrinogen. Can also activate urokinase-type plasminogen activator with low efficiency. May play a specialized role in matrix remodeling processes in liver. Through the cleavage of HJV, a regulator of the expression of the iron absorption-regulating hormone hepicidin/HAMP, plays a role in iron homeostasis.
T16087	BIOCLASS	mRNA target
T16087	ECNUMBER	EC 3.4.21.-
T16087	SEQUENCE	MLLLFHSKRMPVAEAPQVAGGQGDGGDGEEAEPEGMFKACEDSKRKARGYLRLVPLFVLLALLVLASAGVLLWYFLGYKAEVMVSQVYSGSLRVLNRHFSQDLTRRESSAFRSETAKAQKMLKELITSTRLGTYYNSSSVYSFGEGPLTCFFWFILQIPEHRRLMLSPEVVQALLVEELLSTVNSSAAVPYRAEYEVDPEGLVILEASVKDIAALNSTLGCYRYSYVGQGQVLRLKGPDHLASSCLWHLQGPKDLMLKLRLEWTLAECRDRLAMYDVAGPLEKRLITSVYGCSRQEPVVEVLASGAIMAVVWKKGLHSYYDPFVLSVQPVVFQACEVNLTLDNRLDSQGVLSTPYFPSYYSPQTHCSWHLTVPSLDYGLALWFDAYALRRQKYDLPCTQGQWTIQNRRLCGLRILQPYAERIPVVATAGITINFTSQISLTGPGVRVHYGLYNQSDPCPGEFLCSVNGLCVPACDGVKDCPNGLDERNCVCRATFQCKEDSTCISLPKVCDGQPDCLNGSDEEQCQEGVPCGTFTFQCEDRSCVKKPNPQCDGRPDCRDGSDEEHCDCGLQGPSSRIVGGAVSSEGEWPWQASLQVRGRHICGGALIADRWVITAAHCFQEDSMASTVLWTVFLGKVWQNSRWPGEVSFKVSRLLLHPYHEEDSHDYDVALLQLDHPVVRSAAVRPVCLPARSHFFEPGLHCWITGWGALREGGPISNALQKVDVQLIPQDLCSEVYRYQVTPRMLCAGYRKGKKDACQGDSGGPLVCKALSGRWFLAGLVSWGLGCGRPNYFGVYTRITGVISWIQQVVT
T16087	DRUGINFO	D2MA0E	IONIS-TMPRSS6-LRx	Phase 2
T16087	DRUGINFO	D9VR6X	Sapablursen	Phase 2
T16087	DRUGINFO	DJ5XY8	SLN124	Phase 1
T16087	DRUGINFO	D6MEX0	ALN-TMP	Preclinical

T16784	TARGETID	T16784
T16784	TARGNAME	Microtubule polymerization (MicroTu poly)
T16784	TARGTYPE	Clinical trial
T16784	DRUGINFO	D8TE4F	AMXI 5001	Phase 1/2

T16802	TARGETID	T16802
T16802	TARGNAME	Human immunodeficiency virus Attachment (HIV att)
T16802	TARGTYPE	Clinical trial
T16802	DRUGINFO	DNET17	GSK3810109	Phase 2

T17485	TARGETID	T17485
T17485	UNIPROID	MEN1_HUMAN-KMT2A_HUMAN
T17485	TARGNAME	Menin-MLL1 interaction (MEN1-KMT2A PPI)
T17485	GENENAME	MEN1-KMT2A
T17485	TARGTYPE	Clinical trial
T17485	DRUGINFO	D97YGW	SNDX-5613	Phase 1/2
T17485	DRUGINFO	DS4JE8	KO-539	Phase 1/2
T17485	DRUGINFO	DYJ76M	JNJ-75276617	Phase 1

T18356	TARGETID	T18356
T18356	UNIPROID	GLYC_LASSG
T18356	TARGNAME	Lassa virus Pre-glycoprotein polyprotein GP complex (LASV GPC)
T18356	GENENAME	LASV GPC
T18356	TARGTYPE	Clinical trial
T18356	SYNONYMS	Pre-GP-C
T18356	BIOCLASS	Arenaviridae GPC protein
T18356	SEQUENCE	MGQIVTFFQEVPHVIEEVMNIVLIALSILAILKGLYNVATCGLIGLVTFLLLSGRSCSLIYKGTYELQTLELNMETLNMTMPLSCTKNNSHHYIRVGNETGLELTLTNTSILNHKFCNLSDAHKRNLYDHSLMSIISTFHLSIPNFNQYEAMSCDFNGGKITVQYNLSHSFAVDAAGHCGTLANGVLQTFMRMAWGGSYIALDSGRGNWDCIMTSYQYLIIQNTTWDDHCQFSRPSPIGYLGLLSQRTRDIYISRRLLGTFTWTLSDSEGNETPGGYCLTRWMLIEAELKCFGNTAVAKCNEKHDEEFCDMLRLFDFNKQAIRRLKTEAQMSIQLINKAVNALINDQLIMKNHLRDIMGIPYCNYSRYWYLNHTSTGKTSLPRCWLISNGSYLNETKFSDDIEQQADNMITEMLQKEYIDRQGKTPLGLVDLFVFSTSFYLISIFLHLVKIPTHRHIVGKPCPKPHRLNHMGICSCGLYKQPGVPVRWKR
T18356	DRUGINFO	DY03KH	LHF-535	Phase 1

T20185	TARGETID	T20185
T20185	TARGNAME	Fucosyl GM1 (FucGM1)
T20185	TARGTYPE	Clinical trial
T20185	DRUGINFO	D2QO5J	BMS-986012	Phase 2

T20593	TARGETID	T20593
T20593	TARGNAME	Tumor-associated glycan antigen (TAGA)
T20593	TARGTYPE	Clinical trial
T20593	DRUGINFO	D1FO9C	GNX102	Phase 1

T20741	TARGETID	T20741
T20741	UNIPROID	SC6A8_HUMAN
T20741	TARGNAME	Solute carrier family 6 member 8 (SLC6A8)
T20741	GENENAME	SLC6A8
T20741	TARGTYPE	Clinical trial
T20741	SYNONYMS	CT1; Creatine transporter 1; Solute carrier family 6 member 8
T20741	FUNCTION	Required for the uptake of creatine in muscles and brain.
T20741	SEQUENCE	MAKKSAENGIYSVSGDEKKGPLIAPGPDGAPAKGDGPVGLGTPGGRLAVPPRETWTRQMDFIMSCVGFAVGLGNVWRFPYLCYKNGGGVFLIPYVLIALVGGIPIFFLEISLGQFMKAGSINVWNICPLFKGLGYASMVIVFYCNTYYIMVLAWGFYYLVKSFTTTLPWATCGHTWNTPDCVEIFRHEDCANASLANLTCDQLADRRSPVIEFWENKVLRLSGGLEVPGALNWEVTLCLLACWVLVYFCVWKGVKSTGKIVYFTATFPYVVLVVLLVRGVLLPGALDGIIYYLKPDWSKLGSPQVWIDAGTQIFFSYAIGLGALTALGSYNRFNNNCYKDAIILALINSGTSFFAGFVVFSILGFMAAEQGVHISKVAESGPGLAFIAYPRAVTLMPVAPLWAALFFFMLLLLGLDSQFVGVEGFITGLLDLLPASYYFRFQREISVALCCALCFVIDLSMVTDGGMYVFQLFDYYSASGTTLLWQAFWECVVVAWVYGADRFMDDIACMIGYRPCPWMKWCWSFFTPLVCMGIFIFNVVYYEPLVYNNTYVYPWWGEAMGWAFALSSMLCVPLHLLGCLLRAKGTMAERWQHLTQPIWGLHHLEYRAQDADVRGLTTLTPVSESSKVVVVESVM
T20741	DRUGINFO	D0UO9R	RGX-202	Phase 1

T23178	TARGETID	T23178
T23178	UNIPROID	ITB6_HUMAN
T23178	TARGNAME	Integrin beta-6 (ITGB6)
T23178	GENENAME	ITGB6
T23178	TARGTYPE	Clinical trial
T23178	FUNCTION	Integrin alpha-V:beta-6 (ITGAV:ITGB6) is a receptor for fibronectin and cytotactin. It recognizes the sequence R-G-D in its ligands. Internalisation of integrin alpha-V/beta-6 via clathrin-mediated endocytosis promotes carcinoma cell invasion. ITGAV:ITGB6 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1. Integrin alpha-V:beta-6 (ITGAV:ITGB6) mediates R-G-D-dependent release of transforming growth factor beta-1 (TGF-beta-1) from regulatory Latency-associated peptide (LAP), thereby playing a key role in TGF-beta-1 activation.
T23178	SEQUENCE	MGIELLCLFFLFLGRNDHVQGGCALGGAETCEDCLLIGPQCAWCAQENFTHPSGVGERCDTPANLLAKGCQLNFIENPVSQVEILKNKPLSVGRQKNSSDIVQIAPQSLILKLRPGGAQTLQVHVRQTEDYPVDLYYLMDLSASMDDDLNTIKELGSRLSKEMSKLTSNFRLGFGSFVEKPVSPFVKTTPEEIANPCSSIPYFCLPTFGFKHILPLTNDAERFNEIVKNQKISANIDTPEGGFDAIMQAAVCKEKIGWRNDSLHLLVFVSDADSHFGMDSKLAGIVIPNDGLCHLDSKNEYSMSTVLEYPTIGQLIDKLVQNNVLLIFAVTQEQVHLYENYAKLIPGATVGLLQKDSGNILQLIISAYEELRSEVELEVLGDTEGLNLSFTAICNNGTLFQHQKKCSHMKVGDTASFSVTVNIPHCERRSRHIIIKPVGLGDALELLVSPECNCDCQKEVEVNSSKCHHGNGSFQCGVCACHPGHMGPRCECGEDMLSTDSCKEAPDHPSCSGRGDCYCGQCICHLSPYGNIYGPYCQCDNFSCVRHKGLLCGGNGDCDCGECVCRSGWTGEYCNCTTSTDSCVSEDGVLCSGRGDCVCGKCVCTNPGASGPTCERCPTCGDPCNSKRSCIECHLSAAGQAREECVDKCKLAGATISEEEDFSKDGSVSCSLQGENECLITFLITTDNEGKTIIHSINEKDCPKPPNIPMIMLGVSLAILLIGVVLLCIWKLLVSFHDRKEVAKFEAERSKAKWQTGTNPLYRGSTSTFKNVTYKHREKQKVDLSTDC
T23178	DRUGINFO	DJYD13	SGN-B6A	Phase 1

T25419	TARGETID	T25419
T25419	UNIPROID	NTRK1_HUMAN; NTRK2_HUMAN; NTRK3_HUMAN
T25419	TARGNAME	Tropomyosin receptor kinase (Trk)
T25419	TARGTYPE	Clinical trial
T25419	DRUGINFO	D2KV8B	AB-106	Phase 2

T26170	TARGETID	T26170
T26170	UNIPROID	TNR25_HUMAN
T26170	TARGNAME	Tumor necrosis factor receptor member 25 (TNFRSF25)
T26170	GENENAME	TNFRSF25
T26170	TARGTYPE	Clinical trial
T26170	SYNONYMS	Apo-3; Apoptosis-inducing receptor AIR; Apoptosis-mediating receptor DR3; Apoptosis-mediating receptor TRAMP; Death receptor 3; Lymphocyte-associated receptor of death; LARD; Protein WSL; Protein WSL-1
T26170	FUNCTION	Receptor for TNFSF12/APO3L/TWEAK. Interacts directly with the adapter TRADD. Mediates activation of NF-kappa-B and induces apoptosis. May play a role in regulating lymphocyte homeostasis.
T26170	SEQUENCE	MEQRPRGCAAVAAALLLVLLGARAQGGTRSPRCDCAGDFHKKIGLFCCRGCPAGHYLKAPCTEPCGNSTCLVCPQDTFLAWENHHNSECARCQACDEQASQVALENCSAVADTRCGCKPGWFVECQVSQCVSSSPFYCQPCLDCGALHRHTRLLCSRRDTDCGTCLPGFYEHGDGCVSCPTSTLGSCPERCAAVCGWRQMFWVQVLLAGLVVPLLLGATLTYTYRHCWPHKPLVTADEAGMEALTPPPATHLSPLDSAHTLLAPPDSSEKICTVQLVGNSWTPGYPETQEALCPQVTWSWDQLPSRALGPAAAPTLSPESPAGSPAMMLQPGPQLYDVMDAVPARRWKEFVRTLGLREAEIEAVEVEIGRFRDQQYEMLKRWRQQQPAGLGAVYAALERMGLDGCVEDLRSRLQRGP
T26170	DRUGINFO	DBGD91	PTX-35	Phase 1

T26470	TARGETID	T26470
T26470	UNIPROID	BC11A_HUMAN
T26470	TARGNAME	B-cell lymphoma/leukemia 11A (BCL11A)
T26470	GENENAME	BCL11A
T26470	TARGTYPE	Clinical trial
T26470	SYNONYMS	BCL-11A; B-cell CLL/lymphoma 11A; COUP-TF-interacting protein 1; Ecotropic viral integration site 9 protein homolog; EVI-9; Zinc finger protein 856; BCL-11A; B-cell CLL/lymphoma 11A; COUP-TF-interacting protein 1; Ecotropic viral integration site 9 protein homolog; EVI-9; Zinc finger protein 856
T26470	FUNCTION	Transcription factor associated with the BAF SWI/SNF chromatin remodeling complex (By similarity). Repressor of fetal hemoglobin (HbF) level. Involved in brain development. May play a role in hematopoiesis. Essential factor in lymphopoiesis required for B-cell formation in fetal liver. May function as a modulator of the transcriptional repression activity of ARP1 (By similarity).
T26470	SEQUENCE	MSRRKQGKPQHLSKREFSPEPLEAILTDDEPDHGPLGAPEGDHDLLTCGQCQMNFPLGDILIFIEHKRKQCNGSLCLEKAVDKPPSPSPIEMKKASNPVEVGIQVTPEDDDCLSTSSRGICPKQEHIADKLLHWRGLSSPRSAHGALIPTPGMSAEYAPQGICKDEPSSYTCTTCKQPFTSAWFLLQHAQNTHGLRIYLESEHGSPLTPRVGIPSGLGAECPSQPPLHGIHIADNNPFNLLRIPGSVSREASGLAEGRFPPTPPLFSPPPRHHLDPHRIERLGAEEMALATHHPSAFDRVLRLNPMAMEPPAMDFSRRLRELAGNTSSPPLSPGRPSPMQRLLQPFQPGSKPPFLATPPLPPLQSAPPPSQPPVKSKSCEFCGKTFKFQSNLVVHRRSHTGEKPYKCNLCDHACTQASKLKRHMKTHMHKSSPMTVKSDDGLSTASSPEPGTSDLVGSASSALKSVVAKFKSENDPNLIPENGDEEEEEDDEEEEEEEEEEEEELTESERVDYGFGLSLEAARHHENSSRGAVVGVGDESRALPDVMQGMVLSSMQHFSEAFHQVLGEKHKRGHLAEAEGHRDTCDEDSVAGESDRIDDGTVNGRGCSPGESASGGLSKKLLLGSPSSLSPFSKRIKLEKEFDLPPAAMPNTENVYSQWLAGYAASRQLKDPFLSFGDSRQSPFASSSEHSSENGSLRFSTPPGELDGGISGRSGTGSGGSTPHISGPGPGRPSSKEGRRSDTCEYCGKVFKNCSNLTVHRRSHTGERPYKCELCNYACAQSSKLTRHMKTHGQVGKDVYKCEICKMPFSVYSTLEKHMKKWHSDRVLNNDIKTE
T26470	DRUGINFO	DVU2Y5	CTX001	Phase 1/2

T28093	TARGETID	T28093
T28093	UNIPROID	FAF1_HUMAN
T28093	TARGNAME	FAS-associated factor 1 (FAF1)
T28093	GENENAME	FAF1
T28093	TARGTYPE	Clinical trial
T28093	SYNONYMS	hFAF1; UBX domain-containing protein 12; UBX domain-containing protein 3A
T28093	FUNCTION	Ubiquitin-binding protein. Required for the progression of DNA replication forks by targeting DNA replication licensing factor CDT1 for degradation. Potentiates but cannot initiate FAS-induced apoptosis (By similarity).
T28093	SEQUENCE	MASNMDREMILADFQACTGIENIDEAITLLEQNNWDLVAAINGVIPQENGILQSEYGGETIPGPAFNPASHPASAPTSSSSSAFRPVMPSRQIVERQPRMLDFRVEYRDRNVDVVLEDTCTVGEIKQILENELQIPVSKMLLKGWKTGDVEDSTVLKSLHLPKNNSLYVLTPDLPPPSSSSHAGALQESLNQNFMLIITHREVQREYNLNFSGSSTIQEVKRNVYDLTSIPVRHQLWEGWPTSATDDSMCLAESGLSYPCHRLTVGRRSSPAQTREQSEEQITDVHMVSDSDGDDFEDATEFGVDDGEVFGMASSALRKSPMMPENAENEGDALLQFTAEFSSRYGDCHPVFFIGSLEAAFQEAFYVKARDRKLLAIYLHHDESVLTNVFCSQMLCAESIVSYLSQNFITWAWDLTKDSNRARFLTMCNRHFGSVVAQTIRTQKTDQFPLFLIIMGKRSSNEVLNVIQGNTTVDELMMRLMAAMEIFTAQQQEDIKDEDEREARENVKREQDEAYRLSLEADRAKREAHEREMAEQFRLEQIRKEQEEEREAIRLSLEQALPPEPKEENAEPVSKLRIRTPSGEFLERRFLASNKLQIVFDFVASKGFPWDEYKLLSTFPRRDVTQLDPNKSLLEVKLFPQETLFLEAKE
T28093	DRUGINFO	DYNT08	KM-819	Phase 1

T29036	TARGETID	T29036
T29036	UNIPROID	CCN2_HUMAN
T29036	TARGNAME	CCN2 messenger RNA (CCN2 mRNA)
T29036	GENENAME	CCN2
T29036	TARGTYPE	Clinical trial
T29036	SYNONYMS	Cellular communication network factor 2; Connective tissue growth factor; Hypertrophic chondrocyte-specific protein 24; Insulin-like growth factor-binding protein 8; IBP-8; IGF-binding protein 8; IGFBP-8
T29036	FUNCTION	Major connective tissue mitoattractant secreted by vascular endothelial cells. Promotes proliferation and differentiation of chondrocytes. Mediates heparin- and divalent cation-dependent cell adhesion in many cell types including fibroblasts, myofibroblasts, endothelial and epithelial cells. Enhances fibroblast growth factor-induced DNA synthesis.
T29036	BIOCLASS	mRNA target
T29036	SEQUENCE	MTAASMGPVRVAFVVLLALCSRPAVGQNCSGPCRCPDEPAPRCPAGVSLVLDGCGCCRVCAKQLGELCTERDPCDPHKGLFCHFGSPANRKIGVCTAKDGAPCIFGGTVYRSGESFQSSCKYQCTCLDGAVGCMPLCSMDVRLPSPDCPFPRRVKLPGKCCEEWVCDEPKDQTVVGPALAAYRLEDTFGPDPTMIRANCLVQTTEWSACSKTCGMGISTRVTNDNASCRLEKQSRLCMVRPCEADLEENIKKGKKCIRTPKISKPIKFELSGCTSMKTYRAKFCGVCTDGRCCTPHRTTTLPVEFKCPDGEVMKKNMMFIKTCACHYNCPGDNDIFESLYYRKMYGDMA
T29036	DRUGINFO	D2AYS0	PF-06473871	Phase 2
T29036	DRUGINFO	D4ZLC2	RXI-109	Phase 2
T29036	DRUGINFO	DHB2K8	OLX10010	Phase 2

T29345	TARGETID	T29345
T29345	UNIPROID	MUC17_HUMAN
T29345	TARGNAME	Mucin-17 (MUC17)
T29345	GENENAME	MUC17
T29345	TARGTYPE	Clinical trial
T29345	SYNONYMS	MUC-17; Small intestinal mucin-3; MUC-3
T29345	FUNCTION	Probably plays a role in maintaining homeostasis on mucosal surfaces.
T29345	SEQUENCE	MPRPGTMALCLLTLVLSLLPPQAAAEQDLSVNRAVWDGGGCISQGDVLNRQCQQLSQHVRTGSAANTATGTTSTNVVEPRMYLSCSTNPEMTSIESSVTSDTPGVSSTRMTPTESRTTSESTSDSTTLFPSSTEDTSSPTTPEGTDVPMSTPSEESISSTMAFVSTAPLPSFEAYTSLTYKVDMSTPLTTSTQASSSPTTPESTTIPKSTNSEGSTPLTSMPASTMKVASSEAITLLTTPVEISTPVTISAQASSSPTTAEGPSLSNSAPSGGSTPLTRMPLSVMLVVSSEASTLSTTPAATNIPVITSTEASSSPTTAEGTSIPTSTYTEGSTPLTSTPASTMPVATSEMSTLSITPVDTSTLVTTSTEPSSLPTTAEATSMLTSTLSEGSTPLTNMPVSTILVASSEASTTSTIPVDSKTFVTTASEASSSPTTAEDTSIATSTPSEGSTPLTSMPVSTTPVASSEASNLSTTPVDSKTQVTTSTEASSSPPTAEVNSMPTSTPSEGSTPLTSMSVSTMPVASSEASTLSTTPVDTSTPVTTSSEASSSSTTPEGTSIPTSTPSEGSTPLTNMPVSTRLVVSSEASTTSTTPADSNTFVTTSSEASSSSTTAEGTSMPTSTYSERGTTITSMSVSTTLVASSEASTLSTTPVDSNTPVTTSTEATSSSTTAEGTSMPTSTYTEGSTPLTSMPVNTTLVASSEASTLSTTPVDTSTPVTTSTEASSSPTTADGASMPTSTPSEGSTPLTSMPVSKTLLTSSEASTLSTTPLDTSTHITTSTEASCSPTTTEGTSMPISTPSEGSPLLTSIPVSITPVTSPEASTLSTTPVDSNSPVTTSTEVSSSPTPAEGTSMPTSTYSEGRTPLTSMPVSTTLVATSAISTLSTTPVDTSTPVTNSTEARSSPTTSEGTSMPTSTPGEGSTPLTSMPDSTTPVVSSEARTLSATPVDTSTPVTTSTEATSSPTTAEGTSIPTSTPSEGTTPLTSTPVSHTLVANSEASTLSTTPVDSNTPLTTSTEASSPPPTAEGTSMPTSTPSEGSTPLTRMPVSTTMVASSETSTLSTTPADTSTPVTTYSQASSSSTTADGTSMPTSTYSEGSTPLTSVPVSTRLVVSSEASTLSTTPVDTSIPVTTSTEASSSPTTAEGTSIPTSPPSEGTTPLASMPVSTTLVVSSEANTLSTTPVDSKTQVATSTEASSPPPTAEVTSMPTSTPGERSTPLTSMPVRHTPVASSEASTLSTSPVDTSTPVTTSAETSSSPTTAEGTSLPTSTTSEGSTLLTSIPVSTTLVTSPEASTLLTTPVDTKGPVVTSNEVSSSPTPAEGTSMPTSTYSEGRTPLTSIPVNTTLVASSAISILSTTPVDNSTPVTTSTEACSSPTTSEGTSMPNSNPSEGTTPLTSIPVSTTPVVSSEASTLSATPVDTSTPGTTSAEATSSPTTAEGISIPTSTPSEGKTPLKSIPVSNTPVANSEASTLSTTPVDSNSPVVTSTAVSSSPTPAEGTSIAISTPSEGSTALTSIPVSTTTVASSEINSLSTTPAVTSTPVTTYSQASSSPTTADGTSMQTSTYSEGSTPLTSLPVSTMLVVSSEANTLSTTPIDSKTQVTASTEASSSTTAEGSSMTISTPSEGSPLLTSIPVSTTPVASPEASTLSTTPVDSNSPVITSTEVSSSPTPAEGTSMPTSTYTEGRTPLTSITVRTTPVASSAISTLSTTPVDNSTPVTTSTEARSSPTTSEGTSMPNSTPSEGTTPLTSIPVSTTPVLSSEASTLSATPIDTSTPVTTSTEATSSPTTAEGTSIPTSTLSEGMTPLTSTPVSHTLVANSEASTLSTTPVDSNSPVVTSTAVSSSPTPAEGTSIATSTPSEGSTALTSIPVSTTTVASSETNTLSTTPAVTSTPVTTYAQVSSSPTTADGSSMPTSTPREGRPPLTSIPVSTTTVASSEINTLSTTLADTRTPVTTYSQASSSPTTADGTSMPTPAYSEGSTPLTSMPLSTTLVVSSEASTLSTTPVDTSTPATTSTEGSSSPTTAGGTSIQTSTPSERTTPLAGMPVSTTLVVSSEGNTLSTTPVDSKTQVTNSTEASSSATAEGSSMTISAPSEGSPLLTSIPLSTTPVASPEASTLSTTPVDSNSPVITSTEVSSSPIPTEGTSMQTSTYSDRRTPLTSMPVSTTVVASSAISTLSTTPVDTSTPVTNSTEARSSPTTSEGTSMPTSTPSEGSTPFTSMPVSTMPVVTSEASTLSATPVDTSTPVTTSTEATSSPTTAEGTSIPTSTLSEGTTPLTSIPVSHTLVANSEVSTLSTTPVDSNTPFTTSTEASSPPPTAEGTSMPTSTSSEGNTPLTRMPVSTTMVASFETSTLSTTPADTSTPVTTYSQAGSSPTTADDTSMPTSTYSEGSTPLTSVPVSTMPVVSSEASTHSTTPVDTSTPVTTSTEASSSPTTAEGTSIPTSPPSEGTTPLASMPVSTTPVVSSEAGTLSTTPVDTSTPMTTSTEASSSPTTAEDIVVPISTASEGSTLLTSIPVSTTPVASPEASTLSTTPVDSNSPVVTSTEISSSATSAEGTSMPTSTYSEGSTPLRSMPVSTKPLASSEASTLSTTPVDTSIPVTTSTETSSSPTTAKDTSMPISTPSEVSTSLTSILVSTMPVASSEASTLSTTPVDTRTLVTTSTGTSSSPTTAEGSSMPTSTPGERSTPLTNILVSTTLLANSEASTLSTTPVDTSTPVTTSAEASSSPTTAEGTSMRISTPSDGSTPLTSILVSTLPVASSEASTVSTTAVDTSIPVTTSTEASSSPTTAEVTSMPTSTPSETSTPLTSMPVNHTPVASSEAGTLSTTPVDTSTPVTTSTKASSSPTTAEGIVVPISTASEGSTLLTSIPVSTTPVASSEASTLSTTPVDTSIPVTTSTEGSSSPTTAEGTSMPISTPSEVSTPLTSILVSTVPVAGSEASTLSTTPVDTRTPVTTSAEASSSPTTAEGTSMPISTPGERRTPLTSMSVSTMPVASSEASTLSRTPADTSTPVTTSTEASSSPTTAEGTGIPISTPSEGSTPLTSIPVSTTPVAIPEASTLSTTPVDSNSPVVTSTEVSSSPTPAEGTSMPISTYSEGSTPLTGVPVSTTPVTSSAISTLSTTPVDTSTPVTTSTEAHSSPTTSEGTSMPTSTPSEGSTPLTYMPVSTMLVVSSEDSTLSATPVDTSTPVTTSTEATSSTTAEGTSIPTSTPSEGMTPLTSVPVSNTPVASSEASILSTTPVDSNTPLTTSTEASSSPPTAEGTSMPTSTPSEGSTPLTSMPVSTTTVASSETSTLSTTPADTSTPVTTYSQASSSPPIADGTSMPTSTYSEGSTPLTNMSFSTTPVVSSEASTLSTTPVDTSTPVTTSTEASLSPTTAEGTSIPTSSPSEGTTPLASMPVSTTPVVSSEVNTLSTTPVDSNTLVTTSTEASSSPTIAEGTSLPTSTTSEGSTPLSIMPLSTTPVASSEASTLSTTPVDTSTPVTTSSPTNSSPTTAEVTSMPTSTAGEGSTPLTNMPVSTTPVASSEASTLSTTPVDSNTFVTSSSQASSSPATLQVTTMRMSTPSEGSSSLTTMLLSSTYVTSSEASTPSTPSVDRSTPVTTSTQSNSTPTPPEVITLPMSTPSEVSTPLTIMPVSTTSVTISEAGTASTLPVDTSTPVITSTQVSSSPVTPEGTTMPIWTPSEGSTPLTTMPVSTTRVTSSEGSTLSTPSVVTSTPVTTSTEAISSSATLDSTTMSVSMPMEISTLGTTILVSTTPVTRFPESSTPSIPSVYTSMSMTTASEGSSSPTTLEGTTTMPMSTTSERSTLLTTVLISPISVMSPSEASTLSTPPGDTSTPLLTSTKAGSFSIPAEVTTIRISITSERSTPLTTLLVSTTLPTSFPGASIASTPPLDTSTTFTPSTDTASTPTIPVATTISVSVITEGSTPGTTIFIPSTPVTSSTADVFPATTGAVSTPVITSTELNTPSTSSSSTTTSFSTTKEFTTPAMTTAAPLTYVTMSTAPSTPRTTSRGCTTSASTLSATSTPHTSTSVTTRPVTPSSESSRPSTITSHTIPPTFPPAHSSTPPTTSASSTTVNPEAVTTMTTRTKPSTRTTSFPTVTTTAVPTNTTIKSNPTSTPTVPRTTTCFGDGCQNTASRCKNGGTWDGLKCQCPNLYYGELCEEVVSSIDIGPPETISAQMELTVTVTSVKFTEELKNHSSQEFQEFKQTFTEQMNIVYSGIPEYVGVNITKLRLGSVVVEHDVLLRTKYTPEYKTVLDNATEVVKEKITKVTTQQIMINDICSDMMCFNTTGTQVQNITVTQYDPEEDCRKMAKEYGDYFVVEYRDQKPYCISPCEPGFSVSKNCNLGKCQMSLSGPQCLCVTTETHWYSGETCNQGTQKSLVYGLVGAGVVLMLIILVALLMLVFRSKREVKRQKYRLSQLYKWQEEDSGPAPGTFQNIGFDICQDDDSIHLESIYSNFQPSLRHIDPETKIRIQRPQVMTTSF
T29345	DRUGINFO	DEP3Z8	AMG 199	Phase 1

T30827	TARGETID	T30827
T30827	UNIPROID	PLF4_HUMAN
T30827	TARGNAME	Platelet factor 4 (PF4)
T30827	GENENAME	PF4
T30827	TARGTYPE	Clinical trial
T30827	SYNONYMS	PF-4; C-X-C motif chemokine 4; Iroplact; Oncostatin-A
T30827	FUNCTION	Released during platelet aggregation. Neutralizes the anticoagulant effect of heparin because it binds more strongly to heparin than to the chondroitin-4-sulfate chains of the carrier molecule. Chemotactic for neutrophils and monocytes. Inhibits endothelial cell proliferation, the short form is a more potent inhibitor than the longer form.
T30827	SEQUENCE	MSSAAGFCASRPGLLFLGLLLLPLVVAFASAEAEEDGDLQCLCVKTTSQVRPRHITSLEVIKAGPHCPTAQLIATLKNGRKICLDLQAPLYKKIIKKLLES
T30827	DRUGINFO	D5VRX2	Dociparstat sodium	Phase 3

T30846	TARGETID	T30846
T30846	UNIPROID	LIRB4_HUMAN
T30846	TARGNAME	Leukocyte immunoglobulin-like receptor B4 (LILRB4)
T30846	GENENAME	LILRB4
T30846	TARGTYPE	Clinical trial
T30846	SYNONYMS	CD85 antigen-like family member K; Immunoglobulin-like transcript 3; ILT-3; Leukocyte immunoglobulin-like receptor 5; LIR-5; Monocyte inhibitory receptor HM18; DE   AltName: CD_antigen=CD85k
T30846	FUNCTION	Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles. Involved in the down-regulation of the immune response and the development of tolerance, e.g. towards transplants. Interferes with TNFRSF5-signaling and NF-kappa-B up-regulation. Inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.
T30846	SEQUENCE	MIPTFTALLCLGLSLGPRTHMQAGPLPKPTLWAEPGSVISWGNSVTIWCQGTLEAREYRLDKEESPAPWDRQNPLEPKNKARFSIPSMTEDYAGRYRCYYRSPVGWSQPSDPLELVMTGAYSKPTLSALPSPLVTSGKSVTLLCQSRSPMDTFLLIKERAAHPLLHLRSEHGAQQHQAEFPMSPVTSVHGGTYRCFSSHGFSHYLLSHPSDPLELIVSGSLEDPRPSPTRSVSTAAGPEDQPLMPTGSVPHSGLRRHWEVLIGVLVVSILLLSLLLFLLLQHWRQGKHRTLAQRQADFQRPPGAAEPEPKDGGLQRRSSPAADVQGENFCAAVKNTQPEDGVEMDTRQSPHDEDPQAVTYAKVKHSRPRREMASPPSPLSGEFLDTKDRQAEEDRQMDTEAAASEAPQDVTYAQLHSFTLRQKATEPPPSQEGASPAEPSVYATLAIH
T30846	DRUGINFO	DM9GO4	IO-202	Phase 1

T31072	TARGETID	T31072
T31072	UNIPROID	IL12A_HUMAN; IL12B_HUMAN
T31072	TARGNAME	Interleukine 12 (IL-12)
T31072	TARGTYPE	Clinical trial
T31072	DRUGINFO	DVT8O0	ABP 654	Phase 3
T31072	DRUGINFO	D90UZW	Ad-RTS-hIL-12	Phase 2
T31072	DRUGINFO	DRT2P7	GEN-1	Phase 2
T31072	DRUGINFO	DT7O8R	Tavokinogene telseplasmid	Phase 2
T31072	DRUGINFO	DG0NA1	MEDI1191	Phase 1
T31072	DRUGINFO	DO8W9E	M9241	Phase 1
T31072	DRUGINFO	DBTI39	YH010	Investigative

T32984	TARGETID	T32984
T32984	TARGNAME	Microtubule (MicroTu)
T32984	TARGTYPE	Clinical trial
T32984	DRUGINFO	D3X2TH	TPI-287	Phase 2

T36479	TARGETID	T36479
T36479	UNIPROID	TACT_HUMAN
T36479	TARGNAME	T-cell surface protein tactile (CD96)
T36479	GENENAME	CD96
T36479	TARGTYPE	Clinical trial
T36479	SYNONYMS	Cell surface antigen CD96; T cell-activated increased late expression protein; DE   AltName: CD_antigen=CD96
T36479	FUNCTION	May be involved in adhesive interactions of activated T and NK cells during the late phase of the immune response. Promotes NK cell-target adhesion by interacting with PVR present on target cells. May function at a time after T and NK cells have penetrated the endothelium using integrins and selectins, when they are actively engaging diseased cells and moving within areas of inflammation.
T36479	SEQUENCE	MEKKWKYCAVYYIIQIHFVKGVWEKTVNTEENVYATLGSDVNLTCQTQTVGFFVQMQWSKVTNKIDLIAVYHPQYGFYCAYGRPCESLVTFTETPENGSKWTLHLRNMSCSVSGRYECMLVLYPEGIQTKIYNLLIQTHVTADEWNSNHTIEIEINQTLEIPCFQNSSSKISSEFTYAWSVENSSTDSWVLLSKGIKEDNGTQETLISQNHLISNSTLLKDRVKLGTDYRLHLSPVQIFDDGRKFSCHIRVGPNKILRSSTTVKVFAKPEIPVIVENNSTDVLVERRFTCLLKNVFPKANITWFIDGSFLHDEKEGIYITNEERKGKDGFLELKSVLTRVHSNKPAQSDNLTIWCMALSPVPGNKVWNISSEKITFLLGSEISSTDPPLSVTESTLDTQPSPASSVSPARYPATSSVTLVDVSALRPNTTPQPSNSSMTTRGFNYPWTSSGTDTKKSVSRIPSETYSSSPSGAGSTLHDNVFTSTARAFSEVPTTANGSTKTNHVHITGIVVNKPKDGMSWPVIVAALLFCCMILFGLGVRKWCQYQKEIMERPPPFKPPPPPIKYTCIQEPNESDLPYHEMETL
T36479	DRUGINFO	DY36LD	GSK6097608	Phase 1

T36958	TARGETID	T36958
T36958	UNIPROID	FOXP3_HUMAN
T36958	TARGNAME	FOXP3 messenger RNA (FOXP3 mRNA)
T36958	GENENAME	FOXP3
T36958	TARGTYPE	Clinical trial
T36958	SYNONYMS	Scurfin
T36958	FUNCTION	Transcriptional regulator which is crucial for the development and inhibitory function of regulatory T-cells (Treg). Plays an essential role in maintaining homeostasis of the immune system by allowing the acquisition of full suppressive function and stability of the Treg lineage, and by directly modulating the expansion and function of conventional T-cells. Can act either as a transcriptional repressor or a transcriptional activator depending on its interactions with other transcription factors, histone acetylases and deacetylases. The suppressive activity of Treg involves the coordinate activation of many genes, including CTLA4 and TNFRSF18 by FOXP3 along with repression of genes encoding cytokines such as interleukin-2 (IL2) and interferon-gamma (IFNG). Inhibits cytokine production and T-cell effector function by repressing the activity of two key transcription factors, RELA and NFATC2. Mediates transcriptional repression of IL2 via its association with histone acetylase KAT5 and histone deacetylase HDAC7. Can activate the expression of TNFRSF18, IL2RA and CTLA4 and repress the expression of IL2 and IFNG via its association with transcription factor RUNX1. Inhibits the differentiation of IL17 producing helper T-cells (Th17) by antagonizing RORC function, leading to down-regulation of IL17 expression, favoring Treg development. Inhibits the transcriptional activator activity of RORA. Can repress the expression of IL2 and IFNG via its association with transcription factor IKZF4 (By similarity).
T36958	BIOCLASS	mRNA target
T36958	SEQUENCE	MPNPRPGKPSAPSLALGPSPGASPSWRAAPKASDLLGARGPGGTFQGRDLRGGAHASSSSLNPMPPSQLQLPTLPLVMVAPSGARLGPLPHLQALLQDRPHFMHQLSTVDAHARTPVLQVHPLESPAMISLTPPTTATGVFSLKARPGLPPGINVASLEWVSREPALLCTFPNPSAPRKDSTLSAVPQSSYPLLANGVCKWPGCEKVFEEPEDFLKHCQADHLLDEKGRAQCLLQREMVQSLEQQLVLEKEKLSAMQAHLAGKMALTKASSVASSDKGSCCIVAAGSQGPVVPAWSGPREAPDSLFAVRRHLWGSHGNSTFPEFLHNMDYFKFHNMRPPFTYATLIRWAILEAPEKQRTLNEIYHWFTRMFAFFRNHPATWKNAIRHNLSLHKCFVRVESEKGAVWTVDELEFRKKRSQRPSRCSNPTPGP
T36958	DRUGINFO	DX9T0N	AZD8701	Phase 1

T37012	TARGETID	T37012
T37012	UNIPROID	GFRAL_HUMAN
T37012	TARGNAME	GDNF family receptor alpha-like (GFRAL)
T37012	GENENAME	GFRAL
T37012	TARGTYPE	Clinical trial
T37012	FUNCTION	Brainstem-restricted receptor for GDF15 which regulates food intake, energy expenditure and body weight in response to metabolic and toxin-induced stresses. Upon interaction with its ligand, GDF15, interacts with RET and induces cellular signaling through activation of MAPK- and AKT- signaling pathways.
T37012	SEQUENCE	MIVFIFLAMGLSLENEYTSQTNNCTYLREQCLRDANGCKHAWRVMEDACNDSDPGDPCKMRNSSYCNLSIQYLVESNFQFKECLCTDDFYCTVNKLLGKKCINKSDNVKEDKFKWNLTTRSHHGFKGMWSCLEVAEACVGDVVCNAQLASYLKACSANGNPCDLKQCQAAIRFFYQNIPFNIAQMLAFCDCAQSDIPCQQSKEALHSKTCAVNMVPPPTCLSVIRSCQNDELCRRHYRTFQSKCWQRVTRKCHEDENCISTLSKQDLTCSGSDDCKAAYIDILGTVLQVQCTCRTITQSEESLCKIFQHMLHRKSCFNYPTLSNVKGMALYTRKHANKITLTGFHSPFNGEVIYAAMCMTVTCGILLLVMVKLRTSRISSKARDPSSIQIPGEL
T37012	DRUGINFO	D2VRE1	NGM120	Phase 1

T37048	TARGETID	T37048
T37048	UNIPROID	SPA_STAA8
T37048	TARGNAME	Staphylococcus IgG binding protein A  (Stap-coc SpA)
T37048	GENENAME	Stap-coc SpA
T37048	TARGTYPE	Clinical trial
T37048	SYNONYMS	IgG-binding protein A; Staphylococcal protein A; SpA
T37048	FUNCTION	Plays a role in the inhibition of the host innate and adaptive immune responses. Possesses five immunoglobulin-binding domains that capture both the fragment crystallizable region (Fc region) and the Fab region (part of Ig that identifies antigen) of immunoglobulins. In turn, Staphylococcus aureus is protected from phagocytic killing via inhibition of Ig Fc region. In addition, the host elicited B-cell response is prevented due to a decrease of antibody-secreting cell proliferation that enter the bone marrow, thereby decreasing long-term antibody production. Inhibits osteogenesis by preventing osteoblast proliferation and expression of alkaline phosphatase, type I collagen, osteopontin and osteocalcin. Acts directly as a proinflammatory factor in the lung through its ability to bind and activate tumor necrosis factor alpha receptor 1/TNFRSF1A (By similarity).
T37048	SEQUENCE	MKKKNIYSIRKLGVGIASVTLGTLLISGGVTPAANAAQHDEAQQNAFYQVLNMPNLNADQRNGFIQSLKDDPSQSANVLGEAQKLNDSQAPKADAQQNNFNKDQQSAFYEILNMPNLNEAQRNGFIQSLKDDPSQSTNVLGEAKKLNESQAPKADNNFNKEQQNAFYEILNMPNLNEEQRNGFIQSLKDDPSQSANLLSEAKKLNESQAPKADNKFNKEQQNAFYEILHLPNLNEEQRNGFIQSLKDDPSQSANLLAEAKKLNDAQAPKADNKFNKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKEEDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDGNKPGKEDNKKPGKEDGNKPGKEDNKKPGKEDGNKPGKEDGNKPGKEDGNGVHVVKPGDTVNDIAKANGTTADKIAADNKLADKNMIKPGQELVVDKKQPANHADANKAQALPETGEENPFIGTTVFGGLSLALGAALLAGRRREL
T37048	DRUGINFO	D51VYQ	514G3	Phase 1/2

T38201	TARGETID	T38201
T38201	UNIPROID	PARPT_HUMAN
T38201	TARGNAME	Protein mono-ADP-ribosyltransferase TIPARP (TIPARP)
T38201	GENENAME	TIPARP
T38201	TARGTYPE	Clinical trial
T38201	SYNONYMS	ADP-ribosyltransferase diphtheria toxin-like 14; ARTD14; Poly [ADP-ribose] polymerase 7; PARP-7; TCDD-inducible poly [ADP-ribose] polymerase
T38201	FUNCTION	ADP-ribosyltransferase that mediates mono-ADP-ribosylation of glutamate, aspartate and cysteine residues on target proteins. Acts as a negative regulator of AHR by mediating mono-ADP-ribosylation of AHR, leading to inhibit transcription activator activity of AHR.
T38201	ECNUMBER	EC 2.4.2.-
T38201	SEQUENCE	MEMETTEPEPDCVVQPPSPPDDFSCQMRLSEKITPLKTCFKKKDQKRLGTGTLRSLRPILNTLLESGSLDGVFRSRNQSTDENSLHEPMMKKAMEINSSCPPAENNMSVLIPDRTNVGDQIPEAHPSTEAPERVVPIQDHSFPSETLSGTVADSTPAHFQTDLLHPVSSDVPTSPDCLDKVIDYVPGIFQENSFTIQYILDTSDKLSTELFQDKSEEASLDLVFELVNQLQYHTHQENGIEICMDFLQGTCIYGRDCLKHHTVLPYHWQIKRTTTQKWQSVFNDSQEHLERFYCNPENDRMRMKYGGQEFWADLNAMNVYETTEFDQLRRLSTPPSSNVNSIYHTVWKFFCRDHFGWREYPESVIRLIEEANSRGLKEVRFMMWNNHYILHNSFFRREIKRRPLFRSCFILLPYLQTLGGVPTQAPPPLEATSSSQIICPDGVTSANFYPETWVYMHPSQDFIQVPVSAEDKSYRIIYNLFHKTVPEFKYRILQILRVQNQFLWEKYKRKKEYMNRKMFGRDRIINERHLFHGTSQDVVDGICKHNFDPRVCGKHATMFGQGSYFAKKASYSHNFSKKSSKGVHFMFLAKVLTGRYTMGSHGMRRPPPVNPGSVTSDLYDSCVDNFFEPQIFVIFNDDQSYPYFVIQYEEVSNTVSI
T38201	DRUGINFO	DJ7K9G	RBN-2397	Phase 1

T38509	TARGETID	T38509
T38509	UNIPROID	FA12_HUMAN
T38509	TARGNAME	Coagulation factor XII (F12)
T38509	GENENAME	F12
T38509	TARGTYPE	Clinical trial
T38509	SYNONYMS	Hageman factor; HAF
T38509	BIOCLASS	Peptidase
T38509	ECNUMBER	EC 3.4.21.38
T38509	SEQUENCE	MRALLLLGFLLVSLESTLSIPPWEAPKEHKYKAEEHTVVLTVTGEPCHFPFQYHRQLYHKCTHKGRPGPQPWCATTPNFDQDQRWGYCLEPKKVKDHCSKHSPCQKGGTCVNMPSGPHCLCPQHLTGNHCQKEKCFEPQLLRFFHKNEIWYRTEQAAVARCQCKGPDAHCQRLASQACRTNPCLHGGRCLEVEGHRLCHCPVGYTGAFCDVDTKASCYDGRGLSYRGLARTTLSGAPCQPWASEATYRNVTAEQARNWGLGGHAFCRNPDNDIRPWCFVLNRDRLSWEYCDLAQCQTPTQAAPPTPVSPRLHVPLMPAQPAPPKPQPTTRTPPQSQTPGALPAKREQPPSLTRNGPLSCGQRLRKSLSSMTRVVGGLVALRGAHPYIAALYWGHSFCAGSLIAPCWVLTAAHCLQDRPAPEDLTVVLGQERRNHSCEPCQTLAVRSYRLHEAFSPVSYQHDLALLRLQEDADGSCALLSPYVQPVCLPSGAARPSETTLCQVAGWGHQFEGAEEYASFLQEAQVPFLSLERCSAPDVHGSSILPGMLCAGFLEGGTDACQGDSGGPLVCEDQAAERRLTLQGIISWGSGCGDRNKPGVYTDVAYYLAWIREHTVS
T38509	DRUGINFO	DR49KB	CSL312	Phase 3
T38509	DRUGINFO	D5EP4C	ION547	Phase 1

T39047	TARGETID	T39047
T39047	UNIPROID	LAIR1_HUMAN
T39047	TARGNAME	Leukocyte-associated Ig-like receptor 1 (LAIR1)
T39047	GENENAME	LAIR1
T39047	TARGTYPE	Clinical trial
T39047	SYNONYMS	LAIR-1; hLAIR1; DE   AltName: CD_antigen=CD305
T39047	FUNCTION	Functions as an inhibitory receptor that plays a constitutive negative regulatory role on cytolytic function of natural killer (NK) cells, B-cells and T-cells. Activation by Tyr phosphorylation results in recruitment and activation of the phosphatases PTPN6 and PTPN11. It also reduces the increase of intracellular calcium evoked by B-cell receptor ligation. May also play its inhibitory role independently of SH2-containing phosphatases. Modulates cytokine production in CD4+ T-cells, down-regulating IL2 and IFNG production while inducing secretion of transforming growth factor beta. Down-regulates also IgG and IgE production in B-cells as well as IL8, IL10 and TNF secretion. Inhibits proliferation and induces apoptosis in myeloid leukemia cell lines as well as prevents nuclear translocation of NF-kappa-B p65 subunit/RELA and phosphorylation of I-kappa-B alpha/CHUK in these cells. Inhibits the differentiation of peripheral blood precursors towards dendritic cells.
T39047	SEQUENCE	MSPHPTALLGLVLCLAQTIHTQEEDLPRPSISAEPGTVIPLGSHVTFVCRGPVGVQTFRLERESRSTYNDTEDVSQASPSESEARFRIDSVSEGNAGPYRCIYYKPPKWSEQSDYLELLVKETSGGPDSPDTEPGSSAGPTQRPSDNSHNEHAPASQGLKAEHLYILIGVSVVFLFCLLLLVLFCLHRQNQIKQGPPRSKDEEQKPQQRPDLAVDVLERTADKATVNGLPEKDRETDTSALAAGSSQEVTYAQLDHWALTQRTARAVSPQSTKPMAESITYAAVARH
T39047	DRUGINFO	DK6J7M	NC410	Phase 1/2
T39047	DRUGINFO	DF8ZT3	NGM438	Phase 1

T41239	TARGETID	T41239
T41239	TARGNAME	Hydroxyapatite (HA)
T41239	TARGTYPE	Clinical trial
T41239	DRUGINFO	DD76HZ	SNF472	Phase 3

T41380	TARGETID	T41380
T41380	UNIPROID	LRC32_HUMAN
T41380	TARGNAME	Transforming growth factor beta activator LRRC32 (LRRC32)
T41380	GENENAME	LRRC32
T41380	TARGTYPE	Clinical trial
T41380	SYNONYMS	Garpin; Glycoprotein A repetitions predominant; GARP; Leucine-rich repeat-containing protein 32
T41380	FUNCTION	Key regulator of transforming growth factor beta (TGFB1, TGFB2 and TGFB3) that controls TGF-beta activation by maintaining it in a latent state during storage in extracellular space. Associates specifically via disulfide bonds with the Latency-associated peptide (LAP), which is the regulatory chain of TGF-beta, and regulates integrin-dependent activation of TGF-beta. Able to outcompete LTBP1 for binding to LAP regulatory chain of TGF-beta. Controls activation of TGF-beta-1 (TGFB1) on the surface of activated regulatory T-cells (Tregs). Required for epithelial fusion during palate development by regulating activation of TGF-beta-3 (TGFB3) (By similarity).
T41380	SEQUENCE	MRPQILLLLALLTLGLAAQHQDKVPCKMVDKKVSCQVLGLLQVPSVLPPDTETLDLSGNQLRSILASPLGFYTALRHLDLSTNEISFLQPGAFQALTHLEHLSLAHNRLAMATALSAGGLGPLPRVTSLDLSGNSLYSGLLERLLGEAPSLHTLSLAENSLTRLTRHTFRDMPALEQLDLHSNVLMDIEDGAFEGLPRLTHLNLSRNSLTCISDFSLQQLRVLDLSCNSIEAFQTASQPQAEFQLTWLDLRENKLLHFPDLAALPRLIYLNLSNNLIRLPTGPPQDSKGIHAPSEGWSALPLSAPSGNASGRPLSQLLNLDLSYNEIELIPDSFLEHLTSLCFLNLSRNCLRTFEARRLGSLPCLMLLDLSHNALETLELGARALGSLRTLLLQGNALRDLPPYTFANLASLQRLNLQGNRVSPCGGPDEPGPSGCVAFSGITSLRSLSLVDNEIELLRAGAFLHTPLTELDLSSNPGLEVATGALGGLEASLEVLALQGNGLMVLQVDLPCFICLKRLNLAENRLSHLPAWTQAVSLEVLDLRNNSFSLLPGSAMGGLETSLRRLYLQGNPLSCCGNGWLAAQLHQGRVDVDATQDLICRFSSQEEVSLSHVRPEDCEKGGLKNINLIIILTFILVSAILLTTLAACCCVRRQKFNQQYKA
T41380	DRUGINFO	DB6GK4	DS-1055	Phase 1

T41597	TARGETID	T41597
T41597	UNIPROID	DGAT2_HUMAN
T41597	TARGNAME	DGAT2 messenger RNA (DGAT2 mRNA)
T41597	GENENAME	DGAT2
T41597	TARGTYPE	Clinical trial
T41597	SYNONYMS	Acyl-CoA retinol O-fatty-acyltransferase; ARAT; Retinol O-fatty-acyltransferase; Diglyceride acyltransferase 2
T41597	FUNCTION	Essential acyltransferase that catalyzes the terminal and only committed step in triacylglycerol synthesis by using diacylglycerol and fatty acyl CoA as substrates. Required for synthesis and storage of intracellular triglycerides. Probably plays a central role in cytosolic lipid accumulation. In liver, is primarily responsible for incorporating endogenously synthesized fatty acids into triglycerides (By similarity). Functions also as an acyl-CoA retinol acyltransferase (ARAT) (By similarity). Also able to use 1-monoalkylglycerol (1-MAkG) as an acyl acceptor for the synthesis of monoalkyl-monoacylglycerol (MAMAG).
T41597	BIOCLASS	mRNA target
T41597	ECNUMBER	EC 2.3.1.20
T41597	SEQUENCE	MKTLIAAYSGVLRGERQAEADRSQRSHGGPALSREGSGRWGTGSSILSALQDLFSVTWLNRSKVEKQLQVISVLQWVLSFLVLGVACSAILMYIFCTDCWLIAVLYFTWLVFDWNTPKKGGRRSQWVRNWAVWRYFRDYFPIQLVKTHNLLTTRNYIFGYHPHGIMGLGAFCNFSTEATEVSKKFPGIRPYLATLAGNFRMPVLREYLMSGGICPVSRDTIDYLLSKNGSGNAIIIVVGGAAESLSSMPGKNAVTLRNRKGFVKLALRHGADLVPIYSFGENEVYKQVIFEEGSWGRWVQKKFQKYIGFAPCIFHGRGLFSSDTWGLVPYSKPITTVVGEPITIPKLEHPTQQDIDLYHTMYMEALVKLFDKHKTKFGLPETEVLEVN
T41597	DRUGINFO	DK28NV	ION 224	Phase 1

T41756	TARGETID	T41756
T41756	UNIPROID	VP1_POVBK
T41756	TARGNAME	BV virus Major capsid protein VP1 (BKV VP1)
T41756	GENENAME	BKV VP1
T41756	TARGTYPE	Clinical trial
T41756	SYNONYMS	Major structural protein VP1
T41756	FUNCTION	Forms an icosahedral capsid with a T=7 symmetry and a 50 nm diameter. The capsid is composed of 72 pentamers linked to each other by disulfide bonds and associated with VP2 or VP3 proteins. Interacts with gangliosides GT1b and GD1b containing terminal alpha(2-8)-linked sialic acids on the cell surface to provide virion attachment to target cell. This attachment induces virion internalization predominantly through caveolin-mediated endocytosis and traffics to the endoplasmic reticulum. Inside the endoplasmic reticulum, the protein folding machinery isomerizes VP1 interpentamer disulfide bonds, thereby triggering initial uncoating. Next, the virion uses the endoplasmic reticulum-associated degradation machinery to probably translocate in the cytosol before reaching the nucleus. Nuclear entry of the viral DNA involves the selective exposure and importin recognition of VP2/Vp3 nuclear localization signal. In late phase of infection, neo-synthesized VP1 encapsulates replicated genomic DNA in the nucleus, and participates in rearranging nucleosomes around the viral DNA.
T41756	SEQUENCE	MAPTKRKGECPGAAPKKPKEPVQVPKLLIKGGVEVLEVKTGVDAITEVECFLNPEMGDPDENLRGFSLKLSAENDFSSDSPERKMLPCYSTARIPLPNLNEDLTCGNLLMWEAVTVQTEVIGITSMLNLHAGSQKVHEHGGGKPIQGSNFHFFAVGGEPLEMQGVLMNYRSKYPDGTITPKNPTAQSQVMNTDHKAYLDKNNAYPVECWVPDPSRNENARYFGTFTGGENVPPVLHVTNTATTVLLDEQGVGPLCKADSLYVSAADICGLFTNSSGTQQWRGLARYFKIRLRKRSVKNPYPISFLLSDLINRRTQRVDGQPMYGMESQVEEVRVFDGTERLPGDPDMIRYIDKQGQLQTKML
T41756	DRUGINFO	DPTM94	MAU868	Phase 1

T42760	TARGETID	T42760
T42760	UNIPROID	KS6B2_HUMAN
T42760	TARGNAME	Ribosomal protein S6 kinase beta-2 (RPS6KB2)
T42760	GENENAME	RPS6KB2
T42760	TARGTYPE	Clinical trial
T42760	SYNONYMS	S6K-beta-2; S6K2; 70 kDa ribosomal protein S6 kinase 2; P70S6K2; p70-S6K 2; S6 kinase-related kinase; SRK; Serine/threonine-protein kinase 14B; p70 ribosomal S6 kinase beta; S6K-beta; p70 S6 kinase beta; p70 S6K-beta; p70 S6KB; p70-beta
T42760	FUNCTION	Phosphorylates specifically ribosomal protein S6. Seems to act downstream of mTOR signaling in response to growth factors and nutrients to promote cell proliferation, cell growth and cell cycle progression in an alternative pathway regulated by MEAK7.
T42760	BIOCLASS	Kinase
T42760	ECNUMBER	EC 2.7.11.1
T42760	SEQUENCE	MAAVFDLDLETEEGSEGEGEPELSPADACPLAELRAAGLEPVGHYEEVELTETSVNVGPERIGPHCFELLRVLGKGGYGKVFQVRKVQGTNLGKIYAMKVLRKAKIVRNAKDTAHTRAERNILESVKHPFIVELAYAFQTGGKLYLILECLSGGELFTHLEREGIFLEDTACFYLAEITLALGHLHSQGIIYRDLKPENIMLSSQGHIKLTDFGLCKESIHEGAVTHTFCGTIEYMAPEILVRSGHNRAVDWWSLGALMYDMLTGSPPFTAENRKKTMDKIIRGKLALPPYLTPDARDLVKKFLKRNPSQRIGGGPGDAADVQRHPFFRHMNWDDLLAWRVDPPFRPCLQSEEDVSQFDTRFTRQTPVDSPDDTALSESANQAFLGFTYVAPSVLDSIKEGFSFQPKLRSPRRLNSSPRAPVSPLKFSPFEGFRPSPSLPEPTELPLPPLLPPPPPSTTAPLPIRPPSGTKKSKRGRGRPGR
T42760	DRUGINFO	DJR94F	PMD-026	Phase 1

T43658	TARGETID	T43658
T43658	UNIPROID	HAOX1_HUMAN
T43658	TARGNAME	HAO1 messenger RNA (HAO1 mRNA)
T43658	GENENAME	HAO1
T43658	TARGTYPE	Clinical trial
T43658	SYNONYMS	HAOX1; Glycolate oxidase; GOX
T43658	FUNCTION	Has 2-hydroxyacid oxidase activity. Most active on the 2-carbon substrate glycolate, but is also active on 2-hydroxy fatty acids, with high activity towards 2-hydroxy palmitate and 2-hydroxy octanoate.
T43658	BIOCLASS	mRNA target
T43658	ECNUMBER	EC 1.1.3.15
T43658	SEQUENCE	MLPRLICINDYEQHAKSVLPKSIYDYYRSGANDEETLADNIAAFSRWKLYPRMLRNVAETDLSTSVLGQRVSMPICVGATAMQRMAHVDGELATVRACQSLGTGMMLSSWATSSIEEVAEAGPEALRWLQLYIYKDREVTKKLVRQAEKMGYKAIFVTVDTPYLGNRLDDVRNRFKLPPQLRMKNFETSTLSFSPEENFGDDSGLAAYVAKAIDPSISWEDIKWLRRLTSLPIVAKGILRGDDAREAVKHGLNGILVSNHGARQLDGVPATIDVLPEIVEAVEGKVEVFLDGGVRKGTDVLKALALGAKAVFVGRPIVWGLAFQGEKGVQDVLEILKEEFRLAMALSGCQNVKVIDKTLVRKNPLAVSKI
T43658	DRUGINFO	DD1GK8	Lumasiran	Approved

T43980	TARGETID	T43980
T43980	UNIPROID	ILDR2_HUMAN
T43980	TARGNAME	Ig-like domain-containing receptor 2 (ILDR2)
T43980	GENENAME	ILDR2
T43980	TARGTYPE	Clinical trial
T43980	FUNCTION	May be involved in lipid homeostasis and ER stress pathways.
T43980	SEQUENCE	MDRVLLRWISLFWLTAMVEGLQVTVPDKKKVAMLFQPTVLRCHFSTSSHQPAVVQWKFKSYCQDRMGESLGMSSTRAQSLSKRNLEWDPYLDCLDSRRTVRVVASKQGSTVTLGDFYRGREITIVHDADLQIGKLMWGDSGLYYCIITTPDDLEGKNEDSVELLVLGRTGLLADLLPSFAVEIMPEWVFVGLVLLGVFLFFVLVGICWCQCCPHSCCCYVRCPCCPDSCCCPQALYEAGKAAKAGYPPSVSGVPGPYSIPSVPLGGAPSSGMLMDKPHPPPLAPSDSTGGSHSVRKGYRIQADKERDSMKVLYYVEKELAQFDPARRMRGRYNNTISELSSLHEEDSNFRQSFHQMRSKQFPVSGDLESNPDYWSGVMGGSSGASRGPSAMEYNKEDRESFRHSQPRSKSEMLSRKNFATGVPAVSMDELAAFADSYGQRPRRADGNSHEARGGSRFERSESRAHSGFYQDDSLEEYYGQRSRSREPLTDADRGWAFSPARRRPAEDAHLPRLVSRTPGTAPKYDHSYLGSARERQARPEGASRGGSLETPSKRSAQLGPRSASYYAWSPPGTYKAGSSQDDQEDASDDALPPYSELELTRGPSYRGRDLPYHSNSEKKRKKEPAKKTNDFPTRMSLVV
T43980	DRUGINFO	D3SPE5	BAY 1905254	Phase 1

T45760	TARGETID	T45760
T45760	UNIPROID	L_HRSVA
T45760	TARGNAME	HRSV RNA-directed RNA polymerase L (HRSV L)
T45760	GENENAME	HRSV L
T45760	TARGTYPE	Clinical trial
T45760	SYNONYMS	Protein L; Large structural protein; Replicase; Transcriptase
T45760	FUNCTION	Responsible for RNA synthesis (replicase and transcriptase), cap addition, and cap methylation. Performs also the polyadenylation of subgenomic mRNAs by a stuttering mechanism at a slipery stop site present at the end of viral genes. The template is composed of the viral RNA tightly encapsidated by the nucleoprotein (N) (Probable). The viral polymerase binds to the genomic RNA at two differents sites in the 3' leader promoter thereby initiating either genome replication or mRNA transcription. In the transcription mode, the polymerase performs the sequential transcription of all mRNAs using a termination-reinitiation mechanism responding to gene start and gene end signals. Some polymerase disengage from the template at each gene junction, resulting in a decreasing abundance of transcripts from the 3' to the 5' end of the genome (Probable). The first gene is the most transcribed, and the last the least transcribed (Probable). Needs as cofactors the phosphoprotein for processivity and the M2-1 anti-termination protein. Polyribonucleotidyl transferase (PRNTase) adds the cap structure when the nascent RNA chain length has reached few nucleotides. Ribose 2'-O methylation of viral mRNA cap precedes and facilitates subsequent guanine-N-7 methylation (By similarity). In the replication mode, the polymerase replicates the whole viral genome without recognizing the gene end transcriptional signals. The ability of the polymerase to override the gene end signals as it is producing the antigenome is probably due to replicative RNA becoming encapsidated with nucleoprotein as it is synthesized.
T45760	SEQUENCE	MDPIINGNSANVYLTDSYLKGVISFSECNALGSYIFNGPYLKNDYTNLISRQNPLIEHMNLKKLNITQSLISKYHKGEIKLEEPTYFQSLLMTYKSMTSSEQIATTNLLKKIIRRAIEISDVKVYAILNKLGLKEKDKIKSNNGQDEDNSVITTIIKDDILSAVKDNQSHLKADKNHSTKQKDTIKTTLLKKLMCSMQHPPSWLIHWFNLYTKLNNILTQYRSNEVKNHGFTLIDNQTLSGFQFILNQYGCIVYHKELKRITVTTYNQFLTWKDISLSRLNVCLITWISNCLNTLNKSLGLRCGFNNVILTQLFLYGDCILKLFHNEGFYIIKEVEGFIMSLILNITEEDQFRKRFYNSMLNNITDAANKAQKNLLSRVCHTLLDKTVSDNIINGRWIILLSKFLKLIKLAGDNNLNNLSELYFLFRIFGHPMVDERQAMDAVKINCNETKFYLLSSLSMLRGAFIYRIIKGFVNNYNRWPTLRNAIVLPLRWLTYYKLNTYPSLLELTERDLIVLSGLRFYREFRLPKKVDLEMIINDKAISPPKNLIWTSFPRNYMPSHIQNYIEHEKLKFSESDKSRRVLEYYLRDNKFNECDLYNCVVNQSYLNNPNHVVSLTGKERELSVGRMFAMQPGMFRQVQILAEKMIAENILQFFPESLTRYGDLELQKILELKAGISNKSNRYNDNYNNYISKCSIITDLSKFNQAFRYETSCICSDVLDELHGVQSLFSWLHLTIPHVTIICTYRHAPPYIGDHIVDLNNVDEQSGLYRYHMGGIEGWCQKLWTIEAISLLDLISLKGKFSITALINGDNQSIDISKPIRLMEGQTHAQADYLLALNSLKLLYKEYAGIGHKLKGTETYISRDMQFMSKTIQHNGVYYPASIKKVLRVGPWINTILDDFKVSLESIGSLTQELEYRGESLLCSLIFRNVWLYNQIALQLKNHALCNNKLYLDILKVLKHLKTFFNLDNIDTALTLYMNLPMLFGGGDPNLLYRSFYRRTPDFLTEAIVHSVFILSYYTNHDLKDKLQDLSDDRLNKFLTCIITFDKNPNAEFVTLMRDPQALGSERQAKITSEINRLAVTEVLSTAPNKIFSKSAQHYTTTEIDLNDIMQNIEPTYPHGLRVVYESLPFYKAEKIVNLISGTKSITNILEKTSAIDLTDIDRATEMMRKNITLLIRILPLDCNRDKREILSMENLSITELSKYVRERSWSLSNIVGVTSPSIMYTMDIKYTTSTISSGIIIEKYNVNSLTRGERGPTKPWVGSSTQEKKTMPVYNRQVLTKKQRDQIDLLAKLDWVYASIDNKDEFMEELSIGTLGLTYEKAKKLFPQYLSVNYLHRLTVSSRPCEFPASIPAYRTTNYHFDTSPINRILTEKYGDEDIDIVFQNCISFGLSLMSVVEQFTNVCPNRIILIPKLNEIHLMKPPIFTGDVDIHKLKQVIQKQHMFLPDKISLTQYVELFLSNKTLKSGSHVNSNLILAHKISDYFHNTYILSTNLAGHWILIIQLMKDSKGIFEKDWGEGYITDHMFINLKVFFNAYKTYLLCFHKGYGKAKLECDMNTSDLLCVLELIDSSYWKSMSKVFLEQKVIKYILSQDASLHRVKGCHSFKLWFLKRLNVAEFTVCPWVVNIDYHPTHMKAILTYIDLVRMGLINIDRIHIKNKHKFNDEFYTSNLFYINYNFSDNTHLLTKHIRIANSELENNYNKLYHPTPETLENILANPIKSNDKKTLNDYCIGKNVDSIMLPLLSNKKLIKSSAMIRTNYSKQDLYNLFPMVVIDRIIDHSGNTAKSNQLYTTTSHQISLVHNSTSLYCMLPWHHINRFNFVFSSTGCKISIEYILKDLKIKDPNCIAFIGEGAGNLLLRTVVELHPDIRYIYRSLKDCNDHSLPIEFLRLYNGHINIDYGENLTIPATDATNNIHWSYLHIKFAEPISLFVCDAELSVTVNWSKIIIEWSKHVRKCKYCSSVNKCMLIVKYHAQDDIDFKLDNITILKTYVCLGSKLKGSEVYLVLTIGPANIFPVFNVVQNAKLILSRTKNFIMPKKADKESIDANIKSLIPFLCYPITKKGINTALSKLKSVVSGDILSYSIAGRNEVFSNKLINHKHMNILKWFNHVLNFRSTELNYNHLYMVESTYPYLSELLNSLTTNELKKLIKITGSLLYNFHNE
T45760	DRUGINFO	D0TMF3	JNJ-64417184	Phase 1

T46052	TARGETID	T46052
T46052	UNIPROID	LAMP2_HUMAN
T46052	TARGNAME	Lysosome-associated membrane glycoprotein 2 (LAMP2)
T46052	GENENAME	LAMP2
T46052	TARGTYPE	Clinical trial
T46052	SYNONYMS	LAMP-2; Lysosome-associated membrane protein 2; CD107 antigen-like family member B; LGP-96; DE   AltName: CD_antigen=CD107b
T46052	FUNCTION	Plays an important role in chaperone-mediated autophagy, a process that mediates lysosomal degradation of proteins in response to various stresses and as part of the normal turnover of proteins with a long biological half-live. Functions by binding target proteins, such as GAPDH and MLLT11, and targeting them for lysosomal degradation. Plays a role in lysosomal protein degradation in response to starvation (By similarity). Required for the fusion of autophagosomes with lysosomes during autophagy. Cells that lack LAMP2 express normal levels of VAMP8, but fail to accumulate STX17 on autophagosomes, which is the most likely explanation for the lack of fusion between autophagosomes and lysosomes. Required for normal degradation of the contents of autophagosomes. Required for efficient MHCII-mediated presentation of exogenous antigens via its function in lysosomal protein degradation; antigenic peptides generated by proteases in the endosomal/lysosomal compartment are captured by nascent MHCII subunits. Is not required for efficient MHCII-mediated presentation of endogenous antigens.
T46052	SEQUENCE	MVCFRLFPVPGSGLVLVCLVLGAVRSYALELNLTDSENATCLYAKWQMNFTVRYETTNKTYKTVTISDHGTVTYNGSICGDDQNGPKIAVQFGPGFSWIANFTKAASTYSIDSVSFSYNTGDNTTFPDAEDKGILTVDELLAIRIPLNDLFRCNSLSTLEKNDVVQHYWDVLVQAFVQNGTVSTNEFLCDKDKTSTVAPTIHTTVPSPTTTPTPKEKPEAGTYSVNNGNDTCLLATMGLQLNITQDKVASVININPNTTHSTGSCRSHTALLRLNSSTIKYLDFVFAVKNENRFYLKEVNISMYLVNGSVFSIANNNLSYWDAPLGSSYMCNKEQTVSVSGAFQINTFDLRVQPFNVTQGKYSTAQDCSADDDNFLVPIAVGAALAGVLILVLLAYFIGLKHHHAGYEQF
T46052	DRUGINFO	DX36OY	RP-A501	Phase 1

T46789	TARGETID	T46789
T46789	UNIPROID	SHPS1_HUMAN
T46789	TARGNAME	Inhibitory receptor SHPS-1 (SIRPA)
T46789	GENENAME	SIRPA
T46789	TARGTYPE	Clinical trial
T46789	SYNONYMS	SHP substrate 1; SHPS-1; Brain Ig-like molecule with tyrosine-based activation motifs; Bit; CD172 antigen-like family member A; Macrophage fusion receptor; MyD-1 antigen; Signal-regulatory protein alpha-1; Sirp-alpha-1; Signal-regulatory protein alpha-2; Sirp-alpha-2; Signal-regulatory protein alpha-3; Sirp-alpha-3; p84; DE   AltName: CD_antigen=CD172a
T46789	FUNCTION	Immunoglobulin-like cell surface receptor for CD47. Acts as docking protein and induces translocation of PTPN6, PTPN11 and other binding partners from the cytosol to the plasma membrane. Supports adhesion of cerebellar neurons, neurite outgrowth and glial cell attachment. May play a key role in intracellular signaling during synaptogenesis and in synaptic function (By similarity). Involved in the negative regulation of receptor tyrosine kinase-coupled cellular responses induced by cell adhesion, growth factors or insulin. Mediates negative regulation of phagocytosis, mast cell activation and dendritic cell activation. CD47 binding prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells.
T46789	SEQUENCE	MEPAGPAPGRLGPLLCLLLAASCAWSGVAGEEELQVIQPDKSVLVAAGETATLRCTATSLIPVGPIQWFRGAGPGRELIYNQKEGHFPRVTTVSDLTKRNNMDFSIRIGNITPADAGTYYCVKFRKGSPDDVEFKSGAGTELSVRAKPSAPVVSGPAARATPQHTVSFTCESHGFSPRDITLKWFKNGNELSDFQTNVDPVGESVSYSIHSTAKVVLTREDVHSQVICEVAHVTLQGDPLRGTANLSETIRVPPTLEVTQQPVRAENQVNVTCQVRKFYPQRLQLTWLENGNVSRTETASTVTENKDGTYNWMSWLLVNVSAHRDDVKLTCQVEHDGQPAVSKSHDLKVSAHPKEQGSNTAAENTGSNERNIYIVVGVVCTLLVALLMAALYLVRIRQKKAQGSTSSTRLHEPEKNAREITQDTNDITYADLNLPKGKKPAPQAAEPNNHTEYASIQTSPQPASEDTLTYADLDMVHLNRTPKQPAPKPEPSFSEYASVQVPRK
T46789	DRUGINFO	DJ29KW	FSI-189	Phase 1
T46789	DRUGINFO	DKL3Z7	CC-95251	Phase 1
T46789	DRUGINFO	DZBV67	BI 765063	Phase 1

T47381	TARGETID	T47381
T47381	UNIPROID	GSTP1_HUMAN
T47381	TARGNAME	GSTP1 messenger RNA (GSTP1 mRNA)
T47381	GENENAME	GSTP1
T47381	TARGTYPE	Clinical trial
T47381	SYNONYMS	GST class-pi; GSTP1-1
T47381	FUNCTION	Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Involved in the formation of glutathione conjugates of both prostaglandin A2 (PGA2) and prostaglandin J2 (PGJ2). Participates in the formation of novel hepoxilin regioisomers. Regulates negatively CDK5 activity via p25/p35 translocation to prevent neurodegeneration.
T47381	BIOCLASS	mRNA target
T47381	ECNUMBER	EC 2.5.1.18
T47381	SEQUENCE	MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ
T47381	DRUGINFO	D8UZ5R	NBF-006	Phase 1

T49105	TARGETID	T49105
T49105	UNIPROID	PVRIG_HUMAN
T49105	TARGNAME	Transmembrane protein PVRIG (PVRIG)
T49105	GENENAME	PVRIG
T49105	TARGTYPE	Clinical trial
T49105	SYNONYMS	CD112 receptor; CD112R; Poliovirus receptor-related immunoglobulin domain-containing protein
T49105	FUNCTION	Cell surface receptor for NECTIN2. May act as a coinhibitory receptor that suppresses T-cell receptor-mediated signals. Following interaction with NECTIN2, inhibits T-cell proliferation. Competes with CD226 for NECTIN2-binding.
T49105	SEQUENCE	MRTEAQVPALQPPEPGLEGAMGHRTLVLPWVLLTLCVTAGTPEVWVQVRMEATELSSFTIRCGFLGSGSISLVTVSWGGPNGAGGTTLAVLHPERGIRQWAPARQARWETQSSISLILEGSGASSPCANTTFCCKFASFPEGSWEACGSLPPSSDPGLSAPPTPAPILRADLAGILGVSGVLLFGCVYLLHLLRRHKHRPAPRLQPSRTSPQAPRARAWAPSQASQAALHVPYATINTSCRPATLDTAHPHGGPSWWASLPTHAAHRPQGPAAWASTPIPARGSFVSVENGLYAQAGERPPHTGPGLTLFPDPRGPRAMEGPLGVR
T49105	DRUGINFO	D7WOL5	COM701	Phase 1
T49105	DRUGINFO	DM1F3R	GSK4381562	Phase 1

T49156	TARGETID	T49156
T49156	UNIPROID	PTN2_HUMAN
T49156	TARGNAME	Tyrosine-protein phosphatase non-receptor type 2 (PTPN2)
T49156	GENENAME	PTPN2
T49156	TARGTYPE	Clinical trial
T49156	SYNONYMS	T-cell protein-tyrosine phosphatase; TCPTP
T49156	FUNCTION	Non-receptor type tyrosine-specific phosphatase that dephosphorylates receptor protein tyrosine kinases including INSR, EGFR, CSF1R, PDGFR. Also dephosphorylates non-receptor protein tyrosine kinases like JAK1, JAK2, JAK3, Src family kinases, STAT1, STAT3 and STAT6 either in the nucleus or the cytoplasm. Negatively regulates numerous signaling pathways and biological processes like hematopoiesis, inflammatory response, cell proliferation and differentiation, and glucose homeostasis. Plays a multifaceted and important role in the development of the immune system. Functions in T-cell receptor signaling through dephosphorylation of FYN and LCK to control T-cells differentiation and activation. Dephosphorylates CSF1R, negatively regulating its downstream signaling and macrophage differentiation. Negatively regulates cytokine (IL2/interleukin-2 and interferon)-mediated signaling through dephosphorylation of the cytoplasmic kinases JAK1, JAK3 and their substrate STAT1, that propagate signaling downstream of the cytokine receptors. Also regulates the IL6/interleukin-6 and IL4/interleukin-4 cytokine signaling through dephosphorylation of STAT3 and STAT6 respectively. In addition to the immune system, it is involved in anchorage-dependent, negative regulation of EGF-stimulated cell growth. Activated by the integrin ITGA1/ITGB1, it dephosphorylates EGFR and negatively regulates EGF signaling. Dephosphorylates PDGFRB and negatively regulates platelet-derived growth factor receptor-beta signaling pathway and therefore cell proliferation. Negatively regulates tumor necrosis factor-mediated signaling downstream via MAPK through SRC dephosphorylation. May also regulate the hepatocyte growth factor receptor signaling pathway through dephosphorylation of the hepatocyte growth factor receptor MET. Plays also an important role in glucose homeostasis. For instance, negatively regulates the insulin receptor signaling pathway through the dephosphorylation of INSR and control gluconeogenesis and liver glucose production through negative regulation of the IL6 signaling pathways. May also bind DNA.
T49156	ECNUMBER	EC 3.1.3.48
T49156	SEQUENCE	MPTTIEREFEELDTQRRWQPLYLEIRNESHDYPHRVAKFPENRNRNRYRDVSPYDHSRVKLQNAENDYINASLVDIEEAQRSYILTQGPLPNTCCHFWLMVWQQKTKAVVMLNRIVEKESVKCAQYWPTDDQEMLFKETGFSVKLLSEDVKSYYTVHLLQLENINSGETRTISHFHYTTWPDFGVPESPASFLNFLFKVRESGSLNPDHGPAVIHCSAGIGRSGTFSLVDTCLVLMEKGDDINIKQVLLNMRKYRMGLIQTPDQLRFSYMAIIEGAKCIKGDSSIQKRWKELSKEDLSPAFDHSPNKIMTEKYNGNRIGLEEEKLTGDRCTGLSSKMQDTMEENSESALRKRIREDRKATTAQKVQQMKQRLNENERKRKRWLYWQPILTKMGFMSVILVGAFVGWTLFFQQNAL
T49156	DRUGINFO	D5EOV9	ABBV-CLS-579	Phase 1

T50289	TARGETID	T50289
T50289	UNIPROID	BMP7_HUMAN
T50289	TARGNAME	Bone morphogenetic protein 7 (BMP7)
T50289	GENENAME	BMP7
T50289	TARGTYPE	Clinical trial
T50289	SYNONYMS	BMP-7; Osteogenic protein 1; OP-1; Eptotermin alfa
T50289	FUNCTION	Induces cartilage and bone formation. May be the osteoinductive factor responsible for the phenomenon of epithelial osteogenesis. Plays a role in calcium regulation and bone homeostasis. Promotes brown adipocyte differentiation by P38 MAPK pathway-mediated activation of target genes, including members of the SOX family of transcription factors.
T50289	SEQUENCE	MHVRSLRAAAPHSFVALWAPLFLLRSALADFSLDNEVHSSFIHRRLRSQERREMQREILSILGLPHRPRPHLQGKHNSAPMFMLDLYNAMAVEEGGGPGGQGFSYPYKAVFSTQGPPLASLQDSHFLTDADMVMSFVNLVEHDKEFFHPRYHHREFRFDLSKIPEGEAVTAAEFRIYKDYIRERFDNETFRISVYQVLQEHLGRESDLFLLDSRTLWASEEGWLVFDITATSNHWVVNPRHNLGLQLSVETLDGQSINPKLAGLIGRHGPQNKQPFMVAFFKATEVHFRSIRSTGSKQRSQNRSKTPKNQEALRMANVAENSSSDQRQACKKHELYVSFRDLGWQDWIIAPEGYAAYYCEGECAFPLNSYMNATNHAIVQTLVHFINPETVPKPCCAPTQLNAISVLYFDDSSNVILKKYRNMVVRACGCH
T50289	DRUGINFO	DP9SF6	THR-184	Phase 2

T51468	TARGETID	T51468
T51468	UNIPROID	CLK1_HUMAN; CLK2_HUMAN; CLK3_HUMAN; CLK4_HUMAN
T51468	TARGNAME	Cdc-like kinase (CLK)
T51468	TARGTYPE	Clinical trial
T51468	DRUGINFO	DS4M1A	SM09419	Phase 1

T51672	TARGETID	T51672
T51672	UNIPROID	IKBA_HUMAN
T51672	TARGNAME	NF-kappa-B inhibitor alpha (NFKBIA)
T51672	GENENAME	NFKBIA
T51672	TARGTYPE	Clinical trial
T51672	SYNONYMS	I-kappa-B-alpha; IkB-alpha; IkappaBalpha; Major histocompatibility complex enhancer-binding protein MAD3
T51672	FUNCTION	Inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL dimers in the cytoplasm through masking of their nuclear localization signals. On cellular stimulation by immune and proinflammatory responses, becomes phosphorylated promoting ubiquitination and degradation, enabling the dimeric RELA to translocate to the nucleus and activate transcription.
T51672	SEQUENCE	MFQAAERPQEWAMEGPRDGLKKERLLDDRHDSGLDSMKDEEYEQMVKELQEIRLEPQEVPRGSEPWKQQLTEDGDSFLHLAIIHEEKALTMEVIRQVKGDLAFLNFQNNLQQTPLHLAVITNQPEIAEALLGAGCDPELRDFRGNTPLHLACEQGCLASVGVLTQSCTTPHLHSILKATNYNGHTCLHLASIHGYLGIVELLVSLGADVNAQEPCNGRTALHLAVDLQNPDLVSLLLKCGADVNRVTYQGYSPYQLTWGRPSTRIQQQLGQLTLENLQMLPESEDEESYDTESEFTEFTEDELPYDDCVFGGQRLTL
T51672	DRUGINFO	DN62DG	I3C	Phase 3
T51672	DRUGINFO	DEZ3D7	Fucoxanthin	Phase 2

T52034	TARGETID	T52034
T52034	UNIPROID	SERPH_HUMAN
T52034	TARGNAME	SERPINH1 messenger RNA (SERPINH1 mRNA)
T52034	GENENAME	SERPINH1
T52034	TARGTYPE	Clinical trial
T52034	SYNONYMS	47 kDa heat shock protein; Arsenic-transactivated protein 3; AsTP3; Cell proliferation-inducing gene 14 protein; Collagen-binding protein; Colligin; Rheumatoid arthritis-related antigen RA-A47
T52034	FUNCTION	Binds specifically to collagen. Could be involved as a chaperone in the biosynthetic pathway of collagen.
T52034	BIOCLASS	mRNA target
T52034	SEQUENCE	MRSLLLLSAFCLLEAALAAEVKKPAAAAAPGTAEKLSPKAATLAERSAGLAFSLYQAMAKDQAVENILVSPVVVASSLGLVSLGGKATTASQAKAVLSAEQLRDEEVHAGLGELLRSLSNSTARNVTWKLGSRLYGPSSVSFADDFVRSSKQHYNCEHSKINFRDKRSALQSINEWAAQTTDGKLPEVTKDVERTDGALLVNAMFFKPHWDEKFHHKMVDNRGFMVTRSYTVGVMMMHRTGLYNYYDDEKEKLQIVEMPLAHKLSSLIILMPHHVEPLERLEKLLTKEQLKIWMGKMQKKAVAISLPKGVVEVTHDLQKHLAGLGLTEAIDKNKADLSRMSGKKDLYLASVFHATAFELDTDGNPFDQDIYGREELRSPKLFYADHPFIFLVRDTQSGSLLFIGRLVRPKGDKMRDEL
T52034	DRUGINFO	D2H4RZ	BMS-986263	Phase 2

T52098	TARGETID	T52098
T52098	UNIPROID	OTC_HUMAN
T52098	TARGNAME	Ornithine transcarbamylase (OTC)
T52098	GENENAME	OTC
T52098	TARGTYPE	Clinical trial
T52098	SYNONYMS	OTCase; Ornithine carbamoyltransferase, mitochondrial
T52098	FUNCTION	Catalyzes the second step of the urea cycle, the condensation of carbamoyl phosphate with L-ornithine to form L-citrulline. The urea cycle ensures the detoxification of ammonia by converting it to urea for excretion.
T52098	ECNUMBER	EC 2.1.3.3
T52098	SEQUENCE	MLFNLRILLNNAAFRNGHNFMVRNFRCGQPLQNKVQLKGRDLLTLKNFTGEEIKYMLWLSADLKFRIKQKGEYLPLLQGKSLGMIFEKRSTRTRLSTETGFALLGGHPCFLTTQDIHLGVNESLTDTARVLSSMADAVLARVYKQSDLDTLAKEASIPIINGLSDLYHPIQILADYLTLQEHYSSLKGLTLSWIGDGNNILHSIMMSAAKFGMHLQAATPKGYEPDASVTKLAEQYAKENGTKLLLTNDPLEAAHGGNVLITDTWISMGQEEEKKKRLQAFQGYQVTMKTAKVAASDWTFLHCLPRKPEEVDDEVFYSPRSLVFPEAENRKWTIMAVMVSLLTDYSPQLQKPKF
T52098	DRUGINFO	D6V9FN	Avalotcagene ontaparvovec	Phase 3
T52098	DRUGINFO	DQ7I6M	ARCT-810	Phase 2
T52098	DRUGINFO	D6XMS1	DTX301	Phase 1/2

T52138	TARGETID	T52138
T52138	UNIPROID	HBSAG_HBVD3
T52138	TARGNAME	Hepatitis B virus Large envelope protein messenger RNA (HBV S mRNA)
T52138	GENENAME	HBV S mRNA
T52138	TARGTYPE	Clinical trial
T52138	SYNONYMS	L glycoprotein; L-HBsAg; LHB; Large S protein; Large surface protein; Major surface antigen; L glycoprotein; L-HBsAg; LHB; Large S protein; Large surface protein; Major surface antigen
T52138	FUNCTION	The large envelope protein exists in two topological conformations, one which is termed 'external' or Le-HBsAg and the other 'internal' or Li-HBsAg. In its external conformation the protein attaches the virus to cell receptors and thereby initiating infection. This interaction determines the species specificity and liver tropism. This attachment induces virion internalization predominantly through caveolin-mediated endocytosis. The large envelope protein also assures fusion between virion membrane and endosomal membrane. In its internal conformation the protein plays a role in virion morphogenesis and mediates the contact with the nucleocapsid like a matrix protein.
T52138	BIOCLASS	mRNA target
T52138	SEQUENCE	MGQNLSTSNPLGFFPDHQLDPAFRANTANPDWDFNPNKDTWPDANKVGAGAFGLGFTPPHGGLLGWSPQAQGILQTLPANPPPASTNRQSGRQPTPLSPPLRNTHPQAMQWNSTTFHQTLQDPRVRGLYFPAGGSSSGTVNPVLTTASPLSSIFSRIGDPALNMENITSGFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGTTVCLGQNSQSPTSNHSPTSCPPTCPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSSTTSTGPCRTCMTTAQGTSMYPSCCCTKPSDGNCTCIPIPSSWAFGKFLWEWASARFSWLSLLVPFVQWFVGLSPTVWLSVIWMMWYWGPSLYSILSPFLPLLPIFFCLWVYI
T52138	DRUGINFO	D2U5CW	GSK3228836	Phase 2
T52138	DRUGINFO	DOE7C4	GSK3389404	Phase 2
T52138	DRUGINFO	D5LB7Y	RG6346	Phase 1

T52489	TARGETID	T52489
T52489	UNIPROID	RPGF3_HUMAN
T52489	TARGNAME	Rap guanine nucleotide exchange factor 3 (RAPGEF3)
T52489	GENENAME	RAPGEF3
T52489	TARGTYPE	Clinical trial
T52489	SYNONYMS	Exchange factor directly activated by cAMP 1; Exchange protein directly activated by cAMP 1; EPAC 1; Rap1 guanine-nucleotide-exchange factor directly activated by cAMP; cAMP-regulated guanine nucleotide exchange factor I; cAMP-GEFI
T52489	FUNCTION	Guanine nucleotide exchange factor (GEF) for RAP1A and RAP2A small GTPases that is activated by binding cAMP. Through simultaneous binding of PDE3B to RAPGEF3 and PIK3R6 is assembled in a signaling complex in which it activates the PI3K gamma complex and which is involved in angiogenesis. Plays a role in the modulation of the cAMP-induced dynamic control of endothelial barrier function through a pathway that is independent on Rho-mediated signaling. Required for the actin rearrangement at cell-cell junctions, such as stress fibers and junctional actin.
T52489	SEQUENCE	MKVGWPGESCWQVGLAVEDSPALGAPRVGALPDVVPEGTLLNMVLRRMHRPRSCSYQLLLEHQRPSCIQGLRWTPLTNSEESLDFSESLEQASTERVLRAGRQLHRHLLATCPNLIRDRKYHLRLYRQCCSGRELVDGILALGLGVHSRSQVVGICQVLLDEGALCHVKHDWAFQDRDAQFYRFPGPEPEPVRTHEMEEELAEAVALLSQRGPDALLTVALRKPPGQRTDEELDLIFEELLHIKAVAHLSNSVKRELAAVLLFEPHSKAGTVLFSQGDKGTSWYIIWKGSVNVVTHGKGLVTTLHEGDDFGQLALVNDAPRAATIILREDNCHFLRVDKQDFNRIIKDVEAKTMRLEEHGKVVLVLERASQGAGPSRPPTPGRNRYTVMSGTPEKILELLLEAMGPDSSAHDPTETFLSDFLLTHRVFMPSAQLCAALLHHFHVEPAGGSEQERSTYVCNKRQQILRLVSQWVALYGSMLHTDPVATSFLQKLSDLVGRDTRLSNLLREQWPERRRCHRLENGCGNASPQMKARNLPVWLPNQDEPLPGSSCAIQVGDKVPYDICRPDHSVLTLQLPVTASVREVMAALAQEDGWTKGQVLVKVNSAGDAIGLQPDARGVATSLGLNERLFVVNPQEVHELIPHPDQLGPTVGSAEGLDLVSAKDLAGQLTDHDWSLFNSIHQVELIHYVLGPQHLRDVTTANLERFMRRFNELQYWVATELCLCPVPGPRAQLLRKFIKLAAHLKEQKNLNSFFAVMFGLSNSAISRLAHTWERLPHKVRKLYSALERLLDPSWNHRVYRLALAKLSPPVIPFMPLLLKDMTFIHEGNHTLVENLINFEKMRMMARAARMLHHCRSHNPVPLSPLRSRVSHLHEDSQVARISTCSEQSLSTRSPASTWAYVQQLKVIDNQRELSRLSRELEP
T52489	DRUGINFO	D1UA2E	AM001	Phase 2

T54789	TARGETID	T54789
T54789	UNIPROID	RPGR_HUMAN
T54789	TARGNAME	X-linked retinitis pigmentosa GTPase regulator (RPGR)
T54789	GENENAME	RPGR
T54789	TARGTYPE	Clinical trial
T54789	FUNCTION	Could be a guanine-nucleotide releasing factor. Plays a role in ciliogenesis. Probably regulates cilia formation by regulating actin stress filaments and cell contractility. Plays an important role in photoreceptor integrity. May play a critical role in spermatogenesis and in intraflagellar transport processes (By similarity). May be involved in microtubule organization and regulation of transport in primary cilia.
T54789	SEQUENCE	MREPEELMPDSGAVFTFGKSKFAENNPGKFWFKNDVPVHLSCGDEHSAVVTGNNKLYMFGSNNWGQLGLGSKSAISKPTCVKALKPEKVKLAACGRNHTLVSTEGGNVYATGGNNEGQLGLGDTEERNTFHVISFFTSEHKIKQLSAGSNTSAALTEDGRLFMWGDNSEGQIGLKNVSNVCVPQQVTIGKPVSWISCGYYHSAFVTTDGELYVFGEPENGKLGLPNQLLGNHRTPQLVSEIPEKVIQVACGGEHTVVLTENAVYTFGLGQFGQLGLGTFLFETSEPKVIENIRDQTISYISCGENHTALITDIGLMYTFGDGRHGKLGLGLENFTNHFIPTLCSNFLRFIVKLVACGGCHMVVFAAPHRGVAKEIEFDEINDTCLSVATFLPYSSLTSGNVLQRTLSARMRRRERERSPDSFSMRRTLPPIEGTLGLSACFLPNSVFPRCSERNLQESVLSEQDLMQPEEPDYLLDEMTKEAEIDNSSTVESLGETTDILNMTHIMSLNSNEKSLKLSPVQKQKKQQTIGELTQDTALTENDDSDEYEEMSEMKEGKACKQHVSQGIFMTQPATTIEAFSDEEVGNDTGQVGPQADTDGEGLQKEVYRHENNNGVDQLDAKEIEKESDGGHSQKESEAEEIDSEKETKLAEIAGMKDLREREKSTKKMSPFFGNLPDRGMNTESEENKDFVKKRESCKQDVIFDSERESVEKPDSYMEGASESQQGIADGFQQPEAIEFSSGEKEDDEVETDQNIRYGRKLIEQGNEKETKPIISKSMAKYDFKCDRLSEIPEEKEGAEDSKGNGIEEQEVEANEENVKVHGGRKEKTEILSDDLTDKAEDHEFSKTEELKLEDVDEEINAENVESKKKTVGDDESVPTGYHSKTEGAERTNDDSSAETIEKKEKANLEERAICEYNENPKGYMLDDADSSSLEILENSETTPSKDMKKTKKIFLFKRVPSINQKIVKNNNEPLPEIKSIGDQIILKSDNKDADQNHMSQNHQNIPPTNTERRSKSCTIL
T54789	DRUGINFO	DU7XQ3	BIIB112	Phase 3
T54789	DRUGINFO	DKH94Z	BIIB-088	Phase 2/3
T54789	DRUGINFO	DO76YM	AGTC-501	Phase 1/2
T54789	DRUGINFO	DZ8FV2	AAV-RPGR	Phase 1/2

T56349	TARGETID	T56349
T56349	UNIPROID	CXCL9_HUMAN
T56349	TARGNAME	C-X-C motif chemokine 9 (CXCL9)
T56349	GENENAME	CXCL9
T56349	TARGTYPE	Clinical trial
T56349	SYNONYMS	Gamma-interferon-induced monokine; Monokine induced by interferon-gamma; HuMIG; MIG; Small-inducible cytokine B9
T56349	FUNCTION	Cytokine that affects the growth, movement, or activation state of cells that participate in immune and inflammatory response. Chemotactic for activated T-cells. Binds to CXCR3.
T56349	SEQUENCE	MKKSGVLFLLGIILLVLIGVQGTPVVRKGRCSCISTNQGTIHLQSLKDLKQFAPSPSCEKIEIIATLKNGVQTCLNPDSADVKELIKKWEKQVSQKKKQKNGKKHQKKKVLKVRKSQRSRQKKTT
T56349	DRUGINFO	D1A8NU	NG-641	Phase 1

T57941	TARGETID	T57941
T57941	UNIPROID	MAGA6_HUMAN
T57941	TARGNAME	Melanoma-associated antigen 6 (MAGEA6)
T57941	GENENAME	MAGEA6
T57941	TARGTYPE	Clinical trial
T57941	SYNONYMS	Cancer/testis antigen 1.6; CT1.6; MAGE-6 antigen; MAGE3B antigen
T57941	FUNCTION	Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. May enhance ubiquitin ligase activity of TRIM28 and stimulate p53/TP53 ubiquitination by TRIM28. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex. May play a role in tumor transformation or aspects of tumor progression. In vitro promotes cell viability in melanoma cell lines.
T57941	SEQUENCE	MPLEQRSQHCKPEEGLEARGEALGLVGAQAPATEEQEAASSSSTLVEVTLGEVPAAESPDPPQSPQGASSLPTTMNYPLWSQSYEDSSNQEEEGPSTFPDLESEFQAALSRKVAKLVHFLLLKYRAREPVTKAEMLGSVVGNWQYFFPVIFSKASDSLQLVFGIELMEVDPIGHVYIFATCLGLSYDGLLGDNQIMPKTGFLIIILAIIAKEGDCAPEEKIWEELSVLEVFEGREDSIFGDPKKLLTQYFVQENYLEYRQVPGSDPACYEFLWGPRALIETSYVKVLHHMVKISGGPRISYPLLHEWALREGEE
T57941	DRUGINFO	DN46RL	KITE-718	Phase 1

T58679	TARGETID	T58679
T58679	UNIPROID	PABP1_HUMAN
T58679	TARGNAME	Polyadenylate-binding protein 1 (PABPC1)
T58679	GENENAME	PABPC1
T58679	TARGTYPE	Clinical trial
T58679	SYNONYMS	PABP-1; Poly(A)-binding protein 1
T58679	FUNCTION	Binds the poly(A) tail of mRNA, including that of its own transcript, and regulates processes of mRNA metabolism such as pre-mRNA splicing and mRNA stability. Its function in translational initiation regulation can either be enhanced by PAIP1 or repressed by PAIP2. Can probably bind to cytoplasmic RNA sequences other than poly(A) in vivo. Involved in translationally coupled mRNA turnover. Implicated with other RNA-binding proteins in the cytoplasmic deadenylation/translational and decay interplay of the FOS mRNA mediated by the major coding-region determinant of instability (mCRD) domain. Involved in regulation of nonsense-mediated decay (NMD) of mRNAs containing premature stop codons; for the recognition of premature termination codons (PTC) and initiation of NMD a competitive interaction between UPF1 and PABPC1 with the ribosome-bound release factors is proposed. By binding to long poly(A) tails, may protect them from uridylation by ZCCHC6/ZCCHC11 and hence contribute to mRNA stability.
T58679	SEQUENCE	MNPSAPSYPMASLYVGDLHPDVTEAMLYEKFSPAGPILSIRVCRDMITRRSLGYAYVNFQQPADAERALDTMNFDVIKGKPVRIMWSQRDPSLRKSGVGNIFIKNLDKSIDNKALYDTFSAFGNILSCKVVCDENGSKGYGFVHFETQEAAERAIEKMNGMLLNDRKVFVGRFKSRKEREAELGARAKEFTNVYIKNFGEDMDDERLKDLFGKFGPALSVKVMTDESGKSKGFGFVSFERHEDAQKAVDEMNGKELNGKQIYVGRAQKKVERQTELKRKFEQMKQDRITRYQGVNLYVKNLDDGIDDERLRKEFSPFGTITSAKVMMEGGRSKGFGFVCFSSPEEATKAVTEMNGRIVATKPLYVALAQRKEERQAHLTNQYMQRMASVRAVPNPVINPYQPAPPSGYFMAAIPQTQNRAAYYPPSQIAQLRPSPRWTAQGARPHPFQNMPGAIRPAAPRPPFSTMRPASSQVPRVMSTQRVANTSTQTMGPRPAAAAAAATPAVRTVPQYKYAAGVRNPQQHLNAQPQVTMQQPAVHVQGQEPLTASMLASAPPQEQKQMLGERLFPLIQAMHPTLAGKITGMLLEIDNSELLHMLESPESLRSKVDEAVAVLQAHQAKEAAQKAVNSATGVPTV
T58679	DRUGINFO	DO20LT	ATRC-101	Phase 1

T59382	TARGETID	T59382
T59382	UNIPROID	SGCB_HUMAN
T59382	TARGNAME	Beta-sarcoglycan (SGCB)
T59382	GENENAME	SGCB
T59382	TARGTYPE	Clinical trial
T59382	SYNONYMS	Beta-SG; 43 kDa dystrophin-associated glycoprotein; 43DAG; A3b
T59382	FUNCTION	Component of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix.
T59382	SEQUENCE	MAAAAAAAAEQQSSNGPVKKSMREKAVERRSVNKEHNSNFKAGYIPIDEDRLHKTGLRGRKGNLAICVIILLFILAVINLIITLVIWAVIRIGPNGCDSMEFHESGLLRFKQVSDMGVIHPLYKSTVGGRRNENLVITGNNQPIVFQQGTTKLSVENNKTSITSDIGMQFFDPRTQNILFSTDYETHEFHLPSGVKSLNVQKASTERITSNATSDLNIKVDGRAIVRGNEGVFIMGKTIEFHMGGNMELKAENSIILNGSVMVSTTRLPSSSSGDQLGSGDWVRYKLCMCADGTLFKVQVTSQNMGCQISDNPCGNTH
T59382	DRUGINFO	D3RT4A	SRP-9003	Phase 1/2

T59463	TARGETID	T59463
T59463	UNIPROID	RASK_HUMAN
T59463	TARGNAME	KRAS G12D mutant messenger RNA (KRAS mRNA)
T59463	GENENAME	KRAS
T59463	TARGTYPE	Clinical trial
T59463	SYNONYMS	K-Ras 2; Ki-Ras; c-K-ras; c-Ki-ras
T59463	FUNCTION	Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. Plays an important role in the regulation of cell proliferation. Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner.
T59463	BIOCLASS	mRNA target
T59463	ECNUMBER	EC 3.6.5.2
T59463	SEQUENCE	MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM
T59463	DRUGINFO	DNH67V	SiG12D-LODER	Phase 2

T59702	TARGETID	T59702
T59702	UNIPROID	FZD10_HUMAN
T59702	TARGNAME	Frizzled-10 (FZD10)
T59702	GENENAME	FZD10
T59702	TARGTYPE	Clinical trial
T59702	SYNONYMS	Fz-10; hFz10; FzE7; DE   AltName: CD_antigen=CD350
T59702	FUNCTION	Receptor for Wnt proteins. Functions in the canonical Wnt/beta-catenin signaling pathway (By similarity). The canonical Wnt/beta-catenin signaling pathway leads to the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes. A second signaling pathway involving PKC and calcium fluxes has been seen for some family members, but it is not yet clear if it represents a distinct pathway or if it can be integrated in the canonical pathway, as PKC seems to be required for Wnt-mediated inactivation of GSK-3 kinase. Both pathways seem to involve interactions with G-proteins. May be involved in transduction and intercellular transmission of polarity information during tissue morphogenesis and/or in differentiated tissues (Probable).
T59702	SEQUENCE	MQRPGPRLWLVLQVMGSCAAISSMDMERPGDGKCQPIEIPMCKDIGYNMTRMPNLMGHENQREAAIQLHEFAPLVEYGCHGHLRFFLCSLYAPMCTEQVSTPIPACRVMCEQARLKCSPIMEQFNFKWPDSLDCRKLPNKNDPNYLCMEAPNNGSDEPTRGSGLFPPLFRPQRPHSAQEHPLKDGGPGRGGCDNPGKFHHVEKSASCAPLCTPGVDVYWSREDKRFAVVWLAIWAVLCFFSSAFTVLTFLIDPARFRYPERPIIFLSMCYCVYSVGYLIRLFAGAESIACDRDSGQLYVIQEGLESTGCTLVFLVLYYFGMASSLWWVVLTLTWFLAAGKKWGHEAIEANSSYFHLAAWAIPAVKTILILVMRRVAGDELTGVCYVGSMDVNALTGFVLIPLACYLVIGTSFILSGFVALFHIRRVMKTGGENTDKLEKLMVRIGLFSVLYTVPATCVIACYFYERLNMDYWKILAAQHKCKMNNQTKTLDCLMAASIPAVEIFMVKIFMLLVVGITSGMWIWTSKTLQSWQQVCSRRLKKKSRRKPASVITSGGIYKKAQHPQKTHHGKYEIPAQSPTCV
T59702	DRUGINFO	D1ZG5E	OTSA-101-DTPA-90Y	Phase 1

T62047	TARGETID	T62047
T62047	UNIPROID	HBSAG_HBVD3
T62047	TARGNAME	Hepatitis B virus Large envelope protein (HBV S)
T62047	GENENAME	HBV S
T62047	TARGTYPE	Clinical trial
T62047	SYNONYMS	L glycoprotein; L-HBsAg; LHB; Large S protein; Large surface protein; Major surface antigen; L glycoprotein; L-HBsAg; LHB; Large S protein; Large surface protein; Major surface antigen
T62047	FUNCTION	The large envelope protein exists in two topological conformations, one which is termed 'external' or Le-HBsAg and the other 'internal' or Li-HBsAg. In its external conformation the protein attaches the virus to cell receptors and thereby initiating infection. This interaction determines the species specificity and liver tropism. This attachment induces virion internalization predominantly through caveolin-mediated endocytosis. The large envelope protein also assures fusion between virion membrane and endosomal membrane. In its internal conformation the protein plays a role in virion morphogenesis and mediates the contact with the nucleocapsid like a matrix protein.
T62047	BIOCLASS	Orthohepadnavirus major surface antigen
T62047	SEQUENCE	MGQNLSTSNPLGFFPDHQLDPAFRANTANPDWDFNPNKDTWPDANKVGAGAFGLGFTPPHGGLLGWSPQAQGILQTLPANPPPASTNRQSGRQPTPLSPPLRNTHPQAMQWNSTTFHQTLQDPRVRGLYFPAGGSSSGTVNPVLTTASPLSSIFSRIGDPALNMENITSGFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGTTVCLGQNSQSPTSNHSPTSCPPTCPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSSTTSTGPCRTCMTTAQGTSMYPSCCCTKPSDGNCTCIPIPSSWAFGKFLWEWASARFSWLSLLVPFVQWFVGLSPTVWLSVIWMMWYWGPSLYSILSPFLPLLPIFFCLWVYI
T62047	DRUGINFO	DQ1OJ4	VIR-2218	Phase 2

T65074	TARGETID	T65074
T65074	TARGNAME	microRNA hsa-miR-92 (MIR92)
T65074	TARGTYPE	Clinical trial
T65074	DRUGINFO	DBE87X	MRG-110	Phase 1

T65429	TARGETID	T65429
T65429	UNIPROID	GPR20_HUMAN
T65429	TARGNAME	G-protein coupled receptor 20 (GPR20)
T65429	GENENAME	GPR20
T65429	TARGTYPE	Clinical trial
T65429	FUNCTION	Orphan receptor with constitutive G(i) signaling activity that activate cyclic AMP.
T65429	BIOCLASS	G-protein coupled receptor 1 family
T65429	SEQUENCE	MPSVSPAGPSAGAVPNATAVTTVRTNASGLEVPLFHLFARLDEELHGTFPGLWLALMAVHGAIFLAGLVLNGLALYVFCCRTRAKTPSVIYTINLVVTDLLVGLSLPTRFAVYYGARGCLRCAFPHVLGYFLNMHCSILFLTCICVDRYLAIVRPEGSRRCRQPACARAVCAFVWLAAGAVTLSVLGVTGSRPCCRVFALTVLEFLLPLLVISVFTGRIMCALSRPGLLHQGRQRRVRAMQLLLTVLIIFLVCFTPFHARQVAVALWPDMPHHTSLVVYHVAVTLSSLNSCMDPIVYCFVTSGFQATVRGLFGQHGEREPSSGDVVSMHRSSKGSGRHHILSAGPHALTQALANGPEA
T65429	DRUGINFO	DJ4X7D	DS-6157	Phase 1

T65941	TARGETID	T65941
T65941	UNIPROID	A1AT_HUMAN
T65941	TARGNAME	SERPINA1 messenger RNA (SERPINA1 mRNA)
T65941	GENENAME	SERPINA1
T65941	TARGTYPE	Clinical trial
T65941	SYNONYMS	Alpha-1 protease inhibitor; Alpha-1-antiproteinase; Serpin A1
T65941	FUNCTION	Inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. Irreversibly inhibits trypsin, chymotrypsin and plasminogen activator. The aberrant form inhibits insulin-induced NO synthesis in platelets, decreases coagulation time and has proteolytic activity against insulin and plasmin.
T65941	BIOCLASS	mRNA target
T65941	SEQUENCE	MPSSVSWGILLLAGLCCLVPVSLAEDPQGDAAQKTDTSHHDQDHPTFNKITPNLAEFAFSLYRQLAHQSNSTNIFFSPVSIATAFAMLSLGTKADTHDEILEGLNFNLTEIPEAQIHEGFQELLRTLNQPDSQLQLTTGNGLFLSEGLKLVDKFLEDVKKLYHSEAFTVNFGDTEEAKKQINDYVEKGTQGKIVDLVKELDRDTVFALVNYIFFKGKWERPFEVKDTEEEDFHVDQVTTVKVPMMKRLGMFNIQHCKKLSSWVLLMKYLGNATAIFFLPDEGKLQHLENELTHDIITKFLENEDRRSASLHLPKLSITGTYDLKSVLGQLGITKVFSNGADLSGVTEEAPLKLSKAVHKAVLTIDEKGTEAAGAMFLEAIPMSIPPEVKFNKPFVFLMIEQNTKSPLFMGKVVNPTQK
T65941	DRUGINFO	DQ4FR9	Fazirsiran	Phase 3
T65941	DRUGINFO	DOE96M	Belcesiran	Phase 2
T65941	DRUGINFO	DR7EV6	ARO-AAT	Phase 2

T67089	TARGETID	T67089
T67089	UNIPROID	ANT3_HUMAN
T67089	TARGNAME	SERPINC1 messenger RNA (SERPINC1 mRNA)
T67089	GENENAME	SERPINC1
T67089	TARGTYPE	Clinical trial
T67089	SYNONYMS	ATIII; Serpin C1
T67089	FUNCTION	Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa. Its inhibitory activity is greatly enhanced in the presence of heparin.
T67089	BIOCLASS	mRNA target
T67089	SEQUENCE	MYSNVIGTVTSGKRKVYLLSLLLIGFWDCVTCHGSPVDICTAKPRDIPMNPMCIYRSPEKKATEDEGSEQKIPEATNRRVWELSKANSRFATTFYQHLADSKNDNDNIFLSPLSISTAFAMTKLGACNDTLQQLMEVFKFDTISEKTSDQIHFFFAKLNCRLYRKANKSSKLVSANRLFGDKSLTFNETYQDISELVYGAKLQPLDFKENAEQSRAAINKWVSNKTEGRITDVIPSEAINELTVLVLVNTIYFKGLWKSKFSPENTRKELFYKADGESCSASMMYQEGKFRYRRVAEGTQVLELPFKGDDITMVLILPKPEKSLAKVEKELTPEVLQEWLDELEEMMLVVHMPRFRIEDGFSLKEQLQDMGLVDLFSPEKSKLPGIVAEGRDDLYVSDAFHKAFLEVNEEGSEAAASTAVVIAGRSLNPNRVTFKANRPFLVFIREVPLNTIIFMGRVANPCVK
T67089	DRUGINFO	D46RKC	Fitusiran	Phase 3

T67908	TARGETID	T67908
T67908	TARGNAME	Globohexaosylceramide (Globo H)
T67908	TARGTYPE	Clinical trial
T67908	DRUGINFO	D2H6NI	OBI-999	Phase 1/2
T67908	DRUGINFO	D59OTG	OBI-888	Phase 1/2

T69823	TARGETID	T69823
T69823	UNIPROID	P53_HUMAN
T69823	TARGNAME	P53 Y220C mutant (TP53 Y220C)
T69823	GENENAME	TP53
T69823	TARGTYPE	Clinical trial
T69823	SEQUENCE	MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD
T69823	DRUGINFO	D53CGK	PC14586	Phase 1/2

T70134	TARGETID	T70134
T70134	UNIPROID	CI072_HUMAN
T70134	TARGNAME	C9orf72 messenger RNA (C9orf72 mRNA)
T70134	GENENAME	C9orf72
T70134	TARGTYPE	Clinical trial
T70134	FUNCTION	Component of the C9orf72-SMCR8 complex, a complex that has guanine nucleotide exchange factor (GEF) activity and regulates autophagy. In the complex, C9orf72 and SMCR8 probably constitute the catalytic subunits that promote the exchange of GDP to GTP, converting inactive GDP-bound RAB8A and RAB39B into their active GTP-bound form, thereby promoting autophagosome maturation. The C9orf72-SMCR8 complex also acts as a regulator of autophagy initiation by interacting with the ATG1/ULK1 kinase complex and modulating its protein kinase activity. Positively regulates initiation of autophagy by regulating the RAB1A-dependent trafficking of the ATG1/ULK1 kinase complex to the phagophore which leads to autophagosome formation. Acts as a regulator of mTORC1 signaling by promoting phosphorylation of mTORC1 substrates. Plays a role in endosomal trafficking. May be involved in regulating the maturation of phagosomes to lysosomes (By similarity). Regulates actin dynamics in motor neurons by inhibiting the GTP-binding activity of ARF6, leading to ARF6 inactivation. This reduces the activity of the LIMK1 and LIMK2 kinases which are responsible for phosphorylation and inactivation of cofilin, leading to cofilin activation. Positively regulates axon extension and axon growth cone size in spinal motor neurons. Plays a role within the hematopoietic system in restricting inflammation and the development of autoimmunity (By similarity).
T70134	BIOCLASS	mRNA target
T70134	SEQUENCE	MSTLCPPPSPAVAKTEIALSGKSPLLAATFAYWDNILGPRVRHIWAPKTEQVLLSDGEITFLANHTLNGEILRNAESGAIDVKFFVLSEKGVIIVSLIFDGNWNGDRSTYGLSIILPQTELSFYLPLHRVCVDRLTHIIRKGRIWMHKERQENVQKIILEGTERMEDQGQSIIPMLTGEVIPVMELLSSMKSHSVPEEIDIADTVLNDDDIGDSCHEGFLLNAISSHLQTCGCSVVVGSSAEKVNKIVRTLCLFLTPAERKCSRLCEAESSFKYESGLFVQGLLKDSTGSFVLPFRQVMYAPYPTTHIDVDVNTVKQMPPCHEHIYNQRRYMRSELTAFWRATSEEDMAQDTIIYTDESFTPDLNIFQDVLHRDTLVKAFLDQVFQLKPGLSLRSTFLAQFLLVLHRKALTLIKYIEDDTQKGKKPFKSLRNLKIDLDLTAEGDLNIIMALAEKIKPGLHSFIFGRPFYTSVQERDVLMTF
T70134	DRUGINFO	DQ7PB1	IONIS-C9Rx	Phase 2

T71039	TARGETID	T71039
T71039	TARGNAME	Carbohydrate antigen 19-9 (CA 19-9)
T71039	TARGTYPE	Clinical trial
T71039	DRUGINFO	D7AOL8	BNT321	Phase 2

T71369	TARGETID	T71369
T71369	UNIPROID	BC11A_HUMAN
T71369	TARGNAME	BCL11A messenger RNA (BCL11A mRNA)
T71369	GENENAME	BCL11A
T71369	TARGTYPE	Clinical trial
T71369	SYNONYMS	BCL-11A; B-cell CLL/lymphoma 11A; COUP-TF-interacting protein 1; Ecotropic viral integration site 9 protein homolog; EVI-9; Zinc finger protein 856; BCL-11A; B-cell CLL/lymphoma 11A; COUP-TF-interacting protein 1; Ecotropic viral integration site 9 protein homolog; EVI-9; Zinc finger protein 856
T71369	FUNCTION	Transcription factor associated with the BAF SWI/SNF chromatin remodeling complex (By similarity). Repressor of fetal hemoglobin (HbF) level. Involved in brain development. May play a role in hematopoiesis. Essential factor in lymphopoiesis required for B-cell formation in fetal liver. May function as a modulator of the transcriptional repression activity of ARP1 (By similarity).
T71369	BIOCLASS	mRNA target
T71369	SEQUENCE	MSRRKQGKPQHLSKREFSPEPLEAILTDDEPDHGPLGAPEGDHDLLTCGQCQMNFPLGDILIFIEHKRKQCNGSLCLEKAVDKPPSPSPIEMKKASNPVEVGIQVTPEDDDCLSTSSRGICPKQEHIADKLLHWRGLSSPRSAHGALIPTPGMSAEYAPQGICKDEPSSYTCTTCKQPFTSAWFLLQHAQNTHGLRIYLESEHGSPLTPRVGIPSGLGAECPSQPPLHGIHIADNNPFNLLRIPGSVSREASGLAEGRFPPTPPLFSPPPRHHLDPHRIERLGAEEMALATHHPSAFDRVLRLNPMAMEPPAMDFSRRLRELAGNTSSPPLSPGRPSPMQRLLQPFQPGSKPPFLATPPLPPLQSAPPPSQPPVKSKSCEFCGKTFKFQSNLVVHRRSHTGEKPYKCNLCDHACTQASKLKRHMKTHMHKSSPMTVKSDDGLSTASSPEPGTSDLVGSASSALKSVVAKFKSENDPNLIPENGDEEEEEDDEEEEEEEEEEEEELTESERVDYGFGLSLEAARHHENSSRGAVVGVGDESRALPDVMQGMVLSSMQHFSEAFHQVLGEKHKRGHLAEAEGHRDTCDEDSVAGESDRIDDGTVNGRGCSPGESASGGLSKKLLLGSPSSLSPFSKRIKLEKEFDLPPAAMPNTENVYSQWLAGYAASRQLKDPFLSFGDSRQSPFASSSEHSSENGSLRFSTPPGELDGGISGRSGTGSGGSTPHISGPGPGRPSSKEGRRSDTCEYCGKVFKNCSNLTVHRRSHTGERPYKCELCNYACAQSSKLTRHMKTHGQVGKDVYKCEICKMPFSVYSTLEKHMKKWHSDRVLNNDIKTE
T71369	DRUGINFO	D95GKC	BCL11a shRNA	Phase 1

T72514	TARGETID	T72514
T72514	UNIPROID	IL36G_HUMAN
T72514	TARGNAME	Interleukin-36 gamma (IL36G)
T72514	GENENAME	IL36G
T72514	TARGTYPE	Clinical trial
T72514	SYNONYMS	IL-1-related protein 2; IL-1RP2; Interleukin-1 epsilon; IL-1 epsilon; Interleukin-1 family member 9; IL-1F9; Interleukin-1 homolog 1; IL-1H1
T72514	FUNCTION	Cytokine that binds to and signals through the IL1RL2/IL-36R receptor which in turn activates NF-kappa-B and MAPK signaling pathways in target cells. Part of the IL-36 signaling system that is thought to be present in epithelial barriers and to take part in local inflammatory response; similar to the IL-1 system with which it shares the coreceptor IL1RAP. Seems to be involved in skin inflammatory response by acting on keratinocytes, dendritic cells and indirectly on T-cells to drive tissue infiltration, cell maturation and cell proliferation. In cultured keratinocytes induces the expression of macrophage, T-cell, and neutrophil chemokines, such as CCL3, CCL4, CCL5, CCL2, CCL17, CCL22, CL20, CCL5, CCL2, CCL17, CCL22, CXCL8, CCL20 and CXCL1; also stimulates its own expression and that of the prototypic cutaneous proinflammatory parameters TNF-alpha, S100A7/psoriasin and inducible NOS. May play a role in proinflammatory responses during particular neutrophilic airway inflammation: activates mitogen-activated protein kinases and NF-kappa B in primary lung fibroblasts, and stimulates the expression of IL-8 and CXCL3 and Th17 chemokine CCL20 in lung fibroblasts. May be involved in the innate immune response to fungal pathogens, such as Aspergillus fumigatus.
T72514	SEQUENCE	MRGTPGDADGGGRAVYQSMCKPITGTINDLNQQVWTLQGQNLVAVPRSDSVTPVTVAVITCKYPEALEQGRGDPIYLGIQNPEMCLYCEKVGEQPTLQLKEQKIMDLYGQPEPVKPFLFYRAKTGRTSTLESVAFPDWFIASSKRDQPIILTSELGKSYNTAFELNIND
T72514	DRUGINFO	DC5A9Q	mRNA-2752	Phase 1

T73019	TARGETID	T73019
T73019	UNIPROID	PDE7A_HUMAN; PDE7B_HUMAN
T73019	TARGNAME	Phosphodiesterase 7 (PDE7)
T73019	TARGTYPE	Clinical trial
T73019	DRUGINFO	DH1OY4	OMS527	Phase 1

T79051	TARGETID	T79051
T79051	UNIPROID	EWS_HUMAN-FLI1_HUMAN
T79051	TARGNAME	EWS-FLI1 fusion gene mRNA (EWS-FLI1 mRNA)
T79051	GENENAME	EWS-FLI1
T79051	TARGTYPE	Clinical trial
T79051	BIOCLASS	mRNA target
T79051	DRUGINFO	D31ZLD	pbi-shRNA EWS-FLI-Type 1	Phase 1

T79368	TARGETID	T79368
T79368	UNIPROID	CEBPA_HUMAN
T79368	TARGNAME	CEBPA messenger RNA (CEBPA mRNA)
T79368	GENENAME	CEBPA
T79368	TARGTYPE	Clinical trial
T79368	SYNONYMS	C/EBP alpha
T79368	FUNCTION	Transcription factor that coordinates proliferation arrest and the differentiation of myeloid progenitors, adipocytes, hepatocytes, and cells of the lung and the placenta. Binds directly to the consensus DNA sequence 5'-T[TG]NNGNAA[TG]-3' acting as an activator on distinct target genes. During early embryogenesis, plays essential and redundant functions with CEBPB. Essential for the transition from common myeloid progenitors (CMP) to granulocyte/monocyte progenitors (GMP). Critical for the proper development of the liver and the lung (By similarity). Necessary for terminal adipocyte differentiation, is required for postnatal maintenance of systemic energy homeostasis and lipid storage (By similarity). To regulate these different processes at the proper moment and tissue, interplays with other transcription factors and modulators. Downregulates the expression of genes that maintain cells in an undifferentiated and proliferative state through E2F1 repression, which is critical for its ability to induce adipocyte and granulocyte terminal differentiation. Reciprocally E2F1 blocks adipocyte differentiation by binding to specific promoters and repressing CEBPA binding to its target gene promoters. Proliferation arrest also depends on a functional binding to SWI/SNF complex. In liver, regulates gluconeogenesis and lipogenesis through different mechanisms. To regulate gluconeogenesis, functionally cooperates with FOXO1 binding to IRE-controlled promoters and regulating the expression of target genes such as PCK1 or G6PC1. To modulate lipogenesis, interacts and transcriptionally synergizes with SREBF1 in promoter activation of specific lipogenic target genes such as ACAS2. In adipose tissue, seems to act as FOXO1 coactivator accessing to ADIPOQ promoter through FOXO1 binding sites (By similarity).
T79368	BIOCLASS	mRNA target
T79368	SEQUENCE	MESADFYEAEPRPPMSSHLQSPPHAPSSAAFGFPRGAGPAQPPAPPAAPEPLGGICEHETSIDISAYIDPAAFNDEFLADLFQHSRQQEKAKAAVGPTGGGGGGDFDYPGAPAGPGGAVMPGGAHGPPPGYGCAAAGYLDGRLEPLYERVGAPALRPLVIKQEPREEDEAKQLALAGLFPYQPPPPPPPSHPHPHPPPAHLAAPHLQFQIAHCGQTTMHLQPGHPTPPPTPVPSPHPAPALGAAGLPGPGSALKGLGAAHPDLRASGGSGAGKAKKSVDKNSNEYRVRRERNNIAVRKSRDKAKQRNVETQQKVLELTSDNDRLRKRVEQLSRELDTLRGIFRQLPESSLVKAMGNCA
T79368	DRUGINFO	DA01IB	MTL-CEPBA	Phase 1/2

T81569	TARGETID	T81569
T81569	UNIPROID	IKZF2_HUMAN
T81569	TARGNAME	Zinc finger protein Helios (IKZF2)
T81569	GENENAME	IKZF2
T81569	TARGTYPE	Clinical trial
T81569	SYNONYMS	Ikaros family zinc finger protein 2
T81569	FUNCTION	Associates with Ikaros at centromeric heterochromatin.
T81569	SEQUENCE	METEAIDGYITCDNELSPEREHSNMAIDLTSSTPNGQHASPSHMTSTNSVKLEMQSDEECDRKPLSREDEIRGHDEGSSLEEPLIESSEVADNRKVQELQGEGGIRLPNGKLKCDVCGMVCIGPNVLMVHKRSHTGERPFHCNQCGASFTQKGNLLRHIKLHSGEKPFKCPFCSYACRRRDALTGHLRTHSVGKPHKCNYCGRSYKQRSSLEEHKERCHNYLQNVSMEAAGQVMSHHVPPMEDCKEQEPIMDNNISLVPFERPAVIEKLTGNMGKRKSSTPQKFVGEKLMRFSYPDIHFDMNLTYEKEAELMQSHMMDQAINNAITYLGAEALHPLMQHPPSTIAEVAPVISSAYSQVYHPNRIERPISRETADSHENNMDGPISLIRPKSRPQEREASPSNSCLDSTDSESSHDDHQSYQGHPALNPKRKQSPAYMKEDVKALDTTKAPKGSLKDIYKVFNGEGEQIRAFKCEHCRVLFLDHVMYTIHMGCHGYRDPLECNICGYRSQDRYEFSSHIVRGEHTFH
T81569	DRUGINFO	DG9LF8	DKY709	Phase 1

T82105	TARGETID	T82105
T82105	UNIPROID	CEAM1_HUMAN
T82105	TARGNAME	Biliary glycoprotein 1 (CEACAM1)
T82105	GENENAME	CEACAM1
T82105	TARGTYPE	Clinical trial
T82105	SYNONYMS	Biliary glycoprotein 1; BGP-1; DE   AltName: CD_antigen=CD66a
T82105	FUNCTION	Cell adhesion protein that mediates homophilic cell adhesion in a calcium-independent manner (By similarity). Plays a role as coinhibitory receptor in immune response, insulin action and functions also as an activator during angiogenesis. Its coinhibitory receptor function is phosphorylation- and PTPN6 -dependent, which in turn, suppress signal transduction of associated receptors by dephosphorylation of their downstream effectors. Plays a role in immune response, of T cells, natural killer (NK) and neutrophils. Upon TCR/CD3 complex stimulation, inhibits TCR-mediated cytotoxicity by blocking granule exocytosis by mediating homophilic binding to adjacent cells, allowing interaction with and phosphorylation by LCK and interaction with the TCR/CD3 complex which recruits PTPN6 resulting in dephosphorylation of CD247 and ZAP70. Also inhibits T cell proliferation and cytokine production through inhibition of JNK cascade and plays a crucial role in regulating autoimmunity and anti-tumor immunity by inhibiting T cell through its interaction with HAVCR2. Upon natural killer (NK) cells activation, inhibit KLRK1-mediated cytolysis of CEACAM1-bearing tumor cells by trans-homophilic interactions with CEACAM1 on the target cell and lead to cis-interaction between CEACAM1 and KLRK1, allowing PTPN6 recruitment and then VAV1 dephosphorylation. Upon neutrophils activation negatively regulates IL1B production by recruiting PTPN6 to a SYK-TLR4-CEACAM1 complex, that dephosphorylates SYK, reducing the production of reactive oxygen species (ROS) and lysosome disruption, which in turn, reduces the activity of the inflammasome. Downregulates neutrophil production by acting as a coinhibitory receptor for CSF3R by downregulating the CSF3R-STAT3 pathway through recruitment of PTPN6 that dephosphorylates CSF3R (By similarity). Also regulates insulin action by promoting INS clearance and regulating lipogenesis in liver through regulating insulin signaling (By similarity). Upon INS stimulation, undergoes phosphorylation by INSR leading to INS clearance by increasing receptor-mediated insulin endocytosis. This inernalization promotes interaction with FASN leading to receptor-mediated insulin degradation and to reduction of FASN activity leading to negative regulation of fatty acid synthesis. INSR-mediated phosphorylation also provokes a down-regulation of cell proliferation through SHC1 interaction resulting in decrease coupling of SHC1 to the MAPK3/ERK1-MAPK1/ERK2 and phosphatidylinositol 3-kinase pathways (By similarity). Functions as activator in angiogenesis by promoting blood vessel remodeling through endothelial cell differentiation and migration and in arteriogenesis by increasing the number of collateral arteries and collateral vessel calibers after ischemia. Also regulates vascular permeability through the VEGFR2 signaling pathway resulting in control of nitric oxide production (By similarity). Downregulates cell growth in response to EGF through its interaction with SHC1 that mediates interaction with EGFR resulting in decrease coupling of SHC1 to the MAPK3/ERK1-MAPK1/ERK2 pathway (By similarity). Negatively regulates platelet aggregation by decreasing platelet adhesion on type I collagen through the GPVI-FcRgamma complex (By similarity). Inhibits cell migration and cell scattering through interaction with FLNA; interfers with the interaction of FLNA with RALA. Mediates bile acid transport activity in a phosphorylation dependent manner (By similarity). Negatively regulates osteoclastogenesis (By similarity).
T82105	SEQUENCE	MGHLSAPLHRVRVPWQGLLLTASLLTFWNPPTTAQLTTESMPFNVAEGKEVLLLVHNLPQQLFGYSWYKGERVDGNRQIVGYAIGTQQATPGPANSGRETIYPNASLLIQNVTQNDTGFYTLQVIKSDLVNEEATGQFHVYPELPKPSISSNNSNPVEDKDAVAFTCEPETQDTTYLWWINNQSLPVSPRLQLSNGNRTLTLLSVTRNDTGPYECEIQNPVSANRSDPVTLNVTYGPDTPTISPSDTYYRPGANLSLSCYAASNPPAQYSWLINGTFQQSTQELFIPNITVNNSGSYTCHANNSVTGCNRTTVKTIIVTELSPVVAKPQIKASKTTVTGDKDSVNLTCSTNDTGISIRWFFKNQSLPSSERMKLSQGNTTLSINPVKREDAGTYWCEVFNPISKNQSDPIMLNVNYNALPQENGLSPGAIAGIVIGVVALVALIAVALACFLHFGKTGRASDQRDLTEHKPSVSNHTQDHSNDPPNKMNEVTYSTLNFEAQQPTQPTSASPSLTATEIIYSEVKKQ
T82105	DRUGINFO	DR5F9A	CM24	Phase 1/2
T82105	DRUGINFO	D7K5XP	NEO-201	Phase 1

T82463	TARGETID	T82463
T82463	TARGNAME	Cocaine (Coca)
T82463	TARGTYPE	Clinical trial
T82463	DRUGINFO	DS79KP	TNX-1300	Phase 2

T82943	TARGETID	T82943
T82943	TARGNAME	microRNA hsa-miR-17 (MIR17)
T82943	TARGTYPE	Clinical trial
T82943	DRUGINFO	D8XK7F	RGLS4326	Phase 1

T85042	TARGETID	T85042
T85042	UNIPROID	PPARA_HUMAN; PPARD_HUMAN; PPARG_HUMAN
T85042	TARGNAME	Peroxisome proliferator-activated receptor (PPAR)
T85042	TARGTYPE	Clinical trial
T85042	DRUGINFO	D39PWR	A278	IND submitted
T85042	DRUGINFO	DX6RV3	IVA337	Phase 2
T85042	DRUGINFO	DMBQ10	ABTL0812	Phase 1/2

T85076	TARGETID	T85076
T85076	UNIPROID	CBLB_HUMAN
T85076	TARGNAME	CBLB messenger RNA (CBLB mRNA)
T85076	GENENAME	CBLB
T85076	TARGTYPE	Clinical trial
T85076	SYNONYMS	Casitas B-lineage lymphoma proto-oncogene b; RING finger protein 56; RING-type E3 ubiquitin transferase CBL-B; SH3-binding protein CBL-B; Signal transduction protein CBL-B
T85076	FUNCTION	E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. Negatively regulates TCR (T-cell receptor), BCR (B-cell receptor) and FCER1 (high affinity immunoglobulin epsilon receptor) signal transduction pathways. In naive T-cells, inhibits VAV1 activation upon TCR engagement and imposes a requirement for CD28 costimulation for proliferation and IL-2 production. Also acts by promoting PIK3R1/p85 ubiquitination, which impairs its recruitment to the TCR and subsequent activation. In activated T-cells, inhibits PLCG1 activation and calcium mobilization upon restimulation and promotes anergy. In B-cells, acts by ubiquitinating SYK and promoting its proteasomal degradation. Slightly promotes SRC ubiquitination. May be involved in EGFR ubiquitination and internalization. May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3. In association with CBL, required for proper feedback inhibition of ciliary platelet-derived growth factor receptor-alpha (PDGFRA) signaling pathway via ubiquitination and internalization of PDGFRA (By similarity).
T85076	BIOCLASS	mRNA target
T85076	ECNUMBER	EC 2.3.2.27
T85076	SEQUENCE	MANSMNGRNPGGRGGNPRKGRILGIIDAIQDAVGPPKQAAADRRTVEKTWKLMDKVVRLCQNPKLQLKNSPPYILDILPDTYQHLRLILSKYDDNQKLAQLSENEYFKIYIDSLMKKSKRAIRLFKEGKERMYEEQSQDRRNLTKLSLIFSHMLAEIKAIFPNGQFQGDNFRITKADAAEFWRKFFGDKTIVPWKVFRQCLHEVHQISSGLEAMALKSTIDLTCNDYISVFEFDIFTRLFQPWGSILRNWNFLAVTHPGYMAFLTYDEVKARLQKYSTKPGSYIFRLSCTRLGQWAIGYVTGDGNILQTIPHNKPLFQALIDGSREGFYLYPDGRSYNPDLTGLCEPTPHDHIKVTQEQYELYCEMGSTFQLCKICAENDKDVKIEPCGHLMCTSCLTAWQESDGQGCPFCRCEIKGTEPIIVDPFDPRDEGSRCCSIIDPFGMPMLDLDDDDDREESLMMNRLANVRKCTDRQNSPVTSPGSSPLAQRRKPQPDPLQIPHLSLPPVPPRLDLIQKGIVRSPCGSPTGSPKSSPCMVRKQDKPLPAPPPPLRDPPPPPPERPPPIPPDNRLSRHIHHVESVPSRDPPMPLEAWCPRDVFGTNQLVGCRLLGEGSPKPGITASSNVNGRHSRVGSDPVLMRKHRRHDLPLEGAKVFSNGHLGSEEYDVPPRLSPPPPVTTLLPSIKCTGPLANSLSEKTRDPVEEDDDEYKIPSSHPVSLNSQPSHCHNVKPPVRSCDNGHCMLNGTHGPSSEKKSNIPDLSIYLKGDVFDSASDPVPLPPARPPTRDNPKHGSSLNRTPSDYDLLIPPLGEDAFDALPPSLPPPPPPARHSLIEHSKPPGSSSRPSSGQDLFLLPSDPFVDLASGQVPLPPARRLPGENVKTNRTSQDYDQLPSCSDGSQAPARPPKPRPRRTAPEIHHRKPHGPEAALENVDAKIAKLMGEGYAFEEVKRALEIAQNNVEVARSILREFAFPPPVSPRLNL
T85076	DRUGINFO	D1RIW2	APN401	Phase 2

T85426	TARGETID	T85426
T85426	UNIPROID	CAPSD_HBVD3
T85426	TARGNAME	Hepatitis B virus Capsid protein (HBV C)
T85426	GENENAME	HBV C
T85426	TARGTYPE	Clinical trial
T85426	SYNONYMS	Core antigen; Core protein; HBcAg; p21.5
T85426	FUNCTION	Self assembles to form an icosahedral capsid. Most capsid appear to be large particles with an icosahedral symmetry of T=4 and consist of 240 copies of capsid protein, though a fraction forms smaller T=3 particles consisting of 180 capsid proteins. Entering capsid are transported along microtubules to the nucleus. Phosphorylation of the capsid is thought to induce exposure of nuclear localization signal in the C-terminal portion of the capsid protein that allows binding to the nuclear pore complex via the importin (karyopherin-) alpha and beta. Capsids are imported in intact form through the nuclear pore into the nuclear basket, where it probably binds NUP153. Only capsids that contain the mature viral genome can release the viral DNA and capsid protein into the nucleoplasm. Immature capsids get stucked in the basket. Capsids encapsulate the pre-genomic RNA and the P protein. Pre-genomic RNA is reverse transcribed into DNA while the capsid is still in the cytoplasm. The capsid can then either be directed to the nucleus, providing more genome for transcription, or bud through the endoplasmic reticulum to provide new virions.
T85426	SEQUENCE	MDIDPYKEFGATVELLSFLPSDFFPSVRDLLDTASALYREALESPEHCSPHHTALRQAILCWGELMTLATWVGVNLEDPASRDLVVSYVNTNMGLKFRQLLWFHISCLTFGRETVIEYLVSFGVWIRTPPAYRPPNAPILSTLPETTVVRRRGRSPRRRTPSPRRRRSQSPRRRRSQSRESQC
T85426	DRUGINFO	D1X2VT	JNJ-56136379	Phase 2
T85426	DRUGINFO	D6DPI4	ABI-H2158	Phase 2
T85426	DRUGINFO	DHY3Q9	ABI-H0731	Phase 2
T85426	DRUGINFO	D49YEO	ABI-H3733	Phase 1
T85426	DRUGINFO	DDY51F	EDP-514	Phase 1
T85426	DRUGINFO	DTOM05	A204	Phase 1
T85426	DRUGINFO	DW5Z1R	RG7907	Phase 1
T85426	DRUGINFO	DWX4A0	ZM-H1505R	Phase 1

T86072	TARGETID	T86072
T86072	UNIPROID	LRP5_HUMAN
T86072	TARGNAME	Low-density lipoprotein receptor-related protein 5 (LRP5)
T86072	GENENAME	LRP5
T86072	TARGTYPE	Clinical trial
T86072	SYNONYMS	LRP-5; Low-density lipoprotein receptor-related protein 7; LRP-7
T86072	FUNCTION	Acts as a coreceptor with members of the frizzled family of seven-transmembrane spanning receptors to transduce signal by Wnt proteins. Activates the canonical Wnt signaling pathway that controls cell fate determination and self-renewal during embryonic development and adult tissue regeneration. In particular, may play an important role in the development of the posterior patterning of the epiblast during gastrulation (By similarity). During bone development, regulates osteoblast proliferation and differentiation thus determining bone mass. Mechanistically, the formation of the signaling complex between Wnt ligand, frizzled receptor and LRP5 coreceptor promotes the recruitment of AXIN1 to LRP5, stabilizing beta-catenin/CTNNB1 and activating TCF/LEF-mediated transcriptional programs. Acts as a coreceptor for non-Wnt proteins, such as norrin/NDP. Binding of norrin/NDP to frizzled 4/FZD4-LRP5 receptor complex triggers beta-catenin/CTNNB1-dependent signaling known to be required for retinal vascular development. Plays a role in controlling postnatal vascular regression in retina via macrophage-induced endothelial cell apoptosis (By similarity).
T86072	SEQUENCE	MEAAPPGPPWPLLLLLLLLLALCGCPAPAAASPLLLFANRRDVRLVDAGGVKLESTIVVSGLEDAAAVDFQFSKGAVYWTDVSEEAIKQTYLNQTGAAVQNVVISGLVSPDGLACDWVGKKLYWTDSETNRIEVANLNGTSRKVLFWQDLDQPRAIALDPAHGYMYWTDWGETPRIERAGMDGSTRKIIVDSDIYWPNGLTIDLEEQKLYWADAKLSFIHRANLDGSFRQKVVEGSLTHPFALTLSGDTLYWTDWQTRSIHACNKRTGGKRKEILSALYSPMDIQVLSQERQPFFHTRCEEDNGGCSHLCLLSPSEPFYTCACPTGVQLQDNGRTCKAGAEEVLLLARRTDLRRISLDTPDFTDIVLQVDDIRHAIAIDYDPLEGYVYWTDDEVRAIRRAYLDGSGAQTLVNTEINDPDGIAVDWVARNLYWTDTGTDRIEVTRLNGTSRKILVSEDLDEPRAIALHPVMGLMYWTDWGENPKIECANLDGQERRVLVNASLGWPNGLALDLQEGKLYWGDAKTDKIEVINVDGTKRRTLLEDKLPHIFGFTLLGDFIYWTDWQRRSIERVHKVKASRDVIIDQLPDLMGLKAVNVAKVVGTNPCADRNGGCSHLCFFTPHATRCGCPIGLELLSDMKTCIVPEAFLVFTSRAAIHRISLETNNNDVAIPLTGVKEASALDFDVSNNHIYWTDVSLKTISRAFMNGSSVEHVVEFGLDYPEGMAVDWMGKNLYWADTGTNRIEVARLDGQFRQVLVWRDLDNPRSLALDPTKGYIYWTEWGGKPRIVRAFMDGTNCMTLVDKVGRANDLTIDYADQRLYWTDLDTNMIESSNMLGQERVVIADDLPHPFGLTQYSDYIYWTDWNLHSIERADKTSGRNRTLIQGHLDFVMDILVFHSSRQDGLNDCMHNNGQCGQLCLAIPGGHRCGCASHYTLDPSSRNCSPPTTFLLFSQKSAISRMIPDDQHSPDLILPLHGLRNVKAIDYDPLDKFIYWVDGRQNIKRAKDDGTQPFVLTSLSQGQNPDRQPHDLSIDIYSRTLFWTCEATNTINVHRLSGEAMGVVLRGDRDKPRAIVVNAERGYLYFTNMQDRAAKIERAALDGTEREVLFTTGLIRPVALVVDNTLGKLFWVDADLKRIESCDLSGANRLTLEDANIVQPLGLTILGKHLYWIDRQQQMIERVEKTTGDKRTRIQGRVAHLTGIHAVEEVSLEEFSAHPCARDNGGCSHICIAKGDGTPRCSCPVHLVLLQNLLTCGEPPTCSPDQFACATGEIDCIPGAWRCDGFPECDDQSDEEGCPVCSAAQFPCARGQCVDLRLRCDGEADCQDRSDEADCDAICLPNQFRCASGQCVLIKQQCDSFPDCIDGSDELMCEITKPPSDDSPAHSSAIGPVIGIILSLFVMGGVYFVCQRVVCQRYAGANGPFPHEYVSGTPHVPLNFIAPGGSQHGPFTGIACGKSMMSSVSLMGGRGGVPLYDRNHVTGASSSSSSSTKATLYPPILNPPPSPATDPSLYNMDMFYSSNIPATARPYRPYIIRGMAPPTTPCSTDVCDSDYSASRWKASKYYLDLNSDSDPYPPPPTPHSQYLSAEDSCPPSPATERSYFHLFPPPPSPCTDSS
T86072	DRUGINFO	D9DQ1I	BI 905681	Phase 1
T86072	DRUGINFO	DTB43H	BI 905677	Phase 1

T86321	TARGETID	T86321
T86321	UNIPROID	SULF2_HUMAN
T86321	TARGNAME	Extracellular sulfatase Sulf-2 (SULF2)
T86321	GENENAME	SULF2
T86321	TARGTYPE	Clinical trial
T86321	SYNONYMS	hSulf-2
T86321	FUNCTION	Exhibits arylsulfatase activity and highly specific endoglucosamine-6-sulfatase activity. It can remove sulfate from the C-6 position of glucosamine within specific subregions of intact heparin.
T86321	ECNUMBER	EC 3.1.6.-
T86321	SEQUENCE	MGPPSLVLCLLSATVFSLLGGSSAFLSHHRLKGRFQRDRRNIRPNIILVLTDDQDVELGSMQVMNKTRRIMEQGGAHFINAFVTTPMCCPSRSSILTGKYVHNHNTYTNNENCSSPSWQAQHESRTFAVYLNSTGYRTAFFGKYLNEYNGSYVPPGWKEWVGLLKNSRFYNYTLCRNGVKEKHGSDYSKDYLTDLITNDSVSFFRTSKKMYPHRPVLMVISHAAPHGPEDSAPQYSRLFPNASQHITPSYNYAPNPDKHWIMRYTGPMKPIHMEFTNMLQRKRLQTLMSVDDSMETIYNMLVETGELDNTYIVYTADHGYHIGQFGLVKGKSMPYEFDIRVPFYVRGPNVEAGCLNPHIVLNIDLAPTILDIAGLDIPADMDGKSILKLLDTERPVNRFHLKKKMRVWRDSFLVERGKLLHKRDNDKVDAQEENFLPKYQRVKDLCQRAEYQTACEQLGQKWQCVEDATGKLKLHKCKGPMRLGGSRALSNLVPKYYGQGSEACTCDSGDYKLSLAGRRKKLFKKKYKASYVRSRSIRSVAIEVDGRVYHVGLGDAAQPRNLTKRHWPGAPEDQDDKDGGDFSGTGGLPDYSAANPIKVTHRCYILENDTVQCDLDLYKSLQAWKDHKLHIDHEIETLQNKIKNLREVRGHLKKKRPEECDCHKISYHTQHKGRLKHRGSSLHPFRKGLQEKDKVWLLREQKRKKKLRKLLKRLQNNDTCSMPGLTCFTHDNQHWQTAPFWTLGPFCACTSANNNTYWCMRTINETHNFLFCEFATGFLEYFDLNTDPYQLMNAVNTLDRDVLNQLHVQLMELRSCKGYKQCNPRTRNMDLGLKDGGSYEQYRQFQRRKWPEMKRPSSKSLGQLWEGWEG
T86321	DRUGINFO	D7M3JN	Disufenton	Phase 2

T89176	TARGETID	T89176
T89176	UNIPROID	GYRA_CLOAB; GYRB_CLOAB
T89176	TARGNAME	Clostridium difficile DNA gyrase (CD gyr)
T89176	GENENAME	CD gyrA; CD gyrB
T89176	TARGTYPE	Clinical trial
T89176	DRUGINFO	DWJ3A7	DS-2969	Phase 1

T89234	TARGETID	T89234
T89234	UNIPROID	CO5_HUMAN
T89234	TARGNAME	C5 messenger RNA (C5 mRNA)
T89234	GENENAME	C5
T89234	TARGTYPE	Clinical trial
T89234	SYNONYMS	C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4
T89234	FUNCTION	Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.
T89234	BIOCLASS	mRNA target
T89234	SEQUENCE	MGLLGILCFLIFLGKTWGQEQTYVISAPKIFRVGASENIVIQVYGYTEAFDATISIKSYPDKKFSYSSGHVHLSSENKFQNSAILTIQPKQLPGGQNPVSYVYLEVVSKHFSKSKRMPITYDNGFLFIHTDKPVYTPDQSVKVRVYSLNDDLKPAKRETVLTFIDPEGSEVDMVEEIDHIGIISFPDFKIPSNPRYGMWTIKAKYKEDFSTTGTAYFEVKEYVLPHFSVSIEPEYNFIGYKNFKNFEITIKARYFYNKVVTEADVYITFGIREDLKDDQKEMMQTAMQNTMLINGIAQVTFDSETAVKELSYYSLEDLNNKYLYIAVTVIESTGGFSEEAEIPGIKYVLSPYKLNLVATPLFLKPGIPYPIKVQVKDSLDQLVGGVPVTLNAQTIDVNQETSDLDPSKSVTRVDDGVASFVLNLPSGVTVLEFNVKTDAPDLPEENQAREGYRAIAYSSLSQSYLYIDWTDNHKALLVGEHLNIIVTPKSPYIDKITHYNYLILSKGKIIHFGTREKFSDASYQSINIPVTQNMVPSSRLLVYYIVTGEQTAELVSDSVWLNIEEKCGNQLQVHLSPDADAYSPGQTVSLNMATGMDSWVALAAVDSAVYGVQRGAKKPLERVFQFLEKSDLGCGAGGGLNNANVFHLAGLTFLTNANADDSQENDEPCKEILRPRRTLQKKIEEIAAKYKHSVVKKCCYDGACVNNDETCEQRAARISLGPRCIKAFTECCVVASQLRANISHKDMQLGRLHMKTLLPVSKPEIRSYFPESWLWEVHLVPRRKQLQFALPDSLTTWEIQGVGISNTGICVADTVKAKVFKDVFLEMNIPYSVVRGEQIQLKGTVYNYRTSGMQFCVKMSAVEGICTSESPVIDHQGTKSSKCVRQKVEGSSSHLVTFTVLPLEIGLHNINFSLETWFGKEILVKTLRVVPEGVKRESYSGVTLDPRGIYGTISRRKEFPYRIPLDLVPKTEIKRILSVKGLLVGEILSAVLSQEGINILTHLPKGSAEAELMSVVPVFYVFHYLETGNHWNIFHSDPLIEKQKLKKKLKEGMLSIMSYRNADYSYSVWKGGSASTWLTAFALRVLGQVNKYVEQNQNSICNSLLWLVENYQLDNGSFKENSQYQPIKLQGTLPVEARENSLYLTAFTVIGIRKAFDICPLVKIDTALIKADNFLLENTLPAQSTFTLAISAYALSLGDKTHPQFRSIVSALKREALVKGNPPIYRFWKDNLQHKDSSVPNTGTARMVETTAYALLTSLNLKDINYVNPVIKWLSEEQRYGGGFYSTQDTINAIEGLTEYSLLVKQLRLSMDIDVSYKHKGALHNYKMTDKNFLGRPVEVLLNDDLIVSTGFGSGLATVHVTTVVHKTSTSEEVCSFYLKIDTQDIEASHYRGYGNSDYKRIVACASYKPSREESSSGSSHAVMDISLPTGISANEEDLKALVEGVDQLFTDYQIKDGHVILQLNSIPSSDFLCVRFRIFELFEVGFLSPATFTVYEYHRPDKQCTMFYSTSNIKIQKVCEGAACKCVEADCGQMQEELDLTISAETRKQTACKPEIAYAYKVSITSITVENVFVKYKATLLDIYKTGEAVAEKDSEITFIKKVTCTNAELVKGRQYLIMGKEALQIKYNFSFRYIYPLDSLTWIEYWPRDTTCSSCQAFLANLDEFAEDIFLNGC
T89234	DRUGINFO	D3J9XC	Cemdisiran	Phase 2
T89234	DRUGINFO	DHTN76	ALN-CC5	Phase 2

T89251	TARGETID	T89251
T89251	UNIPROID	BAX_HUMAN
T89251	TARGNAME	Apoptosis regulator BAX (BAX)
T89251	GENENAME	BAX
T89251	TARGTYPE	Clinical trial
T89251	SYNONYMS	Bcl-2-like protein 4; Bcl2-L-4
T89251	FUNCTION	Plays a role in the mitochondrial apoptotic process. Under normal conditions, BAX is largely cytosolic via constant retrotranslocation from mitochondria to the cytosol mediated by BCL2L1/Bcl-xL, which avoids accumulation of toxic BAX levels at the mitochondrial outer membrane (MOM). Under stress conditions, undergoes a conformation change that causes translocation to the mitochondrion membrane, leading to the release of cytochrome c that then triggers apoptosis. Promotes activation of CASP3, and thereby apoptosis.
T89251	SEQUENCE	MDGSGEQPRGGGPTSSEQIMKTGALLLQGFIQDRAGRMGGEAPELALDPVPQDASTKKLSECLKRIGDELDSNMELQRMIAAVDTDSPREVFFRVAADMFSDGNFNWGRVVALFYFASKLVLKALCTKVPELIRTIMGWTLDFLRERLLGWIQDQGGWDGLLSYFGTPTWQTVTIFVAGVLTASLTIWKKMG
T89251	DRUGINFO	DY4OZ6	Thymoquinone	Phase 2/3

T90457	TARGETID	T90457
T90457	UNIPROID	PD1L1_HUMAN
T90457	TARGNAME	CD274 messenger RNA (CD274 mRNA)
T90457	GENENAME	CD274
T90457	TARGTYPE	Clinical trial
T90457	SYNONYMS	PD-L1; PDCD1 ligand 1; Programmed death ligand 1; hPD-L1; B7 homolog 1; B7-H1; DE   AltName: CD_antigen=CD274
T90457	FUNCTION	Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10).
T90457	BIOCLASS	mRNA target
T90457	SEQUENCE	MRIFAVFIFMTYWHLLNAFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERTHLVILGAILLCLGVALTFIFRLRKGRMMDVKKCGIQDTNSKKQSDTHLEET
T90457	DRUGINFO	DJX7K9	RG6084	Phase 1

T90628	TARGETID	T90628
T90628	UNIPROID	RAE1_HUMAN
T90628	TARGNAME	Rab proteins geranylgeranyltransferase component A 1 (CHM)
T90628	GENENAME	CHM
T90628	TARGTYPE	Clinical trial
T90628	SYNONYMS	Choroideremia protein; Rab escort protein 1; REP-1; TCD protein
T90628	FUNCTION	Substrate-binding subunit of the Rab geranylgeranyltransferase (GGTase) complex. Binds unprenylated Rab proteins and presents the substrate peptide to the catalytic component B composed of RABGGTA and RABGGTB, and remains bound to it after the geranylgeranyl transfer reaction. The component A is thought to be regenerated by transferring its prenylated Rab back to the donor membrane. Besides, a pre-formed complex consisting of CHM and the Rab GGTase dimer (RGGT or component B) can bind to and prenylate Rab proteins; this alternative pathway is proposed to be the predominant pathway for Rab protein geranylgeranylation.
T90628	SEQUENCE	MADTLPSEFDVIVIGTGLPESIIAAACSRSGRRVLHVDSRSYYGGNWASFSFSGLLSWLKEYQENSDIVSDSPVWQDQILENEEAIALSRKDKTIQHVEVFCYASQDLHEDVEEAGALQKNHALVTSANSTEAADSAFLPTEDESLSTMSCEMLTEQTPSSDPENALEVNGAEVTGEKENHCDDKTCVPSTSAEDMSENVPIAEDTTEQPKKNRITYSQIIKEGRRFNIDLVSKLLYSRGLLIDLLIKSNVSRYAEFKNITRILAFREGRVEQVPCSRADVFNSKQLTMVEKRMLMKFLTFCMEYEKYPDEYKGYEEITFYEYLKTQKLTPNLQYIVMHSIAMTSETASSTIDGLKATKNFLHCLGRYGNTPFLFPLYGQGELPQCFCRMCAVFGGIYCLRHSVQCLVVDKESRKCKAIIDQFGQRIISEHFLVEDSYFPENMCSRVQYRQISRAVLITDRSVLKTDSDQQISILTVPAEEPGTFAVRVIELCSSTMTCMKGTYLVHLTCTSSKTAREDLESVVQKLFVPYTEMEIENEQVEKPRILWALYFNMRDSSDISRSCYNDLPSNVYVCSGPDCGLGNDNAVKQAETLFQEICPNEDFCPPPPNPEDIILDGDSLQPEASESSAIPEANSETFKESTNLGNLEESSE
T90628	DRUGINFO	DW1OK0	BIIB111	Phase 3
T90628	DRUGINFO	DPS6V0	SPK-7001	Phase 1/2
T90628	DRUGINFO	D3UQO1	4D-110	Phase 1

T90835	TARGETID	T90835
T90835	UNIPROID	IL1R1_HUMAN; IL1R2_HUMAN
T90835	TARGNAME	Interleukin-1 receptor (IL1R)
T90835	GENENAME	IL1R1; IL1R2
T90835	TARGTYPE	Clinical trial
T90835	DRUGINFO	DOD24G	Isunakinra	Phase 1/2

T92678	TARGETID	T92678
T92678	UNIPROID	MALT1_HUMAN
T92678	TARGNAME	MALT lymphoma-associated translocation (MALT1)
T92678	GENENAME	MALT1
T92678	TARGTYPE	Clinical trial
T92678	SYNONYMS	MALT lymphoma-associated translocation; Paracaspase
T92678	FUNCTION	Protease that enhances BCL10-induced activation of NF-kappa-B by mediating its cleavage. MALT1-dependent BCL10 cleavage plays an important role in T-cell antigen receptor-induced integrin adhesion. Involved in the induction of T helper 17 cells (Th17) differentiation. Cleaves RC3H1 and ZC3H12A in response to T-cell receptor (TCR) stimulation which releases their cooperatively repressed targets to promote Th17 cell differentiation (By similarity). Also mediates cleavage of N4BP1 in T-cells following TCR-mediated activation, leading to N4BP1 inactivation. Also has ubiquitin ligase activity: binds to TRAF6, inducing TRAF6 oligomerization and activation of its ligase activity.
T92678	BIOCLASS	Peptidase
T92678	ECNUMBER	EC 3.4.22.-
T92678	SEQUENCE	MSLLGDPLQALPPSAAPTGPLLAPPAGATLNRLREPLLRRLSELLDQAPEGRGWRRLAELAGSRGRLRLSCLDLEQCSLKVLEPEGSPSLCLLKLMGEKGCTVTELSDFLQAMEHTEVLQLLSPPGIKITVNPESKAVLAGQFVKLCCRATGHPFVQYQWFKMNKEIPNGNTSELIFNAVHVKDAGFYVCRVNNNFTFEFSQWSQLDVCDIPESFQRSVDGVSESKLQICVEPTSQKLMPGSTLVLQCVAVGSPIPHYQWFKNELPLTHETKKLYMVPYVDLEHQGTYWCHVYNDRDSQDSKKVEIIIGRTDEAVECTEDELNNLGHPDNKEQTTDQPLAKDKVALLIGNMNYREHPKLKAPLVDVYELTNLLRQLDFKVVSLLDLTEYEMRNAVDEFLLLLDKGVYGLLYYAGHGYENFGNSFMVPVDAPNPYRSENCLCVQNILKLMQEKETGLNVFLLDMCRKRNDYDDTIPILDALKVTANIVFGYATCQGAEAFEIQHSGLANGIFMKFLKDRLLEDKKITVLLDEVAEDMGKCHLTKGKQALEIRSSLSEKRALTDPIQGTEYSAESLVRNLQWAKAHELPESMCLKFDCGVQIQLGFAAEFSNVMIIYTSIVYKPPEIIMCDAYVTDFPLDLDIDPKDANKGTPEETGSYLVSKDLPKHCLYTRLSSLQKLKEHLVFTVCLSYQYSGLEDTVEDKQEVNVGKPLIAKLDMHRGLGRKTCFQTCLMSNGPYQSSAATSGGAGHYHSLQDPFHGVYHSHPGNPSNVTPADSCHCSRTPDAFISSFAHHASCHFSRSNVPVETTDEIPFSFSDRLRISEK
T92678	DRUGINFO	D3GIQ9	JNJ-67856633	Phase 1

T93480	TARGETID	T93480
T93480	UNIPROID	UD11_HUMAN
T93480	TARGNAME	UDP-glucuronosyltransferase 1A1 (UGT1A1)
T93480	GENENAME	UGT1A1
T93480	TARGTYPE	Clinical trial
T93480	SYNONYMS	UGT1A1; Bilirubin-specific UDPGT isozyme 1; hUG-BR1; UDP-glucuronosyltransferase 1-1; UDPGT 1-1; UGT1*1; UGT1-01; UGT1.1; UDP-glucuronosyltransferase 1A isoform 1
T93480	FUNCTION	UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile. Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds. Catalyzes the glucuronidation of endogenous estrogen hormones such as estradiol, estrone and estriol. Involved in the glucuronidation of bilirubin, a degradation product occurring in the normal catabolic pathway that breaks down heme in vertebrates. Also catalyzes the glucuronidation the isoflavones genistein, daidzein, glycitein, formononetin, biochanin A and prunetin, which are phytoestrogens with anticancer and cardiovascular properties. Involved in the glucuronidation of the AGTR1 angiotensin receptor antagonist losartan, a drug which can inhibit the effect of angiotensin II. Involved in the biotransformation of 7-ethyl-10-hydroxycamptothecin (SN-38), the pharmacologically active metabolite of the anticancer drug irinotecan.
T93480	ECNUMBER	EC 2.4.1.17
T93480	SEQUENCE	MAVESQGGRPLVLGLLLCVLGPVVSHAGKILLIPVDGSHWLSMLGAIQQLQQRGHEIVVLAPDASLYIRDGAFYTLKTYPVPFQREDVKESFVSLGHNVFENDSFLQRVIKTYKKIKKDSAMLLSGCSHLLHNKELMASLAESSFDVMLTDPFLPCSPIVAQYLSLPTVFFLHALPCSLEFEATQCPNPFSYVPRPLSSHSDHMTFLQRVKNMLIAFSQNFLCDVVYSPYATLASEFLQREVTVQDLLSSASVWLFRSDFVKDYPRPIMPNMVFVGGINCLHQNPLSQEFEAYINASGEHGIVVFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDLLGHPMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMTSEDLENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAHDLTWYQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKTH
T93480	DRUGINFO	D84EGX	AT-342	Phase 1/2

T93548	TARGETID	T93548
T93548	UNIPROID	ITAV_HUMAN-ITB8_HUMAN
T93548	TARGNAME	Integrin alpha-V/beta-8 (ITGAV/B8)
T93548	GENENAME	ITGAV-ITGB8
T93548	TARGTYPE	Clinical trial
T93548	DRUGINFO	DO3E7R	PF-06940434	Phase 1

T94781	TARGETID	T94781
T94781	UNIPROID	NCAP_HRSVA
T94781	TARGNAME	HRSV Nucleoprotein messenger RNA (HRSV N mRNA)
T94781	GENENAME	HRSV N mRNA
T94781	TARGTYPE	Clinical trial
T94781	SYNONYMS	Protein N; Nucleocapsid protein
T94781	FUNCTION	Encapsidates the viral RNA genome by forming a left-handed helical nucleocapsid that protects the RNA from nucleases. RNA replication depends on the availability of soluble nucleoprotein. The encapsidated genomic RNA is termed the NC and serves as template for transcription and replication. Together with the phosphoprotein, sequesters host NF-kappa-B in inclusion bodies (IBs) thereby inhibiting this host defense pathway. May also act as a modulator of the innate immune response by sequestration of host IFIH1/MDA5 and MAVS into IBs.
T94781	BIOCLASS	mRNA target
T94781	SEQUENCE	MALSKVKLNDTLNKDQLLSSSKYTIQRSTGDSIDTPNYDVQKHINKLCGMLLITEDANHKFTGLIGMLYAMSRLGREDTIKILRDAGYHVKANGVDVTTHRQDINGKEMKFEVLTLASLTTEIQINIEIESRKSYKKMLKEMGEVAPEYRHDSPDCGMIILCIAALVITKLAAGDRSGLTAVIRRANNVLKNEMKRYKGLLPKDIANSFYEVFEKHPHFIDVFVHFGIAQSSTRGGSRVEGIFAGLFMNAYGAGQVMLRWGVLAKSVKNIMLGHASVQAEMEQVVEVYEYAQKLGGEAGFYHILNNPKASLLSLTQFPHFSSVVLGNAAGLGIMGEYRGTPRNQDLYDAAKAYAEQLKENGVINYSVLDLTAEELEAIKHQLNPKDNDVEL
T94781	DRUGINFO	DNM9C4	ALN-RSV01	Phase 2

T95108	TARGETID	T95108
T95108	UNIPROID	HLAG_HUMAN
T95108	TARGNAME	MHC class I antigen G (HLA-G)
T95108	GENENAME	HLA-G
T95108	TARGTYPE	Clinical trial
T95108	SYNONYMS	HLA G antigen; MHC class I antigen G
T95108	FUNCTION	Non-classical major histocompatibility class Ib molecule involved in immune regulatory processes at the maternal-fetal interface. In complex with B2M/beta-2 microglobulin binds a limited repertoire of nonamer self-peptides derived from intracellular proteins including histones and ribosomal proteins. Peptide-bound HLA-G-B2M complex acts as a ligand for inhibitory/activating KIR2DL4, LILRB1 and LILRB2 receptors on uterine immune cells to promote fetal development while maintaining maternal-fetal tolerance. Upon interaction with KIR2DL4 and LILRB1 receptors on decidual NK cells, it triggers NK cell senescence-associated secretory phenotype as a molecular switch to promote vascular remodeling and fetal growth in early pregnancy. Through interaction with KIR2DL4 receptor on decidual macrophages induces proinflammatory cytokine production mainly associated with tissue remodeling. Through interaction with LILRB2 receptor triggers differentiation of type 1 regulatory T cells and myeloid-derived suppressor cells, both of which actively maintain maternal-fetal tolerance. May play a role in balancing tolerance and antiviral-immunity at maternal-fetal interface by keeping in check the effector functions of NK, CD8+ T cells and B cells. Reprograms B cells toward an immune suppressive phenotype via LILRB1. May induce immune activation/suppression via intercellular membrane transfer (trogocytosis), likely enabling interaction with KIR2DL4, which resides mostly in endosomes. Through interaction with the inhibitory receptor CD160 on endothelial cells may control angiogenesis in immune privileged sites.
T95108	BIOCLASS	MHC class I
T95108	SEQUENCE	MVVMAPRTLFLLLSGALTLTETWAGSHSMRYFSAAVSRPGRGEPRFIAMGYVDDTQFVRFDSDSACPRMEPRAPWVEQEGPEYWEEETRNTKAHAQTDRMNLQTLRGYYNQSEASSHTLQWMIGCDLGSDGRLLRGYEQYAYDGKDYLALNEDLRSWTAADTAAQISKRKCEAANVAEQRRAYLEGTCVEWLHRYLENGKEMLQRADPPKTHVTHHPVFDYEATLRCWALGFYPAEIILTWQRDGEDQTQDVELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPEPLMLRWKQSSLPTIPIMGIVAGLVVLAAVVTGAAVAAVLWRKKSSD
T95108	DRUGINFO	D7J2NK	TTX-080	Phase 1

T95410	TARGETID	T95410
T95410	UNIPROID	G5EB61_EMENI
T95410	TARGNAME	Aspergillus Dihydroorotate dehydrogenase (Aspergillus DHODH)
T95410	TARGTYPE	Clinical trial
T95410	SYNONYMS	Dihydroorotate oxidase
T95410	ECNUMBER	EC 1.3.5.2
T95410	SEQUENCE	MATNSFRKLTFSGASRLGGCRRLPLTCRQLRFASDSGAAAATTKATAESAAESASINVKEAPKKAGRGLRRTVLGTSLALTLLVGYVYGTDTRASVHRYGVVPLIRALYPDAEDAHHIGVDTLKMLYKYGLHPRERGDPDGDGALATEVFGYTLSNPIGISGGLDKHAEIPDPLFAIGPAIVEVGGTTPLPQDGNPRPRVFRLPSQRAMINRYGLNSKGADHMAAILEQRVRDFAYANGFGAYDAAKQRVLDGEAGVPPGSLQPGKLLAVQVAKNKATPDGDIEAIKRDYVYCVDRVAKYADILVVNVSSPNTPGLRDLQATAPLTAILSAVVGAAKSVNRKTKPYVMVKVSPDEDSDEQVSGICDAVRASGVDGVIVGNTTNRRPDPIPQGYTLPAKEQATLKETGGYSGPQLFDRTVALVARYRSMLDAESETAGSAKDSAATIAQTEPGSENVPPVEAPSGLPRKVIFASGGITNGKQAHAVLDTGASVAMMYTGVVYGGVGTVTRVKQELRTAKKE
T95410	DRUGINFO	DJ8CY4	F901318	Phase 2

T96723	TARGETID	T96723
T96723	UNIPROID	SF3B1_HUMAN-SF3B2_HUMAN-SF3B3_HUMAN-SF3B4_HUMAN-SF3B5_HUMAN-SF3B6_HUMAN
T96723	TARGNAME	SF3b complex (SF3b)
T96723	GENENAME	SF3B1-SF3B2-SF3B3-SF3B4-SF3B5-SF3B6
T96723	TARGTYPE	Clinical trial
T96723	DRUGINFO	DB5O1U	H3B-8800	Phase 1

T97632	TARGETID	T97632
T97632	UNIPROID	HOS2_YEAST
T97632	TARGNAME	Fungal Probable histone deacetylase HOS2 (Fung HOS2)
T97632	GENENAME	Fung HOS2
T97632	TARGTYPE	Clinical trial
T97632	FUNCTION	Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). It is apparently involved in transcriptional activation.
T97632	ECNUMBER	EC 3.5.1.98
T97632	SEQUENCE	MSGTFSYDVKTKENEPLFEFNSAYSPRVSYHFNSKVSHYHYGVKHPMKPFRLMLTDHLVSSYGLHKIMDLYETRSATRDELLQFHSEDYVNFLSKVSPENANKLPRGTLENFNIGDDCPIFQNLYDYTTLYTGASLDATRKLINNQSDIAINWSGGLHHAKKNSPSGFCYVNDIVLSILNLLRYHPRILYIDIDLHHGDGVQEAFYTTDRVFTLSFHKYNGEFFPGTGDLTEIGCDKGKHFALNVPLEDGIDDDSYINLFKSIVDPLIMTFKPTLIVQQCGADSLGHDRLGCFNLNIKAHGECVKFVKSFGLPMLVVGGGGYTPRNVSRLWTYETGILNDVLLPEDIPEDIPFRDSFGPDYSLYPMLDDLYENKNSKKLLEDIRIRCLENIRYLQGAPSVRMDAECIPTQDISALTEEEDKIIQEMNEETEADSSNRLEEMEKENSGLIAFS
T97632	DRUGINFO	DG61OC	MGCD290	Phase 2

T98034	TARGETID	T98034
T98034	UNIPROID	CDK19_HUMAN
T98034	TARGNAME	Cyclin-dependent kinase 19 (CDK19)
T98034	GENENAME	CDK19
T98034	TARGTYPE	Clinical trial
T98034	SYNONYMS	CDC2-related protein kinase 6; Cell division cycle 2-like protein kinase 6; Cell division protein kinase 19; Cyclin-dependent kinase 11; Death-preventing kinase
T98034	FUNCTION	cytosol, mediator complex, nucleus, cyclin-dependent protein serine/threonine kinase activity, RNA polymerase II CTD heptapeptide repeat kinase activity, protein phosphorylation
T98034	BIOCLASS	Kinase
T98034	ECNUMBER	EC 2.7.11.22
T98034	SEQUENCE	MDYDFKAKLAAERERVEDLFEYEGCKVGRGTYGHVYKARRKDGKDEKEYALKQIEGTGISMSACREIALLRELKHPNVIALQKVFLSHSDRKVWLLFDYAEHDLWHIIKFHRASKANKKPMQLPRSMVKSLLYQILDGIHYLHANWVLHRDLKPANILVMGEGPERGRVKIADMGFARLFNSPLKPLADLDPVVVTFWYRAPELLLGARHYTKAIDIWAIGCIFAELLTSEPIFHCRQEDIKTSNPFHHDQLDRIFSVMGFPADKDWEDIRKMPEYPTLQKDFRRTTYANSSLIKYMEKHKVKPDSKVFLLLQKLLTMDPTKRITSEQALQDPYFQEDPLPTLDVFAGCQIPYPKREFLNEDDPEEKGDKNQQQQQNQHQQPTAPPQQAAAPPQAPPPQQNSTQTNGTAGGAGAGVGGTGAGLQHSQDSSLNQVPPNKKPRLGPSGANSGGPVMPSDYQHSSSRLNYQSSVQGSSQSQSTLGYSSSSQQSSQYHPSHQAHRY
T98034	DRUGINFO	DOJG79	SEL120	Phase 1

T98234	TARGETID	T98234
T98234	UNIPROID	TRFM_HUMAN
T98234	TARGNAME	Melanotransferrin (MELTF)
T98234	GENENAME	MELTF
T98234	TARGTYPE	Clinical trial
T98234	SYNONYMS	Melanoma-associated antigen p97; DE   AltName: CD_antigen=CD228
T98234	FUNCTION	Involved in iron cellular uptake. Seems to be internalized and then recycled back to the cell membrane. Binds a single atom of iron per subunit. Could also bind zinc.
T98234	BIOCLASS	Transferrin
T98234	SEQUENCE	MRGPSGALWLLLALRTVLGGMEVRWCATSDPEQHKCGNMSEAFREAGIQPSLLCVRGTSADHCVQLIAAQEADAITLDGGAIYEAGKEHGLKPVVGEVYDQEVGTSYYAVAVVRRSSHVTIDTLKGVKSCHTGINRTVGWNVPVGYLVESGRLSVMGCDVLKAVSDYFGGSCVPGAGETSYSESLCRLCRGDSSGEGVCDKSPLERYYDYSGAFRCLAEGAGDVAFVKHSTVLENTDGKTLPSWGQALLSQDFELLCRDGSRADVTEWRQCHLARVPAHAVVVRADTDGGLIFRLLNEGQRLFSHEGSSFQMFSSEAYGQKDLLFKDSTSELVPIATQTYEAWLGHEYLHAMKGLLCDPNRLPPYLRWCVLSTPEIQKCGDMAVAFRRQRLKPEIQCVSAKSPQHCMERIQAEQVDAVTLSGEDIYTAGKTYGLVPAAGEHYAPEDSSNSYYVVAVVRRDSSHAFTLDELRGKRSCHAGFGSPAGWDVPVGALIQRGFIRPKDCDVLTAVSEFFNASCVPVNNPKNYPSSLCALCVGDEQGRNKCVGNSQERYYGYRGAFRCLVENAGDVAFVRHTTVFDNTNGHNSEPWAAELRSEDYELLCPNGARAEVSQFAACNLAQIPPHAVMVRPDTNIFTVYGLLDKAQDLFGDDHNKNGFKMFDSSNYHGQDLLFKDATVRAVPVGEKTTYRGWLGLDYVAALEGMSSQQCSGAAAPAPGAPLLPLLLPALAARLLPPAL
T98234	DRUGINFO	DS6BE2	SGN-CD228A	Phase 1

T98430	TARGETID	T98430
T98430	UNIPROID	IDUA_HUMAN
T98430	TARGNAME	Alpha-L-iduronidase (IDUA)
T98430	GENENAME	IDUA
T98430	TARGTYPE	Clinical trial
T98430	FUNCTION	extracellular exosome, lysosomal lumen, hydrolase activity, hydrolyzing O-glycosyl compounds, L-iduronidase activity, chondroitin sulfate catabolic process, dermatan sulfate catabolic process, disaccharide metabolic process, glycosaminoglycan catabolic process, heparin catabolic process
T98430	BIOCLASS	Glycosyl hydrolase
T98430	ECNUMBER	EC 3.2.1.76
T98430	SEQUENCE	MRPLRPRAALLALLASLLAAPPVAPAEAPHLVHVDAARALWPLRRFWRSTGFCPPLPHSQADQYVLSWDQQLNLAYVGAVPHRGIKQVRTHWLLELVTTRGSTGRGLSYNFTHLDGYLDLLRENQLLPGFELMGSASGHFTDFEDKQQVFEWKDLVSSLARRYIGRYGLAHVSKWNFETWNEPDHHDFDNVSMTMQGFLNYYDACSEGLRAASPALRLGGPGDSFHTPPRSPLSWGLLRHCHDGTNFFTGEAGVRLDYISLHRKGARSSISILEQEKVVAQQIRQLFPKFADTPIYNDEADPLVGWSLPQPWRADVTYAAMVVKVIAQHQNLLLANTTSAFPYALLSNDNAFLSYHPHPFAQRTLTARFQVNNTRPPHVQLLRKPVLTAMGLLALLDEEQLWAEVSQAGTVLDSNHTVGVLASAHRPQGPADAWRAAVLIYASDDTRAHPNRSVAVTLRLRGVPPGPGLVYVTRYLDNGLCSPDGEWRRLGRPVFPTAEQFRRMRAAEDPVAAAPRPLPAGGRLTLRPALRLPSLLLVHVCARPEKPPGQVTRLRALPLTQGQLVLVWSDEHVGSKCLWTYEIQFSQDGKAYTPVSRKPSTFNLFVFSPDTGAVSGSYRVRALDYWARPGPFSDPVPYLEVPVPRGPPSPGNP
T98430	DRUGINFO	DYWK46	SB-318	Phase 1/2
T98430	DRUGINFO	D8XHT1	RGX-111	Phase 1

T63246	TARGETID	T63246
T63246	UNIPROID	CTNS_HUMAN
T63246	TARGNAME	Cystinosin (CTNS)
T63246	GENENAME	CTNS
T63246	TARGTYPE	Clinical trial
T63246	FUNCTION	Cystine/H(+) symporter that mediates export of cystine, the oxidized dimer of cysteine, from lysosomes (PubMed:11689434, PubMed:18337546, PubMed:22232659, PubMed:29467429, PubMed:33208952, PubMed:15128704). Plays an important role in melanin synthesis by catalyzing cystine export from melanosomes, possibly by inhibiting pheomelanin synthesis (PubMed:22649030). In addition to cystine export, also acts as a positive regulator of mTORC1 signaling in kidney proximal tubular cells, via interactions with components of the v-ATPase and Ragulator complexes (By similarity). Also involved in small GTPase-regulated vesicle trafficking and lysosomal localization of LAMP2A, independently of cystine transporter activity (By similarity). {ECO:0000250|UniProtKB:P57757, ECO:0000269|PubMed:11689434, ECO:0000269|PubMed:15128704, ECO:0000269|PubMed:18337546, ECO:0000269|PubMed:22232659, ECO:0000269|PubMed:22649030, ECO:0000269|PubMed:29467429, ECO:0000269|PubMed:33208952}.
T63246	PDBSTRUC	8DKE;8DKI;8DKM;8DKW;8DKX;8DYP
T63246	SEQUENCE	MIRNWLTIFILFPLKLVEKCESSVSLTVPPVVKLENGSSTNVSLTLRPPLNATLVITFEITFRSKNITILELPDEVVVPPGVTNSSFQVTSQNVGQLTVYLHGNHSNQTGPRIRFLVIRSSAISIINQVIGWIYFVAWSISFYPQVIMNWRRKSVIGLSFDFVALNLTGFVAYSVFNIGLLWVPYIKEQFLLKYPNGVNPVNSNDVFFSLHAVVLTLIIIVQCCLYERGGQRVSWPAIGFLVLAWLFAFVTMIVAAVGVTTWLQFLFCFSYIKLAVTLVKYFPQAYMNFYYKSTEGWSIGNVLLDFTGGSFSLLQMFLQSYNNDQWTLIFGDPTKFGLGVFSIVFDVVFFIQHFCLYRKRPGYDQLN
T63246	DRUGINFO	DO4YS2	AVR-RD-04	Clinical trial

T63163	TARGETID	T63163
T63163	UNIPROID	BCKD_HUMAN
T63163	TARGNAME	[3-methyl-2-oxobutanoate dehydrogenase] kinase (BCKDK)
T63163	GENENAME	BCKDK
T63163	TARGTYPE	Clinical trial
T63163	SYNONYMS	Branched-chain alpha-ketoacid dehydrogenase kinase; BCKD-kinase; BCKDHKIN
T63163	FUNCTION	Catalyzes the phosphorylation and inactivation of the branched-chain alpha-ketoacid dehydrogenase complex, the key regulatory enzyme of the valine, leucine and isoleucine catabolic pathways. Key enzyme that regulate the activity state of the BCKD complex. {ECO:0000269|PubMed:24449431}.
T63163	PDBSTRUC	8F5F;8F5J;8F5S
T63163	BIOCLASS	Kinase
T63163	ECNUMBER	EC 2.7.11.4
T63163	SEQUENCE	MILASVLRSGPGGGLPLRPLLGPALALRARSTSATDTHHVEMARERSKTVTSFYNQSAIDAAAEKPSVRLTPTMMLYAGRSQDGSHLLKSARYLQQELPVRIAHRIKGFRCLPFIIGCNPTILHVHELYIRAFQKLTDFPPIKDQADEAQYCQLVRQLLDDHKDVVTLLAEGLRESRKHIEDEKLVRYFLDKTLTSRLGIRMLATHHLALHEDKPDFVGIICTRLSPKKIIEKWVDFARRLCEHKYGNAPRVRINGHVAARFPFIPMPLDYILPELLKNAMRATMESHLDTPYNVPDVVITIANNDVDLIIRISDRGGGIAHKDLDRVMDYHFTTAEASTQDPRISPLFGHLDMHSGAQSGPMHGFGFGLPTSRAYAEYLGGSLQLQSLQGIGTDVYLRLRHIDGREESFRI
T63163	DRUGINFO	D0S5XD	PF-07328948	Phase 1

T63164	TARGETID	T63164
T63164	UNIPROID	CADH6_HUMAN
T63164	TARGNAME	Cadherin-6 (CDH6)
T63164	GENENAME	CDH6
T63164	TARGTYPE	Clinical trial
T63164	SYNONYMS	Kidney cadherin; K-cadherin
T63164	FUNCTION	Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types.
T63164	PDBSTRUC	5VEB
T63164	SEQUENCE	MRTYRYFLLLFWVGQPYPTLSTPLSKRTSGFPAKKRALELSGNSKNELNRSKRSWMWNQFFLLEEYTGSDYQYVGKLHSDQDRGDGSLKYILSGDGAGDLFIINENTGDIQATKRLDREEKPVYILRAQAINRRTGRPVEPESEFIIKIHDINDNEPIFTKEVYTATVPEMSDVGTFVVQVTATDADDPTYGNSAKVVYSILQGQPYFSVESETGIIKTALLNMDRENREQYQVVIQAKDMGGQMGGLSGTTTVNITLTDVNDNPPRFPQSTYQFKTPESSPPGTPIGRIKASDADVGENAEIEYSITDGEGLDMFDVITDQETQEGIITVKKLLDFEKKKVYTLKVEASNPYVEPRFLYLGPFKDSATVRIVVEDVDEPPVFSKLAYILQIREDAQINTTIGSVTAQDPDAARNPVKYSVDRHTDMDRIFNIDSGNGSIFTSKLLDRETLLWHNITVIATEINNPKQSSRVPLYIKVLDVNDNAPEFAEFYETFVCEKAKADQLIQTLHAVDKDDPYSGHQFSFSLAPEAASGSNFTIQDNKDNTAGILTRKNGYNRHEMSTYLLPVVISDNDYPVQSSTGTVTVRVCACDHHGNMQSCHAEALIHPTGLSTGALVAILLCIVILLVTVVLFAALRRQRKKEPLIISKEDIRDNIVSYNDEGGGEEDTQAFDIGTLRNPEAIEDNKLRRDIVPEALFLPRRTPTARDNTDVRDFINQRLKENDTDPTAPPYDSLATYAYEGTGSVADSLSSLESVTTDADQDYDYLSDWGPRFKKLADMYGGVDSDKDS
T63164	DRUGINFO	DISJ28	DS-6000	Phase 1

T63165	TARGETID	T63165
T63165	UNIPROID	CCR6_HUMAN
T63165	TARGNAME	C-C chemokine receptor type 6 (CCR6)
T63165	GENENAME	CCR6
T63165	TARGTYPE	Clinical trial
T63165	SYNONYMS	C-C CKR-6; CC-CKR-6; CCR-6; Chemokine receptor-like 3; CKR-L3; DRY6; G-protein coupled receptor 29; GPR-CY4; GPRCY4; LARC receptor; CD196
T63165	FUNCTION	Receptor for the C-C type chemokine CCL20 (PubMed:9169459). Binds to CCL20 and subsequently transduces a signal by increasing the intracellular calcium ion levels (PubMed:20068036). Although CCL20 is its major ligand it can also act as a receptor for non-chemokine ligands such as beta-defensins (PubMed:25585877). Binds to defensin DEFB1 leading to increase in intracellular calcium ions and cAMP levels. Its binding to DEFB1 is essential for the function of DEFB1 in regulating sperm motility and bactericidal activity (PubMed:25122636). Binds to defensins DEFB4 and DEFB4A/B and mediates their chemotactic effects (PubMed:20068036). The ligand-receptor pair CCL20-CCR6 is responsible for the chemotaxis of dendritic cells (DC), effector/ memory T-cells and B-cells and plays an important role at skin and mucosal surfaces under homeostatic and inflammatory conditions, as well as in pathology, including cancer and various autoimmune diseases. CCR6-mediated signals are essential for immune responses to microbes in the intestinal mucosa and in the modulation of inflammatory responses initiated by tissue insult and trauma (PubMed:21376174). CCR6 is essential for the recruitment of both the pro-inflammatory IL17 producing helper T-cells (Th17) and the regulatory T-cells (Treg) to sites of inflammation. Required for the normal migration of Th17 cells in Peyers-patches and other related tissue sites of the intestine and plays a role in regulating effector T-cell balance and distribution in inflamed intestine. Plays an important role in the coordination of early thymocyte precursor migration events important for normal subsequent thymocyte precursor development, but is not required for the formation of normal thymic natural regulatory T-cells (nTregs). Required for optimal differentiation of DN2 and DN3 thymocyte precursors. Essential for B-cell localization in the subepithelial dome of Peyers-patches and for efficient B-cell isotype switching to IgA in the Peyers-patches. Essential for appropriate anatomical distribution of memory B-cells in the spleen and for the secondary recall response of memory B-cells (By similarity). Positively regulates sperm motility and chemotaxis via its binding to CCL20 (PubMed:23765988). {ECO:0000250|UniProtKB:O54689, ECO:0000269|PubMed:20068036, ECO:0000269|PubMed:23765988, ECO:0000269|PubMed:25122636, ECO:0000269|PubMed:9169459, ECO:0000303|PubMed:21376174, ECO:0000303|PubMed:25585877}.
T63165	PDBSTRUC	6WWZ
T63165	BIOCLASS	G-protein coupled receptor 1 family
T63165	SEQUENCE	MSGESMNFSDVFDSSEDYFVSVNTSYYSVDSEMLLCSLQEVRQFSRLFVPIAYSLICVFGLLGNILVVITFAFYKKARSMTDVYLLNMAIADILFVLTLPFWAVSHATGAWVFSNATCKLLKGIYAINFNCGMLLLTCISMDRYIAIVQATKSFRLRSRTLPRSKIICLVVWGLSVIISSSTFVFNQKYNTQGSDVCEPKYQTVSEPIRWKLLMLGLELLFGFFIPLMFMIFCYTFIVKTLVQAQNSKRHKAIRVIIAVVLVFLACQIPHNMVLLVTAANLGKMNRSCQSEKLIGYTKTVTEVLAFLHCCLNPVLYAFIGQKFRNYFLKILKDLWCVRRKYKSSGFSCAGRYSENISRQTSETADNDNASSFTM
T63165	DRUGINFO	D1TS9A	PF-07054894	Phase 1

T63166	TARGETID	T63166
T63166	UNIPROID	CLD6_HUMAN
T63166	TARGNAME	Claudin-6 (CLDN6)
T63166	GENENAME	CLDN6
T63166	TARGTYPE	Clinical trial
T63166	SYNONYMS	Skullin
T63166	FUNCTION	Plays a major role in tight junction-specific obliteration of the intercellular space. {ECO:0000250}.; (Microbial infection) Acts as a receptor for hepatitis C virus (HCV) entry into hepatic cells. {ECO:0000269|PubMed:17804490, ECO:0000269|PubMed:20375010}.
T63166	SEQUENCE	MASAGMQILGVVLTLLGWVNGLVSCALPMWKVTAFIGNSIVVAQVVWEGLWMSCVVQSTGQMQCKVYDSLLALPQDLQAARALCVIALLVALFGLLVYLAGAKCTTCVEEKDSKARLVLTSGIVFVISGVLTLIPVCWTAHAIIRDFYNPLVAEAQKRELGASLYLGWAASGLLLLGGGLLCCTCPSGGSQGPSHYMARYSTSAPAISRGPSEYPTKNYV
T63166	DRUGINFO	D9QPI0	AMG 794	Phase 1

T63168	TARGETID	T63168
T63168	UNIPROID	ENTP3_HUMAN
T63168	TARGNAME	Ectonucleoside triphosphate diphosphohydrolase 3 (ENTPD3)
T63168	GENENAME	ENTPD3
T63168	TARGTYPE	Clinical trial
T63168	SYNONYMS	NTPDase 3; CD39 antigen-like 3; Ecto-ATP diphosphohydrolase 3; Ecto-ATPDase 3; Ecto-ATPase 3; Ecto-apyrase 3; HB6
T63168	FUNCTION	Has a threefold preference for the hydrolysis of ATP over ADP. {ECO:0000269|PubMed:10231536, ECO:0000269|PubMed:11300774}.
T63168	ECNUMBER	EC 3.6.1.5
T63168	SEQUENCE	MFTVLTRQPCEQAGLKALYRTPTIIALVVLLVSIVVLVSITVIQIHKQEVLPPGLKYGIVLDAGSSRTTVYVYQWPAEKENNTGVVSQTFKCSVKGSGISSYGNNPQDVPRAFEECMQKVKGQVPSHLHGSTPIHLGATAGMRLLRLQNETAANEVLESIQSYFKSQPFDFRGAQIISGQEEGVYGWITANYLMGNFLEKNLWHMWVHPHGVETTGALDLGGASTQISFVAGEKMDLNTSDIMQVSLYGYVYTLYTHSFQCYGRNEAEKKFLAMLLQNSPTKNHLTNPCYPRDYSISFTMGHVFDSLCTVDQRPESYNPNDVITFEGTGDPSLCKEKVASIFDFKACHDQETCSFDGVYQPKIKGPFVAFAGFYYTASALNLSGSFSLDTFNSSTWNFCSQNWSQLPLLLPKFDEVYARSYCFSANYIYHLFVNGYKFTEETWPQIHFEKEVGNSSIAWSLGYMLSLTNQIPAESPLIRLPIEPPVFVGTLAFFTAAALLCLAFLAYLCSATRRKRHSEHAFDHAVDSD
T63168	DRUGINFO	DKOY58	AZD3366	Phase 1

T63170	TARGETID	T63170
T63170	UNIPROID	HAOX1_HUMAN
T63170	TARGNAME	2-Hydroxyacid oxidase 1 (HAO1)
T63170	GENENAME	HAO1
T63170	TARGTYPE	Clinical trial
T63170	SYNONYMS	HAOX1; Glycolate oxidase; GO; GOX; Glyoxylate oxidase
T63170	FUNCTION	Broad substrate specificity (S)-2-hydroxy-acid oxidase that preferentially oxidizes glycolate (PubMed:10777549, PubMed:17669354, PubMed:18215067, PubMed:10978532). The glyoxylate produced by the oxidation of glycolate can then be utilized by alanine-glyoxylate aminotransferase for the peroxisomal synthesis of glycine; this pathway appears to be an important step for the detoxification of glyoxylate which, if allowed to accumulate, may be metabolized to oxalate with formation of kidney stones (PubMed:10978532, PubMed:17669354). Can also catalyze the oxidation of glyoxylate, and long chain hydroxyacids such as 2-hydroxyhexadecanoate and 2-hydroxyoctanoate, albeit with much lower catalytic efficiency (PubMed:10777549, PubMed:17669354, PubMed:18215067). Active in vitro with the artificial electron acceptor 2,6-dichlorophenolindophenol (DCIP), but O2 is believed to be the physiological electron acceptor, leading to the production of H2O2 (PubMed:10777549, PubMed:17669354, PubMed:18215067, PubMed:10978532). Is not active on L-lactate and 2-hydroxybutanoate (PubMed:10777549). {ECO:0000269|PubMed:10777549, ECO:0000269|PubMed:10978532, ECO:0000269|PubMed:17669354, ECO:0000269|PubMed:18215067, ECO:0000303|PubMed:10978532, ECO:0000303|PubMed:17669354}.
T63170	PDBSTRUC	2NZL;2RDT;2RDU;2RDW;2W0U;5QIB;5QIC;5QID;5QIE;5QIF;5QIG;5QIH;6GMB;6GMC;6W44;6W45;6W4C;7M2O;7R4N;7R4O;7R4P
T63170	ECNUMBER	EC 1.1.3.15; EC 1.2.3.5
T63170	SEQUENCE	MLPRLICINDYEQHAKSVLPKSIYDYYRSGANDEETLADNIAAFSRWKLYPRMLRNVAETDLSTSVLGQRVSMPICVGATAMQRMAHVDGELATVRACQSLGTGMMLSSWATSSIEEVAEAGPEALRWLQLYIYKDREVTKKLVRQAEKMGYKAIFVTVDTPYLGNRLDDVRNRFKLPPQLRMKNFETSTLSFSPEENFGDDSGLAAYVAKAIDPSISWEDIKWLRRLTSLPIVAKGILRGDDAREAVKHGLNGILVSNHGARQLDGVPATIDVLPEIVEAVEGKVEVFLDGGVRKGTDVLKALALGAKAVFVGRPIVWGLAFQGEKGVQDVLEILKEEFRLAMALSGCQNVKVIDKTLVRKNPLAVSKI
T63170	DRUGINFO	D1R9KZ	BBP-711	Phase 1

T63173	TARGETID	T63173
T63173	UNIPROID	IKZF3_HUMAN
T63173	TARGNAME	Zinc finger protein Aiolos (IKZF3)
T63173	GENENAME	IKZF3
T63173	TARGTYPE	Clinical trial
T63173	SYNONYMS	Ikaros family zinc finger protein 3
T63173	FUNCTION	Transcription factor that plays an important role in the regulation of lymphocyte differentiation. Plays an essential role in regulation of B-cell differentiation, proliferation and maturation to an effector state. Involved in regulating BCL2 expression and controlling apoptosis in T-cells in an IL2-dependent manner. {ECO:0000269|PubMed:10369681, ECO:0000269|PubMed:34155405}.
T63173	SEQUENCE	MEDIQTNAELKSTQEQSVPAESAAVLNDYSLTKSHEMENVDSGEGPANEDEDIGDDSMKVKDEYSERDENVLKSEPMGNAEEPEIPYSYSREYNEYENIKLERHVVSFDSSRPTSGKMNCDVCGLSCISFNVLMVHKRSHTGERPFQCNQCGASFTQKGNLLRHIKLHTGEKPFKCHLCNYACQRRDALTGHLRTHSVEKPYKCEFCGRSYKQRSSLEEHKERCRTFLQSTDPGDTASAEARHIKAEMGSERALVLDRLASNVAKRKSSMPQKFIGEKRHCFDVNYNSSYMYEKESELIQTRMMDQAINNAISYLGAEALRPLVQTPPAPTSEMVPVISSMYPIALTRAEMSNGAPQELEKKSIHLPEKSVPSERGLSPNNSGHDSTDTDSNHEERQNHIYQQNHMVLSRARNGMPLLKEVPRSYELLKPPPICPRDSVKVINKEGEVMDVYRCDHCRVLFLDYVMFTIHMGCHGFRDPFECNMCGYRSHDRYEFSSHIARGEHRALLK
T63173	DRUGINFO	D7YN4H	NX-2127	Phase 1

T63174	TARGETID	T63174
T63174	UNIPROID	IL1RA_HUMAN
T63174	TARGNAME	Interleukin-1 receptor antagonist protein (IL1RN)
T63174	GENENAME	IL1RN
T63174	TARGTYPE	Clinical trial
T63174	SYNONYMS	IL-1RN; IL-1ra; IRAP; ICIL-1RA; IL1 inhibitor; Anakinra
T63174	FUNCTION	Anti-inflammatory antagonist of interleukin-1 family of proinflammatory cytokines such as interleukin-1beta/IL1B and interleukin-1alpha/IL1A. Protects from immune dysregulation and uncontrolled systemic inflammation triggered by IL1 for a range of innate stimulatory agents such as pathogens. {ECO:0000250|UniProtKB:P25085, ECO:0000269|PubMed:7775431}.
T63174	PDBSTRUC	1ILR;1ILT;1IRA;1IRP;2IRT
T63174	SEQUENCE	MEICRGLRSHLITLLLFLFHSETICRPSGRKSSKMQAFRIWDVNQKTFYLRNNQLVAGYLQGPNVNLEEKIDVVPIEPHALFLGIHGGKMCLSCVKSGDETRLQLEAVNITDLSENRKQDKRFAFIRSDSGPTTSFESAACPGWFLCTAMEADQPVSLTNMPDEGVMVTKFYFQEDE
T63174	DRUGINFO	D4SE2H	Humantakinogene hadenovec	Phase 1
T63174	DRUGINFO	DVC36K	GNSC-001	Phase 1

T63175	TARGETID	T63175
T63175	UNIPROID	KAT6A_HUMAN
T63175	TARGNAME	Histone acetyltransferase KAT6A (KAT6A)
T63175	GENENAME	KAT6A
T63175	TARGTYPE	Clinical trial
T63175	SYNONYMS	MOZ, YBF2/SAS3, SAS2 and TIP60 protein 3; MYST-3; Monocytic leukemia zinc finger protein; Runt-related transcription factor-binding protein 2; Zinc finger protein 220
T63175	FUNCTION	Histone acetyltransferase that acetylates lysine residues in histone H3 and histone H4 (in vitro). Component of the MOZ/MORF complex which has a histone H3 acetyltransferase activity. May act as a transcriptional coactivator for RUNX1 and RUNX2. Acetylates p53/TP53 at 'Lys-120' and 'Lys-382' and controls its transcriptional activity via association with PML. {ECO:0000269|PubMed:11742995, ECO:0000269|PubMed:11965546, ECO:0000269|PubMed:12771199, ECO:0000269|PubMed:16387653, ECO:0000269|PubMed:17925393, ECO:0000269|PubMed:23431171}.
T63175	PDBSTRUC	1M36;2LN0;2OZU;2RC4;3V43;4LJN;4LK9;4LKA;4LLB;5B75;5B76;5B77;5B78;6LSB;7Y43;8DD5;8H7A
T63175	ECNUMBER	EC 2.3.1.48
T63175	SEQUENCE	MVKLANPLYTEWILEAIKKVKKQKQRPSEERICNAVSSSHGLDRKTVLEQLELSVKDGTILKVSNKGLNSYKDPDNPGRIALPKPRNHGKLDNKQNVDWNKLIKRAVEGLAESGGSTLKSIERFLKGQKDVSALFGGSAASGFHQQLRLAIKRAIGHGRLLKDGPLYRLNTKATNVDGKESCESLSCLPPVSLLPHEKDKPVAEPIPICSFCLGTKEQNREKKPEELISCADCGNSGHPSCLKFSPELTVRVKALRWQCIECKTCSSCRDQGKNADNMLFCDSCDRGFHMECCDPPLTRMPKGMWICQICRPRKKGRKLLQKKAAQIKRRYTNPIGRPKNRLKKQNTVSKGPFSKVRTGPGRGRKRKITLSSQSASSSSEEGYLERIDGLDFCRDSNVSLKFNKKTKGLIDGLTKFFTPSPDGRKARGEVVDYSEQYRIRKRGNRKSSTSDWPTDNQDGWDGKQENEERLFGSQEIMTEKDMELFRDIQEQALQKVGVTGPPDPQVRCPSVIEFGKYEIHTWYSSPYPQEYSRLPKLYLCEFCLKYMKSRTILQQHMKKCGWFHPPANEIYRKNNISVFEVDGNVSTIYCQNLCLLAKLFLDHKTLYYDVEPFLFYVLTQNDVKGCHLVGYFSKEKHCQQKYNVSCIMILPQYQRKGYGRFLIDFSYLLSKREGQAGSPEKPLSDLGRLSYMAYWKSVILECLYHQNDKQISIKKLSKLTGICPQDITSTLHHLRMLDFRSDQFVIIRREKLIQDHMAKLQLNLRPVDVDPECLRWTPVIVSNSVVSEEEEEEAEEGENEEPQCQERELEISVGKSVSHENKEQDSYSVESEKKPEVMAPVSSTRLSKQVLPHDSLPANSQPSRRGRWGRKNRKTQERFGDKDSKLLLEETSSAPQEQYGECGEKSEATQEQYTESEEQLVASEEQPSQDGKPDLPKRRLSEGVEPWRGQLKKSPEALKCRLTEGSERLPRRYSEGDRAVLRGFSESSEEEEEPESPRSSSPPILTKPTLKRKKPFLHRRRRVRKRKHHNSSVVTETISETTEVLDEPFEDSDSERPMPRLEPTFEIDEEEEEEDENELFPREYFRRLSSQDVLRCQSSSKRKSKDEEEDEESDDADDTPILKPVSLLRKRDVKNSPLEPDTSTPLKKKKGWPKGKSRKPIHWKKRPGRKPGFKLSREIMPVSTQACVIEPIVSIPKAGRKPKIQESEETVEPKEDMPLPEERKEEEEMQAEAEEAEEGEEEDAASSEVPAASPADSSNSPETETKEPEVEEEEEKPRVSEEQRQSEEEQQELEEPEPEEEEDAAAETAQNDDHDADDEDDGHLESTKKKELEEQPTREDVKEEPGVQESFLDANMQKSREKIKDKEETELDSEEEQPSHDTSVVSEQMAGSEDDHEEDSHTKEELIELKEEEEIPHSELDLETVQAVQSLTQEESSEHEGAYQDCEETLAACQTLQSYTQADEDPQMSMVEDCHASEHNSPISSVQSHPSQSVRSVSSPNVPALESGYTQISPEQGSLSAPSMQNMETSPMMDVPSVSDHSQQVVDSGFSDLGSIESTTENYENPSSYDSTMGGSICGNSSSQSSCSYGGLSSSSSLTQSSCVVTQQMASMGSSCSMMQQSSVQPAANCSIKSPQSCVVERPPSNQQQQPPPPPPQQPQPPPPQPQPAPQPPPPQQQPQQQPQPQPQQPPPPPPPQQQPPLSQCSMNNSFTPAPMIMEIPESGSTGNISIYERIPGDFGAGSYSQPSATFSLAKLQQLTNTIMDPHAMPYSHSPAVTSYATSVSLSNTGLAQLAPSHPLAGTPQAQATMTPPPNLASTTMNLTSPLLQCNMSATNIGIPHTQRLQGQMPVKGHISIRSKSAPLPSAAAHQQQLYGRSPSAVAMQAGPRALAVQRGMNMGVNLMPTPAYNVNSMNMNTLNAMNSYRMTQPMMNSSYHSNPAYMNQTAQYPMQMQMGMMGSQAYTQQPMQPNPHGNMMYTGPSHHSYMNAAGVPKQSLNGPYMRR
T63175	DRUGINFO	DX31VA	PF-07248144	Phase 1

T63178	TARGETID	T63178
T63178	UNIPROID	MAGAA_HUMAN
T63178	TARGNAME	Melanoma-associated antigen 10 (MAGEA10)
T63178	GENENAME	MAGEA10
T63178	TARGTYPE	Clinical trial
T63178	SYNONYMS	Cancer/testis antigen 1.10; CT1.10; MAGE-10 antigen
T63178	FUNCTION	Not known, though may play a role in embryonal development and tumor transformation or aspects of tumor progression.
T63178	PDBSTRUC	7PBC;7PDW;7QPJ
T63178	SEQUENCE	MPRAPKRQRCMPEEDLQSQSETQGLEGAQAPLAVEEDASSSTSTSSSFPSSFPSSSSSSSSSCYPLIPSTPEEVSADDETPNPPQSAQIACSSPSVVASLPLDQSDEGSSSQKEESPSTLQVLPDSESLPRSEIDEKVTDLVQFLLFKYQMKEPITKAEILESVIRNYEDHFPLLFSEASECMLLVFGIDVKEVDPTGHSFVLVTSLGLTYDGMLSDVQSMPKTGILILILSIVFIEGYCTPEEVIWEALNMMGLYDGMEHLIYGEPRKLLTQDWVQENYLEYRQVPGSDPARYEFLWGPRAHAEIRKMSLLKFLAKVNGSDPRSFPLWYEEALKDEEERAQDRIATTDDTTAMASASSSATGSFSYPE
T63178	DRUGINFO	DM38KC	ADP-A2M10	Phase 1

T63245	TARGETID	T63245
T63245	UNIPROID	MOGT2_HUMAN
T63245	TARGNAME	2-acylglycerol O-acyltransferase 2 (MOGAT2)
T63245	GENENAME	MOGAT2
T63245	TARGTYPE	Clinical trial
T63245	SYNONYMS	Acyl-CoA:monoacylglycerol acyltransferase 2; MGAT2; hMGAT2; Diacylglycerol O-acyltransferase candidate 5; hDC5; Diacylglycerol acyltransferase 2-like protein 5; Monoacylglycerol O-acyltransferase 2
T63245	FUNCTION	Catalyzes the formation of diacylglycerol from 2-monoacylglycerol and fatty acyl-CoA. Has a preference toward monoacylglycerols containing unsaturated fatty acids in an order of C18:3 > C18:2 > C18:1 > C18:0. Plays a central role in absorption of dietary fat in the small intestine by catalyzing the resynthesis of triacylglycerol in enterocytes. May play a role in diet-induced obesity. Also able to use 1-monoalkylglycerol (1-MAkG) as an acyl acceptor for the synthesis of monoalkyl-monoacylglycerol (MAMAG) (PubMed:28420705). {ECO:0000269|PubMed:12621063, ECO:0000269|PubMed:27184406, ECO:0000269|PubMed:28420705}.
T63245	ECNUMBER	EC 2.3.1.22
T63245	SEQUENCE	MVEFAPLFMPWERRLQTLAVLQFVFSFLALAEICTVGFIALLFTRFWLLTVLYAAWWYLDRDKPRQGGRHIQAIRCWTIWKYMKDYFPISLVKTAELDPSRNYIAGFHPHGVLAVGAFANLCTESTGFSSIFPGIRPHLMMLTLWFRAPFFRDYIMSAGLVTSEKESAAHILNRKGGGNLLGIIVGGAQEALDARPGSFTLLLRNRKGFVRLALTHGAPLVPIFSFGENDLFDQIPNSSGSWLRYIQNRLQKIMGISLPLFHGRGVFQYSFGLIPYRRPITTVVGKPIEVQKTLHPSEEEVNQLHQRYIKELCNLFEAHKLKFNIPADQHLEFC
T63245	DRUGINFO	DJ3M0Q	S-309309	Phase 1

T63182	TARGETID	T63182
T63182	UNIPROID	NCAP_SARS2
T63182	TARGNAME	Nucleoprotein (N)
T63182	GENENAME	N
T63182	TARGTYPE	Clinical trial
T63182	SYNONYMS	N; Nucleocapsid protein; NC; Protein N
T63182	FUNCTION	Packages the positive strand viral genome RNA into a helical ribonucleocapsid (RNP) and plays a fundamental role during virion assembly through its interactions with the viral genome and membrane protein M (PubMed:33264373). Plays an important role in enhancing the efficiency of subgenomic viral RNA transcription as well as viral replication. {ECO:0000269|PubMed:32974389, ECO:0000269|PubMed:33264373}.; May block host chemokine function in vivo, facilitating viral replication and transmission (PubMed:35921414). Acts by being secreted into the extracellular space where it competes to host chemokines for binding to host glycosaminoglycans (GAG) (PubMed:35921414). {ECO:0000269|PubMed:35921414}.; May induce inflammasome responses in cultured cells and mice. Acts by interacting with host NLRP3 to facilitate inflammasome assembly, which induces cytokine release that may play a role in COVID lung injury. {ECO:0000269|PubMed:34341353}.
T63182	PDBSTRUC	6M3M;6VYO;6WJI;6WKP;6WZO;6WZQ;6YI3;6YUN;6ZCO;7ACS;7ACT;7C22;7CDZ;7CE0;7CR5;7DE1;7F2B;7F2E;7KGO;7KGP;7KGQ;7KGR;7KGS;7KGT;7LGD;7LTU;7LUX;7LUZ;7LV2;7N0I;7N0R;7N3C;7N3D;7O05;7O35;7O36;7PKU;7QIK;7QIP;7R98;7SD4;7STR;7STS;7SUE;7SUO;7UW3;7UXX;7UXZ;7VBD;7VBE;7VBF;7VNU;7WKJ;7WZO;7XWX;7XWZ;7XX1;7XXK;7ZIT;8DNT;8FD5;8FG2
T63182	SEQUENCE	MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAGLPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGSQASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQQQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKHWPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAYKTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA
T63182	DRUGINFO	DUE5G9	PF-07923567	Phase 1

T63183	TARGETID	T63183
T63183	UNIPROID	PANK3_HUMAN
T63183	TARGNAME	Pantothenate kinase 3 (PANK3)
T63183	GENENAME	PANK3
T63183	TARGTYPE	Clinical trial
T63183	SYNONYMS	hPanK3; Pantothenic acid kinase 3
T63183	FUNCTION	Catalyzes the phosphorylation of pantothenate to generate 4'-phosphopantothenate in the first and rate-determining step of coenzyme A (CoA) synthesis. {ECO:0000269|PubMed:17631502, ECO:0000269|PubMed:20797618, ECO:0000269|PubMed:27555321, ECO:0000269|PubMed:30927326}.
T63183	PDBSTRUC	2I7P;3MK6;3SMS;5KPR;5KPT;5KPZ;5KQ8;5KQD;6B3V;6PE6;6X4J;6X4K;6X4L;7UE3;7UE4;7UE5;7UE6;7UE7;7UE8;7UEO;7UEP;7UEQ;7UER;7UES;7UET;7UEU;7UEV;7UEX;7UEY
T63183	BIOCLASS	Kinase
T63183	ECNUMBER	EC 2.7.1.33
T63183	SEQUENCE	MKIKDAKKPSFPWFGMDIGGTLVKLSYFEPIDITAEEEQEEVESLKSIRKYLTSNVAYGSTGIRDVHLELKDLTLFGRRGNLHFIRFPTQDLPTFIQMGRDKNFSTLQTVLCATGGGAYKFEKDFRTIGNLHLHKLDELDCLVKGLLYIDSVSFNGQAECYYFANASEPERCQKMPFNLDDPYPLLVVNIGSGVSILAVHSKDNYKRVTGTSLGGGTFLGLCSLLTGCESFEEALEMASKGDSTQADKLVRDIYGGDYERFGLPGWAVASSFGNMIYKEKRESVSKEDLARATLVTITNNIGSVARMCAVNEKINRVVFVGNFLRVNTLSMKLLAYALDYWSKGQLKALFLEHEGYFGAVGALLGLPNFS
T63183	DRUGINFO	DXB8M6	BBP-671	Phase 1

T63187	TARGETID	T63187
T63187	UNIPROID	TBL1X_HUMAN
T63187	TARGNAME	F-box-like/WD repeat-containing protein TBL1X (TBL1X)
T63187	GENENAME	TBL1X
T63187	TARGTYPE	Clinical trial
T63187	SYNONYMS	SMAP55; Transducin beta-like protein 1X; Transducin-beta-like protein 1, X-linked
T63187	FUNCTION	F-box-like protein involved in the recruitment of the ubiquitin/19S proteasome complex to nuclear receptor-regulated transcription units (PubMed:14980219). Plays an essential role in transcription activation mediated by nuclear receptors. Probably acts as integral component of corepressor complexes that mediates the recruitment of the 19S proteasome complex, leading to the subsequent proteasomal degradation of transcription repressor complexes, thereby allowing cofactor exchange (PubMed:21240272). {ECO:0000269|PubMed:14980219, ECO:0000269|PubMed:21240272}.
T63187	PDBSTRUC	2XTC;2XTD;2XTE
T63187	SEQUENCE	MTELAGASSSCCHRPAGRGAMQSVLHHFQRLRGREGGSHFINTSSPRGEAKMSITSDEVNFLVYRYLQESGFSHSAFTFGIESHISQSNINGTLVPPAALISILQKGLQYVEAEISINEDGTVFDGRPIESLSLIDAVMPDVVQTRQQAFREKLAQQQASAAAAAAAATAAATAATTTSAGVSHQNPSKNREATVNGEENRAHSVNNHAKPMEIDGEVEIPSSKATVLRGHESEVFICAWNPVSDLLASGSGDSTARIWNLNENSNGGSTQLVLRHCIREGGHDVPSNKDVTSLDWNTNGTLLATGSYDGFARIWTEDGNLASTLGQHKGPIFALKWNRKGNYILSAGVDKTTIIWDAHTGEAKQQFPFHSAPALDVDWQNNTTFASCSTDMCIHVCRLGCDRPVKTFQGHTNEVNAIKWDPSGMLLASCSDDMTLKIWSMKQEVCIHDLQAHNKEIYTIKWSPTGPATSNPNSNIMLASASFDSTVRLWDIERGVCTHTLTKHQEPVYSVAFSPDGKYLASGSFDKCVHIWNTQSGNLVHSYRGTGGIFEVCWNARGDKVGASASDGSVCVLDLRK
T63187	DRUGINFO	DJ4B2E	SY-2101	Phase 1
T63187	DRUGINFO	D54WUR	Tegavivint	Phase 1

T63188	TARGETID	T63188
T63188	UNIPROID	ACY2_HUMAN
T63188	TARGNAME	Aspartoacylase (ASPA)
T63188	GENENAME	ASPA
T63188	TARGTYPE	Clinical trial
T63188	SYNONYMS	Aminoacylase-2; ACY-2
T63188	FUNCTION	Catalyzes the deacetylation of N-acetylaspartic acid (NAA) to produce acetate and L-aspartate. NAA occurs in high concentration in brain and its hydrolysis NAA plays a significant part in the maintenance of intact white matter. In other tissues it acts as a scavenger of NAA from body fluids.
T63188	PDBSTRUC	2I3C;2O4H;2O53;2Q51;4MRI;4MXU;4NFR;4TNU
T63188	ECNUMBER	EC 3.5.1.15
T63188	SEQUENCE	MTSCHIAEEHIQKVAIFGGTHGNELTGVFLVKHWLENGAEIQRTGLEVKPFITNPRAVKKCTRYIDCDLNRIFDLENLGKKMSEDLPYEVRRAQEINHLFGPKDSEDSYDIIFDLHNTTSNMGCTLILEDSRNNFLIQMFHYIKTSLAPLPCYVYLIEHPSLKYATTRSIAKYPVGIEVGPQPQGVLRADILDQMRKMIKHALDFIHHFNEGKEFPPCAIEVYKIIEKVDYPRDENGEIAAIIHPNLQDQDWKPLHPGDPMFLTLDGKTIPLGGDCTVYPVFVNEAAYYEKKEAFAKTTKLTLNAKSIRCCLH
T63188	DRUGINFO	DBKE38	BBP-812	Phase 1/2

T63189	TARGETID	T63189
T63189	UNIPROID	CD123_HUMAN
T63189	TARGNAME	Cell division cycle protein 123 (CDC123)
T63189	GENENAME	CDC123
T63189	TARGTYPE	Clinical trial
T63189	SYNONYMS	Protein D123; HT-1080; PZ32
T63189	FUNCTION	Required for S phase entry of the cell cycle. {ECO:0000250}.
T63189	SEQUENCE	MKKEHVLHCQFSAWYPFFRGVTIKSVILPLPQNVKDYLLDDGTLVVSGRDDPPTHSQPDSDDEAEEIQWSDDENTATLTAPEFPEFATKVQEAINSLGGSVFPKLNWSAPRDAYWIAMNSSLKCKTLSDIFLLFKSSDFITRDFTQPFIHCTDDSPDPCIEYELVLRKWCELIPGAEFRCFVKENKLIGISQRDYTQYYDHISKQKEEIRRCIQDFFKKHIQYKFLDEDFVFDIYRDSRGKVWLIDFNPFGEVTDSLLFTWEELISENNLNGDFSEVDAQEQDSPAFRCTNSEVTVQPSPYLSYRLPKDFVDLSTGEDAHKLIDFLKLKRNQQEDD
T63189	DRUGINFO	DMKG40	SAR443579	Phase 1

T63190	TARGETID	T63190
T63190	UNIPROID	CLN3_HUMAN
T63190	TARGNAME	Battenin (CLN3)
T63190	GENENAME	CLN3
T63190	TARGTYPE	Clinical trial
T63190	SYNONYMS	Batten disease protein; Protein CLN3
T63190	FUNCTION	Mediates microtubule-dependent, anterograde transport connecting the Golgi network, endosomes, autophagosomes, lysosomes and plasma membrane, and participates in several cellular processes such as regulation of lysosomal pH, lysosome protein degradation, receptor-mediated endocytosis, autophagy, transport of proteins and lipids from the TGN, apoptosis and synaptic transmission (PubMed:10924275, PubMed:18817525, PubMed:18317235, PubMed:22261744, PubMed:15471887, PubMed:20850431). Facilitates the proteins transport from trans-Golgi network (TGN)-to other membrane compartments such as transport of microdomain-associated proteins to the plasma membrane, IGF2R transport to the lysosome where it regulates the CTSD release leading to regulation of CTSD maturation and thereby APP intracellular processing (PubMed:10924275, PubMed:18817525). Moreover regulates CTSD activity in response to osmotic stress (PubMed:23840424, PubMed:28390177). Also binds galactosylceramide and transports it from the trans Golgi to the rafts, which may have immediate and downstream effects on cell survival by modulating ceramide synthesis (PubMed:18317235). At the plasma membrane, regulates actin-dependent events including filopodia formation, cell migration, and pinocytosis through ARF1-CDC42 pathway and also the cytoskeleton organization through interaction with MYH10 and fodrin leading to the regulation of the plasma membrane association of Na+, K+ ATPase complex (PubMed:20850431). Regulates synaptic transmission in the amygdala, hippocampus, and cerebellum through regulation of synaptic vesicles density and their proximity to active zones leading to modulation of short-term plasticity and age-dependent anxious behavior, learning and memory (By similarity). Regulates autophagic vacuoles (AVs) maturation by modulating the trafficking between endocytic and autophagolysosomal/lysosomal compartments, which involves vesicle fusion leading to regulation of degradation process (By similarity). Participates also in cellular homeostasis of compounds such as, water, ions, amino acids, proteins and lipids in several tissue namely in brain and kidney through regulation of their transport and synthesis (PubMed:17482562). {ECO:0000250|UniProtKB:Q61124, ECO:0000269|PubMed:10924275, ECO:0000269|PubMed:15471887, ECO:0000269|PubMed:17482562, ECO:0000269|PubMed:18317235, ECO:0000269|PubMed:18817525, ECO:0000269|PubMed:20850431, ECO:0000269|PubMed:22261744, ECO:0000269|PubMed:23840424, ECO:0000269|PubMed:28390177}.
T63190	SEQUENCE	MGGCAGSRRRFSDSEGEETVPEPRLPLLDHQGAHWKNAVGFWLLGLCNNFSYVVMLSAAHDILSHKRTSGNQSHVDPGPTPIPHNSSSRFDCNSVSTAAVLLADILPTLVIKLLAPLGLHLLPYSPRVLVSGICAAGSFVLVAFSHSVGTSLCGVVFASISSGLGEVTFLSLTAFYPRAVISWWSSGTGGAGLLGALSYLGLTQAGLSPQQTLLSMLGIPALLLASYFLLLTSPEAQDPGGEEEAESAARQPLIRTEAPESKPGSSSSLSLRERWTVFKGLLWYIVPLVVVYFAEYFINQGLFELLFFWNTSLSHAQQYRWYQMLYQAGVFASRSSLRCCRIRFTWALALLQCLNLVFLLADVWFGFLPSIYLVFLIILYEGLLGGAAYVNTFHNIALETSDEHREFAMAATCISDTLGISLSGLLALPLHDFLCQLS
T63190	DRUGINFO	DF7R6C	AT-GTX-502	Phase 1/2

T63191	TARGETID	T63191
T63191	UNIPROID	CLN6_HUMAN
T63191	TARGNAME	Ceroid-lipofuscinosis neuronal protein 6 (CLN6)
T63191	GENENAME	CLN6
T63191	TARGTYPE	Clinical trial
T63191	SYNONYMS	Protein CLN6
T63191	SEQUENCE	MEATRRRQHLGATGGPGAQLGASFLQARHGSVSADEAARTAPFHLDLWFYFTLQNWVLDFGRPIAMLVFPLEWFPLNKPSVGDYFHMAYNVITPFLLLKLIERSPRTLPRSITYVSIIIFIMGASIHLVGDSVNHRLLFSGYQHHLSVRENPIIKNLKPETLIDSFELLYYYDEYLGHCMWYIPFFLILFMYFSGCFTASKAESLIPGPALLLVAPSGLYYWYLVTEGQIFILFIFTFFAMLALVLHQKRKRLFLDSNGLFLFSSFALTLLLVALWVAWLWNDPVLRKKYPGVIYVPEPWAFYTLHVSSRH
T63191	DRUGINFO	D0TBF3	AT-GTX-501	Phase 1/2

T63192	TARGETID	T63192
T63192	UNIPROID	CP21A_HUMAN
T63192	TARGNAME	Steroid 21-hydroxylase (CYP21A2)
T63192	GENENAME	CYP21A2
T63192	TARGTYPE	Clinical trial
T63192	SYNONYMS	21-OHase; Cytochrome P-450c21; Cytochrome P450 21; Cytochrome P450 XXI; Cytochrome P450-C21; Cytochrome P450-C21B
T63192	FUNCTION	A cytochrome P450 monooxygenase that plays a major role in adrenal steroidogenesis. Catalyzes the hydroxylation at C-21 of progesterone and 17alpha-hydroxyprogesterone to respectively form 11-deoxycorticosterone and 11-deoxycortisol, intermediate metabolites in the biosynthetic pathway of mineralocorticoids and glucocorticoids (PubMed:25855791, PubMed:10602386, PubMed:16984992, PubMed:22014889, PubMed:27721825). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:25855791). {ECO:0000269|PubMed:10602386, ECO:0000269|PubMed:16984992, ECO:0000269|PubMed:22014889, ECO:0000269|PubMed:25855791, ECO:0000269|PubMed:27721825}.
T63192	PDBSTRUC	4Y8W
T63192	BIOCLASS	Cytochrome P450 family
T63192	ECNUMBER	EC 1.14.14.16
T63192	SEQUENCE	MLLLGLLLLPLLAGARLLWNWWKLRSLHLPPLAPGFLHLLQPDLPIYLLGLTQKFGPIYRLHLGLQDVVVLNSKRTIEEAMVKKWADFAGRPEPLTYKLVSKNYPDLSLGDYSLLWKAHKKLTRSALLLGIRDSMEPVVEQLTQEFCERMRAQPGTPVAIEEEFSLLTCSIICYLTFGDKIKDDNLMPAYYKCIQEVLKTWSHWSIQIVDVIPFLRFFPNPGLRRLKQAIEKRDHIVEMQLRQHKESLVAGQWRDMMDYMLQGVAQPSMEEGSGQLLEGHVHMAAVDLLIGGTETTANTLSWAVVFLLHHPEIQQRLQEELDHELGPGASSSRVPYKDRARLPLLNATIAEVLRLRPVVPLALPHRTTRPSSISGYDIPEGTVIIPNLQGAHLDETVWERPHEFWPDRFLEPGKNSRALAFGCGARVCLGEPLARLELFVVLTRLLQAFTLLPSGDALPSLQPLPHCSVILKMQPFQVRLQPRGMGAHSPGQNQ
T63192	DRUGINFO	DP58GD	BBP-631	Phase 1/2

T63193	TARGETID	T63193
T63193	UNIPROID	DGKZ_HUMAN
T63193	TARGNAME	Diacylglycerol kinase zeta (DGKZ)
T63193	GENENAME	DGKZ
T63193	TARGTYPE	Clinical trial
T63193	SYNONYMS	DAG kinase zeta; Diglyceride kinase zeta; DGK-zeta
T63193	FUNCTION	Diacylglycerol kinase that converts diacylglycerol/DAG into phosphatidic acid/phosphatidate/PA and regulates the respective levels of these two bioactive lipids (PubMed:9159104, PubMed:15544348, PubMed:18004883, PubMed:19744926, PubMed:22108654, PubMed:22627129, PubMed:23949095). Thereby, acts as a central switch between the signaling pathways activated by these second messengers with different cellular targets and opposite effects in numerous biological processes (PubMed:9159104, PubMed:15544348, PubMed:18004883, PubMed:19744926, PubMed:22108654, PubMed:22627129, PubMed:23949095). Also plays an important role in the biosynthesis of complex lipids (Probable). Does not exhibit an acyl chain-dependent substrate specificity among diacylglycerol species (PubMed:9159104, PubMed:19744926, PubMed:22108654). Can also phosphorylate 1-alkyl-2-acylglycerol in vitro but less efficiently and with a preference for alkylacylglycerols containing an arachidonoyl group (PubMed:15544348, PubMed:19744926, PubMed:22627129). The biological processes it is involved in include T cell activation since it negatively regulates T-cell receptor signaling which is in part mediated by diacylglycerol (By similarity). By generating phosphatidic acid, stimulates PIP5KIA activity which regulates actin polymerization (PubMed:15157668). Through the same mechanism could also positively regulate insulin-induced translocation of SLC2A4 to the cell membrane (By similarity). {ECO:0000250|UniProtKB:Q80UP3, ECO:0000269|PubMed:15157668, ECO:0000269|PubMed:15544348, ECO:0000269|PubMed:18004883, ECO:0000269|PubMed:19744926, ECO:0000269|PubMed:22108654, ECO:0000269|PubMed:22627129, ECO:0000269|PubMed:23949095, ECO:0000269|PubMed:9159104, ECO:0000305|PubMed:8626588}.; [Isoform 1]: Regulates RASGRP1 activity. {ECO:0000269|PubMed:11257115}.; [Isoform 2]: Does not regulate RASGRP1 activity. {ECO:0000269|PubMed:11257115}.
T63193	PDBSTRUC	5ELQ
T63193	BIOCLASS	Kinase
T63193	ECNUMBER	EC 2.7.1.107
T63193	SEQUENCE	MEPRDGSPEARSSDSESASASSSGSERDAGPEPDKAPRRLNKRRFPGLRLFGHRKAITKSGLQHLAPPPPTPGAPCSESERQIRSTVDWSESATYGEHIWFETNVSGDFCYVGEQYCVARMLKSVSRRKCAACKIVVHTPCIEQLEKINFRCKPSFRESGSRNVREPTFVRHHWVHRRRQDGKCRHCGKGFQQKFTFHSKEIVAISCSWCKQAYHSKVSCFMLQQIEEPCSLGVHAAVVIPPTWILRARRPQNTLKASKKKKRASFKRKSSKKGPEEGRWRPFIIRPTPSPLMKPLLVFVNPKSGGNQGAKIIQSFLWYLNPRQVFDLSQGGPKEALEMYRKVHNLRILACGGDGTVGWILSTLDQLRLKPPPPVAILPLGTGNDLARTLNWGGGYTDEPVSKILSHVEEGNVVQLDRWDLHAEPNPEAGPEDRDEGATDRLPLDVFNNYFSLGFDAHVTLEFHESREANPEKFNSRFRNKMFYAGTAFSDFLMGSSKDLAKHIRVVCDGMDLTPKIQDLKPQCVVFLNIPRYCAGTMPWGHPGEHHDFEPQRHDDGYLEVIGFTMTSLAALQVGGHGERLTQCREVVLTTSKAIPVQVDGEPCKLAASRIRIALRNQATMVQKAKRRSAAPLHSDQQPVPEQLRIQVSRVSMHDYEALHYDKEQLKEASVPLGTVVVPGDSDLELCRAHIERLQQEPDGAGAKSPTCQKLSPKWCFLDATTASRFYRIDRAQEHLNYVTEIAQDEIYILDPELLGASARPDLPTPTSPLPTSPCSPTPRSLQGDAAPPQGEELIEAAKRNDFCKLQELHRAGGDLMHRDEQSRTLLHHAVSTGSKDVVRYLLDHAPPEILDAVEENGETCLHQAAALGQRTICHYIVEAGASLMKTDQQGDTPRQRAEKAQDTELAAYLENRQHYQMIQREDQETAV
T63193	DRUGINFO	D5GVZ1	ASP1570	Phase 1/2

T63194	TARGETID	T63194
T63194	UNIPROID	ENPP1_HUMAN
T63194	TARGNAME	Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1)
T63194	GENENAME	ENPP1
T63194	TARGTYPE	Clinical trial
T63194	SYNONYMS	E-NPP 1; Membrane component chromosome 6 surface marker 1; Phosphodiesterase I/nucleotide pyrophosphatase 1; Plasma-cell membrane glycoprotein PC-1
T63194	FUNCTION	Nucleotide pyrophosphatase that generates diphosphate (PPi) and functions in bone mineralization and soft tissue calcification by regulating pyrophosphate levels (By similarity). PPi inhibits bone mineralization and soft tissue calcification by binding to nascent hydroxyapatite crystals, thereby preventing further growth of these crystals (PubMed:11004006). Preferentially hydrolyzes ATP, but can also hydrolyze other nucleoside 5' triphosphates such as GTP, CTP and UTP to their corresponding monophosphates with release of pyrophosphate, as well as diadenosine polyphosphates, and also 3',5'-cAMP to AMP (PubMed:27467858, PubMed:8001561, PubMed:25344812, PubMed:28011303, PubMed:35147247). May also be involved in the regulation of the availability of nucleotide sugars in the endoplasmic reticulum and Golgi, and the regulation of purinergic signaling (PubMed:27467858, PubMed:8001561). Inhibits ectopic joint calcification and maintains articular chondrocytes by repressing hedgehog signaling; it is however unclear whether hedgehog inhibition is direct or indirect (By similarity). Appears to modulate insulin sensitivity and function (PubMed:10615944). Also involved in melanogenesis (PubMed:28964717). Also able to hydrolyze 2',3'-cGAMP (cyclic GMP-AMP), a second messenger that activates TMEM173/STING and triggers type-I interferon production (PubMed:25344812). 2',3'-cGAMP degradation takes place in the lumen or extracellular space, and not in the cytosol where it is produced; the role of 2',3'-cGAMP hydrolysis is therefore unclear (PubMed:25344812). Not able to hydrolyze the 2',3'-cGAMP linkage isomer 3'-3'-cGAMP (PubMed:25344812). {ECO:0000250|UniProtKB:P06802, ECO:0000269|PubMed:10615944, ECO:0000269|PubMed:25344812, ECO:0000269|PubMed:27467858, ECO:0000269|PubMed:28011303, ECO:0000269|PubMed:28964717, ECO:0000269|PubMed:35147247, ECO:0000269|PubMed:8001561, ECO:0000305|PubMed:11004006}.
T63194	PDBSTRUC	2YS0;6WET;6WEU;6WEV;6WEW;6WFJ
T63194	ECNUMBER	EC 3.1.4.1; EC 3.6.1.9
T63194	SEQUENCE	MERDGCAGGGSRGGEGGRAPREGPAGNGRDRGRSHAAEAPGDPQAAASLLAPMDVGEEPLEKAARARTAKDPNTYKVLSLVLSVCVLTTILGCIFGLKPSCAKEVKSCKGRCFERTFGNCRCDAACVELGNCCLDYQETCIEPEHIWTCNKFRCGEKRLTRSLCACSDDCKDKGDCCINYSSVCQGEKSWVEEPCESINEPQCPAGFETPPTLLFSLDGFRAEYLHTWGGLLPVISKLKKCGTYTKNMRPVYPTKTFPNHYSIVTGLYPESHGIIDNKMYDPKMNASFSLKSKEKFNPEWYKGEPIWVTAKYQGLKSGTFFWPGSDVEINGIFPDIYKMYNGSVPFEERILAVLQWLQLPKDERPHFYTLYLEEPDSSGHSYGPVSSEVIKALQRVDGMVGMLMDGLKELNLHRCLNLILISDHGMEQGSCKKYIYLNKYLGDVKNIKVIYGPAARLRPSDVPDKYYSFNYEGIARNLSCREPNQHFKPYLKHFLPKRLHFAKSDRIEPLTFYLDPQWQLALNPSERKYCGSGFHGSDNVFSNMQALFVGYGPGFKHGIEADTFENIEVYNLMCDLLNLTPAPNNGTHGSLNHLLKNPVYTPKHPKEVHPLVQCPFTRNPRDNLGCSCNPSILPIEDFQTQFNLTVAEEKIIKHETLPYGRPRVLQKENTICLLSQHQFMSGYSQDILMPLWTSYTVDRNDSFSTEDFSNCLYQDFRIPLSPVHKCSFYKNNTKVSYGFLSPPQLNKNSSGIYSEALLTTNIVPMYQSFQVIWRYFHDTLLRKYAEERNGVNVVSGPVFDFDYDGRCDSLENLRQKRRVIRNQEILIPTHFFIVLTSCKDTSQTPLHCENLDTLAFILPHRTDNSESCVHGKHDSSWVEELLMLHRARITDVEHITGLSFYQQRKEPVSDILKLKTHLPTFSQED
T63194	DRUGINFO	DK0B7G	INZ-701	Phase 1/2

T63195	TARGETID	T63195
T63195	UNIPROID	GAN_HUMAN
T63195	TARGNAME	Gigaxonin (GAN)
T63195	GENENAME	GAN
T63195	TARGTYPE	Clinical trial
T63195	SYNONYMS	Kelch-like protein 16
T63195	FUNCTION	Probable cytoskeletal component that directly or indirectly plays an important role in neurofilament architecture. May act as a substrate-specific adapter of an E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Controls degradation of TBCB. Controls degradation of MAP1B and MAP1S, and is critical for neuronal maintenance and survival. {ECO:0000269|PubMed:12147674, ECO:0000269|PubMed:15983046, ECO:0000269|PubMed:16227972, ECO:0000269|PubMed:16303566}.
T63195	PDBSTRUC	2PPI;3HVE
T63195	SEQUENCE	MAEGSAVSDPQHAARLLRALSSFREESRFCDAHLVLDGEEIPVQKNILAAASPYIRTKLNYNPPKDDGSTYKIELEGISVMVMREILDYIFSGQIRLNEDTIQDVVQAADLLLLTDLKTLCCEFLEGCIAAENCIGIRDFALHYCLHHVHYLATEYLETHFRDVSSTEEFLELSPQKLKEVISLEKLNVGNERYVFEAVIRWIAHDTEIRKVHMKDVMSALWVSGLDSSYLREQMLNEPLVREIVKECSNIPLSQPQQGEAMLANFKPRGYSECIVTVGGEERVSRKPTAAMRCMCPLYDPNRQLWIELAPLSMPRINHGVLSAEGFLFVFGGQDENKQTLSSGEKYDPDANTWTALPPMNEARHNFGIVEIDGMLYILGGEDGEKELISMECYDIYSKTWTKQPDLTMVRKIGCYAAMKKKIYAMGGGSYGKLFESVECYDPRTQQWTAICPLKERRFGAVACGVAMELYVFGGVRSREDAQGSEMVTCKSEFYHDEFKRWIYLNDQNLCIPASSSFVYGAVPIGASIYVIGDLDTGTNYDYVREFKRSTGTWHHTKPLLPSDLRRTGCAALRIANCKLFRLQLQQGLFRIRVHSP
T63195	DRUGINFO	DZ40HL	TSHA-120	Phase 1/2

T63196	TARGETID	T63196
T63196	UNIPROID	HEXA_HUMAN
T63196	TARGNAME	Beta-hexosaminidase subunit alpha (HEXA)
T63196	GENENAME	HEXA
T63196	TARGTYPE	Clinical trial
T63196	SYNONYMS	Beta-N-acetylhexosaminidase subunit alpha; Hexosaminidase subunit A; N-acetyl-beta-glucosaminidase subunit alpha
T63196	FUNCTION	Hydrolyzes the non-reducing end N-acetyl-D-hexosamine and/or sulfated N-acetyl-D-hexosamine of glycoconjugates, such as the oligosaccharide moieties from proteins and neutral glycolipids, or from certain mucopolysaccharides (PubMed:11707436, PubMed:9694901, PubMed:8672428, PubMed:8123671). The isozyme S is as active as the isozyme A on the anionic bis-sulfated glycans, the chondroitin-6-sulfate trisaccharide (C6S-3), and the dermatan sulfate pentasaccharide, and the sulfated glycosphingolipid SM2 (PubMed:11707436). The isozyme B does not hydrolyze each of these substrates, however hydrolyzes efficiently neutral oligosaccharide (PubMed:11707436). Only the isozyme A is responsible for the degradation of GM2 gangliosides in the presence of GM2A (PubMed:9694901, PubMed:8672428, PubMed:8123671). {ECO:0000269|PubMed:11707436, ECO:0000269|PubMed:8123671, ECO:0000269|PubMed:8672428, ECO:0000269|PubMed:9694901}.
T63196	PDBSTRUC	2GJX;2GK1
T63196	BIOCLASS	Glycosyl hydrolase
T63196	ECNUMBER	EC 3.2.1.52
T63196	SEQUENCE	MTSSRLWFSLLLAAAFAGRATALWPWPQNFQTSDQRYVLYPNNFQFQYDVSSAAQPGCSVLDEAFQRYRDLLFGSGSWPRPYLTGKRHTLEKNVLVVSVVTPGCNQLPTLESVENYTLTINDDQCLLLSETVWGALRGLETFSQLVWKSAEGTFFINKTEIEDFPRFPHRGLLLDTSRHYLPLSSILDTLDVMAYNKLNVFHWHLVDDPSFPYESFTFPELMRKGSYNPVTHIYTAQDVKEVIEYARLRGIRVLAEFDTPGHTLSWGPGIPGLLTPCYSGSEPSGTFGPVNPSLNNTYEFMSTFFLEVSSVFPDFYLHLGGDEVDFTCWKSNPEIQDFMRKKGFGEDFKQLESFYIQTLLDIVSSYGKGYVVWQEVFDNKVKIQPDTIIQVWREDIPVNYMKELELVTKAGFRALLSAPWYLNRISYGPDWKDFYIVEPLAFEGTPEQKALVIGGEACMWGEYVDNTNLVPRLWPRAGAVAERLWSNKLTSDLTFAYERLSHFRCELLRRGVQAQPLNVGFCEQEFEQT
T63196	DRUGINFO	D1TS4V	TSHA-101	Phase 1/2
T63196	DRUGINFO	DYK9H4	AXO-AAV-GM2	Phase 1

T63197	TARGETID	T63197
T63197	UNIPROID	HEXB_HUMAN
T63197	TARGNAME	Beta-hexosaminidase subunit beta (HEXB)
T63197	GENENAME	HEXB
T63197	TARGTYPE	Clinical trial
T63197	SYNONYMS	Beta-N-acetylhexosaminidase subunit beta; Hexosaminidase subunit B; Cervical cancer proto-oncogene 7 protein; HCC-7; N-acetyl-beta-glucosaminidase subunit beta
T63197	FUNCTION	Hydrolyzes the non-reducing end N-acetyl-D-hexosamine and/or sulfated N-acetyl-D-hexosamine of glycoconjugates, such as the oligosaccharide moieties from proteins and neutral glycolipids, or from certain mucopolysaccharides (PubMed:11707436, PubMed:9694901, PubMed:8672428, PubMed:8123671). The isozyme B does not hydrolyze each of these substrates, however hydrolyzes efficiently neutral oligosaccharide (PubMed:11707436). Only the isozyme A is responsible for the degradation of GM2 gangliosides in the presence of GM2A (PubMed:9694901, PubMed:8672428, PubMed:8123671). During fertilization is responsible, at least in part, for the zona block to polyspermy. Present in the cortical granules of non-activated oocytes, is exocytosed during the cortical reaction in response to oocyte activation and inactivates the sperm galactosyltransferase-binding site, accounting for the block in sperm binding to the zona pellucida (By similarity). {ECO:0000250|UniProtKB:P20060, ECO:0000269|PubMed:11707436, ECO:0000269|PubMed:8123671, ECO:0000269|PubMed:8672428, ECO:0000269|PubMed:9694901}.
T63197	PDBSTRUC	1NOU;1NOW;1NP0;1O7A;2GJX;2GK1;3LMY;5BRO
T63197	BIOCLASS	Glycosyl hydrolase
T63197	ECNUMBER	EC 3.2.1.52
T63197	SEQUENCE	MELCGLGLPRPPMLLALLLATLLAAMLALLTQVALVVQVAEAARAPSVSAKPGPALWPLPLLVKMTPNLLHLAPENFYISHSPNSTAGPSCTLLEEAFRRYHGYIFGFYKWHHEPAEFQAKTQVQQLLVSITLQSECDAFPNISSDESYTLLVKEPVAVLKANRVWGALRGLETFSQLVYQDSYGTFTINESTIIDSPRFSHRGILIDTSRHYLPVKIILKTLDAMAFNKFNVLHWHIVDDQSFPYQSITFPELSNKGSYSLSHVYTPNDVRMVIEYARLRGIRVLPEFDTPGHTLSWGKGQKDLLTPCYSRQNKLDSFGPINPTLNTTYSFLTTFFKEISEVFPDQFIHLGGDEVEFKCWESNPKIQDFMRQKGFGTDFKKLESFYIQKVLDIIATINKGSIVWQEVFDDKAKLAPGTIVEVWKDSAYPEELSRVTASGFPVILSAPWYLDLISYGQDWRKYYKVEPLDFGGTQKQKQLFIGGEACLWGEYVDATNLTPRLWPRASAVGERLWSSKDVRDMDDAYDRLTRHRCRMVERGIAAQPLYAGYCNHENM
T63197	DRUGINFO	D1TS4V	TSHA-101	Phase 1/2
T63197	DRUGINFO	DYK9H4	AXO-AAV-GM2	Phase 1

T63202	TARGETID	T63202
T63202	UNIPROID	ATP7B_HUMAN
T63202	TARGNAME	Copper-transporting ATPase 2 (ATP7B)
T63202	GENENAME	ATP7B
T63202	TARGTYPE	Clinical trial
T63202	SYNONYMS	Copper pump 2; Wilson disease-associated protein
T63202	FUNCTION	Copper ion transmembrane transporter involved in the export of copper out of the cells. It is involved in copper homeostasis in the liver, where it ensures the efflux of copper from hepatocytes into the bile in response to copper overload. {ECO:0000269|PubMed:18203200, ECO:0000269|PubMed:22240481, ECO:0000269|PubMed:24706876, ECO:0000269|PubMed:26004889}.
T63202	PDBSTRUC	2ARF;2EW9;2KOY;2LQB;2N7Y;2ROP;6A71;6A72;7XUK;7XUM;7XUN;7XUO;8IOY
T63202	ECNUMBER	EC 7.2.2.8
T63202	SEQUENCE	MPEQERQITAREGASRKILSKLSLPTRAWEPAMKKSFAFDNVGYEGGLDGLGPSSQVATSTVRILGMTCQSCVKSIEDRISNLKGIISMKVSLEQGSATVKYVPSVVCLQQVCHQIGDMGFEASIAEGKAASWPSRSLPAQEAVVKLRVEGMTCQSCVSSIEGKVRKLQGVVRVKVSLSNQEAVITYQPYLIQPEDLRDHVNDMGFEAAIKSKVAPLSLGPIDIERLQSTNPKRPLSSANQNFNNSETLGHQGSHVVTLQLRIDGMHCKSCVLNIEENIGQLLGVQSIQVSLENKTAQVKYDPSCTSPVALQRAIEALPPGNFKVSLPDGAEGSGTDHRSSSSHSPGSPPRNQVQGTCSTTLIAIAGMTCASCVHSIEGMISQLEGVQQISVSLAEGTATVLYNPSVISPEELRAAIEDMGFEASVVSESCSTNPLGNHSAGNSMVQTTDGTPTSVQEVAPHTGRLPANHAPDILAKSPQSTRAVAPQKCFLQIKGMTCASCVSNIERNLQKEAGVLSVLVALMAGKAEIKYDPEVIQPLEIAQFIQDLGFEAAVMEDYAGSDGNIELTITGMTCASCVHNIESKLTRTNGITYASVALATSKALVKFDPEIIGPRDIIKIIEEIGFHASLAQRNPNAHHLDHKMEIKQWKKSFLCSLVFGIPVMALMIYMLIPSNEPHQSMVLDHNIIPGLSILNLIFFILCTFVQLLGGWYFYVQAYKSLRHRSANMDVLIVLATSIAYVYSLVILVVAVAEKAERSPVTFFDTPPMLFVFIALGRWLEHLAKSKTSEALAKLMSLQATEATVVTLGEDNLIIREEQVPMELVQRGDIVKVVPGGKFPVDGKVLEGNTMADESLITGEAMPVTKKPGSTVIAGSINAHGSVLIKATHVGNDTTLAQIVKLVEEAQMSKAPIQQLADRFSGYFVPFIIIMSTLTLVVWIVIGFIDFGVVQRYFPNPNKHISQTEVIIRFAFQTSITVLCIACPCSLGLATPTAVMVGTGVAAQNGILIKGGKPLEMAHKIKTVMFDKTGTITHGVPRVMRVLLLGDVATLPLRKVLAVVGTAEASSEHPLGVAVTKYCKEELGTETLGYCTDFQAVPGCGIGCKVSNVEGILAHSERPLSAPASHLNEAGSLPAEKDAVPQTFSVLIGNREWLRRNGLTISSDVSDAMTDHEMKGQTAILVAIDGVLCGMIAIADAVKQEAALAVHTLQSMGVDVVLITGDNRKTARAIATQVGINKVFAEVLPSHKVAKVQELQNKGKKVAMVGDGVNDSPALAQADMGVAIGTGTDVAIEAADVVLIRNDLLDVVASIHLSKRTVRRIRINLVLALIYNLVGIPIAAGVFMPIGIVLQPWMGSAAMAASSVSVVLSSLQLKCYKKPDLERYEAQAHGHMKPLTASQVSVHIGMDDRWRDSPRATPWDQVSYVSQVSLSSLTSDKPSRHSAAADDDGDKWSLLLNGRDEEQYI
T63202	DRUGINFO	DOJ2A5	VTX-801	Phase 2
T63202	DRUGINFO	DCY10V	UX701	Phase 1/2

T63244	TARGETID	T63244
T63244	UNIPROID	FGF19_HUMAN
T63244	TARGNAME	Fibroblast growth factor 19 (FGF19)
T63244	GENENAME	FGF19
T63244	TARGTYPE	Clinical trial
T63244	SYNONYMS	FGF-19
T63244	FUNCTION	Involved in the suppression of bile acid biosynthesis through down-regulation of CYP7A1 expression, following positive regulation of the JNK and ERK1/2 cascades. Stimulates glucose uptake in adipocytes. Activity requires the presence of KLB and FGFR4. {ECO:0000269|PubMed:12815072, ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:19085950}.
T63244	PDBSTRUC	1PWA;2P23;6KTR;6NFJ
T63244	BIOCLASS	Heparin-binding growth factors family
T63244	SEQUENCE	MRSGCVVVHVWILAGLWLAVAGRPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK
T63244	DRUGINFO	D5TJ6M	Aldafermin	Phase 2

T63207	TARGETID	T63207
T63207	UNIPROID	LANC2_HUMAN
T63207	TARGNAME	LanC-like protein 2 (LANCL2)
T63207	GENENAME	LANCL2
T63207	TARGTYPE	Clinical trial
T63207	SYNONYMS	Testis-specific adriamycin sensitivity protein
T63207	FUNCTION	Necessary for abscisic acid (ABA) binding on the cell membrane and activation of the ABA signaling pathway in granulocytes. {ECO:0000269|PubMed:19667068}.
T63207	PDBSTRUC	6WQ1
T63207	SEQUENCE	MGETMSKRLKLHLGGEAEMEERAFVNPFPDYEAAAGALLASGAAEETGCVRPPATTDEPGLPFHQDGKIIHNFIRRIQTKIKDLLQQMEEGLKTADPHDCSAYTGWTGIALLYLQLYRVTCDQTYLLRSLDYVKRTLRNLNGRRVTFLCGDAGPLAVGAVIYHKLRSDCESQECVTKLLQLQRSVVCQESDLPDELLYGRAGYLYALLYLNTEIGPGTVCESAIKEVVNAIIESGKTLSREERKTERCPLLYQWHRKQYVGAAHGMAGIYYMLMQPAAKVDQETLTEMVKPSIDYVRHKKFRSGNYPSSLSNETDRLVHWCHGAPGVIHMLMQAYKVFKEEKYLKEAMECSDVIWQRGLLRKGYGICHGTAGNGYSFLSLYRLTQDKKYLYRACKFAEWCLDYGAHGCRIPDRPYSLFEGMAGAIHFLSDVLGPETSRFPAFELDSSKRD
T63207	DRUGINFO	DC7JQ8	Omilancor	Phase 2
T63207	DRUGINFO	DN2Z5C	LABP-104	Phase 1

T63208	TARGETID	T63208
T63208	UNIPROID	LIRA4_HUMAN
T63208	TARGNAME	Leukocyte immunoglobulin-like receptor subfamily A member 4 (LILRA4)
T63208	GENENAME	LILRA4
T63208	TARGTYPE	Clinical trial
T63208	SYNONYMS	CD85 antigen-like family member G; Immunoglobulin-like transcript 7; ILT-7; CD85g
T63208	FUNCTION	Functions coreceptor to limit the innate immune responses to viral infections; signaling occurs via FCER1G (PubMed:16735691, PubMed:19564354). Down-regulates the production of IFNA1, IFNA2, IFNA4, IFNB1 and TNF by plasmacytoid dendritic cells that have been exposed to influenza virus or cytidine-phosphate-guanosine (CpG) dinucleotides, indicating it functions as negative regulator of TLR7 and TLR9 signaling cascades (PubMed:16735691, PubMed:19564354, PubMed:24586760). Down-regulates interferon production in response to interaction with BST2 on HIV-1 infected cells (PubMed:26172439). Activates a signaling cascade in complex with FCER1G that results in phosphorylation of Src family and Syk kinases and thereby triggers mobilization of intracellular Ca(2+) (PubMed:16735691, PubMed:19564354). Does not interfere with the differentiation of plasmacytoid dendritic cells into antigen-presenting cells (PubMed:24586760). {ECO:0000269|PubMed:16735691, ECO:0000269|PubMed:19564354, ECO:0000269|PubMed:24586760, ECO:0000269|PubMed:26172439}.
T63208	SEQUENCE	MTLILTSLLFFGLSLGPRTRVQAENLLKPILWAEPGPVITWHNPVTIWCQGTLEAQGYRLDKEGNSMSRHILKTLESENKVKLSIPSMMWEHAGRYHCYYQSPAGWSEPSDPLELVVTAYSRPTLSALPSPVVTSGVNVTLRCASRLGLGRFTLIEEGDHRLSWTLNSHQHNHGKFQALFPMGPLTFSNRGTFRCYGYENNTPYVWSEPSDPLQLLVSGVSRKPSLLTLQGPVVTPGENLTLQCGSDVGYIRYTLYKEGADGLPQRPGRQPQAGLSQANFTLSPVSRSYGGQYRCYGAHNVSSEWSAPSDPLDILIAGQISDRPSLSVQPGPTVTSGEKVTLLCQSWDPMFTFLLTKEGAAHPPLRLRSMYGAHKYQAEFPMSPVTSAHAGTYRCYGSRSSNPYLLSHPSEPLELVVSGATETLNPAQKKSDSKTAPHLQDYTVENLIRMGVAGLVLLFLGILLFEAQHSQRSPPRCSQEANSRKDNAPFRVVEPWEQI
T63208	DRUGINFO	DVG1O0	Daxdilimab	Phase 2

T63209	TARGETID	T63209
T63209	UNIPROID	LIRB1_HUMAN
T63209	TARGNAME	Leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1)
T63209	GENENAME	LILRB1
T63209	TARGTYPE	Clinical trial
T63209	SYNONYMS	LIR-1; Leukocyte immunoglobulin-like receptor 1; CD85 antigen-like family member J; Immunoglobulin-like transcript 2; ILT-2; Monocyte/macrophage immunoglobulin-like receptor 7; MIR-7; CD85j
T63209	FUNCTION	Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles (PubMed:16455647, PubMed:28636952). Receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. Engagement of LILRB1 present on natural killer cells or T-cells by class I MHC molecules protects the target cells from lysis. Interaction with HLA-B or HLA-E leads to inhibition of FCER1A signaling and serotonin release. Inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions (PubMed:11907092, PubMed:9285411, PubMed:9842885). Recognizes HLA-G in complex with B2M/beta-2 microglobulin and a nonamer self-peptide (PubMed:16455647). Upon interaction with peptide-bound HLA-G-B2M complex, triggers secretion of growth-promoting factors by decidual NK cells (PubMed:29262349, PubMed:19304799). Reprograms B cells toward an immune suppressive phenotype (PubMed:24453251). {ECO:0000269|PubMed:11907092, ECO:0000269|PubMed:16455647, ECO:0000269|PubMed:19304799, ECO:0000269|PubMed:24453251, ECO:0000269|PubMed:28636952, ECO:0000269|PubMed:29262349, ECO:0000269|PubMed:9285411, ECO:0000269|PubMed:9842885}.
T63209	PDBSTRUC	1G0X;1P7Q;1UFU;1UGN;1VDG;3D2U;4LL9;4NO0;5KNM;6AEE;6EWA;6EWC;6EWO;6K60;6ZDX;7KFK
T63209	SEQUENCE	MTPILTVLICLGLSLGPRTHVQAGHLPKPTLWAEPGSVITQGSPVTLRCQGGQETQEYRLYREKKTALWITRIPQELVKKGQFPIPSITWEHAGRYRCYYGSDTAGRSESSDPLELVVTGAYIKPTLSAQPSPVVNSGGNVILQCDSQVAFDGFSLCKEGEDEHPQCLNSQPHARGSSRAIFSVGPVSPSRRWWYRCYAYDSNSPYEWSLPSDLLELLVLGVSKKPSLSVQPGPIVAPEETLTLQCGSDAGYNRFVLYKDGERDFLQLAGAQPQAGLSQANFTLGPVSRSYGGQYRCYGAHNLSSEWSAPSDPLDILIAGQFYDRVSLSVQPGPTVASGENVTLLCQSQGWMQTFLLTKEGAADDPWRLRSTYQSQKYQAEFPMGPVTSAHAGTYRCYGSQSSKPYLLTHPSDPLELVVSGPSGGPSSPTTGPTSTSGPEDQPLTPTGSDPQSGLGRHLGVVIGILVAVILLLLLLLLLFLILRHRRQGKHWTSTQRKADFQHPAGAVGPEPTDRGLQWRSSPAADAQEENLYAAVKHTQPEDGVEMDTRSPHDEDPQAVTYAEVKHSRPRREMASPPSPLSGEFLDTKDRQAEEDRQMDTEAAASEAPQDVTYAQLHSLTLRREATEPPPSQEGPSPAVPSIYATLAIH
T63209	DRUGINFO	DE61WB	NGM707	Phase 2
T63209	DRUGINFO	D0M3NW	SAR444881	Phase 1

T63210	TARGETID	T63210
T63210	UNIPROID	LX12B_HUMAN
T63210	TARGNAME	Arachidonate 12-lipoxygenase, 12R-type (ALOX12B)
T63210	GENENAME	ALOX12B
T63210	TARGTYPE	Clinical trial
T63210	SYNONYMS	12R-LOX; 12R-lipoxygenase; Epidermis-type lipoxygenase 12
T63210	FUNCTION	Catalyzes the regio and stereo-specific incorporation of a single molecule of dioxygen into free and esterified polyunsaturated fatty acids generating lipid hydroperoxides that can be further reduced to the corresponding hydroxy species (PubMed:9837935, PubMed:9618483, PubMed:21558561). In the skin, acts upstream of ALOXE3 on the lineolate moiety of esterified omega-hydroxyacyl-sphingosine (EOS) ceramides to produce an epoxy-ketone derivative, a crucial step in the conjugation of omega-hydroxyceramide to membrane proteins (PubMed:21558561). Therefore plays a crucial role in the synthesis of corneocytes lipid envelope and the establishment of the skin barrier to water loss (PubMed:21558561). May also play a role in the regulation of the expression of airway mucins (PubMed:22441738). {ECO:0000269|PubMed:21558561, ECO:0000269|PubMed:22441738, ECO:0000269|PubMed:9618483, ECO:0000269|PubMed:9837935}.
T63210	ECNUMBER	EC 1.13.11.-
T63210	SEQUENCE	MATYKVRVATGTDLLSGTRDSISLTIVGTQGESHKQLLNHFGRDFATGAVGQYTVQCPQDLGELIIIRLHKERYAFFPKDPWYCNYVQICAPNGRIYHFPAYQWMDGYETLALREATGKTTADDSLPVLLEHRKEEIRAKQDFYHWRVFLPGLPSYVHIPSYRPPVRRHRNPNRPEWNGYIPGFPILINFKATKFLNLNLRYSFLKTASFFVRLGPMALAFKVRGLLDCKHSWKRLKDIRKIFPGKKSVVSEYVAEHWAEDTFFGYQYLNGVNPGLIRRCTRIPDKFPVTDDMVAPFLGEGTCLQAELEKGNIYLADYRIMEGIPTVELSGRKQHHCAPLCLLHFGPEGKMMPIAIQLSQTPGPDCPIFLPSDSEWDWLLAKTWVRYAEFYSHEAIAHLLETHLIAEAFCLALLRNLPMCHPLYKLLIPHTRYTVQINSIGRAVLLNEGGLSAKGMSLGVEGFAGVMVRALSELTYDSLYLPNDFVERGVQDLPGYYYRDDSLAVWNALEKYVTEIITYYYPSDAAVEGDPELQSWVQEIFKECLLGRESSGFPRCLRTVPELIRYVTIVIYTCSAKHAAVNTGQMEFTAWMPNFPASMRNPPIQTKGLTTLETFMDTLPDVKTTCITLLVLWTLSREPDDRRPLGHFPDIHFVEEAPRRSIEAFRQRLNQISHDIRQRNKCLPIPYYYLDPVLIENSISI
T63210	DRUGINFO	DD1E6R	VLX-1005	Phase 2

T63211	TARGETID	T63211
T63211	UNIPROID	NLRX1_HUMAN
T63211	TARGNAME	NLR family member X1 (NLRX1)
T63211	GENENAME	NLRX1
T63211	TARGTYPE	Clinical trial
T63211	SYNONYMS	Caterpiller protein 11.3; CLR11.3; Nucleotide-binding oligomerization domain protein 5; Nucleotide-binding oligomerization domain protein 9
T63211	FUNCTION	Participates in antiviral signaling. Acts as a negative regulator of MAVS-mediated antiviral responses, through the inhibition of the virus-induced RLH (RIG-like helicase)-MAVS interaction (PubMed:18200010). Instead, promotes autophagy by interacting with TUFM and subsequently recruiting the autophagy-related proteins ATG5 and ATG12 (PubMed:22749352). Regulates also MAVS-dependent NLRP3 inflammasome activation to attenuate apoptosis (PubMed:27393910). Has no inhibitory function on NF-kappa-B signaling pathway, but enhances NF-kappa-B and JUN N-terminal kinase dependent signaling through the production of reactive oxygen species (PubMed:18219313). Regulates viral mediated-inflammation and energy metabolism in a sex-dependent manner (By similarity). In females, prevents uncontrolled inflammation and energy metabolism and thus, may contribute to the sex differences observed in infectious and inflammatory diseases (By similarity). {ECO:0000250|UniProtKB:Q3TL44, ECO:0000269|PubMed:18200010, ECO:0000269|PubMed:18219313, ECO:0000269|PubMed:22749352, ECO:0000269|PubMed:27393910}.
T63211	PDBSTRUC	3UN9
T63211	BIOCLASS	NLRP family
T63211	SEQUENCE	MRWGHHLPRASWGSGFRRALQRPDDRIPFLIHWSWPLQGERPFGPPRAFIRHHGSSVDSAPPPGRHGRLFPSASATEAIQRHRRNLAEWFSRLPREERQFGPTFALDTVHVDPVIRESTPDELLRPPAELALEHQPPQAGLPPLALSQLFNPDACGRRVQTVVLYGTVGTGKSTLVRKMVLDWCYGRLPAFELLIPFSCEDLSSLGPAPASLCQLVAQRYTPLKEVLPLMAAAGSHLLFVLHGLEHLNLDFRLAGTGLCSDPEEPQEPAAIIVNLLRKYMLPQASILVTTRPSAIGRIPSKYVGRYGEICGFSDTNLQKLYFQLRLNQPYCGYAVGGSGVSATPAQRDHLVQMLSRNLEGHHQIAAACFLPSYCWLVCATLHFLHAPTPAGQTLTSIYTSFLRLNFSGETLDSTDPSNLSLMAYAARTMGKLAYEGVSSRKTYFSEEDVCGCLEAGIRTEEEFQLLHIFRRDALRFFLAPCVEPGRAGTFVFTVPAMQEYLAALYIVLGLRKTTLQKVGKEVAELVGRVGEDVSLVLGIMAKLLPLRALPLLFNLIKVVPRVFGRMVGKSREAVAQAMVLEMFREEDYYNDDVLDQMGASILGVEGPRRHPDEPPEDEVFELFPMFMGGLLSAHNRAVLAQLGCPIKNLDALENAQAIKKKLGKLGRQVLPPSELLDHLFFHYEFQNQRFSAEVLSSLRQLNLAGVRMTPVKCTVVAAVLGSGRHALDEVNLASCQLDPAGLRTLLPVFLRARKLGLQLNSLGPEACKDLRDLLLHDQCQITTLRLSNNPLTAAGVAVLMEGLAGNTSVTHLSLLHTGLGDEGLELLAAQLDRNRQLQELNVAYNGAGDTAALALARAAREHPSLELLHLYFNELSSEGRQVLRDLGGAAEGGARVVVSLTEGTAVSEYWSVILSEVQRNLNSWDRARVQRHLELLLRDLEDSRGATLNPWRKAQLLRVEGEVRALLEQLGSSGS
T63211	DRUGINFO	D4W2AC	NX-13	Phase 2

T63215	TARGETID	T63215
T63215	UNIPROID	SEM3A_HUMAN
T63215	TARGNAME	Semaphorin-3A (SEMA3A)
T63215	GENENAME	SEMA3A
T63215	TARGTYPE	Clinical trial
T63215	SYNONYMS	Semaphorin III; Sema III
T63215	FUNCTION	Involved in the development of the olfactory system and in neuronal control of puberty. Induces the collapse and paralysis of neuronal growth cones. Could serve as a ligand that guides specific growth cones by a motility-inhibiting mechanism. Binds to the complex neuropilin-1/plexin-1. {ECO:0000269|PubMed:22416012}.
T63215	SEQUENCE	MGWLTRIVCLFWGVLLTARANYQNGKNNVPRLKLSYKEMLESNNVITFNGLANSSSYHTFLLDEERSRLYVGAKDHIFSFDLVNIKDFQKIVWPVSYTRRDECKWAGKDILKECANFIKVLKAYNQTHLYACGTGAFHPICTYIEIGHHPEDNIFKLENSHFENGRGKSPYDPKLLTASLLIDGELYSGTAADFMGRDFAIFRTLGHHHPIRTEQHDSRWLNDPKFISAHLISESDNPEDDKVYFFFRENAIDGEHSGKATHARIGQICKNDFGGHRSLVNKWTTFLKARLICSVPGPNGIDTHFDELQDVFLMNFKDPKNPVVYGVFTTSSNIFKGSAVCMYSMSDVRRVFLGPYAHRDGPNYQWVPYQGRVPYPRPGTCPSKTFGGFDSTKDLPDDVITFARSHPAMYNPVFPMNNRPIVIKTDVNYQFTQIVVDRVDAEDGQYDVMFIGTDVGTVLKVVSIPKETWYDLEEVLLEEMTVFREPTAISAMELSTKQQQLYIGSTAGVAQLPLHRCDIYGKACAECCLARDPYCAWDGSACSRYFPTAKRRTRRQDIRNGDPLTHCSDLHHDNHHGHSPEERIIYGVENSSTFLECSPKSQRALVYWQFQRRNEERKEEIRVDDHIIRTDQGLLLRSLQQKDSGNYLCHAVEHGFIQTLLKVTLEVIDTEHLEELLHKDDDGDGSKTKEMSNSMTPSQKVWYRDFMQLINHPNLNTMDEFCEQVWKRDRKQRRQRPGHTPGNSNKWKHLQENKKGRNRRTHEFERAPRSV
T63215	DRUGINFO	DJF1S3	BI 764524	Phase 2

T63216	TARGETID	T63216
T63216	UNIPROID	SLIT2_HUMAN
T63216	TARGNAME	Slit homolog 2 protein (SLIT2)
T63216	GENENAME	SLIT2
T63216	TARGTYPE	Clinical trial
T63216	SYNONYMS	Slit-2
T63216	FUNCTION	Thought to act as molecular guidance cue in cellular migration, and function appears to be mediated by interaction with roundabout homolog receptors. During neural development involved in axonal navigation at the ventral midline of the neural tube and projection of axons to different regions. SLIT1 and SLIT2 seem to be essential for midline guidance in the forebrain by acting as repulsive signal preventing inappropriate midline crossing by axons projecting from the olfactory bulb. In spinal cord development may play a role in guiding commissural axons once they reached the floor plate by modulating the response to netrin. In vitro, silences the attractive effect of NTN1 but not its growth-stimulatory effect and silencing requires the formation of a ROBO1-DCC complex. May be implicated in spinal cord midline post-crossing axon repulsion. In vitro, only commissural axons that crossed the midline responded to SLIT2. In the developing visual system appears to function as repellent for retinal ganglion axons by providing a repulsion that directs these axons along their appropriate paths prior to, and after passage through, the optic chiasm. In vitro, collapses and repels retinal ganglion cell growth cones. Seems to play a role in branching and arborization of CNS sensory axons, and in neuronal cell migration. In vitro, Slit homolog 2 protein N-product, but not Slit homolog 2 protein C-product, repels olfactory bulb (OB) but not dorsal root ganglia (DRG) axons, induces OB growth cones collapse and induces branching of DRG axons. Seems to be involved in regulating leukocyte migration. {ECO:0000269|PubMed:10102268, ECO:0000269|PubMed:10864954, ECO:0000269|PubMed:10975526, ECO:0000269|PubMed:11239147, ECO:0000269|PubMed:11309622, ECO:0000269|PubMed:11404413}.
T63216	PDBSTRUC	2V70;2V9S;2V9T;2WFH
T63216	SEQUENCE	MRGVGWQMLSLSLGLVLAILNKVAPQACPAQCSCSGSTVDCHGLALRSVPRNIPRNTERLDLNGNNITRITKTDFAGLRHLRVLQLMENKISTIERGAFQDLKELERLRLNRNHLQLFPELLFLGTAKLYRLDLSENQIQAIPRKAFRGAVDIKNLQLDYNQISCIEDGAFRALRDLEVLTLNNNNITRLSVASFNHMPKLRTFRLHSNNLYCDCHLAWLSDWLRQRPRVGLYTQCMGPSHLRGHNVAEVQKREFVCSGHQSFMAPSCSVLHCPAACTCSNNIVDCRGKGLTEIPTNLPETITEIRLEQNTIKVIPPGAFSPYKKLRRIDLSNNQISELAPDAFQGLRSLNSLVLYGNKITELPKSLFEGLFSLQLLLLNANKINCLRVDAFQDLHNLNLLSLYDNKLQTIAKGTFSPLRAIQTMHLAQNPFICDCHLKWLADYLHTNPIETSGARCTSPRRLANKRIGQIKSKKFRCSAKEQYFIPGTEDYRSKLSGDCFADLACPEKCRCEGTTVDCSNQKLNKIPEHIPQYTAELRLNNNEFTVLEATGIFKKLPQLRKINFSNNKITDIEEGAFEGASGVNEILLTSNRLENVQHKMFKGLESLKTLMLRSNRITCVGNDSFIGLSSVRLLSLYDNQITTVAPGAFDTLHSLSTLNLLANPFNCNCYLAWLGEWLRKKRIVTGNPRCQKPYFLKEIPIQDVAIQDFTCDDGNDDNSCSPLSRCPTECTCLDTVVRCSNKGLKVLPKGIPRDVTELYLDGNQFTLVPKELSNYKHLTLIDLSNNRISTLSNQSFSNMTQLLTLILSYNRLRCIPPRTFDGLKSLRLLSLHGNDISVVPEGAFNDLSALSHLAIGANPLYCDCNMQWLSDWVKSEYKEPGIARCAGPGEMADKLLLTTPSKKFTCQGPVDVNILAKCNPCLSNPCKNDGTCNSDPVDFYRCTCPYGFKGQDCDVPIHACISNPCKHGGTCHLKEGEEDGFWCICADGFEGENCEVNVDDCEDNDCENNSTCVDGINNYTCLCPPEYTGELCEEKLDFCAQDLNPCQHDSKCILTPKGFKCDCTPGYVGEHCDIDFDDCQDNKCKNGAHCTDAVNGYTCICPEGYSGLFCEFSPPMVLPRTSPCDNFDCQNGAQCIVRINEPICQCLPGYQGEKCEKLVSVNFINKESYLQIPSAKVRPQTNITLQIATDEDSGILLYKGDKDHIAVELYRGRVRASYDTGSHPASAIYSVETINDGNFHIVELLALDQSLSLSVDGGNPKIITNLSKQSTLNFDSPLYVGGMPGKSNVASLRQAPGQNGTSFHGCIRNLYINSELQDFQKVPMQTGILPGCEPCHKKVCAHGTCQPSSQAGFTCECQEGWMGPLCDQRTNDPCLGNKCVHGTCLPINAFSYSCKCLEGHGGVLCDEEEDLFNPCQAIKCKHGKCRLSGLGQPYCECSSGYTGDSCDREISCRGERIRDYYQKQQGYAACQTTKKVSRLECRGGCAGGQCCGPLRSKRRKYSFECTDGSSFVDEVEKVVKCGCTRCVS
T63216	DRUGINFO	D6TS7K	PF-06730512	Phase 2

T63217	TARGETID	T63217
T63217	UNIPROID	TGM1_HUMAN
T63217	TARGNAME	Protein-glutamine gamma-glutamyltransferase K (TGM1)
T63217	GENENAME	TGM1
T63217	TARGTYPE	Clinical trial
T63217	SYNONYMS	Epidermal TGase; Transglutaminase K; TG(K); TGK; TGase K; Transglutaminase-1; TGase-1
T63217	FUNCTION	Catalyzes the cross-linking of proteins and the conjugation of polyamines to proteins. Responsible for cross-linking epidermal proteins during formation of the stratum corneum. Involved in cell proliferation (PubMed:26220141). {ECO:0000269|PubMed:26220141}.
T63217	PDBSTRUC	2XZZ
T63217	ECNUMBER	EC 2.3.2.13
T63217	SEQUENCE	MMDGPRSDVGRWGGNPLQPPTTPSPEPEPEPDGRSRRGGGRSFWARCCGCCSCRNAADDDWGPEPSDSRGRGSSSGTRRPGSRGSDSRRPVSRGSGVNAAGDGTIREGMLVVNGVDLLSSRSDQNRREHHTDEYEYDELIVRRGQPFHMLLLLSRTYESSDRITLELLIGNNPEVGKGTHVIIPVGKGGSGGWKAQVVKASGQNLNLRVHTSPNAIIGKFQFTVRTQSDAGEFQLPFDPRNEIYILFNPWCPEDIVYVDHEDWRQEYVLNESGRIYYGTEAQIGERTWNYGQFDHGVLDACLYILDRRGMPYGGRGDPVNVSRVISAMVNSLDDNGVLIGNWSGDYSRGTNPSAWVGSVEILLSYLRTGYSVPYGQCWVFAGVTTTVLRCLGLATRTVTNFNSAHDTDTSLTMDIYFDENMKPLEHLNHDSVWNFHVWNDCWMKRPDLPSGFDGWQVVDATPQETSSGIFCCGPCSVESIKNGLVYMKYDTPFIFAEVNSDKVYWQRQDDGSFKIVYVEEKAIGTLIVTKAISSNMREDITYLYKHPEGSDAERKAVETAAAHGSKPNVYANRGSAEDVAMQVEAQDAVMGQDLMVSVMLINHSSSRRTVKLHLYLSVTFYTGVSGTIFKETKKEVELAPGASDRVTMPVAYKEYRPHLVDQGAMLLNVSGHVKESGQVLAKQHTFRLRTPDLSLTLLGAAVVGQECEVQIVFKNPLPVTLTNVVFRLEGSGLQRPKILNVGDIGGNETVTLRQSFVPVRPGPRQLIASLDSPQLSQVHGVIQVDVAPAPGDGGFFSDAGGDSHLGETIPMASRGGA
T63217	DRUGINFO	DQ8X4A	KB105	Phase 2

T63218	TARGETID	T63218
T63218	UNIPROID	THIM_HUMAN
T63218	TARGNAME	3-ketoacyl-CoA thiolase, mitochondrial (ACAA2)
T63218	GENENAME	ACAA2
T63218	TARGTYPE	Clinical trial
T63218	SYNONYMS	Acetyl-CoA acetyltransferase; Acetyl-CoA acyltransferase; Acyl-CoA hydrolase, mitochondrial; Beta-ketothiolase; Mitochondrial 3-oxoacyl-CoA thiolase; T1
T63218	FUNCTION	In the production of energy from fats, this is one of the enzymes that catalyzes the last step of the mitochondrial beta-oxidation pathway, an aerobic process breaking down fatty acids into acetyl-CoA (Probable). Using free coenzyme A/CoA, catalyzes the thiolytic cleavage of medium- to long-chain unbranched 3-oxoacyl-CoAs into acetyl-CoA and a fatty acyl-CoA shortened by two carbon atoms (Probable). Also catalyzes the condensation of two acetyl-CoA molecules into acetoacetyl-CoA and could be involved in the production of ketone bodies (Probable). Also displays hydrolase activity on various fatty acyl-CoAs (PubMed:25478839). Thereby, could be responsible for the production of acetate in a side reaction to beta-oxidation (Probable). Abolishes BNIP3-mediated apoptosis and mitochondrial damage (PubMed:18371312). {ECO:0000269|PubMed:18371312, ECO:0000269|PubMed:25478839, ECO:0000305|PubMed:25478839}.
T63218	PDBSTRUC	4C2J;4C2K
T63218	ECNUMBER	EC 2.3.1.16; EC 2.3.1.9; EC 3.1.2.-; EC 3.1.2.1; EC 3.1.2.2
T63218	SEQUENCE	MALLRGVFVVAAKRTPFGAYGGLLKDFTATDLSEFAAKAALSAGKVSPETVDSVIMGNVLQSSSDAIYLARHVGLRVGIPKETPALTINRLCGSGFQSIVNGCQEICVKEAEVVLCGGTESMSQAPYCVRNVRFGTKLGSDIKLEDSLWVSLTDQHVQLPMAMTAENLAVKHKISREECDKYALQSQQRWKAANDAGYFNDEMAPIEVKTKKGKQTMQVDEHARPQTTLEQLQKLPPVFKKDGTVTAGNASGVADGAGAVIIASEDAVKKHNFTPLARIVGYFVSGCDPSIMGIGPVPAISGALKKAGLSLKDMDLVEVNEAFAPQYLAVERSLDLDISKTNVNGGAIALGHPLGGSGSRITAHLVHELRRRGGKYAVGSACIGGGQGIAVIIQSTA
T63218	DRUGINFO	DVZJ75	IMB-101	Phase 2

T63243	TARGETID	T63243
T63243	UNIPROID	GBA1_HUMAN
T63243	TARGNAME	Lysosomal acid glucosylceramidase (GBA1)
T63243	GENENAME	GBA1
T63243	TARGTYPE	Clinical trial
T63243	SYNONYMS	Lysosomal acid GCase; Acid beta-glucosidase; Alglucerase; Beta-glucocerebrosidase; Beta-GC; Beta-glucosylceramidase 1; Cholesterol glucosyltransferase; SGTase; Cholesteryl-beta-glucosidase; D-glucosyl-N-acylsphingosine glucohydrolase; Glucosylceramidase beta 1; Imiglucerase; Lysosomal cholesterol glycosyltransferase; Lysosomal galactosylceramidase; Lysosomal glycosylceramidase
T63243	FUNCTION	Glucosylceramidase that catalyzes, within the lysosomal compartment, the hydrolysis of glucosylceramides/GlcCers (such as beta-D-glucosyl-(1<->1')-N-acylsphing-4-enine) into free ceramides (such as N-acylsphing-4-enine) and glucose (PubMed:9201993, PubMed:24211208, PubMed:15916907, PubMed:32144204). Plays a central role in the degradation of complex lipids and the turnover of cellular membranes (PubMed:27378698). Through the production of ceramides, participates in the PKC-activated salvage pathway of ceramide formation (PubMed:19279011). Catalyzes the glucosylation of cholesterol, through a transglucosylation reaction where glucose is transferred from GlcCer to cholesterol (PubMed:24211208, PubMed:26724485, PubMed:32144204). GlcCer containing mono-unsaturated fatty acids (such as beta-D-glucosyl-N-(9Z-octadecenoyl)-sphing-4-enine) are preferred as glucose donors for cholesterol glucosylation when compared with GlcCer containing same chain length of saturated fatty acids (such as beta-D-glucosyl-N-octadecanoyl-sphing-4-enine) (PubMed:24211208). Under specific conditions, may alternatively catalyze the reverse reaction, transferring glucose from cholesteryl 3-beta-D-glucoside to ceramide (PubMed:26724485) (Probable). Can also hydrolyze cholesteryl 3-beta-D-glucoside producing glucose and cholesterol (PubMed:24211208, PubMed:26724485). Catalyzes the hydrolysis of galactosylceramides/GalCers (such as beta-D-galactosyl-(1<->1')-N-acylsphing-4-enine), as well as the transfer of galactose between GalCers and cholesterol in vitro, but with lower activity than with GlcCers (PubMed:32144204). Contrary to GlcCer and GalCer, xylosylceramide/XylCer (such as beta-D-xyosyl-(1<->1')-N-acylsphing-4-enine) is not a good substrate for hydrolysis, however it is a good xylose donor for transxylosylation activity to form cholesteryl 3-beta-D-xyloside (PubMed:33361282). {ECO:0000269|PubMed:15916907, ECO:0000269|PubMed:19279011, ECO:0000269|PubMed:24211208, ECO:0000269|PubMed:26724485, ECO:0000269|PubMed:27378698, ECO:0000269|PubMed:32144204, ECO:0000269|PubMed:33361282, ECO:0000269|PubMed:9201993, ECO:0000305|PubMed:32144204}.
T63243	PDBSTRUC	1OGS;1Y7V;2F61;2J25;2NSX;2NT0;2NT1;2V3D;2V3E;2V3F;2VT0;2WCG;2WKL;2XWD;2XWE;3GXD;3GXF;3GXI;3GXM;3KE0;3KEH;3RIK;3RIL;5LVX;6MOZ;6Q1N;6Q1P;6Q6K;6Q6L;6Q6N;6T13;6TJJ;6TJK;6TJQ;6TN1;6YTP;6YTR;6YUT;6YV3;6Z39;6Z3I;7NWV
T63243	BIOCLASS	Glycosyl hydrolase
T63243	ECNUMBER	EC 2.4.1.-; EC 3.2.1.-; EC 3.2.1.45; EC 3.2.1.46
T63243	SEQUENCE	MEFSSPSREECPKPLSRVSIMAGSLTGLLLLQAVSWASGARPCIPKSFGYSSVVCVCNATYCDSFDPPTFPALGTFSRYESTRSGRRMELSMGPIQANHTGTGLLLTLQPEQKFQKVKGFGGAMTDAAALNILALSPPAQNLLLKSYFSEEGIGYNIIRVPMASCDFSIRTYTYADTPDDFQLHNFSLPEEDTKLKIPLIHRALQLAQRPVSLLASPWTSPTWLKTNGAVNGKGSLKGQPGDIYHQTWARYFVKFLDAYAEHKLQFWAVTAENEPSAGLLSGYPFQCLGFTPEHQRDFIARDLGPTLANSTHHNVRLLMLDDQRLLLPHWAKVVLTDPEAAKYVHGIAVHWYLDFLAPAKATLGETHRLFPNTMLFASEACVGSKFWEQSVRLGSWDRGMQYSHSIITNLLYHVVGWTDWNLALNPEGGPNWVRNFVDSPIIVDITKDTFYKQPMFYHLGHFSKFIPEGSQRVGLVASQKNDLDAVALMHPDGSAVVVVLNRSSKDVPLTIKDPAVGFLETISPGYSIHTYLWRRQ
T63243	DRUGINFO	D23CDU	AVR-RD-02	Phase 2/3
T63243	DRUGINFO	D0XZ4Y	PR001	Phase 1/2

T63221	TARGETID	T63221
T63221	UNIPROID	KLRG1_HUMAN
T63221	TARGNAME	Killer cell lectin-like receptor subfamily G member 1 (KLRG1)
T63221	GENENAME	KLRG1
T63221	TARGTYPE	Clinical trial
T63221	SYNONYMS	C-type lectin domain family 15 member A; ITIM-containing receptor MAFA-L; MAFA-like receptor; Mast cell function-associated antigen
T63221	FUNCTION	Plays an inhibitory role on natural killer (NK) cells and T-cell functions upon binding to their non-MHC ligands. May mediate missing self recognition by binding to a highly conserved site on classical cadherins, enabling it to monitor expression of E-cadherin/CDH1, N-cadherin/CDH2 and R-cadherin/CDH4 on target cells. {ECO:0000269|PubMed:19604491}.
T63221	PDBSTRUC	3FF7
T63221	SEQUENCE	MTDSVIYSMLELPTATQAQNDYGPQQKSSSSRPSCSCLVAIALGLLTAVLLSVLLYQWILCQGSNYSTCASCPSCPDRWMKYGNHCYYFSVEEKDWNSSLEFCLARDSHLLVITDNQEMSLLQVFLSEAFCWIGLRNNSGWRWEDGSPLNFSRISSNSFVQTCGAINKNGLQASSCEVPLHWVCKKCPFADQALF
T63221	DRUGINFO	D3WA2V	ABC008	Phase 2/3

T63224	TARGETID	T63224
T63224	UNIPROID	ARGI1_HUMAN
T63224	TARGNAME	Arginase-1 (ARG1)
T63224	GENENAME	ARG1
T63224	TARGTYPE	Clinical trial
T63224	SYNONYMS	Liver-type arginase; Type I arginase
T63224	FUNCTION	Key element of the urea cycle converting L-arginine to urea and L-ornithine, which is further metabolized into metabolites proline and polyamides that drive collagen synthesis and bioenergetic pathways critical for cell proliferation, respectively; the urea cycle takes place primarily in the liver and, to a lesser extent, in the kidneys. {ECO:0000305}.; Functions in L-arginine homeostasis in nonhepatic tissues characterized by the competition between nitric oxide synthase (NOS) and arginase for the available intracellular substrate arginine. Arginine metabolism is a critical regulator of innate and adaptive immune responses. Involved in an antimicrobial effector pathway in polymorphonuclear granulocytes (PMN). Upon PMN cell death is liberated from the phagolysosome and depletes arginine in the microenvironment leading to suppressed T cell and natural killer (NK) cell proliferation and cytokine secretion (PubMed:15546957, PubMed:16709924, PubMed:19380772). In group 2 innate lymphoid cells (ILC2s) promotes acute type 2 inflammation in the lung and is involved in optimal ILC2 proliferation but not survival (By similarity). In humans, the immunological role in the monocytic/macrophage/dendritic cell (DC) lineage is unsure. {ECO:0000250|UniProtKB:Q61176, ECO:0000269|PubMed:15546957, ECO:0000269|PubMed:16709924, ECO:0000269|PubMed:19380772}.
T63224	PDBSTRUC	1WVA;1WVB;2AEB;2PHA;2PHO;2PLL;2ZAV;3DJ8;3E6K;3E6V;3F80;3GMZ;3GN0;3KV2;3LP4;3LP7;3MFV;3MFW;3MJL;3SJT;3SKK;3TF3;3TH7;3THE;3THH;3THJ;4FCI;4FCK;4GSM;4GSV;4GSZ;4GWC;4GWD;4HWW;4HXQ;4IE1;6Q92;6Q9P;6QAF;6V7C;6V7D;6V7E;6V7F;7K4G;7K4H;7K4I;7K4J;7K4K;7KLK;7KLL;7KLM;7LEX;7LEY;7LEZ;7LF0;7LF1;7LF2;8AUP;8E5M;8E5N
T63224	ECNUMBER	EC 3.5.3.1
T63224	SEQUENCE	MSAKSRTIGIIGAPFSKGQPRGGVEEGPTVLRKAGLLEKLKEQECDVKDYGDLPFADIPNDSPFQIVKNPRSVGKASEQLAGKVAEVKKNGRISLVLGGDHSLAIGSISGHARVHPDLGVIWVDAHTDINTPLTTTSGNLHGQPVSFLLKELKGKIPDVPGFSWVTPCISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRLGIGKVMEETLSYLLGRKKRPIHLSFDVDGLDPSFTPATGTPVVGGLTYREGLYITEEIYKTGLLSGLDIMEVNPSLGKTPEEVTRTVNTAVAITLACFGLAREGNHKPIDYLNPPK
T63224	DRUGINFO	DX2H9P	Pegzilarginase	Phase 3

T63225	TARGETID	T63225
T63225	UNIPROID	ATS13_HUMAN
T63225	TARGNAME	A disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13)
T63225	GENENAME	ADAMTS13
T63225	TARGTYPE	Clinical trial
T63225	SYNONYMS	ADAM-TS 13; ADAM-TS13; ADAMTS-13; von Willebrand factor-cleaving protease; vWF-CP; vWF-cleaving protease
T63225	FUNCTION	Cleaves the vWF multimers in plasma into smaller forms thereby controlling vWF-mediated platelet thrombus formation. {ECO:0000269|PubMed:19880749}.
T63225	PDBSTRUC	3GHM;3GHN;3VN4;6QIG;7B01
T63225	ECNUMBER	EC 3.4.24.87
T63225	SEQUENCE	MHQRHPRARCPPLCVAGILACGFLLGCWGPSHFQQSCLQALEPQAVSSYLSPGAPLKGRPPSPGFQRQRQRQRRAAGGILHLELLVAVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILTEPEGAPNITANLTSSLLSVCGWSQTINPEDDTDPGHADLVLYITRFDLELPDGNRQVRGVTQLGGACSPTWSCLITEDTGFDLGVTIAHEIGHSFGLEHDGAPGSGCGPSGHVMASDGAAPRAGLAWSPCSRRQLLSLLSAGRARCVWDPPRPQPGSAGHPPDAQPGLYYSANEQCRVAFGPKAVACTFAREHLDMCQALSCHTDPLDQSSCSRLLVPLLDGTECGVEKWCSKGRCRSLVELTPIAAVHGRWSSWGPRSPCSRSCGGGVVTRRRQCNNPRPAFGGRACVGADLQAEMCNTQACEKTQLEFMSQQCARTDGQPLRSSPGGASFYHWGAAVPHSQGDALCRHMCRAIGESFIMKRGDSFLDGTRCMPSGPREDGTLSLCVSGSCRTFGCDGRMDSQQVWDRCQVCGGDNSTCSPRKGSFTAGRAREYVTFLTVTPNLTSVYIANHRPLFTHLAVRIGGRYVVAGKMSISPNTTYPSLLEDGRVEYRVALTEDRLPRLEEIRIWGPLQEDADIQVYRRYGEEYGNLTRPDITFTYFQPKPRQAWVWAAVRGPCSVSCGAGLRWVNYSCLDQARKELVETVQCQGSQQPPAWPEACVLEPCPPYWAVGDFGPCSASCGGGLRERPVRCVEAQGSLLKTLPPARCRAGAQQPAVALETCNPQPCPARWEVSEPSSCTSAGGAGLALENETCVPGADGLEAPVTEGPGSVDEKLPAPEPCVGMSCPPGWGHLDATSAGEKAPSPWGSIRTGAQAAHVWTPAAGSCSVSCGRGLMELRFLCMDSALRVPVQEELCGLASKPGSRREVCQAVPCPARWQYKLAACSVSCGRGVVRRILYCARAHGEDDGEEILLDTQCQGLPRPEPQEACSLEPCPPRWKVMSLGPCSASCGLGTARRSVACVQLDQGQDVEVDEAACAALVRPEASVPCLIADCTYRWHVGTWMECSVSCGDGIQRRRDTCLGPQAQAPVPADFCQHLPKPVTVRGCWAGPCVGQGTPSLVPHEEAAAPGRTTATPAGASLEWSQARGLLFSPAPQPRRLLPGPQENSVQSSACGRQHLEPTGTIDMRGPGQADCAVAIGRPLGEVVTLRVLESSLNCSAGDMLLLWGRLTWRKMCRKLLDMTFSSKTNTLVVRQRCGRPGGGVLLRYGSQLAPETFYRECDMQLFGPWGEIVSPSLSPATSNAGGCRLFINVAPHARIAIHALATNMGAGTEGANASYILIRDTHSLRTTAFHGQQVLYWESESSQAEMEFSEGFLKAQASLRGQYWTLQSWVPEMQDPQSWKGKEGT
T63225	DRUGINFO	D6PMR7	TAK-755	Phase 3

T63226	TARGETID	T63226
T63226	UNIPROID	CLC4C_HUMAN
T63226	TARGNAME	C-type lectin domain family 4 member C (CLEC4C)
T63226	GENENAME	CLEC4C
T63226	TARGTYPE	Clinical trial
T63226	SYNONYMS	Blood dendritic cell antigen 2; BDCA-2; C-type lectin superfamily member 7; Dendritic lectin; CD303
T63226	FUNCTION	Lectin-type cell surface receptor which may play a role in antigen capturing by dendritic cells (PubMed:11748283, PubMed:21880719, PubMed:25995448). Specifically recognizes non-sialylated galactose-terminated biantennary glycans containing the trisaccharide epitope Gal(beta1-3/4)GlcNAc(beta1-2)Man (PubMed:21880719, PubMed:25995448). Binds to serum IgG (PubMed:25995448). Efficiently targets ligand into antigen-processing and peptide-loading compartments for presentation to T-cells (PubMed:11748283). May mediate potent inhibition of induction of IFN-alpha/beta expression in plasmacytoid dendritic cells (PubMed:11748283, PubMed:21880719). May act as a signaling receptor that activates protein-tyrosine kinases and mobilizes intracellular calcium (PubMed:11748283). {ECO:0000269|PubMed:11748283, ECO:0000269|PubMed:21880719, ECO:0000269|PubMed:25995448}.
T63226	PDBSTRUC	3WBP;3WBQ;3WBR;4ZES;4ZET
T63226	SEQUENCE	MVPEEEPQDREKGLWWFQLKVWSMAVVSILLLSVCFTVSSVVPHNFMYSKTVKRLSKLREYQQYHPSLTCVMEGKDIEDWSCCPTPWTSFQSSCYFISTGMQSWTKSQKNCSVMGADLVVINTREEQDFIIQNLKRNSSYFLGLSDPGGRRHWQWVDQTPYNENVTFWHSGEPNNLDERCAIINFRSSEEWGWNDIHCHVPQKSICKMKKIYI
T63226	DRUGINFO	DMT2F4	Litifilimab	Phase 3

T63229	TARGETID	T63229
T63229	UNIPROID	ILRL1_HUMAN
T63229	TARGNAME	Interleukin-1 receptor-like 1 (IL1RL1)
T63229	GENENAME	IL1RL1
T63229	TARGTYPE	Clinical trial
T63229	SYNONYMS	Protein ST2
T63229	FUNCTION	Receptor for interleukin-33 (IL-33) which plays crucial roles in innate and adaptive immunity, contributing to tissue homeostasis and responses to environmental stresses together with coreceptor IL1RAP (PubMed:35238669). Its stimulation recruits MYD88, IRAK1, IRAK4, and TRAF6, followed by phosphorylation of MAPK3/ERK1 and/or MAPK1/ERK2, MAPK14, and MAPK8. Possibly involved in helper T-cell function (PubMed:16286016) (Probable). Upon tissue injury, induces UCP2-dependent mitochondrial rewiring that attenuates the generation of reactive oxygen species and preserves the integrity of Krebs cycle required for persistent production of itaconate and subsequent GATA3-dependent differentiation of inflammation-resolving alternatively activated macrophages (By similarity). {ECO:0000250|UniProtKB:P14719, ECO:0000269|PubMed:16286016, ECO:0000269|PubMed:35238669, ECO:0000305|PubMed:19836339}.; [Isoform B]: Inhibits IL-33 signaling. {ECO:0000250|UniProtKB:P14719}.
T63229	PDBSTRUC	4KC3
T63229	ECNUMBER	EC 3.2.2.6
T63229	SEQUENCE	MGFWILAILTILMYSTAAKFSKQSWGLENEALIVRCPRQGKPSYTVDWYYSQTNKSIPTQERNRVFASGQLLKFLPAAVADSGIYTCIVRSPTFNRTGYANVTIYKKQSDCNVPDYLMYSTVSGSEKNSKIYCPTIDLYNWTAPLEWFKNCQALQGSRYRAHKSFLVIDNVMTEDAGDYTCKFIHNENGANYSVTATRSFTVKDEQGFSLFPVIGAPAQNEIKEVEIGKNANLTCSACFGKGTQFLAAVLWQLNGTKITDFGEPRIQQEEGQNQSFSNGLACLDMVLRIADVKEEDLLLQYDCLALNLHGLRRHTVRLSRKNPIDHHSIYCIIAVCSVFLMLINVLVIILKMFWIEATLLWRDIAKPYKTRNDGKLYDAYVVYPRNYKSSTDGASRVEHFVHQILPDVLENKCGYTLCIYGRDMLPGEDVVTAVETNIRKSRRHIFILTPQITHNKEFAYEQEVALHCALIQNDAKVILIEMEALSELDMLQAEALQDSLQHLMKVQGTIKWREDHIANKRSLNSKFWKHVRYQMPVPSKIPRKASSLTPLAAQKQ
T63229	DRUGINFO	DBAL18	Astegolimab	Phase 3
T63229	DRUGINFO	DCSZ97	GSK3772847	Phase 2

T63230	TARGETID	T63230
T63230	UNIPROID	INHBA_HUMAN
T63230	TARGNAME	Inhibin beta A chain (INHBA)
T63230	GENENAME	INHBA
T63230	TARGTYPE	Clinical trial
T63230	SYNONYMS	Activin beta-A chain; Erythroid differentiation protein; EDF
T63230	FUNCTION	Inhibins and activins inhibit and activate, respectively, the secretion of follitropin by the pituitary gland. Inhibins/activins are involved in regulating a number of diverse functions such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell development and maturation, erythroid differentiation, insulin secretion, nerve cell survival, embryonic axial development or bone growth, depending on their subunit composition. Inhibins appear to oppose the functions of activins.
T63230	PDBSTRUC	1NYS;1NYU;1S4Y;2ARP;2ARV;2B0U;2P6A;3B4V;4MID;5HLY;5HLZ;6Y6N;6Y6O;7OLY;7U5P
T63230	SEQUENCE	MPLLWLRGFLLASCWIIVRSSPTPGSEGHSAAPDCPSCALAALPKDVPNSQPEMVEAVKKHILNMLHLKKRPDVTQPVPKAALLNAIRKLHVGKVGENGYVEIEDDIGRRAEMNELMEQTSEIITFAESGTARKTLHFEISKEGSDLSVVERAEVWLFLKVPKANRTRTKVTIRLFQQQKHPQGSLDTGEEAEEVGLKGERSELLLSEKVVDARKSTWHVFPVSSSIQRLLDQGKSSLDVRIACEQCQESGASLVLLGKKKKKEEEGEGKKKGGGEGGAGADEEKEQSHRPFLMLQARQSEDHPHRRRRRGLECDGKVNICCKKQFFVSFKDIGWNDWIIAPSGYHANYCEGECPSHIAGTSGSSLSFHSTVINHYRMRGHSPFANLKSCCVPTKLRPMSMLYYDDGQNIIKKDIQNMIVEECGCS
T63230	DRUGINFO	DKP80T	Garetosmab	Phase 3

T63233	TARGETID	T63233
T63233	UNIPROID	SORT_HUMAN
T63233	TARGNAME	Sortilin (SORT1)
T63233	GENENAME	SORT1
T63233	TARGTYPE	Clinical trial
T63233	SYNONYMS	100 kDa NT receptor; Glycoprotein 95; Gp95; Neurotensin receptor 3; NT3; NTR3
T63233	FUNCTION	Functions as a sorting receptor in the Golgi compartment and as a clearance receptor on the cell surface. Required for protein transport from the Golgi apparatus to the lysosomes by a pathway that is independent of the mannose-6-phosphate receptor (M6PR). Lysosomal proteins bind specifically to the receptor in the Golgi apparatus and the resulting receptor-ligand complex is transported to an acidic prelysosomal compartment where the low pH mediates the dissociation of the complex (PubMed:16787399). The receptor is then recycled back to the Golgi for another round of trafficking through its binding to the retromer. Also required for protein transport from the Golgi apparatus to the endosomes. Promotes neuronal apoptosis by mediating endocytosis of the proapoptotic precursor forms of BDNF (proBDNF) and NGFB (proNGFB). Also acts as a receptor for neurotensin. May promote mineralization of the extracellular matrix during osteogenic differentiation by scavenging extracellular LPL. Probably required in adipocytes for the formation of specialized storage vesicles containing the glucose transporter SLC2A4/GLUT4 (GLUT4 storage vesicles, or GSVs). These vesicles provide a stable pool of SLC2A4 and confer increased responsiveness to insulin. May also mediate transport from the endoplasmic reticulum to the Golgi. {ECO:0000269|PubMed:10085125, ECO:0000269|PubMed:11331584, ECO:0000269|PubMed:11390366, ECO:0000269|PubMed:12209882, ECO:0000269|PubMed:12598608, ECO:0000269|PubMed:14657016, ECO:0000269|PubMed:14985763, ECO:0000269|PubMed:15313463, ECO:0000269|PubMed:15930396, ECO:0000269|PubMed:15987945, ECO:0000269|PubMed:16787399, ECO:0000269|PubMed:18817523}.
T63233	PDBSTRUC	3F6K;3G2U;3G2V;4MSL;4N7E;4PO7;5MRH;5MRI;6EHO;6X3L;6X48;6X4H
T63233	SEQUENCE	MERPWGAADGLSRWPHGLGLLLLLQLLPPSTLSQDRLDAPPPPAAPLPRWSGPIGVSWGLRAAAAGGAFPRGGRWRRSAPGEDEECGRVRDFVAKLANNTHQHVFDDLRGSVSLSWVGDSTGVILVLTTFHVPLVIMTFGQSKLYRSEDYGKNFKDITDLINNTFIRTEFGMAIGPENSGKVVLTAEVSGGSRGGRIFRSSDFAKNFVQTDLPFHPLTQMMYSPQNSDYLLALSTENGLWVSKNFGGKWEEIHKAVCLAKWGSDNTIFFTTYANGSCKADLGALELWRTSDLGKSFKTIGVKIYSFGLGGRFLFASVMADKDTTRRIHVSTDQGDTWSMAQLPSVGQEQFYSILAANDDMVFMHVDEPGDTGFGTIFTSDDRGIVYSKSLDRHLYTTTGGETDFTNVTSLRGVYITSVLSEDNSIQTMITFDQGGRWTHLRKPENSECDATAKNKNECSLHIHASYSISQKLNVPMAPLSEPNAVGIVIAHGSVGDAISVMVPDVYISDDGGYSWTKMLEGPHYYTILDSGGIIVAIEHSSRPINVIKFSTDEGQCWQTYTFTRDPIYFTGLASEPGARSMNISIWGFTESFLTSQWVSYTIDFKDILERNCEEKDYTIWLAHSTDPEDYEDGCILGYKEQFLRLRKSSVCQNGRDYVVTKQPSICLCSLEDFLCDFGYYRPENDSKCVEQPELKGHDLEFCLYGREEHLTTNGYRKIPGDKCQGGVNPVREVKDLKKKCTSNFLSPEKQNSKSNSVPIILAIVGLMLVTVVAGVLIVKKYVCGGRFLVHRYSVLQQHAEANGVDGVDALDTASHTNKSGYHDDSDEDLLE
T63233	DRUGINFO	DO57XC	AL001	Phase 3
T63233	DRUGINFO	DW0E3K	GSK4527223	Phase 3
T63233	DRUGINFO	DG15YL	GSK4527226	Phase 1

T63236	TARGETID	T63236
T63236	UNIPROID	CCL17_HUMAN
T63236	TARGNAME	C-C motif chemokine 17 (CCL17)
T63236	GENENAME	CCL17
T63236	TARGTYPE	Clinical trial
T63236	SYNONYMS	CC chemokine TARC; Small-inducible cytokine A17; Thymus and activation-regulated chemokine
T63236	FUNCTION	Chemokine, which displays chemotactic activity for T lymphocytes, preferentially Th2 cells, but not monocytes or granulocytes. Therefore plays an important role in a wide range of inflammatory and immunological processes (PubMed:8702936, PubMed:9169480). Acts by binding to CCR4 at T-cell surface (PubMed:9169480, PubMed:10540332). Mediates GM-CSF/CSF2-driven pain and inflammation (PubMed:27525438). In the brain, required to maintain the typical, highly branched morphology of hippocampal microglia under homeostatic conditions. May be important for the appropriate adaptation of microglial morphology and synaptic plasticity to acute lipopolysaccharide (LPS)-induced neuroinflammation (By similarity). Plays a role in wound healing, mainly by inducing fibroblast migration into the wound (By similarity). {ECO:0000250|UniProtKB:Q9WUZ6, ECO:0000269|PubMed:10540332, ECO:0000269|PubMed:27525438, ECO:0000269|PubMed:8702936, ECO:0000269|PubMed:9169480}.
T63236	PDBSTRUC	1NR2;1NR4;5WK3;7S4N;7SCV;8FJ2;8SKK
T63236	SEQUENCE	MAPLKMLALVTLLLGASLQHIHAARGTNVGRECCLEYFKGAIPLRKLKTWYQTSEDCSRDAIVFVTVQGRAICSDPNNKRVKNAVKYLQSLERS
T63236	DRUGINFO	D21SVO	GSK3858279	Phase 2

T63237	TARGETID	T63237
T63237	UNIPROID	DHB13_HUMAN
T63237	TARGNAME	17-beta-hydroxysteroid dehydrogenase 13 (HSD17B13)
T63237	GENENAME	HSD17B13
T63237	TARGTYPE	Clinical trial
T63237	SYNONYMS	17-beta-HSD 13; Hepatic retinol/retinal dehydrogenase; Short chain dehydrogenase/reductase family 16C member 3; Short-chain dehydrogenase/reductase 9
T63237	FUNCTION	Plays a pivotal role in hepatic lipid metabolism (PubMed:29562163). In vitro, it catalyzes the oxidation of a variety of lipid substrates, including 17beta-estradiol, retinol, retinal, and leukotriene B4 (PubMed:29562163, PubMed:30415504, PubMed:32973038). {ECO:0000269|PubMed:29562163, ECO:0000269|PubMed:30415504, ECO:0000269|PubMed:32973038}.; [Isoform 2]: Has retinol/retinal dehydrogenase activity in vitro. {ECO:0000269|PubMed:30415504, ECO:0000269|PubMed:32973038}.; [Isoform 1]: Does not have retinol/retinal dehydrogenase activity in vitro. {ECO:0000269|PubMed:30415504}.
T63237	ECNUMBER	EC 1.1.1.-; EC 1.1.1.105; EC 1.1.1.62
T63237	SEQUENCE	MNIILEILLLLITIIYSYLESLVKFFIPQRRKSVAGEIVLITGAGHGIGRQTTYEFAKRQSILVLWDINKRGVEETAAECRKLGVTAHAYVVDCSNREEIYRSLNQVKKEVGDVTIVVNNAGTVYPADLLSTKDEEITKTFEVNILGHFWITKALLPSMMERNHGHIVTVASVCGHEGIPYLIPYCSSKFAAVGFHRGLTSELQALGKTGIKTSCLCPVFVNTGFTKNPSTRLWPVLETDEVVRSLIDGILTNKKMIFVPSYINIFLRLQKFLPERASAILNRMQNIQFEAVVGHKIKMK
T63237	DRUGINFO	DB34JE	GSK4532990	Phase 2

T63238	TARGETID	T63238
T63238	UNIPROID	GPR6_HUMAN
T63238	TARGNAME	G-protein coupled receptor 6 (GPR6)
T63238	GENENAME	GPR6
T63238	TARGTYPE	Clinical trial
T63238	SYNONYMS	Sphingosine 1-phosphate receptor GPR6
T63238	FUNCTION	Orphan receptor with constitutive G(s) signaling activity that activate cyclic AMP. Promotes neurite outgrowth and blocks myelin inhibition in neurons (By similarity). {ECO:0000250}.
T63238	BIOCLASS	G-protein coupled receptor 1 family
T63238	SEQUENCE	MNASAASLNDSQVVVVAAEGAAAAATAAGGPDTGEWGPPAAAALGAGGGANGSLELSSQLSAGPPGLLLPAVNPWDVLLCVSGTVIAGENALVVALIASTPALRTPMFVLVGSLATADLLAGCGLILHFVFQYLVPSETVSLLTVGFLVASFAASVSSLLAITVDRYLSLYNALTYYSRRTLLGVHLLLAATWTVSLGLGLLPVLGWNCLAERAACSVVRPLARSHVALLSAAFFMVFGIMLHLYVRICQVVWRHAHQIALQQHCLAPPHLAATRKGVGTLAVVLGTFGASWLPFAIYCVVGSHEDPAVYTYATLLPATYNSMINPIIYAFRNQEIQRALWLLLCGCFQSKVPFRSRSPSEV
T63238	DRUGINFO	DH3S7V	CVN424	Phase 2

T63239	TARGETID	T63239
T63239	UNIPROID	HLAA_HUMAN
T63239	TARGNAME	HLA class I histocompatibility antigen, A alpha chain (HLA-A)
T63239	GENENAME	HLA-A
T63239	TARGTYPE	Clinical trial
T63239	SYNONYMS	Human leukocyte antigen A; HLA-A
T63239	FUNCTION	Antigen-presenting major histocompatibility complex class I (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays primarily viral and tumor-derived peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-A-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected or transformed cells (PubMed:2456340, PubMed:2784196, PubMed:1402688, PubMed:7504010, PubMed:9862734, PubMed:10449296, PubMed:12138174, PubMed:12393434, PubMed:15893615, PubMed:17189421, PubMed:19543285, PubMed:21498667, PubMed:24192765, PubMed:7694806, PubMed:24395804, PubMed:28250417). May also present self-peptides derived from the signal sequence of secreted or membrane proteins, although T cells specific for these peptides are usually inactivated to prevent autoreactivity (PubMed:25880248, PubMed:7506728, PubMed:7679507). Both the peptide and the MHC molecule are recognized by TCR, the peptide is responsible for the fine specificity of antigen recognition and MHC residues account for the MHC restriction of T cells (PubMed:12796775, PubMed:18275829, PubMed:19542454, PubMed:28250417). Typically presents intracellular peptide antigens of 8 to 13 amino acids that arise from cytosolic proteolysis via IFNG-induced immunoproteasome or via endopeptidase IDE/insulin-degrading enzyme (PubMed:17189421, PubMed:20364150, PubMed:17079320, PubMed:26929325, PubMed:27049119). Can bind different peptides containing allele-specific binding motifs, which are mainly defined by anchor residues at position 2 and 9 (PubMed:7504010, PubMed:9862734). {ECO:0000269|PubMed:10449296, ECO:0000269|PubMed:12138174, ECO:0000269|PubMed:12393434, ECO:0000269|PubMed:12796775, ECO:0000269|PubMed:1402688, ECO:0000269|PubMed:15893615, ECO:0000269|PubMed:17079320, ECO:0000269|PubMed:17189421, ECO:0000269|PubMed:18275829, ECO:0000269|PubMed:19542454, ECO:0000269|PubMed:19543285, ECO:0000269|PubMed:20364150, ECO:0000269|PubMed:21498667, ECO:0000269|PubMed:24192765, ECO:0000269|PubMed:24395804, ECO:0000269|PubMed:2456340, ECO:0000269|PubMed:25880248, ECO:0000269|PubMed:26929325, ECO:0000269|PubMed:27049119, ECO:0000269|PubMed:2784196, ECO:0000269|PubMed:28250417, ECO:0000269|PubMed:7504010, ECO:0000269|PubMed:7506728, ECO:0000269|PubMed:7679507, ECO:0000269|PubMed:7694806, ECO:0000269|PubMed:9862734}.; Allele A*01:01: Presents a restricted peptide repertoire including viral epitopes derived from IAV NP/nucleoprotein (CTELKLSDY), IAV PB1/polymerase basic protein 1 (VSDGGPNLY), HAdV-11 capsid L3/hexon protein (LTDLGQNLLY), SARS-CoV-2 3a/ORF3a (FTSDYYQLY) as well as tumor peptide antigens including MAGE1 (EADPTGHSY), MAGEA3 (EVDPIGHLY) and WT1 (TSEKRPFMCAY), all having in common a canonical motif with a negatively charged Asp or Glu residue at position 3 and a Tyr anchor residue at the C-terminus (PubMed:1402688, PubMed:7504010, PubMed:17189421, PubMed:20364150, PubMed:25880248, PubMed:30530481, PubMed:19177349, PubMed:24395804, PubMed:26758806, PubMed:32887977). A number of HLA-A*01:01-restricted peptides carry a post-translational modification with oxidation and N-terminal acetylation being the most frequent (PubMed:25880248). Fails to present highly immunogenic peptides from the EBV latent antigens (PubMed:18779413). {ECO:0000269|PubMed:1402688, ECO:0000269|PubMed:17189421, ECO:0000269|PubMed:18779413, ECO:0000269|PubMed:19177349, ECO:0000269|PubMed:20364150, ECO:0000269|PubMed:24395804, ECO:0000269|PubMed:25880248, ECO:0000269|PubMed:26758806, ECO:0000269|PubMed:30530481, ECO:0000269|PubMed:7504010}.; Allele A*02:01: A major allele in human populations, presents immunodominant viral epitopes derived from IAV M/matrix protein 1 (GILGFVFTL), HIV-1 env (TLTSCNTSV), HIV-1 gag-pol (ILKEPVHGV), HTLV-1 Tax (LLFGYPVYV), HBV C/core antigen (FLPSDFFPS), HCMV UL83/pp65 (NLVPMVATV) as well as tumor peptide antigens including MAGEA4 (GVYDGREHTV), WT1 (RMFPNAPYL) and CTAG1A/NY-ESO-1 (SLLMWITQC), all having in common hydrophobic amino acids at position 2 and at the C-terminal anchors. {ECO:0000269|PubMed:11502003, ECO:0000269|PubMed:12138174, ECO:0000269|PubMed:12796775, ECO:0000269|PubMed:17079320, ECO:0000269|PubMed:18275829, ECO:0000269|PubMed:19542454, ECO:0000269|PubMed:20619457, ECO:0000269|PubMed:22245737, ECO:0000269|PubMed:26929325, ECO:0000269|PubMed:2784196, ECO:0000269|PubMed:28250417, ECO:0000269|PubMed:7694806, ECO:0000269|PubMed:7935798, ECO:0000269|PubMed:8630735, ECO:0000269|PubMed:8805302, ECO:0000269|PubMed:8906788, ECO:0000269|PubMed:9177355}.; Allele A*03:01: Presents viral epitopes derived from IAV NP (ILRGSVAHK), HIV-1 nef (QVPLRPMTYK), HIV-1 gag-pol (AIFQSSMTK), SARS-CoV-2 N/nucleoprotein (KTFPPTEPK) as well as tumor peptide antigens including PMEL (LIYRRRLMK), NODAL (HAYIQSLLK), TRP-2 (RMYNMVPFF), all having in common hydrophobic amino acids at position 2 and Lys or Arg anchor residues at the C-terminus (PubMed:7504010, PubMed:7679507, PubMed:9862734, PubMed:19543285, PubMed:21943705, PubMed:2456340, PubMed:32887977). May also display spliced peptides resulting from the ligation of two separate proteasomal cleavage products that are not contiguous in the parental protein (PubMed:27049119). {ECO:0000269|PubMed:19543285, ECO:0000269|PubMed:21943705, ECO:0000269|PubMed:2456340, ECO:0000269|PubMed:27049119, ECO:0000269|PubMed:7504010, ECO:0000269|PubMed:7679507, ECO:0000269|PubMed:9862734}.; Allele A*11:01: Presents several immunodominant epitopes derived from HIV-1 gag-pol and HHV-4 EBNA4, containing the peptide motif with Val, Ile, Thr, Leu, Tyr or Phe at position 2 and Lys anchor residue at the C-terminus. Important in the control of HIV-1, EBV and HBV infections (PubMed:10449296). Presents an immunodominant epitope derived from SARS-CoV-2 N/nucleoprotein (KTFPPTEPK) (PubMed:32887977). {ECO:0000269|PubMed:10449296, ECO:0000269|PubMed:32887977}.; Allele A*23:01: Interacts with natural killer (NK) cell receptor KIR3DL1 and may contribute to functional maturation of NK cells and self-nonself discrimination during innate immune response. {ECO:0000269|PubMed:17182537}.; Allele A*24:02: Presents viral epitopes derived from HIV-1 nef (RYPLTFGWCF), EBV lytic- and latent-cycle antigens BRLF1 (TYPVLEEMF), BMLF1 (DYNFVKQLF) and LMP2 (IYVLVMLVL), SARS-CoV nucleocapsid/N (QFKDNVILL), as well as tumor peptide antigens including PRAME (LYVDSLFFL), all sharing a common signature motif, namely an aromatic residue Tyr or Phe at position 2 and a nonhydrophobic anchor residue Phe, Leu or Iso at the C-terminus (PubMed:9047241, PubMed:12393434, PubMed:24192765, PubMed:20844028). Interacts with natural killer (NK) cell receptor KIR3DL1 and may contribute to functional maturation of NK cells and self-nonself discrimination during innate immune response (PubMed:17182537, PubMed:18502829). {ECO:0000269|PubMed:12393434, ECO:0000269|PubMed:17182537, ECO:0000269|PubMed:18502829, ECO:0000269|PubMed:20844028, ECO:0000269|PubMed:24192765, ECO:0000269|PubMed:9047241}.; Allele A*26:01: Presents several epitopes derived from HIV-1 gag-pol (EVIPMFSAL, ETKLGKAGY) and env (LVSDGGPNLY), carrying as anchor residues preferentially Glu at position 1, Val or Thr at position 2 and Tyr at the C-terminus. {ECO:0000269|PubMed:15893615}.; Allele A*29:02: Presents peptides having a common motif, namely a Glu residue at position 2 and Tyr or Leu anchor residues at the C-terminus. {ECO:0000269|PubMed:8622959}.; Allele A*32:01: Interacts with natural killer (NK) cell receptor KIR3DL1 and may contribute to functional maturation of NK cells and self-nonself discrimination during innate immune response. {ECO:0000269|PubMed:17182537}.; Allele A*68:01: Presents viral epitopes derived from IAV NP (KTGGPIYKR) and HIV-1 tat (ITKGLGISYGR), having a common signature motif namely, Val or Thr at position 2 and positively charged residues Arg or Lys at the C-terminal anchor. {ECO:0000269|PubMed:1448153, ECO:0000269|PubMed:1448154, ECO:0000269|PubMed:2784196}.; Allele A*74:01: Presents immunodominant HIV-1 epitopes derived from gag-pol (GQMVHQAISPR, QIYPGIKVR) and rev (RQIHSISER), carrying an aliphatic residue at position 2 and Arg anchor residue at the C-terminus. May contribute to viral load control in chronic HIV-1 infection. {ECO:0000269|PubMed:21498667}.
T63239	PDBSTRUC	1AKJ;1AO7;1AQD;1B0G;1B0R;1BD2;1DUY;1DUZ;1EEY;1EEZ;1HHG;1HHH;1HHI;1HHJ;1HHK;1HLA;1HSB;1I1F;1I1Y;1I4F;1I7R;1I7T;1I7U;1IM3;1JF1;1JHT;1LP9;1OGA;1P7Q;1Q94;1QEW;1QR1;1QRN;1QSE;1QSF;1QVO;1S8D;1S9W;1S9X;1S9Y;1T1W;1T1X;1T1Y;1T1Z;1T20;1T21;1T22;1TMC;1TVB;1TVH;1W72;1X7Q;2AV1;2AV7;2BCK;2BNQ;2BNR;2C7U;2CLR;2F53;2F54;2GIT;2GJ6;2GT9;2GTW;2GTZ;2GUO;2HLA;2HN7;2J8U;2JCC;2P5E;2P5W;2PYE;2UWE;2V2W;2V2X;2VLJ;2VLK;2VLL;2VLR;2X4N;2X4O;2X4P;2X4Q;2X4R;2X4S;2X4T;2X4U;2X70;2XPG;3BGM;3BH8;3BH9;3BHB;3BO8;3D25;3D39;3D3V;3FQN;3FQR;3FQT;3FQU;3FQW;3FQX;3FT2;3FT3;3FT4;3GIV;3GJF;3GSN;3GSO;3GSQ;3GSR;3GSU;3GSV;3GSW;3GSX;3H7B;3H9H;3H9S;3HAE;3HLA;3HPJ;3I6G;3I6K;3I6L;3IXA;3KLA;3MGO;3MGT;3MR9;3MRB;3MRC;3MRD;3MRE;3MRF;3MRG;3MRH;3MRI;3MRJ;3MRK;3MRL;3MRM;3MRN;3MRO;3MRP;3MRQ;3MRR;3MYJ;3NFN;3O3A;3O3B;3O3D;3O3E;3O4L;3PWJ;3PWL;3PWN;3PWP;3QDG;3QDJ;3QDM;3QEQ;3QFD;3QFJ;3QZW;3REW;3RL1;3RL2;3TO2;3UTQ;3UTS;3UTT;3V5D;3V5H;3V5K;3VXM;3VXN;3VXO;3VXP;3VXR;3VXS;3VXU;3W0W;3WL9;3WLB;4E5X;4EMZ;4EN2;4EUP;4F7M;4F7P;4F7T;4FTV;4GKN;4GKS;4HWZ;4HX1;4I48;4I4W;4JFD;4JFE;4JFF;4JFO;4JFP;4JFQ;4K7F;4L29;4L3C;4L3E;4MJ5;4MJ6;4MNQ;4N8V;4NNX;4NNY;4NO0;4NO2;4NO3;4NO5;4NQV;4NQX;4OV5;4QOK;4U6X;4U6Y;4UQ2;4UQ3;4WJ5;4WU5;4WU7;4WUU;5BRZ;5BS0;5C07;5C08;5C09;5C0A;5C0B;5C0C;5C0D;5C0E;5C0F;5C0G;5C0I;5C0J;5D2L;5D2N;5D9S;5DDH;5E00;5E6I;5E9D;5ENW;5EOT;5EU3;5EU4;5EU5;5EU6;5EUO;5F7D;5F9J;5FA3;5FA4;5FDW;5GRD;5GRG;5GSD;5HGA;5HGB;5HGD;5HGH;5HHM;5HHN;5HHO;5HHP;5HHQ;5HYJ;5IRO;5ISZ;5JHD;5JZI;5MEN;5MEO;5MEP;5MEQ;5MER;5N1Y;5N6B;5NHT;5NME;5NMF;5NMG;5NMH;5NMK;5NQK;5SWQ;5TEZ;5W1W;5WJL;5WJN;5WKF;5WKH;5WSH;5WWI;5WWJ;5WWU;5WXC;5WXD;5XOV;5YXN;5YXU;6AM5;6AMT;6AMU;6APN;6AT9;6D78;6D7G;6DKP;6EI2;6ENY;6EQA;6EQB;6EWA;6EWC;6EWO;6G3J;6G3K;6ID4;6J1W;6J29;6J2A;6JOZ;6JP3;6MPP;6NCA;6O9B;6O9C;6OPD;6PBH;6PTB;6PTE;6Q3K;6Q3S;6R2L;6RP9;6RPA;6RPB;6RSY;6SS7;6SS8;6SS9;6SSA;7L1B;7L1C;7L1D;7MLE;7PHR;7QPD;7RK7;7RM4;7RRG;7STF;7UC5;7UX3;8D4C;8D4D;8D4E;8D4F;8D4G;8D9R;8D9S;8D9T;8D9U;8D9V;8D9W;8DVG
T63239	BIOCLASS	MHC class I
T63239	SEQUENCE	MAVMAPRTLLLLLSGALALTQTWAGSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDQETRNVKAQSQTDRVDLGTLRGYYNQSEAGSHTIQIMYGCDVGSDGRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITKRKWEAAHEAEQLRAYLDGTCVEWLRRYLENGKETLQRTDPPKTHMTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWELSSQPTIPIVGIIAGLVLLGAVITGAVVAAVMWRRKSSDRKGGSYTQAASSDSAQGSDVSLTACKV
T63239	DRUGINFO	DHWF68	RG6007	Phase 1

T63240	TARGETID	T63240
T63240	UNIPROID	LEP_ECOLI
T63240	TARGNAME	Signal peptidase I (lepB)
T63240	GENENAME	lepB
T63240	TARGTYPE	Clinical trial
T63240	SYNONYMS	SPase I; Leader peptidase I
T63240	PDBSTRUC	1B12;1KN9;1T7D;3IIQ;3S04;6B88
T63240	BIOCLASS	Peptidase
T63240	ECNUMBER	EC 3.4.21.89
T63240	SEQUENCE	MANMFALILVIATLVTGILWCVDKFFFAPKRRERQAAAQAAAGDSLDKATLKKVAPKPGWLETGASVFPVLAIVLIVRSFIYEPFQIPSGSMMPTLLIGDFILVEKFAYGIKDPIYQKTLIETGHPKRGDIVVFKYPEDPKLDYIKRAVGLPGDKVTYDPVSKELTIQPGCSSGQACENALPVTYSNVEPSDFVQTFSRRNGGEATSGFFEVPKNETKENGIRLSERKETLGDVTHRILTVPIAQDQVGMYYQQPGQQLATWIVPPGQYFMMGDNRDNSADSRYWGFVPEANLVGRATAIWMSFDKQEGEWPTGLRLSRIGGIH
T63240	DRUGINFO	DT7GB8	RG6319	Phase 1

T63241	TARGETID	T63241
T63241	UNIPROID	PAPD5_HUMAN
T63241	TARGNAME	Terminal nucleotidyltransferase 4B (TENT4B)
T63241	GENENAME	TENT4B
T63241	TARGTYPE	Clinical trial
T63241	SYNONYMS	Non-canonical poly(A) RNA polymerase PAPD5; PAP-associated domain-containing protein 5; Terminal guanylyltransferase; Terminal uridylyltransferase 3; TUTase 3; Topoisomerase-related function protein 4-2; TRF4-2
T63241	FUNCTION	Terminal nucleotidyltransferase that catalyzes preferentially the transfer of ATP and GTP on RNA 3' poly(A) tail creating a heterogeneous 3' poly(A) tail leading to mRNAs stabilization by protecting mRNAs from active deadenylation (PubMed:21788334, PubMed:30026317). Also functions as a catalytic subunit of a TRAMP-like complex which has a poly(A) RNA polymerase activity and is involved in a post-transcriptional quality control mechanism. Polyadenylation with short oligo(A) tails is required for the degradative activity of the exosome on several of its nuclear RNA substrates. Doesn't need a cofactor for polyadenylation activity (in vitro) (PubMed:21788334, PubMed:21855801). Required for cytoplasmic polyadenylation of mRNAs involved in carbohydrate metabolism, including the glucose transporter SLC2A1/GLUT1 (PubMed:28383716). Plays a role in replication-dependent histone mRNA degradation, probably through terminal uridylation of mature histone mRNAs. May play a role in sister chromatid cohesion (PubMed:18172165). Mediates 3' adenylation of the microRNA MIR21 followed by its 3'-to-5' trimming by the exoribonuclease PARN leading to degradation (PubMed:25049417). Mediates 3' adenylation of H/ACA box snoRNAs (small nucleolar RNAs) followed by its 3'-to-5' trimming by the exoribonuclease PARN which enhances snoRNA stability and maturation (PubMed:22442037). {ECO:0000269|PubMed:18172165, ECO:0000269|PubMed:21788334, ECO:0000269|PubMed:21855801, ECO:0000269|PubMed:22442037, ECO:0000269|PubMed:25049417, ECO:0000269|PubMed:28383716, ECO:0000269|PubMed:30026317}.
T63241	BIOCLASS	DNA polymerase type-B
T63241	ECNUMBER	EC 2.7.7.-; EC 2.7.7.19
T63241	SEQUENCE	MYRSGERLLGSHALPAEQRDFLPLETTNNNNNHHQPGAWARRAGSSASSPPSASSSPHPSAAVPAADPADSASGSSNKRKRDNKASGGRAAGGGRADGGGVVYSGTPWKRRNYNQGVVGLHEEISDFYEYMSPRPEEEKMRMEVVNRIESVIKELWPSADVQIFGSFKTGLYLPTSDIDLVVFGKWENLPLWTLEEALRKHKVADEDSVKVLDKATVPIIKLTDSFTEVKVDISFNVQNGVRAADLIKDFTKKYPVLPYLVLVLKQFLLQRDLNEVFTGGIGSYSLFLMAVSFLQLHPREDACIPNTNYGVLLIEFFELYGRHFNYLKTGIRIKDGGSYVAKDEVQKNMLDGYRPSMLYIEDPLQPGNDVGRSSYGAMQVKQAFDYAYVVLSHAVSPIAKYYPNNETESILGRIIRVTDEVATYRDWISKQWGLKNRPEPSCNGPVSSSSATQSSSSDVDSDATPCKTPKQLLCRPSTGNRVGSQDVSLESSQAVGKMQSTQTTNTSNSTNKSQHGSARLFRSSSKGFQGTTQTSHGSLMTNKQHQGKSNNQYYHGKKRKHKRDAPLSDLCR
T63241	DRUGINFO	D7PWY2	GSK3965193	Phase 1

T63242	TARGETID	T63242
T63242	UNIPROID	PAPD7_HUMAN
T63242	TARGNAME	Terminal nucleotidyltransferase 4A (TENT4A)
T63242	GENENAME	TENT4A
T63242	TARGTYPE	Clinical trial
T63242	SYNONYMS	DNA polymerase sigma; LAK-1; Non-canonical poly(A) RNA polymerase PAPD7; PAP-associated domain-containing protein 7; TRAMP-like complex polyadenylate polymerase; Terminal guanylyltransferase; Terminal uridylyltransferase 5; TUTase 5; Topoisomerase-related function protein 4-1; TRF4-1
T63242	FUNCTION	Terminal nucleotidyltransferase that catalyzes preferentially the transfer of ATP and GTP on RNA 3' poly(A) tail creating a heterogeneous 3' poly(A) tail leading to mRNAs stabilization by protecting mRNAs from active deadenylation (PubMed:23376078, PubMed:30026317). Also functions as a catalytic subunit of a TRAMP-like complex which has a poly(A) RNA polymerase activity and is involved in a post-transcriptional quality control mechanism. Polyadenylation with short oligo(A) tails is required for the degradative activity of the exosome on several of its nuclear RNA substrates. Has no terminal uridylyltransferase activity, and does not play a role in replication-dependent histone mRNA degradation via uridylation (PubMed:23376078). {ECO:0000269|PubMed:23376078, ECO:0000269|PubMed:30026317}.
T63242	BIOCLASS	DNA polymerase type-B
T63242	ECNUMBER	EC 2.7.7.-; EC 2.7.7.19
T63242	SEQUENCE	MDPRVAWIQPEQKGPANALWMQIWETSQGVGRGGSGFASYFCLNSPALDTAAAAGAAGRGSGGLGPALPAASPPPPGPTAPAALPPALLTALGPAAEGARRLHKSPSLSSSSSSSSSNAESGTESPGCSSSSSSSASLGRPGGGRGGAFFNFADGAPSAPGTANGHPGPRGPAPAGSPSQHQFHPGRRKRENKASTYGLNYLLSGSRAAALSGGGGPGAQAPRPGTPWKSRAYSPGIQGLHEEIIDFYNFMSPCPEEAAMRREVVKRIETVVKDLWPTADVQIFGSFSTGLYLPTSDIDLVVFGKWERPPLQLLEQALRKHNVAEPCSIKVLDKATVPIIKLTDQETEVKVDISFNMETGVRAAEFIKNYMKKYSLLPYLILVLKQFLLQRDLNEVFTGGISSYSLILMAISFLQLHPRIDARRADENLGMLLVEFFELYGRNFNYLKTGIRIKEGGAYIAKEEIMKAMTSGYRPSMLCIEDPLLPGNDVGRSSYGAMQVKQVFDYAYIVLSHAVSPLARSYPNRDAESTLGRIIKVTQEVIDYRRWIKEKWGSKAHPSPGMDSRIKIKERIATCNGEQTQNREPESPYGQRLTLSLSSPQLLSSGSSASSVSSLSGSDVDSDTPPCTTPSVYQFSLQAPAPLMAGLPTALPMPSGKPQPTTSRTLIMTTNNQTRFTIPPPTLGVAPVPCRQAGVEGTASLKAVHHMSSPAIPSASPNPLSSPHLYHKQHNGMKLSMKGSHGHTQGGGYSSVGSGGVRPPVGNRGHHQYNRTGWRRKKHTHTRDSLPVSLSR
T63242	DRUGINFO	D7PWY2	GSK3965193	Phase 1

T63160	TARGETID	T63160
T63160	UNIPROID	APOL1_HUMAN
T63160	TARGNAME	Apolipoprotein L1 messenger RNA (APOL1 mRNA)
T63160	GENENAME	APOL1
T63160	TARGTYPE	Clinical trial
T63160	SYNONYMS	Apolipoprotein L (mRNA); Apo-L (mRNA); ApoL (mRNA); Apolipoprotein L-I (mRNA); ApoL-I (mRNA)
T63160	FUNCTION	May play a role in lipid exchange and transport throughout the body. May participate in reverse cholesterol transport from peripheral cells to the liver.
T63160	PDBSTRUC	7L6K;7LF7;7LFA;7LFB;7LFD
T63160	BIOCLASS	mRNA target
T63160	SEQUENCE	MEGAALLRVSVLCIWMSALFLGVGVRAEEAGARVQQNVPSGTDTGDPQSKPLGDWAAGTMDPESSIFIEDAIKYFKEKVSTQNLLLLLTDNEAWNGFVAAAELPRNEADELRKALDNLARQMIMKDKNWHDKGQQYRNWFLKEFPRLKSELEDNIRRLRALADGVQKVHKGTTIANVVSGSLSISSGILTLVGMGLAPFTEGGSLVLLEPGMELGITAALTGITSSTMDYGKKWWTQAQAHDLVIKSLDKLKEVREFLGENISNFLSLAGNTYQLTRGIGKDIRALRRARANLQSVPHASASRPRVTEPISAESGEQVERVNEPSILEMSRGVKLTDVAPVSFFLVLDVVYLVYESKHLHEGAKSETAEELKKVAQELEEKLNILNNNYKILQADQEL
T63160	DRUGINFO	DR07FQ	ION532	Phase 1

T63161	TARGETID	T63161
T63161	UNIPROID	ATX3_HUMAN
T63161	TARGNAME	Ataxin-3 messenger RNA (ATXN3 mRNA)
T63161	GENENAME	ATXN3
T63161	TARGTYPE	Clinical trial
T63161	SYNONYMS	Machado-Joseph disease protein 1 (mRNA); Spinocerebellar ataxia type 3 protein (mRNA)
T63161	FUNCTION	Deubiquitinating enzyme involved in protein homeostasis maintenance, transcription, cytoskeleton regulation, myogenesis and degradation of misfolded chaperone substrates (PubMed:12297501, PubMed:17696782, PubMed:23625928, PubMed:28445460, PubMed:33157014, PubMed:16118278). Binds long polyubiquitin chains and trims them, while it has weak or no activity against chains of 4 or less ubiquitins (PubMed:17696782). Involved in degradation of misfolded chaperone substrates via its interaction with STUB1/CHIP: recruited to monoubiquitinated STUB1/CHIP, and restricts the length of ubiquitin chain attached to STUB1/CHIP substrates and preventing further chain extension (By similarity). Interacts with key regulators of transcription and represses transcription: acts as a histone-binding protein that regulates transcription (PubMed:12297501). Acts as a negative regulator of mTORC1 signaling in response to amino acid deprivation by mediating deubiquitination of RHEB, thereby promoting RHEB inactivation by the TSC-TBC complex (PubMed:33157014). Regulates autophagy via the deubiquitination of 'Lys-402' of BECN1 leading to the stabilization of BECN1 (PubMed:28445460). {ECO:0000250|UniProtKB:Q9CVD2, ECO:0000269|PubMed:12297501, ECO:0000269|PubMed:16118278, ECO:0000269|PubMed:17696782, ECO:0000269|PubMed:23625928, ECO:0000269|PubMed:28445460, ECO:0000269|PubMed:33157014}.
T63161	PDBSTRUC	1YZB;2AGA;2DOS;2JRI;2KLZ;4WTH;4YS9
T63161	BIOCLASS	mRNA target
T63161	ECNUMBER	EC 3.4.19.12
T63161	SEQUENCE	MESIFHEKQEGSLCAQHCLNNLLQGEYFSPVELSSIAHQLDEEERMRMAEGGVTSEDYRTFLQQPSGNMDDSGFFSIQVISNALKVWGLELILFNSPEYQRLRIDPINERSFICNYKEHWFTVRKLGKQWFNLNSLLTGPELISDTYLALFLAQLQQEGYSIFVVKGDLPDCEADQLLQMIRVQQMHRPKLIGEELAQLKEQRVHKTDLERVLEANDGSGMLDEDEEDLQRALALSRQEIDMEDEEADLRRAIQLSMQGSSRNISQDMTQTSGTNLTSEELRKRREAYFEKQQQKQQQQQQQQQQGDLSGQSSHPCERPATSSGALGSDLGDAMSEEDMLQAAVTMSLETVRNDLKTEGKK
T63161	DRUGINFO	DFXP94	BIIB132	Phase 1
T63161	DRUGINFO	DP5J8S	ION260	Phase 1

T63167	TARGETID	T63167
T63167	UNIPROID	CO3_HUMAN
T63167	TARGNAME	Complement C3 messenger RNA (C3 mRNA)
T63167	GENENAME	C3
T63167	TARGTYPE	Clinical trial
T63167	SYNONYMS	C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1 (mRNA)
T63167	FUNCTION	C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.; Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. In chronic inflammation, acts as a chemoattractant for neutrophils (By similarity). It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes. {ECO:0000250}.; [C3-beta-c]: Acts as a chemoattractant for neutrophils in chronic inflammation. {ECO:0000250}.; [Acylation stimulating protein]: Adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial TG clearance. Appears to stimulate TG synthesis via activation of the PLC, MAPK and AKT signaling pathways. Ligand for C5AR2. Promotes the phosphorylation, ARRB2-mediated internalization and recycling of C5AR2 (PubMed:8376604, PubMed:2909530, PubMed:9059512, PubMed:10432298, PubMed:15833747, PubMed:16333141, PubMed:19615750). {ECO:0000269|PubMed:10432298, ECO:0000269|PubMed:15833747, ECO:0000269|PubMed:16333141, ECO:0000269|PubMed:19615750, ECO:0000269|PubMed:2909530, ECO:0000269|PubMed:8376604, ECO:0000269|PubMed:9059512}.
T63167	PDBSTRUC	1C3D;1GHQ;1W2S;2A73;2A74;2GOX;2I07;2ICE;2ICF;2NOJ;2QKI;2WII;2WIN;2WY7;2WY8;2XQW;2XWB;2XWJ;3D5R;3D5S;3G6J;3L3O;3L5N;3NMS;3OED;3OHX;3OXU;3RJ3;3T4A;4HW5;4HWJ;4I6O;4M76;4ONT;4ZH1;5FO7;5FO8;5FO9;5FOA;5FOB;5NBQ;5O32;5O35;6EHG;6RMT;6RMU;6RUR;6RUV;6S0B;6YO6;7AKK;7BAG;7NOZ;7PI6;7QIV;7TV9;7UE9;7ZGK;8HK2
T63167	BIOCLASS	mRNA target
T63167	SEQUENCE	MGPTSGPSLLLLLLTHLPLALGSPMYSIITPNILRLESEETMVLEAHDAQGDVPVTVTVHDFPGKKLVLSSEKTVLTPATNHMGNVTFTIPANREFKSEKGRNKFVTVQATFGTQVVEKVVLVSLQSGYLFIQTDKTIYTPGSTVLYRIFTVNHKLLPVGRTVMVNIENPEGIPVKQDSLSSQNQLGVLPLSWDIPELVNMGQWKIRAYYENSPQQVFSTEFEVKEYVLPSFEVIVEPTEKFYYIYNEKGLEVTITARFLYGKKVEGTAFVIFGIQDGEQRISLPESLKRIPIEDGSGEVVLSRKVLLDGVQNPRAEDLVGKSLYVSATVILHSGSDMVQAERSGIPIVTSPYQIHFTKTPKYFKPGMPFDLMVFVTNPDGSPAYRVPVAVQGEDTVQSLTQGDGVAKLSINTHPSQKPLSITVRTKKQELSEAEQATRTMQALPYSTVGNSNNYLHLSVLRTELRPGETLNVNFLLRMDRAHEAKIRYYTYLIMNKGRLLKAGRQVREPGQDLVVLPLSITTDFIPSFRLVAYYTLIGASGQREVVADSVWVDVKDSCVGSLVVKSGQSEDRQPVPGQQMTLKIEGDHGARVVLVAVDKGVFVLNKKNKLTQSKIWDVVEKADIGCTPGSGKDYAGVFSDAGLTFTSSSGQQTAQRAELQCPQPAARRRRSVQLTEKRMDKVGKYPKELRKCCEDGMRENPMRFSCQRRTRFISLGEACKKVFLDCCNYITELRRQHARASHLGLARSNLDEDIIAEENIVSRSEFPESWLWNVEDLKEPPKNGISTKLMNIFLKDSITTWEILAVSMSDKKGICVADPFEVTVMQDFFIDLRLPYSVVRNEQVEIRAVLYNYRQNQELKVRVELLHNPAFCSLATTKRRHQQTVTIPPKSSLSVPYVIVPLKTGLQEVEVKAAVYHHFISDGVRKSLKVVPEGIRMNKTVAVRTLDPERLGREGVQKEDIPPADLSDQVPDTESETRILLQGTPVAQMTEDAVDAERLKHLIVTPSGCGEQNMIGMTPTVIAVHYLDETEQWEKFGLEKRQGALELIKKGYTQQLAFRQPSSAFAAFVKRAPSTWLTAYVVKVFSLAVNLIAIDSQVLCGAVKWLILEKQKPDGVFQEDAPVIHQEMIGGLRNNNEKDMALTAFVLISLQEAKDICEEQVNSLPGSITKAGDFLEANYMNLQRSYTVAIAGYALAQMGRLKGPLLNKFLTTAKDKNRWEDPGKQLYNVEATSYALLALLQLKDFDFVPPVVRWLNEQRYYGGGYGSTQATFMVFQALAQYQKDAPDHQELNLDVSLQLPSRSSKITHRIHWESASLLRSEETKENEGFTVTAEGKGQGTLSVVTMYHAKAKDQLTCNKFDLKVTIKPAPETEKRPQDAKNTMILEICTRYRGDQDATMSILDISMMTGFAPDTDDLKQLANGVDRYISKYELDKAFSDRNTLIIYLDKVSHSEDDCLAFKVHQYFNVELIQPGAVKVYAYYNLEESCTRFYHPEKEDGKLNKLCRDELCRCAEENCFIQKSDDKVTLEERLDKACEPGVDYVYKTRLVKVQLSNDFDEYIMAIEQTIKSGSDEVQVGQQRTFISPIKCREALKLEEKKHYLMWGLSSDFWGEKPNLSYIIGKDTWVEHWPEEDECQDEENQKQCQDLGAFTESMVVFGCPN
T63167	DRUGINFO	D2O5WA	ALXN2030	Phase 1

T63169	TARGETID	T63169
T63169	UNIPROID	G6PC1_HUMAN
T63169	TARGNAME	Glucose-6-phosphatase catalytic subunit 1 messenger RNA (G6PC1 mRNA)
T63169	GENENAME	G6PC1
T63169	TARGTYPE	Clinical trial
T63169	SYNONYMS	Glucose-6-phosphatase (mRNA); G-6-Pase (mRNA); G6Pase (mRNA); Glucose-6-phosphatase alpha (mRNA); G6Pase-alpha (mRNA)
T63169	FUNCTION	Hydrolyzes glucose-6-phosphate to glucose in the endoplasmic reticulum. Forms with the glucose-6-phosphate transporter (SLC37A4/G6PT) the complex responsible for glucose production in the terminal step of glycogenolysis and gluconeogenesis. Hence, it is the key enzyme in homeostatic regulation of blood glucose levels. {ECO:0000269|PubMed:10960498, ECO:0000269|PubMed:12093795, ECO:0000269|PubMed:15542400, ECO:0000269|PubMed:9332655, ECO:0000269|PubMed:9497333}.
T63169	BIOCLASS	mRNA target
T63169	ECNUMBER	EC 3.1.3.9
T63169	SEQUENCE	MEEGMNVLHDFGIQSTHYLQVNYQDSQDWFILVSVIADLRNAFYVLFPIWFHLQEAVGIKLLWVAVIGDWLNLVFKWILFGQRPYWWVLDTDYYSNTSVPLIKQFPVTCETGPGSPSGHAMGTAGVYYVMVTSTLSIFQGKIKPTYRFRCLNVILWLGFWAVQLNVCLSRIYLAAHFPHQVVAGVLSGIAVAETFSHIHSIYNASLKKYFLITFFLFSFAIGFYLLLKGLGVDLLWTLEKAQRWCEQPEWVHIDTTPFASLLKNLGTLFGLGLALNSSMYRESCKGKLSKWLPFRLSSIVASLVLLHVFDSLKPPSQVELVFYVLSFCKSAVVPLASVSVIPYCLAQVLGQPHKKSL
T63169	DRUGINFO	DO40BQ	mRNA-3745	Phase 1

T63177	TARGETID	T63177
T63177	UNIPROID	LRRK2_HUMAN
T63177	TARGNAME	Leucine-rich repeat serine/threonine-protein kinase 2 messenger RNA (LRRK2 mRNA)
T63177	GENENAME	LRRK2
T63177	TARGTYPE	Clinical trial
T63177	SYNONYMS	Dardarin (mRNA)
T63177	FUNCTION	Serine/threonine-protein kinase which phosphorylates a broad range of proteins involved in multiple processes such as neuronal plasticity, innate immunity, autophagy, and vesicle trafficking (PubMed:20949042, PubMed:22012985, PubMed:26824392, PubMed:27830463, PubMed:29125462, PubMed:28720718, PubMed:29127255, PubMed:30398148, PubMed:29212815, PubMed:30635421, PubMed:21850687, PubMed:23395371, PubMed:17114044, PubMed:24687852, PubMed:26014385, PubMed:25201882). Is a key regulator of RAB GTPases by regulating the GTP/GDP exchange and interaction partners of RABs through phosphorylation (PubMed:26824392, PubMed:28720718, PubMed:29127255, PubMed:30398148, PubMed:29212815, PubMed:29125462, PubMed:30635421). Phosphorylates RAB3A, RAB3B, RAB3C, RAB3D, RAB5A, RAB5B, RAB5C, RAB8A, RAB8B, RAB10, RAB12, RAB35, and RAB43 (PubMed:26824392, PubMed:28720718, PubMed:29127255, PubMed:30398148, PubMed:29212815, PubMed:29125462, PubMed:30635421, PubMed:23395371). Regulates the RAB3IP-catalyzed GDP/GTP exchange for RAB8A through the phosphorylation of 'Thr-72' on RAB8A (PubMed:26824392). Inhibits the interaction between RAB8A and GDI1 and/or GDI2 by phosphorylating 'Thr-72' on RAB8A (PubMed:26824392). Regulates primary ciliogenesis through phosphorylation of RAB8A and RAB10, which promotes SHH signaling in the brain (PubMed:29125462, PubMed:30398148). Together with RAB29, plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose-6-phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner (PubMed:23395371). Regulates neuronal process morphology in the intact central nervous system (CNS) (PubMed:17114044). Plays a role in synaptic vesicle trafficking (PubMed:24687852). Plays an important role in recruiting SEC16A to endoplasmic reticulum exit sites (ERES) and in regulating ER to Golgi vesicle-mediated transport and ERES organization (PubMed:25201882). Positively regulates autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway (PubMed:22012985). The process involves activation of nicotinic acid adenine dinucleotide phosphate (NAADP) receptors, increase in lysosomal pH, and calcium release from lysosomes (PubMed:22012985). Phosphorylates PRDX3 (PubMed:21850687). By phosphorylating APP on 'Thr-743', which promotes the production and the nuclear translocation of the APP intracellular domain (AICD), regulates dopaminergic neuron apoptosis (PubMed:28720718). Acts as a positive regulator of innate immunity by mediating phosphorylation of RIPK2 downstream of NOD1 and NOD2, thereby enhancing RIPK2 activation (PubMed:27830463). Independent of its kinase activity, inhibits the proteasomal degradation of MAPT, thus promoting MAPT oligomerization and secretion (PubMed:26014385). In addition, has GTPase activity via its Roc domain which regulates LRRK2 kinase activity (PubMed:18230735, PubMed:26824392, PubMed:29125462, PubMed:28720718, PubMed:29212815). {ECO:0000269|PubMed:17114044, ECO:0000269|PubMed:18230735, ECO:0000269|PubMed:20949042, ECO:0000269|PubMed:21850687, ECO:0000269|PubMed:22012985, ECO:0000269|PubMed:23395371, ECO:0000269|PubMed:24687852, ECO:0000269|PubMed:25201882, ECO:0000269|PubMed:26014385, ECO:0000269|PubMed:26824392, ECO:0000269|PubMed:27830463, ECO:0000269|PubMed:28720718, ECO:0000269|PubMed:29125462, ECO:0000269|PubMed:29127255, ECO:0000269|PubMed:29212815, ECO:0000269|PubMed:30398148, ECO:0000269|PubMed:30635421}.
T63177	PDBSTRUC	2ZEJ;3D6T;5MY9;5MYC;6DLO;6DLP;6OJE;6OJF;6VNO;6VP6;6VP7;6XAF;6XR4;7LHT;7LHW;7LI3;7LI4;7THY;7THZ
T63177	BIOCLASS	mRNA target
T63177	ECNUMBER	EC 2.7.11.1; EC 3.6.5.-
T63177	SEQUENCE	MASGSCQGCEEDEETLKKLIVRLNNVQEGKQIETLVQILEDLLVFTYSERASKLFQGKNIHVPLLIVLDSYMRVASVQQVGWSLLCKLIEVCPGTMQSLMGPQDVGNDWEVLGVHQLILKMLTVHNASVNLSVIGLKTLDLLLTSGKITLLILDEESDIFMLIFDAMHSFPANDEVQKLGCKALHVLFERVSEEQLTEFVENKDYMILLSALTNFKDEEEIVLHVLHCLHSLAIPCNNVEVLMSGNVRCYNIVVEAMKAFPMSERIQEVSCCLLHRLTLGNFFNILVLNEVHEFVVKAVQQYPENAALQISALSCLALLTETIFLNQDLEEKNENQENDDEGEEDKLFWLEACYKALTWHRKNKHVQEAACWALNNLLMYQNSLHEKIGDEDGHFPAHREVMLSMLMHSSSKEVFQASANALSTLLEQNVNFRKILLSKGIHLNVLELMQKHIHSPEVAESGCKMLNHLFEGSNTSLDIMAAVVPKILTVMKRHETSLPVQLEALRAILHFIVPGMPEESREDTEFHHKLNMVKKQCFKNDIHKLVLAALNRFIGNPGIQKCGLKVISSIVHFPDALEMLSLEGAMDSVLHTLQMYPDDQEIQCLGLSLIGYLITKKNVFIGTGHLLAKILVSSLYRFKDVAEIQTKGFQTILAILKLSASFSKLLVHHSFDLVIFHQMSSNIMEQKDQQFLNLCCKCFAKVAMDDYLKNVMLERACDQNNSIMVECLLLLGADANQAKEGSSLICQVCEKESSPKLVELLLNSGSREQDVRKALTISIGKGDSQIISLLLRRLALDVANNSICLGGFCIGKVEPSWLGPLFPDKTSNLRKQTNIASTLARMVIRYQMKSAVEEGTASGSDGNFSEDVLSKFDEWTFIPDSSMDSVFAQSDDLDSEGSEGSFLVKKKSNSISVGEFYRDAVLQRCSPNLQRHSNSLGPIFDHEDLLKRKRKILSSDDSLRSSKLQSHMRHSDSISSLASEREYITSLDLSANELRDIDALSQKCCISVHLEHLEKLELHQNALTSFPQQLCETLKSLTHLDLHSNKFTSFPSYLLKMSCIANLDVSRNDIGPSVVLDPTVKCPTLKQFNLSYNQLSFVPENLTDVVEKLEQLILEGNKISGICSPLRLKELKILNLSKNHISSLSENFLEACPKVESFSARMNFLAAMPFLPPSMTILKLSQNKFSCIPEAILNLPHLRSLDMSSNDIQYLPGPAHWKSLNLRELLFSHNQISILDLSEKAYLWSRVEKLHLSHNKLKEIPPEIGCLENLTSLDVSYNLELRSFPNEMGKLSKIWDLPLDELHLNFDFKHIGCKAKDIIRFLQQRLKKAVPYNRMKLMIVGNTGSGKTTLLQQLMKTKKSDLGMQSATVGIDVKDWPIQIRDKRKRDLVLNVWDFAGREEFYSTHPHFMTQRALYLAVYDLSKGQAEVDAMKPWLFNIKARASSSPVILVGTHLDVSDEKQRKACMSKITKELLNKRGFPAIRDYHFVNATEESDALAKLRKTIINESLNFKIRDQLVVGQLIPDCYVELEKIILSERKNVPIEFPVIDRKRLLQLVRENQLQLDENELPHAVHFLNESGVLLHFQDPALQLSDLYFVEPKWLCKIMAQILTVKVEGCPKHPKGIISRRDVEKFLSKKRKFPKNYMSQYFKLLEKFQIALPIGEEYLLVPSSLSDHRPVIELPHCENSEIIIRLYEMPYFPMGFWSRLINRLLEISPYMLSGRERALRPNRMYWRQGIYLNWSPEAYCLVGSEVLDNHPESFLKITVPSCRKGCILLGQVVDHIDSLMEEWFPGLLEIDICGEGETLLKKWALYSFNDGEEHQKILLDDLMKKAEEGDLLVNPDQPRLTIPISQIAPDLILADLPRNIMLNNDELEFEQAPEFLLGDGSFGSVYRAAYEGEEVAVKIFNKHTSLRLLRQELVVLCHLHHPSLISLLAAGIRPRMLVMELASKGSLDRLLQQDKASLTRTLQHRIALHVADGLRYLHSAMIIYRDLKPHNVLLFTLYPNAAIIAKIADYGIAQYCCRMGIKTSEGTPGFRAPEVARGNVIYNQQADVYSFGLLLYDILTTGGRIVEGLKFPNEFDELEIQGKLPDPVKEYGCAPWPMVEKLIKQCLKENPQERPTSAQVFDILNSAELVCLTRRILLPKNVIVECMVATHHNSRNASIWLGCGHTDRGQLSFLDLNTEGYTSEEVADSRILCLALVHLPVEKESWIVSGTQSGTLLVINTEDGKKRHTLEKMTDSVTCLYCNSFSKQSKQKNFLLVGTADGKLAIFEDKTVKLKGAAPLKILNIGNVSTPLMCLSESTNSTERNVMWGGCGTKIFSFSNDFTIQKLIETRTSQLFSYAAFSDSNIITVVVDTALYIAKQNSPVVEVWDKKTEKLCGLIDCVHFLREVMVKENKESKHKMSYSGRVKTLCLQKNTALWIGTGGGHILLLDLSTRRLIRVIYNFCNSVRVMMTAQLGSLKNVMLVLGYNRKNTEGTQKQKEIQSCLTVWDINLPHEVQNLEKHIEVRKELAEKMRRTSVE
T63177	DRUGINFO	D2AO6J	BIIB094	Phase 1

T63180	TARGETID	T63180
T63180	UNIPROID	MUC5A_HUMAN
T63180	TARGNAME	Mucin-5AC messenger RNA (MUC5AC mRNA)
T63180	GENENAME	MUC5AC
T63180	TARGTYPE	Clinical trial
T63180	SYNONYMS	MUC-5AC (mRNA); Gastric mucin (mRNA); Major airway glycoprotein (mRNA); Mucin-5 subtype AC, tracheobronchial (mRNA); Tracheobronchial mucin (mRNA); TBM (mRNA)
T63180	FUNCTION	Gel-forming glycoprotein of gastric and respiratory tract epithelia that protects the mucosa from infection and chemical damage by binding to inhaled microorganisms and particles that are subsequently removed by the mucociliary system (PubMed:14535999, PubMed:14718370). Interacts with H.pylori in the gastric epithelium, Barrett's esophagus as well as in gastric metaplasia of the duodenum (GMD) (PubMed:14535999). {ECO:0000269|PubMed:14535999, ECO:0000303|PubMed:14535999, ECO:0000303|PubMed:14718370}.
T63180	PDBSTRUC	5AJN;5AJO;5AJP
T63180	BIOCLASS	mRNA target
T63180	SEQUENCE	MSVGRRKLALLWALALALACTRHTGHAQDGSSESSYKHHPALSPIARGPSGVPLRGATVFPSLRTIPVVRASNPAHNGRVCSTWGSFHYKTFDGDVFRFPGLCNYVFSEHCGAAYEDFNIQLRRSQESAAPTLSRVLMKVDGVVIQLTKGSVLVNGHPVLLPFSQSGVLIQQSSSYTKVEARLGLVLMWNHDDSLLLELDTKYANKTCGLCGDFNGMPVVSELLSHNTKLTPMEFGNLQKMDDPTDQCQDPVPEPPRNCSTGFGICEELLHGQLFSGCVALVDVGSYLEACRQDLCFCEDTDLLSCVCHTLAEYSRQCTHAGGLPQDWRGPDFCPQKCPNNMQYHECRSPCADTCSNQEHSRACEDHCVAGCFCPEGTVLDDIGQTGCVPVSKCACVYNGAAYAPGATYSTDCTNCTCSGGRWSCQEVPCPGTCSVLGGAHFSTFDGKQYTVHGDCSYVLTKPCDSSAFTVLAELRRCGLTDSETCLKSVTLSLDGAQTVVVIKASGEVFLNQIYTQLPISAANVTIFRPSTFFIIAQTSLGLQLNLQLVPTMQLFMQLAPKLRGQTCGLCGNFNSIQADDFRTLSGVVEATAAAFFNTFKTQAACPNIRNSFEDPCSLSVENEKYAQHWCSQLTDADGPFGRCHAAVKPGTYYSNCMFDTCNCERSEDCLCAALSSYVHACAAKGVQLGGWRDGVCTKPMTTCPKSMTYHYHVSTCQPTCRSLSEGDITCSVGFIPVDGCICPKGTFLDDTGKCVQASNCPCYHRGSMIPNGESVHDSGAICTCTHGKLSCIGGQAPAPVCAAPMVFFDCRNATPGDTGAGCQKSCHTLDMTCYSPQCVPGCVCPDGLVADGEGGCITAEDCPCVHNEASYRAGQTIRVGCNTCTCDSRMWRCTDDPCLATCAVYGDGHYLTFDGQSYSFNGDCEYTLVQNHCGGKDSTQDSFRVVTENVPCGTTGTTCSKAIKIFLGGFELKLSHGKVEVIGTDESQEVPYTIRQMGIYLVVDTDIGLVLLWDKKTSIFINLSPEFKGRVCGLCGNFDDIAVNDFATRSRSVVGDVLEFGNSWKLSPSCPDALAPKDPCTANPFRKSWAQKQCSILHGPTFAACHAHVEPARYYEACVNDACACDSGGDCECFCTAVAAYAQACHEVGLCVSWRTPSICPLFCDYYNPEGQCEWHYQPCGVPCLRTCRNPRGDCLRDVRGLEGCYPKCPPEAPIFDEDKMQCVATCPTPPLPPRCHVHGKSYRPGAVVPSDKNCQSCLCTERGVECTYKAEACVCTYNGQRFHPGDVIYHTTDGTGGCISARCGANGTIERRVYPCSPTTPVPPTTFSFSTPPLVVSSTHTPSNGPSSAHTGPPSSAWPTTAGTSPRTRLPTASASLPPVCGEKCLWSPWMDVSRPGRGTDSGDFDTLENLRAHGYRVCESPRSVECRAEDAPGVPLRALGQRVQCSPDVGLTCRNREQASGLCYNYQIRVQCCTPLPCSTSSSPAQTTPPTTSKTTETRASGSSAPSSTPGTVSLSTARTTPAPGTATSVKKTFSTPSPPPVPATSTSSMSTTAPGTSVVSSKPTPTEPSTSSCLQELCTWTEWIDGSYPAPGINGGDFDTFQNLRDEGYTFCESPRSVQCRAESFPNTPLADLGQDVICSHTEGLICLNKNQLPPICYNYEIRIQCCETVNVCRDITRLPKTVATTRPTPHPTGAQTQTTFTTHMPSASTEQPTATSRGGPTATSVTQGTHTTLVTRNCHPRCTWTKWFDVDFPSPGPHGGDKETYNNIIRSGEKICRRPEEITRLQCRAKSHPEVSIEHLGQVVQCSREEGLVCRNQDQQGPFKMCLNYEVRVLCCETPRGCHMTSTPGSTSSSPAQTTPSTTSKTTETQASGSSAPSSTPGTVSLSTARTTPAPGTATSVKKTFSTPSPPPVPATSTSSMSTTAPGTSVVSSKPTPTEPSTSSCLQELCTWTEWIDGSYPAPGINGGDFDTFQNLRDEGYTFCESPRSVQCRAESFPNTPLADLGQDVICSHTEGLICLNKNQLPPICYNYEIRIQCCETVNVCRDITRPPKTVATTRPTPHPTGAQTQTTFTTHMPSASTEQPTATSRGGPTATSVTQGTHTTPVTRNCHPRCTWTTWFDVDFPSPGPHGGDKETYNNIIRSGEKICRRPEEITRLQCRAKSHPEVSIEHLGQVVQCSREEGLVCRNQDQQGPFKMCLNYEVRVLCCETPKGCPVTSTPVTAPSTPSGRATSPTQSTSSWQKSRTTTLVTTSTTSTPQTSTTYAHTTSTTSAPTARTTSAPTTRTTSASPASTTSGPGNTPSPVPTTSTISAPTTSITSAPTTSTTSAPTSSTTSGPGTTPSPVPTTSITSAPTTSTTSAPTTSTTSARTSSTTSATTTSRISGPETTPSPVPTTSTTSATTTSTTSAPTTSTTSAPTSSTTSSPQTSTTSAPTTSTTSGPGTTPSPVPTTSTTSAPTTRTTSAPKSSTTSAATTSTTSGPETTPRPVPTTSTTSSPTTSTTSAPTTSTTSASTTSTTSGAGTTPSPVPTTSTTSAPTTSTTSAPISSTTSATTTSTTSGPGTTPSPVPTTSTTSAPTTSTTSGPGTTPSAVPTTSITSAPTTSTNSAPISSTTSATTTSRISGPETTPSPVPTASTTSASTTSTTSGPGTTPSPVPTTSTISVPTTSTTSASTTSTTSASTTSTTSGPGTTPSPVPTTSTTSAPTTSTTSAPTTSTISAPTTSTTSATTTSTTSAPTPRRTSAPTTSTISASTTSTTSATTTSTTSATTTSTISAPTTSTTLSPTTSTTSTTITSTTSAPISSTTSTPQTSTTSAPTTSTTSGPGTTSSPVPTTSTTSAPTTSTTSAPTTRTTSVPTSSTTSTATTSTTSGPGTTPSPVPTTSTTSAPTTRTTSAPTTSTTSAPTTSTTSAPTSSTTSATTTSTISVPTTSTTSVPGTTPSPVPTTSTISVPTTSTTSASTTSTTSGPGTTPSPVPTTSTTSAPTTSTTSAPTTSTISAPTTSTPSAPTTSTTLAPTTSTTSAPTTSTTSTPTSSTTSSPQTSTTSASTTSITSGPGTTPSPVPTTSTTSAPTTSTTSAATTSTISAPTTSTTSAPTTSTTSASTASKTSGLGTTPSPIPTTSTTSPPTTSTTSASTASKTSGPGTTPSPVPTTSTIFAPRTSTTSASTTSTTPGPGTTPSPVPTTSTASVSKTSTSHVSISKTTHSQPVTRDCHLRCTWTKWFDIDFPSPGPHGGDKETYNNIIRSGEKICRRPEEITRLQCRAESHPEVSIEHLGQVVQCSREEGLVCRNQDQQGPFKMCLNYEVRVLCCETPKGCPVTSTPVTAPSTPSGRATSPTQSTSSWQKSRTTTLVTTSTTSTPQTSTTSAPTTSTTSAPTTSTTSAPTTSTTSTPQTSISSAPTSSTTSAPTSSTISARTTSIISAPTTSTTSSPTTSTTSATTTSTTSAPTSSTTSTPQTSKTSAATSSTTSGSGTTPSPVTTTSTASVSKTSTSHVSVSKTTHSQPVTRDCHPRCTWTKWFDVDFPSPGPHGGDKETYNNIIRSGEKICRRPEEITRLQCRAKSHPEVSIEHLGQVVQCSREEGLVCRNQDQQGPFKMCLNYEVRVLCCETPKGCPVTSTSVTAPSTPSGRATSPTQSTSSWQKSRTTTLVTSSITSTTQTSTTSAPTTSTTPASIPSTTSAPTTSTTSAPTTSTTSAPTTSTTSTPQTTTSSAPTSSTTSAPTTSTISAPTTSTISAPTTSTTSAPTASTTSAPTSTSSAPTTNTTSAPTTSTTSAPITSTISAPTTSTTSTPQTSTISSPTTSTTSTPQTSTTSSPTTSTTSAPTTSTTSAPTTSTTSTPQTSISSAPTSSTTSAPTASTISAPTTSTTSFHTTSTTSPPTSSTSSTPQTSKTSAATSSTTSGSGTTPSPVPTTSTASVSKTSTSHVSVSKTTHSQPVTRDCHPRCTWTKWFDVDFPSPGPHGGDKETYNNIIRSGEKICRRPEEITRLQCRAESHPEVSIEHLGQVVQCSREEGLVCRNQDQQGPFKMCLNYEVRVLCCETPKGCPVTSTPVTAPSTPSGRATSPTQSTSSWQKSRTTTLVTTSTTSTPQTSTTSAPTTSTIPASTPSTTSAPTTSTTSAPTTSTTSAPTHRTTSGPTTSTTLAPTTSTTSAPTTSTNSAPTTSTISASTTSTISAPTTSTISSPTSSTTSTPQTSKTSAATSSTTSGSGTTPSPVPTTSTTSASTTSTTSAPTTSTTSGPGTTPSPVPSTSTTSAATTSTTSAPTTRTTSAPTSSMTSGPGTTPSPVPTTSTTSAPTTSTTSGPGTTPSPVPTTSTTSAPITSTTSGPGSTPSPVPTTSTTSAPTTSTTSASTASTTSGPGTTPSPVPTTSTTSAPTTRTTSASTASTTSGPGSTPSPVPTTSTTSAPTTRTTPASTASTTSGPGTTPSPVPTTSTTSASTTSTISLPTTSTTSAPITSMTSGPGTTPSPVPTTSTTSAPTTSTTSASTASTTSGPGTTPSPVPTTSTTSAPTTSTTSASTASTTSGPGTSLSPVPTTSTTSAPTTSTTSGPGTTPSPVPTTSTTSAPTTSTTSGPGTTPSPVPTTSTTPVSKTSTSHLSVSKTTHSQPVTSDCHPLCAWTKWFDVDFPSPGPHGGDKETYNNIIRSGEKICRRPEEITRLQCRAESHPEVNIEHLGQVVQCSREEGLVCRNQDQQGPFKMCLNYEVRVLCCETPRGCPVTSVTPYGTSPTNALYPSLSTSMVSASVASTSVASSSVASSSVAYSTQTCFCNVADRLYPAGSTIYRHRDLAGHCYYALCSQDCQVVRGVDSDCPSTTLPPAPATSPSISTSEPVTELGCPNAVPPRKKGETWATPNCSEATCEGNNVISLRPRTCPRVEKPTCANGYPAVKVADQDGCCHHYQCQCVCSGWGDPHYITFDGTYYTFLDNCTYVLVQQIVPVYGHFRVLVDNYFCGAEDGLSCPRSIILEYHQDRVVLTRKPVHGVMTNEIIFNNKVVSPGFRKNGIVVSRIGVKMYATIPELGVQVMFSGLIFSVEVPFSKFANNTEGQCGTCTNDRKDECRTPRGTVVASCSEMSGLWNVSIPDQPACHRPHPTPTTVGPTTVGSTTVGPTTVGSTTVGPTTPPAPCLPSPICQLILSKVFEPCHTVIPPLLFYEGCVFDRCHMTDLDVVCSSLELYAALCASHDICIDWRGRTGHMCPFTCPADKVYQPCGPSNPSYCYGNDSASLGALPEAGPITEGCFCPEGMTLFSTSAQVCVPTGCPRCLGPHGEPVKVGHTVGMDCQECTCEAATWTLTCRPKLCPLPPACPLPGFVPVPAAPQAGQCCPQYSCACNTSRCPAPVGCPEGARAIPTYQEGACCPVQNCSWTVCSINGTLYQPGAVVSSSLCETCRCELPGGPPSDAFVVSCETQICNTHCPVGFEYQEQSGQCCGTCVQVACVTNTSKSPAHLFYPGETWSDAGNHCVTHQCEKHQDGLVVVTTKKACPPLSCSLDEARMSKDGCCRFCPPPPPPYQNQSTCAVYHRSLIIQQQGCSSSEPVRLAYCRGNCGDSSSMYSLEGNTVEHRCQCCQELRTSLRNVTLHCTDGSSRAFSYTEVEECGCMGRRCPAPGDTQHSEEAEPEPSQEAESGSWERGVPVSPMH
T63180	DRUGINFO	D17DXO	ARO-MUC5AC	Phase 1

T63184	TARGETID	T63184
T63184	UNIPROID	RAGE_HUMAN
T63184	TARGNAME	Advanced glycosylation end product-specific receptor messenger RNA (AGER mRNA)
T63184	GENENAME	AGER
T63184	TARGTYPE	Clinical trial
T63184	SYNONYMS	Receptor for advanced glycosylation end products (mRNA)
T63184	FUNCTION	Cell surface pattern recognition receptor that senses endogenous stress signals with a broad ligand repertoire including advanced glycation end products, S100 proteins, high-mobility group box 1 protein/HMGB1, amyloid beta/APP oligomers, nucleic acids, phospholipids and glycosaminoglycans (PubMed:27572515, PubMed:28515150, PubMed:34743181). Advanced glycosylation end products are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes (PubMed:21565706). These ligands accumulate at inflammatory sites during the pathogenesis of various diseases, including diabetes, vascular complications, neurodegenerative disorders, and cancers and RAGE transduces their binding into pro-inflammatory responses. Upon ligand binding, uses TIRAP and MYD88 as adapters to transduce the signal ultimately leading to the induction or inflammatory cytokines IL6, IL8 and TNFalpha through activation of NF-kappa-B (PubMed:21829704). Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key pro-inflammatory mediators (PubMed:19386136). Interaction with S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling (By similarity). Contributes to the translocation of amyloid-beta peptide (ABPP) across the cell membrane from the extracellular to the intracellular space in cortical neurons (PubMed:19906677). ABPP-initiated RAGE signaling, especially stimulation of p38 mitogen-activated protein kinase (MAPK), has the capacity to drive a transport system delivering ABPP as a complex with RAGE to the intraneuronal space. Participates in endothelial albumin transcytosis together with HMGB1 through the RAGE/SRC/Caveolin-1 pathway, leading to endothelial hyperpermeability (PubMed:27572515). Mediates the loading of HMGB1 in extracellular vesicles (EVs) that shuttle HMGB1 to hepatocytes by transferrin-mediated endocytosis and subsequently promote hepatocyte pyroptosis by activating the NLRP3 inflammasome (PubMed:34743181). Promotes also extracellular hypomethylated DNA (CpG DNA) uptake by cells via the endosomal route to activate inflammatory responses (PubMed:24081950, PubMed:28515150). {ECO:0000250|UniProtKB:Q62151, ECO:0000269|PubMed:19906677, ECO:0000269|PubMed:20943659, ECO:0000269|PubMed:21559403, ECO:0000269|PubMed:21565706, ECO:0000269|PubMed:21829704, ECO:0000269|PubMed:24081950, ECO:0000269|PubMed:27572515, ECO:0000269|PubMed:28515150, ECO:0000269|PubMed:34743181}.
T63184	PDBSTRUC	2E5E;2ENS;2L7U;2LE9;2LMB;2M1K;2MJW;2MOV;3CJJ;3O3U;4LP4;4LP5;4OF5;4OFV;4OI7;4OI8;4P2Y;4XYN;4YBH;5D7F;6VXG;6XQ1;6XQ3;6XQ5;6XQ6;6XQ7;6XQ8;6XQ9;7LML;7LMW
T63184	BIOCLASS	mRNA target
T63184	SEQUENCE	MAAGTAVGAWVLVLSLWGAVVGAQNITARIGEPLVLKCKGAPKKPPQRLEWKLNTGRTEAWKVLSPQGGGPWDSVARVLPNGSLFLPAVGIQDEGIFRCQAMNRNGKETKSNYRVRVYQIPGKPEIVDSASELTAGVPNKVGTCVSEGSYPAGTLSWHLDGKPLVPNEKGVSVKEQTRRHPETGLFTLQSELMVTPARGGDPRPTFSCSFSPGLPRHRALRTAPIQPRVWEPVPLEEVQLVVEPEGGAVAPGGTVTLTCEVPAQPSPQIHWMKDGVPLPLPPSPVLILPEIGPQDQGTYSCVATHSSHGPQESRAVSISIIEPGEEGPTAGSVGGSGLGTLALALGILGGLGTAALLIGVILWQRRQRRGEERKAPENQEEEEERAELNQSEEPEAGESSTGGP
T63184	DRUGINFO	D8JN6C	ARO-RAGE	Phase 1

T63200	TARGETID	T63200
T63200	UNIPROID	XDH_HUMAN
T63200	TARGNAME	Xanthine dehydrogenase/oxidase messenger RNA (XDH mRNA)
T63200	GENENAME	XDH
T63200	TARGTYPE	Clinical trial
T63200	FUNCTION	Key enzyme in purine degradation. Catalyzes the oxidation of hypoxanthine to xanthine. Catalyzes the oxidation of xanthine to uric acid. Contributes to the generation of reactive oxygen species. Has also low oxidase activity towards aldehydes (in vitro). {ECO:0000269|PubMed:17301077}.
T63200	PDBSTRUC	2CKJ;2E1Q
T63200	BIOCLASS	mRNA target
T63200	ECNUMBER	EC 1.17.1.4; EC 1.17.3.2
T63200	SEQUENCE	MTADKLVFFVNGRKVVEKNADPETTLLAYLRRKLGLSGTKLGCGEGGCGACTVMLSKYDRLQNKIVHFSANACLAPICSLHHVAVTTVEGIGSTKTRLHPVQERIAKSHGSQCGFCTPGIVMSMYTLLRNQPEPTMEEIENAFQGNLCRCTGYRPILQGFRTFARDGGCCGGDGNNPNCCMNQKKDHSVSLSPSLFKPEEFTPLDPTQEPIFPPELLRLKDTPRKQLRFEGERVTWIQASTLKELLDLKAQHPDAKLVVGNTEIGIEMKFKNMLFPMIVCPAWIPELNSVEHGPDGISFGAACPLSIVEKTLVDAVAKLPAQKTEVFRGVLEQLRWFAGKQVKSVASVGGNIITASPISDLNPVFMASGAKLTLVSRGTRRTVQMDHTFFPGYRKTLLSPEEILLSIEIPYSREGEYFSAFKQASRREDDIAKVTSGMRVLFKPGTTEVQELALCYGGMANRTISALKTTQRQLSKLWKEELLQDVCAGLAEELHLPPDAPGGMVDFRCTLTLSFFFKFYLTVLQKLGQENLEDKCGKLDPTFASATLLFQKDPPADVQLFQEVPKGQSEEDMVGRPLPHLAADMQASGEAVYCDDIPRYENELSLRLVTSTRAHAKIKSIDTSEAKKVPGFVCFISADDVPGSNITGICNDETVFAKDKVTCVGHIIGAVVADTPEHTQRAAQGVKITYEELPAIITIEDAIKNNSFYGPELKIEKGDLKKGFSEADNVVSGEIYIGGQEHFYLETHCTIAVPKGEAGEMELFVSTQNTMKTQSFVAKMLGVPANRIVVRVKRMGGGFGGKETRSTVVSTAVALAAYKTGRPVRCMLDRDEDMLITGGRHPFLARYKVGFMKTGTVVALEVDHFSNVGNTQDLSQSIMERALFHMDNCYKIPNIRGTGRLCKTNLPSNTAFRGFGGPQGMLIAECWMSEVAVTCGMPAEEVRRKNLYKEGDLTHFNQKLEGFTLPRCWEECLASSQYHARKSEVDKFNKENCWKKRGLCIIPTKFGISFTVPFLNQAGALLHVYTDGSVLLTHGGTEMGQGLHTKMVQVASRALKIPTSKIYISETSTNTVPNTSPTAASVSADLNGQAVYAACQTILKRLEPYKKKNPSGSWEDWVTAAYMDTVSLSATGFYRTPNLGYSFETNSGNPFHYFSYGVACSEVEIDCLTGDHKNLRTDIVMDVGSSLNPAIDIGQVEGAFVQGLGLFTLEELHYSPEGSLHTRGPSTYKIPAFGSIPIEFRVSLLRDCPNKKAIYASKAVGEPPLFLAASIFFAIKDAIRAARAQHTGNNVKELFRLDSPATPEKIRNACVDKFTTLCVTGVPENCKPWSVRV
T63200	DRUGINFO	DZDL28	ALN-XDH	Phase 1/2

T63201	TARGETID	T63201
T63201	UNIPROID	ANGT_HUMAN
T63201	TARGNAME	Angiotensinogen messenger RNA (AGT mRNA)
T63201	GENENAME	AGT
T63201	TARGTYPE	Clinical trial
T63201	SYNONYMS	Serpin A8 (mRNA)
T63201	FUNCTION	Essential component of the renin-angiotensin system (RAS), a potent regulator of blood pressure, body fluid and electrolyte homeostasis. {ECO:0000269|PubMed:10619573, ECO:0000269|PubMed:1132082, ECO:0000269|PubMed:17138938}.; [Angiotensin-2]: Acts directly on vascular smooth muscle as a potent vasoconstrictor, affects cardiac contractility and heart rate through its action on the sympathetic nervous system, and alters renal sodium and water absorption through its ability to stimulate the zona glomerulosa cells of the adrenal cortex to synthesize and secrete aldosterone (PubMed:10619573, PubMed:17138938). Acts by binding to angiotensin receptors AGTR1 and AGTR2 (PubMed:1567413). Also binds the DEAR/FBXW7-AS1 receptor (By similarity). {ECO:0000250|UniProtKB:P01015, ECO:0000269|PubMed:10619573, ECO:0000269|PubMed:1567413, ECO:0000269|PubMed:17138938}.; [Angiotensin-3]: Stimulates aldosterone release. {ECO:0000269|PubMed:1132082}.; [Angiotensin 1-7]: Is a ligand for the G-protein coupled receptor MAS1 (By similarity). Has vasodilator and antidiuretic effects. Has an antithrombotic effect that involves MAS1-mediated release of nitric oxide from platelets (By similarity). {ECO:0000250|UniProtKB:P11859}.
T63201	PDBSTRUC	1N9U;1N9V;2JP8;2WXW;2X0B;3CK0;3WOO;3WOR;4AA1;4APH;4FYS;5E2Q;5M3X;5M3Y;5XJM;6I3F;6I3I;6JOD;6OS0;7C6A
T63201	BIOCLASS	mRNA target
T63201	SEQUENCE	MRKRAPQSEMAPAGVSLRATILCLLAWAGLAAGDRVYIHPFHLVIHNESTCEQLAKANAGKPKDPTFIPAPIQAKTSPVDEKALQDQLVLVAAKLDTEDKLRAAMVGMLANFLGFRIYGMHSELWGVVHGATVLSPTAVFGTLASLYLGALDHTADRLQAILGVPWKDKNCTSRLDAHKVLSALQAVQGLLVAQGRADSQAQLLLSTVVGVFTAPGLHLKQPFVQGLALYTPVVLPRSLDFTELDVAAEKIDRFMQAVTGWKTGCSLMGASVDSTLAFNTYVHFQGKMKGFSLLAEPQEFWVDNSTSVSVPMLSGMGTFQHWSDIQDNFSVTQVPFTESACLLLIQPHYASDLDKVEGLTFQQNSLNWMKKLSPRTIHLTMPQLVLQGSYDLQDLLAQAELPAILHTELNLQKLSNDRIRVGEVLNSIFFELEADEREPTESTQQLNKPEVLEVTLNRPFLFAVYDQSATALHFLGRVANPLSTA
T63201	DRUGINFO	D30EZF	Zilebesiran	Phase 2
T63201	DRUGINFO	DLQS16	ION904	Phase 2

T63203	TARGETID	T63203
T63203	UNIPROID	ATX2_HUMAN
T63203	TARGNAME	Ataxin-2 messenger RNA (ATXN2 mRNA)
T63203	GENENAME	ATXN2
T63203	TARGTYPE	Clinical trial
T63203	SYNONYMS	Spinocerebellar ataxia type 2 protein (mRNA); Trinucleotide repeat-containing gene 13 protein (mRNA)
T63203	FUNCTION	Involved in EGFR trafficking, acting as negative regulator of endocytic EGFR internalization at the plasma membrane. {ECO:0000269|PubMed:18602463}.
T63203	PDBSTRUC	3KTR
T63203	BIOCLASS	mRNA target
T63203	SEQUENCE	MRSAAAAPRSPAVATESRRFAAARWPGWRSLQRPARRSGRGGGGAAPGPYPSAAPPPPGPGPPPSRQSSPPSASDCFGSNGNGGGAFRPGSRRLLGLGGPPRPFVVLLLPLASPGAPPAAPTRASPLGARASPPRSGVSLARPAPGCPRPACEPVYGPLTMSLKPQQQQQQQQQQQQQQQQQQQQQQQPPPAAANVRKPGGSGLLASPAAAPSPSSSSVSSSSATAPSSVVAATSGGGRPGLGRGRNSNKGLPQSTISFDGIYANMRMVHILTSVVGSKCEVQVKNGGIYEGVFKTYSPKCDLVLDAAHEKSTESSSGPKREEIMESILFKCSDFVVVQFKDMDSSYAKRDAFTDSAISAKVNGEHKEKDLEPWDAGELTANEELEALENDVSNGWDPNDMFRYNEENYGVVSTYDSSLSSYTVPLERDNSEEFLKREARANQLAEEIESSAQYKARVALENDDRSEEEKYTAVQRNSSEREGHSINTRENKYIPPGQRNREVISWGSGRQNSPRMGQPGSGSMPSRSTSHTSDFNPNSGSDQRVVNGGVPWPSPCPSPSSRPPSRYQSGPNSLPPRAATPTRPPSRPPSRPSRPPSHPSAHGSPAPVSTMPKRMSSEGPPRMSPKAQRHPRNHRVSAGRGSISSGLEFVSHNPPSEAATPPVARTSPSGGTWSSVVSGVPRLSPKTHRPRSPRQNSIGNTPSGPVLASPQAGIIPTEAVAMPIPAASPTPASPASNRAVTPSSEAKDSRLQDQRQNSPAGNKENIKPNETSPSFSKAENKGISPVVSEHRKQIDDLKKFKNDFRLQPSSTSESMDQLLNKNREGEKSRDLIKDKIEPSAKDSFIENSSSNCTSGSSKPNSPSISPSILSNTEHKRGPEVTSQGVQTSSPACKQEKDDKEEKKDAAEQVRKSTLNPNAKEFNPRSFSQPKPSTTPTSPRPQAQPSPSMVGHQQPTPVYTQPVCFAPNMMYPVPVSPGVQPLYPIPMTPMPVNQAKTYRAVPNMPQQRQDQHHQSAMMHPASAAGPPIAATPPAYSTQYVAYSPQQFPNQPLVQHVPHYQSQHPHVYSPVIQGNARMMAPPTHAQPGLVSSSATQYGAHEQTHAMYACPKLPYNKETSPSFYFAISTGSLAQQYAHPNATLHPHTPHPQPSATPTGQQQSQHGGSHPAPSPVQHHQHQAAQALHLASPQQQSAIYHAGLAPTPPSMTPASNTQSPQNSFPAAQQTVFTIHPSHVQPAYTNPPHMAHVPQAHVQSGMVPSHPTAHAPMMLMTTQPPGGPQAALAQSALQPIPVSTTAHFPYMTHPSVQAHHQQQL
T63203	DRUGINFO	D3L7YG	BIIB105	Phase 2

T63212	TARGETID	T63212
T63212	UNIPROID	PCCA_HUMAN
T63212	TARGNAME	Propionyl-CoA carboxylase alpha chain, mitochondrial messenger RNA (PCCA mRNA)
T63212	GENENAME	PCCA
T63212	TARGTYPE	Clinical trial
T63212	SYNONYMS	PCCase subunit alpha (mRNA); Propanoyl-CoA:carbon dioxide ligase subunit alpha (mRNA)
T63212	FUNCTION	This is one of the 2 subunits of the biotin-dependent propionyl-CoA carboxylase (PCC), a mitochondrial enzyme involved in the catabolism of odd chain fatty acids, branched-chain amino acids isoleucine, threonine, methionine, and valine and other metabolites (PubMed:8434582, PubMed:6765947). Propionyl-CoA carboxylase catalyzes the carboxylation of propionyl-CoA/propanoyl-CoA to D-methylmalonyl-CoA/(S)-methylmalonyl-CoA (PubMed:8434582, PubMed:6765947, PubMed:10101253). Within the holoenzyme, the alpha subunit catalyzes the ATP-dependent carboxylation of the biotin carried by the biotin carboxyl carrier (BCC) domain, while the beta subunit then transfers the carboxyl group from carboxylated biotin to propionyl-CoA (By similarity). Propionyl-CoA carboxylase also significantly acts on butyryl-CoA/butanoyl-CoA, which is converted to ethylmalonyl-CoA/(2S)-ethylmalonyl-CoA at a much lower rate (PubMed:6765947). Other alternative minor substrates include (2E)-butenoyl-CoA/crotonoyl-CoA (By similarity). {ECO:0000250|UniProtKB:P0DTA4, ECO:0000250|UniProtKB:Q5LUF3, ECO:0000269|PubMed:10101253, ECO:0000269|PubMed:6765947, ECO:0000269|PubMed:8434582}.
T63212	PDBSTRUC	2CQY;2JKU;7YBU
T63212	BIOCLASS	mRNA target
T63212	ECNUMBER	EC 6.4.1.3
T63212	SEQUENCE	MAGFWVGTAPLVAAGRRGRWPPQQLMLSAALRTLKHVLYYSRQCLMVSRNLGSVGYDPNEKTFDKILVANRGEIACRVIRTCKKMGIKTVAIHSDVDASSVHVKMADEAVCVGPAPTSKSYLNMDAIMEAIKKTRAQAVHPGYGFLSENKEFARCLAAEDVVFIGPDTHAIQAMGDKIESKLLAKKAEVNTIPGFDGVVKDAEEAVRIAREIGYPVMIKASAGGGGKGMRIAWDDEETRDGFRLSSQEAASSFGDDRLLIEKFIDNPRHIEIQVLGDKHGNALWLNERECSIQRRNQKVVEEAPSIFLDAETRRAMGEQAVALARAVKYSSAGTVEFLVDSKKNFYFLEMNTRLQVEHPVTECITGLDLVQEMIRVAKGYPLRHKQADIRINGWAVECRVYAEDPYKSFGLPSIGRLSQYQEPLHLPGVRVDSGIQPGSDISIYYDPMISKLITYGSDRTEALKRMADALDNYVIRGVTHNIALLREVIINSRFVKGDISTKFLSDVYPDGFKGHMLTKSEKNQLLAIASSLFVAFQLRAQHFQENSRMPVIKPDIANWELSVKLHDKVHTVVASNNGSVFSVEVDGSKLNVTSTWNLASPLLSVSVDGTQRTVQCLSREAGGNMSIQFLGTVYKVNILTRLAAELNKFMLEKVTEDTSSVLRSPMPGVVVAVSVKPGDAVAEGQEICVIEAMKMQNSMTAGKTGTVKSVHCQAGDTVGEGDLLVELE
T63212	DRUGINFO	DSC3P4	mRNA-3927	Phase 2

T63213	TARGETID	T63213
T63213	UNIPROID	PCCB_HUMAN
T63213	TARGNAME	Propionyl-CoA carboxylase beta chain, mitochondrial messenger RNA (PCCB mRNA)
T63213	GENENAME	PCCB
T63213	TARGTYPE	Clinical trial
T63213	SYNONYMS	PCCase subunit beta (mRNA); Propanoyl-CoA:carbon dioxide ligase subunit beta (mRNA)
T63213	FUNCTION	This is one of the 2 subunits of the biotin-dependent propionyl-CoA carboxylase (PCC), a mitochondrial enzyme involved in the catabolism of odd chain fatty acids, branched-chain amino acids isoleucine, threonine, methionine, and valine and other metabolites (PubMed:6765947, PubMed:15890657). Propionyl-CoA carboxylase catalyzes the carboxylation of propionyl-CoA/propanoyl-CoA to D-methylmalonyl-CoA/(S)-methylmalonyl-CoA (PubMed:6765947, PubMed:15890657). Within the holoenzyme, the alpha subunit catalyzes the ATP-dependent carboxylation of the biotin carried by the biotin carboxyl carrier (BCC) domain, while the beta subunit then transfers the carboxyl group from carboxylated biotin to propionyl-CoA (By similarity). Propionyl-CoA carboxylase also significantly acts on butyryl-CoA/butanoyl-CoA, which is converted to ethylmalonyl-CoA/(2S)-ethylmalonyl-CoA at a much lower rate (PubMed:6765947). Other alternative minor substrates include (2E)-butenoyl-CoA/crotonoyl-CoA (By similarity). {ECO:0000250|UniProtKB:P79384, ECO:0000250|UniProtKB:Q168G2, ECO:0000269|PubMed:15890657, ECO:0000269|PubMed:6765947}.
T63213	PDBSTRUC	7YBU
T63213	BIOCLASS	mRNA target
T63213	ECNUMBER	EC 6.4.1.3
T63213	SEQUENCE	MAAALRVAAVGARLSVLASGLRAAVRSLCSQATSVNERIENKRRTALLGGGQRRIDAQHKRGKLTARERISLLLDPGSFVESDMFVEHRCADFGMAADKNKFPGDSVVTGRGRINGRLVYVFSQDFTVFGGSLSGAHAQKICKIMDQAITVGAPVIGLNDSGGARIQEGVESLAGYADIFLRNVTASGVIPQISLIMGPCAGGAVYSPALTDFTFMVKDTSYLFITGPDVVKSVTNEDVTQEELGGAKTHTTMSGVAHRAFENDVDALCNLRDFFNYLPLSSQDPAPVRECHDPSDRLVPELDTIVPLESTKAYNMVDIIHSVVDEREFFEIMPNYAKNIIVGFARMNGRTVGIVGNQPKVASGCLDINSSVKGARFVRFCDAFNIPLITFVDVPGFLPGTAQEYGGIIRHGAKLLYAFAEATVPKVTVITRKAYGGAYDVMSSKHLCGDTNYAWPTAEIAVMGAKGAVEIIFKGHENVEAAQAEYIEKFANPFPAAVRGFVDDIIQPSSTRARICCDLDVLASKKVQRPWRKHANIPL
T63213	DRUGINFO	DSC3P4	mRNA-3927	Phase 2

T63214	TARGETID	T63214
T63214	UNIPROID	PLPL3_HUMAN
T63214	TARGNAME	1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 messenger RNA (PNPLA3 mRNA)
T63214	GENENAME	PNPLA3
T63214	TARGTYPE	Clinical trial
T63214	SYNONYMS	Acylglycerol transacylase (mRNA); Adiponutrin (mRNA); ADPN (mRNA); Calcium-independent phospholipase A2-epsilon (mRNA); iPLA2-epsilon (mRNA); Lysophosphatidic acid acyltransferase (mRNA); Patatin-like phospholipase domain-containing protein 3 (mRNA)
T63214	FUNCTION	Specifically catalyzes coenzyme A (CoA)-dependent acylation of 1-acyl-sn-glycerol 3-phosphate (2-lysophosphatidic acid/LPA) to generate phosphatidic acid (PA), an important metabolic intermediate and precursor for both triglycerides and glycerophospholipids. Does not esterify other lysophospholipids. Acyl donors are long chain (at least C16) fatty acyl-CoAs: arachidonoyl-CoA, linoleoyl-CoA, oleoyl-CoA and at a lesser extent palmitoyl-CoA (PubMed:22560221). Additionally possesses low triacylglycerol lipase and CoA-independent acylglycerol transacylase activities and thus may play a role in acyl-chain remodeling of triglycerides (PubMed:15364929, PubMed:20034933, PubMed:22560221). In vitro may express hydrolytic activity against glycerolipids triacylglycerol, diacylglycerol and monoacylglycerol, with a strong preference for oleic acid as the acyl moiety (PubMed:21878620). However, the triacylglycerol hydrolase activity is controversial and may be very low (PubMed:22560221). Possesses phospholipase A2 activity (PubMed:15364929). {ECO:0000269|PubMed:15364929, ECO:0000269|PubMed:20034933, ECO:0000269|PubMed:21878620, ECO:0000269|PubMed:22560221}.
T63214	BIOCLASS	mRNA target
T63214	ECNUMBER	EC 2.3.1.51; EC 3.1.1.3; EC 3.1.1.4
T63214	SEQUENCE	MYDAERGWSLSFAGCGFLGFYHVGATRCLSEHAPHLLRDARMLFGASAGALHCVGVLSGIPLEQTLQVLSDLVRKARSRNIGIFHPSFNLSKFLRQGLCKCLPANVHQLISGKIGISLTRVSDGENVLVSDFRSKDEVVDALVCSCFIPFYSGLIPPSFRGVRYVDGGVSDNVPFIDAKTTITVSPFYGEYDICPKVKSTNFLHVDITKLSLRLCTGNLYLLSRAFVPPDLKVLGEICLRGYLDAFRFLEEKGICNRPQPGLKSSSEGMDPEVAMPSWANMSLDSSPESAALAVRLEGDELLDHLRLSILPWDESILDTLSPRLATALSEEMKDKGGYMSKICNLLPIRIMSYVMLPCTLPVESAIAIVQRLVTWLPDMPDDVLWLQWVTSQVFTRVLMCLLPASRSQMPVSSQQASPCTPEQDWPCWTPCSPKGCPAETKAEATPRSILRSSLNFFLGNKVPAGAEGLSTFPSFSLEKSL
T63214	DRUGINFO	DC86WO	ION839	Phase 2
T63214	DRUGINFO	D3DM8Y	AMG 609	Phase 1

T63222	TARGETID	T63222
T63222	UNIPROID	USH2A_HUMAN
T63222	TARGNAME	Usherin messenger RNA (USH2A mRNA)
T63222	GENENAME	USH2A
T63222	TARGTYPE	Clinical trial
T63222	SYNONYMS	Usher syndrome type IIa protein (mRNA); Usher syndrome type-2A protein (mRNA)
T63222	FUNCTION	Involved in hearing and vision as member of the USH2 complex. In the inner ear, required for the maintenance of the hair bundle ankle formation, which connects growing stereocilia in developing cochlear hair cells. In retina photoreceptors, the USH2 complex is required for the maintenance of periciliary membrane complex that seems to play a role in regulating intracellular protein transport. {ECO:0000250|UniProtKB:Q2QI47}.
T63222	BIOCLASS	mRNA target
T63222	SEQUENCE	MNCPVLSLGSGFLFQVIEMLIFAYFASISLTESRGLFPRLENVGAFKKVSIVPTQAVCGLPDRSTFCHSSAAAESIQFCTQRFCIQDCPYRSSHPTYTALFSAGLSSCITPDKNDLHPNAHSNSASFIFGNHKSCFSSPPSPKLMASFTLAVWLKPEQQGVMCVIEKTVDGQIVFKLTISEKETMFYYRTVNGLQPPIKVMTLGRILVKKWIHLSVQVHQTKISFFINGVEKDHTPFNARTLSGSITDFASGTVQIGQSLNGLEQFVGRMQDFRLYQVALTNREILEVFSGDLLRLHAQSHCRCPGSHPRVHPLAQRYCIPNDAGDTADNRVSRLNPEAHPLSFVNDNDVGTSWVSNVFTNITQLNQGVTISVDLENGQYQVFYIIIQFFSPQPTEIRIQRKKENSLDWEDWQYFARNCGAFGMKNNGDLEKPDSVNCLQLSNFTPYSRGNVTFSILTPGPNYRPGYNNFYNTPSLQEFVKATQIRFHFHGQYYTTETAVNLRHRYYAVDEITISGRCQCHGHADNCDTTSQPYRCLCSQESFTEGLHCDRCLPLYNDKPFRQGDQVYAFNCKPCQCNSHSKSCHYNISVDPFPFEHFRGGGGVCDDCEHNTTGRNCELCKDYFFRQVGADPSAIDVCKPCDCDTVGTRNGSILCDQIGGQCNCKRHVSGRQCNQCQNGFYNLQELDPDGCSPCNCNTSGTVDGDITCHQNSGQCKCKANVIGLRCDHCNFGFKFLRSFNDVGCEPCQCNLHGSVNKFCNPHSGQCECKKEAKGLQCDTCRENFYGLDVTNCKACDCDTAGSLPGTVCNAKTGQCICKPNVEGRQCNKCLEGNFYLRQNNSFLCLPCNCDKTGTINGSLLCNKSTGQCPCKLGVTGLRCNQCEPHRYNLTIDNFQHCQMCECDSLGTLPGTICDPISGQCLCVPNRQGRRCNQCQPGFYISPGNATGCLPCSCHTTGAVNHICNSLTGQCVCQDASIAGQRCDQCKDHYFGFDPQTGRCQPCNCHLSGALNETCHLVTGQCFCKQFVTGSKCDACVPSASHLDVNNLLGCSKTPFQQPPPRGQVQSSSAINLSWSPPDSPNAHWLTYSLLRDGFEIYTTEDQYPYSIQYFLDTDLLPYTKYSYYIETTNVHGSTRSVAVTYKTKPGVPEGNLTLSYIIPIGSDSVTLTWTTLSNQSGPIEKYILSCAPLAGGQPCVSYEGHETSATIWNLVPFAKYDFSVQACTSGGCLHSLPITVTTAQAPPQRLSPPKMQKISSTELHVEWSPPAELNGIIIRYELYMRRLRSTKETTSEESRVFQSSGWLSPHSFVESANENALKPPQTMTTITGLEPYTKYEFRVLAVNMAGSVSSAWVSERTGESAPVFMIPPSVFPLSSYSLNISWEKPADNVTRGKVVGYDINMLSEQSPQQSIPMAFSQLLHTAKSQELSYTVEGLKPYRIYEFTITLCNSVGCVTSASGAGQTLAAAPAQLRPPLVKGINSTTIHLRWFPPEELNGPSPIYQLERRESSLPALMTTMMKGIRFIGNGYCKFPSSTHPVNTDFTGIKASFRTKVPEGLIVFAASPGNQEEYFALQLKKGRLYFLFDPQGSPVEVTTTNDHGKQYSDGKWHEIIAIRHQAFGQITLDGIYTGSSAILNGSTVIGDNTGVFLGGLPRSYTILRKDPEIIQKGFVGCLKDVHFMKNYNPSAIWEPLDWQSSEEQINVYNSWEGCPASLNEGAQFLGAGFLELHPYMFHGGMNFEISFKFRTDQLNGLLLFVYNKDGPDFLAMELKSGILTFRLNTSLAFTQVDLLLGLSYCNGKWNKVIIKKEGSFISASVNGLMKHASESGDQPLVVNSPVYVGGIPQELLNSYQHLCLEQGFGGCMKDVKFTRGAVVNLASVSSGAVRVNLDGCLSTDSAVNCRGNDSILVYQGKEQSVYEGGLQPFTEYLYRVIASHEGGSVYSDWSRGRTTGAAPQSVPTPSRVRSLNGYSIEVTWDEPVVRGVIEKYILKAYSEDSTRPPRMPSASAEFVNTSNLTGILTGLLPFKNYAVTLTACTLAGCTESSHALNISTPQEAPQEVQPPVAKSLPSSLLLSWNPPKKANGIITQYCLYMDGRLIYSGSEENYIVTDLAVFTPHQFLLSACTHVGCTNSSWVLLYTAQLPPEHVDSPVLTVLDSRTIHIQWKQPRKISGILERYVLYMSNHTHDFTIWSVIYNSTELFQDHMLQYVLPGNKYLIKLGACTGGGCTVSEASEALTDEDIPEGVPAPKAHSYSPDSFNVSWTEPEYPNGVITSYGLYLDGILIHNSSELSYRAYGFAPWSLHSFRVQACTAKGCALGPLVENRTLEAPPEGTVNVFVKTQGSRKAHVRWEAPFRPNGLLTHSVLFTGIFYVDPVGNNYTLLNVTKVMYSGEETNLWVLIDGLVPFTNYTVQVNISNSQGSLITDPITIAMPPGAPDGVLPPRLSSATPTSLQVVWSTPARNNAPGSPRYQLQMRSGDSTHGFLELFSNPSASLSYEVSDLQPYTEYMFRLVASNGFGSAHSSWIPFMTAEDKPGPVVPPILLDVKSRMMLVTWQHPRKSNGVITHYNIYLHGRLYLRTPGNVTNCTVMHLHPYTAYKFQVEACTSKGCSLSPESQTVWTLPGAPEGIPSPELFSDTPTSVIISWQPPTHPNGLVENFTIERRVKGKEEVTTLVTLPRSHSMRFIDKTSALSPWTKYEYRVLMSTLHGGTNSSAWVEVTTRPSRPAGVQPPVVTVLEPDAVQVTWKPPLIQNGDILSYEIHMPDPHITLTNVTSAVLSQKVTHLIPFTNYSVTIVACSGGNGYLGGCTESLPTYVTTHPTVPQNVGPLSVIPLSESYVVISWQPPSKPNGPNLRYELLRRKIQQPLASNPPEDLNRWHNIYSGTQWLYEDKGLSRFTTYEYMLFVHNSVGFTPSREVTVTTLAGLPERGANLTASVLNHTAIDVRWAKPTVQDLQGEVEYYTLFWSSATSNDSLKILPDVNSHVIGHLKPNTEYWIFISVFNGVHSINSAGLHATTCDGEPQGMLPPEVVIINSTAVRVIWTSPSNPNGVVTEYSIYVNNKLYKTGMNVPGSFILRDLSPFTIYDIQVEVCTIYACVKSNGTQITTVEDTPSDIPTPTIRGITSRSLQIDWVSPRKPNGIILGYDLLWKTWYPCAKTQKLVQDQSDELCKAVRCQKPESICGHICYSSEAKVCCNGVLYNPKPGHRCCEEKYIPFVLNSTGVCCGGRIQEAQPNHQCCSGYYARILPGEVCCPDEQHNRVSVGIGDSCCGRMPYSTSGNQICCAGRLHDGHGQKCCGRQIVSNDLECCGGEEGVVYNRLPGMFCCGQDYVNMSDTICCSASSGESKAHIKKNDPVPVKCCETELIPKSQKCCNGVGYNPLKYVCSDKISTGMMMKETKECRILCPASMEATEHCGRCDFNFTSHICTVIRGSHNSTGKASIEEMCSSAEETIHTGSVNTYSYTDVNLKPYMTYEYRISAWNSYGRGLSKAVRARTKEDVPQGVSPPTWTKIDNLEDTIVLNWRKPIQSNGPIIYYILLRNGIERFRGTSLSFSDKEGIQPFQEYSYQLKACTVAGCATSSKVVAATTQGVPESILPPSITALSAVALHLSWSVPEKSNGVIKEYQIRQVGKGLIHTDTTDRRQHTVTGLQPYTNYSFTLTACTSAGCTSSEPFLGQTLQAAPEGVWVTPRHIIINSTTVELYWSLPEKPNGLVSQYQLSRNGNLLFLGGSEEQNFTDKNLEPNSRYTYKLEVKTGGGSSASDDYIVQTPMSTPEEIYPPYNITVIGPYSIFVAWIPPGILIPEIPVEYNVLLNDGSVTPLAFSVGHHQSTLLENLTPFTQYEIRIQACQNGSCGVSSRMFVKTPEAAPMDLNSPVLKALGSACIEIKWMPPEKPNGIIINYFIYRRPAGIEEESVLFVWSEGALEFMDEGDTLRPFTLYEYRVRACNSKGSVESLWSLTQTLEAPPQDFPAPWAQATSAHSVLLNWTKPESPNGIISHYRVVYQERPDDPTFNSPTVHAFTVKGTSHQAHLYGLEPFTTYRIGVVAANHAGEILSPWTLIQTLESSPSGLRNFIVEQKENGRALLLQWSEPMRTNGVIKTYNIFSDGFLEYSGLNRQFLFRRLDPFTLYTLTLEACTRAGCAHSAPQPLWTDEAPPDSQLAPTVHSVKSTSVELSWSEPVNPNGKIIRYEVIRRCFEGKAWGNQTIQADEKIVFTEYNTERNTFMYNDTGLQPWTQCEYKIYTWNSAGHTCSSWNVVRTLQAPPEGLSPPVISYVSMNPQKLLISWIPPEQSNGIIQSYRLQRNEMLYPFSFDPVTFNYTDEELLPFSTYSYALQACTSGGCSTSKPTSITTLEAAPSEVSPPDLWAVSATQMNVCWSPPTVQNGKITKYLVRYDNKESLAGQGLCLLVSHLQPYSQYNFSLVACTNGGCTASVSKSAWTMEALPENMDSPTLQVTGSESIEITWKPPRNPNGQIRSYELRRDGTIVYTGLETRYRDFTLTPGVEYSYTVTASNSQGGILSPLVKDRTSPSAPSGMEPPKLQARGPQEILVNWDPPVRTNGDIINYTLFIRELFERETKIIHINTTHNSFGMQSYIVNQLKPFHRYEIRIQACTTLGCASSDWTFIQTPEIAPLMQPPPHLEVQMAPGGFQPTVSLLWTGPLQPNGKVLYYELYRRQIATQPRKSNPVLIYNGSSTSFIDSELLPFTEYEYQVWAVNSAGKAPSSWTWCRTGPAPPEGLRAPTFHVISSTQAVVNISAPGKPNGIVSLYRLFSSSAHGAETVLSEGMATQQTLHGLQAFTNYSIGVEACTCFNCCSKGPTAELRTHPAPPSGLSSPQIGTLASRTASFRWSPPMFPNGVIHSYELQFHVACPPDSALPCTPSQIETKYTGLGQKASLGGLQPYTTYKLRVVAHNEVGSTASEWISFTTQKELPQYRAPFSVDSNLSVVCVNWSDTFLLNGQLKEYVLTDGGRRVYSGLDTTLYIPRTADKTFFFQVICTTDEGSVKTPLIQYDTSTGLGLVLTTPGKKKGSRSKSTEFYSELWFIVLMAMLGLILLAIFLSLILQRKIHKEPYIRERPPLVPLQKRMSPLNVYPPGENHMGLADTKIPRSGTPVSIRSNRSACVLRIPSQNQTSLTYSQGSLHRSVSQLMDIQDKKVLMDNSLWEAIMGHNSGLYVDEEDLMNAIKDFSSVTKERTTFTDTHL
T63222	DRUGINFO	D21URW	QR-421a	Phase 2/3

T63227	TARGETID	T63227
T63227	UNIPROID	FUS_HUMAN
T63227	TARGNAME	RNA-binding protein FUS messenger RNA (FUS mRNA)
T63227	GENENAME	FUS
T63227	TARGTYPE	Clinical trial
T63227	SYNONYMS	75 kDa DNA-pairing protein (mRNA); Oncogene FUS (mRNA); Oncogene TLS (mRNA); POMp75 (mRNA); Translocated in liposarcoma protein (mRNA)
T63227	FUNCTION	DNA/RNA-binding protein that plays a role in various cellular processes such as transcription regulation, RNA splicing, RNA transport, DNA repair and damage response (PubMed:27731383). Binds to nascent pre-mRNAs and acts as a molecular mediator between RNA polymerase II and U1 small nuclear ribonucleoprotein thereby coupling transcription and splicing (PubMed:26124092). Binds also its own pre-mRNA and autoregulates its expression; this autoregulation mechanism is mediated by non-sense-mediated decay (PubMed:24204307). Plays a role in DNA repair mechanisms by promoting D-loop formation and homologous recombination during DNA double-strand break repair (PubMed:10567410). In neuronal cells, plays crucial roles in dendritic spine formation and stability, RNA transport, mRNA stability and synaptic homeostasis (By similarity). {ECO:0000250|UniProtKB:P56959, ECO:0000269|PubMed:10567410, ECO:0000269|PubMed:24204307, ECO:0000269|PubMed:26124092, ECO:0000269|PubMed:27731383}.
T63227	PDBSTRUC	2LA6;2LCW;4FDD;4FQ3;5W3N;5XRR;5XSG;5YVG;5YVH;5YVI;6BWZ;6BXV;6BZP;6G99;6GBM;6KJ1;6KJ2;6KJ3;6KJ4;6SNJ;6XFM;7CYL;7VQQ
T63227	BIOCLASS	mRNA target
T63227	SEQUENCE	MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQSQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSSSYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQDQSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYEPRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIESVADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFSGNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQQRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYDRGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY
T63227	DRUGINFO	DCRJ78	ION363	Phase 3

T63228	TARGETID	T63228
T63228	UNIPROID	GFAP_HUMAN
T63228	TARGNAME	Glial fibrillary acidic protein messenger RNA (GFAP mRNA)
T63228	GENENAME	GFAP
T63228	TARGTYPE	Clinical trial
T63228	SYNONYMS	GFAP (mRNA)
T63228	FUNCTION	GFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells.
T63228	PDBSTRUC	6A9P
T63228	BIOCLASS	mRNA target
T63228	SEQUENCE	MERRRITSAARRSYVSSGEMMVGGLAPGRRLGPGTRLSLARMPPPLPTRVDFSLAGALNAGFKETRASERAEMMELNDRFASYIEKVRFLEQQNKALAAELNQLRAKEPTKLADVYQAELRELRLRLDQLTANSARLEVERDNLAQDLATVRQKLQDETNLRLEAENNLAAYRQEADEATLARLDLERKIESLEEEIRFLRKIHEEEVRELQEQLARQQVHVELDVAKPDLTAALKEIRTQYEAMASSNMHEAEEWYRSKFADLTDAAARNAELLRQAKHEANDYRRQLQSLTCDLESLRGTNESLERQMREQEERHVREAASYQEALARLEEEGQSLKDEMARHLQEYQDLLNVKLALDIEIATYRKLLEGEENRITIPVQTFSNLQIRETSLDTKSVSEGHLKRNIVVKTVEMRDGEVIKESKQEHKDVM
T63228	DRUGINFO	DYR8T5	ION373	Phase 3

T63185	TARGETID	T63185
T63185	UNIPROID	RASK_HUMAN
T63185	TARGNAME	KRas D816V mutant (KRAS D816V)
T63185	GENENAME	KRAS
T63185	TARGTYPE	Clinical trial
T63185	SYNONYMS	K-Ras 2; Ki-Ras; c-K-ras; c-Ki-ras
T63185	FUNCTION	Ras proteins bind GDP/GTP and possess intrinsic GTPase activity (PubMed:20949621). Plays an important role in the regulation of cell proliferation (PubMed:23698361, PubMed:22711838). Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner (PubMed:24623306). {ECO:0000269|PubMed:20949621, ECO:0000269|PubMed:22711838, ECO:0000269|PubMed:23698361, ECO:0000269|PubMed:24623306, ECO:0000305}.
T63185	PDBSTRUC	1D8D;1D8E;1KZO;1KZP;1N4P;1N4Q;1N4R;1N4S;3GFT;4DSN;4DSO;4EPR;4EPT;4EPV;4EPW;4EPX;4EPY;4L8G;4LDJ;4LPK;4LRW;4LUC;4LV6;4LYF;4LYH;4LYJ;4M1O;4M1S;4M1T;4M1W;4M1Y;4M21;4M22;4NMM;4OBE;4PZY;4PZZ;4Q01;4Q02;4Q03;4QL3;4TQ9;4TQA;4WA7;5F2E;5KYK;5MLA;5MLB;5O2S;5O2T;5OCG;5OCO;5OCT;5TAR;5TB5;5UFE;5UFQ;5UK9;5UQW;5US4;5USJ;5V6S;5V6V;5V71;5V9L;5V9O;5V9U;5VBM;5VP7;5VPI;5VPY;5VPZ;5VQ0;5VQ1;5VQ2;5VQ6;5VQ8;5W22;5WHA;5WHB;5WHD;5WHE;5WLB;5WPM;5XCO;5YXZ;5YY1;6ARK;6ASA;6ASE;6B0V;6B0Y;6BOF;6BP1;6CC9;6CCH;6CCX;6CU6;6E6F;6E6G;6EPL;6EPM;6EPN;6EPO;6EPP;6F76;6FA1;6FA2;6FA3;6FA4;6GJ5;6GJ6;6GJ7;6GJ8;6GOD;6GOE;6GOF;6GOG;6GOM;6GQT;6GQW;6GQX;6GQY;6H46;6H47;6JTN;6JTO;6JTP;6M9W;6MBQ;6MBT;6MBU;6MNX;6MQG;6MQN;6MS9;6MTA;6N2J;6N2K;6O36;6O46;6O4Y;6O4Z;6O51;6O53;6OB2;6OB3;6OIM;6P0Z;6P8W;6P8X;6P8Y;6P8Z;6PGO;6PGP;6PQ3;6PTS;6PTW;6QUU;6QUV;6QUW;6QUX;6T5B;6T5U;6T5V;6TAM;6TAN;6USX;6USZ;6UT0;6V5L;6V65;6V6F;6VC8;6VJJ;6W4E;6W4F;6WGN;6WS2;6WS4;6XGU;6XGV;6XHA;6XHB;6YR8;6YXW;6ZL5;6ZLI;7A1W;7A1X;7A1Y;7A47;7ACA;7ACF;7ACH;7ACQ;7C40;7C41;7EW9;7EWA;7EWB;7EYX;7F0W;7KFZ;7KMR;7KYZ;7LC1;7LC2;7LGI;7LZ5;7MDP;7MQU;7NY8;7O70;7OK3;7OK4;7OO7;7Q9U;7R0M;7R0N;7R0Q;7ROV;7RP2;7RP3;7RP4;7RPZ;7RSC;7RSE;7RT1;7RT2;7RT3;7RT4;7RT5;7SCW;7SCX;7T1F;7T47;7TLE;7TLG;7TLK;7U8H;7VVB;7W5R;7YCC;7YCE;8AFB;8AFC;8AFD;8AQ5;8AQ7;8AZR;8AZV;8AZX;8AZY;8AZZ;8B00;8B6I;8B78;8CX5;8DNI;8DNJ;8DNK;8EPW;8EZG;8ONV
T63185	ECNUMBER	EC 3.6.5.2
T63185	SEQUENCE	MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM
T63185	DRUGINFO	DL81ME	ASP3082	Phase 1

T63231	TARGETID	T63231
T63231	UNIPROID	KIT_HUMAN
T63231	TARGNAME	KIT D816V mutant (KIT D816V)
T63231	GENENAME	KIT
T63231	TARGTYPE	Clinical trial
T63231	SYNONYMS	SCFR; Piebald trait protein; PBT; Proto-oncogene c-Kit; Tyrosine-protein kinase Kit; p145 c-kit; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; CD117
T63231	FUNCTION	Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1, SH2B2/APS and CBL. Activates the AKT1 signaling pathway by phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Activated KIT also transmits signals via GRB2 and activation of RAS, RAF1 and the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3, STAT5A and STAT5B. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. KIT signaling is modulated by protein phosphatases, and by rapid internalization and degradation of the receptor. Activated KIT promotes phosphorylation of the protein phosphatases PTPN6/SHP-1 and PTPRU, and of the transcription factors STAT1, STAT3, STAT5A and STAT5B. Promotes phosphorylation of PIK3R1, CBL, CRK (isoform Crk-II), LYN, MAPK1/ERK2 and/or MAPK3/ERK1, PLCG1, SRC and SHC1. {ECO:0000269|PubMed:10397721, ECO:0000269|PubMed:12444928, ECO:0000269|PubMed:12511554, ECO:0000269|PubMed:12878163, ECO:0000269|PubMed:17904548, ECO:0000269|PubMed:19265199, ECO:0000269|PubMed:21135090, ECO:0000269|PubMed:21640708, ECO:0000269|PubMed:7520444, ECO:0000269|PubMed:9528781}.
T63231	PDBSTRUC	1PKG;1T45;1T46;2E9W;2EC8;2IUH;2VIF;3G0E;3G0F;4HVS;4K94;4K9E;4PGZ;4U0I;6GQJ;6GQK;6GQL;6GQM;6HH1;6ITT;6ITV;6KLA;6MOB;6XV9;6XVA;6XVB;7KHG;7KHJ;7KHK;7ZW8;8DFM;8DFP;8DFQ
T63231	BIOCLASS	Kinase
T63231	ECNUMBER	EC 2.7.10.1
T63231	SEQUENCE	MRGARGAWDFLCVLLLLLRVQTGSSQPSVSPGEPSPPSIHPGKSDLIVRVGDEIRLLCTDPGFVKWTFEILDETNENKQNEWITEKAEATNTGKYTCTNKHGLSNSIYVFVRDPAKLFLVDRSLYGKEDNDTLVRCPLTDPEVTNYSLKGCQGKPLPKDLRFIPDPKAGIMIKSVKRAYHRLCLHCSVDQEGKSVLSEKFILKVRPAFKAVPVVSVSKASYLLREGEEFTVTCTIKDVSSSVYSTWKRENSQTKLQEKYNSWHHGDFNYERQATLTISSARVNDSGVFMCYANNTFGSANVTTTLEVVDKGFINIFPMINTTVFVNDGENVDLIVEYEAFPKPEHQQWIYMNRTFTDKWEDYPKSENESNIRYVSELHLTRLKGTEGGTYTFLVSNSDVNAAIAFNVYVNTKPEILTYDRLVNGMLQCVAAGFPEPTIDWYFCPGTEQRCSASVLPVDVQTLNSSGPPFGKLVVQSSIDSSAFKHNGTVECKAYNDVGKTSAYFNFAFKGNNKEQIHPHTLFTPLLIGFVIVAGMMCIIVMILTYKYLQKPMYEVQWKVVEEINGNNYVYIDPTQLPYDHKWEFPRNRLSFGKTLGAGAFGKVVEATAYGLIKSDAAMTVAVKMLKPSAHLTEREALMSELKVLSYLGNHMNIVNLLGACTIGGPTLVITEYCCYGDLLNFLRRKRDSFICSKQEDHAEAALYKNLLHSKESSCSDSTNEYMDMKPGVSYVVPTKADKRRSVRIGSYIERDVTPAIMEDDELALDLEDLLSFSYQVAKGMAFLASKNCIHRDLAARNILLTHGRITKICDFGLARDIKNDSNYVVKGNARLPVKWMAPESIFNCVYTFESDVWSYGIFLWELFSLGSSPYPGMPVDSKFYKMIKEGFRMLSPEHAPAEMYDIMKTCWDADPLKRPTFKQIVQLIEKQISESTNHIYSNLANCSPNRQKPVVDHSVRINSVGSTASSSQPLLVHDDV
T63231	DRUGINFO	DLC7Y9	Bezuclastinib	Phase 3

T63235	TARGETID	T63235
T63235	UNIPROID	BRAF_HUMAN
T63235	TARGNAME	BRAF V600E mutant (BRAF V600E)
T63235	GENENAME	BRAF
T63235	TARGTYPE	Clinical trial
T63235	SYNONYMS	Proto-oncogene B-Raf; p94; v-Raf murine sarcoma viral oncogene homolog B1
T63235	FUNCTION	Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates PFKFB2 (PubMed:36402789). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179). {ECO:0000269|PubMed:1508179, ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126, ECO:0000269|PubMed:36402789, ECO:0000305}.
T63235	PDBSTRUC	1UWH;1UWJ;2FB8;2L05;3C4C;3D4Q;3IDP;3II5;3NY5;3OG7;3PPJ;3PPK;3PRF;3PRI;3PSB;3PSD;3Q4C;3Q96;3SKC;3TV4;3TV6;4CQE;4DBN;4E26;4E4X;4EHE;4EHG;4FC0;4FK3;4G9C;4G9R;4H58;4JVG;4KSP;4KSQ;4MBJ;4MNE;4MNF;4PP7;4R5Y;4RZV;4RZW;4WO5;4XV1;4XV2;4XV3;4XV9;4YHT;5C9C;5CSW;5CSX;5CT7;5FD2;5HI2;5HID;5HIE;5ITA;5J17;5J18;5J2R;5JRQ;5JSM;5JT2;5VAL;5VAM;5VR3;5VYK;6B8U;6CAD;6N0P;6N0Q;6NSQ;6NYB;6P3D;6P7G;6PP9;6Q0J;6Q0K;6Q0T;6U2G;6U2H;6UAN;6UUO;6V2U;6V2W;6V34;6XAG;6XFP;6XLO;7K0V;7M0T;7M0U;7M0V;7M0W;7M0X;7M0Y;7M0Z;7MFD;7MFE;7MFF;7P3V;7SHV;7ZR0;7ZR5;7ZR6;8C7X;8C7Y;8DGS;8DGT;8F7O;8F7P
T63235	BIOCLASS	Kinase
T63235	ECNUMBER	EC 2.7.11.1
T63235	SEQUENCE	MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH
T63235	DRUGINFO	DSF65Q	RG6344	Phase 1

T63198	TARGETID	T63198
T63198	UNIPROID	OPSD_HUMAN
T63198	TARGNAME	Rhodopsin P23H mutant messenger RNA (RHO P23H mRNA)
T63198	GENENAME	RHO
T63198	TARGTYPE	Clinical trial
T63198	SYNONYMS	Opsin-2
T63198	FUNCTION	Photoreceptor required for image-forming vision at low light intensity (PubMed:8107847, PubMed:7846071). Required for photoreceptor cell viability after birth (PubMed:2215617, PubMed:12566452). Light-induced isomerization of the chromophore 11-cis-retinal to all-trans-retinal triggers a conformational change that activates signaling via G-proteins (PubMed:8107847, PubMed:28524165, PubMed:26200343, PubMed:28753425). Subsequent receptor phosphorylation mediates displacement of the bound G-protein alpha subunit by the arrestin SAG and terminates signaling (PubMed:28524165, PubMed:26200343). {ECO:0000269|PubMed:12566452, ECO:0000269|PubMed:2215617, ECO:0000269|PubMed:26200343, ECO:0000269|PubMed:28753425, ECO:0000269|PubMed:7846071, ECO:0000269|PubMed:8107847, ECO:0000305|PubMed:28524165}.
T63198	PDBSTRUC	4ZWJ;5DGY;5W0P;6CMO
T63198	BIOCLASS	mRNA target
T63198	SEQUENCE	MNGTEGPNFYVPFSNATGVVRSPFEYPQYYLAEPWQFSMLAAYMFLLIVLGFPINFLTLYVTVQHKKLRTPLNYILLNLAVADLFMVLGGFTSTLYTSLHGYFVFGPTGCNLEGFFATLGGEIALWSLVVLAIERYVVVCKPMSNFRFGENHAIMGVAFTWVMALACAAPPLAGWSRYIPEGLQCSCGIDYYTLKPEVNNESFVIYMFVVHFTIPMIIIFFCYGQLVFTVKEAAAQQQESATTQKAEKEVTRMVIIMVIAFLICWVPYASVAFYIFTHQGSNFGPIFMTIPAFFAKSAAIYNPVIYIMMNKQFRNCMLTTICCGKNPLGDDEASATVSKTETSQVAPA
T63198	DRUGINFO	DX71CK	QR1123	Phase 1/2

T63176	TARGETID	T63176
T63176	UNIPROID	LIRB4_HUMAN-FINC_HUMAN
T63176	TARGNAME	CD85k-Fibronectin interaction (LILRB4-FN1 PPI)
T63176	TARGTYPE	Clinical trial
T63176	DRUGINFO	DY0IS1	NGM831	Phase 1

T63204	TARGETID	T63204
T63204	UNIPROID	CD47_HUMAN-SHPS1_HUMAN
T63204	TARGNAME	CD47-SHPS1 interaction (CD47-SHPS1 PPI)
T63204	TARGTYPE	Clinical trial
T63204	DRUGINFO	D6SJ0B	PF-07901801	Phase 2

T63206	TARGETID	T63206
T63206	UNIPROID	ITAV_HUMAN-ITB1_HUMAN
T63206	TARGNAME	Integrin alpha-5/beta-1 (ITGA5/B1)
T63206	TARGTYPE	Clinical trial
T63206	DRUGINFO	D3MG8W	PLN-74809	Phase 2

T61746	TARGETID	T61746
T61746	FORMERID	TTDR00886
T61746	UNIPROID	CATB_HUMAN
T61746	TARGNAME	Cathepsin B (CTSB)
T61746	GENENAME	CTSB
T61746	TARGTYPE	Preclinical
T61746	SYNONYMS	Ctsb; Cathepsins B; Cathepsin-B; Cathepsin B1; CPSB; APPS; APP secretase
T61746	FUNCTION	Cleaves matrix extracellular phosphoglycoprotein MEPE. Has also been implicated in tumor invasion and metastasis. Thiol protease which is believed to participate in intracellular degradation and turnover of proteins.
T61746	PDBSTRUC	6AY2; 5MBM; 5MBL; 3PBH; 3K9M
T61746	BIOCLASS	Peptidase
T61746	ECNUMBER	EC 3.4.22.1
T61746	SEQUENCE	MWQLWASLCCLLVLANARSRPSFHPLSDELVNYVNKRNTTWQAGHNFYNVDMSYLKRLCGTFLGGPKPPQRVMFTEDLKLPASFDAREQWPQCPTIKEIRDQGSCGSCWAFGAVEAISDRICIHTNAHVSVEVSAEDLLTCCGSMCGDGCNGGYPAEAWNFWTRKGLVSGGLYESHVGCRPYSIPPCEHHVNGSRPPCTGEGDTPKCSKICEPGYSPTYKQDKHYGYNSYSVSNSEKDIMAEIYKNGPVEGAFSVYSDFLLYKSGVYQHVTGEMMGGHAIRILGWGVENGTPYWLVANSWNTDWGDNGFFKILRGQDHCGIESEVVAGIPRTDQYWEKI
T61746	DRUGINFO	D0A2NA	PMID27998201-Compound-11	Patented
T61746	DRUGINFO	D0E2AF	PMID27998201-Compound-2	Patented
T61746	DRUGINFO	D0KG9M	PMID27998201-Compound-22	Patented
T61746	DRUGINFO	D0L1PP	PMID27998201-Compound-13	Patented
T61746	DRUGINFO	D0UX4J	Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1	Patented
T61746	DRUGINFO	D0WO4T	PMID27998201-Compound-24	Patented
T61746	DRUGINFO	D06XTA	PMID27998201-Compound-17	Patented
T61746	DRUGINFO	D04VGR	PMID27998201-Compound-9	Patented
T61746	DRUGINFO	D05OIU	PMID27998201-Compound-5	Patented
T61746	DRUGINFO	D06XCD	PMID27998201-Compound-12	Patented
T61746	DRUGINFO	D9MT4S	CA-074Me	Preclinical
T61746	DRUGINFO	DCZ16N	SD1002	Preclinical
T61746	DRUGINFO	DM69TL	Z-Phe-Ala-diazomethylketone	Preclinical
T61746	DRUGINFO	DSM03D	SD1003	Preclinical
T61746	DRUGINFO	D0Z0PR	L-006235-1	Preclinical
T61746	DRUGINFO	D06FCP	Gold trichloride sodium chloride	Investigative
T61746	DRUGINFO	D0A5WN	PTosyl-Glu(OtBu)-Ala-LeuVSMe	Investigative
T61746	DRUGINFO	D0B5MF	2-Aminoethanimidic Acid	Investigative
T61746	DRUGINFO	D0D6MZ	3-Amino-4-Oxybenzyl-2-Butanone	Investigative
T61746	DRUGINFO	D0NI5C	2-Pyridinethiol	Investigative
T61746	DRUGINFO	D0Q4UA	Z-Arg-Leu-Val-Agly-Ile-Val-OMe	Investigative
T61746	DRUGINFO	D0X0IT	Diphenylacetic Acid	Investigative
T61746	DRUGINFO	D0X8ZS	3-Methylphenylalanine	Investigative
T61746	DRUGINFO	D00NVC	Z-Ala-Leu-Nal-Agly-Ile-Val-OMe	Investigative
T61746	DRUGINFO	D01BIZ	Z-Arg-Leu-Val-Agly-Trp-Val-Ala-NH2	Investigative
T61746	DRUGINFO	D01TFO	Z-Ala-Leu-lle-Agly-Ile-Val-OMe	Investigative
T61746	DRUGINFO	D03ETT	Z-Ala-Leu-His-Agly-Ile-Val-OMe	Investigative
T61746	DRUGINFO	D03FJH	Z-Arg-Leu-Val-Agly-Ile-Val-Trp-NH2	Investigative
T61746	DRUGINFO	D03JYN	1-(phenyl(p-tolyl)methylene)thiosemicarbazide	Investigative
T61746	DRUGINFO	D03VHO	Z-Ala-Leu-Tyr(Me)-Agly-Ile-Val-OMe	Investigative
T61746	DRUGINFO	D04DFX	Bis(3-bromophenyl)(4-hydroxy)thiosemicarbazone	Investigative
T61746	DRUGINFO	D05VEV	Ac-hPhe-Leu-Ala-LeuVSMe	Investigative
T61746	DRUGINFO	D06NEB	Ac-hPhe-Leu-Phe-LeuVSMe	Investigative
T61746	DRUGINFO	D06QJT	Z-leu-Val-Agly-Val-OBzl	Investigative
T61746	DRUGINFO	D07JLV	Z-Ala-Leu-lle-Agly-Ile-Val-NHBzl	Investigative
T61746	DRUGINFO	D07RDV	Z-Ala-Leu-Phe-Agly-Ile-Val-OMe	Investigative
T61746	DRUGINFO	D0B2JC	[(3-Bromophenyl)-p-tolyl-ketone]thiosemicarbazone	Investigative
T61746	DRUGINFO	D0H8TE	Z-Arg-Leu-Val-Agly-Ala-Gly-NH2	Investigative
T61746	DRUGINFO	D0I0MU	Cbz-Ile-Leu-Ala-LeuVSMe	Investigative
T61746	DRUGINFO	D0N7BP	Z-Arg-Leu-Val-Agly-Val-Ala-NH2	Investigative
T61746	DRUGINFO	D0Q4YY	Z-Arg-Leu-Val-Agly-Ileu-Val-OMe	Investigative
T61746	DRUGINFO	D0QY3R	Cbz-Ile-t-ButylhomoGlu-Ala-LeuVSMe	Investigative
T61746	DRUGINFO	D0VE0F	(S)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate	Investigative
T61746	DRUGINFO	D0D0LD	L-873724	Investigative
T61746	DRUGINFO	D0L9VP	GNF-PF-5434	Investigative

T69375	TARGETID	T69375
T69375	FORMERID	TTDR00334
T69375	UNIPROID	MK09_HUMAN
T69375	TARGNAME	Stress-activated protein kinase JNK2 (JNK2)
T69375	GENENAME	MAPK9
T69375	TARGTYPE	Preclinical
T69375	SYNONYMS	Stress-activated protein kinase 1a; SAPK1a; PRKM9; Mitogen-activated protein kinase 9; Mitogen-activated protein kinase 8-interacting protein 2; MAPK 9; MAP kinase 9; Jun-N-terminal kinase 2; JNK-interacting protein 2; JNK-55; JNK MAP kinase scaffold protein 2; JIP-2; Islet-brain-2; IB-2; C-jun-amino-terminal kinase interacting protein 2; C-Jun N-terminal kinase 2
T69375	FUNCTION	Extracellular stimuli such as proinflammatory cytokines or physical stress stimulate the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and MAP2K7/MKK7 phosphorylate and activate MAPK9/JNK2. In turn, MAPK9/JNK2 phosphorylates a number of transcription factors, primarily components of AP-1 such as JUN and ATF2 and thus regulates AP-1 transcriptional activity. In response to oxidative or ribotoxic stresses, inhibits rRNA synthesis by phosphorylating and inactivating the RNA polymerase 1-specific transcription initiation factor RRN3. Promotes stressed cell apoptosis by phosphorylating key regulatory factors including TP53 and YAP1. In T-cells, MAPK8 and MAPK9 are required for polarized differentiation of T-helper cells into Th1 cells. Upon T-cell receptor (TCR) stimulation, is activated by CARMA1, BCL10, MAP2K7 and MAP3K7/TAK1 to regulate JUN protein levels. Plays an important role in the osmotic stress-induced epithelial tight-junctions disruption. When activated, promotes beta-catenin/CTNNB1 degradation and inhibits the canonical Wnt signaling pathway. Participates also in neurite growth in spiral ganglion neurons. Phosphorylates the CLOCK-ARNTL/BMAL1 heterodimer and plays a role in the regulation of the circadian clock. Phosphorylates POU5F1, which results in the inhibition of POU5F1's transcriptional activity and enhances its proteosomal degradation. Serine/threonine-protein kinase involved in various processes such as cell proliferation, differentiation, migration, transformation and programmed cell death.
T69375	PDBSTRUC	3NPC; 3E7O
T69375	BIOCLASS	Kinase
T69375	ECNUMBER	EC 2.7.11.24
T69375	SEQUENCE	MSDSKCDSQFYSVQVADSTFTVLKRYQQLKPIGSGAQGIVCAAFDTVLGINVAVKKLSRPFQNQTHAKRAYRELVLLKCVNHKNIISLLNVFTPQKTLEEFQDVYLVMELMDANLCQVIHMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTACTNFMMTPYVVTRYYRAPEVILGMGYKENVDIWSVGCIMGELVKGCVIFQGTDHIDQWNKVIEQLGTPSAEFMKKLQPTVRNYVENRPKYPGIKFEELFPDWIFPSESERDKIKTSQARDLLSKMLVIDPDKRISVDEALRHPYITVWYDPAEAEAPPPQIYDAQLEEREHAIEEWKELIYKEVMDWEERSKNGVVKDQPSDAAVSSNATPSQSSSINDISSMSTEQTLASDTDSSLDASTGPLEGCR
T69375	DRUGINFO	D07KVU	PMID25991433-Compound-C1	Patented
T69375	DRUGINFO	D03HEK	PMID25991433-Compound-A10	Patented
T69375	DRUGINFO	D04JUD	PMID25991433-Compound-A6	Patented
T69375	DRUGINFO	D07JQX	PMID25991433-Compound-D2	Patented
T69375	DRUGINFO	D09YEH	PMID25991433-Compound-A11	Patented
T69375	DRUGINFO	D0AM2B	PMID25991433-Compound-A8	Patented
T69375	DRUGINFO	D0B4IH	PMID25991433-Compound-D1	Patented
T69375	DRUGINFO	D0RV2Z	PMID25991433-Compound-A2	Patented
T69375	DRUGINFO	D0S1OV	PMID25991433-Compound-A7	Patented
T69375	DRUGINFO	D0S3AP	PMID25991433-Compound-A9	Patented
T69375	DRUGINFO	D0V1CB	PMID25991433-Compound-A5	Patented
T69375	DRUGINFO	D0VE3Y	PMID25991433-Compound-A3	Patented
T69375	DRUGINFO	D05SJB	7-azaindole derivative 1	Patented
T69375	DRUGINFO	D07KMK	7-azaindole derivative 5	Patented
T69375	DRUGINFO	D08DNZ	PMID25991433-Compound-P6	Patented
T69375	DRUGINFO	D08JOC	PMID25991433-Compound-J3	Patented
T69375	DRUGINFO	D0L2MS	PMID25991433-Compound-P1	Patented
T69375	DRUGINFO	D0Q4WA	PMID25991433-Compound-O3	Patented
T69375	DRUGINFO	D0RQ8Q	PMID25991433-Compound-J2	Patented
T69375	DRUGINFO	D0T6IZ	7-azaindole derivative 3	Patented
T69375	DRUGINFO	D0VR1O	7-azaindole derivative 2	Patented
T69375	DRUGINFO	D0W8BL	PMID25991433-Compound-P5	Patented
T69375	DRUGINFO	D0X2SG	PMID25991433-Compound-P4	Patented
T69375	DRUGINFO	D0ZU8L	PMID25991433-Compound-J5	Patented
T69375	DRUGINFO	D06JRV	PMID25991433-Compound-F2	Patented
T69375	DRUGINFO	D0H4HD	PMID25991433-Compound-A1	Patented
T69375	DRUGINFO	DOJ6D9	COR-D	Preclinical
T69375	DRUGINFO	D02PVB	2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One	Investigative

T14875	TARGETID	T14875
T14875	UNIPROID	UBP14_HUMAN
T14875	TARGNAME	Ubiquitin carboxyl-terminal hydrolase 14 (USP14)
T14875	GENENAME	USP14
T14875	TARGTYPE	Preclinical
T14875	SYNONYMS	Ubiquitin-specific-processing protease 14; Ubiquitin thioesterase 14; TGT; Deubiquitinating enzyme 14
T14875	FUNCTION	Ensures the regeneration of ubiquitin at the proteasome. Is a reversibly associated subunit of the proteasome and a large fraction of proteasome-free protein exists within the cell. Required for the degradation of the chemokine receptor CXCR4 which is critical for CXCL12-induced cell chemotaxis. Serves also as a physiological inhibitor of endoplasmic reticulum-associated degradation (ERAD) under the non-stressed condition by inhibiting the degradation of unfolded endoplasmic reticulum proteins via interaction with ERN1. Indispensable for synaptic development and function at neuromuscular junctions (NMJs). Plays a role in the innate immune defense against viruses by stabilizing the viral DNA sensor CGAS and thus inhibiting its autophagic degradation. Proteasome-associated deubiquitinase which releases ubiquitin from the proteasome targeted ubiquitinated proteins.
T14875	PDBSTRUC	6IIN; 6IIM; 6IIL; 6IIK; 5GJQ
T14875	BIOCLASS	Peptidase
T14875	ECNUMBER	EC 3.4.19.12
T14875	SEQUENCE	MPLYSVTVKWGKEKFEGVELNTDEPPMVFKAQLFALTGVQPARQKVMVKGGTLKDDDWGNIKIKNGMTLLMMGSADALPEEPSAKTVFVEDMTEEQLASAMELPCGLTNLGNTCYMNATVQCIRSVPELKDALKRYAGALRASGEMASAQYITAALRDLFDSMDKTSSSIPPIILLQFLHMAFPQFAEKGEQGQYLQQDANECWIQMMRVLQQKLEAIEDDSVKETDSSSASAATPSKKKSLIDQFFGVEFETTMKCTESEEEEVTKGKENQLQLSCFINQEVKYLFTGLKLRLQEEITKQSPTLQRNALYIKSSKISRLPAYLTIQMVRFFYKEKESVNAKVLKDVKFPLMLDMYELCTPELQEKMVSFRSKFKDLEDKKVNQQPNTSDKKSSPQKEVKYEPFSFADDIGSNNCGYYDLQAVLTHQGRSSSSGHYVSWVKRKQDEWIKFDDDKVSIVTPEDILRLSGGGDWHIAYVLLYGPRRVEIMEEESEQ
T14875	DRUGINFO	D09CIC	Tricyclic heterocycle derivative 4	Patented
T14875	DRUGINFO	D0A8EN	PMID26077642-Compound-Figure3A	Patented
T14875	DRUGINFO	DW0Z1Y	IU1	Preclinical
T14875	DRUGINFO	DGP6V3	BAP-15	Preclinical

T35445	TARGETID	T35445
T35445	FORMERID	TTDR00819
T35445	UNIPROID	SMAD3_HUMAN
T35445	TARGNAME	Mothers against decapentaplegic homolog 3 (SMAD3)
T35445	GENENAME	SMAD3
T35445	TARGTYPE	Preclinical
T35445	SYNONYMS	TGF-beta response effector Smad3; Smad3; SMAD family member 3; SMAD 3; Mothers against DPP homolog 3; Mad3; MMad3; MADH3; MAD homolog 3; JV15-2; HSMAD3; HMAD-3
T35445	FUNCTION	Binds the TRE element in the promoter region of many genes that are regulated by TGF-beta and, on formation of the SMAD3/SMAD4 complex, activates transcription. Also can form a SMAD3/SMAD4/JUN/FOS complex at the AP-1/SMAD site to regulate TGF-beta-mediated transcription. Has an inhibitory effect on wound healing probably by modulating both growth and migration of primary keratinocytes and by altering the TGF-mediated chemotaxis of monocytes. This effect on wound healing appears to be hormone-sensitive. Regulator of chondrogenesis and osteogenesis and inhibits early healing of bone fractures. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator. Receptor-regulated SMAD (R-SMAD) that is an intracellular signal transducer and transcriptional modulator activated by TGF-beta (transforming growth factor) and activin type 1 receptor kinases.
T35445	PDBSTRUC	5XOC; 5ODG; 5OD6; 2LB2; 2LAJ
T35445	SEQUENCE	MSSILPFTPPIVKRLLGWKKGEQNGQEEKWCEKAVKSLVKKLKKTGQLDELEKAITTQNVNTKCITIPRSLDGRLQVSHRKGLPHVIYCRLWRWPDLHSHHELRAMELCEFAFNMKKDEVCVNPYHYQRVETPVLPPVLVPRHTEIPAEFPPLDDYSHSIPENTNFPAGIEPQSNIPETPPPGYLSEDGETSDHQMNHSMDAGSPNLSPNPMSPAHNNLDLQPVTYCEPAFWCSISYYELNQRVGETFHASQPSMTVDGFTDPSNSERFCLGLLSNVNRNAAVELTRRHIGRGVRLYYIGGEVFAECLSDSAIFVQSPNCNQRYGWHPATVCKIPPGCNLKIFNNQEFAALLAQSVNQGFEAVYQLTRMCTIRMSFVKGWGAEYRRQTVTSTPCWIELHLNGPLQWLDKVLTQMGSPSIRCSSVS
T35445	DRUGINFO	DF90DS	SIS-3	Preclinical
T35445	DRUGINFO	D0P0CM	GNF-PF-2272	Investigative
T35445	DRUGINFO	D0A1CM	ELLAGIC ACID	Investigative

T42658	TARGETID	T42658
T42658	FORMERID	TTDI02456
T42658	UNIPROID	UBP7_HUMAN
T42658	TARGNAME	Herpesvirus ubiquitin-specific protease (HAUSP)
T42658	GENENAME	USP7
T42658	TARGTYPE	Preclinical
T42658	SYNONYMS	Ubiquitin-specific-processing protease 7; Ubiquitin thioesterase 7; Ubiquitin carboxyl-terminal hydrolase 7; Herpesvirus-associated ubiquitin-specific protease; Deubiquitinating enzyme 7
T42658	FUNCTION	Together with DAXX, prevents MDM2 self-ubiquitination and enhances the E3 ligase activity of MDM2 towards p53/TP53, thereby promoting p53/TP53 ubiquitination and proteasomal degradation. Deubiquitinates p53/TP53, preventing degradation of p53/TP53, and enhances p53/TP53-dependent transcription regulation, cell growth repression and apoptosis. Deubiquitinates p53/TP53 and MDM2 and strongly stabilizes p53/TP53 even in the presence of excess MDM2, and also induces p53/TP53-dependent cell growth repression and apoptosis. Deubiquitination of FOXO4 in presence of hydrogen peroxide is not dependent on p53/TP53 and inhibits FOXO4-induced transcriptional activity. In association with DAXX, is involved in the deubiquitination and translocation of PTEN from the nucleus to the cytoplasm, both processes that are counteracted by PML. Deubiquitinates KMT2E/MLL5 preventing KMT2E/MLL5 proteasomal-mediated degradation. Involved in cell proliferation during early embryonic development. Involved in transcription-coupled nucleotide excision repair (TC-NER) in response to UV damage: recruited to DNA damage sites following interaction with KIAA1530/UVSSA and promotes deubiquitination of ERCC6, preventing UV-induced degradation of ERCC6. Involved in maintenance of DNA methylation via its interaction with UHRF1 and DNMT1: acts by mediating deubiquitination of UHRF1 and DNMT1, preventing their degradation and promoting DNA methylation by DNMT1. Deubiquitinates alkylation repair enzyme ALKBH3. OTUD4 recruits USP7 and USP9X to stabilize ALKBH3, thereby promoting the repair of alkylated DNA lesions. Acts as a chromatin regulator via its association with the Polycomb group (PcG) multiprotein PRC1-like complex; may act by deubiquitinating components of the PRC1-like complex. Able to mediate deubiquitination of histone H2B; it is however unsure whether this activity takes place in vivo. Exhibits a preference towards 'Lys-48'-linked ubiquitin chains. Increases regulatory T-cells (Treg) suppressive capacity by deubiquitinating and stabilizing the transcription factor FOXP3 which is crucial for Treg cell function. Plays a role in the maintenance of the circadian clock periodicity via deubiquitination and stabilization of the CRY1 and CRY2 proteins. Deubiquitinates REST, thereby stabilizing REST and promoting the maintenance of neural progenitor cells. Hydrolase that deubiquitinates target proteins such as FOXO4, p53/TP53, MDM2, ERCC6, DNMT1, UHRF1, PTEN, KMT2E/MLL5 and DAXX.
T42658	PDBSTRUC	6F5H; 5WHC; 5VSK; 5VSB; 5VS6
T42658	BIOCLASS	Peptidase
T42658	ECNUMBER	EC 3.4.19.12
T42658	SEQUENCE	MNHQQQQQQQKAGEQQLSEPEDMEMEAGDTDDPPRITQNPVINGNVALSDGHNTAEEDMEDDTSWRSEATFQFTVERFSRLSESVLSPPCFVRNLPWKIMVMPRFYPDRPHQKSVGFFLQCNAESDSTSWSCHAQAVLKIINYRDDEKSFSRRISHLFFHKENDWGFSNFMAWSEVTDPEKGFIDDDKVTFEVFVQADAPHGVAWDSKKHTGYVGLKNQGATCYMNSLLQTLFFTNQLRKAVYMMPTEGDDSSKSVPLALQRVFYELQHSDKPVGTKKLTKSFGWETLDSFMQHDVQELCRVLLDNVENKMKGTCVEGTIPKLFRGKMVSYIQCKEVDYRSDRREDYYDIQLSIKGKKNIFESFVDYVAVEQLDGDNKYDAGEHGLQEAEKGVKFLTLPPVLHLQLMRFMYDPQTDQNIKINDRFEFPEQLPLDEFLQKTDPKDPANYILHAVLVHSGDNHGGHYVVYLNPKGDGKWCKFDDDVVSRCTKEEAIEHNYGGHDDDLSVRHCTNAYMLVYIRESKLSEVLQAVTDHDIPQQLVERLQEEKRIEAQKRKERQEAHLYMQVQIVAEDQFCGHQGNDMYDEEKVKYTVFKVLKNSSLAEFVQSLSQTMGFPQDQIRLWPMQARSNGTKRPAMLDNEADGNKTMIELSDNENPWTIFLETVDPELAASGATLPKFDKDHDVMLFLKMYDPKTRSLNYCGHIYTPISCKIRDLLPVMCDRAGFIQDTSLILYEEVKPNLTERIQDYDVSLDKALDELMDGDIIVFQKDDPENDNSELPTAKEYFRDLYHRVDVIFCDKTIPNDPGFVVTLSNRMNYFQVAKTVAQRLNTDPMLLQFFKSQGYRDGPGNPLRHNYEGTLRDLLQFFKPRQPKKLYYQQLKMKITDFENRRSFKCIWLNSQFREEEITLYPDKHGCVRDLLEECKKAVELGEKASGKLRLLEIVSYKIIGVHQEDELLECLSPATSRTFRIEEIPLDQVDIDKENEMLVTVAHFHKEVFGTFGIPFLLRIHQGEHFREVMKRIQSLLDIQEKEFEKFKFAIVMMGRHQYINEDEYEVNLKDFEPQPGNMSHPRPWLGLDHFNKAPKRSRYTYLEKAIKIHN
T42658	DRUGINFO	D03EML	PMID26077642-Compound-Vif2	Patented
T42658	DRUGINFO	D0PT1W	PMID26077642-Compound-Vif1	Patented
T42658	DRUGINFO	D0AN9V	ADC-03	Preclinical
T42658	DRUGINFO	D2K6DU	P22077	Preclinical
T42658	DRUGINFO	DA0OZ2	HBX19818	Preclinical
T42658	DRUGINFO	DRJU35	ADC-01	Preclinical
T42658	DRUGINFO	DV3KC5	P5091	Preclinical

T25315	TARGETID	T25315
T25315	FORMERID	TTDC00125
T25315	UNIPROID	CXCR3_HUMAN
T25315	TARGNAME	C-X-C chemokine receptor type 3 (CXCR3)
T25315	GENENAME	CXCR3
T25315	TARGTYPE	Preclinical
T25315	SYNONYMS	Interferon-inducible protein 10 receptor; IP-10 receptor; GPR9; G protein-coupled receptor 9; Chemokine receptor CXCR3/interferon-inducible protein-10; Chemokine receptor CXCR3; CXCR3/IP-10; CXCR-3; CXC-R3; CKR-L2; CD183 antigen; CD183
T25315	FUNCTION	Binds to CCL21. Probably promotes cell chemotaxis response. Isoform 1: Receptor for the C-X-C chemokine CXCL9, CXCL10 and CXCL11 and mediates the proliferation, survival and angiogenic activity of human mesangial cells (HMC) through a heterotrimeric G-protein signaling pathway.
T25315	BIOCLASS	GPCR rhodopsin
T25315	SEQUENCE	MVLEVSDHQVLNDAEVAALLENFSSSYDYGENESDSCCTSPPCPQDFSLNFDRAFLPALYSLLFLLGLLGNGAVAAVLLSRRTALSSTDTFLLHLAVADTLLVLTLPLWAVDAAVQWVFGSGLCKVAGALFNINFYAGALLLACISFDRYLNIVHATQLYRRGPPARVTLTCLAVWGLCLLFALPDFIFLSAHHDERLNATHCQYNFPQVGRTALRVLQLVAGFLLPLLVMAYCYAHILAVLLVSRGQRRLRAMRLVVVVVVAFALCWTPYHLVVLVDILMDLGALARNCGRESRVDVAKSVTSGLGYMHCCLNPLLYAFVGVKFRERMWMLLLRLGCPNQRGLQRQPSSSRRDSSWSETSEASYSGL
T25315	DRUGINFO	D0E6DI	T487	Discontinued in Phase 2
T25315	DRUGINFO	D0F2AD	dioscin	Preclinical
T25315	DRUGINFO	DBJ36R	JT07	Preclinical
T25315	DRUGINFO	D09LGT	kallstroemin D	Investigative
T25315	DRUGINFO	D0A8PV	NBI-74330	Investigative
T25315	DRUGINFO	D0EK9K	Sch-900875	Investigative
T25315	DRUGINFO	D0T1PA	hypoglaucin A	Investigative

T10491	TARGETID	T10491
T10491	FORMERID	TTDI02326
T10491	UNIPROID	ACKR3_HUMAN
T10491	TARGNAME	C-X-C chemokine receptor type 7 (ACKR3)
T10491	GENENAME	ACKR3
T10491	TARGTYPE	Preclinical
T10491	SYNONYMS	RDC1; RDC-1; Gprotein coupled receptor RDC1 homolog; Gprotein coupled receptor 159; GPR159; G-protein coupled receptor RDC1 homolog; G-protein coupled receptor 159; Chemokine orphan receptor 1; CXCR7; CXCR-7; CXC-R7; CXC chemokine receptor type 7; CMKOR1; Atypical chemokine receptor 3
T10491	FUNCTION	Known as interceptor (internalizing receptor) or chemokine-scavenging receptor or chemokine decoy receptor. Acts as a receptor for chemokines CXCL11 and CXCL12/SDF1. Chemokine binding does not activate G-protein-mediated signal transduction but instead induces beta-arrestin recruitment, leading to ligand internalization and activation of MAPK signaling pathway. Required for regulation of CXCR4 protein levels in migrating interneurons, thereby adapting their chemokine responsiveness. In glioma cells, transduces signals via MEK/ERK pathway, mediating resistance to apoptosis. Promotes cell growth and survival. Not involved in cell migration, adhesion or proliferation of normal hematopoietic progenitors but activated by CXCL11 in malignant hemapoietic cells, leading to phosphorylation of ERK1/2 (MAPK3/MAPK1) and enhanced cell adhesion and migration. Plays a regulatory role in CXCR4-mediated activation of cell surface integrins by CXCL12. Required for heart valve development. Acts as coreceptor with CXCR4 for a restricted number of HIV isolates. Atypical chemokine receptor that controls chemokine levels and localization via high-affinity chemokine binding that is uncoupled from classic ligand-driven signal transduction cascades, resulting instead in chemokine sequestration, degradation, or transcytosis.
T10491	BIOCLASS	GPCR rhodopsin
T10491	SEQUENCE	MDLHLFDYSEPGNFSDISWPCNSSDCIVVDTVMCPNMPNKSVLLYTLSFIYIFIFVIGMIANSVVVWVNIQAKTTGYDTHCYILNLAIADLWVVLTIPVWVVSLVQHNQWPMGELTCKVTHLIFSINLFGSIFFLTCMSVDRYLSITYFTNTPSSRKKMVRRVVCILVWLLAFCVSLPDTYYLKTVTSASNNETYCRSFYPEHSIKEWLIGMELVSVVLGFAVPFSIIAVFYFLLARAISASSDQEKHSSRKIIFSYVVVFLVCWLPYHVAVLLDIFSILHYIPFTCRLEHALFTALHVTQCLSLVHCCVNPVLYSFINRNYRYELMKAFIFKYSAKTGLTKLIDASRVSETEYSALEQSTK
T10491	DRUGINFO	D0N2FI	GW-766994	Discontinued in Phase 2
T10491	DRUGINFO	DBJ36R	JT07	Preclinical
T10491	DRUGINFO	D03LCX	CCX-662	Investigative

T85944	TARGETID	T85944
T85944	FORMERID	TTDR00865
T85944	UNIPROID	LPXC_PSEAE
T85944	TARGNAME	Pseudomonas UDP-3-O-acyl-GlcNAc deacetylase (Pseudo lpxC)
T85944	GENENAME	Pseudo lpxC
T85944	TARGTYPE	Preclinical
T85944	SYNONYMS	Pseudo UDP-3-O-acyl-GlcNAc deacetylase; EnvA protein
T85944	FUNCTION	Involved in the biosynthesis of lipid A, a phosphorylated glycolipid that anchors the lipopolysaccharide to the outer membrane of the cell.
T85944	PDBSTRUC	6MAE; 6CAX; 6C9C; 5VWM; 5UPG
T85944	BIOCLASS	Carbon-nitrogen hydrolase
T85944	ECNUMBER	EC 3.5.1.108
T85944	SEQUENCE	MIKQRTLKNIIRATGVGLHSGEKVYLTLKPAPVDTGIVFCRTDLDPVVEIPARAENVGETTMSTTLVKGDVKVDTVEHLLSAMAGLGIDNAYVELSASEVPIMDGSAGPFVFLIQSAGLQEQEAAKKFIRIKREVSVEEGDKRAVFVPFDGFKVSFEIDFDHPVFRGRTQQASVDFSSTSFVKEVSRARTFGFMRDIEYLRSQNLALGGSVENAIVVDENRVLNEDGLRYEDEFVKHKILDAIGDLYLLGNSLIGEFRGFKSGHALNNQLLRTLIADKDAWEVVTFEDARTAPISYMRPAAAV
T85944	DRUGINFO	DB1P9T	LpxC-1	Preclinical
T85944	DRUGINFO	DC9FD4	RC-01	Terminated
T85944	DRUGINFO	D02TRN	Palmitoleic Acid	Investigative
T85944	DRUGINFO	D05MXM	3-(heptyloxy)benzoic acid	Investigative
T85944	DRUGINFO	D07WFG	BB-78484	Investigative
T85944	DRUGINFO	D0J7FD	BB-78485	Investigative
T85944	DRUGINFO	D0J8BO	Tu-514	Investigative
T85944	DRUGINFO	D09TVP	Cacodylate Ion	Investigative
T85944	DRUGINFO	D08OBF	MYRISTIC ACID	Investigative

T56051	TARGETID	T56051
T56051	FORMERID	TTDR01141
T56051	UNIPROID	UCHL1_HUMAN
T56051	TARGNAME	Ubiquitin thioesterase L1 (UCHL1)
T56051	GENENAME	UCHL1
T56051	TARGTYPE	Preclinical
T56051	SYNONYMS	Ubiquitin thiolesterase L1; Ubiquitin carboxyl-terminal hydrolase isozyme L1; Ubiquitin carboxy-terminal hydrolase L1; UCH-L1; PGP9.5; PGP 9.5; Neuron cytoplasmic protein 9.5
T56051	FUNCTION	Ubiquitin-protein hydrolase involved both in the processing of ubiquitin precursors and of ubiquitinated proteins. This enzyme is a thiol protease that recognizes and hydrolyzes a peptide bond at the C-terminal glycine of ubiquitin. Also binds to free monoubiquitin and may prevent its degradation in lysosomes. The homodimer may have ATP-independent ubiquitin ligase activity.
T56051	PDBSTRUC	4JKJ; 4DM9; 3KW5; 3KVF; 3IRT
T56051	BIOCLASS	Peptidase
T56051	ECNUMBER	EC 3.4.19.12
T56051	SEQUENCE	MQLKPMEINPEMLNKVLSRLGVAGQWRFVDVLGLEEESLGSVPAPACALLLLFPLTAQHENFRKKQIEELKGQEVSPKVYFMKQTIGNSCGTIGLIHAVANNQDKLGFEDGSVLKQFLSETEKMSPEDRAKCFEKNEAIQAAHDAVAQEGQCRVDDKVNFHFILFNNVDGHLYELDGRMPFPVNHGASSEDTLLKDAAKVCREFTEREQGEVRFSAVALCKAA
T56051	DRUGINFO	DCIP24	LDN-57444	Preclinical
T56051	DRUGINFO	DRT90B	NSC632839	Preclinical
T56051	DRUGINFO	D0N6BC	LDN-91946	Investigative

T68706	TARGETID	T68706
T68706	FORMERID	TTDI02227
T68706	UNIPROID	FURIN_HUMAN
T68706	TARGNAME	Dibasic-processing enzyme (Furin)
T68706	GENENAME	FURIN
T68706	TARGTYPE	Preclinical
T68706	SYNONYMS	Paired basic amino acid residuecleaving enzyme; Paired basic amino acid residue-cleaving enzyme; PCSK3; PACE; FUR; Dibasicprocessing enzyme
T68706	FUNCTION	Mediates processing of TGFB1, an essential step in TGF-beta-1 activation. Ubiquitous endoprotease within constitutive secretory pathways capable of cleavage at the RX(K/R)R consensus motif.
T68706	PDBSTRUC	6HZD; 6HZC; 6HZB; 6HZA; 6HLE
T68706	BIOCLASS	Peptidase
T68706	ECNUMBER	EC 3.4.21.75
T68706	SEQUENCE	MELRPWLLWVVAATGTLVLLAADAQGQKVFTNTWAVRIPGGPAVANSVARKHGFLNLGQIFGDYYHFWHRGVTKRSLSPHRPRHSRLQREPQVQWLEQQVAKRRTKRDVYQEPTDPKFPQQWYLSGVTQRDLNVKAAWAQGYTGHGIVVSILDDGIEKNHPDLAGNYDPGASFDVNDQDPDPQPRYTQMNDNRHGTRCAGEVAAVANNGVCGVGVAYNARIGGVRMLDGEVTDAVEARSLGLNPNHIHIYSASWGPEDDGKTVDGPARLAEEAFFRGVSQGRGGLGSIFVWASGNGGREHDSCNCDGYTNSIYTLSISSATQFGNVPWYSEACSSTLATTYSSGNQNEKQIVTTDLRQKCTESHTGTSASAPLAAGIIALTLEANKNLTWRDMQHLVVQTSKPAHLNANDWATNGVGRKVSHSYGYGLLDAGAMVALAQNWTTVAPQRKCIIDILTEPKDIGKRLEVRKTVTACLGEPNHITRLEHAQARLTLSYNRRGDLAIHLVSPMGTRSTLLAARPHDYSADGFNDWAFMTTHSWDEDPSGEWVLEIENTSEANNYGTLTKFTLVLYGTAPEGLPVPPESSGCKTLTSSQACVVCEEGFSLHQKSCVQHCPPGFAPQVLDTHYSTENDVETIRASVCAPCHASCATCQGPALTDCLSCPSHASLDPVEQTCSRQSQSSRESPPQQQPPRLPPEVEAGQRLRAGLLPSHLPEVVAGLSCAFIVLVFVTVFLVLQLRSGFSFRGVKVYTMDRGLISYKGLPPEAWQEECPSDSEEDEGRGERTAFIKDQSAL
T68706	DRUGINFO	D02QTG	US9266828, E	Patented
T68706	DRUGINFO	D0R9MA	US9266828, C	Patented
T68706	DRUGINFO	D0W2BO	US9266828, B	Patented
T68706	DRUGINFO	DXNT71	DecRVKRCMK	Preclinical
T68706	DRUGINFO	D08VTS	MI-1148	Investigative
T68706	DRUGINFO	D0A6FZ	peptide 18	Investigative
T68706	DRUGINFO	D05JJL	furin inhibitor peptide	Investigative

T99912	TARGETID	T99912
T99912	FORMERID	TTDR00950
T99912	UNIPROID	KYNU_HUMAN
T99912	TARGNAME	Kynureninase (KYNU)
T99912	GENENAME	KYNU
T99912	TARGTYPE	Preclinical
T99912	SYNONYMS	L-kynurenine hydrolase; KYNU
T99912	FUNCTION	Catalyzes the cleavage of L-kynurenine (L-Kyn) and L-3- hydroxykynurenine (L-3OHKyn) into anthranilic acid (AA) and 3- hydroxyanthranilic acid (3-OHAA), respectively. Has a preference for the L-3-hydroxy form. Also has cysteine-conjugate-beta-lyase activity.
T99912	PDBSTRUC	3E9K; 2HZP
T99912	BIOCLASS	Carbon-carbon bonds hydrolase
T99912	ECNUMBER	EC 3.7.1.3
T99912	SEQUENCE	MEPSSLELPADTVQRIAAELKCHPTDERVALHLDEEDKLRHFRECFYIPKIQDLPPVDLSLVNKDENAIYFLGNSLGLQPKMVKTYLEEELDKWAKIAAYGHEVGKRPWITGDESIVGLMKDIVGANEKEIALMNALTVNLHLLMLSFFKPTPKRYKILLEAKAFPSDHYAIESQLQLHGLNIEESMRMIKPREGEETLRIEDILEVIEKEGDSIAVILFSGVHFYTGQHFNIPAITKAGQAKGCYVGFDLAHAVGNVELYLHDWGVDFACWCSYKYLNAGAGGIAGAFIHEKHAHTIKPALVGWFGHELSTRFKMDNKLQLIPGVCGFRISNPPILLVCSLHASLEIFKQATMKALRKKSVLLTGYLEYLIKHNYGKDKAATKKPVVNIITPSHVEERGCQLTITFSVPNKDVFQELEKRGVVCDKRNPNGIRVAPVPLYNSFHDVYKFTNLLTSILDSAETKN
T99912	DRUGINFO	D17TRG	2-Amino-4-[3-hydroxyphenyl]-4-hydroxybutanoic acid	Preclinical
T99912	DRUGINFO	D6QA4N	S-(2-Aminophenyl)-L-cysteine S,S-dioxide	Preclinical
T99912	DRUGINFO	D00ASH	3-methoxydesaminokynurenine	Investigative
T99912	DRUGINFO	D05JZS	3-Hydroxyhippuric acid	Investigative
T99912	DRUGINFO	D0V4AX	3-hydroxydesaminokynurenine	Investigative
T99912	DRUGINFO	D02DWE	3,6,9,12,15-Pentaoxaheptadecane	Investigative

T15797	TARGETID	T15797
T15797	FORMERID	TTDI00213
T15797	UNIPROID	SMYD2_HUMAN
T15797	TARGNAME	SET and MYND domain-containing protein 2 (SMYD2)
T15797	GENENAME	SMYD2
T15797	TARGTYPE	Preclinical
T15797	SYNONYMS	Nlysine methyltransferase SMYD2; N-lysine methyltransferase SMYD2; Lysine Nmethyltransferase 3C; Lysine N-methyltransferase 3C; KMT3C; Histone methyltransferase SMYD2; HSKMB; HSKM-B
T15797	FUNCTION	Specifically methylates histone H3 'Lys-4' (H3K4me) and dimethylates histone H3 'Lys-36' (H3K36me2). Shows even higher methyltransferase activity on p53/TP53. Monomethylates 'Lys-370' of p53/TP53, leading to decreased DNA-binding activity and subsequent transcriptional regulation activity of p53/TP53. Monomethylates RB1 at 'Lys-860'. Protein-lysine N-methyltransferase that methylates both histones and non-histone proteins, including p53/TP53 and RB1.
T15797	PDBSTRUC	6MON; 6CBY; 6CBX; 5WCG; 5V3H
T15797	BIOCLASS	Methyltransferase
T15797	ECNUMBER	EC 2.1.1.-
T15797	SEQUENCE	MRAEGLGGLERFCSPGKGRGLRALQPFQVGDLLFSCPAYAYVLTVNERGNHCEYCFTRKEGLSKCGRCKQAFYCNVECQKEDWPMHKLECSPMVVFGENWNPSETVRLTARILAKQKIHPERTPSEKLLAVKEFESHLDKLDNEKKDLIQSDIAALHHFYSKHLGFPDNDSLVVLFAQVNCNGFTIEDEELSHLGSAIFPDVALMNHSCCPNVIVTYKGTLAEVRAVQEIKPGEEVFTSYIDLLYPTEDRNDRLRDSYFFTCECQECTTKDKDKAKVEIRKLSDPPKAEAIRDMVRYARNVIEEFRRAKHYKSPSELLEICELSQEKMSSVFEDSNVYMLHMMYQAMGVCLYMQDWEGALQYGQKIIKPYSKHYPLYSLNVASMWLKLGRLYMGLEHKAAGEKALKKAIAIMEVAHGKDHPYISEIKQEIESH
T15797	DRUGINFO	D06ONB	AZ505	Preclinical
T15797	DRUGINFO	D0X3RK	LLY-507	Preclinical
T15797	DRUGINFO	D35SKV	EPZ032597	Preclinical
T15797	DRUGINFO	DDC63W	EPZ033294	Preclinical
T15797	DRUGINFO	DELC48	A-893	Preclinical
T15797	DRUGINFO	DT6P8M	BAY 598	Preclinical

T95183	TARGETID	T95183
T95183	FORMERID	TTDI02577
T95183	UNIPROID	UBP2_HUMAN
T95183	TARGNAME	Ubiquitin carboxyl-terminal hydrolase 2 (USP2)
T95183	GENENAME	USP2
T95183	TARGTYPE	Preclinical
T95183	SYNONYMS	Ubiquitin-specific-processing protease 2; Ubiquitin thioesterase 2; UBP41; Deubiquitinating enzyme 2; 41 kDa ubiquitin-specific protease
T95183	FUNCTION	Isoform 1 and isoform 4 possess both ubiquitin-specific peptidase and isopeptidase activities. Deubiquitinates MDM2 without reversing MDM2-mediated p53/TP53 ubiquitination and thus indirectly promotes p53/TP53 degradation and limits p53 activity. Has no deubiquitinase activity against p53/TP53. Prevents MDM2-mediated degradation of MDM4. Plays a role in the G1/S cell-cycle progression in normal and cancer cells. Regulates the circadian clock by modulating its intrinsic circadian rhythm and its capacity to respond to external cues. Associates with clock proteins and deubiquitinates core clock component PER1 but does not affect its overall stability. Regulates the nucleocytoplasmic shuttling and nuclear retention of PER1 and its repressive role on the clock transcription factors CLOCK and ARNTL/BMAL1. Plays a role in the regulation of myogenic differentiation of embryonic muscle cells. Hydrolase that deubiquitinates polyubiquitinated target proteins such as MDM2, MDM4 and CCND1.
T95183	PDBSTRUC	6DGF; 5XVE; 5XU8; 3V6E; 3V6C
T95183	BIOCLASS	Peptidase
T95183	ECNUMBER	EC 3.4.19.12
T95183	SEQUENCE	MSQLSSTLKRYTESARYTDAHYAKSGYGAYTPSSYGANLAASLLEKEKLGFKPVPTSSFLTRPRTYGPSSLLDYDRGRPLLRPDITGGGKRAESQTRGTERPLGSGLSGGSGFPYGVTNNCLSYLPINAYDQGVTLTQKLDSQSDLARDFSSLRTSDSYRIDPRNLGRSPMLARTRKELCTLQGLYQTASCPEYLVDYLENYGRKGSASQVPSQAPPSRVPEIISPTYRPIGRYTLWETGKGQAPGPSRSSSPGRDGMNSKSAQGLAGLRNLGNTCFMNSILQCLSNTRELRDYCLQRLYMRDLHHGSNAHTALVEEFAKLIQTIWTSSPNDVVSPSEFKTQIQRYAPRFVGYNQQDAQEFLRFLLDGLHNEVNRVTLRPKSNPENLDHLPDDEKGRQMWRKYLEREDSRIGDLFVGQLKSSLTCTDCGYCSTVFDPFWDLSLPIAKRGYPEVTLMDCMRLFTKEDVLDGDEKPTCCRCRGRKRCIKKFSIQRFPKILVLHLKRFSESRIRTSKLTTFVNFPLRDLDLREFASENTNHAVYNLYAVSNHSGTTMGGHYTAYCRSPGTGEWHTFNDSSVTPMSSSQVRTSDAYLLFYELASPPSRM
T95183	DRUGINFO	DWR6A9	ML364	Preclinical

T43206	TARGETID	T43206
T43206	FORMERID	TTDR00593
T43206	UNIPROID	RORA_HUMAN
T43206	TARGNAME	Nuclear receptor ROR-alpha (RORA)
T43206	GENENAME	RORA
T43206	TARGTYPE	Preclinical
T43206	SYNONYMS	Retinoid-related orphan receptor-alpha; Retinoic acid-related orphan receptor alpha; RZRA; RAR-related orphan receptor A; Nuclear receptor subfamily 1 group F member 1; Nuclear receptor RZR-alpha; NR1F1
T43206	FUNCTION	Key regulator of embryonic development, cellular differentiation, immunity, circadian rhythm as well as lipid, steroid, xenobiotics and glucose metabolism. Considered to have intrinsic transcriptional activity, have some natural ligands like oxysterols that act as agonists (25-hydroxycholesterol) or inverse agonists (7-oxygenated sterols), enhancing or repressing the transcriptional activity, respectively. Recruits distinct combinations of cofactors to target genes regulatory regions to modulate their transcriptional expression, depending on the tissue, time and promoter contexts. Regulates genes involved in photoreceptor development including OPN1SW, OPN1SM and ARR3 and skeletal muscle development with MYOD1. Required for proper cerebellum development. Regulates SHH gene expression, among others, to induce granule cells proliferation as well as expression of genes involved in calcium-mediated signal transduction. Regulates the circadian expression of several clock genes, including CLOCK, ARNTL/BMAL1, NPAS2 and CRY1. Competes with NR1D1 for binding to their shared DNA response element on some clock genes such as ARNTL/BMAL1, CRY1 and NR1D1 itself, resulting in NR1D1-mediated repression or RORA-mediated activation of clock genes expression, leading to the circadian pattern of clock genes expression. Therefore influences the period length and stability of the clock. Regulates genes involved in lipid metabolism such as apolipoproteins APOA1, APOA5, APOC3 and PPARG. In liver, has specific and redundant functions with RORC as positive or negative modulator of expression of genes encoding phase I and phase II proteins involved in the metabolism of lipids, steroids and xenobiotics, such as CYP7B1 and SULT2A1. Induces a rhythmic expression of some of these genes. In addition, interplays functionally with NR1H2 and NR1H3 for the regulation of genes involved in cholesterol metabolism. Also involved in the regulation of hepatic glucose metabolism through the modulation of G6PC and PCK1. In adipose tissue, plays a role as negative regulator of adipocyte differentiation, probably acting through dual mechanisms. May suppress CEBPB-dependent adipogenesis through direct interaction and PPARG-dependent adipogenesis through competition for DNA-binding. Downstream of IL6 and TGFB and synergistically with RORC isoform 2, is implicated in the lineage specification of uncommitted CD4(+) T-helper (T(H)) cells into T(H)17 cells, antagonizing the T(H)1 program. Probably regulates IL17 and IL17F expression on T(H) by binding to the essential enhancer conserved non-coding sequence 2 (CNS2) in the IL17-IL17F locus. Involved in hypoxia signaling by interacting with and activating the transcriptional activity of HIF1A. May inhibit cell growth in response to cellular stress. May exert an anti-inflammatory role by inducing CHUK expression and inhibiting NF-kappa-B signaling. Nuclear receptor that binds DNA as a monomer to ROR response elements (RORE) containing a single core motif half-site 5'-AGGTCA-3' preceded by a short A-T-rich sequence.
T43206	PDBSTRUC	4S15; 1S0X; 1N83
T43206	BIOCLASS	Nuclear hormone receptor
T43206	SEQUENCE	MESAPAAPDPAASEPGSSGADAAAGSRETPLNQESARKSEPPAPVRRQSYSSTSRGISVTKKTHTSQIEIIPCKICGDKSSGIHYGVITCEGCKGFFRRSQQSNATYSCPRQKNCLIDRTSRNRCQHCRLQKCLAVGMSRDAVKFGRMSKKQRDSLYAEVQKHRMQQQQRDHQQQPGEAEPLTPTYNISANGLTELHDDLSNYIDGHTPEGSKADSAVSSFYLDIQPSPDQSGLDINGIKPEPICDYTPASGFFPYCSFTNGETSPTVSMAELEHLAQNISKSHLETCQYLREELQQITWQTFLQEEIENYQNKQREVMWQLCAIKITEAIQYVVEFAKRIDGFMELCQNDQIVLLKAGSLEVVFIRMCRAFDSQNNTVYFDGKYASPDVFKSLGCEDFISFVFEFGKSLCSMHLTEDEIALFSAFVLMSADRSWLQEKVKIEKLQQKIQLALQHVLQKNHREDGILTKLICKVSTLRALCGRHTEKLMAFKAIYPDIVRLHFPPLYKELFTSEFEPAMQIDG
T43206	DRUGINFO	D0SK3V	US9598431, 3	Patented
T43206	DRUGINFO	DZ28EB	SR3335	Preclinical
T43206	DRUGINFO	D9D6QN	SR1078	Preclinical
T43206	DRUGINFO	D01USH	7-hydroxycholesterol	Investigative

T83982	TARGETID	T83982
T83982	FORMERID	TTDI02457
T83982	UNIPROID	UBP8_HUMAN
T83982	TARGNAME	Ubiquitin isopeptidase Y (USP8)
T83982	GENENAME	USP8
T83982	TARGTYPE	Preclinical
T83982	SYNONYMS	hUBPy; Ubiquitin-specific-processing protease 8; Ubiquitin thioesterase 8; Ubiquitin carboxyl-terminal hydrolase 8; UBPY; KIAA0055; Deubiquitinating enzyme 8
T83982	FUNCTION	Converts both 'Lys-48' an 'Lys-63'-linked ubiquitin chains. Catalytic activity is enhanced in the M phase. Involved in cell proliferation. Required to enter into S phase in response to serum stimulation. May regulate T-cell anergy mediated by RNF128 via the formation of a complex containing RNF128 and OTUB1. Probably regulates the stability of STAM2 and RASGRF1. Regulates endosomal ubiquitin dynamics, cargo sorting, membrane traffic at early endosomes, and maintenance of ESCRT-0 stability. The level of protein ubiquitination on endosomes is essential for maintaining the morphology of the organelle. Deubiquitinates EPS15 and controles tyrosine kinase stability. Removes conjugated ubiquitin from EGFR thus regulating EGFR degradation and downstream MAPK signaling. Involved in acrosome biogenesis through interaction with the spermatid ESCRT-0 complex and microtubules. Deubiquitinates BIRC6/bruce and KIF23/MKLP1. Deubiquitinates BACE1 which inhibits BACE1 lysosomal degradation and modulates BACE-medaited APP cleavage and amyloid-beta formation. Hydrolase that can remove conjugated ubiquitin from proteins and therefore plays an important regulatory role at the level of protein turnover by preventing degradation.
T83982	PDBSTRUC	6F09; 3N3K; 2GWF; 2GFO; 2A9U
T83982	BIOCLASS	Peptidase
T83982	ECNUMBER	EC 3.4.19.12
T83982	SEQUENCE	MPAVASVPKELYLSSSLKDLNKKTEVKPEKISTKSYVHSALKIFKTAEECRLDRDEERAYVLYMKYVTVYNLIKKRPDFKQQQDYFHSILGPGNIKKAVEEAERLSESLKLRYEEAEVRKKLEEKDRQEEAQRLQQKRQETGREDGGTLAKGSLENVLDSKDKTQKSNGEKNEKCETKEKGAITAKELYTMMTDKNISLIIMDARRMQDYQDSCILHSLSVPEEAISPGVTASWIEAHLPDDSKDTWKKRGNVEYVVLLDWFSSAKDLQIGTTLRSLKDALFKWESKTVLRNEPLVLEGGYENWLLCYPQYTTNAKVTPPPRRQNEEVSISLDFTYPSLEESIPSKPAAQTPPASIEVDENIELISGQNERMGPLNISTPVEPVAASKSDVSPIIQPVPSIKNVPQIDRTKKPAVKLPEEHRIKSESTNHEQQSPQSGKVIPDRSTKPVVFSPTLMLTDEEKARIHAETALLMEKNKQEKELRERQQEEQKEKLRKEEQEQKAKKKQEAEENEITEKQQKAKEEMEKKESEQAKKEDKETSAKRGKEITGVKRQSKSEHETSDAKKSVEDRGKRCPTPEIQKKSTGDVPHTSVTGDSGSGKPFKIKGQPESGILRTGTFREDTDDTERNKAQREPLTRARSEEMGRIVPGLPSGWAKFLDPITGTFRYYHSPTNTVHMYPPEMAPSSAPPSTPPTHKAKPQIPAERDREPSKLKRSYSSPDITQAIQEEEKRKPTVTPTVNRENKPTCYPKAEISRLSASQIRNLNPVFGGSGPALTGLRNLGNTCYMNSILQCLCNAPHLADYFNRNCYQDDINRSNLLGHKGEVAEEFGIIMKALWTGQYRYISPKDFKITIGKINDQFAGYSQQDSQELLLFLMDGLHEDLNKADNRKRYKEENNDHLDDFKAAEHAWQKHKQLNESIIVALFQGQFKSTVQCLTCHKKSRTFEAFMYLSLPLASTSKCTLQDCLRLFSKEEKLTDNNRFYCSHCRARRDSLKKIEIWKLPPVLLVHLKRFSYDGRWKQKLQTSVDFPLENLDLSQYVIGPKNNLKKYNLFSVSNHYGGLDGGHYTAYCKNAARQRWFKFDDHEVSDISVSSVKSSAAYILFYTSLGPRVTDVAT
T83982	DRUGINFO	D4X9MD	9-(Ethoxyimino)-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile	Preclinical

T17067	TARGETID	T17067
T17067	FORMERID	TTDI03611
T17067	UNIPROID	UBP5_HUMAN
T17067	TARGNAME	Isopeptidase T (USP5)
T17067	GENENAME	USP5
T17067	TARGTYPE	Preclinical
T17067	SYNONYMS	Ubiquitin-specific-processing protease 5; Ubiquitin thioesterase 5; Ubiquitin carboxyl-terminal hydrolase 5; ISOT; Deubiquitinating enzyme 5
T17067	FUNCTION	Involved in unanchored 'Lys-48'-linked polyubiquitin disassembly. Binds linear and 'Lys-63'-linked polyubiquitin with a lower affinity. Knock-down of USP5 causes the accumulation of p53/TP53 and an increase in p53/TP53 transcriptional activity because the unanchored polyubiquitin that accumulates is able to compete with ubiquitinated p53/TP53 but not with MDM2 for proteasomal recognition. Cleaves linear and branched multiubiquitin polymers with a marked preference for branched polymers.
T17067	PDBSTRUC	6NFT; 6DXT; 6DXH; 3IHP; 2G45
T17067	BIOCLASS	Peptidase
T17067	ECNUMBER	EC 3.4.19.12
T17067	SEQUENCE	MAELSEEALLSVLPTIRVPKAGDRVHKDECAFSFDTPESEGGLYICMNTFLGFGKQYVERHFNKTGQRVYLHLRRTRRPKEEDPATGTGDPPRKKPTRLAIGVEGGFDLSEEKFELDEDVKIVILPDYLEIARDGLGGLPDIVRDRVTSAVEALLSADSASRKQEVQAWDGEVRQVSKHAFSLKQLDNPARIPPCGWKCSKCDMRENLWLNLTDGSILCGRRYFDGSGGNNHAVEHYRETGYPLAVKLGTITPDGADVYSYDEDDMVLDPSLAEHLSHFGIDMLKMQKTDKTMTELEIDMNQRIGEWELIQESGVPLKPLFGPGYTGIRNLGNSCYLNSVVQVLFSIPDFQRKYVDKLEKIFQNAPTDPTQDFSTQVAKLGHGLLSGEYSKPVPESGDGERVPEQKEVQDGIAPRMFKALIGKGHPEFSTNRQQDAQEFFLHLINMVERNCRSSENPNEVFRFLVEEKIKCLATEKVKYTQRVDYIMQLPVPMDAALNKEELLEYEEKKRQAEEEKMALPELVRAQVPFSSCLEAYGAPEQVDDFWSTALQAKSVAVKTTRFASFPDYLVIQIKKFTFGLDWVPKKLDVSIEMPEELDISQLRGTGLQPGEEELPDIAPPLVTPDEPKGSLGFYGNEDEDSFCSPHFSSPTSPMLDESVIIQLVEMGFPMDACRKAVYYTGNSGAEAAMNWVMSHMDDPDFANPLILPGSSGPGSTSAAADPPPEDCVTTIVSMGFSRDQALKALRATNNSLERAVDWIFSHIDDLDAEAAMDISEGRSAADSISESVPVGPKVRDGPGKYQLFAFISHMGTSTMCGHYVCHIKKEGRWVIYNDQKVCASEKPPKDLGYIYFYQRVAS
T17067	DRUGINFO	D0Y7OI	vialinin A	Preclinical
T17067	DRUGINFO	DGP6V3	BAP-15	Preclinical

T87109	TARGETID	T87109
T87109	FORMERID	TTDI03080
T87109	UNIPROID	KC1D_HUMAN
T87109	TARGNAME	Casein kinase I delta (CSNK1D)
T87109	GENENAME	CSNK1D
T87109	TARGTYPE	Preclinical
T87109	SYNONYMS	Tau-protein kinase CSNK1D; HCKID; Casein kinase I isoform delta; CKId; CKI-delta
T87109	FUNCTION	It can phosphorylate a large number of proteins. Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. Phosphorylates connexin-43/GJA1, MAP1A, SNAPIN, MAPT/TAU, TOP2A, DCK, HIF1A, EIF6, p53/TP53, DVL2, DVL3, ESR1, AIB1/NCOA3, DNMT1, PKD2, YAP1, PER1 and PER2. Central component of the circadian clock. In balance with PP1, determines the circadian period length through the regulation of the speed and rhythmicity of PER1 and PER2 phosphorylation. Controls PER1 and PER2 nuclear transport and degradation. YAP1 phosphorylation promotes its SCF(beta-TRCP) E3 ubiquitin ligase-mediated ubiquitination and subsequent degradation. DNMT1 phosphorylation reduces its DNA-binding activity. Phosphorylation of ESR1 and AIB1/NCOA3 stimulates their activity and coactivation. Phosphorylation of DVL2 and DVL3 regulates WNT3A signaling pathway that controls neurite outgrowth. EIF6 phosphorylation promotes its nuclear export. Triggers down-regulation of dopamine receptors in the forebrain. Activates DCK in vitro by phosphorylation. TOP2A phosphorylation favors DNA cleavable complex formation. May regulate the formation of the mitotic spindle apparatus in extravillous trophoblast. Modulates connexin-43/GJA1 gap junction assembly by phosphorylation. Probably involved in lymphocyte physiology. Regulates fast synaptic transmission mediated by glutamate. Essential serine/threonine-protein kinase that regulates diverse cellular growth and survival processes including Wnt signaling, DNA repair and circadian rhythms.
T87109	PDBSTRUC	6GZM; 6F26; 6F1W; 5W4W; 5OKT
T87109	BIOCLASS	Kinase
T87109	ECNUMBER	EC 2.7.11.1
T87109	SEQUENCE	MELRVGNRYRLGRKIGSGSFGDIYLGTDIAAGEEVAIKLECVKTKHPQLHIESKIYKMMQGGVGIPTIRWCGAEGDYNVMVMELLGPSLEDLFNFCSRKFSLKTVLLLADQMISRIEYIHSKNFIHRDVKPDNFLMGLGKKGNLVYIIDFGLAKKYRDARTHQHIPYRENKNLTGTARYASINTHLGIEQSRRDDLESLGYVLMYFNLGSLPWQGLKAATKRQKYERISEKKMSTPIEVLCKGYPSEFATYLNFCRSLRFDDKPDYSYLRQLFRNLFHRQGFSYDYVFDWNMLKFGASRAADDAERERRDREERLRHSRNPATRGLPSTASGRLRGTQEVAPPTPLTPTSHTANTSPRPVSGMERERKVSMRLHRGAPVNISSSDLTGRQDTSRMSTSQIPGRVASSGLQSVVHR
T87109	DRUGINFO	D00JGL	D-4476	Preclinical
T87109	DRUGINFO	D06QYR	PF-4800567	Preclinical
T87109	DRUGINFO	DZK7E0	PF-670462	Preclinical
T87109	DRUGINFO	D0UN8H	IC261	Preclinical
T87109	DRUGINFO	D0H4VB	PMID24900428C14	Investigative

T82668	TARGETID	T82668
T82668	FORMERID	TTDI02559
T82668	UNIPROID	AADAT_HUMAN
T82668	TARGNAME	Kynurenine oxoglutarate transaminase II (AADAT)
T82668	GENENAME	AADAT
T82668	TARGTYPE	Preclinical
T82668	SYNONYMS	Kynurenineoxoglutarate transaminase II; Kynurenineoxoglutarate transaminase 2; Kynurenineoxoglutarate aminotransferase II; Kynurenine/alphaaminoadipate aminotransferase, mitochondrial; Kynurenine aminotransferase II; KAT/AadAT; Alphaaminoadipate aminotransferase; AadAT; 2aminoadipate transaminase; 2aminoadipate aminotransferase
T82668	FUNCTION	Transaminase with broad substrate specificity. Has transaminase activity towards aminoadipate, kynurenine, methionine and glutamate. Shows activity also towards tryptophan, aspartate and hydroxykynurenine. Accepts a variety of oxo-acids as amino- group acceptors, with a preference for 2-oxoglutarate, 2- oxocaproic acid, phenylpyruvate and alpha-oxo-gamma-methiol butyric acid. Can also use glyoxylate as amino-group acceptor (in vitro).
T82668	PDBSTRUC	6D0A; 5TF5; 5EUN; 5EFS; 4GEB
T82668	BIOCLASS	Transaminase
T82668	ECNUMBER	EC 2.6.1.39
T82668	SEQUENCE	MNYARFITAASAARNPSPIRTMTDILSRGPKSMISLAGGLPNPNMFPFKTAVITVENGKTIQFGEEMMKRALQYSPSAGIPELLSWLKQLQIKLHNPPTIHYPPSQGQMDLCVTSGSQQGLCKVFEMIINPGDNVLLDEPAYSGTLQSLHPLGCNIINVASDESGIVPDSLRDILSRWKPEDAKNPQKNTPKFLYTVPNGNNPTGNSLTSERKKEIYELARKYDFLIIEDDPYYFLQFNKFRVPTFLSMDVDGRVIRADSFSKIISSGLRIGFLTGPKPLIERVILHIQVSTLHPSTFNQLMISQLLHEWGEEGFMAHVDRVIDFYSNQKDAILAAADKWLTGLAEWHVPAAGMFLWIKVKGINDVKELIEEKAVKMGVLMLPGNAFYVDSSAPSPYLRASFSSASPEQMDVAFQVLAQLIKESL
T82668	DRUGINFO	D03DSN	US10065972, Example 560	Patented
T82668	DRUGINFO	D07JBL	US8933095, 1	Patented
T82668	DRUGINFO	D08ETC	US10065972, Example 281	Patented
T82668	DRUGINFO	D09JPJ	US8933095, 16	Patented
T82668	DRUGINFO	D0QE9Q	US10065972, Example 396	Patented
T82668	DRUGINFO	D0RR5C	US8933095, 18	Patented
T82668	DRUGINFO	D0SZ7H	US8933095, 14	Patented
T82668	DRUGINFO	D9PBQ8	PF-04859989	Preclinical
T82668	DRUGINFO	DPQ4U3	BFF-122	Preclinical
T82668	DRUGINFO	DVQ37G	(S)-4-(Ethylsulfonyl)benzoylalanine	Preclinical

T53251	TARGETID	T53251
T53251	FORMERID	TTDI03186
T53251	UNIPROID	EHMT2_HUMAN
T53251	TARGNAME	Histone-lysine N-methyltransferase EHMT2 (EHMT2)
T53251	GENENAME	EHMT2
T53251	TARGTYPE	Preclinical
T53251	SYNONYMS	Protein G9a; NG36; Lysine N-methyltransferase 1C; KMT1C; Histone H3-K9 methyltransferase 3; HLA-B-associated transcript 8; H3-K9-HMTase 3; G9A; Euchromatic histone-lysine N-methyltransferase 2; C6orf30; BAT8
T53251	FUNCTION	H3K9me represents a specific tag for epigenetic transcriptional repression by recruiting HP1 proteins to methylated histones. Also mediates monomethylation of 'Lys-56' of histone H3 (H3K56me1) in G1 phase, leading to promote interaction between histone H3 and PCNA and regulating DNA replication. Also weakly methylates 'Lys-27' of histone H3 (H3K27me). Also required for DNA methylation, the histone methyltransferase activity is not required for DNA methylation, suggesting that these 2 activities function independently. Probably targeted to histone H3 by different DNA-binding proteins like E2F6, MGA, MAX and/or DP1. May also methylate histone H1. In addition to the histone methyltransferase activity, also methylates non-histone proteins: mediates dimethylation of 'Lys-373' of p53/TP53. Also methylates CDYL, WIZ, ACIN1, DNMT1, HDAC1, ERCC6, KLF12 and itself. Histone methyltransferase that specifically mono- and dimethylates 'Lys-9' of histone H3 (H3K9me1 and H3K9me2, respectively) in euchromatin.
T53251	PDBSTRUC	5VSE; 5VSC; 5V9I; 5TUY; 5TTF
T53251	BIOCLASS	Methyltransferase
T53251	ECNUMBER	EC 2.1.1.-
T53251	SEQUENCE	MAAAAGAAAAAAAEGEAPAEMGALLLEKETRGATERVHGSLGDTPRSEETLPKATPDSLEPAGPSSPASVTVTVGDEGADTPVGATPLIGDESENLEGDGDLRGGRILLGHATKSFPSSPSKGGSCPSRAKMSMTGAGKSPPSVQSLAMRLLSMPGAQGAAAAGSEPPPATTSPEGQPKVHRARKTMSKPGNGQPPVPEKRPPEIQHFRMSDDVHSLGKVTSDLAKRRKLNSGGGLSEELGSARRSGEVTLTKGDPGSLEEWETVVGDDFSLYYDSYSVDERVDSDSKSEVEALTEQLSEEEEEEEEEEEEEEEEEEEEEEEEDEESGNQSDRSGSSGRRKAKKKWRKDSPWVKPSRKRRKREPPRAKEPRGVNGVGSSGPSEYMEVPLGSLELPSEGTLSPNHAGVSNDTSSLETERGFEELPLCSCRMEAPKIDRISERAGHKCMATESVDGELSGCNAAILKRETMRPSSRVALMVLCETHRARMVKHHCCPGCGYFCTAGTFLECHPDFRVAHRFHKACVSQLNGMVFCPHCGEDASEAQEVTIPRGDGVTPPAGTAAPAPPPLSQDVPGRADTSQPSARMRGHGEPRRPPCDPLADTIDSSGPSLTLPNGGCLSAVGLPLGPGREALEKALVIQESERRKKLRFHPRQLYLSVKQGELQKVILMLLDNLDPNFQSDQQSKRTPLHAAAQKGSVEICHVLLQAGANINAVDKQQRTPLMEAVVNNHLEVARYMVQRGGCVYSKEEDGSTCLHHAAKIGNLEMVSLLLSTGQVDVNAQDSGGWTPIIWAAEHKHIEVIRMLLTRGADVTLTDNEENICLHWASFTGSAAIAEVLLNARCDLHAVNYHGDTPLHIAARESYHDCVLLFLSRGANPELRNKEGDTAWDLTPERSDVWFALQLNRKLRLGVGNRAIRTEKIICRDVARGYENVPIPCVNGVDGEPCPEDYKYISENCETSTMNIDRNITHLQHCTCVDDCSSSNCLCGQLSIRCWYDKDGRLLQEFNKIEPPLIFECNQACSCWRNCKNRVVQSGIKVRLQLYRTAKMGWGVRALQTIPQGTFICEYVGELISDAEADVREDDSYLFDLDNKDGEVYCIDARYYGNISRFINHLCDPNIIPVRVFMLHQDLRFPRIAFFSSRDIRTGEELGFDYGDRFWDIKSKYFTCQCGSEKCKHSAEAIALEQSRLARLDPHPELLPELGSLPPVNT
T53251	DRUGINFO	DJ1Q9B	MS012	Preclinical
T53251	DRUGINFO	D06PPL	BIX-01294	Preclinical
T53251	DRUGINFO	D0C5EG	A-366	Preclinical
T53251	DRUGINFO	D0CX4W	UNC0321	Investigative
T53251	DRUGINFO	D0RO9T	BRD9539	Investigative
T53251	DRUGINFO	D0BI4T	UNC0642	Investigative
T53251	DRUGINFO	D0GK7A	UNC0638	Investigative

T94201	TARGETID	T94201
T94201	FORMERID	TTDI03560
T94201	UNIPROID	SRPK1_HUMAN
T94201	TARGNAME	SRSF protein kinase 1 (SRPK1)
T94201	GENENAME	SRPK1
T94201	TARGTYPE	Preclinical
T94201	SYNONYMS	Serine/arginine-rich protein-specific kinase 1; SR-protein-specific kinase 1; SFRS protein kinase 1
T94201	FUNCTION	Plays a central role in the regulatory network for splicing, controlling the intranuclear distribution of splicing factors in interphase cells and the reorganization of nuclear speckles during mitosis. Can influence additional steps of mRNA maturation, as well as other cellular activities, such as chromatin reorganization in somatic and sperm cells and cell cycle progression. Isoform 2 phosphorylates SFRS2, ZRSR2, LBR and PRM1. Isoform 2 phosphorylates SRSF1 using a directional (C-terminal to N-terminal) and a dual-track mechanism incorporating both processive phosphorylation (in which the kinase stays attached to the substrate after each round of phosphorylation) and distributive phosphorylation steps (in which the kinase and substrate dissociate after each phosphorylation event). The RS domain of SRSF1 binds first to a docking groove in the large lobe of the kinase domain of SRPK1. This induces certain structural changes in SRPK1 and/or RRM2 domain of SRSF1, allowing RRM2 to bind the kinase and initiate phosphorylation. The cycles continue for several phosphorylation steps in a processive manner (steps 1-8) until the last few phosphorylation steps (approximately steps 9-12). During that time, a mechanical stress induces the unfolding of the beta-4 motif in RRM2, which then docks at the docking groove of SRPK1. This also signals RRM2 to begin to dissociate, which facilitates SRSF1 dissociation after phosphorylation is completed. Isoform 2 can mediate hepatitis B virus (HBV) core protein phosphorylation. It plays a negative role in the regulation of HBV replication through a mechanism not involving the phosphorylation of the core protein but by reducing the packaging efficiency of the pregenomic RNA (pgRNA) without affecting the formation of the viral core particles. Isoform 1 and isoform 2 can induce splicing of exon 10 in MAPT/TAU. The ratio of isoform 1/isoform 2 plays a decisive role in determining cell fate in K-562 leukaemic cell line: isoform 2 favors proliferation where as isoform 1 favors differentiation. Serine/arginine-rich protein-specific kinase which specifically phosphorylates its substrates at serine residues located in regions rich in arginine/serine dipeptides, known as RS domains and is involved in the phosphorylation of SR splicing factors and the regulation of splicing.
T94201	PDBSTRUC	5XV7; 5NNG; 5MY8; 5MXX; 4WUA
T94201	BIOCLASS	Kinase
T94201	ECNUMBER	EC 2.7.11.1
T94201	SEQUENCE	MERKVLALQARKKRTKAKKDKAQRKSETQHRGSAPHSESDLPEQEEEILGSDDDEQEDPNDYCKGGYHLVKIGDLFNGRYHVIRKLGWGHFSTVWLSWDIQGKKFVAMKVVKSAEHYTETALDEIRLLKSVRNSDPNDPNREMVVQLLDDFKISGVNGTHICMVFEVLGHHLLKWIIKSNYQGLPLPCVKKIIQQVLQGLDYLHTKCRIIHTDIKPENILLSVNEQYIRRLAAEATEWQRSGAPPPSGSAVSTAPQPKPADKMSKNKKKKLKKKQKRQAELLEKRMQEIEEMEKESGPGQKRPNKQEESESPVERPLKENPPNKMTQEKLEESSTIGQDQTLMERDTEGGAAEINCNGVIEVINYTQNSNNETLRHKEDLHNANDCDVQNLNQESSFLSSQNGDSSTSQETDSCTPITSEVSDTMVCQSSSTVGQSFSEQHISQLQESIRAEIPCEDEQEQEHNGPLDNKGKSTAGNFLVNPLEPKNAEKLKVKIADLGNACWVHKHFTEDIQTRQYRSLEVLIGSGYNTPADIWSTACMAFELATGDYLFEPHSGEEYTRDEDHIALIIELLGKVPRKLIVAGKYSKEFFTKKGDLKHITKLKPWGLFEVLVEKYEWSQEEAAGFTDFLLPMLELIPEKRATAAECLRHPWLNS
T94201	DRUGINFO	D03OBN	ZINC959121	Patented
T94201	DRUGINFO	D0LA9D	Sphinx	Patented
T94201	DRUGINFO	D0NY4A	SPHINX scaffold, 3	Patented
T94201	DRUGINFO	D86ILE	SPHINX31	Preclinical
T94201	DRUGINFO	D0J1JB	PMID15925511C13	Investigative

T30420	TARGETID	T30420
T30420	FORMERID	TTDI03543
T30420	UNIPROID	KMT5A_HUMAN
T30420	TARGNAME	SET domain containing 8 (KMT5A)
T30420	GENENAME	KMT5A
T30420	TARGTYPE	Preclinical
T30420	SYNONYMS	SETD8; SET8; SET07; SET domain-containing protein 8; PRSET7; PR/SET07; PR/SET domain-containing protein 07; PR-Set7; N-lysine methyltransferase KMT5A; Lysine-specific methylase 5A; Lysine N-methyltransferase 5A; Histone-lysine N-methyltransferase KMT5A; H4-K20-HMTase KMT5A
T30420	FUNCTION	Specifically monomethylates 'Lys-20' of histone H4 (H4K20me1). H4K20me1 is enriched during mitosis and represents a specific tag for epigenetic transcriptional repression. Mainly functions in euchromatin regions, thereby playing a central role in the silencing of euchromatic genes. Required for cell proliferation, probably by contributing to the maintenance of proper higher-order structure of DNA during mitosis. Involved in chromosome condensation and proper cytokinesis. Nucleosomes are preferred as substrate compared to free histones. Mediates monomethylation of p53/TP53 at 'Lys-382', leading to repress p53/TP53-target genes. Plays a negative role in TGF-beta response regulation and a positive role in cell migration. Protein-lysine N-methyltransferase that monomethylates both histones and non-histone proteins.
T30420	PDBSTRUC	6BOZ; 5W1Y; 5V2N; 5TH7; 5TEG
T30420	BIOCLASS	Methyltransferase
T30420	ECNUMBER	EC 2.1.1.-
T30420	SEQUENCE	MGEGGAAAALVAAAAAAAAAAAAVVAGQRRRRLGRRARCHGPGRAAGGKMSKPCAVEAAAAAVAATAPGPEMVERRGPGRPRTDGENVFTGQSKIYSYMSPNKCSGMRFPLQEENSVTHHEVKCQGKPLAGIYRKREEKRNAGNAVRSAMKSEEQKIKDARKGPLVPFPNQKSEAAEPPKTPPSSCDSTNAAIAKQALKKPIKGKQAPRKKAQGKTQQNRKLTDFYPVRRSSRKSKAELQSEERKRIDELIESGKEEGMKIDLIDGKGRGVIATKQFSRGDFVVEYHGDLIEITDAKKREALYAQDPSTGCYMYYFQYLSKTYCVDATRETNRLGRLINHSKCGNCQTKLHDIDGVPHLILIASRDIAAGEELLYDYGDRSKASIEAHPWLKH
T30420	DRUGINFO	D4V0SI	MS2177	Preclinical
T30420	DRUGINFO	DB4D2N	UNC0379	Preclinical
T30420	DRUGINFO	D0I4DG	nahuoic acid A	Investigative
T30420	DRUGINFO	D83QVW	MS453	Investigative

T89458	TARGETID	T89458
T89458	FORMERID	TTDR00963
T89458	UNIPROID	GTR1_HUMAN
T89458	TARGNAME	HepG2 glucose transporter (SLC2A1)
T89458	GENENAME	SLC2A1
T89458	TARGTYPE	Preclinical
T89458	SYNONYMS	Solute carrier family 2, facilitated glucose transporter member 1; HepG2 glucosetransporter; Glucose transporter type 1, erythrocyte/brain; GLUT1; GLUT-1
T89458	FUNCTION	Facilitative glucose transporter. This isoform may be responsible for constitutive or basal glucose uptake. Has a very broad substrate specificity; can transport a wide range of aldoses including both pentoses and hexoses.
T89458	PDBSTRUC	5EQI; 5EQH; 5EQG; 4PYP; 1SUK
T89458	BIOCLASS	Major facilitator
T89458	SEQUENCE	MEPSSKKLTGRLMLAVGGAVLGSLQFGYNTGVINAPQKVIEEFYNQTWVHRYGESILPTTLTTLWSLSVAIFSVGGMIGSFSVGLFVNRFGRRNSMLMMNLLAFVSAVLMGFSKLGKSFEMLILGRFIIGVYCGLTTGFVPMYVGEVSPTALRGALGTLHQLGIVVGILIAQVFGLDSIMGNKDLWPLLLSIIFIPALLQCIVLPFCPESPRFLLINRNEENRAKSVLKKLRGTADVTHDLQEMKEESRQMMREKKVTILELFRSPAYRQPILIAVVLQLSQQLSGINAVFYYSTSIFEKAGVQQPVYATIGSGIVNTAFTVVSLFVVERAGRRTLHLIGLAGMAGCAILMTIALALLEQLPWMSYLSIVAIFGFVAFFEVGPGPIPWFIVAELFSQGPRPAAIAVAGFSNWTSNFIVGMCFQYVEQLCGPYVFIIFTVLLVLFFIFTYFKVPETKGRTFDEIASGFRQGGASQSDKTPEELFHPLGADSQV
T89458	DRUGINFO	DCL8J5	WZB-117	Preclinical

T01521	TARGETID	T01521
T01521	UNIPROID	GSTO1_HUMAN
T01521	TARGNAME	Glutathione S-transferase omega-1 (GSTO-1)
T01521	GENENAME	GSTO1
T01521	TARGTYPE	Preclinical
T01521	SYNONYMS	SPG-R; S-(Phenacyl)glutathione reductase; Monomethylarsonic acid reductase; MMA(V) reductase; Glutathione-dependent dehydroascorbate reductase; Glutathione S-transferase omega 1-1; GSTTLP28; GSTO-1; GSTO 1-1
T01521	FUNCTION	Exhibits glutathione-dependent thiol transferase and dehydroascorbate reductase activities. Has S-(phenacyl)glutathione reductase activity. Has also glutathione S-transferase activity. Participates in the biotransformation of inorganic arsenic and reduces monomethylarsonic acid (MMA) and dimethylarsonic acid.
T01521	PDBSTRUC	6MHD; 6MHC; 6MHB; 5YVO; 5YVN
T01521	ECNUMBER	EC 2.5.1.18
T01521	SEQUENCE	MSGESARSLGKGSAPPGPVPEGSIRIYSMRFCPFAERTRLVLKAKGIRHEVININLKNKPEWFFKKNPFGLVPVLENSQGQLIYESAITCEYLDEAYPGKKLLPDDPYEKACQKMILELFSKVPSLVGSFIRSQNKEDYAGLKEEFRKEFTKLEEVLTNKKTTFFGGNSISMIDYLIWPWFERLEAMKLNECVDHTPKLKLWMAAMKEDPTVSALLTSEKDWQGFLELYLQNSPEACDYGL
T01521	DRUGINFO	D5R7AE	Piperlongumine	Preclinical

T00254	TARGETID	T00254
T00254	FORMERID	TTDI03516
T00254	UNIPROID	NR1D1_HUMAN
T00254	TARGNAME	V-erbA-related protein 1 (NR1D1)
T00254	GENENAME	NR1D1
T00254	TARGTYPE	Preclinical
T00254	SYNONYMS	THRAL; Rev-erbA-alpha; Nuclear receptor subfamily 1 group D member 1; HREV; EAR1; EAR-1
T00254	FUNCTION	Transcriptional repressor which coordinates circadian rhythm and metabolic pathways in a heme-dependent manner. Integral component of the complex transcription machinery that governs circadian rhythmicity and forms a critical negative limb of the circadian clock by directly repressing the expression of core clock components ARTNL/BMAL1, CLOCK and CRY1. Also regulates genes involved in metabolic functions, including lipid and bile acid metabolism, adipogenesis, gluconeogenesis and the macrophage inflammatory response. Acts as a receptor for heme which stimulates its interaction with the NCOR1/HDAC3 corepressor complex, enhancing transcriptional repression. Recognizes two classes of DNA response elements within the promoter of its target genes and can bind to DNA as either monomers or homodimers, depending on the nature of the response element. Binds as a monomer to a response element composed of the consensus half-site motif 5'-[A/G]GGTCA-3' preceded by an A/T-rich 5' sequence (RevRE), or as a homodimer to a direct repeat of the core motif spaced by two nucleotides (RevDR-2). Acts as a potent competitive repressor of ROR alpha (RORA) function and regulates the levels of its ligand heme by repressing the expression of PPARGC1A, a potent inducer of heme synthesis. Regulates lipid metabolism by repressing the expression of APOC3 and by influencing the activity of sterol response element binding proteins (SREBPs); represses INSIG2 which interferes with the proteolytic activation of SREBPs which in turn govern the rhythmic expression of enzymes with key functions in sterol and fatty acid synthesis. Regulates gluconeogenesis via repression of G6PC and PEPCK and adipocyte differentiation via repression of PPARG. Regulates glucagon release in pancreatic alpha-cells via the AMPK-NAMPT-SIRT1 pathway and the proliferation, glucose-induced insulin secretion and expression of key lipogenic genes in pancreatic-beta cells. Positively regulates bile acid synthesis by increasing hepatic expression of CYP7A1 via repression of NR0B2 and NFIL3 which are negative regulators of CYP7A1. Modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy; controls mitochondrial biogenesis and respiration by interfering with the STK11-PRKAA1/2-SIRT1-PPARGC1A signaling pathway. Represses the expression of SERPINE1/PAI1, an important modulator of cardiovascular disease and the expression of inflammatory cytokines and chemokines in macrophages. Represses gene expression at a distance in macrophages by inhibiting the transcription of enhancer-derived RNAs (eRNAs). Plays a role in the circadian regulation of body temperature and negatively regulates thermogenic transcriptional programs in brown adipose tissue (BAT); imposes a circadian oscillation in BAT activity, increasing body temperature when awake and depressing thermogenesis during sleep. In concert with NR2E3, regulates transcriptional networks critical for photoreceptor development and function. In addition to its activity as a repressor, can also act as a transcriptional activator. In the ovarian granulosa cells acts as a transcriptional activator of STAR which plays a role in steroid biosynthesis. In collaboration with SP1, activates GJA1 transcription in a heme-independent manner. Represses the transcription of CYP2B10, CYP4A10 and CYP4A14 (By similarity). Represses the transcription of CES2 (By similarity). Represses and regulates the circadian expression of TSHB in a NCOR1-dependent manner (By similarity). Negatively regulates the protein stability of NR3C1 and influences the time-dependent subcellular distribution of NR3C1, thereby affecting its transcriptional regulatory activity (By similarity). Plays a critical role in the circadian control of neutrophilic inflammation in the lung; under resting, non-stress conditions, acts as a rhythmic repressor to limit inflammatory activity whereas in the presence of inflammatory triggers undergoes ubiquitin-mediated degradation thereby relieving inhibition of the inflammatory response (By similarity). Plays a key role in the circadian regulation of microglial activation and neuroinflammation; suppresses microglial activation through the NF-kappaB pathway in the central nervous system (By similarity). Plays a role in the regulation of the diurnal rhythms of lipid and protein metabolism in the skeletal muscle via transcriptional repression of genes controlling lipid and amino acid metabolism in the muscle (By similarity).
T00254	PDBSTRUC	3N00; 1HLZ; 1GA5; 1EF6; 1A6Y
T00254	SEQUENCE	MTTLDSNNNTGGVITYIGSSGSSPSRTSPESLYSDNSNGSFQSLTQGCPTYFPPSPTGSLTQDPARSFGSIPPSLSDDGSPSSSSSSSSSSSSFYNGSPPGSLQVAMEDSSRVSPSKSTSNITKLNGMVLLCKVCGDVASGFHYGVHACEGCKGFFRRSIQQNIQYKRCLKNENCSIVRINRNRCQQCRFKKCLSVGMSRDAVRFGRIPKREKQRMLAEMQSAMNLANNQLSSQCPLETSPTQHPTPGPMGPSPPPAPVPSPLVGFSQFPQQLTPPRSPSPEPTVEDVISQVARAHREIFTYAHDKLGSSPGNFNANHASGSPPATTPHRWENQGCPPAPNDNNTLAAQRHNEALNGLRQAPSSYPPTWPPGPAHHSCHQSNSNGHRLCPTHVYAAPEGKAPANSPRQGNSKNVLLACPMNMYPHGRSGRTVQEIWEDFSMSFTPAVREVVEFAKHIPGFRDLSQHDQVTLLKAGTFEVLMVRFASLFNVKDQTVMFLSRTTYSLQELGAMGMGDLLSAMFDFSEKLNSLALTEEELGLFTAVVLVSADRSGMENSASVEQLQETLLRALRALVLKNRPLETSRFTKLLLKLPDLRTLNNMHSEKLLSFRVDAQ
T00254	DRUGINFO	D07IZG	GSK4112	Preclinical
T00254	DRUGINFO	D0K1VV	SR8278	Preclinical
T00254	DRUGINFO	D40DVS	SR9009	Preclinical
T00254	DRUGINFO	DW18LK	SR9011	Preclinical

T28309	TARGETID	T28309
T28309	FORMERID	TTDI03598
T28309	UNIPROID	MCLN1_HUMAN
T28309	TARGNAME	Mucolipin-1 (TRPML1)
T28309	GENENAME	MCOLN1
T28309	TARGTYPE	Preclinical
T28309	SYNONYMS	Transient receptor potential channel mucolipin 1; TRPML1; Mucolipidin; MSTP080; ML4; ML1; MG-2
T28309	FUNCTION	Nonselective cation channel probably playing a role in the regulation of membrane trafficking events and of metal homeostasis. Proposed to play a major role in Ca(2+) release from late endosome and lysosome vesicles to the cytoplasm, which is important for many lysosome-dependent cellular events, including the fusion and trafficking of these organelles, exocytosis and autophagy. Required for efficient uptake of large particles in macrophages in which Ca(2+) release from the lysosomes triggers lysosomal exocytosis. May also play a role in phagosome-lysosome fusion (By similarity). Involved in lactosylceramide trafficking indicative for a role in the regulation of late endocytic membrane fusion/fission events. By mediating lysosomal Ca(2+) release is involved in regulation of mTORC1 signaling and in mTOR/TFEB-dependent lysosomal adaptation to environmental cues such as nutrient levels. Seems to act as lysosomal active oxygen species (ROS) sensor involved in ROS-induced TFEB activation and autophagy. Functions as a Fe(2+) permeable channel in late endosomes and lysosomes. Proposed to play a role in zinc homeostasis probably implicating its association with TMEM163 In adaptive immunity, TRPML2 and TRPML1 may play redundant roles in the function of the specialized lysosomes of B cells (By similarity).
T28309	PDBSTRUC	6E7Z; 6E7Y; 6E7P; 5WJ9; 5WJ5
T28309	SEQUENCE	MTAPAGPRGSETERLLTPNPGYGTQAGPSPAPPTPPEEEDLRRRLKYFFMSPCDKFRAKGRKPCKLMLQVVKILVVTVQLILFGLSNQLAVTFREENTIAFRHLFLLGYSDGADDTFAAYTREQLYQAIFHAVDQYLALPDVSLGRYAYVRGGGDPWTNGSGLALCQRYYHRGHVDPANDTFDIDPMVVTDCIQVDPPERPPPPPSDDLTLLESSSSYKNLTLKFHKLVNVTIHFRLKTINLQSLINNEIPDCYTFSVLITFDNKAHSGRIPISLETQAHIQECKHPSVFQHGDNSFRLLFDVVVILTCSLSFLLCARSLLRGFLLQNEFVGFMWRQRGRVISLWERLEFVNGWYILLVTSDVLTISGTIMKIGIEAKNLASYDVCSILLGTSTLLVWVGVIRYLTFFHNYNILIATLRVALPSVMRFCCCVAVIYLGYCFCGWIVLGPYHVKFRSLSMVSECLFSLINGDDMFVTFAAMQAQQGRSSLVWLFSQLYLYSFISLFIYMVLSLFIALITGAYDTIKHPGGAGAEESELQAYIAQCQDSPTSGKFRRGSGSACSLLCCCGRDPSEEHSLLVN
T28309	DRUGINFO	DNL2F1	MK6-83	Preclinical
T28309	DRUGINFO	D01ZCI	phosphatidyl (3,5) inositol biphosphate	Investigative

T99765	TARGETID	T99765
T99765	FORMERID	TTDI01737
T99765	UNIPROID	SUMO1_HUMAN; SUMO2_HUMAN; SUMO3_HUMAN; SUMO4_HUMAN; SUMO5_HUMAN
T99765	TARGNAME	Small ubiquitin-related modifier (SUMO)
T99765	GENENAME	SUMO1; SUMO2; SUMO3; SUMO4; SUMO1P1
T99765	TARGTYPE	Preclinical
T99765	SYNONYMS	Ubiquitin-like protein; SUMO; SMT3 homolog 1
T99765	FUNCTION	Ubiquitin-like protein that can be covalently attached to proteins as a monomer or as a lysine-linked polymer. Covalent attachment via an isopeptide bond to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be promoted by E3 ligases such as PIAS1-4, RANBP2 or CBX4. This post-translational modification on lysine residues of proteins plays a crucial role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction. Involved for instance in targeting RANGAP1 to the nuclear pore complex protein RANBP2. Covalently attached to the voltage-gated potassium channel KCNB1; this modulates the gating characteristics of KCNB1. Polymeric SUMO1 chains are also susceptible to polyubiquitination which functions as a signal for proteasomal degradation of modified proteins. May also regulate a network of genes involved in palate development. Covalently attached to ZFHX3.
T99765	SEQUENCE	MSDQEAKPSTEDLGDKKEGEYIKLKVIGQDSSEIHFKVKMTTHLKKLKESYCQRQGVPMNSLRFLFEGQRIADNHTPKELGMEEEDVIEVYQEQTGGHSTV
T99765	DRUGINFO	D4UFT5	2-D08	Preclinical

T12108	TARGETID	T12108
T12108	FORMERID	TTDI03124
T12108	UNIPROID	CRY1_HUMAN
T12108	TARGNAME	Cryptochrome circadian clock 1 (CRY1)
T12108	GENENAME	CRY1
T12108	TARGTYPE	Preclinical
T12108	SYNONYMS	PHLL1; Cryptochrome-1
T12108	FUNCTION	The circadian clock, an internal time-keeping system, regulates various physiological processes through the generation of approximately 24 hour circadian rhythms in gene expression, which are translated into rhythms in metabolism and behavior. It is derived from the Latin roots 'circa' (about) and 'diem' (day) and acts as an important regulator of a wide array of physiological functions including metabolism, sleep, body temperature, blood pressure, endocrine, immune, cardiovascular, and renal function. Consists of two major components: the central clock, residing in the suprachiasmatic nucleus (SCN) of the brain, and the peripheral clocks that are present in nearly every tissue and organ system. Both the central and peripheral clocks can be reset by environmental cues, also known as Zeitgebers (German for 'timegivers'). The predominant Zeitgeber for the central clock is light, which is sensed by retina and signals directly to the SCN. The central clock entrains the peripheral clocks through neuronal and hormonal signals, body temperature and feeding-related cues, aligning all clocks with the external light/dark cycle. Circadian rhythms allow an organism to achieve temporal homeostasis with its environment at the molecular level by regulating gene expression to create a peak of protein expression once every 24 hours to control when a particular physiological process is most active with respect to the solar day. Transcription and translation of core clock components (CLOCK, NPAS2, ARNTL/BMAL1, ARNTL2/BMAL2, PER1, PER2, PER3, CRY1 and CRY2) plays a critical role in rhythm generation, whereas delays imposed by post-translational modifications (PTMs) are important for determining the period (tau) of the rhythms (tau refers to the period of a rhythm and is the length, in time, of one complete cycle). A diurnal rhythm is synchronized with the day/night cycle, while the ultradian and infradian rhythms have a period shorter and longer than 24 hours, respectively. Disruptions in the circadian rhythms contribute to the pathology of cardiovascular diseases, cancer, metabolic syndromes and aging. A transcription/translation feedback loop (TTFL) forms the core of the molecular circadian clock mechanism. Transcription factors, CLOCK or NPAS2 and ARNTL/BMAL1 or ARNTL2/BMAL2, form the positive limb of the feedback loop, act in the form of a heterodimer and activate the transcription of core clock genes and clock-controlled genes (involved in key metabolic processes), harboring E-box elements (5'-CACGTG-3') within their promoters. The core clock genes: PER1/2/3 and CRY1/2 which are transcriptional repressors form the negative limb of the feedback loop and interact with the CLOCK|NPAS2-ARNTL/BMAL1|ARNTL2/BMAL2 heterodimer inhibiting its activity and thereby negatively regulating their own expression. This heterodimer also activates nuclear receptors NR1D1/2 and RORA/B/G, which form a second feedback loop and which activate and repress ARNTL/BMAL1 transcription, respectively. CRY1 and CRY2 have redundant functions but also differential and selective contributions at least in defining the pace of the SCN circadian clock and its circadian transcriptional outputs. More potent transcriptional repressor in cerebellum and liver than CRY2, though more effective in lengthening the period of the SCN oscillator. On its side, CRY2 seems to play a critical role in tuning SCN circadian period by opposing the action of CRY1. With CRY2, is dispensable for circadian rhythm generation but necessary for the development of intercellular networks for rhythm synchrony. Capable of translocating circadian clock core proteins such as PER proteins to the nucleus. Interacts with CLOCK-ARNTL/BMAL1 independently of PER proteins and is found at CLOCK-ARNTL/BMAL1-bound sites, suggesting that CRY may act as a molecular gatekeeper to maintain CLOCK-ARNTL/BMAL1 in a poised and repressed state until the proper time for transcriptional activation. Represses the CLOCK-ARNTL/BMAL1 induced transcription of BHLHE40/DEC1. Represses the CLOCK-ARNTL/BMAL1 induced transcription of ATF4, MTA1, KLF10 and NAMPT. May repress circadian target genes expression in collaboration with HDAC1 and HDAC2 through histone deacetylation. Mediates the clock-control activation of ATR and modulates ATR-mediated DNA damage checkpoint. In liver, mediates circadian regulation of cAMP signaling and gluconeogenesis by binding to membrane-coupled G proteins and blocking glucagon-mediated increases in intracellular cAMP concentrations and CREB1 phosphorylation. Inhibits hepatic gluconeogenesis by decreasing nuclear FOXO1 levels that downregulates gluconeogenic gene expression. Besides its role in the maintenance of the circadian clock, is also involved in the regulation of other processes. Represses glucocorticoid receptor NR3C1/GR-induced transcriptional activity by binding to glucocorticoid response elements (GREs). Plays a key role in glucose and lipid metabolism modulation, in part, through the transcriptional regulation of genes involved in these pathways, such as LEP or ACSL4. Represses PPARD and its target genes in the skeletal muscle and limits exercise capacity. Plays an essential role in the generation of circadian rhythms in the retina. Represses the transcriptional activity of NR1I2. Transcriptional repressor which forms a core component of the circadian clock.
T12108	SEQUENCE	MGVNAVHWFRKGLRLHDNPALKECIQGADTIRCVYILDPWFAGSSNVGINRWRFLLQCLEDLDANLRKLNSRLFVIRGQPADVFPRLFKEWNITKLSIEYDSEPFGKERDAAIKKLATEAGVEVIVRISHTLYDLDKIIELNGGQPPLTYKRFQTLISKMEPLEIPVETITSEVIEKCTTPLSDDHDEKYGVPSLEELGFDTDGLSSAVWPGGETEALTRLERHLERKAWVANFERPRMNANSLLASPTGLSPYLRFGCLSCRLFYFKLTDLYKKVKKNSSPPLSLYGQLLWREFFYTAATNNPRFDKMEGNPICVQIPWDKNPEALAKWAEGRTGFPWIDAIMTQLRQEGWIHHLARHAVACFLTRGDLWISWEEGMKVFEELLLDADWSINAGSWMWLSCSSFFQQFFHCYCPVGFGRRTDPNGDYIRRYLPVLRGFPAKYIYDPWNAPEGIQKVAKCLIGVNYPKPMVNHAEASRLNIERMKQIYQQLSRYRGLGLLASVPSNPNGNGGFMGYSAENIPGCSSSGSCSQGSGILHYAHGDSQQTHLLKQGRSSMGTGLSGGKRPSQEEDTQSIGPKVQRQSTN
T12108	DRUGINFO	D4RGV9	2-Ethoxypropanoic acid	Preclinical
T12108	DRUGINFO	D95KWS	KL001	Preclinical
T12108	DRUGINFO	DG90VQ	SHP656	Preclinical
T12108	DRUGINFO	DOZQ70	TH301	Preclinical
T12108	DRUGINFO	D0H0EC	KL044	Investigative

T20103	TARGETID	T20103
T20103	FORMERID	TTDR00563
T20103	TARGNAME	Vacuolar-type proton ATPase (v-ATPase)
T20103	TARGTYPE	Preclinical
T20103	SYNONYMS	Vacuolar-ATPase; Vacuolar ATPase; V-ATPase
T20103	BIOCLASS	Acid anhydrides hydrolase
T20103	DRUGINFO	D0N1EC	WY-47766	Discontinued in Phase 2
T20103	DRUGINFO	D04CFL	SB 242784	Preclinical
T20103	DRUGINFO	D07JSI	Salicylihalamide A	Preclinical
T20103	DRUGINFO	D0KB2E	FR167356	Preclinical
T20103	DRUGINFO	D05OJY	Lobatamide A	Investigative
T20103	DRUGINFO	D06LUW	Lobatamide C	Investigative
T20103	DRUGINFO	D07SKL	Oximidine II	Investigative
T20103	DRUGINFO	D08XYK	Lobatamide D	Investigative
T20103	DRUGINFO	D0FK6J	Lobatamide B	Investigative
T20103	DRUGINFO	D0O9DH	Oximidine I	Investigative
T20103	DRUGINFO	D0Y8VQ	Lobatamide F	Investigative
T20103	DRUGINFO	D4VBY6	Bafilomycin A1	Investigative
T20103	DRUGINFO	DY9CM8	BRD1240	Investigative

T43025	TARGETID	T43025
T43025	FORMERID	TTDI01390
T43025	TARGNAME	Alpha-crystallin (CRYA)
T43025	TARGTYPE	Preclinical
T43025	DRUGINFO	D0OMC3	2E9IgA1	Preclinical

T05164	TARGETID	T05164
T05164	UNIPROID	KMT5B_HUMAN
T05164	TARGNAME	Histone-lysine N-methyltransferase KMT5B (KMT5B)
T05164	GENENAME	KMT5B
T05164	TARGTYPE	Preclinical
T05164	SYNONYMS	Lysine N-methyltransferase 5B; Lysine-specific methyltransferase 5B; Suppressor of variegation 4-20 homolog 1; Su(var)4-20 homolog 1; Suv4-20h1; [histone H4]-N-methyl-L-lysine20 N-methyltransferase KMT5B; [histone H4]-lysine20 N-methyltransferase KMT5B
T05164	FUNCTION	Histone methyltransferase that specifically methylates monomethylated 'Lys-20' (H4K20me1) and dimethylated 'Lys-20' (H4K20me2) of histone H4 to produce respectively dimethylated 'Lys-20' (H4K20me2) and trimethylated 'Lys-20' (H4K20me3) and thus regulates transcription and maintenance of genome integrity. In vitro also methylates unmodified 'Lys-20' (H4K20me0) of histone H4 and nucleosomes. H4 'Lys-20' trimethylation represents a specific tag for epigenetic transcriptional repression. Mainly functions in pericentric heterochromatin regions, thereby playing a central role in the establishment of constitutive heterochromatin in these regions. KMT5B is targeted to histone H3 via its interaction with RB1 family proteins (RB1, RBL1 and RBL2) (By similarity). Plays a role in myogenesis by regulating the expression of target genes, such as EID3. Facilitates TP53BP1 foci formation upon DNA damage and proficient non-homologous end-joining (NHEJ)-directed DNA repair by catalyzing the di- and trimethylation of 'Lys-20' of histone H4. May play a role in class switch reconbination by catalyzing the di- and trimethylation of 'Lys-20' of histone H4 (By similarity).
T05164	ECNUMBER	EC 2.1.1.361
T05164	SEQUENCE	MKWLGESKNMVVNGRRNGGKLSNDHQQNQSKLQHTGKDTLKAGKNAVERRSNRCNGNSGFEGQSRYVPSSGMSAKELCENDDLATSLVLDPYLGFQTHKMNTSAFPSRSSRHFSKSDSFSHNNPVRFRPIKGRQEELKEVIERFKKDEHLEKAFKCLTSGEWARHYFLNKNKMQEKLFKEHVFIYLRMFATDSGFEILPCNRYSSEQNGAKIVATKEWKRNDKIELLVGCIAELSEIEENMLLRHGENDFSVMYSTRKNCAQLWLGPAAFINHDCRPNCKFVSTGRDTACVKALRDIEPGEEISCYYGDGFFGENNEFCECYTCERRGTGAFKSRVGLPAPAPVINSKYGLRETDKRLNRLKKLGDSSKNSDSQSVSSNTDADTTQEKNNATSNRKSSVGVKKNSKSRTLTRQSMSRIPASSNSTSSKLTHINNSRVPKKLKKPAKPLLSKIKLRNHCKRLEQKNASRKLEMGNLVLKEPKVVLYKNLPIKKDKEPEGPAQAAVASGCLTRHAAREHRQNPVRGAHSQGESSPCTYITRRSVRTRTNLKEASDIKLEPNTLNGYKSSVTEPCPDSGEQLQPAPVLQEEELAHETAQKGEAKCHKSDTGMSKKKSRQGKLVKQFAKIEESTPVHDSPGKDDAVPDLMGPHSDQGEHSGTVGVPVSYTDCAPSPVGCSVVTSDSFKTKDSFRTAKSKKKRRITRYDAQLILENNSGIPKLTLRRRHDSSSKTNDQENDGMNSSKISIKLSKDHDNDNNLYVAKLNNGFNSGSGSSSTKLKIQLKRDEENRGSYTEGLHENGVCCSDPLSLLESRMEVDDYSQYEEESTDDSSSSEGDEEEDDYDDDFEDDFIPLPPAKRLRLIVGKDSIDIDISSRRREDQSLRLNA
T05164	DRUGINFO	D0P2EH	A-196	Preclinical

T06281	TARGETID	T06281
T06281	UNIPROID	FM3_KLEPN
T06281	TARGNAME	Klebsiella Fimbrial subunit type 3 (Klebsiella mrkA)
T06281	GENENAME	Klebsiella mrkA
T06281	TARGTYPE	Preclinical
T06281	SEQUENCE	MKKVLLSAAMATAFFGMAAANAADTNVGGGQVNFFGKVTDVSCTVSVNGQGSDANVYLSPVTLTEVKAAAADTYLKPKSFTIDVSDCQAADGTKQDDVSKLGVNWTGGNLLAGATAKQQGYLANTEAAGAQNIQLVLSTDNATALTNKIIPGDSTQPKAAGDASAVQDGARFTYYVGYATSTPTTVTTGVVNSYATYEITYQ
T06281	DRUGINFO	DP8T7K	KP3	Preclinical

T07584	TARGETID	T07584
T07584	UNIPROID	UBP13_HUMAN
T07584	TARGNAME	Ubiquitin carboxyl-terminal hydrolase 13 (USP13)
T07584	GENENAME	USP13
T07584	TARGTYPE	Preclinical
T07584	SYNONYMS	Deubiquitinating enzyme 13; Isopeptidase T-3; ISOT-3; Ubiquitin thioesterase 13; Ubiquitin-specific-processing protease 13
T07584	FUNCTION	Deubiquitinase that mediates deubiquitination of target proteins such as BECN1, MITF, SKP2 and USP10 and is involved in various processes such as autophagy and endoplasmic reticulum-associated degradation (ERAD). Component of a regulatory loop that controls autophagy and p53/TP53 levels: mediates deubiquitination of BECN1, a key regulator of autophagy, leading to stabilize the PIK3C3/VPS34-containing complexes. Also deubiquitinates USP10, an essential regulator of p53/TP53 stability. In turn, PIK3C3/VPS34-containing complexes regulate USP13 stability, suggesting the existence of a regulatory system by which PIK3C3/VPS34-containing complexes regulate p53/TP53 protein levels via USP10 and USP13. Recruited by nuclear UFD1 and mediates deubiquitination of SKP2, thereby regulating endoplasmic reticulum-associated degradation (ERAD). Also regulates ERAD through the deubiquitination of UBL4A a component of the BAG6/BAT3 complex. Mediates stabilization of SIAH2 independently of deubiquitinase activity: binds ubiquitinated SIAH2 and acts by impairing SIAH2 autoubiquitination. Has a weak deubiquitinase activity in vitro and preferentially cleaves 'Lys-63'-linked polyubiquitin chains. In contrast to USP5, it is not able to mediate unanchored polyubiquitin disassembly. Able to cleave ISG15 in vitro; however, additional experiments are required to confirm such data.
T07584	BIOCLASS	Peptidase
T07584	ECNUMBER	EC 3.4.19.12
T07584	SEQUENCE	MQRRGALFGMPGGSGGRKMAAGDIGELLVPHMPTIRVPRSGDRVYKNECAFSYDSPNSEGGLYVCMNTFLAFGREHVERHFRKTGQSVYMHLKRHVREKVRGASGGALPKRRNSKIFLDLDTDDDLNSDDYEYEDEAKLVIFPDHYEIALPNIEELPALVTIACDAVLSSKSPYRKQDPDTWENELPVSKYANNLTQLDNGVRIPPSGWKCARCDLRENLWLNLTDGSVLCGKWFFDSSGGNGHALEHYRDMGYPLAVKLGTITPDGADVYSFQEEEPVLDPHLAKHLAHFGIDMLHMHGTENGLQDNDIKLRVSEWEVIQESGTKLKPMYGPGYTGLKNLGNSCYLSSVMQAIFSIPEFQRAYVGNLPRIFDYSPLDPTQDFNTQMTKLGHGLLSGQYSKPPVKSELIEQVMKEEHKPQQNGISPRMFKAFVSKSHPEFSSNRQQDAQEFFLHLVNLVERNRIGSENPSDVFRFLVEERIQCCQTRKVRYTERVDYLMQLPVAMEAATNKDELIAYELTRREAEANRRPLPELVRAKIPFSACLQAFSEPENVDDFWSSALQAKSAGVKTSRFASFPEYLVVQIKKFTFGLDWVPKKFDVSIDMPDLLDINHLRARGLQPGEEELPDISPPIVIPDDSKDRLMNQLIDPSDIDESSVMQLAEMGFPLEACRKAVYFTGNMGAEVAFNWIIVHMEEPDFAEPLTMPGYGGAASAGASVFGASGLDNQPPEEIVAIITSMGFQRNQAIQALRATNNNLERALDWIFSHPEFEEDSDFVIEMENNANANIISEAKPEGPRVKDGSGTYELFAFISHMGTSTMSGHYICHIKKEGRWVIYNDHKVCASERPPKDLGYMYFYRRIPS
T07584	DRUGINFO	DB0V3R	Spautin 1	Preclinical

T14705	TARGETID	T14705
T14705	UNIPROID	BGLR_ECOLI
T14705	TARGNAME	Bacterial Beta-glucuronidase (Bact uidA)
T14705	GENENAME	Bact uidA
T14705	TARGTYPE	Preclinical
T14705	SYNONYMS	GUS; Beta-D-glucuronoside glucuronosohydrolase
T14705	FUNCTION	cytosol, protein-containing complex, beta-glucuronidase activity, carbohydrate binding, identical protein binding, glucuronoside catabolic process
T14705	BIOCLASS	Glycosyl hydrolase
T14705	ECNUMBER	EC 3.2.1.31
T14705	SEQUENCE	MLRPVETPTREIKKLDGLWAFSLDRENCGIDQRWWESALQESRAIAVPGSFNDQFADADIRNYAGNVWYQREVFIPKGWAGQRIVLRFDAVTHYGKVWVNNQEVMEHQGGYTPFEADVTPYVIAGKSVRITVCVNNELNWQTIPPGMVITDENGKKKQSYFHDFFNYAGIHRSVMLYTTPNTWVDDITVVTHVAQDCNHASVDWQVVANGDVSVELRDADQQVVATGQGTSGTLQVVNPHLWQPGEGYLYELCVTAKSQTECDIYPLRVGIRSVAVKGEQFLINHKPFYFTGFGRHEDADLRGKGFDNVLMVHDHALMDWIGANSYRTSHYPYAEEMLDWADEHGIVVIDETAAVGFNLSLGIGFEAGNKPKELYSEEAVNGETQQAHLQAIKELIARDKNHPSVVMWSIANEPDTRPQGAREYFAPLAEATRKLDPTRPITCVNVMFCDAHTDTISDLFDVLCLNRYYGWYVQSGDLETAEKVLEKELLAWQEKLHQPIIITEYGVDTLAGLHSMYTDMWSEEYQCAWLDMYHRVFDRVSAVVGEQVWNFADFATSQGILRVGGNKKGIFTRDRKPKSAAFLLQKRWTGMNFGEKPQQGGKQ
T14705	DRUGINFO	D86ALC	SBX-101	Preclinical

T20534	TARGETID	T20534
T20534	UNIPROID	LASR_PSEAE
T20534	TARGNAME	Pseudomonas Transcriptional activator protein LasR (Pseudo LasR)
T20534	GENENAME	Pseudo LasR
T20534	TARGTYPE	Preclinical
T20534	FUNCTION	Transcriptional activator of elastase structural gene (LasB). Binds to the PAI autoinducer.
T20534	SEQUENCE	MALVDGFLELERSSGKLEWSAILQKMASDLGFSKILFGLLPKDSQDYENAFIVGNYPAAWREHYDRAGYARVDPTVSHCTQSVLPIFWEPSIYQTRKQHEFFEEASAAGLVYGLTMPLHGARGELGALSLSVEAENRAEANRFMESVLPTLWMLKDYALQSGAGLAFEHPVSKPVVLTSREKEVLQWCAIGKTSWEISVICNCSEANVNFHMGNIRRKFGVTSRRVAAIMAVNLGLITL
T20534	DRUGINFO	D16JNF	3-Oxo-C12-(2-amino-cyclohexanone)	Preclinical
T20534	DRUGINFO	D9SMC5	C30	Preclinical

T24835	TARGETID	T24835
T24835	TARGNAME	Mycobacterial lipoarabinomannan (MycB LAM)
T24835	TARGTYPE	Preclinical
T24835	DRUGINFO	DT29OQ	SMITB14	Preclinical

T25064	TARGETID	T25064
T25064	UNIPROID	D6H5M4_NEIGO
T25064	TARGNAME	Neisseria gonorrhoeae Enoyl-[acyl-carrier-protein] reductase (Neisseria fabI)
T25064	TARGTYPE	Preclinical
T25064	ECNUMBER	EC 1.3.1.9
T25064	SEQUENCE	MGFLQGKKILITGMISERSIAYGIAKACREQGAELAFTYVVDKLEERVRKMAAELDSELVFRCDVASDDEINQVFADLGKHWDGLDGLVHSIGFAPKEALSGDFLDSISREAFNTAHEISAYSLPALAKAARPMMRGRNSAIVALSYLGAVRAIPNYNVMGMAKASLEAGIRFTAACLGKEGIRCNGISAGPIKTLAASGIADFGKLLGHVAAHNPLRRNVTIEEVGNTAAFLLSDLSSGITGEITYVDGGYSINALSTEG
T25064	DRUGINFO	D3Q1OL	Debio1453	Preclinical

T35792	TARGETID	T35792
T35792	UNIPROID	SMYD3_HUMAN
T35792	TARGNAME	Histone-lysine N-methyltransferase SMYD3 (SMYD3)
T35792	GENENAME	SMYD3
T35792	TARGTYPE	Preclinical
T35792	SYNONYMS	SET and MYND domain-containing protein 3; Zinc finger MYND domain-containing protein 1
T35792	FUNCTION	Histone methyltransferase. Specifically methylates 'Lys-4' of histone H3, inducing di- and tri-methylation, but not monomethylation . Also methylates 'Lys-5' of histone H4. Plays an important role in transcriptional activation as a member of an RNA polymerase complex. Binds DNA containing 5'-CCCTCC-3' or 5'-GAGGGG-3' sequences.
T35792	ECNUMBER	EC 2.1.1.354
T35792	SEQUENCE	MEPLKVEKFATAKRGNGLRAVTPLRPGELLFRSDPLAYTVCKGSRGVVCDRCLLGKEKLMRCSQCRVAKYCSAKCQKKAWPDHKRECKCLKSCKPRYPPDSVRLLGRVVFKLMDGAPSESEKLYSFYDLESNINKLTEDKKEGLRQLVMTFQHFMREEIQDASQLPPAFDLFEAFAKVICNSFTICNAEMQEVGVGLYPSISLLNHSCDPNCSIVFNGPHLLLRAVRDIEVGEELTICYLDMLMTSEERRKQLRDQYCFECDCFRCQTQDKDADMLTGDEQVWKEVQESLKKIEELKAHWKWEQVLAMCQAIISSNSERLPDINIYQLKVLDCAMDACINLGLLEEALFYGTRTMEPYRIFFPGSHPVRGVQVMKVGKLQLHQGMFPQAMKNLRLAFDIMRVTHGREHSLIEDLILLLEECDANIRAS
T35792	DRUGINFO	D0X7OH	EPZ028862	Preclinical
T35792	DRUGINFO	DSHE52	EPZ031686	Preclinical
T35792	DRUGINFO	DV74TF	EPZ0330456	Preclinical
T35792	DRUGINFO	DWF98V	GSK2807	Preclinical

T40126	TARGETID	T40126
T40126	UNIPROID	Q9I235_PSEAE
T40126	TARGNAME	Pseudomonas Kynureninase (Pseudo kynU)
T40126	GENENAME	Pseudo kynU
T40126	TARGTYPE	Preclinical
T40126	SYNONYMS	L-kynurenine hydrolase
T40126	FUNCTION	Catalyzes the cleavage of L-kynurenine (L-Kyn) and L-3-hydroxykynurenine (L-3OHKyn) into anthranilic acid (AA) and 3-hydroxyanthranilic acid (3-OHAA), respectively.
T40126	ECNUMBER	EC 3.7.1.3
T40126	SEQUENCE	MTTRDDCLALDAGDPLADLRQLFALPDGVIYLDGNSLGARPRAAVERAAEVVAAEWGEGLIRSWNSADWRGLPERLGDKLAPLIGARAGEVVITDTTSINLFKVLSAALRIQEEDAPGRKVIVSESSNFPTDLYIAEGLTDMLQRGYRLRLVDDPEQLPAAIDADTAVVMLSHVNYKTGYLHDMREVTRLVHENGALAIWDLAHSAGALPLDLHAADADYAIGCTYKYLNGGPGSPAYVWVAPRLRERVWQPLSGWFGHSRQFAMEPRYQPGEGITRFLCGTQPITSLALVECGLDIFARTDMQRLRDKSLALADLFIELVESRCERFGLTLVTPREHARRGSHVSFEHAQGYAIVQALIDRGVIGDYREPGILRFGFTPLYTRFVEVWDAVQALLEILQSEAWKEPRYQVRHKVT
T40126	DRUGINFO	DB1U9N	S-Phenyl-L-cysteine sulfoxide	Preclinical

T51908	TARGETID	T51908
T51908	UNIPROID	CRY2_HUMAN
T51908	TARGNAME	Cryptochrome-2 (CRY2)
T51908	GENENAME	CRY2
T51908	TARGTYPE	Preclinical
T51908	FUNCTION	Transcriptional repressor which forms a core component of the circadian clock. The circadian clock, an internal time-keeping system, regulates various physiological processes through the generation of approximately 24 hour circadian rhythms in gene expression, which are translated into rhythms in metabolism and behavior. It is derived from the Latin roots 'circa' (about) and 'diem' (day) and acts as an important regulator of a wide array of physiological functions including metabolism, sleep, body temperature, blood pressure, endocrine, immune, cardiovascular, and renal function. Consists of two major components: the central clock, residing in the suprachiasmatic nucleus (SCN) of the brain, and the peripheral clocks that are present in nearly every tissue and organ system. Both the central and peripheral clocks can be reset by environmental cues, also known as Zeitgebers (German for 'timegivers'). The predominant Zeitgeber for the central clock is light, which is sensed by retina and signals directly to the SCN. The central clock entrains the peripheral clocks through neuronal and hormonal signals, body temperature and feeding-related cues, aligning all clocks with the external light/dark cycle. Circadian rhythms allow an organism to achieve temporal homeostasis with its environment at the molecular level by regulating gene expression to create a peak of protein expression once every 24 hours to control when a particular physiological process is most active with respect to the solar day. Transcription and translation of core clock components (CLOCK, NPAS2, ARNTL/BMAL1, ARNTL2/BMAL2, PER1, PER2, PER3, CRY1 and CRY2) plays a critical role in rhythm generation, whereas delays imposed by post-translational modifications (PTMs) are important for determining the period (tau) of the rhythms (tau refers to the period of a rhythm and is the length, in time, of one complete cycle). A diurnal rhythm is synchronized with the day/night cycle, while the ultradian and infradian rhythms have a period shorter and longer than 24 hours, respectively. Disruptions in the circadian rhythms contribute to the pathology of cardiovascular diseases, cancer, metabolic syndromes and aging. A transcription/translation feedback loop (TTFL) forms the core of the molecular circadian clock mechanism. Transcription factors, CLOCK or NPAS2 and ARNTL/BMAL1 or ARNTL2/BMAL2, form the positive limb of the feedback loop, act in the form of a heterodimer and activate the transcription of core clock genes and clock-controlled genes (involved in key metabolic processes), harboring E-box elements (5'-CACGTG-3') within their promoters. The core clock genes: PER1/2/3 and CRY1/2 which are transcriptional repressors form the negative limb of the feedback loop and interact with the CLOCK|NPAS2-ARNTL/BMAL1|ARNTL2/BMAL2 heterodimer inhibiting its activity and thereby negatively regulating their own expression. This heterodimer also activates nuclear receptors NR1D1/2 and RORA/B/G, which form a second feedback loop and which activate and repress ARNTL/BMAL1 transcription, respectively. CRY1 and CRY2 have redundant functions but also differential and selective contributions at least in defining the pace of the SCN circadian clock and its circadian transcriptional outputs. Less potent transcriptional repressor in cerebellum and liver than CRY1, though less effective in lengthening the period of the SCN oscillator. Seems to play a critical role in tuning SCN circadian period by opposing the action of CRY1. With CRY1, dispensable for circadian rhythm generation but necessary for the development of intercellular networks for rhythm synchrony. May mediate circadian regulation of cAMP signaling and gluconeogenesis by blocking glucagon-mediated increases in intracellular cAMP concentrations and in CREB1 phosphorylation. Besides its role in the maintenance of the circadian clock, is also involved in the regulation of other processes. Plays a key role in glucose and lipid metabolism modulation, in part, through the transcriptional regulation of genes involved in these pathways, such as LEP or ACSL4. Represses glucocorticoid receptor NR3C1/GR-induced transcriptional activity by binding to glucocorticoid response elements (GREs). Represses the CLOCK-ARNTL/BMAL1 induced transcription of BHLHE40/DEC1. Represses the CLOCK-ARNTL/BMAL1 induced transcription of NAMPT (By similarity). Represses PPARD and its target genes in the skeletal muscle and limits exercise capacity (By similarity). Represses the transcriptional activity of NR1I2 (By similarity).
T51908	SEQUENCE	MAATVATAAAVAPAPAPGTDSASSVHWFRKGLRLHDNPALLAAVRGARCVRCVYILDPWFAASSSVGINRWRFLLQSLEDLDTSLRKLNSRLFVVRGQPADVFPRLFKEWGVTRLTFEYDSEPFGKERDAAIMKMAKEAGVEVVTENSHTLYDLDRIIELNGQKPPLTYKRFQAIISRMELPKKPVGLVTSQQMESCRAEIQENHDETYGVPSLEELGFPTEGLGPAVWQGGETEALARLDKHLERKAWVANYERPRMNANSLLASPTGLSPYLRFGCLSCRLFYYRLWDLYKKVKRNSTPPLSLFGQLLWREFFYTAATNNPRFDRMEGNPICIQIPWDRNPEALAKWAEGKTGFPWIDAIMTQLRQEGWIHHLARHAVACFLTRGDLWVSWESGVRVFDELLLDADFSVNAGSWMWLSCSAFFQQFFHCYCPVGFGRRTDPSGDYIRRYLPKLKAFPSRYIYEPWNAPESIQKAAKCIIGVDYPRPIVNHAETSRLNIERMKQIYQQLSRYRGLCLLASVPSCVEDLSHPVAEPSSSQAGSMSSAGPRPLPSGPASPKRKLEAAEEPPGEELSKRARVAELPTPELPSKDA
T51908	DRUGINFO	D4RGV9	2-Ethoxypropanoic acid	Preclinical
T51908	DRUGINFO	D95KWS	KL001	Preclinical
T51908	DRUGINFO	DG90VQ	SHP656	Preclinical
T51908	DRUGINFO	DOZQ70	TH301	Preclinical

T52036	TARGETID	T52036
T52036	UNIPROID	UBP20_HUMAN
T52036	TARGNAME	Ubiquitin carboxyl-terminal hydrolase 20 (USP20)
T52036	GENENAME	USP20
T52036	TARGTYPE	Preclinical
T52036	SYNONYMS	Deubiquitinating enzyme 20; Ubiquitin thioesterase 20; Ubiquitin-specific-processing protease 20; VHL-interacting deubiquitinating enzyme 2; hVDU2
T52036	FUNCTION	Deubiquitinating enzyme involved in beta-2 adrenergic receptor (ADRB2) recycling. Acts as a regulator of G-protein coupled receptor (GPCR) signaling by mediating the deubiquitination beta-2 adrenergic receptor (ADRB2). Plays a central role in ADRB2 recycling and resensitization after prolonged agonist stimulation by constitutively binding ADRB2, mediating deubiquitination of ADRB2 and inhibiting lysosomal trafficking of ADRB2. Upon dissociation, it is probably transferred to the translocated beta-arrestins, possibly leading to beta-arrestins deubiquitination and disengagement from ADRB2. This suggests the existence of a dynamic exchange between the ADRB2 and beta-arrestins. Deubiquitinates DIO2, thereby regulating thyroid hormone regulation. Deubiquitinates HIF1A, leading to stabilize HIF1A and enhance HIF1A-mediated activity. Mediates deubiquitination of both 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains.
T52036	BIOCLASS	Peptidase
T52036	ECNUMBER	EC 3.4.19.12
T52036	SEQUENCE	MGDSRDLCPHLDSIGEVTKEDLLLKSKGTCQSCGVTGPNLWACLQVACPYVGCGESFADHSTIHAQAKKHNLTVNLTTFRLWCYACEKEVFLEQRLAAPLLGSSSKFSEQDSPPPSHPLKAVPIAVADEGESESEDDDLKPRGLTGMKNLGNSCYMNAALQALSNCPPLTQFFLECGGLVRTDKKPALCKSYQKLVSEVWHKKRPSYVVPTSLSHGIKLVNPMFRGYAQQDTQEFLRCLMDQLHEELKEPVVATVALTEARDSDSSDTDEKREGDRSPSEDEFLSCDSSSDRGEGDGQGRGGGSSQAETELLIPDEAGRAISEKERMKDRKFSWGQQRTNSEQVDEDADVDTAMAALDDQPAEAQPPSPRSSSPCRTPEPDNDAHLRSSSRPCSPVHHHEGHAKLSSSPPRASPVRMAPSYVLKKAQVLSAGSRRRKEQRYRSVISDIFDGSILSLVQCLTCDRVSTTVETFQDLSLPIPGKEDLAKLHSAIYQNVPAKPGACGDSYAAQGWLAFIVEYIRRFVVSCTPSWFWGPVVTLEDCLAAFFAADELKGDNMYSCERCKKLRNGVKYCKVLRLPEILCIHLKRFRHEVMYSFKINSHVSFPLEGLDLRPFLAKECTSQITTYDLLSVICHHGTAGSGHYIAYCQNVINGQWYEFDDQYVTEVHETVVQNAEGYVLFYRKSSEEAMRERQQVVSLAAMREPSLLRFYVSREWLNKFNTFAEPGPITNQTFLCSHGGIPPHKYHYIDDLVVILPQNVWEHLYNRFGGGPAVNHLYVCSICQVEIEALAKRRRIEIDTFIKLNKAFQAEESPGVIYCISMQWFREWEAFVKGKDNEPPGPIDNSRIAQVKGSGHVQLKQGADYGQISEETWTYLNSLYGGGPEIAIRQSVAQPLGPENLHGEQKIEAETRAV
T52036	DRUGINFO	DAD9V4	GSK2643943A	Preclinical

T52349	TARGETID	T52349
T52349	UNIPROID	C3VD18_ENTFC
T52349	TARGNAME	Enterococcus fsrC (Ente-cocc fsrC)
T52349	GENENAME	Ente-cocc fsrC
T52349	TARGTYPE	Preclinical
T52349	SEQUENCE	MILSLLATNVLLVSSFIVFVFLRVTLIKIECKIPLLSLLIVINLCSFAALMLGYSWLIYALTVVVFTGFLLIHKKRFSIFKAIFLSVFTLLMVSFINYTEQTILSVFFQQIYQNKLLWIASNVLLLLINIWIALKIPNSVFLRLNRVLENSRIFFGCLLLLLILLLLFVFLISPEISPDFMRGFVTVNSSKLELLISVGLFLILIGLVIEAYLEEQRINTQLLNNLTIYTEKIESINEELAMFRHDYKNLLYSLQIAISYEDILEIKRIYEETIAPTKKIIDNEEFELMKLNRLKNMELKALISMKINTAKQAKLKVIVDVPEVFILDTSIDLVVVIRLLAILLDNAIENSAKSELKMFAISIFNKNETQEFVITNSVQAEFDFKVMKKTKFSSKSNPEEHGWGLLYVKEIVDFSDQFDLQTSFNEGAVTQHLIIEKNHNSKKVVNE
T52349	DRUGINFO	DNE4B9	ZBzl-YAA5911	Preclinical

T52873	TARGETID	T52873
T52873	TARGNAME	3-oxo-dodecanoyl-homoserine lactone (C12)
T52873	TARGTYPE	Preclinical
T52873	DRUGINFO	D7TIB0	RS2-1G9	Preclinical

T52910	TARGETID	T52910
T52910	UNIPROID	UBP30_HUMAN
T52910	TARGNAME	Ubiquitin carboxyl-terminal hydrolase 30 (USP30)
T52910	GENENAME	USP30
T52910	TARGTYPE	Preclinical
T52910	SYNONYMS	Deubiquitinating enzyme 30; Ubiquitin thioesterase 30; Ubiquitin-specific-processing protease 30; Ub-specific protease 30
T52910	FUNCTION	Deubiquitinating enzyme tethered to the mitochondrial outer membrane that acts as a key inhibitor of mitophagy by counteracting the action of parkin (PRKN): hydrolyzes ubiquitin attached by parkin on target proteins, such as RHOT1/MIRO1 and TOMM20, thereby blocking parkin's ability to drive mitophagy. Preferentially cleaves 'Lys-6'- and 'Lys-11'-linked polyubiquitin chains, 2 types of linkage that participate in mitophagic signaling. Does not cleave efficiently polyubiquitin phosphorylated at 'Ser-65'. Acts as negative regulator of mitochondrial fusion by mediating deubiquitination of MFN1 and MFN2 (By similarity).
T52910	BIOCLASS	Peptidase
T52910	ECNUMBER	EC 3.4.19.12
T52910	SEQUENCE	MLSSRAEAAMTAADRAIQRFLRTGAAVRYKVMKNWGVIGGIAAALAAGIYVIWGPITERKKRRKGLVPGLVNLGNTCFMNSLLQGLSACPAFIRWLEEFTSQYSRDQKEPPSHQYLSLTLLHLLKALSCQEVTDDEVLDASCLLDVLRMYRWQISSFEEQDAHELFHVITSSLEDERDRQPRVTHLFDVHSLEQQSEITPKQITCRTRGSPHPTSNHWKSQHPFHGRLTSNMVCKHCEHQSPVRFDTFDSLSLSIPAATWGHPLTLDHCLHHFISSESVRDVVCDNCTKIEAKGTLNGEKVEHQRTTFVKQLKLGKLPQCLCIHLQRLSWSSHGTPLKRHEHVQFNEFLMMDIYKYHLLGHKPSQHNPKLNKNPGPTLELQDGPGAPTPVLNQPGAPKTQIFMNGACSPSLLPTLSAPMPFPLPVVPDYSSSTYLFRLMAVVVHHGDMHSGHFVTYRRSPPSARNPLSTSNQWLWVSDDTVRKASLQEVLSSSAYLLFYERVLSRMQHQSQECKSEE
T52910	DRUGINFO	DAQ4G0	NC043	Preclinical

T56824	TARGETID	T56824
T56824	UNIPROID	TCPN_VIBCH
T56824	TARGNAME	Vibrio TCP pilus virulence regulatory protein (Vibrio tcpN)
T56824	GENENAME	Vibrio tcpN
T56824	TARGTYPE	Preclinical
T56824	FUNCTION	Probable regulatory protein for the tcp operon.
T56824	SEQUENCE	MIGKKSFQTNVYRMSKFDTYIFNNLYINDYKMFWIDSGIAKLIDKNCLVSYEINSSSIILLKKNSIQRFSLTSLSDENINVSVITISDSFIRSLKSYILGDLMIRNLYSENKDLLLWNCEHNDIAVLSEVVNGFREINYSDEFLKVFFSGFFSKVEKKYNSIFITDDLDAMEKISCLVKSDITRNWRWADICGELRTNRMILKKELESRGVKFRELINSIRISYSISLMKTGEFKIKQIAYQSGFASVSYFSTVFKSTMNVAPSEYLFMLTGVAEK
T56824	DRUGINFO	DL74RO	Virstatin	Preclinical

T65978	TARGETID	T65978
T65978	UNIPROID	MVFR_PSEAE
T65978	TARGNAME	Pseudomonas Multiple virulence factor regulator MvfR (Pseudo MvfR)
T65978	GENENAME	Pseudo MvfR
T65978	TARGTYPE	Preclinical
T65978	SYNONYMS	Transcriptional regulator MvfR
T65978	FUNCTION	Transcription regulator that plays a critical role in virulence by positively regulating the expression of multiple quorum sensing (QS)-regulated virulence factors, genes involved in protein secretion, translation, response to oxidative stress and the phnAB operon. At the stationary phase, negatively autoregulates its function through cleavage and translocation to the extracellular space.
T65978	SEQUENCE	MPIHNLNHVNMFLQVIASGSISSAARILRKSHTAVSSAVSNLEIDLCVELVRRDGYKVEPTEQALRLIPYMRSLLNYQQLIGDIAFNLNKGPRNLRVLLDTAIPPSFCDTVSSVLLDDFNMVSLIRTSPADSLATIKQDNAEIDIAITIDEELKISRFNQCVLGYTKAFVVAHPQHPLCNASLHSIASLANYRQISLGSRSGQHSNLLRPVSDKVLFVENFDDMLRLVEAGVGWGIAPHYFVEERLRNGTLAVLSELYEPGGIDTKVYCYYNTALESERSFLRFLESARQRLRELGRQRFDDAPAWQPSIVETAQRRSGPKALAYRQRAAPE
T65978	DRUGINFO	DS58AE	M64	Preclinical

T68490	TARGETID	T68490
T68490	UNIPROID	KMT5C_HUMAN
T68490	TARGNAME	Histone-lysine N-methyltransferase KMT5C (KMT5C)
T68490	GENENAME	KMT5C
T68490	TARGTYPE	Preclinical
T68490	SYNONYMS	Lysine N-methyltransferase 5C; Lysine-specific methyltransferase 5C; Suppressor of variegation 4-20 homolog 2; Su(var)4-20 homolog 2; Suv4-20h2; [histone H4]-N-methyl-L-lysine20 N-methyltransferase KMT5B; [histone H4]-lysine20 N-methyltransferase KMT5B
T68490	FUNCTION	Histone methyltransferase that specifically methylates monomethylated 'Lys-20' (H4K20me1) and dimethylated 'Lys-20' (H4K20me2) of histone H4 to produce respectively dimethylated 'Lys-20' (H4K20me2) and trimethylated 'Lys-20' (H4K20me3) and thus regulates transcription and maintenance of genome integrity. In vitro also methylates unmodified 'Lys-20' (H4K20me0) of histone H4 and nucleosomes. H4 'Lys-20' trimethylation represents a specific tag for epigenetic transcriptional repression. Mainly functions in pericentric heterochromatin regions, thereby playing a central role in the establishment of constitutive heterochromatin in these regions. KMT5C is targeted to histone H3 via its interaction with RB1 family proteins (RB1, RBL1 and RBL2) (By similarity). Facilitates TP53BP1 foci formation upon DNA damage and proficient non-homologous end-joining (NHEJ)-directed DNA repair by catalyzing the di- and trimethylation of 'Lys-20' of histone H4. May play a role in class switch reconbination by catalyzing the di- and trimethylation of 'Lys-20' of histone H4 (By similarity).
T68490	ECNUMBER	EC 2.1.1.361
T68490	SEQUENCE	MGPDRVTARELCENDDLATSLVLDPYLGFRTHKMNVSPVPPLRRQQHLRSALETFLRQRDLEAAYRALTLGGWTARYFQSRGPRQEAALKTHVYRYLRAFLPESGFTILPCTRYSMETNGAKIVSTRAWKKNEKLELLVGCIAELREADEGLLRAGENDFSIMYSTRKRSAQLWLGPAAFINHDCKPNCKFVPADGNAACVKVLRDIEPGDEVTCFYGEGFFGEKNEHCECHTCERKGEGAFRTRPREPALPPRPLDKYQLRETKRRLQQGLDSGSRQGLLGPRACVHPSPLRRDPFCAACQPLRLPACSARPDTSPLWLQWLPQPQPRVRPRKRRRPRPRRAPVLSTHHAARVSLHRWGGCGPHCRLRGEALVALGQPPHARWAPQQDWHWARRYGLPYVVRVDLRRLAPAPPATPAPAGTPGPILIPKQALAFAPFSPPKRLRLVVSHGSIDLDVGGEEL
T68490	DRUGINFO	D0P2EH	A-196	Preclinical

T72915	TARGETID	T72915
T72915	UNIPROID	KC1A_HUMAN; KC1D_HUMAN; KC1E_HUMAN; KC1G1_HUMAN; KC1G2_HUMAN; KC1G3_HUMAN
T72915	TARGNAME	Casein kinase 1 (CK1)
T72915	TARGTYPE	Preclinical
T72915	DRUGINFO	DLKQ59	LH846	Preclinical
T72915	DRUGINFO	DONA19	CKI-7	Preclinical

T73582	TARGETID	T73582
T73582	UNIPROID	UBP10_HUMAN
T73582	TARGNAME	Ubiquitin carboxyl-terminal hydrolase 10 (USP10)
T73582	GENENAME	USP10
T73582	TARGTYPE	Preclinical
T73582	SYNONYMS	Deubiquitinating enzyme 10; Ubiquitin thioesterase 10; Ubiquitin-specific-processing protease 10
T73582	FUNCTION	Hydrolase that can remove conjugated ubiquitin from target proteins such as p53/TP53, BECN1, SNX3 and CFTR. Acts as an essential regulator of p53/TP53 stability: in unstressed cells, specifically deubiquitinates p53/TP53 in the cytoplasm, leading to counteract MDM2 action and stabilize p53/TP53. Following DNA damage, translocates to the nucleus and deubiquitinates p53/TP53, leading to regulate the p53/TP53-dependent DNA damage response. Component of a regulatory loop that controls autophagy and p53/TP53 levels: mediates deubiquitination of BECN1, a key regulator of autophagy, leading to stabilize the PIK3C3/VPS34-containing complexes. In turn, PIK3C3/VPS34-containing complexes regulate USP10 stability, suggesting the existence of a regulatory system by which PIK3C3/VPS34-containing complexes regulate p53/TP53 protein levels via USP10 and USP13. Does not deubiquitinate MDM2. Deubiquitinates CFTR in early endosomes, enhancing its endocytic recycling. Involved in a TANK-dependent negative feedback response to attenuate NF-kappaB activation via deubiquitinating IKBKG or TRAF6 in response to interleukin-1-beta (IL1B) stimulation or upon DNA damage. Deubiquitinates TBX21 leading to its stabilization.
T73582	BIOCLASS	Peptidase
T73582	ECNUMBER	EC 3.4.19.12
T73582	SEQUENCE	MALHSPQYIFGDFSPDEFNQFFVTPRSSVELPPYSGTVLCGTQAVDKLPDGQEYQRIEFGVDEVIEPSDTLPRTPSYSISSTLNPQAPEFILGCTASKITPDGITKEASYGSIDCQYPGSALALDGSSNVEAEVLENDGVSGGLGQRERKKKKKRPPGYYSYLKDGGDDSISTEALVNGHANSAVPNSVSAEDAEFMGDMPPSVTPRTCNSPQNSTDSVSDIVPDSPFPGALGSDTRTAGQPEGGPGADFGQSCFPAEAGRDTLSRTAGAQPCVGTDTTENLGVANGQILESSGEGTATNGVELHTTESIDLDPTKPESASPPADGTGSASGTLPVSQPKSWASLFHDSKPSSSSPVAYVETKYSPPAISPLVSEKQVEVKEGLVPVSEDPVAIKIAELLENVTLIHKPVSLQPRGLINKGNWCYINATLQALVACPPMYHLMKFIPLYSKVQRPCTSTPMIDSFVRLMNEFTNMPVPPKPRQALGDKIVRDIRPGAAFEPTYIYRLLTVNKSSLSEKGRQEDAEEYLGFILNGLHEEMLNLKKLLSPSNEKLTISNGPKNHSVNEEEQEEQGEGSEDEWEQVGPRNKTSVTRQADFVQTPITGIFGGHIRSVVYQQSSKESATLQPFFTLQLDIQSDKIRTVQDALESLVARESVQGYTTKTKQEVEISRRVTLEKLPPVLVLHLKRFVYEKTGGCQKLIKNIEYPVDLEISKELLSPGVKNKNFKCHRTYRLFAVVYHHGNSATGGHYTTDVFQIGLNGWLRIDDQTVKVINQYQVVKPTAERTAYLLYYRRVDLL
T73582	DRUGINFO	DB0V3R	Spautin 1	Preclinical

T75819	TARGETID	T75819
T75819	UNIPROID	FBX3_HUMAN
T75819	TARGNAME	F-box only protein 3 (FBXO3)
T75819	GENENAME	FBXO3
T75819	TARGTYPE	Preclinical
T75819	FUNCTION	Substrate recognition component of the SCF (SKP1-CUL1-F-box protein)-type E3 ubiquitin ligase complex. Mediates the ubiquitination of HIPK2 and probably that of EP300, leading to rapid degradation by the proteasome. In the presence of PML, HIPK2 ubiquitination still occurs, but degradation is prevented. PML, HIPK2 and FBXO3 may act synergically to activate p53/TP53-dependent transactivation.
T75819	SEQUENCE	MAAMETETAPLTLESLPTDPLLLILSFLDYRDLINCCYVSRRLSQLSSHDPLWRRHCKKYWLISEEEKTQKNQCWKSLFIDTYSDVGRYIDHYAAIKKAWDDLKKYLEPRCPRMVLSLKEGAREEDLDAVEAQIGCKLPDDYRCSYRIHNGQKLVVPGLLGSMALSNHYRSEDLLDVDTAAGGFQQRQGLKYCLPLTFCIHTGLSQYIAVEAAEGRNKNEVFYQCPDQMARNPAAIDMFIIGATFTDWFTSYVKNVVSGGFPIIRDQIFRYVHDPECVATTGDITVSVSTSFLPELSSVHPPHYFFTYRIRIEMSKDALPEKACQLDSRYWRITNAKGDVEEVQGPGVVGEFPIISPGRVYEYTSCTTFSTTSGYMEGYYTFHFLYFKDKIFNVAIPRFHMACPTFRVSIARLEMGPDEYEEMEEEEEEEEEEDEDDDSADMDESDEDDEEERRRRVFDVPIRRRRCSRLF
T75819	DRUGINFO	DA5RC6	BC-1215	Preclinical

T79184	TARGETID	T79184
T79184	UNIPROID	AGRA_STAAU
T79184	TARGNAME	Staphylococcus Accessory gene regulator protein A (Stap-coc agrA)
T79184	GENENAME	Stap-coc agrA
T79184	TARGTYPE	Preclinical
T79184	FUNCTION	Required for high-level post-exponential phase expression of a series of secreted proteins.
T79184	SEQUENCE	MKIFICEDDPKQRENMVTIIKNYIMIEEKPMEIALATDNPYEVLEQAKNMNDIGCYFLDIQLSTDINGIKLGSEIRKHDPVGNIIFVTSHSELTYLTFVYKVAAMDFIFKDDPAELRTRIIDCLETAHTRLQLLSKDNSVETIELKRGSNSVYVQYDDIMFFESSTKSHRLIAHLDNRQIEFYGNLKELSQLDDRFFRCHNSFVVNRHNIESIDSKERIVYFKNKEHCYASVRNVKKI
T79184	DRUGINFO	DS19UZ	Savirin	Preclinical

T79401	TARGETID	T79401
T79401	UNIPROID	POLG_DEN1W (281-775)
T79401	TARGNAME	Dengue virus Envelope (DENV E)
T79401	GENENAME	DENV E
T79401	TARGTYPE	Preclinical
T79401	DRUGINFO	DI8ZG7	VIS513	Preclinical

T85241	TARGETID	T85241
T85241	UNIPROID	CDC20_HUMAN
T85241	TARGNAME	Cell division cycle protein 20 homolog (CDC20)
T85241	GENENAME	CDC20
T85241	TARGTYPE	Preclinical
T85241	SYNONYMS	p55CDC
T85241	FUNCTION	Required for full ubiquitin ligase activity of the anaphase promoting complex/cyclosome (APC/C) and may confer substrate specificity upon the complex. Is regulated by MAD2L1: in metaphase the MAD2L1-CDC20-APC/C ternary complex is inactive and in anaphase the CDC20-APC/C binary complex is active in degrading substrates. The CDC20-APC/C complex positively regulates the formation of synaptic vesicle clustering at active zone to the presynaptic membrane in postmitotic neurons. CDC20-APC/C-induced degradation of NEUROD2 induces presynaptic differentiation.
T85241	SEQUENCE	MAQFAFESDLHSLLQLDAPIPNAPPARWQRKAKEAAGPAPSPMRAANRSHSAGRTPGRTPGKSSSKVQTTPSKPGGDRYIPHRSAAQMEVASFLLSKENQPENSQTPTKKEHQKAWALNLNGFDVEEAKILRLSGKPQNAPEGYQNRLKVLYSQKATPGSSRKTCRYIPSLPDRILDAPEIRNDYYLNLVDWSSGNVLAVALDNSVYLWSASSGDILQLLQMEQPGEYISSVAWIKEGNYLAVGTSSAEVQLWDVQQQKRLRNMTSHSARVGSLSWNSYILSSGSRSGHIHHHDVRVAEHHVATLSGHSQEVCGLRWAPDGRHLASGGNDNLVNVWPSAPGEGGWVPLQTFTQHQGAVKAVAWCPWQSNVLATGGGTSDRHIRIWNVCSGACLSAVDAHSQVCSILWSPHYKELISGHGFAQNQLVIWKYPTMAKVAELKGHTSRVLSLTMSPDGATVASAAADETLRLWRCFELDPARRREREKASAAKSSLIHQGIR
T85241	DRUGINFO	DSU7K2	Tosyl-l-arginine methyl ester	Preclinical

T89573	TARGETID	T89573
T89573	UNIPROID	SRTA_STAA8
T89573	TARGNAME	Staphylococcus Sortase A (Stap-coc srtA)
T89573	GENENAME	Stap-coc srtA
T89573	TARGTYPE	Preclinical
T89573	SYNONYMS	Surface protein sorting A
T89573	FUNCTION	Transpeptidase that anchors surface proteins to the cell wall. Recognizes and modifies its substrate by proteolytic cleavage of a C-terminal sorting signal. Following cleavage, a covalent intermediate is formed via a thioester bond between the sortase and its substrate, which is then transferred and covalently attached to the cell wall. This sortase recognizes a Leu-Pro-x-Thr-Gly (LPXTG) motif, which is cleaved by the sortase between the threonine and glycine residues. Utilizes lipid II as the peptidoglycan substrate for the sorting reaction. Responsible for the display of important virulence factors. Important for interactions with the host and host colonization during infection.
T89573	ECNUMBER	EC 3.4.22.70
T89573	SEQUENCE	MKKWTNRLMTIAGVVLILVAAYLFAKPHIDNYLHDKDKDEKIEQYDKNVKEQASKDKKQQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATPEQLNRGVSFAEENESLDDQNISIAGHTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRDVKPTDVGVLDEQKGKDKQLTLITCDDYNEKTGVWEKRKIFVATEVK
T89573	DRUGINFO	D8WBZ2	PMID25197057-Compound6e	Preclinical

T90672	TARGETID	T90672
T90672	UNIPROID	LGR4_HUMAN
T90672	TARGNAME	G-protein coupled receptor 48 (LGR4)
T90672	GENENAME	LGR4
T90672	TARGTYPE	Preclinical
T90672	SYNONYMS	G-protein coupled receptor 48
T90672	FUNCTION	Receptor for R-spondins that potentiates the canonical Wnt signaling pathway and is involved in the formation of various organs. Upon binding to R-spondins (RSPO1, RSPO2, RSPO3 or RSPO4), associates with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signaling pathway to increase expression of target genes. In contrast to classical G-protein coupled receptors, does not activate heterotrimeric G-proteins to transduce the signal. Its function as activator of the Wnt signaling pathway is required for the development of various organs, including liver, kidney, intestine, bone, reproductive tract and eye. May also act as a receptor for norrin (NDP), such results however require additional confirmation in vivo. Required during spermatogenesis to activate the Wnt signaling pathway in peritubular myoid cells. Required for the maintenance of intestinal stem cells and Paneth cell differentiation in postnatal intestinal crypts. Acts as a regulator of bone formation and remodeling. Involved in kidney development; required for maintaining the ureteric bud in an undifferentiated state. Involved in the development of the anterior segment of the eye. Required during erythropoiesis. Also acts as a negative regulator of innate immunity by inhibiting TLR2/TLR4 associated pattern-recognition and proinflammatory cytokine production. Plays an important role in regulating the circadian rhythms of plasma lipids, partially through regulating the rhythmic expression of MTTP (By similarity).
T90672	BIOCLASS	G-protein coupled receptor 1 family
T90672	SEQUENCE	MPGPLGLLCFLALGLLGSAGPSGAAPPLCAAPCSCDGDRRVDCSGKGLTAVPEGLSAFTQALDISMNNITQLPEDAFKNFPFLEELQLAGNDLSFIHPKALSGLKELKVLTLQNNQLKTVPSEAIRGLSALQSLRLDANHITSVPEDSFEGLVQLRHLWLDDNSLTEVPVHPLSNLPTLQALTLALNKISSIPDFAFTNLSSLVVLHLHNNKIRSLSQHCFDGLDNLETLDLNYNNLGEFPQAIKALPSLKELGFHSNSISVIPDGAFDGNPLLRTIHLYDNPLSFVGNSAFHNLSDLHSLVIRGASMVQQFPNLTGTVHLESLTLTGTKISSIPNNLCQEQKMLRTLDLSYNNIRDLPSFNGCHALEEISLQRNQIYQIKEGTFQGLISLRILDLSRNLIHEIHSRAFATLGPITNLDVSFNELTSFPTEGLNGLNQLKLVGNFKLKEALAAKDFVNLRSLSVPYAYQCCAFWGCDSYANLNTEDNSLQDHSVAQEKGTADAANVTSTLENEEHSQIIIHCTPSTGAFKPCEYLLGSWMIRLTVWFIFLVALFFNLLVILTTFASCTSLPSSKLFIGLISVSNLFMGIYTGILTFLDAVSWGRFAEFGIWWETGSGCKVAGFLAVFSSESAIFLLMLATVERSLSAKDIMKNGKSNHLKQFRVAALLAFLGATVAGCFPLFHRGEYSASPLCLPFPTGETPSLGFTVTLVLLNSLAFLLMAVIYTKLYCNLEKEDLSENSQSSMIKHVAWLIFTNCIFFCPVAFFSFAPLITAISISPEIMKSVTLIFFPLPACLNPVLYVFFNPKFKEDWKLLKRRVTKKSGSVSVSISSQGGCLEQDFYYDCGMYSHLQGNLTVCDCCESFLLTKPVSCKHLIKSHSCPALAVASCQRPEGYWSDCGTQSAHSDYADEEDSFVSDSSDQVQACGRACFYQSRGFPLVRYAYNLPRVKD
T90672	DRUGINFO	D2ZI3H	BNC-102	Preclinical

T95860	TARGETID	T95860
T95860	UNIPROID	FOXO4_HUMAN-P53_HUMAN
T95860	TARGNAME	FOXO4-P53 interaction (FOXO4-P53 PPI)
T95860	GENENAME	FOXO4-TP53
T95860	TARGTYPE	Preclinical
T95860	DRUGINFO	DRO7H6	FOXO4-DRI	Preclinical

T96321	TARGETID	T96321
T96321	TARGNAME	Bacillus poly-gamma-d-glutamic acid (Bacillus PGA)
T96321	TARGTYPE	Preclinical
T96321	DRUGINFO	D23FRK	F26G3	Preclinical
T96321	DRUGINFO	DNE73Q	F26G4	Preclinical
T96321	DRUGINFO	DX1U8I	F24F2	Preclinical

T63234	TARGETID	T63234
T63234	UNIPROID	QCRB_MYCTU
T63234	TARGNAME	Cytochrome bc1 complex cytochrome b subunit (qcrB)
T63234	GENENAME	qcrB
T63234	TARGTYPE	Preclinical
T63234	SYNONYMS	Cytochrome bc1 reductase complex subunit QcrB; Ubiquinol--cytochrome c reductase cytochrome b subunit
T63234	FUNCTION	Cytochrome b subunit of the cytochrome bc1 complex, an essential component of the respiratory electron transport chain required for ATP synthesis. The bc1 complex catalyzes the oxidation of ubiquinol and the reduction of cytochrome c in the respiratory chain. The bc1 complex operates through a Q-cycle mechanism that couples electron transfer to generation of the proton gradient that drives ATP synthesis. The cytochrome b subunit contains two ubiquinol reactive sites: the oxidation (QP) site and the reduction (QN) site. {ECO:0000305, ECO:0000305|PubMed:23913123, ECO:0000305|PubMed:26158909}.
T63234	PDBSTRUC	7E1V;7E1W;7E1X
T63234	BIOCLASS	Cytochrome b family
T63234	ECNUMBER	EC 7.1.1.8
T63234	SEQUENCE	MSPKLSPPNIGEVLARQAEDIDTRYHPSAALRRQLNKVFPTHWSFLLGEIALYSFVVLLITGVYLTLFFDPSMVDVTYNGVYQPLRGVEMSRAYQSALDISFEVRGGLFVRQIHHWAALMFAAAIMVHLARIFFTGAFRRPRETNWVIGSLLLILAMFEGYFGYSLPDDLLSGLGLRAALSSITLGMPVIGTWLHWALFGGDFPGTILIPRLYALHILLLPGIILALIGLHLALVWFQKHTQFPGPGRTEHNVVGVRVMPVFAFKSGAFFAAIVGVLGLMGGLLQINPIWNLGPYKPSQVSAGSQPDFYMMWTEGLARIWPPWEFYFWHHTIPAPVWVAVIMGLVFVLLPAYPFLEKRFTGDYAHHNLLQRPRDVPVRTAIGAMAIAFYMVLTLAAMNDIIALKFHISLNATTWIGRIGMVILPPFVYFITYRWCIGLQRSDRSVLEHGVETGIIKRLPHGAYIELHQPLGPVDEHGHPIPLQYQGAPLPKRMNKLGSAGSPGSGSFLFADSAAEDAALREAGHAAEQRALAALREHQDSIMGSPDGEH
T63234	DRUGINFO	D5Q4NY	TB47	Preclinical

T81850	TARGETID	T81850
T81850	FORMERID	TTDC00106
T81850	UNIPROID	FDFT_HUMAN
T81850	TARGNAME	Squalene synthetase (FDFT1)
T81850	GENENAME	FDFT1
T81850	TARGTYPE	Discontinued
T81850	SYNONYMS	Squalene synthase; SS; SQS; Farnesyl-diphosphate farnesyltransferase; FPP:FPP farnesyltransferase
T81850	FUNCTION	Participates in the isoprenoid biosynthetic pathway, catalyzing a two-step reaction in which two identical molecules of farnesyl pyrophosphate (FPP) are converted into squalene, with the consumption of NADPH.
T81850	PDBSTRUC	3WSA; 3WEK; 3WEJ; 3WEI; 3WEH
T81850	BIOCLASS	Alkyl aryl transferase
T81850	ECNUMBER	EC 2.5.1.21
T81850	SEQUENCE	MEFVKCLGHPEEFYNLVRFRIGGKRKVMPKMDQDSLSSSLKTCYKYLNQTSRSFAAVIQALDGEMRNAVCIFYLVLRALDTLEDDMTISVEKKVPLLHNFHSFLYQPDWRFMESKEKDRQVLEDFPTISLEFRNLAEKYQTVIADICRRMGIGMAEFLDKHVTSEQEWDKYCHYVAGLVGIGLSRLFSASEFEDPLVGEDTERANSMGLFLQKTNIIRDYLEDQQGGREFWPQEVWSRYVKKLGDFAKPENIDLAVQCLNELITNALHHIPDVITYLSRLRNQSVFNFCAIPQVMAIATLAACYNNQQVFKGAVKIRKGQAVTLMMDATNMPAVKAIIYQYMEEIYHRIPDSDPSSSKTRQIISTIRTQNLPNCQLISRSHYSPIYLSFVMLLAALSWQYLTTLSQVTEDYVQTGEH
T81850	DRUGINFO	D02FXU	Lapaquistat acetate	Discontinued in Phase 3
T81850	DRUGINFO	D0N5HO	SQ-32709	Discontinued in Phase 2
T81850	DRUGINFO	D0W1MX	BMS-187745	Discontinued in Phase 2
T81850	DRUGINFO	D04KDA	A-87049	Terminated
T81850	DRUGINFO	D08ALQ	RPR-101821	Terminated
T81850	DRUGINFO	D0RU3M	SQ-34919	Terminated
T81850	DRUGINFO	D0O1AV	Squalestatin 1	Terminated
T81850	DRUGINFO	D00CEN	L-735021	Investigative
T81850	DRUGINFO	D00KMC	PMID19191557C32	Investigative
T81850	DRUGINFO	D00OPO	PMID9871507C14	Investigative
T81850	DRUGINFO	D00QFL	PMID19456099C13	Investigative
T81850	DRUGINFO	D00YIS	PMID19191557C14	Investigative
T81850	DRUGINFO	D01UKV	3-[1'-{4'-(Benzyloxy)-phenyl}]-quinuclidine-2-ene	Investigative
T81850	DRUGINFO	D02VUM	L-731120	Investigative
T81850	DRUGINFO	D03CUH	PMID7966163C6c	Investigative
T81850	DRUGINFO	D03DCE	BPH-830	Investigative
T81850	DRUGINFO	D04AAT	PMID18754614C7	Investigative
T81850	DRUGINFO	D04DZS	PMID8576905C4	Investigative
T81850	DRUGINFO	D04GSN	Zaragozic Acid C	Investigative
T81850	DRUGINFO	D05OHM	PMID9216829C5j	Investigative
T81850	DRUGINFO	D05URH	Zaragozic Acid D	Investigative
T81850	DRUGINFO	D06AJN	PMID7629799C6	Investigative
T81850	DRUGINFO	D06MMN	PMID7966163C4e	Investigative
T81850	DRUGINFO	D06PMR	PMID18754614C18	Investigative
T81850	DRUGINFO	D06RCI	L-731128	Investigative
T81850	DRUGINFO	D06VOJ	J-104118	Investigative
T81850	DRUGINFO	D07ABI	(Z)-3-[2-(9H-fluoren-2-yloxy)ethylidene]-quinuclidine hydrochloride 31	Investigative
T81850	DRUGINFO	D07ICD	PMID12238936C3a	Investigative
T81850	DRUGINFO	D07JLS	E5700	Investigative
T81850	DRUGINFO	D07KJI	PMID7966163C3f	Investigative
T81850	DRUGINFO	D09ATQ	PMID19191557C19	Investigative
T81850	DRUGINFO	D09HKR	PMID20299227C12	Investigative
T81850	DRUGINFO	D09IQG	PMID7966163C6g	Investigative
T81850	DRUGINFO	D09TKC	PMID18754614C8	Investigative
T81850	DRUGINFO	D0A7FI	PMID18754614C19	Investigative
T81850	DRUGINFO	D0AP5M	PMID19191557C3	Investigative
T81850	DRUGINFO	D0B9EV	PMID19456099C15	Investigative
T81850	DRUGINFO	D0D7IQ	PMID18754614C4	Investigative
T81850	DRUGINFO	D0E1BR	PMID19191557C35	Investigative
T81850	DRUGINFO	D0E9TE	PMID22464687C15a	Investigative
T81850	DRUGINFO	D0G4ZT	CP-294838	Investigative
T81850	DRUGINFO	D0G9LW	PMID19191557C21	Investigative
T81850	DRUGINFO	D0I3TX	J-104123	Investigative
T81850	DRUGINFO	D0K1QV	2-[4-(2-Thienyl)phenyl]-4-methylmorpholin-2-ol	Investigative
T81850	DRUGINFO	D0K7GL	PMID7473541C19	Investigative
T81850	DRUGINFO	D0KJ7C	PMID7629799C2e	Investigative
T81850	DRUGINFO	D0L1ND	PMID8709131C2a (+)	Investigative
T81850	DRUGINFO	D0LT7Y	PMID7473541C11	Investigative
T81850	DRUGINFO	D0M0HE	YM-75440	Investigative
T81850	DRUGINFO	D0M1QJ	PMID18754614C10	Investigative
T81850	DRUGINFO	D0MA8Q	PMID8709131C17	Investigative
T81850	DRUGINFO	D0MM5G	PMID7629799C2d	Investigative
T81850	DRUGINFO	D0N4BQ	PMID8709131C4	Investigative
T81850	DRUGINFO	D0NL2L	3-[7'-(Methoxy)-napht-2'-yl]-quinuclidine-2-ene	Investigative
T81850	DRUGINFO	D0OF1X	PMID8709131C15	Investigative
T81850	DRUGINFO	D0OI4E	ZARAGOZIC ACID B	Investigative
T81850	DRUGINFO	D0PP5M	BPH-652	Investigative
T81850	DRUGINFO	D0Q1XK	PMID18754614C9	Investigative
T81850	DRUGINFO	D0Q3DY	PMID12238936C3f	Investigative
T81850	DRUGINFO	D0R8NC	PMID7473541C20	Investigative
T81850	DRUGINFO	D0RN8T	PMID20299227C20	Investigative
T81850	DRUGINFO	D0S4LW	PMID9216829C5m	Investigative
T81850	DRUGINFO	D0S4UA	1-allyl-2-[3-(isopropylamino)propoxy]-9H-xanthen-9-one	Investigative
T81850	DRUGINFO	D0SC4X	Zaragozic Acid D2	Investigative
T81850	DRUGINFO	D0T2DP	PMID8496919C7	Investigative
T81850	DRUGINFO	D0U0NT	ER-119884	Investigative
T81850	DRUGINFO	D0U9GN	PMID18754614C17	Investigative
T81850	DRUGINFO	D0V4FC	PMID7650673C4q	Investigative
T81850	DRUGINFO	D0WG7H	PMID19191557C8	Investigative
T81850	DRUGINFO	D0X4OP	1-allyl-2-[3-(isopropylamino)propoxy]-9H-carbazole	Investigative
T81850	DRUGINFO	D0XN1T	PMID8709131C23	Investigative
T81850	DRUGINFO	D0Z5BQ	PMID17709461C4g	Investigative
T81850	DRUGINFO	D0ZD1B	PMID7473541C21	Investigative
T81850	DRUGINFO	D0ZT0F	PMID7966163C6d	Investigative

T20331	TARGETID	T20331
T20331	FORMERID	TTDC00089
T20331	UNIPROID	NPY5R_HUMAN
T20331	TARGNAME	Neuropeptide Y receptor type 5 (NPY5R)
T20331	GENENAME	NPY5R
T20331	TARGTYPE	Discontinued
T20331	SYNONYMS	Y5 receptor; Neuropeptide Y receptor Y5; Neuropeptide Y (NPY) Y(5) receptor; NPYY5; NPY5R; NPY5-R; NPY-Y5 receptor
T20331	FUNCTION	Receptor for neuropeptide Y and peptide YY. The activity of this receptor is mediated by G proteins that inhibit adenylate cyclase activity. Seems to be associated with food intake. Could be involved in feeding disorders.
T20331	PDBSTRUC	2HE6
T20331	BIOCLASS	GPCR rhodopsin
T20331	SEQUENCE	MDLELDEYYNKTLATENNTAATRNSDFPVWDDYKSSVDDLQYFLIGLYTFVSLLGFMGNLLILMALMKKRNQKTTVNFLIGNLAFSDILVVLFCSPFTLTSVLLDQWMFGKVMCHIMPFLQCVSVLVSTLILISIAIVRYHMIKHPISNNLTANHGYFLIATVWTLGFAICSPLPVFHSLVELQETFGSALLSSRYLCVESWPSDSYRIAFTISLLLVQYILPLVCLTVSHTSVCRSISCGLSNKENRLEENEMINLTLHPSKKSGPQVKLSGSHKWSYSFIKKHRRRYSKKTACVLPAPERPSQENHSRILPENFGSVRSQLSSSSKFIPGVPTCFEIKPEENSDVHELRVKRSVTRIKKRSRSVFYRLTILILVFAVSWMPLHLFHVVTDFNDNLISNRHFKLVYCICHLLGMMSCCLNPILYGFLNNGIKADLVSLIHCLHM
T20331	DRUGINFO	D0W7UO	CGP71683A	Discontinued in Phase 3
T20331	DRUGINFO	D0K4NZ	Velneperit	Discontinued in Phase 2
T20331	DRUGINFO	D0E2KT	S-234462	Discontinued in Phase 1
T20331	DRUGINFO	D0MV3Q	Axovan-3	Discontinued in Phase 1
T20331	DRUGINFO	D02NMO	FR-79620	Preclinical
T20331	DRUGINFO	D0I3TS	GW-594884A	Preclinical
T20331	DRUGINFO	D0I5HE	NPY5RA-972	Preclinical
T20331	DRUGINFO	D05ALG	RWJ-49815	Terminated
T20331	DRUGINFO	D01HFL	2,4,4-triphenylimidazoline	Investigative
T20331	DRUGINFO	D07XFL	FR-226928	Investigative
T20331	DRUGINFO	D09BGI	JCF 109	Investigative
T20331	DRUGINFO	D09VTY	FMS586	Investigative
T20331	DRUGINFO	D0C9XD	L-152,804	Investigative
T20331	DRUGINFO	D0F6WW	LU-AA33810	Investigative
T20331	DRUGINFO	D0K3QL	FR-230481	Investigative
T20331	DRUGINFO	D0L9OS	FR-73966	Investigative
T20331	DRUGINFO	D0N6HL	FR-233118	Investigative
T20331	DRUGINFO	D08ROQ	S-25585	Investigative
T20331	DRUGINFO	D0NY7A	S-19528	Investigative
T20331	DRUGINFO	D0K0KR	AR-129330	Investigative
T20331	DRUGINFO	D0O7PT	Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)]	Investigative

T93566	TARGETID	T93566
T93566	FORMERID	TTDR01369
T93566	UNIPROID	LOX5_HUMAN
T93566	TARGNAME	LOX-5 messenger RNA (ALOX5 mRNA)
T93566	GENENAME	ALOX5
T93566	TARGTYPE	Discontinued
T93566	SYNONYMS	LOG5 (mRNA); 5-lipoxygenase (mRNA); 5-LO (mRNA)
T93566	FUNCTION	Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
T93566	PDBSTRUC	3V99; 3V98; 3V92; 3O8Y; 2ABV
T93566	BIOCLASS	mRNA target
T93566	ECNUMBER	EC 1.13.11.34
T93566	SEQUENCE	MPSYTVTVATGSQWFAGTDDYIYLSLVGSAGCSEKHLLDKPFYNDFERGAVDSYDVTVDEELGEIQLVRIEKRKYWLNDDWYLKYITLKTPHGDYIEFPCYRWITGDVEVVLRDGRAKLARDDQIHILKQHRRKELETRQKQYRWMEWNPGFPLSIDAKCHKDLPRDIQFDSEKGVDFVLNYSKAMENLFINRFMHMFQSSWNDFADFEKIFVKISNTISERVMNHWQEDLMFGYQFLNGCNPVLIRRCTELPEKLPVTTEMVECSLERQLSLEQEVQQGNIFIVDFELLDGIDANKTDPCTLQFLAAPICLLYKNLANKIVPIAIQLNQIPGDENPIFLPSDAKYDWLLAKIWVRSSDFHVHQTITHLLRTHLVSEVFGIAMYRQLPAVHPIFKLLVAHVRFTIAINTKAREQLICECGLFDKANATGGGGHVQMVQRAMKDLTYASLCFPEAIKARGMESKEDIPYYFYRDDGLLVWEAIRTFTAEVVDIYYEGDQVVEEDPELQDFVNDVYVYGMRGRKSSGFPKSVKSREQLSEYLTVVIFTASAQHAAVNFGQYDWCSWIPNAPPTMRAPPPTAKGVVTIEQIVDTLPDRGRSCWHLGAVWALSQFQENELFLGMYPEEHFIEKPVKEAMARFRKNLEAIVSVIAERNKKKQLPYYYLSPDRIPNSVAI
T93566	DRUGINFO	D07HBI	ZD-2138	Discontinued in Phase 2
T93566	DRUGINFO	D0P3KA	TEBUFELONE	Discontinued in Phase 2
T93566	DRUGINFO	D05WPQ	BW A4C	Terminated
T93566	DRUGINFO	D00DYQ	ISIS 2177	Investigative
T93566	DRUGINFO	D00OWZ	4-methoxy-N-(thiazol-2-yl)benzamide	Investigative
T93566	DRUGINFO	D01GSW	ISAINDIGOTONE	Investigative
T93566	DRUGINFO	D01IMJ	N-(4-methylthiazol-2-yl)benzamide	Investigative
T93566	DRUGINFO	D02GJI	3-methoxy-N-(1,3,4-thiadiazol-2-yl)benzamide	Investigative
T93566	DRUGINFO	D03WDY	N-(1,3,4-thiadiazol-2-yl)benzamide	Investigative
T93566	DRUGINFO	D04QVX	N-(5-methylthiazol-2-yl)benzamide	Investigative
T93566	DRUGINFO	D05DAE	2-phenyl-N-(1,3,4-thiadiazol-2-yl)acetamide	Investigative
T93566	DRUGINFO	D05FKT	L-689065	Investigative
T93566	DRUGINFO	D05IQL	Methyl 2-(Benzylamino)-1H-indole-3-carboxylate	Investigative
T93566	DRUGINFO	D05OFR	N-(5-methylthiazol-2-yl)-2-phenylacetamide	Investigative
T93566	DRUGINFO	D05WGA	2-(4-methoxyphenyl)-N-(thiazol-2-yl)acetamide	Investigative
T93566	DRUGINFO	D06DCK	L-746530	Investigative
T93566	DRUGINFO	D06IVU	N-(4-methylthiazol-2-yl)-2-phenylacetamide	Investigative
T93566	DRUGINFO	D07TWV	2-(benzyloxy)naphthalene	Investigative
T93566	DRUGINFO	D08IRN	2,4,5-Triarylimidazole analogue	Investigative
T93566	DRUGINFO	D09DBH	2-phenyl-N-(thiazol-2-yl)acetamide	Investigative
T93566	DRUGINFO	D09MTV	4-(dimethylamino)-N-(thiazol-2-yl)benzamide	Investigative
T93566	DRUGINFO	D09XWS	1-(4-methoxyphenyl)-3-(1,3,4-thiadiazol-2-yl)urea	Investigative
T93566	DRUGINFO	D0EK3T	ISIS 1831	Investigative
T93566	DRUGINFO	D0G3SF	1-(4-methoxyphenyl)-3-(4-methylthiazol-2-yl)urea	Investigative
T93566	DRUGINFO	D0L4NE	ISIS 1820	Investigative
T93566	DRUGINFO	D0PP1I	ISIS 1822	Investigative
T93566	DRUGINFO	D0Q9TL	L-702-539	Investigative
T93566	DRUGINFO	D0SS4S	Methyl 2-(Diallylamino)-1H-indole-3-carboxylate	Investigative
T93566	DRUGINFO	D0UH6R	(N-(3-phenoxycinnamyl)-acetohydroxamic acid	Investigative
T93566	DRUGINFO	D0V8MX	3,4,5-trimethoxy-N-(thiazol-2-yl)benzamide	Investigative
T93566	DRUGINFO	D0W1XD	ISIS 1827	Investigative
T93566	DRUGINFO	D0W3ZN	PD-169316	Investigative
T93566	DRUGINFO	D0X5AY	1-(4-methoxyphenyl)-3-(5-methylthiazol-2-yl)urea	Investigative
T93566	DRUGINFO	D0Y1TA	2,4'-Diacetoxy-5,3'-di-(2-propenyl)-biphenyl	Investigative
T93566	DRUGINFO	D0Y8VJ	ISIS 1821	Investigative
T93566	DRUGINFO	D0Z7QZ	N-(thiazol-2-yl)benzamide	Investigative
T93566	DRUGINFO	D01KTM	(-)-pinoresinol	Investigative
T93566	DRUGINFO	D01PBO	(+)-3,3'-bisdemethyltanegool	Investigative
T93566	DRUGINFO	D07EAJ	JASPAQUINOL	Investigative
T93566	DRUGINFO	D0K7XQ	N-hydroxy-N-[1-(4-isobutylphenyl)ethyl]urea	Investigative
T93566	DRUGINFO	D0L3RY	3-methoxy-N-(4-methylthiazol-2-yl)benzamide	Investigative
T93566	DRUGINFO	D0N7XM	(-)-3,3'-bisdemethylpinoresinol	Investigative
T93566	DRUGINFO	D0S7ZQ	4'-Methoxy-5,3'-dipropyl-biphenyl-2ol	Investigative
T93566	DRUGINFO	D01JYF	2,4'-Dimethoxy-5,3'-di-(2-propenyl)-biphenyl	Investigative
T93566	DRUGINFO	D01OFH	METHYLHONOKIOL	Investigative
T93566	DRUGINFO	D04DQJ	HONOKIOL	Investigative
T93566	DRUGINFO	D05FJM	PUUPEHEDIONE	Investigative
T93566	DRUGINFO	D07BXV	PUUPEHENONE	Investigative
T93566	DRUGINFO	D0F9FG	Isojaspic acid	Investigative
T93566	DRUGINFO	D0R6ZC	5,3'-Dipropyl-biphenyl-2,4'-diol	Investigative
T93566	DRUGINFO	D0G3TK	KAEMPFEROL	Investigative

T69085	TARGETID	T69085
T69085	FORMERID	TTDC00119
T69085	UNIPROID	JUN_HUMAN
T69085	TARGNAME	Transcription factor AP-1 (JUN)
T69085	GENENAME	JUN
T69085	TARGTYPE	Discontinued
T69085	SYNONYMS	V-jun avian sarcoma virus 17 oncogene homolog; Proto-oncogene c-jun; P39; C-jun proto-oncogene; Activator protein-1; Activator protein 1; AP1; AP-1 transcription factor
T69085	FUNCTION	Promotes activity of NR5A1 when phosphorylated by HIPK3 leading to increased steroidogenic gene expression upon cAMP signaling pathway stimulation. Involved in activated KRAS-mediated transcriptional activation of USP28 in colorectal cancer (CRC) cells. Binds to the USP28 promoter in colorectal cancer (CRC) cells. Transcription factor that recognizes and binds to the enhancer heptamer motif 5'-TGA[CG]TCA-3'.
T69085	PDBSTRUC	5T01; 5FV8; 1T2K; 1S9K; 1JNM
T69085	BIOCLASS	Basic leucine zipper bZIP
T69085	SEQUENCE	MTAKMETTFYDDALNASFLPSESGPYGYSNPKILKQSMTLNLADPVGSLKPHLRAKNSDLLTSPDVGLLKLASPELERLIIQSSNGHITTTPTPTQFLCPKNVTDEQEGFAEGFVRALAELHSQNTLPSVTSAAQPVNGAGMVAPAVASVAGGSGSGGFSASLHSEPPVYANLSNFNPGALSSGGGAPSYGAAGLAFPAQPQQQQQPPHHLPQQMPVQHPRLQALKEEPQTVPEMPGETPPLSPIDMESQERIKAERKRMRNRIAASKCRKRKLERIARLEEKVKTLKAQNSELASTANMLREQVAQLKQKVMNHVNSGCQLMLTQQLQTF
T69085	DRUGINFO	D02LCL	T-5224	Discontinued in Phase 2
T69085	DRUGINFO	D06OWM	PNRI-299	Investigative
T69085	DRUGINFO	D0AH5T	TAM-67	Investigative
T69085	DRUGINFO	D0T8KR	TWS-119	Investigative

T37735	TARGETID	T37735
T37735	FORMERID	TTDI02082
T37735	UNIPROID	GLNA_HUMAN
T37735	TARGNAME	Glutamate decarboxylase (GLUL)
T37735	GENENAME	GLUL
T37735	TARGTYPE	Discontinued
T37735	SYNONYMS	Glutamateammonia ligase
T37735	FUNCTION	Its role depends on tissue localization: in the brain, it regulates the levels of toxic ammonia and converts neurotoxic glutamate to harmless glutamine, whereas in the liver, it is one of the enzymes responsible for the removal of ammonia. Essential for proliferation of fetal skin fibroblasts. Independently of its glutamine synthetase activity, required for endothelial cell migration during vascular development: acts by regulating membrane localization and activation of the GTPase RHOJ, possibly by promoting RHOJ palmitoylation. May act as a palmitoyltransferase for RHOJ: able to autopalmitoylate and then transfer the palmitoyl group to RHOJ. Plays a role in ribosomal 40S subunit biogenesis. Glutamine synthetase that catalyzes the ATP-dependent conversion of glutamate and ammonia to glutamine.
T37735	PDBSTRUC	2QC8; 2OJW
T37735	BIOCLASS	Carbon-nitrogen ligase
T37735	ECNUMBER	EC 6.3.1.2
T37735	SEQUENCE	MTTSASSHLNKGIKQVYMSLPQGEKVQAMYIWIDGTGEGLRCKTRTLDSEPKCVEELPEWNFDGSSTLQSEGSNSDMYLVPAAMFRDPFRKDPNKLVLCEVFKYNRRPAETNLRHTCKRIMDMVSNQHPWFGMEQEYTLMGTDGHPFGWPSNGFPGPQGPYYCGVGADRAYGRDIVEAHYRACLYAGVKIAGTNAEVMPAQWEFQIGPCEGISMGDHLWVARFILHRVCEDFGVIATFDPKPIPGNWNGAGCHTNFSTKAMREENGLKYIEEAIEKLSKRHQYHIRAYDPKGGLDNARRLTGFHETSNINDFSAGVANRSASIRIPRTVGQEKKGYFEDRRPSANCDPFSVTEALIRTCLLNETGDEPFQYKN
T37735	DRUGINFO	D0VT0T	NLX-P101	Discontinued in Phase 2

T95446	TARGETID	T95446
T95446	FORMERID	TTDI01943
T95446	UNIPROID	NCPR_HUMAN
T95446	TARGNAME	Cytochrome P450 reductase (P450)
T95446	GENENAME	POR
T95446	TARGTYPE	Discontinued
T95446	SYNONYMS	P450R; NADPH--cytochrome P450 reductase; CYPOR; CPR
T95446	FUNCTION	This enzyme is required for electron transfer from NADP to cytochrome P450 in microsomes. It can also provide electron transfer to heme oxygenase and cytochrome B5.
T95446	PDBSTRUC	5FA6; 5EMN; 3QFT; 3QFS; 3QFR
T95446	BIOCLASS	NADH/NADPH oxidoreductase
T95446	ECNUMBER	EC 1.6.2.4
T95446	SEQUENCE	MGDSHVDTSSTVSEAVAEEVSLFSMTDMILFSLIVGLLTYWFLFRKKKEEVPEFTKIQTLTSSVRESSFVEKMKKTGRNIIVFYGSQTGTAEEFANRLSKDAHRYGMRGMSADPEEYDLADLSSLPEIDNALVVFCMATYGEGDPTDNAQDFYDWLQETDVDLSGVKFAVFGLGNKTYEHFNAMGKYVDKRLEQLGAQRIFELGLGDDDGNLEEDFITWREQFWPAVCEHFGVEATGEESSIRQYELVVHTDIDAAKVYMGEMGRLKSYENQKPPFDAKNPFLAAVTTNRKLNQGTERHLMHLELDISDSKIRYESGDHVAVYPANDSALVNQLGKILGADLDVVMSLNNLDEESNKKHPFPCPTSYRTALTYYLDITNPPRTNVLYELAQYASEPSEQELLRKMASSSGEGKELYLSWVVEARRHILAILQDCPSLRPPIDHLCELLPRLQARYYSIASSSKVHPNSVHICAVVVEYETKAGRINKGVATNWLRAKEPAGENGGRALVPMFVRKSQFRLPFKATTPVIMVGPGTGVAPFIGFIQERAWLRQQGKEVGETLLYYGCRRSDEDYLYREELAQFHRDGALTQLNVAFSREQSHKVYVQHLLKQDREHLWKLIEGGAHIYVCGDARNMARDVQNTFYDIVAELGAMEHAQAVDYIKKLMTKGRYSLDVWS
T95446	DRUGINFO	D0X6XF	VTP-201227	Discontinued in Phase 2
T95446	DRUGINFO	D03PBT	DuP-983	Terminated
T95446	DRUGINFO	D04ICN	DuP-630	Terminated

T27137	TARGETID	T27137
T27137	FORMERID	TTDC00220
T27137	UNIPROID	GRM1_HUMAN
T27137	TARGNAME	Metabotropic glutamate receptor 1 (mGluR1)
T27137	GENENAME	GRM1
T27137	TARGTYPE	Discontinued
T27137	SYNONYMS	mGLUR1; Glutamate receptor mGLU1; GPRC1A
T27137	FUNCTION	Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling activates a phosphatidylinositol-calcium second messenger system. May participate in the central action of glutamate in the CNS, such as long-term potentiation in the hippocampus and long-term depression in the cerebellum. G-protein coupled receptor for glutamate.
T27137	PDBSTRUC	4OR2; 3KS9
T27137	BIOCLASS	GPCR glutamate
T27137	SEQUENCE	MVGLLLFFFPAIFLEVSLLPRSPGRKVLLAGASSQRSVARMDGDVIIGALFSVHHQPPAEKVPERKCGEIREQYGIQRVEAMFHTLDKINADPVLLPNITLGSEIRDSCWHSSVALEQSIEFIRDSLISIRDEKDGINRCLPDGQSLPPGRTKKPIAGVIGPGSSSVAIQVQNLLQLFDIPQIAYSATSIDLSDKTLYKYFLRVVPSDTLQARAMLDIVKRYNWTYVSAVHTEGNYGESGMDAFKELAAQEGLCIAHSDKIYSNAGEKSFDRLLRKLRERLPKARVVVCFCEGMTVRGLLSAMRRLGVVGEFSLIGSDGWADRDEVIEGYEVEANGGITIKLQSPEVRSFDDYFLKLRLDTNTRNPWFPEFWQHRFQCRLPGHLLENPNFKRICTGNESLEENYVQDSKMGFVINAIYAMAHGLQNMHHALCPGHVGLCDAMKPIDGSKLLDFLIKSSFIGVSGEEVWFDEKGDAPGRYDIMNLQYTEANRYDYVHVGTWHEGVLNIDDYKIQMNKSGVVRSVCSEPCLKGQIKVIRKGEVSCCWICTACKENEYVQDEFTCKACDLGWWPNADLTGCEPIPVRYLEWSNIESIIAIAFSCLGILVTLFVTLIFVLYRDTPVVKSSSRELCYIILAGIFLGYVCPFTLIAKPTTTSCYLQRLLVGLSSAMCYSALVTKTNRIARILAGSKKKICTRKPRFMSAWAQVIIASILISVQLTLVVTLIIMEPPMPILSYPSIKEVYLICNTSNLGVVAPLGYNGLLIMSCTYYAFKTRNVPANFNEAKYIAFTMYTTCIIWLAFVPIYFGSNYKIITTCFAVSLSVTVALGCMFTPKMYIIIAKPERNVRSAFTTSDVVRMHVGDGKLPCRSNTFLNIFRRKKAGAGNANSNGKSVSWSEPGGGQVPKGQHMWHRLSVHVKTNETACNQTAVIKPLTKSYQGSGKSLTFSDTSTKTLYNVEEEEDAQPIRFSPPGSPSMVVHRRVPSAATTPPLPSHLTAEETPLFLAEPALPKGLPPPLQQQQQPPPQQKSLMDQLQGVVSNFSTAIPDFHAVLAGPGGPGNGLRSLYPPPPPPQHLQMLPLQLSTFGEELVSPPADDDDDSERFKLLQEYVYEHEREGNTEEDELEEEEEDLQAASKLTPDDSPALTPPSPFRDSVASGSSVPSSPVSESVLCTPPNVSYASVILRDYKQSSSTL
T27137	DRUGINFO	D07ESH	PF-1913539	Discontinued in Phase 3
T27137	DRUGINFO	D01FUB	AZD8529	Discontinued in Phase 2
T27137	DRUGINFO	D0E3SD	AZD-9272	Discontinued in Phase 1
T27137	DRUGINFO	D06LYZ	A-841720	Preclinical
T27137	DRUGINFO	D0W0XM	NPS-2390	Preclinical
T27137	DRUGINFO	D04JQR	LY-367385	Terminated
T27137	DRUGINFO	D00DJE	N-(2,3-dihydro-1H-inden-2-yl)quinazolin-4-amine	Investigative
T27137	DRUGINFO	D00REW	[11C]MMTP	Investigative
T27137	DRUGINFO	D00ZDX	CFMMC	Investigative
T27137	DRUGINFO	D01AZJ	[18F]FPIT	Investigative
T27137	DRUGINFO	D01ERW	CFMTI	Investigative
T27137	DRUGINFO	D01EVA	CPCCOEt	Investigative
T27137	DRUGINFO	D01PGO	DM-PPP	Investigative
T27137	DRUGINFO	D01TMC	PMID16099654C4b	Investigative
T27137	DRUGINFO	D02AYD	PMID19289283C32	Investigative
T27137	DRUGINFO	D02FTR	3,5-dimethyl PPP	Investigative
T27137	DRUGINFO	D02NMN	PMID19433355C11s	Investigative
T27137	DRUGINFO	D02NNU	PMID17929793C23h	Investigative
T27137	DRUGINFO	D02YGR	PMID12470711C3	Investigative
T27137	DRUGINFO	D03MEI	VU0080241	Investigative
T27137	DRUGINFO	D03NFW	PMID19289283C22	Investigative
T27137	DRUGINFO	D03YJD	VU-71	Investigative
T27137	DRUGINFO	D03ZUB	Ro67-7476	Investigative
T27137	DRUGINFO	D04JKL	AIDA	Investigative
T27137	DRUGINFO	D04MVR	A-794282	Investigative
T27137	DRUGINFO	D04RYE	PMID20346665C27	Investigative
T27137	DRUGINFO	D04VOI	PMID17064898C29	Investigative
T27137	DRUGINFO	D05DCW	PMID20346665C24	Investigative
T27137	DRUGINFO	D05KSC	A-850002	Investigative
T27137	DRUGINFO	D05KSW	N-phenethylquinoxaline-2-carboxamide	Investigative
T27137	DRUGINFO	D05NTV	(S)-TBPG	Investigative
T27137	DRUGINFO	D05WPH	Quinoline-3-carboxylic acid adamantan-1-ylamide	Investigative
T27137	DRUGINFO	D05YMP	[3H]EM-TBPC	Investigative
T27137	DRUGINFO	D06GNR	N-(2-methyl-2-phenylpropyl)pyrazine-2-carboxamide	Investigative
T27137	DRUGINFO	D06GPP	(E)-4,4-Dimethyl-1-quinolin-3-yl-pent-1-en-3-one	Investigative
T27137	DRUGINFO	D06RID	4-(cyclohexyloxy)quinazoline	Investigative
T27137	DRUGINFO	D06TYA	PMID17929793C23c	Investigative
T27137	DRUGINFO	D07XMV	YM-202074	Investigative
T27137	DRUGINFO	D08KIG	Ro01-6128	Investigative
T27137	DRUGINFO	D0B3HH	JNJ-16567083	Investigative
T27137	DRUGINFO	D0B4GX	LY456066	Investigative
T27137	DRUGINFO	D0C2IE	N-(2-phenylpropyl)quinoxaline-2-carboxamide	Investigative
T27137	DRUGINFO	D0DC4E	PMID16099654C3a	Investigative
T27137	DRUGINFO	D0E6GG	Ro67-4853	Investigative
T27137	DRUGINFO	D0EI9B	BAY 367620	Investigative
T27137	DRUGINFO	D0G4BW	PMID17929793C23e	Investigative
T27137	DRUGINFO	D0GX5C	PMID23084894C9n	Investigative
T27137	DRUGINFO	D0H6YH	N-cyclohexylquinolin-4-amine	Investigative
T27137	DRUGINFO	D0J7ZK	N-cyclohexylquinazolin-4-amine	Investigative
T27137	DRUGINFO	D0JR0W	[18F]FITM	Investigative
T27137	DRUGINFO	D0M2CT	LY456236	Investigative
T27137	DRUGINFO	D0N2TF	R214127	Investigative
T27137	DRUGINFO	D0O8WT	Ro0711401	Investigative
T27137	DRUGINFO	D0OA3L	VU0469650	Investigative
T27137	DRUGINFO	D0OS8Y	MK-5435	Investigative
T27137	DRUGINFO	D0P6HX	FPTQ	Investigative
T27137	DRUGINFO	D0QC9F	PMID22266036C12e	Investigative
T27137	DRUGINFO	D0QN5E	Quinoline-2-carboxylic acid adamantan-1-ylamide	Investigative
T27137	DRUGINFO	D0R1YT	[18F]MK-1312	Investigative
T27137	DRUGINFO	D0R8EU	FTIDC	Investigative
T27137	DRUGINFO	D0S9TZ	YM298198	Investigative
T27137	DRUGINFO	D0S9WV	Pyrazine-2-carboxylic acid adamantan-1-ylamide	Investigative
T27137	DRUGINFO	D0SB7U	PMID23084894C10i	Investigative
T27137	DRUGINFO	D0SF9Z	PMID22266036C9a	Investigative
T27137	DRUGINFO	D0SG6Q	PMID19433355C11q	Investigative
T27137	DRUGINFO	D0T7UG	N-(2,3-dihydro-1H-inden-2-yl)isoquinolin-1-amine	Investigative
T27137	DRUGINFO	D0T9TC	PMID17276684C22	Investigative
T27137	DRUGINFO	D0V3YX	A-794278	Investigative
T27137	DRUGINFO	D0VN5D	PMID17929793C11c	Investigative
T27137	DRUGINFO	D0W0NJ	PMID17532216C2f	Investigative
T27137	DRUGINFO	D0W2GG	PMID17929793C23i	Investigative
T27137	DRUGINFO	D0W6YX	(3,4-dimethylphenyl)(4-phenoxyphenyl)methanone	Investigative
T27137	DRUGINFO	D0Y3EG	3-MATIDA	Investigative
T27137	DRUGINFO	D01YEN	ibotenate	Investigative
T27137	DRUGINFO	D02FMR	6-bromo-N-(3-chlorophenyl)quinazolin-4-amine	Investigative
T27137	DRUGINFO	D03VAO	N-(3-bromophenyl)-6-fluoroquinazolin-4-amine	Investigative
T27137	DRUGINFO	D04ODF	LY-3390334	Investigative
T27137	DRUGINFO	D0B5RX	(E)-1-Adamantan-1-yl-3-quinolin-3-yl-propenone	Investigative
T27137	DRUGINFO	D0E7LU	3,5-DHPG	Investigative
T27137	DRUGINFO	D0OH2P	(S)-(+)-CBPG	Investigative
T27137	DRUGINFO	D0P3XO	(S)-4CPG	Investigative
T27137	DRUGINFO	D0R6ZS	N-(3-bromophenyl)-6-chloroquinazolin-4-amine	Investigative
T27137	DRUGINFO	D0U5YT	(S)-3HPG	Investigative
T27137	DRUGINFO	D0H6BG	PHCCC	Investigative
T27137	DRUGINFO	D0IO8J	2-methyl-6-(phenylethynyl)pyridine	Investigative
T27137	DRUGINFO	D0S6DK	(S)-4C3HPG	Investigative
T27137	DRUGINFO	D0J8OW	(+)-MCPG	Investigative
T27137	DRUGINFO	D04DKM	(1S,3R)-ACPD	Investigative
T27137	DRUGINFO	D06DUE	[3H]quisqualate	Investigative
T27137	DRUGINFO	D0Z7CZ	L-CCG-I	Investigative

T11253	TARGETID	T11253
T11253	FORMERID	TTDC00269
T11253	UNIPROID	HSPB1_HUMAN
T11253	TARGNAME	HSPB1 messenger RNA (HSPB1 mRNA)
T11253	GENENAME	HSPB1
T11253	TARGTYPE	Discontinued
T11253	SYNONYMS	Stress-responsive protein 27 (mRNA); SRP27 (mRNA); HspB1 (mRNA); Heat shock protein beta-1 (mRNA); Heat shock 27 kDa protein (mRNA); HSP28 (mRNA); HSP 27 (mRNA); Estrogen-regulated 24 kDa protein (mRNA); 28 kDa heat shock protein (mRNA)
T11253	FUNCTION	Plays a role in stress resistance and actin organization. Through its molecular chaperone activity may regulate numerous biological processes including the phosphorylation and the axonal transport of neurofilament proteins. Small heat shock protein which functions as a molecular chaperone probably maintaining denatured proteins in a folding-competent state.
T11253	PDBSTRUC	4MJH; 3Q9Q; 3Q9P; 2N3J
T11253	BIOCLASS	mRNA target
T11253	SEQUENCE	MTERRVPFSLLRGPSWDPFRDWYPHSRLFDQAFGLPRLPEEWSQWLGGSSWPGYVRPLPPAAIESPAVAAPAYSRALSRQLSSGVSEIRHTADRWRVSLDVNHFAPDELTVKTKDGVVEITGKHEERQDEHGYISRCFTRKYTLPPGVDPTQVSSSLSPEGTLTVEAPMPKLATQSNEITIPVTFESRAQLGGPEAAKSDETAAK
T11253	DRUGINFO	D0A9KI	SB-242235	Discontinued in Phase 1
T11253	DRUGINFO	D00ZBZ	OGX-427 + Paclitaxel	Investigative

T23355	TARGETID	T23355
T23355	FORMERID	TTDR01362
T23355	UNIPROID	ITB3_HUMAN
T23355	TARGNAME	ITGB3 messenger RNA (ITGB3 mRNA)
T23355	GENENAME	ITGB3
T23355	TARGTYPE	Discontinued
T23355	SYNONYMS	Platelet membrane glycoprotein IIIa (mRNA); Integrin beta-3 (mRNA); GPIIIa (mRNA); GP3A (mRNA); CD61 (mRNA)
T23355	FUNCTION	Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. Fibrinogen binding enhances SELP expression in activated platelets. ITGAV:ITGB3 binds to fractalkine (CX3CL1) and acts as its coreceptor in CX3CR1-dependent fractalkine signaling. ITGAV:ITGB3 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling. ITGAV:ITGB3 binds to FGF1 and this binding is essential for FGF1 signaling. ITGAV:ITGB3 binds to FGF2 and this binding is essential for FGF2 signaling. ITGAV:ITGB3 binds to IGF1 and this binding is essential for IGF1 signaling. ITGAV:ITGB3 binds to IGF2 and this binding is essential for IGF2 signaling. ITGAV:ITGB3 binds to IL1B and this binding is essential for IL1B signaling. ITGAV:ITGB3 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1. ITGAV:ITGB3 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1. Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor.
T23355	PDBSTRUC	6CKB; 6BXJ; 6BXF; 6BXB; 6AVU
T23355	BIOCLASS	mRNA target
T23355	SEQUENCE	MRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLGSPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRPDDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFGAFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSRNRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCHVGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLSMDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDTVSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGTFECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFGKITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLLCSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRYCRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDILVVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTFTNITYRGT
T23355	DRUGINFO	D07EXV	XEMILOFIBAN	Discontinued in Phase 3
T23355	DRUGINFO	D0K0NP	DMP-802	Discontinued in Phase 1
T23355	DRUGINFO	D03GCN	L-709780	Terminated
T23355	DRUGINFO	D03QHI	Ro-43-8857	Terminated
T23355	DRUGINFO	D08CQL	SKF-107260	Terminated
T23355	DRUGINFO	D08LIG	L-738167	Terminated
T23355	DRUGINFO	D0U4ZY	DMP-757	Terminated
T23355	DRUGINFO	D0Z0XQ	Ro-43-5054	Terminated
T23355	DRUGINFO	D0G9BX	SC-47643	Terminated
T23355	DRUGINFO	D0LT1S	SB-223245	Terminated
T23355	DRUGINFO	D01XUU	L-739758	Investigative
T23355	DRUGINFO	D02MYZ	ISIS 25237	Investigative
T23355	DRUGINFO	D04BHL	ROXIFIBAN	Investigative
T23355	DRUGINFO	D04XTP	RWJ-53419	Investigative
T23355	DRUGINFO	D05AGK	L-750034	Investigative
T23355	DRUGINFO	D06LHH	L-756568	Investigative
T23355	DRUGINFO	D08RLR	SC-54701A	Investigative
T23355	DRUGINFO	D0C8LA	L-734115	Investigative
T23355	DRUGINFO	D0M7KS	SB-207043	Investigative
T23355	DRUGINFO	D0Q2ZS	ISIS 196103	Investigative
T23355	DRUGINFO	D0S8DT	L-746233	Investigative
T23355	DRUGINFO	D0W5ZK	L-767679	Investigative
T23355	DRUGINFO	D00YBU	C(RGDfF)	Investigative
T23355	DRUGINFO	D01AXA	Ac-Asp-Arg-Leu-Asp-Ser-OH	Investigative
T23355	DRUGINFO	D01BZH	C[-Arg-Gly-Asp-Acpca21-]	Investigative
T23355	DRUGINFO	D01MGI	C-[-Arg-Gly-Asp-Acpca32-]	Investigative
T23355	DRUGINFO	D01ZJF	3-(3-(carbamoyl)benzamido)propanoic acid	Investigative
T23355	DRUGINFO	D03KLT	Cyclo-[-Arg-Gly-Asp-Amp22-]	Investigative
T23355	DRUGINFO	D03YLY	Cyclo-[-Arg-Gly-Asp-Amp21-]	Investigative
T23355	DRUGINFO	D04MCL	Cypate-[(RGD)2-NH2]2	Investigative
T23355	DRUGINFO	D04WVG	C[-Arg-Gly-Asp-Acpca35-]	Investigative
T23355	DRUGINFO	D05EWB	C[RGDf-(S)-alpha-TfmV]	Investigative
T23355	DRUGINFO	D05GXK	Cyclo-[-Arg-Gly-Asp-Amp26-]	Investigative
T23355	DRUGINFO	D05MJG	E[c(RGDyK)]2	Investigative
T23355	DRUGINFO	D05VEC	C-[-Arg-Gly-Asp-Acpca30-]	Investigative
T23355	DRUGINFO	D06JLN	C[-Arg-Gly-Asp-Acpca36-]	Investigative
T23355	DRUGINFO	D06LKH	Gly-Arg-Gly-Asp-Ser	Investigative
T23355	DRUGINFO	D07QJD	Cyclo-[-Arg-Gly-Asp-Amp25-]	Investigative
T23355	DRUGINFO	D07UOF	C(RGDfMeF)	Investigative
T23355	DRUGINFO	D08CFM	C[RGDf-(R)-alpha-TfmV]	Investigative
T23355	DRUGINFO	D08DSG	C(Arg-Gly-Asp-D-Phe-Val)	Investigative
T23355	DRUGINFO	D09PLA	C-[-Arg-Gly-Asp-Acpca31-]	Investigative
T23355	DRUGINFO	D0D4QZ	RGDechi	Investigative
T23355	DRUGINFO	D0G7QJ	3-(3-(benzamido)-5-nitrobenzamido)propanoic acid	Investigative
T23355	DRUGINFO	D0G8JI	Cyclo(RGDfV) (control)	Investigative
T23355	DRUGINFO	D0H4EK	C[RGDf-(R)-N-Me-alpha-TfmF]	Investigative
T23355	DRUGINFO	D0H4MB	ISONIPECOTAMIDE	Investigative
T23355	DRUGINFO	D0I5BY	C[RGDf-(S)-alpha-TfmF]	Investigative
T23355	DRUGINFO	D0ID6U	CYCLORGDFV	Investigative
T23355	DRUGINFO	D0J6SP	Cyclo-[-Arg-Gly-Asp-Amp28-]	Investigative
T23355	DRUGINFO	D0K5DM	E[c(RGDyK)]2-PTX conjugate	Investigative
T23355	DRUGINFO	D0L2PQ	Cypate-[(RGD)3-NH2]1	Investigative
T23355	DRUGINFO	D0LF7W	C[-Arg-Gly-Asp-Acpca19-]	Investigative
T23355	DRUGINFO	D0LV6B	Gly-Arg-Gly-Asp-Ser-Pro-Lys	Investigative
T23355	DRUGINFO	D0M0BN	C[RGDf-(R)-alpha-TfmF]	Investigative
T23355	DRUGINFO	D0M6NQ	C[RGDf-(S)-N-Me-alpha-TfmF]	Investigative
T23355	DRUGINFO	D0N9NA	Cypate-[(RGD)4-NH2]2	Investigative
T23355	DRUGINFO	D0O6DN	C[-Arg-Gly-Asp-Acpca34-]	Investigative
T23355	DRUGINFO	D0O9FL	Cyclo-[-Arg-Gly-Asp-Amp24-]	Investigative
T23355	DRUGINFO	D0P4RB	Cypate-[(RGD)2-NH2]1	Investigative
T23355	DRUGINFO	D0R9AD	N-(3,5-dichlorophenyl)imidodicarbonimidic diamide	Investigative
T23355	DRUGINFO	D0R9GW	C[-Arg-Gly-Asp-Acpca22-]	Investigative
T23355	DRUGINFO	D0R9SJ	ST-1646	Investigative
T23355	DRUGINFO	D0T1II	Cyclo[RGDfK(cypate)]	Investigative
T23355	DRUGINFO	D0TP8S	3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid	Investigative
T23355	DRUGINFO	D0U0VF	Cyclo-[-Arg-Gly-Asp-Amp27-]	Investigative
T23355	DRUGINFO	D0U2NV	C[RGD-(R)-alpha-TfmfV]	Investigative
T23355	DRUGINFO	D0UE7H	C-[-Arg-Gly-Asp-Acpca33-]	Investigative
T23355	DRUGINFO	D0UO0Y	Cypate-[(RGD)3-NH2]2	Investigative
T23355	DRUGINFO	D0V0JC	C[RGD-(S)-alpha-TfmfV]	Investigative
T23355	DRUGINFO	D0W6CJ	C[-Arg-Gly-Asp-Acpca20-]	Investigative
T23355	DRUGINFO	D0WK2F	C[RGDf-(S,R)-alpha-Dfm-F]	Investigative
T23355	DRUGINFO	D0X4EE	AcDRGDS	Investigative
T23355	DRUGINFO	D0Y8UD	Cypate-[(RGD)4-NH2]1	Investigative
T23355	DRUGINFO	D0Z6WZ	Cyclo-[-Arg-Gly-Asp-Amp23-]	Investigative
T23355	DRUGINFO	D0R3CY	SB-265123	Investigative
T23355	DRUGINFO	D0B4JU	C(-GRGDfL-)	Investigative

T58940	TARGETID	T58940
T58940	FORMERID	TTDC00009
T58940	UNIPROID	5HT3B_HUMAN
T58940	TARGNAME	5-HT 3B receptor (HTR3B)
T58940	GENENAME	HTR3B
T58940	TARGTYPE	Discontinued
T58940	SYNONYMS	Serotonin receptor 3B; 5-hydroxytryptamine receptor 3B; 5-HT3B; 5-HT3-B; 5-HT-3B
T58940	FUNCTION	This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses. It is a cation-specific, but otherwise relatively nonselective, ion channel.
T58940	BIOCLASS	GPCR rhodopsin
T58940	SEQUENCE	MLSSVMAPLWACILVAAGILATDTHHPQDSALYHLSKQLLQKYHKEVRPVYNWTKATTVYLDLFVHAILDVDAENQILKTSVWYQEVWNDEFLSWNSSMFDEIREISLPLSAIWAPDIIINEFVDIERYPDLPYVYVNSSGTIENYKPIQVVSACSLETYAFPFDVQNCSLTFKSILHTVEDVDLAFLRSPEDIQHDKKAFLNDSEWELLSVSSTYSILQSSAGGFAQIQFNVVMRRHPLVYVVSLLIPSIFLMLVDLGSFYLPPNCRARIVFKTSVLVGYTVFRVNMSNQVPRSVGSTPLIGHFFTICMAFLVLSLAKSIVLVKFLHDEQRGGQEQPFLCLRGDTDADRPRVEPRAQRAVVTESSLYGEHLAQPGTLKEVWSQLQSISNYLQTQDQTDQQEAEWLVLLSRFDRLLFQSYLFMLGIYTITLCSLWALWGGV
T58940	DRUGINFO	D0V3GT	BEMESETRON	Discontinued in Phase 3
T58940	DRUGINFO	D00PCE	BRL-24682	Investigative
T58940	DRUGINFO	D04AXY	6-(4-Methyl-piperazin-1-yl)-phenanthridine	Investigative
T58940	DRUGINFO	D06IRE	trichloroethanol	Investigative
T58940	DRUGINFO	D0H4NK	1-phenylbiguanide	Investigative
T58940	DRUGINFO	D0I4BZ	(S)-zacopride	Investigative
T58940	DRUGINFO	D0L1NS	2-(4-Benzyl-piperazin-1-yl)-benzothiazole	Investigative
T58940	DRUGINFO	D0P2HR	[3H]granisetron	Investigative
T58940	DRUGINFO	D0SA4A	meta-chlorphenylbiguanide	Investigative
T58940	DRUGINFO	D0TJ6Z	2-(1H-Imidazol-4-ylmethyl)-4-phenyl-thiazole	Investigative
T58940	DRUGINFO	D0B0TK	bilobalide	Investigative
T58940	DRUGINFO	D0G2BS	2-(4-Methyl-piperazin-1-yl)-quinoline	Investigative
T58940	DRUGINFO	D0K5NZ	MESULERGINE	Investigative
T58940	DRUGINFO	D08BCF	QUIPAZINE	Investigative
T58940	DRUGINFO	D00CRA	2-methyl-5-HT	Investigative
T58940	DRUGINFO	D0F6CD	SEROTONIN	Investigative

T32282	TARGETID	T32282
T32282	FORMERID	TTDR00418
T32282	UNIPROID	PRL_HUMAN
T32282	TARGNAME	Prolactin (PRL)
T32282	GENENAME	PRL
T32282	TARGTYPE	Discontinued
T32282	SYNONYMS	GHA1
T32282	FUNCTION	Prolactin acts primarily on the mammary gland by promoting lactation.
T32282	PDBSTRUC	3NPZ; 3NCF; 3NCE; 3NCC; 3NCB
T32282	BIOCLASS	Somatotropin/prolactin
T32282	SEQUENCE	MNIKGSPWKGSLLLLLVSNLLLCQSVAPLPICPGGAARCQVTLRDLFDRAVVLSHYIHNLSSEMFSEFDKRYTHGRGFITKAINSCHTSSLATPEDKEQAQQMNQKDFLSLIVSILRSWNEPLYHLVTEVRGMQEAPEAILSKAVEIEEQTKRLLEGMELIVSQVHPETKENEIYPVWSGLPSLQMADEESRLSAYYNLLHCLRRDSHKIDNYLKLLKCRIIHNNNC
T32282	DRUGINFO	D0F2IC	NTx-488	Discontinued in Phase 2

T46642	TARGETID	T46642
T46642	FORMERID	TTDC00062
T46642	UNIPROID	AL5AP_HUMAN
T46642	TARGNAME	Arachidonate 5-lipoxygenase activating protein (FLAP)
T46642	GENENAME	ALOX5AP
T46642	TARGTYPE	Discontinued
T46642	SYNONYMS	MK-886-binding protein; FLAP; ALOX5AP
T46642	FUNCTION	Required for leukotrienebiosynthesis by ALOX5 (5- lipoxygenase). Anchors ALOX5 to the membrane. Binds arachidonic acid, and could play an essential role in the transfer of arachidonic acid to ALOX5. Binds to MK-886, a compound that blocks the biosynthesis of leukotrienes.
T46642	PDBSTRUC	2Q7R; 2Q7M
T46642	SEQUENCE	MDQETVGNVVLLAIVTLISVVQNGFFAHKVEHESRTQNGRSFQRTGTLAFERVYTANQNCVDAYPTFLAVLWSAGLLCSQVPAAFAGLMYLFVRQKYFVGYLGERTQSTPGYIFGKRIILFLFLMSVAGIFNYYLIFFFGSDFENYIKTISTTISPLLLIP
T46642	DRUGINFO	D0S6VB	DG031	Discontinued in Phase 3
T46642	DRUGINFO	D05MCS	GSK2190915	Discontinued in Phase 2
T46642	DRUGINFO	D06UYI	AM103	Discontinued in Phase 2
T46642	DRUGINFO	D07ATG	GSK2190914	Discontinued in Phase 2
T46642	DRUGINFO	D02RZL	AZD4769	Discontinued in Phase 1
T46642	DRUGINFO	D0IL8R	A-93178	Terminated
T46642	DRUGINFO	D01YCW	L-671,480	Investigative
T46642	DRUGINFO	D06VWH	L-689,037	Investigative

T32855	TARGETID	T32855
T32855	FORMERID	TTDR00478
T32855	UNIPROID	NTF3_HUMAN
T32855	TARGNAME	Neurotrophin-3 (NTF3)
T32855	GENENAME	NTF3
T32855	TARGTYPE	Discontinued
T32855	SYNONYMS	Neurotrophic factor; Nerve growth factor 2; NT-3; NGF-2; HDNF
T32855	FUNCTION	Seems to promote the survival of visceral and proprioceptive sensory neurons.
T32855	PDBSTRUC	3BUK; 1NT3; 1BND; 1B8K
T32855	BIOCLASS	Growth factor
T32855	SEQUENCE	MSILFYVIFLAYLRGIQGNNMDQRSLPEDSLNSLIIKLIQADILKNKLSKQMVDVKENYQSTLPKAEAPREPERGGPAKSAFQPVIAMDTELLRQQRRYNSPRVLLSDSTPLEPPPLYLMEDYVGSPVVANRTSRRKRYAEHKSHRGEYSVCDSESLWVTDKSSAIDIRGHQVTVLGEIKTGNSPVKQYFYETRCKEARPVKNGCRGIDDKHWNSQCKTSQTYVRALTSENNKLVGWRWIRIDTSCVCALSRKIGRT
T32855	DRUGINFO	D00YUB	NT-3	Discontinued in Phase 2
T32855	DRUGINFO	D0P3SH	ReN-1826	Terminated

T56625	TARGETID	T56625
T56625	FORMERID	TTDR01033
T56625	UNIPROID	TPP2_HUMAN
T56625	TARGNAME	Tripeptidyl-peptidase II (TPP2)
T56625	GENENAME	TPP2
T56625	TARGTYPE	Discontinued
T56625	SYNONYMS	Tripeptidyl aminopeptidase; TPP2; TPP-II; TPP II; CCK-inactivating peptidase tripeptidyl peptidase
T56625	FUNCTION	Component of the proteolytic cascade acting downstream of the 26S proteasome in the ubiquitin-proteasome pathway. May be able to complement the 26S proteasome function to some extent under conditions in which the latter is inhibited. Stimulates adipogenesis.
T56625	BIOCLASS	Peptidase
T56625	ECNUMBER	EC 3.4.14.10
T56625	SEQUENCE	MATAATEEPFPFHGLLPKKETGAASFLCRYPEYDGRGVLIAVLDTGVDPGAPGMQVTTDGKPKIVDIIDTTGSGDVNTATEVEPKDGEIVGLSGRVLKIPASWTNPSGKYHIGIKNGYDFYPKALKERIQKERKEKIWDPVHRVALAEACRKQEEFDVANNGSSQANKLIKEELQSQVELLNSFEKKYSDPGPVYDCLVWHDGEVWRACIDSNEDGDLSKSTVLRNYKEAQEYGSFGTAEMLNYSVNIYDDGNLLSIVTSGGAHGTHVASIAAGHFPEEPERNGVAPGAQILSIKIGDTRLSTMETGTGLIRAMIEVINHKCDLVNYSYGEATHWPNSGRICEVINEAVWKHNIIYVSSAGNNGPCLSTVGCPGGTTSSVIGVGAYVSPDMMVAEYSLREKLPANQYTWSSRGPSADGALGVSISAPGGAIASVPNWTLRGTQLMNGTSMSSPNACGGIALILSGLKANNIDYTVHSVRRALENTAVKADNIEVFAQGHGIIQVDKAYDYLVQNTSFANKLGFTVTVGNNRGIYLRDPVQVAAPSDHGVGIEPVFPENTENSEKISLQLHLALTSNSSWVQCPSHLELMNQCRHINIRVDPRGLREGLHYTEVCGYDIASPNAGPLFRVPITAVIAAKVNESSHYDLAFTDVHFKPGQIRRHFIEVPEGATWAEVTVCSCSSEVSAKFVLHAVQLVKQRAYRSHEFYKFCSLPEKGTLTEAFPVLGGKAIEFCIARWWASLSDVNIDYTISFHGIVCTAPQLNIHASEGINRFDVQSSLKYEDLAPCITLKNWVQTLRPVSAKTKPLGSRDVLPNNRQLYEMVLTYNFHQPKSGEVTPSCPLLCELLYESEFDSQLWIIFDQNKRQMGSGDAYPHQYSLKLEKGDYTIRLQIRHEQISDLERLKDLPFIVSHRLSNTLSLDIHENHSFALLGKKKSSNLTLPPKYNQPFFVTSLPDDKIPKGAGPGCYLAGSLTLSKTELGKKADVIPVHYYLIPPPTKTKNGSKDKEKDSEKEKDLKEEFTEALRDLKIQWMTKLDSSDIYNELKETYPNYLPLYVARLHQLDAEKERMKRLNEIVDAANAVISHIDQTALAVYIAMKTDPRPDAATIKNDMDKQKSTLVDALCRKGCALADHLLHTQAQDGAISTDAEGKEEEGESPLDSLAETFWETTKWTDLFDNKVLTFAYKHALVNKMYGRGLKFATKLVEEKPTKENWKNCIQLMKLLGWTHCASFTENWLPIMYPPDYCVF
T56625	DRUGINFO	D0T7CM	UCL-2000; butabindide	Discontinued in Phase 1
T56625	DRUGINFO	D00DDH	(2S)-aminobutyryl-L-proline-(2S)-methylbutylamide	Investigative
T56625	DRUGINFO	D00IPP	L-valyl-L-prolinamide	Investigative
T56625	DRUGINFO	D00KTE	(2S)-aminobutyryl-L-proline n-butylamide	Investigative
T56625	DRUGINFO	D02QDW	L-norvalyl-L-prolinamide	Investigative
T56625	DRUGINFO	D03KXQ	L-valyl-L-proline benzylamide	Investigative
T56625	DRUGINFO	D07PHW	(2S)-aminobutyryl-L-prolinamide	Investigative
T56625	DRUGINFO	D0D5XX	peptide 4	Investigative
T56625	DRUGINFO	D0E4KI	example 8 [WO1999033801A1]	Investigative
T56625	DRUGINFO	D0G2NF	(2S)-aminobutyryl-(R)-pipecolinic acid amide	Investigative
T56625	DRUGINFO	D0H9VQ	L-norleucyl-L-prolinamide	Investigative
T56625	DRUGINFO	D0K2GB	(2S)-aminobutyryl-L-proline n-propylamide	Investigative
T56625	DRUGINFO	D0L4DW	(2S)-aminobutyryl-L-proline n-pentylamide	Investigative
T56625	DRUGINFO	D0L4NF	Alpha-methylalanyl-L-proline butylamide	Investigative
T56625	DRUGINFO	D0M0TS	(2S)-aminobutyryl-L-proline (R)-sec-butylamide	Investigative
T56625	DRUGINFO	D0P9II	(2S)-aminobutyryl-L-proline isobutylamide	Investigative
T56625	DRUGINFO	D0R3DP	L-valyl-L-proline hexylamide	Investigative
T56625	DRUGINFO	D0X6BT	L-leucyl-L-prolinamide	Investigative
T56625	DRUGINFO	D0ZW8E	L-isoleucyl-L-prolinamide	Investigative

T02752	TARGETID	T02752
T02752	FORMERID	TTDC00207
T02752	UNIPROID	CCR3_HUMAN
T02752	TARGNAME	C-C chemokine receptor type 3 (CCR3)
T02752	GENENAME	CCR3
T02752	TARGTYPE	Discontinued
T02752	SYNONYMS	Eosinophil eotaxin receptor; Chemokine receptor CCR3; CMKBR3; CKR3; CD193; CCR-3; CC-CKR-3; C-C CKR-3
T02752	FUNCTION	Binds to eotaxin, eotaxin-3, MCP-3, MCP-4, RANTES and MIP-1 delta. Subsequently transduces a signal by increasing the intracellular calcium ions level. Alternative coreceptor with CD4 for HIV-1 infection. Receptor for a C-C type chemokine.
T02752	BIOCLASS	GPCR rhodopsin
T02752	SEQUENCE	MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILIKYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSEIFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEETLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRLIFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSHCCMNPVIYAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF
T02752	DRUGINFO	DFA0W6	AKST4290	Phase 2
T02752	DRUGINFO	D0C2IA	DPC-168	Discontinued in Phase 1
T02752	DRUGINFO	D09UXP	AZD-1744	Discontinued in Phase 1
T02752	DRUGINFO	D04EIL	YM-344031	Preclinical
T02752	DRUGINFO	D0Y6TI	YM-355179	Preclinical
T02752	DRUGINFO	D0Y4PL	QAP-642	Terminated

T96736	TARGETID	T96736
T96736	FORMERID	TTDI02159
T96736	UNIPROID	RHOA_HUMAN
T96736	TARGNAME	Transforming protein RhoA (RHOA)
T96736	GENENAME	RHOA
T96736	TARGTYPE	Discontinued
T96736	SYNONYMS	h12; Rho cDNA clone 12; RHO12; ARHA; ARH12
T96736	FUNCTION	Involved in a microtubule-dependent signal that is required for the myosin contractile ring formation during cell cycle cytokinesis. Plays an essential role in cleavage furrow formation. Required for the apical junction formation of keratinocyte cell-cell adhesion. Stimulates PKN2 kinase activity. May be an activator of PLCE1. Activated by ARHGEF2, which promotes the exchange of GDP for GTP. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. The MEMO1-RHOA-DIAPH1 signaling pathway plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. It controls the localization of APC and CLASP2 to the cell membrane, via the regulation of GSK3B activity. In turn, membrane-bound APC allows the localization of the MACF1 to the cell membrane, which is required for microtubule capture and stabilization. Regulates a signal transduction pathway linking plasma membrane receptors to the assembly of focal adhesions and actin stress fibers. Involved in a microtubule-dependent signal that is required for the myosin contractile ring formation during cell cycle cytokinesis. Plays an essential role in cleavage furrow formation. Required for the apical junction formation of keratinocyte cell-cell adhesion. May be an activator of PLCE1. Activated by ARHGEF2, which promotes the exchange of GDP for GTP. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. The MEMO1-RHOA-DIAPH1 signaling pathway plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. It controls the localization of APC and CLASP2 to the cell membrane, via the regulation of GSK3B activity. In turn, membrane-bound APC allows the localization of the MACF1 to the cell membrane, which is required for microtubule capture and stabilization. Regulates KCNA2 potassium channel activity by reducing its location at the cell surface in response to CHRM1 activation; promotes KCNA2 endocytosis. Regulates a signal transduction pathway linking plasma membrane receptors to the assembly of focal adhesions and actin stress fibers.
T96736	PDBSTRUC	6R3V; 6BCB; 6BCA; 6BC0; 5ZHX
T96736	BIOCLASS	Small GTPase
T96736	ECNUMBER	EC 3.6.5.2
T96736	SEQUENCE	MAAIRKKLVIVGDGACGKTCLLIVFSKDQFPEVYVPTVFENYVADIEVDGKQVELALWDTAGQEDYDRLRPLSYPDTDVILMCFSIDSPDSLENIPEKWTPEVKHFCPNVPIILVGNKKDLRNDEHTRRELAKMKQEPVKPEEGRDMANRIGAFGYMECSAKTKDGVREVFEMATRAALQARRGKKKSGCLVL
T96736	DRUGINFO	D08SUQ	ES-285	Discontinued in Phase 1

T39523	TARGETID	T39523
T39523	FORMERID	TTDI01951
T39523	UNIPROID	PDE7A_HUMAN
T39523	TARGNAME	Phosphodiesterase 7A (PDE7A)
T39523	GENENAME	PDE7A
T39523	TARGTYPE	Discontinued
T39523	SYNONYMS	TM22; High affinity cAMPspecific 3',5'cyclic phosphodiesterase 7A; High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A
T39523	FUNCTION	May have a role in muscle signal transduction. Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
T39523	PDBSTRUC	4Y2B; 4PM0; 3G3N; 1ZKL
T39523	BIOCLASS	Phosphoric diester hydrolase
T39523	ECNUMBER	EC 3.1.4.53
T39523	SEQUENCE	MEVCYQLPVLPLDRPVPQHVLSRRGAISFSSSSALFGCPNPRQLSQRRGAISYDSSDQTALYIRMLGDVRVRSRAGFESERRGSHPYIDFRIFHSQSEIEVSVSARNIRRLLSFQRYLRSSRFFRGTAVSNSLNILDDDYNGQAKCMLEKVGNWNFDIFLFDRLTNGNSLVSLTFHLFSLHGLIEYFHLDMMKLRRFLVMIQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLANSVTPWDILLSLIAAATHDLDHPGVNQPFLIKTNHYLATLYKNTSVLENHHWRSAVGLLRESGLFSHLPLESRQQMETQIGALILATDISRQNEYLSLFRSHLDRGDLCLEDTRHRHLVLQMALKCADICNPCRTWELSKQWSEKVTEEFFHQGDIEKKYHLGVSPLCDRHTESIANIQIGFMTYLVEPLFTEWARFSNTRLSQTMLGHVGLNKASWKGLQREQSSSEDTDAAFELNSQLLPQENRLS
T39523	DRUGINFO	D0PZ4Y	PF-3557156	Discontinued in Phase 1

T29754	TARGETID	T29754
T29754	FORMERID	TTDI02542
T29754	UNIPROID	MAPK5_HUMAN
T29754	TARGNAME	MAPK-activated protein kinase 5 (MAPKAPK5)
T29754	GENENAME	MAPKAPK5
T29754	TARGTYPE	Discontinued
T29754	SYNONYMS	p38regulated/activated protein kinase; p38-regulated/activated protein kinase; PRAK; MK5; MK-5; MAPKactivated protein kinase 5; MAPKAPK-5; MAPKAP-K5; MAPKAP kinase 5; MAP kinaseactivated protein kinase 5; MAP kinase-activated protein kinase 5
T29754	FUNCTION	Phosphorylates FOXO3, ERK3/MAPK6, ERK4/MAPK4, HSP27/HSPB1, p53/TP53 and RHEB. Acts as a tumor suppressor by mediating Ras-induced senescence and phosphorylating p53/TP53. Involved in post-transcriptional regulation of MYC by mediating phosphorylation of FOXO3: phosphorylation of FOXO3 leads to promote nuclear localization of FOXO3, enabling expression of miR-34b and miR-34c, 2 post-transcriptional regulators of MYC that bind to the 3'UTR of MYC transcript and prevent MYC translation. Acts as a negative regulator of mTORC1 signaling by mediating phosphorylation and inhibition of RHEB. Part of the atypical MAPK signaling via its interaction with ERK3/MAPK6 or ERK4/MAPK4: the precise role of the complex formed with ERK3/MAPK6 or ERK4/MAPK4 is still unclear, but the complex follows a complex set of phosphorylation events: upon interaction with atypical MAPK (ERK3/MAPK6 or ERK4/MAPK4), ERK3/MAPK6 (or ERK4/MAPK4) is phosphorylated and then mediates phosphorylation and activation of MAPKAPK5, which in turn phosphorylates ERK3/MAPK6 (or ERK4/MAPK4). Mediates phosphorylation of HSP27/HSPB1 in response to PKA/PRKACA stimulation, inducing F-actin rearrangement. Tumor suppressor serine/threonine-protein kinase involved in mTORC1 signaling and post-transcriptional regulation.
T29754	BIOCLASS	Kinase
T29754	ECNUMBER	EC 2.7.11.1
T29754	SEQUENCE	MSEESDMDKAIKETSILEEYSINWTQKLGAGISGPVRVCVKKSTQERFALKILLDRPKARNEVRLHMMCATHPNIVQIIEVFANSVQFPHESSPRARLLIVMEMMEGGELFHRISQHRHFTEKQASQVTKQIALALRHCHLLNIAHRDLKPENLLFKDNSLDAPVKLCDFGFAKIDQGDLMTPQFTPYYVAPQVLEAQRRHQKEKSGIIPTSPTPYTYNKSCDLWSLGVIIYVMLCGYPPFYSKHHSRTIPKDMRRKIMTGSFEFPEEEWSQISEMAKDVVRKLLKVKPEERLTIEGVLDHPWLNSTEALDNVLPSAQLMMDKAVVAGIQQAHAEQLANMRIQDLKVSLKPLHSVNNPILRKRKLLGTKPKDSVYIHDHENGAEDSNVALEKLRDVIAQCILPQAGKGENEDEKLNEVMQEAWKYNRECKLLRDTLQSFSWNGRGFTDKVDRLKLAEIVKQVIEEQTTSHESQ
T29754	DRUGINFO	D06NPB	GLPG-0259	Discontinued in Phase 2
T29754	DRUGINFO	D0EW9J	PMID17480064C16	Investigative

T39123	TARGETID	T39123
T39123	FORMERID	TTDC00231
T39123	UNIPROID	KISSR_HUMAN
T39123	TARGNAME	G-protein coupled receptor 54 (KISS1R)
T39123	GENENAME	KISS1R
T39123	TARGTYPE	Discontinued
T39123	SYNONYMS	KiSS-1 receptor GPR54; KISS1R; GPR54
T39123	FUNCTION	Receptor for metastin(kisspeptin-54 or kp-54), a C- terminally amidated peptide of KiSS1. KiSS1 is a metastasis suppressor protein that suppresses metastases in malignant melanomas and in some breast carcinomas without affecting tumorigenicity. The metastasis suppressor properties may be mediated in part by cell cycle arrest and induction of apoptosis in malignant cells. The receptor is essential for normal gonadotropin-released hormone physiology and for puberty. The hypothalamic KiSS1/KISS1R system is a pivotal factor in central regulation of the gonadotropic axis at puberty and in adulthood. The receptor is also probably involved in the regulation and fine- tuning of trophoblast invasion generated by the trophoblast itself. Analysis of the transduction pathways activated by the receptor identifies couplingto phospholipase C and intracellular calcium release through pertussis toxin-insensitive G(q) proteins.
T39123	BIOCLASS	GPCR rhodopsin
T39123	SEQUENCE	MHTVATSGPNASWGAPANASGCPGCGANASDGPVPSPRAVDAWLVPLFFAALMLLGLVGNSLVIYVICRHKPMRTVTNFYIANLAATDVTFLLCCVPFTALLYPLPGWVLGDFMCKFVNYIQQVSVQATCATLTAMSVDRWYVTVFPLRALHRRTPRLALAVSLSIWVGSAAVSAPVLALHRLSPGPRAYCSEAFPSRALERAFALYNLLALYLLPLLATCACYAAMLRHLGRVAVRPAPADSALQGQVLAERAGAVRAKVSRLVAAVVLLFAACWGPIQLFLVLQALGPAGSWHPRSYAAYALKTWAHCMSYSNSALNPLLYAFLGSHFRQAFRRVCPCAPRRPRRPRRPGPSDPAAPHAELLRLGSHPAPARAQKPGSSGLAARGLCVLGEDNAPL
T39123	DRUGINFO	D0P9KL	TAK-683	Discontinued in Phase 1
T39123	DRUGINFO	D01VSI	kisspeptin-10	Investigative
T39123	DRUGINFO	D0JE3Z	4-fluorobenzoyl-Phe-Gly-Leu-Arg-Trp-NH2	Investigative

T20578	TARGETID	T20578
T20578	FORMERID	TTDI01952
T20578	UNIPROID	PDE7B_HUMAN
T20578	TARGNAME	Phosphodiesterase 7B (PDE7B)
T20578	GENENAME	PDE7B
T20578	TARGTYPE	Discontinued
T20578	SYNONYMS	cAMPspecific 3',5'cyclic phosphodiesterase 7B; cAMP-specific 3',5'-cyclic phosphodiesterase 7B
T20578	FUNCTION	May be involved in the control of cAMP-mediated neural activity and cAMP metabolism in the brain. Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
T20578	PDBSTRUC	1LXW
T20578	BIOCLASS	Phosphoric diester hydrolase
T20578	ECNUMBER	EC 3.1.4.53
T20578	SEQUENCE	MSCLMVERCGEILFENPDQNAKCVCMLGDIRLRGQTGVRAERRGSYPFIDFRLLNSTTYSGEIGTKKKVKRLLSFQRYFHASRLLRGIIPQAPLHLLDEDYLGQARHMLSKVGMWDFDIFLFDRLTNGNSLVTLLCHLFNTHGLIHHFKLDMVTLHRFLVMVQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPLDIMLGLLAAAAHDVDHPGVNQPFLIKTNHHLANLYQNMSVLENHHWRSTIGMLRESRLLAHLPKEMTQDIEQQLGSLILATDINRQNEFLTRLKAHLHNKDLRLEDAQDRHFMLQIALKCADICNPCRIWEMSKQWSERVCEEFYRQGELEQKFELEISPLCNQQKDSIPSIQIGFMSYIVEPLFREWAHFTGNSTLSENMLGHLAHNKAQWKSLLPRQHRSRGSSGSGPDHDHAGQGTESEEQEGDSP
T20578	DRUGINFO	D0PZ4Y	PF-3557156	Discontinued in Phase 1
T20578	DRUGINFO	D00MBG	BRL50481	Investigative
T20578	DRUGINFO	D02VHD	SCH51866	Investigative

T58716	TARGETID	T58716
T58716	FORMERID	TTDC00057
T58716	UNIPROID	NSMA3_HUMAN
T58716	TARGNAME	Sphingomyelin phosphodiesterase 4 (SMPD4)
T58716	GENENAME	SMPD4
T58716	TARGTYPE	Discontinued
T58716	SYNONYMS	nSMase3; nSMase-3; SKNY; Neutral sphingomyelinase III; Neutral sphingomyelinase 3; KIAA1418
T58716	FUNCTION	Catalyzes the hydrolysis of membrane sphingomyelin to form phosphorylcholine and ceramide. May sensitize cells to DNA damage-induced apoptosis.
T58716	BIOCLASS	Phosphoric diester hydrolase
T58716	ECNUMBER	EC 3.1.4.12
T58716	SEQUENCE	MTTFGAVAEWRLPSLRRATLWIPQWFAKKAIFNSPLEAAMAFPHLQQPSFLLASLKADSINKPFAQQCQDLVKVIEDFPAKELHTIFPWLVESIFGSLDGVLVGWNLRCLQGRVNPVEYSIVMEFLDPGGPMMKLVYKLQAEDYKFDFPVSYLPGPVKASIQECILPDSPLYHNKVQFTPTGGLGLNLALNPFEYYIFFFALSLITQKPLPVSLHVRTSDCAYFILVDRYLSWFLPTEGSVPPPLSSSPGGTSPSPPPRTPAIPFASYGLHHTSLLKRHISHQTSVNADPASHEIWRSETLLQVFVEMWLHHYSLEMYQKMQSPHAKLEVLHYRLSVSSALYSPAQPSLQALHAYQESFTPTEEHVLVVRLLLKHLHAFANSLKPEQASPSAHSHATSPLEEFKRAAVPRFVQQKLYLFLQHCFGHWPLDASFRAVLEMWLSYLQPWRYAPDKQAPGSDSQPRCVSEKWAPFVQENLLMYTKLFVGFLNRALRTDLVSPKHALMVFRVAKVFAQPNLAEMIQKGEQLFLEPELVIPHRQHRLFTAPTFTGSFLSPWPPAVTDASFKVKSHVYSLEGQDCKYTPMFGPEARTLVLRLAQLITQAKHTAKSISDQCAESPAGHSFLSWLGFSSMDTNGSYTANDLDEMGQDSVRKTDEYLEKALEYLRQIFRLSEAQLRQFTLALGTTQDENGKKQLPDCIVGEDGLILTPLGRYQIINGLRRFEIEYQGDPELQPIRSYEIASLVRTLFRLSSAINHRFAGQMAALCSRDDFLGSFCRYHLTEPGLASRHLLSPVGRRQVAGHTRGPRLSLRFLGSYRTLVSLLLAFFVASLFCVGPLPCTLLLTLGYVLYASAMTLLTERGKLHQP
T58716	DRUGINFO	D00ACC	ND1251	Discontinued in Phase 1

T89747	TARGETID	T89747
T89747	FORMERID	TTDI02385
T89747	UNIPROID	ABL1_HUMAN
T89747	TARGNAME	ABL messenger RNA (ABL mRNA)
T89747	GENENAME	ABL1
T89747	TARGTYPE	Discontinued
T89747	SYNONYMS	p150 (mRNA); Proto-oncogene tyrosine-protein kinase ABL1 (mRNA); Proto-oncogene c-Abl (mRNA); JTK7 (mRNA); C-ABL (mRNA); Abl (mRNA); Abelson tyrosine-protein kinase 1 (mRNA); Abelson murine leukemia viral oncogene homolog 1 (mRNA)
T89747	FUNCTION	Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 (involved in branch formation); ANXA1 (involved in membrane anchoring); DBN1, DBNL, CTTN, RAPH1 and ENAH (involved in signaling); or MAPT and PXN (microtubule-binding proteins). Phosphorylation of WASF3 is critical for the stimulation of lamellipodia formation and cell migration. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as BCAR1, CRK, CRKL, DOK1, EFS or NEDD9. Phosphorylates multiple receptor tyrosine kinases and more particularly promotes endocytosis of EGFR, facilitates the formation of neuromuscular synapses through MUSK, inhibits PDGFRB-mediated chemotaxis and modulates the endocytosis of activated B-cell receptor complexes. Other substrates which are involved in endocytosis regulation are the caveolin (CAV1) and RIN1. Moreover, ABL1 regulates the CBL family of ubiquitin ligases that drive receptor down-regulation and actin remodeling. Phosphorylation of CBL leads to increased EGFR stability. Involved in late-stage autophagy by regulating positively the trafficking and function of lysosomal components. ABL1 targets to mitochondria in response to oxidative stress and thereby mediates mitochondrial dysfunction and cell death. In response to oxidative stress, phosphorylates serine/threonine kinase PRKD2 at 'Tyr-717'. ABL1 is also translocated in the nucleus where it has DNA-binding activity and is involved in DNA-damage response and apoptosis. Many substrates are known mediators of DNA repair: DDB1, DDB2, ERCC3, ERCC6, RAD9A, RAD51, RAD52 or WRN. Activates the proapoptotic pathway when the DNA damage is too severe to be repaired. Phosphorylates TP73, a primary regulator for this type of damage-induced apoptosis. Phosphorylates the caspase CASP9 on 'Tyr-153' and regulates its processing in the apoptotic response to DNA damage. Phosphorylates PSMA7 that leads to an inhibition of proteasomal activity and cell cycle transition blocks. ABL1 acts also as a regulator of multiple pathological signaling cascades during infection. Several known tyrosine-phosphorylated microbial proteins have been identified as ABL1 substrates. This is the case of A36R of Vaccinia virus, Tir (translocated intimin receptor) of pathogenic E. coli and possibly Citrobacter, CagA (cytotoxin-associated gene A) of H. pylori, or AnkA (ankyrin repeat-containing protein A) of A. phagocytophilum. Pathogens can highjack ABL1 kinase signaling to reorganize the host actin cytoskeleton for multiple purposes, like facilitating intracellular movement and host cell exit. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1. Regulates T-cell differentiation in a TBX21-dependent manner. Phosphorylates TBX21 on tyrosine residues leading to an enhancement of its transcriptional activator activity. Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis.
T89747	PDBSTRUC	6NPV; 6NPU; 6NPE; 6BL8; 6AMW
T89747	BIOCLASS	mRNA target
T89747	ECNUMBER	EC 2.7.10.2
T89747	SEQUENCE	MLEICLKLVGCKSKKGLSSSSSCYLEEALQRPVASDFEPQGLSEAARWNSKENLLAGPSENDPNLFVALYDFVASGDNTLSITKGEKLRVLGYNHNGEWCEAQTKNGQGWVPSNYITPVNSLEKHSWYHGPVSRNAAEYLLSSGINGSFLVRESESSPGQRSISLRYEGRVYHYRINTASDGKLYVSSESRFNTLAELVHHHSTVADGLITTLHYPAPKRNKPTVYGVSPNYDKWEMERTDITMKHKLGGGQYGEVYEGVWKKYSLTVAVKTLKEDTMEVEEFLKEAAVMKEIKHPNLVQLLGVCTREPPFYIITEFMTYGNLLDYLRECNRQEVNAVVLLYMATQISSAMEYLEKKNFIHRDLAARNCLVGENHLVKVADFGLSRLMTGDTYTAHAGAKFPIKWTAPESLAYNKFSIKSDVWAFGVLLWEIATYGMSPYPGIDLSQVYELLEKDYRMERPEGCPEKVYELMRACWQWNPSDRPSFAEIHQAFETMFQESSISDEVEKELGKQGVRGAVSTLLQAPELPTKTRTSRRAAEHRDTTDVPEMPHSKGQGESDPLDHEPAVSPLLPRKERGPPEGGLNEDERLLPKDKKTNLFSALIKKKKKTAPTPPKRSSSFREMDGQPERRGAGEEEGRDISNGALAFTPLDTADPAKSPKPSNGAGVPNGALRESGGSGFRSPHLWKKSSTLTSSRLATGEEEGGGSSSKRFLRSCSASCVPHGAKDTEWRSVTLPRDLQSTGRQFDSSTFGGHKSEKPALPRKRAGENRSDQVTRGTVTPPPRLVKKNEEAADEVFKDIMESSPGSSPPNLTPKPLRRQVTVAPASGLPHKEEAGKGSALGTPAAAEPVTPTSKAGSGAPGGTSKGPAEESRVRRHKHSSESPGRDKGKLSRLKPAPPPPPAASAGKAGGKPSQSPSQEAAGEAVLGAKTKATSLVDAVNSDAAKPSQPGEGLKKPVLPATPKPQSAKPSGTPISPAPVPSTLPSASSALAGDQPSSTAFIPLISTRVSLRKTRQPPERIASGAITKGVVLDSTEALCLAISRNSEQMASHSAVLEAGKNLYTFCVSYVDSIQQMRNKFAFREAINKLENNLRELQICPATAGSGPAATQDFSKLLSSVKEISDIVQR
T89747	DRUGINFO	D05RUJ	G-1128	Discontinued in Phase 2
T89747	DRUGINFO	D0Q8BK	GNF-5	Investigative
T89747	DRUGINFO	D0JR3W	PMID23441572C24	Investigative
T89747	DRUGINFO	D02BXJ	PMID21561767C8h	Investigative
T89747	DRUGINFO	D03EHM	PP121	Investigative
T89747	DRUGINFO	D0E7VO	PMID24900538C2c	Investigative

T40045	TARGETID	T40045
T40045	FORMERID	TTDI02344
T40045	UNIPROID	RIR1_HUMAN
T40045	TARGNAME	RRM1 messenger RNA (RRM1 mRNA)
T40045	GENENAME	RRM1
T40045	TARGTYPE	Discontinued
T40045	SYNONYMS	Ribonucleotide reductase large subunit (mRNA); Ribonucleoside-diphosphate reductase subunit M1 (mRNA); Ribonucleoside-diphosphate reductase large subunit (mRNA); RR1 (mRNA)
T40045	FUNCTION	Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides. Provides the precursors necessary for DNA synthesis.
T40045	PDBSTRUC	6AUI; 5TUS; 5D1Y; 4X3V; 3HNF
T40045	BIOCLASS	mRNA target
T40045	ECNUMBER	EC 1.17.4.1
T40045	SEQUENCE	MHVIKRDGRQERVMFDKITSRIQKLCYGLNMDFVDPAQITMKVIQGLYSGVTTVELDTLAAETAATLTTKHPDYAILAARIAVSNLHKETKKVFSDVMEDLYNYINPHNGKHSPMVAKSTLDIVLANKDRLNSAIIYDRDFSYNYFGFKTLERSYLLKINGKVAERPQHMLMRVSVGIHKEDIDAAIETYNLLSERWFTHASPTLFNAGTNRPQLSSCFLLSMKDDSIEGIYDTLKQCALISKSAGGIGVAVSCIRATGSYIAGTNGNSNGLVPMLRVYNNTARYVDQGGNKRPGAFAIYLEPWHLDIFEFLDLKKNTGKEEQRARDLFFALWIPDLFMKRVETNQDWSLMCPNECPGLDEVWGEEFEKLYASYEKQGRVRKVVKAQQLWYAIIESQTETGTPYMLYKDSCNRKSNQQNLGTIKCSNLCTEIVEYTSKDEVAVCNLASLALNMYVTSEHTYDFKKLAEVTKVVVRNLNKIIDINYYPVPEACLSNKRHRPIGIGVQGLADAFILMRYPFESAEAQLLNKQIFETIYYGALEASCDLAKEQGPYETYEGSPVSKGILQYDMWNVTPTDLWDWKVLKEKIAKYGIRNSLLIAPMPTASTAQILGNNESIEPYTSNIYTRRVLSGEFQIVNPHLLKDLTERGLWHEEMKNQIIACNGSIQSIPEIPDDLKQLYKTVWEISQKTVLKMAAERGAFIDQSQSLNIHIAEPNYGKLTSMHFYGWKQGLKTGMYYLRTRPAANPIQFTLNKEKLKDKEKVSKEEEEKERNTAAMVCSLENRDECLMCGS
T40045	DRUGINFO	D0K4OL	LOR-2501	Discontinued in Phase 1

T14825	TARGETID	T14825
T14825	FORMERID	TTDC00288
T14825	UNIPROID	VGFR2_HUMAN
T14825	TARGNAME	VEGFR2 messenger RNA (VEGFR2 mRNA)
T14825	GENENAME	KDR
T14825	TARGTYPE	Discontinued
T14825	SYNONYMS	VEGFR2 (mRNA); VEGFR-2 (mRNA); VEGF-2 receptor (mRNA); Protein-tyrosine kinase receptor flk-1 (mRNA); Kinase insert domain receptor (mRNA); Fetal liver kinase 1 (mRNA); FLK1 (mRNA); FLK-1 (mRNA); CD309 (mRNA)
T14825	FUNCTION	Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC. Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD.
T14825	PDBSTRUC	6GQQ; 6GQP; 6GQO; 5OYJ; 5EW3
T14825	BIOCLASS	mRNA target
T14825	ECNUMBER	EC 2.7.10.1
T14825	SEQUENCE	MQSKVLLAVALWLCVETRAASVGLPSVSLDLPRLSIQKDILTIKANTTLQITCRGQRDLDWLWPNNQSGSEQRVEVTECSDGLFCKTLTIPKVIGNDTGAYKCFYRETDLASVIYVYVQDYRSPFIASVSDQHGVVYITENKNKTVVIPCLGSISNLNVSLCARYPEKRFVPDGNRISWDSKKGFTIPSYMISYAGMVFCEAKINDESYQSIMYIVVVVGYRIYDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKPFVAFGSGMESLVEATVGERVRIPAKYLGYPPPEIKWYKNGIPLESNHTIKAGHVLTIMEVSERDTGNYTVILTNPISKEKQSHVVSLVVYVPPQIGEKSLISPVDSYQYGTTQTLTCTVYAIPPPHHIHWYWQLEEECANEPSQAVSVTNPYPCEEWRSVEDFQGGNKIEVNKNQFALIEGKNKTVSTLVIQAANVSALYKCEAVNKVGRGERVISFHVTRGPEITLQPDMQPTEQESVSLWCTADRSTFENLTWYKLGPQPLPIHVGELPTPVCKNLDTLWKLNATMFSNSTNDILIMELKNASLQDQGDYVCLAQDRKTKKRHCVVRQLTVLERVAPTITGNLENQTTSIGESIEVSCTASGNPPPQIMWFKDNETLVEDSGIVLKDGNRNLTIRRVRKEDEGLYTCQACSVLGCAKVEAFFIIEGAQEKTNLEIIILVGTAVIAMFFWLLLVIILRTVKRANGGELKTGYLSIVMDPDELPLDEHCERLPYDASKWEFPRDRLKLGKPLGRGAFGQVIEADAFGIDKTATCRTVAVKMLKEGATHSEHRALMSELKILIHIGHHLNVVNLLGACTKPGGPLMVIVEFCKFGNLSTYLRSKRNEFVPYKTKGARFRQGKDYVGAIPVDLKRRLDSITSSQSSASSGFVEEKSLSDVEEEEAPEDLYKDFLTLEHLICYSFQVAKGMEFLASRKCIHRDLAARNILLSEKNVVKICDFGLARDIYKDPDYVRKGDARLPLKWMAPETIFDRVYTIQSDVWSFGVLLWEIFSLGASPYPGVKIDEEFCRRLKEGTRMRAPDYTTPEMYQTMLDCWHGEPSQRPTFSELVEHLGNLLQANAQQDGKDYIVLPISETLSMEEDSGLSLPTSPVSCMEEEEVCDPKFHYDNTAGISQYLQNSKRKSRPVSVKTFEDIPLEEPEVKVIPDDNQTDSGMVLASEELKTLEDRTKLSPSFGGMVPSKSRESVASEGSNQTSGYQSGYHSDDTDTTVYSSEEAELLKLIEIGVQTGSTAQILQPDSGTTLSSPPV
T14825	DRUGINFO	D08NYL	AGN211745	Discontinued in Phase 2

T62763	TARGETID	T62763
T62763	FORMERID	TTDI02323
T62763	UNIPROID	FGF10_HUMAN
T62763	TARGNAME	Fibroblast growth factor-10 (FGF10)
T62763	GENENAME	FGF10
T62763	TARGTYPE	Discontinued
T62763	SYNONYMS	Fibroblast growth factor 10; FGF10
T62763	FUNCTION	Plays an important role in the regulation of embryonic development, cell proliferation and cell differentiation. Required for normal branching morphogenesis. May play a role in wound healing.
T62763	PDBSTRUC	1NUN
T62763	BIOCLASS	Growth factor
T62763	SEQUENCE	MWKWILTHCASAFPHLPGCCCCCFLLLFLVSSVPVTCQALGQDMVSPEATNSSSSSFSSPSSAGRHVRSYNHLQGDVRWRKLFSFTKYFLKIEKNGKVSGTKKENCPYSILEITSVEIGVVAVKAINSNYYLAMNKKGKLYGSKEFNNDCKLKERIEENGYNTYASFNWQHNGRQMYVALNGKGAPRRGQKTRRKNTSAHFLPMVVHS
T62763	DRUGINFO	D0P4RA	Repifermin	Discontinued in Phase 2

T92424	TARGETID	T92424
T92424	FORMERID	TTDI01781
T92424	UNIPROID	ITAV_HUMAN-ITB5_HUMAN
T92424	TARGNAME	Integrin alpha-V/beta-5 (ITGAV/B5)
T92424	GENENAME	ITGAV-ITGB5
T92424	TARGTYPE	Discontinued
T92424	SYNONYMS	Integrin; Vitronectin receptor
T92424	FUNCTION	Binds to matrix macromolecules and proteinases and thereby stimulates angiogenesis. However, it inhibits angiogenesis.
T92424	BIOCLASS	Integrin
T92424	SEQUENCE	MPRAPAPLYACLLGLCALLPRLAGLNICTSGSATSCEECLLIHPKCAWCSKEDFGSPRSITSRCDLRANLVKNGCGGEIESPASSFHVLRSLPLSSKGSGSAGWDVIQMTPQEIAVNLRPGDKTTFQLQVRQVEDYPVDLYYLMDLSLSMKDDLDNIRSLGTKLAEEMRKLTSNFRLGFGSFVDKDISPFSYTAPRYQTNPCIGYKLFPNCVPSFGFRHLLPLTDRVDSFNEEVRKQRVSRNRDAPEGGFDAVLQAAVCKEKIGWRKDALHLLVFTTDDVPHIALDGKLGGLVQPHDGQCHLNEANEYTASNQMDYPSLALLGEKLAENNINLIFAVTKNHYMLYKNFTALIPGTTVEILDGDSKNIIQLIINAYNSIRSKVELSVWDQPEDLNLFFTATCQDGVSYPGQRKCEGLKIGDTASFEVSLEARSCPSRHTEHVFALRPVGFRDSLEVGVTYNCTCGCSVGLEPNSARCNGSGTYVCGLCECSPGYLGTRCECQDGENQSVYQNLCREAEGKPLCSGRGDCSCNQCSCFESEFGKIYGPFCECDNFSCARNKGVLCSGHGECHCGECKCHAGYIGDNCNCSTDISTCRGRDGQICSERGHCLCGQCQCTEPGAFGEMCEKCPTCPDACSTKRDCVECLLLHSGKPDNQTCHSLCRDEVITWVDTIVKDDQEAVLCFYKTAKDCVMMFTYVELPSGKSNLTVLREPECGNTPNAMTILLAVVGSILLVGLALLAIWKLLVTIHDRREFAKFQSERSRARYEMASNPLYRKPISTHTVDFTFNKFNKSYNGTVDMAFPPRRRLRLGPRGLPLLLSGLLLPLCRAFNLDVDSPAEYSGPEGSYFGFAVDFFVPSASSRMFLLVGAPKANTTQPGIVEGGQVLKCDWSSTRRCQPIEFDATGNRDYAKDDPLEFKSHQWFGASVRSKQDKILACAPLYHWRTEMKQEREPVGTCFLQDGTKTVEYAPCRSQDIDADGQGFCQGGFSIDFTKADRVLLGGPGSFYWQGQLISDQVAEIVSKYDPNVYSIKYNNQLATRTAQAIFDDSYLGYSVAVGDFNGDGIDDFVSGVPRAARTLGMVYIYDGKNMSSLYNFTGEQMAAYFGFSVAATDINGDDYADVFIGAPLFMDRGSDGKLQEVGQVSVSLQRASGDFQTTKLNGFEVFARFGSAIAPLGDLDQDGFNDIAIAAPYGGEDKKGIVYIFNGRSTGLNAVPSQILEGQWAARSMPPSFGYSMKGATDIDKNGYPDLIVGAFGVDRAILYRARPVITVNAGLEVYPSILNQDNKTCSLPGTALKVSCFNVRFCLKADGKGVLPRKLNFQVELLLDKLKQKGAIRRALFLYSRSPSHSKNMTISRGGLMQCEELIAYLRDESEFRDKLTPITIFMEYRLDYRTAADTTGLQPILNQFTPANISRQAHILLDCGEDNVCKPKLEVSVDSDQKKIYIGDDNPLTLIVKAQNQGEGAYEAELIVSIPLQADFIGVVRNNEALARLSCAFKTENQTRQVVCDLGNPMKAGTQLLAGLRFSVHQQSEMDTSVKFDLQIQSSNLFDKVSPVVSHKVDLAVLAAVEIRGVSSPDHVFLPIPNWEHKENPETEEDVGPVVQHIYELRNNGPSSFSKAMLHLQWPYKYNNNTLLYILHYDIDGPMNCTSDMEINPLRIKISSLQTTEKNDTVAGQGERDHLITKRDLALSEGDIHTLGCGVAQCLKIVCQVGRLDRGKSAILYVKSLLWTETFMNKENQNHSYSLKSSASFNVIEFPYKNLPIEDITNSTLVTTNVTWGIQPAPMPVPVWVIILAVLAGLLLLAVLVFVMYRMGFFKRVRPPQEEQEREQLQPHENGEGNSET
T92424	DRUGINFO	D02VIP	SB-267268	Discontinued in Phase 1
T92424	DRUGINFO	D04YEY	PS-388023	Terminated

T08583	TARGETID	T08583
T08583	FORMERID	TTDR00395
T08583	UNIPROID	TRBM_HUMAN
T08583	TARGNAME	Thrombomodulin (THBD)
T08583	GENENAME	THBD
T08583	TARGTYPE	Discontinued
T08583	SYNONYMS	TM; THRM; Fetomodulin; CD141 antigen; CD141
T08583	FUNCTION	Thrombomodulin is a specific endothelial cell receptor that forms a 1:1 stoichiometric complex with thrombin. This complex is responsible for the conversion of protein C to the activated protein C (protein Ca). Once evolved, protein Ca scissions the activated cofactors of the coagulation mechanism, factor Va and factor VIIIa, and thereby reduces the amount of thrombin generated.
T08583	PDBSTRUC	5TO3; 3GIS; 2ADX; 1ZAQ; 1TMR
T08583	BIOCLASS	Growth factor
T08583	SEQUENCE	MLGVLVLGALALAGLGFPAPAEPQPGGSQCVEHDCFALYPGPATFLNASQICDGLRGHLMTVRSSVAADVISLLLNGDGGVGRRRLWIGLQLPPGCGDPKRLGPLRGFQWVTGDNNTSYSRWARLDLNGAPLCGPLCVAVSAAEATVPSEPIWEEQQCEVKADGFLCEFHFPATCRPLAVEPGAAAAAVSITYGTPFAARGADFQALPVGSSAAVAPLGLQLMCTAPPGAVQGHWAREAPGAWDCSVENGGCEHACNAIPGAPRCQCPAGAALQADGRSCTASATQSCNDLCEHFCVPNPDQPGSYSCMCETGYRLAADQHRCEDVDDCILEPSPCPQRCVNTQGGFECHCYPNYDLVDGECVEPVDPCFRANCEYQCQPLNQTSYLCVCAEGFAPIPHEPHRCQMFCNQTACPADCDPNTQASCECPEGYILDDGFICTDIDECENGGFCSGVCHNLPGTFECICGPDSALARHIGTDCDSGKVDGGDSGSGEPPPSPTPGSTLTPPAVGLVHSGLLIGISIASLCLVVALLALLCHLRKKQGAARAKMEYKCAAPSKEVVLQHVRTERTPQRL
T08583	DRUGINFO	D0Y4EM	Thrombomodulin	Discontinued in Phase 3

T26463	TARGETID	T26463
T26463	UNIPROID	DPOLA_HUMAN
T26463	TARGNAME	DNA polymerase alpha catalytic p180 (POLA1)
T26463	GENENAME	POLA1
T26463	TARGTYPE	Discontinued
T26463	SYNONYMS	POLA; DNA polymerase alpha catalytic subunit p180; DNA polymerase alpha catalytic subunit
T26463	FUNCTION	During the S phase of the cell cycle, the DNA polymerase alpha complex (composed of a catalytic subunit POLA1/p180, a regulatory subunit POLA2/p70 and two primase subunits PRIM1/p49 and PRIM2/p58) is recruited to DNA at the replicative forks via direct interactions with MCM10 and WDHD1. The primase subunit of the polymerase alpha complex initiates DNA synthesis by oligomerising short RNA primers on both leading and lagging strands. These primers are initially extended by the polymerase alpha catalytic subunit and subsequently transferred to polymerase delta and polymerase epsilon for processive synthesis on the lagging and leading strand, respectively. The reason this transfer occurs is because the polymerase alpha has limited processivity and lacks intrinsic 3' exonuclease activity for proofreading error, and therefore is not well suited for replicating long complexes. In the cytosol, responsible for a substantial proportion of the physiological concentration of cytosolic RNA:DNA hybrids, which are necessary to prevent spontaneous activation of type I interferon responses. Plays an essential role in the initiation of DNA replication.
T26463	PDBSTRUC	6AS7; 5IUD; 5EXR; 4Y97; 4QCL
T26463	BIOCLASS	Kinase
T26463	ECNUMBER	EC 2.7.7.7
T26463	SEQUENCE	MAPVHGDDSLSDSGSFVSSRARREKKSKKGRQEALERLKKAKAGEKYKYEVEDFTGVYEEVDEEQYSKLVQARQDDDWIVDDDGIGYVEDGREIFDDDLEDDALDADEKGKDGKARNKDKRNVKKLAVTKPNNIKSMFIACAGKKTADKAVDLSKDGLLGDILQDLNTETPQITPPPVMILKKKRSIGASPNPFSVHTATAVPSGKIASPVSRKEPPLTPVPLKRAEFAGDDVQVESTEEEQESGAMEFEDGDFDEPMEVEEVDLEPMAAKAWDKESEPAEEVKQEADSGKGTVSYLGSFLPDVSCWDIDQEGDSSFSVQEVQVDSSHLPLVKGADEEQVFHFYWLDAYEDQYNQPGVVFLFGKVWIESAETHVSCCVMVKNIERTLYFLPREMKIDLNTGKETGTPISMKDVYEEFDEKIATKYKIMKFKSKPVEKNYAFEIPDVPEKSEYLEVKYSAEMPQLPQDLKGETFSHVFGTNTSSLELFLMNRKIKGPCWLEVKSPQLLNQPVSWCKVEAMALKPDLVNVIKDVSPPPLVVMAFSMKTMQNAKNHQNEIIAMAALVHHSFALDKAAPKPPFQSHFCVVSKPKDCIFPYAFKEVIEKKNVKVEVAATERTLLGFFLAKVHKIDPDIIVGHNIYGFELEVLLQRINVCKAPHWSKIGRLKRSNMPKLGGRSGFGERNATCGRMICDVEISAKELIRCKSYHLSELVQQILKTERVVIPMENIQNMYSESSQLLYLLEHTWKDAKFILQIMCELNVLPLALQITNIAGNIMSRTLMGGRSERNEFLLLHAFYENNYIVPDKQIFRKPQQKLGDEDEEIDGDTNKYKKGRKKAAYAGGLVLDPKVGFYDKFILLLDFNSLYPSIIQEFNICFTTVQRVASEAQKVTEDGEQEQIPELPDPSLEMGILPREIRKLVERRKQVKQLMKQQDLNPDLILQYDIRQKALKLTANSMYGCLGFSYSRFYAKPLAALVTYKGREILMHTKEMVQKMNLEVIYGDTDSIMINTNSTNLEEVFKLGNKVKSEVNKLYKLLEIDIDGVFKSLLLLKKKKYAALVVEPTSDGNYVTKQELKGLDIVRRDWCDLAKDTGNFVIGQILSDQSRDTIVENIQKRLIEIGENVLNGSVPVSQFEINKALTKDPQDYPDKKSLPHVHVALWINSQGGRKVKAGDTVSYVICQDGSNLTASQRAYAPEQLQKQDNLTIDTQYYLAQQIHPVVARICEPIDGIDAVLIATWLGLDPTQFRVHHYHKDEENDALLGGPAQLTDEEKYRDCERFKCPCPTCGTENIYDNVFDGSGTDMEPSLYRCSNIDCKASPLTFTVQLSNKLIMDIRRFIKKYYDGWLICEEPTCRNRTRHLPLQFSRTGPLCPACMKATLQPEYSDKSLYTQLCFYRYIFDAECALEKLTTDHEKDKLKKQFFTPKVLQDYRKLKNTAEQFLSRSGYSEVNLSKLFAGCAVKS
T26463	DRUGINFO	D02PIH	HO-221	Discontinued in Phase 1

T77473	TARGETID	T77473
T77473	FORMERID	TTDI02369
T77473	UNIPROID	TCTP_HUMAN
T77473	TARGNAME	Translationally-controlled tumor protein (TPT1)
T77473	GENENAME	TPT1
T77473	TARGTYPE	Discontinued
T77473	SYNONYMS	p23; TPT1; TCTP; Histamine-releasing factor; HRF; Fortilin
T77473	FUNCTION	Involved in calcium binding and microtubule stabilization.
T77473	PDBSTRUC	5O9M; 5O9L; 4Z9V; 3EBM; 2HR9
T77473	SEQUENCE	MIIYRDLISHDEMFSDIYKIREIADGLCLEVEGKMVSRTEGNIDDSLIGGNASAEGPEGEGTESTVITGVDIVMNHHLQETSFTKEAYKKYIKDYMKSIKGKLEEQRPERVKPFMTGAAEQIKHILANFKNYQFFIGENMNPDGMVALLDYREDGVTPYMIFFKDGLEMEKC
T77473	DRUGINFO	D01CEQ	CER-227185	Discontinued in Phase 1/2

T92328	TARGETID	T92328
T92328	FORMERID	TTDS00165
T92328	UNIPROID	RYR1_HUMAN
T92328	TARGNAME	Ryanodine receptor 1 (RYR1)
T92328	GENENAME	RYR1
T92328	TARGTYPE	Discontinued
T92328	SYNONYMS	Type 1 ryanodine receptor; Skeletal muscle-type ryanodine receptor; Skeletal muscle ryanodine receptor; Skeletal muscle calcium release channel; RyR1; RyR; RYR-1; RYDR; Cardiac muscleryanodine receptor-calcium release channel; Cardiac muscle-type ryanodine receptor; Brain-type ryanodine receptor; Brain ryanodine receptor-calcium release channel
T92328	FUNCTION	Repeated very high-level exercise increases the open probability of the channel and leads to Ca(2+) leaking into the cytoplasm. Can also mediate the release of Ca(2+) from intracellular stores in neurons, and may thereby promote prolonged Ca(2+) signaling in the brain. Required for normal embryonic development of muscle fibers and skeletal muscle. Required for normal heart morphogenesis, skin development and ossification during embryogenesis. Calcium channel that mediates the release of Ca(2+) from the sarcoplasmic reticulum into the cytoplasm and thereby plays a key role in triggering muscle contraction following depolarization of T-tubules.
T92328	BIOCLASS	Ryanodine-inositol 1,4,5-triphosphate receptor calcium channel
T92328	SEQUENCE	MGDAEGEDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFVLEQSLSVRALQEMLANTVEAGVESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACWWTMHPASKQRSEGEKVRVGDDIILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPICSRCEEGFVTGGHVLRLFHGHMDECLTISPADSDDQRRLVYYEGGAVCTHARSLWRLEPLRISWSGSHLRWGQPLRVRHVTTGQYLALTEDQGLVVVDASKAHTKATSFCFRISKEKLDVAPKRDVEGMGPPEIKYGESLCFVQHVASGLWLTYAAPDPKALRLGVLKKKAMLHQEGHMDDALSLTRCQQEESQAARMIHSTNGLYNQFIKSLDSFSGKPRGSGPPAGTALPIEGVILSLQDLIIYFEPPSEDLQHEEKQSKLRSLRNRQSLFQEEGMLSMVLNCIDRLNVYTTAAHFAEFAGEEAAESWKEIVNLLYELLASLIRGNRSNCALFSTNLDWLVSKLDRLEASSGILEVLYCVLIESPEVLNIIQENHIKSIISLLDKHGRNHKVLDVLCSLCVCNGVAVRSNQDLITENLLPGRELLLQTNLINYVTSIRPNIFVGRAEGTTQYSKWYFEVMVDEVTPFLTAQATHLRVGWALTEGYTPYPGAGEGWGGNGVGDDLYSYGFDGLHLWTGHVARPVTSPGQHLLAPEDVISCCLDLSVPSISFRINGCPVQGVFESFNLDGLFFPVVSFSAGVKVRFLLGGRHGEFKFLPPPGYAPCHEAVLPRERLHLEPIKEYRREGPRGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPHLERIREKLAENIHELWALTRIEQGWTYGPVRDDNKRLHPCLVDFHSLPEPERNYNLQMSGETLKTLLALGCHVGMADEKAEDNLKKTKLPKTYMMSNGYKPAPLDLSHVRLTPAQTTLVDRLAENGHNVWARDRVGQGWSYSAVQDIPARRNPRLVPYRLLDEATKRSNRDSLCQAVRTLLGYGYNIEPPDQEPSQVENQSRCDRVRIFRAEKSYTVQSGRWYFEFEAVTTGEMRVGWARPELRPDVELGADELAYVFNGHRGQRWHLGSEPFGRPWQPGDVVGCMIDLTENTIIFTLNGEVLMSDSGSETAFREIEIGDGFLPVCSLGPGQVGHLNLGQDVSSLRFFAICGLQEGFEPFAINMQRPVTTWFSKGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLRLTHRTWGSQNSLVEMLFLRLSLPVQFHQHFRCTAGATPLAPPGLQPPAEDEARAAEPDPDYENLRRSAGGWSEAENGKEGTAKEGAPGGTPQAGGEAQPARAENEKDATTEKNKKRGFLFKAKKVAMMTQPPATPTLPRLPHDVVPADNRDDPEIILNTTTYYYSVRVFAGQEPSCVWAGWVTPDYHQHDMSFDLSKVRVVTVTMGDEQGNVHSSLKCSNCYMVWGGDFVSPGQQGRISHTDLVIGCLVDLATGLMTFTANGKESNTFFQVEPNTKLFPAVFVLPTHQNVIQFELGKQKNIMPLSAAMFQSERKNPAPQCPPRLEMQMLMPVSWSRMPNHFLQVETRRAGERLGWAVQCQEPLTMMALHIPEENRCMDILELSERLDLQRFHSHTLRLYRAVCALGNNRVAHALCSHVDQAQLLHALEDAHLPGPLRAGYYDLLISIHLESACRSRRSMLSEYIVPLTPETRAITLFPPGRSTENGHPRHGLPGVGVTTSLRPPHHFSPPCFVAALPAAGAAEAPARLSPAIPLEALRDKALRMLGEAVRDGGQHARDPVGGSVEFQFVPVLKLVSTLLVMGIFGDEDVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVESLAAFAERYVDKLQANQRSRYGLLIKAFSMTAAETARRTREFRSPPQEQINMLLQFKDGTDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLDGEEEEPEEETTLGSRLMSLLEKVRLVKKKEEKPEEERSAEESKPRSLQELVSHMVVRWAQEDFVQSPELVRAMFSLLHRQYDGLGELLRALPRAYTISPSSVEDTMSLLECLGQIRSLLIVQMGPQEENLMIQSIGNIMNNKVFYQHPNLMRALGMHETVMEVMVNVLGGGESKEIRFPKMVTSCCRFLCYFCRISRQNQRSMFDHLSYLLENSGIGLGMQGSTPLDVAAASVIDNNELALALQEQDLEKVVSYLAGCGLQSCPMLVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEGGSGLLAAIEEAIRISEDPARDGPGIRRDRRREHFGEEPPEENRVHLGHAIMSFYAALIDLLGRCAPEMHLIQAGKGEALRIRAILRSLVPLEDLVGIISLPLQIPTLGKDGALVQPKMSASFVPDHKASMVLFLDRVYGIENQDFLLHVLDVGFLPDMRAAASLDTATFSTTEMALALNRYLCLAVLPLITKCAPLFAGTEHRAIMVDSMLHTVYRLSRGRSLTKAQRDVIEDCLMSLCRYIRPSMLQHLLRRLVFDVPILNEFAKMPLKLLTNHYERCWKYYCLPTGWANFGVTSEEELHLTRKLFWGIFDSLAHKKYDPELYRMAMPCLCAIAGALPPDYVDASYSSKAEKKATVDAEGNFDPRPVETLNVIIPEKLDSFINKFAEYTHEKWAFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRWPIKESLKAMIAWEWTIEKAREGEEEKTEKKKTRKISQSAQTYDPREGYNPQPPDLSAVTLSRELQAMAEQLAENYHNTWGRKKKQELEAKGGGTHPLLVPYDTLTAKEKARDREKAQELLKFLQMNGYAVTRGLKDMELDSSSIEKRFAFGFLQQLLRWMDISQEFIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHASNKEKEMITSLFCKLAALVRHRVSLFGTDAPAVVNCLHILARSLDARTVMKSGPEIVKAGLRSFFESASEDIEKMVENLRLGKVSQARTQVKGVGQNLTYTTVALLPVLTTLFQHIAQHQFGDDVILDDVQVSCYRTLCSIYSLGTTKNTYVEKLRPALGECLARLAAAMPVAFLEPQLNEYNACSVYTTKSPRERAILGLPNSVEEMCPDIPVLERLMADIGGLAESGARYTEMPHVIEITLPMLCSYLPRWWERGPEAPPSALPAGAPPPCTAVTSDHLNSLLGNILRIIVNNLGIDEASWMKRLAVFAQPIVSRARPELLQSHFIPTIGRLRKRAGKVVSEEEQLRLEAKAEAQEGELLVRDEFSVLCRDLYALYPLLIRYVDNNRAQWLTEPNPSAEELFRMVGEIFIYWSKSHNFKREEQNFVVQNEINNMSFLTADNKSKMAKAGDIQSGGSDQERTKKKRRGDRYSVQTSLIVATLKKMLPIGLNMCAPTDQDLITLAKTRYALKDTDEEVREFLHNNLHLQGKVEGSPSLRWQMALYRGVPGREEDADDPEKIVRRVQEVSAVLYYLDQTEHPYKSKKAVWHKLLSKQRRRAVVACFRMTPLYNLPTHRACNMFLESYKAAWILTEDHSFEDRMIDDLSKAGEQEEEEEEVEEKKPDPLHQLVLHFSRTALTEKSKLDEDYLYMAYADIMAKSCHLEEGGENGEAEEEVEVSFEEKQMEKQRLLYQQARLHTRGAAEMVLQMISACKGETGAMVSSTLKLGISILNGGNAEVQQKMLDYLKDKKEVGFFQSIQALMQTCSVLDLNAFERQNKAEGLGMVNEDGTVINRQNGEKVMADDEFTQDLFRFLQLLCEGHNNDFQNYLRTQTGNTTTINIIICTVDYLLRLQESISDFYWYYSGKDVIEEQGKRNFSKAMSVAKQVFNSLTEYIQGPCTGNQQSLAHSRLWDAVVGFLHVFAHMMMKLAQDSSQIELLKELLDLQKDMVVMLLSLLEGNVVNGMIARQMVDMLVESSSNVEMILKFFDMFLKLKDIVGSEAFQDYVTDPRGLISKKDFQKAMDSQKQFSGPEIQFLLSCSEADENEMINCEEFANRFQEPARDIGFNVAVLLTNLSEHVPHDPRLHNFLELAESILEYFRPYLGRIEIMGASRRIERIYFEISETNRAQWEMPQVKESKRQFIFDVVNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRRLRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGASEGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPELEPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPGEDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELARKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNFFRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS
T92328	DRUGINFO	D0T2LP	ARM036	Discontinued in Phase 2
T92328	DRUGINFO	D0C3HS	CDP-1050	Discontinued in Phase 1
T92328	DRUGINFO	D01MHP	Benzyloxycarbonyl-glycylryanodine	Investigative
T92328	DRUGINFO	D02DZN	Ruthenium red	Investigative
T92328	DRUGINFO	D04QNI	(O10eq)-beta-alanyl-anhydro-ryanodine	Investigative
T92328	DRUGINFO	D05QKM	GLYCYLRYANODINE	Investigative
T92328	DRUGINFO	D05VJH	N-methyl ryanodine-succinamidate	Investigative
T92328	DRUGINFO	D08LUJ	Ryanodine	Investigative
T92328	DRUGINFO	D0G2RB	Di-Benzyloxycarbonyl-guanidino acetylryanodine	Investigative
T92328	DRUGINFO	D0GM8V	(O10eq)-beta-guanidinopropionylryanodine	Investigative
T92328	DRUGINFO	D0J6WG	(O10eq)-guanidino acetylryanodine	Investigative
T92328	DRUGINFO	D0S6KD	(O10eq)-beta-alanylryanodine	Investigative
T92328	DRUGINFO	D0U3DW	ANHYDRORYANIDINE	Investigative
T92328	DRUGINFO	D0WT2Z	(O10eq)-Benzyloxycarbonyl-beta-alanylryanodine	Investigative

T45074	TARGETID	T45074
T45074	FORMERID	TTDI01936
T45074	UNIPROID	CACP_HUMAN
T45074	TARGNAME	Carnitine acyltransferase (CRAT)
T45074	GENENAME	CRAT
T45074	TARGTYPE	Discontinued
T45074	SYNONYMS	Carnitine acetylase; Carnitine O-acetyltransferase; CRAT
T45074	FUNCTION	Catalyzes the transfer of the acyl group of long-chain fatty acid-CoA conjugates onto carnitine, an essential step for the mitochondrial uptake of long-chain fatty acids and their subsequent beta-oxidation in the mitochondrion. Plays an important role in triglyceride metabolism.
T45074	PDBSTRUC	1S5O; 1NM8
T45074	BIOCLASS	Acyltransferase
T45074	ECNUMBER	EC 2.3.1.7
T45074	SEQUENCE	MLAFAARTVVKPLGFLKPFSLMKASSRFKAHQDALPRLPVPPLQQSLDHYLKALQPIVSEEEWAHTKQLVDEFQASGGVGERLQKGLERRARKTENWLSEWWLKTAYLQYRQPVVIYSSPGVMLPKQDFVDLQGQLRFAAKLIEGVLDFKVMIDNETLPVEYLGGKPLCMNQYYQILSSCRVPGPKQDTVSNFSKTKKPPTHITVVHNYQFFELDVYHSDGTPLTADQIFVQLEKIWNSSLQTNKEPVGILTSNHRNSWAKAYNTLIKDKVNRDSVRSIQKSIFTVCLDATMPRVSEDVYRSHVAGQMLHGGGSRLNSGNRWFDKTLQFIVAEDGSCGLVYEHAAAEGPPIVTLLDYVIEYTKKPELVRSPLVPLPMPKKLRFNITPEIKSDIEKAKQNLSIMIQDLDITVMVFHHFGKDFPKSEKLSPDAFIQMALQLAYYRIYGQACATYESASLRMFHLGRTDTIRSASMDSLTFVKAMDDSSVTEHQKVELLRKAVQAHRGYTDRAIRGEAFDRHLLGLKLQAIEDLVSMPDIFMDTSYAIAMHFHLSTSQVPAKTDCVMFFGPVVPDGYGVCYNPMEAHINFSLSAYNSCAETNAARLAHYLEKALLDMRALLQSHPRAKL
T45074	DRUGINFO	D01FCK	Teglicar	Discontinued in Phase 2
T45074	DRUGINFO	D0LR2Q	LXR-015-2	Terminated
T45074	DRUGINFO	D0W3NA	Coenzyme A	Investigative

T73075	TARGETID	T73075
T73075	FORMERID	TTDI01967
T73075	UNIPROID	PGBM_HUMAN
T73075	TARGNAME	Perlecan (HSPG)
T73075	GENENAME	HSPG2
T73075	TARGTYPE	Discontinued
T73075	SYNONYMS	LG3 peptide; Basement membranespecific heparan sulfate proteoglycan coreprotein; Basement membrane-specific heparan sulfate proteoglycan core protein
T73075	FUNCTION	Component of the glomerular basement membrane (GBM), responsible for the fixed negative electrostatic membrane charge, and which provides a barrier which is both size- and charge-selective. It serves as an attachment substrate for cells. Plays essential roles in vascularization. Critical for normal heart development and for regulating the vascular response to injury. Also required for avascular cartilage development. Integral component of basement membranes.
T73075	PDBSTRUC	3SH5; 3SH4
T73075	SEQUENCE	MGWRAAGALLLALLLHGRLLAVTHGLRAYDGLSLPEDIETVTASQMRWTHSYLSDDEDMLADSISGDDLGSGDLGSGDFQMVYFRALVNFTRSIEYSPQLEDAGSREFREVSEAVVDTLESEYLKIPGDQVVSVVFIKELDGWVFVELDVGSEGNADGAQIQEMLLRVISSGSVASYVTSPQGFQFRRLGTVPQFPRACTEAEFACHSYNECVALEYRCDRRPDCRDMSDELNCEEPVLGISPTFSLLVETTSLPPRPETTIMRQPPVTHAPQPLLPGSVRPLPCGPQEAACRNGHCIPRDYLCDGQEDCEDGSDELDCGPPPPCEPNEFPCGNGHCALKLWRCDGDFDCEDRTDEANCPTKRPEEVCGPTQFRCVSTNMCIPASFHCDEESDCPDRSDEFGCMPPQVVTPPRESIQASRGQTVTFTCVAIGVPTPIINWRLNWGHIPSHPRVTVTSEGGRGTLIIRDVKESDQGAYTCEAMNARGMVFGIPDGVLELVPQRGPCPDGHFYLEHSAACLPCFCFGITSVCQSTRRFRDQIRLRFDQPDDFKGVNVTMPAQPGTPPLSSTQLQIDPSLHEFQLVDLSRRFLVHDSFWALPEQFLGNKVDSYGGSLRYNVRYELARGMLEPVQRPDVVLMGAGYRLLSRGHTPTQPGALNQRQVQFSEEHWVHESGRPVQRAELLQVLQSLEAVLIQTVYNTKMASVGLSDIAMDTTVTHATSHGRAHSVEECRCPIGYSGLSCESCDAHFTRVPGGPYLGTCSGCNCNGHASSCDPVYGHCLNCQHNTEGPQCNKCKAGFFGDAMKATATSCRPCPCPYIDASRRFSDTCFLDTDGQATCDACAPGYTGRRCESCAPGYEGNPIQPGGKCRPVNQEIVRCDERGSMGTSGEACRCKNNVVGRLCNECADGSFHLSTRNPDGCLKCFCMGVSRHCTSSSWSRAQLHGASEEPGHFSLTNAASTHTTNEGIFSPTPGELGFSSFHRLLSGPYFWSLPSRFLGDKVTSYGGELRFTVTQRSQPGSTPLHGQPLVVLQGNNIILEHHVAQEPSPGQPSTFIVPFREQAWQRPDGQPATREHLLMALAGIDTLLIRASYAQQPAESRVSGISMDVAVPEETGQDPALEVEQCSCPPGYRGPSCQDCDTGYTRTPSGLYLGTCERCSCHGHSEACEPETGACQGCQHHTEGPRCEQCQPGYYGDAQRGTPQDCQLCPCYGDPAAGQAAHTCFLDTDGHPTCDACSPGHSGRHCERCAPGYYGNPSQGQPCQRDSQVPGPIGCNCDPQGSVSSQCDAAGQCQCKAQVEGLTCSHCRPHHFHLSASNPDGCLPCFCMGITQQCASSAYTRHLISTHFAPGDFQGFALVNPQRNSRLTGEFTVEPVPEGAQLSFGNFAQLGHESFYWQLPETYQGDKVAAYGGKLRYTLSYTAGPQGSPLSDPDVQITGNNIMLVASQPALQGPERRSYEIMFREEFWRRPDGQPATREHLLMALADLDELLIRATFSSVPLAASISAVSLEVAQPGPSNRPRALEVEECRCPPGYIGLSCQDCAPGYTRTGSGLYLGHCELCECNGHSDLCHPETGACSQCQHNAAGEFCELCAPGYYGDATAGTPEDCQPCACPLTNPENMFSRTCESLGAGGYRCTACEPGYTGQYCEQCGPGYVGNPSVQGGQCLPETNQAPLVVEVHPARSIVPQGGSHSLRCQVSGSPPHYFYWSREDGRPVPSGTQQRHQGSELHFPSVQPSDAGVYICTCRNLHQSNTSRAELLVTEAPSKPITVTVEEQRSQSVRPGADVTFICTAKSKSPAYTLVWTRLHNGKLPTRAMDFNGILTIRNVQLSDAGTYVCTGSNMFAMDQGTATLHVQASGTLSAPVVSIHPPQLTVQPGQLAEFRCSATGSPTPTLEWTGGPGGQLPAKAQIHGGILRLPAVEPTDQAQYLCRAHSSAGQQVARAVLHVHGGGGPRVQVSPERTQVHAGRTVRLYCRAAGVPSATITWRKEGGSLPPQARSERTDIATLLIPAITTADAGFYLCVATSPAGTAQARIQVVVLSASDASPPPVKIESSSPSVTEGQTLDLNCVVAGSAHAQVTWYRRGGSLPPHTQVHGSRLRLPQVSPADSGEYVCRVENGSGPKEASITVSVLHGTHSGPSYTPVPGSTRPIRIEPSSSHVAEGQTLDLNCVVPGQAHAQVTWHKRGGSLPARHQTHGSLLRLHQVTPADSGEYVCHVVGTSGPLEASVLVTIEASVIPGPIPPVRIESSSSTVAEGQTLDLSCVVAGQAHAQVTWYKRGGSLPARHQVRGSRLYIFQASPADAGQYVCRASNGMEASITVTVTGTQGANLAYPAGSTQPIRIEPSSSQVAEGQTLDLNCVVPGQSHAQVTWHKRGGSLPVRHQTHGSLLRLYQASPADSGEYVCRVLGSSVPLEASVLVTIEPAGSVPALGVTPTVRIESSSSQVAEGQTLDLNCLVAGQAHAQVTWHKRGGSLPARHQVHGSRLRLLQVTPADSGEYVCRVVGSSGTQEASVLVTIQQRLSGSHSQGVAYPVRIESSSASLANGHTLDLNCLVASQAPHTITWYKRGGSLPSRHQIVGSRLRIPQVTPADSGEYVCHVSNGAGSRETSLIVTIQGSGSSHVPSVSPPIRIESSSPTVVEGQTLDLNCVVARQPQAIITWYKRGGSLPSRHQTHGSHLRLHQMSVADSGEYVCRANNNIDALEASIVISVSPSAGSPSAPGSSMPIRIESSSSHVAEGETLDLNCVVPGQAHAQVTWHKRGGSLPSHHQTRGSRLRLHHVSPADSGEYVCRVMGSSGPLEASVLVTIEASGSSAVHVPAPGGAPPIRIEPSSSRVAEGQTLDLKCVVPGQAHAQVTWHKRGGNLPARHQVHGPLLRLNQVSPADSGEYSCQVTGSSGTLEASVLVTIEPSSPGPIPAPGLAQPIYIEASSSHVTEGQTLDLNCVVPGQAHAQVTWYKRGGSLPARHQTHGSQLRLHLVSPADSGEYVCRAASGPGPEQEASFTVTVPPSEGSSYRLRSPVISIDPPSSTVQQGQDASFKCLIHDGAAPISLEWKTRNQELEDNVHISPNGSIITIVGTRPSNHGTYRCVASNAYGVAQSVVNLSVHGPPTVSVLPEGPVWVKVGKAVTLECVSAGEPRSSARWTRISSTPAKLEQRTYGLMDSHAVLQISSAKPSDAGTYVCLAQNALGTAQKQVEVIVDTGAMAPGAPQVQAEEAELTVEAGHTATLRCSATGSPAPTIHWSKLRSPLPWQHRLEGDTLIIPRVAQQDSGQYICNATSPAGHAEATIILHVESPPYATTVPEHASVQAGETVQLQCLAHGTPPLTFQWSRVGSSLPGRATARNELLHFERAAPEDSGRYRCRVTNKVGSAEAFAQLLVQGPPGSLPATSIPAGSTPTVQVTPQLETKSIGASVEFHCAVPSDRGTQLRWFKEGGQLPPGHSVQDGVLRIQNLDQSCQGTYICQAHGPWGKAQASAQLVIQALPSVLINIRTSVQTVVVGHAVEFECLALGDPKPQVTWSKVGGHLRPGIVQSGGVVRIAHVELADAGQYRCTATNAAGTTQSHVLLLVQALPQISMPQEVRVPAGSAAVFPCIASGYPTPDISWSKLDGSLPPDSRLENNMLMLPSVRPQDAGTYVCTATNRQGKVKAFAHLQVPERVVPYFTQTPYSFLPLPTIKDAYRKFEIKITFRPDSADGMLLYNGQKRVPGSPTNLANRQPDFISFGLVGGRPEFRFDAGSGMATIRHPTPLALGHFHTVTLLRSLTQGSLIVGDLAPVNGTSQGKFQGLDLNEELYLGGYPDYGAIPKAGLSSGFIGCVRELRIQGEEIVFHDLNLTAHGISHCPTCRDRPCQNGGQCHDSESSSYVCVCPAGFTGSRCEHSQALHCHPEACGPDATCVNRPDGRGYTCRCHLGRSGLRCEEGVTVTTPSLSGAGSYLALPALTNTHHELRLDVEFKPLAPDGVLLFSGGKSGPVEDFVSLAMVGGHLEFRYELGSGLAVLRSAEPLALGRWHRVSAERLNKDGSLRVNGGRPVLRSSPGKSQGLNLHTLLYLGGVEPSVPLSPATNMSAHFRGCVGEVSVNGKRLDLTYSFLGSQGIGQCYDSSPCERQPCQHGATCMPAGEYEFQCLCRDGFKGDLCEHEENPCQLREPCLHGGTCQGTRCLCLPGFSGPRCQQGSGHGIAESDWHLEGSGGNDAPGQYGAYFHDDGFLAFPGHVFSRSLPEVPETIELEVRTSTASGLLLWQGVEVGEAGQGKDFISLGLQDGHLVFRYQLGSGEARLVSEDPINDGEWHRVTALREGRRGSIQVDGEELVSGRSPGPNVAVNAKGSVYIGGAPDVATLTGGRFSSGITGCVKNLVLHSARPGAPPPQPLDLQHRAQAGANTRPCPS
T73075	DRUGINFO	D0ZD6Y	RUS 3108	Discontinued in Phase 1

T68668	TARGETID	T68668
T68668	FORMERID	TTDI02374
T68668	UNIPROID	MA2A1_HUMAN
T68668	TARGNAME	Golgi alpha-mannosidase II (MAN2A1)
T68668	GENENAME	MAN2A1
T68668	TARGTYPE	Discontinued
T68668	SYNONYMS	Mannosyloligosaccharide 1,31,6alphamannosidase; Mannosidase alpha class 2A member 1; Man II; MAN2A1; Alphamannosidase 2; AMan II
T68668	FUNCTION	Catalyzes the first committed step in the biosynthesis of complex N-glycans. It controls conversion of high mannose to complex N-glycans; the final hydrolytic step in the N-glycan maturation pathway.
T68668	BIOCLASS	Glycosylase
T68668	ECNUMBER	EC 3.2.1.114
T68668	SEQUENCE	MKLSRQFTVFGSAIFCVVIFSLYLMLDRGHLDYPRNPRREGSFPQGQLSMLQEKIDHLERLLAENNEIISNIRDSVINLSESVEDGPKSSQSNFSQGAGSHLLPSQLSLSVDTADCLFASQSGSHNSDVQMLDVYSLISFDNPDGGVWKQGFDITYESNEWDTEPLQVFVVPHSHNDPGWLKTFNDYFRDKTQYIFNNMVLKLKEDSRRKFIWSEISYLSKWWDIIDIQKKDAVKSLIENGQLEIVTGGWVMPDEATPHYFALIDQLIEGHQWLENNIGVKPRSGWAIDPFGHSPTMAYLLNRAGLSHMLIQRVHYAVKKHFALHKTLEFFWRQNWDLGSVTDILCHMMPFYSYDIPHTCGPDPKICCQFDFKRLPGGRFGCPWGVPPETIHPGNVQSRARMLLDQYRKKSKLFRTKVLLAPLGDDFRYCEYTEWDLQFKNYQQLFDYMNSQSKFKVKIQFGTLSDFFDALDKADETQRDKGQSMFPVLSGDFFTYADRDDHYWSGYFTSRPFYKRMDRIMESHLRAAEILYYFALRQAHKYKINKFLSSSLYTALTEARRNLGLFQHHDAITGTAKDWVVVDYGTRLFHSLMVLEKIIGNSAFLLILKDKLTYDSYSPDTFLEMDLKQKSQDSLPQKNIIRLSAEPRYLVVYNPLEQDRISLVSVYVSSPTVQVFSASGKPVEVQVSAVWDTANTISETAYEISFRAHIPPLGLKVYKILESASSNSHLADYVLYKNKVEDSGIFTIKNMINTEEGITLENSFVLLRFDQTGLMKQMMTKEDGKHHEVNVQFSWYGTTIKRDKSGAYLFLPDGNAKPYVYTTPPFVRVTHGRIYSEVTCFFDHVTHRVRLYHIQGIEGQSVEVSNIVDIRKVYNREIAMKISSDIKSQNRFYTDLNGYQIQPRMTLSKLPLQANVYPMTTMAYIQDAKHRLTLLSAQSLGVSSLNSGQIEVIMDRRLMQDDNRGLEQGIQDNKITANLFRILLEKRSAVNTEEEKKSVSYPSLLSHITSSLMNHPVIPMANKFSSPTLELQGEFSPLQSSLPCDIHLVNLRTIQSKVGNGHSNEAALILHRKGFDCRFSSKGTGLFCSTTQGKILVQKLLNKFIVESLTPSSLSLMHSPPGTQNISEINLSPMEISTFRIQLR
T68668	DRUGINFO	D0S1AD	Tridolgosir	Discontinued in Phase 2

T03871	TARGETID	T03871
T03871	FORMERID	TTDR01356
T03871	UNIPROID	RASH_HUMAN
T03871	TARGNAME	H-ras messenger RNA (HRAS mRNA)
T03871	GENENAME	HRAS
T03871	TARGTYPE	Discontinued
T03871	SYNONYMS	p21ras (mRNA); cHras (mRNA); c-H-ras (mRNA); Transforming protein p21 (mRNA); HaRas (mRNA); Ha-Ras (mRNA); H-Ras-1 (mRNA); GTPase HRas, Nterminally processed (mRNA); GTPase HRas (mRNA)
T03871	FUNCTION	Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. Involved in the activation of Ras protein signal transduction.
T03871	PDBSTRUC	821P; 721P; 6Q21; 6D5W; 6D5V
T03871	BIOCLASS	mRNA target
T03871	SEQUENCE	MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHQYREQIKRVKDSDDVPMVLVGNKCDLAARTVESRQAQDLARSYGIPYIETSAKTRQGVEDAFYTLVREIRQHKLRKLNPPDESGPGCMSCKCVLS
T03871	DRUGINFO	D01XDN	ISIS 2503	Discontinued in Phase 2
T03871	DRUGINFO	D05VBN	ISIS 6186	Investigative
T03871	DRUGINFO	D07WCX	ISIS 2502	Investigative
T03871	DRUGINFO	D0O8BP	ISIS 13920	Investigative

T16486	TARGETID	T16486
T16486	FORMERID	TTDI02380
T16486	UNIPROID	TNFA_HUMAN
T16486	TARGNAME	TNFA messenger RNA (TNF mRNA)
T16486	GENENAME	TNF
T16486	TARGTYPE	Discontinued
T16486	SYNONYMS	Tumour necrosis factor alpha (mRNA); Tumour necrosis factor (mRNA); Tumor necrosis factor ligand superfamily member 2 (mRNA); Tumor necrosis factor (mRNA); TNFalpha (mRNA); TNFSF2 (mRNA); TNFA (mRNA); TNF-alpha (mRNA); TNF-a (mRNA); TNF alpha (mRNA); Cachectin (mRNA)
T16486	FUNCTION	It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Upregulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective. Key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO/SMAC mimetic in the RT4v6 bladder cancer cell line. Induces insulin resistance in adipocytes via inhibition of insulin-induced IRS1 tyrosine phosphorylation and insulin-induced glucose uptake. Induces GKAP42 protein degradation in adipocytes which is partially responsible for TNF-induced insulin resistance. Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR.
T16486	PDBSTRUC	5YOY; 5WUX; 5UUI; 5TSW; 5MU8
T16486	BIOCLASS	mRNA target
T16486	SEQUENCE	MSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLFCLLHFGVIGPQREEFPRDLSLISPLAQAVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELRDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL
T16486	DRUGINFO	D0FX3P	ISIS 104838	Discontinued in Phase 2
T16486	DRUGINFO	D06LKM	PNU-282987	Terminated

T47087	TARGETID	T47087
T47087	FORMERID	TTDC00277
T47087	UNIPROID	VE1_HPV11
T47087	TARGNAME	Human papillomavirus E1 region messenger RNA (HPV E1 mRNA)
T47087	GENENAME	HPV E1 mRNA
T47087	TARGTYPE	Discontinued
T47087	SYNONYMS	Replication protein E1 (mRNA); E1 (mRNA); ATP-dependent helicase E1 (mRNA)
T47087	FUNCTION	It forms a complex with the viral E2 protein. The E1-E2 complex binds to the replication origin which contains binding sites for both proteins. During the initial step, a dimer of E1 interacts with a dimer of protein E2 leading to a complex that binds the viral origin of replication with high specificity. Then, a second dimer of E1 displaces the E2 dimer in an ATP-dependent manner to form the E1 tetramer. Following this, two E1 monomers are added to each half of the site, which results in the formation of two E1 trimers on the viral ori. Subsequently, two hexamers will be created. The double hexamer acts as a bi-directional helicase machinery and unwinds the viral DNA and then recruits the host DNA polymerase to start replication. ATP-dependent DNA helicase required for initiation of viral DNA replication.
T47087	BIOCLASS	mRNA target
T47087	ECNUMBER	EC 3.6.4.12
T47087	SEQUENCE	MADDSGTENEGSGCTGWFMVEAIVEHTTGTQISEDEEEEVEDSGYDMVDFIDDRHITQNSVEAQALFNRQEADAHYATVQDLKRKYLGSPYVSPISNVANAVESEISPRLDAIKLTTQPKKVKRRLFETRELTDSGYGYSEVEAATQVEKHGDPENGGDGQERDTGRDIEGEGVEHREAEAVDDSTREHADTSGILELLKCKDIRSTLHGKFKDCFGLSFVDLIRPFKSDRTTCADWVVAGFGIHHSIADAFQKLIEPLSLYAHIQWLTNAWGMVLLVLIRFKVNKSRCTVARTLGTLLNIPENHMLIEPPKIQSGVRALYWFRTGISNASTVIGEAPEWITRQTVIEHSLADSQFKLTEMVQWAYDNDICEESEIAFEYAQRGDFDSNARAFLNSNMQAKYVKDCAIMCRHYKHAEMKKMSIKQWIKYRGTKVDSVGNWKPIVQFLRHQNIEFIPFLSKLKLWLHGTPKKNCIAIVGPPDTGKSCFCMSLIKFLGGTVISYVNSCSHFWLQPLTDAKVALLDDATQPCWTYMDTYMRNLLDGNPMSIDRKHRALTLIKCPPLLVTSNIDISKEEKYKYLHSRVTTFTFPNPFPFDRNGNAVYELSDANWKCFFERLSSSLDIEDSEDEEDGSNSQAFRCVPGSVVRTL
T47087	DRUGINFO	D0C9AQ	MBI 1121	Discontinued in Phase 1

T57211	TARGETID	T57211
T57211	FORMERID	TTDR01367
T57211	UNIPROID	DPOL_HCMVA
T57211	TARGNAME	Cytomegalovirus DNA polymerase messenger RNA (CMV DNA polymerase mRNA)
T57211	GENENAME	CMV DNA polymerase mRNA
T57211	TARGTYPE	Discontinued
T57211	SYNONYMS	UL54 (mRNA); HFLF2 (mRNA); DNA polymerase catalytic subunit (mRNA)
T57211	FUNCTION	The replication complex is composed of six viral proteins: the DNA polymerase, processivity factor, primase, primase-associated factor, helicase, and ssDNA-binding protein. Replicates viral genomic DNA in the late phase of lytic infection, producing long concatemeric DNA.
T57211	PDBSTRUC	1YYP
T57211	BIOCLASS	mRNA target
T57211	ECNUMBER	EC 2.7.7.7
T57211	SEQUENCE	MFFNPYLSGGVTGGAVAGGRRQRSQPGSAQGSGKRPPQKQFLQIVPRGVMFDGQTGLIKHKTGRLPLMFYREIKHLLSHDMVWPCPWRETLVGRVVGPIRFHTYDQTDAVLFFDSPENVSPRYRQHLVPSGNVLRFFGATEHGYSICVNVFGQRSYFYCEYSDTDRLREVIASVGELVPEPRTPYAVSVTPATKTSIYGYGTRPVPDLQCVSISNWTMARKIGEYLLEQGFPVYEVRVDPLTRLVIDRRITTFGWCSVNRYDWRQQGRASTCDIEVDCDVSDLVAVPDDSSWPRYRCLSFDIECMSGEGGFPCAEKSDDIVIQISCVCYETGGNTAVDQGIPNGNDGRGCTSEGVIFGHSGLHLFTIGTCGQVGPDVDVYEFPSEYELLLGFMLFFQRYAPAFVTGYNINSFDLKYILTRLEYLYKVDSQRFCKLPTAQGGRFFLHSPAVGFKRQYAAAFPSASHNNPASTAATKVYIAGSVVIDMYPVCMAKTNSPNYKLNTMAELYLRQRKDDLSYKDIPRCFVANAEGRAQVGRYCLQDAVLVRDLFNTINFHYEAGAIARLAKIPLRRVIFDGQQIRIYTSLLDECACRDFILPNHYSKGTTVPETNSVAVSPNAAIISTAAVPGDAGSVAAMFQMSPPLQSAPSSQDGVSPGSGSNSSSSVGVFSVGSGSSGGVGVSNDNHGAGGTAAVSYQGATVFEPEVGYYNDPVAVFDFASLYPSIIMAHNLCYSTLLVPGGEYPVDPADVYSVTLENGVTHRFVRASVRVSVLSELLNKWVSQRRAVRECMRECQDPVRRMLLDKEQMALKVTCNAFYGFTGVVNGMMPCLPIAASITRIGRDMLERTARFIKDNFSEPCFLHNFFNQEDYVVGTREGDSEESSALPEGLETSSGGSNERRVEARVIYGDTDSVFVRFRGLTPQALVARGPSLAHYVTACLFVEPVKLEFEKVFVSLMMICKKRYIGKVEGASGLSMKGVDLVRKTACEFVKGVTRDVLSLLFEDREVSEAAVRLSRLSLDEVKKYGVPRGFWRILRRLVQARDDLYLHRVRVEDLVLSSVLSKDISLYRQSNLPHIAVIKRLAARSEELPSVGDRVFYVLTAPGVRTAPQGSSDNGDSVTAGVVSRSDAIDGTDDDADGGGVEESNRRGGEPAKKRARKPPSAVCNYEVAEDPSYVREHGVPIHADKYFEQVLKAVTNVLSPVFPGGETARKDKFLHMVLPRRLHLEPAFLPYSVKAHECC
T57211	DRUGINFO	D0G1GP	ISIS 2922	Withdrawn from market

T53903	TARGETID	T53903
T53903	FORMERID	TTDC00275
T53903	UNIPROID	POLG_HCV1
T53903	TARGNAME	Hepatitis C virus NS3 helicase messenger RNA (HCV NS3 mRNA)
T53903	GENENAME	HCV NS3 mRNA
T53903	TARGTYPE	Discontinued
T53903	SYNONYMS	HCV Hepacivirin mRNA; HCV NS3P mRNA; HCV p70 Mrna
T53903	FUNCTION	Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity).
T53903	PDBSTRUC	3SU4; 3RC5; 3RC4; 3QGI; 3QGH
T53903	ECNUMBER	EC 3.4.21.98
T53903	SEQUENCE	APITAYAQQTRGLLGCIITSLTGRDKNQVEGEVQIVSTAAQTFLATCINGVCWTVYHGAGTRTIASPKGPVIQMYTNVDQDLVGWPAPQGSRSLTPCTCGSSDLYLVTRHADVIPVRRRGDSRGSLLSPRPISYLKGSSGGPLLCPAGHAVGIFRAAVCTRGVAKAVDFIPVENLETTMRSPVFTDNSSPPVVPQSFQVAHLHAPTGSGKSTKVPAAYAAQGYKVLVLNPSVAATLGFGAYMSKAHGIDPNIRTGVRTITTGSPITYSTYGKFLADGGCSGGAYDIIICDECHSTDATSILGIGTVLDQAETAGARLVVLATATPPGSVTVPHPNIEEVALSTTGEIPFYGKAIPLEVIKGGRHLIFCHSKKKCDELAAKLVALGINAVAYYRGLDVSVIPTSGDVVVVATDALMTGYTGDFDSVIDCNTCVTQTVDFSLDPTFTIETITLPQDAVSRTQRRGRTGRGKPGIYRFVAPGERPSGMFDSSVLCECYDAGCAWYELTPAETTVRLRAYMNTPGLPVCQDHLEFWEGVFTGLTHIDAHFLSQTKQSGENLPYLVAYQATVCARAQAPPPSWDQMWKCLIRLKPTLHGPTPLLYRLGAVQNEITLTHPVTKYIMTCMSADLEVVT
T53903	DRUGINFO	D0W8KT	AVI-4065	Discontinued in Phase 1/2

T86885	TARGETID	T86885
T86885	FORMERID	TTDC00264
T86885	UNIPROID	APOH_HUMAN
T86885	TARGNAME	Beta-2-glycoprotein 1 (APOH)
T86885	GENENAME	APOH
T86885	TARGTYPE	Discontinued
T86885	SYNONYMS	Beta-2-glycoprotein I; Beta(2)GPI; B2GPI; Apolipoprotein H; Apo-H; Anticardiolipin cofactor; Activated protein C-binding protein; APOH; APC inhibitor
T86885	FUNCTION	Binds to various kinds of negatively charged substances such as heparin, phospholipids, and dextran sulfate. May prevent activation of the intrinsic blood coagulation cascade by binding to phospholipids on the surface of damaged cells.
T86885	PDBSTRUC	4JHS; 3OP8; 2KRI; 1QUB; 1G4G
T86885	SEQUENCE	MISPVLILFSSFLCHVAIAGRTCPKPDDLPFSTVVPLKTFYEPGEEITYSCKPGYVSRGGMRKFICPLTGLWPINTLKCTPRVCPFAGILENGAVRYTTFEYPNTISFSCNTGFYLNGADSAKCTEEGKWSPELPVCAPIICPPPSIPTFATLRVYKPSAGNNSLYRDTAVFECLPQHAMFGNDTITCTTHGNWTKLPECREVKCPFPSRPDNGFVNYPAKPTLYYKDKATFGCHDGYSLDGPEEIECTKLGNWSAMPSCKASCKVPVKKATVVYQGERVKIQEKFKNGMLHGDKVSFFCKNKEKKCSYTEDAQCIDGTIEVPKCFKEHSSLAFWKTDASDVKPC
T86885	DRUGINFO	D0Y8PM	LJP-1082	Discontinued in Phase 1
T86885	DRUGINFO	D07LUR	Alpha-D-Mannose	Investigative

T62553	TARGETID	T62553
T62553	FORMERID	TTDS00246
T62553	UNIPROID	RIR1_HHV11
T62553	TARGNAME	Herpes simplex virus Ribonucleoside-diphosphate reductase (HSV RIR1)
T62553	GENENAME	HSV RIR1
T62553	TARGTYPE	Discontinued
T62553	SYNONYMS	HSV Ribonucleotide reductase; HSV Ribonucleoside diphosphate reductase; HSV RIR1
T62553	FUNCTION	Ribonucleoside-diphosphate reductase holoenzyme provides the precursors necessary for viral DNA synthesis. Allows virus growth in non-dividing cells, as well as reactivation from latency in infected hosts. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides. The N-terminal region confers antiapoptotic activity in differentiated cells such as neurons and is importantfor viral reactivation to increase neural survivability.
T62553	BIOCLASS	CH/CH(2) oxidoreductase
T62553	SEQUENCE	MASRPAASSPVEARAPVGGQEAGGPSAATQGEAAGAPLAHGHHVYCQRVNGVMVLSDKTPGSASYRISDNNFVQCGSNCTMIIDGDVVRGRPQDPGAAASPAPFVAVTNIGAGSDGGTAVVAFGGTPRRSAGTSTGTQTADVPTEALGGPPPPPRFTLGGGCCSCRDTRRRSAVFGGEGDPVGPAEFVSDDRSSDSDSDDSEDTDSETLSHASSDVSGGATYDDALDSDSSSDDSLQIDGPVCRPWSNDTAPLDVCPGTPGPGADAGGPSAVDPHAPTPEAGAGLAADPAVARDDAEGLSDPRPRLGTGTAYPVPLELTPENAEAVARFLGDAVNREPALMLEYFCRCAREETKRVPPRTFGSPPRLTEDDFGLLNYALVEMQRLCLDVPPVPPNAYMPYYLREYVTRLVNGFKPLVSRSARLYRILGVLVHLRIRTREASFEEWLRSKEVALDFGLTERLREHEAQLVILAQALDHYDCLIHSTPHTLVERGLQSALKYEEFYLKRFGGHYMESVFQMYTRIAGFLACRATRGMRHIALGREGSWWEMFKFFFHRLYDHQIVPSTPAMLNLGTRNYYTSSCYLVNPQATTNKATLRAITSNVSAILARNGGIGLCVQAFNDSGPGTASVMPALKVLDSLVAAHNKESARPTGACVYLEPWHTDVRAVLRMKGVLAGEEAQRCDNIFSALWMPDLFFKRLIRHLDGEKNVTWTLFDRDTSMSLADFHGEEFEKLYQHLEVMGFGEQIPIQELAYGIVRSAATTGSPFVMFKDAVNRHYIYDTQGAAIAGSNLCTEIVHPASKRSSGVCNLGSVNLARCVSRQTFDFGRLRDAVQACVLMVNIMIDSTLQPTPQCTRGNDNLRSMGIGMQGLHTACLKLGLDLESAEFQDLNKHIAEVMLLSAMKTSNALCVRGARPFNHFKRSMYRAGRFHWERFPDARPRYEGEWEMLRQSMMKHGLRNSQFVALMPTAASAQISDVSEGFAPLFTNLFSKVTRDGETLRPNTLLLKELERTFSGKRLLEVMDSLDAKQWSVAQALPCLEPTHPLRRFKTAFDYDQKLLIDLCADRAPYVDHSQSMTLYVTEKADGTLPASTLVRLLVHAYKRGLKTGMYYCKVRKATNSGVFGGDDNIVCMSCAL
T62553	DRUGINFO	D00FRY	BILD-1351	Terminated
T62553	DRUGINFO	D0HP3M	BILD-1263	Terminated
T62553	DRUGINFO	D0QM0N	BILD-733	Terminated
T62553	DRUGINFO	D0U4WY	BILD-1357	Terminated

T71011	TARGETID	T71011
T71011	FORMERID	TTDI02345
T71011	UNIPROID	STXB_BP933
T71011	TARGNAME	Enterobacteria Shiga-like toxin 2B (EntBac stxB2)
T71011	GENENAME	EntBac stxB2
T71011	TARGTYPE	Discontinued
T71011	SYNONYMS	stxB2; Verotoxin 2 subunit B; Verocytotoxin 2 subunit B; Shiga-like toxin 2 subunit B; SLT-IIb; SLT-2b; SLT-2 B subunit
T71011	FUNCTION	TheB subunit is responsible for the binding of the holotoxin to specific receptors on the target cell surface, such as globotriaosylceramide (Gb3) in human intestinal microvilli.
T71011	PDBSTRUC	6FE4; 2GA4; 1R4P
T71011	BIOCLASS	Shiga-like toxin beta
T71011	SEQUENCE	MKKMFMAVLFALASVNAMAADCAKGKIEFSKYNEDDTFTVKVDGKEYWTSRWNLQPLLQSAQLTGMTVTIKSSTCESGSGFAEVQFNND
T71011	DRUGINFO	D03VCF	Urtoxazumab	Discontinued in Phase 2

T40730	TARGETID	T40730
T40730	FORMERID	TTDR00690
T40730	UNIPROID	FOLB_ECOLI
T40730	TARGNAME	Bacterial Dihydroneopterinaldolase (Bact folB)
T40730	GENENAME	Bact folB
T40730	TARGTYPE	Discontinued
T40730	SYNONYMS	folB  of Escherichia coli; FOLB of Escherichia coli; DHNA of Escherichia coli; 7,8-Dihydroneopterin aldolase
T40730	FUNCTION	Catalyzes the conversion of 7,8-dihydroneopterin to 6- hydroxymethyl-7,8-dihydropterin. Can use L-threo-dihydroneopterin and D-erythro-dihydroneopterin as substrates for the formation of 6-hydroxymethyldihydropterin,but it can also catalyze the epimerization of carbon 2' of dihydroneopterin and dihydromonapterin at appreciable velocity.
T40730	PDBSTRUC	2O90
T40730	BIOCLASS	Carbon-carbon lyase
T40730	SEQUENCE	MDIVFIEQLSVITTIGVYDWEQTIEQKLVFDIEMAWDNRKAAKSDDVADCLSYADIAETVVSHVEGARFALVERVAEEVAELLLARFNSPWVRIKLSKPGAVARAANVGVIIERGNNLKENN
T40730	DRUGINFO	D07RPR	Bropirimine	Discontinued in Phase 3
T40730	DRUGINFO	D00RAK	7,8-Dihydroneopterin	Investigative
T40730	DRUGINFO	D07IWK	9-Methylguanine	Investigative
T40730	DRUGINFO	D0V0HJ	8-Amino-1,3-Dimethyl-3,7-Dihydropurine-2,6-Dione	Investigative
T40730	DRUGINFO	D0W0NE	6-Hydroxymethyl-7,8-Dihydropterin	Investigative
T40730	DRUGINFO	D0F3XT	7,8-dihydrobiopterin	Investigative

T95399	TARGETID	T95399
T95399	UNIPROID	PYGM_HUMAN
T95399	TARGNAME	Myophosphorylase (PYGM)
T95399	GENENAME	PYGM
T95399	TARGTYPE	Discontinued
T95399	SYNONYMS	Glycogen phosphorylase, muscle form; Myophosphorylase
T95399	FUNCTION	Phosphorylase is an important allosteric enzyme in carbohydrate metabolism. Enzymes from different sources differ in their regulatory mechanisms and in their natural substrates. However, all known phosphorylases share catalytic and structural properties.
T95399	PDBSTRUC	1Z8D
T95399	ECNUMBER	EC 2.4.1.1
T95399	SEQUENCE	MSRPLSDQEKRKQISVRGLAGVENVTELKKNFNRHLHFTLVKDRNVATPRDYYFALAHTVRDHLVGRWIRTQQHYYEKDPKRIYYLSLEFYMGRTLQNTMVNLALENACDEATYQLGLDMEELEEIEEDAGLGNGGLGRLAACFLDSMATLGLAAYGYGIRYEFGIFNQKISGGWQMEEADDWLRYGNPWEKARPEFTLPVHFYGHVEHTSQGAKWVDTQVVLAMPYDTPVPGYRNNVVNTMRLWSAKAPNDFNLKDFNVGGYIQAVLDRNLAENISRVLYPNDNFFEGKELRLKQEYFVVAATLQDIIRRFKSSKFGCRDPVRTNFDAFPDKVAIQLNDTHPSLAIPELMRILVDLERMDWDKAWDVTVRTCAYTNHTVLPEALERWPVHLLETLLPRHLQIIYEINQRFLNRVAAAFPGDVDRLRRMSLVEEGAVKRINMAHLCIAGSHAVNGVARIHSEILKKTIFKDFYELEPHKFQNKTNGITPRRWLVLCNPGLAEVIAERIGEDFISDLDQLRKLLSFVDDEAFIRDVAKVKQENKLKFAAYLEREYKVHINPNSLFDIQVKRIHEYKRQLLNCLHVITLYNRIKREPNKFFVPRTVMIGGKAAPGYHMAKMIIRLVTAIGDVVNHDPAVGDRLRVIFLENYRVSLAEKVIPAADLSEQISTAGTEASGTGNMKFMLNGALTIGTMDGANVEMAEEAGEENFFIFGMRVEDVDKLDQRGYNAQEYYDRIPELRQVIEQLSSGFFSPKQPDLFKDIVNMLMHHDRFKVFADYEDYIKCQEKVSALYKNPREWTRMVIRNIATSGKFSSDRTIAQYAREIWGVEPSRQRLPAPDEAI
T95399	DRUGINFO	D0LF1U	Flavopiridol	Phase 2
T95399	DRUGINFO	D0P7WJ	PSN357	Discontinued in Phase 2
T95399	DRUGINFO	D0AL0S	GSK-1362885	Discontinued in Phase 1

T45737	TARGETID	T45737
T45737	FORMERID	TTDR00310
T45737	UNIPROID	FCAR_HUMAN
T45737	TARGNAME	Immunoglobulin alpha Fc receptor (FCAR)
T45737	GENENAME	FCAR
T45737	TARGTYPE	Discontinued
T45737	SYNONYMS	IgA Fc receptor; FCAR; CD89 antigen; CD89
T45737	FUNCTION	Binds to the fc region of immunoglobulins alpha. Mediates several functions including cytokine production.
T45737	PDBSTRUC	1UCT; 1OW0; 1OVZ
T45737	SEQUENCE	MDPKQTTLLCLVLCLGQRIQAQEGDFPMPFISAKSSPVIPLDGSVKIQCQAIREAYLTQLMIIKNSTYREIGRRLKFWNETDPEFVIDHMDANKAGRYQCQYRIGHYRFRYSDTLELVVTGLYGKPFLSADRGLVLMPGENISLTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSLGPVDLNVSGIYRCYGWYNRSPYLWSFPSNALELVVTDSIHQDYTTQNLIRMAVAGLVLVALLAILVENWHSHTALNKEASADVAEPSWSQQMCQPGLTFARTPSVCK
T45737	DRUGINFO	D08PXM	MDX-214	Discontinued in Phase 1/2

T64242	TARGETID	T64242
T64242	FORMERID	TTDI01680
T64242	UNIPROID	CP46A_HUMAN
T64242	TARGNAME	Cholesterol 24-monooxygenase (CYP46A1)
T64242	GENENAME	CYP46A1
T64242	TARGTYPE	Discontinued
T64242	SYNONYMS	Cytochrome P450 46A1; Cholesterol 24S-hydroxylase; CYP46; CH24H
T64242	FUNCTION	P450 monooxygenase that plays a major role in cholesterol homeostasis in the brain. Primarily catalyzes the hydroxylation (with S stereochemistry) at C-24 of cholesterol side chain, triggering cholesterol diffusion out of neurons and its further degradation. By promoting constant cholesterol elimination in neurons, may activate the mevalonate pathway and coordinate the synthesis of new cholesterol and nonsterol isoprenoids involved in synaptic activity and learning (By similarity). Further hydroxylates cholesterol derivatives and hormone steroids on both the ring and side chain of these molecules, converting them into active oxysterols involved in lipid signaling and biosynthesis. Acts as an epoxidase converting cholesta-5,24-dien-3beta-ol/desmosterol into (24S),25-epoxycholesterol, an abundant lipid ligand of nuclear NR1H2 and NR1H3 receptors shown to promote neurogenesis in developing brain. May also catalyze the oxidative metabolism of xenobiotics, such as clotrimazole.
T64242	PDBSTRUC	4J14; 4FIA; 4ENH; 3MDV; 3MDT
T64242	ECNUMBER	EC 1.14.14.25
T64242	SEQUENCE	MSPGLLLLGSAVLLAFGLCCTFVHRARSRYEHIPGPPRPSFLLGHLPCFWKKDEVGGRVLQDVFLDWAKKYGPVVRVNVFHKTSVIVTSPESVKKFLMSTKYNKDSKMYRALQTVFGERLFGQGLVSECNYERWHKQRRVIDLAFSRSSLVSLMETFNEKAEQLVEILEAKADGQTPVSMQDMLTYTAMDILAKAAFGMETSMLLGAQKPLSQAVKLMLEGITASRNTLAKFLPGKRKQLREVRESIRFLRQVGRDWVQRRREALKRGEEVPADILTQILKAEEGAQDDEGLLDNFVTFFIAGHETSANHLAFTVMELSRQPEIVARLQAEVDEVIGSKRYLDFEDLGRLQYLSQVLKESLRLYPPAWGTFRLLEEETLIDGVRVPGNTPLLFSTYVMGRMDTYFEDPLTFNPDRFGPGAPKPRFTYFPFSLGHRSCIGQQFAQMEVKVVMAKLLQRLEFRLVPGQRFGLQEQATLKPLDPVLCTLRPRGWQPAPPPPPC
T64242	DRUGINFO	D09WTQ	RC-8800	Discontinued in Phase 1

T12279	TARGETID	T12279
T12279	FORMERID	TTDR01366
T12279	UNIPROID	VE2_HPV18
T12279	TARGNAME	Human papillomavirus E2 transactivator messenger RNA (HPV E2 mRNA)
T12279	GENENAME	HPV E2 mRNA
T12279	TARGTYPE	Discontinued
T12279	SYNONYMS	Regulatory protein E2 (mRNA)
T12279	FUNCTION	A dimer of E2 interacts with a dimer of E1 in order to improve specificity of E1 DNA binding activity. Once the complex recognizes and binds DNA at specific sites, the E2 dimer is removed from DNA. E2 also regulates viral transcription through binding to the E2RE response element (5'-ACCNNNNNNGGT-3') present in multiple copies in the regulatory regions of the viral genome. Activates or represses transcription depending on E2RE's position with regards to proximal promoter elements including the TATA-box. Repression occurs by sterically hindering the assembly of the transcription initiation complex. Plays a role in the initiation of viral DNA replication.
T12279	PDBSTRUC	1TUE; 1QQH; 1JJ4; 1F9F
T12279	BIOCLASS	mRNA target
T12279	SEQUENCE	MQTPKETLSERLSCVQDKIIDHYENDSKDIDSQIQYWQLIRWENAIFFAAREHGIQTLNHQVVPAYNISKSKAHKAIELQMALQGLAQSAYKTEDWTLQDTCEELWNTEPTHCFKKGGQTVQVYFDGNKDNCMTYVAWDSVYYMTDAGTWDKTATCVSHRGLYYVKEGYNTFYIEFKSECEKYGNTGTWEVHFGNNVIDCNDSMCSTSDDTVSATQLVKQLQHTPSPYSSTVSVGTAKTYGQTSAATRPGHCGLAEKQHCGPVNPLLGAATPTGNNKRRKLCSGNTTPIIHLKGDRNSLKCLRYRLRKHSDHYRDISSTWHWTGAGNEKTGILTVTYHSETQRTKFLNTVAIPDSVQILVGYMTM
T12279	DRUGINFO	D0NC9Y	ISIS 2105	Discontinued in Phase 2

T13609	TARGETID	T13609
T13609	FORMERID	TTDR00258
T13609	UNIPROID	E9BCR2_LEIDB
T13609	TARGNAME	Leishmania Carbamoyl-phosphate synthase (Leishm CPS)
T13609	GENENAME	Leishm CPS
T13609	TARGTYPE	Discontinued
T13609	SYNONYMS	Carbamoyl-phosphate synthase, putative
T13609	FUNCTION	Catalyses the formation of carbamoyl phosphate from L-glutamine, bicarbonate, and 2 moles of MgATP. 
T13609	BIOCLASS	Carbon-nitrogen ligase
T13609	SEQUENCE	MEHYAKAELVLHGGERFEGYSFGYEESVAGEVVFATGMVGYPESLSDPSYHGQILVLTSPMVGNYGVPRVEEDLFGVTKYFESTDGQIHVSAVVVQEYCDQPDHWEMYETLGTWLRKNKVPGMMMVDTRSIVLKLRDMGTALGKVLVAGNDVPFMDPNTRNLVAEVSTKTRVTHGHGTLRILVIDMGVKLNTLRCLLKHDVTLIVVPHDWDITTEVYDGLFITNGPGNPQICTSTIRSVRWALQQDKPIFGICMGNQMLCLAAGGTTYKMKYGHRGQNQPCKCNIDGRVVITTQNHGFAVDFKTLPSGEWEEYFTNSNDGSNEGLWHKTKPFCSVQFHPEGRCGPQDTEYLFSEYVCRVKESKVREVAKFKPRKVLVLGAGGIVIAQAGEFDYSGSQCLKSLREEGMETVLINPNIATVQTDDEMADHIYFVPLTVEAVERVIEKERPDGILLGWGGQTALNCGVKLDELGVLKKYNVQVLGTPVSVIAVTEDRELFRDTLLQINEQVAKSAAVMSVEEAVAASKDIGFPMMVRAAYCLGGQGSGIVENMEELRHKVEVALAASPQVLLEESVAGWKEIEYEVVRDIYDNCITVCNMENFDPMGVHTGESIVVAPSQTLSNDEFHMLRSASIKIIRHLGIVGECNIQYGLDPFSHRYVVIEVNARLSRSSALASKATGYPLAHVATKIALGKGLFEITNGVTKTTMACFEPSMDYIAVKMPRWDLHKFNMVSEEIGSMMKSVGEVMSIGRTFEEALQKAIRMVDPSYTGFSLPDRFAGVDFDYMEHIRHPTPYRLFALCRALLDGHSAEELYQMTKITRFFLYKLEKLVRLSKATSTLYANKLTEMPRENLLNMKAHGFSDRQLAQLLNSTAADVRARRVELNVMPLIKQIDTVAGEYPAAQCCYLYSTYNAQRDDVPFTERMYAVLGCGVYRIGNSVEFDYGGVLVARELRRLGNKVILINYNPETVSTDYDECDRLYFDEVSEETVLDILTKERVRGVVISLGGQIVQNMALSLKKSGLPILGTDPANIDMAEDRNKFSKMCDELGVPQPEWISATSVEQVHEFCDTVGYPALVRPSYVLSGSAMAVIANKEDVTRYLKEASFVSGEHPVVVSKYYEAATEYDVDIVAHHGRVLCYAICEHVENAGVHSGDATMFLPPQNTDKDTMKRIYDSVNRIAEKLDVVGPMNVQFLLTAEGQLRVIEANVRSSRSVPFVSKTLGISFPSVMVSAFLARKDQNLVPIKRAKMTHIGCKASMFSFNRLAGADPILGVEMASTGEIGVFGRDKHEVFLKAMLCQNFKIPQKGVFFSSDVDSQTEALCPYIQHLVRRGLKVYGTTKTAAVLHEYGIQCEVLLQRGELPSGDASESNRLAVYDEEVAKKEKFDLVIQLRDKRRDFVLRRCTRETAPPDYWVRRLAVDYNIPLLTEPSIVKMFCECMDLPASSIEIEPFRHYVPKIYHKVENNNCAMLRCHKVGLMITNNNDSKVLALRLSQEGLNITCFHAYLGGSDIDHFEQAFQSLNVPVEVVDLRSEIANSAFDLIMCQSADERHNWHLSKLSWYIFGKYLIPVMRQRRMSVVAQTSKQNKKEAGFEKYVQSNCPEMGVYNAWRDARLMEDFETVADQISFLRKHGIKATVKSNVQVHSSVCGSTYYGDDMRSLPAPSLVKPVRECSVTPEFVSLTFRGARCVNINGIDVTPLLALQMANEIAGRNGVGITRTREGAMYETPGMNLLSVGLQFLYDVSFDRCAADLFRIYSRHVSQNIGAGQLSEKHTQSAIEAVRFLTSDVSGVVELELHQGEIIFLKLSHVQNPVDRRVAPQLVTEEELEEVFQPGNGSFSDVQW
T13609	DRUGINFO	D02JUT	Acivicin	Discontinued in Phase 3

T03985	TARGETID	T03985
T03985	FORMERID	TTDI01742
T03985	UNIPROID	L0P818_PNEJ8
T03985	TARGNAME	Pneumocystis jirovecii DNA topoisomerase 2 (PJ top2)
T03985	GENENAME	PJ top2
T03985	TARGTYPE	Discontinued
T03985	SYNONYMS	PJ DNA topoisomerase 2
T03985	FUNCTION	Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks.
T03985	ECNUMBER	EC 5.6.2.3
T03985	SEQUENCE	MLRETSSDDSDMSFSLKRKYTNVSKNIKKIRNADVGFDSERQLCSEIASVGRTISENLSYSRHENFSDTVDTIESKNHLLATKTTSEIYQKLSQLEHILKRPDTYIGSIEFTSQHIWVYDDNTNAMKYRQVSIVPGLYKIFDEILVNAADNKIRDPNMDTIKVEFSREKNVISIYNNGRGIPIEIHNKEKVWIPELIFGHLLTSSNYDDEEKKVTGGRNGYGAKLCNIFSTEFIVETADRATKKTYKQVFLNNMTKKKDPVIKENKKDEEYTRITFKPDLERFGMKEIDSDLESVFKRRVYDLAGSVKNVKVFLNGERIKVKSFKQYIEMYLNSDDSENNLKPTIIHEVVNDRWEVAFTVSDGQFNQVSFVNSIATTRGGTHVNYVSDQIVLKLIEAVKKKNKNIPIKPFQVKNHIWVFINSLIENPSFDSQTKETLTLKQTAFGSKCILSDDFIKKVLKTPIMEKILDTAQKKADQLMKKTDGSKKMRITGLPKLEDANKAGTKEGHKCTLILTEGDSAKSLAMSGIGVVGRDYFGVYPLRGKLLNVREASHEQISKNAEINAIKQIMGLQHKKVYTSTSELRYGHLMIMTDQDHDGSHIKGLIINYLESSFPSLLEIPGFLIEFITPIVKATKGTQEKTFFTIPEYEYWKESVDNAKGWKIKYYKGLGTSYGNDVKKYFSDLDTHLKEFHSIREGDKELIDMAFSKKKADERKEWLRLFKPGTYMDHTLDKIPISDFINKELILFSMADNIRSIPSVVDGLKPGQRKVIFGCFKRKLKSEIKVAQLSGYISEHTAYHHGEQSLTQTIIGLAQTFVGSNNINLMKPNGQFGTRLQGGKDAASPRYIFTELSPLTRKIFVESDDALLNYLNEDGQSIEPLWYVPIIPLILVNGCEGIGTGWSSYIPNFNPIDLVNNIRRMMNGEKLEPMHPWYRGFNGSIEKQGDKYKISGCIRQIDDTTVEITELPIRFWTQDMKEFLELSVVGSDKVQPFIKDYSEYHTDTVVHFIIKLTEKGMAESLAQGLEEKFKLIKIQNMTNMVAFDSSGRIKKYNSVEEILLEFYNIRLQFYQKRKDYLVNELESQYNKLSNQVRFVKMVINKEQDFLNRKRKDLLDDLKLKGFIPFPKNKHISVDNATETSNNLAENDDDDATGYDYLLSMPLWSLTAEKVEKLLKDKLDKENELESLLKLTVKDLWNKDLDNFVEEWEMFLKHDENLTSKVKNLKKDKRNSQKLGIVTQKSVVKKRAVNSQNKPSDVDYKPFSKKTLLSAKQTTLPFSVKNVKDTDVDFLKNQESSNKVINESVVAVENDQVFAKTDATAERKYGANAIIVPSLKGDLSDDSDTDYMDDLVKKYTINPSGGKSMTSYIKSVSPSPKKTKIALSTKSRSPPKMSTLLDSSPDYVVPITKSSTKTIHKKKKTLARKININDSEIDIPVRSDISQRPRRQVAVQARQRVVAIINSDDNDTTLDRSSLSSEFDGSSS
T03985	DRUGINFO	D00RIB	RG-201	Discontinued in Phase 1

T28532	TARGETID	T28532
T28532	FORMERID	TTDI01572
T28532	UNIPROID	RPP14_HUMAN; RPP21_HUMAN
T28532	TARGNAME	Ribonuclease P protein (RPP)
T28532	GENENAME	RPP14; RPP21
T28532	TARGTYPE	Discontinued
T28532	SYNONYMS	Ribonuclease P protein
T28532	FUNCTION	Acts as a catalyst in the same way that a protein-based enzyme would. Its function is to cleave off an extra, or precursor, sequence of RNA on tRNA molecules.
T28532	BIOCLASS	Endoribonucleases
T28532	SEQUENCE	MPAPAATYERVVYKNPSEYHYMKVCLEFQDCGVGLNAAQFKQLLISAVKDLFGEVDAALPLDILTYEEKTLSAILRICSSGLVKLWSSLTLLGSYKGKKCAFRVIQVSPFLLALSGNSRELVLD
T28532	DRUGINFO	D0FQ6O	Etarotene	Discontinued in Phase 3

T81694	TARGETID	T81694
T81694	FORMERID	TTDI01604
T81694	UNIPROID	POLG_HRV1B
T81694	TARGNAME	Rhinovirus Protein 1 (HRV P1D)
T81694	GENENAME	HRV P1D
T81694	TARGTYPE	Discontinued
T81694	SYNONYMS	Rhinovirus Capsid protein VP1; Rhinovirus P1D; Rhinovirus Virion protein 1
T81694	FUNCTION	Capsid protein VP1: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host cell receptor to provide virion attachment to target host cells. This attachment induces virion internalization. Tyrosine kinases are probably involved in the entry process. After binding to its receptor, the capsid undergoes conformational changes. Capsid protein VP1 N-terminus (that contains an amphipathic alpha-helix) and capsid protein VP4 are externalized. Together, they shape a pore in the host membrane through which viral genome is translocated to host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).
T81694	PDBSTRUC	1XR6
T81694	SEQUENCE	PIEQNPVENYIDEVLNEVLVVPNIKESHHTTSNSAPLLDAAETGHTSNVQPEDAIETRYVMTSQTRDEMSIESFLGRSGCVHISRIKVDYNDYNGVNKNFTTWKITLQEMAQIRRKFELFTYVRFDSEVTLVPCIAGRGDDIGHVVMQYMYVPPGAPIPKTRNDFSWQSGTNMSIFWQHGQPFPRFSLPFLSIASAYYMFYDGYDGDNSSSKYGSIVTNDMGTICSRIVTEKQEHPVVITTHIYHKAKHTKAWCPRPPRAVPYTHSRVTNYVPKTGDVTTAIVPRASMKTV
T81694	DRUGINFO	D0O7DZ	R-61837	Discontinued in Phase 2

T82083	TARGETID	T82083
T82083	FORMERID	TTDI03439
T82083	UNIPROID	P2RY4_HUMAN
T82083	TARGNAME	P2Y purinoceptor 4 (P2RY4)
T82083	GENENAME	P2RY4
T82083	TARGTYPE	Discontinued
T82083	SYNONYMS	Uridine nucleotide receptor; UNR; P2Y4; P2P; NRU
T82083	FUNCTION	Receptor for UTP and UDP coupled to G-proteins that activate a phosphatidylinositol-calcium second messenger system. Not activated by ATP or ADP.
T82083	PDBSTRUC	2B6Q
T82083	SEQUENCE	MASTESSLLRSLGLSPGPGSSEVELDCWFDEDFKFILLPVSYAVVFVLGLGLNAPTLWLFIFRLRPWDATATYMFHLALSDTLYVLSLPTLIYYYAAHNHWPFGTEICKFVRFLFYWNLYCSVLFLTCISVHRYLGICHPLRALRWGRPRLAGLLCLAVWLVVAGCLVPNLFFVTTSNKGTTVLCHDTTRPEEFDHYVHFSSAVMGLLFGVPCLVTLVCYGLMARRLYQPLPGSAQSSSRLRSLRTIAVVLTVFAVCFVPFHITRTIYYLARLLEADCRVLNIVNVVYKVTRPLASANSCLDPVLYLLTGDKYRRQLRQLCGGGKPQPRTAASSLALVSLPEDSSCRWAATPQDSSCSTPRADRL
T82083	DRUGINFO	D0Z7FU	INS 316	Discontinued in Phase 3
T82083	DRUGINFO	D00PQC	CTP	Investigative
T82083	DRUGINFO	D00WOK	ITP	Investigative
T82083	DRUGINFO	D01ZZJ	2-amino-uridine-5'-monophosphate	Investigative
T82083	DRUGINFO	D02NRP	MRS2927	Investigative
T82083	DRUGINFO	D06PIW	MRS4062	Investigative
T82083	DRUGINFO	D07LYU	N4-phenylethoxycytidine-5'-triphosphate	Investigative
T82083	DRUGINFO	D0M8DU	(N)methanocarba-UTP	Investigative
T82083	DRUGINFO	D02OAJ	UTPgammaS	Investigative
T82083	DRUGINFO	D07QYU	PPADS	Investigative

T54931	TARGETID	T54931
T54931	FORMERID	TTDR00195
T54931	UNIPROID	ACHA2_HUMAN; ACHA3_HUMAN
T54931	TARGNAME	Neuronal acetylcholine receptor alpha-2/alpha-3 (CHRNA2/A3)
T54931	GENENAME	CHRNA2-CHRNA3
T54931	TARGTYPE	Discontinued
T54931	SYNONYMS	CHRNA; nAChR
T54931	FUNCTION	After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
T54931	BIOCLASS	Neurotransmitter receptor
T54931	SEQUENCE	MGPSCPVFLSFTKLSLWWLLLTPAGGEEAKRPPPRAPGDPLSSPSPTALPQGGSHTETEDRLFKHLFRGYNRWARPVPNTSDVVIVRFGLSIAQLIDVDEKNQMMTTNVWLKQEWSDYKLRWNPTDFGNITSLRVPSEMIWIPDIVLYNNADGEFAVTHMTKAHLFSTGTVHWVPPAIYKSSCSIDVTFFPFDQQNCKMKFGSWTYDKAKIDLEQMEQTVDLKDYWESGEWAIVNATGTYNSKKYDCCAEIYPDVTYAFVIRRLPLFYTINLIIPCLLISCLTVLVFYLPSDCGEKITLCISVLLSLTVFLLLITEIIPSTSLVIPLIGEYLLFTMIFVTLSIVITVFVLNVHHRSPSTHTMPHWVRGALLGCVPRWLLMNRPPPPVELCHPLRLKLSPSYHWLESNVDAEEREVVVEEEDRWACAGHVAPSVGTLCSHGHLHSGASGPKAEALLQEGELLLSPHMQKALEGVHYIADHLRSEDADSSVKEDWKYVAMVIDRIFLWLFIIVCFLGTIGLFLPPFLAGMI
T54931	DRUGINFO	D0F7FX	AZD-9684	Discontinued in Phase 2
T54931	DRUGINFO	D02IJB	SIB-1533A	Investigative
T54931	DRUGINFO	D08BKH	18-Methoxycoronaridine	Investigative
T54931	DRUGINFO	D0P0XA	Ibogaine	Investigative

T89772	TARGETID	T89772
T89772	FORMERID	TTDI03614
T89772	UNIPROID	VACHT_HUMAN
T89772	TARGNAME	Vesicular acetylcholine transporter (SLC18A3)
T89772	GENENAME	SLC18A3
T89772	TARGTYPE	Discontinued
T89772	SYNONYMS	VAChT; Solute carrier family 18 member 3
T89772	FUNCTION	Involved in acetylcholine transport into synaptic vesicles.
T89772	SEQUENCE	MESAEPAGQARAAATKLSEAVGAALQEPRRQRRLVLVIVCVALLLDNMLYMVIVPIVPDYIAHMRGGGEGPTRTPEVWEPTLPLPTPANASAYTANTSASPTAAWPAGSALRPRYPTESEDVKIGVLFASKAILQLLVNPLSGPFIDRMSYDVPLLIGLGVMFASTVLFAFAEDYATLFAARSLQGLGSAFADTSGIAMIADKYPEEPERSRALGVALAFISFGSLVAPPFGGILYEFAGKRVPFLVLAAVSLFDALLLLAVAKPFSAAARARANLPVGTPIHRLMLDPYIAVVAGALTTCNIPLAFLEPTIATWMKHTMAASEWEMGMAWLPAFVPHVLGVYLTVRLAARYPHLQWLYGALGLAVIGASSCIVPACRSFAPLVVSLCGLCFGIALVDTALLPTLAFLVDVRHVSVYGSVYAIADISYSVAYALGPIVAGHIVHSLGFEQLSLGMGLANLLYAPVLLLLRNVGLLTRSRSERDVLLDEPPQGLYDAVRLRERPVSGQDGEPRSPPGPFDACEDDYNYYYTRS
T89772	DRUGINFO	D03NZM	T-588	Discontinued in Phase 2
T89772	DRUGINFO	D07EMU	[3H]vesamicol	Investigative
T89772	DRUGINFO	D09AWB	[123I]iodobenzovesamicol	Investigative
T89772	DRUGINFO	D0I1QF	vesamicol	Investigative
T89772	DRUGINFO	D0N8WR	aminobenzovesamicol	Investigative

T35817	TARGETID	T35817
T35817	FORMERID	TTDI00121
T35817	UNIPROID	MSI2H_HUMAN
T35817	TARGNAME	RNA-binding protein Musashi-2 (MSI2)
T35817	GENENAME	MSI2
T35817	TARGTYPE	Discontinued
T35817	SYNONYMS	RNA-binding protein Musashi homolog 2; Musashi-2
T35817	FUNCTION	May play a role in the proliferation and maintenance of stem cells in the central nervous system. RNA binding protein that regulates the expression of target mRNAs at the translation level.
T35817	PDBSTRUC	6DBP; 6C8U
T35817	SEQUENCE	MEANGSQGTSGSANDSQHDPGKMFIGGLSWQTSPDSLRDYFSKFGEIRECMVMRDPTTKRSRGFGFVTFADPASVDKVLGQPHHELDSKTIDPKVAFPRRAQPKMVTRTKKIFVGGLSANTVVEDVKQYFEQFGKVEDAMLMFDKTTNRHRGFGFVTFENEDVVEKVCEIHFHEINNKMVECKKAQPKEVMFPPGTRGRARGLPYTMDAFMLGMGMLGYPNFVATYGRGYPGFAPSYGYQFPGFPAAAYGPVAAAAVAAARGSGSNPARPGGFPGANSPGPVADLYGPASQDSGVGNYISAASPQPGSGFGHGIAGPLIATAFTNGYH

T92689	TARGETID	T92689
T92689	FORMERID	TTDI03436
T92689	UNIPROID	P2Y11_HUMAN
T92689	TARGNAME	P2Y purinoceptor 11 (P2RY11)
T92689	GENENAME	P2RY11
T92689	TARGTYPE	Discontinued
T92689	SYNONYMS	P2Y11
T92689	FUNCTION	Receptor for ATP and ADP coupled to G-proteins that activate both phosphatidylinositol-calcium and adenylyl cyclase second messenger systems. Not activated by UTP or UDP.
T92689	PDBSTRUC	2B6S
T92689	SEQUENCE	MAANVSGAKSCPANFLAAADDKLSGFQGDFLWPILVVEFLVAVASNGLALYRFSIRKQRPWHPAVVFSVQLAVSDLLCALTLPPLAAYLYPPKHWRYGEAACRLERFLFTCNLLGSVIFITCISLNRYLGIVHPFFARSHLRPKHAWAVSAAGWVLAALLAMPTLSFSHLKRPQQGAGNCSVARPEACIKCLGTADHGLAAYRAYSLVLAGLGCGLPLLLTLAAYGALGRAVLRSPGMTVAEKLRVAALVASGVALYASSYVPYHIMRVLNVDARRRWSTRCPSFADIAQATAALELGPYVGYQVMRGLMPLAFCVHPLLYMAAVPSLGCCCRHCPGYRDSWNPEDAKSTGQALPLNATAAPKPSEPQSRELSQ
T92689	DRUGINFO	D0Z7FU	INS 316	Discontinued in Phase 3
T92689	DRUGINFO	D03PEA	NF546	Investigative
T92689	DRUGINFO	D0D8CZ	dATP	Investigative
T92689	DRUGINFO	D0M6TB	NF157	Investigative
T92689	DRUGINFO	D0OR6C	NF340	Investigative
T92689	DRUGINFO	D07RTQ	NAADP	Investigative
T92689	DRUGINFO	D06HDW	BzATP	Investigative
T92689	DRUGINFO	D0S3WN	ATPgammaS	Investigative
T92689	DRUGINFO	D0U1OJ	2MeSATP	Investigative

T30802	TARGETID	T30802
T30802	FORMERID	TTDR01220
T30802	UNIPROID	CALY_HUMAN
T30802	TARGNAME	Neuron-specific vesicular protein calcyon (CALY)
T30802	GENENAME	CALY
T30802	TARGTYPE	Discontinued
T30802	SYNONYMS	Neuronspecific vesicular protein calcyon; CALY
T30802	FUNCTION	Interacts with clathrin light chain A and stimulates clathrin self-assembly and clathrin-mediated endocytosis.
T30802	SEQUENCE	MVKLGCSFSGKPGKDPGDQDGAAMDSVPLISPLDISQLQPPLPDQVVIKTQTEYQLSSPDQQNFPDLEGQRLNCSHPEEGRRLPTARMIAFAMALLGCVLIMYKAIWYDQFTCPDGFLLRHKICTPLTLEMYYTEMDPERHRSILAAIGAYPLSRKHGTETPAAWGDGYRAAKEERKGPTQAGAAAAATEPPGKPSAKAEKEAARKAAGSAAPPPAQ
T30802	DRUGINFO	D0BQ8M	CY-208243	Discontinued in Phase 2
T30802	DRUGINFO	D0B6QP	Apomorphine SL	Investigative

T80701	TARGETID	T80701
T80701	FORMERID	TTDI01154
T80701	UNIPROID	IBP1_HUMAN; IBP2_HUMAN; IBP3_HUMAN
T80701	TARGNAME	Bone resorption factor (BRF)
T80701	GENENAME	IGFBP1; IGFBP2; IGFBP3
T80701	TARGTYPE	Discontinued
T80701	SYNONYMS	Insulin-like growth factor-binding protein; IGFBP; IGF-binding protein; IBP
T80701	FUNCTION	IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. Also exhibits IGF-independent antiproliferative and apoptotic effects mediated by its receptor TMEM219/IGFBP-3R.
T80701	SEQUENCE	MSEVPVARVWLVLLLLTVQVGVTAGAPWQCAPCSAEKLALCPPVSASCSEVTRSAGCGCCPMCALPLGAACGVATARCARGLSCRALPGEQQPLHALTRGQGACVQESDASAPHAAEAGSPESPESTEITEEELLDNFHLMAPSEEDHSILWDAISTYDGSKALHVTNIKKWKEPCRIELYRVVESLAKAQETSGEEISKFYLPNCNKNGFYHSRQCETSMDGEAGLCWCVYPWNGKRIPGSPEIRGDPNCQIYFNVQN
T80701	DRUGINFO	D0B5KE	EB-1053	Discontinued in Phase 2

T81548	TARGETID	T81548
T81548	FORMERID	TTDI01648
T81548	UNIPROID	CH602_MYCBO
T81548	TARGNAME	Mycobacterium Heat shock protein 65 (MycB groL2)
T81548	GENENAME	MycB groL2
T81548	TARGTYPE	Discontinued
T81548	SYNONYMS	Protein Cpn60-2; Heat shock protein 65; GroEL protein 2; Cell wall protein A; Antigen A; 65 kDa antigen; 60 kDa chaperonin 2
T81548	FUNCTION	Prevents misfolding and promotes the refolding and proper assembly of unfolded polypeptides generated under stress conditions.
T81548	SEQUENCE	MAKTIAYDEEARRGLERGLNALADAVKVTLGPKGRNVVLEKKWGAPTITNDGVSIAKEIELEDPYEKIGAELVKEVAKKTDDVAGDGTTTATVLAQALVREGLRNVAAGANPLGLKRGIEKAVEKVTETLLKGAKEVETKEQIAATAAISAGDQSIGDLIAEAMDKVGNEGVITVEESNTFGLQLELTEGMRFDKGYISGYFVTDPERQEAVLEDPYILLVSSKVSTVKDLLPLLEKVIGAGKPLLIIAEDVEGEALSTLVVNKIRGTFKSVAVKAPGFGDRRKAMLQDMAILTGGQVISEEVGLTLENADLSLLGKARKVVVTKDETTIVEGAGDTDAIAGRVAQIRQEIENSDSDYDREKLQERLAKLAGGVAVIKAGAATEVELKERKHRIEDAVRNAKAAVEEGIVAGGGVTLLQAAPTLDELKLEGDEATGANIVKVALEAPLKQIAFNSGLEPGVVAEKVRNLPAGHGLNAQTGVYEDLLAAGVADPVKVTRSALQNAASIAGLFLTTEAVVADKPEKEKASVPGGGDMGGMDF
T81548	DRUGINFO	D06VJK	Verpasep caltespen	Discontinued in Phase 3

T09756	TARGETID	T09756
T09756	FORMERID	TTDI01599
T09756	TARGNAME	Polyamine unspecific (PLA)
T09756	TARGTYPE	Discontinued
T09756	DRUGINFO	D0VR5T	BEPH	Discontinued in Phase 1

T78244	TARGETID	T78244
T78244	FORMERID	TTDR00114
T78244	TARGNAME	Vasoactive intestinal polypeptide receptor (VIPR)
T78244	TARGTYPE	Discontinued
T78244	SYNONYMS	VIP-R; VIP receptor
T78244	BIOCLASS	GPCR secretin
T78244	DRUGINFO	D0F6JI	AR-D-111421	Discontinued in Phase 2
T78244	DRUGINFO	D0O5WV	Ac-HSDAVFTDQYTRLRKQVAAKKYLQSIKQKRYC	Investigative

T92035	TARGETID	T92035
T92035	FORMERID	TTDC00270
T92035	TARGNAME	Hepatitis C virus Internal ribosome entry site messenger RNA (HCV IRES mRNA)
T92035	TARGTYPE	Discontinued
T92035	SYNONYMS	mRNA of HCV IRES
T92035	BIOCLASS	mRNA target
T92035	DRUGINFO	D0VB9J	ISIS 14803	Discontinued in Phase 2

T12189	TARGETID	T12189
T12189	FORMERID	TTDR00551
T12189	TARGNAME	Telomerase messenger RNA (Telomerase mRNA)
T12189	TARGTYPE	Discontinued
T12189	SYNONYMS	mRNA of Terminal transferase
T12189	BIOCLASS	mRNA target
T12189	DRUGINFO	D0N8MQ	GSK-159797	Discontinued in Phase 2

T92653	TARGETID	T92653
T92653	FORMERID	TTDR00973
T92653	TARGNAME	Neuropeptide Y receptor (NPYR)
T92653	TARGTYPE	Discontinued
T92653	SYNONYMS	NPY receptor
T92653	DRUGINFO	D06LEJ	Lu-AA44608	Discontinued in Phase 1

T76701	TARGETID	T76701
T76701	FORMERID	TTDI01543
T76701	TARGNAME	Cyclin D1/E2F pathway (CCND1/E2F pathway)
T76701	TARGTYPE	Discontinued
T76701	SYNONYMS	Cyclin D1/E2F pathway signalling
T76701	DRUGINFO	D08PNQ	Trombodipine	Discontinued in Phase 2

T72957	TARGETID	T72957
T72957	FORMERID	TTDR00426
T72957	TARGNAME	Chemokine receptor (CHR)
T72957	TARGTYPE	Discontinued
T72957	DRUGINFO	D09RGW	AZD-3778	Discontinued in Phase 2
T72957	DRUGINFO	D07TTI	AZD-8309	Discontinued in Phase 1
T72957	DRUGINFO	D0NQ5R	AZD-4750	Discontinued in Phase 1
T72957	DRUGINFO	D0TN3D	AZD-7140	Discontinued in Phase 1
T72957	DRUGINFO	D03DYB	AZD-0275	Terminated

T67084	TARGETID	T67084
T67084	FORMERID	TTDI01603
T67084	TARGNAME	Glucosidase unspecific (GAN)
T67084	TARGTYPE	Discontinued
T67084	DRUGINFO	D09NYB	CASTANOSPERMINE	Discontinued in Phase 2

T74225	TARGETID	T74225
T74225	FORMERID	TTDI01557
T74225	TARGNAME	GPCR secretin protein unspecific (GPCRB)
T74225	TARGTYPE	Discontinued
T74225	DRUGINFO	D06BHQ	YM-17K	Discontinued in Phase 2
T74225	DRUGINFO	D03FAP	A-75729	Terminated

T99935	TARGETID	T99935
T99935	FORMERID	TTDI01589
T99935	TARGNAME	GPCR unspecific (GPCR)
T99935	TARGTYPE	Discontinued
T99935	DRUGINFO	D0K1LO	R-873	Discontinued in Phase 2
T99935	DRUGINFO	D07GZL	R-701	Discontinued in Phase 1
T99935	DRUGINFO	D0L9ZK	R-1068	Discontinued in Phase 1
T99935	DRUGINFO	D0ZM2S	R1204	Discontinued in Phase 1
T99935	DRUGINFO	D02RLS	R-1554	Terminated
T99935	DRUGINFO	D0CX2J	R-1315	Terminated
T99935	DRUGINFO	D0F6CI	R-1437	Terminated

T89846	TARGETID	T89846
T89846	FORMERID	TTDI01595
T89846	TARGNAME	Herpesvirus DNA polymerase (KSHV DNAP)
T89846	TARGTYPE	Discontinued
T89846	DRUGINFO	D04RZZ	A-5021	Discontinued in Phase 2

T21324	TARGETID	T21324
T21324	FORMERID	TTDI01577
T21324	TARGNAME	Isomerase unspecific (IsoM)
T21324	TARGTYPE	Discontinued
T21324	DRUGINFO	D0OO6A	Isbogrel	Discontinued in Preregistration
T21324	DRUGINFO	D0DT2P	Nafagrel	Discontinued in Phase 2

T20278	TARGETID	T20278
T20278	FORMERID	TTDI01647
T20278	TARGNAME	Major histocompatibility complex (MHC)
T20278	TARGTYPE	Discontinued
T20278	DRUGINFO	D0N8JA	Theradigm-HBV	Discontinued in Phase 2

T55269	TARGETID	T55269
T55269	FORMERID	TTDI01606
T55269	TARGNAME	Nucleoside transporter (SLC)
T55269	TARGTYPE	Discontinued
T55269	DRUGINFO	D04NWP	DRAFLAZINE	Discontinued in Phase 2

T96592	TARGETID	T96592
T96592	FORMERID	TTDI01678
T96592	TARGNAME	Phosphoric monoester hydrolase (PMH)
T96592	TARGTYPE	Discontinued
T96592	DRUGINFO	D07KOR	INOC-002	Discontinued in Phase 1

T98906	TARGETID	T98906
T98906	FORMERID	TTDI01584
T98906	TARGNAME	Polymerase unspecific (POL)
T98906	TARGTYPE	Discontinued
T98906	DRUGINFO	D0B9GM	Oxibendazole	Discontinued in Phase 3

T52969	TARGETID	T52969
T52969	FORMERID	TTDR00281
T52969	TARGNAME	CAP-dependent endonuclease (CDE)
T52969	TARGTYPE	Discontinued
T52969	DRUGINFO	D0R3EL	GSK184072	Discontinued in Phase 2
T52969	DRUGINFO	D0V7RG	4-substituted 2,4-dioxobutanoic acids	Investigative

T53549	TARGETID	T53549
T53549	FORMERID	TTDI01583
T53549	TARGNAME	Protein thiol group (PTG)
T53549	TARGTYPE	Discontinued
T53549	DRUGINFO	D0W2SO	Orazipone	Discontinued in Phase 1

T25950	TARGETID	T25950
T25950	FORMERID	TTDI01228
T25950	TARGNAME	Bone metabolism (Bone metab)
T25950	TARGTYPE	Discontinued
T25950	DRUGINFO	D05RBO	OPM-3023	Discontinued in Phase 2

T12719	TARGETID	T12719
T12719	FORMERID	TTDI01222
T12719	TARGNAME	Cytomegalovirus Replication (CMV replication)
T12719	TARGTYPE	Discontinued
T12719	DRUGINFO	D0W9SZ	T611	Discontinued in Phase 2

T27288	TARGETID	T27288
T27288	FORMERID	TTDI01257
T27288	TARGNAME	Food intake (FI)
T27288	TARGTYPE	Discontinued
T27288	DRUGINFO	D00ZNP	HMR-1426	Discontinued in Phase 2

T51694	TARGETID	T51694
T51694	FORMERID	TTDI01181
T51694	TARGNAME	Histone synthesis (Histone synth)
T51694	TARGTYPE	Discontinued
T51694	DRUGINFO	D0J5DL	L-4-OXALYSINE	Discontinued in Phase 2

T87608	TARGETID	T87608
T87608	FORMERID	TTDI01159
T87608	TARGNAME	Mitochondrial gene transcription (MGT)
T87608	TARGTYPE	Discontinued
T87608	DRUGINFO	D0S2YX	Mofarotene	Discontinued in Phase 1

T79534	TARGETID	T79534
T79534	FORMERID	TTDI01219
T79534	TARGNAME	P450-dependent ergosterol synthesis (PDE synth)
T79534	TARGTYPE	Discontinued
T79534	DRUGINFO	D0T5NI	Saperconazole	Discontinued in Phase 2

T78590	TARGETID	T78590
T78590	FORMERID	TTDI01580
T78590	TARGNAME	Polymorphonuclear neutrophil adhesion (PMNA)
T78590	TARGTYPE	Discontinued
T78590	DRUGINFO	D0OB7J	NPC-15669	Discontinued in Phase 1

T86702	TARGETID	T86702
T86702	FORMERID	TTDC00105
T86702	UNIPROID	MMP3_HUMAN
T86702	TARGNAME	Matrix metalloproteinase-3 (MMP-3)
T86702	GENENAME	MMP3
T86702	TARGTYPE	Patented-recorded
T86702	SYNONYMS	Transin-1; Stromelysin-1; STMY1; SL-1; MMP-3
T86702	FUNCTION	Can degrade fibronectin, laminin, gelatins of type I, III, IV, and V; collagens III, IV, X, and IX, and cartilage proteoglycans. Activates procollagenase.
T86702	PDBSTRUC	6N9D; 6MAV; 4JA1; 4G9L; 4DPE
T86702	BIOCLASS	Peptidase
T86702	ECNUMBER	EC 3.4.24.17
T86702	SEQUENCE	MKSLPILLLLCVAVCSAYPLDGAARGEDTSMNLVQKYLENYYDLKKDVKQFVRRKDSGPVVKKIREMQKFLGLEVTGKLDSDTLEVMRKPRCGVPDVGHFRTFPGIPKWRKTHLTYRIVNYTPDLPKDAVDSAVEKALKVWEEVTPLTFSRLYEGEADIMISFAVREHGDFYPFDGPGNVLAHAYAPGPGINGDAHFDDDEQWTKDTTGTNLFLVAAHEIGHSLGLFHSANTEALMYPLYHSLTDLTRFRLSQDDINGIQSLYGPPPDSPETPLVPTEPVPPEPGTPANCDPALSFDAVSTLRGEILIFKDRHFWRKSLRKLEPELHLISSFWPSLPSGVDAAYEVTSKDLVFIFKGNQFWAIRGNEVRAGYPRGIHTLGFPPTVRKIDAAISDKEKNKTYFFVEDKYWRFDEKRNSMEPGFPKQIAEDFPGIDSKIDAVFEEFGFFYFFTGSSQLEFDPNAKKVTHTLKSNSWLNC
T86702	DRUGINFO	D05GAP	PMID29130358-Compound-Figure10(2a)	Patented
T86702	DRUGINFO	D08ZKN	PG-530742	Discontinued in Phase 2
T86702	DRUGINFO	D03BOZ	RS-130830	Discontinued in Phase 2
T86702	DRUGINFO	D0T9HG	GM6001	Discontinued in Phase 2
T86702	DRUGINFO	D0P8YC	Batimastat	Preclinical
T86702	DRUGINFO	D08CEE	L-696418	Terminated
T86702	DRUGINFO	D0E5GY	RO-319790	Terminated
T86702	DRUGINFO	D05VNG	BB-1101	Terminated
T86702	DRUGINFO	D0Y1XT	SC-44463	Terminated
T86702	DRUGINFO	D09EUH	FUTOENONE	Investigative
T86702	DRUGINFO	D0J5EZ	AM-2S	Investigative
T86702	DRUGINFO	D0W3ME	PNU-142372	Investigative
T86702	DRUGINFO	D02EFQ	PD-169469	Investigative
T86702	DRUGINFO	D03MUZ	8-chloro-quinoline-3-carbonitrile	Investigative
T86702	DRUGINFO	D05HOS	Hydroxyaminovaline	Investigative
T86702	DRUGINFO	D07OME	1-Methyloxy-4-Sulfone-Benzene	Investigative
T86702	DRUGINFO	D0F7BE	PNU-107859	Investigative
T86702	DRUGINFO	D0JM0Z	3-Methylpyridine	Investigative
T86702	DRUGINFO	D0OR6O	CM-352	Investigative
T86702	DRUGINFO	D0BI8T	RS-39066	Investigative
T86702	DRUGINFO	D0Y7NV	5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione	Investigative
T86702	DRUGINFO	D0H2PA	PKF-242-484	Investigative
T86702	DRUGINFO	D0NP8A	UK-356618	Investigative
T86702	DRUGINFO	D0XL8K	Ro-37-9790	Investigative
T86702	DRUGINFO	D0W2UK	IK-862	Investigative
T86702	DRUGINFO	D0A4TC	MMI270	Investigative

T98062	TARGETID	T98062
T98062	FORMERID	TTDC00099
T98062	UNIPROID	PYGM_HUMAN
T98062	TARGNAME	Glycogen phosphorylase muscle form (GP)
T98062	GENENAME	PYGM
T98062	TARGTYPE	Patented-recorded
T98062	SYNONYMS	Muscle glycogen phosphorylase; Glycogen phosphorylase, muscle form; Glycogen phosphorylase b
T98062	FUNCTION	Enzymes from different sources differ in their regulatory mechanisms and in their natural substrates. However, all known phosphorylases share catalytic and structural properties. Phosphorylase is an important allosteric enzyme in carbohydrate metabolism.
T98062	PDBSTRUC	1Z8D
T98062	BIOCLASS	Glycosyltransferases
T98062	ECNUMBER	EC 2.4.1.1
T98062	SEQUENCE	MSRPLSDQEKRKQISVRGLAGVENVTELKKNFNRHLHFTLVKDRNVATPRDYYFALAHTVRDHLVGRWIRTQQHYYEKDPKRIYYLSLEFYMGRTLQNTMVNLALENACDEATYQLGLDMEELEEIEEDAGLGNGGLGRLAACFLDSMATLGLAAYGYGIRYEFGIFNQKISGGWQMEEADDWLRYGNPWEKARPEFTLPVHFYGHVEHTSQGAKWVDTQVVLAMPYDTPVPGYRNNVVNTMRLWSAKAPNDFNLKDFNVGGYIQAVLDRNLAENISRVLYPNDNFFEGKELRLKQEYFVVAATLQDIIRRFKSSKFGCRDPVRTNFDAFPDKVAIQLNDTHPSLAIPELMRILVDLERMDWDKAWDVTVRTCAYTNHTVLPEALERWPVHLLETLLPRHLQIIYEINQRFLNRVAAAFPGDVDRLRRMSLVEEGAVKRINMAHLCIAGSHAVNGVARIHSEILKKTIFKDFYELEPHKFQNKTNGITPRRWLVLCNPGLAEVIAERIGEDFISDLDQLRKLLSFVDDEAFIRDVAKVKQENKLKFAAYLEREYKVHINPNSLFDIQVKRIHEYKRQLLNCLHVITLYNRIKREPNKFFVPRTVMIGGKAAPGYHMAKMIIRLVTAIGDVVNHDPAVGDRLRVIFLENYRVSLAEKVIPAADLSEQISTAGTEASGTGNMKFMLNGALTIGTMDGANVEMAEEAGEENFFIFGMRVEDVDKLDQRGYNAQEYYDRIPELRQVIEQLSSGFFSPKQPDLFKDIVNMLMHHDRFKVFADYEDYIKCQEKVSALYKNPREWTRMVIRNIATSGKFSSDRTIAQYAREIWGVEPSRQRLPAPDEAI
T98062	DRUGINFO	D07LUJ	URSOLIC ACID	Phase 2
T98062	DRUGINFO	D09HAL	JTT-651	Discontinued in Phase 1
T98062	DRUGINFO	D00ASL	N-Butyl 2beta-hydroxyolean-12-en-28-oate	Investigative
T98062	DRUGINFO	D02AFI	1-D-glucopyranosyl cytosine	Investigative
T98062	DRUGINFO	D03DUN	C-(1-Hydrogyl-Beta-D-Glucopyranosyl) Formamide	Investigative
T98062	DRUGINFO	D03EDR	N-Acetyl-N'-Beta-D-Glucopyranosyl Urea	Investigative
T98062	DRUGINFO	D03WQK	Alpha-D-Glucopyranosyl-2-Carboxylic Acid Amide	Investigative
T98062	DRUGINFO	D05DGE	Fluoro-Phosphite Ion	Investigative
T98062	DRUGINFO	D05KJY	BETULIN	Investigative
T98062	DRUGINFO	D05LDI	2-isoursolic acid	Investigative
T98062	DRUGINFO	D05WSU	Beta-D-Glucopyranose Spirohydantoin	Investigative
T98062	DRUGINFO	D06YDW	23-hydroxybetulinic acid	Investigative
T98062	DRUGINFO	D07MTU	3alpha-Hydroxyurs-12-en-28-oic Acid	Investigative
T98062	DRUGINFO	D07ZJM	2-Oxoolean-12-en-28-oic acid	Investigative
T98062	DRUGINFO	D08VUO	Ethyl 2beta-hydroxyolean-12-en-28-oate	Investigative
T98062	DRUGINFO	D08ZIA	2-isooleanolic acid	Investigative
T98062	DRUGINFO	D09NIM	Benzyl 2-hydroxyiminoolean-12-en-28-oate	Investigative
T98062	DRUGINFO	D0BU6J	2beta,3alpha-dihydroxyurs-12-en-28-oic acid	Investigative
T98062	DRUGINFO	D0E4SM	4-{2-[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid	Investigative
T98062	DRUGINFO	D0G9FQ	2-Hydroxyiminours-12-en-28-oic acid	Investigative
T98062	DRUGINFO	D0I9PG	1-N-Acetyl-Beta-D-Glucosamine	Investigative
T98062	DRUGINFO	D0J3YD	2-Hydroxyiminoolean-12-en-28-oic acid	Investigative
T98062	DRUGINFO	D0J6KJ	1-Deoxy-1-Methoxycarbamido-Beta-D-Glucopyranose	Investigative
T98062	DRUGINFO	D0KS6A	2alpha-Hydroxyurs-12-en-28-oic acid	Investigative
T98062	DRUGINFO	D0LC7K	ASIATIC ACID	Investigative
T98062	DRUGINFO	D0N2SM	2beta,3alpha-dihydroxyolean-12-en-28-oic acid	Investigative
T98062	DRUGINFO	D0P1XH	1-D-glucopyranosyl uracil	Investigative
T98062	DRUGINFO	D0Q7SP	Acurea	Investigative
T98062	DRUGINFO	D0T9CW	Heptulose-2-Phosphate	Investigative
T98062	DRUGINFO	D0U8RR	2-Deoxy-Glucose-6-Phosphate	Investigative
T98062	DRUGINFO	D0W8RS	C-(1-Azido-Alpha-D-Glucopyranosyl) Formamide	Investigative
T98062	DRUGINFO	D0X5YM	2alpha-Hydroxyolean-12-en-28-oic acid	Investigative
T98062	DRUGINFO	D0X7IZ	N-Benzoyl-N'-Beta-D-Glucopyranosyl Urea	Investigative
T98062	DRUGINFO	D02KKU	Oleanonic acid	Investigative
T98062	DRUGINFO	D0E2BH	Nojirimycine Tetrazole	Investigative
T98062	DRUGINFO	D0S5WE	Alpha-D-Glucose-1-Phosphate	Investigative
T98062	DRUGINFO	D0SJ2Q	OLEANOLIC_ACID	Investigative
T98062	DRUGINFO	D01AWD	Alpha-D-Glucose-6-Phosphate	Investigative
T98062	DRUGINFO	D0I5PZ	N'-Pyridoxyl-Lysine-5'-Monophosphate	Investigative
T98062	DRUGINFO	D0G2CT	Indirubin-5-sulfonate	Investigative
T98062	DRUGINFO	D0H2YT	Inosinic Acid	Investigative
T98062	DRUGINFO	D07ONX	Beta-D-Glucose	Investigative
T98062	DRUGINFO	D07PZQ	L-serine-O-phosphate	Investigative

T16042	TARGETID	T16042
T16042	FORMERID	TTDR00234
T16042	UNIPROID	LOX15_HUMAN
T16042	TARGNAME	Arachidonate 15-lipoxygenase (15-LOX)
T16042	GENENAME	ALOX15
T16042	TARGTYPE	Patented-recorded
T16042	SYNONYMS	LOG15; Arachidonate omega-6 lipoxygenase; Arachidonate 12-lipoxygenase, leukocyte-type; 15-Lipoxygenase; 15-LOX-1; 12/15-lipoxygenase; 12-LOX
T16042	FUNCTION	Converts arachidonic acid into 12-hydroperoxyeicosatetraenoic acid/12-HPETE and 15-hydroperoxyeicosatetraenoic acid/15-HPETE. Also converts linoleic acid to 13-hydroperoxyoctadecadienoic acid. May also act on (12S)-hydroperoxyeicosatetraenoic acid/(12S)-HPETE to produce hepoxilin A3. Probably plays an important role in the immune and inflammatory responses. Through the oxygenation of membrane-bound phosphatidylethanolamine in macrophages may favor clearance of apoptotic cells during inflammation by resident macrophages and prevent an autoimmune response associated with the clearance of apoptotic cells by inflammatory monocytes. In parallel, may regulate actin polymerization which is crucial for several biological processes, including macrophage function. May also regulate macrophage function through regulation of the peroxisome proliferator activated receptor signaling pathway. Finally, it is also involved in the cellular response to IL13/interleukin-13. In addition to its role in the immune and inflammatory responses, may play a role in epithelial wound healing in the cornea maybe through production of lipoxin A4. May also play a role in endoplasmic reticulum stress response and the regulation of bone mass. Non-heme iron-containing dioxygenase that catalyzes the stereo-specific peroxidation of free and esterified polyunsaturated fatty acids generating a spectrum of bioactive lipid mediators.
T16042	PDBSTRUC	2ABT
T16042	BIOCLASS	Oxygenase
T16042	ECNUMBER	EC 1.13.11.33
T16042	SEQUENCE	MGLYRIRVSTGASLYAGSNNQVQLWLVGQHGEAALGKRLWPARGKETELKVEVPEYLGPLLFVKLRKRHLLKDDAWFCNWISVQGPGAGDEVRFPCYRWVEGNGVLSLPEGTGRTVGEDPQGLFQKHREEELEERRKLYRWGNWKDGLILNMAGAKLYDLPVDERFLEDKRVDFEVSLAKGLADLAIKDSLNVLTCWKDLDDFNRIFWCGQSKLAERVRDSWKEDALFGYQFLNGANPVVLRRSAHLPARLVFPPGMEELQAQLEKELEGGTLFEADFSLLDGIKANVILCSQQHLAAPLVMLKLQPDGKLLPMVIQLQLPRTGSPPPPLFLPTDPPMAWLLAKCWVRSSDFQLHELQSHLLRGHLMAEVIVVATMRCLPSIHPIFKLIIPHLRYTLEINVRARTGLVSDMGIFDQIMSTGGGGHVQLLKQAGAFLTYSSFCPPDDLADRGLLGVKSSFYAQDALRLWEIIYRYVEGIVSLHYKTDVAVKDDPELQTWCREITEIGLQGAQDRGFPVSLQARDQVCHFVTMCIFTCTGQHASVHLGQLDWYSWVPNAPCTMRLPPPTTKDATLETVMATLPNFHQASLQMSITWQLGRRQPVMVAVGQHEEEYFSGPEPKAVLKKFREELAALDKEIEIRNAKLDMPYEYLRPSVVENSVAI
T16042	DRUGINFO	D00NVU	Imidazole derivative 10	Patented
T16042	DRUGINFO	D02AAR	Indole and benzimidazole derivative 1	Patented
T16042	DRUGINFO	D09AXR	Triazole derivative 3	Patented
T16042	DRUGINFO	D09ZAJ	Isothiazolone derivative 1	Patented
T16042	DRUGINFO	D0GL1X	PMID26560362-Compound-90	Patented
T16042	DRUGINFO	D0IA4F	Imidazole derivative 11	Patented
T16042	DRUGINFO	D0OW2D	Tri-substituted benzene derivative 1	Patented
T16042	DRUGINFO	D00CKV	Indolizine derivative 1	Patented
T16042	DRUGINFO	D0F4JL	NSC-661755	Terminated
T16042	DRUGINFO	D03NLE	IGERNELLIN	Investigative
T16042	DRUGINFO	D05QOR	SCOPOLETIN	Investigative
T16042	DRUGINFO	D0A8OW	Subersic acid	Investigative
T16042	DRUGINFO	D0E0RW	ISOSCOPOLETIN	Investigative
T16042	DRUGINFO	D0ES6Z	(2E)-3-(2-OCT-1-YN-1-YLPHENYL)ACRYLIC ACID	Investigative
T16042	DRUGINFO	D0F1VR	3,4-Dibromo-2-(5-bromo-2-hydroxy-phenoxy)-phenol	Investigative
T16042	DRUGINFO	D0NQ7I	SPONGIADIOXIN A	Investigative
T16042	DRUGINFO	D0NU1W	3,6,8-Tribromo-dibenzo[1,4]dioxin-1-ol	Investigative
T16042	DRUGINFO	D01KTM	(-)-pinoresinol	Investigative
T16042	DRUGINFO	D01PBO	(+)-3,3'-bisdemethyltanegool	Investigative
T16042	DRUGINFO	D02LUF	(+)-(5S,8S,10S)-20-methoxy-9,15-ene-puupehenol	Investigative
T16042	DRUGINFO	D03YMX	3,4,6-Tribromo-2-(2,4-dibromo-phenoxy)-phenol	Investigative
T16042	DRUGINFO	D07EAJ	JASPAQUINOL	Investigative
T16042	DRUGINFO	D07JRW	Jaspic acid	Investigative
T16042	DRUGINFO	D08WDW	DYSIDENIN	Investigative
T16042	DRUGINFO	D0A3QB	Polybrominated diphenyl ether derivative	Investigative
T16042	DRUGINFO	D0A5BH	Hydrohalisulfate 1	Investigative
T16042	DRUGINFO	D0H8FG	(+)-(5S,8S,9R,10S)-20-methoxypuupehenone	Investigative
T16042	DRUGINFO	D0I6ZS	Dimethylnordihydroguarierate acid	Investigative
T16042	DRUGINFO	D0K0QU	(+)-(5S,8S,10S)-20-methoxypuupehenol	Investigative
T16042	DRUGINFO	D0M9VY	Halisulfate 1	Investigative
T16042	DRUGINFO	D0N7XM	(-)-3,3'-bisdemethylpinoresinol	Investigative
T16042	DRUGINFO	D0W5DZ	CHLOROPUUPEHENONE	Investigative
T16042	DRUGINFO	D0X4BT	NSC-172033	Investigative
T16042	DRUGINFO	D0X4CI	2,3,4,5-Tetrabromo-6-(2,4-dibromo-phenoxy)-phenol	Investigative
T16042	DRUGINFO	D05FJM	PUUPEHEDIONE	Investigative
T16042	DRUGINFO	D06PRC	MANGOSTIN	Investigative
T16042	DRUGINFO	D07BXV	PUUPEHENONE	Investigative
T16042	DRUGINFO	D0F9FG	Isojaspic acid	Investigative
T16042	DRUGINFO	D0G3TK	KAEMPFEROL	Investigative

T00663	TARGETID	T00663
T00663	FORMERID	TTDR00928
T00663	UNIPROID	MK10_HUMAN
T00663	TARGNAME	Stress-activated protein kinase JNK3 (JNK3)
T00663	GENENAME	MAPK10
T00663	TARGTYPE	Patented-recorded
T00663	SYNONYMS	Stress-activated protein kinase 1b; SAPK1b; PRKM10; Mitogen-activated protein kinase 10; MAPK 10; MAP kinase p49 3F12; MAP kinase 10; JNK3A; C-Jun N-terminal kinase 3
T00663	FUNCTION	Extracellular stimuli such as proinflammatory cytokines or physical stress stimulate the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and MAP2K7/MKK7 phosphorylate and activate MAPK10/JNK3. In turn, MAPK10/JNK3 phosphorylates a number of transcription factors, primarily components of AP-1 such as JUN and ATF2 and thus regulates AP-1 transcriptional activity. Plays regulatory roles in the signaling pathways during neuronal apoptosis. Phosphorylates the neuronal microtubule regulator STMN2. Acts in the regulation of the amyloid-beta precursor protein/APP signaling during neuronal differentiation by phosphorylating APP. Participates also in neurite growth in spiral ganglion neurons. Phosphorylates the CLOCK-ARNTL/BMAL1 heterodimer and plays a role in the photic regulation of the circadian clock. Serine/threonine-protein kinase involved in various processes such as neuronal proliferation, differentiation, migration and programmed cell death.
T00663	PDBSTRUC	6EQ9; 6EMH; 6EKD; 4Z9L; 4Y5H
T00663	BIOCLASS	Kinase
T00663	ECNUMBER	EC 2.7.11.24
T00663	SEQUENCE	MSLHFLYYCSEPTLDVKIAFCQGFDKQVDVSYIAKHYNMSKSKVDNQFYSVEVGDSTFTVLKRYQNLKPIGSGAQGIVCAAYDAVLDRNVAIKKLSRPFQNQTHAKRAYRELVLMKCVNHKNIISLLNVFTPQKTLEEFQDVYLVMELMDANLCQVIQMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTAGTSFMMTPYVVTRYYRAPEVILGMGYKENVDIWSVGCIMGEMVRHKILFPGRDYIDQWNKVIEQLGTPCPEFMKKLQPTVRNYVENRPKYAGLTFPKLFPDSLFPADSEHNKLKASQARDLLSKMLVIDPAKRISVDDALQHPYINVWYDPAEVEAPPPQIYDKQLDEREHTIEEWKELIYKEVMNSEEKTKNGVVKGQPSPSGAAVNSSESLPPSSSVNDISSMSTDQTLASDTDSSLEASAGPLGCCR
T00663	DRUGINFO	D04BIF	7-azaindole derivative 7	Patented
T00663	DRUGINFO	D0JB7I	7-azaindole derivative 4	Patented
T00663	DRUGINFO	D0U9RB	7-azaindole derivative 6	Patented
T00663	DRUGINFO	D05SJB	7-azaindole derivative 1	Patented
T00663	DRUGINFO	D07KMK	7-azaindole derivative 5	Patented
T00663	DRUGINFO	D08DNZ	PMID25991433-Compound-P6	Patented
T00663	DRUGINFO	D08JOC	PMID25991433-Compound-J3	Patented
T00663	DRUGINFO	D0L2MS	PMID25991433-Compound-P1	Patented
T00663	DRUGINFO	D0Q4WA	PMID25991433-Compound-O3	Patented
T00663	DRUGINFO	D0RQ8Q	PMID25991433-Compound-J2	Patented
T00663	DRUGINFO	D0T6IZ	7-azaindole derivative 3	Patented
T00663	DRUGINFO	D0VR1O	7-azaindole derivative 2	Patented
T00663	DRUGINFO	D0W8BL	PMID25991433-Compound-P5	Patented
T00663	DRUGINFO	D0X2SG	PMID25991433-Compound-P4	Patented
T00663	DRUGINFO	D0ZU8L	PMID25991433-Compound-J5	Patented
T00663	DRUGINFO	D06JRV	PMID25991433-Compound-F2	Patented
T00663	DRUGINFO	D0H4HD	PMID25991433-Compound-A1	Patented
T00663	DRUGINFO	D0E3KD	9-(4-Hydroxyphenyl)-2,7-Phenanthroline	Investigative
T00663	DRUGINFO	D0YA6U	ELN-864709	Investigative
T00663	DRUGINFO	D0B4CA	NSC-656158	Investigative
T00663	DRUGINFO	D0H2PE	Phenyl-(3-phenyl-1H-indazol-6-yl)-amine	Investigative
T00663	DRUGINFO	D0L0HG	AC1LG8KT	Investigative
T00663	DRUGINFO	D00HVA	Aminopyridine deriv. 2	Investigative
T00663	DRUGINFO	D0Q3NG	N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide	Investigative
T00663	DRUGINFO	D0VJ2S	JNK-IN-8	Investigative
T00663	DRUGINFO	D04QCF	AS-601245	Investigative
T00663	DRUGINFO	D02PVB	2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One	Investigative
T00663	DRUGINFO	D0S7IE	N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide	Investigative
T00663	DRUGINFO	D00ICA	AMP-PNP	Investigative

T20973	TARGETID	T20973
T20973	FORMERID	TTDR00296
T20973	UNIPROID	CDK5_HUMAN
T20973	TARGNAME	Cyclin-dependent kinase 5 (CDK5)
T20973	GENENAME	CDK5
T20973	TARGTYPE	Patented-recorded
T20973	SYNONYMS	Tau protein kinase II catalytic subunit; TPKII catalytic subunit; Serine/threonine-protein kinase PSSALRE; Serine/threonine protein kinase PSSALRE; Proline-directed protein kinase F(A) (PDPK F(A)); Proline-directed protein kinase 33 kDa subunit; PDPK; Cyclin-dependent-like kinase 5; Cyclin-dependent kinase 5 (CDK5); Cell division protein kinase 5; CDKN5
T20973	FUNCTION	Interacts with D1 and D3-type G1 cyclins. Phosphorylates SRC, NOS3, VIM/vimentin, p35/CDK5R1, MEF2A, SIPA1L1, SH3GLB1, PXN, PAK1, MCAM/MUC18, SEPT5, SYN1, DNM1, AMPH, SYNJ1, CDK16, RAC1, RHOA, CDC42, TONEBP/NFAT5, MAPT/TAU, MAP1B, histone H1, p53/TP53, HDAC1, APEX1, PTK2/FAK1, huntingtin/HTT, ATM, MAP2, NEFH and NEFM. Regulates several neuronal development and physiological processes including neuronal survival, migration and differentiation, axonal and neurite growth, synaptogenesis, oligodendrocyte differentiation, synaptic plasticity and neurotransmission, by phosphorylating key proteins. Activated by interaction with CDK5R1 (p35) and CDK5R2 (p39), especially in post-mitotic neurons, and promotes CDK5R1 (p35) expression in an autostimulation loop. Phosphorylates many downstream substrates such as Rho and Ras family small GTPases (e. g. PAK1, RAC1, RHOA, CDC42) or microtubule-binding proteins (e. g. MAPT/TAU, MAP2, MAP1B), and modulates actin dynamics to regulate neurite growth and/or spine morphogenesis. Phosphorylates also exocytosis associated proteins such as MCAM/MUC18, SEPT5, SYN1, and CDK16/PCTAIRE1 as well as endocytosis associated proteins such as DNM1, AMPH and SYNJ1 at synaptic terminals. In the mature central nervous system (CNS), regulates neurotransmitter movements by phosphorylating substrates associated with neurotransmitter release and synapse plasticity; synaptic vesicle exocytosis, vesicles fusion with the presynaptic membrane, and endocytosis. Promotes cell survival by activating anti-apoptotic proteins BCL2 and STAT3, and negatively regulating of JNK3/MAPK10 activity. Phosphorylation of p53/TP53 in response to genotoxic and oxidative stresses enhances its stabilization by preventing ubiquitin ligase-mediated proteasomal degradation, and induces transactivation of p53/TP53 target genes, thus regulating apoptosis. Phosphorylation of p35/CDK5R1 enhances its stabilization by preventing calpain-mediated proteolysis producing p25/CDK5R1 and avoiding ubiquitin ligase-mediated proteasomal degradation. During aberrant cell-cycle activity and DNA damage, p25/CDK5 activity elicits cell-cycle activity and double-strand DNA breaks that precedes neuronal death by deregulating HDAC1. DNA damage triggered phosphorylation of huntingtin/HTT in nuclei of neurons protects neurons against polyglutamine expansion as well as DNA damage mediated toxicity. Phosphorylation of PXN reduces its interaction with PTK2/FAK1 in matrix-cell focal adhesions (MCFA) during oligodendrocytes (OLs) differentiation. Negative regulator of Wnt/beta-catenin signaling pathway. Activator of the GAIT (IFN-gamma-activated inhibitor of translation) pathway, which suppresses expression of a post-transcriptional regulon of proinflammatory genes in myeloid cells; phosphorylates the linker domain of glutamyl-prolyl tRNA synthetase (EPRS) in a IFN-gamma-dependent manner, the initial event in assembly of the GAIT complex. Phosphorylation of SH3GLB1 is required for autophagy induction in starved neurons. Phosphorylation of TONEBP/NFAT5 in response to osmotic stress mediates its rapid nuclear localization. MEF2 is inactivated by phosphorylation in nucleus in response to neurotoxin, thus leading to neuronal apoptosis. APEX1 AP-endodeoxyribonuclease is repressed by phosphorylation, resulting in accumulation of DNA damage and contributing to neuronal death. NOS3 phosphorylation down regulates NOS3-derived nitrite (NO) levels. SRC phosphorylation mediates its ubiquitin-dependent degradation and thus leads to cytoskeletal reorganization. May regulate endothelial cell migration and angiogenesis via the modulation of lamellipodia formation. Involved in dendritic spine morphogenesis by mediating the EFNA1-EPHA4 signaling. The complex p35/CDK5 participates in the regulation of the circadian clock by modulating the function of CLOCK protein: phosphorylates CLOCK at 'Thr-451' and 'Thr-461' and regulates the transcriptional activity of the CLOCK-ARNTL/BMAL1 heterodimer in association with altered stability and subcellular distribution. Proline-directed serine/threonine-protein kinase essential for neuronal cell cycle arrest and differentiation and may be involved in apoptotic cell death in neuronal diseases by triggering abortive cell cycle re-entry.
T20973	PDBSTRUC	4AU8; 3O0G; 1UNL; 1UNH; 1UNG
T20973	BIOCLASS	Kinase
T20973	ECNUMBER	EC 2.7.11.1
T20973	SEQUENCE	MQKYEKLEKIGEGTYGTVFKAKNRETHEIVALKRVRLDDDDEGVPSSALREICLLKELKHKNIVRLHDVLHSDKKLTLVFEFCDQDLKKYFDSCNGDLDPEIVKSFLFQLLKGLGFCHSRNVLHRDLKPQNLLINRNGELKLADFGLARAFGIPVRCYSAEVVTLWYRPPDVLFGAKLYSTSIDMWSAGCIFAELANAGRPLFPGNDVDDQLKRIFRLLGTPTEEQWPSMTKLPDYKPYPMYPATTSLVNVVPKLNATGRDLLQNLLKCNPVQRISAEEALQHPYFSDFCPP
T20973	DRUGINFO	D0KP8N	Flavonoid derivative 7	Patented
T20973	DRUGINFO	D0F7DS	PMID26161698-Compound-18	Patented
T20973	DRUGINFO	D08WJG	Naphthyridine and isoquinoline derivative 1	Patented
T20973	DRUGINFO	D01CJE	4-(thiazol-5-yl)-pyrimidine derivative 2	Patented
T20973	DRUGINFO	D0NB7Y	Pyrazolo[1,5-a]-1,3,5-triazine derivative 1	Patented
T20973	DRUGINFO	D07DUX	Roscovitine derivative 1	Patented
T20973	DRUGINFO	D0NY7M	Tricyclic benzimidazole derivative 1	Patented
T20973	DRUGINFO	D00PWQ	KENPAULLONE	Patented
T20973	DRUGINFO	D0WS1V	L-751250	Preclinical
T20973	DRUGINFO	D00BPA	Olomoucine	Terminated
T20973	DRUGINFO	D04AEG	3-(2-phenylthiazol-4-yl)quinolin-2(1H)-one	Investigative
T20973	DRUGINFO	D0YE4B	1-phenyl-3-(2-(pyridin-4-yl)thiazol-4-yl)urea	Investigative
T20973	DRUGINFO	D03ALC	Oxindole 16 (compound 3)	Investigative
T20973	DRUGINFO	D0MS4R	Oxindole 95	Investigative
T20973	DRUGINFO	D0Q4QF	MANZAMINE A	Investigative
T20973	DRUGINFO	D0F0AX	10Z-Hymenialdisine	Investigative
T20973	DRUGINFO	D0G2GA	aminopurvalanol A	Investigative
T20973	DRUGINFO	D0H3EV	9-Nitropaullone	Investigative
T20973	DRUGINFO	D0L3FK	SU9516	Investigative
T20973	DRUGINFO	D0R5FH	Quinoxaline1	Investigative
T20973	DRUGINFO	D0DR8N	AZAKENPAULLONE	Investigative
T20973	DRUGINFO	D0TF9P	Thieno analogue of kenpaullone	Investigative
T20973	DRUGINFO	D0G2CT	Indirubin-5-sulfonate	Investigative
T20973	DRUGINFO	D02XHC	aloisine A	Investigative
T20973	DRUGINFO	D04WFN	NU6140	Investigative
T20973	DRUGINFO	D0Y0ES	Indirubin-3'-monoxime	Investigative

T15700	TARGETID	T15700
T15700	FORMERID	TTDR00433
T15700	UNIPROID	CASP8_HUMAN
T15700	TARGNAME	Caspase-8 (CASP8)
T15700	GENENAME	CASP8
T15700	TARGTYPE	Patented-recorded
T15700	SYNONYMS	MORT1-associated CED-3 homolog; MCH5; MACH; ICE-like apoptotic protease 5; FLICE; FADD-like ICE; FADD-homologous ICE/CED-3-like protease; CASP-8; CAP4; Apoptotic protease Mch-5; Apoptotic cysteine protease
T15700	FUNCTION	Binding to the adapter molecule FADD recruits it to either receptor. The resulting aggregate called death-inducing signaling complex (DISC) performs CASP8 proteolytic activation. The active dimeric enzyme is then liberated from the DISC and free to activate downstream apoptotic proteases. Proteolytic fragments of the N-terminal propeptide (termed CAP3, CAP5 and CAP6) are likely retained in the DISC. Cleaves and activates CASP3, CASP4, CASP6, CASP7, CASP9 and CASP10. May participate in the GZMB apoptotic pathways. Cleaves ADPRT. Hydrolyzes the small-molecule substrate, Ac-Asp-Glu-Val-Asp-|-AMC. Likely target for the cowpox virus CRMA death inhibitory protein. Isoform 5, isoform 6, isoform 7 and isoform 8 lack the catalytic site and may interfere with the pro-apoptotic activity of the complex. Most upstream protease of the activation cascade of caspases responsible for the TNFRSF6/FAS mediated and TNFRSF1A induced cell death.
T15700	PDBSTRUC	5L08; 5JQE; 5H33; 5H31; 4ZBW
T15700	BIOCLASS	Peptidase
T15700	ECNUMBER	EC 3.4.22.61
T15700	SEQUENCE	MDFSRNLYDIGEQLDSEDLASLKFLSLDYIPQRKQEPIKDALMLFQRLQEKRMLEESNLSFLKELLFRINRLDLLITYLNTRKEEMERELQTPGRAQISAYRVMLYQISEEVSRSELRSFKFLLQEEISKCKLDDDMNLLDIFIEMEKRVILGEGKLDILKRVCAQINKSLLKIINDYEEFSKERSSSLEGSPDEFSNGEELCGVMTISDSPREQDSESQTLDKVYQMKSKPRGYCLIINNHNFAKAREKVPKLHSIRDRNGTHLDAGALTTTFEELHFEIKPHDDCTVEQIYEILKIYQLMDHSNMDCFICCILSHGDKGIIYGTDGQEAPIYELTSQFTGLKCPSLAGKPKVFFIQACQGDNYQKGIPVETDSEEQPYLEMDLSSPQTRYIPDEADFLLGMATVNNCVSYRNPAEGTWYIQSLCQSLRERCPRGDDILTILTEVNYEVSNKDDKKNMGKQMPQPTFTLRKKLVFPSD
T15700	DRUGINFO	D08LIU	Amooranin	Investigative
T15700	DRUGINFO	D0N8TA	Acetyl-Ile-Glu-Thr-Asp-aldehyde	Investigative
T15700	DRUGINFO	D0Y2TI	Glionitrin A	Investigative

T94324	TARGETID	T94324
T94324	FORMERID	TTDR01338
T94324	UNIPROID	HDA10_HUMAN
T94324	TARGNAME	Histone deacetylase 10 (HDAC10)
T94324	GENENAME	HDAC10
T94324	TARGTYPE	Patented-recorded
T94324	SYNONYMS	Polyamine deacetylase HDAC10; HD10
T94324	FUNCTION	Exhibits attenuated catalytic activity toward N(1),N(8)-diacetylspermidine and very low activity, if any, toward N(1)-acetylspermidine. Histone deacetylase activity has been observed in vitro. Has also been shown to be involved in MSH2 deacetylation. The physiological relevance of protein/histone deacetylase activity is unclear and could be very weak. May play a role in the promotion of late stages of autophagy, possibly autophagosome-lysosome fusion and/or lysosomal exocytosis in neuroblastoma cells. May play a role in homologous recombination. May promote DNA mismatch repair. Polyamine deacetylase (PDAC), which acts preferentially on N(8)-acetylspermidine, and also on acetylcadaverine and acetylputrescine.
T94324	BIOCLASS	Carbon-nitrogen hydrolase
T94324	ECNUMBER	EC 3.5.1.48
T94324	SEQUENCE	MGTALVYHEDMTATRLLWDDPECEIERPERLTAALDRLRQRGLEQRCLRLSAREASEEELGLVHSPEYVSLVRETQVLGKEELQALSGQFDAIYFHPSTFHCARLAAGAGLQLVDAVLTGAVQNGLALVRPPGHHGQRAAANGFCVFNNVAIAAAHAKQKHGLHRILVVDWDVHHGQGIQYLFEDDPSVLYFSWHRYEHGRFWPFLRESDADAVGRGQGLGFTVNLPWNQVGMGNADYVAAFLHLLLPLAFEFDPELVLVSAGFDSAIGDPEGQMQATPECFAHLTQLLQVLAGGRVCAVLEGGYHLESLAESVCMTVQTLLGDPAPPLSGPMAPCQSALESIQSARAAQAPHWKSLQQQDVTAVPMSPSSHSPEGRPPPLLPGGPVCKAAASAPSSLLDQPCLCPAPSVRTAVALTTPDITLVLPPDVIQQEASALREETEAWARPHESLAREEALTALGKLLYLLDGMLDGQVNSGIAATPASAAAATLDVAVRRGLSHGAQRLLCVALGQLDRPPDLAHDGRSLWLNIRGKEAAALSMFHVSTPLPVMTGGFLSCILGLVLPLAYGFQPDLVLVALGPGHGLQGPHAALLAAMLRGLAGGRVLALLEENSTPQLAGILARVLNGEAPPSLGPSSVASPEDVQALMYLRGQLEPQWKMLQCHPHLVA
T94324	DRUGINFO	D0LN1T	PMID29671355-Compound-8	Patented
T94324	DRUGINFO	D0N2DK	PMID29671355-Compound-44	Patented
T94324	DRUGINFO	D0CH8Q	PMID29671355-Compound-56	Patented
T94324	DRUGINFO	D0LP1K	PMID29671355-Compound-21	Patented
T94324	DRUGINFO	D07WAT	PMID29671355-Compound-62	Patented
T94324	DRUGINFO	D0BP8I	PMID29671355-Compound-43	Patented
T94324	DRUGINFO	D0RA0D	PMID29671355-Compound-25	Patented
T94324	DRUGINFO	D01YBR	ST-3050	Investigative
T94324	DRUGINFO	D0N9AK	ST-2986	Investigative
T94324	DRUGINFO	D00KFF	9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide	Investigative
T94324	DRUGINFO	D00SEE	7-Mercapto-heptanoic acid phenylamide	Investigative
T94324	DRUGINFO	D00ZSD	6-benzenesulfinylhexanoic acid hydroxamide	Investigative
T94324	DRUGINFO	D01MFV	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	Investigative
T94324	DRUGINFO	D01XWZ	7-Mercapto-heptanoic acid biphenyl-4-ylamide	Investigative
T94324	DRUGINFO	D01XXN	N-Hydroxy-4-phenylacetylamino-benzamide	Investigative
T94324	DRUGINFO	D02MQM	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	Investigative
T94324	DRUGINFO	D02UTC	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	Investigative
T94324	DRUGINFO	D02WZK	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	Investigative
T94324	DRUGINFO	D04GGW	Octanedioic acid hydroxyamide pyridin-4-ylamide	Investigative
T94324	DRUGINFO	D04HSS	N-(6-Mercapto-hexyl)-benzamide	Investigative
T94324	DRUGINFO	D04NSP	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	Investigative
T94324	DRUGINFO	D04ZDI	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	Investigative
T94324	DRUGINFO	D05AHZ	6-benzenesulfonylhexanoic acid hydroxamide	Investigative
T94324	DRUGINFO	D05FEJ	9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one	Investigative
T94324	DRUGINFO	D05GVY	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	Investigative
T94324	DRUGINFO	D05LLX	4-Butyrylamino-N-hydroxy-benzamide	Investigative
T94324	DRUGINFO	D05VFP	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	Investigative
T94324	DRUGINFO	D05XAN	7-Mercapto-heptanoic acid biphenyl-3-ylamide	Investigative
T94324	DRUGINFO	D06IQB	5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione	Investigative
T94324	DRUGINFO	D06VBN	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	Investigative
T94324	DRUGINFO	D06XNP	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	Investigative
T94324	DRUGINFO	D07FJU	7-Mercapto-heptanoic acid pyridin-3-ylamide	Investigative
T94324	DRUGINFO	D09YBN	6-Phenoxy-hexane-1-thiol	Investigative
T94324	DRUGINFO	D09ZNU	4-Benzoylamino-N-hydroxy-benzamide	Investigative
T94324	DRUGINFO	D0A5LS	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	Investigative
T94324	DRUGINFO	D0AX7B	8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one	Investigative
T94324	DRUGINFO	D0B2ZJ	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	Investigative
T94324	DRUGINFO	D0B3ZM	6-Mercapto-hexanoic acid phenylamide	Investigative
T94324	DRUGINFO	D0C0VP	Cyclostellettamine derivative	Investigative
T94324	DRUGINFO	D0C2KD	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	Investigative
T94324	DRUGINFO	D0D2KE	5-Mercapto-pentanoic acid phenylamide	Investigative
T94324	DRUGINFO	D0E8KR	Octanedioic acid hydroxyamide pyridin-2-ylamide	Investigative
T94324	DRUGINFO	D0F0KS	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	Investigative
T94324	DRUGINFO	D0H1FZ	2-(methylsulfonylthio)ethyl 2-propylpentanoate	Investigative
T94324	DRUGINFO	D0KE3I	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	Investigative
T94324	DRUGINFO	D0QO0L	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	Investigative
T94324	DRUGINFO	D0R4BS	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	Investigative
T94324	DRUGINFO	D0R5VG	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	Investigative
T94324	DRUGINFO	D0RU1X	8-Oxo-8-phenyl-octanoic acid	Investigative
T94324	DRUGINFO	D0S7WQ	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	Investigative
T94324	DRUGINFO	D0S9JF	6-phenylsulfanylhexanoic acid hydroxamide	Investigative
T94324	DRUGINFO	D0T0SK	ST-2987	Investigative
T94324	DRUGINFO	D0T4IY	7-Mercapto-heptanoic acid quinolin-3-ylamide	Investigative
T94324	DRUGINFO	D0V2ZO	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	Investigative
T94324	DRUGINFO	D0XZ9Q	8-Mercapto-octanoic acid phenylamide	Investigative
T94324	DRUGINFO	D0YY9M	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	Investigative
T94324	DRUGINFO	D0Z3BM	7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one	Investigative
T94324	DRUGINFO	D0Z5KX	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	Investigative
T94324	DRUGINFO	D0Z7YS	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	Investigative
T94324	DRUGINFO	D0N0TS	PSAMMAPLIN A	Investigative

T77236	TARGETID	T77236
T77236	FORMERID	TTDR01032
T77236	UNIPROID	CATF_HUMAN
T77236	TARGNAME	Cathepsin F (CTSF)
T77236	GENENAME	CTSF
T77236	TARGTYPE	Patented-recorded
T77236	SYNONYMS	CATSF
T77236	FUNCTION	Has also been implicated in tumor invasion and metastasis. Thiol protease which is believed to participate in intracellular degradation and turnover of proteins.
T77236	PDBSTRUC	1M6D; 1D5U
T77236	BIOCLASS	Peptidase
T77236	ECNUMBER	EC 3.4.22.41
T77236	SEQUENCE	MAPWLQLLSLLGLLPGAVAAPAQPRAASFQAWGPPSPELLAPTRFALEMFNRGRAAGTRAVLGLVRGRVRRAGQGSLYSLEATLEEPPCNDPMVCRLPVSKKTLLCSFQVLDELGRHVLLRKDCGPVDTKVPGAGEPKSAFTQGSAMISSLSQNHPDNRNETFSSVISLLNEDPLSQDLPVKMASIFKNFVITYNRTYESKEEARWRLSVFVNNMVRAQKIQALDRGTAQYGVTKFSDLTEEEFRTIYLNTLLRKEPGNKMKQAKSVGDLAPPEWDWRSKGAVTKVKDQGMCGSCWAFSVTGNVEGQWFLNQGTLLSLSEQELLDCDKMDKACMGGLPSNAYSAIKNLGGLETEDDYSYQGHMQSCNFSAEKAKVYINDSVELSQNEQKLAAWLAKRGPISVAINAFGMQFYRHGISRPLRPLCSPWLIDHAVLLVGYGNRSDVPFWAIKNSWGTDWGEKGYYYLHRGSGACGVNTMASSAVVD
T77236	DRUGINFO	D05OIU	PMID27998201-Compound-5	Patented
T77236	DRUGINFO	D06XCD	PMID27998201-Compound-12	Patented
T77236	DRUGINFO	D0L4OT	HOMOPHENYLALANINYLMETHANE	Investigative
T77236	DRUGINFO	D0X6WQ	BENZOYL-TYROSINE-ALANINE-METHYL KETONE	Investigative
T77236	DRUGINFO	D06WQP	PMID22686657C(R)-26	Investigative
T77236	DRUGINFO	D0B5IL	WRR-99	Investigative
T77236	DRUGINFO	D0L5WS	Benzoyl-Arginine-Alanine-Methyl Ketone	Investigative
T77236	DRUGINFO	D0T0IX	WRR-112	Investigative

T93653	TARGETID	T93653
T93653	FORMERID	TTDI02353
T93653	UNIPROID	CATL2_HUMAN
T93653	TARGNAME	Cathepsin V (CTSV)
T93653	GENENAME	CTSV
T93653	TARGTYPE	Patented-recorded
T93653	SYNONYMS	UNQ268/PRO305; Cathepsin U; Cathepsin L2; CTSU; CTSL2; CATL2
T93653	FUNCTION	May have an important role in corneal physiology. Cysteine protease.
T93653	PDBSTRUC	3KFQ; 3H6S; 1FH0
T93653	BIOCLASS	Peptidase
T93653	ECNUMBER	EC 3.4.22.43
T93653	SEQUENCE	MNLSLVLAAFCLGIASAVPKFDQNLDTKWYQWKATHRRLYGANEEGWRRAVWEKNMKMIELHNGEYSQGKHGFTMAMNAFGDMTNEEFRQMMGCFRNQKFRKGKVFREPLFLDLPKSVDWRKKGYVTPVKNQKQCGSCWAFSATGALEGQMFRKTGKLVSLSEQNLVDCSRPQGNQGCNGGFMARAFQYVKENGGLDSEESYPYVAVDEICKYRPENSVANDTGFTVVAPGKEKALMKAVATVGPISVAMDAGHSSFQFYKSGIYFEPDCSSKNLDHGVLVVGYGFEGANSNNSKYWLVKNSWGPEWGSNGYVKIAKDKNNHCGIATAASYPNV
T93653	DRUGINFO	D06XCD	PMID27998201-Compound-12	Patented
T93653	DRUGINFO	D04URI	PMID21277783C7	Investigative

T30803	TARGETID	T30803
T30803	FORMERID	TTDI00816
T30803	UNIPROID	GSHR_HUMAN
T30803	TARGNAME	Glutathione reductase (GR)
T30803	GENENAME	GSR
T30803	TARGTYPE	Patented-recorded
T30803	SYNONYMS	Glutathione reductase, mitochondrial; GRase; GRD1; GLUR
T30803	FUNCTION	Maintains high levels of reduced glutathione in the cytosol.
T30803	PDBSTRUC	5GRT; 4GRT; 4GR1; 3SQP; 3GRT
T30803	BIOCLASS	Sulfur donor oxidoreductase
T30803	ECNUMBER	EC 1.8.1.7
T30803	SEQUENCE	MALLPRALSAGAGPSWRRAARAFRGFLLLLPEPAALTRALSRAMACRQEPQPQGPPPAAGAVASYDYLVIGGGSGGLASARRAAELGARAAVVESHKLGGTCVNVGCVPKKVMWNTAVHSEFMHDHADYGFPSCEGKFNWRVIKEKRDAYVSRLNAIYQNNLTKSHIEIIRGHAAFTSDPKPTIEVSGKKYTAPHILIATGGMPSTPHESQIPGASLGITSDGFFQLEELPGRSVIVGAGYIAVEMAGILSALGSKTSLMIRHDKVLRSFDSMISTNCTEELENAGVEVLKFSQVKEVKKTLSGLEVSMVTAVPGRLPVMTMIPDVDCLLWAIGRVPNTKDLSLNKLGIQTDDKGHIIVDEFQNTNVKGIYAVGDVCGKALLTPVAIAAGRKLAHRLFEYKEDSKLDYNNIPTVVFSHPPIGTVGLTEDEAIHKYGIENVKTYSTSFTPMYHAVTKRKTKCVMKMVCANKEEKVVGIHMQGLGCDEMLQGFAVAVKMGATKADFDNTVAIHPTSSEELVTLR
T30803	DRUGINFO	D0V4TY	Oxidized glutathione	Approved
T30803	DRUGINFO	D02NYT	Golden phosphorous acetyletic compound 2	Patented
T30803	DRUGINFO	D03BPZ	Terpyridineplatinum(II) complexe 3	Patented
T30803	DRUGINFO	D05SHW	Terpyridineplatinum(II) complexe 4	Patented
T30803	DRUGINFO	D0W1DK	Golden phosphorous acetyletic compound 1	Patented
T30803	DRUGINFO	D0Z2MX	Acyl oxymethyl acrylamide ester derivative 1	Patented
T30803	DRUGINFO	D03MJM	Trans-(R(S))-2-Hydroxy-1-phenylethyl nitrate	Investigative
T30803	DRUGINFO	D06ZXT	N-6547	Investigative
T30803	DRUGINFO	D07FGO	3,6-Dihydroxy-Xanthene-9-Propionic Acid	Investigative
T30803	DRUGINFO	D0F4SI	N-9xxx	Investigative
T30803	DRUGINFO	D0K1AW	Meta-Nitro-Tyrosine	Investigative
T30803	DRUGINFO	D0L1AV	Trans-(1S(R),2S(R))-2-Hydroxycyclooctyl nitrate	Investigative
T30803	DRUGINFO	D0P5LX	N-6060	Investigative
T30803	DRUGINFO	D0T9NZ	Glutathionylspermidine Disulfide	Investigative
T30803	DRUGINFO	D0V8FG	4-nitrobenzo[c][1,2,5]thiadiazole	Investigative
T30803	DRUGINFO	D0W4IK	3-(Prop-2-Ene-1-Sulfinyl)-Propene-1-Thiol	Investigative
T30803	DRUGINFO	D0YQ0G	2,4,6 trinitrobenzene sulfonate 1,3-bis (2-chlorethyl)-1-nitrosourea	Investigative
T30803	DRUGINFO	D0I8HK	1-(2'-chlorophenyl)penta-1,4-dien-3-one	Investigative
T30803	DRUGINFO	D0E8JM	3-Sulfinoalanine	Investigative
T30803	DRUGINFO	D00IMW	Flavin-Adenine Dinucleotide	Investigative
T30803	DRUGINFO	D0R6JE	Nicotinamide-Adenine-Dinucleotide	Investigative

T66925	TARGETID	T66925
T66925	UNIPROID	F13A_HUMAN
T66925	TARGNAME	Coagulation factor XIIIA (F13A1)
T66925	GENENAME	F13A1
T66925	TARGTYPE	Patented-recorded
T66925	SYNONYMS	Transglutaminase A chain; Protein-glutamine gamma-glutamyltransferase A chain; F13A; Coagulation factor XIII A chain
T66925	FUNCTION	Cross-link alpha-2-plasmin inhibitor, or fibronectin, to the alpha chains of fibrin. Factor XIII is activated by thrombin and calcium ion to a transglutaminase that catalyzes the formation of gamma-glutamyl-epsilon-lysine cross-links between fibrin chains, thus stabilizing the fibrin clot.
T66925	PDBSTRUC	5MHO; 5MHN; 5MHM; 5MHL; 4KTY
T66925	BIOCLASS	Acyltransferase
T66925	ECNUMBER	EC 2.3.2.13
T66925	SEQUENCE	MSETSRTAFGGRRAVPPNNSNAAEDDLPTVELQGVVPRGVNLQEFLNVTSVHLFKERWDTNKVDHHTDKYENNKLIVRRGQSFYVQIDFSRPYDPRRDLFRVEYVIGRYPQENKGTYIPVPIVSELQSGKWGAKIVMREDRSVRLSIQSSPKCIVGKFRMYVAVWTPYGVLRTSRNPETDTYILFNPWCEDDAVYLDNEKEREEYVLNDIGVIFYGEVNDIKTRSWSYGQFEDGILDTCLYVMDRAQMDLSGRGNPIKVSRVGSAMVNAKDDEGVLVGSWDNIYAYGVPPSAWTGSVDILLEYRSSENPVRYGQCWVFAGVFNTFLRCLGIPARIVTNYFSAHDNDANLQMDIFLEEDGNVNSKLTKDSVWNYHCWNEAWMTRPDLPVGFGGWQAVDSTPQENSDGMYRCGPASVQAIKHGHVCFQFDAPFVFAEVNSDLIYITAKKDGTHVVENVDATHIGKLIVTKQIGGDGMMDITDTYKFQEGQEEERLALETALMYGAKKPLNTEGVMKSRSNVDMDFEVENAVLGKDFKLSITFRNNSHNRYTITAYLSANITFYTGVPKAEFKKETFDVTLEPLSFKKEAVLIQAGEYMGQLLEQASLHFFVTARINETRDVLAKQKSTVLTIPEIIIKVRGTQVVGSDMTVTVQFTNPLKETLRNVWVHLDGPGVTRPMKKMFREIRPNSTVQWEEVCRPWVSGHRKLIASMSSDSLRHVYGELDVQIQRRPSM
T66925	DRUGINFO	D0KK6L	PMID26560530-Compound-13	Patented

T98459	TARGETID	T98459
T98459	FORMERID	TTDR00152
T98459	UNIPROID	CCNB1_HUMAN
T98459	TARGNAME	G2/mitotic-specific cyclin B1 (CCNB1)
T98459	GENENAME	CCNB1
T98459	TARGTYPE	Patented-recorded
T98459	SYNONYMS	G2/mitotic-specific cyclin-B1; Cyclin B1; CCNB
T98459	FUNCTION	Essential for the control of the cell cycle at the G2/M (mitosis) transition.
T98459	PDBSTRUC	6GU4; 6GU3; 6GU2; 5LQF; 5HQ0
T98459	BIOCLASS	Eukaryotic nuclear pore complex
T98459	SEQUENCE	MALRVTRNSKINAENKAKINMAGAKRVPTAPAATSKPGLRPRTALGDIGNKVSEQLQAKMPMKKEAKPSATGKVIDKKLPKPLEKVPMLVPVPVSEPVPEPEPEPEPEPVKEEKLSPEPILVDTASPSPMETSGCAPAEEDLCQAFSDVILAVNDVDAEDGADPNLCSEYVKDIYAYLRQLEEEQAVRPKYLLGREVTGNMRAILIDWLVQVQMKFRLLQETMYMTVSIIDRFMQNNCVPKKMLQLVGVTAMFIASKYEEMYPPEIGDFAFVTDNTYTKHQIRQMEMKILRALNFGLGRPLPLHFLRRASKIGEVDVEQHTLAKYLMELTMLDYDMVHFPPSQIAAGAFCLALKILDNGEWTPTLQHYLSYTEESLLPVMQHLAKNVVMVNQGLTKHMTVKNKYATSKHAKISTLPQLNSALVQDLAKAVAKV
T98459	DRUGINFO	D00PWQ	KENPAULLONE	Patented
T98459	DRUGINFO	D07HRP	3,4-bis(indol-3-yl)maleimide derivative	Investigative
T98459	DRUGINFO	D0L5GS	4-(Quinolin-4-yl)-N-p-tolylpyrimidin-2-amine	Investigative
T98459	DRUGINFO	D0Y7QZ	4-(Quinolin-3-yl)-N-p-tolylpyrimidin-2-amine	Investigative
T98459	DRUGINFO	D0DR8N	AZAKENPAULLONE	Investigative
T98459	DRUGINFO	D0TF9P	Thieno analogue of kenpaullone	Investigative
T98459	DRUGINFO	D06AOY	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	Investigative
T98459	DRUGINFO	D00NYT	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	Investigative
T98459	DRUGINFO	D0C3WY	3,4-diphenyl-1H-pyrrole-2,5-dione	Investigative
T98459	DRUGINFO	D0EK0G	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	Investigative
T98459	DRUGINFO	D0TO6S	Bisindolylmaleimide-I	Investigative
T98459	DRUGINFO	D0L8HO	RO-316233	Investigative

T07217	TARGETID	T07217
T07217	FORMERID	TTDR00476
T07217	UNIPROID	FABP4_HUMAN
T07217	TARGNAME	Fatty acid-binding protein 4 (FABP4)
T07217	GENENAME	FABP4
T07217	TARGTYPE	Patented-recorded
T07217	SYNONYMS	Fatty acid-binding protein, adipocyte; Adipocyte-type fatty acid-binding protein; Adipocyte lipid-binding protein; Adipocyte fatty-acid-binding protein; Adipocyte fatty binding protein; ALBP; AFABP; A-FABP
T07217	FUNCTION	Binds both long chain fatty acids and retinoic acid. Delivers long-chain fatty acids and retinoic acid to their cognate receptors in the nucleus. Lipid transport protein in adipocytes.
T07217	PDBSTRUC	6AYL; 5Y13; 5Y12; 5Y0X; 5Y0G
T07217	BIOCLASS	Fatty acid binding protein
T07217	SEQUENCE	MCDAFVGTWKLVSSENFDDYMKEVGVGFATRKVAGMAKPNMIISVNGDVITIKSESTFKNTEISFILGQEFDEVTADDRKVKSTITLDGGVLVHVQKWDGKSTTIKRKREDDKLVVECVMKGVTSTRVYERA
T07217	DRUGINFO	D05UGS	PMID27109571-Compound-11	Patented
T07217	DRUGINFO	D08SLP	PMID27109571-Compound-9	Patented
T07217	DRUGINFO	D0L4EU	PMID27109571-Compound-8	Patented
T07217	DRUGINFO	D0MO1P	PMID27109571-Compound-10	Patented
T07217	DRUGINFO	D0Q9LM	PMID27109571-Compound-7	Patented
T07217	DRUGINFO	D00KCT	PMID27109571-Compound-27	Patented
T07217	DRUGINFO	D00RDL	PMID27109571-Compound-31	Patented
T07217	DRUGINFO	D01CDK	PMID27109571-Compound-16	Patented
T07217	DRUGINFO	D01GOO	PMID27109571-Compound-14	Patented
T07217	DRUGINFO	D01NVM	PMID27109571-Compound-25	Patented
T07217	DRUGINFO	D01TJW	PMID27109571-Compound-30	Patented
T07217	DRUGINFO	D03CJT	PMID27109571-Compound-29	Patented
T07217	DRUGINFO	D05WXM	PMID27109571-Compound-18	Patented
T07217	DRUGINFO	D05XAT	PMID27109571-Compound-28	Patented
T07217	DRUGINFO	D06JEA	PMID27109571-Compound-20	Patented
T07217	DRUGINFO	D07PLJ	PMID27109571-Compound-17	Patented
T07217	DRUGINFO	D08IIV	PMID27109571-Compound-22	Patented
T07217	DRUGINFO	D08SNH	PMID27109571-Compound-15	Patented
T07217	DRUGINFO	D09VOD	PMID27109571-Compound-12	Patented
T07217	DRUGINFO	D0CT9O	PMID27109571-Compound-26	Patented
T07217	DRUGINFO	D0ND3H	PMID27109571-Compound-13	Patented
T07217	DRUGINFO	D0R9RK	PMID27109571-Compound-23	Patented
T07217	DRUGINFO	D0RZ9C	PMID27109571-Compound-19	Patented
T07217	DRUGINFO	D0SK0L	PMID27109571-Compound-24	Patented
T07217	DRUGINFO	D0U2SI	PMID27109571-Compound-21	Patented
T07217	DRUGINFO	D03DUX	2-(4-Methyl-indole-1-sulfonyl)-benzoic acid	Investigative
T07217	DRUGINFO	D03LOG	LINOLEIC ACID	Investigative
T07217	DRUGINFO	D05GVL	2-(6-Methoxy-indole-1-sulfonyl)-benzoic acid	Investigative
T07217	DRUGINFO	D07OKT	3-Carbazol-9-yl-propionic acid	Investigative
T07217	DRUGINFO	D0H2UM	2-(5-Bromo-indole-1-sulfonyl)-benzoic acid	Investigative
T07217	DRUGINFO	D0I1RP	2-(4-Fluoro-indole-1-sulfonyl)-benzoic acid	Investigative
T07217	DRUGINFO	D0Y8JN	2-(3-Methyl-indole-1-sulfonyl)-benzoic acid	Investigative
T07217	DRUGINFO	D0YW9C	1-benzyl-2,3-dimethyl-1H-indole-7-carboxylic acid	Investigative
T07217	DRUGINFO	D00ORM	5-Carbazol-9-yl-pentanoic acid	Investigative
T07217	DRUGINFO	D05JAH	4-Carbazol-9-yl-butyric acid	Investigative
T07217	DRUGINFO	D08KLL	2-(2,3-bis(2-chlorobenzyloxy)phenyl)acetic acid	Investigative
T07217	DRUGINFO	D0A4EA	OLEIC ACID	Investigative
T07217	DRUGINFO	D0C1DG	2-(Carbazole-9-sulfonyl)-benzoic acid	Investigative
T07217	DRUGINFO	D0WF7I	BMS-480404	Investigative
T07217	DRUGINFO	D02TVS	Hexadecanoic acid	Investigative

T06792	TARGETID	T06792
T06792	UNIPROID	PSB9_HUMAN
T06792	TARGNAME	Proteasome beta-9 (PS beta-9)
T06792	GENENAME	PSMB9
T06792	TARGTYPE	Patented-recorded
T06792	SYNONYMS	Really interesting new gene 12 protein; RING12; Proteasome subunit beta-1i; Proteasome subunit beta type-9; Proteasome chain 7; PSMB6i; Multicatalytic endopeptidase complex chain 7; Macropain chain 7; Low molecular mass protein 2; LMP2
T06792	FUNCTION	The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. Replacement of PSMB6 by PSMB9 increases the capacity of the immunoproteasome to cleave model peptides after hydrophobic and basic residues. The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH.
T06792	PDBSTRUC	6AVO
T06792	BIOCLASS	Peptidase
T06792	ECNUMBER	EC 3.4.25.1
T06792	SEQUENCE	MLRAGAPTGDLPRAGEVHTGTTIMAVEFDGGVVMGSDSRVSAGEAVVNRVFDKLSPLHERIYCALSGSAADAQAVADMAAYQLELHGIELEEPPLVLAAANVVRNISYKYREDLSAHLMVAGWDQREGGQVYGTLGGMLTRQPFAIGGSGSTFIYGYVDAAYKPGMSPEECRRFTTDAIALAMSRDGSSGGVIYLVTITAAGVDHRVILGNELPKFYDE
T06792	DRUGINFO	D0R8XD	Peptide analog 14	Patented
T06792	DRUGINFO	D0B0GG	Dipeptide analog 1	Patented
T06792	DRUGINFO	D01VMN	PMID29865878-Compound-53	Patented
T06792	DRUGINFO	D03CMD	PMID29865878-Compound-55	Patented
T06792	DRUGINFO	D0C2MH	PMID29865878-Compound-46	Patented
T06792	DRUGINFO	D0K0GJ	PMID29865878-Compound-48	Patented
T06792	DRUGINFO	D0NE8M	PMID29865878-Compound-51	Patented
T06792	DRUGINFO	D0TU5R	PMID29865878-Compound-49	Patented
T06792	DRUGINFO	D01OOO	Peptide analog 41	Patented
T06792	DRUGINFO	D02PJI	Peptide analog 21	Patented
T06792	DRUGINFO	D0T1YB	Peptide analog 23	Patented

T49031	TARGETID	T49031
T49031	FORMERID	TTDI03482
T49031	UNIPROID	PSB5_HUMAN
T49031	TARGNAME	Proteasome beta-5 (PS beta-5)
T49031	GENENAME	PSMB5
T49031	TARGTYPE	Patented-recorded
T49031	SYNONYMS	Proteasome subunit beta type-5; Proteasome subunit X; Proteasome subunit MB1; Proteasome epsilon chain; Proteasome chain 6; Multicatalytic endopeptidase complex epsilon chain; Macropain epsilon chain; MB1; LMPX
T49031	FUNCTION	Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins. The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex). Within the 20S core complex, PSMB5 displays a chymotrypsin-like activity.
T49031	PDBSTRUC	6MSK; 6MSJ; 6MSH; 6MSG; 6MSE
T49031	BIOCLASS	Peptidase
T49031	ECNUMBER	EC 3.4.25.1
T49031	SEQUENCE	MALASVLERPLPVNQRGFFGLGGRADLLDLGPGSLSDGLSLAAPGWGVPEEPGIEMLHGTTTLAFKFRHGVIVAADSRATAGAYIASQTVKKVIEINPYLLGTMAGGAADCSFWERLLARQCRIYELRNKERISVAAASKLLANMVYQYKGMGLSMGTMICGWDKRGPGLYYVDSEGNRISGATFSVGSGSVYAYGVMDRGYSYDLEVEQAYDLARRAIYQATYRDAYSGGAVNLYHVREDGWIRVSSDNVADLHEKYSGSTP
T49031	DRUGINFO	D02SYR	Peptide analog 27	Patented
T49031	DRUGINFO	D03JMZ	Peptide analog 28	Patented
T49031	DRUGINFO	D05MVF	Peptide analog 34	Patented
T49031	DRUGINFO	D06OXO	Peptide analog 33	Patented
T49031	DRUGINFO	D07SSU	Peptide analog 31	Patented
T49031	DRUGINFO	D08HPR	PMID29865878-Compound-44	Patented
T49031	DRUGINFO	D09WUW	PMID29865878-Compound-43	Patented
T49031	DRUGINFO	D0AR6B	Peptide analog 13	Patented
T49031	DRUGINFO	D0DK3R	Peptide analog 25	Patented
T49031	DRUGINFO	D0E6ED	Peptide analog 11	Patented
T49031	DRUGINFO	D0L1TT	Peptide analog 17	Patented
T49031	DRUGINFO	D0P8VL	PMID29865878-Compound-8	Patented
T49031	DRUGINFO	D0Q0XN	Peptide analog 19	Patented
T49031	DRUGINFO	D00GGB	Peptide analog 37	Patented
T49031	DRUGINFO	D01GON	Peptide analog 38	Patented
T49031	DRUGINFO	D02CQG	Peptide analog 39	Patented
T49031	DRUGINFO	D0DY3A	Peptide analog 36	Patented
T49031	DRUGINFO	D01VMN	PMID29865878-Compound-53	Patented
T49031	DRUGINFO	D03CMD	PMID29865878-Compound-55	Patented
T49031	DRUGINFO	D0C2MH	PMID29865878-Compound-46	Patented
T49031	DRUGINFO	D0K0GJ	PMID29865878-Compound-48	Patented
T49031	DRUGINFO	D0NE8M	PMID29865878-Compound-51	Patented
T49031	DRUGINFO	D0TU5R	PMID29865878-Compound-49	Patented
T49031	DRUGINFO	D01OOO	Peptide analog 41	Patented
T49031	DRUGINFO	D02PJI	Peptide analog 21	Patented
T49031	DRUGINFO	D0T1YB	Peptide analog 23	Patented
T49031	DRUGINFO	D0Y6HD	PMID24946214C3b	Investigative

T09022	TARGETID	T09022
T09022	UNIPROID	PSB10_HUMAN
T09022	TARGNAME	Proteasome beta-10 (PS beta-10)
T09022	GENENAME	PSMB10
T09022	TARGTYPE	Patented-recorded
T09022	SYNONYMS	Proteasome subunit beta-2i; Proteasome subunit beta type-10; Proteasome MECl-1; Multicatalytic endopeptidase complex subunit MECl-1; Macropain subunit MECl-1; MECL1; Low molecular mass protein 10; LMP10
T09022	FUNCTION	The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH.
T09022	PDBSTRUC	6HVW; 6HVV; 6HVU; 6HVT; 6HVS
T09022	BIOCLASS	Peptidase
T09022	ECNUMBER	EC 3.4.25.1
T09022	SEQUENCE	MLKPALEPRGGFSFENCQRNASLERVLPGLKVPHARKTGTTIAGLVFQDGVILGADTRATNDSVVADKSCEKIHFIAPKIYCCGAGVAADAEMTTRMVASKMELHALSTGREPRVATVTRILRQTLFRYQGHVGASLIVGGVDLTGPQLYGVHPHGSYSRLPFTALGSGQDAALAVLEDRFQPNMTLEAAQGLLVEAVTAGILGDLGSGGNVDACVITKTGAKLLRTLSSPTEPVKRSGRYHFVPGTTAVLTQTVKPLTLELVEETVQAMEVE
T09022	DRUGINFO	D00GGB	Peptide analog 37	Patented
T09022	DRUGINFO	D01GON	Peptide analog 38	Patented
T09022	DRUGINFO	D0DY3A	Peptide analog 36	Patented
T09022	DRUGINFO	D02PJI	Peptide analog 21	Patented
T09022	DRUGINFO	D0T1YB	Peptide analog 23	Patented

T64205	TARGETID	T64205
T64205	FORMERID	TTDC00113
T64205	UNIPROID	STAT1_HUMAN
T64205	TARGNAME	Signal transducer and activator of transcription 1 (STAT1)
T64205	GENENAME	STAT1
T64205	TARGTYPE	Patented-recorded
T64205	SYNONYMS	Transcription factor ISGF-3 components p91/p84; Signal transducers and activators of transcription factor; Signal transducer and activator of transcription 1-alpha/beta; STAT-1; P91
T64205	FUNCTION	Following type I IFN (IFN-alpha and IFN-beta) binding to cell surface receptors, signaling via protein kinases leads to activation of Jak kinases (TYK2 and JAK1) and to tyrosine phosphorylation of STAT1 and STAT2. The phosphorylated STATs dimerize and associate with ISGF3G/IRF-9 to form a complex termed ISGF3 transcription factor, that enters the nucleus. ISGF3 binds to the IFN stimulated response element (ISRE) to activate the transcription of IFN-stimulated genes (ISG), which drive the cell in an antiviral state. In response to type II IFN (IFN-gamma), STAT1 is tyrosine- and serine-phosphorylated. It then forms a homodimer termed IFN-gamma-activated factor (GAF), migrates into the nucleus and binds to the IFN gamma activated sequence (GAS) to drive the expression of the target genes, inducing a cellular antiviral state. Becomes activated in response to KITLG/SCF and KIT signaling. May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4. Signal transducer and transcription activator that mediates cellular responses to interferons (IFNs), cytokine KITLG/SCF and other cytokines and other growth factors.
T64205	PDBSTRUC	3WWT; 2KA6; 1YVL; 1BF5
T64205	BIOCLASS	Transcription factor
T64205	SEQUENCE	MSQWYELQQLDSKFLEQVHQLYDDSFPMEIRQYLAQWLEKQDWEHAANDVSFATIRFHDLLSQLDDQYSRFSLENNFLLQHNIRKSKRNLQDNFQEDPIQMSMIIYSCLKEERKILENAQRFNQAQSGNIQSTVMLDKQKELDSKVRNVKDKVMCIEHEIKSLEDLQDEYDFKCKTLQNREHETNGVAKSDQKQEQLLLKKMYLMLDNKRKEVVHKIIELLNVTELTQNALINDELVEWKRRQQSACIGGPPNACLDQLQNWFTIVAESLQQVRQQLKKLEELEQKYTYEHDPITKNKQVLWDRTFSLFQQLIQSSFVVERQPCMPTHPQRPLVLKTGVQFTVKLRLLVKLQELNYNLKVKVLFDKDVNERNTVKGFRKFNILGTHTKVMNMEESTNGSLAAEFRHLQLKEQKNAGTRTNEGPLIVTEELHSLSFETQLCQPGLVIDLETTSLPVVVISNVSQLPSGWASILWYNMLVAEPRNLSFFLTPPCARWAQLSEVLSWQFSSVTKRGLNVDQLNMLGEKLLGPNASPDGLIPWTRFCKENINDKNFPFWLWIESILELIKKHLLPLWNDGCIMGFISKERERALLKDQQPGTFLLRFSESSREGAITFTWVERSQNGGEPDFHAVEPYTKKELSAVTFPDIIRNYKVMAAENIPENPLKYLYPNIDKDHAFGKYYSRPKEAPEPMELDGPKGTGYIKTELISVSEVHPSRLQTTDNLLPMSPEEFDEVSRIVGSVEFDSMMNTV
T64205	DRUGINFO	D0JF5K	Peptide analog 8	Patented
T64205	DRUGINFO	D0EZ6V	Oxazole derivative 1	Patented
T64205	DRUGINFO	D0XQ3F	Peptidomimetic analog 5	Patented
T64205	DRUGINFO	D01BVU	Platinum IV complexe 1	Patented
T64205	DRUGINFO	D0TU0X	PMID26394986-Compound-10	Patented
T64205	DRUGINFO	D03WRN	AVT-02 UE	Discontinued in Phase 2

T46685	TARGETID	T46685
T46685	FORMERID	TTDI00245
T46685	UNIPROID	CLK1_HUMAN
T46685	TARGNAME	CDC-like kinase 1 (CLK1)
T46685	GENENAME	CLK1
T46685	TARGTYPE	Patented-recorded
T46685	SYNONYMS	Dual specificity protein kinase CLK1; CLK; CDClike kinase 1
T46685	FUNCTION	Phosphorylates serine- and arginine-rich (SR) proteins of the spliceosomal complex and may be a constituent of a network of regulatory mechanisms that enable SR proteins to control RNA splicing. Phosphorylates: SRSF1, SRSF3 and PTPN1. Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells and adenovirus E1A pre-mRNA. Dual specificity kinase acting on both serine/threonine and tyrosine-containing substrates.
T46685	PDBSTRUC	6RAA; 6Q8P; 6Q8K; 6I5L; 6I5K
T46685	BIOCLASS	Kinase
T46685	ECNUMBER	EC 2.7.12.1
T46685	SEQUENCE	MRHSKRTYCPDWDDKDWDYGKWRSSSSHKRRKRSHSSAQENKRCKYNHSKMCDSHYLESRSINEKDYHSRRYIDEYRNDYTQGCEPGHRQRDHESRYQNHSSKSSGRSGRSSYKSKHRIHHSTSHRRSHGKSHRRKRTRSVEDDEEGHLICQSGDVLSARYEIVDTLGEGAFGKVVECIDHKAGGRHVAVKIVKNVDRYCEAARSEIQVLEHLNTTDPNSTFRCVQMLEWFEHHGHICIVFELLGLSTYDFIKENGFLPFRLDHIRKMAYQICKSVNFLHSNKLTHTDLKPENILFVQSDYTEAYNPKIKRDERTLINPDIKVVDFGSATYDDEHHSTLVSTRHYRAPEVILALGWSQPCDVWSIGCILIEYYLGFTVFPTHDSKEHLAMMERILGPLPKHMIQKTRKRKYFHHDRLDWDEHSSAGRYVSRRCKPLKEFMLSQDVEHERLFDLIQKMLEYDPAKRITLREALKHPFFDLLKKSI
T46685	DRUGINFO	D06MBI	TG003	Patented
T46685	DRUGINFO	D00BAJ	KH-CB19	Investigative
T46685	DRUGINFO	D0UI7U	ML315	Investigative
T46685	DRUGINFO	D06CXU	PMID23642479C17	Investigative
T46685	DRUGINFO	D04IMY	leucettine L41	Investigative

T79155	TARGETID	T79155
T79155	FORMERID	TTDR00457
T79155	UNIPROID	KLK7_HUMAN
T79155	TARGNAME	Kallikrein-7 (KLK7)
T79155	GENENAME	KLK7
T79155	TARGTYPE	Patented-recorded
T79155	SYNONYMS	hK7; Stratum corneum chymotryptic enzyme; Serine protease 6; SCCE; PRSS6; HSCCE
T79155	FUNCTION	Specific for amino acid residues with aromatic side chains in the P1 position. Cleaves insulin A chain at '14-Tyr-|-Gln-15' and insulin B chain at '6-Leu-|-Cys-7', '16-Tyr-|-Leu-17', '25-Phe-|-Tyr-26' and '26-Tyr-|-Thr-27'. Could play a role in the activation of precursors to inflammatory cytokines. May catalyze the degradation of intercellular cohesive structures in the cornified layer of the skin in the continuous shedding of cells from the skin surface.
T79155	PDBSTRUC	5YJK; 5Y9L; 5FAH; 3BSQ; 2QXJ
T79155	BIOCLASS	Peptidase
T79155	ECNUMBER	EC 3.4.21.117
T79155	SEQUENCE	MARSLLLPLQILLLSLALETAGEEAQGDKIIDGAPCARGSHPWQVALLSGNQLHCGGVLVNERWVLTAAHCKMNEYTVHLGSDTLGDRRAQRIKASKSFRHPGYSTQTHVNDLMLVKLNSQARLSSMVKKVRLPSRCEPPGTTCTVSGWGTTTSPDVTFPSDLMCVDVKLISPQDCTKVYKDLLENSMLCAGIPDSKKNACNGDSGGPLVCRGTLQGLVSWGTFPCGQPNDPGVYTQVCKFTKWINDTMKKHR
T79155	DRUGINFO	D01JCX	Antileukoprotease (ALP)	Investigative
T79155	DRUGINFO	D00LOL	PMID23849879C3	Investigative
T79155	DRUGINFO	D07OQF	PMID25489658C4d	Investigative

T04123	TARGETID	T04123
T04123	UNIPROID	PPP5_HUMAN
T04123	TARGNAME	Serine/threonine-protein phosphatase 5 (PPP5C)
T04123	GENENAME	PPP5C
T04123	TARGTYPE	Patented-recorded
T04123	SYNONYMS	Protein phosphatase T; PPT protein; PPP5; PP5; PP-T
T04123	FUNCTION	Implicated in wide ranging cellular processes, including apoptosis, differentiation, DNA damage response, cell survival, regulation of ion channels or circadian rhythms, in response to steroid and thyroid hormones, calcium, fatty acids, TGF-beta as well as oxidative and genotoxic stresses. Participates in the control of DNA damage response mechanisms such as checkpoint activation and DNA damage repair through, for instance, the regulation ATM/ATR-signaling and dephosphorylation of PRKDC and TP53BP1. Inhibits ASK1/MAP3K5-mediated apoptosis induced by oxidative stress. Plays a positive role in adipogenesis, mainly through the dephosphorylation and activation of PPARG transactivation function. Also dephosphorylates and inhibits the anti-adipogenic effect of NR3C1. Regulates the circadian rhythms, through the dephosphorylation and activation of CSNK1E. May modulate TGF-beta signaling pathway by the regulation of SMAD3 phosphorylation and protein expression levels. Dephosphorylates and may play a role in the regulation of TAU/MAPT. Through their dephosphorylation, may play a role in the regulation of ions channels such as KCNH2. Serine/threonine-protein phosphatase that dephosphorylates a myriad of proteins involved in different signaling pathways including the kinases CSNK1E, ASK1/MAP3K5, PRKDC and RAF1, the nuclear receptors NR3C1, PPARG, ESR1 and ESR2, SMAD proteins and TAU/MAPT.
T04123	PDBSTRUC	5WG8; 5UI1; 5HPE; 4ZX2; 4ZVZ
T04123	BIOCLASS	Phosphoric monoester hydrolase
T04123	ECNUMBER	EC 3.1.3.16
T04123	SEQUENCE	MAMAEGERTECAEPPRDEPPADGALKRAEELKTQANDYFKAKDYENAIKFYSQAIELNPSNAIYYGNRSLAYLRTECYGYALGDATRAIELDKKYIKGYYRRAASNMALGKFRAALRDYETVVKVKPHDKDAKMKYQECNKIVKQKAFERAIAGDEHKRSVVDSLDIESMTIEDEYSGPKLEDGKVTISFMKELMQWYKDQKKLHRKCAYQILVQVKEVLSKLSTLVETTLKETEKITVCGDTHGQFYDLLNIFELNGLPSETNPYIFNGDFVDRGSFSVEVILTLFGFKLLYPDHFHLLRGNHETDNMNQIYGFEGEVKAKYTAQMYELFSEVFEWLPLAQCINGKVLIMHGGLFSEDGVTLDDIRKIERNRQPPDSGPMCDLLWSDPQPQNGRSISKRGVSCQFGPDVTKAFLEENNLDYIIRSHEVKAEGYEVAHGGRCVTVFSAPNYCDQMGNKASYIHLQGSDLRPQFHQFTAVPHPNVKPMAYANTLLQLGMM

T20600	TARGETID	T20600
T20600	UNIPROID	CASP6_HUMAN
T20600	TARGNAME	Caspase-6 (CASP6)
T20600	GENENAME	CASP6
T20600	TARGTYPE	Patented-recorded
T20600	SYNONYMS	MCH2; Caspase-6 subunit p18; Caspase-6 subunit p11; CASP-6; Apoptotic protease Mch-2
T20600	FUNCTION	Cleaves poly(ADP-ribose) polymerase in vitro, as well as lamins. Overexpression promotes programmed cell death. Involved in the activation cascade of caspases responsible for apoptosis execution.
T20600	PDBSTRUC	6DEV; 6DEU; 4NBN; 4NBL; 4NBK
T20600	BIOCLASS	Peptidase
T20600	ECNUMBER	EC 3.4.22.59
T20600	SEQUENCE	MSSASGLRRGHPAGGEENMTETDAFYKREMFDPAEKYKMDHRRRGIALIFNHERFFWHLTLPERRGTCADRDNLTRRFSDLGFEVKCFNDLKAEELLLKIHEVSTVSHADADCFVCVFLSHGEGNHIYAYDAKIEIQTLTGLFKGDKCHSLVGKPKIFIIQACRGNQHDVPVIPLDVVDNQTEKLDTNITEVDAASVYTLPAGADFLMCYSVAEGYYSHRETVNGSWYIQDLCEMLGKYGSSLEFTELLTLVNRKVSQRRVDFCKDPSAIGKKQVPCFASMLTKKLHFFPKSN

T21507	TARGETID	T21507
T21507	FORMERID	TTDR00309
T21507	UNIPROID	FABP5_HUMAN
T21507	TARGNAME	Fatty acid-binding protein 5 (FABP5)
T21507	GENENAME	FABP5
T21507	TARGTYPE	Patented-recorded
T21507	SYNONYMS	Psoriasis-associated fatty acid-binding protein homolog; PA-FABP; Fatty acid-binding protein, epidermal; Fatty Acid BindingProtein mal1; Epidermal-type fatty acid-binding protein; E-FABP
T21507	FUNCTION	Intracellular carrier for long-chain fatty acids and related active lipids, such as the endocannabinoid, that regulates the metabolism and actions of the ligands they bind. In addition to the cytosolic transport, selectively delivers specific fatty acids from the cytosol to the nucleus, wherein they activate nuclear receptors. Delivers retinoic acid to the nuclear receptor peroxisome proliferator-activated receptor delta; which promotes proliferation and survival. May also serve as a synaptic carrier of endocannabinoid at central synapses and thus controls retrograde endocannabinoid signaling. Modulates inflammation by regulating PTGES induction via NF-kappa-B activation, and prostaglandin E2 (PGE2) biosynthesis during inflammation. May be involved in keratinocyte differentiation.
T21507	PDBSTRUC	5UR9; 5HZ5; 4LKT; 4LKP; 4AZR
T21507	BIOCLASS	Fatty acid binding protein
T21507	SEQUENCE	MATVQQLEGRWRLVDSKGFDEYMKELGVGIALRKMGAMAKPDCIITCDGKNLTIKTESTLKTTQFSCTLGEKFEETTADGRKTQTVCNFTDGALVQHQEWDGKESTITRKLKDGKLVVECVMNNVTCTRIYEKVE
T21507	DRUGINFO	D00KCT	PMID27109571-Compound-27	Patented
T21507	DRUGINFO	D00RDL	PMID27109571-Compound-31	Patented
T21507	DRUGINFO	D01CDK	PMID27109571-Compound-16	Patented
T21507	DRUGINFO	D01GOO	PMID27109571-Compound-14	Patented
T21507	DRUGINFO	D01NVM	PMID27109571-Compound-25	Patented
T21507	DRUGINFO	D01TJW	PMID27109571-Compound-30	Patented
T21507	DRUGINFO	D03CJT	PMID27109571-Compound-29	Patented
T21507	DRUGINFO	D05WXM	PMID27109571-Compound-18	Patented
T21507	DRUGINFO	D05XAT	PMID27109571-Compound-28	Patented
T21507	DRUGINFO	D06JEA	PMID27109571-Compound-20	Patented
T21507	DRUGINFO	D07PLJ	PMID27109571-Compound-17	Patented
T21507	DRUGINFO	D08IIV	PMID27109571-Compound-22	Patented
T21507	DRUGINFO	D08SNH	PMID27109571-Compound-15	Patented
T21507	DRUGINFO	D09VOD	PMID27109571-Compound-12	Patented
T21507	DRUGINFO	D0CT9O	PMID27109571-Compound-26	Patented
T21507	DRUGINFO	D0ND3H	PMID27109571-Compound-13	Patented
T21507	DRUGINFO	D0R9RK	PMID27109571-Compound-23	Patented
T21507	DRUGINFO	D0RZ9C	PMID27109571-Compound-19	Patented
T21507	DRUGINFO	D0SK0L	PMID27109571-Compound-24	Patented
T21507	DRUGINFO	D0U2SI	PMID27109571-Compound-21	Patented
T21507	DRUGINFO	D00ORM	5-Carbazol-9-yl-pentanoic acid	Investigative
T21507	DRUGINFO	D05JAH	4-Carbazol-9-yl-butyric acid	Investigative
T21507	DRUGINFO	D08KLL	2-(2,3-bis(2-chlorobenzyloxy)phenyl)acetic acid	Investigative
T21507	DRUGINFO	D0C1DG	2-(Carbazole-9-sulfonyl)-benzoic acid	Investigative
T21507	DRUGINFO	D0WF7I	BMS-480404	Investigative
T21507	DRUGINFO	D02TVS	Hexadecanoic acid	Investigative

T67812	TARGETID	T67812
T67812	UNIPROID	MGAT2_HUMAN
T67812	TARGNAME	Mannoside acetylglucosaminyltransferase 2 (MGAT2)
T67812	GENENAME	MGAT2
T67812	TARGTYPE	Patented-recorded
T67812	SYNONYMS	N-glycosyl-oligosaccharide-glycoprotein N-acetylglucosaminyltransferase II; GlcNAc-T II; GNT-II; Beta-1,2-N-acetylglucosaminyltransferase II; Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase
T67812	FUNCTION	Catalyzes the transfer of N-acetylglucosamine (GlcNAc) onto the free terminal mannose moiety in the core structure of the nascent N-linked glycan chain, giving rise to the second branch in complex glycans. Plays an essential role in protein N-glycosylation.
T67812	PDBSTRUC	5VCS; 5VCR; 5VCM
T67812	BIOCLASS	Glycosyltransferases
T67812	ECNUMBER	EC 2.4.1.143
T67812	SEQUENCE	MRFRIYKRKVLILTLVVAACGFVLWSSNGRQRKNEALAPPLLDAEPARGAGGRGGDHPSVAVGIRRVSNVSAASLVPAVPQPEADNLTLRYRSLVYQLNFDQTLRNVDKAGTWAPRELVLVVQVHNRPEYLRLLLDSLRKAQGIDNVLVIFSHDFWSTEINQLIAGVNFCPVLQVFFPFSIQLYPNEFPGSDPRDCPRDLPKNAALKLGCINAEYPDSFGHYREAKFSQTKHHWWWKLHFVWERVKILRDYAGLILFLEEDHYLAPDFYHVFKKMWKLKQQECPECDVLSLGTYSASRSFYGMADKVDVKTWKSTEHNMGLALTRNAYQKLIECTDTFCTYDDYNWDWTLQYLTVSCLPKFWKVLVPQIPRIFHAGDCGMHHKKTCRPSTQSAQIESLLNNNKQYMFPETLTISEKFTVVAISPPRKNGGWGDIRDHELCKSYRRLQ
T67812	DRUGINFO	D0B7JY	Phenylmethanesulfonamide derivative 1	Patented
T67812	DRUGINFO	D0F2KN	Dihydropyrimidinone derivative 3	Patented
T67812	DRUGINFO	D0MH7K	Pyrimidine-4(3H)-one derivative 1	Patented
T67812	DRUGINFO	D0NY3W	N-containing heterocyclic derivative 1	Patented
T67812	DRUGINFO	D0RC4W	Bicyclic pyrimidine derivative 1	Patented
T67812	DRUGINFO	D0U2WQ	Dihydropyrimidinone derivative 4	Patented

T55986	TARGETID	T55986
T55986	UNIPROID	PSB7_HUMAN
T55986	TARGNAME	Proteasome beta-2 (PS beta-2)
T55986	GENENAME	PSMB7
T55986	TARGTYPE	Patented-recorded
T55986	SYNONYMS	Proteasome subunit beta type-7; Proteasome subunit Z; Multicatalytic endopeptidase complex chain Z; Macropain chain Z
T55986	FUNCTION	Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins. The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex). Within the 20S core complex, PSMB7 displays a trypsin-like activity.
T55986	PDBSTRUC	6MSK; 6MSJ; 6MSH; 6MSG; 6MSE
T55986	BIOCLASS	Peptidase
T55986	ECNUMBER	EC 3.4.25.1
T55986	SEQUENCE	MAAVSVYAPPVGGFSFDNCRRNAVLEADFAKRGYKLPKVRKTGTTIAGVVYKDGIVLGADTRATEGMVVADKNCSKIHFISPNIYCCGAGTAADTDMTTQLISSNLELHSLSTGRLPRVVTANRMLKQMLFRYQGYIGAALVLGGVDVTGPHLYSIYPHGSTDKLPYVTMGSGSLAAMAVFEDKFRPDMEEEEAKNLVSEAIAAGIFNDLGSGSNIDLCVISKNKLDFLRPYTVPNKKGTRLGRYRCEKGTTAVLTEKITPLEIEVLEETVQTMDTS
T55986	DRUGINFO	D00GGB	Peptide analog 37	Patented
T55986	DRUGINFO	D01GON	Peptide analog 38	Patented
T55986	DRUGINFO	D02CQG	Peptide analog 39	Patented
T55986	DRUGINFO	D0DY3A	Peptide analog 36	Patented
T55986	DRUGINFO	D01OOO	Peptide analog 41	Patented
T55986	DRUGINFO	D02PJI	Peptide analog 21	Patented
T55986	DRUGINFO	D0T1YB	Peptide analog 23	Patented

T29355	TARGETID	T29355
T29355	UNIPROID	DNM3A_HUMAN
T29355	TARGNAME	DNA [cytosine-5]-methyltransferase 3A (DNMT3A)
T29355	GENENAME	DNMT3A
T29355	TARGTYPE	Patented-recorded
T29355	SYNONYMS	M.HsaIIIA; Dnmt3a; DNA methyltransferase HsaIIIA; DNA MTase HsaIIIA; DNA (cytosine-5)-methyltransferase 3A
T29355	FUNCTION	DNA methylation is coordinated with methylation of histones. It modifies DNA in a non-processive manner and also methylates non-CpG sites. May preferentially methylate DNA linker between 2 nucleosomal cores and is inhibited by histone H1. Plays a role in paternal and maternal imprinting. Required for methylation of most imprinted loci in germ cells. Acts as a transcriptional corepressor for ZBTB18. Recruited to trimethylated 'Lys-36' of histone H3 (H3K36me3) sites. Can actively repress transcription through the recruitment of HDAC activity. Required for genome-wide de novo methylation and is essential for the establishment of DNA methylation patterns during development.
T29355	PDBSTRUC	6F57; 6BRR; 5YX2; 4U7T; 4U7P
T29355	BIOCLASS	Methyltransferase
T29355	ECNUMBER	EC 2.1.1.37
T29355	SEQUENCE	MPAMPSSGPGDTSSSAAEREEDRKDGEEQEEPRGKEERQEPSTTARKVGRPGRKRKHPPVESGDTPKDPAVISKSPSMAQDSGASELLPNGDLEKRSEPQPEEGSPAGGQKGGAPAEGEGAAETLPEASRAVENGCCTPKEGRGAPAEAGKEQKETNIESMKMEGSRGRLRGGLGWESSLRQRPMPRLTFQAGDPYYISKRKRDEWLARWKREAEKKAKVIAGMNAVEENQGPGESQKVEEASPPAVQQPTDPASPTVATTPEPVGSDAGDKNATKAGDDEPEYEDGRGFGIGELVWGKLRGFSWWPGRIVSWWMTGRSRAAEGTRWVMWFGDGKFSVVCVEKLMPLSSFCSAFHQATYNKQPMYRKAIYEVLQVASSRAGKLFPVCHDSDESDTAKAVEVQNKPMIEWALGGFQPSGPKGLEPPEEEKNPYKEVYTDMWVEPEAAAYAPPPPAKKPRKSTAEKPKVKEIIDERTRERLVYEVRQKCRNIEDICISCGSLNVTLEHPLFVGGMCQNCKNCFLECAYQYDDDGYQSYCTICCGGREVLMCGNNNCCRCFCVECVDLLVGPGAAQAAIKEDPWNCYMCGHKGTYGLLRRREDWPSRLQMFFANNHDQEFDPPKVYPPVPAEKRKPIRVLSLFDGIATGLLVLKDLGIQVDRYIASEVCEDSITVGMVRHQGKIMYVGDVRSVTQKHIQEWGPFDLVIGGSPCNDLSIVNPARKGLYEGTGRLFFEFYRLLHDARPKEGDDRPFFWLFENVVAMGVSDKRDISRFLESNPVMIDAKEVSAAHRARYFWGNLPGMNRPLASTVNDKLELQECLEHGRIAKFSKVRTITTRSNSIKQGKDQHFPVFMNEKEDILWCTEMERVFGFPVHYTDVSNMSRLARQRLLGRSWSVPVIRHLFAPLKEYFACV
T29355	DRUGINFO	D02VTV	PMID27376512-Compound-Figure3CN	Patented
T29355	DRUGINFO	D03LZO	PMID27376512-Compound-Figure3CG	Patented
T29355	DRUGINFO	D0F8AB	PMID27376512-Compound-Figure3CM	Patented
T29355	DRUGINFO	D01LUJ	PMID27376512-Compound-Figure2aExample1	Patented
T29355	DRUGINFO	D02WRM	PMID27376512-Compound-MTC-424	Patented
T29355	DRUGINFO	D0HA0J	PMID27376512-Compound-MTC-427	Patented
T29355	DRUGINFO	D0QY0N	PMID27376512-Compound-MTC-422 	Patented
T29355	DRUGINFO	D0W9VZ	PMID27376512-Compound-MTC-423	Patented

T17036	TARGETID	T17036
T17036	UNIPROID	KDM4E_HUMAN
T17036	TARGNAME	Lysine-specific demethylase 4E (KDM4E)
T17036	GENENAME	KDM4E
T17036	TARGTYPE	Patented-recorded
T17036	SYNONYMS	Lysine-specific demethylase 4D-like; KDM4DL; KDM4D-like protein
T17036	FUNCTION	Histone demethylase that specifically demethylates 'Lys-9' of histone H3, thereby playing a central role in histone code.
T17036	PDBSTRUC	2W2I
T17036	BIOCLASS	Paired donor oxygen oxidoreductase
T17036	ECNUMBER	EC 1.14.11.-
T17036	SEQUENCE	MKSVHSSPQNTSHTIMTFYPTMEEFADFNTYVAYMESQGAHQAGLAKVIPPKEWKARQMYDDIEDILIATPLQQVTSGQGGVFTQYHKKKKAMRVGQYRRLANSKKYQTPPHQNFADLEQRYWKSHPGNPPIYGADISGSLFEESTKQWNLGHLGTILDLLEQECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHFGEPKTWYVVPPEHGQHLERLARELFPDISRGCEAFLRHKVALISPTVLKENGIPFNCMTQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGESTVTFSMDPFVRIVQPESYELWKHRQDLAIVEHTEPRVAESQELSNWRDDIVLRRAALGLRLLPNLTAQCPTQPVSSGHCYNPKGCGTDAVPGSAFQSSAYHTQTQSLTLGMSARVLLPSTGSWGSGRGRGRGQGQGRGCSRGRGHGCCTRELGTEEPTVQPASKRRLLMGTRSRAQGHRPQLPLANDLMTNLSL
T17036	DRUGINFO	D00VLQ	Hydroxyqunoline analog 1	Patented
T17036	DRUGINFO	D03EOJ	N-oxalyl-D-tyrosine derivative 2	Patented
T17036	DRUGINFO	D03TPE	Hydroxyqunoline analog 2	Patented
T17036	DRUGINFO	D06MHK	N-oxalyl-D-tyrosine derivative 7	Patented
T17036	DRUGINFO	D06ZPF	Pyridine-2,4-dicarboxylic acid analog 4	Patented
T17036	DRUGINFO	D08KYP	Hydroxyqunoline analog 5	Patented
T17036	DRUGINFO	D0C8CI	N-oxalyl-D-tyrosine derivative 9	Patented
T17036	DRUGINFO	D0D0WU	Pyridine-2,4-dicarboxylic acid analog 2	Patented
T17036	DRUGINFO	D0L7HC	N-oxalyl-D-tyrosine derivative 5	Patented
T17036	DRUGINFO	D0LU7U	N-oxalyl-D-tyrosine derivative 4	Patented
T17036	DRUGINFO	D0O9WS	Pyridine-2,4-dicarboxylic acid analog 1	Patented
T17036	DRUGINFO	D0OR0K	Pyridine-2,4-dicarboxylic acid analog 3	Patented
T17036	DRUGINFO	D0P5MY	N-oxalyl-D-tyrosine derivative 3	Patented
T17036	DRUGINFO	D0P7ZY	N-oxalyl-D-tyrosine derivative 1	Patented
T17036	DRUGINFO	D0P8YL	Hydroxyqunoline analog 3	Patented
T17036	DRUGINFO	D0VS3A	Hydroxyqunoline analog 4	Patented
T17036	DRUGINFO	D0WC4Z	N-oxalyl-D-tyrosine derivative 8	Patented
T17036	DRUGINFO	D0YF2M	N-oxalyl-D-tyrosine derivative 6	Patented
T17036	DRUGINFO	D09NCT	PMID25468267-Compound-46	Patented

T34389	TARGETID	T34389
T34389	UNIPROID	FAAH1_HUMAN
T34389	TARGNAME	Fatty-acid amide hydrolase 1 (FAAH1)
T34389	GENENAME	FAAH1
T34389	TARGTYPE	Patented-recorded
T34389	SYNONYMS	Oleamide hydrolase 1  of mouse; Oleamide hydrolase 1; FAAH; Anandamide amidohydrolase 1  of mouse; Anandamide amidohydrolase 1
T34389	FUNCTION	Hydrolyzes polyunsaturated substrate anandamide preferentially as compared to monounsaturated substrates. Degrades bioactive fatty acid amides like oleamide, the endogenous cannabinoid, anandamide and myristic amide to their corresponding acids, thereby serving to terminate the signaling functions of these molecules.
T34389	BIOCLASS	Carbon-nitrogen hydrolase
T34389	ECNUMBER	EC 3.5.1.99
T34389	SEQUENCE	MVQYELWAALPGASGVALACCFVAAAVALRWSGRRTARGAVVRARQRQRAGLENMDRAAQRFRLQNPDLDSEALLALPLPQLVQKLHSRELAPEAVLFTYVGKAWEVNKGTNCVTSYLADCETQLSQAPRQGLLYGVPVSLKECFTYKGQDSTLGLSLNEGVPAECDSVVVHVLKLQGAVPFVHTNVPQSMFSYDCSNPLFGQTVNPWKSSKSPGGSSGGEGALIGSGGSPLGLGTDIGGSIRFPSSFCGICGLKPTGNRLSKSGLKGCVYGQEAVRLSVGPMARDVESLALCLRALLCEDMFRLDPTVPPLPFREEVYTSSQPLRVGYYETDNYTMPSPAMRRAVLETKQSLEAAGHTLVPFLPSNIPHALETLSTGGLFSDGGHTFLQNFKGDFVDPCLGDLVSILKLPQWLKGLLAFLVKPLLPRLSAFLSNMKSRSAGKLWELQHEIEVYRKTVIAQWRALDLDVVLTPMLAPALDLNAPGRATGAVSYTMLYNCLDFPAGVVPVTTVTAEDEAQMEHYRGYFGDIWDKMLQKGMKKSVGLPVAVQCVALPWQEELCLRFMREVERLMTPEKQSS
T34389	DRUGINFO	D00ZCD	Piperazine urea derivative 2	Patented
T34389	DRUGINFO	D0C3OH	Carbamoyl oxime derivative 1	Patented
T34389	DRUGINFO	D0I6VK	Carbamate derivative 6	Patented
T34389	DRUGINFO	D0X9GL	Carbamate derivative 5	Patented
T34389	DRUGINFO	D0ZU3R	Carbamate derivative 4	Patented
T34389	DRUGINFO	D01THA	Ethylaminopyrimidine derivative 1	Patented
T34389	DRUGINFO	D0B7CW	PMID26413912-Compound-84	Patented
T34389	DRUGINFO	D0IA7Z	Carbamide derivative 1	Patented
T34389	DRUGINFO	D0M1ND	Pyrimidinyl ethylenediamine derivative 1	Patented
T34389	DRUGINFO	D0S8TB	Carbamate derivative 2	Patented

T97149	TARGETID	T97149
T97149	FORMERID	TTDI03165
T97149	UNIPROID	DYRK3_HUMAN
T97149	TARGNAME	Dual-specificity tyrosine-phosphorylation regulated kinase 3 (DYRK3)
T97149	GENENAME	DYRK3
T97149	TARGTYPE	Patented-recorded
T97149	SYNONYMS	Regulatory erythroid kinase; REDK; Dual specificity tyrosine-phosphorylation-regulated kinase 3
T97149	FUNCTION	Dual-specificity tyrosine-regulated kinases (DYRKs) autophosphorylate a critical tyrosine residue in their activation loop and phosphorylate their substrate on serine and threonine residues. Acts as a central dissolvase of membraneless organelles during the G2-to-M transition, after the nuclear-envelope breakdown: acts by mediating phosphorylation of multiple serine and threonine residues in unstructured domains of proteins, such as SRRM1 and PCM1. Does not mediate disassembly of all membraneless organelles: disassembly of P-body and nucleolus is not regulated by DYRK3. Dissolution of membraneless organelles at the onset of mitosis is also required to release mitotic regulators, such as ZNF207, from liquid-unmixed organelles where they are sequestered and keep them dissolved during mitosis. Regulates mTORC1 by mediating the dissolution of stress granules: during stressful conditions, DYRK3 partitions from the cytosol to the stress granule, together with mTORC1 components, which prevents mTORC1 signaling. When stress signals are gone, the kinase activity of DYRK3 is required for the dissolution of stress granule and mTORC1 relocation to the cytosol: acts by mediating the phosphorylation of the mTORC1 inhibitor AKT1S1, allowing full reactivation of mTORC1 signaling. Also acts as a negative regulator of EPO-dependent erythropoiesis: may place an upper limit on red cell production during stress erythropoiesis. Inhibits cell death due to cytokine withdrawal in hematopoietic progenitor cells. Promotes cell survival upon genotoxic stress through phosphorylation of SIRT1: this in turn inhibits p53/TP53 activity and apoptosis. Dual-specificity protein kinase that promotes disassembly of several types of membraneless organelles during mitosis, such as stress granules, nuclear speckles and pericentriolar material.
T97149	PDBSTRUC	5Y86
T97149	BIOCLASS	Kinase
T97149	ECNUMBER	EC 2.7.12.1
T97149	SEQUENCE	MGGTARGPGRKDAGPPGAGLPPQQRRLGDGVYDTFMMIDETKCPPCSNVLCNPSEPPPPRRLNMTTEQFTGDHTQHFLDGGEMKVEQLFQEFGNRKSNTIQSDGISDSEKCSPTVSQGKSSDCLNTVKSNSSSKAPKVVPLTPEQALKQYKHHLTAYEKLEIINYPEIYFVGPNAKKRHGVIGGPNNGGYDDADGAYIHVPRDHLAYRYEVLKIIGKGSFGQVARVYDHKLRQYVALKMVRNEKRFHRQAAEEIRILEHLKKQDKTGSMNVIHMLESFTFRNHVCMAFELLSIDLYELIKKNKFQGFSVQLVRKFAQSILQSLDALHKNKIIHCDLKPENILLKHHGRSSTKVIDFGSSCFEYQKLYTYIQSRFYRAPEIILGSRYSTPIDIWSFGCILAELLTGQPLFPGEDEGDQLACMMELLGMPPPKLLEQSKRAKYFINSKGIPRYCSVTTQADGRVVLVGGRSRRGKKRGPPGSKDWGTALKGCDDYLFIEFLKRCLHWDPSARLTPAQALRHPWISKSVPRPLTTIDKVSGKRVVNPASAFQGLGSKLPPVVGIANKLKANLMSETNGSIPLCSVLPKLIS
T97149	DRUGINFO	D00OWF	Harmine	Patented
T97149	DRUGINFO	D02DBH	PMID28766366-Compound-Scheme21Left	Patented
T97149	DRUGINFO	D07BWC	PMID28766366-Compound-Scheme21Right	Patented
T97149	DRUGINFO	D04TPA	PMID24900749C1a	Investigative

T18904	TARGETID	T18904
T18904	UNIPROID	KDM4A_HUMAN
T18904	TARGNAME	Lysine-specific demethylase 4A (KDM4A)
T18904	GENENAME	KDM4A
T18904	TARGTYPE	Patented-recorded
T18904	SYNONYMS	KIAA0677; Jumonji domain-containing protein 2A; JmjC domain-containing histone demethylation protein 3A; JMJD2A; JMJD2; JHDM3A
T18904	FUNCTION	Histone demethylase that specifically demethylates 'Lys-9' and 'Lys-36' residues of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-4', H3 'Lys-27' nor H4 'Lys-20'. Demethylates trimethylated H3 'Lys-9' and H3 'Lys-36' residue, while it has no activity on mono- and dimethylated residues. Demethylation of Lys residue generates formaldehyde and succinate. Participates in transcriptional repression of ASCL2 and E2F-responsive promoters via the recruitment of histone deacetylases and NCOR1, respectively.
T18904	PDBSTRUC	6H8P; 6G5X; 6G5W; 6CG2; 6CG1
T18904	BIOCLASS	Paired donor oxygen oxidoreductase
T18904	ECNUMBER	EC 1.14.11.-
T18904	SEQUENCE	MASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPRASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEELERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYLYFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAQSCEAFLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRWIEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPTPEAAEFLKESELPPRAGNEEECPEEDMEGVEDGEEGDLKTSLAKHRIGTKRHRVCLEIPQEVSQSELFPKEDLSSEQYEMTECPAALAPVRPTHSSVRQVEDGLTFPDYSDSTEVKFEELKNVKLEEEDEEEEQAAAALDLSVNPASVGGRLVFSGSKKKSSSSLGSGSSRDSISSDSETSEPLSCRAQGQTGVLTVHSYAKGDGRVTVGEPCTRKKGSAARSFSERELAEVADEYMFSLEENKKSKGRRQPLSKLPRHHPLVLQECVSDDETSEQLTPEEEAEETEAWAKPLSQLWQNRPPNFEAEKEFNETMAQQAPHCAVCMIFQTYHQVEFGGFNQNCGNASDLAPQKQRTKPLIPEMCFTSTGCSTDINLSTPYLEEDGTSILVSCKKCSVRVHASCYGVPPAKASEDWMCSRCSANALEEDCCLCSLRGGALQRANDDRWVHVSCAVAILEARFVNIAERSPVDVSKIPLPRFKLKCIFCKKRRKRTAGCCVQCSHGRCPTAFHVSCAQAAGVMMQPDDWPFVVFITCFRHKIPNLERAKGALQSITAGQKVISKHKNGRFYQCEVVRLTTETFYEVNFDDGSFSDNLYPEDIVSQDCLQFGPPAEGEVVQVRWTDGQVYGAKFVASHPIQMYQVEFEDGSQLVVKRDDVYTLDEELPKRVKSRLSVASDMRFNEIFTEKEVKQEKKRQRVINSRYREDYIEPALYRAIME
T18904	DRUGINFO	D05PXW	Disulfiram analog 1	Patented
T18904	DRUGINFO	D09YFD	Selenium compound 2	Patented
T18904	DRUGINFO	D0JQ9Z	Disulfiram analog 2	Patented
T18904	DRUGINFO	D0X2AU	Selenium compound 1	Patented
T18904	DRUGINFO	D0X6SJ	Selenium compound 3	Patented
T18904	DRUGINFO	D01CIK	Heteroaryl-cyclopropylamine derivative 4	Patented
T18904	DRUGINFO	D07MQD	PMID27019002-Compound-21b	Patented
T18904	DRUGINFO	D0MJ4L	Hydroxamate analog 1	Patented
T18904	DRUGINFO	D0UE4K	PMID27019002-Compound-21c	Patented
T18904	DRUGINFO	D09NCT	PMID25468267-Compound-46	Patented
T18904	DRUGINFO	D0UL9U	N-(2-phenylcyclopropyl) amino acid derivative 1	Patented

T00348	TARGETID	T00348
T00348	UNIPROID	ABL1_HUMAN
T00348	TARGNAME	ABL T315I mutant (ABL T315I)
T00348	GENENAME	ABL1
T00348	TARGTYPE	Patented-recorded
T00348	SYNONYMS	p150 T315I; T315I Abl; Proto-oncogene tyrosine-protein kinase ABL1 T315I; Proto-oncogene c-Abl T315I; JTK7 T315I; C-ABL T315I; Abl T315I; Abelson tyrosine-protein kinase 1 T315I; Abelson murine leukemia viral oncogene homolog 1 T315I
T00348	FUNCTION	Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 (involved in branch formation); ANXA1 (involved in membrane anchoring); DBN1, DBNL, CTTN, RAPH1 and ENAH (involved in signaling); or MAPT and PXN (microtubule-binding proteins). Phosphorylation of WASF3 is critical for the stimulation of lamellipodia formation and cell migration. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as BCAR1, CRK, CRKL, DOK1, EFS or NEDD9. Phosphorylates multiple receptor tyrosine kinases and more particularly promotes endocytosis of EGFR, facilitates the formation of neuromuscular synapses through MUSK, inhibits PDGFRB-mediated chemotaxis and modulates the endocytosis of activated B-cell receptor complexes. Other substrates which are involved in endocytosis regulation are the caveolin (CAV1) and RIN1. Moreover, ABL1 regulates the CBL family of ubiquitin ligases that drive receptor down-regulation and actin remodeling. Phosphorylation of CBL leads to increased EGFR stability. Involved in late-stage autophagy by regulating positively the trafficking and function of lysosomal components. ABL1 targets to mitochondria in response to oxidative stress and thereby mediates mitochondrial dysfunction and cell death. In response to oxidative stress, phosphorylates serine/threonine kinase PRKD2 at 'Tyr-717'. ABL1 is also translocated in the nucleus where it has DNA-binding activity and is involved in DNA-damage response and apoptosis. Many substrates are known mediators of DNA repair: DDB1, DDB2, ERCC3, ERCC6, RAD9A, RAD51, RAD52 or WRN. Activates the proapoptotic pathway when the DNA damage is too severe to be repaired. Phosphorylates TP73, a primary regulator for this type of damage-induced apoptosis. Phosphorylates the caspase CASP9 on 'Tyr-153' and regulates its processing in the apoptotic response to DNA damage. Phosphorylates PSMA7 that leads to an inhibition of proteasomal activity and cell cycle transition blocks. ABL1 acts also as a regulator of multiple pathological signaling cascades during infection. Several known tyrosine-phosphorylated microbial proteins have been identified as ABL1 substrates. This is the case of A36R of Vaccinia virus, Tir (translocated intimin receptor) of pathogenic E. coli and possibly Citrobacter, CagA (cytotoxin-associated gene A) of H. pylori, or AnkA (ankyrin repeat-containing protein A) of A. phagocytophilum. Pathogens can highjack ABL1 kinase signaling to reorganize the host actin cytoskeleton for multiple purposes, like facilitating intracellular movement and host cell exit. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1. Regulates T-cell differentiation in a TBX21-dependent manner. Phosphorylates TBX21 on tyrosine residues leading to an enhancement of its transcriptional activator activity. Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis.
T00348	PDBSTRUC	6NPV; 6NPU; 6NPE; 6BL8; 6AMW
T00348	BIOCLASS	Kinase
T00348	ECNUMBER	EC 2.7.10.2
T00348	SEQUENCE	MLEICLKLVGCKSKKGLSSSSSCYLEEALQRPVASDFEPQGLSEAARWNSKENLLAGPSENDPNLFVALYDFVASGDNTLSITKGEKLRVLGYNHNGEWCEAQTKNGQGWVPSNYITPVNSLEKHSWYHGPVSRNAAEYLLSSGINGSFLVRESESSPGQRSISLRYEGRVYHYRINTASDGKLYVSSESRFNTLAELVHHHSTVADGLITTLHYPAPKRNKPTVYGVSPNYDKWEMERTDITMKHKLGGGQYGEVYEGVWKKYSLTVAVKTLKEDTMEVEEFLKEAAVMKEIKHPNLVQLLGVCTREPPFYIITEFMTYGNLLDYLRECNRQEVNAVVLLYMATQISSAMEYLEKKNFIHRDLAARNCLVGENHLVKVADFGLSRLMTGDTYTAHAGAKFPIKWTAPESLAYNKFSIKSDVWAFGVLLWEIATYGMSPYPGIDLSQVYELLEKDYRMERPEGCPEKVYELMRACWQWNPSDRPSFAEIHQAFETMFQESSISDEVEKELGKQGVRGAVSTLLQAPELPTKTRTSRRAAEHRDTTDVPEMPHSKGQGESDPLDHEPAVSPLLPRKERGPPEGGLNEDERLLPKDKKTNLFSALIKKKKKTAPTPPKRSSSFREMDGQPERRGAGEEEGRDISNGALAFTPLDTADPAKSPKPSNGAGVPNGALRESGGSGFRSPHLWKKSSTLTSSRLATGEEEGGGSSSKRFLRSCSASCVPHGAKDTEWRSVTLPRDLQSTGRQFDSSTFGGHKSEKPALPRKRAGENRSDQVTRGTVTPPPRLVKKNEEAADEVFKDIMESSPGSSPPNLTPKPLRRQVTVAPASGLPHKEEAGKGSALGTPAAAEPVTPTSKAGSGAPGGTSKGPAEESRVRRHKHSSESPGRDKGKLSRLKPAPPPPPAASAGKAGGKPSQSPSQEAAGEAVLGAKTKATSLVDAVNSDAAKPSQPGEGLKKPVLPATPKPQSAKPSGTPISPAPVPSTLPSASSALAGDQPSSTAFIPLISTRVSLRKTRQPPERIASGAITKGVVLDSTEALCLAISRNSEQMASHSAVLEAGKNLYTFCVSYVDSIQQMRNKFAFREAINKLENNLRELQICPATAGSGPAATQDFSKLLSSVKEISDIVQR
T00348	DRUGINFO	D0MX5B	Indazole derivative 5	Patented
T00348	DRUGINFO	D0ZH4I	PMID25656651-Compound-42	Patented

T92517	TARGETID	T92517
T92517	UNIPROID	CAN1_HUMAN
T92517	TARGNAME	Calpain-1 (CAPN1)
T92517	GENENAME	CAPN1
T92517	TARGTYPE	Patented-recorded
T92517	SYNONYMS	muCANP; PIG30; Micromolar-calpain; Cell proliferation-inducing gene 30 protein; Calpain-1 large subunit; Calpain-1 catalytic subunit; Calpain mu-type; Calcium-activated neutral proteinase 1; CANPL1; CANP 1
T92517	FUNCTION	Calcium-regulated non-lysosomal thiol-protease which catalyzes limited proteolysis of substrates involved in cytoskeletal remodeling and signal transduction.
T92517	BIOCLASS	Peptidase
T92517	ECNUMBER	EC 3.4.22.52
T92517	SEQUENCE	MSEEIITPVYCTGVSAQVQKQRARELGLGRHENAIKYLGQDYEQLRVRCLQSGTLFRDEAFPPVPQSLGYKDLGPNSSKTYGIKWKRPTELLSNPQFIVDGATRTDICQGALGDCWLLAAIASLTLNDTLLHRVVPHGQSFQNGYAGIFHFQLWQFGEWVDVVVDDLLPIKDGKLVFVHSAEGNEFWSALLEKAYAKVNGSYEALSGGSTSEGFEDFTGGVTEWYELRKAPSDLYQIILKALERGSLLGCSIDISSVLDMEAITFKKLVKGHAYSVTGAKQVNYRGQVVSLIRMRNPWGEVEWTGAWSDSSSEWNNVDPYERDQLRVKMEDGEFWMSFRDFMREFTRLEICNLTPDALKSRTIRKWNTTLYEGTWRRGSTAGGCRNYPATFWVNPQFKIRLDETDDPDDYGDRESGCSFVLALMQKHRRRERRFGRDMETIGFAVYEVPPELVGQPAVHLKRDFFLANASRARSEQFINLREVSTRFRLPPGEYVVVPSTFEPNKEGDFVLRFFSEKSAGTVELDDQIQANLPDEQVLSEEEIDENFKALFRQLAGEDMEISVKELRTILNRIISKHKDLRTKGFSLESCRSMVNLMDRDGNGKLGLVEFNILWNRIRNYLSIFRKFDLDKSGSMSAYEMRMAIESAGFKLNKKLYELIITRYSEPDLAVDFDNFVCCLVRLETMFRFFKTLDTDLDGVVTFDLFKWLQLTMFA
T92517	DRUGINFO	D08VAT	Undecylenic acid derivative 1	Patented

T16685	TARGETID	T16685
T16685	UNIPROID	RET_HUMAN
T16685	TARGNAME	RET G691S mutant (RET G691S)
T16685	GENENAME	RET
T16685	TARGTYPE	Patented-recorded
T16685	SYNONYMS	RET51 G691S mutant; Proto-oncogene tyrosine-protein kinase receptor Ret G691S mutant; Proto-oncogene c-Ret G691S mutant; PTC G691S mutant; Cadherin family member 12 G691S mutant; CDHR16 G691S mutant; CDHF12 G691S mutant
T16685	FUNCTION	Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut-associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e. g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration. Mediates, through interaction with GDF15-receptor GFRAL, GDF15-induced cell-signaling in the brainstem which induces inhibition of food-intake. Activates MAPK- and AKT-signaling pathways. Isoform 1 in complex with GFRAL induces higher activation of MAPK-signaling pathway than isoform 2 in complex with GFRAL. Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands.
T16685	PDBSTRUC	6FEK; 5FM3; 5FM2; 5AMN; 4UX8
T16685	BIOCLASS	Kinase
T16685	ECNUMBER	EC 2.7.10.1
T16685	SEQUENCE	MAKATSGAAGLRLLLLLLLPLLGKVALGLYFSRDAYWEKLYVDQAAGTPLLYVHALRDAPEEVPSFRLGQHLYGTYRTRLHENNWICIQEDTGLLYLNRSLDHSSWEKLSVRNRGFPLLTVYLKVFLSPTSLREGECQWPGCARVYFSFFNTSFPACSSLKPRELCFPETRPSFRIRENRPPGTFHQFRLLPVQFLCPNISVAYRLLEGEGLPFRCAPDSLEVSTRWALDREQREKYELVAVCTVHAGAREEVVMVPFPVTVYDEDDSAPTFPAGVDTASAVVEFKRKEDTVVATLRVFDADVVPASGELVRRYTSTLLPGDTWAQQTFRVEHWPNETSVQANGSFVRATVHDYRLVLNRNLSISENRTMQLAVLVNDSDFQGPGAGVLLLHFNVSVLPVSLHLPSTYSLSVSRRARRFAQIGKVCVENCQAFSGINVQYKLHSSGANCSTLGVVTSAEDTSGILFVNDTKALRRPKCAELHYMVVATDQQTSRQAQAQLLVTVEGSYVAEEAGCPLSCAVSKRRLECEECGGLGSPTGRCEWRQGDGKGITRNFSTCSPSTKTCPDGHCDVVETQDINICPQDCLRGSIVGGHEPGEPRGIKAGYGTCNCFPEEEKCFCEPEDIQDPLCDELCRTVIAAAVLFSFIVSVLLSAFCIHCYHKFAHKPPISSAEMTFRRPAQAFPVSYSSSGARRPSLDSMENQVSVDAFKILEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRAGYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDHPDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAASTPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMDTFDS
T16685	DRUGINFO	D0O9JD	Benzo(b)carbazol-11-one compound 2	Patented

T17134	TARGETID	T17134
T17134	UNIPROID	RET_HUMAN
T17134	TARGNAME	RET M918T mutant (RET M918T)
T17134	GENENAME	RET
T17134	TARGTYPE	Patented-recorded
T17134	SYNONYMS	RET51 M918T mutant; Proto-oncogene tyrosine-protein kinase receptor Ret M918T mutant; Proto-oncogene c-Ret M918T mutant; PTC M918T mutant; Cadherin family member 12 M918T mutant; CDHR16 M918T mutant; CDHF12 M918T mutant
T17134	FUNCTION	Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut-associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e. g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration. Mediates, through interaction with GDF15-receptor GFRAL, GDF15-induced cell-signaling in the brainstem which induces inhibition of food-intake. Activates MAPK- and AKT-signaling pathways. Isoform 1 in complex with GFRAL induces higher activation of MAPK-signaling pathway than isoform 2 in complex with GFRAL. Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands.
T17134	PDBSTRUC	6FEK; 5FM3; 5FM2; 5AMN; 4UX8
T17134	BIOCLASS	Kinase
T17134	ECNUMBER	EC 2.7.10.1
T17134	SEQUENCE	MAKATSGAAGLRLLLLLLLPLLGKVALGLYFSRDAYWEKLYVDQAAGTPLLYVHALRDAPEEVPSFRLGQHLYGTYRTRLHENNWICIQEDTGLLYLNRSLDHSSWEKLSVRNRGFPLLTVYLKVFLSPTSLREGECQWPGCARVYFSFFNTSFPACSSLKPRELCFPETRPSFRIRENRPPGTFHQFRLLPVQFLCPNISVAYRLLEGEGLPFRCAPDSLEVSTRWALDREQREKYELVAVCTVHAGAREEVVMVPFPVTVYDEDDSAPTFPAGVDTASAVVEFKRKEDTVVATLRVFDADVVPASGELVRRYTSTLLPGDTWAQQTFRVEHWPNETSVQANGSFVRATVHDYRLVLNRNLSISENRTMQLAVLVNDSDFQGPGAGVLLLHFNVSVLPVSLHLPSTYSLSVSRRARRFAQIGKVCVENCQAFSGINVQYKLHSSGANCSTLGVVTSAEDTSGILFVNDTKALRRPKCAELHYMVVATDQQTSRQAQAQLLVTVEGSYVAEEAGCPLSCAVSKRRLECEECGGLGSPTGRCEWRQGDGKGITRNFSTCSPSTKTCPDGHCDVVETQDINICPQDCLRGSIVGGHEPGEPRGIKAGYGTCNCFPEEEKCFCEPEDIQDPLCDELCRTVIAAAVLFSFIVSVLLSAFCIHCYHKFAHKPPISSAEMTFRRPAQAFPVSYSSSGARRPSLDSMENQVSVDAFKILEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRAGYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDHPDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAASTPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMDTFDS
T17134	DRUGINFO	D0O9JD	Benzo(b)carbazol-11-one compound 2	Patented

T17279	TARGETID	T17279
T17279	UNIPROID	RET_HUMAN
T17279	TARGNAME	RET S891A mutant (RET S891A)
T17279	GENENAME	RET
T17279	TARGTYPE	Patented-recorded
T17279	SYNONYMS	RET51 S891A mutant; Proto-oncogene tyrosine-protein kinase receptor Ret S891A mutant; Proto-oncogene c-Ret S891A mutant; PTC S891A mutant; Cadherin family member 12 S891A mutant; CDHR16 S891A mutant; CDHF12 S891A mutant
T17279	FUNCTION	Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut-associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e. g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration. Mediates, through interaction with GDF15-receptor GFRAL, GDF15-induced cell-signaling in the brainstem which induces inhibition of food-intake. Activates MAPK- and AKT-signaling pathways. Isoform 1 in complex with GFRAL induces higher activation of MAPK-signaling pathway than isoform 2 in complex with GFRAL. Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands.
T17279	PDBSTRUC	6FEK; 5FM3; 5FM2; 5AMN; 4UX8
T17279	BIOCLASS	Kinase
T17279	ECNUMBER	EC 2.7.10.1
T17279	SEQUENCE	MAKATSGAAGLRLLLLLLLPLLGKVALGLYFSRDAYWEKLYVDQAAGTPLLYVHALRDAPEEVPSFRLGQHLYGTYRTRLHENNWICIQEDTGLLYLNRSLDHSSWEKLSVRNRGFPLLTVYLKVFLSPTSLREGECQWPGCARVYFSFFNTSFPACSSLKPRELCFPETRPSFRIRENRPPGTFHQFRLLPVQFLCPNISVAYRLLEGEGLPFRCAPDSLEVSTRWALDREQREKYELVAVCTVHAGAREEVVMVPFPVTVYDEDDSAPTFPAGVDTASAVVEFKRKEDTVVATLRVFDADVVPASGELVRRYTSTLLPGDTWAQQTFRVEHWPNETSVQANGSFVRATVHDYRLVLNRNLSISENRTMQLAVLVNDSDFQGPGAGVLLLHFNVSVLPVSLHLPSTYSLSVSRRARRFAQIGKVCVENCQAFSGINVQYKLHSSGANCSTLGVVTSAEDTSGILFVNDTKALRRPKCAELHYMVVATDQQTSRQAQAQLLVTVEGSYVAEEAGCPLSCAVSKRRLECEECGGLGSPTGRCEWRQGDGKGITRNFSTCSPSTKTCPDGHCDVVETQDINICPQDCLRGSIVGGHEPGEPRGIKAGYGTCNCFPEEEKCFCEPEDIQDPLCDELCRTVIAAAVLFSFIVSVLLSAFCIHCYHKFAHKPPISSAEMTFRRPAQAFPVSYSSSGARRPSLDSMENQVSVDAFKILEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRAGYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDHPDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAASTPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMDTFDS
T17279	DRUGINFO	D0O9JD	Benzo(b)carbazol-11-one compound 2	Patented

T17566	TARGETID	T17566
T17566	UNIPROID	RET_HUMAN
T17566	TARGNAME	RET V804L mutant (RET V804L)
T17566	GENENAME	RET
T17566	TARGTYPE	Patented-recorded
T17566	SYNONYMS	RET51 V804L mutant; Proto-oncogene tyrosine-protein kinase receptor Ret V804L mutant; Proto-oncogene c-Ret V804L mutant; PTC V804L mutant; Cadherin family member 12 V804L mutant; CDHR16 V804L mutant; CDHF12 V804L mutant
T17566	FUNCTION	Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut-associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e. g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration. Mediates, through interaction with GDF15-receptor GFRAL, GDF15-induced cell-signaling in the brainstem which induces inhibition of food-intake. Activates MAPK- and AKT-signaling pathways. Isoform 1 in complex with GFRAL induces higher activation of MAPK-signaling pathway than isoform 2 in complex with GFRAL. Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands.
T17566	PDBSTRUC	6FEK; 5FM3; 5FM2; 5AMN; 4UX8
T17566	BIOCLASS	Kinase
T17566	ECNUMBER	EC 2.7.10.1
T17566	SEQUENCE	MAKATSGAAGLRLLLLLLLPLLGKVALGLYFSRDAYWEKLYVDQAAGTPLLYVHALRDAPEEVPSFRLGQHLYGTYRTRLHENNWICIQEDTGLLYLNRSLDHSSWEKLSVRNRGFPLLTVYLKVFLSPTSLREGECQWPGCARVYFSFFNTSFPACSSLKPRELCFPETRPSFRIRENRPPGTFHQFRLLPVQFLCPNISVAYRLLEGEGLPFRCAPDSLEVSTRWALDREQREKYELVAVCTVHAGAREEVVMVPFPVTVYDEDDSAPTFPAGVDTASAVVEFKRKEDTVVATLRVFDADVVPASGELVRRYTSTLLPGDTWAQQTFRVEHWPNETSVQANGSFVRATVHDYRLVLNRNLSISENRTMQLAVLVNDSDFQGPGAGVLLLHFNVSVLPVSLHLPSTYSLSVSRRARRFAQIGKVCVENCQAFSGINVQYKLHSSGANCSTLGVVTSAEDTSGILFVNDTKALRRPKCAELHYMVVATDQQTSRQAQAQLLVTVEGSYVAEEAGCPLSCAVSKRRLECEECGGLGSPTGRCEWRQGDGKGITRNFSTCSPSTKTCPDGHCDVVETQDINICPQDCLRGSIVGGHEPGEPRGIKAGYGTCNCFPEEEKCFCEPEDIQDPLCDELCRTVIAAAVLFSFIVSVLLSAFCIHCYHKFAHKPPISSAEMTFRRPAQAFPVSYSSSGARRPSLDSMENQVSVDAFKILEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRAGYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDHPDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAASTPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMDTFDS
T17566	DRUGINFO	D0O9JD	Benzo(b)carbazol-11-one compound 2	Patented

T17919	TARGETID	T17919
T17919	UNIPROID	RET_HUMAN
T17919	TARGNAME	RET V804M mutant (RET V804M)
T17919	GENENAME	RET
T17919	TARGTYPE	Patented-recorded
T17919	SYNONYMS	RET51 V804M mutant; Proto-oncogene tyrosine-protein kinase receptor Ret V804M mutant; Proto-oncogene c-Ret V804M mutant; PTC V804M mutant; Cadherin family member 12 V804M mutant; CDHR16 V804M mutant; CDHF12 V804M mutant
T17919	FUNCTION	Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut-associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e. g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration. Mediates, through interaction with GDF15-receptor GFRAL, GDF15-induced cell-signaling in the brainstem which induces inhibition of food-intake. Activates MAPK- and AKT-signaling pathways. Isoform 1 in complex with GFRAL induces higher activation of MAPK-signaling pathway than isoform 2 in complex with GFRAL. Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands.
T17919	PDBSTRUC	6FEK; 5FM3; 5FM2; 5AMN; 4UX8
T17919	BIOCLASS	Kinase
T17919	ECNUMBER	EC 2.7.10.1
T17919	SEQUENCE	MAKATSGAAGLRLLLLLLLPLLGKVALGLYFSRDAYWEKLYVDQAAGTPLLYVHALRDAPEEVPSFRLGQHLYGTYRTRLHENNWICIQEDTGLLYLNRSLDHSSWEKLSVRNRGFPLLTVYLKVFLSPTSLREGECQWPGCARVYFSFFNTSFPACSSLKPRELCFPETRPSFRIRENRPPGTFHQFRLLPVQFLCPNISVAYRLLEGEGLPFRCAPDSLEVSTRWALDREQREKYELVAVCTVHAGAREEVVMVPFPVTVYDEDDSAPTFPAGVDTASAVVEFKRKEDTVVATLRVFDADVVPASGELVRRYTSTLLPGDTWAQQTFRVEHWPNETSVQANGSFVRATVHDYRLVLNRNLSISENRTMQLAVLVNDSDFQGPGAGVLLLHFNVSVLPVSLHLPSTYSLSVSRRARRFAQIGKVCVENCQAFSGINVQYKLHSSGANCSTLGVVTSAEDTSGILFVNDTKALRRPKCAELHYMVVATDQQTSRQAQAQLLVTVEGSYVAEEAGCPLSCAVSKRRLECEECGGLGSPTGRCEWRQGDGKGITRNFSTCSPSTKTCPDGHCDVVETQDINICPQDCLRGSIVGGHEPGEPRGIKAGYGTCNCFPEEEKCFCEPEDIQDPLCDELCRTVIAAAVLFSFIVSVLLSAFCIHCYHKFAHKPPISSAEMTFRRPAQAFPVSYSSSGARRPSLDSMENQVSVDAFKILEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRAGYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDHPDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAASTPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMDTFDS
T17919	DRUGINFO	D0O9JD	Benzo(b)carbazol-11-one compound 2	Patented

T18250	TARGETID	T18250
T18250	UNIPROID	RET_HUMAN
T18250	TARGNAME	RET Y791F mutant (RET Y791F)
T18250	GENENAME	RET
T18250	TARGTYPE	Patented-recorded
T18250	SYNONYMS	RET51 Y791F mutant; Proto-oncogene tyrosine-protein kinase receptor Ret Y791F mutant; Proto-oncogene c-Ret Y791F mutant; PTC Y791F mutant; Cadherin family member 12 Y791F mutant; CDHR16 Y791F mutant; CDHF12 Y791F mutant
T18250	FUNCTION	Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut-associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e. g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration. Mediates, through interaction with GDF15-receptor GFRAL, GDF15-induced cell-signaling in the brainstem which induces inhibition of food-intake. Activates MAPK- and AKT-signaling pathways. Isoform 1 in complex with GFRAL induces higher activation of MAPK-signaling pathway than isoform 2 in complex with GFRAL. Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands.
T18250	PDBSTRUC	6FEK; 5FM3; 5FM2; 5AMN; 4UX8
T18250	BIOCLASS	Kinase
T18250	ECNUMBER	EC 2.7.10.1
T18250	SEQUENCE	MAKATSGAAGLRLLLLLLLPLLGKVALGLYFSRDAYWEKLYVDQAAGTPLLYVHALRDAPEEVPSFRLGQHLYGTYRTRLHENNWICIQEDTGLLYLNRSLDHSSWEKLSVRNRGFPLLTVYLKVFLSPTSLREGECQWPGCARVYFSFFNTSFPACSSLKPRELCFPETRPSFRIRENRPPGTFHQFRLLPVQFLCPNISVAYRLLEGEGLPFRCAPDSLEVSTRWALDREQREKYELVAVCTVHAGAREEVVMVPFPVTVYDEDDSAPTFPAGVDTASAVVEFKRKEDTVVATLRVFDADVVPASGELVRRYTSTLLPGDTWAQQTFRVEHWPNETSVQANGSFVRATVHDYRLVLNRNLSISENRTMQLAVLVNDSDFQGPGAGVLLLHFNVSVLPVSLHLPSTYSLSVSRRARRFAQIGKVCVENCQAFSGINVQYKLHSSGANCSTLGVVTSAEDTSGILFVNDTKALRRPKCAELHYMVVATDQQTSRQAQAQLLVTVEGSYVAEEAGCPLSCAVSKRRLECEECGGLGSPTGRCEWRQGDGKGITRNFSTCSPSTKTCPDGHCDVVETQDINICPQDCLRGSIVGGHEPGEPRGIKAGYGTCNCFPEEEKCFCEPEDIQDPLCDELCRTVIAAAVLFSFIVSVLLSAFCIHCYHKFAHKPPISSAEMTFRRPAQAFPVSYSSSGARRPSLDSMENQVSVDAFKILEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRAGYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDHPDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAASTPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMDTFDS
T18250	DRUGINFO	D0O9JD	Benzo(b)carbazol-11-one compound 2	Patented

T54973	TARGETID	T54973
T54973	UNIPROID	PSB6_HUMAN
T54973	TARGNAME	Proteasome beta-1 (PS beta-1)
T54973	GENENAME	PSMB6
T54973	TARGTYPE	Patented-recorded
T54973	SYNONYMS	Proteasome subunit beta type-6; Proteasome subunit Y; Proteasome delta chain; Multicatalytic endopeptidase complex delta chain; Macropain delta chain; LMPY
T54973	FUNCTION	Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins. The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex). Within the 20S core complex, PSMB6 displays a peptidylglutamyl-hydrolizing activity also termed postacidic or caspase-like activity, meaning that the peptides bond hydrolysis occurs directly after acidic residues.
T54973	PDBSTRUC	6MSK; 6MSJ; 6MSH; 6MSG; 6MSE
T54973	BIOCLASS	Peptidase
T54973	ECNUMBER	EC 3.4.25.1
T54973	SEQUENCE	MAATLLAARGAGPAPAWGPEAFTPDWESREVSTGTTIMAVQFDGGVVLGADSRTTTGSYIANRVTDKLTPIHDRIFCCRSGSAADTQAVADAVTYQLGFHSIELNEPPLVHTAASLFKEMCYRYREDLMAGIIIAGWDPQEGGQVYSVPMGGMMVRQSFAIGGSGSSYIYGYVDATYREGMTKEECLQFTANALALAMERDGSSGGVIRLAAIAESGVERQVLLGDQIPKFAVATLPPA
T54973	DRUGINFO	D02CQG	Peptide analog 39	Patented
T54973	DRUGINFO	D01VMN	PMID29865878-Compound-53	Patented
T54973	DRUGINFO	D03CMD	PMID29865878-Compound-55	Patented
T54973	DRUGINFO	D0C2MH	PMID29865878-Compound-46	Patented
T54973	DRUGINFO	D0K0GJ	PMID29865878-Compound-48	Patented
T54973	DRUGINFO	D0NE8M	PMID29865878-Compound-51	Patented
T54973	DRUGINFO	D0TU5R	PMID29865878-Compound-49	Patented
T54973	DRUGINFO	D01OOO	Peptide analog 41	Patented
T54973	DRUGINFO	D02PJI	Peptide analog 21	Patented
T54973	DRUGINFO	D0T1YB	Peptide analog 23	Patented

T15848	TARGETID	T15848
T15848	FORMERID	TTDI03573
T15848	UNIPROID	TEC_HUMAN
T15848	TARGNAME	Tyrosine-protein kinase Tec (PSCTK4)
T15848	GENENAME	TEC
T15848	TARGTYPE	Patented-recorded
T15848	SYNONYMS	Tec protein tyrosine kinase
T15848	FUNCTION	Plays a redundant role to ITK in regulation of the adaptive immune response. Regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells. Required for TCR-dependent IL2 gene induction. Phosphorylates DOK1, one CD28-specific substrate, and contributes to CD28-signaling. Mediates signals that negatively regulate IL2RA expression induced by TCR cross-linking. Plays a redundant role to BTK in BCR-signaling for B-cell development and activation, especially by phosphorylating STAP1, a BCR-signaling protein. Required in mast cells for efficient cytokine production. Involved in both growth and differentiation mechanisms of myeloid cells through activation by the granulocyte colony-stimulating factor CSF3, a critical cytokine to promoting the growth, differentiation, and functional activation of myeloid cells. Participates in platelet signaling downstream of integrin activation. Cooperates with JAK2 through reciprocal phosphorylation to mediate cytokine-driven activation of FOS transcription. GRB10, a negative modifier of the FOS activation pathway, is another substrate of TEC. TEC is involved in G protein-coupled receptor- and integrin-mediated signalings in blood platelets. Plays a role in hepatocyte proliferation and liver regeneration and is involved in HGF-induced ERK signaling pathway. TEC regulates also FGF2 unconventional secretion (endoplasmic reticulum (ER)/Golgi-independent mechanism) under various physiological conditions through phosphorylation of FGF2 'Tyr-215'. May also be involved in the regulation of osteoclast differentiation. Non-receptor tyrosine kinase that contributes to signaling from many receptors and participates as a signal transducer in multiple downstream pathways, including regulation of the actin cytoskeleton.
T15848	PDBSTRUC	2LUL
T15848	BIOCLASS	Kinase
T15848	ECNUMBER	EC 2.7.10.2
T15848	SEQUENCE	MNFNTILEEILIKRSQQKKKTSPLNYKERLFVLTKSMLTYYEGRAEKKYRKGFIDVSKIKCVEIVKNDDGVIPCQNKYPFQVVHDANTLYIFAPSPQSRDLWVKKLKEEIKNNNNIMIKYHPKFWTDGSYQCCRQTEKLAPGCEKYNLFESSIRKALPPAPETKKRRPPPPIPLEEEDNSEEIVVAMYDFQAAEGHDLRLERGQEYLILEKNDVHWWRARDKYGNEGYIPSNYVTGKKSNNLDQYEWYCRNMNRSKAEQLLRSEDKEGGFMVRDSSQPGLYTVSLYTKFGGEGSSGFRHYHIKETTTSPKKYYLAEKHAFGSIPEIIEYHKHNAAGLVTRLRYPVSVKGKNAPTTAGFSYEKWEINPSELTFMRELGSGLFGVVRLGKWRAQYKVAIKAIREGAMCEEDFIEEAKVMMKLTHPKLVQLYGVCTQQKPIYIVTEFMERGCLLNFLRQRQGHFSRDVLLSMCQDVCEGMEYLERNSFIHRDLAARNCLVSEAGVVKVSDFGMARYVLDDQYTSSSGAKFPVKWCPPEVFNYSRFSSKSDVWSFGVLMWEVFTEGRMPFEKYTNYEVVTMVTRGHRLYQPKLASNYVYEVMLRCWQEKPEGRPSFEDLLRTIDELVECEETFGR
T15848	DRUGINFO	D09PIS	Pyrazolo[4,3-c]pyridine derivative 2	Patented
T15848	DRUGINFO	D01RHR	PMID24915291C31	Investigative
T15848	DRUGINFO	D06BJG	PMID24915291C38	Investigative

T20371	TARGETID	T20371
T20371	FORMERID	TTDI03476
T20371	UNIPROID	PCP_HUMAN
T20371	TARGNAME	Prolylcarboxypeptidase (PRCP)
T20371	GENENAME	PRCP
T20371	TARGTYPE	Patented-recorded
T20371	SYNONYMS	Proline carboxypeptidase; PCP; Lysosomal carboxypeptidase C; Lysosomal Pro-X carboxypeptidase; Angiotensinase C
T20371	FUNCTION	Cleaves C-terminal amino acids linked to proline in peptides such as angiotensin II, III and des-Arg9-bradykinin. This cleavage occurs at acidic pH, but enzymatic activity is retained with some substrates at neutral pH.
T20371	PDBSTRUC	3N2Z
T20371	BIOCLASS	Peptidase
T20371	ECNUMBER	EC 3.4.16.2
T20371	SEQUENCE	MGRRALLLLLLSFLAPWATIALRPALRALGSLHLPTNPTSLPAVAKNYSVLYFQQKVDHFGFNTVKTFNQRYLVADKYWKKNGGSILFYTGNEGDIIWFCNNTGFMWDVAEELKAMLVFAEHRYYGESLPFGDNSFKDSRHLNFLTSEQALADFAELIKHLKRTIPGAENQPVIAIGGSYGGMLAAWFRMKYPHMVVGALAASAPIWQFEDLVPCGVFMKIVTTDFRKSGPHCSESIHRSWDAINRLSNTGSGLQWLTGALHLCSPLTSQDIQHLKDWISETWVNLAMVDYPYASNFLQPLPAWPIKVVCQYLKNPNVSDSLLLQNIFQALNVYYNYSGQVKCLNISETATSSLGTLGWSYQACTEVVMPFCTNGVDDMFEPHSWNLKELSDDCFQQWGVRPRPSWITTMYGGKNISSHTNIVFSNGELDPWSGGGVTKDITDTLVAVTISEGAHHLDLRTKNALDPMSVLLARSLEVRHMKNWIRDFYDSAGKQH
T20371	DRUGINFO	D00YYA	Cyclopentane carboxamide derivative 2	Patented
T20371	DRUGINFO	D01GEE	Piperidinyl pyrazole derivative 4	Patented
T20371	DRUGINFO	D01RBE	Pyrrolidine carboxamide derivative 2	Patented
T20371	DRUGINFO	D03ASG	Piperidinyl pyrazole derivative 1	Patented
T20371	DRUGINFO	D03GPW	Benzodihydroisofuran derivative 1	Patented
T20371	DRUGINFO	D03WDH	Cyclohexane carboxamide derivative 2	Patented
T20371	DRUGINFO	D05NQZ	Benzodihydroisofuran derivative 3	Patented
T20371	DRUGINFO	D07KNI	Benzodihydroisofuran derivative 4	Patented
T20371	DRUGINFO	D07RIZ	Piperidinyl triazole derivative 4	Patented
T20371	DRUGINFO	D0A0QQ	Piperidinyl triazole derivative 5	Patented
T20371	DRUGINFO	D0A6QI	Proline amide derivative 1	Patented
T20371	DRUGINFO	D0AF0O	Cyclohexane carboxamide derivative 1	Patented
T20371	DRUGINFO	D0J3TN	Piperidinyl pyrazole derivative 2	Patented
T20371	DRUGINFO	D0K1GJ	Piperidinyl triazole derivative 1	Patented
T20371	DRUGINFO	D0L6CM	Imidazole derivative 8	Patented
T20371	DRUGINFO	D0L8VH	Cyclopentane carboxamide derivative 1	Patented
T20371	DRUGINFO	D0LZ4A	Benzodihydroisofuran derivative 2	Patented
T20371	DRUGINFO	D0NT8N	Piperidinyl triazole derivative 3	Patented
T20371	DRUGINFO	D0QM9Q	Cyclohexane carboxamide derivative 3	Patented
T20371	DRUGINFO	D0R3WH	Piperidinyl pyrazole derivative 3	Patented
T20371	DRUGINFO	D0S3AL	Piperidinyl triazole derivative 2	Patented
T20371	DRUGINFO	D0S4XV	Piperidinyl triazole derivative 6	Patented
T20371	DRUGINFO	D0X8ZF	Imidazole derivative 9	Patented
T20371	DRUGINFO	D0N6AM	PMID24157366C35	Investigative

T37541	TARGETID	T37541
T37541	UNIPROID	CAH7_HUMAN
T37541	TARGNAME	Carbonic anhydrase VII (CA-VII)
T37541	GENENAME	CA7
T37541	TARGTYPE	Patented-recorded
T37541	SYNONYMS	Carbonic anhydrase 7; Carbonate dehydratase VII
T37541	FUNCTION	Reversible hydration of carbon dioxide.
T37541	PDBSTRUC	6H38; 6H37; 6H36; 6G4T; 3ML5
T37541	BIOCLASS	Alpha-carbonic anhydrase
T37541	ECNUMBER	EC 4.2.1.1
T37541	SEQUENCE	MTGHHGWGYGQDDGPSHWHKLYPIAQGDRQSPINIISSQAVYSPSLQPLELSYEACMSLSITNNGHSVQVDFNDSDDRTVVTGGPLEGPYRLKQFHFHWGKKHDVGSEHTVDGKSFPSELHLVHWNAKKYSTFGEAASAPDGLAVVGVFLETGDEHPSMNRLTDALYMVRFKGTKAQFSCFNPKCLLPASRHYWTYPGSLTTPPLSESVTWIVLREPICISERQMGKFRSLLFTSEDDERIHMVNNFRPPQPLKGRVVKASFRA

T73725	TARGETID	T73725
T73725	FORMERID	TTDI03103
T73725	UNIPROID	CLK2_HUMAN
T73725	TARGNAME	CDC-like kinase 2 (CLK2)
T73725	GENENAME	CLK2
T73725	TARGTYPE	Patented-recorded
T73725	SYNONYMS	Dual specificity protein kinase CLK2
T73725	FUNCTION	Phosphorylates serine- and arginine-rich (SR) proteins of the spliceosomal complex. May be a constituent of a network of regulatory mechanisms that enable SR proteins to control RNA splicing and can cause redistribution of SR proteins from speckles to a diffuse nucleoplasmic distribution. Acts as a suppressor of hepatic gluconeogenesis and glucose output by repressing PPARGC1A transcriptional activity on gluconeogenic genes via its phosphorylation. Phosphorylates PPP2R5B thereby stimulating the assembly of PP2A phosphatase with the PPP2R5B-AKT1 complex leading to dephosphorylation of AKT1. Phosphorylates: PTPN1, SRSF1 and SRSF3. Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells. Dual specificity kinase acting on both serine/threonine and tyrosine-containing substrates.
T73725	PDBSTRUC	6FYL; 6FYK; 6FYI; 5UNP; 3NR9
T73725	BIOCLASS	Kinase
T73725	ECNUMBER	EC 2.7.12.1
T73725	SEQUENCE	MPHPRRYHSSERGSRGSYREHYRSRKHKRRRSRSWSSSSDRTRRRRREDSYHVRSRSSYDDRSSDRRVYDRRYCGSYRRNDYSRDRGDAYYDTDYRHSYEYQRENSSYRSQRSSRRKHRRRRRRSRTFSRSSSQHSSRRAKSVEDDAEGHLIYHVGDWLQERYEIVSTLGEGTFGRVVQCVDHRRGGARVALKIIKNVEKYKEAARLEINVLEKINEKDPDNKNLCVQMFDWFDYHGHMCISFELLGLSTFDFLKDNNYLPYPIHQVRHMAFQLCQAVKFLHDNKLTHTDLKPENILFVNSDYELTYNLEKKRDERSVKSTAVRVVDFGSATFDHEHHSTIVSTRHYRAPEVILELGWSQPCDVWSIGCIIFEYYVGFTLFQTHDNREHLAMMERILGPIPSRMIRKTRKQKYFYRGRLDWDENTSAGRYVRENCKPLRRYLTSEAEEHHQLFDLIESMLEYEPAKRLTLGEALQHPFFARLRAEPPNKLWDSSRDISR
T73725	DRUGINFO	D06MBI	TG003	Patented
T73725	DRUGINFO	D0UI7U	ML315	Investigative
T73725	DRUGINFO	D06CXU	PMID23642479C17	Investigative

T63846	TARGETID	T63846
T63846	FORMERID	TTDI03277
T63846	UNIPROID	IRAK1_HUMAN
T63846	TARGNAME	IL-1 receptor-associated kinase 1 (IRAK1)
T63846	GENENAME	IRAK1
T63846	TARGTYPE	Patented-recorded
T63846	SYNONYMS	Interleukin-1 receptor-associated kinase 1; IRAK-1; IRAK
T63846	FUNCTION	Involved in Toll-like receptor (TLR) and IL-1R signaling pathways. Is rapidly recruited by MYD88 to the receptor-signaling complex upon TLR activation. Association with MYD88 leads to IRAK1 phosphorylation by IRAK4 and subsequent autophosphorylation and kinase activation. Phosphorylates E3 ubiquitin ligases Pellino proteins (PELI1, PELI2 and PELI3) to promote pellino-mediated polyubiquitination of IRAK1. Then, the ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. In turn, MAP3K7/TAK1 activates IKKs (CHUK/IKKA and IKBKB/IKKB) leading to NF-kappa-B nuclear translocation and activation. Alternatively, phosphorylates TIRAP to promote its ubiquitination and subsequent degradation. Phosphorylates the interferon regulatory factor 7 (IRF7) to induce its activation and translocation to the nucleus, resulting in transcriptional activation of type I IFN genes, which drive the cell in an antiviral state. When sumoylated, translocates to the nucleus and phosphorylates STAT3. Serine/threonine-protein kinase that plays a critical role in initiating innate immune response against foreign pathogens.
T63846	PDBSTRUC	6BFN
T63846	BIOCLASS	Kinase
T63846	ECNUMBER	EC 2.7.11.1
T63846	SEQUENCE	MAGGPGPGEPAAPGAQHFLYEVPPWVMCRFYKVMDALEPADWCQFAALIVRDQTELRLCERSGQRTASVLWPWINRNARVADLVHILTHLQLLRARDIITAWHPPAPLPSPGTTAPRPSSIPAPAEAEAWSPRKLPSSASTFLSPAFPGSQTHSGPELGLVPSPASLWPPPPSPAPSSTKPGPESSVSLLQGARPFPFCWPLCEISRGTHNFSEELKIGEGGFGCVYRAVMRNTVYAVKRLKENADLEWTAVKQSFLTEVEQLSRFRHPNIVDFAGYCAQNGFYCLVYGFLPNGSLEDRLHCQTQACPPLSWPQRLDILLGTARAIQFLHQDSPSLIHGDIKSSNVLLDERLTPKLGDFGLARFSRFAGSSPSQSSMVARTQTVRGTLAYLPEEYIKTGRLAVDTDTFSFGVVVLETLAGQRAVKTHGARTKYLKDLVEEEAEEAGVALRSTQSTLQAGLAADAWAAPIAMQIYKKHLDPRPGPCPPELGLGLGQLACCCLHRRAKRRPPMTQVYERLEKLQAVVAGVPGHSEAASCIPPSPQENSYVSSTGRAHSGAAPWQPLAAPSGASAQAAEQLQRGPNQPVESDESLGGLSAALRSWHLTPSCPLDPAPLREAGCPQGDTAGESSWGSGPGSRPTAVEGLALGSSASSSSEPPQIIINPARQKMVQKLALYEDGALDSLQLLSSSSLPGLGLEQDRQGPEESDEFQS
T63846	DRUGINFO	D0E5AT	Pyrazolopyrimidine and thienopyrimidine amide derivative 1	Patented
T63846	DRUGINFO	D0F2NW	Pyrazolopyrimidine and thienopyrimidine amide derivative 2	Patented
T63846	DRUGINFO	D0NT8U	Indazoletriazolephenyl derivative 1	Patented
T63846	DRUGINFO	D0O6GQ	Indazoletriazolephenyl derivative 2	Patented
T63846	DRUGINFO	D04ZIV	WO2012007375C1	Investigative
T63846	DRUGINFO	D0I2FZ	IRAK-1/4 inhibitor	Investigative
T63846	DRUGINFO	D0T2NE	WO2012007375C7 	Investigative

T03279	TARGETID	T03279
T03279	FORMERID	TTDI03520
T03279	UNIPROID	KS6A3_HUMAN
T03279	TARGNAME	Ribosomal protein S6 kinase alpha-3 (RSK3)
T03279	GENENAME	RPS6KA3
T03279	TARGTYPE	Patented-recorded
T03279	SYNONYMS	pp90RSK2; p90RSK3; p90-RSK 3; S6K-alpha-3; Ribosomal S6 kinase 2; RSK2; RSK-2; MAPKAPK1B; MAPKAPK-1b; MAPKAP kinase 1b; MAPK-activated protein kinase 1b; MAP kinase-activated protein kinase 1b; Insulin-stimulated protein kinase 1; ISPK1; ISPK-1; 90 kDa ribosomal protein S6 kinase 3
T03279	FUNCTION	In fibroblast, is required for EGF-stimulated phosphorylation of CREB1 and histone H3 at 'Ser-10', which results in the subsequent transcriptional activation of several immediate-early genes. In response to mitogenic stimulation (EGF and PMA), phosphorylates and activates NR4A1/NUR77 and ETV1/ER81 transcription factors and the cofactor CREBBP. Upon insulin-derived signal, acts indirectly on the transcription regulation of several genes by phosphorylating GSK3B at 'Ser-9' and inhibiting its activity. Phosphorylates RPS6 in response to serum or EGF via an mTOR-independent mechanism and promotes translation initiation by facilitating assembly of the preinitiation complex. In response to insulin, phosphorylates EIF4B, enhancing EIF4B affinity for the EIF3 complex and stimulating cap-dependent translation. Is involved in the mTOR nutrient-sensing pathway by directly phosphorylating TSC2 at 'Ser-1798', which potently inhibits TSC2 ability to suppress mTOR signaling, and mediates phosphorylation of RPTOR, which regulates mTORC1 activity and may promote rapamycin-sensitive signaling independently of the PI3K/AKT pathway. Mediates cell survival by phosphorylating the pro-apoptotic proteins BAD and DAPK1 and suppressing their pro-apoptotic function. Promotes the survival of hepatic stellate cells by phosphorylating CEBPB in response to the hepatotoxin carbon tetrachloride (CCl4). Is involved in cell cycle regulation by phosphorylating the CDK inhibitor CDKN1B, which promotes CDKN1B association with 14-3-3 proteins and prevents its translocation to the nucleus and inhibition of G1 progression. In LPS-stimulated dendritic cells, is involved in TLR4-induced macropinocytosis, and in myeloma cells, acts as effector of FGFR3-mediated transformation signaling, after direct phosphorylation at Tyr-529 by FGFR3. Negatively regulates EGF-induced MAPK1/3 phosphorylation via phosphorylation of SOS1. Phosphorylates SOS1 at 'Ser-1134' and 'Ser-1161' that create YWHAB and YWHAE binding sites and which contribute to the negative regulation of MAPK1/3 phosphorylation. Phosphorylates EPHA2 at 'Ser-897', the RPS6KA-EPHA2 signaling pathway controls cell migration. Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of the transcription factors CREB1, ETV1/ER81 and NR4A1/NUR77, regulates translation through RPS6 and EIF4B phosphorylation, and mediates cellular proliferation, survival, and differentiation by modulating mTOR signaling and repressing pro-apoptotic function of BAD and DAPK1.
T03279	PDBSTRUC	5D9L; 5D9K; 4NW6; 4NW5; 4NUS
T03279	BIOCLASS	Kinase
T03279	ECNUMBER	EC 2.7.11.1
T03279	SEQUENCE	MPLAQLADPWQKMAVESPSDSAENGQQIMDEPMGEEEINPQTEEVSIKEIAITHHVKEGHEKADPSQFELLKVLGQGSFGKVFLVKKISGSDARQLYAMKVLKKATLKVRDRVRTKMERDILVEVNHPFIVKLHYAFQTEGKLYLILDFLRGGDLFTRLSKEVMFTEEDVKFYLAELALALDHLHSLGIIYRDLKPENILLDEEGHIKLTDFGLSKESIDHEKKAYSFCGTVEYMAPEVVNRRGHTQSADWWSFGVLMFEMLTGTLPFQGKDRKETMTMILKAKLGMPQFLSPEAQSLLRMLFKRNPANRLGAGPDGVEEIKRHSFFSTIDWNKLYRREIHPPFKPATGRPEDTFYFDPEFTAKTPKDSPGIPPSANAHQLFRGFSFVAITSDDESQAMQTVGVHSIVQQLHRNSIQFTDGYEVKEDIGVGSYSVCKRCIHKATNMEFAVKIIDKSKRDPTEEIEILLRYGQHPNIITLKDVYDDGKYVYVVTELMKGGELLDKILRQKFFSEREASAVLFTITKTVEYLHAQGVVHRDLKPSNILYVDESGNPESIRICDFGFAKQLRAENGLLMTPCYTANFVAPEVLKRQGYDAACDIWSLGVLLYTMLTGYTPFANGPDDTPEEILARIGSGKFSLSGGYWNSVSDTAKDLVSKMLHVDPHQRLTAALVLRHPWIVHWDQLPQYQLNRQDAPHLVKGAMAATYSALNRNQSPVLEPVGRSTLAQRRGIKKITSTAL
T03279	DRUGINFO	D01IOH	Indole-based analog 14	Patented
T03279	DRUGINFO	D0X8YV	Pyrrolo[2,3-d]pyrimidine derivative 35	Patented
T03279	DRUGINFO	D0O6TG	PMID27410995-Compound-Figure3j	Patented
T03279	DRUGINFO	D02VBF	BI-D1870	Preclinical
T03279	DRUGINFO	D0U3NI	BIX 02565	Investigative
T03279	DRUGINFO	D09AID	PMID22564207C25b	Investigative
T03279	DRUGINFO	D0C2GE	PMID22765894C8h	Investigative

T04820	TARGETID	T04820
T04820	FORMERID	TTDR00301
T04820	UNIPROID	P90584_PLAFA
T04820	TARGNAME	Plasmodium CDK Pfmrk (Malaria Pfmrk)
T04820	GENENAME	Malaria Pfmrk
T04820	TARGTYPE	Patented-recorded
T04820	SYNONYMS	Pfmrk; MO15-related protein kinase Pfmrk
T04820	FUNCTION	Association of Pfmrk with human cyclin H (the cyclin partner for hCDK7) or Pfcyc-1 (a cyclin homologue in P. falciparum) stimulates kinase activity in vitro.
T04820	BIOCLASS	Kinase
T04820	ECNUMBER	EC 2.7.1.37
T04820	SEQUENCE	MENNSTERYIFKPNFLGEGSYGKVYKAYDTILKKEVAIKKMKLNEISNYIDDCGINFVLLREIKIMKEIKHKNIMSALDLYCEKDYINLVMEIMDYDLSKIINRKIFLTDSQKKCILLQILNGLNVLHKYYFMHRDLSPANIFINKKGEVKLADFGLCTKYGYDMYSDKLFRDKYKKNLNLTSKVVTLWYRAPELLLGSNKYNSSIDMWSFGCIFAELLLQKALFPGENEIDQLGKIFFLLGTPNENNWPEALCLPLYTEFTKATKKDFKTYFKIDDDDCIDLLTSFLKLNAHERISAEDAMKHRYFFNDPLPCDISQLPFNDL
T04820	DRUGINFO	D00PWQ	KENPAULLONE	Patented
T04820	DRUGINFO	D04PTI	WR-289010	Investigative
T04820	DRUGINFO	D05SZP	WR-080539	Investigative
T04820	DRUGINFO	D06CTS	5-chloro-4-nitrothiophene-2-sulfonamide	Investigative
T04820	DRUGINFO	D06YUR	Oxindole derivative	Investigative
T04820	DRUGINFO	D08FZK	WR-203581	Investigative
T04820	DRUGINFO	D0A6YW	WR-289009	Investigative
T04820	DRUGINFO	D0C8BV	N-(2-aminoethyl)isoquinoline-5-sulfonamide	Investigative
T04820	DRUGINFO	D0D8MA	2-chloro-N-(o-tolylcarbamoyl)benzamide	Investigative
T04820	DRUGINFO	D0E4AB	N'-(2-fluorobenzoyl)-2-naphthohydrazide	Investigative
T04820	DRUGINFO	D0F1KM	WR-190706	Investigative
T04820	DRUGINFO	D0G2DQ	5-Nitro-1H-indole-2,3-dione	Investigative
T04820	DRUGINFO	D0Q3RF	(E)-1-(4-Nitro-phenyl)-3-pyridin-2-yl-propenone	Investigative
T04820	DRUGINFO	D0Q4PQ	WR-089120	Investigative
T04820	DRUGINFO	D0UH0Q	3-[3-(2-Hydroxy-ethoxy)-phenyl]-1H-quinolin-2-one	Investigative
T04820	DRUGINFO	D0V5ZI	WR-289012	Investigative
T04820	DRUGINFO	D0V8JJ	WR-289016	Investigative
T04820	DRUGINFO	D0W1NH	Thiophene sulfonamide	Investigative
T04820	DRUGINFO	D0Z6LR	2,5-dichloro-N-phenylthiophene-3-sulfonamide	Investigative
T04820	DRUGINFO	D06WUE	2,5-dichloro-N-p-tolylthiophene-3-sulfonamide	Investigative
T04820	DRUGINFO	D00RIX	APIGENIN	Investigative

T70851	TARGETID	T70851
T70851	FORMERID	TTDI03378
T70851	UNIPROID	MK07_HUMAN
T70851	TARGNAME	Extracellular signal-regulated kinase 5 (ERK5)
T70851	GENENAME	MAPK7
T70851	TARGTYPE	Patented-recorded
T70851	SYNONYMS	PRKM7; Mitogen-activated protein kinase 7; MAPK 7; MAP kinase 7; ERK-5; Big MAP kinase 1; BMK1; BMK-1
T70851	FUNCTION	The upstream activator of MAPK7 is the MAPK kinase MAP2K5. Upon activation, it translocates to the nucleus and phosphorylates various downstream targets including MEF2C. EGF activates MAPK7 through a Ras-independent and MAP2K5-dependent pathway. May have a role in muscle cell differentiation. May be important for endothelial function and maintenance of blood vessel integrity. MAP2K5 and MAPK7 interact specifically with one another and not with MEK1/ERK1 or MEK2/ERK2 pathways. Phosphorylates SGK1 at Ser-78 and this is required for growth factor-induced cell cycle progression. Involved in the regulation of p53/TP53 by disrupting the PML-MDM2 interaction. Plays a role in various cellular processes such as proliferation, differentiation and cell survival.
T70851	PDBSTRUC	6HKN; 6HKM; 5O7I; 5BYZ; 5BYY
T70851	BIOCLASS	Kinase
T70851	ECNUMBER	EC 2.7.11.24
T70851	SEQUENCE	MAEPLKEEDGEDGSAEPPGPVKAEPAHTAASVAAKNLALLKARSFDVTFDVGDEYEIIETIGNGAYGVVSSARRRLTGQQVAIKKIPNAFDVVTNAKRTLRELKILKHFKHDNIIAIKDILRPTVPYGEFKSVYVVLDLMESDLHQIIHSSQPLTLEHVRYFLYQLLRGLKYMHSAQVIHRDLKPSNLLVNENCELKIGDFGMARGLCTSPAEHQYFMTEYVATRWYRAPELMLSLHEYTQAIDLWSVGCIFGEMLARRQLFPGKNYVHQLQLIMMVLGTPSPAVIQAVGAERVRAYIQSLPPRQPVPWETVYPGADRQALSLLGRMLRFEPSARISAAAALRHPFLAKYHDPDDEPDCAPPFDFAFDREALTRERIKEAIVAEIEDFHARREGIRQQIRFQPSLQPVASEPGCPDVEMPSPWAPSGDCAMESPPPAPPPCPGPAPDTIDLTLQPPPPVSEPAPPKKDGAISDNTKAALKAALLKSLRSRLRDGPSAPLEAPEPRKPVTAQERQREREEKRRRRQERAKEREKRRQERERKERGAGASGGPSTDPLAGLVLSDNDRSLLERWTRMARPAAPALTSVPAPAPAPTPTPTPVQPTSPPPGPVAQPTGPQPQSAGSTSGPVPQPACPPPGPAPHPTGPPGPIPVPAPPQIATSTSLLAAQSLVPPPGLPGSSTPGVLPYFPPGLPPPDAGGAPQSSMSESPDVNLVTQQLSKSQVEDPLPPVFSGTPKGSGAGYGVGFDLEEFLNQSFDMGVADGPQDGQADSASLSASLLADWLEGHGMNPADIESLQREIQMDSPMLLADLPDLQDP
T70851	DRUGINFO	D0L7SK	PMID26924192-Compound-30	Patented
T70851	DRUGINFO	D0SB3H	PMID26924192-Compound-32	Patented
T70851	DRUGINFO	D0VB3P	PMID26924192-Compound-33	Patented
T70851	DRUGINFO	D0M0QQ	XMD8-92	Investigative

T92803	TARGETID	T92803
T92803	FORMERID	TTDI03162
T92803	UNIPROID	DYR1A_HUMAN
T92803	TARGNAME	Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
T92803	GENENAME	DYRK1A
T92803	TARGTYPE	Patented-recorded
T92803	SYNONYMS	hMNB; Protein kinase minibrain homolog; MNBH; MNB; HP86; Dual specificity tyrosine-phosphorylation-regulated kinase 1A; Dual specificity YAK1-related kinase; DYRK
T92803	FUNCTION	Dual-specificity kinase which possesses both serine/threonine and tyrosine kinase activities. May play a role in a signaling pathway regulating nuclear functions of cell proliferation. Modulates alternative splicing by phosphorylating the splice factor SRSF6 (By similarity). Exhibits a substrate preference for proline at position P+1 and arginine at position P-3. Has pro-survival function and negatively regulates the apoptotic process. Promotes cell survival upon genotoxic stress through phosphorylation of SIRT1. This in turn inhibits TP53 activity and apoptosis (By similarity).
T92803	PDBSTRUC	6EJ4; 6EIV; 6EIS; 6EIR; 6EIQ
T92803	BIOCLASS	Kinase
T92803	ECNUMBER	EC 2.7.12.1
T92803	SEQUENCE	MHTGGETSACKPSSVRLAPSFSFHAAGLQMAGQMPHSHQYSDRRQPNISDQQVSALSYSDQIQQPLTNQVMPDIVMLQRRMPQTFRDPATAPLRKLSVDLIKTYKHINEVYYAKKKRRHQQGQGDDSSHKKERKVYNDGYDDDNYDYIVKNGEKWMDRYEIDSLIGKGSFGQVVKAYDRVEQEWVAIKIIKNKKAFLNQAQIEVRLLELMNKHDTEMKYYIVHLKRHFMFRNHLCLVFEMLSYNLYDLLRNTNFRGVSLNLTRKFAQQMCTALLFLATPELSIIHCDLKPENILLCNPKRSAIKIVDFGSSCQLGQRIYQYIQSRFYRSPEVLLGMPYDLAIDMWSLGCILVEMHTGEPLFSGANEVDQMNKIVEVLGIPPAHILDQAPKARKFFEKLPDGTWNLKKTKDGKREYKPPGTRKLHNILGVETGGPGGRRAGESGHTVADYLKFKDLILRMLDYDPKTRIQPYYALQHSFFKKTADEGTNTSNSVSTSPAMEQSQSSGTTSSTSSSSGGSSGTSNSGRARSDPTHQHRHSGGHFTAAVQAMDCETHSPQVRQQFPAPLGWSGTEAPTQVTVETHPVQETTFHVAPQQNALHHHHGNSSHHHHHHHHHHHHHGQQALGNRTRPRVYNSPTNSSSTQDSMEVGHSHHSMTSLSSSTTSSSTSSSSTGNQGNQAYQNRPVAANTLDFGQNGAMDVNLTVYSNPRQETGIAGHPTYQFSANTGPAHYMTEGHLTMRQGADREESPMTGVCVQQSPVASS
T92803	DRUGINFO	D03TFJ	Benzimidazole	Patented
T92803	DRUGINFO	D05BVP	PMID28766366-Compound-Scheme8NCGC-00010037	Patented
T92803	DRUGINFO	D05ZHR	PMID28766366-Compound-Scheme12-3	Patented
T92803	DRUGINFO	D06TIU	PMID28766366-Compound-Scheme12-1	Patented
T92803	DRUGINFO	D09UNF	PMID28766366-Compound-Scheme24Paprotrain	Patented
T92803	DRUGINFO	D0A7CE	PMID28766366-Compound-Scheme15-1	Patented
T92803	DRUGINFO	D0B0AS	PMID28766366-Compound-Scheme27LeucettineL41derivatives	Patented
T92803	DRUGINFO	D0GV3X	PMID28766366-Compound-Scheme24-11H-pyrido[4,3-a]carbazole	Patented
T92803	DRUGINFO	D0I8CT	PMID28766366-Compound-Scheme15-2	Patented
T92803	DRUGINFO	D0JQ0Z	PMID28766366-Compound-Scheme8NCGC-00189310	Patented
T92803	DRUGINFO	D0K2BT	PMID28766366-Compound-Scheme12-4	Patented
T92803	DRUGINFO	D0L2XV	PMID28766366-Compound-Scheme18	Patented
T92803	DRUGINFO	D0NS6I	PMID28766366-Compound-Scheme27LeucettamineB	Patented
T92803	DRUGINFO	D0O9WA	PMID28766366-Compound-Scheme23MPPDerivatives	Patented
T92803	DRUGINFO	D0PM1B	PMID28766366-Compound-Scheme12-2	Patented
T92803	DRUGINFO	D0Q3VZ	PMID28766366-Compound-Scheme27LeucettineL41	Patented
T92803	DRUGINFO	D0RG1T	PMID28766366-Compound-Scheme13INDY	Patented
T92803	DRUGINFO	D0UY8K	PMID28766366-Compound-Scheme8NCGC-00185981	Patented
T92803	DRUGINFO	D0X0ZC	PMID28766366-Compound-Scheme15-3	Patented
T92803	DRUGINFO	D0X5MW	PMID28766366-Compound-Scheme1WO2011135259	Patented
T92803	DRUGINFO	D0X8NN	PMID28766366-Compound-Scheme11	Patented
T92803	DRUGINFO	D0YT1S	PMID28766366-Compound-Scheme6Pyrrolo[2,3-d]pyrimidines	Patented
T92803	DRUGINFO	D00TFF	PMID28766366-Compound-Scheme2WO2012/098065bottom	Patented
T92803	DRUGINFO	D02GEJ	PMID28766366-Compound-Scheme16DMAT	Patented
T92803	DRUGINFO	D05CLL	PMID28766366-Compound-Scheme7WO2012/098070upper	Patented
T92803	DRUGINFO	D08CUF	PMID28766366-Compound-Scheme9EHT1610	Patented
T92803	DRUGINFO	D08DIJ	PMID28766366-Compound-Scheme9EHT5372	Patented
T92803	DRUGINFO	D09CDR	PMID28766366-Compound-Scheme25-2	Patented
T92803	DRUGINFO	D0B8IQ	PMID28766366-Compound-Scheme2WO2012/098065upper	Patented
T92803	DRUGINFO	D0BP6J	PMID28766366-Compound-Scheme7WO2012/098070bottom	Patented
T92803	DRUGINFO	D0C0BP	PMID28766366-Compound-Scheme4Upper	Patented
T92803	DRUGINFO	D0CC7E	PMID28766366-Compound-Scheme25-3	Patented
T92803	DRUGINFO	D0DT5I	PMID28766366-Compound-Scheme9EHT3356	Patented
T92803	DRUGINFO	D0GE4F	PMID28766366-Compound-Scheme25-4	Patented
T92803	DRUGINFO	D0O9BK	PMID28766366-Compound-Scheme9EHT6840	Patented
T92803	DRUGINFO	D0P7QO	PMID28766366-Compound-Scheme5	Patented
T92803	DRUGINFO	D0PJ1W	PMID28766366-Compound-Scheme9EHT9851	Patented
T92803	DRUGINFO	D0SB1W	PMID28766366-Compound-Scheme4Bottom	Patented
T92803	DRUGINFO	D04SYJ	PMID28766366-Compound-Scheme14BINDY	Patented
T92803	DRUGINFO	D06MBI	TG003	Patented
T92803	DRUGINFO	D00OWF	Harmine	Patented
T92803	DRUGINFO	D02DBH	PMID28766366-Compound-Scheme21Left	Patented
T92803	DRUGINFO	D07BWC	PMID28766366-Compound-Scheme21Right	Patented
T92803	DRUGINFO	D00AQR	WO2013026806C72 	Investigative
T92803	DRUGINFO	D0X9PI	PMID24900699C68	Investigative
T92803	DRUGINFO	D00BAJ	KH-CB19	Investigative
T92803	DRUGINFO	D0UI7U	ML315	Investigative
T92803	DRUGINFO	D06CXU	PMID23642479C17	Investigative
T92803	DRUGINFO	D04IMY	leucettine L41	Investigative

T42932	TARGETID	T42932
T42932	UNIPROID	TLR1_HUMAN
T42932	TARGNAME	Toll-like receptor 1 (TLR1)
T42932	GENENAME	TLR1
T42932	TARGTYPE	Patented-recorded
T42932	SYNONYMS	Toll/interleukin-1 receptor-like protein; TIL; KIAA0012; CD281
T42932	FUNCTION	Specifically recognizes diacylated and triacylated lipopeptides. Cooperates with TLR2 to mediate the innate immune response to bacterial lipoproteins or lipopeptides. Forms the activation cluster TLR2:TLR1:CD14 in response to triacylated lipopeptides, this cluster triggers signaling from the cell surface and subsequently is targeted to the Golgi in a lipid-raft dependent pathway. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Participates in the innate immune response to microbial agents.
T42932	PDBSTRUC	6NIH; 2Z7X; 1FYV
T42932	BIOCLASS	Toll-like receptor
T42932	SEQUENCE	MTSIFHFAIIFMLILQIRIQLSEESEFLVDRSKNGLIHVPKDLSQKTTILNISQNYISELWTSDILSLSKLRILIISHNRIQYLDISVFKFNQELEYLDLSHNKLVKISCHPTVNLKHLDLSFNAFDALPICKEFGNMSQLKFLGLSTTHLEKSSVLPIAHLNISKVLLVLGETYGEKEDPEGLQDFNTESLHIVFPTNKEFHFILDVSVKTVANLELSNIKCVLEDNKCSYFLSILAKLQTNPKLSNLTLNNIETTWNSFIRILQLVWHTTVWYFSISNVKLQGQLDFRDFDYSGTSLKALSIHQVVSDVFGFPQSYIYEIFSNMNIKNFTVSGTRMVHMLCPSKISPFLHLDFSNNLLTDTVFENCGHLTELETLILQMNQLKELSKIAEMTTQMKSLQQLDISQNSVSYDEKKGDCSWTKSLLSLNMSSNILTDTIFRCLPPRIKVLDLHSNKIKSIPKQVVKLEALQELNVAFNSLTDLPGCGSFSSLSVLIIDHNSVSHPSADFFQSCQKMRSIKAGDNPFQCTCELGEFVKNIDQVSSEVLEGWPDSYKCDYPESYRGTLLKDFHMSELSCNITLLIVTIVATMLVLAVTVTSLCSYLDLPWYLRMVCQWTQTRRRARNIPLEELQRNLQFHAFISYSGHDSFWVKNELLPNLEKEGMQICLHERNFVPGKSIVENIITCIEKSYKSIFVLSPNFVQSEWCHYELYFAHHNLFHEGSNSLILILLEPIPQYSIPSSYHKLKSLMARRTYLEWPKEKSKRGLFWANLRAAINIKLTEQAKK

T83202	TARGETID	T83202
T83202	FORMERID	TTDI03518
T83202	UNIPROID	KS6A1_HUMAN
T83202	TARGNAME	Ribosomal protein S6 kinase alpha-1 (RSK1)
T83202	GENENAME	RPS6KA1
T83202	TARGTYPE	Patented-recorded
T83202	SYNONYMS	p90S6K; p90RSK1; p90-RSK 1; S6K-alpha-1; Ribosomal S6 kinase 1; RSK-1; MAPKAPK1A; MAPKAPK-1a; MAPKAP kinase 1a; MAPK-activated protein kinase 1a; MAP kinase-activated protein kinase 1a; 90 kDa ribosomal protein S6 kinase 1
T83202	FUNCTION	In fibroblast, is required for EGF-stimulated phosphorylation of CREB1, which results in the subsequent transcriptional activation of several immediate-early genes. In response to mitogenic stimulation (EGF and PMA), phosphorylates and activates NR4A1/NUR77 and ETV1/ER81 transcription factors and the cofactor CREBBP. Upon insulin-derived signal, acts indirectly on the transcription regulation of several genes by phosphorylating GSK3B at 'Ser-9' and inhibiting its activity. Phosphorylates RPS6 in response to serum or EGF via an mTOR-independent mechanism and promotes translation initiation by facilitating assembly of the pre-initiation complex. In response to insulin, phosphorylates EIF4B, enhancing EIF4B affinity for the EIF3 complex and stimulating cap-dependent translation. Is involved in the mTOR nutrient-sensing pathway by directly phosphorylating TSC2 at 'Ser-1798', which potently inhibits TSC2 ability to suppress mTOR signaling, and mediates phosphorylation of RPTOR, which regulates mTORC1 activity and may promote rapamycin-sensitive signaling independently of the PI3K/AKT pathway. Mediates cell survival by phosphorylating the pro-apoptotic proteins BAD and DAPK1 and suppressing their pro-apoptotic function. Promotes the survival of hepatic stellate cells by phosphorylating CEBPB in response to the hepatotoxin carbon tetrachloride (CCl4). Mediates induction of hepatocyte prolifration by TGFA through phosphorylation of CEBPB. Is involved in cell cycle regulation by phosphorylating the CDK inhibitor CDKN1B, which promotes CDKN1B association with 14-3-3 proteins and prevents its translocation to the nucleus and inhibition of G1 progression. Phosphorylates EPHA2 at 'Ser-897', the RPS6KA-EPHA2 signaling pathway controls cell migration. Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of the transcription factors CREB1, ETV1/ER81 and NR4A1/NUR77, regulates translation through RPS6 and EIF4B phosphorylation, and mediates cellular proliferation, survival, and differentiation by modulating mTOR signaling and repressing pro-apoptotic function of BAD and DAPK1.
T83202	PDBSTRUC	5V62; 5V61; 5N7G; 5N7F; 5N7D
T83202	BIOCLASS	Kinase
T83202	ECNUMBER	EC 2.7.11.1
T83202	SEQUENCE	MPLAQLKEPWPLMELVPLDPENGQTSGEEAGLQPSKDEGVLKEISITHHVKAGSEKADPSHFELLKVLGQGSFGKVFLVRKVTRPDSGHLYAMKVLKKATLKVRDRVRTKMERDILADVNHPFVVKLHYAFQTEGKLYLILDFLRGGDLFTRLSKEVMFTEEDVKFYLAELALGLDHLHSLGIIYRDLKPENILLDEEGHIKLTDFGLSKEAIDHEKKAYSFCGTVEYMAPEVVNRQGHSHSADWWSYGVLMFEMLTGSLPFQGKDRKETMTLILKAKLGMPQFLSTEAQSLLRALFKRNPANRLGSGPDGAEEIKRHVFYSTIDWNKLYRREIKPPFKPAVAQPDDTFYFDTEFTSRTPKDSPGIPPSAGAHQLFRGFSFVATGLMEDDGKPRAPQAPLHSVVQQLHGKNLVFSDGYVVKETIGVGSYSECKRCVHKATNMEYAVKVIDKSKRDPSEEIEILLRYGQHPNIITLKDVYDDGKHVYLVTELMRGGELLDKILRQKFFSEREASFVLHTIGKTVEYLHSQGVVHRDLKPSNILYVDESGNPECLRICDFGFAKQLRAENGLLMTPCYTANFVAPEVLKRQGYDEGCDIWSLGILLYTMLAGYTPFANGPSDTPEEILTRIGSGKFTLSGGNWNTVSETAKDLVSKMLHVDPHQRLTAKQVLQHPWVTQKDKLPQSQLSHQDLQLVKGAMAATYSALNSSKPTPQLKPIESSILAQRRVRKLPSTTL
T83202	DRUGINFO	D00RPW	1,6-diazanaphthalenes and pyrido[2,3-d] pyrimidine derivative 1	Patented
T83202	DRUGINFO	D08QMJ	Heterocyclic derivative 26	Patented
T83202	DRUGINFO	D0I3YK	1,6-diazanaphthalenes and pyrido[2,3-d] pyrimidine derivative 2	Patented
T83202	DRUGINFO	D0R0DW	Pyrrolo[2,3-d]pyrimidine derivative 1	Patented
T83202	DRUGINFO	D0T2CA	Pyrrolo[2,3-d]pyrimidine derivative 2	Patented
T83202	DRUGINFO	D02VBF	BI-D1870	Preclinical
T83202	DRUGINFO	D06PJW	GSK-1838705A	Investigative
T83202	DRUGINFO	D01YWE	PMID19364658C33	Investigative

T09197	TARGETID	T09197
T09197	UNIPROID	LRRK2_HUMAN
T09197	TARGNAME	Leucine-rich repeat kinase 2 G2019S mutant (LRRK2 G2019S)
T09197	GENENAME	LRRK2
T09197	TARGTYPE	Patented-recorded
T09197	SYNONYMS	PARK8 G2019S mutant; LRRK2 G2019S mutant; Dardarin G2019S mutant
T09197	FUNCTION	The process involves activation of nicotinic acid adenine dinucleotide phosphate (NAADP) receptors, increase in lysosomal pH, and calcium release from lysosomes. Together with RAB29, plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner. Regulates neuronal process morphology in the intact central nervous system (CNS). Plays a role in synaptic vesicle trafficking. Phosphorylates PRDX3. Has GTPase activity. May play a role in the phosphorylation of proteins central to Parkinson disease. Plays an important role in recuiting SEC16A to endoplasmic reticulum exit sites (ERES) and in regulating ER to Golgi vesicle-mediated transport and ERES organization. Positively regulates autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway.
T09197	PDBSTRUC	6DLP; 6DLO; 5MYC; 5MY9; 3D6T
T09197	BIOCLASS	Kinase
T09197	ECNUMBER	EC 2.7.11.1
T09197	SEQUENCE	MASGSCQGCEEDEETLKKLIVRLNNVQEGKQIETLVQILEDLLVFTYSERASKLFQGKNIHVPLLIVLDSYMRVASVQQVGWSLLCKLIEVCPGTMQSLMGPQDVGNDWEVLGVHQLILKMLTVHNASVNLSVIGLKTLDLLLTSGKITLLILDEESDIFMLIFDAMHSFPANDEVQKLGCKALHVLFERVSEEQLTEFVENKDYMILLSALTNFKDEEEIVLHVLHCLHSLAIPCNNVEVLMSGNVRCYNIVVEAMKAFPMSERIQEVSCCLLHRLTLGNFFNILVLNEVHEFVVKAVQQYPENAALQISALSCLALLTETIFLNQDLEEKNENQENDDEGEEDKLFWLEACYKALTWHRKNKHVQEAACWALNNLLMYQNSLHEKIGDEDGHFPAHREVMLSMLMHSSSKEVFQASANALSTLLEQNVNFRKILLSKGIHLNVLELMQKHIHSPEVAESGCKMLNHLFEGSNTSLDIMAAVVPKILTVMKRHETSLPVQLEALRAILHFIVPGMPEESREDTEFHHKLNMVKKQCFKNDIHKLVLAALNRFIGNPGIQKCGLKVISSIVHFPDALEMLSLEGAMDSVLHTLQMYPDDQEIQCLGLSLIGYLITKKNVFIGTGHLLAKILVSSLYRFKDVAEIQTKGFQTILAILKLSASFSKLLVHHSFDLVIFHQMSSNIMEQKDQQFLNLCCKCFAKVAMDDYLKNVMLERACDQNNSIMVECLLLLGADANQAKEGSSLICQVCEKESSPKLVELLLNSGSREQDVRKALTISIGKGDSQIISLLLRRLALDVANNSICLGGFCIGKVEPSWLGPLFPDKTSNLRKQTNIASTLARMVIRYQMKSAVEEGTASGSDGNFSEDVLSKFDEWTFIPDSSMDSVFAQSDDLDSEGSEGSFLVKKKSNSISVGEFYRDAVLQRCSPNLQRHSNSLGPIFDHEDLLKRKRKILSSDDSLRSSKLQSHMRHSDSISSLASEREYITSLDLSANELRDIDALSQKCCISVHLEHLEKLELHQNALTSFPQQLCETLKSLTHLDLHSNKFTSFPSYLLKMSCIANLDVSRNDIGPSVVLDPTVKCPTLKQFNLSYNQLSFVPENLTDVVEKLEQLILEGNKISGICSPLRLKELKILNLSKNHISSLSENFLEACPKVESFSARMNFLAAMPFLPPSMTILKLSQNKFSCIPEAILNLPHLRSLDMSSNDIQYLPGPAHWKSLNLRELLFSHNQISILDLSEKAYLWSRVEKLHLSHNKLKEIPPEIGCLENLTSLDVSYNLELRSFPNEMGKLSKIWDLPLDELHLNFDFKHIGCKAKDIIRFLQQRLKKAVPYNRMKLMIVGNTGSGKTTLLQQLMKTKKSDLGMQSATVGIDVKDWPIQIRDKRKRDLVLNVWDFAGREEFYSTHPHFMTQRALYLAVYDLSKGQAEVDAMKPWLFNIKARASSSPVILVGTHLDVSDEKQRKACMSKITKELLNKRGFPAIRDYHFVNATEESDALAKLRKTIINESLNFKIRDQLVVGQLIPDCYVELEKIILSERKNVPIEFPVIDRKRLLQLVRENQLQLDENELPHAVHFLNESGVLLHFQDPALQLSDLYFVEPKWLCKIMAQILTVKVEGCPKHPKGIISRRDVEKFLSKKRKFPKNYMSQYFKLLEKFQIALPIGEEYLLVPSSLSDHRPVIELPHCENSEIIIRLYEMPYFPMGFWSRLINRLLEISPYMLSGRERALRPNRMYWRQGIYLNWSPEAYCLVGSEVLDNHPESFLKITVPSCRKGCILLGQVVDHIDSLMEEWFPGLLEIDICGEGETLLKKWALYSFNDGEEHQKILLDDLMKKAEEGDLLVNPDQPRLTIPISQIAPDLILADLPRNIMLNNDELEFEQAPEFLLGDGSFGSVYRAAYEGEEVAVKIFNKHTSLRLLRQELVVLCHLHHPSLISLLAAGIRPRMLVMELASKGSLDRLLQQDKASLTRTLQHRIALHVADGLRYLHSAMIIYRDLKPHNVLLFTLYPNAAIIAKIADYGIAQYCCRMGIKTSEGTPGFRAPEVARGNVIYNQQADVYSFGLLLYDILTTGGRIVEGLKFPNEFDELEIQGKLPDPVKEYGCAPWPMVEKLIKQCLKENPQERPTSAQVFDILNSAELVCLTRRILLPKNVIVECMVATHHNSRNASIWLGCGHTDRGQLSFLDLNTEGYTSEEVADSRILCLALVHLPVEKESWIVSGTQSGTLLVINTEDGKKRHTLEKMTDSVTCLYCNSFSKQSKQKNFLLVGTADGKLAIFEDKTVKLKGAAPLKILNIGNVSTPLMCLSESTNSTERNVMWGGCGTKIFSFSNDFTIQKLIETRTSQLFSYAAFSDSNIITVVVDTALYIAKQNSPVVEVWDKKTEKLCGLIDCVHFLREVMVKENKESKHKMSYSGRVKTLCLQKNTALWIGTGGGHILLLDLSTRRLIRVIYNFCNSVRVMMTAQLGSLKNVMLVLGYNRKNTEGTQKQKEIQSCLTVWDINLPHEVQNLEKHIEVRKELAEKMRRTSVE
T09197	DRUGINFO	D00FKF	Pyrrolo-pyridine derivative 2	Patented
T09197	DRUGINFO	D08WVK	Oxindole derivative 3	Patented
T09197	DRUGINFO	D0D6DN	Aminopyridine derivative 3	Patented
T09197	DRUGINFO	D0QK7K	Oxindole derivative 4	Patented

T09977	TARGETID	T09977
T09977	UNIPROID	LRRK2_HUMAN
T09977	TARGNAME	Leucine-rich repeat kinase 2 S935 phosphorylation (LRRK2 pS935)
T09977	GENENAME	LRRK2
T09977	TARGTYPE	Patented-recorded
T09977	SYNONYMS	PARK8 S935 phosphorylation; LRRK2 S935 phosphorylation; Dardarin S935 phosphorylation
T09977	FUNCTION	The process involves activation of nicotinic acid adenine dinucleotide phosphate (NAADP) receptors, increase in lysosomal pH, and calcium release from lysosomes. Together with RAB29, plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner. Regulates neuronal process morphology in the intact central nervous system (CNS). Plays a role in synaptic vesicle trafficking. Phosphorylates PRDX3. Has GTPase activity. May play a role in the phosphorylation of proteins central to Parkinson disease. Plays an important role in recuiting SEC16A to endoplasmic reticulum exit sites (ERES) and in regulating ER to Golgi vesicle-mediated transport and ERES organization. Positively regulates autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway.
T09977	PDBSTRUC	6DLP; 6DLO; 5MYC; 5MY9; 3D6T
T09977	BIOCLASS	Kinase
T09977	ECNUMBER	EC 2.7.11.1
T09977	SEQUENCE	MASGSCQGCEEDEETLKKLIVRLNNVQEGKQIETLVQILEDLLVFTYSERASKLFQGKNIHVPLLIVLDSYMRVASVQQVGWSLLCKLIEVCPGTMQSLMGPQDVGNDWEVLGVHQLILKMLTVHNASVNLSVIGLKTLDLLLTSGKITLLILDEESDIFMLIFDAMHSFPANDEVQKLGCKALHVLFERVSEEQLTEFVENKDYMILLSALTNFKDEEEIVLHVLHCLHSLAIPCNNVEVLMSGNVRCYNIVVEAMKAFPMSERIQEVSCCLLHRLTLGNFFNILVLNEVHEFVVKAVQQYPENAALQISALSCLALLTETIFLNQDLEEKNENQENDDEGEEDKLFWLEACYKALTWHRKNKHVQEAACWALNNLLMYQNSLHEKIGDEDGHFPAHREVMLSMLMHSSSKEVFQASANALSTLLEQNVNFRKILLSKGIHLNVLELMQKHIHSPEVAESGCKMLNHLFEGSNTSLDIMAAVVPKILTVMKRHETSLPVQLEALRAILHFIVPGMPEESREDTEFHHKLNMVKKQCFKNDIHKLVLAALNRFIGNPGIQKCGLKVISSIVHFPDALEMLSLEGAMDSVLHTLQMYPDDQEIQCLGLSLIGYLITKKNVFIGTGHLLAKILVSSLYRFKDVAEIQTKGFQTILAILKLSASFSKLLVHHSFDLVIFHQMSSNIMEQKDQQFLNLCCKCFAKVAMDDYLKNVMLERACDQNNSIMVECLLLLGADANQAKEGSSLICQVCEKESSPKLVELLLNSGSREQDVRKALTISIGKGDSQIISLLLRRLALDVANNSICLGGFCIGKVEPSWLGPLFPDKTSNLRKQTNIASTLARMVIRYQMKSAVEEGTASGSDGNFSEDVLSKFDEWTFIPDSSMDSVFAQSDDLDSEGSEGSFLVKKKSNSISVGEFYRDAVLQRCSPNLQRHSNSLGPIFDHEDLLKRKRKILSSDDSLRSSKLQSHMRHSDSISSLASEREYITSLDLSANELRDIDALSQKCCISVHLEHLEKLELHQNALTSFPQQLCETLKSLTHLDLHSNKFTSFPSYLLKMSCIANLDVSRNDIGPSVVLDPTVKCPTLKQFNLSYNQLSFVPENLTDVVEKLEQLILEGNKISGICSPLRLKELKILNLSKNHISSLSENFLEACPKVESFSARMNFLAAMPFLPPSMTILKLSQNKFSCIPEAILNLPHLRSLDMSSNDIQYLPGPAHWKSLNLRELLFSHNQISILDLSEKAYLWSRVEKLHLSHNKLKEIPPEIGCLENLTSLDVSYNLELRSFPNEMGKLSKIWDLPLDELHLNFDFKHIGCKAKDIIRFLQQRLKKAVPYNRMKLMIVGNTGSGKTTLLQQLMKTKKSDLGMQSATVGIDVKDWPIQIRDKRKRDLVLNVWDFAGREEFYSTHPHFMTQRALYLAVYDLSKGQAEVDAMKPWLFNIKARASSSPVILVGTHLDVSDEKQRKACMSKITKELLNKRGFPAIRDYHFVNATEESDALAKLRKTIINESLNFKIRDQLVVGQLIPDCYVELEKIILSERKNVPIEFPVIDRKRLLQLVRENQLQLDENELPHAVHFLNESGVLLHFQDPALQLSDLYFVEPKWLCKIMAQILTVKVEGCPKHPKGIISRRDVEKFLSKKRKFPKNYMSQYFKLLEKFQIALPIGEEYLLVPSSLSDHRPVIELPHCENSEIIIRLYEMPYFPMGFWSRLINRLLEISPYMLSGRERALRPNRMYWRQGIYLNWSPEAYCLVGSEVLDNHPESFLKITVPSCRKGCILLGQVVDHIDSLMEEWFPGLLEIDICGEGETLLKKWALYSFNDGEEHQKILLDDLMKKAEEGDLLVNPDQPRLTIPISQIAPDLILADLPRNIMLNNDELEFEQAPEFLLGDGSFGSVYRAAYEGEEVAVKIFNKHTSLRLLRQELVVLCHLHHPSLISLLAAGIRPRMLVMELASKGSLDRLLQQDKASLTRTLQHRIALHVADGLRYLHSAMIIYRDLKPHNVLLFTLYPNAAIIAKIADYGIAQYCCRMGIKTSEGTPGFRAPEVARGNVIYNQQADVYSFGLLLYDILTTGGRIVEGLKFPNEFDELEIQGKLPDPVKEYGCAPWPMVEKLIKQCLKENPQERPTSAQVFDILNSAELVCLTRRILLPKNVIVECMVATHHNSRNASIWLGCGHTDRGQLSFLDLNTEGYTSEEVADSRILCLALVHLPVEKESWIVSGTQSGTLLVINTEDGKKRHTLEKMTDSVTCLYCNSFSKQSKQKNFLLVGTADGKLAIFEDKTVKLKGAAPLKILNIGNVSTPLMCLSESTNSTERNVMWGGCGTKIFSFSNDFTIQKLIETRTSQLFSYAAFSDSNIITVVVDTALYIAKQNSPVVEVWDKKTEKLCGLIDCVHFLREVMVKENKESKHKMSYSGRVKTLCLQKNTALWIGTGGGHILLLDLSTRRLIRVIYNFCNSVRVMMTAQLGSLKNVMLVLGYNRKNTEGTQKQKEIQSCLTVWDINLPHEVQNLEKHIEVRKELAEKMRRTSVE
T09977	DRUGINFO	D0FS9X	Fused thiophene derivative 1	Patented

T62266	TARGETID	T62266
T62266	UNIPROID	I23O2_HUMAN
T62266	TARGNAME	Indoleamine 2,3-dioxygenase 2 (IDO2)
T62266	GENENAME	IDO2
T62266	TARGTYPE	Patented-recorded
T62266	SYNONYMS	Indoleamine-pyrrole 2,3-dioxygenase-like protein 1; Indoleamine 2,3-dioxygenase-like protein 1; INDOL1; IDO-2
T62266	FUNCTION	Involved in immune regulation. May not play a significant role in tryptophan-related tumoral resistance. Catalyzes the first and rate limiting step of the catabolism of the essential amino acid tryptophan along the kynurenine pathway.
T62266	BIOCLASS	Oxygenase
T62266	ECNUMBER	EC 1.13.11.-
T62266	SEQUENCE	MLHFHYYDTSNKIMEPHRPNVKTAVPLSLESYHISEEYGFLLPDSLKELPDHYRPWMEIANKLPQLIDAHQLQAHVDKMPLLSCQFLKGHREQRLAHLVLSFLTMGYVWQEGEAQPAEVLPRNLALPFVEVSRNLGLPPILVHSDLVLTNWTKKDPDGFLEIGNLETIISFPGGESLHGFILVTALVEKEAVPGIKALVQATNAILQPNQEALLQALQRLRLSIQDITKTLGQMHDYVDPDIFYAGIRIFLSGWKDNPAMPAGLMYEGVSQEPLKYSGGSAAQSTVLHAFDEFLGIRHSKESGDFLYRMRDYMPPSHKAFIEDIHSAPSLRDYILSSGQDHLLTAYNQCVQALAELRSYHITMVTKYLITAAAKAKHGKPNHLPGPPQALKDRGTGGTAVMSFLKSVRDKTLESILHPRG
T62266	DRUGINFO	D04BZI	2,3-diamino-benzo[b]thiophene derivative 4	Patented
T62266	DRUGINFO	D04MIQ	PMID27172114-Compound-30	Patented
T62266	DRUGINFO	D05TIP	2,3-diamino-benzo[b]thiophene derivative 2	Patented
T62266	DRUGINFO	D05ZGX	2,3-diamino-benzo[b]thiophene derivative 8	Patented
T62266	DRUGINFO	D0F4VD	2,3-diamino-benzo[b]thiophene derivative 7	Patented
T62266	DRUGINFO	D0FF6H	2,3-diamino-benzo[b]thiophene derivative 6	Patented
T62266	DRUGINFO	D0HV0Y	2,3-diamino-benzo[b]thiophene derivative 5	Patented
T62266	DRUGINFO	D0RA7I	2,3-diamino-benzo[b]thiophene derivative 1	Patented

T24823	TARGETID	T24823
T24823	UNIPROID	KDM1B_HUMAN
T24823	TARGNAME	Lysine-specific histone demethylase 1B (KDM1B)
T24823	GENENAME	KDM1B
T24823	TARGTYPE	Patented-recorded
T24823	SYNONYMS	Lysine-specific histone demethylase 2; LSD2; Flavin-containing amine oxidase domain-containing protein 1; C6orf193; AOF1
T24823	FUNCTION	Required for de novo DNA methylation of a subset of imprinted genes during oogenesis. Acts by oxidizing the substrate by FAD to generate the corresponding imine that is subsequently hydrolyzed. Demethylates both mono- and di-methylated 'Lys-4' of histone H3. Has no effect on tri-methylated 'Lys-4', mono-, di- or tri-methylated 'Lys-9', mono-, di- or tri-methylated 'Lys-27', mono-, di- or tri-methylated 'Lys-36' of histone H3, or on mono-, di- or tri-methylated 'Lys-20' of histone H4. Histone demethylase that demethylates 'Lys-4' of histone H3, a specific tag for epigenetic transcriptional activation, thereby acting as a corepressor.
T24823	PDBSTRUC	6R25; 6R1U; 4HSU; 4GUU; 4GUT
T24823	BIOCLASS	CH-NH(2) donor oxidoreductase
T24823	ECNUMBER	EC 1.-.-.-
T24823	SEQUENCE	MATPRGRTKKKASFDHSPDSLPLRSSGRQAKKKATETTDEDEDGGSEKKYRKCEKAGCTATCPVCFASASERCAKNGYTSRWYHLSCGEHFCNECFDHYYRSHKDGYDKYTTWKKIWTSNGKTEPSPKAFMADQQLPYWVQCTKPECRKWRQLTKEIQLTPQIAKTYRCGMKPNTAIKPETSDHCSLPEDLRVLEVSNHWWYSMLILPPLLKDSVAAPLLSAYYPDCVGMSPSCTSTNRAAATGNASPGKLEHSKAALSVHVPGMNRYFQPFYQPNECGKALCVRPDVMELDELYEFPEYSRDPTMYLALRNLILALWYTNCKEALTPQKCIPHIIVRGLVRIRCVQEVERILYFMTRKGLINTGVLSVGADQYLLPKDYHNKSVIIIGAGPAGLAAARQLHNFGIKVTVLEAKDRIGGRVWDDKSFKGVTVGRGAQIVNGCINNPVALMCEQLGISMHKFGERCDLIQEGGRITDPTIDKRMDFHFNALLDVVSEWRKDKTQLQDVPLGEKIEEIYKAFIKESGIQFSELEGQVLQFHLSNLEYACGSNLHQVSARSWDHNEFFAQFAGDHTLLTPGYSVIIEKLAEGLDIQLKSPVQCIDYSGDEVQVTTTDGTGYSAQKVLVTVPLALLQKGAIQFNPPLSEKKMKAINSLGAGIIEKIALQFPYRFWDSKVQGADFFGHVPPSASKRGLFAVFYDMDPQKKHSVLMSVIAGEAVASVRTLDDKQVLQQCMATLRELFKEQEVPDPTKYFVTRWSTDPWIQMAYSFVKTGGSGEAYDIIAEDIQGTVFFAGEATNRHFPQTVTGAYLSGVREASKIAAF
T24823	DRUGINFO	D09OMM	PMID27019002-Compound-48	Patented
T24823	DRUGINFO	D0WO5W	PMID27019002-Compound-47	Patented
T24823	DRUGINFO	D0Z7HE	PMID27019002-Compound-46	Patented
T24823	DRUGINFO	D04OHC	Tarnylcypromine derivative 2	Patented
T24823	DRUGINFO	D0O7IH	Tarnylcypromine derivative 3	Patented

T12952	TARGETID	T12952
T12952	UNIPROID	UBP33_HUMAN
T12952	TARGNAME	VHL-interacting deubiquitinating enzyme 1 (VDU1)
T12952	GENENAME	USP33
T12952	TARGTYPE	Patented-recorded
T12952	SYNONYMS	hVDU1; Ubiquitin-specific-processing protease 33; Ubiquitin thioesterase 33; Ubiquitin carboxyl-terminal hydrolase 33; KIAA1097; Deubiquitinating enzyme 33
T12952	FUNCTION	Involved in regulation of centrosome duplication by mediating deubiquitination of CCP110 in S and G2/M phase, leading to stabilize CCP110 during the period which centrioles duplicate and elongate. Involved in cell migration via its interaction with intracellular domain of ROBO1, leading to regulate the Slit signaling. Plays a role in commissural axon guidance cross the ventral midline of the neural tube in a Slit-dependent manner, possibly by mediating the deubiquitination of ROBO1. Acts as a regulator of G-protein coupled receptor (GPCR) signaling by mediating the deubiquitination of beta-arrestins (ARRB1 and ARRB2) and beta-2 adrenergic receptor (ADRB2). Plays a central role in ADRB2 recycling and resensitization after prolonged agonist stimulation by constitutively binding ADRB2, mediating deubiquitination of ADRB2 and inhibiting lysosomal trafficking of ADRB2. Upon dissociation, it is probably transferred to the translocated beta-arrestins, leading to beta-arrestins deubiquitination and disengagement from ADRB2. This suggests the existence of a dynamic exchange between the ADRB2 and beta-arrestins. Deubiquitinates DIO2, thereby regulating thyroid hormone regulation. Mediates deubiquitination of both 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains. Deubiquitinating enzyme involved in various processes such as centrosome duplication, cellular migration and beta-2 adrenergic receptor/ADRB2 recycling.
T12952	PDBSTRUC	2UZG
T12952	BIOCLASS	Peptidase
T12952	ECNUMBER	EC 3.4.19.12
T12952	SEQUENCE	MTGSNSHITILTLKVLPHFESLGKQEKIPNKMSAFRNHCPHLDSVGEITKEDLIQKSLGTCQDCKVQGPNLWACLENRCSYVGCGESQVDHSTIHSQETKHYLTVNLTTLRVWCYACSKEVFLDRKLGTQPSLPHVRQPHQIQENSVQDFKIPSNTTLKTPLVAVFDDLDIEADEEDELRARGLTGLKNIGNTCYMNAALQALSNCPPLTQFFLDCGGLARTDKKPAICKSYLKLMTELWHKSRPGSVVPTTLFQGIKTVNPTFRGYSQQDAQEFLRCLMDLLHEELKEQVMEVEEDPQTITTEETMEEDKSQSDVDFQSCESCSNSDRAENENGSRCFSEDNNETTMLIQDDENNSEMSKDWQKEKMCNKINKVNSEGEFDKDRDSISETVDLNNQETVKVQIHSRASEYITDVHSNDLSTPQILPSNEGVNPRLSASPPKSGNLWPGLAPPHKKAQSASPKRKKQHKKYRSVISDIFDGTIISSVQCLTCDRVSVTLETFQDLSLPIPGKEDLAKLHSSSHPTSIVKAGSCGEAYAPQGWIAFFMEYVKRFVVSCVPSWFWGPVVTLQDCLAAFFARDELKGDNMYSCEKCKKLRNGVKFCKVQNFPEILCIHLKRFRHELMFSTKISTHVSFPLEGLDLQPFLAKDSPAQIVTYDLLSVICHHGTASSGHYIAYCRNNLNNLWYEFDDQSVTEVSESTVQNAEAYVLFYRKSSEEAQKERRRISNLLNIMEPSLLQFYISRQWLNKFKTFAEPGPISNNDFLCIHGGVPPRKAGYIEDLVLMLPQNIWDNLYSRYGGGPAVNHLYICHTCQIEAEKIEKRRKTELEIFIRLNRAFQKEDSPATFYCISMQWFREWESFVKGKDGDPPGPIDNTKIAVTKCGNVMLRQGADSGQISEETWNFLQSIYGGGPEVILRPPVVHVDPDILQAEEKIEVETRSL

T98698	TARGETID	T98698
T98698	FORMERID	TTDI03261
T98698	UNIPROID	HDAC7_HUMAN
T98698	TARGNAME	Histone deacetylase 7 (HDAC7)
T98698	GENENAME	HDAC7
T98698	TARGTYPE	Patented-recorded
T98698	SYNONYMS	Histone deacetylase 7A; HDAC7A; HD7a; HD7
T98698	FUNCTION	Gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Involved in muscle maturation by repressing transcription of myocyte enhancer factors such as MEF2A, MEF2B and MEF2C. During muscle differentiation, it shuttles into the cytoplasm, allowing the expression of myocyte enhancer factors. May be involved in Epstein-Barr virus (EBV) latency, possibly by repressing the viral BZLF1 gene. Positively regulates the transcriptional repressor activity of FOXP3. Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4).
T98698	PDBSTRUC	3ZNS; 3ZNR; 3C10; 3C0Z; 3C0Y
T98698	BIOCLASS	Carbon-nitrogen hydrolase
T98698	ECNUMBER	EC 3.5.1.98
T98698	SEQUENCE	MDLRVGQRPPVEPPPEPTLLALQRPQRLHHHLFLAGLQQQRSVEPMRLSMDTPMPELQVGPQEQELRQLLHKDKSKRSAVASSVVKQKLAEVILKKQQAALERTVHPNSPGIPYRTLEPLETEGATRSMLSSFLPPVPSLPSDPPEHFPLRKTVSEPNLKLRYKPKKSLERRKNPLLRKESAPPSLRRRPAETLGDSSPSSSSTPASGCSSPNDSEHGPNPILGSEALLGQRLRLQETSVAPFALPTVSLLPAITLGLPAPARADSDRRTHPTLGPRGPILGSPHTPLFLPHGLEPEAGGTLPSRLQPILLLDPSGSHAPLLTVPGLGPLPFHFAQSLMTTERLSGSGLHWPLSRTRSEPLPPSATAPPPPGPMQPRLEQLKTHVQVIKRSAKPSEKPRLRQIPSAEDLETDGGGPGQVVDDGLEHRELGHGQPEARGPAPLQQHPQVLLWEQQRLAGRLPRGSTGDTVLLPLAQGGHRPLSRAQSSPAAPASLSAPEPASQARVLSSSETPARTLPFTTGLIYDSVMLKHQCSCGDNSRHPEHAGRIQSIWSRLQERGLRSQCECLRGRKASLEELQSVHSERHVLLYGTNPLSRLKLDNGKLAGLLAQRMFVMLPCGGVGVDTDTIWNELHSSNAARWAAGSVTDLAFKVASRELKNGFAVVRPPGHHADHSTAMGFCFFNSVAIACRQLQQQSKASKILIVDWDVHHGNGTQQTFYQDPSVLYISLHRHDDGNFFPGSGAVDEVGAGSGEGFNVNVAWAGGLDPPMGDPEYLAAFRIVVMPIAREFSPDLVLVSAGFDAAEGHPAPLGGYHVSAKCFGYMTQQLMNLAGGAVVLALEGGHDLTAICDASEACVAALLGNRVDPLSEEGWKQKPNLNAIRSLEAVIRVHSKYWGCMQRLASCPDSWVPRVPGADKEEVEAVTALASLSVGILAEDRPSEQLVEEEEPMNL
T98698	DRUGINFO	D0YN2T	PMID29671355-Compound-45a	Patented
T98698	DRUGINFO	D0CH8Q	PMID29671355-Compound-56	Patented
T98698	DRUGINFO	D0M0RE	PMID29671355-Compound-67	Patented
T98698	DRUGINFO	D0DI9S	PMID29671355-Compound-31	Patented
T98698	DRUGINFO	D0LP1K	PMID29671355-Compound-21	Patented
T98698	DRUGINFO	D07WAT	PMID29671355-Compound-62	Patented
T98698	DRUGINFO	D0BP8I	PMID29671355-Compound-43	Patented
T98698	DRUGINFO	D0RA0D	PMID29671355-Compound-25	Patented
T98698	DRUGINFO	D0R7JA	TMP269	Investigative

T39486	TARGETID	T39486
T39486	FORMERID	TTDI03164
T39486	UNIPROID	DYRK2_HUMAN
T39486	TARGNAME	Dual-specificity tyrosine-phosphorylation regulated kinase 2 (DYRK2)
T39486	GENENAME	DYRK2
T39486	TARGTYPE	Patented-recorded
T39486	SYNONYMS	Dual specificity tyrosine-phosphorylation-regulated kinase 2
T39486	FUNCTION	Functions in part via its role in ubiquitin-dependent proteasomal protein degradation. Functions downstream of ATM and phosphorylates p53/TP53 at 'Ser-46', and thereby contributes to the induction of apoptosis in response to DNA damage. Phosphorylates NFATC1, and thereby inhibits its accumulation in the nucleus and its transcription factor activity. Phosphorylates EIF2B5 at 'Ser-544', enabling its subsequent phosphorylation and inhibition by GSK3B. Likewise, phosphorylation of NFATC1, CRMP2/DPYSL2 and CRMP4/DPYSL3 promotes their subsequent phosphorylation by GSK3B. May play a general role in the priming of GSK3 substrates. Inactivates GYS1 by phosphorylation at 'Ser-641', and potentially also a second phosphorylation site, thus regulating glycogen synthesis. Mediates EDVP E3 ligase complex formation and is required for the phosphorylation and subsequent degradation of KATNA1. Phosphorylates TERT at 'Ser-457', promoting TERT ubiquitination by the EDVP complex. Phosphorylates SIAH2, and thereby increases its ubiquitin ligase activity. Promotes the proteasomal degradation of MYC and JUN, and thereby regulates progress through the mitotic cell cycle and cell proliferation. Promotes proteasomal degradation of GLI2 and GLI3, and thereby plays a role in smoothened and sonic hedgehog signaling. Plays a role in cytoskeleton organization and neurite outgrowth via its phosphorylation of DCX and DPYSL2. Phosphorylates CRMP2/DPYSL2, CRMP4/DPYSL3, DCX, EIF2B5, EIF4EBP1, GLI2, GLI3, GYS1, JUN, MDM2, MYC, NFATC1, p53/TP53, TAU/MAPT and KATNA1. Can phosphorylate histone H1, histone H3 and histone H2B (in vitro). Can phosphorylate CARHSP1 (in vitro). Serine/threonine-protein kinase involved in the regulation of the mitotic cell cycle, cell proliferation, apoptosis, organization of the cytoskeleton and neurite outgrowth.
T39486	PDBSTRUC	5ZTN; 5LXD; 5LXC; 4AZF; 3KVW
T39486	BIOCLASS	Kinase
T39486	ECNUMBER	EC 2.7.12.1
T39486	SEQUENCE	MLTRKPSAAAPAAYPTGRGGDSAVRQLQASPGLGAGATRSGVGTGPPSPIALPPLRASNAAAAAHTIGGSKHTMNDHLHVGSHAHGQIQVQQLFEDNSNKRTVLTTQPNGLTTVGKTGLPVVPERQLDSIHRRQGSSTSLKSMEGMGKVKATPMTPEQAMKQYMQKLTAFEHHEIFSYPEIYFLGLNAKKRQGMTGGPNNGGYDDDQGSYVQVPHDHVAYRYEVLKVIGKGSFGQVVKAYDHKVHQHVALKMVRNEKRFHRQAAEEIRILEHLRKQDKDNTMNVIHMLENFTFRNHICMTFELLSMNLYELIKKNKFQGFSLPLVRKFAHSILQCLDALHKNRIIHCDLKPENILLKQQGRSGIKVIDFGSSCYEHQRVYTYIQSRFYRAPEVILGARYGMPIDMWSLGCILAELLTGYPLLPGEDEGDQLACMIELLGMPSQKLLDASKRAKNFVSSKGYPRYCTVTTLSDGSVVLNGGRSRRGKLRGPPESREWGNALKGCDDPLFLDFLKQCLEWDPAVRMTPGQALRHPWLRRRLPKPPTGEKTSVKRITESTGAITSISKLPPPSSSASKLRTNLAQMTDANGNIQQRTVLPKLVS
T39486	DRUGINFO	D02GEJ	PMID28766366-Compound-Scheme16DMAT	Patented
T39486	DRUGINFO	D04SYJ	PMID28766366-Compound-Scheme14BINDY	Patented
T39486	DRUGINFO	D00OWF	Harmine	Patented
T39486	DRUGINFO	D02DBH	PMID28766366-Compound-Scheme21Left	Patented
T39486	DRUGINFO	D07BWC	PMID28766366-Compound-Scheme21Right	Patented
T39486	DRUGINFO	D04IMY	leucettine L41	Investigative

T14894	TARGETID	T14894
T14894	UNIPROID	CASPA_HUMAN
T14894	TARGNAME	Caspase-10 (CASP10)
T14894	GENENAME	CASP10
T14894	TARGTYPE	Patented-recorded
T14894	SYNONYMS	MCH4; ICE-like apoptotic protease 4; FLICE2; FAS-associated death domain protein interleukin-1B-converting enzyme 2; Caspase-10 subunit p23/17; Caspase-10 subunit p12; CASP-10; Apoptotic protease Mch-4
T14894	FUNCTION	Recruited to both Fas- and TNFR-1 receptors in a FADD dependent manner. May participate in the granzyme B apoptotic pathways. Cleaves and activates caspase-3, -4, -6, -7, -8, and -9. Hydrolyzes the small- molecule substrates, Tyr-Val-Ala-Asp-|-AMC and Asp-Glu-Val-Asp-|-AMC. Involved in the activation cascade of caspases responsible for apoptosis execution.
T14894	BIOCLASS	Peptidase
T14894	ECNUMBER	EC 3.4.22.63
T14894	SEQUENCE	MKSQGQHWYSSSDKNCKVSFREKLLIIDSNLGVQDVENLKFLCIGLVPNKKLEKSSSASDVFEHLLAEDLLSEEDPFFLAELLYIIRQKKLLQHLNCTKEEVERLLPTRQRVSLFRNLLYELSEGIDSENLKDMIFLLKDSLPKTEMTSLSFLAFLEKQGKIDEDNLTCLEDLCKTVVPKLLRNIEKYKREKAIQIVTPPVDKEAESYQGEEELVSQTDVKTFLEALPQESWQNKHAGSNGNRATNGAPSLVSRGMQGASANTLNSETSTKRAAVYRMNRNHRGLCVIVNNHSFTSLKDRQGTHKDAEILSHVFQWLGFTVHIHNNVTKVEMEMVLQKQKCNPAHADGDCFVFCILTHGRFGAVYSSDEALIPIREIMSHFTALQCPRLAEKPKLFFIQACQGEEIQPSVSIEADALNPEQAPTSLQDSIPAEADFLLGLATVPGYVSFRHVEEGSWYIQSLCNHLKKLVPRMLKFLEKTMEIRGRKRTVWGAKQISATSLPTAISAQTPRPPMRRWSSVS

T57050	TARGETID	T57050
T57050	UNIPROID	ZUP1_HUMAN
T57050	TARGNAME	Zinc finger-containing ubiquitin peptidase 1 (ZUP1)
T57050	GENENAME	ZUP1
T57050	TARGTYPE	Patented-recorded
T57050	SYNONYMS	Zinc finger with UFM1-specific peptidase domain protein; ZUFSP; Lys-63-specific deubiquitinase ZUFSP; DUB; C6orf113
T57050	FUNCTION	Shows only weak activity against 'Lys-11' and 'Lys-48'-linked chains. Plays an important role in genome stability pathways, functioning to prevent spontaneous DNA damage and also promote cellular survival in response to exogenous DNA damage. Modulates the ubiquitination status of replication protein A (RPA) complex proteins in response to replication stress. Deubiquitinase with endodeubiquitinase activity that specifically interacts with and cleaves 'Lys-63'-linked long polyubiquitin chains.
T57050	PDBSTRUC	6FGE; 6EI1
T57050	BIOCLASS	Peptidase
T57050	ECNUMBER	EC 3.4.19.12
T57050	SEQUENCE	MLSCNICGETVTSEPDMKAHLIVHMESEIICPFCKLSGVNYDEMCFHIETAHFEQNTLERNFERINTVQYGTSDNKKDNTLQCGMEVNSSILSGCASNHPKNSAQNLTKDSTLKHEGFYSENLTESRKFLKSREKQSSLTEIKGSVYETTYSPPECPFCGKIEEHSEDMETHVKTKHANLLDIPLEDCDQPLYDCPMCGLICTNYHILQEHVDLHLEENSFQQGMDRVQCSGDLQLAHQLQQEEDRKRRSEESRQEIEEFQKLQRQYGLDNSGGYKQQQLRNMEIEVNRGRMPPSEFHRRKADMMESLALGFDDGKTKTSGIIEALHRYYQNAATDVRRVWLSSVVDHFHSSLGDKGWGCGYRNFQMLLSSLLQNDAYNDCLKGMLIPCIPKIQSMIEDAWKEGFDPQGASQLNNRLQGTKAWIGACEVYILLTSLRVKCHIVDFHKSTGPLGTHPRLFEWILNYYSSEGEGSPKVVCTSKPPIYLQHQGHSRTVIGIEEKKNRTLCLLILDPGCPSREMQKLLKQDIEASSLKQLRKSMGNLKHKQYQILAVEGALSLEEKLARRQASQVFTAEKIP
T57050	DRUGINFO	D04MQF	Tricyclic heterocycle derivative 3	Patented
T57050	DRUGINFO	D0EG8Y	PMID26077642-Compound-Figure3H	Patented
T57050	DRUGINFO	D0EM8D	PMID26077642-Compound-Figure3G	Patented
T57050	DRUGINFO	D0HQ8X	Azepan-4-one derivative 1	Patented
T57050	DRUGINFO	D0PY0H	Azepan-4-one derivative 2	Patented

T42247	TARGETID	T42247
T42247	FORMERID	TTDI03049
T42247	UNIPROID	BIRC7_HUMAN
T42247	TARGNAME	Melanoma inhibitor of apoptosis protein (ML-IAP)
T42247	GENENAME	BIRC7
T42247	TARGTYPE	Patented-recorded
T42247	SYNONYMS	UNQ5800/PRO19607/PRO21344; RNF50; RING-type E3 ubiquitin transferase BIRC7; RING finger protein 50; MLIAP; Livin; Kidney inhibitor of apoptosis protein; KIAP; Baculoviral IAP repeat-containing protein 7
T42247	FUNCTION	Its anti-apoptotic activity is mediated through the inhibition of CASP3, CASP7 and CASP9, as well as by its E3 ubiquitin-protein ligase activity. As it is a weak caspase inhibitor, its anti-apoptotic activity is thought to be due to its ability to ubiquitinate DIABLO/SMAC targeting it for degradation thereby promoting cell survival. May contribute to caspase inhibition, by blocking the ability of DIABLO/SMAC to disrupt XIAP/BIRC4-caspase interactions. Protects against apoptosis induced by TNF or by chemical agents such as adriamycin, etoposide or staurosporine. Suppression of apoptosis is mediated by activation of MAPK8/JNK1, and possibly also of MAPK9/JNK2. This activation depends on TAB1 and NR2C2/TAK1. In vitro, inhibits CASP3 and proteolytic activation of pro-CASP9. Isoform 1 blocks staurosporine-induced apoptosis. Isoform 2 blocks etoposide-induced apoptosis. Isoform 2 protects against natural killer (NK) cell killing whereas isoform 1 augments killing. Apoptotic regulator capable of exerting proapoptotic and anti-apoptotic activities and plays crucial roles in apoptosis, cell proliferation, and cell cycle control.
T42247	PDBSTRUC	4AUQ; 3UW5; 3GTA; 3GT9; 3F7I
T42247	BIOCLASS	Acyltransferase
T42247	ECNUMBER	EC 2.3.2.27
T42247	SEQUENCE	MGPKDSAKCLHRGPQPSHWAAGDGPTQERCGPRSLGSPVLGLDTCRAWDHVDGQILGQLRPLTEEEEEEGAGATLSRGPAFPGMGSEELRLASFYDWPLTAEVPPELLAAAGFFHTGHQDKVRCFFCYGGLQSWKRGDDPWTEHAKWFPSCQFLLRSKGRDFVHSVQETHSQLLGSWDPWEEPEDAAPVAPSVPASGYPELPTPRREVQSESAQEPGGVSPAEAQRAWWVLEPPGARDVEAQLRRLQEERTCKVCLDRAVSIVFVPCGHLVCAECAPGLQLCPICRAPVRSRVRTFLS
T42247	DRUGINFO	D09VAX	PMID25980951-Compound-6	Patented

T97903	TARGETID	T97903
T97903	UNIPROID	HDA11_HUMAN
T97903	TARGNAME	Histone deacetylase 11 (HDAC11)
T97903	GENENAME	HDAC11
T97903	TARGTYPE	Patented-recorded
T97903	SYNONYMS	HD11
T97903	FUNCTION	Gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4).
T97903	BIOCLASS	Carbon-nitrogen hydrolase
T97903	ECNUMBER	EC 3.5.1.98
T97903	SEQUENCE	MLHTTQLYQHVPETRWPIVYSPRYNITFMGLEKLHPFDAGKWGKVINFLKEEKLLSDSMLVEAREASEEDLLVVHTRRYLNELKWSFAVATITEIPPVIFLPNFLVQRKVLRPLRTQTGGTIMAGKLAVERGWAINVGGGFHHCSSDRGGGFCAYADITLAIKFLFERVEGISRATIIDLDAHQGNGHERDFMDDKRVYIMDVYNRHIYPGDRFAKQAIRRKVELEWGTEDDEYLDKVERNIKKSLQEHLPDVVVYNAGTDILEGDRLGGLSISPAGIVKRDELVFRMVRGRRVPILMVTSGGYQKRTARIIADSILNLFGLGLIGPESPSVSAQNSDTPLLPPAVP
T97903	DRUGINFO	D04JWR	PMID29671355-Compound-36	Patented
T97903	DRUGINFO	D00HXJ	PMID29671355-Compound-23	Patented
T97903	DRUGINFO	D0N2DK	PMID29671355-Compound-44	Patented
T97903	DRUGINFO	D0LP1K	PMID29671355-Compound-21	Patented
T97903	DRUGINFO	D07WAT	PMID29671355-Compound-62	Patented
T97903	DRUGINFO	D0BP8I	PMID29671355-Compound-43	Patented
T97903	DRUGINFO	D0RA0D	PMID29671355-Compound-25	Patented

T81452	TARGETID	T81452
T81452	UNIPROID	ABHD6_HUMAN
T81452	TARGNAME	Monoacylglycerol lipase ABHD6 (ABHD6)
T81452	GENENAME	ABHD6
T81452	TARGTYPE	Patented-recorded
T81452	SYNONYMS	Abhydrolase domain-containing protein 6; 2-arachidonoylglycerol hydrolase
T81452	FUNCTION	Lipase that preferentially hydrolysis medium-chain saturated monoacylglycerols including 2-arachidonoylglycerol. Through 2-arachidonoylglycerol degradation may regulate endocannabinoid signaling pathways. Also has a lysophosphatidyl lipase activity with a preference for lysophosphatidylglycerol among other lysophospholipids. Also able to degrade bis(monoacylglycero)phosphate (BMP) and constitutes the major enzyme for BMP catabolism. BMP, also known as lysobisphosphatidic acid, is enriched in late endosomes and lysosomes and plays a key role in the formation of intraluminal vesicles and in lipid sorting.
T81452	BIOCLASS	Carboxylic ester hydrolase
T81452	ECNUMBER	EC 3.1.1.23
T81452	SEQUENCE	MDLDVVNMFVIAGGTLAIPILAFVASFLLWPSALIRIYYWYWRRTLGMQVRYVHHEDYQFCYSFRGRPGHKPSILMLHGFSAHKDMWLSVVKFLPKNLHLVCVDMPGHEGTTRSSLDDLSIDGQVKRIHQFVECLKLNKKPFHLVGTSMGGQVAGVYAAYYPSDVSSLCLVCPAGLQYSTDNQFVQRLKELQGSAAVEKIPLIPSTPEEMSEMLQLCSYVRFKVPQQILQGLVDVRIPHNNFYRKLFLEIVSEKSRYSLHQNMDKIKVPTQIIWGKQDQVLDVSGADMLAKSIANCQVELLENCGHSVVMERPRKTAKLIIDFLASVHNTDNNKKLD
T81452	DRUGINFO	D00TVG	Piperazine carbamic compound 4	Patented
T81452	DRUGINFO	D0TU6D	PMID29053063-Compound-11c	Patented
T81452	DRUGINFO	D0Z7FL	Piperazine carbamic compound 5	Patented
T81452	DRUGINFO	D0GT0I	PMID29053063-Compound-11d	Patented
T81452	DRUGINFO	D0J6TA	Piperazine carbamic compound 1	Patented
T81452	DRUGINFO	D0LC5Y	Piperazine carbamic compound 2	Patented
T81452	DRUGINFO	D0LL0X	Pyrazole derivative 82	Patented
T81452	DRUGINFO	D0O9DS	Pyrazole derivative 81	Patented
T81452	DRUGINFO	D0X9GC	Pyrazole derivative 80	Patented

T73863	TARGETID	T73863
T73863	FORMERID	TTDI03362
T73863	UNIPROID	KDM4C_HUMAN
T73863	TARGNAME	Lysine-specific demethylase 4C (KDM4C)
T73863	GENENAME	KDM4C
T73863	TARGTYPE	Patented-recorded
T73863	SYNONYMS	KIAA0780; Jumonji domain-containing protein 2C; JmjC domain-containing histone demethylation protein 3C; JMJD2C; JHDM3C; Gene amplified in squamous cell carcinoma 1 protein; GASC1; GASC-1 protein
T73863	FUNCTION	Does not demethylate histone H3 'Lys-4', H3 'Lys-27' nor H4 'Lys-20'. Demethylates trimethylated H3 'Lys-9' and H3 'Lys-36' residue, while it has no activity on mono- and dimethylated residues. Demethylation of Lys residue generates formaldehyde and succinate. Histone demethylase that specifically demethylates 'Lys-9' and 'Lys-36' residues of histone H3, thereby playing a central role in histone code.
T73863	PDBSTRUC	5KR7; 5FJK; 5FJH; 4XDP; 4XDO
T73863	BIOCLASS	Paired donor oxygen oxidoreductase
T73863	ECNUMBER	EC 1.14.11.-
T73863	SEQUENCE	MEVAEVESPLNPSCKIMTFRPSMEEFREFNKYLAYMESKGAHRAGLAKVIPPKEWKPRQCYDDIDNLLIPAPIQQMVTGQSGLFTQYNIQKKAMTVKEFRQLANSGKYCTPRYLDYEDLERKYWKNLTFVAPIYGADINGSIYDEGVDEWNIARLNTVLDVVEEECGISIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHFGEPKSWYAIPPEHGKRLERLAQGFFPSSSQGCDAFLRHKMTLISPSVLKKYGIPFDKITQEAGEFMITFPYGYHAGFNHGFNCAESTNFATVRWIDYGKVAKLCTCRKDMVKISMDIFVRKFQPDRYQLWKQGKDIYTIDHTKPTPASTPEVKAWLQRRRKVRKASRSFQCARSTSKRPKADEEEEVSDEVDGAEVPNPDSVTDDLKVSEKSEAAVKLRNTEASSEEESSASRMQVEQNLSDHIKLSGNSCLSTSVTEDIKTEDDKAYAYRSVPSISSEADDSIPLSSGYEKPEKSDPSELSWPKSPESCSSVAESNGVLTEGEESDVESHGNGLEPGEIPAVPSGERNSFKVPSIAEGENKTSKSWRHPLSRPPARSPMTLVKQQAPSDEELPEVLSIEEEVEETESWAKPLIHLWQTKSPNFAAEQEYNATVARMKPHCAICTLLMPYHKPDSSNEENDARWETKLDEVVTSEGKTKPLIPEMCFIYSEENIEYSPPNAFLEEDGTSLLISCAKCCVRVHASCYGIPSHEICDGWLCARCKRNAWTAECCLCNLRGGALKQTKNNKWAHVMCAVAVPEVRFTNVPERTQIDVGRIPLQRLKLKCIFCRHRVKRVSGACIQCSYGRCPASFHVTCAHAAGVLMEPDDWPYVVNITCFRHKVNPNVKSKACEKVISVGQTVITKHRNTRYYSCRVMAVTSQTFYEVMFDDGSFSRDTFPEDIVSRDCLKLGPPAEGEVVQVKWPDGKLYGAKYFGSNIAHMYQVEFEDGSQIAMKREDIYTLDEELPKRVKARFSTASDMRFEDTFYGADIIQGERKRQRVLSSRFKNEYVADPVYRTFLKSSFQKKCQKRQ
T73863	DRUGINFO	D02FWO	Pyrido[1,2-a]indole-1.-carboxylic acid analog 4	Patented
T73863	DRUGINFO	D04KUD	Pyrido[1,2-a]indole-1.-carboxylic acid analog 1	Patented
T73863	DRUGINFO	D07CYB	PMID25468267-Compound-56	Patented
T73863	DRUGINFO	D0BK5N	Pyrido[1,2-a]indole-1.-carboxylic acid analog 5	Patented
T73863	DRUGINFO	D0L5RA	PMID25468267-Compound-47	Patented
T73863	DRUGINFO	D0Q5IR	Pyrido[1,2-a]indole-1.-carboxylic acid analog 7	Patented
T73863	DRUGINFO	D0RP4W	Pyrido[1,2-a]indole-1.-carboxylic acid analog 3	Patented
T73863	DRUGINFO	D0S8AZ	Flavonoid derivative 6	Patented
T73863	DRUGINFO	D0U3KT	PMID25468267-Compound-55	Patented
T73863	DRUGINFO	D0UQ2R	Pyrido[1,2-a]indole-1.-carboxylic acid analog 2	Patented
T73863	DRUGINFO	D0Z2YB	Pyrido[1,2-a]indole-1.-carboxylic acid analog 6	Patented
T73863	DRUGINFO	D0MJ4L	Hydroxamate analog 1	Patented
T73863	DRUGINFO	D09NCT	PMID25468267-Compound-46	Patented
T73863	DRUGINFO	D0X5US	IOX1	Investigative

T33492	TARGETID	T33492
T33492	FORMERID	TTDI02629
T33492	UNIPROID	TYDP1_HUMAN
T33492	TARGNAME	Tyrosyl-DNA phosphodiesterase 1 (TDP1)
T33492	GENENAME	TDP1
T33492	TARGTYPE	Patented-recorded
T33492	SYNONYMS	Tyr-DNA phosphodiesterase 1
T33492	FUNCTION	Catalyzes the hydrolysis of dead-end complexes between DNA and the topoisomerase I active site tyrosine residue. Hydrolyzes 3'-phosphoglycolates on protruding 3' ends on DNA double-strand breaks due to DNA damage by radiation and free radicals. Acts on blunt-ended double-strand DNA breaks and on single-stranded DNA. Has low 3'exonuclease activity and can remove a single nucleoside from the 3'end of DNA and RNA molecules with 3'hydroxyl groups. Has no exonuclease activity towards DNA or RNA with a 3'phosphate. DNA repair enzyme that can remove a variety of covalent adducts from DNA through hydrolysis of a 3'-phosphodiester bond, giving rise to DNA with a free 3' phosphate.
T33492	PDBSTRUC	5NWA; 5NW9; 1RH0; 1RGU; 1RGT
T33492	BIOCLASS	Phosphoric diester hydrolase
T33492	ECNUMBER	EC 3.1.4.-
T33492	SEQUENCE	MSQEGDYGRWTISSSDESEEEKPKPDKPSTSSLLCARQGAANEPRYTCSEAQKAAHKRKISPVKFSNTDSVLPPKRQKSGSQEDLGWCLSSSDDELQPEMPQKQAEKVVIKKEKDISAPNDGTAQRTENHGAPACHRLKEEEDEYETSGEGQDIWDMLDKGNPFQFYLTRVSGVKPKYNSGALHIKDILSPLFGTLVSSAQFNYCFDVDWLVKQYPPEFRKKPILLVHGDKREAKAHLHAQAKPYENISLCQAKLDIAFGTHHTKMMLLLYEEGLRVVIHTSNLIHADWHQKTQGIWLSPLYPRIADGTHKSGESPTHFKADLISYLMAYNAPSLKEWIDVIHKHDLSETNVYLIGSTPGRFQGSQKDNWGHFRLKKLLKDHASSMPNAESWPVVGQFSSVGSLGADESKWLCSEFKESMLTLGKESKTPGKSSVPLYLIYPSVENVRTSLEGYPAGGSLPYSIQTAEKQNWLHSYFHKWSAETSGRSNAMPHIKTYMRPSPDFSKIAWFLVTSANLSKAAWGALEKNGTQLMIRSYELGVLFLPSAFGLDSFKVKQKFFAGSQEPMATFPVPYDLPPELYGSKDRPWIWNIPYVKAPDTHGNMWVPS

T63024	TARGETID	T63024
T63024	FORMERID	TTDI03570
T63024	UNIPROID	TBK1_HUMAN
T63024	TARGNAME	NF-kappa-B-activating kinase (TBK1)
T63024	GENENAME	TBK1
T63024	TARGTYPE	Patented-recorded
T63024	SYNONYMS	TANK-binding kinase 1; T2K; Serine/threonine-protein kinase TBK1; NAK
T63024	FUNCTION	Following activation of toll-like receptors by viral or bacterial components, associates with TRAF3 and TANK and phosphorylates interferon regulatory factors (IRFs) IRF3 and IRF7 as well as DDX3X. This activity allows subsequent homodimerization and nuclear translocation of the IRFs leading to transcriptional activation of pro-inflammatory and antiviral genes including IFNA and IFNB. In order to establish such an antiviral state, TBK1 form several different complexes whose composition depends on the type of cell and cellular stimuli. Plays a key role in IRF3 activation: acts by first phosphorylating innate adapter proteins MAVS, TMEM173/STING and TICAM1 on their pLxIS motif, leading to recruitment of IRF3, thereby licensing IRF3 for phosphorylation by TBK1. Phosphorylated IRF3 dissociates from the adapter proteins, dimerizes, and then enters the nucleus to induce expression of interferons. Thus, several scaffolding molecules including FADD, TRADD, MAVS, AZI2, TANK or TBKBP1/SINTBAD can be recruited to the TBK1-containing-complexes. Under particular conditions, functions as a NF-kappa-B effector by phosphorylating NF-kappa-B inhibitor alpha/NFKBIA, IKBKB or RELA to translocate NF-Kappa-B to the nucleus. Restricts bacterial proliferation by phosphorylating the autophagy receptor OPTN/Optineurin on 'Ser-177', thus enhancing LC3 binding affinity and antibacterial autophagy. Phosphorylates SMCR8 component of the C9orf72-SMCR8 complex, promoting autophagosome maturation. Phosphorylates and activates AKT1. Seems to play a role in energy balance regulation by sustaining a state of chronic, low-grade inflammation in obesity, wich leads to a negative impact on insulin sensitivity. Attenuates retroviral budding by phosphorylating the endosomal sorting complex required for transport-I (ESCRT-I) subunit VPS37C. Phosphorylates Borna disease virus (BDV) P protein. Plays an essential role in the TLR3- and IFN-dependent control of herpes virus HSV-1 and HSV-2 infections in the central nervous system. Serine/threonine kinase that plays an essential role in regulating inflammatory responses to foreign agents.
T63024	PDBSTRUC	6O8B; 6NT9; 6CQ5; 6CQ4; 6CQ0
T63024	BIOCLASS	Kinase
T63024	ECNUMBER	EC 2.7.11.1
T63024	SEQUENCE	MQSTSNHLWLLSDILGQGATANVFRGRHKKTGDLFAIKVFNNISFLRPVDVQMREFEVLKKLNHKNIVKLFAIEEETTTRHKVLIMEFCPCGSLYTVLEEPSNAYGLPESEFLIVLRDVVGGMNHLRENGIVHRDIKPGNIMRVIGEDGQSVYKLTDFGAARELEDDEQFVSLYGTEEYLHPDMYERAVLRKDHQKKYGATVDLWSIGVTFYHAATGSLPFRPFEGPRRNKEVMYKIITGKPSGAISGVQKAENGPIDWSGDMPVSCSLSRGLQVLLTPVLANILEADQEKCWGFDQFFAETSDILHRMVIHVFSLQQMTAHKIYIHSYNTATIFHELVYKQTKIISSNQELIYEGRRLVLEPGRLAQHFPKTTEENPIFVVSREPLNTIGLIYEKISLPKVHPRYDLDGDASMAKAITGVVCYACRIASTLLLYQELMRKGIRWLIELIKDDYNETVHKKTEVVITLDFCIRNIEKTVKVYEKLMKINLEAAELGEISDIHTKLLRLSSSQGTIETSLQDIDSRLSPGGSLADAWAHQEGTHPKDRNVEKLQVLLNCMTEIYYQFKKDKAERRLAYNEEQIHKFDKQKLYYHATKAMTHFTDECVKKYEAFLNKSEEWIRKMLHLRKQLLSLTNQCFDIEEEVSKYQEYTNELQETLPQKMFTASSGIKHTMTPIYPSSNTLVEMTLGMKKLKEEMEGVVKELAENNHILERFGSLTMDGGLRNVDCL
T63024	DRUGINFO	D00PFT	PMID26293650-Compound-34	Patented
T63024	DRUGINFO	D02EHR	PMID26293650-Compound-35	Patented
T63024	DRUGINFO	D09FGW	Pyrimidinyl compound 4	Patented
T63024	DRUGINFO	D09JVJ	Aminopyrimidine derivative 10	Patented
T63024	DRUGINFO	D09WTI	Pyrimidinyl compound 7	Patented
T63024	DRUGINFO	D0D2LC	Pyrimidinyl compound 1	Patented
T63024	DRUGINFO	D0IF0T	Aminopyrimidine derivative 7	Patented
T63024	DRUGINFO	D0IF3G	Pyrimidinyl compound 3	Patented
T63024	DRUGINFO	D0J4GP	Aminopyrimidine derivative 9	Patented
T63024	DRUGINFO	D0JU7T	Pyrimidinyl compound 2	Patented
T63024	DRUGINFO	D0SA6L	Aminopyrimidine derivative 8	Patented
T63024	DRUGINFO	D0SM9Y	Pyrimidinyl compound 6	Patented
T63024	DRUGINFO	D0TK5U	Aminopyrimidine derivative 6	Patented
T63024	DRUGINFO	D0YU2R	Pyrimidinyl compound 5	Patented
T63024	DRUGINFO	D06ZIO	MRT67307	Investigative
T63024	DRUGINFO	D03BJF	PMID23099093C17d	Investigative

T07930	TARGETID	T07930
T07930	FORMERID	TTDI03260
T07930	UNIPROID	HDAC5_HUMAN
T07930	TARGNAME	Histone deacetylase 5 (HDAC5)
T07930	GENENAME	HDAC5
T07930	TARGTYPE	Patented-recorded
T07930	SYNONYMS	KIAA0600; HD5; Antigen NY-CO-9
T07930	FUNCTION	Gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Involved in muscle maturation by repressing transcription of myocyte enhancer MEF2C. During muscle differentiation, it shuttles into the cytoplasm, allowing the expression of myocyte enhancer factors. Involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4).
T07930	PDBSTRUC	5UWI
T07930	BIOCLASS	Carbon-nitrogen hydrolase
T07930	ECNUMBER	EC 3.5.1.98
T07930	SEQUENCE	MNSPNESDGMSGREPSLEILPRTSLHSIPVTVEVKPVLPRAMPSSMGGGGGGSPSPVELRGALVGSVDPTLREQQLQQELLALKQQQQLQKQLLFAEFQKQHDHLTRQHEVQLQKHLKQQQEMLAAKQQQEMLAAKRQQELEQQRQREQQRQEELEKQRLEQQLLILRNKEKSKESAIASTEVKLRLQEFLLSKSKEPTPGGLNHSLPQHPKCWGAHHASLDQSSPPQSGPPGTPPSYKLPLPGPYDSRDDFPLRKTASEPNLKVRSRLKQKVAERRSSPLLRRKDGTVISTFKKRAVEITGAGPGASSVCNSAPGSGPSSPNSSHSTIAENGFTGSVPNIPTEMLPQHRALPLDSSPNQFSLYTSPSLPNISLGLQATVTVTNSHLTASPKLSTQQEAERQALQSLRQGGTLTGKFMSTSSIPGCLLGVALEGDGSPHGHASLLQHVLLLEQARQQSTLIAVPLHGQSPLVTGERVATSMRTVGKLPRHRPLSRTQSSPLPQSPQALQQLVMQQQHQQFLEKQKQQQLQLGKILTKTGELPRQPTTHPEETEEELTEQQEVLLGEGALTMPREGSTESESTQEDLEEEDEEDDGEEEEDCIQVKDEEGESGAEEGPDLEEPGAGYKKLFSDAQPLQPLQVYQAPLSLATVPHQALGRTQSSPAAPGGMKSPPDQPVKHLFTTGVVYDTFMLKHQCMCGNTHVHPEHAGRIQSIWSRLQETGLLSKCERIRGRKATLDEIQTVHSEYHTLLYGTSPLNRQKLDSKKLLGPISQKMYAVLPCGGIGVDSDTVWNEMHSSSAVRMAVGCLLELAFKVAAGELKNGFAIIRPPGHHAEESTAMGFCFFNSVAITAKLLQQKLNVGKVLIVDWDIHHGNGTQQAFYNDPSVLYISLHRYDNGNFFPGSGAPEEVGGGPGVGYNVNVAWTGGVDPPIGDVEYLTAFRTVVMPIAHEFSPDVVLVSAGFDAVEGHLSPLGGYSVTARCFGHLTRQLMTLAGGRVVLALEGGHDLTAICDASEACVSALLSVELQPLDEAVLQQKPNINAVATLEKVIEIQSKHWSCVQKFAAGLGRSLREAQAGETEEAETVSAMALLSVGAEQAQAAAAREHSPRPAEEPMEQEPAL
T07930	DRUGINFO	D0YN2T	PMID29671355-Compound-45a	Patented
T07930	DRUGINFO	D00HXJ	PMID29671355-Compound-23	Patented
T07930	DRUGINFO	D0M0RE	PMID29671355-Compound-67	Patented
T07930	DRUGINFO	D0DI9S	PMID29671355-Compound-31	Patented
T07930	DRUGINFO	D07WAT	PMID29671355-Compound-62	Patented
T07930	DRUGINFO	D0BP8I	PMID29671355-Compound-43	Patented
T07930	DRUGINFO	D0RA0D	PMID29671355-Compound-25	Patented
T07930	DRUGINFO	D0R7JA	TMP269	Investigative

T11808	TARGETID	T11808
T11808	FORMERID	TTDI03306
T11808	UNIPROID	KLK5_HUMAN
T11808	TARGNAME	Kallikrein-5 (KLK5)
T11808	GENENAME	KLK5
T11808	TARGTYPE	Patented-recorded
T11808	SYNONYMS	UNQ570/PRO1132; Stratum corneum tryptic enzyme; SCTE; Kallikrein-like protein 2; KLK-L2
T11808	FUNCTION	May be involved in desquamation.
T11808	PDBSTRUC	6QFE; 2PSY; 2PSX
T11808	BIOCLASS	Peptidase
T11808	ECNUMBER	EC 3.4.21.-
T11808	SEQUENCE	MATARPPWMWVLCALITALLLGVTEHVLANNDVSCDHPSNTVPSGSNQDLGAGAGEDARSDDSSSRIINGSDCDMHTQPWQAALLLRPNQLYCGAVLVHPQWLLTAAHCRKKVFRVRLGHYSLSPVYESGQQMFQGVKSIPHPGYSHPGHSNDLMLIKLNRRIRPTKDVRPINVSSHCPSAGTKCLVSGWGTTKSPQVHFPKVLQCLNISVLSQKRCEDAYPRQIDDTMFCAGDKAGRDSCQGDSGGPVVCNGSLQGLVSWGDYPCARPNRPGVYTNLCKFTKWIQETIQANS
T11808	DRUGINFO	D00LOL	PMID23849879C3	Investigative
T11808	DRUGINFO	D07OQF	PMID25489658C4d	Investigative

T58307	TARGETID	T58307
T58307	FORMERID	TTDI03498
T58307	UNIPROID	PPME1_HUMAN
T58307	TARGNAME	Protein phosphatase methylesterase 1 (PME-1)
T58307	GENENAME	PPME1
T58307	TARGTYPE	Patented-recorded
T58307	SYNONYMS	PRO0750; PP2593; PME1
T58307	FUNCTION	Demethylates PPP2CB (in vitro) and PPP2CA. Binding to PPP2CA displaces the manganese ion and inactivates the enzyme. Demethylates proteins that have been reversibly carboxymethylated.
T58307	PDBSTRUC	3C5W; 3C5V
T58307	BIOCLASS	Carboxylic ester hydrolase
T58307	ECNUMBER	EC 3.1.1.89
T58307	SEQUENCE	MSALEKSMHLGRLPSRPPLPGSGGSQSGAKMRMGPGRKRDFSPVPWSQYFESMEDVEVENETGKDTFRVYKSGSEGPVLLLLHGGGHSALSWAVFTAAIISRVQCRIVALDLRSHGETKVKNPEDLSAETMAKDVGNVVEAMYGDLPPPIMLIGHSMGGAIAVHTASSNLVPSLLGLCMIDVVEGTAMDALNSMQNFLRGRPKTFKSLENAIEWSVKSGQIRNLESARVSMVGQVKQCEGITSPEGSKSIVEGIIEEEEEDEEGSESISKRKKEDDMETKKDHPYTWRIELAKTEKYWDGWFRGLSNLFLSCPIPKLLLLAGVDRLDKDLTIGQMQGKFQMQVLPQCGHAVHEDAPDKVAEAVATFLIRHRFAEPIGGFQCVFPGC
T58307	DRUGINFO	D0YH7K	ABL127	Investigative

T79400	TARGETID	T79400
T79400	FORMERID	TTDI00054
T79400	UNIPROID	KLK4_HUMAN
T79400	TARGNAME	Kallikrein-4 (KLK4)
T79400	GENENAME	KLK4
T79400	TARGTYPE	Patented-recorded
T79400	SYNONYMS	Serine protease 17; Prostase; PSTS; PRSS17; Kallikreinlike protein 1; Kallikrein4; Kallikrein-like protein 1; KLKL1; KLK-L1; Enamel matrix serine proteinase 1; EMSP1
T79400	FUNCTION	Required during the maturation stage of tooth development for clearance of enamel proteins and normal structural patterning of the crystalline matrix. Has a major role in enamel formation.
T79400	PDBSTRUC	4KGA; 4KEL; 4K8Y; 4K1E; 2BDI
T79400	BIOCLASS	Peptidase
T79400	ECNUMBER	EC 3.4.21.-
T79400	SEQUENCE	MATAGNPWGWFLGYLILGVAGSLVSGSCSQIINGEDCSPHSQPWQAALVMENELFCSGVLVHPQWVLSAAHCFQNSYTIGLGLHSLEADQEPGSQMVEASLSVRHPEYNRPLLANDLMLIKLDESVSESDTIRSISIASQCPTAGNSCLVSGWGLLANGRMPTVLQCVNVSVVSEEVCSKLYDPLYHPSMFCAGGGHDQKDSCNGDSGGPLICNGYLQGLVSFGKAPCGQVGVPGVYTNLCKFTEWIEKTVQAS
T79400	DRUGINFO	D02MGJ	Benzoxazinone derivative 2	Patented

T15441	TARGETID	T15441
T15441	UNIPROID	UCHL5_HUMAN
T15441	TARGNAME	Ubiquitin C-terminal hydrolase UCH37 (UCHL5)
T15441	GENENAME	UCHL5
T15441	TARGTYPE	Patented-recorded
T15441	SYNONYMS	Ubiquitin thioesterase L5; Ubiquitin carboxyl-terminal hydrolase isozyme L5; UCH37; UCH-L5; CGI-70; AD-019
T15441	FUNCTION	Deubiquitinating enzyme associated with the 19S regulatory subunit of the 26S proteasome. Putative regulatory component of the INO80 complex; however is inactive in the INO80 complex and is activated by a transient interaction of the INO80 complex with the proteasome via ADRM1. Protease that specifically cleaves 'Lys-48'-linked polyubiquitin chains.
T15441	PDBSTRUC	4WLP; 4UF6; 4UF5; 4UEM; 4UEL
T15441	BIOCLASS	Peptidase
T15441	ECNUMBER	EC 3.4.19.12
T15441	SEQUENCE	MTGNAGEWCLMESDPGVFTELIKGFGCRGAQVEEIWSLEPENFEKLKPVHGLIFLFKWQPGEEPAGSVVQDSRLDTIFFAKQVINNACATQAIVSVLLNCTHQDVHLGETLSEFKEFSQSFDAAMKGLALSNSDVIRQVHNSFARQQMFEFDTKTSAKEEDAFHFVSYVPVNGRLYELDGLREGPIDLGACNQDDWISAVRPVIEKRIQKYSEGEIRFNLMAIVSDRKMIYEQKIAELQRQLAEEEPMDTDQGNSMLSAIQSEVAKNQMLIEEEVQKLKRYKIENIRRKHNYLPFIMELLKTLAEHQQLIPLVEKAKEKQNAKKAQETK
T15441	DRUGINFO	D0A8EN	PMID26077642-Compound-Figure3A	Patented

T17228	TARGETID	T17228
T17228	FORMERID	TTDI03472
T17228	UNIPROID	PARP3_HUMAN
T17228	TARGNAME	Poly [ADP-ribose] polymerase 3 (PARP3)
T17228	GENENAME	PARP3
T17228	TARGTYPE	Patented-recorded
T17228	SYNONYMS	pADPRT-3; hPARP-3; Protein mono-ADP-ribosyltransferase PARP3; Poly[ADP-ribose] synthase 3; PARP-3; NAD(+) ADP-ribosyltransferase 3; IRT1; DNA ADP-ribosyltransferase PARP3; ARTD3; ADPRTL3; ADPRT3; ADPRT-3; ADP-ribosyltransferase diphtheria toxin-like 3
T17228	FUNCTION	Mediates mono-ADP-ribosylation of glutamate, aspartate or lysine residues on target proteins. In contrast to PARP1 and PARP2, it is not able to mediate poly-ADP-ribosylation. Associates with a number of DNA repair factors and is involved in the response to exogenous and endogenous DNA strand breaks. Together with APLF, promotes the retention of the LIG4-XRCC4 complex on chromatin and accelerate DNA ligation during non-homologous end-joining (NHEJ). Cooperates with the XRRC6-XRCC5 (Ku70-Ku80) heterodimer to limit end-resection thereby promoting accurate NHEJ. Involved in DNA repair by mediating mono-ADP-ribosylation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism, such as XRRC5 and XRCC6. ADP-ribosylation follows DNA damage and appears as an obligatory step in a detection/signaling pathway leading to the reparation of DNA strand breaks. May link the DNA damage surveillance network to the mitotic fidelity checkpoint. In addition to proteins, also able to ADP-ribosylate DNA: mediates DNA mono-ADP-ribosylation of DNA strand break termini via covalent addition of a single ADP-ribose moiety to a 5'- or 3'-terminal phosphate residues in DNA containing multiple strand breaks. Acts as a negative regulator of immunoglobulin class switch recombination, probably by controlling the level of AICDA /AID on the chromatin. Mono-ADP-ribosyltransferase that mediates mono-ADP-ribosylation of target proteins and plays a key role in the response to DNA damage.
T17228	PDBSTRUC	4L7U; 4L7R; 4L7P; 4L7O; 4L7N
T17228	BIOCLASS	Glycosyltransferases
T17228	ECNUMBER	EC 2.4.2.-
T17228	SEQUENCE	MAPKPKPWVQTEGPEKKKGRQAGREEDPFRSTAEALKAIPAEKRIIRVDPTCPLSSNPGTQVYEDYNCTLNQTNIENNNNKFYIIQLLQDSNRFFTCWNRWGRVGEVGQSKINHFTRLEDAKKDFEKKFREKTKNNWAERDHFVSHPGKYTLIEVQAEDEAQEAVVKVDRGPVRTVTKRVQPCSLDPATQKLITNIFSKEMFKNTMALMDLDVKKMPLGKLSKQQIARGFEALEALEEALKGPTDGGQSLEELSSHFYTVIPHNFGHSQPPPINSPELLQAKKDMLLVLADIELAQALQAVSEQEKTVEEVPHPLDRDYQLLKCQLQLLDSGAPEYKVIQTYLEQTGSNHRCPTLQHIWKVNQEGEEDRFQAHSKLGNRKLLWHGTNMAVVAAILTSGLRIMPHSGGRVGKGIYFASENSKSAGYVIGMKCGAHHVGYMFLGEVALGREHHINTDNPSLKSPPPGFDSVIARGHTEPDPTQDTELELDGQQVVVPQGQPVPCPEFSSSTFSQSEYLIYQESQCRLRYLLEVHL
T17228	DRUGINFO	D0TD8R	3-phenyl isoquinolin-1(2H) derivative 1	Patented
T17228	DRUGINFO	D04QRM	ME0328	Investigative

T80853	TARGETID	T80853
T80853	UNIPROID	RSSA_HUMAN
T80853	TARGNAME	Laminin receptor 37/67kDa (LRP/LR)
T80853	GENENAME	RPSA
T80853	TARGTYPE	Patented-recorded
T80853	SYNONYMS	Small ribosomal subunit protein uS2; NEM/1CHD4; Multidrug resistance-associated protein MGr1-Ag; Laminin-binding protein precursor p40; Laminin receptor 1; LamR; LBP/p40; LAMR1; LAMBR; Colon carcinoma laminin-binding protein; 67LR; 67 kDa laminin receptor; 40S ribosomal protein SA; 37LRP; 37/67 kDa laminin receptor; 37 kDa laminin receptor precursor
T80853	FUNCTION	Required for the processing of the 20S rRNA-precursor to mature 18S rRNA in a late step of the maturation of 40S ribosomal subunits. Also functions as a cell surface receptor for laminin. Plays a role in cell adhesion to the basement membrane and in the consequent activation of signaling transduction pathways. May play a role in cell fate determination and tissue morphogenesis. Acts as a PPP1R16B-dependent substrate of PPP1CA. Required for the assembly and/or stability of the 40S ribosomal subunit.
T80853	PDBSTRUC	6QZP; 6G5I; 6G5H; 6G53; 6G51
T80853	SEQUENCE	MSGALDVLQMKEEDVLKFLAAGTHLGGTNLDFQMEQYIYKRKSDGIYIINLKRTWEKLLLAARAIVAIENPADVSVISSRNTGQRAVLKFAAATGATPIAGRFTPGTFTNQIQAAFREPRLLVVTDPRADHQPLTEASYVNLPTIALCNTDSPLRYVDIAIPCNNKGAHSVGLMWWMLAREVLRMRGTISREHPWEVMPDLYFYRDPEEIEKEEQAAAEKAVTKEEFQGEWTAPAPEFTATQPEVADWSEGVQVPSVPIQQFPTEDWSAQPATEDWSAAPTAQATEWVGATTDWS
T80853	DRUGINFO	D02DOE	PMID25747044-Compound-miRNA	Patented

T90167	TARGETID	T90167
T90167	UNIPROID	UBC_HUMAN
T90167	TARGNAME	Polyubiquitin-C (UBC)
T90167	GENENAME	UBC
T90167	TARGTYPE	Patented-recorded
T90167	SYNONYMS	ubiquitin C; HMG20
T90167	FUNCTION	When covalently bound, it is conjugated to target proteins via an isopeptide bond either as a monomer (monoubiquitin), a polymer linked via different Lys residues of the ubiquitin (polyubiquitin chains) or a linear polymer linked via the initiator Met of the ubiquitin (linear polyubiquitin chains). Polyubiquitin chains, when attached to a target protein, have different functions depending on the Lys residue of the ubiquitin that is linked: Lys-6-linked may be involved in DNA repair; Lys-11-linked is involved in ERAD (endoplasmic reticulum-associated degradation) and in cell-cycle regulation; Lys-29-linked is involved in lysosomal degradation; Lys-33-linked is involved in kinase modification; Lys-48-linked is involved in protein degradation via the proteasome; Lys-63-linked is involved in endocytosis, DNA-damage responses as well as in signaling processes leading to activation of the transcription factor NF-kappa-B. Linear polymer chains formed via attachment by the initiator Met lead to cell signaling. Ubiquitin is usually conjugated to Lys residues of target proteins, however, in rare cases, conjugation to Cys or Ser residues has been observed. When polyubiquitin is free (unanchored-polyubiquitin), it also has distinct roles, such as in activation of protein kinases, and in signaling. Ubiquitin: Exists either covalently attached to another protein, or free (unanchored).
T90167	PDBSTRUC	6OI4; 6NQA; 6N13; 6EQI; 6B7O
T90167	SEQUENCE	MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGV
T90167	DRUGINFO	D0B2AE	PMID25553724-Compound-US20130237529 36	Patented
T90167	DRUGINFO	D0JA8J	PMID25553724-Compound-US20130237529 35	Patented

T09128	TARGETID	T09128
T09128	FORMERID	TTDI02492
T09128	UNIPROID	CASP2_HUMAN
T09128	TARGNAME	Caspase-2 (CASP2)
T09128	GENENAME	CASP2
T09128	TARGTYPE	Patented-recorded
T09128	SYNONYMS	Protease ICH1; Protease ICH-1; Neural precursor cell expressed developmentally downregulated protein 2; Neural precursor cell expressed developmentally down-regulated protein 2; NEDD2; NEDD-2; ICH1; Caspase2 subunit p12; CASP-2
T09128	FUNCTION	Might function by either activating some proteins required for cell death or inactivating proteins necessary for cell survival. Associates with PIDD1 and CRADD to form the PIDDosome, a complex that activates CASP2 and triggers apoptosis in response to genotoxic stress. Involved in the activation cascade of caspases responsible for apoptosis execution.
T09128	BIOCLASS	Peptidase
T09128	ECNUMBER	EC 3.4.22.55
T09128	SEQUENCE	MAAPSAGSWSTFQHKELMAADRGRRILGVCGMHPHHQETLKKNRVVLAKQLLLSELLEHLLEKDIITLEMRELIQAKVGSFSQNVELLNLLPKRGPQAFDAFCEALRETKQGHLEDMLLTTLSGLQHVLPPLSCDYDLSLPFPVCESCPLYKKLRLSTDTVEHSLDNKDGPVCLQVKPCTPEFYQTHFQLAYRLQSRPRGLALVLSNVHFTGEKELEFRSGGDVDHSTLVTLFKLLGYDVHVLCDQTAQEMQEKLQNFAQLPAHRVTDSCIVALLSHGVEGAIYGVDGKLLQLQEVFQLFDNANCPSLQNKPKMFFIQACRGDETDRGVDQQDGKNHAGSPGCEESDAGKEKLPKMRLPTRSDMICGYACLKGTAAMRNTKRGSWYIEALAQVFSERACDMHVADMLVKVNALIKDREGYAPGTEFHRCKEMSEYCSTLCRHLYLFPGHPPT

T53469	TARGETID	T53469
T53469	FORMERID	TTDI03088
T53469	UNIPROID	CASP4_HUMAN
T53469	TARGNAME	Caspase-4 (CASP4)
T53469	GENENAME	CASP4
T53469	TARGTYPE	Patented-recorded
T53469	SYNONYMS	Protease TX; Mih1; ICH2; ICH-2; ICE(rel)-II; ICE and Ced-3 homolog 2; CASP-4
T53469	FUNCTION	Essential effector of NLRP3 inflammasome-dependent CASP1 activation and IL1B and IL18 secretion in response to non-canonical activators, such as UVB radiation, cholera enterotoxin subunit B and cytosolic LPS. Independently of NLRP3 inflammasome and CASP1, promotes pyroptosis, through GSDMD cleavage and activation, and IL1A, IL18 and HMGB1 release in response to non-canonical inflammasome activators. Plays a crucial role in the restriction of Salmonella typhimurium replication in colonic epithelial cells during infection. In later stages of the infection, LPS from cytosolic Salmonella triggers CASP4 activation, which ultimately results in pyroptosis of infected cells and their extrusion into the gut lumen, as well as in IL18 secretion. Pyroptosis limits bacterial replication, while cytokine secretion promotes the recruitment and activation of immune cells and triggers mucosal inflammation. Involved in LPS-induced IL6 secretion; this activity may not require caspase enzymatic activity. Involved in cell death induced by endoplasmic reticulum stress and by treatment with cytotoxic APP peptides found Alzheimer's patient brains. Activated by direct binding to LPS without the need of an upstream sensor. Does not directly process IL1B. During non-canonical inflammasome activation, cuts CGAS and may play a role in the regulation of antiviral innate immune activation. Inflammatory caspase.
T53469	BIOCLASS	Peptidase
T53469	ECNUMBER	EC 3.4.22.57
T53469	SEQUENCE	MAEGNHRKKPLKVLESLGKDFLTGVLDNLVEQNVLNWKEEEKKKYYDAKTEDKVRVMADSMQEKQRMAGQMLLQTFFNIDQISPNKKAHPNMEAGPPESGESTDALKLCPHEEFLRLCKERAEEIYPIKERNNRTRLALIICNTEFDHLPPRNGADFDITGMKELLEGLDYSVDVEENLTARDMESALRAFATRPEHKSSDSTFLVLMSHGILEGICGTVHDEKKPDVLLYDTIFQIFNNRNCLSLKDKPKVIIVQACRGANRGELWVRDSPASLEVASSQSSENLEEDAVYKTHVEKDFIAFCSSTPHNVSWRDSTMGSIFITQLITCFQKYSWCCHLEEVFRKVQQSFETPRAKAQMPTIERLSMTRYFYLFPGN
T53469	DRUGINFO	D0Q9XX	casp 4 inhib	Investigative
T53469	DRUGINFO	D00YNW	M826	Investigative

T74307	TARGETID	T74307
T74307	FORMERID	TTDI03053
T74307	UNIPROID	BLK_HUMAN
T74307	TARGNAME	B lymphocyte kinase (BLK)
T74307	GENENAME	BLK
T74307	TARGTYPE	Patented-recorded
T74307	SYNONYMS	p55-Blk; Tyrosine-protein kinase Blk
T74307	FUNCTION	B-cell receptor (BCR) signaling requires a tight regulation of several protein tyrosine kinases and phosphatases, and associated coreceptors. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation. Signaling through BLK plays an important role in transmitting signals through surface immunoglobulins and supports the pro-B to pre-B transition, as well as the signaling for growth arrest and apoptosis downstream of B-cell receptor. Specifically binds and phosphorylates CD79A at 'Tyr-188'and 'Tyr-199', as well as CD79B at 'Tyr-196' and 'Tyr-207'. Phosphorylates also the immunoglobulin G receptors FCGR2A, FCGR2B and FCGR2C. With FYN and LYN, plays an essential role in pre-B-cell receptor (pre-BCR)-mediated NF-kappa-B activation. Contributes also to BTK activation by indirectly stimulating BTK intramolecular autophosphorylation. In pancreatic islets, acts as a modulator of beta-cells function through the up-regulation of PDX1 and NKX6-1 and consequent stimulation of insulin secretion in response to glucose. Phosphorylates CGAS, promoting retention of CGAS in the cytosol. Non-receptor tyrosine kinase involved in B-lymphocyte development, differentiation and signaling.
T74307	BIOCLASS	Kinase
T74307	ECNUMBER	EC 2.7.10.2
T74307	SEQUENCE	MGLVSSKKPDKEKPIKEKDKGQWSPLKVSAQDKDAPPLPPLVVFNHLTPPPPDEHLDEDKHFVVALYDYTAMNDRDLQMLKGEKLQVLKGTGDWWLARSLVTGREGYVPSNFVARVESLEMERWFFRSQGRKEAERQLLAPINKAGSFLIRESETNKGAFSLSVKDVTTQGELIKHYKIRCLDEGGYYISPRITFPSLQALVQHYSKKGDGLCQRLTLPCVRPAPQNPWAQDEWEIPRQSLRLVRKLGSGQFGEVWMGYYKNNMKVAIKTLKEGTMSPEAFLGEANVMKALQHERLVRLYAVVTKEPIYIVTEYMARGCLLDFLKTDEGSRLSLPRLIDMSAQIAEGMAYIERMNSIHRDLRAANILVSEALCCKIADFGLARIIDSEYTAQEGAKFPIKWTAPEAIHFGVFTIKADVWSFGVLLMEVVTYGRVPYPGMSNPEVIRNLERGYRMPRPDTCPPELYRGVIAECWRSRPEERPTFEFLQSVLEDFYTATERQYELQP
T74307	DRUGINFO	D09PIS	Pyrazolo[4,3-c]pyridine derivative 2	Patented
T74307	DRUGINFO	D01RHR	PMID24915291C31	Investigative
T74307	DRUGINFO	D08RZB	PMID15546730C2	Investigative
T74307	DRUGINFO	D06BJG	PMID24915291C38	Investigative

T89565	TARGETID	T89565
T89565	FORMERID	TTDI03089
T89565	UNIPROID	CASP5_HUMAN
T89565	TARGNAME	Caspase-5 (CASP5)
T89565	GENENAME	CASP5
T89565	TARGTYPE	Patented-recorded
T89565	SYNONYMS	Protease TY; Protease ICH-3; ICH3; ICE(rel)-III; CASP-5
T89565	FUNCTION	During non-canonical inflammasome activation, cuts CGAS and may play a role in the regulation of antiviral innate immune activation. Mediator of programmed cell death (apoptosis).
T89565	BIOCLASS	Peptidase
T89565	ECNUMBER	EC 3.4.22.58
T89565	SEQUENCE	MAEDSGKKKRRKNFEAMFKGILQSGLDNFVINHMLKNNVAGQTSIQTLVPNTDQKSTSVKKDNHKKKTVKMLEYLGKDVLHGVFNYLAKHDVLTLKEEEKKKYYDTKIEDKALILVDSLRKNRVAHQMFTQTLLNMDQKITSVKPLLQIEAGPPESAESTNILKLCPREEFLRLCKKNHDEIYPIKKREDRRRLALIICNTKFDHLPARNGAHYDIVGMKRLLQGLGYTVVDEKNLTARDMESVLRAFAARPEHKSSDSTFLVLMSHGILEGICGTAHKKKKPDVLLYDTIFQIFNNRNCLSLKDKPKVIIVQACRGEKHGELWVRDSPASLALISSQSSENLEADSVCKIHEEKDFIAFCSSTPHNVSWRDRTRGSIFITELITCFQKYSCCCHLMEIFRKVQKSFEVPQAKAQMPTIERATLTRDFYLFPGN
T89565	DRUGINFO	D00YNW	M826	Investigative

T43814	TARGETID	T43814
T43814	UNIPROID	TIRAP_HUMAN
T43814	TARGNAME	Toll/interleukin-1 receptor domain-containing adapter (TIRAP)
T43814	GENENAME	TIRAP
T43814	TARGTYPE	Patented-recorded
T43814	SYNONYMS	Toll/interleukin-1 receptor domain-containing adapter protein; TIR domain-containing adapter protein; MyD88-2; MyD88 adapter-like protein; MAL; Adaptor protein Wyatt
T43814	FUNCTION	Acts via IRAK2 and TRAF-6, leading to the activation of NF-kappa-B, MAPK1, MAPK3 and JNK, and resulting in cytokine secretion and the inflammatory response. Positively regulates the production of TNF-alpha and interleukin-6. Adapter involved in TLR2 and TLR4 signaling pathways in the innate immune response.
T43814	PDBSTRUC	5UZB; 5T7Q; 4LQD; 4FZ5; 3UB4
T43814	SEQUENCE	MASSTSLPAPGSRPKKPLGKMADWFRQTLLKKPKKRPNSPESTSSDASQPTSQDSPLPPSLSSVTSPSLPPTHASDSGSSRWSKDYDVCVCHSEEDLVAAQDLVSYLEGSTASLRCFLQLRDATPGGAIVSELCQALSSSHCRVLLITPGFLQDPWCKYQMLQALTEAPGAEGCTIPLLSGLSRAAYPPELRFMYYVDGRGPDGGFRQVKEAVMRYLQTLS

T07191	TARGETID	T07191
T07191	FORMERID	TTDI03384
T07191	UNIPROID	M4K2_HUMAN
T07191	TARGNAME	MEK kinase kinase 2 (MAP4K2)
T07191	GENENAME	MAP4K2
T07191	TARGTYPE	Patented-recorded
T07191	SYNONYMS	Rab8-interacting protein; RAB8IP; Mitogen-activated protein kinase kinase kinase kinase 2; MEKKK 2; MAPK/ERK kinase kinase kinase 2; Germinal center kinase; GCK; GC kinase; B lymphocyte serine/threonine-protein kinase
T07191	FUNCTION	Acts as a MAPK kinase kinase kinase (MAP4K) and is an upstream activator of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway and to a lesser extent of the p38 MAPKs signaling pathway. Required for the efficient activation of JNKs by TRAF6-dependent stimuli, including pathogen-associated molecular patterns (PAMPs) such as polyinosine-polycytidine (poly(IC)), lipopolysaccharides (LPS), lipid A, peptidoglycan (PGN), or bacterial flagellin. To a lesser degree, IL-1 and engagement of CD40 also stimulate MAP4K2-mediated JNKs activation. The requirement for MAP4K2/GCK is most pronounced for LPS signaling, and extends to LPS stimulation of c-Jun phosphorylation and induction of IL-8. Enhances MAP3K1 oligomerization, which may relieve N-terminal mediated MAP3K1 autoinhibition and lead to activation following autophosphorylation. Mediates also the SAP/JNK signaling pathway and the p38 MAPKs signaling pathway through activation of the MAP3Ks MAP3K10/MLK2 and MAP3K11/MLK3. May play a role in the regulation of vesicle targeting or fusion. regulation of vesicle targeting or fusion. Serine/threonine-protein kinase which acts as an essential component of the MAP kinase signal transduction pathway.
T07191	BIOCLASS	Kinase
T07191	ECNUMBER	EC 2.7.11.1
T07191	SEQUENCE	MALLRDVSLQDPRDRFELLQRVGAGTYGDVYKARDTVTSELAAVKIVKLDPGDDISSLQQEITILRECRHPNVVAYIGSYLRNDRLWICMEFCGGGSLQEIYHATGPLEERQIAYVCREALKGLHHLHSQGKIHRDIKGANLLLTLQGDVKLADFGVSGELTASVAKRRSFIGTPYWMAPEVAAVERKGGYNELCDVWALGITAIELGELQPPLFHLHPMRALMLMSKSSFQPPKLRDKTRWTQNFHHFLKLALTKNPKKRPTAEKLLQHPFTTQQLPRALLTQLLDKASDPHLGTPSPEDCELETYDMFPDTIHSRGQHGPAERTPSEIQFHQVKFGAPRRKETDPLNEPWEEEWTLLGKEELSGSLLQSVQEALEERSLTIRSASEFQELDSPDDTMGTIKRAPFLGPLPTDPPAEEPLSSPPGTLPPPPSGPNSSPLLPTAWATMKQREDPERSSCHGLPPTPKVHMGACFSKVFNGCPLRIHAAVTWIHPVTRDQFLVVGAEEGIYTLNLHELHEDTLEKLISHRCSWLYCVNNVLLSLSGKSTHIWAHDLPGLFEQRRLQQQVPLSIPTNRLTQRIIPRRFALSTKIPDTKGCLQCRVVRNPYTGATFLLAALPTSLLLLQWYEPLQKFLLLKNFSSPLPSPAGMLEPLVLDGKELPQVCVGAEGPEGPGCRVLFHVLPLEAGLTPDILIPPEGIPGSAQQVIQVDRDTILVSFERCVRIVNMQGEPTATLAPELTFDFPIETVVCLQDSVLAFWSHGMQGRSLDTNEVTQEITDETRIFRVLGAHRDIILESIPTDNPEAHSNLYILTGHQSTY
T07191	DRUGINFO	D02GNH	Quinazoline derivative 9	Phase 1
T07191	DRUGINFO	D0X7IC	NG-25	Investigative

T04512	TARGETID	T04512
T04512	UNIPROID	EZH2_HUMAN
T04512	TARGNAME	EZH2 Y641F mutant (EZH2 Y641F)
T04512	GENENAME	EZH2
T04512	TARGTYPE	Patented-recorded
T04512	SYNONYMS	Lysine Nmethyltransferase 6 Y641F mutant; Lysine N-methyltransferase 6 Y641F mutant; KMT6 Y641F mutant; Histonelysine Nmethyltransferase EZH2 Y641F mutant; Histone-lysine N-methyltransferase EZH2 Y641F mutant; EZH2 Y641F mutations; ENX1 Y641F mutant; ENX-1 Y641F mutant
T04512	FUNCTION	Catalytic subunit of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. Displays a preference for substrates with less methylation, loses activity when progressively more methyl groups are incorporated into H3K27, H3K27me0 > H3K27me1 > H3K27me2. Compared to EZH1-containing complexes, it is more abundant in embryonic stem cells and plays a major role in forming H3K27me3, which is required for embryonic stem cell identity and proper differentiation. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1, CDKN2A and retinoic acid target genes. EZH2 can also methylate non-histone proteins such as the transcription factor GATA4 and the nuclear receptor RORA. Regulates the circadian clock via histone methylation at the promoter of the circadian genes. Essential for the CRY1/2-mediated repression of the transcriptional activation of PER1/2 by the CLOCK-ARNTL/BMAL1 heterodimer; involved in the di and trimethylation of 'Lys-27' of histone H3 on PER1/2 promoters which is necessary for the CRY1/2 proteins to inhibit transcription. Polycomb group (PcG) protein.
T04512	PDBSTRUC	6C24; 6C23; 5WUK; 5WG6; 5U62
T04512	ECNUMBER	EC 2.1.1.43
T04512	SEQUENCE	MGQTGKKSEKGPVCWRKRVKSEYMRLRQLKRFRRADEVKSMFSSNRQKILERTEILNQEWKQRRIQPVHILTSVSSLRGTRECSVTSDLDFPTQVIPLKTLNAVASVPIMYSWSPLQQNFMVEDETVLHNIPYMGDEVLDQDGTFIEELIKNYDGKVHGDRECGFINDEIFVELVNALGQYNDDDDDDDGDDPEEREEKQKDLEDHRDDKESRPPRKFPSDKIFEAISSMFPDKGTAEELKEKYKELTEQQLPGALPPECTPNIDGPNAKSVQREQSLHSFHTLFCRRCFKYDCFLHPFHATPNTYKRKNTETALDNKPCGPQCYQHLEGAKEFAAALTAERIKTPPKRPGGRRRGRLPNNSSRPSTPTINVLESKDTDSDREAGTETGGENNDKEEEEKKDETSSSSEANSRCQTPIKMKPNIEPPENVEWSGAEASMFRVLIGTYYDNFCAIARLIGTKTCRQVYEFRVKESSIIAPAPAEDVDTPPRKKKRKHRLWAAHCRKIQLKKDGSSNHVYNYQPCDHPRQPCDSSCPCVIAQNFCEKFCQCSSECQNRFPGCRCKAQCNTKQCPCYLAVRECDPDLCLTCGAADHWDSKNVSCKNCSIQRGSKKHLLLAPSDVAGWGIFIKDPVQKNEFISEYCGEIISQDEADRRGKVYDKYMCSFLFNLNNDFVVDATRKGNKIRFANHSVNPNCYAKVMMVNGDHRIGIFAKRAIQTGEELFFDYRYSQADALKYVGIEREMEIP
T04512	DRUGINFO	D0MH5C	PMID28394193-Compound-11	Patented
T04512	DRUGINFO	D0MZ9P	PMID28394193-Compound-10	Patented
T04512	DRUGINFO	D0GT7A	PMID28394193-Compound-14	Patented
T04512	DRUGINFO	D0H8VN	PMID28394193-Compound-12	Patented
T04512	DRUGINFO	D0TA4N	PMID28394193-Compound-13	Patented

T04980	TARGETID	T04980
T04980	UNIPROID	EZH2_HUMAN
T04980	TARGNAME	EZH2 Y641N mutant (EZH2 Y641N)
T04980	GENENAME	EZH2
T04980	TARGTYPE	Patented-recorded
T04980	SYNONYMS	Lysine Nmethyltransferase 6 Y641N mutant; Lysine N-methyltransferase 6 Y641N mutant; KMT6 Y641N mutant; Histonelysine Nmethyltransferase EZH2 Y641N mutant; Histone-lysine N-methyltransferase EZH2 Y641N mutant; EZH2 Y641N mutations; ENX1 Y641N mutant; ENX-1 Y641N mutant
T04980	FUNCTION	Catalytic subunit of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. Displays a preference for substrates with less methylation, loses activity when progressively more methyl groups are incorporated into H3K27, H3K27me0 > H3K27me1 > H3K27me2. Compared to EZH1-containing complexes, it is more abundant in embryonic stem cells and plays a major role in forming H3K27me3, which is required for embryonic stem cell identity and proper differentiation. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1, CDKN2A and retinoic acid target genes. EZH2 can also methylate non-histone proteins such as the transcription factor GATA4 and the nuclear receptor RORA. Regulates the circadian clock via histone methylation at the promoter of the circadian genes. Essential for the CRY1/2-mediated repression of the transcriptional activation of PER1/2 by the CLOCK-ARNTL/BMAL1 heterodimer; involved in the di and trimethylation of 'Lys-27' of histone H3 on PER1/2 promoters which is necessary for the CRY1/2 proteins to inhibit transcription. Polycomb group (PcG) protein.
T04980	PDBSTRUC	6C24; 6C23; 5WUK; 5WG6; 5U62
T04980	ECNUMBER	EC 2.1.1.43
T04980	SEQUENCE	MGQTGKKSEKGPVCWRKRVKSEYMRLRQLKRFRRADEVKSMFSSNRQKILERTEILNQEWKQRRIQPVHILTSVSSLRGTRECSVTSDLDFPTQVIPLKTLNAVASVPIMYSWSPLQQNFMVEDETVLHNIPYMGDEVLDQDGTFIEELIKNYDGKVHGDRECGFINDEIFVELVNALGQYNDDDDDDDGDDPEEREEKQKDLEDHRDDKESRPPRKFPSDKIFEAISSMFPDKGTAEELKEKYKELTEQQLPGALPPECTPNIDGPNAKSVQREQSLHSFHTLFCRRCFKYDCFLHPFHATPNTYKRKNTETALDNKPCGPQCYQHLEGAKEFAAALTAERIKTPPKRPGGRRRGRLPNNSSRPSTPTINVLESKDTDSDREAGTETGGENNDKEEEEKKDETSSSSEANSRCQTPIKMKPNIEPPENVEWSGAEASMFRVLIGTYYDNFCAIARLIGTKTCRQVYEFRVKESSIIAPAPAEDVDTPPRKKKRKHRLWAAHCRKIQLKKDGSSNHVYNYQPCDHPRQPCDSSCPCVIAQNFCEKFCQCSSECQNRFPGCRCKAQCNTKQCPCYLAVRECDPDLCLTCGAADHWDSKNVSCKNCSIQRGSKKHLLLAPSDVAGWGIFIKDPVQKNEFISEYCGEIISQDEADRRGKVYDKYMCSFLFNLNNDFVVDATRKGNKIRFANHSVNPNCYAKVMMVNGDHRIGIFAKRAIQTGEELFFDYRYSQADALKYVGIEREMEIP
T04980	DRUGINFO	D01PZZ	PMID28394193-Compound-56	Patented
T04980	DRUGINFO	D0D4UH	PMID28394193-Compound-46	Patented
T04980	DRUGINFO	D0G1JR	PMID28394193-Compound-57	Patented
T04980	DRUGINFO	D0M4LK	PMID28394193-Compound-55	Patented
T04980	DRUGINFO	D0M8AA	PMID28394193-Compound-45	Patented

T42157	TARGETID	T42157
T42157	FORMERID	TTDI03382
T42157	UNIPROID	M3K19_HUMAN
T42157	TARGNAME	SPS1/STE20-related protein kinase YSK4 (YSK4)
T42157	GENENAME	MAP3K19
T42157	TARGTYPE	Patented-recorded
T42157	SYNONYMS	Regulated in COPD, protein kinase; RCK; Mitogen-activated protein kinase kinase kinase 19
T42157	FUNCTION	Protein serine/threonine kinase activity, activation of protein kinase activity, signal transduction by protein phosphorylation, stress-activated protein kinase signaling cascade.
T42157	BIOCLASS	Kinase
T42157	ECNUMBER	EC 2.7.11.1
T42157	SEQUENCE	MSSMPKPERHAESLLDICHDTNSSPTDLMTVTKNQNIILQSISRSEEFDQDGDCSHSTLVNEEEDPSGGRQDWQPRTEGVEITVTFPRDVSPPQEMSQEDLKEKNLINSSLQEWAQAHAVSHPNEIETVELRKKKLTMRPLVLQKEESSRELCNVNLGFLLPRSCLELNISKSVTREDAPHFLKEQQRKSEEFSTSHMKYSGRSIKFLLPPLSLLPTRSGVLTIPQNHKFPKEKERNIPSLTSFVPKLSVSVRQSDELSPSNEPPGALVKSLMDPTLRSSDGFIWSRNMCSFPKTNHHRQCLEKEENWKSKEIEECNKIEITHFEKGQSLVSFENLKEGNIPAVREEDIDCHGSKTRKPEEENSQYLSSRKNESSVAKNYEQDPEIVCTIPSKFQETQHSEITPSQDEEMRNNKAASKRVSLHKNEAMEPNNILEECTVLKSLSSVVFDDPIDKLPEGCSSMETNIKISIAERAKPEMSRMVPLIHITFPVDGSPKEPVIAKPSLQTRKGTIHNNHSVNIPVHQENDKHKMNSHRSKLDSKTKTSKKTPQNFVISTEGPIKPTMHKTSIKTQIFPALGLVDPRPWQLPRFQKKMPQIAKKQSTHRTQKPKKQSFPCICKNPGTQKSCVPLSVQPTEPRLNYLDLKYSDMFKEINSTANGPGIYEMFGTPVYCHVRETERDENTYYREICSAPSGRRITNKCRSSHSERKSNIRTRLSQKKTHMKCPKTSFGIKQEHKVLISKEKSSKAVHSNLHDIENGDGISEPDWQIKSSGNEFLSSKDEIHPMNLAQTPEQSMKQNEFPPVSDLSIVEEVSMEESTGDRDISNNQILTTSLRDLQELEELHHQIPFIPSEDSWAVPSEKNSNKYVQQEKQNTASLSKVNASRILTNDLEFDSVSDHSKTLTNFSFQAKQESASSQTYQYWVHYLDHDSLANKSITYQMFGKTLSGTNSISQEIMDSVNNEELTDELLGCLAAELLALDEKDNNSCQKMANETDPENLNLVLRWRGSTPKEMGRETTKVKIQRHSSGLRIYDREEKFLISNEKKIFSENSLKSEEPILWTKGEILGKGAYGTVYCGLTSQGQLIAVKQVALDTSNKLAAEKEYRKLQEEVDLLKALKHVNIVAYLGTCLQENTVSIFMEFVPGGSISSIINRFGPLPEMVFCKYTKQILQGVAYLHENCVVHRDIKGNNVMLMPTGIIKLIDFGCARRLAWAGLNGTHSDMLKSMHGTPYWMAPEVINESGYGRKSDIWSIGCTVFEMATGKPPLASMDRMAAMFYIGAHRGLMPPLPDHFSENAADFVRMCLTRDQHERPSALQLLKHSFLERSH
T42157	DRUGINFO	D02GNH	Quinazoline derivative 9	Phase 1

T44190	TARGETID	T44190
T44190	UNIPROID	TCAM1_HUMAN
T44190	TARGNAME	TIR domain-containing adapter molecule 1 (TICAM1)
T44190	GENENAME	TICAM1
T44190	TARGTYPE	Patented-recorded
T44190	SYNONYMS	Toll-interleukin-1 receptor domain-containing adapter protein inducing interferon beta; TRIF; TIR domain-containing adapter protein inducing IFN-beta; TICAM-1; Putative NF-kappa-B-activating protein 502H; Proline-rich, vinculin and TIR domain-containing protein B; PRVTIRB; MyD88-3
T44190	FUNCTION	Adapter used by TLR3, TLR4 (through TICAM2) and TLR5 to mediate NF-kappa-B and interferon-regulatory factor (IRF) activation, and to induce apoptosis. Ligand binding to these receptors results in TRIF recruitment through its TIR domain. Distinct protein-interaction motifs allow recruitment of the effector proteins TBK1, TRAF6 and RIPK1, which in turn, lead to the activation of transcription factors IRF3 and IRF7, NF-kappa-B and FADD respectively. Phosphorylation by TBK1 on the pLxIS motif leads to recruitment and subsequent activation of the transcription factor IRF3 to induce expression of type I interferon and exert a potent immunity against invading pathogens. Component of a multi-helicase-TICAM1 complex that acts as a cytoplasmic sensor of viral double-stranded RNA (dsRNA) and plays a role in the activation of a cascade of antiviral responses including the induction of proinflammatory cytokines. Involved in innate immunity against invading pathogens.
T44190	PDBSTRUC	5JEL; 4C0M; 4BSX; 3RC4; 2M63
T44190	SEQUENCE	MACTGPSLPSAFDILGAAGQDKLLYLKHKLKTPRPGCQGQDLLHAMVLLKLGQETEARISLEALKADAVARLVARQWAGVDSTEDPEEPPDVSWAVARLYHLLAEEKLCPASLRDVAYQEAVRTLSSRDDHRLGELQDEARNRCGWDIAGDPGSIRTLQSNLGCLPPSSALPSGTRSLPRPIDGVSDWSQGCSLRSTGSPASLASNLEISQSPTMPFLSLHRSPHGPSKLCDDPQASLVPEPVPGGCQEPEEMSWPPSGEIASPPELPSSPPPGLPEVAPDATSTGLPDTPAAPETSTNYPVECTEGSAGPQSLPLPILEPVKNPCSVKDQTPLQLSVEDTTSPNTKPCPPTPTTPETSPPPPPPPPSSTPCSAHLTPSSLFPSSLESSSEQKFYNFVILHARADEHIALRVREKLEALGVPDGATFCEDFQVPGRGELSCLQDAIDHSAFIILLLTSNFDCRLSLHQVNQAMMSNLTRQGSPDCVIPFLPLESSPAQLSSDTASLLSGLVRLDEHSQIFARKVANTFKPHRLQARKAMWRKEQDTRALREQSQHLDGERMQAAALNAAYSAYLQSYLSYQAQMEQLQVAFGSHMSFGTGAPYGARMPFGGQVPLGAPPPFPTWPGCPQPPPLHAWQAGTPPPPSPQPAAFPQSLPFPQSPAFPTASPAPPQSPGLQPLIIHHAQMVQLGLNNHMWNQRGSQAPEDKTQEAE

T15518	TARGETID	T15518
T15518	FORMERID	TTDI03421
T15518	UNIPROID	SO2A1_HUMAN
T15518	TARGNAME	Prostaglandin transporter (SLC21A2)
T15518	GENENAME	SLCO2A1
T15518	TARGTYPE	Patented-recorded
T15518	SYNONYMS	Solute carrier organic anion transporter family member 2A1; Solute carrier family 21 member 2; PGT; OATP2A1
T15518	FUNCTION	Transports PGD2, as well as PGE1, PGE2 and PGF2A. May mediate the release of newly synthesized prostaglandins from cells, the transepithelial transport of prostaglandins, and the clearance of prostaglandins from the circulation.
T15518	PDBSTRUC	3MRR
T15518	BIOCLASS	Organo anion transporter
T15518	SEQUENCE	MGLLPKLGASQGSDTSTSRAGRCARSVFGNIKVFVLCQGLLQLCQLLYSAYFKSSLTTIEKRFGLSSSSSGLISSLNEISNAILIIFVSYFGSRVHRPRLIGIGGLFLAAGAFILTLPHFLSEPYQYTLASTGNNSRLQAELCQKHWQDLPPSKCHSTTQNPQKETSSMWGLMVVAQLLAGIGTVPIQPFGISYVDDFSEPSNSPLYISILFAISVFGPAFGYLLGSVMLQIFVDYGRVNTAAVNLVPGDPRWIGAWWLGLLISSALLVLTSFPFFFFPRAMPIGAKRAPATADEARKLEEAKSRGSLVDFIKRFPCIFLRLLMNSLFVLVVLAQCTFSSVIAGLSTFLNKFLEKQYGTSAAYANFLIGAVNLPAAALGMLFGGILMKRFVFSLQAIPRIATTIITISMILCVPLFFMGCSTPTVAEVYPPSTSSSIHPQSPACRRDCSCPDSIFHPVCGDNGIEYLSPCHAGCSNINMSSATSKQLIYLNCSCVTGGSASAKTGSCPVPCAHFLLPAIFLISFVSLIACISHNPLYMMVLRVVNQEEKSFAIGVQFLLMRLLAWLPSPALYGLTIDHSCIRWNSLCLGRRGACAYYDNDALRDRYLGLQMGYKALGMLLLCFISWRVKKNKEYNVQKAAGLI
T15518	DRUGINFO	D07XPI	PMID26099857-Compound-WO2011037610Formula(I)	Patented
T15518	DRUGINFO	D0KO9R	bromocresol green	Investigative
T15518	DRUGINFO	D0W8GY	bromsulphthalein	Investigative

T45228	TARGETID	T45228
T45228	FORMERID	TTDI02621
T45228	UNIPROID	MBOA4_HUMAN
T45228	TARGNAME	Ghrelin O acyltransferase (GOAT)
T45228	GENENAME	MBOAT4
T45228	TARGTYPE	Patented-recorded
T45228	SYNONYMS	Oacyltransferase domaincontaining protein 4; OACT4; O-acyltransferase domain-containing protein 4; Membranebound Oacyltransferase domaincontaining protein 4; Membrane-bound O-acyltransferase domain-containing protein 4; Ghrelin Oacyltransferase; Ghrelin O-acyltransferase; FKSG89
T45228	FUNCTION	Can use a variety of fatty acids as substrates including octanoic acid, decanoic acid and tetradecanoic acid. Mediates the octanoylation of ghrelin at 'Ser-3'.
T45228	BIOCLASS	Acyltransferase
T45228	ECNUMBER	EC 2.3.1.-
T45228	SEQUENCE	MEWLWLFFLHPISFYQGAAFPFALLFNYLCIMDSFSTRARYLFLLTGGGALAVAAMGSYAVLVFTPAVCAVALLCSLAPQQVHRWTFCFQMSWQTLCHLGLHYTEYYLHEPPSVRFCITLSSLMLLTQRVTSLSLDICEGKVKAASGGFRSRSSLSEHVCKALPYFSYLLFFPALLGGSLCSFQRFQARVQGSSALHPRHSFWALSWRGLQILGLECLNVAVSRVVDAGAGLTDCQQFECIYVVWTTAGLFKLTYYSHWILDDSLLHAAGFGPELGQSPGEEGYVPDADIWTLERTHRISVFSRKWNQSTARWLRRLVFQHSRAWPLLQTFAFSAWWHGLHPGQVFGFVCWAVMVEADYLIHSFANEFIRSWPMRLFYRTLTWAHTQLIIAYIMLAVEVRSLSSLWLLCNSYNSVFPMVYCILLLLLAKRKHKCN
T45228	DRUGINFO	D0YY8N	PMID25470667-Compound-GO-CoA-Tat	Patented

T16215	TARGETID	T16215
T16215	UNIPROID	SMO_HUMAN
T16215	TARGNAME	Smoothened D473H mutant (SMO D473H)
T16215	GENENAME	SMO
T16215	TARGTYPE	Patented-recorded
T16215	SYNONYMS	Smo-D473H mutant; SMOH D473H mutant; Protein Gx D473H mutant
T16215	FUNCTION	Binding of sonic hedgehog (SHH) to its receptor patched is thought to prevent normal inhibition by patched of smoothened (SMO). Required for the accumulation of KIF7, GLI2 and GLI3 in the cilia. Interacts with DLG5 at the ciliary base to induce the accumulation of KIF7 and GLI2 at the ciliary tip for GLI2 activation. G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog's proteins signal.
T16215	PDBSTRUC	5V57; 5V56; 5L7I; 5L7D; 4QIN
T16215	BIOCLASS	GPCR frizzled
T16215	SEQUENCE	MAAARPARGPELPLLGLLLLLLLGDPGRGAASSGNATGPGPRSAGGSARRSAAVTGPPPPLSHCGRAAPCEPLRYNVCLGSVLPYGATSTLLAGDSDSQEEAHGKLVLWSGLRNAPRCWAVIQPLLCAVYMPKCENDRVELPSRTLCQATRGPCAIVERERGWPDFLRCTPDRFPEGCTNEVQNIKFNSSGQCEVPLVRTDNPKSWYEDVEGCGIQCQNPLFTEAEHQDMHSYIAAFGAVTGLCTLFTLATFVADWRNSNRYPAVILFYVNACFFVGSIGWLAQFMDGARREIVCRADGTMRLGEPTSNETLSCVIIFVIVYYALMAGVVWFVVLTYAWHTSFKALGTTYQPLSGKTSYFHLLTWSLPFVLTVAILAVAQVDGDSVSGICFVGYKNYRYRAGFVLAPIGLVLIVGGYFLIRGVMTLFSIKSNHPGLLSEKAASKINETMLRLGIFGFLAFGFVLITFSCHFYDFFNQAEWERSFRDYVLCQANVTIGLPTKQPIPDCEIKNRPSLLVEKINLFAMFGTGIAMSTWVWTKATLLIWRRTWCRLTGQSDDEPKRIKKSKMIAKAFSKRHELLQNPGQELSFSMHTVSHDGPVAGLAFDLNEPSADVSSAWAQHVTKMVARRGAILPQDISVTPVATPVPPEEQANLWLVEAEISPELQKRLGRKKKRRKRKKEVCPLAPPPELHPPAPAPSTIPRLPQLPRQKCLVAAGAWGAGDSCRQGAWTLVSNPFCPEPSPPQDPFLPSAPAPVAWAHGRRQGLGPIHSRTNLMDTELMDADSDF
T16215	DRUGINFO	D07BIQ	PMID25726713-Compound-17	Patented

T50035	TARGETID	T50035
T50035	UNIPROID	PD1L2_HUMAN
T50035	TARGNAME	Programmed cell death 1 ligand 2 (PD-L2)
T50035	GENENAME	PDCD1LG2
T50035	TARGTYPE	Patented-recorded
T50035	SYNONYMS	Programmed death ligand 2; PDL2; PDCD1L2; PDCD1 ligand 2; PD-1 ligand 2; CD273; Butyrophilin B7-DC; B7DC; B7-DC
T50035	FUNCTION	Interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production. Involved in the costimulatory signal, essential for T-cell proliferation and IFNG production in a PDCD1-independent manner.
T50035	BIOCLASS	Immunoglobulin
T50035	SEQUENCE	MIFLLLMLSLELQLHQIAALFTVTVPKELYIIEHGSNVTLECNFDTGSHVNLGAITASLQKVENDTSPHRERATLLEEQLPLGKASFHIPQVQVRDEGQYQCIIIYGVAWDYKYLTLKVKASYRKINTHILKVPETDEVELTCQATGYPLAEVSWPNVSVPANTSHSRTPEGLYQVTSVLRLKPPPGRNFSCVFWNTHVRELTLASIDLQSQMEPRTHPTWLLHIFIPFCIIAFIFIATVIALRKQLCQKLYSSKDTTKRPVTTTKREVNSAI

T39195	TARGETID	T39195
T39195	FORMERID	TTDI03305
T39195	UNIPROID	KLK14_HUMAN
T39195	TARGNAME	Kallikrein-14 (KLK14)
T39195	GENENAME	KLK14
T39195	TARGTYPE	Patented-recorded
T39195	SYNONYMS	hK14; Kallikrein-like protein 6; KLKL6; KLK-L6
T39195	FUNCTION	May activate/inactivate the proteinase-activated receptors F2R, F2RL1 and F2RL3 and other kallikreins including KLK1, KLK3, KLK5 and KLK11. May function in seminal clot liquefaction through direct cleavage of the semenogelin SEMG1 and SEMG2 and activation of KLK3. May function through desmoglein DSG1 cleavage in epidermal desquamation a process by which the most superficial corneocytes are shed from the skin surface. May be involved in several aspects of tumor progression including growth, invasion and angiogenesis. Serine-type endopeptidase with a dual trypsin-like and chymotrypsin-like substrate specificity.
T39195	BIOCLASS	Peptidase
T39195	ECNUMBER	EC 3.4.21.-
T39195	SEQUENCE	MSLRVLGSGTWPSAPKMFLLLTALQVLAIAMTQSQEDENKIIGGHTCTRSSQPWQAALLAGPRRRFLCGGALLSGQWVITAAHCGRPILQVALGKHNLRRWEATQQVLRVVRQVTHPNYNSRTHDNDLMLLQLQQPARIGRAVRPIEVTQACASPGTSCRVSGWGTISSPIARYPASLQCVNINISPDEVCQKAYPRTITPGMVCAGVPQGGKDSCQGDSGGPLVCRGQLQGLVSWGMERCALPGYPGVYTNLCKYRSWIEETMRDK
T39195	DRUGINFO	D00LOL	PMID23849879C3	Investigative
T39195	DRUGINFO	D07OQF	PMID25489658C4d	Investigative

T03687	TARGETID	T03687
T03687	FORMERID	TTDI03262
T03687	UNIPROID	HDAC9_HUMAN
T03687	TARGNAME	Histone deacetylase 9 (HDAC9)
T03687	GENENAME	HDAC9
T03687	TARGTYPE	Patented-recorded
T03687	SYNONYMS	MITR; MEF2-interacting transcription repressor MITR; KIAA0744; Histone deacetylase-related protein; Histone deacetylase 7B; HDRP; HDAC7B; HDAC7; HD9; HD7b
T03687	FUNCTION	Gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Represses MEF2-dependent transcription. Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4).
T03687	BIOCLASS	Carbon-nitrogen hydrolase
T03687	ECNUMBER	EC 3.5.1.98
T03687	SEQUENCE	MHSMISSVDVKSEVPVGLEPISPLDLRTDLRMMMPVVDPVVREKQLQQELLLIQQQQQIQKQLLIAEFQKQHENLTRQHQAQLQEHIKELLAIKQQQELLEKEQKLEQQRQEQEVERHRREQQLPPLRGKDRGRERAVASTEVKQKLQEFLLSKSATKDTPTNGKNHSVSRHPKLWYTAAHHTSLDQSSPPLSGTSPSYKYTLPGAQDAKDDFPLRKTASEPNLKVRSRLKQKVAERRSSPLLRRKDGNVVTSFKKRMFEVTESSVSSSSPGSGPSSPNNGPTGSVTENETSVLPPTPHAEQMVSQQRILIHEDSMNLLSLYTSPSLPNITLGLPAVPSQLNASNSLKEKQKCETQTLRQGVPLPGQYGGSIPASSSHPHVTLEGKPPNSSHQALLQHLLLKEQMRQQKLLVAGGVPLHPQSPLATKERISPGIRGTHKLPRHRPLNRTQSAPLPQSTLAQLVIQQQHQQFLEKQKQYQQQIHMNKLLSKSIEQLKQPGSHLEEAEEELQGDQAMQEDRAPSSGNSTRSDSSACVDDTLGQVGAVKVKEEPVDSDEDAQIQEMESGEQAAFMQQPFLEPTHTRALSVRQAPLAAVGMDGLEKHRLVSRTHSSPAASVLPHPAMDRPLQPGSATGIAYDPLMLKHQCVCGNSTTHPEHAGRIQSIWSRLQETGLLNKCERIQGRKASLEEIQLVHSEHHSLLYGTNPLDGQKLDPRILLGDDSQKFFSSLPCGGLGVDSDTIWNELHSSGAARMAVGCVIELASKVASGELKNGFAVVRPPGHHAEESTAMGFCFFNSVAITAKYLRDQLNISKILIVDLDVHHGNGTQQAFYADPSILYISLHRYDEGNFFPGSGAPNEVGTGLGEGYNINIAWTGGLDPPMGDVEYLEAFRTIVKPVAKEFDPDMVLVSAGFDALEGHTPPLGGYKVTAKCFGHLTKQLMTLADGRVVLALEGGHDLTAICDASEACVNALLGNELEPLAEDILHQSPNMNAVISLQKIIEIQSMSLKFS
T03687	DRUGINFO	D0T7OQ	PMID29671355-Compound-73	Patented
T03687	DRUGINFO	D0YN2T	PMID29671355-Compound-45a	Patented
T03687	DRUGINFO	D0DI9S	PMID29671355-Compound-31	Patented
T03687	DRUGINFO	D0LP1K	PMID29671355-Compound-21	Patented
T03687	DRUGINFO	D07WAT	PMID29671355-Compound-62	Patented
T03687	DRUGINFO	D0BP8I	PMID29671355-Compound-43	Patented
T03687	DRUGINFO	D0RA0D	PMID29671355-Compound-25	Patented
T03687	DRUGINFO	D0R7JA	TMP269	Investigative

T59459	TARGETID	T59459
T59459	UNIPROID	JIP1_HUMAN
T59459	TARGNAME	JNK-interacting protein 1 peptide (pepJIP1)
T59459	GENENAME	MAPK8IP1
T59459	TARGTYPE	Patented-recorded
T59459	SYNONYMS	PRKM8IP; Mitogen-activated protein kinase 8-interacting protein 1; JNK-interacting protein 1; JNK MAP kinase scaffold protein 1; JIP1; JIP-1; Islet-brain 1; IB1; IB-1; C-Jun-amino-terminal kinase-interacting protein 1
T59459	FUNCTION	Required for JNK activation in response to excitotoxic stress. Cytoplasmic MAPK8IP1 causes inhibition of JNK-regulated activity by retaining JNK in the cytoplasm and inhibiting JNK phosphorylation of c-Jun. May also participate in ApoER2-specific reelin signaling. Directly, or indirectly, regulates GLUT2 gene expression and beta-cell function. Appears to have a role in cell signaling in mature and developing nerve terminals. May function as a regulator of vesicle transport, through interactions with the JNK-signaling components and motor proteins. Functions as an anti-apoptotic protein and whose level seems to influence the beta-cell death or survival response. Acts as a scaffold protein that coordinates with SH3RF1 in organizing different components of the JNK pathway, including RAC1 or RAC2, MAP3K11/MLK3 or MAP3K7/TAK1, MAP2K7/MKK7, MAPK8/JNK1 and/or MAPK9/JNK2 into a functional multiprotein complex to ensure the effective activation of the JNK signaling pathway. Regulates the activation of MAPK8/JNK1 and differentiation of CD8(+) T-cells. The JNK-interacting protein (JIP) group of scaffold proteins selectively mediates JNK signaling by aggregating specific components of the MAPK cascade to form a functional JNK signaling module.
T59459	PDBSTRUC	6FUZ; 5LW1; 4IZY; 4HYU; 4HYS
T59459	SEQUENCE	MAERESGGLGGGAASPPAASPFLGLHIASPPNFRLTHDISLEEFEDEDLSEITDECGISLQCKDTLSLRPPRAGLLSAGGGGAGSRLQAEMLQMDLIDATGDTPGAEDDEEDDDEERAARRPGAGPPKAESGQEPASRGQGQSQGQSQGPGSGDTYRPKRPTTLNLFPQVPRSQDTLNNNSLGKKHSWQDRVSRSSSPLKTGEQTPPHEHICLSDELPPQSGPAPTTDRGTSTDSPCRRSTATQMAPPGGPPAAPPGGRGHSHRDRIHYQADVRLEATEEIYLTPVQRPPDAAEPTSAFLPPTESRMSVSSDPDPAAYPSTAGRPHPSISEEEEGFDCLSSPERAEPPGGGWRGSLGEPPPPPRASLSSDTSALSYDSVKYTLVVDEHAQLELVSLRPCFGDYSDESDSATVYDNCASVSSPYESAIGEEYEEAPRPQPPACLSEDSTPDEPDVHFSKKFLNVFMSGRSRSSSAESFGLFSCIINGEEQEQTHRAIFRFVPRHEDELELEVDDPLLVELQAEDYWYEAYNMRTGARGVFPAYYAIEVTKEPEHMAALAKNSDWVDQFRVKFLGSVQVPYHKGNDVLCAAMQKIATTRRLTVHFNPPSSCVLEISVRGVKIGVKADDSQEAKGNKCSHFFQLKNISFCGYHPKNNKYFGFITKHPADHRFACHVFVSEDSTKALAESVGRAFQQFYKQFVEYTCPTEDIYLE
T59459	DRUGINFO	D0ID4H	PMID25991433-Compound-N1	Patented

T82720	TARGETID	T82720
T82720	FORMERID	TTDI03163
T82720	UNIPROID	DYR1B_HUMAN
T82720	TARGNAME	Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B)
T82720	GENENAME	DYRK1B
T82720	TARGTYPE	Patented-recorded
T82720	SYNONYMS	Minibrain-related kinase; MIRK; Dual specificity tyrosine-phosphorylation-regulated kinase 1B
T82720	FUNCTION	Enhances the transcriptional activity of TCF1/HNF1A and FOXO1. Inhibits epithelial cell migration. Mediates colon carcinoma cell survival in mitogen-poor environments. Inhibits the SHH and WNT1 pathways, thereby enhancing adipogenesis. In addition, promotes expression of the gluconeogenic enzyme glucose-6-phosphatase (G6PC). Dual-specificity kinase which possesses both serine/threonine and tyrosine kinase activities.
T82720	BIOCLASS	Kinase
T82720	ECNUMBER	EC 2.7.12.1
T82720	SEQUENCE	MAVPPGHGPFSGFPGPQEHTQVLPDVRLLPRRLPLAFRDATSAPLRKLSVDLIKTYKHINEVYYAKKKRRAQQAPPQDSSNKKEKKVLNHGYDDDNHDYIVRSGERWLERYEIDSLIGKGSFGQVVKAYDHQTQELVAIKIIKNKKAFLNQAQIELRLLELMNQHDTEMKYYIVHLKRHFMFRNHLCLVFELLSYNLYDLLRNTHFRGVSLNLTRKLAQQLCTALLFLATPELSIIHCDLKPENILLCNPKRSAIKIVDFGSSCQLGQRIYQYIQSRFYRSPEVLLGTPYDLAIDMWSLGCILVEMHTGEPLFSGSNEVDQMNRIVEVLGIPPAAMLDQAPKARKYFERLPGGGWTLRRTKELRKDYQGPGTRRLQEVLGVQTGGPGGRRAGEPGHSPADYLRFQDLVLRMLEYEPAARISPLGALQHGFFRRTADEATNTGPAGSSASTSPAPLDTCPSSSTASSISSSGGSSGSSSDNRTYRYSNRYCGGPGPPITDCEMNSPQVPPSQPLRPWAGGDVPHKTHQAPASASSLPGTGAQLPPQPRYLGRPPSPTSPPPPELMDVSLVGGPADCSPPHPAPAPQHPAASALRTRMTGGRPPLPPPDDPATLGPHLGLRGVPQSTAASS
T82720	DRUGINFO	D00TFF	PMID28766366-Compound-Scheme2WO2012/098065bottom	Patented
T82720	DRUGINFO	D05CLL	PMID28766366-Compound-Scheme7WO2012/098070upper	Patented
T82720	DRUGINFO	D08CUF	PMID28766366-Compound-Scheme9EHT1610	Patented
T82720	DRUGINFO	D08DIJ	PMID28766366-Compound-Scheme9EHT5372	Patented
T82720	DRUGINFO	D09CDR	PMID28766366-Compound-Scheme25-2	Patented
T82720	DRUGINFO	D0B8IQ	PMID28766366-Compound-Scheme2WO2012/098065upper	Patented
T82720	DRUGINFO	D0BP6J	PMID28766366-Compound-Scheme7WO2012/098070bottom	Patented
T82720	DRUGINFO	D0C0BP	PMID28766366-Compound-Scheme4Upper	Patented
T82720	DRUGINFO	D0CC7E	PMID28766366-Compound-Scheme25-3	Patented
T82720	DRUGINFO	D0DT5I	PMID28766366-Compound-Scheme9EHT3356	Patented
T82720	DRUGINFO	D0GE4F	PMID28766366-Compound-Scheme25-4	Patented
T82720	DRUGINFO	D0O9BK	PMID28766366-Compound-Scheme9EHT6840	Patented
T82720	DRUGINFO	D0P7QO	PMID28766366-Compound-Scheme5	Patented
T82720	DRUGINFO	D0PJ1W	PMID28766366-Compound-Scheme9EHT9851	Patented
T82720	DRUGINFO	D0SB1W	PMID28766366-Compound-Scheme4Bottom	Patented
T82720	DRUGINFO	D04SYJ	PMID28766366-Compound-Scheme14BINDY	Patented
T82720	DRUGINFO	D02DBH	PMID28766366-Compound-Scheme21Left	Patented
T82720	DRUGINFO	D07BWC	PMID28766366-Compound-Scheme21Right	Patented
T82720	DRUGINFO	D00AQR	WO2013026806C72 	Investigative
T82720	DRUGINFO	D0X9PI	PMID24900699C68	Investigative
T82720	DRUGINFO	D06CXU	PMID23642479C17	Investigative

T03150	TARGETID	T03150
T03150	UNIPROID	DGLA_HUMAN
T03150	TARGNAME	Diacylglycerol lipase alpha (DAGLA)
T03150	GENENAME	DAGLA
T03150	TARGTYPE	Patented-recorded
T03150	SYNONYMS	Sn1-specific diacylglycerol lipase alpha; Neural stem cell-derived dendrite regulator; NSDDR; KIAA0659; DGL-alpha; C11orf11
T03150	FUNCTION	Catalyzes the hydrolysis of diacylglycerol (DAG) to 2-arachidonoyl-glycerol (2-AG), the most abundant endocannabinoid in tissues. Required for axonal growth during development and for retrograde synaptic signaling at mature synapses.
T03150	BIOCLASS	Carboxylic ester hydrolase
T03150	ECNUMBER	EC 3.1.1.-
T03150	SEQUENCE	MPGIVVFRRRWSVGSDDLVLPAIFLFLLHTTWFVILSVVLFGLVYNPHEACSLNLVDHGRGYLGILLSCMIAEMAIIWLSMRGGILYTEPRDSMQYVLYVRLAILVIEFIYAIVGIVWLTQYYTSCNDLTAKNVTLGMVVCNWVVILSVCITVLCVFDPTGRTFVKLRATKRRQRNLRTYNLRHRLEEGQATSWSRRLKVFLCCTRTKDSQSDAYSEIAYLFAEFFRDLDIVPSDIIAGLVLLRQRQRAKRNAVLDEANNDILAFLSGMPVTRNTKYLDLKNSQEMLRYKEVCYYMLFALAAYGWPMYLMRKPACGLCQLARSCSCCLCPARPRFAPGVTIEEDNCCGCNAIAIRRHFLDENMTAVDIVYTSCHDAVYETPFYVAVDHDKKKVVISIRGTLSPKDALTDLTGDAERLPVEGHHGTWLGHKGMVLSAEYIKKKLEQEMVLSQAFGRDLGRGTKHYGLIVVGHSLGAGTAAILSFLLRPQYPTLKCFAYSPPGGLLSEDAMEYSKEFVTAVVLGKDLVPRIGLSQLEGFRRQLLDVLQRSTKPKWRIIVGATKCIPKSELPEEVEVTTLASTRLWTHPSDLTIALSASTPLYPPGRIIHVVHNHPAEQCCCCEQEEPTYFAIWGDNKAFNEVIISPAMLHEHLPYVVMEGLNKVLENYNKGKTALLSAAKVMVSPTEVDLTPELIFQQQPLPTGPPMPTGLALELPTADHRNSSVRSKSQSEMSLEGFSEGRLLSPVVAAAARQDPVELLLLSTQERLAAELQARRAPLATMESLSDTESLYSFDSRRSSGFRSIRGSPSLHAVLERDEGHLFYIDPAIPEENPSLSSRTELLAADSLSKHSQDTQPLEAALGSGGVTPERPPSAAANDEEEEVGGGGGGPASRGELALHNGRLGDSPSPQVLEFAEFIDSLFNLDSKSSSFQDLYCMVVPESPTSDYAEGPKSPSQQEILLRAQFEPNLVPKPPRLFAGSADPSSGISLSPSFPLSSSGELMDLTPTGLSSQECLAADKIRTSTPTGHGASPAKQDELVISAR
T03150	DRUGINFO	D0TL1G	PMID29053063-Compound-15	Patented
T03150	DRUGINFO	D05LXG	RHC80267	Investigative

T22104	TARGETID	T22104
T22104	FORMERID	TTDR00888
T22104	UNIPROID	GREM1_HUMAN
T22104	TARGNAME	Gremlin-1 (Gremlin-1)
T22104	GENENAME	GREM1
T22104	TARGTYPE	Patented-recorded
T22104	SYNONYMS	Proliferation-inducing gene 2; PIG2; Increased in high glucose protein 2; IHG-2; Down-regulated in Mos-transformed cells protein; DRM; DAND2; DAN domain family member 2; Cysteine knot superfamily 1, BMP antagonist 1; Cell proliferation-inducing gene 2 protein; CKTSF1B1
T22104	FUNCTION	Down-regulates the BMP4 signaling in a dose-dependent manner. Antagonist of BMP2; inhibits BMP2-mediated differentiation of osteoblasts (in vitro). Acts as inhibitor of monocyte chemotaxis. Can inhibit the growth or viability of normal cells but not transformed cells when is overexpressed. Cytokine that may play an important role during carcinogenesis and metanephric kidney organogenesis, as a BMP antagonist required for early limb outgrowth and patterning in maintaining the FGF4-SHH feedback loop.
T22104	PDBSTRUC	5AEJ
T22104	SEQUENCE	MSRTAYTVGALLLLLGTLLPAAEGKKKGSQGAIPPPDKAQHNDSEQTQSPQQPGSRNRGRGQGRGTAMPGEEVLESSQEALHVTERKYLKRDWCKTQPLKQTIHEEGCNSRTIINRFCYGQCNSFYIPRHIRKEEGSFQSCSFCKPKKFTTMMVTLNCPELQPPTKKKRVTRVKQCRCISIDLD
T22104	DRUGINFO	D0MP8N	Antibodie derivative 5	Patented

T19184	TARGETID	T19184
T19184	UNIPROID	PYGL_HUMAN; PYGM_HUMAN; PYGB_HUMAN
T19184	TARGNAME	Glycogen phosphorylase (PYG)
T19184	GENENAME	PYGL; PYGM; PYGB
T19184	TARGTYPE	Patented-recorded
T19184	SYNONYMS	Glycogen phosphorylase
T19184	FUNCTION	Phosphorylase is an important allosteric enzyme in carbohydrate metabolism. Enzymes from different sources differ in their regulatory mechanisms and in their natural substrates. However, all known phosphorylases share catalytic and structural properties.
T19184	BIOCLASS	Glycosyltransferases
T19184	SEQUENCE	MAKPLTDQEKRRQISIRGIVGVENVAELKKSFNRHLHFTLVKDRNVATTRDYYFALAHTVRDHLVGRWIRTQQHYYDKCPKRVYYLSLEFYMGRTLQNTMINLGLQNACDEAIYQLGLDIEELEEIEEDAGLGNGGLGRLAACFLDSMATLGLAAYGYGIRYEYGIFNQKIRDGWQVEEADDWLRYGNPWEKSRPEFMLPVHFYGKVEHTNTGTKWIDTQVVLALPYDTPVPGYMNNTVNTMRLWSARAPNDFNLRDFNVGDYIQAVLDRNLAENISRVLYPNDNFFEGKELRLKQEYFVVAATLQDIIRRFKASKFGSTRGAGTVFDAFPDQVAIQLNDTHPALAIPELMRIFVDIEKLPWSKAWELTQKTFAYTNHTVLPEALERWPVDLVEKLLPRHLEIIYEINQKHLDRIVALFPKDVDRLRRMSLIEEEGSKRINMAHLCIVGSHAVNGVAKIHSDIVKTKVFKDFSELEPDKFQNKTNGITPRRWLLLCNPGLAELIAEKIGEDYVKDLSQLTKLHSFLGDDVFLRELAKVKQENKLKFSQFLETEYKVKINPSSMFDVQVKRIHEYKRQLLNCLHVITMYNRIKKDPKKLFVPRTVIIGGKAAPGYHMAKMIIKLITSVADVVNNDPMVGSKLKVIFLENYRVSLAEKVIPATDLSEQISTAGTEASGTGNMKFMLNGALTIGTMDGANVEMAEEAGEENLFIFGMRIDDVAALDKKGYEAKEYYEALPELKLVIDQIDNGFFSPKQPDLFKDIINMLFYHDRFKVFADYEAYVKCQDKVSQLYMNPKAWNTMVLKNIAASGKFSSDRTIKEYAQNIWNVEPSDLKISLSNESNKVNGN
T19184	DRUGINFO	D00PEV	PMID26666989-Compound-Figure9middle03	Patented
T19184	DRUGINFO	D01DXB	PMID26666989-Compound-Figure9middle11	Patented
T19184	DRUGINFO	D02KWZ	PMID26666989-Compound-Figure9middle04	Patented
T19184	DRUGINFO	D03WPO	PMID26666989-Compound-Figure9middle10	Patented
T19184	DRUGINFO	D06PSM	PMID26666989-Compound-Figure9bottomright	Patented
T19184	DRUGINFO	D06TPL	PMID26666989-Compound-Figure11topright	Patented
T19184	DRUGINFO	D07POD	PMID26666989-Compound-Figure9middle05	Patented
T19184	DRUGINFO	D08GSN	PMID26666989-Compound-Figure9middle12	Patented
T19184	DRUGINFO	D08KMR	PMID26666989-Compound-Figure12bottomright	Patented
T19184	DRUGINFO	D09PAZ	PMID26666989-Compound-Figure9middle08	Patented
T19184	DRUGINFO	D09YQO	PMID26666989-Compound-Figure12topmiddile	Patented
T19184	DRUGINFO	D0AJ3H	PMID26666989-Compound-Figure9middle07	Patented
T19184	DRUGINFO	D0H0XX	PMID26666989-Compound-Figure12bottommiddle01	Patented
T19184	DRUGINFO	D0JO2A	PMID26666989-Compound-Figure9left01	Patented
T19184	DRUGINFO	D0KK0E	PMID26666989-Compound-Figure9topright01	Patented
T19184	DRUGINFO	D0MT6D	PMID26666989-Compound-Figure9middle13	Patented
T19184	DRUGINFO	D0N1IA	PMID26666989-Compound-Figure9middle02	Patented
T19184	DRUGINFO	D0S5CP	PMID26666989-Compound-Figure12left	Patented
T19184	DRUGINFO	D0TE4S	PMID26666989-Compound-Figure11Ala down	Patented
T19184	DRUGINFO	D0TY4L	PMID26666989-Compound-Figure9middle06	Patented
T19184	DRUGINFO	D0U7WQ	PMID26666989-Compound-Figure11Ala up	Patented
T19184	DRUGINFO	D0VJ0N	PMID26666989-Compound-Figure9left02	Patented
T19184	DRUGINFO	D0W5DU	PMID26666989-Compound-Figure9toprightR02	Patented
T19184	DRUGINFO	D0Y4KB	PMID26666989-Compound-Figure12bottommiddle02	Patented
T19184	DRUGINFO	D0YE8Q	PMID26666989-Compound-Figure9middle01	Patented

T40890	TARGETID	T40890
T40890	FORMERID	TTDR01298
T40890	UNIPROID	GLI1_HUMAN
T40890	TARGNAME	Zinc finger protein GLI1 (Gli1)
T40890	GENENAME	GLI1
T40890	TARGTYPE	Patented-recorded
T40890	SYNONYMS	Oncogene GLI; Glioma-associated oncogene; GLI
T40890	FUNCTION	Binds to the DNA consensus sequence 5'-GACCACCCA-3'. Regulates the transcription of specific genes during normal development. Plays a role in craniofacial development and digital development, as well as development of the central nervous system and gastrointestinal tract. Mediates SHH signaling. Plays a role in cell proliferation and differentiation via its role in SHH signaling. Acts as a transcriptional activator.
T40890	PDBSTRUC	5OM0; 4KMD; 4BLB; 2GLI
T40890	SEQUENCE	MFNSMTPPPISSYGEPCCLRPLPSQGAPSVGTEGLSGPPFCHQANLMSGPHSYGPARETNSCTEGPLFSSPRSAVKLTKKRALSISPLSDASLDLQTVIRTSPSSLVAFINSRCTSPGGSYGHLSIGTMSPSLGFPAQMNHQKGPSPSFGVQPCGPHDSARGGMIPHPQSRGPFPTCQLKSELDMLVGKCREEPLEGDMSSPNSTGIQDPLLGMLDGREDLEREEKREPESVYETDCRWDGCSQEFDSQEQLVHHINSEHIHGERKEFVCHWGGCSRELRPFKAQYMLVVHMRRHTGEKPHKCTFEGCRKSYSRLENLKTHLRSHTGEKPYMCEHEGCSKAFSNASDRAKHQNRTHSNEKPYVCKLPGCTKRYTDPSSLRKHVKTVHGPDAHVTKRHRGDGPLPRAPSISTVEPKREREGGPIREESRLTVPEGAMKPQPSPGAQSSCSSDHSPAGSAANTDSGVEMTGNAGGSTEDLSSLDEGPCIAGTGLSTLRRLENLRLDQLHQLRPIGTRGLKLPSLSHTGTTVSRRVGPPVSLERRSSSSSSISSAYTVSRRSSLASPFPPGSPPENGASSLPGLMPAQHYLLRARYASARGGGTSPTAASSLDRIGGLPMPPWRSRAEYPGYNPNAGVTRRASDPAQAADRPAPARVQRFKSLGCVHTPPTVAGGGQNFDPYLPTSVYSPQPPSITENAAMDARGLQEEPEVGTSMVGSGLNPYMDFPPTDTLGYGGPEGAAAEPYGARGPGSLPLGPGPPTNYGPNPCPQQASYPDPTQETWGEFPSHSGLYPGPKALGGTYSQCPRLEHYGQVQVKPEQGCPVGSDSTGLAPCLNAHPSEGPPHPQPLFSHYPQPSPPQYLQSGPYTQPPPDYLPSEPRPCLDFDSPTHSTGQLKAQLVCNYVQSQQELLWEGGGREDAPAQEPSYQSPKFLGGSQVSPSRAKAPVNTYGPGFGPNLPNHKSGSYPTPSPCHENFVVGANRASHRAAAPPRLLPPLPTCYGPLKVGGTNPSCGHPEVGRLGGGPALYPPPEGQVCNPLDSLDLDNTQLDFVAILDEPQGLSPPPSHDQRGSSGHTPPPSGPPNMAVGNMSVLLRSLPGETEFLNSSA
T40890	DRUGINFO	D00KXJ	PMID26666870-Compound-16	Patented
T40890	DRUGINFO	D0FL0T	Imidazo bicyclic iminium derivative 1	Patented
T40890	DRUGINFO	D0II7X	Imidazo bicyclic iminium derivative 2	Patented
T40890	DRUGINFO	D00RRB	Isoflavone derivative 1	Patented
T40890	DRUGINFO	D01BGG	Isoflavone derivative 5	Patented
T40890	DRUGINFO	D04IFL	Isoflavone derivative 7	Patented
T40890	DRUGINFO	D05NRG	Isoflavone derivative 8	Patented
T40890	DRUGINFO	D09VIE	Isoflavone derivative 9	Patented
T40890	DRUGINFO	D0J1RB	Isoflavone derivative 6	Patented
T40890	DRUGINFO	D0TP0S	Isoflavone derivative 3	Patented
T40890	DRUGINFO	D0WI1G	Isoflavone derivative 2	Patented
T40890	DRUGINFO	D0Z6IS	Isoflavone derivative 4	Patented

T63303	TARGETID	T63303
T63303	UNIPROID	MMP2_HUMAN; MMP9_HUMAN
T63303	TARGNAME	Gelatinase (GEL)
T63303	GENENAME	MMP2; MMP9
T63303	TARGTYPE	Patented-recorded
T63303	SYNONYMS	Matrix metalloproteinase GEL; Gelatinase B; Gelatinase A; Collagenase IV; CLG4
T63303	FUNCTION	A proteolytic enzyme that allows a living organism to hydrolyse gelatin into its sub-compounds (polypeptides, peptides, and amino acids) that can cross the cell membrane and be used by the organism. It is not a pepsin.
T63303	BIOCLASS	Peptidase
T63303	SEQUENCE	MEALMARGALTGPLRALCLLGCLLSHAAAAPSPIIKFPGDVAPKTDKELAVQYLNTFYGCPKESCNLFVLKDTLKKMQKFFGLPQTGDLDQNTIETMRKPRCGNPDVANYNFFPRKPKWDKNQITYRIIGYTPDLDPETVDDAFARAFQVWSDVTPLRFSRIHDGEADIMINFGRWEHGDGYPFDGKDGLLAHAFAPGTGVGGDSHFDDDELWTLGEGQVVRVKYGNADGEYCKFPFLFNGKEYNSCTDTGRSDGFLWCSTTYNFEKDGKYGFCPHEALFTMGGNAEGQPCKFPFRFQGTSYDSCTTEGRTDGYRWCGTTEDYDRDKKYGFCPETAMSTVGGNSEGAPCVFPFTFLGNKYESCTSAGRSDGKMWCATTANYDDDRKWGFCPDQGYSLFLVAAHEFGHAMGLEHSQDPGALMAPIYTYTKNFRLSQDDIKGIQELYGASPDIDLGTGPTPTLGPVTPEICKQDIVFDGIAQIRGEIFFFKDRFIWRTVTPRDKPMGPLLVATFWPELPEKIDAVYEAPQEEKAVFFAGNEYWIYSASTLERGYPKPLTSLGLPPDVQRVDAAFNWSKNKKTYIFAGDKFWRYNEVKKKMDPGFPKLIADAWNAIPDNLDAVVDLQGGGHSYFFKGAYYLKLENQSLKSVKFGSIKSDWLGC
T63303	DRUGINFO	D01KYS	PMID29130358-Compound-Figure15(8)	Patented
T63303	DRUGINFO	D02YCN	PMID29130358-Compound-Figure14(5)	Patented
T63303	DRUGINFO	D0I6IR	PMID29130358-Compound-Figure14(6)	Patented
T63303	DRUGINFO	D0NF2E	PMID29130358-Compound-Figure9(1)	Patented
T63303	DRUGINFO	D0VM8G	PMID29130358-Compound-Figure15(7)	Patented

T11824	TARGETID	T11824
T11824	UNIPROID	TAU_HUMAN
T11824	TARGNAME	Microtubule-associated protein tau phosphorylation (MAPT p)
T11824	GENENAME	MAPT
T11824	TARGTYPE	Patented-recorded
T11824	SYNONYMS	tau phosphorylation; Paired helical filamenttau phosphorylation; Paired helical filament-tau phosphorylation; PHFtau; PHF-tau; Neurofibrillary tangle protein phosphorylation; MTBT1 phosphorylation; MAPTL phosphorylation
T11824	FUNCTION	The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization. Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity.
T11824	PDBSTRUC	6QJQ; 6QJP; 6QJM; 6QJH; 6NWQ
T11824	SEQUENCE	MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQEPESGKVVQEGFLREPGPPGLSHQLMSGMPGAPLLPEGPREATRQPSGTGPEDTEGGRHAPELLKHQLLGDLHQEGPPLKGAGGKERPGSKEEVDEDRDVDESSPQDSPPSKASPAQDGRPPQTAAREATSIPGFPAEGAIPLPVDFLSKVSTEIPASEPDGPSVGRAKGQDAPLEFTFHVEITPNVQKEQAHSEEHLGRAAFPGAPGEGPEARGPSLGEDTKEADLPEPSEKQPAAAPRGKPVSRVPQLKARMVSKSKDGTGSDDKKAKTSTRSSAKTLKNRPCLSPKHPTPGSSDPLIQPSSPAVCPEPPSSPKYVSSVTSRTGSSGAKEMKLKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGL
T11824	DRUGINFO	D0I3LY	PMID28766366-Compound-Scheme22Middle	Patented

T01271	TARGETID	T01271
T01271	UNIPROID	BCR_HUMAN-ABL1_HUMAN
T01271	TARGNAME	Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)
T01271	GENENAME	BCR-ABL1
T01271	TARGTYPE	Patented-recorded
T01271	SYNONYMS	T315I BCR-ABL; BCR-ABL T315I mutant
T01271	FUNCTION	Difficult to inhibit with ATP mimetics. The mutation eliminates a critical hydrogen bonding interaction required for high-affinity binding of imatinib, nilotinib, and dasatinib and alters the topology of the ATP-binding pocket.
T01271	BIOCLASS	Kinase
T01271	SEQUENCE	MVDPVGFAEAWKAQFPDSEPPRMELRSVGDIEQELERCKASIRRLEQEVNQERFRMIYLQTLLAKEKKSYDRQRWGFRRAAQAPDGASEPRASASRPQPAPADGADPPPAEEPEARPDGEGSPGKARPGTARRPGAAASGERDDRGPPASVAALRSNFERIRKGHGQPGADAEKPFYVNVEFHHERGLVKVNDKEVSDRISSLGSQAMQMERKKSQHGAGSSVGDASRPPYRGRSSESSCGVDGDYEDAELNPRFLKDNLIDANGGSRPPWPPLEYQPYQSIYVGGMMEGEGKGPLLRSQSTSEQEKRLTWPRRSYSPRSFEDCGGGYTPDCSSNENLTSSEEDFSSGQSSRVSPSPTTYRMFRDKSRSPSQNSQQSFDSSSPPTPQCHKRHRHCPVVVSEATIVGVRKTGQIWPNDGEGAFHGDADGSFGTPPGYGCAADRAEEQRRHQDGLPYIDDSPSSSPHLSSKGRGSRDALVSGALESTKASELDLEKGLEMRKWVLSGILASEETYLSHLEALLLPMKPLKAAATTSQPVLTSQQIETIFFKVPELYEIHKEFYDGLFPRVQQWSHQQRVGDLFQKLASQLGVYRAFVDNYGVAMEMAEKCCQANAQFAEISENLRARSNKDAKDPTTKNSLETLLYKPVDRVTRSTLVLHDLLKHTPASHPDHPLLQDALRISQNFLSSINEEITPRRQSMTVKKGEHRQLLKDSFMVELVEGARKLRHVFLFTDLLLCTKLKKQSGGKTQQYDCKWYIPLTDLSFQMVDELEAVPNIPLVPDEELDALKIKISQIKNDIQREKRANKGSKATERLKKKLSEQESLLLLMSPSMAFRVHSRNGKSYTFLISSDYERAEWRENIREQQKKCFRSFSLTSVELQMLTNSCVKLQTVHSIPLTINKEDDESPGLYGFLNVIVHSATGFKQSSNLYCTLEVDSFGYFVNKAKTRVYRDTAEPNWNEEFEIELEGSQTLRILCYEKCYNKTKIPKEDGESTDRLMGKGQVQLDPQALQDRDWQRTVIAMNGIEVKLSVKFNSREFSLKRMPSRKQTGVFGVKIAVVTKRERSKVPYIVRQCVEEIERRGMEEVGIYRVSGVATDIQALKAAFDVNNKDVSVMMSEMDVNAIAGTLKLYFRELPEPLFTDEFYPNFAEGIALSDPVAKESCMLNLLLSLPEANLLTFLFLLDHLKRVAEKEAVNKMSLHNLATVFGPTLLRPSEKESKLPANPSQPITMTDSWSLEVMSQVQVLLYFLQLEAIPAPDSKRQSILFSTEVMLEICLKLVGCKSKKGLSSSSSCYLEEALQRPVASDFEPQGLSEAARWNSKENLLAGPSENDPNLFVALYDFVASGDNTLSITKGEKLRVLGYNHNGEWCEAQTKNGQGWVPSNYITPVNSLEKHSWYHGPVSRNAAEYLLSSGINGSFLVRESESSPGQRSISLRYEGRVYHYRINTASDGKLYVSSESRFNTLAELVHHHSTVADGLITTLHYPAPKRNKPTVYGVSPNYDKWEMERTDITMKHKLGGGQYGEVYEGVWKKYSLTVAVKTLKEDTMEVEEFLKEAAVMKEIKHPNLVQLLGVCTREPPFYIITEFMTYGNLLDYLRECNRQEVNAVVLLYMATQISSAMEYLEKKNFIHRDLAARNCLVGENHLVKVADFGLSRLMTGDTYTAHAGAKFPIKWTAPESLAYNKFSIKSDVWAFGVLLWEIATYGMSPYPGIDLSQVYELLEKDYRMERPEGCPEKVYELMRACWQWNPSDRPSFAEIHQAFETMFQESSISDEVEKELGKQGVRGAVSTLLQAPELPTKTRTSRRAAEHRDTTDVPEMPHSKGQGESDPLDHEPAVSPLLPRKERGPPEGGLNEDERLLPKDKKTNLFSALIKKKKKTAPTPPKRSSSFREMDGQPERRGAGEEEGRDISNGALAFTPLDTADPAKSPKPSNGAGVPNGALRESGGSGFRSPHLWKKSSTLTSSRLATGEEEGGGSSSKRFLRSCSASCVPHGAKDTEWRSVTLPRDLQSTGRQFDSSTFGGHKSEKPALPRKRAGENRSDQVTRGTVTPPPRLVKKNEEAADEVFKDIMESSPGSSPPNLTPKPLRRQVTVAPASGLPHKEEAGKGSALGTPAAAEPVTPTSKAGSGAPGGTSKGPAEESRVRRHKHSSESPGRDKGKLSRLKPAPPPPPAASAGKAGGKPSQSPSQEAAGEAVLGAKTKATSLVDAVNSDAAKPSQPGEGLKKPVLPATPKPQSAKPSGTPISPAPVPSTLPSASSALAGDQPSSTAFIPLISTRVSLRKTRQPPERIASGAITKGVVLDSTEALCLAISRNSEQMASHSAVLEAGKNLYTFCVSYVDSIQQMRNKFAFREAINKLENNLRELQICPATAGSGPAATQDFSKLLSSVKEISDIVQR
T01271	DRUGINFO	D01LMW	Pyrrolo[2,3-b]pyridine derivative 4	Patented
T01271	DRUGINFO	D01UTX	PMID25656651-Compound-31c	Patented
T01271	DRUGINFO	D0C2YI	Alkynyl-heteroaromatic ring compound 1	Patented
T01271	DRUGINFO	D0FB1Q	PMID25656651-Compound-31b	Patented
T01271	DRUGINFO	D0H3VI	PMID25656651-Compound-31a	Patented
T01271	DRUGINFO	D01KIJ	PMID25656651-Compound-37b	Patented
T01271	DRUGINFO	D02KNW	PMID25656651-Compound-36a	Patented
T01271	DRUGINFO	D08IUE	PMID25656651-Compound-37c	Patented
T01271	DRUGINFO	D09WKF	PMID25656651-Compound-36d	Patented
T01271	DRUGINFO	D09ZFM	PMID25656651-Compound-36b	Patented
T01271	DRUGINFO	D0BK6R	PMID25656651-Compound-36c	Patented
T01271	DRUGINFO	D0E6EP	PMID25656651-Compound-19b	Patented
T01271	DRUGINFO	D0IA4G	PMID25656651-Compound-37a	Patented
T01271	DRUGINFO	D0JY1I	PMID25656651-Compound-19a	Patented
T01271	DRUGINFO	D0MX5B	Indazole derivative 5	Patented
T01271	DRUGINFO	D0A7XQ	ON-044580	Investigative
T01271	DRUGINFO	D0D3RL	AP-24163	Investigative

T80423	TARGETID	T80423
T80423	FORMERID	TTDI02613
T80423	UNIPROID	VHL_HUMAN
T80423	TARGNAME	von Hippel-Lindau disease tumor suppressor (VHL)
T80423	GENENAME	VHL
T80423	TARGTYPE	Patented-recorded
T80423	SYNONYMS	pVHL; Protein G7
T80423	FUNCTION	Seems to act as a target recruitment subunit in the E3 ubiquitin ligase complex and recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions. Involved in transcriptional repression through interaction with HIF1A, HIF1AN and histone deacetylases. Ubiquitinates, in an oxygen-responsive manner, ADRB2. Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex.
T80423	PDBSTRUC	6GMX; 6GMR; 6GMQ; 6GMN; 6GFZ
T80423	SEQUENCE	MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD
T80423	DRUGINFO	D0Q2SE	Pyrrolidine carboxamide derivative 1	Patented

T78710	TARGETID	T78710
T78710	FORMERID	TTDI03314
T78710	UNIPROID	KCNJ1_HUMAN
T78710	TARGNAME	Inward rectifier potassium channel Kir1.1 (KCNJ1)
T78710	GENENAME	KCNJ1
T78710	TARGTYPE	Patented-recorded
T78710	SYNONYMS	ROMK1; Potassium channel, inwardly rectifying subfamily J member 1; Inward rectifier K(+) channel Kir1.1; ATP-sensitive inward rectifier potassium channel 1
T78710	FUNCTION	Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. This channel is activated by internal ATP and can be blocked by external barium. In the kidney, probably plays a major role in potassium homeostasis.
T78710	BIOCLASS	Inward rectifier potassium channel
T78710	SEQUENCE	MNASSRNVFDTLIRVLTESMFKHLRKWVVTRFFGHSRQRARLVSKDGRCNIEFGNVEAQSRFIFFVDIWTTVLDLKWRYKMTIFITAFLGSWFFFGLLWYAVAYIHKDLPEFHPSANHTPCVENINGLTSAFLFSLETQVTIGYGFRCVTEQCATAIFLLIFQSILGVIINSFMCGAILAKISRPKKRAKTITFSKNAVISKRGGKLCLLIRVANLRKSLLIGSHIYGKLLKTTVTPEGETIILDQININFVVDAGNENLFFISPLTIYHVIDHNSPFFHMAAETLLQQDFELVVFLDGTVESTSATCQVRTSYVPEEVLWGYRFAPIVSKTKEGKYRVDFHNFSKTVEVETPHCAMCLYNEKDVRARMKRGYDNPNFILSEVNETDDTKM
T78710	DRUGINFO	D00ALX	PMID26004420-Compound-US20140309213B	Patented
T78710	DRUGINFO	D00CMX	PMID26004420-Compound-WO2013062900A	Patented
T78710	DRUGINFO	D00JVQ	PMID26004420-Compound-WO2014099633D	Patented
T78710	DRUGINFO	D00SLD	PMID26004420-Compound-WO2013028474C	Patented
T78710	DRUGINFO	D00WZH	PMID26004420-Compound-WO2015017305F	Patented
T78710	DRUGINFO	D01JCZ	PMID26004420-Compound-U2014S0288042C	Patented
T78710	DRUGINFO	D02HOM	PMID26004420-Compound-WO2013062900B	Patented
T78710	DRUGINFO	D02ZGO	PMID26004420-Compound-WO2010129379A	Patented
T78710	DRUGINFO	D03JCN	PMID26004420-Compound-US20140142115C	Patented
T78710	DRUGINFO	D03PRT	PMID26004420-Compound-WO2014015495A	Patented
T78710	DRUGINFO	D03TGG	PMID26004420-Compound-WO2012058134C	Patented
T78710	DRUGINFO	D05AJX	PMID26004420-Compound-WO2013062892E	Patented
T78710	DRUGINFO	D06CGQ	PMID26004420-Compound-US20140031349B	Patented
T78710	DRUGINFO	D06FLB	PMID26004420-Compound-WO2014150132C	Patented
T78710	DRUGINFO	D06TPB	PMID26004420-Compound-WO2013039802C	Patented
T78710	DRUGINFO	D07CMZ	PMID26004420-Compound-WO2014099633E	Patented
T78710	DRUGINFO	D07TUN	PMID26004420-Compound-WO2014085210B	Patented
T78710	DRUGINFO	D07VUL	PMID26004420-Compound-WO2013039802B	Patented
T78710	DRUGINFO	D08HBF	PMID26004420-Compound-U2014S0288042A	Patented
T78710	DRUGINFO	D08TDJ	PMID26004420-Compound-WO2014126944A	Patented
T78710	DRUGINFO	D08UXR	PMID26004420-Compound-WO2014150132B	Patented
T78710	DRUGINFO	D09KCN	PMID26004420-Compound-WO2015017305E	Patented
T78710	DRUGINFO	D09WRT	PMID26004420-Compound-WO2013039802A	Patented
T78710	DRUGINFO	D0A6EX	PMID26004420-Compound-WO2013062892D	Patented
T78710	DRUGINFO	D0C4BJ	PMID26004420-Compound-WO2014126944B	Patented
T78710	DRUGINFO	D0CC7A	PMID26004420-Compound-WO2010129379C	Patented
T78710	DRUGINFO	D0CI2I	PMID26004420-Compound-WO2012058116B	Patented
T78710	DRUGINFO	D0CI6Y	PMID26004420-Compound-US20140336177D	Patented
T78710	DRUGINFO	D0D7AI	PMID26004420-Compound-WO2013028474B	Patented
T78710	DRUGINFO	D0DG4A	PMID26004420-Compound-WO2014015495B	Patented
T78710	DRUGINFO	D0DX8P	PMID26004420-Compound-WO2010129379B	Patented
T78710	DRUGINFO	D0E2WS	PMID26004420-Compound-US20140275020E	Patented
T78710	DRUGINFO	D0EX9E	PMID26004420-Compound-US20140309213A	Patented
T78710	DRUGINFO	D0F0TY	PMID26004420-Compound-US20140031349C	Patented
T78710	DRUGINFO	D0FC5J	PMID26004420-Compound-US20140031349D	Patented
T78710	DRUGINFO	D0J9JB	PMID26004420-Compound-WO2012058116C	Patented
T78710	DRUGINFO	D0L8FE	PMID26004420-Compound-WO2012058116A	Patented
T78710	DRUGINFO	D0M6JD	PMID26004420-Compound-WO2014085210C	Patented
T78710	DRUGINFO	D0N4DY	PMID26004420-Compound-WO2015017305D	Patented
T78710	DRUGINFO	D0O1RL	PMID26004420-Compound-WO2014015495D	Patented
T78710	DRUGINFO	D0RM6C	PMID26004420-Compound-WO2012058134A	Patented
T78710	DRUGINFO	D0TH5W	PMID26004420-Compound-WO2013062900C	Patented
T78710	DRUGINFO	D0TO9J	PMID26004420-Compound-US20140031349A	Patented
T78710	DRUGINFO	D0U0ZN	PMID26004420-Compound-US20140275020D	Patented
T78710	DRUGINFO	D0UY1A	PMID26004420-Compound-US20140142115B	Patented
T78710	DRUGINFO	D0V0OD	PMID26004420-Compound-WO2014015495C	Patented
T78710	DRUGINFO	D0WP1P	PMID26004420-Compound-WO2014085210A	Patented
T78710	DRUGINFO	D0WX4U	PMID26004420-Compound-US20140142115A	Patented
T78710	DRUGINFO	D0X8YT	PMID26004420-Compound-WO2014150132A	Patented
T78710	DRUGINFO	D0XK7H	PMID26004420-Compound-US20140336177E	Patented
T78710	DRUGINFO	D0XM8F	PMID26004420-Compound-WO2012058134B	Patented
T78710	DRUGINFO	D0ZX6S	PMID26004420-Compound-WO2013028474A	Patented
T78710	DRUGINFO	D05LBC	VU591	Investigative

T46702	TARGETID	T46702
T46702	UNIPROID	PLA2R_HUMAN
T46702	TARGNAME	Secretory phospholipase A2 receptor (PLA2R)
T46702	GENENAME	PLA2R1
T46702	TARGTYPE	Patented-recorded
T46702	SYNONYMS	Soluble secretory phospholipase A2 receptor; Soluble PLA2R; Soluble PLA2-R; PLA2-R; M-type receptor; CLEC13C; C-type lectin domain family 13 member C; 180 kDa secretory phospholipase A2 receptor
T46702	FUNCTION	Acts as a receptor for phosholipase sPLA2-IB/PLA2G1B but not sPLA2-IIA/PLA2G2A. Also able to bind to snake PA2-like toxins. Although its precise function remains unclear, binding of sPLA2 to its receptor participates in both positive and negative regulation of sPLA2 functions as well as clearance of sPLA2. Binding of sPLA2-IB/PLA2G1B induces various effects depending on the cell type, such as activation of the mitogen-activated protein kinase (MAPK) cascade to induce cell proliferation, the production of lipid mediators, selective release of arachidonic acid in bone marrow-derived mast cells. In neutrophils, binding of sPLA2-IB/PLA2G1B can activate p38 MAPK to stimulate elastase release and cell adhesion. May be involved in responses in proinflammatory cytokine productions during endotoxic shock. Also has endocytic properties and rapidly internalizes sPLA2 ligands, which is particularly important for the clearance of extracellular sPLA2s to protect their potent enzymatic activities. The soluble secretory phospholipase A2 receptor form is circulating and acts as a negative regulator of sPLA2 functions by blocking the biological functions of sPLA2-IB/PLA2G1B. Receptor for secretory phospholipase A2 (sPLA2).
T46702	SEQUENCE	MLLSPSLLLLLLLGAPRGCAEGVAAALTPERLLEWQDKGIFVIQSESLKKCIQAGKSVLTLENCKQANKHMLWKWVSNHGLFNIGGSGCLGLNFSAPEQPLSLYECDSTLVSLRWRCNRKMITGPLQYSVQVAHDNTVVASRKYIHKWISYGSGGGDICEYLHKDLHTIKGNTHGMPCMFPFQYNHQWHHECTREGREDDLLWCATTSRYERDEKWGFCPDPTSAEVGCDTIWEKDLNSHICYQFNLLSSLSWSEAHSSCQMQGGTLLSITDETEENFIREHMSSKTVEVWMGLNQLDEHAGWQWSDGTPLNYLNWSPEVNFEPFVEDHCGTFSSFMPSAWRSRDCESTLPYICKKYLNHIDHEIVEKDAWKYYATHCEPGWNPYNRNCYKLQKEEKTWHEALRSCQADNSALIDITSLAEVEFLVTLLGDENASETWIGLSSNKIPVSFEWSNDSSVIFTNWHTLEPHIFPNRSQLCVSAEQSEGHWKVKNCEERLFYICKKAGHVLSDAESGCQEGWERHGGFCYKIDTVLRSFDQASSGYYCPPALVTITNRFEQAFITSLISSVVKMKDSYFWIALQDQNDTGEYTWKPVGQKPEPVQYTHWNTHQPRYSGGCVAMRGRHPLGRWEVKHCRHFKAMSLCKQPVENQEKAEYEERWPFHPCYLDWESEPGLASCFKVFHSEKVLMKRTWREAEAFCEEFGAHLASFAHIEEENFVNELLHSKFNWTEERQFWIGFNKRNPLNAGSWEWSDRTPVVSSFLDNTYFGEDARNCAVYKANKTLLPLHCGSKREWICKIPRDVKPKIPFWYQYDVPWLFYQDAEYLFHTFASEWLNFEFVCSWLHSDLLTIHSAHEQEFIHSKIKALSKYGASWWIGLQEERANDEFRWRDGTPVIYQNWDTGRERTVNNQSQRCGFISSITGLWGSEECSVSMPSICKRKKVWLIEKKKDTPKQHGTCPKGWLYFNYKCLLLNIPKDPSSWKNWTHAQHFCAEEGGTLVAIESEVEQAFITMNLFGQTTSVWIGLQNDDYETWLNGKPVVYSNWSPFDIINIPSHNTTEVQKHIPLCALLSSNPNFHFTGKWYFEDCGKEGYGFVCEKMQDTSGHGVNTSDMYPMPNTLEYGNRTYKIINANMTWYAAIKTCLMHKAQLVSITDQYHQSFLTVVLNRLGYAHWIGLFTTDNGLNFDWSDGTKSSFTFWKDEESSLLGDCVFADSNGRWHSTACESFLQGAICHVPPETRQSEHPELCSETSIPWIKFKSNCYSFSTVLDSMSFEAAHEFCKKEGSNLLTIKDEAENAFLLEELFAFGSSVQMVWLNAQFDGNNETIKWFDGTPTDQSNWGIRKPDTDYFKPHHCVALRIPEGLWQLSPCQEKKGFICKMEADIHTAEALPEKGPSHSIIPLAVVLTLIVIVAICTLSFCIYKHNGGFFRRLAGFRNPYYPATNFSTVYLEENILISDLEKSDQ

T03145	TARGETID	T03145
T03145	UNIPROID	TLR1_HUMAN-TLR2_HUMAN
T03145	TARGNAME	TLR1-TLR2 complex (TLR1/2)
T03145	GENENAME	TLR1-TLR2
T03145	TARGTYPE	Patented-recorded
T03145	SYNONYMS	Toll-like receptor 1 and 2 complex
T03145	FUNCTION	Mediates the innate immune response to bacterial lipoproteins or lipopeptides.
T03145	BIOCLASS	Toll-like receptor
T03145	SEQUENCE	MTSIFHFAIIFMLILQIRIQLSEESEFLVDRSKNGLIHVPKDLSQKTTILNISQNYISELWTSDILSLSKLRILIISHNRIQYLDISVFKFNQELEYLDLSHNKLVKISCHPTVNLKHLDLSFNAFDALPICKEFGNMSQLKFLGLSTTHLEKSSVLPIAHLNISKVLLVLGETYGEKEDPEGLQDFNTESLHIVFPTNKEFHFILDVSVKTVANLELSNIKCVLEDNKCSYFLSILAKLQTNPKLSNLTLNNIETTWNSFIRILQLVWHTTVWYFSISNVKLQGQLDFRDFDYSGTSLKALSIHQVVSDVFGFPQSYIYEIFSNMNIKNFTVSGTRMVHMLCPSKISPFLHLDFSNNLLTDTVFENCGHLTELETLILQMNQLKELSKIAEMTTQMKSLQQLDISQNSVSYDEKKGDCSWTKSLLSLNMSSNILTDTIFRCLPPRIKVLDLHSNKIKSIPKQVVKLEALQELNVAFNSLTDLPGCGSFSSLSVLIIDHNSVSHPSADFFQSCQKMRSIKAGDNPFQCTCELGEFVKNIDQVSSEVLEGWPDSYKCDYPESYRGTLLKDFHMSELSCNITLLIVTIVATMLVLAVTVTSLCSYLDLPWYLRMVCQWTQTRRRARNIPLEELQRNLQFHAFISYSGHDSFWVKNELLPNLEKEGMQICLHERNFVPGKSIVENIITCIEKSYKSIFVLSPNFVQSEWCHYELYFAHHNLFHEGSNSLILILLEPIPQYSIPSSYHKLKSLMARRTYLEWPKEKSKRGLFWANLRAAINIKLTEQAKKMPHTLWMVWVLGVIISLSKEESSNQASLSCDRNGICKGSSGSLNSIPSGLTEAVKSLDLSNNRITYISNSDLQRCVNLQALVLTSNGINTIEEDSFSSLGSLEHLDLSYNYLSNLSSSWFKPLSSLTFLNLLGNPYKTLGETSLFSHLTKLQILRVGNMDTFTKIQRKDFAGLTFLEELEIDASDLQSYEPKSLKSIQNVSHLILHMKQHILLLEIFVDVTSSVECLELRDTDLDTFHFSELSTGETNSLIKKFTFRNVKITDESLFQVMKLLNQISGLLELEFDDCTLNGVGNFRASDNDRVIDPGKVETLTIRRLHIPRFYLFYDLSTLYSLTERVKRITVENSKVFLVPCLLSQHLKSLEYLDLSENLMVEEYLKNSACEDAWPSLQTLILRQNHLASLEKTGETLLTLKNLTNIDISKNSFHSMPETCQWPEKMKYLNLSSTRIHSVTGCIPKTLEILDVSNNNLNLFSLNLPQLKELYISRNKLMTLPDASLLPMLLVLKISRNAITTFSKEQLDSFHTLKTLEAGGNNFICSCEFLSFTQEQQALAKVLIDWPANYLCDSPSHVRGQQVQDVRLSVSECHRTALVSGMCCALFLLILLTGVLCHRFHGLWYMKMMWAWLQAKRKPRKAPSRNICYDAFVSYSERDAYWVENLMVQELENFNPPFKLCLHKRDFIPGKWIIDNIIDSIEKSHKTVFVLSENFVKSEWCKYELDFSHFRLFDENNDAAILILLEPIEKKAIPQRFCKLRKIMNTKTYLEWPMDEAQREGFWVNLRAAIKS

T20958	TARGETID	T20958
T20958	FORMERID	TTDI02517
T20958	UNIPROID	NPSR1_HUMAN
T20958	TARGNAME	Neuropeptide S receptor (NPSR)
T20958	GENENAME	NPSR1
T20958	TARGTYPE	Patented-recorded
T20958	SYNONYMS	PGR14; Gprotein coupled receptor for asthma susceptibility; Gprotein coupled receptor PGR14; Gprotein coupled receptor 154; GPRA; GPR154; G-protein coupled receptor for asthma susceptibility; G-protein coupled receptor PGR14; G-protein coupled receptor 154
T20958	FUNCTION	Promotes mobilization of intracellular Ca(2+) stores. Inhibits cell growth in response to NPS binding. Involved in pathogenesis of asthma and other IgE-mediated diseases. G-protein coupled receptor for neuropeptide S (NPS).
T20958	BIOCLASS	GPCR rhodopsin
T20958	SEQUENCE	MPANFTEGSFDSSGTGQTLDSSPVACTETVTFTEVVEGKEWGSFYYSFKTEQLITLWVLFVFTIVGNSVVLFSTWRRKKKSRMTFFVTQLAITDSFTGLVNILTDINWRFTGDFTAPDLVCRVVRYLQVVLLYASTYVLVSLSIDRYHAIVYPMKFLQGEKQARVLIVIAWSLSFLFSIPTLIIFGKRTLSNGEVQCWALWPDDSYWTPYMTIVAFLVYFIPLTIISIMYGIVIRTIWIKSKTYETVISNCSDGKLCSSYNRGLISKAKIKAIKYSIIIILAFICCWSPYFLFDILDNFNLLPDTQERFYASVIIQNLPALNSAINPLIYCVFSSSISFPCREQRSQDSRMTFRERTERHEMQILSKPEFI
T20958	DRUGINFO	D00IVM	PMID27788040-Compound-6	Patented
T20958	DRUGINFO	D00JCQ	Oxazolo[3,4-a]pyrazine derivative 4	Patented
T20958	DRUGINFO	D00ODC	Imidazo pyridine derivative 4	Patented
T20958	DRUGINFO	D02BPJ	4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 1	Patented
T20958	DRUGINFO	D06FJL	Oxazolo[3,4-a]pyrazine derivative 2	Patented
T20958	DRUGINFO	D06FUK	Imidazo pyridine derivative 6	Patented
T20958	DRUGINFO	D06TFC	4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 3	Patented
T20958	DRUGINFO	D09AVU	PMID27788040-Compound-6b	Patented
T20958	DRUGINFO	D09DZI	Indandione derivative 2	Patented
T20958	DRUGINFO	D09JFR	4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 4	Patented
T20958	DRUGINFO	D0AT0A	PMID27788040-Compound-5a	Patented
T20958	DRUGINFO	D0H1LQ	PMID27788040-Compound-6c	Patented
T20958	DRUGINFO	D0I0BN	Oxazolo[3,4-a]pyrazine derivative 3	Patented
T20958	DRUGINFO	D0I8ZE	PMID27788040-Compound-5b	Patented
T20958	DRUGINFO	D0K1ZY	4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 2	Patented
T20958	DRUGINFO	D0K7OV	Imidazo pyridine derivative 5	Patented
T20958	DRUGINFO	D0M3DM	Indandione derivative 1	Patented
T20958	DRUGINFO	D0O4ML	Indandione derivative 3	Patented
T20958	DRUGINFO	D0QN7I	Oxazolo[3,4-a]pyrazine derivative 6	Patented
T20958	DRUGINFO	D0QY3L	Oxazolo[3,4-a]pyrazine derivative 5	Patented
T20958	DRUGINFO	D0S1AT	Oxazolo[3,4-a]pyrazine derivative 1	Patented
T20958	DRUGINFO	D0S3TL	Oxazolo[3,4-a]pyrazine derivative 7	Patented
T20958	DRUGINFO	D0WI0P	PMID27788040-Compound-5c	Patented
T20958	DRUGINFO	D0X8JD	PMID27788040-Compound-5	Patented
T20958	DRUGINFO	D0Y9XS	Indanone and indandione derivative 1	Patented
T20958	DRUGINFO	D0YU5R	PMID27788040-Compound-6a	Patented
T20958	DRUGINFO	D03EJP	SHA 68	Investigative
T20958	DRUGINFO	D09RIC	PI1	Investigative
T20958	DRUGINFO	D0TX8L	QA1	Investigative

T80487	TARGETID	T80487
T80487	UNIPROID	DNM3L_HUMAN
T80487	TARGNAME	DNA [cytosine-5]-methyltransferase 3-like (DNMT3L)
T80487	GENENAME	DNMT3L
T80487	TARGTYPE	Patented-recorded
T80487	SYNONYMS	DNA (cytosine-5)-methyltransferase 3-like
T80487	FUNCTION	Essential for the function of DNMT3A and DNMT3B: activates DNMT3A and DNMT3B by binding to their catalytic domain. Acts by accelerating the binding of DNA and S-adenosyl-L-methionine (AdoMet) to the methyltransferases and dissociates from the complex after DNA binding to the methyltransferases. Recognizes unmethylated histone H3 lysine 4 (H3K4me0) and induces de novo DNA methylation by recruitment or activation of DNMT3. Plays a key role in embryonic stem cells and germ cells. In germ cells, required for the methylation of imprinted loci together with DNMT3A. In male germ cells, specifically required to methylate retrotransposons, preventing their mobilization. Plays a key role in embryonic stem cells (ESCs) by acting both as an positive and negative regulator of DNA methylation. While it promotes DNA methylation of housekeeping genes together with DNMT3A and DNMT3B, it also acts as an inhibitor of DNA methylation at the promoter of bivalent genes. Interacts with the EZH2 component of the PRC2/EED-EZH2 complex, preventing interaction of DNMT3A and DNMT3B with the PRC2/EED-EZH2 complex, leading to maintain low methylation levels at the promoters of bivalent genes. Promotes differentiation of ESCs into primordial germ cells by inhibiting DNA methylation at the promoter of RHOX5, thereby activating its expression. Catalytically inactive regulatory factor of DNA methyltransferases that can either promote or inhibit DNA methylation depending on the context.
T80487	PDBSTRUC	6F57; 6BRR; 5YX2; 4U7T; 4U7P
T80487	SEQUENCE	MAAIPALDPEAEPSMDVILVGSSELSSSVSPGTGRDLIAYEVKANQRNIEDICICCGSLQVHTQHPLFEGGICAPCKDKFLDALFLYDDDGYQSYCSICCSGETLLICGNPDCTRCYCFECVDSLVGPGTSGKVHAMSNWVCYLCLPSSRSGLLQRRRKWRSQLKAFYDRESENPLEMFETVPVWRRQPVRVLSLFEDIKKELTSLGFLESGSDPGQLKHVVDVTDTVRKDVEEWGPFDLVYGATPPLGHTCDRPPSWYLFQFHRLLQYARPKPGSPRPFFWMFVDNLVLNKEDLDVASRFLEMEPVTIPDVHGGSLQNAVRVWSNIPAIRSRHWALVSEEELSLLAQNKQSSKLAAKWPTKLVKNCFLPLREYFKYFSTELTSSL
T80487	DRUGINFO	D01LUJ	PMID27376512-Compound-Figure2aExample1	Patented

T18551	TARGETID	T18551
T18551	UNIPROID	CD80_HUMAN-PD1L1_HUMAN
T18551	TARGNAME	CD80-PD-L1 interaction (CD80/PD-L1 PPI)
T18551	GENENAME	CD80-CD274
T18551	TARGTYPE	Patented-recorded
T18551	SYNONYMS	T-lymphocyte activation antigen CD80/Programmed cell death 1 ligand 1 PPI
T18551	FUNCTION	Augments activated alloreactive CD4+ T cell proliferation and apoptosis and ameliorates acute graft versus host disease
T18551	SEQUENCE	MRIFAVFIFMTYWHLLNAFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERTHLVILGAILLCLGVALTFIFRLRKGRMMDVKKCGIQDTNSKKQSDTHLEETMGHTRRQGTSPSKCPYLNFFQLLVLAGLSHFCSGVIHVTKEVKEVATLSCGHNVSVEELAQTRIYWQKEKKMVLTMMSGDMNIWPEYKNRTIFDITNNLSIVILALRPSDEGTYECVVLKYEKDAFKREHLAEVTLSVKADFPTPSISDFEIPTSNIRRIICSTSGGFPEPHLSWLENGEELNAINTTVSQDPETELYAVSSKLDFNMTTNHSFMCLIKYGHLRVNQTFNWNTTKQEHFPDNLLPSWAITLISVNGIFVICCLTYCFAPRCRERRRNERLRRESVRPV
T18551	DRUGINFO	D03BCV	Macrocycle derivative 6	Patented
T18551	DRUGINFO	D04PCT	PMID30107136-Compound-Example12	Patented
T18551	DRUGINFO	D06VTI	Macrocycle derivative 1	Patented
T18551	DRUGINFO	D07ZQS	Macrocycle derivative 9	Patented
T18551	DRUGINFO	D08EHL	Macrocycle derivative 2	Patented
T18551	DRUGINFO	D0D3RS	Biaryl compound 1	Patented
T18551	DRUGINFO	D0J4UO	Macrocycle derivative 3	Patented
T18551	DRUGINFO	D0M6WW	PMID30107136-Compound-Example11	Patented
T18551	DRUGINFO	D0N4TZ	Macrocycle derivative 8	Patented
T18551	DRUGINFO	D0N5NV	Biaryl compound 2	Patented
T18551	DRUGINFO	D0NI2B	Macrocycle derivative 5	Patented
T18551	DRUGINFO	D0QF4W	Macrocycle derivative 7	Patented
T18551	DRUGINFO	D0R7JW	Macrocycle derivative 4	Patented

T20027	TARGETID	T20027
T20027	UNIPROID	STA5A_HUMAN; STA5B_HUMAN
T20027	TARGNAME	Signal transducer and activator of transcription 5 (STAT5)
T20027	GENENAME	STAT5A; STAT5B
T20027	TARGTYPE	Patented-recorded
T20027	SYNONYMS	Signal transducer and activator of transcription 5
T20027	FUNCTION	Involved in cytosolic signalling and in mediating the expression of specific genes. Aberrant STAT5 activity has been shown to be closely connected to a wide range of human cancers, and silencing this aberrant activity is an area of active research in medicinal chemistry.
T20027	SEQUENCE	MAGWIQAQQLQGDALRQMQVLYGQHFPIEVRHYLAQWIESQPWDAIDLDNPQDRAQATQLLEGLVQELQKKAEHQVGEDGFLLKIKLGHYATQLQKTYDRCPLELVRCIRHILYNEQRLVREANNCSSPAGILVDAMSQKHLQINQTFEELRLVTQDTENELKKLQQTQEYFIIQYQESLRIQAQFAQLAQLSPQERLSRETALQQKQVSLEAWLQREAQTLQQYRVELAEKHQKTLQLLRKQQTIILDDELIQWKRRQQLAGNGGPPEGSLDVLQSWCEKLAEIIWQNRQQIRRAEHLCQQLPIPGPVEEMLAEVNATITDIISALVTSTFIIEKQPPQVLKTQTKFAATVRLLVGGKLNVHMNPPQVKATIISEQQAKSLLKNENTRNECSGEILNNCCVMEYHQATGTLSAHFRNMSLKRIKRADRRGAESVTEEKFTVLFESQFSVGSNELVFQVKTLSLPVVVIVHGSQDHNATATVLWDNAFAEPGRVPFAVPDKVLWPQLCEALNMKFKAEVQSNRGLTKENLVFLAQKLFNNSSSHLEDYSGLSVSWSQFNRENLPGWNYTFWQWFDGVMEVLKKHHKPHWNDGAILGFVNKQQAHDLLINKPDGTFLLRFSDSEIGGITIAWKFDSPERNLWNLKPFTTRDFSIRSLADRLGDLSYLIYVFPDRPKDEVFSKYYTPVLAKAVDGYVKPQIKQVVPEFVNASADAGGSSATYMDQAPSPAVCPQAPYNMYPQNPDHVLDQDGEFDLDETMDVARHVEELLRRPMDSLDSRLSPPAGLFTSARGSLS
T20027	DRUGINFO	D02MAG	PMID26394986-Compound-56	Patented
T20027	DRUGINFO	D0T8PK	Indirubin derivative 1	Patented
T20027	DRUGINFO	D0W5GX	PMID26394986-Compound-57	Patented
T20027	DRUGINFO	D01BVU	Platinum IV complexe 1	Patented
T20027	DRUGINFO	D0TU0X	PMID26394986-Compound-10	Patented

T72491	TARGETID	T72491
T72491	UNIPROID	KEAP1_HUMAN-NF2L2_HUMAN
T72491	TARGNAME	Keap1-Nrf2[dual DLG and ETGE] PPI (KEAP1-Nrf2 DLG and ETGE)
T72491	GENENAME	KEAP1-NFE2L2
T72491	TARGTYPE	Patented-recorded
T72491	SYNONYMS	Kelch-like protein 19-Nrf2[dual DLG and ETGE]; Kelch-like ECH-associated protein 1-Nrf2[dual DLG and ETGE]; KLHL19-Nrf2[dual DLG and ETGE]; KIAA0132-Nrf2[dual DLG and ETGE]; INrf2-Nrf2[dual DLG and ETGE]; Cytosolic inhibitor of Nrf2-Nrf2[dual DLG and ETGE]
T72491	FUNCTION	Retains NFE2L2/NRF2 and may also retain BPTF in the cytosol. Targets PGAM5 for ubiquitination and degradation by the proteasome. Acts as a substrate adapter protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1 and targets NFE2L2/NRF2 for ubiquitination and degradation by the proteasome, thus resulting in the suppression of its transcriptional activity and the repression of antioxidant response element-mediated detoxifying enzyme gene expression.
T72491	SEQUENCE	MQPDPRPSGAGACCRFLPLQSQCPEGAGDAVMYASTECKAEVTPSQHGNRTFSYTLEDHTKQAFGIMNELRLSQQLCDVTLQVKYQDAPAAQFMAHKVVLASSSPVFKAMFTNGLREQGMEVVSIEGIHPKVMERLIEFAYTASISMGEKCVLHVMNGAVMYQIDSVVRACSDFLVQQLDPSNAIGIANFAEQIGCVELHQRAREYIYMHFGEVAKQEEFFNLSHCQLVTLISRDDLNVRCESEVFHACINWVKYDCEQRRFYVQALLRAVRCHSLTPNFLQMQLQKCEILQSDSRCKDYLVKIFEELTLHKPTQVMPCRAPKVGRLIYTAGGYFRQSLSYLEAYNPSDGTWLRLADLQVPRSGLAGCVVGGLLYAVGGRNNSPDGNTDSSALDCYNPMTNQWSPCAPMSVPRNRIGVGVIDGHIYAVGGSHGCIHHNSVERYEPERDEWHLVAPMLTRRIGVGVAVLNRLLYAVGGFDGTNRLNSAECYYPERNEWRMITAMNTIRSGAGVCVLHNCIYAAGGYDGQDQLNSVERYDVETETWTFVAPMKHRRSALGITVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRMTSGRSGVGVAVTMEPCRKQIDQQNCTCMMDLELPPPGLPSQQDMDLIDILWRQDIDLGVSREVFDFSQRRKEYELEKQKKLEKERQEQLQKEQEKAFFAQLQLDEETGEFLPIQPAQHIQSETSGSANYSQVAHIPKSDALYFDDCMQLLAQTFPFVDDNEVSSATFQSLVPDIPGHIESPVFIATNQAQSPETSVAQVAPVDLDGMQQDIEQVWEELLSIPELQCLNIENDKLVETTMVPSPEAKLTEVDNYHFYSSIPSMEKEVGNCSPHFLNAFEDSFSSILSTEDPNQLTVNSLNSDATVNTDFGDEFYSAFIAEPSISNSMPSPATLSHSLSELLNGPIDVSDLSLCKAFNQNHPESTAEFNDSDSGISLNTSPSVASPEHSVESSSYGDTLLGLSDSEVEELDSAPGSVKQNGPKTPVHSSGDMVQPLSPSQGQSTHVHDAQCENTPEKELPVSPGHRKTPFTKDKHSSRLEAHLTRDELRAKALHIPFPVEKIINLPVVDFNEMMSKEQFNEAQLALIRDIRRRGKNKVAAQNCRKRKLENIVELEQDLDHLKDEKEKLLKEKGENDKSLHLLKKQLSTLYLEVFSMLRDEDGKPYSPSEYSLQQTRDGNVFLVPKSKKPDVKKN
T72491	DRUGINFO	D00TVL	PMID28454500-Compound-57	Patented
T72491	DRUGINFO	D02FWA	Naphthalene derivative 1	Patented
T72491	DRUGINFO	D02JFV	PMID28454500-Compound-58	Patented
T72491	DRUGINFO	D0LL7V	PMID28454500-Compound-60	Patented
T72491	DRUGINFO	D0O3KN	PMID28454500-Compound-59	Patented
T72491	DRUGINFO	D0Q8JZ	3-phenyl propanoic derivative 3	Patented
T72491	DRUGINFO	D0WR1I	1,2,3,4-tetrahydroisoquinoline derivative 1	Patented

T76454	TARGETID	T76454
T76454	UNIPROID	KEAP1_HUMAN-NF2L2_HUMAN
T76454	TARGNAME	Keap1-Nrf2[ETGE] PPI (KEAP1-Nrf2 ETGE)
T76454	GENENAME	KEAP1-NFE2L2
T76454	TARGTYPE	Patented-recorded
T76454	SYNONYMS	Kelch-like protein 19-Nrf2[ETGE]; Kelch-like ECH-associated protein 1-Nrf2[ETGE]; KLHL19-Nrf2[ETGE]; KIAA0132-Nrf2[ETGE]; INrf2-Nrf2[ETGE]; Cytosolic inhibitor of Nrf2-Nrf2[ETGE]
T76454	FUNCTION	Retains NFE2L2/NRF2 and may also retain BPTF in the cytosol. Targets PGAM5 for ubiquitination and degradation by the proteasome. Acts as a substrate adapter protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1 and targets NFE2L2/NRF2 for ubiquitination and degradation by the proteasome, thus resulting in the suppression of its transcriptional activity and the repression of antioxidant response element-mediated detoxifying enzyme gene expression.
T76454	SEQUENCE	MQPDPRPSGAGACCRFLPLQSQCPEGAGDAVMYASTECKAEVTPSQHGNRTFSYTLEDHTKQAFGIMNELRLSQQLCDVTLQVKYQDAPAAQFMAHKVVLASSSPVFKAMFTNGLREQGMEVVSIEGIHPKVMERLIEFAYTASISMGEKCVLHVMNGAVMYQIDSVVRACSDFLVQQLDPSNAIGIANFAEQIGCVELHQRAREYIYMHFGEVAKQEEFFNLSHCQLVTLISRDDLNVRCESEVFHACINWVKYDCEQRRFYVQALLRAVRCHSLTPNFLQMQLQKCEILQSDSRCKDYLVKIFEELTLHKPTQVMPCRAPKVGRLIYTAGGYFRQSLSYLEAYNPSDGTWLRLADLQVPRSGLAGCVVGGLLYAVGGRNNSPDGNTDSSALDCYNPMTNQWSPCAPMSVPRNRIGVGVIDGHIYAVGGSHGCIHHNSVERYEPERDEWHLVAPMLTRRIGVGVAVLNRLLYAVGGFDGTNRLNSAECYYPERNEWRMITAMNTIRSGAGVCVLHNCIYAAGGYDGQDQLNSVERYDVETETWTFVAPMKHRRSALGITVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRMTSGRSGVGVAVTMEPCRKQIDQQNCTCMMDLELPPPGLPSQQDMDLIDILWRQDIDLGVSREVFDFSQRRKEYELEKQKKLEKERQEQLQKEQEKAFFAQLQLDEETGEFLPIQPAQHIQSETSGSANYSQVAHIPKSDALYFDDCMQLLAQTFPFVDDNEVSSATFQSLVPDIPGHIESPVFIATNQAQSPETSVAQVAPVDLDGMQQDIEQVWEELLSIPELQCLNIENDKLVETTMVPSPEAKLTEVDNYHFYSSIPSMEKEVGNCSPHFLNAFEDSFSSILSTEDPNQLTVNSLNSDATVNTDFGDEFYSAFIAEPSISNSMPSPATLSHSLSELLNGPIDVSDLSLCKAFNQNHPESTAEFNDSDSGISLNTSPSVASPEHSVESSSYGDTLLGLSDSEVEELDSAPGSVKQNGPKTPVHSSGDMVQPLSPSQGQSTHVHDAQCENTPEKELPVSPGHRKTPFTKDKHSSRLEAHLTRDELRAKALHIPFPVEKIINLPVVDFNEMMSKEQFNEAQLALIRDIRRRGKNKVAAQNCRKRKLENIVELEQDLDHLKDEKEKLLKEKGENDKSLHLLKKQLSTLYLEVFSMLRDEDGKPYSPSEYSLQQTRDGNVFLVPKSKKPDVKKN
T76454	DRUGINFO	D0MS7G	3-phenyl propanoic derivative 2	Patented
T76454	DRUGINFO	D0O6LW	3-phenyl propanoic derivative 1	Patented

T80959	TARGETID	T80959
T80959	UNIPROID	KEAP1_HUMAN-NF2L2_HUMAN
T80959	TARGNAME	Keap1-Nrf2[DLG] PPI (KEAP1-Nrf2 DLG)
T80959	GENENAME	KEAP1-NFE2L2
T80959	TARGTYPE	Patented-recorded
T80959	SYNONYMS	Kelch-like protein 19-Nrf2[DLG]; Kelch-like ECH-associated protein 1-Nrf2[DLG]; KLHL19-Nrf2[DLG]; KIAA0132-Nrf2[DLG]; INrf2-Nrf2[DLG]; Cytosolic inhibitor of Nrf2-Nrf2[DLG]
T80959	FUNCTION	Retains NFE2L2/NRF2 and may also retain BPTF in the cytosol. Targets PGAM5 for ubiquitination and degradation by the proteasome. Acts as a substrate adapter protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1 and targets NFE2L2/NRF2 for ubiquitination and degradation by the proteasome, thus resulting in the suppression of its transcriptional activity and the repression of antioxidant response element-mediated detoxifying enzyme gene expression.
T80959	SEQUENCE	MQPDPRPSGAGACCRFLPLQSQCPEGAGDAVMYASTECKAEVTPSQHGNRTFSYTLEDHTKQAFGIMNELRLSQQLCDVTLQVKYQDAPAAQFMAHKVVLASSSPVFKAMFTNGLREQGMEVVSIEGIHPKVMERLIEFAYTASISMGEKCVLHVMNGAVMYQIDSVVRACSDFLVQQLDPSNAIGIANFAEQIGCVELHQRAREYIYMHFGEVAKQEEFFNLSHCQLVTLISRDDLNVRCESEVFHACINWVKYDCEQRRFYVQALLRAVRCHSLTPNFLQMQLQKCEILQSDSRCKDYLVKIFEELTLHKPTQVMPCRAPKVGRLIYTAGGYFRQSLSYLEAYNPSDGTWLRLADLQVPRSGLAGCVVGGLLYAVGGRNNSPDGNTDSSALDCYNPMTNQWSPCAPMSVPRNRIGVGVIDGHIYAVGGSHGCIHHNSVERYEPERDEWHLVAPMLTRRIGVGVAVLNRLLYAVGGFDGTNRLNSAECYYPERNEWRMITAMNTIRSGAGVCVLHNCIYAAGGYDGQDQLNSVERYDVETETWTFVAPMKHRRSALGITVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRMTSGRSGVGVAVTMEPCRKQIDQQNCTCMMDLELPPPGLPSQQDMDLIDILWRQDIDLGVSREVFDFSQRRKEYELEKQKKLEKERQEQLQKEQEKAFFAQLQLDEETGEFLPIQPAQHIQSETSGSANYSQVAHIPKSDALYFDDCMQLLAQTFPFVDDNEVSSATFQSLVPDIPGHIESPVFIATNQAQSPETSVAQVAPVDLDGMQQDIEQVWEELLSIPELQCLNIENDKLVETTMVPSPEAKLTEVDNYHFYSSIPSMEKEVGNCSPHFLNAFEDSFSSILSTEDPNQLTVNSLNSDATVNTDFGDEFYSAFIAEPSISNSMPSPATLSHSLSELLNGPIDVSDLSLCKAFNQNHPESTAEFNDSDSGISLNTSPSVASPEHSVESSSYGDTLLGLSDSEVEELDSAPGSVKQNGPKTPVHSSGDMVQPLSPSQGQSTHVHDAQCENTPEKELPVSPGHRKTPFTKDKHSSRLEAHLTRDELRAKALHIPFPVEKIINLPVVDFNEMMSKEQFNEAQLALIRDIRRRGKNKVAAQNCRKRKLENIVELEQDLDHLKDEKEKLLKEKGENDKSLHLLKKQLSTLYLEVFSMLRDEDGKPYSPSEYSLQQTRDGNVFLVPKSKKPDVKKN
T80959	DRUGINFO	D09MSN	1-phenyl-1,3,4-triazole derivative 1	Patented
T80959	DRUGINFO	D0AR0L	1-phenyl-1,3,4-triazole derivative 2	Patented
T80959	DRUGINFO	D0I2DV	1-phenyl-1,3,4-triazole derivative 3	Patented

T13629	TARGETID	T13629
T13629	UNIPROID	PDCD1_HUMAN-PD1L1_HUMAN
T13629	TARGNAME	PD-1-PD-L1 interaction (PD-1/PD-L1 PPI)
T13629	GENENAME	PDCD1-CD274
T13629	TARGTYPE	Patented-recorded
T13629	SYNONYMS	Programmed cell death 1/Programmed cell death 1 ligand 1 PPI
T13629	FUNCTION	The PD-1/PD-L1 axis is probably also important for immune evasion of B-cell lymphomas with a viral aetiology, including those associated with human immunodeficiency virus (HIV) and Epstein-Barr virus (EBV).
T13629	SEQUENCE	MRIFAVFIFMTYWHLLNAFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERTHLVILGAILLCLGVALTFIFRLRKGRMMDVKKCGIQDTNSKKQSDTHLEETMQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQTLVVGVVGGLLGSLVLLVWVLAVICSRAARGTIGARRTGQPLKEDPSAVPVFSVDYGELDFQWREKTPEPPVPCVPEQTEYATIVFPSGMGTSSPARRGSADGPRSAQPLRPEDGHCSWPL
T13629	DRUGINFO	D00CRQ	Phenylate derivative 1	Patented
T13629	DRUGINFO	D01AYP	Bromo benzyl ether derivative 1	Patented
T13629	DRUGINFO	D01MSP	PMID30107136-Compound-Example3	Patented
T13629	DRUGINFO	D01OQQ	PMID30107136-Compound-Example50	Patented
T13629	DRUGINFO	D01PJZ	Cyclic peptidomimetic derivative 1	Patented
T13629	DRUGINFO	D02SES	Peptide analog 2	Patented
T13629	DRUGINFO	D02UJS	PMID30107136-Compound-Example49	Patented
T13629	DRUGINFO	D02XVC	Phenylate derivative 2	Patented
T13629	DRUGINFO	D03HAA	PMID30107136-Compound-Example45	Patented
T13629	DRUGINFO	D03TWD	PMID30107136-Compound-Example4	Patented
T13629	DRUGINFO	D04CCX	PMID30107136-Compound-Example14	Patented
T13629	DRUGINFO	D04ESH	PMID30107136-Compound-Example8	Patented
T13629	DRUGINFO	D04HBL	PMID30107136-Compound-Example59	Patented
T13629	DRUGINFO	D04TLQ	Cyclic peptidomimetic derivative 2	Patented
T13629	DRUGINFO	D05COE	PMID30107136-Compound-Example52	Patented
T13629	DRUGINFO	D06BSV	PMID30107136-Compound-Example46	Patented
T13629	DRUGINFO	D08JWY	PMID30107136-Compound-Example43	Patented
T13629	DRUGINFO	D08RET	PMID30107136-Compound-Example47	Patented
T13629	DRUGINFO	D0A5OT	Aromatic ethylene derivative 1	Patented
T13629	DRUGINFO	D0B2VS	Benzyl phenyl ether derivative 1	Patented
T13629	DRUGINFO	D0CH8E	Macrocyclic peptide analog 2	Patented
T13629	DRUGINFO	D0DP8E	PMID30107136-Compound-Example57	Patented
T13629	DRUGINFO	D0EI4B	N-phenyl-pyridine-2-carboxamide derivative 2	Patented
T13629	DRUGINFO	D0EW3O	Cyclic peptidomimetic derivative 3	Patented
T13629	DRUGINFO	D0EY9S	1,2,4-oxadiazole derivative 4	Patented
T13629	DRUGINFO	D0F4IF	N-phenyl-pyridine-2-carboxamide derivative 1	Patented
T13629	DRUGINFO	D0FJ1N	PMID30107136-Compound-Example42	Patented
T13629	DRUGINFO	D0FK4P	PMID30107136-Compound-Example48	Patented
T13629	DRUGINFO	D0FK6N	Peptide analog 5	Patented
T13629	DRUGINFO	D0FM9V	PMID30107136-Compound-Example60	Patented
T13629	DRUGINFO	D0H0CH	PMID30107136-Compound-Example54	Patented
T13629	DRUGINFO	D0H0MO	1,3,4-oxadiazole derivative 5	Patented
T13629	DRUGINFO	D0H6AL	1,3,4-oxadiazole derivative 4	Patented
T13629	DRUGINFO	D0HC9K	PMID30107136-Compound-Example41	Patented
T13629	DRUGINFO	D0HE8M	1,2,4-oxadiazole derivative 5	Patented
T13629	DRUGINFO	D0HF7V	Peptide analog 3	Patented
T13629	DRUGINFO	D0I0JE	1,3,4-thiadiazole derivative 1	Patented
T13629	DRUGINFO	D0I6RC	Benzyl phenyl ether derivative 2	Patented
T13629	DRUGINFO	D0I7UZ	Peptide analog 6	Patented
T13629	DRUGINFO	D0J4LV	PMID30107136-Compound-Example53	Patented
T13629	DRUGINFO	D0KA7I	PMID30107136-Compound-Example7	Patented
T13629	DRUGINFO	D0MG6V	3-substituted-1,2,4-oxadiazole derivative 2	Patented
T13629	DRUGINFO	D0MK2F	Macrocyclic peptide analog 3	Patented
T13629	DRUGINFO	D0N6NA	1,3,4-thiadiazole derivative 2	Patented
T13629	DRUGINFO	D0O8FI	1,3-dihydroxy phenyl derivative 1	Patented
T13629	DRUGINFO	D0R7CP	Bromo benzyl ether derivative 2	Patented
T13629	DRUGINFO	D0R7YI	PMID30107136-Compound-Example13	Patented
T13629	DRUGINFO	D0RK4V	Aromatic acetylene derivative 1	Patented
T13629	DRUGINFO	D0S0OF	Macrocyclic peptide analog 1	Patented
T13629	DRUGINFO	D0TJ4D	PMID30107136-Compound-Example58	Patented
T13629	DRUGINFO	D0VB9M	Peptide analog 1	Patented
T13629	DRUGINFO	D0W0MT	PMID30107136-Compound-Example51	Patented
T13629	DRUGINFO	D0W0PC	1,2,4-oxadiazole derivative 7	Patented
T13629	DRUGINFO	D0W1RQ	PMID30107136-Compound-Example44	Patented
T13629	DRUGINFO	D0X5IV	1,2,4-oxadiazole derivative 6	Patented
T13629	DRUGINFO	D0XV7Y	1,3-dihydroxy phenyl derivative 2	Patented
T13629	DRUGINFO	D0YK8M	1,3,4-oxadiazole derivative 3	Patented
T13629	DRUGINFO	D0Z0KL	1,3,4-oxadiazole derivative 6	Patented
T13629	DRUGINFO	D0Z4QT	3-substituted-1,2,4-oxadiazole derivative 1	Patented
T13629	DRUGINFO	D0Z9UJ	Peptide analog 4	Patented
T13629	DRUGINFO	D03BCV	Macrocycle derivative 6	Patented
T13629	DRUGINFO	D04PCT	PMID30107136-Compound-Example12	Patented
T13629	DRUGINFO	D06VTI	Macrocycle derivative 1	Patented
T13629	DRUGINFO	D07ZQS	Macrocycle derivative 9	Patented
T13629	DRUGINFO	D08EHL	Macrocycle derivative 2	Patented
T13629	DRUGINFO	D0D3RS	Biaryl compound 1	Patented
T13629	DRUGINFO	D0J4UO	Macrocycle derivative 3	Patented
T13629	DRUGINFO	D0M6WW	PMID30107136-Compound-Example11	Patented
T13629	DRUGINFO	D0N4TZ	Macrocycle derivative 8	Patented
T13629	DRUGINFO	D0N5NV	Biaryl compound 2	Patented
T13629	DRUGINFO	D0NI2B	Macrocycle derivative 5	Patented
T13629	DRUGINFO	D0QF4W	Macrocycle derivative 7	Patented
T13629	DRUGINFO	D0R7JW	Macrocycle derivative 4	Patented
T13629	DRUGINFO	D0ZS1I	MAX-10129	Preclinical
T13629	DRUGINFO	D00VMX	PMID30247903-Compound-General structure26	Investigative
T13629	DRUGINFO	D00VOK	PMID30247903-Compound-General structure37	Investigative
T13629	DRUGINFO	D02OAS	PMID30247903-Compound-General structure40	Investigative
T13629	DRUGINFO	D03UCG	PMID30247903-Compound-General structure29	Investigative
T13629	DRUGINFO	D06BVI	PMID30247903-Compound-General structure44	Investigative
T13629	DRUGINFO	D08EEA	PMID30247903-Compound-General structure36	Investigative
T13629	DRUGINFO	D09MJX	PMID30247903-Compound-General structure41	Investigative
T13629	DRUGINFO	D0BE5U	PMID30247903-Compound-General structure30	Investigative
T13629	DRUGINFO	D0JF0B	PMID30247903-Compound-General structure19	Investigative
T13629	DRUGINFO	D0M8KV	PMID30247903-Compound-General structure39	Investigative
T13629	DRUGINFO	D0ML0X	PMID30247903-Compound-General structure38	Investigative
T13629	DRUGINFO	D0NC8Z	PMID30247903-Compound-General structure45	Investigative
T13629	DRUGINFO	D0P9RV	PMID30247903-Compound-General structure33	Investigative
T13629	DRUGINFO	D0PX7G	PMID30247903-Compound-General structure42	Investigative
T13629	DRUGINFO	D0R6GO	PMID30247903-Compound-General structure43	Investigative
T13629	DRUGINFO	D0TN0G	PMID30247903-Compound-General structure46	Investigative
T13629	DRUGINFO	D0U4JP	PMID30247903-Compound-General structure31	Investigative
T13629	DRUGINFO	D0U5UY	PMID30247903-Compound-General structure18	Investigative
T13629	DRUGINFO	D0U8YP	PMID30247903-Compound-General structure28	Investigative
T13629	DRUGINFO	D0V1CW	PMID30247903-Compound-General structure35	Investigative
T13629	DRUGINFO	D0V4JV	PMID30247903-Compound-General structure27	Investigative
T13629	DRUGINFO	D0YC6Z	PMID30247903-Compound-General structure34	Investigative
T13629	DRUGINFO	D0ZO7D	PMID30247903-Compound-General structure32	Investigative

T05880	TARGETID	T05880
T05880	UNIPROID	APH1A_HUMAN-APH1B_HUMAN
T05880	TARGNAME	Gamma-secretase subunit APH-1A/1B (APH-1)
T05880	GENENAME	APH1A-APH1B
T05880	TARGTYPE	Patented-recorded
T05880	SYNONYMS	Anterior pharynx-defective 1
T05880	FUNCTION	The gamma-secretase complex plays a role in Notch and Wnt signaling cascades and regulation of downstream processes via its role in processing key regulatory proteins, and by regulating cytosolic CTNNB1 levels.
T05880	SEQUENCE	MTAAVFFGCAFIAFGPALALYVFTIATEPLRIIFLIAGAFFWLVSLLISSLVWFMARVIIDNKDGPTQKYLLIFGAFVSVYIQEMFRFAYYKLLKKASEGLKSINPGETAPSMRLLAYVSGLGFGIMSGVFSFVNTLSDSLGPGTVGIHGDSPQFFLYSAFMTLVIILLHVFWGIVFFDGCEKKKWGILLIVLLTHLLVSAQTFISSYYGINLASAFIILVLMGTWAFLAAGGSCRSLKLCLLCQDKNFLLYNQRSRMGAAVFFGCTFVAFGPAFALFLITVAGDPLRVIILVAGAFFWLVSLLLASVVWFILVHVTDRSDARLQYGLLIFGAAVSVLLQEVFRFAYYKLLKKADEGLASLSEDGRSPISIRQMAYVSGLSFGIISGVFSVINILADALGPGVVGIHGDSPYYFLTSAFLTAAIILLHTFWGVVFFDACERRRYWALGLVVGSHLLTSGLTFLNPWYEASLLPIYAVTVSMGLWAFITAGGSLRSIQRSLLCRRQEDSRVMVYSALRIPPED
T05880	DRUGINFO	D04NCC	PMID28350212-Compound-18	Patented
T05880	DRUGINFO	D08VTV	PMID28350212-Compound-7	Patented
T05880	DRUGINFO	D09SSG	PMID28350212-Compound-24	Patented
T05880	DRUGINFO	D09UJB	PMID28350212-Compound-19	Patented
T05880	DRUGINFO	D0A0UX	PMID28350212-Compound-35	Patented
T05880	DRUGINFO	D0C6OW	PMID28350212-Compound-23	Patented
T05880	DRUGINFO	D0D2BV	PMID28350212-Compound-25	Patented
T05880	DRUGINFO	D0D8IZ	PMID28350212-Compound-22	Patented
T05880	DRUGINFO	D0E9IY	PMID28350212-Compound-13	Patented
T05880	DRUGINFO	D0FV9R	PMID28350212-Compound-1	Patented
T05880	DRUGINFO	D0HL6X	PMID28350212-Compound-36	Patented
T05880	DRUGINFO	D0I9VU	PMID28350212-Compound-20	Patented
T05880	DRUGINFO	D0J4PC	PMID28350212-Compound-15	Patented
T05880	DRUGINFO	D0K2YO	Sulfonamide derivative 15	Patented
T05880	DRUGINFO	D0OL7Q	PMID28350212-Compound-21	Patented
T05880	DRUGINFO	D0PG2V	PMID28350212-Compound-12	Patented
T05880	DRUGINFO	D0PS0J	PMID28350212-Compound-16	Patented
T05880	DRUGINFO	D0S5BD	PMID28350212-Compound-30	Patented

T79570	TARGETID	T79570
T79570	FORMERID	TTDR00696
T79570	UNIPROID	ATS4_HUMAN
T79570	TARGNAME	Aggrecanase-1 (ADAMTS4)
T79570	GENENAME	ADAMTS4
T79570	TARGTYPE	Patented-recorded
T79570	SYNONYMS	Aggrecanase 1; ADMP-1; ADAMTS4; ADAM-TS4; ADAM-TS 4; A disintegrin and metalloproteinase with thrombospondin motifs 4
T79570	FUNCTION	Cleaves aggrecan, a cartilage proteoglycan, and may be involved in its turnover. May play an important role in the destruction of aggrecan in arthritic diseases. Could also be a critical factor in the exacerbation of neurodegeneration in Alzheimer disease. Cleaves aggrecan at the '392-Glu-|-Ala-393' site.
T79570	PDBSTRUC	4WKI; 4WKE; 4WK7; 3B2Z; 2RJP
T79570	BIOCLASS	Peptidase
T79570	ECNUMBER	EC 3.4.24.82
T79570	SEQUENCE	MSQTGSHPGRGLAGRWLWGAQPCLLLPIVPLSWLVWLLLLLLASLLPSARLASPLPREEEIVFPEKLNGSVLPGSGAPARLLCRLQAFGETLLLELEQDSGVQVEGLTVQYLGQAPELLGGAEPGTYLTGTINGDPESVASLHWDGGALLGVLQYRGAELHLQPLEGGTPNSAGGPGAHILRRKSPASGQGPMCNVKAPLGSPSPRPRRAKRFASLSRFVETLVVADDKMAAFHGAGLKRYLLTVMAAAAKAFKHPSIRNPVSLVVTRLVILGSGEEGPQVGPSAAQTLRSFCAWQRGLNTPEDSDPDHFDTAILFTRQDLCGVSTCDTLGMADVGTVCDPARSCAIVEDDGLQSAFTAAHELGHVFNMLHDNSKPCISLNGPLSTSRHVMAPVMAHVDPEEPWSPCSARFITDFLDNGYGHCLLDKPEAPLHLPVTFPGKDYDADRQCQLTFGPDSRHCPQLPPPCAALWCSGHLNGHAMCQTKHSPWADGTPCGPAQACMGGRCLHMDQLQDFNIPQAGGWGPWGPWGDCSRTCGGGVQFSSRDCTRPVPRNGGKYCEGRRTRFRSCNTEDCPTGSALTFREEQCAAYNHRTDLFKSFPGPMDWVPRYTGVAPQDQCKLTCQAQALGYYYVLEPRVVDGTPCSPDSSSVCVQGRCIHAGCDRIIGSKKKFDKCMVCGGDGSGCSKQSGSFRKFRYGYNNVVTIPAGATHILVRQQGNPGHRSIYLALKLPDGSYALNGEYTLMPSPTDVVLPGAVSLRYSGATAASETLSGHGPLAQPLTLQVLVAGNPQDTRLRYSFFVPRPTPSTPRPTPQDWLHRRAQILEILRRRPWAGRK
T79570	DRUGINFO	D0G1LL	1607004-34-1	Patented
T79570	DRUGINFO	D0N6ZA	US9206139, 4	Patented
T79570	DRUGINFO	D0UM5R	US9206139, 5	Patented
T79570	DRUGINFO	D0Y1XT	SC-44463	Terminated
T79570	DRUGINFO	D0Y1NM	(R)-2-(biphenyl-4-sulfonylamino)-propionic acid	Investigative
T79570	DRUGINFO	D0A4TC	MMI270	Investigative

T98264	TARGETID	T98264
T98264	FORMERID	TTDC00032
T98264	UNIPROID	PTN6_HUMAN
T98264	TARGNAME	Protein-tyrosine phosphatase SHP-1 (PTPN6)
T98264	GENENAME	PTPN6
T98264	TARGTYPE	Patented-recorded
T98264	SYNONYMS	Tyrosine-protein phosphatase non-receptor type 6; SH-PTP1; Protein-tyrosine phosphatase 1C; PTP1C; PTP-1C; Hematopoietic cell protein-tyrosine phosphatase; HCP
T98264	FUNCTION	The SH2 regions may interact with other cellular components to modulate its own phosphatase activity against interacting substrates. Together with MTUS1, induces UBE2V2 expression upon angiotensin II stimulation. Plays a key role in hematopoiesis. Modulates signaling by tyrosine phosphorylated cell surface receptors such as KIT and the EGF receptor/EGFR.
T98264	PDBSTRUC	4HJQ; 4HJP; 4GS0; 4GRZ; 4GRY
T98264	BIOCLASS	Phosphoric monoester hydrolase
T98264	ECNUMBER	EC 3.1.3.48
T98264	SEQUENCE	MVRWFHRDLSGLDAETLLKGRGVHGSFLARPSRKNQGDFSLSVRVGDQVTHIRIQNSGDFYDLYGGEKFATLTELVEYYTQQQGVLQDRDGTIIHLKYPLNCSDPTSERWYHGHMSGGQAETLLQAKGEPWTFLVRESLSQPGDFVLSVLSDQPKAGPGSPLRVTHIKVMCEGGRYTVGGLETFDSLTDLVEHFKKTGIEEASGAFVYLRQPYYATRVNAADIENRVLELNKKQESEDTAKAGFWEEFESLQKQEVKNLHQRLEGQRPENKGKNRYKNILPFDHSRVILQGRDSNIPGSDYINANYIKNQLLGPDENAKTYIASQGCLEATVNDFWQMAWQENSRVIVMTTREVEKGRNKCVPYWPEVGMQRAYGPYSVTNCGEHDTTEYKLRTLQVSPLDNGDLIREIWHYQYLSWPDHGVPSEPGGVLSFLDQINQRQESLPHAGPIIVHCSAGIGRTGTIIVIDMLMENISTKGLDCDIDIQKTIQMVRAQRSGMVQTEAQYKFIYVAIAQFIETTKKKLEVLQSQKGQESEYGNITYPPAMKNAHAKASRTSSKHKEDVYENLHTKNKREEKVKKQRSADKEKSKGSLKRK
T98264	DRUGINFO	D0I2AN	BDBM50054344	Patented
T98264	DRUGINFO	D00MFW	NSC-87877	Patented

T59190	TARGETID	T59190
T59190	FORMERID	TTDR00557
T59190	UNIPROID	KPCZ_HUMAN
T59190	TARGNAME	Protein kinase C zeta (PRKCZ)
T59190	GENENAME	PRKCZ
T59190	TARGTYPE	Patented-recorded
T59190	SYNONYMS	Protein kinase C zeta type; PKC2; NPKC-zeta
T59190	FUNCTION	Upon lipopolysaccharide (LPS) treatment in macrophages, or following mitogenic stimuli, functions downstream of PI3K to activate MAP2K1/MEK1-MAPK1/ERK2 signaling cascade independently of RAF1 activation. Required for insulin-dependent activation of AKT3, but may function as an adapter rather than a direct activator. Upon insulin treatment may act as a downstream effector of PI3K and contribute to the activation of translocation of the glucose transporter SLC2A4/GLUT4 and subsequent glucose transport in adipocytes. In EGF-induced cells, binds and activates MAP2K5/MEK5-MAPK7/ERK5 independently of its kinase activity and can activate JUN promoter through MEF2C. Through binding with SQSTM1/p62, functions in interleukin-1 signaling and activation of NF-kappa-B with the specific adapters RIPK1 and TRAF6. Participates in TNF-dependent transactivation of NF-kappa-B by phosphorylating and activating IKBKB kinase, which in turn leads to the degradation of NF-kappa-B inhibitors. In migrating astrocytes, forms a cytoplasmic complex with PARD6A and is recruited by CDC42 to function in the establishment of cell polarity along with the microtubule motor and dynein. In association with FEZ1, stimulates neuronal differentiation in PC12 cells. In the inflammatory response, is required for the T-helper 2 (Th2) differentiation process, including interleukin production, efficient activation of JAK1 and the subsequent phosphorylation and nuclear translocation of STAT6. May be involved in development of allergic airway inflammation (asthma), a process dependent on Th2 immune response. In the NF-kappa-B-mediated inflammatory response, can relieve SETD6-dependent repression of NF-kappa-B target genes by phosphorylating the RELA subunit at 'Ser-311'. In vein endothelial cells treated with the oxidant peroxynitrite, phosphorylates STK11 leading to nuclear export of STK11, subsequent inhibition of PI3K/Akt signaling, and increased apoptosis. Phosphorylates VAMP2 in vitro. Calcium- and diacylglycerol-independent serine/threonine-protein kinase that functions in phosphatidylinositol 3-kinase (PI3K) pathway and mitogen-activated protein (MAP) kinase cascade, and is involved in NF-kappa-B activation, mitogenic signaling, cell proliferation, cell polarity, inflammatory response and maintenance of long-term potentiation (LTP).
T59190	BIOCLASS	Kinase
T59190	ECNUMBER	EC 2.7.11.13
T59190	SEQUENCE	MPSRTGPKMEGSGGRVRLKAHYGGDIFITSVDAATTFEELCEEVRDMCRLHQQHPLTLKWVDSEGDPCTVSSQMELEEAFRLARQCRDEGLIIHVFPSTPEQPGLPCPGEDKSIYRRGARRWRKLYRANGHLFQAKRFNRRAYCGQCSERIWGLARQGYRCINCKLLVHKRCHGLVPLTCRKHMDSVMPSQEPPVDDKNEDADLPSEETDGIAYISSSRKHDSIKDDSEDLKPVIDGMDGIKISQGLGLQDFDLIRVIGRGSYAKVLLVRLKKNDQIYAMKVVKKELVHDDEDIDWVQTEKHVFEQASSNPFLVGLHSCFQTTSRLFLVIEYVNGGDLMFHMQRQRKLPEEHARFYAAEICIALNFLHERGIIYRDLKLDNVLLDADGHIKLTDYGMCKEGLGPGDTTSTFCGTPNYIAPEILRGEEYGFSVDWWALGVLMFEMMAGRSPFDIITDNPDMNTEDYLFQVILEKPIRIPRFLSVKASHVLKGFLNKDPKERLGCRPQTGFSDIKSHAFFRSIDWDLLEKKQALPPFQPQITDDYGLDNFDTQFTSEPVQLTPDDEDAIKRIDQSEFEGFEYINPLLLSTEESV
T59190	DRUGINFO	D03VKC	Methyl 2-amino-4-phenylthiophene-3-carboxylate	Patented
T59190	DRUGINFO	D0CV8T	Y-9680	Patented
T59190	DRUGINFO	D0T2KT	US8889696, 39	Patented
T59190	DRUGINFO	D0Y7KX	US8889672, 252-036-001	Patented
T59190	DRUGINFO	D0X0HN	LY-317644	Terminated
T59190	DRUGINFO	D0R5ZR	RO-320432	Terminated
T59190	DRUGINFO	D08JPU	G6976	Investigative
T59190	DRUGINFO	D00TWA	[2,2':5',2'']Terthiophen-4-yl-methanol	Investigative
T59190	DRUGINFO	D02PUV	4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol	Investigative
T59190	DRUGINFO	D02QME	2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile	Investigative
T59190	DRUGINFO	D05LRV	[2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde	Investigative
T59190	DRUGINFO	D09TSC	Ro-32-0557	Investigative
T59190	DRUGINFO	D09XIE	3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile	Investigative
T59190	DRUGINFO	D0A8MN	3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile	Investigative
T59190	DRUGINFO	D0D3MR	[2,2':5',2'']Terthiophene-4-carbaldehyde	Investigative
T59190	DRUGINFO	D0Q3GQ	4-cycloheptyliden(4-hydroxyphenyl)methylphenol	Investigative
T59190	DRUGINFO	D0S9UK	2,3,3-Triphenyl-acrylonitrile	Investigative
T59190	DRUGINFO	D0T0UH	3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile	Investigative
T59190	DRUGINFO	D0V9SW	4-cyclohexyliden(4-hydroxyphenyl)methylphenol	Investigative
T59190	DRUGINFO	D06ZCX	LY-326449	Investigative
T59190	DRUGINFO	D0TO6S	Bisindolylmaleimide-I	Investigative
T59190	DRUGINFO	D0L8HO	RO-316233	Investigative

T21357	TARGETID	T21357
T21357	FORMERID	TTDI02147
T21357	UNIPROID	PDE3B_HUMAN
T21357	TARGNAME	Phosphodiesterase 3B (PDE3B)
T21357	GENENAME	PDE3B
T21357	TARGTYPE	Patented-recorded
T21357	SYNONYMS	cGMPinhibited 3',5'cyclic phosphodiesterase B; cGMP-inhibited 3',5'-cyclic phosphodiesterase B; Cyclic GMPinhibited phosphodiesterase B; Cyclic GMP-inhibited phosphodiesterase B; CGIPDE1; CGIPDE B; CGIP1; CGI-PDE B
T21357	FUNCTION	May play a role in fat metabolism. Regulates cAMP binding of RAPGEF3. Through simultaneous binding to RAPGEF3 and PIK3R6 assembles a signaling complex in which the PI3K gamma complex is activated by RAPGEF3 and which is involved in angiogenesis. Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes.
T21357	PDBSTRUC	1SOJ; 1SO2
T21357	BIOCLASS	Phosphoric diester hydrolase
T21357	ECNUMBER	EC 3.1.4.17
T21357	SEQUENCE	MRRDERDAKAMRSLQPPDGAGSPPESLRNGYVKSCVSPLRQDPPRGFFFHLCRFCNVELRPPPASPQQPRRCSPFCRARLSLGALAAFVLALLLGAEPESWAAGAAWLRTLLSVCSHSLSPLFSIACAFFFLTCFLTRTKRGPGPGRSCGSWWLLALPACCYLGDFLVWQWWSWPWGDGDAGSAAPHTPPEAAAGRLLLVLSCVGLLLTLAHPLRLRHCVLVLLLASFVWWVSFTSLGSLPSALRPLLSGLVGGAGCLLALGLDHFFQIREAPLHPRLSSAAEEKVPVIRPRRRSSCVSLGETAASYYGSCKIFRRPSLPCISREQMILWDWDLKQWYKPHYQNSGGGNGVDLSVLNEARNMVSDLLTDPSLPPQVISSLRSISSLMGAFSGSCRPKINPLTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTHHVGLRRAGVLSSLSPVNSSNHGPVSTGSLTNRSPIEFPDTADFLNKPSVILQRSLGNAPNTPDFYQQLRNSDSNLCNSCGHQMLKYVSTSESDGTDCCSGKSGEEENIFSKESFKLMETQQEEETEKKDSRKLFQEGDKWLTEEAQSEQQTNIEQEVSLDLILVEEYDSLIEKMSNWNFPIFELVEKMGEKSGRILSQVMYTLFQDTGLLEIFKIPTQQFMNYFRALENGYRDIPYHNRIHATDVLHAVWYLTTRPVPGLQQIHNGCGTGNETDSDGRINHGRIAYISSKSCSNPDESYGCLSSNIPALELMALYVAAAMHDYDHPGRTNAFLVATNAPQAVLYNDRSVLENHHAASAWNLYLSRPEYNFLLHLDHVEFKRFRFLVIEAILATDLKKHFDFLAEFNAKANDVNSNGIEWSNENDRLLVCQVCIKLADINGPAKVRDLHLKWTEGIVNEFYEQGDEEANLGLPISPFMDRSSPQLAKLQESFITHIVGPLCNSYDAAGLLPGQWLEAEEDNDTESGDDEDGEELDTEDEEMENNLNPKPPRRKSRRRIFCQLMHHLTENHKIWKEIVEEEEKCKADGNKLQVENSSLPQADEIQVIEEADEEE
T21357	DRUGINFO	D0SG9Q	US9388139, 12	Patented
T21357	DRUGINFO	D0X5XB	US8741907-compound-3	Patented

T38996	TARGETID	T38996
T38996	FORMERID	TTDR00374
T38996	UNIPROID	PLD1_HUMAN
T38996	TARGNAME	Phospholipase D1 (PLD1)
T38996	GENENAME	PLD1
T38996	TARGTYPE	Patented-recorded
T38996	SYNONYMS	Phosphatidylcholine-hydrolyzing phospholipase D1; PLD 1; HPLD1; Choline phosphatase 1
T38996	FUNCTION	May be involved in the regulation of perinuclear intravesicular membrane traffic. Implicated as a critical step in numerous cellular pathways, including signal transduction, membrane trafficking, and the regulation of mitosis.
T38996	BIOCLASS	Phosphoric diester hydrolase
T38996	ECNUMBER	EC 3.1.4.4
T38996	SEQUENCE	MSLKNEPRVNTSALQKIAADMSNIIENLDTRELHFEGEEVDYDVSPSDPKIQEVYIPFSAIYNTQGFKEPNIQTYLSGCPIKAQVLEVERFTSTTRVPSINLYTIELTHGEFKWQVKRKFKHFQEFHRELLKYKAFIRIPIPTRRHTFRRQNVREEPREMPSLPRSSENMIREEQFLGRRKQLEDYLTKILKMPMYRNYHATTEFLDISQLSFIHDLGPKGIEGMIMKRSGGHRIPGLNCCGQGRACYRWSKRWLIVKDSFLLYMKPDSGAIAFVLLVDKEFKIKVGKKETETKYGIRIDNLSRTLILKCNSYRHARWWGGAIEEFIQKHGTNFLKDHRFGSYAAIQENALAKWYVNAKGYFEDVANAMEEANEEIFITDWWLSPEIFLKRPVVEGNRWRLDCILKRKAQQGVRIFIMLYKEVELALGINSEYTKRTLMRLHPNIKVMRHPDHVSSTVYLWAHHEKLVIIDQSVAFVGGIDLAYGRWDDNEHRLTDVGSVKRVTSGPSLGSLPPAAMESMESLRLKDKNEPVQNLPIQKSIDDVDSKLKGIGKPRKFSKFSLYKQLHRHHLHDADSISSIDSTSSYFNHYRSHHNLIHGLKPHFKLFHPSSESEQGLTRPHADTGSIRSLQTGVGELHGETRFWHGKDYCNFVFKDWVQLDKPFADFIDRYSTPRMPWHDIASAVHGKAARDVARHFIQRWNFTKIMKSKYRSLSYPFLLPKSQTTAHELRYQVPGSVHANVQLLRSAADWSAGIKYHEESIHAAYVHVIENSRHYIYIENQFFISCADDKVVFNKIGDAIAQRILKAHRENQKYRVYVVIPLLPGFEGDISTGGGNALQAIMHFNYRTMCRGENSILGQLKAELGNQWINYISFCGLRTHAELEGNLVTELIYVHSKLLIADDNTVIIGSANINDRSMLGKRDSEMAVIVQDTETVPSVMDGKEYQAGRFARGLRLQCFRVVLGYLDDPSEDIQDPVSDKFFKEVWVSTAARNATIYDKVFRCLPNDEVHNLIQLRDFINKPVLAKEDPIRAEEELKKIRGFLVQFPFYFLSEESLLPSVGTKEAIVPMEVWT
T38996	DRUGINFO	D06OKT	US9127005, P2C	Patented
T38996	DRUGINFO	D08SLU	US9453017, 1	Patented
T38996	DRUGINFO	D09BSA	US9127005, P2B	Patented
T38996	DRUGINFO	D0CI4A	ML272	Patented
T38996	DRUGINFO	D0OX9E	US9127005, P0L	Patented
T38996	DRUGINFO	D0X0NV	US9453017, 2	Patented
T38996	DRUGINFO	D0T3HK	1-(pyridin-4-yl)piperazine	Investigative
T38996	DRUGINFO	D07RPV	HALOPEMIDE	Investigative
T38996	DRUGINFO	D07JMN	1-(pyridin-2-yl)piperazine	Investigative

T31543	TARGETID	T31543
T31543	FORMERID	TTDR00644
T31543	UNIPROID	ST14_HUMAN
T31543	TARGNAME	Suppressor of tumorigenicity 14 protein (ST14)
T31543	GENENAME	ST14
T31543	TARGTYPE	Patented-recorded
T31543	SYNONYMS	Tumor-associated differentially-expressed gene 15 protein; Tumor associated differentially-expressed gene-15 protein; TADG15; Serine protease TADG-15; Serine protease 14; SNC19; Prostamin; PRSS14; Membrane-type serine protease 1; Membrane type serine protease 1; Matriptase; MT-SP1
T31543	FUNCTION	Proposed to play a role in breast cancer invasion and metastasis. Exhibits trypsin-like activity as defined by cleavage of synthetic substrates with Arg or Lys as the P1 site. Involved in the terminal differentiation of keratinocytes through prostasin (PRSS8) activation and filaggrin (FLG) processing. Degrades extracellular matrix.
T31543	PDBSTRUC	5LYO; 4R0I; 4O9V; 4O97; 4JZI
T31543	BIOCLASS	Peptidase
T31543	ECNUMBER	EC 3.4.21.109
T31543	SEQUENCE	MGSDRARKGGGGPKDFGAGLKYNSRHEKVNGLEEGVEFLPVNNVKKVEKHGPGRWVVLAAVLIGLLLVLLGIGFLVWHLQYRDVRVQKVFNGYMRITNENFVDAYENSNSTEFVSLASKVKDALKLLYSGVPFLGPYHKESAVTAFSEGSVIAYYWSEFSIPQHLVEEAERVMAEERVVMLPPRARSLKSFVVTSVVAFPTDSKTVQRTQDNSCSFGLHARGVELMRFTTPGFPDSPYPAHARCQWALRGDADSVLSLTFRSFDLASCDERGSDLVTVYNTLSPMEPHALVQLCGTYPPSYNLTFHSSQNVLLITLITNTERRHPGFEATFFQLPRMSSCGGRLRKAQGTFNSPYYPGHYPPNIDCTWNIEVPNNQHVKVRFKFFYLLEPGVPAGTCPKDYVEINGEKYCGERSQFVVTSNSNKITVRFHSDQSYTDTGFLAEYLSYDSSDPCPGQFTCRTGRCIRKELRCDGWADCTDHSDELNCSCDAGHQFTCKNKFCKPLFWVCDSVNDCGDNSDEQGCSCPAQTFRCSNGKCLSKSQQCNGKDDCGDGSDEASCPKVNVVTCTKHTYRCLNGLCLSKGNPECDGKEDCSDGSDEKDCDCGLRSFTRQARVVGGTDADEGEWPWQVSLHALGQGHICGASLISPNWLVSAAHCYIDDRGFRYSDPTQWTAFLGLHDQSQRSAPGVQERRLKRIISHPFFNDFTFDYDIALLELEKPAEYSSMVRPICLPDASHVFPAGKAIWVTGWGHTQYGGTGALILQKGEIRVINQTTCENLLPQQITPRMMCVGFLSGGVDSCQGDSGGPLSSVEADGRIFQAGVVSWGDGCAQRNKPGVYTRLPLFRDWIKENTGV
T31543	DRUGINFO	D0CN2Q	US8569313, Inhibitor 18	Patented
T31543	DRUGINFO	D0PY4S	US8569313, Inhibitor 14	Patented
T31543	DRUGINFO	D0RN9V	US8569313, Inhibitor 19	Patented
T31543	DRUGINFO	D0U4EO	US8569313, Inhibitor 15	Patented
T31543	DRUGINFO	D01TWD	3-tapap	Investigative
T31543	DRUGINFO	D0SP2I	2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine	Investigative
T31543	DRUGINFO	D0W2SV	Inhibitor 1 [Colombo et al., 2012]	Investigative
T31543	DRUGINFO	D00LOL	PMID23849879C3	Investigative
T31543	DRUGINFO	D07OQF	PMID25489658C4d	Investigative
T31543	DRUGINFO	D07SFI	Benzamidine	Investigative

T20669	TARGETID	T20669
T20669	FORMERID	TTDR01375
T20669	UNIPROID	KAPCA_HUMAN
T20669	TARGNAME	PRKACA messenger RNA (PRKACA mRNA)
T20669	GENENAME	PRKACA
T20669	TARGTYPE	Patented-recorded
T20669	SYNONYMS	cAMP-dependent protein kinase catalytic subunit alpha (mRNA); PKACA (mRNA); PKA C-alpha (mRNA)
T20669	FUNCTION	Regulates the abundance of compartmentalized pools of its regulatory subunits through phosphorylation of PJA2 which binds and ubiquitinates these subunits, leading to their subsequent proteolysis. Phosphorylates CDC25B, ABL1, NFKB1, CLDN3, PSMC5/RPT6, PJA2, RYR2, RORA and VASP. RORA is activated by phosphorylation. Required for glucose-mediated adipogenic differentiation increase and osteogenic differentiation inhibition from osteoblasts. Involved in the regulation of platelets in response to thrombin and collagen; maintains circulating platelets in a resting state by phosphorylating proteins in numerous platelet inhibitory pathways when in complex with NF-kappa-B (NFKB1 and NFKB2) and I-kappa-B-alpha (NFKBIA), but thrombin and collagen disrupt these complexes and free active PRKACA stimulates platelets and leads to platelet aggregation by phosphorylating VASP. Prevents the antiproliferative and anti-invasive effects of alpha-difluoromethylornithine in breast cancer cells when activated. RYR2 channel activity is potentiated by phosphorylation in presence of luminal Ca(2+), leading to reduced amplitude and increased frequency of store overload-induced Ca(2+) release (SOICR) characterized by an increased rate of Ca(2+) release and propagation velocity of spontaneous Ca(2+) waves, despite reduced wave amplitude and resting cytosolic Ca(2+). PSMC5/RPT6 activation by phosphorylation stimulates proteasome. Negatively regulates tight junctions (TJs) in ovarian cancer cells via CLDN3 phosphorylation. NFKB1 phosphorylation promotes NF-kappa-B p50-p50 DNA binding. Involved in embryonic development by down-regulating the Hedgehog (Hh) signaling pathway that determines embryo pattern formation and morphogenesis. Prevents meiosis resumption in prophase-arrested oocytes via CDC25B inactivation by phosphorylation. May also regulate rapid eye movement (REM) sleep in the pedunculopontine tegmental (PPT). Phosphorylates APOBEC3G and AICDA. Isoform 2 phosphorylates and activates ABL1 in sperm flagellum to promote spermatozoa capacitation. Phosphorylates HSF1; this phosphorylation promotes HSF1 nuclear localization and transcriptional activity upon heat shock. Phosphorylates a large number of substrates in the cytoplasm and the nucleus.
T20669	PDBSTRUC	6FRX; 6C0U; 6BYS; 6BYR; 5UZK
T20669	BIOCLASS	mRNA target
T20669	ECNUMBER	EC 2.7.11.11
T20669	SEQUENCE	MGNAAAAKKGSEQESVKEFLAKAKEDFLKKWESPAQNTAHLDQFERIKTLGTGSFGRVMLVKHKETGNHYAMKILDKQKVVKLKQIEHTLNEKRILQAVNFPFLVKLEFSFKDNSNLYMVMEYVPGGEMFSHLRRIGRFSEPHARFYAAQIVLTFEYLHSLDLIYRDLKPENLLIDQQGYIQVTDFGFAKRVKGRTWTLCGTPEYLAPEIILSKGYNKAVDWWALGVLIYEMAAGYPPFFADQPIQIYEKIVSGKVRFPSHFSSDLKDLLRNLLQVDLTKRFGNLKNGVNDIKNHKWFATTDWIAIYQRKVEAPFIPKFKGPGDTSNFDDYEEEEIRVSINEKCGKEFSEF
T20669	DRUGINFO	D00QNV	VFEDEOUBYBLDKN-AAFJCEBUSA-N	Patented
T20669	DRUGINFO	D06GXM	XHPNYYOUZWOWNT-PYUWXLGESA-N	Patented
T20669	DRUGINFO	D0B6VY	AGGGWZCOULSEER-PYUWXLGESA-N	Patented
T20669	DRUGINFO	D0R2TM	BALANOL	Terminated
T20669	DRUGINFO	D00ERI	ISIS 102633	Investigative
T20669	DRUGINFO	D00ODF	ISIS 102604	Investigative
T20669	DRUGINFO	D00WZE	ISIS 102619	Investigative
T20669	DRUGINFO	D00YID	ISIS 102462	Investigative
T20669	DRUGINFO	D02XQB	ISIS 102563	Investigative
T20669	DRUGINFO	D03RKU	ISIS 102490	Investigative
T20669	DRUGINFO	D04GPC	ISIS 102664	Investigative
T20669	DRUGINFO	D04OUT	ISIS 102584	Investigative
T20669	DRUGINFO	D06JUQ	ISIS 102629	Investigative
T20669	DRUGINFO	D06NSN	ISIS 102614	Investigative
T20669	DRUGINFO	D08FVO	ISIS 102450	Investigative
T20669	DRUGINFO	D09FFE	H-89	Investigative
T20669	DRUGINFO	D0A5FV	ISIS 102558	Investigative
T20669	DRUGINFO	D0CE4H	ISIS 102599	Investigative
T20669	DRUGINFO	D0D4BR	ISIS 102676	Investigative
T20669	DRUGINFO	D0K7PJ	ISIS 102486	Investigative
T20669	DRUGINFO	D0KL5K	ISIS 102668	Investigative
T20669	DRUGINFO	D0L0IR	ISIS 102454	Investigative
T20669	DRUGINFO	D0M4NN	ISIS 102466	Investigative
T20669	DRUGINFO	D0P0SY	ISIS 102609	Investigative
T20669	DRUGINFO	D0S7SN	ISIS 102478	Investigative
T20669	DRUGINFO	D0T3GH	ISIS 102624	Investigative
T20669	DRUGINFO	D0U3ML	ISIS 102660	Investigative
T20669	DRUGINFO	D0V2VB	ISIS 102458	Investigative
T20669	DRUGINFO	D0Z2QO	ISIS 102482	Investigative
T20669	DRUGINFO	D0GT8N	NM-PP1	Investigative
T20669	DRUGINFO	D09XIL	Ro-4396686	Investigative
T20669	DRUGINFO	D0A5RM	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	Investigative

T71367	TARGETID	T71367
T71367	FORMERID	TTDI00079
T71367	UNIPROID	M4K4_HUMAN
T71367	TARGNAME	MEK kinase kinase 4 (MAP4K4)
T71367	GENENAME	MAP4K4
T71367	TARGTYPE	Patented-recorded
T71367	SYNONYMS	Nckinteracting kinase; Nck-interacting kinase; Mitogenactivated protein kinase kinase kinase kinase 4; Mitogen-activated protein kinase kinase kinase kinase 4; MEKKK 4; MAPK/ERK kinase kinase kinase 4; KIAA0687; HPK/GCKlike kinase HGK; HPK/GCK-like kinase HGK; HGK
T71367	FUNCTION	Appears to act upstream of the JUN N-terminal pathway. Phosphorylates SMAD1 on Thr-322. Serine/threonine kinase that may play a role in the response to environmental stress and cytokines such as TNF-alpha.
T71367	PDBSTRUC	5W5Q; 5J95; 5DI1; 4ZP5; 4ZK5
T71367	BIOCLASS	Kinase
T71367	ECNUMBER	EC 2.7.11.1
T71367	SEQUENCE	MANDSPAKSLVDIDLSSLRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVTEDEEEEIKLEINMLKKYSHHRNIATYYGAFIKKSPPGHDDQLWLVMEFCGAGSITDLVKNTKGNTLKEDWIAYISREILRGLAHLHIHHVIHRDIKGQNVLLTENAEVKLVDFGVSAQLDRTVGRRNTFIGTPYWMAPEVIACDENPDATYDYRSDLWSCGITAIEMAEGAPPLCDMHPMRALFLIPRNPPPRLKSKKWSKKFFSFIEGCLVKNYMQRPSTEQLLKHPFIRDQPNERQVRIQLKDHIDRTRKKRGEKDETEYEYSGSEEEEEEVPEQEGEPSSIVNVPGESTLRRDFLRLQQENKERSEALRRQQLLQEQQLREQEEYKRQLLAERQKRIEQQKEQRRRLEEQQRREREARRQQEREQRRREQEEKRRLEELERRRKEEEERRRAEEEKRRVEREQEYIRRQLEEEQRHLEVLQQQLLQEQAMLLECRWREMEEHRQAERLQRQLQQEQAYLLSLQHDHRRPHPQHSQQPPPPQQERSKPSFHAPEPKAHYEPADRAREVEDRFRKTNHSSPEAQSKQTGRVLEPPVPSRSESFSNGNSESVHPALQRPAEPQVPVRTTSRSPVLSRRDSPLQGSGQQNSQAGQRNSTSIEPRLLWERVEKLVPRPGSGSSSGSSNSGSQPGSHPGSQSGSGERFRVRSSSKSEGSPSQRLENAVKKPEDKKEVFRPLKPADLTALAKELRAVEDVRPPHKVTDYSSSSEESGTTDEEDDDVEQEGADESTSGPEDTRAASSLNLSNGETESVKTMIVHDDVESEPAMTPSKEGTLIVRQTQSASSTLQKHKSSSSFTPFIDPRLLQISPSSGTTVTSVVGFSCDGMRPEAIRQDPTRKGSVVNVNPTNTRPQSDTPEIRKYKKRFNSEILCAALWGVNLLVGTESGLMLLDRSGQGKVYPLINRRRFQQMDVLEGLNVLVTISGKKDKLRVYYLSWLRNKILHNDPEVEKKQGWTTVGDLEGCVHYKVVKYERIKFLVIALKSSVEVYAWAPKPYHKFMAFKSFGELVHKPLLVDLTVEEGQRLKVIYGSCAGFHAVDVDSGSVYDIYLPTHIQCSIKPHAIIILPNTDGMELLVCYEDEGVYVNTYGRITKDVVLQWGEMPTSVAYIRSNQTMGWGEKAIEIRSVETGHLDGVFMHKRAQRLKFLCERNDKVFFASVRSGGSSQVYFMTLGRTSLLSW
T71367	DRUGINFO	D00SDR	BDBM50011553	Patented
T71367	DRUGINFO	D0HK8C	6-Phenylquinazolin-4-amine	Patented
T71367	DRUGINFO	D0L2FW	BDBM50011552	Patented
T71367	DRUGINFO	D0NY6U	PMID24673130C26	Investigative
T71367	DRUGINFO	D0O6OH	PMID23312943C21	Investigative

T73471	TARGETID	T73471
T73471	FORMERID	TTDR00510
T73471	UNIPROID	HEPS_HUMAN
T73471	TARGNAME	Serine protease hepsin (HPN)
T73471	GENENAME	HPN
T73471	TARGTYPE	Patented-recorded
T73471	SYNONYMS	Transmembrane protease, serine 1; HPN; HEPSIN
T73471	FUNCTION	Plays an essential role in cell growth and maintenance of cell morphology. May mediate the activating cleavage of HGF and MST1/HGFL. Plays a role in the proteolytic processing of ACE2.
T73471	PDBSTRUC	5CE1; 3T2N; 1Z8G; 1P57; 1O5F
T73471	BIOCLASS	Peptidase
T73471	ECNUMBER	EC 3.4.21.106
T73471	SEQUENCE	MAQKEGGRTVPCCSRPKVAALTAGTLLLLTAIGAASWAIVAVLLRSDQEPLYPVQVSSADARLMVFDKTEGTWRLLCSSRSNARVAGLSCEEMGFLRALTHSELDVRTAGANGTSGFFCVDEGRLPHTQRLLEVISVCDCPRGRFLAAICQDCGRRKLPVDRIVGGRDTSLGRWPWQVSLRYDGAHLCGGSLLSGDWVLTAAHCFPERNRVLSRWRVFAGAVAQASPHGLQLGVQAVVYHGGYLPFRDPNSEENSNDIALVHLSSPLPLTEYIQPVCLPAAGQALVDGKICTVTGWGNTQYYGQQAGVLQEARVPIISNDVCNGADFYGNQIKPKMFCAGYPEGGIDACQGDSGGPFVCEDSISRTPRWRLCGIVSWGTGCALAQKPGVYTKVSDFREWIFQAIKTHSEASGMVTQL
T73471	DRUGINFO	D04LWZ	AC1LFXA6	Patented
T73471	DRUGINFO	D06MTX	CRA_1144	Investigative
T73471	DRUGINFO	D0PA1G	Benzylsulfinic Acid	Investigative

T04831	TARGETID	T04831
T04831	FORMERID	TTDNR00694
T04831	UNIPROID	E2AK2_HUMAN
T04831	TARGNAME	Tyrosine-protein kinase EIF2AK2 (p68)
T04831	GENENAME	EIF2AK2
T04831	TARGTYPE	Patented-recorded
T04831	SYNONYMS	p68 kinase; Proteinkinase RNA-activated; Interferon-inducible RNA-dependent protein kinase p68; Interferon-induced, double-stranded RNA-activated protein kinase p68
T04831	FUNCTION	Exerts its antiviral activity on a wide range of DNA and RNA viruses including hepatitis C virus (HCV), hepatitis B virus (HBV), measles virus (MV) and herpes simplex virus 1 (HHV-1). Inhibits viral replication via phosphorylation of the alpha subunit of eukaryotic initiation factor 2 (EIF2S1), this phosphorylation impairs the recycling of EIF2S1 between successive rounds of initiation leading to inhibition of translation which eventually results in shutdown of cellular and viral protein synthesis. Also phosphorylates other substrates including p53/TP53, PPP2R5A, DHX9, ILF3, IRS1 and the HHV-1 viral protein US11. In addition to serine/threonine-protein kinase activity, also has tyrosine-protein kinase activity and phosphorylates CDK1 at 'Tyr-4' upon DNA damage, facilitating its ubiquitination and proteosomal degradation. Either as an adapter protein and/or via its kinase activity, can regulate various signaling pathways (p38 MAP kinase, NF-kappa-B and insulin signaling pathways) and transcription factors (JUN, STAT1, STAT3, IRF1, ATF3) involved in the expression of genes encoding proinflammatory cytokines and IFNs. Activates the NF-kappa-B pathway via interaction with IKBKB and TRAF family of proteins and activates the p38 MAP kinase pathway via interaction with MAP2K6. Can act as both a positive and negative regulator of the insulin signaling pathway (ISP). Negatively regulates ISP by inducing the inhibitory phosphorylation of insulin receptor substrate 1 (IRS1) at 'Ser-312' and positively regulates ISP via phosphorylation of PPP2R5A which activates FOXO1, which in turn up-regulates the expression of insulin receptor substrate 2 (IRS2). Can regulate NLRP3 inflammasome assembly and the activation of NLRP3, NLRP1, AIM2 and NLRC4 inflammasomes. Can trigger apoptosis via FADD-mediated activation of CASP8. Plays a role in the regulation of the cytoskeleton by binding to gelsolin (GSN), sequestering the protein in an inactive conformation away from actin. IFN-induced dsRNA-dependent serine/threonine-protein kinase which plays a key role in the innate immune response to viral infection and is also involved in the regulation of signal transduction, apoptosis, cell proliferation and differentiation.
T04831	PDBSTRUC	3UIU; 2A1A; 2A19; 1QU6
T04831	BIOCLASS	Kinase
T04831	ECNUMBER	EC 2.7.11.1
T04831	SEQUENCE	MAGDLSAGFFMEELNTYRQKQGVVLKYQELPNSGPPHDRRFTFQVIIDGREFPEGEGRSKKEAKNAAAKLAVEILNKEKKAVSPLLLTTTNSSEGLSMGNYIGLINRIAQKKRLTVNYEQCASGVHGPEGFHYKCKMGQKEYSIGTGSTKQEAKQLAAKLAYLQILSEETSVKSDYLSSGSFATTCESQSNSLVTSTLASESSSEGDFSADTSEINSNSDSLNSSSLLMNGLRNNQRKAKRSLAPRFDLPDMKETKYTVDKRFGMDFKEIELIGSGGFGQVFKAKHRIDGKTYVIKRVKYNNEKAEREVKALAKLDHVNIVHYNGCWDGFDYDPETSDDSLESSDYDPENSKNSSRSKTKCLFIQMEFCDKGTLEQWIEKRRGEKLDKVLALELFEQITKGVDYIHSKKLIHRDLKPSNIFLVDTKQVKIGDFGLVTSLKNDGKRTRSKGTLRYMSPEQISSQDYGKEVDLYALGLILAELLHVCDTAFETSKFFTDLRDGIISDIFDKKEKTLLQKLLSKKPEDRPNTSEILRTLTVWKKSPEKNERHTC
T04831	DRUGINFO	D05GPF	US9650366, 12	Patented
T04831	DRUGINFO	D0QZ4B	US9650366, 2	Patented
T04831	DRUGINFO	D0Z0BQ	US9650366, 9	Patented
T04831	DRUGINFO	D0C1DQ	ASN-11124542	Investigative
T04831	DRUGINFO	D0N9DU	indirubin derivative E804	Investigative
T04831	DRUGINFO	D04WFN	NU6140	Investigative

T41666	TARGETID	T41666
T41666	FORMERID	TTDR00219
T41666	UNIPROID	HGXR_PLAFG
T41666	TARGNAME	Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ)
T41666	GENENAME	Malaria LACZ
T41666	TARGTYPE	Patented-recorded
T41666	SYNONYMS	LACZ of Plasmodium falciparum (isolate FCR-3 / Gambia); Hypoxanthine phosphoribosyltransferase; HPRT; HGPRTase; HGPRT of Plasmodium falciparum (isolate FCR-3 / Gambia); Guanine phosphoribosyltransferase; GPRT
T41666	FUNCTION	Converts guanine to guanosine monophosphate, and hypoxanthine to inosine monophosphate. Transfers the 5- phosphoribosyl group from 5-phosphoribosylpyrophosphate onto the purine. Plays a central role in the generation of purine nucleotides through the purine salvage pathway.
T41666	PDBSTRUC	3OZG; 3OZF; 2VFA; 1CJB
T41666	BIOCLASS	Pentosyltransferase
T41666	SEQUENCE	MPIPNNPGAGENAFDPVFVNDDDGYDLDSFMIPAHYKKYLTKVLVPNGVIKNRIEKLAYDIKKVYNNEEFHILCLLKGSRGFFTALLKHLSRIHNYSAVETSKPLFGEHYVRVKSYCNDQSTGTLEIVSEDLSCLKGKHVLIVEDIIDTGKTLVKFCEYLKKFEIKTVAIACLFIKRTPLWNGFKADFVGFSIPDHFVVGYSLDYNEIFRDLDHCCLVNDEGKKKYKATSL
T41666	DRUGINFO	D06TXN	US9200020, Table 3, Compound 1B	Patented
T41666	DRUGINFO	D0A5NU	US9200020, Table 3, Compound 2B	Patented
T41666	DRUGINFO	D0J6BK	US9200020, Table 3 compound 8	Patented
T41666	DRUGINFO	D00GHB	Carboxylic PRPP	Investigative
T41666	DRUGINFO	D01IPS	5--Monophosphate-9-Beta-D-Ribofuranosyl Xanthine	Investigative
T41666	DRUGINFO	D03VOB	9-[2-(1-Phosphonopropan-2-yloxy)ethyl]guanine	Investigative
T41666	DRUGINFO	D04ZAO	7-Hydroxy-Pyrazolo[4,3-D]Pyrimidine	Investigative
T41666	DRUGINFO	D06NCQ	3h-Pyrazolo[4,3-D]Pyrimidin-7-Ol	Investigative
T41666	DRUGINFO	D0O7WT	9-[2-(1-Phosphonobutan-2-yloxy)ethyl]hypoxanthine	Investigative
T41666	DRUGINFO	D0Q7WP	9-[2-(1-Phosphonobutan-2-yloxy)ethyl]guanine	Investigative
T41666	DRUGINFO	D0X2GF	9-Deazaguanine	Investigative
T41666	DRUGINFO	D0X2VN	Formycin B	Investigative
T41666	DRUGINFO	D0XB1H	Guanosine-5',3'-Tetraphosphate	Investigative
T41666	DRUGINFO	D08NFH	Alpha-Phosphoribosylpyrophosphoric Acid	Investigative
T41666	DRUGINFO	D04AWP	Guanosine-5'-Monophosphate	Investigative
T41666	DRUGINFO	D0H2YT	Inosinic Acid	Investigative
T41666	DRUGINFO	D0A1DU	Pyrophosphate 2-	Investigative
T41666	DRUGINFO	D06EWG	Formic Acid	Investigative
T41666	DRUGINFO	D0F2ME	Acetate Ion	Investigative

T62548	TARGETID	T62548
T62548	FORMERID	TTDR00280
T62548	UNIPROID	ARBK1_HUMAN
T62548	TARGNAME	Beta-adrenergic receptor kinase 1 (ADRBK1)
T62548	GENENAME	GRK2
T62548	TARGTYPE	Patented-recorded
T62548	SYNONYMS	GRK2; G-protein coupled receptor kinase 2; BetaARK1; Beta-ARK-1; Beta ARK1
T62548	FUNCTION	Specifically phosphorylates the agonist-occupied form of the beta-adrenergic and closely related receptors, probably inducing a desensitization of them. Key regulator of LPAR1 signaling. Competes with RALA for binding to LPAR1 thus affecting the signaling properties of the receptor. Desensitizes LPAR1 and LPAR2 in a phosphorylation-independent manner.
T62548	PDBSTRUC	6C2Y; 5WG5; 5WG4; 5WG3; 5UVC
T62548	BIOCLASS	Kinase
T62548	ECNUMBER	EC 2.7.11.15
T62548	SEQUENCE	MADLEAVLADVSYLMAMEKSKATPAARASKKILLPEPSIRSVMQKYLEDRGEVTFEKIFSQKLGYLLFRDFCLNHLEEARPLVEFYEEIKKYEKLETEEERVARSREIFDSYIMKELLACSHPFSKSATEHVQGHLGKKQVPPDLFQPYIEEICQNLRGDVFQKFIESDKFTRFCQWKNVELNIHLTMNDFSVHRIIGRGGFGEVYGCRKADTGKMYAMKCLDKKRIKMKQGETLALNERIMLSLVSTGDCPFIVCMSYAFHTPDKLSFILDLMNGGDLHYHLSQHGVFSEADMRFYAAEIILGLEHMHNRFVVYRDLKPANILLDEHGHVRISDLGLACDFSKKKPHASVGTHGYMAPEVLQKGVAYDSSADWFSLGCMLFKLLRGHSPFRQHKTKDKHEIDRMTLTMAVELPDSFSPELRSLLEGLLQRDVNRRLGCLGRGAQEVKESPFFRSLDWQMVFLQKYPPPLIPPRGEVNAADAFDIGSFDEEDTKGIKLLDSDQELYRNFPLTISERWQQEVAETVFDTINAETDRLEARKKAKNKQLGHEEDYALGKDCIMHGYMSKMGNPFLTQWQRRYFYLFPNRLEWRGEGEAPQSLLTMEEIQSVEETQIKERKCLLLKIRGGKQFILQCDSDPELVQWKKELRDAYREAQQLVQRVPKMKNKPRSPVVELSKVPLVQRGSANGL
T62548	DRUGINFO	D04WNI	US9493490, E	Patented
T62548	DRUGINFO	D0OE2R	US9493490, D	Patented
T62548	DRUGINFO	D0YB5B	US9493490, C	Patented
T62548	DRUGINFO	D0YD7S	BDBM50173306	Patented
T62548	DRUGINFO	D0ZS0I	US9493490, L	Patented
T62548	DRUGINFO	D02TYC	BetaARKct	Investigative
T62548	DRUGINFO	D0U8UK	PMID21596927C101	Investigative
T62548	DRUGINFO	D04CUA	PMID24210504C1o	Investigative

T64553	TARGETID	T64553
T64553	FORMERID	TTDI02371
T64553	UNIPROID	ZAP70_HUMAN
T64553	TARGNAME	Tyrosine-protein kinase ZAP-70 (ZAP-70)
T64553	GENENAME	ZAP70
T64553	TARGTYPE	Patented-recorded
T64553	SYNONYMS	Syk-related tyrosine kinase; SRK; 70 kDa zeta-chain associated protein
T64553	FUNCTION	Regulates motility, adhesion and cytokine expression of mature T-cells, as well as thymocyte development. Contributes also to the development and activation of primary B-lymphocytes. When antigen presenting cells (APC) activate T-cell receptor (TCR), a serie of phosphorylations lead to the recruitment of ZAP70 to the doubly phosphorylated TCR component CD247/CD3Z through ITAM motif at the plasma membrane. This recruitment serves to localization to the stimulated TCR and to relieve its autoinhibited conformation. Release of ZAP70 active conformation is further stabilized by phosphorylation mediated by LCK. Subsequently, ZAP70 phosphorylates at least 2 essential adapter proteins: LAT and LCP2. In turn, a large number of signaling molecules are recruited and ultimately lead to lymphokine production, T-cell proliferation and differentiation. Furthermore, ZAP70 controls cytoskeleton modifications, adhesion and mobility of T-lymphocytes, thus ensuring correct delivery of effectors to the APC. ZAP70 is also required for TCR-CD247/CD3Z internalization and degradation through interaction with the E3 ubiquitin-protein ligase CBL and adapter proteins SLA and SLA2. Thus, ZAP70 regulates both T-cell activation switch on and switch off by modulating TCR expression at the T-cell surface. During thymocyte development, ZAP70 promotes survival and cell-cycle progression of developing thymocytes before positive selection (when cells are still CD4/CD8 double negative). Additionally, ZAP70-dependent signaling pathway may also contribute to primary B-cells formation and activation through B-cell receptor (BCR). Tyrosine kinase that plays an essential role in regulation of the adaptive immune response.
T64553	PDBSTRUC	5O76; 4XZ1; 4XZ0; 4K2R; 4A4C
T64553	BIOCLASS	Kinase
T64553	ECNUMBER	EC 2.7.10.2
T64553	SEQUENCE	MPDPAAHLPFFYGSISRAEAEEHLKLAGMADGLFLLRQCLRSLGGYVLSLVHDVRFHHFPIERQLNGTYAIAGGKAHCGPAELCEFYSRDPDGLPCNLRKPCNRPSGLEPQPGVFDCLRDAMVRDYVRQTWKLEGEALEQAIISQAPQVEKLIATTAHERMPWYHSSLTREEAERKLYSGAQTDGKFLLRPRKEQGTYALSLIYGKTVYHYLISQDKAGKYCIPEGTKFDTLWQLVEYLKLKADGLIYCLKEACPNSSASNASGAAAPTLPAHPSTLTHPQRRIDTLNSDGYTPEPARITSPDKPRPMPMDTSVYESPYSDPEELKDKKLFLKRDNLLIADIELGCGNFGSVRQGVYRMRKKQIDVAIKVLKQGTEKADTEEMMREAQIMHQLDNPYIVRLIGVCQAEALMLVMEMAGGGPLHKFLVGKREEIPVSNVAELLHQVSMGMKYLEEKNFVHRDLAARNVLLVNRHYAKISDFGLSKALGADDSYYTARSAGKWPLKWYAPECINFRKFSSRSDVWSYGVTMWEALSYGQKPYKKMKGPEVMAFIEQGKRMECPPECPPELYALMSDCWIYKWEDRPDFLTVEQRMRACYYSLASKVEGPPGSTQKAEAACA
T64553	DRUGINFO	D00HGD	US8546370, 102	Patented
T64553	DRUGINFO	D09OGH	US8546370, 11	Patented
T64553	DRUGINFO	D0VE2A	US8546370, 17	Patented
T64553	DRUGINFO	D0T4MJ	K00592a	Investigative
T64553	DRUGINFO	D00SEC	aloisine	Investigative

T46465	TARGETID	T46465
T46465	FORMERID	TTDR00106
T46465	UNIPROID	PLM2_PLAFA
T46465	TARGNAME	Plasmodium Plasmepsin 2 (Malaria PLA2)
T46465	GENENAME	Malaria PLA2
T46465	TARGTYPE	Patented-recorded
T46465	SYNONYMS	Plasmepsin-2; PFAPD; Aspartic hemoglobinase II
T46465	FUNCTION	Hydrolysis of the bonds linking certain hydrophobic residues in hemoglobin or globin. Also cleaves small molecules substrates such as Ala-Leu-Glu-Arg-Thr-Phe-|-Phe(NO(2))-Ser-Phe-Pro-Thr.
T46465	PDBSTRUC	5BWY; 4Z22; 4YA8; 4Y6M; 4CKU
T46465	BIOCLASS	Peptidase
T46465	ECNUMBER	EC 3.4.23.39
T46465	SEQUENCE	MDITVREHDFKHGFIKSNSTFDGLNIDNSKNKKKIQKGFQILYVLLFCSVMCGLFYYVYENVWLQRDNEMNEILKNSEHLTIGFKVENAHDRILKTIKTHKLKNYIKESVNFLNSGLTKTNYLGSSNDNIELVDFQNIMFYGDAEVGDNQQPFTFILDTGSANLWVPSVKCTTAGCLTKHLYDSSKSRTYEKDGTKVEMNYVSGTVSGFFSKDLVTVGNLSLPYKFIEVIDTNGFEPTYTASTFDGILGLGWKDLSIGSVDPIVVELKNQNKIENALFTFYLPVHDKHTGFLTIGGIEERFYEGPLTYEKLNHDLYWQITLDAHVGNIMLEKANCIVDSGTSAITVPTDFLNKMLQNLDVIKVPFLPFYVTLCNNSKLPTFEFTSENGKYTLEPEYYLQHIEDVGPGLCMLNIIGLDFPVPTFILGDPFMRKYFTVFDYDNHSVGIALAKKNL
T46465	DRUGINFO	D03OLC	US9353089, 135	Patented
T46465	DRUGINFO	D0H4IY	US9353089, 330	Patented
T46465	DRUGINFO	D0QX1S	US9353089, 327	Patented
T46465	DRUGINFO	D04ZIJ	Pepstatin	Terminated
T46465	DRUGINFO	D00QMZ	PS-662477	Investigative
T46465	DRUGINFO	D00ZMK	KNI-10740	Investigative
T46465	DRUGINFO	D01RIP	KNI-10265	Investigative
T46465	DRUGINFO	D01TFQ	KNI-10124	Investigative
T46465	DRUGINFO	D02BVS	KNI-10761	Investigative
T46465	DRUGINFO	D02CKL	KNI-10113	Investigative
T46465	DRUGINFO	D03BZY	KNI-10313	Investigative
T46465	DRUGINFO	D03TFP	KNI-10758	Investigative
T46465	DRUGINFO	D04QEO	KNI-10332	Investigative
T46465	DRUGINFO	D04QUO	KNI-10282	Investigative
T46465	DRUGINFO	D04RUS	KNI-10074	Investigative
T46465	DRUGINFO	D05DNU	KNI-1293	Investigative
T46465	DRUGINFO	D05GIB	KNI-10033	Investigative
T46465	DRUGINFO	D05HFQ	KNI-10342	Investigative
T46465	DRUGINFO	D05KWN	KNI-10737	Investigative
T46465	DRUGINFO	D05XTX	KNI-10095	Investigative
T46465	DRUGINFO	D06EJX	KNI-10538	Investigative
T46465	DRUGINFO	D06MPP	KNI-10094	Investigative
T46465	DRUGINFO	D06MZB	KNI-10081	Investigative
T46465	DRUGINFO	D06NEW	KNI-10217	Investigative
T46465	DRUGINFO	D06QBK	KNI-10763	Investigative
T46465	DRUGINFO	D07NFJ	PS-444035	Investigative
T46465	DRUGINFO	D08FQX	KNI-10526	Investigative
T46465	DRUGINFO	D08IXO	KNI-10232	Investigative
T46465	DRUGINFO	D08SCG	PS-222036	Investigative
T46465	DRUGINFO	D08XLM	PS-725074	Investigative
T46465	DRUGINFO	D09DNT	KNI-10061	Investigative
T46465	DRUGINFO	D09XFQ	KNI-10125	Investigative
T46465	DRUGINFO	D0A5AT	KNI-10079	Investigative
T46465	DRUGINFO	D0D5GN	KNI-10314	Investigative
T46465	DRUGINFO	D0E6JX	KNI-10088	Investigative
T46465	DRUGINFO	D0E7XR	KNI-10283	Investigative
T46465	DRUGINFO	D0F8OH	KNI-10260	Investigative
T46465	DRUGINFO	D0G0JA	KNI-10255	Investigative
T46465	DRUGINFO	D0G1AF	KNI-10155	Investigative
T46465	DRUGINFO	D0G6SP	KNI-10529	Investigative
T46465	DRUGINFO	D0H1ZT	KNI-10216	Investigative
T46465	DRUGINFO	D0H6LQ	KNI-10266	Investigative
T46465	DRUGINFO	D0H6UX	KNI-10762	Investigative
T46465	DRUGINFO	D0IM5H	KNI-10541	Investigative
T46465	DRUGINFO	D0J4NN	KNI-10742	Investigative
T46465	DRUGINFO	D0JI2X	PS-154636-1	Investigative
T46465	DRUGINFO	D0JV0F	KNI-10106	Investigative
T46465	DRUGINFO	D0K4WS	KNI-10152	Investigative
T46465	DRUGINFO	D0M4JP	KNI-10759	Investigative
T46465	DRUGINFO	D0M9UG	KNI-10368	Investigative
T46465	DRUGINFO	D0N9ON	KNI-10092	Investigative
T46465	DRUGINFO	D0O0EA	KNI-10087	Investigative
T46465	DRUGINFO	D0O1JH	KNI-727	Investigative
T46465	DRUGINFO	D0O2YF	KNI-10315	Investigative
T46465	DRUGINFO	D0O8JQ	KNI-10256	Investigative
T46465	DRUGINFO	D0P1MT	KNI-10743	Investigative
T46465	DRUGINFO	D0PW4M	KNI-10741	Investigative
T46465	DRUGINFO	D0Q9EB	KNI-227	Investigative
T46465	DRUGINFO	D0R0ZC	KNI-10539	Investigative
T46465	DRUGINFO	D0S4BV	N-(R-Carboxy-Ethyl)-Alpha-(S)-(2-Phenylethyl)	Investigative
T46465	DRUGINFO	D0T3KK	KNI-10093	Investigative
T46465	DRUGINFO	D0UX4C	KNI-10316	Investigative
T46465	DRUGINFO	D0V2ER	KNI-10080	Investigative
T46465	DRUGINFO	D0X2CX	KNI-10062	Investigative
T46465	DRUGINFO	D0XU6H	KNI-10372	Investigative
T46465	DRUGINFO	D0Y1VG	KNI-10369	Investigative
T46465	DRUGINFO	D0YL4X	KNI-10341	Investigative
T46465	DRUGINFO	D0Z3GC	KNI-10760	Investigative
T46465	DRUGINFO	D0Z5MR	KNI-10527	Investigative
T46465	DRUGINFO	D0ZU3S	PS-777621	Investigative
T46465	DRUGINFO	D0S3BO	KNI-10006	Investigative
T46465	DRUGINFO	D08KCA	Leupeptin	Investigative
T46465	DRUGINFO	D09FGQ	E-64	Investigative

T77613	TARGETID	T77613
T77613	FORMERID	TTDI02454
T77613	UNIPROID	PDE1B_HUMAN
T77613	TARGNAME	Phosphodiesterase 1B (PDE1B)
T77613	GENENAME	PDE1B
T77613	TARGTYPE	Patented-recorded
T77613	SYNONYMS	PDES1B; PDE1B1; CamPDE 1B; Cam-PDE 1B; Calcium/calmodulindependent 3',5'cyclicnucleotide phosphodiesterase 1B; Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B; 63 kDa CamPDE; 63 kDa Cam-PDE
T77613	FUNCTION	Has a preference for cGMP as a substrate. Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes.
T77613	PDBSTRUC	5W6E; 5UP0; 5UOY; 5B25; 4NPW
T77613	BIOCLASS	Phosphoric diester hydrolase
T77613	ECNUMBER	EC 3.1.4.17
T77613	SEQUENCE	MELSPRSPPEMLEESDCPSPLELKSAPSKKMWIKLRSLLRYMVKQLENGEINIEELKKNLEYTASLLEAVYIDETRQILDTEDELQELRSDAVPSEVRDWLASTFTQQARAKGRRAEEKPKFRSIVHAVQAGIFVERMFRRTYTSVGPTYSTAVLNCLKNLDLWCFDVFSLNQAADDHALRTIVFELLTRHNLISRFKIPTVFLMSFLDALETGYGKYKNPYHNQIHAADVTQTVHCFLLRTGMVHCLSEIELLAIIFAAAIHDYEHTGTTNSFHIQTKSECAIVYNDRSVLENHHISSVFRLMQDDEMNIFINLTKDEFVELRALVIEMVLATDMSCHFQQVKTMKTALQQLERIDKPKALSLLLHAADISHPTKQWLVHSRWTKALMEEFFRQGDKEAELGLPFSPLCDRTSTLVAQSQIGFIDFIVEPTFSVLTDVAEKSVQPLADEDSKSKNQPSFQWRQPSLDVEVGDPNPDVVSFRSTWVKRIQENKQKWKERAASGITNQMSIDELSPCEEEAPPSPAEDEHNQNGNLD
T77613	DRUGINFO	D00LVD	US10034861, Example 165	Patented
T77613	DRUGINFO	D03GTM	US10092575, Example 101	Patented
T77613	DRUGINFO	D06WJK	US10034861, Example 164	Patented
T77613	DRUGINFO	D0A0ZU	AC1MOZOL	Patented
T77613	DRUGINFO	D0E9JC	US9073936, 1	Patented
T77613	DRUGINFO	D0HO1Q	US9073936, 2	Patented
T77613	DRUGINFO	D0J1LK	US10092575, Example 158	Patented
T77613	DRUGINFO	D0NI7A	AC1LDDOQ	Patented
T77613	DRUGINFO	D0V8ZY	US10034861, Example 1	Patented
T77613	DRUGINFO	D0WS3T	US10092575, Example 141	Patented
T77613	DRUGINFO	D0Z1CK	US9073936, 3	Patented
T77613	DRUGINFO	D01BZR	IC-041	Investigative
T77613	DRUGINFO	D02VHD	SCH51866	Investigative

T63220	TARGETID	T63220
T63220	FORMERID	TTDI02471
T63220	UNIPROID	ACK1_HUMAN
T63220	TARGNAME	Activated CDC42 kinase 1 (ACK-1)
T63220	GENENAME	TNK2
T63220	TARGTYPE	Patented-recorded
T63220	SYNONYMS	Tyrosine kinase non-receptor protein 2; ACK1; ACK-1
T63220	FUNCTION	Non-receptor tyrosine-protein and serine/threonine-protein kinase that is implicated in cell spreading and migration, cell survival, cell growth and proliferation. Transduces extracellular signals to cytosolic and nuclear effectors. Phosphorylates AKT1, AR, MCF2, WASL and WWOX. Implicated in trafficking and clathrin-mediated endocytosis through binding to epidermal growth factor receptor (EGFR) and clathrin. Binds to both poly- and mono-ubiquitin and regulates ligand-induced degradation of EGFR, thereby contributing to the accumulation of EGFR at the limiting membrane of early endosomes. Downstream effector of CDC42 which mediates CDC42-dependent cell migration via phosphorylation of BCAR1. May be involved both in adult synaptic function and plasticity and in brain development. Activates AKT1 by phosphorylating it on 'Tyr-176'. Phosphorylates AR on 'Tyr-267' and 'Tyr-363' thereby promoting its recruitment to androgen-responsive enhancers (AREs). Phosphorylates WWOX on 'Tyr-287'. Phosphorylates MCF2, thereby enhancing its activity as a guanine nucleotide exchange factor (GEF) toward Rho family proteins. Contributes to the control of AXL receptor levels. Confers metastatic properties on cancer cells and promotes tumor growth by negatively regulating tumor suppressor such as WWOX and positively regulating pro-survival factors such as AKT1 and AR. Phosphorylates WASP.
T63220	PDBSTRUC	5ZXB; 4ID7; 4HZS; 4HZR; 4EWH
T63220	BIOCLASS	Kinase
T63220	ECNUMBER	EC 2.7.10.2
T63220	SEQUENCE	MQPEEGTGWLLELLSEVQLQQYFLRLRDDLNVTRLSHFEYVKNEDLEKIGMGRPGQRRLWEAVKRRKALCKRKSWMSKVFSGKRLEAEFPPHHSQSTFRKTSPAPGGPAGEGPLQSLTCLIGEKDLRLLEKLGDGSFGVVRRGEWDAPSGKTVSVAVKCLKPDVLSQPEAMDDFIREVNAMHSLDHRNLIRLYGVVLTPPMKMVTELAPLGSLLDRLRKHQGHFLLGTLSRYAVQVAEGMGYLESKRFIHRDLAARNLLLATRDLVKIGDFGLMRALPQNDDHYVMQEHRKVPFAWCAPESLKTRTFSHASDTWMFGVTLWEMFTYGQEPWIGLNGSQILHKIDKEGERLPRPEDCPQDIYNVMVQCWAHKPEDRPTFVALRDFLLEAQPTDMRALQDFEEPDKLHIQMNDVITVIEGRAENYWWRGQNTRTLCVGPFPRNVVTSVAGLSAQDISQPLQNSFIHTGHGDSDPRHCWGFPDRIDELYLGNPMDPPDLLSVELSTSRPPQHLGGVKKPTYDPVSEDQDPLSSDFKRLGLRKPGLPRGLWLAKPSARVPGTKASRGSGAEVTLIDFGEEPVVPALRPCAPSLAQLAMDACSLLDETPPQSPTRALPRPLHPTPVVDWDARPLPPPPAYDDVAQDEDDFEICSINSTLVGAGVPAGPSQGQTNYAFVPEQARPPPPLEDNLFLPPQGGGKPPSSAQTAEIFQALQQECMRQLQAPAGSPAPSPSPGGDDKPQVPPRVPIPPRPTRPHVQLSPAPPGEEETSQWPGPASPPRVPPREPLSPQGSRTPSPLVPPGSSPLPPRLSSSPGKTMPTTQSFASDPKYATPQVIQAPGPRAGPCILPIVRDGKKVSSTHYYLLPERPSYLERYQRFLREAQSPEEPTPLPVPLLLPPPSTPAPAAPTATVRPMPQAALDPKANFSTNNSNPGARPPPPRATARLPQRGCPGDGPEAGRPADKIQMAMVHGVTTEECQAALQCHGWSVQRAAQYLKVEQLFGLGLRPRGECHKVLEMFDWNLEQAGCHLLGSWGPAHHKR
T63220	DRUGINFO	D04SWX	BDBM50379214	Patented
T63220	DRUGINFO	D0PX1D	US8481733, 95	Patented
T63220	DRUGINFO	D0SZ3I	US8481733, 106	Patented
T63220	DRUGINFO	D0T9JA	US8481733, 118	Patented
T63220	DRUGINFO	D0D5KZ	PMID17280833C30	Investigative

T52297	TARGETID	T52297
T52297	FORMERID	TTDR00420
T52297	UNIPROID	NR1H3_HUMAN
T52297	TARGNAME	Oxysterols receptor LXR-alpha (NR1H3)
T52297	GENENAME	NR1H3
T52297	TARGTYPE	Patented-recorded
T52297	SYNONYMS	Nuclear receptor subfamily 1 group H member 3; Nuclear receptor LXRalpha; Nuclear orphan receptor LXR-alpha; Liver X receptor alpha; LXRalpha; LXRA
T52297	FUNCTION	Interaction with retinoic acid receptor (RXR) shifts RXR from its role as a silent DNA-binding partner to an active ligand-binding subunit in mediating retinoid responses through target genes defined by LXRES. LXRES are DR4-type response elements characterized by direct repeats of two similar hexanuclotide half-sites spaced by four nucleotides. Plays an important role in the regulation of cholesterol homeostasis, regulating cholesterol uptake through MYLIP-dependent ubiquitination of LDLR, VLDLR and LRP8. Interplays functionally with RORA for the regulation of genes involved in liver metabolism. Nuclear receptor that exhibits a ligand-dependent transcriptional activation activity.
T52297	PDBSTRUC	5HJS; 5AVL; 5AVI; 3IPU; 3IPS
T52297	BIOCLASS	Nuclear hormone receptor
T52297	SEQUENCE	MSLWLGAPVPDIPPDSAVELWKPGAQDASSQAQGGSSCILREEARMPHSAGGTAGVGLEAAEPTALLTRAEPPSEPTEIRPQKRKKGPAPKMLGNELCSVCGDKASGFHYNVLSCEGCKGFFRRSVIKGAHYICHSGGHCPMDTYMRRKCQECRLRKCRQAGMREECVLSEEQIRLKKLKRQEEEQAHATSLPPRASSPPQILPQLSPEQLGMIEKLVAAQQQCNRRSFSDRLRVTPWPMAPDPHSREARQQRFAHFTELAIVSVQEIVDFAKQLPGFLQLSREDQIALLKTSAIEVMLLETSRRYNPGSESITFLKDFSYNREDFAKAGLQVEFINPIFEFSRAMNELQLNDAEFALLIAISIFSADRPNVQDQLQVERLQHTYVEALHAYVSIHHPHDRLMFPRMLMKLVSLRTLSSVHSEQVFALRLQDKKLPPLLSEIWDVHE
T52297	DRUGINFO	D03UAE	US9073931, E2	Patented
T52297	DRUGINFO	D04XII	BDBM50177019	Patented
T52297	DRUGINFO	D07QIZ	US9006244, E2b	Patented
T52297	DRUGINFO	D07QYV	US9073931, E1	Patented
T52297	DRUGINFO	D0K8GC	US9006244, E1	Patented
T52297	DRUGINFO	D0TG1V	BDBM50177012	Patented
T52297	DRUGINFO	D0U2EG	US9006244, E2a	Patented
T52297	DRUGINFO	D0W1XE	67S	Patented
T52297	DRUGINFO	D0Y7ZA	US9073931, E3	Patented
T52297	DRUGINFO	D07OBG	5-chloro-2-(4-phenylbutyl)isoindoline-1,3-dione	Investigative
T52297	DRUGINFO	D07XLQ	N-{4-[2-(4-Methoxyphenyl)ethyl]phenyl}phthalimide	Investigative
T52297	DRUGINFO	D09VLE	4,12,17-dehydroxyriccardin C	Investigative
T52297	DRUGINFO	D0D8FE	Guttiferone I	Investigative
T52297	DRUGINFO	D0L1CX	N-{4-[2-(3-Hydroxyphenyl)ethyl]phenyl}phthalimide	Investigative
T52297	DRUGINFO	D0U4TN	2-(2-hexylphenyl)isoindoline-1,3-dione	Investigative
T52297	DRUGINFO	D0X2HK	N-{4-[2-(4-Hydroxyphenyl)ethyl]phenyl}phthalimide	Investigative
T52297	DRUGINFO	D0X5DT	2-(2-phenethylphenyl)isoindoline-1,3-dione	Investigative
T52297	DRUGINFO	D00DLU	GSK-9772	Investigative
T52297	DRUGINFO	D00HVP	Riccardin C	Investigative
T52297	DRUGINFO	D01HDD	2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione	Investigative
T52297	DRUGINFO	D03YUL	AZ12260493	Investigative
T52297	DRUGINFO	D06VRA	4,17-dehydroxyriccardin C	Investigative
T52297	DRUGINFO	D08URT	24(S)-hydroxycholesterol	Investigative
T52297	DRUGINFO	D09UND	12,17-dehydroxyriccardin C	Investigative
T52297	DRUGINFO	D0A1WR	SR9238	Investigative
T52297	DRUGINFO	D0C2CY	WAY-254011	Investigative
T52297	DRUGINFO	D0C6QI	acetyl-podocarpic dimer	Investigative
T52297	DRUGINFO	D0HA0U	12-dehydroxyriccardin C	Investigative
T52297	DRUGINFO	D0IZ9O	4-dehydroxyriccardin C	Investigative
T52297	DRUGINFO	D0PL4F	GW-3965	Investigative
T52297	DRUGINFO	D0Q2RP	24(S), 25-epoxycholesterol	Investigative
T52297	DRUGINFO	D0R8LN	N-{4-[2-(3-Methoxyphenyl)ethyl]phenyl}phthalimide	Investigative
T52297	DRUGINFO	D0V4WT	paxilline	Investigative
T52297	DRUGINFO	D0Z3TJ	GSK2033	Investigative
T52297	DRUGINFO	D0Z8LE	17-dehydroxyriccardin C	Investigative
T52297	DRUGINFO	D0Z8RH	2-Benzyl-3-phenyl-7-(trifluoromethyl)-2H-indazole	Investigative
T52297	DRUGINFO	D01RNA	desmosterol	Investigative
T52297	DRUGINFO	D0H2YM	27-hydroxycholesterol	Investigative
T52297	DRUGINFO	D0K4GK	22R-hydroxycholesterol	Investigative
T52297	DRUGINFO	D08QXD	L-783483	Investigative
T52297	DRUGINFO	D0V4RZ	WAY-214950	Investigative

T13616	TARGETID	T13616
T13616	FORMERID	TTDR00485
T13616	UNIPROID	ILK_HUMAN
T13616	TARGNAME	Integrin-linked protein kinase 1 (ILK)
T13616	GENENAME	ILK
T13616	TARGTYPE	Patented-recorded
T13616	SYNONYMS	P59ILK; Integrin-linked protein kinase; Integrin-linked kinase; ILK2; ILK1; ILK-2; ILK-1; Beta-integrin-linked kinase; 59 kDa serine/threonine-protein kinase; 59 kDa serine/threonine protein kinase
T13616	FUNCTION	May act as a mediator of inside-out integrin signaling. Focal adhesion protein part of the complex ILK-PINCH. This complex is considered to be one of the convergence points of integrin- and growth factor-signaling pathway. Could be implicated in mediating cell architecture, adhesion to integrin substrates and anchorage-dependent growth in epithelial cells. Phosphorylates beta-1 and beta-3 integrin subunit on serine and threonine residues, but also AKT1 and GSK3B. Receptor-proximal protein kinase regulating integrin-mediated signal transduction.
T13616	PDBSTRUC	6MIB; 4HI9; 4HI8; 3REP; 3KMW
T13616	BIOCLASS	Kinase
T13616	ECNUMBER	EC 2.7.11.1
T13616	SEQUENCE	MDDIFTQCREGNAVAVRLWLDNTENDLNQGDDHGFSPLHWACREGRSAVVEMLIMRGARINVMNRGDDTPLHLAASHGHRDIVQKLLQYKADINAVNEHGNVPLHYACFWGQDQVAEDLVANGALVSICNKYGEMPVDKAKAPLRELLRERAEKMGQNLNRIPYKDTFWKGTTRTRPRNGTLNKHSGIDFKQLNFLTKLNENHSGELWKGRWQGNDIVVKVLKVRDWSTRKSRDFNEECPRLRIFSHPNVLPVLGACQSPPAPHPTLITHWMPYGSLYNVLHEGTNFVVDQSQAVKFALDMARGMAFLHTLEPLIPRHALNSRSVMIDEDMTARISMADVKFSFQCPGRMYAPAWVAPEALQKKPEDTNRRSADMWSFAVLLWELVTREVPFADLSNMEIGMKVALEGLRPTIPPGISPHVCKLMKICMNEDPAKRPKFDMIVPILEKMQDK
T13616	DRUGINFO	D09CNM	US8754233, 4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(2-fluoro-phenyl)-2H-pyrazol-3-ylamine	Patented
T13616	DRUGINFO	D0FL7J	US8754233, (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine	Patented
T13616	DRUGINFO	D0Q7KI	US8754233, 2-(3-Amino-1H-pyrazol-4-yl)-5-fluoro-benzothiazole-6-sulfonic acid amide	Patented
T13616	DRUGINFO	D01CTM	PMID21823616C22	Investigative
T13616	DRUGINFO	D09VFU	MST-400	Investigative

T83904	TARGETID	T83904
T83904	FORMERID	TTDNC00633
T83904	UNIPROID	SIR2_HUMAN
T83904	TARGNAME	NAD-dependent deacetylase sirtuin-2 (SIRT2)
T83904	GENENAME	SIRT2
T83904	TARGTYPE	Patented-recorded
T83904	SYNONYMS	SIR2like protein 2; SIR2L2; SIR2L; SIR2-like protein 2; Regulatory protein SIR2 homolog 2; NADdependent protein deacetylase sirtuin2; NAD-dependent protein deacetylase sirtuin-2
T83904	FUNCTION	Participates in the modulation of multiple and diverse biological processes such as cell cycle control, genomic integrity, microtubule dynamics, cell differentiation, metabolic networks, and autophagy. Plays a major role in the control of cell cycle progression and genomic stability. Functions in the antephase checkpoint preventing precocious mitotic entry in response to microtubule stress agents, and hence allowing proper inheritance of chromosomes. Positively regulates the anaphase promoting complex/cyclosome (APC/C) ubiquitin ligase complex activity by deacetylating CDC20 and FZR1, then allowing progression through mitosis. Associates both with chromatin at transcriptional start sites (TSSs) and enhancers of active genes. Plays a role in cell cycle and chromatin compaction through epigenetic modulation of the regulation of histone H4 'Lys-20' methylation (H4K20me1) during early mitosis. Specifically deacetylates histone H4 at 'Lys-16' (H4K16ac) between the G2/M transition and metaphase enabling H4K20me1 deposition by KMT5A leading to ulterior levels of H4K20me2 and H4K20me3 deposition throughout cell cycle, and mitotic S-phase progression. Deacetylates KMT5A modulating KMT5A chromatin localization during the mitotic stress response. Deacetylates also histone H3 at 'Lys-57' (H3K56ac) during the mitotic G2/M transition. Upon bacterium Listeria monocytogenes infection, deacetylates 'Lys-18' of histone H3 in a receptor tyrosine kinase MET- and PI3K/Akt-dependent manner, thereby inhibiting transcriptional activity and promoting late stages of listeria infection. During oocyte meiosis progression, may deacetylate histone H4 at 'Lys-16' (H4K16ac) and alpha-tubulin, regulating spindle assembly and chromosome alignment by influencing microtubule dynamics and kinetochore function. Deacetylates histone H4 at 'Lys-16' (H4K16ac) at the VEGFA promoter and thereby contributes to regulate expression of VEGFA, a key regulator of angiogenesis. Deacetylates alpha-tubulin at 'Lys-40' and hence controls neuronal motility, oligodendroglial cell arbor projection processes and proliferation of non-neuronal cells. Phosphorylation at Ser-368 by a G1/S-specific cyclin E-CDK2 complex inactivates SIRT2-mediated alpha-tubulin deacetylation, negatively regulating cell adhesion, cell migration and neurite outgrowth during neuronal differentiation. Deacetylates PARD3 and participates in the regulation of Schwann cell peripheral myelination formation during early postnatal development and during postinjury remyelination. Involved in several cellular metabolic pathways. Plays a role in the regulation of blood glucose homeostasis by deacetylating and stabilizing phosphoenolpyruvate carboxykinase PCK1 activity in response to low nutrient availability. Acts as a key regulator in the pentose phosphate pathway (PPP) by deacetylating and activating the glucose-6-phosphate G6PD enzyme, and therefore, stimulates the production of cytosolic NADPH to counteract oxidative damage. Maintains energy homeostasis in response to nutrient deprivation as well as energy expenditure by inhibiting adipogenesis and promoting lipolysis. Attenuates adipocyte differentiation by deacetylating and promoting FOXO1 interaction to PPARG and subsequent repression of PPARG-dependent transcriptional activity. Plays a role in the regulation of lysosome-mediated degradation of protein aggregates by autophagy in neuronal cells. Deacetylates FOXO1 in response to oxidative stress or serum deprivation, thereby negatively regulating FOXO1-mediated autophagy. Deacetylates a broad range of transcription factors and co-regulators regulating target gene expression. Deacetylates transcriptional factor FOXO3 stimulating the ubiquitin ligase SCF(SKP2)-mediated FOXO3 ubiquitination and degradation. Deacetylates HIF1A and therefore promotes HIF1A degradation and inhibition of HIF1A transcriptional activity in tumor cells in response to hypoxia. Deacetylates RELA in the cytoplasm inhibiting NF-kappaB-dependent transcription activation upon TNF-alpha stimulation. Inhibits transcriptional activation by deacetylating p53/TP53 and EP300. Deacetylates also EIF5A. Functions as a negative regulator on oxidative stress-tolerance in response to anoxia-reoxygenation conditions. Plays a role as tumor suppressor. NAD-dependent protein deacetylase, which deacetylates internal lysines on histone and alpha-tubulin as well as many other proteins such as key transcription factors.
T83904	PDBSTRUC	5YQO; 5YQN; 5YQM; 5YQL; 5Y5N
T83904	BIOCLASS	Carbon-nitrogen hydrolase
T83904	ECNUMBER	EC 3.5.1.-
T83904	SEQUENCE	MAEPDPSHPLETQAGKVQEAQDSDSDSEGGAAGGEADMDFLRNLFSQTLSLGSQKERLLDELTLEGVARYMQSERCRRVICLVGAGISTSAGIPDFRSPSTGLYDNLEKYHLPYPEAIFEISYFKKHPEPFFALAKELYPGQFKPTICHYFMRLLKDKGLLLRCYTQNIDTLERIAGLEQEDLVEAHGTFYTSHCVSASCRHEYPLSWMKEKIFSEVTPKCEDCQSLVKPDIVFFGESLPARFFSCMQSDFLKVDLLLVMGTSLQVQPFASLISKAPLSTPRLLINKEKAGQSDPFLGMIMGLGGGMDFDSKKAYRDVAWLGECDQGCLALAELLGWKKELEDLVRREHASIDAQSGAGVPNPSTSASPKKSPPPAKDEARTTEREKPQ
T83904	DRUGINFO	D00RNS	BDBM50363780	Patented
T83904	DRUGINFO	D07NKC	BDBM50363782	Patented
T83904	DRUGINFO	D07YHN	AC1LFGWU	Patented
T83904	DRUGINFO	D0F6NT	ZINC915379	Patented
T83904	DRUGINFO	D0MW0K	US9359293, TM	Patented
T83904	DRUGINFO	D0PL1I	US9359293, TA	Patented
T83904	DRUGINFO	D0V2UZ	BDBM50363773	Patented
T83904	DRUGINFO	D0X9SE	US9359293, TB	Patented
T83904	DRUGINFO	D0Y1WA	AC1LOJYQ	Patented
T83904	DRUGINFO	D0E3NT	AGK2	Investigative
T83904	DRUGINFO	D0IR8J	INDUS-815C	Investigative

T32880	TARGETID	T32880
T32880	FORMERID	TTDI02433
T32880	UNIPROID	EGLN1_HUMAN
T32880	TARGNAME	HIF-prolyl hydroxylase 2 (HPH-2)
T32880	GENENAME	EGLN1
T32880	TARGTYPE	Patented-recorded
T32880	SYNONYMS	SM-20; Prolyl hydroxylase domain-containing protein 2; PHD2; Hypoxia-inducible factor prolyl hydroxylase 2; HPH-2; HIF-PH2; Egl nine homolog 1; C1orf12
T32880	FUNCTION	Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. Hydroxylates a specific proline found in each of the oxygen-dependent degradation (ODD) domains (N-terminal, NODD, and C-terminal, CODD) of HIF1A. Also hydroxylates HIF2A. Has a preference for the CODD site for both HIF1A and HIF1B. Hydroxylated HIFs are then targeted for proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Under hypoxic conditions, the hydroxylation reaction is attenuated allowing HIFs to escape degradation resulting in their translocation to the nucleus, heterodimerization with HIF1B, and increased expression of hypoxy-inducible genes. EGLN1 is the most important isozyme under normoxia and, through regulating the stability of HIF1, involved in various hypoxia-influenced processes such as angiogenesis in retinal and cardiac functionality. Target proteins are preferentially recognized via a LXXLAP motif.
T32880	PDBSTRUC	6NMQ; 5V18; 5OX6; 5OX5; 5LBF
T32880	BIOCLASS	Paired donor oxygen oxidoreductase
T32880	ECNUMBER	EC 1.14.11.29
T32880	SEQUENCE	MANDSGGPGGPSPSERDRQYCELCGKMENLLRCSRCRSSFYCCKEHQRQDWKKHKLVCQGSEGALGHGVGPHQHSGPAPPAAVPPPRAGAREPRKAAARRDNASGDAAKGKVKAKPPADPAAAASPCRAAAGGQGSAVAAEAEPGKEEPPARSSLFQEKANLYPPSNTPGDALSPGGGLRPNGQTKPLPALKLALEYIVPCMNKHGICVVDDFLGKETGQQIGDEVRALHDTGKFTDGQLVSQKSDSSKDIRGDKITWIEGKEPGCETIGLLMSSMDDLIRHCNGKLGSYKINGRTKAMVACYPGNGTGYVRHVDNPNGDGRCVTCIYYLNKDWDAKVSGGILRIFPEGKAQFADIEPKFDRLLFFWSDRRNPHEVQPAYATRYAITVWYFDADERARAKVKYLTGEKGVRVELNKPSDSVGKDVF
T32880	DRUGINFO	D03YKE	FG-4592	Phase 3
T32880	DRUGINFO	D00CAO	US9422240, 1-298	Patented
T32880	DRUGINFO	D00ECX	US8598210, Table XV, 2	Patented
T32880	DRUGINFO	D00IKR	US8536181, A41	Patented
T32880	DRUGINFO	D00XHH	US8598210, Table XV, 5	Patented
T32880	DRUGINFO	D01PPR	US8536181, C17	Patented
T32880	DRUGINFO	D01XZT	US8598210, Table XV, 4	Patented
T32880	DRUGINFO	D02IRO	US8921389, 210	Patented
T32880	DRUGINFO	D03PGC	US8536181, C35	Patented
T32880	DRUGINFO	D04BTN	US10100051, Compound 2	Patented
T32880	DRUGINFO	D04YMG	US8921389, 2	Patented
T32880	DRUGINFO	D05EHX	US9422240, 1-282	Patented
T32880	DRUGINFO	D05FDR	US10100051, Compound 1	Patented
T32880	DRUGINFO	D05TTX	US10100051, Compound 10	Patented
T32880	DRUGINFO	D0D8AV	US9340511, 2	Patented
T32880	DRUGINFO	D0F0DX	US10149841, Compound 19	Patented
T32880	DRUGINFO	D0HN5O	US8536181, C14	Patented
T32880	DRUGINFO	D0I4PX	US8921389, 22	Patented
T32880	DRUGINFO	D0JR2Q	US10149841, Compound 1	Patented
T32880	DRUGINFO	D0K5UR	US9422240, 1-297	Patented
T32880	DRUGINFO	D0L9XU	US9422240, 1-286	Patented
T32880	DRUGINFO	D0LO2C	US9340511, 5	Patented
T32880	DRUGINFO	D0MS5W	US9340511, 6	Patented
T32880	DRUGINFO	D0OR4X	US10149841, Compound 5	Patented
T32880	DRUGINFO	D0Q9AF	US8598210, Table XV, 1	Patented
T32880	DRUGINFO	D0QI0J	US10149841, Compound 9	Patented
T32880	DRUGINFO	D0R4CX	US9409892, 59	Patented
T32880	DRUGINFO	D0SM8Z	US9409892, 148	Patented
T32880	DRUGINFO	D0V6AZ	US9340511, 7	Patented
T32880	DRUGINFO	D0V9WU	US9409892, 19	Patented
T32880	DRUGINFO	D0VI2M	US10100051, Compound 11	Patented
T32880	DRUGINFO	D0VK5C	US9409892, 136	Patented
T32880	DRUGINFO	D0Y3NI	US8921389, 123	Patented
T32880	DRUGINFO	D0YY5J	US8921389, 1	Patented
T32880	DRUGINFO	D09SXR	KRH-102053	Investigative
T32880	DRUGINFO	D0WA3E	IOX2	Investigative
T32880	DRUGINFO	D0X5US	IOX1	Investigative

T59654	TARGETID	T59654
T59654	FORMERID	TTDI02482
T59654	UNIPROID	PLK2_HUMAN
T59654	TARGNAME	Polo-like kinase 2 (PLK2)
T59654	GENENAME	PLK2
T59654	TARGTYPE	Patented-recorded
T59654	SYNONYMS	hSNK; hPlk2; Serum-inducible kinase; Serine/threonine-protein kinase SNK; Serine/threonine-protein kinase PLK2; SNK; PLK-2
T59654	FUNCTION	Polo-like kinases act by binding and phosphorylating proteins are that already phosphorylated on a specific motif recognized by the POLO box domains. Phosphorylates CENPJ, NPM1, RAPGEF2, RASGRF1, SNCA, SIPA1L1 and SYNGAP1. Plays a key role in synaptic plasticity and memory by regulating the Ras and Rap protein signaling: required for overactivity-dependent spine remodeling by phosphorylating the Ras activator RASGRF1 and the Rap inhibitor SIPA1L1 leading to their degradation by the proteasome. Conversely, phosphorylates the Rap activator RAPGEF2 and the Ras inhibitor SYNGAP1, promoting their activity. Also regulates synaptic plasticity independently of kinase activity, via its interaction with NSF that disrupts the interaction between NSF and the GRIA2 subunit of AMPARs, leading to a rapid rundown of AMPAR-mediated current that occludes long term depression. Required for procentriole formation and centriole duplication by phosphorylating CENPJ and NPM1, respectively. Its induction by p53/TP53 suggests that it may participate in the mitotic checkpoint following stress. Tumor suppressor serine/threonine-protein kinase involved in synaptic plasticity, centriole duplication and G1/S phase transition.
T59654	PDBSTRUC	4XB0; 4RS6; 4I6H; 4I6F; 4I6B
T59654	BIOCLASS	Kinase
T59654	ECNUMBER	EC 2.7.11.21
T59654	SEQUENCE	MELLRTITYQPAASTKMCEQALGKGCGADSKKKRPPQPPEESQPPQSQAQVPPAAPHHHHHHSHSGPEISRIIVDPTTGKRYCRGKVLGKGGFAKCYEMTDLTNNKVYAAKIIPHSRVAKPHQREKIDKEIELHRILHHKHVVQFYHYFEDKENIYILLEYCSRRSMAHILKARKVLTEPEVRYYLRQIVSGLKYLHEQEILHRDLKLGNFFINEAMELKVGDFGLAARLEPLEHRRRTICGTPNYLSPEVLNKQGHGCESDIWALGCVMYTMLLGRPPFETTNLKETYRCIREARYTMPSSLLAPAKHLIASMLSKNPEDRPSLDDIIRHDFFLQGFTPDRLSSSCCHTVPDFHLSSPAKNFFKKAAAALFGGKKDKARYIDTHNRVSKEDEDIYKLRHDLKKTSITQQPSKHRTDEELQPPTTTVARSGTPAVENKQQIGDAIRMIVRGTLGSCSSSSECLEDSTMGSVADTVARVLRGCLENMPEADCIPKEQLSTSFQWVTKWVDYSNKYGFGYQLSDHTVGVLFNNGAHMSLLPDKKTVHYYAELGQCSVFPATDAPEQFISQVTVLKYFSHYMEENLMDGGDLPSVTDIRRPRLYLLQWLKSDKALMMLFNDGTFQVNFYHDHTKIIICSQNEEYLLTYINEDRISTTFRLTTLLMSGCSSELKNRMEYALNMLLQRCN
T59654	DRUGINFO	D0IQ6R	US8598172, 1	Patented
T59654	DRUGINFO	D02IZN	ON-123	Investigative

T09672	TARGETID	T09672
T09672	FORMERID	TTDR01407
T09672	UNIPROID	PTN13_HUMAN
T09672	TARGNAME	FAP-1 messenger RNA (PTPN13 mRNA)
T09672	GENENAME	PTPN13
T09672	TARGTYPE	Patented-recorded
T09672	SYNONYMS	hPTPE1 (mRNA); Tyrosine-protein phosphatase non-receptor type 13 (mRNA); Protein-tyrosine phosphatase PTPL1 (mRNA); Protein-tyrosine phosphatase 1E (mRNA); PTPL1 (mRNA); PTP1E (mRNA); PTP-E1 (mRNA); PTP-BAS (mRNA); PNP1 (mRNA); Fas-associated protein-tyrosine phosphatase 1 (mRNA); FAP-1 (mRNA)
T09672	FUNCTION	May regulate phosphoinositide 3-kinase (PI3K) signaling through dephosphorylation of PIK3R2. Tyrosine phosphatase which regulates negatively FAS-induced apoptosis and NGFR-mediated pro-apoptotic signaling.
T09672	PDBSTRUC	5GLJ; 3PDZ; 3LNY; 3LNX; 2M10
T09672	BIOCLASS	mRNA target
T09672	ECNUMBER	EC 3.1.3.48
T09672	SEQUENCE	MHVSLAEALEVRGGPLQEEEIWAVLNQSAESLQELFRKVSLADPAALGFIISPWSLLLLPSGSVSFTDENISNQDLRAFTAPEVLQNQSLTSLSDVEKIHIYSLGMTLYWGADYEVPQSQPIKLGDHLNSILLGMCEDVIYARVSVRTVLDACSAHIRNSNCAPSFSYVKHLVKLVLGNLSGTDQLSCNSEQKPDRSQAIRDRLRGKGLPTGRSSTSDVLDIQKPPLSHQTFLNKGLSKSMGFLSIKDTQDENYFKDILSDNSGREDSENTFSPYQFKTSGPEKKPIPGIDVLSKKKIWASSMDLLCTADRDFSSGETATYRRCHPEAVTVRTSTTPRKKEARYSDGSIALDIFGPQKMDPIYHTRELPTSSAISSALDRIRERQKKLQVLREAMNVEEPVRRYKTYHGDVFSTSSESPSIISSESDFRQVRRSEASKRFESSSGLPGVDETLSQGQSQRPSRQYETPFEGNLINQEIMLKRQEEELMQLQAKMALRQSRLSLYPGDTIKASMLDITRDPLREIALETAMTQRKLRNFFGPEFVKMTIEPFISLDLPRSILTKKGKNEDNRRKVNIMLLNGQRLELTCDTKTICKDVFDMVVAHIGLVEHHLFALATLKDNEYFFVDPDLKLTKVAPEGWKEEPKKKTKATVNFTLFFRIKFFMDDVSLIQHTLTCHQYYLQLRKDILEERMHCDDETSLLLASLALQAEYGDYQPEVHGVSYFRMEHYLPARVMEKLDLSYIKEELPKLHNTYVGASEKETELEFLKVCQRLTEYGVHFHRVHPEKKSQTGILLGVCSKGVLVFEVHNGVRTLVLRFPWRETKKISFSKKKITLQNTSDGIKHGFQTDNSKICQYLLHLCSYQHKFQLQMRARQSNQDAQDIERASFRSLNLQAESVRGFNMGRAISTGSLASSTLNKLAVRPLSVQAEILKRLSCSELSLYQPLQNSSKEKNDKASWEEKPREMSKSYHDLSQASLYPHRKNVIVNMEPPPQTVAELVGKPSHQMSRSDAESLAGVTKLNNSKSVASLNRSPERRKHESDSSSIEDPGQAYVLGMTMHSSGNSSSQVPLKENDVLHKRWSIVSSPEREITLVNLKKDAKYGLGFQIIGGEKMGRLDLGIFISSVAPGGPADLDGCLKPGDRLISVNSVSLEGVSHHAAIEILQNAPEDVTLVISQPKEKISKVPSTPVHLTNEMKNYMKKSSYMQDSAIDSSSKDHHWSRGTLRHISENSFGPSGGLREGSLSSQDSRTESASLSQSQVNGFFASHLGDQTWQESQHGSPSPSVISKATEKETFTDSNQSKTKKPGISDVTDYSDRGDSDMDEATYSSSQDHQTPKQESSSSVNTSNKMNFKTFSSSPPKPGDIFEVELAKNDNSLGISVTGGVNTSVRHGGIYVKAVIPQGAAESDGRIHKGDRVLAVNGVSLEGATHKQAVETLRNTGQVVHLLLEKGQSPTSKEHVPVTPQCTLSDQNAQGQGPEKVKKTTQVKDYSFVTEENTFEVKLFKNSSGLGFSFSREDNLIPEQINASIVRVKKLFPGQPAAESGKIDVGDVILKVNGASLKGLSQQEVISALRGTAPEVFLLLCRPPPGVLPEIDTALLTPLQSPAQVLPNSSKDSSQPSCVEQSTSSDENEMSDKSKKQCKSPSRRDSYSDSSGSGEDDLVTAPANISNSTWSSALHQTLSNMVSQAQSHHEAPKSQEDTICTMFYYPQKIPNKPEFEDSNPSPLPPDMAPGQSYQPQSESASSSSMDKYHIHHISEPTRQENWTPLKNDLENHLEDFELEVELLITLIKSEKGSLGFTVTKGNQRIGCYVHDVIQDPAKSDGRLKPGDRLIKVNDTDVTNMTHTDAVNLLRAASKTVRLVIGRVLELPRIPMLPHLLPDITLTCNKEELGFSLCGGHDSLYQVVYISDINPRSVAAIEGNLQLLDVIHYVNGVSTQGMTLEEVNRALDMSLPSLVLKATRNDLPVVPSSKRSAVSAPKSTKGNGSYSVGSCSQPALTPNDSFSTVAGEEINEISYPKGKCSTYQIKGSPNLTLPKESYIQEDDIYDDSQEAEVIQSLLDVVDEEAQNLLNENNAAGYSCGPGTLKMNGKLSEERTEDTDCDGSPLPEYFTEATKMNGCEEYCEEKVKSESLIQKPQEKKTDDDEITWGNDELPIERTNHEDSDKDHSFLTNDELAVLPVVKVLPSGKYTGANLKSVIRVLRGLLDQGIPSKELENLQELKPLDQCLIGQTKENRRKNRYKNILPYDATRVPLGDEGGYINASFIKIPVGKEEFVYIACQGPLPTTVGDFWQMIWEQKSTVIAMMTQEVEGEKIKCQRYWPNILGKTTMVSNRLRLALVRMQQLKGFVVRAMTLEDIQTREVRHISHLNFTAWPDHDTPSQPDDLLTFISYMRHIHRSGPIITHCSAGIGRSGTLICIDVVLGLISQDLDFDISDLVRCMRLQRHGMVQTEDQYIFCYQVILYVLTRLQAEEEQKQQPQLLK
T09672	DRUGINFO	D0CW5D	US9217012, 10	Patented
T09672	DRUGINFO	D09VLX	ISIS 18473	Investigative

T20953	TARGETID	T20953
T20953	FORMERID	TTDI03066
T20953	UNIPROID	BUB1_HUMAN
T20953	TARGNAME	BUB1 mitotic checkpoint serine/threonine kinase (BUB1)
T20953	GENENAME	BUB1
T20953	TARGTYPE	Patented-recorded
T20953	SYNONYMS	hBUB1; Mitotic checkpoint serine/threonine-protein kinase BUB1; BUB1L; BUB1A
T20953	FUNCTION	Has a key role in the assembly of checkpoint proteins at the kinetochore, being required for the subsequent localization of CENPF, BUB1B, CENPE and MAD2L1. Required for the kinetochore localization of PLK1. Required for centromeric enrichment of AUKRB in prometaphase. Plays an important role in defining SGO1 localization and thereby affects sister chromatid cohesion. Acts as a substrate for anaphase-promoting complex or cyclosome (APC/C) in complex with its activator CDH1 (APC/C-Cdh1). Necessary for ensuring proper chromosome segregation and binding to BUB3 is essential for this function. Can regulate chromosome segregation in a kinetochore-independent manner. Can phosphorylate BUB3. The BUB1-BUB3 complex plays a role in the inhibition of APC/C when spindle-assembly checkpoint is activated and inhibits the ubiquitin ligase activity of APC/C by phosphorylating its activator CDC20. This complex can also phosphorylate MAD1L1. Kinase activity is essential for inhibition of APC/CCDC20 and for chromosome alignment but does not play a major role in the spindle-assembly checkpoint activity. Mediates cell death in response to chromosome missegregation and acts to suppress spontaneous tumorigenesis. Serine/threonine-protein kinase that performs 2 crucial functions during mitosis: it is essential for spindle-assembly checkpoint signaling and for correct chromosome alignment.
T20953	PDBSTRUC	6F7B; 5DMZ; 4R8Q; 4QPM; 4A1G
T20953	BIOCLASS	Kinase
T20953	ECNUMBER	EC 2.7.11.1
T20953	SEQUENCE	MDTPENVLQMLEAHMQSYKGNDPLGEWERYIQWVEENFPENKEYLITLLEHLMKEFLDKKKYHNDPRFISYCLKFAEYNSDLHQFFEFLYNHGIGTLSSPLYIAWAGHLEAQGELQHASAVLQRGIQNQAEPREFLQQQYRLFQTRLTETHLPAQARTSEPLHNVQVLNQMITSKSNPGNNMACISKNQGSELSGVISSACDKESNMERRVITISKSEYSVHSSLASKVDVEQVVMYCKEKLIRGESEFSFEELRAQKYNQRRKHEQWVNEDRHYMKRKEANAFEEQLLKQKMDELHKKLHQVVETSHEDLPASQERSEVNPARMGPSVGSQQELRAPCLPVTYQQTPVNMEKNPREAPPVVPPLANAISAALVSPATSQSIAPPVPLKAQTVTDSMFAVASKDAGCVNKSTHEFKPQSGAEIKEGCETHKVANTSSFHTTPNTSLGMVQATPSKVQPSPTVHTKEALGFIMNMFQAPTLPDISDDKDEWQSLDQNEDAFEAQFQKNVRSSGAWGVNKIISSLSSAFHVFEDGNKENYGLPQPKNKPTGARTFGERSVSRLPSKPKEEVPHAEEFLDDSTVWGIRCNKTLAPSPKSPGDFTSAAQLASTPFHKLPVESVHILEDKENVVAKQCTQATLDSCEENMVVPSRDGKFSPIQEKSPKQALSSHMYSASLLRLSQPAAGGVLTCEAELGVEACRLTDTDAAIAEDPPDAIAGLQAEWMQMSSLGTVDAPNFIVGNPWDDKLIFKLLSGLSKPVSSYPNTFEWQCKLPAIKPKTEFQLGSKLVYVHHLLGEGAFAQVYEATQGDLNDAKNKQKFVLKVQKPANPWEFYIGTQLMERLKPSMQHMFMKFYSAHLFQNGSVLVGELYSYGTLLNAINLYKNTPEKVMPQGLVISFAMRMLYMIEQVHDCEIIHGDIKPDNFILGNGFLEQDDEDDLSAGLALIDLGQSIDMKLFPKGTIFTAKCETSGFQCVEMLSNKPWNYQIDYFGVAATVYCMLFGTYMKVKNEGGECKPEGLFRRLPHLDMWNEFFHVMLNIPDCHHLPSLDLLRQKLKKVFQQHYTNKIRALRNRLIVLLLECKRSRK
T20953	DRUGINFO	D01EUT	SCHEMBL16322760	Patented
T20953	DRUGINFO	D03RBY	SCHEMBL17766424	Patented
T20953	DRUGINFO	D0I3PZ	SCHEMBL16365841	Patented
T20953	DRUGINFO	D09BXA	PMID24900824C2-1-1	Investigative
T20953	DRUGINFO	D0F9DD	PMID24900824C2-13-1	Investigative
T20953	DRUGINFO	D0JP7S	PMID24900824C2-3-1	Investigative
T20953	DRUGINFO	D0P4YY	PMID24900824C2-3-2	Investigative

T05904	TARGETID	T05904
T05904	FORMERID	TTDR01310
T05904	UNIPROID	PDE8A_HUMAN
T05904	TARGNAME	Phosphodiesterase 8 (PDE8)
T05904	GENENAME	PDE8A
T05904	TARGTYPE	Patented-recorded
T05904	SYNONYMS	High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A
T05904	FUNCTION	May be involved in maintaining basal levels of the cyclic nucleotide and/or in the cAMP regulation of germ cell development. Binding to RAF1 reduces RAF1 'Ser-259' inhibitory-phosphorylation and stimulates RAF1-dependent EGF-activated ERK-signaling. Protects against cell death induced by hydrogen peroxide and staurosporine. Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
T05904	PDBSTRUC	3ECN; 3ECM; 1LXX; 1LHQ
T05904	BIOCLASS	Phosphoric diester hydrolase
T05904	ECNUMBER	EC 3.1.4.53
T05904	SEQUENCE	MGCAPSIHISERLVAEDAPSPAAPPLSSGGPRLPQGQKTAALPRTRGAGLLESELRDGSGKKVAVADVQFGPMRFHQDQLQVLLVFTKEDNQCNGFCRACEKAGFKCTVTKEAQAVLACFLDKHHDIIIIDHRNPRQLDAEALCRSIRSSKLSENTVIVGVVRRVDREELSVMPFISAGFTRRYVENPNIMACYNELLQLEFGEVRSQLKLRACNSVFTALENSEDAIEITSEDRFIQYANPAFETTMGYQSGELIGKELGEVPINEKKADLLDTINSCIRIGKEWQGIYYAKKKNGDNIQQNVKIIPVIGQGGKIRHYVSIIRVCNGNNKAEKISECVQSDTHTDNQTGKHKDRRKGSLDVKAVASRATEVSSQRRHSSMARIHSMTIEAPITKVINIINAAQESSPMPVTEALDRVLEILRTTELYSPQFGAKDDDPHANDLVGGLMSDGLRRLSGNEYVLSTKNTQMVSSNIITPISLDDVPPRIARAMENEEYWDFDIFELEAATHNRPLIYLGLKMFARFGICEFLHCSESTLRSWLQIIEANYHSSNPYHNSTHSADVLHATAYFLSKERIKETLDPIDEVAALIAATIHDVDHPGRTNSFLCNAGSELAILYNDTAVLESHHAALAFQLTTGDDKCNIFKNMERNDYRTLRQGIIDMVLATEMTKHFEHVNKFVNSINKPLATLEENGETDKNQEVINTMLRTPENRTLIKRMLIKCADVSNPCRPLQYCIEWAARISEEYFSQTDEEKQQGLPVVMPVFDRNTCSIPKSQISFIDYFITDMFDAWDAFVDLPDLMQHLDNNFKYWKGLDEMKLRNLRPPPE
T05904	DRUGINFO	D05SRL	US8846654, 294	Patented
T05904	DRUGINFO	D0A5JS	US8846654, 251	Patented
T05904	DRUGINFO	D0EF6R	US8846654, 11	Patented
T05904	DRUGINFO	D0EN2M	US9493447, 1001	Patented
T05904	DRUGINFO	D0SH7F	BC11-28	Patented
T05904	DRUGINFO	D0Z7YQ	AC1M1SP5	Patented
T05904	DRUGINFO	D04TZA	PF-04957325	Investigative
T05904	DRUGINFO	D0TE9G	PF-4957325-00	Investigative

T50224	TARGETID	T50224
T50224	FORMERID	TTDI03521
T50224	UNIPROID	KS6A5_HUMAN
T50224	TARGNAME	Ribosomal protein S6 kinase alpha-5 (RSK5)
T50224	GENENAME	RPS6KA5
T50224	TARGTYPE	Patented-recorded
T50224	SYNONYMS	S6K-alpha-5; RSKL; RSK-like protein kinase; Nuclear mitogen- and stress-activated protein kinase 1; MSK1; 90 kDa ribosomal protein S6 kinase 5
T50224	FUNCTION	Phosphorylates CREB1 and ATF1 in response to mitogenic or stress stimuli such as UV-C irradiation, epidermal growth factor (EGF) and anisomycin. Plays an essential role in the control of RELA transcriptional activity in response to TNF and upon glucocorticoid, associates in the cytoplasm with the glucocorticoid receptor NR3C1 and contributes to RELA inhibition and repression of inflammatory gene expression. In skeletal myoblasts is required for phosphorylation of RELA at 'Ser-276' during oxidative stress. In erythropoietin-stimulated cells, is necessary for the 'Ser-727' phosphorylation of STAT3 and regulation of its transcriptional potential. Phosphorylates ETV1/ER81 at 'Ser-191' and 'Ser-216', and thereby regulates its ability to stimulate transcription, which may be important during development and breast tumor formation. Directly represses transcription via phosphorylation of 'Ser-1' of histone H2A. Phosphorylates 'Ser-10' of histone H3 in response to mitogenics, stress stimuli and EGF, which results in the transcriptional activation of several immediate early genes, including proto-oncogenes c-fos/FOS and c-jun/JUN. May also phosphorylate 'Ser-28' of histone H3. Mediates the mitogen- and stress-induced phosphorylation of high mobility group protein 1 (HMGN1/HMG14). In lipopolysaccharide-stimulated primary macrophages, acts downstream of the Toll-like receptor TLR4 to limit the production of pro-inflammatory cytokines. Functions probably by inducing transcription of the MAP kinase phosphatase DUSP1 and the anti-inflammatory cytokine interleukin 10 (IL10), via CREB1 and ATF1 transcription factors. Plays a role in neuronal cell death by mediating the downstream effects of excitotoxic injury. Phosphorylates TRIM7 at 'Ser-107' in response to growth factor signaling via the MEK/ERK pathway, thereby stimulating its ubiquitin ligase activity. Serine/threonine-protein kinase that is required for the mitogen or stress-induced phosphorylation of the transcription factors CREB1 and ATF1 and for the regulation of the transcription factors RELA, STAT3 and ETV1/ER81, and that contributes to gene activation by histone phosphorylation and functions in the regulation of inflammatory genes.
T50224	PDBSTRUC	3KN6; 3KN5; 1VZO
T50224	BIOCLASS	Kinase
T50224	ECNUMBER	EC 2.7.11.1
T50224	SEQUENCE	MEEEGGSSGGAAGTSADGGDGGEQLLTVKHELRTANLTGHAEKVGIENFELLKVLGTGAYGKVFLVRKISGHDTGKLYAMKVLKKATIVQKAKTTEHTRTERQVLEHIRQSPFLVTLHYAFQTETKLHLILDYINGGELFTHLSQRERFTEHEVQIYVGEIVLALEHLHKLGIIYRDIKLENILLDSNGHVVLTDFGLSKEFVADETERAYSFCGTIEYMAPDIVRGGDSGHDKAVDWWSLGVLMYELLTGASPFTVDGEKNSQAEISRRILKSEPPYPQEMSALAKDLIQRLLMKDPKKRLGCGPRDADEIKEHLFFQKINWDDLAAKKVPAPFKPVIRDELDVSNFAEEFTEMDPTYSPAALPQSSEKLFQGYSFVAPSILFKRNAAVIDPLQFHMGVERPGVTNVARSAMMKDSPFYQHYDLDLKDKPLGEGSFSICRKCVHKKSNQAFAVKIISKRMEANTQKEITALKLCEGHPNIVKLHEVFHDQLHTFLVMELLNGGELFERIKKKKHFSETEASYIMRKLVSAVSHMHDVGVVHRDLKPENLLFTDENDNLEIKIIDFGFARLKPPDNQPLKTPCFTLHYAAPELLNQNGYDESCDLWSLGVILYTMLSGQVPFQSHDRSLTCTSAVEIMKKIKKGDFSFEGEAWKNVSQEAKDLIQGLLTVDPNKRLKMSGLRYNEWLQDGSQLSSNPLMTPDILGSSGAAVHTCVKATFHAFNKYKREGFCLQNVDKAPLAKRRKMKKTSTSTETRSSSSESSHSSSSHSHGKTTPTKTLQPSNPADSNNPETLFQFSDSVA
T50224	DRUGINFO	D0Y3AM	US9365572, 5	Patented
T50224	DRUGINFO	D05GSF	PMID15955699C24	Investigative

T31406	TARGETID	T31406
T31406	FORMERID	TTDI03254
T31406	UNIPROID	HCK_HUMAN
T31406	TARGNAME	Hematopoietic cell kinase (HCK)
T31406	GENENAME	HCK
T31406	TARGTYPE	Patented-recorded
T31406	SYNONYMS	p61Hck; p59Hck; p59-HCK/p60-HCK; Tyrosine-protein kinase HCK; Hemopoietic cell kinase
T31406	FUNCTION	Acts downstream of receptors that bind the Fc region of immunoglobulins, such as FCGR1A and FCGR2A, but also CSF3R, PLAUR, the receptors for IFNG, IL2, IL6 and IL8, and integrins, such as ITGB1 and ITGB2. During the phagocytic process, mediates mobilization of secretory lysosomes, degranulation, and activation of NADPH oxidase to bring about the respiratory burst. Plays a role in the release of inflammatory molecules. Promotes reorganization of the actin cytoskeleton and actin polymerization, formation of podosomes and cell protrusions. Inhibits TP73-mediated transcription activation and TP73-mediated apoptosis. Phosphorylates CBL in response to activation of immunoglobulin gamma Fc region receptors. Phosphorylates ADAM15, BCR, ELMO1, FCGR2A, GAB1, GAB2, RAPGEF1, STAT5B, TP73, VAV1 and WAS. Non-receptor tyrosine-protein kinase found in hematopoietic cells that transmits signals from cell surface receptors and plays an important role in the regulation of innate immune responses, including neutrophil, monocyte, macrophage and mast cell functions, phagocytosis, cell survival and proliferation, cell adhesion and migration.
T31406	PDBSTRUC	5ZJ6; 5NUH; 5HCK; 5H0H; 5H0G
T31406	BIOCLASS	Kinase
T31406	ECNUMBER	EC 2.7.10.2
T31406	SEQUENCE	MGGRSSCEDPGCPRDEERAPRMGCMKSKFLQVGGNTFSKTETSASPHCPVYVPDPTSTIKPGPNSHNSNTPGIREAGSEDIIVVALYDYEAIHHEDLSFQKGDQMVVLEESGEWWKARSLATRKEGYIPSNYVARVDSLETEEWFFKGISRKDAERQLLAPGNMLGSFMIRDSETTKGSYSLSVRDYDPRQGDTVKHYKIRTLDNGGFYISPRSTFSTLQELVDHYKKGNDGLCQKLSVPCMSSKPQKPWEKDAWEIPRESLKLEKKLGAGQFGEVWMATYNKHTKVAVKTMKPGSMSVEAFLAEANVMKTLQHDKLVKLHAVVTKEPIYIITEFMAKGSLLDFLKSDEGSKQPLPKLIDFSAQIAEGMAFIEQRNYIHRDLRAANILVSASLVCKIADFGLARVIEDNEYTAREGAKFPIKWTAPEAINFGSFTIKSDVWSFGILLMEIVTYGRIPYPGMSNPEVIRALERGYRMPRPENCPEELYNIMMRCWKNRPEERPTFEYIQSVLDDFYTATESQYQQQP
T31406	DRUGINFO	D04XHJ	BK3	Patented
T31406	DRUGINFO	D05CDF	Doramapimod	Patented
T31406	DRUGINFO	D07FAF	3-(6-allyloxy-2-naphthyl)-1-(4-piperidylmethyl)pyrazolo[3,4-d]pyrimidin-4-amine	Patented
T31406	DRUGINFO	D07PDQ	Unii-I92MU0V408	Patented
T31406	DRUGINFO	D0B7VP	US8933228, 3	Patented
T31406	DRUGINFO	D0D5PL	SB19065	Patented
T31406	DRUGINFO	D0H0SM	US9108950, 1	Patented
T31406	DRUGINFO	D0Y4TK	US8933228, Ref 2	Patented
T31406	DRUGINFO	D0Y9PK	BK7	Patented
T31406	DRUGINFO	D08RZB	PMID15546730C2	Investigative
T31406	DRUGINFO	D03EHM	PP121	Investigative

T40488	TARGETID	T40488
T40488	FORMERID	TTDI03388
T40488	UNIPROID	MMP10_HUMAN
T40488	TARGNAME	Matrix metalloproteinase-10 (MMP-10)
T40488	GENENAME	MMP10
T40488	TARGTYPE	Patented-recorded
T40488	SYNONYMS	Transin-2; Stromelysin-2; STMY2; SL-2
T40488	FUNCTION	Activates procollagenase. Can degrade fibronectin, gelatins of type I, III, IV, and V; weakly collagens III, IV, and V.
T40488	PDBSTRUC	4ILW; 3V96; 1Q3A
T40488	BIOCLASS	Peptidase
T40488	ECNUMBER	EC 3.4.24.22
T40488	SEQUENCE	MMHLAFLVLLCLPVCSAYPLSGAAKEEDSNKDLAQQYLEKYYNLEKDVKQFRRKDSNLIVKKIQGMQKFLGLEVTGKLDTDTLEVMRKPRCGVPDVGHFSSFPGMPKWRKTHLTYRIVNYTPDLPRDAVDSAIEKALKVWEEVTPLTFSRLYEGEADIMISFAVKEHGDFYSFDGPGHSLAHAYPPGPGLYGDIHFDDDEKWTEDASGTNLFLVAAHELGHSLGLFHSANTEALMYPLYNSFTELAQFRLSQDDVNGIQSLYGPPPASTEEPLVPTKSVPSGSEMPAKCDPALSFDAISTLRGEYLFFKDRYFWRRSHWNPEPEFHLISAFWPSLPSYLDAAYEVNSRDTVFIFKGNEFWAIRGNEVQAGYPRGIHTLGFPPTIRKIDAAVSDKEKKKTYFFAADKYWRFDENSQSMEQGFPRLIADDFPGVEPKVDAVLQAFGFFYFFSGSSQFEFDPNARMVTHILKSNSWLHC
T40488	DRUGINFO	D09GMS	EEA	Patented
T40488	DRUGINFO	D0KZ0M	3ts4	Patented
T40488	DRUGINFO	D0MK8L	EEC	Patented
T40488	DRUGINFO	D0OR6O	CM-352	Investigative

T88126	TARGETID	T88126
T88126	FORMERID	TTDR00348
T88126	UNIPROID	NADD_ECOLI
T88126	TARGNAME	Bacterial Nicotinate-nucleotide adenylyltransferase (Bact nadD)
T88126	GENENAME	Bact nadD
T88126	TARGTYPE	Patented-recorded
T88126	SYNONYMS	nadD of Escherichia coli (strain K12); Nicotinate mononucleotide adenylyltransferase of Escherichia coli (strain K12); NaMN adenylyltransferase of Escherichia coli (strain K12); Deamido-NAD(+)Nicotinate-nucleotide adenylyltransferase pyrophosphorylase of Escherichia coli (strain K12); Deamido-NAD(+) pyrophosphorylase of Escherichia coli (strain K12); Deamido-NAD(+) diphosphorylase of Escherichia coli (strain K12)
T88126	FUNCTION	Catalyzes the reversible adenylation of nicotinate mononucleotide (namn) to nicotinic acid adenine dinucleotide (naad).
T88126	PDBSTRUC	1K4M; 1K4K
T88126	BIOCLASS	Kinase
T88126	ECNUMBER	EC 2.7.7.18
T88126	SEQUENCE	MKSLQALFGGTFDPVHYGHLKPVETLANLIGLTRVTIIPNNVPPHRPQPEANSVQRKHMLELAIADKPLFTLDERELKRNAPSYTAQTLKEWRQEQGPDVPLAFIIGQDSLLTFPTWYEYETILDNAHLIVCRRPGYPLEMAQPQYQQWLEDHLTHNPEDLHLQPAGKIYLAETPWFNISATIIRERLQNGESCEDLLPEPVLTYINQQGLYR
T88126	DRUGINFO	D0A0BS	DZ9	Patented
T88126	DRUGINFO	D0ND9W	AC1LJNG0	Patented
T88126	DRUGINFO	D0UF5V	STK696827	Patented
T88126	DRUGINFO	D0Y6LK	Deamido-NAD	Investigative
T88126	DRUGINFO	D0R6JE	Nicotinamide-Adenine-Dinucleotide	Investigative

T36725	TARGETID	T36725
T36725	FORMERID	TTDI03076
T36725	UNIPROID	CBPB1_HUMAN
T36725	TARGNAME	Carboxypeptidase B1 (CPB1)
T36725	GENENAME	CPB1
T36725	TARGTYPE	Patented-recorded
T36725	SYNONYMS	Pancreas-specific protein; PASP; Carboxypeptidase B; CPB
T36725	FUNCTION	A carboxypeptidase that preferentially acts upon basic amino acids, such as arginine and lysine. Responsible for rapidly metabolizing the C5a protein into C5a des-Arg, with one less amino acid.
T36725	PDBSTRUC	1ZLI; 1KWM
T36725	BIOCLASS	Peptidase
T36725	ECNUMBER	EC 3.4.17.2
T36725	SEQUENCE	MLALLVLVTVALASAHHGGEHFEGEKVFRVNVEDENHINIIRELASTTQIDFWKPDSVTQIKPHSTVDFRVKAEDTVTVENVLKQNELQYKVLISNLRNVVEAQFDSRVRATGHSYEKYNKWETIEAWTQQVATENPALISRSVIGTTFEGRAIYLLKVGKAGQNKPAIFMDCGFHAREWISPAFCQWFVREAVRTYGREIQVTELLDKLDFYVLPVLNIDGYIYTWTKSRFWRKTRSTHTGSSCIGTDPNRNFDAGWCEIGASRNPCDETYCGPAAESEKETKALADFIRNKLSSIKAYLTIHSYSQMMIYPYSYAYKLGENNAELNALAKATVKELASLHGTKYTYGPGATTIYPAAGGSDDWAYDQGIRYSFTFELRDTGRYGFLLPESQIRATCEETFLAIKYVASYVLEHLY
T36725	DRUGINFO	D01OFO	US8710232, 8	Patented
T36725	DRUGINFO	D01XTB	US8710232, 1	Patented
T36725	DRUGINFO	D0YI7A	US8710232, 7	Patented
T36725	DRUGINFO	D0O3QJ	PMID19954973C4	Investigative
T36725	DRUGINFO	D0XA0N	PMID14640538C3	Investigative

T80526	TARGETID	T80526
T80526	FORMERID	TTDI03086
T80526	UNIPROID	CSK22_HUMAN
T80526	TARGNAME	Casein kinase II alpha prime (CSNK2A2)
T80526	GENENAME	CSNK2A2
T80526	TARGTYPE	Patented-recorded
T80526	SYNONYMS	Casein kinase II subunit alpha'; CK2A2; CK II alpha'
T80526	FUNCTION	Regulates numerous cellular processes, such as cell cycle progression, apoptosis and transcription, as well as viral infection. May act as a regulatory node which integrates and coordinates numerous signals leading to an appropriate cellular response. During mitosis, functions as a component of the p53/TP53-dependent spindle assembly checkpoint (SAC) that maintains cyclin-B-CDK1 activity and G2 arrest in response to spindle damage. Also required for p53/TP53-mediated apoptosis, phosphorylating 'Ser-392' of p53/TP53 following UV irradiation. Can also negatively regulate apoptosis. Phosphorylates the caspases CASP9 and CASP2 and the apoptotic regulator NOL3. Phosphorylation protects CASP9 from cleavage and activation by CASP8, and inhibits the dimerization of CASP2 and activation of CASP8. Regulates transcription by direct phosphorylation of RNA polymerases I, II, III and IV. Also phosphorylates and regulates numerous transcription factors including NF-kappa-B, STAT1, CREB1, IRF1, IRF2, ATF1, SRF, MAX, JUN, FOS, MYC and MYB. Phosphorylates Hsp90 and its co-chaperones FKBP4 and CDC37, which is essential for chaperone function. Regulates Wnt signaling by phosphorylating CTNNB1 and the transcription factor LEF1. Acts as an ectokinase that phosphorylates several extracellular proteins. During viral infection, phosphorylates various proteins involved in the viral life cycles of EBV, HSV, HBV, HCV, HIV, CMV and HPV. Catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine.
T80526	PDBSTRUC	6QY9; 6HMQ; 6HMD; 6HMC; 6HMB
T80526	BIOCLASS	Kinase
T80526	ECNUMBER	EC 2.7.11.1
T80526	SEQUENCE	MPGPAAGSRARVYAEVNSLRSREYWDYEAHVPSWGNQDDYQLVRKLGRGKYSEVFEAINITNNERVVVKILKPVKKKKIKREVKILENLRGGTNIIKLIDTVKDPVSKTPALVFEYINNTDFKQLYQILTDFDIRFYMYELLKALDYCHSKGIMHRDVKPHNVMIDHQQKKLRLIDWGLAEFYHPAQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRREPFFHGQDNYDQLVRIAKVLGTEELYGYLKKYHIDLDPHFNDILGQHSRKRWENFIHSENRHLVSPEALDLLDKLLRYDHQQRLTAKEAMEHPYFYPVVKEQSQPCADNAVLSSGLTAAR
T80526	DRUGINFO	D01QPX	US8940736, 6	Patented
T80526	DRUGINFO	D0D2CR	US8940736, 23	Patented
T80526	DRUGINFO	D0E7ZS	US8791257, 38	Patented
T80526	DRUGINFO	D0H6DS	US8791257, 4	Patented
T80526	DRUGINFO	D0NM6I	US8791257, 17	Patented
T80526	DRUGINFO	D0XY1Z	US8940736, 7	Patented
T80526	DRUGINFO	D0K6BI	PMID22115617C2c	Investigative

T28052	TARGETID	T28052
T28052	FORMERID	TTDNR00703
T28052	UNIPROID	KDM5A_HUMAN
T28052	TARGNAME	Lysine-specific demethylase 5A (KDM5A)
T28052	GENENAME	KDM5A
T28052	TARGTYPE	Patented-recorded
T28052	SYNONYMS	Retinoblastoma-binding protein 2; RBP2; RBBP2; RBBP-2; Jumonji/ARID domain-containing protein 1A; JARID1A; Histone demethylase JARID1A
T28052	FUNCTION	Does not demethylate histone H3 'Lys-9', H3 'Lys-27', H3 'Lys-36', H3 'Lys-79' or H4 'Lys-20'. Demethylates trimethylated and dimethylated but not monomethylated H3 'Lys-4'. Regulates specific gene transcription through DNA-binding on 5'-CCGCCC-3' motif. May stimulate transcription mediated by nuclear receptors. Involved in transcriptional regulation of Hox proteins during cell differentiation. May participate in transcriptional repression of cytokines such as CXCL12. Plays a role in the regulation of the circadian rhythm and in maintaining the normal periodicity of the circadian clock. In a histone demethylase-independent manner, acts as a coactivator of the CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER1/2 and other clock-controlled genes and increases histone acetylation at PER1/2 promoters by inhibiting the activity of HDAC1. Seems to act as a transcriptional corepressor for some genes such as MT1F and to favor the proliferation of cancer cells. Histone demethylase that specifically demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code.
T28052	PDBSTRUC	6DQB; 6DQA; 6DQ9; 6DQ8; 6DQ6
T28052	BIOCLASS	Paired donor oxygen oxidoreductase
T28052	ECNUMBER	EC 1.14.11.-
T28052	SEQUENCE	MAGVGPGGYAAEFVPPPECPVFEPSWEEFTDPLSFIGRIRPLAEKTGICKIRPPKDWQPPFACEVKSFRFTPRVQRLNELEAMTRVRLDFLDQLAKFWELQGSTLKIPVVERKILDLYALSKIVASKGGFEMVTKEKKWSKVGSRLGYLPGKGTGSLLKSHYERILYPYELFQSGVSLMGVQMPNLDLKEKVEPEVLSTDTQTSPEPGTRMNILPKRTRRVKTQSESGDVSRNTELKKLQIFGAGPKVVGLAMGTKDKEDEVTRRRKVTNRSDAFNMQMRQRKGTLSVNFVDLYVCMFCGRGNNEDKLLLCDGCDDSYHTFCLIPPLPDVPKGDWRCPKCVAEECSKPREAFGFEQAVREYTLQSFGEMADNFKSDYFNMPVHMVPTELVEKEFWRLVSSIEEDVIVEYGADISSKDFGSGFPVKDGRRKILPEEEEYALSGWNLNNMPVLEQSVLAHINVDISGMKVPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPSHAAEQLEEVMRELAPELFESQPDLLHQLVTIMNPNVLMEHGVPVYRTNQCAGEFVVTFPRAYHSGFNQGYNFAEAVNFCTADWLPIGRQCVNHYRRLRRHCVFSHEELIFKMAADPECLDVGLAAMVCKELTLMTEEETRLRESVVQMGVLMSEEEVFELVPDDERQCSACRTTCFLSALTCSCNPERLVCLYHPTDLCPCPMQKKCLRYRYPLEDLPSLLYGVKVRAQSYDTWVSRVTEALSANFNHKKDLIELRVMLEDAEDRKYPENDLFRKLRDAVKEAETCASVAQLLLSKKQKHRQSPDSGRTRTKLTVEELKAFVQQLFSLPCVISQARQVKNLLDDVEEFHERAQEAMMDETPDSSKLQMLIDMGSSLYVELPELPRLKQELQQARWLDEVRLTLSDPQQVTLDVMKKLIDSGVGLAPHHAVEKAMAELQELLTVSERWEEKAKVCLQARPRHSVASLESIVNEAKNIPAFLPNVLSLKEALQKAREWTAKVEAIQSGSNYAYLEQLESLSAKGRPIPVRLEALPQVESQVAAARAWRERTGRTFLKKNSSHTLLQVLSPRTDIGVYGSGKNRRKKVKELIEKEKEKDLDLEPLSDLEEGLEETRDTAMVVAVFKEREQKEIEAMHSLRAANLAKMTMVDRIEEVKFCICRKTASGFMLQCELCKDWFHNSCVPLPKSSSQKKGSSWQAKEVKFLCPLCMRSRRPRLETILSLLVSLQKLPVRLPEGEALQCLTERAMSWQDRARQALATDELSSALAKLSVLSQRMVEQAAREKTEKIISAELQKAAANPDLQGHLPSFQQSAFNRVVSSVSSSPRQTMDYDDEETDSDEDIRETYGYDMKDTASVKSSSSLEPNLFCDEEIPIKSEEVVTHMWTAPSFCAEHAYSSASKSCSQGSSTPRKQPRKSPLVPRSLEPPVLELSPGAKAQLEELMMVGDLLEVSLDETQHIWRILQATHPPSEDRFLHIMEDDSMEEKPLKVKGKDSSEKKRKRKLEKVEQLFGEGKQKSKELKKMDKPRKKKLKLGADKSKELNKLAKKLAKEEERKKKKEKAAAAKVELVKESTEKKREKKVLDIPSKYDWSGAEESDDENAVCAAQNCQRPCKDKVDWVQCDGGCDEWFHQVCVGVSPEMAENEDYICINCAKKQGPVSPGPAPPPSFIMSYKLPMEDLKETS
T28052	DRUGINFO	D00SUC	6EP	Patented
T28052	DRUGINFO	D01WHH	BDBM50158803	Patented
T28052	DRUGINFO	D03POM	US10022354, Example 151	Patented
T28052	DRUGINFO	D03TKM	US9714230, 12	Patented
T28052	DRUGINFO	D05CCY	BDBM50158791	Patented
T28052	DRUGINFO	D06TKT	US10040779, Example 4	Patented
T28052	DRUGINFO	D09CWB	US9611221, Example 9	Patented
T28052	DRUGINFO	D0F3TL	US9714230, 46	Patented
T28052	DRUGINFO	D0G8QR	BDBM50158794	Patented
T28052	DRUGINFO	D0GH8J	BDBM50158703	Patented
T28052	DRUGINFO	D0HT9Q	AKOS020330656	Patented
T28052	DRUGINFO	D0K4LW	BDBM50158755	Patented
T28052	DRUGINFO	D0N9JZ	US10174026, Example 99	Patented
T28052	DRUGINFO	D0NG8M	AKOS020330481	Patented
T28052	DRUGINFO	D0NM3B	US10022354, Example 5	Patented
T28052	DRUGINFO	D0PQ5P	NCGC00381656-01	Patented
T28052	DRUGINFO	D0R2GT	US10174026, Example 2	Patented
T28052	DRUGINFO	D0T8YT	US10022354, Example 152	Patented
T28052	DRUGINFO	D0VZ5E	US10040779, Example 1	Patented
T28052	DRUGINFO	D0ZJ0Z	1190312-92-5	Patented
T28052	DRUGINFO	D0IQ7Y	PBIT	Investigative

T08741	TARGETID	T08741
T08741	FORMERID	TTDI03125
T08741	UNIPROID	CSK_HUMAN
T08741	TARGNAME	Tyrosine-protein kinase CSK (CSK)
T08741	GENENAME	CSK
T08741	TARGTYPE	Patented-recorded
T08741	SYNONYMS	Protein-tyrosine kinase CYL; C-Src kinase
T08741	FUNCTION	Phosphorylates tyrosine residues located in the C-terminal tails of Src-family kinases (SFKs) including LCK, SRC, HCK, FYN, LYN, CSK or YES1. Upon tail phosphorylation, Src-family members engage in intramolecular interactions between the phosphotyrosine tail and the SH2 domain that result in an inactive conformation. To inhibit SFKs, CSK is recruited to the plasma membrane via binding to transmembrane proteins or adapter proteins located near the plasma membrane. Suppresses signaling by various surface receptors, including T-cell receptor (TCR) and B-cell receptor (BCR) by phosphorylating and maintaining inactive several positive effectors such as FYN or LCK. Non-receptor tyrosine-protein kinase that plays an important role in the regulation of cell growth, differentiation, migration and immune response.
T08741	PDBSTRUC	3EAZ; 3EAC; 3D7U; 3D7T; 1CSK
T08741	BIOCLASS	Kinase
T08741	ECNUMBER	EC 2.7.10.2
T08741	SEQUENCE	MSAIQAAWPSGTECIAKYNFHGTAEQDLPFCKGDVLTIVAVTKDPNWYKAKNKVGREGIIPANYVQKREGVKAGTKLSLMPWFHGKITREQAERLLYPPETGLFLVRESTNYPGDYTLCVSCDGKVEHYRIMYHASKLSIDEEVYFENLMQLVEHYTSDADGLCTRLIKPKVMEGTVAAQDEFYRSGWALNMKELKLLQTIGKGEFGDVMLGDYRGNKVAVKCIKNDATAQAFLAEASVMTQLRHSNLVQLLGVIVEEKGGLYIVTEYMAKGSLVDYLRSRGRSVLGGDCLLKFSLDVCEAMEYLEGNNFVHRDLAARNVLVSEDNVAKVSDFGLTKEASSTQDTGKLPVKWTAPEALREKKFSTKSDVWSFGILLWEIYSFGRVPYPRIPLKDVVPRVEKGYKMDAPDGCPPAVYEVMKNCWHLDAAMRPSFLQLREQLEHIKTHELHL
T08741	DRUGINFO	D02DJP	936563-93-8	Patented
T08741	DRUGINFO	D0X7IC	NG-25	Investigative

T99990	TARGETID	T99990
T99990	FORMERID	TTDI03055
T99990	UNIPROID	BMX_HUMAN
T99990	TARGNAME	Tyrosine-protein kinase BMX (BMX)
T99990	GENENAME	BMX
T99990	TARGTYPE	Patented-recorded
T99990	SYNONYMS	NTK38; Epithelial and endothelial tyrosine kinase; ETK; Cytoplasmic tyrosine-protein kinase BMX; Bone marrow tyrosine kinase gene in chromosome X protein
T99990	FUNCTION	Non-receptor tyrosine kinase that plays central but diverse modulatory roles in various signaling processes involved in the regulation of actin reorganization, cell migration, cell proliferation and survival, cell adhesion, and apoptosis. Participates in signal transduction stimulated by growth factor receptors, cytokine receptors, G-protein coupled receptors, antigen receptors and integrins. Induces tyrosine phosphorylation of BCAR1 in response to integrin regulation. Activation of BMX by integrins is mediated by PTK2/FAK1, a key mediator of integrin signaling events leading to the regulation of actin cytoskeleton and cell motility. Plays a critical role in TNF-induced angiogenesis, and implicated in the signaling of TEK and FLT1 receptors, 2 important receptor families essential for angiogenesis. Required for the phosphorylation and activation of STAT3, a transcription factor involved in cell differentiation. Also involved in interleukin-6 (IL6) induced differentiation. Plays also a role in programming adaptive cytoprotection against extracellular stress in different cell systems, salivary epithelial cells, brain endothelial cells, and dermal fibroblasts. May be involved in regulation of endocytosis through its interaction with an endosomal protein RUFY1. May also play a role in the growth and differentiation of hematopoietic cells; as well as in signal transduction in endocardial and arterial endothelial cells.
T99990	PDBSTRUC	3SXS; 3SXR; 2YS2; 2EKX
T99990	BIOCLASS	Kinase
T99990	ECNUMBER	EC 2.7.10.2
T99990	SEQUENCE	MDTKSILEELLLKRSQQKKKMSPNNYKERLFVLTKTNLSYYEYDKMKRGSRKGSIEIKKIRCVEKVNLEEQTPVERQYPFQIVYKDGLLYVYASNEESRSQWLKALQKEIRGNPHLLVKYHSGFFVDGKFLCCQQSCKAAPGCTLWEAYANLHTAVNEEKHRVPTFPDRVLKIPRAVPVLKMDAPSSSTTLAQYDNESKKNYGSQPPSSSTSLAQYDSNSKKIYGSQPNFNMQYIPREDFPDWWQVRKLKSSSSSEDVASSNQKERNVNHTTSKISWEFPESSSSEEEENLDDYDWFAGNISRSQSEQLLRQKGKEGAFMVRNSSQVGMYTVSLFSKAVNDKKGTVKHYHVHTNAENKLYLAENYCFDSIPKLIHYHQHNSAGMITRLRHPVSTKANKVPDSVSLGNGIWELKREEITLLKELGSGQFGVVQLGKWKGQYDVAVKMIKEGSMSEDEFFQEAQTMMKLSHPKLVKFYGVCSKEYPIYIVTEYISNGCLLNYLRSHGKGLEPSQLLEMCYDVCEGMAFLESHQFIHRDLAARNCLVDRDLCVKVSDFGMTRYVLDDQYVSSVGTKFPVKWSAPEVFHYFKYSSKSDVWAFGILMWEVFSLGKQPYDLYDNSQVVLKVSQGHRLYRPHLASDTIYQIMYSCWHELPEKRPTFQQLLSSIEPLREKDKH
T99990	DRUGINFO	D01RHR	PMID24915291C31	Investigative
T99990	DRUGINFO	D06BJG	PMID24915291C38	Investigative

T75772	TARGETID	T75772
T75772	FORMERID	TTDNR00667
T75772	UNIPROID	ENTK_HUMAN
T75772	TARGNAME	Enteropeptidase (TMPRSS15)
T75772	GENENAME	TMPRSS15
T75772	TARGTYPE	Patented-recorded
T75772	SYNONYMS	Transmembrane protease serine 15; TMPRSS15; Serine protease 7; Enterokinase
T75772	FUNCTION	Responsible for initiating activation of pancreatic proteolytic proenzymes (trypsin, chymotrypsin and carboxypeptidase A). It catalyzes the conversion of trypsinogen to trypsin which in turn activates other proenzymes including chymotrypsinogen, procarboxypeptidases, and proelastases.
T75772	PDBSTRUC	4DGJ
T75772	BIOCLASS	Peptidase
T75772	ECNUMBER	EC 3.4.21.9
T75772	SEQUENCE	MGSKRGISSRHHSLSSYEIMFAALFAILVVLCAGLIAVSCLTIKESQRGAALGQSHEARATFKITSGVTYNPNLQDKLSVDFKVLAFDLQQMIDEIFLSSNLKNEYKNSRVLQFENGSIIVVFDLFFAQWVSDENVKEELIQGLEANKSSQLVTFHIDLNSVDILDKLTTTSHLATPGNVSIECLPGSSPCTDALTCIKADLFCDGEVNCPDGSDEDNKMCATVCDGRFLLTGSSGSFQATHYPKPSETSVVCQWIIRVNQGLSIKLSFDDFNTYYTDILDIYEGVGSSKILRASIWETNPGTIRIFSNQVTATFLIESDESDYVGFNATYTAFNSSELNNYEKINCNFEDGFCFWVQDLNDDNEWERIQGSTFSPFTGPNFDHTFGNASGFYISTPTGPGGRQERVGLLSLPLDPTLEPACLSFWYHMYGENVHKLSINISNDQNMEKTVFQKEGNYGDNWNYGQVTLNETVKFKVAFNAFKNKILSDIALDDISLTYGICNGSLYPEPTLVPTPPPELPTDCGGPFELWEPNTTFSSTNFPNSYPNLAFCVWILNAQKGKNIQLHFQEFDLENINDVVEIRDGEEADSLLLAVYTGPGPVKDVFSTTNRMTVLLITNDVLARGGFKANFTTGYHLGIPEPCKADHFQCKNGECVPLVNLCDGHLHCEDGSDEADCVRFFNGTTNNNGLVRFRIQSIWHTACAENWTTQISNDVCQLLGLGSGNSSKPIFPTDGGPFVKLNTAPDGHLILTPSQQCLQDSLIRLQCNHKSCGKKLAAQDITPKIVGGSNAKEGAWPWVVGLYYGGRLLCGASLVSSDWLVSAAHCVYGRNLEPSKWTAILGLHMKSNLTSPQTVPRLIDEIVINPHYNRRRKDNDIAMMHLEFKVNYTDYIQPICLPEENQVFPPGRNCSIAGWGTVVYQGTTANILQEADVPLLSNERCQQQMPEYNITENMICAGYEEGGIDSCQGDSGGPLMCQENNRWFLAGVTSFGYKCALPNRPGVYARVSRFTEWIQSFLH
T75772	DRUGINFO	D01MPC	US9024044, 62	Patented
T75772	DRUGINFO	D03SHV	US9346821, B-42	Patented
T75772	DRUGINFO	D09KTX	US9346821, A-20	Patented
T75772	DRUGINFO	D09VFP	US9346821, B-13	Patented
T75772	DRUGINFO	D0G2TL	US8609715, A-1	Patented
T75772	DRUGINFO	D0G4ZU	US8609715, A-26	Patented
T75772	DRUGINFO	D0K3IO	US9024044, 4	Patented
T75772	DRUGINFO	D0L8BY	US8609715, B-61	Patented
T75772	DRUGINFO	D0VE7D	US9024044, 3	Patented
T75772	DRUGINFO	D0W6MZ	US9024044, 1	Patented
T75772	DRUGINFO	D0ZN0D	US9024044, 2	Patented

T09185	TARGETID	T09185
T09185	FORMERID	TTDI03158
T09185	UNIPROID	DDR1_HUMAN
T09185	TARGNAME	Epithelial discoidin domain receptor 1 (DDR1)
T09185	GENENAME	DDR1
T09185	TARGTYPE	Patented-recorded
T09185	SYNONYMS	Tyrosine-protein kinase CAK; Tyrosine kinase DDR; TRKE; TRK E; RTK6; Protein-tyrosine kinase RTK-6; Protein-tyrosine kinase 3A; PTK3A; NTRK4; NEP; Mammary carcinoma kinase 10; MCK-10; HGK2; Epithelial discoidin domain-containing receptor 1; EDDR1; Discoidin receptor tyrosine kinase; Cell adhesion kinase; CD167a; CD167 antigen-like family member A
T09185	FUNCTION	Collagen binding triggers a signaling pathway that involves SRC and leads to the activation of MAP kinases. Regulates remodeling of the extracellular matrix by up-regulation of the matrix metalloproteinases MMP2, MMP7 and MMP9, and thereby facilitates cell migration and wound healing. Required for normal blastocyst implantation during pregnancy, for normal mammary gland differentiation and normal lactation. Required for normal ear morphology and normal hearing. Promotes smooth muscle cell migration, and thereby contributes to arterial wound healing. Also plays a role in tumor cell invasion. Phosphorylates PTPN11. Tyrosine kinase that functions as cell surface receptor for fibrillar collagen and regulates cell attachment to the extracellular matrix, remodeling of the extracellular matrix, cell migration, differentiation, survival and cell proliferation.
T09185	PDBSTRUC	6HP9; 6GWR; 6FIQ; 6FIO; 6FIN
T09185	BIOCLASS	Kinase
T09185	ECNUMBER	EC 2.7.10.1
T09185	SEQUENCE	MGPEALSSLLLLLLVASGDADMKGHFDPAKCRYALGMQDRTIPDSDISASSSWSDSTAARHSRLESSDGDGAWCPAGSVFPKEEEYLQVDLQRLHLVALVGTQGRHAGGLGKEFSRSYRLRYSRDGRRWMGWKDRWGQEVISGNEDPEGVVLKDLGPPMVARLVRFYPRADRVMSVCLRVELYGCLWRDGLLSYTAPVGQTMYLSEAVYLNDSTYDGHTVGGLQYGGLGQLADGVVGLDDFRKSQELRVWPGYDYVGWSNHSFSSGYVEMEFEFDRLRAFQAMQVHCNNMHTLGARLPGGVECRFRRGPAMAWEGEPMRHNLGGNLGDPRARAVSVPLGGRVARFLQCRFLFAGPWLLFSEISFISDVVNNSSPALGGTFPPAPWWPPGPPPTNFSSLELEPRGQQPVAKAEGSPTAILIGCLVAIILLLLLIIALMLWRLHWRRLLSKAERRVLEEELTVHLSVPGDTILINNRPGPREPPPYQEPRPRGNPPHSAPCVPNGSALLLSNPAYRLLLATYARPPRGPGPPTPAWAKPTNTQAYSGDYMEPEKPGAPLLPPPPQNSVPHYAEADIVTLQGVTGGNTYAVPALPPGAVGDGPPRVDFPRSRLRFKEKLGEGQFGEVHLCEVDSPQDLVSLDFPLNVRKGHPLLVAVKILRPDATKNARNDFLKEVKIMSRLKDPNIIRLLGVCVQDDPLCMITDYMENGDLNQFLSAHQLEDKAAEGAPGDGQAAQGPTISYPMLLHVAAQIASGMRYLATLNFVHRDLATRNCLVGENFTIKIADFGMSRNLYAGDYYRVQGRAVLPIRWMAWECILMGKFTTASDVWAFGVTLWEVLMLCRAQPFGQLTDEQVIENAGEFFRDQGRQVYLSRPPACPQGLYELMLRCWSRESEQRPPFSQLHRFLAEDALNTV
T09185	DRUGINFO	D00UAQ	US9567304, Compound N-9	Patented
T09185	DRUGINFO	D0BW9L	US9156852, 83	Patented
T09185	DRUGINFO	D0DA4Y	US9695118, 8	Patented
T09185	DRUGINFO	D0GT9T	NG7	Patented
T09185	DRUGINFO	D0H0GL	US9567304, Compound F-54	Patented
T09185	DRUGINFO	D0LL1P	VAPBGCRAUJRZPO-UHFFFAOYSA-N	Patented
T09185	DRUGINFO	D0Y3FD	BDBM50080408	Patented
T09185	DRUGINFO	D0ZK5P	US9695118, 4	Patented
T09185	DRUGINFO	D0BL0O	PMID23521020C7k	Investigative

T12081	TARGETID	T12081
T12081	FORMERID	TTDI03445
T12081	UNIPROID	PDE4C_HUMAN
T12081	TARGNAME	Phosphodiesterase 4C (PDE4C)
T12081	GENENAME	PDE4C
T12081	TARGTYPE	Patented-recorded
T12081	SYNONYMS	cAMP-specific 3',5'-cyclic phosphodiesterase 4C; PDE21; DPDE1
T12081	FUNCTION	Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
T12081	PDBSTRUC	2QYM; 1LXU
T12081	BIOCLASS	Phosphoric diester hydrolase
T12081	ECNUMBER	EC 3.1.4.53
T12081	SEQUENCE	MENLGVGEGAEACSRLSRSRGRHSMTRAPKHLWRQPRRPIRIQQRFYSDPDKSAGCRERDLSPRPELRKSRLSWPVSSCRRFDLENGLSCGRRALDPQSSPGLGRIMQAPVPHSQRRESFLYRSDSDYELSPKAMSRNSSVASDLHGEDMIVTPFAQVLASLRTVRSNVAALARQQCLGAAKQGPVGNPSSSNQLPPAEDTGQKLALETLDELDWCLDQLETLQTRHSVGEMASNKFKRILNRELTHLSETSRSGNQVSEYISRTFLDQQTEVELPKVTAEEAPQPMSRISGLHGLCHSASLSSATVPRFGVQTDQEEQLAKELEDTNKWGLDVFKVAELSGNRPLTAIIFSIFQERDLLKTFQIPADTLATYLLMLEGHYHANVAYHNSLHAADVAQSTHVLLATPALEAVFTDLEILAALFASAIHDVDHPGVSNQFLINTNSELALMYNDASVLENHHLAVGFKLLQAENCDIFQNLSAKQRLSLRRMVIDMVLATDMSKHMNLLADLKTMVETKKVTSLGVLLLDNYSDRIQVLQNLVHCADLSNPTKPLPLYRQWTDRIMAEFFQQGDRERESGLDISPMCDKHTASVEKSQVGFIDYIAHPLWETWADLVHPDAQDLLDTLEDNREWYQSKIPRSPSDLTNPERDGPDRFQFELTLEEAEEEDEEEEEEGEETALAKEALELPDTELLSPEAGPDPGDLPLDNQRT
T12081	DRUGINFO	D04VJX	ZINC584606052	Patented
T12081	DRUGINFO	D05TQB	US10077269, Example 6	Patented
T12081	DRUGINFO	D0W5OE	CS-W011402	Patented
T12081	DRUGINFO	D0P2HX	RS-25344	Investigative

T94449	TARGETID	T94449
T94449	FORMERID	TTDNC00446
T94449	UNIPROID	PTPRJ_HUMAN
T94449	TARGNAME	Protein-tyrosine phosphatase eta (HPTP)
T94449	GENENAME	PTPRJ
T94449	TARGTYPE	Patented-recorded
T94449	SYNONYMS	Receptor-type tyrosine-protein phosphatase eta; R-PTP-eta; R-PTP-J; Protein-tyrosine phosphatase receptor type J; HPTP eta; Density-enhanced phosphatase 1; DEP1; DEP-1; CD148
T94449	FUNCTION	Plays a role in cell adhesion, migration, proliferation and differentiation. Involved in vascular development. Regulator of macrophage adhesion and spreading. Positively affects cell-matrix adhesion. Positive regulator of platelet activation and thrombosis. Negative regulator of cell proliferation. Negative regulator of PDGF-stimulated cell migration; through dephosphorylation of PDGFR. Positive regulator of endothelial cell survival, as well as of VEGF-induced SRC and AKT activation; through KDR dephosphorylation. Negative regulator of EGFR signaling pathway; through EGFR dephosphorylation. Enhances the barrier function of epithelial junctions during reassembly. Negatively regulates T-cell receptor (TCR) signaling. Upon T-cell TCR activation, it is up-regulated and excluded from the immunological synapses, while upon T-cell-antigen presenting cells (APC) disengagement, it is no longer excluded and can dephosphorylate PLCG1 and LAT to down-regulate prolongation of signaling. Tyrosine phosphatase which dephosphorylates or contributes to the dephosphorylation of CTNND1, FLT3, PDGFRB, MET, RET (variant MEN2A), KDR, LYN, SRC, MAPK1, MAPK3, EGFR, TJP1, OCLN, PIK3R1 and PIK3R2.
T94449	PDBSTRUC	2NZ6; 2DLE; 2CFV
T94449	BIOCLASS	Phosphoric monoester hydrolase
T94449	ECNUMBER	EC 3.1.3.48
T94449	SEQUENCE	MKPAAREARLPPRSPGLRWALPLLLLLLRLGQILCAGGTPSPIPDPSVATVATGENGITQISSTAESFHKQNGTGTPQVETNTSEDGESSGANDSLRTPEQGSNGTDGASQKTPSSTGPSPVFDIKAVSISPTNVILTWKSNDTAASEYKYVVKHKMENEKTITVVHQPWCNITGLRPATSYVFSITPGIGNETWGDPRVIKVITEPIPVSDLRVALTGVRKAALSWSNGNGTASCRVLLESIGSHEELTQDSRLQVNISGLKPGVQYNINPYLLQSNKTKGDPLGTEGGLDASNTERSRAGSPTAPVHDESLVGPVDPSSGQQSRDTEVLLVGLEPGTRYNATVYSQAANGTEGQPQAIEFRTNAIQVFDVTAVNISATSLTLIWKVSDNESSSNYTYKIHVAGETDSSNLNVSEPRAVIPGLRSSTFYNITVCPVLGDIEGTPGFLQVHTPPVPVSDFRVTVVSTTEIGLAWSSHDAESFQMHITQEGAGNSRVEITTNQSIIIGGLFPGTKYCFEIVPKGPNGTEGASRTVCNRTVPSAVFDIHVVYVTTTEMWLDWKSPDGASEYVYHLVIESKHGSNHTSTYDKAITLQGLIPGTLYNITISPEVDHVWGDPNSTAQYTRPSNVSNIDVSTNTTAATLSWQNFDDASPTYSYCLLIEKAGNSSNATQVVTDIGITDATVTELIPGSSYTVEIFAQVGDGIKSLEPGRKSFCTDPASMASFDCEVVPKEPALVLKWTCPPGANAGFELEVSSGAWNNATHLESCSSENGTEYRTEVTYLNFSTSYNISITTVSCGKMAAPTRNTCTTGITDPPPPDGSPNITSVSHNSVKVKFSGFEASHGPIKAYAVILTTGEAGHPSADVLKYTYEDFKKGASDTYVTYLIRTEEKGRSQSLSEVLKYEIDVGNESTTLGYYNGKLEPLGSYRACVAGFTNITFHPQNKGLIDGAESYVSFSRYSDAVSLPQDPGVICGAVFGCIFGALVIVTVGGFIFWRKKRKDAKNNEVSFSQIKPKKSKLIRVENFEAYFKKQQADSNCGFAEEYEDLKLVGISQPKYAAELAENRGKNRYNNVLPYDISRVKLSVQTHSTDDYINANYMPGYHSKKDFIATQGPLPNTLKDFWRMVWEKNVYAIIMLTKCVEQGRTKCEEYWPSKQAQDYGDITVAMTSEIVLPEWTIRDFTVKNIQTSESHPLRQFHFTSWPDHGVPDTTDLLINFRYLVRDYMKQSPPESPILVHCSAGVGRTGTFIAIDRLIYQIENENTVDVYGIVYDLRMHRPLMVQTEDQYVFLNQCVLDIVRSQKDSKVDLIYQNTTAMTIYENLAPVTTFGKTNGYIA
T94449	DRUGINFO	D0H6LK	US9340574, 7	Patented

T11764	TARGETID	T11764
T11764	FORMERID	TTDNR00661
T11764	UNIPROID	DDR2_HUMAN
T11764	TARGNAME	Discoidin domain-containing receptor 2 (DDR2)
T11764	GENENAME	DDR2
T11764	TARGTYPE	Patented-recorded
T11764	SYNONYMS	Tyrosine-protein kinase TYRO10; Receptor protein-tyrosine kinase TKT; Neurotrophic tyrosine kinase, receptor-related 3; Discoidin domain-containing receptor tyrosine kinase 2; Discoidin domain receptor 2; DDR2; CD167 antigen-like family member B
T11764	FUNCTION	Tyrosine kinase that functions as cell surface receptor for fibrillar collagen and regulates cell differentiation, remodeling of the extracellular matrix, cell migration and cell proliferation. Required for normal bone development. Regulates osteoblast differentiation and chondrocyte maturation via a signaling pathway that involves MAP kinases and leads to the activation of the transcription factor RUNX2. Regulates remodeling of the extracellular matrix by up-regulation of the collagenases MMP1, MMP2 and MMP13, and thereby facilitates cell migration and tumor cell invasion. Promotes fibroblast migration and proliferation, and thereby contributes to cutaneous wound healing.
T11764	PDBSTRUC	6FER; 2Z4F; 2WUH
T11764	BIOCLASS	Kinase
T11764	ECNUMBER	EC 2.7.10.1
T11764	SEQUENCE	MILIPRMLLVLFLLLPILSSAKAQVNPAICRYPLGMSGGQIPDEDITASSQWSESTAAKYGRLDSEEGDGAWCPEIPVEPDDLKEFLQIDLHTLHFITLVGTQGRHAGGHGIEFAPMYKINYSRDGTRWISWRNRHGKQVLDGNSNPYDIFLKDLEPPIVARFVRFIPVTDHSMNVCMRVELYGCVWLDGLVSYNAPAGQQFVLPGGSIIYLNDSVYDGAVGYSMTEGLGQLTDGVSGLDDFTQTHEYHVWPGYDYVGWRNESATNGYIEIMFEFDRIRNFTTMKVHCNNMFAKGVKIFKEVQCYFRSEASEWEPNAISFPLVLDDVNPSARFVTVPLHHRMASAIKCQYHFADTWMMFSEITFQSDAAMYNNSEALPTSPMAPTTYDPMLKVDDSNTRILIGCLVAIIFILLAIIVIILWRQFWQKMLEKASRRMLDDEMTVSLSLPSDSSMFNNNRSSSPSEQGSNSTYDRIFPLRPDYQEPSRLIRKLPEFAPGEEESGCSGVVKPVQPSGPEGVPHYAEADIVNLQGVTGGNTYSVPAVTMDLLSGKDVAVEEFPRKLLTFKEKLGEGQFGEVHLCEVEGMEKFKDKDFALDVSANQPVLVAVKMLRADANKNARNDFLKEIKIMSRLKDPNIIHLLAVCITDDPLCMITEYMENGDLNQFLSRHEPPNSSSSDVRTVSYTNLKFMATQIASGMKYLSSLNFVHRDLATRNCLVGKNYTIKIADFGMSRNLYSGDYYRIQGRAVLPIRWMSWESILLGKFTTASDVWAFGVTLWETFTFCQEQPYSQLSDEQVIENTGEFFRDQGRQTYLPQPAICPDSVYKLMLSCWRRDTKNRPSFQEIHLLLLQQGDE
T11764	DRUGINFO	D05AFD	US9156852, 38	Patented
T11764	DRUGINFO	D0CI3N	US9156852, 1	Patented
T11764	DRUGINFO	D0T8BO	US9156852, 105	Patented

T72881	TARGETID	T72881
T72881	FORMERID	TTDR00232
T72881	UNIPROID	LTC4S_HUMAN
T72881	TARGNAME	Leukotriene C4 synthase (LTC4S)
T72881	GENENAME	LTC4S
T72881	TARGTYPE	Patented-recorded
T72881	SYNONYMS	Leukotriene-C(4)Leukotriene C4 synthase synthase; Leukotriene-C(4) synthase; LTC4 synthase
T72881	FUNCTION	Catalyzes the conjugation of leukotriene A4 with reduced glutathione to form leukotriene C4.
T72881	PDBSTRUC	5HV9; 4WAB; 4JRZ; 4JCZ; 4JC7
T72881	BIOCLASS	Carbon-sulfur lyase
T72881	ECNUMBER	EC 4.4.1.20
T72881	SEQUENCE	MKDEVALLAAVTLLGVLLQAYFSLQVISARRAFRVSPPLTTGPPEFERVYRAQVNCSEYFPLFLATLWVAGIFFHEGAAALCGLVYLFARLRYFQGYARSAQLRLAPLYASARALWLLVALAALGLLAHFLPAALRAALLGRLRTLLPWA
T72881	DRUGINFO	D08NHT	US20160326143, 50	Patented
T72881	DRUGINFO	D0CT4T	US20160326143, 28	Patented
T72881	DRUGINFO	D0L5VH	US20160326143, 3	Patented
T72881	DRUGINFO	D0V6RN	US20160326143, 38	Patented

T16596	TARGETID	T16596
T16596	FORMERID	TTDI02151
T16596	UNIPROID	PIM3_HUMAN
T16596	TARGNAME	PIM-3 protein kinase (PIM3)
T16596	GENENAME	PIM3
T16596	TARGTYPE	Patented-recorded
T16596	SYNONYMS	Serine/threonine-protein kinase pim-3
T16596	FUNCTION	May contribute to tumorigenesis through: the delivery of survival signaling through phosphorylation of BAD which induces release of the anti-apoptotic protein Bcl-X(L), the regulation of cell cycle progression, protein synthesis and by regulation of MYC transcriptional activity. Additionally to this role on tumorigenesis, can also negatively regulate insulin secretion by inhibiting the activation of MAPK1/3 (ERK1/2), through SOCS6. Involved also in the control of energy metabolism and regulation of AMPK activity in modulating MYC and PPARGC1A protein levels and cell growth. Proto-oncogene with serine/threonine kinase activity that can prevent apoptosis, promote cell survival and protein translation.
T16596	BIOCLASS	Kinase
T16596	ECNUMBER	EC 2.7.11.1
T16596	SEQUENCE	MLLSKFGSLAHLCGPGGVDHLPVKILQPAKADKESFEKAYQVGAVLGSGGFGTVYAGSRIADGLPVAVKHVVKERVTEWGSLGGATVPLEVVLLRKVGAAGGARGVIRLLDWFERPDGFLLVLERPEPAQDLFDFITERGALDEPLARRFFAQVLAAVRHCHSCGVVHRDIKDENLLVDLRSGELKLIDFGSGALLKDTVYTDFDGTRVYSPPEWIRYHRYHGRSATVWSLGVLLYDMVCGDIPFEQDEEILRGRLLFRRRVSPECQQLIRWCLSLRPSERPSLDQIAAHPWMLGADGGVPESCDLRLCTLDPDDVASTTSSSESL
T16596	DRUGINFO	D00HBJ	US9682991, 23	Patented
T16596	DRUGINFO	D04JJM	US8889696, Staurosporine	Patented
T16596	DRUGINFO	D04MCF	US8829193, 3	Patented
T16596	DRUGINFO	D04VSB	BDBM50061601	Patented
T16596	DRUGINFO	D05ZQI	US9580418, Example 8	Patented
T16596	DRUGINFO	D06OKX	BDBM50061608	Patented
T16596	DRUGINFO	D06TGF	US8481586, 15	Patented
T16596	DRUGINFO	D07SHE	US9434725, 315	Patented
T16596	DRUGINFO	D08JUU	BDBM50061612	Patented
T16596	DRUGINFO	D0D0WQ	US8669361, 102	Patented
T16596	DRUGINFO	D0DT0E	US8669361, 105	Patented
T16596	DRUGINFO	D0EH6G	US9682991, 7	Patented
T16596	DRUGINFO	D0GV1S	US8759338, 2	Patented
T16596	DRUGINFO	D0I0CN	US8669361, 107	Patented
T16596	DRUGINFO	D0J6HN	N-{4	Patented
T16596	DRUGINFO	D0JL8G	US9434725, 285	Patented
T16596	DRUGINFO	D0LK3O	US8987457, 117	Patented
T16596	DRUGINFO	D0M0TH	US8481586, 40	Patented
T16596	DRUGINFO	D0NE0N	US8481586, 5	Patented
T16596	DRUGINFO	D0NX6B	US8987457, 198	Patented
T16596	DRUGINFO	D0OS2I	US8592455, 3	Patented
T16596	DRUGINFO	D0P4NQ	US8759338, 12	Patented
T16596	DRUGINFO	D0P9UF	US8829193, 1	Patented
T16596	DRUGINFO	D0QU7N	US9580418, Example 11	Patented
T16596	DRUGINFO	D0V5JW	US9682991, 2	Patented
T16596	DRUGINFO	D0WH9N	US8669361, 103	Patented
T16596	DRUGINFO	D0WU1C	US8987457, 15	Patented
T16596	DRUGINFO	D0X0BB	US8592455, 90	Patented
T16596	DRUGINFO	D0XJ2J	US8759338, 1	Patented
T16596	DRUGINFO	D0ZC0E	US8829193, 2	Patented
T16596	DRUGINFO	D0ZY3D	US9434725, 113	Patented
T16596	DRUGINFO	D04TPA	PMID24900749C1a	Investigative
T16596	DRUGINFO	D06HVH	PMID22136433C20	Investigative
T16596	DRUGINFO	D06UKS	PMID21982499C14k	Investigative

T82262	TARGETID	T82262
T82262	FORMERID	TTDI03072
T82262	UNIPROID	KKCC2_HUMAN
T82262	TARGNAME	Calmodulin-dependent kinase II (CAMKK2)
T82262	GENENAME	CAMKK2
T82262	TARGTYPE	Patented-recorded
T82262	SYNONYMS	KIAA0787; Calcium/calmodulin-dependent protein kinase kinase beta; Calcium/calmodulin-dependent protein kinase kinase 2; CaMKK beta; CaMKK 2; CaM-kinase kinase beta; CaM-kinase kinase 2; CaM-KK beta; CaM-KK 2; CAMKKB
T82262	FUNCTION	Calcium/calmodulin-dependent protein kinase belonging to a proposed calcium-triggered signaling cascade involved in a number of cellular processes. Isoform 1, isoform 2 and isoform 3 phosphorylate CAMK1 and CAMK4. Isoform 3 phosphorylates CAMK1D. Isoform 4, isoform 5 and isoform 6 lacking part of the calmodulin-binding domain are inactive. Efficiently phosphorylates 5'-AMP-activated protein kinase (AMPK) trimer, including that consisting of PRKAA1, PRKAB1 and PRKAG1. This phosphorylation is stimulated in response to Ca(2+) signals (By similarity). Seems to be involved in hippocampal activation of CREB1 (By similarity). May play a role in neurite growth. Isoform 3 may promote neurite elongation, while isoform 1 may promoter neurite branching.
T82262	PDBSTRUC	6FEL; 6EWW; 6CMJ; 6BRC; 6BQQ
T82262	BIOCLASS	Kinase
T82262	ECNUMBER	EC 2.7.11.17
T82262	SEQUENCE	MSSCVSSQPSSNRAAPQDELGGRGSSSSESQKPCEALRGLSSLSIHLGMESFIVVTECEPGCAVDLGLARDRPLEADGQEVPLDTSGSQARPHLSGRKLSLQERSQGGLAAGGSLDMNGRCICPSLPYSPVSSPQSSPRLPRRPTVESHHVSITGMQDCVQLNQYTLKDEIGKGSYGVVKLAYNENDNTYYAMKVLSKKKLIRQAGFPRRPPPRGTRPAPGGCIQPRGPIEQVYQEIAILKKLDHPNVVKLVEVLDDPNEDHLYMVFELVNQGPVMEVPTLKPLSEDQARFYFQDLIKGIEYLHYQKIIHRDIKPSNLLVGEDGHIKIADFGVSNEFKGSDALLSNTVGTPAFMAPESLSETRKIFSGKALDVWAMGVTLYCFVFGQCPFMDERIMCLHSKIKSQALEFPDQPDIAEDLKDLITRMLDKNPESRIVVPEIKLHPWVTRHGAEPLPSEDENCTLVEVTEEEVENSVKHIPSLATVILVKTMIRKRSFGNPFEGSRREERSLSAPGNLLTKKPTRECESLSELKEARQRRQPPGHRPAPRGGGGSALVRGSPCVESCWAPAPGSPARMHPLRPEEAMEPE
T82262	DRUGINFO	D01UIJ	US9623028, Compound 101	Patented
T82262	DRUGINFO	D0PO8N	CQ7	Patented
T82262	DRUGINFO	D0XF1S	US9623028, Compound 79	Patented
T82262	DRUGINFO	D0HZ8U	STO609	Investigative
T82262	DRUGINFO	D06HVH	PMID22136433C20	Investigative

T11192	TARGETID	T11192
T11192	FORMERID	TTDR00889
T11192	UNIPROID	ADA33_HUMAN
T11192	TARGNAME	ADAM metallopeptidase 33 (ADAM33)
T11192	GENENAME	ADAM33
T11192	TARGTYPE	Patented-recorded
T11192	SYNONYMS	UNQ873/PRO1891; Disintegrin and metalloproteinase domain-containing protein 33; C20orf153; ADAM 33
T11192	FUNCTION	Membrane-anchored protein structurally related to snake venom disintegrins. Invovled in a variety of biological processes involving cell-cell and cell-matrix interactions, including fertilization, muscle development, and neurogenesis.
T11192	PDBSTRUC	1R55; 1R54
T11192	BIOCLASS	Peptidase
T11192	ECNUMBER	EC 3.4.24.-
T11192	SEQUENCE	MGWRPRRARGTPLLLLLLLLLLWPVPGAGVLQGHIPGQPVTPHWVLDGQPWRTVSLEEPVSKPDMGLVALEAEGQELLLELEKNHRLLAPGYIETHYGPDGQPVVLAPNHTDHCHYQGRVRGFPDSWVVLCTCSGMSGLITLSRNASYYLRPWPPRGSKDFSTHEIFRMEQLLTWKGTCGHRDPGNKAGMTSLPGGPQSRGRREARRTRKYLELYIVADHTLFLTRHRNLNHTKQRLLEVANYVDQLLRTLDIQVALTGLEVWTERDRSRVTQDANATLWAFLQWRRGLWAQRPHDSAQLLTGRAFQGATVGLAPVEGMCRAESSGGVSTDHSELPIGAAATMAHEIGHSLGLSHDPDGCCVEAAAESGGCVMAAATGHPFPRVFSACSRRQLRAFFRKGGGACLSNAPDPGLPVPPALCGNGFVEAGEECDCGPGQECRDLCCFAHNCSLRPGAQCAHGDCCVRCLLKPAGALCRQAMGDCDLPEFCTGTSSHCPPDVYLLDGSPCARGSGYCWDGACPTLEQQCQQLWGPGSHPAPEACFQVVNSAGDAHGNCGQDSEGHFLPCAGRDALCGKLQCQGGKPSLLAPHMVPVDSTVHLDGQEVTCRGALALPSAQLDLLGLGLVEPGTQCGPRMVCQSRRCRKNAFQELQRCLTACHSHGVCNSNHNCHCAPGWAPPFCDKPGFGGSMDSGPVQAENHDTFLLAMLLSVLLPLLPGAGLAWCCYRLPGAHLQRCSWGCRRDPACSGPKDGPHRDHPLGGVHPMELGPTATGQPWPLDPENSHEPSSHPEKPLPAVSPDPQADQVQMPRSCLW
T11192	DRUGINFO	D02XAR	US8772478, 5	Patented
T11192	DRUGINFO	D0NW8W	US8772478, 3	Patented
T11192	DRUGINFO	D0O1NA	US8772478, 1	Patented
T11192	DRUGINFO	D0Z7FD	US8772478, 2	Patented
T11192	DRUGINFO	D0W2UK	IK-862	Investigative
T11192	DRUGINFO	D07LUR	Alpha-D-Mannose	Investigative

T97537	TARGETID	T97537
T97537	FORMERID	TTDI03348
T97537	UNIPROID	LCAP_HUMAN
T97537	TARGNAME	Leucyl-cysteinyl aminopeptidase (LNPEP)
T97537	GENENAME	LNPEP
T97537	TARGTYPE	Patented-recorded
T97537	SYNONYMS	Placental leucine aminopeptidase; P-LAP; Oxytocinase; OTase; Leucyl-cystinyl aminopeptidase; Insulin-responsive aminopeptidase; Insulin-regulated membrane aminopeptidase; IRAP; Cystinyl aminopeptidase
T97537	FUNCTION	Degrades peptide hormones such as oxytocin, vasopressin and angiotensin III, and plays a role in maintaining homeostasis during pregnancy. May be involved in the inactivation of neuronal peptides in the brain. Cleaves Met-enkephalin and dynorphin. Binds angiotensin IV and may be the angiotensin IV receptor in the brain. Release of an N-terminal amino acid, cleaves before cysteine, leucine as well as other amino acids.
T97537	PDBSTRUC	5MJ6; 5JHQ; 5C97; 4Z7I; 4PJ6
T97537	BIOCLASS	Peptidase
T97537	ECNUMBER	EC 3.4.11.3
T97537	SEQUENCE	MEPFTNDRLQLPRNMIENSMFEEEPDVVDLAKEPCLHPLEPDEVEYEPRGSRLLVRGLGEHEMEEDEEDYESSAKLLGMSFMNRSSGLRNSATGYRQSPDGACSVPSARTMVVCAFVIVVAVSVIMVIYLLPRCTFTKEGCHKKNQSIGLIQPFATNGKLFPWAQIRLPTAVVPLRYELSLHPNLTSMTFRGSVTISVQALQVTWNIILHSTGHNISRVTFMSAVSSQEKQAEILEYAYHGQIAIVAPEALLAGHNYTLKIEYSANISSSYYGFYGFSYTDESNEKKYFAATQFEPLAARSAFPCFDEPAFKATFIIKIIRDEQYTALSNMPKKSSVVLDDGLVQDEFSESVKMSTYLVAFIVGEMKNLSQDVNGTLVSIYAVPEKIGQVHYALETTVKLLEFFQNYFEIQYPLKKLDLVAIPDFEAGAMENWGLLTFREETLLYDSNTSSMADRKLVTKIIAHELAHQWFGNLVTMKWWNDLWLNEGFATFMEYFSLEKIFKELSSYEDFLDARFKTMKKDSLNSSHPISSSVQSSEQIEEMFDSLSYFKGSSLLLMLKTYLSEDVFQHAVVLYLHNHSYASIQSDDLWDSFNEVTNQTLDVKRMMKTWTLQKGFPLVTVQKKGKELFIQQERFFLNMKPEIQPSDTSYLWHIPLSYVTEGRNYSKYQSVSLLDKKSGVINLTEEVLWVKVNINMNGYYIVHYADDDWEALIHQLKINPYVLSDKDRANLINNIFELAGLGKVPLKRAFDLINYLGNENHTAPITEALFQTDLIYNLLEKLGYMDLASRLVTRVFKLLQNQIQQQTWTDEGTPSMRELRSALLEFACTHNLGNCSTTAMKLFDDWMASNGTQSLPTDVMTTVFKVGAKTDKGWSFLLGKYISIGSEAEKNKILEALASSEDVRKLYWLMKSSLNGDNFRTQKLSFIIRTVGRHFPGHLLAWDFVKENWNKLVQKFPLGSYTIQNIVAGSTYLFSTKTHLSEVQAFFENQSEATFRLRCVQEALEVIQLNIQWMEKNLKSLTWWL
T97537	DRUGINFO	D04AFR	US10059720, Example 80	Patented
T97537	DRUGINFO	D05ZEZ	US10059720, Example 82	Patented
T97537	DRUGINFO	D06JLW	US10059720, Example 84	Patented
T97537	DRUGINFO	D0HO8O	US10023583, Example 5	Patented
T97537	DRUGINFO	D0IC5Y	US10023583, Example 24	Patented
T97537	DRUGINFO	D0V4YX	US10023583, Example 13	Patented
T97537	DRUGINFO	D0X2XN	US10023583, Example 8	Patented
T97537	DRUGINFO	D04DTE	inhibitor 19	Investigative
T97537	DRUGINFO	D02MNM	PMID23916253C17	Investigative

T52888	TARGETID	T52888
T52888	FORMERID	TTDI02158
T52888	UNIPROID	RGS16_HUMAN
T52888	TARGNAME	Regulator of G-protein signaling 16 (RGS16)
T52888	GENENAME	RGS16
T52888	TARGTYPE	Patented-recorded
T52888	SYNONYMS	hRGS-r; Retinally abundant regulator of G-protein signaling; Retinal-specific RGS; RGSR; RGS-r; A28-RGS14P
T52888	FUNCTION	Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits, thereby driving them into their inactive GDP-bound form. Plays an important role in the phototransduction cascade by regulating the lifetime and effective concentration of activated transducin alpha. May regulate extra and intracellular mitogenic signals. Regulates G protein-coupled receptor signaling cascades.
T52888	PDBSTRUC	2IK8; 2BT2
T52888	SEQUENCE	MCRTLAAFPTTCLERAKEFKTRLGIFLHKSELGCDTGSTGKFEWGSKHSKENRNFSEDVLGWRESFDLLLSSKNGVAAFHAFLKTEFSEENLEFWLACEEFKKIRSATKLASRAHQIFEEFICSEAPKEVNIDHETHELTRMNLQTATATCFDAAQGKTRTLMEKDSYPRFLKSPAYRDLAAQASAASATLSSCSLDEPSHT

T42881	TARGETID	T42881
T42881	FORMERID	TTDR00590
T42881	UNIPROID	SCAF_HCMVA
T42881	TARGNAME	Cytomegalovirus Protease (CMV UL80)
T42881	GENENAME	CMV UL80
T42881	TARGTYPE	Patented-recorded
T42881	SYNONYMS	UL80; Capsid protein P40; Assemblin
T42881	FUNCTION	Assembly protein plays a major role in capsid assembly. Acts as a scaffold protein by binding major capsid protein UL86. Multimerizes in the nucleus such as protein UL86 forms the icosahedral T=16 capsid. Cleaved by assemblin after capsid completion. The cleavages products are evicted from the capsid before or during DNA packaging.
T42881	PDBSTRUC	2WPO; 1WPO; 1NKM; 1NKK; 1NJU
T42881	BIOCLASS	Peptidase
T42881	SEQUENCE	MTMDEQQSQAVAPVYVGGFLARYDQSPDEAELLLPRDVVEHWLHAQGQGQPSLSVALPLNINHDDTAVVGHVAAMQSVRDGLFCLGCVTSPRFLEIVRRASEKSELVSRGPVSPLQPDKVVEFLSGSYAGLSLSSRRCDDVEAATSLSGSETTPFKHVALCSVGRRRGTLAVYGRDPEWVTQRFPDLTAADRDGLRAQWQRCGSTAVDASGDPFRSDSYGLLGNSVDALYIRERLPKLRYDKQLVGVTERESYVKASVSPEAACDIKAASAERSGDSRSQAATPAAGARVPSSSPSPPVEPPSPVQPPALPASPSVLPAESPPSLSPSEPAEAASMSHPLSAAVPAATAPPGATVAGASPAVSSLAWPHDGVYLPKDAFFSLLGASRSAVPVMYPGAVAAPPSASPAPLPLPSYPASYGAPVVGYDQLAARHFADYVDPHYPGWGRRYEPAPSLHPSYPVPPPPSPAYYRRRDSPGGMDEPPSGWERYDGGHRGQSQKQHRHGGSGGHNKRRKETAAASSSSSDEDLSFPGEAEHGRARKRLKSHVNSDGGSGGHAGSNQQQQQRYDELRDAIHELKRDLFAARQSSTLLSAALPSAASSSPTTTTVCTPTGELTSGGGETPTALLSGGAKVAERAQAGVVNASCRLATASGSEAATAGPSTAGSSSCPASVVLAAAAAQAAAASQSPPKDMVDLNRRIFVAALNKLE
T42881	DRUGINFO	D0N6ZR	US10071110, Compound cCDV	Patented
T42881	DRUGINFO	D0XA0Y	C06909	Patented
T42881	DRUGINFO	D08ROT	N-(1-PHENYL-PROPYL)-FORMAMIDE	Investigative
T42881	DRUGINFO	D0Y0FC	O-Benzylsulfonyl-Serine	Investigative
T42881	DRUGINFO	D0NL4Z	Monoisopropyl Ester Phosphonic Acid Group	Investigative
T42881	DRUGINFO	D08TGY	S-(Dimethylarsenic)Cysteine	Investigative

T81780	TARGETID	T81780
T81780	FORMERID	TTDR01334
T81780	UNIPROID	UBA1_HUMAN
T81780	TARGNAME	Ubiquitin-activating enzyme E1 (UBAE1)
T81780	GENENAME	UBA1
T81780	TARGTYPE	Patented-recorded
T81780	SYNONYMS	Ubiquitin-like modifier-activating enzyme 1; UBE1; Protein A1S9; A1S9T
T81780	FUNCTION	Catalyzes the first step in ubiquitin conjugation to mark cellular proteins for degradation through the ubiquitin-proteasome system. Activates ubiquitin by first adenylating its C-terminal glycine residue with ATP, and thereafter linking this residue to the side chain of a cysteine residue in E1, yielding a ubiquitin-E1 thioester and free AMP. Essential for the formation of radiation-induced foci, timely DNA repair and for response to replication stress. Promotes the recruitment of TP53BP1 and BRCA1 at DNA damage sites.
T81780	PDBSTRUC	6DC6; 4P22
T81780	ECNUMBER	EC 6.2.1.45
T81780	SEQUENCE	MSSSPLSKKRRVSGPDPKPGSNCSPAQSVLSEVPSVPTNGMAKNGSEADIDEGLYSRQLYVLGHEAMKRLQTSSVLVSGLRGLGVEIAKNIILGGVKAVTLHDQGTAQWADLSSQFYLREEDIGKNRAEVSQPRLAELNSYVPVTAYTGPLVEDFLSGFQVVVLTNTPLEDQLRVGEFCHNRGIKLVVADTRGLFGQLFCDFGEEMILTDSNGEQPLSAMVSMVTKDNPGVVTCLDEARHGFESGDFVSFSEVQGMVELNGNQPMEIKVLGPYTFSICDTSNFSDYIRGGIVSQVKVPKKISFKSLVASLAEPDFVVTDFAKFSRPAQLHIGFQALHQFCAQHGRPPRPRNEEDAAELVALAQAVNARALPAVQQNNLDEDLIRKLAYVAAGDLAPINAFIGGLAAQEVMKACSGKFMPIMQWLYFDALECLPEDKEVLTEDKCLQRQNRYDGQVAVFGSDLQEKLGKQKYFLVGAGAIGCELLKNFAMIGLGCGEGGEIIVTDMDTIEKSNLNRQFLFRPWDVTKLKSDTAAAAVRQMNPHIRVTSHQNRVGPDTERIYDDDFFQNLDGVANALDNVDARMYMDRRCVYYRKPLLESGTLGTKGNVQVVIPFLTESYSSSQDPPEKSIPICTLKNFPNAIEHTLQWARDEFEGLFKQPAENVNQYLTDPKFVERTLRLAGTQPLEVLEAVQRSLVLQRPQTWADCVTWACHHWHTQYSNNIRQLLHNFPPDQLTSSGAPFWSGPKRCPHPLTFDVNNPLHLDYVMAAANLFAQTYGLTGSQDRAAVATFLQSVQVPEFTPKSGVKIHVSDQELQSANASVDDSRLEELKATLPSPDKLPGFKMYPIDFEKDDDSNFHMDFIVAASNLRAENYDIPSADRHKSKLIAGKIIPAIATTTAAVVGLVCLELYKVVQGHRQLDSYKNGFLNLALPFFGFSEPLAAPRHQYYNQEWTLWDRFEVQGLQPNGEEMTLKQFLDYFKTEHKLEITMLSQGVSMLYSFFMPAAKLKERLDQPMTEIVSRVSKRKLGRHVRALVLELCCNDESGEDVEVPYVRYTIR
T81780	DRUGINFO	D0P3PT	SCHEMBL15198145	Patented
T81780	DRUGINFO	D0QQ3B	SCHEMBL15198146	Patented
T81780	DRUGINFO	D0YE0V	QCPOIDRINIAUKU-SRBBEKPSSA-N	Patented
T81780	DRUGINFO	D0A0YZ	PYZD-4409	Investigative

T12241	TARGETID	T12241
T12241	FORMERID	TTDI03149
T12241	UNIPROID	CGL_HUMAN
T12241	TARGNAME	Cystathionine gamma-lyase (CTH)
T12241	GENENAME	CTH
T12241	TARGTYPE	Patented-recorded
T12241	SYNONYMS	Gamma-cystathionase; Cysteine-protein sulfhydrase
T12241	FUNCTION	Catalyzes the last step in the trans-sulfuration pathway from methionine to cysteine. Has broad substrate specificity. Converts cystathionine to cysteine, ammonia and 2-oxobutanoate. Converts two cysteine molecules to lanthionine and hydrogen sulfide. Can also accept homocysteine as substrate. Specificity depends on the levels of the endogenous substrates. Generates the endogenous signaling molecule hydrogen sulfide (H2S), and so contributes to the regulation of blood pressure. Acts as a cysteine-protein sulfhydrase by mediating sulfhydration of target proteins: sulfhydration consists of converting -SH groups into -SSH on specific cysteine residues of target proteins such as GAPDH, PTPN1 and NF-kappa-B subunit RELA, thereby regulating their function.
T12241	PDBSTRUC	5TT2; 5TSU; 5EIG; 3ELP; 3COG
T12241	ECNUMBER	EC 4.4.1.1
T12241	SEQUENCE	MQEKDASSQGFLPHFQHFATQAIHVGQDPEQWTSRAVVPPISLSTTFKQGAPGQHSGFEYSRSGNPTRNCLEKAVAALDGAKYCLAFASGLAATVTITHLLKAGDQIICMDDVYGGTNRYFRQVASEFGLKISFVDCSKIKLLEAAITPETKLVWIETPTNPTQKVIDIEGCAHIVHKHGDIILVVDNTFMSPYFQRPLALGADISMYSATKYMNGHSDVVMGLVSVNCESLHNRLRFLQNSLGAVPSPIDCYLCNRGLKTLHVRMEKHFKNGMAVAQFLESNPWVEKVIYPGLPSHPQHELVKRQCTGCTGMVTFYIKGTLQHAEIFLKNLKLFTLAESLGGFESLAELPAIMTHASVLKNDRDVLGISDTLIRLSVGLEDEEDLLEDLDQALKAAHPPSGSHS
T12241	DRUGINFO	D06BHM	AKOS003197197	Patented
T12241	DRUGINFO	D0BB4J	Hydrazinoacetic acid	Patented
T12241	DRUGINFO	D0EC1A	5-Hydrazino-1H-tetrazole	Patented
T12241	DRUGINFO	D06HNS	propargylglycine	Investigative

T69612	TARGETID	T69612
T69612	FORMERID	TTDI03205
T69612	UNIPROID	GRK5_HUMAN
T69612	TARGNAME	G protein-coupled receptor kinase 5 (GRK5)
T69612	GENENAME	GRK5
T69612	TARGTYPE	Patented-recorded
T69612	SYNONYMS	GPRK5; G protein-coupled receptor kinase GRK5
T69612	FUNCTION	Serine/threonine kinase that phosphorylates preferentially the activated forms of a variety of G-protein-coupled receptors (GPCRs). Such receptor phosphorylation initiates beta-arrestin-mediated receptor desensitization, internalization, and signaling events leading to their down-regulation. Phosphorylates a variety of GPCRs, including adrenergic receptors, muscarinic acetylcholine receptors (more specifically Gi-coupled M2/M4 subtypes), dopamine receptors and opioid receptors. In addition to GPCRs, also phosphorylates various substrates: Hsc70-interacting protein/ST13, TP53/p53, HDAC5, and arrestin-1/ARRB1. Phosphorylation of ARRB1 by GRK5 inhibits G-protein independent MAPK1/MAPK3 signaling downstream of 5HT4-receptors. Phosphorylation of HDAC5, a repressor of myocyte enhancer factor 2 (MEF2) leading to nuclear export of HDAC5 and allowing MEF2-mediated transcription. Phosphorylation of TP53/p53, a crucial tumor suppressor, inhibits TP53/p53-mediated apoptosis. Phosphorylation of ST13 regulates internalization of the chemokine receptor. Phosphorylates rhodopsin (RHO) (in vitro) and a non G-protein-coupled receptor, LRP6 during Wnt signaling (in vitro).
T69612	PDBSTRUC	4TND; 4TNB
T69612	ECNUMBER	EC 2.7.11.16
T69612	SEQUENCE	MELENIVANTVLLKAREGGGGKRKGKSKKWKEILKFPHISQCEDLRRTIDRDYCSLCDKQPIGRLLFRQFCETRPGLECYIQFLDSVAEYEVTPDEKLGEKGKEIMTKYLTPKSPVFIAQVGQDLVSQTEEKLLQKPCKELFSACAQSVHEYLRGEPFHEYLDSMFFDRFLQWKWLERQPVTKNTFRQYRVLGKGGFGEVCACQVRATGKMYACKRLEKKRIKKRKGESMALNEKQILEKVNSQFVVNLAYAYETKDALCLVLTIMNGGDLKFHIYNMGNPGFEEERALFYAAEILCGLEDLHRENTVYRDLKPENILLDDYGHIRISDLGLAVKIPEGDLIRGRVGTVGYMAPEVLNNQRYGLSPDYWGLGCLIYEMIEGQSPFRGRKEKVKREEVDRRVLETEEVYSHKFSEEAKSICKMLLTKDAKQRLGCQEEGAAEVKRHPFFRNMNFKRLEAGMLDPPFVPDPRAVYCKDVLDIEQFSTVKGVNLDHTDDDFYSKFSTGSVSIPWQNEMIETECFKELNVFGPNGTLPPDLNRNHPPEPPKKGLLQRLFKRQHQNNSKSSPSSKTSFNHHINSNHVSSNSTGSS
T69612	DRUGINFO	D00YYO	BDBM50173323	Patented
T69612	DRUGINFO	D05PTF	BDBM50173330	Patented
T69612	DRUGINFO	D0U5IW	BDBM50173327	Patented
T69612	DRUGINFO	D04CUA	PMID24210504C1o	Investigative

T47594	TARGETID	T47594
T47594	FORMERID	TTDI03011
T47594	UNIPROID	ACV1B_HUMAN
T47594	TARGNAME	Activin receptor type IB (ACVR1B)
T47594	GENENAME	ACVR1B
T47594	TARGTYPE	Patented-recorded
T47594	SYNONYMS	Serine/threonine-protein kinase receptor R2; SKR2; Activin receptor-like kinase 4; Activin receptor type-1B; ALK4; ALK-4; ACVRLK4; ACTR-IB
T47594	FUNCTION	Transduces the activin signal from the cell surface to the cytoplasm and is thus regulating a many physiological and pathological processes including neuronal differentiation and neuronal survival, hair follicle development and cycling, FSH production by the pituitary gland, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. Activin is also thought to have a paracrine or autocrine role in follicular development in the ovary. Within the receptor complex, type-2 receptors (ACVR2A and/or ACVR2B) act as a primary activin receptors whereas the type-1 receptors like ACVR1B act as downstream transducers of activin signals. Activin binds to type-2 receptor at the plasma membrane and activates its serine-threonine kinase. The activated receptor type-2 then phosphorylates and activates the type-1 receptor such as ACVR1B. Once activated, the type-1 receptor binds and phosphorylates the SMAD proteins SMAD2 and SMAD3, on serine residues of the C-terminal tail. Soon after their association with the activin receptor and subsequent phosphorylation, SMAD2 and SMAD3 are released into the cytoplasm where they interact with the common partner SMAD4. This SMAD complex translocates into the nucleus where it mediates activin-induced transcription. Inhibitory SMAD7, which is recruited to ACVR1B through FKBP1A, can prevent the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal. Activin signal transduction is also antagonized by the binding to the receptor of inhibin-B via the IGSF1 inhibin coreceptor. ACVR1B also phosphorylates TDP2. Transmembrane serine/threonine kinase activin type-1 receptor forming an activin receptor complex with activin receptor type-2 (ACVR2A or ACVR2B).
T47594	BIOCLASS	Kinase
T47594	ECNUMBER	EC 2.7.11.30
T47594	SEQUENCE	MAESAGASSFFPLVVLLLAGSGGSGPRGVQALLCACTSCLQANYTCETDGACMVSIFNLDGMEHHVRTCIPKVELVPAGKPFYCLSSEDLRNTHCCYTDYCNRIDLRVPSGHLKEPEHPSMWGPVELVGIIAGPVFLLFLIIIIVFLVINYHQRVYHNRQRLDMEDPSCEMCLSKDKTLQDLVYDLSTSGSGSGLPLFVQRTVARTIVLQEIIGKGRFGEVWRGRWRGGDVAVKIFSSREERSWFREAEIYQTVMLRHENILGFIAADNKDNGTWTQLWLVSDYHEHGSLFDYLNRYTVTIEGMIKLALSAASGLAHLHMEIVGTQGKPGIAHRDLKSKNILVKKNGMCAIADLGLAVRHDAVTDTIDIAPNQRVGTKRYMAPEVLDETINMKHFDSFKCADIYALGLVYWEIARRCNSGGVHEEYQLPYYDLVPSDPSIEEMRKVVCDQKLRPNIPNWWQSYEALRVMGKMMRECWYANGAARLTALRIKKTLSQLSVQEDVKI
T47594	DRUGINFO	D01RXV	US9682983, 1	Patented
T47594	DRUGINFO	D05YMG	BDBM108945	Patented
T47594	DRUGINFO	D0E9VJ	US10030004, Compound 19	Patented
T47594	DRUGINFO	D0F7CA	US9682983, 33	Patented
T47594	DRUGINFO	D0IA7H	US10030004, Compound 33	Patented
T47594	DRUGINFO	D0Z9FM	US10030004, Compound 11a	Patented
T47594	DRUGINFO	D05NEC	PMID23639540C13r	Investigative
T47594	DRUGINFO	D0F2MP	PMID23639540C13d	Investigative

T52447	TARGETID	T52447
T52447	FORMERID	TTDR00907
T52447	UNIPROID	PPID_HUMAN
T52447	TARGNAME	Rotamase D (PPID)
T52447	GENENAME	PPID
T52447	TARGTYPE	Patented-recorded
T52447	SYNONYMS	Peptidylprolyl isomerase D; Peptidyl-prolyl cis-trans isomerase D; PPIase D; Cyclophilin-related protein; Cyclophilin-40; CYP40; CYP-40; 40 kDa peptidyl-prolyl cis-trans isomerase
T52447	FUNCTION	Proposed to act as a co-chaperone in HSP90 complexes such as in unligated steroid receptors heterocomplexes. Different co-chaperones seem to compete for association with HSP90 thus establishing distinct HSP90-co-chaperone-receptor complexes with the potential to exert tissue-specific receptor activity control. May have a preference for estrogen receptor complexes and is not found in glucocorticoid receptor complexes. May be involved in cytoplasmic dynein-dependent movement of the receptor from the cytoplasm to the nucleus. May regulate MYB by inhibiting its DNA-binding activity. Involved in regulation of AHR signaling by promoting the formation of the AHR:ARNT dimer; the function is independent of HSP90 but requires the chaperone activity. Involved in regulation of UV radiation-induced apoptosis. Promotes cell viability in anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma (ALK+ ALCL) cell lines. PPIase that catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides and may therefore assist protein folding.
T52447	BIOCLASS	Cis-trans-isomerase
T52447	ECNUMBER	EC 5.2.1.8
T52447	SEQUENCE	MSHPSPQAKPSNPSNPRVFFDVDIGGERVGRIVLELFADIVPKTAENFRALCTGEKGIGHTTGKPLHFKGCPFHRIIKKFMIQGGDFSNQNGTGGESIYGEKFEDENFHYKHDREGLLSMANAGRNTNGSQFFITTVPTPHLDGKHVVFGQVIKGIGVARILENVEVKGEKPAKLCVIAECGELKEGDDGGIFPKDGSGDSHPDFPEDADIDLKDVDKILLITEDLKNIGNTFFKSQNWEMAIKKYAEVLRYVDSSKAVIETADRAKLQPIALSCVLNIGACKLKMSNWQGAIDSCLEALELDPSNTKALYRRAQGWQGLKEYDQALADLKKAQGIAPEDKAIQAELLKVKQKIKAQKDKEKAVYAKMFA
T52447	DRUGINFO	D08YMT	US8901295, F609	Patented
T52447	DRUGINFO	D0KO5D	US8901295, F673	Patented
T52447	DRUGINFO	D0M2OY	1313212-89-3	Patented

T85115	TARGETID	T85115
T85115	FORMERID	TTDI02521
T85115	UNIPROID	PKR1_HUMAN
T85115	TARGNAME	Prokineticin receptor-1 (PROKR1)
T85115	GENENAME	PROKR1
T85115	TARGTYPE	Patented-recorded
T85115	SYNONYMS	Prokineticin receptor 1; PROKR1; Gprotein coupled receptor ZAQ; Gprotein coupled receptor 73; GPR73a
T85115	FUNCTION	Receptor for prokineticin 1. Exclusively coupled to the G(q) subclass of heteromeric G proteins. Activation leads to mobilization of calcium, stimulation of phosphoinositide turnover and activation of p44/p42 mitogen-activated protein kinase. May play a role during early pregnancy.
T85115	BIOCLASS	GPCR rhodopsin
T85115	SEQUENCE	METTMGFMDDNATNTSTSFLSVLNPHGAHATSFPFNFSYSDYDMPLDEDEDVTNSRTFFAAKIVIGMALVGIMLVCGIGNFIFIAALVRYKKLRNLTNLLIANLAISDFLVAIVCCPFEMDYYVVRQLSWEHGHVLCTSVNYLRTVSLYVSTNALLAIAIDRYLAIVHPLRPRMKCQTATGLIALVWTVSILIAIPSAYFTTETVLVIVKSQEKIFCGQIWPVDQQLYYKSYFLFIFGIEFVGPVVTMTLCYARISRELWFKAVPGFQTEQIRKRLRCRRKTVLVLMCILTAYVLCWAPFYGFTIVRDFFPTVFVKEKHYLTAFYIVECIAMSNSMINTLCFVTVKNDTVKYFKKIMLLHWKASYNGGKSSADLDLKTIGMPATEEVDCIRLK
T85115	DRUGINFO	D00LHT	US9475795, 80	Patented
T85115	DRUGINFO	D04LJF	ZINC19658740	Patented
T85115	DRUGINFO	D0U5VO	US9475795, 89	Patented
T85115	DRUGINFO	D0X1ZY	US9475795, 19	Patented
T85115	DRUGINFO	D0P5QU	IS1	Investigative
T85115	DRUGINFO	D0R5NA	IS20	Investigative
T85115	DRUGINFO	D02VQO	triazine compound PC10	Investigative

T11241	TARGETID	T11241
T11241	FORMERID	TTDI02523
T11241	UNIPROID	S1PR3_HUMAN
T11241	TARGNAME	Sphingosine-1-phosphate receptor 3 (S1PR3)
T11241	GENENAME	S1PR3
T11241	TARGTYPE	Patented-recorded
T11241	SYNONYMS	Sphingosine 1-phosphate receptor Edg-3; S1PR3; S1P3; S1P receptor Edg-3; S1P receptor 3; Endothelial differentiation G-protein coupled receptor 3
T11241	FUNCTION	Receptor for the lysosphingolipid sphingosine 1- phosphate (S1P). S1P is a bioactive lysophospholipid that elicits diverse physiological effect on most types of cells and tissues. When expressed in rat HTC4 hepatoma cells, is capable of mediating S1P-induced cell proliferation and suppression of apoptosis.
T11241	BIOCLASS	GPCR rhodopsin
T11241	SEQUENCE	MATALPPRLQPVRGNETLREHYQYVGKLAGRLKEASEGSTLTTVLFLVICSFIVLENLMVLIAIWKNNKFHNRMYFFIGNLALCDLLAGIAYKVNILMSGKKTFSLSPTVWFLREGSMFVALGASTCSLLAIAIERHLTMIKMRPYDANKRHRVFLLIGMCWLIAFTLGALPILGWNCLHNLPDCSTILPLYSKKYIAFCISIFTAILVTIVILYARIYFLVKSSSRKVANHNNSERSMALLRTVVIVVSVFIACWSPLFILFLIDVACRVQACPILFKAQWFIVLAVLNSAMNPVIYTLASKEMRRAFFRLVCNCLVRGRGARASPIQPALDPSRSKSSSSNNSSHSPKVKEDLPHTAPSSCIMDKNAALQNGIFCN
T11241	DRUGINFO	D02WVW	US9522888, 575	Patented
T11241	DRUGINFO	D04NEO	US9617250, Example 1 Example 204 of D1	Patented
T11241	DRUGINFO	D04UXN	YYDJCLCSBYCSCO-UHFFFAOYSA-N	Patented
T11241	DRUGINFO	D06DRH	US9216972, 61	Patented
T11241	DRUGINFO	D07JOR	US9670220, 77	Patented
T11241	DRUGINFO	D08BFF	US10179791, Compound 296	Patented
T11241	DRUGINFO	D09LDU	JCXGHZCWAHCYGY-UHFFFAOYSA-N	Patented
T11241	DRUGINFO	D09RDP	US9216972, 67	Patented
T11241	DRUGINFO	D09SKG	US10166249, Example 695	Patented
T11241	DRUGINFO	D0A0VI	US9181182, 40	Patented
T11241	DRUGINFO	D0AK7K	US9187437, 8	Patented
T11241	DRUGINFO	D0CV8R	US8524917, 12	Patented
T11241	DRUGINFO	D0E5OA	US9522888, 412	Patented
T11241	DRUGINFO	D0EP8Y	BDBM50080563	Patented
T11241	DRUGINFO	D0F4TB	US8563594, 152	Patented
T11241	DRUGINFO	D0HW8T	BDBM50080570	Patented
T11241	DRUGINFO	D0I5TH	MHHFJYABEVJNEG-UHFFFAOYSA-N	Patented
T11241	DRUGINFO	D0IL0J	US9522888, 695	Patented
T11241	DRUGINFO	D0K8FK	US8524917, 11	Patented
T11241	DRUGINFO	D0LT2N	ZNFTXQFGUIKQQE-UHFFFAOYSA-N	Patented
T11241	DRUGINFO	D0LT5U	US10179791, Compound 171	Patented
T11241	DRUGINFO	D0MH3Y	US9181182, 34	Patented
T11241	DRUGINFO	D0O4RX	US10179791, Compound 176	Patented
T11241	DRUGINFO	D0OH0T	US9522888, 618	Patented
T11241	DRUGINFO	D0OW3S	US9187437, 38	Patented
T11241	DRUGINFO	D0Q4XE	US9670220, 33	Patented
T11241	DRUGINFO	D0R7ED	BDBM50080559	Patented
T11241	DRUGINFO	D0RL7G	US8524917, 60	Patented
T11241	DRUGINFO	D0RQ0B	US9187437, 24	Patented
T11241	DRUGINFO	D0S0MC	US8524917, 10	Patented
T11241	DRUGINFO	D0T4SV	US9216972, 132	Patented
T11241	DRUGINFO	D0U4IE	US9181182, 47	Patented
T11241	DRUGINFO	D0VJ8Y	US9707205, 40	Patented
T11241	DRUGINFO	D0WA4F	US9216972, 94	Patented
T11241	DRUGINFO	D0WC1D	US9670220, 76	Patented
T11241	DRUGINFO	D0Q2HM	EDD7H9	Preclinical
T11241	DRUGINFO	D05EDD	VPC23019	Investigative
T11241	DRUGINFO	D06GFH	VPC44116	Investigative
T11241	DRUGINFO	D0PI4H	VPC12249	Investigative
T11241	DRUGINFO	D05KEE	AFD(R)	Investigative
T11241	DRUGINFO	D06DYN	FTY720-phosphate	Investigative
T11241	DRUGINFO	D0W1ZW	VPC03090-P	Investigative
T11241	DRUGINFO	D03BRM	AUY954	Investigative

T10118	TARGETID	T10118
T10118	FORMERID	TTDI03111
T10118	UNIPROID	CTRC_HUMAN
T10118	TARGNAME	Chymotrypsin-C (CLCR)
T10118	GENENAME	CTRC
T10118	TARGTYPE	Patented-recorded
T10118	SYNONYMS	Caldecrin; CLCR
T10118	FUNCTION	Regulates activation and degradation of trypsinogens and procarboxypeptidases by targeting specific cleavage sites within their zymogen precursors. Has chymotrypsin-type protease activity and hypocalcemic activity.
T10118	PDBSTRUC	4H4F
T10118	ECNUMBER	EC 3.4.21.2
T10118	SEQUENCE	MLGITVLAALLACASSCGVPSFPPNLSARVVGGEDARPHSWPWQISLQYLKNDTWRHTCGGTLIASNFVLTAAHCISNTRTYRVAVGKNNLEVEDEEGSLFVGVDTIHVHKRWNALLLRNDIALIKLAEHVELSDTIQVACLPEKDSLLPKDYPCYVTGWGRLWTNGPIADKLQQGLQPVVDHATCSRIDWWGFRVKKTMVCAGGDGVISACNGDSGGPLNCQLENGSWEVFGIVSFGSRRGCNTRKKPVVYTRVSAYIDWINEKMQL
T10118	DRUGINFO	D00PVE	Z223457004	Patented
T10118	DRUGINFO	D01IXT	STK296197	Patented
T10118	DRUGINFO	D05CJM	Z90308237	Patented
T10118	DRUGINFO	D0P0OH	AC1LCOK0	Patented
T10118	DRUGINFO	D0Q7ST	PMID12372533C20	Investigative

T50773	TARGETID	T50773
T50773	FORMERID	TTDI03155
T50773	UNIPROID	DPP2_HUMAN
T50773	TARGNAME	Dipeptidyl-peptidase 7 (DPP7)
T50773	GENENAME	DPP7
T50773	TARGTYPE	Patented-recorded
T50773	SYNONYMS	Quiescent cell proline dipeptidase; QPP; Dipeptidyl peptidase II; Dipeptidyl peptidase 7; Dipeptidyl peptidase 2; Dipeptidyl aminopeptidase II; DPP2; DPP II
T50773	FUNCTION	Plays an important role in the degradation of some oligopeptides.
T50773	PDBSTRUC	4EBB; 3N0T; 3JYH
T50773	ECNUMBER	EC 3.4.14.2
T50773	SEQUENCE	MGSAPWAPVLLLALGLRGLQAGARRAPDPGFQERFFQQRLDHFNFERFGNKTFPQRFLVSDRFWVRGEGPIFFYTGNEGDVWAFANNSAFVAELAAERGALLVFAEHRYYGKSLPFGAQSTQRGHTELLTVEQALADFAELLRALRRDLGAQDAPAIAFGGSYGGMLSAYLRMKYPHLVAGALAASAPVLAVAGLGDSNQFFRDVTADFEGQSPKCTQGVREAFRQIKDLFLQGAYDTVRWEFGTCQPLSDEKDLTQLFMFARNAFTVLAMMDYPYPTDFLGPLPANPVKVGCDRLLSEAQRITGLRALAGLVYNASGSEHCYDIYRLYHSCADPTGCGTGPDARAWDYQACTEINLTFASNNVTDMFPDLPFTDELRQRYCLDTWGVWPRPDWLLTSFWGGDLRAASNIIFSNGNLDPWAGGGIRRNLSASVIAVTIQGGAHHLDLRASHPEDPASVVEARKLEATIIGEWVKAARREQQPALRGGPRLSL
T50773	DRUGINFO	D05FMP	BDBM50382283	Patented
T50773	DRUGINFO	D07JHU	BDBM50434165	Patented
T50773	DRUGINFO	D0C6NX	BDBM50434164	Patented
T50773	DRUGINFO	D0M6CN	US8470836, 5	Patented
T50773	DRUGINFO	D0MF7O	US8470836, 8	Patented
T50773	DRUGINFO	D0QX2U	CRWCYVOHVXAEMF-LBPRGKRZSA-N	Patented
T50773	DRUGINFO	D0S8CH	US8470836, 2	Patented
T50773	DRUGINFO	D0SH7G	US8470836, 6	Patented
T50773	DRUGINFO	D07ALM	N4-(4-chlorobenzyl)-2,4-diaminobutanoylpiperidine	Investigative

T95878	TARGETID	T95878
T95878	FORMERID	TTDI03522
T95878	UNIPROID	KS6A6_HUMAN
T95878	TARGNAME	Ribosomal protein S6 kinase alpha-6 (RSK6)
T95878	GENENAME	RPS6KA6
T95878	TARGTYPE	Patented-recorded
T95878	SYNONYMS	pp90RSK4; p90RSK6; p90-RSK 6; S6K-alpha-6; Ribosomal S6 kinase 4; RSK4; RSK-4; 90 kDa ribosomal protein S6 kinase 6
T95878	FUNCTION	Constitutively active serine/threonine-protein kinase that exhibits growth-factor-independent kinase activity and that may participate in p53/TP53-dependent cell growth arrest signaling and play an inhibitory role during embryogenesis.
T95878	PDBSTRUC	6G78; 6G77; 6G76
T95878	ECNUMBER	EC 2.7.11.1
T95878	SEQUENCE	MLPFAPQDEPWDREMEVFSGGGASSGEVNGLKMVDEPMEEGEADSCHDEGVVKEIPITHHVKEGYEKADPAQFELLKVLGQGSFGKVFLVRKKTGPDAGQLYAMKVLKKASLKVRDRVRTKMERDILVEVNHPFIVKLHYAFQTEGKLYLILDFLRGGDVFTRLSKEVLFTEEDVKFYLAELALALDHLHQLGIVYRDLKPENILLDEIGHIKLTDFGLSKESVDQEKKAYSFCGTVEYMAPEVVNRRGHSQSADWWSYGVLMFEMLTGTLPFQGKDRNETMNMILKAKLGMPQFLSAEAQSLLRMLFKRNPANRLGSEGVEEIKRHLFFANIDWDKLYKREVQPPFKPASGKPDDTFCFDPEFTAKTPKDSPGLPASANAHQLFKGFSFVATSIAEEYKITPITSANVLPIVQINGNAAQFGEVYELKEDIGVGSYSVCKRCIHATTNMEFAVKIIDKSKRDPSEEIEILMRYGQHPNIITLKDVFDDGRYVYLVTDLMKGGELLDRILKQKCFSEREASDILYVISKTVDYLHCQGVVHRDLKPSNILYMDESASADSIRICDFGFAKQLRGENGLLLTPCYTANFVAPEVLMQQGYDAACDIWSLGVLFYTMLAGYTPFANGPNDTPEEILLRIGNGKFSLSGGNWDNISDGAKDLLSHMLHMDPHQRYTAEQILKHSWITHRDQLPNDQPKRNDVSHVVKGAMVATYSALTHKTFQPVLEPVAASSLAQRRSMKKRTSTGL
T95878	DRUGINFO	D0X7ZB	US10081632, Compound 25	Patented
T95878	DRUGINFO	D0Z6IH	CID 138805970	Patented
T95878	DRUGINFO	D02VBF	BI-D1870	Preclinical
T95878	DRUGINFO	D09AID	PMID22564207C25b	Investigative

T09874	TARGETID	T09874
T09874	FORMERID	TTDR01382
T09874	UNIPROID	POLG_HCV1
T09874	TARGNAME	Hepatitis C virus Core protein messenger RNA (HCV Core mRNA)
T09874	GENENAME	HCV Core mRNA
T09874	TARGTYPE	Patented-recorded
T09874	SYNONYMS	p70 (2-191) (mRNA); p56 (2-191) (mRNA); p27 (2-191) (mRNA); gp70 (2-191) (mRNA); gp68 (2-191) (mRNA); gp35 (2-191) (mRNA); gp32 (2-191) (mRNA); NS5B (2-191) (mRNA); NS3P (2-191) (mRNA); NS1 (2-191) (mRNA); Hepacivirin (2-191) (mRNA); Genome polyprotein (2-191) (mRNA); Capsid protein C (mRNA)
T09874	FUNCTION	Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis). Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding.
T09874	PDBSTRUC	3SU4; 3RC5; 3RC4; 3QGI; 3QGH
T09874	BIOCLASS	mRNA target
T09874	SEQUENCE	MSTNPKPQKKNKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLGVRATRKTSERSQPRGRRQPIPKARRPEGRTWAQPGYPWPLYGNEGCGWAGWLLSPRGSRPSWGPTDPRRRSRNLGKVIDTLTCGFADLMGYIPLVGAPLGGAARALAHGVRVLEDGVNYATGNLPGCSFSIFLLALLSCLTVPASAYQVRNSTGLYHVTNDCPNSSIVYEAADAILHTPGCVPCVREGNASRCWVAMTPTVATRDGKLPATQLRRHIDLLVGSATLCSALYVGDLCGSVFLVGQLFTFSPRRHWTTQGCNCSIYPGHITGHRMAWDMMMNWSPTTALVMAQLLRIPQAILDMIAGAHWGVLAGIAYFSMVGNWAKVLVVLLLFAGVDAETHVTGGSAGHTVSGFVSLLAPGAKQNVQLINTNGSWHLNSTALNCNDSLNTGWLAGLFYHHKFNSSGCPERLASCRPLTDFDQGWGPISYANGSGPDQRPYCWHYPPKPCGIVPAKSVCGPVYCFTPSPVVVGTTDRSGAPTYSWGENDTDVFVLNNTRPPLGNWFGCTWMNSTGFTKVCGAPPCVIGGAGNNTLHCPTDCFRKHPDATYSRCGSGPWITPRCLVDYPYRLWHYPCTINYTIFKIRMYVGGVEHRLEAACNWTRGERCDLEDRDRSELSPLLLTTTQWQVLPCSFTTLPALSTGLIHLHQNIVDVQYLYGVGSSIASWAIKWEYVVLLFLLLADARVCSCLWMMLLISQAEAALENLVILNAASLAGTHGLVSFLVFFCFAWYLKGKWVPGAVYTFYGMWPLLLLLLALPQRAYALDTEVAASCGGVVLVGLMALTLSPYYKRYISWCLWWLQYFLTRVEAQLHVWIPPLNVRGGRDAVILLMCAVHPTLVFDITKLLLAVFGPLWILQASLLKVPYFVRVQGLLRFCALARKMIGGHYVQMVIIKLGALTGTYVYNHLTPLRDWAHNGLRDLAVAVEPVVFSQMETKLITWGADTAACGDIINGLPVSARRGREILLGPADGMVSKGWRLLAPITAYAQQTRGLLGCIITSLTGRDKNQVEGEVQIVSTAAQTFLATCINGVCWTVYHGAGTRTIASPKGPVIQMYTNVDQDLVGWPAPQGSRSLTPCTCGSSDLYLVTRHADVIPVRRRGDSRGSLLSPRPISYLKGSSGGPLLCPAGHAVGIFRAAVCTRGVAKAVDFIPVENLETTMRSPVFTDNSSPPVVPQSFQVAHLHAPTGSGKSTKVPAAYAAQGYKVLVLNPSVAATLGFGAYMSKAHGIDPNIRTGVRTITTGSPITYSTYGKFLADGGCSGGAYDIIICDECHSTDATSILGIGTVLDQAETAGARLVVLATATPPGSVTVPHPNIEEVALSTTGEIPFYGKAIPLEVIKGGRHLIFCHSKKKCDELAAKLVALGINAVAYYRGLDVSVIPTSGDVVVVATDALMTGYTGDFDSVIDCNTCVTQTVDFSLDPTFTIETITLPQDAVSRTQRRGRTGRGKPGIYRFVAPGERPSGMFDSSVLCECYDAGCAWYELTPAETTVRLRAYMNTPGLPVCQDHLEFWEGVFTGLTHIDAHFLSQTKQSGENLPYLVAYQATVCARAQAPPPSWDQMWKCLIRLKPTLHGPTPLLYRLGAVQNEITLTHPVTKYIMTCMSADLEVVTSTWVLVGGVLAALAAYCLSTGCVVIVGRVVLSGKPAIIPDREVLYREFDEMEECSQHLPYIEQGMMLAEQFKQKALGLLQTASRQAEVIAPAVQTNWQKLETFWAKHMWNFISGIQYLAGLSTLPGNPAIASLMAFTAAVTSPLTTSQTLLFNILGGWVAAQLAAPGAATAFVGAGLAGAAIGSVGLGKVLIDILAGYGAGVAGALVAFKIMSGEVPSTEDLVNLLPAILSPGALVVGVVCAAILRRHVGPGEGAVQWMNRLIAFASRGNHVSPTHYVPESDAAARVTAILSSLTVTQLLRRLHQWISSECTTPCSGSWLRDIWDWICEVLSDFKTWLKAKLMPQLPGIPFVSCQRGYKGVWRVDGIMHTRCHCGAEITGHVKNGTMRIVGPRTCRNMWSGTFPINAYTTGPCTPLPAPNYTFALWRVSAEEYVEIRQVGDFHYVTGMTTDNLKCPCQVPSPEFFTELDGVRLHRFAPPCKPLLREEVSFRVGLHEYPVGSQLPCEPEPDVAVLTSMLTDPSHITAEAAGRRLARGSPPSVASSSASQLSAPSLKATCTANHDSPDAELIEANLLWRQEMGGNITRVESENKVVILDSFDPLVAEEDEREISVPAEILRKSRRFAQALPVWARPDYNPPLVETWKKPDYEPPVVHGCPLPPPKSPPVPPPRKKRTVVLTESTLSTALAELATRSFGSSSTSGITGDNTTTSSEPAPSGCPPDSDAESYSSMPPLEGEPGDPDLSDGSWSTVSSEANAEDVVCCSMSYSWTGALVTPCAAEEQKLPINALSNSLLRHHNLVYSTTSRSACQRQKKVTFDRLQVLDSHYQDVLKEVKAAASKVKANLLSVEEACSLTPPHSAKSKFGYGAKDVRCHARKAVTHINSVWKDLLEDNVTPIDTTIMAKNEVFCVQPEKGGRKPARLIVFPDLGVRVCEKMALYDVVTKLPLAVMGSSYGFQYSPGQRVEFLVQAWKSKKTPMGFSYDTRCFDSTVTESDIRTEEAIYQCCDLDPQARVAIKSLTERLYVGGPLTNSRGENCGYRRCRASGVLTTSCGNTLTCYIKARAACRAAGLQDCTMLVCGDDLVVICESAGVQEDAASLRAFTEAMTRYSAPPGDPPQPEYDLELITSCSSNVSVAHDGAGKRVYYLTRDPTTPLARAAWETARHTPVNSWLGNIIMFAPTLWARMILMTHFFSVLIARDQLEQALDCEIYGACYSIEPLDLPPIIQRLHGLSAFSLHSYSPGEINRVAACLRKLGVPPLRAWRHRARSVRARLLARGGRAAICGKYLFNWAVRTKLKLTPIAAAGQLDLSGWFTAGYSGGDIYHSVSHARPRWIWFCLLLLAAGVGIYLLPNR
T09874	DRUGINFO	D04NQY	US10087167, Compound 4001	Patented
T09874	DRUGINFO	D05ETL	US10087167, Compound 3002	Patented
T09874	DRUGINFO	D08VSV	US10150740, Example 4	Patented
T09874	DRUGINFO	D0CD5P	US10150740, Example 9	Patented
T09874	DRUGINFO	D0E7TM	US8877733, 27	Patented
T09874	DRUGINFO	D0G4LV	US10087167, Compound 3003	Patented
T09874	DRUGINFO	D0L3TL	US8877733, 28	Patented
T09874	DRUGINFO	D0PG7W	US10150740, Example 1	Patented
T09874	DRUGINFO	D00KVH	ISIS 11155	Investigative

T58440	TARGETID	T58440
T58440	FORMERID	TTDI02682
T58440	UNIPROID	SCN1A_HUMAN
T58440	TARGNAME	SCN1A messenger RNA (SCN1A mRNA)
T58440	GENENAME	SCN1A
T58440	TARGTYPE	Patented-recorded
T58440	SYNONYMS	Voltage-gated sodium channel subunit alpha Nav1.1 (mRNA); Sodium channel protein type I subunit alpha (mRNA); Sodium channel protein type 1 subunit alpha (mRNA); Sodium channel protein brain I subunit alpha (mRNA); SCN1 (mRNA)
T58440	FUNCTION	Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. Plays a key role in brain, probably by regulating the moment when neurotransmitters are released in neurons. Involved in sensory perception of mechanical pain: activation in somatosensory neurons induces pain without neurogenic inflammation and produces hypersensitivity to mechanical, but not thermal stimuli. Mediates the voltage-dependent sodium ion permeability of excitable membranes.
T58440	BIOCLASS	mRNA target
T58440	SEQUENCE	MEQTVLVPPGPDSFNFFTRESLAAIERRIAEEKAKNPKPDKKDDDENGPKPNSDLEAGKNLPFIYGDIPPEMVSEPLEDLDPYYINKKTFIVLNKGKAIFRFSATSALYILTPFNPLRKIAIKILVHSLFSMLIMCTILTNCVFMTMSNPPDWTKNVEYTFTGIYTFESLIKIIARGFCLEDFTFLRDPWNWLDFTVITFAYVTEFVDLGNVSALRTFRVLRALKTISVIPGLKTIVGALIQSVKKLSDVMILTVFCLSVFALIGLQLFMGNLRNKCIQWPPTNASLEEHSIEKNITVNYNGTLINETVFEFDWKSYIQDSRYHYFLEGFLDALLCGNSSDAGQCPEGYMCVKAGRNPNYGYTSFDTFSWAFLSLFRLMTQDFWENLYQLTLRAAGKTYMIFFVLVIFLGSFYLINLILAVVAMAYEEQNQATLEEAEQKEAEFQQMIEQLKKQQEAAQQAATATASEHSREPSAAGRLSDSSSEASKLSSKSAKERRNRRKKRKQKEQSGGEEKDEDEFQKSESEDSIRRKGFRFSIEGNRLTYEKRYSSPHQSLLSIRGSLFSPRRNSRTSLFSFRGRAKDVGSENDFADDEHSTFEDNESRRDSLFVPRRHGERRNSNLSQTSRSSRMLAVFPANGKMHSTVDCNGVVSLVGGPSVPTSPVGQLLPEVIIDKPATDDNGTTTETEMRKRRSSSFHVSMDFLEDPSQRQRAMSIASILTNTVEELEESRQKCPPCWYKFSNIFLIWDCSPYWLKVKHVVNLVVMDPFVDLAITICIVLNTLFMAMEHYPMTDHFNNVLTVGNLVFTGIFTAEMFLKIIAMDPYYYFQEGWNIFDGFIVTLSLVELGLANVEGLSVLRSFRLLRVFKLAKSWPTLNMLIKIIGNSVGALGNLTLVLAIIVFIFAVVGMQLFGKSYKDCVCKIASDCQLPRWHMNDFFHSFLIVFRVLCGEWIETMWDCMEVAGQAMCLTVFMMVMVIGNLVVLNLFLALLLSSFSADNLAATDDDNEMNNLQIAVDRMHKGVAYVKRKIYEFIQQSFIRKQKILDEIKPLDDLNNKKDSCMSNHTAEIGKDLDYLKDVNGTTSGIGTGSSVEKYIIDESDYMSFINNPSLTVTVPIAVGESDFENLNTEDFSSESDLEESKEKLNESSSSSEGSTVDIGAPVEEQPVVEPEETLEPEACFTEGCVQRFKCCQINVEEGRGKQWWNLRRTCFRIVEHNWFETFIVFMILLSSGALAFEDIYIDQRKTIKTMLEYADKVFTYIFILEMLLKWVAYGYQTYFTNAWCWLDFLIVDVSLVSLTANALGYSELGAIKSLRTLRALRPLRALSRFEGMRVVVNALLGAIPSIMNVLLVCLIFWLIFSIMGVNLFAGKFYHCINTTTGDRFDIEDVNNHTDCLKLIERNETARWKNVKVNFDNVGFGYLSLLQVATFKGWMDIMYAAVDSRNVELQPKYEESLYMYLYFVIFIIFGSFFTLNLFIGVIIDNFNQQKKKFGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPGNKFQGMVFDFVTRQVFDISIMILICLNMVTMMVETDDQSEYVTTILSRINLVFIVLFTGECVLKLISLRHYYFTIGWNIFDFVVVILSIVGMFLAELIEKYFVSPTLFRVIRLARIGRILRLIKGAKGIRTLLFALMMSLPALFNIGLLLFLVMFIYAIFGMSNFAYVKREVGIDDMFNFETFGNSMICLFQITTSAGWDGLLAPILNSKPPDCDPNKVNPGSSVKGDCGNPSVGIFFFVSYIIISFLVVVNMYIAVILENFSVATEESAEPLSEDDFEMFYEVWEKFDPDATQFMEFEKLSQFAAALEPPLNLPQPNKLQLIAMDLPMVSGDRIHCLDILFAFTKRVLGESGEMDALRIQMEERFMASNPSKVSYQPITTTLKRKQEEVSAVIIQRAYRRHLLKRTVKQASFTYNKNKIKGGANLLIKEDMIIDRINENSITEKTDLTMSTAACPPSYDRVTKPIVEKHEQEGKDEKAKGK
T58440	DRUGINFO	D05EMC	US9694002, 495	Patented
T58440	DRUGINFO	D05HMS	US9694002, 59	Patented
T58440	DRUGINFO	D05YDJ	US9694002, 129	Patented
T58440	DRUGINFO	D0G9WE	batrachotoxin	Investigative
T58440	DRUGINFO	D0S4MN	veratridine	Investigative

T11791	TARGETID	T11791
T11791	FORMERID	TTDI03007
T11791	UNIPROID	ACATN_HUMAN
T11791	TARGNAME	Acetyl-CoA transporter (SLC33A1)
T11791	GENENAME	SLC33A1
T11791	TARGTYPE	Patented-recorded
T11791	SYNONYMS	Solute carrier family 33 member 1; Acetyl-coenzyme A transporter 1; Acetyl-CoA transporter 1; AT1 protein; AT-1; ACATN
T11791	FUNCTION	Negatively regulates BMP signaling. Probable acetyl-CoA transporter necessary for O-acetylation of gangliosides.
T11791	BIOCLASS	Major facilitator
T11791	SEQUENCE	MSPTISHKDSSRQRRPGNFSHSLDMKSGPLPPGGWDDSHLDSAGREGDREALLGDTGTGDFLKAPQSFRAELSSILLLLFLYVLQGIPLGLAGSIPLILQSKNVSYTDQAFFSFVFWPFSLKLLWAPLVDAVYVKNFGRRKSWLVPTQYILGLFMIYLSTQVDRLLGNTDDRTPDVIALTVAFFLFEFLAATQDIAVDGWALTMLSRENVGYASTCNSVGQTAGYFLGNVLFLALESADFCNKYLRFQPQPRGIVTLSDFLFFWGTVFLITTTLVALLKKENEVSVVKEETQGITDTYKLLFAIIKMPAVLTFCLLILTAKIGFSAADAVTGLKLVEEGVPKEHLALLAVPMVPLQIILPLIISKYTAGPQPLNTFYKAMPYRLLLGLEYALLVWWTPKVEHQGGFPIYYYIVVLLSYALHQVTVYSMYVSIMAFNAKVSDPLIGGTYMTLLNTVSNLGGNWPSTVALWLVDPLTVKECVGASNQNCRTPDAVELCKKLGGSCVTALDGYYVESIICVFIGFGWWFFLGPKFKKLQDEGSSSWKCKRNN
T11791	DRUGINFO	D0K8EF	US8592431, 457	Patented
T11791	DRUGINFO	D0TI5Y	US8592431, 181	Patented
T11791	DRUGINFO	D0Z5GO	US8592431, 185	Patented
T11791	DRUGINFO	D0K0FZ	[14C]acetylCoA	Investigative

T83196	TARGETID	T83196
T83196	FORMERID	TTDNR00700
T83196	UNIPROID	PSIP1_HUMAN
T83196	TARGNAME	PC4 and SFRS1-interacting protein (PSIP1)
T83196	GENENAME	PSIP1
T83196	TARGTYPE	Patented-recorded
T83196	SYNONYMS	Transcriptional coactivator p75/p52; PSIP2; Lens epithelium-derived growth factor; LEDGF; Dense fine speckles 70 kDa protein; DFS70; DFS 70; CLL-associated antigen KW-7
T83196	FUNCTION	Transcriptional coactivator involved in neuroepithelial stem cell differentiation and neurogenesis. Involved in particular in lens epithelial cell gene regulation and stress responses. May play an important role in lens epithelial to fiber cell terminal differentiation. May play a protective role during stress-induced apoptosis. Isoform 2 is a more general and stronger transcriptional coactivator. Isoform 2 may also act as an adapter to coordinate pre-mRNA splicing. Cellular cofactor for lentiviral integration.
T83196	PDBSTRUC	6EMR; 6EMQ; 6EMP; 6EMO; 5YI9
T83196	SEQUENCE	MTRDFKPGDLIFAKMKGYPHWPARVDEVPDGAVKPPTNKLPIFFFGTHETAFLGPKDIFPYSENKEKYGKPNKRKGFNEGLWEIDNNPKVKFSSQQAATKQSNASSDVEVEEKETSVSKEDTDHEEKASNEDVTKAVDITTPKAARRGRKRKAEKQVETEEAGVVTTATASVNLKVSPKRGRPAATEVKIPKPRGRPKMVKQPCPSESDIITEEDKSKKKGQEEKQPKKQPKKDEEGQKEEDKPRKEPDKKEGKKEVESKRKNLAKTGVTSTSDSEEEGDDQEGEKKRKGGRNFQTAHRRNMLKGQHEKEAADRKRKQEEQMETEQQNKDEGKKPEVKKVEKKRETSMDSRLQRIHAEIKNSLKIDNLDVNRCIEALDELASLQVTMQQAQKHTEMITTLKKIRRFKVSQVIMEKSTMLYNKFKNMFLVGEGDSVITQVLNKSLAEQRQHEEANKTKDQGKKGPNKKLEKEQTGSKTLNGGSDAQDGNQPQHNGESNEDSKDNHEASTKKKPSSEERETEISLKDSTLDN
T83196	DRUGINFO	D08LBW	US9132129, Cpd023	Patented
T83196	DRUGINFO	D09SDN	US9132129, Cpd002	Patented
T83196	DRUGINFO	D0RP0H	US9132129, Cpd047	Patented

T09544	TARGETID	T09544
T09544	FORMERID	TTDI02573
T09544	UNIPROID	LEG1_HUMAN
T09544	TARGNAME	Galectin-1 (LGALS1)
T09544	GENENAME	LGALS1
T09544	TARGTYPE	Patented-recorded
T09544	SYNONYMS	SLac lectin 1; S-Lac lectin 1; Putative MAPKactivating protein PM12; Putative MAPK-activating protein PM12; Lectin galactosidebinding soluble 1; Lectin galactoside-binding soluble 1; Lactosebinding lectin 1; Lactose-binding lectin 1; HPL; HLBP14; HBL; Galaptin; Gal1; Gal-1; Betagalactosidebinding lectin L14I; Beta-galactoside-binding lectin L-14-I; 14 kDa lectin; 14 kDa lamininbinding protein; 14 kDa laminin-binding protein
T09544	FUNCTION	Plays a role in regulating apoptosis, cell proliferation and cell differentiation. Inhibits CD45 protein phosphatase activity and therefore the dephosphorylation of Lyn kinase. Strong inducer of T-cell apoptosis. Lectin that binds beta-galactoside and a wide array of complex carbohydrates.
T09544	PDBSTRUC	6F83; 6B94; 5MWX; 5MWT; 4Y24
T09544	SEQUENCE	MACGLVASNLNLKPGECLRVRGEVAPDAKSFVLNLGKDSNNLCLHFNPRFNAHGDANTIVCNSKDGGAWGTEQREAVFPFQPGSVAEVCITFDQANLTVKLPDGYEFKFPNRLNLEAINYMAADGDFKIKCVAFD
T09544	DRUGINFO	D0D1JC	US8703720, 15	Patented
T09544	DRUGINFO	D0N0DD	US8703720, Reference Compound 1	Patented
T09544	DRUGINFO	D0N5RH	US8703720, Reference Compound 2	Patented

T90751	TARGETID	T90751
T90751	UNIPROID	MGAT1_HUMAN
T90751	TARGNAME	N-acetylglucosaminyltransferase I (NAGAT1)
T90751	GENENAME	MGAT1
T90751	TARGTYPE	Patented-recorded
T90751	SYNONYMS	N-glycosyl-oligosaccharide-glycoprotein N-acetylglucosaminyltransferase I; MGAT; GlcNAc-T I; GNT-I; GLCT1; GGNT1; Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase
T90751	FUNCTION	Initiates complex N-linked carbohydrate formation. Essential for the conversion of high-mannose to hybrid and complex N-glycans.
T90751	ECNUMBER	EC 2.4.1.101
T90751	SEQUENCE	MLKKQSAGLVLWGAILFVAWNALLLLFFWTRPAPGRPPSVSALDGDPASLTREVIRLAQDAEVELERQRGLLQQIGDALSSQRGRVPTAAPPAQPRVPVTPAPAVIPILVIACDRSTVRRCLDKLLHYRPSAELFPIIVSQDCGHEETAQAIASYGSAVTHIRQPDLSSIAVPPDHRKFQGYYKIARHYRWALGQVFRQFRFPAAVVVEDDLEVAPDFFEYFRATYPLLKADPSLWCVSAWNDNGKEQMVDASRPELLYRTDFFPGLGWLLLAELWAELEPKWPKAFWDDWMRRPEQRQGRACIRPEISRTMTFGRKGVSHGQFFDQHLKFIKLNQQFVHFTQLDLSYLQREAYDRDFLARVYGAPQLQVEKVRTNDRKELGEVRVQYTGRDSFKAFAKALGVMDDLKSGVPRAGYRGIVTFQFRGRRVHLAPPLTWEGYDPSWN
T90751	DRUGINFO	D01DYO	US9656955, Example 652	Patented
T90751	DRUGINFO	D01OZO	US9586945, 1	Patented
T90751	DRUGINFO	D06WEY	US9586945, 19a	Patented
T90751	DRUGINFO	D0A0ND	US9586942, 2	Patented
T90751	DRUGINFO	D0BJ3R	US9656955, Example 540	Patented
T90751	DRUGINFO	D0L5AE	US9586942, 16	Patented
T90751	DRUGINFO	D0NT3V	US9586942, 3*	Patented
T90751	DRUGINFO	D0V1PW	US9656955, Example 351	Patented
T90751	DRUGINFO	D0Y6FF	US9586945, 5	Patented

T03529	TARGETID	T03529
T03529	FORMERID	TTDI03513
T03529	UNIPROID	RGS8_HUMAN
T03529	TARGNAME	Regulator of G-protein signaling 8 (RGS8)
T03529	GENENAME	RGS8
T03529	TARGTYPE	Patented-recorded
T03529	SYNONYMS	RGS8
T03529	FUNCTION	Regulates G protein-coupled receptor signaling cascades, including signaling via muscarinic acetylcholine receptor CHRM2 and dopamine receptor DRD2 (By similarity). Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits, thereby driving them into their inactive GDP-bound form. Modulates the activity of potassium channels that are activated in response to DRD2 and CHRM2 signaling (By similarity).
T03529	PDBSTRUC	5DO9; 2ODE; 2IHD
T03529	SEQUENCE	MAALLMPRRNKGMRTRLGCLSHKSDSCSDFTAILPDKPNRALKRLSTEEATRWADSFDVLLSHKYGVAAFRAFLKTEFSEENLEFWLACEEFKKTRSTAKLVSKAHRIFEEFVDVQAPREVNIDFQTREATRKNLQEPSLTCFDQAQGKVHSLMEKDSYPRFLRSKMYLDLLSQSQRRLS
T03529	DRUGINFO	D01GFH	1-Benzyl-3-bromo-1H-pyrrole-2,5-dione	Patented
T03529	DRUGINFO	D0E9JL	1-Benzyl-3-p-tolyl-1H-pyrrole-2,5-dione	Patented
T03529	DRUGINFO	D05AMQ	thiadiazolidinone (TDZD) deriv. 6	Investigative
T03529	DRUGINFO	D0C2GR	CCG-50014	Investigative
T03529	DRUGINFO	D0M5DR	RGS4 inhibitor 13	Investigative

T12797	TARGETID	T12797
T12797	FORMERID	TTDR00711
T12797	UNIPROID	B2LA1_HUMAN
T12797	TARGNAME	Bcl-2-related protein A1 (BCL2A1)
T12797	GENENAME	BCL2A1
T12797	TARGTYPE	Patented-recorded
T12797	SYNONYMS	Protein GRS; Protein BFL-1; Hemopoietic-specific early response protein; HBPA1; GRS; Bcl2-L-5; Bcl-2-like protein 5; BFL1; BCL2L5
T12797	FUNCTION	Retards apoptosis induced by IL-3 deprivation. May function in the response of hemopoietic cells to external signals and in maintaining endothelial survival during infection (By similarity). Can inhibit apoptosis induced by serum starvation in the mammary epithelial cell line HC11 (By similarity).
T12797	PDBSTRUC	6MBC; 6MBB; 6E3J; 6E3I; 5WHI
T12797	SEQUENCE	MTDCEFGYIYRLAQDYLQCVLQIPQPGSGPSKTSRVLQNVAFSVQKEVEKNLKSCLDNVNVVSVDTARTLFNQVMEKEFEDGIINWGRIVTIFAFEGILIKKLLRQQIAPDVDTYKEISYFVAEFIMNNTGEWIRQNGGWENGFVKKFEPKSGWMTFLEVTGKICEMLSLLKQYC
T12797	DRUGINFO	D03TTE	Apogossypolone	Patented
T12797	DRUGINFO	D0B1UL	US8937193-compound-7	Patented
T12797	DRUGINFO	D0CR9A	US8937193-compound-6b	Patented

T48812	TARGETID	T48812
T48812	FORMERID	TTDI03507
T48812	UNIPROID	RORB_HUMAN
T48812	TARGNAME	RAR-related orphan receptor-beta (RORB)
T48812	GENENAME	RORB
T48812	TARGTYPE	Patented-recorded
T48812	SYNONYMS	Retinoid-related orphan receptor-beta; RZRB; Nuclear receptor subfamily 1 group F member 2; Nuclear receptor RZR-beta; Nuclear receptor ROR-beta; NR1F2
T48812	FUNCTION	Nuclear receptor that binds DNA as a monomer to ROR response elements (RORE) containing a single core motif half-site 5'-AGGTCA-3' preceded by a short A-T-rich sequence. Considered to have intrinsic transcriptional activity, have some natural ligands such as all-trans retinoic acid (ATRA) and other retinoids which act as inverse agonists repressing the transcriptional activity. Required for normal postnatal development of rod and cone photoreceptor cells. Modulates rod photoreceptors differentiation at least by inducing the transcription factor NRL-mediated pathway. In cone photoreceptor cells, regulates transcription of OPN1SW. Involved in the regulation of the period length and stability of the circadian rhythm. May control cytoarchitectural patterning of neocortical neurons during development. May act in a dose-dependent manner to regulate barrel formation upon innervation of layer IV neurons by thalamocortical axons. May play a role in the suppression of osteoblastic differentiation through the inhibition of RUNX2 transcriptional activity (By similarity).
T48812	SEQUENCE	MCENQLKTKADATAQIEVIPCKICGDKSSGIHYGVITCEGCKGFFRRSQQNNASYSCPRQRNCLIDRTNRNRCQHCRLQKCLALGMSRDAVKFGRMSKKQRDSLYAEVQKHQQRLQEQRQQQSGEAEALARVYSSSISNGLSNLNNETSGTYANGHVIDLPKSEGYYNVDSGQPSPDQSGLDMTGIKQIKQEPIYDLTSVPNLFTYSSFNNGQLAPGITMTEIDRIAQNIIKSHLETCQYTMEELHQLAWQTHTYEEIKAYQSKSREALWQQCAIQITHAIQYVVEFAKRITGFMELCQNDQILLLKSGCLEVVLVRMCRAFNPLNNTVLFEGKYGGMQMFKALGSDDLVNEAFDFAKNLCSLQLTEEEIALFSSAVLISPDRAWLIEPRKVQKLQEKIYFALQHVIQKNHLDDETLAKLIAKIPTITAVCNLHGEKLQVFKQSHPEIVNTLFPPLYKELFNPDCATGCK
T48812	DRUGINFO	D09YHB	US9598431, 5	Patented
T48812	DRUGINFO	D0A9KU	US9598431, 2	Patented
T48812	DRUGINFO	D0ZX6M	US9598431, 1	Patented
T48812	DRUGINFO	D02EMH	all-trans-4-oxo-retinoic acid	Investigative

T32335	TARGETID	T32335
T32335	FORMERID	TTDC00222
T32335	TARGNAME	Inhibitor of nuclear factor kappa-B kinase (IKK)
T32335	TARGTYPE	Patented-recorded
T32335	SYNONYMS	IB kinase; IkappaB kinase; IKK
T32335	FUNCTION	Serine kinase that plays an essential role in the NF- kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues. These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome. In turn, free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. In addition to the NF-kappa-B inhibitors, phosphorylates several other components of the signaling pathway including NEMO/IKBKG, NF-kappa-B subunits RELA and NFKB1, as well as IKK-related kinases TBK1 and IKBKE. IKK-related kinase phosphorylations may prevent the overproduction of inflammatory mediators sincethey exert a negative regulation on canonical IKKs. Also phosphorylates other substrates including NCOA3, BCL10 and IRS1. Within the nucleus, acts as an adapter protein for NFKBIA degradation in UV-induced NF-kappa-B activation.
T32335	DRUGINFO	D04HQH	Dihydrothieno [2,3-e]indazole derivative 1	Patented
T32335	DRUGINFO	D07DBU	Dihydrothieno [2,3-e]indazole derivative 4	Patented
T32335	DRUGINFO	D0EX5A	Dihydrothieno [2,3-e]indazole derivative 3	Patented
T32335	DRUGINFO	D0T1MA	Dihydrothieno [2,3-e]indazole derivative 2	Patented
T32335	DRUGINFO	D00YTQ	BMS-345541	Investigative
T32335	DRUGINFO	D08UPA	4-hydroxy-2-nonenal	Investigative
T32335	DRUGINFO	D0E0XV	TPCA-1	Investigative
T32335	DRUGINFO	D0I7YL	S1627	Investigative
T32335	DRUGINFO	D0T8IS	MLN-120B	Investigative
T32335	DRUGINFO	D0X8KC	Arsenite	Investigative
T32335	DRUGINFO	D06ZIO	MRT67307	Investigative
T32335	DRUGINFO	D07MQC	PS-1145	Investigative
T32335	DRUGINFO	D01OBJ	5-Bromo-6-methoxy-9H-beta-carboline	Investigative
T32335	DRUGINFO	D03BJF	PMID23099093C17d	Investigative

T05034	TARGETID	T05034
T05034	TARGNAME	Fatty acid-binding protein (FABP)
T05034	TARGTYPE	Patented-recorded
T05034	SYNONYMS	Fatty acid binding protein
T05034	DRUGINFO	D00PES	PMID27109571-Compound-5	Patented
T05034	DRUGINFO	D00SAR	PMID27109571-Compound-41	Patented
T05034	DRUGINFO	D01ENV	PMID27109571-Compound-4	Patented
T05034	DRUGINFO	D03JDH	PMID27109571-Compound-32	Patented
T05034	DRUGINFO	D04OXI	PMID27109571-Compound-42	Patented
T05034	DRUGINFO	D06RWL	PMID27109571-Compound-35	Patented
T05034	DRUGINFO	D07SSO	PMID27109571-Compound-39	Patented
T05034	DRUGINFO	D08KCW	PMID27109571-Compound-37	Patented
T05034	DRUGINFO	D0A6TU	PMID27109571-Compound-40	Patented
T05034	DRUGINFO	D0FM6W	PMID27109571-Compound-34	Patented
T05034	DRUGINFO	D0G4IS	PMID27109571-Compound-2	Patented
T05034	DRUGINFO	D0J5AB	PMID27109571-Compound-44	Patented
T05034	DRUGINFO	D0JI3T	PMID27109571-Compound-43	Patented
T05034	DRUGINFO	D0KI1H	PMID27109571-Compound-33	Patented
T05034	DRUGINFO	D0M6MM	PMID27109571-Compound-3	Patented
T05034	DRUGINFO	D0MM7U	PMID27109571-Compound-36	Patented
T05034	DRUGINFO	D0ST2K	PMID27109571-Compound-6	Patented
T05034	DRUGINFO	D0XH0I	PMID27109571-Compound-38	Patented
T05034	DRUGINFO	D0ZC2K	PMID27109571-Compound-1	Patented
T05034	DRUGINFO	D0U5NW	BVT-24834	Terminated

T67054	TARGETID	T67054
T67054	FORMERID	TTDR00155
T67054	TARGNAME	5-HT 1 receptor (5HT1R)
T67054	TARGTYPE	Patented-recorded
T67054	SYNONYMS	Serotonin receptor 1; 5-hydroxytryptamine receptor 1; 5-HT1 receptor
T67054	BIOCLASS	GPCR rhodopsin
T67054	DRUGINFO	D0F9TY	Aryl piperazine derivative 16	Patented
T67054	DRUGINFO	D0M9LM	Aryl piperazine derivative 14	Patented
T67054	DRUGINFO	D0T7HK	Aryl piperazine derivative 15	Patented
T67054	DRUGINFO	D03PJW	RU 24969	Terminated
T67054	DRUGINFO	D0IJ5I	Befiperide	Terminated
T67054	DRUGINFO	D0MS1D	FCE-25876	Terminated
T67054	DRUGINFO	D0O8UF	SRSS-023	Terminated
T67054	DRUGINFO	D0X8ZA	Cyanopindolol	Investigative

T02629	TARGETID	T02629
T02629	TARGNAME	JNK-interacting protein peptide (pepJIP)
T02629	TARGTYPE	Patented-recorded
T02629	SYNONYMS	pepJIP
T02629	DRUGINFO	D08JIS	PMID25991433-Compound-N3	Patented
T02629	DRUGINFO	D08OJQ	PMID25991433-Compound-L2	Patented
T02629	DRUGINFO	D0G7LB	PMID25991433-Compound-L3	Patented
T02629	DRUGINFO	D0Q8CR	PMID25991433-Compound-L1	Patented

T06773	TARGETID	T06773
T06773	TARGNAME	Hypoxia-inducible factor 1 (HIF-1)
T06773	TARGTYPE	Patented-recorded
T06773	SYNONYMS	HIF-1
T06773	DRUGINFO	D00GOM	2,2-dimethylbenzopyran derivative 2	Patented
T06773	DRUGINFO	D00KDT	Oligooxopiperazine derivative 1	Patented
T06773	DRUGINFO	D00WZJ	2,2-dimethylbenzopyran derivative 3	Patented
T06773	DRUGINFO	D01DSL	Triptolidenol analog 1	Patented
T06773	DRUGINFO	D02JDR	Aromatic and heteroaryl compound 1	Patented
T06773	DRUGINFO	D02PFE	Steroid derivative 4	Patented
T06773	DRUGINFO	D03OYJ	PMID26882240-Compound-32	Patented
T06773	DRUGINFO	D04AQR	Imidazo [1,2-a]pyridine compound 1	Patented
T06773	DRUGINFO	D05MTZ	PMID26882240-Compound-7	Patented
T06773	DRUGINFO	D06CBI	PMID26882240-Compound-4	Patented
T06773	DRUGINFO	D07MRK	Tlouidine sulfonamide derivative 1	Patented
T06773	DRUGINFO	D08VON	PMID26882240-Compound-15	Patented
T06773	DRUGINFO	D09BXO	Steroid derivative 2	Patented
T06773	DRUGINFO	D09GXN	Benzanilide compound 2	Patented
T06773	DRUGINFO	D09NFI	Steroid derivative 3	Patented
T06773	DRUGINFO	D0AY8W	Benzanilide compound 1	Patented
T06773	DRUGINFO	D0E6VS	Steroid derivative 1	Patented
T06773	DRUGINFO	D0EO1L	PMID26882240-Compound-3	Patented
T06773	DRUGINFO	D0FB3R	Alkaloid derivative 4	Patented
T06773	DRUGINFO	D0H4WT	Peptidomimetic analog 7	Patented
T06773	DRUGINFO	D0HJ2J	Cyclic octapeptide derivative 1	Patented
T06773	DRUGINFO	D0J3NY	Benzene sulfonamide derivative 8	Patented
T06773	DRUGINFO	D0JJ1N	Matairesinol derivative 1	Patented
T06773	DRUGINFO	D0K0PG	PMID26882240-Compound-6	Patented
T06773	DRUGINFO	D0LK6V	2,2-dimethylbenzopyran derivative 1	Patented
T06773	DRUGINFO	D0M0UE	PMID26882240-Compound-2	Patented
T06773	DRUGINFO	D0N4ON	Aryl methoxyacrylate derivative 1	Patented
T06773	DRUGINFO	D0OQ2S	PMID26882240-Compound-14	Patented
T06773	DRUGINFO	D0RT4U	Aryl carbamate analog 1	Patented
T06773	DRUGINFO	D0TV4O	Aryl methoxyacrylate derivative 2	Patented
T06773	DRUGINFO	D0V7OU	PMID26882240-Compound-8	Patented
T06773	DRUGINFO	D0L1TA	PMID26882240-Compound-1	Patented

T10565	TARGETID	T10565
T10565	TARGNAME	Lysine-specific demethylase 4 (KDM4)
T10565	TARGTYPE	Patented-recorded
T10565	SYNONYMS	KDM4
T10565	DRUGINFO	D01IYF	N-oxalylglycine derivative 2	Patented
T10565	DRUGINFO	D02URA	Pyridine-2,4-dicarboxylic acid derivative 1	Patented
T10565	DRUGINFO	D05HBS	Hydroxamate analog 3	Patented
T10565	DRUGINFO	D05YBG	PMID25468267-Compound-51	Patented
T10565	DRUGINFO	D06XXJ	PMID25468267-Compound-54	Patented
T10565	DRUGINFO	D07GAP	N-oxalylglycine derivative 3	Patented
T10565	DRUGINFO	D0B4VO	PMID25468267-Compound-48	Patented
T10565	DRUGINFO	D0B5WF	Pyridine-2,4-dicarboxylic acid derivative 2	Patented
T10565	DRUGINFO	D0B7GQ	2,2-bipyridyl derivative 5	Patented
T10565	DRUGINFO	D0C1CV	Pyridine-2,4-dicarboxylic acid derivative 3	Patented
T10565	DRUGINFO	D0EY9Y	PMID25468267-Compound-53	Patented
T10565	DRUGINFO	D0G8SB	2,2-bipyridyl derivative 3	Patented
T10565	DRUGINFO	D0J1OK	N-oxalylglycine derivative 1	Patented
T10565	DRUGINFO	D0J6OC	PMID25468267-Compound-52	Patented
T10565	DRUGINFO	D0K1PP	Hydroxamate analog 2	Patented
T10565	DRUGINFO	D0K2OT	2,2-bipyridyl derivative 2	Patented
T10565	DRUGINFO	D0R1OG	2,2-bipyridyl derivative 1	Patented
T10565	DRUGINFO	D0TH2W	PMID25468267-Compound-49	Patented
T10565	DRUGINFO	D0YZ1B	PMID25468267-Compound-50	Patented
T10565	DRUGINFO	D0ZW5H	2,2-bipyridyl derivative 4	Patented

T12183	TARGETID	T12183
T12183	TARGNAME	NAD-dependent deacetylase sirtuin (SIRT)
T12183	TARGTYPE	Patented-recorded
T12183	SYNONYMS	NAD+-dependent deacetylase SIRT
T12183	DRUGINFO	D04MTT	PMID25435179-Compound-WO2012006391H3K9TSu	Patented
T12183	DRUGINFO	D06XWC	PMID25435179-Compound-WO2014110399Splitomycin	Patented
T12183	DRUGINFO	D09HHL	Quinoline derivative 19	Patented
T12183	DRUGINFO	D0D7MV	Quinoline derivative 18	Patented
T12183	DRUGINFO	D0F5ND	PMID25435179-Compound-WO2013059594(IV)	Patented
T12183	DRUGINFO	D0FU6L	Quinoline derivative 20	Patented
T12183	DRUGINFO	D0GD7H	PMID25435179-Compound-WO2013059594(III)	Patented
T12183	DRUGINFO	D0IG7E	H3K7T	Patented
T12183	DRUGINFO	D0JN5O	PMID25435179-Compound-EP20142759295NP-1	Patented
T12183	DRUGINFO	D0N9RD	PMID25435179-Compound-US2012165330(I)	Patented
T12183	DRUGINFO	D0OQ7S	PMID25435179-Compound-WO2013059587(VI, 2nd set)	Patented
T12183	DRUGINFO	D0Q8VI	PMID25435179-Compound-WO2013059587(V, 1st set)	Patented
T12183	DRUGINFO	D0WW2H	Triazolo[4,3-b]pyridazine derivative 1	Patented
T12183	DRUGINFO	D0X2BO	PMID25435179-Compound-WO2012149608USYDS1	Patented

T15923	TARGETID	T15923
T15923	TARGNAME	Serine/threonine-protein phosphatase (PSP)
T15923	TARGTYPE	Patented-recorded
T15923	SYNONYMS	Protein serine/threonine phosphatase

T16224	TARGETID	T16224
T16224	TARGNAME	Sphingosine kinase (SphK)
T16224	TARGTYPE	Patented-recorded
T16224	SYNONYMS	SphK
T16224	DRUGINFO	D01XFM	2-piperidine thiazole derivative 2	Patented
T16224	DRUGINFO	D0A9KH	PMID27539678-Compound-3	Patented
T16224	DRUGINFO	D0AH8N	Imidamide derivative 1	Patented
T16224	DRUGINFO	D0AR5O	PMID27539678-Compound-4	Patented
T16224	DRUGINFO	D0GS2P	2-piperidine thiazole derivative 1	Patented
T16224	DRUGINFO	D0I8RX	Sulfonamide derivative 17	Patented
T16224	DRUGINFO	D0IH3T	PMID27539678-Compound-8	Patented

T19543	TARGETID	T19543
T19543	TARGNAME	Phosphoprotein phosphatases 1 (PP1)
T19543	TARGTYPE	Patented-recorded
T19543	SYNONYMS	Protein phosphatase 1

T12819	TARGETID	T12819
T12819	FORMERID	TTDI01954
T12819	UNIPROID	COP1_HUMAN
T12819	TARGNAME	E3 ubiquitin-protein ligase COP1 (RFWD2)
T12819	GENENAME	RFWD2
T12819	TARGTYPE	Literature-reported
T12819	SYNONYMS	hCOP1; RNF200; RING-type E3 ubiquitin transferase RFWD2; RING finger protein 200; RING finger and WD repeat domain protein 2; E3 ubiquitinprotein ligase RFWD2; Constitutive photomorphogenesis protein 1 homolog; COP1
T12819	FUNCTION	E3 ubiquitin ligases accept ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. Involved in JUN ubiquitination and degradation. Directly involved in p53 (TP53) ubiquitination and degradation, thereby abolishing p53-dependent transcription and apoptosis. Ubiquitinates p53 independently of MDM2 or RCHY1. Probably mediates E3 ubiquitin ligase activity by functioning as the essential RING domain subunit of larger E3 complexes. In contrast, it does not constitute the catalytic RING subunit in the DCX DET1-COP1 complex that negatively regulates JUN, the ubiquitin ligase activity being mediated by RBX1. Involved in 14-3-3 protein sigma/SFN ubiquitination and proteasomal degradation, leading to AKT activation and promotion of cell survival. Ubiquitinates MTA1 leading to its proteasomal degradation. Upon binding to TRIB1, ubiquitinates CEBPA, which lacks a canonical COP1-binding motif. E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of target proteins.
T12819	PDBSTRUC	5IGQ; 5HQG
T12819	BIOCLASS	Acyltransferase
T12819	ECNUMBER	EC 2.3.2.27
T12819	SEQUENCE	MSGSRQAGSGSAGTSPGSSAASSVTSASSSLSSSPSPPSVAVSAAALVSGGVAQAAGSGGLGGPVRPVLVAPAVSGSGGGAVSTGLSRHSCAARPSAGVGGSSSSLGSGSRKRPLLAPLCNGLINSYEDKSNDFVCPICFDMIEEAYMTKCGHSFCYKCIHQSLEDNNRCPKCNYVVDNIDHLYPNFLVNELILKQKQRFEEKRFKLDHSVSSTNGHRWQIFQDWLGTDQDNLDLANVNLMLELLVQKKKQLEAESHAAQLQILMEFLKVARRNKREQLEQIQKELSVLEEDIKRVEEMSGLYSPVSEDSTVPQFEAPSPSHSSIIDSTEYSQPPGFSGSSQTKKQPWYNSTLASRRKRLTAHFEDLEQCYFSTRMSRISDDSRTASQLDEFQECLSKFTRYNSVRPLATLSYASDLYNGSSIVSSIEFDRDCDYFAIAGVTKKIKVYEYDTVIQDAVDIHYPENEMTCNSKISCISWSSYHKNLLASSDYEGTVILWDGFTGQRSKVYQEHEKRCWSVDFNLMDPKLLASGSDDAKVKLWSTNLDNSVASIEAKANVCCVKFSPSSRYHLAFGCADHCVHYYDLRNTKQPIMVFKGHRKAVSYAKFVSGEEIVSASTDSQLKLWNVGKPYCLRSFKGHINEKNFVGLASNGDYIACGSENNSLYLYYKGLSKTLLTFKFDTVKSVLDKDRKEDDTNEFVSAVCWRALPDGESNVLIAANSQGTIKVLELV

T99295	TARGETID	T99295
T99295	UNIPROID	PI4KA_HUMAN
T99295	TARGNAME	Phosphatidylinositol-4-kinase alpha (PI4KA)
T99295	GENENAME	PI4KA
T99295	TARGTYPE	Literature-reported
T99295	SYNONYMS	PtdIns-4-kinase alpha; PI4K-alpha; PI4-kinase alpha
T99295	FUNCTION	Acts on phosphatidylinositol (PtdIns) in the first committed step in the production of the second messenger inositol-1,4,5,-trisphosphate.
T99295	PDBSTRUC	6BQ1
T99295	BIOCLASS	PI3/PI4-kinase family. Type III PI4K subfamily
T99295	ECNUMBER	EC 2.7.1.67
T99295	SEQUENCE	MAAAPARGGGGGGGGGGGCSGSGSSASRGFYFNTVLSLARSLAVQRPASLEKVQKLLCMCPVDFHGIFQLDERRRDAVIALGIFLIESDLQHKDCVVPYLLRLLKGLPKVYWVEESTARKGRGALPVAESFSFCLVTLLSDVAYRDPSLRDEILEVLLQVLHVLLGMCQALEIQDKEYLCKYAIPCLIGISRAFGRYSNMEESLLSKLFPKIPPHSLRVLEELEGVRRRSFNDFRSILPSNLLTVCQEGTLKRKTSSVSSISQVSPERGMPPPSSPGGSAFHYFEASCLPDGTALEPEYYFSTISSSFSVSPLFNGVTYKEFNIPLEMLRELLNLVKKIVEEAVLKSLDAIVASVMEANPSADLYYTSFSDPLYLTMFKMLRDTLYYMKDLPTSFVKEIHDFVLEQFNTSQGELQKILHDADRIHNELSPLKLRCQANAACVDLMVWAVKDEQGAENLCIKLSEKLQSKTSSKVIIAHLPLLICCLQGLGRLCERFPVVVHSVTPSLRDFLVIPSPVLVKLYKYHSQYHTVAGNDIKISVTNEHSESTLNVMSGKKSQPSMYEQLRDIAIDNICRCLKAGLTVDPVIVEAFLASLSNRLYISQESDKDAHLIPDHTIRALGHIAVALRDTPKVMEPILQILQQKFCQPPSPLDVLIIDQLGCLVITGNQYIYQEVWNLFQQISVKASSVVYSATKDYKDHGYRHCSLAVINALANIAANIQDEHLVDELLMNLLELFVQLGLEGKRASERASEKGPALKASSSAGNLGVLIPVIAVLTRRLPPIKEAKPRLQKLFRDFWLYSVLMGFAVEGSGLWPEEWYEGVCEIATKSPLLTFPSKEPLRSVLQYNSAMKNDTVTPAELSELRSTIINLLDPPPEVSALINKLDFAMSTYLLSVYRLEYMRVLRSTDPDRFQVMFCYFEDKAIQKDKSGMMQCVIAVADKVFDAFLNMMADKAKTKENEEELERHAQFLLVNFNHIHKRIRRVADKYLSGLVDKFPHLLWSGTVLKTMLDILQTLSLSLSADIHKDQPYYDIPDAPYRITVPDTYEARESIVKDFAARCGMILQEAMKWAPTVTKSHLQEYLNKHQNWVSGLSQHTGLAMATESILHFAGYNKQNTTLGATQLSERPACVKKDYSNFMASLNLRNRYAGEVYGMIRFSGTTGQMSDLNKMMVQDLHSALDRSHPQHYTQAMFKLTAMLISSKDCDPQLLHHLCWGPLRMFNEHGMETALACWEWLLAGKDGVEVPFMREMAGAWHMTVEQKFGLFSAEIKEADPLAASEASQPKPCPPEVTPHYIWIDFLVQRFEIAKYCSSDQVEIFSSLLQRSMSLNIGGAKGSMNRHVAAIGPRFKLLTLGLSLLHADVVPNATIRNVLREKIYSTAFDYFSCPPKFPTQGEKRLREDISIMIKFWTAMFSDKKYLTASQLVPPDNQDTRSNLDITVGSRQQATQGWINTYPLSSGMSTISKKSGMSKKTNRGSQLHKYYMKRRTLLLSLLATEIERLITWYNPLSAPELELDQAGENSVANWRSKYISLSEKQWKDNVNLAWSISPYLAVQLPARFKNTEAIGNEVTRLVRLDPGAVSDVPEAIKFLVTWHTIDADAPELSHVLCWAPTDPPTGLSYFSSMYPPHPLTAQYGVKVLRSFPPDAILFYIPQIVQALRYDKMGYVREYILWAASKSQLLAHQFIWNMKTNIYLDEEGHQKDPDIGDLLDQLVEEITGSLSGPAKDFYQREFDFFNKITNVSAIIKPYPKGDERKKACLSALSEVKVQPGCYLPSNPEAIVLDIDYKSGTPMQSAAKAPYLAKFKVKRCGVSELEKEGLRCRSDSEDECSTQEADGQKISWQAAIFKVGDDCRQDMLALQIIDLFKNIFQLVGLDLFVFPYRVVATAPGCGVIECIPDCTSRDQLGRQTDFGMYDYFTRQYGDESTLAFQQARYNFIRSMAAYSLLLFLLQIKDRHNGNIMLDKKGHIIHIDFGFMFESSPGGNLGWEPDIKLTDEMVMIMGGKMEATPFKWFMEMCVRGYLAVRPYMDAVVSLVTLMLDTGLPCFRGQTIKLLKHRFSPNMTEREAANFIMKVIQSCFLSNRSRTYDMIQYYQNDIPY

T88451	TARGETID	T88451
T88451	UNIPROID	KIT_HUMAN
T88451	TARGNAME	Mutated tyrosine-protein kinase Kit (mKIT)
T88451	GENENAME	KIT
T88451	TARGTYPE	Literature-reported
T88451	SYNONYMS	v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (mutated); p145 c-kit (mutated); Tyrosine-protein kinase Kit (mutated); SCFR; Proto-oncogene c-Kit (mutated); Piebald trait protein (mutated); PBT (mutated); Mast/stem cell growth factor receptor Kit (mutated); CD117 (mutated)
T88451	FUNCTION	Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1, SH2B2/APS and CBL. Activates the AKT1 signaling pathway by phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Activated KIT also transmits signals via GRB2 and activation of RAS, RAF1 and the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3, STAT5A and STAT5B. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. KIT signaling is modulated by protein phosphatases, and by rapid internalization and degradation of the receptor. Activated KIT promotes phosphorylation of the protein phosphatases PTPN6/SHP-1 and PTPRU, and of the transcription factors STAT1, STAT3, STAT5A and STAT5B. Promotes phosphorylation of PIK3R1, CBL, CRK (isoform Crk-II), LYN, MAPK1/ERK2 and/or MAPK3/ERK1, PLCG1, SRC and SHC1.
T88451	PDBSTRUC	6GQM; 6GQL; 6GQK; 6GQJ; 4U0I
T88451	BIOCLASS	Kinase
T88451	ECNUMBER	EC 2.7.10.1
T88451	SEQUENCE	MRGARGAWDFLCVLLLLLRVQTGSSQPSVSPGEPSPPSIHPGKSDLIVRVGDEIRLLCTDPGFVKWTFEILDETNENKQNEWITEKAEATNTGKYTCTNKHGLSNSIYVFVRDPAKLFLVDRSLYGKEDNDTLVRCPLTDPEVTNYSLKGCQGKPLPKDLRFIPDPKAGIMIKSVKRAYHRLCLHCSVDQEGKSVLSEKFILKVRPAFKAVPVVSVSKASYLLREGEEFTVTCTIKDVSSSVYSTWKRENSQTKLQEKYNSWHHGDFNYERQATLTISSARVNDSGVFMCYANNTFGSANVTTTLEVVDKGFINIFPMINTTVFVNDGENVDLIVEYEAFPKPEHQQWIYMNRTFTDKWEDYPKSENESNIRYVSELHLTRLKGTEGGTYTFLVSNSDVNAAIAFNVYVNTKPEILTYDRLVNGMLQCVAAGFPEPTIDWYFCPGTEQRCSASVLPVDVQTLNSSGPPFGKLVVQSSIDSSAFKHNGTVECKAYNDVGKTSAYFNFAFKGNNKEQIHPHTLFTPLLIGFVIVAGMMCIIVMILTYKYLQKPMYEVQWKVVEEINGNNYVYIDPTQLPYDHKWEFPRNRLSFGKTLGAGAFGKVVEATAYGLIKSDAAMTVAVKMLKPSAHLTEREALMSELKVLSYLGNHMNIVNLLGACTIGGPTLVITEYCCYGDLLNFLRRKRDSFICSKQEDHAEAALYKNLLHSKESSCSDSTNEYMDMKPGVSYVVPTKADKRRSVRIGSYIERDVTPAIMEDDELALDLEDLLSFSYQVAKGMAFLASKNCIHRDLAARNILLTHGRITKICDFGLARDIKNDSNYVVKGNARLPVKWMAPESIFNCVYTFESDVWSYGIFLWELFSLGSSPYPGMPVDSKFYKMIKEGFRMLSPEHAPAEMYDIMKTCWDADPLKRPTFKQIVQLIEKQISESTNHIYSNLANCSPNRQKPVVDHSVRINSVGSTASSSQPLLVHDDV

T98134	TARGETID	T98134
T98134	FORMERID	TTDI03415
T98134	UNIPROID	NUCB1_HUMAN
T98134	TARGNAME	Nucleobindin-1 (NUCB1)
T98134	GENENAME	NUCB1
T98134	TARGTYPE	Literature-reported
T98134	SYNONYMS	NUC; CALNUC
T98134	FUNCTION	Major calcium-binding protein of the Golgi. May have a role in calcium homeostasis (By similarity).
T98134	PDBSTRUC	1SNL
T98134	SEQUENCE	MPPSGPRGTLLLLPLLLLLLLRAVLAVPLERGAPNKEETPATESPDTGLYYHRYLQEVIDVLETDGHFREKLQAANAEDIKSGKLSRELDFVSHHVRTKLDELKRQEVSRLRMLLKAKMDAEQDPNVQVDHLNLLKQFEHLDPQNQHTFEARDLELLIQTATRDLAQYDAAHHEEFKRYEMLKEHERRRYLESLGEEQRKEAERKLEEQQRRHREHPKVNVPGSQAQLKEVWEELDGLDPNRFNPKTFFILHDINSDGVLDEQELEALFTKELEKVYDPKNEEDDMREMEEERLRMREHVMKNVDTNQDRLVTLEEFLASTQRKEFGDTGEGWETVEMHPAYTEEELRRFEEELAAREAELNAKAQRLSQETEALGRSQGRLEAQKRELQQAVLHMEQRKQQQQQQQGHKAPAAHPEGQLKFHPDTDDVPVPAPAGDQKEVDTSEKKLLERLPEVEVPQHL
T98134	DRUGINFO	D01XLZ	MJN228	Investigative
T98134	DRUGINFO	D0S9AT	KML110	Investigative

T95295	TARGETID	T95295
T95295	UNIPROID	RPB1_HUMAN; RPB2_HUMAN; RPB3_HUMAN
T95295	TARGNAME	DNA-directed RNA polymerase II (RNAP II)
T95295	GENENAME	POLR2A; POLR2B; POLR2C
T95295	TARGTYPE	Literature-reported
T95295	SYNONYMS	RPB; RNA-directed RNA polymerase II; RNA polymerase II
T95295	FUNCTION	DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. Largest and catalytic component of RNA polymerase II which synthesizes mRNA precursors and many functional non-coding RNAs. Forms the polymerase active center together with the second largest subunit. Pol II is the central component of the basal RNA polymerase II transcription machinery. It is composed of mobile elements that move relative to each other.  RPB1/RPB2/RPB3 is part of the core element with the central large cleft, the clamp element that moves to open and close the cleft and the jaws that are thought to grab the incoming DNA template. 
T95295	SEQUENCE	MHGGGPPSGDSACPLRTIKRVQFGVLSPDELKRMSVTEGGIKYPETTEGGRPKLGGLMDPRQGVIERTGRCQTCAGNMTECPGHFGHIELAKPVFHVGFLVKTMKVLRCVCFFCSKLLVDSNNPKIKDILAKSKGQPKKRLTHVYDLCKGKNICEGGEEMDNKFGVEQPEGDEDLTKEKGHGGCGRYQPRIRRSGLELYAEWKHVNEDSQEKKILLSPERVHEIFKRISDEECFVLGMEPRYARPEWMIVTVLPVPPLSVRPAVVMQGSARNQDDLTHKLADIVKINNQLRRNEQNGAAAHVIAEDVKLLQFHVATMVDNELPGLPRAMQKSGRPLKSLKQRLKGKEGRVRGNLMGKRVDFSARTVITPDPNLSIDQVGVPRSIAANMTFAEIVTPFNIDRLQELVRRGNSQYPGAKYIIRDNGDRIDLRFHPKPSDLHLQTGYKVERHMCDGDIVIFNRQPTLHKMSMMGHRVRILPWSTFRLNLSVTTPYNADFDGDEMNLHLPQSLETRAEIQELAMVPRMIVTPQSNRPVMGIVQDTLTAVRKFTKRDVFLERGEVMNLLMFLSTWDGKVPQPAILKPRPLWTGKQIFSLIIPGHINCIRTHSTHPDDEDSGPYKHISPGDTKVVVENGELIMGILCKKSLGTSAGSLVHISYLEMGHDITRLFYSNIQTVINNWLLIEGHTIGIGDSIADSKTYQDIQNTIKKAKQDVIEVIEKAHNNELEPTPGNTLRQTFENQVNRILNDARDKTGSSAQKSLSEYNNFKSMVVSGAKGSKINISQVIAVVGQQNVEGKRIPFGFKHRTLPHFIKDDYGPESRGFVENSYLAGLTPTEFFFHAMGGREGLIDTAVKTAETGYIQRRLIKSMESVMVKYDATVRNSINQVVQLRYGEDGLAGESVEFQNLATLKPSNKAFEKKFRFDYTNERALRRTLQEDLVKDVLSNAHIQNELEREFERMREDREVLRVIFPTGDSKVVLPCNLLRMIWNAQKIFHINPRLPSDLHPIKVVEGVKELSKKLVIVNGDDPLSRQAQENATLLFNIHLRSTLCSRRMAEEFRLSGEAFDWLLGEIESKFNQAIAHPGEMVGALAAQSLGEPATQMTLNTFHYAGVSAKNVTLGVPRLKELINISKKPKTPSLTVFLLGQSARDAERAKDILCRLEHTTLRKVTANTAIYYDPNPQSTVVAEDQEWVNVYYEMPDFDVARISPWLLRVELDRKHMTDRKLTMEQIAEKINAGFGDDLNCIFNDDNAEKLVLRIRIMNSDENKMQEEEEVVDKMDDDVFLRCIESNMLTDMTLQGIEQISKVYMHLPQTDNKKKIIITEDGEFKALQEWILETDGVSLMRVLSEKDVDPVRTTSNDIVEIFTVLGIEAVRKALERELYHVISFDGSYVNYRHLALLCDTMTCRGHLMAITRHGVNRQDTGPLMKCSFEETVDVLMEAAAHGESDPMKGVSENIMLGQLAPAGTGCFDLLLDAEKCKYGMEIPTNIPGLGAAGPTGMFFGSAPSPMGGISPAMTPWNQGATPAYGAWSPSVGSGMTPGAAGFSPSAASDASGFSPGYSPAWSPTPGSPGSPGPSSPYIPSPGGAMSPSYSPTSPAYEPRSPGGYTPQSPSYSPTSPSYSPTSPSYSPTSPNYSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPSYSPTSPNYSPTSPNYTPTSPSYSPTSPSYSPTSPNYTPTSPNYSPTSPSYSPTSPSYSPTSPSYSPSSPRYTPQSPTYTPSSPSYSPSSPSYSPASPKYTPTSPSYSPSSPEYTPTSPKYSPTSPKYSPTSPKYSPTSPTYSPTTPKYSPTSPTYSPTSPVYTPTSPKYSPTSPTYSPTSPKYSPTSPTYSPTSPKGSTYSPTSPGYSPTSPTYSLTSPAISPDDSDEEN

T03818	TARGETID	T03818
T03818	FORMERID	TTDR01386
T03818	UNIPROID	PPARG_HUMAN
T03818	TARGNAME	PPAR-gamma messenger RNA (PPARG mRNA)
T03818	GENENAME	PPARG
T03818	TARGTYPE	Literature-reported
T03818	SYNONYMS	Transcription factor PPAR gamma receptor (mRNA); Peroxisome proliferator-activated receptor gamma (mRNA); PPARgamma (mRNA); PPAR-gamma (mRNA); Nuclear receptor subfamily 1 group C member 3 (mRNA); NR1C3 (mRNA)
T03818	FUNCTION	Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses. Plays a role in the regulation of cardiovascular circadian rhythms by regulating the transcription of ARNTL/BMAL1 in the blood vessels. Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids.
T03818	PDBSTRUC	6MD4; 6MD2; 6MD1; 6MD0; 6MCZ
T03818	BIOCLASS	mRNA target
T03818	SEQUENCE	MGETLGDSPIDPESDSFTDTLSANISQEMTMVDTEMPFWPTNFGISSVDLSVMEDHSHSFDIKPFTTVDFSSISTPHYEDIPFTRTDPVVADYKYDLKLQEYQSAIKVEPASPPYYSEKTQLYNKPHEEPSNSLMAIECRVCGDKASGFHYGVHACEGCKGFFRRTIRLKLIYDRCDLNCRIHKKSRNKCQYCRFQKCLAVGMSHNAIRFGRMPQAEKEKLLAEISSDIDQLNPESADLRALAKHLYDSYIKSFPLTKAKARAILTGKTTDKSPFVIYDMNSLMMGEDKIKFKHITPLQEQSKEVAIRIFQGCQFRSVEAVQEITEYAKSIPGFVNLDLNDQVTLLKYGVHEIIYTMLASLMNKDGVLISEGQGFMTREFLKSLRKPFGDFMEPKFEFAVKFNALELDDSDLAIFIAVIILSGDRPGLLNVKPIEDIQDNLLQALELQLKLNHPESSQLFAKLLQKMTDLRQIVTEHVQLLQVIKKTETDMSLHPLLQEIYKDLY
T03818	DRUGINFO	D0JU5X	Bardoxolone methyl	Phase 3
T03818	DRUGINFO	D0LB4T	AD-5075	Terminated
T03818	DRUGINFO	D01RPM	(E)-9-nitrooctadec-9-enoic acid	Investigative
T03818	DRUGINFO	D01UVA	tagitinin A	Investigative
T03818	DRUGINFO	D03BPG	T0070907	Investigative
T03818	DRUGINFO	D04DYM	GW1929	Investigative
T03818	DRUGINFO	D04FVX	(E)-9-Nitrohexadec-9-enoicAcid	Investigative
T03818	DRUGINFO	D06IHG	(E)-10-nitrooctadec-9-enoic acid	Investigative
T03818	DRUGINFO	D06NHI	SB-213068	Investigative
T03818	DRUGINFO	D06OBX	tirotundin	Investigative
T03818	DRUGINFO	D06UVY	L-Tryptophan-L-aspartic acid	Investigative
T03818	DRUGINFO	D07IHY	BRL-48482	Investigative
T03818	DRUGINFO	D08QKF	nTzDpa	Investigative
T03818	DRUGINFO	D0A1SP	COOH	Investigative
T03818	DRUGINFO	D0B2UF	ISIS 105990	Investigative
T03818	DRUGINFO	D0B9MZ	ISIS 106008	Investigative
T03818	DRUGINFO	D0D0FQ	CHLOROCYCLINONE A	Investigative
T03818	DRUGINFO	D0G3IV	ISIS 105987	Investigative
T03818	DRUGINFO	D0G9AI	L-Tryptophan-L-glutamine	Investigative
T03818	DRUGINFO	D0HI6O	PAT5A	Investigative
T03818	DRUGINFO	D0I2DF	GNF-PF-2893	Investigative
T03818	DRUGINFO	D0IW8V	L-Tryptophan-L-asparagine	Investigative
T03818	DRUGINFO	D0J9ZA	L-Tryptophan-L-2-aminoadipic acid	Investigative
T03818	DRUGINFO	D0L4PT	L-764406	Investigative
T03818	DRUGINFO	D0M7AT	L-Tryptophan-L-arginine	Investigative
T03818	DRUGINFO	D0NW8N	ISIS 105989	Investigative
T03818	DRUGINFO	D0P1US	[125I]SB-236636	Investigative
T03818	DRUGINFO	D0Q4EU	BADGE	Investigative
T03818	DRUGINFO	D0Q4UD	(E)-5-Nitrooctadec-5-enoic Acid	Investigative
T03818	DRUGINFO	D0R9VV	CHLOROCYCLINONE C	Investigative
T03818	DRUGINFO	D0RL8P	CHLOROCYCLINONE B	Investigative
T03818	DRUGINFO	D0SO9Q	GW0072	Investigative
T03818	DRUGINFO	D0T8JM	[3H]GW2331	Investigative
T03818	DRUGINFO	D0U5HX	CHLOROCYCLINONE D	Investigative
T03818	DRUGINFO	D0W9WU	(E)-10-Nitrohexadec-9-enoic Acid	Investigative
T03818	DRUGINFO	D0X3RZ	L-Tryptophan-L-leucine	Investigative
T03818	DRUGINFO	D0X9UJ	PD-068235	Investigative
T03818	DRUGINFO	D0Z2CY	Ploglitazone	Investigative
T03818	DRUGINFO	D0Z4NW	(E)-6-Nitrooctadec-5-enoic Acid	Investigative
T03818	DRUGINFO	D00EOP	AD-5061	Investigative
T03818	DRUGINFO	D04JOG	TZD18	Investigative
T03818	DRUGINFO	D06GYO	(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid	Investigative
T03818	DRUGINFO	D08XGH	reglitazar	Investigative
T03818	DRUGINFO	D0M8VN	DRF 2519	Investigative
T03818	DRUGINFO	D0M9LL	(E)-12-Nitrooctadec-12-enoic Acid	Investigative
T03818	DRUGINFO	D0P5QM	(E)-13-Nitrooctadec-12-enoic Acid	Investigative
T03818	DRUGINFO	D0P8XE	GNF-PF-3037	Investigative
T03818	DRUGINFO	D0Z7OX	LY-465608	Investigative
T03818	DRUGINFO	D00ACX	2-chloro-5-nitro-N-phenylbenzamide	Investigative
T03818	DRUGINFO	D09JII	L-796449	Investigative
T03818	DRUGINFO	D0F0MP	L-165461	Investigative
T03818	DRUGINFO	D08QXD	L-783483	Investigative
T03818	DRUGINFO	D0Q9FZ	LG100754	Investigative

T85250	TARGETID	T85250
T85250	FORMERID	TTDR01394
T85250	UNIPROID	GSK3A_HUMAN
T85250	TARGNAME	GSK3A messenger RNA (GSK3A mRNA)
T85250	GENENAME	GSK3A
T85250	TARGTYPE	Literature-reported
T85250	SYNONYMS	Serine/threonineprotein kinase GSK3A (mRNA); Serine/threonine-protein kinase GSK3A (mRNA); Glycogen synthase kinase3 alpha (mRNA); Glycogen synthase kinase 3 (mRNA); GSK3 alpha (mRNA); GSK-3 alpha (mRNA); GSK-3 (mRNA)
T85250	FUNCTION	Requires primed phosphorylation of the majority of its substrates. Contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glycogen synthesis. Regulates glycogen metabolism in liver, but not in muscle. May also mediate the development of insulin resistance by regulating activation of transcription factors. In Wnt signaling, regulates the level and transcriptional activity of nuclear CTNNB1/beta-catenin. Facilitates amyloid precursor protein (APP) processing and the generation of APP-derived amyloid plaques found in Alzheimer disease. May be involved in the regulation of replication in pancreatic beta-cells. Is necessary for the establishment of neuronal polarity and axon outgrowth. Through phosphorylation of the anti-apoptotic protein MCL1, may control cell apoptosis in response to growth factors deprivation. Acts as a regulator of autophagy by mediating phosphorylation of KAT5/TIP60 under starvation conditions, leading to activate KAT5/TIP60 acetyltransferase activity and promote acetylation of key autophagy regulators, such as ULK1 and RUBCNL/Pacer. Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), CTNNB1/beta-catenin, APC and AXIN1.
T85250	PDBSTRUC	2DFM
T85250	BIOCLASS	mRNA target
T85250	ECNUMBER	EC 2.7.11.26
T85250	SEQUENCE	MSGGGPSGGGPGGSGRARTSSFAEPGGGGGGGGGGPGGSASGPGGTGGGKASVGAMGGGVGASSSGGGPGGSGGGGSGGPGAGTSFPPPGVKLGRDSGKVTTVVATLGQGPERSQEVAYTDIKVIGNGSFGVVYQARLAETRELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFYSSGEKKDELYLNLVLEYVPETVYRVARHFTKAKLTIPILYVKVYMYQLFRSLAYIHSQGVCHRDIKPQNLLVDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSSIDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIKAHPWTKVFKSRTPPEAIALCSSLLEYTPSSRLSPLEACAHSFFDELRCLGTQLPNNRPLPPLFNFSAGELSIQPSLNAILIPPHLRSPAGTTTLTPSSQALTETPTSSDWQSTDATPTLTNSS
T85250	DRUGINFO	D01YSX	ISIS 116625	Investigative
T85250	DRUGINFO	D02EIC	ISIS 116648	Investigative
T85250	DRUGINFO	D03YXG	ISIS 116632	Investigative
T85250	DRUGINFO	D05PRC	ISIS 116631	Investigative
T85250	DRUGINFO	D0H1OB	ISIS 116670	Investigative
T85250	DRUGINFO	D0O7MX	ISIS 116654	Investigative
T85250	DRUGINFO	D04ZWF	CHIR-98014	Investigative
T85250	DRUGINFO	D0B3ZB	indirubin deriv. 8a	Investigative
T85250	DRUGINFO	D0K1DR	LEUCETTAMINE B	Investigative
T85250	DRUGINFO	D02XHC	aloisine A	Investigative

T75386	TARGETID	T75386
T75386	FORMERID	TTDR01352
T75386	UNIPROID	DGAT1_HUMAN
T75386	TARGNAME	DGAT1 messenger RNA (DGAT1 mRNA)
T75386	GENENAME	DGAT1
T75386	TARGTYPE	Literature-reported
T75386	SYNONYMS	Retinol O-fatty-acyltransferase (mRNA); Diglyceride acyltransferase (mRNA); Diacylglycerol O-acyltransferase 1 (mRNA); DGAT (mRNA); Acyl-CoA retinol O-fatty-acyltransferase (mRNA); ARAT (mRNA); AGRP1 (mRNA); ACAT-related gene product 1 (mRNA)
T75386	FUNCTION	In contrast to DGAT2 it is not essential for survival. May be involved in VLDL (very low density lipoprotein) assembly. In liver, plays a role in esterifying exogenous fatty acids to glycerol. Functions as the major acyl-CoA retinol acyltransferase (ARAT) in the skin, where it acts to maintain retinoid homeostasis and prevent retinoid toxicity leading to skin and hair disorders. Catalyzes the terminal and only committed step in triacylglycerol synthesis by using diacylglycerol and fatty acyl CoA as substrates.
T75386	BIOCLASS	mRNA target
T75386	ECNUMBER	EC 2.3.1.20
T75386	SEQUENCE	MGDRGSSRRRRTGSRPSSHGGGGPAAAEEEVRDAAAGPDVGAAGDAPAPAPNKDGDAGVGSGHWELRCHRLQDSLFSSDSGFSNYRGILNWCVVMLILSNARLFLENLIKYGILVDPIQVVSLFLKDPYSWPAPCLVIAANVFAVAAFQVEKRLAVGALTEQAGLLLHVANLATILCFPAAVVLLVESITPVGSLLALMAHTILFLKLFSYRDVNSWCRRARAKAASAGKKASSAAAPHTVSYPDNLTYRDLYYFLFAPTLCYELNFPRSPRIRKRFLLRRILEMLFFTQLQVGLIQQWMVPTIQNSMKPFKDMDYSRIIERLLKLAVPNHLIWLIFFYWLFHSCLNAVAELMQFGDREFYRDWWNSESVTYFWQNWNIPVHKWCIRHFYKPMLRRGSSKWMARTGVFLASAFFHEYLVSVPLRMFRLWAFTGMMAQIPLAWFVGRFFQGNYGNAAVWLSLIIGQPIAVLMYVHDYYVLNYEAPAAEA
T75386	DRUGINFO	D01PKX	ISIS 191731	Investigative
T75386	DRUGINFO	D01ZCH	ISIS 191756	Investigative
T75386	DRUGINFO	D06YZW	ISIS 191755	Investigative
T75386	DRUGINFO	D0D0OO	ISIS 191759	Investigative
T75386	DRUGINFO	D0I4JB	ISIS 191761	Investigative
T75386	DRUGINFO	D0T7SU	ISIS 191729	Investigative

T28043	TARGETID	T28043
T28043	FORMERID	TTDI03519
T28043	UNIPROID	KS6A2_HUMAN
T28043	TARGNAME	Ribosomal protein S6 kinase alpha-2 (RSK2)
T28043	GENENAME	RPS6KA2
T28043	TARGTYPE	Literature-reported
T28043	SYNONYMS	pp90RSK3; p90RSK2; p90-RSK 2; S6K-alpha-2; Ribosomal S6 kinase 3; RSK3; RSK-3; MAPKAPK1C; MAPKAPK-1c; MAPKAP kinase 1c; MAPK-activated protein kinase 1c; MAP kinase-activated protein kinase 1c; 90 kDa ribosomal protein S6 kinase 2
T28043	FUNCTION	May function as tumor suppressor in epithelial ovarian cancer cells. Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of transcription factors, regulates translation, and mediates cellular proliferation, survival, and differentiation.
T28043	BIOCLASS	Kinase
T28043	ECNUMBER	EC 2.7.11.1
T28043	SEQUENCE	MDLSMKKFAVRRFFSVYLRRKSRSKSSSLSRLEEEGVVKEIDISHHVKEGFEKADPSQFELLKVLGQGSYGKVFLVRKVKGSDAGQLYAMKVLKKATLKVRDRVRSKMERDILAEVNHPFIVKLHYAFQTEGKLYLILDFLRGGDLFTRLSKEVMFTEEDVKFYLAELALALDHLHSLGIIYRDLKPENILLDEEGHIKITDFGLSKEAIDHDKRAYSFCGTIEYMAPEVVNRRGHTQSADWWSFGVLMFEMLTGSLPFQGKDRKETMALILKAKLGMPQFLSGEAQSLLRALFKRNPCNRLGAGIDGVEEIKRHPFFVTIDWNTLYRKEIKPPFKPAVGRPEDTFHFDPEFTARTPTDSPGVPPSANAHHLFRGFSFVASSLIQEPSQQDLHKVPVHPIVQQLHGNNIHFTDGYEIKEDIGVGSYSVCKRCVHKATDTEYAVKIIDKSKRDPSEEIEILLRYGQHPNIITLKDVYDDGKFVYLVMELMRGGELLDRILRQRYFSEREASDVLCTITKTMDYLHSQGVVHRDLKPSNILYRDESGSPESIRVCDFGFAKQLRAGNGLLMTPCYTANFVAPEVLKRQGYDAACDIWSLGILLYTMLAGFTPFANGPDDTPEEILARIGSGKYALSGGNWDSISDAAKDVVSKMLHVDPHQRLTAMQVLKHPWVVNREYLSPNQLSRQDVHLVKGAMAATYFALNRTPQAPRLEPVLSSNLAQRRGMKRLTSTRL
T28043	DRUGINFO	D02VBF	BI-D1870	Preclinical
T28043	DRUGINFO	D09AID	PMID22564207C25b	Investigative

T51385	TARGETID	T51385
T51385	FORMERID	TTDI02509
T51385	UNIPROID	FFAR4_HUMAN
T51385	TARGNAME	G-protein coupled receptor 120 (GPR120)
T51385	GENENAME	FFAR4
T51385	TARGTYPE	Literature-reported
T51385	SYNONYMS	PGR4; Omega3 fatty acid receptor 1; Omega-3 fatty acid receptor 1; O3FAR1; Gprotein coupled receptor PGR4; Gprotein coupled receptor GT01; Gprotein coupled receptor 129; GPR129; G-protein coupled receptor PGR4; G-protein coupled receptor GT01; G-protein coupled receptor 129; Free fatty acid receptor 4
T51385	FUNCTION	Signals via a G(q)/G(11)-coupled pathway. Acts as a receptor for omega-3 fatty acids and mediates robust anti-inflammatory effects, particularly in macrophages and fat cells. The anti-inflammatory effects involve inhibition of TAK1 through a beta-arrestin 2 (ARRB2)/TAB1-dependent effect, but independent of the G(q)/G(11)-coupled pathway. Mediates potent insulin sensitizing and antidiabetic effects by repressing macrophage-induced tissue inflammation. May mediate the taste of fatty acids. Mediates FFA-induced inhibition of apoptosis in enteroendocrine cells. May play a role in the regulation of adipocyte development and differentiation. Receptor for medium and long-chain free fatty acids (FFAs).
T51385	BIOCLASS	GPCR rhodopsin
T51385	SEQUENCE	MSPECARAAGDAPLRSLEQANRTRFPFFSDVKGDHRLVLAAVETTVLVLIFAVSLLGNVCALVLVARRRRRGATACLVLNLFCADLLFISAIPLVLAVRWTEAWLLGPVACHLLFYVMTLSGSVTILTLAAVSLERMVCIVHLQRGVRGPGRRARAVLLALIWGYSAVAALPLCVFFRVVPQRLPGADQEISICTLIWPTIPGEISWDVSFVTLNFLVPGLVIVISYSKILQITKASRKRLTVSLAYSESHQIRVSQQDFRLFRTLFLLMVSFFIMWSPIIITILLILIQNFKQDLVIWPSLFFWVVAFTFANSALNPILYNMTLCRNEWKKIFCCFWFPEKGAILTDTSVKRNDLSIISG
T51385	DRUGINFO	D01VIX	PMID24997608CA 	Investigative
T51385	DRUGINFO	D0E9AY	grifolic acid	Investigative
T51385	DRUGINFO	D0K6EG	TUG-891	Investigative
T51385	DRUGINFO	D0N9SV	NCG21	Investigative
T51385	DRUGINFO	D08ZYC	GW9508	Investigative
T51385	DRUGINFO	D0C5SV	alpha-linolenic acid	Investigative

T75476	TARGETID	T75476
T75476	FORMERID	TTDR01108
T75476	UNIPROID	MYD88_HUMAN
T75476	TARGNAME	Myeloid differentiation primary response protein MyD88 (MYD88)
T75476	GENENAME	MYD88
T75476	TARGTYPE	Literature-reported
T75476	SYNONYMS	MyD88
T75476	FUNCTION	Acts via IRAK1, IRAK2, IRF7 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Increases IL-8 transcription. Involved in IL-18-mediated signaling pathway. Activates IRF1 resulting in its rapid migration into the nucleus to mediate an efficient induction of IFN-beta, NOS2/INOS, and IL12A genes. MyD88-mediated signaling in intestinal epithelial cells is crucial for maintenance of gut homeostasis and controls the expression of the antimicrobial lectin REG3G in the small intestine. Adapter protein involved in the Toll-like receptor and IL-1 receptor signaling pathway in the innate immune response.
T75476	PDBSTRUC	4EO7; 4DOM; 3MOP; 2Z5V; 2JS7
T75476	SEQUENCE	MAAGGPGAGSAAPVSSTSSLPLAALNMRVRRRLSLFLNVRTQVAADWTALAEEMDFEYLEIRQLETQADPTGRLLDAWQGRPGASVGRLLELLTKLGRDDVLLELGPSIEEDCQKYILKQQQEEAEKPLQVAAVDSSVPRTAELAGITTLDDPLGHMPERFDAFICYCPSDIQFVQEMIRQLEQTNYRLKLCVSDRDVLPGTCVWSIASELIEKRCRRMVVVVSDDYLQSKECDFQTKFALSLSPGAHQKRLIPIKYKAMKKEFPSILRFITVCDYTNPCTKSWFWTRLAKALSLP

T96311	TARGETID	T96311
T96311	FORMERID	TTDC00245
T96311	UNIPROID	UBA3_HUMAN
T96311	TARGNAME	NEDD8-activating enzyme E1C (UBA3)
T96311	GENENAME	UBA3
T96311	TARGTYPE	Literature-reported
T96311	SYNONYMS	Ubiquitin-like modifier-activating enzyme 3; Ubiquitin-activating enzyme E1C; Ubiquitin-activating enzyme 3; UBE1C; NEDD8-activating enzyme E1 catalytic subunit
T96311	FUNCTION	E1 activates NEDD8 by first adenylating its C-terminal glycine residue with ATP, thereafter linking this residue to the side chain of the catalytic cysteine, yielding a NEDD8-UBA3 thioester and free AMP. E1 finally transfers NEDD8 to the catalytic cysteine of UBE2M. Down-regulates steroid receptor activity. Necessary for cell cycle progression. Catalytic subunit of the dimeric UBA3-NAE1 E1 enzyme.
T96311	PDBSTRUC	5JJM; 3GZN; 3FN1; 3DBR; 3DBL
T96311	BIOCLASS	Carbon-sulfur ligase
T96311	ECNUMBER	EC 6.2.1.-
T96311	SEQUENCE	MADGEEPEKKRRRIEELLAEKMAVDGGCGDTGDWEGRWNHVKKFLERSGPFTHPDFEPSTESLQFLLDTCKVLVIGAGGLGCELLKNLALSGFRQIHVIDMDTIDVSNLNRQFLFRPKDIGRPKAEVAAEFLNDRVPNCNVVPHFNKIQDFNDTFYRQFHIIVCGLDSIIARRWINGMLISLLNYEDGVLDPSSIVPLIDGGTEGFKGNARVILPGMTACIECTLELYPPQVNFPMCTIASMPRLPEHCIEYVRMLQWPKEQPFGEGVPLDGDDPEHIQWIFQKSLERASQYNIRGVTYRLTQGVVKRIIPAVASTNAVIAAVCATEVFKIATSAYIPLNNYLVFNDVDGLYTYTFEAERKENCPACSQLPQNIQFSPSAKLQEVLDYLTNSASLQMKSPAITATLEGKNRTLYLQSVTSIEERTRPNLSKTLKELGLVDGQELAVADVTTPQTVLFKLHFTS

T77997	TARGETID	T77997
T77997	FORMERID	TTDR01342
T77997	UNIPROID	ADA10_HUMAN
T77997	TARGNAME	ADAM10 messenger RNA (ADAM10 mRNA)
T77997	GENENAME	ADAM10
T77997	TARGTYPE	Literature-reported
T77997	SYNONYMS	Mammalian disintegrinmetalloprotease (mRNA); MADM (mRNA); Kuzbanian protein homolog (mRNA); KUZ (mRNA); Disintegrin and metalloproteinase domaincontaining protein 10 (mRNA); Disintegrin and metalloproteinase domain-containing protein 10 (mRNA); CDw156 (mRNA); CD156c (mRNA); ADAM 10 (mRNA)
T77997	FUNCTION	Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface. Responsible for the proteolytic release of several other cell-surface proteins, including heparin-binding epidermal growth-like factor, ephrin-A2, CD44, CDH2 and for constitutive and regulated alpha-secretase cleavage of amyloid precursor protein (APP). Contributes to the normal cleavage of the cellular prion protein. Involved in the cleavage of the adhesion molecule L1 at the cell surface and in released membrane vesicles, suggesting a vesicle-based protease activity. Controls also the proteolytic processing of Notch and mediates lateral inhibition during neurogenesis. Responsible for the FasL ectodomain shedding and for the generation of the remnant ADAM10-processed FasL (FasL APL) transmembrane form. Also cleaves the ectodomain of the integral membrane proteins CORIN and ITM2B. Mediates the proteolytic cleavage of LAG3, leading to release the secreted form of LAG3. May regulate the EFNA5-EPHA3 signaling. Cleaves the membrane-bound precursor of TNF-alpha at '76-Ala-|-Val-77' to its mature soluble form.
T77997	PDBSTRUC	6BE6; 6BDZ; 1M1I
T77997	BIOCLASS	mRNA target
T77997	ECNUMBER	EC 3.4.24.81
T77997	SEQUENCE	MVLLRVLILLLSWAAGMGGQYGNPLNKYIRHYEGLSYNVDSLHQKHQRAKRAVSHEDQFLRLDFHAHGRHFNLRMKRDTSLFSDEFKVETSNKVLDYDTSHIYTGHIYGEEGSFSHGSVIDGRFEGFIQTRGGTFYVEPAERYIKDRTLPFHSVIYHEDDINYPHKYGPQGGCADHSVFERMRKYQMTGVEEVTQIPQEEHAANGPELLRKKRTTSAEKNTCQLYIQTDHLFFKYYGTREAVIAQISSHVKAIDTIYQTTDFSGIRNISFMVKRIRINTTADEKDPTNPFRFPNIGVEKFLELNSEQNHDDYCLAYVFTDRDFDDGVLGLAWVGAPSGSSGGICEKSKLYSDGKKKSLNTGIITVQNYGSHVPPKVSHITFAHEVGHNFGSPHDSGTECTPGESKNLGQKENGNYIMYARATSGDKLNNNKFSLCSIRNISQVLEKKRNNCFVESGQPICGNGMVEQGEECDCGYSDQCKDECCFDANQPEGRKCKLKPGKQCSPSQGPCCTAQCAFKSKSEKCRDDSDCAREGICNGFTALCPASDPKPNFTDCNRHTQVCINGQCAGSICEKYGLEECTCASSDGKDDKELCHVCCMKKMDPSTCASTGSVQWSRHFSGRTITLQPGSPCNDFRGYCDVFMRCRLVDADGPLARLKKAIFSPELYENIAEWIVAHWWAVLLMGIALIMLMAGFIKICSVHTPSSNPKLPPPKPLPGTLKRRRPPQPIQQPQRQRPRESYQMGHMRR
T77997	DRUGINFO	D02CNG	ISIS 100748	Investigative
T77997	DRUGINFO	D0J2VN	ISIS 100742	Investigative
T77997	DRUGINFO	D0JV0I	ISIS 100743	Investigative
T77997	DRUGINFO	D0Q6MK	ISIS 100749	Investigative
T77997	DRUGINFO	D0VI2A	PMID18068976C25	Investigative
T77997	DRUGINFO	D0X7FV	ISIS 100750	Investigative

T28705	TARGETID	T28705
T28705	FORMERID	TTDR01413
T28705	UNIPROID	CASP8_HUMAN
T28705	TARGNAME	Caspase 8 messenger RNA (CASP8 mRNA)
T28705	GENENAME	CASP8
T28705	TARGTYPE	Literature-reported
T28705	SYNONYMS	MORT1-associated CED-3 homolog (mRNA); MCH5 (mRNA); MACH (mRNA); ICE-like apoptotic protease 5 (mRNA); FLICE (mRNA); FADD-like ICE (mRNA); FADD-homologous ICE/CED-3-like protease (mRNA); CASP-8 (mRNA); CAP4 (mRNA); Apoptotic protease Mch-5 (mRNA); Apoptotic cysteine protease (mRNA)
T28705	FUNCTION	Binding to the adapter molecule FADD recruits it to either receptor. The resulting aggregate called death-inducing signaling complex (DISC) performs CASP8 proteolytic activation. The active dimeric enzyme is then liberated from the DISC and free to activate downstream apoptotic proteases. Proteolytic fragments of the N-terminal propeptide (termed CAP3, CAP5 and CAP6) are likely retained in the DISC. Cleaves and activates CASP3, CASP4, CASP6, CASP7, CASP9 and CASP10. May participate in the GZMB apoptotic pathways. Cleaves ADPRT. Hydrolyzes the small-molecule substrate, Ac-Asp-Glu-Val-Asp-|-AMC. Likely target for the cowpox virus CRMA death inhibitory protein. Isoform 5, isoform 6, isoform 7 and isoform 8 lack the catalytic site and may interfere with the pro-apoptotic activity of the complex. Most upstream protease of the activation cascade of caspases responsible for the TNFRSF6/FAS mediated and TNFRSF1A induced cell death.
T28705	PDBSTRUC	5L08; 5JQE; 5H33; 5H31; 4ZBW
T28705	BIOCLASS	mRNA target
T28705	ECNUMBER	EC 3.4.22.61
T28705	SEQUENCE	MDFSRNLYDIGEQLDSEDLASLKFLSLDYIPQRKQEPIKDALMLFQRLQEKRMLEESNLSFLKELLFRINRLDLLITYLNTRKEEMERELQTPGRAQISAYRVMLYQISEEVSRSELRSFKFLLQEEISKCKLDDDMNLLDIFIEMEKRVILGEGKLDILKRVCAQINKSLLKIINDYEEFSKERSSSLEGSPDEFSNGEELCGVMTISDSPREQDSESQTLDKVYQMKSKPRGYCLIINNHNFAKAREKVPKLHSIRDRNGTHLDAGALTTTFEELHFEIKPHDDCTVEQIYEILKIYQLMDHSNMDCFICCILSHGDKGIIYGTDGQEAPIYELTSQFTGLKCPSLAGKPKVFFIQACQGDNYQKGIPVETDSEEQPYLEMDLSSPQTRYIPDEADFLLGMATVNNCVSYRNPAEGTWYIQSLCQSLRERCPRGDDILTILTEVNYEVSNKDDKKNMGKQMPQPTFTLRKKLVFPSD
T28705	DRUGINFO	D00JXJ	ISIS 107612	Investigative
T28705	DRUGINFO	D04RGM	ISIS 107676	Investigative
T28705	DRUGINFO	D06YDM	ISIS 107681	Investigative
T28705	DRUGINFO	D06ZTM	ISIS 107652	Investigative
T28705	DRUGINFO	D07QZA	ISIS 107642	Investigative
T28705	DRUGINFO	D0N8TA	Acetyl-Ile-Glu-Thr-Asp-aldehyde	Investigative
T28705	DRUGINFO	D0V6DX	Isoquinoline-1,3,4(2H)-trione	Investigative

T94788	TARGETID	T94788
T94788	FORMERID	TTDR01028
T94788	UNIPROID	BCAT2_HUMAN
T94788	TARGNAME	Branched-chain-amino-acid transaminase 2 (BCAT2)
T94788	GENENAME	BCAT2
T94788	TARGTYPE	Literature-reported
T94788	SYNONYMS	Placental protein 18; PP18; ECA39 protein; Branched-chain amino acid aminotransferase; BCAT2; BCAT(m); BCAT
T94788	FUNCTION	Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine. May also function as a transporter of branched chain alpha-keto acids.
T94788	PDBSTRUC	5MPR; 5I60; 5I5Y; 5I5X; 5I5W
T94788	BIOCLASS	Transaminase
T94788	ECNUMBER	EC 2.6.1.42
T94788	SEQUENCE	MAAAALGQIWARKLLSVPWLLCGPRRYASSSFKAADLQLEMTQKPHKKPGPGEPLVFGKTFTDHMLMVEWNDKGWGQPRIQPFQNLTLHPASSSLHYSLQLFEGMKAFKGKDQQVRLFRPWLNMDRMLRSAMRLCLPSFDKLELLECIRRLIEVDKDWVPDAAGTSLYVRPVLIGNEPSLGVSQPTRALLFVILCPVGAYFPGGSVTPVSLLADPAFIRAWVGGVGNYKLGGNYGPTVLVQQEALKRGCEQVLWLYGPDHQLTEVGTMNIFVYWTHEDGVLELVTPPLNGVILPGVVRQSLLDMAQTWGEFRVVERTITMKQLLRALEEGRVREVFGSGTACQVCPVHRILYKDRNLHIPTMENGPELILRFQKELKEIQYGIRAHEWMFPV
T94788	DRUGINFO	D03NOU	Alpha-ketoisovalerate	Investigative
T94788	DRUGINFO	D05QCG	N-[O-Phosphono-Pyridoxyl]-Isoleucine	Investigative
T94788	DRUGINFO	D0AW6C	N'-(phenylsulfonyl)benzofuran-2-carbohydrazide	Investigative
T94788	DRUGINFO	D0W0FI	N'-(phenylsulfonyl)quinoline-6-carbohydrazide	Investigative
T94788	DRUGINFO	D01NBK	Pyridoxamine-5'-Phosphate	Investigative

T72444	TARGETID	T72444
T72444	FORMERID	TTDR00361
T72444	UNIPROID	FABH_ECOLI
T72444	TARGNAME	Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH)
T72444	GENENAME	Bact fabH
T72444	TARGTYPE	Literature-reported
T72444	SYNONYMS	KAS III; FabH; EcFabH; Condensing enzyme FabH; Beta-ketoacyl-acyl carrier protein synthase III; Acetoacetyl-acyl carrier protein synthase; Acetoacetyl-ACP synthase; 3-oxoacyl-[acyl-carrier-protein] synthase III
T72444	FUNCTION	Catalyzes the condensation reaction of fatty acid synthesis by the addition to an acyl acceptor of two carbons from malonyl-ACP. Catalyzes the first condensation reaction which initiates fatty acid synthesis and may therefore play a role in governing the total rate of fatty acid production. Possesses both acetoacetyl-ACP synthase and acetyl transacylase activities. Has some substrate specificity for acetyl-CoA. Its substrate specificity determines the biosynthesis of straight-chain of fatty acids instead of branched-chain.
T72444	PDBSTRUC	5BNS; 5BNR; 5BNM; 4Z8D; 3IL9
T72444	BIOCLASS	Acyltransferase
T72444	ECNUMBER	EC 2.3.1.180
T72444	SEQUENCE	MYTKIIGTGSYLPEQVRTNADLEKMVDTSDEWIVTRTGIRERHIAAPNETVSTMGFEAATRAIEMAGIEKDQIGLIVVATTSATHAFPSAACQIQSMLGIKGCPAFDVAAACAGFTYALSVADQYVKSGAVKYALVVGSDVLARTCDPTDRGTIIIFGDGAGAAVLAASEEPGIISTHLHADGSYGELLTLPNADRVNPENSIHLTMAGNEVFKVAVTELAHIVDETLAANNLDRSQLDWLVPHQANLRIISATAKKLGMSMDNVVVTLDRHGNTSAASVPCALDEAVRDGRIKPGQLVLLEAFGGGFTWGSALVRF
T72444	DRUGINFO	D00GIB	2-(4-Bromo-3-phenoxy-benzoylamino)-benzoic acid	Investigative
T72444	DRUGINFO	D09EYO	2-(4-Fluoro-3-phenoxy-benzoylamino)-benzoic acid	Investigative
T72444	DRUGINFO	D09RXJ	2-Hydroxy-6-(3-phenoxy-benzoylamino)-benzoic acid	Investigative
T72444	DRUGINFO	D0A0CZ	2-Tosylnaphthalene-1,4-diol	Investigative
T72444	DRUGINFO	D0BT1W	2-(p-tolylthio)naphthalene-1,4-dione	Investigative
T72444	DRUGINFO	D0GU4M	2-tosylnaphthalene	Investigative
T72444	DRUGINFO	D0I7IH	2-(4-propylphenylsulfonyl)naphthalene-1,4-diol	Investigative
T72444	DRUGINFO	D0J3DB	2-tosylanthracene-1,4-diol	Investigative
T72444	DRUGINFO	D0K1CU	2-(4-chlorophenylsulfonyl)naphthalene-1,4-diol	Investigative
T72444	DRUGINFO	D0K9GC	2-[3-(Pyridin-4-yloxy)-benzoylamino]-benzoic acid	Investigative
T72444	DRUGINFO	D0MF1G	2-(naphthalen-2-ylsulfonyl)naphthalene-1,4-diol	Investigative
T72444	DRUGINFO	D0O4IV	2-Fluoro-6-(3-phenoxy-benzoylamino)-benzoic acid	Investigative
T72444	DRUGINFO	D0O5KG	2-(3-Phenoxy-benzoylamino)-benzoic acid	Investigative
T72444	DRUGINFO	D0OL2D	2-(phenylsulfonyl)naphthalene-1,4-diol	Investigative
T72444	DRUGINFO	D0TU2Z	2-tosylbenzene-1,4-diol	Investigative
T72444	DRUGINFO	D0W0IX	2-tosylnaphthalene-1,4-dione	Investigative
T72444	DRUGINFO	D0W7JJ	2-(methylsulfonyl)naphthalene-1,4-diol	Investigative
T72444	DRUGINFO	D04JTY	Thiolactomycin	Investigative

T53350	TARGETID	T53350
T53350	FORMERID	TTDR01035
T53350	UNIPROID	BMP1_HUMAN
T53350	TARGNAME	Bone morphogenetic protein 1 (BMP1)
T53350	GENENAME	BMP1
T53350	TARGTYPE	Literature-reported
T53350	SYNONYMS	Procollagen C-proteinase; PCP protein; PCOLC; Mammalian tolloid protein; MTld; BMP-1
T53350	FUNCTION	Induces cartilage and bone formation. May participate in dorsoventral patterning during early development by cleaving chordin (CHRD). Responsible for the proteolytic activation of lysyl oxidase LOX. Cleaves the C-terminal propeptides of procollagen I, II and III.
T53350	PDBSTRUC	6BTQ; 6BTP; 6BTO; 6BTN; 6BSM
T53350	BIOCLASS	Peptidase
T53350	ECNUMBER	EC 3.4.24.19
T53350	SEQUENCE	MPGVARLPLLLGLLLLPRPGRPLDLADYTYDLAEEDDSEPLNYKDPCKAAAFLGDIALDEEDLRAFQVQQAVDLRRHTARKSSIKAAVPGNTSTPSCQSTNGQPQRGACGRWRGRSRSRRAATSRPERVWPDGVIPFVIGGNFTGSQRAVFRQAMRHWEKHTCVTFLERTDEDSYIVFTYRPCGCCSYVGRRGGGPQAISIGKNCDKFGIVVHELGHVVGFWHEHTRPDRDRHVSIVRENIQPGQEYNFLKMEPQEVESLGETYDFDSIMHYARNTFSRGIFLDTIVPKYEVNGVKPPIGQRTRLSKGDIAQARKLYKCPACGETLQDSTGNFSSPEYPNGYSAHMHCVWRISVTPGEKIILNFTSLDLYRSRLCWYDYVEVRDGFWRKAPLRGRFCGSKLPEPIVSTDSRLWVEFRSSSNWVGKGFFAVYEAICGGDVKKDYGHIQSPNYPDDYRPSKVCIWRIQVSEGFHVGLTFQSFEIERHDSCAYDYLEVRDGHSESSTLIGRYCGYEKPDDIKSTSSRLWLKFVSDGSINKAGFAVNFFKEVDECSRPNRGGCEQRCLNTLGSYKCSCDPGYELAPDKRRCEAACGGFLTKLNGSITSPGWPKEYPPNKNCIWQLVAPTQYRISLQFDFFETEGNDVCKYDFVEVRSGLTADSKLHGKFCGSEKPEVITSQYNNMRVEFKSDNTVSKKGFKAHFFSDKDECSKDNGGCQQDCVNTFGSYECQCRSGFVLHDNKHDCKEAGCDHKVTSTSGTITSPNWPDKYPSKKECTWAISSTPGHRVKLTFMEMDIESQPECAYDHLEVFDGRDAKAPVLGRFCGSKKPEPVLATGSRMFLRFYSDNSVQRKGFQASHATECGGQVRADVKTKDLYSHAQFGDNNYPGGVDCEWVIVAEEGYGVELVFQTFEVEEETDCGYDYMELFDGYDSTAPRLGRYCGSGPPEEVYSAGDSVLVKFHSDDTITKKGFHLRYTSTKFQDTLHSRK
T53350	DRUGINFO	D02DQT	PMID11934595C2	Investigative
T53350	DRUGINFO	D0P2TS	UK-383367	Investigative

T35527	TARGETID	T35527
T35527	FORMERID	TTDR00239
T35527	UNIPROID	LOX12_HUMAN
T35527	TARGNAME	Arachidonate 12-lipoxygenase (12-LOX)
T35527	GENENAME	ALOX12
T35527	TARGTYPE	Literature-reported
T35527	SYNONYMS	Platelet-type lipoxygenase 12; Lipoxin synthase 12-LO; LOG12; Arachidonate 12-lipoxygenase, 12S-type; 12S-lipoxygenase; 12S-LOX; 12LO; 12-lipoxygenase
T35527	FUNCTION	Mainly converts arachidonic acid to (12S)-hydroperoxyeicosatetraenoic acid/(12S)-HPETE but can also metabolize linoleic acid. Has a dual activity since it also converts leukotriene A4/LTA4 into both the bioactive lipoxin A4/LXA4 and lipoxin B4/LXB4. Through the production of specific bioactive lipids like (12S)-HPETE it regulates different biological processes including platelet activation. It also probably positively regulates angiogenesis through regulation of the expression of the vascular endothelial growth factor. Plays a role in apoptotic process, promoting the survival of vascular smooth muscle cells for instance. May also play a role in the control of cell migration and proliferation. Non-heme iron-containing dioxygenase that catalyzes the stereo-specific peroxidation of free and esterified polyunsaturated fatty acids generating a spectrum of bioactive lipid mediators.
T35527	PDBSTRUC	3D3L; 2ABU
T35527	BIOCLASS	Oxygenase
T35527	ECNUMBER	EC 1.13.11.31
T35527	SEQUENCE	MGRYRIRVATGAWLFSGSYNRVQLWLVGTRGEAELELQLRPARGEEEEFDHDVAEDLGLLQFVRLRKHHWLVDDAWFCDRITVQGPGACAEVAFPCYRWVQGEDILSLPEGTARLPGDNALDMFQKHREKELKDRQQIYCWATWKEGLPLTIAADRKDDLPPNMRFHEEKRLDFEWTLKAGALEMALKRVYTLLSSWNCLEDFDQIFWGQKSALAEKVRQCWQDDELFSYQFLNGANPMLLRRSTSLPSRLVLPSGMEELQAQLEKELQNGSLFEADFILLDGIPANVIRGEKQYLAAPLVMLKMEPNGKLQPMVIQIQPPNPSSPTPTLFLPSDPPLAWLLAKSWVRNSDFQLHEIQYHLLNTHLVAEVIAVATMRCLPGLHPIFKFLIPHIRYTMEINTRARTQLISDGGIFDKAVSTGGGGHVQLLRRAAAQLTYCSLCPPDDLADRGLLGLPGALYAHDALRLWEIIARYVEGIVHLFYQRDDIVKGDPELQAWCREITEVGLCQAQDRGFPVSFQSQSQLCHFLTMCVFTCTAQHAAINQGQLDWYAWVPNAPCTMRMPPPTTKEDVTMATVMGSLPDVRQACLQMAISWHLSRRQPDMVPLGHHKEKYFSGPKPKAVLNQFRTDLEKLEKEITARNEQLDWPYEYLKPSCIENSVTI
T35527	DRUGINFO	D0F4JL	NSC-661755	Terminated
T35527	DRUGINFO	D0M6KL	(-)-7-N-methyldibromophakellin	Investigative
T35527	DRUGINFO	D0Q0LD	NEODYSIDENIN	Investigative
T35527	DRUGINFO	D0S7AY	NSC-125034	Investigative
T35527	DRUGINFO	D02LUF	(+)-(5S,8S,10S)-20-methoxy-9,15-ene-puupehenol	Investigative
T35527	DRUGINFO	D03YMX	3,4,6-Tribromo-2-(2,4-dibromo-phenoxy)-phenol	Investigative
T35527	DRUGINFO	D04JWS	NSC-292213	Investigative
T35527	DRUGINFO	D07JRW	Jaspic acid	Investigative
T35527	DRUGINFO	D08WDW	DYSIDENIN	Investigative
T35527	DRUGINFO	D0A3QB	Polybrominated diphenyl ether derivative	Investigative
T35527	DRUGINFO	D0H8FG	(+)-(5S,8S,9R,10S)-20-methoxypuupehenone	Investigative
T35527	DRUGINFO	D0I6ZS	Dimethylnordihydroguarierate acid	Investigative
T35527	DRUGINFO	D0K0QU	(+)-(5S,8S,10S)-20-methoxypuupehenol	Investigative
T35527	DRUGINFO	D0W5DZ	CHLOROPUUPEHENONE	Investigative
T35527	DRUGINFO	D0X4BT	NSC-172033	Investigative
T35527	DRUGINFO	D0X4CI	2,3,4,5-Tetrabromo-6-(2,4-dibromo-phenoxy)-phenol	Investigative
T35527	DRUGINFO	D05FJM	PUUPEHEDIONE	Investigative
T35527	DRUGINFO	D06PRC	MANGOSTIN	Investigative
T35527	DRUGINFO	D07BXV	PUUPEHENONE	Investigative
T35527	DRUGINFO	D0F9FG	Isojaspic acid	Investigative

T68698	TARGETID	T68698
T68698	FORMERID	TTDR00957
T68698	UNIPROID	SAHH_HUMAN
T68698	TARGNAME	Adenosylhomocysteinase (AHCY)
T68698	GENENAME	AHCY
T68698	TARGTYPE	Literature-reported
T68698	SYNONYMS	SAHH; SAH hydrolase; S-adenosyl-L-homocysteine hydrolase
T68698	FUNCTION	Adenosylhomocysteine is a competitive inhibitor of S-adenosyl-L-methionine-dependent methyl transferase reactions; therefore adenosylhomocysteinase may play a key role in the control of methylations via regulation of the intracellular concentration of adenosylhomocysteine.
T68698	PDBSTRUC	5W4B; 5W49; 4YVF; 4PGF; 4PFJ
T68698	BIOCLASS	Ether bond hydrolase
T68698	ECNUMBER	EC 3.3.1.1
T68698	SEQUENCE	MSDKLPYKVADIGLAAWGRKALDIAENEMPGLMRMRERYSASKPLKGARIAGCLHMTVETAVLIETLVTLGAEVQWSSCNIFSTQDHAAAAIAKAGIPVYAWKGETDEEYLWCIEQTLYFKDGPLNMILDDGGDLTNLIHTKYPQLLPGIRGISEETTTGVHNLYKMMANGILKVPAINVNDSVTKSKFDNLYGCRESLIDGIKRATDVMIAGKVAVVAGYGDVGKGCAQALRGFGARVIITEIDPINALQAAMEGYEVTTMDEACQEGNIFVTTTGCIDIILGRHFEQMKDDAIVCNIGHFDVEIDVKWLNENAVEKVNIKPQVDRYRLKNGRRIILLAEGRLVNLGCAMGHPSFVMSNSFTNQVMAQIELWTHPDKYPVGVHFLPKKLDEAVAEAHLGKLNVKLTKLTEKQAQYLGMSCDGPFKPDHYRY
T68698	DRUGINFO	D0I7BL	ARISTEROMYCIN	Terminated
T68698	DRUGINFO	D02YYQ	5'-deoxy-5'-ureidoadenosine	Investigative
T68698	DRUGINFO	D0B0QY	5(E)-(5'-Deoxyadenosin-5'-ylidene)pentanoic acid	Investigative
T68698	DRUGINFO	D0D2MS	5-methylenearisteromycin	Investigative
T68698	DRUGINFO	D0F5AJ	NORARISTEROMYCIN	Investigative
T68698	DRUGINFO	D0G3CQ	D-Eritadenine	Investigative
T68698	DRUGINFO	D0LM6A	5'-S-ethyl-5'-thioadenosine	Investigative
T68698	DRUGINFO	D0O2CM	FLUORO-NEPLANOCIN A	Investigative
T68698	DRUGINFO	D0S1VT	4(Z)-(5'-Deoxyadenosin-5'-ylidene)butanoic acid	Investigative
T68698	DRUGINFO	D0T7QT	3'-Oxo-Adenosine	Investigative
T68698	DRUGINFO	D0X3MK	DZNep	Investigative
T68698	DRUGINFO	D0R2QS	Neplanocin A	Investigative
T68698	DRUGINFO	D0W7LK	2-Propanol, Isopropanol	Investigative
T68698	DRUGINFO	D0R6JE	Nicotinamide-Adenine-Dinucleotide	Investigative

T30823	TARGETID	T30823
T30823	FORMERID	TTDR00202
T30823	UNIPROID	MPIP1_HUMAN
T30823	TARGNAME	M-phase inducer phosphatase 1 (MPIP1)
T30823	GENENAME	CDC25A
T30823	TARGTYPE	Literature-reported
T30823	SYNONYMS	Dual specificity phosphatase Cdc25A; Cdc25A phosphatase
T30823	FUNCTION	Directly dephosphorylates CDK1 and stimulates its kinase activity. Also dephosphorylates CDK2 in complex with cyclin E, in vitro. Tyrosine protein phosphatase which functions as a dosage-dependent inducer of mitotic progression.
T30823	PDBSTRUC	1C25
T30823	BIOCLASS	Phosphoric monoester hydrolase
T30823	ECNUMBER	EC 3.1.3.48
T30823	SEQUENCE	MELGPEPPHRRRLLFACSPPPASQPVVKALFGASAAGGLSPVTNLTVTMDQLQGLGSDYEQPLEVKNNSNLQRMGSSESTDSGFCLDSPGPLDSKENLENPMRRIHSLPQKLLGCSPALKRSHSDSLDHDIFQLIDPDENKENEAFEFKKPVRPVSRGCLHSHGLQEGKDLFTQRQNSAPARMLSSNERDSSEPGNFIPLFTPQSPVTATLSDEDDGFVDLLDGENLKNEEETPSCMASLWTAPLVMRTTNLDNRCKLFDSPSLCSSSTRSVLKRPERSQEESPPGSTKRRKSMSGASPKESTNPEKAHETLHQSLSLASSPKGTIENILDNDPRDLIGDFSKGYLFHTVAGKHQDLKYISPEIMASVLNGKFANLIKEFVIIDCRYPYEYEGGHIKGAVNLHMEEEVEDFLLKKPIVPTDGKRVIVVFHCEFSSERGPRMCRYVRERDRLGNEYPKLHYPELYVLKGGYKEFFMKCQSYCEPPSYRPMHHEDFKEDLKKFRTKSRTWAGEKSKREMYSRLKKL
T30823	DRUGINFO	D07FHZ	Ro 20-1724	Terminated
T30823	DRUGINFO	D06REJ	MX-7065	Terminated
T30823	DRUGINFO	D00SAA	3-isopropylnaphthalene-1,2-dione	Investigative
T30823	DRUGINFO	D0CJ6P	2-(1-dodecyl-1H-indol-3-yl)acetic acid	Investigative
T30823	DRUGINFO	D0GE3O	(E)-2-(1-decyl-2-oxoindolin-3-ylidene)acetic acid	Investigative
T30823	DRUGINFO	D0W1SP	(Z)-2-(1-decyl-2-oxoindolin-3-ylidene)acetic acid	Investigative
T30823	DRUGINFO	D00ANJ	1-dodecyl-1H-indole-2,3-dione	Investigative
T30823	DRUGINFO	D07JRA	3-isopropyl-4-phenylnaphthalene-1,2-dione	Investigative
T30823	DRUGINFO	D0J1KH	NSC-95397	Investigative
T30823	DRUGINFO	D0X5WD	3-isopropyl-4-(phenylamino)naphthalene-1,2-dione	Investigative
T30823	DRUGINFO	D08GWQ	3-isopropyl-4-(phenylthio)naphthalene-1,2-dione	Investigative
T30823	DRUGINFO	D0N7YT	4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione	Investigative

T19011	TARGETID	T19011
T19011	FORMERID	TTDR00208
T19011	UNIPROID	MPIP3_HUMAN
T19011	TARGNAME	M-phase inducer phosphatase 3 (MPIP3)
T19011	GENENAME	CDC25C
T19011	TARGTYPE	Literature-reported
T19011	SYNONYMS	Dual specificity phosphatase Cdc25C; Cdc25C phosphatase
T19011	FUNCTION	Tyrosine protein phosphatase required for progression of the cell cycle. When phosphorylated, highly effective in activating G2 cells into prophase. Directly dephosphorylates CDK1 and activates its kinase activity. Functions as a dosage-dependent inducer in mitotic control.
T19011	PDBSTRUC	5M37; 5M36; 5M35; 3OP3; 3BZI
T19011	BIOCLASS	Phosphoric monoester hydrolase
T19011	ECNUMBER	EC 3.1.3.48
T19011	SEQUENCE	MSTELFSSTREEGSSGSGPSFRSNQRKMLNLLLERDTSFTVCPDVPRTPVGKFLGDSANLSILSGGTPKRCLDLSNLSSGEITATQLTTSADLDETGHLDSSGLQEVHLAGMNHDQHLMKCSPAQLLCSTPNGLDRGHRKRDAMCSSSANKENDNGNLVDSEMKYLGSPITTVPKLDKNPNLGEDQAEEISDELMEFSLKDQEAKVSRSGLYRSPSMPENLNRPRLKQVEKFKDNTIPDKVKKKYFSGQGKLRKGLCLKKTVSLCDITITQMLEEDSNQGHLIGDFSKVCALPTVSGKHQDLKYVNPETVAALLSGKFQGLIEKFYVIDCRYPYEYLGGHIQGALNLYSQEELFNFFLKKPIVPLDTQKRIIIVFHCEFSSERGPRMCRCLREEDRSLNQYPALYYPELYILKGGYRDFFPEYMELCEPQSYCPMHHQDHKTELLRCRSQSKVQEGERQLREQIALLVKDMSP
T19011	DRUGINFO	D06REJ	MX-7065	Terminated
T19011	DRUGINFO	D0G8AG	BN-82685	Investigative
T19011	DRUGINFO	D0GX8F	BN-82002	Investigative
T19011	DRUGINFO	D0XU7M	NSC-663284	Investigative

T50970	TARGETID	T50970
T50970	FORMERID	TTDR00135
T50970	UNIPROID	ECE1_HUMAN
T50970	TARGNAME	Endothelin-converting enzyme 1 (ECE1)
T50970	GENENAME	ECE1
T50970	TARGTYPE	Literature-reported
T50970	SYNONYMS	ECE-1
T50970	FUNCTION	Converts big endothelin-1 to endothelin-1.
T50970	PDBSTRUC	3DWB
T50970	BIOCLASS	Peptidase
T50970	ECNUMBER	EC 3.4.24.71
T50970	SEQUENCE	MRGVWPPPVSALLSALGMSTYKRATLDEEDLVDSLSEGDAYPNGLQVNFHSPRSGQRCWAARTQVEKRLVVLVVLLAAGLVACLAALGIQYQTRSPSVCLSEACVSVTSSILSSMDPTVDPCHDFFSYACGGWIKANPVPDGHSRWGTFSNLWEHNQAIIKHLLENSTASVSEAERKAQVYYRACMNETRIEELRAKPLMELIERLGGWNITGPWAKDNFQDTLQVVTAHYRTSPFFSVYVSADSKNSNSNVIQVDQSGLGLPSRDYYLNKTENEKVLTGYLNYMVQLGKLLGGGDEEAIRPQMQQILDFETALANITIPQEKRRDEELIYHKVTAAELQTLAPAINWLPFLNTIFYPVEINESEPIVVYDKEYLEQISTLINTTDRCLLNNYMIWNLVRKTSSFLDQRFQDADEKFMEVMYGTKKTCLPRWKFCVSDTENNLGFALGPMFVKATFAEDSKSIATEIILEIKKAFEESLSTLKWMDEETRKSAKEKADAIYNMIGYPNFIMDPKELDKVFNDYTAVPDLYFENAMRFFNFSWRVTADQLRKAPNRDQWSMTPPMVNAYYSPTKNEIVFPAGILQAPFYTRSSPKALNFGGIGVVVGHELTHAFDDQGREYDKDGNLRPWWKNSSVEAFKRQTECMVEQYSNYSVNGEPVNGRHTLGENIADNGGLKAAYRAYQNWVKKNGAEHSLPTLGLTNNQLFFLGFAQVWCSVRTPESSHEGLITDPHSPSRFRVIGSLSNSKEFSEHFRCPPGSPMNPPHKCEVW
T50970	DRUGINFO	D0K9YR	SCH-54470	Terminated
T50970	DRUGINFO	D02FGF	PO3 2-Nle-Trp-O-3K	Investigative
T50970	DRUGINFO	D0F8AR	PMID19899765C22	Investigative
T50970	DRUGINFO	D0I6EU	PO3 2-Leu-Trp-O-3K	Investigative
T50970	DRUGINFO	D0I6RE	5-(2-hydroxyethyl)nonane-1,9-diol	Investigative
T50970	DRUGINFO	D0P1UW	PO3 2-Ile-Trp-O-3K	Investigative
T50970	DRUGINFO	D0U0ST	PD159790	Investigative
T50970	DRUGINFO	D0ZY2T	PO3 2-Leu-Nal-O-3K	Investigative
T50970	DRUGINFO	D0G9UX	CGS 35066	Investigative
T50970	DRUGINFO	D07APP	LY-292223	Investigative

T56175	TARGETID	T56175
T56175	FORMERID	TTDR00866
T56175	UNIPROID	ERG7_HUMAN
T56175	TARGNAME	Lanosterol synthase (LSS)
T56175	GENENAME	LSS
T56175	TARGTYPE	Literature-reported
T56175	SYNONYMS	Oxidosqualene--lanosterol cyclase; Oxidosqualene cyclase; OSC; LSS; 2,3-epoxysqualene--lanosterol cyclase
T56175	FUNCTION	Catalyzes the cyclization of (S)-2,3 oxidosqualene to lanosterol, a reaction that forms the sterol nucleus.
T56175	PDBSTRUC	1W6K; 1W6J
T56175	BIOCLASS	Intramolecular transferases
T56175	ECNUMBER	EC 5.4.99.7
T56175	SEQUENCE	MTEGTCLRRRGGPYKTEPATDLGRWRLNCERGRQTWTYLQDERAGREQTGLEAYALGLDTKNYFKDLPKAHTAFEGALNGMTFYVGLQAEDGHWTGDYGGPLFLLPGLLITCHVARIPLPAGYREEIVRYLRSVQLPDGGWGLHIEDKSTVFGTALNYVSLRILGVGPDDPDLVRARNILHKKGGAVAIPSWGKFWLAVLNVYSWEGLNTLFPEMWLFPDWAPAHPSTLWCHCRQVYLPMSYCYAVRLSAAEDPLVQSLRQELYVEDFASIDWLAQRNNVAPDELYTPHSWLLRVVYALLNLYEHHHSAHLRQRAVQKLYEHIVADDRFTKSISIGPISKTINMLVRWYVDGPASTAFQEHVSRIPDYLWMGLDGMKMQGTNGSQIWDTAFAIQALLEAGGHHRPEFSSCLQKAHEFLRLSQVPDNPPDYQKYYRQMRKGGFSFSTLDCGWIVSDCTAEALKAVLLLQEKCPHVTEHIPRERLCDAVAVLLNMRNPDGGFATYETKRGGHLLELLNPSEVFGDIMIDYTYVECTSAVMQALKYFHKRFPEHRAAEIRETLTQGLEFCRRQQRADGSWEGSWGVCFTYGTWFGLEAFACMGQTYRDGTACAEVSRACDFLLSRQMADGGWGEDFESCEERRYLQSAQSQIHNTCWAMMGLMAVRHPDIEAQERGVRCLLEKQLPNGDWPQENIAGVFNKSCAISYTSYRNIFPIWALGRFSQLYPERALAGHP
T56175	DRUGINFO	D04GJX	ZD-9720	Terminated
T56175	DRUGINFO	D0I2YV	BIBB-515	Terminated
T56175	DRUGINFO	D0S1XO	BIBX-79	Terminated
T56175	DRUGINFO	D00XPB	PMID22533316C1	Investigative
T56175	DRUGINFO	D00ZEY	PMID22533316C4	Investigative
T56175	DRUGINFO	D05VRO	PMID9003518C4	Investigative
T56175	DRUGINFO	D0C4PT	29-methylidene-2,3-oxidosqualene	Investigative
T56175	DRUGINFO	D0J0JY	Tetradecane	Investigative
T56175	DRUGINFO	D0K3TQ	PMID9003518C3	Investigative
T56175	DRUGINFO	D0P4PQ	Lanosterol	Investigative
T56175	DRUGINFO	D0R1EO	[3-(Biphenyl-4-yloxy)-propyl]-dimethyl-amine	Investigative
T56175	DRUGINFO	D0X3GG	Ro48-8071	Investigative
T56175	DRUGINFO	D0Z3CK	PMID22533316C3	Investigative
T56175	DRUGINFO	D02UVH	B-Octylglucoside	Investigative

T86428	TARGETID	T86428
T86428	FORMERID	TTDR01076
T86428	UNIPROID	FNTB_HUMAN
T86428	TARGNAME	CAAX farnesyltransferase beta (FNTB)
T86428	GENENAME	FNTB
T86428	TARGTYPE	Literature-reported
T86428	SYNONYMS	RAS proteins prenyltransferasebeta; FTase-beta; FNTB; CAAX farnesyltransferase beta subunit
T86428	FUNCTION	Essential subunit of the farnesyltransferase complex. Catalyzes the transfer of a farnesyl moiety from farnesyl diphosphate to a cysteine at the fourth position from the C- terminus of several proteins having the C-terminal sequence Cys- aliphatic-aliphatic-X.
T86428	PDBSTRUC	3.00E+37; 2IEJ; 2H6I; 2H6H; 2H6G
T86428	BIOCLASS	Alkyl aryl transferase
T86428	ECNUMBER	EC 2.5.1.58
T86428	SEQUENCE	MASPSSFTYYCPPSSSPVWSEPLYSLRPEHARERLQDDSVETVTSIEQAKVEEKIQEVFSSYKFNHLVPRLVLQREKHFHYLKRGLRQLTDAYECLDASRPWLCYWILHSLELLDEPIPQIVATDVCQFLELCQSPEGGFGGGPGQYPHLAPTYAAVNALCIIGTEEAYDIINREKLLQYLYSLKQPDGSFLMHVGGEVDVRSAYCAASVASLTNIITPDLFEGTAEWIARCQNWEGGIGGVPGMEAHGGYTFCGLAALVILKRERSLNLKSLLQWVTSRQMRFEGGFQGRCNKLVDGCYSFWQAGLLPLLHRALHAQGDPALSMSHWMFHQQALQEYILMCCQCPAGGLLDKPGKSRDFYHTCYCLSGLSIAQHFGSGAMLHDVVLGVPENALQPTHPVYNIGPDKVIQATTYFLQKPVPGFEELKDETSAEPATD
T86428	DRUGINFO	D03FZA	FUSIDIENOL	Terminated
T86428	DRUGINFO	D05XTO	ABT-100	Terminated
T86428	DRUGINFO	D07PAY	B-956	Terminated
T86428	DRUGINFO	D09DLN	L-739749	Terminated
T86428	DRUGINFO	D0E7BP	CP-663427	Terminated
T86428	DRUGINFO	D0H2AM	XR-3054	Terminated
T86428	DRUGINFO	D0I9AR	BMS-185857	Terminated
T86428	DRUGINFO	D0O1XU	XR-3005	Terminated
T86428	DRUGINFO	D0V3WQ	Sch-207758	Terminated
T86428	DRUGINFO	D0W3OQ	BMS-182566	Terminated
T86428	DRUGINFO	D04DYZ	ABT-839	Terminated
T86428	DRUGINFO	D0C2UY	MANUMYCIN A	Terminated
T86428	DRUGINFO	D0EY9P	SCH-44342	Terminated
T86428	DRUGINFO	D0H5VF	RPR-113829	Terminated
T86428	DRUGINFO	D0L5AS	RPR-114334	Terminated
T86428	DRUGINFO	D0W2ED	L-731735	Terminated
T86428	DRUGINFO	D03OLA	L-745631	Terminated
T86428	DRUGINFO	D00OMV	Arteminolide	Investigative
T86428	DRUGINFO	D04ETB	CYLINDROL A	Investigative
T86428	DRUGINFO	D05IVD	PREUSSOMERIN	Investigative
T86428	DRUGINFO	D07ZTG	L-739750	Investigative
T86428	DRUGINFO	D08SZO	F-12458	Investigative
T86428	DRUGINFO	D08VBE	LB42908	Investigative
T86428	DRUGINFO	D0M5PB	FTI 276	Investigative
T86428	DRUGINFO	D0OC3P	Prenyl pyrophosphate analogue	Investigative
T86428	DRUGINFO	D0PK8Y	BMS-316810	Investigative
T86428	DRUGINFO	D0X5KQ	H-SMGLPCVVM-OH	Investigative
T86428	DRUGINFO	D00LAR	BMS-404683	Investigative
T86428	DRUGINFO	D01DTW	FARNESYL	Investigative
T86428	DRUGINFO	D01OFD	ACTINOPLANIC ACID A	Investigative
T86428	DRUGINFO	D06JMV	PB-27	Investigative
T86428	DRUGINFO	D0H4QM	PB-80	Investigative
T86428	DRUGINFO	D0L4RX	PB-81	Investigative
T86428	DRUGINFO	D0R3PD	CLAVARINONE	Investigative
T86428	DRUGINFO	D0T2SJ	A-313326	Investigative
T86428	DRUGINFO	D0TC4Z	ALPHA-HYDROXYFARNESYLPHOSPHONIC ACID	Investigative
T86428	DRUGINFO	D0VD2C	(Z)-2-Methyl-3-tetradecyl-but-2-enedioic acid	Investigative
T86428	DRUGINFO	D06DSE	PD-83176	Investigative
T86428	DRUGINFO	D0QX6B	GERANYLGERANYL DIPHOSPHATE	Investigative

T62265	TARGETID	T62265
T62265	FORMERID	TTDR00848
T62265	UNIPROID	DHYS_HUMAN
T62265	TARGNAME	Deoxyhypusine synthase (DHPS)
T62265	GENENAME	DHPS
T62265	TARGTYPE	Literature-reported
T62265	SYNONYMS	DHS
T62265	FUNCTION	Catalyzes the NAD-dependent oxidativecleavage of spermidine and the subsequent transfer of the butylamine moiety of spermidine to the epsilon-amino group of a specific lysine residue of the eIF-5A precursor protein to form the intermediate deoxyhypusine residue.
T62265	PDBSTRUC	1RQD; 1ROZ; 1RLZ; 1DHS
T62265	BIOCLASS	Alkyl aryl transferase
T62265	ECNUMBER	EC 2.5.1.46
T62265	SEQUENCE	MEGSLEREAPAGALAAVLKHSSTLPPESTQVRGYDFNRGVNYRALLEAFGTTGFQATNFGRAVQQVNAMIEKKLEPLSQDEDQHADLTQSRRPLTSCTIFLGYTSNLISSGIRETIRYLVQHNMVDVLVTTAGGVEEDLIKCLAPTYLGEFSLRGKELRENGINRIGNLLVPNENYCKFEDWLMPILDQMVMEQNTEGVKWTPSKMIARLGKEINNPESVYYWAQKNHIPVFSPALTDGSLGDMIFFHSYKNPGLVLDIVEDLRLINTQAIFAKCTGMIILGGGVVKHHIANANLMRNGADYAVYINTAQEFDGSDSGARPDEAVSWGKIRVDAQPVKVYADASLVFPLLVAETFAQKMDAFMHEKNED
T62265	DRUGINFO	D00UDX	1-Guanidinium-7-Aminoheptane	Investigative
T62265	DRUGINFO	D08PKS	N-guanyl-1,7-diaminoheptane	Investigative
T62265	DRUGINFO	D0FI8L	N1-guanyl-1,7-diaminoheptane	Investigative
T62265	DRUGINFO	D0R6JE	Nicotinamide-Adenine-Dinucleotide	Investigative

T55916	TARGETID	T55916
T55916	FORMERID	TTDS00149
T55916	UNIPROID	KCNQ4_HUMAN
T55916	TARGNAME	Voltage-gated potassium channel Kv7.4 (KCNQ4)
T55916	GENENAME	KCNQ4
T55916	TARGTYPE	Literature-reported
T55916	SYNONYMS	Voltage-gated potassium channel subunit Kv7.4; Potassium channel alpha subunit KvLQT4; KQT-like 4; KCNQ4
T55916	FUNCTION	Probably important in the regulation of neuronal excitability. May underlie a potassium current involved in regulating the excitability of sensory cells of the cochlea. KCNQ4 channels are blocked by linopirdin, XE991 and bepridil, whereas clofilium is without significant effect. Muscarinic agonist oxotremorine-M strongly suppress KCNQ4 current in CHO cells in which cloned KCNQ4 channels were coexpressed with M1muscarinic receptors.
T55916	PDBSTRUC	6N5W; 4GOW; 2OVC
T55916	BIOCLASS	Voltage-gated ion channel
T55916	SEQUENCE	MAEAPPRRLGLGPPPGDAPRAELVALTAVQSEQGEAGGGGSPRRLGLLGSPLPPGAPLPGPGSGSGSACGQRSSAAHKRYRRLQNWVYNVLERPRGWAFVYHVFIFLLVFSCLVLSVLSTIQEHQELANECLLILEFVMIVVFGLEYIVRVWSAGCCCRYRGWQGRFRFARKPFCVIDFIVFVASVAVIAAGTQGNIFATSALRSMRFLQILRMVRMDRRGGTWKLLGSVVYAHSKELITAWYIGFLVLIFASFLVYLAEKDANSDFSSYADSLWWGTITLTTIGYGDKTPHTWLGRVLAAGFALLGISFFALPAGILGSGFALKVQEQHRQKHFEKRRMPAANLIQAAWRLYSTDMSRAYLTATWYYYDSILPSFRELALLFEHVQRARNGGLRPLEVRRAPVPDGAPSRYPPVATCHRPGSTSFCPGESSRMGIKDRIRMGSSQRRTGPSKQHLAPPTMPTSPSSEQVGEATSPTKVQKSWSFNDRTRFRASLRLKPRTSAEDAPSEEVAEEKSYQCELTVDDIMPAVKTVIRSIRILKFLVAKRKFKETLRPYDVKDVIEQYSAGHLDMLGRIKSLQTRVDQIVGRGPGDRKAREKGDKGPSDAEVVDEISMMGRVVKVEKQVQSIEHKLDLLLGFYSRCLRSGTSASLGAVQVPLFDPDITSDYHSPVDHEDISVSAQTLSISRSVSTNMD
T55916	DRUGINFO	D0FR6J	NC00075159	Investigative
T55916	DRUGINFO	D0XY2M	ML213	Investigative
T55916	DRUGINFO	D02BGR	(S)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide	Investigative
T55916	DRUGINFO	D07FTI	zinc pyrithione	Investigative
T55916	DRUGINFO	D0P8PH	XE991	Investigative
T55916	DRUGINFO	D07ZAJ	PIP2	Investigative
T55916	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T44515	TARGETID	T44515
T44515	FORMERID	TTDR00633
T44515	UNIPROID	NADC_MYCTU
T44515	TARGNAME	Mycobacterium Nicotinate-nucleotide pyrophosphorylase (MycB nadC)
T44515	GENENAME	MycB nadC
T44515	TARGTYPE	Literature-reported
T44515	SYNONYMS	nadC; Quinolinic acid phosphoribosyltransferase; Quinolinate phosphoribosyltransferase [decarboxylating]; QAPRTase
T44515	FUNCTION	Involved in the catabolism of quinolinic acid (QA).
T44515	PDBSTRUC	1QPR; 1QPQ; 1QPO; 1QPN
T44515	BIOCLASS	Pentosyltransferase
T44515	ECNUMBER	EC 2.4.2.19
T44515	SEQUENCE	MGLSDWELAAARAAIARGLDEDLRYGPDVTTLATVPASATTTASLVTREAGVVAGLDVALLTLNEVLGTNGYRVLDRVEDGARVPPGEALMTLEAQTRGLLTAERTMLNLVGHLSGIATATAAWVDAVRGTKAKIRDTRKTLPGLRALQKYAVRTGGGVNHRLGLGDAALIKDNHVAAAGSVVDALRAVRNAAPDLPCEVEVDSLEQLDAVLPEKPELILLDNFAVWQTQTAVQRRDSRAPTVMLESSGGLSLQTAATYAETGVDYLAVGALTHSVRVLDIGLDM
T44515	DRUGINFO	D08PEM	5-Phosphoribosyl-1-(Beta-Methylene) Pyrophosphate	Investigative
T44515	DRUGINFO	D0L8CF	Quinolinic Acid	Investigative
T44515	DRUGINFO	D0OP3Y	Namn	Investigative
T44515	DRUGINFO	D0VH8M	Phthalic Acid	Investigative

T94400	TARGETID	T94400
T94400	FORMERID	TTDR00929
T94400	UNIPROID	KTHY_MYCTU
T94400	TARGNAME	Mycobacterium Thymidine monophosphate kinase (MycB tmk)
T94400	GENENAME	MycB tmk
T94400	TARGTYPE	Literature-reported
T94400	SYNONYMS	tmk; Thymidylic kinase; Thymidylic acid kinase; Thymidylate monophosphate kinase; Thymidylate kinase; Thymidine 5'-monophosphate kinase; TMPK; Deoxythymidine 5'-monophosphate kinase; DTMPkinase
T94400	FUNCTION	Catalyzes the reversible phosphorylation of deoxythymidine monophosphate (dTMP) to deoxythymidine diphosphate (dTDP), using ATP as its preferred phosphoryl donor. Situated at the junction of both de novo and salvage pathways of deoxythymidine triphosphate (dTTP) synthesis, is essential for DNA synthesis and cellular growth. Has a broad specificity for nucleoside triphosphates, being highly active withATP or dATP as phosphate donors, and less active with ITP, GTP, CTP and UTP.
T94400	PDBSTRUC	5NRQ; 5NRN; 5NR7; 5NQ5; 4UNS
T94400	BIOCLASS	Kinase
T94400	ECNUMBER	EC 2.7.4.9
T94400	SEQUENCE	MLIAIEGVDGAGKRTLVEKLSGAFRAAGRSVATLAFPRYGQSVAADIAAEALHGEHGDLASSVYAMATLFALDRAGAVHTIQGLCRGYDVVILDRYVASNAAYSAARLHENAAGKAAAWVQRIEFARLGLPKPDWQVLLAVSAELAGERSRGRAQRDPGRARDNYERDAELQQRTGAVYAELAAQGWGGRWLVVGADVDPGRLAATLAPPDVPS
T94400	DRUGINFO	D0A2IQ	3'-Azido-3'-Deoxythymidine-5'-Monophosphate	Investigative
T94400	DRUGINFO	D0I9ZJ	5-Hydroxymethyluridine-2'-Deoxy-5'-Monophosphate	Investigative
T94400	DRUGINFO	D0K6QS	CHLORODEOXYURIDINE	Investigative
T94400	DRUGINFO	D0M4MA	BROMODEOXYURIDINE	Investigative
T94400	DRUGINFO	D0P2IN	5'-amino-5'-deoxy-alpha-D-thymidine	Investigative
T94400	DRUGINFO	D0SC7C	2',3'-Dideoxythymidine-5'-Monophosphate	Investigative
T94400	DRUGINFO	D0U2KT	5'-deoxythymidine	Investigative
T94400	DRUGINFO	D01GLG	Deoxythymidine	Investigative
T94400	DRUGINFO	D04BBF	P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate	Investigative
T94400	DRUGINFO	D0R4PI	Diphosphate	Investigative
T94400	DRUGINFO	D0ZH0I	Thymidine-5'-Phosphate	Investigative
T94400	DRUGINFO	D09WYY	2'-deoxythymidine triphosphate	Investigative
T94400	DRUGINFO	D00ICA	AMP-PNP	Investigative
T94400	DRUGINFO	D0F2ME	Acetate Ion	Investigative

T09215	TARGETID	T09215
T09215	FORMERID	TTDR00619
T09215	UNIPROID	ACEA_MYCTU
T09215	TARGNAME	Mycobacterium Isocitrate lyase (MycB icl)
T09215	GENENAME	MycB icl
T09215	TARGTYPE	Literature-reported
T09215	SYNONYMS	Isocitratase; Isocitrase; ICL
T09215	FUNCTION	Catalyzes the formation of succinate and glyoxylate from isocitrate, a key step of the glyoxylate cycle. May be involved in the assimilation of one-carbon compounds via the isocitrate lyase- positive serine pathway.
T09215	PDBSTRUC	5DQL; 1F8M; 1F8I; 1F61
T09215	BIOCLASS	Carbon-carbon lyase
T09215	ECNUMBER	EC 4.1.3.1
T09215	SEQUENCE	MSVVGTPKSAEQIQQEWDTNPRWKDVTRTYSAEDVVALQGSVVEEHTLARRGAEVLWEQLHDLEWVNALGALTGNMAVQQVRAGLKAIYLSGWQVAGDANLSGHTYPDQSLYPANSVPQVVRRINNALQRADQIAKIEGDTSVENWLAPIVADGEAGFGGALNVYELQKALIAAGVAGSHWEDQLASEKKCGHLGGKVLIPTQQHIRTLTSARLAADVADVPTVVIARTDAEAATLITSDVDERDQPFITGERTREGFYRTKNGIEPCIARAKAYAPFADLIWMETGTPDLEAARQFSEAVKAEYPDQMLAYNCSPSFNWKKHLDDATIAKFQKELAAMGFKFQFITLAGFHALNYSMFDLAYGYAQNQMSAYVELQEREFAAEERGYTATKHQREVGAGYFDRIATTVDPNSSTTALTGSTEEGQFH
T09215	DRUGINFO	D03SKE	2,2',3-Tribromo-4,4',5,5'-tetrahydroxybibenzyl	Investigative
T09215	DRUGINFO	D05FWW	Bis(2,3-dibromo-4,5-dihydroxyphenyl)ether	Investigative
T09215	DRUGINFO	D08MOJ	3-bromopyruvate	Investigative
T09215	DRUGINFO	D0B2NG	Bis(3-bromo-4,5-dihydroxyphenyl)methanone	Investigative
T09215	DRUGINFO	D0C0DM	5,5'-methylenebis(3,4-dibromobenzene-1,2-diol)	Investigative
T09215	DRUGINFO	D0U9EW	Glyoxalate, Glyoxylate	Investigative
T09215	DRUGINFO	D0Z1ZI	3-nitropropionate	Investigative
T09215	DRUGINFO	D0A5BH	Hydrohalisulfate 1	Investigative
T09215	DRUGINFO	D0M9VY	Halisulfate 1	Investigative

T89323	TARGETID	T89323
T89323	FORMERID	TTDR00340
T89323	UNIPROID	M3K10_HUMAN
T89323	TARGNAME	Mixed lineage kinase 2 (MAP3K10)
T89323	GENENAME	MAP3K10
T89323	TARGTYPE	Literature-reported
T89323	SYNONYMS	Protein kinase MST; Mitogen-activated protein kinase kinase kinase 10; MST; MLK2
T89323	FUNCTION	Activates the JUN N-terminal pathway.
T89323	PDBSTRUC	2RF0
T89323	BIOCLASS	Kinase
T89323	ECNUMBER	EC 2.7.11.25
T89323	SEQUENCE	MEEEEGAVAKEWGTTPAGPVWTAVFDYEAAGDEELTLRRGDRVQVLSQDCAVSGDEGWWTGQLPSGRVGVFPSNYVAPGAPAAPAGLQLPQEIPFHELQLEEIIGVGGFGKVYRALWRGEEVAVKAARLDPEKDPAVTAEQVCQEARLFGALQHPNIIALRGACLNPPHLCLVMEYARGGALSRVLAGRRVPPHVLVNWAVQVARGMNYLHNDAPVPIIHRDLKSINILILEAIENHNLADTVLKITDFGLAREWHKTTKMSAAGTYAWMAPEVIRLSLFSKSSDVWSFGVLLWELLTGEVPYREIDALAVAYGVAMNKLTLPIPSTCPEPFARLLEECWDPDPHGRPDFGSILKRLEVIEQSALFQMPLESFHSLQEDWKLEIQHMFDDLRTKEKELRSREEELLRAAQEQRFQEEQLRRREQELAEREMDIVERELHLLMCQLSQEKPRVRKRKGNFKRSRLLKLREGGSHISLPSGFEHKITVQASPTLDKRKGSDGASPPASPSIIPRLRAIRLTPVDCGGSSSGSSSGGSGTWSRGGPPKKEELVGGKKKGRTWGPSSTLQKERVGGEERLKGLGEGSKQWSSSAPNLGKSPKHTPIAPGFASLNEMEEFAEAEDGGSSVPPSPYSTPSYLSVPLPAEPSPGARAPWEPTPSAPPARWGHGARRRCDLALLGCATLLGAVGLGADVAEARAADGEEQRRWLDGLFFPRAGRFPRGLSPPARPHGRREDVGPGLGLAPSATLVSLSSVSDCNSTRSLLRSDSDEAAPAAPSPPPSPPAPTPTPSPSTNPLVDLELESFKKDPRQSLTPTHVTAACAVSRGHRRTPSDGALGQRGPPEPAGHGPGPRDLLDFPRLPDPQALFPARRRPPEFPGRPTTLTFAPRPRPAASRPRLDPWKLVSFGRTLTISPPSRPDTPESPGPPSVQPTLLDMDMEGQNQDSTVPLCGAHGSH
T89323	DRUGINFO	D0V4IH	CEP1348	Investigative
T89323	DRUGINFO	D07IHM	CEP-6331	Investigative
T89323	DRUGINFO	D09QBA	CEP-5104	Investigative
T89323	DRUGINFO	D07ADX	URMC-099	Investigative

T96014	TARGETID	T96014
T96014	FORMERID	TTDR00662
T96014	UNIPROID	GALE_HUMAN
T96014	TARGNAME	UDP-glucose 4-epimerase (GALE)
T96014	GENENAME	GALE
T96014	TARGTYPE	Literature-reported
T96014	SYNONYMS	UDP-galactose4-epimerase; UDP-galactose4'-epimerase; UDP-galactose 4-epimerase; UDP-N-acetylglucosamine 4-epimerase; UDP-N-acetylgalactosamine 4-epimerase; UDP-GlcNAc 4-epimerase; UDP-GalNAc 4-epimerase; Galactowaldenase
T96014	FUNCTION	The reaction with UDP-Gal plays a critical role in the Leloir pathway of galactose catabolism in which galactose is converted to the glycolytic intermediate glucose 6-phosphate. It contributes to the catabolism of dietary galactose and enables the endogenous biosynthesis of both UDP-Gal and UDP-GalNAc when exogenous sources are limited. Both UDP-sugar interconversions are important in the synthesis of glycoproteins and glycolipids. Catalyzes two distinct but analogous reactions: the reversible epimerization of UDP-glucose to UDP-galactose and the reversible epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine.
T96014	PDBSTRUC	1I3N; 1I3M; 1I3L; 1I3K; 1HZJ
T96014	BIOCLASS	Racemases and epimerase
T96014	ECNUMBER	EC 5.1.3.2
T96014	SEQUENCE	MAEKVLVTGGAGYIGSHTVLELLEAGYLPVVIDNFHNAFRGGGSLPESLRRVQELTGRSVEFEEMDILDQGALQRLFKKYSFMAVIHFAGLKAVGESVQKPLDYYRVNLTGTIQLLEIMKAHGVKNLVFSSSATVYGNPQYLPLDEAHPTGGCTNPYGKSKFFIEEMIRDLCQADKTWNAVLLRYFNPTGAHASGCIGEDPQGIPNNLMPYVSQVAIGRREALNVFGNDYDTEDGTGVRDYIHVVDLAKGHIAALRKLKEQCGCRIYNLGTGTGYSVLQMVQAMEKASGKKIPYKVVARREGDVAACYANPSLAQEELGWTAALGLDRMCEDLWRWQKQNPSGFGTQA
T96014	DRUGINFO	D02HAL	Uridine-5'-Diphosphate	Investigative
T96014	DRUGINFO	D05PNI	Phenyl-Uridine-5'-Diphosphate	Investigative
T96014	DRUGINFO	D0K7WW	Uridine Diphosphate Galactose	Investigative
T96014	DRUGINFO	D0T9SK	Tetramethylammonium Ion	Investigative
T96014	DRUGINFO	D0Z9JO	Uridine-5'-Diphosphate-Mannose	Investigative
T96014	DRUGINFO	D06UGK	Uridine-Diphosphate-N-Acetylgalactosamine	Investigative
T96014	DRUGINFO	D0KC2Z	Uridine-Diphosphate-N-Acetylglucosamine	Investigative
T96014	DRUGINFO	D07MIE	UDP-glucose	Investigative
T96014	DRUGINFO	D0N0TS	PSAMMAPLIN A	Investigative
T96014	DRUGINFO	D0R6JE	Nicotinamide-Adenine-Dinucleotide	Investigative

T00820	TARGETID	T00820
T00820	FORMERID	TTDR01270
T00820	UNIPROID	KCJ11_HUMAN
T00820	TARGNAME	Inward rectifier potassium channel Kir6.2 (KCNJ11)
T00820	GENENAME	KCNJ11
T00820	TARGTYPE	Literature-reported
T00820	SYNONYMS	Potassium channel, inwardly rectifying, subfamily J, member 11; KCNJ11; KATP channel (Kir6.2/SUR2A); Inward rectifier K+ channel Kir6.2; IKATP
T00820	FUNCTION	This receptor is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. Can be blocked by extracellular barium. Subunit of ATP-sensitive potassium channels (KATP). Can form cardiac and smooth muscle-type KATP channels with ABCC9. KCNJ11 forms the channel pore while ABCC9 is required for activation and regulation.
T00820	PDBSTRUC	6C3P; 6C3O
T00820	BIOCLASS	Inward rectifier potassium channel
T00820	SEQUENCE	MLSRKGIIPEEYVLTRLAEDPAEPRYRARQRRARFVSKKGNCNVAHKNIREQGRFLQDVFTTLVDLKWPHTLLIFTMSFLCSWLLFAMAWWLIAFAHGDLAPSEGTAEPCVTSIHSFSSAFLFSIEVQVTIGFGGRMVTEECPLAILILIVQNIVGLMINAIMLGCIFMKTAQAHRRAETLIFSKHAVIALRHGRLCFMLRVGDLRKSMIISATIHMQVVRKTTSPEGEVVPLHQVDIPMENGVGGNSIFLVAPLIIYHVIDANSPLYDLAPSDLHHHQDLEIIVILEGVVETTGITTQARTSYLADEILWGQRFVPIVAEEDGRYSVDYSKFGNTIKVPTPLCTARQLDEDHSLLEALTLASARGPLRKRSVPMAKAKPKFSISPDSLS
T00820	DRUGINFO	D0U1XJ	HBR-985	Investigative

T12126	TARGETID	T12126
T12126	FORMERID	TTDR00341
T12126	UNIPROID	M3K11_HUMAN
T12126	TARGNAME	Mixed lineage kinase 3 (MAP3K11)
T12126	GENENAME	MAP3K11
T12126	TARGTYPE	Literature-reported
T12126	SYNONYMS	Src-homology 3 domain-containing proline-rich kinase; SPRK; SH3 domain-containing proline-rich kinase; Protein-tyrosine kinase PTK1; PTK1; Mixed-lineage protein kinase 3; Mitogen-activated protein kinase kinase kinase 11; MLK3
T12126	FUNCTION	Required for serum-stimulated cell proliferation and for mitogen and cytokine activation of MAPK14 (p38), MAPK3 (ERK) and MAPK8 (JNK1) through phosphorylation and activation of MAP2K4/MKK4 and MAP2K7/MKK7. Plays a role in mitogen-stimulated phosphorylation and activation of BRAF, but does not phosphorylate BRAF directly. Influences microtubule organization during the cell cycle. Activates the JUN N-terminal pathway.
T12126	PDBSTRUC	6CQ7; 6AQB; 5K28; 5K26
T12126	BIOCLASS	Kinase
T12126	ECNUMBER	EC 2.7.11.25
T12126	SEQUENCE	MEPLKSLFLKSPLGSWNGSGSGGGGGGGGGRPEGSPKAAGYANPVWTALFDYEPSGQDELALRKGDRVEVLSRDAAISGDEGWWAGQVGGQVGIFPSNYVSRGGGPPPCEVASFQELRLEEVIGIGGFGKVYRGSWRGELVAVKAARQDPDEDISVTAESVRQEARLFAMLAHPNIIALKAVCLEEPNLCLVMEYAAGGPLSRALAGRRVPPHVLVNWAVQIARGMHYLHCEALVPVIHRDLKSNNILLLQPIESDDMEHKTLKITDFGLAREWHKTTQMSAAGTYAWMAPEVIKASTFSKGSDVWSFGVLLWELLTGEVPYRGIDCLAVAYGVAVNKLTLPIPSTCPEPFAQLMADCWAQDPHRRPDFASILQQLEALEAQVLREMPRDSFHSMQEGWKREIQGLFDELRAKEKELLSREEELTRAAREQRSQAEQLRRREHLLAQWELEVFERELTLLLQQVDRERPHVRRRRGTFKRSKLRARDGGERISMPLDFKHRITVQASPGLDRRRNVFEVGPGDSPTFPRFRAIQLEPAEPGQAWGRQSPRRLEDSSNGERRACWAWGPSSPKPGEAQNGRRRSRMDEATWYLDSDDSSPLGSPSTPPALNGNPPRPSLEPEEPKRPVPAERGSSSGTPKLIQRALLRGTALLASLGLGRDLQPPGGPGRERGESPTTPPTPTPAPCPTEPPPSPLICFSLKTPDSPPTPAPLLLDLGIPVGQRSAKSPRREEEPRGGTVSPPPGTSRSAPGTPGTPRSPPLGLISRPRPSPLRSRIDPWSFVSAGPRPSPLPSPQPAPRRAPWTLFPDSDPFWDSPPANPFQGGPQDCRAQTKDMGAQAPWVPEAGP
T12126	DRUGINFO	D0O7HD	CEP1349	Investigative
T12126	DRUGINFO	D0YQ8V	PMID24044867C8	Investigative
T12126	DRUGINFO	D07IHM	CEP-6331	Investigative
T12126	DRUGINFO	D09QBA	CEP-5104	Investigative
T12126	DRUGINFO	D07ADX	URMC-099	Investigative

T26774	TARGETID	T26774
T26774	FORMERID	TTDR00489
T26774	UNIPROID	NCOA3_HUMAN
T26774	TARGNAME	Nuclear receptor coactivator 3 (NCOA3)
T26774	GENENAME	NCOA3
T26774	TARGTYPE	Literature-reported
T26774	SYNONYMS	bHLHe42; Thyroid hormone receptor activator molecule 1; TRAM1; TRAM-1; Steroid receptor coactivator protein 3; SRC-3; Receptor-associated coactivator 3; RAC3; RAC-3; PCIP; NCoA-3; Class E basic helix-loop-helix protein 42; CBP-interacting protein; Amplified in breast cancer-1 protein; Amplified in breast cancer 1 protein; AIB1 (SRC-3); AIB1; AIB-1; ACTR
T26774	FUNCTION	Plays a central role in creating a multisubunit coactivator complex, which probably acts via remodeling of chromatin. Involved in the coactivation of different nuclear receptors, such as for steroids (GR and ER), retinoids (RARs and RXRs), thyroid hormone (TRs), vitamin D3 (VDR) and prostanoids (PPARs). Displays histone acetyltransferase activity. Also involved in the coactivation of the NF-kappa-B pathway via its interaction with the NFKB1 subunit. Nuclear receptor coactivator that directly binds nuclear receptors and stimulates the transcriptional activities in a hormone-dependent fashion.
T26774	PDBSTRUC	6ES7; 3L3Z; 3L3X; 1KBH
T26774	BIOCLASS	Acyltransferase
T26774	ECNUMBER	EC 2.3.1.48
T26774	SEQUENCE	MSGLGENLDPLASDSRKRKLPCDTPGQGLTCSGEKRRREQESKYIEELAELISANLSDIDNFNVKPDKCAILKETVRQIRQIKEQGKTISNDDDVQKADVSSTGQGVIDKDSLGPLLLQALDGFLFVVNRDGNIVFVSENVTQYLQYKQEDLVNTSVYNILHEEDRKDFLKNLPKSTVNGVSWTNETQRQKSHTFNCRMLMKTPHDILEDINASPEMRQRYETMQCFALSQPRAMMEEGEDLQSCMICVARRITTGERTFPSNPESFITRHDLSGKVVNIDTNSLRSSMRPGFEDIIRRCIQRFFSLNDGQSWSQKRHYQEAYLNGHAETPVYRFSLADGTIVTAQTKSKLFRNPVTNDRHGFVSTHFLQREQNGYRPNPNPVGQGIRPPMAGCNSSVGGMSMSPNQGLQMPSSRAYGLADPSTTGQMSGARYGGSSNIASLTPGPGMQSPSSYQNNNYGLNMSSPPHGSPGLAPNQQNIMISPRNRGSPKIASHQFSPVAGVHSPMASSGNTGNHSFSSSSLSALQAISEGVGTSLLSTLSSPGPKLDNSPNMNITQPSKVSNQDSKSPLGFYCDQNPVESSMCQSNSRDHLSDKESKESSVEGAENQRGPLESKGHKKLLQLLTCSSDDRGHSSLTNSPLDSSCKESSVSVTSPSGVSSSTSGGVSSTSNMHGSLLQEKHRILHKLLQNGNSPAEVAKITAEATGKDTSSITSCGDGNVVKQEQLSPKKKENNALLRYLLDRDDPSDALSKELQPQVEGVDNKMSQCTSSTIPSSSQEKDPKIKTETSEEGSGDLDNLDAILGDLTSSDFYNNSISSNGSHLGTKQQVFQGTNSLGLKSSQSVQSIRPPYNRAVSLDSPVSVGSSPPVKNISAFPMLPKQPMLGGNPRMMDSQENYGSSMGGPNRNVTVTQTPSSGDWGLPNSKAGRMEPMNSNSMGRPGGDYNTSLPRPALGGSIPTLPLRSNSIPGARPVLQQQQQMLQMRPGEIPMGMGANPYGQAAASNQLGSWPDGMLSMEQVSHGTQNRPLLRNSLDDLVGPPSNLEGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPKQDAFQGQEAAVMMDQKAGLYGQTYPAQGPPMQGGFHLQGQSPSFNSMMNQMNQQGNFPLQGMHPRANIMRPRTNTPKQLRMQLQQRLQGQQFLNQSRQALELKMENPTAGGAAVMRPMMQPQVSSQQGFLNAQMVAQRSRELLSHHFRQQRVAMMMQQQQQQQQQQQQQQQQQQQQQQQQQQQQQTQAFSPPPNVTASPSMDGLLAGPTMPQAPPQQFPYQPNYGMGQQPDPAFGRVSSPPNAMMSSRMGPSQNPMMQHPQAASIYQSSEMKGWPSGNLARNSSFSQQQFAHQGNPAVYSMVHMNGSSGHMGQMNMNPMPMSGMPMGPDQKYC
T26774	DRUGINFO	D09ESF	GNF-PF-78	Investigative
T26774	DRUGINFO	D0R2ZN	GNF-PF-826	Investigative

T91173	TARGETID	T91173
T91173	FORMERID	TTDR01344
T91173	UNIPROID	IKKA_HUMAN
T91173	TARGNAME	IKKA messenger RNA (IKKA mRNA)
T91173	GENENAME	CHUK
T91173	TARGTYPE	Literature-reported
T91173	SYNONYMS	Transcription factor 16 (mRNA); TCF16 (mRNA); TCF-16 (mRNA); Nuclear factor NFkappaB inhibitor kinase alpha (mRNA); Nuclear factor NF-kappa-B inhibitor kinase alpha (mRNA); NFKBIKA (mRNA); Inhibitory kappa B kinasea (mRNA); Inhibitor of nuclear factor kappa-B kinase subunit alpha (mRNA); IkappaB kinase (mRNA); IkBKA (mRNA); IKK1 (mRNA); IKK-alpha (mRNA); IKK-A (mRNA); I-kappa-B kinase alpha (mRNA); I-kappa-B kinase 1 (mRNA); I kappa-B kinase alpha (mRNA); Conserved helix-loop-helix ubiquitous kinase (mRNA)
T91173	FUNCTION	Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on serine residues. These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome. In turn, free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. Negatively regulates the pathway by phosphorylating the scaffold protein TAXBP1 and thus promoting the assembly of the A20/TNFAIP3 ubiquitin-editing complex (composed of A20/TNFAIP3, TAX1BP1, and the E3 ligases ITCH and RNF11). Therefore, CHUK plays a key role in the negative feedback of NF-kappa-B canonical signaling to limit inflammatory gene activation. As part of the non-canonical pathway of NF-kappa-B activation, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. In turn, these complexes regulate genes encoding molecules involved in B-cell survival and lymphoid organogenesis. Participates also in the negative feedback of the non-canonical NF-kappa-B signaling pathway by phosphorylating and destabilizing MAP3K14/NIK. Within the nucleus, phosphorylates CREBBP and consequently increases both its transcriptional and histone acetyltransferase activities. Modulates chromatin accessibility at NF-kappa-B-responsive promoters by phosphorylating histones H3 at 'Ser-10' that are subsequently acetylated at 'Lys-14' by CREBBP. Additionally, phosphorylates the CREBBP-interacting protein NCOA3. Also phosphorylates FOXO3 and may regulate this pro-apoptotic transcription factor. Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses.
T91173	PDBSTRUC	5TQY; 5TQX; 5TQW; 5EBZ; 3BRT
T91173	BIOCLASS	mRNA target
T91173	ECNUMBER	EC 2.7.11.10
T91173	SEQUENCE	MERPPGLRPGAGGPWEMRERLGTGGFGNVCLYQHRELDLKIAIKSCRLELSTKNRERWCHEIQIMKKLNHANVVKACDVPEELNILIHDVPLLAMEYCSGGDLRKLLNKPENCCGLKESQILSLLSDIGSGIRYLHENKIIHRDLKPENIVLQDVGGKIIHKIIDLGYAKDVDQGSLCTSFVGTLQYLAPELFENKPYTATVDYWSFGTMVFECIAGYRPFLHHLQPFTWHEKIKKKDPKCIFACEEMSGEVRFSSHLPQPNSLCSLVVEPMENWLQLMLNWDPQQRGGPVDLTLKQPRCFVLMDHILNLKIVHILNMTSAKIISFLLPPDESLHSLQSRIERETGINTGSQELLSETGISLDPRKPASQCVLDGVRGCDSYMVYLFDKSKTVYEGPFASRSLSDCVNYIVQDSKIQLPIIQLRKVWAEAVHYVSGLKEDYSRLFQGQRAAMLSLLRYNANLTKMKNTLISASQQLKAKLEFFHKSIQLDLERYSEQMTYGISSEKMLKAWKEMEEKAIHYAEVGVIGYLEDQIMSLHAEIMELQKSPYGRRQGDLMESLEQRAIDLYKQLKHRPSDHSYSDSTEMVKIIVHTVQSQDRVLKELFGHLSKLLGCKQKIIDLLPKVEVALSNIKEADNTVMFMQGKRQKEIWHLLKIACTQSSARSLVGSSLEGAVTPQTSAWLPPTSAEHDHSLSCVVTPQDGETSAQMIEENLNCLGHLSTIIHEANEEQGNSMMNLDWSWLTE
T91173	DRUGINFO	D06UNC	ISIS 23559	Investigative
T91173	DRUGINFO	D0AJ5N	ISIS 23544	Investigative
T91173	DRUGINFO	D01OBJ	5-Bromo-6-methoxy-9H-beta-carboline	Investigative
T91173	DRUGINFO	D0S7IE	N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide	Investigative

T08074	TARGETID	T08074
T08074	FORMERID	TTDR01345
T08074	UNIPROID	PDPK1_HUMAN
T08074	TARGNAME	PDK-1 messenger RNA (PDK-1 mRNA)
T08074	GENENAME	PDPK1
T08074	TARGTYPE	Literature-reported
T08074	SYNONYMS	PDK1 (mRNA); HPDK1 (mRNA); 3-phosphoinositide-dependent protein kinase 1 (mRNA); 3-Phosphoinositide-dependent kinase-1 (mRNA); 3'-phosphoinositide dependent kinase 1 (mRNA)
T08074	FUNCTION	Its targets include: protein kinase B (PKB/AKT1, PKB/AKT2, PKB/AKT3), p70 ribosomal protein S6 kinase (RPS6KB1), p90 ribosomal protein S6 kinase (RPS6KA1, RPS6KA2 and RPS6KA3), cyclic AMP-dependent protein kinase (PRKACA), protein kinase C (PRKCD and PRKCZ), serum and glucocorticoid-inducible kinase (SGK1, SGK2 and SGK3), p21-activated kinase-1 (PAK1), protein kinase PKN (PKN1 and PKN2). Plays a central role in the transduction of signals from insulin by providing the activating phosphorylation to PKB/AKT1, thus propagating the signal to downstream targets controlling cell proliferation and survival, as well as glucose and amino acid uptake and storage. Negatively regulates the TGF-beta-induced signaling by: modulating the association of SMAD3 and SMAD7 with TGF-beta receptor, phosphorylating SMAD2, SMAD3, SMAD4 and SMAD7, preventing the nuclear translocation of SMAD3 and SMAD4 and the translocation of SMAD7 from the nucleus to the cytoplasm in response to TGF-beta. Activates PPARG transcriptional activity and promotes adipocyte differentiation. Activates the NF-kappa-B pathway via phosphorylation of IKKB. The tyrosine phosphorylated form is crucial for the regulation of focal adhesions by angiotensin II. Controls proliferation, survival, and growth of developing pancreatic cells. Participates in the regulation of Ca(2+) entry and Ca(2+)-activated K(+) channels of mast cells. Essential for the motility of vascular endothelial cells (ECs) and is involved in the regulation of their chemotaxis. Plays a critical role in cardiac homeostasis by serving as a dual effector for cell survival and beta-adrenergic response. Plays an important role during thymocyte development by regulating the expression of key nutrient receptors on the surface of pre-T cells and mediating Notch-induced cell growth and proliferative responses. Provides negative feedback inhibition to toll-like receptor-mediated NF-kappa-B activation in macrophages. Isoform 3 is catalytically inactive. Serine/threonine kinase which acts as a master kinase, phosphorylating and activating a subgroup of the AGC family of protein kinases.
T08074	PDBSTRUC	5MRD; 5LVP; 5LVO; 5LVN; 5LVM
T08074	BIOCLASS	mRNA target
T08074	ECNUMBER	EC 2.7.11.1
T08074	SEQUENCE	MARTTSQLYDAVPIQSSVVLCSCPSPSMVRTQTESSTPPGIPGGSRQGPAMDGTAAEPRPGAGSLQHAQPPPQPRKKRPEDFKFGKILGEGSFSTVVLARELATSREYAIKILEKRHIIKENKVPYVTRERDVMSRLDHPFFVKLYFTFQDDEKLYFGLSYAKNGELLKYIRKIGSFDETCTRFYTAEIVSALEYLHGKGIIHRDLKPENILLNEDMHIQITDFGTAKVLSPESKQARANSFVGTAQYVSPELLTEKSACKSSDLWALGCIIYQLVAGLPPFRAGNEYLIFQKIIKLEYDFPEKFFPKARDLVEKLLVLDATKRLGCEEMEGYGPLKAHPFFESVTWENLHQQTPPKLTAYLPAMSEDDEDCYGNYDNLLSQFGCMQVSSSSSSHSLSASDTGLPQRSGSNIEQYIHDLDSNSFELDLQFSEDEKRLLLEKQAGGNPWHQFVENNLILKMGPVDKRKGLFARRRQLLLTEGPHLYYVDPVNKVLKGEIPWSQELRPEAKNFKTFFVHTPNRTYYLMDPSGNAHKWCRKIQEVWRQRYQSHPDAAVQ
T08074	DRUGINFO	D00SNI	ISIS 29475	Investigative
T08074	DRUGINFO	D00XPD	ISIS 29233	Investigative
T08074	DRUGINFO	D01IHU	ISIS 29471	Investigative
T08074	DRUGINFO	D03RER	ISIS 29470	Investigative
T08074	DRUGINFO	D04REL	ISIS 29477	Investigative
T08074	DRUGINFO	D08OLG	ISIS 29239	Investigative
T08074	DRUGINFO	D09EAE	SU-6689	Investigative
T08074	DRUGINFO	D09NFR	ISIS 29257	Investigative
T08074	DRUGINFO	D09OFM	MiR-375	Investigative
T08074	DRUGINFO	D0A3PB	ISIS 29256	Investigative
T08074	DRUGINFO	D0C1ZW	ISIS 29232	Investigative
T08074	DRUGINFO	D0CS4K	ISIS 29224	Investigative
T08074	DRUGINFO	D0D3MV	ISIS 29255	Investigative
T08074	DRUGINFO	D0H6DN	ISIS 29469	Investigative
T08074	DRUGINFO	D0I8KZ	ISIS 29223	Investigative
T08074	DRUGINFO	D0K8NI	ISIS 29246	Investigative
T08074	DRUGINFO	D0M5DM	ISIS 29236	Investigative
T08074	DRUGINFO	D0ML3Q	ISIS 29243	Investigative
T08074	DRUGINFO	D0PY4Z	ISIS 29219	Investigative
T08074	DRUGINFO	D0S4RZ	ISIS 29234	Investigative
T08074	DRUGINFO	D0V6GX	BX-201	Investigative
T08074	DRUGINFO	D0ZL8O	ISIS 29244	Investigative
T08074	DRUGINFO	D0ZQ0Y	ISIS 29237	Investigative
T08074	DRUGINFO	D0L5AB	BX-517	Investigative
T08074	DRUGINFO	D00ATA	(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one	Investigative
T08074	DRUGINFO	D0Y5RO	NU-6102	Investigative

T98315	TARGETID	T98315
T98315	FORMERID	TTDR01353
T98315	UNIPROID	SOAT2_HUMAN
T98315	TARGNAME	SOAT2 messenger RNA (SOAT2 mRNA)
T98315	GENENAME	SOAT2
T98315	TARGTYPE	Literature-reported
T98315	SYNONYMS	Sterol O-acyltransferase 2 (mRNA); Cholesterol acyltransferase 2 (mRNA); Acyl-coenzyme A:cholesterol acyltransferase 2 (mRNA); ACAT2 (mRNA); ACAT-2 (mRNA); ACACT2 (mRNA)
T98315	FUNCTION	Plays a role in lipoprotein assembly and dietary cholesterol absorption. In addition to its acyltransferase activity, it may act as a ligase. May provide cholesteryl esters for lipoprotein secretion from hepatocytes and intestinal mucosa.
T98315	BIOCLASS	mRNA target
T98315	ECNUMBER	EC 2.3.1.26
T98315	SEQUENCE	MEPGGARLRLQRTEGLGGERERQPCGDGNTETHRAPDLVQWTRHMEAVKAQLLEQAQGQLRELLDRAMREAIQSYPSQDKPLPPPPPGSLSRTQEPSLGKQKVFIIRKSLLDELMEVQHFRTIYHMFIAGLCVFIISTLAIDFIDEGRLLLEFDLLIFSFGQLPLALVTWVPMFLSTLLAPYQALRLWARGTWTQATGLGCALLAAHAVVLCALPVHVAVEHQLPPASRCVLVFEQVRFLMKSYSFLREAVPGTLRARRGEGIQAPSFSSYLYFLFCPTLIYRETYPRTPYVRWNYVAKNFAQALGCVLYACFILGRLCVPVFANMSREPFSTRALVLSILHATLPGIFMLLLIFFAFLHCWLNAFAEMLRFGDRMFYRDWWNSTSFSNYYRTWNVVVHDWLYSYVYQDGLRLLGARARGVAMLGVFLVSAVAHEYIFCFVLGFFYPVMLILFLVIGGMLNFMMHDQRTGPAWNVLMWTMLFLGQGIQVSLYCQEWYARRHCPLPQATFWGLVTPRSWSCHT
T98315	DRUGINFO	D02YNE	ISIS 140158	Investigative
T98315	DRUGINFO	D0A9LB	ISIS 140153	Investigative
T98315	DRUGINFO	D0B1US	ISIS 140157	Investigative
T98315	DRUGINFO	D0I2SY	ISIS 140148	Investigative
T98315	DRUGINFO	D0O1CN	ISIS 140161	Investigative
T98315	DRUGINFO	D0A2NK	PYRIPYROPENE A	Investigative
T98315	DRUGINFO	D0T7YM	Oleic acid anilide	Investigative

T48614	TARGETID	T48614
T48614	FORMERID	TTDC00228
T48614	UNIPROID	IF4E_HUMAN
T48614	TARGNAME	EIF4E messenger RNA (EIF4E mRNA)
T48614	GENENAME	EIF4E
T48614	TARGTYPE	Literature-reported
T48614	SYNONYMS	mRNA capbinding protein (mRNA); mRNA cap-binding protein (mRNA); eIF4F 25 kDa subunit (mRNA); eIF4E (mRNA); eIF-4F 25 kDa subunit (mRNA); eIF-4E (mRNA); Eukaryotic translation initiation factor 4E (mRNA); EIF4F (mRNA); EIF4EL1 (mRNA)
T48614	FUNCTION	Component of the CYFIP1-EIF4E-FMR1 complex which binds to the mRNA cap and mediates translational repression. In the CYFIP1-EIF4E-FMR1 complex this subunit mediates the binding to the mRNA cap. Recognizes and binds the 7-methylguanosine-containing mRNA cap during an early step in the initiation of protein synthesis and facilitates ribosome binding by inducing the unwinding of the mRNAs secondary structures.
T48614	PDBSTRUC	5ZML; 5ZK9; 5ZK7; 5ZK5; 5ZJZ
T48614	BIOCLASS	mRNA target
T48614	SEQUENCE	MATVEPETTPTPNPPTTEEEKTESNQEVANPEHYIKHPLQNRWALWFFKNDKSKTWQANLRLISKFDTVEDFWALYNHIQLSSNLMPGCDYSLFKDGIEPMWEDEKNKRGGRWLITLNKQQRRSDLDRFWLETLLCLIGESFDDYSDDVCGAVVNVRAKGDKIAIWTTECENREAVTHIGRVYKERLGLPPKIVIGYQSHADTATKSGSTTKNRFVV
T48614	DRUGINFO	D00FPT	7-Methyl-Guanosine-5'-Triphosphate	Investigative
T48614	DRUGINFO	D00MZD	7n-Methyl-8-Hydroguanosine-5'-Diphosphate	Investigative
T48614	DRUGINFO	D06NGR	7-Methyl-Gpppa	Investigative

T55414	TARGETID	T55414
T55414	FORMERID	TTDI02252
T55414	UNIPROID	CSF1R_HUMAN
T55414	TARGNAME	CSF1R messenger RNA (CSF1R mRNA)
T55414	GENENAME	CSF1R
T55414	TARGTYPE	Literature-reported
T55414	SYNONYMS	Proto-oncogene c-Fms (mRNA); M-CSF-R (mRNA); FMS (mRNA); CSF-1R (mRNA); CSF-1-R (mRNA); CSF-1 receptor (mRNA); CD115 (mRNA)
T55414	FUNCTION	Promotes the release of proinflammatory chemokines in response to IL34 and CSF1, and thereby plays an important role in innate immunity and in inflammatory processes. Plays an important role in the regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone and tooth development. Required for normal male and female fertility, and for normal development of milk ducts and acinar structures in the mammary gland during pregnancy. Promotes reorganization of the actin cytoskeleton, regulates formation of membrane ruffles, cell adhesion and cell migration, and promotes cancer cell invasion. Activates several signaling pathways in response to ligand binding. Phosphorylates PIK3R1, PLCG2, GRB2, SLA2 and CBL. Activation of PLCG2 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, that then lead to the activation of protein kinase C family members, especially PRKCD. Phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leads to activation of the AKT1 signaling pathway. Activated CSF1R also mediates activation of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1, and of the SRC family kinases SRC, FYN and YES1. Activated CSF1R transmits signals both via proteins that directly interact with phosphorylated tyrosine residues in its intracellular domain, or via adapter proteins, such as GRB2. Promotes activation of STAT family members STAT3, STAT5A and/or STAT5B. Promotes tyrosine phosphorylation of SHC1 and INPP5D/SHIP-1. Receptor signaling is down-regulated by protein phosphatases, such as INPP5D/SHIP-1, that dephosphorylate the receptor and its downstream effectors, and by rapid internalization of the activated receptor. Tyrosine-protein kinase that acts as cell-surface receptor for CSF1 and IL34 and plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes.
T55414	PDBSTRUC	4WRM; 4WRL; 4R7I; 4R7H; 4LIQ
T55414	BIOCLASS	mRNA target
T55414	ECNUMBER	EC 2.7.10.1
T55414	SEQUENCE	MGPGVLLLLLVATAWHGQGIPVIEPSVPELVVKPGATVTLRCVGNGSVEWDGPPSPHWTLYSDGSSSILSTNNATFQNTGTYRCTEPGDPLGGSAAIHLYVKDPARPWNVLAQEVVVFEDQDALLPCLLTDPVLEAGVSLVRVRGRPLMRHTNYSFSPWHGFTIHRAKFIQSQDYQCSALMGGRKVMSISIRLKVQKVIPGPPALTLVPAELVRIRGEAAQIVCSASSVDVNFDVFLQHNNTKLAIPQQSDFHNNRYQKVLTLNLDQVDFQHAGNYSCVASNVQGKHSTSMFFRVVESAYLNLSSEQNLIQEVTVGEGLNLKVMVEAYPGLQGFNWTYLGPFSDHQPEPKLANATTKDTYRHTFTLSLPRLKPSEAGRYSFLARNPGGWRALTFELTLRYPPEVSVIWTFINGSGTLLCAASGYPQPNVTWLQCSGHTDRCDEAQVLQVWDDPYPEVLSQEPFHKVTVQSLLTVETLEHNQTYECRAHNSVGSGSWAFIPISAGAHTHPPDEFLFTPVVVACMSIMALLLLLLLLLLYKYKQKPKYQVRWKIIESYEGNSYTFIDPTQLPYNEKWEFPRNNLQFGKTLGAGAFGKVVEATAFGLGKEDAVLKVAVKMLKSTAHADEKEALMSELKIMSHLGQHENIVNLLGACTHGGPVLVITEYCCYGDLLNFLRRKAEAMLGPSLSPGQDPEGGVDYKNIHLEKKYVRRDSGFSSQGVDTYVEMRPVSTSSNDSFSEQDLDKEDGRPLELRDLLHFSSQVAQGMAFLASKNCIHRDVAARNVLLTNGHVAKIGDFGLARDIMNDSNYIVKGNARLPVKWMAPESIFDCVYTVQSDVWSYGILLWEIFSLGLNPYPGILVNSKFYKLVKDGYQMAQPAFAPKNIYSIMQACWALEPTHRPTFQQICSFLQEQAQEDRRERDYTNLPSSSRSGGSGSSSSELEEESSSEHLTCCEQGDIAQPLLQPNNYQFC
T55414	DRUGINFO	D0D6MH	GW-2580	Investigative
T55414	DRUGINFO	D08BJR	Ki-20227	Investigative
T55414	DRUGINFO	D0UN9O	GTP-14564	Investigative
T55414	DRUGINFO	D0Y4BL	JNJ-28312141	Investigative

T78393	TARGETID	T78393
T78393	FORMERID	TTDR01372
T78393	UNIPROID	MIF_HUMAN
T78393	TARGNAME	MIF messenger RNA (MIF mRNA)
T78393	GENENAME	MIF
T78393	TARGTYPE	Literature-reported
T78393	SYNONYMS	Phenylpyruvate tautomerase (mRNA); MMIF (mRNA); L-dopachrome tautomerase (mRNA); L-dopachrome isomerase (mRNA); Glycosylation-inhibiting factor (mRNA); GLIF (mRNA); GIF (mRNA)
T78393	FUNCTION	Involved in the innate immune response to bacterial pathogens. The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense. Counteracts the anti-inflammatory activity of glucocorticoids. Has phenylpyruvate tautomerase and dopachrome tautomerase activity (in vitro), but the physiological substrate is not known. It is not clear whether the tautomerase activity has any physiological relevance, and whether it is important for cytokine activity. Pro-inflammatory cytokine.
T78393	PDBSTRUC	6FVH; 6FVE; 6CBH; 6CBG; 6CBF
T78393	BIOCLASS	mRNA target
T78393	ECNUMBER	EC 5.3.2.1
T78393	SEQUENCE	MPMFIVNTNVPRASVPDGFLSELTQQLAQATGKPPQYIAVHVVPDQLMAFGGSSEPCALCSLHSIGKIGGAQNRSYSKLLCGLLAERLRISPDRVYINYYDMNAANVGWNNSTFA
T78393	DRUGINFO	D01DCZ	ISIS 112690	Investigative
T78393	DRUGINFO	D01HJN	Ethyl 7-hydroxy-2-oxo-2H-chromene-3-carboxylate	Investigative
T78393	DRUGINFO	D02CBE	ISIS 112724	Investigative
T78393	DRUGINFO	D03IWC	3-benzyl-6-methylbenzo[d]oxazol-2(3H)-one	Investigative
T78393	DRUGINFO	D03QDS	2-(4-hydroxystyryl)quinolin-8-ol	Investigative
T78393	DRUGINFO	D03QNS	7-hydroxy-3-phenyl-2H-chromen-2-one	Investigative
T78393	DRUGINFO	D04MZK	6-phenylpyridazin-3-yl thiophene-2-carboxylate	Investigative
T78393	DRUGINFO	D05RSQ	3-benzyl-5-fluorobenzo[d]oxazol-2(3H)-one	Investigative
T78393	DRUGINFO	D06HPB	ISIS 112696	Investigative
T78393	DRUGINFO	D07OLL	4-((pyridin-4-ylthio)methyl)benzene-1,2-diol	Investigative
T78393	DRUGINFO	D09BVA	3-acetyl-7-hydroxy-2H-chromen-2-one	Investigative
T78393	DRUGINFO	D0A5XY	N-(2-bromobenzoyloxy)-4-chlorobenzamide	Investigative
T78393	DRUGINFO	D0C4ET	ISIS 112592	Investigative
T78393	DRUGINFO	D0E1HP	3,3,3-tris(4-chlorophenyl)propanoic acid	Investigative
T78393	DRUGINFO	D0G2XI	4-(4-benzyl-1H-1,2,3-triazol-1-yl)phenol	Investigative
T78393	DRUGINFO	D0G9JB	ISIS 112699	Investigative
T78393	DRUGINFO	D0O4BU	S-benzo[d]oxazol-2-yl O-butyl carbonothioate	Investigative
T78393	DRUGINFO	D0R4LX	ISIS 112590	Investigative
T78393	DRUGINFO	D0S0YQ	1-(2-chlorophenyl)-3-(pyridin-2-yl)thiourea	Investigative
T78393	DRUGINFO	D0T3FE	ISIS 112711	Investigative
T78393	DRUGINFO	D0TX9P	3-(1H-pyrazol-3-yl)benzoic acid	Investigative
T78393	DRUGINFO	D0V4SG	3-benzyl-5-methylbenzo[d]oxazol-2(3H)-one	Investigative
T78393	DRUGINFO	D0W0QS	ISIS 112580	Investigative
T78393	DRUGINFO	D0W1WF	4-iodo-6-phenylpyrimidine	Investigative
T78393	DRUGINFO	D0WO4V	ISIS 112599	Investigative
T78393	DRUGINFO	D0X3TX	ISIS 112694	Investigative
T78393	DRUGINFO	D0Y2OB	Benzofuran-2-yl(indolin-1-yl)methanone	Investigative
T78393	DRUGINFO	D0YY2W	1-phenyl-3-(1,3,4-thiadiazol-2-yl)thiourea	Investigative

T40149	TARGETID	T40149
T40149	FORMERID	TTDR01379
T40149	UNIPROID	KPCL_HUMAN
T40149	TARGNAME	PKC-eta messenger RNA (PRKCH mRNA)
T40149	GENENAME	PRKCH
T40149	TARGTYPE	Literature-reported
T40149	SYNONYMS	nPKC-eta (mRNA); Protein kinase C eta type (mRNA); PRKCL (mRNA); PKCL (mRNA); PKC-L (mRNA)
T40149	FUNCTION	In keratinocytes, binds and activates the tyrosine kinase FYN, which in turn blocks epidermal growth factor receptor (EGFR) signaling and leads to keratinocyte growth arrest and differentiation. Associates with the cyclin CCNE1-CDK2-CDKN1B complex and inhibits CDK2 kinase activity, leading to RB1 dephosphorylation and thereby G1 arrest in keratinocytes. In association with RALA activates actin depolymerization, which is necessary for keratinocyte differentiation. In the pre-B cell receptor signaling, functions downstream of BLNK by up-regulating IRF4, which in turn activates L chain gene rearrangement. Regulates epithelial tight junctions (TJs) by phosphorylating occludin (OCLN) on threonine residues, which is necessary for the assembly and maintenance of TJs. In association with PLD2 and via TLR4 signaling, is involved in lipopolysaccharide (LPS)-induced RGS2 down-regulation and foam cell formation. Upon PMA stimulation, mediates glioblastoma cell proliferation by activating the mTOR pathway, the PI3K/AKT pathway and the ERK1-dependent phosphorylation of ELK1. Involved in the protection of glioblastoma cells from irradiation-induced apoptosis by preventing caspase-9 activation. In camptothecin-treated MCF-7 cells, regulates NF-kappa-B upstream signaling by activating IKBKB, and confers protection against DNA damage-induced apoptosis. Promotes oncogenic functions of ATF2 in the nucleus while blocking its apoptotic function at mitochondria. Phosphorylates ATF2 which promotes its nuclear retention and transcriptional activity and negatively regulates its mitochondrial localization. Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that is involved in the regulation of cell differentiation in keratinocytes and pre-B cell receptor, mediates regulation of epithelial tight junction integrity and foam cell formation, and is required for glioblastoma proliferation and apoptosis prevention in MCF-7 cells.
T40149	PDBSTRUC	3TXO; 2FK9
T40149	BIOCLASS	mRNA target
T40149	ECNUMBER	EC 2.7.11.13
T40149	SEQUENCE	MSSGTMKFNGYLRVRIGEAVGLQPTRWSLRHSLFKKGHQLLDPYLTVSVDQVRVGQTSTKQKTNKPTYNEEFCANVTDGGHLELAVFHETPLGYDHFVANCTLQFQELLRTTGASDTFEGWVDLEPEGKVFVVITLTGSFTEATLQRDRIFKHFTRKRQRAMRRRVHQINGHKFMATYLRQPTYCSHCREFIWGVFGKQGYQCQVCTCVVHKRCHHLIVTACTCQNNINKVDSKIAEQRFGINIPHKFSIHNYKVPTFCDHCGSLLWGIMRQGLQCKICKMNVHIRCQANVAPNCGVNAVELAKTLAGMGLQPGNISPTSKLVSRSTLRRQGKESSKEGNGIGVNSSNRLGIDNFEFIRVLGKGSFGKVMLARVKETGDLYAVKVLKKDVILQDDDVECTMTEKRILSLARNHPFLTQLFCCFQTPDRLFFVMEFVNGGDLMFHIQKSRRFDEARARFYAAEIISALMFLHDKGIIYRDLKLDNVLLDHEGHCKLADFGMCKEGICNGVTTATFCGTPDYIAPEILQEMLYGPAVDWWAMGVLLYEMLCGHAPFEAENEDDLFEAILNDEVVYPTWLHEDATGILKSFMTKNPTMRLGSLTQGGEHAILRHPFFKEIDWAQLNHRQIEPPFRPRIKSREDVSNFDPDFIKEEPVLTPIDEGHLPMINQDEFRNFSYVSPELQP
T40149	DRUGINFO	D0R2TM	BALANOL	Terminated
T40149	DRUGINFO	D01YJD	ISIS 6445	Investigative
T40149	DRUGINFO	D02NUN	ISIS 6432	Investigative
T40149	DRUGINFO	D04YKA	ISIS 6553	Investigative
T40149	DRUGINFO	D05ZZH	ISIS 6581	Investigative
T40149	DRUGINFO	D07TMI	ISIS 6442	Investigative
T40149	DRUGINFO	D0DS2V	ISIS 6434	Investigative
T40149	DRUGINFO	D0HU4L	ISIS 6431	Investigative
T40149	DRUGINFO	D0LL1H	ISIS 6603	Investigative
T40149	DRUGINFO	D0UH5I	ISIS 6443	Investigative
T40149	DRUGINFO	D0Z3TU	ISIS 6435	Investigative
T40149	DRUGINFO	D04AXH	8-Octyl-benzolactam-V9	Investigative
T40149	DRUGINFO	D04JNZ	PROSTRATIN	Investigative
T40149	DRUGINFO	D06ZCX	LY-326449	Investigative

T54779	TARGETID	T54779
T54779	FORMERID	TTDI02259
T54779	UNIPROID	RIR2_HUMAN
T54779	TARGNAME	RRM2 messenger RNA (RRM2 mRNA)
T54779	GENENAME	RRM2
T54779	TARGTYPE	Literature-reported
T54779	SYNONYMS	Ribonucleotide reductase small subunit (mRNA); Ribonucleotide reductase small chain (mRNA); Ribonucleoside-diphosphate reductase subunit M2 (mRNA); RR2 (mRNA)
T54779	FUNCTION	Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides. Inhibits Wnt signaling. Provides the precursors necessary for DNA synthesis.
T54779	PDBSTRUC	3VPO; 3VPN; 3VPM; 3OLJ; 2UW2
T54779	BIOCLASS	mRNA target
T54779	ECNUMBER	EC 1.17.4.1
T54779	SEQUENCE	MLSLRVPLAPITDPQQLQLSPLKGLSLVDKENTPPALSGTRVLASKTARRIFQEPTEPKTKAAAPGVEDEPLLRENPRRFVIFPIEYHDIWQMYKKAEASFWTAEEVDLSKDIQHWESLKPEERYFISHVLAFFAASDGIVNENLVERFSQEVQITEARCFYGFQIAMENIHSEMYSLLIDTYIKDPKEREFLFNAIETMPCVKKKADWALRWIGDKEATYGERVVAFAAVEGIFFSGSFASIFWLKKRGLMPGLTFSNELISRDEGLHCDFACLMFKHLVHKPSEERVREIIINAVRIEQEFLTEALPVKLIGMNCTLMKQYIEFVADRLMLELGFSKVFRVENPFDFMENISLEGKTNFFEKRVGEYQRMGVMSSPTENSFTLDADF

T31032	TARGETID	T31032
T31032	FORMERID	TTDR01385
T31032	UNIPROID	MP2K2_HUMAN
T31032	TARGNAME	MEK2 messenger RNA (MEK2 mRNA)
T31032	GENENAME	MAP2K2
T31032	TARGTYPE	Literature-reported
T31032	SYNONYMS	PRKMK2 (mRNA); MKK2 (mRNA); MEK 2 (mRNA); MAPKK 2 (mRNA); MAPK/ERK kinase 2 (mRNA); MAP kinase kinase 2 (mRNA); Dual specificity mitogenactivated protein kinase kinase 2 (mRNA); Dual specificity mitogen-activated protein kinase kinase 2 (mRNA)
T31032	FUNCTION	Activates the ERK1 and ERK2 MAP kinases. Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases.
T31032	PDBSTRUC	4H3Q; 1S9I
T31032	BIOCLASS	mRNA target
T31032	ECNUMBER	EC 2.7.12.2
T31032	SEQUENCE	MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQKAKVGELKDDDFERISELGAGNGGVVTKVQHRPSGLIMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIAVLRGLAYLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQGTHYSVQSDIWSMGLSLVELAVGRYPIPPPDAKELEAIFGRPVVDGEEGEPHSISPRPRPPGRPVSGHGMDSRPAMAIFELLDYIVNEPPPKLPNGVFTPDFQEFVNKCLIKNPAERADLKMLTNHTFIKRSEVEEVDFAGWLCKTLRLNQPGTPTRTAV
T31032	DRUGINFO	D01KTB	ISIS 25080	Investigative
T31032	DRUGINFO	D02YXE	ISIS 25124	Investigative
T31032	DRUGINFO	D04CYY	ISIS 25123	Investigative
T31032	DRUGINFO	D04LLB	ISIS 25078	Investigative
T31032	DRUGINFO	D05GCI	ISIS 25082	Investigative
T31032	DRUGINFO	D06DMT	ISIS 25074	Investigative
T31032	DRUGINFO	D07ZWS	ISIS 25126	Investigative
T31032	DRUGINFO	D08DCT	ISIS 25079	Investigative
T31032	DRUGINFO	D09LKE	ISIS 25113	Investigative
T31032	DRUGINFO	D0C3UV	ISIS 25117	Investigative
T31032	DRUGINFO	D0F8LL	ISIS 25115	Investigative
T31032	DRUGINFO	D0H2LG	ISIS 25128	Investigative
T31032	DRUGINFO	D0LS4V	ISIS 25081	Investigative
T31032	DRUGINFO	D0M3UJ	ISIS 25073	Investigative
T31032	DRUGINFO	D0M7OE	ISIS 25127	Investigative
T31032	DRUGINFO	D0OV0A	ISIS 25114	Investigative
T31032	DRUGINFO	D0PK2K	ISIS 25125	Investigative
T31032	DRUGINFO	D0RX1E	ISIS 25116	Investigative
T31032	DRUGINFO	D0TY2O	ISIS 25075	Investigative
T31032	DRUGINFO	D0U4ZT	ISIS 25118	Investigative

T46700	TARGETID	T46700
T46700	FORMERID	TTDR01388
T46700	UNIPROID	M3K8_HUMAN
T46700	TARGNAME	Cot oncogene messenger RNA (MAP3K8 mRNA)
T46700	GENENAME	MAP3K8
T46700	TARGTYPE	Literature-reported
T46700	SYNONYMS	Tumor progression locus 2 (mRNA); TPL-2 (mRNA); Serine/threonine-protein kinase cot (mRNA); Proto-oncogene c-Cot (mRNA); Mitogen-activated protein kinase kinase kinase 8 (mRNA); ESTF (mRNA); Cancer Osaka thyroid oncogene (mRNA); COT (mRNA)
T46700	FUNCTION	Involved in the regulation of T-helper cell differentiation and IFNG expression in T-cells. Involved in mediating host resistance to bacterial infection through negative regulation of type I interferon (IFN) production. In vitro, activates MAPK/ERK pathway in response to IL1 in an IRAK1-independent manner, leading to up-regulation of IL8 and CCL4. Transduces CD40 and TNFRSF1A signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production. May also play a role in the transduction of TNF signals that activate JNK and NF-kappa-B in some cell types. In adipocytes, activates MAPK/ERK pathway in an IKBKB-dependent manner in response to IL1B and TNF, but not insulin, leading to induction of lipolysis. Plays a role in the cell cycle. Isoform 1 shows some transforming activity, although it is much weaker than that of the activated oncogenic variant. Required for lipopolysaccharide (LPS)-induced, TLR4-mediated activation of the MAPK/ERK pathway in macrophages, thus being critical for production of the proinflammatory cytokine TNF-alpha (TNF) during immune responses.
T46700	PDBSTRUC	5IU2; 4Y85; 4Y83
T46700	BIOCLASS	mRNA target
T46700	ECNUMBER	EC 2.7.11.25
T46700	SEQUENCE	MEYMSTGSDNKEEIDLLIKHLNVSDVIDIMENLYASEEPAVYEPSLMTMCQDSNQNDERSKSLLLSGQEVPWLSSVRYGTVEDLLAFANHISNTAKHFYGQRPQESGILLNMVITPQNGRYQIDSDVLLIPWKLTYRNIGSDFIPRGAFGKVYLAQDIKTKKRMACKLIPVDQFKPSDVEIQACFRHENIAELYGAVLWGETVHLFMEAGEGGSVLEKLESCGPMREFEIIWVTKHVLKGLDFLHSKKVIHHDIKPSNIVFMSTKAVLVDFGLSVQMTEDVYFPKDLRGTEIYMSPEVILCRGHSTKADIYSLGATLIHMQTGTPPWVKRYPRSAYPSYLYIIHKQAPPLEDIADDCSPGMRELIEASLERNPNHRPRAADLLKHEALNPPREDQPRCQSLDSALLERKRLLSRKELELPENIADSSCTGSTEESEMLKRQRSLYIDLGALAGYFNLVRGPPTLEYG
T46700	DRUGINFO	D03JVY	ISIS 116361	Investigative
T46700	DRUGINFO	D06KSF	Tpl2 kinase inhibitor	Investigative
T46700	DRUGINFO	D09WUL	ISIS 116414	Investigative
T46700	DRUGINFO	D0C5VI	ISIS 116360	Investigative
T46700	DRUGINFO	D0I1AW	ISIS 116359	Investigative
T46700	DRUGINFO	D0M6ZQ	ISIS 116362	Investigative
T46700	DRUGINFO	D0TQ1F	ISIS 116363	Investigative
T46700	DRUGINFO	D03MUZ	8-chloro-quinoline-3-carbonitrile	Investigative
T46700	DRUGINFO	D0V0QJ	NSC-686549	Investigative

T06037	TARGETID	T06037
T06037	FORMERID	TTDR01391
T06037	UNIPROID	MK09_HUMAN
T06037	TARGNAME	JNK2 messenger RNA (JNK2 mRNA)
T06037	GENENAME	MAPK9
T06037	TARGTYPE	Literature-reported
T06037	SYNONYMS	Stress-activated protein kinase 1a (mRNA); SAPK1a (mRNA); PRKM9 (mRNA); Mitogen-activated protein kinase 9 (mRNA); Mitogen-activated protein kinase 8-interacting protein 2 (mRNA); MAPK 9 (mRNA); MAP kinase 9 (mRNA); Jun-N-terminal kinase 2 (mRNA); JNK-interacting protein 2 (mRNA); JNK-55 (mRNA); JNK MAP kinase scaffold protein 2 (mRNA); JIP-2 (mRNA); Islet-brain-2 (mRNA); IB-2 (mRNA); C-jun-amino-terminal kinase interacting protein 2 (mRNA); C-Jun N-terminal kinase 2 (mRNA)
T06037	FUNCTION	Extracellular stimuli such as proinflammatory cytokines or physical stress stimulate the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and MAP2K7/MKK7 phosphorylate and activate MAPK9/JNK2. In turn, MAPK9/JNK2 phosphorylates a number of transcription factors, primarily components of AP-1 such as JUN and ATF2 and thus regulates AP-1 transcriptional activity. In response to oxidative or ribotoxic stresses, inhibits rRNA synthesis by phosphorylating and inactivating the RNA polymerase 1-specific transcription initiation factor RRN3. Promotes stressed cell apoptosis by phosphorylating key regulatory factors including TP53 and YAP1. In T-cells, MAPK8 and MAPK9 are required for polarized differentiation of T-helper cells into Th1 cells. Upon T-cell receptor (TCR) stimulation, is activated by CARMA1, BCL10, MAP2K7 and MAP3K7/TAK1 to regulate JUN protein levels. Plays an important role in the osmotic stress-induced epithelial tight-junctions disruption. When activated, promotes beta-catenin/CTNNB1 degradation and inhibits the canonical Wnt signaling pathway. Participates also in neurite growth in spiral ganglion neurons. Phosphorylates the CLOCK-ARNTL/BMAL1 heterodimer and plays a role in the regulation of the circadian clock. Phosphorylates POU5F1, which results in the inhibition of POU5F1's transcriptional activity and enhances its proteosomal degradation. Serine/threonine-protein kinase involved in various processes such as cell proliferation, differentiation, migration, transformation and programmed cell death.
T06037	PDBSTRUC	3NPC; 3E7O
T06037	BIOCLASS	mRNA target
T06037	ECNUMBER	EC 2.7.11.24
T06037	SEQUENCE	MSDSKCDSQFYSVQVADSTFTVLKRYQQLKPIGSGAQGIVCAAFDTVLGINVAVKKLSRPFQNQTHAKRAYRELVLLKCVNHKNIISLLNVFTPQKTLEEFQDVYLVMELMDANLCQVIHMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTACTNFMMTPYVVTRYYRAPEVILGMGYKENVDIWSVGCIMGELVKGCVIFQGTDHIDQWNKVIEQLGTPSAEFMKKLQPTVRNYVENRPKYPGIKFEELFPDWIFPSESERDKIKTSQARDLLSKMLVIDPDKRISVDEALRHPYITVWYDPAEAEAPPPQIYDAQLEEREHAIEEWKELIYKEVMDWEERSKNGVVKDQPSDAAVSSNATPSQSSSINDISSMSTEQTLASDTDSSLDASTGPLEGCR
T06037	DRUGINFO	D0I3QU	ISIS 18078	Investigative
T06037	DRUGINFO	D0F5BY	N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide	Investigative
T06037	DRUGINFO	D0L0HG	AC1LG8KT	Investigative
T06037	DRUGINFO	D00HVA	Aminopyridine deriv. 2	Investigative
T06037	DRUGINFO	D0H6ZP	IN-1166	Investigative
T06037	DRUGINFO	D0Q3NG	N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide	Investigative
T06037	DRUGINFO	D0VJ2S	JNK-IN-8	Investigative
T06037	DRUGINFO	D04QCF	AS-601245	Investigative
T06037	DRUGINFO	D0S7IE	N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide	Investigative

T25927	TARGETID	T25927
T25927	FORMERID	TTDR01396
T25927	UNIPROID	CASP6_HUMAN
T25927	TARGNAME	Caspase 6 messenger RNA (CASP6 mRNA)
T25927	GENENAME	CASP6
T25927	TARGTYPE	Literature-reported
T25927	SYNONYMS	MCH2 (mRNA); Caspase-6 subunit p18 (mRNA); Caspase-6 subunit p11 (mRNA); CASP-6 (mRNA); Apoptotic protease Mch-2 (mRNA)
T25927	FUNCTION	Cleaves poly(ADP-ribose) polymerase in vitro, as well as lamins. Overexpression promotes programmed cell death. Involved in the activation cascade of caspases responsible for apoptosis execution.
T25927	PDBSTRUC	6DEV; 6DEU; 4NBN; 4NBL; 4NBK
T25927	BIOCLASS	mRNA target
T25927	ECNUMBER	EC 3.4.22.59
T25927	SEQUENCE	MSSASGLRRGHPAGGEENMTETDAFYKREMFDPAEKYKMDHRRRGIALIFNHERFFWHLTLPERRGTCADRDNLTRRFSDLGFEVKCFNDLKAEELLLKIHEVSTVSHADADCFVCVFLSHGEGNHIYAYDAKIEIQTLTGLFKGDKCHSLVGKPKIFIIQACRGNQHDVPVIPLDVVDNQTEKLDTNITEVDAASVYTLPAGADFLMCYSVAEGYYSHRETVNGSWYIQDLCEMLGKYGSSLEFTELLTLVNRKVSQRRVDFCKDPSAIGKKQVPCFASMLTKKLHFFPKSN
T25927	DRUGINFO	D01GTL	ISIS 134602	Investigative
T25927	DRUGINFO	D04EVL	ISIS 134583	Investigative
T25927	DRUGINFO	D04VQC	ISIS 134566	Investigative
T25927	DRUGINFO	D05CCZ	ISIS 134524	Investigative
T25927	DRUGINFO	D05ZQZ	ISIS 134532	Investigative
T25927	DRUGINFO	D08ORM	Ac-VEID-CHO	Investigative
T25927	DRUGINFO	D08WXD	ISIS 134609	Investigative
T25927	DRUGINFO	D0D3QG	ISIS 134608	Investigative
T25927	DRUGINFO	D0I1FS	ISIS 134499	Investigative
T25927	DRUGINFO	D0J5PL	ISIS 134528	Investigative
T25927	DRUGINFO	D0J7EZ	ISIS 134604	Investigative
T25927	DRUGINFO	D0K9BQ	ISIS 134603	Investigative
T25927	DRUGINFO	D0L7AG	ISIS 134564	Investigative
T25927	DRUGINFO	D0L8WW	ISIS 134606	Investigative
T25927	DRUGINFO	D0M7ZC	ISIS 134605	Investigative
T25927	DRUGINFO	D0P4WQ	ISIS 134565	Investigative
T25927	DRUGINFO	D0Q4SJ	ISIS 134607	Investigative
T25927	DRUGINFO	D0S5MC	ISIS 134601	Investigative
T25927	DRUGINFO	D0V1PK	ISIS 134563	Investigative
T25927	DRUGINFO	D0V6DX	Isoquinoline-1,3,4(2H)-trione	Investigative

T10937	TARGETID	T10937
T10937	FORMERID	TTDR01399
T10937	UNIPROID	MDM2_HUMAN
T10937	TARGNAME	Mdm2 messenger RNA (MDM2 mRNA)
T10937	GENENAME	MDM2
T10937	TARGTYPE	Literature-reported
T10937	SYNONYMS	RING-type E3 ubiquitin transferase Mdm2 (mRNA); P53-binding protein Mdm2 (mRNA); Oncoprotein Mdm2 (mRNA); MDM2 protein (mRNA); Hdm2 (mRNA); E3 ubiquitin-protein ligase Mdm2 (mRNA); Double minute 2 protein (mRNA)
T10937	FUNCTION	Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. Also acts as a ubiquitin ligase E3 toward itself and ARRB1. Permits the nuclear export of p53/TP53. Promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. Inhibits DAXX-mediated apoptosis by inducing its ubiquitination and degradation. Component of the TRIM28/KAP1-MDM2-p53/TP53 complex involved in stabilizing p53/TP53. Also component of the TRIM28/KAP1-ERBB4-MDM2 complex which links growth factor and DNA damage response pathways. Mediates ubiquitination and subsequent proteasome degradation of DYRK2 in nucleus. Ubiquitinates IGF1R and SNAI1 and promotes them to proteasomal degradation. Ubiquitinates DCX, leading to DCX degradation and reduction of the dendritic spine density of olfactory bulb granule cells. Ubiquitinates DLG4, leading to proteasomal degradation of DLG4 which is required for AMPA receptor endocytosis. E3 ubiquitin-protein ligase that mediates ubiquitination of p53/TP53, leading to its degradation by the proteasome.
T10937	PDBSTRUC	6Q9O; 6Q9L; 6Q9H; 6Q96; 6IM9
T10937	BIOCLASS	mRNA target
T10937	ECNUMBER	EC 2.3.2.27
T10937	SEQUENCE	MCNTNMSVPTDGAVTTSQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQESSDSGTSVSENRCHLEGGSDQKDLVQELQEEKPSSSHLVSRPSTSSRRRAISETEENSDELSGERQRKRHKSDSISLSFDESLALCVIREICCERSSSSESTGTPSNPDLDAGVSEHSGDWLDQDSVSDQFSVEFEVESLDSEDYSLSEEGQELSDEDDEVYQVTVYQAGESDTDSFEEDPEISLADYWKCTSCNEMNPPLPSHCNRCWALRENWLPEDKGKDKGEISEKAKLENSTQAEEGFDVPDCKKTIVNDSRESCVEENDDKITQASQSQESEDYSQPSTSSSIIYSSQEDVKEFEREETQDKEESVESSLPLNAIEPCVICQGRPKNGCIVHGKTGHLMACFTCAKKLKKRNKPCPVCRQPIQMIVLTYFP
T10937	DRUGINFO	D02JFF	ISIS 16518	Investigative
T10937	DRUGINFO	D08YAF	PLSQETFSDLWKLLPEN-NH2	Investigative
T10937	DRUGINFO	D0C0TN	NSC-66811	Investigative
T10937	DRUGINFO	D0Y3JR	ISIS 16507	Investigative
T10937	DRUGINFO	D01QKK	NUTLIN-3	Investigative
T10937	DRUGINFO	D0F1SN	NU-8231	Investigative

T93262	TARGETID	T93262
T93262	FORMERID	TTDR01401
T93262	UNIPROID	KPCE_HUMAN
T93262	TARGNAME	PKC-epsilon messenger RNA (PRKCE mRNA)
T93262	GENENAME	PRKCE
T93262	TARGTYPE	Literature-reported
T93262	SYNONYMS	Protein kinase C epsilon type (mRNA); Protein Kinase C epsilon (mRNA); PKCE (mRNA); PKC epsilon (mRNA); NPKC-epsilon (mRNA)
T93262	FUNCTION	Mediates cell adhesion to the extracellular matrix via integrin-dependent signaling, by mediating angiotensin-2-induced activation of integrin beta-1 (ITGB1) in cardiac fibroblasts. Phosphorylates MARCKS, which phosphorylates and activates PTK2/FAK, leading to the spread of cardiomyocytes. Involved in the control of the directional transport of ITGB1 in mesenchymal cells by phosphorylating vimentin (VIM), an intermediate filament (IF) protein. In epithelial cells, associates with and phosphorylates keratin-8 (KRT8), which induces targeting of desmoplakin at desmosomes and regulates cell-cell contact. Phosphorylates IQGAP1, which binds to CDC42, mediating epithelial cell-cell detachment prior to migration. In HeLa cells, contributes to hepatocyte growth factor (HGF)-induced cell migration, and in human corneal epithelial cells, plays a critical role in wound healing after activation by HGF. During cytokinesis, forms a complex with YWHAB, which is crucial for daughter cell separation, and facilitates abscission by a mechanism which may implicate the regulation of RHOA. In cardiac myocytes, regulates myofilament function and excitation coupling at the Z-lines, where it is indirectly associated with F-actin via interaction with COPB1. During endothelin-induced cardiomyocyte hypertrophy, mediates activation of PTK2/FAK, which is critical for cardiomyocyte survival and regulation of sarcomere length. Plays a role in the pathogenesis of dilated cardiomyopathy via persistent phosphorylation of troponin I (TNNI3). Involved in nerve growth factor (NFG)-induced neurite outgrowth and neuron morphological change independently of its kinase activity, by inhibition of RHOA pathway, activation of CDC42 and cytoskeletal rearrangement. May be involved in presynaptic facilitation by mediating phorbol ester-induced synaptic potentiation. Phosphorylates gamma-aminobutyric acid receptor subunit gamma-2 (GABRG2), which reduces the response of GABA receptors to ethanol and benzodiazepines and may mediate acute tolerance to the intoxicating effects of ethanol. Upon PMA treatment, phosphorylates the capsaicin- and heat-activated cation channel TRPV1, which is required for bradykinin-induced sensitization of the heat response in nociceptive neurons. Is able to form a complex with PDLIM5 and N-type calcium channel, and may enhance channel activities and potentiates fast synaptic transmission by phosphorylating the pore-forming alpha subunit CACNA1B (CaV2. 2). In prostate cancer cells, interacts with and phosphorylates STAT3, which increases DNA-binding and transcriptional activity of STAT3 and seems to be essential for prostate cancer cell invasion. Downstream of TLR4, plays an important role in the lipopolysaccharide (LPS)-induced immune response by phosphorylating and activating TICAM2/TRAM, which in turn activates the transcription factor IRF3 and subsequent cytokines production. In differentiating erythroid progenitors, is regulated by EPO and controls the protection against the TNFSF10/TRAIL-mediated apoptosis, via BCL2. May be involved in the regulation of the insulin-induced phosphorylation and activation of AKT1. Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays essential roles in the regulation of multiple cellular processes linked to cytoskeletal proteins, such as cell adhesion, motility, migration and cell cycle, functions in neuron growth and ion channel regulation, and is involved in immune response, cancer cell invasion and regulation of apoptosis.
T93262	PDBSTRUC	5LIH; 2WH0
T93262	BIOCLASS	mRNA target
T93262	ECNUMBER	EC 2.7.11.13
T93262	SEQUENCE	MVVFNGLLKIKICEAVSLKPTAWSLRHAVGPRPQTFLLDPYIALNVDDSRIGQTATKQKTNSPAWHDEFVTDVCNGRKIELAVFHDAPIGYDDFVANCTIQFEELLQNGSRHFEDWIDLEPEGRVYVIIDLSGSSGEAPKDNEERVFRERMRPRKRQGAVRRRVHQVNGHKFMATYLRQPTYCSHCRDFIWGVIGKQGYQCQVCTCVVHKRCHELIITKCAGLKKQETPDQVGSQRFSVNMPHKFGIHNYKVPTFCDHCGSLLWGLLRQGLQCKVCKMNVHRRCETNVAPNCGVDARGIAKVLADLGVTPDKITNSGQRRKKLIAGAESPQPASGSSPSEEDRSKSAPTSPCDQEIKELENNIRKALSFDNRGEEHRAASSPDGQLMSPGENGEVRQGQAKRLGLDEFNFIKVLGKGSFGKVMLAELKGKDEVYAVKVLKKDVILQDDDVDCTMTEKRILALARKHPYLTQLYCCFQTKDRLFFVMEYVNGGDLMFQIQRSRKFDEPRSRFYAAEVTSALMFLHQHGVIYRDLKLDNILLDAEGHCKLADFGMCKEGILNGVTTTTFCGTPDYIAPEILQELEYGPSVDWWALGVLMYEMMAGQPPFEADNEDDLFESILHDDVLYPVWLSKEAVSILKAFMTKNPHKRLGCVASQNGEDAIKQHPFFKEIDWVLLEQKKIKPPFKPRIKTKRDVNNFDQDFTREEPVLTLVDEAIVKQINQEEFKGFSYFGEDLMP
T93262	DRUGINFO	D0R2TM	BALANOL	Terminated
T93262	DRUGINFO	D02VLL	ISIS 7942	Investigative
T93262	DRUGINFO	D09RFD	ISIS 7948	Investigative
T93262	DRUGINFO	D0T9ZL	chelerythrine	Investigative
T93262	DRUGINFO	D04AXH	8-Octyl-benzolactam-V9	Investigative
T93262	DRUGINFO	D04JNZ	PROSTRATIN	Investigative
T93262	DRUGINFO	D0TO6S	Bisindolylmaleimide-I	Investigative
T93262	DRUGINFO	D0L8HO	RO-316233	Investigative

T72295	TARGETID	T72295
T72295	FORMERID	TTDR01402
T72295	UNIPROID	KPCT_HUMAN
T72295	TARGNAME	PKC-theta messenger RNA (PRKCQ mRNA)
T72295	GENENAME	PRKCQ
T72295	TARGTYPE	Literature-reported
T72295	SYNONYMS	Protein kinase C theta type (mRNA); PRKCT (mRNA); NPKC-theta (mRNA)
T72295	FUNCTION	In TCR-CD3/CD28-co-stimulated T-cells, is required for the activation of NF-kappa-B and JUN, which in turn are essential for IL2 production, and participates in the calcium-dependent NFATC1 and NFATC2 transactivation. Mediates the activation of the canonical NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11 on several serine residues, inducing CARD11 association with lipid rafts and recruitment of the BCL10-MALT1 complex, which then activates IKK complex, resulting in nuclear translocation and activation of NFKB1. May also play an indirect role in activation of the non-canonical NF-kappa-B (NFKB2) pathway. In the signaling pathway leading to JUN activation, acts by phosphorylating the mediator STK39/SPAK and may not act through MAP kinases signaling. Plays a critical role in TCR/CD28-induced NFATC1 and NFATC2 transactivation by participating in the regulation of reduced inositol 1,4,5-trisphosphate generation and intracellular calcium mobilization. After costimulation of T-cells through CD28 can phosphorylate CBLB and is required for the ubiquitination and subsequent degradation of CBLB, which is a prerequisite for the activation of TCR. During T-cells differentiation, plays an important role in the development of T-helper 2 (Th2) cells following immune and inflammatory responses, and, in the development of inflammatory autoimmune diseases, is necessary for the activation of IL17-producing Th17 cells. May play a minor role in Th1 response. Upon TCR stimulation, mediates T-cell protective survival signal by phosphorylating BAD, thus protecting T-cells from BAD-induced apoptosis, and by up-regulating BCL-X(L)/BCL2L1 levels through NF-kappa-B and JUN pathways. In platelets, regulates signal transduction downstream of the ITGA2B, CD36/GP4, F2R/PAR1 and F2RL3/PAR4 receptors, playing a positive role in 'outside-in' signaling and granule secretion signal transduction. May relay signals from the activated ITGA2B receptor by regulating the uncoupling of WASP and WIPF1, thereby permitting the regulation of actin filament nucleation and branching activity of the Arp2/3 complex. May mediate inhibitory effects of free fatty acids on insulin signaling by phosphorylating IRS1, which in turn blocks IRS1 tyrosine phosphorylation and downstream activation of the PI3K/AKT pathway. Phosphorylates MSN (moesin) in the presence of phosphatidylglycerol or phosphatidylinositol. Phosphorylates PDPK1 at 'Ser-504' and 'Ser-532' and negatively regulates its ability to phosphorylate PKB/AKT1. Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that mediates non-redundant functions in T-cell receptor (TCR) signaling, including T-cells activation, proliferation, differentiation and survival, by mediating activation of multiple transcription factors such as NF-kappa-B, JUN, NFATC1 and NFATC2.
T72295	PDBSTRUC	5F9E; 4RA5; 4Q9Z; 2JED; 2ENZ
T72295	BIOCLASS	mRNA target
T72295	ECNUMBER	EC 2.7.11.13
T72295	SEQUENCE	MSPFLRIGLSNFDCGSCQSCQGEAVNPYCAVLVKEYVESENGQMYIQKKPTMYPPWDSTFDAHINKGRVMQIIVKGKNVDLISETTVELYSLAERCRKNNGKTEIWLELKPQGRMLMNARYFLEMSDTKDMNEFETEGFFALHQRRGAIKQAKVHHVKCHEFTATFFPQPTFCSVCHEFVWGLNKQGYQCRQCNAAIHKKCIDKVIAKCTGSAINSRETMFHKERFKIDMPHRFKVYNYKSPTFCEHCGTLLWGLARQGLKCDACGMNVHHRCQTKVANLCGINQKLMAEALAMIESTQQARCLRDTEQIFREGPVEIGLPCSIKNEARPPCLPTPGKREPQGISWESPLDEVDKMCHLPEPELNKERPSLQIKLKIEDFILHKMLGKGSFGKVFLAEFKKTNQFFAIKALKKDVVLMDDDVECTMVEKRVLSLAWEHPFLTHMFCTFQTKENLFFVMEYLNGGDLMYHIQSCHKFDLSRATFYAAEIILGLQFLHSKGIVYRDLKLDNILLDKDGHIKIADFGMCKENMLGDAKTNTFCGTPDYIAPEILLGQKYNHSVDWWSFGVLLYEMLIGQSPFHGQDEEELFHSIRMDNPFYPRWLEKEAKDLLVKLFVREPEKRLGVRGDIRQHPLFREINWEELERKEIDPPFRPKVKSPFDCSNFDKEFLNEKPRLSFADRALINSMDQNMFRNFSFMNPGMERLIS
T72295	DRUGINFO	D00NQN	ISIS 109351	Investigative
T72295	DRUGINFO	D00PYD	ISIS 109352	Investigative
T72295	DRUGINFO	D00XRM	ISIS 109353	Investigative
T72295	DRUGINFO	D05QWZ	ISIS 109355	Investigative
T72295	DRUGINFO	D08HCY	4-(1H-indol-6-ylamino)-5-styrylnicotinonitrile	Investigative
T72295	DRUGINFO	D0S7UD	4-(1H-indol-5-yloxy)-5-styrylnicotinonitrile	Investigative
T72295	DRUGINFO	D0TT6X	ISIS 109354	Investigative
T72295	DRUGINFO	D0U9YY	4-(1H-indol-5-ylamino)-5-styrylnicotinonitrile	Investigative
T72295	DRUGINFO	D0W1FM	4-(3H-indol-4-ylamino)-5-styrylnicotinonitrile	Investigative
T72295	DRUGINFO	D04AXH	8-Octyl-benzolactam-V9	Investigative
T72295	DRUGINFO	D04JNZ	PROSTRATIN	Investigative

T49368	TARGETID	T49368
T49368	FORMERID	TTDR01404
T49368	UNIPROID	KPCD_HUMAN
T49368	TARGNAME	PKC-delta messenger RNA (PRKCD mRNA)
T49368	GENENAME	PRKCD
T49368	TARGTYPE	Literature-reported
T49368	SYNONYMS	nPKC-delta (mRNA); Tyrosine-protein kinase PRKCD (mRNA); SDK1 (mRNA); Protein kinase C delta type catalytic subunit (mRNA); Protein kinase C delta type (mRNA); Protein Kinase C delta (mRNA); PKC-delta (mRNA)
T49368	FUNCTION	Negatively regulates B cell proliferation and also has an important function in self-antigen induced B cell tolerance induction. Upon DNA damage, activates the promoter of the death-promoting transcription factor BCLAF1/Btf to trigger BCLAF1-mediated p53/TP53 gene transcription and apoptosis. In response to oxidative stress, interact with and activate CHUK/IKKA in the nucleus, causing the phosphorylation of p53/TP53. In the case of ER stress or DNA damage-induced apoptosis, can form a complex with the tyrosine-protein kinase ABL1 which trigger apoptosis independently of p53/TP53. In cytosol can trigger apoptosis by activating MAPK11 or MAPK14, inhibiting AKT1 and decreasing the level of X-linked inhibitor of apoptosis protein (XIAP), whereas in nucleus induces apoptosis via the activation of MAPK8 or MAPK9. Upon ionizing radiation treatment, is required for the activation of the apoptosis regulators BAX and BAK, which trigger the mitochondrial cell death pathway. Can phosphorylate MCL1 and target it for degradation which is sufficient to trigger for BAX activation and apoptosis. Is required for the control of cell cycle progression both at G1/S and G2/M phases. Mediates phorbol 12-myristate 13-acetate (PMA)-induced inhibition of cell cycle progression at G1/S phase by up-regulating the CDK inhibitor CDKN1A/p21 and inhibiting the cyclin CCNA2 promoter activity. In response to UV irradiation can phosphorylate CDK1, which is important for the G2/M DNA damage checkpoint activation. Can protect glioma cells from the apoptosis induced by TNFSF10/TRAIL, probably by inducing increased phosphorylation and subsequent activation of AKT1. Is highly expressed in a number of cancer cells and promotes cell survival and resistance against chemotherapeutic drugs by inducing cyclin D1 (CCND1) and hyperphosphorylation of RB1, and via several pro-survival pathways, including NF-kappa-B, AKT1 and MAPK1/3 (ERK1/2). Can also act as tumor suppressor upon mitogenic stimulation with PMA or TPA. In N-formyl-methionyl-leucyl-phenylalanine (fMLP)-treated cells, is required for NCF1 (p47-phox) phosphorylation and activation of NADPH oxidase activity, and regulates TNF-elicited superoxide anion production in neutrophils, by direct phosphorylation and activation of NCF1 or indirectly through MAPK1/3 (ERK1/2) signaling pathways. May also play a role in the regulation of NADPH oxidase activity in eosinophil after stimulation with IL5, leukotriene B4 or PMA. In collagen-induced platelet aggregation, acts a negative regulator of filopodia formation and actin polymerization by interacting with and negatively regulating VASP phosphorylation. Downstream of PAR1, PAR4 and CD36/GP4 receptors, regulates differentially platelet dense granule secretion; acts as a positive regulator in PAR-mediated granule secretion, whereas it negatively regulates CD36/GP4-mediated granule release. Phosphorylates MUC1 in the C-terminal and regulates the interaction between MUC1 and beta-catenin. The catalytic subunit phosphorylates 14-3-3 proteins (YWHAB, YWHAZ and YWHAH) in a sphingosine-dependent fashion. Phosphorylates ELAVL1 in response to angiotensin-2 treatment. Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays contrasting roles in cell death and cell survival by functioning as a pro-apoptotic protein during DNA damage-induced apoptosis, but acting as an anti-apoptotic protein during cytokine receptor-initiated cell death, is involved in tumor suppression as well as survival of several cancers, is required for oxygen radical production by NADPH oxidase and acts as positive or negative regulator in platelet functional responses.
T49368	PDBSTRUC	2YUU; 1YRK
T49368	BIOCLASS	mRNA target
T49368	ECNUMBER	EC 2.7.11.13
T49368	SEQUENCE	MAPFLRIAFNSYELGSLQAEDEANQPFCAVKMKEALSTERGKTLVQKKPTMYPEWKSTFDAHIYEGRVIQIVLMRAAEEPVSEVTVGVSVLAERCKKNNGKAEFWLDLQPQAKVLMSVQYFLEDVDCKQSMRSEDEAKFPTMNRRGAIKQAKIHYIKNHEFIATFFGQPTFCSVCKDFVWGLNKQGYKCRQCNAAIHKKCIDKIIGRCTGTAANSRDTIFQKERFNIDMPHRFKVHNYMSPTFCDHCGSLLWGLVKQGLKCEDCGMNVHHKCREKVANLCGINQKLLAEALNQVTQRASRRSDSASSEPVGIYQGFEKKTGVAGEDMQDNSGTYGKIWEGSSKCNINNFIFHKVLGKGSFGKVLLGELKGRGEYFAIKALKKDVVLIDDDVECTMVEKRVLTLAAENPFLTHLICTFQTKDHLFFVMEFLNGGDLMYHIQDKGRFELYRATFYAAEIMCGLQFLHSKGIIYRDLKLDNVLLDRDGHIKIADFGMCKENIFGESRASTFCGTPDYIAPEILQGLKYTFSVDWWSFGVLLYEMLIGQSPFHGDDEDELFESIRVDTPHYPRWITKESKDILEKLFEREPTKRLGVTGNIKIHPFFKTINWTLLEKRRLEPPFRPKVKSPRDYSNFDQEFLNEKARLSYSDKNLIDSMDQSAFAGFSFVNPKFEHLLED
T49368	DRUGINFO	D0R2TM	BALANOL	Terminated
T49368	DRUGINFO	D07WBD	ISIS 10310	Investigative
T49368	DRUGINFO	D08CMT	ISIS 17252	Investigative
T49368	DRUGINFO	D08SPM	ISIS 10303	Investigative
T49368	DRUGINFO	D0M0JF	ISIS 10311	Investigative
T49368	DRUGINFO	D05SLL	Diheptan-3-yl 5-(hydroxymethyl)isophthalate	Investigative
T49368	DRUGINFO	D0J4NI	Dihexan-3-yl 5-(hydroxymethyl)isophthalate	Investigative
T49368	DRUGINFO	D04AXH	8-Octyl-benzolactam-V9	Investigative
T49368	DRUGINFO	D06TLL	Go 6983	Investigative
T49368	DRUGINFO	D04JNZ	PROSTRATIN	Investigative
T49368	DRUGINFO	D06ZCX	LY-326449	Investigative
T49368	DRUGINFO	D0TO6S	Bisindolylmaleimide-I	Investigative

T19923	TARGETID	T19923
T19923	FORMERID	TTDR01405
T19923	UNIPROID	B2CL1_HUMAN
T19923	TARGNAME	Bcl-x messenger RNA (BCL2L1 mRNA)
T19923	GENENAME	BCL2L1
T19923	TARGTYPE	Literature-reported
T19923	SYNONYMS	Bcl2like protein 1 (mRNA); Bcl2L1 (mRNA); Bcl2-L-1 (mRNA); Bcl-XL (mRNA); Bcl-2-like protein 1 (mRNA); BCLX (mRNA); BCL2L (mRNA); Apoptosis regulator Bcl-X (mRNA)
T19923	FUNCTION	Inhibits activation of caspases. Appears to regulate cell death by blocking the voltage-dependent anion channel (VDAC) by binding to it and preventing the release of the caspase activator, CYC1, from the mitochondrial membrane. Also acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis. Potent inhibitor of cell death.
T19923	PDBSTRUC	6IJQ; 6F46; 6DCO; 6DCN; 6BF2
T19923	BIOCLASS	mRNA target
T19923	SEQUENCE	MSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAINGNPSWHLADSPAVNGATGHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAYQSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEPWIQENGGWDTFVELYGNNAAAESRKGQERFNRWFLTGMTVAGVVLLGSLFSRK
T19923	DRUGINFO	D0R7MJ	PURPUROGALLIN	Terminated
T19923	DRUGINFO	D00AJF	ISIS 11219	Investigative
T19923	DRUGINFO	D04YWU	ISIS 11220	Investigative
T19923	DRUGINFO	D05RJQ	ISIS 11224	Investigative
T19923	DRUGINFO	D06LOB	ISIS 11223	Investigative
T19923	DRUGINFO	D07NIM	ISIS 16010	Investigative
T19923	DRUGINFO	D0A6NK	ISIS 16009	Investigative
T19923	DRUGINFO	D0C1YA	ISIS 15998	Investigative
T19923	DRUGINFO	D0DX4W	ISIS 11221	Investigative
T19923	DRUGINFO	D0H5MZ	ISIS 15999	Investigative
T19923	DRUGINFO	D0S6MQ	ISIS 16005	Investigative
T19923	DRUGINFO	D0D6BH	4,5-dibenzylbenzene-1,2-diol	Investigative
T19923	DRUGINFO	D00LHS	TW-37	Investigative
T19923	DRUGINFO	D0S6IW	QEDIIRNIARHLAQVGDSMDR	Investigative

T59479	TARGETID	T59479
T59479	FORMERID	TTDR01410
T59479	UNIPROID	BIRC3_HUMAN
T59479	TARGNAME	Apoptosis-2 messenger RNA (BIRC3 mRNA)
T59479	GENENAME	BIRC3
T59479	TARGTYPE	Literature-reported
T59479	SYNONYMS	hIAP1 (mRNA); hIAP-1 (mRNA); TNFR2TRAFsignaling complex protein 1 (mRNA); TNFR2-TRAF-signaling complex protein 1 (mRNA); RNF49 (mRNA); RING-type E3 ubiquitin transferase BIRC3 (mRNA); RING finger protein 49 (mRNA); MIHC (mRNA); Inhibitor of apoptosis protein 1 (mRNA); IAP1 (mRNA); IAP homolog C (mRNA); CIAP2 (mRNA); C-IAP2 (mRNA); Baculoviral IAP repeatcontaining protein3 (mRNA); Baculoviral IAP repeat-containing protein 3 (mRNA); Apoptosis inhibitor 2 (mRNA); API2 (mRNA)
T59479	FUNCTION	Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and regulates both canonical and non-canonical NF-kappa-B signaling by acting in opposite directions: acts as a positive regulator of the canonical pathway and suppresses constitutive activation of non-canonical NF-kappa-B signaling. The target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4, CASP3, CASP7, CASP8, IKBKE, TRAF1, and BCL10. Acts as an important regulator of innate immune signaling via regulation of Toll-like receptors (TLRs), Nodlike receptors (NLRs) and RIG-I like receptors (RLRs), collectively referred to as pattern recognition receptors (PRRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8. Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, mitogenic kinase signaling and cell proliferation, as well as cell invasion and metastasis.
T59479	PDBSTRUC	3M0D; 3M0A; 3EB6; 3EB5; 2UVL
T59479	BIOCLASS	mRNA target
T59479	ECNUMBER	EC 2.3.2.27
T59479	SEQUENCE	MNIVENSIFLSNLMKSANTFELKYDLSCELYRMSTYSTFPAGVPVSERSLARAGFYYTGVNDKVKCFCCGLMLDNWKRGDSPTEKHKKLYPSCRFVQSLNSVNNLEATSQPTFPSSVTNSTHSLLPGTENSGYFRGSYSNSPSNPVNSRANQDFSALMRSSYHCAMNNENARLLTFQTWPLTFLSPTDLAKAGFYYIGPGDRVACFACGGKLSNWEPKDNAMSEHLRHFPKCPFIENQLQDTSRYTVSNLSMQTHAARFKTFFNWPSSVLVNPEQLASAGFYYVGNSDDVKCFCCDGGLRCWESGDDPWVQHAKWFPRCEYLIRIKGQEFIRQVQASYPHLLEQLLSTSDSPGDENAESSIIHFEPGEDHSEDAIMMNTPVINAAVEMGFSRSLVKQTVQRKILATGENYRLVNDLVLDLLNAEDEIREEERERATEEKESNDLLLIRKNRMALFQHLTCVIPILDSLLTAGIINEQEHDVIKQKTQTSLQARELIDTILVKGNIAATVFRNSLQEAEAVLYEHLFVQQDIKYIPTEDVSDLPVEEQLRRLQEERTCKVCMDKEVSIVFIPCGHLVVCKDCAPSLRKCPICRSTIKGTVRTFLS
T59479	DRUGINFO	D00UDL	ISIS 23452	Investigative
T59479	DRUGINFO	D01MCF	ISIS 23454	Investigative
T59479	DRUGINFO	D03SQZ	ISIS 23459	Investigative
T59479	DRUGINFO	D09LXC	ISIS 23414	Investigative
T59479	DRUGINFO	D0AI1L	ISIS 23416	Investigative
T59479	DRUGINFO	D0H6LU	ISIS 23412	Investigative
T59479	DRUGINFO	D03KZH	SM-337	Investigative
T59479	DRUGINFO	D0BW7P	SM-131	Investigative
T59479	DRUGINFO	D0Q7TL	SM-122	Investigative

T06559	TARGETID	T06559
T06559	FORMERID	TTDR01414
T06559	UNIPROID	ERBB4_HUMAN
T06559	TARGNAME	HER4 messenger RNA (ERBB4 mRNA)
T06559	GENENAME	ERBB4
T06559	TARGTYPE	Literature-reported
T06559	SYNONYMS	Tyrosine kinase-type cell surface receptor HER4 (mRNA); Receptor tyrosine-protein kinase erbB-4 (mRNA); Proto-oncogene-like protein c-ErbB-4 (mRNA); P180erbB4 (mRNA); HER4 (mRNA)
T06559	FUNCTION	Required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyocyte proliferation. Required for normal development of the embryonic central nervous system, especially for normal neural crest cell migration and normal axon guidance. Required for mammary gland differentiation, induction of milk proteins and lactation. Acts as cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and the EGF family members BTC, EREG and HBEGF. Ligand binding triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Ligand specificity and signaling is modulated by alternative splicing, proteolytic processing, and by the formation of heterodimers with other ERBB family members, thereby creating multiple combinations of intracellular phosphotyrosines that trigger ligand- and context-specific cellular responses. Mediates phosphorylation of SHC1 and activation of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Isoform JM-A CYT-1 and isoform JM-B CYT-1 phosphorylate PIK3R1, leading to the activation of phosphatidylinositol 3-kinase and AKT1 and protect cells against apoptosis. Isoform JM-A CYT-1 and isoform JM-B CYT-1 mediate reorganization of the actin cytoskeleton and promote cell migration in response to NRG1. Isoform JM-A CYT-2 and isoform JM-B CYT-2 lack the phosphotyrosine that mediates interaction with PIK3R1, and hence do not phosphorylate PIK3R1, do not protect cells against apoptosis, and do not promote reorganization of the actin cytoskeleton and cell migration. Proteolytic processing of isoform JM-A CYT-1 and isoform JM-A CYT-2 gives rise to the corresponding soluble intracellular domains (4ICD) that translocate to the nucleus, promote nuclear import of STAT5A, activation of STAT5A, mammary epithelium differentiation, cell proliferation and activation of gene expression. The ERBB4 soluble intracellular domains (4ICD) colocalize with STAT5A at the CSN2 promoter to regulate transcription of milk proteins during lactation. The ERBB4 soluble intracellular domains can also translocate to mitochondria and promote apoptosis. Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis.
T06559	PDBSTRUC	3U9U; 3U7U; 3U2P; 3BCE; 3BBW
T06559	BIOCLASS	mRNA target
T06559	ECNUMBER	EC 2.7.10.1
T06559	SEQUENCE	MKPATGLWVWVSLLVAAGTVQPSDSQSVCAGTENKLSSLSDLEQQYRALRKYYENCEVVMGNLEITSIEHNRDLSFLRSVREVTGYVLVALNQFRYLPLENLRIIRGTKLYEDRYALAIFLNYRKDGNFGLQELGLKNLTEILNGGVYVDQNKFLCYADTIHWQDIVRNPWPSNLTLVSTNGSSGCGRCHKSCTGRCWGPTENHCQTLTRTVCAEQCDGRCYGPYVSDCCHRECAGGCSGPKDTDCFACMNFNDSGACVTQCPQTFVYNPTTFQLEHNFNAKYTYGAFCVKKCPHNFVVDSSSCVRACPSSKMEVEENGIKMCKPCTDICPKACDGIGTGSLMSAQTVDSSNIDKFINCTKINGNLIFLVTGIHGDPYNAIEAIDPEKLNVFRTVREITGFLNIQSWPPNMTDFSVFSNLVTIGGRVLYSGLSLLILKQQGITSLQFQSLKEISAGNIYITDNSNLCYYHTINWTTLFSTINQRIVIRDNRKAENCTAEGMVCNHLCSSDGCWGPGPDQCLSCRRFSRGRICIESCNLYDGEFREFENGSICVECDPQCEKMEDGLLTCHGPGPDNCTKCSHFKDGPNCVEKCPDGLQGANSFIFKYADPDRECHPCHPNCTQGCNGPTSHDCIYYPWTGHSTLPQHARTPLIAAGVIGGLFILVIVGLTFAVYVRRKSIKKKRALRRFLETELVEPLTPSGTAPNQAQLRILKETELKRVKVLGSGAFGTVYKGIWVPEGETVKIPVAIKILNETTGPKANVEFMDEALIMASMDHPHLVRLLGVCLSPTIQLVTQLMPHGCLLEYVHEHKDNIGSQLLLNWCVQIAKGMMYLEERRLVHRDLAARNVLVKSPNHVKITDFGLARLLEGDEKEYNADGGKMPIKWMALECIHYRKFTHQSDVWSYGVTIWELMTFGGKPYDGIPTREIPDLLEKGERLPQPPICTIDVYMVMVKCWMIDADSRPKFKELAAEFSRMARDPQRYLVIQGDDRMKLPSPNDSKFFQNLLDEEDLEDMMDAEEYLVPQAFNIPPPIYTSRARIDSNRSEIGHSPPPAYTPMSGNQFVYRDGGFAAEQGVSVPYRAPTSTIPEAPVAQGATAEIFDDSCCNGTLRKPVAPHVQEDSSTQRYSADPTVFAPERSPRGELDEEGYMTPMRDKPKQEYLNPVEENPFVSRRKNGDLQALDNPEYHNASNGPPKAEDEYVNEPLYLNTFANTLGKAEYLKNNILSMPEKAKKAFDNPDYWNHSLPPRSTLQHPDYLQEYSTKYFYKQNGRIRPIVAENPEYLSEFSLKPGTVLPPPPYRHRNTVV
T06559	DRUGINFO	D01IRX	ISIS 19657	Investigative
T06559	DRUGINFO	D02DXI	ISIS 19650	Investigative
T06559	DRUGINFO	D08FVS	ISIS 19647	Investigative
T06559	DRUGINFO	D0C3LW	ISIS 19649	Investigative
T06559	DRUGINFO	D0DO6G	ISIS 19677	Investigative
T06559	DRUGINFO	D0I0DE	ISIS 19658	Investigative
T06559	DRUGINFO	D0I9GE	ISIS 19659	Investigative
T06559	DRUGINFO	D0M8BV	ISIS 19651	Investigative
T06559	DRUGINFO	D0T0SR	ISIS 19676	Investigative
T06559	DRUGINFO	D0W0QO	ISIS 19639	Investigative
T06559	DRUGINFO	D0Z0XJ	ISIS 19675	Investigative
T06559	DRUGINFO	D0Z7BO	ISIS 19634	Investigative
T06559	DRUGINFO	D00TZD	CL-387785	Investigative

T41766	TARGETID	T41766
T41766	FORMERID	TTDR01426
T41766	UNIPROID	IRAK4_HUMAN
T41766	TARGNAME	IRAK4 messenger RNA (IRAK4 mRNA)
T41766	GENENAME	IRAK4
T41766	TARGTYPE	Literature-reported
T41766	SYNONYMS	Renal carcinoma antigenNYREN64 (mRNA); Renal carcinoma antigen NY-REN-64 (mRNA); NY-REN-64 antigen (mRNA); Interleukin1 receptorassociated kinase 4 (mRNA); Interleukin-1 receptor-associated kinase 4 (mRNA); IRAK-4 (mRNA)
T41766	FUNCTION	Involved in Toll-like receptor (TLR) and IL-1R signaling pathways. Is rapidly recruited by MYD88 to the receptor-signaling complex upon TLR activation to form the Myddosome together with IRAK2. Phosphorylates initially IRAK1, thus stimulating the kinase activity and intensive autophosphorylation of IRAK1. Phosphorylates E3 ubiquitin ligases Pellino proteins (PELI1, PELI2 and PELI3) to promote pellino-mediated polyubiquitination of IRAK1. Then, the ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. In turn, MAP3K7/TAK1 activates IKKs (CHUK/IKKA and IKBKB/IKKB) leading to NF-kappa-B nuclear translocation and activation. Alternatively, phosphorylates TIRAP to promote its ubiquitination and subsequent degradation. Phosphorylates NCF1 and regulates NADPH oxidase activation after LPS stimulation suggesting a similar mechanism during microbial infections. Serine/threonine-protein kinase that plays a critical role in initiating innate immune response against foreign pathogens.
T41766	PDBSTRUC	6O9D; 6O95; 6O94; 6O8U; 6N8G
T41766	BIOCLASS	mRNA target
T41766	ECNUMBER	EC 2.7.11.1
T41766	SEQUENCE	MNKPITPSTYVRCLNVGLIRKLSDFIDPQEGWKKLAVAIKKPSGDDRYNQFHIRRFEALLQTGKSPTSELLFDWGTTNCTVGDLVDLLIQNEFFAPASLLLPDAVPKTANTLPSKEAITVQQKQMPFCDKDRTLMTPVQNLEQSYMPPDSSSPENKSLEVSDTRFHSFSFYELKNVTNNFDERPISVGGNKMGEGGFGVVYKGYVNNTTVAVKKLAAMVDITTEELKQQFDQEIKVMAKCQHENLVELLGFSSDGDDLCLVYVYMPNGSLLDRLSCLDGTPPLSWHMRCKIAQGAANGINFLHENHHIHRDIKSANILLDEAFTAKISDFGLARASEKFAQTVMTSRIVGTTAYMAPEALRGEITPKSDIYSFGVVLLEIITGLPAVDEHREPQLLLDIKEEIEDEEKTIEDYIDKKMNDADSTSVEAMYSVASQCLHEKKNKRPDIKKVQQLLQEMTAS
T41766	DRUGINFO	D02AMI	ISIS 156452	Investigative
T41766	DRUGINFO	D02JBK	ISIS 156453	Investigative
T41766	DRUGINFO	D02JIL	N-(1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide	Investigative
T41766	DRUGINFO	D06DVW	ISIS 156451	Investigative
T41766	DRUGINFO	D06LVL	ISIS 156473	Investigative
T41766	DRUGINFO	D0B2EL	ISIS 156449	Investigative
T41766	DRUGINFO	D0B5OL	ISIS 156474	Investigative
T41766	DRUGINFO	D0F5SD	ISIS 156475	Investigative
T41766	DRUGINFO	D0LY5S	N-(1H-benzo[d]imidazol-2-yl)-3-cyanobenzamide	Investigative
T41766	DRUGINFO	D0N4TF	ISIS 156472	Investigative
T41766	DRUGINFO	D0U9JR	ISIS 156471	Investigative

T91149	TARGETID	T91149
T91149	FORMERID	TTDR01431
T91149	UNIPROID	AKT3_HUMAN
T91149	TARGNAME	AKT3 messenger RNA (AKT3 mRNA)
T91149	GENENAME	AKT3
T91149	TARGTYPE	Literature-reported
T91149	SYNONYMS	STK-2 (mRNA); RAC-PK-gamma (mRNA); Protein kinase B gamma (mRNA); Protein kinase Akt-3 (mRNA); PKBG (mRNA); PKB gamma (mRNA)
T91149	FUNCTION	AKT3 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT3 is the least studied AKT isoform. It plays an important role in brain development and is crucial for the viability of malignant glioma cells. AKT3 isoform may also be the key molecule in up-regulation and down-regulation of MMP13 via IL13. Required for the coordination of mitochondrial biogenesis with growth factor-induced increases in cellular energy demands. Down-regulation by RNA interference reduces the expression of the phosphorylated form of BAD, resulting in the induction of caspase-dependent apoptosis.
T91149	PDBSTRUC	2X18
T91149	BIOCLASS	mRNA target
T91149	ECNUMBER	EC 2.7.11.1
T91149	SEQUENCE	MSDVTIVKEGWVQKRGEYIKNWRPRYFLLKTDGSFIGYKEKPQDVDLPYPLNNFSVAKCQLMKTERPKPNTFIIRCLQWTTVIERTFHVDTPEEREEWTEAIQAVADRLQRQEEERMNCSPTSQIDNIGEEEMDASTTHHKRKTMNDFDYLKLLGKGTFGKVILVREKASGKYYAMKILKKEVIIAKDEVAHTLTESRVLKNTRHPFLTSLKYSFQTKDRLCFVMEYVNGGELFFHLSRERVFSEDRTRFYGAEIVSALDYLHSGKIVYRDLKLENLMLDKDGHIKITDFGLCKEGITDAATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEDIKFPRTLSSDAKSLLSGLLIKDPNKRLGGGPDDAKEIMRHSFFSGVNWQDVYDKKLVPPFKPQVTSETDTRYFDEEFTAQTITITPPEKYDEDGMDCMDNERRPHFPQFSYSASGRE
T91149	DRUGINFO	D00NPN	ISIS 29202	Investigative
T91149	DRUGINFO	D02UHI	ISIS 29136	Investigative
T91149	DRUGINFO	D03EYM	ISIS 29112	Investigative
T91149	DRUGINFO	D04IBO	ISIS 29161	Investigative
T91149	DRUGINFO	D04QYU	ISIS 29200	Investigative
T91149	DRUGINFO	D04YQN	ISIS 29135	Investigative
T91149	DRUGINFO	D05BFX	ISIS 29177	Investigative
T91149	DRUGINFO	D06AOQ	ISIS 29160	Investigative
T91149	DRUGINFO	D06AZX	ISIS 29176	Investigative
T91149	DRUGINFO	D07CCC	ISIS 29159	Investigative
T91149	DRUGINFO	D0AH5P	ISIS 29201	Investigative
T91149	DRUGINFO	D0M2JX	ISIS 29137	Investigative
T91149	DRUGINFO	D0N7AF	ISIS 29155	Investigative
T91149	DRUGINFO	D0N9AT	ISIS 29178	Investigative
T91149	DRUGINFO	D0O7OI	ISIS 29138	Investigative
T91149	DRUGINFO	D0Q0FZ	ISIS 29139	Investigative
T91149	DRUGINFO	D0U1QU	ISIS 29156	Investigative
T91149	DRUGINFO	D0W4XP	ISIS 29154	Investigative
T91149	DRUGINFO	D0I1FJ	SB-747651A	Investigative

T77548	TARGETID	T77548
T77548	FORMERID	TTDR00755
T77548	UNIPROID	GRM8_HUMAN
T77548	TARGNAME	Metabotropic glutamate receptor 8 (mGluR8)
T77548	GENENAME	GRM8
T77548	TARGTYPE	Literature-reported
T77548	SYNONYMS	MGluR8a; MGLUR8; Glutamate receptor mGLU8; GRM8
T77548	FUNCTION	Receptor for glutamate. The activity of this receptor is mediated by a g-protein that inhibits adenylate cyclase activity.
T77548	PDBSTRUC	6E5V; 6BT5; 6BSZ
T77548	BIOCLASS	GPCR glutamate
T77548	SEQUENCE	MVCEGKRSASCPCFFLLTAKFYWILTMMQRTHSQEYAHSIRVDGDIILGGLFPVHAKGERGVPCGELKKEKGIHRLEAMLYAIDQINKDPDLLSNITLGVRILDTCSRDTYALEQSLTFVQALIEKDASDVKCANGDPPIFTKPDKISGVIGAAASSVSIMVANILRLFKIPQISYASTAPELSDNTRYDFFSRVVPPDSYQAQAMVDIVTALGWNYVSTLASEGNYGESGVEAFTQISREIGGVCIAQSQKIPREPRPGEFEKIIKRLLETPNARAVIMFANEDDIRRILEAAKKLNQSGHFLWIGSDSWGSKIAPVYQQEEIAEGAVTILPKRASIDGFDRYFRSRTLANNRRNVWFAEFWEENFGCKLGSHGKRNSHIKKCTGLERIARDSSYEQEGKVQFVIDAVYSMAYALHNMHKDLCPGYIGLCPRMSTIDGKELLGYIRAVNFNGSAGTPVTFNENGDAPGRYDIFQYQITNKSTEYKVIGHWTNQLHLKVEDMQWAHREHTHPASVCSLPCKPGERKKTVKGVPCCWHCERCEGYNYQVDELSCELCPLDQRPNMNRTGCQLIPIIKLEWHSPWAVVPVFVAILGIIATTFVIVTFVRYNDTPIVRASGRELSYVLLTGIFLCYSITFLMIAAPDTIICSFRRVFLGLGMCFSYAALLTKTNRIHRIFEQGKKSVTAPKFISPASQLVITFSLISVQLLGVFVWFVVDPPHIIIDYGEQRTLDPEKARGVLKCDISDLSLICSLGYSILLMVTCTVYAIKTRGVPETFNEAKPIGFTMYTTCIIWLAFIPIFFGTAQSAEKMYIQTTTLTVSMSLSASVSLGMLYMPKVYIIIFHPEQNVQKRKRSFKAVVTAATMQSKLIQKGNDRPNGEVKSELCESLETNTSSTKTTYISYSNHSI
T77548	DRUGINFO	D00IGI	2-Amino-4-phosphono-butyric acid	Investigative
T77548	DRUGINFO	D09AQK	(R,S)-4-phosphonophenylglycine	Investigative
T77548	DRUGINFO	D0G7TT	D-AP4	Investigative
T77548	DRUGINFO	D0H8XQ	AZ12216052	Investigative
T77548	DRUGINFO	D06PHE	CPPG	Investigative
T77548	DRUGINFO	D0LC5O	(S)-3,4-DCPG	Investigative
T77548	DRUGINFO	D0W3PY	ACPT-I	Investigative
T77548	DRUGINFO	D09SXN	MAP4	Investigative
T77548	DRUGINFO	D0D2GL	MPPG	Investigative
T77548	DRUGINFO	D0O8AK	alpha-methylserine-O-phosphate	Investigative
T77548	DRUGINFO	D0PN6Z	L-AP4	Investigative
T77548	DRUGINFO	D04DKM	(1S,3R)-ACPD	Investigative
T77548	DRUGINFO	D06DUE	[3H]quisqualate	Investigative
T77548	DRUGINFO	D0Z7CZ	L-CCG-I	Investigative
T77548	DRUGINFO	D07PZQ	L-serine-O-phosphate	Investigative

T76522	TARGETID	T76522
T76522	FORMERID	TTDR01201
T76522	UNIPROID	PDXK_HUMAN
T76522	TARGNAME	Pyridoxal kinase (PDXK)
T76522	GENENAME	PDXK
T76522	TARGTYPE	Literature-reported
T76522	SYNONYMS	Pyridoxine kinase; PDXK
T76522	FUNCTION	Required for synthesisof pyridoxal-5-phosphate from vitamin B6.
T76522	PDBSTRUC	4EOH; 4EN4; 3KEU; 3FHY; 3FHX
T76522	BIOCLASS	Kinase
T76522	ECNUMBER	EC 2.7.1.35
T76522	SEQUENCE	MEEECRVLSIQSHVIRGYVGNRAATFPLQVLGFEIDAVNSVQFSNHTGYAHWKGQVLNSDELQELYEGLRLNNMNKYDYVLTGYTRDKSFLAMVVDIVQELKQQNPRLVYVCDPVLGDKWDGEGSMYVPEDLLPVYKEKVVPLADIITPNQFEAELLSGRKIHSQEEALRVMDMLHSMGPDTVVITSSDLPSPQGSNYLIVLGSQRRRNPAGSVVMERIRMDIRKVDAVFVGTGDLFAAMLLAWTHKHPNNLKVACEKTVSTLHHVLQRTIQCAKAQAGEGVRPSPMQLELRMVQSKRDIEDPEIVVQATVL
T76522	DRUGINFO	D0UG4S	L-betagamma-meATP	Investigative

T76012	TARGETID	T76012
T76012	FORMERID	TTDR01202
T76012	UNIPROID	IMPA2_HUMAN
T76012	TARGNAME	Inositol-1(or4)-monophosphatase (IMPA2)
T76012	GENENAME	IMPA2
T76012	TARGTYPE	Literature-reported
T76012	SYNONYMS	Myo-inositol-1-phosphate phosphohydrolase; Myo-inositol monophosphatase: IMP.18p; Lithium-sensitive myo-inositol monophosphatase A1; Inositol monophosphatase; IMPase; IMPA2; IMP
T76012	FUNCTION	Can use myo-inositol monophosphates, scylloinositol 1,4- diphosphate, glucose-1-phosphate, beta-glycerophosphate, and 2'- AMP as substrates. Has been implicated as the pharmacological target for lithium Li(+) action in brain.
T76012	PDBSTRUC	2FVZ; 2DDK; 2CZK; 2CZI; 2CZH
T76012	BIOCLASS	Phosphoric monoester hydrolase
T76012	ECNUMBER	EC 3.1.3.25
T76012	SEQUENCE	MKPSGEDQAALAAGPWEECFQAAVQLALRAGQIIRKALTEEKRVSTKTSAADLVTETDHLVEDLIISELRERFPSHRFIAEEAAASGAKCVLTHSPTWIIDPIDGTCNFVHRFPTVAVSIGFAVRQELEFGVIYHCTEERLYTGRRGRGAFCNGQRLRVSGETDLSKALVLTEIGPKRDPATLKLFLSNMERLLHAKAHGVRVIGSSTLALCHLASGAADAYYQFGLHCWDLAAATVIIREAGGIVIDTSGGPLDLMACRVVAASTREMAMLIAQALQTINYGRDDEK
T76012	DRUGINFO	D08MFC	L-Myo-Inositol-1-Phosphate	Investigative

T65879	TARGETID	T65879
T65879	FORMERID	TTDR00255
T65879	UNIPROID	IKKA_HUMAN
T65879	TARGNAME	Inhibitor of nuclear factor kappa-B kinase alpha (IKKA)
T65879	GENENAME	CHUK
T65879	TARGTYPE	Literature-reported
T65879	SYNONYMS	Transcription factor 16; TCF16; TCF-16; Nuclear factor NFkappaB inhibitor kinase alpha; Nuclear factor NF-kappa-B inhibitor kinase alpha; NFKBIKA; Inhibitory kappa B kinasea; Inhibitor of nuclear factor kappa-B kinase subunit alpha; IkappaB kinase A; IkBKA; IKK1; IKK-alpha; IKK-A; I-kappa-B kinase alpha; I-kappa-B kinase 1; I kappa-B kinase alpha; Conserved helix-loop-helix ubiquitous kinase
T65879	FUNCTION	Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on serine residues. These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome. In turn, free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. Negatively regulates the pathway by phosphorylating the scaffold protein TAXBP1 and thus promoting the assembly of the A20/TNFAIP3 ubiquitin-editing complex (composed of A20/TNFAIP3, TAX1BP1, and the E3 ligases ITCH and RNF11). Therefore, CHUK plays a key role in the negative feedback of NF-kappa-B canonical signaling to limit inflammatory gene activation. As part of the non-canonical pathway of NF-kappa-B activation, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. In turn, these complexes regulate genes encoding molecules involved in B-cell survival and lymphoid organogenesis. Participates also in the negative feedback of the non-canonical NF-kappa-B signaling pathway by phosphorylating and destabilizing MAP3K14/NIK. Within the nucleus, phosphorylates CREBBP and consequently increases both its transcriptional and histone acetyltransferase activities. Modulates chromatin accessibility at NF-kappa-B-responsive promoters by phosphorylating histones H3 at 'Ser-10' that are subsequently acetylated at 'Lys-14' by CREBBP. Additionally, phosphorylates the CREBBP-interacting protein NCOA3. Also phosphorylates FOXO3 and may regulate this pro-apoptotic transcription factor. Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses.
T65879	PDBSTRUC	5TQY; 5TQX; 5TQW; 5EBZ; 3BRT
T65879	BIOCLASS	Kinase
T65879	ECNUMBER	EC 2.7.11.10
T65879	SEQUENCE	MERPPGLRPGAGGPWEMRERLGTGGFGNVCLYQHRELDLKIAIKSCRLELSTKNRERWCHEIQIMKKLNHANVVKACDVPEELNILIHDVPLLAMEYCSGGDLRKLLNKPENCCGLKESQILSLLSDIGSGIRYLHENKIIHRDLKPENIVLQDVGGKIIHKIIDLGYAKDVDQGSLCTSFVGTLQYLAPELFENKPYTATVDYWSFGTMVFECIAGYRPFLHHLQPFTWHEKIKKKDPKCIFACEEMSGEVRFSSHLPQPNSLCSLVVEPMENWLQLMLNWDPQQRGGPVDLTLKQPRCFVLMDHILNLKIVHILNMTSAKIISFLLPPDESLHSLQSRIERETGINTGSQELLSETGISLDPRKPASQCVLDGVRGCDSYMVYLFDKSKTVYEGPFASRSLSDCVNYIVQDSKIQLPIIQLRKVWAEAVHYVSGLKEDYSRLFQGQRAAMLSLLRYNANLTKMKNTLISASQQLKAKLEFFHKSIQLDLERYSEQMTYGISSEKMLKAWKEMEEKAIHYAEVGVIGYLEDQIMSLHAEIMELQKSPYGRRQGDLMESLEQRAIDLYKQLKHRPSDHSYSDSTEMVKIIVHTVQSQDRVLKELFGHLSKLLGCKQKIIDLLPKVEVALSNIKEADNTVMFMQGKRQKEIWHLLKIACTQSSARSLVGSSLEGAVTPQTSAWLPPTSAEHDHSLSCVVTPQDGETSAQMIEENLNCLGHLSTIIHEANEEQGNSMMNLDWSWLTE
T65879	DRUGINFO	D03JMF	IKI-1	Investigative

T08280	TARGETID	T08280
T08280	FORMERID	TTDR00635
T08280	UNIPROID	PFKA_TRYBB
T08280	TARGNAME	Trypanosoma Pyrophosphate-dependent phosphofructokinase (Trypano pfk)
T08280	GENENAME	Trypano pfk
T08280	TARGTYPE	Literature-reported
T08280	SYNONYMS	Pyrophosphate-dependent 6-phosphofructose-1-kinase; Pyrophosphate--fructose 6-phosphate 1-phosphotransferase alpha subunit; PPi-PFK; PFP-ALPHA; PFP; 6-phosphofructokinase, pyrophosphate dependent
T08280	FUNCTION	Regulatory subunit of pyrophosphate--fructose 6- phosphate 1-phosphotransferase.
T08280	PDBSTRUC	3F5M; 3CVL; 2HIG
T08280	BIOCLASS	Kinase
T08280	ECNUMBER	EC 2.7.1.11
T08280	SEQUENCE	MAVESRSRVTSKLVKAHRAMLNSVTQEDLKVDRLPGADYPNPSKKYSSRTEFRDKTDYIMYNPRPRDEPSSENPVSVSPLLCELAAARSRIHFNPTETTIGIVTCGGICPGLNDVIRSITLTGINVYNVKRVIGFRFGYWGLSKKGSQTAIELHRGRVTNIHHYGGTILGSSRGPQDPKEMVDTLERLGVNILFTVGGDGTQRGALVISQEAKRRGVDISVFGVPKTIDNDLSFSHRTFGFQTAVEKAVQAIRAAYAEAVSANYGVGVVKLMGRDSGFIAAQAAVASAQANICLVPENPISEQEVMSLLERRFCHSRSCVIIVAEGFGQDWGRGSGGYDASGNKKLIDIGVILTEKVKAFLKANKSRYPDSTVKYIDPSYMIRACPPSANDALFCATLATLAVHEAMAGATGCIIAMRHNNYILVPIKVATSVRRVLDLRGQLWRQVREITVDLGSDVRLARKLEIRRELEAINRNRDRLHEELAKL
T08280	DRUGINFO	D0M5KC	POLYSIN	Investigative

T04361	TARGETID	T04361
T04361	FORMERID	TTDNR00706
T04361	UNIPROID	M3K7_HUMAN
T04361	TARGNAME	TGF-beta-activated kinase 1 (MAP3K7)
T04361	GENENAME	MAP3K7
T04361	TARGTYPE	Literature-reported
T04361	SYNONYMS	Transforming growth factor-beta-activated kinase 1; TAK1; Mitogen-activated protein kinase kinase kinase 7
T04361	FUNCTION	Plays an important role in the cascades of cellular responses evoked by changes in the environment. Mediates signal transduction of TRAF6, various cytokines including interleukin-1 (IL-1), transforming growth factor-beta (TGFB), TGFB-related factors like BMP2 and BMP4, toll-like receptors (TLR), tumor necrosis factor receptor CD40 and B-cell receptor (BCR). Ceramides are also able to activate MAP3K7/TAK1. Once activated, acts as an upstream activator of the MKK/JNK signal transduction cascade and the p38 MAPK signal transduction cascade through the phosphorylation and activation of several MAP kinase kinases like MAP2K1/MEK1, MAP2K3/MKK3, MAP2K6/MKK6 and MAP2K7/MKK7. These MAP2Ks in turn activate p38 MAPKs, c-jun N-terminal kinases (JNKs) and I-kappa-B kinase complex (IKK). Both p38 MAPK and JNK pathways control the transcription factors activator protein-1 (AP-1), while nuclear factor-kappa B is activated by IKK. MAP3K7 activates also IKBKB and MAPK8/JNK1 in response to TRAF6 signaling and mediates BMP2-induced apoptosis. In osmotic stress signaling, plays a major role in the activation of MAPK8/JNK1, but not that of NF-kappa-B. Promotes TRIM5 capsid-specific restriction activity. Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway.
T04361	PDBSTRUC	5V5N; 5JK3; 5JH6; 5JGD; 5JGB
T04361	BIOCLASS	Kinase
T04361	ECNUMBER	EC 2.7.11.25
T04361	SEQUENCE	MSTASAASSSSSSSAGEMIEAPSQVLNFEEIDYKEIEVEEVVGRGAFGVVCKAKWRAKDVAIKQIESESERKAFIVELRQLSRVNHPNIVKLYGACLNPVCLVMEYAEGGSLYNVLHGAEPLPYYTAAHAMSWCLQCSQGVAYLHSMQPKALIHRDLKPPNLLLVAGGTVLKICDFGTACDIQTHMTNNKGSAAWMAPEVFEGSNYSEKCDVFSWGIILWEVITRRKPFDEIGGPAFRIMWAVHNGTRPPLIKNLPKPIESLMTRCWSKDPSQRPSMEEIVKIMTHLMRYFPGADEPLQYPCQYSDEGQSNSATSTGSFMDIASTNTSNKSDTNMEQVPATNDTIKRLESKLLKNQAKQQSESGRLSLGASRGSSVESLPPTSEGKRMSADMSEIEARIAATTAYSKPKRGHRKTASFGNILDVPEIVISGNGQPRRRSIQDLTVTGTEPGQVSSRSSSPSVRMITTSGPTSEKPTRSHPWTPDDSTDTNGSDNSIPMAYLTLDHQLQPLAPCPNSKESMAVFEQHCKMAQEYMKVQTEIALLLQRKQELVAELDQDEKDQQNTSRLVQEHKKLLDENKSLSTYYQQCKKQLEVIRSQQQKRQGTS
T04361	DRUGINFO	D0H9QN	AZ-TAK1	Investigative
T04361	DRUGINFO	D03BJF	PMID23099093C17d	Investigative
T04361	DRUGINFO	D0X7IC	NG-25	Investigative

T82702	TARGETID	T82702
T82702	FORMERID	TTDR01273
T82702	UNIPROID	NR1I2_HUMAN
T82702	TARGNAME	Pregnane X receptor (NR1I2)
T82702	GENENAME	NR1I2
T82702	TARGTYPE	Literature-reported
T82702	SYNONYMS	Steroid and xenobiotic receptor; SXR; PXR; Orphan nuclear receptor PXR; Orphan nuclear receptor PAR1; Nuclear receptor subfamily 1 group I member 2
T82702	FUNCTION	Transcription factor that activates the transcription of multiple genes involved in the metabolism and secretion of potentially harmful xenobiotics, drugs and endogenous compounds. Activated by the antibiotic rifampicin and various plant metabolites, such as hyperforin, guggulipid, colupulone, and isoflavones. Response to specific ligands is species-specific. Activated by naturally occurring steroids, such as pregnenolone and progesterone. Binds to a response element in the promoters of the CYP3A4 and ABCB1/MDR1 genes. Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds.
T82702	PDBSTRUC	6DUP; 6BNS; 5X0R; 5A86; 4XHD
T82702	BIOCLASS	Nuclear hormone receptor
T82702	SEQUENCE	MEVRPKESWNHADFVHCEDTESVPGKPSVNADEEVGGPQICRVCGDKATGYHFNVMTCEGCKGFFRRAMKRNARLRCPFRKGACEITRKTRRQCQACRLRKCLESGMKKEMIMSDEAVEERRALIKRKKSERTGTQPLGVQGLTEEQRMMIRELMDAQMKTFDTTFSHFKNFRLPGVLSSGCELPESLQAPSREEAAKWSQVRKDLCSLKVSLQLRGEDGSVWNYKPPADSGGKEIFSLLPHMADMSTYMFKGIISFAKVISYFRDLPIEDQISLLKGAAFELCQLRFNTVFNAETGTWECGRLSYCLEDTAGGFQQLLLEPMLKFHYMLKKLQLHEEEYVLMQAISLFSPDRPGVLQHRVVDQLQEQFAITLKSYIECNRPQPAHRFLFLKIMAMLTELRSINAQHTQRLLRIQDIHPFATPLMQELFGITGS
T82702	DRUGINFO	D01BJB	pregnenolone-16alpha-carbonitrile	Investigative
T82702	DRUGINFO	D0FI7B	trihydroxycholestane	Investigative
T82702	DRUGINFO	D0Y4YV	schisandrin A	Investigative
T82702	DRUGINFO	D06RBG	3-keto-lithocholic acid	Investigative
T82702	DRUGINFO	D09VTJ	Hyperforin	Investigative
T82702	DRUGINFO	D0V4RZ	WAY-214950	Investigative

T91605	TARGETID	T91605
T91605	UNIPROID	TRI37_HUMAN
T91605	TARGNAME	E3 ubiquitin-protein ligase TRIM37 (TRIM37)
T91605	GENENAME	TRIM37
T91605	TARGTYPE	Literature-reported
T91605	SYNONYMS	Tripartite motif-containing protein 37; RING-type E3 ubiquitin transferase TRIM37; Mulibrey nanism protein
T91605	FUNCTION	E3 ubiquitin-protein ligase required to prevent centriole reduplication (PubMed:15885686, PubMed:23769972). Probably acts by ubiquitinating positive regulators of centriole reduplication (PubMed:23769972). Mediates monoubiquitination of 'Lys-119' of histone H2A (H2AK119Ub), a specific tag for epigenetic transcriptional repression: associates with some Polycomb group (PcG) multiprotein PRC2-like complex and mediates repression of target genes (PubMed:25470042). Has anti-HIV activity (PubMed:24317724).
T91605	PDBSTRUC	3LRQ
T91605	BIOCLASS	TRIM/RBCC family
T91605	ECNUMBER	EC 2.3.2.27
T91605	SEQUENCE	MDEQSVESIAEVFRCFICMEKLRDARLCPHCSKLCCFSCIRRWLTEQRAQCPHCRAPLQLRELVNCRWAEEVTQQLDTLQLCSLTKHEENEKDKCENHHEKLSVFCWTCKKCICHQCALWGGMHGGHTFKPLAEIYEQHVTKVNEEVAKLRRRLMELISLVQEVERNVEAVRNAKDERVREIRNAVEMMIARLDTQLKNKLITLMGQKTSLTQETELLESLLQEVEHQLRSCSKSELISKSSEILMMFQQVHRKPMASFVTTPVPPDFTSELVPSYDSATFVLENFSTLRQRADPVYSPPLQVSGLCWRLKVYPDGNGVVRGYYLSVFLELSAGLPETSKYEYRVEMVHQSCNDPTKNIIREFASDFEVGECWGYNRFFRLDLLANEGYLNPQNDTVILRFQVRSPTFFQKSRDQHWYITQLEAAQTSYIQQINNLKERLTIELSRTQKSRDLSPPDNHLSPQNDDALETRAKKSACSDMLLEGGPTTASVREAKEDEEDEEKIQNEDYHHELSDGDLDLDLVYEDEVNQLDGSSSSASSTATSNTEENDIDEETMSGENDVEYNNMELEEGELMEDAAAAGPAGSSHGYVGSSSRISRRTHLCSAATSSLLDIDPLILIHLLDLKDRSSIENLWGLQPRPPASLLQPTASYSRKDKDQRKQQAMWRVPSDLKMLKRLKTQMAEVRCMKTDVKNTLSEIKSSSAASGDMQTSLFSADQAALAACGTENSGRLQDLGMELLAKSSVANCYIRNSTNKKSNSPKPARSSVAGSLSLRRAVDPGENSRSKGDCQTLSEGSPGSSQSGSRHSSPRALIHGSIGDILPKTEDRQCKALDSDAVVVAVFSGLPAVEKRRKMVTLGANAKGGHLEGLQMTDLENNSETGELQPVLPEGASAAPEEGMSSDSDIECDTENEEQEEHTSVGGFHDSFMVMTQPPDEDTHSSFPDGEQIGPEDLSFNTDENSGR

T63159	TARGETID	T63159
T63159	FORMERID	TTDR00916
T63159	UNIPROID	AMP1_PLAFQ
T63159	TARGNAME	Plasmodium M1-family aminopeptidase (Malaria MFA)
T63159	GENENAME	Malaria MFA
T63159	TARGTYPE	Literature-reported
T63159	SYNONYMS	Pfa-M1
T63159	FUNCTION	Displays aminopeptidase activity with a broad substrate specificity. Preferentially hydrolyzes L-Lys-AMC but also shows strong activity against L-Ala-AMC, L-Arg-AMC and L-Leu-AMC.
T63159	PDBSTRUC	6EED; 6EE6; 6EE4; 6EE3; 6EAB
T63159	BIOCLASS	Peptidase
T63159	ECNUMBER	EC 3.4.11.-
T63159	SEQUENCE	MKLTKGCAYKYIIFTVLILANILYDNKKRCMIKKNLRISSCGIISRLLKSNSNYNSFNKNYNFTSAISELQFSNFWNLDILQKDIFSNIHNNKNKPQSYIIHKRLMSEKGDNNNNNHQNNNGNDNKKRLGSVVNNEENTCSDKRMKPFEEGHGITQVDKMNNNSDHLQQNGVMNLNSNNVENNNNNNSVVVKKNEPKIHYRKDYKPSGFIINNVTLNINIHDNETIVRSVLDMDISKHNVGEDLVFDGVGLKINEISINNKKLVEGEEYTYDNEFLTIFSKFVPKSKFAFSSEVIIHPETNYALTGLYKSKNIIVSQCEATGFRRITFFIDRPDMMAKYDVTVTADKEKYPVLLSNGDKVNEFEIPGGRHGARFNDPHLKPCYLFAVVAGDLKHLSATYITKYTKKKVELYVFSEEKYVSKLQWALECLKKSMAFDEDYFGLEYDLSRLNLVAVSDFNVGAMENKGLNIFNANSLLASKKNSIDFSYARILTVVGHEYFHNYTGNRVTLRDWFQLTLKEGLTVHRENLFSEEMTKTVTTRLSHVDLLRSVQFLEDSSPLSHPIRPESYVSMENFYTTTVYDKGSEVMRMYLTILGEEYYKKGFDIYIKKNDGNTATCEDFNYAMEQAYKMKKADNSANLNQYLLWFSQSGTPHVSFKYNYDAEKKQYSIHVNQYTKPDENQKEKKPLFIPISVGLINPENGKEMISQTTLELTKESDTFVFNNIAVKPIPSLFRGFSAPVYIEDNLTDEERILLLKYDSDAFVRYNSCTNIYMKQILMNYNEFLKAKNEKLESFNLTPVNAQFIDAIKYLLEDPHADAGFKSYIVSLPQDRYIINFVSNLDTDVLADTKEYIYKQIGDKLNDVYYKMFKSLEAKADDLTYFNDESHVDFDQMNMRTLRNTLLSLLSKAQYPNILNEIIEHSKSPYPSNWLTSLSVSAYFDKYFELYDKTYKLSKDDELLLQEWLKTVSRSDRKDIYEILKKLENEVLKDSKNPNDIRAVYLPFTNNLRRFHDISGKGYKLIAEVITKTDKFNPMVATQLCEPFKLWNKLDTKRQELMLNEMNTMLQEPNISNNLKEYLLRLTNKL
T63159	DRUGINFO	D03MLC	EUPAFOLIN	Investigative

T36121	TARGETID	T36121
T36121	FORMERID	TTDC00271
T36121	UNIPROID	MYC_HUMAN
T36121	TARGNAME	Proto-oncogene c-Myc (MYC)
T36121	GENENAME	MYC
T36121	TARGTYPE	Literature-reported
T36121	SYNONYMS	Transcription factor p64; Myc proto-oncogene protein; Class E basic helix-loop-helix protein 39; BHLHE39
T36121	FUNCTION	Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes. Binds to the VEGFA promoter, promoting VEGFA production and subsequent sprouting angiogenesis.
T36121	PDBSTRUC	6G6L; 6G6K; 6G6J; 6C4U; 5I50
T36121	SEQUENCE	MPLNVSFTNRNYDLDYDSVQPYFYCDEEENFYQQQQQSELQPPAPSEDIWKKFELLPTPPLSPSRRSGLCSPSYVAVTPFSLRGDNDGGGGSFSTADQLEMVTELLGGDMVNQSFICDPDDETFIKNIIIQDCMWSGFSAAAKLVSEKLASYQAARKDSGSPNPARGHSVCSTSSLYLQDLSAAASECIDPSVVFPYPLNDSSSPKSCASQDSSAFSPSSDSLLSSTESSPQGSPEPLVLHEETPPTTSSDSEEEQEDEEEIDVVSVEKRQAPGKRSESGSPSAGGHSKPPHSPLVLKRCHVSTHQHNYAAPPSTRKDYPAAKRVKLDSVRVLRQISNNRKCTSPRSSDTEENVKRRTHNVLERQRRNELKRSFFALRDQIPELENNEKAPKVVILKKATAYILSVQAEEQKLISEEDLLRKRREQLKHKLEQLRNSCA
T36121	DRUGINFO	D0T8KR	TWS-119	Investigative

T09694	TARGETID	T09694
T09694	FORMERID	TTDC00205
T09694	UNIPROID	GLUC_HUMAN
T09694	TARGNAME	Glucagon-like peptide 1 (GLP-1:7-37)
T09694	GENENAME	GCG
T09694	TARGTYPE	Literature-reported
T09694	SYNONYMS	Glucagon-like peptide-1(7-36)-amide; GLP-1 (92-128); GLP; GCG
T09694	FUNCTION	Glicentin may modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life.
T09694	PDBSTRUC	6EDS; 5YQZ; 5VAI; 5OTX; 5OTW
T09694	BIOCLASS	Glucagon
T09694	SEQUENCE	HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG

T54229	TARGETID	T54229
T54229	FORMERID	TTDR00240
T54229	UNIPROID	ANGI_HUMAN
T54229	TARGNAME	Angiogenin (ANG)
T54229	GENENAME	ANG
T54229	TARGTYPE	Literature-reported
T54229	SYNONYMS	Ribonuclease 5; RNase 5; RNASE5
T54229	FUNCTION	Stimulates ribosomal RNA synthesis including that containing the initiation site sequences of 45S rRNA. Cleaves tRNA within anticodon loops to produce tRNA-derived stress-induced fragments (tiRNAs) which inhibit protein synthesis and triggers the assembly of stress granules (SGs). Angiogenin induces vascularization of normal and malignant tissues. Angiogenic activity is regulated by interaction with RNH1 in vivo. Binds to actin on the surface of endothelial cells; once bound, angiogenin is endocytosed and translocated to the nucleus.
T54229	PDBSTRUC	5M9V; 5M9T; 5M9S; 5M9R; 5M9Q
T54229	BIOCLASS	Endoribonucleases
T54229	ECNUMBER	EC 3.1.27.-
T54229	SEQUENCE	MVMGLGVLLLVFVLGLGLTPPTLAQDNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLTSPCKDINTFIHGNKRSIKAICENKNGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYRATAGFRNVVVACENGLPVHLDQSIFRRP
T54229	DRUGINFO	D0U7QA	Pyroglutamic Acid	Investigative
T54229	DRUGINFO	D0A1DU	Pyrophosphate 2-	Investigative

T62073	TARGETID	T62073
T62073	FORMERID	TTDR00249
T62073	UNIPROID	OAT_HUMAN
T62073	TARGNAME	Ornithine delta-aminotransferase (OAT)
T62073	GENENAME	OAT
T62073	TARGTYPE	Literature-reported
T62073	SYNONYMS	Ornithine--oxo-acid aminotransferase; Ornithine aminotransferase, mitochondrial
T62073	FUNCTION	Catalyzes the transfer of the delta-amino group from L-ornithine.
T62073	PDBSTRUC	5VWO; 2OAT; 2CAN; 2BYL; 2BYJ
T62073	BIOCLASS	Transaminase
T62073	ECNUMBER	EC 2.6.1.13
T62073	SEQUENCE	MFSKLAHLQRFAVLSRGVHSSVASATSVATKKTVQGPPTSDDIFEREYKYGAHNYHPLPVALERGKGIYLWDVEGRKYFDFLSSYSAVNQGHCHPKIVNALKSQVDKLTLTSRAFYNNVLGEYEEYITKLFNYHKVLPMNTGVEAGETACKLARKWGYTVKGIQKYKAKIVFAAGNFWGRTLSAISSSTDPTSYDGFGPFMPGFDIIPYNDLPALERALQDPNVAAFMVEPIQGEAGVVVPDPGYLMGVRELCTRHQVLFIADEIQTGLARTGRWLAVDYENVRPDIVLLGKALSGGLYPVSAVLCDDDIMLTIKPGEHGSTYGGNPLGCRVAIAALEVLEEENLAENADKLGIILRNELMKLPSDVVTAVRGKGLLNAIVIKETKDWDAWKVCLRLRDNGLLAKPTHGDIIRFAPPLVIKEDELRESIEIINKTILSF
T62073	DRUGINFO	D08KEZ	Canaline	Investigative

T92750	TARGETID	T92750
T92750	FORMERID	TTDI02355
T92750	UNIPROID	CFAI_HUMAN
T92750	TARGNAME	Complement factor I (CFI)
T92750	GENENAME	CFI
T92750	TARGTYPE	Literature-reported
T92750	SYNONYMS	IF; Complement factor I light chain; C3B/C4B inactivator
T92750	FUNCTION	Inhibits these pathways by cleaving three peptide bonds in the alpha-chain of C3b and two bonds in the alpha-chain of C4b thereby inactivating these proteins. Essential cofactors for these reactions include factor H and C4BP in the fluid phase and membrane cofactor protein/CD46 and CR1 on cell surfaces. The presence of these cofactors on healthy cells allows degradation of deposited C3b by CFI in order to prevent undesired complement activation, while in apoptotic cells or microbes, the absence of such cofactors leads to C3b-mediated complement activation and subsequent opsonization. Trypsin-like serine protease that plays an essential role in regulating the immune response by controlling all complement pathways.
T92750	PDBSTRUC	5O32; 2XRC
T92750	BIOCLASS	Peptidase
T92750	ECNUMBER	EC 3.4.21.45
T92750	SEQUENCE	MKLLHVFLLFLCFHLRFCKVTYTSQEDLVEKKCLAKKYTHLSCDKVFCQPWQRCIEGTCVCKLPYQCPKNGTAVCATNRRSFPTYCQQKSLECLHPGTKFLNNGTCTAEGKFSVSLKHGNTDSEGIVEVKLVDQDKTMFICKSSWSMREANVACLDLGFQQGADTQRRFKLSDLSINSTECLHVHCRGLETSLAECTFTKRRTMGYQDFADVVCYTQKADSPMDDFFQCVNGKYISQMKACDGINDCGDQSDELCCKACQGKGFHCKSGVCIPSQYQCNGEVDCITGEDEVGCAGFASVTQEETEILTADMDAERRRIKSLLPKLSCGVKNRMHIRRKRIVGGKRAQLGDLPWQVAIKDASGITCGGIYIGGCWILTAAHCLRASKTHRYQIWTTVVDWIHPDLKRIVIEYVDRIIFHENYNAGTYQNDIALIEMKKDGNKKDCELPRSIPACVPWSPYLFQPNDTCIVSGWGREKDNERVFSLQWGEVKLISNCSKFYGNRFYEKEMECAGTYDGSIDACKGDSGGPLVCMDANNVTYVWGVVSWGENCGKPEFPGVYTKVANYFDWISYHVGRPFISQYNV
T92750	DRUGINFO	D03QSR	TP-20	Terminated

T40000	TARGETID	T40000
T40000	FORMERID	TTDI02552
T40000	UNIPROID	KLK1_HUMAN
T40000	TARGNAME	Tissue kallikrein (KLK1)
T40000	GENENAME	KLK1
T40000	TARGTYPE	Literature-reported
T40000	SYNONYMS	Kidney/pancreas/salivary gland kallikrein; Kallikrein1; Kallikrein-1
T40000	FUNCTION	Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin.
T40000	PDBSTRUC	1SPJ
T40000	BIOCLASS	Peptidase
T40000	ECNUMBER	EC 3.4.21.35
T40000	SEQUENCE	MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS
T40000	DRUGINFO	D00LAA	VA-118020	Investigative
T40000	DRUGINFO	D0D1WN	SBTI	Investigative
T40000	DRUGINFO	D0Q9VD	example 131 [WO2009133348]	Investigative

T24334	TARGETID	T24334
T24334	FORMERID	TTDR00596
T24334	UNIPROID	DUT_ECOLI
T24334	TARGNAME	Bacterial Deoxyuridine triphosphate nucleotidohydrolase (Bact dut)
T24334	GENENAME	Bact dut
T24334	TARGTYPE	Literature-reported
T24334	SYNONYMS	Deoxyuridine triphosphate nucleotidohydrolase; Deoxyuridine 5'-triphosphate nucleotidohydrolase; DUTPase; DUTP pyrophosphatase of Escherichia coli; Bact dut
T24334	FUNCTION	This enzyme is involved in nucleotide metabolism: it produces dUMP, the immediate precursor of thymidine nucleotides and it decreases the intracellular concentration of dUTP so that uracil cannot be incorporated into DNA.
T24334	PDBSTRUC	2HRM; 2HR6; 1SYL; 1SEH; 1RNJ
T24334	BIOCLASS	Acid anhydrides hydrolase
T24334	SEQUENCE	MMKKIDVKILDPRVGKEFPLPTYATSGSAGLDLRACLNDAVELAPGDTTLVPTGLAIHIADPSLAAMMLPRSGLGHKHGIVLGNLVGLIDSDYQGQLMISVWNRGQDSFTIQPGERIAQMIFVPVVQAEFNLVEDFDATDRGEGGFGHSGRQ
T24334	DRUGINFO	D01PSS	Deoxyuridine-5'-Triphosphate	Investigative
T24334	DRUGINFO	D01SLZ	1-[(Z)-4-trityloxy-2-butenyl]uracil	Investigative
T24334	DRUGINFO	D03EQN	2'-deoxyuridine 5'-alpha,beta-imido-diphosphate	Investigative
T24334	DRUGINFO	D0E2IH	1-[2-(trityloxy)ethoxymethyl]uracil	Investigative
T24334	DRUGINFO	D0K4DP	1-[4-hydroxy-3-(tritylaminomethyl)butyl]uracil	Investigative
T24334	DRUGINFO	D0RV7M	Deoxyuridine-5'-Diphosphate	Investigative
T24334	DRUGINFO	D0W5QR	1-(3-tritylaminopropyl)uracil	Investigative
T24334	DRUGINFO	D0Z9TM	2'-Deoxyuridine 5'-Alpha,Beta-Imido-Triphosphate	Investigative
T24334	DRUGINFO	D0CZ3C	2'-deoxyuridylic acid	Investigative
T24334	DRUGINFO	D0F2ME	Acetate Ion	Investigative

T10091	TARGETID	T10091
T10091	FORMERID	TTDR00221
T10091	UNIPROID	OPSD_HUMAN
T10091	TARGNAME	Rhodopsin (RHO)
T10091	GENENAME	RHO
T10091	TARGTYPE	Literature-reported
T10091	SYNONYMS	Opsin-2; OPN2
T10091	FUNCTION	Required for photoreceptor cell viability after birth. Light-induced isomerization of the chromophore 11-cis-retinal to all-trans-retinal triggers a conformational change that activates signaling via G-proteins. Subsequent receptor phosphorylation mediates displacement of the bound G-protein alpha subunit by the arrestin SAG and terminates signaling. Photoreceptor required for image-forming vision at low light intensity.
T10091	PDBSTRUC	6CMO; 5W0P; 5DGY; 4ZWJ
T10091	BIOCLASS	GPCR rhodopsin
T10091	SEQUENCE	MNGTEGPNFYVPFSNATGVVRSPFEYPQYYLAEPWQFSMLAAYMFLLIVLGFPINFLTLYVTVQHKKLRTPLNYILLNLAVADLFMVLGGFTSTLYTSLHGYFVFGPTGCNLEGFFATLGGEIALWSLVVLAIERYVVVCKPMSNFRFGENHAIMGVAFTWVMALACAAPPLAGWSRYIPEGLQCSCGIDYYTLKPEVNNESFVIYMFVVHFTIPMIIIFFCYGQLVFTVKEAAAQQQESATTQKAEKEVTRMVIIMVIAFLICWVPYASVAFYIFTHQGSNFGPIFMTIPAFFAKSAAIYNPVIYIMMNKQFRNCMLTTICCGKNPLGDDEASATVSKTETSQVAPA
T10091	DRUGINFO	D03YHE	N-Acetylmethionine	Investigative
T10091	DRUGINFO	D06PXR	Hexadecanal	Investigative
T10091	DRUGINFO	D0I2IS	Heptane-1,2,3-Triol	Investigative
T10091	DRUGINFO	D0NW6E	Heptyl 1-Thiohexopyranoside	Investigative
T10091	DRUGINFO	D01ILH	B-2-Octylglucoside	Investigative
T10091	DRUGINFO	D06PVF	(Hydroxyethyloxy)Tri(Ethyloxy)Octane	Investigative
T10091	DRUGINFO	D0K1UI	B-Nonylglucoside	Investigative
T10091	DRUGINFO	D02TVS	Hexadecanoic acid	Investigative
T10091	DRUGINFO	D09KUE	NSC-88915	Investigative
T10091	DRUGINFO	D0C7PY	Lauryl Dimethylamine-N-Oxide	Investigative
T10091	DRUGINFO	D0SD9H	Beta-D-Mannose	Investigative
T10091	DRUGINFO	D05BHG	Phosphonothreonine	Investigative
T10091	DRUGINFO	D07PZQ	L-serine-O-phosphate	Investigative
T10091	DRUGINFO	D02UVH	B-Octylglucoside	Investigative
T10091	DRUGINFO	D07LUR	Alpha-D-Mannose	Investigative

T08298	TARGETID	T08298
T08298	FORMERID	TTDI02550
T08298	UNIPROID	GRAB_HUMAN
T08298	TARGNAME	Granzyme B (GZMB)
T08298	GENENAME	GZMB
T08298	TARGTYPE	Literature-reported
T08298	SYNONYMS	Tcell serine protease 13E; SECT; Lymphocyte protease; Human lymphocyte protein; Granzyme2; GZMB; Fragmentin2; Cytotoxic Tlymphocyte proteinase 2; Cathepsin Glike 1; CTSGL1; CTLA1; C11
T08298	FUNCTION	This enzyme is necessary for target cell lysis in cell- mediated immune responses. It cleaves after Asp. Seems to be linked to an activation cascade of caspases (aspartate-specific cysteine proteases) responsible for apoptosis execution. Cleaves caspase-3, -7, -9and 10 to give rise to active enzymes mediating apoptosis.
T08298	PDBSTRUC	1IAU; 1FQ3
T08298	BIOCLASS	Peptidase
T08298	ECNUMBER	EC 3.4.21.79
T08298	SEQUENCE	MQPILLLLAFLLLPRADAGEIIGGHEAKPHSRPYMAYLMIWDQKSLKRCGGFLIRDDFVLTAAHCWGSSINVTLGAHNIKEQEPTQQFIPVKRPIPHPAYNPKNFSNDIMLLQLERKAKRTRAVQPLRLPSNKAQVKPGQTCSVAGWGQTAPLGKHSHTLQEVKMTVQEDRKCESDLRHYYDSTIELCVGDPEIKKTSFKGDSGGPLVCNKVAQGIVSYGRNNGMPPRACTKVSSFVHWIKKTMKRY
T08298	DRUGINFO	D06UZS	VDA-1124	Investigative
T08298	DRUGINFO	D0Y7HC	PMID12127536C20 	Investigative

T08813	TARGETID	T08813
T08813	FORMERID	TTDR00977
T08813	UNIPROID	KAP0_HUMAN
T08813	TARGNAME	cAMP-dependent protein kinase A type I (PRKAR1A)
T08813	GENENAME	PRKAR1A
T08813	TARGTYPE	Literature-reported
T08813	SYNONYMS	cAMP-dependent protein kinase type I-alpha regulatory subunit; Tissue-specific extinguisher 1; TSE1; PRKAR1; PKR1
T08813	FUNCTION	Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signaling in cells.
T08813	PDBSTRUC	5KJZ; 5KJY; 5KJX
T08813	BIOCLASS	Kinase
T08813	SEQUENCE	MESGSTAASEEARSLRECELYVQKHNIQALLKDSIVQLCTARPERPMAFLREYFERLEKEEAKQIQNLQKAGTRTDSREDEISPPPPNPVVKGRRRRGAISAEVYTEEDAASYVRKVIPKDYKTMAALAKAIEKNVLFSHLDDNERSDIFDAMFSVSFIAGETVIQQGDEGDNFYVIDQGETDVYVNNEWATSVGEGGSFGELALIYGTPRAATVKAKTNVKLWGIDRDSYRRILMGSTLRKRKMYEEFLSKVSILESLDKWERLTVADALEPVQFEDGQKIVVQGEPGDEFFIILEGSAAVLQRRSENEEFVEVGRLGPSDYFGEIALLMNRPRAATVVARGPLKCVKLDRPRFERVLGPCSDILKRNIQQYNSFVSLSV
T08813	DRUGINFO	D0H1BF	Sp-Adenosine-3',5'-Cyclic-Monophosphorothioate	Investigative
T08813	DRUGINFO	D0Z3CZ	5-(2-methylpiperazin-1-ylsulfonyl)isoquinoline	Investigative
T08813	DRUGINFO	D00OCS	AdcAhxArg4NH(CH2)6NH2	Investigative
T08813	DRUGINFO	D02GEW	AdcAhxArg4Lys-PEGOMe	Investigative
T08813	DRUGINFO	D02ZWX	AdoC(GABA)Arg6	Investigative
T08813	DRUGINFO	D03GNM	AdcAhxArg4Lys(biotin)-PEG-OMe	Investigative
T08813	DRUGINFO	D08GIG	AdoC(Aun)Arg6	Investigative
T08813	DRUGINFO	D09LAQ	Cyclic Guanosine Monophosphate	Investigative
T08813	DRUGINFO	D0A5YR	AdoCGlyArg6	Investigative
T08813	DRUGINFO	D0F3XS	AdoC(Aoc)Arg6	Investigative
T08813	DRUGINFO	D0I4MQ	AdcAhxArg6	Investigative
T08813	DRUGINFO	D0KZ2I	AdoC(betaAsp)2AlaArg6	Investigative
T08813	DRUGINFO	D0QS6O	AdoC(Ahx)Arg6	Investigative
T08813	DRUGINFO	D0RC8H	AdoC(beta-Ala)2AlaArg6	Investigative
T08813	DRUGINFO	D0V3TE	AdoC(beta-Ala)Arg6	Investigative
T08813	DRUGINFO	D07MMG	AdoC(Dpr)2AlaArg6	Investigative
T08813	DRUGINFO	D0UB2J	[3H]cAMP	Investigative
T08813	DRUGINFO	D0L8HO	RO-316233	Investigative

T12817	TARGETID	T12817
T12817	FORMERID	TTDS00234
T12817	UNIPROID	HSP7C_HUMAN
T12817	TARGNAME	Lipopolysaccharide-associated protein 1 (HSPA8)
T12817	GENENAME	HSPA8
T12817	TARGTYPE	Literature-reported
T12817	SYNONYMS	LPS-associated protein 1; LAP-1; Heat shock protein 73; Heat shock cognate 71 kDa protein; Heat shock 70 kDa protein 8; HSPA10; HSP73; HSC70
T12817	FUNCTION	Plays a pivotal role in the protein quality control system, ensuring the correct folding of proteins, the re-folding of misfolded proteins and controlling the targeting of proteins for subsequent degradation. This is achieved through cycles of ATP binding, ATP hydrolysis and ADP release, mediated by co-chaperones. The co-chaperones have been shown to not only regulate different steps of the ATPase cycle of HSP70, but they also have an individual specificity such that one co-chaperone may promote folding of a substrate while another may promote degradation. The affinity of HSP70 for polypeptides is regulated by its nucleotide bound state. In the ATP-bound form, it has a low affinity for substrate proteins. However, upon hydrolysis of the ATP to ADP, it undergoes a conformational change that increases its affinity for substrate proteins. HSP70 goes through repeated cycles of ATP hydrolysis and nucleotide exchange, which permits cycles of substrate binding and release. The HSP70-associated co-chaperones are of three types: J-domain co-chaperones HSP40s (stimulate ATPase hydrolysis by HSP70), the nucleotide exchange factors (NEF) such as BAG1/2/3 (facilitate conversion of HSP70 from the ADP-bound to the ATP-bound state thereby promoting substrate release), and the TPR domain chaperones such as HOPX and STUB1. Acts as a repressor of transcriptional activation. Inhibits the transcriptional coactivator activity of CITED1 on Smad-mediated transcription. Component of the PRP19-CDC5L complex that forms an integral part of the spliceosome and is required for activating pre-mRNA splicing. May have a scaffolding role in the spliceosome assembly as it contacts all other components of the core complex. Binds bacterial lipopolysaccharide (LPS) and mediates LPS-induced inflammatory response, including TNF secretion by monocytes. Participates in the ER-associated degradation (ERAD) quality control pathway in conjunction with J domain-containing co-chaperones and the E3 ligase STUB1. Interacts with VGF-derived peptide TLQP-21. Molecular chaperone implicated in a wide variety of cellular processes, including protection of the proteome from stress, folding and transport of newly synthesized polypeptides, activation of proteolysis of misfolded proteins and the formation and dissociation of protein complexes.
T12817	PDBSTRUC	6B1N; 6B1M; 6B1I; 5AQV; 5AQU
T12817	BIOCLASS	Heat shock protein
T12817	SEQUENCE	MSKGPAVGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVAMNPTNTVFDAKRLIGRRFDDAVVQSDMKHWPFMVVNDAGRPKVQVEYKGETKSFYPEEVSSMVLTKMKEIAEAYLGKTVTNAVVTVPAYFNDSQRQATKDAGTIAGLNVLRIINEPTAAAIAYGLDKKVGAERNVLIFDLGGGTFDVSILTIEDGIFEVKSTAGDTHLGGEDFDNRMVNHFIAEFKRKHKKDISENKRAVRRLRTACERAKRTLSSSTQASIEIDSLYEGIDFYTSITRARFEELNADLFRGTLDPVEKALRDAKLDKSQIHDIVLVGGSTRIPKIQKLLQDFFNGKELNKSINPDEAVAYGAAVQAAILSGDKSENVQDLLLLDVTPLSLGIETAGGVMTVLIKRNTTIPTKQTQTFTTYSDNQPGVLIQVYEGERAMTKDNNLLGKFELTGIPPAPRGVPQIEVTFDIDANGILNVSAVDKSTGKENKITITNDKGRLSKEDIERMVQEAEKYKAEDEKQRDKVSSKNSLESYAFNMKATVEDEKLQGKINDEDKQKILDKCNEIINWLDKNQTAEKEEFEHQQKELEKVCNPIITKLYQSAGGMPGGMPGGFPGGGAPPSGGASSGPTIEEVD
T12817	DRUGINFO	D0GP7D	NSC-119911	Investigative
T12817	DRUGINFO	D0Z5LU	NSC-119913	Investigative

T15851	TARGETID	T15851
T15851	FORMERID	TTDR00231
T15851	UNIPROID	UMPS_HUMAN
T15851	TARGNAME	Orotidine 5'-monophosphate decarboxylase (UMPS)
T15851	GENENAME	UMPS
T15851	TARGTYPE	Literature-reported
T15851	SYNONYMS	Uridine 5'-monophosphate synthase; UMP synthase
T15851	FUNCTION	Catalyses the formation of uridine monophosphate (UMP), an energy-carrying molecule in many important biosynthetic pathways.
T15851	PDBSTRUC	4HKP; 4HIB; 3MW7; 3MO7; 3MI2
T15851	BIOCLASS	Pentosyltransferase
T15851	SEQUENCE	MAVARAALGPLVTGLYDVQAFKFGDFVLKSGLSSPIYIDLRGIVSRPRLLSQVADILFQTAQNAGISFDTVCGVPYTALPLATVICSTNQIPMLIRRKETKDYGTKRLVEGTINPGETCLIIEDVVTSGSSVLETVEVLQKEGLKVTDAIVLLDREQGGKDKLQAHGIRLHSVCTLSKMLEILEQQKKVDAETVGRVKRFIQENVFVAANHNGSPLSIKEAPKELSFGARAELPRIHPVASKLLRLMQKKETNLCLSADVSLARELLQLADALGPSICMLKTHVDILNDFTLDVMKELITLAKCHEFLIFEDRKFADIGNTVKKQYEGGIFKIASWADLVNAHVVPGSGVVKGLQEVGLPLHRGCLLIAEMSSTGSLATGDYTRAAVRMAEEHSEFVVGFISGSRVSMKPEFLHLTPGVQLEAGGDNLGQQYNSPQEVIGKRGSDIIIVGRGIISAADRLEAAEMYRKAAWEAYLSRLGV
T15851	DRUGINFO	D00GOC	Pyrazofurin	Investigative
T15851	DRUGINFO	D08OFS	5-fluoro-6-azido-UMP	Investigative
T15851	DRUGINFO	D0C7PT	5-fluoro-6-amino-UMP	Investigative
T15851	DRUGINFO	D0DW2F	5-fluoro-6-iodo-UMP	Investigative
T15851	DRUGINFO	D0P7AS	5-Fluoro-6-ethyluridine-5'-O-monophosphate	Investigative
T15851	DRUGINFO	D08NFH	Alpha-Phosphoribosylpyrophosphoric Acid	Investigative
T15851	DRUGINFO	D0P0EP	6-Hydroxyuridine-5'-Phosphate	Investigative

T70310	TARGETID	T70310
T70310	FORMERID	TTDR00898
T70310	UNIPROID	DNLJ_ECOLI
T70310	TARGNAME	Bacterial DNA ligase (Bact ligA)
T70310	GENENAME	Bact ligA
T70310	TARGTYPE	Literature-reported
T70310	SYNONYMS	ligA; Polydeoxyribonucleotide synthase [NAD+]; NAD+-dependent DNA ligase
T70310	FUNCTION	DNA ligase that catalyzes the formation of phosphodiester linkages between 5'-phosphoryl and 3'-hydroxyl groups in double-stranded DNA using NAD as a coenzyme and as the energy source for the reaction. It is essential for DNA replication and repair of damaged DNA.
T70310	PDBSTRUC	5TT5; 4GLX; 2OWO
T70310	BIOCLASS	Phosphoric ester ligase
T70310	ECNUMBER	EC 6.5.1.2
T70310	SEQUENCE	MESIEQQLTELRTTLRHHEYLYHVMDAPEIPDAEYDRLMRELRELETKHPELITPDSPTQRVGAAPLAAFSQIRHEVPMLSLDNVFDEESFLAFNKRVQDRLKNNEKVTWCCELKLDGLAVSILYENGVLVSAATRGDGTTGEDITSNVRTIRAIPLKLHGENIPARLEVRGEVFLPQAGFEKINEDARRTGGKVFANPRNAAAGSLRQLDPRITAKRPLTFFCYGVGVLEGGELPDTHLGRLLQFKKWGLPVSDRVTLCESAEEVLAFYHKVEEDRPTLGFDIDGVVIKVNSLAQQEQLGFVARAPRWAVAFKFPAQEQMTFVRDVEFQVGRTGAITPVARLEPVHVAGVLVSNATLHNADEIERLGLRIGDKVVIRRAGDVIPQVVNVVLSERPEDTREVVFPTHCPVCGSDVERVEGEAVARCTGGLICGAQRKESLKHFVSRRAMDVDGMGDKIIDQLVEKEYVHTPADLFKLTAGKLTGLERMGPKSAQNVVNALEKAKETTFARFLYALGIREVGEATAAGLAAYFGTLEALEAASIEELQKVPDVGIVVASHVHNFFAEESNRNVISELLAEGVHWPAPIVINAEEIDSPFAGKTVVLTGSLSQMSRDDAKARLVELGAKVAGSVSKKTDLVIAGEAAGSKLAKAQELGIEVIDEAEMLRLLGS
T70310	DRUGINFO	D04NGC	5-(methylthio)thiophene-2-carboxylic acid	Investigative
T70310	DRUGINFO	D07MKJ	7-(4-methoxyphenyl)pteridine-2,4-diol	Investigative
T70310	DRUGINFO	D07YPS	(2-hydroxyphenyl)(4-hydroxyphenyl)methanone	Investigative
T70310	DRUGINFO	D0C0FK	3-amino-2-(benzylideneamino)-5-mercaptophenol	Investigative
T70310	DRUGINFO	D0Y0XQ	2,3-dioxoindoline-7-carboxylic acid	Investigative

T33966	TARGETID	T33966
T33966	FORMERID	TTDR01204
T33966	UNIPROID	CBPA1_HUMAN
T33966	TARGNAME	Carboxypeptidase A1 (CPA1)
T33966	GENENAME	CPA1
T33966	TARGTYPE	Literature-reported
T33966	SYNONYMS	CPA
T33966	FUNCTION	Carboxypeptidase that catalyzes the release of a C-terminal amino acid, but has little or no action with -Asp, -Glu, -Arg, -Lys or -Pro.
T33966	PDBSTRUC	6I6Z; 5OM9; 4UF4; 4UEZ; 4UEF
T33966	BIOCLASS	Peptidase
T33966	ECNUMBER	EC 3.4.17.1
T33966	SEQUENCE	MRGLLVLSVLLGAVFGKEDFVGHQVLRISVADEAQVQKVKELEDLEHLQLDFWRGPAHPGSPIDVRVPFPSIQAVKIFLESHGISYETMIEDVQSLLDEEQEQMFAFRSRARSTDTFNYATYHTLEEIYDFLDLLVAENPHLVSKIQIGNTYEGRPIYVLKFSTGGSKRPAIWIDTGIHSREWVTQASGVWFAKKITQDYGQDAAFTAILDTLDIFLEIVTNPDGFAFTHSTNRMWRKTRSHTAGSLCIGVDPNRNWDAGFGLSGASSNPCSETYHGKFANSEVEVKSIVDFVKDHGNIKAFISIHSYSQLLMYPYGYKTEPVPDQDELDQLSKAAVTALASLYGTKFNYGSIIKAIYQASGSTIDWTYSQGIKYSFTFELRDTGRYGFLLPASQIIPTAKETWLALLTIMEHTLNHPY
T33966	DRUGINFO	D07CVG	SQ-14603	Investigative
T33966	DRUGINFO	D06LNX	DL-benzylsuccinic acid	Investigative
T33966	DRUGINFO	D0N4RO	PMID18078750C1b	Investigative
T33966	DRUGINFO	D0W3UL	2-Thiomethyl-3-Phenylpropanoic Acid	Investigative

T97749	TARGETID	T97749
T97749	FORMERID	TTDR00825
T97749	UNIPROID	NEC2_HUMAN
T97749	TARGNAME	Neuroendocrine convertase 2 (PCSK2)
T97749	GENENAME	PCSK2
T97749	TARGTYPE	Literature-reported
T97749	SYNONYMS	Proprotein convertase 2; Prohormone convertase 2; PCSK2; PC2; NEC 2; KEX2-like endoprotease 2
T97749	FUNCTION	Involved in the processing of hormone and other protein precursors at sites comprised of pairs of basic amino acid residues.
T97749	BIOCLASS	Peptidase
T97749	ECNUMBER	EC 3.4.21.94
T97749	SEQUENCE	MKGGCVSQWKAAAGFLFCVMVFASAERPVFTNHFLVELHKGGEDKARQVAAEHGFGVRKLPFAEGLYHFYHNGLAKAKRRRSLHHKQQLERDPRVKMALQQEGFDRKKRGYRDINEIDINMNDPLFTKQWYLINTGQADGTPGLDLNVAEAWELGYTGKGVTIGIMDDGIDYLHPDLASNYNAEASYDFSSNDPYPYPRYTDDWFNSHGTRCAGEVSAAANNNICGVGVAYNSKVAGIRMLDQPFMTDIIEASSISHMPQLIDIYSASWGPTDNGKTVDGPRELTLQAMADGVNKGRGGKGSIYVWASGDGGSYDDCNCDGYASSMWTISINSAINDGRTALYDESCSSTLASTFSNGRKRNPEAGVATTDLYGNCTLRHSGTSAAAPEAAGVFALALEANLGLTWRDMQHLTVLTSKRNQLHDEVHQWRRNGVGLEFNHLFGYGVLDAGAMVKMAKDWKTVPERFHCVGGSVQDPEKIPSTGKLVLTLTTDACEGKENFVRYLEHVQAVITVNATRRGDLNINMTSPMGTKSILLSRRPRDDDSKVGFDKWPFMTTHTWGEDARGTWTLELGFVGSAPQKGVLKEWTLMLHGTQSAPYIDQVVRDYQSKLAMSKKEELEEELDEAVERSLKSILNKN
T97749	DRUGINFO	D0Y9PH	Phenylacetyl-Arg-Val-Arg-4-amidinobenzylamide	Investigative
T97749	DRUGINFO	D0A6FZ	peptide 18	Investigative

T62815	TARGETID	T62815
T62815	FORMERID	TTDR00561
T62815	UNIPROID	UD2B7_HUMAN
T62815	TARGNAME	UDP-glucuronosyltransferase 2B7 (UGT2B7)
T62815	GENENAME	ugt3
T62815	TARGTYPE	Literature-reported
T62815	SYNONYMS	ugt3; Uridine diphosphate glucuronosyltransferase; UDPGT
T62815	FUNCTION	UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.
T62815	PDBSTRUC	2O6L
T62815	BIOCLASS	Hexosyltransferase
T62815	ECNUMBER	EC 2.4.1.17
T62815	SEQUENCE	MSVKWTSVILLIQLSFCFSSGNCGKVLVWAAEYSHWMNIKTILDELIQRGHEVTVLASSASILFDPNNSSALKIEIYPTSLTKTELENFIMQQIKRWSDLPKDTFWLYFSQVQEIMSIFGDITRKFCKDVVSNKKFMKKVQESRFDVIFADAIFPCSELLAELFNIPFVYSLSFSPGYTFEKHSGGFIFPPSYVPVVMSELTDQMTFMERVKNMIYVLYFDFWFEIFDMKKWDQFYSEVLGRPTTLSETMGKADVWLIRNSWNFQFPYPLLPNVDFVGGLHCKPAKPLPKEMEDFVQSSGENGVVVFSLGSMVSNMTEERANVIASALAQIPQKVLWRFDGNKPDTLGLNTRLYKWIPQNDLLGHPKTRAFITHGGANGIYEAIYHGIPMVGIPLFADQPDNIAHMKARGAAVRVDFNTMSSTDLLNALKRVINDPSYKENVMKLSRIQHDQPVKPLDRAVFWIEFVMRHKGAKHLRVAAHDLTWFQYHSLDVIGFLLVCVATVIFIVTKCCLFCFWKFARKAKKGKND
T62815	DRUGINFO	D0HP6W	Autoantibody LKM-3	Investigative
T62815	DRUGINFO	D0M7YB	ISOLONGIFOLOL	Investigative

T33367	TARGETID	T33367
T33367	FORMERID	TTDR00222
T33367	UNIPROID	AATC_HUMAN
T33367	TARGNAME	Cytoplasmic aspartate aminotransferase (GOT1)
T33367	GENENAME	GOT1
T33367	TARGTYPE	Literature-reported
T33367	SYNONYMS	Glutamate oxaloacetate transaminase-1; GOT1
T33367	FUNCTION	Biosynthesis of L-glutamate from L-aspartate or L- cysteine. Important regulator of levels of glutamate, the major excitatory neurotransmitter of the vertebrate central nervous system. Acts as a scavenger of glutamate in brain neuroprotection. The aspartate aminotransferase activity is involved in hepatic glucose synthesis during development and in adipocyte glyceroneogenesis. Using L-cysteine as substrate, regulates levels of mercaptopyruvate, an important source of hydrogen sulfide. Mercaptopyruvate is converted into H(2)S via the action of 3- mercaptopyruvate sulfurtransferase (3MST). Hydrogen sulfide is an important synaptic modulator and neuroprotectant in the brain.
T33367	PDBSTRUC	6DND; 6DNB; 6DNA; 3WZF; 3II0
T33367	BIOCLASS	Transaminase
T33367	ECNUMBER	EC 2.6.1.1
T33367	SEQUENCE	MAPPSVFAEVPQAQPVLVFKLTADFREDPDPRKVNLGVGAYRTDDCHPWVLPVVKKVEQKIANDNSLNHEYLPILGLAEFRSCASRLALGDDSPALKEKRVGGVQSLGGTGALRIGADFLARWYNGTNNKNTPVYVSSPTWENHNAVFSAAGFKDIRSYRYWDAEKRGLDLQGFLNDLENAPEFSIVVLHACAHNPTGIDPTPEQWKQIASVMKHRFLFPFFDSAYQGFASGNLERDAWAIRYFVSEGFEFFCAQSFSKNFGLYNERVGNLTVVGKEPESILQVLSQMEKIVRITWSNPPAQGARIVASTLSNPELFEEWTGNVKTMADRILTMRSELRARLEALKTPGTWNHITDQIGMFSFTGLNPKQVEYLVNEKHIYLLPSGRINVSGLTTKNLDYVATSIHEAVTKIQ
T33367	DRUGINFO	D01BTV	aminooxyacetic acid	Investigative
T33367	DRUGINFO	D0E7UH	Maleic Acid	Investigative

T07466	TARGETID	T07466
T07466	FORMERID	TTDR00030
T07466	UNIPROID	MURG_ECOLI
T07466	TARGNAME	Bacterial Glycosyltransferase MurG (Bact murG)
T07466	GENENAME	Bact murG
T07466	TARGTYPE	Literature-reported
T07466	SYNONYMS	Undecaprenyl-PP-MurNAc-pentapeptide-UDPGlcNAc GlcNAc transferase; MurG
T07466	FUNCTION	Cell wall formation. Catalyzes the transfer of a GlcNAc subunit on undecaprenyl-pyrophosphoryl-MurNAc-pentapeptide (lipid intermediate I) to form undecaprenyl-pyrophosphoryl-MurNAc- (pentapeptide)GlcNAc (lipid intermediate II).
T07466	PDBSTRUC	1NLM; 1F0K
T07466	BIOCLASS	Hexosyltransferase
T07466	ECNUMBER	EC 2.4.1.227
T07466	SEQUENCE	MSGQGKRLMVMAGGTGGHVFPGLAVAHHLMAQGWQVRWLGTADRMEADLVPKHGIEIDFIRISGLRGKGIKALIAAPLRIFNAWRQARAIMKAYKPDVVLGMGGYVSGPGGLAAWSLGIPVVLHEQNGIAGLTNKWLAKIATKVMQAFPGAFPNAEVVGNPVRTDVLALPLPQQRLAGREGPVRVLVVGGSQGARILNQTMPQVAAKLGDSVTIWHQSGKGSQQSVEQAYAEAGQPQHKVTEFIDDMAAAYAWADVVVCRSGALTVSEIAAAGLPALFVPFQHKDRQQYWNALPLEKAGAAKIIEQPQLSVDAVANTLAGWSRETLLTMAERARAASIPDATERVANEVSRVARA
T07466	DRUGINFO	D06UGK	Uridine-Diphosphate-N-Acetylgalactosamine	Investigative

T77546	TARGETID	T77546
T77546	FORMERID	TTDR00010
T77546	UNIPROID	AOC1_HUMAN
T77546	TARGNAME	Diamine oxidase (AOC1)
T77546	GENENAME	AOC1
T77546	TARGTYPE	Literature-reported
T77546	SYNONYMS	Kidney amine oxidase; KAO; Histaminase; Amiloride-binding protein; AOC1; ABP
T77546	FUNCTION	Catalyzes the degradation of compounds such as putrescine, histamine, spermine, and spermidine, substances involved in allergic and immune responses, cell proliferation, tissue differentiation, tumor formation, and possibly apoptosis. Placental DAO is thought to play a role in the regulation of the female reproductive function.
T77546	PDBSTRUC	3MPH; 3K5T; 3HII; 3HIG; 3HI7
T77546	BIOCLASS	CH-NH(2) donor oxidoreductase
T77546	ECNUMBER	EC 1.4.3.22
T77546	SEQUENCE	MPALGWAVAAILMLQTAMAEPSPGTLPRKAGVFSDLSNQELKAVHSFLWSKKELRLQPSSTTTMAKNTVFLIEMLLPKKYHVLRFLDKGERHPVREARAVIFFGDQEHPNVTEFAVGPLPGPCYMRALSPRPGYQSSWASRPISTAEYALLYHTLQEATKPLHQFFLNTTGFSFQDCHDRCLAFTDVAPRGVASGQRRSWLIIQRYVEGYFLHPTGLELLVDHGSTDAGHWAVEQVWYNGKFYGSPEELARKYADGEVDVVVLEDPLPGGKGHDSTEEPPLFSSHKPRGDFPSPIHVSGPRLVQPHGPRFRLEGNAVLYGGWSFAFRLRSSSGLQVLNVHFGGERIAYEVSVQEAVALYGGHTPAGMQTKYLDVGWGLGSVTHELAPGIDCPETATFLDTFHYYDADDPVHYPRALCLFEMPTGVPLRRHFNSNFKGGFNFYAGLKGQVLVLRTTSTVYNYDYIWDFIFYPNGVMEAKMHATGYVHATFYTPEGLRHGTRLHTHLIGNIHTHLVHYRVDLDVAGTKNSFQTLQMKLENITNPWSPRHRVVQPTLEQTQYSWERQAAFRFKRKLPKYLLFTSPQENPWGHKRTYRLQIHSMADQVLPPGWQEEQAITWARYPLAVTKYRESELCSSSIYHQNDPWHPPVVFEQFLHNNENIENEDLVAWVTVGFLHIPHSEDIPNTATPGNSVGFLLRPFNFFPEDPSLASRDTVIVWPRDNGPNYVQRWIPEDRDCSMPPPFSYNGTYRPV
T77546	DRUGINFO	D0B8TJ	Diminazene	Investigative

T11793	TARGETID	T11793
T11793	FORMERID	TTDR01444
T11793	UNIPROID	CP2B6_HUMAN
T11793	TARGNAME	Cytochrome P450 2B6 (CYP2B6)
T11793	GENENAME	CYP2B6
T11793	TARGTYPE	Literature-reported
T11793	SYNONYMS	Cytochrome P450 IIB1; CYPIIB6; 1,4-cineole 2-exo-monooxygenase
T11793	FUNCTION	In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase. Cytochromes P450 are a group of heme-thiolate monooxygenases.
T11793	PDBSTRUC	5WBG; 5UFG; 5UEC; 5UDA; 5UAP
T11793	BIOCLASS	Paired donor oxygen oxidoreductase
T11793	ECNUMBER	EC 1.14.13.-
T11793	SEQUENCE	MELSVLLFLALLTGLLLLLVQRHPNTHDRLPPGPRPLPLLGNLLQMDRRGLLKSFLRFREKYGDVFTVHLGPRPVVMLCGVEAIREALVDKAEAFSGRGKIAMVDPFFRGYGVIFANGNRWKVLRRFSVTTMRDFGMGKRSVEERIQEEAQCLIEELRKSKGALMDPTFLFQSITANIICSIVFGKRFHYQDQEFLKMLNLFYQTFSLISSVFGQLFELFSGFLKYFPGAHRQVYKNLQEINAYIGHSVEKHRETLDPSAPKDLIDTYLLHMEKEKSNAHSEFSHQNLNLNTLSLFFAGTETTSTTLRYGFLLMLKYPHVAERVYREIEQVIGPHRPPELHDRAKMPYTEAVIYEIQRFSDLLPMGVPHIVTQHTSFRGYIIPKDTEVFLILSTALHDPHYFEKPDAFNPDHFLDANGALKKTEAFIPFSLGKRICLGEGIARAELFLFFTTILQNFSMASPVAPEDIDLTPQECGVGKIPPTYQIRFLPR

T06365	TARGETID	T06365
T06365	FORMERID	TTDI02368
T06365	UNIPROID	SPYA_HUMAN
T06365	TARGNAME	Alanine glyoxylate aminotransferase (AGXT)
T06365	GENENAME	AGXT
T06365	TARGTYPE	Literature-reported
T06365	SYNONYMS	Serine--pyruvate aminotransferase; SPAT; Alanine--glyoxylate aminotransferase; AGT1; AGT
T06365	FUNCTION	Catalyzes  L-alanine and glyoxylate to  pyruvate and glycine. Participates in alanine and aspartate metabolism and glycine, serine and threonine metabolism.
T06365	PDBSTRUC	5OG0; 5OFY; 5LUC; 5HHY; 5F9S
T06365	BIOCLASS	Transaminase
T06365	ECNUMBER	EC 2.6.1.51
T06365	SEQUENCE	MASHKLLVTPPKALLKPLSIPNQLLLGPGPSNLPPRIMAAGGLQMIGSMSKDMYQIMDEIKEGIQYVFQTRNPLTLVISGSGHCALEAALVNVLEPGDSFLVGANGIWGQRAVDIGERIGARVHPMTKDPGGHYTLQEVEEGLAQHKPVLLFLTHGESSTGVLQPLDGFGELCHRYKCLLLVDSVASLGGTPLYMDRQGIDILYSGSQKALNAPPGTSLISFSDKAKKKMYSRKTKPFSFYLDIKWLANFWGCDDQPRMYHHTIPVISLYSLRESLALIAEQGLENSWRQHREAAAYLHGRLQALGLQLFVKDPALRLPTVTTVAVPAGYDWRDIVSYVIDHFDIEIMGGLGPSTGKVLRIGLLGCNATRENVDRVTEALRAALQHCPKKKL
T06365	DRUGINFO	D0M9WX	AMT-030	Terminated

T98089	TARGETID	T98089
T98089	FORMERID	TTDI01948
T98089	UNIPROID	DCK_HUMAN
T98089	TARGNAME	Deoxycytidine kinase (DCK)
T98089	GENENAME	DCK
T98089	TARGTYPE	Literature-reported
T98089	SYNONYMS	dCK
T98089	FUNCTION	Required for the phosphorylation of the deoxyribonucleosides deoxycytidine (dC), deoxyguanosine (dG) and deoxyadenosine (dA). Has broad substrate specificity, and does not display selectivity based on the chirality of the substrate. It is also an essential enzyme for the phosphorylation of numerous nucleoside analogs widely employed as antiviral and chemotherapeutic agents.
T98089	PDBSTRUC	5MQT; 5MQL; 5MQJ; 4Q1F; 4Q1E
T98089	BIOCLASS	Kinase
T98089	ECNUMBER	EC 2.7.1.74
T98089	SEQUENCE	MATPPKRSCPSFSASSEGTRIKKISIEGNIAAGKSTFVNILKQLCEDWEVVPEPVARWCNVQSTQDEFEELTMSQKNGGNVLQMMYEKPERWSFTFQTYACLSRIRAQLASLNGKLKDAEKPVLFFERSVYSDRYIFASNLYESECMNETEWTIYQDWHDWMNNQFGQSLELDGIIYLQATPETCLHRIYLRGRNEEQGIPLEYLEKLHYKHESWLLHRTLKTNFDYLQEVPILTLDVNEDFKDKYESLVEKVKEFLSTL
T98089	DRUGINFO	D06CYQ	LP-661438	Investigative

T36445	TARGETID	T36445
T36445	FORMERID	TTDR00824
T36445	UNIPROID	NEC1_HUMAN
T36445	TARGNAME	Neuroendocrine convertase 1 (PCSK1)
T36445	GENENAME	PCSK1
T36445	TARGTYPE	Literature-reported
T36445	SYNONYMS	Proprotein convertase 1; Prohormone convertase 1; PCSK1; PC1; NEC 1
T36445	FUNCTION	Involved in the processing of hormone and other protein precursors at sites comprised of pairs of basic amino acid residues. Substrates include POMC, renin, enkephalin, dynorphin, somatostatin and insulin.
T36445	BIOCLASS	Peptidase
T36445	ECNUMBER	EC 3.4.21.93
T36445	SEQUENCE	MERRAWSLQCTAFVLFCAWCALNSAKAKRQFVNEWAAEIPGGPEAASAIAEELGYDLLGQIGSLENHYLFKHKNHPRRSRRSAFHITKRLSDDDRVIWAEQQYEKERSKRSALRDSALNLFNDPMWNQQWYLQDTRMTAALPKLDLHVIPVWQKGITGKGVVITVLDDGLEWNHTDIYANYDPEASYDFNDNDHDPFPRYDPTNENKHGTRCAGEIAMQANNHKCGVGVAYNSKVGGIRMLDGIVTDAIEASSIGFNPGHVDIYSASWGPNDDGKTVEGPGRLAQKAFEYGVKQGRQGKGSIFVWASGNGGRQGDNCDCDGYTDSIYTISISSASQQGLSPWYAEKCSSTLATSYSSGDYTDQRITSADLHNDCTETHTGTSASAPLAAGIFALALEANPNLTWRDMQHLVVWTSEYDPLANNPGWKKNGAGLMVNSRFGFGLLNAKALVDLADPRTWRSVPEKKECVVKDNDFEPRALKANGEVIIEIPTRACEGQENAIKSLEHVQFEATIEYSRRGDLHVTLTSAAGTSTVLLAERERDTSPNGFKNWDFMSVHTWGENPIGTWTLRITDMSGRIQNEGRIVNWKLILHGTSSQPEHMKQPRVYTSYNTVQNDRRGVEKMVDPGEEQPTQENPKENTLVSKSPSSSSVGGRRDELEEGAPSQAMLRLLQSAFSKNSPPKQSPKKSPSAKLNIPYENFYEALEKLNKPSQLKDSEDSLYNDYVDVFYNTKPYKHRDDRLLQALVDILNEEN
T36445	DRUGINFO	D0Y9PH	Phenylacetyl-Arg-Val-Arg-4-amidinobenzylamide	Investigative

T67754	TARGETID	T67754
T67754	FORMERID	TTDR00094
T67754	UNIPROID	TKT_HUMAN
T67754	TARGNAME	Transketolase (TK)
T67754	GENENAME	TKT
T67754	TARGTYPE	Literature-reported
T67754	SYNONYMS	TKT1; SDDHD; HEL107; HEL-S-48
T67754	FUNCTION	Catalyzes the transfer of a two-carbon ketol group from a ketose donor to an aldose acceptor, via a covalent intermediate with the cofactor thiamine pyrophosphate.
T67754	PDBSTRUC	4KXY; 4KXX; 4KXW; 4KXV; 4KXU
T67754	BIOCLASS	Transketolase
T67754	ECNUMBER	EC 2.2.1.1
T67754	SEQUENCE	MESYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHTMRYKSQDPRNPHNDRFVLSKGHAAPILYAVWAEAGFLAEAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSEGSVWEAMAFASIYKLDNLVAILDINRLGQSDPAPLQHQMDIYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQPTAIIAKTFKGRGITGVEDKESWHGKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPSVDIANIRMPSLPSYKVGDKIATRKAYGQALAKLGHASDRIIALDGDTKNSTFSEIFKKEHPDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTRAFDQIRMAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIRTSRPENAIIYNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPFTIKPLDRKLILDSARATKGRILTVEDHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRSGKPAELLKMFGIDRDAIAQAVRGLITKA
T67754	DRUGINFO	D0OD8N	1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane	Investigative

T62450	TARGETID	T62450
T62450	FORMERID	TTDR00592
T62450	UNIPROID	NMT_CANAL
T62450	TARGNAME	Candida Peptide N-myristoyltransferase (Candi NMT1)
T62450	GENENAME	Candi NMT1
T62450	TARGTYPE	Literature-reported
T62450	SYNONYMS	Peptide N-myristoyltransferase; NMT1; NMT; Myristoyl-CoA:protein N-myristoyltransferase
T62450	FUNCTION	Adds a myristoyl group to the N-terminal glycine residue of certain cellular proteins. Substrate specificity requires an N- terminal glycine in the nascent polypeptide substrates. Ser is presentat position 5 in almost all known N-myristoyl proteins and Lys is commonly encountered at postion 6. Basic residues are preferred at positions 7 and 8.
T62450	PDBSTRUC	1NMT; 1IYL; 1IYK
T62450	BIOCLASS	Acyltransferase
T62450	ECNUMBER	EC 2.3.1.97
T62450	SEQUENCE	MSGDNTGNKSNSAPSKSIEELLKLLAMGQELSPAQQKEMKDYKFWKTQPVPSLSETVTEEGPIDKLKTPEDVPNDPLPLISDFEWSTLDIDDNLQLDELYKLLYDNYVEDIDATFRFKYSHEFFQWALKPPGWRKDWHVGVRVKSTGKLVAFIAATPVTFKLNKSNKVIDSVEINFLCIHKKLRNKRLAPVLIKEITRRVNKQNIWQALYTGGSILPTPLTTCRYQHRPINWSKLHDVGFSHLPPNQTKSSMVASYTLPNNPKLKGLRPMTGKDVSTVLSLLYKYQERFDIVQLFTEEEFKHWMLGHDENSDSNVVKSYVVEDENGVITDYFSYYLLPFTVLDNAQHDELGIAYLFYYASDSFEKPNYKKRLNELITDALITSKKFGVDVFNCLTCQDNTYFLKDCKFGSGDGFLNYYLFNYRTFPMDGGIDKKTKEVVEDQTSGIGVVLL
T62450	DRUGINFO	D08TSK	SC-58272	Investigative
T62450	DRUGINFO	D0N3CC	(S-(2-oxo)pentadecyl-CoA)	Investigative
T62450	DRUGINFO	D0QD8P	Myristoyl-Coa	Investigative

T94621	TARGETID	T94621
T94621	FORMERID	TTDI00101
T94621	UNIPROID	AKT2_HUMAN
T94621	TARGNAME	RAC-beta serine/threonine-protein kinase (AKT2)
T94621	GENENAME	AKT2
T94621	TARGTYPE	Literature-reported
T94621	SYNONYMS	RAC-PK-beta; Protein kinase B beta; Protein kinase Akt-2; PKB beta
T94621	FUNCTION	AKT2 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. Phosphorylation of PTPN1 at 'Ser-50' negatively modulates its phosphatase activity preventing dephosphorylation of the insulin receptor and the attenuation of insulin signaling. Phosphorylation of TBC1D4 triggers the binding of this effector to inhibitory 14-3-3 proteins, which is required for insulin-stimulated glucose transport. AKT regulates also the storage of glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity. Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven. AKT regulates also cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related kinase). Phosphorylation of 'Ser-83' decreases MAP3K5 kinase activity stimulated by oxidative stress and thereby prevents apoptosis. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT is involved in the phosphorylation of members of the FOXO factors (Forkhead family of transcription factors), leading to binding of 14-3-3 proteins and cytoplasmic localization. In particular, FOXO1 is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 and FOXO4 are phosphorylated on equivalent sites. AKT has an important role in the regulation of NF-kappa-B-dependent gene transcription and positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein). The phosphorylation of CREB1 induces the binding of accessory proteins that are necessary for the transcription of pro-survival genes such as BCL2 and MCL1. AKT phosphorylates 'Ser-454' on ATP citrate lyase (ACLY), thereby potentially regulating ACLY activity and fatty acid synthesis. Activates the 3B isoform of cyclic nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', resulting in reduced cyclic AMP levels and inhibition of lipolysis. Phosphorylates PIKFYVE on 'Ser-318', which results in increased PI(3)P-5 activity. The Rho GTPase-activating protein DLC1 is another substrate and its phosphorylation is implicated in the regulation cell proliferation and cell growth. AKT plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). AKT mediates the antiapoptotic effects of IGF-I. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. May be involved in the regulation of the placental development.
T94621	PDBSTRUC	3E8D; 3D0E; 3.00E+88; 3.00E+87; 2XH5
T94621	BIOCLASS	Kinase
T94621	ECNUMBER	EC 2.7.11.1
T94621	SEQUENCE	MNEVSVIKEGWLHKRGEYIKTWRPRYFLLKSDGSFIGYKERPEAPDQTLPPLNNFSVAECQLMKTERPRPNTFVIRCLQWTTVIERTFHVDSPDEREEWMRAIQMVANSLKQRAPGEDPMDYKCGSPSDSSTTEEMEVAVSKARAKVTMNDFDYLKLLGKGTFGKVILVREKATGRYYAMKILRKEVIIAKDEVAHTVTESRVLQNTRHPFLTALKYAFQTHDRLCFVMEYANGGELFFHLSRERVFTEERARFYGAEIVSALEYLHSRDVVYRDIKLENLMLDKDGHIKITDFGLCKEGISDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHERLFELILMEEIRFPRTLSPEAKSLLAGLLKKDPKQRLGGGPSDAKEVMEHRFFLSINWQDVVQKKLLPPFKPQVTSEVDTRYFDDEFTAQSITITPPDRYDSLGLLELDQRTHFPQFSYSASIRE
T94621	DRUGINFO	D0M9QJ	PHT-427	Investigative
T94621	DRUGINFO	D05APZ	Akt inhibitor VIII	Investigative
T94621	DRUGINFO	D0L2WP	PMID20005102C1	Investigative

T90358	TARGETID	T90358
T90358	FORMERID	TTDNC00400
T90358	UNIPROID	PIK1_YEAST
T90358	TARGNAME	Fungal Phosphatidylinositol 4-kinase PIK1 (Fung PIK1)
T90358	GENENAME	Fung PIK1
T90358	TARGTYPE	Literature-reported
T90358	SYNONYMS	PtdIns4kinase; Phosphatidylinositol 4kinase PIK1; PIK1; PI4kinase
T90358	FUNCTION	Acts on phosphatidylinositol (PI) in the first committed step in the production of the second messenger inositol 1,4,5,- trisphosphate. PIK1 is part of a nuclear phosphoinositide cycle and could control cytokinesis through the actin cytoskeleton.
T90358	PDBSTRUC	2JU0
T90358	BIOCLASS	Kinase
T90358	ECNUMBER	EC 2.7.1.67
T90358	SEQUENCE	MHKASSSKKSFDDTIELKKNEQLLKLINSSEFTLHNCVELLCKHSENIGIHYYLCQKLATFPHSELQFYIPQLVQVLVTMETESMALEDLLLRLRAENPHFALLTFWQLQALLTDLSTDPASYGFQVARRVLNNLQTNLFNTSSGSDKNVKIHENVAPALVLSSMIMSAIAFPQLSEVTKPLVESQGRRQKAFVFKLARSAMKDFTKNMTLKNTLLNKKTSRSKRVSSNRSSTPTSPIDLIDPIKTKEDASFRKSRHSEVKLDFDIVDDIGNQVFEERISSSIKLPKRKPKYLDNSYVHRTYDGKNINRDGSISNTAKALDGNKGDYISPKGRNDENNEIGNNEDETGGETEEDADALNSDHFTSSMPDLHNIQPRTSSASSASLEGTPKLNRTNSQPLSRQAFKNSKKANSSLSQEIDLSQLSTTSKIKMLKANYFRCETQFAIALETISQRLARVPTEARLSALRAELFLLNRDLPAEVDIPTLLPPNKKGKLHKLVTITANEAQVLNSAEKVPYLLLIEYLRDEFDFDPTSETNERLLKKISGNQGGLIFDLNYMNRKENNENRNESTLTSNNTRSSVYDSNSFNNGASRNEGLSSTSRSDSASTAHVRTEVNKEEDLGDMSMVKVRNRTDDEAYRNALVIQSAANVPILPDDSQDRSPELNFGSNLDEVLIENGINSKNIHSQTDALADQMRVSAVMLAQLDKSPQQLSESTKQIRAQIISSMKEVQDKFGYHDLEALHGMAGERKLENDLMTGGIDTSYLGEDWATKKERIRKTSEYGHFENWDLCSVIAKTGDDLRQEAFAYQMIQAMANIWVKEKVDVWVKRMKILITSANTGLVETITNAMSVHSIKKALTKKMIEDAELDDKGGIASLNDHFLRAFGNPNGFKYRRAQDNFASSLAAYSVICYLLQVKDRHNGNIMIDNEGHVSHIDFGFMLSNSPGSVGFEAAPFKLTYEYIELLGGVEGEAFKKFVELTKSSFKALRKYADQIVSMCEIMQKDNMQPCFDAGEQTSVQLRQRFQLDLSEKEVDDFVENFLIGKSLGSIYTRIYDQFQLITQGIYS

T83174	TARGETID	T83174
T83174	FORMERID	TTDI01949
T83174	UNIPROID	KPCI_HUMAN
T83174	TARGNAME	Protein kinase C iota (PRKCI)
T83174	GENENAME	PRKCI
T83174	TARGTYPE	Literature-reported
T83174	SYNONYMS	nPKC-iota; aPKC-lambda/iota; Protein kinase C iota type; PRKC-lambda/iota; DXS1179E; Atypical protein kinase C-lambda/iota
T83174	FUNCTION	Is necessary for BCR-ABL oncogene-mediated resistance to apoptotic drug in leukemia cells, protecting leukemia cells against drug-induced apoptosis. In cultured neurons, prevents amyloid beta protein-induced apoptosis by interrupting cell death process at a very early step. In glioblastoma cells, may function downstream of phosphatidylinositol 3-kinase (PI(3)K) and PDPK1 in the promotion of cell survival by phosphorylating and inhibiting the pro-apoptotic factor BAD. Can form a protein complex in non-small cell lung cancer (NSCLC) cells with PARD6A and ECT2 and regulate ECT2 oncogenic activity by phosphorylation, which in turn promotes transformed growth and invasion. In response to nerve growth factor (NGF), acts downstream of SRC to phosphorylate and activate IRAK1, allowing the subsequent activation of NF-kappa-B and neuronal cell survival. Functions in the organization of the apical domain in epithelial cells by phosphorylating EZR. This step is crucial for activation and normal distribution of EZR at the early stages of intestinal epithelial cell differentiation. Forms a protein complex with LLGL1 and PARD6B independently of PARD3 to regulate epithelial cell polarity. Plays a role in microtubule dynamics in the early secretory pathway through interaction with RAB2A and GAPDH and recruitment to vesicular tubular clusters (VTCs). In human coronary artery endothelial cells (HCAEC), is activated by saturated fatty acids and mediates lipid-induced apoptosis. Involved in early synaptic long term potentiation phase in CA1 hippocampal cells and short term memory formation. Calcium- and diacylglycerol-independent serine/ threonine-protein kinase that plays a general protective role against apoptotic stimuli, is involved in NF-kappa-B activation, cell survival, differentiation and polarity, and contributes to the regulation of microtubule dynamics in the early secretory pathway.
T83174	PDBSTRUC	5LIH; 5LI9; 5LI1; 3ZH8; 3A8X
T83174	BIOCLASS	Kinase
T83174	ECNUMBER	EC 2.7.11.13
T83174	SEQUENCE	MPTQRDSSTMSHTVAGGGSGDHSHQVRVKAYYRGDIMITHFEPSISFEGLCNEVRDMCSFDNEQLFTMKWIDEEGDPCTVSSQLELEEAFRLYELNKDSELLIHVFPCVPERPGMPCPGEDKSIYRRGARRWRKLYCANGHTFQAKRFNRRAHCAICTDRIWGLGRQGYKCINCKLLVHKKCHKLVTIECGRHSLPQEPVMPMDQSSMHSDHAQTVIPYNPSSHESLDQVGEEKEAMNTRESGKASSSLGLQDFDLLRVIGRGSYAKVLLVRLKKTDRIYAMKVVKKELVNDDEDIDWVQTEKHVFEQASNHPFLVGLHSCFQTESRLFFVIEYVNGGDLMFHMQRQRKLPEEHARFYSAEISLALNYLHERGIIYRDLKLDNVLLDSEGHIKLTDYGMCKEGLRPGDTTSTFCGTPNYIAPEILRGEDYGFSVDWWALGVLMFEMMAGRSPFDIVGSSDNPDQNTEDYLFQVILEKQIRIPRSLSVKAASVLKSFLNKDPKERLGCHPQTGFADIQGHPFFRNVDWDMMEQKQVVPPFKPNISGEFGLDNFDSQFTNEPVQLTPDDDDIVRKIDQSEFEGFEYINPLLMSAEECV
T83174	DRUGINFO	D0B8NW	ICA-1	Terminated
T83174	DRUGINFO	D0K6ES	CRT-0004592	Investigative

T67818	TARGETID	T67818
T67818	FORMERID	TTDR00081
T67818	UNIPROID	P2RY1_HUMAN
T67818	TARGNAME	P2Y purinoceptor 1 (P2RY1)
T67818	GENENAME	P2RY1
T67818	TARGTYPE	Literature-reported
T67818	SYNONYMS	P2Y1; P2Y(1) receptor; P2RY1; Adenosine P2Y1 receptor
T67818	FUNCTION	Receptor for extracellular adenine nucleotides such as ATP and ADP. In platelets binding to ADP leads to mobilization of intracellular calcium ions via activation of phospholipase C, a change in platelet shape, and probably to platelet aggregation.
T67818	PDBSTRUC	4XNW; 4XNV; 1Y36
T67818	BIOCLASS	GPCR rhodopsin
T67818	SEQUENCE	MTEVLWPAVPNGTDAAFLAGPGSSWGNSTVASTAAVSSSFKCALTKTGFQFYYLPAVYILVFIIGFLGNSVAIWMFVFHMKPWSGISVYMFNLALADFLYVLTLPALIFYYFNKTDWIFGDAMCKLQRFIFHVNLYGSILFLTCISAHRYSGVVYPLKSLGRLKKKNAICISVLVWLIVVVAISPILFYSGTGVRKNKTITCYDTTSDEYLRSYFIYSMCTTVAMFCVPLVLILGCYGLIVRALIYKDLDNSPLRRKSIYLVIIVLTVFAVSYIPFHVMKTMNLRARLDFQTPAMCAFNDRVYATYQVTRGLASLNSCVDPILYFLAGDTFRRRLSRATRKASRRSEANLQSKSEDMTLNILPEFKQNGDTSL
T67818	DRUGINFO	D00PAG	[35S]ADPbetaS	Investigative
T67818	DRUGINFO	D00PRR	MRS2298	Investigative
T67818	DRUGINFO	D03ERS	MRS2500	Investigative
T67818	DRUGINFO	D04DBR	2,2'-pyridylisatogen tosylate	Investigative
T67818	DRUGINFO	D07MTB	PMID23368907C16 	Investigative
T67818	DRUGINFO	D08BXO	MRS2950	Investigative
T67818	DRUGINFO	D08FOV	MRS2279	Investigative
T67818	DRUGINFO	D09DLY	1-(3,4-dichlorophenyl)-3-(3,5-dichlorophenyl)urea	Investigative
T67818	DRUGINFO	D09POE	N-(6)-methyl-2'-deoxyadenosine-3',5'-bisphosphate	Investigative
T67818	DRUGINFO	D0D4TY	PMID22873688C3a	Investigative
T67818	DRUGINFO	D0D5NP	MRS2496	Investigative
T67818	DRUGINFO	D0E9DE	BMS compound 4c	Investigative
T67818	DRUGINFO	D0G8KA	PMID18445527C11 	Investigative
T67818	DRUGINFO	D0I5TV	dATPalphaS	Investigative
T67818	DRUGINFO	D0L5BW	GlaxoSmithKline compound 6i	Investigative
T67818	DRUGINFO	D0M0GV	[32P]MRS2500	Investigative
T67818	DRUGINFO	D0NH6Q	MRS2365	Investigative
T67818	DRUGINFO	D0NJ7Y	GlaxoSmithKline compound 5h	Investigative
T67818	DRUGINFO	D0O5ZY	MRS-2179	Investigative
T67818	DRUGINFO	D0U4ZV	2-Cl-ADP(alpha-BH3)	Investigative
T67818	DRUGINFO	D0U8HD	2-chloroadenosine-5-triphosphate	Investigative
T67818	DRUGINFO	D0VY2Z	adenosine-3'-5'-bisphosphate	Investigative
T67818	DRUGINFO	D0W8WZ	PMID18445527C67 	Investigative
T67818	DRUGINFO	D0WG9Y	A2P5P	Investigative
T67818	DRUGINFO	D0BK8V	2',3'-ddATP	Investigative
T67818	DRUGINFO	D07QYU	PPADS	Investigative
T67818	DRUGINFO	D0BB0O	2MeSADP	Investigative
T67818	DRUGINFO	D0S3WN	ATPgammaS	Investigative
T67818	DRUGINFO	D0U1OJ	2MeSATP	Investigative
T67818	DRUGINFO	D05NWF	adenosine diphosphate	Investigative

T75517	TARGETID	T75517
T75517	FORMERID	TTDR00774
T75517	UNIPROID	GUAA_HUMAN
T75517	TARGNAME	Glutamine amidotransferase (GMPS)
T75517	GENENAME	GMPS
T75517	TARGTYPE	Literature-reported
T75517	SYNONYMS	GMP synthetase; GMP synthase [glutamine-hydrolyzing]
T75517	FUNCTION	Involved in the de novo synthesis of guanine nucleotides which are not only essential for DNA and RNA synthesis, but also provide GTP, which is involved in a number of cellular processes important for cell division.
T75517	PDBSTRUC	2VXO; 2VPI
T75517	BIOCLASS	Carbon-nitrogen ligase
T75517	ECNUMBER	EC 6.3.5.2
T75517	SEQUENCE	MALCNGDSKLENAGGDLKDGHHHYEGAVVILDAGAQYGKVIDRRVRELFVQSEIFPLETPAFAIKEQGFRAIIISGGPNSVYAEDAPWFDPAIFTIGKPVLGICYGMQMMNKVFGGTVHKKSVREDGVFNISVDNTCSLFRGLQKEEVVLLTHGDSVDKVADGFKVVARSGNIVAGIANESKKLYGAQFHPEVGLTENGKVILKNFLYDIAGCSGTFTVQNRELECIREIKERVGTSKVLVLLSGGVDSTVCTALLNRALNQEQVIAVHIDNGFMRKRESQSVEEALKKLGIQVKVINAAHSFYNGTTTLPISDEDRTPRKRISKTLNMTTSPEEKRKIIGDTFVKIANEVIGEMNLKPEEVFLAQGTLRPDLIESASLVASGKAELIKTHHNDTELIRKLREEGKVIEPLKDFHKDEVRILGRELGLPEELVSRHPFPGPGLAIRVICAEEPYICKDFPETNNILKIVADFSASVKKPHTLLQRVKACTTEEDQEKLMQITSLHSLNAFLLPIKTVGVQGDCRSYSYVCGISSKDEPDWESLIFLARLIPRMCHNVNRVVYIFGPPVKEPPTDVTPTFLTTGVLSTLRQADFEAHNILRESGYAGKISQMPVILTPLHFDRDPLQKQPSCQRSVVIRTFITSDFMTGIPATPGNEIPVEVVLKMVTEIKKIPGISRIMYDLTSKPPGTTEWE
T75517	DRUGINFO	D0C3AG	2,3,4-tribromo-6-(2,4-dibromophenoxy)phenol	Investigative
T75517	DRUGINFO	D0L6RV	3,5-dibromo-2-(2,4-dibromophenoxy)phenol	Investigative
T75517	DRUGINFO	D0L9WG	Decoyinine	Investigative
T75517	DRUGINFO	D0V1DW	3,4,5-tribromo-2-(2', 4'-dibromo-phenoxy)phenol	Investigative
T75517	DRUGINFO	D0A1DU	Pyrophosphate 2-	Investigative

T96862	TARGETID	T96862
T96862	FORMERID	TTDR00413
T96862	UNIPROID	MVD1_HUMAN
T96862	TARGNAME	Diphosphomevalonate decarboxylase (MVD)
T96862	GENENAME	MVD
T96862	TARGTYPE	Literature-reported
T96862	SYNONYMS	Mevalonate pyrophosphate decarboxylase; Mevalonate (diphospho)decarboxylase; Mevalonate (diphospho)Diphosphomevalonate decarboxylasedecarboxylase; MVD
T96862	FUNCTION	Performs the first committed step in the biosynthesis of isoprenes.
T96862	PDBSTRUC	3D4J
T96862	BIOCLASS	Carbon-carbon lyase
T96862	ECNUMBER	EC 4.1.1.33
T96862	SEQUENCE	MASEKPLAAVTCTAPVNIAVIKYWGKRDEELVLPINSSLSVTLHQDQLKTTTTAVISKDFTEDRIWLNGREEDVGQPRLQACLREIRCLARKRRNSRDGDPLPSSLSCKVHVASVNNFPTAAGLASSAAGYACLAYTLARVYGVESDLSEVARRGSGSACRSLYGGFVEWQMGEQADGKDSIARQVAPESHWPELRVLILVVSAEKKLTGSTVGMRASVETSPLLRFRAESVVPARMAEMARCIRERDFPSFAQLTMKDSNQFHATCLDTFPPISYLNAISWRIIHLVHRFNAHHGDTKVAYTFDAGPNAVIFTLDDTVAEFVAAVWHGFPPGSNGDTFLKGLQVRPAPLSAELQAALAMEPTPGGVKYIIVTQVGPGPQILDDPCAHLLGPDGLPKPAA
T96862	DRUGINFO	D00KPR	PMID17888661C18	Investigative
T96862	DRUGINFO	D00ZWA	P'-geranyl 3,5,8-trihydroxy-3-methyloctanate 8-diphosphate	Investigative
T96862	DRUGINFO	D01ENO	P'-geranyl 3,5,9-trihydroxy-3-methylnonanate 9-diphosphate	Investigative
T96862	DRUGINFO	D01JCH	P'-geranyl 3,5,7-trihydroxy-3-methylheptanate 7-diphosphate	Investigative
T96862	DRUGINFO	D01SPH	diphosphoglycolyl proline	Investigative
T96862	DRUGINFO	D03LRN	PMID17888661C19	Investigative
T96862	DRUGINFO	D07GAU	analog 3 (Vlattas et al., 1996)	Investigative
T96862	DRUGINFO	D0G7HQ	2,2-difluoromevalonate 5-diphosphate	Investigative
T96862	DRUGINFO	D0I0QH	6-fluoromevalonate pyrophosphate	Investigative
T96862	DRUGINFO	D0P6GH	P'-geranyl 2-fluoromevalonate 5-diphosphate	Investigative
T96862	DRUGINFO	D0S4YV	2-fluoromevalonate 5-diphosphate	Investigative
T96862	DRUGINFO	D0U7OO	6-fluoromevalonate 5-diphosphate	Investigative

T92557	TARGETID	T92557
T92557	UNIPROID	BCAT1_HUMAN
T92557	TARGNAME	Branched-chain-amino-acid transaminase 1 (BCAT1)
T92557	GENENAME	BCAT1
T92557	TARGTYPE	Literature-reported
T92557	SYNONYMS	Protein ECA39; ECA39; Branched-chain-amino-acid aminotransferase, cytosolic; BCT1; BCAT(c)
T92557	FUNCTION	Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine.
T92557	PDBSTRUC	2COJ; 2COI; 2COG; 2ABJ
T92557	BIOCLASS	Transaminase
T92557	ECNUMBER	EC 2.6.1.42
T92557	SEQUENCE	MKDCSNGCSAECTGEGGSKEVVGTFKAKDLIVTPATILKEKPDPNNLVFGTVFTDHMLTVEWSSEFGWEKPHIKPLQNLSLHPGSSALHYAVELFEGLKAFRGVDNKIRLFQPNLNMDRMYRSAVRATLPVFDKEELLECIQQLVKLDQEWVPYSTSASLYIRPTFIGTEPSLGVKKPTKALLFVLLSPVGPYFSSGTFNPVSLWANPKYVRAWKGGTGDCKMGGNYGSSLFAQCEAVDNGCQQVLWLYGEDHQITEVGTMNLFLYWINEDGEEELATPPLDGIILPGVTRRCILDLAHQWGEFKVSERYLTMDDLTTALEGNRVREMFGSGTACVVCPVSDILYKGETIHIPTMENGPKLASRILSKLTDIQYGREESDWTIVLS

T70234	TARGETID	T70234
T70234	FORMERID	TTDI02377
T70234	UNIPROID	EPHA4_HUMAN
T70234	TARGNAME	Ephrin type-A receptor 4 (EPHA4)
T70234	GENENAME	EPHA4
T70234	TARGTYPE	Literature-reported
T70234	SYNONYMS	hEK8; Tyrosineprotein kinase receptor SEK; Tyrosineprotein kinase TYRO1; Tyrosine-protein kinase receptor SEK; Tyrosine-protein kinase TYRO1; TYRO1; SEK; Ephrin typeA receptor 4; EPHlike kinase 8; EPH-like kinase 8; EK8
T70234	FUNCTION	The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Highly promiscuous, it has the unique property among Eph receptors to bind and to be physiologically activated by both GPI-anchored ephrin-A and transmembrane ephrin-B ligands including EFNA1 and EFNB3. Upon activation by ephrin ligands, modulates cell morphology and integrin-dependent cell adhesion through regulation of the Rac, Rap and Rho GTPases activity. Plays an important role in the development of the nervous system controlling different steps of axonal guidance including the establishment of the corticospinal projections. May also control the segregation of motor and sensory axons during neuromuscular circuit development. In addition to its role in axonal guidance plays a role in synaptic plasticity. Activated by EFNA1 phosphorylates CDK5 at 'Tyr-15' which in turn phosphorylates NGEF regulating RHOA and dendritic spine morphogenesis. In the nervous system, plays also a role in repair after injury preventing axonal regeneration and in angiogenesis playing a role in central nervous system vascular formation. Additionally, its promiscuity makes it available to participate in a variety of cell-cell signaling regulating for instance the development of the thymic epithelium. Receptor tyrosine kinase which binds membrane-bound ephrin family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells.
T70234	PDBSTRUC	5JR2; 4W50; 4W4Z; 4M4R; 4M4P
T70234	BIOCLASS	Kinase
T70234	ECNUMBER	EC 2.7.10.1
T70234	SEQUENCE	MAGIFYFALFSCLFGICDAVTGSRVYPANEVTLLDSRSVQGELGWIASPLEGGWEEVSIMDEKNTPIRTYQVCNVMEPSQNNWLRTDWITREGAQRVYIEIKFTLRDCNSLPGVMGTCKETFNLYYYESDNDKERFIRENQFVKIDTIAADESFTQVDIGDRIMKLNTEIRDVGPLSKKGFYLAFQDVGACIALVSVRVFYKKCPLTVRNLAQFPDTITGADTSSLVEVRGSCVNNSEEKDVPKMYCGADGEWLVPIGNCLCNAGHEERSGECQACKIGYYKALSTDATCAKCPPHSYSVWEGATSCTCDRGFFRADNDAASMPCTRPPSAPLNLISNVNETSVNLEWSSPQNTGGRQDISYNVVCKKCGAGDPSKCRPCGSGVHYTPQQNGLKTTKVSITDLLAHTNYTFEIWAVNGVSKYNPNPDQSVSVTVTTNQAAPSSIALVQAKEVTRYSVALAWLEPDRPNGVILEYEVKYYEKDQNERSYRIVRTAARNTDIKGLNPLTSYVFHVRARTAAGYGDFSEPLEVTTNTVPSRIIGDGANSTVLLVSVSGSVVLVVILIAAFVISRRRSKYSKAKQEADEEKHLNQGVRTYVDPFTYEDPNQAVREFAKEIDASCIKIEKVIGVGEFGEVCSGRLKVPGKREICVAIKTLKAGYTDKQRRDFLSEASIMGQFDHPNIIHLEGVVTKCKPVMIITEYMENGSLDAFLRKNDGRFTVIQLVGMLRGIGSGMKYLSDMSYVHRDLAARNILVNSNLVCKVSDFGMSRVLEDDPEAAYTTRGGKIPIRWTAPEAIAYRKFTSASDVWSYGIVMWEVMSYGERPYWDMSNQDVIKAIEEGYRLPPPMDCPIALHQLMLDCWQKERSDRPKFGQIVNMLDKLIRNPNSLKRTGTESSRPNTALLDPSSPEFSAVVSVGDWLQAIKMDRYKDNFTAAGYTTLEAVVHVNQEDLARIGITAITHQNKILSSVQAMRTQMQQMHGRMVPV
T70234	DRUGINFO	D0I0SY	MEDI-542	Terminated
T70234	DRUGINFO	D05FXD	PMID19788238C66	Investigative
T70234	DRUGINFO	D0X8BU	PMID23489211C20	Investigative

T89082	TARGETID	T89082
T89082	FORMERID	TTDR00381
T89082	UNIPROID	HMCS2_HUMAN
T89082	TARGNAME	Hydroxymethylglutaryl-CoA synthase 2 (HMGCS2)
T89082	GENENAME	HMGCS2
T89082	TARGTYPE	Literature-reported
T89082	SYNONYMS	HMGCS2; HMG-CoAsynthase; 3-hydroxy-3-methylglutaryl coenzyme A synthase 2
T89082	FUNCTION	This enzyme condenses acetyl-CoA with acetoacetyl-CoA to form HMG-CoA, which is the substrate for HMG-CoA reductase.
T89082	PDBSTRUC	2WYA
T89082	BIOCLASS	Acyltransferase
T89082	ECNUMBER	EC 2.3.3.10
T89082	SEQUENCE	MQRLLTPVKRILQLTRAVQETSLTPARLLPVAHQRFSTASAVPLAKTDTWPKDVGILALEVYFPAQYVDQTDLEKYNNVEAGKYTVGLGQTRMGFCSVQEDINSLCLTVVQRLMERIQLPWDSVGRLEVGTETIIDKSKAVKTVLMELFQDSGNTDIEGIDTTNACYGGTASLFNAANWMESSSWDGRYAMVVCGDIAVYPSGNARPTGGAGAVAMLIGPKAPLALERGLRGTHMENVYDFYKPNLASEYPIVDGKLSIQCYLRALDRCYTSYRKKIQNQWKQAGSDRPFTLDDLQYMIFHTPFCKMVQKSLARLMFNDFLSASSDTQTSLYKGLEAFGGLKLEDTYTNKDLDKALLKASQDMFDKKTKASLYLSTHNGNMYTSSLYGCLASLLSHHSAQELAGSRIGAFSYGSGLAASFFSFRVSQDAAPGSPLDKLVSSTSDLPKRLASRKCVSPEEFTEIMNQREQFYHKVNFSPPGDTNSLFPGTWYLERVDEQHRRKYARRPV
T89082	DRUGINFO	D06CGD	Acetoacetyl-Coenzyme A	Investigative
T89082	DRUGINFO	D0E8JM	3-Sulfinoalanine	Investigative

T86829	TARGETID	T86829
T86829	FORMERID	TTDR00037
T86829	UNIPROID	SCYD_MAGO7
T86829	TARGNAME	Fungal Scytalone dehydratase (Fung SDH1)
T86829	GENENAME	Fung SDH1
T86829	TARGTYPE	Literature-reported
T86829	SYNONYMS	SDH1
T86829	FUNCTION	Catalyzes two steps in melanin biosynthesis. From scytalone they are two dehydration steps and one reduction step to yield melanin.
T86829	PDBSTRUC	7STD; 6STD; 5STD; 4STD; 3STD
T86829	BIOCLASS	Alpha-carbonic anhydrase
T86829	ECNUMBER	EC 4.2.1.94
T86829	SEQUENCE	MGSQVQKSDEITFSDYLGLMTCVYEWADSYDSKDWDRLRKVIAPTLRIDYRSFLDKLWEAMPAEEFVGMVSSKQVLGDPTLRTQHFIGGTRWEKVSEDEVIGYHQLRVPHQRYKDTTMKEVTMKGHAHSANLHWYKKIDGVWKFAGLKPDIRWGEFDFDRIFEDGRETFGDK
T86829	DRUGINFO	D05OPY	(3-Phenyl-propyl)-quinazolin-4-yl-amine	Investigative
T86829	DRUGINFO	D07CEB	Isoquinolin-1-yl-(3-phenyl-propyl)-amine	Investigative
T86829	DRUGINFO	D09FJW	Carpropamid	Investigative
T86829	DRUGINFO	D09XXN	2-Hydroxy-N-(3-phenyl-propyl)-benzamide	Investigative
T86829	DRUGINFO	D0N7RW	5-Fluoro-2-hydroxy-N-isopropyl-benzamide	Investigative

T38257	TARGETID	T38257
T38257	FORMERID	TTDI00078
T38257	UNIPROID	PTEN_HUMAN
T38257	TARGNAME	Phosphatase and tensin homolog (PTEN)
T38257	GENENAME	PTEN
T38257	TARGTYPE	Literature-reported
T38257	SYNONYMS	TEP1; Phosphatidylinositol 3,4,5trisphosphate 3phosphatase and dualspecificity protein phosphatase PTEN; Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; Mutated in multiple advanced cancers 1; MMAC1
T38257	FUNCTION	Acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. Also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3-phosphate and inositol 1,3,4,5-tetrakisphosphate with order of substrate preference in vitro PtdIns(3,4,5)P3 > PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4. The lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. The nuclear monoubiquitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiquitinated form induces less tumor suppressive ability. In motile cells, suppresses the formation of lateral pseudopods and thereby promotes cell polarization and directed movement. Tumor suppressor.
T38257	PDBSTRUC	5BZZ; 5BZX; 5BUG; 4O1V; 2KYL
T38257	BIOCLASS	Phosphoric monoester hydrolase
T38257	ECNUMBER	EC 3.1.3.16
T38257	SEQUENCE	MTAIIKEIVSRNKRRYQEDGFDLDLTYIYPNIIAMGFPAERLEGVYRNNIDDVVRFLDSKHKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLELIKPFCEDLDQWLSEDDNHVAAIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRTRDKKGVTIPSQRRYVYYYSYLLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSGPTRREDKFMYFEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEETSEKVENGSLCDQEIDSICSIERADNDKEYLVLTLTKNDLDKANKDKANRYFSPNFKVKLYFTKTVEEPSNPEASSSTSVTPDVSDNEPDHYRYSDTTDSDPENEPFDEDQHTQITKV

T88752	TARGETID	T88752
T88752	FORMERID	TTDI02365
T88752	UNIPROID	RAC1_HUMAN
T88752	TARGNAME	Ras-related C3 botulinum toxin substrate 1 (RAC1)
T88752	GENENAME	RAC1
T88752	TARGTYPE	Literature-reported
T88752	SYNONYMS	Cell migration-inducing gene5 protein
T88752	FUNCTION	In its active state, binds to a variety of effector proteins to regulate cellular responses such as secretory processes, phagocytosis of apoptotic cells, epithelial cell polarization, neurons adhesion, migration and differentiation, and growth-factor induced formation of membrane ruffles. Rac1 p21/rho GDI heterodimer is the active component of the cytosolic factor sigma 1, which is involved in stimulation of the NADPH oxidase activity in macrophages. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. Stimulates PKN2 kinase activity. In concert with RAB7A, plays a role in regulating the formation of RBs (ruffled borders) in osteoclasts. In podocytes, promotes nuclear shuttling of NR3C2; this modulation is required for a proper kidney functioning. Required for atypical chemokine receptor ACKR2-induced LIMK1-PAK1-dependent phosphorylation of cofilin (CFL1) and for up-regulation of ACKR2 from endosomal compartment to cell membrane, increasing its efficiency in chemokine uptake and degradation. In synapses, seems to mediate the regulation of F-actin cluster formation performed by SHANK3. Plasma membrane-associated small GTPase which cycles between active GTP-bound and inactive GDP-bound states.
T88752	PDBSTRUC	6BC1; 6AGP; 5O33; 5N6O; 5HZH
T88752	BIOCLASS	Small GTPase
T88752	ECNUMBER	EC 3.6.5.2
T88752	SEQUENCE	MQAIKCVVVGDGAVGKTCLLISYTTNAFPGEYIPTVFDNYSANVMVDGKPVNLGLWDTAGQEDYDRLRPLSYPQTDVFLICFSLVSPASFENVRAKWYPEVRHHCPNTPIILVGTKLDLRDDKDTIEKLKEKKLTPITYPQGLAMAKEIGAVKYLECSALTQRGLKTVFDEAIRAVLCPPPVKKRKRKCLLL
T88752	DRUGINFO	D0M9ER	EHT-1864	Terminated

T52617	TARGETID	T52617
T52617	FORMERID	TTDR01245
T52617	UNIPROID	FAB1_MYCTU
T52617	TARGNAME	Mycobacterium 3-oxoacyl-[acyl-carrier-protein] synthase 1 (MycB kasA)
T52617	GENENAME	MycB kasA
T52617	TARGTYPE	Literature-reported
T52617	SYNONYMS	kasA; KAS 1; Beta-ketoacyl-ACP synthase 1
T52617	FUNCTION	Catalyzes the condensation reaction of fatty acid synthesis by the addition to an acyl acceptor of two carbons from malonyl-acp.
T52617	PDBSTRUC	5LD8; 2WGG; 2WGF; 2WGE; 2WGD
T52617	BIOCLASS	Acyltransferase
T52617	ECNUMBER	EC 2.3.1.41
T52617	SEQUENCE	MSQPSTANGGFPSVVVTAVTATTSISPDIESTWKGLLAGESGIHALEDEFVTKWDLAVKIGGHLKDPVDSHMGRLDMRRMSYVQRMGKLLGGQLWESAGSPEVDPDRFAVVVGTGLGGAERIVESYDLMNAGGPRKVSPLAVQMIMPNGAAAVIGLQLGARAGVMTPVSACSSGSEAIAHAWRQIVMGDADVAVCGGVEGPIEALPIAAFSMMRAMSTRNDEPERASRPFDKDRDGFVFGEAGALMLIETEEHAKARGAKPLARLLGAGITSDAFHMVAPAADGVRAGRAMTRSLELAGLSPADIDHVNAHGTATPIGDAAEANAIRVAGCDQAAVYAPKSALGHSIGAVGALESVLTVLTLRDGVIPPTLNYETPDPEIDLDVVAGEPRYGDYRYAVNNSFGFGGHNVALAFGRY
T52617	DRUGINFO	D0E7NO	Decanoic Acid	Investigative
T52617	DRUGINFO	D0V1EK	2-PHENYLAMINO-4-METHYL-5-ACETYL THIAZOLE	Investigative
T52617	DRUGINFO	D0XS4G	Caprylic acid	Investigative
T52617	DRUGINFO	D0N0UC	Lauric Acid	Investigative

T59445	TARGETID	T59445
T59445	FORMERID	TTDR00879
T59445	UNIPROID	DHSO_HUMAN
T59445	TARGNAME	Sorbitoldehydrogenase (SORD)
T59445	GENENAME	SORD
T59445	TARGTYPE	Literature-reported
T59445	SYNONYMS	SORD; SDH; L-iditol2-dehydrogenase
T59445	FUNCTION	Convertssorbitol to fructose. Part of the polyol pathway that plays an important role in sperm physiology. May play a role in the sperm motility by providing an energetic source for sperm.
T59445	PDBSTRUC	1PL8; 1PL7; 1PL6
T59445	BIOCLASS	Short-chain dehydrogenases reductase
T59445	ECNUMBER	EC 1.1.1.-
T59445	SEQUENCE	MAAAAKPNNLSLVVHGPGDLRLENYPIPEPGPNEVLLRMHSVGICGSDVHYWEYGRIGNFIVKKPMVLGHEASGTVEKVGSSVKHLKPGDRVAIEPGAPRENDEFCKMGRYNLSPSIFFCATPPDDGNLCRFYKHNAAFCYKLPDNVTFEEGALIEPLSVGIHACRRGGVTLGHKVLVCGAGPIGMVTLLVAKAMGAAQVVVTDLSATRLSKAKEIGADLVLQISKESPQEIARKVEGQLGCKPEVTIECTGAEASIQAGIYATRSGGNLVLVGLGSEMTTVPLLHAAIREVDIKGVFRYCNTWPVAISMLASKSVNVKPLVTHRFPLEKALEAFETFKKGLGLKIMLKCDPSDQNP
T59445	DRUGINFO	D05DAN	CP-470,711	Investigative
T59445	DRUGINFO	D0R6JE	Nicotinamide-Adenine-Dinucleotide	Investigative

T48330	TARGETID	T48330
T48330	FORMERID	TTDR00626
T48330	UNIPROID	LAT1_HUMAN
T48330	TARGNAME	Large neutral amino acids transporter 1 (SLC7A5)
T48330	GENENAME	SLC7A5
T48330	TARGTYPE	Literature-reported
T48330	SYNONYMS	y+ system cationic amino acid transporter; Solute carrier family 7 member 5; MPE16; Large neutral amino acids transporter small subunit 1; LAT1; L-type amino acid transporter LAT1; L-type amino acid transporter 1; Integral membrane protein E16; HLAT1; CD98LC; CD98 light chain; 4F2LC; 4F2 light chain; 4F2 LC
T48330	FUNCTION	Involved in cellular amino acid uptake. Acts as an amino acid exchanger. Involved in the transport of L-DOPA across the blood-brain barrier, and that of thyroid hormones triiodothyronine (T3) and thyroxine (T4) across the cell membrane in tissues such as placenta. Plays a role in neuronal cell proliferation (neurogenesis) in brain. Involved in the uptake of methylmercury (MeHg) when administered as the L-cysteine or D,L-homocysteine complexes, and hence plays a role in metal ion homeostasis and toxicity. Involved in the cellular activity of small molecular weight nitrosothiols, via the stereoselective transport of L-nitrosocysteine (L-CNSO) across the transmembrane. May play an important role in high-grade gliomas. Mediates blood-to-retina L-leucine transport across the inner blood-retinal barrier which in turn may play a key role in maintaining large neutral amino acids as well as neurotransmitters in the neural retina. Acts as the major transporter of tyrosine in fibroblasts. When associated with LAPTM4B, recruits SLC3A2 and SLC7A5 to lysosomes to promote leucine uptake into these organelles and is required for mTORC1 activation. Sodium-independent, high-affinity transport of large neutral amino acids such as phenylalanine, tyrosine, leucine, arginine and tryptophan, when associated with SLC3A2/4F2hc.
T48330	PDBSTRUC	6IRT; 6IRS
T48330	BIOCLASS	Amino acid-polyamine-organocation
T48330	SEQUENCE	MAGAGPKRRALAAPAAEEKEEAREKMLAAKSADGSAPAGEGEGVTLQRNITLLNGVAIIVGTIIGSGIFVTPTGVLKEAGSPGLALVVWAACGVFSIVGALCYAELGTTISKSGGDYAYMLEVYGSLPAFLKLWIELLIIRPSSQYIVALVFATYLLKPLFPTCPVPEEAAKLVACLCVLLLTAVNCYSVKAATRVQDAFAAAKLLALALIILLGFVQIGKGDVSNLDPNFSFEGTKLDVGNIVLALYSGLFAYGGWNYLNFVTEEMINPYRNLPLAIIISLPIVTLVYVLTNLAYFTTLSTEQMLSSEAVAVDFGNYHLGVMSWIIPVFVGLSCFGSVNGSLFTSSRLFFVGSREGHLPSILSMIHPQLLTPVPSLVFTCVMTLLYAFSKDIFSVINFFSFFNWLCVALAIIGMIWLRHRKPELERPIKVNLALPVFFILACLFLIAVSFWKTPVECGIGFTIILSGLPVYFFGVWWKNKPKWLLQGIFSTTVLCQKLMQVVPQET
T48330	DRUGINFO	D01BCL	(+/-)-2-Amino-1,2,3,4-tetrahydro-2-naphthoic acid	Investigative
T48330	DRUGINFO	D05BOD	BCH	Investigative
T48330	DRUGINFO	D0SC5V	(+/-)-2-Aminoindane-2-carboxylic acid	Investigative

T78326	TARGETID	T78326
T78326	FORMERID	TTDI00195
T78326	UNIPROID	NAAA_HUMAN
T78326	TARGNAME	N-acylethanolamine-hydrolyzing acidamidase (NAAA)
T78326	GENENAME	NAAA
T78326	TARGTYPE	Literature-reported
T78326	SYNONYMS	Nacylsphingosine amidohydrolaselike; Nacylethanolaminehydrolyzing acid amidase subunit beta; NAAA; Acid ceramidaselike protein; ASAHlike protein
T78326	FUNCTION	Degrades bioactive fatty acid amides to their corresponding acids, with the following preference: N- palmitoylethanolamine > N-myristoylethanolamine > N- lauroylethanolamine = N-stearoylethanolamine > N- arachidonoylethanolamine > N-oleoylethanolamine. Also exhibits weak hydrolytic activity against the ceramides N- lauroylsphingosine and N-palmitoylsphingosine.
T78326	PDBSTRUC	6DXX; 6DXW
T78326	BIOCLASS	Carbon-nitrogen hydrolase
T78326	ECNUMBER	EC 3.5.1.-
T78326	SEQUENCE	MRTADREARPGLPSLLLLLLAGAGLSAASPPAAPRFNVSLDSVPELRWLPVLRHYDLDLVRAAMAQVIGDRVPKWVHVLIGKVVLELERFLPQPFTGEIRGMCDFMNLSLADCLLVNLAYESSVFCTSIVAQDSRGHIYHGRNLDYPFGNVLRKLTVDVQFLKNGQIAFTGTTFIGYVGLWTGQSPHKFTVSGDERDKGWWWENAIAALFRRHIPVSWLIRATLSESENFEAAVGKLAKTPLIADVYYIVGGTSPREGVVITRNRDGPADIWPLDPLNGAWFRVETNYDHWKPAPKEDDRRTSAIKALNATGQANLSLEALFQILSVVPVYNNFTIYTTVMSAGSPDKYMTRIRNPSRK
T78326	DRUGINFO	D0G6RN	S-OOPP	Investigative
T78326	DRUGINFO	D0X3AT	CCP	Investigative

T14945	TARGETID	T14945
T14945	FORMERID	TTDC00064
T14945	UNIPROID	CENPE_HUMAN
T14945	TARGNAME	Centromeric protein E (CENPE)
T14945	GENENAME	CENPE
T14945	TARGTYPE	Literature-reported
T14945	SYNONYMS	Centromere-associated protein E; CENPE; CENP-E
T14945	FUNCTION	Essential for the maintenance of chromosomal stability through efficient stabilization of microtubule capture at kinetochores. Plays a key role in the movement of chromosomes toward the metaphase plate during mitosis. Is a slow plus end- directed motor whose activity is essential for metaphase chromosome alignment. Couples chromosome position to microtubule depolymerizing activity. The highly processive microtubule- dependent motor activity of CENPE servesto power chromosome congression and provides a flexible, motile tether linking kinetochores to dynamic spindle microtubules. Necessary for the mitotic checkpoint signal at individual kinetochores to prevent aneuploidy due to single chromosome loss. Required for the efficient recruitment of BUBR1, MAD1 and MAD2 to attached and newly unattached kinetochores. Stimulates mammalian BUBR1 kinase activity. Accumulates just before mitosis at the G2 phase of the cell cycle.
T14945	PDBSTRUC	5JVP; 1T5C
T14945	BIOCLASS	TRAFAC class myosin-kinesin ATPase
T14945	SEQUENCE	MAEEGAVAVCVRVRPLNSREESLGETAQVYWKTDNNVIYQVDGSKSFNFDRVFHGNETTKNVYEEIAAPIIDSAIQGYNGTIFAYGQTASGKTYTMMGSEDHLGVIPRAIHDIFQKIKKFPDREFLLRVSYMEIYNETITDLLCGTQKMKPLIIREDVNRNVYVADLTEEVVYTSEMALKWITKGEKSRHYGETKMNQRSSRSHTIFRMILESREKGEPSNCEGSVKVSHLNLVDLAGSERAAQTGAAGVRLKEGCNINRSLFILGQVIKKLSDGQVGGFINYRDSKLTRILQNSLGGNAKTRIICTITPVSFDETLTALQFASTAKYMKNTPYVNEVSTDEALLKRYRKEIMDLKKQLEEVSLETRAQAMEKDQLAQLLEEKDLLQKVQNEKIENLTRMLVTSSSLTLQQELKAKRKRRVTWCLGKINKMKNSNYADQFNIPTNITTKTHKLSINLLREIDESVCSESDVFSNTLDTLSEIEWNPATKLLNQENIESELNSLRADYDNLVLDYEQLRTEKEEMELKLKEKNDLDEFEALERKTKKDQEMQLIHEISNLKNLVKHAEVYNQDLENELSSKVELLREKEDQIKKLQEYIDSQKLENIKMDLSYSLESIEDPKQMKQTLFDAETVALDAKRESAFLRSENLELKEKMKELATTYKQMENDIQLYQSQLEAKKKMQVDLEKELQSAFNEITKLTSLIDGKVPKDLLCNLELEGKITDLQKELNKEVEENEALREEVILLSELKSLPSEVERLRKEIQDKSEELHIITSEKDKLFSEVVHKESRVQGLLEEIGKTKDDLATTQSNYKSTDQEFQNFKTLHMDFEQKYKMVLEENERMNQEIVNLSKEAQKFDSSLGALKTELSYKTQELQEKTREVQERLNEMEQLKEQLENRDSTLQTVEREKTLITEKLQQTLEEVKTLTQEKDDLKQLQESLQIERDQLKSDIHDTVNMNIDTQEQLRNALESLKQHQETINTLKSKISEEVSRNLHMEENTGETKDEFQQKMVGIDKKQDLEAKNTQTLTADVKDNEIIEQQRKIFSLIQEKNELQQMLESVIAEKEQLKTDLKENIEMTIENQEELRLLGDELKKQQEIVAQEKNHAIKKEGELSRTCDRLAEVEEKLKEKSQQLQEKQQQLLNVQEEMSEMQKKINEIENLKNELKNKELTLEHMETERLELAQKLNENYEEVKSITKERKVLKELQKSFETERDHLRGYIREIEATGLQTKEELKIAHIHLKEHQETIDELRRSVSEKTAQIINTQDLEKSHTKLQEEIPVLHEEQELLPNVKEVSETQETMNELELLTEQSTTKDSTTLARIEMERLRLNEKFQESQEEIKSLTKERDNLKTIKEALEVKHDQLKEHIRETLAKIQESQSKQEQSLNMKEKDNETTKIVSEMEQFKPKDSALLRIEIEMLGLSKRLQESHDEMKSVAKEKDDLQRLQEVLQSESDQLKENIKEIVAKHLETEEELKVAHCCLKEQEETINELRVNLSEKETEISTIQKQLEAINDKLQNKIQEIYEKEEQFNIKQISEVQEKVNELKQFKEHRKAKDSALQSIESKMLELTNRLQESQEEIQIMIKEKEEMKRVQEALQIERDQLKENTKEIVAKMKESQEKEYQFLKMTAVNETQEKMCEIEHLKEQFETQKLNLENIETENIRLTQILHENLEEMRSVTKERDDLRSVEETLKVERDQLKENLRETITRDLEKQEELKIVHMHLKEHQETIDKLRGIVSEKTNEISNMQKDLEHSNDALKAQDLKIQEELRIAHMHLKEQQETIDKLRGIVSEKTDKLSNMQKDLENSNAKLQEKIQELKANEHQLITLKKDVNETQKKVSEMEQLKKQIKDQSLTLSKLEIENLNLAQKLHENLEEMKSVMKERDNLRRVEETLKLERDQLKESLQETKARDLEIQQELKTARMLSKEHKETVDKLREKISEKTIQISDIQKDLDKSKDELQKKIQELQKKELQLLRVKEDVNMSHKKINEMEQLKKQFEAQNLSMQSVRMDNFQLTKKLHESLEEIRIVAKERDELRRIKESLKMERDQFIATLREMIARDRQNHQVKPEKRLLSDGQQHLTESLREKCSRIKELLKRYSEMDDHYECLNRLSLDLEKEIEFQKELSMRVKANLSLPYLQTKHIEKLFTANQRCSMEFHRIMKKLKYVLSYVTKIKEEQHESINKFEMDFIDEVEKQKELLIKIQHLQQDCDVPSRELRDLKLNQNMDLHIEEILKDFSESEFPSIKTEFQQVLSNRKEMTQFLEEWLNTRFDIEKLKNGIQKENDRICQVNNFFNNRIIAIMNESTEFEERSATISKEWEQDLKSLKEKNEKLFKNYQTLKTSLASGAQVNPTTQDNKNPHVTSRATQLTTEKIRELENSLHEAKESAMHKESKIIKMQKELEVTNDIIAKLQAKVHESNKCLEKTKETIQVLQDKVALGAKPYKEEIEDLKMKLVKIDLEKMKNAKEFEKEISATKATVEYQKEVIRLLRENLRRSQQAQDTSVISEHTDPQPSNKPLTCGGGSGIVQNTKALILKSEHIRLEKEISKLKQQNEQLIKQKNELLSNNQHLSNEVKTWKERTLKREAHKQVTCENSPKSPKVTGTASKKKQITPSQCKERNLQDPVPKESPKSCFFDSRSKSLPSPHPVRYFDNSSLGLCPEVQNAGAESVDSQPGPWHASSGKDVPECKTQ
T14945	DRUGINFO	D00XEU	GSK-923295	Terminated

T47164	TARGETID	T47164
T47164	FORMERID	TTDI02447
T47164	UNIPROID	STK4_HUMAN
T47164	TARGNAME	MST-1 protein kinase (STK4)
T47164	GENENAME	STK4
T47164	TARGTYPE	Literature-reported
T47164	SYNONYMS	Serine/threonine-protein kinase Krs-2; Serine/threonine-protein kinase 4 18kDa subunit; Serine/threonine-protein kinase 4; STE20-like kinase MST1; Mammalian STE20-like protein kinase 1; MST1/N; MST1/C; MST1; MST-1; KRS2
T47164	FUNCTION	Key component of the Hippo signaling pathway which plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS2 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. STK3/MST2 and STK4/MST1 are required to repress proliferation of mature hepatocytes, to prevent activation of facultative adult liver stem cells (oval cells), and to inhibit tumor formation. Phosphorylates 'Ser-14' of histone H2B (H2BS14ph) during apoptosis. Phosphorylates FOXO3 upon oxidative stress, which results in its nuclear translocation and cell death initiation. Phosphorylates MOBKL1A, MOBKL1B and RASSF2. Phosphorylates TNNI3 (cardiac Tn-I) and alters its binding affinity to TNNC1 (cardiac Tn-C) and TNNT2 (cardiac Tn-T). Phosphorylates FOXO1 on 'Ser-212' and regulates its activation and stimulates transcription of PMAIP1 in a FOXO1-dependent manner. Phosphorylates SIRT1 and inhibits SIRT1-mediated p53/TP53 deacetylation, thereby promoting p53/TP53 dependent transcription and apoptosis upon DNA damage. Acts as an inhibitor of PKB/AKT1. Phosphorylates AR on 'Ser-650' and suppresses its activity by intersecting with PKB/AKT1 signaling and antagonizing formation of AR-chromatin complexes. Stress-activated, pro-apoptotic kinase which, following caspase-cleavage, enters the nucleus and induces chromatin condensation followed by internucleosomal DNA fragmentation.
T47164	PDBSTRUC	5TWH; 5TWG; 4OH8; 4NR2; 3COM
T47164	BIOCLASS	Kinase
T47164	ECNUMBER	EC 2.7.11.1
T47164	SEQUENCE	METVQLRNPPRRQLKKLDEDSLTKQPEEVFDVLEKLGEGSYGSVYKAIHKETGQIVAIKQVPVESDLQEIIKEISIMQQCDSPHVVKYYGSYFKNTDLWIVMEYCGAGSVSDIIRLRNKTLTEDEIATILQSTLKGLEYLHFMRKIHRDIKAGNILLNTEGHAKLADFGVAGQLTDTMAKRNTVIGTPFWMAPEVIQEIGYNCVADIWSLGITAIEMAEGKPPYADIHPMRAIFMIPTNPPPTFRKPELWSDNFTDFVKQCLVKSPEQRATATQLLQHPFVRSAKGVSILRDLINEAMDVKLKRQESQQREVDQDDEENSEEDEMDSGTMVRAVGDEMGTVRVASTMTDGANTMIEHDDTLPSQLGTMVINAEDEEEEGTMKRRDETMQPAKPSFLEYFEQKEKENQINSFGKSVPGPLKNSSDWKIPQDGDYEFLKSWTVEDLQKRLLALDPMMEQEIEEIRQKYQSKRQPILDAIEAKKRRQQNF
T47164	DRUGINFO	D0A7HY	TAT-120	Investigative

T40787	TARGETID	T40787
T40787	FORMERID	TTDR00959
T40787	UNIPROID	MTAP_HUMAN
T40787	TARGNAME	S-methyl-5'-thioadenosine phosphorylase (MTAP)
T40787	GENENAME	MTAP
T40787	TARGTYPE	Literature-reported
T40787	SYNONYMS	Methylthioadenosine phosphorylase; MTAPase; MTA phosphorylase; MSAP; 5'-methylthioadenosine phosphorylase
T40787	FUNCTION	Involved in the breakdown of MTA, a major by-product of polyamine biosynthesis. Responsible for the first step in the methionine salvage pathway after MTA has been generated from S-adenosylmethionine. Has broad substrate specificity with 6-aminopurine nucleosides as preferred substrates. Catalyzes the reversible phosphorylation of S-methyl-5'-thioadenosine (MTA) to adenine and 5-methylthioribose-1-phosphate.
T40787	PDBSTRUC	6DZ3; 6DZ2; 6DZ0; 6DYZ; 5TC8
T40787	BIOCLASS	Glycosyltransferases
T40787	ECNUMBER	EC 2.4.2.28
T40787	SEQUENCE	MASGTTTTAVKIGIIGGTGLDDPEILEGRTEKYVDTPFGKPSDALILGKIKNVDCVLLARHGRQHTIMPSKVNYQANIWALKEEGCTHVIVTTACGSLREEIQPGDIVIIDQFIDRTTMRPQSFYDGSHSCARGVCHIPMAEPFCPKTREVLIETAKKLGLRCHSKGTMVTIEGPRFSSRAESFMFRTWGADVINMTTVPEVVLAKEAGICYASIAMATDYDCWKEHEEAVSVDRVLKTLKENANKAKSLLLTTIPQIGSTEWSETLHNLKNMAQFSVLLPRH
T40787	DRUGINFO	D0E4WF	METHYLTHIOADENOSINE	Terminated
T40787	DRUGINFO	D02JUP	5'-Deoxy-5'-(Methylthio)-Tubercidin	Investigative
T40787	DRUGINFO	D0NH1Y	Formycin	Investigative

T17143	TARGETID	T17143
T17143	FORMERID	TTDR00149
T17143	UNIPROID	MP2K5_HUMAN
T17143	TARGNAME	ERK activator kinase 5 (MAP2K5)
T17143	GENENAME	MAP2K5
T17143	TARGTYPE	Literature-reported
T17143	SYNONYMS	PRKMK5; Mitogen-activatedprotein kinase kinase 5; MKK5; MEK5; MEK 5; MAPKK 5; MAPK/ERK kinase 5; MAP kinase kinase5; MAP kinase kinase 5; Dual specificity mitogen-activated protein kinase kinase 5
T17143	FUNCTION	Activation of this pathway appears to play a critical role in protecting cells from stress-induced apoptosis, neuronal survival and cardiac development and angiogenesis. Acts as a scaffold for the formation of a ternary MAP3K2/MAP3K3-MAP3K5-MAPK7 signaling complex.
T17143	PDBSTRUC	4IC7; 2O2V; 2NPT
T17143	BIOCLASS	Kinase
T17143	ECNUMBER	EC 2.7.12.2
T17143	SEQUENCE	MLWLALGPFPAMENQVLVIRIKIPNSGAVDWTVHSGPQLLFRDVLDVIGQVLPEATTTAFEYEDEDGDRITVRSDEEMKAMLSYYYSTVMEQQVNGQLIEPLQIFPRACKPPGERNIHGLKVNTRAGPSQHSSPAVSDSLPSNSLKKSSAELKKILANGQMNEQDIRYRDTLGHGNGGTVYKAYHVPSGKILAVKVILLDITLELQKQIMSELEILYKCDSSYIIGFYGAFFVENRISICTEFMDGGSLDVYRKMPEHVLGRIAVAVVKGLTYLWSLKILHRDVKPSNMLVNTRGQVKLCDFGVSTQLVNSIAKTYVGTNAYMAPERISGEQYGIHSDVWSLGISFMELALGRFPYPQIQKNQGSLMPLQLLQCIVDEDSPVLPVGEFSEPFVHFITQCMRKQPKERPAPEELMGHPFIVQFNDGNAAVVSMWVCRALEERRSQQGPP
T17143	DRUGINFO	D0R6JG	BIX 02188	Investigative

T91681	TARGETID	T91681
T91681	UNIPROID	TDG_HUMAN
T91681	TARGNAME	Thymine-DNA glycosylase (TDG)
T91681	GENENAME	TDG
T91681	TARGTYPE	Literature-reported
T91681	SYNONYMS	hTDG
T91681	FUNCTION	DNA glycosylase that plays a key role in active DNA demethylation: specifically recognizes and binds 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) in the context of CpG sites and mediates their excision through base-excision repair (BER) to install an unmethylated cytosine. Cannot remove 5-hydroxymethylcytosine (5hmC). According to an alternative model, involved in DNA demethylation by mediating DNA glycolase activity toward 5-hydroxymethyluracil (5hmU) produced by deamination of 5hmC. Also involved in DNA repair by acting as a thymine-DNA glycosylase that mediates correction of G/T mispairs to G/C pairs: in the DNA of higher eukaryotes, hydrolytic deamination of 5-methylcytosine to thymine leads to the formation of G/T mismatches. Its role in the repair of canonical base damage is however minor compared to its role in DNA demethylation. It is capable of hydrolyzing the carbon-nitrogen bond between the sugar-phosphate backbone of the DNA and a mispaired thymine. In addition to the G/T, it can remove thymine also from C/T and T/T mispairs in the order G/T >> C/T > T/T. It has no detectable activity on apyrimidinic sites and does not catalyze the removal of thymine from A/T pairs or from single-stranded DNA. It can also remove uracil and 5-bromouracil from mispairs with guanine.
T91681	PDBSTRUC	5T2W; 5JXY; 5HF7; 5FF8; 5CYS
T91681	BIOCLASS	Uracil-DNA glycosylase (UDG) superfamily. TDG/mug family
T91681	ECNUMBER	EC 3.2.2.29
T91681	SEQUENCE	MEAENAGSYSLQQAQAFYTFPFQQLMAEAPNMAVVNEQQMPEEVPAPAPAQEPVQEAPKGRKRKPRTTEPKQPVEPKKPVESKKSGKSAKSKEKQEKITDTFKVKRKVDRFNGVSEAELLTKTLPDILTFNLDIVIIGINPGLMAAYKGHHYPGPGNHFWKCLFMSGLSEVQLNHMDDHTLPGKYGIGFTNMVERTTPGSKDLSSKEFREGGRILVQKLQKYQPRIAVFNGKCIYEIFSKEVFGVKVKNLEFGLQPHKIPDTETLCYVMPSSSARCAQFPRAQDKVHYYIKLKDLRDQLKGIERNMDVQEVQYTFDLQLAQEDAKKMAVKEEKYDPGYEAAYGGAYGENPCSSEPCGFSSNGLIESVELRGESAFSGIPNGQWMTQSFTDQIPSFSNHCGTQEQEEESHA

T80338	TARGETID	T80338
T80338	FORMERID	TTDI02445
T80338	UNIPROID	AVR2B_HUMAN
T80338	TARGNAME	Activin receptor type IIB (ACVR2B)
T80338	GENENAME	ACVR2B
T80338	TARGTYPE	Literature-reported
T80338	SYNONYMS	Activin receptor type2B; Activin receptor type-2B; ACTRIIB; ACTR-IIB
T80338	FUNCTION	Transduces the activin signal from the cell surface to the cytoplasm and is thus regulating many physiological and pathological processes including neuronal differentiation and neuronal survival, hair follicle development and cycling, FSH production by the pituitary gland, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. Activin is also thought to have a paracrine or autocrine role in follicular development in the ovary. Within the receptor complex, the type-2 receptors act as a primary activin receptors (binds activin-A/INHBA, activin-B/INHBB as well as inhibin-A/INHA-INHBA). The type-1 receptors like ACVR1B act as downstream transducers of activin signals. Activin binds to type-2 receptor at the plasma membrane and activates its serine-threonine kinase. The activated receptor type-2 then phosphorylates and activates the type-1 receptor. Once activated, the type-1 receptor binds and phosphorylates the SMAD proteins SMAD2 and SMAD3, on serine residues of the C-terminal tail. Soon after their association with the activin receptor and subsequent phosphorylation, SMAD2 and SMAD3 are released into the cytoplasm where they interact with the common partner SMAD4. This SMAD complex translocates into the nucleus where it mediates activin-induced transcription. Inhibitory SMAD7, which is recruited to ACVR1B through FKBP1A, can prevent the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal. Activin signal transduction is also antagonized by the binding to the receptor of inhibin-B via the IGSF1 inhibin coreceptor. Transmembrane serine/threonine kinase activin type-2 receptor forming an activin receptor complex with activin type-1 serine/threonine kinase receptors (ACVR1, ACVR1B or ACVR1c).
T80338	PDBSTRUC	5NHR; 5NGV; 4FAO; 2QLU; 2H62
T80338	BIOCLASS	Kinase
T80338	ECNUMBER	EC 2.7.11.30
T80338	SEQUENCE	MTAPWVALALLWGSLCAGSGRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWLDDFNCYDRQECVATEENPQVYFCCCEGNFCNERFTHLPEAGGPEVTYEPPPTAPTLLTVLAYSLLPIGGLSLIVLLAFWMYRHRKPPYGHVDIHEDPGPPPPSPLVGLKPLQLLEIKARGRFGCVWKAQLMNDFVAVKIFPLQDKQSWQSEREIFSTPGMKHENLLQFIAAEKRGSNLEVELWLITAFHDKGSLTDYLKGNIITWNELCHVAETMSRGLSYLHEDVPWCRGEGHKPSIAHRDFKSKNVLLKSDLTAVLADFGLAVRFEPGKPPGDTHGQVGTRRYMAPEVLEGAINFQRDAFLRIDMYAMGLVLWELVSRCKAADGPVDEYMLPFEEEIGQHPSLEELQEVVVHKKMRPTIKDHWLKHPGLAQLCVTIEECWDHDAEARLSAGCVEERVSLIRRSVNGTTSDCLVSLVTSVTNVDLPPKESSI
T80338	DRUGINFO	D0GK9J	ACVR2B	Investigative

T60213	TARGETID	T60213
T60213	FORMERID	TTDI01817
T60213	UNIPROID	BMPR2_HUMAN
T60213	TARGNAME	Bone morphogenetic protein receptor (BMPR2)
T60213	GENENAME	BMPR2
T60213	TARGTYPE	Literature-reported
T60213	SYNONYMS	PPH1; Bone morphogenetic protein receptor type-2; Bone morphogenetic protein receptor type II; BMPR-II; BMPR-2; BMP type-2 receptor; BMP type II receptor
T60213	FUNCTION	Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Binds to BMP7, BMP2 and, less efficiently, BMP4. Binding is weak but enhanced by the presence of type I receptors for BMPs. Mediates induction of adipogenesis by GDF6. On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases.
T60213	PDBSTRUC	3G2F; 2HLQ
T60213	BIOCLASS	Kinase
T60213	ECNUMBER	EC 2.7.11.30
T60213	SEQUENCE	MTSSLQRPWRVPWLPWTILLVSTAAASQNQERLCAFKDPYQQDLGIGESRISHENGTILCSKGSTCYGLWEKSKGDINLVKQGCWSHIGDPQECHYEECVVTTTPPSIQNGTYRFCCCSTDLCNVNFTENFPPPDTTPLSPPHSFNRDETIIIALASVSVLAVLIVALCFGYRMLTGDRKQGLHSMNMMEAAASEPSLDLDNLKLLELIGRGRYGAVYKGSLDERPVAVKVFSFANRQNFINEKNIYRVPLMEHDNIARFIVGDERVTADGRMEYLLVMEYYPNGSLCKYLSLHTSDWVSSCRLAHSVTRGLAYLHTELPRGDHYKPAISHRDLNSRNVLVKNDGTCVISDFGLSMRLTGNRLVRPGEEDNAAISEVGTIRYMAPEVLEGAVNLRDCESALKQVDMYALGLIYWEIFMRCTDLFPGESVPEYQMAFQTEVGNHPTFEDMQVLVSREKQRPKFPEAWKENSLAVRSLKETIEDCWDQDAEARLTAQCAEERMAELMMIWERNKSVSPTVNPMSTAMQNERNLSHNRRVPKIGPYPDYSSSSYIEDSIHHTDSIVKNISSEHSMSSTPLTIGEKNRNSINYERQQAQARIPSPETSVTSLSTNTTTTNTTGLTPSTGMTTISEMPYPDETNLHTTNVAQSIGPTPVCLQLTEEDLETNKLDPKEVDKNLKESSDENLMEHSLKQFSGPDPLSSTSSSLLYPLIKLAVEATGQQDFTQTANGQACLIPDVLPTQIYPLPKQQNLPKRPTSLPLNTKNSTKEPRLKFGSKHKSNLKQVETGVAKMNTINAAEPHVVTVTMNGVAGRNHSVNSHAATTQYANGTVLSGQTTNIVTHRAQEMLQNQFIGEDTRLNINSSPDEHEPLLRREQQAGHDEGVLDRLVDRRERPLEGGRTNSNNNNSNPCSEQDVLAQGVPSTAADPGPSKPRRAQRPNSLDLSATNVLDGSSIQIGESTQDGKSGSGEKIKKRVKTPYSLKRWRPSTWVISTESLDCEVNNNGSNRAVHSKSSTAVYLAEGGTATTMVSKDIGMNCL
T60213	DRUGINFO	D00LZY	AA-184	Investigative
T60213	DRUGINFO	D04JCT	AA-204	Investigative
T60213	DRUGINFO	D0B8ES	AA-123	Investigative
T60213	DRUGINFO	D0F8VH	AA-166	Investigative
T60213	DRUGINFO	D0RF7O	ML347	Investigative
T60213	DRUGINFO	D06CMG	LDN-214117	Investigative
T60213	DRUGINFO	D05NEC	PMID23639540C13r	Investigative
T60213	DRUGINFO	D0F2MP	PMID23639540C13d	Investigative
T60213	DRUGINFO	D0PP6Y	PMID23639540C13a	Investigative

T07087	TARGETID	T07087
T07087	FORMERID	TTDI02472
T07087	UNIPROID	FAK2_HUMAN
T07087	TARGNAME	Focal adhesion kinase 2 (PTK2B)
T07087	GENENAME	PTK2B
T07087	TARGTYPE	Literature-reported
T07087	SYNONYMS	Related adhesion focal tyrosine kinase; RAFTK; Protein-tyrosine kinase 2-beta; Proline-rich tyrosine kinase 2; PYK2; FAK2; FADK 2; Cell adhesion kinase beta; Calcium-regulated non-receptor proline-rich tyrosine kinase; Calcium-dependent tyrosine kinase; CAKB; CAK-beta; CADTK
T07087	FUNCTION	Plays a role in the regulation of the humoral immune response, and is required for normal levels of marginal B-cells in the spleen and normal migration of splenic B-cells. Required for normal macrophage polarization and migration towards sites of inflammation. Regulates cytoskeleton rearrangement and cell spreading in T-cells, and contributes to the regulation of T-cell responses. Promotes osteoclastic bone resorption; this requires both PTK2B/PYK2 and SRC. May inhibit differentiation and activity of osteoprogenitor cells. Functions in signaling downstream of integrin and collagen receptors, immune receptors, G-protein coupled receptors (GPCR), cytokine, chemokine and growth factor receptors, and mediates responses to cellular stress. Forms multisubunit signaling complexes with SRC and SRC family members upon activation; this leads to the phosphorylation of additional tyrosine residues, creating binding sites for scaffold proteins, effectors and substrates. Regulates numerous signaling pathways. Promotes activation of phosphatidylinositol 3-kinase and of the AKT1 signaling cascade. Promotes activation of NOS3. Regulates production of the cellular messenger cGMP. Promotes activation of the MAP kinase signaling cascade, including activation of MAPK1/ERK2, MAPK3/ERK1 and MAPK8/JNK1. Promotes activation of Rho family GTPases, such as RHOA and RAC1. Recruits the ubiquitin ligase MDM2 to P53/TP53 in the nucleus, and thereby regulates P53/TP53 activity, P53/TP53 ubiquitination and proteasomal degradation. Acts as a scaffold, binding to both PDPK1 and SRC, thereby allowing SRC to phosphorylate PDPK1 at 'Tyr-9, 'Tyr-373', and 'Tyr-376'. Promotes phosphorylation of NMDA receptors by SRC family members, and thereby contributes to the regulation of NMDA receptor ion channel activity and intracellular Ca(2+) levels. May also regulate potassium ion transport by phosphorylation of potassium channel subunits. Phosphorylates SRC; this increases SRC kinase activity. Phosphorylates ASAP1, NPHP1, KCNA2 and SHC1. Promotes phosphorylation of ASAP2, RHOU and PXN; this requires both SRC and PTK2/PYK2. Non-receptor protein-tyrosine kinase that regulates reorganization of the actin cytoskeleton, cell polarization, cell migration, adhesion, spreading and bone remodeling.
T07087	PDBSTRUC	5TOB; 5TO8; 4XEV; 4XEK; 4XEF
T07087	BIOCLASS	Kinase
T07087	ECNUMBER	EC 2.7.10.2
T07087	SEQUENCE	MSGVSEPLSRVKLGTLRRPEGPAEPMVVVPVDVEKEDVRILKVCFYSNSFNPGKNFKLVKCTVQTEIREIITSILLSGRIGPNIRLAECYGLRLKHMKSDEIHWLHPQMTVGEVQDKYECLHVEAEWRYDLQIRYLPEDFMESLKEDRTTLLYFYQQLRNDYMQRYASKVSEGMALQLGCLELRRFFKDMPHNALDKKSNFELLEKEVGLDLFFPKQMQENLKPKQFRKMIQQTFQQYASLREEECVMKFFNTLAGFANIDQETYRCELIQGWNITVDLVIGPKGIRQLTSQDAKPTCLAEFKQIRSIRCLPLEEGQAVLQLGIEGAPQALSIKTSSLAEAENMADLIDGYCRLQGEHQGSLIIHPRKDGEKRNSLPQIPMLNLEARRSHLSESCSIESDIYAEIPDETLRRPGGPQYGIAREDVVLNRILGEGFFGEVYEGVYTNHKGEKINVAVKTCKKDCTLDNKEKFMSEAVIMKNLDHPHIVKLIGIIEEEPTWIIMELYPYGELGHYLERNKNSLKVLTLVLYSLQICKAMAYLESINCVHRDIAVRNILVASPECVKLGDFGLSRYIEDEDYYKASVTRLPIKWMSPESINFRRFTTASDVWMFAVCMWEILSFGKQPFFWLENKDVIGVLEKGDRLPKPDLCPPVLYTLMTRCWDYDPSDRPRFTELVCSLSDVYQMEKDIAMEQERNARYRTPKILEPTAFQEPPPKPSRPKYRPPPQTNLLAPKLQFQVPEGLCASSPTLTSPMEYPSPVNSLHTPPLHRHNVFKRHSMREEDFIQPSSREEAQQLWEAEKVKMRQILDKQQKQMVEDYQWLRQEEKSLDPMVYMNDKSPLTPEKEVGYLEFTGPPQKPPRLGAQSIQPTANLDRTDDLVYLNVMELVRAVLELKNELCQLPPEGYVVVVKNVGLTLRKLIGSVDDLLPSLPSSSRTEIEGTQKLLNKDLAELINKMRLAQQNAVTSLSEECKRQMLTASHTLAVDAKNLLDAVDQAKVLANLAHPPAE
T07087	DRUGINFO	D00SEC	aloisine	Investigative

T67231	TARGETID	T67231
T67231	FORMERID	TTDR00712
T67231	UNIPROID	MBTP1_HUMAN
T67231	TARGNAME	Endopeptidase S1P (MBTPS1)
T67231	GENENAME	MBTPS1
T67231	TARGTYPE	Literature-reported
T67231	SYNONYMS	Subtilisin/kexin-isozyme-1; Subtilisin/kexin-isozyme 1; Site-1 protease; SKI1; SKI-1; S1P; Membrane-bound transcription factor site-1 protease; KIAA0091
T67231	FUNCTION	Other known substrates are BDNF, GNPTAB and ATF6. Cleaves after hydrophobic or small residues, provided that Arg or Lys is in position P4. Cleaves known substrates after Arg-Ser-Val-Leu (SERBP-2), Arg-His-Leu-Leu (ATF6), Arg-Gly-Leu-Thr (BDNF) and its own propeptide after Arg-Arg-Leu-Leu. Mediates the protein cleavage of GNPTAB into subunit alpha and beta, thereby participating in biogenesis of lysosomes. Serine protease that catalyzes the first step in the proteolytic activation of the sterol regulatory element-binding proteins (SREBPs).
T67231	BIOCLASS	Peptidase
T67231	ECNUMBER	EC 3.4.21.112
T67231	SEQUENCE	MKLVNIWLLLLVVLLCGKKHLGDRLEKKSFEKAPCPGCSHLTLKVEFSSTVVEYEYIVAFNGYFTAKARNSFISSALKSSEVDNWRIIPRNNPSSDYPSDFEVIQIKEKQKAGLLTLEDHPNIKRVTPQRKVFRSLKYAESDPTVPCNETRWSQKWQSSRPLRRASLSLGSGFWHATGRHSSRRLLRAIPRQVAQTLQADVLWQMGYTGANVRVAVFDTGLSEKHPHFKNVKERTNWTNERTLDDGLGHGTFVAGVIASMRECQGFAPDAELHIFRVFTNNQVSYTSWFLDAFNYAILKKIDVLNLSIGGPDFMDHPFVDKVWELTANNVIMVSAIGNDGPLYGTLNNPADQMDVIGVGGIDFEDNIARFSSRGMTTWELPGGYGRMKPDIVTYGAGVRGSGVKGGCRALSGTSVASPVVAGAVTLLVSTVQKRELVNPASMKQALIASARRLPGVNMFEQGHGKLDLLRAYQILNSYKPQASLSPSYIDLTECPYMWPYCSQPIYYGGMPTVVNVTILNGMGVTGRIVDKPDWQPYLPQNGDNIEVAFSYSSVLWPWSGYLAISISVTKKAASWEGIAQGHVMITVASPAETESKNGAEQTSTVKLPIKVKIIPTPPRSKRVLWDQYHNLRYPPGYFPRDNLRMKNDPLDWNGDHIHTNFRDMYQHLRSMGYFVEVLGAPFTCFDASQYGTLLMVDSEEEYFPEEIAKLRRDVDNGLSLVIFSDWYNTSVMRKVKFYDENTRQWWMPDTGGANIPALNELLSVWNMGFSDGLYEGEFTLANHDMYYASGCSIAKFPEDGVVITQTFKDQGLEVLKQETAVVENVPILGLYQIPAEGGGRIVLYGDSNCLDDSHRQKDCFWLLDALLQYTSYGVTPPSLSHSGNRQRPPSGAGSVTPERMEGNHLHRYSKVLEAHLGDPKPRPLPACPRLSWAKPQPLNETAPSNLWKHQKLLSIDLDKVVLPNFRSNRPQVRPLSPGESGAWDIPGGIMPGRYNQEVGQTIPVFAFLGAMVVLAFFVVQINKAKSRPKRRKPRVKRPQLMQQVHPPKTPSV
T67231	DRUGINFO	D0P7NY	PF-429242	Investigative

T61243	TARGETID	T61243
T61243	FORMERID	TTDR00821
T61243	UNIPROID	GRM7_HUMAN
T61243	TARGNAME	Metabotropic glutamate receptor 7 (mGluR7)
T61243	GENENAME	GRM7
T61243	TARGTYPE	Literature-reported
T61243	SYNONYMS	mGluR7; GPRC1G
T61243	FUNCTION	Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. G-protein coupled receptor for glutamate.
T61243	PDBSTRUC	5C5C; 3MQ4
T61243	BIOCLASS	GPCR glutamate
T61243	SEQUENCE	MVQLRKLLRVLTLMKFPCCVLEVLLCALAAAARGQEMYAPHSIRIEGDVTLGGLFPVHAKGPSGVPCGDIKRENGIHRLEAMLYALDQINSDPNLLPNVTLGARILDTCSRDTYALEQSLTFVQALIQKDTSDVRCTNGEPPVFVKPEKVVGVIGASGSSVSIMVANILRLFQIPQISYASTAPELSDDRRYDFFSRVVPPDSFQAQAMVDIVKALGWNYVSTLASEGSYGEKGVESFTQISKEAGGLCIAQSVRIPQERKDRTIDFDRIIKQLLDTPNSRAVVIFANDEDIKQILAAAKRADQVGHFLWVGSDSWGSKINPLHQHEDIAEGAITIQPKRATVEGFDAYFTSRTLENNRRNVWFAEYWEENFNCKLTISGSKKEDTDRKCTGQERIGKDSNYEQEGKVQFVIDAVYAMAHALHHMNKDLCADYRGVCPEMEQAGGKKLLKYIRNVNFNGSAGTPVMFNKNGDAPGRYDIFQYQTTNTSNPGYRLIGQWTDELQLNIEDMQWGKGVREIPASVCTLPCKPGQRKKTQKGTPCCWTCEPCDGYQYQFDEMTCQHCPYDQRPNENRTGCQDIPIIKLEWHSPWAVIPVFLAMLGIIATIFVMATFIRYNDTPIVRASGRELSYVLLTGIFLCYIITFLMIAKPDVAVCSFRRVFLGLGMCISYAALLTKTNRIYRIFEQGKKSVTAPRLISPTSQLAITSSLISVQLLGVFIWFGVDPPNIIIDYDEHKTMNPEQARGVLKCDITDLQIICSLGYSILLMVTCTVYAIKTRGVPENFNEAKPIGFTMYTTCIVWLAFIPIFFGTAQSAEKLYIQTTTLTISMNLSASVALGMLYMPKVYIIIFHPELNVQKRKRSFKAVVTAATMSSRLSHKPSDRPNGEAKTELCENVDPNSPAAKKKYVSYNNLVI
T61243	DRUGINFO	D02ETA	AMN082	Investigative
T61243	DRUGINFO	D08UOW	MMPIP	Investigative
T61243	DRUGINFO	D0K2XD	ADX71743	Investigative
T61243	DRUGINFO	D0R2DP	XAP044	Investigative
T61243	DRUGINFO	D0S8HE	MSOPPE	Investigative
T61243	DRUGINFO	D0W2TQ	PPG	Investigative
T61243	DRUGINFO	D0YO8B	MCCG	Investigative
T61243	DRUGINFO	D0KL4K	LSP4-2022	Investigative
T61243	DRUGINFO	D0XG6U	LSP1-2111	Investigative
T61243	DRUGINFO	D09SXN	MAP4	Investigative
T61243	DRUGINFO	D0D2GL	MPPG	Investigative
T61243	DRUGINFO	D0N9UZ	[3H]LY341495	Investigative
T61243	DRUGINFO	D0O8AK	alpha-methylserine-O-phosphate	Investigative
T61243	DRUGINFO	D0PN6Z	L-AP4	Investigative
T61243	DRUGINFO	D0J8OW	(+)-MCPG	Investigative
T61243	DRUGINFO	D04DKM	(1S,3R)-ACPD	Investigative
T61243	DRUGINFO	D06DUE	[3H]quisqualate	Investigative
T61243	DRUGINFO	D0Z7CZ	L-CCG-I	Investigative
T61243	DRUGINFO	D07PZQ	L-serine-O-phosphate	Investigative

T17967	TARGETID	T17967
T17967	FORMERID	TTDI02231
T17967	UNIPROID	PDK2_HUMAN
T17967	TARGNAME	Pyruvate dehydrogenase kinase 2 (PDHK2)
T17967	GENENAME	PDK2
T17967	TARGTYPE	Literature-reported
T17967	SYNONYMS	PDKII; PDK2; PDH kinase 2; [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 2, mitochondrial
T17967	FUNCTION	Kinase that plays a key role in the regulation of glucose and fatty acid metabolism and homeostasis via phosphorylation of the pyruvate dehydrogenase subunits PDHA1 and PDHA2. This inhibits pyruvate dehydrogenase activity, and thereby regulates metabolite flux through the tricarboxylic acid cycle, down-regulates aerobic respiration and inhibits the formation of acetyl-coenzyme A from pyruvate. Inhibition of pyruvate dehydrogenase decreases glucose utilization and increases fat metabolism. Mediates cellular responses to insulin. Plays an important role in maintaining normal blood glucose levels and in metabolic adaptation to nutrient availability. Via its regulation of pyruvate dehydrogenase activity, plays an important role in maintaining normal blood pH and in preventing the accumulation of ketone bodies under starvation. Plays a role in the regulation of cell proliferation and in resistance to apoptosis under oxidative stress. Plays a role in p53/TP53-mediated apoptosis.
T17967	PDBSTRUC	5M4P; 5M4N; 5M4M; 5M4K; 5J71
T17967	BIOCLASS	Kinase
T17967	ECNUMBER	EC 2.7.11.2
T17967	SEQUENCE	MRWVWALLKNASLAGAPKYIEHFSKFSPSPLSMKQFLDFGSSNACEKTSFTFLRQELPVRLANIMKEINLLPDRVLSTPSVQLVQSWYVQSLLDIMEFLDKDPEDHRTLSQFTDALVTIRNRHNDVVPTMAQGVLEYKDTYGDDPVSNQNIQYFLDRFYLSRISIRMLINQHTLIFDGSTNPAHPKHIGSIDPNCNVSEVVKDAYDMAKLLCDKYYMASPDLEIQEINAANSKQPIHMVYVPSHLYHMLFELFKNAMRATVESHESSLILPPIKVMVALGEEDLSIKMSDRGGGVPLRKIERLFSYMYSTAPTPQPGTGGTPLAGFGYGLPISRLYAKYFQGDLQLFSMEGFGTDAVIYLKALSTDSVERLPVYNKSAWRHYQTIQEAGDWCVPSTEPKNTSTYRVS
T17967	DRUGINFO	D03GFC	AZD-7545	Terminated

T55826	TARGETID	T55826
T55826	FORMERID	TTDR00226
T55826	UNIPROID	Q8I566_PLAF7
T55826	TARGNAME	Plasmodium Serine hydroxymethyltransferase (Malaria SHMT)
T55826	GENENAME	Malaria SHMT
T55826	TARGTYPE	Literature-reported
T55826	SYNONYMS	Serine methylase; SHMT; Glycine hydroxymethyltransferase
T55826	FUNCTION	Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Required to prevent uracil accumulation in mtDNA. Interconversion of serine and glycine. Associates with mitochondrial DNA.
T55826	PDBSTRUC	4O6Z
T55826	BIOCLASS	Methyltransferase
T55826	ECNUMBER	EC 2.1.2.1
T55826	SEQUENCE	MFNNDPLQKYDKELFDLLEKEKNRQIETINLIASENLTNTAVRECLGDRISNKYSEGYPHKRYYGGNDYVDKIEELCYKRALEAFNVSEEEWGVNVQPLSGSAANVQALYALVGVKGKIMGMHLCSGGHLTHGFFDEKKKVSITSDLFESKLYKCNSEGYVDMESVRNLALSFQPKVIICGYTSYPRDIDYKGFREICDEVNAYLFADISHISSFVACNLLNNPFTYADVVTTTTHKILRGPRSALIFFNKKRNPGIDQKINSSVFPSFQGGPHNNKIAAVACQLKEVNTPFFKEYTKQVLLNSKALAECLLKRNLDLVTNGTDNHLIVVDLRKYNITGSKLQETCNAINIALNKNTIPSDVDCVSPSGIRIGTPALTTRGCKEKDMEFIADMLLKAILLTDELQQKYGKKLVDFKKGLVNNPKIDELKKEVVQWAKNLPFA
T55826	DRUGINFO	D04ZWL	Mimosine	Terminated

T98275	TARGETID	T98275
T98275	FORMERID	TTDI01825
T98275	UNIPROID	KAT6B_HUMAN
T98275	TARGNAME	Histone acetyltransferase KAT6B (KAT6B)
T98275	GENENAME	KAT6B
T98275	TARGTYPE	Literature-reported
T98275	SYNONYMS	KAT6B
T98275	FUNCTION	Functions as histone acetyltransferase and regulates transcription via chromatin remodeling. Acetylates all four core histones in nucleosomes. Histone acetylation gives an epigenetic tag for transcriptional activation. Mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein. Mediates acetylation of histone H3 at 'Lys-122' (H3K122ac), a modification that localizes at the surface of the histone octamer and stimulates transcription, possibly by promoting nucleosome instability. Mediates acetylation of histone H3 at 'Lys-27' (H3K27ac). Also functions as acetyltransferase for nonhistone targets. Acetylates 'Lys-131' of ALX1 and acts as its coactivator in the presence of CREBBP. Acetylates SIRT2 and is proposed to indirectly increase the transcriptional activity of TP53 through acetylation and subsequent attenuation ofSIRT2 deacetylase function. Acetylates HDAC1 leading to its inactivation and modulation of transcription. Acts as a TFAP2A-mediated transcriptional coactivator in presence of CITED2. Plays a role as a coactivator of NEUROD1-dependent transcription of the secretin and p21 genes and controls terminal differentiation of cells in the intestinal epithelium. Promotes cardiac myocyte enlargement. Can also mediate transcriptional repression. Binds to and may be involved in the transforming capacity of the adenovirus E1A protein. In case of HIV-1 infection, it is recruited by the viral protein Tat. Regulates Tat's transactivating activity and may help inducing chromatin remodeling of proviral genes. Acetylates FOXO1 and enhances its transcriptional activity. Acetylates BCL6 wich disrupts its ability to recruit histone deacetylases and hinders its transcriptional repressor activity. Participates in CLOCK or NPAS2-regulated rhythmic gene transcription; exhibits a circadian association with CLOCKor NPAS2, correlating with increase in PER1/2 mRNA and histone H3 acetylation on the PER1/2 promoter. Acetylates MTA1 at 'Lys-626' which is essential for its transcriptional coactivator activity (PubMed:10733570, PubMed:11430825, PubMed:11701890, PubMed:12402037, PubMed:12586840, PubMed:12929931, PubMed:14645221, PubMed:15186775, PubMed:15890677, PubMed:16617102, PubMed:16762839, PubMed:18722353,PubMed:18995842, PubMed:23415232, PubMed:23911289, PubMed:23934153, PubMed:8945521). Acetylates XBP1 isoform 2; acetylation increases protein stability of XBP1 isoform 2 and enhances its transcriptional activity.
T98275	PDBSTRUC	5U2J
T98275	BIOCLASS	Acyltransferase
T98275	ECNUMBER	EC 2.3.1.48
T98275	SEQUENCE	MVKLANPLYTEWILEAIQKIKKQKQRPSEERICHAVSTSHGLDKKTVSEQLELSVQDGSVLKVTNKGLASYKDPDNPGRFSSVKPGTFPKSAKGSRGSCNDLRNVDWNKLLRRAIEGLEEPNGSSLKNIEKYLRSQSDLTSTTNNPAFQQRLRLGAKRAVNNGRLLKDGPQYRVNYGSLDGKGAPQYPSAFPSSLPPVSLLPHEKDQPRADPIPICSFCLGTKESNREKKPEELLSCADCGSSGHPSCLKFCPELTTNVKALRWQCIECKTCSACRVQGRNADNMLFCDSCDRGFHMECCDPPLSRMPKGMWICQVCRPKKKGRKLLHEKAAQIKRRYAKPIGRPKNKLKQRLLSVTSDEGSMNAFTGRGSPGRGQKTKVCTTPSSGHAASGKDSSSRLAVTDPTRPGATTKITTTSTYISASTLKVNKKTKGLIDGLTKFFTPSPDGRRSRGEIIDFSKHYRPRKKVSQKQSCTSHVLATGTTQKLKPPPSSLPPPTPISGQSPSSQKSSTATSSPSPQSSSSQCSVPSLSSLTTNSQLKALFDGLSHIYTTQGQSRKKGHPSYAPPKRMRRKTELSSTAKSKAHFFGKRDIRSRFISHSSSSSWGMARGSIFKAIAHFKRTTFLKKHRMLGRLKYKVTPQMGTPSPGKGSLTDGRIKPDQDDDTEIKINIKQESADVNVIGNKDVVTEEDLDVFKQAQELSWEKIECESGVEDCGRYPSVIEFGKYEIQTWYSSPYPQEYARLPKLYLCEFCLKYMKSKNILLRHSKKCGWFHPPANEIYRRKDLSVFEVDGNMSKIYCQNLCLLAKLFLDHKTLYYDVEPFLFYVLTKNDEKGCHLVGYFSKEKLCQQKYNVSCIMIMPQHQRQGFGRFLIDFSYLLSRREGQAGSPEKPLSDLGRLSYLAYWKSVILEYLYHHHERHISIKAISRATGMCPHDIATTLQHLHMIDKRDGRFVIIRREKLILSHMEKLKTCSRANELDPDSLRWTPILISNAAVSEEEREAEKEAERLMEQASCWEKEEQEILSTRANSRQSPAKVQSKNKYLHSPESRPVTGERGQLLELSKESSEEEEEEEDEEEEEEEEEEEEDEEEEEEEEEEEEEENIQSSPPRLTKPQSVAIKRKRPFVLKKKRGRKRRRINSSVTTETISETTEVLNEPFDNSDEERPMPQLEPTCEIEVEEDGRKPVLRKAFQHQPGKKRQTEEEEGKDNHCFKNADPCRNNMNDDSSNLKEGSKDNPEPLKCKQVWPKGTKRGLSKWRQNKERKTGFKLNLYTPPETPMEPDEQVTVEEQKETSEGKTSPSPIRIEEEVKETGEALLPQEENRREETCAPVSPNTSPGEKPEDDLIKPEEEEEEEEEEEEEEEEEEGEEEEGGGNVEKDPDGAKSQEKEEPEISTEKEDSARLDDHEEEEEEDEEPSHNEDHDADDEDDSHMESAEVEKEELPRESFKEVLENQETFLDLNVQPGHSNPEVLMDCGVDLTASCNSEPKELAGDPEAVPESDEEPPPGEQAQKQDQKNSKEVDTEFKEGNPATMEIDSETVQAVQSLTQESSEQDDTFQDCAETQEACRSLQNYTRADQSPQIATTLDDCQQSDHSSPVSSVHSHPGQSVRSVNSPSVPALENSYAQISPDQSAISVPSLQNMETSPMMDVPSVSDHSQQVVDSGFSDLGSIESTTENYENPSSYDSTMGGSICGNGSSQNSCSYSNLTSSSLTQSSCAVTQQMSNISGSCSMLQQTSISSPPTCSVKSPQGCVVERPPSSSQQLAQCSMAANFTPPMQLAEIPETSNANIGLYERMGQSDFGAGHYPQPSATFSLAKLQQLTNTLIDHSLPYSHSAAVTSYANSASLSTPLSNTGLVQLSQSPHSVPGGPQAQATMTPPPNLTPPPMNLPPPLLQRNMAASNIGISHSQRLQTQIASKGHISMRTKSASLSPAAATHQSQIYGRSQTVAMQGPARTLTMQRGMNMSVNLMPAPAYNVNSVNMNMNTLNAMNGYSMSQPMMNSGYHSNHGYMNQTPQYPMQMQMGMMGTQPYAQQPMQTPPHGNMMYTAPGHHGYMNTGMSKQSLNGSYMRR
T98275	DRUGINFO	D0YL8Z	C646	Investigative
T98275	DRUGINFO	D0Z3MT	MG149	Investigative
T98275	DRUGINFO	D03JNC	garcinol	Investigative
T98275	DRUGINFO	D03XXT	SGC-CBP30	Investigative
T98275	DRUGINFO	D0E6JS	anacardic acid	Investigative
T98275	DRUGINFO	D0J3JI	I-CBP112	Investigative

T16902	TARGETID	T16902
T16902	FORMERID	TTDI00174
T16902	UNIPROID	KAT2B_HUMAN
T16902	TARGNAME	Histone acetyltransferase KAT2B (KAT2B)
T16902	GENENAME	KAT2B
T16902	TARGTYPE	Literature-reported
T16902	SYNONYMS	Spermidine acetyltransferase KAT2B; PCAF; P300/CBP-associated factor; P/CAF; Lysine acetyltransferase 2B; Histone acetyltransferase PCAF; Histone acetylase PCAF
T16902	FUNCTION	Has significant histone acetyltransferase activity with core histones (H3 and H4), and also with nucleosome core particles. Also acetylates non-histone proteins, such as ACLY, PLK4 and TBX5. Inhibits cell-cycle progression and counteracts the mitogenic activity of the adenoviral oncoprotein E1A. Acts as a circadian transcriptional coactivator which enhances the activity of the circadian transcriptional activators: NPAS2-ARNTL/BMAL1 and CLOCK-ARNTL/BMAL1 heterodimers. Involved in heart and limb development by mediating acetylation of TBX5, acetylation regulating nucleocytoplasmic shuttling of TBX5. Acts as a negative regulator of centrosome amplification by mediating acetylation of PLK4. Also acetylates spermidine. Functions as a histone acetyltransferase (HAT) to promote transcriptional activation.
T16902	PDBSTRUC	6J3O; 5MKX; 5LVR; 5LVQ; 5FE9
T16902	BIOCLASS	Acyltransferase
T16902	ECNUMBER	EC 2.3.1.48
T16902	SEQUENCE	MSEAGGAGPGGCGAGAGAGAGPGALPPQPAALPPAPPQGSPCAAAAGGSGACGPATAVAAAGTAEGPGGGGSARIAVKKAQLRSAPRAKKLEKLGVYSACKAEESCKCNGWKNPNPSPTPPRADLQQIIVSLTESCRSCSHALAAHVSHLENVSEEEMNRLLGIVLDVEYLFTCVHKEEDADTKQVYFYLFKLLRKSILQRGKPVVEGSLEKKPPFEKPSIEQGVNNFVQYKFSHLPAKERQTIVELAKMFLNRINYWHLEAPSQRRLRSPNDDISGYKENYTRWLCYCNVPQFCDSLPRYETTQVFGRTLLRSVFTVMRRQLLEQARQEKDKLPLEKRTLILTHFPKFLSMLEEEVYSQNSPIWDQDFLSASSRTSQLGIQTVINPPPVAGTISYNSTSSSLEQPNAGSSSPACKASSGLEANPGEKRKMTDSHVLEEAKKPRVMGDIPMELINEVMSTITDPAAMLGPETNFLSAHSARDEAARLEERRGVIEFHVVGNSLNQKPNKKILMWLVGLQNVFSHQLPRMPKEYITRLVFDPKHKTLALIKDGRVIGGICFRMFPSQGFTEIVFCAVTSNEQVKGYGTHLMNHLKEYHIKHDILNFLTYADEYAIGYFKKQGFSKEIKIPKTKYVGYIKDYEGATLMGCELNPRIPYTEFSVIIKKQKEIIKKLIERKQAQIRKVYPGLSCFKDGVRQIPIESIPGIRETGWKPSGKEKSKEPRDPDQLYSTLKSILQQVKSHQSAWPFMEPVKRTEAPGYYEVIRFPMDLKTMSERLKNRYYVSKKLFMADLQRVFTNCKEYNPPESEYYKCANILEKFFFSKIKEAGLIDK
T16902	DRUGINFO	D07JMJ	PMID15724976C1	Investigative
T16902	DRUGINFO	D0G4ET	MB-3	Investigative
T16902	DRUGINFO	D0M6YZ	LTK-14	Investigative
T16902	DRUGINFO	D03JNC	garcinol	Investigative
T16902	DRUGINFO	D0E6JS	anacardic acid	Investigative

T53612	TARGETID	T53612
T53612	FORMERID	TTDR01120
T53612	UNIPROID	KLK6_HUMAN
T53612	TARGNAME	Kallikrein-6 (KLK6)
T53612	GENENAME	KLK6
T53612	TARGTYPE	Literature-reported
T53612	SYNONYMS	Zyme; Serine protease 9; Serine protease 18; SP59; Protease M; PRSS9; PRSS18; Neurosin; MSP; K6
T53612	FUNCTION	Shows activity against amyloid precursor protein, myelin basic protein, gelatin, casein and extracellular matrix proteins such as fibronectin, laminin, vitronectin and collagen. Degrades alpha-synuclein and prevents its polymerization, indicating that it may be involved in the pathogenesis of Parkinson disease and other synucleinopathies. May be involved in regulation of axon outgrowth following spinal cord injury. Tumor cells treated with a neutralizing KLK6 antibody migrate less than control cells, suggesting a role in invasion and metastasis. Serine protease which exhibits a preference for Arg over Lys in the substrate P1 position and for Ser or Pro in the P2 position.
T53612	PDBSTRUC	6QHC; 6QHB; 6QHA; 6QH9; 6QFH
T53612	BIOCLASS	Peptidase
T53612	ECNUMBER	EC 3.4.21.-
T53612	SEQUENCE	MKKLMVVLSLIAAAWAEEQNKLVHGGPCDKTSHPYQAALYTSGHLLCGGVLIHPLWVLTAAHCKKPNLQVFLGKHNLRQRESSQEQSSVVRAVIHPDYDAASHDQDIMLLRLARPAKLSELIQPLPLERDCSANTTSCHILGWGKTADGDFPDTIQCAYIHLVSREECEHAYPGQITQNMLCAGDEKYGKDSCQGDSGGPLVCGDHLRGLVSWGNIPCGSKEKPGVYTNVCRYTNWIQKTIQAK
T53612	DRUGINFO	D00HWJ	PMID24900446C5 	Investigative
T53612	DRUGINFO	D07SFI	Benzamidine	Investigative

T61792	TARGETID	T61792
T61792	FORMERID	TTDR00020
T61792	UNIPROID	MRP2_HUMAN
T61792	TARGNAME	Multidrug resistance-associated protein 2 (ABCC2)
T61792	GENENAME	ABCC2
T61792	TARGTYPE	Literature-reported
T61792	SYNONYMS	MRP2; Canalicular multispecific organic anion transporter 1; Canalicular multidrug resistance protein; CMRP; CMOAT1; CMOAT; ATP-binding cassette, sub-family C, member 2; ATP-binding cassette sub-family C member 2
T61792	FUNCTION	May function as a cellular cisplatin transporter. Mediates hepatobiliary excretion of numerous organic anions.
T61792	BIOCLASS	ABC transporter
T61792	ECNUMBER	EC 7.6.2.2
T61792	SEQUENCE	MLEKFCNSTFWNSSFLDSPEADLPLCFEQTVLVWIPLGYLWLLAPWQLLHVYKSRTKRSSTTKLYLAKQVFVGFLLILAAIELALVLTEDSGQATVPAVRYTNPSLYLGTWLLVLLIQYSRQWCVQKNSWFLSLFWILSILCGTFQFQTLIRTLLQGDNSNLAYSCLFFISYGFQILILIFSAFSENNESSNNPSSIASFLSSITYSWYDSIILKGYKRPLTLEDVWEVDEEMKTKTLVSKFETHMKRELQKARRALQRRQEKSSQQNSGARLPGLNKNQSQSQDALVLEDVEKKKKKSGTKKDVPKSWLMKALFKTFYMVLLKSFLLKLVNDIFTFVSPQLLKLLISFASDRDTYLWIGYLCAILLFTAALIQSFCLQCYFQLCFKLGVKVRTAIMASVYKKALTLSNLARKEYTVGETVNLMSVDAQKLMDVTNFMHMLWSSVLQIVLSIFFLWRELGPSVLAGVGVMVLVIPINAILSTKSKTIQVKNMKNKDKRLKIMNEILSGIKILKYFAWEPSFRDQVQNLRKKELKNLLAFSQLQCVVIFVFQLTPVLVSVVTFSVYVLVDSNNILDAQKAFTSITLFNILRFPLSMLPMMISSMLQASVSTERLEKYLGGDDLDTSAIRHDCNFDKAMQFSEASFTWEHDSEATVRDVNLDIMAGQLVAVIGPVGSGKSSLISAMLGEMENVHGHITIKGTTAYVPQQSWIQNGTIKDNILFGTEFNEKRYQQVLEACALLPDLEMLPGGDLAEIGEKGINLSGGQKQRISLARATYQNLDIYLLDDPLSAVDAHVGKHIFNKVLGPNGLLKGKTRLLVTHSMHFLPQVDEIVVLGNGTIVEKGSYSALLAKKGEFAKNLKTFLRHTGPEEEATVHDGSEEEDDDYGLISSVEEIPEDAASITMRRENSFRRTLSRSSRSNGRHLKSLRNSLKTRNVNSLKEDEELVKGQKLIKKEFIETGKVKFSIYLEYLQAIGLFSIFFIILAFVMNSVAFIGSNLWLSAWTSDSKIFNSTDYPASQRDMRVGVYGALGLAQGIFVFIAHFWSAFGFVHASNILHKQLLNNILRAPMRFFDTTPTGRIVNRFAGDISTVDDTLPQSLRSWITCFLGIISTLVMICMATPVFTIIVIPLGIIYVSVQMFYVSTSRQLRRLDSVTRSPIYSHFSETVSGLPVIRAFEHQQRFLKHNEVRIDTNQKCVFSWITSNRWLAIRLELVGNLTVFFSALMMVIYRDTLSGDTVGFVLSNALNITQTLNWLVRMTSEIETNIVAVERITEYTKVENEAPWVTDKRPPPDWPSKGKIQFNNYQVRYRPELDLVLRGITCDIGSMEKIGVVGRTGAGKSSLTNCLFRILEAAGGQIIIDGVDIASIGLHDLREKLTIIPQDPILFSGSLRMNLDPFNNYSDEEIWKALELAHLKSFVASLQLGLSHEVTEAGGNLSIGQRQLLCLGRALLRKSKILVLDEATAAVDLETDNLIQTTIQNEFAHCTVITIAHRLHTIMDSDKVMVLDNGKIIECGSPEELLQIPGPFYFMAKEAGIENVNSTKF

T30414	TARGETID	T30414
T30414	FORMERID	TTDR00111
T30414	UNIPROID	PAR4_HUMAN
T30414	TARGNAME	Proteinase activated receptor 4 (F2RL3)
T30414	GENENAME	F2RL3
T30414	TARGTYPE	Literature-reported
T30414	SYNONYMS	Thrombin receptor-like 3; Protease activated receptor 4; F2RL3; Coagulation factor II receptor-like3
T30414	FUNCTION	Receptor for activated thrombin or trypsin coupled to G proteins that stimulate phosphoinositide hydrolysis. May play a role in platelets activation.
T30414	PDBSTRUC	3QDZ; 2ZPK
T30414	BIOCLASS	GPCR rhodopsin
T30414	SEQUENCE	MWGRLLLWPLVLGFSLSGGTQTPSVYDESGSTGGGDDSTPSILPAPRGYPGQVCANDSDTLELPDSSRALLLGWVPTRLVPALYGLVLVVGLPANGLALWVLATQAPRLPSTMLLMNLAAADLLLALALPPRIAYHLRGQRWPFGEAACRLATAALYGHMYGSVLLLAAVSLDRYLALVHPLRARALRGRRLALGLCMAAWLMAAALALPLTLQRQTFRLARSDRVLCHDALPLDAQASHWQPAFTCLALLGCFLPLLAMLLCYGATLHTLAASGRRYGHALRLTAVVLASAVAFFVPSNLLLLLHYSDPSPSAWGNLYGAYVPSLALSTLNSCVDPFIYYYVSAEFRDKVRAGLFQRSPGDTVASKASAEGGSRGMGTHSSLLQ
T30414	DRUGINFO	D0G9BX	SC-47643	Terminated
T30414	DRUGINFO	D00KRL	Ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate	Investigative

T84359	TARGETID	T84359
T84359	FORMERID	TTDR00972
T84359	UNIPROID	KCY_STRPN
T84359	TARGNAME	Streptococcus Cytidylate kinase (Stre-coc cmk)
T84359	GENENAME	Stre-coc cmk
T84359	TARGTYPE	Literature-reported
T84359	SYNONYMS	cmk; TIGR4; MssA protein; Cytidine monophosphate kinase; CMP kinase
T84359	FUNCTION	Atp, datp, and gtp are equally effective as phosphate donors. Cmp and dcmp are the best phosphate acceptors.
T84359	PDBSTRUC	1Q3T
T84359	BIOCLASS	Kinase
T84359	ECNUMBER	EC 2.7.4.25
T84359	SEQUENCE	MKTIQIAIDGPASSGKSTVAKIIAKDFGFTYLDTGAMYRAATYMALKNQLGVEEVEALLALLDQHPISFGRSETGDQLVFVGDVDITHPIRENEVTNHVSAIAAIPQVREKLVSLQQEIAQQGGIVMDGRDIGTVVLPQAELKIFLVASVDERAERRYKENIAKGIETDLETLKKEIAARDYKDSHRETSPLKQAEDAVYLDTTGLNIQEVVEKIKAEAEKRM
T84359	DRUGINFO	D03SAZ	Cytosine Arabinose-5'-Phosphate	Investigative
T84359	DRUGINFO	D09ZMS	2',3'-Dideoxycytidine-5'-Monophosphate	Investigative
T84359	DRUGINFO	D07XZT	Cytidine-5'-Diphosphate	Investigative
T84359	DRUGINFO	D0S2QZ	Cytidine-5'-Monophosphate	Investigative

T77139	TARGETID	T77139
T77139	FORMERID	TTDR01005
T77139	UNIPROID	M3K3_HUMAN
T77139	TARGNAME	MAPK/ERK kinase kinase 3 (MAP3K3)
T77139	GENENAME	MAP3K3
T77139	TARGTYPE	Literature-reported
T77139	SYNONYMS	Mitogen-activated protein kinase kinase kinase 3; MEKK3; MEKK 3; MEK kinase 3; MAPKKK3
T77139	FUNCTION	Mediates activation of the NF-kappa-B, AP1 and DDIT3 transcriptional regulators. Component of a protein kinase signal transduction cascade.
T77139	PDBSTRUC	4YL6; 4Y5O; 2PPH; 2O2V; 2JRH
T77139	BIOCLASS	Kinase
T77139	ECNUMBER	EC 2.7.11.25
T77139	SEQUENCE	MDEQEALNSIMNDLVALQMNRRHRMPGYETMKNKDTGHSNRQSDVRIKFEHNGERRIIAFSRPVKYEDVEHKVTTVFGQPLDLHYMNNELSILLKNQDDLDKAIDILDRSSSMKSLRILLLSQDRNHNSSSPHSGVSRQVRIKASQSAGDINTIYQPPEPRSRHLSVSSQNPGRSSPPPGYVPERQQHIARQGSYTSINSEGEFIPETSEQCMLDPLSSAENSLSGSCQSLDRSADSPSFRKSRMSRAQSFPDNRQEYSDRETQLYDKGVKGGTYPRRYHVSVHHKDYSDGRRTFPRIRRHQGNLFTLVPSSRSLSTNGENMGLAVQYLDPRGRLRSADSENALSVQERNVPTKSPSAPINWRRGKLLGQGAFGRVYLCYDVDTGRELASKQVQFDPDSPETSKEVSALECEIQLLKNLQHERIVQYYGCLRDRAEKTLTIFMEYMPGGSVKDQLKAYGALTESVTRKYTRQILEGMSYLHSNMIVHRDIKGANILRDSAGNVKLGDFGASKRLQTICMSGTGMRSVTGTPYWMSPEVISGEGYGRKADVWSLGCTVVEMLTEKPPWAEYEAMAAIFKIATQPTNPQLPSHISEHGRDFLRRIFVEARQRPSAEELLTHHFAQLMY
T77139	DRUGINFO	D08TVU	PMID20483621C5n	Investigative

T94594	TARGETID	T94594
T94594	FORMERID	TTDR01157
T94594	UNIPROID	NADD_PSEAE
T94594	TARGNAME	Pseudomonas Nicotinate-nucleotide adenylyltransferase (Pseudo nadD)
T94594	GENENAME	Pseudo nadD
T94594	TARGTYPE	Literature-reported
T94594	SYNONYMS	nadD of Pseudomonas aeruginosa; Nicotinic acid mononucleotide adenylyltransferase of Pseudomonas aeruginosa; Nicotinatemononucleotide adenylyltransferase of Pseudomonas aeruginosa; Nicotinate-nucleotide adenylyltransferase of Pseudomonas aeruginosa; NaMN-Atase; NaMN adenylyltransferase of Pseudomonas aeruginosa; NaMN AT of Pseudomonas aeruginosa; Deamido-NAD(+) pyrophosphorylase of Pseudomonas aeruginosa; Deamido-NAD(+) diphosphorylase of Pseudomonas aeruginosa
T94594	FUNCTION	Catalyzes the reversible adenylation of nicotinate mononucleotide (NaMN) to nicotinic acid adenine dinucleotide (NaAD).
T94594	PDBSTRUC	1YUN; 1YUM; 1YUL
T94594	BIOCLASS	Kinase
T94594	ECNUMBER	EC 2.7.7.18
T94594	SEQUENCE	MGKRIGLFGGTFDPVHIGHMRSAVEMAEQFALDELRLLPNARPPHRETPQVSAAQRLAMVERAVAGVERLTVDPRELQRDKPSYTIDTLESVRAELAADDQLFMLIGWDAFCGLPTWHRWEALLDHCHIVVLQRPDADSEPPESLRDLLAARSVADPQALKGPGGQITFVWQTPLAVSATQIRALLGAGRSVRFLVPDAVLNYIEAHHLYRAPH
T94594	DRUGINFO	D0R6JE	Nicotinamide-Adenine-Dinucleotide	Investigative

T44614	TARGETID	T44614
T44614	FORMERID	TTDR00606
T44614	UNIPROID	Q9N6S8_PLAFA
T44614	TARGNAME	Plasmodium Cysteine protease falcipain-2 (Malaria CPF2)
T44614	GENENAME	Malaria CPF2
T44614	TARGTYPE	Literature-reported
T44614	SYNONYMS	Falcipain 2; Cysteine proteinase falcipain 2a
T44614	FUNCTION	A papain family cysteine protease and important hemoglobinase of erythrocytic Plasmodium falciparum parasites.
T44614	PDBSTRUC	3PNR; 3BPF; 2GHU; 1YVB
T44614	BIOCLASS	Protease
T44614	ECNUMBER	EC 3.4.22.-
T44614	SEQUENCE	MDYNMDYAPHEVISQQGERFVDKYVDRKILKNKKSLLVIISLSVLSVVGFVLFYFTPNSRKSDLFKNSSVENNNDDYIINSLLKSPNGKKFIVSKIDEALSFYDSKKNDINKYNEGNNNNNADFKGLSLFKENTPSNNFIHNKDYFINFFDNKFLMNNAEHINQFYMFIKTNNKQYNSPNEMKERFQVFLQNAHKVNMHNNNKNSLYKKELNRFADLTYHEFKNKYLSLRSSKPLKNSKYLLDQMNYEEVIKKYRGEENFDHAAYDWRLHSGVTPVKDQKNCGSCWAFSSIGSVESQYAIRKNKLITLSEQELVDCSFKNYGCNGGLINNAFEDMIELGGICPDGDYPYVSDAPNLCNIDRCTEKYGIKNYLSVPDNKLKEALRFLGPISISVAVSDDFAFYKEGIFDGECGDQLNHAVMLVGFGMKEIVNPLTKKGEKHYYYIIKNSWGQQWGERGFINIETDESGLMRKCGLGTDAFIPLIE
T44614	DRUGINFO	D04ZIJ	Pepstatin	Terminated
T44614	DRUGINFO	D05TNI	FITC-LMNNAEHINQFYMFI	Investigative
T44614	DRUGINFO	D0PB3X	Vinylsulphones	Investigative
T44614	DRUGINFO	D08KCA	Leupeptin	Investigative

T18390	TARGETID	T18390
T18390	FORMERID	TTDI00083
T18390	UNIPROID	LATS2_HUMAN
T18390	TARGNAME	Large tumor suppressor homolog 2 (LATS2)
T18390	GENENAME	LATS2
T18390	TARGTYPE	Literature-reported
T18390	SYNONYMS	Warts-like kinase; Serine/threonine-protein kinase kpm; Serine/threonine-protein kinase LATS2; Kinase phosphorylated during mitosis protein; KPM
T18390	FUNCTION	The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS2 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. Acts as a tumor suppressor which plays a critical role in centrosome duplication, maintenance of mitotic fidelity and genomic stability. Negatively regulates G1/S transition by down-regulating cyclin E/CDK2 kinase activity. Negative regulator of the androgen receptor. Phosphorylates SNAI1 in the nucleus leading to its nuclear retention and stabilization, which enhances its epithelial-mesenchymal transition and tumor cell invasion/migration activities. This tumor-promoting activity is independent of its effects upon YAP1 or WWTR1/TAZ. Negative regulator of YAP1 in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis.
T18390	PDBSTRUC	4ZRI
T18390	BIOCLASS	Kinase
T18390	ECNUMBER	EC 2.7.11.1
T18390	SEQUENCE	MRPKTFPATTYSGNSRQRLQEIREGLKQPSKSSVQGLPAGPNSDTSLDAKVLGSKDATRQQQQMRATPKFGPYQKALREIRYSLLPFANESGTSAAAEVNRQMLQELVNAGCDQEMAGRALKQTGSRSIEAALEYISKMGYLDPRNEQIVRVIKQTSPGKGLMPTPVTRRPSFEGTGDSFASYHQLSGTPYEGPSFGADGPTALEEMPRPYVDYLFPGVGPHGPGHQHQHPPKGYGASVEAAGAHFPLQGAHYGRPHLLVPGEPLGYGVQRSPSFQSKTPPETGGYASLPTKGQGGPPGAGLAFPPPAAGLYVPHPHHKQAGPAAHQLHVLGSRSQVFASDSPPQSLLTPSRNSLNVDLYELGSTSVQQWPAATLARRDSLQKPGLEAPPRAHVAFRPDCPVPSRTNSFNSHQPRPGPPGKAEPSLPAPNTVTAVTAAHILHPVKSVRVLRPEPQTAVGPSHPAWVPAPAPAPAPAPAPAAEGLDAKEEHALALGGAGAFPLDVEYGGPDRRCPPPPYPKHLLLRSKSEQYDLDSLCAGMEQSLRAGPNEPEGGDKSRKSAKGDKGGKDKKQIQTSPVPVRKNSRDEEKRESRIKSYSPYAFKFFMEQHVENVIKTYQQKVNRRLQLEQEMAKAGLCEAEQEQMRKILYQKESNYNRLKRAKMDKSMFVKIKTLGIGAFGEVCLACKVDTHALYAMKTLRKKDVLNRNQVAHVKAERDILAEADNEWVVKLYYSFQDKDSLYFVMDYIPGGDMMSLLIRMEVFPEHLARFYIAELTLAIESVHKMGFIHRDIKPDNILIDLDGHIKLTDFGLCTGFRWTHNSKYYQKGSHVRQDSMEPSDLWDDVSNCRCGDRLKTLEQRARKQHQRCLAHSLVGTPNYIAPEVLLRKGYTQLCDWWSVGVILFEMLVGQPPFLAPTPTETQLKVINWENTLHIPAQVKLSPEARDLITKLCCSADHRLGRNGADDLKAHPFFSAIDFSSDIRKQPAPYVPTISHPMDTSNFDPVDEESPWNDASEGSTKAWDTLTSPNNKHPEHAFYEFTFRRFFDDNGYPFRCPKPSGAEASQAESSDLESSDLVDQTEGCQPVYV
T18390	DRUGINFO	D0R3MO	PMID20684608C35	Investigative

T91959	TARGETID	T91959
T91959	UNIPROID	SIR3_HUMAN
T91959	TARGNAME	NAD-dependent deacetylase sirtuin-3 (SIRT3)
T91959	GENENAME	SIRT3
T91959	TARGTYPE	Literature-reported
T91959	SYNONYMS	hSIRT3; SIR2L3; SIR2-like protein 3; Regulatory protein SIR2 homolog 3
T91959	FUNCTION	NAD-dependent protein deacetylase (PubMed:12186850, PubMed:12374852, PubMed:16788062, PubMed:18680753, PubMed:18794531, PubMed:23283301, PubMed:24121500, PubMed:24252090, PubMed:19535340). Activates or deactivates mitochondrial target proteins by deacetylating key lysine residues (PubMed:12186850, PubMed:12374852, PubMed:16788062, PubMed:18680753, PubMed:18794531, PubMed:23283301, PubMed:24121500, PubMed:24252090). Known targets include ACSS1, IDH, GDH, SOD2, PDHA1, LCAD, SDHA and the ATP synthase subunit ATP5PO (PubMed:16788062, PubMed:18680753, PubMed:24121500, PubMed:24252090, PubMed:19535340). Contributes to the regulation of the cellular energy metabolism (PubMed:24252090). Important for regulating tissue-specific ATP levels (PubMed:18794531). In response to metabolic stress, deacetylates transcription factor FOXO3 and recruits FOXO3 and mitochondrial RNA polymerase POLRMT to mtDNA to promote mtDNA transcription (PubMed:23283301).
T91959	PDBSTRUC	6ISO; 5ZGC; 5Z94; 5Z93; 5YTK
T91959	BIOCLASS	Sirtuin family. Class I subfamily
T91959	ECNUMBER	EC 3.5.1.-
T91959	SEQUENCE	MAFWGWRAAAALRLWGRVVERVEAGGGVGPFQACGCRLVLGGRDDVSAGLRGSHGARGEPLDPARPLQRPPRPEVPRAFRRQPRAAAPSFFFSSIKGGRRSISFSVGASSVVGSGGSSDKGKLSLQDVAELIRARACQRVVVMVGAGISTPSGIPDFRSPGSGLYSNLQQYDLPYPEAIFELPFFFHNPKPFFTLAKELYPGNYKPNVTHYFLRLLHDKGLLLRLYTQNIDGLERVSGIPASKLVEAHGTFASATCTVCQRPFPGEDIRADVMADRVPRCPVCTGVVKPDIVFFGEPLPQRFLLHVVDFPMADLLLILGTSLEVEPFASLTEAVRSSVPRLLINRDLVGPLAWHPRSRDVAQLGDVVHGVESLVELLGWTEEMRDLVQRETGKLDGPDK

T13795	TARGETID	T13795
T13795	FORMERID	TTDC00239
T13795	UNIPROID	ACHA9_HUMAN
T13795	TARGNAME	Neuronal acetylcholine receptor alpha-9 (CHRNA9)
T13795	GENENAME	CHRNA9
T13795	TARGTYPE	Literature-reported
T13795	SYNONYMS	Nicotinic acetylcholine receptor subunit alpha 9; NACHR alpha 9; CHRNA9
T13795	FUNCTION	Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding induces a conformation change that leads to the opening of an ion-conducting channel across the plasma membrane (PubMed:11752216, PubMed:25282151). The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes the cell membrane (PubMed:11752216, PubMed:25282151). In the ear, this may lead to a reduction in basilar membrane motion, altering the activity of auditory nerve fibers and reducing the range of dynamic hearing. This may protect against acoustic trauma. May also regulate keratinocyte adhesion (PubMed:11021840).
T13795	PDBSTRUC	6HY7; 4UY2; 4UXU; 4D01
T13795	BIOCLASS	Neurotransmitter receptor
T13795	SEQUENCE	MNWSHSCISFCWIYFAASRLRAAETADGKYAQKLFNDLFEDYSNALRPVEDTDKVLNVTLQITLSQIKDMDERNQILTAYLWIRQIWHDAYLTWDRDQYDGLDSIRIPSDLVWRPDIVLYNKADDESSEPVNTNVVLRYDGLITWDAPAITKSSCVVDVTYFPFDNQQCNLTFGSWTYNGNQVDIFNALDSGDLSDFIEDVEWEVHGMPAVKNVISYGCCSEPYPDVTFTLLLKRRSSFYIVNLLIPCVLISFLAPLSFYLPAASGEKVSLGVTILLAMTVFQLMVAEIMPASENVPLIGKYYIATMALITASTALTIMVMNIHFCGAEARPVPHWARVVILKYMSRVLFVYDVGESCLSPHHSRERDHLTKVYSKLPESNLKAARNKDLSRKKDMNKRLKNDLGCQGKNPQEAESYCAQYKVLTRNIEYIAKCLKDHKATNSKGSEWKKVAKVIDRFFMWIFFIMVFVMTILIIARAD
T13795	DRUGINFO	D09VJI	[3H]methyllycaconitine	Investigative

T92460	TARGETID	T92460
T92460	UNIPROID	GUAD_HUMAN
T92460	TARGNAME	Guanine deaminase (GDA)
T92460	GENENAME	GDA
T92460	TARGTYPE	Literature-reported
T92460	SYNONYMS	p51-nedasin; KIAA1258; Guanine aminohydrolase; Guanase; GAH
T92460	FUNCTION	Catalyzes the hydrolytic deamination of guanine, producing xanthine and ammonia.
T92460	PDBSTRUC	4AQL; 3E0L; 2UZ9
T92460	BIOCLASS	Metallo-dependent hydrolase superfamily. ATZ/TRZ family
T92460	ECNUMBER	EC 3.5.4.3
T92460	SEQUENCE	MCAAQMPPLAHIFRGTFVHSTWTCPMEVLRDHLLGVSDSGKIVFLEEASQQEKLAKEWCFKPCEIRELSHHEFFMPGLVDTHIHASQYSFAGSSIDLPLLEWLTKYTFPAEHRFQNIDFAEEVYTRVVRRTLKNGTTTACYFATIHTDSSLLLADITDKFGQRAFVGKVCMDLNDTFPEYKETTEESIKETERFVSEMLQKNYSRVKPIVTPRFSLSCSETLMGELGNIAKTRDLHIQSHISENRDEVEAVKNLYPSYKNYTSVYDKNNLLTNKTVMAHGCYLSAEELNVFHERGASIAHCPNSNLSLSSGFLNVLEVLKHEVKIGLGTDVAGGYSYSMLDAIRRAVMVSNILLINKVNEKSLTLKEVFRLATLGGSQALGLDGEIGNFEVGKEFDAILINPKASDSPIDLFYGDFFGDISEAVIQKFLYLGDDRNIEEVYVGGKQVVPFSSSV

T73502	TARGETID	T73502
T73502	FORMERID	TTDR01340
T73502	UNIPROID	WWP2_HUMAN
T73502	TARGNAME	WWP2 messenger RNA (WWP2 mRNA)
T73502	GENENAME	WWP2
T73502	TARGTYPE	Literature-reported
T73502	SYNONYMS	WW domaincontaining protein 2 (mRNA); WW domain-containing protein 2 (mRNA); NEDD4like E3 ubiquitinprotein ligaseWWP2 (mRNA); HECT-type E3 ubiquitin transferase WWP2 (mRNA); Atrophin1interacting protein 2 (mRNA); Atrophin-1-interacting protein 2 (mRNA); AIP2 (mRNA)
T73502	FUNCTION	Polyubiquitinates POU5F1 by 'Lys-63'-linked conjugation and promotes it to proteasomal degradation; in embryonic stem cells (ESCs) the ubiquitination is proposed to regulate POU5F1 protein level. Ubiquitinates EGR2 and promotes it to proteasomal degradation; in T-cells the ubiquitination inhibits activation-induced cell death. Ubiquitinates SLC11A2; the ubiquitination is enhanced by presence of NDFIP1 and NDFIP2. Ubiquitinates RPB1 and promotes it to proteasomal degradation. E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates.
T73502	PDBSTRUC	5TJQ; 5TJ8; 5TJ7; 4Y07
T73502	BIOCLASS	mRNA target
T73502	ECNUMBER	EC 2.3.2.26
T73502	SEQUENCE	MASASSSRAGVALPFEKSQLTLKVVSAKPKVHNRQPRINSYVEVAVDGLPSETKKTGKRIGSSELLWNEIIILNVTAQSHLDLKVWSCHTLRNELLGTASVNLSNVLKNNGGKMENMQLTLNLQTENKGSVVSGGELTIFLDGPTVDLGNVPNGSALTDGSQLPSRDSSGTAVAPENRHQPPSTNCFGGRSRTHRHSGASARTTPATGEQSPGARSRHRQPVKNSGHSGLANGTVNDEPTTATDPEEPSVVGVTSPPAAPLSVTPNPNTTSLPAPATPAEGEEPSTSGTQQLPAAAQAPDALPAGWEQRELPNGRVYYVDHNTKTTTWERPLPPGWEKRTDPRGRFYYVDHNTRTTTWQRPTAEYVRNYEQWQSQRNQLQGAMQHFSQRFLYQSSSASTDHDPLGPLPPGWEKRQDNGRVYYVNHNTRTTQWEDPRTQGMIQEPALPPGWEMKYTSEGVRYFVDHNTRTTTFKDPRPGFESGTKQGSPGAYDRSFRWKYHQFRFLCHSNALPSHVKISVSRQTLFEDSFQQIMNMKPYDLRRRLYIIMRGEEGLDYGGIAREWFFLLSHEVLNPMYCLFEYAGKNNYCLQINPASSINPDHLTYFRFIGRFIAMALYHGKFIDTGFTLPFYKRMLNKRPTLKDLESIDPEFYNSIVWIKENNLEECGLELYFIQDMEILGKVTTHELKEGGESIRVTEENKEEYIMLLTDWRFTRGVEEQTKAFLDGFNEVAPLEWLRYFDEKELELMLCGMQEIDMSDWQKSTIYRHYTKNSKQIQWFWQVVKEMDNEKRIRLLQFVTGTCRLPVGGFAELIGSNGPQKFCIDKVGKETWLPRSHTCFNRLDLPPYKSYEQLREKLLYAIEETEGFGQE
T73502	DRUGINFO	D02LZA	ISIS 103669	Investigative
T73502	DRUGINFO	D03IWY	ISIS 103806	Investigative
T73502	DRUGINFO	D04WJM	ISIS 103803	Investigative
T73502	DRUGINFO	D07WFF	ISIS 103708	Investigative
T73502	DRUGINFO	D08CQR	ISIS 103771	Investigative
T73502	DRUGINFO	D08CYT	ISIS 103701	Investigative
T73502	DRUGINFO	D0DR3J	ISIS 103752	Investigative
T73502	DRUGINFO	D0F5YL	ISIS 103736	Investigative
T73502	DRUGINFO	D0F8GZ	ISIS 103819	Investigative
T73502	DRUGINFO	D0J2ZI	ISIS 103747	Investigative
T73502	DRUGINFO	D0M4LN	ISIS 103671	Investigative

T57292	TARGETID	T57292
T57292	FORMERID	TTDC00284
T57292	UNIPROID	POL_HV1B1
T57292	TARGNAME	Human immunodeficiency virus RT messenger RNA (HIV RT mRNA)
T57292	GENENAME	HIV RT mRNA
T57292	TARGTYPE	Literature-reported
T57292	SYNONYMS	gag-pol (588-1147) (mRNA); Pr160Gag-Pol (588-1147) (mRNA); Gag-Pol polyprotein (588-1147) (mRNA)
T57292	FUNCTION	Gag-Pol polyprotein may regulate its own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, the polyprotein would promote translation, whereas at high concentration, the polyprotein would encapsidate genomic RNA and then shut off translation. Gag-Pol polyprotein: Mediates, with Gag polyprotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi).
T57292	PDBSTRUC	6OE3; 6HAK; 6ELI; 6DUH; 6DUG
T57292	BIOCLASS	mRNA target
T57292	ECNUMBER	EC 2.7.7.49
T57292	SEQUENCE	PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKITTESIVIWGKTPKFKLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTNKGRQKVVPLTNTTNQKTELQAIYLALQDSGLEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKEKVYLAWVPAHKGIGGNEQVDKLVSAGIRKIL

T68227	TARGETID	T68227
T68227	FORMERID	TTDR01363
T68227	UNIPROID	JUN_HUMAN
T68227	TARGNAME	c-Jun messenger RNA (c-Jun mRNA)
T68227	GENENAME	JUN
T68227	TARGTYPE	Literature-reported
T68227	SYNONYMS	V-jun avian sarcoma virus 17 oncogene homolog (mRNA); Transcription factor AP-1 (mRNA); Proto-oncogene c-jun (mRNA); P39 (mRNA); C-jun proto-oncogene (mRNA); Activator protein-1 (mRNA); Activator protein 1 (mRNA); AP1 (mRNA); AP-1 transcription factor (mRNA)
T68227	FUNCTION	Promotes activity of NR5A1 when phosphorylated by HIPK3 leading to increased steroidogenic gene expression upon cAMP signaling pathway stimulation. Involved in activated KRAS-mediated transcriptional activation of USP28 in colorectal cancer (CRC) cells. Binds to the USP28 promoter in colorectal cancer (CRC) cells. Transcription factor that recognizes and binds to the enhancer heptamer motif 5'-TGA[CG]TCA-3'.
T68227	PDBSTRUC	5T01; 5FV8; 1T2K; 1S9K; 1JNM
T68227	BIOCLASS	mRNA target
T68227	SEQUENCE	MTAKMETTFYDDALNASFLPSESGPYGYSNPKILKQSMTLNLADPVGSLKPHLRAKNSDLLTSPDVGLLKLASPELERLIIQSSNGHITTTPTPTQFLCPKNVTDEQEGFAEGFVRALAELHSQNTLPSVTSAAQPVNGAGMVAPAVASVAGGSGSGGFSASLHSEPPVYANLSNFNPGALSSGGGAPSYGAAGLAFPAQPQQQQQPPHHLPQQMPVQHPRLQALKEEPQTVPEMPGETPPLSPIDMESQERIKAERKRMRNRIAASKCRKRKLERIARLEEKVKTLKAQNSELASTANMLREQVAQLKQKVMNHVNSGCQLMLTQQLQTF
T68227	DRUGINFO	D04HFC	[(R)-(+)-deoxytylophorinidine	Investigative
T68227	DRUGINFO	D0B0PX	ISIS 10582	Investigative
T68227	DRUGINFO	D0Y9AQ	DCB-3503	Investigative
T68227	DRUGINFO	D0T1XE	Pergularinine	Investigative

T64977	TARGETID	T64977
T64977	FORMERID	TTDI02245
T64977	UNIPROID	IGF1R_HUMAN
T64977	TARGNAME	IGF1R messenger RNA (IGF1R mRNA)
T64977	GENENAME	IGF1R
T64977	TARGTYPE	Literature-reported
T64977	SYNONYMS	Type 1 insulin-like growth factor receptor (mRNA); Insulin-like growth factor 1 receptor (mRNA); IGF-IR (mRNA); IGF-I receptor (mRNA); IGF-1R (mRNA); IGF-1 receptor (mRNA); CD221 antigen (mRNA); CD221 (mRNA)
T64977	FUNCTION	Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R. Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1).
T64977	PDBSTRUC	5U8R; 5U8Q; 5HZN; 5FXS; 5FXR
T64977	BIOCLASS	mRNA target
T64977	ECNUMBER	EC 2.7.10.1
T64977	SEQUENCE	MKSGSGGGSPTSLWGLLFLSAALSLWPTSGEICGPGIDIRNDYQQLKRLENCTVIEGYLHILLISKAEDYRSYRFPKLTVITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIFEMTNLKDIGLYNLRNITRGAIRIEKNADLCYLSTVDWSLILDAVSNNYIVGNKPPKECGDLCPGTMEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSTCGKRACTENNECCHPECLGSCSAPDNDTACVACRHYYYAGVCVPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHDGECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEEKKTKTIDSVTSAQMLQGCTIFKGNLLINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSFYVLDNQNLQQLWDWDHRNLTIKAGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTRNNGERASCESDVLHFTSTTTSKNRIIITWHRYRPPDYRDLISFTVYYKEAPFKNVTEYDGQDACGSNSWNMVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAVTLTMVENDHIRGAKSEILYIRTNASVPSIPLDVLSASNSSSQLIVKWNPPSLPNGNLSYYIVRWQRQPQDGYLYRHNYCSKDKIPIRKYADGTIDIEEVTENPKTEVCGGEKGPCCACPKTEAEKQAEKEEAEYRKVFENFLHNSIFVPRPERKRRDVMQVANTTMSSRSRNTTAADTYNITDPEELETEYPFFESRVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEGADDIPGPVTWEPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECVSRQEYRKYGGAKLNRLNPGNYTARIQATSLSGNGSWTDPVFFYVQAKTGYENFIHLIIALPVAVLLIVGGLVIMLYVFHRKRNNSRLGNGVLYASVNPEYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKGVVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIMELMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARNCMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGVVLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFLEIISSIKEEMEPGFREVSFYYSEENKLPEPEELDLEPENMESVPLDPSASSSSLPLPDRHSGHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALPLPQSSTC
T64977	DRUGINFO	D01QKD	ATL-1101	Preclinical
T64977	DRUGINFO	D01ODR	AG 1024	Investigative
T64977	DRUGINFO	D0B4SU	PQ401	Investigative
T64977	DRUGINFO	D0E4LC	GSK1511931	Investigative
T64977	DRUGINFO	D0O7LU	AZD3463	Investigative
T64977	DRUGINFO	D06PJW	GSK-1838705A	Investigative

T58074	TARGETID	T58074
T58074	FORMERID	TTDI02659
T58074	UNIPROID	MMP2_HUMAN
T58074	TARGNAME	MMP2 messenger RNA (MMP2 mRNA)
T58074	GENENAME	MMP2
T58074	TARGTYPE	Literature-reported
T58074	SYNONYMS	TBE-1 (mRNA); Matrix metalloproteinase 2 (mRNA); Gelatinase A (mRNA); CLG4A (mRNA); 72 kDa type IV collagenase (mRNA); 72 kDa gelatinase (mRNA)
T58074	FUNCTION	As well as degrading extracellular matrix proteins, can also act on several nonmatrix proteins such as big endothelial 1 and beta-type CGRP promoting vasoconstriction. Also cleaves KISS at a Gly-|-Leu bond. Appears to have a role in myocardial cell death pathways. Contributes to myocardial oxidative stress by regulating the activity of GSK3beta. Cleaves GSK3beta in vitro. Involved in the formation of the fibrovascular tissues in association with MMP14. Ubiquitinous metalloproteinase that is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture.
T58074	PDBSTRUC	3AYU; 1RTG; 1QIB; 1KS0; 1J7M
T58074	BIOCLASS	mRNA target
T58074	ECNUMBER	EC 3.4.24.24
T58074	SEQUENCE	MEALMARGALTGPLRALCLLGCLLSHAAAAPSPIIKFPGDVAPKTDKELAVQYLNTFYGCPKESCNLFVLKDTLKKMQKFFGLPQTGDLDQNTIETMRKPRCGNPDVANYNFFPRKPKWDKNQITYRIIGYTPDLDPETVDDAFARAFQVWSDVTPLRFSRIHDGEADIMINFGRWEHGDGYPFDGKDGLLAHAFAPGTGVGGDSHFDDDELWTLGEGQVVRVKYGNADGEYCKFPFLFNGKEYNSCTDTGRSDGFLWCSTTYNFEKDGKYGFCPHEALFTMGGNAEGQPCKFPFRFQGTSYDSCTTEGRTDGYRWCGTTEDYDRDKKYGFCPETAMSTVGGNSEGAPCVFPFTFLGNKYESCTSAGRSDGKMWCATTANYDDDRKWGFCPDQGYSLFLVAAHEFGHAMGLEHSQDPGALMAPIYTYTKNFRLSQDDIKGIQELYGASPDIDLGTGPTPTLGPVTPEICKQDIVFDGIAQIRGEIFFFKDRFIWRTVTPRDKPMGPLLVATFWPELPEKIDAVYEAPQEEKAVFFAGNEYWIYSASTLERGYPKPLTSLGLPPDVQRVDAAFNWSKNKKTYIFAGDKFWRYNEVKKKMDPGFPKLIADAWNAIPDNLDAVVDLQGGGHSYFFKGAYYLKLENQSLKSVKFGSIKSDWLGC

T93690	TARGETID	T93690
T93690	FORMERID	TTDI02660
T93690	UNIPROID	MMP9_HUMAN
T93690	TARGNAME	MMP9 messenger RNA (MMP9 mRNA)
T93690	GENENAME	MMP9
T93690	TARGTYPE	Literature-reported
T93690	SYNONYMS	Matrix metalloproteinase 9 (mRNA); Gelatinase B (mRNA); GELB (mRNA); CLG4B (mRNA); 92 kDa type IV collagenase (mRNA); 92 kDa gelatinase (mRNA)
T93690	FUNCTION	Could play a role in bone osteoclastic resorption. Cleaves KiSS1 at a Gly-|-Leu bond. Cleaves type IV and type V collagen into large C-terminal three quarter fragments and shorter N-terminal one quarter fragments. Degrades fibronectin but not laminin or Pz-peptide. May play an essential role in local proteolysis of the extracellular matrix and in leukocyte migration.
T93690	PDBSTRUC	6ESM; 5UE4; 5UE3; 5TH9; 5TH6
T93690	BIOCLASS	mRNA target
T93690	ECNUMBER	EC 3.4.24.35
T93690	SEQUENCE	MSLWQPLVLVLLVLGCCFAAPRQRQSTLVLFPGDLRTNLTDRQLAEEYLYRYGYTRVAEMRGESKSLGPALLLLQKQLSLPETGELDSATLKAMRTPRCGVPDLGRFQTFEGDLKWHHHNITYWIQNYSEDLPRAVIDDAFARAFALWSAVTPLTFTRVYSRDADIVIQFGVAEHGDGYPFDGKDGLLAHAFPPGPGIQGDAHFDDDELWSLGKGVVVPTRFGNADGAACHFPFIFEGRSYSACTTDGRSDGLPWCSTTANYDTDDRFGFCPSERLYTQDGNADGKPCQFPFIFQGQSYSACTTDGRSDGYRWCATTANYDRDKLFGFCPTRADSTVMGGNSAGELCVFPFTFLGKEYSTCTSEGRGDGRLWCATTSNFDSDKKWGFCPDQGYSLFLVAAHEFGHALGLDHSSVPEALMYPMYRFTEGPPLHKDDVNGIRHLYGPRPEPEPRPPTTTTPQPTAPPTVCPTGPPTVHPSERPTAGPTGPPSAGPTGPPTAGPSTATTVPLSPVDDACNVNIFDAIAEIGNQLYLFKDGKYWRFSEGRGSRPQGPFLIADKWPALPRKLDSVFEERLSKKLFFFSGRQVWVYTGASVLGPRRLDKLGLGADVAQVTGALRSGRGKMLLFSGRRLWRFDVKAQMVDPRSASEVDRMFPGVPLDTHDVFQYREKAYFCQDRFYWRVSSRSELNQVDQVGYVTYDILQCPED

T06413	TARGETID	T06413
T06413	FORMERID	TTDC00287
T06413	UNIPROID	KPCA_HUMAN
T06413	TARGNAME	PKC-alpha messenger RNA (PRKCA mRNA)
T06413	GENENAME	PRKCA
T06413	TARGTYPE	Literature-reported
T06413	SYNONYMS	Protein kinase C alpha type (mRNA); Protein Kinase C alpha (mRNA); PRKACA (mRNA); PKCalpha (mRNA); PKCA (mRNA); PKC-alpha (mRNA); PKC-A (mRNA)
T06413	FUNCTION	Involved in cell proliferation and cell growth arrest by positive and negative regulation of the cell cycle. Can promote cell growth by phosphorylating and activating RAF1, which mediates the activation of the MAPK/ERK signaling cascade, and/or by up-regulating CDKN1A, which facilitates active cyclin-dependent kinase (CDK) complex formation in glioma cells. In intestinal cells stimulated by the phorbol ester PMA, can trigger a cell cycle arrest program which is associated with the accumulation of the hyper-phosphorylated growth-suppressive form of RB1 and induction of the CDK inhibitors CDKN1A and CDKN1B. Exhibits anti-apoptotic function in glioma cells and protects them from apoptosis by suppressing the p53/TP53-mediated activation of IGFBP3, and in leukemia cells mediates anti-apoptotic action by phosphorylating BCL2. During macrophage differentiation induced by macrophage colony-stimulating factor (CSF1), is translocated to the nucleus and is associated with macrophage development. After wounding, translocates from focal contacts to lamellipodia and participates in the modulation of desmosomal adhesion. Plays a role in cell motility by phosphorylating CSPG4, which induces association of CSPG4 with extensive lamellipodia at the cell periphery and polarization of the cell accompanied by increases in cell motility. During chemokine-induced CD4(+) T cell migration, phosphorylates CDC42-guanine exchange factor DOCK8 resulting in its dissociation from LRCH1 and the activation of GTPase CDC42. Is highly expressed in a number of cancer cells where it can act as a tumor promoter and is implicated in malignant phenotypes of several tumors such as gliomas and breast cancers. Negatively regulates myocardial contractility and positively regulates angiogenesis, platelet aggregation and thrombus formation in arteries. Mediates hypertrophic growth of neonatal cardiomyocytes, in part through a MAPK1/3 (ERK1/2)-dependent signaling pathway, and upon PMA treatment, is required to induce cardiomyocyte hypertrophy up to heart failure and death, by increasing protein synthesis, protein-DNA ratio and cell surface area. Regulates cardiomyocyte function by phosphorylating cardiac troponin T (TNNT2/CTNT), which induces significant reduction in actomyosin ATPase activity, myofilament calcium sensitivity and myocardial contractility. In angiogenesis, is required for full endothelial cell migration, adhesion to vitronectin (VTN), and vascular endothelial growth factor A (VEGFA)-dependent regulation of kinase activation and vascular tube formation. Involved in the stabilization of VEGFA mRNA at post-transcriptional level and mediates VEGFA-induced cell proliferation. In the regulation of calcium-induced platelet aggregation, mediates signals from the CD36/GP4 receptor for granule release, and activates the integrin heterodimer ITGA2B-ITGB3 through the RAP1GAP pathway for adhesion. During response to lipopolysaccharides (LPS), may regulate selective LPS-induced macrophage functions involved in host defense and inflammation. But in some inflammatory responses, may negatively regulate NF-kappa-B-induced genes, through IL1A-dependent induction of NF-kappa-B inhibitor alpha (NFKBIA/IKBA). Upon stimulation with 12-O-tetradecanoylphorbol-13-acetate (TPA), phosphorylates EIF4G1, which modulates EIF4G1 binding to MKNK1 and may be involved in the regulation of EIF4E phosphorylation. Phosphorylates KIT, leading to inhibition of KIT activity. Phosphorylates ATF2 which promotes cooperation between ATF2 and JUN, activating transcription. Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that is involved in positive and negative regulation of cell proliferation, apoptosis, differentiation, migration and adhesion, tumorigenesis, cardiac hypertrophy, angiogenesis, platelet function and inflammation, by directly phosphorylating targets such as RAF1, BCL2, CSPG4, TNNT2/CTNT, or activating signaling cascade involving MAPK1/3 (ERK1/2) and RAP1GAP.
T06413	PDBSTRUC	4RA4; 4DNL; 3IW4; 2ELI
T06413	BIOCLASS	mRNA target
T06413	ECNUMBER	EC 2.7.11.13
T06413	SEQUENCE	MADVFPGNDSTASQDVANRFARKGALRQKNVHEVKDHKFIARFFKQPTFCSHCTDFIWGFGKQGFQCQVCCFVVHKRCHEFVTFSCPGADKGPDTDDPRSKHKFKIHTYGSPTFCDHCGSLLYGLIHQGMKCDTCDMNVHKQCVINVPSLCGMDHTEKRGRIYLKAEVADEKLHVTVRDAKNLIPMDPNGLSDPYVKLKLIPDPKNESKQKTKTIRSTLNPQWNESFTFKLKPSDKDRRLSVEIWDWDRTTRNDFMGSLSFGVSELMKMPASGWYKLLNQEEGEYYNVPIPEGDEEGNMELRQKFEKAKLGPAGNKVISPSEDRKQPSNNLDRVKLTDFNFLMVLGKGSFGKVMLADRKGTEELYAIKILKKDVVIQDDDVECTMVEKRVLALLDKPPFLTQLHSCFQTVDRLYFVMEYVNGGDLMYHIQQVGKFKEPQAVFYAAEISIGLFFLHKRGIIYRDLKLDNVMLDSEGHIKIADFGMCKEHMMDGVTTRTFCGTPDYIAPEIIAYQPYGKSVDWWAYGVLLYEMLAGQPPFDGEDEDELFQSIMEHNVSYPKSLSKEAVSVCKGLMTKHPAKRLGCGPEGERDVREHAFFRRIDWEKLENREIQPPFKPKVCGKGAENFDKFFTRGQPVLTPPDQLVIANIDQSDFEGFSYVNPQFVHPILQSAV
T06413	DRUGINFO	D00SIC	ISIS 4189	Investigative
T06413	DRUGINFO	D02MFK	Affinitak + Cisplatin	Investigative
T06413	DRUGINFO	D0A2PN	ISIS 9606	Investigative
T06413	DRUGINFO	D0K4GI	Affinitak + Gemcitabine	Investigative

T04084	TARGETID	T04084
T04084	FORMERID	TTDI02685
T04084	UNIPROID	ERBB3_HUMAN
T04084	TARGNAME	ERBB3 messenger RNA (ERBB3 mRNA)
T04084	GENENAME	ERBB3
T04084	TARGTYPE	Literature-reported
T04084	SYNONYMS	Tyrosine kinase-type cell surface receptor HER3 (mRNA); Receptor tyrosine-protein kinase erbB-3 (mRNA); Proto-oncogene-like protein c-ErbB-3 (mRNA); HER3 (mRNA); C-erbB3 (mRNA); C-erbB-3 protein (mRNA)
T04084	FUNCTION	Binds to neuregulin-1 (NRG1) and is activated by it; ligand-binding increases phosphorylation on tyrosine residues and promotes its association with the p85 subunit of phosphatidylinositol 3-kinase. May also be activated by CSPG5. Involved in the regulation of myeloid cell differentiation. Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins.
T04084	PDBSTRUC	5O7P; 5O4O; 5CUS; 4RIY; 4RIX
T04084	BIOCLASS	mRNA target
T04084	ECNUMBER	EC 2.7.10.1
T04084	SEQUENCE	MRANDALQVLGLLFSLARGSEVGNSQAVCPGTLNGLSVTGDAENQYQTLYKLYERCEVVMGNLEIVLTGHNADLSFLQWIREVTGYVLVAMNEFSTLPLPNLRVVRGTQVYDGKFAIFVMLNYNTNSSHALRQLRLTQLTEILSGGVYIEKNDKLCHMDTIDWRDIVRDRDAEIVVKDNGRSCPPCHEVCKGRCWGPGSEDCQTLTKTICAPQCNGHCFGPNPNQCCHDECAGGCSGPQDTDCFACRHFNDSGACVPRCPQPLVYNKLTFQLEPNPHTKYQYGGVCVASCPHNFVVDQTSCVRACPPDKMEVDKNGLKMCEPCGGLCPKACEGTGSGSRFQTVDSSNIDGFVNCTKILGNLDFLITGLNGDPWHKIPALDPEKLNVFRTVREITGYLNIQSWPPHMHNFSVFSNLTTIGGRSLYNRGFSLLIMKNLNVTSLGFRSLKEISAGRIYISANRQLCYHHSLNWTKVLRGPTEERLDIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEPREFAHEAECFSCHPECQPMEGTATCNGSGSDTCAQCAHFRDGPHCVSSCPHGVLGAKGPIYKYPDVQNECRPCHENCTQGCKGPELQDCLGQTLVLIGKTHLTMALTVIAGLVVIFMMLGGTFLYWRGRRIQNKRAMRRYLERGESIEPLDPSEKANKVLARIFKETELRKLKVLGSGVFGTVHKGVWIPEGESIKIPVCIKVIEDKSGRQSFQAVTDHMLAIGSLDHAHIVRLLGLCPGSSLQLVTQYLPLGSLLDHVRQHRGALGPQLLLNWGVQIAKGMYYLEEHGMVHRNLAARNVLLKSPSQVQVADFGVADLLPPDDKQLLYSEAKTPIKWMALESIHFGKYTHQSDVWSYGVTVWELMTFGAEPYAGLRLAEVPDLLEKGERLAQPQICTIDVYMVMVKCWMIDENIRPTFKELANEFTRMARDPPRYLVIKRESGPGIAPGPEPHGLTNKKLEEVELEPELDLDLDLEAEEDNLATTTLGSALSLPVGTLNRPRGSQSLLSPSSGYMPMNQGNLGESCQESAVSGSSERCPRPVSLHPMPRGCLASESSEGHVTGSEAELQEKVSMCRSRSRSRSPRPRGDSAYHSQRHSLLTPVTPLSPPGLEEEDVNGYVMPDTHLKGTPSSREGTLSSVGLSSVLGTEEEDEDEEYEYMNRRRRHSPPHPPRPSSLEELGYEYMDVGSDLSASLGSTQSCPLHPVPIMPTAGTTPDEDYEYMNRQRDGGGPGGDYAAMGACPASEQGYEEMRAFQGPGHQAPHVHYARLKTLRSLEATDSAFDNPDYWHSRLFPKANAQRT
T04084	DRUGINFO	D0VV5X	EZN-3920	Investigative

T95594	TARGETID	T95594
T95594	FORMERID	TTDR01390
T95594	UNIPROID	PK3CB_HUMAN
T95594	TARGNAME	PI3K p110 beta messenger RNA (PIK3CB mRNA)
T95594	GENENAME	PIK3CB
T95594	TARGTYPE	Literature-reported
T95594	SYNONYMS	p110beta (mRNA); PtdIns3kinase subunit p110beta (mRNA); PtdIns3kinase subunit beta (mRNA); PtdIns-3-kinase subunit p110-beta (mRNA); PtdIns-3-kinase subunit beta (mRNA); Phosphatidylinositol 4,5bisphosphate 3kinase catalytic subunitbeta isoform (mRNA); Phosphatidylinositol 4,5bisphosphate 3kinase 110 kDa catalyticsubunit beta (mRNA); Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform (mRNA); Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit beta (mRNA); PIK3C1 (mRNA); PI3kinase subunit beta (mRNA); PI3Kbeta (mRNA); PI3K-beta (mRNA); PI3-kinase subunit beta (mRNA)
T95594	FUNCTION	Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns (Phosphatidylinositol), PtdIns4P (Phosphatidylinositol 4-phosphate) and PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Involved in the activation of AKT1 upon stimulation by G-protein coupled receptors (GPCRs) ligands such as CXCL12, sphingosine 1-phosphate, and lysophosphatidic acid. May also act downstream receptor tyrosine kinases. Required in different signaling pathways for stable platelet adhesion and aggregation. Plays a role in platelet activation signaling triggered by GPCRs, alpha-IIb/beta-3 integrins (ITGA2B/ ITGB3) and ITAM (immunoreceptor tyrosine-based activation motif)-bearing receptors such as GP6. Regulates the strength of adhesion of ITGA2B/ ITGB3 activated receptors necessary for the cellular transmission of contractile forces. Required for platelet aggregation induced by F2 (thrombin) and thromboxane A2 (TXA2). Has a role in cell survival. May have a role in cell migration. Involved in the early stage of autophagosome formation. Modulates the intracellular level of PtdIns3P (Phosphatidylinositol 3-phosphate) and activates PIK3C3 kinase activity. May act as a scaffold, independently of its lipid kinase activity to positively regulate autophagy. May have a role in insulin signaling as scaffolding protein in which the lipid kinase activity is not required. May have a kinase-independent function in regulating cell proliferation and in clathrin-mediated endocytosis. Mediator of oncogenic signal in cell lines lacking PTEN. The lipid kinase activity is necessary for its role in oncogenic transformation. Required for the growth of ERBB2 and RAS driven tumors.
T95594	BIOCLASS	mRNA target
T95594	ECNUMBER	EC 2.7.1.153
T95594	SEQUENCE	MCFSFIMPPAMADILDIWAVDSQIASDGSIPVDFLLPTGIYIQLEVPREATISYIKQMLWKQVHNYPMFNLLMDIDSYMFACVNQTAVYEELEDETRRLCDVRPFLPVLKLVTRSCDPGEKLDSKIGVLIGKGLHEFDSLKDPEVNEFRRKMRKFSEEKILSLVGLSWMDWLKQTYPPEHEPSIPENLEDKLYGGKLIVAVHFENCQDVFSFQVSPNMNPIKVNELAIQKRLTIHGKEDEVSPYDYVLQVSGRVEYVFGDHPLIQFQYIRNCVMNRALPHFILVECCKIKKMYEQEMIAIEAAINRNSSNLPLPLPPKKTRIISHVWENNNPFQIVLVKGNKLNTEETVKVHVRAGLFHGTELLCKTIVSSEVSGKNDHIWNEPLEFDINICDLPRMARLCFAVYAVLDKVKTKKSTKTINPSKYQTIRKAGKVHYPVAWVNTMVFDFKGQLRTGDIILHSWSSFPDELEEMLNPMGTVQTNPYTENATALHVKFPENKKQPYYYPPFDKIIEKAAEIASSDSANVSSRGGKKFLPVLKEILDRDPLSQLCENEMDLIWTLRQDCREIFPQSLPKLLLSIKWNKLEDVAQLQALLQIWPKLPPREALELLDFNYPDQYVREYAVGCLRQMSDEELSQYLLQLVQVLKYEPFLDCALSRFLLERALGNRRIGQFLFWHLRSEVHIPAVSVQFGVILEAYCRGSVGHMKVLSKQVEALNKLKTLNSLIKLNAVKLNRAKGKEAMHTCLKQSAYREALSDLQSPLNPCVILSELYVEKCKYMDSKMKPLWLVYNNKVFGEDSVGVIFKNGDDLRQDMLTLQMLRLMDLLWKEAGLDLRMLPYGCLATGDRSGLIEVVSTSETIADIQLNSSNVAAAAAFNKDALLNWLKEYNSGDDLDRAIEEFTLSCAGYCVASYVLGIGDRHSDNIMVKKTGQLFHIDFGHILGNFKSKFGIKRERVPFILTYDFIHVIQQGKTGNTEKFGRFRQCCEDAYLILRRHGNLFITLFALMLTAGLPELTSVKDIQYLKDSLALGKSEEEALKQFKQKFDEALRESWTTKVNWMAHTVRKDYRS
T95594	DRUGINFO	D00TQI	ISIS 32014	Investigative
T95594	DRUGINFO	D01DFK	ISIS 32024	Investigative
T95594	DRUGINFO	D02IBE	ISIS 32035	Investigative
T95594	DRUGINFO	D04PYV	ISIS 32000	Investigative
T95594	DRUGINFO	D05YJU	ISIS 32021	Investigative
T95594	DRUGINFO	D06FJE	ISIS 32003	Investigative
T95594	DRUGINFO	D06IZU	ISIS 32028	Investigative
T95594	DRUGINFO	D07NAT	ISIS 32039	Investigative
T95594	DRUGINFO	D08SMF	ISIS 32005	Investigative
T95594	DRUGINFO	D09WIW	ISIS 32008	Investigative
T95594	DRUGINFO	D0A5LZ	ISIS 32006	Investigative
T95594	DRUGINFO	D0C1NA	ISIS 31982	Investigative
T95594	DRUGINFO	D0D9PL	ISIS 31963	Investigative
T95594	DRUGINFO	D0H7CG	ISIS 32020	Investigative
T95594	DRUGINFO	D0QH9X	ISIS 32004	Investigative
T95594	DRUGINFO	D0U8DY	ISIS 32002	Investigative
T95594	DRUGINFO	D0V9MH	ISIS 32015	Investigative
T95594	DRUGINFO	D0W3RP	ISIS 32010	Investigative
T95594	DRUGINFO	D0Z4LP	ISIS 31996	Investigative
T95594	DRUGINFO	D05BPX	3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol	Investigative
T95594	DRUGINFO	D07APP	LY-292223	Investigative
T95594	DRUGINFO	D0W1ST	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	Investigative

T91292	TARGETID	T91292
T91292	FORMERID	TTDR00989
T91292	UNIPROID	MTHR_HUMAN
T91292	TARGNAME	MTHFR messenger RNA (MTHFR mRNA)
T91292	GENENAME	MTHFR
T91292	TARGTYPE	Literature-reported
T91292	SYNONYMS	Methylenetetrahydrofolate reductase (mRNA)
T91292	FUNCTION	Catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-substrate for homocysteine remethylation to methionine.
T91292	PDBSTRUC	6FCX
T91292	BIOCLASS	mRNA target
T91292	ECNUMBER	EC 1.5.1.20
T91292	SEQUENCE	MVNEARGNSSLNPCLEGSASSGSESSKDSSRCSTPGLDPERHERLREKMRRRLESGDKWFSLEFFPPRTAEGAVNLISRFDRMAAGGPLYIDVTWHPAGDPGSDKETSSMMIASTAVNYCGLETILHMTCCRQRLEEITGHLHKAKQLGLKNIMALRGDPIGDQWEEEEGGFNYAVDLVKHIRSEFGDYFDICVAGYPKGHPEAGSFEADLKHLKEKVSAGADFIITQLFFEADTFFRFVKACTDMGITCPIVPGIFPIQGYHSLRQLVKLSKLEVPQEIKDVIEPIKDNDAAIRNYGIELAVSLCQELLASGLVPGLHFYTLNREMATTEVLKRLGMWTEDPRRPLPWALSAHPKRREEDVRPIFWASRPKSYIYRTQEWDEFPNGRWGNSSSPAFGELKDYYLFYLKSKSPKEELLKMWGEELTSEESVFEVFVLYLSGEPNRNGHKVTCLPWNDEPLAAETSLLKEELLRVNRQGILTINSQPNINGKPSSDPIVGWGPSGGYVFQKAYLEFFTSRETAEALLQVLKKYELRVNYHLVNVKGENITNAPELQPNAVTWGIFPGREIIQPTVVDPVSFMFWKDEAFALWIERWGKLYEEESPSRTIIQYIHDNYFLVNLVDNDFPLDNCLWQVVEDTLELLNRPTQNARETEAP
T91292	DRUGINFO	D08VKT	EX5	Investigative
T91292	DRUGINFO	D0L0AI	677T	Investigative

T58474	TARGETID	T58474
T58474	FORMERID	TTDR01398
T58474	UNIPROID	RHOA_HUMAN
T58474	TARGNAME	RhoA messenger RNA (RHOA mRNA)
T58474	GENENAME	RHOA
T58474	TARGTYPE	Literature-reported
T58474	SYNONYMS	h12 (mRNA); Transforming protein RhoA (mRNA); Rho cDNA clone 12 (mRNA); RHO12 (mRNA); ARHA (mRNA); ARH12 (mRNA)
T58474	FUNCTION	Involved in a microtubule-dependent signal that is required for the myosin contractile ring formation during cell cycle cytokinesis. Plays an essential role in cleavage furrow formation. Required for the apical junction formation of keratinocyte cell-cell adhesion. Stimulates PKN2 kinase activity. May be an activator of PLCE1. Activated by ARHGEF2, which promotes the exchange of GDP for GTP. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. The MEMO1-RHOA-DIAPH1 signaling pathway plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. It controls the localization of APC and CLASP2 to the cell membrane, via the regulation of GSK3B activity. In turn, membrane-bound APC allows the localization of the MACF1 to the cell membrane, which is required for microtubule capture and stabilization. Regulates a signal transduction pathway linking plasma membrane receptors to the assembly of focal adhesions and actin stress fibers. Involved in a microtubule-dependent signal that is required for the myosin contractile ring formation during cell cycle cytokinesis. Plays an essential role in cleavage furrow formation. Required for the apical junction formation of keratinocyte cell-cell adhesion. May be an activator of PLCE1. Activated by ARHGEF2, which promotes the exchange of GDP for GTP. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. The MEMO1-RHOA-DIAPH1 signaling pathway plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. It controls the localization of APC and CLASP2 to the cell membrane, via the regulation of GSK3B activity. In turn, membrane-bound APC allows the localization of the MACF1 to the cell membrane, which is required for microtubule capture and stabilization. Regulates KCNA2 potassium channel activity by reducing its location at the cell surface in response to CHRM1 activation; promotes KCNA2 endocytosis. Regulates a signal transduction pathway linking plasma membrane receptors to the assembly of focal adhesions and actin stress fibers.
T58474	PDBSTRUC	6R3V; 6BCB; 6BCA; 6BC0; 5ZHX
T58474	BIOCLASS	mRNA target
T58474	ECNUMBER	EC 3.6.5.2
T58474	SEQUENCE	MAAIRKKLVIVGDGACGKTCLLIVFSKDQFPEVYVPTVFENYVADIEVDGKQVELALWDTAGQEDYDRLRPLSYPDTDVILMCFSIDSPDSLENIPEKWTPEVKHFCPNVPIILVGNKKDLRNDEHTRRELAKMKQEPVKPEEGRDMANRIGAFGYMECSAKTKDGVREVFEMATRAALQARRGKKKSGCLVL
T58474	DRUGINFO	D00CWJ	ISIS 25565	Investigative
T58474	DRUGINFO	D09LKZ	ISIS 25554	Investigative
T58474	DRUGINFO	D0A5LC	ISIS 25563	Investigative
T58474	DRUGINFO	D0BJ0W	ISIS 25566	Investigative
T58474	DRUGINFO	D0L0UV	ISIS 25551	Investigative
T58474	DRUGINFO	D0L6LC	ISIS 25567	Investigative
T58474	DRUGINFO	D0NH5A	ISIS 25547	Investigative
T58474	DRUGINFO	D0NV8X	ISIS 25552	Investigative
T58474	DRUGINFO	D0R3CV	ISIS 25564	Investigative
T58474	DRUGINFO	D0XV1M	ISIS 25549	Investigative
T58474	DRUGINFO	D0Z5NN	ISIS 25544	Investigative

T74258	TARGETID	T74258
T74258	FORMERID	TTDR01403
T74258	UNIPROID	KPCZ_HUMAN
T74258	TARGNAME	PKC-zeta messenger RNA (PRKCZ mRNA)
T74258	GENENAME	PRKCZ
T74258	TARGTYPE	Literature-reported
T74258	SYNONYMS	Protein kinase C zeta type (mRNA); PKC2 (mRNA); NPKC-zeta (mRNA)
T74258	FUNCTION	Upon lipopolysaccharide (LPS) treatment in macrophages, or following mitogenic stimuli, functions downstream of PI3K to activate MAP2K1/MEK1-MAPK1/ERK2 signaling cascade independently of RAF1 activation. Required for insulin-dependent activation of AKT3, but may function as an adapter rather than a direct activator. Upon insulin treatment may act as a downstream effector of PI3K and contribute to the activation of translocation of the glucose transporter SLC2A4/GLUT4 and subsequent glucose transport in adipocytes. In EGF-induced cells, binds and activates MAP2K5/MEK5-MAPK7/ERK5 independently of its kinase activity and can activate JUN promoter through MEF2C. Through binding with SQSTM1/p62, functions in interleukin-1 signaling and activation of NF-kappa-B with the specific adapters RIPK1 and TRAF6. Participates in TNF-dependent transactivation of NF-kappa-B by phosphorylating and activating IKBKB kinase, which in turn leads to the degradation of NF-kappa-B inhibitors. In migrating astrocytes, forms a cytoplasmic complex with PARD6A and is recruited by CDC42 to function in the establishment of cell polarity along with the microtubule motor and dynein. In association with FEZ1, stimulates neuronal differentiation in PC12 cells. In the inflammatory response, is required for the T-helper 2 (Th2) differentiation process, including interleukin production, efficient activation of JAK1 and the subsequent phosphorylation and nuclear translocation of STAT6. May be involved in development of allergic airway inflammation (asthma), a process dependent on Th2 immune response. In the NF-kappa-B-mediated inflammatory response, can relieve SETD6-dependent repression of NF-kappa-B target genes by phosphorylating the RELA subunit at 'Ser-311'. In vein endothelial cells treated with the oxidant peroxynitrite, phosphorylates STK11 leading to nuclear export of STK11, subsequent inhibition of PI3K/Akt signaling, and increased apoptosis. Phosphorylates VAMP2 in vitro. Calcium- and diacylglycerol-independent serine/threonine-protein kinase that functions in phosphatidylinositol 3-kinase (PI3K) pathway and mitogen-activated protein (MAP) kinase cascade, and is involved in NF-kappa-B activation, mitogenic signaling, cell proliferation, cell polarity, inflammatory response and maintenance of long-term potentiation (LTP).
T74258	BIOCLASS	mRNA target
T74258	ECNUMBER	EC 2.7.11.13
T74258	SEQUENCE	MPSRTGPKMEGSGGRVRLKAHYGGDIFITSVDAATTFEELCEEVRDMCRLHQQHPLTLKWVDSEGDPCTVSSQMELEEAFRLARQCRDEGLIIHVFPSTPEQPGLPCPGEDKSIYRRGARRWRKLYRANGHLFQAKRFNRRAYCGQCSERIWGLARQGYRCINCKLLVHKRCHGLVPLTCRKHMDSVMPSQEPPVDDKNEDADLPSEETDGIAYISSSRKHDSIKDDSEDLKPVIDGMDGIKISQGLGLQDFDLIRVIGRGSYAKVLLVRLKKNDQIYAMKVVKKELVHDDEDIDWVQTEKHVFEQASSNPFLVGLHSCFQTTSRLFLVIEYVNGGDLMFHMQRQRKLPEEHARFYAAEICIALNFLHERGIIYRDLKLDNVLLDADGHIKLTDYGMCKEGLGPGDTTSTFCGTPNYIAPEILRGEEYGFSVDWWALGVLMFEMMAGRSPFDIITDNPDMNTEDYLFQVILEKPIRIPRFLSVKASHVLKGFLNKDPKERLGCRPQTGFSDIKSHAFFRSIDWDLLEKKQALPPFQPQITDDYGLDNFDTQFTSEPVQLTPDDEDAIKRIDQSEFEGFEYINPLLLSTEESV
T74258	DRUGINFO	D0R2TM	BALANOL	Terminated
T74258	DRUGINFO	D05WAM	ISIS 9008	Investigative
T74258	DRUGINFO	D06EPV	ISIS 9022	Investigative
T74258	DRUGINFO	D07AUV	ISIS 9023	Investigative
T74258	DRUGINFO	D0C1CA	ISIS 9007	Investigative
T74258	DRUGINFO	D0M2SC	ISIS 9025	Investigative
T74258	DRUGINFO	D06TLL	Go 6983	Investigative
T74258	DRUGINFO	D06ZCX	LY-326449	Investigative

T28444	TARGETID	T28444
T28444	FORMERID	TTDR01408
T28444	UNIPROID	DUS8_HUMAN
T28444	TARGNAME	DUSP8 messenger RNA (DUSP8 mRNA)
T28444	GENENAME	DUSP8
T28444	TARGTYPE	Literature-reported
T28444	SYNONYMS	VH5 (mRNA); Dual specificity protein phosphatase hVH-5 (mRNA); Dual specificity protein phosphatase 8 (mRNA); C11orf81 (mRNA)
T28444	FUNCTION	Expected to display protein phosphatase activity toward phosphotyrosine, phosphoserine and phosphothreonine residues. Has phosphatase activity with synthetic phosphatase substrates and negatively regulates mitogen-activated protein kinase activity, presumably by catalysing their dephosphorylation.
T28444	PDBSTRUC	4JMK
T28444	BIOCLASS	mRNA target
T28444	ECNUMBER	EC 3.1.3.16
T28444	SEQUENCE	MAGDRLPRKVMDAKKLASLLRGGPGGPLVIDSRSFVEYNSWHVLSSVNICCSKLVKRRLQQGKVTIAELIQPAARSQVEATEPQDVVVYDQSTRDASVLAADSFLSILLSKLDGCFDSVAILTGGFATFSSCFPGLCEGKPAALLPMSLSQPCLPVPSVGLTRILPHLYLGSQKDVLNKDLMTQNGISYVLNASNSCPKPDFICESRFMRVPINDNYCEKLLPWLDKSIEFIDKAKLSSCQVIVHCLAGISRSATIAIAYIMKTMGMSSDDAYRFVKDRRPSISPNFNFLGQLLEYERSLKLLAALQGDPGTPSGTPEPPPSPAAGAPLPRLPPPTSESAATGNAAAREGGLSAGGEPPAPPTPPATSALQQGLRGLHLSSDRLQDTNRLKRSFSLDIKSAYAPSRRPDGPGPPDPGEAPKLCKLDSPSGAALGLSSPSPDSPDAAPEARPRPRRRPRPPAGSPARSPAHSLGLNFGDAARQTPRHGLSALSAPGLPGPGQPAGPGAWAPPLDSPGTPSPDGPWCFSPEGAQGAGGVLFAPFGRAGAPGPGGGSDLRRREAARAEPRDARTGWPEEPAPETQFKRRSCQMEFEEGMVEGRARGEELAALGKQASFSGSVEVIEVS
T28444	DRUGINFO	D01GLR	ISIS 103387	Investigative
T28444	DRUGINFO	D0O3WF	ISIS 103386	Investigative
T28444	DRUGINFO	D0XO0T	ISIS 103375	Investigative

T83398	TARGETID	T83398
T83398	FORMERID	TTDR01417
T83398	UNIPROID	DUS5_HUMAN
T83398	TARGNAME	DUSP5 messenger RNA (DUSP5 mRNA)
T83398	GENENAME	DUSP5
T83398	TARGTYPE	Literature-reported
T83398	SYNONYMS	VH3 (mRNA); Dual specificity protein phosphatase hVH3 (mRNA); Dual specificity protein phosphatase 5 (mRNA)
T83398	FUNCTION	The highest relative activity is toward ERK1. Dual specificity protein phosphatase; active with phosphotyrosine, phosphoserine and phosphothreonine residues.
T83398	PDBSTRUC	2G6Z
T83398	BIOCLASS	mRNA target
T83398	ECNUMBER	EC 3.1.3.16
T83398	SEQUENCE	MKVTSLDGRQLRKMLRKEAAARCVVLDCRPYLAFAASNVRGSLNVNLNSVVLRRARGGAVSARYVLPDEAARARLLQEGGGGVAAVVVLDQGSRHWQKLREESAARVVLTSLLACLPAGPRVYFLKGGYETFYSEYPECCVDVKPISQEKIESERALISQCGKPVVNVSYRPAYDQGGPVEILPFLYLGSAYHASKCEFLANLHITALLNVSRRTSEACATHLHYKWIPVEDSHTADISSHFQEAIDFIDCVREKGGKVLVHCEAGISRSPTICMAYLMKTKQFRLKEAFDYIKQRRSMVSPNFGFMGQLLQYESEILPSTPNPQPPSCQGEAAGSSLIGHLQTLSPDMQGAYCTFPASVLAPVPTHSTVSELSRSPVATATSC
T83398	DRUGINFO	D01EAV	ISIS 133244	Investigative
T83398	DRUGINFO	D02DHS	ISIS 133245	Investigative
T83398	DRUGINFO	D03PCV	ISIS 133207	Investigative
T83398	DRUGINFO	D05PDW	ISIS 133206	Investigative
T83398	DRUGINFO	D09PFL	ISIS 133208	Investigative
T83398	DRUGINFO	D0C8WA	ISIS 133242	Investigative
T83398	DRUGINFO	D0ND6Y	ISIS 133211	Investigative
T83398	DRUGINFO	D0W5FH	ISIS 133243	Investigative

T11747	TARGETID	T11747
T11747	FORMERID	TTDR01422
T11747	UNIPROID	M3K3_HUMAN
T11747	TARGNAME	MEKK3 messenger RNA (MAP3K3 mRNA)
T11747	GENENAME	MAP3K3
T11747	TARGTYPE	Literature-reported
T11747	SYNONYMS	Mitogen-activated protein kinase kinase kinase 3 (mRNA); MEKK3 (mRNA); MEKK 3 (mRNA); MEK kinase 3 (mRNA); MAPKKK3 (mRNA)
T11747	FUNCTION	Mediates activation of the NF-kappa-B, AP1 and DDIT3 transcriptional regulators. Component of a protein kinase signal transduction cascade.
T11747	PDBSTRUC	4YL6; 4Y5O; 2PPH; 2O2V; 2JRH
T11747	BIOCLASS	mRNA target
T11747	ECNUMBER	EC 2.7.11.25
T11747	SEQUENCE	MDEQEALNSIMNDLVALQMNRRHRMPGYETMKNKDTGHSNRQSDVRIKFEHNGERRIIAFSRPVKYEDVEHKVTTVFGQPLDLHYMNNELSILLKNQDDLDKAIDILDRSSSMKSLRILLLSQDRNHNSSSPHSGVSRQVRIKASQSAGDINTIYQPPEPRSRHLSVSSQNPGRSSPPPGYVPERQQHIARQGSYTSINSEGEFIPETSEQCMLDPLSSAENSLSGSCQSLDRSADSPSFRKSRMSRAQSFPDNRQEYSDRETQLYDKGVKGGTYPRRYHVSVHHKDYSDGRRTFPRIRRHQGNLFTLVPSSRSLSTNGENMGLAVQYLDPRGRLRSADSENALSVQERNVPTKSPSAPINWRRGKLLGQGAFGRVYLCYDVDTGRELASKQVQFDPDSPETSKEVSALECEIQLLKNLQHERIVQYYGCLRDRAEKTLTIFMEYMPGGSVKDQLKAYGALTESVTRKYTRQILEGMSYLHSNMIVHRDIKGANILRDSAGNVKLGDFGASKRLQTICMSGTGMRSVTGTPYWMSPEVISGEGYGRKADVWSLGCTVVEMLTEKPPWAEYEAMAAIFKIATQPTNPQLPSHISEHGRDFLRRIFVEARQRPSAEELLTHHFAQLMY
T11747	DRUGINFO	D05QQI	ISIS 122971	Investigative
T11747	DRUGINFO	D05RDM	ISIS 122976	Investigative
T11747	DRUGINFO	D08SHY	ISIS 122985	Investigative
T11747	DRUGINFO	D09TIM	ISIS 122991	Investigative
T11747	DRUGINFO	D0F7AP	ISIS 122974	Investigative
T11747	DRUGINFO	D0H8BJ	ISIS 122975	Investigative
T11747	DRUGINFO	D0JZ4R	ISIS 122970	Investigative
T11747	DRUGINFO	D0M5OL	ISIS 122984	Investigative
T11747	DRUGINFO	D0N9VK	ISIS 122986	Investigative
T11747	DRUGINFO	D0Z4CC	ISIS 122990	Investigative

T00564	TARGETID	T00564
T00564	FORMERID	TTDR01424
T00564	UNIPROID	DUS9_HUMAN
T00564	TARGNAME	DUSP9 messenger RNA (DUSP9 mRNA)
T00564	GENENAME	DUSP9
T00564	TARGTYPE	Literature-reported
T00564	SYNONYMS	Mitogen-activated protein kinase phosphatase 4 (mRNA); MKP4 (mRNA); MKP-4 (mRNA); MAP kinase phosphatase 4 (mRNA); Dual specificity protein phosphatase 9 (mRNA)
T00564	FUNCTION	Has a specificity for the ERK family. Inactivates MAP kinases.
T00564	PDBSTRUC	3LJ8; 2HXP
T00564	BIOCLASS	mRNA target
T00564	ECNUMBER	EC 3.1.3.16
T00564	SEQUENCE	MEGLGRSCLWLRRELSPPRPRLLLLDCRSRELYESARIGGALSVALPALLLRRLRRGSLSVRALLPGPPLQPPPPAPVLLYDQGGGRRRRGEAEAEAEEWEAESVLGTLLQKLREEGYLAYYLQGGFSRFQAECPHLCETSLAGRAGSSMAPVPGPVPVVGLGSLCLGSDCSDAESEADRDSMSCGLDSEGATPPPVGLRASFPVQILPNLYLGSARDSANLESLAKLGIRYILNVTPNLPNFFEKNGDFHYKQIPISDHWSQNLSRFFPEAIEFIDEALSQNCGVLVHCLAGVSRSVTVTVAYLMQKLHLSLNDAYDLVKRKKSNISPNFNFMGQLLDFERSLRLEERHSQEQGSGGQASAASNPPSFFTTPTSDGAFELAPT
T00564	DRUGINFO	D07HIJ	ISIS 103473	Investigative
T00564	DRUGINFO	D07RVX	ISIS 103471	Investigative
T00564	DRUGINFO	D0Q3KN	ISIS 103489	Investigative
T00564	DRUGINFO	D0S4BJ	ISIS 103486	Investigative

T91154	TARGETID	T91154
T91154	FORMERID	TTDR01425
T91154	UNIPROID	WWP1_HUMAN
T91154	TARGNAME	WWP1 messenger RNA (WWP1 mRNA)
T91154	GENENAME	WWP1
T91154	TARGTYPE	Literature-reported
T91154	SYNONYMS	WW domain-containing protein 1 (mRNA); Tiul1 (mRNA); TGIF-interacting ubiquitin ligase 1 (mRNA); NEDD4-like E3 ubiquitin-protein ligase WWP1 (mRNA); HECT-type E3 ubiquitin transferase WWP1 (mRNA); Atrophin-1-interacting protein 5 (mRNA); AIP5 (mRNA)
T91154	FUNCTION	Ubiquitinates ERBB4 isoforms JM-A CYT-1 and JM-B CYT-1, KLF2, KLF5 and TP63 and promotes their proteasomal degradation. Ubiquitinates RNF11 without targeting it for degradation. Ubiquitinates and promotes degradation of TGFBR1; the ubiquitination is enhanced by SMAD7. Ubiquitinates SMAD6 and SMAD7. Ubiquitinates and promotes degradation of SMAD2 in response to TGF-beta signaling, which requires interaction with TGIF. E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates.
T91154	PDBSTRUC	5HPT; 5HPS; 2OP7; 1ND7
T91154	BIOCLASS	mRNA target
T91154	ECNUMBER	EC 2.3.2.26
T91154	SEQUENCE	MATASPRSDTSNNHSGRLQLQVTVSSAKLKRKKNWFGTAIYTEVVVDGEITKTAKSSSSSNPKWDEQLTVNVTPQTTLEFQVWSHRTLKADALLGKATIDLKQALLIHNRKLERVKEQLKLSLENKNGIAQTGELTVVLDGLVIEQENITNCSSSPTIEIQENGDALHENGEPSARTTARLAVEGTNGIDNHVPTSTLVQNSCCSYVVNGDNTPSSPSQVAARPKNTPAPKPLASEPADDTVNGESSSFAPTDNASVTGTPVVSEENALSPNCTSTTVEDPPVQEILTSSENNECIPSTSAELESEARSILEPDTSNSRSSSAFEAAKSRQPDGCMDPVRQQSGNANTETLPSGWEQRKDPHGRTYYVDHNTRTTTWERPQPLPPGWERRVDDRRRVYYVDHNTRTTTWQRPTMESVRNFEQWQSQRNQLQGAMQQFNQRYLYSASMLAAENDPYGPLPPGWEKRVDSTDRVYFVNHNTKTTQWEDPRTQGLQNEEPLPEGWEIRYTREGVRYFVDHNTRTTTFKDPRNGKSSVTKGGPQIAYERGFRWKLAHFRYLCQSNALPSHVKINVSRQTLFEDSFQQIMALKPYDLRRRLYVIFRGEEGLDYGGLAREWFFLLSHEVLNPMYCLFEYAGKNNYCLQINPASTINPDHLSYFCFIGRFIAMALFHGKFIDTGFSLPFYKRMLSKKLTIKDLESIDTEFYNSLIWIRDNNIEECGLEMYFSVDMEILGKVTSHDLKLGGSNILVTEENKDEYIGLMTEWRFSRGVQEQTKAFLDGFNEVVPLQWLQYFDEKELEVMLCGMQEVDLADWQRNTVYRHYTRNSKQIIWFWQFVKETDNEVRMRLLQFVTGTCRLPLGGFAELMGSNGPQKFCIEKVGKDTWLPRSHTCFNRLDLPPYKSYEQLKEKLLFAIEETEGFGQE
T91154	DRUGINFO	D01NSO	ISIS 103616	Investigative
T91154	DRUGINFO	D04CLQ	ISIS 103615	Investigative
T91154	DRUGINFO	D06GOO	ISIS 103624	Investigative
T91154	DRUGINFO	D08IBR	ISIS 103619	Investigative
T91154	DRUGINFO	D09GRF	ISIS 103582	Investigative
T91154	DRUGINFO	D0AD7L	ISIS 103631	Investigative
T91154	DRUGINFO	D0I8BN	ISIS 103612	Investigative
T91154	DRUGINFO	D0K8XK	ISIS 103621	Investigative
T91154	DRUGINFO	D0M2PZ	ISIS 103613	Investigative
T91154	DRUGINFO	D0P2AR	ISIS 103629	Investigative
T91154	DRUGINFO	D0T5RJ	ISIS 103620	Investigative
T91154	DRUGINFO	D0TS6S	ISIS 103622	Investigative
T91154	DRUGINFO	D0V8KZ	ISIS 103601	Investigative
T91154	DRUGINFO	D0Y9ZR	ISIS 103635	Investigative

T25386	TARGETID	T25386
T25386	FORMERID	TTDR01427
T25386	UNIPROID	DICER_HUMAN
T25386	TARGNAME	Helicase-moi messenger RNA (DICER1 mRNA)
T25386	GENENAME	DICER1
T25386	TARGTYPE	Literature-reported
T25386	SYNONYMS	KIAA0928 (mRNA); Helicase with RNase motif (mRNA); Helicase MOI (mRNA); HERNA (mRNA); Endoribonuclease Dicer (mRNA); DICER (mRNA)
T25386	FUNCTION	Cleaves naturally occurring long dsRNAs and short hairpin pre-microRNAs (miRNA) into fragments of twenty-one to twenty-three nucleotides with 3' overhang of two nucleotides, producing respectively short interfering RNAs (siRNA) and mature microRNAs. SiRNAs and miRNAs serve as guide to direct the RNA-induced silencing complex (RISC) to complementary RNAs to degrade them or prevent their translation. Gene silencing mediated by siRNAs, also called RNA interference, controls the elimination of transcripts from mobile and repetitive DNA elements of the genome but also the degradation of exogenous RNA of viral origin for instance. The miRNA pathway on the other side is a mean to specifically regulate the expression of target genes. Double-stranded RNA (dsRNA) endoribonuclease playing a central role in short dsRNA-mediated post-transcriptional gene silencing.
T25386	PDBSTRUC	5ZAM; 5ZAL; 5ZAK; 4WYQ; 4NHA
T25386	BIOCLASS	mRNA target
T25386	ECNUMBER	EC 3.1.26.3
T25386	SEQUENCE	MKSPALQPLSMAGLQLMTPASSPMGPFFGLPWQQEAIHDNIYTPRKYQVELLEAALDHNTIVCLNTGSGKTFIAVLLTKELSYQIRGDFSRNGKRTVFLVNSANQVAQQVSAVRTHSDLKVGEYSNLEVNASWTKERWNQEFTKHQVLIMTCYVALNVLKNGYLSLSDINLLVFDECHLAILDHPYREIMKLCENCPSCPRILGLTASILNGKCDPEELEEKIQKLEKILKSNAETATDLVVLDRYTSQPCEIVVDCGPFTDRSGLYERLLMELEEALNFINDCNISVHSKERDSTLISKQILSDCRAVLVVLGPWCADKVAGMMVRELQKYIKHEQEELHRKFLLFTDTFLRKIHALCEEHFSPASLDLKFVTPKVIKLLEILRKYKPYERQQFESVEWYNNRNQDNYVSWSDSEDDDEDEEIEEKEKPETNFPSPFTNILCGIIFVERRYTAVVLNRLIKEAGKQDPELAYISSNFITGHGIGKNQPRNKQMEAEFRKQEEVLRKFRAHETNLLIATSIVEEGVDIPKCNLVVRFDLPTEYRSYVQSKGRARAPISNYIMLADTDKIKSFEEDLKTYKAIEKILRNKCSKSVDTGETDIDPVMDDDDVFPPYVLRPDDGGPRVTINTAIGHINRYCARLPSDPFTHLAPKCRTRELPDGTFYSTLYLPINSPLRASIVGPPMSCVRLAERVVALICCEKLHKIGELDDHLMPVGKETVKYEEELDLHDEEETSVPGRPGSTKRRQCYPKAIPECLRDSYPRPDQPCYLYVIGMVLTTPLPDELNFRRRKLYPPEDTTRCFGILTAKPIPQIPHFPVYTRSGEVTISIELKKSGFMLSLQMLELITRLHQYIFSHILRLEKPALEFKPTDADSAYCVLPLNVVNDSSTLDIDFKFMEDIEKSEARIGIPSTKYTKETPFVFKLEDYQDAVIIPRYRNFDQPHRFYVADVYTDLTPLSKFPSPEYETFAEYYKTKYNLDLTNLNQPLLDVDHTSSRLNLLTPRHLNQKGKALPLSSAEKRKAKWESLQNKQILVPELCAIHPIPASLWRKAVCLPSILYRLHCLLTAEELRAQTASDAGVGVRSLPADFRYPNLDFGWKKSIDSKSFISISNSSSAENDNYCKHSTIVPENAAHQGANRTSSLENHDQMSVNCRTLLSESPGKLHVEVSADLTAINGLSYNQNLANGSYDLANRDFCQGNQLNYYKQEIPVQPTTSYSIQNLYSYENQPQPSDECTLLSNKYLDGNANKSTSDGSPVMAVMPGTTDTIQVLKGRMDSEQSPSIGYSSRTLGPNPGLILQALTLSNASDGFNLERLEMLGDSFLKHAITTYLFCTYPDAHEGRLSYMRSKKVSNCNLYRLGKKKGLPSRMVVSIFDPPVNWLPPGYVVNQDKSNTDKWEKDEMTKDCMLANGKLDEDYEEEDEEEESLMWRAPKEEADYEDDFLEYDQEHIRFIDNMLMGSGAFVKKISLSPFSTTDSAYEWKMPKKSSLGSMPFSSDFEDFDYSSWDAMCYLDPSKAVEEDDFVVGFWNPSEENCGVDTGKQSISYDLHTEQCIADKSIADCVEALLGCYLTSCGERAAQLFLCSLGLKVLPVIKRTDREKALCPTRENFNSQQKNLSVSCAAASVASSRSSVLKDSEYGCLKIPPRCMFDHPDADKTLNHLISGFENFEKKINYRFKNKAYLLQAFTHASYHYNTITDCYQRLEFLGDAILDYLITKHLYEDPRQHSPGVLTDLRSALVNNTIFASLAVKYDYHKYFKAVSPELFHVIDDFVQFQLEKNEMQGMDSELRRSEEDEEKEEDIEVPKAMGDIFESLAGAIYMDSGMSLETVWQVYYPMMRPLIEKFSANVPRSPVRELLEMEPETAKFSPAERTYDGKVRVTVEVVGKGKFKGVGRSYRIAKSAAARRALRSLKANQPQVPNS
T25386	DRUGINFO	D07NRU	ISIS 138649	Investigative
T25386	DRUGINFO	D0D7NA	ISIS 138647	Investigative
T25386	DRUGINFO	D0DH8B	ISIS 138616	Investigative
T25386	DRUGINFO	D0LF3W	ISIS 138678	Investigative
T25386	DRUGINFO	D0O2ZR	ISIS 138612	Investigative
T25386	DRUGINFO	D0O4MI	ISIS 138648	Investigative
T25386	DRUGINFO	D0OV0E	ISIS 138613	Investigative

T52501	TARGETID	T52501
T52501	FORMERID	TTDR01432
T52501	UNIPROID	M3K2_HUMAN
T52501	TARGNAME	MEKK2 messenger RNA (MAP3K2 mRNA)
T52501	GENENAME	MAP3K2
T52501	TARGTYPE	Literature-reported
T52501	SYNONYMS	Mitogen-activated protein kinase kinase kinase 2 (mRNA); MEKK2 (mRNA); MEKK 2 (mRNA); MEK kinase 2 (mRNA); MAPKKK2 (mRNA)
T52501	FUNCTION	Regulates the JNK and ERK5 pathways by phosphorylating and activating MAP2K5 and MAP2K7. Plays a role in caveolae kiss-and-run dynamics. Component of a protein kinase signal transduction cascade.
T52501	PDBSTRUC	5HQ8; 5EX0; 2NPT; 2CU1
T52501	BIOCLASS	mRNA target
T52501	ECNUMBER	EC 2.7.11.25
T52501	SEQUENCE	MDDQQALNSIMQDLAVLHKASRPALSLQETRKAKSSSPKKQNDVRVKFEHRGEKRILQFPRPVKLEDLRSKAKIAFGQSMDLHYTNNELVIPLTTQDDLDKAVELLDRSIHMKSLKILLVINGSTQATNLEPLPSLEDLDNTVFGAERKKRLSIIGPTSRDRSSPPPGYIPDELHQVARNGSFTSINSEGEFIPESMDQMLDPLSLSSPENSGSGSCPSLDSPLDGESYPKSRMPRAQSYPDNHQEFSDYDNPIFEKFGKGGTYPRRYHVSYHHQEYNDGRKTFPRARRTQGTSLRSPVSFSPTDHSLSTSSGSSIFTPEYDDSRIRRRGSDIDNPTLTVMDISPPSRSPRAPTNWRLGKLLGQGAFGRVYLCYDVDTGRELAVKQVQFDPDSPETSKEVNALECEIQLLKNLLHERIVQYYGCLRDPQEKTLSIFMEYMPGGSIKDQLKAYGALTENVTRKYTRQILEGVHYLHSNMIVHRDIKGANILRDSTGNVKLGDFGASKRLQTICLSGTGMKSVTGTPYWMSPEVISGEGYGRKADIWSVACTVVEMLTEKPPWAEFEAMAAIFKIATQPTNPKLPPHVSDYTRDFLKRIFVEAKLRPSADELLRHMFVHYH
T52501	DRUGINFO	D00GKE	ISIS 113909	Investigative
T52501	DRUGINFO	D04LHI	ISIS 113871	Investigative
T52501	DRUGINFO	D05AYU	ISIS 113874	Investigative
T52501	DRUGINFO	D05HUP	ISIS 113908	Investigative
T52501	DRUGINFO	D07EFO	ISIS 113902	Investigative
T52501	DRUGINFO	D0D5HE	ISIS 113906	Investigative
T52501	DRUGINFO	D0E3AR	ISIS 113904	Investigative
T52501	DRUGINFO	D0F9AI	ISIS 113907	Investigative
T52501	DRUGINFO	D0M9JK	ISIS 113903	Investigative
T52501	DRUGINFO	D0QP0H	ISIS 113858	Investigative
T52501	DRUGINFO	D0V7SZ	ISIS 113905	Investigative
T52501	DRUGINFO	D0X7DN	ISIS 113872	Investigative
T52501	DRUGINFO	D0Y3OV	ISIS 113873	Investigative

T01054	TARGETID	T01054
T01054	FORMERID	TTDI00139
T01054	UNIPROID	WWP2_HUMAN
T01054	TARGNAME	NEDD4-like E3 ubiquitin-protein ligase WWP2 (WWP2)
T01054	GENENAME	WWP2
T01054	TARGTYPE	Literature-reported
T01054	SYNONYMS	WW domaincontaining protein 2; WW domain-containing protein 2; NEDD4like E3 ubiquitinprotein ligaseWWP2; HECT-type E3 ubiquitin transferase WWP2; Atrophin1interacting protein 2; Atrophin-1-interacting protein 2; AIP2
T01054	FUNCTION	Polyubiquitinates POU5F1 by 'Lys-63'-linked conjugation and promotes it to proteasomal degradation; in embryonic stem cells (ESCs) the ubiquitination is proposed to regulate POU5F1 protein level. Ubiquitinates EGR2 and promotes it to proteasomal degradation; in T-cells the ubiquitination inhibits activation-induced cell death. Ubiquitinates SLC11A2; the ubiquitination is enhanced by presence of NDFIP1 and NDFIP2. Ubiquitinates RPB1 and promotes it to proteasomal degradation. E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates.
T01054	PDBSTRUC	5TJQ; 5TJ8; 5TJ7; 4Y07
T01054	BIOCLASS	Acyltransferase
T01054	ECNUMBER	EC 2.3.2.26
T01054	SEQUENCE	MASASSSRAGVALPFEKSQLTLKVVSAKPKVHNRQPRINSYVEVAVDGLPSETKKTGKRIGSSELLWNEIIILNVTAQSHLDLKVWSCHTLRNELLGTASVNLSNVLKNNGGKMENMQLTLNLQTENKGSVVSGGELTIFLDGPTVDLGNVPNGSALTDGSQLPSRDSSGTAVAPENRHQPPSTNCFGGRSRTHRHSGASARTTPATGEQSPGARSRHRQPVKNSGHSGLANGTVNDEPTTATDPEEPSVVGVTSPPAAPLSVTPNPNTTSLPAPATPAEGEEPSTSGTQQLPAAAQAPDALPAGWEQRELPNGRVYYVDHNTKTTTWERPLPPGWEKRTDPRGRFYYVDHNTRTTTWQRPTAEYVRNYEQWQSQRNQLQGAMQHFSQRFLYQSSSASTDHDPLGPLPPGWEKRQDNGRVYYVNHNTRTTQWEDPRTQGMIQEPALPPGWEMKYTSEGVRYFVDHNTRTTTFKDPRPGFESGTKQGSPGAYDRSFRWKYHQFRFLCHSNALPSHVKISVSRQTLFEDSFQQIMNMKPYDLRRRLYIIMRGEEGLDYGGIAREWFFLLSHEVLNPMYCLFEYAGKNNYCLQINPASSINPDHLTYFRFIGRFIAMALYHGKFIDTGFTLPFYKRMLNKRPTLKDLESIDPEFYNSIVWIKENNLEECGLELYFIQDMEILGKVTTHELKEGGESIRVTEENKEEYIMLLTDWRFTRGVEEQTKAFLDGFNEVAPLEWLRYFDEKELELMLCGMQEIDMSDWQKSTIYRHYTKNSKQIQWFWQVVKEMDNEKRIRLLQFVTGTCRLPVGGFAELIGSNGPQKFCIDKVGKETWLPRSHTCFNRLDLPPYKSYEQLREKLLYAIEETEGFGQE

T71374	TARGETID	T71374
T71374	FORMERID	TTDI03470
T71374	UNIPROID	PLK4_HUMAN
T71374	TARGNAME	Polo-like kinase 4 (PLK4)
T71374	GENENAME	PLK4
T71374	TARGTYPE	Literature-reported
T71374	SYNONYMS	Serine/threonine-protein kinase Sak; Serine/threonine-protein kinase PLK4; Serine/threonine-protein kinase 18; STK18; SAK; PLK-4
T71374	FUNCTION	Able to trigger procentriole formation on the surface of the parental centriole cylinder, leading to the recruitment of centriole biogenesis proteins such as SASS6, CENPJ/CPAP, CCP110, CEP135 and gamma-tubulin. When overexpressed, it is able to induce centrosome amplification through the simultaneous generation of multiple procentrioles adjoining each parental centriole during S phase. Phosphorylates 'Ser-151' of FBXW5 during the G1/S transition, leading to inhibit FBXW5 ability to ubiquitinate SASS6. Its central role in centriole replication suggests a possible role in tumorigenesis, centrosome aberrations being frequently observed in tumors. Also involved in deuterosome-mediated centriole amplification in multiciliated that can generate more than 100 centrioles. Also involved in trophoblast differentiation by phosphorylating HAND1, leading to disrupt the interaction between HAND1 and MDFIC and activate HAND1. Phosphorylates CDC25C and CHEK2. Required for the recruitment of STIL to the centriole and for STIL-mediated centriole amplification. Serine/threonine-protein kinase that plays a central role in centriole duplication.
T71374	PDBSTRUC	5LHZ; 5LHY; 4YYP; 4YUR; 4N9J
T71374	BIOCLASS	Kinase
T71374	ECNUMBER	EC 2.7.11.21
T71374	SEQUENCE	MATCIGEKIEDFKVGNLLGKGSFAGVYRAESIHTGLEVAIKMIDKKAMYKAGMVQRVQNEVKIHCQLKHPSILELYNYFEDSNYVYLVLEMCHNGEMNRYLKNRVKPFSENEARHFMHQIITGMLYLHSHGILHRDLTLSNLLLTRNMNIKIADFGLATQLKMPHEKHYTLCGTPNYISPEIATRSAHGLESDVWSLGCMFYTLLIGRPPFDTDTVKNTLNKVVLADYEMPSFLSIEAKDLIHQLLRRNPADRLSLSSVLDHPFMSRNSSTKSKDLGTVEDSIDSGHATISTAITASSSTSISGSLFDKRRLLIGQPLPNKMTVFPKNKSSTDFSSSGDGNSFYTQWGNQETSNSGRGRVIQDAEERPHSRYLRRAYSSDRSGTSNSQSQAKTYTMERCHSAEMLSVSKRSGGGENEERYSPTDNNANIFNFFKEKTSSSSGSFERPDNNQALSNHLCPGKTPFPFADPTPQTETVQQWFGNLQINAHLRKTTEYDSISPNRDFQGHPDLQKDTSKNAWTDTKVKKNSDASDNAHSVKQQNTMKYMTALHSKPEIIQQECVFGSDPLSEQSKTRGMEPPWGYQNRTLRSITSPLVAHRLKPIRQKTKKAVVSILDSEEVCVELVKEYASQEYVKEVLQISSDGNTITIYYPNGGRGFPLADRPPSPTDNISRYSFDNLPEKYWRKYQYASRFVQLVRSKSPKITYFTRYAKCILMENSPGADFEVWFYDGVKIHKTEDFIQVIEKTGKSYTLKSESEVNSLKEEIKMYMDHANEGHRICLALESIISEEERKTRSAPFFPIIIGRKPGSTSSPKALSPPPSVDSNYPTRERASFNRMVMHSAASPTQAPILNPSMVTNEGLGLTTTASGTDISSNSLKDCLPKSAQLLKSVFVKNVGWATQLTSGAVWVQFNDGSQLVVQAGVSSISYTSPNGQTTRYGENEKLPDYIKQKLQCLSSILLMFSNPTPNFH
T71374	DRUGINFO	D0X2XZ	CFI-400945	Phase 2
T71374	DRUGINFO	D0M0QQ	XMD8-92	Investigative

T70027	TARGETID	T70027
T70027	FORMERID	TTDI02631
T70027	UNIPROID	TOR1A_HUMAN
T70027	TARGNAME	Torsin-1A (TOR1A)
T70027	GENENAME	TOR1A
T70027	TARGTYPE	Literature-reported
T70027	SYNONYMS	Torsin family 1 member A; Torsin ATPase-1A; TORA; TA; Dystonia 1 protein; DYT1; DQ2
T70027	FUNCTION	Involved in the regulation of synaptic vesicle recycling, controls STON2 protein stability in collaboration with the COP9 signalosome complex (CSN). In the nucleus, may link the cytoskeleton with the nuclear envelope, this mechanism seems to be crucial for the control of nuclear polarity, cell movement and, specifically in neurons, nuclear envelope integrity. Participates in the cellular trafficking and may regulate the subcellular location of multipass membrane proteins such as the dopamine transporter SLC6A3, leading to the modulation of dopamine neurotransmission. In the endoplasmic reticulum, plays a role in the quality control of protein folding by increasing clearance of misfolded proteins such as SGCE variants or holding them in an intermediate state for proper refolding. May have a redundant function with TOR1B in non-neural tissues. Protein with chaperone functions important for the control of protein folding, processing, stability and localization as well as for the reduction of misfolded protein aggregates.
T70027	PDBSTRUC	5J1T; 5J1S
T70027	BIOCLASS	Acid anhydride hydrolase
T70027	ECNUMBER	EC 3.6.4.-
T70027	SEQUENCE	MKLGRAVLGLLLLAPSVVQAVEPISLGLALAGVLTGYIYPRLYCLFAECCGQKRSLSREALQKDLDDNLFGQHLAKKIILNAVFGFINNPKPKKPLTLSLHGWTGTGKNFVSKIIAENIYEGGLNSDYVHLFVATLHFPHASNITLYKDQLQLWIRGNVSACARSIFIFDEMDKMHAGLIDAIKPFLDYYDLVDGVSYQKAMFIFLSNAGAERITDVALDFWRSGKQREDIKLKDIEHALSVSVFNNKNSGFWHSSLIDRNLIDYFVPFLPLEYKHLKMCIRVEMQSRGYEIDEDIVSRVAEEMTFFPKEERVFSDKGCKTVFTKLDYYYDD

T59537	TARGETID	T59537
T59537	FORMERID	TTDR01062
T59537	UNIPROID	PMYT1_HUMAN
T59537	TARGNAME	Membrane-associated kinase (PKMYT1)
T59537	GENENAME	PKMYT1
T59537	TARGTYPE	Literature-reported
T59537	SYNONYMS	Myt1 kinase; Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase; MYT1
T59537	FUNCTION	Mediates phosphorylation of CDK1 predominantly on 'Thr-14'. Also involved in Golgi fragmentation. May be involved in phosphorylation of CDK1 on 'Tyr-15' to a lesser degree, however tyrosine kinase activity is unclear and may be indirect. May be a downstream target of Notch signaling pathway during eye development. Acts as a negative regulator of entry into mitosis (G2 to M transition) by phosphorylation of the CDK1 kinase specifically when CDK1 is complexed to cyclins.
T59537	PDBSTRUC	5VD3; 5VD1; 5VD0; 5VCZ; 5VCY
T59537	BIOCLASS	Kinase
T59537	ECNUMBER	EC 2.7.11.1
T59537	SEQUENCE	MLERPPALAMPMPTEGTPPPLSGTPIPVPAYFRHAEPGFSLKRPRGLSRSLPPPPPAKGSIPISRLFPPRTPGWHQLQPRRVSFRGEASETLQSPGYDPSRPESFFQQSFQRLSRLGHGSYGEVFKVRSKEDGRLYAVKRSMSPFRGPKDRARKLAEVGSHEKVGQHPCCVRLEQAWEEGGILYLQTELCGPSLQQHCEAWGASLPEAQVWGYLRDTLLALAHLHSQGLVHLDVKPANIFLGPRGRCKLGDFGLLVELGTAGAGEVQEGDPRYMAPELLQGSYGTAADVFSLGLTILEVACNMELPHGGEGWQQLRQGYLPPEFTAGLSSELRSVLVMMLEPDPKLRATAEALLALPVLRQPRAWGVLWCMAAEALSRGWALWQALLALLCWLWHGLAHPASWLQPLGPPATPPGSPPCSLLLDSSLSSNWDDDSLGPSLSPEAVLARTVGSTSTPRSRCTPRDALDLSDINSEPPRGSFPSFEPRNLLSLFEDTLDPT

T53159	TARGETID	T53159
T53159	FORMERID	TTDR00147
T53159	UNIPROID	MP2K7_HUMAN
T53159	TARGNAME	ERK activator kinase 7 (MAP2K7)
T53159	GENENAME	MAP2K7
T53159	TARGTYPE	Literature-reported
T53159	SYNONYMS	Stress-activated protein kinase kinase 4; SKK4; SAPKK4; SAPKK-4; SAPK kinase 4; PRKMK7; Mitogen-activated protein kinase kinase 7; MKK7; MEK7; MEK 7; MAPKK 7; MAPK/ERK kinase7; MAPK/ERK kinase 7; MAP kinase kinase 7; JNKK2; JNKK 2; JNK-activating kinase 2; JNK kinase 2; JNK activating kinase 2; Dual specificity mitogen-activated protein kinase kinase 7; C-Jun N-terminal kinase kinase 2
T53159	FUNCTION	Essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. With MAP2K4/MKK4, is the one of the only known kinase to directly activate the stress-activated protein kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation, but they differ in their preference for the phosphorylation site in the Thr-Pro-Tyr motif. MAP2K4/MKK4 shows preference for phosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thr residue. The monophosphorylation of JNKs on the Thr residue is sufficient to increase JNK activity indicating that MAP2K7/MKK7 is important to trigger JNK activity, while the additional phosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimal JNK activation. Has a specific role in JNK signal transduction pathway activated by proinflammatory cytokines. The MKK/JNK signaling pathway is also involved in mitochondrial death signaling pathway, including the release cytochrome c, leading to apoptosis. Part of a non-canonical MAPK signaling pathway, composed of the upstream MAP3K12 kinase and downstream MAP kinases MAPK1/ERK2 and MAPK3/ERK1, that enhances the AP-1-mediated transcription of APP in response to APOE. Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway.
T53159	PDBSTRUC	6QHR; 6QHO; 6QG7; 6QG4; 6QFT
T53159	BIOCLASS	Kinase
T53159	ECNUMBER	EC 2.7.12.2
T53159	SEQUENCE	MAASSLEQKLSRLEAKLKQENREARRRIDLNLDISPQRPRPTLQLPLANDGGSRSPSSESSPQHPTPPARPRHMLGLPSTLFTPRSMESIEIDQKLQEIMKQTGYLTIGGQRYQAEINDLENLGEMGSGTCGQVWKMRFRKTGHVIAVKQMRRSGNKEENKRILMDLDVVLKSHDCPYIVQCFGTFITNTDVFIAMELMGTCAEKLKKRMQGPIPERILGKMTVAIVKALYYLKEKHGVIHRDVKPSNILLDERGQIKLCDFGISGRLVDSKAKTRSAGCAAYMAPERIDPPDPTKPDYDIRADVWSLGISLVELATGQFPYKNCKTDFEVLTKVLQEEPPLLPGHMGFSGDFQSFVKDCLTKDHRKRPKYNKLLEHSFIKRYETLEVDVASWFKDVMAKTESPRTSGVLSQPHLPFFR

T42447	TARGETID	T42447
T42447	FORMERID	TTDI03159
T42447	UNIPROID	DCLK1_HUMAN
T42447	TARGNAME	Doublecortin-like kinase 1 (DCLK1)
T42447	GENENAME	DCLK1
T42447	TARGTYPE	Literature-reported
T42447	SYNONYMS	Serine/threonine-protein kinase DCLK1; KIAA0369; Doublecortin-like and CAM kinase-like 1; Doublecortin domain-containing protein 3A; DCDC3A; DCAMKL1
T42447	FUNCTION	May also participate in functions of the mature nervous system. Probable kinase that may be involved in a calcium-signaling pathway controlling neuronal migration in the developing brain.
T42447	PDBSTRUC	5JZN; 5JZJ; 1UF0; 1MG4; 1MFW
T42447	BIOCLASS	Kinase
T42447	ECNUMBER	EC 2.7.11.1
T42447	SEQUENCE	MSFGRDMELEHFDERDKAQRYSRGSRVNGLPSPTHSAHCSFYRTRTLQTLSSEKKAKKVRFYRNGDRYFKGIVYAISPDRFRSFEALLADLTRTLSDNVNLPQGVRTIYTIDGLKKISSLDQLVEGESYVCGSIEPFKKLEYTKNVNPNWSVNVKTTSASRAVSSLATAKGSPSEVRENKDFIRPKLVTIIRSGVKPRKAVRILLNKKTAHSFEQVLTDITDAIKLDSGVVKRLYTLDGKQVMCLQDFFGDDDIFIACGPEKFRYQDDFLLDESECRVVKSTSYTKIASSSRRSTTKSPGPSRRSKSPASTSSVNGTPGSQLSTPRSGKSPSPSPTSPGSLRKQRSSQHGGSSTSLASTKVCSSMDENDGPGEEVSEEGFQIPATITERYKVGRTIGDGNFAVVKECVERSTAREYALKIIKKSKCRGKEHMIQNEVSILRRVKHPNIVLLIEEMDVPTELYLVMELVKGGDLFDAITSTNKYTERDASGMLYNLASAIKYLHSLNIVHRDIKPENLLVYEHQDGSKSLKLGDFGLATIVDGPLYTVCGTPTYVAPEIIAETGYGLKVDIWAAGVITYILLCGFPPFRGSGDDQEVLFDQILMGQVDFPSPYWDNVSDSAKELITMMLLVDVDQRFSAVQVLEHPWVNDDGLPENEHQLSVAGKIKKHFNTGPKPNSTAAGVSVIATTALDKERQVFRRRRNQDVRSRYKAQPAPPELNSESEDYSPSSSETVRSPNSPF
T42447	DRUGINFO	D0H0LP	PMID20483621C5g	Investigative

T56108	TARGETID	T56108
T56108	FORMERID	TTDI03589
T56108	UNIPROID	TIF1A_HUMAN
T56108	TARGNAME	Tripartite motif-containing 24 (TRIM24)
T56108	GENENAME	TRIM24
T56108	TARGTYPE	Literature-reported
T56108	SYNONYMS	Tripartite motif-containing protein 24; Transcription intermediary factor 1-alpha; TIF1A; TIF1-alpha; TIF1; RNF82; RING-type E3 ubiquitin transferase TIF1-alpha; RING finger protein 82; E3 ubiquitin-protein ligase TRIM24
T56108	FUNCTION	Interacts with chromatin depending on histone H3 modifications, having the highest affinity for histone H3 that is both unmodified at 'Lys-4' (H3K4me0) and acetylated at 'Lys-23' (H3K23ac). Has E3 protein-ubiquitin ligase activity. Promotes ubiquitination and proteasomal degradation of p53/TP53. Plays a role in the regulation of cell proliferation and apoptosis, at least in part via its effects on p53/TP53 levels. Up-regulates ligand-dependent transcription activation by AR, GCR/NR3C1, thyroid hormone receptor (TR) and ESR1. Modulates transcription activation by retinoic acid (RA) receptors, including RARA. Plays a role in regulating retinoic acid-dependent proliferation of hepatocytes. Transcriptional coactivator that interacts with numerous nuclear receptors and coactivators and modulates the transcription of target genes.
T56108	PDBSTRUC	5H1V; 5H1U; 5H1T; 4ZQL; 4YC9
T56108	BIOCLASS	Acyltransferase
T56108	ECNUMBER	EC 2.3.2.27
T56108	SEQUENCE	MEVAVEKAVAAAAAASAAASGGPSAAPSGENEAESRQGPDSERGGEAARLNLLDTCAVCHQNIQSRAPKLLPCLHSFCQRCLPAPQRYLMLPAPMLGSAETPPPVPAPGSPVSGSSPFATQVGVIRCPVCSQECAERHIIDNFFVKDTTEVPSSTVEKSNQVCTSCEDNAEANGFCVECVEWLCKTCIRAHQRVKFTKDHTVRQKEEVSPEAVGVTSQRPVFCPFHKKEQLKLYCETCDKLTCRDCQLLEHKEHRYQFIEEAFQNQKVIIDTLITKLMEKTKYIKFTGNQIQNRIIEVNQNQKQVEQDIKVAIFTLMVEINKKGKALLHQLESLAKDHRMKLMQQQQEVAGLSKQLEHVMHFSKWAVSSGSSTALLYSKRLITYRLRHLLRARCDASPVTNNTIQFHCDPSFWAQNIINLGSLVIEDKESQPQMPKQNPVVEQNSQPPSGLSSNQLSKFPTQISLAQLRLQHMQQQVMAQRQQVQRRPAPVGLPNPRMQGPIQQPSISHQQPPPRLINFQNHSPKPNGPVLPPHPQQLRYPPNQNIPRQAIKPNPLQMAFLAQQAIKQWQISSGQGTPSTTNSTSSTPSSPTITSAAGYDGKAFGSPMIDLSSPVGGSYNLPSLPDIDCSSTIMLDNIVRKDTNIDHGQPRPPSNRTVQSPNSSVPSPGLAGPVTMTSVHPPIRSPSASSVGSRGSSGSSSKPAGADSTHKVPVVMLEPIRIKQENSGPPENYDFPVVIVKQESDEESRPQNANYPRSILTSLLLNSSQSSTSEETVLRSDAPDSTGDQPGLHQDNSSNGKSEWLDPSQKSPLHVGETRKEDDPNEDWCAVCQNGGELLCCEKCPKVFHLSCHVPTLTNFPSGEWICTFCRDLSKPEVEYDCDAPSHNSEKKKTEGLVKLTPIDKRKCERLLLFLYCHEMSLAFQDPVPLTVPDYYKIIKNPMDLSTIKKRLQEDYSMYSKPEDFVADFRLIFQNCAEFNEPDSEVANAGIKLENYFEELLKNLYPEKRFPKPEFRNESEDNKFSDDSDDDFVQPRKKRLKSIEERQLLK
T56108	DRUGINFO	D0C2PD	PMID25974391C34	Investigative

T01282	TARGETID	T01282
T01282	FORMERID	TTDR00733
T01282	UNIPROID	TMPS2_HUMAN
T01282	TARGNAME	Transmembrane protease serine 2 (TMPRSS2)
T01282	GENENAME	TMPRSS2
T01282	TARGTYPE	Literature-reported
T01282	SYNONYMS	TMPRSS2 protease; TMPRSS2
T01282	FUNCTION	Serine protease that proteolytically cleaves and activates the viral spike glycoproteins which facilitate virus- cell membrane fusions; spike proteins are synthesized and maintained in precursor intermediate folding states and proteolysis permits the refolding and energy release required to create stable virus-cell linkages and membrane coalescence. Facilitates human SARS coronavirus (SARS-CoV) infection via two independent mechanisms, proteolytic cleavage of ACE2, which might promote viral uptake, and cleavage of coronavirus spike glycoprotein which activates the glycoprotein for cathepsin L- independent host cell entry. Proteolytically cleaves and activates the spike glycoproteins of human coronavirus 229E (HCoV-229E) and human coronavirus EMC (HCoV-EMC) and the fusion glycoproteins F0 of Sendai virus (SeV), human metapneumovirus (HMPV), human parainfluenza 1, 2, 3, 4a and 4b viruses (HPIV). Essential for spread and pathogenesis of influenza A virus (strains H1N1, H3N2 and H7N9); involved in proteolytic cleavage and activation of hemagglutinin (HA) protein which is essential for viral infectivity.
T01282	BIOCLASS	Peptidase
T01282	ECNUMBER	EC 3.4.21.-
T01282	SEQUENCE	MALNSGSPPAIGPYYENHGYQPENPYPAQPTVVPTVYEVHPAQYYPSPVPQYAPRVLTQASNPVVCTQPKSPSGTVCTSKTKKALCITLTLGTFLVGAALAAGLLWKFMGSKCSNSGIECDSSGTCINPSNWCDGVSHCPGGEDENRCVRLYGPNFILQVYSSQRKSWHPVCQDDWNENYGRAACRDMGYKNNFYSSQGIVDDSGSTSFMKLNTSAGNVDIYKKLYHSDACSSKAVVSLRCIACGVNLNSSRQSRIVGGESALPGAWPWQVSLHVQNVHVCGGSIITPEWIVTAAHCVEKPLNNPWHWTAFAGILRQSFMFYGAGYQVEKVISHPNYDSKTKNNDIALMKLQKPLTFNDLVKPVCLPNPGMMLQPEQLCWISGWGATEEKGKTSEVLNAAKVLLIETQRCNSRYVYDNLITPAMICAGFLQGNVDSCQGDSGGPLVTSKNNIWWLIGDTSWGSGCAKAYRPGVYGNVMVFTDWIYRQMRADG
T01282	DRUGINFO	D07ZRG	PMID21741839C5	Investigative

T92189	TARGETID	T92189
T92189	UNIPROID	OGG1_HUMAN
T92189	TARGNAME	N-glycosylase/DNA lyase (OGG1)
T92189	GENENAME	OGG1
T92189	TARGTYPE	Literature-reported
T92189	SYNONYMS	OGH1; MUTM; MMH
T92189	FUNCTION	DNA repair enzyme that incises DNA at 8-oxoG residues. Excises 7,8-dihydro-8-oxoguanine and 2,6-diamino-4-hydroxy-5-N-methylformamidopyrimidine (FAPY) from damaged DNA. Has a beta-lyase activity that nicks DNA 3' to the lesion.
T92189	PDBSTRUC	5AN4; 3KTU; 3IH7; 2XHI; 2NOZ
T92189	BIOCLASS	Type-1 OGG1 family
T92189	SEQUENCE	MPARALLPRRMGHRTLASTPALWASIPCPRSELRLDLVLPSGQSFRWREQSPAHWSGVLADQVWTLTQTEEQLHCTVYRGDKSQASRPTPDELEAVRKYFQLDVTLAQLYHHWGSVDSHFQEVAQKFQGVRLLRQDPIECLFSFICSSNNNIARITGMVERLCQAFGPRLIQLDDVTYHGFPSLQALAGPEVEAHLRKLGLGYRARYVSASARAILEEQGGLAWLQQLRESSYEEAHKALCILPGVGTKVADCICLMALDKPQAVPVDVHMWHIAQRDYSWHPTTSQAKGPSPQTNKELGNFFRSLWGPYAGWAQAVLFSADLRQSRHAQEPPAKRRKGSKGPEG

T15139	TARGETID	T15139
T15139	FORMERID	TTDI00155
T15139	UNIPROID	SERA_HUMAN
T15139	TARGNAME	Phosphoglycerate dehydrogenase (PHGDH)
T15139	GENENAME	PHGDH
T15139	TARGTYPE	Literature-reported
T15139	SYNONYMS	PGDH3; Malate dehydrogenase; D-3-phosphoglycerate dehydrogenase; 3-PGDH; 2-oxoglutarate reductase
T15139	FUNCTION	Catalyzes the reversible oxidation of 3-phospho-D-glycerate to 3-phosphonooxypyruvate, the first step of the phosphorylated L-serine biosynthesis pathway. Also catalyzes the reversible oxidation of 2-hydroxyglutarate to 2-oxoglutarate and the reversible oxidation of (S)-malate to oxaloacetate.
T15139	PDBSTRUC	5OFW; 5OFV; 5OFM; 5NZQ; 5NZP
T15139	BIOCLASS	Short-chain dehydrogenases reductase
T15139	ECNUMBER	EC 1.1.1.95
T15139	SEQUENCE	MAFANLRKVLISDSLDPCCRKILQDGGLQVVEKQNLSKEELIAELQDCEGLIVRSATKVTADVINAAEKLQVVGRAGTGVDNVDLEAATRKGILVMNTPNGNSLSAAELTCGMIMCLARQIPQATASMKDGKWERKKFMGTELNGKTLGILGLGRIGREVATRMQSFGMKTIGYDPIISPEVSASFGVQQLPLEEIWPLCDFITVHTPLLPSTTGLLNDNTFAQCKKGVRVVNCARGGIVDEGALLRALQSGQCAGAALDVFTEEPPRDRALVDHENVISCPHLGASTKEAQSRCGEEIAVQFVDMVKGKSLTGVVNAQALTSAFSPHTKPWIGLAEALGTLMRAWAGSPKGTIQVITQGTSLKNAGNCLSPAVIVGLLKEASKQADVNLVNAKLLVKEAGLNVTTSHSPAAPGEQGFGECLLAVALAGAPYQAVGLVQGTTPVLQGLNGAVFRPEVPLRRDLPLLLFRTQTSDPAMLPTMIGLLAEAGVRLLSYQTSLVSDGETWHVMGISSLLPSLEAWKQHVTEAFQFHF

T81623	TARGETID	T81623
T81623	FORMERID	TTDI03152
T81623	UNIPROID	DAPK3_HUMAN
T81623	TARGNAME	Death-associated protein kinase 3 (DAPK3)
T81623	GENENAME	DAPK3
T81623	TARGTYPE	Literature-reported
T81623	SYNONYMS	Zipper-interacting protein kinase; ZIPK; ZIP-kinase; MYPT1 kinase; DAP-like kinase; DAP kinase 3
T81623	FUNCTION	Involved in the regulation of smooth muscle contraction. Regulates both type I (caspase-dependent) apoptotic and type II (caspase-independent) autophagic cell deaths signal, depending on the cellular setting. Involved in regulation of starvation-induced autophagy. Regulates myosin phosphorylation in both smooth muscle and non-muscle cells. In smooth muscle, regulates myosin either directly by phosphorylating MYL12B and MYL9 or through inhibition of smooth muscle myosin phosphatase (SMPP1M) via phosphorylation of PPP1R12A; the inhibition of SMPP1M functions to enhance muscle responsiveness to Ca(2+) and promote a contractile state. Phosphorylates MYL12B in non-muscle cells leading to reorganization of actin cytoskeleton. Isoform 2 can phosphorylate myosin, PPP1R12A and MYL12B. Overexpression leads to condensation of actin stress fibers into thick bundles. Involved in actin filament focal adhesion dynamics. The function in both reorganization of actin cytoskeleton and focal adhesion dissolution is modulated by RhoD. Positively regulates canonical Wnt/beta-catenin signaling through interaction with NLK and TCF7L2. Phosphorylates RPL13A on 'Ser-77' upon interferon-gamma activation which is causing RPL13A release from the ribosome, RPL13A association with the GAIT complex and its subsequent involvement in transcript-selective translation inhibition. Enhances transcription from AR-responsive promoters in a hormone- and kinase-dependent manner. Involved in regulation of cell cycle progression and cell proliferation. May be a tumor suppressor. Serine/threonine kinase which is involved in the regulation of apoptosis, autophagy, transcription, translation and actin cytoskeleton reorganization.
T81623	PDBSTRUC	5VJA; 5A6O; 5A6N; 3BQR; 3BHY
T81623	BIOCLASS	Kinase
T81623	ECNUMBER	EC 2.7.11.1
T81623	SEQUENCE	MSTFRQEDVEDHYEMGEELGSGQFAIVRKCRQKGTGKEYAAKFIKKRRLSSSRRGVSREEIEREVNILREIRHPNIITLHDIFENKTDVVLILELVSGGELFDFLAEKESLTEDEATQFLKQILDGVHYLHSKRIAHFDLKPENIMLLDKNVPNPRIKLIDFGIAHKIEAGNEFKNIFGTPEFVAPEIVNYEPLGLEADMWSIGVITYILLSGASPFLGETKQETLTNISAVNYDFDEEYFSNTSELAKDFIRRLLVKDPKRRMTIAQSLEHSWIKAIRRRNVRGEDSGRKPERRRLKTTRLKEYTIKSHSSLPPNNSYADFERFSKVLEEAAAAEEGLRELQRSRRLCHEDVEALAAIYEEKEAWYREESDSLGQDLRRLRQELLKTEALKRQAQEEAKGALLGTSGLKRRFSRLENRYEALAKQVASEMRFVQDLVRALEQEKLQGVECGLR
T81623	DRUGINFO	D07ADX	URMC-099	Investigative

T39519	TARGETID	T39519
T39519	FORMERID	TTDI03565
T39519	UNIPROID	SUV91_HUMAN
T39519	TARGNAME	Lysine N-methyltransferase 1A (SUV39H1)
T39519	GENENAME	SUV39H1
T39519	TARGTYPE	Literature-reported
T39519	SYNONYMS	Suppressor of variegation 3-9 homolog 1; Su(var)3-9 homolog 1; SUV39H; Position-effect variegation 3-9 homolog; KMT1A; Histone-lysine N-methyltransferase SUV39H1; Histone H3-K9 methyltransferase 1; H3-K9-HMTase 1
T39519	FUNCTION	Weakly methylates histone H1 (in vitro). H3 'Lys-9' trimethylation represents a specific tag for epigenetic transcriptional repression by recruiting HP1 (CBX1, CBX3 and/or CBX5) proteins to methylated histones. Mainly functions in heterochromatin regions, thereby playing a central role in the establishment of constitutive heterochromatin at pericentric and telomere regions. H3 'Lys-9' trimethylation is also required to direct DNA methylation at pericentric repeats. SUV39H1 is targeted to histone H3 via its interaction with RB1 and is involved in many processes, such as repression of MYOD1-stimulated differentiation, regulation of the control switch for exiting the cell cycle and entering differentiation, repression by the PML-RARA fusion protein, BMP-induced repression, repression of switch recombination to IgA and regulation of telomere length. Component of the eNoSC (energy-dependent nucleolar silencing) complex, a complex that mediates silencing of rDNA in response to intracellular energy status and acts by recruiting histone-modifying enzymes. The eNoSC complex is able to sense the energy status of cell: upon glucose starvation, elevation of NAD(+)/NADP(+) ratio activates SIRT1, leading to histone H3 deacetylation followed by dimethylation of H3 at 'Lys-9' (H3K9me2) by SUV39H1 and the formation of silent chromatin in the rDNA locus. Recruited by the large PER complex to the E-box elements of the circadian target genes such as PER2 itself or PER1, contributes to the conversion of local chromatin to a heterochromatin-like repressive state through H3 'Lys-9' trimethylation. Histone methyltransferase that specifically trimethylates 'Lys-9' of histone H3 using monomethylated H3 'Lys-9' as substrate.
T39519	PDBSTRUC	3MTS
T39519	BIOCLASS	Methyltransferase
T39519	ECNUMBER	EC 2.1.1.43
T39519	SEQUENCE	MAENLKGCSVCCKSSWNQLQDLCRLAKLSCPALGISKRNLYDFEVEYLCDYKKIREQEYYLVKWRGYPDSESTWEPRQNLKCVRILKQFHKDLERELLRRHHRSKTPRHLDPSLANYLVQKAKQRRALRRWEQELNAKRSHLGRITVENEVDLDGPPRAFVYINEYRVGEGITLNQVAVGCECQDCLWAPTGGCCPGASLHKFAYNDQGQVRLRAGLPIYECNSRCRCGYDCPNRVVQKGIRYDLCIFRTDDGRGWGVRTLEKIRKNSFVMEYVGEIITSEEAERRGQIYDRQGATYLFDLDYVEDVYTVDAAYYGNISHFVNHSCDPNLQVYNVFIDNLDERLPRIAFFATRTIRAGEELTFDYNMQVDPVDMESTRMDSNFGLAGLPGSPKKRVRIECKCGTESCRKYLF
T39519	DRUGINFO	D04FNI	chaetocin	Investigative

T74483	TARGETID	T74483
T74483	FORMERID	TTDR00544
T74483	UNIPROID	KCNQ2_HUMAN
T74483	TARGNAME	Voltage-gated potassium channel Kv7.2 (KCNQ2)
T74483	GENENAME	KCNQ2
T74483	TARGTYPE	Literature-reported
T74483	SYNONYMS	Voltage-gated potassium channel subunit Kv7.2; Neuroblastoma-specific potassium channel alpha subunit KvLQT2; Neuroblastoma-specific potassium channel KQT-like 2; KQT-like 2; KCNQ2; K+ channel KCNQ2
T74483	FUNCTION	Probably importantin the regulation of neuronal excitability. Associates with kcnq3 to form a potassium channel with essentially identical properties to the channel underlying the native m-current.
T74483	PDBSTRUC	6FEH; 6FEG; 5J03
T74483	BIOCLASS	Voltage-gated ion channel
T74483	SEQUENCE	MVQKSRNGGVYPGPSGEKKLKVGFVGLDPGAPDSTRDGALLIAGSEAPKRGSILSKPRAGGAGAGKPPKRNAFYRKLQNFLYNVLERPRGWAFIYHAYVFLLVFSCLVLSVFSTIKEYEKSSEGALYILEIVTIVVFGVEYFVRIWAAGCCCRYRGWRGRLKFARKPFCVIDIMVLIASIAVLAAGSQGNVFATSALRSLRFLQILRMIRMDRRGGTWKLLGSVVYAHSKELVTAWYIGFLCLILASFLVYLAEKGENDHFDTYADALWWGLITLTTIGYGDKYPQTWNGRLLAATFTLIGVSFFALPAGILGSGFALKVQEQHRQKHFEKRRNPAAGLIQSAWRFYATNLSRTDLHSTWQYYERTVTVPMYSSQTQTYGASRLIPPLNQLELLRNLKSKSGLAFRKDPPPEPSPSKGSPCRGPLCGCCPGRSSQKVSLKDRVFSSPRGVAAKGKGSPQAQTVRRSPSADQSLEDSPSKVPKSWSFGDRSRARQAFRIKGAASRQNSEEASLPGEDIVDDKSCPCEFVTEDLTPGLKVSIRAVCVMRFLVSKRKFKESLRPYDVMDVIEQYSAGHLDMLSRIKSLQSRVDQIVGRGPAITDKDRTKGPAEAELPEDPSMMGRLGKVEKQVLSMEKKLDFLVNIYMQRMGIPPTETEAYFGAKEPEPAPPYHSPEDSREHVDRHGCIVKIVRSSSSTGQKNFSAPPAAPPVQCPPSTSWQPQSHPRQGHGTSPVGDHGSLVRIPPPPAHERSLSAYGGGNRASMEFLRQEDTPGCRPPEGNLRDSDTSISIPSVDHEELERSFSGFSISQSKENLDALNSCYAAVAPCAKVRPYIAEGESDTDSDLCTPCGPPPRSATGEGPFGDVGWAGPRK
T74483	DRUGINFO	D0E2FZ	ICA-69673	Preclinical
T74483	DRUGINFO	D08ATZ	QO-58	Investigative
T74483	DRUGINFO	D0N5CH	ICA-27243	Investigative
T74483	DRUGINFO	D0O4IO	ztz240	Investigative
T74483	DRUGINFO	D02BGR	(S)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide	Investigative
T74483	DRUGINFO	D07FTI	zinc pyrithione	Investigative
T74483	DRUGINFO	D0P8PH	XE991	Investigative
T74483	DRUGINFO	D08RJC	PD-32577	Investigative
T74483	DRUGINFO	D07ZAJ	PIP2	Investigative
T74483	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T13453	TARGETID	T13453
T13453	FORMERID	TTDR01044
T13453	UNIPROID	GALR2_HUMAN
T13453	TARGNAME	Galanin receptor type 2 (GAL2-R)
T13453	GENENAME	GALR2
T13453	TARGTYPE	Literature-reported
T13453	SYNONYMS	GALR2; GALR-2; GALNR2; GAL2-R
T13453	FUNCTION	The activity of this receptor is mediated by G proteins that activate the phospholipase C/protein kinase C pathway (via G(q)) and that inhibit adenylyl cyclase (via G(i)). Receptor for the hormone galanin and GALP. Receptor for the hormone spexin-1.
T13453	BIOCLASS	GPCR rhodopsin
T13453	SEQUENCE	MNVSGCPGAGNASQAGGGGGWHPEAVIVPLLFALIFLVGTVGNTLVLAVLLRGGQAVSTTNLFILNLGVADLCFILCCVPFQATIYTLDGWVFGSLLCKAVHFLIFLTMHASSFTLAAVSLDRYLAIRYPLHSRELRTPRNALAAIGLIWGLSLLFSGPYLSYYRQSQLANLTVCHPAWSAPRRRAMDICTFVFSYLLPVLVLGLTYARTLRYLWRAVDPVAAGSGARRAKRKVTRMILIVAALFCLCWMPHHALILCVWFGQFPLTRATYALRILSHLVSYANSCVNPIVYALVSKHFRKGFRTICAGLLGRAPGRASGRVCAAARGTHSGSVLERESSDLLHMSEAAGALRPCPGASQPCILEPCPGPSWQGPKAGDSILTVDVA
T13453	DRUGINFO	D00RWP	GwTLNSAGYLLGPHAVGNHRSFSDKNGLTS-CONH2	Investigative
T13453	DRUGINFO	D01LMH	[Sar1Gly]GAL-B2	Investigative
T13453	DRUGINFO	D02GOE	(Sar)WTLNSAGYLLGPKK(Lys-lauroyl)K	Investigative
T13453	DRUGINFO	D02JQP	GalB2	Investigative
T13453	DRUGINFO	D03ECE	(Sar)WTLNSAGYLLGPKK(Lys-octanoyl)K	Investigative
T13453	DRUGINFO	D05GFD	(Sar)WTLNSAGYLLGPKK(Lys-decanoyl)K	Investigative
T13453	DRUGINFO	D06DWA	(Sar)WTLNSAGYLLGPKK(Lys-MPEG4)K	Investigative
T13453	DRUGINFO	D07NOJ	[Sar1Ala]GAL-B2	Investigative
T13453	DRUGINFO	D09SDZ	GWTLNSAGYLLGPHAV-NH2	Investigative
T13453	DRUGINFO	D0D3CG	GWTLNSAGYLLGPrPKPQQwFwLL-CONH2	Investigative
T13453	DRUGINFO	D0DD3F	(Sar)WTLNSAGYLLGPKK(Lys-myristoyl)K	Investigative
T13453	DRUGINFO	D0EO5F	(Sar)WTLNSAGYLLGPKK(Lys-palmitoyl)K	Investigative
T13453	DRUGINFO	D0H4DF	GALANTIDE	Investigative
T13453	DRUGINFO	D0H9QA	Gal-B5	Investigative
T13453	DRUGINFO	D0NJ4R	GALANIN	Investigative
T13453	DRUGINFO	D0PY7O	WTLNSAGYLL-CONH2	Investigative
T13453	DRUGINFO	D0Q3CB	GWTLNSAGYLLGPPPALALA-CONH2	Investigative
T13453	DRUGINFO	D0S4VO	[N-Me,des-Sar]Gal-B2	Investigative
T13453	DRUGINFO	D0SV5D	GWTLNSAGYLLGPPPGFSPFR-CONH2	Investigative
T13453	DRUGINFO	D0T6CU	WTLNSAGYLLGPHAVGNHPSFSDKNGLTS-CONH2	Investigative
T13453	DRUGINFO	D0TF7R	(Sar)WTLNSAGYLLGPKKKK	Investigative
T13453	DRUGINFO	D0V7UG	[N-Ac,des-Sar]Gal-B2	Investigative
T13453	DRUGINFO	D0Z3QG	(Sar)WTLNSAGYLLGPKK(Lys-stearoyl)K	Investigative
T13453	DRUGINFO	D0Z7QU	GWTLNSAGYLLGPRHYINLITRQRY-CONH2	Investigative

T43289	TARGETID	T43289
T43289	FORMERID	TTDR00461
T43289	UNIPROID	KLK8_HUMAN
T43289	TARGNAME	Neuropsin (KLK8)
T43289	GENENAME	KLK8
T43289	TARGTYPE	Literature-reported
T43289	SYNONYMS	hK8; UNQ283/PRO322; Tumor-associated differentially expressed gene-14 protein; Tumor-associated differentially expressed gene 14 protein; TADG14; Serine protease TADG-14; Serine protease 19; PRSS19; Ovasin; Neuropsin (M(r) 25032); NRPN; NP; Kallikrein-8; Kallikrein 8; KLK8 (neuropsin/ovasin)
T43289	FUNCTION	Cleaves L1CAM in response to increased neural activity. Induces neurite outgrowth and fasciculation of cultured hippocampal neurons. Plays a role in the formation and maturation of orphan and small synaptic boutons in the Schaffer-collateral pathway, regulates Schaffer-collateral long-term potentiation in the hippocampus and is required for memory acquisition and synaptic plasticity. Involved in skin desquamation and keratinocyte proliferation. Plays a role in the secondary phase of pathogenesis following spinal cord injury. Serine protease which is capable of degrading a number of proteins such as casein, fibrinogen, kininogen, fibronectin and collagen type IV.
T43289	PDBSTRUC	5MS4; 5MS3
T43289	BIOCLASS	Peptidase
T43289	ECNUMBER	EC 3.4.21.118
T43289	SEQUENCE	MGRPRPRAAKTWMFLLLLGGAWAGHSRAQEDKVLGGHECQPHSQPWQAALFQGQQLLCGGVLVGGNWVLTAAHCKKPKYTVRLGDHSLQNKDGPEQEIPVVQSIPHPCYNSSDVEDHNHDLMLLQLRDQASLGSKVKPISLADHCTQPGQKCTVSGWGTVTSPRENFPDTLNCAEVKIFPQKKCEDAYPGQITDGMVCAGSSKGADTCQGDSGGPLVCDGALQGITSWGSDPCGRSDKPGVYTNICRYLDWIKKIIGSKG

T78019	TARGETID	T78019
T78019	FORMERID	TTDI00244
T78019	UNIPROID	TP4A3_HUMAN
T78019	TARGNAME	Protein tyrosine phosphatase IVA 3 (PRL-3)
T78019	GENENAME	PTP4A3
T78019	TARGTYPE	Literature-reported
T78019	SYNONYMS	Protein-tyrosine phosphatase of regenerating liver 3; Protein-tyrosine phosphatase 4a3; Protein tyrosine phosphatase type IVA 3; PRL3; PRL-3
T78019	FUNCTION	Protein tyrosine phosphatase which stimulates progression from G1 into S phase during mitosis. Enhances cell proliferation, cell motility and invasive activity, and promotes cancer metastasis. May be involved in the progression of cardiac hypertrophy by inhibiting intracellular calcium mobilization in response to angiotensin II.
T78019	PDBSTRUC	5TSR; 2MBC; 1V3A; 1R6H
T78019	BIOCLASS	Phosphoric monoester hydrolase
T78019	ECNUMBER	EC 3.1.3.48
T78019	SEQUENCE	MARMNRPAPVEVSYKHMRFLITHNPTNATLSTFIEDLKKYGATTVVRVCEVTYDKTPLEKDGITVVDWPFDDGAPPPGKVVEDWLSLVKAKFCEAPGSCVAVHCVAGLGRAPVLVALALIESGMKYEDAIQFIRQKRRGAINSKQLTYLEKYRPKQRLRFKDPHTHKTRCCVM
T78019	DRUGINFO	D0C6RO	Sodium orthovanadate	Investigative

T79307	TARGETID	T79307
T79307	FORMERID	TTDI03612
T79307	UNIPROID	ULK1_HUMAN
T79307	TARGNAME	Serine/threonine-protein kinase ULK1 (ULK1)
T79307	GENENAME	ULK1
T79307	TARGTYPE	Literature-reported
T79307	SYNONYMS	hATG1; Unc-51-like kinase 1; KIAA0722; Autophagy-related protein 1 homolog; ATG1
T79307	FUNCTION	Acts upstream of phosphatidylinositol 3-kinase PIK3C3 to regulate the formation of autophagophores, the precursors of autophagosomes. Part of regulatory feedback loops in autophagy: acts both as a downstream effector and negative regulator of mammalian target of rapamycin complex 1 (mTORC1) via interaction with RPTOR. Activated via phosphorylation by AMPK and also acts as a regulator of AMPK by mediating phosphorylation of AMPK subunits PRKAA1, PRKAB2 and PRKAG1, leading to negatively regulate AMPK activity. May phosphorylate ATG13/KIAA0652 and RPTOR; however such data need additional evidences. Plays a role early in neuronal differentiation and is required for granule cell axon formation. May also phosphorylate SESN2 and SQSTM1 to regulate autophagy. Serine/threonine-protein kinase involved in autophagy in response to starvation.
T79307	PDBSTRUC	6QAS; 6MNH; 6HYO; 5CI7; 4WNP
T79307	BIOCLASS	Kinase
T79307	ECNUMBER	EC 2.7.11.1
T79307	SEQUENCE	MEPGRGGTETVGKFEFSRKDLIGHGAFAVVFKGRHREKHDLEVAVKCINKKNLAKSQTLLGKEIKILKELKHENIVALYDFQEMANSVYLVMEYCNGGDLADYLHAMRTLSEDTIRLFLQQIAGAMRLLHSKGIIHRDLKPQNILLSNPAGRRANPNSIRVKIADFGFARYLQSNMMAATLCGSPMYMAPEVIMSQHYDGKADLWSIGTIVYQCLTGKAPFQASSPQDLRLFYEKNKTLVPTIPRETSAPLRQLLLALLQRNHKDRMDFDEFFHHPFLDASPSVRKSPPVPVPSYPSSGSGSSSSSSSTSHLASPPSLGEMQQLQKTLASPADTAGFLHSSRDSGGSKDSSCDTDDFVMVPAQFPGDLVAEAPSAKPPPDSLMCSGSSLVASAGLESHGRTPSPSPPCSSSPSPSGRAGPFSSSRCGASVPIPVPTQVQNYQRIERNLQSPTQFQTPRSSAIRRSGSTSPLGFARASPSPPAHAEHGGVLARKMSLGGGRPYTPSPQVGTIPERPGWSGTPSPQGAEMRGGRSPRPGSSAPEHSPRTSGLGCRLHSAPNLSDLHVVRPKLPKPPTDPLGAVFSPPQASPPQPSHGLQSCRNLRGSPKLPDFLQRNPLPPILGSPTKAVPSFDFPKTPSSQNLLALLARQGVVMTPPRNRTLPDLSEVGPFHGQPLGPGLRPGEDPKGPFGRSFSTSRLTDLLLKAAFGTQAPDPGSTESLQEKPMEIAPSAGFGGSLHPGARAGGTSSPSPVVFTVGSPPSGSTPPQGPRTRMFSAGPTGSASSSARHLVPGPCSEAPAPELPAPGHGCSFADPITANLEGAVTFEAPDLPEETLMEQEHTEILRGLRFTLLFVQHVLEIAALKGSASEAAGGPEYQLQESVVADQISLLSREWGFAEQLVLYLKVAELLSSGLQSAIDQIRAGKLCLSSTVKQVVRRLNELYKASVVSCQGLSLRLQRFFLDKQRLLDRIHSITAERLIFSHAVQMVQSAALDEMFQHREGCVPRYHKALLLLEGLQHMLSDQADIENVTKCKLCIERRLSALLTGICA
T79307	DRUGINFO	D00EMH	PMID21967808CR-16	Investigative

T25690	TARGETID	T25690
T25690	FORMERID	TTDI00166
T25690	UNIPROID	CISY_HUMAN
T25690	TARGNAME	Citrate synthase (CS)
T25690	GENENAME	CS
T25690	TARGTYPE	Literature-reported
T25690	SYNONYMS	Citrate synthase, mitochondrial; Citrate (Si)-synthase
T25690	FUNCTION	extracellular exosome, mitochondrial matrix, mitochondrion, nucleus, citrate (Si)-synthase activity, RNA binding, carbohydrate metabolic process, tricarboxylic acid cycle.
T25690	PDBSTRUC	5UZR; 5UZQ; 5UZP
T25690	BIOCLASS	Acyltransferase
T25690	ECNUMBER	EC 2.3.3.1
T25690	SEQUENCE	MALLTAAARLLGTKNASCLVLAARHASASSTNLKDILADLIPKEQARIKTFRQQHGKTVVGQITVDMMYGGMRGMKGLVYETSVLDPDEGIRFRGFSIPECQKLLPKAKGGEEPLPEGLFWLLVTGHIPTEEQVSWLSKEWAKRAALPSHVVTMLDNFPTNLHPMSQLSAAVTALNSESNFARAYAQGISRTKYWELIYEDSMDLIAKLPCVAAKIYRNLYREGSGIGAIDSNLDWSHNFTNMLGYTDHQFTELTRLYLTIHSDHEGGNVSAHTSHLVGSALSDPYLSFAAAMNGLAGPLHGLANQEVLVWLTQLQKEVGKDVSDEKLRDYIWNTLNSGRVVPGYGHAVLRKTDPRYTCQREFALKHLPNDPMFKLVAQLYKIVPNVLLEQGKAKNPWPNVDAHSGVLLQYYGMTEMNYYTVLFGVSRALGVLAQLIWSRALGFPLERPKSMSTEGLMKFVDSKSG

T78205	TARGETID	T78205
T78205	FORMERID	TTDR00987
T78205	UNIPROID	TRPM2_HUMAN
T78205	TARGNAME	Long transient receptor potential channel 2 (TRPM2)
T78205	GENENAME	TRPM2
T78205	TARGTYPE	Literature-reported
T78205	SYNONYMS	TrpC7; Transient receptor potential melastatin 2; Transient receptor potential channel 7; Transient receptor potential cation channel subfamily M member 2; LTrpC2; LTrpC-2; Estrogen-responsive element-associated gene 1 protein; EREG1
T78205	FUNCTION	Isoform 1: Nonselective, voltage-independent cation channel that mediates Na(+) and Ca(2+) influx, leading to increased cytoplasmic Ca(2+) levels. Functions as ligand-gated ion channel. Binding of ADP-ribose to the cytoplasmic Nudix domain causes a conformation change; the channel is primed but still requires Ca(2+) binding to trigger channel opening. Extracellular calcium passes through the channel and increases channel activity. Contributes to Ca(2+) release from intracellular stores in response to ADP-ribose. Plays a role in numerous processes that involve signaling via intracellular Ca(2+) levels (Probable). Besides, mediates the release of lysosomal Zn(2+) stores in response to reactive oxygen species, leading to increased cytosolic Zn(2+) levels. Activated by moderate heat (35 to 40 degrees Celsius). Activated by intracellular ADP-ribose, beta-NAD (NAD(+)) and similar compounds, and by oxidative stress caused by reactive oxygen or nitrogen species. The precise physiological activators are under debate; the true, physiological activators may be ADP-ribose and ADP-ribose-2'-phosphate. Activation by ADP-ribose and beta-NAD is strongly increased by moderate heat (35 to 40 degrees Celsius). Likewise, reactive oxygen species lower the threshold for activation by moderate heat (37 degrees Celsius). Plays a role in mediating behavorial and physiological responses to moderate heat and thereby contributes to body temperature homeostasis. Plays a role in insulin secretion, a process that requires increased cytoplasmic Ca(2+) levels (By similarity). Required for normal IFNG and cytokine secretion and normal innate immune immunity in response to bacterial infection. Required for normal phagocytosis and cytokine release by macrophages exposed to zymosan (in vitro). Plays a role in dendritic cell differentiation and maturation, and in dendritic cell chemotaxis via its role in regulating cytoplasmic Ca(2+) levels (By similarity). Plays a role in the regulation of the reorganization of the actin cytoskeleton and filopodia formation in response to reactive oxygen species via its role in increasing cytoplasmic Ca(2+) and Zn(2+) levels. Confers susceptibility to cell death following oxidative stress.
T78205	PDBSTRUC	6MJ2; 6MIZ; 6MIX
T78205	BIOCLASS	Transient receptor potential catioin channel
T78205	SEQUENCE	MEPSALRKAGSEQEEGFEGLPRRVTDLGMVSNLRRSNSSLFKSWRLQCPFGNNDKQESLSSWIPENIKKKECVYFVESSKLSDAGKVVCQCGYTHEQHLEEATKPHTFQGTQWDPKKHVQEMPTDAFGDIVFTGLSQKVKKYVRVSQDTPSSVIYHLMTQHWGLDVPNLLISVTGGAKNFNMKPRLKSIFRRGLVKVAQTTGAWIITGGSHTGVMKQVGEAVRDFSLSSSYKEGELITIGVATWGTVHRREGLIHPTGSFPAEYILDEDGQGNLTCLDSNHSHFILVDDGTHGQYGVEIPLRTRLEKFISEQTKERGGVAIKIPIVCVVLEGGPGTLHTIDNATTNGTPCVVVEGSGRVADVIAQVANLPVSDITISLIQQKLSVFFQEMFETFTESRIVEWTKKIQDIVRRRQLLTVFREGKDGQQDVDVAILQALLKASRSQDHFGHENWDHQLKLAVAWNRVDIARSEIFMDEWQWKPSDLHPTMTAALISNKPEFVKLFLENGVQLKEFVTWDTLLYLYENLDPSCLFHSKLQKVLVEDPERPACAPAAPRLQMHHVAQVLRELLGDFTQPLYPRPRHNDRLRLLLPVPHVKLNVQGVSLRSLYKRSSGHVTFTMDPIRDLLIWAIVQNRRELAGIIWAQSQDCIAAALACSKILKELSKEEEDTDSSEEMLALAEEYEHRAIGVFTECYRKDEERAQKLLTRVSEAWGKTTCLQLALEAKDMKFVSHGGIQAFLTKVWWGQLSVDNGLWRVTLCMLAFPLLLTGLISFREKRLQDVGTPAARARAFFTAPVVVFHLNILSYFAFLCLFAYVLMVDFQPVPSWCECAIYLWLFSLVCEEMRQLFYDPDECGLMKKAALYFSDFWNKLDVGAILLFVAGLTCRLIPATLYPGRVILSLDFILFCLRLMHIFTISKTLGPKIIIVKRMMKDVFFFLFLLAVWVVSFGVAKQAILIHNERRVDWLFRGAVYHSYLTIFGQIPGYIDGVNFNPEHCSPNGTDPYKPKCPESDATQQRPAFPEWLTVLLLCLYLLFTNILLLNLLIAMFNYTFQQVQEHTDQIWKFQRHDLIEEYHGRPAAPPPFILLSHLQLFIKRVVLKTPAKRHKQLKNKLEKNEEAALLSWEIYLKENYLQNRQFQQKQRPEQKIEDISNKVDAMVDLLDLDPLKRSGSMEQRLASLEEQVAQTAQALHWIVRTLRASGFSSEADVPTLASQKAAEEPDAEPGGRKKTEEPGDSYHVNARHLLYPNCPVTRFPVPNEKVPWETEFLIYDPPFYTAERKDAAAMDPMGDTLEPLSTIQYNVVDGLRDRRSFHGPYTVQAGLPLNPMGRTGLRGRGSLSCFGPNHTLYPMVTRWRRNEDGAICRKSIKKMLEVLVVKLPLSEHWALPGGSREPGEMLPRKLKRILRQEHWPSFENLLKCGMEVYKGYMDDPRNTDNAWIETVAVSVHFQDQNDVELNRLNSNLHACDSGASIRWQVVDRRIPLYANHKTLLQKAAAEFGAHY
T78205	DRUGINFO	D01CNF	OAADPR	Investigative
T78205	DRUGINFO	D0E9LJ	ADP ribose	Investigative
T78205	DRUGINFO	D0Q1HN	GEA 3162	Investigative
T78205	DRUGINFO	D0YO2D	cADPR	Investigative
T78205	DRUGINFO	D07RTQ	NAADP	Investigative
T78205	DRUGINFO	D0N7MS	ACAA	Investigative
T78205	DRUGINFO	D00HCI	2-APB	Investigative

T68470	TARGETID	T68470
T68470	FORMERID	TTDI03610
T68470	UNIPROID	UBP1_HUMAN
T68470	TARGNAME	Deubiquitinating enzyme 1 (USP1)
T68470	GENENAME	USP1
T68470	TARGTYPE	Literature-reported
T68470	SYNONYMS	hUBP; Ubiquitin-specific-processing protease 1; Ubiquitin thioesterase 1; Ubiquitin carboxyl-terminal hydrolase 1
T68470	FUNCTION	Involved in PCNA-mediated translesion synthesis (TLS) by deubiquitinating monoubiquitinated PCNA. Has almost no deubiquitinating activity by itself and requires the interaction with WDR48 to have a high activity. Negative regulator of DNA damage repair which specifically deubiquitinates monoubiquitinated FANCD2.
T68470	PDBSTRUC	6DO5
T68470	BIOCLASS	Peptidase
T68470	ECNUMBER	EC 3.4.19.12
T68470	SEQUENCE	MPGVIPSESNGLSRGSPSKKNRLSLKFFQKKETKRALDFTDSQENEEKASEYRASEIDQVVPAAQSSPINCEKRENLLPFVGLNNLGNTCYLNSILQVLYFCPGFKSGVKHLFNIISRKKEALKDEANQKDKGNCKEDSLASYELICSLQSLIISVEQLQASFLLNPEKYTDELATQPRRLLNTLRELNPMYEGYLQHDAQEVLQCILGNIQETCQLLKKEEVKNVAELPTKVEEIPHPKEEMNGINSIEMDSMRHSEDFKEKLPKGNGKRKSDTEFGNMKKKVKLSKEHQSLEENQRQTRSKRKATSDTLESPPKIIPKYISENESPRPSQKKSRVKINWLKSATKQPSILSKFCSLGKITTNQGVKGQSKENECDPEEDLGKCESDNTTNGCGLESPGNTVTPVNVNEVKPINKGEEQIGFELVEKLFQGQLVLRTRCLECESLTERREDFQDISVPVQEDELSKVEESSEISPEPKTEMKTLRWAISQFASVERIVGEDKYFCENCHHYTEAERSLLFDKMPEVITIHLKCFAASGLEFDCYGGGLSKINTPLLTPLKLSLEEWSTKPTNDSYGLFAVVMHSGITISSGHYTASVKVTDLNSLELDKGNFVVDQMCEIGKPEPLNEEEARGVVENYNDEEVSIRVGGNTQPSKVLNKKNVEAIGLLGGQKSKADYELYNKASNPDKVASTAFAENRNSETSDTTGTHESDRNKESSDQTGINISGFENKISYVVQSLKEYEGKWLLFDDSEVKVTEEKDFLNSLSPSTSPTSTPYLLFYKKL
T68470	DRUGINFO	D0M5FO	ML323	Preclinical

T33969	TARGETID	T33969
T33969	FORMERID	TTDS00278
T33969	UNIPROID	ABCBB_HUMAN
T33969	TARGNAME	ATP-binding cassette transporter B11 (ABCB11)
T33969	GENENAME	ABCB11
T33969	TARGTYPE	Literature-reported
T33969	SYNONYMS	BSEP; ATP-binding cassette, sub-family B, member 11; ATP-binding cassette sub-family B member 11
T33969	FUNCTION	Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
T33969	BIOCLASS	ABC transporter
T33969	SEQUENCE	MSDSVILRSIKKFGEENDGFESDKSYNNDKKSRLQDEKKGDGVRVGFFQLFRFSSSTDIWLMFVGSLCAFLHGIAQPGVLLIFGTMTDVFIDYDVELQELQIPGKACVNNTIVWTNSSLNQNMTNGTRCGLLNIESEMIKFASYYAGIAVAVLITGYIQICFWVIAAARQIQKMRKFYFRRIMRMEIGWFDCNSVGELNTRFSDDINKINDAIADQMALFIQRMTSTICGFLLGFFRGWKLTLVIISVSPLIGIGAATIGLSVSKFTDYELKAYAKAGVVADEVISSMRTVAAFGGEKREVERYEKNLVFAQRWGIRKGIVMGFFTGFVWCLIFLCYALAFWYGSTLVLDEGEYTPGTLVQIFLSVIVGALNLGNASPCLEAFATGRAAATSIFETIDRKPIIDCMSEDGYKLDRIKGEIEFHNVTFHYPSRPEVKILNDLNMVIKPGEMTALVGPSGAGKSTALQLIQRFYDPCEGMVTVDGHDIRSLNIQWLRDQIGIVEQEPVLFSTTIAENIRYGREDATMEDIVQAAKEANAYNFIMDLPQQFDTLVGEGGGQMSGGQKQRVAIARALIRNPKILLLDMATSALDNESEAMVQEVLSKIQHGHTIISVAHRLSTVRAADTIIGFEHGTAVERGTHEELLERKGVYFTLVTLQSQGNQALNEEDIKDATEDDMLARTFSRGSYQDSLRASIRQRSKSQLSYLVHEPPLAVVDHKSTYEEDRKDKDIPVQEEVEPAPVRRILKFSAPEWPYMLVGSVGAAVNGTVTPLYAFLFSQILGTFSIPDKEEQRSQINGVCLLFVAMGCVSLFTQFLQGYAFAKSGELLTKRLRKFGFRAMLGQDIAWFDDLRNSPGALTTRLATDASQVQGAAGSQIGMIVNSFTNVTVAMIIAFSFSWKLSLVILCFFPFLALSGATQTRMLTGFASRDKQALEMVGQITNEALSNIRTVAGIGKERRFIEALETELEKPFKTAIQKANIYGFCFAFAQCIMFIANSASYRYGGYLISNEGLHFSYVFRVISAVVLSATALGRAFSYTPSYAKAKISAARFFQLLDRQPPISVYNTAGEKWDNFQGKIDFVDCKFTYPSRPDSQVLNGLSVSISPGQTLAFVGSSGCGKSTSIQLLERFYDPDQGKVMIDGHDSKKVNVQFLRSNIGIVSQEPVLFACSIMDNIKYGDNTKEIPMERVIAAAKQAQLHDFVMSLPEKYETNVGSQGSQLSRGEKQRIAIARAIVRDPKILLLDEATSALDTESEKTVQVALDKAREGRTCIVIAHRLSTIQNADIIAVMAQGVVIEKGTHEELMAQKGAYYKLVTTGSPIS

T04696	TARGETID	T04696
T04696	FORMERID	TTDNR00765
T04696	UNIPROID	TYDP2_HUMAN
T04696	TARGNAME	Tyrosyl-DNA phosphodiesterase 2 (TDP2)
T04696	GENENAME	TDP2
T04696	TARGTYPE	Literature-reported
T04696	SYNONYMS	hTDP2; VPg unlinkase; Tyrosyl-RNA phosphodiesterase; Tyr-DNA phosphodiesterase 2; TRAF and TNF receptor-associated protein; TDP2; ETS1-associated protein II; ETS1-associated protein 2; EAPII; 5'-tyrosyl-DNA phosphodiesterase; 5'-Tyr-DNA phosphodiesterase
T04696	FUNCTION	DNA repair enzyme that can remove a variety of covalent adducts from DNA through hydrolysis of a 5'-phosphodiester bond, giving rise to DNA with a free 5' phosphate. Catalyzes the hydrolysis of dead-end complexes between DNA and the topoisomerase 2 (TOP2) active site tyrosine residue. Hydrolyzes 5'- phosphoglycolates on protruding 5' ends on DNA double-strand breaks (DSBs) due to DNA damage by radiation and free radicals. The 5'-tyrosyl DNA phosphodiesterase activity can enable the repair of TOP2-induced DSBs without the need for nuclease activity, creating a 'clean' DSB with 5'-phosphate termini that are ready for ligation. Has preference for single-stranded DNA or duplex DNA with a 4 base pair overhang as substrate. Has also 3'- tyrosyl DNA phosphodiesterase activity, but less efficiently and much slower than TDP1. Constitutes the major if not only 5'- tyrosyl-DNA phosphodiesterase in cells. Also acts as a 5'-tyrosyl- RNA phosphodiesterase following picornavirus infection: its activity is hijacked by picornavirus and acts by specifically cleaving the protein-RNA covalent linkage generated during the viral genomic RNA replication steps of a picornavirus infection, without impairing the integrity of viral RNA. Also acts as an adapter by participating in the specific activation of MAP3K7/TAK1 in response to TGF-beta: associates with components of the TGF- beta receptor-TRAF6-TAK1 signaling module and promotes their ubiquitination dependent complex formation. Involved in non- canonical TGF-beta induced signaling routes. May also act as a negative regulator of ETS1 and may inhibit NF-kappa-B activation. Acts as a regulator of ribosome biogenesis following stress.
T04696	PDBSTRUC	5J3S; 5J3P; 5INO
T04696	BIOCLASS	Phosphoric diester hydrolase
T04696	ECNUMBER	EC 3.1.4.-
T04696	SEQUENCE	MELGSCLEGGREAAEEEGEPEVKKRRLLCVEFASVASCDAAVAQCFLAENDWEMERALNSYFEPPVEESALERRPETISEPKTYVDLTNEETTDSTTSKISPSEDTQQENGSMFSLITWNIDGLDLNNLSERARGVCSYLALYSPDVIFLQEVIPPYYSYLKKRSSNYEIITGHEEGYFTAIMLKKSRVKLKSQEIIPFPSTKMMRNLLCVHVNVSGNELCLMTSHLESTRGHAAERMNQLKMVLKKMQEAPESATVIFAGDTNLRDREVTRCGGLPNNIVDVWEFLGKPKHCQYTWDTQMNSNLGITAACKLRFDRIFFRAAAEEGHIIPRSLDLLGLEKLDCGRFPSDHWGLLCNLDIIL

T13086	TARGETID	T13086
T13086	FORMERID	TTDNR00709
T13086	UNIPROID	NET1_HUMAN
T13086	TARGNAME	Netrin-1 (NTN1)
T13086	GENENAME	NTN1
T13086	TARGTYPE	Literature-reported
T13086	SYNONYMS	NTN1; Epididymis tissue protein Li 131P
T13086	FUNCTION	Netrins control guidance of CNS commissural axons and peripheral motor axons. Its association with either Dor some UNC5 receptors will lead to axon attraction or repulsion, respectively. It also serve as a survival factor via its association with its receptors which prevent the initiation of apoptosis. Involved in tumorigenesis by regulating apoptosis.
T13086	PDBSTRUC	6FKQ; 4URT
T13086	SEQUENCE	MMRAVWEALAALAAVACLVGAVRGGPGLSMFAGQAAQPDPCSDENGHPRRCIPDFVNAAFGKDVRVSSTCGRPPARYCVVSERGEERLRSCHLCNASDPKKAHPPAFLTDLNNPHNLTCWQSENYLQFPHNVTLTLSLGKKFEVTYVSLQFCSPRPESMAIYKSMDYGRTWVPFQFYSTQCRKMYNRPHRAPITKQNEQEAVCTDSHTDMRPLSGGLIAFSTLDGRPSAHDFDNSPVLQDWVTATDIRVAFSRLHTFGDENEDDSELARDSYFYAVSDLQVGGRCKCNGHAARCVRDRDDSLVCDCRHNTAGPECDRCKPFHYDRPWQRATAREANECVACNCNLHARRCRFNMELYKLSGRKSGGVCLNCRHNTAGRHCHYCKEGYYRDMGKPITHRKACKACDCHPVGAAGKTCNQTTGQCPCKDGVTGITCNRCAKGYQQSRSPIAPCIKIPVAPPTTAASSVEEPEDCDSYCKASKGKLKINMKKYCKKDYAVQIHILKADKAGDWWKFTVNIISVYKQGTSRIRRGDQSLWIRSRDIACKCPKIKPLKKYLLLGNAEDSPDQSGIVADKSSLVIQWRDTWARRLRKFQQREKKGKCKKA

T26748	TARGETID	T26748
T26748	FORMERID	TTDR00710
T26748	UNIPROID	NUDT3_HUMAN
T26748	TARGNAME	Diphosphoinositol polyphosphate phosphohydrolase 2 (NUDT3)
T26748	GENENAME	NUDT3
T26748	TARGTYPE	Literature-reported
T26748	SYNONYMS	NUDT3; Diphosphoinositol polyphosphate phosphohydrolase; DIPP2
T26748	FUNCTION	Cleaves a beta-phosphate from the diphosphate groups in PP-InsP5 (diphosphoinositol pentakisphosphate) and [PP]2-InsP4 (bisdiphosphoinositol tetrakisphosphate), suggesting that it may play a role in signal transduction. InsP6 (inositol hexakisphophate) is not a substrate. Acts as a negative regulator of the ERK1/2 pathway. Also able to catalyze the hydrolysis of dinucleoside oligophosphates, with Ap6A and Ap5A being the preferred substrates. The major reaction products are ADP and p4a from Ap6A and ADP and ATP from Ap5A. Also able to hydrolyze 5- phosphoribose 1-diphosphate.
T26748	PDBSTRUC	2Q9P; 2FVV
T26748	BIOCLASS	Acid anhydrides hydrolase
T26748	ECNUMBER	EC 3.6.1.52
T26748	SEQUENCE	MMKLKSNQTRTYDGDGYKKRAACLCFRSESEEEVLLVSSSRHPDRWIVPGGGMEPEEEPSVAAVREVCEEAGVKGTLGRLVGIFENQERKHRTYVYVLIVTEVLEDWEDSVNIGRKREWFKIEDAIKVLQYHKPVQASYFETLRQGYSANNGTPVVATTYSVSAQSSMSGIR

T15053	TARGETID	T15053
T15053	FORMERID	TTDI00006
T15053	UNIPROID	LDHA_HUMAN
T15053	TARGNAME	Lactate dehydrogenase A (LDHA)
T15053	GENENAME	LDHA
T15053	TARGTYPE	Literature-reported
T15053	SYNONYMS	Renal carcinoma antigen NYREN59; Renal carcinoma antigen NY-REN-59; PIG19; Llactate dehydrogenase A chain; LDHM; LDH-M; LDH-A; LDH muscle subunit; L-lactate dehydrogenase A chain; Cell proliferationinducing gene 19 protein; Cell proliferation-inducing gene 19 protein
T15053	FUNCTION	Cadherin binding, L-lactate dehydrogenase activity, glycolytic process, pyruvate metabolic process, substantia nigra development.
T15053	PDBSTRUC	6BB3; 6BB2; 6BB1; 6BB0; 6BAZ
T15053	BIOCLASS	CH-OH donor oxidoreductase
T15053	ECNUMBER	EC 1.1.1.27
T15053	SEQUENCE	MATLKDQLIYNLLKEEQTPQNKITVVGVGAVGMACAISILMKDLADELALVDVIEDKLKGEMMDLQHGSLFLRTPKIVSGKDYNVTANSKLVIITAGARQQEGESRLNLVQRNVNIFKFIIPNVVKYSPNCKLLIVSNPVDILTYVAWKISGFPKNRVIGSGCNLDSARFRYLMGERLGVHPLSCHGWVLGEHGDSSVPVWSGMNVAGVSLKTLHPDLGTDKDKEQWKEVHKQVVESAYEVIKLKGYTSWAIGLSVADLAESIMKNLRRVHPVSTMIKGLYGIKDDVFLSVPCILGQNGISDLVKVTLTSEEEARLKKSADTLWGIQKELQF

T95408	TARGETID	T95408
T95408	FORMERID	TTDR00739
T95408	UNIPROID	SODM_ECOLI
T95408	TARGNAME	Bacterial Superoxide dismutase Mn (Bact sodA)
T95408	GENENAME	Bact sodA
T95408	TARGTYPE	Literature-reported
T95408	SYNONYMS	sodA; MnSOD; Mn-SOD; Manganese superoxide dismutase
T95408	FUNCTION	Destroys superoxide anion radicals which are normally produced within the cells and which are toxic to biological systems.
T95408	PDBSTRUC	3OT7; 3K9S; 1ZLZ; 1VEW; 1MMM
T95408	BIOCLASS	Superoxide acceptor oxidoreductase
T95408	ECNUMBER	EC 1.15.1.1
T95408	SEQUENCE	MSYTLPSLPYAYDALEPHFDKQTMEIHHTKHHQTYVNNANAALESLPEFANLPVEELITKLDQLPADKKTVLRNNAGGHANHSLFWKGLKKGTTLQGDLKAAIERDFGSVDNFKAEFEKAAASRFGSGWAWLVLKGDKLAVVSTANQDSPLMGEAISGASGFPIMGLDVWEHAYYLKFQNRRPDYIKEFWNVVNWDEAAARFAAKK

T67942	TARGETID	T67942
T67942	FORMERID	TTDR00871
T67942	UNIPROID	METB_ECOLI
T67942	TARGNAME	Bacterial Cystathionine gamma-synthase (Bact metB)
T67942	GENENAME	Bact metB
T67942	TARGTYPE	Literature-reported
T67942	SYNONYMS	metB; O-succinylhomoserine (Thiol)-lyase; CGS
T67942	FUNCTION	Catalyzes the formation of L-cystathionine from O- succinyl-L-homoserine (OSHS) and L-cysteine, via a gamma- replacement reaction. In the absence of thiol, catalyzes gamma- elimination to form 2-oxobutanoate, succinate and ammonia.
T67942	PDBSTRUC	1CS1
T67942	BIOCLASS	Alkyl aryl transferase
T67942	ECNUMBER	EC 2.5.1.48
T67942	SEQUENCE	MTRKQATIAVRSGLNDDEQYGCVVPPIHLSSTYNFTGFNEPRAHDYSRRGNPTRDVVQRALAELEGGAGAVLTNTGMSAIHLVTTVFLKPGDLLVAPHDCYGGSYRLFDSLAKRGCYRVLFVDQGDEQALRAALAEKPKLVLVESPSNPLLRVVDIAKICHLAREVGAVSVVDNTFLSPALQNPLALGADLVLHSCTKYLNGHSDVVAGVVIAKDPDVVTELAWWANNIGVTGGAFDSYLLLRGLRTLVPRMELAQRNAQAIVKYLQTQPLVKKLYHPSLPENQGHEIAARQQKGFGAMLSFELDGDEQTLRRFLGGLSLFTLAESLGGVESLISHAATMTHAGMAPEARAAAGISETLLRISTGIEDGEDLIADLENGFRAANKG
T67942	DRUGINFO	D03ESO	GW-3333	Preclinical
T67942	DRUGINFO	D0I5PZ	N'-Pyridoxyl-Lysine-5'-Monophosphate	Investigative

T16650	TARGETID	T16650
T16650	FORMERID	TTDR00389
T16650	UNIPROID	GLHA_HUMAN
T16650	TARGNAME	Glycoprotein hormones alpha (CGA)
T16650	GENENAME	CGA
T16650	TARGTYPE	Literature-reported
T16650	SYNONYMS	Thyrotropin alpha chain; Thyroid-stimulating hormone alpha chain; TSH-alpha; Lutropin alpha chain; Luteinizing hormone alpha chain; LSH-alpha; Glycoprotein hormones alpha chain; Follitropin alpha chain; Follicle-stimulating hormone alpha chain; FSH-alpha; Chorionic gonadotrophin subunit alpha; Choriogonadotropin alpha chain; CG-alpha; Anterior pituitary glycoprotein hormones common subunit alpha
T16650	FUNCTION	Shared alpha chain of the active heterodimeric glycoprotein hormones thyrotropin/thyroid stimulating hormone/TSH, lutropin/luteinizing hormone/LH, follitropin/follicle stimulating hormone/FSH and choriogonadotropin/CG. These hormones bind specific receptors on target cells that in turn activate downstream signaling pathways.
T16650	PDBSTRUC	4MQW; 4AY9; 1XWD; 1XUL; 1QFW
T16650	BIOCLASS	Glycoprotein hormone
T16650	SEQUENCE	MDYYRKYAAIFLVTLSVFLHVLHSAPDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS
T16650	DRUGINFO	D07LUR	Alpha-D-Mannose	Investigative

T25136	TARGETID	T25136
T25136	FORMERID	TTDR00448
T25136	UNIPROID	POL_HV1B1
T25136	TARGNAME	Human immunodeficiency virus Ribonuclease H (HIV RNH)
T25136	GENENAME	HIV RNH
T25136	TARGTYPE	Literature-reported
T25136	SYNONYMS	Retroviral ribonuclease H; RNase H (600-1159); RNH1
T25136	FUNCTION	Endonuclease that specifically degrades the RNA of RNA- DNA hybrids.
T25136	PDBSTRUC	6OE3; 6HAK; 6ELI; 6DUH; 6DUG
T25136	ECNUMBER	EC 2.7.7.49
T25136	SEQUENCE	PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKITTESIVIWGKTPKFKLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTNKGRQKVVPLTNTTNQKTELQAIYLALQDSGLEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKEKVYLAWVPAHKGIGGNEQVDKLVSAGIRKIL
T25136	DRUGINFO	D05SSB	2-hydroxyisoquinoline-1,3(2H,4H)-dione	Investigative
T25136	DRUGINFO	D0NS0E	3-hydroxyquinazoline-2,4(1H,3H)-dione	Investigative

T36729	TARGETID	T36729
T36729	FORMERID	TTDI02469
T36729	UNIPROID	CY24B_HUMAN
T36729	TARGNAME	NADPH oxidase 2 (CYBB)
T36729	GENENAME	CYBB
T36729	TARGTYPE	Literature-reported
T36729	SYNONYMS	p22 phagocyte Bcytochrome; p22 phagocyte B-cytochrome; gp91phox; gp911; gp91-phox; gp91-1; Superoxidegenerating NADPH oxidase heavy chain subunit; Superoxide-generating NADPH oxidase heavy chain subunit; Neutrophil cytochrome b 91 kDa polypeptide; NOX2; Hemebinding membrane glycoprotein gp91phox; Heme-binding membrane glycoprotein gp91phox; Cytochrome b558 subunit beta; Cytochrome b245 heavy chain; Cytochrome b-245 heavy chain; Cytochrome b(558) subunit beta; CGD91phox; CGD91-phox
T36729	FUNCTION	It is the terminal component of a respiratory chain that transfers single electrons from cytoplasmic NADPH across the plasma membrane to molecular oxygen on the exterior. Also functions as a voltage-gated proton channel that mediates the H(+) currents of resting phagocytes. It participates in the regulation of cellular pH and is blocked by zinc. Critical component of the membrane-bound oxidase of phagocytes that generates superoxide.
T36729	PDBSTRUC	3A1F
T36729	BIOCLASS	Phagocyte NADPH oxidase
T36729	ECNUMBER	EC 1.-.-.-
T36729	SEQUENCE	MGNWAVNEGLSIFVILVWLGLNVFLFVWYYRVYDIPPKFFYTRKLLGSALALARAPAACLNFNCMLILLPVCRNLLSFLRGSSACCSTRVRRQLDRNLTFHKMVAWMIALHSAIHTIAHLFNVEWCVNARVNNSDPYSVALSELGDRQNESYLNFARKRIKNPEGGLYLAVTLLAGITGVVITLCLILIITSSTKTIRRSYFEVFWYTHHLFVIFFIGLAIHGAERIVRGQTAESLAVHNITVCEQKISEWGKIKECPIPQFAGNPPMTWKWIVGPMFLYLCERLVRFWRSQQKVVITKVVTHPFKTIELQMKKKGFKMEVGQYIFVKCPKVSKLEWHPFTLTSAPEEDFFSIHIRIVGDWTEGLFNACGCDKQEFQDAWKLPKIAVDGPFGTASEDVFSYEVVMLVGAGIGVTPFASILKSVWYKYCNNATNLKLKKIYFYWLCRDTHAFEWFADLLQLLESQMQERNNAGFLSYNIYLTGWDESQANHFAVHHDEEKDVITGLKQKTLYGRPNWDNEFKTIASQHPNTRIGVFLCGPEALAETLSKQSISNSESGPRGVHFIFNKENF

T79476	TARGETID	T79476
T79476	FORMERID	TTDR00137
T79476	UNIPROID	ILVA_ECOLI
T79476	TARGNAME	Bacterial Threonine deaminase (Bact ilvA)
T79476	GENENAME	Bact ilvA
T79476	TARGTYPE	Literature-reported
T79476	SYNONYMS	ilvA; Putative threonine dehydratase
T79476	FUNCTION	Catalyzes the anaerobic formation of alpha-ketobutyrate and ammonia from threonine in a two-step reaction. The first step involved a dehydration of threonine and a production of enamine intermediates (aminocrotonate), which tautomerizes to its imine form(iminobutyrate). Both intermediates are unstable and short- lived. The second step is the nonenzymatic hydrolysis of the enamine/imine intermediates to form 2-ketobutyrate and free ammonia. In the low water environment of the cell, the second step is accelerated by RidA.
T79476	PDBSTRUC	1TDJ
T79476	BIOCLASS	Carbon-nitrogen lyases
T79476	ECNUMBER	EC 4.3.1.19
T79476	SEQUENCE	MADSQPLSGAPEGAEYLRAVLRAPVYEAAQVTPLQKMEKLSSRLDNVILVKREDRQPVHSFKLRGAYAMMAGLTEEQKAHGVITASAGNHAQGVAFSSARLGVKALIVMPTATADIKVDAVRGFGGEVLLHGANFDEAKAKAIELSQQQGFTWVPPFDHPMVIAGQGTLALELLQQDAHLDRVFVPVGGGGLAAGVAVLIKQLMPQIKVIAVEAEDSACLKAALDAGHPVDLPRVGLFAEGVAVKRIGDETFRLCQEYLDDIITVDSDAICAAMKDLFEDVRAVAEPSGALALAGMKKYIALHNIRGERLAHILSGANVNFHGLRYVSERCELGEQREALLAVTIPEEKGSFLKFCQLLGGRSVTEFNYRFADAKNACIFVGVRLSRGLEERKEILQMLNDGGYSVVDLSDDEMAKLHVRYMVGGRPSHPLQERLYSFEFPESPGALLRFLNTLGTYWNISLFHYRSHGTDYGRVLAAFELGDHEPDFETRLNELGYDCHDETNNPAFRFFLAG

T67258	TARGETID	T67258
T67258	FORMERID	TTDS00378
T67258	UNIPROID	HEP2_HUMAN
T67258	TARGNAME	Heparin cofactor II (SERPIND1)
T67258	GENENAME	SERPIND1
T67258	TARGTYPE	Literature-reported
T67258	SYNONYMS	SERPIND1; Protease inhibitor leuserpin 2; HLS2; HC-II
T67258	FUNCTION	Peptides at the N-terminal of HC-II have chemotactic activity for both monocytes and neutrophils.
T67258	PDBSTRUC	6J12; 2NCW; 2NCV; 2NCU; 2NAT
T67258	BIOCLASS	Serpin protein
T67258	SEQUENCE	MKHSLNALLIFLIITSAWGGSKGPLDQLEKGGETAQSADPQWEQLNNKNLSMPLLPADFHKENTVTNDWIPEGEEDDDYLDLEKIFSEDDDYIDIVDSLSVSPTDSDVSAGNILQLFHGKSRIQRLNILNAKFAFNLYRVLKDQVNTFDNIFIAPVGISTAMGMISLGLKGETHEQVHSILHFKDFVNASSKYEITTIHNLFRKLTHRLFRRNFGYTLRSVNDLYIQKQFPILLDFKTKVREYYFAEAQIADFSDPAFISKTNNHIMKLTKGLIKDALENIDPATQMMILNCIYFKGSWVNKFPVEMTHNHNFRLNEREVVKVSMMQTKGNFLAANDQELDCDILQLEYVGGISMLIVVPHKMSGMKTLEAQLTPRVVERWQKSMTNRTREVLLPKFKLEKNYNLVESLKLMGIRMLFDKNGNMAGISDQRIAIDLFKHQGTITVNEEGTQATTVTTVGFMPLSTQVRFTVDRPFLFLIYEHRTSCLLFMGRVANPSRS
T67258	DRUGINFO	D07LUR	Alpha-D-Mannose	Investigative

T49948	TARGETID	T49948
T49948	FORMERID	TTDR00104
T49948	UNIPROID	METC_ECOLI
T49948	TARGNAME	Bacterial Cystathionine beta-lyase (Bact metC)
T49948	GENENAME	Bact metC
T49948	TARGTYPE	Literature-reported
T49948	SYNONYMS	Cysteine-S-conjugate beta-lyase MetC; Cysteine lyase MetC; Cysteine desulfhydrase MetC; Cystathionine beta-lyase MetC; CL; CBL; Beta-cystathionase MetC; Bacterial CD
T49948	FUNCTION	Primarily catalyzes the cleavage of cystathionine to homocysteine, pyruvate and ammonia during methionine biosynthesis. Also exhibits cysteine desulfhydrase activity, producing sulfide from cysteine. In addition, under certain growth conditions, exhibits significant alanine racemase coactivity.
T49948	PDBSTRUC	4ITX; 4ITG; 2GQN; 2FQ6; 1CL2
T49948	BIOCLASS	Carbon-sulfur lyases
T49948	ECNUMBER	EC 4.4.1.13
T49948	SEQUENCE	MADKKLDTQLVNAGRSKKYTLGAVNSVIQRASSLVFDSVEAKKHATRNRANGELFYGRRGTLTHFSLQQAMCELEGGAGCVLFPCGAAAVANSILAFIEQGDHVLMTNTAYEPSQDFCSKILSKLGVTTSWFDPLIGADIVKHLQPNTKIVFLESPGSITMEVHDVPAIVAAVRSVVPDAIIMIDNTWAAGVLFKALDFGIDVSIQAATKYLVGHSDAMIGTAVCNARCWEQLRENAYLMGQMVDADTAYITSRGLRTLGVRLRQHHESSLKVAEWLAEHPQVARVNHPALPGSKGHEFWKRDFTGSSGLFSFVLKKKLNNEELANYLDNFSLFSMAYSWGGYESLILANQPEHIAAIRPQGEIDFSGTLIRLHIGLEDVDDLIADLDAGFARIV

T54316	TARGETID	T54316
T54316	FORMERID	TTDNR00680
T54316	UNIPROID	G6PI_HUMAN
T54316	TARGNAME	Glucose-6-phosphate isomerase (GPI)
T54316	GENENAME	GPI
T54316	TARGTYPE	Literature-reported
T54316	SYNONYMS	Sperm antigen 36; SA-36; Phosphohexose isomerase; Phosphoglucose isomerase; PHI; PGI; Neuroleukin; NLK; GPI; Autocrine motility factor; AMF
T54316	FUNCTION	Besides it's role as a glycolytic enzyme, mammalian GPI can function as a tumor-secreted cytokine and an angiogenic factor (AMF) that stimulates endothelial cell motility. GPI is also a neurotrophic factor (Neuroleukin) for spinal and sensory neurons.
T54316	PDBSTRUC	1NUH; 1JLH; 1JIQ; 1IRI; 1IAT
T54316	BIOCLASS	Intramolecular oxidoreductases
T54316	ECNUMBER	EC 5.3.1.9
T54316	SEQUENCE	MAALTRDPQFQKLQQWYREHRSELNLRRLFDANKDRFNHFSLTLNTNHGHILVDYSKNLVTEDVMRMLVDLAKSRGVEAARERMFNGEKINYTEGRAVLHVALRNRSNTPILVDGKDVMPEVNKVLDKMKSFCQRVRSGDWKGYTGKTITDVINIGIGGSDLGPLMVTEALKPYSSGGPRVWYVSNIDGTHIAKTLAQLNPESSLFIIASKTFTTQETITNAETAKEWFLQAAKDPSAVAKHFVALSTNTTKVKEFGIDPQNMFEFWDWVGGRYSLWSAIGLSIALHVGFDNFEQLLSGAHWMDQHFRTTPLEKNAPVLLALLGIWYINCFGCETHAMLPYDQYLHRFAAYFQQGDMESNGKYITKSGTRVDHQTGPIVWGEPGTNGQHAFYQLIHQGTKMIPCDFLIPVQTQHPIRKGLHHKILLANFLAQTEALMRGKSTEEARKELQAAGKSPEDLERLLPHKVFEGNRPTNSIVFTKLTPFMLGALVAMYEHKIFVQGIIWDINSFDQWGVELGKQLAKKIEPELDGSAQVTSHDASTNGLINFIKQQREARVQ

T70654	TARGETID	T70654
T70654	FORMERID	TTDR00320
T70654	UNIPROID	GPX1_HUMAN
T70654	TARGNAME	Glutathione peroxidase (GPX1)
T70654	GENENAME	GPX1
T70654	TARGTYPE	Literature-reported
T70654	SYNONYMS	GSHPx-1; GPX1; Cellular glutathione peroxidase
T70654	FUNCTION	Protects the hemoglobin in erythrocytes from oxidative breakdown.
T70654	PDBSTRUC	2F8A
T70654	BIOCLASS	Peroxidases
T70654	ECNUMBER	EC 1.11.1.9
T70654	SEQUENCE	MCAARLAAAAAAAQSVYAFSARPLAGGEPVSLGSLRGKVLLIENVASLUGTTVRDYTQMNELQRRLGPRGLVVLGFPCNQFGHQENAKNEEILNSLKYVRPGGGFEPNFMLFEKCEVNGAGAHPLFAFLREALPAPSDDATALMTDPKLITWSPVCRNDVAWNFEKFLVGPDGVPLRRYSRRFQTIDIEPDIEALLSQGPSCA

T29083	TARGETID	T29083
T29083	FORMERID	TTDI03196
T29083	UNIPROID	FES_HUMAN
T29083	TARGNAME	Proto-oncogene c-Fes (FES)
T29083	GENENAME	FES
T29083	TARGTYPE	Literature-reported
T29083	SYNONYMS	p93c-fes; Tyrosine-protein kinase Fes/Fps; Proto-oncogene c-Fps; Feline sarcoma/Fujinami avian sarcoma oncogene homolog; FPS
T29083	FUNCTION	Plays a role in FCER1 (high affinity immunoglobulin epsilon receptor)-mediated signaling in mast cells. Acts down-stream of the activated FCER1 receptor and the mast/stem cell growth factor receptor KIT. Plays a role in the regulation of mast cell degranulation. Plays a role in the regulation of cell differentiation and promotes neurite outgrowth in response to NGF signaling. Plays a role in cell scattering and cell migration in response to HGF-induced activation of EZR. Phosphorylates BCR and down-regulates BCR kinase activity. Phosphorylates HCLS1/HS1, PECAM1, STAT3 and TRIM28. Tyrosine-protein kinase that acts downstream of cell surface receptors and plays a role in the regulation of the actin cytoskeleton, microtubule assembly, cell attachment and cell spreading.
T29083	PDBSTRUC	4DYL; 4.00E+93; 3CD3; 3CBL; 3BKB
T29083	BIOCLASS	Kinase
T29083	ECNUMBER	EC 2.7.10.2
T29083	SEQUENCE	MGFSSELCSPQGHGVLQQMQEAELRLLEGMRKWMAQRVKSDREYAGLLHHMSLQDSGGQSRAISPDSPISQSWAEITSQTEGLSRLLRQHAEDLNSGPLSKLSLLIRERQQLRKTYSEQWQQLQQELTKTHSQDIEKLKSQYRALARDSAQAKRKYQEASKDKDRDKAKDKYVRSLWKLFAHHNRYVLGVRAAQLHHQHHHQLLLPGLLRSLQDLHEEMACILKEILQEYLEISSLVQDEVVAIHREMAAAAARIQPEAEYQGFLRQYGSAPDVPPCVTFDESLLEEGEPLEPGELQLNELTVESVQHTLTSVTDELAVATEMVFRRQEMVTQLQQELRNEEENTHPRERVQLLGKRQVLQEALQGLQVALCSQAKLQAQQELLQTKLEHLGPGEPPPVLLLQDDRHSTSSSEQEREGGRTPTLEILKSHISGIFRPKFSLPPPLQLIPEVQKPLHEQLWYHGAIPRAEVAELLVHSGDFLVRESQGKQEYVLSVLWDGLPRHFIIQSLDNLYRLEGEGFPSIPLLIDHLLSTQQPLTKKSGVVLHRAVPKDKWVLNHEDLVLGEQIGRGNFGEVFSGRLRADNTLVAVKSCRETLPPDLKAKFLQEARILKQYSHPNIVRLIGVCTQKQPIYIVMELVQGGDFLTFLRTEGARLRVKTLLQMVGDAAAGMEYLESKCCIHRDLAARNCLVTEKNVLKISDFGMSREEADGVYAASGGLRQVPVKWTAPEALNYGRYSSESDVWSFGILLWETFSLGASPYPNLSNQQTREFVEKGGRLPCPELCPDAVFRLMEQCWAYEPGQRPSFSTIYQELQSIRKRHR
T29083	DRUGINFO	D0K5UF	PMID24432909C8e	Investigative
T29083	DRUGINFO	D09AID	PMID22564207C25b	Investigative

T51464	TARGETID	T51464
T51464	FORMERID	TTDR00680
T51464	UNIPROID	CN37_HUMAN
T51464	TARGNAME	Cyclic nucleotide phosphodiesterase (CNP)
T51464	GENENAME	CNP
T51464	TARGTYPE	Literature-reported
T51464	SYNONYMS	CNPase; CNP; 2',3'-cyclic-nucleotide 3'-phosphodiesterase
T51464	FUNCTION	May participate in RNA metabolism in the myelinating cell, CNP is the third most abundant protein in central nervous system myelin.
T51464	PDBSTRUC	1WOJ
T51464	BIOCLASS	Phosphoric diester hydrolase
T51464	ECNUMBER	EC 3.1.4.37
T51464	SEQUENCE	MNRGFSRKSHTFLPKIFFRKMSSSGAKDKPELQFPFLQDEDTVATLLECKTLFILRGLPGSGKSTLARVIVDKYRDGTKMVSADAYKITPGARGAFSEEYKRLDEDLAAYCRRRDIRILVLDDTNHERERLEQLFEMADQYQYQVVLVEPKTAWRLDCAQLKEKNQWQLSADDLKKLKPGLEKDFLPLYFGWFLTKKSSETLRKAGQVFLEELGNHKAFKKELRQFVPGDEPREKMDLVTYFGKRPPGVLHCTTKFCDYGKAPGAEEYAQQDVLKKSYSKAFTLTISALFVTPKTTGARVELSEQQLQLWPSDVDKLSPTDNLPRGSRAHITLGCAADVEAVQTGLDLLEILRQEKGGSRGEEVGELSRGKLYSLGNGRWMLTLAKNMEVRAIFTGYYGKGKPVPTQGSRKGGALQSCTII

T26617	TARGETID	T26617
T26617	FORMERID	TTDR00154
T26617	UNIPROID	LPH_HUMAN
T26617	TARGNAME	Lactase-phlorizin hydrolase (LCT)
T26617	GENENAME	LCT
T26617	TARGTYPE	Literature-reported
T26617	SYNONYMS	Lactase-glycosylceramidase; LCT; Glycosyl-hydrolase
T26617	FUNCTION	LPH splits lactose in the small intestine.
T26617	BIOCLASS	Glycosylase
T26617	SEQUENCE	MELSWHVVFIALLSFSCWGSDWESDRNFISTAGPLTNDLLHNLSGLLGDQSSNFVAGDKDMYVCHQPLPTFLPEYFSSLHASQITHYKVFLSWAQLLPAGSTQNPDEKTVQCYRRLLKALKTARLQPMVILHHQTLPASTLRRTEAFADLFADYATFAFHSFGDLVGIWFTFSDLEEVIKELPHQESRASQLQTLSDAHRKAYEIYHESYAFQGGKLSVVLRAEDIPELLLEPPISALAQDTVDFLSLDLSYECQNEASLRQKLSKLQTIEPKVKVFIFNLKLPDCPSTMKNPASLLFSLFEAINKDQVLTIGFDINEFLSCSSSSKKSMSCSLTGSLALQPDQQQDHETTDSSPASAYQRIWEAFANQSRAERDAFLQDTFPEGFLWGASTGAFNVEGGWAEGGRGVSIWDPRRPLNTTEGQATLEVASDSYHKVASDVALLCGLRAQVYKFSISWSRIFPMGHGSSPSLPGVAYYNKLIDRLQDAGIEPMATLFHWDLPQALQDHGGWQNESVVDAFLDYAAFCFSTFGDRVKLWVTFHEPWVMSYAGYGTGQHPPGISDPGVASFKVAHLVLKAHARTWHHYNSHHRPQQQGHVGIVLNSDWAEPLSPERPEDLRASERFLHFMLGWFAHPVFVDGDYPATLRTQIQQMNRQCSHPVAQLPEFTEAEKQLLKGSADFLGLSHYTSRLISNAPQNTCIPSYDTIGGFSQHVNHVWPQTSSSWIRVVPWGIRRLLQFVSLEYTRGKVPIYLAGNGMPIGESENLFDDSLRVDYFNQYINEVLKAIKEDSVDVRSYIARSLIDGFEGPSGYSQRFGLHHVNFSDSSKSRTPRKSAYFFTSIIEKNGFLTKGAKRLLPPNTVNLPSKVRAFTFPSEVPSKAKVVWEKFSSQPKFERDLFYHGTFRDDFLWGVSSSAYQIEGAWDADGKGPSIWDNFTHTPGSNVKDNATGDIACDSYHQLDADLNMLRALKVKAYRFSISWSRIFPTGRNSSINSHGVDYYNRLINGLVASNIFPMVTLFHWDLPQALQDIGGWENPALIDLFDSYADFCFQTFGDRVKFWMTFNEPMYLAWLGYGSGEFPPGVKDPGWAPYRIAHAVIKAHARVYHTYDEKYRQEQKGVISLSLSTHWAEPKSPGVPRDVEAADRMLQFSLGWFAHPIFRNGDYPDTMKWKVGNRSELQHLATSRLPSFTEEEKRFIRATADVFCLNTYYSRIVQHKTPRLNPPSYEDDQEMAEEEDPSWPSTAMNRAAPWGTRRLLNWIKEEYGDIPIYITENGVGLTNPNTEDTDRIFYHKTYINEALKAYRLDGIDLRGYVAWSLMDNFEWLNGYTVKFGLYHVDFNNTNRPRTARASARYYTEVITNNGMPLAREDEFLYGRFPEGFIWSAASAAYQIEGAWRADGKGLSIWDTFSHTPLRVENDAIGDVACDSYHKIAEDLVTLQNLGVSHYRFSISWSRILPDGTTRYINEAGLNYYVRLIDTLLAASIQPQVTIYHWDLPQTLQDVGGWENETIVQRFKEYADVLFQRLGDKVKFWITLNEPFVIAYQGYGYGTAAPGVSNRPGTAPYIVGHNLIKAHAEAWHLYNDVYRASQGGVISITISSDWAEPRDPSNQEDVEAARRYVQFMGGWFAHPIFKNGDYNEVMKTRIRDRSLAAGLNKSRLPEFTESEKRRINGTYDFFGFNHYTTVLAYNLNYATAISSFDADRGVASIADRSWPDSGSFWLKMTPFGFRRILNWLKEEYNDPPIYVTENGVSQREETDLNDTARIYYLRTYINEALKAVQDKVDLRGYTVWSAMDNFEWATGFSERFGLHFVNYSDPSLPRIPKASAKFYASVVRCNGFPDPATGPHACLHQPDAGPTISPVRQEEVQFLGLMLGTTEAQTALYVLFSLVLLGVCGLAFLSYKYCKRSKQGKTQRSQQELSPVSSF
T26617	DRUGINFO	D04QWD	Gluconolactone	Investigative
T26617	DRUGINFO	D05RSP	ETHYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE	Investigative
T26617	DRUGINFO	D07ATW	Hyacinthacine B3	Investigative
T26617	DRUGINFO	D0R2BA	D-Gluconhydroximo-1,5-Lactam	Investigative
T26617	DRUGINFO	D0R5RE	2,5-dideoxy-2,5-imino-dl-glycero-D-manno-heptitol	Investigative
T26617	DRUGINFO	D0X4EB	2-Deoxy-2fluoro-Glucose	Investigative
T26617	DRUGINFO	D0E2BH	Nojirimycine Tetrazole	Investigative
T26617	DRUGINFO	D0SQ1T	2,5-dideoxy-2,5-imino-D-altritol	Investigative
T26617	DRUGINFO	D0G6XS	Fucose	Investigative
T26617	DRUGINFO	D07LUR	Alpha-D-Mannose	Investigative

T49627	TARGETID	T49627
T49627	FORMERID	TTDR01243
T49627	UNIPROID	CP121_MYCBO
T49627	TARGNAME	Mycobacterium Cytochrome p450 121 (MycB cyp121)
T49627	GENENAME	MycB cyp121
T49627	TARGTYPE	Literature-reported
T49627	SYNONYMS	Cytochrome P450 MT2; Cytochrome P450 121
T49627	FUNCTION	Catalyzes the formation of an intramolecular C-C bond between two tyrosyl carbon atoms of Cyy.
T49627	PDBSTRUC	5EDT
T49627	BIOCLASS	Paired donor oxygen oxidoreductase
T49627	ECNUMBER	EC 1.14.-.-
T49627	SEQUENCE	MTATVLLEVPFSARGDRIPDAVAELRTREPIRKVRTITGAEAWLVSSYALCTQVLEDRRFSMKETAAAGAPRLNALTVPPEVVNNMGNIADAGLRKAVMKAITPKAPGLEQFLRDTANSLLDNLITEGAPADLRNDFADPLATALHCKVLGIPQEDGPKLFRSLSIAFMSSADPIPAAKINWDRDIEYMAGILENPNITTGLMGELSRLRKDPAYSHVSDELFATIGVTFFGAGVISTGSFLTTALISLIQRPQLRNLLHEKPELIPAGVEELLRINLSFADGLPRLATADIQVGDVLVRKGELVLVLLEGANFDPEHFPNPGSIELDRPNPTSHLAFGRGQHFCPGSALGRRHAQIGIEALLKKMPGVDLAVPIDQLVWRTRFQRRIPERLPVLW
T49627	DRUGINFO	D0RM7D	4-Iodopyrazole	Investigative
T49627	DRUGINFO	D0UU1I	Heme	Investigative

T80855	TARGETID	T80855
T80855	FORMERID	TTDI02391
T80855	UNIPROID	AAC2_MYCTU
T80855	TARGNAME	Mycobacterium Aminoglycoside 2'-N-acetyltransferase (MycB aac)
T80855	GENENAME	MycB aac
T80855	TARGTYPE	Literature-reported
T80855	SYNONYMS	Aminoglycoside 2'-N-acetyltransferase; AAC(2')-Ic
T80855	FUNCTION	May catalyze the coenzyme A-dependent acetylation of the 2' hydroxyl or amino group of a broad spectrum of aminoglycosides and confer resistance to aminoglycosides (By similarity). In vitro assays show no significant increase of resistance to aminoglycosides, possibly due to low expression in a heterologous system.
T80855	PDBSTRUC	1M4I; 1M4G; 1M4D; 1M44
T80855	BIOCLASS	Acyltransferase
T80855	ECNUMBER	EC 2.3.1.-
T80855	SEQUENCE	MHTQVHTARLVHTADLDSETRQDIRQMVTGAFAGDFTETDWEHTLGGMHALIWHHGAIIAHAAVIQRRLIYRGNALRCGYVEGVAVRADWRGQRLVSALLDAVEQVMRGAYQLGALSSSARARRLYASRGWLPWHGPTSVLAPTGPVRTPDDDGTVFVLPIDISLDTSAELMCDWRAGDVW

T54065	TARGETID	T54065
T54065	FORMERID	TTDR01019
T54065	UNIPROID	AROA_ECOLI
T54065	TARGNAME	Bacterial Phosphoshikimate1-carboxyvinyltransferase (Bact aroA)
T54065	GENENAME	Bact aroA
T54065	TARGTYPE	Literature-reported
T54065	SYNONYMS	aroA of Escherichia coli; EPSPS of Escherichia coli; EPSP synthase of Escherichia coli; 5-enolpyruvylshikimate-3-phosphate synthase of Escherichia coli
T54065	FUNCTION	Catalyzes the transfer of the enolpyruvyl moiety of phosphoenolpyruvate (PEP) to the 5-hydroxyl of shikimate-3- phosphate (S3P) to produce enolpyruvyl shikimate-3-phosphate and inorganic phosphate.
T54065	PDBSTRUC	3FK1; 3FK0; 3FJZ; 3FJX; 2QFU
T54065	BIOCLASS	Alkyl aryl transferase
T54065	ECNUMBER	EC 2.5.1.19
T54065	SEQUENCE	MESLTLQPIARVDGTINLPGSKSVSNRALLLAALAHGKTVLTNLLDSDDVRHMLNALTALGVSYTLSADRTRCEIIGNGGPLHAEGALELFLGNAGTAMRPLAAALCLGSNDIVLTGEPRMKERPIGHLVDALRLGGAKITYLEQENYPPLRLQGGFTGGNVDVDGSVSSQFLTALLMTAPLAPEDTVIRIKGDLVSKPYIDITLNLMKTFGVEIENQHYQQFVVKGGQSYQSPGTYLVEGDASSASYFLAAAAIKGGTVKVTGIGRNSMQGDIRFADVLEKMGATICWGDDYISCTRGELNAIDMDMNHIPDAAMTIATAALFAKGTTTLRNIYNWRVKETDRLFAMATELRKVGAEVEEGHDYIRITPPEKLNFAEIATYNDHRMAMCFSLVALSDTPVTILDPKCTAKTFPDYFEQLARISQAA
T54065	DRUGINFO	D0ZS5F	Shikimate-3-Phosphate	Investigative
T54065	DRUGINFO	D04HMD	Glyphosate	Investigative
T54065	DRUGINFO	D06EWG	Formic Acid	Investigative

T91895	TARGETID	T91895
T91895	FORMERID	TTDR00354
T91895	UNIPROID	COAA_ECOLI
T91895	TARGNAME	Bacterial Pantothenate kinase (Bact coaA)
T91895	GENENAME	Bact coaA
T91895	TARGTYPE	Literature-reported
T91895	SYNONYMS	Rts protein; Pantothenic acid kinase; Pantothenate kinase
T91895	FUNCTION	Phosphorylates pantothenate (vitamin B5) to form 4'-phosphopantothenate at the expense of a molecule of adenosine triphosphate (ATP). It is the rate-limiting step in the biosynthesis of CoA.
T91895	PDBSTRUC	1SQ5; 1ESN; 1ESM
T91895	BIOCLASS	Kinase
T91895	ECNUMBER	EC 2.7.1.33
T91895	SEQUENCE	MSIKEQTLMTPYLQFDRNQWAALRDSVPMTLSEDEIARLKGINEDLSLEEVAEIYLPLSRLLNFYISSNLRRQAVLEQFLGTNGQRIPYIISIAGSVAVGKSTTARVLQALLSRWPEHRRVELITTDGFLHPNQVLKERGLMKKKGFPESYDMHRLVKFVSDLKSGVPNVTAPVYSHLIYDVIPDGDKTVVQPDILILEGLNVLQSGMDYPHDPHHVFVSDFVDFSIYVDAPEDLLQTWYINRFLKFREGAFTDPDSYFHNYAKLTKEEAIKTAMTLWKEINWLNLKQNILPTRERASLILTKSANHAVEEVRLRK
T91895	DRUGINFO	D0W3NA	Coenzyme A	Investigative
T91895	DRUGINFO	D00ICA	AMP-PNP	Investigative

T13236	TARGETID	T13236
T13236	FORMERID	TTDR00785
T13236	UNIPROID	RIBB_ECOLI
T13236	TARGNAME	Bacterial Dihydroxy-2-butanone-4-phosphate synthase (Bact ribB)
T13236	GENENAME	Bact ribB
T13236	TARGTYPE	Literature-reported
T13236	SYNONYMS	RibB; DHBP synthase
T13236	FUNCTION	Catalyzes the conversion of D-ribulose 5-phosphate to formate and 3,4-dihydroxy-2-butanone 4-phosphate.
T13236	PDBSTRUC	1IEZ; 1G58; 1G57
T13236	BIOCLASS	DHBP synthase family
T13236	ECNUMBER	EC 4.1.99.12
T13236	SEQUENCE	MNQTLLSSFGTPFERVENALAALREGRGVMVLDDEDRENEGDMIFPAETMTVEQMALTIRHGSGIVCLCITEDRRKQLDLPMMVENNTSAYGTGFTVTIEAAEGVTTGVSAADRITTVRAAIADGAKPSDLNRPGHVFPLRAQAGGVLTRGGHTEATIDLMTLAGFKPAGVLCELTNDDGTMARAPECIEFANKHNMALVTIEDLVAYRQAHERKAS

T63890	TARGETID	T63890
T63890	FORMERID	TTDNR00665
T63890	UNIPROID	YBEY_ECOLI
T63890	TARGNAME	Bacterial Endoribonuclease YbeY (Bact YbeY)
T63890	GENENAME	Bact YbeY
T63890	TARGTYPE	Literature-reported
T63890	SYNONYMS	ybeY; b0659; JW0656
T63890	FUNCTION	Acts together with the RNase R to eliminate defective 70S ribosomes, but not properly matured 70S ribosomes or individual subunits, by a process mediated specifically by the 30S ribosomal subunit. Involved in the processing of 16S, 23S and 5S rRNAs, with a particularly strong effect on maturation at both the 5'-and 3'-ends of 16S rRNA as well as maturation of the 5'-end of 23S and 5S rRNAs. Single strand-specific metallo-endoribonuclease involved in late-stage 70S ribosome quality control and in maturation of the 3' terminus of the 16S rRNA.
T63890	PDBSTRUC	1XM5
T63890	BIOCLASS	Carboxylic ester hydrolase
T63890	ECNUMBER	EC 3.1.-.-
T63890	SEQUENCE	MSQVILDLQLACEDNSGLPEESQFQTWLNAVIPQFQEESEVTIRVVDTAESHSLNLTYRGKDKPTNVLSFPFEVPPGMEMSLLGDLVICRQVVEKEAQEQGKPLEAHWAHMVVHGSLHLLGYDHIEDDEAEEMEALETEIMLALGYEDPYIAEKE

T54711	TARGETID	T54711
T54711	FORMERID	TTDR01087
T54711	UNIPROID	SYK1_ECOLI
T54711	TARGNAME	Bacterial Lysyl-tRNA synthetase (Bact lysS)
T54711	GENENAME	Bact lysS
T54711	TARGTYPE	Literature-reported
T54711	SYNONYMS	Lysyl-tRNA synthetase; Lysine--tRNA ligase; LysRS
T54711	FUNCTION	Catalyses the formation of lysyl-transfer RNA, Lys-tRNA(Lys), which then is ready to insert lysine into proteins.
T54711	PDBSTRUC	1KRT; 1KRS; 1BBW; 1BBU
T54711	BIOCLASS	Carbon-oxygen ligase
T54711	ECNUMBER	EC 6.1.1.6
T54711	SEQUENCE	MSEQHAQGADAVVDLNNELKTRREKLANLREQGIAFPNDFRRDHTSDQLHAEFDGKENEELEALNIEVAVAGRMMTRRIMGKASFVTLQDVGGRIQLYVARDDLPEGVYNEQFKKWDLGDILGAKGKLFKTKTGELSIHCTELRLLTKALRPLPDKFHGLQDQEARYRQRYLDLISNDESRNTFKVRSQILSGIRQFMVNRGFMEVETPMMQVIPGGAAARPFITHHNALDLDMYLRIAPELYLKRLVVGGFERVFEINRNFRNEGISVRHNPEFTMMELYMAYADYKDLIELTESLFRTLAQDILGKTEVTYGDVTLDFGKPFEKLTMREAIKKYRPETDMADLDNFDSAKAIAESIGIHVEKSWGLGRIVTEIFEEVAEAHLIQPTFITEYPAEVSPLARRNDVNPEITDRFEFFIGGREIGNGFSELNDAEDQAQRFLDQVAAKDAGDDEAMFYDEDYVTALEHGLPPTAGLGIGIDRMVMLFTNSHTIRDVILFPAMRPVK

T82723	TARGETID	T82723
T82723	FORMERID	TTDR00292
T82723	UNIPROID	FABF_ECOLI
T82723	TARGNAME	Bacterial Oxoacyl-[acyl-carrier-protein] synthase II (Bact fabF)
T82723	GENENAME	Bact fabF
T82723	TARGTYPE	Literature-reported
T82723	SYNONYMS	KASB; KAS II; KAS 2; FabF; Condensing enzyme FabF; Beta-ketoacyl-acyl carrier protein synthase B; Beta-ketoacyl-ACP synthase II; Beta-ketoacyl-ACP synthase 2; 3-oxoacyl-[acyl-carrier-protein] synthase 2
T82723	FUNCTION	Catalyzes the condensation reaction of fatty acid synthesis by the addition to an acyl acceptor of two carbons from malonyl-ACP. Has a preference for short chain acid substrates and may function to supply the octanoic substrates for lipoic acid biosynthesis.
T82723	PDBSTRUC	3I8P; 3HO9; 3HO2; 3HNZ; 3G11
T82723	BIOCLASS	Acyltransferase
T82723	ECNUMBER	EC 2.3.1.179
T82723	SEQUENCE	MSKRRVVVTGLGMLSPVGNTVESTWKALLAGQSGISLIDHFDTSAYATKFAGLVKDFNCEDIISRKEQRKMDAFIQYGIVAGVQAMQDSGLEITEENATRIGAAIGSGIGGLGLIEENHTSLMNGGPRKISPFFVPSTIVNMVAGHLTIMYGLRGPSISIATACTSGVHNIGHAARIIAYGDADVMVAGGAEKASTPLGVGGFGAARALSTRNDNPQAASRPWDKERDGFVLGDGAGMLVLEEYEHAKKRGAKIYAELVGFGMSSDAYHMTSPPENGAGAALAMANALRDAGIEASQIGYVNAHGTSTPAGDKAEAQAVKTIFGEAASRVLVSSTKSMTGHLLGAAGAVESIYSILALRDQAVPPTINLDNPDEGCDLDFVPHEARQVSGMEYTLCNSFGFGGTNGSLIFKKI
T82723	DRUGINFO	D0D9YU	PLATENSIMYCIN	Investigative
T82723	DRUGINFO	D04JTY	Thiolactomycin	Investigative
T82723	DRUGINFO	D0N0UC	Lauric Acid	Investigative

T91001	TARGETID	T91001
T91001	FORMERID	TTDNC00628
T91001	UNIPROID	EFTU1_ECOLI
T91001	TARGNAME	Bacterial Elongation factor Tu (Bact EFTu)
T91001	GENENAME	Bact EFTu
T91001	TARGTYPE	Literature-reported
T91001	SYNONYMS	tufA; P43; Elongation factor Tu 1; EFTu 1
T91001	FUNCTION	May play an important regulatory rolein cell growth and in the bacterial response to nutrient deprivation.
T91001	PDBSTRUC	5UYQ; 5UYP; 5UYN; 5UYM; 5UYL
T91001	BIOCLASS	GTP-binding elongation factor family
T91001	SEQUENCE	MSKEKFERTKPHVNVGTIGHVDHGKTTLTAAITTVLAKTYGGAARAFDQIDNAPEEKARGITINTSHVEYDTPTRHYAHVDCPGHADYVKNMITGAAQMDGAILVVAATDGPMPQTREHILLGRQVGVPYIIVFLNKCDMVDDEELLELVEMEVRELLSQYDFPGDDTPIVRGSALKALEGDAEWEAKILELAGFLDSYIPEPERAIDKPFLLPIEDVFSISGRGTVVTGRVERGIIKVGEEVEIVGIKETQKSTCTGVEMFRKLLDEGRAGENVGVLLRGIKREEIERGQVLAKPGTIKPHTKFESEVYILSKDEGGRHTPFFKGYRPQFYFRTTDVTGTIELPEGVEMVMPGDNIKMVVTLIHPIAMDDGLRFAIREGGRTVGAGVVAKVLG

T79001	TARGETID	T79001
T79001	FORMERID	TTDR00992
T79001	UNIPROID	AROC_ECOLI
T79001	TARGNAME	Bacterial Chorismate synthase (Bact aroC)
T79001	GENENAME	Bact aroC
T79001	TARGTYPE	Literature-reported
T79001	SYNONYMS	aroC; Chorismate synthase; CS; 5enolpyruvylshikimate3phosphate phospholyase; 5-enolpyruvylshikimate-3-phosphate phospholyase
T79001	FUNCTION	Catalyzes the anti-1,4-elimination of the C-3 phosphate and the C-6 proR hydrogen from 5-enolpyruvylshikimate-3-phosphate (EPSP) to yield chorismate, which is the branch point compound that serves as the starting substrate for the three terminal pathways of aromatic amino acid biosynthesis. This reaction introduces a second double bond into the aromatic ring system. It uses NADPH to reduce FMN.
T79001	BIOCLASS	Alpha-carbonic anhydrase
T79001	ECNUMBER	EC 4.2.3.5
T79001	SEQUENCE	MAGNTIGQLFRVTTFGESHGLALGCIVDGVPPGIPLTEADLQHDLDRRRPGTSRYTTQRREPDQVKILSGVFEGVTTGTSIGLLIENTDQRSQDYSAIKDVFRPGHADYTYEQKYGLRDYRGGGRSSARETAMRVAAGAIAKKYLAEKFGIEIRGCLTQMGDIPLDIKDWSQVEQNPFFCPDPDKIDALDELMRALKKEGDSIGAKVTVVASGVPAGLGEPVFDRLDADIAHALMSINAVKGVEIGDGFDVVALRGSQNRDEITKDGFQSNHAGGILGGISSGQQIIAHMALKPTSSITVPGRTINRFGEEVEMITKGRHDPCVGIRAVPIAEAMLAIVLMDHLLRQRAQNADVKTDIPRW
T79001	DRUGINFO	D0W0RT	PTX-008313	Terminated
T79001	DRUGINFO	D0M1KX	Cobalt Hexammine Ion	Investigative

T94823	TARGETID	T94823
T94823	FORMERID	TTDR00759
T94823	UNIPROID	PEPD_HUMAN
T94823	TARGNAME	Xaa-Pro dipeptidase (PEPD)
T94823	GENENAME	PEPD
T94823	TARGTYPE	Literature-reported
T94823	SYNONYMS	X-Pro dipeptidase; Proline dipeptidase; Prolidase; PEPD; Imidodipeptidase
T94823	FUNCTION	Splits dipeptides with a prolyl or hydroxyprolyl residuein the carboxyl terminal position. Plays an important role in collagen metabolism because the high level of iminoacids in collagen.
T94823	PDBSTRUC	6H2Q; 6H2P; 5MC5; 5MC4; 5MC3
T94823	BIOCLASS	Peptidase
T94823	ECNUMBER	EC 3.4.13.9
T94823	SEQUENCE	MAAATGPSFWLGNETLKVPLALFALNRQRLCERLRKNPAVQAGSIVVLQGGEETQRYCTDTGVLFRQESFFHWAFGVTEPGCYGVIDVDTGKSTLFVPRLPASHATWMGKIHSKEHFKEKYAVDDVQYVDEIASVLTSQKPSVLLTLRGVNTDSGSVCREASFDGISKFEVNNTILHPEIVECRVFKTDMELEVLRYTNKISSEAHREVMKAVKVGMKEYELESLFEHYCYSRGGMRHSSYTCICGSGENSAVLHYGHAGAPNDRTIQNGDMCLFDMGGEYYCFASDITCSFPANGKFTADQKAVYEAVLRSSRAVMGAMKPGVWWPDMHRLADRIHLEELAHMGILSGSVDAMVQAHLGAVFMPHGLGHFLGIDVHDVGGYPEGVERIDEPGLRSLRTARHLQPGMVLTVEPGIYFIDHLLDEALADPARASFLNREVLQRFRGFGGVRIEEDVVVTDSGIELLTCVPRTVEEIEACMAGCDKAFTPFSGPK

T53562	TARGETID	T53562
T53562	FORMERID	TTDI00081
T53562	UNIPROID	XRCC5_HUMAN
T53562	TARGNAME	X-ray repair cross-complementing 5 (Ku80)
T53562	GENENAME	XRCC5
T53562	TARGTYPE	Literature-reported
T53562	SYNONYMS	X-ray repair cross-complementing protein 5; X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining); Thyroid-lupus autoantigen; TLAA; Nuclear factor IV; Lupus Ku autoantigen protein p86; Ku86; G22P2; DNA repair protein XRCC5; CTCBF; CTC85; CTC box-binding factor 85 kDa subunit; ATP-dependent DNA helicase II 80 kDa subunit; ATP-dependent DNA helicase 2 subunit 2; 86 kDa subunit of Ku antigen
T53562	FUNCTION	Has a role in chromosome translocation. The DNA helicase II complex binds preferentially to fork-like ends of double-stranded DNA in a cell cycle-dependent manner. It works in the 3'-5' direction. Binding to DNA may be mediated by XRCC6. Involved in DNA non-homologous end joining (NHEJ) required for double-strand break repair and V(D)J recombination. The XRCC5/6 dimer acts as regulatory subunit of the DNA-dependent protein kinase complex DNA-PK by increasing the affinity of the catalytic subunit PRKDC to DNA by 100-fold. The XRCC5/6 dimer is probably involved in stabilizing broken DNA ends and bringing them together. The assembly of the DNA-PK complex to DNA ends is required for the NHEJ ligation step. In association with NAA15, the XRCC5/6 dimer binds to the osteocalcin promoter and activates osteocalcin expression. The XRCC5/6 dimer probably also acts as a 5'-deoxyribose-5-phosphate lyase (5'-dRP lyase), by catalyzing the beta-elimination of the 5' deoxyribose-5-phosphate at an abasic site near double-strand breaks. XRCC5 probably acts as the catalytic subunit of 5'-dRP activity, and allows to 'clean' the termini of abasic sites, a class of nucleotide damage commonly associated with strand breaks, before such broken ends can be joined. The XRCC5/6 dimer together with APEX1 acts as a negative regulator of transcription. Plays a role in the regulation of DNA virus-mediated innate immune response by assembling into the HDP-RNP complex, a complex that serves as a platform for IRF3 phosphorylation and subsequent innate immune response activation through the cGAS-STING pathway. Single-stranded DNA-dependent ATP-dependent helicase.
T53562	PDBSTRUC	6ERH; 6ERG; 6ERF; 5Y3R; 3RZ9
T53562	BIOCLASS	Acid anhydride hydrolase
T53562	ECNUMBER	EC 3.6.4.-
T53562	SEQUENCE	MVRSGNKAAVVLCMDVGFTMSNSIPGIESPFEQAKKVITMFVQRQVFAENKDEIALVLFGTDGTDNPLSGGDQYQNITVHRHLMLPDFDLLEDIESKIQPGSQQADFLDALIVSMDVIQHETIGKKFEKRHIEIFTDLSSRFSKSQLDIIIHSLKKCDISLQFFLPFSLGKEDGSGDRGDGPFRLGGHGPSFPLKGITEQQKEGLEIVKMVMISLEGEDGLDEIYSFSESLRKLCVFKKIERHSIHWPCRLTIGSNLSIRIAAYKSILQERVKKTWTVVDAKTLKKEDIQKETVYCLNDDDETEVLKEDIIQGFRYGSDIVPFSKVDEEQMKYKSEGKCFSVLGFCKSSQVQRRFFMGNQVLKVFAARDDEAAAVALSSLIHALDDLDMVAIVRYAYDKRANPQVGVAFPHIKHNYECLVYVQLPFMEDLRQYMFSSLKNSKKYAPTEAQLNAVDALIDSMSLAKKDEKTDTLEDLFPTTKIPNPRFQRLFQCLLHRALHPREPLPPIQQHIWNMLNPPAEVTTKSQIPLSKIKTLFPLIEAKKKDQVTAQEIFQDNHEDGPTAKKLKTEQGGAHFSVSSLAEGSVTSVGSVNPAENFRVLVKQKKASFEEASNQLINHIEQFLDTNETPYFMKSIDCIRAFREEAIKFSEEQRFNNFLKALQEKVEIKQLNHFWEIVVQDGITLITKEEASGSSVTAEEAKKFLAPKDKPSGDTAAVFEEGGDVDDLLDMI

T06397	TARGETID	T06397
T06397	FORMERID	TTDR00610
T06397	UNIPROID	MEGL_PSEPU
T06397	TARGNAME	Pseudomonas Methionine gamma-lyase (Pseudo mdeA)
T06397	GENENAME	Pseudo mdeA
T06397	TARGTYPE	Literature-reported
T06397	SYNONYMS	Pseudo MGL; L-methionine gamma-lyase; L-methioninase; Homocysteine desulfhydrase
T06397	FUNCTION	Catalyzes the alpha,gamma-elimination of L-methionine to produce methanethiol, 2-oxobutanoate and ammonia. Is involved in L-methionine catabolism. In fact, shows a multicatalytic function since it also catalyzes gamma-replacement of L-methionine with thiol compounds, alpha,gamma-elimination and gamma-replacement reactions of L-homocysteine and its S-substituted derivatives, O-substituted-L-homoserines and DL-selenomethionine, and, to a lesser extent, alpha,beta-elimination and beta-replacement reactions of L-cysteine, S-methyl-L-cysteine, and O-acetyl-L-serine. Also catalyzes deamination and gamma-addition reactions of L-vinylglycine. Thus, the enzyme is able to cleave C-S, C-Se, and C-O bonds of sulfur, selenium, and oxygen amino acids, respectively.
T06397	PDBSTRUC	5X30; 5X2Z; 5X2Y; 5X2X; 5X2W
T06397	BIOCLASS	Carbon-sulfur lyases
T06397	ECNUMBER	EC 4.4.1.11
T06397	SEQUENCE	MHGSNKLPGFATRAIHHGYDPQDHGGALVPPVYQTATFTFPTVEYGAACFAGEQAGHFYSRISNPTLNLLEARMASLEGGEAGLALASGMGAITSTLWTLLRPGDEVLLGNTLYGCTFAFLHHGIGEFGVKLRHVDMADLQALEAAMTPATRVIYFESPANPNMHMADIAGVAKIARKHGATVVVDNTYCTPYLQRPLELGADLVVHSATKYLSGHGDITAGIVVGSQALVDRIRLQGLKDMTGAVLSPHDAALLMRGIKTLNLRMDRHCANAQVLAEFLARQPQVELIHYPGLASFPQYTLARQQMSQPGGMIAFELKGGIGAGRRFMNALQLFSRAVSLGDAESLAQHPASMTHSSYTPEERAHYGISEGLVRLSVGLEDIDDLLADVQQALKASA
T06397	DRUGINFO	D0ZU4S	Trifluoromethionine	Investigative
T06397	DRUGINFO	D0I5PZ	N'-Pyridoxyl-Lysine-5'-Monophosphate	Investigative

T38877	TARGETID	T38877
T38877	FORMERID	TTDR01015
T38877	UNIPROID	ARCA_PSEAE
T38877	TARGNAME	Pseudomonas Arginine deiminase (Pseudo arcA)
T38877	GENENAME	Pseudo arcA
T38877	TARGTYPE	Literature-reported
T38877	SYNONYMS	Arginine dihydrolase; Arginine deiminase; ADI; AD
T38877	FUNCTION	Catalyzes the irreversible hydrolysis of arginine to citrulline and ammonia. Involved in the first step of the most widespread anaerobic route of arginine degradation
T38877	PDBSTRUC	2ACI; 2ABR; 2AAF; 2A9G; 1RXX
T38877	BIOCLASS	Carbon-nitrogen hydrolase
T38877	ECNUMBER	EC 3.5.3.6
T38877	SEQUENCE	MSTEKTKLGVHSEAGKLRKVMVCSPGLAHQRLTPSNCDELLFDDVIWVNQAKRDHFDFVTKMRERGIDVLEMHNLLTETIQNPEALKWILDRKITADSVGLGLTSELRSWLESLEPRKLAEYLIGGVAADDLPASEGANILKMYREYLGHSSFLLPPLPNTQFTRDTTCWIYGGVTLNPMYWPARRQETLLTTAIYKFHPEFANAEFEIWYGDPDKDHGSSTLEGGDVMPIGNGVVLIGMGERSSRQAIGQVAQSLFAKGAAERVIVAGLPKSRAAMHLDTVFSFCDRDLVTVFPEVVKEIVPFSLRPDPSSPYGMNIRREEKTFLEVVAESLGLKKLRVVETGGNSFAAEREQWDDGNNVVCLEPGVVVGYDRNTYTNTLLRKAGVEVITISASELGRGRGGGHCMTCPIVRDPIDY

T16891	TARGETID	T16891
T16891	FORMERID	TTDI03091
T16891	UNIPROID	CATE_HUMAN
T16891	TARGNAME	Cathepsin E (CTSE)
T16891	GENENAME	CTSE
T16891	TARGTYPE	Literature-reported
T16891	SYNONYMS	Cathepsin E
T16891	FUNCTION	May have a role in immune function. Probably involved in the processing of antigenic peptides during MHC class II-mediated antigen presentation. May play a role in activation-induced lymphocyte depletion in the thymus, and in neuronal degeneration and glial cell activation in the brain.
T16891	PDBSTRUC	1TZS; 1LCG
T16891	BIOCLASS	Peptidase
T16891	ECNUMBER	EC 3.4.23.34
T16891	SEQUENCE	MKTLLLLLLVLLELGEAQGSLHRVPLRRHPSLKKKLRARSQLSEFWKSHNLDMIQFTESCSMDQSAKEPLINYLDMEYFGTISIGSPPQNFTVIFDTGSSNLWVPSVYCTSPACKTHSRFQPSQSSTYSQPGQSFSIQYGTGSLSGIIGADQVSVEGLTVVGQQFGESVTEPGQTFVDAEFDGILGLGYPSLAVGGVTPVFDNMMAQNLVDLPMFSVYMSSNPEGGAGSELIFGGYDHSHFSGSLNWVPVTKQAYWQIALDNIQVGGTVMFCSEGCQAIVDTGTSLITGPSDKIKQLQNAIGAAPVDGEYAVECANLNVMPDVTFTINGVPYTLSPTAYTLLDFVDGMQFCSSGFQGLDIHPPAGPLWILGDVFIRQFYSVFDRGNNRVGLAPAVP
T16891	DRUGINFO	D0KK6A	PMID8410973C2	Investigative
T16891	DRUGINFO	D0P6RT	PMID8410973C3	Investigative

T31674	TARGETID	T31674
T31674	FORMERID	TTDR00640
T31674	UNIPROID	ALF_PLAFA
T31674	TARGNAME	Plasmodium Fructose-bisphosphate aldolase (Malaria FBA)
T31674	GENENAME	Malaria FBA
T31674	TARGTYPE	Literature-reported
T31674	SYNONYMS	Fructose-bisphosphate aldolase; 41 kDa antigen
T31674	FUNCTION	Catalyzes carboncarbon bond formation (or cleavage). Participate in the metabolically important pathways of gluconeogenesis and glycolysis.
T31674	PDBSTRUC	2PC4; 2EPH; 1A5C
T31674	BIOCLASS	Carbon-carbon lyase
T31674	SEQUENCE	MAHCTEYMNAPKKLPADVAEELATTAQKLVQAGKGILAADESTQTIKKRFDNIKLENTIENRASYRDLLFGTKGLGKFISGAILFEETLFQKNEAGVPMVNLLHNENIIPGIKVDKGLVNIPCTDEEKSTQGLDGLAERCKEYYKAGARFAKWRTVLVIDTAKGKPTDLSIHETAWGLARYASICQQNRLVPIVEPEILADGPHSIEVCAVVTQKVLSCVFKALQENGVLLEGALLKPNMVTAGYECTAKTTTQDVGFLTVRTLRRTVPPALPGVVFLSGGQSEEEASVNLNSINALGPHPWALTFSYGRALQASVLNTWQGKKENVAKAREVLLQRAEANSLATYGKYKGGAGGENAGASLYEKKYVY
T31674	DRUGINFO	D0RO6K	PHOSPHOGLYCOLOHYDROXAMATE	Investigative

T65483	TARGETID	T65483
T65483	FORMERID	TTDI03077
T65483	UNIPROID	CBPM_HUMAN
T65483	TARGNAME	Carboxypeptidase M (CPM)
T65483	GENENAME	CPM
T65483	TARGTYPE	Literature-reported
T65483	SYNONYMS	Human carboxypeptidase M
T65483	FUNCTION	It is believed to play important roles in the control of peptide hormone and growth factor activity at the cell surface, and in the membrane-localized degradation of extracellular proteins. Specifically removes C-terminal basic residues (Arg or Lys) from peptides and proteins.
T65483	PDBSTRUC	1UWY
T65483	BIOCLASS	Peptidase
T65483	ECNUMBER	EC 3.4.17.12
T65483	SEQUENCE	MDFPCLWLGLLLPLVAALDFNYHRQEGMEAFLKTVAQNYSSVTHLHSIGKSVKGRNLWVLVVGRFPKEHRIGIPEFKYVANMHGDETVGRELLLHLIDYLVTSDGKDPEITNLINSTRIHIMPSMNPDGFEAVKKPDCYYSIGRENYNQYDLNRNFPDAFEYNNVSRQPETVAVMKWLKTETFVLSANLHGGALVASYPFDNGVQATGALYSRSLTPDDDVFQYLAHTYASRNPNMKKGDECKNKMNFPNGVTNGYSWYPLQGGMQDYNYIWAQCFEITLELSCCKYPREEKLPSFWNNNKASLIEYIKQVHLGVKGQVFDQNGNPLPNVIVEVQDRKHICPYRTNKYGEYYLLLLPGSYIINVTVPGHDPHITKVIIPEKSQNFSALKKDILLPFQGQLDSIPVSNPSCPMIPLYRNLPDHSAATKPSLFLFLVSLLHIFFK
T65483	DRUGINFO	D0XA0N	PMID14640538C3	Investigative

T77181	TARGETID	T77181
T77181	FORMERID	TTDI03609
T77181	UNIPROID	UCHL3_HUMAN
T77181	TARGNAME	Ubiquitin thioesterase L3 (UCHL3)
T77181	GENENAME	UCHL3
T77181	TARGTYPE	Literature-reported
T77181	SYNONYMS	Ubiquitin carboxyl-terminal hydrolase isozyme L3; UCH-L3
T77181	FUNCTION	Thiol protease that recognizes and hydrolyzes a peptide bond at the C-terminal glycine of either ubiquitin or NEDD8. Has a 10-fold preference for Arg and Lys at position P3", and exhibits a preference towards 'Lys-48'-linked ubiquitin chains. Deubiquitinates ENAC in apical compartments, thereby regulating apical membrane recycling. Indirectly increases the phosphorylation of IGFIR, AKT and FOXO1 and promotes insulin-signaling and insulin-induced adipogenesis. Required for stress-response retinal, skeletal muscle and germ cell maintenance. May be involved in working memory. Can hydrolyze UBB(+1), a mutated form of ubiquitin which is not effectively degraded by the proteasome and is associated with neurogenerative disorders. Deubiquitinating enzyme (DUB) that controls levels of cellular ubiquitin through processing of ubiquitin precursors and ubiquitinated proteins.
T77181	PDBSTRUC	6ISU; 1XD3; 1UCH
T77181	BIOCLASS	Peptidase
T77181	ECNUMBER	EC 3.4.19.12
T77181	SEQUENCE	MEGQRWLPLEANPEVTNQFLKQLGLHPNWQFVDVYGMDPELLSMVPRPVCAVLLLFPITEKYEVFRTEEEEKIKSQGQDVTSSVYFMKQTISNACGTIGLIHAIANNKDKMHFESGSTLKKFLEESVSMSPEERARYLENYDAIRVTHETSAHEGQTEAPSIDEKVDLHFIALVHVDGHLYELDGRKPFPINHGETSDETLLEDAIEVCKKFMERDPDELRFNAIALSAA

T42533	TARGETID	T42533
T42533	FORMERID	TTDI00226
T42533	UNIPROID	NDKA_HUMAN
T42533	TARGNAME	Nucleoside diphosphate kinase A (NM23-H1)
T42533	GENENAME	NME1
T42533	TARGTYPE	Literature-reported
T42533	SYNONYMS	nm23H1; Tumor metastatic processassociated protein; Tumor metastatic process-associated protein; NM23; NDPKA; NDP kinase A; NDK A; Metastasis inhibition factor nm23; Granzyme Aactivated DNase; Granzyme A-activated DNase; GAAD
T42533	FUNCTION	The ATP gamma phosphate is transferred to the NDP beta phosphate via a ping-pong mechanism, using a phosphorylated active-site intermediate. Possesses nucleoside-diphosphate kinase, serine/threonine-specific protein kinase, geranyl and farnesyl pyrophosphate kinase, histidine protein kinase and 3'-5' exonuclease activities. Involved in cell proliferation, differentiation and development, signal transduction, G protein-coupled receptor endocytosis, and gene expression. Required for neural development including neural patterning and cell fate determination. During GZMA-mediated cell death, works in concert with TREX1. NME1 nicks one strand of DNA and TREX1 removes bases from the free 3' end to enhance DNA damage and prevent DNA end reannealing and rapid repair. Major role in the synthesis of nucleoside triphosphates other than ATP.
T42533	PDBSTRUC	5UI4; 4ENO; 3L7U; 2HVE; 2HVD
T42533	BIOCLASS	Kinase
T42533	ECNUMBER	EC 2.7.4.6
T42533	SEQUENCE	MANCERTFIAIKPDGVQRGLVGEIIKRFEQKGFRLVGLKFMQASEDLLKEHYVDLKDRPFFAGLVKYMHSGPVVAMVWEGLNVVKTGRVMLGETNPADSKPGTIRGDFCIQVGRNIIHGSDSVESAEKEIGLWFHPEELVDYTSCAQNWIYE

T16993	TARGETID	T16993
T16993	FORMERID	TTDI03195
T16993	UNIPROID	FER_HUMAN
T16993	TARGNAME	Proto-oncogene c-Fer (FER)
T16993	GENENAME	FER
T16993	TARGTYPE	Literature-reported
T16993	SYNONYMS	p94-Fer; Tyrosine-protein kinase Fer; Tyrosine kinase 3; TYK3; Fujinami poultry sarcoma/Feline sarcoma-related protein Fer; Feline encephalitis virus-related kinase FER
T16993	FUNCTION	Acts downstream of EGFR, KIT, PDGFRA and PDGFRB. Acts downstream of EGFR to promote activation of NF-kappa-B and cell proliferation. May play a role in the regulation of the mitotic cell cycle. Plays a role in the insulin receptor signaling pathway and in activation of phosphatidylinositol 3-kinase. Acts downstream of the activated FCER1 receptor and plays a role in FCER1 (high affinity immunoglobulin epsilon receptor)-mediated signaling in mast cells. Plays a role in the regulation of mast cell degranulation. Plays a role in leukocyte recruitment and diapedesis in response to bacterial lipopolysaccharide (LPS). Plays a role in synapse organization, trafficking of synaptic vesicles, the generation of excitatory postsynaptic currents and neuron-neuron synaptic transmission. Plays a role in neuronal cell death after brain damage. Phosphorylates CTTN, CTNND1, PTK2/FAK1, GAB1, PECAM1 and PTPN11. May phosphorylate JUP and PTPN1. Can phosphorylate STAT3, but the biological relevance of this depends on cell type and stimulus. Tyrosine-protein kinase that acts downstream of cell surface receptors for growth factors and plays a role in the regulation of the actin cytoskeleton, microtubule assembly, lamellipodia formation, cell adhesion, cell migration and chemotaxis.
T16993	PDBSTRUC	2KK6
T16993	BIOCLASS	Kinase
T16993	ECNUMBER	EC 2.7.10.2
T16993	SEQUENCE	MGFGSDLKNSHEAVLKLQDWELRLLETVKKFMALRIKSDKEYASTLQNLCNQVDKESTVQMNYVSNVSKSWLLMIQQTEQLSRIMKTHAEDLNSGPLHRLTMMIKDKQQVKKSYIGVHQQIEAEMIKVTKTELEKLKCSYRQLIKEMNSAKEKYKEALAKGKETEKAKERYDKATMKLHMLHNQYVLALKGAQLHQNQYYDITLPLLLDSLQKMQEEMIKALKGIFDEYSQITSLVTEEIVNVHKEIQMSVEQIDPSTEYNNFIDVHRTTAAKEQEIEFDTSLLEENENLQANEIMWNNLTAESLQVMLKTLAEELMQTQQMLLNKEEAVLELEKRIEESSETCEKKSDIVLLLSQKQALEELKQSVQQLRCTEAKFSAQKELLEQKVQENDGKEPPPVVNYEEDARSVTSMERKERLSKFESIRHSIAGIIRSPKSALGSSALSDMISISEKPLAEQDWYHGAIPRIEAQELLKKQGDFLVRESHGKPGEYVLSVYSDGQRRHFIIQYVDNMYRFEGTGFSNIPQLIDHHYTTKQVITKKSGVVLLNPIPKDKKWILSHEDVILGELLGKGNFGEVYKGTLKDKTSVAVKTCKEDLPQELKIKFLQEAKILKQYDHPNIVKLIGVCTQRQPVYIIMELVSGGDFLTFLRRKKDELKLKQLVKFSLDAAAGMLYLESKNCIHRDLAARNCLVGENNVLKISDFGMSRQEDGGVYSSSGLKQIPIKWTAPEALNYGRYSSESDVWSFGILLWETFSLGVCPYPGMTNQQAREQVERGYRMSAPQHCPEDISKIMMKCWDYKPENRPKFSELQKELTIIKRKLT
T16993	DRUGINFO	D0K5UF	PMID24432909C8e	Investigative
T16993	DRUGINFO	D09AID	PMID22564207C25b	Investigative

T55302	TARGETID	T55302
T55302	FORMERID	TTDI02438
T55302	UNIPROID	ANFB_HUMAN
T55302	TARGNAME	B-type natriuretic peptide (BNP)
T55302	GENENAME	NPPB
T55302	TARGTYPE	Literature-reported
T55302	SYNONYMS	Natriuretic peptides B; NPPB; Gammabrain natriuretic peptide; BNP32; BNP(529); BNP(132)
T55302	FUNCTION	Cardiac hormone which may function as a paracrine antifibrotic factor in the heart. Also plays a key role in cardiovascular homeostasis through natriuresis, diuresis, vasorelaxation, and inhibition of renin and aldosterone secretion. Specifically binds and stimulates the cGMP production of the NPR1 receptor. Binds the clearance receptor NPR3.
T55302	PDBSTRUC	3N56; 1YK1
T55302	BIOCLASS	Natriuretic peptide family
T55302	SEQUENCE	MDPQTAPSRALLLLLFLHLAFLGGRSHPLGSPGSASDLETSGLQEQRNHLQGKLSELQVEQTSLEPLQESPRPTGVWKSREVATEGIRGHRKMVLYTLRAPRSPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH
T55302	DRUGINFO	D06MPJ	BD-NP	Investigative

T00329	TARGETID	T00329
T00329	FORMERID	TTDR00487
T00329	UNIPROID	COLY_YERPE
T00329	TARGNAME	Bacterial Plasminogen activator (Bact pla)
T00329	GENENAME	Bact pla
T00329	TARGTYPE	Literature-reported
T00329	SYNONYMS	pla; Coagulase/fibrinolysin
T00329	FUNCTION	Seems to play an essential role in plague transmission by mediating flea blockage in a temperature-dependent fashion. Fibrinolytic activity prevails at 37 degrees Celsius whereas coagulase expression predominates at lower temperatures (<30 degrees Celsius). Activates plasminogen by cleaving it.
T00329	PDBSTRUC	4DCB; 2X56; 2X55; 2X4M
T00329	BIOCLASS	Peptidase
T00329	ECNUMBER	EC 3.4.23.48
T00329	SEQUENCE	MKKSSIVATIITILSGSANAASSQLIPNISPDSFTVAASTGMLSGKSHEMLYDAETGRKISQLDWKIKNVAILKGDISWDPYSFLTLNARGWTSLASGSGNMDDYDWMNENQSEWTDHSSHPATNVNHANEYDLNVKGWLLQDENYKAGITAGYQETRFSWTATGGSYSYNNGAYTGNFPKGVRVIGYNQRFSMPYIGLAGQYRINDFELNALFKFSDWVRAHDNDEHYMRDLTFREKTSGSRYYGTVINAGYYVTPNAKVFAEFTYSKYDEGKGGTQTIDKNSGDSVSIGGDAAGISNKNYTVTAGLQYRF

T49995	TARGETID	T49995
T49995	FORMERID	TTDR01211
T49995	UNIPROID	ARY1_HUMAN; ARY2_HUMAN
T49995	TARGNAME	Arylamine N-acetyltransferase (NAT)
T49995	GENENAME	NAT1; NAT2
T49995	TARGTYPE	Literature-reported
T49995	SYNONYMS	NAT; N-acetyltransferase; Arylamide acetylase; AAC
T49995	FUNCTION	Could have a role in acetylating, and hence inactivating, the antitubercular drug isoniazid.
T49995	BIOCLASS	Acyltransferase
T49995	SEQUENCE	MDIEAYLERIGYKKSRNKLDLETLTDILQHQIRAVPFENLNIHCGDAMDLGLEAIFDQVVRRNRGGWCLQVNHLLYWALTTIGFETTMLGGYVYSTPAKKYSTGMIHLLLQVTIDGRNYIVDAGFGRSYQMWQPLELISGKDQPQVPCVFRLTEENGFWYLDQIRREQYIPNEEFLHSDLLEDSKYRKIYSFTLKPRTIEDFESMNTYLQTSPSSVFTSKSFCSLQTPDGVHCLVGFTLTHRRFNYKDNTDLIEFKTLSEEEIEKVLKNIFNISLQRKLVPKHGDRFFTI
T49995	DRUGINFO	D07VGG	(Z)-5-Benzylidene-2-thioxothiazolidin-4-one	Investigative
T49995	DRUGINFO	D08HQB	(Z)-5-Octylidene-2-thioxothiazolidin-4-one	Investigative
T49995	DRUGINFO	D0A5CN	(Z)-5-Hexylidene-2-thioxothiazolidin-4-one	Investigative
T49995	DRUGINFO	D0H9VW	(Z)-5-Decylidene-2-thioxothiazolidin-4-one	Investigative
T49995	DRUGINFO	D0W5ED	(Z)-5-Butylidene-2-thioxothiazolidin-4-one	Investigative

T58470	TARGETID	T58470
T58470	FORMERID	TTDR00224
T58470	UNIPROID	CCNA2_HUMAN
T58470	TARGNAME	Cyclin A2 (CCNA2)
T58470	GENENAME	CCNA2
T58470	TARGTYPE	Literature-reported
T58470	SYNONYMS	Cyclin-A2; Cyclin-A; Cyclin A; CCNA
T58470	FUNCTION	Functions through the formation of specific serine/threonine protein kinase holoenzyme complexes with the cyclin-dependent protein kinases CDK1 or CDK2. The cyclin subunit confers the substrate specificity of these complexes and differentially interacts with and activates CDK1 and CDK2 throughout the cell cycle. Cyclin which controls both the G1/S and the G2/M transition phases of the cell cycle.
T58470	PDBSTRUC	6GVA; 6ATH; 5NEV; 5LMK; 5IF1
T58470	SEQUENCE	MLGNSAPGPATREAGSALLALQQTALQEDQENINPEKAAPVQQPRTRAALAVLKSGNPRGLAQQQRPKTRRVAPLKDLPVNDEHVTVPPWKANSKQPAFTIHVDEAEKEAQKKPAESQKIEREDALAFNSAISLPGPRKPLVPLDYPMDGSFESPHTMDMSIILEDEKPVSVNEVPDYHEDIHTYLREMEVKCKPKVGYMKKQPDITNSMRAILVDWLVEVGEEYKLQNETLHLAVNYIDRFLSSMSVLRGKLQLVGTAAMLLASKFEEIYPPEVAEFVYITDDTYTKKQVLRMEHLVLKVLTFDLAAPTVNQFLTQYFLHQQPANCKVESLAMFLGELSLIDADPYLKYLPSVIAGAAFHLALYTVTGQSWPESLIRKTGYTLESLKPCLMDLHQTYLKAPQHAQQSIREKYKNSKYHGVSLLNPPETLNL
T58470	DRUGINFO	D0Z0KD	PD-0183812	Terminated
T58470	DRUGINFO	D01FJB	6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine	Investigative
T58470	DRUGINFO	D02ZYA	6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine	Investigative
T58470	DRUGINFO	D03XKK	6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine	Investigative
T58470	DRUGINFO	D04RBG	GW-8510	Investigative
T58470	DRUGINFO	D04UNQ	4-(phenyldiazenyl)-1H-pyrazole-3,5-diamine	Investigative
T58470	DRUGINFO	D07AEC	RESCOVITINE	Investigative
T58470	DRUGINFO	D07JHG	6-(3-Amino-benzyloxy)-9H-purin-2-ylamine	Investigative
T58470	DRUGINFO	D0E3FK	MERIOLIN 7	Investigative
T58470	DRUGINFO	D0R1FT	6-O-Cyclohexylmethyl Guanine	Investigative
T58470	DRUGINFO	D0U8YN	NU-6027	Investigative
T58470	DRUGINFO	D01PEF	MERIOLIN 8	Investigative
T58470	DRUGINFO	D06WUE	2,5-dichloro-N-p-tolylthiophene-3-sulfonamide	Investigative
T58470	DRUGINFO	D07OAT	Purvalanol A	Investigative
T58470	DRUGINFO	D08KSQ	MERIOLIN 1	Investigative
T58470	DRUGINFO	D0B9YR	MERIOLIN 4	Investigative
T58470	DRUGINFO	D0D0ZQ	MERIOLIN 6	Investigative
T58470	DRUGINFO	D0H6CQ	MERIOLIN 5	Investigative
T58470	DRUGINFO	D0S8VE	MERIOLIN 3	Investigative
T58470	DRUGINFO	D0U1WL	MERIOLIN 2	Investigative
T58470	DRUGINFO	D0W0BL	3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol	Investigative
T58470	DRUGINFO	D02XHC	aloisine A	Investigative
T58470	DRUGINFO	D0A5RM	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	Investigative

T36657	TARGETID	T36657
T36657	FORMERID	TTDR01445
T36657	UNIPROID	CP2A7_HUMAN
T36657	TARGNAME	Cytochrome P450 2A5 (CYP2A5)
T36657	GENENAME	Cyp2a5
T36657	TARGTYPE	Literature-reported
T36657	SYNONYMS	Cytochrome P450-IIA3.2; Cytochrome P450-15-COH; Cyp2a5; Cyp2a-5; CYPIIA5
T36657	FUNCTION	Exhibits a high coumarin 7-hydroxylase activity.
T36657	BIOCLASS	Paired donor oxygen oxidoreductase
T36657	ECNUMBER	EC 1.14.14.1
T36657	SEQUENCE	MLASGLLLVALLACLTVMVLMSVWQQRKSRGKLPPGPTPLPFIGNYLQLNTEHICDSIMKFSECYGPVFTIHLGPRRVVVLCGHDAVREALVDQAEEFSGRGEQATFDWVFKGYGVAFSNGERAKQLLRFAIATLRDFGVGKRGIEERIQEESGFLIEAIRSTHGANIDPTFFLSRTVSNVISSIVFGDRFDYEDKEFLSLLSMMLGIFQFTSTSTGQLYEMFSSVMKHLPGPQQQAFKLLQGLEDFIAKKVEHNQRTLDPNSPQDFIDSFLIHMQEEEKNPNTEFYLKNLMMSTLNLFIAGTETVSTTLRYGFLLLMKHPEVEAKVHEEIDRVIGKNRQPKFEDRTKMPYMEAVIHEIQRFGDVIPMSLARRVKKDTKFRDFFLPKGTEVFPMLGSVLRDPSFFSNPQDFNPQHFLDDKGQFKKSDAFVPFSIGKRNCFGEGLARMELFLFFTTVMQNFRLKSSQSPKDIDVSPKHVVFATIPRNYTMSFLPR

T56474	TARGETID	T56474
T56474	FORMERID	TTDR00499
T56474	UNIPROID	TNAP3_HUMAN
T56474	TARGNAME	Zinc finger protein A20 (TNFAIP3)
T56474	GENENAME	TNFAIP3
T56474	TARGTYPE	Literature-reported
T56474	SYNONYMS	Tumor necrosis factor, alpha-induced protein3; Tumor necrosis factor alpha-induced protein 3; TNF alpha-induced protein 3; Putative DNA-binding protein A20; Putative DNA binding protein A20; OTUD7C; OTU domain-containing protein 7C; A20
T56474	FUNCTION	Involved in immune and inflammatory responses signaled by cytokines, such as TNF-alpha and IL-1 beta, or pathogens via Toll-like receptors (TLRs) through terminating NF-kappa-B activity. Essential component of a ubiquitin-editing protein complex, comprising also RNF11, ITCH and TAX1BP1, that ensures the transient nature of inflammatory signaling pathways. In cooperation with TAX1BP1 promotes disassembly of E2-E3 ubiquitin protein ligase complexes in IL-1R and TNFR-1 pathways; affected are at least E3 ligases TRAF6, TRAF2 and BIRC2, and E2 ubiquitin-conjugating enzymes UBE2N and UBE2D3. In cooperation with TAX1BP1 promotes ubiquitination of UBE2N and proteasomal degradation of UBE2N and UBE2D3. Upon TNF stimulation, deubiquitinates 'Lys-63'-polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys-48'-polyubiquitin chains. This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NF-kappa-B. Deubiquitinates TRAF6 probably acting on 'Lys-63'-linked polyubiquitin. Upon T-cell receptor (TCR)-mediated T-cell activation, deubiquitinates 'Lys-63'-polyubiquitin chains on MALT1 thereby mediating disassociation of the CBM (CARD11:BCL10:MALT1) and IKK complexes and preventing sustained IKK activation. Deubiquitinates NEMO/IKBKG; the function is facilitated by TNIP1 and leads to inhibition of NF-kappa-B activation. Upon stimulation by bacterial peptidoglycans, probably deubiquitinates RIPK2. Can also inhibit I-kappa-B-kinase (IKK) through a non-catalytic mechanism which involves polyubiquitin; polyubiquitin promotes association with IKBKG and prevents IKK MAP3K7-mediated phosphorylation. Targets TRAF2 for lysosomal degradation. In vitro able to deubiquitinate 'Lys-11'-, 'Lys-48'- and 'Lys-63' polyubiquitin chains. Inhibitor of programmed cell death. Has a role in the function of the lymphoid system. Required for LPS-induced production of proinflammatory cytokines and IFN beta in LPS-tolerized macrophages. Ubiquitin-editing enzyme that contains both ubiquitin ligase and deubiquitinase activities.
T56474	PDBSTRUC	5V3P; 5V3B; 5LRX; 3ZJG; 3ZJF
T56474	BIOCLASS	Acyltransferase
T56474	ECNUMBER	EC 2.3.2.-
T56474	SEQUENCE	MAEQVLPQALYLSNMRKAVKIRERTPEDIFKPTNGIIHHFKTMHRYTLEMFRTCQFCPQFREIIHKALIDRNIQATLESQKKLNWCREVRKLVALKTNGDGNCLMHATSQYMWGVQDTDLVLRKALFSTLKETDTRNFKFRWQLESLKSQEFVETGLCYDTRNWNDEWDNLIKMASTDTPMARSGLQYNSLEEIHIFVLCNILRRPIIVISDKMLRSLESGSNFAPLKVGGIYLPLHWPAQECYRYPIVLGYDSHHFVPLVTLKDSGPEIRAVPLVNRDRGRFEDLKVHFLTDPENEMKEKLLKEYLMVIEIPVQGWDHGTTHLINAAKLDEANLPKEINLVDDYFELVQHEYKKWQENSEQGRREGHAQNPMEPSVPQLSLMDVKCETPNCPFFMSVNTQPLCHECSERRQKNQNKLPKLNSKPGPEGLPGMALGASRGEAYEPLAWNPEESTGGPHSAPPTAPSPFLFSETTAMKCRSPGCPFTLNVQHNGFCERCHNARQLHASHAPDHTRHLDPGKCQACLQDVTRTFNGICSTCFKRTTAEASSSLSTSLPPSCHQRSKSDPSRLVRSPSPHSCHRAGNDAPAGCLSQAARTPGDRTGTSKCRKAGCVYFGTPENKGFCTLCFIEYRENKHFAAASGKVSPTASRFQNTIPCLGRECGTLGSTMFEGYCQKCFIEAQNQRFHEAKRTEEQLRSSQRRDVPRTTQSTSRPKCARASCKNILACRSEELCMECQHPNQRMGPGAHRGEPAPEDPPKQRCRAPACDHFGNAKCNGYCNECFQFKQMYG

T77721	TARGETID	T77721
T77721	FORMERID	TTDR00623
T77721	UNIPROID	GPDA_HUMAN
T77721	TARGNAME	Glycerol-3-phosphate dehydrogenase (GPD1)
T77721	GENENAME	GPD1
T77721	TARGTYPE	Literature-reported
T77721	SYNONYMS	Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic; GPDH-C; GPD-C
T77721	FUNCTION	Catalyzes the reversible redox conversion of dihydroxyacetone phosphate (a.k.a. glycerone phosphate, outdated) to sn-glycerol 3-phosphate. serves as a major link between carbohydrate metabolism and lipid metabolism. A major contributor of electrons to the electron transport chain in the mitochondria.
T77721	PDBSTRUC	6E8Z; 6E8Y; 6.00E+90; 1X0X; 1X0V
T77721	BIOCLASS	Short-chain dehydrogenases reductase
T77721	ECNUMBER	EC 1.1.1.8
T77721	SEQUENCE	MASKKVCIVGSGNWGSAIAKIVGGNAAQLAQFDPRVTMWVFEEDIGGKKLTEIINTQHENVKYLPGHKLPPNVVAVPDVVQAAEDADILIFVVPHQFIGKICDQLKGHLKANATGISLIKGVDEGPNGLKLISEVIGERLGIPMSVLMGANIASEVADEKFCETTIGCKDPAQGQLLKELMQTPNFRITVVQEVDTVEICGALKNVVAVGAGFCDGLGFGDNTKAAVIRLGLMEMIAFAKLFCSGPVSSATFLESCGVADLITTCYGGRNRKVAEAFARTGKSIEQLEKELLNGQKLQGPETARELYSILQHKGLVDKFPLFMAVYKVCYEGQPVGEFIHCLQNHPEHM

T28418	TARGETID	T28418
T28418	FORMERID	TTDI03175
T28418	UNIPROID	EPHA1_HUMAN
T28418	TARGNAME	Ephrin type-A receptor 1 (EPHA1)
T28418	GENENAME	EPHA1
T28418	TARGTYPE	Literature-reported
T28418	SYNONYMS	hEpha1; Tyrosine-protein kinase receptor EPH; Erythropoietin-producing hepatoma receptor; EPHT1; EPHT; EPH tyrosine kinase 1; EPH tyrosine kinase; EPH
T28418	FUNCTION	The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Binds with a low affinity EFNA3 and EFNA4 and with a high affinity to EFNA1 which most probably constitutes its cognate/functional ligand. Upon activation by EFNA1 induces cell attachment to the extracellular matrix inhibiting cell spreading and motility through regulation of ILK and downstream RHOA and RAC. Plays also a role in angiogenesis and regulates cell proliferation. May play a role in apoptosis. Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells.
T28418	PDBSTRUC	3KKA; 3HIL; 2K1L; 2K1K
T28418	BIOCLASS	Kinase
T28418	ECNUMBER	EC 2.7.10.1
T28418	SEQUENCE	MERRWPLGLGLVLLLCAPLPPGARAKEVTLMDTSKAQGELGWLLDPPKDGWSEQQQILNGTPLYMYQDCPMQGRRDTDHWLRSNWIYRGEEASRVHVELQFTVRDCKSFPGGAGPLGCKETFNLLYMESDQDVGIQLRRPLFQKVTTVAADQSFTIRDLVSGSVKLNVERCSLGRLTRRGLYLAFHNPGACVALVSVRVFYQRCPETLNGLAQFPDTLPGPAGLVEVAGTCLPHARASPRPSGAPRMHCSPDGEWLVPVGRCHCEPGYEEGGSGEACVACPSGSYRMDMDTPHCLTCPQQSTAESEGATICTCESGHYRAPGEGPQVACTGPPSAPRNLSFSASGTQLSLRWEPPADTGGRQDVRYSVRCSQCQGTAQDGGPCQPCGVGVHFSPGARGLTTPAVHVNGLEPYANYTFNVEAQNGVSGLGSSGHASTSVSISMGHAESLSGLSLRLVKKEPRQLELTWAGSRPRSPGANLTYELHVLNQDEERYQMVLEPRVLLTELQPDTTYIVRVRMLTPLGPGPFSPDHEFRTSPPVSRGLTGGEIVAVIFGLLLGAALLLGILVFRSRRAQRQRQQRQRDRATDVDREDKLWLKPYVDLQAYEDPAQGALDFTRELDPAWLMVDTVIGEGEFGEVYRGTLRLPSQDCKTVAIKTLKDTSPGGQWWNFLREATIMGQFSHPHILHLEGVVTKRKPIMIITEFMENGALDAFLREREDQLVPGQLVAMLQGIASGMNYLSNHNYVHRDLAARNILVNQNLCCKVSDFGLTRLLDDFDGTYETQGGKIPIRWTAPEAIAHRIFTTASDVWSFGIVMWEVLSFGDKPYGEMSNQEVMKSIEDGYRLPPPVDCPAPLYELMKNCWAYDRARRPHFQKLQAHLEQLLANPHSLRTIANFDPRMTLRLPSLSGSDGIPYRTVSEWLESIRMKRYILHFHSAGLDTMECVLELTAEDLTQMGITLPGHQKRILCSIQGFKD
T28418	DRUGINFO	D05FXD	PMID19788238C66	Investigative
T28418	DRUGINFO	D0X8BU	PMID23489211C20	Investigative

T04685	TARGETID	T04685
T04685	FORMERID	TTDI02012
T04685	UNIPROID	ADRO_HUMAN
T04685	TARGNAME	NADPH:adrenodoxin oxidoreductase (FDXR)
T04685	GENENAME	FDXR
T04685	TARGTYPE	Literature-reported
T04685	SYNONYMS	NADPH:adrenodoxin oxidoreductase, mitochondrial; FerredoxinNADP(+) reductase; Ferredoxin reductase; FDXR; Adrenodoxin reductase
T04685	FUNCTION	Serves as the first electron transfer protein in all the mitochondrial P450 systems. Including cholesterol side chain cleavage in all steroidogenic tissues, steroid 11-beta hydroxylation in the adrenal cortex, 25-OH-vitaminD3-24 hydroxylation in the kidney, and sterol C-27 hydroxylation in the liver.
T04685	BIOCLASS	Ferredoxin--NADP reductase type 1
T04685	ECNUMBER	EC 1.18.1.6
T04685	SEQUENCE	MASRCWRWWGWSAWPRTRLPPAGSTPSFCHHFSTQEKTPQICVVGSGPAGFYTAQHLLKHPQAHVDIYEKQPVPFGLVRFGVAPDHPEVKNVINTFTQTAHSGRCAFWGNVEVGRDVTVPELREAYHAVVLSYGAEDHRALEIPGEELPGVCSARAFVGWYNGLPENQELEPDLSCDTAVILGQGNVALDVARILLTPPEHLERTDITKAALGVLRQSRVKTVWLVGRRGPLQVAFTIKELREMIQLPGARPILDPVDFLGLQDKIKEVPRPRKRLTELLLRTATEKPGPAEAARQASASRAWGLRFFRSPQQVLPSPDGRRAAGVRLAVTRLEGVDEATRAVPTGDMEDLPCGLVLSSIGYKSRPVDPSVPFDSKLGVIPNVEGRVMDVPGLYCSGWVKRGPTGVIATTMTDSFLTGQMLLQDLKAGLLPSGPRPGYAAIQALLSSRGVRPVSFSDWEKLDAEEVARGQGTGKPREKLVDPQEMLRLLGH

T25309	TARGETID	T25309
T25309	FORMERID	TTDR00741
T25309	UNIPROID	CBL_HUMAN
T25309	TARGNAME	Signal transduction protein CBL (CBL)
T25309	GENENAME	CBL
T25309	TARGTYPE	Literature-reported
T25309	SYNONYMS	RNF55; RING-type E3 ubiquitin transferase CBL; RING finger protein 55; Proto-oncogene c-CBL; E3 ubiquitin-protein ligase CBL; Casitas B-lineage lymphoma proto-oncogene; CBL2; C-Cbl
T25309	FUNCTION	Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including KIT, FLT1, FGFR1, FGFR2, PDGFRA, PDGFRB, EGFR, CSF1R, EPHA8 and KDR and terminates signaling. Recognizes membrane-bound HCK, SRC and other kinases of the SRC family and mediates their ubiquitination and degradation. Participates in signal transduction in hematopoietic cells. Plays an important role in the regulation of osteoblast differentiation and apoptosis. Essential for osteoclastic bone resorption. The 'Tyr-731' phosphorylated form induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function. May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3. In association with CBLB, required for proper feedback inhibition of ciliary platelet-derived growth factor receptor-alpha (PDGFRA) signaling pathway via ubiquitination and internalization of PDGFRA. Adapter protein that functions as a negative regulator of many signaling pathways that are triggered by activation of cell surface receptors.
T25309	PDBSTRUC	5O76; 5J3X; 5HL0; 5HKZ; 5HKY
T25309	BIOCLASS	Acyltransferase
T25309	ECNUMBER	EC 2.3.2.27
T25309	SEQUENCE	MAGNVKKSSGAGGGSGSGGSGSGGLIGLMKDAFQPHHHHHHHLSPHPPGTVDKKMVEKCWKLMDKVVRLCQNPKLALKNSPPYILDLLPDTYQHLRTILSRYEGKMETLGENEYFRVFMENLMKKTKQTISLFKEGKERMYEENSQPRRNLTKLSLIFSHMLAELKGIFPSGLFQGDTFRITKADAAEFWRKAFGEKTIVPWKSFRQALHEVHPISSGLEAMALKSTIDLTCNDYISVFEFDIFTRLFQPWSSLLRNWNSLAVTHPGYMAFLTYDEVKARLQKFIHKPGSYIFRLSCTRLGQWAIGYVTADGNILQTIPHNKPLFQALIDGFREGFYLFPDGRNQNPDLTGLCEPTPQDHIKVTQEQYELYCEMGSTFQLCKICAENDKDVKIEPCGHLMCTSCLTSWQESEGQGCPFCRCEIKGTEPIVVDPFDPRGSGSLLRQGAEGAPSPNYDDDDDERADDTLFMMKELAGAKVERPPSPFSMAPQASLPPVPPRLDLLPQRVCVPSSASALGTASKAASGSLHKDKPLPVPPTLRDLPPPPPPDRPYSVGAESRPQRRPLPCTPGDCPSRDKLPPVPSSRLGDSWLPRPIPKVPVSAPSSSDPWTGRELTNRHSLPFSLPSQMEPRPDVPRLGSTFSLDTSMSMNSSPLVGPECDHPKIKPSSSANAIYSLAARPLPVPKLPPGEQCEGEEDTEYMTPSSRPLRPLDTSQSSRACDCDQQIDSCTYEAMYNIQSQAPSITESSTFGEGNLAAAHANTGPEESENEDDGYDVPKPPVPAVLARRTLSDISNASSSFGWLSLDGDPTTNVTEGSQVPERPPKPFPRRINSERKAGSCQQGSGPAASAATASPQLSSEIENLMSQGYSYQDIQKALVIAQNNIEMAKNILREFVSISSPAHVAT

T59729	TARGETID	T59729
T59729	FORMERID	TTDR00862
T59729	UNIPROID	DHAS2_VIBCH
T59729	TARGNAME	Bacterial Aspartate-semialdehyde dehydrogenase (Bact asd2)
T59729	GENENAME	Bact asd2
T59729	TARGTYPE	Literature-reported
T59729	SYNONYMS	asd2; L-Aspartate-beta-semialdehyde dehydrogenase; ASADH; ASA dehydrogenase
T59729	FUNCTION	Catalyzes the NADPH-dependent formation of L-aspartate- semialdehyde (L-ASA) by the reductive dephosphorylation of L- aspartyl-4-phosphate.
T59729	PDBSTRUC	2R00; 2QZ9
T59729	BIOCLASS	Aldehyde/oxo donor oxidoreductase
T59729	SEQUENCE	MSQQFNVAIFGATGAVGETMLEVLQEREFPVDELFLLASERSEGKTYRFNGKTVRVQNVEEFDWSQVHIALFSAGGELSAKWAPIAAEAGVVVIDNTSHFRYDYDIPLVVPEVNPEAIAEFRNRNIIANPNCSTIQMLVALKPIYDAVGIERINVTTYQSVSGAGKAGIDELAGQTAKLLNGYPAETNTFSQQIAFNCIPQIDQFMDNGYTKEEMKMVWETQKIFNDPSIMVNPTCVRVPVFYGHAEAVHVETRAPIDAEQVMDMLEQTDGIELFRGADFPTQVRDAGGKDHVLVGRVRNDISHHSGINLWVVADNVRKGAATNAVQIAELLVRDYF
T59729	DRUGINFO	D00EUE	S-sulpho-L-cysteine	Investigative
T59729	DRUGINFO	D06SIH	Aspartate Semialdehyde	Investigative
T59729	DRUGINFO	D09TVP	Cacodylate Ion	Investigative
T59729	DRUGINFO	D0J2FY	2'-Monophosphoadenosine 5'-Diphosphoribose	Investigative

T72653	TARGETID	T72653
T72653	FORMERID	TTDR01166
T72653	UNIPROID	CHS1_CANAX
T72653	TARGNAME	Candida Chitin synthase 1 (Candi CHS1)
T72653	GENENAME	Candi CHS1
T72653	TARGTYPE	Literature-reported
T72653	SYNONYMS	Chitin-UDP acetyl-glucosaminyl transferase 1; CHS1
T72653	FUNCTION	Formation and repair of the disk-shaped septumin yeast and the cross walls of the hyphal phase.
T72653	BIOCLASS	Hexosyltransferase
T72653	ECNUMBER	EC 2.4.1.16
T72653	SEQUENCE	MHNINNGYVPNREKTITKRKVRLVGGKAGNLVLENPVPTELRKVLTRTESPFGEFTNMTYTACTSQPDTFSAEGFTLRAAKYGRETEIVICITMYNEDEVAFARTMHGVMKNIAHLCSRHKSKIWGKDSWKKVQVIIVADGRNKVQQSVLELLTATGCYQENLARPYVNNSKVNAHLFEYTTQISIDENLKFKGDEKNLAPVQVLFCLKESNQKKINSHRWLFNAFCPVLDPNVIVLLDVGTKPDNHAIYNLWKAFDRDSNVAGAAGEIKAMKGKGWINLTNPLVASQNFEYKLSNILDKPLESLFGYISVLPGALSAYRYIALKNHDDGTGPLASYFKGEDLLCSHDKDKENTKANFFEANMYLAEDRILCWELVSKRNDNWVLKFVKSATGETDVPETIAEFLSQRRRWINGAFFAALYSLYHFRKIWTTDHSYARKFWLHVEEFIYQLVSLLFSFFSLSNFYLTFYFLTGSLVSYKSLGKKGGFWIFTLFNYLCIGVLTSLFIVSIGNRPHASKNIFKTLIILLTICALYALVVGFVFVINTIATFGTGGTSTYVLVSIVVSLLSTYGLYTLMSILYLDPWHMLTCSVQYFLMIPSYTCTLQIFAFCNTHDVSWGTKGDNNPKEDLSNQYIIEKNASGEFEAVIVDTNIDEDYLETLYNIRSKRSNKKVALGHSEKTPLDGDDYAKDVRTRVVLFWMIANLVFIMTMVQVYEPGDTGRNIYLAFILWAVAVLALVRAIGSLGYLIQTYARFFVESKSKWMKRGYTAPSHNPLN

T88415	TARGETID	T88415
T88415	FORMERID	TTDR01149
T88415	UNIPROID	PTPRZ_HUMAN
T88415	TARGNAME	Receptor-type protein-tyrosine phosphatase zeta (PTPRZ1)
T88415	GENENAME	PTPRZ1
T88415	TARGTYPE	Literature-reported
T88415	SYNONYMS	Receptor protein tyrosine phosphatase zeta; R-PTP-zeta; PTPRZ1
T88415	FUNCTION	Protein tyrosine phosphatase that negatively regulates oligodendrocyte precursor proliferation in the embryonic spinal cord. Required for normal differentiation of the precursor cells into mature, fully myelinating oligodendrocytes. May play a role in protecting oligondendrocytes against apoptosis. May play a role in the establishment of contextual memory, probably via the dephosphorylation of proteins that are part of important signaling cascades.
T88415	PDBSTRUC	5H08; 5AWX; 3S97; 3JXF
T88415	BIOCLASS	Phosphoric monoester hydrolase
T88415	ECNUMBER	EC 3.1.3.48
T88415	SEQUENCE	MRILKRFLACIQLLCVCRLDWANGYYRQQRKLVEEIGWSYTGALNQKNWGKKYPTCNSPKQSPINIDEDLTQVNVNLKKLKFQGWDKTSLENTFIHNTGKTVEINLTNDYRVSGGVSEMVFKASKITFHWGKCNMSSDGSEHSLEGQKFPLEMQIYCFDADRFSSFEEAVKGKGKLRALSILFEVGTEENLDFKAIIDGVESVSRFGKQAALDPFILLNLLPNSTDKYYIYNGSLTSPPCTDTVDWIVFKDTVSISESQLAVFCEVLTMQQSGYVMLMDYLQNNFREQQYKFSRQVFSSYTGKEEIHEAVCSSEPENVQADPENYTSLLVTWERPRVVYDTMIEKFAVLYQQLDGEDQTKHEFLTDGYQDLGAILNNLLPNMSYVLQIVAICTNGLYGKYSDQLIVDMPTDNPELDLFPELIGTEEIIKEEEEGKDIEEGAIVNPGRDSATNQIRKKEPQISTTTHYNRIGTKYNEAKTNRSPTRGSEFSGKGDVPNTSLNSTSQPVTKLATEKDISLTSQTVTELPPHTVEGTSASLNDGSKTVLRSPHMNLSGTAESLNTVSITEYEEESLLTSFKLDTGAEDSSGSSPATSAIPFISENISQGYIFSSENPETITYDVLIPESARNASEDSTSSGSEESLKDPSMEGNVWFPSSTDITAQPDVGSGRESFLQTNYTEIRVDESEKTTKSFSAGPVMSQGPSVTDLEMPHYSTFAYFPTEVTPHAFTPSSRQQDLVSTVNVVYSQTTQPVYNGETPLQPSYSSEVFPLVTPLLLDNQILNTTPAASSSDSALHATPVFPSVDVSFESILSSYDGAPLLPFSSASFSSELFRHLHTVSQILPQVTSATESDKVPLHASLPVAGGDLLLEPSLAQYSDVLSTTHAASETLEFGSESGVLYKTLMFSQVEPPSSDAMMHARSSGPEPSYALSDNEGSQHIFTVSYSSAIPVHDSVGVTYQGSLFSGPSHIPIPKSSLITPTASLLQPTHALSGDGEWSGASSDSEFLLPDTDGLTALNISSPVSVAEFTYTTSVFGDDNKALSKSEIIYGNETELQIPSFNEMVYPSESTVMPNMYDNVNKLNASLQETSVSISSTKGMFPGSLAHTTTKVFDHEISQVPENNFSVQPTHTVSQASGDTSLKPVLSANSEPASSDPASSEMLSPSTQLLFYETSASFSTEVLLQPSFQASDVDTLLKTVLPAVPSDPILVETPKVDKISSTMLHLIVSNSASSENMLHSTSVPVFDVSPTSHMHSASLQGLTISYASEKYEPVLLKSESSHQVVPSLYSNDELFQTANLEINQAHPPKGRHVFATPVLSIDEPLNTLINKLIHSDEILTSTKSSVTGKVFAGIPTVASDTFVSTDHSVPIGNGHVAITAVSPHRDGSVTSTKLLFPSKATSELSHSAKSDAGLVGGGEDGDTDDDGDDDDDDRGSDGLSIHKCMSCSSYRESQEKVMNDSDTHENSLMDQNNPISYSLSENSEEDNRVTSVSSDSQTGMDRSPGKSPSANGLSQKHNDGKEENDIQTGSALLPLSPESKAWAVLTSDEESGSGQGTSDSLNENETSTDFSFADTNEKDADGILAAGDSEITPGFPQSPTSSVTSENSEVFHVSEAEASNSSHESRIGLAEGLESEKKAVIPLVIVSALTFICLVVLVGILIYWRKCFQTAHFYLEDSTSPRVISTPPTPIFPISDDVGAIPIKHFPKHVADLHASSGFTEEFETLKEFYQEVQSCTVDLGITADSSNHPDNKHKNRYINIVAYDHSRVKLAQLAEKDGKLTDYINANYVDGYNRPKAYIAAQGPLKSTAEDFWRMIWEHNVEVIVMITNLVEKGRRKCDQYWPADGSEEYGNFLVTQKSVQVLAYYTVRNFTLRNTKIKKGSQKGRPSGRVVTQYHYTQWPDMGVPEYSLPVLTFVRKAAYAKRHAVGPVVVHCSAGVGRTGTYIVLDSMLQQIQHEGTVNIFGFLKHIRSQRNYLVQTEEQYVFIHDTLVEAILSKETEVLDSHIHAYVNALLIPGPAGKTKLEKQFQLLSQSNIQQSDYSAALKQCNREKNRTSSIIPVERSRVGISSLSGEGTDYINASYIMGYYQSNEFIITQHPLLHTIKDFWRMIWDHNAQLVVMIPDGQNMAEDEFVYWPNKDEPINCESFKVTLMAEEHKCLSNEEKLIIQDFILEATQDDYVLEVRHFQCPKWPNPDSPISKTFELISVIKEEAANRDGPMIVHDEHGGVTAGTFCALTTLMHQLEKENSVDVYQVAKMINLMRPGVFADIEQYQFLYKVILSLVSTRQEENPSTSLDSNGAALPDGNIAESLESLV

T25164	TARGETID	T25164
T25164	FORMERID	TTDR00747
T25164	UNIPROID	HMP_ECOLI
T25164	TARGNAME	Bacterial Flavohemoglobin (Bact hmp)
T25164	GENENAME	Bact hmp
T25164	TARGTYPE	Literature-reported
T25164	SYNONYMS	Nitric oxide dioxygenase; NOD; NO oxygenase; Hemoglobin-like protein; HMP; Ferrisiderophore reductase B; Dihydropteridine reductase
T25164	FUNCTION	Various electron acceptors arealso reduced by HMP in vitro, including dihydropterine, ferrisiderophores, ferric citrate, cytochrome c, nitrite, S-nitrosoglutathione, and alkylhydroperoxides. However, it is unknown if these reactions are of any biological significance in vivo.
T25164	PDBSTRUC	1GVH
T25164	BIOCLASS	Paired donor oxygen oxidoreductase
T25164	ECNUMBER	EC 1.14.12.17
T25164	SEQUENCE	MLDAQTIATVKATIPLLVETGPKLTAHFYDRMFTHNPELKEIFNMSNQRNGDQREALFNAIAAYASNIENLPALLPAVEKIAQKHTSFQIKPEQYNIVGEHLLATLDEMFSPGQEVLDAWGKAYGVLANVFINREAEIYNENASKAGGWEGTRDFRIVAKTPRSALITSFELEPVDGGAVAEYRPGQYLGVWLKPEGFPHQEIRQYSLTRKPDGKGYRIAVKREEGGQVSNWLHNHANVGDVVKLVAPAGDFFMAVADDTPVTLISAGVGQTPMLAMLDTLAKAGHTAQVNWFHAAENGDVHAFADEVKELGQSLPRFTAHTWYRQPSEADRAKGQFDSEGLMDLSKLEGAFSDPTMQFYLCGPVGFMQFTAKQLVDLGVKQENIHYECFGPHKVL
T25164	DRUGINFO	D07KZA	2-(N-Morpholino)-Ethanesulfonic Acid	Investigative
T25164	DRUGINFO	D0UU1I	Heme	Investigative
T25164	DRUGINFO	D00IMW	Flavin-Adenine Dinucleotide	Investigative
T25164	DRUGINFO	D0R6JE	Nicotinamide-Adenine-Dinucleotide	Investigative

T73180	TARGETID	T73180
T73180	FORMERID	TTDR01252
T73180	UNIPROID	MMP11_HUMAN
T73180	TARGNAME	Matrix metalloproteinase-11 (MMP-11)
T73180	GENENAME	MMP11
T73180	TARGTYPE	Literature-reported
T73180	SYNONYMS	Stromelysin-3 (ST3) gene; Stromelysin-3; STR-3; STMY3; ST3/MMP11; ST3; SL-3
T73180	FUNCTION	May play an important role in the progression of epithelial malignancies.
T73180	BIOCLASS	Peptidase
T73180	ECNUMBER	EC 3.4.24.-
T73180	SEQUENCE	MAPAAWLRSAAARALLPPMLLLLLQPPPLLARALPPDAHHLHAERRGPQPWHAALPSSPAPAPATQEAPRPASSLRPPRCGVPDPSDGLSARNRQKRFVLSGGRWEKTDLTYRILRFPWQLVQEQVRQTMAEALKVWSDVTPLTFTEVHEGRADIMIDFARYWHGDDLPFDGPGGILAHAFFPKTHREGDVHFDYDETWTIGDDQGTDLLQVAAHEFGHVLGLQHTTAAKALMSAFYTFRYPLSLSPDDCRGVQHLYGQPWPTVTSRTPALGPQAGIDTNEIAPLEPDAPPDACEASFDAVSTIRGELFFFKAGFVWRLRGGQLQPGYPALASRHWQGLPSPVDAAFEDAQGHIWFFQGAQYWVYDGEKPVLGPAPLTELGLVRFPVHAALVWGPEKNKIYFFRGRDYWRFHPSTRRVDSPVPRRATDWRGVPSEIDAAFQDADGYAYFLRGRLYWKFDPVKVKALEGFPRLVGPDFFGCAEPANTFL
T73180	DRUGINFO	D01UNE	PMID18790648C10	Investigative

T85223	TARGETID	T85223
T85223	FORMERID	TTDR00828
T85223	UNIPROID	DNAS1_HUMAN
T85223	TARGNAME	Deoxyribonuclease I (DNASE1)
T85223	GENENAME	DNASE1
T85223	TARGTYPE	Literature-reported
T85223	SYNONYMS	Herpesvirus alkaline deoxyribonuclease; Herpesvirus alkaline DNase; Dornase alfa; DNase I; DNASE1; Alkaline deoxyribonuclease
T85223	FUNCTION	Among other functions, seems to be involved in cell death by apoptosis. Binds specifically to G-actin and blocks actin polymerization.
T85223	PDBSTRUC	4AWN
T85223	BIOCLASS	Endodeoxyribonucleases
T85223	ECNUMBER	EC 3.1.21.1
T85223	SEQUENCE	MRGMKLLGALLALAALLQGAVSLKIAAFNIQTFGETKMSNATLVSYIVQILSRYDIALVQEVRDSHLTAVGKLLDNLNQDAPDTYHYVVSEPLGRNSYKERYLFVYRPDQVSAVDSYYYDDGCEPCGNDTFNREPAIVRFFSRFTEVREFAIVPLHAAPGDAVAEIDALYDVYLDVQEKWGLEDVMLMGDFNAGCSYVRPSQWSSIRLWTSPTFQWLIPDSADTTATPTHCAYDRIVVAGMLLRGAVVPDSALPFNFQAAYGLSDQLAQAISDHYPVEVMLK
T85223	DRUGINFO	D07LUR	Alpha-D-Mannose	Investigative

T10052	TARGETID	T10052
T10052	FORMERID	TTDR00786
T10052	UNIPROID	CCNE1_HUMAN
T10052	TARGNAME	G1/S-specific cyclin-E1 (CCNE1)
T10052	GENENAME	CCNE1
T10052	TARGTYPE	Literature-reported
T10052	SYNONYMS	G1/S-specific cyclin E; Cyclin E; CCNE
T10052	FUNCTION	Essential for the control of the cell cycle at the G1/S (start) transition.
T10052	PDBSTRUC	5L2W; 1W98
T10052	SEQUENCE	MPRERRERDAKERDTMKEDGGAEFSARSRKRKANVTVFLQDPDEEMAKIDRTARDQCGSQPWDNNAVCADPCSLIPTPDKEDDDRVYPNSTCKPRIIAPSRGSPLPVLSWANREEVWKIMLNKEKTYLRDQHFLEQHPLLQPKMRAILLDWLMEVCEVYKLHRETFYLAQDFFDRYMATQENVVKTLLQLIGISSLFIAAKLEEIYPPKLHQFAYVTDGACSGDEILTMELMIMKALKWRLSPLTIVSWLNVYMQVAYLNDLHEVLLPQYPQQIFIQIAELLDLCVLDVDCLEFPYGILAASALYHFSSSELMQKVSGYQWCDIENCVKWMVPFAMVIRETGSSKLKHFRGVADEDAHNIQTHRDSLDLLDKARAKKAMLSEQNRASPLPSGLLTPPQSGKKQSSGPEMA
T10052	DRUGINFO	D0Z0KD	PD-0183812	Terminated
T10052	DRUGINFO	D01PSU	(2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime	Investigative
T10052	DRUGINFO	D03KLM	(2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime	Investigative
T10052	DRUGINFO	D04AGE	(2'Z,3'E)-5-Fluoro-5'-methoxy-indirubin-3'-oxime	Investigative
T10052	DRUGINFO	D06GLV	(2'Z,3'E)-5-Fluoro-5'-fluoro-indirubin-3'-oxime	Investigative
T10052	DRUGINFO	D06XIW	(2'Z,3'E)-5-Fluoro-5'-chloro-indirubin-3'-oxime	Investigative
T10052	DRUGINFO	D0B1LM	(2'Z,3'E)-5-Chloro-5'-fluoro-indirubin-3'-oxime	Investigative
T10052	DRUGINFO	D0F3OM	2-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol	Investigative
T10052	DRUGINFO	D0GP3R	5-nitroindirubin-3'-oxime	Investigative
T10052	DRUGINFO	D0H0EN	(2'Z,3'E)-5-Nitro-5'-methyl-indirubin-3'-oxime	Investigative
T10052	DRUGINFO	D0I6AE	(2'Z,3'E)-5-Nitro-5'-chloro-indirubin-3'-oxime	Investigative
T10052	DRUGINFO	D0J3RS	(2'Z,3'E)-5-Fluoro-5'-hydroxy-indirubin-3'-oxime	Investigative
T10052	DRUGINFO	D0JR0G	(2'Z,3'E)-5-Chloro-5'-hydroxy-indirubin-3'-oxime	Investigative
T10052	DRUGINFO	D0L5PI	(2'Z,3'E)-5-Nitro-5'-fluoro-indirubin-3'-oxime	Investigative
T10052	DRUGINFO	D0M4XD	(2'Z,3'E)-5-Nitro-5'-methoxy-indirubin-3'-oxime	Investigative
T10052	DRUGINFO	D0W2FM	(2'Z,3'E)-5-Fluoro-5'-methyl-indirubin-3'-oxime	Investigative
T10052	DRUGINFO	D0YZ9Y	(2'Z,3'E)-5-Nitro-5'-hydroxy-indirubin-3'-oxime	Investigative
T10052	DRUGINFO	D0W0BL	3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol	Investigative
T10052	DRUGINFO	D02XHC	aloisine A	Investigative
T10052	DRUGINFO	D06AOY	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	Investigative
T10052	DRUGINFO	D0M4SY	BMS-536924	Investigative
T10052	DRUGINFO	D00NYT	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	Investigative
T10052	DRUGINFO	D0C3WY	3,4-diphenyl-1H-pyrrole-2,5-dione	Investigative
T10052	DRUGINFO	D0EK0G	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	Investigative
T10052	DRUGINFO	D0A5RM	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	Investigative

T35265	TARGETID	T35265
T35265	FORMERID	TTDI02166
T35265	UNIPROID	S10A4_HUMAN
T35265	TARGNAME	S100 calcium-binding protein A4 (S100A4)
T35265	GENENAME	S100A4
T35265	TARGTYPE	Literature-reported
T35265	SYNONYMS	Protein S100-A4; Protein Mts1; Placental calcium-binding protein; Metastasin; MTS1; Calvasculin; CAPL
T35265	FUNCTION	collagen-containing extracellular matrix, extracellular exosome, extracellular region, extracellular space, nucleus, perinuclear region of cytoplasm, calcium ion binding, identical protein binding, RAGE receptor binding, RNA binding
T35265	PDBSTRUC	5LPU; 4HSZ; 4ETO; 4CFR; 4CFQ
T35265	BIOCLASS	S100 calcium-binding protein
T35265	SEQUENCE	MACPLEKALDVMVSTFHKYSGKEGDKFKLNKSELKELLTRELPSFLGKRTDEAAFQKLMSNLDSNRDNEVDFQEYCVFLSCIAMMCNEFFEGFPDKQPRKK
T35265	DRUGINFO	D0U7ZY	SP-MET-1	Preclinical

T34562	TARGETID	T34562
T34562	FORMERID	TTDR00684
T34562	UNIPROID	PON1_HUMAN
T34562	TARGNAME	Serum paraoxonase/arylesterase 1 (PON1)
T34562	GENENAME	PON1
T34562	TARGTYPE	Literature-reported
T34562	SYNONYMS	Serum paraoxonase; Serum aryldialkylphosphatase 1; Serum aryldiakylphosphatase 1; PON 1; PON; K-45; Aromatic esterase 1; A-esterase 1
T34562	FUNCTION	Capable of hydrolyzing a broad spectrum of organophosphate substrates and lactones, and a number of aromatic carboxylic acid esters. Mediates an enzymatic protection of low density lipoproteins against oxidative modification and the consequent series of events leading to atheroma formation. Hydrolyzes the toxic metabolites of a variety of organophosphorus insecticides.
T34562	PDBSTRUC	1XHR; 1V04
T34562	BIOCLASS	Carboxylic ester hydrolase
T34562	ECNUMBER	EC 3.1.1.2
T34562	SEQUENCE	MAKLIALTLLGMGLALFRNHQSSYQTRLNALREVQPVELPNCNLVKGIETGSEDLEILPNGLAFISSGLKYPGIKSFNPNSPGKILLMDLNEEDPTVLELGITGSKFDVSSFNPHGISTFTDEDNAMYLLVVNHPDAKSTVELFKFQEEEKSLLHLKTIRHKLLPNLNDIVAVGPEHFYGTNDHYFLDPYLQSWEMYLGLAWSYVVYYSPSEVRVVAEGFDFANGINISPDGKYVYIAELLAHKIHVYEKHANWTLTPLKSLDFNTLVDNISVDPETGDLWVGCHPNGMKIFFYDSENPPASEVLRIQNILTEEPKVTQVYAENGTVLQGSTVASVYKGKLLIGTVFHKALYCEL

T24548	TARGETID	T24548
T24548	FORMERID	TTDR00171
T24548	UNIPROID	PYR1_HUMAN
T24548	TARGNAME	Aspartate carbamoyltransferase (CAD)
T24548	GENENAME	CAD
T24548	TARGTYPE	Literature-reported
T24548	SYNONYMS	CAD
T24548	FUNCTION	This protein is a "fusion" protein encoding four enzymatic activities of the pyrimidine pathway (GATase, CPSase, ATCase and DHOase).
T24548	PDBSTRUC	6HG1; 6HFU; 6HFS; 6HFR; 6HFQ
T24548	BIOCLASS	Carbon-nitrogen ligase
T24548	SEQUENCE	MAALVLEDGSVLRGQPFGAAVSTAGEVVFQTGMVGYPEALTDPSYKAQILVLTYPLIGNYGIPPDEMDEFGLCKWFESSGIHVAALVVGECCPTPSHWSATRTLHEWLQQHGIPGLQGVDTRELTKKLREQGSLLGKLVQNGTEPSSLPFLDPNARPLVPEVSIKTPRVFNTGGAPRILALDCGLKYNQIRCLCQRGAEVTVVPWDHALDSQEYEGLFLSNGPGDPASYPSVVSTLSRVLSEPNPRPVFGICLGHQLLALAIGAKTYKMRYGNRGHNQPCLLVGSGRCFLTSQNHGFAVETDSLPADWAPLFTNANDGSNEGIVHNSLPFFSVQFHPEHQAGPSDMELLFDIFLETVKEATAGNPGGQTVRERLTERLCPPGIPTPGSGLPPPRKVLILGSGGLSIGQAGEFDYSGSQAIKALKEENIQTLLINPNIATVQTSQGLADKVYFLPITPHYVTQVIRNERPDGVLLTFGGQTALNCGVELTKAGVLARYGVRVLGTPVETIELTEDRRAFAARMAEIGEHVAPSEAANSLEQAQAAAERLGYPVLVRAAFALGGLGSGFASNREELSALVAPAFAHTSQVLVDKSLKGWKEIEYEVVRDAYGNCVTVCNMENLDPLGIHTGESIVVAPSQTLNDREYQLLRQTAIKVTQHLGIVGECNVQYALNPESEQYYIIEVNARLSRSSALASKATGYPLAYVAAKLALGIPLPELRNSVTGGTAAFEPSVDYCVVKIPRWDLSKFLRVSTKIGSCMKSVGEVMGIGRSFEEAFQKALRMVDENCVGFDHTVKPVSDMELETPTDKRIFVVAAALWAGYSVDRLYELTRIDRWFLHRMKRIIAHAQLLEQHRGQPLPPDLLQQAKCLGFSDKQIALAVLSTELAVRKLRQELGICPAVKQIDTVAAEWPAQTNYLYLTYWGTTHDLTFRTPHVLVLGSGVYRIGSSVEFDWCAVGCIQQLRKMGYKTIMVNYNPETVSTDYDMCDRLYFDEISFEVVMDIYELENPEGVILSMGGQLPNNMAMALHRQQCRVLGTSPEAIDSAENRFKFSRLLDTIGISQPQWRELSDLESARQFCQTVGYPCVVRPSYVLSGAAMNVAYTDGDLERFLSSAAAVSKEHPVVISKFIQEAKEIDVDAVASDGVVAAIAISEHVENAGVHSGDATLVTPPQDITAKTLERIKAIVHAVGQELQVTGPFNLQLIAKDDQLKVIECNVRVSRSFPFVSKTLGVDLVALATRVIMGEEVEPVGLMTGSGVVGVKVPQFSFSRLAGADVVLGVEMTSTGEVAGFGESRCEAYLKAMLSTGFKIPKKNILLTIGSYKNKSELLPTVRLLESLGYSLYASLGTADFYTEHGVKVTAVDWHFEEAVDGECPPQRSILEQLAEKNFELVINLSMRGAGGRRLSSFVTKGYRTRRLAADFSVPLIIDIKCTKLFVEALGQIGPAPPLKVHVDCMTSQKLVRLPGLIDVHVHLREPGGTHKEDFASGTAAALAGGITMVCAMPNTRPPIIDAPALALAQKLAEAGARCDFALFLGASSENAGTLGTVAGSAAGLKLYLNETFSELRLDSVVQWMEHFETWPSHLPIVAHAEQQTVAAVLMVAQLTQRSVHICHVARKEEILLIKAAKARGLPVTCEVAPHHLFLSHDDLERLGPGKGEVRPELGSRQDVEALWENMAVIDCFASDHAPHTLEEKCGSRPPPGFPGLETMLPLLLTAVSEGRLSLDDLLQRLHHNPRRIFHLPPQEDTYVEVDLEHEWTIPSHMPFSKAHWTPFEGQKVKGTVRRVVLRGEVAYIDGQVLVPPGYGQDVRKWPQGAVPQLPPSAPATSEMTTTPERPRRGIPGLPDGRFHLPPRIHRASDPGLPAEEPKEKSSRKVAEPELMGTPDGTCYPPPPVPRQASPQNLGTPGLLHPQTSPLLHSLVGQHILSVQQFTKDQMSHLFNVAHTLRMMVQKERSLDILKGKVMASMFYEVSTRTSSSFAAAMARLGGAVLSFSEATSSVQKGESLADSVQTMSCYADVVVLRHPQPGAVELAAKHCRRPVINAGDGVGEHPTQALLDIFTIREELGTVNGMTITMVGDLKHGRTVHSLACLLTQYRVSLRYVAPPSLRMPPTVRAFVASRGTKQEEFESIEEALPDTDVLYMTRIQKERFGSTQEYEACFGQFILTPHIMTRAKKKMVVMHPMPRVNEISVEVDSDPRAAYFRQAENGMYIRMALLATVLGRF
T24548	DRUGINFO	D0L6CN	N-(phosphonacetyl)-L-aspartate	Investigative

T48543	TARGETID	T48543
T48543	FORMERID	TTDR00223
T48543	UNIPROID	OAPT_PSEPU
T48543	TARGNAME	Pseudomonas Omega-amino acid:pyruvate aminotransferase (Pseudo Omega-APT)
T48543	GENENAME	Pseudo Omega-APT
T48543	TARGTYPE	Literature-reported
T48543	SYNONYMS	Omega-APT; Beta-alanine--pyruvate aminotransferase
T48543	FUNCTION	Catalyzes transamination between a variety of omega- amino acids, mono and diamines, and pyruvate. Plays a pivotal role in the metabolism of the omega amino acids.
T48543	PDBSTRUC	3A8U
T48543	BIOCLASS	Transaminase
T48543	ECNUMBER	EC 2.6.1.18
T48543	SEQUENCE	NMPEHAGASLASQLKLDAHWMPYTANRNFLRDPRLIVAAEGSWLVDDKGRKVYDSLSGLWTCGAGHTRKEIQEAVAKQLSTLDYSPGFQYGHPLSFQLAEKITDLTPGNLNHVFFTDSGSECALTAVKMVRAYWRLKGQATKTKMIGRARGYHGVNIAGTSLGGVNGNRKLFGQPMQDVDHLPHTLLASNAYSRGMPKEGGIALADELLKLIELHDASNIAAVFVEPLAGSAGVLVPPEGYLKRNREICNQHNILLVFDEVITGFGRTGSMFGADSFGVTPDLMCIAKQVTNGAIPMGAVIASTEIYQTFMNQPTPEYAVEFPHGYTYSAHPVACAAGLAALCLLQKENLVQSVAEVAPHFEKALHGIKGAKNVIDIRNFGLAGAIQIAPRDGDAIVRPFEAGMALWKAGFYVRFGGDTLQFGPTFNSKPQDLDRLFDAVGEVLNKLLD

T58266	TARGETID	T58266
T58266	FORMERID	TTDI03179
T58266	UNIPROID	EPHA8_HUMAN
T58266	TARGNAME	Ephrin type-A receptor 8 (EPHA8)
T58266	GENENAME	EPHA8
T58266	TARGTYPE	Literature-reported
T58266	SYNONYMS	hEK3; Tyrosine-protein kinase receptor EEK; KIAA1459; EPH-like kinase 3; EPH- and ELK-related kinase; EK3; EEK
T58266	FUNCTION	The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. The GPI-anchored ephrin-A EFNA2, EFNA3, and EFNA5 are able to activate EPHA8 through phosphorylation. With EFNA5 may regulate integrin-mediated cell adhesion and migration on fibronectin substrate but also neurite outgrowth. During development of the nervous system plays also a role in axon guidance. Downstream effectors of the EPHA8 signaling pathway include FYN which promotes cell adhesion upon activation by EPHA8 and the MAP kinases in the stimulation of neurite outgrowth. Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells.
T58266	PDBSTRUC	3KUL; 1X5L; 1UCV
T58266	BIOCLASS	Kinase
T58266	ECNUMBER	EC 2.7.10.1
T58266	SEQUENCE	MAPARGRLPPALWVVTAAAAAATCVSAARGEVNLLDTSTIHGDWGWLTYPAHGWDSINEVDESFQPIHTYQVCNVMSPNQNNWLRTSWVPRDGARRVYAEIKFTLRDCNSMPGVLGTCKETFNLYYLESDRDLGASTQESQFLKIDTIAADESFTGADLGVRRLKLNTEVRSVGPLSKRGFYLAFQDIGACLAILSLRIYYKKCPAMVRNLAAFSEAVTGADSSSLVEVRGQCVRHSEERDTPKMYCSAEGEWLVPIGKCVCSAGYEERRDACVACELGFYKSAPGDQLCARCPPHSHSAAPAAQACHCDLSYYRAALDPPSSACTRPPSAPVNLISSVNGTSVTLEWAPPLDPGGRSDITYNAVCRRCPWALSRCEACGSGTRFVPQQTSLVQASLLVANLLAHMNYSFWIEAVNGVSDLSPEPRRAAVVNITTNQAAPSQVVVIRQERAGQTSVSLLWQEPEQPNGIILEYEIKYYEKDKEMQSYSTLKAVTTRATVSGLKPGTRYVFQVRARTSAGCGRFSQAMEVETGKPRPRYDTRTIVWICLTLITGLVVLLLLLICKKRHCGYSKAFQDSDEEKMHYQNGQAPPPVFLPLHHPPGKLPEPQFYAEPHTYEEPGRAGRSFTREIEASRIHIEKIIGSGDSGEVCYGRLRVPGQRDVPVAIKALKAGYTERQRRDFLSEASIMGQFDHPNIIRLEGVVTRGRLAMIVTEYMENGSLDTFLRTHDGQFTIMQLVGMLRGVGAGMRYLSDLGYVHRDLAARNVLVDSNLVCKVSDFGLSRVLEDDPDAAYTTTGGKIPIRWTAPEAIAFRTFSSASDVWSFGVVMWEVLAYGERPYWNMTNRDVISSVEEGYRLPAPMGCPHALHQLMLDCWHKDRAQRPRFSQIVSVLDALIRSPESLRATATVSRCPPPAFVRSCFDLRGGSGGGGGLTVGDWLDSIRMGRYRDHFAAGGYSSLGMVLRMNAQDVRALGITLMGHQKKILGSIQTMRAQLTSTQGPRRHL
T58266	DRUGINFO	D05FXD	PMID19788238C66	Investigative
T58266	DRUGINFO	D0X8BU	PMID23489211C20	Investigative

T62746	TARGETID	T62746
T62746	FORMERID	TTDI02437
T62746	UNIPROID	PPIF_HUMAN
T62746	TARGNAME	Rotamase F (PPIF)
T62746	GENENAME	PPIF
T62746	TARGTYPE	Literature-reported
T62746	SYNONYMS	Peptidylprolyl cistrans isomerase F, mitochondrial; Peptidyl-prolyl cis-trans isomerase F, mitochondrial; PPIase F; Mitochondrial cyclophilin; Cyclophilin F; CyPM; CyP-M; CyP-D; CYP3
T62746	FUNCTION	Involved in regulation of the mitochondrial permeability transition pore (mPTP). It is proposed that its association with the mPTP is masking a binding site for inhibiting inorganic phosphate (Pi) and promotes the open probability of the mPTP leading to apoptosis or necrosis; the requirement of the PPIase activity for this function is debated. In cooperation with mitochondrial TP53 is involved in activating oxidative stress-induced necrosis. Involved in modulation of mitochondrial membrane F(1)F(0) ATP synthase activity and regulation of mitochondrial matrix adenine nucleotide levels. Has anti-apoptotic activity independently of mPTP and in cooperation with BCL2 inhibits cytochrome c-dependent apoptosis. PPIase that catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides and may therefore assist protein folding.
T62746	PDBSTRUC	5NWO; 5CCS; 5CCR; 5CCQ; 5CCN
T62746	BIOCLASS	Cis-trans-isomerase
T62746	ECNUMBER	EC 5.2.1.8
T62746	SEQUENCE	MLALRCGSRWLGLLSVPRSVPLRLPAARACSKGSGDPSSSSSSGNPLVYLDVDANGKPLGRVVLELKADVVPKTAENFRALCTGEKGFGYKGSTFHRVIPSFMCQAGDFTNHNGTGGKSIYGSRFPDENFTLKHVGPGVLSMANAGPNTNGSQFFICTIKTDWLDGKHVVFGHVKEGMDVVKKIESFGSKSGRTSKKIVITDCGQLS

T86808	TARGETID	T86808
T86808	FORMERID	TTDI01793
T86808	UNIPROID	HMOX2_HUMAN
T86808	TARGNAME	Heme oxygenase 2 (HMOX2)
T86808	GENENAME	HMOX2
T86808	TARGTYPE	Literature-reported
T86808	SYNONYMS	HO2; HO-2
T86808	FUNCTION	Biliverdin is subsequently converted to bilirubin by biliverdin reductase. Under physiological conditions, the activity of heme oxygenase is highest in the spleen, where senescent erythrocytes are sequestrated and destroyed. Heme oxygenase 2 could be implicated in the production of carbon monoxide in brain where it could act as a neurotransmitter. Heme oxygenase cleaves the heme ring at the alpha methene bridge to form biliverdin.
T86808	PDBSTRUC	5UCA; 5UC9; 5UC8; 4WMH; 2RGZ
T86808	BIOCLASS	Paired donor oxygen oxidoreductase
T86808	ECNUMBER	EC 1.14.14.18
T86808	SEQUENCE	MSAEVETSEGVDESEKKNSGALEKENQMRMADLSELLKEGTKEAHDRAENTQFVKDFLKGNIKKELFKLATTALYFTYSALEEEMERNKDHPAFAPLYFPMELHRKEALTKDMEYFFGENWEEQVQCPKAAQKYVERIHYIGQNEPELLVAHAYTRYMGDLSGGQVLKKVAQRALKLPSTGEGTQFYLFENVDNAQQFKQLYRARMNALDLNMKTKERIVEEANKAFEYNMQIFNELDQAGSTLARETLEDGFPVHDGKGDMRKCPFYAAEQDKGALEGSSCPFRTAMAVLRKPSLQFILAAGVALAAGLLAWYYM

T74952	TARGETID	T74952
T74952	FORMERID	TTDR00978
T74952	UNIPROID	KAP3_HUMAN
T74952	TARGNAME	cAMP protein kinase type II-beta (PRKAR2B)
T74952	GENENAME	PRKAR2B
T74952	TARGTYPE	Literature-reported
T74952	SYNONYMS	cAMP-dependent protein kinase type II-beta regulatory subunit; Type RIIbeta regulatory subunit of protein kinase A; RIIbeta subunit of cAMP-dependent protein kinase; PKA RIIbeta-subunit
T74952	FUNCTION	Type II regulatory chains mediate membrane association by binding to anchoring proteins, including the MAP2 kinase. Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signaling in cells.
T74952	BIOCLASS	Kinase
T74952	SEQUENCE	MSIEIPAGLTELLQGFTVEVLRHQPADLLEFALQHFTRLQQENERKGTARFGHEGRTWGDLGAAAGGGTPSKGVNFAEEPMQSDSEDGEEEEAAPADAGAFNAPVINRFTRRASVCAEAYNPDEEEDDAESRIIHPKTDDQRNRLQEACKDILLFKNLDPEQMSQVLDAMFEKLVKDGEHVIDQGDDGDNFYVIDRGTFDIYVKCDGVGRCVGNYDNRGSFGELALMYNTPRAATITATSPGALWGLDRVTFRRIIVKNNAKKRKMYESFIESLPFLKSLEFSERLKVVDVIGTKVYNDGEQIIAQGDSADSFFIVESGEVKITMKRKGKSEVEENGAVEIARCSRGQYFGELALVTNKPRAASAHAIGTVKCLAMDVQAFERLLGPCMEIMKRNIATYEEQLVALFGTNMDIVEPTA
T74952	DRUGINFO	D0R2TM	BALANOL	Terminated
T74952	DRUGINFO	D00OCS	AdcAhxArg4NH(CH2)6NH2	Investigative
T74952	DRUGINFO	D02GEW	AdcAhxArg4Lys-PEGOMe	Investigative
T74952	DRUGINFO	D02ZWX	AdoC(GABA)Arg6	Investigative
T74952	DRUGINFO	D03GNM	AdcAhxArg4Lys(biotin)-PEG-OMe	Investigative
T74952	DRUGINFO	D08GIG	AdoC(Aun)Arg6	Investigative
T74952	DRUGINFO	D0A5YR	AdoCGlyArg6	Investigative
T74952	DRUGINFO	D0F3XS	AdoC(Aoc)Arg6	Investigative
T74952	DRUGINFO	D0I4MQ	AdcAhxArg6	Investigative
T74952	DRUGINFO	D0KZ2I	AdoC(betaAsp)2AlaArg6	Investigative
T74952	DRUGINFO	D0QS6O	AdoC(Ahx)Arg6	Investigative
T74952	DRUGINFO	D0RC8H	AdoC(beta-Ala)2AlaArg6	Investigative
T74952	DRUGINFO	D0V3TE	AdoC(beta-Ala)Arg6	Investigative
T74952	DRUGINFO	D07MMG	AdoC(Dpr)2AlaArg6	Investigative
T74952	DRUGINFO	D0UB2J	[3H]cAMP	Investigative
T74952	DRUGINFO	D09XIL	Ro-4396686	Investigative
T74952	DRUGINFO	D0A5RM	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	Investigative

T04741	TARGETID	T04741
T04741	FORMERID	TTDR00945
T04741	UNIPROID	PUR9_HUMAN
T04741	TARGNAME	Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC)
T04741	GENENAME	ATIC
T04741	TARGTYPE	Literature-reported
T04741	SYNONYMS	PURH; OK/SW-cl.86; Bifunctional purine biosynthesis protein PURH
T04741	FUNCTION	Bifunctional enzyme that catalyzes 2 steps in purine biosynthesis.
T04741	PDBSTRUC	5UZ0; 5UY8; 1PL0; 1PKX; 1P4R
T04741	BIOCLASS	Methyltransferase
T04741	SEQUENCE	MAPGQLALFSVSDKTGLVEFARNLTALGLNLVASGGTAKALRDAGLAVRDVSELTGFPEMLGGRVKTLHPAVHAGILARNIPEDNADMARLDFNLIRVVACNLYPFVKTVASPGVTVEEAVEQIDIGGVTLLRAAAKNHARVTVVCEPEDYVVVSTEMQSSESKDTSLETRRQLALKAFTHTAQYDEAISDYFRKQYSKGVSQMPLRYGMNPHQTPAQLYTLQPKLPITVLNGAPGFINLCDALNAWQLVKELKEALGIPAAASFKHVSPAGAAVGIPLSEDEAKVCMVYDLYKTLTPISAAYARARGADRMSSFGDFVALSDVCDVPTAKIISREVSDGIIAPGYEEEALTILSKKKNGNYCVLQMDQSYKPDENEVRTLFGLHLSQKRNNGVVDKSLFSNVVTKNKDLPESALRDLIVATIAVKYTQSNSVCYAKNGQVIGIGAGQQSRIHCTRLAGDKANYWWLRHHPQVLSMKFKTGVKRAEISNAIDQYVTGTIGEDEDLIKWKALFEEVPELLTEAEKKEWVEKLTEVSISSDAFFPFRDNVDRAKRSGVAYIAAPSGSAADKVVIEACDELGIILAHTNLRLFHH
T04741	DRUGINFO	D02HXC	NSC-30171	Investigative
T04741	DRUGINFO	D03NSJ	NSC-45592	Investigative
T04741	DRUGINFO	D05YCQ	NSC-47729	Investigative
T04741	DRUGINFO	D0A2JV	NSC-26699	Investigative
T04741	DRUGINFO	D0B3XP	NSC-37173	Investigative
T04741	DRUGINFO	D0D9NQ	NSC-58046	Investigative
T04741	DRUGINFO	D0I2DB	NSC-37031	Investigative
T04741	DRUGINFO	D0T4JD	NSC-324572	Investigative
T04741	DRUGINFO	D0X2NH	NSC-126445	Investigative
T04741	DRUGINFO	D0Z5WG	FAICAR	Investigative
T04741	DRUGINFO	D04JWS	NSC-292213	Investigative
T04741	DRUGINFO	D09KUE	NSC-88915	Investigative

T00902	TARGETID	T00902
T00902	FORMERID	TTDI02363
T00902	UNIPROID	NTF4_HUMAN
T00902	TARGNAME	Neurotrophin-4 (NTF4)
T00902	GENENAME	NTF4
T00902	TARGTYPE	Literature-reported
T00902	SYNONYMS	Neutrophic factor 4; Neurotrophin5; Neurotrophin4; Neurotrophin-5; NTF5; NT4; NT-5; NT-4
T00902	FUNCTION	Target-derived survival factor for peripheral sensory sympathetic neurons.
T00902	PDBSTRUC	1HCF; 1B98; 1B8M
T00902	BIOCLASS	Growth factor
T00902	SEQUENCE	MLPLPSCSLPILLLFLLPSVPIESQPPPSTLPPFLAPEWDLLSPRVVLSRGAPAGPPLLFLLEAGAFRESAGAPANRSRRGVSETAPASRRGELAVCDAVSGWVTDRRTAVDLRGREVEVLGEVPAAGGSPLRQYFFETRCKADNAEEGGPGAGGGGCRGVDRRHWVSECKAKQSYVRALTADAQGRVGWRWIRIDTACVCTLLSRTGRA
T00902	DRUGINFO	D0P3SH	ReN-1826	Terminated

T76894	TARGETID	T76894
T76894	FORMERID	TTDR01138
T76894	UNIPROID	RECO_HUMAN
T76894	TARGNAME	Recoverin (RCVRN)
T76894	GENENAME	RCVRN
T76894	TARGTYPE	Literature-reported
T76894	SYNONYMS	RCVRN; Cancer associated retinopathy protein; CAR protein
T76894	FUNCTION	Seems to be implicated in the pathway from retinal rod guanylatecyclase to rhodopsin. May be involved in the inhibition of the phosphorylation of rhodopsin in a calcium-dependent manner. The calcium-bound recoverin prolongs the photoresponse.
T76894	PDBSTRUC	2D8N
T76894	BIOCLASS	Recoverin family
T76894	SEQUENCE	MGNSKSGALSKEILEELQLNTKFSEEELCSWYQSFLKDCPTGRITQQQFQSIYAKFFPDTDPKAYAQHVFRSFDSNLDGTLDFKEYVIALHMTTAGKTNQKLEWAFSLYDVDGNGTISKNEVLEIVMAIFKMITPEDVKLLPDDENTPEKRAEKIWKYFGKNDDDKLTEKEFIEGTLANKEILRLIQFEPQKVKEKMKNA
T76894	DRUGINFO	D08OBF	MYRISTIC ACID	Investigative

T98539	TARGETID	T98539
T98539	FORMERID	TTDI02502
T98539	UNIPROID	TIE1_HUMAN
T98539	TARGNAME	Tie-1 tyrosine kinase receptor (TIE1)
T98539	GENENAME	TIE1
T98539	TARGTYPE	Literature-reported
T98539	SYNONYMS	Tyrosine-protein kinase receptor Tie-1; TIE1
T98539	FUNCTION	Transmembrane tyrosine-protein kinase that may modulate TEK/TIE2 activity and contribute to the regulation of angiogenesis.
T98539	PDBSTRUC	5N06
T98539	BIOCLASS	Kinase
T98539	ECNUMBER	EC 2.7.10.1
T98539	SEQUENCE	MVWRVPPFLLPILFLASHVGAAVDLTLLANLRLTDPQRFFLTCVSGEAGAGRGSDAWGPPLLLEKDDRIVRTPPGPPLRLARNGSHQVTLRGFSKPSDLVGVFSCVGGAGARRTRVIYVHNSPGAHLLPDKVTHTVNKGDTAVLSARVHKEKQTDVIWKSNGSYFYTLDWHEAQDGRFLLQLPNVQPPSSGIYSATYLEASPLGSAFFRLIVRGCGAGRWGPGCTKECPGCLHGGVCHDHDGECVCPPGFTGTRCEQACREGRFGQSCQEQCPGISGCRGLTFCLPDPYGCSCGSGWRGSQCQEACAPGHFGADCRLQCQCQNGGTCDRFSGCVCPSGWHGVHCEKSDRIPQILNMASELEFNLETMPRINCAAAGNPFPVRGSIELRKPDGTVLLSTKAIVEPEKTTAEFEVPRLVLADSGFWECRVSTSGGQDSRRFKVNVKVPPVPLAAPRLLTKQSRQLVVSPLVSFSGDGPISTVRLHYRPQDSTMDWSTIVVDPSENVTLMNLRPKTGYSVRVQLSRPGEGGEGAWGPPTLMTTDCPEPLLQPWLEGWHVEGTDRLRVSWSLPLVPGPLVGDGFLLRLWDGTRGQERRENVSSPQARTALLTGLTPGTHYQLDVQLYHCTLLGPASPPAHVLLPPSGPPAPRHLHAQALSDSEIQLTWKHPEALPGPISKYVVEVQVAGGAGDPLWIDVDRPEETSTIIRGLNASTRYLFRMRASIQGLGDWSNTVEESTLGNGLQAEGPVQESRAAEEGLDQQLILAVVGSVSATCLTILAALLTLVCIRRSCLHRRRTFTYQSGSGEETILQFSSGTLTLTRRPKLQPEPLSYPVLEWEDITFEDLIGEGNFGQVIRAMIKKDGLKMNAAIKMLKEYASENDHRDFAGELEVLCKLGHHPNIINLLGACKNRGYLYIAIEYAPYGNLLDFLRKSRVLETDPAFAREHGTASTLSSRQLLRFASDAANGMQYLSEKQFIHRDLAARNVLVGENLASKIADFGLSRGEEVYVKKTMGRLPVRWMAIESLNYSVYTTKSDVWSFGVLLWEIVSLGGTPYCGMTCAELYEKLPQGYRMEQPRNCDDEVYELMRQCWRDRPYERPPFAQIALQLGRMLEARKAYVNMSLFENFTYAGIDATAEEA
T98539	DRUGINFO	D00EMH	PMID21967808CR-16	Investigative

T86773	TARGETID	T86773
T86773	FORMERID	TTDNR00701
T86773	UNIPROID	LONM_HUMAN
T86773	TARGNAME	ATP-dependent protease Lon (LONP1)
T86773	GENENAME	LONP1
T86773	TARGTYPE	Literature-reported
T86773	SYNONYMS	Serine protease 15; Mitochondrial ATP-dependent protease Lon; Lon protease-like protein; LONP1; LONP; LONHs
T86773	FUNCTION	ATP-dependent serine protease that mediates the selective degradation of misfolded, unassembled or oxidatively damaged polypeptides as well as certain short-lived regulatory proteins in the mitochondrial matrix. May also have a chaperone function in the assembly of inner membrane protein complexes. Participates in the regulation of mitochondrial gene expression and in the maintenance of the integrity of the mitochondrial genome. Binds to mitochondrial promoters and RNA in a single- stranded, site-specific, and strand-specific manner. May regulate mitochondrial DNA replication and/or gene expression using site- specific, single-stranded DNA binding to target the degradation of regulatory proteins binding to adjacent sites in mitochondrial promoters. Endogenous substrates include mitochondrial steroidogenic acute regulatory (StAR) protein.
T86773	PDBSTRUC	2X36
T86773	BIOCLASS	Peptidase
T86773	ECNUMBER	EC 3.4.21.53
T86773	SEQUENCE	MAASTGYVRLWGAARCWVLRRPMLAAAGGRVPTAAGAWLLRGQRTCDASPPWALWGRGPAIGGQWRGFWEASSRGGGAFSGGEDASEGGAEEGAGGAGGSAGAGEGPVITALTPMTIPDVFPHLPLIAITRNPVFPRFIKIIEVKNKKLVELLRRKVRLAQPYVGVFLKRDDSNESDVVESLDEIYHTGTFAQIHEMQDLGDKLRMIVMGHRRVHISRQLEVEPEEPEAENKHKPRRKSKRGKKEAEDELSARHPAELAMEPTPELPAEVLMVEVENVVHEDFQVTEEVKALTAEIVKTIRDIIALNPLYRESVLQMMQAGQRVVDNPIYLSDMGAALTGAESHELQDVLEETNIPKRLYKALSLLKKEFELSKLQQRLGREVEEKIKQTHRKYLLQEQLKIIKKELGLEKDDKDAIEEKFRERLKELVVPKHVMDVVDEELSKLGLLDNHSSEFNVTRNYLDWLTSIPWGKYSNENLDLARAQAVLEEDHYGMEDVKKRILEFIAVSQLRGSTQGKILCFYGPPGVGKTSIARSIARALNREYFRFSVGGMTDVAEIKGHRRTYVGAMPGKIIQCLKKTKTENPLILIDEVDKIGRGYQGDPSSALLELLDPEQNANFLDHYLDVPVDLSKVLFICTANVTDTIPEPLRDRMEMINVSGYVAQEKLAIAERYLVPQARALCGLDESKAKLSSDVLTLLIKQYCRESGVRNLQKQVEKVLRKSAYKIVSGEAESVEVTPENLQDFVGKPVFTVERMYDVTPPGVVMGLAWTAMGGSTLFVETSLRRPQDKDAKGDKDGSLEVTGQLGEVMKESARIAYTFARAFLMQHAPANDYLVTSHIHLHVPEGATPKDGPSAGCTIVTALLSLAMGRPVRQNLAMTGEVSLTGKILPVGGIKEKTIAAKRAGVTCIVLPAENKKDFYDLAAFITEGLEVHFVEHYREIFDIAFPDEQAEALAVER

T72779	TARGETID	T72779
T72779	FORMERID	TTDR00983
T72779	UNIPROID	SPB5_HUMAN
T72779	TARGNAME	Maspin (SERPINB5)
T72779	GENENAME	SERPINB5
T72779	TARGTYPE	Literature-reported
T72779	SYNONYMS	Serpin B5; Protease inhibitor 5; Peptidase inhibitor 5; PI5; PI-5
T72779	FUNCTION	It blocks the growth, invasion, and metastatic properties of mammary tumors. As it does not undergo the S (stressed) to R (relaxed) conformational transition characteristic of active serpins, it exhibits no serine protease inhibitory activity. Tumor suppressor.
T72779	PDBSTRUC	1XU8; 1XQJ; 1XQG; 1WZ9
T72779	BIOCLASS	Serpin protein
T72779	SEQUENCE	MDALQLANSAFAVDLFKQLCEKEPLGNVLFSPICLSTSLSLAQVGAKGDTANEIGQVLHFENVKDVPFGFQTVTSDVNKLSSFYSLKLIKRLYVDKSLNLSTEFISSTKRPYAKELETVDFKDKLEETKGQINNSIKDLTDGHFENILADNSVNDQTKILVVNAAYFVGKWMKKFSESETKECPFRVNKTDTKPVQMMNMEATFCMGNIDSINCKIIELPFQNKHLSMFILLPKDVEDESTGLEKIEKQLNSESLSQWTNPSTMANAKVKLSIPKFKVEKMIDPKACLENLGLKHIFSEDTSDFSGMSETKGVALSNVIHKVCLEITEDGGDSIEVPGARILQHKDELNADHPFIYIIRHNKTRNIIFFGKFCSP
T72779	DRUGINFO	D0P7JE	S,S-(2-Hydroxyethyl)Thiocysteine	Investigative

T16731	TARGETID	T16731
T16731	FORMERID	TTDS00427
T16731	UNIPROID	VATA_HUMAN
T16731	TARGNAME	Vacuolar-type proton ATPase catalytic A (v-ATPase-A)
T16731	GENENAME	ATP6V1A
T16731	TARGTYPE	Literature-reported
T16731	SYNONYMS	Vacuolar proton pump subunit alpha; Vacuolar ATPase isoform VA68; VPP2; V-ATPase subunit A; V-ATPase 69 kDa subunit; ATP6V1A1; ATP6V1A; ATP6A1
T16731	FUNCTION	Catalytic subunit of the peripheral V1 complex of vacuolar ATPase. V-ATPase vacuolar ATPase is responsible for acidifying a variety of intracellular compartments in eukaryotic cells.
T16731	BIOCLASS	Acid anhydrides hydrolase
T16731	ECNUMBER	EC 7.1.2.2
T16731	SEQUENCE	MDFSKLPKILDEDKESTFGYVHGVSGPVVTACDMAGAAMYELVRVGHSELVGEIIRLEGDMATIQVYEETSGVSVGDPVLRTGKPLSVELGPGIMGAIFDGIQRPLSDISSQTQSIYIPRGVNVSALSRDIKWDFTPCKNLRVGSHITGGDIYGIVSENSLIKHKIMLPPRNRGTVTYIAPPGNYDTSDVVLELEFEGVKEKFTMVQVWPVRQVRPVTEKLPANHPLLTGQRVLDALFPCVQGGTTAIPGAFGCGKTVISQSLSKYSNSDVIIYVGCGERGNEMSEVLRDFPELTMEVDGKVESIMKRTALVANTSNMPVAAREASIYTGITLSEYFRDMGYHVSMMADSTSRWAEALREISGRLAEMPADSGYPAYLGARLASFYERAGRVKCLGNPEREGSVSIVGAVSPPGGDFSDPVTSATLGIVQVFWGLDKKLAQRKHFPSVNWLISYSKYMRALDEYYDKHFTEFVPLRTKAKEILQEEEDLAEIVQLVGKASLAETDKITLEVAKLIKDDFLQQNGYTPYDRFCPFYKTVGMLSNMIAFYDMARRAVETTAQSDNKITWSIIREHMGDILYKLSSMKFKDPLKDGEAKIKSDYAQLLEDMQNAFRSLED
T16731	DRUGINFO	D09IFW	Cruentaren	Preclinical

T50547	TARGETID	T50547
T50547	FORMERID	TTDR00107
T50547	UNIPROID	PLM1_PLAFA
T50547	TARGNAME	Plasmodium Plasmepsin 1 (Malaria PLA1)
T50547	GENENAME	Malaria PLA1
T50547	TARGTYPE	Literature-reported
T50547	SYNONYMS	Plasmepsin I; PFAPG; Aspartic hemoglobinase I
T50547	FUNCTION	Participates in the digestion of the host hemoglobin. Initial cleavage at the hinge region of hemoglobin, than cleaves at other sites, leading to denaturation of the molecule and to further degradation.
T50547	PDBSTRUC	3QS1; 3QRV; 1LDU; 1LCR
T50547	BIOCLASS	Peptidase
T50547	SEQUENCE	MALSIKEDFSSAFAKNESAVNSSTFNNNMKTWKIQKRFQILYVFFFLLITGALFYYLIDNVLFPKNKKINEIMNTSKHVIIGFSIENSHDRIMKTVKQHRLKNYIKESLKFFKTGLTQKPHLGNAGDSVTLNDVANVMYYGEAQIGDNKQKFAFIFDTGSANLWVPSAQCNTIGCKTKNLYDSNKSKTYEKDGTKVEMNYVSGTVSGFFSKDIVTIANLSFPYKFIEVTDTNGFEPAYTLGQFDGIVGLGWKDLSIGSVDPVVVELKNQNKIEQAVFTFYLPFDDKHKGYLTIGGIEDRFYEGQLTYEKLNHDLYWQVDLDLHFGNLTVEKATAIVDSGTSSITAPTEFLNKFFEGLDVVKIPFLPLYITTCNNPKLPTLEFRSATNVYTLEPEYYLQQIFDFGISLCMVSIIPVDLNKNTFILGDPFMRKYFTVFDYDNHTVGFALAKKKL
T50547	DRUGINFO	D04ZIJ	Pepstatin	Terminated
T50547	DRUGINFO	D06BKP	SC-5003	Investigative
T50547	DRUGINFO	D08AES	L-mannitol derivative	Investigative
T50547	DRUGINFO	D0ZU3S	PS-777621	Investigative
T50547	DRUGINFO	D0S3BO	KNI-10006	Investigative
T50547	DRUGINFO	D08KCA	Leupeptin	Investigative
T50547	DRUGINFO	D09FGQ	E-64	Investigative

T09770	TARGETID	T09770
T09770	FORMERID	TTDI02473
T09770	UNIPROID	ADH7_HUMAN
T09770	TARGNAME	Gastric alcohol dehydrogenase (ADH7)
T09770	GENENAME	ADH7
T09770	TARGTYPE	Literature-reported
T09770	SYNONYMS	Alcohol dehydrogenase class IV mu/sigma chain; Alcohol dehydrogenase class 4 mu/sigma chain; ADH7
T09770	FUNCTION	Could function in retinol oxidation for the synthesis of retinoic acid, a hormone important for cellular differentiation. Medium-chain (octanol) and aromatic (m-nitrobenzaldehyde) compounds are the best substrates. Ethanol is not a good substrate but at the high ethanol concentrations reached in the digestive tract, it plays a role in the ethanol oxidation and contributes to the first pass ethanol metabolism.
T09770	PDBSTRUC	1D1T; 1D1S; 1AGN
T09770	BIOCLASS	Short-chain dehydrogenases reductase
T09770	ECNUMBER	EC 1.1.1.1
T09770	SEQUENCE	MFAEIQIQDKDRMGTAGKVIKCKAAVLWEQKQPFSIEEIEVAPPKTKEVRIKILATGICRTDDHVIKGTMVSKFPVIVGHEATGIVESIGEGVTTVKPGDKVIPLFLPQCRECNACRNPDGNLCIRSDITGRGVLADGTTRFTCKGKPVHHFMNTSTFTEYTVVDESSVAKIDDAAPPEKVCLIGCGFSTGYGAAVKTGKVKPGSTCVVFGLGGVGLSVIMGCKSAGASRIIGIDLNKDKFEKAMAVGATECISPKDSTKPISEVLSEMTGNNVGYTFEVIGHLETMIDALASCHMNYGTSVVVGVPPSAKMLTYDPMLLFTGRTWKGCVFGGLKSRDDVPKLVTEFLAKKFDLDQLITHVLPFKKISEGFELLNSGQSIRTVLTF

T85540	TARGETID	T85540
T85540	FORMERID	TTDI03363
T85540	UNIPROID	KDM5C_HUMAN
T85540	TARGNAME	Lysine-specific demethylase 5C (KDM5C)
T85540	GENENAME	KDM5C
T85540	TARGTYPE	Literature-reported
T85540	SYNONYMS	XE169; SMCX; Protein Xe169; Protein SmcX; Jumonji/ARID domain-containing protein 1C; JARID1C; Histone demethylase JARID1C; DXS1272E
T85540	FUNCTION	Does not demethylate histone H3 'Lys-9', H3 'Lys-27', H3 'Lys-36', H3 'Lys-79' or H4 'Lys-20'. Demethylates trimethylated and dimethylated but not monomethylated H3 'Lys-4'. Participates in transcriptional repression of neuronal genes by recruiting histone deacetylases and REST at neuron-restrictive silencer elements. Represses the CLOCK-ARNTL/BMAL1 heterodimer-mediated transcriptional activation of the core clock component PER2. Histone demethylase that specifically demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code.
T85540	PDBSTRUC	5FWJ; 2JRZ
T85540	BIOCLASS	Paired donor oxygen oxidoreductase
T85540	ECNUMBER	EC 1.14.11.-
T85540	SEQUENCE	MEPGSDDFLPPPECPVFEPSWAEFRDPLGYIAKIRPIAEKSGICKIRPPADWQPPFAVEVDNFRFTPRIQRLNELEAQTRVKLNYLDQIAKFWEIQGSSLKIPNVERRILDLYSLSKIVVEEGGYEAICKDRRWARVAQRLNYPPGKNIGSLLRSHYERIVYPYEMYQSGANLVQCNTRPFDNEEKDKEYKPHSIPLRQSVQPSKFNSYGRRAKRLQPDPEPTEEDIEKNPELKKLQIYGAGPKMMGLGLMAKDKTLRKKDKEGPECPPTVVVKEELGGDVKVESTSPKTFLESKEELSHSPEPCTKMTMRLRRNHSNAQFIESYVCRMCSRGDEDDKLLLCDGCDDNYHIFCLLPPLPEIPKGVWRCPKCVMAECKRPPEAFGFEQATREYTLQSFGEMADSFKADYFNMPVHMVPTELVEKEFWRLVNSIEEDVTVEYGADIHSKEFGSGFPVSDSKRHLTPEEEEYATSGWNLNVMPVLEQSVLCHINADISGMKVPWLYVGMVFSAFCWHIEDHWSYSINYLHWGEPKTWYGVPSLAAEHLEEVMKKLTPELFDSQPDLLHQLVTLMNPNTLMSHGVPVVRTNQCAGEFVITFPRAYHSGFNQGYNFAEAVNFCTADWLPAGRQCIEHYRRLRRYCVFSHEELICKMAACPEKLDLNLAAAVHKEMFIMVQEERRLRKALLEKGITEAEREAFELLPDDERQCIKCKTTCFLSALACYDCPDGLVCLSHINDLCKCSSSRQYLRYRYTLDELPAMLHKLKVRAESFDTWANKVRVALEVEDGRKRSLEELRALESEARERRFPNSELLQQLKNCLSEAEACVSRALGLVSGQEAGPHRVAGLQMTLTELRAFLDQMNNLPCAMHQIGDVKGVLEQVEAYQAEAREALASLPSSPGLLQSLLERGRQLGVEVPEAQQLQRQVEQARWLDEVKRTLAPSARRGTLAVMRGLLVAGASVAPSPAVDKAQAELQELLTIAERWEEKAHLCLEARQKHPPATLEAIIREAENIPVHLPNIQALKEALAKARAWIADVDEIQNGDHYPCLDDLEGLVAVGRDLPVGLEELRQLELQVLTAHSWREKASKTFLKKNSCYTLLEVLCPCADAGSDSTKRSRWMEKELGLYKSDTELLGLSAQDLRDPGSVIVAFKEGEQKEKEGILQLRRTNSAKPSPLASSSTASSTTSICVCGQVLAGAGALQCDLCQDWFHGRCVSVPRLLSSPRPNPTSSPLLAWWEWDTKFLCPLCMRSRRPRLETILALLVALQRLPVRLPEGEALQCLTERAISWQGRARQALASEDVTALLGRLAELRQRLQAEPRPEEPPNYPAAPASDPLREGSGKDMPKVQGLLENGDSVTSPEKVAPEEGSGKRDLELLSSLLPQLTGPVLELPEATRAPLEELMMEGDLLEVTLDENHSIWQLLQAGQPPDLERIRTLLELEKAERHGSRARGRALERRRRRKVDRGGEGDDPAREELEPKRVRSSGPEAEEVQEEEELEEETGGEGPPAPIPTTGSPSTQENQNGLEPAEGTTSGPSAPFSTLTPRLHLPCPQQPPQQQL
T85540	DRUGINFO	D0IQ7Y	PBIT	Investigative
T85540	DRUGINFO	D0WA3E	IOX2	Investigative

T15514	TARGETID	T15514
T15514	FORMERID	TTDR00269
T15514	UNIPROID	HNF4A_HUMAN
T15514	TARGNAME	Hepatocyte nuclear factor 4-alpha (HNF4A)
T15514	GENENAME	HNF4A
T15514	TARGTYPE	Literature-reported
T15514	SYNONYMS	Transcription factor HNF-4; Transcription factor 14; TCF14; TCF-14; Nuclear receptor subfamily 2 group A member 1; NR2A1; HNF4; HNF-4-alpha
T15514	FUNCTION	Activates the transcription of CYP2C38. Represses the CLOCK-ARNTL/BMAL1 transcriptional activity and is essential for circadian rhythm maintenance and period regulation in the liver and colon cells. Transcriptional regulator which controls the expression of hepatic genes during the transition of endodermal cells to hepatic progenitor cells, facilitating the recruitment of RNA pol II to the promoters of target genes.
T15514	PDBSTRUC	6CHT; 4IQR; 4B7W; 3FS1; 3CBB
T15514	BIOCLASS	Nuclear hormone receptor
T15514	SEQUENCE	MRLSKTLVDMDMADYSAALDPAYTTLEFENVQVLTMGNDTSPSEGTNLNAPNSLGVSALCAICGDRATGKHYGASSCDGCKGFFRRSVRKNHMYSCRFSRQCVVDKDKRNQCRYCRLKKCFRAGMKKEAVQNERDRISTRRSSYEDSSLPSINALLQAEVLSRQITSPVSGINGDIRAKKIASIADVCESMKEQLLVLVEWAKYIPAFCELPLDDQVALLRAHAGEHLLLGATKRSMVFKDVLLLGNDYIVPRHCPELAEMSRVSIRILDELVLPFQELQIDDNEYAYLKAIIFFDPDAKGLSDPGKIKRLRSQVQVSLEDYINDRQYDSRGRFGELLLLLPTLQSITWQMIEQIQFIKLFGMAKIDNLLQEMLLGGSPSDAPHAHHPLHPHLMQEHMGTNVIVANTMPTHLSNGQMCEWPRPRGQAATPETPQPSPPGGSGSEPYKLLPGAVATIVKPLSAIPQPTITKQEVI
T15514	DRUGINFO	D02RRY	BI6015	Investigative
T15514	DRUGINFO	D0N0UC	Lauric Acid	Investigative
T15514	DRUGINFO	D08OBF	MYRISTIC ACID	Investigative

T46515	TARGETID	T46515
T46515	FORMERID	TTDR00159
T46515	UNIPROID	SYIC_HUMAN
T46515	TARGNAME	Isoleucyl-tRNA synthetase (IARS)
T46515	GENENAME	IARS
T46515	TARGTYPE	Literature-reported
T46515	SYNONYMS	Isoleucine--tRNA ligase, cytoplasmic; Isoleucine--tRNA ligase; IleRS; IRS
T46515	FUNCTION	Catalyzes the specific attachment of an amino acid to its cognate tRNA in a 2 step reaction: the amino acid (AA) is first activated by ATP to form AA-AMP and then transferred to the acceptor end of the tRNA.
T46515	BIOCLASS	Carbon-oxygen ligase
T46515	ECNUMBER	EC 6.1.1.5
T46515	SEQUENCE	MLQQVPENINFPAEEEKILEFWTEFNCFQECLKQSKHKPKFTFYDGPPFATGLPHYGHILAGTIKDIVTRYAHQSGFHVDRRFGWDCHGLPVEYEIDKTLGIRGPEDVAKMGITEYNNQCRAIVMRYSAEWKSTVSRLGRWIDFDNDYKTLYPQFMESVWWVFKQLYDKGLVYRGVKVMPFSTACNTPLSNFESHQNYKDVQDPSVFVTFPLEEDETVSLVAWTTTPWTLPSNLAVCVNPEMQYVKIKDVARGRLLILMEARLSALYKLESDYEILERFPGAYLKGKKYRPLFDYFLKCKENGAFTVLVDNYVKEEEGTGVVHQAPYFGAEDYRVCMDFNIIRKDSLPVCPVDASGCFTTEVTDFAGQYVKDADKSIIRTLKEQGRLLVATTFTHSYPFCWRSDTPLIYKAVPSWFVRVENMVDQLLRNNDLCYWVPELVREKRFGNWLKDARDWTISRNRYWGTPIPLWVSDDFEEVVCIGSVAELEELSGAKISDLHRESVDHLTIPSRCGKGSLHRISEVFDCWFESGSMPYAQVHYPFENKREFEDAFPADFIAEGIDQTRGWFYTLLVLATALFGQPPFKNVIVNGLVLASDGQKMSKRKKNYPDPVSIIQKYGADALRLYLINSPVVRAENLRFKEEGVRDVLKDVLLPWYNAYRFLIQNVLRLQKEEEIEFLYNENTVRESPNITDRWILSFMQSLIGFFETEMAAYRLYTVVPRLVKFVDILTNWYVRMNRRRLKGENGMEDCVMALETLFSVLLSLCRLMAPYTPFLTELMYQNLKVLIDPVSVQDKDTLSIHYLMLPRVREELIDKKTESAVSQMQSVIELGRVIRDRKTIPIKYPLKEIVVIHQDPEALKDIKSLEKYIIEELNVRKVTLSTDKNKYGIRLRAEPDHMVLGKRLKGAFKAVMTSIKQLSSEELEQFQKTGTIVVEGHELHDEDIRLMYTFDQATGGTAQFEAHSDAQALVLLDVTPDQSMVDEGMAREVINRIQKLRKKCNLVPTDEITVYYKAKSEGTYLNSVIESHTEFIFTTIKAPLKPYPVSPSDKVLIQEKTQLKGSELEITLTRGSSLPGPACAYVNLNICANGSEQGGVLLLENPKGDNRLDLLKLKSVVTSIFGVKNTELAVFHDETEIQNQTDLLSLSGKTLCVTAGSAPSLINSSSTLLCQYINLQLLNAKPQECLMGTVGTLLLENPLGQNGLTHQGLLYEAAKVFGLRSRKLKLFLNETQTQEITEDIPVKTLNMKTVYVSVLPTTADF
T46515	DRUGINFO	D0N1BC	Reveromycin A	Terminated

T76846	TARGETID	T76846
T76846	FORMERID	TTDR00375
T76846	UNIPROID	MC3R_HUMAN
T76846	TARGNAME	Melanocortin receptor 3 (MC3R)
T76846	GENENAME	MC3R
T76846	TARGTYPE	Literature-reported
T76846	SYNONYMS	MC3-R
T76846	FUNCTION	Receptor for MSH (alpha, beta and gamma) and ACTH. This receptor is mediated by G proteins which activate adenylate cyclase. Required for expression of anticipatory patterns of activity and wakefulness during periods of limited nutrient availability and for the normal regulation of circadian clock activity in the brain.
T76846	BIOCLASS	GPCR rhodopsin
T76846	SEQUENCE	MNASCCLPSVQPTLPNGSEHLQAPFFSNQSSSAFCEQVFIKPEVFLSLGIVSLLENILVILAVVRNGNLHSPMYFFLCSLAVADMLVSVSNALETIMIAIVHSDYLTFEDQFIQHMDNIFDSMICISLVASICNLLAIAVDRYVTIFYALRYHSIMTVRKALTLIVAIWVCCGVCGVVFIVYSESKMVIVCLITMFFAMMLLMGTLYVHMFLFARLHVKRIAALPPADGVAPQQHSCMKGAVTITILLGVFIFCWAPFFLHLVLIITCPTNPYCICYTAHFNTYLVLIMCNSVIDPLIYAFRSLELRNTFREILCGCNGMNLG
T76846	DRUGINFO	D06SDP	Melanotetan II	Preclinical
T76846	DRUGINFO	D08XNQ	SHU9119	Investigative
T76846	DRUGINFO	D0F0CP	MK-9	Investigative
T76846	DRUGINFO	D01VMU	C[CO-(CH2)3-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2	Investigative
T76846	DRUGINFO	D0B9NH	C[Nle-Glu-D-Phe-Arg-Trp-Glu]-NH2	Investigative
T76846	DRUGINFO	D0GN9K	C[CO-2,3-pyrazine-CO-D-Phe-Arg-Trp-Lys]-NH2	Investigative
T76846	DRUGINFO	D00NOG	MK-11	Investigative
T76846	DRUGINFO	D00TSX	C[Nle-His-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T76846	DRUGINFO	D00VYC	Ac-YR[CEHdFRWC]-NH2	Investigative
T76846	DRUGINFO	D01HTX	C[Nle-Nle-D-Phe-Arg-Trp-Glu]-NH2	Investigative
T76846	DRUGINFO	D02MPZ	C[Nle-His-D-Phe-Arg-Trp-Glu]-NH2	Investigative
T76846	DRUGINFO	D04YZZ	C[CO-(CH2)3-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2	Investigative
T76846	DRUGINFO	D05WNC	C[Nle-Glu-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T76846	DRUGINFO	D05XRI	Ac-R[CEHdFRWC]-NH2	Investigative
T76846	DRUGINFO	D06PNU	Tic-D-Phe-Arg-2-Nal-NHCH3	Investigative
T76846	DRUGINFO	D07DWH	Ac-dR[CEHdFRWC]-NH2	Investigative
T76846	DRUGINFO	D07UXW	C[Nle-Asp-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T76846	DRUGINFO	D08DND	C[CO-(CH2)2-CO-Nle-D-Phe-Arg-Trp-Lys]-NH2	Investigative
T76846	DRUGINFO	D09OMI	Ac-YK[CEHdFRWC]-NH2	Investigative
T76846	DRUGINFO	D09UUC	MK-10	Investigative
T76846	DRUGINFO	D0A8ME	Ac-[CEHdFRWC]-NH2	Investigative
T76846	DRUGINFO	D0B8GR	Ac-His-D-Phe-Arg-2-Nal-NHCH3	Investigative
T76846	DRUGINFO	D0C7VI	Ac-YR[CEHdFRWC]SPPKD-NH2	Investigative
T76846	DRUGINFO	D0F6GX	Ac-Tyr-D-Phe-Arg-2-Nal-NHCH3	Investigative
T76846	DRUGINFO	D0M4EF	C[Nle-Val-D-Phe-Arg-Trp-Glu]-NH2	Investigative
T76846	DRUGINFO	D0P4GI	C[Nle-Pro-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T76846	DRUGINFO	D0VD7R	C[Nle-Pro-D-Phe-Arg-Trp-Glu]-NH2	Investigative
T76846	DRUGINFO	D0W1SM	C[Nle-Gln-D-Phe-Arg-Trp-Glu]-NH2	Investigative
T76846	DRUGINFO	D0XQ5U	C[CO-2,3-pyrazine-CO-D-Nal(2)-Arg-Trp-Lys]-NH2	Investigative
T76846	DRUGINFO	D0ZD3M	Ac-YCit[CEHdFRWC]-NH2	Investigative
T76846	DRUGINFO	D02JVA	C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T76846	DRUGINFO	D03AZC	Ac-YRMEHdFRWG-NH2	Investigative
T76846	DRUGINFO	D05LLI	C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T76846	DRUGINFO	D06RTP	C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T76846	DRUGINFO	D07SFD	C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2	Investigative
T76846	DRUGINFO	D07TBR	Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2	Investigative
T76846	DRUGINFO	D09PDT	C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2	Investigative
T76846	DRUGINFO	D0AU4C	AEKKDEGPYRMEHFRWGSPPKD	Investigative
T76846	DRUGINFO	D0B4OL	Ac-YRMEHdFRWGSPPKD-NH2	Investigative
T76846	DRUGINFO	D0CK0K	Ac-Nle-c[Asp-His-DNal(2')-Pro-Trp-Lys]-NH2	Investigative
T76846	DRUGINFO	D0I8SJ	NDP-SYSMEHFRWGKPVG	Investigative
T76846	DRUGINFO	D0ID5M	GPYRMEHFRWGSPPKD-NH2	Investigative
T76846	DRUGINFO	D0L1MJ	C[Nle-Nle-D-Nal(2')-Arg-Trp-Glu]-NH2	Investigative
T76846	DRUGINFO	D0R0BY	Ac-YR[CEH(pCl-dF)RWC]-NH2	Investigative
T76846	DRUGINFO	D0WG8P	Ac-YR[CEH(pF-dF)RWC]-NH2	Investigative
T76846	DRUGINFO	D0WI8M	C[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2	Investigative
T76846	DRUGINFO	D0X1YL	Ac-YRC(Me)*EHdFRWC(Me)NH2	Investigative
T76846	DRUGINFO	D0YB7F	MT-II	Investigative

T83009	TARGETID	T83009
T83009	FORMERID	TTDI03005
T83009	UNIPROID	ABL2_HUMAN
T83009	TARGNAME	Tyrosine-protein kinase ABL2 (ABL2)
T83009	GENENAME	ABL2
T83009	TARGTYPE	Literature-reported
T83009	SYNONYMS	Tyrosine-protein kinase ARG; Abelson-related gene protein; Abelson tyrosine-protein kinase 2; Abelson murine leukemia viral oncogene homolog 2; ARG; ABLL
T83009	FUNCTION	Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like MYH10 (involved in movement); CTTN (involved in signaling); or TUBA1 and TUBB (microtubule subunits). Binds directly F-actin and regulates actin cytoskeletal structure through its F-actin-bundling activity. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as CRK, CRKL, DOK1 or ARHGAP35. Adhesion-dependent phosphorylation of ARHGAP35 promotes its association with RASA1, resulting in recruitment of ARHGAP35 to the cell periphery where it inhibits RHO. Phosphorylates multiple receptor tyrosine kinases like PDGFRB and other substrates which are involved in endocytosis regulation such as RIN1. In brain, may regulate neurotransmission by phosphorylating proteins at the synapse. ABL2 acts also as a regulator of multiple pathological signaling cascades during infection. Pathogens can highjack ABL2 kinase signaling to reorganize the host actin cytoskeleton for multiple purposes, like facilitating intracellular movement and host cell exit. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1. Non-receptor tyrosine-protein kinase that plays an ABL1-overlapping role in key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion and receptor endocytosis.
T83009	PDBSTRUC	5NP5; 5NP3; 4EIH; 3ULR; 3HMI
T83009	BIOCLASS	Kinase
T83009	ECNUMBER	EC 2.7.10.2
T83009	SEQUENCE	MGQQVGRVGEAPGLQQPQPRGIRGSSAARPSGRRRDPAGRTTETGFNIFTQHDHFASCVEDGFEGDKTGGSSPEALHRPYGCDVEPQALNEAIRWSSKENLLGATESDPNLFVALYDFVASGDNTLSITKGEKLRVLGYNQNGEWSEVRSKNGQGWVPSNYITPVNSLEKHSWYHGPVSRSAAEYLLSSLINGSFLVRESESSPGQLSISLRYEGRVYHYRINTTADGKVYVTAESRFSTLAELVHHHSTVADGLVTTLHYPAPKCNKPTVYGVSPIHDKWEMERTDITMKHKLGGGQYGEVYVGVWKKYSLTVAVKTLKEDTMEVEEFLKEAAVMKEIKHPNLVQLLGVCTLEPPFYIVTEYMPYGNLLDYLRECNREEVTAVVLLYMATQISSAMEYLEKKNFIHRDLAARNCLVGENHVVKVADFGLSRLMTGDTYTAHAGAKFPIKWTAPESLAYNTFSIKSDVWAFGVLLWEIATYGMSPYPGIDLSQVYDLLEKGYRMEQPEGCPPKVYELMRACWKWSPADRPSFAETHQAFETMFHDSSISEEVAEELGRAASSSSVVPYLPRLPILPSKTRTLKKQVENKENIEGAQDATENSASSLAPGFIRGAQASSGSPALPRKQRDKSPSSLLEDAKETCFTRDRKGGFFSSFMKKRNAPTPPKRSSSFREMENQPHKKYELTGNFSSVASLQHADGFSFTPAQQEANLVPPKCYGGSFAQRNLCNDDGGGGGGSGTAGGGWSGITGFFTPRLIKKTLGLRAGKPTASDDTSKPFPRSNSTSSMSSGLPEQDRMAMTLPRNCQRSKLQLERTVSTSSQPEENVDRANDMLPKKSEESAAPSRERPKAKLLPRGATALPLRTPSGDLAITEKDPPGVGVAGVAAAPKGKEKNGGARLGMAGVPEDGEQPGWPSPAKAAPVLPTTHNHKVPVLISPTLKHTPADVQLIGTDSQGNKFKLLSEHQVTSSGDKDRPRRVKPKCAPPPPPVMRLLQHPSICSDPTEEPTALTAGQSTSETQEGGKKAALGAVPISGKAGRPVMPPPQVPLPTSSISPAKMANGTAGTKVALRKTKQAAEKISADKISKEALLECADLLSSALTEPVPNSQLVDTGHQLLDYCSGYVDCIPQTRNKFAFREAVSKLELSLQELQVSSAAAGVPGTNPVLNNLLSCVQEISDVVQR
T83009	DRUGINFO	D0JR3W	PMID23441572C24	Investigative

T06980	TARGETID	T06980
T06980	FORMERID	TTDR00958
T06980	UNIPROID	XAPA_ECOLI
T06980	TARGNAME	Bacterial Purine nucleoside phosphorylase (Bact xapA)
T06980	GENENAME	Bact xapA
T06980	TARGTYPE	Literature-reported
T06980	SYNONYMS	Xanthosine phosphorylase; Purine nucleoside phosphorylase II; Purine nucleoside phosphorylase 2; PNP II; Bact Inosine-guanosine phosphorylase
T06980	FUNCTION	The purine nucleoside phosphorylases catalyze the phosphorolytic breakdown of the N-glycosidic bond in the beta-(deoxy)ribonucleoside molecules, with the formation of the corresponding free purine bases and pentose-1-phosphate. This protein can degrade all purine nucleosides including xanthosine, inosine and guanosine, but cannot cleave adenosine, deoxyadenosine or hypoxanthine arabinoside. Has a preference for the neutral over the monoanionic form of xanthosine.
T06980	PDBSTRUC	1YR3; 1YQU; 1YQQ
T06980	BIOCLASS	Kinase
T06980	ECNUMBER	EC 2.4.2.1
T06980	SEQUENCE	MSQVQFSHNPLFCIDIIKTYKPDFTPRVAFILGSGLGALADQIENAVAISYEKLPGFPVSTVHGHAGELVLGHLQGVPVVCMKGRGHFYEGRGMTIMTDAIRTFKLLGCELLFCTNAAGSLRPEVGAGSLVALKDHINTMPGTPMVGLNDDRFGERFFSLANAYDAEYRALLQKVAKEEGFPLTEGVFVSYPGPNFETAAEIRMMQIIGGDVVGMSVVPEVISARHCDLKVVAVSAITNMAEGLSDVKLSHAQTLAAAELSKQNFINLICGFLRKIA

T35158	TARGETID	T35158
T35158	FORMERID	TTDC00038
T35158	UNIPROID	VDAC2_HUMAN
T35158	TARGNAME	Voltage-dependent anion-selective channel 2 (VDAC2)
T35158	GENENAME	VDAC2
T35158	TARGTYPE	Literature-reported
T35158	SYNONYMS	hVDAC2; VDAC2; VDAC-2; Outer mitochondrial membrane protein porin 2
T35158	FUNCTION	Forms a channel through the mitochondrial outer membrane that allows diffusion of small hydrophilic molecules. The channel adopts an open conformation at low or zero membrane potential and a closed conformation at potentials above 30-40 mV. The open state has a weak anion selectivity whereas the closed state is cation- selective.
T35158	BIOCLASS	Eukaryotic mitochondrial porin
T35158	SEQUENCE	MATHGQTCARPMCIPPSYADLGKAARDIFNKGFGFGLVKLDVKTKSCSGVEFSTSGSSNTDTGKVTGTLETKYKWCEYGLTFTEKWNTDNTLGTEIAIEDQICQGLKLTFDTTFSPNTGKKSGKIKSSYKRECINLGCDVDFDFAGPAIHGSAVFGYEGWLAGYQMTFDSAKSKLTRNNFAVGYRTGDFQLHTNVNDGTEFGGSIYQKVCEDLDTSVNLAWTSGTNCTRFGIAAKYQLDPTASISAKVNNSSLIGVGYTQTLRPGVKLTLSALVDGKSINAGGHKVGLALELEA

T27297	TARGETID	T27297
T27297	FORMERID	TTDR00470
T27297	UNIPROID	CRK_HUMAN
T27297	TARGNAME	Proto-oncogene c-Crk (c-Crk)
T27297	GENENAME	CRK
T27297	TARGTYPE	Literature-reported
T27297	SYNONYMS	P38; Adapter molecule crk
T27297	FUNCTION	Mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility in a Rac-dependent manner. Involved in phagocytosis of apoptotic cells and cell motility via its interaction with DOCK1 and DOCK4. May regulate the EFNA5-EPHA3 signaling. Isoform Crk-II: Regulates cell adhesion, spreading and migration.
T27297	PDBSTRUC	6ATV; 5UL6; 2MS4; 2EYZ; 2EYY
T27297	SEQUENCE	MAGNFDSEERSSWYWGRLSRQEAVALLQGQRHGVFLVRDSSTSPGDYVLSVSENSRVSHYIINSSGPRPPVPPSPAQPPPGVSPSRLRIGDQEFDSLPALLEFYKIHYLDTTTLIEPVSRSRQGSGVILRQEEAEYVRALFDFNGNDEEDLPFKKGDILRIRDKPEEQWWNAEDSEGKRGMIPVPYVEKYRPASASVSALIGGNQEGSHPQPLGGPEPGPYAQPSVNTPLPNLQNGPIYARVIQKRVPNAYDKTALALEVGELVKVTKINVSGQWEGECNGKRGHFPFTHVRLLDQQNPDEDFS

T94980	TARGETID	T94980
T94980	UNIPROID	NEDD4_HUMAN
T94980	TARGNAME	E3 ubiquitin-protein ligase NEDD4 (NEDD4)
T94980	GENENAME	NEDD4
T94980	TARGTYPE	Literature-reported
T94980	SYNONYMS	Neural precursor cell expressed developmentally down-regulated protein 4; NEDD4-1; NEDD-4; KIAA0093; HECT-type E3 ubiquitin transferase NEDD4; Cell proliferation-inducing gene 53 protein
T94980	FUNCTION	E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. Specifically ubiquitinates 'Lys-63' in target proteins (PubMed:23644597). Involved in the pathway leading to the degradation of VEGFR-2/KDFR, independently of its ubiquitin-ligase activity. Monoubiquitinates IGF1R at multiple sites, thus leading to receptor internalization and degradation in lysosomes. Ubiquitinates FGFR1, leading to receptor internalization and degradation in lysosomes. Promotes ubiquitination of RAPGEF2. According to PubMed:18562292 the direct link between NEDD4 and PTEN regulation through polyubiquitination described in PubMed:17218260 is questionable. Involved in ubiquitination of ERBB4 intracellular domain E4ICD. Involved in the budding of many viruses. Part of a signaling complex composed of NEDD4, RAP2A and TNIK which regulates neuronal dendrite extension and arborization during development. Ubiquitinates TNK2 and regulates EGF-induced degradation of EGFR and TNF2. Ubiquitinates BRAT1 and this ubiquitination is enhanced in the presence of NDFIP1 (PubMed:25631046).
T94980	PDBSTRUC	5C91; 5C7J; 5AHT; 4N7H; 4N7F
T94980	ECNUMBER	EC 2.3.2.26
T94980	SEQUENCE	MAQSLRLHFAARRSNTYPLSETSGDDLDSHVHMCFKRPTRISTSNVVQMKLTPRQTALAPLIKENVQSQERSSVPSSENVNKKSSCLQISLQPTRYSGYLQSSNVLADSDDASFTCILKDGIYSSAVVDNELNAVNDGHLVSSPAICSGSLSNFSTSDNGSYSSNGSDFGSCASITSGGSYTNSVISDSSSYTFPPSDDTFLGGNLPSDSTSNRSVPNRNTTPCEIFSRSTSTDPFVQDDLEHGLEIMKLPVSRNTKIPLKRYSSLVIFPRSPSTTRPTSPTSLCTLLSKGSYQTSHQFIISPSEIAHNEDGTSAKGFLSTAVNGLRLSKTICTPGEVRDIRPLHRKGSLQKKIVLSNNTPRQTVCEKSSEGYSCVSVHFTQRKAATLDCETTNGDCKPEMSEIKLNSDSEYIKLMHRTSACLPSSQNVDCQININGELERPHSQMNKNHGILRRSISLGGAYPNISCLSSLKHNCSKGGPSQLLIKFASGNEGKVDNLSRDSNRDCTNELSNSCKTRDDFLGQVDVPLYPLPTENPRLERPYTFKDFVLHPRSHKSRVKGYLRLKMTYLPKTSGSEDDNAEQAEELEPGWVVLDQPDAACHLQQQQEPSPLPPGWEERQDILGRTYYVNHESRRTQWKRPTPQDNLTDAENGNIQLQAQRAFTTRRQISEETESVDNRESSENWEIIREDEATMYSNQAFPSPPPSSNLDVPTHLAEELNARLTIFGNSAVSQPASSSNHSSRRGSLQAYTFEEQPTLPVLLPTSSGLPPGWEEKQDERGRSYYVDHNSRTTTWTKPTVQATVETSQLTSSQSSAGPQSQASTSDSGQQVTQPSEIEQGFLPKGWEVRHAPNGRPFFIDHNTKTTTWEDPRLKIPAHLRGKTSLDTSNDLGPLPPGWEERTHTDGRIFYINHNIKRTQWEDPRLENVAITGPAVPYSRDYKRKYEFFRRKLKKQNDIPNKFEMKLRRATVLEDSYRRIMGVKRADFLKARLWIEFDGEKGLDYGGVAREWFFLISKEMFNPYYGLFEYSATDNYTLQINPNSGLCNEDHLSYFKFIGRVAGMAVYHGKLLDGFFIRPFYKMMLHKPITLHDMESVDSEYYNSLRWILENDPTELDLRFIIDEELFGQTHQHELKNGGSEIVVTNKNKKEYIYLVIQWRFVNRIQKQMAAFKEGFFELIPQDLIKIFDENELELLMCGLGDVDVNDWREHTKYKNGYSANHQVIQWFWKAVLMMDSEKRIRLLQFVTGTSRVPMNGFAELYGSNGPQSFTVEQWGTPEKLPRAHTCFNRLDLPPYESFEELWDKLQMAIENTQGFDGVD

T46527	TARGETID	T46527
T46527	FORMERID	TTDR01339
T46527	UNIPROID	3HAO_HUMAN
T46527	TARGNAME	3-hydroxyanthranilate oxygenase (HAAO)
T46527	GENENAME	HAAO
T46527	TARGTYPE	Literature-reported
T46527	SYNONYMS	h3HAO; HAD; 3-hydroxyanthranilic acid dioxygenase; 3-hydroxyanthranilate 3,4-dioxygenase; 3-HAO
T46527	FUNCTION	Catalyzes the oxidative ring opening of 3-hydroxyanthranilate to 2-amino-3-carboxymuconate semialdehyde, which spontaneously cyclizes to quinolinate.
T46527	PDBSTRUC	5TKQ; 5TK5; 2QNK
T46527	ECNUMBER	EC 1.13.11.6
T46527	SEQUENCE	MERRLGVRAWVKENRGSFQPPVCNKLMHQEQLKVMFIGGPNTRKDYHIEEGEEVFYQLEGDMVLRVLEQGKHRDVVIRQGEIFLLPARVPHSPQRFANTVGLVVERRRLETELDGLRYYVGDTMDVLFEKWFYCKDLGTQLAPIIQEFFSSEQYRTGKPIPDQLLKEPPFPLSTRSIMEPMSLDAWLDSHHRELQAGTPLSLFGDTYETQVIAYGQGSSEGLRQNVDVWLWQLEGSSVVTMGGRRLSLAPDDSLLVLAGTSYAWERTQGSVALSVTQDPACKKPLG

T78581	TARGETID	T78581
T78581	FORMERID	TTDR00184
T78581	UNIPROID	GALR1_HUMAN
T78581	TARGNAME	Galanin receptor type 1 (GAL1-R)
T78581	GENENAME	GALR1
T78581	TARGTYPE	Literature-reported
T78581	SYNONYMS	GALR1; GALR-1; GALNR1; GALN1R; GAL1-R
T78581	FUNCTION	The activity of this receptor is mediated by G proteins that inhibit adenylate cyclase activity. Receptor for the hormone galanin. G protein-coupled peptide receptor activity. Neuropeptide binding. Peptide hormone binding.
T78581	BIOCLASS	GPCR rhodopsin
T78581	SEQUENCE	MELAVGNLSEGNASWPEPPAPEPGPLFGIGVENFVTLVVFGLIFALGVLGNSLVITVLARSKPGKPRSTTNLFILNLSIADLAYLLFCIPFQATVYALPTWVLGAFICKFIHYFFTVSMLVSIFTLAAMSVDRYVAIVHSRRSSSLRVSRNALLGVGCIWALSIAMASPVAYHQGLFHPRASNQTFCWEQWPDPRHKKAYVVCTFVFGYLLPLLLICFCYAKVLNHLHKKLKNMSKKSEASKKKTAQTVLVVVVVFGISWLPHHIIHLWAEFGVFPLTPASFLFRITAHCLAYSNSSVNPIIYAFLSENFRKAYKQVFKCHIRKDSHLSDTKESKSRIDTPPSTNCTHV
T78581	DRUGINFO	D0G9ME	NAX-5055	Investigative
T78581	DRUGINFO	D0W6PP	Galnon	Investigative
T78581	DRUGINFO	D00RWP	GwTLNSAGYLLGPHAVGNHRSFSDKNGLTS-CONH2	Investigative
T78581	DRUGINFO	D01LMH	[Sar1Gly]GAL-B2	Investigative
T78581	DRUGINFO	D02GOE	(Sar)WTLNSAGYLLGPKK(Lys-lauroyl)K	Investigative
T78581	DRUGINFO	D02JQP	GalB2	Investigative
T78581	DRUGINFO	D03ECE	(Sar)WTLNSAGYLLGPKK(Lys-octanoyl)K	Investigative
T78581	DRUGINFO	D05GFD	(Sar)WTLNSAGYLLGPKK(Lys-decanoyl)K	Investigative
T78581	DRUGINFO	D06DWA	(Sar)WTLNSAGYLLGPKK(Lys-MPEG4)K	Investigative
T78581	DRUGINFO	D07NOJ	[Sar1Ala]GAL-B2	Investigative
T78581	DRUGINFO	D09SDZ	GWTLNSAGYLLGPHAV-NH2	Investigative
T78581	DRUGINFO	D0D3CG	GWTLNSAGYLLGPrPKPQQwFwLL-CONH2	Investigative
T78581	DRUGINFO	D0DD3F	(Sar)WTLNSAGYLLGPKK(Lys-myristoyl)K	Investigative
T78581	DRUGINFO	D0EO5F	(Sar)WTLNSAGYLLGPKK(Lys-palmitoyl)K	Investigative
T78581	DRUGINFO	D0H4DF	GALANTIDE	Investigative
T78581	DRUGINFO	D0H9QA	Gal-B5	Investigative
T78581	DRUGINFO	D0NJ4R	GALANIN	Investigative
T78581	DRUGINFO	D0PY7O	WTLNSAGYLL-CONH2	Investigative
T78581	DRUGINFO	D0Q3CB	GWTLNSAGYLLGPPPALALA-CONH2	Investigative
T78581	DRUGINFO	D0S4VO	[N-Me,des-Sar]Gal-B2	Investigative
T78581	DRUGINFO	D0SV5D	GWTLNSAGYLLGPPPGFSPFR-CONH2	Investigative
T78581	DRUGINFO	D0T6CU	WTLNSAGYLLGPHAVGNHPSFSDKNGLTS-CONH2	Investigative
T78581	DRUGINFO	D0TF7R	(Sar)WTLNSAGYLLGPKKKK	Investigative
T78581	DRUGINFO	D0V7UG	[N-Ac,des-Sar]Gal-B2	Investigative
T78581	DRUGINFO	D0Z3QG	(Sar)WTLNSAGYLLGPKK(Lys-stearoyl)K	Investigative
T78581	DRUGINFO	D0Z7QU	GWTLNSAGYLLGPRHYINLITRQRY-CONH2	Investigative

T30727	TARGETID	T30727
T30727	FORMERID	TTDR00455
T30727	UNIPROID	CASP4_HUMAN
T30727	TARGNAME	Caspase-11 (CASP11)
T30727	GENENAME	Casp4
T30727	TARGTYPE	Literature-reported
T30727	SYNONYMS	ICH-3 protease; Casp4 of Mus musculus
T30727	FUNCTION	Involved in ER-stress induced apoptosis. Cleaves caspase-1. Involved in the activation cascade of caspases responsible for apoptosis execution. Promotes IL-1 beta processing by ICE, so may also have a role in inflammatory responses.
T30727	BIOCLASS	Peptidase
T30727	ECNUMBER	EC 3.4.22.57
T30727	SEQUENCE	MAEGNHRKKPLKVLESLGKDFLTGVLDNLVEQNVLNWKEEEKKKYYDAKTEDKVRVMADSMQEKQRMAGQMLLQTFFNIDQISPNKKAHPNMEAGPPESGESTDALKLCPHEEFLRLCKERAEEIYPIKERNNRTRLALIICNTEFDHLPPRNGADFDITGMKELLEGLDYSVDVEENLTARDMESALRAFATRPEHKSSDSTFLVLMSHGILEGICGTVHDEKKPDVLLYDTIFQIFNNRNCLSLKDKPKVIIVQACRGANRGELWVRDSPASLEVASSQSSENLEEDAVYKTHVEKDFIAFCSSTPHNVSWRDSTMGSIFITQLITCFQKYSWCCHLEEVFRKVQQSFETPRAKAQMPTIERLSMTRYFYLFPGN
T30727	DRUGINFO	D0Y5IQ	Grassystatin a	Investigative

T21585	TARGETID	T21585
T21585	FORMERID	TTDI03104
T21585	UNIPROID	CLK3_HUMAN
T21585	TARGNAME	CDC-like kinase 3 (CLK3)
T21585	GENENAME	CLK3
T21585	TARGTYPE	Literature-reported
T21585	SYNONYMS	Dual specificity protein kinase CLK3
T21585	FUNCTION	Phosphorylates serine- and arginine-rich (SR) proteins of the spliceosomal complex. May be a constituent of a network of regulatory mechanisms that enable SR proteins to control RNA splicing and can cause redistribution of SR proteins from speckles to a diffuse nucleoplasmic distribution. Phosphorylates SRSF1 and SRSF3. Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells. Dual specificity kinase acting on both serine/threonine and tyrosine-containing substrates.
T21585	PDBSTRUC	6RCT; 6FYR; 6FYP; 6FT7; 3RAW
T21585	BIOCLASS	Kinase
T21585	ECNUMBER	EC 2.7.12.1
T21585	SEQUENCE	MPVLSARRRELADHAGSGRRSGPSPTARSGPHLSALRAQPARAAHLSGRGTYVRRDTAGGGPGQARPLGPPGTSLLGRGARRSGEGWCPGAFESGARAARPPSRVEPRLATAASREGAGLPRAEVAAGSGRGARSGEWGLAAAGAWETMHHCKRYRSPEPDPYLSYRWKRRRSYSREHEGRLRYPSRREPPPRRSRSRSHDRLPYQRRYRERRDSDTYRCEERSPSFGEDYYGPSRSRHRRRSRERGPYRTRKHAHHCHKRRTRSCSSASSRSQQSSKRSSRSVEDDKEGHLVCRIGDWLQERYEIVGNLGEGTFGKVVECLDHARGKSQVALKIIRNVGKYREAARLEINVLKKIKEKDKENKFLCVLMSDWFNFHGHMCIAFELLGKNTFEFLKENNFQPYPLPHVRHMAYQLCHALRFLHENQLTHTDLKPENILFVNSEFETLYNEHKSCEEKSVKNTSIRVADFGSATFDHEHHTTIVATRHYRPPEVILELGWAQPCDVWSIGCILFEYYRGFTLFQTHENREHLVMMEKILGPIPSHMIHRTRKQKYFYKGGLVWDENSSDGRYVKENCKPLKSYMLQDSLEHVQLFDLMRRMLEFDPAQRITLAEALLHPFFAGLTPEERSFHTSRNPSR
T21585	DRUGINFO	D00BAJ	KH-CB19	Investigative
T21585	DRUGINFO	D04IMY	leucettine L41	Investigative

T79326	TARGETID	T79326
T79326	FORMERID	TTDI02570
T79326	UNIPROID	KHK_HUMAN
T79326	TARGNAME	Ketohexokinase (KHK)
T79326	GENENAME	KHK
T79326	TARGTYPE	Literature-reported
T79326	SYNONYMS	Hepatic fructokinase
T79326	FUNCTION	Catalyzes the phosphorylation of the ketose sugar fructose to fructose-1-phosphate.
T79326	PDBSTRUC	5WBZ; 5WBR; 5WBQ; 5WBP; 5WBO
T79326	BIOCLASS	Kinase
T79326	ECNUMBER	EC 2.7.1.3
T79326	SEQUENCE	MEEKQILCVGLVVLDVISLVDKYPKEDSEIRCLSQRWQRGGNASNSCTVLSLLGAPCAFMGSMAPGHVADFLVADFRRRGVDVSQVAWQSKGDTPSSCCIINNSNGNRTIVLHDTSLPDVSATDFEKVDLTQFKWIHIEGRNASEQVKMLQRIDAHNTRQPPEQKIRVSVEVEKPREELFQLFGYGDVVFVSKDVAKHLGFQSAEEALRGLYGRVRKGAVLVCAWAEEGADALGPDGKLLHSDAFPPPRVVDTLGAGDTFNASVIFSLSQGRSVQEALRFGCQVAGKKCGLQGFDGIV

T35824	TARGETID	T35824
T35824	FORMERID	TTDI03390
T35824	UNIPROID	MMP16_HUMAN
T35824	TARGNAME	Matrix metalloproteinase-16 (MMP-16)
T35824	GENENAME	MMP16
T35824	TARGTYPE	Literature-reported
T35824	SYNONYMS	Membrane-type-3 matrix metalloproteinase; Membrane-type matrix metalloproteinase 3; MTMMP3; MT3MMP; MT3-MMP; MT-MMP 3; MMPX2; MMP-X2; C8orf57
T35824	FUNCTION	Activates progelatinase A. Involved in the matrix remodeling of blood vessels. Isoform short cleaves fibronectin and also collagen type III, but at lower rate. It has no effect on type I, II, IV and V collagen. However, upon interaction with CSPG4, it may be involved in degradation and invasion of type I collagen by melanoma cells. Endopeptidase that degrades various components of the extracellular matrix, such as collagen type III and fibronectin.
T35824	PDBSTRUC	1RM8
T35824	BIOCLASS	Peptidase
T35824	ECNUMBER	EC 3.4.24.-
T35824	SEQUENCE	MILLTFSTGRRLDFVHHSGVFFLQTLLWILCATVCGTEQYFNVEVWLQKYGYLPPTDPRMSVLRSAETMQSALAAMQQFYGINMTGKVDRNTIDWMKKPRCGVPDQTRGSSKFHIRRKRYALTGQKWQHKHITYSIKNVTPKVGDPETRKAIRRAFDVWQNVTPLTFEEVPYSELENGKRDVDITIIFASGFHGDSSPFDGEGGFLAHAYFPGPGIGGDTHFDSDEPWTLGNPNHDGNDLFLVAVHELGHALGLEHSNDPTAIMAPFYQYMETDNFKLPNDDLQGIQKIYGPPDKIPPPTRPLPTVPPHRSIPPADPRKNDRPKPPRPPTGRPSYPGAKPNICDGNFNTLAILRREMFVFKDQWFWRVRNNRVMDGYPMQITYFWRGLPPSIDAVYENSDGNFVFFKGNKYWVFKDTTLQPGYPHDLITLGSGIPPHGIDSAIWWEDVGKTYFFKGDRYWRYSEEMKTMDPGYPKPITVWKGIPESPQGAFVHKENGFTYFYKGKEYWKFNNQILKVEPGYPRSILKDFMGCDGPTDRVKEGHSPPDDVDIVIKLDNTASTVKAIAIVIPCILALCLLVLVYTVFQFKRKGTPRHILYCKRSMQEWV
T35824	DRUGINFO	D07GEL	SL422	Investigative

T69200	TARGETID	T69200
T69200	FORMERID	TTDI03566
T69200	UNIPROID	SMCA4_HUMAN
T69200	TARGNAME	Mitotic growth and transcription activator (BAF190A)
T69200	GENENAME	SMARCA4
T69200	TARGTYPE	Literature-reported
T69200	SYNONYMS	Transcription activator BRG1; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4; SNF2L4; SNF2B; SNF2-beta; Protein brahma homolog 1; Protein BRG-1; BRG1-associated factor 190A; BRG1; ATP-dependent helicase SMARCA4
T69200	FUNCTION	Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating the calcium-dependent release of a repressor complex and the recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by SMARCA4-dependent recruitment of a phospho-RB1-HDAC repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves the release of HDAC1 and recruitment of CREBBP. Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). During neural development, a switch from a stem/progenitor to a postmitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to postmitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. As neural progenitors exit mitosis and differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A and PHF10/BAF45A, are exchanged for homologous alternative ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron-specific complexes (nBAF). The npBAF complex is essential for the self-renewal/proliferative capacity of the multipotent neural stem cells. The nBAF complex along with CREST plays a role regulating the activity of genes essential for dendrite growth. SMARCA4/BAF190A may promote neural stem cell self-renewal/proliferation by enhancing Notch-dependent proliferative signals, while concurrently making the neural stem cell insensitive to SHH-dependent differentiating cues. Acts as a corepressor of ZEB1 to regulate E-cadherin transcription and is required for induction of epithelial-mesenchymal transition (EMT) by ZEB1. Binds via DLX1 to enhancers located in the intergenic region between DLX5 and DLX6 and this binding is stabilized by the long non-coding RNA (lncRNA) Evf2. Binds to RNA in a promiscuous manner. Binding to RNAs including lncRNA Evf2 leads to inhibition of SMARCA4 ATPase and chromatin remodeling activities. Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology).
T69200	PDBSTRUC	6BGH; 5EA1; 5DKD; 3UVD; 2H60
T69200	BIOCLASS	Acid anhydride hydrolase
T69200	ECNUMBER	EC 3.6.4.-
T69200	SEQUENCE	MSTPDPPLGGTPRPGPSPGPGPSPGAMLGPSPGPSPGSAHSMMGPSPGPPSAGHPIPTQGPGGYPQDNMHQMHKPMESMHEKGMSDDPRYNQMKGMGMRSGGHAGMGPPPSPMDQHSQGYPSPLGGSEHASSPVPASGPSSGPQMSSGPGGAPLDGADPQALGQQNRGPTPFNQNQLHQLRAQIMAYKMLARGQPLPDHLQMAVQGKRPMPGMQQQMPTLPPPSVSATGPGPGPGPGPGPGPGPAPPNYSRPHGMGGPNMPPPGPSGVPPGMPGQPPGGPPKPWPEGPMANAAAPTSTPQKLIPPQPTGRPSPAPPAVPPAASPVMPPQTQSPGQPAQPAPMVPLHQKQSRITPIQKPRGLDPVEILQEREYRLQARIAHRIQELENLPGSLAGDLRTKATIELKALRLLNFQRQLRQEVVVCMRRDTALETALNAKAYKRSKRQSLREARITEKLEKQQKIEQERKRRQKHQEYLNSILQHAKDFKEYHRSVTGKIQKLTKAVATYHANTEREQKKENERIEKERMRRLMAEDEEGYRKLIDQKKDKRLAYLLQQTDEYVANLTELVRQHKAAQVAKEKKKKKKKKKAENAEGQTPAIGPDGEPLDETSQMSDLPVKVIHVESGKILTGTDAPKAGQLEAWLEMNPGYEVAPRSDSEESGSEEEEEEEEEEQPQAAQPPTLPVEEKKKIPDPDSDDVSEVDARHIIENAKQDVDDEYGVSQALARGLQSYYAVAHAVTERVDKQSALMVNGVLKQYQIKGLEWLVSLYNNNLNGILADEMGLGKTIQTIALITYLMEHKRINGPFLIIVPLSTLSNWAYEFDKWAPSVVKVSYKGSPAARRAFVPQLRSGKFNVLLTTYEYIIKDKHILAKIRWKYMIVDEGHRMKNHHCKLTQVLNTHYVAPRRLLLTGTPLQNKLPELWALLNFLLPTIFKSCSTFEQWFNAPFAMTGEKVDLNEEETILIIRRLHKVLRPFLLRRLKKEVEAQLPEKVEYVIKCDMSALQRVLYRHMQAKGVLLTDGSEKDKKGKGGTKTLMNTIMQLRKICNHPYMFQHIEESFSEHLGFTGGIVQGLDLYRASGKFELLDRILPKLRATNHKVLLFCQMTSLMTIMEDYFAYRGFKYLRLDGTTKAEDRGMLLKTFNEPGSEYFIFLLSTRAGGLGLNLQSADTVIIFDSDWNPHQDLQAQDRAHRIGQQNEVRVLRLCTVNSVEEKILAAAKYKLNVDQKVIQAGMFDQKSSSHERRAFLQAILEHEEQDESRHCSTGSGSASFAHTAPPPAGVNPDLEEPPLKEEDEVPDDETVNQMIARHEEEFDLFMRMDLDRRREEARNPKRKPRLMEEDELPSWIIKDDAEVERLTCEEEEEKMFGRGSRHRKEVDYSDSLTEKQWLKAIEEGTLEEIEEEVRQKKSSRKRKRDSDAGSSTPTTSTRSRDKDDESKKQKKRGRPPAEKLSPNPPNLTKKMKKIVDAVIKYKDSSSGRQLSEVFIQLPSRKELPEYYELIRKPVDFKKIKERIRNHKYRSLNDLEKDVMLLCQNAQTFNLEGSLIYEDSIVLQSVFTSVRQKIEKEDDSEGEESEEEEEGEEEGSESESRSVKVKIKLGRKEKAQDRLKGGRRRPSRGSRAKPVVSDDDSEEEQEEDRSGSGSEED
T69200	DRUGINFO	D09GNM	PFI-3	Investigative

T59230	TARGETID	T59230
T59230	FORMERID	TTDR00811
T59230	UNIPROID	DHB4_HUMAN
T59230	TARGNAME	Estradiol 17 beta-dehydrogenase 4 (HSD17B4)
T59230	GENENAME	HSD17B4
T59230	TARGTYPE	Literature-reported
T59230	SYNONYMS	MFE-2; HSD17B4; DBP; D-bifunctional protein; 17-beta-hydroxysteroid dehydrogenase 4; 17-beta-HSD 4; 17 beta-hydroxysteroid dehydrogenase type 4
T59230	FUNCTION	Bifunctional enzymeacting on the peroxisomal beta- oxidation pathway for fatty acids. Catalyzes the formation of 3- ketoacyl-CoA intermediates from both straight-chain and 2-methyl- branched-chain fatty acids.
T59230	PDBSTRUC	1ZBQ; 1S9C; 1IKT
T59230	BIOCLASS	Short-chain dehydrogenases reductase
T59230	SEQUENCE	MGSPLRFDGRVVLVTGAGAGLGRAYALAFAERGALVVVNDLGGDFKGVGKGSLAADKVVEEIRRRGGKAVANYDSVEEGEKVVKTALDAFGRIDVVVNNAGILRDRSFARISDEDWDIIHRVHLRGSFQVTRAAWEHMKKQKYGRIIMTSSASGIYGNFGQANYSAAKLGLLGLANSLAIEGRKSNIHCNTIAPNAGSRMTQTVMPEDLVEALKPEYVAPLVLWLCHESCEENGGLFEVGAGWIGKLRWERTLGAIVRQKNHPMTPEAVKANWKKICDFENASKPQSIQESTGSIIEVLSKIDSEGGVSANHTSRATSTATSGFAGAIGQKLPPFSYAYTELEAIMYALGVGASIKDPKDLKFIYEGSSDFSCLPTFGVIIGQKSMMGGGLAEIPGLSINFAKVLHGEQYLELYKPLPRAGKLKCEAVVADVLDKGSGVVIIMDVYSYSEKELICHNQFSLFLVGSGGFGGKRTSDKVKVAVAIPNRPPDAVLTDTTSLNQAALYRLSGDWNPLHIDPNFASLAGFDKPILHGLCTFGFSARRVLQQFADNDVSRFKAIKARFAKPVYPGQTLQTEMWKEGNRIHFQTKVQETGDIVISNAYVDLAPTSGTSAKTPSEGGKLQSTFVFEEIGRRLKDIGPEVVKKVNAVFEWHITKGGNIGAKWTIDLKSGSGKVYQGPAKGAADTTIILSDEDFMEVVLGKLDPQKAFFSGRLKARGNIMLSQKLQMILKDYAKL
T59230	DRUGINFO	D04TMV	3r-Hydroxydecanoyl-Coa	Investigative
T59230	DRUGINFO	D0R6JE	Nicotinamide-Adenine-Dinucleotide	Investigative

T91617	TARGETID	T91617
T91617	UNIPROID	TKTL1_HUMAN
T91617	TARGNAME	Transketolase-like protein 1 (TKTL1)
T91617	GENENAME	TKTL1
T91617	TARGTYPE	Literature-reported
T91617	SYNONYMS	Transketolase-related protein; Transketolase 2; TKT2; TKR; TK 2
T91617	FUNCTION	Catalyzes the transfer of a two-carbon ketol group from a ketose donor to an aldose acceptor, via a covalent intermediate with the cofactor thiamine pyrophosphate.
T91617	BIOCLASS	Transketolase family
T91617	ECNUMBER	EC 2.2.1.1
T91617	SEQUENCE	MADAEARAEFPEEARPDRGTLQVLQDMASRLRIHSIRATCSTSSGHPTSCSSSSEIMSVLFFYIMRYKQSDPENPDNDRFVLAKRLSFVDVATGWLGQGLGVACGMAYTGKYFDRASYRVFCLMSDGESSEGSVWEAMAFASYYSLDNLVAIFDVNRLGHSGALPAEHCINIYQRRCEAFGWNTYVVDGRDVEALCQVFWQASQVKHKPTAVVAKTFKGRGTPSIEDAESWHAKPMPRERADAIIKLIESQIQTSRNLDPQPPIEDSPEVNITDVRMTSPPDYRVGDKIATRKACGLALAKLGYANNRVVVLDGDTRYSTFSEIFNKEYPERFIECFMAEQNMVSVALGCASRGRTIAFASTFAAFLTRAFDHIRIGGLAESNINIIGSHCGVSVGDDGASQMALEDIAMFRTIPKCTIFYPTDAVSTEHAVALAANAKGMCFIRTTRPETMVIYTPQERFEIGQAKVLRHCVSDKVTVIGAGITVYEALAAADELSKQDIFIRVIDLFTIKPLDVATIVSSAKATEGRIITVEDHYPQGGIGEAVCAAVSMDPDIQVHSLAVSGVPQSGKSEELLDMYGISARHIIVAVKCMLLN

T49102	TARGETID	T49102
T49102	FORMERID	TTDI03401
T49102	UNIPROID	NEK2_HUMAN
T49102	TARGNAME	NIMA-related kinase 2 (NEK2)
T49102	GENENAME	NEK2
T49102	TARGTYPE	Literature-reported
T49102	SYNONYMS	Serine/threonine-protein kinase Nek2; NimA-related protein kinase 2; NimA-like protein kinase 1; Never in mitosis A-related kinase 2; NLK1; NEK2A; HSPK 21
T49102	FUNCTION	Regulates centrosome separation (essential for the formation of bipolar spindles and high-fidelity chromosome separation) by phosphorylating centrosomal proteins such as CROCC, CEP250 and NINL, resulting in their displacement from the centrosomes. Regulates kinetochore microtubule attachment stability in mitosis via phosphorylation of NDC80. Involved in regulation of mitotic checkpoint protein complex via phosphorylation of CDC20 and MAD2L1. Plays an active role in chromatin condensation during the first meiotic division through phosphorylation of HMGA2. Phosphorylates: PPP1CC; SGO1; NECAB3 and NPM1. Essential for localization of MAD2L1 to kinetochore and MAPK1 and NPM1 to the centrosome. Phosphorylates CEP68 and CNTLN directly or indirectly. NEK2-mediated phosphorylation of CEP68 promotes CEP68 dissociation from the centrosome and its degradation at the onset of mitosis. Involved in the regulation of centrosome disjunction. Protein kinase which is involved in the control of centrosome separation and bipolar spindle formation in mitotic cells and chromatin condensation in meiotic cells.
T49102	PDBSTRUC	6H0O; 5M57; 5M55; 5M53; 5M51
T49102	BIOCLASS	Kinase
T49102	ECNUMBER	EC 2.7.11.1
T49102	SEQUENCE	MPSRAEDYEVLYTIGTGSYGRCQKIRRKSDGKILVWKELDYGSMTEAEKQMLVSEVNLLRELKHPNIVRYYDRIIDRTNTTLYIVMEYCEGGDLASVITKGTKERQYLDEEFVLRVMTQLTLALKECHRRSDGGHTVLHRDLKPANVFLDGKQNVKLGDFGLARILNHDTSFAKTFVGTPYYMSPEQMNRMSYNEKSDIWSLGCLLYELCALMPPFTAFSQKELAGKIREGKFRRIPYRYSDELNEIITRMLNLKDYHRPSVEEILENPLIADLVADEQRRNLERRGRQLGEPEKSQDSSPVLSELKLKEIQLQERERALKAREERLEQKEQELCVRERLAEDKLARAENLLKNYSLLKERKFLSLASNPELLNLPSSVIKKKVHFSGESKENIMRSENSESQLTSKSKCKDLKKRLHAAQLRAQALSDIEKNYQLKSRQILGMR
T49102	DRUGINFO	D0C3KE	PMID21627121C2	Investigative
T49102	DRUGINFO	D0K0UJ	PMID20936789C31	Investigative
T49102	DRUGINFO	D0X1RH	GSK579289A	Investigative

T70840	TARGETID	T70840
T70840	FORMERID	TTDI03352
T70840	UNIPROID	LIMK1_HUMAN
T70840	TARGNAME	LIM domain kinase-1 (LIMK-1)
T70840	GENENAME	LIMK1
T70840	TARGTYPE	Literature-reported
T70840	SYNONYMS	LIMK-1; LIMK
T70840	FUNCTION	Acts downstream of several Rho family GTPase signal transduction pathways. Activated by upstream kinases including ROCK1, PAK1 and PAK4, which phosphorylate LIMK1 on a threonine residue located in its activation loop. LIMK1 subsequently phosphorylates and inactivates the actin binding/depolymerizing factors cofilin-1/CFL1, cofilin-2/CFL2 and destrin/DSTN, thereby preventing the cleavage of filamentous actin (F-actin), and stabilizing the actin cytoskeleton. In this way LIMK1 regulates several actin-dependent biological processes including cell motility, cell cycle progression, and differentiation. Phosphorylates TPPP on serine residues, thereby promoting microtubule disassembly. Stimulates axonal outgrowth and may be involved in brain development. Isoform 3 has a dominant negative effect on actin cytoskeletal changes. Required for atypical chemokine receptor ACKR2-induced phosphorylation of cofilin (CFL1). Serine/threonine-protein kinase that plays an essential role in the regulation of actin filament dynamics.
T70840	PDBSTRUC	5NXC; 5L6W; 5HVK; 5HVJ; 3S95
T70840	BIOCLASS	Kinase
T70840	ECNUMBER	EC 2.7.11.1
T70840	SEQUENCE	MRLTLLCCTWREERMGEEGSELPVCASCGQRIYDGQYLQALNADWHADCFRCCDCSASLSHQYYEKDGQLFCKKDYWARYGESCHGCSEQITKGLVMVAGELKYHPECFICLTCGTFIGDGDTYTLVEHSKLYCGHCYYQTVVTPVIEQILPDSPGSHLPHTVTLVSIPASSHGKRGLSVSIDPPHGPPGCGTEHSHTVRVQGVDPGCMSPDVKNSIHVGDRILEINGTPIRNVPLDEIDLLIQETSRLLQLTLEHDPHDTLGHGLGPETSPLSSPAYTPSGEAGSSARQKPVLRSCSIDRSPGAGSLGSPASQRKDLGRSESLRVVCRPHRIFRPSDLIHGEVLGKGCFGQAIKVTHRETGEVMVMKELIRFDEETQRTFLKEVKVMRCLEHPNVLKFIGVLYKDKRLNFITEYIKGGTLRGIIKSMDSQYPWSQRVSFAKDIASGMAYLHSMNIIHRDLNSHNCLVRENKNVVVADFGLARLMVDEKTQPEGLRSLKKPDRKKRYTVVGNPYWMAPEMINGRSYDEKVDVFSFGIVLCEIIGRVNADPDYLPRTMDFGLNVRGFLDRYCPPNCPPSFFPITVRCCDLDPEKRPSFVKLEHWLETLRMHLAGHLPLGPQLEQLDRGFWETYRRGESGLPAHPEVPD
T70840	DRUGINFO	D07XWC	PMID19831390C14	Investigative
T70840	DRUGINFO	D0F6NZ	PMID22902653C30	Investigative
T70840	DRUGINFO	D0FC4Y	PMID22902653C31	Investigative
T70840	DRUGINFO	D0S0XD	PMID22902653C35	Investigative
T70840	DRUGINFO	D03CPB	RKI-1447	Investigative

T09133	TARGETID	T09133
T09133	FORMERID	TTDI03353
T09133	UNIPROID	LIMK2_HUMAN
T09133	TARGNAME	LIM domain kinase-2 (LIMK-2)
T09133	GENENAME	LIMK2
T09133	TARGTYPE	Literature-reported
T09133	SYNONYMS	LIMK-2; LIM domain kinase 2
T09133	FUNCTION	Displays serine/threonine-specific phosphorylation of myelin basic protein and histone (MBP) in vitro.
T09133	PDBSTRUC	5NXD; 4TPT; 1X6A
T09133	BIOCLASS	Kinase
T09133	ECNUMBER	EC 2.7.11.1
T09133	SEQUENCE	MSALAGEDVWRCPGCGDHIAPSQIWYRTVNETWHGSCFRCSECQDSLTNWYYEKDGKLYCPKDYWGKFGEFCHGCSLLMTGPFMVAGEFKYHPECFACMSCKVIIEDGDAYALVQHATLYCGKCHNEVVLAPMFERLSTESVQEQLPYSVTLISMPATTEGRRGFSVSVESACSNYATTVQVKEVNRMHISPNNRNAIHPGDRILEINGTPVRTLRVEEVEDAISQTSQTLQLLIEHDPVSQRLDQLRLEARLAPHMQNAGHPHALSTLDTKENLEGTLRRRSLRRSNSISKSPGPSSPKEPLLFSRDISRSESLRCSSSYSQQIFRPCDLIHGEVLGKGFFGQAIKVTHKATGKVMVMKELIRCDEETQKTFLTEVKVMRSLDHPNVLKFIGVLYKDKKLNLLTEYIEGGTLKDFLRSMDPFPWQQKVRFAKGIASGMAYLHSMCIIHRDLNSHNCLIKLDKTVVVADFGLSRLIVEERKRAPMEKATTKKRTLRKNDRKKRYTVVGNPYWMAPEMLNGKSYDETVDIFSFGIVLCEIIGQVYADPDCLPRTLDFGLNVKLFWEKFVPTDCPPAFFPLAAICCRLEPESRPAFSKLEDSFEALSLYLGELGIPLPAELEELDHTVSMQYGLTRDSPP
T09133	DRUGINFO	D0YI1Z	PMID19831390C22m	Investigative
T09133	DRUGINFO	D07XWC	PMID19831390C14	Investigative
T09133	DRUGINFO	D0F6NZ	PMID22902653C30	Investigative
T09133	DRUGINFO	D0FC4Y	PMID22902653C31	Investigative
T09133	DRUGINFO	D0S0XD	PMID22902653C35	Investigative

T81637	TARGETID	T81637
T81637	FORMERID	TTDI03443
T81637	UNIPROID	PDE1A_HUMAN
T81637	TARGNAME	Phosphodiesterase 1A (PDE1A)
T81637	GENENAME	PDE1A
T81637	TARGTYPE	Literature-reported
T81637	SYNONYMS	hCam-1; Cam-PDE 1A; Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A; 61 kDa Cam-PDE
T81637	FUNCTION	Has a higher affinity for cGMP than for cAMP. Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes.
T81637	PDBSTRUC	1LXQ
T81637	BIOCLASS	Phosphoric diester hydrolase
T81637	ECNUMBER	EC 3.1.4.17
T81637	SEQUENCE	MGSSATEIEELENTTFKYLTGEQTEKMWQRLKGILRCLVKQLERGDVNVVDLKKNIEYAASVLEAVYIDETRRLLDTEDELSDIQTDSVPSEVRDWLASTFTRKMGMTKKKPEEKPKFRSIVHAVQAGIFVERMYRKTYHMVGLAYPAAVIVTLKDVDKWSFDVFALNEASGEHSLKFMIYELFTRYDLINRFKIPVSCLITFAEALEVGYSKYKNPYHNLIHAADVTQTVHYIMLHTGIMHWLTELEILAMVFAAAIHDYEHTGTTNNFHIQTRSDVAILYNDRSVLENHHVSAAYRLMQEEEMNILINLSKDDWRDLRNLVIEMVLSTDMSGHFQQIKNIRNSLQQPEGIDRAKTMSLILHAADISHPAKSWKLHYRWTMALMEEFFLQGDKEAELGLPFSPLCDRKSTMVAQSQIGFIDFIVEPTFSLLTDSTEKIVIPLIEEASKAETSSYVASSSTTIVGLHIADALRRSNTKGSMSDGSYSPDYSLAAVDLKSFKNNLVDIIQQNKERWKELAAQEARTSSQKCEFIHQ
T81637	DRUGINFO	D02VHD	SCH51866	Investigative

T56121	TARGETID	T56121
T56121	FORMERID	TTDI03181
T56121	UNIPROID	EPHB3_HUMAN
T56121	TARGNAME	Ephrin type-B receptor 3 (EPHB3)
T56121	GENENAME	EPHB3
T56121	TARGTYPE	Literature-reported
T56121	SYNONYMS	hEK2; Tyrosine-protein kinase TYRO6; TYRO6; Embryonic kinase 2; ETK2; EPH-like tyrosine kinase 2; EPH-like kinase 2; EK2
T56121	FUNCTION	The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Generally has an overlapping and redundant function with EPHB2. Like EPHB2, functions in axon guidance during development regulating for instance the neurons forming the corpus callosum and the anterior commissure, 2 major interhemispheric connections between the temporal lobes of the cerebral cortex. In addition to its role in axon guidance plays also an important redundant role with other ephrin-B receptors in development and maturation of dendritic spines and the formation of excitatory synapses. Controls other aspects of development through regulation of cell migration and positioning. This includes angiogenesis, palate development and thymic epithelium development for instance. Forward and reverse signaling through the EFNB2/EPHB3 complex also regulate migration and adhesion of cells that tubularize the urethra and septate the cloaca. Finally, plays an important role in intestinal epithelium differentiation segregating progenitor from differentiated cells in the crypt. Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells.
T56121	PDBSTRUC	5L6P; 5L6O; 3ZFY; 3P1I
T56121	BIOCLASS	Kinase
T56121	ECNUMBER	EC 2.7.10.1
T56121	SEQUENCE	MARARPPPPPSPPPGLLPLLPPLLLLPLLLLPAGCRALEETLMDTKWVTSELAWTSHPESGWEEVSGYDEAMNPIRTYQVCNVRESSQNNWLRTGFIWRRDVQRVYVELKFTVRDCNSIPNIPGSCKETFNLFYYEADSDVASASSPFWMENPYVKVDTIAPDESFSRLDAGRVNTKVRSFGPLSKAGFYLAFQDQGACMSLISVRAFYKKCASTTAGFALFPETLTGAEPTSLVIAPGTCIPNAVEVSVPLKLYCNGDGEWMVPVGACTCATGHEPAAKESQCRPCPPGSYKAKQGEGPCLPCPPNSRTTSPAASICTCHNNFYRADSDSADSACTTVPSPPRGVISNVNETSLILEWSEPRDLGGRDDLLYNVICKKCHGAGGASACSRCDDNVEFVPRQLGLTERRVHISHLLAHTRYTFEVQAVNGVSGKSPLPPRYAAVNITTNQAAPSEVPTLRLHSSSGSSLTLSWAPPERPNGVILDYEMKYFEKSEGIASTVTSQMNSVQLDGLRPDARYVVQVRARTVAGYGQYSRPAEFETTSERGSGAQQLQEQLPLIVGSATAGLVFVVAVVVIAIVCLRKQRHGSDSEYTEKLQQYIAPGMKVYIDPFTYEDPNEAVREFAKEIDVSCVKIEEVIGAGEFGEVCRGRLKQPGRREVFVAIKTLKVGYTERQRRDFLSEASIMGQFDHPNIIRLEGVVTKSRPVMILTEFMENCALDSFLRLNDGQFTVIQLVGMLRGIAAGMKYLSEMNYVHRDLAARNILVNSNLVCKVSDFGLSRFLEDDPSDPTYTSSLGGKIPIRWTAPEAIAYRKFTSASDVWSYGIVMWEVMSYGERPYWDMSNQDVINAVEQDYRLPPPMDCPTALHQLMLDCWVRDRNLRPKFSQIVNTLDKLIRNAASLKVIASAQSGMSQPLLDRTVPDYTTFTTVGDWLDAIKMGRYKESFVSAGFASFDLVAQMTAEDLLRIGVTLAGHQKKILSSIQDMRLQMNQTLPVQV
T56121	DRUGINFO	D05FXD	PMID19788238C66	Investigative
T56121	DRUGINFO	D0X8BU	PMID23489211C20	Investigative

T18474	TARGETID	T18474
T18474	FORMERID	TTDI03176
T18474	UNIPROID	EPHA5_HUMAN
T18474	TARGNAME	Ephrin type-A receptor 5 (EPHA5)
T18474	GENENAME	EPHA5
T18474	TARGTYPE	Literature-reported
T18474	SYNONYMS	hEK7; EPH-like kinase 7; EPH homology kinase 1; EK7; EHK1; EHK-1; Brain-specific kinase; BSK
T18474	FUNCTION	The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Among GPI-anchored ephrin-A ligands, EFNA5 most probably constitutes the cognate/functional ligand for EPHA5. Functions as an axon guidance molecule during development and may be involved in the development of the retinotectal, entorhino-hippocampal and hippocamposeptal pathways. Together with EFNA5 plays also a role in synaptic plasticity in adult brain through regulation of synaptogenesis. In addition to its function in the nervous system, the interaction of EPHA5 with EFNA5 mediates communication between pancreatic islet cells to regulate glucose-stimulated insulin secretion. Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells.
T18474	PDBSTRUC	4ET7; 2R2P
T18474	BIOCLASS	Kinase
T18474	ECNUMBER	EC 2.7.10.1
T18474	SEQUENCE	MRGSGPRGAGRRRPPSGGGDTPITPASLAGCYSAPRRAPLWTCLLLCAALRTLLASPSNEVNLLDSRTVMGDLGWIAFPKNGWEEIGEVDENYAPIHTYQVCKVMEQNQNNWLLTSWISNEGASRIFIELKFTLRDCNSLPGGLGTCKETFNMYYFESDDQNGRNIKENQYIKIDTIAADESFTELDLGDRVMKLNTEVRDVGPLSKKGFYLAFQDVGACIALVSVRVYYKKCPSVVRHLAVFPDTITGADSSQLLEVSGSCVNHSVTDEPPKMHCSAEGEWLVPIGKCMCKAGYEEKNGTCQVCRPGFFKASPHIQSCGKCPPHSYTHEEASTSCVCEKDYFRRESDPPTMACTRPPSAPRNAISNVNETSVFLEWIPPADTGGRKDVSYYIACKKCNSHAGVCEECGGHVRYLPRQSGLKNTSVMMVDLLAHTNYTFEIEAVNGVSDLSPGARQYVSVNVTTNQAAPSPVTNVKKGKIAKNSISLSWQEPDRPNGIILEYEIKYFEKDQETSYTIIKSKETTITAEGLKPASVYVFQIRARTAAGYGVFSRRFEFETTPVFAASSDQSQIPVIAVSVTVGVILLAVVIGVLLSGSCCECGCGRASSLCAVAHPSLIWRCGYSKAKQDPEEEKMHFHNGHIKLPGVRTYIDPHTYEDPNQAVHEFAKEIEASCITIERVIGAGEFGEVCSGRLKLPGKRELPVAIKTLKVGYTEKQRRDFLGEASIMGQFDHPNIIHLEGVVTKSKPVMIVTEYMENGSLDTFLKKNDGQFTVIQLVGMLRGISAGMKYLSDMGYVHRDLAARNILINSNLVCKVSDFGLSRVLEDDPEAAYTTRGGKIPIRWTAPEAIAFRKFTSASDVWSYGIVMWEVVSYGERPYWEMTNQDVIKAVEEGYRLPSPMDCPAALYQLMLDCWQKERNSRPKFDEIVNMLDKLIRNPSSLKTLVNASCRVSNLLAEHSPLGSGAYRSVGEWLEAIKMGRYTEIFMENGYSSMDAVAQVTLEDLRRLGVTLVGHQKKIMNSLQEMKVQLVNGMVPL
T18474	DRUGINFO	D05FXD	PMID19788238C66	Investigative
T18474	DRUGINFO	D0X8BU	PMID23489211C20	Investigative

T02446	TARGETID	T02446
T02446	FORMERID	TTDI03180
T02446	UNIPROID	EPHB1_HUMAN
T02446	TARGNAME	Ephrin type-B receptor 1 (EPHB1)
T02446	GENENAME	EPHB1
T02446	TARGTYPE	Literature-reported
T02446	SYNONYMS	hEK6; Tyrosine-protein kinase receptor EPH-2; Neuronally-expressed EPH-related tyrosine kinase; EPHT2; EPH-like kinase 6; EPH tyrosine kinase 2; ELK; EK6
T02446	FUNCTION	The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Cognate/functional ephrin ligands for this receptor include EFNB1, EFNB2 and EFNB3. During nervous system development, regulates retinal axon guidance redirecting ipsilaterally ventrotemporal retinal ganglion cells axons at the optic chiasm midline. This probably requires repulsive interaction with EFNB2. In the adult nervous system together with EFNB3, regulates chemotaxis, proliferation and polarity of the hippocampus neural progenitors. In addition to its role in axon guidance plays also an important redundant role with other ephrin-B receptors in development and maturation of dendritic spines and synapse formation. May also regulate angiogenesis. More generally, may play a role in targeted cell migration and adhesion. Upon activation by EFNB1 and probably other ephrin-B ligands activates the MAPK/ERK and the JNK signaling cascades to regulate cell migration and adhesion respectively. Involved in the maintenance of the pool of satellite cells (muscle stem cells) by promoting their self-renewal and reducing their activation and differentiation. Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells.
T02446	PDBSTRUC	5MJB; 5MJA; 3ZFX; 2EAO; 2DJS
T02446	BIOCLASS	Kinase
T02446	ECNUMBER	EC 2.7.10.1
T02446	SEQUENCE	MALDYLLLLLLASAVAAMEETLMDTRTATAELGWTANPASGWEEVSGYDENLNTIRTYQVCNVFEPNQNNWLLTTFINRRGAHRIYTEMRFTVRDCSSLPNVPGSCKETFNLYYYETDSVIATKKSAFWSEAPYLKVDTIAADESFSQVDFGGRLMKVNTEVRSFGPLTRNGFYLAFQDYGACMSLLSVRVFFKKCPSIVQNFAVFPETMTGAESTSLVIARGTCIPNAEEVDVPIKLYCNGDGEWMVPIGRCTCKPGYEPENSVACKACPAGTFKASQEAEGCSHCPSNSRSPAEASPICTCRTGYYRADFDPPEVACTSVPSGPRNVISIVNETSIILEWHPPRETGGRDDVTYNIICKKCRADRRSCSRCDDNVEFVPRQLGLTECRVSISSLWAHTPYTFDIQAINGVSSKSPFPPQHVSVNITTNQAAPSTVPIMHQVSATMRSITLSWPQPEQPNGIILDYEIRYYEKEHNEFNSSMARSQTNTARIDGLRPGMVYVVQVRARTVAGYGKFSGKMCFQTLTDDDYKSELREQLPLIAGSAAAGVVFVVSLVAISIVCSRKRAYSKEAVYSDKLQHYSTGRGSPGMKIYIDPFTYEDPNEAVREFAKEIDVSFVKIEEVIGAGEFGEVYKGRLKLPGKREIYVAIKTLKAGYSEKQRRDFLSEASIMGQFDHPNIIRLEGVVTKSRPVMIITEFMENGALDSFLRQNDGQFTVIQLVGMLRGIAAGMKYLAEMNYVHRDLAARNILVNSNLVCKVSDFGLSRYLQDDTSDPTYTSSLGGKIPVRWTAPEAIAYRKFTSASDVWSYGIVMWEVMSFGERPYWDMSNQDVINAIEQDYRLPPPMDCPAALHQLMLDCWQKDRNSRPRFAEIVNTLDKMIRNPASLKTVATITAVPSQPLLDRSIPDFTAFTTVDDWLSAIKMVQYRDSFLTAGFTSLQLVTQMTSEDLLRIGITLAGHQKKILNSIHSMRVQISQSPTAMA
T02446	DRUGINFO	D05FXD	PMID19788238C66	Investigative
T02446	DRUGINFO	D0X8BU	PMID23489211C20	Investigative

T34337	TARGETID	T34337
T34337	FORMERID	TTDR01143
T34337	UNIPROID	UPPS_ECOLI
T34337	TARGNAME	Bacterial Undecaprenyl pyrophosphate synthetase (Bact ispU)
T34337	GENENAME	Bact ispU
T34337	TARGTYPE	Literature-reported
T34337	SYNONYMS	ispU; Undecaprenyl diphosphate synthase; Undecaprenyl diphosphate  synthase; UPP synthetase; UPP synthase; UDS; Di-trans-poly-cis-decaprenylcistransferase
T34337	FUNCTION	Generates ditrans,octacis-undecaprenyl pyrophosphate (UPP) from isopentenyl pyrophosphate (IPP) and farnesyl diphosphate (FPP). UPP is the precursor of glycosyl carrier lipid in the biosynthesis of bacterial cell wall polysaccharide components such as peptidoglycan and lipopolysaccharide.
T34337	PDBSTRUC	5ZHE; 5CQJ; 5CQB; 4H3C; 4H3A
T34337	BIOCLASS	Alkyl aryl transferase
T34337	ECNUMBER	EC 2.5.1.31
T34337	SEQUENCE	MMLSATQPLSEKLPAHGCRHVAIIMDGNGRWAKKQGKIRAFGHKAGAKSVRRAVSFAANNGIEALTLYAFSSENWNRPAQEVSALMELFVWALDSEVKSLHRHNVRLRIIGDTSRFNSRLQERIRKSEALTAGNTGLTLNIAANYGGRWDIVQGVRQLAEKVQQGNLQPDQIDEEMLNQHVCMHELAPVDLVIRTGGEHRISNFLLWQIAYAELYFTDVLWPDFDEQDFEGALNAFANRERRFGGTEPGDETA
T34337	DRUGINFO	D0Y1JB	E-pentenylbutanedioic acid 32	Investigative
T34337	DRUGINFO	D0J8KR	ISOPENTENYL PYROPHOSPHATE	Investigative

T10586	TARGETID	T10586
T10586	FORMERID	TTDI02118
T10586	UNIPROID	LYSC_HUMAN
T10586	TARGNAME	Lysozyme (LYZ)
T10586	GENENAME	LYZ
T10586	TARGTYPE	Literature-reported
T10586	SYNONYMS	Lysozyme C; LYZ; 1,4betaNacetylmuramidase C
T10586	FUNCTION	Lysozymes have primarily a bacteriolytic function; those intissues and body fluids are associated with the monocyte- macrophage system and enhance the activity of immunoagents.
T10586	PDBSTRUC	5LVK; 5LSH; 4R0P; 4ML7; 4I0C
T10586	BIOCLASS	Glycosylase
T10586	ECNUMBER	EC 3.2.1.17
T10586	SEQUENCE	MKALIVLGLVLLSVTVQGKVFERCELARTLKRLGMDGYRGISLANWMCLAKWESGYNTRATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACHLSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNRCQNRDVRQYVQGCGV

T93712	TARGETID	T93712
T93712	UNIPROID	RACK1_HUMAN
T93712	TARGNAME	Receptor of activated protein C kinase 1 (RACK1)
T93712	GENENAME	RACK1
T93712	TARGTYPE	Literature-reported
T93712	SYNONYMS	Small ribosomal subunit protein RACK1; Receptor of activated protein C kinase 1, N-terminally processed; Receptor for activated C kinase; Human lung cancer oncogene 7 protein; HLC-7; Guanine nucleotide-binding protein subunit beta-like protein 12.3; Guanine nucleotide-binding protein subunit beta-2-like 1, N-terminally processed; Guanine nucleotide-binding protein subunit beta-2-like 1; GNB2L1; Cell proliferation-inducing gene 21 protein
T93712	FUNCTION	Scaffolding protein involved in the recruitment, assembly and/or regulation of a variety of signaling molecules. Interacts with a wide variety of proteins and plays a role in many cellular processes. Component of the 40S ribosomal subunit involved in translational repression (PubMed:23636399). Involved in the initiation of the ribosome quality control (RQC), a pathway that takes place when a ribosome has stalled during translation, by promoting ubiquitination of a subset of 40S ribosomal subunits (PubMed:28132843). Binds to and stabilizes activated protein kinase C (PKC), increasing PKC-mediated phosphorylation. May recruit activated PKC to the ribosome, leading to phosphorylation of EIF6. Inhibits the activity of SRC kinases including SRC, LCK and YES1. Inhibits cell growth by prolonging the G0/G1 phase of the cell cycle. Enhances phosphorylation of BMAL1 by PRKCA and inhibits transcriptional activity of the BMAL1-CLOCK heterodimer. Facilitates ligand-independent nuclear translocation of AR following PKC activation, represses AR transactivation activity and is required for phosphorylation of AR by SRC. Modulates IGF1R-dependent integrin signaling and promotes cell spreading and contact with the extracellular matrix. Involved in PKC-dependent translocation of ADAM12 to the cell membrane. Promotes the ubiquitination and proteasome-mediated degradation of proteins such as CLEC1B and HIF1A. Required for VANGL2 membrane localization, inhibits Wnt signaling, and regulates cellular polarization and oriented cell division during gastrulation. Required for PTK2/FAK1 phosphorylation and dephosphorylation. Regulates internalization of the muscarinic receptor CHRM2. Promotes apoptosis by increasing oligomerization of BAX and disrupting the interaction of BAX with the anti-apoptotic factor BCL2L. Inhibits TRPM6 channel activity. Regulates cell surface expression of some GPCRs such as TBXA2R. Plays a role in regulation of FLT1-mediated cell migration. Involved in the transport of ABCB4 from the Golgi to the apical bile canalicular membrane (PubMed:19674157). Promotes migration of breast carcinoma cells by binding to and activating RHOA (PubMed:20499158).
T93712	PDBSTRUC	6QZP; 6G5I; 6G5H; 6G53; 6G51
T93712	BIOCLASS	WD repeat G protein beta family. Ribosomal protein RACK1 subfamily
T93712	SEQUENCE	MTEQMTLRGTLKGHNGWVTQIATTPQFPDMILSASRDKTIIMWKLTRDETNYGIPQRALRGHSHFVSDVVISSDGQFALSGSWDGTLRLWDLTTGTTTRRFVGHTKDVLSVAFSSDNRQIVSGSRDKTIKLWNTLGVCKYTVQDESHSEWVSCVRFSPNSSNPIIVSCGWDKLVKVWNLANCKLKTNHIGHTGYLNTVTVSPDGSLCASGGKDGQAMLWDLNEGKHLYTLDGGDIINALCFSPNRYWLCAATGPSIKIWDLEGKIIVDELKQEVISTSSKAEPPQCTSLAWSADGQTLFAGYTDNLVRVWQVTIGTR

T95761	TARGETID	T95761
T95761	FORMERID	TTDR00920
T95761	UNIPROID	ADAM8_HUMAN
T95761	TARGNAME	Cell surface antigen MS2 (ADAM8)
T95761	GENENAME	ADAM8
T95761	TARGTYPE	Literature-reported
T95761	SYNONYMS	CD156a antigen; CD156; ADAM8; A disintegrin and metalloproteinase domain 8
T95761	FUNCTION	Possible involvement in extravasation of leukocytes.
T95761	PDBSTRUC	4DD8
T95761	BIOCLASS	Peptidase
T95761	ECNUMBER	EC 3.4.24.-
T95761	SEQUENCE	MRGLGLWLLGAMMLPAIAPSRPWALMEQYEVVLPWRLPGPRVRRALPSHLGLHPERVSYVLGATGHNFTLHLRKNRDLLGSGYTETYTAANGSEVTEQPRGQDHCFYQGHVEGYPDSAASLSTCAGLRGFFQVGSDLHLIEPLDEGGEGGRHAVYQAEHLLQTAGTCGVSDDSLGSLLGPRTAAVFRPRPGDSLPSRETRYVELYVVVDNAEFQMLGSEAAVRHRVLEVVNHVDKLYQKLNFRVVLVGLEIWNSQDRFHVSPDPSVTLENLLTWQARQRTRRHLHDNVQLITGVDFTGTTVGFARVSAMCSHSSGAVNQDHSKNPVGVACTMAHEMGHNLGMDHDENVQGCRCQERFEAGRCIMAGSIGSSFPRMFSDCSQAYLESFLERPQSVCLANAPDLSHLVGGPVCGNLFVERGEQCDCGPPEDCRNRCCNSTTCQLAEGAQCAHGTCCQECKVKPAGELCRPKKDMCDLEEFCDGRHPECPEDAFQENGTPCSGGYCYNGACPTLAQQCQAFWGPGGQAAEESCFSYDILPGCKASRYRADMCGVLQCKGGQQPLGRAICIVDVCHALTTEDGTAYEPVPEGTRCGPEKVCWKGRCQDLHVYRSSNCSAQCHNHGVCNHKQECHCHAGWAPPHCAKLLTEVHAASGSLPVFVVVVLVLLAVVLVTLAGIIVYRKARSRILSRNVAPKTTMGRSNPLFHQAASRVPAKGGAPAPSRGPQELVPTTHPGQPARHPASSVALKRPPPAPPVTVSSPPFPVPVYTRQAPKQVIKPTFAPPVPPVKPGAGAANPGPAEGAVGPKVALKPPIQRKQGAGAPTAP

T58924	TARGETID	T58924
T58924	FORMERID	TTDI03561
T58924	UNIPROID	SRPK2_HUMAN
T58924	TARGNAME	SRSF protein kinase 2 (SRPK2)
T58924	GENENAME	SRPK2
T58924	TARGTYPE	Literature-reported
T58924	SYNONYMS	Serine/arginine-rich protein-specific kinase 2; SR-protein-specific kinase 2; SFRS protein kinase 2
T58924	FUNCTION	Promotes neuronal apoptosis by up-regulating cyclin-D1 (CCND1) expression. This is done by the phosphorylation of SRSF2, leading to the suppression of p53/TP53 phosphorylation thereby relieving the repressive effect of p53/TP53 on cyclin-D1 (CCND1) expression. Phosphorylates ACIN1, and redistributes it from the nuclear speckles to the nucleoplasm, resulting in cyclin A1 but not cyclin A2 up-regulation. Plays an essential role in spliceosomal B complex formation via the phosphorylation of DDX23/PRP28. Can mediate hepatitis B virus (HBV) core protein phosphorylation. Plays a negative role in the regulation of HBV replication through a mechanism not involving the phosphorylation of the core protein but by reducing the packaging efficiency of the pregenomic RNA (pgRNA) without affecting the formation of the viral core particles. Serine/arginine-rich protein-specific kinase which specifically phosphorylates its substrates at serine residues located in regions rich in arginine/serine dipeptides, known as RS domains and is involved in the phosphorylation of SR splicing factors and the regulation of splicing.
T58924	PDBSTRUC	5MYV; 2X7G
T58924	BIOCLASS	Kinase
T58924	ECNUMBER	EC 2.7.11.1
T58924	SEQUENCE	MSVNSEKSSSSERPEPQQKAPLVPPPPPPPPPPPPPLPDPTPPEPEEEILGSDDEEQEDPADYCKGGYHPVKIGDLFNGRYHVIRKLGWGHFSTVWLCWDMQGKRFVAMKVVKSAQHYTETALDEIKLLKCVRESDPSDPNKDMVVQLIDDFKISGMNGIHVCMVFEVLGHHLLKWIIKSNYQGLPVRCVKSIIRQVLQGLDYLHSKCKIIHTDIKPENILMCVDDAYVRRMAAEATEWQKAGAPPPSGSAVSTAPQQKPIGKISKNKKKKLKKKQKRQAELLEKRLQEIEELEREAERKIIEENITSAAPSNDQDGEYCPEVKLKTTGLEEAAEAETAKDNGEAEDQEEKEDAEKENIEKDEDDVDQELANIDPTWIESPKTNGHIENGPFSLEQQLDDEDDDEEDCPNPEEYNLDEPNAESDYTYSSSYEQFNGELPNGRHKIPESQFPEFSTSLFSGSLEPVACGSVLSEGSPLTEQEESSPSHDRSRTVSASSTGDLPKAKTRAADLLVNPLDPRNADKIRVKIADLGNACWVHKHFTEDIQTRQYRSIEVLIGAGYSTPADIWSTACMAFELATGDYLFEPHSGEDYSRDEDHIAHIIELLGSIPRHFALSGKYSREFFNRRGELRHITKLKPWSLFDVLVEKYGWPHEDAAQFTDFLIPMLEMVPEKRASAGECLRHPWLNS
T58924	DRUGINFO	D07ADX	URMC-099	Investigative

T82773	TARGETID	T82773
T82773	FORMERID	TTDI03083
T82773	UNIPROID	KC1G2_HUMAN
T82773	TARGNAME	Casein kinase I gamma-2 (CSNK1G2)
T82773	GENENAME	CSNK1G2
T82773	TARGTYPE	Literature-reported
T82773	SYNONYMS	Casein kinase I isoform gamma-2; CKI-gamma 2; CK1G2
T82773	FUNCTION	Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. It can phosphorylate a large number of proteins. Participates in Wnt signaling. Phosphorylates COL4A3BP/CERT, MTA1 and SMAD3. Involved in brain development and vesicular trafficking and neurotransmitter releasing from small synaptic vesicles. Regulates fast synaptic transmission mediated by glutamate. SMAD3 phosphorylation promotes its ligand-dependent ubiquitination and subsequent proteasome degradation, thus inhibiting SMAD3-mediated TGF-beta responses. Hyperphosphorylation of the serine-repeat motif of COL4A3BP/CERT leads to its inactivation by dissociation from the Golgi complex, thus down-regulating ER-to-Golgi transport of ceramide and sphingomyelin synthesis. Triggers PER1 proteasomal degradation probably through phosphorylation. Serine/threonine-protein kinase.
T82773	PDBSTRUC	2C47
T82773	BIOCLASS	Kinase
T82773	ECNUMBER	EC 2.7.11.1
T82773	SEQUENCE	MDFDKKGGKGETEEGRRMSKAGGGRSSHGIRSSGTSSGVLMVGPNFRVGKKIGCGNFGELRLGKNLYTNEYVAIKLEPIKSRAPQLHLEYRFYKQLSATEGVPQVYYFGPCGKYNAMVLELLGPSLEDLFDLCDRTFTLKTVLMIAIQLITRMEYVHTKSLIYRDVKPENFLVGRPGTKRQHAIHIIDFGLAKEYIDPETKKHIPYREHKSLTGTARYMSINTHLGKEQSRRDDLEALGHMFMYFLRGSLPWQGLKADTLKERYQKIGDTKRATPIEVLCENFPEEMATYLRYVRRLDFFEKPDYDYLRKLFTDLFDRSGFVFDYEYDWAGKPLPTPIGTVHTDLPSQPQLRDKTQPHSKNQALNSTNGELNADDPTAGHSNAPITAPAEVEVADETKCCCFFKRRKRKSLQRHK
T82773	DRUGINFO	D0H4VB	PMID24900428C14	Investigative

T08218	TARGETID	T08218
T08218	FORMERID	TTDR00023
T08218	UNIPROID	RMLC_MYCTU
T08218	TARGNAME	Mycobacterium DTDP-dehydrorhamnose epimerase rmlC (MycB rmlC)
T08218	GENENAME	MycB rmlC
T08218	TARGTYPE	Literature-reported
T08218	SYNONYMS	dTDP-L-rhamnose synthase; dTDP-6-deoxy-D-xylo-4-hexulose 3,5-epimerase; dTDP-4-keto-6-deoxyglucose 3,5-epimerase; dTDP-4-dehydrorhamnose 3,5-epimerase; Thymidine diphospho-4-keto-rhamnose 3,5-epimerase
T08218	FUNCTION	Catalyzes the epimerization of the C3' and C5'positions of dTDP-6-deoxy-D-xylo-4-hexulose, forming dTDP-6-deoxy-L-lyxo-4-hexulose. Involved in the biosynthesis of the dTDP-L-rhamnose which is a component of the critical linker, D-N-acetylglucosamine-L-rhamnose disaccharide, which connects the galactan region of arabinogalactan to peptidoglycan via a phosphodiester linkage.
T08218	PDBSTRUC	2IXC; 1UPI; 1PM7
T08218	BIOCLASS	Racemases and epimerases
T08218	ECNUMBER	EC 5.1.3.13
T08218	SEQUENCE	MKARELDVPGAWEITPTIHVDSRGLFFEWLTDHGFRAFAGHSLDVRQVNCSVSSAGVLRGLHFAQLPPSQAKYVTCVSGSVFDVVVDIREGSPTFGRWDSVLLDDQDRRTIYVSEGLAHGFLALQDNSTVMYLCSAEYNPQREHTICATDPTLAVDWPLVDGAAPSLSDRDAAAPSFEDVRASGLLPRWEQTQRFIGEMRGT
T08218	DRUGINFO	D0P7JE	S,S-(2-Hydroxyethyl)Thiocysteine	Investigative

T81015	TARGETID	T81015
T81015	FORMERID	TTDR01089
T81015	UNIPROID	PYRF_MYCTO
T81015	TARGNAME	Mycobacterium Orotidine phosphate decarboxylase (MycB pyrF)
T81015	GENENAME	MycB pyrF
T81015	TARGTYPE	Literature-reported
T81015	SYNONYMS	Orotidine 5'-phosphate decarboxylase; OMPdecase; OMPDCase; OMP decarboxylase
T81015	FUNCTION	Catalyzes the decarboxylation of orotidine monophosphate (OMP), producing uridine monophosphate (UMP).
T81015	BIOCLASS	Carbon-carbon lyase
T81015	ECNUMBER	EC 4.1.1.23
T81015	SEQUENCE	MTGFGLRLAEAKARRGPLCLGIDPHPELLRGWDLATTADGLAAFCDICVRAFADFAVVKPQVAFFESYGAAGFAVLERTIAELRAADVLVLADAKRGDIGATMSAYATAWVGDSPLAADAVTASPYLGFGSLRPLLEVAAAHGRGVFVLAATSNPEGAAVQNAAADGRSVAQLVVDQVGAANEAAGPGPGSIGVVVGATAPQAPDLSAFTGPVLVPGVGVQGGRPEALGGLGGAASSQLLPAVAREVLRAGPGVPELRAAGERMRDAVAYLAAV
T81015	DRUGINFO	D03GVL	6-aza-uridine monophosphate	Investigative
T81015	DRUGINFO	D0ST0H	Xanthosine-5'-monophosphate disodium salt	Investigative
T81015	DRUGINFO	D0W3ZW	6-amino-uridine monophosphate	Investigative
T81015	DRUGINFO	D0H9DJ	Uridine-5'-Monophosphate	Investigative
T81015	DRUGINFO	D0P0EP	6-Hydroxyuridine-5'-Phosphate	Investigative

T63851	TARGETID	T63851
T63851	FORMERID	TTDI03147
T63851	UNIPROID	CDKL1_HUMAN
T63851	TARGNAME	Cyclin-dependent kinase-like 1 (CDKL1)
T63851	GENENAME	CDKL1
T63851	TARGTYPE	Literature-reported
T63851	SYNONYMS	Serine/threonine-protein kinase KKIALRE; Protein kinase p42 KKIALRE
T63851	FUNCTION	Ciliary transition zone, extracellular exosome, intracellular membrane-bounded organelle, nucleoplasm, nucleus, cyclin-dependent protein serine/threonine kinase activity, protein phosphorylation, regulation of cilium assembly.
T63851	PDBSTRUC	4AGU
T63851	BIOCLASS	Kinase
T63851	ECNUMBER	EC 2.7.11.22
T63851	SEQUENCE	MMEKYEKIGKIGEGSYGVVFKCRNRDTGQIVAIKKFLESEDDPVIKKIALREIRMLKQLKHPNLVNLLEVFRRKRRLHLVFEYCDHTVLHELDRYQRGVPEHLVKSITWQTLQAVNFCHKHNCIHRDVKPENILITKHSVIKLCDFGFARLLAGPSDYYTDYVATRWYRSPELLVGDTQYGPPVDVWAIGCVFAELLSGVPLWPGKSDVDQLYLIRKTLGDLIPRHQQVFSTNQYFSGVKIPDPEDMEPLELKFPNISYPALGLLKGCLHMDPTQRLTCEQLLHHPYFENIREIEDLAKEHNKPTRKTLRKSRKHHCFTETSKLQYLPQLTGSSILPALDNKKYYCDTKKLNYRFPNI
T63851	DRUGINFO	D0P6JS	PMID18986805C9b	Investigative

T53489	TARGETID	T53489
T53489	FORMERID	TTDR01230
T53489	UNIPROID	CYB_PLAFA
T53489	TARGNAME	Plasmodium Cytochrome B (Malaria MT-CYB)
T53489	GENENAME	Malaria MT-CYB
T53489	TARGTYPE	Literature-reported
T53489	SYNONYMS	MT-CYB; Cyb
T53489	FUNCTION	Component of the ubiquinol-cytochrome c reductase complex (complex III or cytochrome b-c1 complex), which is a respiratory chain that generates an electrochemical potential coupled to ATP synthesis.
T53489	BIOCLASS	Cytochrome b family
T53489	SEQUENCE	MNFYSINLVKAHLINYPCPLNINFLWNYGFLLGIIFFIQIITGVFLASRYTPDVSYAYYSIQHILRELWSGWCFRYMHATGASLVFLLTYLHILRGLNYSYMYLPLSWISGLILFMIFIVTAFVGYVLPWGQMSYWGATVITNLLSSIPVAVIWICGGYTVSDPTIKRFFVLHFILPFIGLCIVFIHIFFLHLHGSTNPLGYDTALKIPFYPNLLSLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVVNTYVTPSQIVPEWYFLPFYAMLKTVPSKPAGLVIVLLSLQLLFLLAEQRSLTTIIQFKMIFGARDYSVPIIWFMCAFYALLWIGCQLPQDIFILYGRLFIVLFFCSGLFVLVHYRRTHYDYSSQANI
T53489	DRUGINFO	D0C3YJ	UBIQUINONE-2	Investigative
T53489	DRUGINFO	D0N7NB	5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole	Investigative
T53489	DRUGINFO	D0O1FU	FAMOXADONE	Investigative
T53489	DRUGINFO	D0X4DY	2-NONYL-4-HYDROXYQUINOLINE N-OXIDE	Investigative
T53489	DRUGINFO	D0YF6S	5-heptyl-6-hydroxy-1,3-benzothiazole-4,7-dione	Investigative
T53489	DRUGINFO	D01ILH	B-2-Octylglucoside	Investigative
T53489	DRUGINFO	D02UVH	B-Octylglucoside	Investigative

T87020	TARGETID	T87020
T87020	FORMERID	TTDR01039
T87020	UNIPROID	FKBP4_HUMAN
T87020	TARGNAME	FK506-binding protein 4 (FKBP4)
T87020	GENENAME	FKBP4
T87020	TARGTYPE	Literature-reported
T87020	SYNONYMS	p59; Peptidyl-prolyl cis-trans isomerase FKBP4; PPIase FKBP4; P59 protein; Immunophilin FKBP52; HSP-binding immunophilin; HSP binding immunophilin; HBI; FKBP59; FKBP52 protein; FKBP52; FKBP-52; FKBP-4; 59 kDa immunophilin; 52 kDa FKBP; 52 kDa FK506-binding protein; 52 kDa FK506 binding protein
T87020	FUNCTION	Component of steroid receptors heterocomplexes through interaction with heat-shock protein 90 (HSP90). May play a role in the intracellular trafficking of heterooligomeric forms of steroid hormone receptors between cytoplasm and nuclear compartments. The isomerase activity controls neuronal growth cones via regulation of TRPC1 channel opening. Acts also as a regulator of microtubule dynamics by inhibiting MAPT/TAU ability to promote microtubule assembly. May have a protective role against oxidative stress in mitochondria. Immunophilin protein with PPIase and co-chaperone activities.
T87020	PDBSTRUC	4TW8; 4LAY; 4LAX; 4LAW; 4LAV
T87020	BIOCLASS	Cis-trans-isomerase
T87020	ECNUMBER	EC 5.2.1.8
T87020	SEQUENCE	MTAEEMKATESGAQSAPLPMEGVDISPKQDEGVLKVIKREGTGTEMPMIGDRVFVHYTGWLLDGTKFDSSLDRKDKFSFDLGKGEVIKAWDIAIATMKVGEVCHITCKPEYAYGSAGSPPKIPPNATLVFEVELFEFKGEDLTEEEDGGIIRRIQTRGEGYAKPNEGAIVEVALEGYYKDKLFDQRELRFEIGEGENLDLPYGLERAIQRMEKGEHSIVYLKPSYAFGSVGKEKFQIPPNAELKYELHLKSFEKAKESWEMNSEEKLEQSTIVKERGTVYFKEGKYKQALLQYKKIVSWLEYESSFSNEEAQKAQALRLASHLNLAMCHLKLQAFSAAIESCNKALELDSNNEKGLFRRGEAHLAVNDFELARADFQKVLQLYPNNKAAKTQLAVCQQRIRRQLAREKKLYANMFERLAEEENKAKAEASSGDHPTDTEMKEEQKSNTAGSQSQVETEA

T25462	TARGETID	T25462
T25462	FORMERID	TTDI00064
T25462	UNIPROID	KMT2A_HUMAN
T25462	TARGNAME	Mixed-lineage leukemia protein (MLL)
T25462	GENENAME	KMT2A
T25462	TARGTYPE	Literature-reported
T25462	SYNONYMS	p320; p180; Zinc finger protein HRX; Trithoraxlike protein; Trithorax-like protein; Myeloid/lymphoid or mixed-lineage leukemia protein 1; Myeloid/lymphoid or mixed-lineage leukemia; MLL1; MLL cleavage product C180; Lysine Nmethyltransferase 2A; Lysine N-methyltransferase 2A; Histonelysine Nmethyltransferase MLL; Histone-lysine N-methyltransferase 2A; HTRX; HRX; CXXCtype zinc finger protein 7; CXXC7; CXXC-type zinc finger protein 7; ALL1; ALL-1
T25462	FUNCTION	Catalytic subunit of the MLL1/MLL complex, a multiprotein complex that mediates both methylation of 'Lys-4' of histone H3 (H3K4me) complex and acetylation of 'Lys-16' of histone H4 (H4K16ac). In the MLL1/MLL complex, it specifically mediates H3K4me, a specific tag for epigenetic transcriptional activation. Has weak methyltransferase activity by itself, and requires other component of the MLL1/MLL complex to obtain full methyltransferase activity. Has no activity toward histone H3 phosphorylated on 'Thr-3', less activity toward H3 dimethylated on 'Arg-8' or 'Lys-9', while it has higher activity toward H3 acetylated on 'Lys-9'. Binds to unmethylated CpG elements in the promoter of target genes and helps maintain them in the nonmethylated state. Required for transcriptional activation of HOXA9. Promotes PPP1R15A-induced apoptosis. Plays a critical role in the control of circadian gene expression and is essential for the transcriptional activation mediated by the CLOCK-ARNTL/BMAL1 heterodimer. Establishes a permissive chromatin state for circadian transcription by mediating a rhythmic methylation of 'Lys-4' of histone H3 (H3K4me) and this histone modification directs the circadian acetylation at H3K9 and H3K14 allowing the recruitment of CLOCK-ARNTL/BMAL1 to chromatin. Histone methyltransferase that plays an essential role in early development and hematopoiesis.
T25462	PDBSTRUC	6EMQ; 5SVH; 5F6L; 5F5E; 4NW3
T25462	BIOCLASS	Methyltransferase
T25462	ECNUMBER	EC 2.1.1.43
T25462	SEQUENCE	MAHSCRWRFPARPGTTGGGGGGGRRGLGGAPRQRVPALLLPPGPPVGGGGPGAPPSPPAVAAAAAAAGSSGAGVPGGAAAASAASSSSASSSSSSSSSASSGPALLRVGPGFDAALQVSAAIGTNLRRFRAVFGESGGGGGSGEDEQFLGFGSDEEVRVRSPTRSPSVKTSPRKPRGRPRSGSDRNSAILSDPSVFSPLNKSETKSGDKIKKKDSKSIEKKRGRPPTFPGVKIKITHGKDISELPKGNKEDSLKKIKRTPSATFQQATKIKKLRAGKLSPLKSKFKTGKLQIGRKGVQIVRRRGRPPSTERIKTPSGLLINSELEKPQKVRKDKEGTPPLTKEDKTVVRQSPRRIKPVRIIPSSKRTDATIAKQLLQRAKKGAQKKIEKEAAQLQGRKVKTQVKNIRQFIMPVVSAISSRIIKTPRRFIEDEDYDPPIKIARLESTPNSRFSAPSCGSSEKSSAASQHSSQMSSDSSRSSSPSVDTSTDSQASEEIQVLPEERSDTPEVHPPLPISQSPENESNDRRSRRYSVSERSFGSRTTKKLSTLQSAPQQQTSSSPPPPLLTPPPPLQPASSISDHTPWLMPPTIPLASPFLPASTAPMQGKRKSILREPTFRWTSLKHSRSEPQYFSSAKYAKEGLIRKPIFDNFRPPPLTPEDVGFASGFSASGTAASARLFSPLHSGTRFDMHKRSPLLRAPRFTPSEAHSRIFESVTLPSNRTSAGTSSSGVSNRKRKRKVFSPIRSEPRSPSHSMRTRSGRLSSSELSPLTPPSSVSSSLSISVSPLATSALNPTFTFPSHSLTQSGESAEKNQRPRKQTSAPAEPFSSSSPTPLFPWFTPGSQTERGRNKDKAPEELSKDRDADKSVEKDKSRERDREREKENKRESRKEKRKKGSEIQSSSALYPVGRVSKEKVVGEDVATSSSAKKATGRKKSSSHDSGTDITSVTLGDTTAVKTKILIKKGRGNLEKTNLDLGPTAPSLEKEKTLCLSTPSSSTVKHSTSSIGSMLAQADKLPMTDKRVASLLKKAKAQLCKIEKSKSLKQTDQPKAQGQESDSSETSVRGPRIKHVCRRAAVALGRKRAVFPDDMPTLSALPWEEREKILSSMGNDDKSSIAGSEDAEPLAPPIKPIKPVTRNKAPQEPPVKKGRRSRRCGQCPGCQVPEDCGVCTNCLDKPKFGGRNIKKQCCKMRKCQNLQWMPSKAYLQKQAKAVKKKEKKSKTSEKKDSKESSVVKNVVDSSQKPTPSAREDPAPKKSSSEPPPRKPVEEKSEEGNVSAPGPESKQATTPASRKSSKQVSQPALVIPPQPPTTGPPRKEVPKTTPSEPKKKQPPPPESGPEQSKQKKVAPRPSIPVKQKPKEKEKPPPVNKQENAGTLNILSTLSNGNSSKQKIPADGVHRIRVDFKEDCEAENVWEMGGLGILTSVPITPRVVCFLCASSGHVEFVYCQVCCEPFHKFCLEENERPLEDQLENWCCRRCKFCHVCGRQHQATKQLLECNKCRNSYHPECLGPNYPTKPTKKKKVWICTKCVRCKSCGSTTPGKGWDAQWSHDFSLCHDCAKLFAKGNFCPLCDKCYDDDDYESKMMQCGKCDRWVHSKCENLSDEMYEILSNLPESVAYTCVNCTERHPAEWRLALEKELQISLKQVLTALLNSRTTSHLLRYRQAAKPPDLNPETEESIPSRSSPEGPDPPVLTEVSKQDDQQPLDLEGVKRKMDQGNYTSVLEFSDDIVKIIQAAINSDGGQPEIKKANSMVKSFFIRQMERVFPWFSVKKSRFWEPNKVSSNSGMLPNAVLPPSLDHNYAQWQEREENSHTEQPPLMKKIIPAPKPKGPGEPDSPTPLHPPTPPILSTDRSREDSPELNPPPGIEDNRQCALCLTYGDDSANDAGRLLYIGQNEWTHVNCALWSAEVFEDDDGSLKNVHMAVIRGKQLRCEFCQKPGATVGCCLTSCTSNYHFMCSRAKNCVFLDDKKVYCQRHRDLIKGEVVPENGFEVFRRVFVDFEGISLRRKFLNGLEPENIHMMIGSMTIDCLGILNDLSDCEDKLFPIGYQCSRVYWSTTDARKRCVYTCKIVECRPPVVEPDINSTVEHDENRTIAHSPTSFTESSSKESQNTAEIISPPSPDRPPHSQTSGSCYYHVISKVPRIRTPSYSPTQRSPGCRPLPSAGSPTPTTHEIVTVGDPLLSSGLRSIGSRRHSTSSLSPQRSKLRIMSPMRTGNTYSRNNVSSVSTTGTATDLESSAKVVDHVLGPLNSSTSLGQNTSTSSNLQRTVVTVGNKNSHLDGSSSSEMKQSSASDLVSKSSSLKGEKTKVLSSKSSEGSAHNVAYPGIPKLAPQVHNTTSRELNVSKIGSFAEPSSVSFSSKEALSFPHLHLRGQRNDRDQHTDSTQSANSSPDEDTEVKTLKLSGMSNRSSIINEHMGSSSRDRRQKGKKSCKETFKEKHSSKSFLEPGQVTTGEEGNLKPEFMDEVLTPEYMGQRPCNNVSSDKIGDKGLSMPGVPKAPPMQVEGSAKELQAPRKRTVKVTLTPLKMENESQSKNALKESSPASPLQIESTSPTEPISASENPGDGPVAQPSPNNTSCQDSQSNNYQNLPVQDRNLMLPDGPKPQEDGSFKRRYPRRSARARSNMFFGLTPLYGVRSYGEEDIPFYSSSTGKKRGKRSAEGQVDGADDLSTSDEDDLYYYNFTRTVISSGGEERLASHNLFREEEQCDLPKISQLDGVDDGTESDTSVTATTRKSSQIPKRNGKENGTENLKIDRPEDAGEKEHVTKSSVGHKNEPKMDNCHSVSRVKTQGQDSLEAQLSSLESSRRVHTSTPSDKNLLDTYNTELLKSDSDNNNSDDCGNILPSDIMDFVLKNTPSMQALGESPESSSSELLNLGEGLGLDSNREKDMGLFEVFSQQLPTTEPVDSSVSSSISAEEQFELPLELPSDLSVLTTRSPTVPSQNPSRLAVISDSGEKRVTITEKSVASSESDPALLSPGVDPTPEGHMTPDHFIQGHMDADHISSPPCGSVEQGHGNNQDLTRNSSTPGLQVPVSPTVPIQNQKYVPNSTDSPGPSQISNAAVQTTPPHLKPATEKLIVVNQNMQPLYVLQTLPNGVTQKIQLTSSVSSTPSVMETNTSVLGPMGGGLTLTTGLNPSLPTSQSLFPSASKGLLPMSHHQHLHSFPAATQSSFPPNISNPPSGLLIGVQPPPDPQLLVSESSQRTDLSTTVATPSSGLKKRPISRLQTRKNKKLAPSSTPSNIAPSDVVSNMTLINFTPSQLPNHPSLLDLGSLNTSSHRTVPNIIKRSKSSIMYFEPAPLLPQSVGGTAATAAGTSTISQDTSHLTSGSVSGLASSSSVLNVVSMQTTTTPTSSASVPGHVTLTNPRLLGTPDIGSISNLLIKASQQSLGIQDQPVALPPSSGMFPQLGTSQTPSTAAITAASSICVLPSTQTTGITAASPSGEADEHYQLQHVNQLLASKTGIHSSQRDLDSASGPQVSNFTQTVDAPNSMGLEQNKALSSAVQASPTSPGGSPSSPSSGQRSASPSVPGPTKPKPKTKRFQLPLDKGNGKKHKVSHLRTSSSEAHIPDQETTSLTSGTGTPGAEAEQQDTASVEQSSQKECGQPAGQVAVLPEVQVTQNPANEQESAEPKTVEEEESNFSSPLMLWLQQEQKRKESITEKKPKKGLVFEISSDDGFQICAESIEDAWKSLTDKVQEARSNARLKQLSFAGVNGLRMLGILHDAVVFLIEQLSGAKHCRNYKFRFHKPEEANEPPLNPHGSARAEVHLRKSAFDMFNFLASKHRQPPEYNPNDEEEEEVQLKSARRATSMDLPMPMRFRHLKKTSKEAVGVYRSPIHGRGLFCKRNIDAGEMVIEYAGNVIRSIQTDKREKYYDSKGIGCYMFRIDDSEVVDATMHGNAARFINHSCEPNCYSRVINIDGQKHIVIFAMRKIYRGEELTYDYKFPIEDASNKLPCNCGAKKCRKFLN

T03453	TARGETID	T03453
T03453	FORMERID	TTDI03372
T03453	UNIPROID	KIME_HUMAN
T03453	TARGNAME	Mevalonate kinase (MVK)
T03453	GENENAME	MVK
T03453	TARGTYPE	Literature-reported
T03453	SYNONYMS	POROK3; MVLK; LRBP
T03453	FUNCTION	Catalyzes the phosphorylation of mevalonate to mevalonate 5-phosphate, a key step in isoprenoid and cholesterol biosynthesis.
T03453	PDBSTRUC	2R3V
T03453	BIOCLASS	Kinase
T03453	ECNUMBER	EC 2.7.1.36
T03453	SEQUENCE	MLSEVLLVSAPGKVILHGEHAVVHGKVALAVSLNLRTFLRLQPHSNGKVDLSLPNIGIKRAWDVARLQSLDTSFLEQGDVTTPTSEQVEKLKEVAGLPDDCAVTERLAVLAFLYLYLSICRKQRALPSLDIVVWSELPPGAGLGSSAAYSVCLAAALLTVCEEIPNPLKDGDCVNRWTKEDLELINKWAFQGERMIHGNPSGVDNAVSTWGGALRYHQGKISSLKRSPALQILLTNTKVPRNTRALVAGVRNRLLKFPEIVAPLLTSIDAISLECERVLGEMGEAPAPEQYLVLEELIDMNQHHLNALGVGHASLDQLCQVTRARGLHSKLTGAGGGGCGITLLKPGLEQPEVEATKQALTSCGFDCLETSIGAPGVSIHSATSLDSRVQQALDGL
T03453	DRUGINFO	D0A5IX	(RS)-5-diphosphomevalonate	Investigative
T03453	DRUGINFO	D0P9IA	dolichol phosphate	Investigative

T38584	TARGETID	T38584
T38584	FORMERID	TTDI02483
T38584	UNIPROID	HGFA_HUMAN
T38584	TARGNAME	Hepatocyte growth factor activator (HGFAC)
T38584	GENENAME	HGFAC
T38584	TARGTYPE	Literature-reported
T38584	SYNONYMS	Hepatocyte growth factor activator long chain; HGFAC; HGFA; HGF activator
T38584	FUNCTION	Activates hepatocyte growth factor (HGF) by convertingit from a single chain to a heterodimeric form.
T38584	PDBSTRUC	3K2U; 2WUC; 2WUB; 2R0L; 2R0K
T38584	BIOCLASS	Peptidase
T38584	ECNUMBER	EC 3.4.21.-
T38584	SEQUENCE	MGRWAWVPSPWPPPGLGPFLLLLLLLLLLPRGFQPQPGGNRTESPEPNATATPAIPTILVTSVTSETPATSAPEAEGPQSGGLPPPPRAVPSSSSPQAQALTEDGRPCRFPFRYGGRMLHACTSEGSAHRKWCATTHNYDRDRAWGYCVEATPPPGGPAALDPCASGPCLNGGSCSNTQDPQSYHCSCPRAFTGKDCGTEKCFDETRYEYLEGGDRWARVRQGHVEQCECFGGRTWCEGTRHTACLSSPCLNGGTCHLIVATGTTVCACPPGFAGRLCNIEPDERCFLGNGTGYRGVASTSASGLSCLAWNSDLLYQELHVDSVGAAALLGLGPHAYCRNPDNDERPWCYVVKDSALSWEYCRLEACESLTRVQLSPDLLATLPEPASPGRQACGRRHKKRTFLRPRIIGGSSSLPGSHPWLAAIYIGDSFCAGSLVHTCWVVSAAHCFSHSPPRDSVSVVLGQHFFNRTTDVTQTFGIEKYIPYTLYSVFNPSDHDLVLIRLKKKGDRCATRSQFVQPICLPEPGSTFPAGHKCQIAGWGHLDENVSGYSSSLREALVPLVADHKCSSPEVYGADISPNMLCAGYFDCKSDACQGDSGGPLACEKNGVAYLYGIISWGDGCGRLHKPGVYTRVANYVDWINDRIRPPRRLVAPS

T87376	TARGETID	T87376
T87376	FORMERID	TTDR00905
T87376	UNIPROID	UBE3A_HUMAN
T87376	TARGNAME	Renal carcinoma antigen NY-REN-54 (UBE3A)
T87376	GENENAME	UBE3A
T87376	TARGTYPE	Literature-reported
T87376	SYNONYMS	Ubiquitin-protein ligase E3A; Oncogenic protein-associated protein E6-AP; Human papillomavirus E6-associated protein; HPVE6A; HECT-type ubiquitin transferase E3A; EPVE6AP; E6AP ubiquitin-protein ligase; E6AP
T87376	FUNCTION	Several substrates have been identified including the ARNTL/BMAL1, ARC, RAD23A and RAD23B, MCM7 (which is involved in DNA replication), annexin A1, the PML tumor suppressor, and the cell cycle regulator CDKN1B. Additionally, may function as a cellular quality control ubiquitin ligase by helping the degradation of the cytoplasmic misfolded proteins. Finally, UBE3A also promotes its own degradation in vivo. Plays an important role in the regulation of the circadian clock: involved in the ubiquitination of the core clock component ARNTL/BMAL1, leading to its proteasomal degradation. Acts as transcriptional coactivator of progesterone receptor PGR upon progesterone hormone activation. Acts as a regulator of synaptic development by mediating ubiquitination and degradation of ARC. Synergizes with WBP2 in enhancing PGR activity. E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and transfers it to its substrates.
T87376	PDBSTRUC	4XR8; 4GIZ; 2KR1; 1EQX; 1D5F
T87376	BIOCLASS	Acyltransferase
T87376	ECNUMBER	EC 2.3.2.26
T87376	SEQUENCE	MEKLHQCYWKSGEPQSDDIEASRMKRAAAKHLIERYYHQLTEGCGNEACTNEFCASCPTFLRMDNNAAAIKALELYKINAKLCDPHPSKKGASSAYLENSKGAPNNSCSEIKMNKKGARIDFKDVTYLTEEKVYEILELCREREDYSPLIRVIGRVFSSAEALVQSFRKVKQHTKEELKSLQAKDEDKDEDEKEKAACSAAAMEEDSEASSSRIGDSSQGDNNLQKLGPDDVSVDIDAIRRVYTRLLSNEKIETAFLNALVYLSPNVECDLTYHNVYSRDPNYLNLFIIVMENRNLHSPEYLEMALPLFCKAMSKLPLAAQGKLIRLWSKYNADQIRRMMETFQQLITYKVISNEFNSRNLVNDDDAIVAASKCLKMVYYANVVGGEVDTNHNEEDDEEPIPESSELTLQELLGEERRNKKGPRVDPLETELGVKTLDCRKPLIPFEEFINEPLNEVLEMDKDYTFFKVETENKFSFMTCPFILNAVTKNLGLYYDNRIRMYSERRITVLYSLVQGQQLNPYLRLKVRRDHIIDDALVRLEMIAMENPADLKKQLYVEFEGEQGVDEGGVSKEFFQLVVEEIFNPDIGMFTYDESTKLFWFNPSSFETEGQFTLIGIVLGLAIYNNCILDVHFPMVVYRKLMGKKGTFRDLGDSHPVLYQSLKDLLEYEGNVEDDMMITFQISQTDLFGNPMMYDLKENGDKIPITNENRKEFVNLYSDYILNKSVEKQFKAFRRGFHMVTNESPLKYLFRPEEIELLICGSRNLDFQALEETTEYDGGYTRDSVLIREFWEIVHSFTDEQKRLFLQFTTGTDRAPVGGLGKLKMIIAKNGPDTERLPTSHTCFNVLLLPEYSSKEKLKERLLKAITYAKGFGML

T25200	TARGETID	T25200
T25200	FORMERID	TTDI02446
T25200	UNIPROID	RN5A_HUMAN
T25200	TARGNAME	Ribonuclease L (RNASEL)
T25200	GENENAME	RNASEL
T25200	TARGTYPE	Literature-reported
T25200	SYNONYMS	Ribonuclease 4; RNase L; RNS4; 25Adependent ribonuclease; 25Adependent RNase; 2-5A-dependent ribonuclease; 2-5A-dependent RNase
T25200	FUNCTION	In INF treated and virus infected cells, RNASEL probably mediates its antiviral effects through a combination of direct cleavage of single-stranded viral RNAs, inhibition of protein synthesis through the degradation of rRNA, induction of apoptosis, and induction of other antiviral genes. RNASEL mediated apoptosis is the result of a JNK-dependent stress-response pathway leading to cytochrome c release from mitochondria and caspase-dependent apoptosis. Therefore, activation of RNASEL could lead to elimination of virus infected cells under some circumstances. In the crosstalk between autophagy and apoptosis proposed to induce autophagy as an early stress response to small double-stranded RNA and at later stages of prolonged stress to activate caspase-dependent proteolytic cleavage of BECN1 to terminate autophagy and promote apoptosis. Might play a central role in the regulation of mRNA turnover. Cleaves 3' of UpNp dimers, with preference for UU and UA sequences, to sets of discrete products ranging from between 4 and 22 nucleotides in length. Endoribonuclease that functions in the interferon (IFN) antiviral response.
T25200	PDBSTRUC	4OAV; 4OAU; 4G8L; 4G8K; 1WDY
T25200	BIOCLASS	Endoribonucleases
T25200	ECNUMBER	EC 3.1.26.-
T25200	SEQUENCE	MESRDHNNPQEGPTSSSGRRAAVEDNHLLIKAVQNEDVDLVQQLLEGGANVNFQEEEGGWTPLHNAVQMSREDIVELLLRHGADPVLRKKNGATPFILAAIAGSVKLLKLFLSKGADVNECDFYGFTAFMEAAVYGKVKALKFLYKRGANVNLRRKTKEDQERLRKGGATALMDAAEKGHVEVLKILLDEMGADVNACDNMGRNALIHALLSSDDSDVEAITHLLLDHGADVNVRGERGKTPLILAVEKKHLGLVQRLLEQEHIEINDTDSDGKTALLLAVELKLKKIAELLCKRGASTDCGDLVMTARRNYDHSLVKVLLSHGAKEDFHPPAEDWKPQSSHWGAALKDLHRIYRPMIGKLKFFIDEKYKIADTSEGGIYLGFYEKQEVAVKTFCEGSPRAQREVSCLQSSRENSHLVTFYGSESHRGHLFVCVTLCEQTLEACLDVHRGEDVENEEDEFARNVLSSIFKAVQELHLSCGYTHQDLQPQNILIDSKKAAHLADFDKSIKWAGDPQEVKRDLEDLGRLVLYVVKKGSISFEDLKAQSNEEVVQLSPDEETKDLIHRLFHPGEHVRDCLSDLLGHPFFWTWESRYRTLRNVGNESDIKTRKSESEILRLLQPGPSEHSKSFDKWTTKINECVMKKMNKFYEKRGNFYQNTVGDLLKFIRNLGEHIDEEKHKKMKLKIGDPSLYFQKTFPDLVIYVYTKLQNTEYRKHFPQTHSPNKPQCDGAGGASGLASPGC

T59130	TARGETID	T59130
T59130	FORMERID	TTDR00637
T59130	UNIPROID	TPIS_PLAFA
T59130	TARGNAME	Bacterial Triosephosphate isomerase (Bact TPI)
T59130	GENENAME	Bact TPI
T59130	TARGTYPE	Literature-reported
T59130	SYNONYMS	Triose-phosphate isomerase; TPI; TIM
T59130	FUNCTION	identical protein binding, triose-phosphate isomerase activity.
T59130	PDBSTRUC	5GZP; 5GV4; 5BRB; 5BNK; 5BMX
T59130	BIOCLASS	Intramolecular oxidoreductase
T59130	ECNUMBER	EC 5.3.1.1
T59130	SEQUENCE	MARKYFVAANWKCNGTLESIKSLTNSFNNLDFDPSKLDVVVFPVSVHYDHTRKLLQSKFSTGIQNVSKFGNGSYTGEVSAEIAKDLNIEYVIIGHFERRKYFHETDEDVREKLQASLKNNLKAVVCFGESLEQREQNKTIEVITKQVKAFVDLIDNFDNVILAYEPLWAIGTGKTATPEQAQLVHKEIRKIVKDTCGEKQANQIRILYGGSVNTENCSSLIQQEDIDGFLVGNASLKESFVDIIKSAM
T59130	DRUGINFO	D08XXE	2-Phosphoglycolic Acid	Investigative
T59130	DRUGINFO	D0MN3X	Glycerol-2-Phosphate	Investigative
T59130	DRUGINFO	D0Q7SY	3-Hydroxypyruvic Acid	Investigative
T59130	DRUGINFO	D03MUW	3-Phosphoglycerol	Investigative
T59130	DRUGINFO	D0WQ7U	3-Phosphoglyceric Acid	Investigative
T59130	DRUGINFO	D03KBV	2-Phosphoglyceric Acid	Investigative

T83284	TARGETID	T83284
T83284	FORMERID	TTDI02224
T83284	UNIPROID	QOR_HUMAN
T83284	TARGNAME	Quinone oxidoreductase (CRYZ)
T83284	GENENAME	CRYZ
T83284	TARGTYPE	Literature-reported
T83284	SYNONYMS	Zeta-crystallin; NADPH:quinone reductase; CRYZ
T83284	FUNCTION	Does not have alcohol dehydrogenase activity. Binds NADP and acts through a one-electron transfer process. Orthoquinones, such as 1,2-naphthoquinone or 9,10-phenanthrenequinone, are the best substrates (in vitro). May act in the detoxification of xenobiotics. Interacts with (AU)-rich elements (ARE) in the 3'-UTR of target mRNA species. Enhances the stability of mRNA coding for BCL2. NADPH binding interferes with mRNA binding.
T83284	PDBSTRUC	1YB5
T83284	ECNUMBER	EC 1.6.5.5
T83284	SEQUENCE	MATGQKLMRAVRVFEFGGPEVLKLRSDIAVPIPKDHQVLIKVHACGVNPVETYIRSGTYSRKPLLPYTPGSDVAGVIEAVGDNASAFKKGDRVFTSSTISGGYAEYALAADHTVYKLPEKLDFKQGAAIGIPYFTAYRALIHSACVKAGESVLVHGASGGVGLAACQIARAYGLKILGTAGTEEGQKIVLQNGAHEVFNHREVNYIDKIKKYVGEKGIDIIIEMLANVNLSKDLSLLSHGGRVIVVGSRGTIEINPRDTMAKESSIIGVTLFSSTKEEFQQYAAALQAGMEIGWLKPVIGSQYPLEKVAEAHENIIHGSGATGKMILLL

T14557	TARGETID	T14557
T14557	FORMERID	TTDI01973
T14557	UNIPROID	I10R2_HUMAN
T14557	TARGNAME	Interleukin 10 receptor (IL10RB)
T14557	GENENAME	IL10RB
T14557	TARGTYPE	Literature-reported
T14557	SYNONYMS	Interleukin-10 receptor subunit beta; Interleukin-10 receptor subunit 2; IL-10RB; IL-10R2; IL-10R subunit beta; IL-10R subunit 2; IL-10 receptor subunit beta; D21S66; D21S58; Cytokine receptor family 2 member 4; Cytokine receptor class-II member 4; CRFB4; CRF2-4; CDw210b
T14557	FUNCTION	The IFNLR1/IL10RB dimer is a receptor for the cytokine ligands IFNL2 and IFNL3 and mediates their antiviral activity. The ligand/receptor complex stimulate the activation of the JAK/STAT signaling pathway leading to the expression of IFN-stimulated genes (ISG), which contribute to the antiviral state. Shared cell surface receptor required for the activation of five class 2 cytokines: IL10, IL22, IL26, IL28, and IFNL1.
T14557	PDBSTRUC	5T5W; 3LQM
T14557	BIOCLASS	Cytokine receptor
T14557	SEQUENCE	MAWSLGSWLGGCLLVSALGMVPPPENVRMNSVNFKNILQWESPAFAKGNLTFTAQYLSYRIFQDKCMNTTLTECDFSSLSKYGDHTLRVRAEFADEHSDWVNITFCPVDDTIIGPPGMQVEVLADSLHMRFLAPKIENEYETWTMKNVYNSWTYNVQYWKNGTDEKFQITPQYDFEVLRNLEPWTTYCVQVRGFLPDRNKAGEWSEPVCEQTTHDETVPSWMVAVILMASVFMVCLALLGCFALLWCVYKKTKYAFSPRNSLPQHLKEFLGHPHHNTLLFFSFPLSDENDVFDKLSVIAEDSESGKQNPGDSCSLGTPPGQGPQS
T14557	DRUGINFO	D02JRD	VT-310	Investigative
T14557	DRUGINFO	D0A9TR	XT-101	Investigative
T14557	DRUGINFO	D0I7VI	EG-10	Investigative

T97655	TARGETID	T97655
T97655	FORMERID	TTDR00173
T97655	UNIPROID	ADCY2_HUMAN
T97655	TARGNAME	Adenylate cyclase type 2 (ADCY2)
T97655	GENENAME	ADCY2
T97655	TARGTYPE	Literature-reported
T97655	SYNONYMS	ADCY2
T97655	FUNCTION	This is a membrane-bound, calmodulin-insensitive adenylyl cyclase.
T97655	BIOCLASS	Phosphorus-oxygen lyase
T97655	ECNUMBER	EC 4.6.1.1
T97655	SEQUENCE	MWQEAMRRRRYLRDRSEEAAGGGDGLPRSRDWLYESYYCMSQQHPLIVFLLLIVMGSCLALLAVFFALGLEVEDHVAFLITVPTALAIFFAIFILVCIESVFKKLLRLFSLVIWICLVAMGYLFMCFGGTVSPWDQVSFFLFIIFVVYTMLPFNMRDAIIASVLTSSSHTIVLSVCLSATPGGKEHLVWQILANVIIFICGNLAGAYHKHLMELALQQTYQDTCNCIKSRIKLEFEKRQQERLLLSLLPAHIAMEMKAEIIQRLQGPKAGQMENTNNFHNLYVKRHTNVSILYADIVGFTRLASDCSPGELVHMLNELFGKFDQIAKENECMRIKILGDCYYCVSGLPISLPNHAKNCVKMGLDMCEAIKKVRDATGVDINMRVGVHSGNVLCGVIGLQKWQYDVWSHDVTLANHMEAGGVPGRVHISSVTLEHLNGAYKVEEGDGDIRDPYLKQHLVKTYFVINPKGERRSPQHLFRPRHTLDGAKMRASVRMTRYLESWGAAKPFAHLHHRDSMTTENGKISTTDVPMGQHNFQNRTLRTKSQKKRFEEELNERMIQAIDGINAQKQWLKSEDIQRISLLFYNKVLEKEYRATALPAFKYYVTCACLIFFCIFIVQILVLPKTSVLGISFGAAFLLLAFILFVCFAGQLLQCSKKASPLLMWLLKSSGIIANRPWPRISLTIITTAIILMMAVFNMFFLSDSEETIPPTANTTNTSFSASNNQVAILRAQNLFFLPYFIYSCILGLISCSVFLRVNYELKMLIMMVALVGYNTILLHTHAHVLGDYSQVLFERPGIWKDLKTMGSVSLSIFFITLLVLGRQNEYYCRLDFLWKNKFKKEREEIETMENLNRVLLENVLPAHVAEHFLARSLKNEELYHQSYDCVCVMFASIPDFKEFYTESDVNKEGLECLRLLNEIIADFDDLLSKPKFSGVEKIKTIGSTYMAATGLSAVPSQEHSQEPERQYMHIGTMVEFAFALVGKLDAINKHSFNDFKLRVGINHGPVIAGVIGAQKPQYDIWGNTVNVASRMDSTGVLDKIQVTEETSLVLQTLGYTCTCRGIINVKGKGDLKTYFVNTEMSRSLSQSNVAS
T97655	DRUGINFO	D0K7HT	2',5'-DIDEOXY-ADENOSINE 3'-MONOPHOSPHATE	Investigative
T97655	DRUGINFO	D0Y7VM	Forskolin	Investigative

T85272	TARGETID	T85272
T85272	FORMERID	TTDI02460
T85272	UNIPROID	KCNA1_HUMAN
T85272	TARGNAME	Voltage-gated potassium channel Kv1.1 (KCNA1)
T85272	GENENAME	KCNA1
T85272	TARGTYPE	Literature-reported
T85272	SYNONYMS	Voltagegated potassium channel subunit Kv1.1; Voltagegated potassium channel HBK1; Voltagegated K(+) channel HuKI; Potassium voltagegated channel subfamily A member 1; KCNA1
T85272	FUNCTION	Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and the central nervous system, but also in the kidney (PubMed:19903818). Contributes to the regulation of the membrane potential and nerve signaling, and prevents neuronal hyperexcitability (PubMed:17156368). Forms tetrameric potassium- selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage difference across the membrane (PubMed:19912772). Can form functional homotetrameric channels and heterotetrameric channels that contain variable proportions of KCNA1, KCNA2, KCNA4, KCNA5, KCNA6, KCNA7, and possibly other family members as well; channel properties depend on the type of alpha subunits that are part of the channel (PubMed:12077175, PubMed:17156368). Channel properties are modulated by cytoplasmic beta subunits that regulate the subcellular location of the alpha subunits and promote rapid inactivation of delayed rectifier potassium channels (PubMed:12077175, PubMed:17156368). In vivo, membranes probably contain a mixture of heteromeric potassium channel complexes, making it difficult to assign currents observed in intact tissues to any particular potassium channel family member. Homotetrameric KCNA1 forms a delayed-rectifier potassium channel that opens inresponse to membrane depolarization, followed by slow spontaneous channel closure (PubMed:19912772, PubMed:19968958, PubMed:19307729, PubMed:19903818). In contrast, a heterotetrameric channel formed by KCNA1 and KCNA4 shows rapid inactivation (PubMed:17156368). Regulates neuronal excitability in hippocampus, especially in mossy fibers and medial perforant path axons, preventing neuronal hyperexcitability. Response to toxins that are selective for KCNA1, respectively for KCNA2, suggests that heteromeric potassium channels composed of both KCNA1 and KCNA2 play a role in pacemaking and regulate the output of deep cerebellar nuclear neurons. May function as down- stream effector for G protein-coupled receptors and inhibit GABAergic inputs to basolateral amygdala neurons. May contribute to the regulation of neurotransmitter release, such as gamma-aminobutyric acid (GABA) release. Plays a role in regulating the generation of action potentials and preventing hyperexcitability in myelinated axons of the vagus nerve, and thereby contributes to the regulation of heart contraction. Required for normal neuromuscular responses (PubMed:11026449, PubMed:17136396). Regulates the frequency of neuronal action potential firing in response to mechanical stimuli, and plays a role in the perception of pain caused by mechanical stimuli,but does not play a role in the perception of pain due to heat stimuli. Required for normal responses to auditory stimuli and precise location of sound sources, but not for sound perception. The use of toxins that block specific channels suggest that it contributes to the regulation of the axonal release of the neurotransmitter dopamine. Required for normal postnatal brain development and normal proliferation of neuronal precursor cells in the brain. Plays a role in the reabsorption of Mg(2+) in the distal convoluted tubules in the kidney and in magnesium ion homeostasis, probably via its effect on the membrane potential (PubMed:23903368, PubMed:19307729).
T85272	PDBSTRUC	2AFL
T85272	BIOCLASS	Voltage-gated ion channel
T85272	SEQUENCE	MTVMSGENVDEASAAPGHPQDGSYPRQADHDDHECCERVVINISGLRFETQLKTLAQFPNTLLGNPKKRMRYFDPLRNEYFFDRNRPSFDAILYYYQSGGRLRRPVNVPLDMFSEEIKFYELGEEAMEKFREDEGFIKEEERPLPEKEYQRQVWLLFEYPESSGPARVIAIVSVMVILISIVIFCLETLPELKDDKDFTGTVHRIDNTTVIYNSNIFTDPFFIVETLCIIWFSFELVVRFFACPSKTDFFKNIMNFIDIVAIIPYFITLGTEIAEQEGNQKGEQATSLAILRVIRLVRVFRIFKLSRHSKGLQILGQTLKASMRELGLLIFFLFIGVILFSSAVYFAEAEEAESHFSSIPDAFWWAVVSMTTVGYGDMYPVTIGGKIVGSLCAIAGVLTIALPVPVIVSNFNYFYHRETEGEEQAQLLHVSSPNLASDSDLSRRSSSTMSKSEYMEIEEDMNNSIAHYRQVNIRTANCTTANQNCVNKSKLLTDV
T85272	DRUGINFO	D02VKU	mast cell degranulating peptide	Investigative
T85272	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T52133	TARGETID	T52133
T52133	FORMERID	TTDI02424
T52133	UNIPROID	ASPH_HUMAN
T52133	TARGNAME	Aspartate beta-hydroxylase (ASPH)
T52133	GENENAME	ASPH
T52133	TARGTYPE	Literature-reported
T52133	SYNONYMS	Peptideaspartate betadioxygenase; Aspartyl/asparaginyl betahydroxylase; ASPH; ASP betahydroxylase
T52133	FUNCTION	Isoform 8: membrane-bound Ca(2+)-sensing protein, which is a structural component of the ER-plasma membrane junctions. Isoform 8 regulates the activity of Ca(+2) released-activated Ca(+2) (CRAC) channels in T-cells. {ECO:0000269|PubMed:22586105}.
T52133	PDBSTRUC	6RK9; 5JZU; 5JZA; 5JZ8; 5JZ6
T52133	BIOCLASS	Paired donor oxygen oxidoreductase
T52133	ECNUMBER	EC 1.14.11.16
T52133	SEQUENCE	MAQRKNAKSSGNSSSSGSGSGSTSAGSSSPGARRETKHGGHKNGRKGGLSGTSFFTWFMVIALLGVWTSVAVVWFDLVDYEEVLGKLGIYDADGDGDFDVDDAKVLLGLKERSTSEPAVPPEEAEPHTEPEEQVPVEAEPQNIEDEAKEQIQSLLHEMVHAEHVEGEDLQQEDGPTGEPQQEDDEFLMATDVDDRFETLEPEVSHEETEHSYHVEETVSQDCNQDMEEMMSEQENPDSSEPVVEDERLHHDTDDVTYQVYEEQAVYEPLENEGIEITEVTAPPEDNPVEDSQVIVEEVSIFPVEEQQEVPPETNRKTDDPEQKAKVKKKKPKLLNKFDKTIKAELDAAEKLRKRGKIEEAVNAFKELVRKYPQSPRARYGKAQCEDDLAEKRRSNEVLRGAIETYQEVASLPDVPADLLKLSLKRRSDRQQFLGHMRGSLLTLQRLVQLFPNDTSLKNDLGVGYLLIGDNDNAKKVYEEVLSVTPNDGFAKVHYGFILKAQNKIAESIPYLKEGIESGDPGTDDGRFYFHLGDAMQRVGNKEAYKWYELGHKRGHFASVWQRSLYNVNGLKAQPWWTPKETGYTELVKSLERNWKLIRDEGLAVMDKAKGLFLPEDENLREKGDWSQFTLWQQGRRNENACKGAPKTCTLLEKFPETTGCRRGQIKYSIMHPGTHVWPHTGPTNCRLRMHLGLVIPKEGCKIRCANETKTWEEGKVLIFDDSFEHEVWQDASSFRLIFIVDVWHPELTPQQRRSLPAI

T60897	TARGETID	T60897
T60897	FORMERID	TTDI00242
T60897	UNIPROID	TP4A2_HUMAN
T60897	TARGNAME	Protein tyrosine phosphatase IVA 2 (PRL-2)
T60897	GENENAME	PTP4A2
T60897	TARGTYPE	Literature-reported
T60897	SYNONYMS	Protein-tyrosine phosphatase of regenerating liver 2; Protein-tyrosine phosphatase 4a2; Protein tyrosine phosphatase type IVA 2; PTPCAAX2; PTP(CAAXII); PRL2; OV-1; HU-PP-1; BM-008
T60897	FUNCTION	Promotes tumors. Inhibits geranylgeranyl transferase type II activity by blocking the association between RABGGTA and RABGGTB. Protein tyrosine phosphatase which stimulates progression from G1 into S phase during mitosis.
T60897	PDBSTRUC	5K25; 5K23; 5K22
T60897	BIOCLASS	Phosphoric monoester hydrolase
T60897	ECNUMBER	EC 3.1.3.48
T60897	SEQUENCE	MNRPAPVEISYENMRFLITHNPTNATLNKFTEELKKYGVTTLVRVCDATYDKAPVEKEGIHVLDWPFDDGAPPPNQIVDDWLNLLKTKFREEPGCCVAVHCVAGLGRAPVLVALALIECGMKYEDAVQFIRQKRRGAFNSKQLLYLEKYRPKMRLRFRDTNGHCCVQ

T98179	TARGETID	T98179
T98179	FORMERID	TTDR01018
T98179	UNIPROID	COASY_HUMAN
T98179	TARGNAME	Phosphopantetheine adenylyltransferase (PPAT)
T98179	GENENAME	COASY
T98179	TARGTYPE	Literature-reported
T98179	SYNONYMS	Pantetheine-phosphate adenylyltransferase; Dephospho-CoA pyrophosphorylase; COASY
T98179	FUNCTION	Bifunctional enzyme that catalyzes the fourth and fifth sequential steps of CoA biosynthetic pathway. The fourth reaction is catalyzed by the phosphopantetheine adenylyltransferase, coded by the coaD domain; the fifth reaction is catalyzed by the dephospho-CoA kinase, coded by the coaE domain. May act as a point of CoA biosynthesis regulation.
T98179	BIOCLASS	Kinase
T98179	ECNUMBER	EC 2.7.7.3
T98179	SEQUENCE	VAGSPKQPVRGYYRGAVGGTFDRLHNAHKVLLSVACILAQEQLVVGVADKDLLKSKLLPELLQPYTERVEHLSEFLVDIKPSLTFDVIPLLDPYGPAGSDPSLEFLVVSEETYRGGMAINRFRLENDLEELALYQIQLLKDLRHTENEEDKVSSSSFRQRMLGNLLRPPYERPELPTCL
T98179	DRUGINFO	D03CIN	PTX-007011	Terminated
T98179	DRUGINFO	D09HSI	4'-Phosphopantetheine	Investigative
T98179	DRUGINFO	D0SK8U	Dephospho Coenzyme A	Investigative
T98179	DRUGINFO	D0W3NA	Coenzyme A	Investigative
T98179	DRUGINFO	D06GOK	2-Methyl-2,4-Pentanediol	Investigative

T37961	TARGETID	T37961
T37961	FORMERID	TTDI03430
T37961	UNIPROID	PAK1_HUMAN
T37961	TARGNAME	PAK-1 protein kinase (PAK1)
T37961	GENENAME	PAK1
T37961	TARGTYPE	Literature-reported
T37961	SYNONYMS	p65-PAK; p21-activated kinase 1; Serine/threonine-protein kinase PAK 1; PAK-1; Alpha-PAK
T37961	FUNCTION	Can directly phosphorylate BAD and protects cells against apoptosis. Activated by interaction with CDC42 and RAC1. Functions as GTPase effector that links the Rho-related GTPases CDC42 and RAC1 to the JNK MAP kinase pathway. Phosphorylates and activates MAP2K1, and thereby mediates activation of downstream MAP kinases. Involved in the reorganization of the actin cytoskeleton, actin stress fibers and of focal adhesion complexes. Phosphorylates the tubulin chaperone TBCB and thereby plays a role in the regulation of microtubule biogenesis and organization of the tubulin cytoskeleton. Plays a role in the regulation of insulin secretion in response to elevated glucose levels. Part of a ternary complex that contains PAK1, DVL1 and MUSK that is important for MUSK-dependent regulation of AChR clustering during the formation of the neuromuscular junction (NMJ). Activity is inhibited in cells undergoing apoptosis, potentially due to binding of CDC2L1 and CDC2L2. Phosphorylates MYL9/MLC2. Phosphorylates RAF1 at 'Ser-338' and 'Ser-339' resulting in: activation of RAF1, stimulation of RAF1 translocation to mitochondria, phosphorylation of BAD by RAF1, and RAF1 binding to BCL2. Phosphorylates SNAI1 at 'Ser-246' promoting its transcriptional repressor activity by increasing its accumulation in the nucleus. In podocytes, promotes NR3C2 nuclear localization. Required for atypical chemokine receptor ACKR2-induced phosphorylation of LIMK1 and cofilin (CFL1) and for the up-regulation of ACKR2 from endosomal compartment to cell membrane, increasing its efficiency in chemokine uptake and degradation. In synapses, seems to mediate the regulation of F-actin cluster formation performed by SHANK3, maybe through CFL1 phosphorylation and inactivation. Plays a role in RUFY3-mediated facilitating gastric cancer cells migration and invasion. In response to DNA damage, phosphorylates MORC2 which activates its ATPase activity and facilitates chromatin remodeling. Protein kinase involved in intracellular signaling pathways downstream of integrins and receptor-type kinases that plays an important role in cytoskeleton dynamics, in cell adhesion, migration, proliferation, apoptosis, mitosis, and in vesicle-mediated transport processes.
T37961	PDBSTRUC	6B16; 5KBR; 5KBQ; 5IME; 5DFP
T37961	BIOCLASS	Kinase
T37961	ECNUMBER	EC 2.7.11.1
T37961	SEQUENCE	MSNNGLDIQDKPPAPPMRNTSTMIGAGSKDAGTLNHGSKPLPPNPEEKKKKDRFYRSILPGDKTNKKKEKERPEISLPSDFEHTIHVGFDAVTGEFTGMPEQWARLLQTSNITKSEQKKNPQAVLDVLEFYNSKKTSNSQKYMSFTDKSAEDYNSSNALNVKAVSETPAVPPVSEDEDDDDDDATPPPVIAPRPEHTKSVYTRSVIEPLPVTPTRDVATSPISPTENNTTPPDALTRNTEKQKKKPKMSDEEILEKLRSIVSVGDPKKKYTRFEKIGQGASGTVYTAMDVATGQEVAIKQMNLQQQPKKELIINEILVMRENKNPNIVNYLDSYLVGDELWVVMEYLAGGSLTDVVTETCMDEGQIAAVCRECLQALEFLHSNQVIHRDIKSDNILLGMDGSVKLTDFGFCAQITPEQSKRSTMVGTPYWMAPEVVTRKAYGPKVDIWSLGIMAIEMIEGEPPYLNENPLRALYLIATNGTPELQNPEKLSAIFRDFLNRCLEMDVEKRGSAKELLQHQFLKIAKPLSSLTPLIAAAKEATKNNH
T37961	DRUGINFO	D07ORL	Il-94	Investigative
T37961	DRUGINFO	D0L2WP	PMID20005102C1	Investigative
T37961	DRUGINFO	D03CPB	RKI-1447	Investigative

T76888	TARGETID	T76888
T76888	FORMERID	TTDI02430
T76888	UNIPROID	PRDX4_HUMAN
T76888	TARGNAME	Peroxiredoxin-4 (PRDX4)
T76888	GENENAME	PRDX4
T76888	TARGTYPE	Literature-reported
T76888	SYNONYMS	Thioredoxindependent peroxide reductase A0372; Thioredoxin peroxidase AO372; PrxIV; Peroxiredoxin4; Peroxiredoxin IV; PRDX4; Antioxidant enzyme AOE372; AOE372
T76888	FUNCTION	Probably involved in redox regulation of the cell. Regulates the activation of NF-kappa-B in the cytosol by a modulation of I-kappa-B-alpha phosphorylation.
T76888	PDBSTRUC	5HQP; 4RQX; 3TKS; 3TKR; 3TKQ
T76888	BIOCLASS	Peroxidases
T76888	ECNUMBER	EC 1.11.1.15
T76888	SEQUENCE	MEALPLLAATTPDHGRHRRLLLLPLLLFLLPAGAVQGWETEERPRTREEECHFYAGGQVYPGEASRVSVADHSLHLSKAKISKPAPYWEGTAVIDGEFKELKLTDYRGKYLVFFFYPLDFTFVCPTEIIAFGDRLEEFRSINTEVVACSVDSQFTHLAWINTPRRQGGLGPIRIPLLSDLTHQISKDYGVYLEDSGHTLRGLFIIDDKGILRQITLNDLPVGRSVDETLRLVQAFQYTDKHGEVCPAGWKPGSETIIPDPAGKLKYFDKLN

T07766	TARGETID	T07766
T07766	FORMERID	TTDI03431
T07766	UNIPROID	PAK2_HUMAN
T07766	TARGNAME	PAK-2 protein kinase (PAK2)
T07766	GENENAME	PAK2
T07766	TARGTYPE	Literature-reported
T07766	SYNONYMS	p21-activated kinase 2; Serine/threonine-protein kinase PAK 2; S6/H4 kinase; PAK65; PAK-2; Gamma-PAK
T07766	FUNCTION	Acts as downstream effector of the small GTPases CDC42 and RAC1. Activation by the binding of active CDC42 and RAC1 results in a conformational change and a subsequent autophosphorylation on several serine and/or threonine residues. Full-length PAK2 stimulates cell survival and cell growth. Phosphorylates MAPK4 and MAPK6 and activates the downstream target MAPKAPK5, a regulator of F-actin polymerization and cell migration. Phosphorylates JUN and plays an important role in EGF-induced cell proliferation. Phosphorylates many other substrates including histone H4 to promote assembly of H3. 3 and H4 into nucleosomes, BAD, ribosomal protein S6, or MBP. Additionally, associates with ARHGEF7 and GIT1 to perform kinase-independent functions such as spindle orientation control during mitosis. On the other hand, apoptotic stimuli such as DNA damage lead to caspase-mediated cleavage of PAK2, generating PAK-2p34, an active p34 fragment that translocates to the nucleus and promotes cellular apoptosis involving the JNK signaling pathway. Caspase-activated PAK2 phosphorylates MKNK1 and reduces cellular translation. Serine/threonine protein kinase that plays a role in a variety of different signaling pathways including cytoskeleton regulation, cell motility, cell cycle progression, apoptosis or proliferation.
T07766	PDBSTRUC	3PCS
T07766	BIOCLASS	Kinase
T07766	ECNUMBER	EC 2.7.11.1
T07766	SEQUENCE	MSDNGELEDKPPAPPVRMSSTIFSTGGKDPLSANHSLKPLPSVPEEKKPRHKIISIFSGTEKGSKKKEKERPEISPPSDFEHTIHVGFDAVTGEFTGMPEQWARLLQTSNITKLEQKKNPQAVLDVLKFYDSNTVKQKYLSFTPPEKDGFPSGTPALNAKGTEAPAVVTEEEDDDEETAPPVIAPRPDHTKSIYTRSVIDPVPAPVGDSHVDGAAKSLDKQKKKTKMTDEEIMEKLRTIVSIGDPKKKYTRYEKIGQGASGTVFTATDVALGQEVAIKQINLQKQPKKELIINEILVMKELKNPNIVNFLDSYLVGDELFVVMEYLAGGSLTDVVTETCMDEAQIAAVCRECLQALEFLHANQVIHRDIKSDNVLLGMEGSVKLTDFGFCAQITPEQSKRSTMVGTPYWMAPEVVTRKAYGPKVDIWSLGIMAIEMVEGEPPYLNENPLRALYLIATNGTPELQNPEKLSPIFRDFLNRCLEMDVEKRGSAKELLQHPFLKLAKPLSSLTPLIMAAKEAMKSNR
T07766	DRUGINFO	D07ORL	Il-94	Investigative

T04393	TARGETID	T04393
T04393	FORMERID	TTDI02419
T04393	UNIPROID	CBLB_HUMAN
T04393	TARGNAME	E3 ubiquitin protein ligase CBLB (CBLB)
T04393	GENENAME	CBLB
T04393	TARGTYPE	Literature-reported
T04393	SYNONYMS	Signal transduction protein CBLB; Signal transduction protein CBL-B; SH3binding protein CBLB; SH3-binding protein CBL-B; RNF56; RING-type E3 ubiquitin transferase CBL-B; RING finger protein 56; Nbla00127; E3 ubiquitinprotein ligase CBLB; E3 ubiquitin-protein ligase CBL-B; Casitas Blineage lymphoma protooncogene b; Casitas B-lineage lymphoma proto-oncogene b
T04393	FUNCTION	Negatively regulates TCR (T-cell receptor), BCR (B-cell receptor) and FCER1 (high affinity immunoglobulin epsilon receptor) signal transduction pathways. In naive T-cells, inhibits VAV1 activation upon TCR engagement and imposes a requirement for CD28 costimulation for proliferation and IL-2 production. Also acts by promoting PIK3R1/p85 ubiquitination, which impairs its recruitment to the TCR and subsequent activation. In activated T-cells, inhibits PLCG1 activation and calcium mobilization upon restimulation and promotes anergy. In B-cells, acts by ubiquitinating SYK and promoting its proteasomal degradation. Slightly promotes SRC ubiquitination. May be involved in EGFR ubiquitination and internalization. May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3. In association with CBL, required for proper feedback inhibition of ciliary platelet-derived growth factor receptor-alpha (PDGFRA) signaling pathway via ubiquitination and internalization of PDGFRA. E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome.
T04393	PDBSTRUC	3ZNI; 3VGO; 3PFV; 2OOB; 2OOA
T04393	BIOCLASS	Acyltransferase
T04393	ECNUMBER	EC 2.3.2.27
T04393	SEQUENCE	MANSMNGRNPGGRGGNPRKGRILGIIDAIQDAVGPPKQAAADRRTVEKTWKLMDKVVRLCQNPKLQLKNSPPYILDILPDTYQHLRLILSKYDDNQKLAQLSENEYFKIYIDSLMKKSKRAIRLFKEGKERMYEEQSQDRRNLTKLSLIFSHMLAEIKAIFPNGQFQGDNFRITKADAAEFWRKFFGDKTIVPWKVFRQCLHEVHQISSGLEAMALKSTIDLTCNDYISVFEFDIFTRLFQPWGSILRNWNFLAVTHPGYMAFLTYDEVKARLQKYSTKPGSYIFRLSCTRLGQWAIGYVTGDGNILQTIPHNKPLFQALIDGSREGFYLYPDGRSYNPDLTGLCEPTPHDHIKVTQEQYELYCEMGSTFQLCKICAENDKDVKIEPCGHLMCTSCLTAWQESDGQGCPFCRCEIKGTEPIIVDPFDPRDEGSRCCSIIDPFGMPMLDLDDDDDREESLMMNRLANVRKCTDRQNSPVTSPGSSPLAQRRKPQPDPLQIPHLSLPPVPPRLDLIQKGIVRSPCGSPTGSPKSSPCMVRKQDKPLPAPPPPLRDPPPPPPERPPPIPPDNRLSRHIHHVESVPSRDPPMPLEAWCPRDVFGTNQLVGCRLLGEGSPKPGITASSNVNGRHSRVGSDPVLMRKHRRHDLPLEGAKVFSNGHLGSEEYDVPPRLSPPPPVTTLLPSIKCTGPLANSLSEKTRDPVEEDDDEYKIPSSHPVSLNSQPSHCHNVKPPVRSCDNGHCMLNGTHGPSSEKKSNIPDLSIYLKGDVFDSASDPVPLPPARPPTRDNPKHGSSLNRTPSDYDLLIPPLGEDAFDALPPSLPPPPPPARHSLIEHSKPPGSSSRPSSGQDLFLLPSDPFVDLASGQVPLPPARRLPGENVKTNRTSQDYDQLPSCSDGSQAPARPPKPRPRRTAPEIHHRKPHGPEAALENVDAKIAKLMGEGYAFEEVKRALEIAQNNVEVARSILREFAFPPPVSPRLNL

T09395	TARGETID	T09395
T09395	FORMERID	TTDI02356
T09395	UNIPROID	CHIT1_HUMAN
T09395	TARGNAME	Chitinase (CHIT1)
T09395	GENENAME	CHIT1
T09395	TARGTYPE	Literature-reported
T09395	SYNONYMS	Chitotriosidase1; Chitinase1; CHIT1
T09395	FUNCTION	Degrades chitin, chitotriose and chitobiose. May participate in the defense against nematodes and other pathogens. Isoform 3 has no enzymatic activity. {ECO:0000269|PubMed:7592832, ECO:0000269|PubMed:7836450}.
T09395	PDBSTRUC	5NRF; 5NRA; 5NR8; 5HBF; 4WKH
T09395	BIOCLASS	Glycosylase
T09395	ECNUMBER	EC 3.2.1.14
T09395	SEQUENCE	MVRSVAWAGFMVLLMIPWGSAAKLVCYFTNWAQYRQGEARFLPKDLDPSLCTHLIYAFAGMTNHQLSTTEWNDETLYQEFNGLKKMNPKLKTLLAIGGWNFGTQKFTDMVATANNRQTFVNSAIRFLRKYSFDGLDLDWEYPGSQGSPAVDKERFTTLVQDLANAFQQEAQTSGKERLLLSAAVPAGQTYVDAGYEVDKIAQNLDFVNLMAYDFHGSWEKVTGHNSPLYKRQEESGAAASLNVDAAVQQWLQKGTPASKLILGMPTYGRSFTLASSSDTRVGAPATGSGTPGPFTKEGGMLAYYEVCSWKGATKQRIQDQKVPYIFRDNQWVGFDDVESFKTKVSYLKQKGLGGAMVWALDLDDFAGFSCNQGRYPLIQTLRQELSLPYLPSGTPELEVPKPGQPSEPEHGPSPGQDTFCQGKADGLYPNPRERSSFYSCAAGRLFQQSCPTGLVFSNSCKCCTWN

T91624	TARGETID	T91624
T91624	UNIPROID	TIF1B_HUMAN
T91624	TARGNAME	Transcription intermediary factor 1-beta (TRIM28)
T91624	GENENAME	TRIM28
T91624	TARGTYPE	Literature-reported
T91624	SYNONYMS	Tripartite motif-containing protein 28; TIF1B; TIF1-beta; RNF96; RING-type E3 ubiquitin transferase TIF1-beta; RING finger protein 96; Nuclear corepressor KAP-1; KRIP-1; KRAB-interacting protein 1; KRAB-associated protein 1; KAP1; KAP-1; E3 SUMO-protein ligase TRIM28
T91624	FUNCTION	Nuclear corepressor for KRAB domain-containing zinc finger proteins (KRAB-ZFPs). Mediates gene silencing by recruiting CHD3, a subunit of the nucleosome remodeling and deacetylation (NuRD) complex, and SETDB1 (which specifically methylates histone H3 at 'Lys-9' (H3K9me)) to the promoter regions of KRAB target genes. Enhances transcriptional repression by coordinating the increase in H3K9me, the decrease in histone H3 'Lys-9 and 'Lys-14' acetylation (H3K9ac and H3K14ac, respectively) and the disposition of HP1 proteins to silence gene expression. Recruitment of SETDB1 induces heterochromatinization. May play a role as a coactivator for CEBPB and NR3C1 in the transcriptional activation of ORM1. Also corepressor for ERBB4. Inhibits E2F1 activity by stimulating E2F1-HDAC1 complex formation and inhibiting E2F1 acetylation. May serve as a partial backup to prevent E2F1-mediated apoptosis in the absence of RB1. Important regulator of CDKN1A/p21(CIP1). Has E3 SUMO-protein ligase activity toward itself via its PHD-type zinc finger. Also specifically sumoylates IRF7, thereby inhibiting its transactivation activity. Ubiquitinates p53/TP53 leading to its proteosomal degradation; the function is enhanced by MAGEC2 and MAGEA2, and possibly MAGEA3 and MAGEA6. Mediates the nuclear localization of KOX1, ZNF268 and ZNF300 transcription factors. In association with isoform 2 of ZFP90, is required for the transcriptional repressor activity of FOXP3 and the suppressive function of regulatory T-cells (Treg) (PubMed:23543754). Probably forms a corepressor complex required for activated KRAS-mediated promoter hypermethylation and transcriptional silencing of tumor suppressor genes (TSGs) or other tumor-related genes in colorectal cancer (CRC) cells (PubMed:24623306). Required to maintain a transcriptionally repressive state of genes in undifferentiated embryonic stem cells (ESCs) (PubMed:24623306). In ESCs, in collaboration with SETDB1, is also required for H3K9me3 and silencing of endogenous and introduced retroviruses in a DNA-methylation independent-pathway. Associates at promoter regions of tumor suppressor genes (TSGs) leading to their gene silencing (PubMed:24623306). The SETDB1-TRIM28-ZNF274 complex may play a role in recruiting ATRX to the 3'-exons of zinc-finger coding genes with atypical chromatin signatures to establish or maintain/protect H3K9me3 at these transcriptionally active regions (PubMed:27029610). Acts as a corepressor for ZFP568.
T91624	PDBSTRUC	6I9H; 2YVR; 2RO1; 1FP0
T91624	BIOCLASS	TRIM/RBCC family
T91624	ECNUMBER	EC 2.3.2.27
T91624	SEQUENCE	MAASAAAASAAAASAASGSPGPGEGSAGGEKRSTAPSAAASASASAAASSPAGGGAEALELLEHCGVCRERLRPEREPRLLPCLHSACSACLGPAAPAAANSSGDGGAAGDGTVVDCPVCKQQCFSKDIVENYFMRDSGSKAATDAQDANQCCTSCEDNAPATSYCVECSEPLCETCVEAHQRVKYTKDHTVRSTGPAKSRDGERTVYCNVHKHEPLVLFCESCDTLTCRDCQLNAHKDHQYQFLEDAVRNQRKLLASLVKRLGDKHATLQKSTKEVRSSIRQVSDVQKRVQVDVKMAILQIMKELNKRGRVLVNDAQKVTEGQQERLERQHWTMTKIQKHQEHILRFASWALESDNNTALLLSKKLIYFQLHRALKMIVDPVEPHGEMKFQWDLNAWTKSAEAFGKIVAERPGTNSTGPAPMAPPRAPGPLSKQGSGSSQPMEVQEGYGFGSGDDPYSSAEPHVSGVKRSRSGEGEVSGLMRKVPRVSLERLDLDLTADSQPPVFKVFPGSTTEDYNLIVIERGAAAAATGQPGTAPAGTPGAPPLAGMAIVKEEETEAAIGAPPTATEGPETKPVLMALAEGPGAEGPRLASPSGSTSSGLEVVAPEGTSAPGGGPGTLDDSATICRVCQKPGDLVMCNQCEFCFHLDCHLPALQDVPGEEWSCSLCHVLPDLKEEDGSLSLDGADSTGVVAKLSPANQRKCERVLLALFCHEPCRPLHQLATDSTFSLDQPGGTLDLTLIRARLQEKLSPPYSSPQEFAQDVGRMFKQFNKLTEDKADVQSIIGLQRFFETRMNEAFGDTKFSAVLVEPPPMSLPGAGLSSQELSGGPGDGP

T16886	TARGETID	T16886
T16886	FORMERID	TTDI00013
T16886	UNIPROID	G3BP1_HUMAN
T16886	TARGNAME	GAP SH3 domain-binding protein 1 (G3BP1)
T16886	GENENAME	G3BP1
T16886	TARGTYPE	Literature-reported
T16886	SYNONYMS	hDH VIII; Ras GTPase-activating protein-binding protein 1; G3BP-1; G3BP; ATP-dependent DNA helicase VIII
T16886	FUNCTION	Participates in the DNA-triggered cGAS/STING pathway by promoting the DNA binding and activation of CGAS. Enhances also DDX58-induced type I interferon production probably by helping DDX58 at sensing pathogenic RNA. In addition, plays an essential role in stress granule formation. Unwinds preferentially partial DNA and RNA duplexes having a 17 bp annealed portion and either a hanging 3' tail or hanging tails at both 5'- and 3'-ends. Unwinds DNA/DNA, RNA/DNA, and RNA/RNA substrates with comparable efficiency. Acts unidirectionally by moving in the 5' to 3' direction along the bound single-stranded DNA. Phosphorylation-dependent sequence-specific endoribonuclease in vitro. Cleaves exclusively between cytosine and adenine and cleaves MYC mRNA preferentially at the 3'-UTR. ATP- and magnesium-dependent helicase that plays an essential role in innate immunity.
T16886	PDBSTRUC	5FW5; 4IIA; 4FCM; 4FCJ; 3Q90
T16886	BIOCLASS	Acid anhydride hydrolase
T16886	ECNUMBER	EC 3.6.4.12
T16886	SEQUENCE	MVMEKPSPLLVGREFVRQYYTLLNQAPDMLHRFYGKNSSYVHGGLDSNGKPADAVYGQKEIHRKVMSQNFTNCHTKIRHVDAHATLNDGVVVQVMGLLSNNNQALRRFMQTFVLAPEGSVANKFYVHNDIFRYQDEVFGGFVTEPQEESEEEVEEPEERQQTPEVVPDDSGTFYDQAVVSNDMEEHLEEPVAEPEPDPEPEPEQEPVSEIQEEKPEPVLEETAPEDAQKSSSPAPADIAQTVQEDLRTFSWASVTSKNLPPSGAVPVTGIPPHVVKVPASQPRPESKPESQIPPQRPQRDQRVREQRINIPPQRGPRPIREAGEQGDIEPRRMVRHPDSHQLFIGNLPHEVDKSELKDFFQSYGNVVELRINSGGKLPNFGFVVFDDSEPVQKVLSNRPIMFRGEVRLNVEEKKTRAAREGDRRDNRLRGPGGPRGGLGGGMRGPPRGGMVQKPGFGVGRGLAPRQ

T98337	TARGETID	T98337
T98337	FORMERID	TTDNR00722
T98337	UNIPROID	FKBP5_HUMAN
T98337	TARGNAME	FK506-binding protein 5 (FKBP5)
T98337	GENENAME	FKBP5
T98337	TARGTYPE	Literature-reported
T98337	SYNONYMS	Peptidyl-prolyl cis-trans isomerase FKBP5; PPIase FKBP5; HSP90-binding immunophilin; FKBP54; FKBP51; FKBP-51; FKBP-5; FF1 antigen; Androgen-regulated protein 6; AIG6; 54 kDa progesterone receptor-associated immunophilin; 51 kDa FKBP; 51 kDa FK506-binding protein
T98337	FUNCTION	Component of unligated steroid receptors heterocomplexes through interaction with heat-shock protein 90 (HSP90). Plays a role in the intracellular trafficking of heterooligomeric forms of steroid hormone receptors maintaining the complex into the cytoplasm when unliganded. Immunophilin protein with PPIase and co-chaperone activities.
T98337	PDBSTRUC	5OMP; 5OBK; 5NJX; 5DIV; 5DIU
T98337	BIOCLASS	Cis-trans-isomerase
T98337	ECNUMBER	EC 5.2.1.8
T98337	SEQUENCE	MTTDEGAKNNEESPTATVAEQGEDITSKKDRGVLKIVKRVGNGEETPMIGDKVYVHYKGKLSNGKKFDSSHDRNEPFVFSLGKGQVIKAWDIGVATMKKGEICHLLCKPEYAYGSAGSLPKIPSNATLFFEIELLDFKGEDLFEDGGIIRRTKRKGEGYSNPNEGATVEIHLEGRCGGRMFDCRDVAFTVGEGEDHDIPIGIDKALEKMQREEQCILYLGPRYGFGEAGKPKFGIEPNAELIYEVTLKSFEKAKESWEMDTKEKLEQAAIVKEKGTVYFKGGKYMQAVIQYGKIVSWLEMEYGLSEKESKASESFLLAAFLNLAMCYLKLREYTKAVECCDKALGLDSANEKGLYRRGEAQLLMNEFESAKGDFEKVLEVNPQNKAARLQISMCQKKAKEHNERDRRIYANMFKKFAEQDAKEEANKAMGKKTSEGVTNEKGTDSQAMEEEKPEGHV

T17367	TARGETID	T17367
T17367	FORMERID	TTDI02182
T17367	UNIPROID	SQSTM_HUMAN
T17367	TARGNAME	Sequestosome-1 p62 (SQSTM1)
T17367	GENENAME	SQSTM1
T17367	TARGTYPE	Literature-reported
T17367	SYNONYMS	Ubiquitin-binding protein p62; Sequestosome-1; Phosphotyrosine-independent ligand for the Lck SH2 domain of 62kDa; Phosphotyrosine-independent ligand for the Lck SH2 domain of 62 kDa; OSIL; ORCA; EBIAP; EBI3-associated protein of 60 kDa
T17367	FUNCTION	Functions as a bridge between polyubiquitinated cargo and autophagosomes. Interacts directly with both the cargo to become degraded and an autophagy modifier of the MAP1 LC3 family. Along with WDFY3, involved in the formation and autophagic degradation of cytoplasmic ubiquitin-containing inclusions (p62 bodies, ALIS/aggresome-like induced structures). Along with WDFY3, required to recruit ubiquitinated proteins to PML bodies in the nucleus. May regulate the activation of NFKB1 by TNF-alpha, nerve growth factor (NGF) and interleukin-1. May play a role in titin/TTN downstream signaling in muscle cells. May regulate signaling cascades through ubiquitination. Adapter that mediates the interaction between TRAF6 and CYLD. May be involved in cell differentiation, apoptosis, immune response and regulation of K(+) channels. Involved in endosome organization by retaining vesicles in the perinuclear cloud: following ubiquitination by RNF26, attracts specific vesicle-associated adapters, forming a molecular bridge that restrains cognate vesicles in the perinuclear region and organizes the endosomal pathway for efficient cargo transport. Promotes relocalization of 'Lys-63'-linked ubiquitinated TMEM173/STING to autophagosomes. Autophagy receptor required for selective macroautophagy (aggrephagy).
T17367	PDBSTRUC	6MJ7; 5YPH; 5YPG; 5YPF; 5YPE
T17367	BIOCLASS	Zinc-finger
T17367	SEQUENCE	MASLTVKAYLLGKEDAAREIRRFSFCCSPEPEAEAEAAAGPGPCERLLSRVAALFPALRPGGFQAHYRDEDGDLVAFSSDEELTMAMSYVKDDIFRIYIKEKKECRRDHRPPCAQEAPRNMVHPNVICDGCNGPVVGTRYKCSVCPDYDLCSVCEGKGLHRGHTKLAFPSPFGHLSEGFSHSRWLRKVKHGHFGWPGWEMGPPGNWSPRPPRAGEARPGPTAESASGPSEDPSVNFLKNVGESVAAALSPLGIEVDIDVEHGGKRSRLTPVSPESSSTEEKSSSQPSSCCSDPSKPGGNVEGATQSLAEQMRKIALESEGRPEEQMESDNCSGGDDDWTHLSSKEVDPSTGELQSLQMPESEGPSSLDPSQEGPTGLKEAALYPHLPPEADPRLIESLSQMLSMGFSDEGGWLTRLLQTKNYDIGAALDTIQYSKHPPPL
T17367	DRUGINFO	D02NEZ	IMX-942	Preclinical

T25861	TARGETID	T25861
T25861	FORMERID	TTDR00902
T25861	UNIPROID	TRPC3_HUMAN
T25861	TARGNAME	Short transient receptor potential channel 3 (TRPC3)
T25861	GENENAME	TRPC3
T25861	TARGTYPE	Literature-reported
T25861	SYNONYMS	TrpC3; Htrp3; Htrp-3
T25861	FUNCTION	Thought to form a receptor-activated non-selective calcium permeant cation channel. Probably is operated by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases or G-protein coupled receptors. Activated by diacylglycerol (DAG) in a membrane-delimited fashion, independently of protein kinase C, and by inositol 1,4,5- triphosphate receptors (ITPR) with bound IP3. May also be activated by internalcalcium store depletion.
T25861	PDBSTRUC	6DJS; 6D7L; 6CUD; 5ZBG
T25861	BIOCLASS	Transient receptor potential catioin channel
T25861	SEQUENCE	MREKGRRQAVRGPAFMFNDRGTSLTAEEERFLDAAEYGNIPVVRKMLEESKTLNVNCVDYMGQNALQLAVGNEHLEVTELLLKKENLARIGDALLLAISKGYVRIVEAILNHPGFAASKRLTLSPCEQELQDDDFYAYDEDGTRFSPDITPIILAAHCQKYEVVHMLLMKGARIERPHDYFCKCGDCMEKQRHDSFSHSRSRINAYKGLASPAYLSLSSEDPVLTALELSNELAKLANIEKEFKNDYRKLSMQCKDFVVGVLDLCRDSEEVEAILNGDLESAEPLEVHRHKASLSRVKLAIKYEVKKFVAHPNCQQQLLTIWYENLSGLREQTIAIKCLVVLVVALGLPFLAIGYWIAPCSRLGKILRSPFMKFVAHAASFIIFLGLLVFNASDRFEGITTLPNITVTDYPKQIFRVKTTQFTWTEMLIMVWVLGMMWSECKELWLEGPREYILQLWNVLDFGMLSIFIAAFTARFLAFLQATKAQQYVDSYVQESDLSEVTLPPEIQYFTYARDKWLPSDPQIISEGLYAIAVVLSFSRIAYILPANESFGPLQISLGRTVKDIFKFMVLFIMVFFAFMIGMFILYSYYLGAKVNAAFTTVEESFKTLFWSIFGLSEVTSVVLKYDHKFIENIGYVLYGIYNVTMVVVLLNMLIAMINSSYQEIEDDSDVEWKFARSKLWLSYFDDGKTLPPPFSLVPSPKSFVYFIMRIVNFPKCRRRRLQKDIEMGMGNSKSRLNLFTQSNSRVFESHSFNSILNQPTRYQQIMKRLIKRYVLKAQVDKENDEVNEGELKEIKQDISSLRYELLEDKSQATEELAILIHKLSEKLNPSMLRCE
T25861	DRUGINFO	D0T7GC	Pyr3	Investigative
T25861	DRUGINFO	D0F4FK	KB-R7943	Investigative
T25861	DRUGINFO	D0JV2P	BTP2	Investigative
T25861	DRUGINFO	D0N7MS	ACAA	Investigative
T25861	DRUGINFO	D0T6DU	OAG	Investigative
T25861	DRUGINFO	D00HCI	2-APB	Investigative

T53124	TARGETID	T53124
T53124	FORMERID	TTDR00812
T53124	UNIPROID	MTMR1_HUMAN
T53124	TARGNAME	Myotubularin-related protein 1 (MTMR1)
T53124	GENENAME	MTMR1
T53124	TARGTYPE	Literature-reported
T53124	SYNONYMS	MTMR1
T53124	FUNCTION	Lipid phosphatase that has high specificity for phosphatidylinositol 3-phosphate and has no activity with phosphatidylinositol (3,5)-bisphosphate.
T53124	PDBSTRUC	5C16
T53124	BIOCLASS	Phosphoric monoester hydrolase
T53124	ECNUMBER	EC 3.1.3.95
T53124	SEQUENCE	MDRPAAAAAAGCEGGGGPNPGPAGGRRPPRAAGGATAGSRQPSVETLDSPTGSHVEWCKQLIAATISSQISGSVTSENVSRDYKALRDGNKLAQMEEAPLFPGESIKAIVKDVMYICPFMGAVSGTLTVTDFKLYFKNVERDPHFILDVPLGVISRVEKIGAQSHGDNSCGIEIVCKDMRNLRLAYKQEEQSKLGIFENLNKHAFPLSNGQALFAFSYKEKFPINGWKVYDPVSEYKRQGLPNESWKISKINSNYEFCDTYPAIIVVPTSVKDDDLSKVAAFRAKGRVPVLSWIHPESQATITRCSQPLVGPNDKRCKEDEKYLQTIMDANAQSHKLIIFDARQNSVADTNKTKGGGYESESAYPNAELVFLEIHNIHVMRESLRKLKEIVYPSIDEARWLSNVDGTHWLEYIRMLLAGAVRIADKIESGKTSVVVHCSDGWDRTAQLTSLAMLMLDSYYRTIKGFETLVEKEWISFGHRFALRVGHGNDNHADADRSPIFLQFVDCVWQMTRQFPSAFEFNELFLITILDHLYSCLFGTFLCNCEQQRFKEDVYTKTISLWSYINSQLDEFSNPFFVNYENHVLYPVASLSHLELWVNYYVRWNPRMRPQMPIHQNLKELLAVRAELQKRVEGLQREVATRAVSSSSERGSSPSHSATSVHTSV

T78543	TARGETID	T78543
T78543	FORMERID	TTDI03491
T78543	UNIPROID	KGP1_HUMAN
T78543	TARGNAME	Protein kinase G1 (PRKG1)
T78543	GENENAME	PRKG1
T78543	TARGTYPE	Literature-reported
T78543	SYNONYMS	cGMP-dependent protein kinase I; cGMP-dependent protein kinase 1; cGKI; cGK1; cGK 1; PRKGR1B; PRKGR1A; PRKG1B
T78543	FUNCTION	GMP binding activates PRKG1, which phosphorylates serines and threonines on many cellular proteins. Numerous protein targets for PRKG1 phosphorylation are implicated in modulating cellular calcium, but the contribution of each of these targets may vary substantially among cell types. Proteins that are phosphorylated by PRKG1 regulate platelet activation and adhesion, smooth muscle contraction, cardiac function, gene expression, feedback of the NO-signaling pathway, and other processes involved in several aspects of the CNS like axon guidance, hippocampal and cerebellar learning, circadian rhythm and nociception. Smooth muscle relaxation is mediated through lowering of intracellular free calcium, by desensitization of contractile proteins to calcium, and by decrease in the contractile state of smooth muscle or in platelet activation. Regulates intracellular calcium levels via several pathways: phosphorylates MRVI1/IRAG and inhibits IP3-induced Ca(2+) release from intracellular stores, phosphorylation of KCNMA1 (BKCa) channels decreases intracellular Ca(2+) levels, which leads to increased opening of this channel. PRKG1 phosphorylates the canonical transient receptor potential channel (TRPC) family which inactivates the associated inward calcium current. Another mode of action of NO/cGMP/PKGI signaling involves PKGI-mediated inactivation of the Ras homolog gene family member A (RhoA). Phosphorylation of RHOA by PRKG1 blocks the action of this protein in myriad processes: regulation of RHOA translocation; decreasing contraction; controlling vesicle trafficking, reduction of myosin light chain phosphorylation resulting in vasorelaxation. Activation of PRKG1 by NO signaling alters also gene expression in a number of tissues. In smooth muscle cells, increased cGMP and PRKG1 activity influence expression of smooth muscle-specific contractile proteins, levels of proteins in the NO/cGMP signaling pathway, down-regulation of the matrix proteins osteopontin and thrombospondin-1 to limit smooth muscle cell migration and phenotype. Regulates vasodilator-stimulated phosphoprotein (VASP) functions in platelets and smooth muscle. Serine/threonine protein kinase that acts as key mediator of the nitric oxide (NO)/cGMP signaling pathway.
T78543	PDBSTRUC	6C0T; 6BG2; 6BDL; 5L0N; 5JD7
T78543	BIOCLASS	Kinase
T78543	ECNUMBER	EC 2.7.11.12
T78543	SEQUENCE	MSELEEDFAKILMLKEERIKELEKRLSEKEEEIQELKRKLHKCQSVLPVPSTHIGPRTTRAQGISAEPQTYRSFHDLRQAFRKFTKSERSKDLIKEAILDNDFMKNLELSQIQEIVDCMYPVEYGKDSCIIKEGDVGSLVYVMEDGKVEVTKEGVKLCTMGPGKVFGELAILYNCTRTATVKTLVNVKLWAIDRQCFQTIMMRTGLIKHTEYMEFLKSVPTFQSLPEEILSKLADVLEETHYENGEYIIRQGARGDTFFIISKGTVNVTREDSPSEDPVFLRTLGKGDWFGEKALQGEDVRTANVIAAEAVTCLVIDRDSFKHLIGGLDDVSNKAYEDAEAKAKYEAEAAFFANLKLSDFNIIDTLGVGGFGRVELVQLKSEESKTFAMKILKKRHIVDTRQQEHIRSEKQIMQGAHSDFIVRLYRTFKDSKYLYMLMEACLGGELWTILRDRGSFEDSTTRFYTACVVEAFAYLHSKGIIYRDLKPENLILDHRGYAKLVDFGFAKKIGFGKKTWTFCGTPEYVAPEIILNKGHDISADYWSLGILMYELLTGSPPFSGPDPMKTYNIILRGIDMIEFPKKIAKNAANLIKKLCRDNPSERLGNLKNGVKDIQKHKWFEGFNWEGLRKGTLTPPIIPSVASPTDTSNFDSFPEDNDEPPPDDNSGWDIDF
T78543	DRUGINFO	D0T0CG	Rp-8-CPT-cGMPS	Investigative

T92439	TARGETID	T92439
T92439	FORMERID	TTDI03444
T92439	UNIPROID	PDE1C_HUMAN
T92439	TARGNAME	Phosphodiesterase 1C (PDE1C)
T92439	GENENAME	PDE1C
T92439	TARGTYPE	Literature-reported
T92439	SYNONYMS	Hcam3; Cam-PDE 1C; Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C; 3',5'-cyclic-GMP phosphodiesterase; 3',5'-cyclic-AMP phosphodiesterase
T92439	FUNCTION	Has a high affinity for both cAMP and cGMP. Modulates the amplitude and duration of the cAMP signal in sensory cilia in response to odorant stimulation, hence contributing to the generation of action potentials. Regulates smooth muscle cell proliferation. Regulates the stability of growth factor receptors, including PDGFRB. Calmodulin-dependent cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes.
T92439	PDBSTRUC	1LXS
T92439	BIOCLASS	Phosphoric diester hydrolase
T92439	ECNUMBER	EC 3.1.4.-
T92439	SEQUENCE	MESPTKEIEEFESNSLKYLQPEQIEKIWLRLRGLRKYKKTSQRLRSLVKQLERGEASVVDLKKNLEYAATVLESVYIDETRRLLDTEDELSDIQSDAVPSEVRDWLASTFTRQMGMMLRRSDEKPRFKSIVHAVQAGIFVERMYRRTSNMVGLSYPPAVIEALKDVDKWSFDVFSLNEASGDHALKFIFYELLTRYDLISRFKIPISALVSFVEALEVGYSKHKNPYHNLMHAADVTQTVHYLLYKTGVANWLTELEIFAIIFSAAIHDYEHTGTTNNFHIQTRSDPAILYNDRSVLENHHLSAAYRLLQDDEEMNILINLSKDDWREFRTLVIEMVMATDMSCHFQQIKAMKTALQQPEAIEKPKALSLMLHTADISHPAKAWDLHHRWTMSLLEEFFRQGDREAELGLPFSPLCDRKSTMVAQSQVGFIDFIVEPTFTVLTDMTEKIVSPLIDETSQTGGTGQRRSSLNSISSSDAKRSGVKTSGSEGSAPINNSVISVDYKSFKATWTEVVHINRERWRAKVPKEEKAKKEAEEKARLAAEEQQKEMEAKSQAEEGASGKAEKKTSGETKNQVNGTRANKSDNPRGKNSKAEKSSGEQQQNGDFKDGKNKTDKKDHSNIGNDSKKTDGTKQRSHGSPAPSTSSTCRLTLPVIKPPLRHFKRPAYASSSYAPSVSKKTDEHPARYKMLDQRIKMKKIQNISHNWNRK
T92439	DRUGINFO	D02VHD	SCH51866	Investigative

T30502	TARGETID	T30502
T30502	FORMERID	TTDR00491
T30502	UNIPROID	MCM6_HUMAN
T30502	TARGNAME	DNA replication licensing factor MCM6 (MCM6)
T30502	GENENAME	MCM6
T30502	TARGTYPE	Literature-reported
T30502	SYNONYMS	p105MCM; Minichromosome maintenanceprotein 6
T30502	FUNCTION	The active ATPase sites in the MCM2-7 ring are formed through the interaction surfaces of two neighboring subunits such that a critical structure of a conserved arginine finger motif is provided in trans relative to the ATP-binding site of the Walker A box of the adjacent subunit. The six ATPase active sites, however, are likely to contribute differentially to the complex helicase activity. Acts as component of the MCM2-7 complex (MCM complex) which is the putative replicative helicase essential for 'once per cell cycle' DNA replication initiation and elongation in eukaryotic cells.
T30502	PDBSTRUC	2LE8; 2KLQ
T30502	BIOCLASS	Acid anhydride hydrolase
T30502	ECNUMBER	EC 3.6.4.12
T30502	SEQUENCE	MDLAAAAEPGAGSQHLEVRDEVAEKCQKLFLDFLEEFQSSDGEIKYLQLAEELIRPERNTLVVSFVDLEQFNQQLSTTIQEEFYRVYPYLCRALKTFVKDRKEIPLAKDFYVAFQDLPTRHKIRELTSSRIGLLTRISGQVVRTHPVHPELVSGTFLCLDCQTVIRDVEQQFKYTQPNICRNPVCANRRRFLLDTNKSRFVDFQKVRIQETQAELPRGSIPRSLEVILRAEAVESAQAGDKCDFTGTLIVVPDVSKLSTPGARAETNSRVSGVDGYETEGIRGLRALGVRDLSYRLVFLACCVAPTNPRFGGKELRDEEQTAESIKNQMTVKEWEKVFEMSQDKNLYHNLCTSLFPTIHGNDEVKRGVLLMLFGGVPKTTGEGTSLRGDINVCIVGDPSTAKSQFLKHVEEFSPRAVYTSGKASSAAGLTAAVVRDEESHEFVIEAGALMLADNGVCCIDEFDKMDVRDQVAIHEAMEQQTISITKAGVKATLNARTSILAAANPISGHYDRSKSLKQNINLSAPIMSRFDLFFILVDECNEVTDYAIARRIVDLHSRIEESIDRVYSLDDIRRYLLFARQFKPKISKESEDFIVEQYKHLRQRDGSGVTKSSWRITVRQLESMIRLSEAMARMHCCDEVQPKHVKEAFRLLNKSIIRVETPDVNLDQEEEIQMEVDEGAGGINGHADSPAPVNGINGYNEDINQESAPKASLRLGFSEYCRISNLIVLHLRKVEEEEDESALKRSELVNWYLKEIESEIDSEEELINKKRIIEKVIHRLTHYDHVLIELTQAGLKGSTEGSESYEEDPYLVVNPNYLLED

T99402	TARGETID	T99402
T99402	FORMERID	TTDR00965
T99402	UNIPROID	GRM4_HUMAN
T99402	TARGNAME	Metabotropic glutamate receptor 4 (mGluR4)
T99402	GENENAME	GRM4
T99402	TARGTYPE	Literature-reported
T99402	SYNONYMS	mGluR4; Group III metabotropic glutamate receptor 4; GPRC1D
T99402	FUNCTION	Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling inhibits adenylate cyclase activity. G-protein coupled receptor for glutamate.
T99402	BIOCLASS	GPCR glutamate
T99402	SEQUENCE	MPGKRGLGWWWARLPLCLLLSLYGPWMPSSLGKPKGHPHMNSIRIDGDITLGGLFPVHGRGSEGKPCGELKKEKGIHRLEAMLFALDRINNDPDLLPNITLGARILDTCSRDTHALEQSLTFVQALIEKDGTEVRCGSGGPPIITKPERVVGVIGASGSSVSIMVANILRLFKIPQISYASTAPDLSDNSRYDFFSRVVPSDTYQAQAMVDIVRALKWNYVSTVASEGSYGESGVEAFIQKSREDGGVCIAQSVKIPREPKAGEFDKIIRRLLETSNARAVIIFANEDDIRRVLEAARRANQTGHFFWMGSDSWGSKIAPVLHLEEVAEGAVTILPKRMSVRGFDRYFSSRTLDNNRRNIWFAEFWEDNFHCKLSRHALKKGSHVKKCTNRERIGQDSAYEQEGKVQFVIDAVYAMGHALHAMHRDLCPGRVGLCPRMDPVDGTQLLKYIRNVNFSGIAGNPVTFNENGDAPGRYDIYQYQLRNDSAEYKVIGSWTDHLHLRIERMHWPGSGQQLPRSICSLPCQPGERKKTVKGMPCCWHCEPCTGYQYQVDRYTCKTCPYDMRPTENRTGCRPIPIIKLEWGSPWAVLPLFLAVVGIAATLFVVITFVRYNDTPIVKASGRELSYVLLAGIFLCYATTFLMIAEPDLGTCSLRRIFLGLGMSISYAALLTKTNRIYRIFEQGKRSVSAPRFISPASQLAITFSLISLQLLGICVWFVVDPSHSVVDFQDQRTLDPRFARGVLKCDISDLSLICLLGYSMLLMVTCTVYAIKTRGVPETFNEAKPIGFTMYTTCIVWLAFIPIFFGTSQSADKLYIQTTTLTVSVSLSASVSLGMLYMPKVYIILFHPEQNVPKRKRSLKAVVTAATMSNKFTQKGNFRPNGEAKSELCENLEAPALATKQTYVTYTNHAI
T99402	DRUGINFO	D0L2YR	DT-1687	Phase 2
T99402	DRUGINFO	D00NCL	PMID21688779C22a	Investigative
T99402	DRUGINFO	D01JFF	VU0361737	Investigative
T99402	DRUGINFO	D03PGL	PMID20638279C11	Investigative
T99402	DRUGINFO	D05GQH	ADX-88178	Investigative
T99402	DRUGINFO	D06DRY	FP0429	Investigative
T99402	DRUGINFO	D07IOB	VU0092145	Investigative
T99402	DRUGINFO	D09ONV	VU0359516	Investigative
T99402	DRUGINFO	D0AY5T	VU0400195	Investigative
T99402	DRUGINFO	D0GI1D	Lu AF21934	Investigative
T99402	DRUGINFO	D0P2VP	(2S,1'R,2'S)-2-(2'-phosphonocyclopropyl)glycine	Investigative
T99402	DRUGINFO	D0T1SP	PMID22465637C1	Investigative
T99402	DRUGINFO	D0V8KA	PMID20638279C7	Investigative
T99402	DRUGINFO	D0W9VN	VU0364770	Investigative
T99402	DRUGINFO	D0X3VM	VU0155041	Investigative
T99402	DRUGINFO	D0Z5JT	VU0001171	Investigative
T99402	DRUGINFO	D06PHE	CPPG	Investigative
T99402	DRUGINFO	D0H6BG	PHCCC	Investigative
T99402	DRUGINFO	D0IO8J	2-methyl-6-(phenylethynyl)pyridine	Investigative
T99402	DRUGINFO	D0KL4K	LSP4-2022	Investigative
T99402	DRUGINFO	D0LC5O	(S)-3,4-DCPG	Investigative
T99402	DRUGINFO	D0W3PY	ACPT-I	Investigative
T99402	DRUGINFO	D0XG6U	LSP1-2111	Investigative
T99402	DRUGINFO	D09SXN	MAP4	Investigative
T99402	DRUGINFO	D0D2GL	MPPG	Investigative
T99402	DRUGINFO	D0PN6Z	L-AP4	Investigative
T99402	DRUGINFO	D0Z7CZ	L-CCG-I	Investigative
T99402	DRUGINFO	D07PZQ	L-serine-O-phosphate	Investigative

T99029	TARGETID	T99029
T99029	FORMERID	TTDNR00633
T99029	UNIPROID	PDK3_HUMAN
T99029	TARGNAME	Pyruvate dehydrogenase kinase 3 (PDHK3)
T99029	GENENAME	PDK3
T99029	TARGTYPE	Literature-reported
T99029	SYNONYMS	Pyruvate dehydrogenase kinase isoform 3; PDK3
T99029	FUNCTION	Inhibits pyruvatedehydrogenase activity by phosphorylation of the E1 subunit PDHA1, and thereby regulates glucose metabolism and aerobic respiration. Can also phosphorylate PDHA2. Decreases glucose utilization and increases fat metabolism in response to prolonged fasting, and as adaptation to a high-fat diet. Plays a role in glucose homeostasis and in maintaining normal blood glucose levels in function of nutrient levels and under starvation. Plays a role in the generation of reactive oxygen species.
T99029	PDBSTRUC	2Q8I; 2PNR; 1Y8P; 1Y8O; 1Y8N
T99029	BIOCLASS	Kinase
T99029	ECNUMBER	EC 2.7.11.2
T99029	SEQUENCE	MRLFRWLLKQPVPKQIERYSRFSPSPLSIKQFLDFGRDNACEKTSYMFLRKELPVRLANTMREVNLLPDNLLNRPSVGLVQSWYMQSFLELLEYENKSPEDPQVLDNFLQVLIKVRNRHNDVVPTMAQGVIEYKEKFGFDPFISTNIQYFLDRFYTNRISFRMLINQHTLLFGGDTNPVHPKHIGSIDPTCNVADVVKDAYETAKMLCEQYYLVAPELEVEEFNAKAPDKPIQVVYVPSHLFHMLFELFKNSMRATVELYEDRKEGYPAVKTLVTLGKEDLSIKISDLGGGVPLRKIDRLFNYMYSTAPRPSLEPTRAAPLAGFGYGLPISRLYARYFQGDLKLYSMEGVGTDAVIYLKALSSESFERLPVFNKSAWRHYKTTPEADDWSNPSSEPRDASKYKAKQ

T47885	TARGETID	T47885
T47885	FORMERID	TTDR01317
T47885	UNIPROID	KPCD1_HUMAN
T47885	TARGNAME	Protein kinase D (PRKD1)
T47885	GENENAME	PRKD1
T47885	TARGTYPE	Literature-reported
T47885	SYNONYMS	nPKC-mu; nPKC-D1; Serine/threonine-protein kinase D1; Protein kinase C mu type; PRKCM; PKD1; PKD
T47885	FUNCTION	Phosphorylates the epidermal growth factor receptor (EGFR) on dual threonine residues, which leads to the suppression of epidermal growth factor (EGF)-induced MAPK8/JNK1 activation and subsequent JUN phosphorylation. Phosphorylates RIN1, inducing RIN1 binding to 14-3-3 proteins YWHAB, YWHAE and YWHAZ and increased competition with RAF1 for binding to GTP-bound form of Ras proteins (NRAS, HRAS and KRAS). Acts downstream of the heterotrimeric G-protein beta/gamma-subunit complex to maintain the structural integrity of the Golgi membranes, and is required for protein transport along the secretory pathway. In the trans-Golgi network (TGN), regulates the fission of transport vesicles that are on their way to the plasma membrane. May act by activating the lipid kinase phosphatidylinositol 4-kinase beta (PI4KB) at the TGN for the local synthesis of phosphorylated inositol lipids, which induces a sequential production of DAG, phosphatidic acid (PA) and lyso-PA (LPA) that are necessary for membrane fission and generation of specific transport carriers to the cell surface. Under oxidative stress, is phosphorylated at Tyr-463 via SRC-ABL1 and contributes to cell survival by activating IKK complex and subsequent nuclear translocation and activation of NFKB1. Involved in cell migration by regulating integrin alpha-5/beta-3 recycling and promoting its recruitment in newly forming focal adhesion. In osteoblast differentiation, mediates the bone morphogenetic protein 2 (BMP2)-induced nuclear export of HDAC7, which results in the inhibition of HDAC7 transcriptional repression of RUNX2. In neurons, plays an important role in neuronal polarity by regulating the biogenesis of TGN-derived dendritic vesicles, and is involved in the maintenance of dendritic arborization and Golgi structure in hippocampal cells. May potentiate mitogenesis induced by the neuropeptide bombesin or vasopressin by mediating an increase in the duration of MAPK1/3 (ERK1/2) signaling, which leads to accumulation of immediate-early gene products including FOS that stimulate cell cycle progression. Plays an important role in the proliferative response induced by low calcium in keratinocytes, through sustained activation of MAPK1/3 (ERK1/2) pathway. Downstream of novel PKC signaling, plays a role in cardiac hypertrophy by phosphorylating HDAC5, which in turn triggers XPO1/CRM1-dependent nuclear export of HDAC5, MEF2A transcriptional activation and induction of downstream target genes that promote myocyte hypertrophy and pathological cardiac remodeling. Mediates cardiac troponin I (TNNI3) phosphorylation at the PKA sites, which results in reduced myofilament calcium sensitivity, and accelerated crossbridge cycling kinetics. The PRKD1-HDAC5 pathway is also involved in angiogenesis by mediating VEGFA-induced specific subset of gene expression, cell migration, and tube formation. In response to VEGFA, is necessary and required for HDAC7 phosphorylation which induces HDAC7 nuclear export and endothelial cell proliferation and migration. During apoptosis induced by cytarabine and other genotoxic agents, PRKD1 is cleaved by caspase-3 at Asp-378, resulting in activation of its kinase function and increased sensitivity of cells to the cytotoxic effects of genotoxic agents. In epithelial cells, is required for transducing flagellin-stimulated inflammatory responses by binding and phosphorylating TLR5, which contributes to MAPK14/p38 activation and production of inflammatory cytokines. May play a role in inflammatory response by mediating activation of NF-kappa-B. May be involved in pain transmission by directly modulating TRPV1 receptor. Plays a role in activated KRAS-mediated stabilization of ZNF304 in colorectal cancer (CRC) cells. Regulates nuclear translocation of transcription factor TFEB in macrophages upon live S. enterica infection. Serine/threonine-protein kinase that converts transient diacylglycerol (DAG) signals into prolonged physiological effects downstream of PKC, and is involved in the regulation of MAPK8/JNK1 and Ras signaling, Golgi membrane integrity and trafficking, cell survival through NF-kappa-B activation, cell migration, cell differentiation by mediating HDAC7 nuclear export, cell proliferation via MAPK1/3 (ERK1/2) signaling, and plays a role in cardiac hypertrophy, VEGFA-induced angiogenesis, genotoxic-induced apoptosis and flagellin-stimulated inflammatory response.
T47885	BIOCLASS	Kinase
T47885	ECNUMBER	EC 2.7.11.13
T47885	SEQUENCE	MSAPPVLRPPSPLLPVAAAAAAAAAALVPGSGPGPAPFLAPVAAPVGGISFHLQIGLSREPVLLLQDSSGDYSLAHVREMACSIVDQKFPECGFYGMYDKILLFRHDPTSENILQLVKAASDIQEGDLIEVVLSASATFEDFQIRPHALFVHSYRAPAFCDHCGEMLWGLVRQGLKCEGCGLNYHKRCAFKIPNNCSGVRRRRLSNVSLTGVSTIRTSSAELSTSAPDEPLLQKSPSESFIGREKRSNSQSYIGRPIHLDKILMSKVKVPHTFVIHSYTRPTVCQYCKKLLKGLFRQGLQCKDCRFNCHKRCAPKVPNNCLGEVTINGDLLSPGAESDVVMEEGSDDNDSERNSGLMDDMEEAMVQDAEMAMAECQNDSGEMQDPDPDHEDANRTISPSTSNNIPLMRVVQSVKHTKRKSSTVMKEGWMVHYTSKDTLRKRHYWRLDSKCITLFQNDTGSRYYKEIPLSEILSLEPVKTSALIPNGANPHCFEITTANVVYYVGENVVNPSSPSPNNSVLTSGVGADVARMWEIAIQHALMPVIPKGSSVGTGTNLHRDISVSISVSNCQIQENVDISTVYQIFPDEVLGSGQFGIVYGGKHRKTGRDVAIKIIDKLRFPTKQESQLRNEVAILQNLHHPGVVNLECMFETPERVFVVMEKLHGDMLEMILSSEKGRLPEHITKFLITQILVALRHLHFKNIVHCDLKPENVLLASADPFPQVKLCDFGFARIIGEKSFRRSVVGTPAYLAPEVLRNKGYNRSLDMWSVGVIIYVSLSGTFPFNEDEDIHDQIQNAAFMYPPNPWKEISHEAIDLINNLLQVKMRKRYSVDKTLSHPWLQDYQTWLDLRELECKIGERYITHESDDLRWEKYAGEQGLQYPTHLINPSASHSDTPETEETEMKALGERVSIL
T47885	DRUGINFO	D03DYT	K252a	Investigative
T47885	DRUGINFO	D03HQE	CRT0066101	Investigative
T47885	DRUGINFO	D0F2SA	BPKDi	Investigative
T47885	DRUGINFO	D0MC3K	CID755673	Investigative
T47885	DRUGINFO	D0O8FN	INDUS-815B	Investigative
T47885	DRUGINFO	D08JPU	G6976	Investigative

T03581	TARGETID	T03581
T03581	FORMERID	TTDI03539
T03581	UNIPROID	STK38_HUMAN
T03581	TARGNAME	NDR1 protein kinase (STK38)
T03581	GENENAME	STK38
T03581	TARGTYPE	Literature-reported
T03581	SYNONYMS	Serine/threonine-protein kinase 38; Nuclear Dbf2-related kinase 1; NDR1
T03581	FUNCTION	Converts MAP3K2 from its phosphorylated form to its non-phosphorylated form and inhibits autophosphorylation of MAP3K2. Negative regulator of MAP3K1/2 signaling.
T03581	PDBSTRUC	6BXI; 1PSB
T03581	BIOCLASS	Kinase
T03581	ECNUMBER	EC 2.7.11.1
T03581	SEQUENCE	MAMTGSTPCSSMSNHTKERVTMTKVTLENFYSNLIAQHEEREMRQKKLEKVMEEEGLKDEEKRLRRSAHARKETEFLRLKRTRLGLEDFESLKVIGRGAFGEVRLVQKKDTGHVYAMKILRKADMLEKEQVGHIRAERDILVEADSLWVVKMFYSFQDKLNLYLIMEFLPGGDMMTLLMKKDTLTEEETQFYIAETVLAIDSIHQLGFIHRDIKPDNLLLDSKGHVKLSDFGLCTGLKKAHRTEFYRNLNHSLPSDFTFQNMNSKRKAETWKRNRRQLAFSTVGTPDYIAPEVFMQTGYNKLCDWWSLGVIMYEMLIGYPPFCSETPQETYKKVMNWKETLTFPPEVPISEKAKDLILRFCCEWEHRIGAPGVEEIKSNSFFEGVDWEHIRERPAAISIEIKSIDDTSNFDEFPESDILKPTVATSNHPETDYKNKDWVFINYTYKRFEGLTARGAIPSYMKAAK
T03581	DRUGINFO	D0R3MO	PMID20684608C35	Investigative

T57006	TARGETID	T57006
T57006	FORMERID	TTDI03178
T57006	UNIPROID	EPHA7_HUMAN
T57006	TARGNAME	Ephrin type-A receptor 7 (EPHA7)
T57006	GENENAME	EPHA7
T57006	TARGTYPE	Literature-reported
T57006	SYNONYMS	hEK11; EPH-like kinase 11; EPH homology kinase 3; EK11; EHK3; EHK-3
T57006	FUNCTION	The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Among GPI-anchored ephrin-A ligands, EFNA5 is a cognate/functional ligand for EPHA7 and their interaction regulates brain development modulating cell-cell adhesion and repulsion. Has a repellent activity on axons and is for instance involved in the guidance of corticothalamic axons and in the proper topographic mapping of retinal axons to the colliculus. May also regulate brain development through a caspase(CASP3)-dependent proapoptotic activity. Forward signaling may result in activation of components of the ERK signaling pathway including MAP2K1, MAP2K2, MAPK1 AND MAPK3 which are phosphorylated upon activation of EPHA7. Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells.
T57006	PDBSTRUC	3NRU; 3H8M; 3DKO; 2REI
T57006	BIOCLASS	Kinase
T57006	ECNUMBER	EC 2.7.10.1
T57006	SEQUENCE	MVFQTRYPSWIILCYIWLLRFAHTGEAQAAKEVLLLDSKAQQTELEWISSPPNGWEEISGLDENYTPIRTYQVCQVMEPNQNNWLRTNWISKGNAQRIFVELKFTLRDCNSLPGVLGTCKETFNLYYYETDYDTGRNIRENLYVKIDTIAADESFTQGDLGERKMKLNTEVREIGPLSKKGFYLAFQDVGACIALVSVKVYYKKCWSIIENLAIFPDTVTGSEFSSLVEVRGTCVSSAEEEAENAPRMHCSAEGEWLVPIGKCICKAGYQQKGDTCEPCGRGFYKSSSQDLQCSRCPTHSFSDKEGSSRCECEDGYYRAPSDPPYVACTRPPSAPQNLIFNINQTTVSLEWSPPADNGGRNDVTYRILCKRCSWEQGECVPCGSNIGYMPQQTGLEDNYVTVMDLLAHANYTFEVEAVNGVSDLSRSQRLFAAVSITTGQAAPSQVSGVMKERVLQRSVELSWQEPEHPNGVITEYEIKYYEKDQRERTYSTVKTKSTSASINNLKPGTVYVFQIRAFTAAGYGNYSPRLDVATLEEATGKMFEATAVSSEQNPVIIIAVVAVAGTIILVFMVFGFIIGRRHCGYSKADQEGDEELYFHFKFPGTKTYIDPETYEDPNRAVHQFAKELDASCIKIERVIGAGEFGEVCSGRLKLPGKRDVAVAIKTLKVGYTEKQRRDFLCEASIMGQFDHPNVVHLEGVVTRGKPVMIVIEFMENGALDAFLRKHDGQFTVIQLVGMLRGIAAGMRYLADMGYVHRDLAARNILVNSNLVCKVSDFGLSRVIEDDPEAVYTTTGGKIPVRWTAPEAIQYRKFTSASDVWSYGIVMWEVMSYGERPYWDMSNQDVIKAIEEGYRLPAPMDCPAGLHQLMLDCWQKERAERPKFEQIVGILDKMIRNPNSLKTPLGTCSRPISPLLDQNTPDFTTFCSVGEWLQAIKMERYKDNFTAAGYNSLESVARMTIEDVMSLGITLVGHQKKIMSSIQTMRAQMLHLHGTGIQV
T57006	DRUGINFO	D02BXJ	PMID21561767C8h	Investigative
T57006	DRUGINFO	D05FXD	PMID19788238C66	Investigative
T57006	DRUGINFO	D0X8BU	PMID23489211C20	Investigative

T90935	TARGETID	T90935
T90935	FORMERID	TTDR00018
T90935	UNIPROID	DHC24_HUMAN
T90935	TARGNAME	Delta(24)-sterol reductase (DHCR24)
T90935	GENENAME	DHCR24
T90935	TARGTYPE	Literature-reported
T90935	SYNONYMS	Seladin-1; Diminuto/dwarf1 homolog; DHCR24
T90935	FUNCTION	Catalyzes the reduction of the delta-24 double bond of sterol intermediates. Protects cells from oxidative stress by reducing caspase 3 activity during apoptosis induced by oxidative stress. Also protects against amyloid-beta peptide-induced apoptosis.
T90935	BIOCLASS	CH-CH donor oxidoreductase
T90935	ECNUMBER	EC 1.3.1.72
T90935	SEQUENCE	MEPAVSLAVCALLFLLWVRLKGLEFVLIHQRWVFVCLFLLPLSLIFDIYYYVRAWVVFKLSSAPRLHEQRVRDIQKQVREWKEQGSKTFMCTGRPGWLTVSLRVGKYKKTHKNIMINLMDILEVDTKKQIVRVEPLVTMGQVTALLTSIGWTLPVLPELDDLTVGGLIMGTGIESSSHKYGLFQHICTAYELVLADGSFVRCTPSENSDLFYAVPWSCGTLGFLVAAEIRIIPAKKYVKLRFEPVRGLEAICAKFTHESQRQENHFVEGLLYSLDEAVIMTGVMTDEAEPSKLNSIGNYYKPWFFKHVENYLKTNREGLEYIPLRHYYHRHTRSIFWELQDIIPFGNNPIFRYLFGWMVPPKISLLKLTQGETLRKLYEQHHVVQDMLVPMKCLQQALHTFQNDIHVYPIWLCPFILPSQPGLVHPKGNEAELYIDIGAYGEPRVKHFEARSCMRQLEKFVRSVHGFQMLYADCYMNREEFWEMFDGSLYHKLREKLGCQDAFPEVYDKICKAARH
T90935	DRUGINFO	D0K6NS	T-226293	Preclinical
T90935	DRUGINFO	D06IAT	Diazacholesterol	Investigative

T82848	TARGETID	T82848
T82848	FORMERID	TTDI00077
T82848	UNIPROID	PTN14_HUMAN
T82848	TARGNAME	Protein-tyrosine phosphatase pez (PTPN14)
T82848	GENENAME	PTPN14
T82848	TARGTYPE	Literature-reported
T82848	SYNONYMS	Tyrosine-protein phosphatase non-receptor type 14; PTPD2; PEZ
T82848	FUNCTION	Mediates beta-catenin dephosphorylation at adhesion junctions. Acts as a negative regulator of the oncogenic property of YAP, a downstream target of the hippo pathway, in a cell density-dependent manner. May function as a tumor suppressor. Protein tyrosine phosphatase which may play a role in the regulation of lymphangiogenesis, cell-cell adhesion, cell-matrix adhesion, cell migration, cell growth and also regulates TGF-beta gene expression, thereby modulating epithelial-mesenchymal transition.
T82848	PDBSTRUC	2BZL
T82848	BIOCLASS	Phosphoric monoester hydrolase
T82848	ECNUMBER	EC 3.1.3.48
T82848	SEQUENCE	MPFGLKLRRTRRYNVLSKNCFVTRIRLLDSNVIECTLSVESTGQECLEAVAQRLELRETHYFGLWFLSKSQQARWVELEKPLKKHLDKFANEPLLFFGVMFYVPNVSWLQQEATRYQYYLQVKKDVLEGRLRCTLDQVIRLAGLAVQADFGDYNQFDSQDFLREYVLFPMDLALEEAVLEELTQKVAQEHKAHSGILPAEAELMYINEVERLDGFGQEIFPVKDNHGNCVHLGIFFMGIFVRNRIGRQAVIYRWNDMGNITHNKSTILVELINKEETALFHTDDIENAKYISRLFATRHKFYKQNKICTEQSNSPPPIRRQPTWSRSSLPRQQPYILPPVHVQCGEHYSETHTSQDSIFHGNEEALYCNSHNSLDLNYLNGTVTNGSVCSVHSVNSLNCSQSFIQASPVSSNLSIPGSDIMRADYIPSHRHSAIIVPSYRPTPDYETVMRQMKRGILHTDSQSQSLRNLNIINTHAYNQPEDLVYSQPEMRERHPYTVPYGPQGVYSNKLVSPSDQRNPKNNVVPSKPGASAISHTVSTPELANMQLQGSHNYSTAHMLKNYLFRPPPPYPRPRPATSTPDLASHRHKYVSGSSPDLVTRKVQLSVKTFQEDSSPVVHQSLQEVSEPLTATKHHGTVNKRHSLEVMNSMVRGMEAMTLKSLHLPMARRNTLREQGPPEEGSGSHEVPQLPQYHHKKTFSDATMLIHSSESEEEEEEAPESVPQIPMLREKMEYSAQLQAALARIPNKPPPEYPGPRKSVSNGALRQDQASLPPAMARARVLRHGPAKAISMSRTDPPAVNGASLGPSISEPDLTSVKERVKKEPVKERPVSEMFSLEDSIIEREMMIRNLEKQKMAGLEAQKRPLMLAALNGLSVARVSGREENRVDATRVPMDERFRTLKKKLEEGMVFTEYEQIPKKKANGIFSTAALPENAERSRIREVVPYEENRVELIPTKENNTGYINASHIKVVVGGAEWHYIATQGPLPHTCHDFWQMVWEQGVNVIAMVTAEEEGGRTKSHRYWPKLGSKHSSATYGKFKVTTKFRTDSVCYATTGLKVKHLLSGQERTVWHLQYTDWPDHGCPEDVQGFLSYLEEIQSVRRHTNSMLEGTKNRHPPIVVHCSAGVGRTGVLILSELMIYCLEHNEKVEVPMMLRLLREQRMFMIQTIAQYKFVYQVLIQFLQNSRLI

T73977	TARGETID	T73977
T73977	FORMERID	TTDR00200
T73977	UNIPROID	CAC1E_HUMAN
T73977	TARGNAME	Voltage-gated calcium channel alpha Cav2.3 (CACNA1E)
T73977	GENENAME	CACNA1E
T73977	TARGTYPE	Literature-reported
T73977	SYNONYMS	Voltage-gated calcium channel subunit alpha Cav2.3; Voltage-gated calcium channel alpha subunit Cav2.3; Voltage-dependent R-type calcium channel subunit alpha-1E; Voltage-dependent R-type calcium channel; R-type voltage-gated calcium channel; Class E voltage-gated calcium channel; Calcium channel, Ltype, alpha-1 polypeptide, isoform 6; Calcium channel, L type, alpha-1 polypeptide, isoform 6; CACNL1A6; CACH6; Brain calcium channel II; BII
T73977	FUNCTION	The isoform alpha-1E gives rise to R-type calcium currents. R-type calcium channels belong to the 'high-voltage activated' (HVA) group and are blocked by nickel. They are however insensitive to dihydropyridines (DHP). Calcium channels containing alpha-1E subunit could be involved in the modulation of firing patterns of neurons which is important for information processing. Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death.
T73977	PDBSTRUC	3BXL
T73977	BIOCLASS	Voltage-gated ion channel
T73977	SEQUENCE	MARFGEAVVARPGSGDGDSDQSRNRQGTPVPASGQAAAYKQTKAQRARTMALYNPIPVRQNCFTVNRSLFIFGEDNIVRKYAKKLIDWPPFEYMILATIIANCIVLALEQHLPEDDKTPMSRRLEKTEPYFIGIFCFEAGIKIVALGFIFHKGSYLRNGWNVMDFIVVLSGILATAGTHFNTHVDLRTLRAVRVLRPLKLVSGIPSLQIVLKSIMKAMVPLLQIGLLLFFAILMFAIIGLEFYSGKLHRACFMNNSGILEGFDPPHPCGVQGCPAGYECKDWIGPNDGITQFDNILFAVLTVFQCITMEGWTTVLYNTNDALGATWNWLYFIPLIIIGSFFVLNLVLGVLSGEFAKERERVENRRAFMKLRRQQQIERELNGYRAWIDKAEEVMLAEENKNAGTSALEVLRRATIKRSRTEAMTRDSSDEHCVDISSVGTPLARASIKSAKVDGVSYFRHKERLLRISIRHMVKSQVFYWIVLSLVALNTACVAIVHHNQPQWLTHLLYYAEFLFLGLFLLEMSLKMYGMGPRLYFHSSFNCFDFGVTVGSIFEVVWAIFRPGTSFGISVLRALRLLRIFKITKYWASLRNLVVSLMSSMKSIISLLFLLFLFIVVFALLGMQLFGGRFNFNDGTPSANFDTFPAAIMTVFQILTGEDWNEVMYNGIRSQGGVSSGMWSAIYFIVLTLFGNYTLLNVFLAIAVDNLANAQELTKDEQEEEEAFNQKHALQKAKEVSPMSAPNMPSIERDRRRRHHMSMWEPRSSHLRERRRRHHMSVWEQRTSQLRKHMQMSSQEALNREEAPTMNPLNPLNPLSSLNPLNAHPSLYRRPRAIEGLALGLALEKFEEERISRGGSLKGDGGDRSSALDNQRTPLSLGQREPPWLARPCHGNCDPTQQEAGGGEAVVTFEDRARHRQSQRRSRHRRVRTEGKESSSASRSRSASQERSLDEAMPTEGEKDHELRGNHGAKEPTIQEERAQDLRRTNSLMVSRGSGLAGGLDEADTPLVLPHPELEVGKHVVLTEQEPEGSSEQALLGNVQLDMGRVISQSEPDLSCITANTDKATTESTSVTVAIPDVDPLVDSTVVHISNKTDGEASPLKEAEIREDEEEVEKKKQKKEKRETGKAMVPHSSMFIFSTTNPIRRACHYIVNLRYFEMCILLVIAASSIALAAEDPVLTNSERNKVLRYFDYVFTGVFTFEMVIKMIDQGLILQDGSYFRDLWNILDFVVVVGALVAFALANALGTNKGRDIKTIKSLRVLRVLRPLKTIKRLPKLKAVFDCVVTSLKNVFNILIVYKLFMFIFAVIAVQLFKGKFFYCTDSSKDTEKECIGNYVDHEKNKMEVKGREWKRHEFHYDNIIWALLTLFTVSTGEGWPQVLQHSVDVTEEDRGPSRSNRMEMSIFYVVYFVVFPFFFVNIFVALIIITFQEQGDKMMEECSLEKNERACIDFAISAKPLTRYMPQNRHTFQYRVWHFVVSPSFEYTIMAMIALNTVVLMMKYYSAPCTYELALKYLNIAFTMVFSLECVLKVIAFGFLNYFRDTWNIFDFITVIGSITEIILTDSKLVNTSGFNMSFLKLFRAARLIKLLRQGYTIRILLWTFVQSFKALPYVCLLIAMLFFIYAIIGMQVFGNIKLDEESHINRHNNFRSFFGSLMLLFRSATGEAWQEIMLSCLGEKGCEPDTTAPSGQNENERCGTDLAYVYFVSFIFFCSFLMLNLFVAVIMDNFEYLTRDSSILGPHHLDEFVRVWAEYDRAACGRIHYTEMYEMLTLMSPPLGLGKRCPSKVAYKRLVLMNMPVAEDMTVHFTSTLMALIRTALDIKIAKGGADRQQLDSELQKETLAIWPHLSQKMLDLLVPMPKASDLTVGKIYAAMMIMDYYKQSKVKKQRQQLEEQKNAPMFQRMEPSSLPQEIIANAKALPYLQQDPVSGLSGRSGYPSMSPLSPQDIFQLACMDPADDGQFQERQSLEPEVSELKSVQPSNHGIYLPSDTQEHAGSGRASSMPRLTVDPQVVTDPSSMRRSFSTIRDKRSNSSWLEEFSMERSSENTYKSRRRSYHSSLRLSAHRLNSDSGHKSDTHRSGGRERGRSKERKHLLSPDVSRCNSEERGTQADWESPERRQSRSPSEGRSQTPNRQGTGSLSESSIPSVSDTSTPRRSRRQLPPVPPKPRPLLSYSSLIRHAGSISPPADGSEEGSPLTSQALESNNACLTESSNSPHPQQSQHASPQRYISEPYLALHEDSHASDCGEEETLTFEAAVATSLGRSNTIGSAPPLRHSWQMPNGHYRRRRRGGPGPGMMCGAVNNLLSDTEEDDKC
T73977	DRUGINFO	D0QQ7N	TH-9229	Terminated
T73977	DRUGINFO	D09YTH	CPU-228	Investigative

T60003	TARGETID	T60003
T60003	FORMERID	TTDI03493
T60003	UNIPROID	PKN1_HUMAN
T60003	TARGNAME	Protein kinase N1 (PKN1)
T60003	GENENAME	PKN1
T60003	TARGTYPE	Literature-reported
T60003	SYNONYMS	Serine/threonine-protein kinase N1; Serine-threonine protein kinase N; Protein-kinase C-related kinase 1; Protein kinase PKN-alpha; Protein kinase C-like PKN; Protein kinase C-like 1; Protease-activated kinase 1; PRKCL1; PRK1; PKN; PAK1
T60003	FUNCTION	Part of a signaling cascade that begins with the activation of the adrenergic receptor ADRA1B and leads to the activation of MAPK14. Regulates the cytoskeletal network by phosphorylating proteins such as VIM and neurofilament proteins NEFH, NEFL and NEFM, leading to inhibit their polymerization. Phosphorylates 'Ser-575', 'Ser-637' and 'Ser-669' of MAPT/Tau, lowering its ability to bind to microtubules, resulting in disruption of tubulin assembly. Acts as a key coactivator of androgen receptor (ANDR)-dependent transcription, by being recruited to ANDR target genes and specifically mediating phosphorylation of 'Thr-11' of histone H3 (H3T11ph), a specific tag for epigenetic transcriptional activation that promotes demethylation of histone H3 'Lys-9' (H3K9me) by KDM4C/JMJD2C. Phosphorylates HDAC5, HDAC7 and HDAC9, leading to impair their import in the nucleus. Phosphorylates 'Thr-38' of PPP1R14A, 'Ser-159', 'Ser-163' and 'Ser-170' of MARCKS, and GFAP. Able to phosphorylate RPS6 in vitro. PKC-related serine/threonine-protein kinase involved in various processes such as regulation of the intermediate filaments of the actin cytoskeleton, cell migration, tumor cell invasion and transcription regulation.
T60003	PDBSTRUC	4OTI; 4OTH; 4OTG; 4OTD; 4NKG
T60003	BIOCLASS	Kinase
T60003	ECNUMBER	EC 2.7.11.13
T60003	SEQUENCE	MASDAVQSEPRSWSLLEQLGLAGADLAAPGVQQQLELERERLRREIRKELKLKEGAENLRRATTDLGRSLGPVELLLRGSSRRLDLLHQQLQELHAHVVLPDPAATHDGPQSPGAGGPTCSATNLSRVAGLEKQLAIELKVKQGAENMIQTYSNGSTKDRKLLLTAQQMLQDSKTKIDIIRMQLRRALQAGQLENQAAPDDTQGSPDLGAVELRIEELRHHFRVEHAVAEGAKNVLRLLSAAKAPDRKAVSEAQEKLTESNQKLGLLREALERRLGELPADHPKGRLLREELAAASSAAFSTRLAGPFPATHYSTLCKPAPLTGTLEVRVVGCRDLPETIPWNPTPSMGGPGTPDSRPPFLSRPARGLYSRSGSLSGRSSLKAEAENTSEVSTVLKLDNTVVGQTSWKPCGPNAWDQSFTLELERARELELAVFWRDQRGLCALKFLKLEDFLDNERHEVQLDMEPQGCLVAEVTFRNPVIERIPRLRRQKKIFSKQQGKAFQRARQMNIDVATWVRLLRRLIPNATGTGTFSPGASPGSEARTTGDISVEKLNLGTDSDSSPQKSSRDPPSSPSSLSSPIQESTAPELPSETQETPGPALCSPLRKSPLTLEDFKFLAVLGRGHFGKVLLSEFRPSGELFAIKALKKGDIVARDEVESLMCEKRILAAVTSAGHPFLVNLFGCFQTPEHVCFVMEYSAGGDLMLHIHSDVFSEPRAIFYSACVVLGLQFLHEHKIVYRDLKLDNLLLDTEGYVKIADFGLCKEGMGYGDRTSTFCGTPEFLAPEVLTDTSYTRAVDWWGLGVLLYEMLVGESPFPGDDEEEVFDSIVNDEVRYPRFLSAEAIGIMRRLLRRNPERRLGSSERDAEDVKKQPFFRTLGWEALLARRLPPPFVPTLSGRTDVSNFDEEFTGEAPTLSPPRDARPLTAAEQAAFLDFDFVAGGC
T60003	DRUGINFO	D06HVH	PMID22136433C20	Investigative
T60003	DRUGINFO	D03CPB	RKI-1447	Investigative

T94197	TARGETID	T94197
T94197	FORMERID	TTDI03494
T94197	UNIPROID	PKN2_HUMAN
T94197	TARGNAME	Protein kinase N2 (PKN2)
T94197	GENENAME	PKN2
T94197	TARGTYPE	Literature-reported
T94197	SYNONYMS	Serine/threonine-protein kinase N2; Protein-kinase C-related kinase 2; Protein kinase C-like 2; PRKCL2; PRK2; PKN gamma
T94197	FUNCTION	Plays a role in the regulation of cell cycle progression, actin cytoskeleton assembly, cell migration, cell adhesion, tumor cell invasion and transcription activation signaling processes. Phosphorylates CTTN in hyaluronan-induced astrocytes and hence decreases CTTN ability to associate with filamentous actin. Phosphorylates HDAC5, therefore lead to impair HDAC5 import. Direct RhoA target required for the regulation of the maturation of primordial junctions into apical junction formation in bronchial epithelial cells. Required for G2/M phases of the cell cycle progression and abscission during cytokinesis in a ECT2-dependent manner. Stimulates FYN kinase activity that is required for establishment of skin cell-cell adhesion during keratinocytes differentiation. Regulates epithelial bladder cells speed and direction of movement during cell migration and tumor cell invasion. Inhibits Akt pro-survival-induced kinase activity. Mediates Rho protein-induced transcriptional activation via the c-fos serum response factor (SRF). Involved in the negative regulation of ciliogenesis. PKC-related serine/threonine-protein kinase and Rho/Rac effector protein that participates in specific signal transduction responses in the cell.
T94197	PDBSTRUC	6GBE; 6CCY; 4RRV; 4CRS
T94197	BIOCLASS	Kinase
T94197	ECNUMBER	EC 2.7.11.13
T94197	SEQUENCE	MASNPERGEILLTELQGDSRSLPFSENVSAVQKLDFSDTMVQQKLDDIKDRIKREIRKELKIKEGAENLRKVTTDKKSLAYVDNILKKSNKKLEELHHKLQELNAHIVVSDPEDITDCPRTPDTPNNDPRCSTSNNRLKALQKQLDIELKVKQGAENMIQMYSNGSSKDRKLHGTAQQLLQDSKTKIEVIRMQILQAVQTNELAFDNAKPVISPLELRMEELRHHFRIEFAVAEGAKNVMKLLGSGKVTDRKALSEAQARFNESSQKLDLLKYSLEQRLNEVPKNHPKSRIIIEELSLVAASPTLSPRQSMISTQNQYSTLSKPAALTGTLEVRLMGCQDILENVPGRSKATSVALPGWSPSETRSSFMSRTSKSKSGSSRNLLKTDDLSNDVCAVLKLDNTVVGQTSWKPISNQSWDQKFTLELDRSRELEISVYWRDWRSLCAVKFLRLEDFLDNQRHGMCLYLEPQGTLFAEVTFFNPVIERRPKLQRQKKIFSKQQGKTFLRAPQMNINIATWGRLVRRAIPTVNHSGTFSPQAPVPTTVPVVDVRIPQLAPPASDSTVTKLDFDLEPEPPPAPPRASSLGEIDESSELRVLDIPGQDSETVFDIQNDRNSILPKSQSEYKPDTPQSGLEYSGIQELEDRRSQQRFQFNLQDFRCCAVLGRGHFGKVLLAEYKNTNEMFAIKALKKGDIVARDEVDSLMCEKRIFETVNSVRHPFLVNLFACFQTKEHVCFVMEYAAGGDLMMHIHTDVFSEPRAVFYAACVVLGLQYLHEHKIVYRDLKLDNLLLDTEGFVKIADFGLCKEGMGYGDRTSTFCGTPEFLAPEVLTETSYTRAVDWWGLGVLIYEMLVGESPFPGDDEEEVFDSIVNDEVRYPRFLSTEAISIMRRLLRRNPERRLGASEKDAEDVKKHPFFRLIDWSALMDKKVKPPFIPTIRGREDVSNFDDEFTSEAPILTPPREPRILSEEEQEMFRDFDYIADWC
T94197	DRUGINFO	D0N1UU	PMID20471253C32	Investigative

T83979	TARGETID	T83979
T83979	FORMERID	TTDI02539
T83979	UNIPROID	PTGIS_HUMAN
T83979	TARGNAME	Prostacyclin synthase (PTGIS)
T83979	GENENAME	PTGIS
T83979	TARGTYPE	Literature-reported
T83979	SYNONYMS	Prostaglandin I2 synthase; PTGIS
T83979	FUNCTION	Catalyzes the isomerization of prostaglandin H2 to prostacyclin (= prostaglandin I2).
T83979	PDBSTRUC	3B6H; 2IAG
T83979	BIOCLASS	Intramolecular oxidoreductases
T83979	ECNUMBER	EC 5.3.99.4
T83979	SEQUENCE	MAWAALLGLLAALLLLLLLSRRRTRRPGEPPLDLGSIPWLGYALDFGKDAASFLTRMKEKHGDIFTILVGGRYVTVLLDPHSYDAVVWEPRTRLDFHAYAIFLMERIFDVQLPHYSPSDEKARMKLTLLHRELQALTEAMYTNLHAVLLGDATEAGSGWHEMGLLDFSYSFLLRAGYLTLYGIEALPRTHESQAQDRVHSADVFHTFRQLDRLLPKLARGSLSVGDKDHMCSVKSRLWKLLSPARLARRAHRSKWLESYLLHLEEMGVSEEMQARALVLQLWATQGNMGPAAFWLLLFLLKNPEALAAVRGELESILWQAEQPVSQTTTLPQKVLDSTPVLDSVLSESLRLTAAPFITREVVVDLAMPMADGREFNLRRGDRLLLFPFLSPQRDPEIYTDPEVFKYNRFLNPDGSEKKDFYKDGKRLKNYNMPWGAGHNHCLGRSYAVNSIKQFVFLVLVHLDLELINADVEIPEFDLSRYGFGLMQPEHDVPVRYRIRP

T72701	TARGETID	T72701
T72701	FORMERID	TTDI02304
T72701	UNIPROID	RPOC_STAA8
T72701	TARGNAME	Bacterial DNA-directed RNA polymerase beta' (Bact rpoC)
T72701	GENENAME	Bact rpoC
T72701	TARGTYPE	Literature-reported
T72701	SYNONYMS	rpoC; Transcriptase subunit beta'; RNAP subunit beta'; RNA polymerasesubunit beta'; DNAdirected RNA polymerase subunit beta'
T72701	FUNCTION	DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates.
T72701	BIOCLASS	Nucleotidyltransferase
T72701	ECNUMBER	EC 2.7.7.6
T72701	SEQUENCE	MIDVNNFHYMKIGLASPEKIRSWSFGEVKKPETINYRTLKPEKDGLFCERIFGPTKDWECSCGKYKRVRYKGMVCDRCGVEVTKSKVRRERMGHIELAAPVSHIWYFKGIPSRMGLLLDMSPRALEEVIYFASYVVVDPGPTGLEKKTLLSEAEFRDYYDKYPGQFVAKMGAEGIKDLLEEIDLDEELKLLRDELESATGQRLTRAIKRLEVVESFRNSGNKPSWMILDVLPIIPPEIRPMVQLDGGRFATSDLNDLYRRVINRNNRLKRLLDLGAPGIIVQNEKRMLQEAVDALIDNGRRGRPVTGPGNRPLKSLSHMLKGKQGRFRQNLLGKRVDYSGRSVIAVGPSLKMYQCGLPKEMALELFKPFVMKELVQREIATNIKNAKSKIERMDDEVWDVLEEVIREHPVLLNRAPTLHRLGIQAFEPTLVEGRAIRLHPLVTTAYNADFDGDQMAVHVPLSKEAQAEARMLMLAAQNILNPKDGKPVVTPSQDMVLGNYYLTLERKDAVNTGAIFNNTNEVLKAYANGFVHLHTRIGVHASSFNNPTFTEEQNKKILATSVGKIIFNEIIPDSFAYINEPTQENLERKTPNRYFIDPTTLGEGGLKEYFENEELIEPFNKKFLGNIIAEVFNRFSITDTSMMLDRMKDLGFKFSSKAGITVGVADIVVLPDKQQILDEHEKLVDRITKQFNRGLITEEERYNAVVEIWTDAKDQIQGELMQSLDKTNPIFMMSDSGARGNASNFTQLAGMRGLMAAPSGKIIELPITSSFREGLTVLEYFISTHGARKGLADTALKTADSGYLTRRLVDVAQDVIVREEDCGTDRGLLVSDIKEGTEMIEPFIERIEGRYSKETIRHPETDEIIIRPDELITPEIAKKITDAGIEQMYIRSAFTCNARHGVCEKCYGKNLATGEKVEVGEAVGTIAAQSIGEPGTQLTMRTFHTGGVAGSDITQGLPRIQEIFEARNPKGQAVITEIEGVVEDIKLAKDRQQEIVVKGANETRSYLASGTSRIIVEIGQPVQRGEVLTEGSIEPKNYLSVAGLNATESYLLKEVQKVYRMQGVEIDDKHVEVMVRQMLRKVRIIEAGDTKLLPGSLVDIHNFTDANREAFKHRKRPATAKPVLLGITKASLETESFLSAASFQETTRVLTDAAIKGKRDDLLGLKENVIIGKLIPAGTGMRRYSDVKYEKTAKPVAEVESQTEVTE

T92639	TARGETID	T92639
T92639	UNIPROID	ATAT_HUMAN
T92639	TARGNAME	Alpha-tubulin N-acetyltransferase 1 (ATAT1)
T92639	GENENAME	ATAT1
T92639	TARGTYPE	Literature-reported
T92639	SYNONYMS	MEC17; C6orf134; Alpha-TAT; Acetyltransferase mec-17 homolog
T92639	FUNCTION	Specifically acetylates 'Lys-40' in alpha-tubulin on the lumenal side of microtubules. Promotes microtubule destabilization and accelerates microtubule dynamics; this activity may be independent of acetylation activity. Acetylates alpha-tubulin with a slow enzymatic rate, due to a catalytic site that is not optimized for acetyl transfer. Enters the microtubule through each end and diffuses quickly throughout the lumen of microtubules. Acetylates only long/old microtubules because of its slow acetylation rate since it does not have time to act on dynamically unstable microtubules before the enzyme is released. Required for normal sperm flagellar function. Promotes directional cell locomotion and chemotaxis, through AP2A2-dependent acetylation of alpha-tubulin at clathrin-coated pits that are concentrated at the leading edge of migrating cells. May facilitate primary cilium assembly.
T92639	PDBSTRUC	4U9Z; 4U9Y; 4PK3; 4PK2; 4IF5
T92639	BIOCLASS	Acetyltransferase ATAT1 family
T92639	ECNUMBER	EC 2.3.1.108
T92639	SEQUENCE	MEFPFDVDALFPERITVLDQHLRPPARRPGTTTPARVDLQQQIMTIIDELGKASAKAQNLSAPITSASRMQSNRHVVYILKDSSARPAGKGAIIGFIKVGYKKLFVLDDREAHNEVEPLCILDFYIHESVQRHGHGRELFQYMLQKERVEPHQLAIDRPSQKLLKFLNKHYNLETTVPQVNNFVIFEGFFAHQHRPPAPSLRATRHSRAAAVDPTPAAPARKLPPKRAEGDIKPYSSSDREFLKVAVEPPWPLNRAPRRATPPAHPPPRSSSLGNSPERGPLRPFVPEQELLRSLRLCPPHPTARLLLAADPGGSPAQRRRTRGTPPGLVAQSCCYSRHGGVNSSSPNTGNQDSKQGEQETKNRSASEEQALSQDGSGEKPMHTAPPQAPAPPAQSWTVGGDILNARFIRNLQERRSTRPW

T92334	TARGETID	T92334
T92334	UNIPROID	M3K21_HUMAN
T92334	TARGNAME	Mixed lineage kinase 4 (MAP3K21)
T92334	GENENAME	MAP3K21
T92334	TARGTYPE	Literature-reported
T92334	SYNONYMS	Mitogen-activated protein kinase kinase kinase MLK4; MLK4beta
T92334	FUNCTION	Negative regulator of TLR4 signaling. Does not activate JNK1/MAPK8 pathway, p38/MAPK14, nor ERK2/MAPK1 pathways.
T92334	PDBSTRUC	4UYA
T92334	BIOCLASS	Protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase kinase subfamily
T92334	ECNUMBER	EC 2.7.11.25
T92334	SEQUENCE	MALRGAAGATDTPVSSAGGAPGGSASSSSTSSGGSASAGAGLWAALYDYEARGEDELSLRRGQLVEVLSQDAAVSGDEGWWAGQVQRRLGIFPANYVAPCRPAASPAPPPSRPSSPVHVAFERLELKELIGAGGFGQVYRATWQGQEVAVKAARQDPEQDAAAAAESVRREARLFAMLRHPNIIELRGVCLQQPHLCLVLEFARGGALNRALAAANAAPDPRAPGPRRARRIPPHVLVNWAVQIARGMLYLHEEAFVPILHRDLKSSNILLLEKIEHDDICNKTLKITDFGLAREWHRTTKMSTAGTYAWMAPEVIKSSLFSKGSDIWSYGVLLWELLTGEVPYRGIDGLAVAYGVAVNKLTLPIPSTCPEPFAKLMKECWQQDPHIRPSFALILEQLTAIEGAVMTEMPQESFHSMQDDWKLEIQQMFDELRTKEKELRSREEELTRAALQQKSQEELLKRREQQLAEREIDVLERELNILIFQLNQEKPKVKKRKGKFKRSRLKLKDGHRISLPSDFQHKITVQASPNLDKRRSLNSSSSSPPSSPTMMPRLRAIQLTSDESNKTWGRNTVFRQEEFEDVKRNFKKKGCTWGPNSIQMKDRTDCKERIRPLSDGNSPWSTILIKNQKTMPLASLFVDQPGSCEEPKLSPDGLEHRKPKQIKLPSQAYIDLPLGKDAQRENPAEAESWEEAASANAATVSIEMTPTNSLSRSPQRKKTESALYGCTVLLASVALGLDLRELHKAQAAEEPLPKEEKKKREGIFQRASKSRRSASPPTSLPSTCGEASSPPSLPLSSALGILSTPSFSTKCLLQMDSEDPLVDSAPVTCDSEMLTPDFCPTAPGSGREPALMPRLDTDCSVSRNLPSSFLQQTCGNVPYCASSKHRPSHHRRTMSDGNPTPTGATIISATGASALPLCPSPAPHSHLPREVSPKKHSTVHIVPQRRPASLRSRSDLPQAYPQTAVSQLAQTACVVGRPGPHPTQFLAAKERTKSHVPSLLDADVEGQSRDYTVPLCRMRSKTSRPSIYELEKEFLS

T15636	TARGETID	T15636
T15636	FORMERID	TTDR00588
T15636	UNIPROID	TTBK1_HUMAN
T15636	TARGNAME	Tau-tubulin kinase (TTBK1)
T15636	GENENAME	TTBK1
T15636	TARGTYPE	Literature-reported
T15636	SYNONYMS	Tau-tubulin kinase 1; KIAA1855; Brain-derived tau kinase; BDTK
T15636	FUNCTION	Serine/threonine kinase which is able to phosphorylate TAU on serine, threonine and tyrosine residues. Induces aggregation of TAU.
T15636	PDBSTRUC	4NFN; 4NFM; 4BTM; 4BTK; 4BTJ
T15636	BIOCLASS	Kinase
T15636	ECNUMBER	EC 2.7.11.1
T15636	SEQUENCE	MQCLAAALKDETNMSGGGEQADILPANYVVKDRWKVLKKIGGGGFGEIYEAMDLLTRENVALKVESAQQPKQVLKMEVAVLKKLQGKDHVCRFIGCGRNEKFNYVVMQLQGRNLADLRRSQPRGTFTLSTTLRLGKQILESIEAIHSVGFLHRDIKPSNFAMGRLPSTYRKCYMLDFGLARQYTNTTGDVRPPRNVAGFRGTVRYASVNAHKNREMGRHDDLWSLFYMLVEFAVGQLPWRKIKDKEQVGMIKEKYEHRMLLKHMPSEFHLFLDHIASLDYFTKPDYQLIMSVFENSMKERGIAENEAFDWEKAGTDALLSTSTSTPPQQNTRQTAAMFGVVNVTPVPGDLLRENTEDVLQGEHLSDQENAPPILPGRPSEGLGPSPHLVPHPGGPEAEVWEETDVNRNKLRINIGKSPCVEEEQSRGMGVPSSPVRAPPDSPTTPVRSLRYRRVNSPESERLSTADGRVELPERRSRMDLPGSPSRQACSSQPAQMLSVDTGHADRQASGRMDVSASVEQEALSNAFRSVPLAEEEDFDSKEWVIIDKETELKDFPPGAEPSTSGTTDEEPEELRPLPEEGEERRRLGAEPTVRPRGRSMQALAEEDLQHLPPQPLPPQLSQGDGRSETSQPPTPGSPSHSPLHSGPRPRRRESDPTGPQRQVFSVAPPFEVNGLPRAVPLSLPYQDFKRDLSDYRERARLLNRVRRVGFSHMLLTTPQVPLAPVQPQANGKEEEEEEEEDEEEEEEDEEEEEEEEEEEEEEEEEEEEEEEAAAAVALGEVLGPRSGSSSEGSERSTDRSQEGAPSTLLADDQKESRGRASMADGDLEPEEGSKTLVLVSPGDMKKSPVTAELAPDPDLGTLAALTPQHERPQPTGSQLDVSEPGTLSSVLKSEPKPPGPGAGLGAGTVTTGVGGVAVTSSPFTKVERTFVHIAEKTHLNVMSSGGQALRSEEFSAGGELGLELASDGGAVEEGARAPLENGLALSGLNGAEIEGSALSGAPRETPSEMATNSLPNGPALADGPAPVSPLEPSPEKVATISPRRHAMPGSRPRSRIPVLLSEEDTGSEPSGSLSAKERWSKRARPQQDLARLVMEKRQGRLLLRLASGASSSSSEEQRRASETLSGTGSEEDTPASEPAAALPRKSGRAAATRSRIPRPIGLRMPMPVAAQQPASRSHGAAPALDTAITSRLQLQTPPGSATAADLRPKQPPGRGLGPGRAQAGARPPAPRSPRLPASTSAARNASASPRSQSLSRRESPSPSHQARPGVPPPRGVPPARAQPDGTPSPGGSKKGPRGKLQAQRATTKGRAGGAEGRAGAR

T65084	TARGETID	T65084
T65084	FORMERID	TTDI00096
T65084	UNIPROID	OTU1_HUMAN
T65084	TARGNAME	Ubiquitin thioesterase OTU1 (YOD1)
T65084	GENENAME	YOD1
T65084	TARGTYPE	Literature-reported
T65084	SYNONYMS	PRO0907; OTUD2; OTU domain-containing protein 2; HsHIN7; HIV-1-induced protease 7; HIN7; HIN-7; DUBA8; DUBA-8
T65084	FUNCTION	May act by triming the ubiquitin chain on the associated substrate to facilitate their threading through the VCP/p97 pore. Ubiquitin moieties on substrates may present a steric impediment to the threading process when the substrate is transferred to the VCP pore and threaded through VCP's axial channel. Mediates deubiquitination of 'Lys-27'-, 'Lys-29'- and 'Lys-33'-linked polyubiquitin chains. Also able to hydrolyze 'Lys-11'-linked ubiquitin chains. Cleaves both polyubiquitin and di-ubiquitin. May play a role in macroautophagy, regulating for instance the clearance of damaged lysosomes. May recruit PLAA, UBXN6 and VCP to damaged lysosome membranes decorated with K48-linked ubiquitin chains and remove these chains allowing autophagosome formation. Hydrolase that can remove conjugated ubiquitin from proteins and participates in endoplasmic reticulum-associated degradation (ERAD) for misfolded lumenal proteins.
T65084	PDBSTRUC	4BOZ; 4BOS; 4BOQ
T65084	BIOCLASS	Peptidase
T65084	ECNUMBER	EC 3.4.19.12
T65084	SEQUENCE	MFGPAKGRHFGVHPAPGFPGGVSQQAAGTKAGPAGAWPVGSRTDTMWRLRCKAKDGTHVLQGLSSRTRVRELQGQIAAITGIAPGGQRILVGYPPECLDLSNGDTILEDLPIQSGDMLIIEEDQTRPRSSPAFTKRGASSYVRETLPVLTRTVVPADNSCLFTSVYYVVEGGVLNPACAPEMRRLIAQIVASDPDFYSEAILGKTNQEYCDWIKRDDTWGGAIEISILSKFYQCEICVVDTQTVRIDRFGEDAGYTKRVLLIYDGIHYDPLQRNFPDPDTPPLTIFSSNDDIVLVQALELADEARRRRQFTDVNRFTLRCMVCQKGLTGQAEAREHAKETGHTNFGEV

T65818	TARGETID	T65818
T65818	FORMERID	TTDI03171
T65818	UNIPROID	ERAP2_HUMAN
T65818	TARGNAME	Endoplasmic reticulum aminopeptidase 2 (ERAP2)
T65818	GENENAME	ERAP2
T65818	TARGTYPE	Literature-reported
T65818	SYNONYMS	Leukocyte-derived arginine aminopeptidase; LRAP; L-RAP
T65818	FUNCTION	Peptide trimming is essential to customize longer precursor peptides to fit them to the correct length required for presentation on MHC class I molecules. Preferentially hydrolyzes the basic residues Arg and Lys. Aminopeptidase that plays a central role in peptide trimming, a step required for the generation of most HLA class I-binding peptides.
T65818	PDBSTRUC	5K1V; 5J6S; 5CU5; 5AB2; 5AB0
T65818	BIOCLASS	Peptidase
T65818	ECNUMBER	EC 3.4.11.-
T65818	SEQUENCE	MFHSSAMVNSHRKPMFNIHRGFYCLTAILPQICICSQFSVPSSYHFTEDPGAFPVATNGERFPWQELRLPSVVIPLHYDLFVHPNLTSLDFVASEKIEVLVSNATQFIILHSKDLEITNATLQSEEDSRYMKPGKELKVLSYPAHEQIALLVPEKLTPHLKYYVAMDFQAKLGDGFEGFYKSTYRTLGGETRILAVTDFEPTQARMAFPCFDEPLFKANFSIKIRRESRHIALSNMPKVKTIELEGGLLEDHFETTVKMSTYLVAYIVCDFHSLSGFTSSGVKVSIYASPDKRNQTHYALQASLKLLDFYEKYFDIYYPLSKLDLIAIPDFAPGAMENWGLITYRETSLLFDPKTSSASDKLWVTRVIAHELAHQWFGNLVTMEWWNDIWLKEGFAKYMELIAVNATYPELQFDDYFLNVCFEVITKDSLNSSRPISKPAETPTQIQEMFDEVSYNKGACILNMLKDFLGEEKFQKGIIQYLKKFSYRNAKNDDLWSSLSNSCLESDFTSGGVCHSDPKMTSNMLAFLGENAEVKEMMTTWTLQKGIPLLVVKQDGCSLRLQQERFLQGVFQEDPEWRALQERYLWHIPLTYSTSSSNVIHRHILKSKTDTLDLPEKTSWVKFNVDSNGYYIVHYEGHGWDQLITQLNQNHTLLRPKDRVGLIHDVFQLVGAGRLTLDKALDMTYYLQHETSSPALLEGLSYLESFYHMMDRRNISDISENLKRYLLQYFKPVIDRQSWSDKGSVWDRMLRSALLKLACDLNHAPCIQKAAELFSQWMESSGKLNIPTDVLKIVYSVGAQTTAGWNYLLEQYELSMSSAEQNKILYALSTSKHQEKLLKLIELGMEGKVIKTQNLAALLHAIARRPKGQQLAWDFVRENWTHLLKKFDLGSYDIRMIISGTTAHFSSKDKLQEVKLFFESLEAQGSHLDIFQTVLETITKNIKWLEKNLPTLRTWLMVNT
T65818	DRUGINFO	D02MNM	PMID23916253C17	Investigative

T82467	TARGETID	T82467
T82467	FORMERID	TTDI03046
T82467	UNIPROID	ATAD2_HUMAN
T82467	TARGNAME	ATPase family AAA domain containing 2 (ATAD2)
T82467	GENENAME	ATAD2
T82467	TARGTYPE	Literature-reported
T82467	SYNONYMS	PRO2000; L16; ATPase family AAA domain-containing protein 2; ANCCA; AAA nuclear coregulator cancer-associated protein
T82467	FUNCTION	May play a role in the recruitment or occupancy of CREBBP at some ESR1 target gene promoters. May be required for histone hyperacetylation. Involved in the estrogen-induced cell proliferation and cell cycle progression of breast cancer cells. May be a transcriptional coactivator of the nuclear receptor ESR1 required to induce the expression of a subset of estradiol target genes, such as CCND1, MYC and E2F1.
T82467	PDBSTRUC	6HIE; 6HID; 6HIC; 6HIB; 6HIA
T82467	BIOCLASS	Acid anhydride hydrolase
T82467	ECNUMBER	EC 3.6.1.3
T82467	SEQUENCE	MVVLRSSLELHNHSAASATGSLDLSSDFLSLEHIGRRRLRSAGAAQKKPAATTAKAGDGSSVKEVETYHRTRALRSLRKDAQNSSDSSFEKNVEITEQLANGRHFTRQLARQQADKKKEEHREDKVIPVTRSLRARNIVQSTEHLHEDNGDVEVRRSCRIRSRYSGVNQSMLFDKLITNTAEAVLQKMDDMKKMRRQRMRELEDLGVFNETEESNLNMYTRGKQKDIQRTDEETTDNQEGSVESSEEGEDQEHEDDGEDEDDEDDDDDDDDDDDDDDEDDEDEEDGEEENQKRYYLRQRKATVYYQAPLEKPRHQRKPNIFYSGPASPARPRYRLSSAGPRSPYCKRMNRRRHAIHSSDSTSSSSSEDEQHFERRRKRSRNRAINRCLPLNFRKDELKGIYKDRMKIGASLADVDPMQLDSSVRFDSVGGLSNHIAALKEMVVFPLLYPEVFEKFKIQPPRGCLFYGPPGTGKTLVARALANECSQGDKRVAFFMRKGADCLSKWVGESERQLRLLFDQAYQMRPSIIFFDEIDGLAPVRSSRQDQIHSSIVSTLLALMDGLDSRGEIVVIGATNRLDSIDPALRRPGRFDREFLFSLPDKEARKEILKIHTRDWNPKPLDTFLEELAENCVGYCGADIKSICAEAALCALRRRYPQIYTTSEKLQLDLSSINISAKDFEVAMQKMIPASQRAVTSPGQALSTVVKPLLQNTVDKILEALQRVFPHAEFRTNKTLDSDISCPLLESDLAYSDDDVPSVYENGLSQKSSHKAKDNFNFLHLNRNACYQPMSFRPRILIVGEPGFGQGSHLAPAVIHALEKFTVYTLDIPVLFGVSTTSPEETCAQVIREAKRTAPSIVYVPHIHVWWEIVGPTLKATFTTLLQNIPSFAPVLLLATSDKPHSALPEEVQELFIRDYGEIFNVQLPDKEERTKFFEDLILKQAAKPPISKKKAVLQALEVLPVAPPPEPRSLTAEEVKRLEEQEEDTFRELRIFLRNVTHRLAIDKRFRVFTKPVDPDEVPDYVTVIKQPMDLSSVISKIDLHKYLTVKDYLRDIDLICSNALEYNPDRDPGDRLIRHRACALRDTAYAIIKEELDEDFEQLCEEIQESRKKRGCSSSKYAPSYYHVMPKQNSTLVGDKRSDPEQNEKLKTPSTPVACSTPAQLKRKIRKKSNWYLGTIKKRRKISQAKDDSQNAIDHKIESDTEETQDTSVDHNETGNTGESSVEENEKQQNASESKLELRNNSNTCNIENELEDSRKTTACTELRDKIACNGDASSSQIIHISDENEGKEMCVLRMTRARRSQVEQQQLITVEKALAILSQPTPSLVVDHERLKNLLKTVVKKSQNYNIFQLENLYAVISQCIYRHRKDHDKTSLIQKMEQEVENFSCSR
T82467	DRUGINFO	D00XRH	PMID26155854C60	Investigative
T82467	DRUGINFO	D0F5TZ	PMID26155854C57	Investigative

T10899	TARGETID	T10899
T10899	FORMERID	TTDI00224
T10899	UNIPROID	UBP37_HUMAN
T10899	TARGNAME	Ubiquitin carboxyl-terminal hydrolase 37 (USP37)
T10899	GENENAME	USP37
T10899	TARGTYPE	Literature-reported
T10899	SYNONYMS	Ubiquitin-specific-processing protease 37; Ubiquitin thioesterase 37; KIAA1594; Deubiquitinating enzyme 37
T10899	FUNCTION	Specifically mediates deubiquitination of 'Lys-11'-linked polyubiquitin chains, a specific ubiquitin-linkage type mediated by the APC/C complex. Also mediates deubiquitination of 'Lys-48'-linked polyubiquitin chains in vitro. Phosphorylation at Ser-628 during G1/S phase maximizes the deubiquitinase activity, leading to prevent degradation of cyclin-A (CCNA1 and CCNA2). Plays an important role in the regulation of DNA replication by stabilizing the licensing factor CDT1. Deubiquitinase that antagonizes the anaphase-promoting complex (APC/C) during G1/S transition by mediating deubiquitination of cyclin-A (CCNA1 and CCNA2), thereby promoting S phase entry.
T10899	PDBSTRUC	3U12
T10899	BIOCLASS	Peptidase
T10899	ECNUMBER	EC 3.4.19.12
T10899	SEQUENCE	MSPLKIHGPIRIRSMQTGITKWKEGSFEIVEKENKVSLVVHYNTGGIPRIFQLSHNIKNVVLRPSGAKQSRLMLTLQDNSFLSIDKVPSKDAEEMRLFLDAVHQNRLPAAMKPSQGSGSFGAILGSRTSQKETSRQLSYSDNQASAKRGSLETKDDIPFRKVLGNPGRGSIKTVAGSGIARTIPSLTSTSTPLRSGLLENRTEKRKRMISTGSELNEDYPKENDSSSNNKAMTDPSRKYLTSSREKQLSLKQSEENRTSGLLPLQSSSFYGSRAGSKEHSSGGTNLDRTNVSSQTPSAKRSLGFLPQPVPLSVKKLRCNQDYTGWNKPRVPLSSHQQQQLQGFSNLGNTCYMNAILQSLFSLQSFANDLLKQGIPWKKIPLNALIRRFAHLLVKKDICNSETKKDLLKKVKNAISATAERFSGYMQNDAHEFLSQCLDQLKEDMEKLNKTWKTEPVSGEENSPDISATRAYTCPVITNLEFEVQHSIICKACGEIIPKREQFNDLSIDLPRRKKPLPPRSIQDSLDLFFRAEELEYSCEKCGGKCALVRHKFNRLPRVLILHLKRYSFNVALSLNNKIGQQVIIPRYLTLSSHCTENTKPPFTLGWSAHMAISRPLKASQMVNSCITSPSTPSKKFTFKSKSSLALCLDSDSEDELKRSVALSQRLCEMLGNEQQQEDLEKDSKLCPIEPDKSELENSGFDRMSEEELLAAVLEISKRDASPSLSHEDDDKPTSSPDTGFAEDDIQEMPENPDTMETEKPKTITELDPASFTEITKDCDENKENKTPEGSQGEVDWLQQYDMEREREEQELQQALAQSLQEQEAWEQKEDDDLKRATELSLQEFNNSFVDALGSDEDSGNEDVFDMEYTEAEAEELKRNAETGNLPHSYRLISVVSHIGSTSSSGHYISDVYDIKKQAWFTYNDLEVSKIQEAAVQSDRDRSGYIFFYMHKEIFDELLETEKNSQSLSTEVGKTTRQAL

T89466	TARGETID	T89466
T89466	FORMERID	TTDI02412
T89466	UNIPROID	TRXR3_HUMAN
T89466	TARGNAME	Thioredoxin glutathione reductase (TGR)
T89466	GENENAME	TXNRD3
T89466	TARGTYPE	Literature-reported
T89466	SYNONYMS	Thioredoxin reductase TR2; Thioredoxin reductase 3; Thioredoxin and glutathione reductase; TGR
T89466	FUNCTION	Displays thioredoxin reductase, glutaredoxin and glutathione reductase activities. Catalyzes disulfide bond isomerization. Promotes disulfide bond formation between GPX4 and various sperm proteins and may play a role in sperm maturation by promoting formation of sperm structural components (By similarity).
T89466	PDBSTRUC	3H8Q
T89466	BIOCLASS	Sulfur donor oxidoreductase
T89466	ECNUMBER	EC 1.8.1.9
T89466	SEQUENCE	MERSPPQSPGPGKAGDAPNRRSGHVRGARVLSPPGRRARLSSPGPSRSSEAREELRRHLVGLIERSRVVIFSKSYCPHSTRVKELFSSLGVECNVLELDQVDDGARVQEVLSEITNQKTVPNIFVNKVHVGGCDQTFQAYQSGLLQKLLQEDLAYDYDLIIIGGGSGGLSCAKEAAILGKKVMVLDFVVPSPQGTSWGLGGTCVNVGCIPKKLMHQAALLGQALCDSRKFGWEYNQQVRHNWETMTKAIQNHISSLNWGYRLSLREKAVAYVNSYGEFVEHHKIKATNKKGQETYYTAAQFVIATGERPRYLGIQGDKEYCITSDDLFSLPYCPGKTLVVGASYVALECAGFLAGFGLDVTVMVRSILLRGFDQEMAEKVGSYMEQHGVKFLRKFIPVMVQQLEKGSPGKLKVLAKSTEGTETIEGVYNTVLLAIGRDSCTRKIGLEKIGVKINEKSGKIPVNDVEQTNVPYVYAVGDILEDKPELTPVAIQSGKLLAQRLFGASLEKCDYINVPTTVFTPLEYGCCGLSEEKAIEVYKKENLEIYHTLFWPLEWTVAGRENNTCYAKIICNKFDHDRVIGFHILGPNAGEVTQGFAAAMKCGLTKQLLDDTIGIHPTCGEVFTTLEITKSSGLDITQKGCUG

T05806	TARGETID	T05806
T05806	FORMERID	TTDR00853
T05806	UNIPROID	BPHL_HUMAN
T05806	TARGNAME	Valacyclovir hydrolase (BPHL)
T05806	GENENAME	BPHL
T05806	TARGTYPE	Literature-reported
T05806	SYNONYMS	VACVase; MCNAA; DJ40E16.6.1; Breast epithelial mucin-associated antigen; Bph-rp; Biphenyl hydrolase-like protein (Serine hydrolase) (Breast epithelial mucin-associated antigen, MCNAA, Bph-rp), variant 1; Biphenyl hydrolase-like protein; BPHL
T05806	FUNCTION	Serine hydrolase that catalyzes the hydrolytic activation of amino acid ester prodrugs of nucleoside analogs such as valacyclovir and valganciclovir. Activates valacyclovir to acyclovir. May play a role in detoxification processes. It is a specific alpha-amino acid ester hydrolase that prefers small, hydrophobic, and aromatic side chains and does not have a stringent requirement for the leaving group other than preferring aprimary alcohol.
T05806	PDBSTRUC	2OCL; 2OCK; 2OCI; 2OCG
T05806	BIOCLASS	Carboxylic ester hydrolase
T05806	ECNUMBER	EC 3.1.-.-
T05806	SEQUENCE	MVAVLGGRGVLRLRLLLSALKPGIHVPRAGPAAAFGTSVTSAKVAVNGVQLHYQQTGEGDHAVLLLPGMLGSGETDFGPQLKNLNKKLFTVVAWDPRGYGHSRPPDRDFPADFFERDAKDAVDLMKALKFKKVSLLGWSDGGITALIAAAKYPSYIHKMVIWGANAYVTDEDSMIYEGIRDVSKWSERTRKPLEALYGYDYFARTCEKWVDGIRQFKHLPDGNICRHLLPRVQCPALIVHGEKDPLVPRFHADFIHKHVKGSRLHLMPEGKHNLHLRFADEFNKLAEDFLQ
T05806	DRUGINFO	D0DO9W	L-Tyrosinamide	Investigative

T12837	TARGETID	T12837
T12837	FORMERID	TTDI02431
T12837	UNIPROID	CARM1_HUMAN
T12837	TARGNAME	Histone-arginine methyltransferase CARM1 (CARM1)
T12837	GENENAME	CARM1
T12837	TARGTYPE	Literature-reported
T12837	SYNONYMS	Protein arginine N-methyltransferase 4; PRMT4; Histonearginine methyltransferase CARM1; Coactivatorassociated arginine methyltransferase 1; Coactivator-associated arginine methyltransferase 1
T12837	FUNCTION	Recruited to promoters upon gene activation together with histone acetyltransferases from EP300/P300 and p160 families, methylates histone H3 at 'Arg-17' (H3R17me), forming mainly asymmetric dimethylarginine (H3R17me2a), leading to activate transcription via chromatin remodeling. During nuclear hormone receptor activation and TCF7L2/TCF4 activation, acts synergically with EP300/P300 and either one of the p160 histone acetyltransferases NCOA1/SRC1, NCOA2/GRIP1 and NCOA3/ACTR or CTNNB1/beta-catenin to activate transcription. During myogenic transcriptional activation, acts together with NCOA3/ACTR as a coactivator for MEF2C. During monocyte inflammatory stimulation, acts together with EP300/P300 as a coactivator for NF-kappa-B. Acts as coactivator for PPARG, promotes adipocyte differentiation and the accumulation of brown fat tissue. Plays a role in the regulation of pre-mRNA alternative splicing by methylation of splicing factors. Also seems to be involved in p53/TP53 transcriptional activation. Methylates EP300/P300, both at 'Arg-2142', which may loosen its interaction with NCOA2/GRIP1, and at 'Arg-580' and 'Arg-604' in the KIX domain, which impairs its interaction with CREB and inhibits CREB-dependent transcriptional activation. Also methylates arginine residues in RNA-binding proteins PABPC1, ELAVL1 and ELAV4, which may affect their mRNA-stabilizing properties and the half-life of their target mRNAs. Methylates (mono- and asymmetric dimethylation) the guanidino nitrogens of arginyl residues in several proteins involved in DNA packaging, transcription regulation, pre-mRNA splicing, and mRNA stability.
T12837	BIOCLASS	Methyltransferase
T12837	ECNUMBER	EC 2.1.1.319
T12837	SEQUENCE	MAAAAAAVGPGAGGAGSAVPGGAGPCATVSVFPGARLLTIGDANGEIQRHAEQQALRLEVRAGPDSAGIALYSHEDVCVFKCSVSRETECSRVGKQSFIITLGCNSVLIQFATPNDFCSFYNILKTCRGHTLERSVFSERTEESSAVQYFQFYGYLSQQQNMMQDYVRTGTYQRAILQNHTDFKDKIVLDVGCGSGILSFFAAQAGARKIYAVEASTMAQHAEVLVKSNNLTDRIVVIPGKVEEVSLPEQVDIIISEPMGYMLFNERMLESYLHAKKYLKPSGNMFPTIGDVHLAPFTDEQLYMEQFTKANFWYQPSFHGVDLSALRGAAVDEYFRQPVVDTFDIRILMAKSVKYTVNFLEAKEGDLHRIEIPFKFHMLHSGLVHGLAFWFDVAFIGSIMTVWLSTAPTEPLTHWYQVRCLFQSPLFAKAGDTLSGTCLLIANKRQSYDISIVAQVDQTGSKSSNLLDLKNPFFRYTGTTPSPPPGSHYTSPSENMWNTGSTYNLSSGMAVAGMPTAYDLSSVIASGSSVGHNNLIPLANTGIVNHTHSRMGSIMSTGIVQGSSGAQGSGGGSTSAHYAVNSQFTMGGPAISMASPMSIPTNTMHYGS
T12837	DRUGINFO	D0BU8W	BMS pyrazole inhibitor 7f	Investigative
T12837	DRUGINFO	D0Q3FY	PMID19632837C17f	Investigative

T46000	TARGETID	T46000
T46000	FORMERID	TTDI03385
T46000	UNIPROID	M4K3_HUMAN
T46000	TARGNAME	MEK kinase kinase 3 (MAP4K3)
T46000	GENENAME	MAP4K3
T46000	TARGTYPE	Literature-reported
T46000	SYNONYMS	RAB8IPL1; Mitogen-activated protein kinase kinase kinase kinase 3; MEKKK 3; MAPK/ERK kinase kinase kinase 3; Germinal center kinase-related protein kinase; GLK
T46000	FUNCTION	Appears to act upstream of the JUN N-terminal pathway. May play a role in the response to environmental stress.
T46000	PDBSTRUC	5J5T
T46000	BIOCLASS	Kinase
T46000	ECNUMBER	EC 2.7.11.1
T46000	SEQUENCE	MNPGFDLSRRNPQEDFELIQRIGSGTYGDVYKARNVNTGELAAIKVIKLEPGEDFAVVQQEIIMMKDCKHPNIVAYFGSYLRRDKLWICMEFCGGGSLQDIYHVTGPLSELQIAYVSRETLQGLYYLHSKGKMHRDIKGANILLTDNGHVKLADFGVSAQITATIAKRKSFIGTPYWMAPEVAAVERKGGYNQLCDLWAVGITAIELAELQPPMFDLHPMRALFLMTKSNFQPPKLKDKMKWSNSFHHFVKMALTKNPKKRPTAEKLLQHPFVTQHLTRSLAIELLDKVNNPDHSTYHDFDDDDPEPLVAVPHRIHSTSRNVREEKTRSEITFGQVKFDPPLRKETEPHHELPDSDGFLDSSEEIYYTARSNLDLQLEYGQGHQGGYFLGANKSLLKSVEEELHQRGHVAHLEDDEGDDDESKHSTLKAKIPPPLPPKPKSIFIPQEMHSTEDENQGTIKRCPMSGSPAKPSQVPPRPPPPRLPPHKPVALGNGMSSFQLNGERDGSLCQQQNEHRGTNLSRKEKKDVPKPISNGLPPTPKVHMGACFSKVFNGCPLKIHCASSWINPDTRDQYLIFGAEEGIYTLNLNELHETSMEQLFPRRCTWLYVMNNCLLSISGKASQLYSHNLPGLFDYARQMQKLPVAIPAHKLPDRILPRKFSVSAKIPETKWCQKCCVVRNPYTGHKYLCGALQTSIVLLEWVEPMQKFMLIKHIDFPIPCPLRMFEMLVVPEQEYPLVCVGVSRGRDFNQVVRFETVNPNSTSSWFTESDTPQTNVTHVTQLERDTILVCLDCCIKIVNLQGRLKSSRKLSSELTFDFQIESIVCLQDSVLAFWKHGMQGRSFRSNEVTQEISDSTRIFRLLGSDRVVVLESRPTDNPTANSNLYILAGHENSY
T46000	DRUGINFO	D0C2GE	PMID22765894C8h	Investigative

T27954	TARGETID	T27954
T27954	FORMERID	TTDR01253
T27954	UNIPROID	CA2D3_HUMAN
T27954	TARGNAME	Voltage-gated calcium channel alpha-2/delta-3 (CACNA2D3)
T27954	GENENAME	CACNA2D3
T27954	TARGTYPE	Literature-reported
T27954	SYNONYMS	Voltage-gated calcium channel subunit alpha-2/delta-3; Voltage-dependent calcium channel subunit delta-3; Voltage-dependent calcium channel subunit alpha-2-3; CACNA2D3
T27954	FUNCTION	The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-type calcium channel (CACNA1A), N-type (CACNA1B), L-type (CACNA1C OR CACNA1D) but not T-type (CACNA1G).
T27954	BIOCLASS	Voltage-gated ion channel
T27954	SEQUENCE	MAGPGSPRRASRGASALLAAALLYAALGDVVRSEQQIPLSVVKLWASAFGGEIKSIAAKYSGSQLLQKKYKEYEKDVAIEEIDGLQLVKKLAKNMEEMFHKKSEAVRRLVEAAEEAHLKHEFDADLQYEYFNAVLINERDKDGNFLELGKEFILAPNDHFNNLPVNISLSDVQVPTNMYNKDPAIVNGVYWSESLNKVFVDNFDRDPSLIWQYFGSAKGFFRQYPGIKWEPDENGVIAFDCRNRKWYIQAATSPKDVVILVDVSGSMKGLRLTIAKQTVSSILDTLGDDDFFNIIAYNEELHYVEPCLNGTLVQADRTNKEHFREHLDKLFAKGIGMLDIALNEAFNILSDFNHTGQGSICSQAIMLITDGAVDTYDTIFAKYNWPDRKVRIFTYLIGREAAFADNLKWMACANKGFFTQISTLADVQENVMEYLHVLSRPKVIDQEHDVVWTEAYIDSTLPQAQKLTDDQGPVLMTTVAMPVFSKQNETRSKGILLGVVGTDVPVKELLKTIPKYKLGIHGYAFAITNNGYILTHPELRLLYEEGKKRRKPNYSSVDLSEVEWEDRDDVLRNAMVNRKTGKFSMEVKKTVDKGKRVLVMTNDYYYTDIKGTPFSLGVALSRGHGKYFFRGNVTIEEGLHDLEHPDVSLADEWSYCNTDLHPEHRHLSQLEAIKLYLKGKEPLLQCDKELIQEVLFDAVVSAPIEAYWTSLALNKSENSDKGVEVAFLGTRTGLSRINLFVGAEQLTNQDFLKAGDKENIFNADHFPLWYRRAAEQIPGSFVYSIPFSTGPVNKSNVVTASTSIQLLDERKSPVVAAVGIQMKLEFFQRKFWTASRQCASLDGKCSISCDDETVNCYLIDNNGFILVSEDYTQTGDFFGEIEGAVMNKLLTMGSFKRITLYDYQAMCRANKESSDGAHGLLDPYNAFLSAVKWIMTELVLFLVEFNLCSWWHSDMTAKAQKLKQTLEPCDTEYPAFVSERTIKETTGNIACEDCSKSFVIQQIPSSNLFMVVVDSSCLCESVAPITMAPIEIRYNESLKCERLKAQKIRRRPESCHGFHPEENARECGGAPSLQAQTVLLLLPLLLMLFSR
T27954	DRUGINFO	D0D1EU	PD-144550	Investigative
T27954	DRUGINFO	D0T6DR	3-Aminomethyl-5-methyl-hexanoic acid	Investigative

T68443	TARGETID	T68443
T68443	FORMERID	TTDR00338
T68443	UNIPROID	MMP21_HUMAN
T68443	TARGNAME	Matrix metalloproteinase-21 (MMP-21)
T68443	GENENAME	MMP21
T68443	TARGTYPE	Literature-reported
T68443	SYNONYMS	MMP
T68443	FUNCTION	May act as a negative regulator of the NOTCH-signaling pathway. Cleaves alpha-1-antitrypsin. Plays a specialized role in the generation of left-right asymmetry during embryogenesis.
T68443	BIOCLASS	Peptidase
T68443	ECNUMBER	EC 3.4.24.-
T68443	SEQUENCE	MLAASIFRPTLLLCWLAAPWPTQPESLFHSRDRSDLEPSPLRQAKPIADLHAAQRFLSRYGWSGVWAAWGPSPEGPPETPKGAALAEAVRRFQRANALPASGELDAATLAAMNRPRCGVPDMRPPPPSAPPSPPGPPPRARSRRSPRAPLSLSRRGWQPRGYPDGGAAQAFSKRTLSWRLLGEALSSQLSVADQRRIVALAFRMWSEVTPLDFREDLAAPGAAVDIKLGFGRGRHLGCPRAFDGSGQEFAHAWRLGDIHFDDDEHFTPPTSDTGISLLKVAVHEIGHVLGLPHTYRTGSIMQPNYIPQEPAFELDWSDRKAIQKLYGSCEGSFDTAFDWIRKERNQYGEVMVRFSTYFFRNSWYWLYENRNNRTRYGDPIQILTGWPGIPTHNIDAFVHIWTWKRDERYFFQGNQYWRYDSDKDQALTEDEQGKSYPKLISEGFPGIPSPLDTAFYDRRQKLIYFFKESLVFAFDVNRNRVLNSYPKRITEVFPAVIPQNHPFRNIDSAYYSYAYNSIFFFKGNAYWKVVNDKDKQQNSWLPANGLFPKKFISEKWFDVCDVHISTLNM
T68443	DRUGINFO	D0T9HG	GM6001	Discontinued in Phase 2
T68443	DRUGINFO	D07SPC	N-hydroxy-2,3-bis(phenylsulfonamido)propanamide	Investigative
T68443	DRUGINFO	D0L4EO	3-(4-(2-phenylethynyl)benzoyl)pentanoic acid	Investigative
T68443	DRUGINFO	D05THD	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	Investigative
T68443	DRUGINFO	D07MJD	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	Investigative
T68443	DRUGINFO	D0S9OL	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	Investigative
T68443	DRUGINFO	D03AMR	SR-973	Investigative
T68443	DRUGINFO	D0W2UK	IK-862	Investigative

T38134	TARGETID	T38134
T38134	FORMERID	TTDI03070
T38134	UNIPROID	KKCC1_HUMAN
T38134	TARGNAME	CaM-kinase IV kinase (CAMKK1)
T38134	GENENAME	CAMKK1
T38134	TARGTYPE	Literature-reported
T38134	SYNONYMS	Calcium/calmodulin-dependent protein kinase kinase alpha; Calcium/calmodulin-dependent protein kinase kinase 1; CaMKK alpha; CaMKK 1; CaM-kinase kinase alpha; CaM-kinase kinase 1; CaM-KK alpha; CaM-KK 1; CAMKKA
T38134	FUNCTION	Calcium/calmodulin-dependent protein kinase that belongs to a proposed calcium-triggered signaling cascade involved in a number of cellular processes. Phosphorylates CAMK1, CAMK1D, CAMK1G and CAMK4. Involved in regulating cell apoptosis. Promotes cell survival by phosphorylating AKT1/PKB that inhibits pro-apoptotic BAD/Bcl2-antagonist of cell death.
T38134	PDBSTRUC	6CD6; 6CCF
T38134	BIOCLASS	Kinase
T38134	ECNUMBER	EC 2.7.11.17
T38134	SEQUENCE	MEGGPAVCCQDPRAELVERVAAIDVTHLEEADGGPEPTRNGVDPPPRARAASVIPGSTSRLLPARPSLSARKLSLQERPAGSYLEAQAGPYATGPASHISPRAWRRPTIESHHVAISDAEDCVQLNQYKLQSEIGKGAYGVVRLAYNESEDRHYAMKVLSKKKLLKQYGFPRRPPPRGSQAAQGGPAKQLLPLERVYQEIAILKKLDHVNVVKLIEVLDDPAEDNLYLVFDLLRKGPVMEVPCDKPFSEEQARLYLRDVILGLEYLHCQKIVHRDIKPSNLLLGDDGHVKIADFGVSNQFEGNDAQLSSTAGTPAFMAPEAISDSGQSFSGKALDVWATGVTLYCFVYGKCPFIDDFILALHRKIKNEPVVFPEEPEISEELKDLILKMLDKNPETRIGVPDIKLHPWVTKNGEEPLPSEEEHCSVVEVTEEEVKNSVRLIPSWTTVILVKSMLRKRSFGNPFEPQARREERSMSAPGNLLVKEGFGEGGKSPELPGVQEDEAAS
T38134	DRUGINFO	D0HZ8U	STO609	Investigative

T73184	TARGETID	T73184
T73184	FORMERID	TTDI03542
T73184	UNIPROID	SETD7_HUMAN
T73184	TARGNAME	Histone-lysine N-methyltransferase SETD7 (SETD7)
T73184	GENENAME	SETD7
T73184	TARGTYPE	Literature-reported
T73184	SYNONYMS	SET9; SET7/9; SET7; SET domain-containing protein 7; Lysine N-methyltransferase 7; KMT7; KIAA1717; Histone H3-K4 methyltransferase SETD7; H3-K4-HMTase SETD7
T73184	FUNCTION	H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation. Plays a central role in the transcriptional activation of genes such as collagenase or insulin. Recruited by IPF1/PDX-1 to the insulin promoter, leading to activate transcription. Has also methyltransferase activity toward non-histone proteins such as p53/TP53, TAF10, and possibly TAF7 by recognizing and binding the [KR]-[STA]-K in substrate proteins. Monomethylates 'Lys-189' of TAF10, leading to increase the affinity of TAF10 for RNA polymerase II. Monomethylates 'Lys-372' of p53/TP53, stabilizing p53/TP53 and increasing p53/TP53-mediated transcriptional activation. Histone methyltransferase that specifically monomethylates 'Lys-4' of histone H3.
T73184	PDBSTRUC	5YLT; 5EG2; 5AYF; 4JLG; 4JDS
T73184	BIOCLASS	Methyltransferase
T73184	ECNUMBER	EC 2.1.1.43
T73184	SEQUENCE	MDSDDEMVEEAVEGHLDDDGLPHGFCTVTYSSTDRFEGNFVHGEKNGRGKFFFFDGSTLEGYYVDDALQGQGVYTYEDGGVLQGTYVDGELNGPAQEYDTDGRLIFKGQYKDNIRHGVCWIYYPDGGSLVGEVNEDGEMTGEKIAYVYPDERTALYGKFIDGEMIEGKLATLMSTEEGRPHFELMPGNSVYHFDKSTSSCISTNALLPDPYESERVYVAESLISSAGEGLFSKVAVGPNTVMSFYNGVRITHQEVDSRDWALNGNTLSLDEETVIDVPEPYNHVSKYCASLGHKANHSFTPNCIYDMFVHPRFGPIKCIRTLRAVEADEELTVAYGYDHSPPGKSGPEAPEWYQVELKAFQATQQK
T73184	DRUGINFO	D0J6OV	(R)-PFI-2	Preclinical

T03593	TARGETID	T03593
T03593	FORMERID	TTDNR00656
T03593	UNIPROID	SIA8D_HUMAN
T03593	TARGNAME	Sialyltransferase 8D (ST8SIA4)
T03593	GENENAME	ST8SIA4
T03593	TARGTYPE	Literature-reported
T03593	SYNONYMS	Sialyltransferase St8Sia IV; ST8SiaIV; SIAT8D; SIAT8-D; Polysialyltransferase-1; PST1; PST; CMP-N-acetylneuraminate-poly-alpha-2,8-sialyltransferase; Alpha-2,8-sialyltransferase 8D
T03593	FUNCTION	Catalyzes the polycondensation of alpha-2,8-linked sialic acid required for the synthesis of polysialic acid (PSA), which is present on the embryonic neural cell adhesion molecule (N-CAM), necessary for plasticity of neural cells.
T03593	PDBSTRUC	6AHZ; 5Y3U; 5Y22
T03593	BIOCLASS	Glycosyltransferases
T03593	ECNUMBER	EC 2.4.99.-
T03593	SEQUENCE	MRSIRKRWTICTISLLLIFYKTKEIARTEEHQETQLIGDGELSLSRSLVNSSDKIIRKAGSSIFQHNVEGWKINSSLVLEIRKNILRFLDAERDVSVVKSSFKPGDVIHYVLDRRRTLNISHDLHSLLPEVSPMKNRRFKTCAVVGNSGILLDSECGKEIDSHNFVIRCNLAPVVEFAADVGTKSDFITMNPSVVQRAFGGFRNESDREKFVHRLSMLNDSVLWIPAFMVKGGEKHVEWVNALILKNKLKVRTAYPSLRLIHAVRGYWLTNKVPIKRPSTGLLMYTLATRFCDEIHLYGFWPFPKDLNGKAVKYHYYDDLKYRYFSNASPHRMPLEFKTLNVLHNRGALKLTTGKCVKQ

T17642	TARGETID	T17642
T17642	FORMERID	TTDI02462
T17642	UNIPROID	HTRA1_HUMAN
T17642	TARGNAME	Serine protease HTRA1 (HTRA1)
T17642	GENENAME	HTRA1
T17642	TARGTYPE	Literature-reported
T17642	SYNONYMS	Serine protease 11; L56; High-temperature requirement A serine peptidase 1; HTRA1
T17642	FUNCTION	Serine protease with a variety of targets, including extracellular matrix proteins such as fibronectin. HTRA1-generated fibronectin fragments further induce synovial cells to up-regulate MMP1 and MMP3 production. May also degrade proteoglycans, such as aggrecan, decorin and fibromodulin. Through cleavage of proteoglycans, may release soluble FGF-glycosaminoglycan complexes that promote the range and intensity of FGF signals in the extracellular space. Regulates the availability of insulin-like growth factors (IGFs) by cleaving IGF-binding proteins. Inhibits signaling mediated by TGF-beta family members. This activity requires the integrity of the catalytic site, although it is unclear whether TGF-beta proteins are themselves degraded. By acting on TGF-beta signaling, may regulate many physiological processes, including retinal angiogenesis and neuronal survival and maturation during development. Intracellularly, degrades TSC2, leading to the activation of TSC2 downstream targets.
T17642	PDBSTRUC	3TJQ; 3TJO; 3TJN; 3NZI; 3NWU
T17642	BIOCLASS	Peptidase
T17642	ECNUMBER	EC 3.4.21.-
T17642	SEQUENCE	MQIPRAALLPLLLLLLAAPASAQLSRAGRSAPLAAGCPDRCEPARCPPQPEHCEGGRARDACGCCEVCGAPEGAACGLQEGPCGEGLQCVVPFGVPASATVRRRAQAGLCVCASSEPVCGSDANTYANLCQLRAASRRSERLHRPPVIVLQRGACGQGQEDPNSLRHKYNFIADVVEKIAPAVVHIELFRKLPFSKREVPVASGSGFIVSEDGLIVTNAHVVTNKHRVKVELKNGATYEAKIKDVDEKADIALIKIDHQGKLPVLLLGRSSELRPGEFVVAIGSPFSLQNTVTTGIVSTTQRGGKELGLRNSDMDYIQTDAIINYGNSGGPLVNLDGEVIGINTLKVTAGISFAIPSDKIKKFLTESHDRQAKGKAITKKKYIGIRMMSLTSSKAKELKDRHRDFPDVISGAYIIEVIPDTPAEAGGLKENDVIISINGQSVVSANDVSDVIKRESTLNMVVRRGNEDIMITVIPEEIDP

T44341	TARGETID	T44341
T44341	FORMERID	TTDI03148
T44341	UNIPROID	CDKL2_HUMAN
T44341	TARGNAME	Cyclin-dependent kinase-like 2 (CDKL2)
T44341	GENENAME	CDKL2
T44341	TARGTYPE	Literature-reported
T44341	SYNONYMS	Serine/threonine-protein kinase KKIAMRE; Protein kinase p56 KKIAMRE
T44341	FUNCTION	centrosome, nucleus, cyclin-dependent protein serine/threonine kinase activity, protein kinase activity, protein phosphorylation, sex differentiation, signal transduction.
T44341	PDBSTRUC	4BBM; 4AAA
T44341	BIOCLASS	Kinase
T44341	ECNUMBER	EC 2.7.11.22
T44341	SEQUENCE	MEKYENLGLVGEGSYGMVMKCRNKDTGRIVAIKKFLESDDDKMVKKIAMREIKLLKQLRHENLVNLLEVCKKKKRWYLVFEFVDHTILDDLELFPNGLDYQVVQKYLFQIINGIGFCHSHNIIHRDIKPENILVSQSGVVKLCDFGFARTLAAPGEVYTDYVATRWYRAPELLVGDVKYGKAVDVWAIGCLVTEMFMGEPLFPGDSDIDQLYHIMMCLGNLIPRHQELFNKNPVFAGVRLPEIKEREPLERRYPKLSEVVIDLAKKCLHIDPDKRPFCAELLHHDFFQMDGFAERFSQELQLKVQKDARNVSLSKKSQNRKKEKEKDDSLVEERKTLVVQDTNADPKIKDYKLFKIKGSKIDGEKAEKGNRASNASCLHDSRTSHNKIVPSTSLKDCSNVSVDHTRNPSVAIPPLTHNLSAVAPSINSGMGTETIPIQGYRVDEKTKKCSIPFVKPNRHSPSGIYNINVTTLVSGPPLSDDSGADLPQMEHQH
T44341	DRUGINFO	D07ADX	URMC-099	Investigative

T71646	TARGETID	T71646
T71646	FORMERID	TTDR00572
T71646	UNIPROID	GGH_HUMAN
T71646	TARGNAME	Gamma-glutamyl hydrolase (GGH)
T71646	GENENAME	GGH
T71646	TARGTYPE	Literature-reported
T71646	SYNONYMS	Human glutamyl hydrolase; Gamma-Glu-X carboxypeptidase; GGH; Conjugase
T71646	FUNCTION	Hydrolyzes the polyglutamate sidechains of pteroylpolyglutamates. Progressively removes gamma-glutamyl residues from pteroylpoly-gamma-glutamate to yield pteroyl-alpha- glutamate (folic acid) and free glutamate. May play an important role in the bioavailability ofdietary pteroylpolyglutamates and in the metabolism of pteroylpolyglutamates and antifolates.
T71646	PDBSTRUC	1L9X
T71646	BIOCLASS	Peptidase
T71646	ECNUMBER	EC 3.4.19.9
T71646	SEQUENCE	MASPGCLLCVLGLLLCGAASLELSRPHGDTAKKPIIGILMQKCRNKVMKNYGRYYIAASYVKYLESAGARVVPVRLDLTEKDYEILFKSINGILFPGGSVDLRRSDYAKVAKIFYNLSIQSFDDGDYFPVWGTCLGFEELSLLISGECLLTATDTVDVAMPLNFTGGQLHSRMFQNFPTELLLSLAVEPLTANFHKWSLSVKNFTMNEKLKKFFNVLTTNTDGKIEFISTMEGYKYPVYGVQWHPEKAPYEWKNLDGISHAPNAVKTAFYLAEFFVNEARKNNHHFKSESEEEKALIYQFSPIYTGNISSFQQCYIFD

T38581	TARGETID	T38581
T38581	FORMERID	TTDI00205
T38581	UNIPROID	PCSK5_HUMAN
T38581	TARGNAME	Proprotein convertase subtilisin/kexin type 5 (PCSK5)
T38581	GENENAME	PCSK5
T38581	TARGTYPE	Literature-reported
T38581	SYNONYMS	hPC6; Subtilisin/kexin-like protease PC5; Proprotein convertase 6; Proprotein convertase 5; PCSK5; PC6; PC5
T38581	FUNCTION	Likely to represent a widespread endoprotease activity within the constitutive and regulated secretory pathway. Capable of cleavage at the RX(K/R)R consensus motif. Plays an essential role in pregnancy establishment by proteolytic activation of a number of important factors such as BMP2, CALD1 and alpha- integrins.
T38581	BIOCLASS	Peptidase
T38581	ECNUMBER	EC 3.4.21.-
T38581	SEQUENCE	MGWGSRCCCPGRLDLLCVLALLGGCLLPVCRTRVYTNHWAVKIAGGFPEANRIASKYGFINIGQIGALKDYYHFYHSRTIKRSVISSRGTHSFISMEPKVEWIQQQVVKKRTKRDYDFSRAQSTYFNDPKWPSMWYMHCSDNTHPCQSDMNIEGAWKRGYTGKNIVVTILDDGIERTHPDLMQNYDALASCDVNGNDLDPMPRYDASNENKHGTRCAGEVAAAANNSHCTVGIAFNAKIGGVRMLDGDVTDMVEAKSVSFNPQHVHIYSASWGPDDDGKTVDGPAPLTRQAFENGVRMGRRGLGSVFVWASGNGGRSKDHCSCDGYTNSIYTISISSTAESGKKPWYLEECSSTLATTYSSGESYDKKIITTDLRQRCTDNHTGTSASAPMAAGIIALALEANPFLTWRDVQHVIVRTSRAGHLNANDWKTNAAGFKVSHLYGFGLMDAEAMVMEAEKWTTVPRQHVCVESTDRQIKTIRPNSAVRSIYKASGCSDNPNRHVNYLEHVVVRITITHPRRGDLAIYLTSPSGTRSQLLANRLFDHSMEGFKNWEFMTIHCWGERAAGDWVLEVYDTPSQLRNFKTPGKLKEWSLVLYGTSVQPYSPTNEFPKVERFRYSRVEDPTDDYGTEDYAGPCDPECSEVGCDGPGPDHCNDCLHYYYKLKNNTRICVSSCPPGHYHADKKRCRKCAPNCESCFGSHGDQCMSCKYGYFLNEETNSCVTHCPDGSYQDTKKNLCRKCSENCKTCTEFHNCTECRDGLSLQGSRCSVSCEDGRYFNGQDCQPCHRFCATCAGAGADGCINCTEGYFMEDGRCVQSCSISYYFDHSSENGYKSCKKCDISCLTCNGPGFKNCTSCPSGYLLDLGMCQMGAICKDGEYVDEHGHCQTCEASCAKCQGPTQEDCTTCPMTRIFDDGRCVSNCPSWKFEFENQCHPCHHTCQRCQGSGPTHCTSCGADNYGREHFLYQGECGDSCPEGHYATEGNTCLPCPDNCELCHSVHVCTRCMKGYFIAPTNHTCQKLECGQGEVQDPDYEECVPCEEGCLGCSLDDPGTCTSCAMGYYRFDHHCYKTCPEKTYSEEVECKACDSNCGSCDQNGCYWCEEGFFLLGGSCVRKCGPGFYGDQEMGECESCHRACETCTGPGHDECSSCQEGLQLLRGMCVHATKTQEEGKFWNDILRKLQPCHSSCKTCNGSATLCTSCPKGAYLLAQACVSSCPQGTWPSVRSGSCENCTEACAICSGADLCKKCQMQPGHPLFLHEGRCYSKCPEGSYAEDGICERCSSPCRTCEGNATNCHSCEGGHVLHHGVCQENCPERHVAVKGVCKHCPEMCQDCIHEKTCKECTPEFFLHDDMCHQSCPRGFYADSRHCVPCHKDCLECSGPKADDCELCLESSWVLYDGLCLEECPAGTYYEKETKECRDCHKSCLTCSSSGTCTTCQKGLIMNPRGSCMANEKCSPSEYWDEDAPGCKPCHVKCFHCMGPAEDQCQTCPMNSLLLNTTCVKDCPEGYYADEDSNRCAHCHSSCRTCEGRHSRQCHSCRPGWFQLGKECLLQCREGYYADNSTGRCERCNRSCKGCQGPRPTDCLSCDRFFFLLRSKGECHRSCPDHYYVEQSTQTCERCHPTCDQCKGKGALNCLSCVWSYHLMGGICTSDCLVGEYRVGEGEKFNCEKCHESCMECKGPGAKNCTLCPANLVLHMDDSHCLHCCNTSDPPSAQECCDCQDTTDECILRTSKVRPATEHFKTALFITSSMMLVLLLGAAVVVWKKSRGRVQPAAKAGYEKLADPNKSYSSYKSSYRESTSFEEDQVIEYRDRDYDEDDDDDIVYMGQDGTVYRKFKYGLLDDDDIDELEYDDESYSYYQ
T38581	DRUGINFO	D05JJL	furin inhibitor peptide	Investigative

T84791	TARGETID	T84791
T84791	FORMERID	TTDR00901
T84791	UNIPROID	CSN5_HUMAN
T84791	TARGNAME	JUN activation domain binding protein (COPS5)
T84791	GENENAME	COPS5
T84791	TARGTYPE	Literature-reported
T84791	SYNONYMS	Signalosome subunit 5; SGN5; Jun activation domain-binding protein 1; JAB1; CSN5; COP9 signalosome complex subunit 5
T84791	FUNCTION	The CSN complex is an essential regulator of the ubiquitin (Ubl) conjugation pathway by mediating the deneddylation of the cullin subunits of the SCF-type E3 ligase complexes, leading to decrease the Ubl ligase activity of SCF-type complexes such as SCF, CSA or DDB2. The complex is also involved in phosphorylation of p53/TP53, c-jun/JUN, IkappaBalpha/NFKBIA, ITPK1 and IRF8, possibly via its association with CK2 and PKD kinases. CSN-dependent phosphorylation of TP53 and JUN promotes and protects degradation by the Ubl system, respectively. In the complex, it probably acts as the catalytic center that mediates the cleavage of Nedd8 from cullins. It however has no metalloprotease activity by itself and requires the other subunits of the CSN complex. Interacts directly with a large number of proteins that are regulated by the CSN complex, confirming a key role in the complex. Promotes the proteasomal degradation of BRSK2. Probable protease subunit of the COP9 signalosome complex (CSN), a complex involved in various cellular and developmental processes.
T84791	PDBSTRUC	5M5Q; 5JOH; 5JOG; 4WSN; 4F7O
T84791	BIOCLASS	Peptidase
T84791	ECNUMBER	EC 3.4.-.-
T84791	SEQUENCE	MAASGSGMAQKTWELANNMQEAQSIDEIYKYDKKQQQEILAAKPWTKDHHYFKYCKISALALLKMVMHARSGGNLEVMGLMLGKVDGETMIIMDSFALPVEGTETRVNAQAAAYEYMAAYIENAKQVGRLENAIGWYHSHPGYGCWLSGIDVSTQMLNQQFQEPFVAVVIDPTRTISAGKVNLGAFRTYPKGYKPPDEGPSEYQTIPLNKIEDFGVHCKQYYALEVSYFKSSLDRKLLELLWNKYWVNTLSSSSLLTNADYTTGQVFDLSEKLEQSEAQLGRGSFMLGLETHDRKSEDKLAKATRDSCKTTIEAIHGLMSQVIKDKLFNQINIS

T85328	TARGETID	T85328
T85328	FORMERID	TTDI00240
T85328	UNIPROID	TP4A1_HUMAN
T85328	TARGNAME	Protein tyrosine phosphatase IVA 1 (PRL-1)
T85328	GENENAME	PTP4A1
T85328	TARGTYPE	Literature-reported
T85328	SYNONYMS	Protein-tyrosine phosphatase of regenerating liver 1; Protein-tyrosine phosphatase 4a1; Protein tyrosine phosphatase type IVA 1; PTPCAAX1; PTP(CAAXI); PRL1
T85328	FUNCTION	May play a role in the development and maintenance of differentiating epithelial tissues. Enhances cell proliferation, cell motility and invasive activity, and promotes cancer metastasis. Protein tyrosine phosphatase which stimulates progression from G1 into S phase during mitosis.
T85328	PDBSTRUC	5BX1; 1XM2; 1RXD
T85328	BIOCLASS	Phosphoric monoester hydrolase
T85328	ECNUMBER	EC 3.1.3.48
T85328	SEQUENCE	MARMNRPAPVEVTYKNMRFLITHNPTNATLNKFIEELKKYGVTTIVRVCEATYDTTLVEKEGIHVLDWPFDDGAPPSNQIVDDWLSLVKIKFREEPGCCIAVHCVAGLGRAPVLVALALIEGGMKYEDAVQFIRQKRRGAFNSKQLLYLEKYRPKMRLRFKDSNGHRNNCCIQ

T68265	TARGETID	T68265
T68265	FORMERID	TTDI02161
T68265	UNIPROID	RNF34_HUMAN
T68265	TARGNAME	RING finger protein RIFF (RNF34)
T68265	GENENAME	RNF34
T68265	TARGTYPE	Literature-reported
T68265	SYNONYMS	hRFI; RNF34; RING finger protein 34; Human RING finger homologous to inhibitor of apoptosis protein; FYVERING finger protein Momo; E3 ubiquitinprotein ligase RNF34; Caspases8 and 10associated RING finger protein 1; Caspase regulator CARP1; CARP1
T68265	FUNCTION	E3 ubiquitin-protein ligase that regulates several biological processes through the ubiquitin-mediated proteasomal degradation of various target proteins. Ubiquitinates the caspases CASP8 and CASP10, promoting their proteasomal degradation, to negatively regulate cell death downstream of death domain receptors in the extrinsic pathway of apoptosis (PubMed:15069192). May mediate 'Lys-48'-linked polyubiquitination of RIPK1 and its subsequent proteasomal degradation thereby indirectly regulating the tumor necrosis factor-mediated signaling pathway (Ref.13). Negatively regulates p53/TP53 through its direct ubiquitination and targeting to proteasomal degradation (PubMed:17121812). Indirectly, may also negatively regulate p53/TP53 through ubiquitination and degradation of SFN (PubMed:18382127). Mediates PPARGC1A proteasomal degradation probably through ubiquitination thereby indirectly regulating the metabolism of brown fat cells (PubMed:22064484). Possibly involved in innate immunity, through 'Lys-48'-linked polyubiquitination of NOD1and its subsequent proteasomal degradation (PubMed:25012219).
T68265	BIOCLASS	Carbon-nitrogen ligase
T68265	ECNUMBER	EC 2.3.2.27
T68265	SEQUENCE	MKAGATSMWASCCGLLNEVMGTGAVRGQQSAFAGATGPFRFTPNPEFSTYPPAATEGPNIVCKACGLSFSVFRKKHVCCDCKKDFCSVCSVLQENLRRCSTCHLLQETAFQRPQLMRLKVKDLRQYLILRNIPIDTCREKEDLVDLVLCHHGLGSEDDMDTSSLNSSRSQTSSFFTRSFFSNYTAPSATMSSFQGELMDGDQTSRSGVPAQVQSEITSANTEDDDDDDDEDDDDEEENAEDRNPGLSKERVRASLSDLSSLDDVEGMSVRQLKEILARNFVNYSGCCEKWELVEKVNRLYKENEENQKSYGERLQLQDEEDDSLCRICMDAVIDCVLLECGHMVTCTKCGKRMSECPICRQYVVRAVHVFKS

T02587	TARGETID	T02587
T02587	FORMERID	TTDR01249
T02587	UNIPROID	PLPP_HUMAN
T02587	TARGNAME	Pyridoxal phosphate phosphatase (PDXP)
T02587	GENENAME	PDXP
T02587	TARGTYPE	Literature-reported
T02587	SYNONYMS	PLPP; PLP phosphatase; PDXP
T02587	FUNCTION	Protein serine phosphatase that dephosphorylates 'Ser-3' in cofilin and probably also dephosphorylates phospho-serine residues in DSTN. Regulates cofilin-dependent actin cytoskeleton reorganization. Required for normal progress through mitosis and normal cytokinesis. Does not dephosphorylate phospho-threonines in LIMK1. Does not dephosphorylate peptides containing phospho- tyrosine. Pyridoxal phosphate phosphatase. Has some activity towards pyridoxal 5'-phosphate (PLP), pyridoxine 5'-phosphate (PMP) and pyridoxine 5'-phosphate (PNP), with a highest activity with PLP followed by PNP.
T02587	PDBSTRUC	5GYN; 2P69; 2P27; 2OYC; 2CFT
T02587	BIOCLASS	Phosphoric monoester hydrolase
T02587	ECNUMBER	EC 3.1.3.3
T02587	SEQUENCE	MARCERLRGAALRDVLGRAQGVLFDCDGVLWNGERAVPGAPELLERLARAGKAALFVSNNSRRARPELALRFARLGFGGLRAEQLFSSALCAARLLRQRLPGPPDAPGAVFVLGGEGLRAELRAAGLRLAGDPSAGDGAAPRVRAVLVGYDEHFSFAKLREACAHLRDPECLLVATDRDPWHPLSDGSRTPGTGSLAAAVETASGRQALVVGKPSPYMFECITENFSIDPARTLMVGDRLETDILFGHRCGMTTVLTLTGVSRLEEAQAYLAAGQHDLVPHYYVESIADLTEGLED

T81240	TARGETID	T81240
T81240	FORMERID	TTDNR00663
T81240	UNIPROID	ITCH_HUMAN
T81240	TARGNAME	E3 ubiquitin protein ligase Itchy (ITCH)
T81240	GENENAME	ITCH
T81240	TARGTYPE	Literature-reported
T81240	SYNONYMS	NFE2-associated polypeptide 1; NAPP1; Itch; HECT-type E3 ubiquitin transferase Itchy homolog; E3 ubiquitin-protein ligase Itchy homolog; Atrophin-1-interacting protein 4; AIP4
T81240	FUNCTION	Catalyzes 'Lys-29'-, 'Lys-48'- and 'Lys-63'-linked ubiquitin conjugation. Involved in the control of inflammatory signaling pathways. Essential component of a ubiquitin-editing protein complex, comprising also TNFAIP3, TAX1BP1 and RNF11, that ensures the transient nature of inflammatory signaling pathways. Promotes the association of the complex after TNF stimulation. Once the complex is formed, TNFAIP3 deubiquitinates 'Lys-63' polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys-48'-polyubiquitin chains. This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NFKB1. Ubiquitinates RIPK2 by 'Lys-63'-linked conjugation and influences NOD2-dependent signal transduction pathways. Regulates the transcriptional activity of several transcription factors, and probably plays an important role in the regulation of immune response. Ubiquitinates NFE2 by 'Lys-63' linkages and is implicated in the control of the development of hematopoietic lineages. Mediates JUN ubiquitination and degradation. Mediates JUNB ubiquitination and degradation. Critical regulator of type 2 helper T (Th2) cell cytokine production by inducing JUNB ubiquitination and degradation. Involved in the negative regulation of MAVS-dependent cellular antiviral responses. Ubiquitinates MAVS through 'Lys-48'-linked conjugation resulting in MAVS proteasomal degradation. Following ligand stimulation, regulates sorting of Wnt receptor FZD4 to the degradative endocytic pathway probably by modulating PI42KA activity. Ubiquitinates PI4K2A and negatively regulates its catalytic activity. Ubiquitinates chemokine receptor CXCR4 and regulates sorting of CXCR4 to the degradative endocytic pathway following ligand stimulation by ubiquitinating endosomal sorting complex required for transport ESCRT-0 components HGS and STAM. Targets DTX1 for lysosomal degradation and controls NOTCH1 degradation, in the absence of ligand, through 'Lys-29'-linked polyubiquitination. Ubiquitinates SNX9. Ubiquitinates MAP3K7 through 'Lys-48'-linked conjugation. Involved in the regulation of apoptosis and reactive oxygen species levels through the ubiquitination and proteasomal degradation of TXNIP. Mediates the antiapoptotic activity of epidermal growth factor through the ubiquitination and proteasomal degradation of p15 BID. Ubiquitinates BRAT1 and this ubiquitination is enhanced in the presence of NDFIP1. Acts as an E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates.
T81240	PDBSTRUC	5SXP; 5DZD; 5DWS; 5CQ2; 5C7M
T81240	BIOCLASS	Acyltransferase
T81240	ECNUMBER	EC 2.3.2.26
T81240	SEQUENCE	MSDSGSQLGSMGSLTMKSQLQITVISAKLKENKKNWFGPSPYVEVTVDGQSKKTEKCNNTNSPKWKQPLTVIVTPVSKLHFRVWSHQTLKSDVLLGTAALDIYETLKSNNMKLEEVVVTLQLGGDKEPTETIGDLSICLDGLQLESEVVTNGETTCSENGVSLCLPRLECNSAISAHCNLCLPGLSDSPISASRVAGFTGASQNDDGSRSKDETRVSTNGSDDPEDAGAGENRRVSGNNSPSLSNGGFKPSRPPRPSRPPPPTPRRPASVNGSPSATSESDGSSTGSLPPTNTNTNTSEGATSGLIIPLTISGGSGPRPLNPVTQAPLPPGWEQRVDQHGRVYYVDHVEKRTTWDRPEPLPPGWERRVDNMGRIYYVDHFTRTTTWQRPTLESVRNYEQWQLQRSQLQGAMQQFNQRFIYGNQDLFATSQSKEFDPLGPLPPGWEKRTDSNGRVYFVNHNTRITQWEDPRSQGQLNEKPLPEGWEMRFTVDGIPYFVDHNRRTTTYIDPRTGKSALDNGPQIAYVRDFKAKVQYFRFWCQQLAMPQHIKITVTRKTLFEDSFQQIMSFSPQDLRRRLWVIFPGEEGLDYGGVAREWFFLLSHEVLNPMYCLFEYAGKDNYCLQINPASYINPDHLKYFRFIGRFIAMALFHGKFIDTGFSLPFYKRILNKPVGLKDLESIDPEFYNSLIWVKENNIEECDLEMYFSVDKEILGEIKSHDLKPNGGNILVTEENKEEYIRMVAEWRLSRGVEEQTQAFFEGFNEILPQQYLQYFDAKELEVLLCGMQEIDLNDWQRHAIYRHYARTSKQIMWFWQFVKEIDNEKRMRLLQFVTGTCRLPVGGFADLMGSNGPQKFCIEKVGKENWLPRSHTCFNRLDLPPYKSYEQLKEKLLFAIEETEGFGQE

T98642	TARGETID	T98642
T98642	FORMERID	TTDI03448
T98642	UNIPROID	TOPK_HUMAN
T98642	TARGNAME	PDZ binding kinase (PBK)
T98642	GENENAME	PBK
T98642	TARGTYPE	Literature-reported
T98642	SYNONYMS	TOPK; T-LAK cell-originated protein kinase; Spermatogenesis-related protein kinase; SPK protein; PDZ-binding kinase; Nori-3; MAPKK-like protein kinase; Lymphokine-activated killer T-cell-originated protein kinase; Cancer/testis antigen 84; CT84
T98642	FUNCTION	Seems to be active only in mitosis. May also play a role in the activation of lymphoid cells. When phosphorylated, forms a complex with TP53, leading to TP53 destabilization and attenuation of G2/M checkpoint during doxorubicin-induced DNA damage. Phosphorylates MAP kinase p38.
T98642	PDBSTRUC	5J0A
T98642	BIOCLASS	Kinase
T98642	ECNUMBER	EC 2.7.12.2
T98642	SEQUENCE	MEGISNFKTPSKLSEKKKSVLCSTPTINIPASPFMQKLGFGTGVNVYLMKRSPRGLSHSPWAVKKINPICNDHYRSVYQKRLMDEAKILKSLHHPNIVGYRAFTEANDGSLCLAMEYGGEKSLNDLIEERYKASQDPFPAAIILKVALNMARGLKYLHQEKKLLHGDIKSSNVVIKGDFETIKICDVGVSLPLDENMTVTDPEACYIGTEPWKPKEAVEENGVITDKADIFAFGLTLWEMMTLSIPHINLSNDDDDEDKTFDESDFDDEAYYAALGTRPPINMEELDESYQKVIELFSVCTNEDPKDRPSAAHIVEALETDV
T98642	DRUGINFO	D06DPJ	HITOPK-032	Investigative
T98642	DRUGINFO	D0Y2WP	OTS964	Investigative

T68777	TARGETID	T68777
T68777	FORMERID	TTDR00391
T68777	UNIPROID	NSD1_HUMAN
T68777	TARGNAME	Lysine N-methyltransferase 3B (NSD1)
T68777	GENENAME	NSD1
T68777	TARGTYPE	Literature-reported
T68777	SYNONYMS	Nuclear receptor-binding SET domain-containing protein 1; NR-binding SET domain-containing protein; NR-binding SET domain containing protein; KMT3B; Hypothetical protein FLJ22263 similar to nuclear receptor-binding SET-domain protein 1; Histone-lysine N-methyltransferase, H3 lysine-36 and H4 lysine-20 specific; H4-K20-HMTase; H3-K36-HMTase; Androgen receptor-associated protein of 267 kDa; Androgen receptor-associated coregulator 267; Androgen receptor coactivator 267 kDa protein; Androgen receptor associated coregulator 267; ARA267
T68777	FUNCTION	Preferentially methylates 'Lys-36' of histone H3 and 'Lys-20' of histone H4 (in vitro). Transcriptional intermediary factor capable of both negatively or positively influencing transcription, depending on the cellular context. Histone methyltransferase.
T68777	PDBSTRUC	3OOI
T68777	BIOCLASS	Methyltransferase
T68777	ECNUMBER	EC 2.1.1.43
T68777	SEQUENCE	MDQTCELPRRNCLLPFSNPVNLDAPEDKDSPFGNGQSNFSEPLNGCTMQLSTVSGTSQNAYGQDSPSCYIPLRRLQDLASMINVEYLNGSADGSESFQDPEKSDSRAQTPIVCTSLSPGGPTALAMKQEPSCNNSPELQVKVTKTIKNGFLHFENFTCVDDADVDSEMDPEQPVTEDESIEEIFEETQTNATCNYETKSENGVKVAMGSEQDSTPESRHGAVKSPFLPLAPQTETQKNKQRNEVDGSNEKAALLPAPFSLGDTNITIEEQLNSINLSFQDDPDSSTSTLGNMLELPGTSSSSTSQELPFCQPKKKSTPLKYEVGDLIWAKFKRRPWWPCRICSDPLINTHSKMKVSNRRPYRQYYVEAFGDPSERAWVAGKAIVMFEGRHQFEELPVLRRRGKQKEKGYRHKVPQKILSKWEASVGLAEQYDVPKGSKNRKCIPGSIKLDSEEDMPFEDCTNDPESEHDLLLNGCLKSLAFDSEHSADEKEKPCAKSRARKSSDNPKRTSVKKGHIQFEAHKDERRGKIPENLGLNFISGDISDTQASNELSRIANSLTGSNTAPGSFLFSSCGKNTAKKEFETSNGDSLLGLPEGALISKCSREKNKPQRSLVCGSKVKLCYIGAGDEEKRSDSISICTTSDDGSSDLDPIEHSSESDNSVLEIPDAFDRTENMLSMQKNEKIKYSRFAATNTRVKAKQKPLISNSHTDHLMGCTKSAEPGTETSQVNLSDLKASTLVHKPQSDFTNDALSPKFNLSSSISSENSLIKGGAANQALLHSKSKQPKFRSIKCKHKENPVMAEPPVINEECSLKCCSSDTKGSPLASISKSGKVDGLKLLNNMHEKTRDSSDIETAVVKHVLSELKELSYRSLGEDVSDSGTSKPSKPLLFSSASSQNHIPIEPDYKFSTLLMMLKDMHDSKTKEQRLMTAQNLVSYRSPGRGDCSTNSPVGVSKVLVSGGSTHNSEKKGDGTQNSANPSPSGGDSALSGELSASLPGLLSDKRDLPASGKSRSDCVTRRNCGRSKPSSKLRDAFSAQMVKNTVNRKALKTERKRKLNQLPSVTLDAVLQGDRERGGSLRGGAEDPSKEDPLQIMGHLTSEDGDHFSDVHFDSKVKQSDPGKISEKGLSFENGKGPELDSVMNSENDELNGVNQVVPKKRWQRLNQRRTKPRKRMNRFKEKENSECAFRVLLPSDPVQEGRDEFPEHRTPSASILEEPLTEQNHADCLDSAGPRLNVCDKSSASIGDMEKEPGIPSLTPQAELPEPAVRSEKKRLRKPSKWLLEYTEEYDQIFAPKKKQKKVQEQVHKVSSRCEEESLLARGRSSAQNKQVDENSLISTKEEPPVLEREAPFLEGPLAQSELGGGHAELPQLTLSVPVAPEVSPRPALESEELLVKTPGNYESKRQRKPTKKLLESNDLDPGFMPKKGDLGLSKKCYEAGHLENGITESCATSYSKDFGGGTTKIFDKPRKRKRQRHAAAKMQCKKVKNDDSSKEIPGSEGELMPHRTATSPKETVEEGVEHDPGMPASKKMQGERGGGAALKENVCQNCEKLGELLLCEAQCCGAFHLECLGLTEMPRGKFICNECRTGIHTCFVCKQSGEDVKRCLLPLCGKFYHEECVQKYPPTVMQNKGFRCSLHICITCHAANPANVSASKGRLMRCVRCPVAYHANDFCLAAGSKILASNSIICPNHFTPRRGCRNHEHVNVSWCFVCSEGGSLLCCDSCPAAFHRECLNIDIPEGNWYCNDCKAGKKPHYREIVWVKVGRYRWWPAEICHPRAVPSNIDKMRHDVGEFPVLFFGSNDYLWTHQARVFPYMEGDVSSKDKMGKGVDGTYKKALQEAAARFEELKAQKELRQLQEDRKNDKKPPPYKHIKVNRPIGRVQIFTADLSEIPRCNCKATDENPCGIDSECINRMLLYECHPTVCPAGGRCQNQCFSKRQYPEVEIFRTLQRGWGLRTKTDIKKGEFVNEYVGELIDEEECRARIRYAQEHDITNFYMLTLDKDRIIDAGPKGNYARFMNHCCQPNCETQKWSVNGDTRVGLFALSDIKAGTELTFNYNLECLGNGKTVCKCGAPNCSGFLGVRPKNQPIATEEKSKKFKKKQQGKRRTQGEITKEREDECFSCGDAGQLVSCKKPGCPKVYHADCLNLTKRPAGKWECPWHQCDICGKEAASFCEMCPSSFCKQHREGMLFISKLDGRLSCTEHDPCGPNPLEPGEIREYVPPPVPLPPGPSTHLAEQSTGMAAQAPKMSDKPPADTNQMLSLSKKALAGTCQRPLLPERPLERTDSRPQPLDKVRDLAGSGTKSQSLVSSQRPLDRPPAVAGPRPQLSDKPSPVTSPSSSPSVRSQPLERPLGTADPRLDKSIGAASPRPQSLEKTSVPTGLRLPPPDRLLITSSPKPQTSDRPTDKPHASLSQRLPPPEKVLSAVVQTLVAKEKALRPVDQNTQSKNRAALVMDLIDLTPRQKERAASPHQVTPQADEKMPVLESSSWPASKGLGHMPRAVEKGCVSDPLQTSGKAAAPSEDPWQAVKSLTQARLLSQPPAKAFLYEPTTQASGRASAGAEQTPGPLSQSPGLVKQAKQMVGGQQLPALAAKSGQSFRSLGKAPASLPTEEKKLVTTEQSPWALGKASSRAGLWPIVAGQTLAQSCWSAGSTQTLAQTCWSLGRGQDPKPEQNTLPALNQAPSSHKCAESEQK

T13928	TARGETID	T13928
T13928	FORMERID	TTDI03564
T13928	UNIPROID	SENP8_HUMAN
T13928	TARGNAME	Deneddylase-1 (SENP8)
T13928	GENENAME	SENP8
T13928	TARGTYPE	Literature-reported
T13928	SYNONYMS	Sentrin/SUMO-specific protease SENP8; Sentrin-specific protease 8; Protease, cysteine 2; PRSC2; NEDP1; NEDD8-specific protease 1; FKSG8; DEN1
T13928	FUNCTION	Protease that catalyzes two essential functions in the NEDD8 pathway: processing of full-length NEDD8 to its mature form and deconjugation of NEDD8 from targeted proteins such as cullins or p53.
T13928	PDBSTRUC	2BKR; 2BKQ; 1XT9
T13928	BIOCLASS	Peptidase
T13928	ECNUMBER	EC 3.4.22.-
T13928	SEQUENCE	MDPVVLSYMDSLLRQSDVSLLDPPSWLNDHIIGFAFEYFANSQFHDCSDHVSFISPEVTQFIKCTSNPAEIAMFLEPLDLPNKRVVFLAINDNSNQAAGGTHWSLLVYLQDKNSFFHYDSHSRSNSVHAKQVAEKLEAFLGRKGDKLAFVEEKAPAQQNSYDCGMYVICNTEALCQNFFRQQTESLLQLLTPAYITKKRGEWKDLITTLAKK
T13928	DRUGINFO	D05TNT	ST074946	Investigative

T90113	TARGETID	T90113
T90113	FORMERID	TTDI02561
T90113	UNIPROID	UB2E2_HUMAN
T90113	TARGNAME	Ubiquitin-protein ligase E2 (UBE2E2)
T90113	GENENAME	UBE2E2
T90113	TARGTYPE	Literature-reported
T90113	SYNONYMS	Ubiquitin-conjugating enzyme E2 E2; Ubiquitin carrier protein E2; UbcH8; E2 ubiquitin-conjugating enzyme E2
T90113	FUNCTION	In vitro catalyzes 'Lys-11'- and 'Lys-48'-, as well as 'Lys-63'-linked polyubiquitination. Catalyzes the ISGylation of influenza A virus NS1 protein. Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins.
T90113	PDBSTRUC	1Y6L
T90113	BIOCLASS	Ubiquitin-conjugating enzyme
T90113	ECNUMBER	EC 2.3.2.23
T90113	SEQUENCE	MSTEAQRVDDSPSTSGGSSDGDQRESVQQEPEREQVQPKKKEGKISSKTAAKLSTSAKRIQKELAEITLDPPPNCSAGPKGDNIYEWRSTILGPPGSVYEGGVFFLDITFSPDYPFKPPKVTFRTRIYHCNINSQGVICLDILKDNWSPALTISKVLLSICSLLTDCNPADPLVGSIATQYMTNRAEHDRMARQWTKRYAT

T00037	TARGETID	T00037
T00037	FORMERID	TTDR00601
T00037	UNIPROID	ERG6_PNEC8
T00037	TARGNAME	Fungal Sterol 24-C-methyltransferase (Fung erg6)
T00037	GENENAME	Fung erg6
T00037	TARGTYPE	Literature-reported
T00037	SYNONYMS	erg6; SAM:SMT; S-adenosyl-L-methionine:sterol C-24 methyl transferase; S-adenosyl-L-methionine-C-24-delta-sterol-methyltransferase
T00037	FUNCTION	Catalyzes the methyl transfer from S-adenosyl-methionine to the C-24 of zymosterol to form fecosterol.
T00037	BIOCLASS	Methyltransferase
T00037	ECNUMBER	EC 2.1.1.-
T00037	SEQUENCE	MSFELERIDIEKDREFSEIMHGKDAAKERGLLSSFRKDKEAQKIALDSYFGFWGDKCTSEKNDIHQQERFKFYATLTRHYYNLVTDFYEYGWSTSFHFCRFAKDESFSQAIARHEHYIALHAGIREGETVLDVGCGVGGPACQISVFTGANIVGLNNNDYQIQRAKYYSEKKGLSDKLKFIKGDFMQMPFPENSFDKIYSIEATIHAPSLEGVYSEIYRVLKPGGLYASYEWVMLNKYDENDPEHQQIVYGIEIGDSIPKISKIGEAEAALIKVGFEIIHSEELSTKNSPLPWYYYLDGDLRKVRSFRDFISIARMTTIGKWLISSFIGLMEFIGLLPKGSKKVNDILLVAADSLVKAGKKEIFTPMQLWVCRKPLV
T00037	DRUGINFO	D0M7DG	24-thiacycloartanol	Investigative

T95736	TARGETID	T95736
T95736	FORMERID	TTDI03381
T95736	UNIPROID	M3K14_HUMAN
T95736	TARGNAME	Serine/threonine-protein kinase NIK (MAP3K14)
T95736	GENENAME	MAP3K14
T95736	TARGTYPE	Literature-reported
T95736	SYNONYMS	NIK; NF-kappa-beta-inducing kinase; Mitogen-activated protein kinase kinase kinase 14; HsNIK
T95736	FUNCTION	Promotes proteolytic processing of NFKB2/P100, which leads to activation of NF-kappa-B via the non-canonical pathway. Could act in a receptor-selective manner. Lymphotoxin beta-activated kinase which seems to be exclusively involved in the activation of NF-kappa-B and its transcriptional activity.
T95736	PDBSTRUC	4IDV; 4IDT; 4G3D; 4DN5
T95736	BIOCLASS	Kinase
T95736	ECNUMBER	EC 2.7.11.25
T95736	SEQUENCE	MAVMEMACPGAPGSAVGQQKELPKAKEKTPPLGKKQSSVYKLEAVEKSPVFCGKWEILNDVITKGTAKEGSEAGPAAISIIAQAECENSQEFSPTFSERIFIAGSKQYSQSESLDQIPNNVAHATEGKMARVCWKGKRRSKARKKRKKKSSKSLAHAGVALAKPLPRTPEQESCTIPVQEDESPLGAPYVRNTPQFTKPLKEPGLGQLCFKQLGEGLRPALPRSELHKLISPLQCLNHVWKLHHPQDGGPLPLPTHPFPYSRLPHPFPFHPLQPWKPHPLESFLGKLACVDSQKPLPDPHLSKLACVDSPKPLPGPHLEPSCLSRGAHEKFSVEEYLVHALQGSVSSGQAHSLTSLAKTWAARGSRSREPSPKTEDNEGVLLTEKLKPVDYEYREEVHWATHQLRLGRGSFGEVHRMEDKQTGFQCAVKKVRLEVFRAEELMACAGLTSPRIVPLYGAVREGPWVNIFMELLEGGSLGQLVKEQGCLPEDRALYYLGQALEGLEYLHSRRILHGDVKADNVLLSSDGSHAALCDFGHAVCLQPDGLGKSLLTGDYIPGTETHMAPEVVLGRSCDAKVDVWSSCCMMLHMLNGCHPWTQFFRGPLCLKIASEPPPVREIPPSCAPLTAQAIQEGLRKEPIHRVSAAELGGKVNRALQQVGGLKSPWRGEYKEPRHPPPNQANYHQTLHAQPRELSPRAPGPRPAEETTGRAPKLQPPLPPEPPEPNKSPPLTLSKEESGMWEPLPLSSLEPAPARNPSSPERKATVPEQELQQLEIELFLNSLSQPFSLEEQEQILSCLSIDSLSLSDDSEKNPSKASQSSRDTLSSGVHSWSSQAEARSSSWNMVLARGRPTDTPSYFNGVKVQIQSLNGEHLHIREFHRVKVGDIATGISSQIPAAAFSLVTKDGQPVRYDMEVPDSGIDLQCTLAPDGSFAWSWRVKHGQLENRP
T95736	DRUGINFO	D0LE7J	PMID23374866C31	Investigative

T21661	TARGETID	T21661
T21661	FORMERID	TTDR00247
T21661	UNIPROID	METH_HUMAN
T21661	TARGNAME	Methionine synthase (MTR)
T21661	GENENAME	MTR
T21661	TARGTYPE	Literature-reported
T21661	SYNONYMS	Methionine synthase, vitamin-B12dependent; MTR; MS; Cobalamin-dependent methionine synthase; B12 dependent methionine synthetase; 5-methyltetrahydrofolate:homocysteine methyltransferase; 5-methyltetrahydrofolate-homocysteine methyltransferase; 5-methyltetrahydrofolate homocysteine methyltransferase
T21661	FUNCTION	Catalyzes the transfer of a methyl group from methyl- cobalamin to homocysteine, yielding enzyme-bound cob(I)alamin and methionine. Subsequently, remethylates the cofactor using methyltetrahydrofolate.
T21661	PDBSTRUC	4CCZ; 2O2K
T21661	BIOCLASS	Methyltransferase
T21661	ECNUMBER	EC 2.1.1.13
T21661	SEQUENCE	MSPALQDLSQPEGLKKTLRDEINAILQKRIMVLDGGMGTMIQREKLNEEHFRGQEFKDHARPLKGNNDILSITQPDVIYQIHKEYLLAGADIIETNTFSSTSIAQADYGLEHLAYRMNMCSAGVARKAAEEVTLQTGIKRFVAGALGPTNKTLSVSPSVERPDYRNITFDELVEAYQEQAKGLLDGGVDILLIETIFDTANAKAALFALQNLFEEKYAPRPIFISGTIVDKSGRTLSGQTGEGFVISVSHGEPLCIGLNCALGAAEMRPFIEIIGKCTTAYVLCYPNAGLPNTFGDYDETPSMMAKHLKDFAMDGLVNIVGGCCGSTPDHIREIAEAVKNCKPRVPPATAFEGHMLLSGLEPFRIGPYTNFVNIGERCNVAGSRKFAKLIMAGNYEEALCVAKVQVEMGAQVLDVNMDDGMLDGPSAMTRFCNLIASEPDIAKVPLCIDSSNFAVIEAGLKCCQGKCIVNSISLKEGEDDFLEKARKIKKYGAAMVVMAFDEEGQATETDTKIRVCTRAYHLLVKKLGFNPNDIIFDPNILTIGTGMEEHNLYAINFIHATKVIKETLPGARISGGLSNLSFSFRGMEAIREAMHGVFLYHAIKSGMDMGIVNAGNLPVYDDIHKELLQLCEDLIWNKDPEATEKLLRYAQTQGTGGKKVIQTDEWRNGPVEERLEYALVKGIEKHIIEDTEEARLNQKKYPRPLNIIEGPLMNGMKIVGDLFGAGKMFLPQVIKSARVMKKAVGHLIPFMEKEREETRVLNGTVEEEDPYQGTIVLATVKGDVHDIGKNIVGVVLGCNNFRVIDLGVMTPCDKILKAALDHKADIIGLSGLITPSLDEMIFVAKEMERLAIRIPLLIGGATTSKTHTAVKIAPRYSAPVIHVLDASKSVVVCSQLLDENLKDEYFEEIMEEYEDIRQDHYESLKERRYLPLSQARKSGFQMDWLSEPHPVKPTFIGTQVFEDYDLQKLVDYIDWKPFFDVWQLRGKYPNRGFPKIFNDKTVGGEARKVYDDAHNMLNTLISQKKLRARGVVGFWPAQSIQDDIHLYAEAAVPQAAEPIATFYGLRQQAEKDSASTEPYYCLSDFIAPLHSGIRDYLGLFAVACFGVEELSKAYEDDGDDYSSIMVKALGDRLAEAFAEELHERVRRELWAYCGSEQLDVADLRRLRYKGIRPAPGYPSQPDHTEKLTMWRLADIEQSTGIRLTESLAMAPASAVSGLYFSNLKSKYFAVGKISKDQVEDYALRKNISVAEVEKWLGPILGYDTD

T12627	TARGETID	T12627
T12627	FORMERID	TTDR00661
T12627	UNIPROID	ACON_HUMAN
T12627	TARGNAME	Citrate hydro-lyase (ACO2)
T12627	GENENAME	ACO2
T12627	TARGTYPE	Literature-reported
T12627	SYNONYMS	Aconitase; ACO2
T12627	FUNCTION	Catalyzes the isomerization of citrate to isocitrate via cis-aconitate.
T12627	BIOCLASS	Alpha-carbonic anhydrase
T12627	ECNUMBER	EC 4.2.1.3
T12627	SEQUENCE	MAPYSLLVTRLQKALGVRQYHVASVLCQRAKVAMSHFEPNEYIHYDLLEKNINIVRKRLNRPLTLSEKIVYGHLDDPASQEIERGKSYLRLRPDRVAMQDATAQMAMLQFISSGLSKVAVPSTIHCDHLIEAQVGGEKDLRRAKDINQEVYNFLATAGAKYGVGFWKPGSGIIHQIILENYAYPGVLLIGTDSHTPNGGGLGGICIGVGGADAVDVMAGIPWELKCPKVIGVKLTGSLSGWSSPKDVILKVAGILTVKGGTGAIVEYHGPGVDSISCTGMATICNMGAEIGATTSVFPYNHRMKKYLSKTGREDIANLADEFKDHLVPDPGCHYDQLIEINLSELKPHINGPFTPDLAHPVAEVGKVAEKEGWPLDIRVGLIGSCTNSSYEDMGRSAAVAKQALAHGLKCKSQFTITPGSEQIRATIERDGYAQILRDLGGIVLANACGPCIGQWDRKDIKKGEKNTIVTSYNRNFTGRNDANPETHAFVTSPEIVTALAIAGTLKFNPETDYLTGTDGKKFRLEAPDADELPKGEFDPGQDTYQHPPKDSSGQHVDVSPTSQRLQLLEPFDKWDGKDLEDLQILIKVKGKCTTDHISAAGPWLKFRGHLDNISNNLLIGAINIENGKANSVRNAVTQEFGPVPDTARYYKKHGIRWVVIGDENYGEGSSREHAALEPRHLGGRAIITKSFARIHETNLKKQGLLPLTFADPADYNKIHPVDKLTIQGLKDFTPGKPLKCIIKHPNGTQETILLNHTFNETQIEWFRAGSALNRMKELQQ
T12627	DRUGINFO	D00UFR	Aconitate Ion	Investigative
T12627	DRUGINFO	D01EVI	Alpha-Methylisocitric Acid	Investigative
T12627	DRUGINFO	D02UII	4-Hydroxy-Aconitate Ion	Investigative
T12627	DRUGINFO	D08ZAO	Tricarballylic Acid	Investigative
T12627	DRUGINFO	D0R6GQ	Isocitric Acid	Investigative

T64716	TARGETID	T64716
T64716	FORMERID	TTDNR00737
T64716	UNIPROID	Q9A1S9_STRP1
T64716	TARGNAME	Streptococcus Pyrroline carboxylate reductase (Stre-coc proC)
T64716	GENENAME	Stre-coc proC
T64716	TARGTYPE	Literature-reported
T64716	SYNONYMS	Pyrroline-5-carboxylate reductase; PCA reductase; P5CR; P5C reductase
T64716	FUNCTION	Catalyzes the reduction of 1-pyrroline-5-carboxylate (PCA) to L-proline.
T64716	PDBSTRUC	2AMF; 2AHR
T64716	BIOCLASS	CH-NH donor oxidoreductase
T64716	ECNUMBER	EC 1.5.1.2
T64716	SEQUENCE	MKIGIIGVGKMASAIIKGLKQTPHELIISGSSLERSKEIAEQLALPYAMSHQDLIDQVDLVILGIKPQLFETVLKPLHFKQPIISMAAGISLQRLATFVGQDLPLLRIMPNMNAQILQSSTALTGNALVSQELQARVRDLTDSFGSTFDISEKDFDTFTALAGSSPAYIYLFIEALAKAGVKNGIPKAKALEIVTQTVLASASNLKTSSQSPHDFIDAICSPGGTTIAGLMELERLGLTATVSSAIDKTIDKAKSL

T71055	TARGETID	T71055
T71055	FORMERID	TTDI00002
T71055	UNIPROID	HOIL1_HUMAN
T71055	TARGNAME	Linear ubiquitin chain assembly complex (RBCK1)
T71055	GENENAME	RBCK1
T71055	TARGTYPE	Literature-reported
T71055	SYNONYMS	XAP4; XAP3; Ubiquitin-conjugating enzyme 7-interacting protein 3; UBCE7IP3; RanBP-type and C3HC4-type zinc finger-containing protein 1; RNF54; RING-type E3 ubiquitin transferase HOIL-1; RING finger protein 54; Hepatitis B virus X-associated protein 4; Heme-oxidized IRP2 ubiquitin ligase 1; HOIL-1; HBV-associated factor 4; C20orf18
T71055	FUNCTION	Functions as an E3 ligase for oxidized IREB2 and both heme and oxygen are necessary for IREB2 ubiquitination. Promotes ubiquitination of TAB2 and IRF3 and their degradation by the proteasome. Component of the LUBAC complex which conjugates linear ('Met-1'-linked) polyubiquitin chains to substrates and plays a key role in NF-kappa-B activation and regulation of inflammation. LUBAC conjugates linear polyubiquitin to IKBKG and RIPK1 and is involved in activation of the canonical NF-kappa-B and the JNK signaling pathways. Linear ubiquitination mediated by the LUBAC complex interferes with TNF-induced cell death and thereby prevents inflammation. LUBAC is recruited to the TNF-R1 signaling complex (TNF-RSC) following polyubiquitination of TNF-RSC components by BIRC2 and/or BIRC3 and to conjugate linear polyubiquitin to IKBKG and possibly other components contributing to the stability of the complex. Together with OTULIN, the LUBAC complex regulates the canonical Wnt signaling during angiogenesis. Binds polyubiquitin of different linkage types. E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, such as UBE2L3/UBCM4, and then transfers it to substrates.
T71055	PDBSTRUC	4DBG; 2LGY; 2CRC
T71055	BIOCLASS	Acyltransferase
T71055	ECNUMBER	EC 2.3.2.31
T71055	SEQUENCE	MDEKTKKAEEMALSLTRAVAGGDEQVAMKCAIWLAEQRVPLSVQLKPEVSPTQDIRLWVSVEDAQMHTVTIWLTVRPDMTVASLKDMVFLDYGFPPVLQQWVIGQRLARDQETLHSHGVRQNGDSAYLYLLSARNTSLNPQELQRERQLRMLEDLGFKDLTLQPRGPLEPGPPKPGVPQEPGRGQPDAVPEPPPVGWQCPGCTFINKPTRPGCEMCCRARPEAYQVPASYQPDEEERARLAGEEEALRQYQQRKQQQQEGNYLQHVQLDQRSLVLNTEPAECPVCYSVLAPGEAVVLRECLHTFCRECLQGTIRNSQEAEVSCPFIDNTYSCSGKLLEREIKALLTPEDYQRFLDLGISIAENRSAFSYHCKTPDCKGWCFFEDDVNEFTCPVCFHVNCLLCKAIHEQMNCKEYQEDLALRAQNDVAARQTTEMLKVMLQQGEAMRCPQCQIVVQKKDGCDWIRCTVCHTEICWVTKGPRWGPGGPGDTSGGCRCRVNGIPCHPSCQNCH

T73551	TARGETID	T73551
T73551	UNIPROID	SETD2_HUMAN
T73551	TARGNAME	Lysine N-methyltransferase 3A (SETD2)
T73551	GENENAME	SETD2
T73551	TARGTYPE	Literature-reported
T73551	SYNONYMS	p231HBP; hSET2; SET2; SET domain-containing protein 2; Protein-lysine N-methyltransferase SETD2; KMT3A; KIAA1732; Huntingtin-interacting protein B; Huntingtin-interacting protein 1; Huntingtin yeast partner B; Histone-lysine N-methyltransferase SETD2; HYPB; HSPC069; HIP-1; HIF1
T73551	FUNCTION	Represents the main enzyme generating H3K36me3, a specific tag for epigenetic transcriptional activation. Plays a role in chromatin structure modulation during elongation by coordinating recruitment of the FACT complex and by interacting with hyperphosphorylated POLR2A. Acts as a key regulator of DNA mismatch repair in G1 and early S phase by generating H3K36me3, a mark required to recruit MSH6 subunit of the MutS alpha complex: early recruitment of the MutS alpha complex to chromatin to be replicated allows a quick identification of mismatch DNA to initiate the mismatch repair reaction. Required for DNA double-strand break repair in response to DNA damage: acts by mediating formation of H3K36me3, promoting recruitment of RAD51 and DNA repair via homologous recombination (HR). Acts as a tumor suppressor. H3K36me3 also plays an essential role in the maintenance of a heterochromatic state, by recruiting DNA methyltransferase DNMT3A. H3K36me3 is also enhanced in intron-containing genes, suggesting that SETD2 recruitment is enhanced by splicing and that splicing is coupled to recruitment of elongating RNA polymerase. Required during angiogenesis. Required for endoderm development by promoting embryonic stem cell differentiation toward endoderm: acts by mediating formation of H3K36me3 in distal promoter regions of FGFR3, leading to regulate transcription initiation of FGFR3. In addition to histones, also mediates methylation of other proteins, such as tubulins and STAT1. Trimethylates 'Lys-40' of alpha-tubulins such as TUBA1B (alpha-TubK40me3); alpha-TubK40me3 is required for normal mitosis and cytokinesis and may be a specific tag in cytoskeletal remodeling. Involved in interferon-alpha-induced antiviral defense by mediating both monomethylation of STAT1 at 'Lys-525' and catalyzing H3K36me3 on promoters of some interferon-stimulated genes (ISGs) to activate gene transcription. Histone methyltransferase that specifically trimethylates 'Lys-36' of histone H3 (H3K36me3) using dimethylated 'Lys-36' (H3K36me2) as substrate.
T73551	PDBSTRUC	5V22; 5V21; 5LT8; 5LT7; 5LT6
T73551	BIOCLASS	Methyltransferase
T73551	ECNUMBER	EC 2.1.1.43
T73551	SEQUENCE	MKQLQPQPPPKMGDFYDPEHPTPEEEENEAKIENVQKTGFIKGPMFKGVASSRFLPKGTKTKVNLEEQGRQKVSFSFSLTKKTLQNRFLTALGNEKQSDTPNPPAVPLQVDSTPKMKMEIGDTLSTAEESSPPKSRVELGKIHFKKHLLHVTSRPLLATTTAVASPPTHAAPLPAVIAESTTVDSPPSSPPPPPPPAQATTLSSPAPVTEPVALPHTPITVLMAAPVPLPVDVAVRSLKEPPIIIVPESLEADTKQDTISNSLEEHVTQILNEQADISSKKEDSHIGKDEEIPDSSKISLSCKKTGSKKKSSQSEGIFLGSESDEDSVRTSSSQRSHDLKFSASIEKERDFKKSSAPLKSEDLGKPSRSKTDRDDKYFSYSKLERDTRYVSSRCRSERERRRSRSHSRSERGSRTNLSYSRSERSHYYDSDRRYHRSSPYRERTRYSRPYTDNRARESSDSEEEYKKTYSRRTSSHSSSYRDLRTSSYSKSDRDCKTETSYLEMERRGKYSSKLERESKRTSENEAIKRCCSPPNELGFRRGSSYSKHDSSASRYKSTLSKPIPKSDKFKNSFCCTELNEEIKQSHSFSLQTPCSKGSELRMINKNPEREKAGSPAPSNRLNDSPTLKKLDELPIFKSEFITHDSHDSIKELDSLSKVKNDQLRSFCPIELNINGSPGAESDLATFCTSKTDAVLMTSDDSVTGSELSPLVKACMLSSNGFQNISRCKEKDLDDTCMLHKKSESPFRETEPLVSPHQDKLMSMPVMTVDYSKTVVKEPVDTRVSCCKTKDSDIYCTLNDSNPSLCNSEAENIEPSVMKISSNSFMNVHLESKPVICDSRNLTDHSKFACEEYKQSIGSTSSASVNHFDDLYQPIGSSGIASSLQSLPPGIKVDSLTLLKCGENTSPVLDAVLKSKKSSEFLKHAGKETIVEVGSDLPDSGKGFASRENRRNNGLSGKCLQEAQEEGNSILPERRGRPEISLDERGEGGHVHTSDDSEVVFSSCDLNLTMEDSDGVTYALKCDSSGHAPEIVSTVHEDYSGSSESSNDESDSEDTDSDDSSIPRNRLQSVVVVPKNSTLPMEETSPCSSRSSQSYRHYSDHWEDERLESRRHLYEEKFESIASKACPQTDKFFLHKGTEKNPEISFTQSSRKQIDNRLPELSHPQSDGVDSTSHTDVKSDPLGHPNSEETVKAKIPSRQQEELPIYSSDFEDVPNKSWQQTTFQNRPDSRLGKTELSFSSSCEIPHVDGLHSSEELRNLGWDFSQEKPSTTYQQPDSSYGACGGHKYQQNAEQYGGTRDYWQGNGYWDPRSGRPPGTGVVYDRTQGQVPDSLTDDREEEENWDQQDGSHFSDQSDKFLLSLQKDKGSVQAPEISSNSIKDTLAVNEKKDFSKNLEKNDIKDRGPLKKRRQEIESDSESDGELQDRKKVRVEVEQGETSVPPGSALVGPSCVMDDFRDPQRWKECAKQGKMPCYFDLIEENVYLTERKKNKSHRDIKRMQCECTPLSKDERAQGEIACGEDCLNRLLMIECSSRCPNGDYCSNRRFQRKQHADVEVILTEKKGWGLRAAKDLPSNTFVLEYCGEVLDHKEFKARVKEYARNKNIHYYFMALKNDEIIDATQKGNCSRFMNHSCEPNCETQKWTVNGQLRVGFFTTKLVPSGSELTFDYQFQRYGKEAQKCFCGSANCRGYLGGENRVSIRAAGGKMKKERSRKKDSVDGELEALMENGEGLSDKNQVLSLSRLMVRIETLEQKLTCLELIQNTHSQSCLKSFLERHGLSLLWIWMAELGDGRESNQKLQEEIIKTLEHLPIPTKNMLEESKVLPIIQRWSQTKTAVPPLSEGDGYSSENTSRAHTPLNTPDPSTKLSTEADTDTPKKLMFRRLKIISENSMDSAISDATSELEGKDGKEDLDQLENVPVEEEEELQSQQLLPQQLPECKVDSETNIEASKLPTSEPEADAEIEPKESNGTKLEEPINEETPSQDEEEGVSDVESERSQEQPDKTVDISDLATKLLDSWKDLKEVYRIPKKSQTEKENTTTERGRDAVGFRDQTPAPKTPNRSRERDPDKQTQNKEKRKRRSSLSPPSSAYERGTKRPDDRYDTPTSKKKVRIKDRNKLSTEERRKLFEQEVAQREAQKQQQQMQNLGMTSPLPYDSLGYNAPHHPFAGYPPGYPMQAYVDPSNPNAGKVLLPTPSMDPVCSPAPYDHAQPLVGHSTEPLSAPPPVPVVPHVAAPVEVSSSQYVAQSDGVVHQDSSVAVLPVPAPGPVQGQNYSVWDSNQQSVSVQQQYSPAQSQATIYYQGQTCPTVYGVTSPYSQTTPPIVQSYAQPSLQYIQGQQIFTAHPQGVVVQPAAAVTTIVAPGQPQPLQPSEMVVTNNLLDLPPPSPPKPKTIVLPPNWKTARDPEGKIYYYHVITRQTQWDPPTWESPGDDASLEHEAEMDLGTPTYDENPMKASKKPKTAEADTSSELAKKSKEVFRKEMSQFIVQCLNPYRKPDCKVGRITTTEDFKHLARKLTHGVMNKELKYCKNPEDLECNENVKHKTKEYIKKYMQKFGAVYKPKEDTELE

T67730	TARGETID	T67730
T67730	FORMERID	TTDR00170
T67730	UNIPROID	TRYD_HUMAN
T67730	TARGNAME	Delta-tryptase (TPSD1)
T67730	GENENAME	TPSD1
T67730	TARGTYPE	Literature-reported
T67730	SYNONYMS	TPSD1; Mast cell mMCP-7-like; HmMCP-3-like tryptase III; Delta tryptase
T67730	FUNCTION	Tryptase is the major neutral protease present in mast cells and is secreted upon the coupled activation-degranulation response of this cell type.
T67730	BIOCLASS	Peptidase
T67730	ECNUMBER	EC 3.4.21.59
T67730	SEQUENCE	MLLLAPQMLSLLLLALPVLASPAYVAPAPGQALQQTGIVGGQEAPRSKWPWQVSLRVRGPYWMHFCGGSLIHPQWVLTAAHCVEPDIKDLAALRVQLREQHLYYQDQLLPVSRIIVHPQFYIIQTGADIALLELEEPVNISSHIHTVTLPPASETFPPGMPCWVTGWGDVDNNVHLPPPYPLKEVEVPVVENHLCNAEYHTGLHTGHSFQIVRDDMLCAGSENHDSCQGDSGGPLVCKVNGT
T67730	DRUGINFO	D09YQM	BMS-262084	Investigative

T51597	TARGETID	T51597
T51597	FORMERID	TTDNR00634
T51597	UNIPROID	CHIA_HUMAN
T51597	TARGNAME	Acidic mammalian chitinase (CHIA)
T51597	GENENAME	CHIA
T51597	TARGTYPE	Literature-reported
T51597	SYNONYMS	Lung-specific protein TSA1902; CHIA; AMCase
T51597	FUNCTION	Degrades chitin and chitotriose. May participate in the defense against nematodes, fungi and other pathogens. Plays a role in T-helper cell type 2 (Th2) immune response. Contributes to the response to IL-13 and inflammation in response to IL-13. Stimulates chemokine production by pulmonary epithelial cells. Protects lung epithelial cells against apoptosis and promotes phosphorylation of AKT1. Its function in the inflammatory response and in protecting cells against apoptosis is inhibited by allosamidin, suggesting that the function of this protein depends on carbohydrate binding. .
T51597	PDBSTRUC	3RME; 3RM9; 3RM8; 3RM4; 3FY1
T51597	BIOCLASS	Glycosylase
T51597	ECNUMBER	EC 3.2.1.14
T51597	SEQUENCE	MTKLILLTGLVLILNLQLGSAYQLTCYFTNWAQYRPGLGRFMPDNIDPCLCTHLIYAFAGRQNNEITTIEWNDVTLYQAFNGLKNKNSQLKTLLAIGGWNFGTAPFTAMVSTPENRQTFITSVIKFLRQYEFDGLDFDWEYPGSRGSPPQDKHLFTVLVQEMREAFEQEAKQINKPRLMVTAAVAAGISNIQSGYEIPQLSQYLDYIHVMTYDLHGSWEGYTGENSPLYKYPTDTGSNAYLNVDYVMNYWKDNGAPAEKLIVGFPTYGHNFILSNPSNTGIGAPTSGAGPAGPYAKESGIWAYYEICTFLKNGATQGWDAPQEVPYAYQGNVWVGYDNIKSFDIKAQWLKHNKFGGAMVWAIDLDDFTGTFCNQGKFPLISTLKKALGLQSASCTAPAQPIEPITAAPSGSGNGSGSSSSGGSSGGSGFCAVRANGLYPVANNRNAFWHCVNGVTYQQNCQAGLVFDTSCDCCNWA

T00477	TARGETID	T00477
T00477	FORMERID	TTDR01324
T00477	UNIPROID	SRR_HUMAN
T00477	TARGNAME	Serine Racemase (SRR)
T00477	GENENAME	SRR
T00477	TARGTYPE	Literature-reported
T00477	SYNONYMS	L-serine dehydratase; L-serine ammonia-lyase; D-serine dehydratase; D-serine ammonia-lyase
T00477	FUNCTION	D-serine is a key coagonist with glutamate at NMDA receptors. Has dehydratase activity towards both L-serine and D-serine. Catalyzes the synthesis of D-serine from L-serine.
T00477	PDBSTRUC	5X2L; 3L6R; 3L6B
T00477	BIOCLASS	Racemases and epimerase
T00477	ECNUMBER	EC 5.1.1.18
T00477	SEQUENCE	MCAQYCISFADVEKAHINIRDSIHLTPVLTSSILNQLTGRNLFFKCELFQKTGSFKIRGALNAVRSLVPDALERKPKAVVTHSSGNHGQALTYAAKLEGIPAYIVVPQTAPDCKKLAIQAYGASIVYCEPSDESRENVAKRVTEETEGIMVHPNQEPAVIAGQGTIALEVLNQVPLVDALVVPVGGGGMLAGIAITVKALKPSVKVYAAEPSNADDCYQSKLKGKLMPNLYPPETIADGVKSSIGLNTWPIIRDLVDDIFTVTEDEIKCATQLVWERMKLLIEPTAGVGVAAVLSQHFQTVSPEVKNICIVLSGGNVDLTSSITWVKQAERPASYQSVSV
T00477	DRUGINFO	D08JNG	Malonic acid	Investigative
T00477	DRUGINFO	D0U6DZ	L-erythro-3-hydroxyaspartate	Investigative

T98225	TARGETID	T98225
T98225	FORMERID	TTDI03105
T98225	UNIPROID	CLK4_HUMAN
T98225	TARGNAME	CDC-like kinase 4 (CLK4)
T98225	GENENAME	CLK4
T98225	TARGTYPE	Literature-reported
T98225	SYNONYMS	Dual specificity protein kinase CLK4
T98225	FUNCTION	Phosphorylates serine- and arginine-rich (SR) proteins of the spliceosomal complex and may be a constituent of a network of regulatory mechanisms that enable SR proteins to control RNA splicing. Phosphorylates SRSF1 and SRSF3. Required for the regulation of alternative splicing of MAPT/TAU. Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells. Dual specificity kinase acting on both serine/threonine and tyrosine-containing substrates.
T98225	PDBSTRUC	6FYV
T98225	BIOCLASS	Kinase
T98225	ECNUMBER	EC 2.7.12.1
T98225	SEQUENCE	MRHSKRTHCPDWDSRESWGHESYRGSHKRKRRSHSSTQENRHCKPHHQFKESDCHYLEARSLNERDYRDRRYVDEYRNDYCEGYVPRHYHRDIESGYRIHCSKSSVRSRRSSPKRKRNRHCSSHQSRSKSHRRKRSRSIEDDEEGHLICQSGDVLRARYEIVDTLGEGAFGKVVECIDHGMDGMHVAVKIVKNVGRYREAARSEIQVLEHLNSTDPNSVFRCVQMLEWFDHHGHVCIVFELLGLSTYDFIKENSFLPFQIDHIRQMAYQICQSINFLHHNKLTHTDLKPENILFVKSDYVVKYNSKMKRDERTLKNTDIKVVDFGSATYDDEHHSTLVSTRHYRAPEVILALGWSQPCDVWSIGCILIEYYLGFTVFQTHDSKEHLAMMERILGPIPQHMIQKTRKRKYFHHNQLDWDEHSSAGRYVRRRCKPLKEFMLCHDEEHEKLFDLVRRMLEYDPTQRITLDEALQHPFFDLLKKK
T98225	DRUGINFO	D0UI7U	ML315	Investigative
T98225	DRUGINFO	D06CXU	PMID23642479C17	Investigative

T90961	TARGETID	T90961
T90961	FORMERID	TTDI03054
T90961	UNIPROID	BMP2K_HUMAN
T90961	TARGNAME	BMP-2-inducible protein kinase (BMP2K)
T90961	GENENAME	BMP2K
T90961	TARGTYPE	Literature-reported
T90961	SYNONYMS	HRIHFB2017; BIKe
T90961	FUNCTION	May be involved in osteoblast differentiation.
T90961	PDBSTRUC	5IKW; 5I3R; 5I3O; 4W9X; 4W9W
T90961	BIOCLASS	Kinase
T90961	ECNUMBER	EC 2.7.11.1
T90961	SEQUENCE	MKKFSRMPKSEGGSGGGAAGGGAGGAGAGAGCGSGGSSVGVRVFAVGRHQVTLEESLAEGGFSTVFLVRTHGGIRCALKRMYVNNMPDLNVCKREITIMKELSGHKNIVGYLDCAVNSISDNVWEVLILMEYCRAGQVVNQMNKKLQTGFTEPEVLQIFCDTCEAVARLHQCKTPIIHRDLKVENILLNDGGNYVLCDFGSATNKFLNPQKDGVNVVEEEIKKYTTLSYRAPEMINLYGGKPITTKADIWALGCLLYKLCFFTLPFGESQVAICDGNFTIPDNSRYSRNIHCLIRFMLEPDPEHRPDIFQVSYFAFKFAKKDCPVSNINNSSIPSALPEPMTASEAAARKSQIKARITDTIGPTETSIAPRQRPKANSATTATPSVLTIQSSATPVKVLAPGEFGNHRPKGALRPGNGPEILLGQGPPQQPPQQHRVLQQLQQGDWRLQQLHLQHRHPHQQQQQQQQQQQQQQQQQQQQQQQQQQQHHHHHHHHLLQDAYMQQYQHATQQQQMLQQQFLMHSVYQPQPSASQYPTMMPQYQQAFFQQQMLAQHQPSQQQASPEYLTSPQEFSPALVSYTSSLPAQVGTIMDSSYSANRSVADKEAIANFTNQKNISNPPDMSGWNPFGEDNFSKLTEEELLDREFDLLRSNRLEERASSDKNVDSLSAPHNHPPEDPFGSVPFISHSGSPEKKAEHSSINQENGTANPIKNGKTSPASKDQRTGKKTSVQGQVQKGNDESESDFESDPPSPKSSEEEEQDDEEVLQGEQGDFNDDDTEPENLGHRPLLMDSEDEEEEEKHSSDSDYEQAKAKYSDMSSVYRDRSGSGPTQDLNTILLTSAQLSSDVAVETPKQEFDVFGAVPFFAVRAQQPQQEKNEKNLPQHRFPAAGLEQEEFDVFTKAPFSKKVNVQECHAVGPEAHTIPGYPKSVDVFGSTPFQPFLTSTSKSESNEDLFGLVPFDEITGSQQQKVKQRSLQKLSSRQRRTKQDMSKSNGKRHHGTPTSTKKTLKPTYRTPERARRHKKVGRRDSQSSNEFLTISDSKENISVALTDGKDRGNVLQPEESLLDPFGAKPFHSPDLSWHPPHQGLSDIRADHNTVLPGRPRQNSLHGSFHSADVLKMDDFGAVPFTELVVQSITPHQSQQSQPVELDPFGAAPFPSKQ
T90961	DRUGINFO	D02NZE	PMID20483621C5m	Investigative

T86454	TARGETID	T86454
T86454	FORMERID	TTDR00632
T86454	UNIPROID	OXSM_HUMAN
T86454	TARGNAME	Beta-ketoacyl-ACP synthase (OXSM)
T86454	GENENAME	OXSM
T86454	TARGTYPE	Literature-reported
T86454	SYNONYMS	3-oxoacyl-[acyl-carrier-protein] synthase, mitochondrial
T86454	FUNCTION	May play a role in the biosynthesis of lipoic acid as well as longer chain fatty acids required for optimal mitochondrial function.
T86454	PDBSTRUC	2IWZ; 2IWY; 2C9H
T86454	BIOCLASS	Acyltransferase
T86454	ECNUMBER	EC 2.3.1.41
T86454	SEQUENCE	MSNCLQNFLKITSTRLLCSRLCQQLRSKRKFFGTVPISRLHRRVVITGIGLVTPLGVGTHLVWDRLIGGESGIVSLVGEEYKSIPCSVAAYVPRGSDEGQFNEQNFVSKSDIKSMSSPTIMAIGAAELAMKDSGWHPQSEADQVATGVAIGMGMIPLEVVSETALNFQTKGYNKVSPFFVPKILVNMAAGQVSIRYKLKGPNHAVSTACTTGAHAVGDSFRFIAHGDADVMVAGGTDSCISPLSLAGFSRARALSTNSDPKLACRPFHPKRDGFVMGEGAAVLVLEEYEHAVQRRARIYAEVLGYGLSGDAGHITAPDPEGEGALRCMAAALKDAGVQPEEISYINAHATSTPLGDAAENKAIKHLFKDHAYALAVSSTKGATGHLLGAAGAVEAAFTTLACYYQKLPPTLNLDCSEPEFDLNYVPLKAQEWKTEKRFIGLTNSFGFGGTNATLCIAGL

T91940	TARGETID	T91940
T91940	UNIPROID	SIR5_HUMAN
T91940	TARGNAME	NAD-dependent deacetylase sirtuin-5 (SIRT5)
T91940	GENENAME	SIRT5
T91940	TARGTYPE	Literature-reported
T91940	SYNONYMS	SIR2L5; SIR2-like protein 5; Regulatory protein SIR2 homolog 5
T91940	FUNCTION	NAD-dependent lysine demalonylase, desuccinylase and deglutarylase that specifically removes malonyl, succinyl and glutaryl groups on target proteins (PubMed:21908771, PubMed:22076378, PubMed:24703693, PubMed:29180469). Activates CPS1 and contributes to the regulation of blood ammonia levels during prolonged fasting: acts by mediating desuccinylation and deglutarylation of CPS1, thereby increasing CPS1 activity in response to elevated NAD levels during fasting (PubMed:22076378, PubMed:24703693). Activates SOD1 by mediating its desuccinylation, leading to reduced reactive oxygen species (PubMed:24140062). Activates SHMT2 by mediating its desuccinylation (PubMed:29180469). Modulates ketogenesis through the desuccinylation and activation of HMGCS2. Has weak NAD-dependent protein deacetylase activity; however this activity may not be physiologically relevant in vivo. Can deacetylate cytochrome c (CYCS) and a number of other proteins in vitro such as UOX.
T91940	PDBSTRUC	6EQS; 5XHS; 5BWL; 4HDA; 4G1C
T91940	BIOCLASS	Sirtuin family. Class III subfamily
T91940	ECNUMBER	EC 3.5.1.-
T91940	SEQUENCE	MRPLQIVPSRLISQLYCGLKPPASTRNQICLKMARPSSSMADFRKFFAKAKHIVIISGAGVSAESGVPTFRGAGGYWRKWQAQDLATPLAFAHNPSRVWEFYHYRREVMGSKEPNAGHRAIAECETRLGKQGRRVVVITQNIDELHRKAGTKNLLEIHGSLFKTRCTSCGVVAENYKSPICPALSGKGAPEPGTQDASIPVEKLPRCEEAGCGGLLRPHVVWFGENLDPAILEEVDRELAHCDLCLVVGTSSVVYPAAMFAPQVAARGVPVAEFNTETTPATNRFRFHFQGPCGTTLPEALACHENETVS

T28132	TARGETID	T28132
T28132	FORMERID	TTDC00240
T28132	UNIPROID	CA2D2_HUMAN
T28132	TARGNAME	Voltage-gated calcium channel alpha-2/delta-2 (CACNA2D2)
T28132	GENENAME	CACNA2D2
T28132	TARGTYPE	Literature-reported
T28132	SYNONYMS	Voltage-gated calcium channel subunit alpha-2/delta-2; Voltage-dependent calcium channel subunit delta-2; Voltage-dependent calcium channel subunit alpha-2-2; CACNA2D2
T28132	FUNCTION	The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-type calcium channel (CACNA1A), N-type (CACNA1B), L-type (CACNA1C OR CACNA1D) and possibly T-type (CACNA1G). Overexpression induces apoptosis.
T28132	BIOCLASS	Voltage-gated ion channel
T28132	SEQUENCE	MAVPARTCGASRPGPARTARPWPGCGPHPGPGTRRPTSGPPRPLWLLLPLLPLLAAPGASAYSFPQQHTMQHWARRLEQEVDGVMRIFGGVQQLREIYKDNRNLFEVQENEPQKLVEKVAGDIESLLDRKVQALKRLADAAENFQKAHRWQDNIKEEDIVYYDAKADAELDDPESEDVERGSKASTLRLDFIEDPNFKNKVNYSYAAVQIPTDIYKGSTVILNELNWTEALENVFMENRRQDPTLLWQVFGSATGVTRYYPATPWRAPKKIDLYDVRRRPWYIQGASSPKDMVIIVDVSGSVSGLTLKLMKTSVCEMLDTLSDDDYVNVASFNEKAQPVSCFTHLVQANVRNKKVFKEAVQGMVAKGTTGYKAGFEYAFDQLQNSNITRANCNKMIMMFTDGGEDRVQDVFEKYNWPNRTVRVFTFSVGQHNYDVTPLQWMACANKGYYFEIPSIGAIRINTQEYLDVLGRPMVLAGKEAKQVQWTNVYEDALGLGLVVTGTLPVFNLTQDGPGEKKNQLILGVMGIDVALNDIKRLTPNYTLGANGYVFAIDLNGYVLLHPNLKPQTTNFREPVTLDFLDAELEDENKEEIRRSMIDGNKGHKQIRTLVKSLDERYIDEVTRNYTWVPIRSTNYSLGLVLPPYSTFYLQANLSDQILQVKLPISKLKDFEFLLPSSFESEGHVFIAPREYCKDLNASDNNTEFLKNFIELMEKVTPDSKQCNNFLLHNLILDTGITQQLVERVWRDQDLNTYSLLAVFAATDGGITRVFPNKAAEDWTENPEPFNASFYRRSLDNHGYVFKPPHQDALLRPLELENDTVGILVSTAVELSLGRRTLRPAVVGVKLDLEAWAEKFKVLASNRTHQDQPQKCGPNSHCEMDCEVNNEDLLCVLIDDGGFLVLSNQNHQWDQVGRFFSEVDANLMLALYNNSFYTRKESYDYQAACAPQPPGNLGAAPRGVFVPTVADFLNLAWWTSAAAWSLFQQLLYGLIYHSWFQADPAEAEGSPETRESSCVMKQTQYYFGSVNASYNAIIDCGNCSRLFHAQRLTNTNLLFVVAEKPLCSQCEAGRLLQKETHSDGPEQCELVQRPRYRRGPHICFDYNATEDTSDCGRGASFPPSLGVLVSLQLLLLLGLPPRPQPQVLVHASRRL
T28132	DRUGINFO	D0D1EU	PD-144550	Investigative
T28132	DRUGINFO	D0T6DR	3-Aminomethyl-5-methyl-hexanoic acid	Investigative

T72849	TARGETID	T72849
T72849	FORMERID	TTDR00913
T72849	UNIPROID	ERAP1_HUMAN
T72849	TARGNAME	Adipocyte-derived leucine aminopeptidase (ERAP1)
T72849	GENENAME	ERAP1
T72849	TARGTYPE	Literature-reported
T72849	SYNONYMS	Type 1 tumor necrosis factor receptor shedding aminopeptidase regulator; Puromycin-insensitive leucyl-specific aminopeptidase; PILS-AP; ERAP1; Aminopeptidase PILS; ARTS-1; ALAP; A-LAP
T72849	FUNCTION	Aminopeptidase that plays a central role in peptide trimming, a step required for the generation of most HLA class I- binding peptides. Peptide trimming is essential to customize longer precursor peptides to fit them to the correct length required for presentation on MHC class I molecules. Strongly prefers substrates 9-16 residues long. Rapidly degrades 13-mer to a 9-mer and then stops. Preferentially hydrolyzes the residue Leu and peptides with a hydrophobic C-terminus, while it has weak activity toward peptides with charged C-terminus. May play a role in the inactivation of peptide hormones. May be involved in the regulationof blood pressure through the inactivation of angiotensin II and/or the generation of bradykinin in the kidney.
T72849	PDBSTRUC	6Q4R; 5J5E; 3RJO; 3QNF; 3MDJ
T72849	BIOCLASS	Peptidase
T72849	ECNUMBER	EC 3.4.11.-
T72849	SEQUENCE	MVFLPLKWSLATMSFLLSSLLALLTVSTPSWCQSTEASPKRSDGTPFPWNKIRLPEYVIPVHYDLLIHANLTTLTFWGTTKVEITASQPTSTIILHSHHLQISRATLRKGAGERLSEEPLQVLEHPRQEQIALLAPEPLLVGLPYTVVIHYAGNLSETFHGFYKSTYRTKEGELRILASTQFEPTAARMAFPCFDEPAFKASFSIKIRREPRHLAISNMPLVKSVTVAEGLIEDHFDVTVKMSTYLVAFIISDFESVSKITKSGVKVSVYAVPDKINQADYALDAAVTLLEFYEDYFSIPYPLPKQDLAAIPDFQSGAMENWGLTTYRESALLFDAEKSSASSKLGITMTVAHELAHQWFGNLVTMEWWNDLWLNEGFAKFMEFVSVSVTHPELKVGDYFFGKCFDAMEVDALNSSHPVSTPVENPAQIREMFDDVSYDKGACILNMLREYLSADAFKSGIVQYLQKHSYKNTKNEDLWDSMASICPTDGVKGMDGFCSRSQHSSSSSHWHQEGVDVKTMMNTWTLQKGFPLITITVRGRNVHMKQEHYMKGSDGAPDTGYLWHVPLTFITSKSDMVHRFLLKTKTDVLILPEEVEWIKFNVGMNGYYIVHYEDDGWDSLTGLLKGTHTAVSSNDRASLINNAFQLVSIGKLSIEKALDLSLYLKHETEIMPVFQGLNELIPMYKLMEKRDMNEVETQFKAFLIRLLRDLIDKQTWTDEGSVSERMLRSQLLLLACVHNYQPCVQRAEGYFRKWKESNGNLSLPVDVTLAVFAVGAQSTEGWDFLYSKYQFSLSSTEKSQIEFALCRTQNKEKLQWLLDESFKGDKIKTQEFPQILTLIGRNPVGYPLAWQFLRKNWNKLVQKFELGSSSIAHMVMGTTNQFSTRTRLEEVKGFFSSLKENGSQLRCVQQTIETIEENIGWMDKNFDKIRVWLQSEKLERM
T72849	DRUGINFO	D02MNM	PMID23916253C17	Investigative

T92288	TARGETID	T92288
T92288	UNIPROID	MSRB1_HUMAN
T92288	TARGNAME	Methionine-R-sulfoxide reductase B1 (MSRB1)
T92288	GENENAME	MSRB1
T92288	TARGTYPE	Literature-reported
T92288	SYNONYMS	Selenoprotein X; SelX; SEPX1; MsrB1
T92288	FUNCTION	Methionine-sulfoxide reductase that specifically reduces methionine (R)-sulfoxide back to methionine. While in many cases, methionine oxidation is the result of random oxidation following oxidative stress, methionine oxidation is also a post-translational modification that takes place on specific residue. Acts as a regulator of actin assembly by reducing methionine (R)-sulfoxide mediated by MICALs (MICAL1, MICAL2 or MICAL3) on actin, thereby promoting filament repolymerization. Plays a role in innate immunity by reducing oxidized actin, leading to actin repolymerization in macrophages.
T92288	PDBSTRUC	3MAO
T92288	BIOCLASS	MsrB Met sulfoxide reductase family
T92288	ECNUMBER	EC 1.8.4.12
T92288	SEQUENCE	MSFCSFFGGEVFQNHFEPGVYVCAKCGYELFSSRSKYAHSSPWPAFTETIHADSVAKRPEHNRSEALKVSCGKCGNGLGHEFLNDGPKPGQSRFUIFSSSLKFVPKGKETSASQGH

T96435	TARGETID	T96435
T96435	FORMERID	TTDI02619
T96435	UNIPROID	SENP1_HUMAN
T96435	TARGNAME	Sentrin specific protease-1 (SENP1)
T96435	GENENAME	SENP1
T96435	TARGTYPE	Literature-reported
T96435	SYNONYMS	Sentrin/SUMO-specific protease SENP1; Sentrin-specific protease 1
T96435	FUNCTION	The first is the hydrolysis of an alpha-linked peptide bond at the C-terminal end of the small ubiquitin-like modifier (SUMO) propeptides, SUMO1, SUMO2 and SUMO3 leading to the mature form of the proteins. The second is the deconjugation of SUMO1, SUMO2 and SUMO3 from targeted proteins, by cleaving an epsilon-linked peptide bond between the C-terminal glycine of the mature SUMO and the lysine epsilon-amino group of the target protein. Deconjugates SUMO1 from HIPK2. Deconjugates SUMO1 from HDAC1 and BHLHE40/DEC1, which decreases its transcriptional repression activity. Deconjugates SUMO1 from CLOCK, which decreases its transcriptional activation activity. Deconjugates SUMO2 from MTA1. Deconjugates SUMO1 from METTL3. Desumoylates CCAR2 which decreases its interaction with SIRT1. Deconjugates SUMO1 from GPS2. Protease that catalyzes two essential functions in the SUMO pathway.
T96435	PDBSTRUC	6NNQ; 2XRE; 2XPH; 2IYD; 2IYC
T96435	BIOCLASS	Peptidase
T96435	ECNUMBER	EC 3.4.22.-
T96435	SEQUENCE	MDDIADRMRMDAGEVTLVNHNSVFKTHLLPQTGFPEDQLSLSDQQILSSRQGHLDRSFTCSTRSAAYNPSYYSDNPSSDSFLGSGDLRTFGQSANGQWRNSTPSSSSSLQKSRNSRSLYLETRKTSSGLSNSFAGKSNHHCHVSAYEKSFPIKPVPSPSWSGSCRRSLLSPKKTQRRHVSTAEETVQEEEREIYRQLLQMVTGKQFTIAKPTTHFPLHLSRCLSSSKNTLKDSLFKNGNSCASQIIGSDTSSSGSASILTNQEQLSHSVYSLSSYTPDVAFGSKDSGTLHHPHHHHSVPHQPDNLAASNTQSEGSDSVILLKVKDSQTPTPSSTFFQAELWIKELTSVYDSRARERLRQIEEQKALALQLQNQRLQEREHSVHDSVELHLRVPLEKEIPVTVVQETQKKGHKLTDSEDEFPEITEEMEKEIKNVFRNGNQDEVLSEAFRLTITRKDIQTLNHLNWLNDEIINFYMNMLMERSKEKGLPSVHAFNTFFFTKLKTAGYQAVKRWTKKVDVFSVDILLVPIHLGVHWCLAVVDFRKKNITYYDSMGGINNEACRILLQYLKQESIDKKRKEFDTNGWQLFSKKSQEIPQQMNGSDCGMFACKYADCITKDRPINFTQQHMPYFRKRMVWEILHRKLL

T79694	TARGETID	T79694
T79694	FORMERID	TTDR00048
T79694	UNIPROID	CAC1I_HUMAN
T79694	TARGNAME	Voltage-gated calcium channel alpha Cav3.3 (CACNA1I)
T79694	GENENAME	CACNA1I
T79694	TARGTYPE	Literature-reported
T79694	SYNONYMS	Voltage-gated calcium channel subunit alpha Cav3.3; Voltage-dependent T-type calcium channel subunit alpha-1I; KIAA1120; Ca(v)3.3
T79694	FUNCTION	Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. This channel gives rise to T-type calcium currents. T-type calcium channels belong to the "low-voltage activated (LVA)" group and are strongly blocked by nickel and mibefradil. A particularity of this type of channels is an opening at quite negative potentials, and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes. Gates in voltage ranges similar to, but higher than alpha 1G or alpha 1H (By similarity).
T79694	BIOCLASS	Voltage-gated ion channel
T79694	SEQUENCE	MAESASPPSSSAAAPAAEPGVTTEQPGPRSPPSSPPGLEEPLDGADPHVPHPDLAPIAFFCLRQTTSPRNWCIKMVCNPWFECVSMLVILLNCVTLGMYQPCDDMDCLSDRCKILQVFDDFIFIFFAMEMVLKMVALGIFGKKCYLGDTWNRLDFFIVMAGMVEYSLDLQNINLSAIRTVRVLRPLKAINRVPSMRILVNLLLDTLPMLGNVLLLCFFVFFIFGIIGVQLWAGLLRNRCFLEENFTIQGDVALPPYYQPEEDDEMPFICSLSGDNGIMGCHEIPPLKEQGRECCLSKDDVYDFGAGRQDLNASGLCVNWNRYYNVCRTGSANPHKGAINFDNIGYAWIVIFQVITLEGWVEIMYYVMDAHSFYNFIYFILLIIVGSFFMINLCLVVIATQFSETKQREHRLMLEQRQRYLSSSTVASYAEPGDCYEEIFQYVCHILRKAKRRALGLYQALQSRRQALGPEAPAPAKPGPHAKEPRHYHGKTKGQGDEGRHLGSRHCQTLHGPASPGNDHSGRELCPQHSPLDATPHTLVQPIPATLASDPASCPCCQHEDGRRPSGLGSTDSGQEGSGSGSSAGGEDEADGDGARSSEDGASSELGKEEEEEEQADGAVWLCGDVWRETRAKLRGIVDSKYFNRGIMMAILVNTVSMGIEHHEQPEELTNILEICNVVFTSMFALEMILKLAAFGLFDYLRNPYNIFDSIIVIISIWEIVGQADGGLSVLRTFRLLRVLKLVRFMPALRRQLVVLMKTMDNVATFCMLLMLFIFIFSILGMHIFGCKFSLRTDTGDTVPDRKNFDSLLWAIVTVFQILTQEDWNVVLYNGMASTSPWASLYFVALMTFGNYVLFNLLVAILVEGFQAEGDANRSYSDEDQSSSNIEEFDKLQEGLDSSGDPKLCPIPMTPNGHLDPSLPLGGHLGPAGAAGPAPRLSLQPDPMLVALGSRKSSVMSLGRMSYDQRSLSSSRSSYYGPWGRSAAWASRRSSWNSLKHKPPSAEHESLLSAERGGGARVCEVAADEGPPRAAPLHTPHAHHIHHGPHLAHRHRHHRRTLSLDNRDSVDLAELVPAVGAHPRAAWRAAGPAPGHEDCNGRMPSIAKDVFTKMGDRGDRGEDEEEIDYTLCFRVRKMIDVYKPDWCEVREDWSVYLFSPENRFRVLCQTIIAHKLFDYVVLAFIFLNCITIALERPQIEAGSTERIFLTVSNYIFTAIFVGEMTLKVVSLGLYFGEQAYLRSSWNVLDGFLVFVSIIDIVVSLASAGGAKILGVLRVLRLLRTLRPLRVISRAPGLKLVVETLISSLKPIGNIVLICCAFFIIFGILGVQLFKGKFYHCLGVDTRNITNRSDCMAANYRWVHHKYNFDNLGQALMSLFVLASKDGWVNIMYNGLDAVAVDQQPVTNHNPWMLLYFISFLLIVSFFVLNMFVGVVVENFHKCRQHQEAEEARRREEKRLRRLEKKRRKAQRLPYYATYCHTRLLIHSMCTSHYLDIFITFIICLNVVTMSLEHYNQPTSLETALKYCNYMFTTVFVLEAVLKLVAFGLRRFFKDRWNQLDLAIVLLSVMGITLEEIEINAALPINPTIIRIMRVLRIARVLKLLKMATGMRALLDTVVQALPQVGNLGLLFMLLFFIYAALGVELFGKLVCNDENPCEGMSRHATFENFGMAFLTLFQVSTGDNWNGIMKDTLRDCTHDERSCLSSLQFVSPLYFVSFVLTAQFVLINVVVAVLMKHLDDSNKEAQEDAEMDAELELEMAHGLGPGPRLPTGSPGAPGRGPGGAGGGGDTEGGLCRRCYSPAQENLWLDSVSLIIKDSLEGELTIIDNLSGSIFHHYSSPAGCKKCHHDKQEVQLAETEAFSLNSDRSSSILLGDDLSLEDPTACPPGRKDSKGELDPPEPMRVGDLGECFFPLSSTAVSPDPENFLCEMEEIPFNPVRSWLKHDSSQAPPSPFSPDASSPLLPMPAEFFHPAVSASQKGPEKGTGTGTLPKIALQGSWASLRSPRVNCTLLRQATGSDTSLDASPSSSAGSLQTTLEDSLTLSDSPRRALGPPAPAPGPRAGLSPAARRRLSLRGRGLFSLRGLRAHQRSHSSGGSTSPGCTHHDSMDPSDEEGRGGAGGGGAGSEHSETLSSLSLTSLFCPPPPPPAPGLTPARKFSSTSSLAAPGRPHAAALAHGLARSPSWAADRSKDPPGRAPLPMGLGPLAPPPQPLPGELEPGDAASKRKR
T79694	DRUGINFO	D0OW2O	U-92032	Terminated
T79694	DRUGINFO	D09PWJ	ML218	Investigative

T52188	TARGETID	T52188
T52188	FORMERID	TTDR00275
T52188	UNIPROID	Q9U752_PLAFA
T52188	TARGNAME	Plasmodium Acetyl-CoA carboxylase 1 (Malaria ACC1)
T52188	GENENAME	Malaria ACC1
T52188	TARGTYPE	Literature-reported
T52188	SYNONYMS	Acetyl-CoA carboxylase; ACC1; ACC-alpha
T52188	FUNCTION	Catalyzes the rate-limiting reaction in the biogenesis of long-chain fatty acids. This protein carries three functions: biotin carboxyl carrier protein, biotin carboxylase, and carboxyltransferase.
T52188	BIOCLASS	Carbon-carbon ligase
T52188	SEQUENCE	SQGGGGKGIRKVENEYEIKKAYEQVQNELPNSPIFLMKVCNNVRHIEIQVVGDMYGNVCSLSGRDCTTQRRFQKIFEEGPPSVVPYPIFREMEKSSIRLTKMIKYRGAGTIEYLYDQINKKYFFLELNPRL
T52188	DRUGINFO	D04MKK	Haloxyfop	Investigative
T52188	DRUGINFO	D05RRI	Clodinafop	Investigative
T52188	DRUGINFO	D07DRJ	Quizalofop	Investigative
T52188	DRUGINFO	D07WIC	CP-640186	Investigative
T52188	DRUGINFO	D0IY5Y	A-80040	Investigative
T52188	DRUGINFO	D0P7HI	AC-8632	Investigative

T56871	TARGETID	T56871
T56871	FORMERID	TTDI00137
T56871	UNIPROID	KDM5B_HUMAN
T56871	TARGNAME	Lysine-specific demethylase 5B (KDM5B)
T56871	GENENAME	KDM5B
T56871	TARGTYPE	Literature-reported
T56871	SYNONYMS	Retinoblastomabinding protein 2 homolog 1; Retinoblastoma-binding protein 2 homolog 1; RBP2H1; RBP2-H1; RBBP2H1; PLU1; PLU-1; Lysinespecific demethylase 5B; Jumonji/ARID domaincontaining protein 1B; Jumonji/ARID domain-containing protein 1B; JARID1B; Histone demethylase JARID1B; Cancer/testis antigen 31; CT31
T56871	FUNCTION	Does not demethylate histone H3 'Lys-9' or H3 'Lys-27'. Demethylates trimethylated, dimethylated and monomethylated H3 'Lys-4'. Acts as a transcriptional corepressor for FOXG1B and PAX9. Favors the proliferation of breast cancer cells by repressing tumor suppressor genes such as BRCA1 and HOXA5. In contrast, may act as a tumor suppressor for melanoma. Represses the CLOCK-ARNTL/BMAL1 heterodimer-mediated transcriptional activation of the core clock component PER2. Histone demethylase that demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code.
T56871	PDBSTRUC	6EK6; 6EJ1; 6EJ0; 6EIY; 6EIU
T56871	BIOCLASS	Paired donor oxygen oxidoreductase
T56871	ECNUMBER	EC 1.14.11.-
T56871	SEQUENCE	MEAATTLHPGPRPALPLGGPGPLGEFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLNFLDQIAKYWELQGSTLKIPHVERKILDLFQLNKLVAEEGGFAVVCKDRKWTKIATKMGFAPGKAVGSHIRGHYERILNPYNLFLSGDSLRCLQKPNLTTDTKDKEYKPHDIPQRQSVQPSETCPPARRAKRMRAEAMNIKIEPEETTEARTHNLRRRMGCPTPKCENEKEMKSSIKQEPIERKDYIVENEKEKPKSRSKKATNAVDLYVCLLCGSGNDEDRLLLCDGCDDSYHTFCLIPPLHDVPKGDWRCPKCLAQECSKPQEAFGFEQAARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKINKKKSLVSFKALIEESEMKKFPDNDLLRHLRLVTQDAEKCASVAQQLLNGKRQTRYRSGGGKSQNQLTVNELRQFVTQLYALPCVLSQTPLLKDLLNRVEDFQQHSQKLLSEETPSAAELQDLLDVSFEFDVELPQLAEMRIRLEQARWLEEVQQACLDPSSLTLDDMRRLIDLGVGLAPYSAVEKAMARLQELLTVSEHWDDKAKSLLKARPRHSLNSLATAVKEIEEIPAYLPNGAALKDSVQRARDWLQDVEGLQAGGRVPVLDTLIELVTRGRSIPVHLNSLPRLETLVAEVQAWKECAVNTFLTENSPYSLLEVLCPRCDIGLLGLKRKQRKLKEPLPNGKKKSTKLESLSDLERALTESKETASAMATLGEARLREMEALQSLRLANEGKLLSPLQDVDIKICLCQKAPAAPMIQCELCRDAFHTSCVAVPSISQGLRIWLCPHCRRSEKPPLEKILPLLASLQRIRVRLPEGDALRYMIERTVNWQHRAQQLLSSGNLKFVQDRVGSGLLYSRWQASAGQVSDTNKVSQPPGTTSFSLPDDWDNRTSYLHSPFSTGRSCIPLHGVSPEVNELLMEAQLLQVSLPEIQELYQTLLAKPSPAQQTDRSSPVRPSSEKNDCCRGKRDGINSLERKLKRRLEREGLSSERWERVKKMRTPKKKKIKLSHPKDMNNFKLERERSYELVRSAETHSLPSDTSYSEQEDSEDEDAICPAVSCLQPEGDEVDWVQCDGSCNQWFHQVCVGVSPEMAEKEDYICVRCTVKDAPSRK
T56871	DRUGINFO	D0IQ7Y	PBIT	Investigative

T90987	TARGETID	T90987
T90987	FORMERID	TTDI03017
T90987	UNIPROID	ATS1_HUMAN
T90987	TARGNAME	ADAM metallopeptidase with thrombospondin 1 (ADAMTS1)
T90987	GENENAME	ADAMTS1
T90987	TARGTYPE	Literature-reported
T90987	SYNONYMS	METH1; METH-1; KIAA1346; ADAMTS-1; ADAM-TS1; ADAM-TS 1
T90987	FUNCTION	Has angiogenic inhibitor activity. Active metalloprotease, which may be associated with various inflammatory processes as well as development of cancer cachexia. May play a critical role in follicular rupture. Cleaves aggrecan, a cartilage proteoglycan, at the '1938-Glu-|-Leu-1939' site (within the chondroitin sulfate attachment domain), and may be involved in its turnover.
T90987	PDBSTRUC	3Q2H; 3Q2G; 2V4B; 2JIH
T90987	BIOCLASS	Peptidase
T90987	ECNUMBER	EC 3.4.24.-
T90987	SEQUENCE	MQRAVPEGFGRRKLGSDMGNAERAPGSRSFGPVPTLLLLAAALLAVSDALGRPSEEDEELVVPELERAPGHGTTRLRLHAFDQQLDLELRPDSSFLAPGFTLQNVGRKSGSETPLPETDLAHCFYSGTVNGDPSSAAALSLCEGVRGAFYLLGEAYFIQPLPAASERLATAAPGEKPPAPLQFHLLRRNRQGDVGGTCGVVDDEPRPTGKAETEDEDEGTEGEDEGAQWSPQDPALQGVGQPTGTGSIRKKRFVSSHRYVETMLVADQSMAEFHGSGLKHYLLTLFSVAARLYKHPSIRNSVSLVVVKILVIHDEQKGPEVTSNAALTLRNFCNWQKQHNPPSDRDAEHYDTAILFTRQDLCGSQTCDTLGMADVGTVCDPSRSCSVIEDDGLQAAFTTAHELGHVFNMPHDDAKQCASLNGVNQDSHMMASMLSNLDHSQPWSPCSAYMITSFLDNGHGECLMDKPQNPIQLPGDLPGTSYDANRQCQFTFGEDSKHCPDAASTCSTLWCTGTSGGVLVCQTKHFPWADGTSCGEGKWCINGKCVNKTDRKHFDTPFHGSWGMWGPWGDCSRTCGGGVQYTMRECDNPVPKNGGKYCEGKRVRYRSCNLEDCPDNNGKTFREEQCEAHNEFSKASFGSGPAVEWIPKYAGVSPKDRCKLICQAKGIGYFFVLQPKVVDGTPCSPDSTSVCVQGQCVKAGCDRIIDSKKKFDKCGVCGGNGSTCKKISGSVTSAKPGYHDIITIPTGATNIEVKQRNQRGSRNNGSFLAIKAADGTYILNGDYTLSTLEQDIMYKGVVLRYSGSSAALERIRSFSPLKEPLTIQVLTVGNALRPKIKYTYFVKKKKESFNAIPTFSAWVIEEWGECSKSCELGWQRRLVECRDINGQPASECAKEVKPASTRPCADHPCPQWQLGEWSSCSKTCGKGYKKRSLKCLSHDGGVLSHESCDPLKKPKHFIDFCTMAECS
T90987	DRUGINFO	D0H6CK	PMID16516466C12c	Investigative

T50429	TARGETID	T50429
T50429	FORMERID	TTDI03455
T50429	UNIPROID	PADI4_HUMAN
T50429	TARGNAME	Peptidyl arginine deiminase type IV (PADI4)
T50429	GENENAME	PADI4
T50429	TARGTYPE	Literature-reported
T50429	SYNONYMS	Protein-arginine deiminase type-4; Protein-arginine deiminase type IV; Peptidylarginine deiminase IV; PDI5; PADI5; PAD4; HL-60 PAD
T50429	FUNCTION	Citrullinates histone H1 at 'Arg-54' (to form H1R54ci), histone H3 at 'Arg-2', 'Arg-8', 'Arg-17' and/or 'Arg-26' (to form H3R2ci, H3R8ci, H3R17ci, H3R26ci, respectively) and histone H4 at 'Arg-3' (to form H4R3ci). Acts as a key regulator of stem cell maintenance by mediating citrullination of histone H1: citrullination of 'Arg-54' of histone H1 (H1R54ci) results in H1 displacement from chromatin and global chromatin decondensation, thereby promoting pluripotency and stem cell maintenance. Promotes profound chromatin decondensation during the innate immune response to infection in neutrophils by mediating formation of H1R54ci. Citrullination of histone H3 prevents their methylation by CARM1 and HRMT1L2/PRMT1 and represses transcription. Citrullinates EP300/P300 at 'Arg-2142', which favors its interaction with NCOA2/GRIP1. Catalyzes the citrullination/deimination of arginine residues of proteins such as histones, thereby playing a key role in histone code and regulation of stem cell maintenance.
T50429	PDBSTRUC	5N1B; 5N0Z; 5N0Y; 5N0M; 4X8G
T50429	BIOCLASS	Carbon-nitrogen hydrolase
T50429	ECNUMBER	EC 3.5.3.15
T50429	SEQUENCE	MAQGTLIRVTPEQPTHAVCVLGTLTQLDICSSAPEDCTSFSINASPGVVVDIAHGPPAKKKSTGSSTWPLDPGVEVTLTMKVASGSTGDQKVQISYYGPKTPPVKALLYLTGVEISLCADITRTGKVKPTRAVKDQRTWTWGPCGQGAILLVNCDRDNLESSAMDCEDDEVLDSEDLQDMSLMTLSTKTPKDFFTNHTLVLHVARSEMDKVRVFQATRGKLSSKCSVVLGPKWPSHYLMVPGGKHNMDFYVEALAFPDTDFPGLITLTISLLDTSNLELPEAVVFQDSVVFRVAPWIMTPNTQPPQEVYACSIFENEDFLKSVTTLAMKAKCKLTICPEEENMDDQWMQDEMEIGYIQAPHKTLPVVFDSPRNRGLKEFPIKRVMGPDFGYVTRGPQTGGISGLDSFGNLEVSPPVTVRGKEYPLGRILFGDSCYPSNDSRQMHQALQDFLSAQQVQAPVKLYSDWLSVGHVDEFLSFVPAPDRKGFRLLLASPRSCYKLFQEQQNEGHGEALLFEGIKKKKQQKIKNILSNKTLREHNSFVERCIDWNRELLKRELGLAESDIIDIPQLFKLKEFSKAEAFFPNMVNMLVLGKHLGIPKPFGPVINGRCCLEEKVCSLLEPLGLQCTFINDFFTYHIRHGEVHCGTNVRRKPFSFKWWNMVP
T50429	DRUGINFO	D01FNC	PMID24440480C3	Investigative
T50429	DRUGINFO	D02ZNQ	streptonigrin	Investigative
T50429	DRUGINFO	D0C4DE	PMID25742366C14b	Investigative
T50429	DRUGINFO	D0YP0A	Cl-amidine	Investigative

T37271	TARGETID	T37271
T37271	FORMERID	TTDR00415
T37271	UNIPROID	SIAT9_HUMAN
T37271	TARGNAME	Lactosylceramide alpha-2,3-sialyltransferase (ST3GAL5)
T37271	GENENAME	ST3GAL5
T37271	TARGTYPE	Literature-reported
T37271	SYNONYMS	UNQ2510/PRO5998; Sialyltransferase 9; ST3Gal V; ST3GAL5; Ganglioside GM3 synthase; CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase
T37271	FUNCTION	Catalyzes the formation of ganglioside GM3 (alpha-N- acetylneuraminyl-2,3-beta-D-galactosyl-1, 4-beta-D- glucosylceramide).
T37271	BIOCLASS	Glycosyl transferase
T37271	ECNUMBER	EC 2.4.99.9
T37271	SEQUENCE	MRTKAAGCAERRPLQPRTEAAAAPAGRAMPSEYTYVKLRSDCSRPSLQWYTRAQSKMRRPSLLLKDILKCTLLVFGVWILYILKLNYTTEECDMKKMHYVDPDHVKRAQKYAQQVLQKECRPKFAKTSMALLFEHRYSVDLLPFVQKAPKDSEAESKYDPPFGFRKFSSKVQTLLELLPEHDLPEHLKAKTCRRCVVIGSGGILHGLELGHTLNQFDVVIRLNSAPVEGYSEHVGNKTTIRMTYPEGAPLSDLEYYSNDLFVAVLFKSVDFNWLQAMVKKETLPFWVRLFFWKQVAEKIPLQPKHFRILNPVIIKETAFDILQYSEPQSRFWGRDKNVPTIGVIAVVLATHLCDEVSLAGFGYDLNQPRTPLHYFDSQCMAAMNFQTMHNVTTETKFLLKLVKEGVVKDLSGGIDREF
T37271	DRUGINFO	D0V2QF	5'-deoxy-5'-[(3-hydrazinopropyl)methylamino]adenosine	Investigative

T00933	TARGETID	T00933
T00933	FORMERID	TTDI03456
T00933	UNIPROID	PHF8_HUMAN
T00933	TARGNAME	Histone lysine demethylase PHF8 (PHF8)
T00933	GENENAME	PHF8
T00933	TARGTYPE	Literature-reported
T00933	SYNONYMS	ZNF422; PHD finger protein 8; KIAA1111
T00933	FUNCTION	Demethylates mono- and dimethylated histone H3 'Lys-9' residue (H3K9Me1 and H3K9Me2), dimethylated H3 'Lys-27' (H3K27Me2) and monomethylated histone H4 'Lys-20' residue (H4K20Me1). Acts as a transcription activator as H3K9Me1, H3K9Me2, H3K27Me2 and H4K20Me1 are epigenetic repressive marks. Involved in cell cycle progression by being required to control G1-S transition. Acts as a coactivator of rDNA transcription, by activating polymerase I (pol I) mediated transcription of rRNA genes. Required for brain development, probably by regulating expression of neuron-specific genes. Only has activity toward H4K20Me1 when nucleosome is used as a substrate and when not histone octamer is used as substrate. May also have weak activity toward dimethylated H3 'Lys-36' (H3K36Me2), however, the relevance of this result remains unsure in vivo. Specifically binds trimethylated 'Lys-4' of histone H3 (H3K4me3), affecting histone demethylase specificity: has weak activity toward H3K9Me2 in absence of H3K4me3, while it has high activity toward H3K9me2 when binding H3K4me3. Histone lysine demethylase with selectivity for the di- and monomethyl states that plays a key role cell cycle progression, rDNA transcription and brain development.
T00933	PDBSTRUC	4DO0; 3KV4; 3K3O; 3K3N; 2WWU
T00933	BIOCLASS	Paired donor oxygen oxidoreductase
T00933	ECNUMBER	EC 1.14.11.27
T00933	SEQUENCE	MNRSRAIVQRGRVLPPPAPLDTTNLAGRRTLQGRAKMASVPVYCLCRLPYDVTRFMIECDMCQDWFHGSCVGVEEEKAADIDLYHCPNCEVLHGPSIMKKRRGSSKGHDTHKGKPVKTGSPTFVRELRSRTFDSSDEVILKPTGNQLTVEFLEENSFSVPILVLKKDGLGMTLPSPSFTVRDVEHYVGSDKEIDVIDVTRQADCKMKLGDFVKYYYSGKREKVLNVISLEFSDTRLSNLVETPKIVRKLSWVENLWPEECVFERPNVQKYCLMSVRDSYTDFHIDFGGTSVWYHVLKGEKIFYLIRPTNANLTLFECWSSSSNQNEMFFGDQVDKCYKCSVKQGQTLFIPTGWIHAVLTPVDCLAFGGNFLHSLNIEMQLKAYEIEKRLSTADLFRFPNFETICWYVGKHILDIFRGLRENRRHPASYLVHGGKALNLAFRAWTRKEALPDHEDEIPETVRTVQLIKDLAREIRLVEDIFQQNVGKTSNIFGLQRIFPAGSIPLTRPAHSTSVSMSRLSLPSKNGSKKKGLKPKELFKKAERKGKESSALGPAGQLSYNLMDTYSHQALKTGSFQKAKFNITGACLNDSDDDSPDLDLDGNESPLALLMSNGSTKRVKSLSKSRRTKIAKKVDKARLMAEQVMEDEFDLDSDDELQIDERLGKEKATLIIRPKFPRKLPRAKPCSDPNRVREPGEVEFDIEEDYTTDEDMVEGVEGKLGNGSGAGGILDLLKASRQVGGPDYAALTEAPASPSTQEAIQGMLCMANLQSSSSSPATSSLQAWWTGGQDRSSGSSSSGLGTVSNSPASQRTPGKRPIKRPAYWRTESEEEEENASLDEQDSLGACFKDAEYIYPSLESDDDDPALKSRPKKKKNSDDAPWSPKARVTPTLPKQDRPVREGTRVASIETGLAAAAAKLAQQELQKAQKKKYIKKKPLLKEVEQPRPQDSNLSLTVPAPTVAATPQLVTSSSPLPPPEPKQEALSGSLADHEYTARPNAFGMAQANRSTTPMAPGVFLTQRRPSVGSQSNQAGQGKRPKKGLATAKQRLGRILKIHRNGKLLL
T00933	DRUGINFO	D0B2WZ	daminozide	Investigative

T85924	TARGETID	T85924
T85924	FORMERID	TTDR01446
T85924	UNIPROID	COLG_HATHI
T85924	TARGNAME	Clostridium histolyticum Collagenase (CH colG)
T85924	GENENAME	CH colG
T85924	TARGTYPE	Literature-reported
T85924	SYNONYMS	Microbial collagenase; Gelatinase ColG; Collagenase ColG; Class I collagenase
T85924	FUNCTION	Clostridial collagenases are among the most efficient degraders of eukaryotic collagen known; saprophytes use collagen as a carbon source while pathogens additionally digest collagen to aid in host colonization. Has both tripeptidylcarboxypeptidase on Gly-X-Y and endopeptidase activities; the endopeptidase cuts within the triple helix region of collagen while tripeptidylcarboxypeptidase successively digests the exposed ends, thus clostridial collagenases can digest large sections of collagen. Active on soluble type I collagen, insoluble collagen, azocoll, soluble PZ-peptide (all collagenase substrates) and gelatin. The full-length protein has collagenase activity, while the in vivo derived C-terminally truncated shorter versions only act on gelatin. In vitro digestion of soluble calf skin collagen fibrils requires both ColG and ColH; ColG forms missing the second collagen-binding domain are also synergistic with ColH, although their overall efficiency is decreased. The activator domain (residues 119-388) and catalytic subdomain (389-670) open and close around substrate using a Gly-rich hinge (387-397), allowing digestion when the protein is closed. Binding of collagen requires Ca(2+) and is inhibited by EGTA; the collagen-binding domain (CBD, S3a plus S3b) specifically recognizes the triple-helical conformation made by 3 collagen protein chains in the triple-helical region. Isolated CBD (S3a plus S3b) binds collagen fibrils and sheets of many tissues.
T85924	PDBSTRUC	5IKU; 4TN9; 4JRW; 4HPK; 4ARE
T85924	ECNUMBER	EC 3.4.24.3
T85924	SEQUENCE	MKKNILKILMDSYSKESKIQTVRRVTSVSLLAVYLTMNTSSLVLAKPIENTNDTSIKNVEKLRNAPNEENSKKVEDSKNDKVEHVKNIEEAKVEQVAPEVKSKSTLRSASIANTNSEKYDFEYLNGLSYTELTNLIKNIKWNQINGLFNYSTGSQKFFGDKNRVQAIINALQESGRTYTANDMKGIETFTEVLRAGFYLGYYNDGLSYLNDRNFQDKCIPAMIAIQKNPNFKLGTAVQDEVITSLGKLIGNASANAEVVNNCVPVLKQFRENLNQYAPDYVKGTAVNELIKGIEFDFSGAAYEKDVKTMPWYGKIDPFINELKALGLYGNITSATEWASDVGIYYLSKFGLYSTNRNDIVQSLEKAVDMYKYGKIAFVAMERITWDYDGIGSNGKKVDHDKFLDDAEKHYLPKTYTFDNGTFIIRAGDKVSEEKIKRLYWASREVKSQFHRVVGNDKALEVGNADDVLTMKIFNSPEEYKFNTNINGVSTDNGGLYIEPRGTFYTYERTPQQSIFSLEELFRHEYTHYLQARYLVDGLWGQGPFYEKNRLTWFDEGTAEFFAGSTRTSGVLPRKSILGYLAKDKVDHRYSLKKTLNSGYDDSDWMFYNYGFAVAHYLYEKDMPTFIKMNKAILNTDVKSYDEIIKKLSDDANKNTEYQNHIQELADKYQGAGIPLVSDDYLKDHGYKKASEVYSEISKAASLTNTSVTAEKSQYFNTFTLRGTYTGETSKGEFKDWDEMSKKLDGTLESLAKNSWSGYKTLTAYFTNYRVTSDNKVQYDVVFHGVLTDNADISNNKAPIAKVTGPSTGAVGRNIEFSGKDSKDEDGKIVSYDWDFGDGATSRGKNSVHAYKKAGTYNVTLKVTDDKGATATESFTIEIKNEDTTTPITKEMEPNDDIKEANGPIVEGVTVKGDLNGSDDADTFYFDVKEDGDVTIELPYSGSSNFTWLVYKEGDDQNHIASGIDKNNSKVGTFKSTKGRHYVFIYKHDSASNISYSLNIKGLGNEKLKEKENNDSSDKATVIPNFNTTMQGSLLGDDSRDYYSFEVKEEGEVNIELDKKDEFGVTWTLHPESNINDRITYGQVDGNKVSNKVKLRPGKYYLLVYKYSGSGNYELRVNK

T80165	TARGETID	T80165
T80165	FORMERID	TTDR00988
T80165	UNIPROID	TRPC6_HUMAN
T80165	TARGNAME	Short transient receptor potential channel 6 (TRPC6)
T80165	GENENAME	TRPC6
T80165	TARGTYPE	Literature-reported
T80165	SYNONYMS	TRPC6; TRP6; STrpC6
T80165	FUNCTION	Thought to form a receptor-activated non-selective calcium permeant cation channel. Probably is operated by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases or G-protein coupled receptors. Activated by diacylglycerol (DAG) in a membrane-delimited fashion, independently of protein kinase C. Seems not to be activated by intracellular calcium store depletion.
T80165	PDBSTRUC	5YX9
T80165	BIOCLASS	Transient receptor potential catioin channel
T80165	SEQUENCE	MSQSPAFGPRRGSSPRGAAGAAARRNESQDYLLMDSELGEDGCPQAPLPCYGYYPCFRGSDNRLAHRRQTVLREKGRRLANRGPAYMFSDRSTSLSIEEERFLDAAEYGNIPVVRKMLEECHSLNVNCVDYMGQNALQLAVANEHLEITELLLKKENLSRVGDALLLAISKGYVRIVEAILSHPAFAEGKRLATSPSQSELQQDDFYAYDEDGTRFSHDVTPIILAAHCQEYEIVHTLLRKGARIERPHDYFCKCNDCNQKQKHDSFSHSRSRINAYKGLASPAYLSLSSEDPVMTALELSNELAVLANIEKEFKNDYKKLSMQCKDFVVGLLDLCRNTEEVEAILNGDVETLQSGDHGRPNLSRLKLAIKYEVKKFVAHPNCQQQLLSIWYENLSGLRQQTMAVKFLVVLAVAIGLPFLALIYWFAPCSKMGKIMRGPFMKFVAHAASFTIFLGLLVMNAADRFEGTKLLPNETSTDNAKQLFRMKTSCFSWMEMLIISWVIGMIWAECKEIWTQGPKEYLFELWNMLDFGMLAIFAASFIARFMAFWHASKAQSIIDANDTLKDLTKVTLGDNVKYYNLARIKWDPSDPQIISEGLYAIAVVLSFSRIAYILPANESFGPLQISLGRTVKDIFKFMVIFIMVFVAFMIGMFNLYSYYIGAKQNEAFTTVEESFKTLFWAIFGLSEVKSVVINYNHKFIENIGYVLYGVYNVTMVIVLLNMLIAMINSSFQEIEDDADVEWKFARAKLWFSYFEEGRTLPVPFNLVPSPKSLFYLLLKLKKWISELFQGHKKGFQEDAEMNKINEEKKLGILGSHEDLSKLSLDKKQVGHNKQPSIRSSEDFHLNSFNNPPRQYQKIMKRLIKRYVLQAQIDKESDEVNEGELKEIKQDISSLRYELLEEKSQNTEDLAELIRELGEKLSMEPNQEETNR
T80165	DRUGINFO	D01SLS	ML9	Investigative
T80165	DRUGINFO	D02DPK	hyp 9	Investigative
T80165	DRUGINFO	D03LLM	SLG	Investigative
T80165	DRUGINFO	D07UFO	20-HETE	Investigative
T80165	DRUGINFO	D0TV1R	flufenamate	Investigative
T80165	DRUGINFO	D0Y6ST	SAG	Investigative
T80165	DRUGINFO	D0F4FK	KB-R7943	Investigative
T80165	DRUGINFO	D0KT5E	lysophosphatidylcholine	Investigative
T80165	DRUGINFO	D0N7MS	ACAA	Investigative
T80165	DRUGINFO	D0T6DU	OAG	Investigative
T80165	DRUGINFO	D00HCI	2-APB	Investigative

T37417	TARGETID	T37417
T37417	FORMERID	TTDI03540
T37417	UNIPROID	ST38L_HUMAN
T37417	TARGNAME	NDR2 protein kinase (STK38L)
T37417	GENENAME	STK38L
T37417	TARGTYPE	Literature-reported
T37417	SYNONYMS	Serine/threonine-protein kinase 38-like; Nuclear Dbf2-related kinase 2; NDR2; KIAA0965
T37417	FUNCTION	Involved in the regulation of structural processes in differentiating and mature neuronal cells.
T37417	PDBSTRUC	5XQZ
T37417	BIOCLASS	Kinase
T37417	ECNUMBER	EC 2.7.11.1
T37417	SEQUENCE	MAMTAGTTTTFPMSNHTRERVTVAKLTLENFYSNLILQHEERETRQKKLEVAMEEEGLADEEKKLRRSQHARKETEFLRLKRTRLGLDDFESLKVIGRGAFGEVRLVQKKDTGHIYAMKILRKSDMLEKEQVAHIRAERDILVEADGAWVVKMFYSFQDKRNLYLIMEFLPGGDMMTLLMKKDTLTEEETQFYISETVLAIDAIHQLGFIHRDIKPDNLLLDAKGHVKLSDFGLCTGLKKAHRTEFYRNLTHNPPSDFSFQNMNSKRKAETWKKNRRQLAYSTVGTPDYIAPEVFMQTGYNKLCDWWSLGVIMYEMLIGYPPFCSETPQETYRKVMNWKETLVFPPEVPISEKAKDLILRFCIDSENRIGNSGVEEIKGHPFFEGVDWEHIRERPAAIPIEIKSIDDTSNFDDFPESDILQPVPNTTEPDYKSKDWVFLNYTYKRFEGLTQRGSIPTYMKAGKL
T37417	DRUGINFO	D0RO9R	PMID21123062C27	Investigative

T70036	TARGETID	T70036
T70036	FORMERID	TTDR01065
T70036	UNIPROID	NALD2_HUMAN
T70036	TARGNAME	Glutamate carboxypeptidase III (NAALAD2)
T70036	GENENAME	NAALAD2
T70036	TARGTYPE	Literature-reported
T70036	SYNONYMS	NAALADase II; NAALAD2
T70036	FUNCTION	Has N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. Also exhibits a dipeptidyl-peptidase IV type activity. Inactivate the peptide neurotransmitter N- acetylaspartylglutamate.
T70036	PDBSTRUC	3FF3; 3FEE; 3FED; 3FEC
T70036	BIOCLASS	Peptidase
T70036	ECNUMBER	EC 3.4.17.21
T70036	SEQUENCE	MAESRGRLYLWMCLAAALASFLMGFMVGWFIKPLKETTTSVRYHQSIRWKLVSEMKAENIKSFLRSFTKLPHLAGTEQNFLLAKKIQTQWKKFGLDSAKLVHYDVLLSYPNETNANYISIVDEHETEIFKTSYLEPPPDGYENVTNIVPPYNAFSAQGMPEGDLVYVNYARTEDFFKLEREMGINCTGKIVIARYGKIFRGNKVKNAMLAGAIGIILYSDPADYFAPEVQPYPKGWNLPGTAAQRGNVLNLNGAGDPLTPGYPAKEYTFRLDVEEGVGIPRIPVHPIGYNDAEILLRYLGGIAPPDKSWKGALNVSYSIGPGFTGSDSFRKVRMHVYNINKITRIYNVVGTIRGSVEPDRYVILGGHRDSWVFGAIDPTSGVAVLQEIARSFGKLMSKGWRPRRTIIFASWDAEEFGLLGSTEWAEENVKILQERSIAYINSDSSIEGNYTLRVDCTPLLYQLVYKLTKEIPSPDDGFESKSLYESWLEKDPSPENKNLPRINKLGSGSDFEAYFQRLGIASGRARYTKNKKTDKYSSYPVYHTIYETFELVEKFYDPTFKKQLSVAQLRGALVYELVDSKIIPFNIQDYAEALKNYAASIYNLSKKHDQQLTDHGVSFDSLFSAVKNFSEAASDFHKRLIQVDLNNPIAVRMMNDQLMLLERAFIDPLGLPGKLFYRHIIFAPSSHNKYAGESFPGIYDAIFDIENKANSRLAWKEVKKHISIAAFTIQAAAGTLKEVL

T15051	TARGETID	T15051
T15051	FORMERID	TTDI00232
T15051	UNIPROID	TRAF6_HUMAN
T15051	TARGNAME	TNF receptor-associated factor 6 (TRAF6)
T15051	GENENAME	TRAF6
T15051	TARGTYPE	Literature-reported
T15051	SYNONYMS	RNF85; RING-type E3 ubiquitin transferase TRAF6; RING finger protein 85; Interleukin-1 signal transducer; E3 ubiquitin-protein ligase TRAF6
T15051	FUNCTION	Mediates ubiquitination of free/unanchored polyubiquitin chain that leads to MAP3K7 activation. Leads to the activation of NF-kappa-B and JUN. May be essential for the formation of functional osteoclasts. Seems to also play a role in dendritic cells (DCs) maturation and/or activation. Represses c-Myb-mediated transactivation, in B-lymphocytes. Adapter protein that seems to play a role in signal transduction initiated via TNF receptor, IL-1 receptor and IL-17 receptor. Regulates osteoclast differentiation by mediating the activation of adapter protein complex 1 (AP-1) and NF-kappa-B, in response to RANK-L stimulation. Together with MAP3K8, mediates CD40 signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production. E3 ubiquitin ligase that, together with UBE2N and UBE2V1, mediates the synthesis of 'Lys-63'-linked-polyubiquitin chains conjugated to proteins, such as IKBKG, IRAK1, AKT1 and AKT2.
T15051	PDBSTRUC	6A33; 5ZUJ; 4Z8M; 3HCU; 3HCT
T15051	BIOCLASS	Acyltransferase
T15051	ECNUMBER	EC 2.3.2.27
T15051	SEQUENCE	MSLLNCENSCGSSQSESDCCVAMASSCSAVTKDDSVGGTASTGNLSSSFMEEIQGYDVEFDPPLESKYECPICLMALREAVQTPCGHRFCKACIIKSIRDAGHKCPVDNEILLENQLFPDNFAKREILSLMVKCPNEGCLHKMELRHLEDHQAHCEFALMDCPQCQRPFQKFHINIHILKDCPRRQVSCDNCAASMAFEDKEIHDQNCPLANVICEYCNTILIREQMPNHYDLDCPTAPIPCTFSTFGCHEKMQRNHLARHLQENTQSHMRMLAQAVHSLSVIPDSGYISEVRNFQETIHQLEGRLVRQDHQIRELTAKMETQSMYVSELKRTIRTLEDKVAEIEAQQCNGIYIWKIGNFGMHLKCQEEEKPVVIHSPGFYTGKPGYKLCMRLHLQLPTAQRCANYISLFVHTMQGEYDSHLPWPFQGTIRLTILDQSEAPVRQNHEEIMDAKPELLAFQRPTIPRNPKGFGYVTFMHLEALRQRTFIKDDTLLVRCEVSTRFDMGSLRREGFQPRSTDAGV

T66935	TARGETID	T66935
T66935	FORMERID	TTDR00894
T66935	UNIPROID	PARG_HUMAN
T66935	TARGNAME	Poly [ADP-ribose] glycohydrolase (PARG)
T66935	GENENAME	PARG
T66935	TARGTYPE	Literature-reported
T66935	SYNONYMS	Poly(ADP-ribose) glycohydrolase
T66935	FUNCTION	Poly(ADP-ribose) glycohydrolase that degrades poly(ADP-ribose) by hydrolyzing the ribose-ribose bonds present in poly(ADP-ribose). PARG acts both as an endo- and exoglycosidase, releasing poly(ADP-ribose) of different length as well as ADP-ribose monomers. It is however unable to cleave the ester bond between the terminal ADP-ribose and ADP-ribosylated residues, leaving proteins that are mono-ADP-ribosylated. Poly(ADP-ribose) is synthesized after DNA damage is only present transiently and is rapidly degraded by PARG. Required to prevent detrimental accumulation of poly(ADP-ribose) upon prolonged replicative stress, while it is not required for recovery from transient replicative stress. Required for retinoid acid-dependent gene transactivation, probably by removing poly(ADP-ribose) from histone demethylase KDM4D, allowing chromatin derepression at RAR-dependent gene promoters. Involved in the synthesis of ATP in the nucleus, together with PARP1, NMNAT1 and NUDT5. Nuclear ATP generation is required for extensive chromatin remodeling events that are energy-consuming.
T66935	PDBSTRUC	6HMN; 6HMM; 6HML; 6HMK; 6HH6
T66935	BIOCLASS	Glycosylase
T66935	ECNUMBER	EC 3.2.1.143
T66935	SEQUENCE	MNAGPGCEPCTKRPRWGAATTSPAASDARSFPSRQRRVLDPKDAHVQFRVPPSSPACVPGRAGQHRGSATSLVFKQKTITSWMDTKGIKTAESESLDSKENNNTRIESMMSSVQKDNFYQHNVEKLENVSQLSLDKSPTEKSTQYLNQHQTAAMCKWQNEGKHTEQLLESEPQTVTLVPEQFSNANIDRSPQNDDHSDTDSEENRDNQQFLTTVKLANAKQTTEDEQAREAKSHQKCSKSCDPGEDCASCQQDEIDVVPESPLSDVGSEDVGTGPKNDNKLTRQESCLGNSPPFEKESEPESPMDVDNSKNSCQDSEADEETSPGFDEQEDGSSSQTANKPSRFQARDADIEFRKRYSTKGGEVRLHFQFEGGESRTGMNDLNAKLPGNISSLNVECRNSKQHGKKDSKITDHFMRLPKAEDRRKEQWETKHQRTERKIPKYVPPHLSPDKKWLGTPIEEMRRMPRCGIRLPLLRPSANHTVTIRVDLLRAGEVPKPFPTHYKDLWDNKHVKMPCSEQNLYPVEDENGERTAGSRWELIQTALLNKFTRPQNLKDAILKYNVAYSKKWDFTALIDFWDKVLEEAEAQHLYQSILPDMVKIALCLPNICTQPIPLLKQKMNHSITMSQEQIASLLANAFFCTFPRRNAKMKSEYSSYPDINFNRLFEGRSSRKPEKLKTLFCYFRRVTEKKPTGLVTFTRQSLEDFPEWERCEKPLTRLHVTYEGTIEENGQGMLQVDFANRFVGGGVTSAGLVQEEIRFLINPELIISRLFTEVLDHNECLIITGTEQYSEYTGYAETYRWSRSHEDGSERDDWQRRCTEIVAIDALHFRRYLDQFVPEKMRRELNKAYCGFLRPGVSSENLSAVATGNWGCGAFGGDARLKALIQILAAAAAERDVVYFTFGDSELMRDIYSMHIFLTERKLTVGDVYKLLLRYYNEECRNCSTPGPDIKLYPFIYHAVESCAETADHSGQRTGT
T66935	DRUGINFO	D09XJJ	N-bis-(3-phenyl-propyl)9-oxo-fluorene-2,7-diamide	Investigative
T66935	DRUGINFO	D0YM5S	GPI 18214	Investigative

T87981	TARGETID	T87981
T87981	FORMERID	TTDI03278
T87981	UNIPROID	IRAK3_HUMAN
T87981	TARGNAME	IL-1 receptor-associated kinase 3 (IRAK3)
T87981	GENENAME	IRAK3
T87981	TARGTYPE	Literature-reported
T87981	SYNONYMS	Interleukin-1 receptor-associated kinase 3; IRAK-M; IRAK-3; IL-1 receptor-associated kinase M
T87981	FUNCTION	Inhibits dissociation of IRAK1 and IRAK4 from the Toll-like receptor signaling complex by either inhibiting the phosphorylation of IRAK1 and IRAK4 or stabilizing the receptor complex.
T87981	PDBSTRUC	5UKE
T87981	BIOCLASS	Kinase
T87981	ECNUMBER	EC 2.7.11.1
T87981	SEQUENCE	MAGNCGARGALSAHTLLFDLPPALLGELCAVLDSCDGALGWRGLAERLSSSWLDVRHIEKYVDQGKSGTRELLWSWAQKNKTIGDLLQVLQEMGHRRAIHLITNYGAVLSPSEKSYQEGGFPNILFKETANVTVDNVLIPEHNEKGILLKSSISFQNIIEGTRNFHKDFLIGEGEIFEVYRVEIQNLTYAVKLFKQEKKMQCKKHWKRFLSELEVLLLFHHPNILELAAYFTETEKFCLIYPYMRNGTLFDRLQCVGDTAPLPWHIRIGILIGISKAIHYLHNVQPCSVICGSISSANILLDDQFQPKLTDFAMAHFRSHLEHQSCTINMTSSSSKHLWYMPEEYIRQGKLSIKTDVYSFGIVIMEVLTGCRVVLDDPKHIQLRDLLRELMEKRGLDSCLSFLDKKVPPCPRNFSAKLFCLAGRCAATRAKLRPSMDEVLNTLESTQASLYFAEDPPTSLKSFRCPSPLFLENVPSIPVEDDESQNNNLLPSDEGLRIDRMTQKTPFECSQSEVMFLSLDKKPESKRNEEACNMPSSSCEESWFPKYIVPSQDLRPYKVNIDPSSEAPGHSCRSRPVESSCSSKFSWDEYEQYKKE
T87981	DRUGINFO	D00EMH	PMID21967808CR-16	Investigative

T17339	TARGETID	T17339
T17339	FORMERID	TTDNR00662
T17339	UNIPROID	DUS10_HUMAN
T17339	TARGNAME	Dual specificity protein phosphatase 10 (DUSP10)
T17339	GENENAME	DUSP10
T17339	TARGTYPE	Literature-reported
T17339	SYNONYMS	Mitogen-activated protein kinase phosphatase 5; MKP5; MKP-5; MAP kinase phosphatase 5
T17339	FUNCTION	Has a specificity for the MAPK11/MAPK12/MAPK13/MAPK14 subfamily. It preferably dephosphorylates p38. Protein phosphatase involved in the inactivation of MAP kinases.
T17339	PDBSTRUC	3TG1; 2OUD; 2OUC; 1ZZW
T17339	BIOCLASS	Phosphoric monoester hydrolase
T17339	ECNUMBER	EC 3.1.3.16
T17339	SEQUENCE	MPPSPLDDRVVVALSRPVRPQDLNLCLDSSYLGSANPGSNSHPPVIATTVVSLKAANLTYMPSSSGSARSLNCGCSSASCCTVATYDKDNQAQTQAIAAGTTTTAIGTSTTCPANQMVNNNENTGSLSPSSGVGSPVSGTPKQLASIKIIYPNDLAKKMTKCSKSHLPSQGPVIIDCRPFMEYNKSHIQGAVHINCADKISRRRLQQGKITVLDLISCREGKDSFKRIFSKEIIVYDENTNEPSRVMPSQPLHIVLESLKREGKEPLVLKGGLSSFKQNHENLCDNSLQLQECREVGGGASAASSLLPQPIPTTPDIENAELTPILPFLFLGNEQDAQDLDTMQRLNIGYVINVTTHLPLYHYEKGLFNYKRLPATDSNKQNLRQYFEEAFEFIEEAHQCGKGLLIHCQAGVSRSATIVIAYLMKHTRMTMTDAYKFVKGKRPIISPNLNFMGQLLEFEEDLNNGVTPRILTPKLMGVETVV

T60688	TARGETID	T60688
T60688	FORMERID	TTDC00285
T60688	UNIPROID	BIRC5_HUMAN
T60688	TARGNAME	Survivin messenger RNA (Survivin mRNA)
T60688	GENENAME	BIRC5
T60688	TARGTYPE	Literature-reported
T60688	SYNONYMS	Survivin (mRNA); IAP4 (mRNA); Baculoviral IAP repeat-containing protein 5 (mRNA); Apoptosis inhibitor survivin (mRNA); Apoptosis inhibitor 4 (mRNA); API4 (mRNA)
T60688	FUNCTION	Component of a chromosome passage protein complex (CPC) which is essential for chromosome alignment and segregation during mitosis and cytokinesis. Acts as an important regulator of the localization of this complex; directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organization of the center spindle by associating with polymerized microtubules. Involved in the recruitment of CPC to centromeres during early mitosis via association with histone H3 phosphorylated at 'Thr-3' (H3pT3) during mitosis. The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules. May counteract a default induction of apoptosis in G2/M phase. The acetylated form represses STAT3 transactivation of target gene promoters. May play a role in neoplasia. Inhibitor of CASP3 and CASP7. Isoform 2 and isoform 3 do not appear to play vital roles in mitosis. Isoform 3 shows a marked reduction in its anti-apoptotic effects when compared with the displayed wild-type isoform. Multitasking protein that has dual roles in promoting cell proliferation and preventing apoptosis.
T60688	PDBSTRUC	4A0N; 4A0J; 4A0I; 3UIK; 3UIJ
T60688	BIOCLASS	mRNA target
T60688	SEQUENCE	MGAPTLPPAWQPFLKDHRISTFKNWPFLEGCACTPERMAEAGFIHCPTENEPDLAQCFFCFKELEGWEPDDDPIEEHKKHSSGCAFLSVKKQFEELTLGEFLKLDRERAKNKIAKETNNKKKEFEETAKKVRRAIEQLAAMD
T60688	DRUGINFO	D05FGY	ISIS 343867	Investigative
T60688	DRUGINFO	D09KDC	ISIS 341881	Investigative
T60688	DRUGINFO	D0F9EM	ISIS 23707	Investigative
T60688	DRUGINFO	D0M3BA	ISIS 23718	Investigative
T60688	DRUGINFO	D0U8JD	ISIS 23705	Investigative

T77174	TARGETID	T77174
T77174	FORMERID	TTDI02623
T77174	UNIPROID	MCES_HUMAN
T77174	TARGNAME	mRNA cap guanine-N7 methyltransferase (RNMT)
T77174	GENENAME	RNMT
T77174	TARGTYPE	Literature-reported
T77174	SYNONYMS	hcm1p; hMet; hCMT1; RG7MT1; KIAA0398
T77174	FUNCTION	Binds RNA containing 5'-terminal GpppC. Catalytic subunit of the mRNA-capping methyltransferase RNMT:RAMAC complex that methylates the N7 position of the added guanosine to the 5'-cap structure of mRNAs.
T77174	PDBSTRUC	5E9W; 5E9J; 5E8J; 3EPP; 3BGV
T77174	BIOCLASS	Methyltransferase
T77174	ECNUMBER	EC 2.1.1.56
T77174	SEQUENCE	MANSAKAEEYEKMSLEQAKASVNSETESSFNINENTTASGTGLSEKTSVCRQVDIARKRKEFEDDLVKESSSCGKDTPSKKRKLDPEIVPEEKDCGDAEGNSKKRKRETEDVPKDKSSTGDGTQNKRKIALEDVPEKQKNLEEGHSSTVAAHYNELQEVGLEKRSQSRIFYLRNFNNWMKSVLIGEFLEKVRQKKKRDITVLDLGCGKGGDLLKWKKGRINKLVCTDIADVSVKQCQQRYEDMKNRRDSEYIFSAEFITADSSKELLIDKFRDPQMCFDICSCQFVCHYSFESYEQADMMLRNACERLSPGGYFIGTTPNSFELIRRLEASETESFGNEIYTVKFQKKGDYPLFGCKYDFNLEGVVDVPEFLVYFPLLNEMAKKYNMKLVYKKTFLEFYEEKIKNNENKMLLKRMQALEPYPANESSKLVSEKVDDYEHAAKYMKNSQVRLPLGTLSKSEWEATSIYLVFAFEKQQ

T35474	TARGETID	T35474
T35474	FORMERID	TTDI02684
T35474	UNIPROID	RASK_HUMAN
T35474	TARGNAME	KRAS messenger RNA (KRAS mRNA)
T35474	GENENAME	KRAS
T35474	TARGTYPE	Literature-reported
T35474	SYNONYMS	c-Ki-ras (mRNA); c-K-ras (mRNA); RASK2 (mRNA); Ki-Ras (mRNA); KRAS2 (mRNA); K-Ras 2 (mRNA); GTPase KRas (mRNA)
T35474	FUNCTION	Plays an important role in the regulation of cell proliferation. Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner. Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.
T35474	PDBSTRUC	6N2K; 6N2J; 6H47; 6H46; 6GQY
T35474	BIOCLASS	mRNA target
T35474	SEQUENCE	MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM
T35474	DRUGINFO	D04GPF	ISIS 6958	Investigative
T35474	DRUGINFO	D09ENF	PNT-300	Investigative
T35474	DRUGINFO	D0A4MW	ISIS 7453	Investigative
T35474	DRUGINFO	D0O2LY	ISIS 6957	Investigative

T33529	TARGETID	T33529
T33529	FORMERID	TTDI02678
T33529	UNIPROID	TGFB1_HUMAN
T33529	TARGNAME	TGFB1 messenger RNA (TGFB1 mRNA)
T33529	GENENAME	TGFB1
T33529	TARGTYPE	Literature-reported
T33529	SYNONYMS	Transforming growth factor beta-1 proprotein (mRNA); Transforming growth factor beta-1 (mRNA); TGFB (mRNA); TGF-beta1 (mRNA); TGF-beta 1 (mRNA)
T33529	FUNCTION	Transforming growth factor beta-1 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-1 (TGF-beta-1) chains, which constitute the regulatory and active subunit of TGF-beta-1, respectively.
T33529	PDBSTRUC	5VQP; 5FFO; 4KV5; 3KFD; 1KLD
T33529	BIOCLASS	mRNA target
T33529	SEQUENCE	MPPSGLRLLLLLLPLLWLLVLTPGRPAAGLSTCKTIDMELVKRKRIEAIRGQILSKLRLASPPSQGEVPPGPLPEAVLALYNSTRDRVAGESAEPEPEPEADYYAKEVTRVLMVETHNEIYDKFKQSTHSIYMFFNTSELREAVPEPVLLSRAELRLLRLKLKVEQHVELYQKYSNNSWRYLSNRLLAPSDSPEWLSFDVTGVVRQWLSRGGEIEGFRLSAHCSCDSRDNTLQVDINGFTTGRRGDLATIHGMNRPFLLLMATPLERAQHLQSSRHRRALDTNYCFSSTEKNCCVRQLYIDFRKDLGWKWIHEPKGYHANFCLGPCPYIWSLDTQYSKVLALYNQHNPGASAAPCCVPQALEPLPIVYYVGRKPKVEQLSNMIVRSCKCS

T90163	TARGETID	T90163
T90163	FORMERID	TTDR01357
T90163	UNIPROID	APOA1_HUMAN
T90163	TARGNAME	APOA1 messenger RNA (APOA1 mRNA)
T90163	GENENAME	APOA1
T90163	TARGTYPE	Literature-reported
T90163	SYNONYMS	Truncated apolipoprotein AI (mRNA); Apolipoprotein A1 (mRNA); Apolipoprotein A-I (mRNA); ApoAI (mRNA); ApoA-I (mRNA); Apo-AI (mRNA)
T90163	FUNCTION	As part of the SPAP complex, activates spermatozoa motility. Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT).
T90163	PDBSTRUC	6CM1; 6CLZ; 6CCX; 6CCH; 6CC9
T90163	BIOCLASS	mRNA target
T90163	SEQUENCE	MKAAVLTLAVLFLTGSQARHFWQQDEPPQSPWDRVKDLATVYVDVLKDSGRDYVSQFEGSALGKQLNLKLLDNWDSVTSTFSKLREQLGPVTQEFWDNLEKETEGLRQEMSKDLEEVKAKVQPYLDDFQKKWQEEMELYRQKVEPLRAELQEGARQKLHELQEKLSPLGEEMRDRARAHVDALRTHLAPYSDELRQRLAARLEALKENGGARLAEYHAKATEHLSTLSEKAKPALEDLRQGLLPVLESFKVSFLSALEEYTKKLNTQ
T90163	DRUGINFO	D09HDQ	ISIS 144379	Investigative
T90163	DRUGINFO	D0I2VG	ISIS 144396	Investigative
T90163	DRUGINFO	D0T5JP	ISIS 144368	Investigative

T73245	TARGETID	T73245
T73245	FORMERID	TTDI02248
T73245	UNIPROID	TRFE_HUMAN
T73245	TARGNAME	Transferrin messenger RNA (TF mRNA)
T73245	GENENAME	TF
T73245	TARGTYPE	Literature-reported
T73245	SYNONYMS	Transferrin (mRNA); Siderophilin (mRNA); Serotransferrin (mRNA); PRO1400 (mRNA); Beta-1 metal-binding globulin (mRNA)
T73245	FUNCTION	It is responsible for the transport of iron from sites of absorption and heme degradation to those of storage and utilization. Serum transferrin may also have a further role in stimulating cell proliferation. Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate.
T73245	PDBSTRUC	6D05; 6D04; 6D03; 6CTC; 5Y6K
T73245	BIOCLASS	mRNA target
T73245	SEQUENCE	MRLAVGALLVCAVLGLCLAVPDKTVRWCAVSEHEATKCQSFRDHMKSVIPSDGPSVACVKKASYLDCIRAIAANEADAVTLDAGLVYDAYLAPNNLKPVVAEFYGSKEDPQTFYYAVAVVKKDSGFQMNQLRGKKSCHTGLGRSAGWNIPIGLLYCDLPEPRKPLEKAVANFFSGSCAPCADGTDFPQLCQLCPGCGCSTLNQYFGYSGAFKCLKDGAGDVAFVKHSTIFENLANKADRDQYELLCLDNTRKPVDEYKDCHLAQVPSHTVVARSMGGKEDLIWELLNQAQEHFGKDKSKEFQLFSSPHGKDLLFKDSAHGFLKVPPRMDAKMYLGYEYVTAIRNLREGTCPEAPTDECKPVKWCALSHHERLKCDEWSVNSVGKIECVSAETTEDCIAKIMNGEADAMSLDGGFVYIAGKCGLVPVLAENYNKSDNCEDTPEAGYFAIAVVKKSASDLTWDNLKGKKSCHTAVGRTAGWNIPMGLLYNKINHCRFDEFFSEGCAPGSKKDSSLCKLCMGSGLNLCEPNNKEGYYGYTGAFRCLVEKGDVAFVKHQTVPQNTGGKNPDPWAKNLNEKDYELLCLDGTRKPVEEYANCHLARAPNHAVVTRKDKEACVHKILRQQQHLFGSNVTDCSGNFCLFRSETKDLLFRDDTVCLAKLHDRNTYEKYLGEEYVKAVGNLRKCSTSSLLEACTFRRP

T77927	TARGETID	T77927
T77927	FORMERID	TTDI02386
T77927	UNIPROID	GAG_HV1H2
T77927	TARGNAME	Human immunodeficiency virus GAG messenger RNA (HIV gag mRNA)
T77927	GENENAME	HIV gag mRNA
T77927	TARGTYPE	Literature-reported
T77927	SYNONYMS	gag (mRNA); Pr55Gag (mRNA); Gag polyprotein (mRNA)
T77927	FUNCTION	Gag polyprotein: Mediates, with Gag-Pol polyprotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi).
T77927	PDBSTRUC	6CQR; 6CQQ; 6CQN; 6CQL; 6CQJ
T77927	BIOCLASS	mRNA target
T77927	SEQUENCE	MGARASVLSGGELDRWEKIRLRPGGKKKYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQTGSEELRSLYNTVATLYCVHQRIEIKDTKEALDKIEEEQNKSKKKAQQAAADTGHSNQVSQNYPIVQNIQGQMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAAEWDRVHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKARVLAEAMSQVTNSATIMMQRGNFRNQRKIVKCFNCGKEGHTARNCRAPRKKGCWKCGKEGHQMKDCTERQANFLGKIWPSYKGRPGNFLQSRPEPTAPPEESFRSGVETTTPPQKQEPIDKELYPLTSLRSLFGNDPSSQ

T33913	TARGETID	T33913
T33913	FORMERID	TTDR01162
T33913	UNIPROID	PGFRB_HUMAN
T33913	TARGNAME	PDGFR beta messenger RNA (PDGFRB mRNA)
T33913	GENENAME	PDGFRB
T33913	TARGTYPE	Literature-reported
T33913	SYNONYMS	Platelet-derived growth factor receptor 1 (mRNA); PDGFR1 (mRNA); PDGFR-beta (mRNA); PDGFR-1 (mRNA); PDGFR (mRNA); PDGF-R-beta (mRNA); CD140b antigen (mRNA); CD140b (mRNA); CD140 antigen-like family member B (mRNA); Beta-type platelet-derived growth factor receptor (mRNA); Beta-PDGFR (mRNA); Beta platelet-derived growth factor receptor (mRNA)
T33913	FUNCTION	Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of pericytes and smooth muscle cells to endothelial cells. Plays a role in the migration of vascular smooth muscle cells and the formation of neointima at vascular injury sites. Required for normal development of the cardiovascular system. Required for normal recruitment of pericytes (mesangial cells) in the kidney glomerulus, and for normal formation of a branched network of capillaries in kidney glomeruli. Promotes rearrangement of the actin cytoskeleton and the formation of membrane ruffles. Binding of its cognate ligands - homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFD -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PLCG1, PIK3R1, PTPN11, RASA1/GAP, CBL, SHC1 and NCK1. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leads to the activation of the AKT1 signaling pathway. Phosphorylation of SHC1, or of the C-terminus of PTPN11, creates a binding site for GRB2, resulting in the activation of HRAS, RAF1 and down-stream MAP kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation and activation of SRC family kinases. Promotes phosphorylation of PDCD6IP/ALIX and STAM. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor. Tyrosine-protein kinase that acts as cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration.
T33913	PDBSTRUC	3MJG; 2PLE; 2PLD; 2L6W; 2IUI
T33913	BIOCLASS	mRNA target
T33913	ECNUMBER	EC 2.7.10.1
T33913	SEQUENCE	MRLPGAMPALALKGELLLLSLLLLLEPQISQGLVVTPPGPELVLNVSSTFVLTCSGSAPVVWERMSQEPPQEMAKAQDGTFSSVLTLTNLTGLDTGEYFCTHNDSRGLETDERKRLYIFVPDPTVGFLPNDAEELFIFLTEITEITIPCRVTDPQLVVTLHEKKGDVALPVPYDHQRGFSGIFEDRSYICKTTIGDREVDSDAYYVYRLQVSSINVSVNAVQTVVRQGENITLMCIVIGNEVVNFEWTYPRKESGRLVEPVTDFLLDMPYHIRSILHIPSAELEDSGTYTCNVTESVNDHQDEKAINITVVESGYVRLLGEVGTLQFAELHRSRTLQVVFEAYPPPTVLWFKDNRTLGDSSAGEIALSTRNVSETRYVSELTLVRVKVAEAGHYTMRAFHEDAEVQLSFQLQINVPVRVLELSESHPDSGEQTVRCRGRGMPQPNIIWSACRDLKRCPRELPPTLLGNSSEEESQLETNVTYWEEEQEFEVVSTLRLQHVDRPLSVRCTLRNAVGQDTQEVIVVPHSLPFKVVVISAILALVVLTIISLIILIMLWQKKPRYEIRWKVIESVSSDGHEYIYVDPMQLPYDSTWELPRDQLVLGRTLGSGAFGQVVEATAHGLSHSQATMKVAVKMLKSTARSSEKQALMSELKIMSHLGPHLNVVNLLGACTKGGPIYIITEYCRYGDLVDYLHRNKHTFLQHHSDKRRPPSAELYSNALPVGLPLPSHVSLTGESDGGYMDMSKDESVDYVPMLDMKGDVKYADIESSNYMAPYDNYVPSAPERTCRATLINESPVLSYMDLVGFSYQVANGMEFLASKNCVHRDLAARNVLICEGKLVKICDFGLARDIMRDSNYISKGSTFLPLKWMAPESIFNSLYTTLSDVWSFGILLWEIFTLGGTPYPELPMNEQFYNAIKRGYRMAQPAHASDEIYEIMQKCWEEKFEIRPPFSQLVLLLERLLGEGYKKKYQQVDEEFLRSDHPAILRSQARLPGFHGLRSPLDTSSVLYTAVQPNEGDNDYIIPLPDPKPEVADEGPLEGSPSLASSTLNEVNTSSTISCDSPLEPQDEPEPEPQLELQVEPEPELEQLPDSGCPAPRAEAEDSFL

T12052	TARGETID	T12052
T12052	FORMERID	TTDR01368
T12052	UNIPROID	ROA1_HUMAN
T12052	TARGNAME	hnRNP A1 messenger RNA (HNRNPA1 mRNA)
T12052	GENENAME	HNRNPA1
T12052	TARGTYPE	Literature-reported
T12052	SYNONYMS	hnRNP core protein A1 (mRNA); hnRNP A1 (mRNA); Single-strand RNA-binding protein (mRNA); Heterogeneous nuclear ribonucleoprotein A1 (mRNA); Helix-destabilizing protein (mRNA); HNRPA1 (mRNA)
T12052	FUNCTION	May bind to specific miRNA hairpins. Involved in the packaging of pre-mRNA into hnRNP particles, transport of poly(A) mRNA from the nucleus to the cytoplasm and may modulate splice site selection.
T12052	PDBSTRUC	6DCL; 6BXX; 5ZGL; 5MPL; 5MPG
T12052	BIOCLASS	mRNA target
T12052	SEQUENCE	MSKSESPKEPEQLRKLFIGGLSFETTDESLRSHFEQWGTLTDCVVMRDPNTKRSRGFGFVTYATVEEVDAAMNARPHKVDGRVVEPKRAVSREDSQRPGAHLTVKKIFVGGIKEDTEEHHLRDYFEQYGKIEVIEIMTDRGSGKKRGFAFVTFDDHDSVDKIVIQKYHTVNGHNCEVRKALSKQEMASASSSQRGRSGSGNFGGGRGGGFGGNDNFGRGGNFSGRGGFGGSRGGGGYGGSGDGYNGFGNDGGYGGGGPGYSGGSRGYGSGGQGYGNQGSGYGGSGSYDSYNNGGGGGFGGGSGSNFGGGGSYNDFGNYNNQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGYGGSSSSSSYGSGRRF
T12052	DRUGINFO	D00LSM	ISIS 112000	Investigative
T12052	DRUGINFO	D00SQD	ISIS 112022	Investigative
T12052	DRUGINFO	D04XOE	ISIS 112019	Investigative
T12052	DRUGINFO	D06QZK	ISIS 112005	Investigative
T12052	DRUGINFO	D07FSX	ISIS 112002	Investigative
T12052	DRUGINFO	D07RUF	ISIS 112023	Investigative
T12052	DRUGINFO	D0D9OL	ISIS 111992	Investigative
T12052	DRUGINFO	D0GD1R	ISIS 112003	Investigative
T12052	DRUGINFO	D0H0YU	ISIS 111997	Investigative
T12052	DRUGINFO	D0H6OL	ISIS 112004	Investigative
T12052	DRUGINFO	D0N7OK	ISIS 112001	Investigative
T12052	DRUGINFO	D0QU6S	ISIS 112024	Investigative
T12052	DRUGINFO	D0T0XZ	ISIS 112020	Investigative
T12052	DRUGINFO	D0Y4TS	ISIS 111993	Investigative
T12052	DRUGINFO	D0Z4RI	ISIS 112021	Investigative

T79690	TARGETID	T79690
T79690	FORMERID	TTDR00217
T79690	UNIPROID	ITA4_HUMAN-ITB1_HUMAN
T79690	TARGNAME	VLA-4 messenger RNA (VLA-4 mRNA)
T79690	GENENAME	ITGA4-ITGB1
T79690	TARGTYPE	Literature-reported
T79690	SYNONYMS	VLA-4 (mRNA); Integrin alpha-4/beta-1 (mRNA)
T79690	FUNCTION	Integrins alpha-4/beta-1 (VLA-4) and alpha-4/beta-7 are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1. Integrin alpha- 4/beta-1 recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha- 4/beta-7 is also a receptor for MADCAM1. It recognizes the sequence L-D-T in MADCAM1. On activated endothelial cells integrin VLA-4 triggers homotypic aggregation for most VLA-4-positive leukocyte cell lines. It may also participate in cytolytic T-cell interactions with target cells.
T79690	BIOCLASS	mRNA target
T79690	SEQUENCE	MNLQPIFWIGLISSVCCVFAQTDENRCLKANAKSCGECIQAGPNCGWCTNSTFLQEGMPTSARCDDLEALKKKGCPPDDIENPRGSKDIKKNKNVTNRSKGTAEKLKPEDITQIQPQQLVLRLRSGEPQTFTLKFKRAEDYPIDLYYLMDLSYSMKDDLENVKSLGTDLMNEMRRITSDFRIGFGSFVEKTVMPYISTTPAKLRNPCTSEQNCTSPFSYKNVLSLTNKGEVFNELVGKQRISGNLDSPEGGFDAIMQVAVCGSLIGWRNVTRLLVFSTDAGFHFAGDGKLGGIVLPNDGQCHLENNMYTMSHYYDYPSIAHLVQKLSENNIQTIFAVTEEFQPVYKELKNLIPKSAVGTLSANSSNVIQLIIDAYNSLSSEVILENGKLSEGVTISYKSYCKNGVNGTGENGRKCSNISIGDEVQFEISITSNKCPKKDSDSFKIRPLGFTEEVEVILQYICECECQSEGIPESPKCHEGNGTFECGACRCNEGRVGRHCECSTDEVNSEDMDAYCRKENSSEICSNNGECVCGQCVCRKRDNTNEIYSGKFCECDNFNCDRSNGLICGGNGVCKCRVCECNPNYTGSACDCSLDTSTCEASNGQICNGRGICECGVCKCTDPKFQGQTCEMCQTCLGVCAEHKECVQCRAFNKGEKKDTCTQECSYFNITKVESRDKLPQPVQPDPVSHCKEKDVDDCWFYFTYSVNGNNEVMVHVVENPECPTGPDIIPIVAGVVAGIVLIGLALLLIWKLLMIIHDRREFAKFEKEKMNAKWDTGENPIYKSAVTTVVNPKYEGKMAWEARREPGPRRAAVRETVMLLLCLGVPTGRPYNVDTESALLYQGPHNTLFGYSVVLHSHGANRWLLVGAPTANWLANASVINPGAIYRCRIGKNPGQTCEQLQLGSPNGEPCGKTCLEERDNQWLGVTLSRQPGENGSIVTCGHRWKNIFYIKNENKLPTGGCYGVPPDLRTELSKRIAPCYQDYVKKFGENFASCQAGISSFYTKDLIVMGAPGSSYWTGSLFVYNITTNKYKAFLDKQNQVKFGSYLGYSVGAGHFRSQHTTEVVGGAPQHEQIGKAYIFSIDEKELNILHEMKGKKLGSYFGASVCAVDLNADGFSDLLVGAPMQSTIREEGRVFVYINSGSGAVMNAMETNLVGSDKYAARFGESIVNLGDIDNDGFEDVAIGAPQEDDLQGAIYIYNGRADGISSTFSQRIEGLQISKSLSMFGQSISGQIDADNNGYVDVAVGAFRSDSAVLLRTRPVVIVDASLSHPESVNRTKFDCVENGWPSVCIDLTLCFSYKGKEVPGYIVLFYNMSLDVNRKAESPPRFYFSSNGTSDVITGSIQVSSREANCRTHQAFMRKDVRDILTPIQIEAAYHLGPHVISKRSTEEFPPLQPILQQKKEKDIMKKTINFARFCAHENCSADLQVSAKIGFLKPHENKTYLAVGSMKTLMLNVSLFNAGDDAYETTLHVKLPVGLYFIKILELEEKQINCEVTDNSGVVQLDCSIGYIYVDHLSRIDISFLLDVSSLSRAEEDLSITVHATCENEEEMDNLKHSRVTVAIPLKYEVKLTVHGFVNPTSFVYGSNDENEPETCMVEKMNLTFHVINTGNSMAPNVSVEIMVPNSFSPQTDKLFNILDVQTTTGECHFENYQRVCALEQQKSAMQTLKGIVRFLSKTDKRLLYCIKADPHCLNFLCNFGKMESGKEASVHIQLEGRPSILEMDETSALKFEIRATGFPEPNPRVIELNKDENVAHVLLEGLHHQRPKRYFTIVIISSSLLLGLIVLLLISYVMWKAGFFKRQYKSILQEENRRDSWSYINSKSNDD

T44846	TARGETID	T44846
T44846	FORMERID	TTDC00289
T44846	UNIPROID	VEGFA_HUMAN
T44846	TARGNAME	VEGF A165 messenger RNA (VEGF A165 mRNA)
T44846	GENENAME	VEGFA A165
T44846	TARGTYPE	Literature-reported
T44846	SYNONYMS	Vascular permeability factor A165 (mRNA); Vascular endothelial growth factor A A165 (mRNA); VPF A165 (mRNA); VEGF-A A165 (mRNA); VEGF A165 (mRNA)
T44846	FUNCTION	Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development. Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth.
T44846	PDBSTRUC	6D3O; 6BFT; 5T89; 5O4E; 5HHD
T44846	BIOCLASS	mRNA target
T44846	SEQUENCE	MNFLLSWVHWSLALLLYLHHAKWSQAAPMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGEMSFLQHNKCECRPKKDRARQEKKSVRGKGKGQKRKRKKSRYKSWSVYVGARCCLMPWSLPGPHPCGPCSERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR

T58479	TARGETID	T58479
T58479	FORMERID	TTDI02235
T58479	UNIPROID	VEGFA_HUMAN
T58479	TARGNAME	VEGF messenger RNA (VEGF mRNA)
T58479	GENENAME	VEGFA
T58479	TARGTYPE	Literature-reported
T58479	SYNONYMS	Vascular permeability factor (mRNA); Vascular endothelial growth factor A (mRNA); VPF (mRNA); VEGF-A (mRNA); VEGF (mRNA)
T58479	FUNCTION	Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development. Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth.
T58479	PDBSTRUC	6D3O; 6BFT; 5T89; 5O4E; 5HHD
T58479	BIOCLASS	mRNA target
T58479	SEQUENCE	MNFLLSWVHWSLALLLYLHHAKWSQAAPMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGEMSFLQHNKCECRPKKDRARQEKKSVRGKGKGQKRKRKKSRYKSWSVYVGARCCLMPWSLPGPHPCGPCSERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR
T58479	DRUGINFO	D05ITS	ALN-VEG01	Terminated

T87916	TARGETID	T87916
T87916	FORMERID	TTDR01374
T87916	UNIPROID	LYAM2_HUMAN
T87916	TARGNAME	E-selectin messenger RNA (SELE mRNA)
T87916	GENENAME	SELE
T87916	TARGTYPE	Literature-reported
T87916	SYNONYMS	Leukocyte-endothelial cell adhesion molecule 2 (mRNA); LECAM2 (mRNA); Endothelial leukocyte adhesion molecule 1 (mRNA); ELAM1 (mRNA); ELAM-1 (mRNA); E-selectin (mRNA); CD62E antigen (mRNA); CD62E (mRNA); CD62 antigen-like family member E (mRNA)
T87916	FUNCTION	Mediates in the adhesion of blood neutrophils in cytokine-activated endothelium through interaction with SELPLG/PSGL1. May have a role in capillary morphogenesis. Cell-surface glycoprotein having a role in immunoadhesion.
T87916	PDBSTRUC	6EYK; 6EYJ; 6EYI; 4CSY; 4C16
T87916	BIOCLASS	mRNA target
T87916	SEQUENCE	MIASQFLSALTLVLLIKESGAWSYNTSTEAMTYDEASAYCQQRYTHLVAIQNKEEIEYLNSILSYSPSYYWIGIRKVNNVWVWVGTQKPLTEEAKNWAPGEPNNRQKDEDCVEIYIKREKDVGMWNDERCSKKKLALCYTAACTNTSCSGHGECVETINNYTCKCDPGFSGLKCEQIVNCTALESPEHGSLVCSHPLGNFSYNSSCSISCDRGYLPSSMETMQCMSSGEWSAPIPACNVVECDAVTNPANGFVECFQNPGSFPWNTTCTFDCEEGFELMGAQSLQCTSSGNWDNEKPTCKAVTCRAVRQPQNGSVRCSHSPAGEFTFKSSCNFTCEEGFMLQGPAQVECTTQGQWTQQIPVCEAFQCTALSNPERGYMNCLPSASGSFRYGSSCEFSCEQGFVLKGSKRLQCGPTGEWDNEKPTCEAVRCDAVHQPPKGLVRCAHSPIGEFTYKSSCAFSCEEGFELHGSTQLECTSQGQWTEEVPSCQVVKCSSLAVPGKINMSCSGEPVFGTVCKFACPEGWTLNGSAARTCGATGHWSGLLPTCEAPTESNIPLVAGLSAAGLSLLTLAPFLLWLRKCLRKAKKFVPASSCQSLESDGSYQKPSYIL
T87916	DRUGINFO	D02MDK	ISIS 2674	Investigative
T87916	DRUGINFO	D04KSX	ISIS 9984	Investigative
T87916	DRUGINFO	D07BCS	ISIS 2686	Investigative
T87916	DRUGINFO	D0E6KA	ISIS 4730	Investigative
T87916	DRUGINFO	D0E8OO	ISIS 4764	Investigative
T87916	DRUGINFO	D0L1ZC	ISIS 4759	Investigative
T87916	DRUGINFO	D0N5AF	ISIS 11929	Investigative
T87916	DRUGINFO	D0OQ2Q	ISIS 2678	Investigative
T87916	DRUGINFO	D0QR1L	ISIS 4756	Investigative
T87916	DRUGINFO	D0R4BK	ISIS 4729	Investigative
T87916	DRUGINFO	D0Y4RS	ISIS 4719	Investigative

T10252	TARGETID	T10252
T10252	FORMERID	TTDR01376
T10252	UNIPROID	CEBPB_HUMAN
T10252	TARGNAME	C/EBP beta messenger RNA (CEBPB mRNA)
T10252	GENENAME	CEBPB
T10252	TARGTYPE	Literature-reported
T10252	SYNONYMS	Transcription factor CCAAT/enhancer-binding protein beta (mRNA); Transcription factor 5 (mRNA); TCF5 (mRNA); TCF-5 (mRNA); PP9092 (mRNA); Nuclear factor NF-IL6 (mRNA); Liver-enriched inhibitory protein (mRNA); Liver activator protein (mRNA); LIP (mRNA); LAP (mRNA); CCAAT/enhancer-binding protein beta (mRNA); C/EBP beta (mRNA)
T10252	FUNCTION	Plays also a significant role in adipogenesis, as well as in the gluconeogenic pathway, liver regeneration, and hematopoiesis. The consensus recognition site is 5'-T[TG]NNGNAA[TG]-3'. Its functional capacity is governed by protein interactions and post-translational protein modifications. During early embryogenesis, plays essential and redundant functions with CEBPA. Has a promitotic effect on many cell types such as hepatocytes and adipocytes but has an antiproliferative effect on T-cells by repressing MYC expression, facilitating differentiation along the T-helper 2 lineage. Binds to regulatory regions of several acute-phase and cytokines genes and plays a role in the regulation of acute-phase reaction and inflammation. Plays also a role in intracellular bacteria killing. During adipogenesis, is rapidly expressed and, after activation by phosphorylation, induces CEBPA and PPARG, which turn on the series of adipocyte genes that give rise to the adipocyte phenotype. The delayed transactivation of the CEBPA and PPARG genes by CEBPB appears necessary to allow mitotic clonal expansion and thereby progression of terminal differentiation. Essential for female reproduction because of a critical role in ovarian follicle development. Restricts osteoclastogenesis: together with NFE2L1; represses expression of DSPP during odontoblast differentiation. Important transcription factor regulating the expression of genes involved in immune and inflammatory responses.
T10252	PDBSTRUC	6MG3; 6MG2; 6MG1; 2.00E+43; 2.00E+42
T10252	BIOCLASS	mRNA target
T10252	SEQUENCE	MQRLVAWDPACLPLPPPPPAFKSMEVANFYYEADCLAAAYGGKAAPAAPPAARPGPRPPAGELGSIGDHERAIDFSPYLEPLGAPQAPAPATATDTFEAAPPAPAPAPASSGQHHDFLSDLFSDDYGGKNCKKPAEYGYVSLGRLGAAKGALHPGCFAPLHPPPPPPPPPAELKAEPGFEPADCKRKEEAGAPGGGAGMAAGFPYALRAYLGYQAVPSGSSGSLSTSSSSSPPGTPSPADAKAPPTACYAGAAPAPSQVKSKAKKTVDKHSDEYKIRRERNNIAVRKSRDKAKMRNLETQHKVLELTAENERLQKKVEQLSRELSTLRNLFKQLPEPLLASSGHC
T10252	DRUGINFO	D0TC8O	ISIS 116508	Investigative
T10252	DRUGINFO	D0TD0K	ISIS 116507	Investigative
T10252	DRUGINFO	D0Z5SL	ISIS 116505	Investigative

T68026	TARGETID	T68026
T68026	FORMERID	TTDR01377
T68026	UNIPROID	VCAM1_HUMAN
T68026	TARGNAME	VCAM-1 messenger RNA (VCAM1 mRNA)
T68026	GENENAME	VCAM1
T68026	TARGTYPE	Literature-reported
T68026	SYNONYMS	Vascular cell adhesion protein 1 (mRNA); Vascular cell adhesion molecule 1 (mRNA); VCAM-1 (mRNA); V-CAM 1 (mRNA); INCAM-100 (mRNA); CD106 antigen (mRNA); CD106 (mRNA)
T68026	FUNCTION	Appears to function in leukocyte-endothelial cell adhesion. Interacts with integrin alpha-4/beta-1 (ITGA4/ITGB1) on leukocytes, and mediates both adhesion and signal transduction. The VCAM1/ITGA4/ITGB1 interaction may play a pathophysiologic role both in immune responses and in leukocyte emigration to sites of inflammation. Important in cell-cell recognition.
T68026	PDBSTRUC	1VSC; 1VCA; 1IJ9
T68026	BIOCLASS	mRNA target
T68026	SEQUENCE	MPGKMVVILGASNILWIMFAASQAFKIETTPESRYLAQIGDSVSLTCSTTGCESPFFSWRTQIDSPLNGKVTNEGTTSTLTMNPVSFGNEHSYLCTATCESRKLEKGIQVEIYSFPKDPEIHLSGPLEAGKPITVKCSVADVYPFDRLEIDLLKGDHLMKSQEFLEDADRKSLETKSLEVTFTPVIEDIGKVLVCRAKLHIDEMDSVPTVRQAVKELQVYISPKNTVISVNPSTKLQEGGSVTMTCSSEGLPAPEIFWSKKLDNGNLQHLSGNATLTLIAMRMEDSGIYVCEGVNLIGKNRKEVELIVQEKPFTVEISPGPRIAAQIGDSVMLTCSVMGCESPSFSWRTQIDSPLSGKVRSEGTNSTLTLSPVSFENEHSYLCTVTCGHKKLEKGIQVELYSFPRDPEIEMSGGLVNGSSVTVSCKVPSVYPLDRLEIELLKGETILENIEFLEDTDMKSLENKSLEMTFIPTIEDTGKALVCQAKLHIDDMEFEPKQRQSTQTLYVNVAPRDTTVLVSPSSILEEGSSVNMTCLSQGFPAPKILWSRQLPNGELQPLSENATLTLISTKMEDSGVYLCEGINQAGRSRKEVELIIQVTPKDIKLTAFPSESVKEGDTVIISCTCGNVPETWIILKKKAETGDTVLKSIDGAYTIRKAQLKDAGVYECESKNKVGSQLRSLTLDVQGRENNKDYFSPELLVLYFASSLIIPAIGMIIYFARKANMKGSYSLVEAQKSKV
T68026	DRUGINFO	D02TPS	ISIS 3792	Investigative
T68026	DRUGINFO	D02WXX	ISIS 3801	Investigative
T68026	DRUGINFO	D04RGN	SYMBIOPOLYOL	Investigative
T68026	DRUGINFO	D08YCI	ISIS 5876	Investigative
T68026	DRUGINFO	D0A7AV	ISIS 5875	Investigative
T68026	DRUGINFO	D0A7SE	ISIS 3804	Investigative
T68026	DRUGINFO	D0J7IV	ISIS 5884	Investigative
T68026	DRUGINFO	D0P3FU	ISIS 3805	Investigative
T68026	DRUGINFO	D0R5NX	ISIS 5874	Investigative

T42004	TARGETID	T42004
T42004	FORMERID	TTDR01378
T42004	UNIPROID	NUCL_HUMAN
T42004	TARGNAME	Nucleolin messenger RNA (NCL mRNA)
T42004	GENENAME	NCL
T42004	TARGTYPE	Literature-reported
T42004	SYNONYMS	Protein C23 (mRNA); Nucleolin (mRNA)
T42004	FUNCTION	It is found associated with intranucleolar chromatin and pre-ribosomal particles. It induces chromatin decondensation by binding to histone H1. It is thought to play a role in pre-rRNA transcription and ribosome assembly. May play a role in the process of transcriptional elongation. Binds RNA oligonucleotides with 5'-UUAGGG-3' repeats more tightly than the telomeric single-stranded DNA 5'-TTAGGG-3' repeats. Nucleolin is the major nucleolar protein of growing eukaryotic cells.
T42004	PDBSTRUC	2KRR; 2FC9; 2FC8
T42004	BIOCLASS	mRNA target
T42004	SEQUENCE	MVKLAKAGKNQGDPKKMAPPPKEVEEDSEDEEMSEDEEDDSSGEEVVIPQKKGKKAAATSAKKVVVSPTKKVAVATPAKKAAVTPGKKAAATPAKKTVTPAKAVTTPGKKGATPGKALVATPGKKGAAIPAKGAKNGKNAKKEDSDEEEDDDSEEDEEDDEDEDEDEDEIEPAAMKAAAAAPASEDEDDEDDEDDEDDDDDEEDDSEEEAMETTPAKGKKAAKVVPVKAKNVAEDEDEEEDDEDEDDDDDEDDEDDDDEDDEEEEEEEEEEPVKEAPGKRKKEMAKQKAAPEAKKQKVEGTEPTTAFNLFVGNLNFNKSAPELKTGISDVFAKNDLAVVDVRIGMTRKFGYVDFESAEDLEKALELTGLKVFGNEIKLEKPKGKDSKKERDARTLLAKNLPYKVTQDELKEVFEDAAEIRLVSKDGKSKGIAYIEFKTEADAEKTFEEKQGTEIDGRSISLYYTGEKGQNQDYRGGKNSTWSGESKTLVLSNLSYSATEETLQEVFEKATFIKVPQNQNGKSKGYAFIEFASFEDAKEALNSCNKREIEGRAIRLELQGPRGSPNARSQPSKTLFVKGLSEDTTEETLKESFDGSVRARIVTDRETGSSKGFGFVDFNSEEDAKAAKEAMEDGEIDGNKVTLDWAKPKGEGGFGGRGGGRGGFGGRGGGRGGRGGFGGRGRGGFGGRGGFRGGRGGGGDHKPQGKKTKFE
T42004	DRUGINFO	D00FEY	ISIS 110074	Investigative
T42004	DRUGINFO	D02YVB	ISIS 110065	Investigative
T42004	DRUGINFO	D07XNG	ISIS 110067	Investigative
T42004	DRUGINFO	D0E5TD	ISIS 110068	Investigative
T42004	DRUGINFO	D0KO1E	ISIS 110073	Investigative
T42004	DRUGINFO	D0S6OP	ISIS 110066	Investigative
T42004	DRUGINFO	D0W7DK	ISIS 110064	Investigative

T04945	TARGETID	T04945
T04945	FORMERID	TTDR01380
T04945	UNIPROID	TNR6_HUMAN
T04945	TARGNAME	Fas messenger RNA (FAS mRNA)
T04945	GENENAME	FAS
T04945	TARGTYPE	Literature-reported
T04945	SYNONYMS	Tumor necrosis factor receptor superfamily member 6 (mRNA); TNFRSF6 (mRNA); FASLG receptor (mRNA); FAS1 (mRNA); CD95 (mRNA); Apoptosis-mediating surface antigen FAS (mRNA); Apo-1 antigen (mRNA); APT1 (mRNA)
T04945	FUNCTION	The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. FAS-mediated apoptosis may have a role in the induction of peripheral tolerance, in the antigen-stimulated suicide of mature T-cells, or both. The secreted isoforms 2 to 6 block apoptosis (in vitro). Receptor for TNFSF6/FASLG.
T04945	PDBSTRUC	3TJE; 3THM; 3EZQ; 3EWT; 2NA7
T04945	BIOCLASS	mRNA target
T04945	SEQUENCE	MLGIWTLLPLVLTSVARLSSKSVNAQVTDINSKGLELRKTVTTVETQNLEGLHHDGQFCHKPCPPGERKARDCTVNGDEPDCVPCQEGKEYTDKAHFSSKCRRCRLCDEGHGLEVEINCTRTQNTKCRCKPNFFCNSTVCEHCDPCTKCEHGIIKECTLTSNTKCKEEGSRSNLGWLCLLLLPIPLIVWVKRKEVQKTCRKHRKENQGSHESPTLNPETVAINLSDVDLSKYITTIAGVMTLSQVKGFVRKNGVNEAKIDEIKNDNVQDTAEQKVQLLRNWHQLHGKKEAYDTLIKDLKKANLCTLAEKIQTIILKDITSDSENSNFRNEIQSLV
T04945	DRUGINFO	D0J1SU	ISIS 17020	Investigative

T50678	TARGETID	T50678
T50678	FORMERID	TTDI02681
T50678	UNIPROID	CD40L_HUMAN
T50678	TARGNAME	CD40LG messenger RNA (CD40LG mRNA)
T50678	GENENAME	CD40LG
T50678	TARGTYPE	Literature-reported
T50678	SYNONYMS	Tumor necrosis factor ligand superfamily member 5 (mRNA); TRAP (mRNA); TNFSF5 (mRNA); TNF-related activation protein (mRNA); T-cell antigen Gp39 (mRNA); T cell antigen Gp39 (mRNA); CD40L (mRNA); CD40-L (mRNA); CD40 ligand (mRNA); CD154 antigen (mRNA); CD154 (mRNA)
T50678	FUNCTION	Costimulates T-cell proliferation and cytokine production. Its cross-linking on T-cells generates a costimulatory signal which enhances the production of IL4 and IL10 in conjunction with the TCR/CD3 ligation and CD28 costimulation. Induces the activation of NF-kappa-B and kinases MAPK8 and PAK2 in T-cells. Induces tyrosine phosphorylation of isoform 3 of CD28. Mediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL4. Involved in immunoglobulin class switching. Cytokine that binds to CD40/TNFRSF5.
T50678	PDBSTRUC	6BRB; 3QD6; 3LKJ; 1I9R; 1ALY
T50678	BIOCLASS	mRNA target
T50678	SEQUENCE	MIETYNQTSPRSAATGLPISMKIFMYLLTVFLITQMIGSALFAVYLHRRLDKIEDERNLHEDFVFMKTIQRCNTGERSLSLLNCEEIKSQFEGFVKDIMLNKEETKKENSFEMQKGDQNPQIAAHVISEASSKTTSVLQWAEKGYYTMSNNLVTLENGKQLTVKRQGLYYIYAQVTFCSNREASSQAPFIASLCLKSPGRFERILLRAANTHSSAKPCGQQSIHLGGVFELQPGASVFVNVTDPSQVSHGTGFTSFGLLKL

T79799	TARGETID	T79799
T79799	FORMERID	TTDR01383
T79799	UNIPROID	GNA11_HUMAN
T79799	TARGNAME	G-alpha-11 messenger RNA (GNA11 mRNA)
T79799	GENENAME	GNA11
T79799	TARGTYPE	Literature-reported
T79799	SYNONYMS	Guanine nucleotide-binding protein subunit alpha-11 (mRNA); Guanine nucleotide-binding protein G(y) subunit alpha (mRNA); GA11 (mRNA); G-protein subunit alpha-11 (mRNA); G alpha-11 (mRNA)
T79799	FUNCTION	Acts as an activator of phospholipase C. Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signaling systems.
T79799	PDBSTRUC	6OIJ
T79799	BIOCLASS	mRNA target
T79799	SEQUENCE	MTLESMMACCLSDEVKESKRINAEIEKQLRRDKRDARRELKLLLLGTGESGKSTFIKQMRIIHGAGYSEEDKRGFTKLVYQNIFTAMQAMIRAMETLKILYKYEQNKANALLIREVDVEKVTTFEHQYVSAIKTLWEDPGIQECYDRRREYQLSDSAKYYLTDVDRIATLGYLPTQQDVLRVRVPTTGIIEYPFDLENIIFRMVDVGGQRSERRKWIHCFENVTSIMFLVALSEYDQVLVESDNENRMEESKALFRTIITYPWFQNSSVILFLNKKDLLEDKILYSHLVDYFPEFDGPQRDAQAAREFILKMFVDLNPDSDKIIYSHFTCATDTENIRFVFAAVKDTILQLNLKEYNLV
T79799	DRUGINFO	D02FVN	ISIS 20585	Investigative
T79799	DRUGINFO	D02QWL	ISIS 20995	Investigative
T79799	DRUGINFO	D0F4UV	ISIS 20586	Investigative
T79799	DRUGINFO	D0KX4U	ISIS 20579	Investigative
T79799	DRUGINFO	D0L8AJ	ISIS 20994	Investigative
T79799	DRUGINFO	D0L9DW	ISIS 20993	Investigative
T79799	DRUGINFO	D0M5GP	ISIS 20990	Investigative
T79799	DRUGINFO	D0O4HL	ISIS 20577	Investigative

T10939	TARGETID	T10939
T10939	FORMERID	TTDI02666
T10939	UNIPROID	WEE1_HUMAN
T10939	TARGNAME	WEE1 messenger RNA (WEE1 mRNA)
T10939	GENENAME	WEE1
T10939	TARGTYPE	Literature-reported
T10939	SYNONYMS	Wee1A kinase (mRNA); WEE1hu (mRNA)
T10939	FUNCTION	Specifically phosphorylates and inactivates cyclin B1-complexed CDK1 reaching a maximum during G2 phase and a minimum as cells enter M phase. Phosphorylation of cyclin B1-CDK1 occurs exclusively on 'Tyr-15' and phosphorylation of monomeric CDK1 does not occur. Its activity increases during S and G2 phases and decreases at M phase when it is hyperphosphorylated. A correlated decrease in protein level occurs at M/G1 phase, probably due to its degradation. Acts as a negative regulator of entry into mitosis (G2 to M transition) by protecting the nucleus from cytoplasmically activated cyclin B1-complexed CDK1 before the onset of mitosis by mediating phosphorylation of CDK1 on 'Tyr-15'.
T10939	PDBSTRUC	5VDA; 5VD9; 5VD8; 5VD7; 5VD5
T10939	BIOCLASS	mRNA target
T10939	ECNUMBER	EC 2.7.10.2
T10939	SEQUENCE	MSFLSRQQPPPPRRAGAACTLRQKLIFSPCSDCEEEEEEEEEEGSGHSTGEDSAFQEPDSPLPPARSPTEPGPERRRSPGPAPGSPGELEEDLLLPGACPGADEAGGGAEGDSWEEEGFGSSSPVKSPAAPYFLGSSFSPVRCGGPGDASPRGCGARRAGEGRRSPRPDHPGTPPHKTFRKLRLFDTPHTPKSLLSKARGIDSSSVKLRGSSLFMDTEKSGKREFDVRQTPQVNINPFTPDSLLLHSSGQCRRRKRTYWNDSCGEDMEASDYELEDETRPAKRITITESNMKSRYTTEFHELEKIGSGEFGSVFKCVKRLDGCIYAIKRSKKPLAGSVDEQNALREVYAHAVLGQHSHVVRYFSAWAEDDHMLIQNEYCNGGSLADAISENYRIMSYFKEAELKDLLLQVGRGLRYIHSMSLVHMDIKPSNIFISRTSIPNAASEEGDEDDWASNKVMFKIGDLGHVTRISSPQVEEGDSRFLANEVLQENYTHLPKADIFALALTVVCAAGAEPLPRNGDQWHEIRQGRLPRIPQVLSQEFTELLKVMIHPDPERRPSAMALVKHSVLLSASRKSAEQLRIELNAEKFKNSLLQKELKKAQMAKAAAEERALFTDRMATRSTTQSNRTSRLIGKKMNRSVSLTIY

T22306	TARGETID	T22306
T22306	FORMERID	TTDI02311
T22306	UNIPROID	AKT1_HUMAN
T22306	TARGNAME	AKT1 messenger RNA (AKT1 mRNA)
T22306	GENENAME	AKT1
T22306	TARGTYPE	Literature-reported
T22306	SYNONYMS	RAC-PK-alpha (mRNA); RAC (mRNA); Proto-oncogene c-Akt (mRNA); Protein kinase B alpha (mRNA); Protein kinase B (mRNA); PKB alpha (mRNA); PKB (mRNA)
T22306	FUNCTION	AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. Phosphorylation of PTPN1 at 'Ser-50' negatively modulates its phosphatase activity preventing dephosphorylation of the insulin receptor and the attenuation of insulin signaling. Phosphorylation of TBC1D4 triggers the binding of this effector to inhibitory 14-3-3 proteins, which is required for insulin-stimulated glucose transport. AKT regulates also the storage of glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity. Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven. AKT regulates also cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related kinase). Phosphorylation of 'Ser-83' decreases MAP3K5 kinase activity stimulated by oxidative stress and thereby prevents apoptosis. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT is involved in the phosphorylation of members of the FOXO factors (Forkhead family of transcription factors), leading to binding of 14-3-3 proteins and cytoplasmic localization. In particular, FOXO1 is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 and FOXO4 are phosphorylated on equivalent sites. AKT has an important role in the regulation of NF-kappa-B-dependent gene transcription and positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein). The phosphorylation of CREB1 induces the binding of accessory proteins that are necessary for the transcription of pro-survival genes such as BCL2 and MCL1. AKT phosphorylates 'Ser-454' on ATP citrate lyase (ACLY), thereby potentially regulating ACLY activity and fatty acid synthesis. Activates the 3B isoform of cyclic nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', resulting in reduced cyclic AMP levels and inhibition of lipolysis. Phosphorylates PIKFYVE on 'Ser-318', which results in increased PI(3)P-5 activity. The Rho GTPase-activating protein DLC1 is another substrate and its phosphorylation is implicated in the regulation cell proliferation and cell growth. AKT plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). AKT mediates the antiapoptotic effects of IGF-I. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. May be involved in the regulation of the placental development. Phosphorylates STK4/MST1 at 'Thr-120' and 'Thr-387' leading to inhibition of its: kinase activity, nuclear translocation, autophosphorylation and ability to phosphorylate FOXO3. Phosphorylates STK3/MST2 at 'Thr-117' and 'Thr-384' leading to inhibition of its: cleavage, kinase activity, autophosphorylation at Thr-180, binding to RASSF1 and nuclear translocation. Phosphorylates SRPK2 and enhances its kinase activity towards SRSF2 and ACIN1 and promotes its nuclear translocation. Phosphorylates RAF1 at 'Ser-259' and negatively regulates its activity. Phosphorylation of BAD stimulates its pro-apoptotic activity. Phosphorylates KAT6A at 'Thr-369' and this phosphorylation inhibits the interaction of KAT6A with PML and negatively regulates its acetylation activity towards p53/TP53.
T22306	PDBSTRUC	6NPZ; 6HHJ; 6HHI; 6HHH; 6HHG
T22306	BIOCLASS	mRNA target
T22306	ECNUMBER	EC 2.7.11.1
T22306	SEQUENCE	MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA

T45433	TARGETID	T45433
T45433	FORMERID	TTDI02254
T45433	UNIPROID	IL3RB_HUMAN
T45433	TARGNAME	GM-CSFR/IL-3R/IL-5R common beta messenger RNA (CSF2RB mRNA)
T45433	GENENAME	CSF2RB
T45433	TARGTYPE	Literature-reported
T45433	SYNONYMS	IL5RB (mRNA); IL3RB (mRNA); IL-5R (mRNA); GM-CSF/IL-3/IL-5 receptor common beta subunit (mRNA); Cytokine receptor common subunit beta (mRNA); CDw131 (mRNA); CD131 (mRNA)
T45433	FUNCTION	High affinity receptor for interleukin-3, interleukin-5 and granulocyte-macrophage colony-stimulating factor.
T45433	PDBSTRUC	5DWU; 4NKQ; 2NA9; 2NA8; 2GYS
T45433	BIOCLASS	mRNA target
T45433	SEQUENCE	MVLAQGLLSMALLALCWERSLAGAEETIPLQTLRCYNDYTSHITCRWADTQDAQRLVNVTLIRRVNEDLLEPVSCDLSDDMPWSACPHPRCVPRRCVIPCQSFVVTDVDYFSFQPDRPLGTRLTVTLTQHVQPPEPRDLQISTDQDHFLLTWSVALGSPQSHWLSPGDLEFEVVYKRLQDSWEDAAILLSNTSQATLGPEHLMPSSTYVARVRTRLAPGSRLSGRPSKWSPEVCWDSQPGDEAQPQNLECFFDGAAVLSCSWEVRKEVASSVSFGLFYKPSPDAGEEECSPVLREGLGSLHTRHHCQIPVPDPATHGQYIVSVQPRRAEKHIKSSVNIQMAPPSLNVTKDGDSYSLRWETMKMRYEHIDHTFEIQYRKDTATWKDSKTETLQNAHSMALPALEPSTRYWARVRVRTSRTGYNGIWSEWSEARSWDTESVLPMWVLALIVIFLTIAVLLALRFCGIYGYRLRRKWEEKIPNPSKSHLFQNGSAELWPPGSMSAFTSGSPPHQGPWGSRFPELEGVFPVGFGDSEVSPLTIEDPKHVCDPPSGPDTTPAASDLPTEQPPSPQPGPPAASHTPEKQASSFDFNGPYLGPPHSRSLPDILGQPEPPQEGGSQKSPPPGSLEYLCLPAGGQVQLVPLAQAMGPGQAVEVERRPSQGAAGSPSLESGGGPAPPALGPRVGGQDQKDSPVAIPMSSGDTEDPGVASGYVSSADLVFTPNSGASSVSLVPSLGLPSDQTPSLCPGLASGPPGAPGPVKSGFEGYVELPPIEGRSPRSPRNNPVPPEAKSPVLNPGERPADVSPTSPQPEGLLVLQQVGDYCFLPGLGPGPLSLRSKPSSPGPGPEIKNLDQAFQVKKPPGQAVPQVPVIQLFKALKQQDYLSLPPWEVNKPGEVC

T29148	TARGETID	T29148
T29148	FORMERID	TTDR01384
T29148	UNIPROID	CD80_HUMAN
T29148	TARGNAME	B7 translation initiation codon region messenger RNA (CD80 mRNA)
T29148	GENENAME	CD80
T29148	TARGTYPE	Literature-reported
T29148	SYNONYMS	T-lymphocyte activation antigen CD80 (mRNA); LAB7 (mRNA); CTLA-4 counter-receptor B7.1 (mRNA); CD28LG1 (mRNA); CD28LG (mRNA); BB1 (mRNA); B7 (mRNA); Activation B7-1 antigen (mRNA)
T29148	FUNCTION	T-cell proliferation and cytokine production is induced by the binding of CD28, binding to CTLA-4 has opposite effects and inhibits T-cell activation. Involved in the costimulatory signal essential for T-lymphocyte activation.
T29148	PDBSTRUC	1I8L; 1DR9
T29148	BIOCLASS	mRNA target
T29148	SEQUENCE	MGHTRRQGTSPSKCPYLNFFQLLVLAGLSHFCSGVIHVTKEVKEVATLSCGHNVSVEELAQTRIYWQKEKKMVLTMMSGDMNIWPEYKNRTIFDITNNLSIVILALRPSDEGTYECVVLKYEKDAFKREHLAEVTLSVKADFPTPSISDFEIPTSNIRRIICSTSGGFPEPHLSWLENGEELNAINTTVSQDPETELYAVSSKLDFNMTTNHSFMCLIKYGHLRVNQTFNWNTTKQEHFPDNLLPSWAITLISVNGIFVICCLTYCFAPRCRERRRNERLRRESVRPV
T29148	DRUGINFO	D07QCW	ISIS 13805	Investigative
T29148	DRUGINFO	D0LH7O	ISIS 13812	Investigative

T71268	TARGETID	T71268
T71268	FORMERID	TTDI02299
T71268	UNIPROID	IRS1_HUMAN
T71268	TARGNAME	IRS1 messenger RNA (IRS1 mRNA)
T71268	GENENAME	IRS1
T71268	TARGTYPE	Literature-reported
T71268	SYNONYMS	Insulin receptor substrate 1 (mRNA); IRS-1 (mRNA)
T71268	FUNCTION	When phosphorylated by the insulin receptor binds specifically to various cellular proteins containing SH2 domains such as phosphatidylinositol 3-kinase p85 subunit or GRB2. Activates phosphatidylinositol 3-kinase when bound to the regulatory p85 subunit. May mediate the control of various cellular processes by insulin.
T71268	PDBSTRUC	6BNT; 5U1M; 2Z8C; 1QQG; 1K3A
T71268	BIOCLASS	mRNA target
T71268	SEQUENCE	MASPPESDGFSDVRKVGYLRKPKSMHKRFFVLRAASEAGGPARLEYYENEKKWRHKSSAPKRSIPLESCFNINKRADSKNKHLVALYTRDEHFAIAADSEAEQDSWYQALLQLHNRAKGHHDGAAALGAGGGGGSCSGSSGLGEAGEDLSYGDVPPGPAFKEVWQVILKPKGLGQTKNLIGIYRLCLTSKTISFVKLNSEAAAVVLQLMNIRRCGHSENFFFIEVGRSAVTGPGEFWMQVDDSVVAQNMHETILEAMRAMSDEFRPRSKSQSSSNCSNPISVPLRRHHLNNPPPSQVGLTRRSRTESITATSPASMVGGKPGSFRVRASSDGEGTMSRPASVDGSPVSPSTNRTHAHRHRGSARLHPPLNHSRSIPMPASRCSPSATSPVSLSSSSTSGHGSTSDCLFPRRSSASVSGSPSDGGFISSDEYGSSPCDFRSSFRSVTPDSLGHTPPARGEEELSNYICMGGKGPSTLTAPNGHYILSRGGNGHRCTPGTGLGTSPALAGDEAASAADLDNRFRKRTHSAGTSPTITHQKTPSQSSVASIEEYTEMMPAYPPGGGSGGRLPGHRHSAFVPTRSYPEEGLEMHPLERRGGHHRPDSSTLHTDDGYMPMSPGVAPVPSGRKGSGDYMPMSPKSVSAPQQIINPIRRHPQRVDPNGYMMMSPSGGCSPDIGGGPSSSSSSSNAVPSGTSYGKLWTNGVGGHHSHVLPHPKPPVESSGGKLLPCTGDYMNMSPVGDSNTSSPSDCYYGPEDPQHKPVLSYYSLPRSFKHTQRPGEPEEGARHQHLRLSTSSGRLLYAATADDSSSSTSSDSLGGGYCGARLEPSLPHPHHQVLQPHLPRKVDTAAQTNSRLARPTRLSLGDPKASTLPRAREQQQQQQPLLHPPEPKSPGEYVNIEFGSDQSGYLSGPVAFHSSPSVRCPSQLQPAPREEETGTEEYMKMDLGPGRRAAWQESTGVEMGRLGPAPPGAASICRPTRAVPSSRGDYMTMQMSCPRQSYVDTSPAAPVSYADMRTGIAAEEVSLPRATMAAASSSSAASASPTGPQGAAELAAHSSLLGGPQGPGGMSAFTRVNLSPNRNQSAKVIRADPQGCRRRHSSETFSSTPSATRVGNTVPFGAGAAVGGGGGSSSSSEDVKRHSSASFENVWLRPGELGGAPKEPAKLCGAAGGLENGLNYIDLDLVKDFKQCPQECTPEPQPPPPPPPHQPLGSGESSSTRRSSEDLSAYASISFQKQPEDRQ

T97783	TARGETID	T97783
T97783	FORMERID	TTDR01389
T97783	UNIPROID	CD86_HUMAN
T97783	TARGNAME	CD86 messenger RNA (CD86 mRNA)
T97783	GENENAME	CD86
T97783	TARGTYPE	Literature-reported
T97783	SYNONYMS	T-lymphocyte activation antigen CD86 (mRNA); FUN-1 (mRNA); CTLA-4 counter-receptor B7.2 (mRNA); CD86 (mRNA); CD28LG2 (mRNA); BU63 (mRNA); B70 (mRNA); Activation B7-2 antigen (mRNA)
T97783	FUNCTION	May play a critical role in the early events of T-cell activation and costimulation of naive T-cells, such as deciding between immunity and anergy that is made by T-cells within 24 hours after activation. Isoform 2 interferes with the formation of CD86 clusters, and thus acts as a negative regulator of T-cell activation. Receptor involved in the costimulatory signal essential for T-lymphocyte proliferation and interleukin-2 production, by binding CD28 or CTLA-4.
T97783	PDBSTRUC	5YXK; 1NCN; 1I85
T97783	BIOCLASS	mRNA target
T97783	SEQUENCE	MDPQCTMGLSNILFVMAFLLSGAAPLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSKYMGRTSFDSDSWTLRLHNLQIKDKGLYQCIIHHKKPTGMIRIHQMNSELSVLANFSQPEIVPISNITENVYINLTCSSIHGYPEPKKMSVLLRTKNSTIEYDGVMQKSQDNVTELYDVSISLSVSFPDVTSNMTIFCILETDKTRLLSSPFSIELEDPQPPPDHIPWITAVLPTVIICVMVFCLILWKWKKKKRPRNSYKCGTNTMEREESEQTKKREKIHIPERSDEAQRVFKSSKTSSCDKSDTCF
T97783	DRUGINFO	D07RML	ISIS 9133	Investigative
T97783	DRUGINFO	D0N4CJ	ISIS 9139	Investigative
T97783	DRUGINFO	D0O0BZ	ISIS 10373	Investigative
T97783	DRUGINFO	D0V2AQ	ISIS 113131	Investigative

T97044	TARGETID	T97044
T97044	FORMERID	TTDR01392
T97044	UNIPROID	NOP2_HUMAN
T97044	TARGNAME	P120 messenger RNA (NOP2 mRNA)
T97044	GENENAME	NOP2
T97044	TARGTYPE	Literature-reported
T97044	SYNONYMS	Proliferation-associated nucleolar protein p120 (mRNA); Proliferating-cell nucleolar antigen p120 (mRNA); Probable 28S rRNA (cytosine(4447)-C(5))-methyltransferase (mRNA); Nucleolar protein 2 homolog (mRNA); Nucleolar protein 1 (mRNA); NSUN1 (mRNA); NOL1 (mRNA)
T97044	FUNCTION	S-adenosyl-L-methionine-dependent methyltransferase that specifically methylates the C(5) position of cytosine 4447 in 28S rRNA. May play a role in the regulation of the cell cycle and the increased nucleolar activity that is associated with the cell proliferation. Involved in ribosomal large subunit assembly.
T97044	BIOCLASS	mRNA target
T97044	ECNUMBER	EC 2.1.1.-
T97044	SEQUENCE	MGRKLDPTKEKRGPGRKARKQKGAETELVRFLPAVSDENSKRLSSRARKRAAKRRLGSVEAPKTNKSPEAKPLPGKLPKGISAGAVQTAGKKGPQSLFNAPRGKKRPAPGSDEEEEEEDSEEDGMVNHGDLWGSEDDADTVDDYGADSNSEDEEEGEALLPIERAARKQKAREAAAGIQWSEEETEDEEEEKEVTPESGPPKVEEADGGLQINVDEEPFVLPPAGEMEQDAQAPDLQRVHKRIQDIVGILRDFGAQREEGRSRSEYLNRLKKDLAIYYSYGDFLLGKLMDLFPLSELVEFLEANEVPRPVTLRTNTLKTRRRDLAQALINRGVNLDPLGKWSKTGLVVYDSSVPIGATPEYLAGHYMLQGASSMLPVMALAPQEHERILDMCCAPGGKTSYMAQLMKNTGVILANDANAERLKSVVGNLHRLGVTNTIISHYDGRQFPKVVGGFDRVLLDAPCSGTGVISKDPAVKTNKDEKDILRCAHLQKELLLSAIDSVNATSKTGGYLVYCTCSITVEENEWVVDYALKKRNVRLVPTGLDFGQEGFTRFRERRFHPSLRSTRRFYPHTHNMDGFFIAKFKKFSNSIPQSQTGNSETATPTNVDLPQVIPKSENSSQPAKKAKGAAKTKQQLQKQQHPKKASFQKLNGISKGADSELSTVPSVTKTQASSSFQDSSQPAGKAEGIREPKVTGKLKQRSPKLQSSKKVAFLRQNAPPKGTDTQTPAVLSPSKTQATLKPKDHHQPLGRAKGVEKQQLPEQPFEKAAFQKQNDTPKGPQPPTVSPIRSSRPPPAKRKKSQSRGNSQLLLS
T97044	DRUGINFO	D04AJS	ISIS 6756	Investigative
T97044	DRUGINFO	D04NBZ	ISIS 6755	Investigative
T97044	DRUGINFO	D08NLU	ISIS 6748	Investigative
T97044	DRUGINFO	D09LXU	ISIS 6739	Investigative

T37077	TARGETID	T37077
T37077	FORMERID	TTDR01393
T37077	UNIPROID	TNFL6_HUMAN
T37077	TARGNAME	FasL messenger RNA (FASLG mRNA)
T37077	GENENAME	FASLG
T37077	TARGTYPE	Literature-reported
T37077	SYNONYMS	Tumor necrosis factor ligand superfamily member 6 (mRNA); TNFSF6 (mRNA); FasL (mRNA); Fas ligand (mRNA); FAS antigen ligand (mRNA); CD95L (mRNA); CD95-L (mRNA); CD95 ligand (mRNA); CD178 antigen (mRNA); CD178 (mRNA); Apoptosis antigen ligand (mRNA); APTL (mRNA); APT1LG1 (mRNA)
T37077	FUNCTION	Involved in cytotoxic T-cell-mediated apoptosis, natural killer cell-mediated apoptosis and in T-cell development. Initiates fratricidal/suicidal activation-induced cell death (AICD) in antigen-activated T-cells contributing to the termination of immune responses. TNFRSF6/FAS-mediated apoptosis has also a role in the induction of peripheral tolerance. Binds to TNFRSF6B/DcR3, a decoy receptor that blocks apoptosis. Cytokine that binds to TNFRSF6/FAS, a receptor that transduces the apoptotic signal into cells.
T37077	PDBSTRUC	5L36; 5L19; 4MSV; 1BZI
T37077	BIOCLASS	mRNA target
T37077	SEQUENCE	MQQPFNYPYPQIYWVDSSASSPWAPPGTVLPCPTSVPRRPGQRRPPPPPPPPPLPPPPPPPPLPPLPLPPLKKRGNHSTGLCLLVMFFMVLVALVGLGLGMFQLFHLQKELAELRESTSQMHTASSLEKQIGHPSPPPEKKELRKVAHLTGKSNSRSMPLEWEDTYGIVLLSGVKYKKGGLVINETGLYFVYSKVYFRGQSCNNLPLSHKVYMRNSKYPQDLVMMEGKMMSYCTTGQMWARSSYLGAVFNLTSADHLYVNVSELSLVNFEESQTFFGLYKL
T37077	DRUGINFO	D0BR7X	ISIS 16179	Investigative

T03551	TARGETID	T03551
T03551	FORMERID	TTDR01397
T03551	UNIPROID	PTEN_HUMAN
T03551	TARGNAME	PTEN messenger RNA (PTEN mRNA)
T03551	GENENAME	PTEN
T03551	TARGTYPE	Literature-reported
T03551	SYNONYMS	TEP1 (mRNA); Phosphatidylinositol 3,4,5trisphosphate 3phosphatase and dualspecificity protein phosphatase PTEN (mRNA); Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (mRNA); Mutated in multiple advanced cancers 1 (mRNA); MMAC1 (mRNA)
T03551	FUNCTION	Acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. Also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3-phosphate and inositol 1,3,4,5-tetrakisphosphate with order of substrate preference in vitro PtdIns(3,4,5)P3 > PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4. The lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. The nuclear monoubiquitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiquitinated form induces less tumor suppressive ability. In motile cells, suppresses the formation of lateral pseudopods and thereby promotes cell polarization and directed movement. Tumor suppressor.
T03551	PDBSTRUC	5BZZ; 5BZX; 5BUG; 4O1V; 2KYL
T03551	BIOCLASS	mRNA target
T03551	ECNUMBER	EC 3.1.3.16
T03551	SEQUENCE	MTAIIKEIVSRNKRRYQEDGFDLDLTYIYPNIIAMGFPAERLEGVYRNNIDDVVRFLDSKHKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLELIKPFCEDLDQWLSEDDNHVAAIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRTRDKKGVTIPSQRRYVYYYSYLLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSGPTRREDKFMYFEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEETSEKVENGSLCDQEIDSICSIERADNDKEYLVLTLTKNDLDKANKDKANRYFSPNFKVKLYFTKTVEEPSNPEASSSTSVTPDVSDNEPDHYRYSDTTDSDPENEPFDEDQHTQITKV

T28729	TARGETID	T28729
T28729	FORMERID	TTDR01400
T28729	UNIPROID	E2F1_HUMAN
T28729	TARGNAME	E2F1 messenger RNA (E2F1 mRNA)
T28729	GENENAME	E2F1
T28729	TARGTYPE	Literature-reported
T28729	SYNONYMS	pRB-binding protein E2F-1 (mRNA); Transcription factor E2F1 (mRNA); Retinoblastoma-binding protein 3 (mRNA); Retinoblastoma-associated protein 1 (mRNA); RBBP3 (mRNA); RBBP-3 (mRNA); RBAP-1 (mRNA); PBR3 (mRNA); E2F-1 (mRNA)
T28729	FUNCTION	The DRTF1/E2F complex functions in the control of cell-cycle progression from G1 to S phase. E2F1 binds preferentially RB1 in a cell-cycle dependent manner. It can mediate both cell proliferation and TP53/p53-dependent apoptosis. Blocks adipocyte differentiation by binding to specific promoters repressing CEBPA binding to its target gene promoters. Positively regulates transcription of RRP1B. Transcription activator that binds DNA cooperatively with DP proteins through the E2 recognition site, 5'-TTTC[CG]CGC-3' found in the promoter region of a number of genes whose products are involved in cell cycle regulation or in DNA replication.
T28729	PDBSTRUC	6G0P; 5M9O; 5M9N; 2AZE; 1O9K
T28729	BIOCLASS	mRNA target
T28729	SEQUENCE	MALAGAPAGGPCAPALEALLGAGALRLLDSSQIVIISAAQDASAPPAPTGPAAPAAGPCDPDLLLFATPQAPRPTPSAPRPALGRPPVKRRLDLETDHQYLAESSGPARGRGRHPGKGVKSPGEKSRYETSLNLTTKRFLELLSHSADGVVDLNWAAEVLKVQKRRIYDITNVLEGIQLIAKKSKNHIQWLGSHTTVGVGGRLEGLTQDLRQLQESEQQLDHLMNICTTQLRLLSEDTDSQRLAYVTCQDLRSIADPAEQMVMVIKAPPETQLQAVDSSENFQISLKSKQGPIDVFLCPEETVGGISPGKTPSQEVTSEEENRATDSATIVSPPPSSPPSSLTTDPSQSLLSLEQEPLLSRMGSLRAPVDEDRLSPLVAADSLLEHVREDFSGLLPEEFISLSPPHEALDYHFGLEEGEGIRDLFDCDFGDLTPLDF
T28729	DRUGINFO	D01KTF	ISIS 113048	Investigative
T28729	DRUGINFO	D08YXP	ISIS 113020	Investigative
T28729	DRUGINFO	D09RTT	ISIS 113022	Investigative
T28729	DRUGINFO	D0E4IZ	ISIS 113019	Investigative
T28729	DRUGINFO	D0WM1A	ISIS 113021	Investigative

T09935	TARGETID	T09935
T09935	FORMERID	TTDR01406
T09935	UNIPROID	FOXO1_HUMAN
T09935	TARGNAME	Forkhead box O1A messenger RNA (FOXO1 mRNA)
T09935	GENENAME	FOXO1
T09935	TARGTYPE	Literature-reported
T09935	SYNONYMS	Forkhead in rhabdomyosarcoma (mRNA); Forkhead box protein O1A (mRNA); Forkhead box protein O1 (mRNA); FOXO1A (mRNA); FKHR (mRNA)
T09935	FUNCTION	Binds to the insulin response element (IRE) with consensus sequence 5'-TT[G/A]TTTTG-3' and the related Daf-16 family binding element (DBE) with consensus sequence 5'-TT[G/A]TTTAC-3'. Activity suppressed by insulin. Main regulator of redox balance and osteoblast numbers and controls bone mass. Orchestrates the endocrine function of the skeleton in regulating glucose metabolism. Acts synergistically with ATF4 to suppress osteocalcin/BGLAP activity, increasing glucose levels and triggering glucose intolerance and insulin insensitivity. Also suppresses the transcriptional activity of RUNX2, an upstream activator of osteocalcin/BGLAP. In hepatocytes, promotes gluconeogenesis by acting together with PPARGC1A and CEBPA to activate the expression of genes such as IGFBP1, G6PC and PCK1. Important regulator of cell death acting downstream of CDK1, PKB/AKT1 and STK4/MST1. Promotes neural cell death. Mediates insulin action on adipose tissue. Regulates the expression of adipogenic genes such as PPARG during preadipocyte differentiation and, adipocyte size and adipose tissue-specific gene expression in response to excessive calorie intake. Regulates the transcriptional activity of GADD45A and repair of nitric oxide-damaged DNA in beta-cells. Required for the autophagic cell death induction in response to starvation or oxidative stress in a transcription-independent manner. Mediates the function of MLIP in cardiomyocytes hypertrophy and cardiac remodeling. Transcription factor that is the main target of insulin signaling and regulates metabolic homeostasis in response to oxidative stress.
T09935	PDBSTRUC	5DUI; 4LG0; 3COA; 3CO7; 3CO6
T09935	BIOCLASS	mRNA target
T09935	SEQUENCE	MAEAPQVVEIDPDFEPLPRPRSCTWPLPRPEFSQSNSATSSPAPSGSAAANPDAAAGLPSASAAAVSADFMSNLSLLEESEDFPQAPGSVAAAVAAAAAAAATGGLCGDFQGPEAGCLHPAPPQPPPPGPLSQHPPVPPAAAGPLAGQPRKSSSSRRNAWGNLSYADLITKAIESSAEKRLTLSQIYEWMVKSVPYFKDKGDSNSSAGWKNSIRHNLSLHSKFIRVQNEGTGKSSWWMLNPEGGKSGKSPRRRAASMDNNSKFAKSRSRAAKKKASLQSGQEGAGDSPGSQFSKWPASPGSHSNDDFDNWSTFRPRTSSNASTISGRLSPIMTEQDDLGEGDVHSMVYPPSAAKMASTLPSLSEISNPENMENLLDNLNLLSSPTSLTVSTQSSPGTMMQQTPCYSFAPPNTSLNSPSPNYQKYTYGQSSMSPLPQMPIQTLQDNKSSYGGMSQYNCAPGLLKELLTSDSPPHNDIMTPVDPGVAQPNSRVLGQNVMMGPNSVMSTYGSQASHNKMMNPSSHTHPGHAQQTSAVNGRPLPHTVSTMPHTSGMNRLTQVKTPVQVPLPHPMQMSALGGYSSVSSCNGYGRMGLLHQEKLPSDLDGMFIERLDCDMESIIRNDLMDGDTLDFNFDNVLPNQSFPHSVKTTTHSWVSG
T09935	DRUGINFO	D02DUM	ISIS 188780	Investigative
T09935	DRUGINFO	D09NLT	ISIS 188763	Investigative
T09935	DRUGINFO	D09XIQ	ISIS 188761	Investigative
T09935	DRUGINFO	D0D6YO	ISIS 188778	Investigative
T09935	DRUGINFO	D0L0JX	ISIS 188782	Investigative
T09935	DRUGINFO	D0L0WC	ISIS 188781	Investigative
T09935	DRUGINFO	D0N1RP	ISIS 188759	Investigative
T09935	DRUGINFO	D0O3QM	ISIS 188757	Investigative
T09935	DRUGINFO	D0U0OE	ISIS 188755	Investigative

T48791	TARGETID	T48791
T48791	FORMERID	TTDR01409
T48791	UNIPROID	M3K1_HUMAN
T48791	TARGNAME	MEKK1 messenger RNA (MAP3K1 mRNA)
T48791	GENENAME	MAP3K1
T48791	TARGTYPE	Literature-reported
T48791	SYNONYMS	Mitogenactivated protein kinase kinase kinase 1 (mRNA); Mitogen-activated protein kinase kinase kinase 1 (mRNA); MEKK1 (mRNA); MEKK 1 (mRNA); MEKK (mRNA); MEK kinase 1 (mRNA); MAPKKK1 (mRNA)
T48791	FUNCTION	Activates the ERK and JNK kinase pathways by phosphorylation of MAP2K1 and MAP2K4. May phosphorylate the MAPK8/JNK1 kinase. Activates CHUK and IKBKB, the central protein kinases of the NF-kappa-B pathway. Component of a protein kinase signal transduction cascade.
T48791	BIOCLASS	mRNA target
T48791	ECNUMBER	EC 2.7.11.25
T48791	SEQUENCE	MAAAAGNRASSSGFPGARATSPEAGGGGGALKASSAPAAAAGLLREAGSGGRERADWRRRQLRKVRSVELDQLPEQPLFLAASPPASSTSPSPEPADAAGSGTGFQPVAVPPPHGAASRGGAHLTESVAAPDSGASSPAAAEPGEKRAPAAEPSPAAAPAGREMENKETLKGLHKMDDRPEERMIREKLKATCMPAWKHEWLERRNRRGPVVVKPIPVKGDGSEMNHLAAESPGEVQASAASPASKGRRSPSPGNSPSGRTVKSESPGVRRKRVSPVPFQSGRITPPRRAPSPDGFSPYSPEETNRRVNKVMRARLYLLQQIGPNSFLIGGDSPDNKYRVFIGPQNCSCARGTFCIHLLFVMLRVFQLEPSDPMLWRKTLKNFEVESLFQKYHSRRSSRIKAPSRNTIQKFVSRMSNSHTLSSSSTSTSSSENSIKDEEEQMCPICLLGMLDEESLTVCEDGCRNKLHHHCMSIWAEECRRNREPLICPLCRSKWRSHDFYSHELSSPVDSPSSLRAAQQQTVQQQPLAGSRRNQESNFNLTHYGTQQIPPAYKDLAEPWIQVFGMELVGCLFSRNWNVREMALRRLSHDVSGALLLANGESTGNSGGSSGSSPSGGATSGSSQTSISGDVVEACCSVLSMVCADPVYKVYVAALKTLRAMLVYTPCHSLAERIKLQRLLQPVVDTILVKCADANSRTSQLSISTLLELCKGQAGELAVGREILKAGSIGIGGVDYVLNCILGNQTESNNWQELLGRLCLIDRLLLEFPAEFYPHIVSTDVSQAEPVEIRYKKLLSLLTFALQSIDNSHSMVGKLSRRIYLSSARMVTTVPHVFSKLLEMLSVSSSTHFTRMRRRLMAIADEVEIAEAIQLGVEDTLDGQQDSFLQASVPNNYLETTENSSPECTVHLEKTGKGLCATKLSASSEDISERLASISVGPSSSTTTTTTTTEQPKPMVQTKGRPHSQCLNSSPLSHHSQLMFPALSTPSSSTPSVPAGTATDVSKHRLQGFIPCRIPSASPQTQRKFSLQFHRNCPENKDSDKLSPVFTQSRPLPSSNIHRPKPSRPTPGNTSKQGDPSKNSMTLDLNSSSKCDDSFGCSSNSSNAVIPSDETVFTPVEEKCRLDVNTELNSSIEDLLEASMPSSDTTVTFKSEVAVLSPEKAENDDTYKDDVNHNQKCKEKMEAEEEEALAIAMAMSASQDALPIVPQLQVENGEDIIIIQQDTPETLPGHTKAKQPYREDTEWLKGQQIGLGAFSSCYQAQDVGTGTLMAVKQVTYVRNTSSEQEEVVEALREEIRMMSHLNHPNIIRMLGATCEKSNYNLFIEWMAGGSVAHLLSKYGAFKESVVINYTEQLLRGLSYLHENQIIHRDVKGANLLIDSTGQRLRIADFGAAARLASKGTGAGEFQGQLLGTIAFMAPEVLRGQQYGRSCDVWSVGCAIIEMACAKPPWNAEKHSNHLALIFKIASATTAPSIPSHLSPGLRDVALRCLELQPQDRPPSRELLKHPVFRTTW
T48791	DRUGINFO	D00UDD	ISIS 100913	Investigative
T48791	DRUGINFO	D01DVV	ISIS 100939	Investigative
T48791	DRUGINFO	D09BIH	ISIS 100935	Investigative
T48791	DRUGINFO	D0Q8XG	ISIS 100929	Investigative

T39134	TARGETID	T39134
T39134	FORMERID	TTDR01412
T39134	UNIPROID	NCOA4_HUMAN
T39134	TARGNAME	ARA70 messenger RNA (NCOA4 mRNA)
T39134	GENENAME	NCOA4
T39134	TARGTYPE	Literature-reported
T39134	SYNONYMS	Ret-activating protein ELE1 (mRNA); RFG (mRNA); Nuclear receptor coactivator 4 (mRNA); NCoA-4 (mRNA); ELE1 (mRNA); Androgen receptor-associated protein of 70 kDa (mRNA); Androgen receptor coactivator 70 kDa protein (mRNA); ARA70 (mRNA); ARA70 (dARA70N) (mRNA); 70 kDa androgen receptor coactivator (mRNA); 70 kDa AR-activator (mRNA)
T39134	FUNCTION	Ligand-independent coactivator of the peroxisome proliferator-activated receptor (PPAR) gamma. Enhances the androgen receptor transcriptional activity in prostate cancer cells.
T39134	PDBSTRUC	1T5Z
T39134	BIOCLASS	mRNA target
T39134	SEQUENCE	MNTFQDQSGSSSNREPLLRCSDARRDLELAIGGVLRAEQQIKDNLREVKAQIHSCISRHLECLRSREVWLYEQVDLIYQLKEETLQQQAQQLYSLLGQFNCLTHQLECTQNKDLANQVSVCLERLGSLTLKPEDSTVLLFEADTITLRQTITTFGSLKTIQIPEHLMAHASSANIGPFLEKRGCISMPEQKSASGIVAVPFSEWLLGSKPASGYQAPYIPSTDPQDWLTQKQTLENSQTSSRACNFFNNVGGNLKGLENWLLKSEKSSYQKCNSHSTTSSFSIEMEKVGDQELPDQDEMDLSDWLVTPQESHKLRKPENGSRETSEKFKLLFQSYNVNDWLVKTDSCTNCQGNQPKGVEIENLGNLKCLNDHLEAKKPLSTPSMVTEDWLVQNHQDPCKVEEVCRANEPCTSFAECVCDENCEKEALYKWLLKKEGKDKNGMPVEPKPEPEKHKDSLNMWLCPRKEVIEQTKAPKAMTPSRIADSFQVIKNSPLSEWLIRPPYKEGSPKEVPGTEDRAGKQKFKSPMNTSWCSFNTADWVLPGKKMGNLSQLSSGEDKWLLRKKAQEVLLNSPLQEEHNFPPDHYGLPAVCDLFACMQLKVDKEKWLYRTPLQM
T39134	DRUGINFO	D00EPB	ISIS 114397	Investigative
T39134	DRUGINFO	D01OOI	ISIS 114399	Investigative
T39134	DRUGINFO	D03MWW	ISIS 114372	Investigative
T39134	DRUGINFO	D03OGC	ISIS 114388	Investigative
T39134	DRUGINFO	D08RDK	ISIS 114371	Investigative
T39134	DRUGINFO	D0A2OL	ISIS 114390	Investigative
T39134	DRUGINFO	D0A6GY	ISIS 114442	Investigative
T39134	DRUGINFO	D0N7AB	ISIS 114404	Investigative

T78475	TARGETID	T78475
T78475	FORMERID	TTDR01415
T78475	UNIPROID	SMAD1_HUMAN
T78475	TARGNAME	Smad1 messenger RNA (SMAD1 mRNA)
T78475	GENENAME	SMAD1
T78475	TARGTYPE	Literature-reported
T78475	SYNONYMS	Transforming growth factor-beta-signaling protein 1 (mRNA); Smad1 (mRNA); SMAD family member 1 (mRNA); SMAD 1 (mRNA); Mothers against decapentaplegic homolog 1 (mRNA); Mothers against DPP homolog 1 (mRNA); Mad-related protein 1 (mRNA); MADR1 (mRNA); MADH1 (mRNA); MAD homolog 1 (mRNA); JV4-1 (mRNA); BSP1 (mRNA); BSP-1 (mRNA)
T78475	FUNCTION	SMAD1 is a receptor-regulated SMAD (R-SMAD). SMAD1/OAZ1/PSMB4 complex mediates the degradation of the CREBBP/EP300 repressor SNIP1. May act synergistically with SMAD4 and YY1 in bone morphogenetic protein (BMP)-mediated cardiac-specific gene expression. Transcriptional modulator activated by BMP (bone morphogenetic proteins) type 1 receptor kinase.
T78475	PDBSTRUC	5ZOK; 3Q4A; 3Q47; 2LB1; 2LB0
T78475	BIOCLASS	mRNA target
T78475	SEQUENCE	MNVTSLFSFTSPAVKRLLGWKQGDEEEKWAEKAVDALVKKLKKKKGAMEELEKALSCPGQPSNCVTIPRSLDGRLQVSHRKGLPHVIYCRVWRWPDLQSHHELKPLECCEFPFGSKQKEVCINPYHYKRVESPVLPPVLVPRHSEYNPQHSLLAQFRNLGQNEPHMPLNATFPDSFQQPNSHPFPHSPNSSYPNSPGSSSSTYPHSPTSSDPGSPFQMPADTPPPAYLPPEDPMTQDGSQPMDTNMMAPPLPSEINRGDVQAVAYEEPKHWCSIVYYELNNRVGEAFHASSTSVLVDGFTDPSNNKNRFCLGLLSNVNRNSTIENTRRHIGKGVHLYYVGGEVYAECLSDSSIFVQSRNCNYHHGFHPTTVCKIPSGCSLKIFNNQEFAQLLAQSVNHGFETVYELTKMCTIRMSFVKGWGAEYHRQDVTSTPCWIEIHLHGPLQWLDKVLTQMGSPHNPISSVS
T78475	DRUGINFO	D03IPJ	ISIS 28425	Investigative
T78475	DRUGINFO	D0D9WM	ISIS 28407	Investigative
T78475	DRUGINFO	D0X2HI	ISIS 28405	Investigative

T82372	TARGETID	T82372
T82372	FORMERID	TTDR01418
T82372	UNIPROID	STXB4_HUMAN
T82372	TARGNAME	STXBP4 messenger RNA (STXBP4 mRNA)
T82372	GENENAME	STXBP4
T82372	TARGTYPE	Literature-reported
T82372	SYNONYMS	Syntaxin-binding protein 4 (mRNA); Syntaxin 4-interacting protein (mRNA); Synip (mRNA); STX4-interacting protein (mRNA)
T82372	FUNCTION	Inhibits the translocation of SLC2A4 from intracellular vesicles to the plasma membrane by STX4A binding and preventing the interaction between STX4A and VAMP2. Stimulation with insulin disrupts the interaction with STX4A, leading to increased levels of SLC2A4 at the plasma membrane. May also play a role in the regulation of insulin release by pancreatic beta cells after stimulation by glucose. Plays a role in the translocation of transport vesicles from the cytoplasm to the plasma membrane.
T82372	PDBSTRUC	2YSG
T82372	BIOCLASS	mRNA target
T82372	SEQUENCE	MNKNTSTVVSPSLLEKDPAFQMITIAKETGLGLKVLGGINRNEGPLVYIQEIIPGGDCYKDGRLKPGDQLVSVNKESMIGVSFEEAKSIITGAKLRLESAWEIAFIRQKSDNIQPENLSCTSLIEASGEYGPQASTLSLFSSPPEILIPKTSSTPKTNNDILSSCEIKTGYNKTVQIPITSENSTVGLSNTDVASAWTENYGLQEKISLNPSVRFKAEKLEMALNYLGIQPTKEQHQALRQQVQADSKGTVSFGDFVQVARNLFCLQLDEVNVGAHEISNILDSQLLPCDSSEADEMERLKCERDDALKEVNTLKEKLLESDKQRKQLTEELQNVKQEAKAVVEETRALRSRIHLAEAAQRQAHGMEMDYEEVIRLLEAKITELKAQLADYSDQNKESVQDLKKRIMVLDCQLRKSEMARKTFEASTEKLLHFVEAIQEVFSDNSTPLSNLSERRAVLASQTSLTPLGRNGRSIPATLALESKELVKSVRALLDMDCLPYGWEEAYTADGIKYFINHVTQTTSWIHPVMSVLNLSRSEENEEDCSRELPNQKS
T82372	DRUGINFO	D06DMI	ISIS 119286	Investigative
T82372	DRUGINFO	D06LLJ	ISIS 119283	Investigative
T82372	DRUGINFO	D07JFD	ISIS 119263	Investigative
T82372	DRUGINFO	D0G0JO	ISIS 119282	Investigative
T82372	DRUGINFO	D0G9WZ	ISIS 119262	Investigative
T82372	DRUGINFO	D0L6SQ	ISIS 119284	Investigative
T82372	DRUGINFO	D0M2JM	ISIS 119285	Investigative
T82372	DRUGINFO	D0RD7X	ISIS 119281	Investigative
T82372	DRUGINFO	D0Y5GA	ISIS 119264	Investigative

T53734	TARGETID	T53734
T53734	FORMERID	TTDI02661
T53734	UNIPROID	COP1_HUMAN
T53734	TARGNAME	COP1 messenger RNA (COP1 mRNA)
T53734	GENENAME	RFWD2
T53734	TARGTYPE	Literature-reported
T53734	SYNONYMS	hCOP1 (mRNA); RNF200 (mRNA); RING-type E3 ubiquitin transferase RFWD2 (mRNA); RING finger protein 200 (mRNA); RING finger and WD repeat domain protein 2 (mRNA); E3 ubiquitinprotein ligase RFWD2 (mRNA); Constitutive photomorphogenesis protein 1 homolog (mRNA); COP1 (mRNA)
T53734	FUNCTION	E3 ubiquitin ligases accept ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. Involved in JUN ubiquitination and degradation. Directly involved in p53 (TP53) ubiquitination and degradation, thereby abolishing p53-dependent transcription and apoptosis. Ubiquitinates p53 independently of MDM2 or RCHY1. Probably mediates E3 ubiquitin ligase activity by functioning as the essential RING domain subunit of larger E3 complexes. In contrast, it does not constitute the catalytic RING subunit in the DCX DET1-COP1 complex that negatively regulates JUN, the ubiquitin ligase activity being mediated by RBX1. Involved in 14-3-3 protein sigma/SFN ubiquitination and proteasomal degradation, leading to AKT activation and promotion of cell survival. Ubiquitinates MTA1 leading to its proteasomal degradation. Upon binding to TRIB1, ubiquitinates CEBPA, which lacks a canonical COP1-binding motif. E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of target proteins.
T53734	PDBSTRUC	5IGQ; 5HQG
T53734	BIOCLASS	mRNA target
T53734	ECNUMBER	EC 2.3.2.27
T53734	SEQUENCE	MSGSRQAGSGSAGTSPGSSAASSVTSASSSLSSSPSPPSVAVSAAALVSGGVAQAAGSGGLGGPVRPVLVAPAVSGSGGGAVSTGLSRHSCAARPSAGVGGSSSSLGSGSRKRPLLAPLCNGLINSYEDKSNDFVCPICFDMIEEAYMTKCGHSFCYKCIHQSLEDNNRCPKCNYVVDNIDHLYPNFLVNELILKQKQRFEEKRFKLDHSVSSTNGHRWQIFQDWLGTDQDNLDLANVNLMLELLVQKKKQLEAESHAAQLQILMEFLKVARRNKREQLEQIQKELSVLEEDIKRVEEMSGLYSPVSEDSTVPQFEAPSPSHSSIIDSTEYSQPPGFSGSSQTKKQPWYNSTLASRRKRLTAHFEDLEQCYFSTRMSRISDDSRTASQLDEFQECLSKFTRYNSVRPLATLSYASDLYNGSSIVSSIEFDRDCDYFAIAGVTKKIKVYEYDTVIQDAVDIHYPENEMTCNSKISCISWSSYHKNLLASSDYEGTVILWDGFTGQRSKVYQEHEKRCWSVDFNLMDPKLLASGSDDAKVKLWSTNLDNSVASIEAKANVCCVKFSPSSRYHLAFGCADHCVHYYDLRNTKQPIMVFKGHRKAVSYAKFVSGEEIVSASTDSQLKLWNVGKPYCLRSFKGHINEKNFVGLASNGDYIACGSENNSLYLYYKGLSKTLLTFKFDTVKSVLDKDRKEDDTNEFVSAVCWRALPDGESNVLIAANSQGTIKVLELV

T60004	TARGETID	T60004
T60004	FORMERID	TTDI02656
T60004	UNIPROID	CSN5_HUMAN
T60004	TARGNAME	COPS5 messenger RNA (COPS5 mRNA)
T60004	GENENAME	COPS5
T60004	TARGTYPE	Literature-reported
T60004	SYNONYMS	Signalosome subunit 5 (mRNA); SGN5 (mRNA); Jun activation domain-binding protein 1 (mRNA); JAB1 (mRNA); CSN5 (mRNA); COP9 signalosome complex subunit 5 (mRNA)
T60004	FUNCTION	The CSN complex is an essential regulator of the ubiquitin (Ubl) conjugation pathway by mediating the deneddylation of the cullin subunits of the SCF-type E3 ligase complexes, leading to decrease the Ubl ligase activity of SCF-type complexes such as SCF, CSA or DDB2. The complex is also involved in phosphorylation of p53/TP53, c-jun/JUN, IkappaBalpha/NFKBIA, ITPK1 and IRF8, possibly via its association with CK2 and PKD kinases. CSN-dependent phosphorylation of TP53 and JUN promotes and protects degradation by the Ubl system, respectively. In the complex, it probably acts as the catalytic center that mediates the cleavage of Nedd8 from cullins. It however has no metalloprotease activity by itself and requires the other subunits of the CSN complex. Interacts directly with a large number of proteins that are regulated by the CSN complex, confirming a key role in the complex. Promotes the proteasomal degradation of BRSK2. Probable protease subunit of the COP9 signalosome complex (CSN), a complex involved in various cellular and developmental processes.
T60004	PDBSTRUC	5M5Q; 5JOH; 5JOG; 4WSN; 4F7O
T60004	BIOCLASS	mRNA target
T60004	ECNUMBER	EC 3.4.-.-
T60004	SEQUENCE	MAASGSGMAQKTWELANNMQEAQSIDEIYKYDKKQQQEILAAKPWTKDHHYFKYCKISALALLKMVMHARSGGNLEVMGLMLGKVDGETMIIMDSFALPVEGTETRVNAQAAAYEYMAAYIENAKQVGRLENAIGWYHSHPGYGCWLSGIDVSTQMLNQQFQEPFVAVVIDPTRTISAGKVNLGAFRTYPKGYKPPDEGPSEYQTIPLNKIEDFGVHCKQYYALEVSYFKSSLDRKLLELLWNKYWVNTLSSSSLLTNADYTTGQVFDLSEKLEQSEAQLGRGSFMLGLETHDRKSEDKLAKATRDSCKTTIEAIHGLMSQVIKDKLFNQINIS

T85056	TARGETID	T85056
T85056	FORMERID	TTDR01421
T85056	UNIPROID	CYH2_HUMAN
T85056	TARGNAME	Cytohesin-2 messenger RNA (CYTH2 mRNA)
T85056	GENENAME	CYTH2
T85056	TARGTYPE	Literature-reported
T85056	SYNONYMS	Protein ARNO (mRNA); PSCD2L (mRNA); PSCD2 (mRNA); PH, SEC7 and coiled-coil domain-containing protein 2 (mRNA); Cytohesin-2 (mRNA); CYTH2 (mRNA); ARNO (mRNA); ARF nucleotide-binding site opener (mRNA); ARF exchange factor (mRNA)
T85056	FUNCTION	Promotes guanine-nucleotide exchange on ARF1, ARF3 and ARF6. Activates ARF factors through replacement of GDP with GTP. The cell membrane form, in association with ARL4 proteins, recruits ARF6 to the plasma membrane. Involved in neurite growth. Acts as a guanine-nucleotide exchange factor (GEF).
T85056	PDBSTRUC	4Z21; 4L5M; 4JXH; 4JWL; 4JMO
T85056	BIOCLASS	mRNA target
T85056	SEQUENCE	MEDGVYEPPDLTPEERMELENIRRRKQELLVEIQRLREELSEAMSEVEGLEANEGSKTLQRNRKMAMGRKKFNMDPKKGIQFLVENELLQNTPEEIARFLYKGEGLNKTAIGDYLGEREELNLAVLHAFVDLHEFTDLNLVQALRQFLWSFRLPGEAQKIDRMMEAFAQRYCLCNPGVFQSTDTCYVLSFAVIMLNTSLHNPNVRDKPGLERFVAMNRGINEGGDLPEELLRNLYDSIRNEPFKIPEDDGNDLTHTFFNPDREGWLLKLGGGRVKTWKRRWFILTDNCLYYFEYTTDKEPRGIIPLENLSIREVDDPRKPNCFELYIPNNKGQLIKACKTEADGRVVEGNHMVYRISAPTQEEKDEWIKSIQAAVSVDPFYEMLAARKKRISVKKKQEQP
T85056	DRUGINFO	D01QNF	ISIS 111117	Investigative
T85056	DRUGINFO	D02GIB	ISIS 111119	Investigative
T85056	DRUGINFO	D05ZKG	ISIS 111105	Investigative
T85056	DRUGINFO	D08JIG	ISIS 111086	Investigative
T85056	DRUGINFO	D0A0VB	ISIS 111118	Investigative
T85056	DRUGINFO	D0F3PC	ISIS 111121	Investigative
T85056	DRUGINFO	D0F8HG	ISIS 111120	Investigative
T85056	DRUGINFO	D0L7DD	ISIS 111085	Investigative
T85056	DRUGINFO	D0Q6XR	ISIS 111084	Investigative

T14113	TARGETID	T14113
T14113	FORMERID	TTDR01429
T14113	UNIPROID	RDRP_I97A1
T14113	TARGNAME	Influenza PB1 messenger RNA (Influ PB1 mRNA)
T14113	GENENAME	Influ PB1 mRNA
T14113	TARGTYPE	Literature-reported
T14113	SYNONYMS	RNA-directed RNA polymerase subunit P1 (mRNA); RNA-directed RNA polymerase catalytic subunit (mRNA); Polymerase basic protein 1 (mRNA)
T14113	FUNCTION	The transcription of viral mRNAs occurs by a unique mechanism called cap-snatching. 5' methylated caps of cellular mRNAs are cleaved after 10-13 nucleotides by PA. In turn, these short capped RNAs are used as primers by PB1 for transcription of viral mRNAs. During virus replication, PB1 initiates RNA synthesis and copy vRNA into complementary RNA (cRNA) which in turn serves as a template for the production of more vRNAs. RNA-dependent RNA polymerase which is responsible for replication and transcription of virus RNA segments.
T14113	PDBSTRUC	3CM8
T14113	BIOCLASS	mRNA target
T14113	ECNUMBER	EC 2.7.7.48
T14113	SEQUENCE	MDVNPTLLFLKVPAQNAISTTFPYTGDPPYSHGTGTGYTMDTVNRTHQYSEKGRWTTNTETGAPQLNPIDGPLPEDNEPSGYAQTDCVLEAMAFLEESHPGLFENSCLETMEVVQQTRMDKLTQGRQTYDWTLNRNQPAATALANTIEVFRSNGLTANESGRLIDFLKDVMESMDKEEMEITTHFQRKRRVRDNMTKKMVTQRTIGKKKQRLTKKSYLIRALTLNTMTKDAERGKLKRRAIATPGMQIRGFVHFVEALARSICEKLEQSGLPVGGNEKKAKLANVVRKMMTNSQDTELSFTVTGDNTKWNENQNPRIFLAMITYITRNQPEWFRNVLSIAPIMFSNKMARLGKGYMFESKSMKLRTQIPAEMLANIDLKYFNESTRKKIEKIRPLLVEGTASLSPGMMMGMFNMLSTVLGVSILNLGQKRYTKTTYWWDGLQSSDDFALIVNAPNHEGIQAGVDRFYRTCKLVGINMSKKKSYINRTGTFEFTSFFYRYGFVANFSMELPSFGVSGINESADMSIGVTVIKNNMINNDLGPATAQMALQLFIKDYRYTYRCHRGDTQIQTRRSFELKKLWEQTRSKAGLLVSDGGPNLYNIRNLHIPEVGLKWELMDEDYQGRLCNPLNPFVSHKEVESVNNAVVMPAHGPAKSMEYDAVATTHSWIPKRNRSILNTSQRGILEDEQMYQKCCTLFEKFFPSSSYRRPVGISSMMEAMVSRARIDARIDFESGRIKKEEFAEILKICSTIEELGRQGK
T14113	DRUGINFO	D0EJ7Q	ISIS 3304	Investigative

T52796	TARGETID	T52796
T52796	FORMERID	TTDR01430
T52796	UNIPROID	JAG2_HUMAN
T52796	TARGNAME	Jagged2 messenger RNA (JAG2 mRNA)
T52796	GENENAME	JAG2
T52796	TARGTYPE	Literature-reported
T52796	SYNONYMS	hJ2 (mRNA); Protein jagged-2 (mRNA); Jagged2 (mRNA)
T52796	FUNCTION	Involved in limb development. Putative Notch ligand involved in the mediation of Notch signaling.
T52796	PDBSTRUC	5MWF; 5MW7; 5MW5
T52796	BIOCLASS	mRNA target
T52796	SEQUENCE	MRAQGRGRLPRRLLLLLALWVQAARPMGYFELQLSALRNVNGELLSGACCDGDGRTTRAGGCGHDECDTYVRVCLKEYQAKVTPTGPCSYGHGATPVLGGNSFYLPPAGAAGDRARARARAGGDQDPGLVVIPFQFAWPRSFTLIVEAWDWDNDTTPNEELLIERVSHAGMINPEDRWKSLHFSGHVAHLELQIRVRCDENYYSATCNKFCRPRNDFFGHYTCDQYGNKACMDGWMGKECKEAVCKQGCNLLHGGCTVPGECRCSYGWQGRFCDECVPYPGCVHGSCVEPWQCNCETNWGGLLCDKDLNYCGSHHPCTNGGTCINAEPDQYRCTCPDGYSGRNCEKAEHACTSNPCANGGSCHEVPSGFECHCPSGWSGPTCALDIDECASNPCAAGGTCVDQVDGFECICPEQWVGATCQLDANECEGKPCLNAFSCKNLIGGYYCDCIPGWKGINCHINVNDCRGQCQHGGTCKDLVNGYQCVCPRGFGGRHCELERDECASSPCHSGGLCEDLADGFHCHCPQGFSGPLCEVDVDLCEPSPCRNGARCYNLEGDYYCACPDDFGGKNCSVPREPCPGGACRVIDGCGSDAGPGMPGTAASGVCGPHGRCVSQPGGNFSCICDSGFTGTYCHENIDDCLGQPCRNGGTCIDEVDAFRCFCPSGWEGELCDTNPNDCLPDPCHSRGRCYDLVNDFYCACDDGWKGKTCHSREFQCDAYTCSNGGTCYDSGDTFRCACPPGWKGSTCAVAKNSSCLPNPCVNGGTCVGSGASFSCICRDGWEGRTCTHNTNDCNPLPCYNGGICVDGVNWFRCECAPGFAGPDCRINIDECQSSPCAYGATCVDEINGYRCSCPPGRAGPRCQEVIGFGRSCWSRGTPFPHGSSWVEDCNSCRCLDGRRDCSKVWCGWKPCLLAGQPEALSAQCPLGQRCLEKAPGQCLRPPCEAWGECGAEEPPSTPCLPRSGHLDNNCARLTLHFNRDHVPQGTTVGAICSGIRSLPATRAVARDRLLVLLCDRASSGASAVEVAVSFSPARDLPDSSLIQGAAHAIVAAITQRGNSSLLLAVTEVKVETVVTGGSSTGLLVPVLCGAFSVLWLACVVLCVWWTRKRRKERERSRLPREESANNQWAPLNPIRNPIERPGGHKDVLYQCKNFTPPPRRADEALPGPAGHAAVREDEEDEDLGRGEEDSLEAEKFLSHKFTKDPGRSPGRPAHWASGPKVDNRAVRSINEARYAGKE
T52796	DRUGINFO	D0T5NX	ISIS 148715	Investigative

T70367	TARGETID	T70367
T70367	FORMERID	TTDR01433
T70367	UNIPROID	TLN1_HUMAN
T70367	TARGNAME	Talin messenger RNA (TLN1 mRNA)
T70367	GENENAME	TLN1
T70367	TARGTYPE	Literature-reported
T70367	SYNONYMS	Talin-1 (mRNA); TLN (mRNA); KIAA1027 (mRNA)
T70367	FUNCTION	High molecular weight cytoskeletal protein concentrated at regions of cell-substratum contact and, in lymphocytes, at cell-cell contacts. Probably involved in connections of major cytoskeletal structures to the plasma membrane.
T70367	PDBSTRUC	4DJ9; 2MWN; 1SYQ
T70367	BIOCLASS	mRNA target
T70367	SEQUENCE	MVALSLKISIGNVVKTMQFEPSTMVYDACRIIRERIPEAPAGPPSDFGLFLSDDDPKKGIWLEAGKALDYYMLRNGDTMEYRKKQRPLKIRMLDGTVKTIMVDDSKTVTDMLMTICARIGITNHDEYSLVRELMEEKKEEITGTLRKDKTLLRDEKKMEKLKQKLHTDDELNWLDHGRTLREQGVEEHETLLLRRKFFYSDQNVDSRDPVQLNLLYVQARDDILNGSHPVSFDKACEFAGFQCQIQFGPHNEQKHKAGFLDLKDFLPKEYVKQKGERKIFQAHKNCGQMSEIEAKVRYVKLARSLKTYGVSFFLVKEKMKGKNKLVPRLLGITKECVMRVDEKTKEVIQEWNLTNIKRWAASPKSFTLDFGDYQDGYYSVQTTEGEQIAQLIAGYIDIILKKKKSKDHFGLEGDEESTMLEDSVSPKKSTVLQQQYNRVGKVEHGSVALPAIMRSGASGPENFQVGSMPPAQQQITSGQMHRGHMPPLTSAQQALTGTINSSMQAVQAAQATLDDFDTLPPLGQDAASKAWRKNKMDESKHEIHSQVDAITAGTASVVNLTAGDPAETDYTAVGCAVTTISSNLTEMSRGVKLLAALLEDEGGSGRPLLQAAKGLAGAVSELLRSAQPASAEPRQNLLQAAGNVGQASGELLQQIGESDTDPHFQDALMQLAKAVASAAAALVLKAKSVAQRTEDSGLQTQVIAAATQCALSTSQLVACTKVVAPTISSPVCQEQLVEAGRLVAKAVEGCVSASQAATEDGQLLRGVGAAATAVTQALNELLQHVKAHATGAGPAGRYDQATDTILTVTENIFSSMGDAGEMVRQARILAQATSDLVNAIKADAEGESDLENSRKLLSAAKILADATAKMVEAAKGAAAHPDSEEQQQRLREAAEGLRMATNAAAQNAIKKKLVQRLEHAAKQAAASATQTIAAAQHAASTPKASAGPQPLLVQSCKAVAEQIPLLVQGVRGSQAQPDSPSAQLALIAASQSFLQPGGKMVAAAKASVPTIQDQASAMQLSQCAKNLGTALAELRTAAQKAQEACGPLEMDSALSVVQNLEKDLQEVKAAARDGKLKPLPGETMEKCTQDLGNSTKAVSSAIAQLLGEVAQGNENYAGIAARDVAGGLRSLAQAARGVAALTSDPAVQAIVLDTASDVLDKASSLIEEAKKAAGHPGDPESQQRLAQVAKAVTQALNRCVSCLPGQRDVDNALRAVGDASKRLLSDSLPPSTGTFQEAQSRLNEAAAGLNQAATELVQASRGTPQDLARASGRFGQDFSTFLEAGVEMAGQAPSQEDRAQVVSNLKGISMSSSKLLLAAKALSTDPAAPNLKSQLAAAARAVTDSINQLITMCTQQAPGQKECDNALRELETVRELLENPVQPINDMSYFGCLDSVMENSKVLGEAMTGISQNAKNGNLPEFGDAISTASKALCGFTEAAAQAAYLVGVSDPNSQAGQQGLVEPTQFARANQAIQMACQSLGEPGCTQAQVLSAATIVAKHTSALCNSCRLASARTTNPTAKRQFVQSAKEVANSTANLVKTIKALDGAFTEENRAQCRAATAPLLEAVDNLSAFASNPEFSSIPAQISPEGRAAMEPIVISAKTMLESAGGLIQTARALAVNPRDPPSWSVLAGHSRTVSDSIKKLITSMRDKAPGQLECETAIAALNSCLRDLDQASLAAVSQQLAPREGISQEALHTQMLTAVQEISHLIEPLANAARAEASQLGHKVSQMAQYFEPLTLAAVGAASKTLSHPQQMALLDQTKTLAESALQLLYTAKEAGGNPKQAAHTQEALEEAVQMMTEAVEDLTTTLNEAASAAGVVGGMVDSITQAINQLDEGPMGEPEGSFVDYQTTMVRTAKAIAVTVQEMVTKSNTSPEELGPLANQLTSDYGRLASEAKPAAVAAENEEIGSHIKHRVQELGHGCAALVTKAGALQCSPSDAYTKKELIECARRVSEKVSHVLAALQAGNRGTQACITAASAVSGIIADLDTTIMFATAGTLNREGTETFADHREGILKTAKVLVEDTKVLVQNAAGSQEKLAQAAQSSVATITRLADVVKLGAASLGAEDPETQVVLINAVKDVAKALGDLISATKAAAGKVGDDPAVWQLKNSAKVMVTNVTSLLKTVKAVEDEATKGTRALEATTEHIRQELAVFCSPEPPAKTSTPEDFIRMTKGITMATAKAVAAGNSCRQEDVIATANLSRRAIADMLRACKEAAYHPEVAPDVRLRALHYGRECANGYLELLDHVLLTLQKPSPELKQQLTGHSKRVAGSVTELIQAAEAMKGTEWVDPEDPTVIAENELLGAAAAIEAAAKKLEQLKPRAKPKEADESLNFEEQILEAAKSIAAATSALVKAASAAQRELVAQGKVGAIPANALDDGQWSQGLISAARMVAAATNNLCEAANAAVQGHASQEKLISSAKQVAASTAQLLVACKVKADQDSEAMKRLQAAGNAVKRASDNLVKAAQKAAAFEEQENETVVVKEKMVGGIAQIIAAQEEMLRKERELEEARKKLAQIRQQQYKFLPSELRDEH
T70367	DRUGINFO	D01XJR	ISIS 109116	Investigative
T70367	DRUGINFO	D08IDM	ISIS 109111	Investigative
T70367	DRUGINFO	D09JJF	ISIS 109113	Investigative
T70367	DRUGINFO	D0A9EI	ISIS 109114	Investigative
T70367	DRUGINFO	D0E8IK	ISIS 109112	Investigative
T70367	DRUGINFO	D0V2QL	ISIS 109110	Investigative
T70367	DRUGINFO	D0Z8DM	ISIS 109115	Investigative

T24800	TARGETID	T24800
T24800	FORMERID	TTDR01434
T24800	UNIPROID	TNR11_HUMAN
T24800	TARGNAME	RANK messenger RNA (RANK mRNA)
T24800	GENENAME	TNFRSF11A
T24800	TARGTYPE	Literature-reported
T24800	SYNONYMS	Tumor necrosis factor receptor superfamily member 11A (mRNA); Receptor activator of NF-KB (mRNA); RANK (mRNA); Osteoclast differentiation factor receptor (mRNA); ODFR (mRNA); CD265 (mRNA)
T24800	FUNCTION	Involved in the regulation of interactions between T-cells and dendritic cells. Receptor for TNFSF11/RANKL/TRANCE/OPGL; essential for RANKL-mediated osteoclastogenesis.
T24800	PDBSTRUC	1LB5
T24800	BIOCLASS	mRNA target
T24800	SEQUENCE	MAPRARRRRPLFALLLLCALLARLQVALQIAPPCTSEKHYEHLGRCCNKCEPGKYMSSKCTTTSDSVCLPCGPDEYLDSWNEEDKCLLHKVCDTGKALVAVVAGNSTTPRRCACTAGYHWSQDCECCRRNTECAPGLGAQHPLQLNKDTVCKPCLAGYFSDAFSSTDKCRPWTNCTFLGKRVEHHGTEKSDAVCSSSLPARKPPNEPHVYLPGLIILLLFASVALVAAIIFGVCYRKKGKALTANLWHWINEACGRLSGDKESSGDSCVSTHTANFGQQGACEGVLLLTLEEKTFPEDMCYPDQGGVCQGTCVGGGPYAQGEDARMLSLVSKTEIEEDSFRQMPTEDEYMDRPSQPTDQLLFLTEPGSKSTPPFSEPLEVGENDSLSQCFTGTQSTVGSESCNCTEPLCRTDWTPMSSENYLQKEVDSGHCPHWAASPSPNWADVCTGCRNPPGEDCEPLVGSPKRGPLPQCAYGMGLPPEEEASRTEARDQPEDGADGRLPSSARAGAGSGSSPGGQSPASGNVTGNSNSTFISSGQVMNFKGDIIVVYVSQTSQEGAAAAAEPMGRPVQEETLARRDSFAGNGPRFPDPCGGPEGLREPEKASRPVQEQGGAKA
T24800	DRUGINFO	D01TAJ	ISIS 109525	Investigative
T24800	DRUGINFO	D02VPR	ISIS 109491	Investigative
T24800	DRUGINFO	D02ZTS	ISIS 109526	Investigative
T24800	DRUGINFO	D07HSU	ISIS 109524	Investigative
T24800	DRUGINFO	D0E8GT	ISIS 109502	Investigative
T24800	DRUGINFO	D0U7AA	ISIS 109490	Investigative

T96816	TARGETID	T96816
T96816	FORMERID	TTDR00360
T96816	UNIPROID	A0A1C3KAW3_PLAMA
T96816	TARGNAME	Plasmodium Enopyruvyl shikimate phosphate synthase (Malaria ESPS)
T96816	GENENAME	Malaria ESPS
T96816	TARGTYPE	Literature-reported
T96816	SYNONYMS	aroA of Aeropyrum pernix; Probable 3-phosphoshikimate 1-carboxyvinyltransferase of Aeropyrum pernix; EPSPS of Aeropyrum pernix; EPSP synthase of Aeropyrum pernix; 5-enolpyruvylshikimate-3-phosphate synthase of Aeropyrum pernix
T96816	FUNCTION	Catalyzes the transfer of the enolpyruvyl moiety of phosphoenolpyruvate (PEP) to the 5-hydroxyl of shikimate-3- phosphate (S3P) to produce enolpyruvyl shikimate-3-phosphate and inorganic phosphate.
T96816	BIOCLASS	Alkyl aryl transferase
T96816	ECNUMBER	EC 1.1.1.25
T96816	SEQUENCE	MCNKKCGPKCNEKYSEGGRNKGRTTNSSVEMIKHKNILSENKKRNRSDVEKYVQEEYTISDKFKGIIKQMINNHGTGSFEIGNVLIIVLNMKKYHDKSEKCKEFGKMLQEISISSKNELICFADTNIMDLLHFTYHLYFKGAHGTVALHSIEVYILTSLFKTSNAKEHKRGLSEALRLAILNDKNMFIRIKKNDLNYFVKNLKYFLNKCILNIRDIIKKGENNAKYIHVLSFGNTIGNAIKNVIKNSPGCTYINDRDYINYGIFYELKIMYELDAIDMLLLLNIEEIMIKYKLKYKLDSNFVNYYTNDIITYLHKTHSSTTNEIPLVHILNINKIQKNVLVHTPLSIIIKVFYPFICLSPFHNISTTSAQEGEFIGIVNEDRDGMIHTSTTIDMVQKKKEHTIRKINYVYLQGVGNKSEIIRVIYVSTMGRQNVRIENMNLCFDVIVFIKILKDLNFQIFLKKKKSNDIYTNVNRTVIRNCLFINGNVEQTVFLFKNFIFQKKIILNIYNSGTVCRFLLPLLCLYICKQNLKAKEEKKQLLKYIILKGDEQMESHRVINPLVNVVLKCFKYVKIKYLKKKNYLPICIYVKREIHESYTLFCSNDVAIDNYHSSQFVSSMLLISVYSETDTCIRLKFKKIHNCLNRSKKIKVKKEQKKKKITIFRKYIKRKEVSRFKCSYYTMLSICWSCNGKKCNSINKGSTLCCKCSSSPDFNFDENYRHPRKRYNWYNFGYPINEIRNRMNSSNFSTTSKAFIDLTVRVMKLWGVRVKMKRNNYTIKKNEKYLLYSNNNDSTSIRGIAGNRSSIKSRTSNRICRSGGNKNERFNNVHYKYASMINRKHHFNDSRHILFPGIHNKKEKMLVYSLHGRGEKSSKGSCDTCKQKGVDEVKKEVHNNPHEEYNFVMLKQKEKVDQINNKEKEEDKNISNDVTNDGGYTLVKNILRYEINNDLGLYFYFIIGSLIKRQNCVIFLKLNINRMKLKNVGKGYYKIETIDFQKNVLNYFLLNILLLLGINMYINMNDEIRKIYLLTSKRMNIKKKKIIRHLEKAIRNKWKRKNGYYKKRHRNIYTTACYGVNNSTCEHLSQGECTFKYYIFEKIYMKYKIMHFRNVLLKIVVDAEYFSDDFFSICVLFCYYLLTHERENNTELLFKIKNIHNQNIKESIRILNAVLILKICFHNILFIFCDNNSIYITKTHHQIQNCLFFKCKREHWALLCTSSDNNERKNNSSSIGSNSNNGNNNRRSRCKKKLFFNNSKYVINDDQELYLYIDAKKDHRIIFMATILSLIFKNIIIDNSYEVEKSYPHFYEQARKYLEININYVNSDNVKFHNFEEVNNYNILNEQDSKSCVEVISSSIESHESTYSCTDASRSDVDMLKNYKSPTMSTEGNYSINTRSKKLINKHTNCNSLNRPMENNTCTEKNFYKTNGAHIIHKKEANRTHRSTRGNLYFMNHEYWKTSNLNLKNVVMKKTKKCIHRKRAPKGIINLCNLTNPMLQLHTCGSTGSIASEENELTVMRCGERKGIISRKGIFTVSNSGGSDSYSDSYSDSYSDSFMKCNEDPSNERSNECNKDHSNERSNGSSKWFERRGGTEEGYQTKLRLNLRERLRSGKSSSFLNKVKNQLNGDKTNLFLPSDTNYMRTYKYEEVKVNNGNVFYLLKEINNLNVHIICGIRNVGKSYLGHRIENSLVIDIDEYILNGQISFDKLTIDDFRFYEYITFVSALYLSYCLLTLKNYLWANISGSISCNDRGDVWSNIQSSMHGNDDKKDVFLCRAENSKVCINRSCVAVHAYFDNIFFCMGNDIIFYNKKINDLYYNLKNKLLTCKNYDINSITIVLGGGIIEFYKSRQVLKKLKNVVLIKRNKRELCDICINDNVKPKLSGNIKEIINRRTVLFDELNSFHFSIPSEIKISNHIKNLKESRNKLIVSSFINFFNYKFFVKPTILDWGAIRTLSIHLKFFHSFDYELLRSSYDVVEIVYEHIGSTKDGQSEQKDGSGQRGCVEQRGCNERRCRGEELDMGGQHDQRGKNRKYAKNEEKLLALAIFIIRSYTTKPIAVKLHTSIFHAQFFKIKNRCTKLKKDGKKNVAHLFCNNLLNVLYKYKINIVEVDIKFLKVVKYFLAHKKKKANIFFIISKHRNKVNKLKIKSDLNKLNIFHADLIKLTYNYASKSDKEFLSKTINAYNSHRLINTKLSRIKNVYNNTNEEISLYSCYVNNSFVFLYNNVTHLEYQKTNLRNLETGKNSKNIENHNYDENKKNRDFYHNNFMYGFYYQKVKSIISYVPTEGDK
T96816	DRUGINFO	D04HMD	Glyphosate	Investigative

T10063	TARGETID	T10063
T10063	FORMERID	TTDNR00723
T10063	UNIPROID	GLMM_MYCTA
T10063	TARGNAME	Mycobacterium Phosphoglucosamine mutase (MycB glmM)
T10063	GENENAME	MycB glmM
T10063	TARGTYPE	Literature-reported
T10063	SYNONYMS	glmM of Mycobacterium tuberculosis
T10063	FUNCTION	Catalyzes the conversion of glucosamine-6-phosphate to glucosamine-1-phosphate.
T10063	BIOCLASS	Intramolecular transferases
T10063	ECNUMBER	EC 5.4.2.10
T10063	SEQUENCE	MGRLFGTDGVRGVANRELTAELALALGAAAARRLSRSGAPGRRVAVLGRDPRASGEMLEAAVIAGLTSEGVDALRVGVLPTPAVAYLTGAYDADFGVMISASHNPMPDNGIKIFGPGGHKLDDDTEDQIEDLVLGVSRGPGLRPAGAGIGRVIDAEDATERYLRHVAKAATARLDDLAVVVDCAHGAASSAAPRAYRAAGARVIAINAEPNGRNINDGCGSTHLDPLRAAVLAHRADLGLAHDGDADRCLAVDANGDLVDGDAIMVVLALAMKEAGELACNTLVATVMSNLGLHLAMRSAGVTVRTTAVGDRYVLEELRAGDYSLGGEQSGHIVMPALGSTGDGIVTGLRLMTRMVQTGSSLSDLASAMRTLPQVLINVEVVDKATAAAAPSVRTAVEQAAAELGDTGRILLRPSGTEPMIRVMVEAADEGVAQRLAATVADAVSTAR

T47995	TARGETID	T47995
T47995	FORMERID	TTDR00495
T47995	UNIPROID	CLCA1_HUMAN
T47995	TARGNAME	Calcium-activated chloride channel protein 1 (CaCC-1)
T47995	GENENAME	CLCA1
T47995	TARGTYPE	Literature-reported
T47995	SYNONYMS	hCaCC-1; hCLCA1; Calcium-activated chloride channel regulator 1; Calcium-activated chloride channel family member 1; CaCC-1; CACC1
T47995	FUNCTION	May be involved in mediating calcium-activated chloride conductance. May play critical roles in goblet cell metaplasia, mucus hypersecretion, cystic fibrosis and AHR. May be involved in the regulation of mucus production and/or secretion by goblet cells. Involved in the regulation of tissue inflammation in the innate immune response. May play a role as a tumor suppressor. Induces MUC5AC.
T47995	BIOCLASS	Voltage-gated ion channel
T47995	ECNUMBER	EC 3.4.-.-
T47995	SEQUENCE	MGPFKSSVFILILHLLEGALSNSLIQLNNNGYEGIVVAIDPNVPEDETLIQQIKDMVTQASLYLLEATGKRFYFKNVAILIPETWKTKADYVRPKLETYKNADVLVAESTPPGNDEPYTEQMGNCGEKGERIHLTPDFIAGKKLAEYGPQGRAFVHEWAHLRWGVFDEYNNDEKFYLSNGRIQAVRCSAGITGTNVVKKCQGGSCYTKRCTFNKVTGLYEKGCEFVLQSRQTEKASIMFAQHVDSIVEFCTEQNHNKEAPNKQNQKCNLRSTWEVIRDSEDFKKTTPMTTQPPNPTFSLLQIGQRIVCLVLDKSGSMATGNRLNRLNQAGQLFLLQTVELGSWVGMVTFDSAAHVQNELIQINSGSDRDTLAKRLPAAASGGTSICSGLRSAFTVIRKKYPTDGSEIVLLTDGEDNTISGCFNEVKQSGAIIHTVALGPSAAQELEELSKMTGGLQTYASDQVQNNGLIDAFGALSSGNGAVSQRSIQLESKGLTLQNSQWMNGTVIVDSTVGKDTLFLITWTMQPPQILLWDPSGQKQGGFVVDKNTKMAYLQIPGIAKVGTWKYSLQASSQTLTLTVTSRASNATLPPITVTSKTNKDTSKFPSPLVVYANIRQGASPILRASVTALIESVNGKTVTLELLDNGAGADATKDDGVYSRYFTTYDTNGRYSVKVRALGGVNAARRRVIPQQSGALYIPGWIENDEIQWNPPRPEINKDDVQHKQVCFSRTSSGGSFVASDVPNAPIPDLFPPGQITDLKAEIHGGSLINLTWTAPGDDYDHGTAHKYIIRISTSILDLRDKFNESLQVNTTALIPKEANSEEVFLFKPENITFENGTDLFIAIQAVDKVDLKSEISNIARVSLFIPPQTPPETPSPDETSAPCPNIHINSTIPGIHILKIMWKWIGELQLSIA

T36292	TARGETID	T36292
T36292	FORMERID	TTDI03311
T36292	UNIPROID	KCNU1_HUMAN
T36292	TARGNAME	Calcium-activated potassium channel KCa5.1 (KCNU1)
T36292	GENENAME	KCNU1
T36292	TARGTYPE	Literature-reported
T36292	SYNONYMS	Slowpoke homolog 3; SLO3; Potassium channel subfamily U member 1; KCa5; KCNMC1; KCNMA3; Calcium-activated potassium channel, subfamily M subunit alpha-3; Calcium-activated potassium channel subunit alpha-3
T36292	FUNCTION	Testis-specific potassium channel activated by both intracellular pH and membrane voltage that mediates export of K(+). May represent the primary spermatozoan K(+) current. In contrast to KCNMA1/SLO1, it is not activated by Ca(2+) or Mg(2+). Critical for fertility. May play an important role in sperm osmoregulation required for the acquisition of normal morphology and motility when faced with osmotic challenges, such as those experienced after mixing with seminal fluid and entry into the vagina.
T36292	PDBSTRUC	4HPF
T36292	BIOCLASS	Voltage-gated ion channel
T36292	SEQUENCE	MFQTKLRNETWEDLPKMSCTTEIQAAFILSSFVTFFSGLIILLIFRLIWRSVKKWQIIKGTGIILELFTSGTIARSHVRSLHFQGQFRDHIEMLLSAQTFVGQVLVILVFVLSIGSLIIYFINSADPVGSCSSYEDKTIPIDLVFNAFFSFYFGLRFMAADDKIKFWLEMNSIVDIFTIPPTFISYYLKSNWLGLRFLRALRLLELPQILQILRAIKTSNSVKFSKLLSIILSTWFTAAGFIHLVENSGDPWLKGRNSQNISYFESIYLVMATTSTVGFGDVVAKTSLGRTFIMFFTLGSLILFANYIPEMVELFANKRKYTSSYEALKGKKFIVVCGNITVDSVTAFLRNFLRDKSGEINTEIVFLGETPPSLELETIFKCYLAYTTFISGSAMKWEDLRRVAVESAEACLIIANPLCSDSHAEDISNIMRVLSIKNYDSTTRIIIQILQSHNKVYLPKIPSWNWDTGDNIICFAELKLGFIAQGCLVPGLCTFLTSLFVEQNKKVMPKQTWKKHFLNSMKNKILTQRLSDDFAGMSFPEVARLCFLKMHLLLIAIEYKSLFTDGFCGLILNPPPQVRIRKNTLGFFIAETPKDVRRALFYCSVCHDDVFIPELITNCGCKSRSRQHITVPSVKRMKKCLKGISSRISGQDSPPRVSASTSSISNFTTRTLQHDVEQDSDQLDSSGMFHWCKPTSLDKVTLKRTGKSKYKFRNHIVACVFGDAHSAPMGLRNFVMPLRASNYTRKELKDIVFIGSLDYLQREWRFLWNFPQIYILPGCALYSGDLHAANIEQCSMCAVLSPPPQPSSNQTLVDTEAIMATLTIGSLQIDSSSDPSPSVSEETPGYTNGHNEKSNCRKVPILTELKNPSNIHFIEQLGGLEGSLQETNLHLSTAFSTGTVFSGSFLDSLLATAFYNYHVLELLQMLVTGGVSSQLEQHLDKDKVYGVADSCTSLLSGRNRCKLGLLSLHETILSDVNPRNTFGQLFCGSLDLFGILCVGLYRIIDEEELNPENKRFVITRPANEFKLLPSDLVFCAIPFSTACYKRNEEFSLQKSYEIVNKASQTTETHSDTNCPPTIDSVTETLYSPVYSYQPRTNSLSFPKQIAWNQSRTNSIISSQIPLGDNAKENERKTSDEVYDEDPFAYSEPL
T36292	DRUGINFO	D0O2TC	iberiotoxin	Investigative
T36292	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T70065	TARGETID	T70065
T70065	FORMERID	TTDR00167
T70065	UNIPROID	A9CSR1_PLAFA
T70065	TARGNAME	Plasmodium Dihydroorotase (Malaria dho)
T70065	GENENAME	Malaria dho
T70065	TARGTYPE	Literature-reported
T70065	SYNONYMS	Dihydroorotase
T70065	FUNCTION	A Zn2+ amidohydrolase superfamily that catalyzes reversible cyclization of N-carbamoyl-L-aspartate (L-CA) to form L-dihydroorotate (L-DHO).
T70065	BIOCLASS	Carbon-nitrogen hydrolase
T70065	ECNUMBER	EC 3.5.2.3
T70065	SEQUENCE	MKNYFYIPIADDMHCHLRQGDMLDFTVNSIRRGGCNRVLVMPNTHPIISTCSDAQKYLYQLKSRDDDIEYLMTLYLNKNTDENDILSNYYKCNLQGVKIYPSNVTTNSSDGITSLEPYYKVFHALEKLNKSIHIHCEEPNINPLYAEEKYLPHIHDLAIKFPGLNIVLEHISSSESINVIKEFRNVAGSITPHHLYLTIDDVVNMDIYDHAIDNTYIEKYIKNTYHYCKPLPKLLEDKIALQDVIKDDFPRVFLGSDSAPHYKVMKRKPYYKPGIYTQPFLINYVAHILNKFDALDKMENFTSKNASLFLNLAEKKKLAKYYICVEKHPFKLPREYNGVVPFLAGKTLDYDIHYVSKF
T70065	DRUGINFO	D0DN4W	5-bromo orotate	Investigative
T70065	DRUGINFO	D0E1IO	N-Carbamoyl-L-Aspartate	Investigative
T70065	DRUGINFO	D0J2FJ	5-iodo orotate	Investigative
T70065	DRUGINFO	D0S7BE	5-methyl orotate	Investigative
T70065	DRUGINFO	D0AZ4T	Dihydroorotate	Investigative
T70065	DRUGINFO	D0B1TS	Orotate	Investigative
T70065	DRUGINFO	D0E2WX	5-Fluoro orotate	Investigative
T70065	DRUGINFO	D0CC0B	Lysine Nz-Carboxylic Acid	Investigative

T17814	TARGETID	T17814
T17814	FORMERID	TTDI02150
T17814	UNIPROID	PGRC1_HUMAN
T17814	TARGNAME	Opioid receptor sigma 2 (PGRMC1)
T17814	GENENAME	PGRMC1
T17814	TARGTYPE	Literature-reported
T17814	SYNONYMS	mPR; PGRMC; Membraneassociated progesterone receptor component 1; Membrane-associated progesterone receptor component 1; IZA; HPR6.6; Dap1
T17814	FUNCTION	Binds progesterone. Has many reported cellular functions (heme homeostasis, interaction with CYPs). Component of a progesterone-binding protein complex.
T17814	PDBSTRUC	4X8Y
T17814	BIOCLASS	GPCR rhodopsin
T17814	SEQUENCE	MAAEDVVATGADPSDLESGGLLHEIFTSPLNLLLLGLCIFLLYKIVRGDQPAASGDSDDDEPPPLPRLKRRDFTPAELRRFDGVQDPRILMAINGKVFDVTKGRKFYGPEGPYGVFAGRDASRGLATFCLDKEALKDEYDDLSDLTAAQQETLSDWESQFTFKYHHVGKLLKEGEEPTVYSDEEEPKDESARKND

T13902	TARGETID	T13902
T13902	FORMERID	TTDI00024
T13902	UNIPROID	NR5A2_HUMAN
T13902	TARGNAME	Liver receptor homolog-1 (NR5A2)
T13902	GENENAME	NR5A2
T13902	TARGTYPE	Literature-reported
T13902	SYNONYMS	LRH1; CYP7A promoterbinding factor; B1binding factor; Alpha1fetoprotein transcription factor
T13902	FUNCTION	Together with the oxysterol receptors NR1H3/LXR-alpha and NR1H2/LXR-beta, acts as an essential transcriptional regulator of lipid metabolism. Plays an anti-inflammatory role during the hepatic acute phase response by acting as a corepressor: inhibits the hepatic acute phase response by preventing dissociation of the N-Cor corepressor complex. Binds to the sequence element 5'-AACGACCGACCTTGAG-3' of the enhancer II of hepatitis B virus genes, a critical cis-element of their expression and regulation. May be responsible for the liver-specific activity of enhancer II, probably in combination with other hepatocyte transcription factors. Key regulator of cholesterol 7-alpha-hydroxylase gene (CYP7A) expression in liver. May also contribute to the regulation of pancreas-specific genes and play important roles in embryonic development. Activates the transcription of CYP2C38. Nuclear receptor that acts as a key metabolic sensor by regulating the expression of genes involved in bile acid synthesis, cholesterol homeostasis and triglyceride synthesis.
T13902	PDBSTRUC	5UNJ; 5SYZ; 5L11; 5L0M; 4RWV
T13902	BIOCLASS	Nuclear hormone receptor
T13902	SEQUENCE	MSSNSDTGDLQESLKHGLTPIGAGLPDRHGSPIPARGRLVMLPKVETEALGLARSHGEQGQMPENMQVSQFKMVNYSYDEDLEELCPVCGDKVSGYHYGLLTCESCKGFFKRTVQNNKRYTCIENQNCQIDKTQRKRCPYCRFQKCLSVGMKLEAVRADRMRGGRNKFGPMYKRDRALKQQKKALIRANGLKLEAMSQVIQAMPSDLTISSAIQNIHSASKGLPLNHAALPPTDYDRSPFVTSPISMTMPPHGSLQGYQTYGHFPSRAIKSEYPDPYTSSPESIMGYSYMDSYQTSSPASIPHLILELLKCEPDEPQVQAKIMAYLQQEQANRSKHEKLSTFGLMCKMADQTLFSIVEWARSSIFFRELKVDDQMKLLQNCWSELLILDHIYRQVVHGKEGSIFLVTGQQVDYSIIASQAGATLNNLMSHAQELVAKLRSLQFDQREFVCLKFLVLFSLDVKNLENFQLVEGVQEQVNAALLDYTMCNYPQQTEKFGQLLLRLPEIRAISMQAEEYLYYKHLNGDVPYNNLLIEMLHAKRA

T53975	TARGETID	T53975
T53975	FORMERID	TTDR00534
T53975	UNIPROID	CXCR6_HUMAN
T53975	TARGNAME	C-X-C chemokine receptor type 6 (CXCR6)
T53975	GENENAME	CXCR6
T53975	TARGTYPE	Literature-reported
T53975	SYNONYMS	TYMSTR; STRL33; G-protein coupled receptor bonzo; G-protein coupled receptor STRL33; G protein-coupled receptor bonzo; G protein-coupled receptor STRL33; Chemokine receptor CXCR6; CXCR-6; CXC-R6; CDw186; CD186; BONZO
T53975	FUNCTION	Used as a coreceptor by SIVs and by strains of HIV-2 and m-tropic HIV-1. Receptor for the C-X-C chemokine CXCL16.
T53975	BIOCLASS	GPCR rhodopsin
T53975	SEQUENCE	MAEHDYHEDYGFSSFNDSSQEEHQDFLQFSKVFLPCMYLVVFVCGLVGNSLVLVISIFYHKLQSLTDVFLVNLPLADLVFVCTLPFWAYAGIHEWVFGQVMCKSLLGIYTINFYTSMLILTCITVDRFIVVVKATKAYNQQAKRMTWGKVTSLLIWVISLLVSLPQIIYGNVFNLDKLICGYHDEAISTVVLATQMTLGFFLPLLTMIVCYSVIIKTLLHAGGFQKHRSLKIIFLVMAVFLLTQMPFNLMKFIRSTHWEYYAMTSFHYTIMVTEAIAYLRACLNPVLYAFVSLKFRKNFWKLVKDIGCLPYLGVSHQWKSSEDNSKTFSASHNVEATSMFQL
T53975	DRUGINFO	D00RXS	AMD3101	Investigative

T93237	TARGETID	T93237
T93237	FORMERID	TTDNR00654
T93237	UNIPROID	CCL21_HUMAN
T93237	TARGNAME	Secondary lymphoid-tissue chemokine (CCL21)
T93237	GENENAME	CCL21
T93237	TARGTYPE	Literature-reported
T93237	SYNONYMS	UNQ784/PRO1600; Small-inducible cytokine A21; SLC; SCYA21; C-C motif chemokine 21; Beta-chemokine exodus-2; 6Ckine
T93237	FUNCTION	Chemotactic in vitro for thymocytes and activated T-cells, but not for B-cells, macrophages, or neutrophils. Shows preferential activity towards naive T-cells. May play a role in mediating homing of lymphocytes to secondary lymphoid organs. Binds to atypical chemokine receptor ACKR4 and mediates the recruitment of beta-arrestin (ARRB1/2) to ACKR4. Inhibits hemopoiesis and stimulates chemotaxis.
T93237	PDBSTRUC	5EKI; 2L4N
T93237	BIOCLASS	Cytokine: CC chemokine
T93237	SEQUENCE	MAQSLALSLLILVLAFGIPRTQGSDGGAQDCCLKYSQRKIPAKVVRSYRKQEPSLGCSIPAILFLPRKRSQAELCADPKELWVQQLMQHLDKTPSPQKPAQGCRKDRGASKTGKKGKGSKGCKRTERSQTPKGP

T82183	TARGETID	T82183
T82183	FORMERID	TTDR00726
T82183	UNIPROID	LEP_STRPN
T82183	TARGNAME	Streptococcus Signal peptidase I (Stre-coc lepB)
T82183	GENENAME	Stre-coc lepB
T82183	TARGTYPE	Literature-reported
T82183	SYNONYMS	Signal peptidase I; SPase I; Leader peptidase I
T82183	FUNCTION	Cleavage of hydrophobic, N-terminal signal or leader sequences from secreted and periplasmic proteins.
T82183	BIOCLASS	Peptidase
T82183	ECNUMBER	EC 3.4.21.89
T82183	SEQUENCE	MNSFKNFLKEWGLFLLILSLLALSRIFFWSNVRVEGHSMDPTLADGEILFVVKHLPIDRFDIVVAHEEDGNKDIVKRVIGMPGDTIRYENDKLYINDKETDEPYLADYIKRFKDDKLQSTYSGKGFEGNKGTFFRSIAQKAQAFTVDVNYNTNFSFTVPEGEYLLLGDDRLVSSDSRHVGTFKAKDITGEAKFRLWPITRIGTF

T22604	TARGETID	T22604
T22604	FORMERID	TTDR00609
T22604	UNIPROID	CET1_YEAST
T22604	TARGNAME	Fungal RNA triphosphatase (Fung CET1)
T22604	GENENAME	Fung CET1
T22604	TARGTYPE	Literature-reported
T22604	SYNONYMS	TPase; Polynucleotide 5'-triphosphatase; MRNA capping enzyme beta subunit; MRNA 5'-triphosphatase; CET1
T22604	FUNCTION	First step of mRNA capping. Converts the 5'-triphosphate end of a nascent mRNA chain into a diphosphate end.
T22604	PDBSTRUC	3KYH; 1D8I; 1D8H
T22604	BIOCLASS	Phosphoric monoester hydrolase
T22604	SEQUENCE	MSYTDNPPQTKRALSLDDLVNHDENEKVKLQKLSEAANGSRPFAENLESDINQTETGQAAPIDNYKESTGHGSHSQKPKSRKSSNDDEETDTDDEMGASGEINFDSEMDFDYDKQHRNLLSNGSPPMNDGSDANAKLEKPSDDSIHQNSKSDEEQRIPKQGNEGNIASNYITQVPLQKQKQTEKKIAGNAVGSVVKKEEEANAAVDNIFEEKATLQSKKNNIKRDLEVLNEISASSKPSKYRNVPIWAQKWKPTIKALQSINVKDLKIDPSFLNIIPDDDLTKSVQDWVYATIYSIAPELRSFIELEMKFGVIIDAKGPDRVNPPVSSQCVFTELDAHLTPNIDASLFKELSKYIRGISEVTENTGKFSIIESQTRDSVYRVGLSTQRPRFLRMSTDIKTGRVGQFIEKRHVAQLLLYSPKDSYDVKISLNLELPVPDNDPPEKYKSQSPISERTKDRVSYIHNDSCTRIDITKVENHNQNSKSRQSETTHEVELEINTPALLNAFDNITNDSKEYASLIRTFLNNGTIIRRKLSSLSYEIFEGSKKVM

T94438	TARGETID	T94438
T94438	UNIPROID	AQP7_HUMAN
T94438	TARGNAME	Aquaporin-7 (AQP7)
T94438	GENENAME	AQP7
T94438	TARGTYPE	Literature-reported
T94438	SYNONYMS	Aquaporin-7-like; Aquaporin adipose; Aquaglyceroporin-7; AQPap; AQP7L; AQP-7
T94438	FUNCTION	Forms a channel for water and glycerol.
T94438	BIOCLASS	Major intrinsic protein
T94438	SEQUENCE	MVQASGHRRSTRGSKMVSWSVIAKIQEILQRKMVREFLAEFMSTYVMMVFGLGSVAHMVLNKKYGSYLGVNLGFGFGVTMGVHVAGRISGAHMNAAVTFANCALGRVPWRKFPVYVLGQFLGSFLAAATIYSLFYTAILHFSGGQLMVTGPVATAGIFATYLPDHMTLWRGFLNEAWLTGMLQLCLFAITDQENNPALPGTEALVIGILVVIIGVSLGMNTGYAINPSRDLPPRIFTFIAGWGKQVFSNGENWWWVPVVAPLLGAYLGGIIYLVFIGSTIPREPLKLEDSVAYEDHGITVLPKMGSHEPTISPLTPVSVSPANRSSVHPAPPLHESMALEHF

T68465	TARGETID	T68465
T68465	FORMERID	TTDI01444
T68465	UNIPROID	CXL11_HUMAN
T68465	TARGNAME	C-X-C motif chemokine 11 (CXCL11)
T68465	GENENAME	CXCL11
T68465	TARGTYPE	Literature-reported
T68465	SYNONYMS	Small-inducible cytokine B11; SCYB9B; SCYB11; Interferon-inducible T-cell alpha chemoattractant; Interferon gamma-inducible protein 9; ITAC; IP-9; I-TAC; H174; Beta-R1
T68465	FUNCTION	Induces calcium release in activated T-cells. Binds to CXCR3. May play an important role in CNS diseases which involve T-cell recruitment. May play a role in skin immune responses. Chemotactic for interleukin-activated T-cells but not unstimulated T-cells, neutrophils or monocytes.
T68465	PDBSTRUC	1RJT
T68465	BIOCLASS	Cytokine: CXC chemokine
T68465	SEQUENCE	MSVKGMAIALAVILCATVVQGFPMFKRGRCLCIGPGVKAVKVADIEKASIMYPSNNCDKIEVIITLKENKGQRCLNPKSKQARLIIKKVERKNF

T56057	TARGETID	T56057
T56057	FORMERID	TTDI03364
T56057	UNIPROID	KDM6B_HUMAN
T56057	TARGNAME	Lysine-specific demethylase 6B (KDM6B)
T56057	GENENAME	KDM6B
T56057	TARGTYPE	Literature-reported
T56057	SYNONYMS	Lysine demethylase 6B; KIAA0346; Jumonji domain-containing protein 3; JmjC domain-containing protein 3; JMJD3
T56057	FUNCTION	Histone demethylase that specifically demethylates 'Lys-27' of histone H3, thereby playing a central role in histone code. Demethylates trimethylated and dimethylated H3 'Lys-27'. Plays a central role in regulation of posterior development, by regulating HOX gene expression. Involved in inflammatory response by participating in macrophage differentiation in case of inflammation by regulating gene expression and macrophage differentiation. Plays a demethylase-independent role in chromatin remodeling to regulate T-box family member-dependent gene expression by acting as a link between T-box factors and the SMARCA4-containing SWI/SNF remodeling complex (By similarity).
T56057	PDBSTRUC	6F6D; 5OY3; 5FP3; 4ASK; 2XXZ
T56057	ECNUMBER	EC 1.14.11.-
T56057	SEQUENCE	MHRAVDPPGARAAREAFALGGLSCAGAWSSCPPHPPPRSAWLPGGRCSASIGQPPLPAPLPPSHGSSSGHPSKPYYAPGAPTPRPLHGKLESLHGCVQALLREPAQPGLWEQLGQLYESEHDSEEATRCYHSALRYGGSFAELGPRIGRLQQAQLWNFHTGSCQHRAKVLPPLEQVWNLLHLEHKRNYGAKRGGPPVKRAAEPPVVQPVPPAALSGPSGEEGLSPGGKRRRGCNSEQTGLPPGLPLPPPPLPPPPPPPPPPPPPLPGLATSPPFQLTKPGLWSTLHGDAWGPERKGSAPPERQEQRHSLPHPYPYPAPAYTAHPPGHRLVPAAPPGPGPRPPGAESHGCLPATRPPGSDLRESRVQRSRMDSSVSPAATTACVPYAPSRPPGLPGTTTSSSSSSSSNTGLRGVEPNPGIPGADHYQTPALEVSHHGRLGPSAHSSRKPFLGAPAATPHLSLPPGPSSPPPPPCPRLLRPPPPPAWLKGPACRAAREDGEILEELFFGTEGPPRPAPPPLPHREGFLGPPASRFSVGTQDSHTPPTPPTPTTSSSNSNSGSHSSSPAGPVSFPPPPYLARSIDPLPRPPSPAQNPQDPPLVPLTLALPPAPPSSCHQNTSGSFRRPESPRPRVSFPKTPEVGPGPPPGPLSKAPQPVPPGVGELPARGPRLFDFPPTPLEDQFEEPAEFKILPDGLANIMKMLDESIRKEEEQQQHEAGVAPQPPLKEPFASLQSPFPTDTAPTTTAPAVAVTTTTTTTTTTTATQEEEKKPPPALPPPPPLAKFPPPSQPQPPPPPPPSPASLLKSLASVLEGQKYCYRGTGAAVSTRPGPLPTTQYSPGPPSGATALPPTSAAPSAQGSPQPSASSSSQFSTSGGPWARERRAGEEPVPGPMTPTQPPPPLSLPPARSESEVLEEISRACETLVERVGRSATDPADPVDTAEPADSGTERLLPPAQAKEEAGGVAAVSGSCKRRQKEHQKEHRRHRRACKDSVGRRPREGRAKAKAKVPKEKSRRVLGNLDLQSEEIQGREKSRPDLGGASKAKPPTAPAPPSAPAPSAQPTPPSASVPGKKAREEAPGPPGVSRADMLKLRSLSEGPPKELKIRLIKVESGDKETFIASEVEERRLRMADLTISHCAADVVRASRNAKVKGKFRESYLSPAQSVKPKINTEEKLPREKLNPPTPSIYLESKRDAFSPVLLQFCTDPRNPITVIRGLAGSLRLNLGLFSTKTLVEASGEHTVEVRTQVQQPSDENWDLTGTRQIWPCESSRSHTTIAKYAQYQASSFQESLQEEKESEDEESEEPDSTTGTPPSSAPDPKNHHIIKFGTNIDLSDAKRWKPQLQELLKLPAFMRVTSTGNMLSHVGHTILGMNTVQLYMKVPGSRTPGHQENNNFCSVNINIGPGDCEWFAVHEHYWETISAFCDRHGVDYLTGSWWPILDDLYASNIPVYRFVQRPGDLVWINAGTVHWVQATGWCNNIAWNVGPLTAYQYQLALERYEWNEVKNVKSIVPMIHVSWNVARTVKISDPDLFKMIKFCLLQSMKHCQVQRESLVRAGKKIAYQGRVKDEPAYYCNECDVEVFNILFVTSENGSRNTYLVHCEGCARRRSAGLQGVVVLEQYRTEELAQAYDAFTLAPASTSR
T56057	DRUGINFO	D0S3DD	GSK-J1	Investigative
T56057	DRUGINFO	D0X5US	IOX1	Investigative

T32821	TARGETID	T32821
T32821	FORMERID	TTDR00924
T32821	UNIPROID	PLCB_HUMAN
T32821	TARGNAME	Lysophosphatidic acid acyltransferase beta (LPAATB)
T32821	GENENAME	AGPAT2
T32821	TARGTYPE	Literature-reported
T32821	SYNONYMS	Lysophosphatidic acid acyltransferase-beta; LPAAT-beta; AGPAT2; 1-acylglycerol-3-phosphate O-acyltransferase 2; 1-AGPAT 2; 1-AGP acyltransferase 2
T32821	FUNCTION	Converts lysophosphatidic acid (LPA) into phosphatidic acid by incorporating an acyl moiety at the sn-2 position of the glycerol backbone.
T32821	BIOCLASS	Acyltransferase
T32821	ECNUMBER	EC 2.3.1.51
T32821	SEQUENCE	MELWPCLAAALLLLLLLVQLSRAAEFYAKVALYCALCFTVSAVASLVCLLRHGGRTVENMSIIGWFVRSFKYFYGLRFEVRDPRRLQEARPCVIVSNHQSILDMMGLMEVLPERCVQIAKRELLFLGPVGLIMYLGGVFFINRQRSSTAMTVMADLGERMVRENLKVWIYPEGTRNDNGDLLPFKKGAFYLAVQAQVPIVPVVYSSFSSFYNTKKKFFTSGTVTVQVLEAIPTSGLTAADVPALVDTCHRAMRTTFLHISKTPQENGATAGSGVQPAQ

T50914	TARGETID	T50914
T50914	FORMERID	TTDI02578
T50914	UNIPROID	PPM1D_HUMAN
T50914	TARGNAME	Protein phosphatase 1D (PPM1D)
T50914	GENENAME	PPM1D
T50914	TARGTYPE	Literature-reported
T50914	SYNONYMS	p53-induced protein phosphatase 1; WIP1; Protein phosphatase magnesium-dependent 1 delta; Protein phosphatase 2C isoform delta; PP2C-delta
T50914	FUNCTION	Required for the relief of p53-dependent checkpoint mediated cell cycle arrest. Binds to and dephosphorylates 'Ser-15' of TP53 and 'Ser-345' of CHEK1 which contributes to the functional inactivation of these proteins. Mediates MAPK14 dephosphorylation and inactivation. Is also an important regulator of global heterochromatin silencing and critical in maintaining genome integrity. Involved in the negative regulation of p53 expression.
T50914	BIOCLASS	Phosphoric monoester hydrolase
T50914	ECNUMBER	EC 3.1.3.16
T50914	SEQUENCE	MAGLYSLGVSVFSDQGGRKYMEDVTQIVVEPEPTAEEKPSPRRSLSQPLPPRPSPAALPGGEVSGKGPAVAAREARDPLPDAGASPAPSRCCRRRSSVAFFAVCDGHGGREAAQFAREHLWGFIKKQKGFTSSEPAKVCAAIRKGFLACHLAMWKKLAEWPKTMTGLPSTSGTTASVVIIRGMKMYVAHVGDSGVVLGIQDDPKDDFVRAVEVTQDHKPELPKERERIEGLGGSVMNKSGVNRVVWKRPRLTHNGPVRRSTVIDQIPFLAVARALGDLWSYDFFSGEFVVSPEPDTSVHTLDPQKHKYIILGSDGLWNMIPPQDAISMCQDQEEKKYLMGEHGQSCAKMLVNRALGRWRQRMLRADNTSAIVICISPEVDNQGNFTNEDELYLNLTDSPSYNSQETCVMTPSPCSTPPVKSLEEDPWPRVNSKDHIPALVRSNAFSENFLEVSAEIARENVQGVVIPSKDPEPLEENCAKALTLRIHDSLNNSLPIGLVPTNSTNTVMDQKNLKMSTPGQMKAQEIERTPPTNFKRTLEESNSGPLMKKHRRNGLSRSSGAQPASLPTTSQRKNSVKLTMRRRLRGQKKIGNPLLHQHRKTVCVC

T14306	TARGETID	T14306
T14306	FORMERID	TTDI02464
T14306	UNIPROID	CFLAR_HUMAN
T14306	TARGNAME	CASP8-FADD-like regulator (CFLAR)
T14306	GENENAME	CFLAR
T14306	TARGTYPE	Literature-reported
T14306	SYNONYMS	cFLIP; c-FLIP; Usurpin; MRIT; MACHrelated inducer of toxicity; MACH-related inducer of toxicity; Inhibitor of FLICE; IFLICE; I-FLICE; FLAME1; FLAME-1; FADDlike antiapoptotic molecule 1; FADD-like antiapoptotic molecule 1; Cellular FLICElike inhibitory protein; Cellular FLICE-like inhibitory protein; Casper; Caspaselike apoptosis regulatory protein; Caspaseeightrelated protein; Caspase-like apoptosis regulatory protein; Caspase-eight-related protein; Caspase homolog; CLARP; CASP8AP1; CASP8 and FADDlike apoptosis regulator subunit p12; CASP8 and FADDlike apoptosis regulator; CASP8 and FADD-like apoptosis regulator; CASH
T14306	FUNCTION	Acts as an inhibitor of TNFRSF6 mediated apoptosis. A proteolytic fragment (p43) is likely retained in the death-inducing signaling complex (DISC) thereby blocking further recruitment and processing of caspase-8 at the complex. Full length and shorter isoforms have been shown either to induce apoptosis or to reduce TNFRSF-triggered apoptosis. Lacks enzymatic (caspase) activity. Apoptosis regulator protein which may function as a crucial link between cell survival and cell death pathways in mammalian cells.
T14306	PDBSTRUC	3H13; 3H11; 2N5R
T14306	BIOCLASS	Peptidase
T14306	SEQUENCE	MSAEVIHQVEEALDTDEKEMLLFLCRDVAIDVVPPNVRDLLDILRERGKLSVGDLAELLYRVRRFDLLKRILKMDRKAVETHLLRNPHLVSDYRVLMAEIGEDLDKSDVSSLIFLMKDYMGRGKISKEKSFLDLVVELEKLNLVAPDQLDLLEKCLKNIHRIDLKTKIQKYKQSVQGAGTSYRNVLQAAIQKSLKDPSNNFRLHNGRSKEQRLKEQLGAQQEPVKKSIQESEAFLPQSIPEERYKMKSKPLGICLIIDCIGNETELLRDTFTSLGYEVQKFLHLSMHGISQILGQFACMPEHRDYDSFVCVLVSRGGSQSVYGVDQTHSGLPLHHIRRMFMGDSCPYLAGKPKMFFIQNYVVSEGQLEDSSLLEVDGPAMKNVEFKAQKRGLCTVHREADFFWSLCTADMSLLEQSHSSPSLYLQCLSQKLRQERKRPLLDLHIELNGYMYDWNSRVSAKEKYYVWLQHTLRKKLILSYT

T88531	TARGETID	T88531
T88531	FORMERID	TTDI02513
T88531	UNIPROID	GPR39_HUMAN
T88531	TARGNAME	G-protein coupled receptor 39 (GPR39)
T88531	GENENAME	GPR39
T88531	TARGTYPE	Literature-reported
T88531	SYNONYMS	Gprotein coupled receptor 39; GPR39
T88531	FUNCTION	Zn(2+) acts as a agonist. Thisreceptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated mainly through G(q)-alpha and G(12)/G(13) proteins. Involved in regulation of body weight, gastrointestinal mobility, hormone secretion and cell death.
T88531	BIOCLASS	GPCR rhodopsin
T88531	SEQUENCE	MASPSLPGSDCSQIIDHSHVPEFEVATWIKITLILVYLIIFVMGLLGNSATIRVTQVLQKKGYLQKEVTDHMVSLACSDILVFLIGMPMEFYSIIWNPLTTSSYTLSCKLHTFLFEACSYATLLHVLTLSFERYIAICHPFRYKAVSGPCQVKLLIGFVWVTSALVALPLLFAMGTEYPLVNVPSHRGLTCNRSSTRHHEQPETSNMSICTNLSSRWTVFQSSIFGAFVVYLVVLLSVAFMCWNMMQVLMKSQKGSLAGGTRPPQLRKSESEESRTARRQTIIFLRLIVVTLAVCWMPNQIRRIMAAAKPKHDWTRSYFRAYMILLPFSETFFYLSSVINPLLYTVSSQQFRRVFVQVLCCRLSLQHANHEKRLRVHAHSTTDSARFVQRPLLFASRRQSSARRTEKIFLSTFQSEAEPQSKSQSLSLESLEPNSGAKPANSAAENGFQEHEV
T88531	DRUGINFO	D0E1HY	GPCR39 pepducins	Investigative
T88531	DRUGINFO	D0H4UN	PMID24900608C1	Investigative
T88531	DRUGINFO	D0V6KN	PMID25313322C15	Investigative

T60744	TARGETID	T60744
T60744	FORMERID	TTDR00119
T60744	UNIPROID	OREX_HUMAN
T60744	TARGNAME	Orexin (HCRT)
T60744	GENENAME	HCRT
T60744	TARGTYPE	Literature-reported
T60744	SYNONYMS	Hypocretin; Hcrt
T60744	FUNCTION	Neuropeptides that play a significant role in the regulationof food intake and sleep-wakefulness, possibly by coordinating the complex behavioral and physiologic responses of these complementary homeostatic functions. A broader role in the homeostatic regulation of energy metabolism, autonomic function, hormonal balance and the regulation of body fluids, is also suggested. Orexin-A binds to both OX1R and OX2R with a high affinity, whereas orexin-B binds only to OX2R with a similar high affinity.
T60744	PDBSTRUC	1WSO; 1UVQ; 1R02; 1CQ0
T60744	SEQUENCE	MNLPSTKVSWAAVTLLLLLLLLPPALLSSGAAAQPLPDCCRQKTCSCRLYELLHGAGNHAAGILTLGKRRSGPPGLQGRLQRLLQASGNHAAGILTMGRRAGAEPAPRPCLGRRCSAPAAASVAPGGQSGI
T60744	DRUGINFO	D0U7QA	Pyroglutamic Acid	Investigative

T97637	TARGETID	T97637
T97637	UNIPROID	LANC1_HUMAN
T97637	TARGNAME	Glutathione S-transferase LANCL1 (LANCL1)
T97637	GENENAME	LANCL1
T97637	TARGTYPE	Literature-reported
T97637	SYNONYMS	p40; LanC-like protein 1; GPR69A; 40 kDa erythrocyte membrane protein
T97637	FUNCTION	Functions as glutathione transferase. Catalyzes conjugation of the glutathione (GSH) to artificial substrates 1-chloro-2,4-dinitrobenzene (CDNB) and p-nitrophenyl acetate. Mitigates neuronal oxidative stress during normal postnatal development and in response to oxidative stresses probably through GSH antioxidant defense mechanism (By similarity). May play a role in EPS8 signaling. Binds glutathione.
T97637	PDBSTRUC	3E6U; 3.00E+73
T97637	ECNUMBER	EC 2.5.1.18
T97637	SEQUENCE	MAQRAFPNPYADYNKSLAEGYFDAAGRLTPEFSQRLTNKIRELLQQMERGLKSADPRDGTGYTGWAGIAVLYLHLYDVFGDPAYLQLAHGYVKQSLNCLTKRSITFLCGDAGPLAVAAVLYHKMNNEKQAEDCITRLIHLNKIDPHAPNEMLYGRIGYIYALLFVNKNFGVEKIPQSHIQQICETILTSGENLARKRNFTAKSPLMYEWYQEYYVGAAHGLAGIYYYLMQPSLQVSQGKLHSLVKPSVDYVCQLKFPSGNYPPCIGDNRDLLVHWCHGAPGVIYMLIQAYKVFREEKYLCDAYQCADVIWQYGLLKKGYGLCHGSAGNAYAFLTLYNLTQDMKYLYRACKFAEWCLEYGEHGCRTPDTPFSLFEGMAGTIYFLADLLVPTKARFPAFEL

T47306	TARGETID	T47306
T47306	FORMERID	TTDR01132
T47306	UNIPROID	G6PT1_HUMAN
T47306	TARGNAME	Glucose-6-phosphate translocase (SLC37A4)
T47306	GENENAME	SLC37A4
T47306	TARGTYPE	Literature-reported
T47306	SYNONYMS	Transformation-related gene 19 protein; TRG19; TRG-19; Solute carrier family 37 member 4; PRO0685; Glucose-6-phosphate exchanger SLC37A4; Glucose-5-phosphate transporter; Glucose 5-phosphate transporter; G6PT1
T47306	FUNCTION	Transports cytoplasmic glucose-6-phosphate into the lumen of the endoplasmic reticulum and translocates inorganic phosphate into the opposite direction. Forms with glucose-6-phosphatase the complex responsible for glucose production through glycogenolysis and gluconeogenesis. Hence, it plays a central role in homeostatic regulation of blood glucose levels. Inorganic phosphate and glucose-6-phosphate antiporter of the endoplasmic reticulum.
T47306	BIOCLASS	Major facilitator
T47306	SEQUENCE	MAAQGYGYYRTVIFSAMFGGYSLYYFNRKTFSFVMPSLVEEIPLDKDDLGFITSSQSAAYAISKFVSGVLSDQMSARWLFSSGLLLVGLVNIFFAWSSTVPVFAALWFLNGLAQGLGWPPCGKVLRKWFEPSQFGTWWAILSTSMNLAGGLGPILATILAQSYSWRSTLALSGALCVVVSFLCLLLIHNEPADVGLRNLDPMPSEGKKGSLKEESTLQELLLSPYLWVLSTGYLVVFGVKTCCTDWGQFFLIQEKGQSALVGSSYMSALEVGGLVGSIAAGYLSDRAMAKAGLSNYGNPRHGLLLFMMAGMTVSMYLFRVTVTSDSPKLWILVLGAVFGFSSYGPIALFGVIANESAPPNLCGTSHAIVGLMANVGGFLAGLPFSTIAKHYSWSTAFWVAEVICAASTAAFFLLRNIRTKMGRVSKKAE
T47306	DRUGINFO	D00UCE	S 0957	Investigative
T47306	DRUGINFO	D01NIJ	S 1743	Investigative
T47306	DRUGINFO	D02HCQ	Chlorogenic acid	Investigative
T47306	DRUGINFO	D0A9CK	S-4048	Investigative
T47306	DRUGINFO	D0GG6X	Kodaistatin A	Investigative
T47306	DRUGINFO	D0I3IR	Kodaistatin C	Investigative
T47306	DRUGINFO	D0S5RY	S 3025	Investigative
T47306	DRUGINFO	D0Z6OT	Mumbaistatin	Investigative

T27700	TARGETID	T27700
T27700	FORMERID	TTDI00003
T27700	UNIPROID	CXL13_HUMAN
T27700	TARGNAME	C-X-C motif chemokine 13 (CXCL13)
T27700	GENENAME	CXCL13
T27700	TARGTYPE	Literature-reported
T27700	SYNONYMS	Smallinducible cytokine B13; Small-inducible cytokine B13; SCYB13; CXC chemokine BLC; BLC; BCA1; BCA-1; B lymphocyte chemoattractant; B cellattracting chemokine 1; B cell-attracting chemokine 1; Angie
T27700	FUNCTION	Does not induce calcium release in B-lymphocytes. Binds to BLR1/CXCR5. Chemotactic for B-lymphocytes but not for T-lymphocytes, monocytes and neutrophils.
T27700	PDBSTRUC	5CBE; 5CBA; 4ZAI
T27700	BIOCLASS	Cytokine: CXC chemokine
T27700	SEQUENCE	MKFISTSLLLMLLVSSLSPVQGVLEVYYTSLRCRCVQESSVFIPRRFIDRIQILPRGNGCPRKEIIVWKKNKSIVCVDPQAEWIQRMMEVLRKRSSSTLPVPVFKRKIP

T00302	TARGETID	T00302
T00302	FORMERID	TTDR00876
T00302	UNIPROID	TM11D_HUMAN
T00302	TARGNAME	Airway trypsin-like protease (TMPRSS11D)
T00302	GENENAME	TMPRSS11D
T00302	TARGTYPE	Literature-reported
T00302	SYNONYMS	TMPRSS11D; Human airway trypsin-like protease; HAT
T00302	FUNCTION	May play some biological role in the host defense system on the mucous membrane independently of or in cooperation with other substances in airway mucous or bronchial secretions. Plays a role in the proteolytic processing of ACE2. Proteolytically cleaves and activates the human coronavirus 229E (HCoV-229E) spike glycoprotein which facilitate virus-cell membrane fusions; spike proteins are synthesized andmaintained in precursor intermediate folding states and proteolysis permits the refolding and energy release required to create stable virus-cell linkages and membrane coalescence.
T00302	BIOCLASS	Peptidase
T00302	ECNUMBER	EC 3.4.21.-
T00302	SEQUENCE	MYRPARVTSTSRFLNPYVVCFIVVAGVVILAVTIALLVYFLAFDQKSYFYRSSFQLLNVEYNSQLNSPATQEYRTLSGRIESLITKTFKESNLRNQFIRAHVAKLRQDGSGVRADVVMKFQFTRNNNGASMKSRIESVLRQMLNNSGNLEINPSTEITSLTDQAAANWLINECGAGPDLITLSEQRILGGTEAEEGSWPWQVSLRLNNAHHCGGSLINNMWILTAAHCFRSNSNPRDWIATSGISTTFPKLRMRVRNILIHNNYKSATHENDIALVRLENSVTFTKDIHSVCLPAATQNIPPGSTAYVTGWGAQEYAGHTVPELRQGQVRIISNDVCNAPHSYNGAILSGMLCAGVPQGGVDACQGDSGGPLVQEDSRRLWFIVGIVSWGDQCGLPDKPGVYTRVTAYLDWIRQQTGI
T00302	DRUGINFO	D07ZRG	PMID21741839C5	Investigative
T00302	DRUGINFO	D0W2SV	Inhibitor 1 [Colombo et al., 2012]	Investigative

T21653	TARGETID	T21653
T21653	FORMERID	TTDI03413
T21653	UNIPROID	NUAK1_HUMAN
T21653	TARGNAME	Omphalocele kinase 1 (NUAK1)
T21653	GENENAME	NUAK1
T21653	TARGTYPE	Literature-reported
T21653	SYNONYMS	OMPHK1; NUAK family SNF1-like kinase 1; KIAA0537; ARK5; AMPK-related protein kinase 5
T21653	FUNCTION	Phosphorylates ATM, CASP6, LATS1, PPP1R12A and p53/TP53. Acts as a regulator of cellular senescence and cellular ploidy by mediating phosphorylation of 'Ser-464' of LATS1, thereby controlling its stability. Controls cell adhesion by regulating activity of the myosin protein phosphatase 1 (PP1) complex. Acts by mediating phosphorylation of PPP1R12A subunit of myosin PP1: phosphorylated PPP1R12A then interacts with 14-3-3, leading to reduced dephosphorylation of myosin MLC2 by myosin PP1. May be involved in DNA damage response: phosphorylates p53/TP53 at 'Ser-15' and 'Ser-392' and is recruited to the CDKN1A/WAF1 promoter to participate to transcription activation by p53/TP53. May also act as a tumor malignancy-associated factor by promoting tumor invasion and metastasis under regulation and phosphorylation by AKT1. Suppresses Fas-induced apoptosis by mediating phosphorylation of CASP6, thereby suppressing the activation of the caspase and the subsequent cleavage of CFLAR. Regulates UV radiation-induced DNA damage response mediated by CDKN1A. In association with STK11, phosphorylates CDKN1A in response to UV radiation and contributes to its degradation which is necessary for optimal DNA repair. Serine/threonine-protein kinase involved in various processes such as cell adhesion, regulation of cell ploidy and senescence, cell proliferation and tumor progression.
T21653	BIOCLASS	Kinase
T21653	ECNUMBER	EC 2.7.11.1
T21653	SEQUENCE	MEGAAAPVAGDRPDLGLGAPGSPREAVAGATAALEPRKPHGVKRHHHKHNLKHRYELQETLGKGTYGKVKRATERFSGRVVAIKSIRKDKIKDEQDMVHIRREIEIMSSLNHPHIISIYEVFENKDKIVIIMEYASKGELYDYISERRRLSERETRHFFRQIVSAVHYCHKNGVVHRDLKLENILLDDNCNIKIADFGLSNLYQKDKFLQTFCGSPLYASPEIVNGRPYRGPEVDSWALGVLLYTLVYGTMPFDGFDHKNLIRQISSGEYREPTQPSDARGLIRWMLMVNPDRRATIEDIANHWWVNWGYKSSVCDCDALHDSESPLLARIIDWHHRSTGLQADTEAKMKGLAKPTTSEVMLERQRSLKKSKKENDFAQSGQDAVPESPSKLSSKRPKGILKKRSNSEHRSHSTGFIEGVVGPALPSTFKMEQDLCRTGVLLPSSPEAEVPGKLSPKQSATMPKKGILKKTQQRESGYYSSPERSESSELLDSNDVMGSSIPSPSPPDPARVTSHSLSCRRKGILKHSSKYSAGTMDPALVSPEMPTLESLSEPGVPAEGLSRSYSRPSSVISDDSVLSSDSFDLLDLQENRPARQRIRSCVSAENFLQIQDFEGLQNRPRPQYLKRYRNRLADSSFSLLTDMDDVTQVYKQALEICSKLN
T21653	DRUGINFO	D00HLW	WZ4003	Investigative
T21653	DRUGINFO	D09AID	PMID22564207C25b	Investigative

T88404	TARGETID	T88404
T88404	FORMERID	TTDI00160
T88404	UNIPROID	OPA1_HUMAN
T88404	TARGNAME	Optic atrophy protein 1 (OPA1)
T88404	GENENAME	OPA1
T88404	TARGTYPE	Literature-reported
T88404	SYNONYMS	OPA1; Dynaminlike 120 kDa protein, mitochondrial; Dynaminlike 120 kDa protein, form S1
T88404	FUNCTION	Dynamin-like 120 kDa protein, form S1: Inactive form produced by cleavage at S1 position by OMA1 following stress conditions that induce loss of mitochondrial membrane potential, leading to negative regulation of mitochondrial fusion.
T88404	BIOCLASS	Carbon-carbon hydrolase
T88404	ECNUMBER	EC 3.6.5.5
T88404	SEQUENCE	MWRLRRAAVACEVCQSLVKHSSGIKGSLPLQKLHLVSRSIYHSHHPTLKLQRPQLRTSFQQFSSLTNLPLRKLKFSPIKYGYQPRRNFWPARLATRLLKLRYLILGSAVGGGYTAKKTFDQWKDMIPDLSEYKWIVPDIVWEIDEYIDFEKIRKALPSSEDLVKLAPDFDKIVESLSLLKDFFTSGSPEETAFRATDRGSESDKHFRKVSDKEKIDQLQEELLHTQLKYQRILERLEKENKELRKLVLQKDDKGIHHRKLKKSLIDMYSEVLDVLSDYDASYNTQDHLPRVVVVGDQSAGKTSVLEMIAQARIFPRGSGEMMTRSPVKVTLSEGPHHVALFKDSSREFDLTKEEDLAALRHEIELRMRKNVKEGCTVSPETISLNVKGPGLQRMVLVDLPGVINTVTSGMAPDTKETIFSISKAYMQNPNAIILCIQDGSVDAERSIVTDLVSQMDPHGRRTIFVLTKVDLAEKNVASPSRIQQIIEGKLFPMKALGYFAVVTGKGNSSESIEAIREYEEEFFQNSKLLKTSMLKAHQVTTRNLSLAVSDCFWKMVRESVEQQADSFKATRFNLETEWKNNYPRLRELDRNELFEKAKNEILDEVISLSQVTPKHWEEILQQSLWERVSTHVIENIYLPAAQTMNSGTFNTTVDIKLKQWTDKQLPNKAVEVAWETLQEEFSRFMTEPKGKEHDDIFDKLKEAVKEESIKRHKWNDFAEDSLRVIQHNALEDRSISDKQQWDAAIYFMEEALQARLKDTENAIENMVGPDWKKRWLYWKNRTQEQCVHNETKNELEKMLKCNEEHPAYLASDEITTVRKNLESRGVEVDPSLIKDTWHQVYRRHFLKTALNHCNLCRRGFYYYQRHFVDSELECNDVVLFWRIQRMLAITANTLRQQLTNTEVRRLEKNVKEVLEDFAEDGEKKIKLLTGKRVQLAEDLKKVREIQEKLDAFIEALHQEK

T16799	TARGETID	T16799
T16799	FORMERID	TTDR00136
T16799	UNIPROID	ECE2_HUMAN
T16799	TARGNAME	Endothelin-converting enzyme 2 (ECE2)
T16799	GENENAME	ECE2
T16799	TARGTYPE	Literature-reported
T16799	SYNONYMS	UNQ403/PRO740; KIAA0604; ECE-2
T16799	FUNCTION	Converts big endothelin-1 to endothelin-1. Also involved in the processing of various neuroendocrine peptides, including neurotensin, angiotensin I, substance P, proenkephalin-derived peptides, and prodynorphin-derived peptides. May limit beta- amyloid peptide accumulation in brain. May also have methyltransferase activity.
T16799	ECNUMBER	EC 3.4.24.71
T16799	SEQUENCE	MNVALQELGAGSNMVEYKRATLRDEDAPETPVEGGASPDAMEVGKGASPFSPGPSPGMTPGTPRSSGLFWRVTCPHLRSISGLCSRTMVGFQKGTRQLLGSRTQLELVLAGASLLLAALLLGCLVALGVQYHRDPSHSTCLTEACIRVAGKILESLDRGVSPCEDFYQFSCGGWIRRNPLPDGRSRWNTFNSLWDQNQAILKHLLENTTFNSSSEAEQKTQRFYLSCLQVERIEELGAQPLRDLIEKIGGWNITGPWDQDNFMEVLKAVAGTYRATPFFTVYISADSKSSNSNVIQVDQSGLFLPSRDYYLNRTANEKVLTAYLDYMEELGMLLGGRPTSTREQMQQVLELEIQLANITVPQDQRRDEEKIYHKMSISELQALAPSMDWLEFLSFLLSPLELSDSEPVVVYGMDYLQQVSELINRTEPSILNNYLIWNLVQKTTSSLDRRFESAQEKLLETLYGTKKSCVPRWQTCISNTDDALGFALGSLFVKATFDRQSKEIAEGMISEIRTAFEEALGQLVWMDEKTRQAAKEKADAIYDMIGFPDFILEPKELDDVYDGYEISEDSFFQNMLNLYNFSAKVMADQLRKPPSRDQWSMTPQTVNAYYLPTKNEIVFPAGILQAPFYARNHPKALNFGGIGVVMGHELTHAFDDQGREYDKEGNLRPWWQNESLAAFRNHTACMEEQYNQYQVNGERLNGRQTLGENIADNGGLKAAYNAYKAWLRKHGEEQQLPAVGLTNHQLFFVGFAQVWCSVRTPESSHEGLVTDPHSPARFRVLGTLSNSRDFLRHFGCPVGSPMNPGQLCEVW
T16799	DRUGINFO	D0P4KL	S136492	Investigative
T16799	DRUGINFO	D0G9UX	CGS 35066	Investigative

T47721	TARGETID	T47721
T47721	FORMERID	TTDR00535
T47721	UNIPROID	CUBN_HUMAN
T47721	TARGNAME	Intrinsic factor-B12 receptor (CUBN)
T47721	GENENAME	CUBN
T47721	TARGTYPE	Literature-reported
T47721	SYNONYMS	Intrinsic factor-vitamin B12 receptor; Cubilin; CUBN
T47721	FUNCTION	Cotransporter which plays a role in lipoprotein, vitamin and iron metabolism, by facilitating their uptake. Binds to ALB, MB, Kappa and lambda-light chains, TF, hemoglobin, GC, SCGB1A1, APOA1, high density lipoprotein, and the GIF-cobalamin complex. The binding of all ligands requires calcium. Serves as important transporter in several absorptive epithelia, including intestine, renal proximal tubules and embryonic yolk sac. Interaction with LRP2 mediates its trafficking throughout vesicles and facilitates the uptake of specific ligands like GC, hemoglobin, ALB, TF and SCGB1A1. Interaction with AMN controls its trafficking to the plasma membrane and facilitates endocytosis of ligands. May play an important role in the development of the peri-implantation embryo through internalization of APOA1 and cholesterol. Binds to LGALS3 at the maternal-fetal interface.
T47721	PDBSTRUC	6GJE; 3KQ4
T47721	BIOCLASS	Growth factor
T47721	SEQUENCE	MMNMSLPFLWSLLTLLIFAEVNGEAGELELQRQKRSINLQQPRMATERGNLVFLTGSAQNIEFRTGSLGKIKLNDEDLSECLHQIQKNKEDIIELKGSAIGLPQNISSQIYQLNSKLVDLERKFQGLQQTVDKKVCSSNPCQNGGTCLNLHDSFFCICPPQWKGPLCSADVNECEIYSGTPLSCQNGGTCVNTMGSYSCHCPPETYGPQCASKYDDCEGGSVARCVHGICEDLMREQAGEPKYSCVCDAGWMFSPNSPACTLDRDECSFQPGPCSTLVQCFNTQGSFYCGACPTGWQGNGYICEDINECEINNGGCSVAPPVECVNTPGSSHCQACPPGYQGDGRVCTLTDICSVSNGGCHPDASCSSTLGSLPLCTCLPGYTGNGYGPNGCVQLSNICLSHPCLNGQCIDTVSGYFCKCDSGWTGVNCTENINECLSNPCLNGGTCVDGVDSFSCECTRLWTGALCQVPQQVCGESLSGINGSFSYRSPDVGYVHDVNCFWVIKTEMGKVLRITFTFFRLESMDNCPHEFLQVYDGDSSSAFQLGRFCGSSLPHELLSSDNALYFHLYSEHLRNGRGFTVRWETQQPECGGILTGPYGSIKSPGYPGNYPPGRDCVWIVVTSPDLLVTFTFGTLSLEHHDDCNKDYLEIRDGPLYQDPLLGKFCTTFSVPPLQTTGPFARIHFHSDSQISDQGFHITYLTSPSDLRCGGNYTDPEGELFLPELSGPFTHTRQCVYMMKQPQGEQIQINFTHVELQCQSDSSQNYIEVRDGETLLGKVCGNGTISHIKSITNSVWIRFKIDASVEKASFRAVYQVACGDELTGEGVIRSPFFPNVYPGERTCRWTIHQPQSQVILLNFTVFEIGSSAHCETDYVEIGSSSILGSPENKKYCGTDIPSFITSVYNFLYVTFVKSSSTENHGFMAKFSAEDLACGEILTESTGTIQSPGHPNVYPHGINCTWHILVQPNHLIHLMFETFHLEFHYNCTNDYLEVYDTDSETSLGRYCGKSIPPSLTSSGNSLMLVFVTDSDLAYEGFLINYEAISAATACLQDYTDDLGTFTSPNFPNNYPNNWECIYRITVRTGQLIAVHFTNFSLEEAIGNYYTDFLEIRDGGYEKSPLLGIFYGSNLPPTIISHSNKLWLKFKSDQIDTRSGFSAYWDGSSTGCGGNLTTSSGTFISPNYPMPYYHSSECYWWLKSSHGSAFELEFKDFHLEHHPNCTLDYLAVYDGPSSNSHLLTQLCGDEKPPLIRSSGDSMFIKLRTDEGQQGRGFKAEYRQTCENVVIVNQTYGILESIGYPNPYSENQHCNWTIRATTGNTVNYTFLAFDLEHHINCSTDYLELYDGPRQMGRYCGVDLPPPGSTTSSKLQVLLLTDGVGRREKGFQMQWFVYGCGGELSGATGSFSSPGFPNRYPPNKECIWYIRTDPGSSIQLTIHDFDVEYHSRCNFDVLEIYGGPDFHSPRIAQLCTQRSPENPMQVSSTGNELAIRFKTDLSINGRGFNASWQAVTGGCGGIFQAPSGEIHSPNYPSPYRSNTDCSWVIRVDRNHRVLLNFTDFDLEPQDSCIMAYDGLSSTMSRLARTCGREQLANPIVSSGNSLFLRFQSGPSRQNRGFRAQFRQACGGHILTSSFDTVSSPRFPANYPNNQNCSWIIQAQPPLNHITLSFTHFELERSTTCARDFVEILDGGHEDAPLRGRYCGTDMPHPITSFSSALTLRFVSDSSISAGGFHTTVTASVSACGGTFYMAEGIFNSPGYPDIYPPNVECVWNIVSSPGNRLQLSFISFQLEDSQDCSRDFVEIREGNATGHLVGRYCGNSFPLNYSSIVGHTLWVRFISDGSGSGTGFQATFMKIFGNDNIVGTHGKVASPFWPENYPHNSNYQWTVNVNASHVVHGRILEMDIEEIQNCYYDKLRIYDGPSIHARLIGAYCGTQTESFSSTGNSLTFHFYSDSSISGKGFLLEWFAVDAPDGVLPTIAPGACGGFLRTGDAPVFLFSPGWPDSYSNRVDCTWLIQAPDSTVELNILSLDIESHRTCAYDSLVIRDGDNNLAQQLAVLCGREIPGPIRSTGEYMFIRFTSDSSVTRAGFNASFHKSCGGYLHADRGIITSPKYPETYPSNLNCSWHVLVQSGLTIAVHFEQPFQIPNGDSSCNQGDYLVLRNGPDICSPPLGPPGGNGHFCGSHASSTLFTSDNQMFVQFISDHSNEGQGFKIKYEAKSLACGGNVYIHDADSAGYVTSPNHPHNYPPHADCIWILAAPPETRIQLQFEDRFDIEVTPNCTSNYLELRDGVDSDAPILSKFCGTSLPSSQWSSGEVMYLRFRSDNSPTHVGFKAKYSIAQCGGRVPGQSGVVESIGHPTLPYRDNLFCEWHLQGLSGHYLTISFEDFNLQNSSGCEKDFVEIWDNHTSGNILGRYCGNTIPDSIDTSSNTAVVRFVTDGSVTASGFRLRFESSMEECGGDLQGSIGTFTSPNYPNPNPHGRICEWRITAPEGRRITLMFNNLRLATHPSCNNEHVIVFNGIRSNSPQLEKLCSSVNVSNEIKSSGNTMKVIFFTDGSRPYGGFTASYTSSEDAVCGGSLPNTPEGNFTSPGYDGVRNYSRNLNCEWTLSNPNQGNSSISIHFEDFYLESHQDCQFDVLEFRVGDADGPLMWRLCGPSKPTLPLVIPYSQVWIHFVTNERVEHIGFHAKYSFTDCGGIQIGDSGVITSPNYPNAYDSLTHCSSLLEAPQGHTITLTFSDFDIEPHTTCAWDSVTVRNGGSPESPIIGQYCGNSNPRTIQSGSNQLVVTFNSDHSLQGGGFYATWNTQTLGCGGIFHSDNGTIRSPHWPQNFPENSRCSWTAITHKSKHLEISFDNNFLIPSGDGQCQNSFVKVWAGTEEVDKALLATGCGNVAPGPVITPSNTFTAVFQSQEAPAQGFSASFVSRCGSNFTGPSGYIISPNYPKQYDNNMNCTYVIEANPLSVVLLTFVSFHLEARSAVTGSCVNDGVHIIRGYSVMSTPFATVCGDEMPAPLTIAGPVLLNFYSNEQITDFGFKFSYRIISCGGVFNFSSGIITSPAYSYADYPNDMHCLYTITVSDDKVIELKFSDFDVVPSTSCSHDYLAIYDGANTSDPLLGKFCGSKRPPNVKSSNNSMLLVFKTDSFQTAKGWKMSFRQTLGPQQGCGGYLTGSNNTFASPDSDSNGMYDKNLNCVWIIIAPVNKVIHLTFNTFALEAASTRQRCLYDYVKLYDGDSENANLAGTFCGSTVPAPFISSGNFLTVQFISDLTLEREGFNATYTIMDMPCGGTYNATWTPQNISSPNSSDPDVPFSICTWVIDSPPHQQVKITVWALQLTSQDCTQNYLQLQDSPQGHGNSRFQFCGRNASAVPVFYSSMSTAMVIFKSGVVNRNSRMSFTYQIADCNRDYHKAFGNLRSPGWPDNYDNDKDCTVTLTAPQNHTISLFFHSLGIENSVECRNDFLEVRNGSNSNSPLLGKYCGTLLPNPVFSQNNELYLRFKSDSVTSDRGYEIIWTSSPSGCGGTLYGDRGSFTSPGYPGTYPNNTYCEWVLVAPAGRLVTINFYFISIDDPGDCVQNYLTLYDGPNASSPSSGPYCGGDTSIAPFVASSNQVFIKFHADYARRPSAFRLTWDS

T76723	TARGETID	T76723
T76723	FORMERID	TTDI03485
T76723	UNIPROID	ANM3_HUMAN
T76723	TARGNAME	Protein arginine methyltransferase 3 (PRMT3)
T76723	GENENAME	PRMT3
T76723	TARGTYPE	Literature-reported
T76723	SYNONYMS	Protein arginine N-methyltransferase 3; Heterogeneous nuclear ribonucleoprotein methyltransferase-like protein 3; HRMT1L3
T76723	FUNCTION	Methylates (mono and asymmetric dimethylation) the guanidino nitrogens of arginyl residues in some proteins.
T76723	PDBSTRUC	4RYL; 4QQN; 4HSG; 3SMQ; 2FYT
T76723	ECNUMBER	EC 2.1.1.-
T76723	SEQUENCE	MCSLASGATGGRGAVENEEDLPELSDSGDEAAWEDEDDADLPHGKQQTPCLFCNRLFTSAEETFSHCKSEHQFNIDSMVHKHGLEFYGYIKLINFIRLKNPTVEYMNSIYNPVPWEKEEYLKPVLEDDLLLQFDVEDLYEPVSVPFSYPNGLSENTSVVEKLKHMEARALSAEAALARAREDLQKMKQFAQDFVMHTDVRTCSSSTSVIADLQEDEDGVYFSSYGHYGIHEEMLKDKIRTESYRDFIYQNPHIFKDKVVLDVGCGTGILSMFAAKAGAKKVLGVDQSEILYQAMDIIRLNKLEDTITLIKGKIEEVHLPVEKVDVIISEWMGYFLLFESMLDSVLYAKNKYLAKGGSVYPDICTISLVAVSDVNKHADRIAFWDDVYGFKMSCMKKAVIPEAVVEVLDPKTLISEPCGIKHIDCHTTSISDLEFSSDFTLKITRTSMCTAIAGYFDIYFEKNCHNRVVFSTGPQSTKTHWKQTVFLLEKPFSVKAGEALKGKVTVHKNKKDPRSLTVTLTLNNSTQTYGLQ
T76723	DRUGINFO	D00JWB	SGC707	Investigative
T76723	DRUGINFO	D0AF1J	PMID22795084C1	Investigative

T93266	TARGETID	T93266
T93266	FORMERID	TTDI03255
T93266	UNIPROID	HCN1_HUMAN
T93266	TARGNAME	Hyperpolarization cyclic nucleotide-gated channel 1 (HCN1)
T93266	GENENAME	HCN1
T93266	TARGTYPE	Literature-reported
T93266	SYNONYMS	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1; Brain cyclic nucleotide-gated channel 1; BCNG1; BCNG-1
T93266	FUNCTION	Contributes to the native pacemaker currents in heart (If) and in neurons (Ih). May mediate responses to sour stimuli. Hyperpolarization-activated ion channel exhibiting weak selectivity for potassium over sodium ions.
T93266	PDBSTRUC	5U6P; 5U6O
T93266	BIOCLASS	Voltage-gated ion channel
T93266	SEQUENCE	MEGGGKPNSSSNSRDDGNSVFPAKASATGAGPAAAEKRLGTPPGGGGAGAKEHGNSVCFKVDGGGGGGGGGGGGEEPAGGFEDAEGPRRQYGFMQRQFTSMLQPGVNKFSLRMFGSQKAVEKEQERVKTAGFWIIHPYSDFRFYWDLIMLIMMVGNLVIIPVGITFFTEQTTTPWIIFNVASDTVFLLDLIMNFRTGTVNEDSSEIILDPKVIKMNYLKSWFVVDFISSIPVDYIFLIVEKGMDSEVYKTARALRIVRFTKILSLLRLLRLSRLIRYIHQWEEIFHMTYDLASAVVRIFNLIGMMLLLCHWDGCLQFLVPLLQDFPPDCWVSLNEMVNDSWGKQYSYALFKAMSHMLCIGYGAQAPVSMSDLWITMLSMIVGATCYAMFVGHATALIQSLDSSRRQYQEKYKQVEQYMSFHKLPADMRQKIHDYYEHRYQGKIFDEENILNELNDPLREEIVNFNCRKLVATMPLFANADPNFVTAMLSKLRFEVFQPGDYIIREGAVGKKMYFIQHGVAGVITKSSKEMKLTDGSYFGEICLLTKGRRTASVRADTYCRLYSLSVDNFNEVLEEYPMMRRAFETVAIDRLDRIGKKNSILLQKFQKDLNTGVFNNQENEILKQIVKHDREMVQAIAPINYPQMTTLNSTSSTTTPTSRMRTQSPPVYTATSLSHSNLHSPSPSTQTPQPSAILSPCSYTTAVCSPPVQSPLAARTFHYASPTASQLSLMQQQPQQQVQQSQPPQTQPQQPSPQPQTPGSSTPKNEVHKSTQALHNTNLTREVRPLSASQPSLPHEVSTLISRPHPTVGESLASIPQPVTAVPGTGLQAGGRSTVPQRVTLFRQMSSGAIPPNRGVPPAPPPPAAALPRESSSVLNTDPDAEKPRFASNL
T93266	DRUGINFO	D0J0ZK	MEL57A	Investigative

T20776	TARGETID	T20776
T20776	FORMERID	TTDR00737
T20776	UNIPROID	F262_HUMAN
T20776	TARGNAME	Fru-2,6-P2ase 2/6PF-2-K (PFK/FBPase 2)
T20776	GENENAME	PFKFB2
T20776	TARGTYPE	Literature-reported
T20776	SYNONYMS	PFKFB2; PFK-2/FBPase-2; 6PF-2-K/Fru-2,6-P2ASE heart-typeisozyme
T20776	FUNCTION	Synthesis and degradation of fructose 2,6-bisphosphate.
T20776	PDBSTRUC	5HTK
T20776	BIOCLASS	Kinase
T20776	SEQUENCE	MSGASSSEQNNNSYETKTPNLRMSEKKCSWASYMTNSPTLIVMIGLPARGKTYVSKKLTRYLNWIGVPTKVFNLGVYRREAVKSYKSYDFFRHDNEEAMKIRKQCALVALEDVKAYLTEENGQIAVFDATNTTRERRDMILNFAEQNSFKVFFVESVCDDPDVIAANILEVKVSSPDYPERNRENVMEDFLKRIECYKVTYRPLDPDNYDKDLSFIKVINVGQRFLVNRVQDYIQSKIVYYLMNIHVQPRTIYLCRHGESEFNLLGKIGGDSGLSVRGKQFAQALRKFLEEQEITDLKVWTSQLKRTIQTAESLGVPYEQWKILNEIDAGVCEEMTYAEIEKRYPEEFALRDQEKYLYRYPGGESYQDLVQRLEPVIMELERQGNVLVISHQAVMRCLLAYFLDKGADELPYLRCPLHTIFKLTPVAYGCKVETIKLNVEAVNTHRDKPTNNFPKNQTPVRMRRNSFTPLSSSNTIRRPRNYSVGSRPLKPLSPLRAQDMQEGAD

T57316	TARGETID	T57316
T57316	FORMERID	TTDR01067
T57316	UNIPROID	NSMA_HUMAN
T57316	TARGNAME	Sphingomyelin phosphodiesterase 2 (SMPD2)
T57316	GENENAME	SMPD2
T57316	TARGTYPE	Literature-reported
T57316	SYNONYMS	SMPD2; Neutral sphingomyelinase; NSMase; N-SMase; Lyso-platelet activating factor-phospholipase C; Lyso-PAF-PLC
T57316	FUNCTION	Converts sphingomyelin to ceramide. Hydrolyze 1-acyl-2- lyso-sn-glycero-3-phosphocholine (lyso-PC) and 1-O-alkyl-2-lyso- sn-glycero-3-phosphocholine (lyso-platelet-activating factor). The physiological substrate seems to be Lyso-PAF.
T57316	BIOCLASS	Phosphoric diester hydrolase
T57316	ECNUMBER	EC 3.1.4.12
T57316	SEQUENCE	MKPNFSLRLRIFNLNCWGIPYLSKHRADRMRRLGDFLNQESFDLALLEEVWSEQDFQYLRQKLSPTYPAAHHFRSGIIGSGLCVFSKHPIQELTQHIYTLNGYPYMIHHGDWFSGKAVGLLVLHLSGMVLNAYVTHLHAEYNRQKDIYLAHRVAQAWELAQFIHHTSKKADVVLLCGDLNMHPEDLGCCLLKEWTGLHDAYLETRDFKGSEEGNTMVPKNCYVSQQELKPFPFGVRIDYVLYKAVSGFYISCKSFETTTGFDPHRGTPLSDHEALMATLFVRHSPPQQNPSSTHGPAERSPLMCVLKEAWTELGLGMAQARWWATFASYVIGLGLLLLALLCVLAAGGGAGEAAILLWTPSVGLVLWAGAFYLFHVQEVNGLYRAQAELQHVLGRAREAQDLGPEPQPALLLGQQEGDRTKEQ

T04303	TARGETID	T04303
T04303	FORMERID	TTDI03534
T04303	UNIPROID	STK16_HUMAN
T04303	TARGNAME	TGF-beta-stimulated factor 1 (STK16)
T04303	GENENAME	STK16
T04303	TARGTYPE	Literature-reported
T04303	SYNONYMS	hPSK; Tyrosine-protein kinase STK16; TSF1; TSF-1; Serine/threonine-protein kinase 16; Protein kinase PKL12; PKL12; Myristoylated and palmitoylated serine/threonine-protein kinase; MPSK1; MPSK
T04303	FUNCTION	Membrane-associated protein kinase that phosphorylates on serine and threonine residues. In vitro substrates include DRG1, ENO1 and EIF4EBP1. Also autophosphorylates. May be involved in secretory vesicle trafficking or intracellular signaling. May have a role in regulating stromal-epithelial interactions that occur during ductal morphogenesis in the mammary gland. May be involved in TGF-beta signaling. Able to autophosphorylate on Tyr residue; it is however unclear whether it has tyrosine-protein kinase toward other proteins.
T04303	PDBSTRUC	2BUJ
T04303	ECNUMBER	EC 2.7.11.1
T04303	SEQUENCE	MGHALCVCSRGTVIIDNKRYLFIQKLGEGGFSYVDLVEGLHDGHFYALKRILCHEQQDREEAQREADMHRLFNHPNILRLVAYCLRERGAKHEAWLLLPFFKRGTLWNEIERLKDKGNFLTEDQILWLLLGICRGLEAIHAKGYAHRDLKPTNILLGDEGQPVLMDLGSMNQACIHVEGSRQALTLQDWAAQRCTISYRAPELFSVQSHCVIDERTDVWSLGCVLYAMMFGEGPYDMVFQKGDSVALAVQNQLSIPQSPRHSSALRQLLNSMMTVDPHQRPHIPLLLSQLEALQPPAPGQHTTQI
T04303	DRUGINFO	D0RO9R	PMID21123062C27	Investigative

T12084	TARGETID	T12084
T12084	FORMERID	TTDI03514
T12084	UNIPROID	RBBP9_HUMAN
T12084	TARGNAME	Retinoblastoma-binding protein 9 (RBBP9)
T12084	GENENAME	RBBP9
T12084	TARGTYPE	Literature-reported
T12084	SYNONYMS	Retinoblastoma-binding protein 10; RBBP10; RBBP-9; RBBP-10; Putative hydrolase RBBP9; Protein BOG; BOG; B5T-overexpressed gene protein
T12084	FUNCTION	May play a role in the transformation process due to its capacity to confer resistance to the growth-inhibitory effects of TGF-beta1 through interaction with retinoblastoma and the subsequent displacement of E2F-1.
T12084	PDBSTRUC	2QS9
T12084	ECNUMBER	EC 3.-.-.-
T12084	SEQUENCE	MASPSKAVIVPGNGGGDVTTHGWYGWVKKELEKIPGFQCLAKNMPDPITARESIWLPFMETELHCDEKTIIIGHSSGAIAAMRYAETHRVYAIVLVSAYTSDLGDENERASGYFTRPWQWEKIKANCPYIVQFGSTDDPFLPWKEQQEVADRLETKLHKFTDCGHFQNTEFHELITVVKSLLKVPA
T12084	DRUGINFO	D06WSN	Ala(1-naph)-Pro-CN	Investigative

T91020	TARGETID	T91020
T91020	FORMERID	TTDR00700
T91020	UNIPROID	DFFB_HUMAN
T91020	TARGNAME	Caspase-activated deoxyribonuclease (DFFB)
T91020	GENENAME	DFFB
T91020	TARGTYPE	Literature-reported
T91020	SYNONYMS	DFFB; DFF-40; Caspase-activated nuclease; Caspase-activated DNase; CPAN
T91020	FUNCTION	Nuclease that induces DNA fragmentation andchromatin condensation during apoptosis. Degrades naked DNA and induces apoptotic morphology.
T91020	PDBSTRUC	1IBX
T91020	ECNUMBER	EC 3.-.-.-
T91020	SEQUENCE	MLQKPKSVKLRALRSPRKFGVAGRSCQEVLRKGCLRFQLPERGSRLCLYEDGTELTEDYFPSVPDNAELVLLTLGQAWQGYVSDIRRFLSAFHEPQVGLIQAAQQLLCDEQAPQRQRLLADLLHNVSQNIAAETRAEDPPWFEGLESRFQSKSGYLRYSCESRIRSYLREVSSYPSTVGAEAQEEFLRVLGSMCQRLRSMQYNGSYFDRGAKGGSRLCTPEGWFSCQGPFDMDSCLSRHSINPYSNRESRILFSTWNLDHIIEKKRTIIPTLVEAIKEQDGREVDWEYFYGLLFTSENLKLVHIVCHKKTTHKLNCDPSRIYKPQTRLKRKQPVRKRQ

T35272	TARGETID	T35272
T35272	FORMERID	TTDR01090
T35272	UNIPROID	FOLB_CHLTR
T35272	TARGNAME	Bacterial Dihydroneopterin aldolase (Bact folB)
T35272	GENENAME	Bact folB
T35272	TARGTYPE	Literature-reported
T35272	SYNONYMS	folB of Chlamydia trachomatis; DhnA-type aldolase; DHNA of Chlamydia trachomatis
T35272	FUNCTION	Catalyzes the conversion of 7,8-dihydroneopterin to 6- hydroxymethyl-7,8-dihydropterin.
T35272	BIOCLASS	Carbon-carbon lyase
T35272	ECNUMBER	EC 4.1.2.25
T35272	SEQUENCE	MLLYRLDIADFRVWVSIGVSEQERHYPQPVLVSLSLFFKEEPKACSTDKVSDSVCYAELVSLIEEVATNNPCALIERLAKVLLEKIEKALAGQVSRIDLRVSKERPPIPDLLSPVSFSISREVP

T30292	TARGETID	T30292
T30292	FORMERID	TTDR00769
T30292	UNIPROID	CATV_GVCPM
T30292	TARGNAME	Virus Cysteine proteinase (Viru VCATH)
T30292	GENENAME	Viru VCATH
T30292	TARGTYPE	Literature-reported
T30292	SYNONYMS	Viral cathepsin; VCATH; V-cath; CP of Cydia pomonella granulosis virus
T30292	FUNCTION	Cysteine protease that plays an essential role in host liquefactionto facilitate horizontal transmission of the virus. May participate in the degradation of foreign protein expressed by the baculovirus system.
T30292	BIOCLASS	Peptidase
T30292	ECNUMBER	EC 3.4.22.50
T30292	SEQUENCE	MTKLLNFVILASVLTVTAHALTYDLNNSDELFKNFAIKYNKTYVSDEERAIKLENFKNNLKMINEKNMASKYAVFDINEYSDLNKNALLRRTTGFRLGLKKNPSAFTMTECSVVVIKDEPQALLPETLDWRDKHGVTPVKNQMECGSCWAFSTIANIESLYNIKYDKALNLSEQHLVNCDNINNGCAGGLMHWALESILQEGGVVSAENEPYYGFDGVCKKSPFELSISGSRRYVLQNENKLRELLVVNGPISVAIDVSDLINYKAGIADICENNEGLNHAVLLVGYGVKNDVPYWILKNSWGAEWGEEGYFRVQRDKNSCGMMNEYASSAIL
T30292	DRUGINFO	D09FGQ	E-64	Investigative

T40545	TARGETID	T40545
T40545	FORMERID	TTDR00838
T40545	UNIPROID	S27A4_HUMAN
T40545	TARGNAME	Solute carrier family 27 member 4 (SLC27A4)
T40545	GENENAME	SLC27A4
T40545	TARGTYPE	Literature-reported
T40545	SYNONYMS	Long-chain fatty acid transport protein 4; Fatty acid transport protein 4; FATP4; FATP-4; ACSVL4
T40545	FUNCTION	Involved in translocation of long-chain fatty acids (LFCA) across the plasma membrane. Appears to be the principal fatty acid transporter in small intestinal enterocytes. Plays a role in the formation of the epidermal barrier. Required for fat absorption in early embryogenesis. Has acyl-CoA ligase activity for long-chain and very-long-chain fatty acids (VLCFAs). Indirectly inhibits RPE65 via substrate competition and via production of VLCFA derivatives like lignoceroyl-CoA. Prevents light-induced degeneration of rods and cones (By similarity).
T40545	BIOCLASS	Carbon-sulfur ligase
T40545	ECNUMBER	EC 6.2.1.-
T40545	SEQUENCE	MLLGASLVGVLLFSKLVLKLPWTQVGFSLLFLYLGSGGWRFIRVFIKTIRRDIFGGLVLLKVKAKVRQCLQERRTVPILFASTVRRHPDKTALIFEGTDTHWTFRQLDEYSSSVANFLQARGLASGDVAAIFMENRNEFVGLWLGMAKLGVEAALINTNLRRDALLHCLTTSRARALVFGSEMASAICEVHASLDPSLSLFCSGSWEPGAVPPSTEHLDPLLKDAPKHLPSCPDKGFTDKLFYIYTSGTTGLPKAAIVVHSRYYRMAALVYYGFRMRPNDIVYDCLPLYHSAGNIVGIGQCLLHGMTVVIRKKFSASRFWDDCIKYNCTIVQYIGELCRYLLNQPPREAENQHQVRMALGNGLRQSIWTNFSSRFHIPQVAEFYGATECNCSLGNFDSQVGACGFNSRILSFVYPIRLVRVNEDTMELIRGPDGVCIPCQPGEPGQLVGRIIQKDPLRRFDGYLNQGANNKKIAKDVFKKGDQAYLTGDVLVMDELGYLYFRDRTGDTFRWKGENVSTTEVEGTLSRLLDMADVAVYGVEVPGTEGRAGMAAVASPTGNCDLERFAQVLEKELPLYARPIFLRLLPELHKTGTYKFQKTELRKEGFDPAIVKDPLFYLDAQKGRYVPLDQEAYSRIQAGEEKL

T48518	TARGETID	T48518
T48518	FORMERID	TTDI02408
T48518	UNIPROID	SPDEF_HUMAN
T48518	TARGNAME	Prostate derived ETS factor (SPDEF)
T48518	GENENAME	SPDEF
T48518	TARGTYPE	Literature-reported
T48518	SYNONYMS	SAM pointed domain-containing Ets transcription factor; Prostate-specific Ets; Prostate-derived Ets factor; Prostate epithelium-specific Ets transcription factor; PSE; PDEF
T48518	FUNCTION	Binds to 5'-GGAT-3' DNA sequences. May play a role in the regulation of the prostate gland and/or prostate cancer development. Acts as a transcriptional activator for SERPINB5 promoter. May function as an androgen-independent transactivator of the prostate-specific antigen (PSA) promoter.
T48518	PDBSTRUC	2DKX; 1YO5
T48518	BIOCLASS	E26 transformation-specific ETS
T48518	SEQUENCE	MGSASPGLSSVSPSHLLLPPDTVSRTGLEKAAAGAVGLERRDWSPSPPATPEQGLSAFYLSYFDMLYPEDSSWAAKAPGASSREEPPEEPEQCPVIDSQAPAGSLDLVPGGLTLEEHSLEQVQSMVVGEVLKDIETACKLLNITADPMDWSPSNVQKWLLWTEHQYRLPPMGKAFQELAGKELCAMSEEQFRQRSPLGGDVLHAHLDIWKSAAWMKERTSPGAIHYCASTSEESWTDSEVDSSCSGQPIHLWQFLKELLLKPHSYGRFIRWLNKEKGIFKIEDSAQVARLWGIRKNRPAMNYDKLSRSIRQYYKKGIIRKPDISQRLVYQFVHPI

T71362	TARGETID	T71362
T71362	FORMERID	TTDI02610
T71362	UNIPROID	I18RA_HUMAN
T71362	TARGNAME	Interleukin 18 receptor (IL18RAP)
T71362	GENENAME	IL18RAP
T71362	TARGTYPE	Literature-reported
T71362	SYNONYMS	Interleukin18 receptor beta; Interleukin18 receptor accessory proteinlike; Interleukin18 receptor accessory protein; Interleukin1 receptor 7; Interleukin-18 receptor beta; Interleukin-18 receptor accessory protein-like; Interleukin-18 receptor accessory protein; Interleukin-1 receptor 7; IL1RAcPL; IL1R7; IL1R accessory proteinlike; IL18Rbeta; IL18RAcP; IL18 receptor accessory protein; IL-1RAcPL; IL-1R7; IL-1R-7; IL-1R accessory protein-like; IL-18Rbeta; IL-18RAcP; IL-18R-beta; IL-18 receptor accessory protein; CDw218b; CD218b; CD218 antigenlike family member B; CD218 antigen-like family member B; Accessory proteinlike; Accessory protein-like; AcPL
T71362	FUNCTION	May play a role in IL18-mediated IFNG synthesis from T-helper 1 (Th1) cells. Within the IL18 receptor complex, does not mediate IL18-binding, but involved in IL18-dependent signal transduction, leading to NF-kappa-B and JNK activation.
T71362	PDBSTRUC	3WO4
T71362	BIOCLASS	Cytokine receptor
T71362	SEQUENCE	MLCLGWIFLWLVAGERIKGFNISGCSTKKLLWTYSTRSEEEFVLFCDLPEPQKSHFCHRNRLSPKQVPEHLPFMGSNDLSDVQWYQQPSNGDPLEDIRKSYPHIIQDKCTLHFLTPGVNNSGSYICRPKMIKSPYDVACCVKMILEVKPQTNASCEYSASHKQDLLLGSTGSISCPSLSCQSDAQSPAVTWYKNGKLLSVERSNRIVVDEVYDYHQGTYVCDYTQSDTVSSWTVRAVVQVRTIVGDTKLKPDILDPVEDTLEVELGKPLTISCKARFGFERVFNPVIKWYIKDSDLEWEVSVPEAKSIKSTLKDEIIERNIILEKVTQRDLRRKFVCFVQNSIGNTTQSVQLKEKRGVVLLYILLGTIGTLVAVLAASALLYRHWIEIVLLYRTYQSKDQTLGDKKDFDAFVSYAKWSSFPSEATSSLSEEHLALSLFPDVLENKYGYSLCLLERDVAPGGVYAEDIVSIIKRSRRGIFILSPNYVNGPSIFELQAAVNLALDDQTLKLILIKFCYFQEPESLPHLVKKALRVLPTVTWRGLKSVPPNSRFWAKMRYHMPVKNSQGFTWNQLRITSRIFQWKGLSRTETTGRSSQPKEW

T60254	TARGETID	T60254
T60254	FORMERID	TTDI03331
T60254	UNIPROID	KCNH1_HUMAN
T60254	TARGNAME	Voltage-gated potassium channel Kv10.1 (KCNH1)
T60254	GENENAME	KCNH1
T60254	TARGTYPE	Literature-reported
T60254	SYNONYMS	hEAG1; h-eag; Voltage-gated potassium channel subunit Kv10.1; Potassium voltage-gated channel subfamily H member 1; EAG1; EAG channel 1; EAG
T60254	FUNCTION	Channel properties are modulated by subunit assembly. Mediates IK(NI) current in myoblasts. Involved in the regulation of cell proliferation and differentiation, in particular adipogenic and osteogenic differentiation in bone marrow-derived mesenchymal stem cells (MSCs). Pore-forming (alpha) subunit of a voltage-gated delayed rectifier potassium channel.
T60254	PDBSTRUC	5J7E
T60254	BIOCLASS	Voltage-gated ion channel
T60254	SEQUENCE	MTMAGGRRGLVAPQNTFLENIVRRSNDTNFVLGNAQIVDWPIVYSNDGFCKLSGYHRAEVMQKSSTCSFMYGELTDKDTIEKVRQTFENYEMNSFEILMYKKNRTPVWFFVKIAPIRNEQDKVVLFLCTFSDITAFKQPIEDDSCKGWGKFARLTRALTSSRGVLQQLAPSVQKGENVHKHSRLAEVLQLGSDILPQYKQEAPKTPPHIILHYCVFKTTWDWIILILTFYTAILVPYNVSFKTRQNNVAWLVVDSIVDVIFLVDIVLNFHTTFVGPAGEVISDPKLIRMNYLKTWFVIDLLSCLPYDVINAFENVDEVSAFMGDPGKIGFADQIPPPLEGRESQGISSLFSSLKVVRLLRLGRVARKLDHYIEYGAAVLVLLVCVFGLAAHWMACIWYSIGDYEIFDEDTKTIRNNSWLYQLAMDIGTPYQFNGSGSGKWEGGPSKNSVYISSLYFTMTSLTSVGFGNIAPSTDIEKIFAVAIMMIGSLLYATIFGNVTTIFQQMYANTNRYHEMLNSVRDFLKLYQVPKGLSERVMDYIVSTWSMSRGIDTEKVLQICPKDMRADICVHLNRKVFKEHPAFRLASDGCLRALAMEFQTVHCAPGDLIYHAGESVDSLCFVVSGSLEVIQDDEVVAILGKGDVFGDVFWKEATLAQSCANVRALTYCDLHVIKRDALQKVLEFYTAFSHSFSRNLILTYNLRKRIVFRKISDVKREEEERMKRKNEAPLILPPDHPVRRLFQRFRQQKEARLAAERGGRDLDDLDVEKGNVLTEHASANHSLVKASVVTVRESPATPVSFQAASTSGVPDHAKLQAPGSECLGPKGGGGDCAKRKSWARFKDACGKSEDWNKVSKAESMETLPERTKASGEATLKKTDSCDSGITKSDLRLDNVGEARSPQDRSPILAEVKHSFYPIPEQTLQATVLEVRHELKEDIKALNAKMTNIEKQLSEILRILTSRRSSQSPQELFEISRPQSPESERDIFGAS
T60254	DRUGINFO	D02QJW	clofilium	Investigative
T60254	DRUGINFO	D02WWM	LY97241	Investigative
T60254	DRUGINFO	D0XH1N	ICA-105574	Investigative

T95154	TARGETID	T95154
T95154	UNIPROID	FMNL1_HUMAN
T95154	TARGNAME	Formin-like protein 1 (FMNL1)
T95154	GENENAME	FMNL1
T95154	TARGTYPE	Literature-reported
T95154	SYNONYMS	Leukocyte formin; FRL1; FMNL; CLL-associated antigen KW-13; C17orf1B; C17orf1
T95154	FUNCTION	May play a role in the control of cell motility and survival of macrophages. Plays a role in the regulation of cell morphology and cytoskeletal organization. Required in the cortical actin filament dynamics and cell shape.
T95154	PDBSTRUC	4YDH
T95154	BIOCLASS	Formin homology family
T95154	SEQUENCE	MGNAAGSAEQPAGPAAPPPKQPAPPKQPMPAAGELEERFNRALNCMNLPPDKVQLLSQYDNEKKWELICDQERFQVKNPPAAYIQKLKSYVDTGGVSRKVAADWMSNLGFKRRVQESTQVLRELETSLRTNHIGWVQEFLNEENRGLDVLLEYLAFAQCSVTYDMESTDNGASNSEKNKPLEQSVEDLSKGPPSSVPKSRHLTIKLTPAHSRKALRNSRIVSQKDDVHVCIMCLRAIMNYQSGFSLVMNHPACVNEIALSLNNKNPRTKALVLELLAAVCLVRGGHDIILAAFDNFKEVCGEQHRFEKLMEYFRNEDSNIDFMVACMQFINIVVHSVENMNFRVFLQYEFTHLGLDLYLERLRLTESDKLQVQIQAYLDNIFDVGALLEDTETKNAVLEHMEELQEQVALLTERLRDAENESMAKIAELEKQLSQARKELETLRERFSESTAMGPSRRPPEPEKAPPAAPTRPSALELKVEELEEKGLIRILRGPGDAVSIEILPVAVATPSGGDAPTPGVPTGSPSPDLAPAAEPAPGAAPPPPPPLPGLPSPQEAPPSAPPQAPPLPGSPEPPPAPPLPGDLPPPPPPPPPPPGTDGPVPPPPPPPPPPPGGPPDALGRRDSELGPGVKAKKPIQTKFRMPLLNWVALKPSQITGTVFTELNDEKVLQELDMSDFEEQFKTKSQGPSLDLSALKSKAAQKAPSKATLIEANRAKNLAITLRKGNLGAERICQAIEAYDLQALGLDFLELLMRFLPTEYERSLITRFEREQRPMEELSEEDRFMLCFSRIPRLPERMTTLTFLGNFPDTAQLLMPQLNAIIAASMSIKSSDKLRQILEIVLAFGNYMNSSKRGAAYGFRLQSLDALLEMKSTDRKQTLLHYLVKVIAEKYPQLTGFHSDLHFLDKAGSVSLDSVLADVRSLQRGLELTQREFVRQDDCMVLKEFLRANSPTMDKLLADSKTAQEAFESVVEYFGENPKTTSPGLFFSLFSRFIKAYKKAEQEVEQWKKEAAAQEAGADTPGKGEPPAPKSPPKARRPQMDLISELKRRQQKEPLIYESDRDGAIEDIITVIKTVPFTARTGKRTSRLLCEASLGEEMPL

T19531	TARGETID	T19531
T19531	FORMERID	TTDI01386
T19531	UNIPROID	ADCY5_HUMAN
T19531	TARGNAME	Adenylate cyclase type 5 (AC5)
T19531	GENENAME	ADCY5
T19531	TARGTYPE	Literature-reported
T19531	SYNONYMS	Adenylyl cyclase 5; Adenylate cyclase type V; ATP pyrophosphate-lyase 5; AC5
T19531	FUNCTION	Catalyzes the formation of the signaling molecule cAMP in response to G-protein signaling. Mediates signaling downstream of ADRB1. Regulates the increase of free cytosolic Ca(2+) in response to increased blood glucose levels and contributes to the regulation of Ca(2+)-dependent insulin secretion.
T19531	BIOCLASS	Phosphorus-oxygen lyase
T19531	ECNUMBER	EC 4.6.1.1
T19531	SEQUENCE	MSGSKSVSPPGYAAQKTAAPAPRGGPEHRSAWGEADSRANGYPHAPGGSARGSTKKPGGAVTPQQQQRLASRWRSDDDDDPPLSGDDPLAGGFGFSFRSKSAWQERGGDDCGRGSRRQRRGAASGGSTRAPPAGGGGGSAAAAASAGGTEVRPRSVEVGLEERRGKGRAADELEAGAVEGGEGSGDGGSSADSGSGAGPGAVLSLGACCLALLQIFRSKKFPSDKLERLYQRYFFRLNQSSLTMLMAVLVLVCLVMLAFHAARPPLQLPYLAVLAAAVGVILIMAVLCNRAAFHQDHMGLACYALIAVVLAVQVVGLLLPQPRSASEGIWWTVFFIYTIYTLLPVRMRAAVLSGVLLSALHLAIALRTNAQDQFLLKQLVSNVLIFSCTNIVGVCTHYPAEVSQRQAFQETRECIQARLHSQRENQQQERLLLSVLPRHVAMEMKADINAKQEDMMFHKIYIQKHDNVSILFADIEGFTSLASQCTAQELVMTLNELFARFDKLAAENHCLRIKILGDCYYCVSGLPEARADHAHCCVEMGMDMIEAISLVREVTGVNVNMRVGIHSGRVHCGVLGLRKWQFDVWSNDVTLANHMEAGGKAGRIHITKATLNYLNGDYEVEPGCGGERNAYLKEHSIETFLILRCTQKRKEEKAMIAKMNRQRTNSIGHNPPHWGAERPFYNHLGGNQVSKEMKRMGFEDPKDKNAQESANPEDEVDEFLGRAIDARSIDRLRSEHVRKFLLTFREPDLEKKYSKQVDDRFGAYVACASLVFLFICFVQITIVPHSIFMLSFYLTCSLLLTLVVFVSVIYSCVKLFPSPLQTLSRKIVRSKMNSTLVGVFTITLVFLAAFVNMFTCNSRDLLGCLAQEHNISASQVNACHVAESAVNYSLGDEQGFCGSPWPNCNFPEYFTYSVLLSLLACSVFLQISCIGKLVLMLAIELIYVLIVEVPGVTLFDNADLLVTANAIDFFNNGTSQCPEHATKVALKVVTPIIISVFVLALYLHAQQVESTARLDFLWKLQATEEKEEMEELQAYNRRLLHNILPKDVAAHFLARERRNDELYYQSCECVAVMFASIANFSEFYVELEANNEGVECLRLLNEIIADFDEIISEDRFRQLEKIKTIGSTYMAASGLNDSTYDKVGKTHIKALADFAMKLMDQMKYINEHSFNNFQMKIGLNIGPVVAGVIGARKPQYDIWGNTVNVASRMDSTGVPDRIQVTTDMYQVLAANTYQLECRGVVKVKGKGEMMTYFLNGGPPLS
T19531	DRUGINFO	D03UXO	NKY80	Investigative

T35809	TARGETID	T35809
T35809	FORMERID	TTDI03063
T35809	UNIPROID	BRD1_HUMAN
T35809	TARGNAME	Bromodomain-containing protein 1 (BRD1)
T35809	GENENAME	BRD1
T35809	TARGTYPE	Literature-reported
T35809	SYNONYMS	Bromodomain and PHD finger-containing protein 2; BRPF2; BRL; BR140-like protein
T35809	FUNCTION	Component of the MOZ/MORF complex which has a histone H3 acetyltransferase activity.
T35809	PDBSTRUC	5PWB; 5PWA; 5PW9; 5PW8; 5PW7
T35809	BIOCLASS	Bromodomain
T35809	SEQUENCE	MRRKGRCHRGSAARHPSSPCSVKHSPTRETLTYAQAQRMVEIEIEGRLHRISIFDPLEIILEDDLTAQEMSECNSNKENSERPPVCLRTKRHKNNRVKKKNEALPSAHGTPASASALPEPKVRIVEYSPPSAPRRPPVYYKFIEKSAEELDNEVEYDMDEEDYAWLEIVNEKRKGDCVPAVSQSMFEFLMDRFEKESHCENQKQGEQQSLIDEDAVCCICMDGECQNSNVILFCDMCNLAVHQECYGVPYIPEGQWLCRHCLQSRARPADCVLCPNKGGAFKKTDDDRWGHVVCALWIPEVGFANTVFIEPIDGVRNIPPARWKLTCYLCKQKGVGACIQCHKANCYTAFHVTCAQKAGLYMKMEPVKELTGGGTTFSVRKTAYCDVHTPPGCTRRPLNIYGDVEMKNGVCRKESSVKTVRSTSKVRKKAKKAKKALAEPCAVLPTVCAPYIPPQRLNRIANQVAIQRKKQFVERAHSYWLLKRLSRNGAPLLRRLQSSLQSQRSSQQRENDEEMKAAKEKLKYWQRLRHDLERARLLIELLRKREKLKREQVKVEQVAMELRLTPLTVLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPAAAPRRPFSWEDVDRLLDPANRAHLGLEEQLRELLDMLDLTCAMKSSGSRSKRAKLLKKEIALLRNKLSQQHSQPLPTGPGLEGFEEDGAALGPEAGEEVLPRLETLLQPRKRSRSTCGDSEVEEESPGKRLDAGLTNGFGGARSEQEPGGGLGRKATPRRRCASESSISSSNSPLCDSSFNAPKCGRGKPALVRRHTLEDRSELISCIENGNYAKAARIAAEVGQSSMWISTDAAASVLEPLKVVWAKCSGYPSYPALIIDPKMPRVPGHHNGVTIPAPPLDVLKIGEHMQTKSDEKLFLVLFFDNKRSWQWLPKSKMVPLGIDETIDKLKMMEGRNSSIRKAVRIAFDRAMNHLSRVHGEPTSDLSDID
T35809	DRUGINFO	D08RDI	OF-1	Investigative
T35809	DRUGINFO	D0O6XT	NI-57	Investigative

T42025	TARGETID	T42025
T42025	FORMERID	TTDI03183
T42025	UNIPROID	ERR2_HUMAN
T42025	TARGNAME	Estrogen-related receptor-beta (ESRRB)
T42025	GENENAME	ESRRB
T42025	TARGTYPE	Literature-reported
T42025	SYNONYMS	Steroid hormone receptor ERR2; Nuclear receptor subfamily 3 group B member 2; NR3B2; Estrogen-related receptor beta; Estrogen receptor-like 2; ESRL2; ERRB2; ERR-beta; ERR beta-2
T42025	FUNCTION	Isoform 3: Transcription factor that binds a canonical ESRRB recognition (ERRE) sequence 5'TCAAGGTCA-3' localized on promoter and enhancer of targets genes regulating their expression or their transcription activity. Plays a role, in a LIF-independent manner, in maintainance of self-renewal and pluripotency of embryonic and trophoblast stem cells through different signaling pathways including FGF signaling pathway and Wnt signaling pathways. Upon FGF signaling pathway activation, interacts with KDM1A by directly binding to enhancer site of ELF5 and EOMES and activating their transcription leading to self-renewal of trophoblast stem cells. Also regulates expression of multiple rod-specific genes and is required for survival of this cell type (By similarity). Plays a role as transcription factor activator of GATA6, NR0B1, POU5F1 and PERM1. Plays a role as transcription factor repressor of NFE2L2 transcriptional activity and ESR1 transcriptional activity. During mitosis remains bound to a subset of interphase target genes, including pluripotency regulators, through the canonical ESRRB recognition (ERRE) sequence, leading to their transcriptional activation in early G1 phase. Can coassemble on structured DNA elements with other transcription factors like SOX2, POU5F1, KDM1A and NCOA3 to trigger ESRRB-dependent gene activation. This mechanism, in the case of SOX2 corecruitment prevents the embryonic stem cells (ESCs) to epiblast stem cells (EpiSC) transition through positive regulation of NR0B1 that inhibits the EpiSC transcriptional program. Also plays a role inner ear development by controlling expression of ion channels and transporters and in early placentation (By similarity).
T42025	PDBSTRUC	1LO1
T42025	BIOCLASS	Nuclear hormone receptor
T42025	SEQUENCE	MSSDDRHLGSSCGSFIKTEPSSPSSGIDALSHHSPSGSSDASGGFGLALGTHANGLDSPPMFAGAGLGGTPCRKSYEDCASGIMEDSAIKCEYMLNAIPKRLCLVCGDIASGYHYGVASCEACKAFFKRTIQGNIEYSCPATNECEITKRRRKSCQACRFMKCLKVGMLKEGVRLDRVRGGRQKYKRRLDSESSPYLSLQISPPAKKPLTKIVSYLLVAEPDKLYAMPPPGMPEGDIKALTTLCDLADRELVVIIGWAKHIPGFSSLSLGDQMSLLQSAWMEILILGIVYRSLPYDDKLVYAEDYIMDEEHSRLAGLLELYRAILQLVRRYKKLKVEKEEFVTLKALALANSDSMYIEDLEAVQKLQDLLHEALQDYELSQRHEEPWRTGKLLLTLPLLRQTAAKAVQHFYSVKLQGKVPMHKLFLEMLEAKV
T42025	DRUGINFO	D06JPQ	DY131	Investigative
T42025	DRUGINFO	D0S9YX	biochanin A	Investigative
T42025	DRUGINFO	D0SY2M	daidzein	Investigative

T08198	TARGETID	T08198
T08198	FORMERID	TTDI03428
T08198	UNIPROID	OXSR1_HUMAN
T08198	TARGNAME	Oxidative stress responsive 1 (OXSR1)
T08198	GENENAME	OXSR1
T08198	TARGTYPE	Literature-reported
T08198	SYNONYMS	Serine/threonine-protein kinase OSR1; Oxidative stress-responsive 1 protein; KIAA1101
T08198	FUNCTION	Phosphorylates RELL1, RELL2 and RELT. Phosphorylates PAK1. Phosphorylates PLSCR1 in the presence of RELT.
T08198	PDBSTRUC	3DAK; 2VWI; 2V3S
T08198	ECNUMBER	EC 2.7.11.1
T08198	SEQUENCE	MSEDSSALPWSINRDDYELQEVIGSGATAVVQAAYCAPKKEKVAIKRINLEKCQTSMDELLKEIQAMSQCHHPNIVSYYTSFVVKDELWLVMKLLSGGSVLDIIKHIVAKGEHKSGVLDESTIATILREVLEGLEYLHKNGQIHRDVKAGNILLGEDGSVQIADFGVSAFLATGGDITRNKVRKTFVGTPCWMAPEVMEQVRGYDFKADIWSFGITAIELATGAAPYHKYPPMKVLMLTLQNDPPSLETGVQDKEMLKKYGKSFRKMISLCLQKDPEKRPTAAELLRHKFFQKAKNKEFLQEKTLQRAPTISERAKKVRRVPGSSGRLHKTEDGGWEWSDDEFDEESEEGKAAISQLRSPRVKESISNSELFPTTDPVGTLLQVPEQISAHLPQPAGQIATQPTQVSLPPTAEPAKTAQALSSGSGSQETKIPISLVLRLRNSKKELNDIRFEFTPGRDTAEGVSQELISAGLVDGRDLVIVAANLQKIVEEPQSNRSVTFKLASGVEGSDIPDDGKLIGFAQLSIS
T08198	DRUGINFO	D0RJ8J	PMID24793884C74	Investigative

T98078	TARGETID	T98078
T98078	FORMERID	TTDI01362
T98078	UNIPROID	DCMC_HUMAN
T98078	TARGNAME	Malonyl-CoA decarboxylase (MLYCD)
T98078	GENENAME	MLYCD
T98078	TARGTYPE	Literature-reported
T98078	SYNONYMS	Malonyl-CoA decarboxylase, mitochondrial; MCD
T98078	FUNCTION	Catalyzes the conversion of malonyl-CoA to acetyl-CoA. In the fatty acid biosynthesis MCD selectively removes malonyl-CoA and thus assures that methyl-malonyl-CoA is the only chain elongating substrate for fatty acid synthase and that fatty acids with multiple methyl side chains are produced. In peroxisomes it may be involved in degrading intraperoxisomal malonyl-CoA, which is generated by the peroxisomal beta-oxidation of odd chain-length dicarboxylic fatty acids. Plays a role in the metabolic balance between glucose and lipid oxidation in muscle independent of alterations in insulin signaling. May play a role in controlling the extent of ischemic injury by promoting glucose oxidation.
T98078	PDBSTRUC	4F0X; 2YGW
T98078	ECNUMBER	EC 4.1.1.9
T98078	SEQUENCE	MRGFGPGLTARRLLPLRLPPRPPGPRLASGQAAGALERAMDELLRRAVPPTPAYELREKTPAPAEGQCADFVSFYGGLAETAQRAELLGRLARGFGVDHGQVAEQSAGVLHLRQQQREAAVLLQAEDRLRYALVPRYRGLFHHISKLDGGVRFLVQLRADLLEAQALKLVEGPDVREMNGVLKGMLSEWFSSGFLNLERVTWHSPCEVLQKISEAEAVHPVKNWMDMKRRVGPYRRCYFFSHCSTPGEPLVVLHVALTGDISSNIQAIVKEHPPSETEEKNKITAAIFYSISLTQQGLQGVELGTFLIKRVVKELQREFPHLGVFSSLSPIPGFTKWLLGLLNSQTKEHGRNELFTDSECKEISEITGGPINETLKLLLSSSEWVQSEKLVRALQTPLMRLCAWYLYGEKHRGYALNPVANFHLQNGAVLWRINWMADVSLRGITGSCGLMANYRYFLEETGPNSTSYLGSKIIKASEQVLSLVAQFQKNSKL

T64725	TARGETID	T64725
T64725	FORMERID	TTDNR00674
T64725	UNIPROID	FADS2_HUMAN
T64725	TARGNAME	Fatty acid desaturase 2 (FADS2)
T64725	GENENAME	FADS2
T64725	TARGTYPE	Literature-reported
T64725	SYNONYMS	FADS2; Delta-6 desaturase; Delta(6) fatty acid desaturase; Delta(6) desaturase; D6D
T64725	FUNCTION	Component of a lipid metabolic pathway that catalyzes biosynthesis of highly unsaturated fatty acids (HUFA) from precursor essential polyunsaturated fatty acids (PUFA) linoleic acid (LA) (18:2n-6) and alpha-linolenic acid (ALA) (18:3n-3). Catalyzes the first andrate limiting step in this pathway which is the desaturation of LA (18:2n-6) and ALA (18:3n-3) into gamma- linoleic acid (GLA) (18:3n-6) and stearidonic acid (18:4n-3) respectively and other desaturation steps. Highly unsaturated fatty acids (HUFA) play pivotal roles in many biological functions. It catalizes as well the introduction of a cis double bond in palmitate to produce the mono-unsaturated fatty acid sapienate, the most abundant fatty acid in sebum.
T64725	BIOCLASS	Paired donor oxygen oxidoreductase
T64725	ECNUMBER	EC 1.14.19.3
T64725	SEQUENCE	MGKGGNQGEGAAEREVSVPTFSWEEIQKHNLRTDRWLVIDRKVYNITKWSIQHPGGQRVIGHYAGEDATDAFRAFHPDLEFVGKFLKPLLIGELAPEEPSQDHGKNSKITEDFRALRKTAEDMNLFKTNHVFFLLLLAHIIALESIAWFTVFYFGNGWIPTLITAFVLATSQAQAGWLQHDYGHLSVYRKPKWNHLVHKFVIGHLKGASANWWNHRHFQHHAKPNIFHKDPDVNMLHVFVLGEWQPIEYGKKKLKYLPYNHQHEYFFLIGPPLLIPMYFQYQIIMTMIVHKNWVDLAWAVSYYIRFFITYIPFYGILGALLFLNFIRFLESHWFVWVTQMNHIVMEIDQEAYRDWFSSQLTATCNVEQSFFNDWFSGHLNFQIEHHLFPTMPRHNLHKIAPLVKSLCAKHGIEYQEKPLLRALLDIIRSLKKSGKLWLDAYLHK

T36419	TARGETID	T36419
T36419	FORMERID	TTDI01445
T36419	UNIPROID	TXD12_HUMAN
T36419	TARGNAME	Thioredoxin domain-contained protein 12 (TXNDC12)
T36419	GENENAME	TXNDC12
T36419	TARGTYPE	Literature-reported
T36419	SYNONYMS	hTLP19; UNQ713/PRO1376; Thioredoxin-like protein p19; Thioredoxin domain-containing protein 12; TLP19; Endoplasmic reticulum resident protein 19; Endoplasmic reticulum resident protein 18; ERp19; ERp18; ER protein 19; ER protein 18
T36419	FUNCTION	Possesses significant protein thiol-disulfide oxidase activity.
T36419	PDBSTRUC	2K8V; 1SEN
T36419	ECNUMBER	EC 1.8.4.2
T36419	SEQUENCE	METRPRLGATCLLGFSFLLLVISSDGHNGLGKGFGDHIHWRTLEDGKKEAAASGLPLMVIIHKSWCGACKALKPKFAESTEISELSHNFVMVNLEDEEEPKDEDFSPDGGYIPRILFLDPSGKVHPEIINENGNPSYKYFYVSAEQVVQGMKEAQERLTGDAFRKKHLEDEL

T17523	TARGETID	T17523
T17523	FORMERID	TTDI03528
T17523	UNIPROID	S1PR4_HUMAN
T17523	TARGNAME	Sphingosine-1-phosphate receptor 4 (S1PR4)
T17523	GENENAME	S1PR4
T17523	TARGTYPE	Literature-reported
T17523	SYNONYMS	Sphingosine 1-phosphate receptor Edg-6; Sphingosine 1-phosphate receptor 4; S1P4; S1P receptor Edg-6; S1P receptor 4; Endothelial differentiation G-protein coupled receptor 6; EDG6
T17523	FUNCTION	Receptor for the lysosphingolipid sphingosine 1-phosphate (S1P). S1P is a bioactive lysophospholipid that elicits diverse physiological effect on most types of cells and tissues. May be involved in cell migration processes that are specific for lymphocytes.
T17523	PDBSTRUC	2DCO
T17523	BIOCLASS	GPCR rhodopsin
T17523	SEQUENCE	MNATGTPVAPESCQQLAAGGHSRLIVLHYNHSGRLAGRGGPEDGGLGALRGLSVAASCLVVLENLLVLAAITSHMRSRRWVYYCLVNITLSDLLTGAAYLANVLLSGARTFRLAPAQWFLREGLLFTALAASTFSLLFTAGERFATMVRPVAESGATKTSRVYGFIGLCWLLAALLGMLPLLGWNCLCAFDRCSSLLPLYSKRYILFCLVIFAGVLATIMGLYGAIFRLVQASGQKAPRPAARRKARRLLKTVLMILLAFLVCWGPLFGLLLADVFGSNLWAQEYLRGMDWILALAVLNSAVNPIIYSFRSREVCRAVLSFLCCGCLRLGMRGPGDCLARAVEAHSGASTTDSSLRPRDSFRGSRSLSFRMREPLSSISSVRSI
T17523	DRUGINFO	D0L8NF	phytosphingosine 1-phosphate	Investigative
T17523	DRUGINFO	D02UUO	dihydrosphingosine-1-phosphate	Investigative
T17523	DRUGINFO	D0U7YK	KRP 203-phosphate	Investigative
T17523	DRUGINFO	D05KEE	AFD(R)	Investigative
T17523	DRUGINFO	D06DYN	FTY720-phosphate	Investigative
T17523	DRUGINFO	D0W1ZW	VPC03090-P	Investigative
T17523	DRUGINFO	D03BRM	AUY954	Investigative

T64485	TARGETID	T64485
T64485	FORMERID	TTDNR00643
T64485	UNIPROID	ANGT_HUMAN
T64485	TARGNAME	Angiotensinogen (AGT)
T64485	GENENAME	AGT
T64485	TARGTYPE	Literature-reported
T64485	SYNONYMS	Serpin A8; SERPINA8
T64485	FUNCTION	Essential component of the renin-angiotensin system (RAS), a potent regulator of blood pressure, body fluid and electrolyte homeostasis.
T64485	PDBSTRUC	6I3I; 6I3F; 5XJM; 5M3Y; 5M3X
T64485	BIOCLASS	Serpin protein
T64485	SEQUENCE	MRKRAPQSEMAPAGVSLRATILCLLAWAGLAAGDRVYIHPFHLVIHNESTCEQLAKANAGKPKDPTFIPAPIQAKTSPVDEKALQDQLVLVAAKLDTEDKLRAAMVGMLANFLGFRIYGMHSELWGVVHGATVLSPTAVFGTLASLYLGALDHTADRLQAILGVPWKDKNCTSRLDAHKVLSALQAVQGLLVAQGRADSQAQLLLSTVVGVFTAPGLHLKQPFVQGLALYTPVVLPRSLDFTELDVAAEKIDRFMQAVTGWKTGCSLMGASVDSTLAFNTYVHFQGKMKGFSLLAEPQEFWVDNSTSVSVPMLSGMGTFQHWSDIQDNFSVTQVPFTESACLLLIQPHYASDLDKVEGLTFQQNSLNWMKKLSPRTIHLTMPQLVLQGSYDLQDLLAQAELPAILHTELNLQKLSNDRIRVGEVLNSIFFELEADEREPTESTQQLNKPEVLEVTLNRPFLFAVYDQSATALHFLGRVANPLSTA

T28025	TARGETID	T28025
T28025	FORMERID	TTDR00099
T28025	UNIPROID	FOS_HUMAN
T28025	TARGNAME	Proto-oncogene c-Fos (c-Fos)
T28025	GENENAME	FOS
T28025	TARGTYPE	Literature-reported
T28025	SYNONYMS	G0S7; G0/G1 switch regulatory protein 7; Cellular oncogene fos; C-fos
T28025	FUNCTION	In the heterodimer, FOS and JUN/AP-1 basic regions each seems to interact with symmetrical DNA half sites. On TGF-beta activation, forms a multimeric SMAD3/SMAD4/JUN/FOS complex at the AP1/SMAD-binding site to regulate TGF-beta-mediated signaling. Has a critical function in regulating the development of cells destined to form and maintain the skeleton. It is thought to have an important role in signal transduction, cell proliferation and differentiation. In growing cells, activates phospholipid synthesis, possibly by activating CDS1 and PI4K2A. This activity requires Tyr-dephosphorylation and association with the endoplasmic reticulum. Nuclear phosphoprotein which forms a tight but non-covalently linked complex with the JUN/AP-1 transcription factor.
T28025	PDBSTRUC	1S9K; 1FOS; 1A02
T28025	BIOCLASS	Basic leucine zipper bZIP
T28025	SEQUENCE	MMFSGFNADYEASSSRCSSASPAGDSLSYYHSPADSFSSMGSPVNAQDFCTDLAVSSANFIPTVTAISTSPDLQWLVQPALVSSVAPSQTRAPHPFGVPAPSAGAYSRAGVVKTMTGGRAQSIGRRGKVEQLSPEEEEKRRIRRERNKMAAAKCRNRRRELTDTLQAETDQLEDEKSALQTEIANLLKEKEKLEFILAAHRPACKIPDDLGFPEEMSVASLDLTGGLPEVATPESEEAFTLPLLNDPEPKPSVEPVKSISSMELKTEPFDDFLFPASSRPSGSETARSVPDMDLSGSFYAADWEPLHSGSLGMGPMATELEPLCTPVVTCTPSCTAYTSSFVFTYPEADSFPSCAAAHRKGSSSNEPSSDSLSSPTLLAL

T71081	TARGETID	T71081
T71081	FORMERID	TTDI02547
T71081	UNIPROID	RASH_HUMAN
T71081	TARGNAME	GTPase HRas (HRAS)
T71081	GENENAME	HRAS
T71081	TARGTYPE	Literature-reported
T71081	SYNONYMS	p21ras; cHras; c-H-ras; Transforming protein p21; HaRas; Ha-Ras; H-Ras-1; GTPase HRas, Nterminally processed
T71081	FUNCTION	Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. Involved in the activation of Ras protein signal transduction.
T71081	PDBSTRUC	821P; 721P; 6Q21; 6D5W; 6D5V
T71081	BIOCLASS	Small GTPase
T71081	SEQUENCE	MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHQYREQIKRVKDSDDVPMVLVGNKCDLAARTVESRQAQDLARSYGIPYIETSAKTRQGVEDAFYTLVREIRQHKLRKLNPPDESGPGCMSCKCVLS

T62912	TARGETID	T62912
T62912	FORMERID	TTDR00261
T62912	UNIPROID	COLI_HUMAN
T62912	TARGNAME	Corticotropin-lipotropin (POMC)
T62912	GENENAME	POMC
T62912	TARGTYPE	Literature-reported
T62912	SYNONYMS	Pro-opiomelanocortin
T62912	FUNCTION	Corticotropin: Stimulates the adrenal glands to release cortisol.
T62912	PDBSTRUC	4Y49; 4XPD; 4XNH
T62912	SEQUENCE	MPRSCCSRSGALLLALLLQASMEVRGWCLESSQCQDLTTESNLLECIRACKPDLSAETPMFPGNGDEQPLTENPRKYVMGHFRWDRFGRRNSSSSGSSGAGQKREDVSAGEDCGPLPEGGPEPRSDGAKPGPREGKRSYSMEHFRWGKPVGKKRRPVKVYPNGAEDESAEAFPLEFKRELTGQRLREGDGPDGPADDGAGAQADLEHSLLVAAEKKDEGPYRMEHFRWGSPPKDKRYGGFMTSEKSQTPLVTLFKNAIIKNAYKKGE
T62912	DRUGINFO	D0B7GU	Dihydromorphine	Investigative

T51671	TARGETID	T51671
T51671	FORMERID	TTDR00777
T51671	UNIPROID	NPY_HUMAN
T51671	TARGNAME	Neuropeptide Y (NPY)
T51671	GENENAME	NPY
T51671	TARGTYPE	Literature-reported
T51671	SYNONYMS	Pro-neuropeptide Y
T51671	FUNCTION	NPY is implicated in the control of feeding and in secretion of gonadotrophin-release hormone.
T51671	PDBSTRUC	1RON; 1QFA
T51671	SEQUENCE	MLGNKRLGLSGLTLALSLLVCLGALAEAYPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRYGKRSSPETLISDLLMRESTENVPRTRLEDPAMW
T51671	DRUGINFO	D08JUG	Alpha-Aminoisobutyric Acid	Investigative
T51671	DRUGINFO	D0DO9W	L-Tyrosinamide	Investigative

T50768	TARGETID	T50768
T50768	FORMERID	TTDI02055
T50768	UNIPROID	DQA1_HUMAN
T50768	TARGNAME	HLA class II antigen DQ-2 alpha (HLA-DQA1)
T50768	GENENAME	HLA-DQA1
T50768	TARGTYPE	Literature-reported
T50768	SYNONYMS	MHC class II DQA1; HLADQA1; HLADCA; HLA-DQA1; HLA class II histocompatibility antigen, DQ alpha 1 chain; DCalpha; DC1 alpha chain
T50768	FUNCTION	Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs,other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM andMHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.
T50768	PDBSTRUC	6MFG; 6MFF; 5KSV; 5KSU; 5KSB
T50768	BIOCLASS	MHC class II
T50768	SEQUENCE	MILNKALMLGALALTTVMSPCGGEDIVADHVASYGVNLYQSYGPSGQYTHEFDGDEQFYVDLGRKETVWCLPVLRQFRFDPQFALTNIAVLKHNLNSLIKRSNSTAATNEVPEVTVFSKSPVTLGQPNILICLVDNIFPPVVNITWLSNGHSVTEGVSETSFLSKSDHSFFKISYLTLLPSAEESYDCKVEHWGLDKPLLKHWEPEIPAPMSELTETVVCALGLSVGLVGIVVGTVFIIRGLRSVGASRHQGPL

T75655	TARGETID	T75655
T75655	FORMERID	TTDR00441
T75655	UNIPROID	APOA2_HUMAN
T75655	TARGNAME	Apolipoprotein A-II (APOA2)
T75655	GENENAME	APOA2
T75655	TARGTYPE	Literature-reported
T75655	SYNONYMS	Apolipoprotein A2; ApoA-II; Apo-AII
T75655	FUNCTION	May stabilize HDL (high density lipoprotein) structure by its association with lipids, and affect the HDL metabolism.
T75655	BIOCLASS	Apolipoprotein
T75655	SEQUENCE	MKLLAATVLLLTICSLEGALVRRQAKEPCVESLVSQYFQTVTDYGKDLMEKVKSPELQAEAKSYFEKSKEQLTPLIKKAGTELVNFLSYFVELGTQPATQ
T75655	DRUGINFO	D02UVH	B-Octylglucoside	Investigative

T26144	TARGETID	T26144
T26144	FORMERID	TTDI01765
T26144	UNIPROID	FIBG_HUMAN
T26144	TARGNAME	Fibrinogen (FGG)
T26144	GENENAME	FGG
T26144	TARGTYPE	Literature-reported
T26144	SYNONYMS	PRO2061; Fibrinogen gamma chain
T26144	FUNCTION	Has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However, subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets via an ITGB3-dependent pathway. Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the antibacterial immune response via both innate and T-cell mediated pathways. Together with fibrinogen alpha (FGA) and fibrinogen beta (FGB), polymerizes to form an insoluble fibrin matrix.
T26144	PDBSTRUC	4B60; 3HUS; 3H32; 3GHG; 3FIB
T26144	BIOCLASS	Fibrinogen protein
T26144	SEQUENCE	MSWSLHPRNLILYFYALLFLSSTCVAYVATRDNCCILDERFGSYCPTTCGIADFLSTYQTKVDKDLQSLEDILHQVENKTSEVKQLIKAIQLTYNPDESSKPNMIDAATLKSRKMLEEIMKYEASILTHDSSIRYLQEIYNSNNQKIVNLKEKVAQLEAQCQEPCKDTVQIHDITGKDCQDIANKGAKQSGLYFIKPLKANQQFLVYCEIDGSGNGWTVFQKRLDGSVDFKKNWIQYKEGFGHLSPTGTTEFWLGNEKIHLISTQSAIPYALRVELEDWNGRTSTADYAMFKVGPEADKYRLTYAYFAGGDAGDAFDGFDFGDDPSDKFFTSHNGMQFSTWDNDNDKFEGNCAEQDGSGWWMNKCHAGHLNGVYYQGGTYSKASTPNGYDNGIIWATWKTRWYSMKKTTMKIIPFNRLTIGEGQQHHLGGAKQVRPEHPAETEYDSLYPEDDL

T66686	TARGETID	T66686
T66686	FORMERID	TTDR00666
T66686	UNIPROID	PBPB_ECOLI
T66686	TARGNAME	Bacterial Penicillin-binding protein 1B (Bact mrcB)
T66686	GENENAME	Bact mrcB
T66686	TARGTYPE	Literature-reported
T66686	SYNONYMS	mrcB; PBP1b; PBP-1b; PBP 1b; Murein polymerase
T66686	FUNCTION	Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan strands) and a penicillin-sensitive transpeptidase C-terminal domain (cross-linking of the peptide subunits).
T66686	PDBSTRUC	6G5R; 6FZK; 5HLD; 5HLB; 5HLA
T66686	BIOCLASS	Acyltransferase
T66686	SEQUENCE	MAGNDREPIGRKGKPTRPVKQKVSRRRYEDDDDYDDYDDYEDEEPMPRKGKGKGKGRKPRGKRGWLWLLLKLAIVFAVLIAIYGVYLDQKIRSRIDGKVWQLPAAVYGRMVNLEPDMTISKNEMVKLLEATQYRQVSKMTRPGEFTVQANSIEMIRRPFDFPDSKEGQVRARLTFDGDHLATIVNMENNRQFGFFRLDPRLITMISSPNGEQRLFVPRSGFPDLLVDTLLATEDRHFYEHDGISLYSIGRAVLANLTAGRTVQGASTLTQQLVKNLFLSSERSYWRKANEAYMALIMDARYSKDRILELYMNEVYLGQSGDNEIRGFPLASLYYFGRPVEELSLDQQALLVGMVKGASIYNPWRNPKLALERRNLVLRLLQQQQIIDQELYDMLSARPLGVQPRGGVISPQPAFMQLVRQELQAKLGDKVKDLSGVKIFTTFDSVAQDAAEKAAVEGIPALKKQRKLSDLETAIVVVDRFSGEVRAMVGGSEPQFAGYNRAMQARRSIGSLAKPATYLTALSQPKIYRLNTWIADAPIALRQPNGQVWSPQNDDRRYSESGRVMLVDALTRSMNVPTVNLGMALGLPAVTETWIKLGVPKDQLHPVPAMLLGALNLTPIEVAQAFQTIASGGNRAPLSALRSVIAEDGKVLYQSFPQAERAVPAQAAYLTLWTMQQVVQRGTGRQLGAKYPNLHLAGKTGTTNNNVDTWFAGIDGSTVTITWVGRDNNQPTKLYGASGAMSIYQRYLANQTPTPLNLVPPEDIADMGVDYDGNFVCSGGMRILPVWTSDPQSLCQQSEMQQQPSGNPFDQSSQPQQQPQQQPAQQEQKDSDGVAGWIKDMFGSN
T66686	DRUGINFO	D08COD	N-BENZOYL-D-ALANINE	Investigative
T66686	DRUGINFO	D0O4TL	Cephalosporin C	Investigative

T78338	TARGETID	T78338
T78338	FORMERID	TTDNR00676
T78338	UNIPROID	POLG_YEFV1
T78338	TARGNAME	Flavivirus RNA-directed RNA polymerase NS5 (FlaV NS5)
T78338	GENENAME	FlaV NS5
T78338	TARGTYPE	Literature-reported
T78338	SYNONYMS	Flavivirus Non-structural protein 5
T78338	FUNCTION	Capsid protein C: Plays a role in virus budding by binding to the cell membrane and gathering the viral RNA into a nucleocapsid that forms the core of a mature virus particle. During virus entry, may induce genome penetration into the host cytoplasm after hemifusion induced by the surface proteins. Can migrate to the cell nucleus where it modulates host functions.
T78338	PDBSTRUC	6IW4; 6IW2; 6IW1; 6IW0; 6EPK
T78338	ECNUMBER	EC 2.1.1.56
T78338	SEQUENCE	GSANGKTLGEVWKRELNLLDKRQFELYKRTDIVEVDRDTARRHLAEGKVDTGVAVSRGTAKLRWFHERGYVKLEGRVIDLGCGRGGWCYYAAAQKEVSGVKGFTLGRDGHEKPMNVQSLGWNIITFKDKTDIHRLEPVKCDTLLCDIGESSSSSVTEGERTVRVLDTVEKWLACGVDNFCVKVLAPYMPDVLEKLELLQRRFGGTVIRNPLSRNSTHEMYYVSGARSNVTFTVNQTSRLLMRRMRRPTGKVTLEADVILPIGTRSVETDKGPLDKEAIEERVERIKSEYMTSWFYDNDNPYRTWHYCGSYVTKTSGSAASMVNGVIKILTYPWDRIEEVTRMAMTDTTPFGQQRVFKEKVDTRAKDPPAGTRKIMKVVNRWLFRHLAREKNPRLCTKEEFIAKVRSHAAIGAYLEEQEQWKTANEAVQDPKFWELVDEERKLHQQGRCRTCVYNMMGKREKKLSEFGKAKGSRAIWYMWLGARYLEFEALGFLNEDHWASRENSGGGVEGIGLQYLGYVIRDLAAMDGGGFYADDTAGWDTRITEADLDDEQEILNYMSPHHKKLAQAVMEMTYKNKVVKVLRPAPGGKAYMDVISRRDQRGSGQVVTYALNTITNLKVQLIRMAEAEMVIHHQHVQDCDESVLTRLEAWLTEHGCDRLKRMAVSGDDCVVRPIDDRFGLALSHLNAMSKVRKDISEWQPSKGWNDWENVPFCSHHFHELQLKDGRRIVVPCREQDELIGRGRVSPGNGWMIKETACLSKAYANMWSLMYFHKRDMRLLSLAVSSAVPTSWVPQGRTTWSIHGKGEWMTTEDMLEVWNRVWITNNPHMQDKTMVKKWRDVPYLTKRQDKLCGSLIGMTNRATWASHIHLVIHRIRTLIGQEKYTDYLTVMDRYSVDADLQLGELI

T26457	TARGETID	T26457
T26457	FORMERID	TTDI02427
T26457	UNIPROID	ITB3_HUMAN
T26457	TARGNAME	Integrin beta-3 (ITGB3)
T26457	GENENAME	ITGB3
T26457	TARGTYPE	Literature-reported
T26457	SYNONYMS	GPIIIa; GP3A; CD61
T26457	FUNCTION	Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. Fibrinogen binding enhances SELP expression in activated platelets. ITGAV:ITGB3 binds to fractalkine (CX3CL1) and acts as its coreceptor in CX3CR1-dependent fractalkine signaling. ITGAV:ITGB3 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling. ITGAV:ITGB3 binds to FGF1 and this binding is essential for FGF1 signaling. ITGAV:ITGB3 binds to FGF2 and this binding is essential for FGF2 signaling. ITGAV:ITGB3 binds to IGF1 and this binding is essential for IGF1 signaling. ITGAV:ITGB3 binds to IGF2 and this binding is essential for IGF2 signaling. ITGAV:ITGB3 binds to IL1B and this binding is essential for IL1B signaling. ITGAV:ITGB3 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1. ITGAV:ITGB3 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1. Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor.
T26457	PDBSTRUC	6CKB; 6BXJ; 6BXF; 6BXB; 6AVU
T26457	BIOCLASS	Integrin
T26457	SEQUENCE	MRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLGSPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRPDDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFGAFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSRNRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCHVGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLSMDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDTVSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGTFECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFGKITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLLCSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRYCRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDILVVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTFTNITYRGT

T27402	TARGETID	T27402
T27402	FORMERID	TTDR00789
T27402	UNIPROID	S10A8_HUMAN
T27402	TARGNAME	Calgranulin A (S100A8)
T27402	GENENAME	S100A8
T27402	TARGTYPE	Literature-reported
T27402	SYNONYMS	Urinary stone protein band A; S100 calcium-binding protein A8; Protein S100-A8; P8; Myeloid-related protein 8; Migration inhibitory factor-related protein 8; MRP8; MRP-8; Leukocyte L1 complex light chain; Cystic fibrosis antigen; Calprotectin L1L subunit; Calgranulin-A; CFAG; CAGA
T27402	FUNCTION	It can induce neutrophil chemotaxis and adhesion. Predominantly found as calprotectin (S100A8/A9) which has a wide plethora of intra- and extracellular functions. The intracellular functions include: facilitating leukocyte arachidonic acid trafficking and metabolism, modulation of the tubulin-dependent cytoskeleton during migration of phagocytes and activation of the neutrophilic NADPH-oxidase. Activates NADPH-oxidase by facilitating the enzyme complex assembly at the cell membrane, transferring arachidonic acid, an essential cofactor, to the enzyme complex and S100A8 contributes to the enzyme assembly by directly binding to NCF2/P67PHOX. The extracellular functions involve proinflammatory, antimicrobial, oxidant-scavenging and apoptosis-inducing activities. Its proinflammatory activity includes recruitment of leukocytes, promotion of cytokine and chemokine production, and regulation of leukocyte adhesion and migration. Acts as an alarmin or a danger associated molecular pattern (DAMP) molecule and stimulates innate immune cells via binding to pattern recognition receptors such as Toll-like receptor 4 (TLR4) and receptor for advanced glycation endproducts (AGER). Binding to TLR4 and AGER activates the MAP-kinase and NF-kappa-B signaling pathways resulting in the amplification of the proinflammatory cascade. Has antimicrobial activity towards bacteria and fungi and exerts its antimicrobial activity probably via chelation of Zn(2+) which is essential for microbial growth. Can induce cell death via autophagy and apoptosis and this occurs through the cross-talk of mitochondria and lysosomes via reactive oxygen species (ROS) and the process involves BNIP3. Can regulate neutrophil number and apoptosis by an anti-apoptotic effect; regulates cell survival via ITGAM/ITGB and TLR4 and a signaling mechanism involving MEK-ERK. Its role as an oxidant scavenger has a protective role in preventing exaggerated tissue damage by scavenging oxidants. Can act as a potent amplifier of inflammation in autoimmunity as well as in cancer development and tumor spread. The iNOS-S100A8/A9 transnitrosylase complex directs selective inflammatory stimulus-dependent S-nitrosylation of GAPDH and probably multiple targets such as ANXA5, EZR, MSN and VIM by recognizing a [IL]-x-C-x-x-[DE] motif; S100A8 seems to contribute to S-nitrosylation site selectivity. S100A8 is a calcium- and zinc-binding protein which plays a prominent role in the regulation of inflammatory processes and immune response.
T27402	PDBSTRUC	6DS2; 5W1F; 5HLV; 5HLO; 4XJK
T27402	BIOCLASS	S100 calcium-binding protein
T27402	SEQUENCE	MLTELEKALNSIIDVYHKYSLIKGNFHAVYRDDLKKLLETECPQYIRKKGADVWFKELDINTDGAVNFQEFLILVIKMGVAAHKKSHEESHKE

T25076	TARGETID	T25076
T25076	FORMERID	TTDR00412
T25076	UNIPROID	EDN1_HUMAN
T25076	TARGNAME	Endothelin-1 (EDN1)
T25076	GENENAME	EDN1
T25076	TARGTYPE	Literature-reported
T25076	SYNONYMS	Preproendothelin-1; PPET1
T25076	FUNCTION	Endothelins are endothelium-derived vasoconstrictor peptides.
T25076	PDBSTRUC	6DK5; 5GLH; 1V6R; 1T7H; 1EDP
T25076	BIOCLASS	Endothelin/sarafotoxin
T25076	SEQUENCE	MDYLLMIFSLLFVACQGAPETAVLGAELSAVGENGGEKPTPSPPWRLRRSKRCSCSSLMDKECVYFCHLDIIWVNTPEHVVPYGLGSPRSKRALENLLPTKATDRENRCQCASQKDKKCWNFCQAGKELRAEDIMEKDWNNHKKGKDCSKLGKKCIYQQLVRGRKIRRSSEEHLRQTRSETMRNSVKSSFHDPKLKGKPSRERYVTHNRAHW
T25076	DRUGINFO	D09WFI	Tetramethylpyrazine	Discontinued in Phase 2

T28153	TARGETID	T28153
T28153	FORMERID	TTDR00570
T28153	UNIPROID	ILVC_ECOLI
T28153	TARGNAME	Bacterial Ketol-acid reductoisomerase (Bact ilvC)
T28153	GENENAME	Bact ilvC
T28153	TARGTYPE	Literature-reported
T28153	SYNONYMS	Ketol-acid reductoisomerase type II; Ketol-acid reductoisomerase type 2; Ketol-acid reductoisomerase (NADP(+)); KARI; Alpha-keto-beta-hydroxylacyl reductoisomerase; Acetohydroxy-acid isomeroreductase; AHIR
T28153	FUNCTION	Involved in the biosynthesis of branched-chain amino acids (BCAA). Catalyzes an alkyl-migration followed by a ketol-acid reduction of (S)-2-acetolactate (S2AL) to yield (R)-2,3-dihydroxy-isovalerate. In the isomerase reaction, S2AL is rearranged via a Mg-dependent methyl migration to produce 3-hydroxy-3-methyl-2-ketobutyrate (HMKB). In the reductase reaction, this 2-ketoacid undergoes a metal-dependent reduction by NADPH to yield (R)-2,3-dihydroxy-isovalerate. Also able to use 2-ketopantoate, 2-ketoisovalerate, 2-ketovalerate, 2-ketobutyrate, 3-hydroxypyruvate, 3-hydroxy-2-ketobutyrate and pyruvate.
T28153	PDBSTRUC	3ULK; 1YRL
T28153	BIOCLASS	Short-chain dehydrogenases reductase
T28153	SEQUENCE	MANYFNTLNLRQQLAQLGKCRFMGRDEFADGASYLQGKKVVIVGCGAQGLNQGLNMRDSGLDISYALRKEAIAEKRASWRKATENGFKVGTYEELIPQADLVINLTPDKQHSDVVRTVQPLMKDGAALGYSHGFNIVEVGEQIRKDITVVMVAPKCPGTEVREEYKRGFGVPTLIAVHPENDPKGEGMAIAKAWAAATGGHRAGVLESSFVAEVKSDLMGEQTILCGMLQAGSLLCFDKLVEEGTDPAYAEKLIQFGWETITEALKQGGITLMMDRLSNPAKLRAYALSEQLKEIMAPLFQKHMDDIISGEFSSGMMADWANDDKKLLTWREETGKTAFETAPQYEGKIGEQEYFDKGVLMIAMVKAGVELAFETMVDSGIIEESAYYESLHELPLIANTIARKRLYEMNVVISDTAEYGNYLFSYACVPLLKPFMAELQPGDLGKAIPEGAVDNGQLRDVNEAIRSHAIEQVGKKLRGYMTDMKRIAVAG

T23000	TARGETID	T23000
T23000	FORMERID	TTDI02079
T23000	UNIPROID	GELS_HUMAN
T23000	TARGNAME	Gelsolin (GSN)
T23000	GENENAME	GSN
T23000	TARGTYPE	Literature-reported
T23000	SYNONYMS	GSN; Brevin; Actindepolymerizing factor; AGEL
T23000	FUNCTION	Calcium-regulated, actin-modulating protein that binds to the plus (or barbed) ends of actin monomers or filaments, preventing monomer exchange (end-blocking or capping). It can promote the assembly of monomers into filaments (nucleation) as well as sever filaments already formed. Plays a role in ciliogenesis. {ECO:0000269|PubMed:20393563}.
T23000	PDBSTRUC	6H1F; 5UBO; 5O2Z; 5H3N; 5H3M
T23000	SEQUENCE	MAPHRPAPALLCALSLALCALSLPVRAATASRGASQAGAPQGRVPEARPNSMVVEHPEFLKAGKEPGLQIWRVEKFDLVPVPTNLYGDFFTGDAYVILKTVQLRNGNLQYDLHYWLGNECSQDESGAAAIFTVQLDDYLNGRAVQHREVQGFESATFLGYFKSGLKYKKGGVASGFKHVVPNEVVVQRLFQVKGRRVVRATEVPVSWESFNNGDCFILDLGNNIHQWCGSNSNRYERLKATQVSKGIRDNERSGRARVHVSEEGTEPEAMLQVLGPKPALPAGTEDTAKEDAANRKLAKLYKVSNGAGTMSVSLVADENPFAQGALKSEDCFILDHGKDGKIFVWKGKQANTEERKAALKTASDFITKMDYPKQTQVSVLPEGGETPLFKQFFKNWRDPDQTDGLGLSYLSSHIANVERVPFDAATLHTSTAMAAQHGMDDDGTGQKQIWRIEGSNKVPVDPATYGQFYGGDSYIILYNYRHGGRQGQIIYNWQGAQSTQDEVAASAILTAQLDEELGGTPVQSRVVQGKEPAHLMSLFGGKPMIIYKGGTSREGGQTAPASTRLFQVRANSAGATRAVEVLPKAGALNSNDAFVLKTPSAAYLWVGTGASEAEKTGAQELLRVLRAQPVQVAEGSEPDGFWEALGGKAAYRTSPRLKDKKMDAHPPRLFACSNKIGRFVIEEVPGELMQEDLATDDVMLLDTWDQVFVWVGKDSQEEEKTEALTSAKRYIETDPANRDRRTPITVVKQGFEPPSFVGWFLGWDDDYWSVDPLDRAMAELAA

T68513	TARGETID	T68513
T68513	FORMERID	TTDI00080
T68513	UNIPROID	S10A6_HUMAN
T68513	TARGNAME	S100 calcium-binding protein A6 (S100A6)
T68513	GENENAME	S100A6
T68513	TARGTYPE	Literature-reported
T68513	SYNONYMS	Protein S100-A6; Prolactin receptor-associated protein; PRA; MLN 4; Growth factor-inducible protein 2A9; Calcyclin; CACY
T68513	FUNCTION	May function by interacting with other proteins, such as TPR-containing proteins, and indirectly play a role in many physiological processes such as the reorganization of the actin cytoskeleton and in cell motility. Binds 2 calcium ions. Calcium binding is cooperative. May function as calcium sensor and modulator, contributing to cellular calcium signaling.
T68513	PDBSTRUC	4YBH; 2M1K; 1K9P; 1K9K; 1K96
T68513	BIOCLASS	S100 calcium-binding protein
T68513	SEQUENCE	MACPLDQAIGLLVAIFHKYSGREGDKHTLSKKELKELIQKELTIGSKLQDAEIARLMEDLDRNKDQEVNFQEYVTFLGALALIYNEALKG

T68829	TARGETID	T68829
T68829	FORMERID	TTDI02351
T68829	UNIPROID	APOA4_HUMAN
T68829	TARGNAME	Apolipoprotein A-IV (APOA4)
T68829	GENENAME	APOA4
T68829	TARGTYPE	Literature-reported
T68829	SYNONYMS	Apolipoprotein A4; ApoAIV; APOA4
T68829	FUNCTION	May have a role in chylomicrons and VLDL secretion and catabolism. Required for efficient activation of lipoprotein lipase by ApoC-II; potent activator of LCAT. Apoa-IV is a major component of HDL and chylomicrons.
T68829	PDBSTRUC	3S84
T68829	BIOCLASS	Apolipoprotein
T68829	SEQUENCE	MFLKAVVLTLALVAVAGARAEVSADQVATVMWDYFSQLSNNAKEAVEHLQKSELTQQLNALFQDKLGEVNTYAGDLQKKLVPFATELHERLAKDSEKLKEEIGKELEELRARLLPHANEVSQKIGDNLRELQQRLEPYADQLRTQVSTQAEQLRRQLTPYAQRMERVLRENADSLQASLRPHADELKAKIDQNVEELKGRLTPYADEFKVKIDQTVEELRRSLAPYAQDTQEKLNHQLEGLTFQMKKNAEELKARISASAEELRQRLAPLAEDVRGNLRGNTEGLQKSLAELGGHLDQQVEEFRRRVEPYGENFNKALVQQMEQLRQKLGPHAGDVEGHLSFLEKDLRDKVNSFFSTFKEKESQDKTLSLPELEQQQEQQQEQQQEQVQMLAPLES

T64137	TARGETID	T64137
T64137	FORMERID	TTDR00387
T64137	UNIPROID	CRF_HUMAN
T64137	TARGNAME	Corticoliberin (CRH)
T64137	GENENAME	CRH
T64137	TARGTYPE	Literature-reported
T64137	SYNONYMS	Corticotropin-releasing hormone; Corticotropin-releasing factor; Corticotropin releasing hormone; Corticotropin; CRF; Adrenocorticotropic hormone
T64137	FUNCTION	Induces NLRP6 in intestinal epithelial cells, hence may influence gut microbiota profile. Hormone regulating the release of corticotropin from pituitary gland.
T64137	PDBSTRUC	3EHU; 3EHT; 1GOE; 1GO9
T64137	SEQUENCE	MRLPLLVSAGVLLVALLPCPPCRALLSRGPVPGARQAPQHPQPLDFFQPPPQSEQPQQPQARPVLLRMGEEYFLRLGNLNKSPAAPLSPASSLLAGGSGSRPSPEQATANFFRVLLQQLLLPRRSLDSPAALAERGARNALGGHQEAPERERRSEEPPISLDLTFHLLREVLEMARAEQLAQQAHSNRKLMEIIGK
T64137	DRUGINFO	D0B3LN	D-Phenylalanine	Investigative
T64137	DRUGINFO	D08JUG	Alpha-Aminoisobutyric Acid	Investigative

T04386	TARGETID	T04386
T04386	FORMERID	TTDNR00644
T04386	UNIPROID	ANXA2_HUMAN
T04386	TARGNAME	Annexin A2 (ANXA2)
T04386	GENENAME	ANXA2
T04386	TARGTYPE	Literature-reported
T04386	SYNONYMS	p36; Protein I; Placental anticoagulant protein IV; PAP-IV; Lipocortin II; LPC2D; Chromobindin-8; Calpactin-1 heavy chain; Calpactin I heavy chain; CAL1H; Annexin-2; Annexin II; ANX2L4; ANX2
T04386	FUNCTION	It binds two calcium ions with high affinity. May be involved in heat-stress response. Inhibits PCSK9-enhanced LDLR degradation, probably reduces PCSK9 protein levels via a translational mechanism but also competes with LDLR for binding with PCSK9. Calcium-regulated membrane-binding protein whose affinity for calcium is greatly enhanced by anionic phospholipids.
T04386	PDBSTRUC	5N7G; 5N7F; 5N7D; 5LQ2; 5LQ0
T04386	BIOCLASS	Annexin protein
T04386	SEQUENCE	MSTVHEILCKLSLEGDHSTPPSAYGSVKAYTNFDAERDALNIETAIKTKGVDEVTIVNILTNRSNAQRQDIAFAYQRRTKKELASALKSALSGHLETVILGLLKTPAQYDASELKASMKGLGTDEDSLIEIICSRTNQELQEINRVYKEMYKTDLEKDIISDTSGDFRKLMVALAKGRRAEDGSVIDYELIDQDARDLYDAGVKRKGTDVPKWISIMTERSVPHLQKVFDRYKSYSPYDMLESIRKEVKGDLENAFLNLVQCIQNKPLYFADRLYDSMKGKGTRDKVLIRIMVSRSEVDMLKIRSEFKRKYGKSLYYYIQQDTKGDYQKALLYLCGGDD

T86717	TARGETID	T86717
T86717	FORMERID	TTDR00762
T86717	UNIPROID	AROB_ECOLI
T86717	TARGNAME	Bacterial Dehydroquinate synthase (Bact aroB)
T86717	GENENAME	Bact aroB
T86717	TARGTYPE	Literature-reported
T86717	SYNONYMS	DHQS; 3-dehydroquinate synthase
T86717	FUNCTION	Catalyzes the conversion of 3-deoxy-D-arabino-heptulosonate 7-phosphate (DAHP) to dehydroquinate (DHQ).
T86717	BIOCLASS	Alpha-carbonic anhydrase
T86717	SEQUENCE	MERIVVTLGERSYPITIASGLFNEPASFLPLKSGEQVMLVTNETLAPLYLDKVRGVLEQAGVNVDSVILPDGEQYKSLAVLDTVFTALLQKPHGRDTTLVALGGGVVGDLTGFAAASYQRGVRFIQVPTTLLSQVDSSVGGKTAVNHPLGKNMIGAFYQPASVVVDLDCLKTLPPRELASGLAEVIKYGIILDGAFFNWLEENLDALLRLDGPAMAYCIRRCCELKAEVVAADERETGLRALLNLGHTFGHAIEAEMGYGNWLHGEAVAAGMVMAARTSERLGQFSSAETQRIITLLKRAGLPVNGPREMSAQAYLPHMLRDKKVLAGEMRLILPLAIGKSEVRSGVSHELVLNAIADCQSA
T86717	DRUGINFO	D02XNU	Carbaphosphonate	Investigative
T86717	DRUGINFO	D0R6JE	Nicotinamide-Adenine-Dinucleotide	Investigative

T52936	TARGETID	T52936
T52936	FORMERID	TTDI03135
T52936	UNIPROID	CXB1_HUMAN
T52936	TARGNAME	Connexin-32 (Cx32)
T52936	GENENAME	GJB1
T52936	TARGTYPE	Literature-reported
T52936	SYNONYMS	Gap junction beta-1 protein; GAP junction 28 kDa liver protein; CX32
T52936	FUNCTION	One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell.
T52936	PDBSTRUC	5KK9; 1TXH
T52936	BIOCLASS	Gap junction-forming connexin
T52936	SEQUENCE	MNWTGLYTLLSGVNRHSTAIGRVWLSVIFIFRIMVLVVAAESVWGDEKSSFICNTLQPGCNSVCYDQFFPISHVRLWSLQLILVSTPALLVAMHVAHQQHIEKKMLRLEGHGDPLHLEEVKRHKVHISGTLWWTYVISVVFRLLFEAVFMYVFYLLYPGYAMVRLVKCDVYPCPNTVDCFVSRPTEKTVFTVFMLAASGICIILNVAEVVYLIIRACARRAQRRSNPPSRKGSGFGHRLSPEYKQNEINKLLSEQDGSLKDILRRSPGTGAGLAEKSDRCSAC
T52936	DRUGINFO	D00VJY	octanol	Investigative

T63179	TARGETID	T63179
T63179	FORMERID	TTDS00196
T63179	UNIPROID	MCR_HUMAN
T63179	TARGNAME	Aldosterone receptor (NR3C2)
T63179	GENENAME	NR3C2
T63179	TARGTYPE	Literature-reported
T63179	SYNONYMS	MR
T63179	FUNCTION	Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates target genes. The effect of MC is to increase ion and water transport and thus raise extracellular fluid volume and blood pressure and lower potassium levels.
T63179	PDBSTRUC	6GGG; 6GG8; 6GEV; 5MWY; 5MWP
T63179	SEQUENCE	METKGYHSLPEGLDMERRWGQVSQAVERSSLGPTERTDENNYMEIVNVSCVSGAIPNNSTQGSSKEKQELLPCLQQDNNRPGILTSDIKTELESKELSATVAESMGLYMDSVRDADYSYEQQNQQGSMSPAKIYQNVEQLVKFYKGNGHRPSTLSCVNTPLRSFMSDSGSSVNGGVMRAVVKSPIMCHEKSPSVCSPLNMTSSVCSPAGINSVSSTTASFGSFPVHSPITQGTPLTCSPNVENRGSRSHSPAHASNVGSPLSSPLSSMKSSISSPPSHCSVKSPVSSPNNVTLRSSVSSPANINNSRCSVSSPSNTNNRSTLSSPAASTVGSICSPVNNAFSYTASGTSAGSSTLRDVVPSPDTQEKGAQEVPFPKTEEVESAISNGVTGQLNIVQYIKPEPDGAFSSSCLGGNSKINSDSSFSVPIKQESTKHSCSGTSFKGNPTVNPFPFMDGSYFSFMDDKDYYSLSGILGPPVPGFDGNCEGSGFPVGIKQEPDDGSYYPEASIPSSAIVGVNSGGQSFHYRIGAQGTISLSRSARDQSFQHLSSFPPVNTLVESWKSHGDLSSRRSDGYPVLEYIPENVSSSTLRSVSTGSSRPSKICLVCGDEASGCHYGVVTCGSCKVFFKRAVEGQHNYLCAGRNDCIIDKIRRKNCPACRLQKCLQAGMNLGARKSKKLGKLKGIHEEQPQQQQPPPPPPPPQSPEEGTTYIAPAKEPSVNTALVPQLSTISRALTPSPVMVLENIEPEIVYAGYDSSKPDTAENLLSTLNRLAGKQMIQVVKWAKVLPGFKNLPLEDQITLIQYSWMCLSSFALSWRSYKHTNSQFLYFAPDLVFNEEKMHQSAMYELCQGMHQISLQFVRLQLTFEEYTIMKVLLLLSTIPKDGLKSQAAFEEMRTNYIKELRKMVTKCPNNSGQSWQRFYQLTKLLDSMHDLVSDLLEFCFYTFRESHALKVEFPAMLVEIISDQLPKVESGNAKPLYFHRK

T17221	TARGETID	T17221
T17221	UNIPROID	GSTA1_HUMAN
T17221	TARGNAME	Glutathione S-transferase A1 (GSTA1)
T17221	GENENAME	GSTA1
T17221	TARGTYPE	Literature-reported
T17221	SYNONYMS	GTH1; GSTA1-1; GST-epsilon; GST class-alpha member 1; GST HA subunit 1; Androst-5-ene-3,17-dione isomerase; 13-hydroperoxyoctadecadienoate peroxidase
T17221	FUNCTION	Glutathione S-transferase that catalyzes the nucleophilic attack of the sulfur atom of glutathione on the electrophilic groups of a wide range of exogenous and endogenous compounds (Probable). Involved in the formation of glutathione conjugates of both prostaglandin A2 (PGA2) and prostaglandin J2 (PGJ2). It also catalyzes the isomerization of D5-androstene-3,17-dione (AD) into D4-androstene-3,17-dione and may therefore play an important role in hormone biosynthesis. Through its glutathione-dependent peroxidase activity toward the fatty acid hydroperoxide (13S)-hydroperoxy-(9Z,11E)-octadecadienoate/13-HPODE it is also involved in the metabolism of oxidized linoleic acid.
T17221	PDBSTRUC	6ATR; 6ATQ; 6ATP; 6ATO; 5LD0
T17221	ECNUMBER	EC 2.5.1.18
T17221	SEQUENCE	MAEKPKLHYFNARGRMESTRWLLAAAGVEFEEKFIKSAEDLDKLRNDGYLMFQQVPMVEIDGMKLVQTRAILNYIASKYNLYGKDIKERALIDMYIEGIADLGEMILLLPVCPPEEKDAKLALIKEKIKNRYFPAFEKVLKSHGQDYLVGNKLSRADIHLVELLYYVEELDSSLISSFPLLKALKTRISNLPTVKKFLQPGSPRKPPMDEKSLEEARKIFRF

T63359	TARGETID	T63359
T63359	FORMERID	TTDR01102
T63359	UNIPROID	MURB_ECOLI
T63359	TARGNAME	Bacterial UDP-N-acetylenolpyruvylglucosamine reductase (Bact murB)
T63359	GENENAME	Bact murB
T63359	TARGTYPE	Literature-reported
T63359	SYNONYMS	UDP-N-acetylmuramate dehydrogenase; MurB
T63359	FUNCTION	Cell wall formation.
T63359	PDBSTRUC	2Q85; 2MBR; 1UXY; 1MBT; 1MBB
T63359	BIOCLASS	Short-chain dehydrogenases reductase
T63359	SEQUENCE	MNHSLKPWNTFGIDHNAQHIVCAEDEQQLLNAWQYATAEGQPVLILGEGSNVLFLEDYRGTVIINRIKGIEIHDEPDAWYLHVGAGENWHRLVKYTLQEGMPGLENLALIPGCVGSSPIQNIGAYGVELQRVCAYVDSVELATGKQVRLTAKECRFGYRDSIFKHEYQDRFAIVAVGLRLPKEWQPVLTYGDLTRLDPTTVTPQQVFNAVCHMRTTKLPDPKVNGNAGSFFKNPVVSAETAKALLSQFPTAPNYPQADGSVKLAAGWLIDQCQLKGMQIGGAAVHRQQALVLINEDNAKSEDVVQLAHHVRQKVGEKFNVWLEPEVRFIGASGEVSAVETIS
T63359	DRUGINFO	D00IMW	Flavin-Adenine Dinucleotide	Investigative

T78241	TARGETID	T78241
T78241	FORMERID	TTDI01453
T78241	UNIPROID	ICP0_HHV11
T78241	TARGNAME	Herpes simplex virus E3 ubiquitin-protein ligase ICP0 (HSV ICP0)
T78241	GENENAME	HSV ICP0
T78241	TARGTYPE	Literature-reported
T78241	SYNONYMS	VMW110; Trans-acting transcriptional protein ICP0; RING-type E3 ubiquitin transferase ICP0; Immediate-early protein IE110; E3 ubiquitin-protein ligase ICP0; Alpha-0 protein
T78241	FUNCTION	Evades nuclear antiviral defenses triggered by dsDNA viruses. Acts during the initial stages of lytic infection and the reactivation of latent viral genome. Prevents the antiviral effect of nuclear bodies by degrading host PML and SP100. Prevents antiviral response to viral DNA induced by IFI16 by degrading it. Additionally, inhibits host IRF3 nuclear signaling to prevent interferon production by the infected cells. Interestingly, the E3 ubiquitin ligase activity associated with the RING finger domain does not seem to be directly required to inhibit the activation of IRF3 but instead plays a critical role in modulating the cellular localization of ICP0. Upon reactivation of latent genome, suppresses the silencing of viral DNA by dissociating either HDAC1 or HDAC2 from the HDAC-RCOR1-REST-KDM1A complex localized at the ND10 structures and causes their dispersal. Two cellular histone ubiquitin ligases RNF8 and RNF168 are also targeted by ICP0 for degradation, leading to a loss of ubiquitinated forms of H2A, a relief of transcriptional repression, and the activation of latent viral genomes. Enhances the localization of host CCND3 to ND10 bodies that serve as precursors of replication compartments to enable efficient viral replication. Like many RING-finger E3 ubiquitin ligases, ICP0 can induce its own ubiquitination, an activity that promotes its instability due to its targeting to the 26S proteasome for degradation. ICP0 restricts this process by recruiting the cellular ubiquitin-specific protease USP7 that cleaves the anchored ubiquitin chains from ICP0, thereby promoting its stabilization.
T78241	PDBSTRUC	5C56; 4WPI; 4WPH
T78241	ECNUMBER	EC 2.3.2.27
T78241	SEQUENCE	MEPRPGASTRRPEGRPQREPAPDVWVFPCDRDLPDSSDSEAETEVGGRGDADHHDDDSASEADSTDTELFETGLLGPQGVDGGAVSGGSPPREEDPGSCGGAPPREDGGSDEGDVCAVCTDEIAPHLRCDTFPCMHRFCIPCMKTWMQLRNTCPLCNAKLVYLIVGVTPSGSFSTIPIVNDPQTRMEAEEAVRAGTAVDFIWTGNQRFAPRYLTLGGHTVRALSPTHPEPTTDEDDDDLDDADYVPPAPRRTPRAPPRRGAAAPPVTGGASHAAPQPAAARTAPPSAPIGPHGSSNTNTTTNSSGGGGSRQSRAAAPRGASGPSGGVGVGVGVVEAEAGRPRGRTGPLVNRPAPLANNRDPIVISDSPPASPHRPPAAPMPGSAPRPGPPASAAASGPARPRAAVAPCVRAPPPGPGPRAPAPGAEPAARPADARRVPQSHSSLAQAANQEQSLCRARATVARGSGGPGVEGGHGPSRGAAPSGAAPLPSAASVEQEAAVRPRKRRGSGQENPSPQSTRPPLAPAGAKRAATHPPSDSGPGGRGQGGPGTPLTSSAASASSSSASSSSAPTPAGAASSAAGAASSSASASSGGAVGALGGRQEETSLGPRAASGPRGPRKCARKTRHAETSGAVPAGGLTRYLPISGVSSVVALSPYVNKTITGDCLPILDMETGNIGAYVVLVDQTGNMATRLRAAVPGWSRRTLLPETAGNHVMPPEYPTAPASEWNSLWMTPVGNMLFDQGTLVGALDFRSLRSRHPWSGEQGASTRDEGKQ

T15048	TARGETID	T15048
T15048	FORMERID	TTDR00333
T15048	UNIPROID	IBP1_HUMAN
T15048	TARGNAME	Insulin-like growth factor-binding protein 1 (IGFBP1)
T15048	GENENAME	IGFBP1
T15048	TARGTYPE	Literature-reported
T15048	SYNONYMS	Placental protein 12; PP12; KITLG; IGFBP-1; IGF-binding protein 1; IBP1; IBP-1
T15048	FUNCTION	IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. Promotes cell migration.
T15048	PDBSTRUC	2DSQ; 1ZT5; 1ZT3
T15048	BIOCLASS	Insulin-like growth factor binding
T15048	SEQUENCE	MSEVPVARVWLVLLLLTVQVGVTAGAPWQCAPCSAEKLALCPPVSASCSEVTRSAGCGCCPMCALPLGAACGVATARCARGLSCRALPGEQQPLHALTRGQGACVQESDASAPHAAEAGSPESPESTEITEEELLDNFHLMAPSEEDHSILWDAISTYDGSKALHVTNIKKWKEPCRIELYRVVESLAKAQETSGEEISKFYLPNCNKNGFYHSRQCETSMDGEAGLCWCVYPWNGKRIPGSPEIRGDPNCQIYFNVQN

T95409	TARGETID	T95409
T95409	FORMERID	TTDR00357
T95409	UNIPROID	PT1_ECOLI
T95409	TARGNAME	Bacterial Phosphoenolpyruvate transferase (Bact ptsI)
T95409	GENENAME	Bact ptsI
T95409	TARGTYPE	Literature-reported
T95409	SYNONYMS	ptsI; Phosphotransferase system, enzyme I; Phosphoenolpyruvate-protein phosphotransferase
T95409	FUNCTION	General (non sugar-specific) component of the phosphoenolpyruvate-dependent sugar phosphotransferase system (sugar PTS). This major carbohydrate active-transport system catalyzes the phosphorylation of incoming sugar substrates concomitantly with their translocation across the cell membrane. Enzyme I transfers the phosphoryl group from phosphoenolpyruvate (PEP) to the phosphoryl carrier protein (HPr).
T95409	PDBSTRUC	3EZE; 3EZB; 3EZA; 2XDF; 2N5T
T95409	BIOCLASS	Kinase
T95409	SEQUENCE	MISGILASPGIAFGKALLLKEDEIVIDRKKISADQVDQEVERFLSGRAKASAQLETIKTKAGETFGEEKEAIFEGHIMLLEDEELEQEIIALIKDKHMTADAAAHEVIEGQASALEELDDEYLKERAADVRDIGKRLLRNILGLKIIDLSAIQDEVILVAADLTPSETAQLNLKKVLGFITDAGGRTSHTSIMARSLELPAIVGTGSVTSQVKNDDYLILDAVNNQVYVNPTNEVIDKMRAVQEQVASEKAELAKLKDLPAITLDGHQVEVCANIGTVRDVEGAERNGAEGVGLYRTEFLFMDRDALPTEEEQFAAYKAVAEACGSQAVIVRTMDIGGDKELPYMNFPKEENPFLGWRAIRIAMDRREILRDQLRAILRASAFGKLRIMFPMIISVEEVRALRKEIEIYKQELRDEGKAFDESIEIGVMVETPAAATIARHLAKEVDFFSIGTNDLTQYTLAVDRGNDMISHLYQPMSPSVLNLIKQVIDASHAEGKWTGMCGELAGDERATLLLLGMGLDEFSMSAISIPRIKKIIRNTNFEDAKVLAEQALAQPTTDELMTLVNKFIEEKTIC
T95409	DRUGINFO	D0L3IS	1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE	Investigative

T53510	TARGETID	T53510
T53510	UNIPROID	GSTA2_HUMAN
T53510	TARGNAME	Glutathione S-transferase A2 (GSTA2)
T53510	GENENAME	GSTA2
T53510	TARGTYPE	Literature-reported
T53510	SYNONYMS	GTH2; GSTA2-2; GST2; GST-gamma; GST class-alpha member 2; GST HA subunit 2
T53510	FUNCTION	Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.
T53510	PDBSTRUC	4ACS; 2WJU; 2VCT; 1AGS
T53510	ECNUMBER	EC 2.5.1.18
T53510	SEQUENCE	MAEKPKLHYSNIRGRMESIRWLLAAAGVEFEEKFIKSAEDLDKLRNDGYLMFQQVPMVEIDGMKLVQTRAILNYIASKYNLYGKDIKEKALIDMYIEGIADLGEMILLLPFSQPEEQDAKLALIQEKTKNRYFPAFEKVLKSHGQDYLVGNKLSRADIHLVELLYYVEELDSSLISSFPLLKALKTRISNLPTVKKFLQPGSPRKPPMDEKSLEESRKIFRF

T96005	TARGETID	T96005
T96005	FORMERID	TTDR00743
T96005	UNIPROID	GROA_HUMAN
T96005	TARGNAME	C-X-C motif chemokine 1 (CXCL1)
T96005	GENENAME	CXCL1
T96005	TARGTYPE	Literature-reported
T96005	SYNONYMS	SCYB1; Neutrophil-activating protein 3; NAP-3; Melanoma growth stimulatory activity; MGSA; Growth-regulated alpha protein; Growth regulated protein; GROA; GRO1; GRO-alpha(1-73); GRO-alpha; GRO-a protein; GRO
T96005	FUNCTION	May play a role in inflammation and exerts its effects on endothelial cells in an autocrine fashion. In vitro, the processed forms GRO-alpha(4-73), GRO-alpha(5-73) and GRO-alpha(6-73) show a 30-fold higher chemotactic activity. Has chemotactic activity for neutrophils.
T96005	PDBSTRUC	1ROD; 1MSH; 1MSG; 1MGS
T96005	BIOCLASS	Cytokine: CXC chemokine
T96005	SEQUENCE	MARAALSAAPSNPRLLRVALLLLLLVAAGRRAAGASVATELRCQCLQTLQGIHPKNIQSVNVKSPGPHCAQTEVIATLKNGRKACLNPASPIVKKIIEKMLNSDKSN

T63595	TARGETID	T63595
T63595	FORMERID	TTDR00518
T63595	UNIPROID	HMGB1_HUMAN
T63595	TARGNAME	High mobility group protein B1 (HMGB1)
T63595	GENENAME	HMGB1
T63595	TARGTYPE	Literature-reported
T63595	SYNONYMS	High mobility group protein 1; High mobility group box chromosomal protein 1; HMG1; HMG-1
T63595	FUNCTION	In the nucleus is one of the major chromatin-associated non-histone proteins and acts as a DNA chaperone involved in replication, transcription, chromatin remodeling, V(D)J recombination, DNA repair and genome stability. Proposed to be an universal biosensor for nucleic acids. Promotes host inflammatory response to sterile and infectious signals and is involved in the coordination and integration of innate and adaptive immune responses. In the cytoplasm functions as sensor and/or chaperone for immunogenic nucleic acids implicating the activation of TLR9-mediated immune responses, and mediates autophagy. Acts as danger associated molecular pattern (DAMP) molecule that amplifies immune responses during tissue injury. Released to the extracellular environment can bind DNA, nucleosomes, IL-1 beta, CXCL12, AGER isoform 2/sRAGE, lipopolysaccharide (LPS) and lipoteichoic acid (LTA), and activates cells through engagement of multiple surface receptors. In the extracellular compartment fully reduced HMGB1 (released by necrosis) acts as a chemokine, disulfide HMGB1 (actively secreted) as a cytokine, and sulfonyl HMGB1 (released from apoptotic cells) promotes immunological tolerance. Has proangiogdenic activity. May be involved in platelet activation. Binds to phosphatidylserine and phosphatidylethanolamide. Bound to RAGE mediates signaling for neuronal outgrowth. May play a role in accumulation of expanded polyglutamine (polyQ) proteins such as huntingtin (HTT) or TBP. Multifunctional redox sensitive protein with various roles in different cellular compartments.
T63595	PDBSTRUC	6CIM; 6CIL; 6CIK; 6CIJ; 6CG0
T63595	SEQUENCE	MGKGDPKKPRGKMSSYAFFVQTCREEHKKKHPDASVNFSEFSKKCSERWKTMSAKEKGKFEDMAKADKARYEREMKTYIPPKGETKKKFKDPNAPKRPPSAFFLFCSEYRPKIKGEHPGLSIGDVAKKLGEMWNNTAADDKQPYEKKAAKLKEKYEKDIAAYRAKGKPDAAKKGVVKAEKSKKKKEEEEDEEDEEDEEEEEDEEDEDEEEDDDDE
T63595	DRUGINFO	D0Q5FV	2-Sulfhydryl-Ethanol	Investigative

T40103	TARGETID	T40103
T40103	FORMERID	TTDI03092
T40103	UNIPROID	CATH_HUMAN
T40103	TARGNAME	Cathepsin H (CTSH)
T40103	GENENAME	CTSH
T40103	TARGTYPE	Literature-reported
T40103	SYNONYMS	Pro-cathepsin H
T40103	FUNCTION	Important for the overall degradation of proteins in lysosomes.
T40103	PDBSTRUC	6CZS; 6CZK; 1BZN
T40103	BIOCLASS	Peptidase
T40103	SEQUENCE	MWATLPLLCAGAWLLGVPVCGAAELCVNSLEKFHFKSWMSKHRKTYSTEEYHHRLQTFASNWRKINAHNNGNHTFKMALNQFSDMSFAEIKHKYLWSEPQNCSATKSNYLRGTGPYPPSVDWRKKGNFVSPVKNQGACGSCWTFSTTGALESAIAIATGKMLSLAEQQLVDCAQDFNNHGCQGGLPSQAFEYILYNKGIMGEDTYPYQGKDGYCKFQPGKAIGFVKDVANITIYDEEAMVEAVALYNPVSFAFEVTQDFMMYRTGIYSSTSCHKTPDKVNHAVLAVGYGEKNGIPYWIVKNSWGPQWGMNGYFLIERGKNMCGLAACASYPIPLV
T40103	DRUGINFO	D0G2QG	PMID16290936C1b	Investigative

T49925	TARGETID	T49925
T49925	FORMERID	TTDI03198
T49925	UNIPROID	FGR_HUMAN
T49925	TARGNAME	Tyrosine-protein kinase Fgr (FGR)
T49925	GENENAME	FGR
T49925	TARGTYPE	Literature-reported
T49925	SYNONYMS	p58c-Fgr; p58-Fgr; p55-Fgr; SRC2; Proto-oncogene c-Fgr; Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog
T49925	FUNCTION	Promotes mast cell degranulation, release of inflammatory cytokines and IgE-mediated anaphylaxis. Acts downstream of receptors that bind the Fc region of immunoglobulins, such as MS4A2/FCER1B, FCGR2A and/or FCGR2B. Acts downstream of ITGB1 and ITGB2, and regulates actin cytoskeleton reorganization, cell spreading and adhesion. Depending on the context, activates or inhibits cellular responses. Functions as negative regulator of ITGB2 signaling, phagocytosis and SYK activity in monocytes. Required for normal ITGB1 and ITGB2 signaling, normal cell spreading and adhesion in neutrophils and macrophages. Functions as positive regulator of cell migration and regulates cytoskeleton reorganization via RAC1 activation. Phosphorylates SYK (in vitro) and promotes SYK-dependent activation of AKT1 and MAP kinase signaling. Phosphorylates PLD2 in antigen-stimulated mast cells, leading to PLD2 activation and the production of the signaling molecules lysophosphatidic acid and diacylglycerol. Promotes activation of PIK3R1. Phosphorylates FASLG, and thereby regulates its ubiquitination and subsequent internalization. Phosphorylates ABL1. Promotes phosphorylation of CBL, CTTN, PIK3R1, PTK2/FAK1, PTK2B/PYK2 and VAV2. Phosphorylates HCLS1 that has already been phosphorylated by SYK, but not unphosphorylated HCLS1. Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors devoid of kinase activity and contributes to the regulation of immune responses, including neutrophil, monocyte, macrophage and mast cell functions, cytoskeleton remodeling in response to extracellular stimuli, phagocytosis, cell adhesion and migration.
T49925	BIOCLASS	Kinase
T49925	ECNUMBER	EC 2.7.10.2
T49925	SEQUENCE	MGCVFCKKLEPVATAKEDAGLEGDFRSYGAADHYGPDPTKARPASSFAHIPNYSNFSSQAINPGFLDSGTIRGVSGIGVTLFIALYDYEARTEDDLTFTKGEKFHILNNTEGDWWEARSLSSGKTGCIPSNYVAPVDSIQAEEWYFGKIGRKDAERQLLSPGNPQGAFLIRESETTKGAYSLSIRDWDQTRGDHVKHYKIRKLDMGGYYITTRVQFNSVQELVQHYMEVNDGLCNLLIAPCTIMKPQTLGLAKDAWEISRSSITLERRLGTGCFGDVWLGTWNGSTKVAVKTLKPGTMSPKAFLEEAQVMKLLRHDKLVQLYAVVSEEPIYIVTEFMCHGSLLDFLKNPEGQDLRLPQLVDMAAQVAEGMAYMERMNYIHRDLRAANILVGERLACKIADFGLARLIKDDEYNPCQGSKFPIKWTAPEAALFGRFTIKSDVWSFGILLTELITKGRIPYPGMNKREVLEQVEQGYHMPCPPGCPASLYEAMEQTWRLDPEERPTFEYLQSFLEDYFTSAEPQYQPGDQT
T49925	DRUGINFO	D08RZB	PMID15546730C2	Investigative
T49925	DRUGINFO	D0E7VO	PMID24900538C2c	Investigative

T70019	TARGETID	T70019
T70019	FORMERID	TTDR01441
T70019	UNIPROID	NORA_STAAU
T70019	TARGNAME	Staphylococcus Quinolone resistance protein norA (Stap-coc norA)
T70019	GENENAME	Stap-coc norA
T70019	TARGTYPE	Literature-reported
T70019	SYNONYMS	norA
T70019	FUNCTION	Involved in quinolone resistance. May constitute a membrane-associated active efflux pump of hydrophilic quinolones.
T70019	BIOCLASS	Major facilitator superfamily
T70019	SEQUENCE	MNKQIFVLYFNIFLIFLGIGLVIPVLPVYLKDLGLTGSDLGLLVAAFALSQMIISPFGGTLADKLGKKLIICIGLILFSVSEFMFAVGHNFSVLMLSRVIGGMSAGMVMPGVTGLIADISPSHQKAKNFGYMSAIINSGFILGPGIGGFMAEVSHRMPFYFAGALGILAFIMSIVLIHDPKKSTTSGFQKLEPQLLTKINWKVFITPVILTLVLSFGLSAFETLYSLYTADKVNYSPKDISIAITGGGIFGALFQIYFFDKFMKYFSELTFIAWSLLYSVVVLILLVFANGYWSIMLISFVVFIGFDMIRPAITNYFSNIAGERQGFAGGLNSTFTSMGNFIGPLIAGALFDVHIEAPIYMAIGVSLAGVVIVLIEKQHRAKLKEQNM

T23688	TARGETID	T23688
T23688	FORMERID	TTDR00022
T23688	UNIPROID	KDSA_ECOLI
T23688	TARGNAME	Bacterial Deoxy-D-manno-octulosonate 8-phosphate synthase (Bact kdsA)
T23688	GENENAME	Bact kdsA
T23688	TARGTYPE	Literature-reported
T23688	SYNONYMS	kdsA; Phospho-2-dehydro-3-deoxyoctonate aldolase; KDOPS; KDOP synthase; KDO8PS; KDO8P synthase; KDO8-P synthase; KDO-8-phosphate synthetase; 3-deoxy-D-manno-octulosonic acid 8-phosphate synthetase; 3-Deoxy-d-manno-2-octulosonate-8-phosphate synthase; 2-dehydro-3-deoxyphosphooctonate aldolase
T23688	FUNCTION	Synthesis of KDO 8-P which is required for lipid A maturation and cellular growth.
T23688	PDBSTRUC	1X8F; 1X6U; 1Q3N; 1PL9; 1PHW
T23688	BIOCLASS	Alkyl aryl transferase
T23688	SEQUENCE	MKQKVVSIGDINVANDLPFVLFGGMNVLESRDLAMRICEHYVTVTQKLGIPYVFKASFDKANRSSIHSYRGPGLEEGMKIFQELKQTFGVKIITDVHEPSQAQPVADVVDVIQLPAFLARQTDLVEAMAKTGAVINVKKPQFVSPGQMGNIVDKFKEGGNEKVILCDRGANFGYDNLVVDMLGFSIMKKVSGNSPVIFDVTHALQCRDPFGAASGGRRAQVAELARAGMAVGLAGLFIEAHPDPEHAKCDGPSALPLAKLEPFLKQMKAIDDLVKGFEELDTSK
T23688	DRUGINFO	D02KLU	Ribose-5-Phosphate	Investigative
T23688	DRUGINFO	D04OQZ	Arabinose-5-Phosphate	Investigative
T23688	DRUGINFO	D05FBL	1-Deoxy-Ribofuranose-5'-Phosphate	Investigative
T23688	DRUGINFO	D0C1PC	3-Fluoro-2-(Phosphonooxy)Propanoic Acid	Investigative
T23688	DRUGINFO	D0KT4N	Erythose-4-Phosphate	Investigative
T23688	DRUGINFO	D0RK2I	2-(Phosphonooxy)Butanoic Acid	Investigative
T23688	DRUGINFO	D0T3AE	Phosphoenolpyruvate	Investigative
T23688	DRUGINFO	D03KBV	2-Phosphoglyceric Acid	Investigative

T51284	TARGETID	T51284
T51284	FORMERID	TTDR00655
T51284	UNIPROID	PDXJ_ECOLI
T51284	TARGNAME	Bacterial Pyridoxal phosphate biosynthetic pdxJ (Bact pdxJ)
T51284	GENENAME	Bact pdxJ
T51284	TARGTYPE	Literature-reported
T51284	SYNONYMS	pdxJ; Pyridoxine 5'-phosphate synthase; PNP synthase
T51284	FUNCTION	Catalyzes the condensation of 1-deoxy-d-xylulose-5- phosphate (dxp) and 1-amino-3-(phosphohydroxy)propan-2-one to form pyridoxine 5'-phosphate (pnp).
T51284	PDBSTRUC	1M5W; 1IXQ; 1IXP; 1IXO; 1IXN
T51284	ECNUMBER	EC 2.6.99.2
T51284	SEQUENCE	MAELLLGVNIDHIATLRNARGTAYPDPVQAAFIAEQAGADGITVHLREDRRHITDRDVRILRQTLDTRMNLEMAVTEEMLAIAVETKPHFCCLVPEKRQEVTTEGGLDVAGQRDKMRDACKRLADAGIQVSLFIDADEEQIKAAAEVGAPFIEIHTGCYADAKTDAEQAQELARIAKAATFAASLGLKVNAGHGLTYHNVKAIAAIPEMHELNIGHAIIGRAVMTGLKDAVAEMKRLMLEARG
T51284	DRUGINFO	D09JAO	1-Deoxy-D-Xylulose-5-Phosphate	Investigative
T51284	DRUGINFO	D03MUW	3-Phosphoglycerol	Investigative
T51284	DRUGINFO	D0B8JD	Pyridoxine-5'-Phosphate	Investigative

T32468	TARGETID	T32468
T32468	FORMERID	TTDR00291
T32468	UNIPROID	FABB_ECOL6
T32468	TARGNAME	Bacterial Beta-ketoacyl-ACP synthase I (Bact fabB)
T32468	GENENAME	Bact fabB
T32468	TARGTYPE	Literature-reported
T32468	SYNONYMS	fabB; KAS I; Condensing enzyme FabB; 3-oxoacyl-[acyl-carrier-protein] synthase I
T32468	FUNCTION	Catalyzes the condensation reactionof fatty acid synthesis by the addition to an acyl acceptor of two carbons from malonyl-acp. Specific for elongation from c-10 to unsaturated c-16 and c-18 fatty acids.
T32468	BIOCLASS	Acyltransferase
T32468	ECNUMBER	EC 2.3.1.41
T32468	SEQUENCE	MKRAVITGLGIVSSIGNNQQEVLASLREGRSGITFSQELKDSGMRSHVWGNVKLDTTGLIDRKVVRFMSDASIYAFLSMEQAIADAGLSPEAYQNNPRVGLIAGSGGGSPRFQVFGADAMRGPRGLKAVGPYVVTKAMASGVSACLATPFKIHGVNYSISSACATSAHCIGNAVEQIQLGKQDIVFAGGGEELCWEMACEFDAMGALSTKYNDTPEKASRTYDAHRDGFVIAGGGGMVVVEELEHALARGAHIYAEIVGYGATSDGADMVAPSGEGAVRCMKMAMHGVDTPIDYLNSHGTSTPVGDVKELAAIREVFGDKSPAISATKAMTGHSLGAAGVQEAIYSLLMLEHGFIAPSINIEELDEQAAGLNIVTETTDRELTTVMSNSFGFGGTNATLVMRKLKD
T32468	DRUGINFO	D04JTY	Thiolactomycin	Investigative

T66964	TARGETID	T66964
T66964	FORMERID	TTDR00218
T66964	UNIPROID	CYSK_ECOLI
T66964	TARGNAME	Bacterial O-acetylserine sulfhydrylase A (Bact cysK)
T66964	GENENAME	Bact cysK
T66964	TARGTYPE	Literature-reported
T66964	SYNONYMS	Sulfate starvation-induced protein 5; SSI5; S-carboxymethylcysteine synthase; OAS-TL A; O-acetylserine sulfhydrylase A; O-acetylserine (thiol)-lyase A; Cysteine synthase A; CSase A
T66964	FUNCTION	In addition to its role in cysteine synthesis, stimulates the tRNase activity of CdiA-CT from E.coli strain 536 / UPEC in microbial infection; stimulation does not require O-acetylserine sulfhydrylase activity. CdiA is the toxic component of a toxin-immunity protein module, which functions as a cellular contact-dependent growth inhibition (CDI) system. CDI modules allow bacteria to communicate with and inhibit the growth of closely related neighboring bacteria in a contact-dependent fashion (experiments done in strains BW25113 and X90, both K12 derivatives). This protein is not required for CDI of strain EC93, whose toxin may function by forming inner cell membrane pores. CysK stabilizes CdiA-CT, allowing it to bind tRNA substrate; neither CdiA-CT nor CysK bind tRNA alone in vitro.
T66964	PDBSTRUC	5J5V; 5J43
T66964	BIOCLASS	Alkyl aryl transferase
T66964	SEQUENCE	MSKIFEDNSLTIGHTPLVRLNRIGNGRILAKVESRNPSFSVKCRIGANMIWDAEKRGVLKPGVELVEPTSGNTGIALAYVAAARGYKLTLTMPETMSIERRKLLKALGANLVLTEGAKGMKGAIQKAEEIVASNPEKYLLLQQFSNPANPEIHEKTTGPEIWEDTDGQVDVFIAGVGTGGTLTGVSRYIKGTKGKTDLISVAVEPTDSPVIAQALAGEEIKPGPHKIQGIGAGFIPANLDLKLVDKVIGITNEEAISTARRLMEEEGILAGISSGAAVAAALKLQEDESFTNKNIVVILPSSGERYLSTALFADLFTEKELQQ

T53588	TARGETID	T53588
T53588	FORMERID	TTDI02066
T53588	UNIPROID	FABI_ECOLI
T53588	TARGNAME	Bacterial NADH-dependent enoyl-ACP reductase (Bact fabI)
T53588	GENENAME	Bact fabI
T53588	TARGTYPE	Literature-reported
T53588	SYNONYMS	Enoyl[acylcarrierprotein] reductase [NADH] FabI; ENR of Mycobacterium tuberculosis
T53588	FUNCTION	Catalyzes the reduction of a carbon-carbon double bond in an enoyl moiety that is covalently linked to an acyl carrier protein (ACP). Involved in the elongation cycle of fatty acid which are used in the lipid metabolism and in the biotin biosynthesis.
T53588	PDBSTRUC	5CG2; 5CG1; 5CFZ; 4JX8; 4JQC
T53588	BIOCLASS	Short-chain dehydrogenases reductase
T53588	SEQUENCE	MGFLSGKRILVTGVASKLSIAYGIAQAMHREGAELAFTYQNDKLKGRVEEFAAQLGSDIVLQCDVAEDASIDTMFAELGKVWPKFDGFVHSIGFAPGDQLDGDYVNAVTREGFKIAHDISSYSFVAMAKACRSMLNPGSALLTLSYLGAERAIPNYNVMGLAKASLEANVRYMANAMGPEGVRVNAISAGPIRTLAASGIKDFRKMLAHCEAVTPIRRTVTIEDVGNSAAFLCSDLSAGISGEVVHVDGGFSIAAMNELELK
T53588	DRUGINFO	D00KJO	MUT-056399	Preclinical

T70521	TARGETID	T70521
T70521	FORMERID	TTDR00591
T70521	UNIPROID	MTNN_ECOLI
T70521	TARGNAME	Bacterial MTA/SAH nucleosidase (Bact mtnN)
T70521	GENENAME	Bact mtnN
T70521	TARGTYPE	Literature-reported
T70521	SYNONYMS	mtnN; S-adenosylhomocysteine nucleosidase; P46; 5'-methylthioadenosine nucleosidase; 5'-Methylthioadenosine/S-adenosylhomocysteine (MTA/AdoHcy) nucleosidase
T70521	FUNCTION	Catalyzes the irreversible cleavage of the glycosidic bond in both 5'-methylthioadenosine (MTA) and S- adenosylhomocysteine (SAH/AdoHcy) to adenine and the corresponding thioribose, 5'-methylthioribose and S-ribosylhomocysteine, respectively. Can also use 5'-isobutylthioadenosine, 5'-n- butylthioadenosine, S-adenosyl-D-homocysteine, decarboxylated adenosylhomocysteine, deaminated adenosylhomocysteine and S-2-aza- adenosylhomocysteine as substrates.
T70521	PDBSTRUC	4YML; 4WKC; 3O4V; 1Z5P; 1Z5O
T70521	BIOCLASS	Glycosylase
T70521	SEQUENCE	MKIGIIGAMEEEVTLLRDKIENRQTISLGGCEIYTGQLNGTEVALLKSGIGKVAAALGATLLLEHCKPDVIINTGSAGGLAPTLKVGDIVVSDEARYHDADVTAFGYEYGQLPGCPAGFKADDKLIAAAEACIAELNLNAVRGLIVSGDAFINGSVGLAKIRHNFPQAIAVEMEATAIAHVCHNFNVPFVVVRAISDVADQQSHLSFDEFLAVAAKQSSLMVESLVQKLAHG
T70521	DRUGINFO	D02JUP	5'-Deoxy-5'-(Methylthio)-Tubercidin	Investigative
T70521	DRUGINFO	D0NH1Y	Formycin	Investigative

T92724	TARGETID	T92724
T92724	FORMERID	TTDNR00744
T92724	UNIPROID	R1AB_CVHSA
T92724	TARGNAME	Virus Replicase polyprotein 1ab (Viru rep)
T92724	GENENAME	Viru rep
T92724	TARGTYPE	Literature-reported
T92724	SYNONYMS	rep of Human SARS coronavirus; pp1ab; ORF1ab polyprotein
T92724	FUNCTION	O-methyltransferase: Methyltransferase that mediates mRNAcap 2'-O-ribose methylation to the 5'-cap structure of viral mRNAs. N7-methyl guanosine cap is a prerequisite for binding of nsp16. Therefore plays an essential role in viral mRNAs cap methylation which is essential to evade immune system.
T92724	PDBSTRUC	5NFY; 5N5O; 5N19; 5F22; 5E6J
T92724	BIOCLASS	Viral RNA helicase
T92724	SEQUENCE	MESLVLGVNEKTHVQLSLPVLQVRDVLVRGFGDSVEEALSEAREHLKNGTCGLVELEKGVLPQLEQPYVFIKRSDALSTNHGHKVVELVAEMDGIQYGRSGITLGVLVPHVGETPIAYRNVLLRKNGNKGAGGHSYGIDLKSYDLGDELGTDPIEDYEQNWNTKHGSGALRELTRELNGGAVTRYVDNNFCGPDGYPLDCIKDFLARAGKSMCTLSEQLDYIESKRGVYCCRDHEHEIAWFTERSDKSYEHQTPFEIKSAKKFDTFKGECPKFVFPLNSKVKVIQPRVEKKKTEGFMGRIRSVYPVASPQECNNMHLSTLMKCNHCDEVSWQTCDFLKATCEHCGTENLVIEGPTTCGYLPTNAVVKMPCPACQDPEIGPEHSVADYHNHSNIETRLRKGGRTRCFGGCVFAYVGCYNKRAYWVPRASADIGSGHTGITGDNVETLNEDLLEILSRERVNINIVGDFHLNEEVAIILASFSASTSAFIDTIKSLDYKSFKTIVESCGNYKVTKGKPVKGAWNIGQQRSVLTPLCGFPSQAAGVIRSIFARTLDAANHSIPDLQRAAVTILDGISEQSLRLVDAMVYTSDLLTNSVIIMAYVTGGLVQQTSQWLSNLLGTTVEKLRPIFEWIEAKLSAGVEFLKDAWEILKFLITGVFDIVKGQIQVASDNIKDCVKCFIDVVNKALEMCIDQVTIAGAKLRSLNLGEVFIAQSKGLYRQCIRGKEQLQLLMPLKAPKEVTFLEGDSHDTVLTSEEVVLKNGELEALETPVDSFTNGAIVGTPVCVNGLMLLEIKDKEQYCALSPGLLATNNVFRLKGGAPIKGVTFGEDTVWEVQGYKNVRITFELDERVDKVLNEKCSVYTVESGTEVTEFACVVAEAVVKTLQPVSDLLTNMGIDLDEWSVATFYLFDDAGEENFSSRMYCSFYPPDEEEEDDAECEEEEIDETCEHEYGTEDDYQGLPLEFGASAETVRVEEEEEEDWLDDTTEQSEIEPEPEPTPEEPVNQFTGYLKLTDNVAIKCVDIVKEAQSANPMVIVNAANIHLKHGGGVAGALNKATNGAMQKESDDYIKLNGPLTVGGSCLLSGHNLAKKCLHVVGPNLNAGEDIQLLKAAYENFNSQDILLAPLLSAGIFGAKPLQSLQVCVQTVRTQVYIAVNDKALYEQVVMDYLDNLKPRVEAPKQEEPPNTEDSKTEEKSVVQKPVDVKPKIKACIDEVTTTLEETKFLTNKLLLFADINGKLYHDSQNMLRGEDMSFLEKDAPYMVGDVITSGDITCVVIPSKKAGGTTEMLSRALKKVPVDEYITTYPGQGCAGYTLEEAKTALKKCKSAFYVLPSEAPNAKEEILGTVSWNLREMLAHAEETRKLMPICMDVRAIMATIQRKYKGIKIQEGIVDYGVRFFFYTSKEPVASIITKLNSLNEPLVTMPIGYVTHGFNLEEAARCMRSLKAPAVVSVSSPDAVTTYNGYLTSSSKTSEEHFVETVSLAGSYRDWSYSGQRTELGVEFLKRGDKIVYHTLESPVEFHLDGEVLSLDKLKSLLSLREVKTIKVFTTVDNTNLHTQLVDMSMTYGQQFGPTYLDGADVTKIKPHVNHEGKTFFVLPSDDTLRSEAFEYYHTLDESFLGRYMSALNHTKKWKFPQVGGLTSIKWADNNCYLSSVLLALQQLEVKFNAPALQEAYYRARAGDAANFCALILAYSNKTVGELGDVRETMTHLLQHANLESAKRVLNVVCKHCGQKTTTLTGVEAVMYMGTLSYDNLKTGVSIPCVCGRDATQYLVQQESSFVMMSAPPAEYKLQQGTFLCANEYTGNYQCGHYTHITAKETLYRIDGAHLTKMSEYKGPVTDVFYKETSYTTTIKPVSYKLDGVTYTEIEPKLDGYYKKDNAYYTEQPIDLVPTQPLPNASFDNFKLTCSNTKFADDLNQMTGFTKPASRELSVTFFPDLNGDVVAIDYRHYSASFKKGAKLLHKPIVWHINQATTKTTFKPNTWCLRCLWSTKPVDTSNSFEVLAVEDTQGMDNLACESQQPTSEEVVENPTIQKEVIECDVKTTEVVGNVILKPSDEGVKVTQELGHEDLMAAYVENTSITIKKPNELSLALGLKTIATHGIAAINSVPWSKILAYVKPFLGQAAITTSNCAKRLAQRVFNNYMPYVFTLLFQLCTFTKSTNSRIRASLPTTIAKNSVKSVAKLCLDAGINYVKSPKFSKLFTIAMWLLLLSICLGSLICVTAAFGVLLSNFGAPSYCNGVRELYLNSSNVTTMDFCEGSFPCSICLSGLDSLDSYPALETIQVTISSYKLDLTILGLAAEWVLAYMLFTKFFYLLGLSAIMQVFFGYFASHFISNSWLMWFIISIVQMAPVSAMVRMYIFFASFYYIWKSYVHIMDGCTSSTCMMCYKRNRATRVECTTIVNGMKRSFYVYANGGRGFCKTHNWNCLNCDTFCTGSTFISDEVARDLSLQFKRPINPTDQSSYIVDSVAVKNGALHLYFDKAGQKTYERHPLSHFVNLDNLRANNTKGSLPINVIVFDGKSKCDESASKSASVYYSQLMCQPILLLDQALVSDVGDSTEVSVKMFDAYVDTFSATFSVPMEKLKALVATAHSELAKGVALDGVLSTFVSAARQGVVDTDVDTKDVIECLKLSHHSDLEVTGDSCNNFMLTYNKVENMTPRDLGACIDCNARHINAQVAKSHNVSLIWNVKDYMSLSEQLRKQIRSAAKKNNIPFRLTCATTRQVVNVITTKISLKGGKIVSTCFKLMLKATLLCVLAALVCYIVMPVHTLSIHDGYTNEIIGYKAIQDGVTRDIISTDDCFANKHAGFDAWFSQRGGSYKNDKSCPVVAAIITREIGFIVPGLPGTVLRAINGDFLHFLPRVFSAVGNICYTPSKLIEYSDFATSACVLAAECTIFKDAMGKPVPYCYDTNLLEGSISYSELRPDTRYVLMDGSIIQFPNTYLEGSVRVVTTFDAEYCRHGTCERSEVGICLSTSGRWVLNNEHYRALSGVFCGVDAMNLIANIFTPLVQPVGALDVSASVVAGGIIAILVTCAAYYFMKFRRVFGEYNHVVAANALLFLMSFTILCLVPAYSFLPGVYSVFYLYLTFYFTNDVSFLAHLQWFAMFSPIVPFWITAIYVFCISLKHCHWFFNNYLRKRVMFNGVTFSTFEEAALCTFLLNKEMYLKLRSETLLPLTQYNRYLALYNKYKYFSGALDTTSYREAACCHLAKALNDFSNSGADVLYQPPQTSITSAVLQSGFRKMAFPSGKVEGCMVQVTCGTTTLNGLWLDDTVYCPRHVICTAEDMLNPNYEDLLIRKSNHSFLVQAGNVQLRVIGHSMQNCLLRLKVDTSNPKTPKYKFVRIQPGQTFSVLACYNGSPSGVYQCAMRPNHTIKGSFLNGSCGSVGFNIDYDCVSFCYMHHMELPTGVHAGTDLEGKFYGPFVDRQTAQAAGTDTTITLNVLAWLYAAVINGDRWFLNRFTTTLNDFNLVAMKYNYEPLTQDHVDILGPLSAQTGIAVLDMCAALKELLQNGMNGRTILGSTILEDEFTPFDVVRQCSGVTFQGKFKKIVKGTHHWMLLTFLTSLLILVQSTQWSLFFFVYENAFLPFTLGIMAIAACAMLLVKHKHAFLCLFLLPSLATVAYFNMVYMPASWVMRIMTWLELADTSLSGYRLKDCVMYASALVLLILMTARTVYDDAARRVWTLMNVITLVYKVYYGNALDQAISMWALVISVTSNYSGVVTTIMFLARAIVFVCVEYYPLLFITGNTLQCIMLVYCFLGYCCCCYFGLFCLLNRYFRLTLGVYDYLVSTQEFRYMNSQGLLPPKSSIDAFKLNIKLLGIGGKPCIKVATVQSKMSDVKCTSVVLLSVLQQLRVESSSKLWAQCVQLHNDILLAKDTTEAFEKMVSLLSVLLSMQGAVDINRLCEEMLDNRATLQAIASEFSSLPSYAAYATAQEAYEQAVANGDSEVVLKKLKKSLNVAKSEFDRDAAMQRKLEKMADQAMTQMYKQARSEDKRAKVTSAMQTMLFTMLRKLDNDALNNIINNARDGCVPLNIIPLTTAAKLMVVVPDYGTYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEINMDNSPNLAWPLIVTALRANSAVKLQNNELSPVALRQMSCAAGTTQTACTDDNALAYYNNSKGGRFVLALLSDHQDLKWARFPKSDGTGTIYTELEPPCRFVTDTPKGPKVKYLYFIKGLNNLNRGMVLGSLAATVRLQAGNATEVPANSTVLSFCAFAVDPAKAYKDYLASGGQPITNCVKMLCTHTGTGQAITVTPEANMDQESFGGASCCLYCRCHIDHPNPKGFCDLKGKYVQIPTTCANDPVGFTLRNTVCTVCGMWKGYGCSCDQLREPLMQSADASTFLNRVCGVSAARLTPCGTGTSTDVVYRAFDIYNEKVAGFAKFLKTNCCRFQEKDEEGNLLDSYFVVKRHTMSNYQHEETIYNLVKDCPAVAVHDFFKFRVDGDMVPHISRQRLTKYTMADLVYALRHFDEGNCDTLKEILVTYNCCDDDYFNKKDWYDFVENPDILRVYANLGERVRQSLLKTVQFCDAMRDAGIVGVLTLDNQDLNGNWYDFGDFVQVAPGCGVPIVDSYYSLLMPILTLTRALAAESHMDADLAKPLIKWDLLKYDFTEERLCLFDRYFKYWDQTYHPNCINCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQDVNLHSSRLSFKELLVYAADPAMHAASGNLLLDKRTTCFSVAALTNNVAFQTVKPGNFNKDFYDFAVSKGFFKEGSSVELKHFFFAQDGNAAISDYDYYRYNLPTMCDIRQLLFVVEVVDKYFDCYDGGCINANQVIVNNLDKSAGFPFNKWGKARLYYDSMSYEDQDALFAYTKRNVIPTITQMNLKYAISAKNRARTVAGVSICSTMTNRQFHQKLLKSIAATRGATVVIGTSKFYGGWHNMLKTVYSDVETPHLMGWDYPKCDRAMPNMLRIMASLVLARKHNTCCNLSHRFYRLANECAQVLSEMVMCGGSLYVKPGGTSSGDATTAYANSVFNICQAVTANVNALLSTDGNKIADKYVRNLQHRLYECLYRNRDVDHEFVDEFYAYLRKHFSMMILSDDAVVCYNSNYAAQGLVASIKNFKAVLYYQNNVFMSEAKCWTETDLTKGPHEFCSQHTMLVKQGDDYVYLPYPDPSRILGAGCFVDDIVKTDGTLMIERFVSLAIDAYPLTKHPNQEYADVFHLYLQYIRKLHDELTGHMLDMYSVMLTNDNTSRYWEPEFYEAMYTPHTVLQAVGACVLCNSQTSLRCGACIRRPFLCCKCCYDHVISTSHKLVLSVNPYVCNAPGCDVTDVTQLYLGGMSYYCKSHKPPISFPLCANGQVFGLYKNTCVGSDNVTDFNAIATCDWTNAGDYILANTCTERLKLFAAETLKATEETFKLSYGIATVREVLSDRELHLSWEVGKPRPPLNRNYVFTGYRVTKNSKVQIGEYTFEKGDYGDAVVYRGTTTYKLNVGDYFVLTSHTVMPLSAPTLVPQEHYVRITGLYPTLNISDEFSSNVANYQKVGMQKYSTLQGPPGTGKSHFAIGLALYYPSARIVYTACSHAAVDALCEKALKYLPIDKCSRIIPARARVECFDKFKVNSTLEQYVFCTVNALPETTADIVVFDEISMATNYDLSVVNARLRAKHYVYIGDPAQLPAPRTLLTKGTLEPEYFNSVCRLMKTIGPDMFLGTCRRCPAEIVDTVSALVYDNKLKAHKDKSAQCFKMFYKGVITHDVSSAINRPQIGVVREFLTRNPAWRKAVFISPYNSQNAVASKILGLPTQTVDSSQGSEYDYVIFTQTTETAHSCNVNRFNVAITRAKIGILCIMSDRDLYDKLQFTSLEIPRRNVATLQAENVTGLFKDCSKIITGLHPTQAPTHLSVDIKFKTEGLCVDIPGIPKDMTYRRLISMMGFKMNYQVNGYPNMFITREEAIRHVRAWIGFDVEGCHATRDAVGTNLPLQLGFSTGVNLVAVPTGYVDTENNTEFTRVNAKPPPGDQFKHLIPLMYKGLPWNVVRIKIVQMLSDTLKGLSDRVVFVLWAHGFELTSMKYFVKIGPERTCCLCDKRATCFSTSSDTYACWNHSVGFDYVYNPFMIDVQQWGFTGNLQSNHDQHCQVHGNAHVASCDAIMTRCLAVHECFVKRVDWSVEYPIIGDELRVNSACRKVQHMVVKSALLADKFPVLHDIGNPKAIKCVPQAEVEWKFYDAQPCSDKAYKIEELFYSYATHHDKFTDGVCLFWNCNVDRYPANAIVCRFDTRVLSNLNLPGCDGGSLYVNKHAFHTPAFDKSAFTNLKQLPFFYYSDSPCESHGKQVVSDIDYVPLKSATCITRCNLGGAVCRHHANEYRQYLDAYNMMISAGFSLWIYKQFDTYNLWNTFTRLQSLENVAYNVVNKGHFDGHAGEAPVSIINNAVYTKVDGIDVEIFENKTTLPVNVAFELWAKRNIKPVPEIKILNNLGVDIAANTVIWDYKREAPAHVSTIGVCTMTDIAKKPTESACSSLTVLFDGRVEGQVDLFRNARNGVLITEGSVKGLTPSKGPAQASVNGVTLIGESVKTQFNYFKKVDGIIQQLPETYFTQSRDLEDFKPRSQMETDFLELAMDEFIQRYKLEGYAFEHIVYGDFSHGQLGGLHLMIGLAKRSQDSPLKLEDFIPMDSTVKNYFITDAQTGSSKCVCSVIDLLLDDFVEIIKSQDLSVISKVVKVTIDYAEISFMLWCKDGHVETFYPKLQASQAWQPGVAMPNLYKMQRMLLEKCDLQNYGENAVIPKGIMMNVAKYTQLCQYLNTLTLAVPYNMRVIHFGAGSDKGVAPGTAVLRQWLPTGTLLVDSDLNDFVSDADSTLIGDCATVHTANKWDLIISDMYDPRTKHVTKENDSKEGFFTYLCGFIKQKLALGGSIAVKITEHSWNADLYKLMGHFSWWTAFVTNVNASSSEAFLIGANYLGKPKEQIDGYTMHANYIFWRNTNPIQLSSYSLFDMSKFPLKLRGTAVMSLKENQINDMIYSLLEKGRLIIRENNRVVVSSDILVNN

T78540	TARGETID	T78540
T78540	FORMERID	TTDR00638
T78540	UNIPROID	PAP_HHV11
T78540	TARGNAME	Herpes simplex virus DNA polymerase processivity factor (HSV UL42)
T78540	GENENAME	HSV UL42
T78540	TARGTYPE	Literature-reported
T78540	SYNONYMS	UL42; Protein UL42; Polymerase accessory protein; HSV PAP; DNA-binding protein UL42
T78540	FUNCTION	Plays an essential role in viral DNA replication by acting as the polymerase accessory subunit. Associates with the viral polymerase to increase its processivity and forms high- affinity direct interactions with DNA. Facilitates the origin- binding protein UL9 loading onto DNA thus increasing its ability to assemble into a functional complex capable of unwinding duplex DNA.
T78540	PDBSTRUC	1DML
T78540	BIOCLASS	Herpesviridae DNA polymerase
T78540	SEQUENCE	MTDSPGGVAPASPVEDASDASLGQPEEGAPCQVVLQGAELNGILQAFAPLRTSLLDSLLVMGDRGILIHNTIFGEQVFLPLEHSQFSRYRWRGPTAAFLSLVDQKRSLLSVFRANQYPDLRRVELAITGQAPFRTLVQRIWTTTSDGEAVELASETLMKRELTSFVVLVPQGTPDVQLRLTRPQLTKVLNATGADSATPTTFELGVNGKFSVFTTSTCVTFAAREEGVSSSTSTQVQILSNALTKAGQAAANAKTVYGENTHRTFSVVVDDCSMRAVLRRLQVGGGTLKFFLTTPVPSLCVTATGPNAVSAVFLLKPQKICLDWLGHSQGSPSAGSSASRASGSEPTDSQDSASDAVSHGDPEDLDGAARAGEAGALHACPMPSSTTRVTPTTKRGRSGGEDARADTALKKPKTGSPTAPPPADPVPLDTEDDSDAADGTAARPAAPDARSGSRYACYFRDLPTGEASPGAFSAFRGGPQTPYGFGFP

T35565	TARGETID	T35565
T35565	FORMERID	TTDI01826
T35565	UNIPROID	PPBN_HUMAN
T35565	TARGNAME	Alkaline phosphatase (ALPPL2)
T35565	GENENAME	ALPPL2
T35565	TARGTYPE	Literature-reported
T35565	SYNONYMS	Placental alkaline phosphatase-like; PLAP-like; Germ cell alkaline phosphatase; GCAP; Alkaline phosphatase, placental-like; Alkaline phosphatase, germ cell type; Alkaline phosphatase Nagao isozyme; ALPPL; ALPG; ALP-1
T35565	FUNCTION	extracellular region, plasma membrane, alkaline phosphatase activity.
T35565	BIOCLASS	Phosphoric monoester hydrolase
T35565	ECNUMBER	EC 3.1.3.1
T35565	SEQUENCE	MQGPWVLLLLGLRLQLSLGIIPVEEENPDFWNRQAAEALGAAKKLQPAQTAAKNLIIFLGDGMGVSTVTAARILKGQKKDKLGPETFLAMDRFPYVALSKTYSVDKHVPDSGATATAYLCGVKGNFQTIGLSAAARFNQCNTTRGNEVISVMNRAKKAGKSVGVVTTTRVQHASPAGAYAHTVNRNWYSDADVPASARQEGCQDIATQLISNMDIDVILGGGRKYMFPMGTPDPEYPDDYSQGGTRLDGKNLVQEWLAKHQGARYVWNRTELLQASLDPSVTHLMGLFEPGDMKYEIHRDSTLDPSLMEMTEAALLLLSRNPRGFFLFVEGGRIDHGHHESRAYRALTETIMFDDAIERAGQLTSEEDTLSLVTADHSHVFSFGGYPLRGSSIFGLAPGKARDRKAYTVLLYGNGPGYVLKDGARPDVTESESGSPEYRQQSAVPLDGETHAGEDVAVFARGPQAHLVHGVQEQTFIAHVMAFAACLEPYTACDLAPRAGTTDAAHPGPSVVPALLPLLAGTLLLLGTATAP

T04233	TARGETID	T04233
T04233	FORMERID	TTDI02417
T04233	UNIPROID	BXB_CLOBO
T04233	TARGNAME	Bacterial Botulinum toxin B (Bact botB)
T04233	GENENAME	Bact botB
T04233	TARGTYPE	Literature-reported
T04233	SYNONYMS	botB; Botulinum neurotoxin type B; Botulinum neurotoxin B heavy chain; BontoxilysinB; BoNT/B
T04233	FUNCTION	Botulinum toxin acts by inhibiting neurotransmitter release. It binds to peripheral neuronal synapses, is internalized and moves by retrograde transport up the axon into the spinal cord where it can move between postsynaptic and presynaptic neurons. It inhibits neurotransmitter release by acting as a zinc endopeptidase that cleaves the '76-Gln-|-Phe-77' bond of synaptobrevin-2.
T04233	PDBSTRUC	6G5K; 6G5G; 6G5F; 5VMR; 5VID
T04233	BIOCLASS	Peptidase
T04233	SEQUENCE	MPVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFNKSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLGDRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNHFASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLYGIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIVDRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETNIAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKDMEKEYRGQNKAINKQAYEEISKEHLAVYKIQMCKSVKAPGICIDVDNEDLFFIADKNSFSDDLSKNERIEYNTQSNYIENDFPINELILDTDLISKIELPSENTESLTDFNVDVPVYEKQPAIKKIFTDENTIFQYLYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVNDFVIEANKSNTMDKIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLIPVVGAFLLESYIDNKNKIIKTIDNALTKRNEKWSDMYGLIVAQWLSTVNTQFYTIKEGMYKALNYQAQALEEIIKYRYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNINNFINGCSVSYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVNKYLKTIMPFDLSIYTNDTILIEMFNKYNSEILNNIILNLRYKDNNLIDLSGYGAKVEVYDGVELNDKNQFKLTSSANSKIRVTQNQNIIFNSVFLDFSVSFWIRIPKYKNDGIQNYIHNEYTIINCMKNNSGWKISIRGNRIIWTLIDINGKTKSVFFEYNIREDISEYINRWFFVTITNNLNNAKIYINGKLESNTDIKDIREVIANGEIIFKLDGDIDRTQFIWMKYFSIFNTELSQSNIEERYKIQSYSEYLKDFWGNPLMYNKEYYMFNAGNKNSYIKLKKDSPVGEILTRSKYNQNSKYINYRDLYIGEKFIIRRKSNSQSINDDIVRKEDYIYLDFFNLNQEWRVYTYKYFKKEEEKLFLAPISDSDEFYNTIQIKEYDEQPTYSCQLLFKKDEESTDEIGLIGIHRFYESGIVFEEYKDYFCISKWYLKEVKRKPYNLKLGCNWQFIPKDEGWTE

T56496	TARGETID	T56496
T56496	FORMERID	TTDI03457
T56496	UNIPROID	PNMT_HUMAN
T56496	TARGNAME	Phenylethanolamine N-methyltransferase (PNMT)
T56496	GENENAME	PNMT
T56496	TARGTYPE	Literature-reported
T56496	SYNONYMS	PNMTase; PENT; Noradrenaline N-methyltransferase
T56496	FUNCTION	Converts noradrenaline to adrenaline.
T56496	PDBSTRUC	4MQ4; 4MIK; 4DM3; 3KR2; 3KR1
T56496	ECNUMBER	EC 2.1.1.28
T56496	SEQUENCE	MSGADRSPNAGAAPDSAPGQAAVASAYQRFEPRAYLRNNYAPPRGDLCNPNGVGPWKLRCLAQTFATGEVSGRTLIDIGSGPTVYQLLSACSHFEDITMTDFLEVNRQELGRWLQEEPGAFNWSMYSQHACLIEGKGECWQDKERQLRARVKRVLPIDVHQPQPLGAGSPAPLPADALVSAFCLEAVSPDLASFQRALDHITTLLRPGGHLLLIGALEESWYLAGEARLTVVPVSEEEVREALVRSGYKVRDLRTYIMPAHLQTGVDDVKGVFFAWAQKVGL
T56496	DRUGINFO	D05ZKW	LY134046	Investigative

T42319	TARGETID	T42319
T42319	FORMERID	TTDR00423
T42319	UNIPROID	PERE_HUMAN
T42319	TARGNAME	Eosinophil peroxidase (EPX)
T42319	GENENAME	EPX
T42319	TARGTYPE	Literature-reported
T42319	SYNONYMS	EPX
T42319	FUNCTION	Mediates tyrosine nitration of secondary granule proteins in mature resting eosinophils. Shows significant inhibitory activity towards Mycobacterium tuberculosis H37Rv by inducing bacterial fragmentation and lysis.
T42319	BIOCLASS	Peroxidases
T42319	ECNUMBER	EC 1.11.1.7
T42319	SEQUENCE	MHLLPALAGVLATLVLAQPCEGTDPASPGAVETSVLRDCIAEAKLLVDAAYNWTQKSIKQRLRSGSASPMDLLSYFKQPVAATRTVVRAADYMHVALGLLEEKLQPQRSGPFNVTDVLTEPQLRLLSQASGCALRDQAERCSDKYRTITGRCNNKRRPLLGASNQALARWLPAEYEDGLSLPFGWTPSRRRNGFLLPLVRAVSNQIVRFPNERLTSDRGRALMFMQWGQFIDHDLDFSPESPARVAFTAGVDCERTCAQLPPCFPIKIPPNDPRIKNQRDCIPFFRSAPSCPQNKNRVRNQINALTSFVDASMVYGSEVSLSLRLRNRTNYLGLLAINQRFQDNGRALLPFDNLHDDPCLLTNRSARIPCFLAGDTRSTETPKLAAMHTLFMREHNRLATELRRLNPRWNGDKLYNEARKIMGAMVQIITYRDFLPLVLGKARARRTLGHYRGYCSNVDPRVANVFTLAFRFGHTMLQPFMFRLDSQYRASAPNSHVPLSSAFFASWRIVYEGGIDPILRGLMATPAKLNRQDAMLVDELRDRLFRQVRRIGLDLAALNMQRSRDHGLPGYNAWRRFCGLSQPRNLAQLSRVLKNQDLARKFLNLYGTPDNIDIWIGAIAEPLLPGARVGPLLACLFENQFRRARDGDRFWWQKRGVFTKRQRKALSRISLSRIICDNTGITTVSRDIFRANIYPRGFVNCSRIPRLNLSAWRGT

T10844	TARGETID	T10844
T10844	FORMERID	TTDR00311
T10844	UNIPROID	FCGR1_HUMAN
T10844	TARGNAME	Immunoglobulin gamma Fc receptor I (FCGR1)
T10844	GENENAME	FCGR1A
T10844	TARGTYPE	Literature-reported
T10844	SYNONYMS	IgG Fc receptor I; FcRI; Fc-gamma RI; FCGR1A; CD64 antigen; CD64
T10844	FUNCTION	High affinity receptor for the Fc region of immunoglobulins gamma. Functions in both innate and adaptive immune responses.
T10844	PDBSTRUC	4ZNE; 4X4M; 4W4O; 3RJD
T10844	BIOCLASS	Immunoglobulin
T10844	SEQUENCE	MWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNGTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPLALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAGISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRNTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVGIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQLQEGVHRKEPQGAT

T37986	TARGETID	T37986
T37986	FORMERID	TTDR00027
T37986	UNIPROID	CARB_STRTH
T37986	TARGNAME	Streptomyces RNA methyltransferase (Stre-myc carB)
T37986	GENENAME	Stre-myc carB
T37986	TARGTYPE	Literature-reported
T37986	SYNONYMS	carB; RNA methyltransferase
T37986	FUNCTION	Probable RNA methylase. Confers resistance to carbomycin and several other macrolides, lincomycin and vernamycin B, but not to all macrolide-lincosamide-streptogramin B antibiotics.
T37986	BIOCLASS	Methyltransferase
T37986	ECNUMBER	EC 2.1.1.-
T37986	SEQUENCE	MAALLKRILRRRMAEKRSGRGRMAAARTTGAQSRKTAQRSGRSEADRRRRVHGQNFLVDRETVQRFVRFADPDPGEVVLEVGAGNGAITRELARLCRRVVAYEIDRHFADRLREATAEDPRIEVVAGDFLKTSQPKVPFSVVGNIPFGNTADIVDWCLNARRLRTTTLVTQLEYARKRTGGYRRWSRLTVATWPEVEWRMGERISRRWFRPVPAVDSAVLRLERRPVPLIPPGLMHDFRDLVETGFTGKGGSLDASLRRRFPARRVAAGFRRARLEQGVVVAYVTPGQWITLFEELHGR
T37986	DRUGINFO	D00FLT	Sinefungin	Investigative

T57421	TARGETID	T57421
T57421	FORMERID	TTDR00740
T57421	UNIPROID	ACPH_HUMAN
T57421	TARGNAME	Acylamino-acid-releasing enzyme (APEH)
T57421	GENENAME	APEH
T57421	TARGTYPE	Literature-reported
T57421	SYNONYMS	Oxidized protein hydrolase; OPH; DNF15S2 protein; Acylpeptide hydrolase; Acylaminoacyl-peptidase; Acyl-peptide hydrolase; APH; APEH; AARE
T57421	FUNCTION	This enzyme catalyzes the hydrolysis of the N-terminal peptide bond of an N-acetylated peptide to generate an N- acetylated amino acid and a peptide with a free N-terminus. It preferentially cleaves off Ac-Ala, Ac-Met and Ac-Ser.
T57421	BIOCLASS	Peptidase
T57421	ECNUMBER	EC 3.4.19.1
T57421	SEQUENCE	MERQVLLSEPEEAAALYRGLSRQPALSAACLGPEVTTQYGGQYRTVHTEWTQRDLERMENIRFCRQYLVFHDGDSVVFAGPAGNSVETRGELLSRESPSGTMKAVLRKAGGTGPGEEKQFLEVWEKNRKLKSFNLSALEKHGPVYEDDCFGCLSWSHSETHLLYVAEKKRPKAESFFQTKALDVSASDDEIARLKKPDQAIKGDQFVFYEDWGENMVSKSIPVLCVLDVESGNISVLEGVPENVSPGQAFWAPGDAGVVFVGWWHEPFRLGIRFCTNRRSALYYVDLIGGKCELLSDDSLAVSSPRLSPDQCRIVYLQYPSLIPHHQCSQLCLYDWYTKVTSVVVDVVPRQLGENFSGIYCSLLPLGCWSADSQRVVFDSAQRSRQDLFAVDTQVGTVTSLTAGGSGGSWKLLTIDQDLMVAQFSTPSLPPTLKVGFLPSAGKEQSVLWVSLEEAEPIPDIHWGIRVLQPPPEQENVQYAGLDFEAILLQPGSPPDKTQVPMVVMPHGGPHSSFVTAWMLFPAMLCKMGFAVLLVNYRGSTGFGQDSILSLPGNVGHQDVKDVQFAVEQVLQEEHFDASHVALMGGSHGGFISCHLIGQYPETYRACVARNPVINIASMLGSTDIPDWCVVEAGFPFSSDCLPDLSVWAEMLDKSPIRYIPQVKTPLLLMLGQEDRRVPFKQGMEYYRALKTRNVPVRLLLYPKSTHALSEVEVESDSFMNAVLWLRTHLGS
T57421	DRUGINFO	D03DNV	ARI-3099	Investigative

T16578	TARGETID	T16578
T16578	FORMERID	TTDI00229
T16578	UNIPROID	ANXA8_HUMAN
T16578	TARGNAME	Annexin A8 (ANXA8)
T16578	GENENAME	ANXA8
T16578	TARGTYPE	Literature-reported
T16578	SYNONYMS	Vascular anticoagulant-beta; VAC-beta; Annexin-8; Annexin VIII; ANX8
T16578	FUNCTION	This protein is an anticoagulant protein that acts as an indirect inhibitor of the thromboplastin-specific complex, which is involved in the blood coagulation cascade.
T16578	PDBSTRUC	1W45; 1W3W
T16578	BIOCLASS	Annexin protein
T16578	SEQUENCE	MAWWKSWIEQEGVTVKSSSHFNPDPDAETLYKAMKGIGTNEQAIIDVLTKRSNTQRQQIAKSFKAQFGKDLTETLKSELSGKFERLIVALMYPPYRYEAKELHDAMKGLGTKEGVIIEILASRTKNQLREIMKAYEEDYGSSLEEDIQADTSGYLERILVCLLQGSRDDVSSFVDPGLALQDAQDLYAAGEKIRGTDEMKFITILCTRSATHLLRVFEEYEKIANKSIEDSIKSETHGSLEEAMLTVVKCTQNLHSYFAERLYYAMKGAGTRDGTLIRNIVSRSEIDLNLIKCHFKKMYGKTLSSMIMEDTSGDYKNALLSLVGSDP

T40628	TARGETID	T40628
T40628	FORMERID	TTDS00055
T40628	UNIPROID	3BHS1_HUMAN; 3BHS2_HUMAN
T40628	TARGNAME	Hydroxysteroid dehydrogenase 3-beta (HSD3B)
T40628	GENENAME	HSD3B1; HSD3B2
T40628	TARGTYPE	Literature-reported
T40628	SYNONYMS	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase
T40628	FUNCTION	Catalyzes the biosynthesis of the steroid progesterone from pregnenolone, 17-hydroxyprogesterone from 17-hydroxypregnenolone, and androstenedione from dehydroepiandrosterone (DHEA) in the adrenal gland.  Also catalyzes the oxidative conversion of 5-3-hydroxysteroids to the 4-3-keto configuration and is, therefore, essential for the biosynthesis of all classes of hormonal steroids, namely progesterone, glucocorticoids, mineralocorticoids, androgens, and estrogens.
T40628	BIOCLASS	Short-chain dehydrogenases reductase
T40628	SEQUENCE	MTGWSCLVTGAGGFLGQRIIRLLVKEKELKEIRVLDKAFGPELREEFSKLQNKTKLTVLEGDILDEPFLKRACQDVSVIIHTACIIDVFGVTHRESIMNVNVKGTQLLLEACVQASVPVFIYTSSIEVAGPNSYKEIIQNGHEEEPLENTWPAPYPHSKKLAEKAVLAANGWNLKNGGTLYTCALRPMYIYGEGSRFLSASINEALNNNGILSSVGKFSTVNPVYVGNVAWAHILALRALQDPKKAPSIRGQFYYISDDTPHQSYDNLNYTLSKEFGLRLDSRWSFPLSLMYWIGFLLEIVSFLLRPIYTYRPPFNRHIVTLSNSVFTFSYKKAQRDLAYKPLYSWEEAKQKTVEWVGSLVDRHKETLKSKTQ
T40628	DRUGINFO	D05ZPJ	4-MA	Investigative
T40628	DRUGINFO	D06LVG	17 beta-N,N-diethylcarbamoyl-4-aza-5 alpha-androstan-3-one (4MA)	Investigative
T40628	DRUGINFO	D08WDY	Equilenin	Investigative
T40628	DRUGINFO	D09SWM	Epostane	Investigative
T40628	DRUGINFO	D0T5MO	5alpha-Androstan-3,17-Dione	Investigative
T40628	DRUGINFO	D0M8RO	4-ANDROSTENE-3-17-DIONE	Investigative
T40628	DRUGINFO	D0Q5FV	2-Sulfhydryl-Ethanol	Investigative

T82297	TARGETID	T82297
T82297	FORMERID	TTDR00687
T82297	UNIPROID	FOLR2_HUMAN
T82297	TARGNAME	Folate receptor beta (FOLR2)
T82297	GENENAME	FOLR2
T82297	TARGTYPE	Literature-reported
T82297	SYNONYMS	Placental folate-binding protein; Folate receptor, fetal/placental; Folate receptor type-beta; Folate receptor 2; FR-beta; FOLR2
T82297	FUNCTION	Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate and folate analogs into the interior of cells. Has high affinity for folate and folic acid analogs at neutral pH. Exposure to slightly acidic pH after receptor endocytosis triggers a conformation change that strongly reduces its affinity for folates and mediates their release.
T82297	PDBSTRUC	4KN2; 4KN1; 4KN0; 4KMZ; 4KMY
T82297	BIOCLASS	Folate receptor
T82297	SEQUENCE	MVWKWMPLLLLLVCVATMCSAQDRTDLLNVCMDAKHHKTKPGPEDKLHDQCSPWKKNACCTASTSQELHKDTSRLYNFNWDHCGKMEPACKRHFIQDTCLYECSPNLGPWIQQVNQSWRKERFLDVPLCKEDCQRWWEDCHTSHTCKSNWHRGWDWTSGVNKCPAGALCRTFESYFPTPAALCEGLWSHSYKVSNYSRGSGRCIQMWFDSAQGNPNEEVARFYAAAMHVNAGEMLHGTGGLLLSLALMLQLWLLG

T91614	TARGETID	T91614
T91614	UNIPROID	TRI27_HUMAN
T91614	TARGNAME	Zinc finger protein RFP (TRIM27)
T91614	GENENAME	TRIM27
T91614	TARGTYPE	Literature-reported
T91614	SYNONYMS	Tripartite motif-containing protein 27; Ret finger protein; RNF76; RING-type E3 ubiquitin transferase TRIM27; RING finger protein 76
T91614	FUNCTION	E3 ubiquitin-protein ligase that mediates ubiquitination of PIK3C2B and inhibits its activity; mediates the formation of 'Lys-48'-linked polyubiquitin chains; the function inhibits CD4 T-cell activation. Acts as a regulator of retrograde transport: together with MAGEL2, mediates the formation of 'Lys-63'-linked polyubiquitin chains at 'Lys-220' of WASHC1, leading to promote endosomal F-actin assembly (PubMed:23452853). Has a transcriptional repressor activity by cooperating with EPC1. Induces apoptosis by activating Jun N-terminal kinase and p38 kinase and also increases caspase-3-like activity independently of mitochondrial events. May function in male germ cell development. Has DNA-binding activity and preferentially bound to double-stranded DNA.
T91614	BIOCLASS	TRIM/RBCC family
T91614	ECNUMBER	EC 2.3.2.27
T91614	SEQUENCE	MASGSVAECLQQETTCPVCLQYFAEPMMLDCGHNICCACLARCWGTAETNVSCPQCRETFPQRHMRPNRHLANVTQLVKQLRTERPSGPGGEMGVCEKHREPLKLYCEEDQMPICVVCDRSREHRGHSVLPLEEAVEGFKEQIQNQLDHLKRVKDLKKRRRAQGEQARAELLSLTQMEREKIVWEFEQLYHSLKEHEYRLLARLEELDLAIYNSINGAITQFSCNISHLSSLIAQLEEKQQQPTRELLQDIGDTLSRAERIRIPEPWITPPDLQEKIHIFAQKCLFLTESLKQFTEKMQSDMEKIQELREAQLYSVDVTLDPDTAYPSLILSDNLRQVRYSYLQQDLPDNPERFNLFPCVLGSPCFIAGRHYWEVEVGDKAKWTIGVCEDSVCRKGGVTSAPQNGFWAVSLWYGKEYWALTSPMTALPLRTPLQRVGIFLDYDAGEVSFYNVTERCHTFTFSHATFCGPVRPYFSLSYSGGKSAAPLIICPMSGIDGFSGHVGNHGHSMETSP

T38983	TARGETID	T38983
T38983	FORMERID	TTDR00198
T38983	UNIPROID	ETS1_HUMAN
T38983	TARGNAME	Protein C-ets-1 (ETS1)
T38983	GENENAME	ETS1
T38983	TARGTYPE	Literature-reported
T38983	SYNONYMS	P54; EWSR2
T38983	FUNCTION	Directly controls the expression of cytokine and chemokine genes in a wide variety of different cellular contexts. May control the differentiation, survival and proliferation of lymphoid cells. May also regulate angiogenesis through regulation of expression of genes controlling endothelial cell migration and invasion. Transcription factor.
T38983	PDBSTRUC	5ZMC; 4LG0; 4L18; 4L0Z; 4L0Y
T38983	BIOCLASS	E26 transformation-specific ETS
T38983	SEQUENCE	MKAAVDLKPTLTIIKTEKVDLELFPSPDMECADVPLLTPSSKEMMSQALKATFSGFTKEQQRLGIPKDPRQWTETHVRDWVMWAVNEFSLKGVDFQKFCMNGAALCALGKDCFLELAPDFVGDILWEHLEILQKEDVKPYQVNGVNPAYPESRYTSDYFISYGIEHAQCVPPSEFSEPSFITESYQTLHPISSEELLSLKYENDYPSVILRDPLQTDTLQNDYFAIKQEVVTPDNMCMGRTSRGKLGGQDSFESIESYDSCDRLTQSWSSQSSFNSLQRVPSYDSFDSEDYPAALPNHKPKGTFKDYVRDRADLNKDKPVIPAAALAGYTGSGPIQLWQFLLELLTDKSCQSFISWTGDGWEFKLSDPDEVARRWGKRKNKPKMNYEKLSRGLRYYYDKNIIHKTAGKRYVYRFVCDLQSLLGYTPEELHAMLDVKPDADE

T82685	TARGETID	T82685
T82685	FORMERID	TTDR01007
T82685	UNIPROID	PLAK_HUMAN
T82685	TARGNAME	Junction plakoglobin (JUP)
T82685	GENENAME	JUP
T82685	TARGTYPE	Literature-reported
T82685	SYNONYMS	Plakoglobin; Desmoplakin-3; Desmoplakin III; DP3; Catenin gamma; CTNNG
T82685	FUNCTION	The membrane-associated plaques are architectural elements in an important strategic position to influence the arrangement and function of both the cytoskeleton and the cells within the tissue. The presence of plakoglobin in both the desmosomes and in the intermediate junctions suggests that it plays a central role in the structure and function of submembranous plaques. Acts as a substrate for VE-PTP and is required by it to stimulate VE-cadherin function in endothelial cells. Can replace beta-catenin in E-cadherin/catenin adhesion complexes which are proposed to couple cadherins to the actin cytoskeleton. Common junctional plaque protein.
T82685	PDBSTRUC	3IFQ
T82685	BIOCLASS	Beta-catenin
T82685	SEQUENCE	MEVMNLMEQPIKVTEWQQTYTYDSGIHSGANTCVPSVSSKGIMEEDEACGRQYTLKKTTTYTQGVPPSQGDLEYQMSTTARAKRVREAMCPGVSGEDSSLLLATQVEGQATNLQRLAEPSQLLKSAIVHLINYQDDAELATRALPELTKLLNDEDPVVVTKAAMIVNQLSKKEASRRALMGSPQLVAAVVRTMQNTSDLDTARCTTSILHNLSHHREGLLAIFKSGGIPALVRMLSSPVESVLFYAITTLHNLLLYQEGAKMAVRLADGLQKMVPLLNKNNPKFLAITTDCLQLLAYGNQESKLIILANGGPQALVQIMRNYSYEKLLWTTSRVLKVLSVCPSNKPAIVEAGGMQALGKHLTSNSPRLVQNCLWTLRNLSDVATKQEGLESVLKILVNQLSVDDVNVLTCATGTLSNLTCNNSKNKTLVTQNSGVEALIHAILRAGDKDDITEPAVCALRHLTSRHPEAEMAQNSVRLNYGIPAIVKLLNQPNQWPLVKATIGLIRNLALCPANHAPLQEAAVIPRLVQLLVKAHQDAQRHVAAGTQQPYTDGVRMEEIVEGCTGALHILARDPMNRMEIFRLNTIPLFVQLLYSSVENIQRVAAGVLCELAQDKEAADAIDAEGASAPLMELLHSRNEGTATYAAAVLFRISEDKNPDYRKRVSVELTNSLFKHDPAAWEAAQSMIPINEPYGDDMDATYRPMYSSDVPLDPLEMHMDMDGDYPIDTYSDGLRPPYPTADHMLA

T73557	TARGETID	T73557
T73557	FORMERID	TTDR01279
T73557	UNIPROID	GLNA_HUMAN
T73557	TARGNAME	Astrocyte glutamine synthetase (GLUL)
T73557	GENENAME	GLUL
T73557	TARGTYPE	Literature-reported
T73557	SYNONYMS	Palmitoyltransferase GLUL; Glutamine synthetase; Glutamate--ammonia ligase; GS; GLNS
T73557	FUNCTION	Glutamine synthetase that catalyzes the ATP-dependent conversion of glutamate and ammonia to glutamine. Its role depends on tissue localization: in the brain, it regulates the levels of toxic ammonia and converts neurotoxic glutamate to harmless glutamine, whereas in the liver, it is one of the enzymes responsible for the removal of ammonia (By similarity). Essential for proliferation of fetal skin fibroblasts. Independently of its glutamine synthetase activity, required for endothelial cell migration during vascular development: acts by regulating membrane localization and activation of the GTPase RHOJ, possibly by promoting RHOJ palmitoylation. May act as a palmitoyltransferase for RHOJ: able to autopalmitoylate and then transfer the palmitoyl group to RHOJ. Plays a role in ribosomal 40S subunit biogenesis.
T73557	PDBSTRUC	2QC8; 2OJW
T73557	ECNUMBER	EC 6.3.1.2
T73557	SEQUENCE	MTTSASSHLNKGIKQVYMSLPQGEKVQAMYIWIDGTGEGLRCKTRTLDSEPKCVEELPEWNFDGSSTLQSEGSNSDMYLVPAAMFRDPFRKDPNKLVLCEVFKYNRRPAETNLRHTCKRIMDMVSNQHPWFGMEQEYTLMGTDGHPFGWPSNGFPGPQGPYYCGVGADRAYGRDIVEAHYRACLYAGVKIAGTNAEVMPAQWEFQIGPCEGISMGDHLWVARFILHRVCEDFGVIATFDPKPIPGNWNGAGCHTNFSTKAMREENGLKYIEEAIEKLSKRHQYHIRAYDPKGGLDNARRLTGFHETSNINDFSAGVANRSASIRIPRTVGQEKKGYFEDRRPSANCDPFSVTEALIRTCLLNETGDEPFQYKN

T34471	TARGETID	T34471
T34471	FORMERID	TTDI03078
T34471	UNIPROID	CBPN_HUMAN
T34471	TARGNAME	Arginine carboxypeptidase (CPN1)
T34471	GENENAME	CPN1
T34471	TARGTYPE	Literature-reported
T34471	SYNONYMS	Serum carboxypeptidase N; SCPN; Plasma carboxypeptidase N; Lysine carboxypeptidase; Kininase-1; Carboxypeptidase N small subunit; Carboxypeptidase N polypeptide 1; Carboxypeptidase N catalytic chain; CPN; Anaphylatoxin inactivator; ACBP
T34471	FUNCTION	Protects the body from potent vasoactive and inflammatory peptides containing C-terminal Arg or Lys (such as kinins or anaphylatoxins) which are released into the circulation.
T34471	PDBSTRUC	2NSM
T34471	ECNUMBER	EC 3.4.17.3
T34471	SEQUENCE	MSDLLSVFLHLLLLFKLVAPVTFRHHRYDDLVRTLYKVQNECPGITRVYSIGRSVEGRHLYVLEFSDHPGIHEPLEPEVKYVGNMHGNEALGRELMLQLSEFLCEEFRNRNQRIVQLIQDTRIHILPSMNPDGYEVAAAQGPNKPGYLVGRNNANGVDLNRNFPDLNTYIYYNEKYGGPNHHLPLPDNWKSQVEPETRAVIRWMHSFNFVLSANLHGGAVVANYPYDKSFEHRVRGVRRTASTPTPDDKLFQKLAKVYSYAHGWMFQGWNCGDYFPDGITNGASWYSLSKGMQDFNYLHTNCFEITLELSCDKFPPEEELQREWLGNREALIQFLEQVHQGIKGMVLDENYNNLANAVISVSGINHDVTSGDHGDYFRLLLPGIYTVSATAPGYDPETVTVTVGPAEPTLVNFHLKRSIPQVSPVRRAPSRRHGVRAKVQPQARKKEMEMRQLQRGPA
T34471	DRUGINFO	D0XA0N	PMID14640538C3	Investigative

T96256	TARGETID	T96256
T96256	UNIPROID	EZRI_HUMAN
T96256	TARGNAME	Cytovillin (EZR)
T96256	GENENAME	EZR
T96256	TARGTYPE	Literature-reported
T96256	SYNONYMS	p81; Villin-2; VIL2
T96256	FUNCTION	Probably involved in connections of major cytoskeletal structures to the plasma membrane. In epithelial cells, required for the formation of microvilli and membrane ruffles on the apical pole. Along with PLEKHG6, required for normal macropinocytosis.
T96256	PDBSTRUC	4RMA; 4RM9; 4RM8; 1NI2
T96256	SEQUENCE	MPKPINVRVTTMDAELEFAIQPNTTGKQLFDQVVKTIGLREVWYFGLHYVDNKGFPTWLKLDKKVSAQEVRKENPLQFKFRAKFYPEDVAEELIQDITQKLFFLQVKEGILSDEIYCPPETAVLLGSYAVQAKFGDYNKEVHKSGYLSSERLIPQRVMDQHKLTRDQWEDRIQVWHAEHRGMLKDNAMLEYLKIAQDLEMYGINYFEIKNKKGTDLWLGVDALGLNIYEKDDKLTPKIGFPWSEIRNISFNDKKFVIKPIDKKAPDFVFYAPRLRINKRILQLCMGNHELYMRRRKPDTIEVQQMKAQAREEKHQKQLERQQLETEKKRRETVEREKEQMMREKEELMLRLQDYEEKTKKAERELSEQIQRALQLEEERKRAQEEAERLEADRMAALRAKEELERQAVDQIKSQEQLAAELAEYTAKIALLEEARRRKEDEVEEWQHRAKEAQDDLVKTKEELHLVMTAPPPPPPPVYEPVSYHVQESLQDEGAEPTGYSAELSSEGIRDDRNEEKRITEAEKNERVQRQLLTLSSELSQARDENKRTHNDIIHNENMRQGRDKYKTLRQIRQGNTKQRIDEFEAL

T69208	TARGETID	T69208
T69208	FORMERID	TTDI03465
T69208	UNIPROID	PHKG2_HUMAN
T69208	TARGNAME	Phosphorylase kinase testis gamma 2 (PHKG2)
T69208	GENENAME	PHKG2
T69208	TARGTYPE	Literature-reported
T69208	SYNONYMS	Phosphorylase kinase subunit gamma-2; Phosphorylase b kinase gamma catalytic chain, liver/testis isoform; PSK-C3; PHK-gamma-T; PHK-gamma-LT
T69208	FUNCTION	Catalytic subunit of the phosphorylase b kinase (PHK), which mediates the neural and hormonal regulation of glycogen breakdown (glycogenolysis) by phosphorylating and thereby activating glycogen phosphorylase. May regulate glycogeneolysis in the testis. In vitro, phosphorylates PYGM (By similarity).
T69208	PDBSTRUC	2Y7J
T69208	ECNUMBER	EC 2.7.11.19
T69208	SEQUENCE	MTLDVGPEDELPDWAAAKEFYQKYDPKDVIGRGVSSVVRRCVHRATGHEFAVKIMEVTAERLSPEQLEEVREATRRETHILRQVAGHPHIITLIDSYESSSFMFLVFDLMRKGELFDYLTEKVALSEKETRSIMRSLLEAVSFLHANNIVHRDLKPENILLDDNMQIRLSDFGFSCHLEPGEKLRELCGTPGYLAPEILKCSMDETHPGYGKEVDLWACGVILFTLLAGSPPFWHRRQILMLRMIMEGQYQFSSPEWDDRSSTVKDLISRLLQVDPEARLTAEQALQHPFFERCEGSQPWNLTPRQRFRVAVWTVLAAGRVALSTHRVRPLTKNALLRDPYALRSVRHLIDNCAFRLYGHWVKKGEQQNRAALFQHRPPGPFPIMGPEEEGDSAAITEDEAVLVLG
T69208	DRUGINFO	D0E7VO	PMID24900538C2c	Investigative

T95715	TARGETID	T95715
T95715	UNIPROID	TFE2_HUMAN
T95715	TARGNAME	Transcription factor E2-alpha (TCF3)
T95715	GENENAME	TCF3
T95715	TARGTYPE	Literature-reported
T95715	SYNONYMS	bHLHb21; Transcription factor ITF-1; Transcription factor 3; TCF-3; Kappa-E2-binding factor; Immunoglobulin transcription factor 1; Immunoglobulin enhancer-binding factor E12/E47; ITF1; E2A; Class B basic helix-loop-helix protein 21
T95715	FUNCTION	Transcriptional regulator. Involved in the initiation of neuronal differentiation. Heterodimers between TCF3 and tissue-specific basic helix-loop-helix (bHLH) proteins play major roles in determining tissue-specific cell fate during embryogenesis, like muscle or early B-cell differentiation. Dimers bind DNA on E-box motifs: 5'-CANNTG-3'. Binds to the kappa-E2 site in the kappa immunoglobulin gene enhancer. Binds to IEB1 and IEB2, which are short DNA sequences in the insulin gene transcription control region.
T95715	PDBSTRUC	3U5V; 2YPB; 2YPA; 2MH0; 1HLH
T95715	SEQUENCE	MNQPQRMAPVGTDKELSDLLDFSMMFPLPVTNGKGRPASLAGAQFGGSGLEDRPSSGSWGSGDQSSSSFDPSRTFSEGTHFTESHSSLSSSTFLGPGLGGKSGERGAYASFGRDAGVGGLTQAGFLSGELALNSPGPLSPSGMKGTSQYYPSYSGSSRRRAADGSLDTQPKKVRKVPPGLPSSVYPPSSGEDYGRDATAYPSAKTPSSTYPAPFYVADGSLHPSAELWSPPGQAGFGPMLGGGSSPLPLPPGSGPVGSSGSSSTFGGLHQHERMGYQLHGAEVNGGLPSASSFSSAPGATYGGVSSHTPPVSGADSLLGSRGTTAGSSGDALGKALASIYSPDHSSNNFSSSPSTPVGSPQGLAGTSQWPRAGAPGALSPSYDGGLHGLQSKIEDHLDEAIHVLRSHAVGTAGDMHTLLPGHGALASGFTGPMSLGGRHAGLVGGSHPEDGLAGSTSLMHNHAALPSQPGTLPDLSRPPDSYSGLGRAGATAAASEIKREEKEDEENTSAADHSEEEKKELKAPRARTSPDEDEDDLLPPEQKAEREKERRVANNARERLRVRDINEAFKELGRMCQLHLNSEKPQTKLLILHQAVSVILNLEQQVRERNLNPKAACLKRREEEKVSGVVGDPQMVLSAPHPGLSEAHNPAGHM

T92098	TARGETID	T92098
T92098	FORMERID	TTDI00219
T92098	UNIPROID	CREB1_HUMAN
T92098	TARGNAME	Cyclic AMP-responsive element-binding protein (CREB1)
T92098	GENENAME	CREB1
T92098	TARGTYPE	Literature-reported
T92098	SYNONYMS	cAMP-responsive element-binding protein 1; Cyclic AMP-responsive element-binding protein 1; Cyclic AMP responseelement-binding protein; CREB-1; CREB; CAMP-response element binding protein
T92098	FUNCTION	Transcription activation is enhanced by the TORC coactivators which act independently of Ser-133 phosphorylation. Involved in different cellular processes including the synchronization of circadian rhythmicity and the differentiation of adipose cells. Phosphorylation-dependent transcription factor that stimulates transcription upon binding to the DNA cAMP response element (CRE), a sequence present in many viral and cellular promoters.
T92098	PDBSTRUC	5ZKO; 5ZK1; 2LXT
T92098	BIOCLASS	Basic leucine zipper bZIP
T92098	SEQUENCE	MTMESGAENQQSGDAAVTEAENQQMTVQAQPQIATLAQVSMPAAHATSSAPTVTLVQLPNGQTVQVHGVIQAAQPSVIQSPQVQTVQISTIAESEDSQESVDSVTDSQKRREILSRRPSYRKILNDLSSDAPGVPRIEEEKSEEETSAPAITTVTVPTPIYQTSSGQYIAITQGGAIQLANNGTDGVQGLQTLTMTNAAATQPGTTILQYAQTTDGQQILVPSNQVVVQAASGDVQTYQIRTAPTSTIAPGVVMASSPALPTQPAEEAARKREVRLMKNREAARECRRKKKEYVKCLENRVAVLENQNKTLIEELKALKDLYCHKSD

T33491	TARGETID	T33491
T33491	FORMERID	TTDR00329
T33491	UNIPROID	KINA_BACSU
T33491	TARGNAME	Bacterial Sporulation kinase A (Bact kinA)
T33491	GENENAME	Bact kinA
T33491	TARGTYPE	Literature-reported
T33491	SYNONYMS	Stage II sporulation protein J; Stage II sporulation protein F; Sporulation kinase A
T33491	FUNCTION	Phosphorylates the sporulation-regulatory proteins spo0A and spo0F. It also autophosphorylates in the presence of ATP.
T33491	PDBSTRUC	2VLG
T33491	ECNUMBER	EC 2.7.13.3
T33491	SEQUENCE	MEQDTQHVKPLQTKTDIHAVLASNGRIIYISANSKLHLGYLQGEMIGSFLKTFLHEEDQFLVESYFYNEHHLMPCTFRFIKKDHTIVWVEAAVEIVTTRAERTEREIILKMKVLEEETGHQSLNCEKHEIEPASPESTTYITDDYERLVENLPSPLCISVKGKIVYVNSAMLSMLGAKSKDAIIGKSSYEFIEEEYHDIVKNRIIRMQKGMEVGMIEQTWKRLDGTPVHLEVKASPTVYKNQQAELLLLIDISSRKKFQTILQKSRERYQLLIQNSIDTIAVIHNGKWVFMNESGISLFEAATYEDLIGKNIYDQLHPCDHEDVKERIQNIAEQKTESEIVKQSWFTFQNRVIYTEMVCIPTTFFGEAAVQVILRDISERKQTEELMLKSEKLSIAGQLAAGIAHEIRNPLTAIKGFLQLMKPTMEGNEHYFDIVFSELSRIELILSELLMLAKPQQNAVKEYLNLKKLIGEVSALLETQANLNGIFIRTSYEKDSIYINGDQNQLKQVFINLIKNAVESMPDGGTVDIIITEDEHSVHVTVKDEGEGIPEKVLNRIGEPFLTTKEKGTGLGLMVTFNIIENHQGVIHVDSHPEKGTAFKISFPKK
T33491	DRUGINFO	D05ALG	RWJ-49815	Terminated
T33491	DRUGINFO	D00VFM	RWJ-49968	Investigative
T33491	DRUGINFO	D02MQL	RWJ-61907	Investigative
T33491	DRUGINFO	D00MZS	SK509	Investigative

T76286	TARGETID	T76286
T76286	FORMERID	TTDNR00726
T76286	UNIPROID	CD36_HUMAN
T76286	TARGNAME	Platelet glycoprotein 4 (CD36)
T76286	GENENAME	CD36
T76286	TARGTYPE	Literature-reported
T76286	SYNONYMS	Thrombospondin receptor; Platelet glycoprotein IV; Platelet collagen receptor; PAS-4; PAS IV; Leukocyte differentiation antigen CD36; Glycoprotein IIIb; GPIV; GPIIIB; GP4; GP3B; Fatty acid translocase; FAT
T76286	FUNCTION	Ligands can be of proteinaceous nature like thrombospondin, fibronectin, collagen or amyloid-beta as well as of lipidic nature such as oxidized low-density lipoprotein (oxLDL), anionic phospholipids, long-chain fatty acids and bacterial diacylated lipopeptides. They are generally multivalent and can therefore engage multiple receptors simultaneously, the resulting formation of CD36 clusters initiates signal transduction and internalization of receptor-ligand complexes. The dependency on coreceptor signaling is strongly ligand specific. Cellular responses to these ligands are involved in angiogenesis, inflammatory response, fatty acid metabolism, taste and dietary fat processing in the intestine. Binds long-chain fatty acids and facilitates their transport into cells, thus participating in muscle lipid utilization, adipose energy storage, and gut fat absorption. In the small intestine, plays a role in proximal absorption of dietary fatty acid and cholesterol for optimal chylomicron formation, possibly through the activation of MAPK1/3 (ERK1/2) signaling pathway. Involved in oral fat perception and preferences. Detection into the tongue of long-chain fatty acids leads to a rapid and sustained rise in flux and protein content of pancreatobiliary secretions. In taste receptor cells, mediates the induction of an increase in intracellular calcium levels by long-chain fatty acids, leading to the activation of the gustatory neurons in the nucleus of the solitary tract. Important factor in both ventromedial hypothalamus neuronal sensing of long-chain fatty acid and the regulation of energy and glucose homeostasis. Receptor for thombospondins, THBS1 and THBS2, mediating their antiangiogenic effects. As a coreceptor for TLR4:TLR6 heterodimer, promotes inflammation in monocytes/macrophages. Upon ligand binding, such as oxLDL or amyloid-beta 42, interacts with the heterodimer TLR4:TLR6, the complex is internalized and triggers inflammatory response, leading to NF-kappa-B-dependent production of CXCL1, CXCL2 and CCL9 cytokines, via MYD88 signaling pathway, and CCL5 cytokine, via TICAM1 signaling pathway, as well as IL1B secretion, through the priming and activation of the NLRP3 inflammasome. Selective and nonredundant sensor of microbial diacylated lipopeptide that signal via TLR2:TLR6 heterodimer, this cluster triggers signaling from the cell surface, leading to the NF-kappa-B-dependent production of TNF, via MYD88 signaling pathway and subsequently is targeted to the Golgi in a lipid-raft dependent pathway. Multifunctional glycoprotein that acts as receptor for a broad range of ligands.
T76286	PDBSTRUC	5LGD
T76286	BIOCLASS	Long chain fatty acid translocase
T76286	SEQUENCE	MGCDRNCGLIAGAVIGAVLAVFGGILMPVGDLLIQKTIKKQVVLEEGTIAFKNWVKTGTEVYRQFWIFDVQNPQEVMMNSSNIQVKQRGPYTYRVRFLAKENVTQDAEDNTVSFLQPNGAIFEPSLSVGTEADNFTVLNLAVAAASHIYQNQFVQMILNSLINKSKSSMFQVRTLRELLWGYRDPFLSLVPYPVTTTVGLFYPYNNTADGVYKVFNGKDNISKVAIIDTYKGKRNLSYWESHCDMINGTDAASFPPFVEKSQVLQFFSSDICRSIYAVFESDVNLKGIPVYRFVLPSKAFASPVENPDNYCFCTEKIISKNCTSYGVLDISKCKEGRPVYISLPHFLYASPDVSEPIDGLNPNEEEHRTYLDIEPITGFTLQFAKRLQVNLLVKPSEKIQVLKNLKRNYIVPILWLNETGTIGDEKANMFRSQVTGKINLLGLIEMILLSVGVVMFVAFMISYCACRSKTIK

T45888	TARGETID	T45888
T45888	FORMERID	TTDR00218
T45888	UNIPROID	CYSM_ECOLI
T45888	TARGNAME	Bacterial O-acetylserine sulfhydrylase B (Bact cysM)
T45888	GENENAME	Bact cysM
T45888	TARGTYPE	Literature-reported
T45888	SYNONYMS	OAS-TL B; O-acetylserine sulfhydrylase B; O-acetylserine (thiol)-lyase B; Cysteine synthase B; CSase B
T45888	FUNCTION	Two cysteine synthase enzymes are found. Both catalyze the same reaction. Cysteine synthase B can also use thiosulfate in place of sulfide to give cysteine thiosulfonate as a product.
T45888	PDBSTRUC	2V03; 2BHT; 2BHS
T45888	BIOCLASS	Alkyl aryl transferase
T45888	SEQUENCE	MSTLEQTIGNTPLVKLQRMGPDNGSEVWLKLEGNNPAGSVKDRAALSMIVEAEKRGEIKPGDVLIEATSGNTGIALAMIAALKGYRMKLLMPDNMSQERRAAMRAYGAELILVTKEQGMEGARDLALEMANRGEGKLLDQFNNPDNPYAHYTTTGPEIWQQTGGRITHFVSSMGTTGTITGVSRFMREQSKPVTIVGLQPEEGSSIPGIRRWPTEYLPGIFNASLVDEVLDIHQRDAENTMRELAVREGIFCGVSSGGAVAGALRVAKANPDAVVVAIICDRGDRYLSTGVFGEEHFSQGAGI

T46546	TARGETID	T46546
T46546	FORMERID	TTDR01030
T46546	UNIPROID	CBPE_HUMAN
T46546	TARGNAME	Carboxypeptidase E (CPE)
T46546	GENENAME	CPE
T46546	TARGTYPE	Literature-reported
T46546	SYNONYMS	Prohormone processing carboxypeptidase; Enkephalin convertase; CPH; CPE
T46546	FUNCTION	Removes residual C-terminal Arg or Lys remaining after initial endoprotease cleavage during prohormone processing. Processes proinsulin.
T46546	BIOCLASS	Peptidase
T46546	ECNUMBER	EC 3.4.17.10
T46546	SEQUENCE	MAGRGGSALLALCGALAACGWLLGAEAQEPGAPAAGMRRRRRLQQEDGISFEYHRYPELREALVSVWLQCTAISRIYTVGRSFEGRELLVIELSDNPGVHEPGEPEFKYIGNMHGNEAVGRELLIFLAQYLCNEYQKGNETIVNLIHSTRIHIMPSLNPDGFEKAASQPGELKDWFVGRSNAQGIDLNRNFPDLDRIVYVNEKEGGPNNHLLKNMKKIVDQNTKLAPETKAVIHWIMDIPFVLSANLHGGDLVANYPYDETRSGSAHEYSSSPDDAIFQSLARAYSSFNPAMSDPNRPPCRKNDDDSSFVDGTTNGGAWYSVPGGMQDFNYLSSNCFEITVELSCEKFPPEETLKTYWEDNKNSLISYLEQIHRGVKGFVRDLQGNPIANATISVEGIDHDVTSAKDGDYWRLLIPGNYKLTASAPGYLAITKKVAVPYSPAAGVDFELESFSERKEEEKEELMEWWKMMSETLNF

T06767	TARGETID	T06767
T06767	FORMERID	TTDR01186
T06767	UNIPROID	BETB_ECOLI
T06767	TARGNAME	Bacterial Betaine aldehyde dehydrogenase (Bact betB)
T06767	GENENAME	Bact betB
T06767	TARGTYPE	Literature-reported
T06767	SYNONYMS	betB; BADH
T06767	FUNCTION	Involved in the biosynthesis of the osmoprotectant glycine betaine. Catalyzes the reversible oxidation of betaine aldehyde to the corresponding acid. It is highly specific for betaine and has a significantly higher affinity for NAD than for NADP.
T06767	BIOCLASS	Aldehyde/oxo donor oxidoreductase
T06767	ECNUMBER	EC 1.2.1.8
T06767	SEQUENCE	MSRMAEQQLYIHGGYTSATSGRTFETINPANGNVLATVQAAGREDVDRAVKSAQQGQKIWASMTAMERSRILRRAVDILRERNDELAKLETLDTGKAYSETSTVDIVTGADVLEYYAGLIPALEGSQIPLRETSFVYTRREPLGVVAGIGAWNYPIQIALWKSAPALAAGNAMIFKPSEVTPLTALKLAEIYSEAGLPDGVFNVLPGVGAETGQYLTEHPGIAKVSFTGGVASGKKVMANSAASSLKEVTMELGGKSPLIVFDDADLDLAADIAMMANFFSSGQVCTNGTRVFVPAKCKAAFEQKILARVERIRAGDVFDPQTNFGPLVSFPHRDNVLRYIAKGKEEGARVLCGGDVLKGDGFDNGAWVAPTVFTDCSDDMTIVREEIFGPVMSILTYESEDEVIRRANDTDYGLAAGIVTADLNRAHRVIHQLEAGICWINTWGESPAEMPVGGYKHSGIGRENGVMTLQSYTQVKSIQVEMAKFQSIF

T51734	TARGETID	T51734
T51734	FORMERID	TTDR00419
T51734	UNIPROID	CEBPB_HUMAN
T51734	TARGNAME	CCAAT/enhancer binding protein beta (CEBPB)
T51734	GENENAME	CEBPB
T51734	TARGTYPE	Literature-reported
T51734	SYNONYMS	Transcription factor CCAAT/enhancer-binding protein beta; Transcription factor 5; TCF5; TCF-5; PP9092; Nuclear factor NF-IL6; Liver-enriched inhibitory protein; Liver activator protein; LIP; LAP; CCAAT/enhancer-binding protein beta; C/EBP beta
T51734	FUNCTION	Plays also a significant role in adipogenesis, as well as in the gluconeogenic pathway, liver regeneration, and hematopoiesis. The consensus recognition site is 5'-T[TG]NNGNAA[TG]-3'. Its functional capacity is governed by protein interactions and post-translational protein modifications. During early embryogenesis, plays essential and redundant functions with CEBPA. Has a promitotic effect on many cell types such as hepatocytes and adipocytes but has an antiproliferative effect on T-cells by repressing MYC expression, facilitating differentiation along the T-helper 2 lineage. Binds to regulatory regions of several acute-phase and cytokines genes and plays a role in the regulation of acute-phase reaction and inflammation. Plays also a role in intracellular bacteria killing. During adipogenesis, is rapidly expressed and, after activation by phosphorylation, induces CEBPA and PPARG, which turn on the series of adipocyte genes that give rise to the adipocyte phenotype. The delayed transactivation of the CEBPA and PPARG genes by CEBPB appears necessary to allow mitotic clonal expansion and thereby progression of terminal differentiation. Essential for female reproduction because of a critical role in ovarian follicle development. Restricts osteoclastogenesis: together with NFE2L1; represses expression of DSPP during odontoblast differentiation. Important transcription factor regulating the expression of genes involved in immune and inflammatory responses.
T51734	PDBSTRUC	6MG3; 6MG2; 6MG1; 2.00E+43; 2.00E+42
T51734	BIOCLASS	Basic leucine zipper bZIP
T51734	SEQUENCE	MQRLVAWDPACLPLPPPPPAFKSMEVANFYYEADCLAAAYGGKAAPAAPPAARPGPRPPAGELGSIGDHERAIDFSPYLEPLGAPQAPAPATATDTFEAAPPAPAPAPASSGQHHDFLSDLFSDDYGGKNCKKPAEYGYVSLGRLGAAKGALHPGCFAPLHPPPPPPPPPAELKAEPGFEPADCKRKEEAGAPGGGAGMAAGFPYALRAYLGYQAVPSGSSGSLSTSSSSSPPGTPSPADAKAPPTACYAGAAPAPSQVKSKAKKTVDKHSDEYKIRRERNNIAVRKSRDKAKMRNLETQHKVLELTAENERLQKKVEQLSRELSTLRNLFKQLPEPLLASSGHC

T64268	TARGETID	T64268
T64268	FORMERID	TTDI02449
T64268	UNIPROID	IBP2_HUMAN
T64268	TARGNAME	Insulin-like growth factor-binding protein 2 (IGFBP2)
T64268	GENENAME	IGFBP2
T64268	TARGTYPE	Literature-reported
T64268	SYNONYMS	IGFBP-2; IGF-binding protein 2; IBP2; IBP-2; BP2
T64268	FUNCTION	Inhibits IGF-mediated growth and developmental rates. IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors.
T64268	PDBSTRUC	2H7T
T64268	BIOCLASS	Insulin-like growth factor binding
T64268	SEQUENCE	MLPRVGCPALPLPPPPLLPLLLLLLGASGGGGGARAEVLFRCPPCTPERLAACGPPPVAPPAAVAAVAGGARMPCAELVREPGCGCCSVCARLEGEACGVYTPRCGQGLRCYPHPGSELPLQALVMGEGTCEKRRDAEYGASPEQVADNGDDHSEGGLVENHVDSTMNMLGGGGSAGRKPLKSGMKELAVFREKVTEQHRQMGKGGKHHLGLEEPKKLRPPPARTPCQQELDQVLERISTMRLPDERGPLEHLYSLHIPNCDKHGLYNLKQCKMSLNGQRGECWCVNPNTGKLIQGAPTIRGDPECHLFYNEQQEARGVHTQRMQ

T86152	TARGETID	T86152
T86152	FORMERID	TTDR00895
T86152	UNIPROID	NADE_ECOLI
T86152	TARGNAME	Bacterial NH(3)-dependent NAD(+) synthetase (Bact nadE)
T86152	GENENAME	Bact nadE
T86152	TARGTYPE	Literature-reported
T86152	SYNONYMS	efg; Nitrogen-regulatory protein; Nicotinamide adenine dinucleotide synthetase; NadE; NAD+ synthetase; NAD+ synthase; NAD(+)-synthetase; NAD synthetase; NAD synthase; Diphosphopyridine nucleotide synthetase
T86152	FUNCTION	Catalyzes a keystep in NAD biosynthesis, transforming deamido-NAD into NAD by a two-step reaction.
T86152	PDBSTRUC	1WXI; 1WXH; 1WXG; 1WXF; 1WXE
T86152	BIOCLASS	Carbon-nitrogen ligase
T86152	SEQUENCE	MTLQQQIIKALGAKPQINAEEEIRRSVDFLKSYLQTYPFIKSLVLGISGGQDSTLAGKLCQMAINELRLETGNESLQFIAVRLPYGVQADEQDCQDAIAFIQPDRVLTVNIKGAVLASEQALREAGIELSDFVRGNEKARERMKAQYSIAGMTSGVVVGTDHAAEAITGFFTKYGDGGTDINPLYRLNKRQGKQLLAALACPEHLYKKAPTADLEDDRPSLPDEVALGVTYDNIDDYLEGKNVPQQVARTIENWYLKTEHKRRPPITVFDDFWKK
T86152	DRUGINFO	D00QLM	[3H]alphabeta-meATP	Investigative
T86152	DRUGINFO	D0R4PI	Diphosphate	Investigative
T86152	DRUGINFO	D0A1DU	Pyrophosphate 2-	Investigative
T86152	DRUGINFO	D0R6JE	Nicotinamide-Adenine-Dinucleotide	Investigative

T53270	TARGETID	T53270
T53270	FORMERID	TTDI00061
T53270	UNIPROID	ATF4_HUMAN
T53270	TARGNAME	Activating transcription factor 4 (ATF-4)
T53270	GENENAME	ATF4
T53270	TARGTYPE	Literature-reported
T53270	SYNONYMS	cAMPresponsive elementbinding protein 2; cAMPdependent transcription factor ATF4; cAMP-responsive element-binding protein 2; cAMP-dependent transcription factor ATF-4; Taxresponsive enhancer elementbinding protein 67; TaxREB67; Tax-responsive enhancer element-binding protein 67; TXREB; DNAbinding protein TAXREB67; DNA-binding protein TAXREB67; Cyclic AMPresponsive elementbinding protein 2; Cyclic AMPdependent transcription factor ATF4; Cyclic AMP-responsive element-binding protein 2; Cyclic AMP-dependent transcription factor ATF-4; CREB2; CREB-2
T53270	FUNCTION	Binds the cAMP response element (CRE) (consensus: 5'-GTGACGT[AC][AG]-3'), a sequence present in many viral and cellular promoters. Cooperates with FOXO1 in osteoblasts to regulate glucose homeostasis through suppression of beta-cell production and decrease in insulin production. It binds to a Tax-responsive enhancer element in the long terminal repeat of HTLV-I. Regulates the induction of DDIT3/CHOP and asparagine synthetase (ASNS) in response to endoplasmic reticulum (ER) stress. In concert with DDIT3/CHOP, activates the transcription of TRIB3 and promotes ER stress-induced neuronal apoptosis by regulating the transcriptional induction of BBC3/PUMA. Activates transcription of SIRT4. Regulates the circadian expression of the core clock component PER2 and the serotonin transporter SLC6A4. Binds in a circadian time-dependent manner to the cAMP response elements (CRE) in the SLC6A4 and PER2 promoters and periodically activates the transcription of these genes. During ER stress response, activates the transcription of NLRP1, possibly in concert with other factors. Transcriptional activator.
T53270	PDBSTRUC	1CI6
T53270	BIOCLASS	Basic leucine zipper bZIP
T53270	SEQUENCE	MTEMSFLSSEVLVGDLMSPFDQSGLGAEESLGLLDDYLEVAKHFKPHGFSSDKAKAGSSEWLAVDGLVSPSNNSKEDAFSGTDWMLEKMDLKEFDLDALLGIDDLETMPDDLLTTLDDTCDLFAPLVQETNKQPPQTVNPIGHLPESLTKPDQVAPFTFLQPLPLSPGVLSSTPDHSFSLELGSEVDITEGDRKPDYTAYVAMIPQCIKEEDTPSDNDSGICMSPESYLGSPQHSPSTRGSPNRSLPSPGVLCGSARPKPYDPPGEKMVAAKVKGEKLDKKLKKMEQNKTAATRYRQKKRAEQEALTGECKELEKKNEALKERADSLAKEIQYLKDLIEEVRKARGKKRVP

T44991	TARGETID	T44991
T44991	FORMERID	TTDR00453
T44991	UNIPROID	VCAM1_HUMAN
T44991	TARGNAME	Vascular cell adhesion protein 1 (VCAM1)
T44991	GENENAME	VCAM1
T44991	TARGTYPE	Literature-reported
T44991	SYNONYMS	Vascular cell adhesion molecule 1; VCAM-1; V-CAM 1; INCAM-100; CD106 antigen; CD106
T44991	FUNCTION	Appears to function in leukocyte-endothelial cell adhesion. Interacts with integrin alpha-4/beta-1 (ITGA4/ITGB1) on leukocytes, and mediates both adhesion and signal transduction. The VCAM1/ITGA4/ITGB1 interaction may play a pathophysiologic role both in immune responses and in leukocyte emigration to sites of inflammation. Important in cell-cell recognition.
T44991	PDBSTRUC	1VSC; 1VCA; 1IJ9
T44991	SEQUENCE	MPGKMVVILGASNILWIMFAASQAFKIETTPESRYLAQIGDSVSLTCSTTGCESPFFSWRTQIDSPLNGKVTNEGTTSTLTMNPVSFGNEHSYLCTATCESRKLEKGIQVEIYSFPKDPEIHLSGPLEAGKPITVKCSVADVYPFDRLEIDLLKGDHLMKSQEFLEDADRKSLETKSLEVTFTPVIEDIGKVLVCRAKLHIDEMDSVPTVRQAVKELQVYISPKNTVISVNPSTKLQEGGSVTMTCSSEGLPAPEIFWSKKLDNGNLQHLSGNATLTLIAMRMEDSGIYVCEGVNLIGKNRKEVELIVQEKPFTVEISPGPRIAAQIGDSVMLTCSVMGCESPSFSWRTQIDSPLSGKVRSEGTNSTLTLSPVSFENEHSYLCTVTCGHKKLEKGIQVELYSFPRDPEIEMSGGLVNGSSVTVSCKVPSVYPLDRLEIELLKGETILENIEFLEDTDMKSLENKSLEMTFIPTIEDTGKALVCQAKLHIDDMEFEPKQRQSTQTLYVNVAPRDTTVLVSPSSILEEGSSVNMTCLSQGFPAPKILWSRQLPNGELQPLSENATLTLISTKMEDSGVYLCEGINQAGRSRKEVELIIQVTPKDIKLTAFPSESVKEGDTVIISCTCGNVPETWIILKKKAETGDTVLKSIDGAYTIRKAQLKDAGVYECESKNKVGSQLRSLTLDVQGRENNKDYFSPELLVLYFASSLIIPAIGMIIYFARKANMKGSYSLVEAQKSKV

T20186	TARGETID	T20186
T20186	FORMERID	TTDR00670
T20186	UNIPROID	TNNI3_HUMAN
T20186	TARGNAME	Cardiac troponin I (TNNI3)
T20186	GENENAME	TNNI3
T20186	TARGTYPE	Literature-reported
T20186	SYNONYMS	TNNI3
T20186	FUNCTION	Troponin I is the inhibitory subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity.
T20186	PDBSTRUC	6MV3; 5WCL; 5W88; 5VLN; 4Y99
T20186	BIOCLASS	Troponin
T20186	SEQUENCE	MADGSSDAAREPRPAPAPIRRRSSNYRAYATEPHAKKKSKISASRKLQLKTLLLQIAKQELEREAEERRGEKGRALSTRCQPLELAGLGFAELQDLCRQLHARVDKVDEERYDIEAKVTKNITEIADLTQKIFDLRGKFKRPTLRRVRISADAMMQALLGARAKESLDLRAHLKQVKKEDTEKENREVGDWRKNIDALSGMEGRKKKFES

T51102	TARGETID	T51102
T51102	FORMERID	TTDI01524
T51102	UNIPROID	E2AK2_HUMAN
T51102	TARGNAME	Protein kinase R (PKR)
T51102	GENENAME	EIF2AK2
T51102	TARGTYPE	Literature-reported
T51102	SYNONYMS	eIF-2A protein kinase 2; Protein kinase RNA-activated; PRKR; PKR; P1/eIF-2A protein kinase; Interferon-inducible RNA-dependent protein kinase; Interferon-induced, double-stranded RNA-activated protein kinase; Eukaryotic translation initiation factor 2-alpha kinase 2
T51102	FUNCTION	IFN-induced dsRNA-dependent serine/threonine-protein kinase which plays a key role in the innate immune response to viral infection and is also involved in the regulation of signal transduction, apoptosis, cell proliferation and differentiation. Exerts its antiviral activity on a wide range of DNA and RNA viruses including hepatitis C virus (HCV), hepatitis B virus (HBV), measles virus (MV) and herpes simplex virus 1 (HHV-1). Inhibits viral replication via phosphorylation of the alpha subunit of eukaryotic initiation factor 2 (EIF2S1), this phosphorylation impairs the recycling of EIF2S1 between successive rounds of initiation leading to inhibition of translation which eventually results in shutdown of cellular and viral protein synthesis. Also phosphorylates other substrates including p53/TP53, PPP2R5A, DHX9, ILF3, IRS1 and the HHV-1 viral protein US11. In addition to serine/threonine-protein kinase activity, also has tyrosine-protein kinase activity and phosphorylates CDK1 at 'Tyr-4' upon DNA damage, facilitating its ubiquitination and proteosomal degradation. Either as an adapter protein and/or via its kinase activity, can regulate various signaling pathways (p38 MAP kinase, NF-kappa-B and insulin signaling pathways) and transcription factors (JUN, STAT1, STAT3, IRF1, ATF3) involved in the expression of genes encoding proinflammatory cytokines and IFNs. Activates the NF-kappa-B pathway via interaction with IKBKB and TRAF family of proteins and activates the p38 MAP kinase pathway via interaction with MAP2K6. Can act as both a positive and negative regulator of the insulin signaling pathway (ISP). Negatively regulates ISP by inducing the inhibitory phosphorylation of insulin receptor substrate 1 (IRS1) at 'Ser-312' and positively regulates ISP via phosphorylation of PPP2R5A which activates FOXO1, which in turn up-regulates the expression of insulin receptor substrate 2 (IRS2). Can regulate NLRP3 inflammasome assembly and the activation of NLRP3, NLRP1, AIM2 and NLRC4 inflammasomes. Can trigger apoptosis via FADD-mediated activation of CASP8. Plays a role in the regulation of the cytoskeleton by binding to gelsolin (GSN), sequestering the protein in an inactive conformation away from actin.
T51102	PDBSTRUC	3UIU; 2A1A; 2A19; 1QU6
T51102	ECNUMBER	EC 2.7.11.1
T51102	SEQUENCE	MAGDLSAGFFMEELNTYRQKQGVVLKYQELPNSGPPHDRRFTFQVIIDGREFPEGEGRSKKEAKNAAAKLAVEILNKEKKAVSPLLLTTTNSSEGLSMGNYIGLINRIAQKKRLTVNYEQCASGVHGPEGFHYKCKMGQKEYSIGTGSTKQEAKQLAAKLAYLQILSEETSVKSDYLSSGSFATTCESQSNSLVTSTLASESSSEGDFSADTSEINSNSDSLNSSSLLMNGLRNNQRKAKRSLAPRFDLPDMKETKYTVDKRFGMDFKEIELIGSGGFGQVFKAKHRIDGKTYVIKRVKYNNEKAEREVKALAKLDHVNIVHYNGCWDGFDYDPETSDDSLESSDYDPENSKNSSRSKTKCLFIQMEFCDKGTLEQWIEKRRGEKLDKVLALELFEQITKGVDYIHSKKLIHRDLKPSNIFLVDTKQVKIGDFGLVTSLKNDGKRTRSKGTLRYMSPEQISSQDYGKEVDLYALGLILAELLHVCDTAFETSKFFTDLRDGIISDIFDKKEKTLLQKLLSKKPEDRPNTSEILRTLTVWKKSPEKNERHTC

T11861	TARGETID	T11861
T11861	FORMERID	TTDR00625
T11861	UNIPROID	DHOM_BACSU
T11861	TARGNAME	Bacterial Homoserine dehydrogenase (Bact hom)
T11861	GENENAME	Bact hom
T11861	TARGTYPE	Literature-reported
T11861	SYNONYMS	Homoserine dehydrogenase; HDH
T11861	FUNCTION	A dimer enzyme, with each monomer composed of three regions, the nucleotide-binding region, the dimerization region and the catalytic region. Required for the biosynthesis of the three essential amino acids, methionine, isoleucine and threonine from aspartate. Participates in this aspartate pathway of the NAD(P)H-dependent reduction of L-aspartate semialdehyde (L-ASA) to L-homoserine (L-Hse). 
T11861	BIOCLASS	Short-chain dehydrogenases reductase
T11861	ECNUMBER	EC 1.1.1.3
T11861	SEQUENCE	MKAIRVGLLGLGTVGSGVVKIIQDHQDKLMHQVGCPVTIKKVLVKDLEKKREVDLPKEVLTTEVYDVIDDPDVDVVIEVIGGVEQTKQYLVDALRSKKHVVTANKDLMAVYGSELLAEAKENGCDIYFEASVAGGIPILRTLEEGLSSDRITKMMGIVNGTTNFILTKMIKEKSPYEEVLKEAQDLGFAEADPTSDVEGLDAARKMAILARLGFSMNVDLEDVKVKGISQITDEDISFSKRLGYTMKLIGIAQRDGSKIEVSVQPTLLPDHHPLSAVHNEFNAVYVYGEAVGETMFYGPGAGSMPTATSVVSDLVAVMKNMRLGVTGNSFVGPQYEKNMKSPSDIYAQQFLRIHVKDEVGSFSKITSVFSERGVSFEKILQLPIKGHDELAEIVIVTHHTSEADFSDILQNLNDLEVVQEVKSTYRVEGNGWS

T45601	TARGETID	T45601
T45601	FORMERID	TTDI03474
T45601	UNIPROID	PEPC_HUMAN
T45601	TARGNAME	Progastricsin pepsinogen C (PGC)
T45601	GENENAME	PGC
T45601	TARGTYPE	Literature-reported
T45601	SYNONYMS	Pepsinogen C; Gastricsin
T45601	FUNCTION	Hydrolyzes a variety of proteins.
T45601	PDBSTRUC	1HTR; 1AVF
T45601	ECNUMBER	EC 3.4.23.3
T45601	SEQUENCE	MKWMVVVLVCLQLLEAAVVKVPLKKFKSIRETMKEKGLLGEFLRTHKYDPAWKYRFGDLSVTYEPMAYMDAAYFGEISIGTPPQNFLVLFDTGSSNLWVPSVYCQSQACTSHSRFNPSESSTYSTNGQTFSLQYGSGSLTGFFGYDTLTVQSIQVPNQEFGLSENEPGTNFVYAQFDGIMGLAYPALSVDEATTAMQGMVQEGALTSPVFSVYLSNQQGSSGGAVVFGGVDSSLYTGQIYWAPVTQELYWQIGIEEFLIGGQASGWCSEGCQAIVDTGTSLLTVPQQYMSALLQATGAQEDEYGQFLVNCNSIQNLPSLTFIINGVEFPLPPSSYILSNNGYCTVGVEPTYLSSQNGQPLWILGDVFLRSYYSVYDLGNNRVGFATAA
T45601	DRUGINFO	D0P6RT	PMID8410973C3	Investigative

T15722	TARGETID	T15722
T15722	FORMERID	TTDI02540
T15722	UNIPROID	CD11B_HUMAN
T15722	TARGNAME	Cyclin-dependent kinase 11B (CDK11B)
T15722	GENENAME	CDK11B
T15722	TARGTYPE	Literature-reported
T15722	SYNONYMS	p58 CLK1; p58 CLK-1; PK58; PITSLREA; PITSLRE serine/threonineprotein kinase CDC2L1; PITSLRE serine/threonine-protein kinase CDC2L1; Galactosyltransferaseassociated protein kinase p58/GTA; Galactosyltransferase-associated protein kinase p58/GTA; Cyclindependent kinase 11B; Cell division protein kinase 11B; Cell division cycle 2-like protein kinase 1; CLK-1; CDK11; CDC2L1
T15722	FUNCTION	Involved in pre-mRNA splicing in a kinase activity-dependent manner. Isoform 7 may act as a negative regulator of normal cell cycle progression. Plays multiple roles in cell cycle progression, cytokinesis and apoptosis.
T15722	BIOCLASS	Kinase
T15722	ECNUMBER	EC 2.7.11.22
T15722	SEQUENCE	MGDEKDSWKVKTLDEILQEKKRRKEQEEKAEIKRLKNSDDRDSKRDSLEEGELRDHRMEITIRNSPYRREDSMEDRGEEDDSLAIKPPQQMSRKEKAHHRKDEKRKEKRRHRSHSAEGGKHARVKEKEREHERRKRHREEQDKARREWERQKRREMAREHSRRERDRLEQLERKRERERKMREQQKEQREQKERERRAEERRKEREARREVSAHHRTMREDYSDKVKASHWSRSPPRPPRERFELGDGRKPGEARPAPAQKPAQLKEEKMEERDLLSDLQDISDSERKTSSAESSSAESGSGSEEEEEEEEEEEEEGSTSEESEEEEEEEEEEEEETGSNSEEASEQSAEEVSEEEMSEDEERENENHLLVVPESRFDRDSGESEEAEEEVGEGTPQSSALTEGDYVPDSPALSPIELKQELPKYLPALQGCRSVEEFQCLNRIEEGTYGVVYRAKDKKTDEIVALKRLKMEKEKEGFPITSLREINTILKAQHPNIVTVREIVVGSNMDKIYIVMNYVEHDLKSLMETMKQPFLPGEVKTLMIQLLRGVKHLHDNWILHRDLKTSNLLLSHAGILKVGDFGLAREYGSPLKAYTPVVVTLWYRAPELLLGAKEYSTAVDMWSVGCIFGELLTQKPLFPGKSEIDQINKVFKDLGTPSEKIWPGYSELPAVKKMTFSEHPYNNLRKRFGALLSDQGFDLMNKFLTYFPGRRISAEDGLKHEYFRETPLPIDPSMFPTWPAKSEQQRVKRGTSPRPPEGGLGYSQLGDDDLKETGFHLTTTNQGASAAGPGFSLKF

T41119	TARGETID	T41119
T41119	FORMERID	TTDNR00715
T41119	UNIPROID	NR4A1_HUMAN
T41119	TARGNAME	Early response protein NAK1 (NR4A1)
T41119	GENENAME	NR4A1
T41119	TARGTYPE	Literature-reported
T41119	SYNONYMS	Testicular receptor 3; ST-59; Orphan nuclear receptor TR3; Orphan nuclear receptor HMR; Nur77; Nuclear receptor subfamily 4 group A member 1; Nuclear hormone receptor NUR/77; NAK1; GFRP1
T41119	FUNCTION	May act concomitantly with NURR1 in regulating the expression of delayed-early genes during liver regeneration. Binds the NGFI-B response element (NBRE) 5'-AAAAGGTCA-3'. May inhibit NF-kappa-B transactivation of IL2. Participates in energy homeostasis by sequestrating the kinase STK11 in the nucleus, thereby attenuating cytoplasmic AMPK activation. Plays a role in the vascular response to injury. Orphan nuclear receptor.
T41119	PDBSTRUC	4WHG; 4WHF; 4RZG; 4RZF; 4RZE
T41119	BIOCLASS	Nuclear hormone receptor
T41119	SEQUENCE	MPCIQAQYGTPAPSPGPRDHLASDPLTPEFIKPTMDLASPEAAPAAPTALPSFSTFMDGYTGEFDTFLYQLPGTVQPCSSASSSASSTSSSSATSPASASFKFEDFQVYGCYPGPLSGPVDEALSSSGSDYYGSPCSAPSPSTPSFQPPQLSPWDGSFGHFSPSQTYEGLRAWTEQLPKASGPPQPPAFFSFSPPTGPSPSLAQSPLKLFPSQATHQLGEGESYSMPTAFPGLAPTSPHLEGSGILDTPVTSTKARSGAPGGSEGRCAVCGDNASCQHYGVRTCEGCKGFFKRTVQKNAKYICLANKDCPVDKRRRNRCQFCRFQKCLAVGMVKEVVRTDSLKGRRGRLPSKPKQPPDASPANLLTSLVRAHLDSGPSTAKLDYSKFQELVLPHFGKEDAGDVQQFYDLLSGSLEVIRKWAEKIPGFAELSPADQDLLLESAFLELFILRLAYRSKPGEGKLIFCSGLVLHRLQCARGFGDWIDSILAFSRSLHSLLVDVPAFACLSALVLITDRHGLQEPRRVEELQNRIASCLKEHVAAVAGEPQPASCLSRLLGKLPELRTLCTQGLQRIFYLKLEDLVPPPPIIDKIFMDTLPF

T93278	TARGETID	T93278
T93278	FORMERID	TTDI02434
T93278	UNIPROID	MRC1_HUMAN
T93278	TARGNAME	Mannose receptor (MRC1)
T93278	GENENAME	MRC1
T93278	TARGTYPE	Literature-reported
T93278	SYNONYMS	Macrophage mannose receptor 1like protein 1; Macrophage mannose receptor 1-like protein 1; Macrophage mannose receptor 1; MRC1L1; MMR; Human mannose receptor; Ctype lectin domain family 13 member Dlike; Ctype lectin domain family 13 member D; CLEC13DL; CLEC13D; CD206; C-type lectin domain family 13 member D-like; C-type lectin domain family 13 member D
T93278	FUNCTION	Binds both sulfated and non-sulfated polysaccharide chains. Mediates the endocytosis of glycoproteins by macrophages.
T93278	PDBSTRUC	5XTW; 5XTS; 1EGI; 1EGG
T93278	BIOCLASS	Fibronectin protein
T93278	SEQUENCE	MRLPLLLVFASVIPGAVLLLDTRQFLIYNEDHKRCVDAVSPSAVQTAACNQDAESQKFRWVSESQIMSVAFKLCLGVPSKTDWVAITLYACDSKSEFQKWECKNDTLLGIKGEDLFFNYGNRQEKNIMLYKGSGLWSRWKIYGTTDNLCSRGYEAMYTLLGNANGATCAFPFKFENKWYADCTSAGRSDGWLWCGTTTDYDTDKLFGYCPLKFEGSESLWNKDPLTSVSYQINSKSALTWHQARKSCQQQNAELLSITEIHEQTYLTGLTSSLTSGLWIGLNSLSFNSGWQWSDRSPFRYLNWLPGSPSAEPGKSCVSLNPGKNAKWENLECVQKLGYICKKGNTTLNSFVIPSESDVPTHCPSQWWPYAGHCYKIHRDEKKIQRDALTTCRKEGGDLTSIHTIEELDFIISQLGYEPNDELWIGLNDIKIQMYFEWSDGTPVTFTKWLRGEPSHENNRQEDCVVMKGKDGYWADRGCEWPLGYICKMKSRSQGPEIVEVEKGCRKGWKKHHFYCYMIGHTLSTFAEANQTCNNENAYLTTIEDRYEQAFLTSFVGLRPEKYFWTGLSDIQTKGTFQWTIEEEVRFTHWNSDMPGRKPGCVAMRTGIAGGLWDVLKCDEKAKFVCKHWAEGVTHPPKPTTTPEPKCPEDWGASSRTSLCFKLYAKGKHEKKTWFESRDFCRALGGDLASINNKEEQQTIWRLITASGSYHKLFWLGLTYGSPSEGFTWSDGSPVSYENWAYGEPNNYQNVEYCGELKGDPTMSWNDINCEHLNNWICQIQKGQTPKPEPTPAPQDNPPVTEDGWVIYKDYQYYFSKEKETMDNARAFCKRNFGDLVSIQSESEKKFLWKYVNRNDAQSAYFIGLLISLDKKFAWMDGSKVDYVSWATGEPNFANEDENCVTMYSNSGFWNDINCGYPNAFICQRHNSSINATTVMPTMPSVPSGCKEGWNFYSNKCFKIFGFMEEERKNWQEARKACIGFGGNLVSIQNEKEQAFLTYHMKDSTFSAWTGLNDVNSEHTFLWTDGRGVHYTNWGKGYPGGRRSSLSYEDADCVVIIGGASNEAGKWMDDTCDSKRGYICQTRSDPSLTNPPATIQTDGFVKYGKSSYSLMRQKFQWHEAETYCKLHNSLIASILDPYSNAFAWLQMETSNERVWIALNSNLTDNQYTWTDKWRVRYTNWAADEPKLKSACVYLDLDGYWKTAHCNESFYFLCKRSDEIPATEPPQLPGRCPESDHTAWIPFHGHCYYIESSYTRNWGQASLECLRMGSSLVSIESAAESSFLSYRVEPLKSKTNFWIGLFRNVEGTWLWINNSPVSFVNWNTGDPSGERNDCVALHASSGFWSNIHCSSYKGYICKRPKIIDAKPTHELLTTKADTRKMDPSKPSSNVAGVVIIVILLILTGAGLAAYFFYKKRRVHLPQEGAFENTLYFNSQSSPGTSDMKDLVGNIEQNEHSVI

T92635	TARGETID	T92635
T92635	FORMERID	TTDR00744
T92635	UNIPROID	GATA3_HUMAN
T92635	TARGNAME	GATA-binding factor 3 (GATA3)
T92635	GENENAME	GATA3
T92635	TARGTYPE	Literature-reported
T92635	SYNONYMS	Trans-acting T-cell-specific transcription factor GATA-3
T92635	FUNCTION	Transcriptional activator which binds to the enhancer of the T-cell receptor alpha and delta genes. Binds to the consensus sequence 5'-AGATAG-3'. Required for the T-helper 2 (Th2) differentiation process following immune and inflammatory responses.
T92635	PDBSTRUC	4HCA; 4HC9; 4HC7
T92635	BIOCLASS	Zinc-finger
T92635	SEQUENCE	MEVTADQPRWVSHHHPAVLNGQHPDTHHPGLSHSYMDAAQYPLPEEVDVLFNIDGQGNHVPPYYGNSVRATVQRYPPTHHGSQVCRPPLLHGSLPWLDGGKALGSHHTASPWNLSPFSKTSIHHGSPGPLSVYPPASSSSLSGGHASPHLFTFPPTPPKDVSPDPSLSTPGSAGSARQDEKECLKYQVPLPDSMKLESSHSRGSMTALGGASSSTHHPITTYPPYVPEYSSGLFPPSSLLGGSPTGFGCKSRPKARSSTGRECVNCGATSTPLWRRDGTGHYLCNACGLYHKMNGQNRPLIKPKRRLSAARRAGTSCANCQTTTTTLWRRNANGDPVCNACGLYYKLHNINRPLTMKKEGIQTRNRKMSSKSKKCKKVHDSLEDFPKNSSFNPAALSRHMSSLSHISPFSHSSHMLTTPTPMHPPSSLSFGPHHPSSMVTAMG

T87542	TARGETID	T87542
T87542	FORMERID	TTDR00166
T87542	UNIPROID	GSA_ECOLI
T87542	TARGNAME	Bacterial Glutamate-1-semialdehyde aminomutase (Bact hemL)
T87542	GENENAME	Bact hemL
T87542	TARGTYPE	Literature-reported
T87542	SYNONYMS	Glutamate-1-semialdehyde aminotransferase; Glutamate-1-semialdehyde 2,1-aminomutase; GSA-AT; GSA
T87542	FUNCTION	Catalyses the formation of this key precursor of tetrapyrroles.
T87542	BIOCLASS	Intramolecular transferases
T87542	SEQUENCE	MSKSENLYSAARELIPGGVNSPVRAFTGVGGTPLFIEKADGAYLYDVDGKAYIDYVGSWGPMVLGHNHPAIRNAVIEAAERGLSFGAPTEMEVKMAQLVTELVPTMDMVRMVNSGTEATMSAIRLARGFTGRDKIIKFEGCYHGHADCLLVKAGSGALTLGQPNSPGVPADFAKYTLTCTYNDLASVRAAFEQYPQEIACIIVEPVAGNMNCVPPLPEFLPGLRALCDEFGALLIIDEVMTGFRVALAGAQDYYGVVPDLTCLGKIIGGGMPVGAFGGRRDVMDALAPTGPVYQAGTLSGNPIAMAAGFACLNEVAQPGVHETLDELTTRLAEGLLEAAEEAGIPLVVNHVGGMFGIFFTDAESVTCYQDVMACDVERFKRFFHMMLDEGVYLAPSAFEAGFMSVAHSMEDINNTIDAARRVFAKL
T87542	DRUGINFO	D03DVF	Gabaculine	Investigative
T87542	DRUGINFO	D0VF4Q	Diaminopropyl sulfate	Investigative

T96028	TARGETID	T96028
T96028	UNIPROID	IL32_HUMAN
T96028	TARGNAME	Interleukin-32 (IL32)
T96028	GENENAME	IL32
T96028	TARGTYPE	Literature-reported
T96028	SYNONYMS	Tumor necrosis factor alpha-inducing factor; TAIF; Natural killer cells protein 4; NK4; IL-32
T96028	FUNCTION	It induces various cytokines such as TNFA/TNF-alpha and IL8. It activates typical cytokine signal pathways of NF-kappa-B and p38 MAPK. Cytokine that may play a role in innate and adaptive immune responses.
T96028	BIOCLASS	Cytokine: interleukin
T96028	SEQUENCE	MCFPKVLSDDMKKLKARMVMLLPTSAQGLGAWVSACDTEDTVGHLGPWRDKDPALWCQLCLSSQHQAIERFYDKMQNAESGRGQVMSSLAELEDDFKEGYLETVAAYYEEQHPELTPLLEKERDGLRCRGNRSPVPDVEDPATEEPGESFCDKVMRWFQAMLQRLQTWWHGVLAWVKEKVVALVHAVQALWKQFQSFCCSLSELFMSSFQSYGAPRGDKEELTPQKCSEPQSSK

T94083	TARGETID	T94083
T94083	FORMERID	TTDR00331
T94083	UNIPROID	ACPS_ECOLI
T94083	TARGNAME	Bacterial Holo-ACP synthase (Bact acpS)
T94083	GENENAME	Bact acpS
T94083	TARGTYPE	Literature-reported
T94083	SYNONYMS	acpS; Holo-[acyl-carrier protein] synthase; 4'-phosphopantetheinyl transferase acpS
T94083	FUNCTION	Transfers the 4'-phosphopantetheine moiety from coenzyme A to the 'Ser-36' of acyl-carrier-protein.
T94083	PDBSTRUC	5XUH; 5XU7; 5VCB; 5VBX
T94083	BIOCLASS	Kinase
T94083	SEQUENCE	MAILGLGTDIVEIARIEAVIARSGDRLARRVLSDNEWAIWKTHHQPVRFLAKRFAVKEAAAKAFGTGIRNGLAFNQFEVFNDELGKPRLRLWGEALKLAEKLGVANMHVTLADERHYACATVIIES

T67540	TARGETID	T67540
T67540	FORMERID	TTDR00816
T67540	UNIPROID	PTRB_ECOLI
T67540	TARGNAME	Bacterial Protease II (Bact ptrB)
T67540	GENENAME	Bact ptrB
T67540	TARGTYPE	Literature-reported
T67540	SYNONYMS	ptrB; Oligopeptidase B
T67540	FUNCTION	Cleaves peptide bonds on the C-terminal side of lysyl and argininyl residues.
T67540	BIOCLASS	Peptidase
T67540	ECNUMBER	EC 3.4.21.83
T67540	SEQUENCE	MLPKAARIPHAMTLHGDTRIDNYYWLRDDTRSQPEVLDYLQQENSYGHRVMASQQALQDRILKEIIDRIPQREVSAPYIKNGYRYRHIYEPGCEYAIYQRQSAFSEEWDEWETLLDANKRAAHSEFYSMGGMAITPDNTIMALAEDFLSRRQYGIRFRNLETGNWYPELLDNVEPSFVWANDSWIFYYVRKHPVTLLPYQVWRHAIGTPASQDKLIYEEKDDTYYVSLHKTTSKHYVVIHLASATTSEVRLLDAEMADAEPFVFLPRRKDHEYSLDHYQHRFYLRSNRHGKNFGLYRTRMRDEQQWEELIPPRENIMLEGFTLFTDWLVVEERQRGLTSLRQINRKTREVIGIAFDDPAYVTWIAYNPEPETARLRYGYSSMTTPDTLFELDMDTGERRVLKQTEVPGFYAANYRSEHLWIVARDGVEVPVSLVYHRKHFRKGHNPLLVYGYGSYGASIDADFSFSRLSLLDRGFVYAIVHVRGGGELGQQWYEDGKFLKKKNTFNDYLDACDALLKLGYGSPSLCYAMGGSAGGMLMGVAINQRPELFHGVIAQVPFVDVVTTMLDESIPLTTGEFEEWGNPQDPQYYEYMKSYSPYDNVTAQAYPHLLVTTGLHDSQVQYWEPAKWVAKLRELKTDDHLLLLCTDMDSGHGGKSGRFKSYEGVAMEYAFLVALAQGTLPATPAD

T61800	TARGETID	T61800
T61800	FORMERID	TTDR00586
T61800	UNIPROID	IBP6_HUMAN
T61800	TARGNAME	Insulin-like growth factor-binding protein 6 (IGFBP6)
T61800	GENENAME	IGFBP6
T61800	TARGTYPE	Literature-reported
T61800	SYNONYMS	IGFBP-6; IGF-binding protein 6; IBP6; IBP-6
T61800	FUNCTION	IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors.
T61800	PDBSTRUC	1RMJ
T61800	BIOCLASS	Insulin-like growth factor binding
T61800	SEQUENCE	MTPHRLLPPLLLLLALLLAASPGGALARCPGCGQGVQAGCPGGCVEEEDGGSPAEGCAEAEGCLRREGQECGVYTPNCAPGLQCHPPKDDEAPLRALLLGRGRCLPARAPAVAEENPKESKPQAGTARPQDVNRRDQQRNPGTSTTPSQPNSAGVQDTEMGPCRRHLDSVLQQLQTEVYRGAQTLYVPNCDHRGFYRKRQCRSSQGQRRGPCWCVDRMGKSLPGSPDGNGSSSCPTGSSG

T97917	TARGETID	T97917
T97917	FORMERID	TTDR00540
T97917	UNIPROID	FPR2_HUMAN
T97917	TARGNAME	FMLP-related receptor I (FPR2)
T97917	GENENAME	FPR2
T97917	TARGTYPE	Literature-reported
T97917	SYNONYMS	RFP; Lipoxin A4 receptor; LXA4 receptor; HM63; G-protein-coupled receptor FPR-Like-1; Formyl peptide receptor-like 1; FPRL1; FPR2; FMLP-R-I
T97917	FUNCTION	Low affinity receptor for N-formyl-methionyl peptides, which are powerful neutrophils chemotactic factors. Binding of FMLP to the receptor causes activation of neutrophils. This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system. The activation of LXA4R could result in an anti-inflammatory outcome counteracting the actions of proinflammatory signals such as LTB4 (leukotrieneB4).
T97917	BIOCLASS	GPCR rhodopsin
T97917	SEQUENCE	METNFSTPLNEYEEVSYESAGYTVLRILPLVVLGVTFVLGVLGNGLVIWVAGFRMTRTVTTICYLNLALADFSFTATLPFLIVSMAMGEKWPFGWFLCKLIHIVVDINLFGSVFLIGFIALDRCICVLHPVWAQNHRTVSLAMKVIVGPWILALVLTLPVFLFLTTVTIPNGDTYCTFNFASWGGTPEERLKVAITMLTARGIIRFVIGFSLPMSIVAICYGLIAAKIHKKGMIKSSRPLRVLTAVVASFFICWFPFQLVALLGTVWLKEMLFYGKYKIIDILVNPTSSLAFFNSCLNPMLYVFVGQDFRERLIHSLPTSLERALSEDSAPTNDTAANSASPPAETELQAM
T97917	DRUGINFO	D09TXO	humanin	Preclinical
T97917	DRUGINFO	D04NBD	quin-C7	Investigative
T97917	DRUGINFO	D07PSF	aspirin triggered lipoxin A4	Investigative
T97917	DRUGINFO	D0C3HQ	quin-C1	Investigative
T97917	DRUGINFO	D0H1EB	ATLa2	Investigative
T97917	DRUGINFO	D0MU1V	AG-26	Investigative
T97917	DRUGINFO	D0NL4R	PMID23788657C1754-31	Investigative
T97917	DRUGINFO	D01EOQ	PMID22607879CR-(-)-5f	Investigative
T97917	DRUGINFO	D05PYO	aspirin-triggered resolvin D1	Investigative
T97917	DRUGINFO	D0M0YH	fMet-Leu-Phe	Investigative
T97917	DRUGINFO	D0V8YH	RvD1-ME	Investigative
T97917	DRUGINFO	D0WB8E	pyrazolone, 1	Investigative
T97917	DRUGINFO	D0P0KG	[3H]resolvin D1	Investigative
T97917	DRUGINFO	D0R1FZ	LXA4	Investigative

T89215	TARGETID	T89215
T89215	FORMERID	TTDR00706
T89215	UNIPROID	RS12_HUMAN
T89215	TARGNAME	Small ribosomal subunit protein eS12 (RPS12)
T89215	GENENAME	RPS12
T89215	TARGTYPE	Literature-reported
T89215	SYNONYMS	40S ribosomal protein S12
T89215	FUNCTION	A component of the 40S ribosome subunit. Ribosome, the organelle that catalyzes protein synthesis, consists of a small 40S subunit and a large 60S subunit. Increased expression  in colorectal cancers compared to matched normal colonic mucosa.
T89215	PDBSTRUC	6QZP; 6G5I; 6G5H; 6G53; 6G51
T89215	BIOCLASS	Ribosomal protein
T89215	SEQUENCE	MAEEGIAAGGVMDVNTALQEVLKTALIHDGLARGIREAAKALDKRQAHLCVLASNCDEPMYVKLVEALCAEHQINLIKVDDNKKLGEWVGLCKIDREGKPRKVVGCSCVVVKDYGKESQAKDVIEEYFKCKK

T96704	TARGETID	T96704
T96704	FORMERID	TTDR00986
T96704	UNIPROID	DNJB1_HUMAN
T96704	TARGNAME	Heat shock protein 40 (HSP40)
T96704	GENENAME	DNAJB1
T96704	TARGTYPE	Literature-reported
T96704	SYNONYMS	Heat shock 40 kDa protein 1; HSP40; HDJ-1; DnaJ protein homolog 1; DnaJ homolog subfamily B member 1; DNAJB1
T96704	FUNCTION	Interacts with HSP70 and can stimulate its ATPase activity. Stimulates the association between HSC70 and HIP.
T96704	PDBSTRUC	6BYR; 4WB7; 3AGZ; 3AGY; 3AGX
T96704	BIOCLASS	Heat shock protein
T96704	SEQUENCE	MGKDYYQTLGLARGASDEEIKRAYRRQALRYHPDKNKEPGAEEKFKEIAEAYDVLSDPRKREIFDRYGEEGLKGSGPSGGSGGGANGTSFSYTFHGDPHAMFAEFFGGRNPFDTFFGQRNGEEGMDIDDPFSGFPMGMGGFTNVNFGRSRSAQEPARKKQDPPVTHDLRVSLEEIYSGCTKKMKISHKRLNPDGKSIRNEDKILTIEVKKGWKEGTKITFPKEGDQTSNNIPADIVFVLKDKPHNIFKRDGSDVIYPARISLREALCGCTVNVPTLDGRTIPVVFKDVIRPGMRRKVPGEGLPLPKTPEKRGDLIIEFEVIFPERIPQTSRTVLEQVLPI

T70850	TARGETID	T70850
T70850	FORMERID	TTDR00558
T70850	UNIPROID	END1_ECOLI
T70850	TARGNAME	Bacterial RNA endonuclease (Bact endA)
T70850	GENENAME	Bact endA
T70850	TARGTYPE	Literature-reported
T70850	SYNONYMS	endA; Endonuclease I; Endo I
T70850	FUNCTION	Has double-strand break activity.
T70850	BIOCLASS	Endodeoxyribonucleases
T70850	ECNUMBER	EC 3.1.21.1
T70850	SEQUENCE	MYRYLSIAAVVLSAAFSGPALAEGINSFSQAKAAAVKVHADAPGTFYCGCKINWQGKKGVVDLQSCGYQVRKNENRASRVEWEHVVPAWQFGHQRQCWQDGGRKNCAKDPVYRKMESDMHNLQPSVGEVNGDRGNFMYSQWNGGEGQYGQCAMKVDFKEKAAEPPARARGAIARTYFYMRDQYNLTLSRQQTQLFNAWNKMYPVTDWECERDERIAKVQGNHNPYVQRACQARKS

T85801	TARGETID	T85801
T85801	FORMERID	TTDR00746
T85801	UNIPROID	ALGC_PSEAE
T85801	TARGNAME	Pseudomonas Phosphomannomutase/phosphoglucomutase (Pseudo algC)
T85801	GENENAME	Pseudo algC
T85801	TARGTYPE	Literature-reported
T85801	SYNONYMS	algC; PMM/PGM; PMM / PGM
T85801	FUNCTION	Highly reversible phosphoryltransferase. The phosphomannomutase activity produces a precursor for alginate polymerization, the alginate layer causes a mucoid phenotype and provides a protective barrier against host immune defenses and antibiotics. Also involved in core lipopolysaccaride (LPS) biosynthesis due to its phosphoglucomutase activity. Essential for rhamnolipid production, an exoproduct correlated with pathogenicity (PubMed:10481091). Required for biofilm production. The reaction proceeds via 2 processive phosphoryl transferase reactions; first from enzyme-phospho-Ser-108 to the substrate (generatinga bisphosphorylated substrate intermediate and a dephosphorylated enzyme), a 180 degree rotation of the intermediate (probably aided by movement of domain 4), and subsequent transfer of phosphate back to the enzyme (PubMed:11716469, PubMed:16880541, PubMed:16595672, PubMed:22242625).
T85801	PDBSTRUC	4MRQ; 4IL8; 3RSM; 3C04; 3BKQ
T85801	BIOCLASS	Intramolecular transferases
T85801	SEQUENCE	MSTAKAPTLPASIFRAYDIRGVVGDTLTAETAYWIGRAIGSESLARGEPCVAVGRDGRLSGPELVKQLIQGLVDCGCQVSDVGMVPTPVLYYAANVLEGKSGVMLTGSHNPPDYNGFKIVVAGETLANEQIQALRERIEKNDLASGVGSVEQVDILPRYFKQIRDDIAMAKPMKVVVDCGNGVAGVIAPQLIEALGCSVIPLYCEVDGNFPNHHPDPGKPENLKDLIAKVKAENADLGLAFDGDGDRVGVVTNTGTIIYPDRLLMLFAKDVVSRNPGADIIFDVKCTRRLIALISGYGGRPVMWKTGHSLIKKKMKETGALLAGEMSGHVFFKERWFGFDDGIYSAARLLEILSQDQRDSEHVFSAFPSDISTPEINITVTEDSKFAIIEALQRDAQWGEGNITTLDGVRVDYPKGWGLVRASNTTPVLVLRFEADTEEELERIKTVFRNQLKAVDSSLPVPF
T85801	DRUGINFO	D03AZI	D-Mannose 1-Phosphate	Investigative
T85801	DRUGINFO	D0Q0OH	Alpha-D-Mannose-6-Phosphate	Investigative
T85801	DRUGINFO	D0S5WE	Alpha-D-Glucose-1-Phosphate	Investigative
T85801	DRUGINFO	D01AWD	Alpha-D-Glucose-6-Phosphate	Investigative
T85801	DRUGINFO	D07PZQ	L-serine-O-phosphate	Investigative

T79724	TARGETID	T79724
T79724	FORMERID	TTDR00748
T79724	UNIPROID	HPPK_ECOLI
T79724	TARGNAME	Bacterial Hydroxymethyl-dihydropterin pyrophosphokinase (Bact folK)
T79724	GENENAME	Bact folK
T79724	TARGTYPE	Literature-reported
T79724	SYNONYMS	PPPK; HPPK; 7,8-dihydro-6-hydroxymethylpterin-pyrophosphokinase; 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase; 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase
T79724	FUNCTION	2-amino-4-hydroxy-6-hydroxymethyldihydropteridine diphosphokinase activity, magnesium ion binding
T79724	PDBSTRUC	6AN6; 6AN4; 5ETP; 5ETO; 5ETN
T79724	BIOCLASS	Kinase
T79724	SEQUENCE	MTVAYIAIGSNLASPLEQVNAALKALGDIPESHILTVSSFYRTPPLGPQDQPDYLNAAVALETSLAPEELLNHTQRIELQQGRVRKAERWGPRTLDLDIMLFGNEVINTERLTVPHYDMKNRGFMLWPLFEIAPELVFPDGEMLRQILHTRAFDKLNKW
T79724	DRUGINFO	D0F6WV	PD-157695	Preclinical
T79724	DRUGINFO	D02UKY	6-Hydroxymethylpterin	Investigative
T79724	DRUGINFO	D05BQE	P(1)-(6-Hydroxymethylpterin)-P(4)-(5'-adenosyl)tetraphosphate	Investigative
T79724	DRUGINFO	D03BIT	[Pterin-6-Yl Methanyl]-Phosphonophosphate	Investigative
T79724	DRUGINFO	D0W0NE	6-Hydroxymethyl-7,8-Dihydropterin	Investigative
T79724	DRUGINFO	D00QLM	[3H]alphabeta-meATP	Investigative
T79724	DRUGINFO	D0F2ME	Acetate Ion	Investigative

T43773	TARGETID	T43773
T43773	FORMERID	TTDI01927
T43773	UNIPROID	POLG_HCV1
T43773	TARGNAME	Hepatitis C virus Protease NS2-3/3 (HCV NS2-3/3)
T43773	GENENAME	HCV NS2-3/3
T43773	TARGTYPE	Literature-reported
T43773	SYNONYMS	HCV p23/p70
T43773	FUNCTION	NS5B is an RNA-dependent RNA polymerase that plays an essential role in the virus replication.
T43773	PDBSTRUC	3SU4; 3RC5; 3RC4; 3QGI; 3QGH
T43773	ECNUMBER	EC 3.4.-.-
T43773	SEQUENCE	LDTEVAASCGGVVLVGLMALTLSPYYKRYISWCLWWLQYFLTRVEAQLHVWIPPLNVRGGRDAVILLMCAVHPTLVFDITKLLLAVFGPLWILQASLLKVPYFVRVQGLLRFCALARKMIGGHYVQMVIIKLGALTGTYVYNHLTPLRDWAHNGLRDLAVAVEPVVFSQMETKLITWGADTAACGDIINGLPVSARRGREILLGPADGMVSKGWRLLAPITAYAQQTRGLLGCIITSLTGRDKNQVEGEVQIVSTAAQTFLATCINGVCWTVYHGAGTRTIASPKGPVIQMYTNVDQDLVGWPAPQGSRSLTPCTCGSSDLYLVTRHADVIPVRRRGDSRGSLLSPRPISYLKGSSGGPLLCPAGHAVGIFRAAVCTRGVAKAVDFIPVENLETTMRSPVFTDNSSPPVVPQSFQVAHLHAPTGSGKSTKVPAAYAAQGYKVLVLNPSVAATLGFGAYMSKAHGIDPNIRTGVRTITTGSPITYSTYGKFLADGGCSGGAYDIIICDECHSTDATSILGIGTVLDQAETAGARLVVLATATPPGSVTVPHPNIEEVALSTTGEIPFYGKAIPLEVIKGGRHLIFCHSKKKCDELAAKLVALGINAVAYYRGLDVSVIPTSGDVVVVATDALMTGYTGDFDSVIDCNTCVTQTVDFSLDPTFTIETITLPQDAVSRTQRRGRTGRGKPGIYRFVAPGERPSGMFDSSVLCECYDAGCAWYELTPAETTVRLRAYMNTPGLPVCQDHLEFWEGVFTGLTHIDAHFLSQTKQSGENLPYLVAYQATVCARAQAPPPSWDQMWKCLIRLKPTLHGPTPLLYRLGAVQNEITLTHPVTKYIMTCMSADLEVV

T46318	TARGETID	T46318
T46318	FORMERID	TTDI03014
T46318	UNIPROID	AOAH_HUMAN
T46318	TARGNAME	Acyloxyacyl hydrolase (neutrophil)
T46318	GENENAME	AOAH
T46318	TARGTYPE	Literature-reported
T46318	SYNONYMS	Acyloxyacyl hydrolase
T46318	FUNCTION	Removes the secondary (acyloxyacyl-linked) fatty acyl chains from the lipid A region of bacterial lipopolysaccharides. By breaking down LPS, terminates the host response to bacterial infection and prevents prolonged and damaging inflammatory responses (By similarity). In peritoneal macrophages, seems to be important for recovery from a state of immune tolerance following infection by Gram-negative bacteria (By similarity).
T46318	PDBSTRUC	5W7C; 5W78
T46318	ECNUMBER	EC 3.1.1.77
T46318	SEQUENCE	MQSPWKILTVAPLFLLLSLQSSASPANDDQSRPSLSNGHTCVGCVLVVSVIEQLAQVHNSTVQASMERLCSYLPEKLFLKTTCYLVIDKFGSDIIKLLSADMNADVVCHTLEFCKQNTGQPLCHLYPLPKETWKFTLQKARQIVKKSPILKYSRSGSDICSLPVLAKICQKIKLAMEQSVPFKDVDSDKYSVFPTLRGYHWRGRDCNDSDESVYPGRRPNNWDVHQDSNCNGIWGVDPKDGVPYEKKFCEGSQPRGIILLGDSAGAHFHISPEWITASQMSLNSFINLPTALTNELDWPQLSGATGFLDSTVGIKEKSIYLRLWKRNHCNHRDYQNISRNGASSRNLKKFIESLSRNKVLDYPAIVIYAMIGNDVCSGKSDPVPAMTTPEKLYSNVMQTLKHLNSHLPNGSHVILYGLPDGTFLWDNLHNRYHPLGQLNKDMTYAQLYSFLNCLQVSPCHGWMSSNKTLRTLTSERAEQLSNTLKKIAASEKFTNFNLFYMDFAFHEIIQEWQKRGGQPWQLIEPVDGFHPNEVALLLLADHFWKKVQLQWPQILGKENPFNPQIKQVFGDQGGH
T46318	DRUGINFO	D06UDN	JZL195	Investigative

T75152	TARGETID	T75152
T75152	FORMERID	TTDR00512
T75152	UNIPROID	LYOX_HUMAN
T75152	TARGNAME	Lysyl oxidase (LOX)
T75152	GENENAME	LOX
T75152	TARGTYPE	Literature-reported
T75152	SYNONYMS	Protein-lysine 6-oxidase
T75152	FUNCTION	Regulator of Ras expression. May play a role in tumor suppression. Plays a role in the aortic wall architecture. Responsible for the post-translational oxidative deamination of peptidyl lysine residues in precursors to fibrous collagen and elastin.
T75152	BIOCLASS	CH-NH(2) donor oxidoreductase
T75152	ECNUMBER	EC 1.4.3.13
T75152	SEQUENCE	MRFAWTVLLLGPLQLCALVHCAPPAAGQQQPPREPPAAPGAWRQQIQWENNGQVFSLLSLGSQYQPQRRRDPGAAVPGAANASAQQPRTPILLIRDNRTAAARTRTAGSSGVTAGRPRPTARHWFQAGYSTSRAREAGASRAENQTAPGEVPALSNLRPPSRVDGMVGDDPYNPYKYSDDNPYYNYYDTYERPRPGGRYRPGYGTGYFQYGLPDLVADPYYIQASTYVQKMSMYNLRCAAEENCLASTAYRADVRDYDHRVLLRFPQRVKNQGTSDFLPSRPRYSWEWHSCHQHYHSMDEFSHYDLLDANTQRRVAEGHKASFCLEDTSCDYGYHRRFACTAHTQGLSPGCYDTYGADIDCQWIDITDVKPGNYILKVSVNPSYLVPESDYTNNVVRCDIRYTGHHAYASGCTISPY

T88947	TARGETID	T88947
T88947	FORMERID	TTDI03128
T88947	UNIPROID	CXB2_HUMAN
T88947	TARGNAME	Gap junction beta-2 protein (Cx26)
T88947	GENENAME	GJB2
T88947	TARGTYPE	Literature-reported
T88947	SYNONYMS	Connexin-26
T88947	FUNCTION	Gap junctions are dodecameric channels that connect the cytoplasm of adjoining cells. They are formed by the docking of two hexameric hemichannels, one from each cell membrane. Small molecules and ions diffuse from one cell to a neighboring cell via the central pore. Structural component of gap junctions.
T88947	PDBSTRUC	5KJG; 5KJ3; 5ERA; 5ER7; 3IZ2
T88947	BIOCLASS	Gap junction-forming connexin
T88947	SEQUENCE	MDWGTLQTILGGVNKHSTSIGKIWLTVLFIFRIMILVVAAKEVWGDEQADFVCNTLQPGCKNVCYDHYFPISHIRLWALQLIFVSTPALLVAMHVAYRRHEKKRKFIKGEIKSEFKDIEEIKTQKVRIEGSLWWTYTSSIFFRVIFEAAFMYVFYVMYDGFSMQRLVKCNAWPCPNTVDCFVSRPTEKTVFTVFMIAVSGICILLNVTELCYLLIRYCSGKSKKPV
T88947	DRUGINFO	D00VJY	octanol	Investigative

T47657	TARGETID	T47657
T47657	FORMERID	TTDI03349
T47657	UNIPROID	LTK_HUMAN
T47657	TARGNAME	Leukocyte receptor tyrosine kinase (LTK)
T47657	GENENAME	LTK
T47657	TARGTYPE	Literature-reported
T47657	SYNONYMS	TYK1; Protein tyrosine kinase 1; Leukocyte tyrosine kinase receptor
T47657	FUNCTION	The exact function of this protein is not known. Studies with chimeric proteins (replacing its extracellular region with that of several known growth factor receptors, such as EGFR and CSFIR) demonstrate its ability to promote growth and specifically neurite outgrowth, and cell survival. Signaling appears to involve the PI3 kinase pathway. Involved in regulation of the secretory pathway involving endoplasmic reticulum (ER) export sites (ERESs) and ER to Golgi transport. Receptor with a tyrosine-protein kinase activity.
T47657	BIOCLASS	Kinase
T47657	ECNUMBER	EC 2.7.10.1
T47657	SEQUENCE	MGCWGQLLVWFGAAGAILCSSPGSQETFLRSSPLPLASPSPRDPKVSAPPSILEPASPLNSPGTEGSWLFSTCGASGRHGPTQTQCDGAYAGTSVVVTVGAAGQLRGVQLWRVPGPGQYLISAYGAAGGKGAKNHLSRAHGVFVSAIFSLGLGESLYILVGQQGEDACPGGSPESQLVCLGESRAVEEHAAMDGSEGVPGSRRWAGGGGGGGGATYVFRVRAGELEPLLVAAGGGGRAYLRPRDRGRTQASPEKLENRSEAPGSGGRGGAAGGGGGWTSRAPSPQAGRSLQEGAEGGQGCSEAWATLGWAAAGGFGGGGGACTAGGGGGGYRGGDASETDNLWADGEDGVSFIHPSSELFLQPLAVTENHGEVEIRRHLNCSHCPLRDCQWQAELQLAECLCPEGMELAVDNVTCMDLHKPPGPLVLMVAVVATSTLSLLMVCGVLILVKQKKWQGLQEMRLPSPELELSKLRTSAIRTAPNPYYCQVGLGPAQSWPLPPGVTEVSPANVTLLRALGHGAFGEVYEGLVIGLPGDSSPLQVAIKTLPELCSPQDELDFLMEALIISKFRHQNIVRCVGLSLRATPRLILLELMSGGDMKSFLRHSRPHLGQPSPLVMRDLLQLAQDIAQGCHYLEENHFIHRDIAARNCLLSCAGPSRVAKIGDFGMARDIYRASYYRRGDRALLPVKWMPPEAFLEGIFTSKTDSWSFGVLLWEIFSLGYMPYPGRTNQEVLDFVVGGGRMDPPRGCPGPVYRIMTQCWQHEPELRPSFASILERLQYCTQDPDVLNSLLPMELGPTPEEEGTSGLGNRSLECLRPPQPQELSPEKLKSWGGSPLGPWLSSGLKPLKSRGLQPQNLWNPTYRS
T47657	DRUGINFO	D0K5UF	PMID24432909C8e	Investigative

T93904	TARGETID	T93904
T93904	UNIPROID	PEBP1_HUMAN
T93904	TARGNAME	Phosphatidylethanolamine-binding protein 1 (PEBP1)
T93904	GENENAME	PEBP1
T93904	TARGTYPE	Literature-reported
T93904	SYNONYMS	Raf kinase inhibitor protein; RKIP; Prostatic-binding protein; PEBP-1; PEBP; PBP; Neuropolypeptide h3; Hippocampal cholinergic neurostimulating peptide; HCNPpp; HCNP
T93904	FUNCTION	Binds ATP, opioids and phosphatidylethanolamine. Has lower affinity for phosphatidylinositol and phosphatidylcholine. Serine protease inhibitor which inhibits thrombin, neuropsin and chymotrypsin but not trypsin, tissue type plasminogen activator and elastase. Inhibits the kinase activity of RAF1 by inhibiting its activation and by dissociating the RAF1/MEK complex and acting as a competitive inhibitor of MEK phosphorylation.
T93904	PDBSTRUC	2QYQ; 2L7W; 1BEH; 1BD9
T93904	BIOCLASS	Phosphatidylethanolamine-binding protein family
T93904	SEQUENCE	MPVDLSKWSGPLSLQEVDEQPQHPLHVTYAGAAVDELGKVLTPTQVKNRPTSISWDGLDSGKLYTLVLTDPDAPSRKDPKYREWHHFLVVNMKGNDISSGTVLSDYVGSGPPKGTGLHRYVWLVYEQDRPLKCDEPILSNRSGDHRGKFKVASFRKKYELRAPVAGTCYQAEWDDYVPKLYEQLSGK

T00299	TARGETID	T00299
T00299	FORMERID	TTDR01260
T00299	UNIPROID	ACHA5_HUMAN
T00299	TARGNAME	Neuronal acetylcholine receptor alpha-5 (CHRNA5)
T00299	GENENAME	CHRNA5
T00299	TARGTYPE	Literature-reported
T00299	SYNONYMS	NACHRA5; CHRNA5
T00299	FUNCTION	After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
T00299	BIOCLASS	Neurotransmitter receptor
T00299	SEQUENCE	MAARGSGPRALRLLLLVQLVAGRCGLAGAAGGAQRGLSEPSSIAKHEDSLLKDLFQDYERWVRPVEHLNDKIKIKFGLAISQLVDVDEKNQLMTTNVWLKQEWIDVKLRWNPDDYGGIKVIRVPSDSVWTPDIVLFDNADGRFEGTSTKTVIRYNGTVTWTPPANYKSSCTIDVTFFPFDLQNCSMKFGSWTYDGSQVDIILEDQDVDKRDFFDNGEWEIVSATGSKGNRTDSCCWYPYVTYSFVIKRLPLFYTLFLIIPCIGLSFLTVLVFYLPSNEGEKICLCTSVLVSLTVFLLVIEEIIPSSSKVIPLIGEYLVFTMIFVTLSIMVTVFAINIHHRSSSTHNAMAPLVRKIFLHTLPKLLCMRSHVDRYFTQKEETESGSGPKSSRNTLEAALDSIRYITRHIMKENDVREVVEDWKFIAQVLDRMFLWTFLFVSIVGSLGLFVPVIYKWANILIPVHIGNANK
T00299	DRUGINFO	D00YUX	alpha-conotoxin PnIA	Investigative

T31297	TARGETID	T31297
T31297	FORMERID	TTDR00613
T31297	UNIPROID	A85B_MYCTU
T31297	TARGNAME	Mycobacterium 30kDa major secretory protein (MycB fbpB)
T31297	GENENAME	MycB fbpB
T31297	TARGTYPE	Literature-reported
T31297	SYNONYMS	Mycolyl transferase 85B; Fibronectin-binding protein B; Extracellular alpha-antigen; Antigen 85B; Antigen 85 complex B; Ag85B; 85B; 30 kDa extracellular protein
T31297	FUNCTION	Proteins of the antigen 85 complex are responsible for the high affinity of mycobacteria to fibronectin. Possesses a mycolyltransferase activity required for the biogenesis of trehalose dimycolate (cord factor).
T31297	PDBSTRUC	5TS1; 5TRZ; 1F0P; 1F0N
T31297	BIOCLASS	Acyltransferase
T31297	SEQUENCE	MTDVSRKIRAWGRRLMIGTAAAVVLPGLVGLAGGAATAGAFSRPGLPVEYLQVPSPSMGRDIKVQFQSGGNNSPAVYLLDGLRAQDDYNGWDINTPAFEWYYQSGLSIVMPVGGQSSFYSDWYSPACGKAGCQTYKWETFLTSELPQWLSANRAVKPTGSAAIGLSMAGSSAMILAAYHPQQFIYAGSLSALLDPSQGMGPSLIGLAMGDAGGYKAADMWGPSSDPAWERNDPTQQIPKLVANNTRLWVYCGNGTPNELGGANIPAEFLENFVRSSNLKFQDAYNAAGGHNAVFNFPPNGTHSWEYWGAQLNAMKGDLQSSLGAG

T93537	TARGETID	T93537
T93537	UNIPROID	S10A3_HUMAN
T93537	TARGNAME	S100 calcium-binding protein A3 (S100A3)
T93537	GENENAME	S100A3
T93537	TARGTYPE	Literature-reported
T93537	SYNONYMS	S100E; Protein S-100E
T93537	FUNCTION	Binds both calcium and zinc. May be involved in calcium-dependent cuticle cell differentiation, hair shaft and hair cuticular barrier formation.
T93537	PDBSTRUC	3NSO; 3NSL; 3NSK; 3NSI; 1KSO
T93537	BIOCLASS	S100 calcium-binding protein
T93537	SEQUENCE	MARPLEQAVAAIVCTFQEYAGRCGDKYKLCQAELKELLQKELATWTPTEFRECDYNKFMSVLDTNKDCEVDFVEYVRSLACLCLYCHEYFKDCPSEPPCSQ

T96972	TARGETID	T96972
T96972	FORMERID	TTDR00492
T96972	UNIPROID	MCM7_HUMAN
T96972	TARGNAME	DNA replication licensing factor MCM7 (MCM7)
T96972	GENENAME	MCM7
T96972	TARGTYPE	Literature-reported
T96972	SYNONYMS	P1.1-MCM3; Minichromosome maintenanceprotein 7; MCM2; CDC47 homolog; CDC47
T96972	FUNCTION	The active ATPase sites in the MCM2-7 ring are formed through the interaction surfaces of two neighboring subunits such that a critical structure of a conserved arginine finger motif is provided in trans relative to the ATP-binding site of the Walker A box of the adjacent subunit. The six ATPase active sites, however, are likely to contribute differentially to the complex helicase activity. Required for S-phase checkpoint activation upon UV-induced damage. Acts as component of the MCM2-7 complex (MCM complex) which is the putative replicative helicase essential for 'once per cell cycle' DNA replication initiation and elongation in eukaryotic cells.
T96972	BIOCLASS	Acid anhydride hydrolase
T96972	ECNUMBER	EC 3.6.4.12
T96972	SEQUENCE	MALKDYALEKEKVKKFLQEFYQDDELGKKQFKYGNQLVRLAHREQVALYVDLDDVAEDDPELVDSICENARRYAKLFADAVQELLPQYKEREVVNKDVLDVYIEHRLMMEQRSRDPGMVRSPQNQYPAELMRRFELYFQGPSSNKPRVIREVRADSVGKLVTVRGIVTRVSEVKPKMVVATYTCDQCGAETYQPIQSPTFMPLIMCPSQECQTNRSGGRLYLQTRGSRFIKFQEMKMQEHSDQVPVGNIPRSITVLVEGENTRIAQPGDHVSVTGIFLPILRTGFRQVVQGLLSETYLEAHRIVKMNKSEDDESGAGELTREELRQIAEEDFYEKLAASIAPEIYGHEDVKKALLLLLVGGVDQSPRGMKIRGNINICLMGDPGVAKSQLLSYIDRLAPRSQYTTGRGSSGVGLTAAVLRDSVSGELTLEGGALVLADQGVCCIDEFDKMAEADRTAIHEVMEQQTISIAKAGILTTLNARCSILAAANPAYGRYNPRRSLEQNIQLPAALLSRFDLLWLIQDRPDRDNDLRLAQHITYVHQHSRQPPSQFEPLDMKLMRRYIAMCREKQPMVPESLADYITAAYVEMRREAWASKDATYTSARTLLAILRLSTALARLRMVDVVEKEDVNEAIRLMEMSKDSLLGDKGQTARTQRPADVIFATVRELVSGGRSVRFSEAEQRCVSRGFTPAQFQAALDEYEELNVWQVNASRTRITFV

T80848	TARGETID	T80848
T80848	FORMERID	TTDNR00757
T80848	UNIPROID	SDC2_HUMAN
T80848	TARGNAME	Syndecan-2 (SDC2)
T80848	GENENAME	SDC2
T80848	TARGTYPE	Literature-reported
T80848	SYNONYMS	SYND2; Heparan sulfate proteoglycan core protein; HSPG1; HSPG; Fibroglycan; CD362
T80848	FUNCTION	Cell surface proteoglycan that bears heparan sulfate. Regulates dendritic arbor morphogenesis (By similarity).
T80848	PDBSTRUC	6ITH
T80848	BIOCLASS	Peptide translocating syndecan
T80848	SEQUENCE	MRRAWILLTLGLVACVSAESRAELTSDKDMYLDNSSIEEASGVYPIDDDDYASASGSGADEDVESPELTTSRPLPKILLTSAAPKVETTTLNIQNKIPAQTKSPEETDKEKVHLSDSERKMDPAEEDTNVYTEKHSDSLFKRTEVLAAVIAGGVIGFLFAIFLILLLVYRMRKKDEGSYDLGERKPSSAAYQKAPTKEFYA

T72467	TARGETID	T72467
T72467	FORMERID	TTDI03113
T72467	UNIPROID	CLCN1_HUMAN
T72467	TARGNAME	Chloride channel protein 1 (ClC-1)
T72467	GENENAME	CLCN1
T72467	TARGTYPE	Literature-reported
T72467	SYNONYMS	ClC-1; Chloride channel protein, skeletal muscle; CLC1
T72467	FUNCTION	Voltage-gated chloride channel. Plays an important role in membrane repolarization in skeletal muscle cells after muscle contraction.
T72467	PDBSTRUC	6QVU; 6QVD; 6QVC; 6QVB; 6QV6
T72467	BIOCLASS	Chloride channel
T72467	SEQUENCE	MEQSRSQQRGGEQSWWGSDPQYQYMPFEHCTSYGLPSENGGLQHRLRKDAGPRHNVHPTQIYGHHKEQFSDREQDIGMPKKTGSSSTVDSKDEDHYSKCQDCIHRLGQVVRRKLGEDGIFLVLLGLLMALVSWSMDYVSAKSLQAYKWSYAQMQPSLPLQFLVWVTFPLVLILFSALFCHLISPQAVGSGIPEMKTILRGVVLKEYLTMKAFVAKVVALTAGLGSGIPVGKEGPFVHIASICAAVLSKFMSVFCGVYEQPYYYSDILTVGCAVGVGCCFGTPLGGVLFSIEVTSTYFAVRNYWRGFFAATFSAFVFRVLAVWNKDAVTITALFRTNFRMDFPFDLKELPAFAAIGICCGLLGAVFVYLHRQVMLGVRKHKALSQFLAKHRLLYPGIVTFVIASFTFPPGMGQFMAGELMPREAISTLFDNNTWVKHAGDPESLGQSAVWIHPRVNVVIIIFLFFVMKFWMSIVATTMPIPCGGFMPVFVLGAAFGRLVGEIMAMLFPDGILFDDIIYKILPGGYAVIGAAALTGAVSHTVSTAVICFELTGQIAHILPMMVAVILANMVAQSLQPSLYDSIIQVKKLPYLPDLGWNQLSKYTIFVEDIMVRDVKFVSASYTYGELRTLLQTTTVKTLPLVDSKDSMILLGSVERSELQALLQRHLCPERRLRAAQEMARKLSELPYDGKARLAGEGLPGAPPGRPESFAFVDEDEDEDLSGKSELPPSLALHPSTTAPLSPEEPNGPLPGHKQQPEAPEPAGQRPSIFQSLLHCLLGRARPTKKKTTQDSTDLVDNMSPEEIEAWEQEQLSQPVCFDSCCIDQSPFQLVEQTTLHKTHTLFSLLGLHLAYVTSMGKLRGVLALEELQKAIEGHTKSGVQLRPPLASFRNTTSTRKSTGAPPSSAENWNLPEDRPGATGTGDVIAASPETPVPSPSPEPPLSLAPGKVEGELEELELVESPGLEEELADILQGPSLRSTDEEDEDELIL
T72467	DRUGINFO	D02FUG	S-(-)CPP	Investigative
T72467	DRUGINFO	D0YK1E	S-(-)CPB	Investigative
T72467	DRUGINFO	D0O6KR	9-anthroic acid	Investigative

T96387	TARGETID	T96387
T96387	FORMERID	TTDR00766
T96387	UNIPROID	FBPA_HAEIN
T96387	TARGNAME	Haemophilus influenzae Iron-transporter ferric ion-binding (Hae-influ fbpA)
T96387	GENENAME	Hae-influ fbpA
T96387	TARGTYPE	Literature-reported
T96387	SYNONYMS	Major ferric iron binding protein; MIRP; Iron-regulated 40 kDa protein; Fe(3+)-binding protein; Fe(+3)Iron-utilization periplasmic protein precursor-binding protein
T96387	FUNCTION	Part of the ABC transporter complex FbpABC (TC 3.A.1.10.1) involved in Fe(3+) ions import. This protein specifically binds Fe(3+) and is involved in its transmembrane transport.
T96387	PDBSTRUC	3ODB; 3OD7; 3KN8; 3KN7; 2O6A
T96387	BIOCLASS	ABC transporter
T96387	SEQUENCE	MQFKHFKLATLAAALAFSANSFADITVYNGQHKEAATAVAKAFEQETGIKVTLNSGKSEQLAGQLKEEGDKTPADVFYTEQTATFADLSEAGLLAPISEQTIQQTAQKGVPLAPKKDWIALSGRSRVVVYDHTKLSEKDMEKSVLDYATPKWKGKIGYVSTSGAFLEQVVALSKMKGDKVALNWLKGLKENGKLYAKNSVALQAVENGEVPAALINNYYWYNLAKEKGVENLKSRLYFVRHQDPGALVSYSGAAVLKASKNQAEAQKFVDFLASKKGQEALVAARAEYPLRADVVSPFNLEPYEKLEAPVVSATTAQDKEHAIKLIEEAGLK

T05828	TARGETID	T05828
T05828	FORMERID	TTDI03140
T05828	UNIPROID	CXG1_HUMAN
T05828	TARGNAME	Connexin-45 (Cx45)
T05828	GENENAME	GJC1
T05828	TARGTYPE	Literature-reported
T05828	SYNONYMS	Gap junction gamma-1 protein; Gap junction alpha-7 protein; GJA7
T05828	FUNCTION	One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell.
T05828	PDBSTRUC	3SHW
T05828	BIOCLASS	Gap junction-forming connexin
T05828	SEQUENCE	MSWSFLTRLLEEIHNHSTFVGKIWLTVLIVFRIVLTAVGGESIYYDEQSKFVCNTEQPGCENVCYDAFAPLSHVRFWVFQIILVATPSVMYLGYAIHKIAKMEHGEADKKAARSKPYAMRWKQHRALEETEEDNEEDPMMYPEMELESDKENKEQSQPKPKHDGRRRIREDGLMKIYVLQLLARTVFEVGFLIGQYFLYGFQVHPFYVCSRLPCPHKIDCFISRPTEKTIFLLIMYGVTGLCLLLNIWEMLHLGFGTIRDSLNSKRRELEDPGAYNYPFTWNTPSAPPGYNIAVKPDQIQYTELSNAKIAYKQNKANTAQEQQYGSHEENLPADLEALQREIRMAQERLDLAVQAYSHQNNPHGPREKKAKVGSKAGSNKSTASSKSGDGKTSVWI
T05828	DRUGINFO	D00VJY	octanol	Investigative

T95553	TARGETID	T95553
T95553	FORMERID	TTDI00140
T95553	UNIPROID	ARL2_HUMAN
T95553	TARGNAME	ADP-ribosylation factor-like protein 2 (ARL2)
T95553	GENENAME	ARL2
T95553	TARGTYPE	Literature-reported
T95553	SYNONYMS	ARFL2
T95553	FUNCTION	GTP-binding protein that does not act as an allosteric activator of the cholera toxin catalytic subunit. Regulates formation of new microtubules and centrosome integrity. Prevents the TBCD-induced microtubule destruction. Participates in association with TBCD, in the disassembly of the apical junction complexes. Antagonizes the effect of TBCD on epithelial cell detachment and tight and adherens junctions disassembly. Together with ARL2, plays a role in the nuclear translocation, retention and transcriptional activity of STAT3. Component of a regulated secretory pathway involved in Ca(2+)-dependent release of acetylcholine. Required for normal progress through the cell cycle. Small GTP-binding protein which cycles between an inactive GDP-bound and an active GTP-bound form, and the rate of cycling is regulated by guanine nucleotide exchange factors (GEF) and GTPase-activating proteins (GAP).
T95553	PDBSTRUC	3DOF; 3DOE
T95553	BIOCLASS	Small GTPase
T95553	SEQUENCE	MGLLTILKKMKQKERELRLLMLGLDNAGKTTILKKFNGEDIDTISPTLGFNIKTLEHRGFKLNIWDVGGQKSLRSYWRNYFESTDGLIWVVDSADRQRMQDCQRELQSLLVEERLAGATLLIFANKQDLPGALSSNAIREVLELDSIRSHHWCIQGCSAVTGENLLPGIDWLLDDISSRIFTAD

T93147	TARGETID	T93147
T93147	UNIPROID	TAGL2_HUMAN
T93147	TARGNAME	Transgelin-2 (TAGLN2)
T93147	GENENAME	TAGLN2
T93147	TARGTYPE	Literature-reported
T93147	SYNONYMS	SM22-alpha homolog; KIAA0120; Epididymis tissue protein Li 7e
T93147	FUNCTION	cytosol, extracellular exosome, extracellular region, vesicle, cadherin binding, epithelial cell differentiation, platelet degranulation.
T93147	PDBSTRUC	1WYM
T93147	BIOCLASS	Calponin family
T93147	SEQUENCE	MANRGPAYGLSREVQQKIEKQYDADLEQILIQWITTQCRKDVGRPQPGRENFQNWLKDGTVLCELINALYPEGQAPVKKIQASTMAFKQMEQISQFLQAAERYGINTTDIFQTVDLWEGKNMACVQRTLMNLGGLAVARDDGLFSGDPNWFPKKSKENPRNFSDNQLQEGKNVIGLQMGTNRGASQAGMTGYGMPRQIL

T90122	TARGETID	T90122
T90122	FORMERID	TTDI01359
T90122	UNIPROID	QSEC_ECOLI
T90122	TARGNAME	Bacterial Sensor protein QseC (Bact QseC)
T90122	GENENAME	Bact QseC
T90122	TARGTYPE	Literature-reported
T90122	SYNONYMS	Sensor protein QseC
T90122	FUNCTION	Member of a two-component regulatory system QseB/QseC. Activates the flagella regulon by activating transcription of FlhDC. May activate QseB by phosphorylation.
T90122	PDBSTRUC	3JZ3; 2KSE
T90122	ECNUMBER	EC 2.7.13.3
T90122	SEQUENCE	MKFTQRLSLRVRLTLIFLILASVTWLLSSFVAWKQTTDNVDELFDTQLMLFAKRLSTLDLNEINAADRMAQTPNRLKHGHVDDDALTFAIFTHDGRMVLNDGDNGEDIPYSYQREGFADGQLVGEDDPWRFVWMTSPDGKYRIVVGQEWEYREDMALAIVAGQLIPWLVALPIMLIIMMVLLGRELAPLNKLALALRMRDPDSEKPLNATGVPSEVRPLVESLNQLFARTHAMMVRERRFTSDAAHELRSPLTALKVQTEVAQLSDDDPQARKKALLQLHSGIDRATRLVDQLLTLSRLDSLDNLQDVAEIPLEDLLQSSVMDIYHTAQQAKIDVRLTLNAHSIKRTGQPLLLSLLVRNLLDNAVRYSPQGSVVDVTLNADNFIVRDNGPGVTPEALARIGERFYRPPGQTATGSGLGLSIVQRIAKLHGMNVEFGNAEQGGFEAKVSW

T20585	TARGETID	T20585
T20585	FORMERID	TTDNR00750
T20585	UNIPROID	STAT6_HUMAN
T20585	TARGNAME	Signal transducer and activator of transcription 6 (STAT6)
T20585	GENENAME	STAT6
T20585	TARGTYPE	Literature-reported
T20585	SYNONYMS	IL-4 Stat
T20585	FUNCTION	Involved in IL4/interleukin-4- and IL3/interleukin-3-mediated signaling. Carries out a dual function: signal transduction and activation of transcription.
T20585	PDBSTRUC	5NWX; 5NWM; 5D39; 4Y5W; 4Y5U
T20585	BIOCLASS	Transcription factor
T20585	SEQUENCE	MSLWGLVSKMPPEKVQRLYVDFPQHLRHLLGDWLESQPWEFLVGSDAFCCNLASALLSDTVQHLQASVGEQGEGSTILQHISTLESIYQRDPLKLVATFRQILQGEKKAVMEQFRHLPMPFHWKQEELKFKTGLRRLQHRVGEIHLLREALQKGAEAGQVSLHSLIETPANGTGPSEALAMLLQETTGELEAAKALVLKRIQIWKRQQQLAGNGAPFEESLAPLQERCESLVDIYSQLQQEVGAAGGELEPKTRASLTGRLDEVLRTLVTSCFLVEKQPPQVLKTQTKFQAGVRFLLGLRFLGAPAKPPLVRADMVTEKQARELSVPQGPGAGAESTGEIINNTVPLENSIPGNCCSALFKNLLLKKIKRCERKGTESVTEEKCAVLFSASFTLGPGKLPIQLQALSLPLVVIVHGNQDNNAKATILWDNAFSEMDRVPFVVAERVPWEKMCETLNLKFMAEVGTNRGLLPEHFLFLAQKIFNDNSLSMEAFQHRSVSWSQFNKEILLGRGFTFWQWFDGVLDLTKRCLRSYWSDRLIIGFISKQYVTSLLLNEPDGTFLLRFSDSEIGGITIAHVIRGQDGSPQIENIQPFSAKDLSIRSLGDRIRDLAQLKNLYPKKPKDEAFRSHYKPEQMGKDGRGYVPATIKMTVERDQPLPTPELQMPTMVPSYDLGMAPDSSMSMQLGPDMVPQVYPPHSHSIPPYQGLSPEESVNVLSAFQEPHLQMPPSLGQMSLPFDQPHPQGLLPCQPQEHAVSSPDPLLCSDVTMVEDSCLSQPVTAFPQGTWIGEDIFPPLLPPTEQDLTKLLLEGQGESGGGSLGAQPLLQPSHYGQSGISMSHMDLRANPSW

T36456	TARGETID	T36456
T36456	FORMERID	TTDI02563
T36456	UNIPROID	HUTH_HUMAN
T36456	TARGNAME	Histidine ammonia-lyase (HAL)
T36456	GENENAME	HAL
T36456	TARGTYPE	Literature-reported
T36456	SYNONYMS	Histidine ammonialyase; Histidase; HIS
T36456	FUNCTION	Histidine ammonia-lyase activity, histidine catabolic process.
T36456	BIOCLASS	Carbon-nitrogen lyase
T36456	ECNUMBER	EC 4.3.1.3
T36456	SEQUENCE	MPRYTVHVRGEWLAVPCQDAQLTVGWLGREAVRRYIKNKPDNGGFTSVDDAHFLVRRCKGLGLLDNEDRLEVALENNEFVEVVIEGDAMSPDFIPSQPEGVYLYSKYREPEKYIELDGDRLTTEDLVNLGKGRYKIKLTPTAEKRVQKSREVIDSIIKEKTVVYGITTGFGKFARTVIPINKLQELQVNLVRSHSSGVGKPLSPERCRMLLALRINVLAKGYSGISLETLKQVIEMFNASCLPYVPEKGTVGASGDLAPLSHLALGLVGEGKMWSPKSGWADAKYVLEAHGLKPVILKPKEGLALINGTQMITSLGCEAVERASAIARQADIVAALTLEVLKGTTKAFDTDIHALRPHRGQIEVAFRFRSLLDSDHHPSEIAESHRFCDRVQDAYTLRCCPQVHGVVNDTIAFVKNIITTELNSATDNPMVFANRGETVSGGNFHGEYPAKALDYLAIGIHELAAISERRIERLCNPSLSELPAFLVAEGGLNSGFMIAHCTAAALVSENKALCHPSSVDSLSTSAATEDHVSMGGWAARKALRVIEHVEQVLAIELLAACQGIEFLRPLKTTTPLEKVYDLVRSVVRPWIKDRFMAPDIEAAHRLLLEQKVWEVAAPYIEKYRMEHIPESRPLSPTAFSLQFLHKKSTKIPESEDL

T32590	TARGETID	T32590
T32590	FORMERID	TTDI03606
T32590	UNIPROID	TXK_HUMAN
T32590	TARGNAME	Tyrosine-protein kinase TXK (TXK)
T32590	GENENAME	TXK
T32590	TARGTYPE	Literature-reported
T32590	SYNONYMS	Resting lymphocyte kinase; RLK; Protein-tyrosine kinase 4; PTK4
T32590	FUNCTION	Non-receptor tyrosine kinase that plays a redundant role with ITK in regulation of the adaptive immune response. Regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells. When antigen presenting cells (APC) activate T-cell receptor (TCR), a series of phosphorylation lead to the recruitment of TXK to the cell membrane, where it is phosphorylated at Tyr-420. Phosphorylation leads to TXK full activation. Contributes also to signaling from many receptors and participates in multiple downstream pathways, including regulation of the actin cytoskeleton. Like ITK, can phosphorylate PLCG1, leading to its localization in lipid rafts and activation, followed by subsequent cleavage of its substrates. In turn, the endoplasmic reticulum releases calcium in the cytoplasm and the nuclear activator of activated T-cells (NFAT) translocates into the nucleus to perform its transcriptional duty. With PARP1 and EEF1A1, TXK forms a complex that acts as a T-helper 1 (Th1) cell-specific transcription factor and binds the promoter of IFNG to directly regulate its transcription, and is thus involved importantly in Th1 cytokine production. Phosphorylates both PARP1 and EEF1A1. Phosphorylates also key sites in LCP2 leading to the up-regulation of Th1 preferred cytokine IL-2. Phosphorylates 'Tyr-201' of CTLA4 which leads to the association of PI-3 kinase with the CTLA4 receptor.
T32590	PDBSTRUC	2DM0
T32590	ECNUMBER	EC 2.7.10.2
T32590	SEQUENCE	MILSSYNTIQSVFCCCCCCSVQKRQMRTQISLSTDEELPEKYTQRRRPWLSQLSNKKQSNTGRVQPSKRKPLPPLPPSEVAEEKIQVKALYDFLPREPCNLALRRAEEYLILEKYNPHWWKARDRLGNEGLIPSNYVTENKITNLEIYEWYHRNITRNQAEHLLRQESKEGAFIVRDSRHLGSYTISVFMGARRSTEAAIKHYQIKKNDSGQWYVAERHAFQSIPELIWYHQHNAAGLMTRLRYPVGLMGSCLPATAGFSYEKWEIDPSELAFIKEIGSGQFGVVHLGEWRSHIQVAIKAINEGSMSEEDFIEEAKVMMKLSHSKLVQLYGVCIQRKPLYIVTEFMENGCLLNYLRENKGKLRKEMLLSVCQDICEGMEYLERNGYIHRDLAARNCLVSSTCIVKISDFGMTRYVLDDEYVSSFGAKFPIKWSPPEVFLFNKYSSKSDVWSFGVLMWEVFTEGKMPFENKSNLQVVEAISEGFRLYRPHLAPMSIYEVMYSCWHEKPEGRPTFAELLRAVTEIAETW
T32590	DRUGINFO	D04TLI	PMID17600705C23	Investigative
T32590	DRUGINFO	D01RHR	PMID24915291C31	Investigative
T32590	DRUGINFO	D06BJG	PMID24915291C38	Investigative

T87756	TARGETID	T87756
T87756	FORMERID	TTDR00701
T87756	UNIPROID	IGA1_HAEIF
T87756	TARGNAME	Haemophilus influenzae Immunoglobulin A1 protease (Hae-influ iga)
T87756	GENENAME	Hae-influ iga
T87756	TARGTYPE	Literature-reported
T87756	SYNONYMS	iga; IGA1 protease
T87756	FUNCTION	Virulence factor; cleaves host immunoglobulin A producing intact Fc and Fab fragments.
T87756	BIOCLASS	Peptidase
T87756	ECNUMBER	EC 3.4.21.72
T87756	SEQUENCE	MLNKKFKLNFIALTVAYALTPYTEAALVRDDVDYQIFRDFAENKGKFSVGATNVLVKDKNNKDLGTALPNGIPMIDFSVVDVDKRIATLINPQYVVGVKHVSNGVSELHFGNLNGNMNNGNAKAHRDVSSEENRYFSVEKNEYPTKLNGKTVTTEDQTQKRREDYYMPRLDKFVTEVAPIEASTASSDAGTYNDQNKYPAFVRLGSGSQFIYKKGDNYSLILNNHEVGGNNLKLVGDAYTYGIAGTPYKVNHENNGLIGFGNSKEEHSDPKGILSQDPLTNYAVLGDSGSPLFVYDREKGKWLFLGSYDFWAGYNKKSWQEWNIYKSQFTKDVLNKDSAGSLIGSKTDYSWSSNGKTSTITGGEKSLNVDLADGKDKPNHGKSVTFEGSGTLTLNNNIDQGAGGLFFEGDYEVKGTSDNTTWKGAGVSVAEGKTVTWKVHNPQYDRLAKIGKGTLIVEGTGDNKGSLKVGDGTVILKQQTNGSGQHAFASVGIVSGRSTLVLNDDKQVDPNSIYFGFRGGRLDLNGNSLTFDHIRNIDDGARLVNHNMTNASNITITGESLITDPNTITPYNIDAPDEDNPYAFRRIKDGGQLYLNLENYTYYALRKGASTRSELPKNSGESNENWLYMGKTSDEAKRNVMNHINNERMNGFNGYFGEEEGKNNGNLNVTFKGKSEQNRFLLTGGTNLNGDLTVEKGTLFLSGRPTPHARDIAGISSTKKDPHFAENNEVVVEDDWINRNFKATTMNVTGNASLYSGRNVANITSNITASNKAQVHIGYKTGDTVCVRSDYTGYVTCTTDKLSDKALNSFNPTNLRGNVNLTESANFVLGKANLFGTIQSRGNSQVRLTENSHWHLTGNSDVHQLDLANGHIHLNSADNSNNVTKYNTLTVNSLSGNGSFYYLTDLSNKQGDKVVVTKSATGNFTLQVADKTGEPNHNELTLFDASKAQRDHLNVSLVGNTVDLGAWKYKLRNVNGRYDLYNPEVEKRNQTVDTTNITTPNNIQADVPSVPSNNEEIARVDEAPVPPPAPATPSETTETVAENSKQESKTVEKNEQDATETTAQNREVAKEAKSNVKANTQTNEVAQSGSETKETQTTETKETATVEKEEKAKVETEKTQEVPKVTSQVSPKQEQSETVQPQAEPARENDPTVNIKEPQSQTNTTADTEQPAKETSSNVEQPVTESTTVNTGNSVVENPENTTPATTQPTVNSESSNKPKNRHRRSVRSVPHNVEPATTSSNDRSTVALCDLTSTNTNAVLSDARAKAQFVALNVGKAVSQHISQLEMNNEGQYNVWVSNTSMNKNYSSSQYRRFSSKSTQTQLGWDQTISNNVQLGGVFTYVRNSNNFDKATSKNTLAQVNFYSKYYADNHWYLGIDLGYGKFQSKLQTNHNAKFARHTAQFGLTAGKAFNLGNFGITPIVGVRYSYLSNADFALDQARIKVNPISVKTAFAQVDLSYTYHLGEFSVTPILSARYDANQGSGKINVNGYDFAYNVENQQQYNAGLKLKYHNVKLSLIGGLTKAKQAEKQKTAELKLSFSF

T95438	TARGETID	T95438
T95438	FORMERID	TTDNR00670
T95438	UNIPROID	EAA2_HUMAN
T95438	TARGNAME	Excitatory amino acid transporter 2 (SLC1A2)
T95438	GENENAME	SLC1A2
T95438	TARGTYPE	Literature-reported
T95438	SYNONYMS	Solute carrier family 1 member 2; Sodium-dependent glutamate/aspartate transporter 2; Glutamate/aspartatetransporter II; Glutamate/aspartate transporter II; GLT1; EAAT2
T95438	FUNCTION	Functions as a symporter that transports one amino acid molecule together with two or three Na(+) ions and one proton, in parallel with the counter-transport of one K(+) ion. Mediates Cl(-) flux that is not coupled to amino acid transport; this avoids the accumulation of negative charges due to aspartate and Na(+) symport. Essential for the rapid removal of released glutamate from the synaptic cleft, and for terminating the postsynaptic action of glutamate. Sodium-dependent, high-affinity amino acid transporter that mediates the uptake of L-glutamate and also L-aspartate and D-aspartate.
T95438	BIOCLASS	Dicarboxylate/amino acid:cation symporter
T95438	SEQUENCE	MASTEGANNMPKQVEVRMHDSHLGSEEPKHRHLGLRLCDKLGKNLLLTLTVFGVILGAVCGGLLRLASPIHPDVVMLIAFPGDILMRMLKMLILPLIISSLITGLSGLDAKASGRLGTRAMVYYMSTTIIAAVLGVILVLAIHPGNPKLKKQLGPGKKNDEVSSLDAFLDLIRNLFPENLVQACFQQIQTVTKKVLVAPPPDEEANATSAVVSLLNETVTEVPEETKMVIKKGLEFKDGMNVLGLIGFFIAFGIAMGKMGDQAKLMVDFFNILNEIVMKLVIMIMWYSPLGIACLICGKIIAIKDLEVVARQLGMYMVTVIIGLIIHGGIFLPLIYFVVTRKNPFSFFAGIFQAWITALGTASSAGTLPVTFRCLEENLGIDKRVTRFVLPVGATINMDGTALYEAVAAIFIAQMNGVVLDGGQIVTVSLTATLASVGAASIPSAGLVTMLLILTAVGLPTEDISLLVAVDWLLDRMRTSVNVVGDSFGAGIVYHLSKSELDTIDSQHRVHEDIEMTKTQSIYDDMKNHRESNSNQCVYAAHNSVIVDECKVTLAANGKSADCSVEEEPWKREK
T95438	DRUGINFO	D02JJX	WAY-213613	Investigative
T95438	DRUGINFO	D04MSI	threo-3-methylglutamate	Investigative
T95438	DRUGINFO	D07CIW	[3H]ETB-TBOA	Investigative
T95438	DRUGINFO	D07GUB	DL-TBOA	Investigative
T95438	DRUGINFO	D0S8AN	SYM2081	Investigative
T95438	DRUGINFO	D08CAB	D-aspartic acid	Investigative

T67163	TARGETID	T67163
T67163	FORMERID	TTDR00554
T67163	UNIPROID	NR4A2_HUMAN
T67163	TARGNAME	Orphan nuclear receptor NURR1 (NR4A2)
T67163	GENENAME	NR4A2
T67163	TARGTYPE	Literature-reported
T67163	SYNONYMS	Transcriptionally-inducible nuclear receptor; Transcriptionally inducible nuclear receptor; TINUR; Nuclear receptor subfamily 4 group A member 2; NURR1; NOT; Immediate-early response protein NOT
T67163	FUNCTION	It is crucial for expression of a set of genes such as SLC6A3, SLC18A2, TH and DRD2 which are essential for development of mdDA neurons. Transcriptional regulator which is important for the differentiation and maintenance of meso-diencephalic dopaminergic (mdDA) neurons during development.
T67163	PDBSTRUC	6DDA; 5YD6; 5Y41; 1OVL
T67163	BIOCLASS	Nuclear hormone receptor
T67163	SEQUENCE	MPCVQAQYGSSPQGASPASQSYSYHSSGEYSSDFLTPEFVKFSMDLTNTEITATTSLPSFSTFMDNYSTGYDVKPPCLYQMPLSGQQSSIKVEDIQMHNYQQHSHLPPQSEEMMPHSGSVYYKPSSPPTPTTPGFQVQHSPMWDDPGSLHNFHQNYVATTHMIEQRKTPVSRLSLFSFKQSPPGTPVSSCQMRFDGPLHVPMNPEPAGSHHVVDGQTFAVPNPIRKPASMGFPGLQIGHASQLLDTQVPSPPSRGSPSNEGLCAVCGDNAACQHYGVRTCEGCKGFFKRTVQKNAKYVCLANKNCPVDKRRRNRCQYCRFQKCLAVGMVKEVVRTDSLKGRRGRLPSKPKSPQEPSPPSPPVSLISALVRAHVDSNPAMTSLDYSRFQANPDYQMSGDDTQHIQQFYDLLTGSMEIIRGWAEKIPGFADLPKADQDLLFESAFLELFVLRLAYRSNPVEGKLIFCNGVVLHRLQCVRGFGEWIDSIVEFSSNLQNMNIDISAFSCIAALAMVTERHGLKEPKRVEELQNKIVNCLKDHVTFNNGGLNRPNYLSKLLGKLPELRTLCTQGLQRIFYLKLEDLVPPPAIIDKLFLDTLPF

T51817	TARGETID	T51817
T51817	FORMERID	TTDR00488
T51817	UNIPROID	GATA4_HUMAN
T51817	TARGNAME	GATA-binding factor 4 (GATA4)
T51817	GENENAME	GATA4
T51817	TARGTYPE	Literature-reported
T51817	SYNONYMS	Transcription factor GATA-4; GATA-4; GATA binding factor-4
T51817	FUNCTION	In cooperation with TBX5, it binds to cardiac super-enhancers and promotes cardiomyocyte gene expression, while it downregulates endocardial and endothelial gene expression. Involved in bone morphogenetic protein (BMP)-mediated induction of cardiac-specific gene expression. Binds to BMP response element (BMPRE) DNA sequences within cardiac activating regions. Acts as a transcriptional activator of ANF in cooperation with NKX2-5. Promotes cardiac myocyte enlargement. Required during testicular development. May play a role in sphingolipid signaling by regulating the expression of sphingosine-1-phosphate degrading enzyme, spingosine-1-phosphate lyase. Transcriptional activator that binds to the consensus sequence 5'-AGATAG-3' and plays a key role in cardiac development and function.
T51817	PDBSTRUC	2M9W
T51817	BIOCLASS	Zinc-finger
T51817	SEQUENCE	MYQSLAMAANHGPPPGAYEAGGPGAFMHGAGAASSPVYVPTPRVPSSVLGLSYLQGGGAGSASGGASGGSSGGAASGAGPGTQQGSPGWSQAGADGAAYTPPPVSPRFSFPGTTGSLAAAAAAAAAREAAAYSSGGGAAGAGLAGREQYGRAGFAGSYSSPYPAYMADVGASWAAAAAASAGPFDSPVLHSLPGRANPAARHPNLDMFDDFSEGRECVNCGAMSTPLWRRDGTGHYLCNACGLYHKMNGINRPLIKPQRRLSASRRVGLSCANCQTTTTTLWRRNAEGEPVCNACGLYMKLHGVPRPLAMRKEGIQTRKRKPKNLNKSKTPAAPSGSESLPPASGASSNSSNATTSSSEEMRPIKTEPGLSSHYGHSSSVSQTFSVSAMSGHGPSIHPVLSALKLSPQGYASPVSQSPQTSSKQDSWNSLVLADSHGDIITA

T23831	TARGETID	T23831
T23831	FORMERID	TTDR00602
T23831	UNIPROID	NADR_HAEIN
T23831	TARGNAME	Haemophilus influenzae NadR protein (Hae-influ nadR)
T23831	GENENAME	Hae-influ nadR
T23831	TARGTYPE	Literature-reported
T23831	SYNONYMS	nadR; Transcriptional regulator nadR
T23831	FUNCTION	This enzyme has twoactivities: nicotinamide mononucleotide (NMN) adenylyltransferase and ribosylnicotinamide (RN) kinase. The RN kinase activity catalyzes the phosphorylation of RN to form nicotinamide ribonucleotide. The NMN adenylyltransferase activity catalyzes the transfer of the AMP moiety of ATP to nicotinamide ribonucleotide to form NAD(+).
T23831	PDBSTRUC	1LW7
T23831	BIOCLASS	Nicotinamide ribonucleoside uptake permease
T23831	SEQUENCE	MGFTTGREFHPALRMRAKYNAKYLGTKSEREKYFHLAYNKHTQFLRYQEQIMSKTKEKKVGVIFGKFYPVHTGHINMIYEAFSKVDELHVIVCSDTVRDLKLFYDSKMKRMPTVQDRLRWMQQIFKYQKNQIFIHHLVEDGIPSYPNGWQSWSEAVKTLFHEKHFEPSIVFSSEPQDKAPYEKYLGLEVSLVDPDRTFFNVSATKIRTTPFQYWKFIPKEARPFFAKTVAILGGESSGKSVLVNKLAAVFNTTSAWEYGREFVFEKLGGDEQAMQYSDYPQMALGHQRYIDYAVRHSHKIAFIDTDFITTQAFCIQYEGKAHPFLDSMIKEYPFDVTILLKNNTEWVDDGLRSLGSQKQRQQFQQLLKKLLDKYKVPYIEIESPSYLDRYNQVKAVIEKVLNEEEISELQNTTFPIKGTSQ
T23831	DRUGINFO	D0R6JE	Nicotinamide-Adenine-Dinucleotide	Investigative

T05887	TARGETID	T05887
T05887	FORMERID	TTDR00689
T05887	UNIPROID	TNNT2_HUMAN
T05887	TARGNAME	Cardiac muscle troponin T (TNNT2)
T05887	GENENAME	TNNT2
T05887	TARGTYPE	Literature-reported
T05887	SYNONYMS	TnTC; TNNT2; Cardiac troponin C (cTnC); CTnT
T05887	FUNCTION	Troponin T is the tropomyosin-binding subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity.
T05887	PDBSTRUC	4Y99; 1J1E; 1J1D
T05887	BIOCLASS	Troponin
T05887	SEQUENCE	MSDIEEVVEEYEEEEQEEAAVEEEEDWREDEDEQEEAAEEDAEAEAETEETRAEEDEEEEEAKEAEDGPMEESKPKPRSFMPNLVPPKIPDGERVDFDDIHRKRMEKDLNELQALIEAHFENRKKEEEELVSLKDRIERRRAERAEQQRIRNEREKERQNRLAEERARREEEENRRKAEDEARKKKALSNMMHFGGYIQKQAQTERKSGKRQTEREKKKKILAERRKVLAIDHLNEDQLREKAKELWQSIYNLEAEKFDLQEKFKQQKYEINVLRNRINDNQKVSKTRGKAKVTGRWK

T54526	TARGETID	T54526
T54526	FORMERID	TTDR01085
T54526	UNIPROID	GPMI_MYCGE
T54526	TARGNAME	Mycobacterium Bisphosphoglycerate phosphoglycerate mutase (MycB gpmI)
T54526	GENENAME	MycB gpmI
T54526	TARGTYPE	Literature-reported
T54526	SYNONYMS	gpmI; Phosphoglyceromutase; Phosphoglycerate mutase; IPGM; BPG-independent PGAM
T54526	FUNCTION	Catalyzes the interconversion of 2-phosphoglycerate and 3-phosphoglycerate.
T54526	BIOCLASS	Intramolecular transferases
T54526	SEQUENCE	MHKKVLLAILDGYGISNAIYGNAVQNANTPMLDELINSYPCVLLDASGEAVGLPMGQIGNSEVGHLNIGAGRVVYTGLSLINQHIKDRSFFANKAFLKTIEHVEKNHSKIHLIGLFSNGGVHSHNEHLLALIELFSKHAKVVLHLFGDGRDVAPCSLKQDLEKLMIFLKNYPNVVIGTIGGRYYGMDRDQRWDREMIAYKALLGVSKNKFNDPIGYIETQYQNQITDEFIYPAINANLNSDQFALNNNDGVIFFNFRPDRARQMSHLIFNSNYYNYQPELKRKENLFFVTMMNYEGIVPSEFAFPPQTIKNSLGEVIANNNLKQLRIAETEKYAHVTFFFDGGFEVNLSNETKTLIPSLKVATYDLAPEMSCKAITDALLEKLNNFDFTVLNFANPDMVGHTGNYQACIKALEALDVQIKRIVDFCKANQITMFLTADHGNAEVMIDNNNNPVTKHTINPVPFVCTDKNVNFNQTGILANIAPTILEYLNLSKPKEMTAKSLLKNNN
T54526	DRUGINFO	D0V6EH	Clorsulon	Investigative
T54526	DRUGINFO	D0WQ7U	3-Phosphoglyceric Acid	Investigative
T54526	DRUGINFO	D03KBV	2-Phosphoglyceric Acid	Investigative

T64245	TARGETID	T64245
T64245	FORMERID	TTDR00462
T64245	UNIPROID	TNFL6_HUMAN
T64245	TARGNAME	Apoptosis antigen ligand (CD178)
T64245	GENENAME	FASLG
T64245	TARGTYPE	Literature-reported
T64245	SYNONYMS	Tumor necrosis factor ligand superfamily member 6; TNFSF6; FasL; Fas ligand; FAS antigen ligand; CD95L; CD95-L; CD95 ligand; CD178 antigen; CD178; APTL; APT1LG1
T64245	FUNCTION	Involved in cytotoxic T-cell-mediated apoptosis, natural killer cell-mediated apoptosis and in T-cell development. Initiates fratricidal/suicidal activation-induced cell death (AICD) in antigen-activated T-cells contributing to the termination of immune responses. TNFRSF6/FAS-mediated apoptosis has also a role in the induction of peripheral tolerance. Binds to TNFRSF6B/DcR3, a decoy receptor that blocks apoptosis. Cytokine that binds to TNFRSF6/FAS, a receptor that transduces the apoptotic signal into cells.
T64245	PDBSTRUC	5L36; 5L19; 4MSV; 1BZI
T64245	BIOCLASS	Cytokine: tumor necrosis factor
T64245	SEQUENCE	MQQPFNYPYPQIYWVDSSASSPWAPPGTVLPCPTSVPRRPGQRRPPPPPPPPPLPPPPPPPPLPPLPLPPLKKRGNHSTGLCLLVMFFMVLVALVGLGLGMFQLFHLQKELAELRESTSQMHTASSLEKQIGHPSPPPEKKELRKVAHLTGKSNSRSMPLEWEDTYGIVLLSGVKYKKGGLVINETGLYFVYSKVYFRGQSCNNLPLSHKVYMRNSKYPQDLVMMEGKMMSYCTTGQMWARSSYLGAVFNLTSADHLYVNVSELSLVNFEESQTFFGLYKL

T07740	TARGETID	T07740
T07740	FORMERID	TTDI03317
T07740	UNIPROID	KCNJ4_HUMAN
T07740	TARGNAME	Inward rectifier potassium channel Kir2.3 (KCNJ4)
T07740	GENENAME	KCNJ4
T07740	TARGTYPE	Literature-reported
T07740	SYNONYMS	Potassium channel, inwardly rectifying subfamily J member 4; Inward rectifier potassium channel 4; Inward rectifier K(+) channel Kir2.3; IRK3; IRK-3; Hippocampal inward rectifier; HRK1; HIRK2; HIR
T07740	FUNCTION	Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. Can be blocked by extracellular barium and cesium (By similarity).
T07740	PDBSTRUC	3GJ9
T07740	BIOCLASS	Inward rectifier potassium channel
T07740	SEQUENCE	MHGHSRNGQAHVPRRKRRNRFVKKNGQCNVYFANLSNKSQRYMADIFTTCVDTRWRYMLMIFSAAFLVSWLFFGLLFWCIAFFHGDLEASPGVPAAGGPAAGGGGAAPVAPKPCIMHVNGFLGAFLFSVETQTTIGYGFRCVTEECPLAVIAVVVQSIVGCVIDSFMIGTIMAKMARPKKRAQTLLFSHHAVISVRDGKLCLMWRVGNLRKSHIVEAHVRAQLIKPYMTQEGEYLPLDQRDLNVGYDIGLDRIFLVSPIIIVHEIDEDSPLYGMGKEELESEDFEIVVILEGMVEATAMTTQARSSYLASEILWGHRFEPVVFEEKSHYKVDYSRFHKTYEVAGTPCCSARELQESKITVLPAPPPPPSAFCYENELALMSQEEEEMEEEAAAAAAVAAGLGLEAGSKEEAGIIRMLEFGSHLDLERMQASLPLDNISYRRESAI
T07740	DRUGINFO	D07LZY	rose bengal (photoactivated)	Investigative
T07740	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T38012	TARGETID	T38012
T38012	FORMERID	TTDI02593
T38012	UNIPROID	KCNJ3_HUMAN
T38012	TARGNAME	Inward rectifier potassium channel Kir3.1 (KCNJ3)
T38012	GENENAME	KCNJ3
T38012	TARGTYPE	Literature-reported
T38012	SYNONYMS	Potassium channel, inwardly rectifying subfamily J member 3; KCNJ3; Inward rectifier K(+) channel Kir3.1; GIRK1; G proteinactivated inward rectifier potassium channel 1
T38012	FUNCTION	This potassium channel is controlled byG proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. This receptor plays a crucial role in regulating the heartbeat.
T38012	BIOCLASS	Inward rectifier potassium channel
T38012	SEQUENCE	MSALRRKFGDDYQVVTTSSSGSGLQPQGPGQDPQQQLVPKKKRQRFVDKNGRCNVQHGNLGSETSRYLSDLFTTLVDLKWRWNLFIFILTYTVAWLFMASMWWVIAYTRGDLNKAHVGNYTPCVANVYNFPSAFLFFIETEATIGYGYRYITDKCPEGIILFLFQSILGSIVDAFLIGCMFIKMSQPKKRAETLMFSEHAVISMRDGKLTLMFRVGNLRNSHMVSAQIRCKLLKSRQTPEGEFLPLDQLELDVGFSTGADQLFLVSPLTICHVIDAKSPFYDLSQRSMQTEQFEIVVILEGIVETTGMTCQARTSYTEDEVLWGHRFFPVISLEEGFFKVDYSQFHATFEVPTPPYSVKEQEEMLLMSSPLIAPAITNSKERHNSVECLDGLDDITTKLPSKLQKITGREDFPKKLLRMSSTTSEKAYSLGDLPMKLQRISSVPGNSEEKLVSKTTKMLSDPMSQSVADLPPKLQKMAGGAARMEGNLPAKLRKMNSDRFT
T38012	DRUGINFO	D0E3FR	ML297	Investigative
T38012	DRUGINFO	D07ZAJ	PIP2	Investigative

T69420	TARGETID	T69420
T69420	UNIPROID	GSHB_HUMAN
T69420	TARGNAME	Glutathione synthetase (GSS)
T69420	GENENAME	GSS
T69420	TARGTYPE	Literature-reported
T69420	SYNONYMS	Glutathione synthase; GSH-S; GSH synthetase
T69420	FUNCTION	Catalyzes the oxidation of GSH to glutathione disulfide (GSSG) by reducing free radicals and reactive oxygen species such as hydrogen peroxide. Uses GSH to clean up various metabolites, xenobiotics, and electrophiles to mercapturates for excretion.
T69420	PDBSTRUC	2HGS
T69420	ECNUMBER	EC 6.3.2.3
T69420	SEQUENCE	MATNWGSLLQDKQQLEELARQAVDRALAEGVLLRTSQEPTSSEVVSYAPFTLFPSLVPSALLEQAYAVQMDFNLLVDAVSQNAAFLEQTLSSTIKQDDFTARLFDIHKQVLKEGIAQTVFLGLNRSDYMFQRSADGSPALKQIEINTISASFGGLASRTPAVHRHVLSVLSKTKEAGKILSNNPSKGLALGIAKAWELYGSPNALVLLIAQEKERNIFDQRAIENELLARNIHVIRRTFEDISEKGSLDQDRRLFVDGQEIAVVYFRDGYMPRQYSLQNWEARLLLERSHAAKCPDIATQLAGTKKVQQELSRPGMLEMLLPGQPEAVARLRATFAGLYSLDVGEEGDQAIAEALAAPSRFVLKPQREGGGNNLYGEEMVQALKQLKDSEERASYILMEKIEPEPFENCLLRPGSPARVVQCISELGIFGVYVRQEKTLVMNKHVGHLLRTKAIEHADGGVAAGVAVLDNPYPV

T74448	TARGETID	T74448
T74448	FORMERID	TTDI02441
T74448	UNIPROID	CD97_HUMAN
T74448	TARGNAME	Leukocyte antigen CD97 (CD97)
T74448	GENENAME	CD97
T74448	TARGTYPE	Literature-reported
T74448	SYNONYMS	CD97 antigen subunit beta; CD97 antigen
T74448	FUNCTION	Plays an essential role in leukocyte migration. Receptor potentially involved in both adhesion and signaling processes early after leukocyte activation.
T74448	PDBSTRUC	2BOU
T74448	BIOCLASS	GPCR secretin
T74448	SEQUENCE	MGGRVFLAFCVWLTLPGAETQDSRGCARWCPQNSSCVNATACRCNPGFSSFSEIITTPTETCDDINECATPSKVSCGKFSDCWNTEGSYDCVCSPGYEPVSGAKTFKNESENTCQDVDECQQNPRLCKSYGTCVNTLGSYTCQCLPGFKFIPEDPKVCTDVNECTSGQNPCHSSTHCLNNVGSYQCRCRPGWQPIPGSPNGPNNTVCEDVDECSSGQHQCDSSTVCFNTVGSYSCRCRPGWKPRHGIPNNQKDTVCEDMTFSTWTPPPGVHSQTLSRFFDKVQDLGRDSKTSSAEVTIQNVIKLVDELMEAPGDVEALAPPVRHLIATQLLSNLEDIMRILAKSLPKGPFTYISPSNTELTLMIQERGDKNVTMGQSSARMKLNWAVAAGAEDPGPAVAGILSIQNMTTLLANASLNLHSKKQAELEEIYESSIRGVQLRRLSAVNSIFLSHNNTKELNSPILFAFSHLESSDGEAGRDPPAKDVMPGPRQELLCAFWKSDSDRGGHWATEGCQVLGSKNGSTTCQCSHLSSFAILMAHYDVEDWKLTLITRVGLALSLFCLLLCILTFLLVRPIQGSRTTIHLHLCICLFVGSTIFLAGIENEGGQVGLRCRLVAGLLHYCFLAAFCWMSLEGLELYFLVVRVFQGQGLSTRWLCLIGYGVPLLIVGVSAAIYSKGYGRPRYCWLDFEQGFLWSFLGPVTFIILCNAVIFVTTVWKLTQKFSEINPDMKKLKKARALTITAIAQLFLLGCTWVFGLFIFDDRSLVLTYVFTILNCLQGAFLYLLHCLLNKKVREEYRKWACLVAGGSKYSEFTSTTSGTGHNQTRALRASESGI

T33586	TARGETID	T33586
T33586	FORMERID	TTDNR00748
T33586	UNIPROID	TRPC1_HUMAN
T33586	TARGNAME	Short transient receptor potential channel 1 (TRPC1)
T33586	GENENAME	TRPC1
T33586	TARGTYPE	Literature-reported
T33586	SYNONYMS	TrpC1; Transient receptor protein 1; TRP-1
T33586	FUNCTION	Thought to form a receptor-activated non-selective calcium permeant cation channel. Probably is operated by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases or G-protein coupled receptors. Seems to be also activated by intracellular calcium store depletion.
T33586	BIOCLASS	Transient receptor potential catioin channel
T33586	SEQUENCE	MMAALYPSTDLSGASSSSLPSSPSSSSPNEVMALKDVREVKEENTLNEKLFLLACDKGDYYMVKKILEENSSGDLNINCVDVLGRNAVTITIENENLDILQLLLDYGCQSADALLVAIDSEVVGAVDILLNHRPKRSSRPTIVKLMERIQNPEYSTTMDVAPVILAAHRNNYEILTMLLKQDVSLPKPHAVGCECTLCSAKNKKDSLRHSRFRLDIYRCLASPALIMLTEEDPILRAFELSADLKELSLVEVEFRNDYEELARQCKMFAKDLLAQARNSRELEVILNHTSSDEPLDKRGLLEERMNLSRLKLAIKYNQKEFVSQSNCQQFLNTVWFGQMSGYRRKPTCKKIMTVLTVGIFWPVLSLCYLIAPKSQFGRIIHTPFMKFIIHGASYFTFLLLLNLYSLVYNEDKKNTMGPALERIDYLLILWIIGMIWSDIKRLWYEGLEDFLEESRNQLSFVMNSLYLATFALKVVAHNKFHDFADRKDWDAFHPTLVAEGLFAFANVLSYLRLFFMYTTSSILGPLQISMGQMLQDFGKFLGMFLLVLFSFTIGLTQLYDKGYTSKEQKDCVGIFCEQQSNDTFHSFIGTCFALFWYIFSLAHVAIFVTRFSYGEELQSFVGAVIVGTYNVVVVIVLTKLLVAMLHKSFQLIANHEDKEWKFARAKLWLSYFDDKCTLPPPFNIIPSPKTICYMISSLSKWICSHTSKGKVKRQNSLKEWRNLKQKRDENYQKVMCCLVHRYLTSMRQKMQSTDQATVENLNELRQDLSKFRNEIRDLLGFRTSKYAMFYPRN
T33586	DRUGINFO	D00HCI	2-APB	Investigative

T22717	TARGETID	T22717
T22717	FORMERID	TTDI02607
T22717	UNIPROID	NRAM2_HUMAN
T22717	TARGNAME	Divalent metal transporter 1 (SLC11A2)
T22717	GENENAME	SLC11A2
T22717	TARGTYPE	Literature-reported
T22717	SYNONYMS	Solute carrier family 11 member 2; OK/SW-cl.20; Natural resistanceassociated macrophage protein 2; Natural resistance-associated macrophage protein 2; NRAMP2; NRAMP 2; Divalent cation transporter 1; DMT1; DMT-1; DCT1
T22717	FUNCTION	Can also transport manganese, cobalt, cadmium, nickel, vanadium and lead. Involved in apical iron uptake into duodenal enterocytes. Involved in iron transport from acidified endosomes into the cytoplasm of erythroid precursor cells. May play an important role in hepatic iron accumulation and tissue iron distribution. May serve to import iron into the mitochondria. Important in metal transport, in particular iron.
T22717	PDBSTRUC	5F0P; 5F0M; 5F0L
T22717	BIOCLASS	Natural resistance-associated macrophage protein
T22717	SEQUENCE	MVLGPEQKMSDDSVSGDHGESASLGNINPAYSNPSLSQSPGDSEEYFATYFNEKISIPEEEYSCFSFRKLWAFTGPGFLMSIAYLDPGNIESDLQSGAVAGFKLLWILLLATLVGLLLQRLAARLGVVTGLHLAEVCHRQYPKVPRVILWLMVELAIIGSDMQEVIGSAIAINLLSVGRIPLWGGVLITIADTFVFLFLDKYGLRKLEAFFGFLITIMALTFGYEYVTVKPSQSQVLKGMFVPSCSGCRTPQIEQAVGIVGAVIMPHNMYLHSALVKSRQVNRNNKQEVREANKYFFIESCIALFVSFIINVFVVSVFAEAFFGKTNEQVVEVCTNTSSPHAGLFPKDNSTLAVDIYKGGVVLGCYFGPAALYIWAVGILAAGQSSTMTGTYSGQFVMEGFLNLKWSRFARVVLTRSIAIIPTLLVAVFQDVEHLTGMNDFLNVLQSLQLPFALIPILTFTSLRPVMSDFANGLGWRIAGGILVLIICSINMYFVVVYVRDLGHVALYVVAAVVSVAYLGFVFYLGWQCLIALGMSFLDCGHTCHLGLTAQPELYLLNTMDADSLVSR

T41646	TARGETID	T41646
T41646	FORMERID	TTDI00183
T41646	UNIPROID	ARRB1_HUMAN
T41646	TARGNAME	Beta-arrestin-1 (ARRB1)
T41646	GENENAME	ARRB1
T41646	TARGTYPE	Literature-reported
T41646	SYNONYMS	Non-visual arrestin-2; Betaarrestin1; Arrestin beta1; Arrestin beta-1; ARR1
T41646	FUNCTION	During homologous desensitization, beta-arrestins bind to the GPRK-phosphorylated receptor and sterically preclude its coupling to the cognate G-protein; the binding appears to require additional receptor determinants exposed only in the active receptor conformation. The beta-arrestins target many receptors for internalization by acting as endocytic adapters (CLASPs, clathrin-associated sorting proteins) and recruiting the GPRCs to the adapter protein 2 complex 2 (AP-2) in clathrin-coated pits (CCPs). However, the extent of beta-arrestin involvement appears to vary significantly depending on the receptor, agonist and cell type. Internalized arrestin-receptor complexes traffic to intracellular endosomes, where they remain uncoupled from G-proteins. Two different modes of arrestin-mediated internalization occur. Class A receptors, like ADRB2, OPRM1, ENDRA, D1AR and ADRA1B dissociate from beta-arrestin at or near the plasma membrane and undergo rapid recycling. Class B receptors, like AVPR2, AGTR1, NTSR1, TRHR and TACR1 internalize as a complex with arrestin and traffic with it to endosomal vesicles, presumably as desensitized receptors, for extended periods of time. Receptor resensitization then requires that receptor-bound arrestin is removed so that the receptor can be dephosphorylated and returned to the plasma membrane. Involved in internalization of P2RY4 and UTP-stimulated internalization of P2RY2. Involved in phosphorylation-dependent internalization of OPRD1 ands subsequent recycling. Involved in the degradation of cAMP by recruiting cAMP phosphodiesterases to ligand-activated receptors. Beta-arrestins function as multivalent adapter proteins that can switch the GPCR from a G-protein signaling mode that transmits short-lived signals from the plasma membrane via small molecule second messengers and ion channels to a beta-arrestin signaling mode that transmits a distinct set of signals that are initiated as the receptor internalizes and transits the intracellular compartment. Acts as signaling scaffold for MAPK pathways such as MAPK1/3 (ERK1/2). ERK1/2 activated by the beta-arrestin scaffold is largely excluded from the nucleus and confined to cytoplasmic locations such as endocytic vesicles, also called beta-arrestin signalosomes. Recruits c-Src/SRC to ADRB2 resulting in ERK activation. GPCRs for which the beta-arrestin-mediated signaling relies on both ARRB1 and ARRB2 (codependent regulation) include ADRB2, F2RL1 and PTH1R. For some GPCRs the beta-arrestin-mediated signaling relies on either ARRB1 or ARRB2 and is inhibited by the other respective beta-arrestin form (reciprocal regulation). Inhibits ERK1/2 signaling in AGTR1- and AVPR2-mediated activation (reciprocal regulation). Is required for SP-stimulated endocytosis of NK1R and recruits c-Src/SRC to internalized NK1R resulting in ERK1/2 activation, which is required for the antiapoptotic effects of SP. Is involved in proteinase-activated F2RL1-mediated ERK activity. Acts as signaling scaffold for the AKT1 pathway. Is involved in alpha-thrombin-stimulated AKT1 signaling. Is involved in IGF1-stimulated AKT1 signaling leading to increased protection from apoptosis. Involved in activation of the p38 MAPK signaling pathway and in actin bundle formation. Involved in F2RL1-mediated cytoskeletal rearrangement and chemotaxis. Involved in AGTR1-mediated stress fiber formation by acting together with GNAQ to activate RHOA. Appears to function as signaling scaffold involved in regulation of MIP-1-beta-stimulated CCR5-dependent chemotaxis. Involved in attenuation of NF-kappa-B-dependent transcription in response to GPCR or cytokine stimulation by interacting with and stabilizing CHUK. May serve as nuclear messenger for GPCRs. Involved in OPRD1-stimulated transcriptional regulation by translocating to CDKN1B and FOS promoter regions and recruiting EP300 resulting in acetylation of histone H4. Involved in regulation of LEF1 transcriptional activity via interaction with DVL1 and/or DVL2 Also involved in regulation of receptors other than GPCRs. Involved in Toll-like receptor and IL-1 receptor signaling through the interaction with TRAF6 which prevents TRAF6 autoubiquitination and oligomerization required for activation of NF-kappa-B and JUN. Binds phosphoinositides. Binds inositolhexakisphosphate (InsP6). Involved in IL8-mediated granule release in neutrophils. Required for atypical chemokine receptor ACKR2-induced RAC1-LIMK1-PAK1-dependent phosphorylation of cofilin (CFL1) and for the up-regulation of ACKR2 from endosomal compartment to cell membrane, increasing its efficiency in chemokine uptake and degradation. Involved in the internalization of the atypical chemokine receptor ACKR3. Negatively regulates the NOTCH signaling pathway by mediating the ubiquitination and degradation of NOTCH1 by ITCH. Participates to the recruitment of the ubiquitin-protein ligase to the receptor. Functions in regulating agonist-mediated G-protein coupled receptor (GPCR) signaling by mediating both receptor desensitization and resensitization processes.
T41646	PDBSTRUC	2IV8
T41646	BIOCLASS	Arrestin protein
T41646	SEQUENCE	MGDKGTRVFKKASPNGKLTVYLGKRDFVDHIDLVDPVDGVVLVDPEYLKERRVYVTLTCAFRYGREDLDVLGLTFRKDLFVANVQSFPPAPEDKKPLTRLQERLIKKLGEHAYPFTFEIPPNLPCSVTLQPGPEDTGKACGVDYEVKAFCAENLEEKIHKRNSVRLVIRKVQYAPERPGPQPTAETTRQFLMSDKPLHLEASLDKEIYYHGEPISVNVHVTNNTNKTVKKIKISVRQYADICLFNTAQYKCPVAMEEADDTVAPSSTFCKVYTLTPFLANNREKRGLALDGKLKHEDTNLASSTLLREGANREILGIIVSYKVKVKLVVSRGGLLGDLASSDVAVELPFTLMHPKPKEEPPHREVPENETPVDTNLIELDTNDDDIVFEDFARQRLKGMKDDKEEEEDGTGSPQLNNR

T92095	TARGETID	T92095
T92095	FORMERID	TTDR00709
T92095	UNIPROID	INPP_HUMAN
T92095	TARGNAME	Inositol polyphosphate 1-phosphatase (INPP1)
T92095	GENENAME	INPP1
T92095	TARGTYPE	Literature-reported
T92095	SYNONYMS	IPPase; IPP
T92095	FUNCTION	Removes the phosphate group at position 1 of the inositol ring from the polyphosphates inositol 1,4-bisphosphate and inositol 1,3,4-trisphophosphate.
T92095	BIOCLASS	Phosphoric monoester hydrolase
T92095	ECNUMBER	EC 3.1.3.57
T92095	SEQUENCE	MSDILRELLCVSEKAANIARACRQQEALFQLLIEEKKEGEKNKKFAVDFKTLADVLVQEVIKQNMENKFPGLEKNIFGEESNEFTNDWGEKITLRLCSTEEETAELLSKVLNGNKVASEALARVVHQDVAFTDPTLDSTEINVPQDILGIWVDPIDSTYQYIKGSADIKSNQGIFPCGLQCVTILIGVYDIQTGVPLMGVINQPFVSRDPNTLRWKGQCYWGLSYMGTNMHSLQLTISRRNGSETHTGNTGSEAAFSPSFSAVISTSEKETIKAALSRVCGDRIFGAAGAGYKSLCVVQGLVDIYIFSEDTTFKWDSCAAHAILRAMGGGIVDLKECLERNPETGLDLPQLVYHVENEGAAGVDRWANKGGLIAYRSRKRLETFLSLLVQNLAPAETHT

T86731	TARGETID	T86731
T86731	FORMERID	TTDR00214
T86731	UNIPROID	AT1A2_HUMAN
T86731	TARGNAME	Sodium pump alpha-2 (ATP1A2)
T86731	GENENAME	ATP1A2
T86731	TARGTYPE	Literature-reported
T86731	SYNONYMS	Sodium/potassium-transporting ATPase subunit alpha-2; Sodium/potassium-transporting ATPase alpha2; Sodium pump 2; Na+/K+ ATPase 2; Na(+)/K(+) ATPase alpha-2 subunit; KIAA0778; Alpha(+)Sodium/potassium-transporting ATPase alpha-2 chain
T86731	FUNCTION	This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium, providing the energy for active transport of various nutrients.
T86731	BIOCLASS	Cation transporting ATPase
T86731	ECNUMBER	EC 7.2.2.13
T86731	SEQUENCE	MGRGAGREYSPAATTAENGGGKKKQKEKELDELKKEVAMDDHKLSLDELGRKYQVDLSKGLTNQRAQDVLARDGPNALTPPPTTPEWVKFCRQLFGGFSILLWIGAILCFLAYGIQAAMEDEPSNDNLYLGVVLAAVVIVTGCFSYYQEAKSSKIMDSFKNMVPQQALVIREGEKMQINAEEVVVGDLVEVKGGDRVPADLRIISSHGCKVDNSSLTGESEPQTRSPEFTHENPLETRNICFFSTNCVEGTARGIVIATGDRTVMGRIATLASGLEVGRTPIAMEIEHFIQLITGVAVFLGVSFFVLSLILGYSWLEAVIFLIGIIVANVPEGLLATVTVCLTLTAKRMARKNCLVKNLEAVETLGSTSTICSDKTGTLTQNRMTVAHMWFDNQIHEADTTEDQSGATFDKRSPTWTALSRIAGLCNRAVFKAGQENISVSKRDTAGDASESALLKCIELSCGSVRKMRDRNPKVAEIPFNSTNKYQLSIHEREDSPQSHVLVMKGAPERILDRCSTILVQGKEIPLDKEMQDAFQNAYMELGGLGERVLGFCQLNLPSGKFPRGFKFDTDELNFPTEKLCFVGLMSMIDPPRAAVPDAVGKCRSAGIKVIMVTGDHPITAKAIAKGVGIISEGNETVEDIAARLNIPMSQVNPREAKACVVHGSDLKDMTSEQLDEILKNHTEIVFARTSPQQKLIIVEGCQRQGAIVAVTGDGVNDSPALKKADIGIAMGISGSDVSKQAADMILLDDNFASIVTGVEEGRLIFDNLKKSIAYTLTSNIPEITPFLLFIIANIPLPLGTVTILCIDLGTDMVPAISLAYEAAESDIMKRQPRNSQTDKLVNERLISMAYGQIGMIQALGGFFTYFVILAENGFLPSRLLGIRLDWDDRTMNDLEDSYGQEWTYEQRKVVEFTCHTAFFASIVVVQWADLIICKTRRNSVFQQGMKNKILIFGLLEETALAAFLSYCPGMGVALRMYPLKVTWWFCAFPYSLLIFIYDEVRKLILRRYPGGWVEKETYY

T14030	TARGETID	T14030
T14030	FORMERID	TTDNR00740
T14030	UNIPROID	RAB7A_HUMAN
T14030	TARGNAME	Ras-related protein Rab-7a (RAB7A)
T14030	GENENAME	RAB7A
T14030	TARGTYPE	Literature-reported
T14030	SYNONYMS	RAB7
T14030	FUNCTION	Governs early-to-late endosomal maturation, microtubule minus-end as well as plus-end directed endosomal migration and positioning, and endosome-lysosome transport through different protein-protein interaction cascades. Plays a central role, not only in endosomal traffic, but also in many other cellular and physiological events, such as growth-factor-mediated cell signaling, nutrient-transportor mediated nutrient uptake, neurotrophin transport in the axons of neurons and lipid metabolism. Also involved in regulation of some specialized endosomal membrane trafficking, such as maturation of melanosomes, pathogen-induced phagosomes (or vacuoles) and autophagosomes. Plays a role in the maturation and acidification of phagosomes that engulf pathogens, such as S. aureus and M. tuberculosis. Plays a role in the fusion of phagosomes with lysosomes. Plays important roles in microbial pathogen infection and survival, as well as in participating in the life cycle of viruses. Microbial pathogens possess survival strategies governed by RAB7A, sometimes by employing RAB7A function (e. g. Salmonella) and sometimes by excluding RAB7A function (e. g. Mycobacterium). In concert with RAC1, plays a role in regulating the formation of RBs (ruffled borders) in osteoclasts. Controls the endosomal trafficking and neurite outgrowth signaling of NTRK1/TRKA. Regulates the endocytic trafficking of the EGF-EGFR complex by regulating its lysosomal degradation. Involved in the ADRB2-stimulated lipolysis through lipophagy, a cytosolic lipase-independent autophagic pathway. Required for the exosomal release of SDCBP, CD63 and syndecan. Key regulator in endo-lysosomal trafficking.
T14030	PDBSTRUC	6IYB; 3LAW; 1YHN; 1T91
T14030	BIOCLASS	Small GTPase
T14030	SEQUENCE	MTSRKKVLLKVIILGDSGVGKTSLMNQYVNKKFSNQYKATIGADFLTKEVMVDDRLVTMQIWDTAGQERFQSLGVAFYRGADCCVLVFDVTAPNTFKTLDSWRDEFLIQASPRDPENFPFVVLGNKIDLENRQVATKRAQAWCYSKNNIPYFETSAKEAINVEQAFQTIARNALKQETEVELYNEFPEPIKLDKNDRAKASAESCSC

T81658	TARGETID	T81658
T81658	FORMERID	TTDI03389
T81658	UNIPROID	MMP15_HUMAN
T81658	TARGNAME	Matrix metalloproteinase-15 (MMP-15)
T81658	GENENAME	MMP15
T81658	TARGTYPE	Literature-reported
T81658	SYNONYMS	SMCP-2; Membrane-type-2 matrix metalloproteinase; Membrane-type matrix metalloproteinase 2; MTMMP2; MT2MMP; MT2-MMP; MT-MMP 2
T81658	FUNCTION	May activate progelatinase A. Endopeptidase that degrades various components of the extracellular matrix.
T81658	BIOCLASS	Peptidase
T81658	ECNUMBER	EC 3.4.24.-
T81658	SEQUENCE	MGSDPSAPGRPGWTGSLLGDREEAARPRLLPLLLVLLGCLGLGVAAEDAEVHAENWLRLYGYLPQPSRHMSTMRSAQILASALAEMQRFYGIPVTGVLDEETKEWMKRPRCGVPDQFGVRVKANLRRRRKRYALTGRKWNNHHLTFSIQNYTEKLGWYHSMEAVRRAFRVWEQATPLVFQEVPYEDIRLRRQKEADIMVLFASGFHGDSSPFDGTGGFLAHAYFPGPGLGGDTHFDADEPWTFSSTDLHGNNLFLVAVHELGHALGLEHSSNPNAIMAPFYQWKDVDNFKLPEDDLRGIQQLYGTPDGQPQPTQPLPTVTPRRPGRPDHRPPRPPQPPPPGGKPERPPKPGPPVQPRATERPDQYGPNICDGDFDTVAMLRGEMFVFKGRWFWRVRHNRVLDNYPMPIGHFWRGLPGDISAAYERQDGRFVFFKGDRYWLFREANLEPGYPQPLTSYGLGIPYDRIDTAIWWEPTGHTFFFQEDRYWRFNEETQRGDPGYPKPISVWQGIPASPKGAFLSNDAAYTYFYKGTKYWKFDNERLRMEPGYPKSILRDFMGCQEHVEPGPRWPDVARPPFNPHGGAEPGADSAEGDVGDGDGDFGAGVNKDGGSRVVVQMEEVARTVNVVMVLVPLLLLLCVLGLTYALVQMQRKGAPRVLLYCKRSLQEWV
T81658	DRUGINFO	D07GEL	SL422	Investigative

T08165	TARGETID	T08165
T08165	FORMERID	TTDR00909
T08165	UNIPROID	BLI4_CAEEL
T08165	TARGNAME	Elegans Endoprotease bli-4 (Elegans bli-4)
T08165	GENENAME	Elegans bli-4
T08165	TARGTYPE	Literature-reported
T08165	SYNONYMS	kpc-4; bli-4; K04F10.4; Endoprotease bli-4; Blistered cuticle protein 4; Blisterase
T08165	FUNCTION	Involved in cuticle biosynthesis probably by cleaving pro-collagen into its mature form. Acts in ASEL sensory neurons to regulate high salt chemotaxis responses probably by cleaving insulin-like protein ins-6 into its mature and active form. Essential for embryonic and larval development. isoform a, isoform e, isoform f, isoform g and isoform h are involved in cuticle biosynthesis but are dispensable for larval development. Serine endoprotease which cleaves proproteins at paired basic amino acids.
T08165	BIOCLASS	Peptidase
T08165	ECNUMBER	EC 3.4.21.-
T08165	SEQUENCE	MRISIGRIAWQILAVLIAVAFTIEHDSICDESIGACGEPIHTVIRLAKRDDELARRIAADHDMHVKGDPFLDTHYFLYHSETTRTRRHKRAIVERLDSHPAVEWVEEQRPKKRVKRDYILLDNDVHHSNPFRRSVLNRDGTRRAQRQQPQSPREIPSLPFPDPLYKDQWYLHGGAVGGYDMNVRQAWLQGYAGRNVSVSILDDGIQRDHPDLAANYDPLASTDINDHDDDPTPQNNGDNKHGTRCAGEVAALAGNNQCGVGVAFKAKIGGVRMLDGAVSDSVEAASLSLNQDHIDIYSASWGPEDDGKTFDGPGPLAREAFYRGIKNGRGGKGNIFVWASGNGGSRQDSCSADGYTTSVYTLSISSATYDNHRPWYLEECPSSIATTYSSADFRQPAIVTVDVPGGCTDKHTGTSASAPLAAGIIALALEANPELTWRDMQHLVLRTANWKPLENNPGWSRNGVGRMVSNKFGYGLIDGGALVNMAKTWKTVPEQHICTYEYRLANPNPRPIVGRFQLNFTLDVNGCESGTPVLYLEHVQVHATVRYLKRGDLKLTLFSPSGTRSVLLPPRPQDFNANGFHKWPFLSVQQWGEDPRGTWLLMVESVTTNPAATGTFHDWTLLLYGTADPAQSGDPVYSATPATSQGVLSRVHQLTSQVEESAPISFPDLTSAGNCHDECNGGCTESSSATSCFACKHLTQTLRNKGGSGFKCVQKCDDTYYLDGDKCKMCSSHCHTCTKAEVCETCPGSLLLIDVDNMPHYDHGKCVESCPPGLVADYESNLVQAKCIWRKDLCGDGYYINAVGKCDLCDSSCETCTAPGPMSCEKCSKGYGKGSIGYCRPCCPEGSTKSWQCEDCSKPDPTLLIDSNKSSGFGLMFWIVVSLIAACGICACKKCASETKSSNVEYAPLAQYNATNGAINLGAHTDDEDDDEDEVFVNPQIV
T08165	DRUGINFO	D00KEP	Edetic acid	Investigative

T15823	TARGETID	T15823
T15823	FORMERID	TTDR01106
T15823	UNIPROID	BRCA2_HUMAN
T15823	TARGNAME	Breast cancer type 2 susceptibility protein (BRCA2)
T15823	GENENAME	BRCA2
T15823	TARGTYPE	Literature-reported
T15823	SYNONYMS	Fanconi anemia group D1 protein; FANCD1; FACD
T15823	FUNCTION	Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. Part of a PALB2-scaffolded HR complex containing RAD51C and which is thought to play a role in DNA repair by HR. May participate in S phase checkpoint activation. Binds selectively to ssDNA, and to ssDNA in tailed duplexes and replication fork structures. May play a role in the extension step after strand invasion at replication-dependent DNA double-strand breaks; together with PALB2 is involved in both POLH localization at collapsed replication forks and DNA polymerization activity. In concert with NPM1, regulates centrosome duplication. Interacts with the TREX-2 complex (transcription and export complex 2) subunits PCID2 and SEM1, and is required to prevent R-loop-associated DNA damage and thus transcription-associated genomic instability. Silencing of BRCA2 promotes R-loop accumulation at actively transcribed genes in replicating and non-replicating cells, suggesting that BRCA2 mediates the control of R-loop associated genomic instability, independently of its known role in homologous recombination. Involved in double-strand break repair and/or homologous recombination.
T15823	PDBSTRUC	3EU7; 1N0W
T15823	SEQUENCE	MPIGSKERPTFFEIFKTRCNKADLGPISLNWFEELSSEAPPYNSEPAEESEHKNNNYEPNLFKTPQRKPSYNQLASTPIIFKEQGLTLPLYQSPVKELDKFKLDLGRNVPNSRHKSLRTVKTKMDQADDVSCPLLNSCLSESPVVLQCTHVTPQRDKSVVCGSLFHTPKFVKGRQTPKHISESLGAEVDPDMSWSSSLATPPTLSSTVLIVRNEEASETVFPHDTTANVKSYFSNHDESLKKNDRFIASVTDSENTNQREAASHGFGKTSGNSFKVNSCKDHIGKSMPNVLEDEVYETVVDTSEEDSFSLCFSKCRTKNLQKVRTSKTRKKIFHEANADECEKSKNQVKEKYSFVSEVEPNDTDPLDSNVANQKPFESGSDKISKEVVPSLACEWSQLTLSGLNGAQMEKIPLLHISSCDQNISEKDLLDTENKRKKDFLTSENSLPRISSLPKSEKPLNEETVVNKRDEEQHLESHTDCILAVKQAISGTSPVASSFQGIKKSIFRIRESPKETFNASFSGHMTDPNFKKETEASESGLEIHTVCSQKEDSLCPNLIDNGSWPATTTQNSVALKNAGLISTLKKKTNKFIYAIHDETSYKGKKIPKDQKSELINCSAQFEANAFEAPLTFANADSGLLHSSVKRSCSQNDSEEPTLSLTSSFGTILRKCSRNETCSNNTVISQDLDYKEAKCNKEKLQLFITPEADSLSCLQEGQCENDPKSKKVSDIKEEVLAAACHPVQHSKVEYSDTDFQSQKSLLYDHENASTLILTPTSKDVLSNLVMISRGKESYKMSDKLKGNNYESDVELTKNIPMEKNQDVCALNENYKNVELLPPEKYMRVASPSRKVQFNQNTNLRVIQKNQEETTSISKITVNPDSEELFSDNENNFVFQVANERNNLALGNTKELHETDLTCVNEPIFKNSTMVLYGDTGDKQATQVSIKKDLVYVLAEENKNSVKQHIKMTLGQDLKSDISLNIDKIPEKNNDYMNKWAGLLGPISNHSFGGSFRTASNKEIKLSEHNIKKSKMFFKDIEEQYPTSLACVEIVNTLALDNQKKLSKPQSINTVSAHLQSSVVVSDCKNSHITPQMLFSKQDFNSNHNLTPSQKAEITELSTILEESGSQFEFTQFRKPSYILQKSTFEVPENQMTILKTTSEECRDADLHVIMNAPSIGQVDSSKQFEGTVEIKRKFAGLLKNDCNKSASGYLTDENEVGFRGFYSAHGTKLNVSTEALQKAVKLFSDIENISEETSAEVHPISLSSSKCHDSVVSMFKIENHNDKTVSEKNNKCQLILQNNIEMTTGTFVEEITENYKRNTENEDNKYTAASRNSHNLEFDGSDSSKNDTVCIHKDETDLLFTDQHNICLKLSGQFMKEGNTQIKEDLSDLTFLEVAKAQEACHGNTSNKEQLTATKTEQNIKDFETSDTFFQTASGKNISVAKESFNKIVNFFDQKPEELHNFSLNSELHSDIRKNKMDILSYEETDIVKHKILKESVPVGTGNQLVTFQGQPERDEKIKEPTLLGFHTASGKKVKIAKESLDKVKNLFDEKEQGTSEITSFSHQWAKTLKYREACKDLELACETIEITAAPKCKEMQNSLNNDKNLVSIETVVPPKLLSDNLCRQTENLKTSKSIFLKVKVHENVEKETAKSPATCYTNQSPYSVIENSALAFYTSCSRKTSVSQTSLLEAKKWLREGIFDGQPERINTADYVGNYLYENNSNSTIAENDKNHLSEKQDTYLSNSSMSNSYSYHSDEVYNDSGYLSKNKLDSGIEPVLKNVEDQKNTSFSKVISNVKDANAYPQTVNEDICVEELVTSSSPCKNKNAAIKLSISNSNNFEVGPPAFRIASGKIVCVSHETIKKVKDIFTDSFSKVIKENNENKSKICQTKIMAGCYEALDDSEDILHNSLDNDECSTHSHKVFADIQSEEILQHNQNMSGLEKVSKISPCDVSLETSDICKCSIGKLHKSVSSANTCGIFSTASGKSVQVSDASLQNARQVFSEIEDSTKQVFSKVLFKSNEHSDQLTREENTAIRTPEHLISQKGFSYNVVNSSAFSGFSTASGKQVSILESSLHKVKGVLEEFDLIRTEHSLHYSPTSRQNVSKILPRVDKRNPEHCVNSEMEKTCSKEFKLSNNLNVEGGSSENNHSIKVSPYLSQFQQDKQQLVLGTKVSLVENIHVLGKEQASPKNVKMEIGKTETFSDVPVKTNIEVCSTYSKDSENYFETEAVEIAKAFMEDDELTDSKLPSHATHSLFTCPENEEMVLSNSRIGKRRGEPLILVGEPSIKRNLLNEFDRIIENQEKSLKASKSTPDGTIKDRRLFMHHVSLEPITCVPFRTTKERQEIQNPNFTAPGQEFLSKSHLYEHLTLEKSSSNLAVSGHPFYQVSATRNEKMRHLITTGRPTKVFVPPFKTKSHFHRVEQCVRNINLEENRQKQNIDGHGSDDSKNKINDNEIHQFNKNNSNQAAAVTFTKCEEEPLDLITSLQNARDIQDMRIKKKQRQRVFPQPGSLYLAKTSTLPRISLKAAVGGQVPSACSHKQLYTYGVSKHCIKINSKNAESFQFHTEDYFGKESLWTGKGIQLADGGWLIPSNDGKAGKEEFYRALCDTPGVDPKLISRIWVYNHYRWIIWKLAAMECAFPKEFANRCLSPERVLLQLKYRYDTEIDRSRRSAIKKIMERDDTAAKTLVLCVSDIISLSANISETSSNKTSSADTQKVAIIELTDGWYAVKAQLDPPLLAVLKNGRLTVGQKIILHGAELVGSPDACTPLEAPESLMLKISANSTRPARWYTKLGFFPDPRPFPLPLSSLFSDGGNVGCVDVIIQRAYPIQWMEKTSSGLYIFRNEREEEKEAAKYVEAQQKRLEALFTKIQEEFEEHEENTTKPYLPSRALTRQQVRALQDGAELYEAVKNAADPAYLEGYFSEEQLRALNNHRQMLNDKKQAQIQLEIRKAMESAEQKEQGLSRDVTTVWKLRIVSYSKKEKDSVILSIWRPSSDLYSLLTEGKRYRIYHLATSKSKSKSERANIQLAATKKTQYQQLPVSDEILFQIYQPREPLHFSKFLDPDFQPSCSEVDLIGFVVSVVKKTGLAPFVYLSDECYNLLAIKFWIDLNEDIIKPHMLIAASNLQWRPESKSGLLTLFAGDFSVFSASPKEGHFQETFNKMKNTVENIDILCNEAENKLMHILHANDPKWSTPTKDCTSGPYTAQIIPGTGNKLLMSSPNCEIYYQSPLSLCMAKRKSVSTPVSAQMTSKSCKGEKEIDDQKNCKKRRALDFLSRLPLPPPVSPICTFVSPAAQKAFQPPRSCGTKYETPIKKKELNSPQMTPFKKFNEISLLESNSIADEELALINTQALLSGSTGEKQFISVSESTRTAPTSSEDYLRLKRRCTTSLIKEQESSQASTEECEKNKQDTITTKKYI

T24588	TARGETID	T24588
T24588	FORMERID	TTDR01248
T24588	UNIPROID	RENBP_HUMAN
T24588	TARGNAME	N-acylglucosamine 2-epimerase (RENBP)
T24588	GENENAME	RENBP
T24588	TARGTYPE	Literature-reported
T24588	SYNONYMS	RnBP; Renin-binding protein; RENBP; N-acetyl-D-glucosamine 2-epimerase; GlcNAc 2-epimerase; AGE
T24588	FUNCTION	Catalyzes the interconversion of N-acetylglucosamine to N-acetylmannosamine. Binds to renin forming a protein complex called high molecular weight (HMW) renin and inhibits renin activity. Involved in the N-glycolylneuraminic acid (Neu5Gc) degradation pathway: although human is not able to catalyze formation of Neu5Gc due to the inactive CMAHP enzyme, Neu5Gc is present in food and must be degraded.
T24588	BIOCLASS	Racemases and epimerases
T24588	ECNUMBER	EC 5.1.3.8
T24588	SEQUENCE	MSKGLPARQDMEKERETLQAWKERVGQELDRVVAFWMEHSHDQEHGGFFTCLGREGRVYDDLKYVWLQGRQVWMYCRLYRTFERFRHAQLLDAAKAGGEFLLRYARVAPPGKKCAFVLTRDGRPVKVQRTIFSECFYTMAMNELWRATGEVRYQTEAVEMMDQIVHWVQEDASGLGRPQLQGAPAAEPMAVPMMLLNLVEQLGEADEELAGKYAELGDWCARRILQHVQRDGQAVLENVSEGGKELPGCLGRQQNPGHTLEAGWFLLRHCIRKGDPELRAHVIDKFLLLPFHSGWDPDHGGLFYFQDADNFCPTQLEWAMKLWWPHSEAMIAFLMGYSDSGDPVLLRLFYQVAEYTFRQFRDPEYGEWFGYLSREGKVALSIKGGPFKGCFHVPRCLAMCEEMLGALLSRPAPAPSPAPTPACRGAE

T04149	TARGETID	T04149
T04149	FORMERID	TTDI03118
T04149	UNIPROID	CLCKA_HUMAN
T04149	TARGNAME	Chloride channel protein ClC-Ka (ClC-K1)
T04149	GENENAME	CLCNKA
T04149	TARGTYPE	Literature-reported
T04149	SYNONYMS	ClC-K1; Chloride channel Ka
T04149	FUNCTION	Voltage-gated chloride channel. Chloride channels have several functions including the regulation of cell volume; membrane potential stabilization, signal transduction and transepithelial transport. May be important in urinary concentrating mechanisms.
T04149	PDBSTRUC	2PFI
T04149	BIOCLASS	Chloride channel
T04149	SEQUENCE	MEELVGLREGFSGDPVTLQELWGPCPHIRRAIQGGLEWLKQKVFRLGEDWYFLMTLGVLMALVSYAMNFAIGCVVRAHQWLYREIGDSHLLRYLSWTVYPVALVSFSSGFSQSITPSSGGSGIPELKTMLAGVILEDYLDIKNFGAKVVGLSCTLATGSTLFLGKVGPFVHLSVMIAAYLGRVRTTTIGEPENKSKQNEMLVAAAAVGVATVFAAPFSGVLFSIEVMSSHFSVRDYWRGFFAATCGAFIFRLLAVFNSEQETITSLYKTSFRVDVPFDLPEIFFFVALGGICGVLSCAYLFCQRTFLSFIKTNRYSSKLLATSKPVYSALATLLLASITYPPGVGHFLASRLSMKQHLDSLFDNHSWALMTQNSSPPWPEELDPQHLWWEWYHPRFTIFGTLAFFLVMKFWMLILATTIPMPAGYFMPIFILGAAIGRLLGEALAVAFPEGIVTGGVTNPIMPGGYALAGAAAFSGAVTHTISTALLAFELTGQIVHALPVLMAVLAANAIAQSCQPSFYDGTIIVKKLPYLPRILGRNIGSHHVRVEHFMNHSITTLAKDTPLEEVVKVVTSTDVTEYPLVESTESQILVGIVQRAQLVQALQAEPPSRAPGHQQCLQDILARGCPTEPVTLTLFSETTLHQAQNLFKLLNLQSLFVTSRGRAVGCVSWVEMKKAISNLTNPPAPK
T04149	DRUGINFO	D0S2HQ	3-phenyl-CPP	Investigative
T04149	DRUGINFO	D0PW7B	DIDS	Investigative

T23191	TARGETID	T23191
T23191	FORMERID	TTDR00271
T23191	UNIPROID	NR0B1_HUMAN
T23191	TARGNAME	Orphan nuclear receptor DAX-1 (NR0B1)
T23191	GENENAME	NR0B1
T23191	TARGTYPE	Literature-reported
T23191	SYNONYMS	Nuclear receptor subfamily 0 group B member 1; Nuclear receptor DAX-1; DSS-AHC critical region on the X chromosome protein 1; DAX1; AHC
T23191	FUNCTION	Component of a cascade required for the development of the hypothalamic-pituitary-adrenal-gonadal axis. Acts as a coregulatory protein that inhibits the transcriptional activity of other nuclear receptors through heterodimeric interactions. May also have a role in the development of the embryo and in the maintenance of embryonic stem cell pluripotency. Orphan nuclear receptor.
T23191	PDBSTRUC	4RWV
T23191	BIOCLASS	Nuclear hormone receptor
T23191	SEQUENCE	MAGENHQWQGSILYNMLMSAKQTRAAPEAPETRLVDQCWGCSCGDEPGVGREGLLGGRNVALLYRCCFCGKDHPRQGSILYSMLTSAKQTYAAPKAPEATLGPCWGCSCGSDPGVGRAGLPGGRPVALLYRCCFCGEDHPRQGSILYSLLTSSKQTHVAPAAPEARPGGAWWDRSYFAQRPGGKEALPGGRATALLYRCCFCGEDHPQQGSTLYCVPTSTNQAQAAPEERPRAPWWDTSSGALRPVALKSPQVVCEAASAGLLKTLRFVKYLPCFQVLPLDQQLVLVRNCWASLLMLELAQDRLQFETVEVSEPSMLQKILTTRRRETGGNEPLPVPTLQHHLAPPAEARKVPSASQVQAIKCFLSKCWSLNISTKEYAYLKGTVLFNPDVPGLQCVKYIQGLQWGTQQILSEHTRMTHQGPHDRFIELNSTLFLLRFINANVIAELFFRPIIGTVSMDDMMLEMLCTKI

T52566	TARGETID	T52566
T52566	FORMERID	TTDR00846
T52566	UNIPROID	CHIO_HUMAN
T52566	TARGNAME	Beta-chimaerin (CHN2)
T52566	GENENAME	CHN2
T52566	TARGTYPE	Literature-reported
T52566	SYNONYMS	Rho-GTPase-activating protein 3; CHN2; Beta2-chimaerin; Beta-chimerin
T52566	FUNCTION	Gtpase activating protein for p21-rac. Insufficient expression of beta-2 chimaerin is expected to lead to higher rac activity and could therefore play a role in the progression from low-grade to high-grade tumors.
T52566	PDBSTRUC	1XA6
T52566	BIOCLASS	Zinc-finger
T52566	SEQUENCE	MAASSNSSLSGSSVSSDAEEYQPPIWKSYLYQLQQEAPRPKRIICPREVENRPKYYGREFHGIISREQADELLGGVEGAYILRESQRQPGCYTLALRFGNQTLNYRLFHDGKHFVGEKRFESIHDLVTDGLITLYIETKAAEYISKMTTNPIYEHIGYATLLREKVSRRLSRSKNEPRKTNVTHEEHTAVEKISSLVRRAALTHNDNHFNYEKTHNFKVHTFRGPHWCEYCANFMWGLIAQGVRCSDCGLNVHKQCSKHVPNDCQPDLKRIKKVYCCDLTTLVKAHNTQRPMVVDICIREIEARGLKSEGLYRVSGFTEHIEDVKMAFDRDGEKADISANVYPDINIITGALKLYFRDLPIPVITYDTYSKFIDAAKISNADERLEAVHEVLMLLPPAHYETLRYLMIHLKKVTMNEKDNFMNAENLGIVFGPTLMRPPEDSTLTTLHDMRYQKLIVQILIENEDVLF

T42337	TARGETID	T42337
T42337	FORMERID	TTDI03371
T42337	UNIPROID	MAP11_HUMAN
T42337	TARGNAME	Methionyl aminopeptidase 1 (METAP1)
T42337	GENENAME	METAP1
T42337	TARGTYPE	Literature-reported
T42337	SYNONYMS	Peptidase M 1; Methionine aminopeptidase 1; MetAP 1; MAP 1; KIAA0094
T42337	FUNCTION	Cotranslationally removes the N-terminal methionine from nascent proteins. The N-terminal methionine is often cleaved when the second residue in the primary sequence is small and uncharged (Met-Ala-, Cys, Gly, Pro, Ser, Thr, or Val). Required for normal progression through the cell cycle.
T42337	PDBSTRUC	5YR7; 5YR6; 5YR5; 5YR4; 5YKP
T42337	ECNUMBER	EC 3.4.11.18
T42337	SEQUENCE	MAAVETRVCETDGCSSEAKLQCPTCIKLGIQGSYFCSQECFKGSWATHKLLHKKAKDEKAKREVSSWTVEGDINTDPWAGYRYTGKLRPHYPLMPTRPVPSYIQRPDYADHPLGMSESEQALKGTSQIKLLSSEDIEGMRLVCRLAREVLDVAAGMIKPGVTTEEIDHAVHLACIARNCYPSPLNYYNFPKSCCTSVNEVICHGIPDRRPLQEGDIVNVDITLYRNGYHGDLNETFFVGEVDDGARKLVQTTYECLMQAIDAVKPGVRYRELGNIIQKHAQANGFSVVRSYCGHGIHKLFHTAPNVPHYAKNKAVGVMKSGHVFTIEPMICEGGWQDETWPDGWTAVTRDGKRSAQFEHTLLVTDTGCEILTRRLDSARPHFMSQF
T42337	DRUGINFO	D0Z7RB	PMID23634668C14	Investigative

T34563	TARGETID	T34563
T34563	FORMERID	TTDR00089
T34563	UNIPROID	DAAA_STAHA
T34563	TARGNAME	Staphylococcus D-amino acid aminotransferase (Stap-coc dat)
T34563	GENENAME	Stap-coc dat
T34563	TARGTYPE	Literature-reported
T34563	SYNONYMS	Stap-coc dat; DAAT; D-aspartate aminotransferase; D-amino acid transaminase; D-alanine aminotransferase
T34563	FUNCTION	Acts on the D-isomers of alanine, leucine, aspartate, glutamate, aminobutyrate, norvaline and asparagine. The enzyme transfers an amino group from a substrate D-amino acid to the pyridoxal phosphate cofactor to form pyridoxamine andan alpha- keto acid in the first half-reaction. The second half-reaction is the reverse of the first, transferring the amino group from the pyridoxamine to a second alpha-keto acid to form the product D- amino acid via a ping-pong mechanism. This is an important process in the formation of D-alanine and D-glutamate, which are essential bacterial cell wall components.
T34563	BIOCLASS	Transaminase
T34563	ECNUMBER	EC 2.6.1.21
T34563	SEQUENCE	MTKVFINGEFIDQNEAKVSYEDRGYVFGDGIYEYIRAYDGKLFTVTEHFERFIRSASEIQLDLGYTVEELIDVVRELLKVNNIQNGGIYIQATRGVAPRNHSFPTPEVKPVIMAFAKSYDRPYDDLENGINAATVEDIRWLRCDIKSLNLLGNVLAKEYAVKYNAGEAIQHRGETVTEGASSNVYAIKDGAIYTHPVNNYILNGITRKVIKWISEDEDIPFKEETFTVEFLKNADEVIVSSTSAEVTPVVKIDGEQVGDGKVGPVTRQLQEGFNKYIESRSS
T34563	DRUGINFO	D01NBK	Pyridoxamine-5'-Phosphate	Investigative
T34563	DRUGINFO	D0F2ME	Acetate Ion	Investigative

T69580	TARGETID	T69580
T69580	FORMERID	TTDR01105
T69580	UNIPROID	FGF8_HUMAN
T69580	TARGNAME	Fibroblast growth factor-8 (FGF8)
T69580	GENENAME	FGF8
T69580	TARGTYPE	Literature-reported
T69580	SYNONYMS	Heparin-binding growth factor 8; HBGF-8; Fibroblast growth factor 8; FGF-8; Androgen-induced growth factor; AIGF
T69580	FUNCTION	Required for normal brain, eye, ear and limb development during embryogenesis. Required for normal development of the gonadotropin-releasing hormone (GnRH) neuronal system. Plays a role in neurite outgrowth in hippocampal cells. Plays an important role in the regulation of embryonic development, cell proliferation, cell differentiation and cell migration.
T69580	PDBSTRUC	2FDB
T69580	BIOCLASS	Growth factor
T69580	SEQUENCE	MGSPRSALSCLLLHLLVLCLQAQEGPGRGPALGRELASLFRAGREPQGVSQQHVREQSLVTDQLSRRLIRTYQLYSRTSGKHVQVLANKRINAMAEDGDPFAKLIVETDTFGSRVRVRGAETGLYICMNKKGKLIAKSNGKGKDCVFTEIVLENNYTALQNAKYEGWYMAFTRKGRPRKGSKTRQHQREVHFMKRLPRGHHTTEQSLRFEFLNYPPFTRSLRGSQRTWAPEPR

T23934	TARGETID	T23934
T23934	FORMERID	TTDI01443
T23934	UNIPROID	CCL23_HUMAN
T23934	TARGNAME	C-C motif chemokine 23 (CCL23)
T23934	GENENAME	CCL23
T23934	TARGTYPE	Literature-reported
T23934	SYNONYMS	Small-inducible cytokine A23; SCYA23; Myeloid progenitor inhibitory factor 1; Macrophage inflammatory protein 3; MPIF1; MPIF-1; MIP3; MIP-3; CKB-8; CK-beta-8
T23934	FUNCTION	Inhibits proliferation of myeloid progenitor cells in colony formation assays. This protein can bind heparin. Binds CCR1. CCL23(19-99), CCL23(22-99), CCL23(27-99), CCL23(30-99) are more potent chemoattractants than the small-inducible cytokine A23. Shows chemotactic activity for monocytes, resting T-lymphocytes, and neutrophils, but not for activated lymphocytes.
T23934	PDBSTRUC	1G91
T23934	BIOCLASS	Cytokine: CC chemokine
T23934	SEQUENCE	MKVSVAALSCLMLVTALGSQARVTKDAETEFMMSKLPLENPVLLDRFHATSADCCISYTPRSIPCSLLESYFETNSECSKPGVIFLTKKGRRFCANPSDKQVQVCVRMLKLDTRIKTRKN

T97731	TARGETID	T97731
T97731	FORMERID	TTDI02485
T97731	UNIPROID	NETR_HUMAN
T97731	TARGNAME	Neurotrypsin (PRSS12)
T97731	GENENAME	PRSS12
T97731	TARGTYPE	Literature-reported
T97731	SYNONYMS	Serine protease 12; PRSS12; Motopsin; Leydin
T97731	FUNCTION	Plays a role in neuronal plasticity and the proteolytic action may subserve structural reorganizations associated with learning and memory operations.
T97731	BIOCLASS	Peptidase
T97731	ECNUMBER	EC 3.4.21.-
T97731	SEQUENCE	MTLARFVLALMLGALPEVVGFDSVLNDSLHHSHRHSPPAGPHYPYYLPTQQRPPRTRPPPPLPRFPRPPRALPAQRPHALQAGHTPRPHPWGCPAGEPWVSVTDFGAPCLRWAEVPPFLERSPPASWAQLRGQRHNFCRSPDGAGRPWCFYGDARGKVDWGYCDCRHGSVRLRGGKNEFEGTVEVYASGVWGTVCSSHWDDSDASVICHQLQLGGKGIAKQTPFSGLGLIPIYWSNVRCRGDEENILLCEKDIWQGGVCPQKMAAAVTCSFSHGPTFPIIRLAGGSSVHEGRVELYHAGQWGTVCDDQWDDADAEVICRQLGLSGIAKAWHQAYFGEGSGPVMLDEVRCTGNELSIEQCPKSSWGEHNCGHKEDAGVSCTPLTDGVIRLAGGKGSHEGRLEVYYRGQWGTVCDDGWTELNTYVVCRQLGFKYGKQASANHFEESTGPIWLDDVSCSGKETRFLQCSRRQWGRHDCSHREDVSIACYPGGEGHRLSLGFPVRLMDGENKKEGRVEVFINGQWGTICDDGWTDKDAAVICRQLGYKGPARARTMAYFGEGKGPIHVDNVKCTGNERSLADCIKQDIGRHNCRHSEDAGVICDYFGKKASGNSNKESLSSVCGLRLLHRRQKRIIGGKNSLRGGWPWQVSLRLKSSHGDGRLLCGATLLSSCWVLTAAHCFKRYGNSTRSYAVRVGDYHTLVPEEFEEEIGVQQIVIHREYRPDRSDYDIALVRLQGPEEQCARFSSHVLPACLPLWRERPQKTASNCYITGWGDTGRAYSRTLQQAAIPLLPKRFCEERYKGRFTGRMLCAGNLHEHKRVDSCQGDSGGPLMCERPGESWVVYGVTSWGYGCGVKDSPGVYTKVSAFVPWIKSVTKL

T11317	TARGETID	T11317
T11317	FORMERID	TTDI03529
T11317	UNIPROID	SIK1_HUMAN
T11317	TARGNAME	Salt-inducible kinase 1 (SIK1)
T11317	GENENAME	SIK1
T11317	TARGTYPE	Literature-reported
T11317	SYNONYMS	Serine/threonine-protein kinase SNF1LK; Serine/threonine-protein kinase SNF1-like kinase 1; Serine/threonine-protein kinase SIK1; SNF1LK; SIK-1; SIK
T11317	FUNCTION	Phosphorylates HDAC4, HDAC5, PPME1, SREBF1, CRTC1/TORC1. Inhibits CREB activity by phosphorylating and inhibiting activity of TORCs, the CREB-specific coactivators, like CRTC2/TORC2 and CRTC3/TORC3 in response to cAMP signaling. Acts as a tumor suppressor and plays a key role in p53/TP53-dependent anoikis, a type of apoptosis triggered by cell detachment: required for phosphorylation of p53/TP53 in response to loss of adhesion and is able to suppress metastasis. Part of a sodium-sensing signaling network, probably by mediating phosphorylation of PPME1: following increases in intracellular sodium, SIK1 is activated by CaMK1 and phosphorylates PPME1 subunit of protein phosphatase 2A (PP2A), leading to dephosphorylation of sodium/potassium-transporting ATPase ATP1A1 and subsequent increase activity of ATP1A1. Acts as a regulator of muscle cells by phosphorylating and inhibiting class II histone deacetylases HDAC4 and HDAC5, leading to promote expression of MEF2 target genes in myocytes. Also required during cardiomyogenesis by regulating the exit of cardiomyoblasts from the cell cycle via down-regulation of CDKN1C/p57Kip2. Acts as a regulator of hepatic gluconeogenesis by phosphorylating and repressing the CREB-specific coactivators CRTC1/TORC1 and CRTC2/TORC2, leading to inhibit CREB activity. Also regulates hepatic lipogenesis by phosphorylating and inhibiting SREBF1. In concert with CRTC1/TORC1, regulates the light-induced entrainment of the circadian clock by attenuating PER1 induction; represses CREB-mediated transcription of PER1 by phosphorylating and deactivating CRTC1/TORC1. Serine/threonine-protein kinase involved in various processes such as cell cycle regulation, gluconeogenesis and lipogenesis regulation, muscle growth and differentiation and tumor suppression.
T11317	BIOCLASS	Kinase
T11317	ECNUMBER	EC 2.7.11.1
T11317	SEQUENCE	MVIMSEFSADPAGQGQGQQKPLRVGFYDIERTLGKGNFAVVKLARHRVTKTQVAIKIIDKTRLDSSNLEKIYREVQLMKLLNHPHIIKLYQVMETKDMLYIVTEFAKNGEMFDYLTSNGHLSENEARKKFWQILSAVEYCHDHHIVHRDLKTENLLLDGNMDIKLADFGFGNFYKSGEPLSTWCGSPPYAAPEVFEGKEYEGPQLDIWSLGVVLYVLVCGSLPFDGPNLPTLRQRVLEGRFRIPFFMSQDCESLIRRMLVVDPARRITIAQIRQHRWMRAEPCLPGPACPAFSAHSYTSNLGDYDEQALGIMQTLGVDRQRTVESLQNSSYNHFAAIYYLLLERLKEYRNAQCARPGPARQPRPRSSDLSGLEVPQEGLSTDPFRPALLCPQPQTLVQSVLQAEMDCELQSSLQWPLFFPVDASCSGVFRPRPVSPSSLLDTAISEEARQGPGLEEEQDTQESLPSSTGRRHTLAEVSTRLSPLTAPCIVVSPSTTASPAEGTSSDSCLTFSASKSPAGLSGTPATQGLLGACSPVRLASPFLGSQSATPVLQAQGGLGGAVLLPVSFQEGRRASDTSLTQGLKAFRQQLRKTTRTKGFLGLNKIKGLARQVCQAPASRASRGGLSPFHAPAQSPGLHGGAAGSREGWSLLEEVLEQQRLLQLQHHPAAAPGCSQAPQPAPAPFVIAPCDGPGAAPLPSTLLTSGLPLLPPPLLQTGASPVASAAQLLDTHLHIGTGPTALPAVPPPRLARLAPGCEPLGLLQGDCEMEDLMPCSLGTFVLVQ
T11317	DRUGINFO	D03YVB	HG-9-91-01	Investigative
T11317	DRUGINFO	D0E7VO	PMID24900538C2c	Investigative

T93594	TARGETID	T93594
T93594	UNIPROID	RIPK4_HUMAN
T93594	TARGNAME	PKC-delta-interacting protein kinase (RIPK4)
T93594	GENENAME	RIPK4
T93594	TARGTYPE	Literature-reported
T93594	SYNONYMS	DIK; Ankyrin repeat domain-containing protein 3; ANKRD3
T93594	FUNCTION	Involved in stratified epithelial development. It is a direct transcriptional target of TP63. Plays a role in NF-kappa-B activation.
T93594	BIOCLASS	Protein kinase superfamily. TKL Ser/Thr protein kinase family
T93594	ECNUMBER	EC 2.7.11.1
T93594	SEQUENCE	MEGDGGTPWALALLRTFDAGEFTGWEKVGSGGFGQVYKVRHVHWKTWLAIKCSPSLHVDDRERMELLEEAKKMEMAKFRYILPVYGICREPVGLVMEYMETGSLEKLLASEPLPWDLRFRIIHETAVGMNFLHCMAPPLLHLDLKPANILLDAHYHVKISDFGLAKCNGLSHSHDLSMDGLFGTIAYLPPERIREKSRLFDTKHDVYSFAIVIWGVLTQKKPFADEKNILHIMVKVVKGHRPELPPVCRARPRACSHLIRLMQRCWQGDPRVRPTFQGNGLNGELIRQVLAALLPVTGRWRSPGEGFRLESEVIIRVTCPLSSPQEITSETEDLCEKPDDEVKETAHDLDVKSPPEPRSEVVPARLKRASAPTFDNDYSLSELLSQLDSGVSQAVEGPEELSRSSSESKLPSSGSGKRLSGVSSVDSAFSSRGSLSLSFEREPSTSDLGTTDVQKKKLVDAIVSGDTSKLMKILQPQDVDLALDSGASLLHLAVEAGQEECAKWLLLNNANPNLSNRRGSTPLHMAVERRVRGVVELLLARKISVNAKDEDQWTALHFAAQNGDESSTRLLLEKNASVNEVDFEGRTPMHVACQHGQENIVRILLRRGVDVSLQGKDAWLPLHYAAWQGHLPIVKLLAKQPGVSVNAQTLDGRTPLHLAAQRGHYRVARILIDLCSDVNVCSLLAQTPLHVAAETGHTSTARLLLHRGAGKEAMTSDGYTALHLAARNGHLATVKLLVEEKADVLARGPLNQTALHLAAAHGHSEVVEELVSADVIDLFDEQGLSALHLAAQGRHAQTVETLLRHGAHINLQSLKFQGGHGPAATLLRRSKT

T53578	TARGETID	T53578
T53578	FORMERID	TTDR00303
T53578	UNIPROID	FABI1_RHIME
T53578	TARGNAME	Bacterial NADH-dependent enoyl-ACP reductase 1 (Bact fabI1)
T53578	GENENAME	Bact fabI1
T53578	TARGTYPE	Literature-reported
T53578	SYNONYMS	NADH-dependent enoyl-ACP reductase 1; Enoyl-[acyl-carrier-protein] reductase [NADH] 1
T53578	FUNCTION	A key enzyme of the type II fatty acid synthesis (FAS) system. Essential for bacterial metabolism and its sequence conservation across many bacterial species but distinctly different from those of mammalian fatty acid biosynthesis enzymes.
T53578	BIOCLASS	CH-CH donor oxidoreductase
T53578	SEQUENCE	MAQASGLMNGKRGVIMGVANNRSIAWGIAKALAEAGAEIALTWQGDALKKRVEPLAQELGAFMAGHCDVTDLATIDAVFSALEEKWGKIDFVVHAIAFSDKDELTGRYLDTSRDNFARTMDISVYSFTAVAARADRVMNDGGSILTLTYYGAEKVMPHYNVMGVAKAALEASVRYLAVDLGNRGIRVNAISAGPIKTLAASGIGDFRYILKWNEYNAPLKRTVSIEEVGNSALYLLSDLSSGVTGEVHHVDSGYHTVGMKAVDAPDISVLKD
T53578	DRUGINFO	D08ZHT	Diazaborines	Investigative

T79589	TARGETID	T79589
T79589	FORMERID	TTDR00304
T79589	UNIPROID	FABI2_RHIME
T79589	TARGNAME	Bacterial NADH-dependent enoyl-ACP reductase 2 (Bact fabI2)
T79589	GENENAME	Bact fabI2
T79589	TARGTYPE	Literature-reported
T79589	SYNONYMS	NADH-dependent enoyl-ACP reductase 2; Enoyl-[acyl-carrier-protein] reductase [NADH] 2
T79589	FUNCTION	Identified as the FabI protein, which is the target of a group of antibacterial compounds, the diazaborines.
T79589	BIOCLASS	CH-CH donor oxidoreductase
T79589	SEQUENCE	MNGLMNGKRGLIMGVANSHSIAWGIAKSLAAQGAELAFTYQGEALGKRVKPLAAEVNSDFLLPCDVEDIGSVDAVVDAIKERWGKLDFVVHAIGFSDKNELKGLYADTTRDNFSRTMVISCFSFTEIAKRAAELMSEGGTMLTLTYGGSMRVMPNYNVMGVAKAALEASVRYLAADYGSRGIRVNAISAGPIRTLAGAGISDARAMLSWQQKNSPLRRTVTIEDVGSSALYLLSDLSRGVTGEIHYVDSGYNITSMPTLEALRVADAD
T79589	DRUGINFO	D08ZHT	Diazaborines	Investigative

T32445	TARGETID	T32445
T32445	FORMERID	TTDI01414
T32445	UNIPROID	CABC1_PROVU
T32445	TARGNAME	Proteus vulgaris Chondroitin ABC endolyase 1 (PROVU cABC1)
T32445	GENENAME	PROVU cABC1
T32445	TARGTYPE	Literature-reported
T32445	SYNONYMS	cABC I; INN=Condoliase; Endochondroitinase ABC; Chondroitinase ABC I; Chondroitin sulfate ABC lyase I; Chondroitin sulfate ABC endolyase; Chondroitin ABC lyase I; Chondroitin ABC endoeliminase; ChS ABC lyase I
T32445	FUNCTION	Endolytic, broad-specificity glycosaminoglycan lyase, which degrades the polysaccharides chondroitin, chondroitin-4-sulfate, chondroitin-6-sulfate, dermatan sulfate and to a lesser extent hyaluronan, by beta-elimination of 1,4-hexosaminidic bond to unsaturated tetrasaccharides and disaccharides. Is not active against keratan sulfate, heparan sulfate, and heparin. Is able to promote functional recovery in the injured central nervous system (CNS), via its role in the disruption of the normal organization of the extracellular matrix (ECM).
T32445	PDBSTRUC	1HN0
T32445	ECNUMBER	EC 4.2.2.20
T32445	SEQUENCE	MPIFRFTALAMTLGLLSAPYNAMAATSNPAFDPKNLMQSEIYHFAQNNPLADFSSDKNSILTLSDKRSIMGNQSLLWKWKGGSSFTLHKKLIVPTDKEASKAWGRSSTPVFSFWLYNEKPIDGYLTIDFGEKLISTSEAQAGFKVKLDFTGWRAVGVSLNNDLENREMTLNATNTSSDGTQDSIGRSLGAKVDSIRFKAPSNVSQGEIYIDRIMFSVDDARYQWSDYQVKTRLSEPEIQFHNVKPQLPVTPENLAAIDLIRQRLINEFVGGEKETNLALEENISKLKSDFDALNIHTLANGGTQGRHLITDKQIIIYQPENLNSQDKQLFDNYVILGNYTTLMFNISRAYVLEKDPTQKAQLKQMYLLMTKHLLDQGFVKGSALVTTHHWGYSSRWWYISTLLMSDALKEANLQTQVYDSLLWYSREFKSSFDMKVSADSSDLDYFNTLSRQHLALLLLEPDDQKRINLVNTFSHYITGALTQVPPGGKDGLRPDGTAWRHEGNYPGYSFPAFKNASQLIYLLRDTPFSVGESGWNNLKKAMVSAWIYSNPEVGLPLAGRHPFNSPSLKSVAQGYYWLAMSAKSSPDKTLASIYLAISDKTQNESTAIFGETITPASLPQGFYAFNGGAFGIHRWQDKMVTLKAYNTNVWSSEIYNKDNRYGRYQSHGVAQIVSNGSQLSQGYQQEGWDWNRMQGATTIHLPLKDLDSPKPHTLMQRGERGFSGTSSLEGQYGMMAFDLIYPANLERFDPNFTAKKSVLAADNHLIFIGSNINSSDKNKNVETTLFQHAITPTLNTLWINGQKIENMPYQTTLQQGDWLIDSNGNGYLITQAEKVNVSRQHQVSAENKNRQPTEGNFSSAWIDHSTRPKDASYEYMVFLDATPEKMGEMAQKFRENNGLYQVLRKDKDVHIILDKLSNVTGYAFYQPASIEDKWIKKVNKPAIVMTHRQKDTLIVSAVTPDLNMTRQKAATPVTINVTINGKWQSADKNSEVKYQVSGDNTELTFTSYFGIPQEIKLSPLP

T85005	TARGETID	T85005
T85005	FORMERID	TTDNR00760
T85005	UNIPROID	TYB4_HUMAN
T85005	TARGNAME	Thymosin beta-4 (TMSB4X)
T85005	GENENAME	TMSB4X
T85005	TARGTYPE	Literature-reported
T85005	SYNONYMS	TMSB4X; T beta-4; Fx
T85005	FUNCTION	Seraspenide inhibits the entry of hematopoietic pluripotent stem cellsinto the S-phase.
T85005	PDBSTRUC	4PL8; 4PL7; 3TU5; 1UY5
T85005	BIOCLASS	Thymosin family
T85005	SEQUENCE	MSDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES

T24255	TARGETID	T24255
T24255	FORMERID	TTDR00723
T24255	UNIPROID	ISPF_PLAF7
T24255	TARGNAME	Plasmodium MECDP-synthase (Malaria ISPF)
T24255	GENENAME	Malaria ISPF
T24255	TARGTYPE	Literature-reported
T24255	SYNONYMS	MECPS; MECDP-synthase; ISPF
T24255	FUNCTION	Converts 4-diphosphocytidyl-2C-methyl-D-erythritol 2- phosphate into 2C-methyl-D-erythritol 2,4-cyclodiphosphate and CMP.
T24255	PDBSTRUC	4C82; 4C81
T24255	BIOCLASS	Phosphorus-oxygen lyase
T24255	SEQUENCE	MFLKGYTSNVVLIILTFFILLTKEEKNIKNNISGYCFLNFGLKKNAIIKKREKQNLKLFCYNGIRIGQGYDIHKIKVLDEEYNTYANNDFNKNEQSFKTLTLGGVKINNVLVLSHSDGDIIYHSIVDSILGALGSLDIGTLFPDKDEKNKNKNSAIFLRYARLLIYKKNYDIGNVDINVIAQVPKISNIRKNIIKNISTVLNIDESQISVKGKTHEKLGVIGEKKAIECFANILLIPKNS

T07607	TARGETID	T07607
T07607	FORMERID	TTDR00897
T07607	UNIPROID	RPB7_HUMAN
T07607	TARGNAME	DNA-directed RNA polymerase II RPB7 (hsRPB7)
T07607	GENENAME	POLR2G
T07607	TARGTYPE	Literature-reported
T07607	SYNONYMS	RPB7; Human RNA polymerase II seventh subunit; HsRPB7
T07607	FUNCTION	Dna-dependent rna polymerase catalyzes the transcription of dna into rna using the four ribonucleoside triphosphates as substrates. It is suggested that rpb7 contributes to the function of rna polymerase ii in the absence of rpb4.
T07607	PDBSTRUC	5IYD; 5IYC; 5IYB; 5IYA; 5IY9
T07607	BIOCLASS	Kinase
T07607	SEQUENCE	MFYHISLEHEILLHPRYFGPNLLNTVKQKLFTEVEGTCTGKYGFVIAVTTIDNIGAGVIQPGRGFVLYPVKYKAIVFRPFKGEVVDAVVTQVNKVGLFTEIGPMSCFISRHSIPSEMEFDPNSNPPCYKTMDEDIVIQQDDEIRLKIVGTRVDKNDIFAIGSLMDDYLGLVS

T59875	TARGETID	T59875
T59875	FORMERID	TTDI03184
T59875	UNIPROID	ERR3_HUMAN
T59875	TARGNAME	Estrogen-related receptor-gamma (ESRRG)
T59875	GENENAME	ESRRG
T59875	TARGTYPE	Literature-reported
T59875	SYNONYMS	Nuclear receptor subfamily 3 group B member 3; NR3B3; KIAA0832; Estrogen-related receptor gamma; Estrogen receptor-related protein 3; ERRG2; ERR3; ERR gamma-2
T59875	FUNCTION	Binds specifically to an estrogen response element and activates reporter genes controlled by estrogen response elements. Induces the expression of PERM1 in the skeletal muscle. Orphan receptor that acts as transcription activator in the absence of bound ligand.
T59875	PDBSTRUC	6A6K; 5YSO; 2ZKC; 2ZBS; 2ZAS
T59875	BIOCLASS	Nuclear hormone receptor
T59875	SEQUENCE	MDSVELCLPESFSLHYEEELLCRMSNKDRHIDSSCSSFIKTEPSSPASLTDSVNHHSPGGSSDASGSYSSTMNGHQNGLDSPPLYPSAPILGGSGPVRKLYDDCSSTIVEDPQTKCEYMLNSMPKRLCLVCGDIASGYHYGVASCEACKAFFKRTIQGNIEYSCPATNECEITKRRRKSCQACRFMKCLKVGMLKEGVRLDRVRGGRQKYKRRIDAENSPYLNPQLVQPAKKPYNKIVSHLLVAEPEKIYAMPDPTVPDSDIKALTTLCDLADRELVVIIGWAKHIPGFSTLSLADQMSLLQSAWMEILILGVVYRSLSFEDELVYADDYIMDEDQSKLAGLLDLNNAILQLVKKYKSMKLEKEEFVTLKAIALANSDSMHIEDVEAVQKLQDVLHEALQDYEAGQHMEDPRRAGKMLMTLPLLRQTSTKAVQHFYNIKLEGKVPMHKLFLEMLEAKV
T59875	DRUGINFO	D0DX8T	GSK4716	Investigative
T59875	DRUGINFO	D06JPQ	DY131	Investigative
T59875	DRUGINFO	D0S9YX	biochanin A	Investigative
T59875	DRUGINFO	D0SY2M	daidzein	Investigative

T65721	TARGETID	T65721
T65721	FORMERID	TTDI01371
T65721	UNIPROID	RAC1_HUMAN
T65721	TARGNAME	Ras-like protein TC25 (RAC1)
T65721	GENENAME	RAC1
T65721	TARGTYPE	Literature-reported
T65721	SYNONYMS	p21-Rac1; TC25; MIG5; Cell migration-inducing gene 5 protein
T65721	FUNCTION	Plasma membrane-associated small GTPase which cycles between active GTP-bound and inactive GDP-bound states. In its active state, binds to a variety of effector proteins to regulate cellular responses such as secretory processes, phagocytosis of apoptotic cells, epithelial cell polarization, neurons adhesion, migration and differentiation, and growth-factor induced formation of membrane ruffles. Rac1 p21/rho GDI heterodimer is the active component of the cytosolic factor sigma 1, which is involved in stimulation of the NADPH oxidase activity in macrophages. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. Stimulates PKN2 kinase activity. In concert with RAB7A, plays a role in regulating the formation of RBs (ruffled borders) in osteoclasts. In podocytes, promotes nuclear shuttling of NR3C2; this modulation is required for a proper kidney functioning. Required for atypical chemokine receptor ACKR2-induced LIMK1-PAK1-dependent phosphorylation of cofilin (CFL1) and for up-regulation of ACKR2 from endosomal compartment to cell membrane, increasing its efficiency in chemokine uptake and degradation. In neurons, is involved in dendritic spine formation and synaptic plasticity (By similarity). In synapses, seems to mediate the regulation of F-actin cluster formation performed by SHANK3.
T65721	PDBSTRUC	6BC1; 6AGP; 5O33; 5N6O; 5HZH
T65721	ECNUMBER	EC 3.6.5.2
T65721	SEQUENCE	MQAIKCVVVGDGAVGKTCLLISYTTNAFPGEYIPTVFDNYSANVMVDGKPVNLGLWDTAGQEDYDRLRPLSYPQTDVFLICFSLVSPASFENVRAKWYPEVRHHCPNTPIILVGTKLDLRDDKDTIEKLKEKKLTPITYPQGLAMAKEIGAVKYLECSALTQRGLKTVFDEAIRAVLCPPPVKKRKRKCLLL

T16398	TARGETID	T16398
T16398	FORMERID	TTDR01212
T16398	UNIPROID	FABD_MYCBO
T16398	TARGNAME	Mycobacterium Malonyl-CoA:acyl carrier transacylase (MycB fabD)
T16398	GENENAME	MycB fabD
T16398	TARGTYPE	Literature-reported
T16398	SYNONYMS	Malonyl CoA-acyl carrier protein transacylase; MCT
T16398	FUNCTION	Essential for the biosynthesis of fatty acids in all bacteria. Catalyzes the transacylation of malonate from malonyl-CoA to activated holo-ACP, to generate malonyl-ACP, which is an elongation substrate in fatty acid biosynthesis.
T16398	BIOCLASS	Acyltransferase
T16398	ECNUMBER	EC 2.3.1.39
T16398	SEQUENCE	MIALLAPGQGSQTEGMLSPWLQLPGAADQIAAWSKAADLDLARLGTTASTEEITDTAVAQPLIVAATLLAHQELARRCVLAGKDVIVAGHSVGEIAAYAIAGVIAADDAVALAATRGAEMAKACATEPTGMSAVLGGDETEVLSRLEQLDLVPANRNAAGQIVAAGRLTALEKLAEDPPAKARVRALGVAGAFHTEFMAPALDGFAAAAANIATADPTATLLSNRDGKPVTSAAAAMDTLVSQLTQPVRWDLCTATLREHTVTAIVEFPPAGTLSGIAKRELRGVPARAVKSPADLDELANL

T91449	TARGETID	T91449
T91449	FORMERID	TTDI01416
T91449	UNIPROID	CLPP_STAAW
T91449	TARGNAME	Staphylococcus ATP-dependent protease ClpP (Stap-coc CLPP)
T91449	GENENAME	Stap-coc CLPP
T91449	TARGTYPE	Literature-reported
T91449	SYNONYMS	Stap-coc Endopeptidase Clp; ATP-dependent Clp protease proteolytic subunit
T91449	FUNCTION	Cleaves peptides in various proteins in a process that requires ATP hydrolysis. Has a chymotrypsin-like activity. Plays a major role in the degradation of misfolded proteins.
T91449	PDBSTRUC	4EMP; 4EMM; 3STA; 3ST9
T91449	ECNUMBER	EC 3.4.21.92
T91449	SEQUENCE	MNLIPTVIETTNRGERAYDIYSRLLKDRIIMLGSQIDDNVANSIVSQLLFLQAQDSEKDIYLYINSPGGSVTAGFAIYDTIQHIKPDVQTICIGMAASMGSFLLAAGAKGKRFALPNAEVMIHQPLGGAQGQATEIEIAANHILKTREKLNRILSERTGQSIEKIQKDTDRDNFLTAEEAKEYGLIDEVMVPETK

T15526	TARGETID	T15526
T15526	FORMERID	TTDR00678
T15526	UNIPROID	US28_HCMVT
T15526	TARGNAME	Cytomegalovirus Glycoprotein coupled receptor (CMV US28)
T15526	GENENAME	CMV US28
T15526	TARGTYPE	Literature-reported
T15526	SYNONYMS	HHRF3; G-protein coupled receptor homolog US28
T15526	FUNCTION	Receptor for a C-C type chemokine. Binds to MIP-1 alpha, RANTES, and MCP-1 and subsequently transduces a signal by increasing the intracellular calcium ions level. May regulate viral latency or reactivation; potential pathway for virally transformed cell proliferation.
T15526	PDBSTRUC	5WB2; 5WB1
T15526	BIOCLASS	GPCR rhodopsin
T15526	SEQUENCE	MTPTTTTAELTTEFDYDEDATPCVFTDVLNQSKPVTLFLYGVVFLFGSIGNFLVIFTITWRRRIQCSGDVYFINLAAADLLFVCTLPLWMQYLLDHNSLASVPCTLLTACFYVAMFASLCFITEIALDRYYAIVYMRYRPVKQACLFSIFWWIFAVIIAIPHFMVVTKKDNQCMTDYDYLEVSYPIILNVELMLGAFVIPLSVISYCYYRISRIVAVSQSRHKGRIVRVLIAVVLVFIIFWLPYHLTLFVDTLKLLKWISSSCEFERSLKRALILTESLAFCHCCLNPLLYVFVGTKFRQELHCLLAEFRQRLFSRDVSWYHSMSFSRRSSPSRRETSSDTLSDEVCRVSQIIP

T95961	TARGETID	T95961
T95961	FORMERID	TTDR01264
T95961	UNIPROID	I13R1_HUMAN
T95961	TARGNAME	Interleukin 13 receptor alpha-1 (IL13RA1)
T95961	GENENAME	IL13RA1
T95961	TARGTYPE	Literature-reported
T95961	SYNONYMS	Interleukin-13 receptor subunit alpha-1; IL13RA; IL13R; IL-13RA1; IL-13RA-1; IL-13R-alpha-1; IL-13R subunit alpha-1; IL-13R alpha-1 chain; IL-13 receptor subunit alpha-1; Cancer/testis antigen 19; CT19; CD213a1 antigen; CD213a1
T95961	FUNCTION	Together with IL4RA can form a functional receptor for IL13. Also serves as an alternate accessory protein to the common cytokine receptor gamma chain for interleukin-4 (IL4) signaling, but cannot replace the function of IL2RG in allowing enhanced interleukin-2 (IL2) binding activity. Binds with low affinity to interleukin-13 (IL13).
T95961	PDBSTRUC	5E4E; 4HWB; 3BPO; 3BPN
T95961	BIOCLASS	Cytokine receptor
T95961	SEQUENCE	MEWPARLCGLWALLLCAGGGGGGGGAAPTETQPPVTNLSVSVENLCTVIWTWNPPEGASSNCSLWYFSHFGDKQDKKIAPETRRSIEVPLNERICLQVGSQCSTNESEKPSILVEKCISPPEGDPESAVTELQCIWHNLSYMKCSWLPGRNTSPDTNYTLYYWHRSLEKIHQCENIFREGQYFGCSFDLTKVKDSSFEQHSVQIMVKDNAGKIKPSFNIVPLTSRVKPDPPHIKNLSFHNDDLYVQWENPQNFISRCLFYEVEVNNSQTETHNVFYVQEAKCENPEFERNVENTSCFMVPGVLPDTLNTVRIRVKTNKLCYEDDKLWSNWSQEMSIGKKRNSTLYITMLLIVPVIVAGAIIVLLLYLKRLKIIIFPPIPDPGKIFKEMFGDQNDDTLHWKKYDIYEKQTKEETDSVVLIENLKKASQ

T72010	TARGETID	T72010
T72010	FORMERID	TTDNR00711
T72010	UNIPROID	NGAL_HUMAN
T72010	TARGNAME	Neutrophil gelatinase-associated lipocalin (LCN2)
T72010	GENENAME	LCN2
T72010	TARGTYPE	Literature-reported
T72010	SYNONYMS	p25; Siderocalin LCN2; Oncogene 24p3; NGAL; Lipocalin-2; LCN2; 25 kDa alpha-2-microglobulin-related subunit of MMP-9
T72010	FUNCTION	Iron-trafficking protein involved in multiple processes such as apoptosis, innate immunity and renal development. Binds iron through association with 2,5-dihydroxybenzoic acid (2,5- DHBA), a siderophore that shares structural similarities withbacterial enterobactin, and delivers or removes iron from the cell, depending on the context. Iron-bound form (holo-24p3) is internalized following binding to the SLC22A17 (24p3R) receptor, leading to release of iron and subsequent increase of intracellular iron concentration. In contrast, association of the iron-free form (apo-24p3) with the SLC22A17 (24p3R) receptor is followed by association with an intracellular siderophore, iron chelation and iron transfer to the extracellular medium, thereby reducing intracellular iron concentration. Involved in apoptosis due to interleukin-3 (IL3) deprivation: iron-loaded form increases intracellular iron concentration without promoting apoptosis, while iron-free form decreases intracellular iron levels, inducing expression of the proapoptotic protein BCL2L11/BIM, resulting in apoptosis. Involved in innate immunity, possibly by sequestrating iron, leading to limit bacterial growth. .
T72010	PDBSTRUC	6GR0; 6GQZ; 5NKN; 5N48; 5N47
T72010	BIOCLASS	Calycin family
T72010	SEQUENCE	MPLGLLWLGLALLGALHAQAQDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFIRFSKSLGLPENHIVFPVPIDQCIDG

T38093	TARGETID	T38093
T38093	FORMERID	TTDI02538
T38093	UNIPROID	RET5_HUMAN
T38093	TARGNAME	Cellular retinol binding protein III (RBP5)
T38093	GENENAME	RBP5
T38093	TARGTYPE	Literature-reported
T38093	SYNONYMS	Retinol-binding protein 5; RBP5; HRBPiso; CRBP-III
T38093	FUNCTION	Intracellular transport of retinol.
T38093	PDBSTRUC	6E5W; 1GGL
T38093	BIOCLASS	Calycin family
T38093	SEQUENCE	MPPNLTGYYRFVSQKNMEDYLQALNISLAVRKIALLLKPDKEIEHQGNHMTVRTLSTFRNYTVQFDVGVEFEEDLRSVDGRKCQTIVTWEEEHLVCVQKGEVPNRGWRHWLEGEMLYLELTARDAVCEQVFRKVR

T47351	TARGETID	T47351
T47351	FORMERID	TTDNR00636
T47351	UNIPROID	ARF1_HUMAN
T47351	TARGNAME	ADP-ribosylation factor 1 (ARF1)
T47351	GENENAME	ARF1
T47351	TARGTYPE	Literature-reported
T47351	SYNONYMS	PVNH8
T47351	FUNCTION	Modulates vesicle budding and uncoating within the Golgi complex. Deactivation induces the redistribution of the entire Golgi complex to the endoplasmic reticulum, suggesting a crucial role in protein trafficking. In its GTP-bound form, its triggers the association with coat proteins with the Golgi membrane. The hydrolysis of ARF1-bound GTP, which is mediated by ARFGAPs proteins, is required for dissociation of coat proteins from Golgi membranes and vesicles. The GTP-bound form interacts with PICK1 to limit PICK1-mediated inhibition of Arp2/3 complex activity; the function is linked to AMPA receptor (AMPAR) trafficking, regulation of synaptic plasicity of excitatory synapses and spine shrinkage during long-term depression (LTD). GTP-binding protein involved in protein trafficking among different compartments.
T47351	PDBSTRUC	6FAE; 6DFF; 6D84; 6D83; 6CRI
T47351	BIOCLASS	Small GTPase
T47351	SEQUENCE	MGNIFANLFKGLFGKKEMRILMVGLDAAGKTTILYKLKLGEIVTTIPTIGFNVETVEYKNISFTVWDVGGQDKIRPLWRHYFQNTQGLIFVVDSNDRERVNEAREELMRMLAEDELRDAVLLVFANKQDLPNAMNAAEITDKLGLHSLRHRNWYIQATCATSGDGLYEGLDWLSNQLRNQK

T80175	TARGETID	T80175
T80175	FORMERID	TTDR00955
T80175	UNIPROID	DLDH_TRYCR
T80175	TARGNAME	Trypanosoma Dihydrolipoamide dehydrogenase (Trypano LPD)
T80175	GENENAME	Trypano LPD
T80175	TARGTYPE	Literature-reported
T80175	SYNONYMS	Lipoamide dehydrogenase; LipDH; LPD; Glycine cleavage system L protein; Dihydrolipoamide dehydrogenase
T80175	FUNCTION	Lipoamide dehydrogenase is a component of the glycine cleavage system as well as of the alpha-ketoacid dehydrogenase complexes.
T80175	PDBSTRUC	2QAE
T80175	BIOCLASS	Sulfur donor oxidoreductase
T80175	SEQUENCE	MFRRCAVKLNPYDVVVIGGGPGGYVASIKAAQLGMKTACVEKRGALGGTCLNVGCIPSKALLHATHVYHDAHANFARYGLMGGEGVTMDSAKMQQQKERAVKGLTGGVEYLFKKNKVTYYKGEGSFETAHSIRVNGLDGKQEMFETKKTIIATGSEPTELPFLPFDEKVVLSSTGALALPRVPKTMVVIGGGVIGLELGSVWARLGAKVTVVEFAPRCAPTLDEDVTNALVGALAKNEKMKFMTSTKVVGGTNNGDSVSLEVEGKNGKRETVTCEALLVSVGRRPFTGGLGLDKINVAKNERGFVKIGDHFETSIPDVYAIGDVVDKGPMLAHKAEDEGVACAEILAGKPGHVNYGVIPAVIYTMPEVASVGKSEEELKKEGVAYKVGKFPFNANSRAKAVSTEDGFVKVLVDKATDRILGVHIVCTTAGELIGEACLAMEYGASSEDVGRTCHAHPTMSEALKEACMALVAKTINF
T80175	DRUGINFO	D00IMW	Flavin-Adenine Dinucleotide	Investigative
T80175	DRUGINFO	D0R6JE	Nicotinamide-Adenine-Dinucleotide	Investigative

T75210	TARGETID	T75210
T75210	FORMERID	TTDR00546
T75210	UNIPROID	LRP2_HUMAN
T75210	TARGNAME	LDL receptor related protein-2 (LRP-2)
T75210	GENENAME	LRP2
T75210	TARGTYPE	Literature-reported
T75210	SYNONYMS	Megalin; Lowdensity lipoprotein receptorrelated protein 2; Low-density lipoprotein receptor-related protein 2; Gp330; Glycoprotein 330
T75210	FUNCTION	Acts together with CUBN to mediate endocytosis of high-density lipoproteins. Mediates receptor-mediated uptake of polybasic drugs such as aprotinin, aminoglycosides and polymyxin B. In the kidney, mediates the tubular uptake and clearance of leptin. Also mediates transport of leptin across the blood-brain barrier through endocytosis at the choroid plexus epithelium. Endocytosis of leptin in neuronal cells is required for hypothalamic leptin signaling and leptin-mediated regulation of feeding and body weight. Mediates endocytosis and subsequent lysosomal degradation of CST3 in kidney proximal tubule cells. Mediates renal uptake of 25-hydroxyvitamin D3 in complex with the vitamin D3 transporter GC/DBP. Mediates renal uptake of metallothionein-bound heavy metals. Together with CUBN, mediates renal reabsorption of myoglobin. Mediates renal uptake and subsequent lysosomal degradation of APOM. Plays a role in kidney selenium homeostasis by mediating renal endocytosis of selenoprotein SEPP1. Mediates renal uptake of the antiapoptotic protein BIRC5/survivin which may be important for functional integrity of the kidney. Mediates renal uptake of matrix metalloproteinase MMP2 in complex with metalloproteinase inhibitor TIMP1. Mediates endocytosis of Sonic hedgehog protein N-product (ShhN), the active product of SHH. Also mediates ShhN transcytosis. In the embryonic neuroepithelium, mediates endocytic uptake and degradation of BMP4, is required for correct SHH localization in the ventral neural tube and plays a role in patterning of the ventral telencephalon. Required at the onset of neurulation to sequester SHH on the apical surface of neuroepithelial cells of the rostral diencephalon ventral midline and to control PTCH1-dependent uptake and intracellular trafficking of SHH. During neurulation, required in neuroepithelial cells for uptake of folate bound to the folate receptor FOLR1 which is necessary for neural tube closure. In the adult brain, negatively regulates BMP signaling in the subependymal zone which enables neurogenesis to proceed. In astrocytes, mediates endocytosis of ALB which is required for the synthesis of the neurotrophic factor oleic acid. Involved in neurite branching. During optic nerve development, required for SHH-mediated migration and proliferation of oligodendrocyte precursor cells. Mediates endocytic uptake and clearance of SHH in the retinal margin which protects retinal progenitor cells from mitogenic stimuli and keeps them quiescent. Plays a role in reproductive organ development by mediating uptake in reproductive tissues of androgen and estrogen bound to the sex hormone binding protein SHBG. Mediates endocytosis of angiotensin-2. Also mediates endocytosis of angiotensis 1-7. Binds to the complex composed of beta-amyloid protein 40 and CLU/APOJ and mediates its endocytosis and lysosomal degradation. Required for embryonic heart development. Required for normal hearing, possibly through interaction with estrogen in the inner ear. Multiligand endocytic receptor.
T75210	PDBSTRUC	2M0P
T75210	BIOCLASS	Low density lipoprotein receptor
T75210	SEQUENCE	MDRGPAAVACTLLLALVACLAPASGQECDSAHFRCGSGHCIPADWRCDGTKDCSDDADEIGCAVVTCQQGYFKCQSEGQCIPNSWVCDQDQDCDDGSDERQDCSQSTCSSHQITCSNGQCIPSEYRCDHVRDCPDGADENDCQYPTCEQLTCDNGACYNTSQKCDWKVDCRDSSDEINCTEICLHNEFSCGNGECIPRAYVCDHDNDCQDGSDEHACNYPTCGGYQFTCPSGRCIYQNWVCDGEDDCKDNGDEDGCESGPHDVHKCSPREWSCPESGRCISIYKVCDGILDCPGREDENNTSTGKYCSMTLCSALNCQYQCHETPYGGACFCPPGYIINHNDSRTCVEFDDCQIWGICDQKCESRPGRHLCHCEEGYILERGQYCKANDSFGEASIIFSNGRDLLIGDIHGRSFRILVESQNRGVAVGVAFHYHLQRVFWTDTVQNKVFSVDINGLNIQEVLNVSVETPENLAVDWVNNKIYLVETKVNRIDMVNLDGSYRVTLITENLGHPRGIAVDPTVGYLFFSDWESLSGEPKLERAFMDGSNRKDLVKTKLGWPAGVTLDMISKRVYWVDSRFDYIETVTYDGIQRKTVVHGGSLIPHPFGVSLFEGQVFFTDWTKMAVLKANKFTETNPQVYYQASLRPYGVTVYHSLRQPYATNPCKDNNGGCEQVCVLSHRTDNDGLGFRCKCTFGFQLDTDERHCIAVQNFLIFSSQVAIRGIPFTLSTQEDVMVPVSGNPSFFVGIDFDAQDSTIFFSDMSKHMIFKQKIDGTGREILAANRVENVESLAFDWISKNLYWTDSHYKSISVMRLADKTRRTVVQYLNNPRSVVVHPFAGYLFFTDWFRPAKIMRAWSDGSHLLPVINTTLGWPNGLAIDWAASRLYWVDAYFDKIEHSTFDGLDRRRLGHIEQMTHPFGLAIFGEHLFFTDWRLGAIIRVRKADGGEMTVIRSGIAYILHLKSYDVNIQTGSNACNQPTHPNGDCSHFCFPVPNFQRVCGCPYGMRLASNHLTCEGDPTNEPPTEQCGLFSFPCKNGRCVPNYYLCDGVDDCHDNSDEQLCGTLNNTCSSSAFTCGHGECIPAHWRCDKRNDCVDGSDEHNCPTHAPASCLDTQYTCDNHQCISKNWVCDTDNDCGDGSDEKNCNSTETCQPSQFNCPNHRCIDLSFVCDGDKDCVDGSDEVGCVLNCTASQFKCASGDKCIGVTNRCDGVFDCSDNSDEAGCPTRPPGMCHSDEFQCQEDGICIPNFWECDGHPDCLYGSDEHNACVPKTCPSSYFHCDNGNCIHRAWLCDRDNDCGDMSDEKDCPTQPFRCPSWQWQCLGHNICVNLSVVCDGIFDCPNGTDESPLCNGNSCSDFNGGCTHECVQEPFGAKCLCPLGFLLANDSKTCEDIDECDILGSCSQHCYNMRGSFRCSCDTGYMLESDGRTCKVTASESLLLLVASQNKIIADSVTSQVHNIYSLVENGSYIVAVDFDSISGRIFWSDATQGKTWSAFQNGTDRRVVFDSSIILTETIAIDWVGRNLYWTDYALETIEVSKIDGSHRTVLISKNLTNPRGLALDPRMNEHLLFWSDWGHHPRIERASMDGSMRTVIVQDKIFWPCGLTIDYPNRLLYFMDSYLDYMDFCDYNGHHRRQVIASDLIIRHPYALTLFEDSVYWTDRATRRVMRANKWHGGNQSVVMYNIQWPLGIVAVHPSKQPNSVNPCAFSRCSHLCLLSSQGPHFYSCVCPSGWSLSPDLLNCLRDDQPFLITVRQHIIFGISLNPEVKSNDAMVPIAGIQNGLDVEFDDAEQYIYWVENPGEIHRVKTDGTNRTVFASISMVGPSMNLALDWISRNLYSTNPRTQSIEVLTLHGDIRYRKTLIANDGTALGVGFPIGITVDPARGKLYWSDQGTDSGVPAKIASANMDGTSVKTLFTGNLEHLECVTLDIEEQKLYWAVTGRGVIERGNVDGTDRMILVHQLSHPWGIAVHDSFLYYTDEQYEVIERVDKATGANKIVLRDNVPNLRGLQVYHRRNAAESSNGCSNNMNACQQICLPVPGGLFSCACATGFKLNPDNRSCSPYNSFIVVSMLSAIRGFSLELSDHSETMVPVAGQGRNALHVDVDVSSGFIYWCDFSSSVASDNAIRRIKPDGSSLMNIVTHGIGENGVRGIAVDWVAGNLYFTNAFVSETLIEVLRINTTYRRVLLKVTVDMPRHIVVDPKNRYLFWADYGQRPKIERSFLDCTNRTVLVSEGIVTPRGLAVDRSDGYVYWVDDSLDIIARIRINGENSEVIRYGSRYPTPYGITVFENSIIWVDRNLKKIFQASKEPENTEPPTVIRDNINWLRDVTIFDKQVQPRSPAEVNNNPCLENNGGCSHLCFALPGLHTPKCDCAFGTLQSDGKNCAISTENFLIFALSNSLRSLHLDPENHSPPFQTINVERTVMSLDYDSVSDRIYFTQNLASGVGQISYATLSSGIHTPTVIASGIGTADGIAFDWITRRIYYSDYLNQMINSMAEDGSNRTVIARVPKPRAIVLDPCQGYLYWADWDTHAKIERATLGGNFRVPIVNSSLVMPSGLTLDYEEDLLYWVDASLQRIERSTLTGVDREVIVNAAVHAFGLTLYGQYIYWTDLYTQRIYRANKYDGSGQIAMTTNLLSQPRGINTVVKNQKQQCNNPCEQFNGGCSHICAPGPNGAECQCPHEGNWYLANNRKHCIVDNGERCGASSFTCSNGRCISEEWKCDNDNDCGDGSDEMESVCALHTCSPTAFTCANGRCVQYSYRCDYYNDCGDGSDEAGCLFRDCNATTEFMCNNRRCIPREFICNGVDNCHDNNTSDEKNCPDRTCQSGYTKCHNSNICIPRVYLCDGDNDCGDNSDENPTYCTTHTCSSSEFQCASGRCIPQHWYCDQETDCFDASDEPASCGHSERTCLADEFKCDGGRCIPSEWICDGDNDCGDMSDEDKRHQCQNQNCSDSEFLCVNDRPPDRRCIPQSWVCDGDVDCTDGYDENQNCTRRTCSENEFTCGYGLCIPKIFRCDRHNDCGDYSDERGCLYQTCQQNQFTCQNGRCISKTFVCDEDNDCGDGSDELMHLCHTPEPTCPPHEFKCDNGRCIEMMKLCNHLDDCLDNSDEKGCGINECHDPSISGCDHNCTDTLTSFYCSCRPGYKLMSDKRTCVDIDECTEMPFVCSQKCENVIGSYICKCAPGYLREPDGKTCRQNSNIEPYLIFSNRYYLRNLTIDGYFYSLILEGLDNVVALDFDRVEKRLYWIDTQRQVIERMFLNKTNKETIINHRLPAAESLAVDWVSRKLYWLDARLDGLFVSDLNGGHRRMLAQHCVDANNTFCFDNPRGLALHPQYGYLYWADWGHRAYIGRVGMDGTNKSVIISTKLEWPNGITIDYTNDLLYWADAHLGYIEYSDLEGHHRHTVYDGALPHPFAITIFEDTIYWTDWNTRTVEKGNKYDGSNRQTLVNTTHRPFDIHVYHPYRQPIVSNPCGTNNGGCSHLCLIKPGGKGFTCECPDDFRTLQLSGSTYCMPMCSSTQFLCANNEKCIPIWWKCDGQKDCSDGSDELALCPQRFCRLGQFQCSDGNCTSPQTLCNAHQNCPDGSDEDRLLCENHHCDSNEWQCANKRCIPESWQCDTFNDCEDNSDEDSSHCASRTCRPGQFRCANGRCIPQAWKCDVDNDCGDHSDEPIEECMSSAHLCDNFTEFSCKTNYRCIPKWAVCNGVDDCRDNSDEQGCEERTCHPVGDFRCKNHHCIPLRWQCDGQNDCGDNSDEENCAPRECTESEFRCVNQQCIPSRWICDHYNDCGDNSDERDCEMRTCHPEYFQCTSGHCVHSELKCDGSADCLDASDEADCPTRFPDGAYCQATMFECKNHVCIPPYWKCDGDDDCGDGSDEELHLCLDVPCNSPNRFRCDNNRCIYSHEVCNGVDDCGDGTDETEEHCRKPTPKPCTEYEYKCGNGHCIPHDNVCDDADDCGDWSDELGCNKGKERTCAENICEQNCTQLNEGGFICSCTAGFETNVFDRTSCLDINECEQFGTCPQHCRNTKGSYECVCADGFTSMSDRPGKRCAAEGSSPLLLLPDNVRIRKYNLSSERFSEYLQDEEYIQAVDYDWDPKDIGLSVVYYTVRGEGSRFGAIKRAYIPNFESGRNNLVQEVDLKLKYVMQPDGIAVDWVGRHIYWSDVKNKRIEVAKLDGRYRKWLISTDLDQPAAIAVNPKLGLMFWTDWGKEPKIESAWMNGEDRNILVFEDLGWPTGLSIDYLNNDRIYWSDFKEDVIETIKYDGTDRRVIAKEAMNPYSLDIFEDQLYWISKEKGEVWKQNKFGQGKKEKTLVVNPWLTQVRIFHQLRYNKSVPNLCKQICSHLCLLRPGGYSCACPQGSSFIEGSTTECDAAIELPINLPPPCRCMHGGNCYFDETDLPKCKCPSGYTGKYCEMAFSKGISPGTTAVAVLLTILLIVVIGALAIAGFFHYRRTGSLLPALPKLPSLSSLVKPSENGNGVTFRSGADLNMDIGVSGFGPETAIDRSMAMSEDFVMEMGKQPIIFENPMYSARDSAVKVVQPIQVTVSENVDNKNYGSPINPSEIVPETNPTSPAADGTQVTKWNLFKRKSKQTTNFENPIYAQMENEQKESVAATPPPSPSLPAKPKPPSRRDPTPTYSATEDTFKDTANLVKEDSEV

T23489	TARGETID	T23489
T23489	UNIPROID	SMASE_MYCTU
T23489	TARGNAME	Mycobacterium Sphingomyelinase (MycB spmT)
T23489	GENENAME	MycB spmT
T23489	TARGTYPE	Literature-reported
T23489	SYNONYMS	SMase
T23489	FUNCTION	Catalyzes the cleavage of sphingomyelin, a major lipid in eukaryotic cells, into ceramide and phosphocholine, which are then utilized by M.tuberculosis as carbon, nitrogen and phosphorus sources, respectively. Thus, enables M.tuberculosis to utilize sphingomyelin as a source of several essential nutrients for intracellular growth during infection. Furthermore, lyses erythrocytes and constitutes the main hemolytic factor of M.tuberculosis.
T23489	BIOCLASS	SpmT family
T23489	ECNUMBER	EC 3.1.4.12
T23489	SEQUENCE	MDYAKRIGQVGALAVVLGVGAAVTTHAIGSAAPTDPSSSSTDSPVDACSPLGGSASSLAAIPGASVPQVGVRQVDPGSIPDDLLNALIDFLAAVRNGLVPIIENRTPVANPQQVSVPEGGTVGPVRFDACDPDGNRMTFAVRERGAPGGPQHGIVTVDQRTASFIYTADPGFVGTDTFSVNVSDDTSLHVHGLAGYLGPFHGHDDVATVTVFVGNTPTDTISGDFSMLTYNIAGLPFPLSSAILPRFFYTKEIGKRLNAYYVANVQEDFAYHQFLIKKSKMPSQTPPEPPTLLWPIGVPFSDGLNTLSEFKVQRLDRQTWYECTSDNCLTLKGFTYSQMRLPGGDTVDVYNLHTNTGGGPTTNANLAQVANYIQQNSAGRAVIVTGDFNARYSDDQSALLQFAQVNGLTDAWVQVEHGPTTPPFAPTCMVGNECELLDKIFYRSGQGVTLQAVSYGNEAPKFFNSKGEPLSDHSPAVVGFHYVADNVAVR

T90808	TARGETID	T90808
T90808	UNIPROID	HSAD_MYCTU
T90808	TARGNAME	Mycobacterium Meta-cleavage product hydrolase (MycB HsaD)
T90808	GENENAME	MycB HsaD
T90808	TARGTYPE	Literature-reported
T90808	SYNONYMS	Meta-cleavage product hydrolase; MCP hydrolase; HOPDA hydrolase; 4,5:9,10-diseco-3-hydroxy-5,9,17-trioxoandrosta-1(10),2-diene-4-oate hydrolase; 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoate hydrolase
T90808	FUNCTION	Catalyzes the hydrolysis of a carbon-carbon bond in 4,5: 9,10-diseco-3-hydroxy-5,9,17-trioxoandrosta-1(10),2-diene-4-oate (4,9-DSHA) to yield 9,17-dioxo-1,2,3,4,10,19-hexanorandrostan-5-oate (DOHNAA) and 2-hydroxy-hexa-2,4-dienoate (HHD). Is also able to catalyze the hydrolysis of 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoic acid (HOPDA) and the synthetic analog 8-(2-chlorophenyl)-2-hydroxy-5-methyl-6-oxoocta-2,4-dienoic acid (HOPODA).
T90808	PDBSTRUC	5JZS; 5JZB; 2WUG; 2WUF; 2WUE
T90808	ECNUMBER	EC 3.7.1.17
T90808	SEQUENCE	MTATEELTFESTSRFAEVDVDGPLKLHYHEAGVGNDQTVVLLHGGGPGAASWTNFSRNIAVLARHFHVLAVDQPGYGHSDKRAEHGQFNRYAAMALKGLFDQLGLGRVPLVGNSLGGGTAVRFALDYPARAGRLVLMGPGGLSINLFAPDPTEGVKRLSKFSVAPTRENLEAFLRVMVYDKNLITPELVDQRFALASTPESLTATRAMGKSFAGADFEAGMMWREVYRLRQPVLLIWGREDRVNPLDGALVALKTIPRAQLHVFGQCGHWVQVEKFDEFNKLTIEFLGGGR

T90800	TARGETID	T90800
T90800	FORMERID	TTDI02634
T90800	UNIPROID	CD83_HUMAN
T90800	TARGNAME	Cell surface protein HB15 (CD83)
T90800	GENENAME	CD83
T90800	TARGTYPE	Literature-reported
T90800	SYNONYMS	hCD83; CD83 antigen; Bcell activation protein; B-cell activation protein
T90800	FUNCTION	May play a significant role in antigen presentation or the cellular interactions that follow lymphocyte activation.
T90800	PDBSTRUC	5MJ2; 5MJ1; 5MJ0; 5MIX
T90800	BIOCLASS	Immunoglobulin
T90800	SEQUENCE	MSRGLQLLLLSCAYSLAPATPEVKVACSEDVDLPCTAPWDPQVPYTVSWVKLLEGGEERMETPQEDHLRGQHYHQKGQNGSFDAPNERPYSLKIRNTTSCNSGTYRCTLQDPDGQRNLSGKVILRVTGCPAQRKEETFKKYRAEIVLLLALVIFYLTLIIFTCKFARLQSIFPDFSKAGMERAFLPVTSPNKHLGLVTPHKTELV

T41195	TARGETID	T41195
T41195	FORMERID	TTDI03267
T41195	UNIPROID	HMCS1_HUMAN
T41195	TARGNAME	Hydroxymethylglutaryl-CoA synthase 1 (HMGCS1)
T41195	GENENAME	HMGCS1
T41195	TARGTYPE	Literature-reported
T41195	SYNONYMS	Hydroxymethylglutaryl-CoA synthase, cytoplasmic; HMGCS; HMG-CoA synthase; 3-hydroxy-3-methylglutaryl coenzyme A synthase 1
T41195	FUNCTION	This enzyme condenses acetyl-CoA with acetoacetyl-CoA to form HMG-CoA, which is the substrate for HMG-CoA reductase.
T41195	PDBSTRUC	2P8U
T41195	ECNUMBER	EC 2.3.3.10
T41195	SEQUENCE	MPGSLPLNAEACWPKDVGIVALEIYFPSQYVDQAELEKYDGVDAGKYTIGLGQAKMGFCTDREDINSLCMTVVQNLMERNNLSYDCIGRLEVGTETIIDKSKSVKTNLMQLFEESGNTDIEGIDTTNACYGGTAAVFNAVNWIESSSWDGRYALVVAGDIAVYATGNARPTGGVGAVALLIGPNAPLIFERGLRGTHMQHAYDFYKPDMLSEYPIVDGKLSIQCYLSALDRCYSVYCKKIHAQWQKEGNDKDFTLNDFGFMIFHSPYCKLVQKSLARMLLNDFLNDQNRDKNSIYSGLEAFGDVKLEDTYFDRDVEKAFMKASSELFSQKTKASLLVSNQNGNMYTSSVYGSLASVLAQYSPQQLAGKRIGVFSYGSGLAATLYSLKVTQDATPGSALDKITASLCDLKSRLDSRTGVAPDVFAENMKLREDTHHLVNYIPQGSIDSLFEGTWYLVRVDEKHRRTYARRPTPNDDTLDEGVGLVHSNIATEHIPSPAKKVPRLPATAAEPEAAVISNGEH
T41195	DRUGINFO	D06XQX	(S)-3-hydroxy-3-methylglutaryl-CoA	Investigative
T41195	DRUGINFO	D07SEU	L-659,699	Investigative

T93331	TARGETID	T93331
T93331	UNIPROID	SATB1_HUMAN
T93331	TARGNAME	DNA-binding protein SATB1 (SATB1)
T93331	GENENAME	SATB1
T93331	TARGTYPE	Literature-reported
T93331	SYNONYMS	Special AT-rich sequence-binding protein 1
T93331	FUNCTION	Crucial silencing factor contributing to the initiation of X inactivation mediated by Xist RNA that occurs during embryogenesis and in lymphoma. Binds to DNA at special AT-rich sequences, the consensus SATB1-binding sequence (CSBS), at nuclear matrix- or scaffold-associated regions. Thought to recognize the sugar-phosphate structure of double-stranded DNA. Transcriptional repressor controlling nuclear and viral gene expression in a phosphorylated and acetylated status-dependent manner, by binding to matrix attachment regions (MARs) of DNA and inducing a local chromatin-loop remodeling. Acts as a docking site for several chromatin remodeling enzymes (e.g. PML at the MHC-I locus) and also by recruiting corepressors (HDACs) or coactivators (HATs) directly to promoters and enhancers. Modulates genes that are essential in the maturation of the immune T-cell CD8SP from thymocytes. Required for the switching of fetal globin species, and beta- and gamma-globin genes regulation during erythroid differentiation. Plays a role in chromatin organization and nuclear architecture during apoptosis. Interacts with the unique region (UR) of cytomegalovirus (CMV). Alu-like motifs and SATB1-binding sites provide a unique chromatin context which seems preferentially targeted by the HIV-1 integration machinery. Moreover, HIV-1 Tat may overcome SATB1-mediated repression of IL2 and IL2RA (interleukin) in T-cells by binding to the same domain than HDAC1. Delineates specific epigenetic modifications at target gene loci, directly up-regulating metastasis-associated genes while down-regulating tumor-suppressor genes. Reprograms chromatin organization and the transcription profiles of breast tumors to promote growth and metastasis.
T93331	PDBSTRUC	3TUO; 3NZL; 2O4A; 2O49; 2MW8
T93331	BIOCLASS	CUT homeobox family
T93331	SEQUENCE	MDHLNEATQGKEHSEMSNNVSDPKGPPAKIARLEQNGSPLGRGRLGSTGAKMQGVPLKHSGHLMKTNLRKGTMLPVFCVVEHYENAIEYDCKEEHAEFVLVRKDMLFNQLIEMALLSLGYSHSSAAQAKGLIQVGKWNPVPLSYVTDAPDATVADMLQDVYHVVTLKIQLHSCPKLEDLPPEQWSHTTVRNALKDLLKDMNQSSLAKECPLSQSMISSIVNSTYYANVSAAKCQEFGRWYKHFKKTKDMMVEMDSLSELSQQGANHVNFGQQPVPGNTAEQPPSPAQLSHGSQPSVRTPLPNLHPGLVSTPISPQLVNQQLVMAQLLNQQYAVNRLLAQQSLNQQYLNHPPPVSRSMNKPLEQQVSTNTEVSSEIYQWVRDELKRAGISQAVFARVAFNRTQGLLSEILRKEEDPKTASQSLLVNLRAMQNFLQLPEAERDRIYQDERERSLNAASAMGPAPLISTPPSRPPQVKTATIATERNGKPENNTMNINASIYDEIQQEMKRAKVSQALFAKVAATKSQGWLCELLRWKEDPSPENRTLWENLSMIRRFLSLPQPERDAIYEQESNAVHHHGDRPPHIIHVPAEQIQQQQQQQQQQQQQQQAPPPPQPQQQPQTGPRLPPRQPTVASPAESDEENRQKTRPRTKISVEALGILQSFIQDVGLYPDEEAIQTLSAQLDLPKYTIIKFFQNQRYYLKHHGKLKDNSGLEVDVAEYKEEELLKDLEESVQDKNTNTLFSVKLEEELSVEGNTDINTDLKD

T57582	TARGETID	T57582
T57582	FORMERID	TTDR00728
T57582	UNIPROID	CNTN2_HUMAN
T57582	TARGNAME	Contactin-2 (CNTN2)
T57582	GENENAME	CNTN2
T57582	TARGTYPE	Literature-reported
T57582	SYNONYMS	Transient axonal glycoprotein 1; TAX-1 gene; TAX-1; CNTN2; Axonin-1; Axonal glycoprotein TAG-1
T57582	FUNCTION	In conjunction with another transmembrane protein, CNTNAP2, contributes to the organization of axonal domains at nodes of Ranvier by maintaining voltage-gated potassium channels at the juxtaparanodal region. May be involved in cell adhesion.
T57582	PDBSTRUC	2OM5
T57582	BIOCLASS	Basigin family
T57582	SEQUENCE	MGTATRRKPHLLLVAAVALVSSSAWSSALGSQTTFGPVFEDQPLSVLFPEESTEEQVLLACRARASPPATYRWKMNGTEMKLEPGSRHQLVGGNLVIMNPTKAQDAGVYQCLASNPVGTVVSREAILRFGFLQEFSKEERDPVKAHEGWGVMLPCNPPAHYPGLSYRWLLNEFPNFIPTDGRHFVSQTTGNLYIARTNASDLGNYSCLATSHMDFSTKSVFSKFAQLNLAAEDTRLFAPSIKARFPAETYALVGQQVTLECFAFGNPVPRIKWRKVDGSLSPQWTTAEPTLQIPSVSFEDEGTYECEAENSKGRDTVQGRIIVQAQPEWLKVISDTEADIGSNLRWGCAAAGKPRPTVRWLRNGEPLASQNRVEVLAGDLRFSKLSLEDSGMYQCVAENKHGTIYASAELAVQALAPDFRLNPVRRLIPAARGGEILIPCQPRAAPKAVVLWSKGTEILVNSSRVTVTPDGTLIIRNISRSDEGKYTCFAENFMGKANSTGILSVRDATKITLAPSSADINLGDNLTLQCHASHDPTMDLTFTWTLDDFPIDFDKPGGHYRRTNVKETIGDLTILNAQLRHGGKYTCMAQTVVDSASKEATVLVRGPPGPPGGVVVRDIGDTTIQLSWSRGFDNHSPIAKYTLQARTPPAGKWKQVRTNPANIEGNAETAQVLGLTPWMDYEFRVIASNILGTGEPSGPSSKIRTREAAPSVAPSGLSGGGGAPGELIVNWTPMSREYQNGDGFGYLLSFRRQGSTHWQTARVPGADAQYFVYSNESVRPYTPFEVKIRSYNRRGDGPESLTALVYSAEEEPRVAPTKVWAKGVSSSEMNVTWEPVQQDMNGILLGYEIRYWKAGDKEAAADRVRTAGLDTSARVSGLHPNTKYHVTVRAYNRAGTGPASPSANATTMKPPPRRPPGNISWTFSSSSLSIKWDPVVPFRNESAVTGYKMLYQNDLHLTPTLHLTGKNWIEIPVPEDIGHALVQIRTTGPGGDGIPAEVHIVRNGGTSMMVENMAVRPAPHPGTVISHSVAMLILIGSLEL

T64053	TARGETID	T64053
T64053	FORMERID	TTDR00077
T64053	UNIPROID	COX1_PLAFA
T64053	TARGNAME	Plasmodium Cytochrome C oxidoreductase (Malaria MT-CO1)
T64053	GENENAME	Malaria MT-CO1
T64053	TARGTYPE	Literature-reported
T64053	SYNONYMS	MT-CO1; Cytochrome c oxidase subunit 1; Cytochrome c oxidase polypeptide I
T64053	FUNCTION	Cytochrome c oxidase is the component of the respiratory chain that catalyzes the reduction of oxygen to water. Subunits 1- 3 form the functional core of the enzyme complex. CO I is the catalytic subunit of the enzyme. Electrons originating in cytochrome c aretransferred via the copper A center of subunit 2 and heme A of subunit 1 to the bimetallic center formed by heme A3 and copper B.
T64053	BIOCLASS	Heme-copper respiratory oxidase family
T64053	ECNUMBER	EC 1.9.3.1
T64053	SEQUENCE	MVLNRYSLITNCNHKTLGLYYLWFSFLFGSYGFLLSVILRTELYSSSLRIIAQENVNLYNMIFTIHGIIMIFFNIMPGLFGGFGNYFLPILCGSPELAYPRINSISLLLQPIAFVLVILSTAAEFGGGTGWTLYPPLSTSLMSLSPVAVDVIIFGLLVSGVASIMSSLNFITTVMHLRAKGLTLGILSVSTWSLIITSGMLLLTLPVLTGGVLMLLSDLHFNTLFFDPTFAGDPILYQHLFWFFGHPEVYILILPAFGVISHVISTNYCRNLFGNQSMILAMGCIAVLGSLVWVHHMYTTGLEVDTRAYFTSTTILISIPTGTKVFNWICTYMSSNFGMIHSSSLLSLLFICTFTFGGTTGVILGNAAIDVALHDTYYVIAHFHFVLSIGAIIGLFTTVSAFQDNFFGKNLRENSIVILWSMLFFVGVILTFLPMHFLGFNVMPRRIPDYPDALNGWNMICSIGSTMTLFGLLIFK

T45158	TARGETID	T45158
T45158	FORMERID	TTDR01084
T45158	UNIPROID	SNZ1_YEAST
T45158	TARGNAME	Fungal Pyridoxin biosynthesis protein SNZ1 (Fung SNZ1)
T45158	GENENAME	Fung SNZ1
T45158	TARGTYPE	Literature-reported
T45158	SYNONYMS	SNZ1; PDX1 homolog 1; Fung P35
T45158	FUNCTION	Catalyzes the formation of pyridoxal 5'-phosphate from ribose 5-phosphate (RBP), glyceraldehyde 3-phosphate (G3P) and ammonia. The ammonia is provided by a SNO isoform. Can also use ribulose 5-phosphate and dihydroxyacetone phosphate as substrates, resulting from enzyme-catalyzed isomerization of RBP and G3P, respectively.
T45158	PDBSTRUC	3O07; 3O06; 3O05; 3FEM
T45158	ECNUMBER	EC 4.3.3.6
T45158	SEQUENCE	MTGEDFKIKSGLAQMLKGGVIMDVVTPEQAKIAEKSGACAVMALESIPADMRKSGKVCRMSDPKMIKDIMNSVSIPVMAKVRIGHFVEAQIIEALEVDYIDESEVLTPADWTHHIEKDKFKVPFVCGAKDLGEALRRINEGAAMIRTKGEAGTGDVSEAVKHIRRITEEIKACQQLKSEDDIAKVAEEMRVPVSLLKDVLEKGKLPVVNFAAGGVATPADAALLMQLGCDGVFVGSGIFKSSNPVRLATAVVEATTHFDNPSKLLEVSSDLGELMGGVSIESISHASNGVRLSEIGW

T29635	TARGETID	T29635
T29635	FORMERID	TTDI03341
T29635	UNIPROID	KCNC4_HUMAN
T29635	TARGNAME	Voltage-gated potassium channel Kv3.4 (KCNC4)
T29635	GENENAME	KCNC4
T29635	TARGTYPE	Literature-reported
T29635	SYNONYMS	Voltage-gated potassium channel subunit Kv3.4; Potassium voltage-gated channel subfamily C member 4; KSHIIIC; C1orf30
T29635	FUNCTION	This protein mediates the voltage-dependent potassium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a potassium-selective channel through which potassium ions may pass in accordance with their electrochemical gradient.
T29635	PDBSTRUC	1ZTN; 1B4I; 1B4G
T29635	BIOCLASS	Voltage-gated ion channel
T29635	SEQUENCE	MISSVCVSSYRGRKSGNKPPSKTCLKEEMAKGEASEKIIINVGGTRHETYRSTLRTLPGTRLAWLADPDGGGRPETDGGGVGSSGSSGGGGCEFFFDRHPGVFAYVLNYYRTGKLHCPADVCGPLFEEELTFWGIDETDVEPCCWMTYRQHRDAEEALDIFESPDGGGSGAGPSDEAGDDERELALQRLGPHEGGAGHGAGSGGCRGWQPRMWALFEDPYSSRAARVVAFASLFFILVSITTFCLETHEAFNIDRNVTEILRVGNITSVHFRREVETEPILTYIEGVCVLWFTLEFLVRIVCCPDTLDFVKNLLNIIDFVAILPFYLEVGLSGLSSKAARDVLGFLRVVRFVRILRIFKLTRHFVGLRVLGHTLRASTNEFLLLIIFLALGVLIFATMIYYAERIGARPSDPRGNDHTDFKNIPIGFWWAVVTMTTLGYGDMYPKTWSGMLVGALCALAGVLTIAMPVPVIVNNFGMYYSLAMAKQKLPKKRKKHVPRPAQLESPMYCKSEETSPRDSTCSDTSPPAREEGMIERKRADSKQNGDANAVLSDEEGAGLTQPLASSPTPEERRALRRSTTRDRNKKAAACFLLSTGDYACADGSVRKGTFVLRDLPLQHSPEAACPPTAGTLFLPH
T29635	DRUGINFO	D0Y4AS	DABCO	Investigative
T29635	DRUGINFO	D0A1IR	DABCO-C16	Investigative
T29635	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T20221	TARGETID	T20221
T20221	FORMERID	TTDR00508
T20221	UNIPROID	TNFC_HUMAN
T20221	TARGNAME	Lymphotoxin-beta (LTB)
T20221	GENENAME	LTB
T20221	TARGTYPE	Literature-reported
T20221	SYNONYMS	Tumor necrosis factor ligand superfamily member 3; Tumor necrosis factor C; TNF-C; LTB; LT-beta
T20221	FUNCTION	Cytokine that binds to LTBR/TNFRSF3. May play a specific role in immune response regulation. Provides the membrane anchor for the attachment of the heterotrimeric complex to the cell surface. Isoform 2 is probably non-functional.
T20221	PDBSTRUC	4MXW
T20221	BIOCLASS	Cytokine: tumor necrosis factor
T20221	SEQUENCE	MGALGLEGRGGRLQGRGSLLLAVAGATSLVTLLLAVPITVLAVLALVPQDQGGLVTETADPGAQAQQGLGFQKLPEEEPETDLSPGLPAAHLIGAPLKGQGLGWETTKEQAFLTSGTQFSDAEGLALPQDGLYYLYCLVGYRGRAPPGGGDPQGRSVTLRSSLYRAGGAYGPGTPELLLEGAETVTPVLDPARRQGYGPLWYTSVGFGGLVQLRRGERVYVNISHPDMVDFARGKTFFGAVMVG

T27577	TARGETID	T27577
T27577	FORMERID	TTDI03146
T27577	UNIPROID	CDK18_HUMAN
T27577	TARGNAME	Cyclin-dependent kinase 18 (CDK18)
T27577	GENENAME	CDK18
T27577	TARGTYPE	Literature-reported
T27577	SYNONYMS	Serine/threonine-protein kinase PCTAIRE-3; PCTK3; PCTAIRE3; PCTAIRE-motif protein kinase 3; Cell division protein kinase 18
T27577	FUNCTION	May play a role in signal transduction cascades in terminally differentiated cells.
T27577	BIOCLASS	Kinase
T27577	ECNUMBER	EC 2.7.11.22
T27577	SEQUENCE	MIMNKMKNFKRRFSLSVPRTETIEESLAEFTEQFNQLHNRRNENLQLGPLGRDPPQECSTFSPTDSGEEPGQLSPGVQFQRRQNQRRFSMEDVSKRLSLPMDIRLPQEFLQKLQMESPDLPKPLSRMSRRASLSDIGFGKLETYVKLDKLGEGTYATVFKGRSKLTENLVALKEIRLEHEEGAPCTAIREVSLLKNLKHANIVTLHDLIHTDRSLTLVFEYLDSDLKQYLDHCGNLMSMHNVKIFMFQLLRGLAYCHHRKILHRDLKPQNLLINERGELKLADFGLARAKSVPTKTYSNEVVTLWYRPPDVLLGSTEYSTPIDMWGVGCIHYEMATGRPLFPGSTVKEELHLIFRLLGTPTEETWPGVTAFSEFRTYSFPCYLPQPLINHAPRLDTDGIHLLSSLLLYESKSRMSAEAALSHSYFRSLGERVHQLEDTASIFSLKEIQLQKDPGYRGLAFQQPGRGKNRRQSIF
T27577	DRUGINFO	D0N3LC	PMID24793884C77	Investigative

T54472	TARGETID	T54472
T54472	FORMERID	TTDR00299
T54472	UNIPROID	CDC2H_PLAFK
T54472	TARGNAME	Plasmodium CDK PfPK5 (Malaria PfPK5)
T54472	GENENAME	Malaria PfPK5
T54472	TARGTYPE	Literature-reported
T54472	SYNONYMS	PfPK5; PK5; Cell division control protein 2 homolog; CRK2
T54472	FUNCTION	It is required in higher cells for entry into S-phase and mitosis. Component of the kinase complex that phosphorylates the repetitive C-terminus of RNA polymerase II. Plays a key role in the control of the eukaryotic cell cycle.
T54472	PDBSTRUC	1V0P; 1V0O; 1V0B; 1OB3; 1LCH
T54472	BIOCLASS	Kinase
T54472	SEQUENCE	MEKYHGLEKIGEGTYGVVYKAQNNYGETFALKKIRLEKEDEGIPSTTIREISILKELKHSNIVKLYDVIHTKKRLVLVFEHLDQDLKKLLDVCEGGLESVTAKSFLLQLLNGIAYCHDRRVLHRDLKPQNLLINREGELKIADFGLARAFGIPVRKYTHEVVTLWYRAPDVLMGSKKYSTTIDIWSVGCIFAEMVNGTPLFPGVSEADQLMRIFRILGTPNSKNWPNVTELPKYDPNFTVYEPLPWESFLKGLDESGIDLLSKMLKLDPNQRITAKQALEHAYFKENN
T54472	DRUGINFO	D0G2CT	Indirubin-5-sulfonate	Investigative

T91130	TARGETID	T91130
T91130	FORMERID	TTDR01159
T91130	UNIPROID	LRP1_HUMAN
T91130	TARGNAME	LDL receptor related protein-1 (LRP-1)
T91130	GENENAME	LRP1
T91130	TARGTYPE	Literature-reported
T91130	SYNONYMS	Alpha-2-macroglobulin receptor; A2MR
T91130	FUNCTION	Required for early embryonic development. Involved in cellular lipid homeostasis. Involved in the plasma clearance of chylomicron remnants and activated LRPAP1 (alpha 2-macroglobulin), as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. May modulate cellular events, such as APP metabolism, kinase-dependent intracellular signaling, neuronal calcium signaling as well as neurotransmission. Acts as an alpha-2-macroglobulin receptor. Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells.
T91130	PDBSTRUC	2KNY; 2KNX; 2FYL; 2FYJ; 1J8E
T91130	BIOCLASS	Low density lipoprotein receptor
T91130	SEQUENCE	MLTPPLLLLLPLLSALVAAAIDAPKTCSPKQFACRDQITCISKGWRCDGERDCPDGSDEAPEICPQSKAQRCQPNEHNCLGTELCVPMSRLCNGVQDCMDGSDEGPHCRELQGNCSRLGCQHHCVPTLDGPTCYCNSSFQLQADGKTCKDFDECSVYGTCSQLCTNTDGSFICGCVEGYLLQPDNRSCKAKNEPVDRPPVLLIANSQNILATYLSGAQVSTITPTSTRQTTAMDFSYANETVCWVHVGDSAAQTQLKCARMPGLKGFVDEHTINISLSLHHVEQMAIDWLTGNFYFVDDIDDRIFVCNRNGDTCVTLLDLELYNPKGIALDPAMGKVFFTDYGQIPKVERCDMDGQNRTKLVDSKIVFPHGITLDLVSRLVYWADAYLDYIEVVDYEGKGRQTIIQGILIEHLYGLTVFENYLYATNSDNANAQQKTSVIRVNRFNSTEYQVVTRVDKGGALHIYHQRRQPRVRSHACENDQYGKPGGCSDICLLANSHKARTCRCRSGFSLGSDGKSCKKPEHELFLVYGKGRPGIIRGMDMGAKVPDEHMIPIENLMNPRALDFHAETGFIYFADTTSYLIGRQKIDGTERETILKDGIHNVEGVAVDWMGDNLYWTDDGPKKTISVARLEKAAQTRKTLIEGKMTHPRAIVVDPLNGWMYWTDWEEDPKDSRRGRLERAWMDGSHRDIFVTSKTVLWPNGLSLDIPAGRLYWVDAFYDRIETILLNGTDRKIVYEGPELNHAFGLCHHGNYLFWTEYRSGSVYRLERGVGGAPPTVTLLRSERPPIFEIRMYDAQQQQVGTNKCRVNNGGCSSLCLATPGSRQCACAEDQVLDADGVTCLANPSYVPPPQCQPGEFACANSRCIQERWKCDGDNDCLDNSDEAPALCHQHTCPSDRFKCENNRCIPNRWLCDGDNDCGNSEDESNATCSARTCPPNQFSCASGRCIPISWTCDLDDDCGDRSDESASCAYPTCFPLTQFTCNNGRCININWRCDNDNDCGDNSDEAGCSHSCSSTQFKCNSGRCIPEHWTCDGDNDCGDYSDETHANCTNQATRPPGGCHTDEFQCRLDGLCIPLRWRCDGDTDCMDSSDEKSCEGVTHVCDPSVKFGCKDSARCISKAWVCDGDNDCEDNSDEENCESLACRPPSHPCANNTSVCLPPDKLCDGNDDCGDGSDEGELCDQCSLNNGGCSHNCSVAPGEGIVCSCPLGMELGPDNHTCQIQSYCAKHLKCSQKCDQNKFSVKCSCYEGWVLEPDGESCRSLDPFKPFIIFSNRHEIRRIDLHKGDYSVLVPGLRNTIALDFHLSQSALYWTDVVEDKIYRGKLLDNGALTSFEVVIQYGLATPEGLAVDWIAGNIYWVESNLDQIEVAKLDGTLRTTLLAGDIEHPRAIALDPRDGILFWTDWDASLPRIEAASMSGAGRRTVHRETGSGGWPNGLTVDYLEKRILWIDARSDAIYSARYDGSGHMEVLRGHEFLSHPFAVTLYGGEVYWTDWRTNTLAKANKWTGHNVTVVQRTNTQPFDLQVYHPSRQPMAPNPCEANGGQGPCSHLCLINYNRTVSCACPHLMKLHKDNTTCYEFKKFLLYARQMEIRGVDLDAPYYNYIISFTVPDIDNVTVLDYDAREQRVYWSDVRTQAIKRAFINGTGVETVVSADLPNAHGLAVDWVSRNLFWTSYDTNKKQINVARLDGSFKNAVVQGLEQPHGLVVHPLRGKLYWTDGDNISMANMDGSNRTLLFSGQKGPVGLAIDFPESKLYWISSGNHTINRCNLDGSGLEVIDAMRSQLGKATALAIMGDKLWWADQVSEKMGTCSKADGSGSVVLRNSTTLVMHMKVYDESIQLDHKGTNPCSVNNGDCSQLCLPTSETTRSCMCTAGYSLRSGQQACEGVGSFLLYSVHEGIRGIPLDPNDKSDALVPVSGTSLAVGIDFHAENDTIYWVDMGLSTISRAKRDQTWREDVVTNGIGRVEGIAVDWIAGNIYWTDQGFDVIEVARLNGSFRYVVISQGLDKPRAITVHPEKGYLFWTEWGQYPRIERSRLDGTERVVLVNVSISWPNGISVDYQDGKLYWCDARTDKIERIDLETGENREVVLSSNNMDMFSVSVFEDFIYWSDRTHANGSIKRGSKDNATDSVPLRTGIGVQLKDIKVFNRDRQKGTNVCAVANGGCQQLCLYRGRGQRACACAHGMLAEDGASCREYAGYLLYSERTILKSIHLSDERNLNAPVQPFEDPEHMKNVIALAFDYRAGTSPGTPNRIFFSDIHFGNIQQINDDGSRRITIVENVGSVEGLAYHRGWDTLYWTSYTTSTITRHTVDQTRPGAFERETVITMSGDDHPRAFVLDECQNLMFWTNWNEQHPSIMRAALSGANVLTLIEKDIRTPNGLAIDHRAEKLYFSDATLDKIERCEYDGSHRYVILKSEPVHPFGLAVYGEHIFWTDWVRRAVQRANKHVGSNMKLLRVDIPQQPMGIIAVANDTNSCELSPCRINNGGCQDLCLLTHQGHVNCSCRGGRILQDDLTCRAVNSSCRAQDEFECANGECINFSLTCDGVPHCKDKSDEKPSYCNSRRCKKTFRQCSNGRCVSNMLWCNGADDCGDGSDEIPCNKTACGVGEFRCRDGTCIGNSSRCNQFVDCEDASDEMNCSATDCSSYFRLGVKGVLFQPCERTSLCYAPSWVCDGANDCGDYSDERDCPGVKRPRCPLNYFACPSGRCIPMSWTCDKEDDCEHGEDETHCNKFCSEAQFECQNHRCISKQWLCDGSDDCGDGSDEAAHCEGKTCGPSSFSCPGTHVCVPERWLCDGDKDCADGADESIAAGCLYNSTCDDREFMCQNRQCIPKHFVCDHDRDCADGSDESPECEYPTCGPSEFRCANGRCLSSRQWECDGENDCHDQSDEAPKNPHCTSQEHKCNASSQFLCSSGRCVAEALLCNGQDDCGDSSDERGCHINECLSRKLSGCSQDCEDLKIGFKCRCRPGFRLKDDGRTCADVDECSTTFPCSQRCINTHGSYKCLCVEGYAPRGGDPHSCKAVTDEEPFLIFANRYYLRKLNLDGSNYTLLKQGLNNAVALDFDYREQMIYWTDVTTQGSMIRRMHLNGSNVQVLHRTGLSNPDGLAVDWVGGNLYWCDKGRDTIEVSKLNGAYRTVLVSSGLREPRALVVDVQNGYLYWTDWGDHSLIGRIGMDGSSRSVIVDTKITWPNGLTLDYVTERIYWADAREDYIEFASLDGSNRHVVLSQDIPHIFALTLFEDYVYWTDWETKSINRAHKTTGTNKTLLISTLHRPMDLHVFHALRQPDVPNHPCKVNNGGCSNLCLLSPGGGHKCACPTNFYLGSDGRTCVSNCTASQFVCKNDKCIPFWWKCDTEDDCGDHSDEPPDCPEFKCRPGQFQCSTGICTNPAFICDGDNDCQDNSDEANCDIHVCLPSQFKCTNTNRCIPGIFRCNGQDNCGDGEDERDCPEVTCAPNQFQCSITKRCIPRVWVCDRDNDCVDGSDEPANCTQMTCGVDEFRCKDSGRCIPARWKCDGEDDCGDGSDEPKEECDERTCEPYQFRCKNNRCVPGRWQCDYDNDCGDNSDEESCTPRPCSESEFSCANGRCIAGRWKCDGDHDCADGSDEKDCTPRCDMDQFQCKSGHCIPLRWRCDADADCMDGSDEEACGTGVRTCPLDEFQCNNTLCKPLAWKCDGEDDCGDNSDENPEECARFVCPPNRPFRCKNDRVCLWIGRQCDGTDNCGDGTDEEDCEPPTAHTTHCKDKKEFLCRNQRCLSSSLRCNMFDDCGDGSDEEDCSIDPKLTSCATNASICGDEARCVRTEKAAYCACRSGFHTVPGQPGCQDINECLRFGTCSQLCNNTKGGHLCSCARNFMKTHNTCKAEGSEYQVLYIADDNEIRSLFPGHPHSAYEQAFQGDESVRIDAMDVHVKAGRVYWTNWHTGTISYRSLPPAAPPTTSNRHRRQIDRGVTHLNISGLKMPRGIAIDWVAGNVYWTDSGRDVIEVAQMKGENRKTLISGMIDEPHAIVVDPLRGTMYWSDWGNHPKIETAAMDGTLRETLVQDNIQWPTGLAVDYHNERLYWADAKLSVIGSIRLNGTDPIVAADSKRGLSHPFSIDVFEDYIYGVTYINNRVFKIHKFGHSPLVNLTGGLSHASDVVLYHQHKQPEVTNPCDRKKCEWLCLLSPSGPVCTCPNGKRLDNGTCVPVPSPTPPPDAPRPGTCNLQCFNGGSCFLNARRQPKCRCQPRYTGDKCELDQCWEHCRNGGTCAASPSGMPTCRCPTGFTGPKCTQQVCAGYCANNSTCTVNQGNQPQCRCLPGFLGDRCQYRQCSGYCENFGTCQMAADGSRQCRCTAYFEGSRCEVNKCSRCLEGACVVNKQSGDVTCNCTDGRVAPSCLTCVGHCSNGGSCTMNSKMMPECQCPPHMTGPRCEEHVFSQQQPGHIASILIPLLLLLLLVLVAGVVFWYKRRVQGAKGFQHQRMTNGAMNVEIGNPTYKMYEGGEPDDVGGLLDADFALDPDKPTNFTNPVYATLYMGGHGSRHSLASTDEKRELLGRGPEDEIGDPLA

T85273	TARGETID	T85273
T85273	FORMERID	TTDR01130
T85273	UNIPROID	FOXM1_HUMAN
T85273	TARGNAME	Forkhead box protein M1 (FOXM1)
T85273	GENENAME	FOXM1
T85273	TARGTYPE	Literature-reported
T85273	SYNONYMS	Winged-helix factor from INS-1 cells; Winged helix factor from INS-1 cells; WIN; Transcription factor Trident; MPP2; MPM-2 reactive phosphoprotein 2; M-phase phosphoprotein 2; Hepatocyte nuclear factor 3 forkhead homolog 11; HNF-3/fork-head homolog-11; HNF-3/fork-head homolog 11; HFH11; HFH-11; Foxm1b; Foxm1; Forkhead-related protein FKHL16; Forkhead Box (Fox) m1b; FKHL16
T85273	FUNCTION	Plays a role in the control of cell proliferation. Plays also a role in DNA breaks repair participating in the DNA damage checkpoint response. Transcriptional factor regulating the expression of cell cycle genes essential for DNA replication and mitosis.
T85273	PDBSTRUC	3G73
T85273	SEQUENCE	MKTSPRRPLILKRRRLPLPVQNAPSETSEEEPKRSPAQQESNQAEASKEVAESNSCKFPAGIKIINHPTMPNTQVVAIPNNANIHSIITALTAKGKESGSSGPNKFILISCGGAPTQPPGLRPQTQTSYDAKRTEVTLETLGPKPAARDVNLPRPPGALCEQKRETCADGEAAGCTINNSLSNIQWLRKMSSDGLGSRSIKQEMEEKENCHLEQRQVKVEEPSRPSASWQNSVSERPPYSYMAMIQFAINSTERKRMTLKDIYTWIEDHFPYFKHIAKPGWKNSIRHNLSLHDMFVRETSANGKVSFWTIHPSANRYLTLDQVFKPLDPGSPQLPEHLESQQKRPNPELRRNMTIKTELPLGARRKMKPLLPRVSSYLVPIQFPVNQSLVLQPSVKVPLPLAASLMSSELARHSKRVRIAPKVLLAEEGIAPLSSAGPGKEEKLLFGEGFSPLLPVQTIKEEEIQPGEEMPHLARPIKVESPPLEEWPSPAPSFKEESSHSWEDSSQSPTPRPKKSYSGLRSPTRCVSEMLVIQHRERRERSRSRRKQHLLPPCVDEPELLFSEGPSTSRWAAELPFPADSSDPASQLSYSQEVGGPFKTPIKETLPISSTPSKSVLPRTPESWRLTPPAKVGGLDFSPVQTSQGASDPLPDPLGLMDLSTTPLQSAPPLESPQRLLSSEPLDLISVPFGNSSPSDIDVPKPGSPEPQVSGLAANRSLTEGLVLDTMNDSLSKILLDISFPGLDEDPLGPDNINWSQFIPELQ
T85273	DRUGINFO	D01FSW	(D-Arg)(9)-p19(ARF) 26-44 peptide	Investigative

T77537	TARGETID	T77537
T77537	FORMERID	TTDI01356
T77537	UNIPROID	ITK_HUMAN
T77537	TARGNAME	Tyrosine-protein kinase ITK (ITK)
T77537	GENENAME	ITK
T77537	TARGTYPE	Literature-reported
T77537	SYNONYMS	Tyrosine-protein kinase Lyk; Tyrosine-protein kinase ITK/TSK; LYK; Kinase EMT; Interleukin-2-inducible T-cell kinase; IL-2-inducible T-cell kinase
T77537	FUNCTION	Tyrosine kinase that plays an essential role in regulation of the adaptive immune response. Regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells. When antigen presenting cells (APC) activate T-cell receptor (TCR), a series of phosphorylation lead to the recruitment of ITK to the cell membrane, in the vicinity of the stimulated TCR receptor, where it is phosphorylated by LCK. Phosphorylation leads to ITK autophosphorylation and full activation. Once activated, phosphorylates PLCG1, leading to the activation of this lipase and subsequent cleavage of its substrates. In turn, the endoplasmic reticulum releases calcium in the cytoplasm and the nuclear activator of activated T-cells (NFAT) translocates into the nucleus to perform its transcriptional duty. Phosphorylates 2 essential adapter proteins: the linker for activation of T-cells/LAT protein and LCP2. Then, a large number of signaling molecules such as VAV1 are recruited and ultimately lead to lymphokine production, T-cell proliferation and differentiation. Phosphorylates TBX21 at 'Tyr-530' and mediates its interaction with GATA3 (By similarity).
T77537	PDBSTRUC	4RFM; 4QD6; 4PQN; 4PPC; 4PPB
T77537	ECNUMBER	EC 2.7.10.2
T77537	SEQUENCE	MNNFILLEEQLIKKSQQKRRTSPSNFKVRFFVLTKASLAYFEDRHGKKRTLKGSIELSRIKCVEIVKSDISIPCHYKYPFQVVHDNYLLYVFAPDRESRQRWVLALKEETRNNNSLVPKYHPNFWMDGKWRCCSQLEKLATGCAQYDPTKNASKKPLPPTPEDNRRPLWEPEETVVIALYDYQTNDPQELALRRNEEYCLLDSSEIHWWRVQDRNGHEGYVPSSYLVEKSPNNLETYEWYNKSISRDKAEKLLLDTGKEGAFMVRDSRTAGTYTVSVFTKAVVSENNPCIKHYHIKETNDNPKRYYVAEKYVFDSIPLLINYHQHNGGGLVTRLRYPVCFGRQKAPVTAGLRYGKWVIDPSELTFVQEIGSGQFGLVHLGYWLNKDKVAIKTIREGAMSEEDFIEEAEVMMKLSHPKLVQLYGVCLEQAPICLVFEFMEHGCLSDYLRTQRGLFAAETLLGMCLDVCEGMAYLEEACVIHRDLAARNCLVGENQVIKVSDFGMTRFVLDDQYTSSTGTKFPVKWASPEVFSFSRYSSKSDVWSFGVLMWEVFSEGKIPYENRSNSEVVEDISTGFRLYKPRLASTHVYQIMNHCWKERPEDRPAFSRLLRQLAEIAESGL

T77745	TARGETID	T77745
T77745	FORMERID	TTDI02401
T77745	UNIPROID	BST2_HUMAN
T77745	TARGNAME	Bone marrow stromal antigen 2 (BST2)
T77745	GENENAME	BST2
T77745	TARGTYPE	Literature-reported
T77745	SYNONYMS	Tetherin; HM1.24 antigen; CD317; BST2
T77745	FUNCTION	IFN-induced antiviral host restriction factor which efficiently blocks the release of diverse mammalian enveloped viruses by directly tethering nascent virions to the membranes of infected cells. Acts as a direct physical tether, holding virions to the cell membrane and linking virions to each other. The tethered virions can be internalized by endocytosis and subsequently degraded or they can remain on the cell surface. In either case, their spread as cell-free virions is restricted. Its target viruses belong to diverse families, including retroviridae: human immunodeficiency virus type 1 (HIV-1), human immunodeficiency virus type 2 (HIV-2), simian immunodeficiency viruses (SIVs), equine infectious anemia virus (EIAV), feline immunodeficiency virus (FIV), prototype foamy virus (PFV), Mason- Pfizer monkey virus (MPMV), human T-cell leukemia virus type 1 (HTLV-1), Rous sarcoma virus (RSV) and murine leukemia virus (MLV), flavivirideae: hepatitis C virus (HCV), filoviridae: ebola virus (EBOV) and marburg virus (MARV), arenaviridae: lassa virus (LASV) and machupo virus (MACV), herpesviridae: kaposis sarcoma- associated herpesvirus (KSHV), rhabdoviridae: vesicular stomatitis virus (VSV), orthomyxoviridae: influenza A virus, and paramyxoviridae: nipah virus. Can inhibit cell surface proteolytic activity of MMP14 causing decreased activation of MMP15 which results in inhibition of cell growth and migration. Can stimulate signaling by LILRA4/ILT7 and consequently provide negative feedback to the production of IFN by plasmacytoid dendritic cells in response to viral infection. Plays a role in the organization of the subapical actin cytoskeleton in polarized epithelial cells. Isoform 1 and isoform 2 are both effective viral restriction factors but have differing antiviral and signaling activities. Isoform 2 is resistant to HIV-1 Vpu-mediated degradation and restricts HIV-1 viral budding in the presence of Vpu. Isoform 1 acts as an activator of NF-kappa-B and this activity is inhibited by isoform 2.
T77745	PDBSTRUC	6DFF; 6D84; 6D83; 6CRI; 6CM9
T77745	BIOCLASS	Tetherin family
T77745	SEQUENCE	MASTSYDYCRVPMEDGDKRCKLLLGIGILVLLIIVILGVPLIIFTIKANSEACRDGLRAVMECRNVTHLLQQELTEAQKGFQDVEAQAATCNHTVMALMASLDAEKAQGQKKVEELEGEITTLNHKLQDASAEVERLRRENQVLSVRIADKKYYPSSQDSSSAAAPQLLIVLLGLSALLQ

T49649	TARGETID	T49649
T49649	FORMERID	TTDR00636
T49649	UNIPROID	LAC1_BOTFU
T49649	TARGNAME	Fungal Laccase (Fung lcc1)
T49649	GENENAME	Fung lcc1
T49649	TARGTYPE	Literature-reported
T49649	SYNONYMS	lcc1; Urishiol oxidase; Fragment; Diphenol oxidase; Benzenediol:oxygen oxidoreductase
T49649	FUNCTION	Lignin degradation and detoxification of lignin-derived products.
T49649	BIOCLASS	Diphenol donor oxidoreductase
T49649	ECNUMBER	EC 1.10.3.2
T49649	SEQUENCE	MKNSFFSSLAKFASLSLAFALPTAEVIPSALEERQSCANTATTRSCWGQYSASTNSYTTVPKTGYWLVVQNTTLSADGVSRPTLNFNGTIPGPQITADWGDDVIVHVTNKLTSNGTSIHWHGIRQLNNAQYDGVPGITQCPIAPGGTLTYKFHADNYGSSWYHSHFILQYGDGLFGPLVINGPATANYDVDLGMLFLNDWNHVPVQSLWDKAKTGAPPTLLTGLMNGTNTYNGAGKKFQTTFTPGLKYRIRVVNTAVDGHFQFSIDGHSFQVIAMDFVPIVPYNATSILVSIAQRYDIIVTANAAVGNYWIRAGWQTACSGNTNAANITGILRYTGSSSTADPTTTSTVTASTSCLDEPLASLVPFVPINPVASSIMKTTLTTGGGQWLFNGSSLLLNWTDPTLLTVLNSGNIWPTEYNVIPIESTTANKGWAVLAISGPNGPNHPIHLHGHDFWTLSQGTGAYTATTALNLVNPPRRDVMTLPTGGHLVIAFQIDNPGSWLMHCHIAWHASEGLALQFVESESSILPTIGTADVSTFQNTCAAWKAWTPTEPFPQDDSGI

T72850	TARGETID	T72850
T72850	FORMERID	TTDR00040
T72850	UNIPROID	FOXO1_HUMAN
T72850	TARGNAME	Forkhead box protein O1A (FOXO1)
T72850	GENENAME	FOXO1
T72850	TARGTYPE	Literature-reported
T72850	SYNONYMS	Forkhead in rhabdomyosarcoma; Forkhead box protein O1; FOXO1A; FKHR
T72850	FUNCTION	Transcription factor that is the main target of insulin signaling and regulates metabolic homeostasis in response to oxidative stress. Binds to the insulin response element (IRE) with consensus sequence 5'-TT[G/A]TTTTG-3' and the related Daf-16 family binding element (DBE) with consensus sequence 5'-TT[G/A]TTTAC-3'. Activity suppressed by insulin. Main regulator of redox balance and osteoblast numbers and controls bone mass. Orchestrates the endocrine function of the skeleton in regulating glucose metabolism. Acts synergistically with ATF4 to suppress osteocalcin/BGLAP activity, increasing glucose levels and triggering glucose intolerance and insulin insensitivity. Also suppresses the transcriptional activity of RUNX2, an upstream activator of osteocalcin/BGLAP. In hepatocytes, promotes gluconeogenesis by acting together with PPARGC1A and CEBPA to activate the expression of genes such as IGFBP1, G6PC and PCK1. Important regulator of cell death acting downstream of CDK1, PKB/AKT1 and STK4/MST1. Promotes neural cell death. Mediates insulin action on adipose tissue. Regulates the expression of adipogenic genes such as PPARG during preadipocyte differentiation and, adipocyte size and adipose tissue-specific gene expression in response to excessive calorie intake. Regulates the transcriptional activity of GADD45A and repair of nitric oxide-damaged DNA in beta-cells. Required for the autophagic cell death induction in response to starvation or oxidative stress in a transcription-independent manner. Mediates the function of MLIP in cardiomyocytes hypertrophy and cardiac remodeling (By similarity).
T72850	PDBSTRUC	5DUI; 4LG0; 3COA; 3CO7; 3CO6
T72850	SEQUENCE	MAEAPQVVEIDPDFEPLPRPRSCTWPLPRPEFSQSNSATSSPAPSGSAAANPDAAAGLPSASAAAVSADFMSNLSLLEESEDFPQAPGSVAAAVAAAAAAAATGGLCGDFQGPEAGCLHPAPPQPPPPGPLSQHPPVPPAAAGPLAGQPRKSSSSRRNAWGNLSYADLITKAIESSAEKRLTLSQIYEWMVKSVPYFKDKGDSNSSAGWKNSIRHNLSLHSKFIRVQNEGTGKSSWWMLNPEGGKSGKSPRRRAASMDNNSKFAKSRSRAAKKKASLQSGQEGAGDSPGSQFSKWPASPGSHSNDDFDNWSTFRPRTSSNASTISGRLSPIMTEQDDLGEGDVHSMVYPPSAAKMASTLPSLSEISNPENMENLLDNLNLLSSPTSLTVSTQSSPGTMMQQTPCYSFAPPNTSLNSPSPNYQKYTYGQSSMSPLPQMPIQTLQDNKSSYGGMSQYNCAPGLLKELLTSDSPPHNDIMTPVDPGVAQPNSRVLGQNVMMGPNSVMSTYGSQASHNKMMNPSSHTHPGHAQQTSAVNGRPLPHTVSTMPHTSGMNRLTQVKTPVQVPLPHPMQMSALGGYSSVSSCNGYGRMGLLHQEKLPSDLDGMFIERLDCDMESIIRNDLMDGDTLDFNFDNVLPNQSFPHSVKTTTHSWVSG
T72850	DRUGINFO	D0W9KE	AS-1708727	Investigative

T93716	TARGETID	T93716
T93716	FORMERID	TTDR00207
T93716	UNIPROID	KIF5A_HUMAN
T93716	TARGNAME	Kinesin heavy chain neuron-specific 1 (KIF5A)
T93716	GENENAME	KIF5A
T93716	TARGTYPE	Literature-reported
T93716	SYNONYMS	NKHC; Kinesin heavy chain isoform 5A; KIF5A
T93716	FUNCTION	Microtubule-dependent motor required for slow axonal transport of neurofilament proteins (NFH, NFM and NFL).
T93716	PDBSTRUC	4UY0; 4UXY; 4UXT
T93716	BIOCLASS	Kinesin-like protein family
T93716	SEQUENCE	MAETNNECSIKVLCRFRPLNQAEILRGDKFIPIFQGDDSVVIGGKPYVFDRVFPPNTTQEQVYHACAMQIVKDVLAGYNGTIFAYGQTSSGKTHTMEGKLHDPQLMGIIPRIARDIFNHIYSMDENLEFHIKVSYFEIYLDKIRDLLDVTKTNLSVHEDKNRVPFVKGCTERFVSSPEEILDVIDEGKSNRHVAVTNMNEHSSRSHSIFLINIKQENMETEQKLSGKLYLVDLAGSEKVSKTGAEGAVLDEAKNINKSLSALGNVISALAEGTKSYVPYRDSKMTRILQDSLGGNCRTTMFICCSPSSYNDAETKSTLMFGQRAKTIKNTASVNLELTAEQWKKKYEKEKEKTKAQKETIAKLEAELSRWRNGENVPETERLAGEEAALGAELCEETPVNDNSSIVVRIAPEERQKYEEEIRRLYKQLDDKDDEINQQSQLIEKLKQQMLDQEELLVSTRGDNEKVQRELSHLQSENDAAKDEVKEVLQALEELAVNYDQKSQEVEEKSQQNQLLVDELSQKVATMLSLESELQRLQEVSGHQRKRIAEVLNGLMKDLSEFSVIVGNGEIKLPVEISGAIEEEFTVARLYISKIKSEVKSVVKRCRQLENLQVECHRKMEVTGRELSSCQLLISQHEAKIRSLTEYMQSVELKKRHLEESYDSLSDELAKLQAQETVHEVALKDKEPDTQDADEVKKALELQMESHREAHHRQLARLRDEINEKQKTIDELKDLNQKLQLELEKLQADYEKLKSEEHEKSTKLQELTFLYERHEQSKQDLKGLEETVARELQTLHNLRKLFVQDVTTRVKKSAEMEPEDSGGIHSQKQKISFLENNLEQLTKVHKQLVRDNADLRCELPKLEKRLRATAERVKALEGALKEAKEGAMKDKRRYQQEVDRIKEAVRYKSSGKRGHSAQIAKPVRPGHYPASSPTNPYGTRSPECISYTNSLFQNYQNLYLQATPSSTSDMYFANSCTSSGATSSGGPLASYQKANMDNGNATDINDNRSDLPCGYEAEDQAKLFPLHQETAAS

T58393	TARGETID	T58393
T58393	FORMERID	TTDI00023
T58393	UNIPROID	CNTN1_HUMAN
T58393	TARGNAME	Contactin-1 (CNTN1)
T58393	GENENAME	CNTN1
T58393	TARGTYPE	Literature-reported
T58393	SYNONYMS	Neural cell surface protein F3; Glycoprotein gp135; CNTN1
T58393	FUNCTION	Contactins mediate cell surface interactions during nervous system development. Involved in the formation of paranodal axo-glial junctions in myelinated peripheral nerves and in the signaling between axons and myelinating glial cells via its association with CNTNAP1. Participates in oligodendrocytes generation by acting as a ligand of NOTCH1. Its association with NOTCH1 promotes NOTCH1 activation through the released notch intracellular domain (NICD) and subsequent translocation to the nucleus. Interaction with TNR induces a repulsion of neurons and an inhibition of neurite outgrowth.
T58393	PDBSTRUC	3S97; 2EE2
T58393	BIOCLASS	Immunoglobulin
T58393	SEQUENCE	MKMWLLVSHLVIISITTCLAEFTWYRRYGHGVSEEDKGFGPIFEEQPINTIYPEESLEGKVSLNCRARASPFPVYKWRMNNGDVDLTSDRYSMVGGNLVINNPDKQKDAGIYYCLASNNYGMVRSTEATLSFGYLDPFPPEERPEVRVKEGKGMVLLCDPPYHFPDDLSYRWLLNEFPVFITMDKRRFVSQTNGNLYIANVEASDKGNYSCFVSSPSITKSVFSKFIPLIPIPERTTKPYPADIVVQFKDVYALMGQNVTLECFALGNPVPDIRWRKVLEPMPSTAEISTSGAVLKIFNIQLEDEGIYECEAENIRGKDKHQARIYVQAFPEWVEHINDTEVDIGSDLYWPCVATGKPIPTIRWLKNGYAYHKGELRLYDVTFENAGMYQCIAENTYGAIYANAELKILALAPTFEMNPMKKKILAAKGGRVIIECKPKAAPKPKFSWSKGTEWLVNSSRILIWEDGSLEINNITRNDGGIYTCFAENNRGKANSTGTLVITDPTRIILAPINADITVGENATMQCAASFDPALDLTFVWSFNGYVIDFNKENIHYQRNFMLDSNGELLIRNAQLKHAGRYTCTAQTIVDNSSASADLVVRGPPGPPGGLRIEDIRATSVALTWSRGSDNHSPISKYTIQTKTILSDDWKDAKTDPPIIEGNMEAARAVDLIPWMEYEFRVVATNTLGRGEPSIPSNRIKTDGAAPNVAPSDVGGGGGRNRELTITWAPLSREYHYGNNFGYIVAFKPFDGEEWKKVTVTNPDTGRYVHKDETMSPSTAFQVKVKAFNNKGDGPYSLVAVINSAQDAPSEAPTEVGVKVLSSSEISVHWEHVLEKIVESYQIRYWAAHDKEEAANRVQVTSQEYSARLENLLPDTQYFIEVGACNSAGCGPPSDMIEAFTKKAPPSQPPRIISSVRSGSRYIITWDHVVALSNESTVTGYKVLYRPDGQHDGKLYSTHKHSIEVPIPRDGEYVVEVRAHSDGGDGVVSQVKISGAPTLSPSLLGLLLPAFGILVYLEF

T58178	TARGETID	T58178
T58178	FORMERID	TTDI03220
T58178	UNIPROID	GRIK2_HUMAN
T58178	TARGNAME	Glutamate receptor ionotropic kainate 2 (GRIK2)
T58178	GENENAME	GRIK2
T58178	TARGTYPE	Literature-reported
T58178	SYNONYMS	Glutamate receptor ionotropic, kainate 2; Glutamate receptor 6; GluR6; GluR-6; GluK2; Excitatory amino acid receptor 4; EAA4
T58178	FUNCTION	L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist. May be involved in the transmission of light information from the retina to the hypothalamus. Modulates cell surface expression of NETO2. Ionotropic glutamate receptor.
T58178	PDBSTRUC	5CMM; 3QXM
T58178	BIOCLASS	Glutamate-gated ion channel
T58178	SEQUENCE	MKIIFPILSNPVFRRTVKLLLCLLWIGYSQGTTHVLRFGGIFEYVESGPMGAEELAFRFAVNTINRNRTLLPNTTLTYDTQKINLYDSFEASKKACDQLSLGVAAIFGPSHSSSANAVQSICNALGVPHIQTRWKHQVSDNKDSFYVSLYPDFSSLSRAILDLVQFFKWKTVTVVYDDSTGLIRLQELIKAPSRYNLRLKIRQLPADTKDAKPLLKEMKRGKEFHVIFDCSHEMAAGILKQALAMGMMTEYYHYIFTTLDLFALDVEPYRYSGVNMTGFRILNTENTQVSSIIEKWSMERLQAPPKPDSGLLDGFMTTDAALMYDAVHVVSVAVQQFPQMTVSSLQCNRHKPWRFGTRFMSLIKEAHWEGLTGRITFNKTNGLRTDFDLDVISLKEEGLEKIGTWDPASGLNMTESQKGKPANITDSLSNRSLIVTTILEEPYVLFKKSDKPLYGNDRFEGYCIDLLRELSTILGFTYEIRLVEDGKYGAQDDANGQWNGMVRELIDHKADLAVAPLAITYVREKVIDFSKPFMTLGISILYRKPNGTNPGVFSFLNPLSPDIWMYILLAYLGVSCVLFVIARFSPYEWYNPHPCNPDSDVVENNFTLLNSFWFGVGALMQQGSELMPKALSTRIVGGIWWFFTLIIISSYTANLAAFLTVERMESPIDSADDLAKQTKIEYGAVEDGATMTFFKKSKISTYDKMWAFMSSRRQSVLVKSNEEGIQRVLTSDYAFLMESTTIEFVTQRNCNLTQIGGLIDSKGYGVGTPMGSPYRDKITIAILQLQEEGKLHMMKEKWWRGNGCPEEESKEASALGVQNIGGIFIVLAAGLVLSVFVAVGEFLYKSKKNAQLEKRSFCSAMVEELRMSLKCQRRLKHKPQAPVIVKTEEVINMHTFNDRRLPGKETMA
T58178	DRUGINFO	D00VEZ	2,4-epi-neodysiherbaine	Investigative
T58178	DRUGINFO	D09KRH	domoic acid	Investigative
T58178	DRUGINFO	D0K6AF	dysiherbaine	Investigative
T58178	DRUGINFO	D0S8AN	SYM2081	Investigative
T58178	DRUGINFO	D04PFN	[3H]kainate	Investigative

T23606	TARGETID	T23606
T23606	FORMERID	TTDI03492
T23606	UNIPROID	KGP2_HUMAN
T23606	TARGNAME	Protein kinase G2 (PRKG2)
T23606	GENENAME	PRKG2
T23606	TARGTYPE	Literature-reported
T23606	SYNONYMS	cGMP-dependent protein kinase II; cGMP-dependent protein kinase 2; cGKII; cGK2; cGK 2; PRKGR2
T23606	FUNCTION	Crucial regulator of intestinal secretion and bone growth (By similarity). Phosphorylates and activates CFTR on the plasma membrane. Plays a key role in intestinal secretion by regulating cGMP-dependent translocation of CFTR in jejunum (By similarity). Acts downstream of NMDAR to activate the plasma membrane accumulation of GRIA1/GLUR1 in synapse and increase synaptic plasticity. Phosphorylates GRIA1/GLUR1 at Ser-863 (By similarity). Acts as regulator of gene expression and activator of the extracellular signal-regulated kinases MAPK3/ERK1 and MAPK1/ERK2 in mechanically stimulated osteoblasts. Under fluid shear stress, mediates ERK activation and subsequent induction of FOS, FOSL1/FRA1, FOSL2/FRA2 and FOSB that play a key role in the osteoblast anabolic response to mechanical stimulation (By similarity).
T23606	PDBSTRUC	6BQ8; 5JIZ; 5JIX; 5C8W; 5C6C
T23606	ECNUMBER	EC 2.7.11.12
T23606	SEQUENCE	MGNGSVKPKHSKHPDGHSGNLTTDALRNKVTELERELRRKDAEIQEREYHLKELREQLSKQTVAIAELTEELQNKCIQLNKLQDVVHMQGGSPLQASPDKVPLEVHRKTSGLVSLHSRRGAKAGVSAEPTTRTYDLNKPPEFSFEKARVRKDSSEKKLITDALNKNQFLKRLDPQQIKDMVECMYGRNYQQGSYIIKQGEPGNHIFVLAEGRLEVFQGEKLLSSIPMWTTFGELAILYNCTRTASVKAITNVKTWALDREVFQNIMRRTAQARDEQYRNFLRSVSLLKNLPEDKLTKIIDCLEVEYYDKGDYIIREGEEGSTFFILAKGKVKVTQSTEGHDQPQLIKTLQKGEYFGEKALISDDVRSANIIAEENDVACLVIDRETFNQTVGTFEELQKYLEGYVANLNRDDEKRHAKRSMSNWKLSKALSLEMIQLKEKVARFSSSSPFQNLEIIATLGVGGFGRVELVKVKNENVAFAMKCIRKKHIVDTKQQEHVYSEKRILEELCSPFIVKLYRTFKDNKYVYMLLEACLGGELWSILRDRGSFDEPTSKFCVACVTEAFDYLHRLGIIYRDLKPENLILDAEGYLKLVDFGFAKKIGSGQKTWTFCGTPEYVAPEVILNKGHDFSVDFWSLGILVYELLTGNPPFSGVDQMMTYNLILKGIEKMDFPRKITRRPEDLIRRLCRQNPTERLGNLKNGINDIKKHRWLNGFNWEGLKARSLPSPLQRELKGPIDHSYFDKYPPEKGMPPDELSGWDKDF
T23606	DRUGINFO	D0N1UU	PMID20471253C32	Investigative

T23619	TARGETID	T23619
T23619	FORMERID	TTDI00007
T23619	UNIPROID	MTA1_HUMAN
T23619	TARGNAME	Metastasis associated gene-1 (MTA1)
T23619	GENENAME	MTA1
T23619	TARGTYPE	Literature-reported
T23619	SYNONYMS	Metastasisassociated protein MTA1; Metastasis-associated protein MTA1
T23619	FUNCTION	As a part of the histone-deacetylase multiprotein complex (NuRD), regulates transcription of its targets by modifying the acetylation status of the target chromatin and cofactor accessibility to the target DNA. In conjunction with other components of NuRD, acts as a transcriptional corepressor of BRCA1, ESR1, TFF1 and CDKN1A. Acts as a transcriptional coactivator of BCAS3, PAX5 and SUMO2, independent of the NuRD complex. Stimulates the expression of WNT1 by inhibiting the expression of its transcriptional corepressor SIX3. Regulates p53-dependent and -independent DNA repair processes following genotoxic stress. Regulates the stability and function of p53/TP53 by inhibiting its ubiquitination by COP1 and MDM2 thereby regulating the p53-dependent DNA repair. Plays an important role in tumorigenesis, tumor invasion, and metastasis. Involved in the epigenetic regulation of ESR1 expression in breast cancer in a TFAP2C, IFI16 and HDAC4/5/6-dependent manner. Plays a role in the regulation of the circadian clock and is essential for the generation and maintenance of circadian rhythms under constant light and for normal entrainment of behavior to light-dark (LD) cycles. Positively regulates the CLOCK-ARNTL/BMAL1 heterodimer mediated transcriptional activation of its own transcription and the transcription of CRY1. Regulates deacetylation of ARNTL/BMAL1 by regulating SIRT1 expression, resulting in derepressing CRY1-mediated transcription repression. Isoform Short binds to ESR1 and sequesters it in the cytoplasm and enhances its non-genomic responses. With TFCP2L1, promotes establishment and maintenance of pluripotency in embryonic stem cells (ESCs) and inhibits endoderm differentiation. Transcriptional coregulator which can act as both a transcriptional corepressor and coactivator.
T23619	PDBSTRUC	6G16; 5ICN; 5FXY; 4PC0; 4PBZ
T23619	SEQUENCE	MAANMYRVGDYVYFENSSSNPYLIRRIEELNKTANGNVEAKVVCFYRRRDISSTLIALADKHATLSVCYKAGPGADNGEEGEIEEEMENPEMVDLPEKLKHQLRHRELFLSRQLESLPATHIRGKCSVTLLNETESLKSYLEREDFFFYSLVYDPQQKTLLADKGEIRVGNRYQADITDLLKEGEEDGRDQSRLETQVWEAHNPLTDKQIDQFLVVARSVGTFARALDCSSSVRQPSLHMSAAAASRDITLFHAMDTLHKNIYDISKAISALVPQGGPVLCRDEMEEWSASEANLFEEALEKYGKDFTDIQQDFLPWKSLTSIIEYYYMWKTTDRYVQQKRLKAAEAESKLKQVYIPNYNKPNPNQISVNNVKAGVVNGTGAPGQSPGAGRACESCYTTQSYQWYSWGPPNMQCRLCASCWTYWKKYGGLKMPTRLDGERPGPNRSNMSPHGLPARSSGSPKFAMKTRQAFYLHTTKLTRIARRLCREILRPWHAARHPYLPINSAAIKAECTARLPEASQSPLVLKQAVRKPLEAVLRYLETHPRPPKPDPVKSVSSVLSSLTPAKVAPVINNGSPTILGKRSYEQHNGVDGNMKKRLLMPSRGLANHGQARHMGPSRNLLLNGKSYPTKVRLIRGGSLPPVKRRRMNWIDAPDDVFYMATEETRKIRKLLSSSETKRAARRPYKPIALRQSQALPPRPPPPAPVNDEPIVIED

T92794	TARGETID	T92794
T92794	UNIPROID	UT1_HUMAN
T92794	TARGNAME	Urea transporter 1 (SLC14A1)
T92794	GENENAME	SLC14A1
T92794	TARGTYPE	Literature-reported
T92794	SYNONYMS	Urea transporter, erythrocyte; UTE; UT1; Solute carrier family 14 member 1; RACH1; JK; HUT11
T92794	FUNCTION	Urea channel that facilitates transmembrane urea transport down a concentration gradient. A constriction of the transmembrane channel functions as selectivity filter through which urea is expected to pass in dehydrated form. The rate of urea conduction is increased by hypotonic stress. Plays an important role in the kidney medulla collecting ducts, where it allows rapid equilibration between the lumen of the collecting ducts and the interstitium, and thereby prevents water loss driven by the high concentration of urea in the urine. Facilitates urea transport across erythrocyte membranes. May also play a role in transmembrane water transport, possibly by indirect means.
T92794	PDBSTRUC	6QD5
T92794	BIOCLASS	Urea transporter family
T92794	SEQUENCE	MEDSPTMVRVDSPTMVRGENQVSPCQGRRCFPKALGYVTGDMKELANQLKDKPVVLQFIDWILRGISQVVFVNNPVSGILILVGLLVQNPWWALTGWLGTVVSTLMALLLSQDRSLIASGLYGYNATLVGVLMAVFSDKGDYFWWLLLPVCAMSMTCPIFSSALNSMLSKWDLPVFTLPFNMALSMYLSATGHYNPFFPAKLVIPITTAPNISWSDLSALELLKSIPVGVGQIYGCDNPWTGGIFLGAILLSSPLMCLHAAIGSLLGIAAGLSLSAPFEDIYFGLWGFNSSLACIAMGGMFMALTWQTHLLALGCALFTAYLGVGMANFMAEVGLPACTWPFCLATLLFLIMTTKNSNIYKMPLSKVTYPEENRIFYLQAKKRMVESPL

T02484	TARGETID	T02484
T02484	FORMERID	TTDI01479
T02484	UNIPROID	NNTM_HUMAN
T02484	TARGNAME	Pyridine nucleotide transhydrogenase (NNT)
T02484	GENENAME	NNT
T02484	TARGTYPE	Literature-reported
T02484	SYNONYMS	Nicotinamide nucleotide transhydrogenase; NAD(P) transhydrogenase, mitochondrial
T02484	FUNCTION	The transhydrogenation between NADH and NADP is coupled to respiration and ATP hydrolysis and functions as a proton pump across the membrane. May play a role in reactive oxygen species (ROS) detoxification in the adrenal gland.
T02484	PDBSTRUC	1U31; 1PT9; 1DJL
T02484	ECNUMBER	EC 7.1.1.1
T02484	SEQUENCE	MANLLKTVVTGCSCPLLSNLGSCKGLRVKKDFLRTFYTHQELWCKAPVKPGIPYKQLTVGVPKEIFQNEKRVALSPAGVQNLVKQGFNVVVESGAGEASKFSDDHYRVAGAQIQGAKEVLASDLVVKVRAPMVNPTLGVHEADLLKTSGTLISFIYPAQNPELLNKLSQRKTTVLAMDQVPRVTIAQGYDALSSMANIAGYKAVVLAANHFGRFFTGQITAAGKVPPAKILIVGGGVAGLASAGAAKSMGAIVRGFDTRAAALEQFKSLGAEPLEVDLKESGEGQGGYAKEMSKEFIEAEMKLFAQQCKEVDILISTALIPGKKAPVLFNKEMIESMKEGSVVVDLAAEAGGNFETTKPGELYIHKGITHIGYTDLPSRMATQASTLYSNNITKLLKAISPDKDNFYFDVKDDFDFGTMGHVIRGTVVMKDGKVIFPAPTPKNIPQGAPVKQKTVAELEAEKAATITPFRKTMSTASAYTAGLTGILGLGIAAPNLAFSQMVTTFGLAGIVGYHTVWGVTPALHSPLMSVTNAISGLTAVGGLALMGGHLYPSTTSQGLAALAAFISSVNIAGGFLVTQRMLDMFKRPTDPPEYNYLYLLPAGTFVGGYLAALYSGYNIEQIMYLGSGLCCVGALAGLSTQGTARLGNALGMIGVAGGLAATLGVLKPGPELLAQMSGAMALGGTIGLTIAKRIQISDLPQLVAAFHSLVGLAAVLTCIAEYIIEYPHFATDAAANLTKIVAYLGTYIGGVTFSGSLIAYGKLQGLLKSAPLLLPGRHLLNAGLLAASVGGIIPFMVDPSFTTGITCLGSVSALSAVMGVTLTAAIGGADMPVVITVLNSYSGWALCAEGFLLNNNLLTIVGALIGSSGAILSYIMCVAMNRSLANVILGGYGTTSTAGGKPMEISGTHTEINLDNAIDMIREANSIIITPGYGLCAAKAQYPIADLVKMLTEQGKKVRFGIHPVAGRMPGQLNVLLAEAGVPYDIVLEMDEINHDFPDTDLVLVIGANDTVNSAAQEDPNSIIAGMPVLEVWKSKQVIVMKRSLGVGYAAVDNPIFYKPNTAMLLGDAKKTCDALQAKVRESYQK

T04499	TARGETID	T04499
T04499	FORMERID	TTDR00891
T04499	UNIPROID	KSR1_HUMAN
T04499	TARGNAME	Kinase suppressor of Ras-1 (KSR1)
T04499	GENENAME	KSR1
T04499	TARGTYPE	Literature-reported
T04499	SYNONYMS	Kinase suppressor of Ras 1; KSR
T04499	FUNCTION	Promotes phosphorylation of Raf family members and activation of downstream MAP kinases. Promotes activation of MAPK1 and/or MAPK3, both in response to EGF and to cAMP. Does not have kinase activity by itself. Scaffolding protein that is part of a multiprotein signaling complex.
T04499	PDBSTRUC	5VYK
T04499	BIOCLASS	Kinase
T04499	SEQUENCE	MDRAALRAAAMGEKKEGGGGGDAAAAEGGAGAAASRALQQCGQLQKLIDISIGSLRGLRTKCAVSNDLTQQEIRTLEAKLVRYICKQRQCKLSVAPGERTPELNSYPRFSDWLYTFNVRPEVVQEIPRDLTLDALLEMNEAKVKETLRRCGASGDECGRLQYALTCLRKVTGLGGEHKEDSSWSSLDARRESGSGPSTDTLSAASLPWPPGSSQLGRAGNSAQGPRSISVSALPASDSPTPSFSEGLSDTCIPLHASGRLTPRALHSFITPPTTPQLRRHTKLKPPRTPPPPSRKVFQLLPSFPTLTRSKSHESQLGNRIDDVSSMRFDLSHGSPQMVRRDIGLSVTHRFSTKSWLSQVCHVCQKSMIFGVKCKHCRLKCHNKCTKEAPACRISFLPLTRLRRTESVPSDINNPVDRAAEPHFGTLPKALTKKEHPPAMNHLDSSSNPSSTTSSTPSSPAPFPTSSNPSSATTPPNPSPGQRDSRFNFPAAYFIHHRQQFIFPVPSAGHCWKCLLIAESLKENAFNISAFAHAAPLPEAADGTRLDDQPKADVLEAHEAEAEEPEAGKSEAEDDEDEVDDLPSSRRPWRGPISRKASQTSVYLQEWDIPFEQVELGEPIGQGRWGRVHRGRWHGEVAIRLLEMDGHNQDHLKLFKKEVMNYRQTRHENVVLFMGACMNPPHLAIITSFCKGRTLHSFVRDPKTSLDINKTRQIAQEIIKGMGYLHAKGIVHKDLKSKNVFYDNGKVVITDFGLFGISGVVREGRRENQLKLSHDWLCYLAPEIVREMTPGKDEDQLPFSKAADVYAFGTVWYELQARDWPLKNQAAEASIWQIGSGEGMKRVLTSVSLGKEVSEILSACWAFDLQERPSFSLLMDMLEKLPKLNRRLSHPGHFWKSADINSSKVVPRFERFGLGVLESSNPKM

T52409	TARGETID	T52409
T52409	FORMERID	TTDI02420
T52409	UNIPROID	MTM1_HUMAN
T52409	TARGNAME	Myotubularin (MTM1)
T52409	GENENAME	MTM1
T52409	TARGTYPE	Literature-reported
T52409	SYNONYMS	MTM1
T52409	FUNCTION	Lipid phosphatase which dephosphorylates phosphatidylinositol 3-monophosphate (PI3P) and phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2). Has also been shown to dephosphorylate phosphotyrosine- and phosphoserine- containing peptides. Negatively regulates EGFR degradation through regulation of EGFR trafficking from the late endosome to the lysosome. Plays a role in vacuolar formation and morphology. Regulates desmin intermediate filament assembly and architecture. Plays a role in mitochondrial morphology and positioning. Required for skeletal muscle maintenance but not for myogenesis.
T52409	BIOCLASS	Phosphoric monoester hydrolase
T52409	ECNUMBER	EC 3.1.3.95
T52409	SEQUENCE	MASASTSKYNSHSLENESIKRTSRDGVNRDLTEAVPRLPGETLITDKEVIYICPFNGPIKGRVYITNYRLYLRSLETDSSLILDVPLGVISRIEKMGGATSRGENSYGLDITCKDMRNLRFALKQEGHSRRDMFEILTRYAFPLAHSLPLFAFLNEEKFNVDGWTVYNPVEEYRRQGLPNHHWRITFINKCYELCDTYPALLVVPYRASDDDLRRVATFRSRNRIPVLSWIHPENKTVIVRCSQPLVGMSGKRNKDDEKYLDVIRETNKQISKLTIYDARPSVNAVANKATGGGYESDDAYHNAELFFLDIHNIHVMRESLKKVKDIVYPNVEESHWLSSLESTHWLEHIKLVLTGAIQVADKVSSGKSSVLVHCSDGWDRTAQLTSLAMLMLDSFYRSIEGFEILVQKEWISFGHKFASRIGHGDKNHTDADRSPIFLQFIDCVWQMSKQFPTAFEFNEQFLIIILDHLYSCRFGTFLFNCESARERQKVTERTVSLWSLINSNKEKFKNPFYTKEINRVLYPVASMRHLELWVNYYIRWNPRIKQQQPNPVEQRYMELLALRDEYIKRLEELQLANSAKLSDPPTSPSSPSQMMPHVQTHF

T24965	TARGETID	T24965
T24965	FORMERID	TTDI03097
T24965	UNIPROID	CAC1S_HUMAN
T24965	TARGNAME	Voltage-gated calcium channel alpha Cav1.1 (CACNA1S)
T24965	GENENAME	CACNA1S
T24965	TARGTYPE	Literature-reported
T24965	SYNONYMS	Voltage-gated calcium channel subunit alpha Cav1.1; Voltage-dependent L-type calcium channel subunit alpha-1S; Calcium channel, L type, alpha-1 polypeptide, isoform 3, skeletal muscle; CACNL1A3; CACN1; CACH1
T24965	FUNCTION	Pore-forming, alpha-1S subunit of the voltage-gated calcium channel that gives rise to L-type calcium currents in skeletal muscle. Calcium channels containing the alpha-1S subunit play an important role in excitation-contraction coupling in skeletal muscle via their interaction with RYR1, which triggers Ca(2+) release from the sarcplasmic reticulum and ultimately results in muscle contraction. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group.
T24965	PDBSTRUC	6B27; 2VAY
T24965	BIOCLASS	Voltage-gated ion channel
T24965	SEQUENCE	MEPSSPQDEGLRKKQPKKPVPEILPRPPRALFCLTLENPLRKACISIVEWKPFETIILLTIFANCVALAVYLPMPEDDNNSLNLGLEKLEYFFLIVFSIEAAMKIIAYGFLFHQDAYLRSGWNVLDFTIVFLGVFTVILEQVNVIQSHTAPMSSKGAGLDVKALRAFRVLRPLRLVSGVPSLQVVLNSIFKAMLPLFHIALLVLFMVIIYAIIGLELFKGKMHKTCYFIGTDIVATVENEEPSPCARTGSGRRCTINGSECRGGWPGPNHGITHFDNFGFSMLTVYQCITMEGWTDVLYWVNDAIGNEWPWIYFVTLILLGSFFILNLVLGVLSGEFTKEREKAKSRGTFQKLREKQQLDEDLRGYMSWITQGEVMDVEDFREGKLSLDEGGSDTESLYEIAGLNKIIQFIRHWRQWNRIFRWKCHDIVKSKVFYWLVILIVALNTLSIASEHHNQPLWLTRLQDIANRVLLSLFTTEMLMKMYGLGLRQYFMSIFNRFDCFVVCSGILEILLVESGAMTPLGISVLRCIRLLRIFKITKYWTSLSNLVASLLNSIRSIASLLLLLFLFIVIFALLGMQLFGGRYDFEDTEVRRSNFDNFPQALISVFQVLTGEDWTSMMYNGIMAYGGPSYPGMLVCIYFIILFVCGNYILLNVFLAIAVDNLAEAESLTSAQKAKAEEKKRRKMSKGLPDKSEEEKSTMAKKLEQKPKGEGIPTTAKLKIDEFESNVNEVKDPYPSADFPGDDEEDEPEIPLSPRPRPLAELQLKEKAVPIPEASSFFIFSPTNKIRVLCHRIVNATWFTNFILLFILLSSAALAAEDPIRADSMRNQILKHFDIGFTSVFTVEIVLKMTTYGAFLHKGSFCRNYFNMLDLLVVAVSLISMGLESSAISVVKILRVLRVLRPLRAINRAKGLKHVVQCMFVAISTIGNIVLVTTLLQFMFACIGVQLFKGKFFRCTDLSKMTEEECRGYYYVYKDGDPMQIELRHREWVHSDFHFDNVLSAMMSLFTVSTFEGWPQLLYKAIDSNAEDVGPIYNNRVEMAIFFIIYIILIAFFMMNIFVGFVIVTFQEQGETEYKNCELDKNQRQCVQYALKARPLRCYIPKNPYQYQVWYIVTSSYFEYLMFALIMLNTICLGMQHYNQSEQMNHISDILNVAFTIIFTLEMILKLMAFKARGYFGDPWNVFDFLIVIGSIIDVILSEIDTFLASSGGLYCLGGGCGNVDPDESARISSAFFRLFRVMRLIKLLSRAEGVRTLLWTFIKSFQALPYVALLIVMLFFIYAVIGMQMFGKIALVDGTQINRNNNFQTFPQAVLLLFRCATGEAWQEILLACSYGKLCDPESDYAPGEEYTCGTNFAYYYFISFYMLCAFLVINLFVAVIMDNFDYLTRDWSILGPHHLDEFKAIWAEYDPEAKGRIKHLDVVTLLRRIQPPLGFGKFCPHRVACKRLVGMNMPLNSDGTVTFNATLFALVRTALKIKTEGNFEQANEELRAIIKKIWKRTSMKLLDQVIPPIGDDEVTVGKFYATFLIQEHFRKFMKRQEEYYGYRPKKDIVQIQAGLRTIEEEAAPEICRTVSGDLAAEEELERAMVEAAMEEGIFRRTGGLFGQVDNFLERTNSLPPVMANQRPLQFAEIEMEEMESPVFLEDFPQDPRTNPLARANTNNANANVAYGNSNHSNSHVFSSVHYEREFPEETETPATRGRALGQPCRVLGPHSKPCVEMLKGLLTQRAMPRGQAPPAPCQCPRVESSMPEDRKSSTPGSLHEETPHSRSTRENTSRCSAPATALLIQKALVRGGLGTLAADANFIMATGQALADACQMEPEEVEIMATELLKGREAPEGMASSLGCLNLGSSLGSLDQHQGSQETLIPPRL
T24965	DRUGINFO	D04ALU	[3H](+)-cis-diltiazem	Investigative
T24965	DRUGINFO	D06XTT	FPL64176	Investigative
T24965	DRUGINFO	D0U7BI	SZ(+)-(S)-202-791	Investigative
T24965	DRUGINFO	D03UJT	[3H](-)devapamil	Investigative
T24965	DRUGINFO	D0S3YP	[3H](+)-isradipine	Investigative
T24965	DRUGINFO	D02RIH	(-)-(S)-BayK8644	Investigative

T56035	TARGETID	T56035
T56035	FORMERID	TTDR00051
T56035	UNIPROID	KGP1_HUMAN; KGP2_HUMAN
T56035	TARGNAME	cGMP-dependent protein kinase (cGK)
T56035	GENENAME	PRKG1; PRKG2
T56035	TARGTYPE	Literature-reported
T56035	SYNONYMS	cGK; PRKGR
T56035	FUNCTION	Activated by cGMP. Phosphorylates a number of biologically important targets and is implicated in the regulation of smooth muscle relaxation, platelet function, sperm metabolism, cell division, and nucleic acid synthesis.
T56035	BIOCLASS	Kinase
T56035	SEQUENCE	MSELEEDFAKILMLKEERIKELEKRLSEKEEEIQELKRKLHKCQSVLPVPSTHIGPRTTRAQGISAEPQTYRSFHDLRQAFRKFTKSERSKDLIKEAILDNDFMKNLELSQIQEIVDCMYPVEYGKDSCIIKEGDVGSLVYVMEDGKVEVTKEGVKLCTMGPGKVFGELAILYNCTRTATVKTLVNVKLWAIDRQCFQTIMMRTGLIKHTEYMEFLKSVPTFQSLPEEILSKLADVLEETHYENGEYIIRQGARGDTFFIISKGTVNVTREDSPSEDPVFLRTLGKGDWFGEKALQGEDVRTANVIAAEAVTCLVIDRDSFKHLIGGLDDVSNKAYEDAEAKAKYEAEAAFFANLKLSDFNIIDTLGVGGFGRVELVQLKSEESKTFAMKILKKRHIVDTRQQEHIRSEKQIMQGAHSDFIVRLYRTFKDSKYLYMLMEACLGGELWTILRDRGSFEDSTTRFYTACVVEAFAYLHSKGIIYRDLKPENLILDHRGYAKLVDFGFAKKIGFGKKTWTFCGTPEYVAPEIILNKGHDISADYWSLGILMYELLTGSPPFSGPDPMKTYNIILRGIDMIEFPKKIAKNAANLIKKLCRDNPSERLGNLKNGVKDIQKHKWFEGFNWEGLRKGTLTPPIIPSVASPTDTSNFDSFPEDNDEPPPDDNSGWDIDF
T56035	DRUGINFO	D01MMM	TENELLONE A	Investigative
T56035	DRUGINFO	D04KSU	TENELLONE B	Investigative
T56035	DRUGINFO	D05JRA	ARC-1028	Investigative
T56035	DRUGINFO	D0GB4V	STAUROSPORINONE	Investigative

T51698	TARGETID	T51698
T51698	FORMERID	TTDI00558
T51698	UNIPROID	IL16_HUMAN
T51698	TARGNAME	Interleukin-16 (IL16)
T51698	GENENAME	IL16
T51698	TARGTYPE	Literature-reported
T51698	SYNONYMS	Prointerleukin16; Pro-interleukin-16; LCF; Interleukin16
T51698	FUNCTION	Primes CD4+ T-cells for IL-2 and IL-15 responsiveness. Also induces T-lymphocyte expression of interleukin 2 receptor. Ligand for CD4. Interleukin-16 stimulates a migratory response in CD4+ lymphocytes, monocytes, and eosinophils.
T51698	PDBSTRUC	5FB8; 1X6D; 1I16
T51698	BIOCLASS	Cytokine: interleukin
T51698	SEQUENCE	MESHSRAGKSRKSAKFRSISRSLMLCNAKTSDDGSSPDEKYPDPFEISLAQGKEGIFHSSVQLADTSEAGPSSVPDLALASEAAQLQAAGNDRGKTCRRIFFMKESSTASSREKPGKLEAQSSNFLFPKACHQRARSNSTSVNPYCTREIDFPMTKKSAAPTDRQPYSLCSNRKSLSQQLDCPAGKAAGTSRPTRSLSTAQLVQPSGGLQASVISNIVLMKGQAKGLGFSIVGGKDSIYGPIGIYVKTIFAGGAAAADGRLQEGDEILELNGESMAGLTHQDALQKFKQAKKGLLTLTVRTRLTAPPSLCSHLSPPLCRSLSSSTCITKDSSSFALESPSAPISTAKPNYRIMVEVSLQKEAGVGLGIGLCSVPYFQCISGIFVHTLSPGSVAHLDGRLRCGDEIVEISDSPVHCLTLNEVYTILSHCDPGPVPIIVSRHPDPQVSEQQLKEAVAQAVENTKFGKERHQWSLEGVKRLESSWHGRPTLEKEREKNSAPPHRRAQKVMIRSSSDSSYMSGSPGGSPGSGSAEKPSSDVDISTHSPSLPLAREPVVLSIASSRLPQESPPLPESRDSHPPLRLKKSFEILVRKPMSSKPKPPPRKYFKSDSDPQKSLEERENSSCSSGHTPPTCGQEARELLPLLLPQEDTAGRSPSASAGCPGPGIGPQTKSSTEGEPGWRRASPVTQTSPIKHPLLKRQARMDYSFDTTAEDPWVRISDCIKNLFSPIMSENHGHMPLQPNASLNEEEGTQGHPDGTPPKLDTANGTPKVYKSADSSTVKKGPPVAPKPAWFRQSLKGLRNRASDPRGLPDPALSTQPAPASREHLGSHIRASSSSSSIRQRISSFETFGSSQLPDKGAQRLSLQPSSGEAAKPLGKHEEGRFSGLLGRGAAPTLVPQQPEQVLSSGSPAASEARDPGVSESPPPGRQPNQKTLPPGPDPLLRLLSTQAEESQGPVLKMPSQRARSFPLTRSQSCETKLLDEKTSKLYSISSQVSSAVMKSLLCLPSSISCAQTPCIPKEGASPTSSSNEDSAANGSAETSALDTGFSLNLSELREYTEGLTEAKEDDDGDHSSLQSGQSVISLLSSEELKKLIEEVKVLDEATLKQLDGIHVTILHKEEGAGLGFSLAGGADLENKVITVHRVFPNGLASQEGTIQKGNEVLSINGKSLKGTTHHDALAILRQAREPRQAVIVTRKLTPEAMPDLNSSTDSAASASAASDVSVESTAEATVCTVTLEKMSAGLGFSLEGGKGSLHGDKPLTINRIFKGAASEQSETVQPGDEILQLGGTAMQGLTRFEAWNIIKALPDGPVTIVIRRKSLQSKETTAAGDS

T63883	TARGETID	T63883
T63883	FORMERID	TTDR00705
T63883	UNIPROID	DAG1_HUMAN
T63883	TARGNAME	Dystroglycan (DAG1)
T63883	GENENAME	DAG1
T63883	TARGTYPE	Literature-reported
T63883	SYNONYMS	Dystrophin-associated glycoprotein 1; Alpha-dystroglycan
T63883	FUNCTION	The dystroglycan complex is involved in a number of processes including laminin and basement membrane assembly, sarcolemmal stability, cell survival, peripheral nerve myelination, nodal structure, cell migration, and epithelial polarization.
T63883	PDBSTRUC	5LLK; 5GGP; 2MK7; 1EG4
T63883	BIOCLASS	Dystroglycan protein
T63883	SEQUENCE	MRMSVGLSLLLPLSGRTFLLLLSVVMAQSHWPSEPSEAVRDWENQLEASMHSVLSDLHEAVPTVVGIPDGTAVVGRSFRVTIPTDLIASSGDIIKVSAAGKEALPSWLHWDSQSHTLEGLPLDTDKGVHYISVSATRLGANGSHIPQTSSVFSIEVYPEDHSELQSVRTASPDPGEVVSSACAADEPVTVLTVILDADLTKMTPKQRIDLLHRMRSFSEVELHNMKLVPVVNNRLFDMSAFMAGPGNAKKVVENGALLSWKLGCSLNQNSVPDIHGVEAPAREGAMSAQLGYPVVGWHIANKKPPLPKRVRRQIHATPTPVTAIGPPTTAIQEPPSRIVPTPTSPAIAPPTETMAPPVRDPVPGKPTVTIRTRGAIIQTPTLGPIQPTRVSEAGTTVPGQIRPTMTIPGYVEPTAVATPPTTTTKKPRVSTPKPATPSTDSTTTTTRRPTKKPRTPRPVPRVTTKVSITRLETASPPTRIRTTTSGVPRGGEPNQRPELKNHIDRVDAWVGTYFEVKIPSDTFYDHEDTTTDKLKLTLKLREQQLVGEKSWVQFNSNSQLMYGLPDSSHVGKHEYFMHATDKGGLSAVDAFEIHVHRRPQGDRAPARFKAKFVGDPALVLNDIHKKIALVKKLAFAFGDRNCSTITLQNITRGSIVVEWTNNTLPLEPCPKEQIAGLSRRIAEDDGKPRPAFSNALEPDFKATSITVTGSGSCRHLQFIPVVPPRRVPSEAPPTEVPDRDPEKSSEDDVYLHTVIPAVVVAAILLIAGIIAMICYRKKRKGKLTLEDQATFIKKGVPIIFADELDDSKPPPSSSMPLILQEEKAPLPPPEYPNQSVPETTPLNQDTMGEYTPLRDEDPNAPPYQPPPPFTAPMEGKGSRPKNMTPYRSPPPYVPP

T12581	TARGETID	T12581
T12581	FORMERID	TTDI03296
T12581	UNIPROID	ITPR3_HUMAN
T12581	TARGNAME	IP3 receptor isoform 3 (ITPR3)
T12581	GENENAME	ITPR3
T12581	TARGTYPE	Literature-reported
T12581	SYNONYMS	Type 3 inositol 1,4,5-trisphosphate receptor; Type 3 InsP3 receptor; InsP3R3; Inositol 1,4,5-trisphosphate receptor type 3; IP3R 3
T12581	FUNCTION	Receptor for inositol 1,4,5-trisphosphate, a second messenger that mediates the release of intracellular calcium.
T12581	PDBSTRUC	6DRC; 6DRA; 6DR2; 6DR0; 6DQZ
T12581	BIOCLASS	Ryanodine-inositol triphosphate calcium channel
T12581	SEQUENCE	MSEMSSFLHIGDIVSLYAEGSVNGFISTLGLVDDRCVVEPAAGDLDNPPKKFRDCLFKVCPMNRYSAQKQYWKAKQTKQDKEKIADVVLLQKLQHAAQMEQKQNDTENKKVHGDVVKYGSVIQLLHMKSNKYLTVNKRLPALLEKNAMRVTLDATGNEGSWLFIQPFWKLRSNGDNVVVGDKVILNPVNAGQPLHASNYELSDNAGCKEVNSVNCNTSWKINLFMQFRDHLEEVLKGGDVVRLFHAEQEKFLTCDEYKGKLQVFLRTTLRQSATSATSSNALWEVEVVHHDPCRGGAGHWNGLYRFKHLATGNYLAAEENPSYKGDASDPKAAGMGAQGRTGRRNAGEKIKYCLVAVPHGNDIASLFELDPTTLQKTDSFVPRNSYVRLRHLCTNTWIQSTNVPIDIEEERPIRLMLGTCPTKEDKEAFAIVSVPVSEIRDLDFANDASSMLASAVEKLNEGFISQNDRRFVIQLLEDLVFFVSDVPNNGQNVLDIMVTKPNRERQKLMREQNILKQVFGILKAPFREKGGEGPLVRLEELSDQKNAPYQHMFRLCYRVLRHSQEDYRKNQEHIAKQFGMMQSQIGYDILAEDTITALLHNNRKLLEKHITKTEVETFVSLVRKNREPRFLDYLSDLCVSNHIAIPVTQELICKCVLDPKNSDILIRTELRPVKEMAQSHEYLSIEYSEEEVWLTWTDKNNEHHEKSVRQLAQEARAGNAHDENVLSYYRYQLKLFARMCLDRQYLAIDEISQQLGVDLIFLCMADEMLPFDLRASFCHLMLHVHVDRDPQELVTPVKFARLWTEIPTAITIKDYDSNLNASRDDKKNKFANTMEFVEDYLNNVVSEAVPFANEEKNKLTFEVVSLAHNLIYFGFYSFSELLRLTRTLLGIIDCVQGPPAMLQAYEDPGGKNVRRSIQGVGHMMSTMVLSRKQSVFSAPSLSAGASAAEPLDRSKFEENEDIVVMETKLKILEILQFILNVRLDYRISYLLSVFKKEFVEVFPMQDSGADGTAPAFDSTTANMNLDRIGEQAEAMFGVGKTSSMLEVDDEGGRMFLRVLIHLTMHDYAPLVSGALQLLFKHFSQRQEAMHTFKQVQLLISAQDVENYKVIKSELDRLRTMVEKSELWVDKKGSGKGEEVEAGAAKDKKERPTDEEGFLHPPGEKSSENYQIVKGILERLNKMCGVGEQMRKKQQRLLKNMDAHKVMLDLLQIPYDKGDAKMMEILRYTHQFLQKFCAGNPGNQALLHKHLHLFLTPGLLEAETMQHIFLNNYQLCSEISEPVLQHFVHLLATHGRHVQYLDFLHTVIKAEGKYVKKCQDMIMTELTNAGDDVVVFYNDKASLAHLLDMMKAARDGVEDHSPLMYHISLVDLLAACAEGKNVYTEIKCTSLLPLEDVVSVVTHEDCITEVKMAYVNFVNHCYVDTEVEMKEIYTSNHIWTLFENFTLDMARVCSKREKRVADPTLEKYVLSVVLDTINAFFSSPFSENSTSLQTHQTIVVQLLQSTTRLLECPWLQQQHKGSVEACIRTLAMVAKGRAILLPMDLDAHISSMLSSGASCAAAAQRNASSYKATTRAFPRVTPTANQWDYKNIIEKLQDIITALEERLKPLVQAELSVLVDVLHWPELLFLEGSEAYQRCESGGFLSKLIQHTKDLMESEEKLCIKVLRTLQQMLLKKTKYGDRGNQLRKMLLQNYLQNRKSTSRGDLPDPIGTGLDPDWSAIAATQCRLDKEGATKLVCDLITSTKNEKIFQESIGLAIHLLDGGNTEIQKSFHNLMMSDKKSERFFKVLHDRMKRAQQETKSTVAVNMNDLGSQPHEDREPVDPTTKGRVASFSIPGSSSRYSLGPSLRRGHEVSERVQSSEMGTSVLIMQPILRFLQLLCENHNRDLQNFLRCQNNKTNYNLVCETLQFLDIMCGSTTGGLGLLGLYINEDNVGLVIQTLETLTEYCQGPCHENQTCIVTHESNGIDIITALILNDISPLCKYRMDLVLQLKDNASKLLLALMESRHDSENAERILISLRPQELVDVIKKAYLQEEERENSEVSPREVGHNIYILALQLSRHNKQLQHLLKPVKRIQEEEAEGISSMLSLNNKQLSQMLKSSAPAQEEEEDPLAYYENHTSQIEIVRQDRSMEQIVFPVPGICQFLTEETKHRLFTTTEQDEQGSKVSDFFDQSSFLHNEMEWQRKLRSMPLIYWFSRRMTLWGSISFNLAVFINIIIAFFYPYMEGASTGVLDSPLISLLFWILICFSIAALFTKRYSIRPLIVALILRSIYYLGIGPTLNILGALNLTNKIVFVVSFVGNRGTFIRGYKAMVMDMEFLYHVGYILTSVLGLFAHELFYSILLFDLIYREETLFNVIKSVTRNGRSILLTALLALILVYLFSIVGFLFLKDDFILEVDRLPNNHSTASPLGMPHGAAAFVDTCSGDKMDCVSGLSVPEVLEEDRELDSTERACDTLLMCIVTVMNHGLRNGGGVGDILRKPSKDESLFPARVVYDLLFFFIVIIIVLNLIFGVIIDTFADLRSEKQKKEEILKTTCFICGLERDKFDNKTVSFEEHIKLEHNMWNYLYFIVLVRVKNKTDYTGPESYVAQMIKNKNLDWFPRMRAMSLVSNEGEGEQNEIRILQDKLNSTMKLVSHLTAQLNELKEQMTEQRKRRQRLGFVDVQNCISR
T12581	DRUGINFO	D06KHR	decavanadate	Investigative

T38017	TARGETID	T38017
T38017	FORMERID	TTDR01134
T38017	UNIPROID	IRF3_HUMAN
T38017	TARGNAME	Interferon regulatory factor 3 (IRF3)
T38017	GENENAME	IRF3
T38017	TARGTYPE	Literature-reported
T38017	SYNONYMS	IRF-3
T38017	FUNCTION	Regulates the transcription of type I IFN genes (IFN-alpha and IFN-beta) and IFN-stimulated genes (ISG) by binding to an interferon-stimulated response element (ISRE) in their promoters. Acts as a more potent activator of the IFN-beta (IFNB) gene than the IFN-alpha (IFNA) gene and plays a critical role in both the early and late phases of the IFNA/B gene induction. Found in an inactive form in the cytoplasm of uninfected cells and following viral infection, double-stranded RNA (dsRNA), or toll-like receptor (TLR) signaling, is phosphorylated by IKBKE and TBK1 kinases. This induces a conformational change, leading to its dimerization and nuclear localization and association with CREB binding protein (CREBBP) to form dsRNA-activated factor 1 (DRAF1), a complex which activates the transcription of the type I IFN and ISG genes. Can activate distinct gene expression programs in macrophages and can induce significant apoptosis in primary macrophages. Key transcriptional regulator of type I interferon (IFN)-dependent immune responses which plays a critical role in the innate immune response against DNA and RNA viruses.
T38017	PDBSTRUC	5JER; 5JEO; 5JEM; 5JEL; 5JEK
T38017	SEQUENCE	MGTPKPRILPWLVSQLDLGQLEGVAWVNKSRTRFRIPWKHGLRQDAQQEDFGIFQAWAEATGAYVPGRDKPDLPTWKRNFRSALNRKEGLRLAEDRSKDPHDPHKIYEFVNSGVGDFSQPDTSPDTNGGGSTSDTQEDILDELLGNMVLAPLPDPGPPSLAVAPEPCPQPLRSPSLDNPTPFPNLGPSENPLKRLLVPGEEWEFEVTAFYRGRQVFQQTISCPEGLRLVGSEVGDRTLPGWPVTLPDPGMSLTDRGVMSYVRHVLSCLGGGLALWRAGQWLWAQRLGHCHTYWAVSEELLPNSGHGPDGEVPKDKEGGVFDLGPFIVDLITFTEGSGRSPRYALWFCVGESWPQDQPWTKRLVMVKVVPTCLRALVEMARVGGASSLENTVDLHISNSHPLSLTSDQYKAYLQDLVEGMDFQGPGES
T38017	DRUGINFO	D0O0VZ	Piceatannol	Investigative

T24714	TARGETID	T24714
T24714	FORMERID	TTDI00159
T24714	UNIPROID	TRIPC_HUMAN
T24714	TARGNAME	E3 ubiquitin-protein ligase TRIP12 (TRIP12)
T24714	GENENAME	TRIP12
T24714	TARGTYPE	Literature-reported
T24714	SYNONYMS	ULF; Thyroid receptorinteracting protein 12; TRinteracting protein 12; TRIP12; E3 ubiquitinprotein ligase for Arf; E3 ubiquitinprotein ligase TRIP12
T24714	FUNCTION	E3 ubiquitin-protein ligase involved inubiquitin fusion degradation (UFD) pathway and regulation of DNA repair. Part of the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination of protein at their N-terminus,regardeless of the presence of lysine residues in target proteins. In normal cells, mediates ubiquitination and degradation of isoform p19ARF/ARF of CDKN2A, a lysine-less tumor suppressor required for p53/TP53 activation under oncogenic stress. In cancer cells, however, isoform p19ARF/ARF and TRIP12 are located in different cell compartments, preventing isoform p19ARF/ARF ubiquitination and degradation. Does not mediate ubiquitination of isoform p16-INK4a of CDKN2A. Also catalyzes ubiquitination of NAE1 and SMARCE1, leading to their degradation. Ubiquitination and degradation of target proteins is regulated by interaction with proteins such as MYC, TRADD or SMARCC1, which disrupt the interaction between TRIP12 and target proteins. Acts as a key regulator of DNA damage response by acting as a suppressor of RNF168, an E3 ubiquitin-protein ligase that promotes accumulation of 'Lys-63'-linked histone H2A and H2AX at DNA damage sites, thereby acting as a guard against excessive spreading of ubiquitinated chromatin at damaged chromosomes.
T24714	BIOCLASS	Carbon-nitrogen ligase
T24714	ECNUMBER	EC 2.3.2.26
T24714	SEQUENCE	MSNRPNNNPGGSLRRSQRNTAGAQPQDDSIGGRSCSSSSAVIVPQPEDPDRANTSERQKTGQVPKKDNSRGVKRSASPDYNRTNSPSSAKKPKALQHTESPSETNKPHSKSKKRHLDQEQQLKSAQSPSTSKAHTRKSGATGGSRSQKRKRTESSCVKSGSGSESTGAEERSAKPTKLASKSATSAKAGCSTITDSSSAASTSSSSSAVASASSTVPPGARVKQGKDQNKARRSRSASSPSPRRSSREKEQSKTGGSSKFDWAARFSPKVSLPKTKLSLPGSSKSETSKPGPSGLQAKLASLRKSTKKRSESPPAELPSLRRSTRQKTTGSCASTSRRGSGLGKRGAAEARRQEKMADPESNQEAVNSSAARTDEAPQGAAGAVGMTTSGESESDDSEMGRLQALLEARGLPPHLFGPLGPRMSQLFHRTIGSGASSKAQQLLQGLQASDESQQLQAVIEMCQLLVMGNEETLGGFPVKSVVPALITLLQMEHNFDIMNHACRALTYMMEALPRSSAVVVDAIPVFLEKLQVIQCIDVAEQALTALEMLSRRHSKAILQAGGLADCLLYLEFFSINAQRNALAIAANCCQSITPDEFHFVADSLPLLTQRLTHQDKKSVESTCLCFARLVDNFQHEENLLQQVASKDLLTNVQQLLVVTPPILSSGMFIMVVRMFSLMCSNCPTLAVQLMKQNIAETLHFLLCGASNGSCQEQIDLVPRSPQELYELTSLICELMPCLPKEGIFAVDTMLKKGNAQNTDGAIWQWRDDRGLWHPYNRIDSRIIEQINEDTGTARAIQRKPNPLANSNTSGYSESKKDDARAQLMKEDPELAKSFIKTLFGVLYEVYSSSAGPAVRHKCLRAILRIIYFADAELLKDVLKNHAVSSHIASMLSSQDLKIVVGALQMAEILMQKLPDIFSVYFRREGVMHQVKHLAESESLLTSPPKACTNGSGSMGSTTSVSSGTATAATHAAADLGSPSLQHSRDDSLDLSPQGRLSDVLKRKRLPKRGPRRPKYSPPRDDDKVDNQAKSPTTTQSPKSSFLASLNPKTWGRLSTQSNSNNIEPARTAGGSGLARAASKDTISNNREKIKGWIKEQAHKFVERYFSSENMDGSNPALNVLQRLCAATEQLNLQVDGGAECLVEIRSIVSESDVSSFEIQHSGFVKQLLLYLTSKSEKDAVSREIRLKRFLHVFFSSPLPGEEPIGRVEPVGNAPLLALVHKMNNCLSQMEQFPVKVHDFPSGNGTGGSFSLNRGSQALKFFNTHQLKCQLQRHPDCANVKQWKGGPVKIDPLALVQAIERYLVVRGYGRVREDDEDSDDDGSDEEIDESLAAQFLNSGNVRHRLQFYIGEHLLPYNMTVYQAVRQFSIQAEDERESTDDESNPLGRAGIWTKTHTIWYKPVREDEESNKDCVGGKRGRAQTAPTKTSPRNAKKHDELWHDGVCPSVSNPLEVYLIPTPPENITFEDPSLDVILLLRVLHAISRYWYYLYDNAMCKEIIPTSEFINSKLTAKANRQLQDPLVIMTGNIPTWLTELGKTCPFFFPFDTRQMLFYVTAFDRDRAMQRLLDTNPEINQSDSQDSRVAPRLDRKKRTVNREELLKQAESVMQDLGSSRAMLEIQYENEVGTGLGPTLEFYALVSQELQRADLGLWRGEEVTLSNPKGSQEGTKYIQNLQGLFALPFGRTAKPAHIAKVKMKFRFLGKLMAKAIMDFRLVDLPLGLPFYKWMLRQETSLTSHDLFDIDPVVARSVYHLEDIVRQKKRLEQDKSQTKESLQYALETLTMNGCSVEDLGLDFTLPGFPNIELKKGGKDIPVTIHNLEEYLRLVIFWALNEGVSRQFDSFRDGFESVFPLSHLQYFYPEELDQLLCGSKADTWDAKTLMECCRPDHGYTHDSRAVKFLFEILSSFDNEQQRLFLQFVTGSPRLPVGGFRSLNPPLTIVRKTFESTENPDDFLPSVMTCVNYLKLPDYSSIEIMREKLLIAAREGQQSFHLS

T44516	TARGETID	T44516
T44516	FORMERID	TTDR00071
T44516	UNIPROID	KCNB1_HUMAN
T44516	TARGNAME	Voltage-gated potassium channel Kv2.1 (KCNB1)
T44516	GENENAME	KCNB1
T44516	TARGTYPE	Literature-reported
T44516	SYNONYMS	Voltage-gated potassium channel subunit Kv2.1; Rectifier potassium channel Kv2.1; Potassium voltage-gated channel subfamily B member 1; Potassium channel Kv2.1; H-DRK1; DRK1
T44516	FUNCTION	Contributes to the regulation of the action potential (AP) repolarization, duration and frequency of repetitive AP firing in neurons, muscle cells and endocrine cells and plays a role in homeostatic attenuation of electrical excitability throughout the brain. Plays also a role in the regulation of exocytosis independently of its electrical function. Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage difference across the membrane. Homotetrameric channels mediate a delayed-rectifier voltage-dependent outward potassium current that display rapid activation and slow inactivation in response to membrane depolarization. Can form functional homotetrameric and heterotetrameric channels that contain variable proportions of KCNB2; channel properties depend on the type of alpha subunits that are part of the channel. Can also form functional heterotetrameric channels with other alpha subunits that are non-conducting when expressed alone, such as KCNF1, KCNG1, KCNG3, KCNG4, KCNH1, KCNH2, KCNS1, KCNS2, KCNS3 and KCNV1, creating a functionally diverse range of channel complexes. Heterotetrameric channel activity formed with KCNS3 show increased current amplitude with the threshold for action potential activation shifted towards more negative values in hypoxic-treated pulmonary artery smooth muscle cells. Channel properties are also modulated by cytoplasmic ancillary beta subunits such as AMIGO1, KCNE1, KCNE2 and KCNE3, slowing activation and inactivation rate of the delayed rectifier potassium channels. In vivo, membranes probably contain a mixture of heteromeric potassium channel complexes, making it difficult to assign currents observed in intact tissues to any particular potassium channel family member. Major contributor to the slowly inactivating delayed-rectifier voltage-gated potassium current in neurons of the central nervous system, sympathetic ganglion neurons, neuroendocrine cells, pancreatic beta cells, cardiomyocytes and smooth muscle cells. Mediates the major part of the somatodendritic delayed-rectifier potassium current in hippocampal and cortical pyramidal neurons and sympathetic superior cervical ganglion (CGC) neurons that acts to slow down periods of firing, especially during high frequency stimulation. Plays a role in the induction of long-term potentiation (LTP) of neuron excitability in the CA3 layer of the hippocampus. Contributes to the regulation of glucose-induced action potential amplitude and duration in pancreatic beta cells, hence limiting calcium influx and insulin secretion. Plays a role in the regulation of resting membrane potential and contraction in hypoxia-treated pulmonary artery smooth muscle cells. May contribute to the regulation of the duration of both the action potential of cardiomyocytes and the heart ventricular repolarization QT interval. Contributes to the pronounced pro-apoptotic potassium current surge during neuronal apoptotic cell death in response to oxidative injury. May confer neuroprotection in response to hypoxia/ischemic insults by suppressing pyramidal neurons hyperexcitability in hippocampal and cortical regions. Promotes trafficking of KCNG3, KCNH1 and KCNH2 to the cell surface membrane, presumably by forming heterotetrameric channels with these subunits. Plays a role in the calcium-dependent recruitment and release of fusion-competent vesicles from the soma of neurons, neuroendocrine and glucose-induced pancreatic beta cells by binding key components of the fusion machinery in a pore-independent manner. Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain, but also in the pancreas and cardiovascular system.
T44516	BIOCLASS	Voltage-gated ion channel
T44516	SEQUENCE	MPAGMTKHGSRSTSSLPPEPMEIVRSKACSRRVRLNVGGLAHEVLWRTLDRLPRTRLGKLRDCNTHDSLLEVCDDYSLDDNEYFFDRHPGAFTSILNFYRTGRLHMMEEMCALSFSQELDYWGIDEIYLESCCQARYHQKKEQMNEELKREAETLREREGEEFDNTCCAEKRKKLWDLLEKPNSSVAAKILAIISIMFIVLSTIALSLNTLPELQSLDEFGQSTDNPQLAHVEAVCIAWFTMEYLLRFLSSPKKWKFFKGPLNAIDLLAILPYYVTIFLTESNKSVLQFQNVRRVVQIFRIMRILRILKLARHSTGLQSLGFTLRRSYNELGLLILFLAMGIMIFSSLVFFAEKDEDDTKFKSIPASFWWATITMTTVGYGDIYPKTLLGKIVGGLCCIAGVLVIALPIPIIVNNFSEFYKEQKRQEKAIKRREALERAKRNGSIVSMNMKDAFARSIEMMDIVVEKNGENMGKKDKVQDNHLSPNKWKWTKRTLSETSSSKSFETKEQGSPEKARSSSSPQHLNVQQLEDMYNKMAKTQSQPILNTKESAAQSKPKEELEMESIPSPVAPLPTRTEGVIDMRSMSSIDSFISCATDFPEATRFSHSPLTSLPSKTGGSTAPEVGWRGALGASGGRFVEANPSPDASQHSSFFIESPKSSMKTNNPLKLRALKVNFMEGDPSPLLPVLGMYHDPLRNRGSAAAAVAGLECATLLDKAVLSPESSIYTTASAKTPPRSPEKHTAIAFNFEAGVHQYIDADTDDEGQLLYSVDSSPPKSLPGSTSPKFSTGTRSEKNHFESSPLPTSPKFLRQNCIYSTEALTGKGPSGQEKCKLENHISPDVRVLPGGGAHGSTRDQSI
T44516	DRUGINFO	D0O8MU	3-bicyclo[2.2.1]hept-2-yl-benzene-1,2-diol	Investigative
T44516	DRUGINFO	D0A1IR	DABCO-C16	Investigative
T44516	DRUGINFO	D0I7VY	RY796	Investigative
T44516	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T64022	TARGETID	T64022
T64022	FORMERID	TTDI02102
T64022	UNIPROID	IMB1_HUMAN
T64022	TARGNAME	Importin beta (KPNB1)
T64022	GENENAME	KPNB1
T64022	TARGTYPE	Literature-reported
T64022	SYNONYMS	Pore targeting complex 97 kDa subunit; PTAC97; Nuclear factor p97; NTF97; Karyopherin subunit beta1; Karyopherin subunit beta-1; Importin90; Importin-90; Importin subunit beta1; Importin subunit beta-1
T64022	FUNCTION	Acting autonomously, serves itself as NLS receptor. Docking of the importin/substrate complex to the nuclear pore complex (NPC) is mediated by KPNB1 through binding to nucleoporin FxFG repeats and the complex is subsequently translocated through the pore by an energy requiring, Ran-dependent mechanism. At the nucleoplasmic side of the NPC, Ran binds to importin-beta and the three components separate and importin-alpha and -beta are re-exported from the nucleus to the cytoplasm where GTP hydrolysis releases Ran from importin. The directionality of nuclear import is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus. Mediates autonomously the nuclear import of ribosomal proteins RPL23A, RPS7 and RPL5. Binds to a beta-like import receptor binding (BIB) domain of RPL23A. In association with IPO7 mediates the nuclear import of H1 histone. In vitro, mediates nuclear import of H2A, H2B, H3 and H4 histones. In case of HIV-1 infection, binds and mediates the nuclear import of HIV-1 Rev. Imports SNAI1 and PRKCI into the nucleus. Functions in nuclear protein import, either in association with an adapter protein, like an importin-alpha subunit, which binds to nuclear localization signals (NLS) in cargo substrates, or by acting as autonomous nuclear transport receptor.
T64022	PDBSTRUC	6N89; 6N88; 3W5K; 3LWW; 2QNA
T64022	BIOCLASS	Eukaryotic nuclear pore complex
T64022	SEQUENCE	MELITILEKTVSPDRLELEAAQKFLERAAVENLPTFLVELSRVLANPGNSQVARVAAGLQIKNSLTSKDPDIKAQYQQRWLAIDANARREVKNYVLQTLGTETYRPSSASQCVAGIACAEIPVNQWPELIPQLVANVTNPNSTEHMKESTLEAIGYICQDIDPEQLQDKSNEILTAIIQGMRKEEPSNNVKLAATNALLNSLEFTKANFDKESERHFIMQVVCEATQCPDTRVRVAALQNLVKIMSLYYQYMETYMGPALFAITIEAMKSDIDEVALQGIEFWSNVCDEEMDLAIEASEAAEQGRPPEHTSKFYAKGALQYLVPILTQTLTKQDENDDDDDWNPCKAAGVCLMLLATCCEDDIVPHVLPFIKEHIKNPDWRYRDAAVMAFGCILEGPEPSQLKPLVIQAMPTLIELMKDPSVVVRDTAAWTVGRICELLPEAAINDVYLAPLLQCLIEGLSAEPRVASNVCWAFSSLAEAAYEAADVADDQEEPATYCLSSSFELIVQKLLETTDRPDGHQNNLRSSAYESLMEIVKNSAKDCYPAVQKTTLVIMERLQQVLQMESHIQSTSDRIQFNDLQSLLCATLQNVLRKVQHQDALQISDVVMASLLRMFQSTAGSGGVQEDALMAVSTLVEVLGGEFLKYMEAFKPFLGIGLKNYAEYQVCLAAVGLVGDLCRALQSNIIPFCDEVMQLLLENLGNENVHRSVKPQILSVFGDIALAIGGEFKKYLEVVLNTLQQASQAQVDKSDYDMVDYLNELRESCLEAYTGIVQGLKGDQENVHPDVMLVQPRVEFILSFIDHIAGDEDHTDGVVACAAGLIGDLCTAFGKDVLKLVEARPMIHELLTEGRRSKTNKAKTLATWATKELRKLKNQA

T53892	TARGETID	T53892
T53892	FORMERID	TTDI03463
T53892	UNIPROID	PMVK_HUMAN
T53892	TARGNAME	Phosphomevalonate kinase (PMVK)
T53892	GENENAME	PMVK
T53892	TARGTYPE	Literature-reported
T53892	SYNONYMS	hPMK; PMKase; PMKI
T53892	FUNCTION	Regulated in response to dietary sterol levels and that this regulation is coordinate with 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme of cholesterol biosynthesis.
T53892	PDBSTRUC	3CH4
T53892	ECNUMBER	EC 2.7.4.2
T53892	SEQUENCE	MAPLGGAPRLVLLFSGKRKSGKDFVTEALQSRLGADVCAVLRLSGPLKEQYAQEHGLNFQRLLDTSTYKEAFRKDMIRWGEEKRQADPGFFCRKIVEGISQPIWLVSDTRRVSDIQWFREAYGAVTQTVRVVALEQSRQQRGWVFTPGVDDAESECGLDNFGDFDWVIENHGVEQRLEEQLENLIEFIRSRL
T53892	DRUGINFO	D04EWW	isoferulic acid	Investigative
T53892	DRUGINFO	D08ERD	(R)-5-diphosphomevalonate	Investigative
T53892	DRUGINFO	D08QCI	3-hydroxy-3-methyl-6-phosphohexanoic acid	Investigative
T53892	DRUGINFO	D0T2QL	cinnamic acid	Investigative

T20498	TARGETID	T20498
T20498	FORMERID	TTDI02583
T20498	UNIPROID	RBP1_HUMAN
T20498	TARGNAME	RalA binding protein 1 (RALBP1)
T20498	GENENAME	RALBP1
T20498	TARGTYPE	Literature-reported
T20498	SYNONYMS	RalBP1; RalA-binding protein 1; Ral-interacting protein 1; RLIP76; RLIP1; Dinitrophenyl S-glutathione ATPase; DNP-SG ATPase; 76 kDa Ral-interacting protein
T20498	FUNCTION	Mediates ATP-dependent transport of S-(2,4-dinitrophenyl)-glutathione (DNP-SG) and doxorubicin (DOX) and is the major ATP-dependent transporter of glutathione conjugates of electrophiles (GS-E) and DOX in erythrocytes. Can catalyze transport of glutathione conjugates and xenobiotics, and may contribute to the multidrug resistance phenomenon. Serves as a scaffold protein that brings together proteins forming an endocytotic complex during interphase and also with CDK1 to switch off endocytosis, One of its substrates would be EPN1/Epsin. Can activate specifically hydrolysis of GTP bound to RAC1 and CDC42, but not RALA.
T20498	PDBSTRUC	2MBG; 2KWI; 2KWH
T20498	BIOCLASS	Non ABC multidrug exporter
T20498	SEQUENCE	MTECFLPPTSSPSEHRRVEHGSGLTRTPSSEEISPTKFPGLYRTGEPSPPHDILHEPPDVVSDDEKDHGKKKGKFKKKEKRTEGYAAFQEDSSGDEAESPSKMKRSKGIHVFKKPSFSKKKEKDFKIKEKPKEEKHKEEKHKEEKHKEKKSKDLTAADVVKQWKEKKKKKKPIQEPEVPQIDVPNLKPIFGIPLADAVERTMMYDGIRLPAVFRECIDYVEKYGMKCEGIYRVSGIKSKVDELKAAYDREESTNLEDYEPNTVASLLKQYLRDLPENLLTKELMPRFEEACGRTTETEKVQEFQRLLKELPECNYLLISWLIVHMDHVIAKELETKMNIQNISIVLSPTVQISNRVLYVFFTHVQELFGNVVLKQVMKPLRWSNMATMPTLPETQAGIKEEIRRQEFLLNCLHRDLQGGIKDLSKEERLWEVQRILTALKRKLREAKRQECETKIAQEIASLSKEDVSKEEMNENEEVINILLAQENEILTEQEELLAMEQFLRRQIASEKEEIERLRAEIAEIQSRQQHGRSETEEYSSESESESEDEEELQIILEDLQRQNEELEIKNNHLNQAIHEEREAIIELRVQLRLLQMQRAKAEQQAQEDEEPEWRGGAVQPPRDGVLEPKAAKEQPKAGKEPAKPSPSRDRKETSI

T12075	TARGETID	T12075
T12075	FORMERID	TTDI02226
T12075	UNIPROID	SHH_HUMAN
T12075	TARGNAME	Hedgehog protein (SHH)
T12075	GENENAME	SHH
T12075	TARGTYPE	Literature-reported
T12075	SYNONYMS	Sonic hedgehog protein C-product; Sonic hedgehog protein; SHH; HHG-1
T12075	FUNCTION	Intercellular signal essential for a variety of patterning events duringdevelopment: signal produced by the notochord that induces ventral cell fate in the neural tube and somites, and the polarizing signal for patterning of the anterior- posterior axis of the developinglimb bud. Displays both floor plate- and motor neuron-inducing activity. The threshold concentration of N-product required for motor neuron induction is 5-fold lower than that required for floor plate induction. Activates the transcription of target genes by interacting with its receptor PTCH1 to prevent normal inhibition by PTCH1 on the constitutive signaling activity of SMO.
T12075	PDBSTRUC	6OEV; 6E1H; 6DMY; 3MXW; 3M1N
T12075	BIOCLASS	Hedgehog
T12075	SEQUENCE	MLLLARCLLLVLVSSLLVCSGLACGPGRGFGKRRHPKKLTPLAYKQFIPNVAEKTLGASGRYEGKISRNSERFKELTPNYNPDIIFKDEENTGADRLMTQRCKDKLNALAISVMNQWPGVKLRVTEGWDEDGHHSEESLHYEGRAVDITTSDRDRSKYGMLARLAVEAGFDWVYYESKAHIHCSVKAENSVAAKSGGCFPGSATVHLEQGGTKLVKDLSPGDRVLAADDQGRLLYSDFLTFLDRDDGAKKVFYVIETREPRERLLLTAAHLLFVAPHNDSATGEPEASSGSGPPSGGALGPRALFASRVRPGQRVYVVAERDGDRRLLPAAVHSVTLSEEAAGAYAPLTAQGTILINRVLASCYAVIEEHSWAHRAFAPFRLAHALLAALAPARTDRGGDSGGGDRGGGGGRVALTAPGAADAPGAGATAGIHWYSQLLYQIGTWLLDSEALHPLGMAVKSS

T89859	TARGETID	T89859
T89859	FORMERID	TTDR00817
T89859	UNIPROID	NR0B2_HUMAN
T89859	TARGNAME	Orphan nuclear receptor SHP (NR0B2)
T89859	GENENAME	NR0B2
T89859	TARGTYPE	Literature-reported
T89859	SYNONYMS	Small heterodimer partner; Short heterodimer partner; SHP; Nuclear receptor subfamily 0 group B member 2
T89859	FUNCTION	Specifically inhibits transactivation of the nuclear receptor with which it interacts. Inhibits transcriptional activity of NEUROD1 on E-box-containing promoter by interfering with the coactivation function of the p300/CBP-mediated transcription complex for NEUROD1. Essential component of the liver circadian clock which via its interaction with NR1D1 and RORG regulates NPAS2-mediated hepatic lipid metabolism. Regulates the circadian expression of cytochrome P450 (CYP) enzymes. Represses: NR5A2 and HNF4A to down-regulate CYP2C38, NFLI3 to up-regulate CYP2A5, BHLHE41/HNF1A axis to up-regulate CYP1A2, CYP2E1 and CYP3A11, and NR1D1 to up-regulate CYP2B10, CYP4A10 and CYP4A14. Transcriptional regulator that acts as a negative regulator of receptor-dependent signaling pathways.
T89859	PDBSTRUC	5UFS; 4ONI; 4DOR; 2Z4J; 2Q3Y
T89859	BIOCLASS	Nuclear hormone receptor
T89859	SEQUENCE	MSTSQPGACPCQGAASRPAILYALLSSSLKAVPRPRSRCLCRQHRPVQLCAPHRTCREALDVLAKTVAFLRNLPSFWQLPPQDQRRLLQGCWGPLFLLGLAQDAVTFEVAEAPVPSILKKILLEEPSSSGGSGQLPDRPQPSLAAVQWLQCCLESFWSLELSPKEYACLKGTILFNPDVPGLQAASHIGHLQQEAHWVLCEVLEPWCPAAQGRLTRVLLTASTLKSIPTSLLGDLFFRPIIGDVDIAGLLGDMLLLR

T94364	TARGETID	T94364
T94364	UNIPROID	CIP4_HUMAN
T94364	TARGNAME	Thyroid receptor-interacting protein 10 (TRIP10)
T94364	GENENAME	TRIP10
T94364	TARGTYPE	Literature-reported
T94364	SYNONYMS	hSTP; TRIP-10; TR-interacting protein 10; Salt tolerant protein; STP; STOT; Protein Felic; Cdc42-interacting protein 4; CIP4
T94364	FUNCTION	Required to coordinate membrane tubulation with reorganization of the actin cytoskeleton during endocytosis. Binds to lipids such as phosphatidylinositol 4,5-bisphosphate and phosphatidylserine and promotes membrane invagination and the formation of tubules. Also promotes CDC42-induced actin polymerization by recruiting WASL/N-WASP which in turn activates the Arp2/3 complex. Actin polymerization may promote the fission of membrane tubules to form endocytic vesicles. Required for the formation of podosomes, actin-rich adhesion structures specific to monocyte-derived cells. May be required for the lysosomal retention of FASLG/FASL. Required for translocation of GLUT4 to the plasma membrane in response to insulin signaling.
T94364	PDBSTRUC	2KE4; 2EFK; 2CT4
T94364	SEQUENCE	MDWGTELWDQFEVLERHTQWGLDLLDRYVKFVKERTEVEQAYAKQLRSLVKKYLPKRPAKDDPESKFSQQQSFVQILQEVNDFAGQRELVAENLSVRVCLELTKYSQEMKQERKMHFQEGRRAQQQLENGFKQLENSKRKFERDCREAEKAAQTAERLDQDINATKADVEKAKQQAHLRSHMAEESKNEYAAQLQRFNRDQAHFYFSQMPQIFDKLQDMDERRATRLGAGYGLLSEAELEVVPIIAKCLEGMKVAANAVDPKNDSHVLIELHKSGFARPGDVEFEDFSQPMNRAPSDSSLGTPSDGRPELRGPGRSRTKRWPFGKKNKPRPPPLSPLGGPVPSALPNGPPSPRSGRDPLAILSEISKSVKPRLASFRSLRGSRGTVVTEDFSHLPPEQQRKRLQQQLEERSRELQKEVDQREALKKMKDVYEKTPQMGDPASLEPQIAETLSNIERLKLEVQKYEAWLAEAESRVLSNRGDSLSRHARPPDPPASAPPDSSSNSASQDTKESSEEPPSEESQDTPIYTEFDEDFEEEPTSPIGHCVAIYHFEGSSEGTISMAEGEDLSLMEEDKGDGWTRVRRKEGGEGYVPTSYLRVTLN

T75792	TARGETID	T75792
T75792	FORMERID	TTDI01449
T75792	UNIPROID	JHD2C_HUMAN
T75792	TARGNAME	Jumonji domain-containing protein 1C (JMJD1C)
T75792	GENENAME	JMJD1C
T75792	TARGTYPE	Literature-reported
T75792	SYNONYMS	Thyroid receptor-interacting protein 8; TRIP8; TRIP-8; TR-interacting protein 8; Probable JmjC domain-containing histone demethylation protein 2C; KIAA1380; JHDM2C
T75792	FUNCTION	Probable histone demethylase that specifically demethylates 'Lys-9' of histone H3, thereby playing a central role in histone code. Demethylation of Lys residue generates formaldehyde and succinate. May be involved in hormone-dependent transcriptional activation, by participating in recruitment to androgen-receptor target genes (By similarity).
T75792	PDBSTRUC	5FZO; 2YPD
T75792	ECNUMBER	EC 1.14.11.-
T75792	SEQUENCE	MAVETRAELVGKRFLCVAVGDEARSERWESGRGWRSWRAGVIRAVSHRDSRNPDLAVYVEFDDLEWDKREWVKVYEDFSTFLVEYHLIWAKRNDPSQTQGSKSKQIQWPALTFKPLVERNIPSSVTAVEFLVDKQLDFLTEDSAFQPYQDDIDSLNPVLRDNPQLHEEVKVWVKEQKVQEIFMQGPYSLNGYRVRVYRQDSATQWFTGIITHHDLFTRTMIVMNDQVLEPQNVDPSMVQMTFLDDVVHSLLKGENIGITSRRRSRANQNVNAVHSHYTRAQANSPRPAMNSQAAVPKQNTHQQQQQRSIRPNKRKGSDSSIPDEEKMKEEKYDYISRGENPKGKNKHLMNKRRKPEEDEKKLNMKRLRTDNVSDFSESSDSENSNKRIIDNSSEQKPENELKNKNTSKINGEEGKPHNNEKAGEETLKNSQPPWDQIQEDKKHEEAEKRKSVDTQLQEDMIIHSSEQSTVSDHNSNDLLPQECNMDKTHTMELLPKEKFVSRPPTPKCVIDITNDTNLEKVAQENSSTFGLQTLQKMDPNVSDSKHSIANAKFLETAKKDSDQSWVSDVVKVDLTQSSVTNASSGNDHLNMEKEKYVSYISPLSAVSVMEDKLHKRSPPPETIKSKLNTSVDTHKIKSSPSPEVVKPKITHSPDSVKSKATYVNSQATGERRLANKIEHELSRCSFHPIPTRSSTLETTKSPLIIDKNEHFTVYRDPALIGSETGANHISPFLSQHPFPLHSSSHRTCLNPGTHHPALTPAPHLLAGSSSQTPLPTINTHPLTSGPHHAVHHPHLLPTVLPGVPTASLLGGHPRLESAHASSLSHLALAHQQQQQLLQHQSPHLLGQAHPSASYNQLGLYPIIWQYPNGTHAYSGLGLPSSKWVHPENAVNAEASLRRNSPSPWLHQPTPVTSADGIGLLSHIPVRPSSAEPHRPLKITAHSSPPLTKTLVDHHKEELERKAFMEPLRSVASTSAKNDLDLNRSQTGKDCHLHRHFVDPVLNQLQRPPQETGERLNKYKEEHRRILQESIDVAPFTTKIKGLEGERENYSRVASSSSSPKSHIIKQDMDVERSVSDLYKMKHSVPQSLPQSNYFTTLSNSVVNEPPRSYPSKEVSNIYGDKQSNALAAAAANPQTLTSFITSLSKPPPLIKHQPESEGLVGKIPEHLPHQIASHSVTTFRNDCRSPTHLTVSSTNTLRSMPALHRAPVFHPPIHHSLERKEGSYSSLSPPTLTPVMPVNAGGKVQESQKPPTLIPEPKDSQANFKSSSEQSLTEMWRPNNNLSKEKTEWHVEKSSGKLQAAMASVIVRPSSSTKTDSMPAMQLASKDRVSERSSAGAHKTDCLKLAEAGETGRIILPNVNSDSVHTKSEKNFQAVSQGSVPSSVMSAVNTMCNTKTDVITSAADTTSVSSWGGSEVISSLSNTILASTSSECVSSKSVSQPVAQKQECKVSTTAPVTLASSKTGSVVQPSSGFSGTTDFIHLKKHKAALAAAQYKSSNASETEPNAIKNQTLSASLPLDSTVICSTINKANSVGNGQASQTSQPNYHTKLKKAWLTRHSEEDKNTNKMENSGNSVSEIIKPCSVNLIASTSSDIQNSVDSKIIVDKYVKDDKVNRRKAKRTYESGSESGDSDESESKSEQRTKRQPKPTYKKKQNDLQKRKGEIEEDLKPNGVLSRSAKERSKLKLQSNSNTGIPRSVLKDWRKVKKLKQTGESFLQDDSCCEIGPNLQKCRECRLIRSKKGEEPAHSPVFCRFYYFRRLSFSKNGVVRIDGFSSPDQYDDEAMSLWTHENFEDDELDIETSKYILDIIGDKFCQLVTSEKTALSWVKKDAKIAWKRAVRGVREMCDACEATLFNIHWVCQKCGFVVCLDCYKAKERKSSRDKELYAWMKCVKGQPHDHKHLMPTQIIPGSVLTDLLDAMHTLREKYGIKSHCHCTNKQNLQVGNFPTMNGVSQVLQNVLNHSNKISLCMPESQQQNTPPKSEKNGGSSPESDVGTDNKLTPPESQSPLHWLADLAEQKAREEKKENKELTLENQIKEEREQDNSESPNGRTSPLVSQNNEQGSTLRDLLTTTAGKLRVGSTDAGIAFAPVYSMGAPSSKSGRTMPNILDDIIASVVENKIPPSKTSKINVKPELKEEPEESIISAVDENNKLYSDIPHSWICEKHILWLKDYKNSSNWKLFKECWKQGQPAVVSGVHKKMNISLWKAESISLDFGDHQADLLNCKDSIISNANVKEFWDGFEEVSKRQKNKSGETVVLKLKDWPSGEDFKTMMPARYEDLLKSLPLPEYCNPEGKFNLASHLPGFFVRPDLGPRLCSAYGVVAAKDHDIGTTNLHIEVSDVVNILVYVGIAKGNGILSKAGILKKFEEEDLDDILRKRLKDSSEIPGALWHIYAGKDVDKIREFLQKISKEQGLEVLPEHDPIRDQSWYVNKKLRQRLLEEYGVRTCTLIQFLGDAIVLPAGALHQVQNFHSCIQVTEDFVSPEHLVESFHLTQELRLLKEEINYDDKLQVKNILYHAVKEMVRALKIHEDEVEDMEEN

T95660	TARGETID	T95660
T95660	UNIPROID	TWST1_HUMAN
T95660	TARGNAME	Twist-related protein 1 (TWIST1)
T95660	GENENAME	TWIST1
T95660	TARGTYPE	Literature-reported
T95660	SYNONYMS	bHLHa38; TWIST; H-twist; Class A basic helix-loop-helix protein 38
T95660	FUNCTION	Acts as a transcriptional regulator. Inhibits myogenesis by sequestrating E proteins, inhibiting trans-activation by MEF2, and inhibiting DNA-binding by MYOD1 through physical interaction. This interaction probably involves the basic domains of both proteins. Also represses expression of proinflammatory cytokines such as TNFA and IL1B. Regulates cranial suture patterning and fusion. Activates transcription as a heterodimer with E proteins. Regulates gene expression differentially, depending on dimer composition. Homodimers induce expression of FGFR2 and POSTN while heterodimers repress FGFR2 and POSTN expression and induce THBS1 expression. Heterodimerization is also required for osteoblast differentiation. Represses the activity of the circadian transcriptional activator: NPAS2-ARNTL/BMAL1 heterodimer.
T95660	PDBSTRUC	2MJV
T95660	SEQUENCE	MMQDVSSSPVSPADDSLSNSEEEPDRQQPPSGKRGGRKRRSSRRSAGGGAGPGGAAGGGVGGGDEPGSPAQGKRGKKSAGCGGGGGAGGGGGSSSGGGSPQSYEELQTQRVMANVRERQRTQSLNEAFAALRKIIPTLPSDKLSKIQTLKLAARYIDFLYQVLQSDELDSKMASCSYVAHERLSYAFSVWRMEGAWSMSASH

T15572	TARGETID	T15572
T15572	FORMERID	TTDR00799
T15572	UNIPROID	ADIPO_HUMAN
T15572	TARGNAME	Adiponectin (ADIPOQ)
T15572	GENENAME	ADIPOQ
T15572	TARGTYPE	Literature-reported
T15572	SYNONYMS	Gelatin-binding protein; GBP28; ApM-1; Adipose most abundant gene transcript 1 protein; Adipose most abundant gene transcript 1; Adipocyte, C1q and collagen domain-containing protein; Adipocyte, C1q and collagen domain containingprotein; Adipocyte complement-related 30 kDa protein; APM1; ACRP30; ACDC; 30 kDa adipocyte complement-related protein
T15572	FUNCTION	Stimulates AMPK phosphorylation and activation in the liver and the skeletal muscle, enhancing glucose utilization and fatty-acid combustion. Antagonizes TNF-alpha by negatively regulating its expression in various tissues such as liver and macrophages, and also by counteracting its effects. Inhibits endothelial NF-kappa-B signaling through a cAMP-dependent pathway. May play a role in cell growth, angiogenesis and tissue remodeling by binding and sequestering various growth factors with distinct binding affinities, depending on the type of complex, LMW, MMW or HMW. Important adipokine involved in the control of fat metabolism and insulin sensitivity, with direct anti-diabetic, anti-atherogenic and anti-inflammatory activities.
T15572	PDBSTRUC	4DOU
T15572	BIOCLASS	Adiponectin protein
T15572	SEQUENCE	MLLLGAVLLLLALPGHDQETTTQGPGVLLPLPKGACTGWMAGIPGHPGHNGAPGRDGRDGTPGEKGEKGDPGLIGPKGDIGETGVPGAEGPRGFPGIQGRKGEPGEGAYVYRSAFSVGLETYVTIPNMPIRFTKIFYNQQNHYDGSTGKFHCNIPGLYYFAYHITVYMKDVKVSLFKKDKAMLFTYDQYQENNVDQASGSVLLHLEVGDQVWLQVYGEGERNGLYADNDNDSTFTGFLLYHDTN

T86541	TARGETID	T86541
T86541	FORMERID	TTDI02591
T86541	UNIPROID	ASIC2_HUMAN
T86541	TARGNAME	Acid-sensing ion channel 2 (ASIC2)
T86541	GENENAME	ASIC2
T86541	TARGTYPE	Literature-reported
T86541	SYNONYMS	Mammalian degenerin homolog; Brain sodium channel 1; BNaC1; BNC1; Amiloridesensitive cation channelneuronal 1; Amiloridesensitive cation channel1, neuronal; Amiloridesensitive brain sodium channel; Acidsensing ion channel 2; ASIC2
T86541	FUNCTION	Cation channel with high affinityfor sodium, which is gated by extracellular protons and inhibited by the diuretic amiloride. Also permeable for Li(+) and K(+). Generates a biphasic current with a fast inactivating and a slow sustained phase. Heteromeric channel assembly seems to modulate.
T86541	BIOCLASS	Amiloride-sensitive sodium channel
T86541	SEQUENCE	MDLKESPSEGSLQPSSIQIFANTSTLHGIRHIFVYGPLTIRRVLWAVAFVGSLGLLLVESSERVSYYFSYQHVTKVDEVVAQSLVFPAVTLCNLNGFRFSRLTTNDLYHAGELLALLDVNLQIPDPHLADPSVLEALRQKANFKHYKPKQFSMLEFLHRVGHDLKDMMLYCKFKGQECGHQDFTTVFTKYGKCYMFNSGEDGKPLLTTVKGGTGNGLEIMLDIQQDEYLPIWGETEETTFEAGVKVQIHSQSEPPFIQELGFGVAPGFQTFVATQEQRLTYLPPPWGECRSSEMGLDFFPVYSITACRIDCETRYIVENCNCRMVHMPGDAPFCTPEQHKECAEPALGLLAEKDSNYCLCRTPCNLTRYNKELSMVKIPSKTSAKYLEKKFNKSEKYISENILVLDIFFEALNYETIEQKKAYEVAALLGDIGGQMGLFIGASILTILELFDYIYELIKEKLLDLLGKEEDEGSHDENVSTCDTMPNHSETISHTVNVPLQTTLGTLEEIAC
T86541	DRUGINFO	D07VOF	THA-904	Investigative
T86541	DRUGINFO	D06AVE	A-317567	Investigative

T94366	TARGETID	T94366
T94366	UNIPROID	CDC37_HUMAN
T94366	TARGNAME	Hsp90 co-chaperone Cdc37 (CDC37)
T94366	GENENAME	CDC37
T94366	TARGTYPE	Literature-reported
T94366	SYNONYMS	p50Cdc37; Hsp90 co-chaperone Cdc37, N-terminally processed; Hsp90 chaperone protein kinase-targeting subunit; CDC37A
T94366	FUNCTION	Inhibits HSP90AA1 ATPase activity. Co-chaperone that binds to numerous kinases and promotes their interaction with the Hsp90 complex, resulting in stabilization and promotion of their activity.
T94366	PDBSTRUC	5HPE; 5FWP; 5FWM; 5FWL; 5FWK
T94366	SEQUENCE	MVDYSVWDHIEVSDDEDETHPNIDTASLFRWRHQARVERMEQFQKEKEELDRGCRECKRKVAECQRKLKELEVAEGGKAELERLQAEAQQLRKEERSWEQKLEEMRKKEKSMPWNVDTLSKDGFSKSMVNTKPEKTEEDSEEVREQKHKTFVEKYEKQIKHFGMLRRWDDSQKYLSDNVHLVCEETANYLVIWCIDLEVEEKCALMEQVAHQTIVMQFILELAKSLKVDPRACFRQFFTKIKTADRQYMEGFNDELEAFKERVRGRAKLRIEKAMKEYEEEERKKRLGPGGLDPVEVYESLPEELQKCFDVKDVQMLQDAISKMDPTDAKYHMQRCIDSGLWVPNSKASEAKEGEEAGPGDPLLEAVPKTGDEKDVSV

T82254	TARGETID	T82254
T82254	FORMERID	TTDI02372
T82254	UNIPROID	BAK_HUMAN
T82254	TARGNAME	Apoptosis regulator BAK (BAK)
T82254	GENENAME	BAK1
T82254	TARGTYPE	Literature-reported
T82254	SYNONYMS	CDN1; Bcl2like protein 7; Bcl2L7; Bcl2-L-7; Bcl2 homologous antagonist/killer; Bcl-2-like protein 7; Bcl-2 homologous antagonist/killer
T82254	FUNCTION	Upon arrival of cell death signals, promotes mitochondrial outer membrane (MOM) permeabilization by oligomerizing to form pores within the MOM. This releases apoptogenic factors into the cytosol, including cytochrome c, promoting the activation of caspase 9 which in turn processes and activates the effector caspases. Plays a role in the mitochondrial apoptosic process.
T82254	PDBSTRUC	5VX1; 5VX0; 5VWZ; 5VWY; 5VWX
T82254	BIOCLASS	B-cell lymphoma Bcl-2
T82254	SEQUENCE	MASGQGPGPPRQECGEPALPSASEEQVAQDTEEVFRSYVFYRHQQEQEAEGVAAPADPEMVTLPLQPSSTMGQVGRQLAIIGDDINRRYDSEFQTMLQHLQPTAENAYEYFTKIATSLFESGINWGRVVALLGFGYRLALHVYQHGLTGFLGQVTRFVVDFMLHHCIARWIAQRGGWVAALNLGNGPILNVLVVLGVVLLGQFVVRRFFKS

T36581	TARGETID	T36581
T36581	FORMERID	TTDI03387
T36581	UNIPROID	MAPK3_HUMAN
T36581	TARGNAME	MAPK-activated protein kinase 3 (MAPKAPK3)
T36581	GENENAME	MAPKAPK3
T36581	TARGTYPE	Literature-reported
T36581	SYNONYMS	MAPKAPK3
T36581	FUNCTION	Stress-activated serine/threonine-protein kinase involved in cytokines production, endocytosis, cell migration, chromatin remodeling and transcriptional regulation. Following stress, it is phosphorylated and activated by MAP kinase p38-alpha/MAPK14, leading to phosphorylation of substrates. Phosphorylates serine in the peptide sequence, Hyd-X-R-X2-S, where Hyd is a large hydrophobic residue. MAPKAPK2 and MAPKAPK3, share the same function and substrate specificity, but MAPKAPK3 kinase activity and level in protein expression are lower compared to MAPKAPK2. Phosphorylates HSP27/HSPB1, KRT18, KRT20, RCSD1, RPS6KA3, TAB3 and TTP/ZFP36. Mediates phosphorylation of HSP27/HSPB1 in response to stress, leading to dissociate HSP27/HSPB1 from large small heat-shock protein (sHsps) oligomers and impair their chaperone activities and ability to protect against oxidative stress effectively. Involved in inflammatory response by regulating tumor necrosis factor (TNF) and IL6 production post-transcriptionally: acts by phosphorylating AU-rich elements (AREs)-binding proteins, such as TTP/ZFP36, leading to regulate the stability and translation of TNF and IL6 mRNAs. Phosphorylation of TTP/ZFP36, a major post-transcriptional regulator of TNF, promotes its binding to 14-3-3 proteins and reduces its ARE mRNA affinity leading to inhibition of dependent degradation of ARE-containing transcript. Involved in toll-like receptor signaling pathway (TLR) in dendritic cells: required for acute TLR-induced macropinocytosis by phosphorylating and activating RPS6KA3. Also acts as a modulator of Polycomb-mediated repression.
T36581	PDBSTRUC	3SHE; 3R1N; 3FXW; 3FHR
T36581	ECNUMBER	EC 2.7.11.1
T36581	SEQUENCE	MDGETAEEQGGPVPPPVAPGGPGLGGAPGGRREPKKYAVTDDYQLSKQVLGLGVNGKVLECFHRRTGQKCALKLLYDSPKARQEVDHHWQASGGPHIVCILDVYENMHHGKRCLLIIMECMEGGELFSRIQERGDQAFTEREAAEIMRDIGTAIQFLHSHNIAHRDVKPENLLYTSKEKDAVLKLTDFGFAKETTQNALQTPCYTPYYVAPEVLGPEKYDKSCDMWSLGVIMYILLCGFPPFYSNTGQAISPGMKRRIRLGQYGFPNPEWSEVSEDAKQLIRLLLKTDPTERLTITQFMNHPWINQSMVVPQTPLHTARVLQEDKDHWDEVKEEMTSALATMRVDYDQVKIKDLKTSNNRLLNKRRKKQAGSSSASQGCNNQ
T36581	DRUGINFO	D0EW9J	PMID17480064C16	Investigative

T67339	TARGETID	T67339
T67339	FORMERID	TTDI03481
T67339	UNIPROID	PRSS8_HUMAN
T67339	TARGNAME	Channel-activating protease 1 (CAP1)
T67339	GENENAME	PRSS8
T67339	TARGTYPE	Literature-reported
T67339	SYNONYMS	Serine protease 8; Prostasin; CAP1
T67339	FUNCTION	Possesses a trypsin-like cleavage specificity with a preference for poly-basic substrates. Stimulates epithelial sodium channel (ENaC) activity through activating cleavage of the gamma subunits (SCNN1G).
T67339	PDBSTRUC	3GYM; 3GYL; 3FVF; 3E1X; 3E0P
T67339	ECNUMBER	EC 3.4.21.-
T67339	SEQUENCE	MAQKGVLGPGQLGAVAILLYLGLLRSGTGAEGAEAPCGVAPQARITGGSSAVAGQWPWQVSITYEGVHVCGGSLVSEQWVLSAAHCFPSEHHKEAYEVKLGAHQLDSYSEDAKVSTLKDIIPHPSYLQEGSQGDIALLQLSRPITFSRYIRPICLPAANASFPNGLHCTVTGWGHVAPSVSLLTPKPLQQLEVPLISRETCNCLYNIDAKPEEPHFVQEDMVCAGYVEGGKDACQGDSGGPLSCPVEGLWYLTGIVSWGDACGARNRPGVYTLASSYASWIQSKVTELQPRVVPQTQESQPDSNLCGSHLAFSSAPAQGLLRPILFLPLGLALGLLSPWLSEH
T67339	DRUGINFO	D00XOV	B3C	Investigative

T00295	TARGETID	T00295
T00295	FORMERID	TTDR00656
T00295	UNIPROID	MOG_HUMAN
T00295	TARGNAME	Myelin-oligodendrocyte glycoprotein (MOG)
T00295	GENENAME	MOG
T00295	TARGTYPE	Literature-reported
T00295	SYNONYMS	Myelinoligodendrocyte glycoprotein; MOG
T00295	FUNCTION	Mediates homophilic cell-cell adhesion. Minor component of the myelin sheath. May be involved in completion and/or maintenance of the myelin sheath and in cell- cell communication. {ECO:0000250}.
T00295	PDBSTRUC	1Q70
T00295	BIOCLASS	Immunoglobulin
T00295	SEQUENCE	MASLSRPSLPSCLCSFLLLLLLQVSSSYAGQFRVIGPRHPIRALVGDEVELPCRISPGKNATGMEVGWYRPPFSRVVHLYRNGKDQDGDQAPEYRGRTELLKDAIGEGKVTLRIRNVRFSDEGGFTCFFRDHSYQEEAAMELKVEDPFYWVSPGVLVLLAVLPVLLLQITVGLIFLCLQYRLRGKLRAEIENLHRTFDPHFLRVPCWKITLFVIVPVLGPLVALIICYNWLHRRLAGQFLEELRNPF

T42976	TARGETID	T42976
T42976	UNIPROID	GSTA3_HUMAN
T42976	TARGNAME	Glutathione S-transferase A3 (GSTA3)
T42976	GENENAME	GSTA3
T42976	TARGTYPE	Literature-reported
T42976	SYNONYMS	Glutathione S-transferase A3-3; GST class-alpha member 3
T42976	FUNCTION	Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Catalyzes isomerization reactions that contribute to the biosynthesis of steroid hormones. Efficiently catalyze obligatory double-bond isomerizations of delta(5)-androstene-3,17-dione and delta(5)-pregnene-3,20-dione, precursors to testosterone and progesterone, respectively.
T42976	PDBSTRUC	2VCV; 1TDI
T42976	ECNUMBER	EC 2.5.1.18
T42976	SEQUENCE	MAGKPKLHYFNGRGRMEPIRWLLAAAGVEFEEKFIGSAEDLGKLRNDGSLMFQQVPMVEIDGMKLVQTRAILNYIASKYNLYGKDIKERALIDMYTEGMADLNEMILLLPLCRPEEKDAKIALIKEKTKSRYFPAFEKVLQSHGQDYLVGNKLSRADISLVELLYYVEELDSSLISNFPLLKALKTRISNLPTVKKFLQPGSPRKPPADAKALEEARKIFRF

T05722	TARGETID	T05722
T05722	FORMERID	TTDR00019
T05722	UNIPROID	ADH2_ENTHI
T05722	TARGNAME	Entamoeba Alcohol dehydrogenase 2 (Entamo ADH2)
T05722	GENENAME	Entamo ADH2
T05722	TARGTYPE	Literature-reported
T05722	SYNONYMS	Aldehydealcohol dehydrogenase 2; Aldehyde-alcohol dehydrogenase 2; Alcohol dehydrogenase; ADH; ACDH
T05722	FUNCTION	May be a critical enzyme in the fermentative pathway. This enzyme has two NAD(+)-dependent activities: ADH and ACDH.
T05722	BIOCLASS	CH-OH donor oxidoreductase
T05722	SEQUENCE	MSTQQTMTVDEHINQLVRKAQVALKEYLKPEYTQEKIDYIVKKASVAALDQHCALAAAAVEETGRGIFEDKATKNIFACEHVTHEMRHAKTVGIINVDPLYGITEIAEPVGVVCGVTPVTNPTSTAIFKSLISIKTRNPIVFSFHPSALKCSIMAAKIVRDAAIAAGAPENCIQWIEFGGIEASNKLMNHPGVATILATGGNAMVKAAYSSGKPALGVGAGNVPTYIEKTCNIKQAANDVVMSKSFDNGMICASEQAAIIDKEIYDQVVEEMKTLGAYFINEEEKAKLEKFMFGVNAYSADVNNARLNPKCPGMSPQWFAEQVGIKVPEDCNIICAVCKEVGPNEPLTREKLSPVLAILKAENTQDGIDKAEAMVEFNGRGHSAAIHSNDKAVVEKYALTMKACRILHNTPSSQGGIGSIYNYIWPSFTLGCGSYGGNSVSANVTYHNLLNIKRLADRRNNLQWFRVPPKIFFEPHSIRYLAELKELSKIFIVSDRMMYKLGYVDRVMDVLKRRSNEVEIEIFIDVEPDPSIQTVQKGLAVMNTFGPDNIIAIGGGSAMDAAKIMWLLYEHPEADFFAMKQKFIDLRKRAFKFPTMGKKARLICIPTTSGTGSEVTPFAVISDHETGKKYPLADYSLTPSVAIVDPMFTMSLPKRAIADTGLDVLVHATEAYVSVMANEYTDGLAREAVKLVFENLLKSYNGDLEAREKMHNAATIAGMAFASAFLGMDHSMAHKVGAAFHLPHGRCVAVLLPHVIRYNGQKPRKLAMWPKYNFYKADQRYMELAQMVGLKCNTPAEGVEAFAKACEELMKATETITGFKKANIDEAAWMSKVPEMALLAFEDQCSPANPRVPMVKDMEKILKAAYYPIA
T05722	DRUGINFO	D08NRK	Cyclopropyl	Investigative
T05722	DRUGINFO	D09NJF	Trifluoroethanol	Investigative
T05722	DRUGINFO	D0R5AJ	Cyclobutyl	Investigative
T05722	DRUGINFO	D06SPO	3,5-dichlorosalicylic acid	Investigative
T05722	DRUGINFO	D0J2FY	2'-Monophosphoadenosine 5'-Diphosphoribose	Investigative
T05722	DRUGINFO	D0R6JE	Nicotinamide-Adenine-Dinucleotide	Investigative

T27020	TARGETID	T27020
T27020	FORMERID	TTDR00600
T27020	UNIPROID	Q27733_PLAFA
T27020	TARGNAME	Plasmodium Delta-aminolevulinic acid synthetase (Malaria DAAS)
T27020	GENENAME	Malaria DAAS
T27020	TARGTYPE	Literature-reported
T27020	SYNONYMS	Delta-aminolevulinic acid synthetase
T27020	FUNCTION	Vital for parasite haem synthesis and parasite survival.
T27020	BIOCLASS	Acyltransferase
T27020	ECNUMBER	EC 2.3.1.37
T27020	SEQUENCE	MRKKRTLKVSINEIKKYCPFVKNIQFLYNTNEKKNNLVLSVMSDLCPVGKAINEKHFIIIDNKSKINIIKILKQANMQSKVLVQCIKNKNIEKENMSNDDLLKSGKRNNNVLFYDILEKNKNDHSFQINDNTIQKNNIIYKYINSLDEYKLFKNNCNNNLKDLLNKLYTDKRYRIFTILNKYRINYPNVYIENNKLMLPSFYEFYQKYGYKPCIGNIRYQLSASFEDNNKNICSFSHKNKENYLFNFWNLHIDNVSNEKTVVWCSNDYLCLSNNEKIIEVGIETLKKIGNSSGGTRNISGSLLNHTHLEYIIAKWYNKESSLLFTSGYIANVGALETLGKLLNLIYISDEMNHASIINGIRESRCEKFIFKHNDMNDLERILYNLRINKQYENRKIMIVFESIYSMSGHISNIEYIVQLAKKYNALTYVDEVHAVGLYGNKGSGYLEELHLCNHIDIINGTLSKAIGSLGGFICANKYYIDVIRSYSSHFIFTTSLTPVNINTSAEAIHIIQNDMSLRKKLTQVVNKTKQKLQERGIQVLHNNSHIVVLMINSAEKCKQICDDLLKEYNIYIQPINYPTVPMGMERIRITPSPFHTDEQIFKLVNSLYTLFKKYQVNMFDKKNKHTLMKL

T92770	TARGETID	T92770
T92770	UNIPROID	ZIK1_HUMAN
T92770	TARGNAME	Zinc finger protein 762 (ZIK1)
T92770	GENENAME	ZIK1
T92770	TARGTYPE	Literature-reported
T92770	SYNONYMS	ZNF762
T92770	FUNCTION	May be a transcriptional repressor.
T92770	BIOCLASS	Krueppel C2H2-type zinc-finger protein family
T92770	SEQUENCE	MAAAALRAPTQVTVSPETHMDLTKGCVTFEDIAIYFSQDEWGLLDEAQRLLYLEVMLENFALVASLGCGHGTEDEETPSDQNVSVGVSQSKAGSSTQKTQSCEMCVPVLKDILHLADLPGQKPYLVGECTNHHQHQKHHSAKKSLKRDMDRASYVKCCLFCMSLKPFRKWEVGKDLPAMLRLLRSLVFPGGKKPGTITECGEDIRSQKSHYKSGECGKASRHKHTPVYHPRVYTGKKLYECSKCGKAFRGKYSLVQHQRVHTGERPWECNECGKFFSQTSHLNDHRRIHTGERPYECSECGKLFRQNSSLVDHQKIHTGARPYECSQCGKSFSQKATLVKHQRVHTGERPYKCGECGNSFSQSAILNQHRRIHTGAKPYECGQCGKSFSQKATLIKHQRVHTGERPYKCGDCGKSFSQSSILIQHRRIHTGARPYECGQCGKSFSQKSGLIQHQVVHTGERPYECNKCGNSFSQCSSLIHHQKCHNT

T91842	TARGETID	T91842
T91842	FORMERID	TTDNC00393
T91842	UNIPROID	CRTC2_HUMAN
T91842	TARGNAME	CREB-regulated transcription coactivator 2 (TORC2)
T91842	GENENAME	CRTC2
T91842	TARGTYPE	Literature-reported
T91842	SYNONYMS	Transducer of regulated cAMP response elementbinding protein 2; Transducer of CREB protein 2; CRTC2; CREBregulated transcription coactivator 2
T91842	FUNCTION	Transcriptional coactivator for CREB1 which activates transcription through both consensus and variant cAMP response element (CRE) sites. Acts as a coactivator, in the SIK/TORC signaling pathway, being active when dephosphorylated and acts independently of CREB1 'Ser-133'phosphorylation. Enhances the interaction of CREB1 with TAF4. Regulates gluconeogenesis as a component of the LKB1/AMPK/TORC2 signaling pathway. Regulates the expression of specific genes such as thesteroidogenic gene, StAR. Potent coactivator of PPARGC1A and inducer of mitochondrial biogenesis in muscle cells. Also coactivator for TAX activation of the human T-cell leukemia virus type 1 (HTLV-1) long terminal repeats (LTR).
T91842	PDBSTRUC	4HTM
T91842	BIOCLASS	Transducer of regulated CREB
T91842	SEQUENCE	MATSGANGPGSATASASNPRKFSEKIALQKQRQAEETAAFEEVMMDIGSTRLQAQKLRLAYTRSSHYGGSLPNVNQIGSGLAEFQSPLHSPLDSSRSTRHHGLVERVQRDPRRMVSPLRRYTRHIDSSPYSPAYLSPPPESSWRRTMAWGNFPAEKGQLFRLPSALNRTSSDSALHTSVMNPSPQDTYPGPTPPSILPSRRGGILDGEMDPKVPAIEENLLDDKHLLKPWDAKKLSSSSSRPRSCEVPGINIFPSPDQPANVPVLPPAMNTGGSLPDLTNLHFPPPLPTPLDPEETAYPSLSGGNSTSNLTHTMTHLGISRGMGLGPGYDAPGLHSPLSHPSLQSSLSNPNLQASLSSPQPQLQGSHSHPSLPASSLARHVLPTTSLGHPSLSAPALSSSSSSSSTSSPVLGAPSYPASTPGASPHHRRVPLSPLSLLAGPADARRSQQQLPKQFSPTMSPTLSSITQGVPLDTSKLSTDQRLPPYPYSSPSLVLPTQPHTPKSLQQPGLPSQSCSVQSSGGQPPGRQSHYGTPYPPGPSGHGQQSYHRPMSDFNLGNLEQFSMESPSASLVLDPPGFSEGPGFLGGEGPMGGPQDPHTFNHQNLTHCSRHGSGPNIILTGDSSPGFSKEIAAALAGVPGFEVSAAGLELGLGLEDELRMEPLGLEGLNMLSDPCALLPDPAVEESFRSDRLQ

T77616	TARGETID	T77616
T77616	FORMERID	TTDI00017
T77616	UNIPROID	AGK_HUMAN
T77616	TARGNAME	Acylglycerol kinase (AGK)
T77616	GENENAME	AGK
T77616	TARGTYPE	Literature-reported
T77616	SYNONYMS	hAGK; Multisubstrate lipid kinase; Multiple substrate lipid kinase; MuLK; HsMuLK; Acylglycerol kinase, mitochondrial; AGK
T77616	FUNCTION	Lipid kinase that can phosphorylate both monoacylglycerol and diacylglycerol to form lysophosphatidic acid (LPA) and phosphatidic acid (PA), respectively. Does not phosphorylate sphingosine. Overexpression increases the formation and secretion of LPA, resulting in transactivation of EGFR and activation of the downstream MAPK signaling pathway, leading to increased cell growth.
T77616	BIOCLASS	Kinase
T77616	ECNUMBER	EC 2.7.1.107
T77616	SEQUENCE	MTVFFKTLRNHWKKTTAGLCLLTWGGHWLYGKHCDNLLRRAACQEAQVFGNQLIPPNAQVKKATVFLNPAACKGKARTLFEKNAAPILHLSGMDVTIVKTDYEGQAKKLLELMENTDVIIVAGGDGTLQEVVTGVLRRTDEATFSKIPIGFIPLGETSSLSHTLFAESGNKVQHITDATLAIVKGETVPLDVLQIKGEKEQPVFAMTGLRWGSFRDAGVKVSKYWYLGPLKIKAAHFFSTLKEWPQTHQASISYTGPTERPPNEPEETPVQRPSLYRRILRRLASYWAQPQDALSQEVSPEVWKDVQLSTIELSITTRNNQLDPTSKEDFLNICIEPDTISKGDFITIGSRKVRNPKLHVEGTECLQASQCTLLIPEGAGGSFSIDSEEYEAMPVEVKLLPRKLQFFCDPRKREQMLTSPTQ

T87463	TARGETID	T87463
T87463	FORMERID	TTDR00260
T87463	UNIPROID	Q56921_YEREN
T87463	TARGNAME	Fungal Protein kinase A (Fung ypkA)
T87463	GENENAME	Fung ypkA
T87463	TARGTYPE	Literature-reported
T87463	SYNONYMS	Protein kinase A
T87463	FUNCTION	Exists as a heterotetramer consisting of two regulatory subunits that bind and inactivate two catalytic subunits.
T87463	BIOCLASS	Kinase
T87463	SEQUENCE	MKIMGTMSPSISLAKAHERISKHWQNPVGELNIEGKRYRIIDNQVVRLNPHSGFSLFREGVGKIFSGKMFSFSIARNLTDTLHAAQKTTSQELRSDIPNALSNLFGAKPQTELPLGWKGKPLSGAPDLEGMRVAETDKFAEGESHISIIETKDKQRLVAKIERSIAEGHLFAELEAYKHIYKTAGKHPNLANVHGMAVVPYGNRKEEALLMDEVDGWRCSDTLRSLADSWKQGKINSEAYWGTIKFIAHRLLDVTNHLAKAGIVHNDIKPGNVVFDRASGEPVVIDLGLHSRSGEQPKGFTESFKAPELGVGNLGASEKSDVFLVVSSLLHGIEGFEKDPEIKPNQGLRFITSEPAHVMDENGYPIHRPGIAGVETAYTRFITDILGVSADSRPDSNEARLHEFLSDGTIDEESAKQILKDTLTGEMSPLPTDVRRITPKKLRELSDLLRTHLSSAATKQLDMGVVLSDLDTMLVALDKAEREGGVDKDQLKSFNSLILKTYSVIGAYIKGREGDTKSSSTEVSPYHRSNFMLSIVEPSLQRIQKHLDQTHSSDIGSLMRAHKHLETLLEVLVTLSQQGQPVTSETYSFLNRLAEAKVTLSQQLNTLQQQQESAKAQLSILINRSGSWADVARQSLLRFDSTRPVVKFGTEQYTAIHRQMMAAHAAITLQEVSEFTDDMRNFTADSIPLLIQLGRSSLMDEHLVEQREKLRELTTIAERLNRLEREWM
T87463	DRUGINFO	D0R2TM	BALANOL	Terminated
T87463	DRUGINFO	D06NOJ	Rp-adenosine 3',5'-cyclic monophosphothioate triethylamine (Rp-cAMPS)	Investigative
T87463	DRUGINFO	D08OBO	Rp-cAMPS	Investigative
T87463	DRUGINFO	D0M5NU	N6 benzyl-cAMP	Investigative
T87463	DRUGINFO	D01TDV	PMID21742770C1	Investigative
T87463	DRUGINFO	D0T9ZL	chelerythrine	Investigative
T87463	DRUGINFO	D0UB2J	[3H]cAMP	Investigative
T87463	DRUGINFO	D01YWE	PMID19364658C33	Investigative
T87463	DRUGINFO	D0IX7Y	BX-912	Investigative
T87463	DRUGINFO	D0RG0Z	BX-795	Investigative
T87463	DRUGINFO	D0L2WP	PMID20005102C1	Investigative
T87463	DRUGINFO	D09XIL	Ro-4396686	Investigative
T87463	DRUGINFO	D0A5RM	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	Investigative

T26357	TARGETID	T26357
T26357	FORMERID	TTDR00254
T26357	UNIPROID	PYRB_PSEPU
T26357	TARGNAME	Pseudomonas Aspartate carbamoyltransferase (Pseudo pyrB)
T26357	GENENAME	Pseudo pyrB
T26357	TARGTYPE	Literature-reported
T26357	SYNONYMS	PYRB; L-aspartic acid transcarbamylase; L-aspartate transcarbamoylase; Aspartate transcarbamylase; ATCase; ACTase
T26357	FUNCTION	Involved in allosteric regulation of aspartate carbamoyltransferase.
T26357	BIOCLASS	Methyltransferase
T26357	ECNUMBER	EC 2.1.3.2
T26357	SEQUENCE	MTPIDAKRPLQLNDQGQLRHFLSLDGLPRELLTEILDTADSFLEVGARAVKKVPLLRGKTVCNVFFENSTRTRTTFELAAQRLSADVISLNVSTSSTSKGETLFDTLRNLEAMAADMFVVRHSDSGAAHFIAEHVCPDVAVINGGDGRHAHPTQGMLDMLTIRRHKGSFENLSVAIVGDILHSRVARSDMLALKALGCPDIRVIGPKTLIPIGIEQYGVKVYTDLAEGLKDVDVVIMLRLQRERMAGGLLPSEGEFYRLFGLTTARLACAKPDAIVMHPGPINRGVEIESAVADGKHSVILNQVTYGIAVRMAVLSMAMSGQNAQRQFDQENAQ
T26357	DRUGINFO	D0L6CN	N-(phosphonacetyl)-L-aspartate	Investigative

T85161	TARGETID	T85161
T85161	FORMERID	TTDNR00645
T85161	UNIPROID	CLPP_WOLTR
T85161	TARGNAME	Bacterial ATP-dependent Clp proteolytic protease (Bact clpP)
T85161	GENENAME	Bact clpP
T85161	TARGTYPE	Literature-reported
T85161	SYNONYMS	clpP; Bact Endopeptidase Clp
T85161	FUNCTION	Cleaves peptides in various proteins ina process that requires ATP hydrolysis. Has a chymotrypsin-like activity. Plays a major role in the degradation of misfolded proteins.
T85161	BIOCLASS	Peptidase
T85161	ECNUMBER	EC 3.4.21.92
T85161	SEQUENCE	MTLIPIVIEQTSRGERAYDIYSRLVKERIIFVTGPVEDNMASVIVAQLLFLESENPDKDIYMYINSPGGVVTAGLSIYDTMQYIKPDVSTLCIGQAASMGSLLLAAGTEGKRYSLPHSRIMIHQPSGGYQGQATDIEIHANEILRVKRKLNQIYEKHTGNSLKKIEGMMERDKFMDPEEARRIGLIDRVIAERKDIKVENIKVEQKVG

T57750	TARGETID	T57750
T57750	FORMERID	TTDR00024
T57750	UNIPROID	MENB_STAAC
T57750	TARGNAME	Staphylococcus DHNA-CoA synthase (Stap-coc menB)
T57750	GENENAME	Stap-coc menB
T57750	TARGTYPE	Literature-reported
T57750	SYNONYMS	DHNA-CoA synthase; 1,4-dihydroxy-2-naphthoyl-CoA synthase
T57750	FUNCTION	Converts o-succinylbenzoyl-CoA (OSB-CoA) to 1,4-dihydroxy-2-naphthoyl-CoA (DHNA-CoA).
T57750	PDBSTRUC	2UZF
T57750	BIOCLASS	Carbon-carbon lyase
T57750	SEQUENCE	MTNRQWETLREYDEIKYEFYEGIAKVTINRPEVRNAFTPKTVAEMIDAFSRARDDQNVSVIVLTGEGDLAFCSGGDQKKRGHGGYVGEDQIPRLNVLDLQRLIRIIPKPVIAMVKGYAVGGGNVLNVVCDLTIAADNAIFGQTGPKVGSFDAGYGSGYLARIVGHKKAREIWYLCRQYNAQEALDMGLVNTVVPLEKVEDETVQWCKEIMKHSPTALRFLKAAMNADTDGLAGLQQMAGDATLLYYTTDEAKEGRDAFKEKRDPDFDQFPKFP
T57750	DRUGINFO	D06CGD	Acetoacetyl-Coenzyme A	Investigative
T57750	DRUGINFO	D0W3NA	Coenzyme A	Investigative

T00075	TARGETID	T00075
T00075	FORMERID	TTDI03101
T00075	UNIPROID	MRCKA_HUMAN
T00075	TARGNAME	CDC42 binding protein kinase alpha (DMPK-like alpha)
T00075	GENENAME	CDC42BPA
T00075	TARGTYPE	Literature-reported
T00075	SYNONYMS	Serine/threonine-protein kinase MRCK alpha; Myotonic dystrophy protein kinase-like alpha; Myotonic dystrophy kinase-related CDC42-binding kinase alpha; MRCK alpha; KIAA0451; CDC42-binding protein kinase alpha
T00075	FUNCTION	Regulates actin cytoskeletal reorganization via phosphorylation of PPP1R12C and MYL9/MLC2. In concert with MYO18A and LURAP1, is involved in modulating lamellar actomyosin retrograde flow that is crucial to cell protrusion and migration. Phosphorylates: PPP1R12A, LIMK1 and LIMK2. May play a role in TFRC-mediated iron uptake. In concert with FAM89B/LRAP25 mediates the targeting of LIMK1 to the lamellipodium resulting in its activation and subsequent phosphorylation of CFL1 which is important for lamellipodial F-actin regulation. Serine/threonine-protein kinase which is an important downstream effector of CDC42 and plays a role in the regulation of cytoskeleton reorganization and cell migration.
T00075	BIOCLASS	Kinase
T00075	ECNUMBER	EC 2.7.11.1
T00075	SEQUENCE	MSGEVRLRQLEQFILDGPAQTNGQCFSVETLLDILICLYDECNNSPLRREKNILEYLEWAKPFTSKVKQMRLHREDFEILKVIGRGAFGEVAVVKLKNADKVFAMKILNKWEMLKRAETACFREERDVLVNGDNKWITTLHYAFQDDNNLYLVMDYYVGGDLLTLLSKFEDRLPEDMARFYLAEMVIAIDSVHQLHYVHRDIKPDNILMDMNGHIRLADFGSCLKLMEDGTVQSSVAVGTPDYISPEILQAMEDGKGRYGPECDWWSLGVCMYEMLYGETPFYAESLVETYGKIMNHKERFQFPAQVTDVSENAKDLIRRLICSREHRLGQNGIEDFKKHPFFSGIDWDNIRNCEAPYIPEVSSPTDTSNFDVDDDCLKNSETMPPPTHTAFSGHHLPFVGFTYTSSCVLSDRSCLRVTAGPTSLDLDVNVQRTLDNNLATEAYERRIKRLEQEKLELSRKLQESTQTVQALQYSTVDGPLTASKDLEIKNLKEEIEKLRKQVTESSHLEQQLEEANAVRQELDDAFRQIKAYEKQIKTLQQEREDLNKELVQASERLKNQSKELKDAHCQRKLAMQEFMEINERLTELHTQKQKLARHVRDKEEEVDLVMQKVESLRQELRRTERAKKELEVHTEALAAEASKDRKLREQSEHYSKQLENELEGLKQKQISYSPGVCSIEHQQEITKLKTDLEKKSIFYEEELSKREGIHANEIKNLKKELHDSEGQQLALNKEIMILKDKLEKTRRESQSEREEFESEFKQQYEREKVLLTEENKKLTSELDKLTTLYENLSIHNQQLEEEVKDLADKKESVAHWEAQITEIIQWVSDEKDARGYLQALASKMTEELEALRNSSLGTRATDMPWKMRRFAKLDMSARLELQSALDAEIRAKQAIQEELNKVKASNIITECKLKDSEKKNLELLSEIEQLIKDTEELRSEKGIEHQDSQHSFLAFLNTPTDALDQFERSPSCTPASKGRRTVDSTPLSVHTPTLRKKGCPGSTGFPPKRKTHQFFVKSFTTPTKCHQCTSLMVGLIRQGCSCEVCGFSCHITCVNKAPTTCPVPPEQTKGPLGIDPQKGIGTAYEGHVRIPKPAGVKKGWQRALAIVCDFKLFLYDIAEGKASQPSVVISQVIDMRDEEFSVSSVLASDVIHASRKDIPCIFRVTASQLSASNNKCSILMLADTENEKNKWVGVLSELHKILKKNKFRDRSVYVPKEAYDSTLPLIKTTQAAAIIDHERIALGNEEGLFVVHVTKDEIIRVGDNKKIHQIELIPNDQLVAVISGRNRHVRLFPMSALDGRETDFYKLSETKGCQTVTSGKVRHGALTCLCVAMKRQVLCYELFQSKTRHRKFKEIQVPYNVQWMAIFSEQLCVGFQSGFLRYPLNGEGNPYSMLHSNDHTLSFIAHQPMDAICAVEISSKEYLLCFNSIGIYTDCQGRRSRQQELMWPANPSSCCYNAPYLSVYSENAVDIFDVNSMEWIQTLPLKKVRPLNNEGSLNLLGLETIRLIYFKNKMAEGDELVVPETSDNSRKQMVRNINNKRRYSFRVPEEERMQQRREMLRDPEMRNKLISNPTNFNHIAHMGPGDGIQILKDLPMNPRPQESRTVFSGSVSIPSITKSRPEPGRSMSASSGLSARSSAQNGSALKREFSGGSYSAKRQPMPSPSEGSLSSGGMDQGSDAPARDFDGEDSDSPRHSTASNSSNLSSPPSPASPRKTKSLSLESTDRGSWDP
T00075	DRUGINFO	D03CPB	RKI-1447	Investigative

T01725	TARGETID	T01725
T01725	FORMERID	TTDNR00736
T01725	UNIPROID	HHAT_HUMAN
T01725	TARGNAME	Protein-cysteine N-palmitoyltransferase HHAT (HHAT)
T01725	GENENAME	HHAT
T01725	TARGTYPE	Literature-reported
T01725	SYNONYMS	Skinny hedgehog protein 1; Melanoma antigen recognized by T-cells 2; MART-2; Hedgehog acyltransferase; HHAT
T01725	FUNCTION	Catalyzes N-terminal palmitoylation of SHH; which is required for SHH signaling. May bind GTP. .
T01725	BIOCLASS	Acyltransferase
T01725	ECNUMBER	EC 2.3.1.-
T01725	SEQUENCE	MLPRWELALYLLASLGFHFYSFYEVYKVSREHEEELDQEFELETDTLFGGLKKDATDFEWSFWMEWGKQWLVWLLLGHMVVSQMATLLARKHRPWILMLYGMWACWCVLGTPGVAMVLLHTTISFCVAQFRSQLLTWLCSLLLLSTLRLQGVEEVKRRWYKTENEYYLLQFTLTVRCLYYTSFSLELCWQQLPAASTSYSFPWMLAYVFYYPVLHNGPILSFSEFIKQMQQQEHDSLKASLCVLALGLGRLLCWWWLAELMAHLMYMHAIYSSIPLLETVSCWTLGGLALAQVLFFYVKYLVLFGVPALLMRLDGLTPPALPRCVSTMFSFTGMWRYFDVGLHNFLIRYVYIPVGGSQHGLLGTLFSTAMTFAFVSYWHGGYDYLWCWAALNWLGVTVENGVRRLVETPCIQDSLARYFSPQARRRFHAALASCSTSMLILSNLVFLGGNEVGKTYWNRIFIQGWPWVTLSVLGFLYCYSHVGIAWAQTYATD

T79332	TARGETID	T79332
T79332	FORMERID	TTDNR00675
T79332	UNIPROID	FAAH2_HUMAN
T79332	TARGNAME	Fatty-acid amide hydrolase 2 (FAAH2)
T79332	GENENAME	FAAH2
T79332	TARGTYPE	Literature-reported
T79332	SYNONYMS	Oleamide hydrolase 2; Anandamide amidohydrolase 2; Amidase domain-containing protein; AMDD
T79332	FUNCTION	Hydrolyzes monounsaturated substrate anandamide preferentially as compared to polyunsaturated substrates. Degrades bioactive fatty acid amides like oleamide, the endogenous cannabinoid, anandamide and myristic amide to their corresponding acids, thereby serving to terminate the signaling functions of these molecules.
T79332	BIOCLASS	Carbon-nitrogen hydrolase
T79332	ECNUMBER	EC 3.5.1.99
T79332	SEQUENCE	MAPSFTARIQLFLLRALGFLIGLVGRAALVLGGPKFASKTPRPVTEPLLLLSGMQLAKLIRQRKVKCIDVVQAYINRIKDVNPMINGIVKYRFEEAMKEAHAVDQKLAEKQEDEATLENKWPFLGVPLTVKEAFQLQGMPNSSGLMNRRDAIAKTDATVVALLKGAGAIPLGITNCSELCMWYESSNKIYGRSNNPYDLQHIVGGSSGGEGCTLAAACSVIGVGSDIGGSIRMPAFFNGIFGHKPSPGVVPNKGQFPLAVGAQELFLCTGPMCRYAEDLAPMLKVMAGPGIKRLKLDTKVHLKDLKFYWMEHDGGSFLMSKVDQDLIMTQKKVVVHLETILGASVQHVKLKKMKYSFQLWIAMMSAKGHDGKEPVKFVDLLGDHGKHVSPLWELIKWCLGLSVYTIPSIGLALLEEKLRYSNEKYQKFKAVEESLRKELVDMLGDDGVFLYPSHPTVAPKHHVPLTRPFNFAYTGVFSALGLPVTQCPLGLNAKGLPLGIQVVAGPFNDHLTLAVAQYLEKTFGGWVCPGKF

T90787	TARGETID	T90787
T90787	UNIPROID	NAPEP_HUMAN
T90787	TARGNAME	NAPE-hydrolyzing phospholipase D (NAPE-PLD)
T90787	GENENAME	NAPEPLD
T90787	TARGTYPE	Literature-reported
T90787	SYNONYMS	NAPE-PLD; N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D; N-acyl phosphatidylethanolamine phospholipase D; C7orf18
T90787	FUNCTION	Hydrolyzes N-acyl-phosphatidylethanolamines (NAPEs) to produce N-acylethanolamines (NAEs) and phosphatidic acid. Responsible for the generation of these bioactive fatty acid ethanolamides (FAEs), including anandamide (N-arachidonoylethanolamine), the ligand of cannabinoid and vanilloid receptors. As a regulator of lipid metabolism in the adipose tissue, mediates the crosstalk between adipocytes, gut microbiota and immune cells to control body temperature and weight. In particular, regulates energy homeostasis by promoting cold-induced brown or beige adipocyte differentiation program to generate heat from fatty acids and glucose (By similarity).
T90787	PDBSTRUC	4QN9
T90787	ECNUMBER	EC 3.1.4.54
T90787	SEQUENCE	MDENESNQSLMTSSQYPKEAVRKRQNSARNSGASDSSRFSRKSFKLDYRLEEDVTKSKKGKDGRFVNPWPTWKNPSIPNVLRWLIMEKDHSSVPSSKEELDKELPVLKPYFITNPEEAGVREAGLRVTWLGHATVMVEMDELIFLTDPIFSSRASPSQYMGPKRFRRSPCTISELPPIDAVLISHNHYDHLDYNSVIALNERFGNELRWFVPLGLLDWMQKCGCENVIELDWWEENCVPGHDKVTFVFTPSQHWCKRTLMDDNKVLWGSWSVLGPWNRFFFAGDTGYCPAFEEIGKRFGPFDLAAIPIGAYEPRWFMKYQHVDPEEAVRIHTDVQTKKSMAIHWGTFALANEHYLEPPVKLNEALERYGLNAEDFFVLKHGESRYLNNDDENF

T91786	TARGETID	T91786
T91786	UNIPROID	STYK1_HUMAN
T91786	TARGNAME	Tyrosine-protein kinase STYK1 (STYK1)
T91786	GENENAME	STYK1
T91786	TARGTYPE	Literature-reported
T91786	SYNONYMS	Serine/threonine/tyrosine kinase 1; Protein PK-unique; Novel oncogene with kinase domain; NOK
T91786	FUNCTION	Probable tyrosine protein-kinase, which has strong transforming capabilities on a variety of cell lines. When overexpressed, it can also induce tumor cell invasion as well as metastasis in distant organs. May act by activating both MAP kinase and phosphatidylinositol 3'-kinases (PI3K) pathways.
T91786	BIOCLASS	Protein kinase superfamily. Tyr protein kinase family
T91786	ECNUMBER	EC 2.7.10.2
T91786	SEQUENCE	MGMTRMLLECSLSDKLCVIQEKQYEVIIVPTLLVTIFLILLGVILWLFIREQRTQQQRSGPQGIAPVPPPRDLSWEAGHGGNVALPLKETSVENFLGATTPALAKLQVPREQLSEVLEQICSGSCGPIFRANMNTGDPSKPKSVILKALKEPAGLHEVQDFLGRIQFHQYLGKHKNLVQLEGCCTEKLPLYMVLEDVAQGDLLSFLWTCRRDVMTMDGLLYDLTEKQVYHIGKQVLLALEFLQEKHLFHGDVAARNILMQSDLTAKLCGLGLAYEVYTRGAISSTQTIPLKWLAPERLLLRPASIRADVWSFGILLYEMVTLGAPPYPEVPPTSILEHLQRRKIMKRPSSCTHTMYSIMKSCWRWREADRPSPRELRLRLEAAIKTADDEAVLQVPELVVPELYAAVAGIRVESLFYNYSML

T16188	TARGETID	T16188
T16188	FORMERID	TTDI03613
T16188	UNIPROID	ULK3_HUMAN
T16188	TARGNAME	Unc-51 like kinase 3 (ULK3)
T16188	GENENAME	ULK3
T16188	TARGTYPE	Literature-reported
T16188	SYNONYMS	Unc-51-like kinase 3; Serine/threonine-protein kinase ULK3
T16188	FUNCTION	Serine/threonine protein kinase that acts as a regulator of Sonic hedgehog (SHH) signaling and autophagy. Acts as a negative regulator of SHH signaling in the absence of SHH ligand: interacts with SUFU, thereby inactivating the protein kinase activity and preventing phosphorylation of GLI proteins (GLI1, GLI2 and/or GLI3). Positively regulates SHH signaling in the presence of SHH: dissociates from SUFU, autophosphorylates and mediates phosphorylation of GLI2, activating it and promoting its nuclear translocation. Phosphorylates in vitro GLI2, as well as GLI1 and GLI3, although less efficiently. Also acts as a regulator of autophagy: following cellular senescence, able to induce autophagy.
T16188	PDBSTRUC	6FDZ; 6FDY; 4WZX
T16188	ECNUMBER	EC 2.7.11.1
T16188	SEQUENCE	MAGPGWGPPRLDGFILTERLGSGTYATVYKAYAKKDTREVVAIKCVAKKSLNKASVENLLTEIEILKGIRHPHIVQLKDFQWDSDNIYLIMEFCAGGDLSRFIHTRRILPEKVARVFMQQLASALQFLHERNISHLDLKPQNILLSSLEKPHLKLADFGFAQHMSPWDEKHVLRGSPLYMAPEMVCQRQYDARVDLWSMGVILYEALFGQPPFASRSFSELEEKIRSNRVIELPLRPLLSRDCRDLLQRLLERDPSRRISFQDFFAHPWVDLEHMPSGESLGRATALVVQAVKKDQEGDSAAALSLYCKALDFFVPALHYEVDAQRKEAIKAKVGQYVSRAEELKAIVSSSNQALLRQGTSARDLLREMARDKPRLLAALEVASAAMAKEEAAGGEQDALDLYQHSLGELLLLLAAEPPGRRRELLHTEVQNLMARAEYLKEQVKMRESRWEADTLDKEGLSESVRSSCTLQ
T16188	DRUGINFO	D0G4CS	PMID24900237C15	Investigative

T88699	TARGETID	T88699
T88699	FORMERID	TTDI02611
T88699	UNIPROID	PAOX_HUMAN
T88699	TARGNAME	Polyamine oxidase (PAOX)
T88699	GENENAME	PAOX
T88699	TARGTYPE	Literature-reported
T88699	SYNONYMS	Peroxisomal N(1)acetylspermine/spermidine oxidase; PAOX
T88699	FUNCTION	Flavoenzyme which catalyzes the oxidation of N(1)- acetylspermine to spermidine and is thus involved in the polyamine back-conversion. Can also oxidize N(1)-acetylspermidine to putrescine. Substrate specificity: N(1)-acetylspermine = N(1)- acetylspermidine > N(1),N(12)-diacylspermine >> spermine. Does not oxidize spermidine. Plays an important role in the regulation of polyamine intracellular concentration and has the potential to act as a determinant of cellular sensitivity to the antitumor polyamine analogs.
T88699	BIOCLASS	CH-NH donor oxidoreductase
T88699	ECNUMBER	EC 1.5.3.13
T88699	SEQUENCE	MESTGSVGEAPGGPRVLVVGGGIAGLGAAQRLCGHSAFPHLRVLEATARAGGRIRSERCFGGVVEVGAHWIHGPSRGNPVFQLAAEYGLLGEKELSQENQLVETGGHVGLPSVSYASSGASVSLQLVAEMATLFYGLIDQTREFLHAAETPVPSVGEYLKKEIGQHVAGWTEDEETRKLKLAVLNSFFNLECCVSGTHSMDLVALAPFGEYTVLPGLDCTFSKGYQGLTNCMMAALPEDTVVFEKPVKTIHWNGSFQEAAFPGETFPVSVECEDGDRFPAHHVIVTVPLGFLREHLDTFFDPPLPAEKAEAIRKIGFGTNNKIFLEFEEPFWEPDCQLIQLVWEDTSPLEDAAPELQDAWFRKLIGFVVLPAFASVHVLCGFIAGLESEFMETLSDEEVLLCLTQVLRRVTGNPRLPAPKSVLRSRWHSAPYTRGSYSYVAVGSTGGDLDLLAQPLPADGAGAQLQILFAGEATHRTFYSTTHGALLSGWREADRLLSLWAPQVQQPRPRL

T18784	TARGETID	T18784
T18784	FORMERID	TTDI03365
T18784	UNIPROID	KDM7A_HUMAN
T18784	TARGNAME	Lysine-specific demethylase 7A (KDM7A)
T18784	GENENAME	KDM7A
T18784	TARGTYPE	Literature-reported
T18784	SYNONYMS	Lysine-specific demethylase 7; KIAA1718; KDM7; JmjC domain-containing histone demethylation protein 1D; JHDM1D
T18784	FUNCTION	Histone demethylase required for brain development. Specifically demethylates dimethylated 'Lys-9' and 'Lys-27' (H3K9me2 and H3K27me2, respectively) of histone H3 and monomethylated histone H4 'Lys-20' residue (H4K20Me1), thereby playing a central role in histone code. Specifically binds trimethylated 'Lys-4' of histone H3 (H3K4me3), affecting histone demethylase specificity: in presence of H3K4me3, it has no demethylase activity toward H3K9me2, while it has high activity toward H3K27me2. Demethylates H3K9me2 in absence of H3K4me3. Has activity toward H4K20Me1 only when nucleosome is used as a substrate and when not histone octamer is used as substrate.
T18784	PDBSTRUC	3U78; 3KVB; 3KVA; 3KV9; 3KV6
T18784	ECNUMBER	EC 1.14.11.-
T18784	SEQUENCE	MAGAAAAVAAGAAAGAAAAAVSVAAPGRASAPPPPPPVYCVCRQPYDVNRFMIECDICKDWFHGSCVGVEEHHAVDIDLYHCPNCAVLHGSSLMKKRRNWHRHDYTEIDDGSKPVQAGTRTFIKELRSRVFPSADEIIIKMHGSQLTQRYLEKHGFDVPIMVPKLDDLGLRLPSPTFSVMDVERYVGGDKVIDVIDVARQADSKMTLHNYVKYFMNPNRPKVLNVISLEFSDTKMSELVEVPDIAKKLSWVENYWPDDSVFPKPFVQKYCLMGVQDSYTDFHIDFGGTSVWYHVLWGEKIFYLIKPTDENLARYESWSSSVTQSEVFFGDKVDKCYKCVVKQGHTLFVPTGWIHAVLTSQDCMAFGGNFLHNLNIGMQLRCYEMEKRLKTPDLFKFPFFEAICWFVAKNLLETLKELREDGFQPQTYLVQGVKALHTALKLWMKKELVSEHAFEIPDNVRPGHLIKELSKVIRAIEEENGKPVKSQGIPIVCPVSRSSNEATSPYHSRRKMRKLRDHNVRTPSNLDILELHTREVLKRLEMCPWEEDILSSKLNGKFNKHLQPSSTVPEWRAKDNDLRLLLTNGRIIKDERQPFADQSLYTADSENEEDKRRTKKAKMKIEESSGVEGVEHEESQKPLNGFFTRVKSELRSRSSGYSDISESEDSGPECTALKSIFTTEESESSGDEKKQEITSNFKEESNVMRNFLQKSQKPSRSEIPIKRECPTSTSTEEEAIQGMLSMAGLHYSTCLQRQIQSTDCSGERNSLQDPSSCHGSNHEVRQLYRYDKPVECGYHVKTEDPDLRTSSWIKQFDTSRFHPQDLSRSQKCIRKEGSSEISQRVQSRNYVDSSGSSLQNGKYMQNSNLTSGACQISNGSLSPERPVGETSFSVPLHPTKRPASNPPPISNQATKGKRPKKGMATAKQRLGKILKLNRNGHARFFV
T18784	DRUGINFO	D0B2WZ	daminozide	Investigative

T68208	TARGETID	T68208
T68208	FORMERID	TTDNR00635
T68208	UNIPROID	ADM2_HUMAN
T68208	TARGNAME	Adrenomedullin 2 (ADM2)
T68208	GENENAME	ADM2
T68208	TARGTYPE	Literature-reported
T68208	SYNONYMS	Intermedin; ADM2
T68208	FUNCTION	IMDL and IMDS may play a role as physiological regulators of gastrointestinal, cardiovascular bioactivities mediated by the CALCRL/RAMPs receptor complexes. Activates the cAMP-dependent pathway.
T68208	PDBSTRUC	6D1U
T68208	BIOCLASS	Adrenomedullin
T68208	SEQUENCE	MARIPTAALGCISLLCLQLPGSLSRSLGGDPRPVKPREPPARSPSSSLQPRHPAPRPVVWKLHRALQAQRGAGLAPVMGQPLRDGGRQHSGPRRHSGPRRTQAQLLRVGCVLGTCQVQNLSHRLWQLMGPAGRQDSAPVDPSSPHSYG

T92208	TARGETID	T92208
T92208	UNIPROID	NEK8_HUMAN
T92208	TARGNAME	Serine/threonine-protein kinase Nek8 (NEK8)
T92208	GENENAME	NEK8
T92208	TARGTYPE	Literature-reported
T92208	SYNONYMS	Nima-related protein kinase 12a; NimA-related protein kinase 8; Never in mitosis A-related kinase 8; NEK12A; JCK
T92208	FUNCTION	Required for renal tubular integrity. May regulate local cytoskeletal structure in kidney tubule epithelial cells. May regulate ciliary biogenesis through targeting of proteins to the cilia. Plays a role in organogenesis and is involved in the regulation of the Hippo signaling pathway.
T92208	BIOCLASS	Protein kinase superfamily. NEK Ser/Thr protein kinase family
T92208	ECNUMBER	EC 2.7.11.1
T92208	SEQUENCE	MEKYERIRVVGRGAFGIVHLCLRKADQKLVIIKQIPVEQMTKEERQAAQNECQVLKLLNHPNVIEYYENFLEDKALMIAMEYAPGGTLAEFIQKRCNSLLEEETILHFFVQILLALHHVHTHLILHRDLKTQNILLDKHRMVVKIGDFGISKILSSKSKAYTVVGTPCYISPELCEGKPYNQKSDIWALGCVLYELASLKRAFEAANLPALVLKIMSGTFAPISDRYSPELRQLVLSLLSLEPAQRPPLSHIMAQPLCIRALLNLHTDVGSVRMRRAEKSVAPSNTGSRTTSVRCRGIPRGPVRPAIPPPLSSVYAWGGGLGTPLRLPMLNTEVVQVAAGRTQKAGVTRSGRLILWEAPPLGAGGGSLLPGAVEQPQPQFISRFLEGQSGVTIKHVACGDFFTACLTDRGIIMTFGSGSNGCLGHGSLTDISQPTIVEALLGYEMVQVACGASHVLALSTERELFAWGRGDSGRLGLGTRESHSCPQQVPMPPGQEAQRVVCGIDSSMILTVPGQALACGSNRFNKLGLDHLSLGEEPVPHQQVEEALSFTLLGSAPLDQEPLLSIDLGTAHSAAVTASGDCYTFGSNQHGQLGTNTRRGSRAPCKVQGLEGIKMAMVACGDAFTVAIGAESEVYSWGKGARGRLGRRDEDAGLPRPVQLDETHPYTVTSVSCCHGNTLLAVRSVTDEPVPP

T01441	TARGETID	T01441
T01441	FORMERID	TTDI00111
T01441	UNIPROID	SYVN1_HUMAN
T01441	TARGNAME	Synovial apoptosis inhibitor 1 (SYVN1)
T01441	GENENAME	SYVN1
T01441	TARGTYPE	Literature-reported
T01441	SYNONYMS	RING-type E3 ubiquitin transferase synoviolin; KIAA1810; HRD1; E3 ubiquitinprotein ligase synoviolin; E3 ubiquitin-protein ligase synoviolin
T01441	FUNCTION	Component of the endoplasmic reticulum quality control (ERQC) system also called ER-associated degradation (ERAD) involved in ubiquitin-dependent degradation of misfolded endoplasmic reticulum proteins. Also promotes the degradation of normal but naturally short-lived proteins such as SGK. Protects cells from ER stress-induced apoptosis. Protects neurons from apoptosis induced by polyglutamine-expanded huntingtin (HTT) or unfolded GPR37 by promoting their degradation. Sequesters p53/TP53 in the cytoplasm and promotes its degradation, thereby negatively regulating its biological function in transcription, cell cycle regulation and apoptosis. Mediates the ubiquitination and subsequent degradation of cytoplasmic NFE2L1. Acts as an E3 ubiquitin-protein ligase which accepts ubiquitin specifically from endoplasmic reticulum-associated UBC7 E2 ligase and transfers it to substrates, promoting their degradation.
T01441	BIOCLASS	Acyltransferase
T01441	ECNUMBER	EC 2.3.2.27
T01441	SEQUENCE	MFRTAVMMAASLALTGAVVAHAYYLKHQFYPTVVYLTKSSPSMAVLYIQAFVLVFLLGKVMGKVFFGQLRAAEMEHLLERSWYAVTETCLAFTVFRDDFSPRFVALFTLLLFLKCFHWLAEDRVDFMERSPNISWLFHCRIVSLMFLLGILDFLFVSHAYHSILTRGASVQLVFGFEYAILMTMVLTIFIKYVLHSVDLQSENPWDNKAVYMLYTELFTGFIKVLLYMAFMTIMIKVHTFPLFAIRPMYLAMRQFKKAVTDAIMSRRAIRNMNTLYPDATPEELQAMDNVCIICREEMVTGAKRLPCNHIFHTSCLRSWFQRQQTCPTCRMDVLRASLPAQSPPPPEPADQGPPPAPHPPPLLPQPPNFPQGLLPPFPPGMFPLWPPMGPFPPVPPPPSSGEAVAPPSTSAAALSRPSGAATTTAAGTSATAASATASGPGSGSAPEAGPAPGFPFPPPWMGMPLPPPFAFPPMPVPPAGFAGLTPEELRALEGHERQHLEARLQSLRNIHTLLDAAMLQINQYLTVLASLGPPRPATSVNSTEETATTVVAAASSTSIPSSEATTPTPGASPPAPEMERPPAPESVGTEEMPEDGEPDAAELRRRRLQKLESPVAH

T98395	TARGETID	T98395
T98395	FORMERID	TTDI00112
T98395	UNIPROID	PRGC2_HUMAN
T98395	TARGNAME	PPAR-gamma coactivator 1-beta (PPARGC1B)
T98395	GENENAME	PPARGC1B
T98395	TARGTYPE	Literature-reported
T98395	SYNONYMS	Peroxisome proliferator-activated receptor gamma coactivator 1-beta; PPARGC1; PPARGC-1-beta; PGC1B; PGC1; PGC-1-related estrogen receptor alpha coactivator; PGC-1-beta; PERC
T98395	FUNCTION	Plays a role of stimulator of transcription factors and nuclear receptors activities. Activates transcriptional activity of estrogen receptor alpha, nuclear respiratory factor 1 (NRF1) and glucocorticoid receptor in the presence of glucocorticoids. May play a role in constitutive non-adrenergic-mediated mitochondrial biogenesis as suggested by increased basal oxygen consumption and mitochondrial number when overexpressed. May be involved in fat oxidation and non-oxidative glucose metabolism and in the regulation of energy expenditure. Induces the expression of PERM1 in the skeletal muscle in an ESRRA-dependent manner.
T98395	PDBSTRUC	6D0Y; 3SP6
T98395	BIOCLASS	RNA recognition motif
T98395	SEQUENCE	MAGNDCGALLDEELSSFFLNYLADTQGGGSGEEQLYADFPELDLSQLDASDFDSATCFGELQWCPENSETEPNQYSPDDSELFQIDSENEALLAELTKTLDDIPEDDVGLAAFPALDGGDALSCTSASPAPSSAPPSPAPEKPSAPAPEVDELSLLQKLLLATSYPTSSSDTQKEGTAWRQAGLRSKSQRPCVKADSTQDKKAPMMQSQSRSCTELHKHLTSAQCCLQDRGLQPPCLQSPRLPAKEDKEPGEDCPSPQPAPASPRDSLALGRADPGAPVSQEDMQAMVQLIRYMHTYCLPQRKLPPQTPEPLPKACSNPSQQVRSRPWSRHHSKASWAEFSILRELLAQDVLCDVSKPYRLATPVYASLTPRSRPRPPKDSQASPGRPSSVEEVRIAASPKSTGPRPSLRPLRLEVKREVRRPARLQQQEEEDEEEEEEEEEEEKEEEEEWGRKRPGRGLPWTKLGRKLESSVCPVRRSRRLNPELGPWLTFADEPLVPSEPQGALPSLCLAPKAYDVERELGSPTDEDSGQDQQLLRGPQIPALESPCESGCGDMDEDPSCPQLPPRDSPRCLMLALSQSDPTFGKKSFEQTLTVELCGTAGLTPPTTPPYKPTEEDPFKPDIKHSLGKEIALSLPSPEGLSLKATPGAAHKLPKKHPERSELLSHLRHATAQPASQAGQKRPFSCSFGDHDYCQVLRPEGVLQRKVLRSWEPSGVHLEDWPQQGAPWAEAQAPGREEDRSCDAGAPPKDSTLLRDHEIRASLTKHFGLLETALEEEDLASCKSPEYDTVFEDSSSSSGESSFLPEEEEEEGEEEEEDDEEEDSGVSPTCSDHCPYQSPPSKANRQLCSRSRSSSGSSPCHSWSPATRRNFRCESRGPCSDRTPSIRHARKRREKAIGEGRVVYIQNLSSDMSSRELKRRFEVFGEIEECEVLTRNRRGEKYGFITYRCSEHAALSLTKGAALRKRNEPSFQLSYGGLRHFCWPRYTDYDSNSEEALPASGKSKYEAMDFDSLLKEAQQSLH

T92858	TARGETID	T92858
T92858	FORMERID	TTDR01139
T92858	UNIPROID	Q8IDQ9_PLAF7
T92858	TARGNAME	Plasmodium Phosphoethanolamine N-methyltransferase (Malaria PNM)
T92858	GENENAME	Malaria PNM
T92858	TARGTYPE	Literature-reported
T92858	SYNONYMS	Phosphoethanolamine N-methyltransferase
T92858	FUNCTION	Golgi apparatus, phosphoethanolamine N-methyltransferase activity, phosphatidylcholine biosynthetic process
T92858	BIOCLASS	Transferases of one-carbon groups
T92858	ECNUMBER	EC 2.1.1.103
T92858	SEQUENCE	MTLIENLNSDKTFLENNQYTDEGVKVYEFIFGENYISSGGLEATKKILSDIELNENSKVLDIGSGLGGGCMYINEKYGAHTHGIDICSNIVNMANERVSGNNKIIFEANDILTKEFPENNFDLIYSRDAILHLSLENKNKLFQKCYKWLKPTGTLLITDYCATEKENWDDEFKEYVKQRKYTLITVEEYADILTACNFKNVVSKDLSDYWNQLLEVEHKYLHENKEEFLKLFSEKKFISLDDGWSRKIKDSKRKMQRWGYFKATKN

T47543	TARGETID	T47543
T47543	FORMERID	TTDR00300
T47543	UNIPROID	Q8IDW1_PLAF7
T47543	TARGNAME	Plasmodium CDK PfPK6 (Malaria PfPK6)
T47543	GENENAME	Malaria PfPK6
T47543	TARGTYPE	Literature-reported
T47543	SYNONYMS	Protein kinase 6; PF3D7_1337100; CDK-related protein kinase 6
T47543	FUNCTION	Cyclin-dependent protein serine/threonine kinase activity, protein phosphorylation.
T47543	BIOCLASS	Kinase
T47543	ECNUMBER	EC 2.7.11.22
T47543	SEQUENCE	MNRIDISNFDFLYVIGKGTYGIVYKALDKKENNFVAIKKIINLCDENYGISKCILRELTILQKIKHKNIINLKYVFYGKDIEDKLKGENLENSCLYLAFEYCDIDLFNLIKKHNLNIKEIKYIIFELLLALSYFHSNNYIHRDIKPENIFITSEGEIKLGDLGMSVEKSDHMTPTVVTLWYRAPEILLKSTNYDQKVDIWSLGCLFMELIQGRPLFPGKNDCTQLELIYLLLGDKDKLTTVDKERKDMFPYFEINMLKDAIDDEHTLDLISKMLIYDPNYRISSKEALKHPCFQDIEQVKFSYNF

T34816	TARGETID	T34816
T34816	FORMERID	TTDR00704
T34816	UNIPROID	Q8IM16_PLAF7
T34816	TARGNAME	Plasmodium Plasmepsin 4 (Malaria PLA4)
T34816	GENENAME	Malaria PLA4
T34816	TARGTYPE	Literature-reported
T34816	SYNONYMS	Plasmepsin IV
T34816	FUNCTION	Plays a crucial role in this critical process which yields nutrients for parasite growth.
T34816	PDBSTRUC	1LS5
T34816	ECNUMBER	EC 3.4.23.-
T34816	SEQUENCE	MALTVKEEEFSNTLIKNASAFDRLKLGNLKNLKIQKKLQFLYLILFVLITGVFFFFLIGNFYSHRKLYQVIKNTKHTTIGFKIDRPHDKVLSSVLKNKLSTYVKESFKFFKSGYAQKGYLGSENDSIELDDVANLMFYGEGQIGTNKQPFMFIFDTGSANLWVPSVNCDSIGCSTKHLYDASASKSYEKDGTKVEISYGSGTVRGYFSKDVISLGDLSLPYKFIEVTDADDLEPIYSGSEFDGILGLGWKDLSIGSIDPVVVELKKQNKIDNALFTFYLPVHDKHVGYLTIGGIESDFYEGPLTYEKLNHDLYWQIDLDIHFGKYVMQKANAVVDSGTSTITAPTSFLNKFFRDMNVIKVPFLPLYVTTCDNDDLPTLEFHSRNNKYTLEPEFYMDPLSDIDPALCMLYILPVDIDDNTFILGDPFMRKYFTVFDYEKESVGFAVAKNL

T85915	TARGETID	T85915
T85915	FORMERID	TTDI03359
T85915	UNIPROID	TPH2_HUMAN
T85915	TARGNAME	L-Tryptophan hydroxylase 2 (TPH2)
T85915	GENENAME	TPH2
T85915	TARGTYPE	Literature-reported
T85915	SYNONYMS	Tryptophan 5-monooxygenase 2; Tryptophan 5-hydroxylase 2; Neuronal tryptophan hydroxylase; NTPH
T85915	FUNCTION	Rate-limiting enzyme in the synthesis of serotonin (5-hydroxytryptamine, or 5HT). Has functions in peripheral tissues, including the maintenance of vascular tone and gut motility.
T85915	PDBSTRUC	4V06
T85915	ECNUMBER	EC 1.14.16.4
T85915	SEQUENCE	MQPAMMMFSSKYWARRGFSLDSAVPEEHQLLGSSTLNKPNSGKNDDKGNKGSSKREAATESGKTAVVFSLKNEVGGLVKALRLFQEKRVNMVHIESRKSRRRSSEVEIFVDCECGKTEFNELIQLLKFQTTIVTLNPPENIWTEEEELEDVPWFPRKISELDKCSHRVLMYGSELDADHPGFKDNVYRQRRKYFVDVAMGYKYGQPIPRVEYTEEETKTWGVVFRELSKLYPTHACREYLKNFPLLTKYCGYREDNVPQLEDVSMFLKERSGFTVRPVAGYLSPRDFLAGLAYRVFHCTQYIRHGSDPLYTPEPDTCHELLGHVPLLADPKFAQFSQEIGLASLGASDEDVQKLATCYFFTIEFGLCKQEGQLRAYGAGLLSSIGELKHALSDKACVKAFDPKTTCLQECLITTFQEAYFVSESFEEAKEKMRDFAKSITRPFSVYFNPYTQSIEILKDTRSIENVVQDLRSDLNTVCDALNKMNQYLGI
T85915	DRUGINFO	D0U9QD	6-fluorotryptophan	Investigative
T85915	DRUGINFO	D0F2GG	fenclonine	Investigative
T85915	DRUGINFO	D0IT5D	alpha-propyldopacetamide	Investigative

T38166	TARGETID	T38166
T38166	FORMERID	TTDI00153
T38166	UNIPROID	PLPL6_HUMAN
T38166	TARGNAME	Neuropathy target esterase (PNPLA6)
T38166	GENENAME	PNPLA6
T38166	TARGTYPE	Literature-reported
T38166	SYNONYMS	Patatin-like phospholipase domain-containing protein 6; NTE
T38166	FUNCTION	Phospholipase B that deacylates intracellular phosphatidylcholine (PtdCho), generating glycerophosphocholine (GroPtdCho). This deacylation occurs at both sn-2 and sn-1 positions of PtdCho. Its specific chemical modification by certain organophosphorus (OP) compounds leads to distal axonopathy.
T38166	BIOCLASS	Carboxylic ester hydrolase
T38166	ECNUMBER	EC 3.1.1.5
T38166	SEQUENCE	MEAPLQTGMMGTSSHGLATNSSGAKVAERDGFQDVLAPGEGSAGRICGAQPVPFVPQVLGVMIGAGVAVVVTAVLILLVVRRLRVPKTPAPDGPRYRFRKRDKVLFYGRKIMRKVSQSTSSLVDTSVSATSRPRMRKKLKMLNIAKKILRIQKETPTLQRKEPPPAVLEADLTEGDLANSHLPSEVLYMLKNVRVLGHFEKPLFLELCRHMVFQRLGQGDYVFRPGQPDASIYVVQDGLLELCLPGPDGKECVVKEVVPGDSVNSLLSILDVITGHQHPQRTVSARAARDSTVLRLPVEAFSAVFTKYPESLVRVVQIIMVRLQRVTFLALHNYLGLTNELFSHEIQPLRLFPSPGLPTRTSPVRGSKRMVSTSATDEPRETPGRPPDPTGAPLPGPTGDPVKPTSLETPSAPLLSRCVSMPGDISGLQGGPRSDFDMAYERGRISVSLQEEASGGSLAAPARTPTQEPREQPAGACEYSYCEDESATGGCPFGPYQGRQTSSIFEAAKQELAKLMRIEDPSLLNSRVLLHHAKAGTIIARQGDQDVSLHFVLWGCLHVYQRMIDKAEDVCLFVAQPGELVGQLAVLTGEPLIFTLRAQRDCTFLRISKSDFYEIMRAQPSVVLSAAHTVAARMSPFVRQMDFAIDWTAVEAGRALYRQGDRSDCTYIVLNGRLRSVIQRGSGKKELVGEYGRGDLIGVVEALTRQPRATTVHAVRDTELAKLPEGTLGHIKRRYPQVVTRLIHLLSQKILGNLQQLQGPFPAGSGLGVPPHSELTNPASNLATVAILPVCAEVPMVAFTLELQHALQAIGPTLLLNSDIIRARLGASALDSIQEFRLSGWLAQQEDAHRIVLYQTDASLTPWTVRCLRQADCILIVGLGDQEPTLGQLEQMLENTAVRALKQLVLLHREEGAGPTRTVEWLNMRSWCSGHLHLRCPRRLFSRRSPAKLHELYEKVFSRRADRHSDFSRLARVLTGNTIALVLGGGGARGCSHIGVLKALEEAGVPVDLVGGTSIGSFIGALYAEERSASRTKQRAREWAKSMTSVLEPVLDLTYPVTSMFTGSAFNRSIHRVFQDKQIEDLWLPYFNVTTDITASAMRVHKDGSLWRYVRASMTLSGYLPPLCDPKDGHLLMDGGYINNLPADIARSMGAKTVIAIDVGSQDETDLSTYGDSLSGWWLLWKRLNPWADKVKVPDMAEIQSRLAYVSCVRQLEVVKSSSYCEYLRPPIDCFKTMDFGKFDQIYDVGYQYGKAVFGGWSRGNVIEKMLTDRRSTDLNESRRADVLAFPSSGFTDLAEIVSRIEPPTSYVSDGCADGEESDCLTEYEEDAGPDCSRDEGGSPEGASPSTASEMEEEKSILRQRRCLPQEPPGSATDA

T81903	TARGETID	T81903
T81903	FORMERID	TTDI00105
T81903	UNIPROID	OSCAR_HUMAN
T81903	TARGNAME	Osteoclast-associated receptor (OSCAR)
T81903	GENENAME	OSCAR
T81903	TARGTYPE	Literature-reported
T81903	SYNONYMS	hOSCAR; Polymeric immunoglobulin receptor 3; PolyIg receptor 3; PIgR3; Osteoclastassociated immunoglobulinlike receptor; OSCAR
T81903	FUNCTION	Regulator of osteoclastogenesis which plays an importantbone-specific function in osteoclast differentiation.
T81903	PDBSTRUC	5EIV; 5EIQ; 5CJB; 5CJ8
T81903	BIOCLASS	Leukocyte receptor complex
T81903	SEQUENCE	MALVLILQLLTLWPLCHTDITPSVPPASYHPKPWLGAQPATVVTPGVNVTLRCRAPQPAWRFGLFKPGEIAPLLFRDVSSELAEFFLEEVTPAQGGIYRCCYRRPDWGPGVWSQPSDVLELLVTEELPRPSLVALPGPVVGPGANVSLRCAGRLRNMSFVLYREGVAAPLQYRHSAQPWADFTLLGARAPGTYSCYYHTPSAPYVLSQRSEVLVISWEGEGPEARPASSAPGMQAPGPPPSDPGAQAPSLSSFRPRGLVLQPLLPQTQDSWDPAPPPSDPGV

T78865	TARGETID	T78865
T78865	FORMERID	TTDI02627
T78865	UNIPROID	CHSS2_HUMAN
T78865	TARGNAME	N-acetylgalactosaminyltransferase 2 (CHPF)
T78865	GENENAME	CHPF
T78865	TARGTYPE	Literature-reported
T78865	SYNONYMS	Nacetylgalactosaminylproteoglycan 3betaglucuronosyltransferase II; GlucuronosylNacetylgalactosaminylproteoglycan 4betaNacetylgalactosaminyltransferase II; Chondroitinpolymerizing factor; Chondroitin sulfate synthase 2; Chondroitin glucuronyltransferase 2; ChPF
T78865	FUNCTION	Has both beta-1,3-glucuronic acid and beta-1,4-N- acetylgalactosamine transferase activity. Transfers glucuronic acid (GlcUA) from UDP-GlcUA and N-acetylgalactosamine (GalNAc) from UDP-GalNAc to the non-reducing end of the elongating chondroitin polymer. Isoform 2 may facilitate PARK2 transport into the mitochondria. In collaboration with PARK2, isoform 2 may enhance cell viability and protect cells from oxidative stress.
T78865	BIOCLASS	Hexosyltransferase
T78865	ECNUMBER	EC 2.4.1.175
T78865	SEQUENCE	MRASLLLSVLRPAGPVAVGISLGFTLSLLSVTWVEEPCGPGPPQPGDSELPPRGNTNAARRPNSVQPGAEREKPGAGEGAGENWEPRVLPYHPAQPGQAAKKAVRTRYISTELGIRQRLLVAVLTSQTTLPTLGVAVNRTLGHRLERVVFLTGARGRRAPPGMAVVTLGEERPIGHLHLALRHLLEQHGDDFDWFFLVPDTTYTEAHGLARLTGHLSLASAAHLYLGRPQDFIGGEPTPGRYCHGGFGVLLSRMLLQQLRPHLEGCRNDIVSARPDEWLGRCILDATGVGCTGDHEGVHYSHLELSPGEPVQEGDPHFRSALTAHPVRDPVHMYQLHKAFARAELERTYQEIQELQWEIQNTSHLAVDGDQAAAWPVGIPAPSRPASRFEVLRWDYFTEQHAFSCADGSPRCPLRGADRADVADVLGTALEELNRRYHPALRLQKQQLVNGYRRFDPARGMEYTLDLQLEALTPQGGRRPLTRRVQLLRPLSRVEILPVPYVTEASRLTVLLPLAAAERDLAPGFLEAFATAALEPGDAAAALTLLLLYEPRQAQRVAHADVFAPVKAHVAELERRFPGARVPWLSVQTAAPSPLRLMDLLSKKHPLDTLFLLAGPDTVLTPDFLNRCRMHAISGWQAFFPMHFQAFHPAVAPPQGPGPPELGRDTGRFDRQAASEACFYNSDYVAARGRLAAASEQEEELLESLDVYELFLHFSSLHVLRAVEPALLQRYRAQTCSARLSEDLYHRCLQSVLEGLGSRTQLAMLLFEQEQGNST

T55242	TARGETID	T55242
T55242	FORMERID	TTDI02649
T55242	UNIPROID	IFNL3_HUMAN
T55242	TARGNAME	Interferon-lambda 3 (IFNL3)
T55242	GENENAME	IFNL3
T55242	TARGTYPE	Literature-reported
T55242	SYNONYMS	ZCYTO22; Interleukin28C; Interleukin28B; Interleukin-28C; Interleukin-28B; Interferon lambda3; Interferon lambda-3; IL28C; IL28B; IL-28C; IL-28B; IFNlambda3; IFN-lambda-3; Cytokine Zcyto22
T55242	FUNCTION	Plays a critical role in the antiviral host defense, predominantly in the epithelial tissues. Acts as a ligand for the heterodimeric class II cytokine receptor composed of IL10RB and IFNLR1, and receptor engagement leads to the activation of the JAK/STAT signaling pathway resulting in the expression of IFN-stimulated genes (ISG), which mediate the antiviral state. Has a restricted receptor distribution and therefore restricted targets: is primarily active in epithelial cells and this cell type-selective action is because of the epithelial cell-specific expression of its receptor IFNLR1. Seems not to be essential for early virus-activated host defense in vaginal infection, but plays an important role in Toll-like receptor (TLR)-induced antiviral defense. Plays a significant role in the antiviral immune defense in the intestinal epithelium. Exerts an immunomodulatory effect by up-regulating MHC class I antigen expression. Cytokine with antiviral, antitumour and immunomodulatory activities.
T55242	PDBSTRUC	5T5W; 3HHC
T55242	BIOCLASS	Cytokine: interferon
T55242	SEQUENCE	MTGDCMPVLVLMAAVLTVTGAVPVARLRGALPDARGCHIAQFKSLSPQELQAFKRAKDALEESLLLKDCKCRSRLFPRTWDLRQLQVRERPVALEAELALTLKVLEATADTDPALGDVLDQPLHTLHHILSQLRACIQPQPTAGPRTRGRLHHWLHRLQEAPKKESPGCLEASVTFNLFRLLTRDLNCVASGDLCV

T63298	TARGETID	T63298
T63298	FORMERID	TTDI03160
T63298	UNIPROID	DCLK2_HUMAN
T63298	TARGNAME	Doublecortin-like kinase 2 (DCLK2)
T63298	GENENAME	DCLK2
T63298	TARGTYPE	Literature-reported
T63298	SYNONYMS	Serine/threonine-protein kinase DCLK2; Doublecortin-like and CAM kinase-like 2; Doublecortin domain-containing protein 3B; DCK2; DCDC3B; DCAMKL2; CaMK-like CREB regulatory kinase 2; CLICK2; CLICK-II; CL2
T63298	FUNCTION	May play a role in the down-regulation of CRE-dependent gene activation probably by phosphorylation of the CREB coactivator CRTC2/TORC2 and the resulting retention of TORC2 in the cytoplasm. Protein kinase with a significantly reduced C(a2+)/CAM affinity and dependence compared to other members of the CaMK family.
T63298	BIOCLASS	Kinase
T63298	ECNUMBER	EC 2.7.11.1
T63298	SEQUENCE	MASTRSIELEHFEERDKRPRPGSRRGAPSSSGGSSSSGPKGNGLIPSPAHSAHCSFYRTRTLQALSSEKKAKKARFYRNGDRYFKGLVFAISSDRFRSFDALLIELTRSLSDNVNLPQGVRTIYTIDGSRKVTSLDELLEGESYVCASNEPFRKVDYTKNINPNWSVNIKGGTSRALAAASSVKSEVKESKDFIKPKLVTVIRSGVKPRKAVRILLNKKTAHSFEQVLTDITEAIKLDSGVVKRLCTLDGKQVTCLQDFFGDDDVFIACGPEKFRYAQDDFVLDHSECRVLKSSYSRSSAVKYSGSKSPGPSRRSKSPASVNGTPSSQLSTPKSTKSSSSSPTSPGSFRGLKQISAHGRSSSNVNGGPELDRCISPEGVNGNRCSESSTLLEKYKIGKVIGDGNFAVVKECIDRSTGKEFALKIIDKAKCCGKEHLIENEVSILRRVKHPNIIMLVEEMETATELFLVMELVKGGDLFDAITSSTKYTERDGSAMVYNLANALRYLHGLSIVHRDIKPENLLVCEYPDGTKSLKLGDFGLATVVEGPLYTVCGTPTYVAPEIIAETGYGLKVDIWAAGVITYILLCGFPPFRSENNLQEDLFDQILAGKLEFPAPYWDNITDSAKELISQMLQVNVEARCTAGQILSHPWVSDDASQENNMQAEVTGKLKQHFNNALPKQNSTTTGVSVIMNTALDKEGQIFCSKHCQDSGRPGMEPISPVPPSVEEIPVPGEAVPAPTPPESPTPHPPPAAPGGERAGTWRRHRD
T63298	DRUGINFO	D0M0QQ	XMD8-92	Investigative

T43102	TARGETID	T43102
T43102	FORMERID	TTDR00971
T43102	UNIPROID	DPP10_HUMAN
T43102	TARGNAME	Similar to dipeptidyl aminopeptidase-like protein (DPP10)
T43102	GENENAME	DPP10
T43102	TARGTYPE	Literature-reported
T43102	SYNONYMS	KIAA1492; Inactive dipeptidyl peptidase 10; Dipeptidyl peptidase-like protein 2; Dipeptidyl peptidase X; Dipeptidyl peptidase IV-related protein 3; DPRP3; DPRP-3; DPP X; DPL2
T43102	FUNCTION	Promotes cell surface expression of the potassium channel KCND2. Modulates the activity and gating characteristics of the potassium channel KCND2. Has no dipeptidyl aminopeptidase activity.
T43102	PDBSTRUC	4WJL
T43102	BIOCLASS	Prolyl oligopeptidase family
T43102	SEQUENCE	MNQTASVSHHIKCQPSKTIKELGSNSPPQRNWKGIAIALLVILVVCSLITMSVILLTPDELTNSSETRLSLEDLFRKDFVLHDPEARWINDTDVVYKSENGHVIKLNIETNATTLLLENTTFVTFKASRHSVSPDLKYVLLAYDVKQIFHYSYTASYVIYNIHTREVWELNPPEVEDSVLQYAAWGVQGQQLIYIFENNIYYQPDIKSSSLRLTSSGKEEIIFNGIADWLYEEELLHSHIAHWWSPDGERLAFLMINDSLVPTMVIPRFTGALYPKGKQYPYPKAGQVNPTIKLYVVNLYGPTHTLELMPPDSFKSREYYITMVKWVSNTKTVVRWLNRAQNISILTVCETTTGACSKKYEMTSDTWLSQQNEEPVFSRDGSKFFMTVPVKQGGRGEFHHVAMFLIQSKSEQITVRHLTSGNWEVIKILAYDETTQKIYFLSTESSPRGRQLYSASTEGLLNRQCISCNFMKEQCTYFDASFSPMNQHFLLFCEGPRVPVVSLHSTDNPAKYFILESNSMLKEAILKKKIGKPEIKILHIDDYELPLQLSLPKDFMDRNQYALLLIMDEEPGGQLVTDKFHIDWDSVLIDMDNVIVARFDGRGSGFQGLKILQEIHRRLGSVEVKDQITAVKFLLKLPYIDSKRLSIFGKGYGGYIASMILKSDEKLFKCGSVVAPITDLKLYASAFSERYLGMPSKEESTYQAASVLHNVHGLKEENILIIHGTADTKVHFQHSAELIKHLIKAGVNYTMQVYPDEGHNVSEKSKYHLYSTILKFFSDCLKEEISVLPQEPEEDE

T95238	TARGETID	T95238
T95238	UNIPROID	ENAH_HUMAN
T95238	TARGNAME	Protein enabled homolog MENA (ENAH)
T95238	GENENAME	ENAH
T95238	TARGTYPE	Literature-reported
T95238	SYNONYMS	MENA
T95238	FUNCTION	Ena/VASP proteins are actin-associated proteins involved in a range of processes dependent on cytoskeleton remodeling and cell polarity such as axon guidance and lamellipodial and filopodial dynamics in migrating cells. ENAH induces the formation of F-actin rich outgrowths in fibroblasts. Acts synergistically with BAIAP2-alpha and downstream of NTN1 to promote filipodia formation.
T95238	PDBSTRUC	5NEG; 5NDU; 5ND0; 5NCP; 5NCG
T95238	SEQUENCE	MSEQSICQARAAVMVYDDANKKWVPAGGSTGFSRVHIYHHTGNNTFRVVGRKIQDHQVVINCAIPKGLKYNQATQTFHQWRDARQVYGLNFGSKEDANVFASAMMHALEVLNSQETGPTLPRQNSQLPAQVQNGPSQEELEIQRRQLQEQQRQKELERERLERERMERERLERERLERERLERERLEQEQLERERQERERQERLERQERLERQERLERQERLDRERQERQERERLERLERERQERERQEQLEREQLEWERERRISSAAAPASVETPLNSVLGDSSASEPGLQAASQPAETPSQQGIVLGPLAPPPPPPLPPGPAQASVALPPPPGPPPPPPLPSTGPPPPPPPPPLPNQVPPPPPPPPAPPLPASGFFLASMSEDNRPLTGLAAAIAGAKLRKVSRMEDTSFPSGGNAIGVNSASSKTDTGRGNGPLPLGGSGLMEEMSALLARRRRIAEKGSTIETEQKEDKGEDSEPVTSKASSTSTPEPTRKPWERTNTMNGSKSPVISRRDSPRKNQIVFDNRSYDSLHRPKSTPLSQPSANGVQTEGLDYDRLKQDILDEMRKELTKLKEELIDAIRQELSKSNTA

T23485	TARGETID	T23485
T23485	FORMERID	TTDR00450
T23485	UNIPROID	STEA2_HUMAN
T23485	TARGNAME	Metalloreductase STEAP2 (STEAP2)
T23485	GENENAME	STEAP2
T23485	TARGTYPE	Literature-reported
T23485	SYNONYMS	STEAP2
T23485	FUNCTION	Metalloreductase that hasthe ability to reduce both Fe(3+) to Fe(2+) and Cu(2+) to Cu(1+). Uses NAD(+) as acceptor.
T23485	BIOCLASS	Metal ion oxidoreductase
T23485	ECNUMBER	EC 1.16.1.-
T23485	SEQUENCE	MESISMMGSPKSLSETFLPNGINGIKDARKVTVGVIGSGDFAKSLTIRLIRCGYHVVIGSRNPKFASEFFPHVVDVTHHEDALTKTNIIFVAIHREHYTSLWDLRHLLVGKILIDVSNNMRINQYPESNAEYLASLFPDSLIVKGFNVVSAWALQLGPKDASRQVYICSNNIQARQQVIELARQLNFIPIDLGSLSSAREIENLPLRLFTLWRGPVVVAISLATFFFLYSFVRDVIHPYARNQQSDFYKIPIEIVNKTLPIVAITLLSLVYLAGLLAAAYQLYYGTKYRRFPPWLETWLQCRKQLGLLSFFFAMVHVAYSLCLPMRRSERYLFLNMAYQQVHANIENSWNEEEVWRIEMYISFGIMSLGLLSLLAVTSIPSVSNALNWREFSFIQSTLGYVALLISTFHVLIYGWKRAFEEEYYRFYTPPNFVLALVLPSIVILGKIILFLPCISRKLKRIKKGWEKSQFLEEGMGGTIPHVSPERVTVM

T39698	TARGETID	T39698
T39698	FORMERID	TTDI03403
T39698	UNIPROID	NEK7_HUMAN
T39698	TARGNAME	NIMA-related kinase 7 (NEK7)
T39698	GENENAME	NEK7
T39698	TARGTYPE	Literature-reported
T39698	SYNONYMS	Serine/threonine-protein kinase Nek7; NimA-related protein kinase 7; Never in mitosis A-related kinase 7
T39698	FUNCTION	Protein kinase which plays an important role in mitotic cell cycle progression. Required for microtubule nucleation activity of the centrosome, robust mitotic spindle formation and cytokinesis. Phosphorylates RPS6KB1.
T39698	PDBSTRUC	6GT1; 5DE2; 2WQN; 2WQM
T39698	ECNUMBER	EC 2.7.11.1
T39698	SEQUENCE	MDEQSQGMQGPPVPQFQPQKALRPDMGYNTLANFRIEKKIGRGQFSEVYRAACLLDGVPVALKKVQIFDLMDAKARADCIKEIDLLKQLNHPNVIKYYASFIEDNELNIVLELADAGDLSRMIKHFKKQKRLIPERTVWKYFVQLCSALEHMHSRRVMHRDIKPANVFITATGVVKLGDLGLGRFFSSKTTAAHSLVGTPYYMSPERIHENGYNFKSDIWSLGCLLYEMAALQSPFYGDKMNLYSLCKKIEQCDYPPLPSDHYSEELRQLVNMCINPDPEKRPDVTYVYDVAKRMHACTASS
T39698	DRUGINFO	D0V0KA	PMID20462760C22	Investigative

T52604	TARGETID	T52604
T52604	FORMERID	TTDR00827
T52604	UNIPROID	PUR6_CANAL
T52604	TARGNAME	Candida AIR carboxylase (Candi ADE2)
T52604	GENENAME	Candi ADE2
T52604	TARGTYPE	Literature-reported
T52604	SYNONYMS	Phosphoribosylaminoimidazole carboxylase; AIRC; AIR carboxylase
T52604	FUNCTION	Catalyzes the sixth step of the de novo purine biosynthesis pathway.
T52604	BIOCLASS	Carbon-carbon lyase
T52604	ECNUMBER	EC 4.1.1.21
T52604	SEQUENCE	MDSKTVGILGGGQLGRMIVEAAHRLNIKTVILDAAKSPAKQINALDDHVDGSFTNYDSIVKLAEKADVLTVEIEHVDVDALIKVQEKFPKVEIYPLPETIRLIQDKYLQKNHLIKHDVAVTESVAVETNTVDDLLHIGEKFGYPYMLKSRTLAYDGRGNFVVKDKSYCEKALEFLKDRPLYAEKWCPFTKELAVMVVRSLEGEVFAYPTVETIHENNICHLVYAPARIPDTLAKKASILAKNAVKSFLGCGIFGVEMFLLENNELLINEIAPRPHNSGHYTIDACVTSQFEAHVRAVTGLPMPKGFTEFSTSITNAIMLNVLGDKATPNKELEICRRALETPHASVYLYGKTTRPERKMGHINVVTSSMQDAESRLSYILGDTTEIPKSLATDKESPLVGIIMGSDSDLPVMAVGARILKQFGVPFELTIVSAHRTPHRMSEYAIEAPKRGLKCIIAGAGGAAHLPGMVAAMTPLPVIGVPVKGSTLDGVDSLHSIVQMPRGIPVATVAINNSTNAALLAIRILGAYDSKWLTEMNQYMLNMETEVLGKAETLEEIGYEDYLTDKLKK

T30661	TARGETID	T30661
T30661	FORMERID	TTDR00735
T30661	UNIPROID	VPS34_CANAX
T30661	TARGNAME	Candida PtdIns-3-kinase VPS34 (Candi VPS34)
T30661	GENENAME	Candi VPS34
T30661	TARGTYPE	Literature-reported
T30661	SYNONYMS	Vacuolar sorting protein 34; VPS34; PtdIns-3-kinase; Phosphatidylinositol 3-kinase VPS34
T30661	FUNCTION	Phosphatidylinositol 3-kinase homolog required for vacuolar sorting and segregation.
T30661	BIOCLASS	Kinase
T30661	ECNUMBER	EC 2.7.1.137
T30661	SEQUENCE	MATLSQPQSALPKTKIATTFGLSKDLKSPISVKVCYLECTRNNVSLVPLSTKFEDPTVFKKLSQIYKNSDLFVEIRVYDGKNNNLISTPVRTSYKAFNNKGRTWNQQLKLNIDYNQISIDAYLKFSICEIIDTKPSVFGVSYLSLFSHDSSTLRSGSHKIPVFMEDDPQYSKNIQYGTLIGLTDLEKRLIDYENGKYPRLNWLDKMVLPKVDATFLKTNNKDHDYYLYIELPQFEFPIVYSDIIYQIPTIEPITETTSKIPPDDTLNSNIIINSIDIPMATSHDPSIMKVYDPDFHITANNHLNPNATTFDPVELKYRKLERNIDNNTILDKELKPTPQLRDELLRIMIKPSNAESTDNEKNLIWKFRYYFSKNNSGNDPSNKSVKSFLPKFLRSINWENDYELDHTFKEIIPFYWNVDKLQIGDALELLGDYFNPYTLGKPTYQDDSMTSKSSKMKSDEKRFIKIYNNVCFLRKLAVERLKLANSEELLLYLLQLVQALKYEALIYEKSPPFCERSDQIEDNASSTLKSPLADFLIERAVENEKLGNFFYWYVKVENEDQLNNPHIDGPIKIYMDILNRYIELLKAHCHENRLPYYKHLKHQIWFIKKLTSLVELLRASFKKNEATAKKVEYLREYLANSGNELLKFPEPFPLPLDPSVMICGCYPEESSVFKSSLAPLKITLKTIEKKKHGHATSQLFGKRSRYGKYPLMFKIGDDLRQDQLVIQIIDLMDQLLKNENLDLKLTPYKILATSPISGLIQFVPNETLDSILSKTYPTSVTYSGGGETSDGPPSVSNNGILNYLRLHSQEQQSEEPISKSILSTNTSQSNTEIPVLPRQPKPTITSDLGVSPILMDNYVKSCAGYCVITYILGVGDRHLDNLLLSPNGKFWHADFGYILGRDPKPFPPLMKLPIQVIDGMGGLHHENYNVFKSYCFITYTTLRKNSNLILNLFQLMLDANIPDIQFDPSRVIEKVQEKFCLQMTEEEAILHFQNLINDSVNAFLPVVIDRLHSLAQYWRA

T92628	TARGETID	T92628
T92628	UNIPROID	BAP1_HUMAN
T92628	TARGNAME	Ubiquitin carboxyl-terminal hydrolase BAP1 (BAP1)
T92628	GENENAME	BAP1
T92628	TARGTYPE	Literature-reported
T92628	SYNONYMS	KIAA0272; Cerebral protein 6; BRCA1-associated protein 1
T92628	FUNCTION	Deubiquitinating enzyme that plays a key role in chromatin by mediating deubiquitination of histone H2A and HCFC1. Catalytic component of the PR-DUB complex, a complex that specifically mediates deubiquitination of histone H2A monoubiquitinated at 'Lys-119' (H2AK119ub1). Does not deubiquitinate monoubiquitinated histone H2B. Acts as a regulator of cell growth by mediating deubiquitination of HCFC1 N-terminal and C-terminal chains, with some specificity toward 'Lys-48'-linked polyubiquitin chains compared to 'Lys-63'-linked polyubiquitin chains. Deubiquitination of HCFC1 does not lead to increase stability of HCFC1. Interferes with the BRCA1 and BARD1 heterodimer activity by inhibiting their ability to mediate ubiquitination and autoubiquitination. It however does not mediate deubiquitination of BRCA1 and BARD1. Able to mediate autodeubiquitination via intramolecular interactions to couteract monoubiquitination at the nuclear localization signal (NLS), thereby protecting it from cytoplasmic sequestration (PubMed:24703950). Acts as a tumor suppressor.
T92628	BIOCLASS	Peptidase C12 family. BAP1 subfamily
T92628	ECNUMBER	EC 3.4.19.12
T92628	SEQUENCE	MNKGWLELESDPGLFTLLVEDFGVKGVQVEEIYDLQSKCQGPVYGFIFLFKWIEERRSRRKVSTLVDDTSVIDDDIVNNMFFAHQLIPNSCATHALLSVLLNCSSVDLGPTLSRMKDFTKGFSPESKGYAIGNAPELAKAHNSHARPEPRHLPEKQNGLSAVRTMEAFHFVSYVPITGRLFELDGLKVYPIDHGPWGEDEEWTDKARRVIMERIGLATAGEPYHDIRFNLMAVVPDRRIKYEARLHVLKVNRQTVLEALQQLIRVTQPELIQTHKSQESQLPEESKSASNKSPLVLEANRAPAASEGNHTDGAEEAAGSCAQAPSHSPPNKPKLVVKPPGSSLNGVHPNPTPIVQRLPAFLDNHNYAKSPMQEEEDLAAGVGRSRVPVRPPQQYSDDEDDYEDDEEDDVQNTNSALRYKGKGTGKPGALSGSADGQLSVLQPNTINVLAEKLKESQKDLSIPLSIKTSSGAGSPAVAVPTHSQPSPTPSNESTDTASEIGSAFNSPLRSPIRSANPTRPSSPVTSHISKVLFGEDDSLLRVDCIRYNRAVRDLGPVISTGLLHLAEDGVLSPLALTEGGKGSSPSIRPIQGSQGSSSPVEKEVVEATDSREKTGMVRPGEPLSGEKYSPKELLALLKCVEAEIANYEACLKEEVEKRKKFKIDDQRRTHNYDEFICTFISMLAQEGMLANLVEQNISVRRRQGVSIGRLHKQRKPDRRKRSRPYKAKRQ

T93949	TARGETID	T93949
T93949	UNIPROID	NR4A3_HUMAN
T93949	TARGNAME	Nuclear hormone receptor NOR-1 (NR4A3)
T93949	GENENAME	NR4A3
T93949	TARGTYPE	Literature-reported
T93949	SYNONYMS	Neuron-derived orphan receptor 1; NOR1; Mitogen-induced nuclear orphan receptor; MINOR; CSMF; CHN
T93949	FUNCTION	Transcriptional activator that binds to regulatory elements in promoter regions in a cell- and response element (target)-specific manner. Induces gene expression by binding as monomers to the NR4A1 response element (NBRE) 5'-AAAAGGTCA-3' site and as homodimers to the Nur response element (NurRE) site in the promoter of their regulated target genes. Plays a role in the regulation of proliferation, survival and differentiation of many different cell types and also in metabolism and inflammation. Mediates proliferation of vascular smooth muscle, myeloid progenitor cell and type B pancreatic cells; promotes mitogen-induced vascular smooth muscle cell proliferation through transactivation of SKP2 promoter by binding a NBRE site. Upon PDGF stimulation, stimulates vascular smooth muscle cell proliferation by regulating CCND1 and CCND2 expression. In islets, induces type B pancreatic cell proliferation through up-regulation of genes that activate cell cycle, as well as genes that cause degradation of the CDKN1A. Negatively regulates myeloid progenitor cell proliferation by repressing RUNX1 in a NBRE site-independent manner. During inner ear, plays a role as a key mediator of the proliferative growth phase of semicircular canal development. Mediates also survival of neuron and smooth muscle cells; mediates CREB-induced neuronal survival, and during hippocampus development, plays a critical role in pyramidal cell survival and axonal guidance. Is required for S phase entry of the cell cycle and survival of smooth muscle cells by inducing CCND1, resulting in RB1 phosphorylation. Binds to NBRE motif in CCND1 promoter, resulting in the activation of the promoter and CCND1 transcription. Plays also a role in inflammation; upon TNF stimulation, mediates monocyte adhesion by inducing the expression of VCAM1 and ICAM1 by binding to the NBRE consensus site. In mast cells activated by Fc-epsilon receptor cross-linking, promotes the synthesis and release of cytokines but impairs events leading to degranulation. Plays also a role in metabolism; by modulating feeding behavior; and by playing a role in energy balance by inhibiting the glucocorticoid-induced orexigenic neuropeptides AGRP expression, at least in part by forming a complex with activated NR3C1 on the AGRP- glucocorticoid response element (GRE), and thus weakening the DNA binding activity of NR3C1. Upon catecholamines stimulation, regulates gene expression that controls oxidative metabolism in skeletal muscle. Plays a role in glucose transport by regulating translocation of the SLC2A4 glucose transporter to the cell surface (PubMed:24022864). Finally, during gastrulation plays a crucial role in the formation of anterior mesoderm by controlling cell migration. Inhibits adipogenesis. Also participates in cardiac hypertrophy by activating PARP1.
T93949	BIOCLASS	Nuclear hormone receptor family. NR4 subfamily
T93949	SEQUENCE	MPCVQAQYSPSPPGSSYAAQTYSSEYTTEIMNPDYTKLTMDLGSTEITATATTSLPSISTFVEGYSSNYELKPSCVYQMQRPLIKVEEGRAPSYHHHHHHHHHHHHHHQQQHQQPSIPPASSPEDEVLPSTSMYFKQSPPSTPTTPAFPPQAGALWDEALPSAPGCIAPGPLLDPPMKAVPTVAGARFPLFHFKPSPPHPPAPSPAGGHHLGYDPTAAAALSLPLGAAAAAGSQAAALESHPYGLPLAKRAAPLAFPPLGLTPSPTASSLLGESPSLPSPPSRSSSSGEGTCAVCGDNAACQHYGVRTCEGCKGFFKRTVQKNAKYVCLANKNCPVDKRRRNRCQYCRFQKCLSVGMVKEVVRTDSLKGRRGRLPSKPKSPLQQEPSQPSPPSPPICMMNALVRALTDSTPRDLDYSRYCPTDQAAAGTDAEHVQQFYNLLTASIDVSRSWAEKIPGFTDLPKEDQTLLIESAFLELFVLRLSIRSNTAEDKFVFCNGLVLHRLQCLRGFGEWLDSIKDFSLNLQSLNLDIQALACLSALSMITERHGLKEPKRVEELCNKITSSLKDHQSKGQALEPTESKVLGALVELRKICTLGLQRIFYLKLEDLVSPPSIIDKLFLDTLPF

T03772	TARGETID	T03772
T03772	FORMERID	TTDI00095
T03772	UNIPROID	TNR14_HUMAN
T03772	TARGNAME	Herpesvirus entry mediator (CD270)
T03772	GENENAME	TNFRSF14
T03772	TARGTYPE	Literature-reported
T03772	SYNONYMS	UNQ329/PRO509; Tumor necrosis factor receptor-like 2; Tumor necrosis factor receptor superfamily member 14; TR2; HveA; Herpesvirus entry mediator A; Herpes virus entry mediator A; HVEM
T03772	FUNCTION	Signals via the TRAF2-TRAF3 E3 ligase pathway to promote immune cell survival and differentiation. Participates in bidirectional cell-cell contact signaling between antigen presenting cells and lymphocytes. In response to ligation of TNFSF14/LIGHT, delivers costimulatory signals to T cells, promoting cell proliferation and effector functions. Interacts with CD160 on NK cells, enhancing IFNG production and anti-tumor immune response. In the context of bacterial infection, acts as a signaling receptor on epithelial cells for CD160 from intraepithelial lymphocytes, triggering the production of antimicrobial proteins and proinflammatory cytokines. Upon binding to CD160 on activated CD4+ T cells, downregulates CD28 costimulatory signaling, restricting memory and alloantigen-specific immune response. May interact in cis (on the same cell) or in trans (on other cells) with BTLA. In cis interactions, appears to play an immune regulatory role inhibiting in trans interactions in naive T cells to maintain a resting state. In trans interactions, can predominate during adaptive immune response to provide survival signals to effector T cells. Receptor for four distinct ligands: The TNF superfamily members TNFSF14/LIGHT and homotrimeric LTA/lymphotoxin-alpha and the immunoglobulin superfamily members BTLA and CD160, altogether defining a complex stimulatory and inhibitory signaling network.
T03772	PDBSTRUC	5T2R; 5T2Q; 4RSU; 4FHQ; 2AW2
T03772	BIOCLASS	Cytokine receptor
T03772	SEQUENCE	MEPPGDWGPPPWRSTPKTDVLRLVLYLTFLGAPCYAPALPSCKEDEYPVGSECCPKCSPGYRVKEACGELTGTVCEPCPPGTYIAHLNGLSKCLQCQMCDPAMGLRASRNCSRTENAVCGCSPGHFCIVQDGDHCAACRAYATSSPGQRVQKGGTESQDTLCQNCPPGTFSPNGTLEECQHQTKCSWLVTKAGAGTSSSHWVWWFLSGSLVIVIVCSTVGLIICVKRRKPRGDVVKVIVSVQRKRQEAEGEATVIEALQAPPDVTTVAVEETIPSFTGRSPNH

T00455	TARGETID	T00455
T00455	FORMERID	TTDR00043
T00455	UNIPROID	Q937U6_BORHE
T00455	TARGNAME	Bacterial Class 1 lysyl-tRNA synthetase (Bact lysK)
T00455	GENENAME	Bact lysK
T00455	TARGTYPE	Literature-reported
T00455	SYNONYMS	Class 1 lysyl-tRNA synthetase
T00455	FUNCTION	Catalyses the formation of lysyl-transfer RNA, Lys-tRNA(Lys), which then is ready to insert lysine into proteins. Only found in a few bacteria such as -proteobacteria. Functionally equivalent but structurally unrelated compared with class II LysRS. Requires tRNALys binding prior to aminoacyl-adenylate synthesis.
T00455	BIOCLASS	Carbon-oxygen ligase
T00455	ECNUMBER	EC 6.1.1.6
T00455	SEQUENCE	DFYAKKIIEEKGEKEQYTVASGITPSGTVHIGNFREVISVDLVARALKDAGRNVRFIYSWDNYDVFRKVPKNMPNQELLTTHLRQAITRVPDTQTNQSSYARANEVEFEKYLPIVGIKPEFIDQSLKYMSSDYSSQIKFALDHKDEIEKVLNKYRTTKLADNWYPISIFCTKCNRDTTTIKNYNHCYSIEYCCECGNKESLDLRKTWAVKLPWRIDWPMRWKYENVDFEPAGKDHHSSGGSFDTSIEIVKIFGGTPPITFQYDFISIKGRGGKISSSSGDVGSLKDVLEIYTPEVTRFLFASTKPNTEFSISFDLDVIKIYEDYDKFERVYYGIDDIKENKKEAFKRIYELSQPKLPDKEIPYQIGFRHLSTICQIFEGDKDKIFKLLNDVKESQKAKLINKIECAINWIKKFAPEDFKFSLRYTFDNIEPLKDNNKQGVTQLLDFLKKDFNNITEKEIQDEIYNIARNNNIEPPLFFKQLYNILINKDKGPKLAGFIKIIGIKKFEEIVKHYI

T70539	TARGETID	T70539
T70539	FORMERID	TTDR00612
T70539	UNIPROID	MCHR2_HUMAN
T70539	TARGNAME	Melanin-concentrating hormone receptor 2 (MCHR2)
T70539	GENENAME	MCHR2
T70539	TARGTYPE	Literature-reported
T70539	SYNONYMS	SLT; MCHR-2; MCH2R; MCH2 protein; MCH-R2; MCH-2R; MCH(2) receptor; MCH receptor 2; GPRv17; GPR145; G-protein coupled receptor 145; G protein coupled receptor 145
T70539	FUNCTION	Receptor for melanin-concentrating hormone, coupled to G proteins that activate phosphoinositide hydrolysis.
T70539	BIOCLASS	GPCR rhodopsin
T70539	SEQUENCE	MNPFHASCWNTSAELLNKSWNKEFAYQTASVVDTVILPSMIGIICSTGLVGNILIVFTIIRSRKKTVPDIYICNLAVADLVHIVGMPFLIHQWARGGEWVFGGPLCTIITSLDTCNQFACSAIMTVMSVDRYFALVQPFRLTRWRTRYKTIRINLGLWAASFILALPVWVYSKVIKFKDGVESCAFDLTSPDDVLWYTLYLTITTFFFPLPLILVCYILILCYTWEMYQQNKDARCCNPSVPKQRVMKLTKMVLVLVVVFILSAAPYHVIQLVNLQMEQPTLAFYVGYYLSICLSYASSSINPFLYILLSGNFQKRLPQIQRRATEKEINNMGNTLKSHF
T70539	DRUGINFO	D04BDL	PMID22123324C38	Investigative
T70539	DRUGINFO	D01BTF	melanin-concentrating hormone	Investigative
T70539	DRUGINFO	D0V5ZP	ATC0065	Investigative

T54460	TARGETID	T54460
T54460	FORMERID	TTDI02637
T54460	UNIPROID	SLAF6_HUMAN
T54460	TARGNAME	SLAM family member 6 (SLAMF6)
T54460	GENENAME	SLAMF6
T54460	TARGTYPE	Literature-reported
T54460	SYNONYMS	SLAMF6; NTB-A; NK-T-B-antigen; CD352; Activating NK receptor
T54460	FUNCTION	Triggers cytolytic activity only in natural killer cells (NK) expressing high surface densities of natural cytotoxicity receptors.
T54460	PDBSTRUC	2IF7
T54460	BIOCLASS	Immunoglobulin
T54460	SEQUENCE	MLWLFQSLLFVFCFGPGNVVSQSSLTPLMVNGILGESVTLPLEFPAGEKVNFITWLFNETSLAFIVPHETKSPEIHVTNPKQGKRLNFTQSYSLQLSNLKMEDTGSYRAQISTKTSAKLSSYTLRILRQLRNIQVTNHSQLFQNMTCELHLTCSVEDADDNVSFRWEALGNTLSSQPNLTVSWDPRISSEQDYTCIAENAVSNLSFSVSAQKLCEDVKIQYTDTKMILFMVSGICIVFGFIILLLLVLRKRRDSLSLSTQRTQGPAESARNLEYVSVSPTNNTVYASVTHSNRETEIWTPRENDTITIYSTINHSKESKPTFSRATALDNVV

T38187	TARGETID	T38187
T38187	FORMERID	TTDI02127
T38187	UNIPROID	MRGX2_HUMAN
T38187	TARGNAME	Mas-related gene 2 (MRGX2)
T38187	GENENAME	MRGPRX2
T38187	TARGTYPE	Literature-reported
T38187	SYNONYMS	Masrelated Gprotein coupled receptormember X2; MRGPRX2
T38187	FUNCTION	Mast cell-specific receptor for basic secretagogues (PubMed:25517090). Basic secretagogues are a set of cationic amphiphilic drugs, as well as endo- and exogenous peptides, which share basic head group combined with a hydrophobic core of the molecule. Recognizes and binds small molecules containing a cyclized a tetrahydroisoquinoline (THIQ), such as non-steroidal neuromuscular blocking drugs (NMBDs), including tubocurarine and atracurium. Mediates mast cell responsiveness and side effects of small-molecule therapeutic drugs by acting as a specific receptor for basic secretagogues drugs in mast cells: binding to drugs induces pseudo-allergic reactions characterized by histamine release, inflammation and airway contraction. Acts as a receptor for a number of ligands, including peptides: acts as a receptor of cortistatin-14, a regulator of sleep regulation locomotor activity, and cortical function (PubMed:12915402). Acts as a receptor for proadrenomedullin N- terminal peptides PAMP-12, and atlower extent PAMP-20 (PubMed:15823563). Acts as a receptor for antibacterial protein LL-37, promoting chemotaxis, degranulation and chemokine production in mast cells (PubMed:22069323). Acts as a receptor for PMX-53 peptide, a potent antagonist of C5AR1/CD88 (PubMed:21441599). Acts as a receptor for beta-defensins (PubMed:23698749). Acts as a receptor for complanadine A, an alkaloid (PubMed:24930830). {ECO:0000250|UniProtKB:Q3UG50, ECO:0000269|PubMed:15823563, ECO:0000269|PubMed:21441599, ECO:0000269|PubMed:22069323, ECO:0000269|PubMed:23698749, ECO:0000269|PubMed:24930830, ECO:0000269|PubMed:25517090, ECO:0000305|PubMed:12915402}.
T38187	BIOCLASS	GPCR rhodopsin
T38187	SEQUENCE	MDPTTPAWGTESTTVNGNDQALLLLCGKETLIPVFLILFIALVGLVGNGFVLWLLGFRMRRNAFSVYVLSLAGADFLFLCFQIINCLVYLSNFFCSISINFPSFFTTVMTCAYLAGLSMLSTVSTERCLSVLWPIWYRCRRPRHLSAVVCVLLWALSLLLSILEGKFCGFLFSDGDSGWCQTFDFITAAWLIFLFMVLCGSSLALLVRILCGSRGLPLTRLYLTILLTVLVFLLCGLPFGIQWFLILWIWKDSDVLFCHIHPVSVVLSSLNSSANPIIYFFVGSFRKQWRLQQPILKLALQRALQDIAEVDHSEGCFRQGTPEMSRSSLV

T43031	TARGETID	T43031
T43031	FORMERID	TTDI03400
T43031	UNIPROID	NEK1_HUMAN
T43031	TARGNAME	NIMA-related kinase 1 (NEK1)
T43031	GENENAME	NEK1
T43031	TARGTYPE	Literature-reported
T43031	SYNONYMS	Serine/threonine-protein kinase Nek1; Renal carcinoma antigen NY-REN-55; NimA-related protein kinase 1; Never in mitosis A-related kinase 1; KIAA1901
T43031	FUNCTION	Phosphorylates serines and threonines, but also appears to possess tyrosine kinase activity. Involved in DNA damage checkpoint control and for proper DNA damage repair. In response to injury that includes DNA damage, NEK1 phosphorylates VDAC1 to limit mitochondrial cell death. May be implicated in the control of meiosis (By similarity). Involved in cilium assembly.
T43031	PDBSTRUC	4B9D; 4APC
T43031	ECNUMBER	EC 2.7.11.1
T43031	SEQUENCE	MEKYVRLQKIGEGSFGKAILVKSTEDGRQYVIKEINISRMSSKEREESRREVAVLANMKHPNIVQYRESFEENGSLYIVMDYCEGGDLFKRINAQKGVLFQEDQILDWFVQICLALKHVHDRKILHRDIKSQNIFLTKDGTVQLGDFGIARVLNSTVELARTCIGTPYYLSPEICENKPYNNKSDIWALGCVLYELCTLKHAFEAGSMKNLVLKIISGSFPPVSLHYSYDLRSLVSQLFKRNPRDRPSVNSILEKGFIAKRIEKFLSPQLIAEEFCLKTFSKFGSQPIPAKRPASGQNSISVMPAQKITKPAAKYGIPLAYKKYGDKKLHEKKPLQKHKQAHQTPEKRVNTGEERRKISEEAARKRRLEFIEKEKKQKDQIISLMKAEQMKRQEKERLERINRAREQGWRNVLSAGGSGEVKAPFLGSGGTIAPSSFSSRGQYEHYHAIFDQMQQQRAEDNEAKWKREIYGRGLPERGILPGVRPGFPYGAAGHHHFPDADDIRKTLKRLKAVSKQANANRQKGQLAVERAKQVEEFLQRKREAMQNKARAEGHMVYLARLRQIRLQNFNERQQIKAKLRGEKKEANHSEGQEGSEEADMRRKKIESLKAHANARAAVLKEQLERKRKEAYEREKKVWEEHLVAKGVKSSDVSPPLGQHETGGSPSKQQMRSVISVTSALKEVGVDSSLTDTRETSEEMQKTNNAISSKREILRRLNENLKAQEDEKGKQNLSDTFEINVHEDAKEHEKEKSVSSDRKKWEAGGQLVIPLDELTLDTSFSTTERHTVGEVIKLGPNGSPRRAWGKSPTDSVLKILGEAELQLQTELLENTTIRSEISPEGEKYKPLITGEKKVQCISHEINPSAIVDSPVETKSPEFSEASPQMSLKLEGNLEEPDDLETEILQEPSGTNKDESLPCTITDVWISEEKETKETQSADRITIQENEVSEDGVSSTVDQLSDIHIEPGTNDSQHSKCDVDKSVQPEPFFHKVVHSEHLNLVPQVQSVQCSPEESFAFRSHSHLPPKNKNKNSLLIGLSTGLFDANNPKMLRTCSLPDLSKLFRTLMDVPTVGDVRQDNLEIDEIEDENIKEGPSDSEDIVFEETDTDLQELQASMEQLLREQPGEEYSEEEESVLKNSDVEPTANGTDVADEDDNPSSESALNEEWHSDNSDGEIASECECDSVFNHLEELRLHLEQEMGFEKFFEVYEKIKAIHEDEDENIEICSKIVQNILGNEHQHLYAKILHLVMADGAYQEDNDE
T43031	DRUGINFO	D0K0UJ	PMID20936789C31	Investigative

T11906	TARGETID	T11906
T11906	FORMERID	TTDI03597
T11906	UNIPROID	TRPM7_HUMAN
T11906	TARGNAME	Long transient receptor potential channel 7 (TRPM7)
T11906	GENENAME	TRPM7
T11906	TARGTYPE	Literature-reported
T11906	SYNONYMS	Transient receptor potential cation channel subfamily M member 7; LTrpC-7; LTRPC7; Channel-kinase 1; CHAK1
T11906	FUNCTION	Essential ion channel and serine/threonine-protein kinase. Divalent cation channel permeable to calcium and magnesium. Has a central role in magnesium ion homeostasis and in the regulation of anoxic neuronal cell death. Involved in TNF-induced necroptosis downstream of MLKL by mediating calcium influx. The kinase activity is essential for the channel function. May be involved in a fundamental process that adjusts plasma membrane divalent cation fluxes according to the metabolic state of the cell. Phosphorylates annexin A1 (ANXA1).
T11906	BIOCLASS	Transient receptor potential catioin channel
T11906	ECNUMBER	EC 2.7.11.1
T11906	SEQUENCE	MSQKSWIESTLTKRECVYIIPSSKDPHRCLPGCQICQQLVRCFCGRLVKQHACFTASLAMKYSDVKLGDHFNQAIEEWSVEKHTEQSPTDAYGVINFQGGSHSYRAKYVRLSYDTKPEVILQLLLKEWQMELPKLVISVHGGMQKFELHPRIKQLLGKGLIKAAVTTGAWILTGGVNTGVAKHVGDALKEHASRSSRKICTIGIAPWGVIENRNDLVGRDVVAPYQTLLNPLSKLNVLNNLHSHFILVDDGTVGKYGAEVRLRRELEKTINQQRIHARIGQGVPVVALIFEGGPNVILTVLEYLQESPPVPVVVCEGTGRAADLLAYIHKQTEEGGNLPDAAEPDIISTIKKTFNFGQNEALHLFQTLMECMKRKELITVFHIGSDEHQDIDVAILTALLKGTNASAFDQLILTLAWDRVDIAKNHVFVYGQQWLVGSLEQAMLDALVMDRVAFVKLLIENGVSMHKFLTIPRLEELYNTKQGPTNPMLFHLVRDVKQGNLPPGYKITLIDIGLVIEYLMGGTYRCTYTRKRFRLIYNSLGGNNRRSGRNTSSSTPQLRKSHESFGNRADKKEKMRHNHFIKTAQPYRPKIDTVMEEGKKKRTKDEIVDIDDPETKRFPYPLNELLIWACLMKRQVMARFLWQHGEESMAKALVACKIYRSMAYEAKQSDLVDDTSEELKQYSNDFGQLAVELLEQSFRQDETMAMKLLTYELKNWSNSTCLKLAVSSRLRPFVAHTCTQMLLSDMWMGRLNMRKNSWYKVILSILVPPAILLLEYKTKAEMSHIPQSQDAHQMTMDDSENNFQNITEEIPMEVFKEVRILDSNEGKNEMEIQMKSKKLPITRKFYAFYHAPIVKFWFNTLAYLGFLMLYTFVVLVQMEQLPSVQEWIVIAYIFTYAIEKVREIFMSEAGKVNQKIKVWFSDYFNISDTIAIISFFIGFGLRFGAKWNFANAYDNHVFVAGRLIYCLNIIFWYVRLLDFLAVNQQAGPYVMMIGKMVANMFYIVVIMALVLLSFGVPRKAILYPHEAPSWTLAKDIVFHPYWMIFGEVYAYEIDVCANDSVIPQICGPGTWLTPFLQAVYLFVQYIIMVNLLIAFFNNVYLQVKAISNIVWKYQRYHFIMAYHEKPVLPPPLIILSHIVSLFCCICKRRKKDKTSDGPKLFLTEEDQKKLHDFEEQCVEMYFNEKDDKFHSGSEERIRVTFERVEQMCIQIKEVGDRVNYIKRSLQSLDSQIGHLQDLSALTVDTLKTLTAQKASEASKVHNEITRELSISKHLAQNLIDDGPVRPSVWKKHGVVNTLSSSLPQGDLESNNPFHCNILMKDDKDPQCNIFGQDLPAVPQRKEFNFPEAGSSSGALFPSAVSPPELRQRLHGVELLKIFNKNQKLGSSSTSIPHLSSPPTKFFVSTPSQPSCKSHLETGTKDQETVCSKATEGDNTEFGAFVGHRDSMDLQRFKETSNKIKILSNNNTSENTLKRVSSLAGFTDCHRTSIPVHSKQAEKISRRPSTEDTHEVDSKAALIPDWLQDRPSNREMPSEEGTLNGLTSPFKPAMDTNYYYSAVERNNLMRLSQSIPFTPVPPRGEPVTVYRLEESSPNILNNSMSSWSQLGLCAKIEFLSKEEMGGGLRRAVKVQCTWSEHDILKSGHLYIIKSFLPEVVNTWSSIYKEDTVLHLCLREIQQQRAAQKLTFAFNQMKPKSIPYSPRFLEVFLLYCHSAGQWFAVEECMTGEFRKYNNNNGDEIIPTNTLEEIMLAFSHWTYEYTRGELLVLDLQGVGENLTDPSVIKAEEKRSCDMVFGPANLGEDAIKNFRAKHHCNSCCRKLKLPDLKRNDYTPDKIIFPQDEPSDLNLQPGNSTKESESTNSVRLML
T11906	DRUGINFO	D0T0JU	waixenicin A	Investigative
T11906	DRUGINFO	D07JDC	carvacrol	Investigative
T11906	DRUGINFO	D07ZAJ	PIP2	Investigative
T11906	DRUGINFO	D00HCI	2-APB	Investigative

T37371	TARGETID	T37371
T37371	FORMERID	TTDI03441
T37371	UNIPROID	PASK_HUMAN
T37371	TARGNAME	PAS domain-containing serine/threonine-protein kinase (PASK)
T37371	GENENAME	PASK
T37371	TARGTYPE	Literature-reported
T37371	SYNONYMS	hPASK; PASKIN; PAS-kinase; KIAA0135
T37371	FUNCTION	Serine/threonine-protein kinase involved in energy homeostasis and protein translation. Phosphorylates EEF1A1, GYS1, PDX1 and RPS6. Probably plays a role under changing environmental conditions (oxygen, glucose, nutrition), rather than under standard conditions. Acts as a sensor involved in energy homeostasis: regulates glycogen synthase synthesis by mediating phosphorylation of GYS1, leading to GYS1 inactivation. May be involved in glucose-stimulated insulin production in pancreas and regulation of glucagon secretion by glucose in alpha cells; however such data require additional evidences. May play a role in regulation of protein translation by phosphorylating EEF1A1, leading to increase translation efficiency. May also participate to respiratory regulation.
T37371	PDBSTRUC	3DLS; 1LL8
T37371	ECNUMBER	EC 2.7.11.1
T37371	SEQUENCE	MEDGGLTAFEEDQRCLSQSLPLPVSAEGPAAQTTAEPSRSFSSAHRHLSRRNGLSRLCQSRTALSEDRWSSYCLSSLAAQNICTSKLHCPAAPEHTDPSEPRGSVSCCSLLRGLSSGWSSPLLPAPVCNPNKAIFTVDAKTTEILVANDKACGLLGYSSQDLIGQKLTQFFLRSDSDVVEALSEEHMEADGHAAVVFGTVVDIISRSGEKIPVSVWMKRMRQERRLCCVVVLEPVERVSTWVAFQSDGTVTSCDSLFAHLHGYVSGEDVAGQHITDLIPSVQLPPSGQHIPKNLKIQRSVGRARDGTTFPLSLKLKSQPSSEEATTGEAAPVSGYRASVWVFCTISGLITLLPDGTIHGINHSFALTLFGYGKTELLGKNITFLIPGFYSYMDLAYNSSLQLPDLASCLDVGNESGCGERTLDPWQGQDPAEGGQDPRINVVLAGGHVVPRDEIRKLMESQDIFTGTQTELIAGGQLLSCLSPQPAPGVDNVPEGSLPVHGEQALPKDQQITALGREEPVAIESPGQDLLGESRSEPVDVKPFASCEDSEAPVPAEDGGSDAGMCGLCQKAQLERMGVSGPSGSDLWAGAAVAKPQAKGQLAGGSLLMHCPCYGSEWGLWWRSQDLAPSPSGMAGLSFGTPTLDEPWLGVENDREELQTCLIKEQLSQLSLAGALDVPHAELVPTECQAVTAPVSSCDLGGRDLCGGCTGSSSACYALATDLPGGLEAVEAQEVDVNSFSWNLKELFFSDQTDQTSSNCSCATSELRETPSSLAVGSDPDVGSLQEQGSCVLDDRELLLLTGTCVDLGQGRRFRESCVGHDPTEPLEVCLVSSEHYAASDRESPGHVPSTLDAGPEDTCPSAEEPRLNVQVTSTPVIVMRGAAGLQREIQEGAYSGSCYHRDGLRLSIQFEVRRVELQGPTPLFCCWLVKDLLHSQRDSAARTRLFLASLPGSTHSTAAELTGPSLVEVLRARPWFEEPPKAVELEGLAACEGEYSQKYSTMSPLGSGAFGFVWTAVDKEKNKEVVVKFIKKEKVLEDCWIEDPKLGKVTLEIAILSRVEHANIIKVLDIFENQGFFQLVMEKHGSGLDLFAFIDRHPRLDEPLASYIFRQLVSAVGYLRLKDIIHRDIKDENIVIAEDFTIKLIDFGSAAYLERGKLFYTFCGTIEYCAPEVLMGNPYRGPELEMWSLGVTLYTLVFEENPFCELEETVEAAIHPPYLVSKELMSLVSGLLQPVPERRTTLEKLVTDPWVTQPVNLADYTWEEVFRVNKPESGVLSAASLEMGNRSLSDVAQAQELCGGPVPGEAPNGQGCLHPGDPRLLTS
T37371	DRUGINFO	D0H2CM	PP-242	Investigative

T87448	TARGETID	T87448
T87448	FORMERID	TTDI02478
T87448	UNIPROID	NODAL_HUMAN
T87448	TARGNAME	Nodal homolog (NODAL)
T87448	GENENAME	NODAL
T87448	TARGTYPE	Literature-reported
T87448	SYNONYMS	nodal growth differentiation factor; HTX5
T87448	FUNCTION	Essential for mesoderm formation and axial patterning during embryonic development.
T87448	PDBSTRUC	4N1D
T87448	BIOCLASS	Growth factor
T87448	SEQUENCE	MHAHCLPFLLHAWWALLQAGAATVATALLRTRGQPSSPSPLAYMLSLYRDPLPRADIIRSLQAEDVAVDGQNWTFAFDFSFLSQQEDLAWAELRLQLSSPVDLPTEGSLAIEIFHQPKPDTEQASDSCLERFQMDLFTVTLSQVTFSLGSMVLEVTRPLSKWLKHPGALEKQMSRVAGECWPRPPTPPATNVLLMLYSNLSQEQRQLGGSTLLWEAESSWRAQEGQLSWEWGKRHRRHHLPDRSQLCRKVKFQVDFNLIGWGSWIIYPKQYNAYRCEGECPNPVGEEFHPTNHAYIQSLLKRYQPHRVPSTCCAPVKTKPLSMLYVDNGRVLLDHHKDMIVEECGCL

T29678	TARGETID	T29678
T29678	FORMERID	TTDI01968
T29678	UNIPROID	SCN2A_HUMAN
T29678	TARGNAME	Voltage-gated sodium channel alpha Nav1.2 (SCN2A)
T29678	GENENAME	SCN2A
T29678	TARGTYPE	Literature-reported
T29678	SYNONYMS	Voltage-gated sodium channelsubunit alpha Nav1.2; Sodium channel protein type II subunit alpha; Sodium channel protein brainII subunit alpha; SCN2A; HBSC II
T29678	FUNCTION	Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient.
T29678	PDBSTRUC	6J8E; 4RLY; 4JPZ; 2KAV
T29678	BIOCLASS	Voltage-gated ion channel
T29678	SEQUENCE	MAQSVLVPPGPDSFRFFTRESLAAIEQRIAEEKAKRPKQERKDEDDENGPKPNSDLEAGKSLPFIYGDIPPEMVSVPLEDLDPYYINKKTFIVLNKGKAISRFSATPALYILTPFNPIRKLAIKILVHSLFNMLIMCTILTNCVFMTMSNPPDWTKNVEYTFTGIYTFESLIKILARGFCLEDFTFLRDPWNWLDFTVITFAYVTEFVDLGNVSALRTFRVLRALKTISVIPGLKTIVGALIQSVKKLSDVMILTVFCLSVFALIGLQLFMGNLRNKCLQWPPDNSSFEINITSFFNNSLDGNGTTFNRTVSIFNWDEYIEDKSHFYFLEGQNDALLCGNSSDAGQCPEGYICVKAGRNPNYGYTSFDTFSWAFLSLFRLMTQDFWENLYQLTLRAAGKTYMIFFVLVIFLGSFYLINLILAVVAMAYEEQNQATLEEAEQKEAEFQQMLEQLKKQQEEAQAAAAAASAESRDFSGAGGIGVFSESSSVASKLSSKSEKELKNRRKKKKQKEQSGEEEKNDRVRKSESEDSIRRKGFRFSLEGSRLTYEKRFSSPHQSLLSIRGSLFSPRRNSRASLFSFRGRAKDIGSENDFADDEHSTFEDNDSRRDSLFVPHRHGERRHSNVSQASRASRVLPILPMNGKMHSAVDCNGVVSLVGGPSTLTSAGQLLPEGTTTETEIRKRRSSSYHVSMDLLEDPTSRQRAMSIASILTNTMEELEESRQKCPPCWYKFANMCLIWDCCKPWLKVKHLVNLVVMDPFVDLAITICIVLNTLFMAMEHYPMTEQFSSVLSVGNLVFTGIFTAEMFLKIIAMDPYYYFQEGWNIFDGFIVSLSLMELGLANVEGLSVLRSFRLLRVFKLAKSWPTLNMLIKIIGNSVGALGNLTLVLAIIVFIFAVVGMQLFGKSYKECVCKISNDCELPRWHMHDFFHSFLIVFRVLCGEWIETMWDCMEVAGQTMCLTVFMMVMVIGNLVVLNLFLALLLSSFSSDNLAATDDDNEMNNLQIAVGRMQKGIDFVKRKIREFIQKAFVRKQKALDEIKPLEDLNNKKDSCISNHTTIEIGKDLNYLKDGNGTTSGIGSSVEKYVVDESDYMSFINNPSLTVTVPIAVGESDFENLNTEEFSSESDMEESKEKLNATSSSEGSTVDIGAPAEGEQPEVEPEESLEPEACFTEDCVRKFKCCQISIEEGKGKLWWNLRKTCYKIVEHNWFETFIVFMILLSSGALAFEDIYIEQRKTIKTMLEYADKVFTYIFILEMLLKWVAYGFQVYFTNAWCWLDFLIVDVSLVSLTANALGYSELGAIKSLRTLRALRPLRALSRFEGMRVVVNALLGAIPSIMNVLLVCLIFWLIFSIMGVNLFAGKFYHCINYTTGEMFDVSVVNNYSECKALIESNQTARWKNVKVNFDNVGLGYLSLLQVATFKGWMDIMYAAVDSRNVELQPKYEDNLYMYLYFVIFIIFGSFFTLNLFIGVIIDNFNQQKKKFGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPANKFQGMVFDFVTKQVFDISIMILICLNMVTMMVETDDQSQEMTNILYWINLVFIVLFTGECVLKLISLRYYYFTIGWNIFDFVVVILSIVGMFLAELIEKYFVSPTLFRVIRLARIGRILRLIKGAKGIRTLLFALMMSLPALFNIGLLLFLVMFIYAIFGMSNFAYVKREVGIDDMFNFETFGNSMICLFQITTSAGWDGLLAPILNSGPPDCDPDKDHPGSSVKGDCGNPSVGIFFFVSYIIISFLVVVNMYIAVILENFSVATEESAEPLSEDDFEMFYEVWEKFDPDATQFIEFAKLSDFADALDPPLLIAKPNKVQLIAMDLPMVSGDRIHCLDILFAFTKRVLGESGEMDALRIQMEERFMASNPSKVSYEPITTTLKRKQEEVSAIIIQRAYRRYLLKQKVKKVSSIYKKDKGKECDGTPIKEDTLIDKLNENSTPEKTDMTPSTTSPPSYDSVTKPEKEKFEKDKSEKEDKGKDIRESKK
T29678	DRUGINFO	D0A1MW	aconitine	Investigative
T29678	DRUGINFO	D0G9WE	batrachotoxin	Investigative
T29678	DRUGINFO	D0S4MN	veratridine	Investigative

T05739	TARGETID	T05739
T05739	FORMERID	TTDNC00444
T05739	UNIPROID	PLCA_HUMAN
T05739	TARGNAME	Lysophosphatidic acid transferase (AGPAT1)
T05739	GENENAME	AGPAT1
T05739	TARGTYPE	Literature-reported
T05739	SYNONYMS	Protein G15; AGPAT1; 1acylsnglycerol3phosphate acyltransferase alpha; 1acylglycerol3phosphate Oacyltransferase 1; 1AGPAT 1; 1AGP acyltransferase 1
T05739	FUNCTION	Converts lysophosphatidic acid (LPA) into phosphatidic acid by incorporating an acyl moiety at the sn-2 position of the glycerol backbone.
T05739	BIOCLASS	Acyltransferase
T05739	ECNUMBER	EC 2.3.1.51
T05739	SEQUENCE	MDLWPGAWMLLLLLFLLLLFLLPTLWFCSPSAKYFFKMAFYNGWILFLAVLAIPVCAVRGRNVENMKILRLMLLHIKYLYGIRVEVRGAHHFPPSQPYVVVSNHQSSLDLLGMMEVLPGRCVPIAKRELLWAGSAGLACWLAGVIFIDRKRTGDAISVMSEVAQTLLTQDVRVWVFPEGTRNHNGSMLPFKRGAFHLAVQAQVPIVPIVMSSYQDFYCKKERRFTSGQCQVRVLPPVPTEGLTPDDVPALADRVRHSMLTVFREISTDGRGGGDYLKKPGGGG

T93263	TARGETID	T93263
T93263	UNIPROID	SH3G1_HUMAN
T93263	TARGNAME	Endophilin-A2 (SH3GL1)
T93263	GENENAME	SH3GL1
T93263	TARGTYPE	Literature-reported
T93263	SYNONYMS	SH3D2B; SH3 domain-containing GRB2-like protein 1; SH3 domain protein 2B; Extra eleven-nineteen leukemia fusion gene protein; Endophilin-2; EEN fusion partner of MLL; EEN; CNSA1
T93263	FUNCTION	Implicated in endocytosis. May recruit other proteins to membranes with high curvature.
T93263	BIOCLASS	Endophilin family
T93263	SEQUENCE	MSVAGLKKQFYKASQLVSEKVGGAEGTKLDDDFKEMEKKVDVTSKAVTEVLARTIEYLQPNPASRAKLTMLNTVSKIRGQVKNPGYPQSEGLLGECMIRHGKELGGESNFGDALLDAGESMKRLAEVKDSLDIEVKQNFIDPLQNLCEKDLKEIQHHLKKLEGRRLDFDYKKKRQGKIPDEELRQALEKFEESKEVAETSMHNLLETDIEQVSQLSALVDAQLDYHRQAVQILDELAEKLKRRMREASSRPKREYKPKPREPFDLGEPEQSNGGFPCTTAPKIAASSSFRSSDKPIRTPSRSMPPLDQPSCKALYDFEPENDGELGFHEGDVITLTNQIDENWYEGMLDGQSGFFPLSYVEVLVPLPQ

T22769	TARGETID	T22769
T22769	FORMERID	TTDC00055
T22769	UNIPROID	TEP1_HUMAN
T22769	TARGNAME	Telomerase protein component 1 (TEP1)
T22769	GENENAME	TEP1
T22769	TARGTYPE	Literature-reported
T22769	SYNONYMS	p80 telomerase homolog; p240; Telomerase-associated protein 1; Telomerase protein 1; TP1; TLP1
T22769	FUNCTION	Component of the ribonucleoprotein vaults particle, a multi-subunit structure involved in nucleo-cytoplasmic transport. Responsible for the localizing and stabilizing vault RNA (vRNA) association in the vault ribonucleoprotein particle. Binds to TERC. Component of the telomerase ribonucleoprotein complex that is essential for the replication of chromosome termini.
T22769	SEQUENCE	MEKLHGHVSAHPDILSLENRCLAMLPDLQPLEKLHQHVSTHSDILSLKNQCLATLPDLKTMEKPHGYVSAHPDILSLENQCLATLSDLKTMEKPHGHVSAHPDILSLENRCLATLSSLKSTVSASPLFQSLQISHMTQADLYRVNNSNCLLSEPPSWRAQHFSKGLDLSTCPIALKSISATETAQEATLGRWFDSEEKKGAETQMPSYSLSLGEEEEVEDLAVKLTSGDSESHPEPTDHVLQEKKMALLSLLCSTLVSEVNMNNTSDPTLAAIFEICRELALLEPEFILKASLYARQQLNVRNVANNILAIAAFLPACRPHLRRYFCAIVQLPSDWIQVAELYQSLAEGDKNKLVPLPACLRTAMTDKFAQFDEYQLAKYNPRKHRAKRHPRRPPRSPGMEPPFSHRCFPRYIGFLREEQRKFEKAGDTVSEKKNPPRFTLKKLVQRLHIHKPAQHVQALLGYRYPSNLQLFSRSRLPGPWDSSRAGKRMKLSRPETWERELSLRGNKASVWEELIENGKLPFMAMLRNLCNLLRVGISSRHHELILQRLQHAKSVIHSRQFPFRFLNAHDAIDALEAQLRNQALPFPSNITLMRRILTRNEKNRPRRRFLCHLSRQQLRMAMRIPVLYEQLKREKLRVHKARQWKYDGEMLNRYRQALETAVNLSVKHSLPLLPGRTVLVYLTDANADRLCPKSNPQGPPLNYALLLIGMMITRAEQVDVVLCGGDTLKTAVLKAEEGILKTAIKLQAQVQEFDENDGWSLNTFGKYLLSLAGQRVPVDRVILLGQSMDDGMINVAKQLYWQRVNSKCLFVGILLRRVQYLSTDLNPNDVTLSGCTDAILKFIAEHGASHLLEHVGQMDKIFKIPPPPGKTGVQSLRPLEEDTPSPLAPVSQQGWRSIRLFISSTFRDMHGERDLLLRSVLPALQARAAPHRISLHGIDLRWGVTEEETRRNRQLEVCLGEVENAQLFVGILGSRYGYIPPSYNLPDHPHFHWAQQYPSGRSVTEMEVMQFLNRNQRLQPSAQALIYFRDSSFLSSVPDAWKSDFVSESEEAARRISELKSYLSRQKGITCRRYPCEWGGVAAGRPYVGGLEEFGQLVLQDVWNMIQKLYLQPGALLEQPVSIPDDDLVQATFQQLQKPPSPARPRLLQDTVQRLMLPHGRLSLVTGQSGQGKTAFLASLVSALQAPDGAKVASLVFFHFSGARPDQGLALTLLRRLCTYLRGQLKEPGALPSTYRSLVWELQQRLLPKSAESLHPGQTQVLIIDGADRLVDQNGQLISDWIPKKLPRCVHLVLSVSSDAGLGETLEQSQGAHVLALGPLEASARARLVREELALYGKRLEESPFNNQMRLLLVKRESGRPLYLRLVTDHLRLFTLYEQVSERLRTLPATVPLLLQHILSTLEKEHGPDVLPQALTALEVTRSGLTVDQLHGVLSVWRTLPKGTKSWEEAVAAGNSGDPYPMGPFACLVQSLRSLLGEGPLERPGARLCLPDGPLRTAAKRCYGKRPGLEDTAHILIAAQLWKTCDADASGTFRSCPPEALGDLPYHLLQSGNRGLLSKFLTNLHVVAAHLELGLVSRLLEAHALYASSVPKEEQKLPEADVAVFRTFLRQQASILSQYPRLLPQQAANQPLDSPLCHQASLLSRRWHLQHTLRWLNKPRTMKNQQSSSLSLAVSSSPTAVAFSTNGQRAAVGTANGTVYLLDLRTWQEEKSVVSGCDGISACLFLSDDTLFLTAFDGLLELWDLQHGCRVLQTKAHQYQITGCCLSPDCRLLATVCLGGCLKLWDTVRGQLAFQHTYPKSLNCVAFHPEGQVIATGSWAGSISFFQVDGLKVTKDLGAPGASIRTLAFNVPGGVVAVGRLDSMVELWAWREGARLAAFPAHHGFVAAALFLHAGCQLLTAGEDGKVQVWSGSLGRPRGHLGSLSLSPALSVALSPDGDRVAVGYRADGIRIYKISSGSQGAQGQALDVAVSALAWLSPKVLVSGAEDGSLQGWALKECSLQSLWLLSRFQKPVLGLATSQELLASASEDFTVQLWPRQLLTRPHKAEDFPCGTELRGHEGPVSCCSFSTDGGSLATGGRDRSLLCWDVRTPKTPVLIHSFPACHRDWVTGCAWTKDNLLISCSSDGSVGLWDPESGQRLGQFLGHQSAVSAVAAVEEHVVSVSRDGTLKVWDHQGVELTSIPAHSGPISHCAAAMEPRAAGQPGSELLVVTVGLDGATRLWHPLLVCQTHTLLGHSGPVRAAAVSETSGLMLTASEDGSVRLWQVPKEADDTCIPRSSAAVTAVAWAPDGSMAVSGNQAGELILWQEAKAVATAQAPGHIGALIWSSAHTFFVLSADEKISEWQVKLRKGSAPGNLSLHLNRILQEDLGVLTSLDWAPDGHFLILAKADLKLLCMKPGDAPSEIWSSYTENPMILSTHKEYGIFVLQPKDPGVLSFLRQKESGEFEERLNFDINLENPSRTLISITQAKPESESSFLCASSDGILWNLAKCSPEGEWTTGNMWQKKANTPETQTPGTDPSTCRESDASMDSDASMDSEPTPHLKTRQRRKIHSGSVTALHVLPELLVTASKDRDVKLWERPSMQLLGLFRCEGSVSCLEPWLGANSTLQLAVGDVQGNVYFLNWE

T32498	TARGETID	T32498
T32498	FORMERID	TTDR00044
T32498	UNIPROID	Q9BLW4_LEIME
T32498	TARGNAME	Leishmania GDP-mannose pyrophosphorylase (Leishm exgmp)
T32498	GENENAME	Leishm exgmp
T32498	TARGTYPE	Literature-reported
T32498	SYNONYMS	GDP-mannose pyrophosphorylase
T32498	FUNCTION	Assembles as a hexamer of 240 kDa in several Leishmania species. Critical for cell integrity and survival.
T32498	BIOCLASS	Transferases of phosphorus-containing groups
T32498	ECNUMBER	EC 2.7.7.22
T32498	SEQUENCE	MSASDGQGMRAVILVGGFGTRLRPLTLTTPKPLVPFCNKPMIIHQIEALKAVGVTEVILAVAYRPEAMKEQMDEWSRKLGVSFVFSVEEDPLGTAGPLALARDILMQDDKPFFVLNSDVTCMFPLQELLDFHKARGGEGTIMVSQVTQWEKYGVVVYSQQSYQIERFVEKPSSFLGDRVNAGIYIFNKSILDRIPPCRTSIEKEIFPAMAAEGELYAFNLEGFWMDVGQPKDYILGMTKFIPSLLDGDRKTEQLHTEATEHQHGGRFTVVGASLIDPSAKIGDGAVIGPCASIGANCVIGESCRIDNAAILENSKVGKGTMVSRSIVGWNNRIGSWCHIEDISVLGDDVEVKDGVVLIGTKVLPNKDVGEHHFQAGIIM

T95033	TARGETID	T95033
T95033	UNIPROID	HTAI2_HUMAN
T95033	TARGNAME	Oxidoreductase HTATIP2 (HTATIP2)
T95033	GENENAME	HTATIP2
T95033	TARGTYPE	Literature-reported
T95033	SYNONYMS	HIV-1 TAT-interactive protein 2; 30 kDa HIV-1 TAT-interacting protein
T95033	FUNCTION	Oxidoreductase required for tumor suppression. NAPDH-bound form inhibits nuclear import by competing with nuclear import substrates for binding to a subset of nuclear transport receptors. May act as a redox sensor linked to transcription through regulation of nuclear import. Isoform 1 is a metastasis suppressor with proapoptotic as well as antiangiogenic properties. Isoform 2 has an antiapoptotic effect.
T95033	PDBSTRUC	2BKA
T95033	ECNUMBER	EC 1.1.1.-
T95033	SEQUENCE	MAETEALSKLREDFRMQNKSVFILGASGETGRVLLKEILEQGLFSKVTLIGRRKLTFDEEAYKNVNQEVVDFEKLDDYASAFQGHDVGFCCLGTTRGKAGAEGFVRVDRDYVLKSAELAKAGGCKHFNLLSSKGADKSSNFLYLQVKGEVEAKVEELKFDRYSVFRPGVLLCDRQESRPGEWLVRKFFGSLPDSWASGHSVPVVTVVRAMLNNVVRPRDKQMELLENKAIHDLGKAHGSLKP

T22335	TARGETID	T22335
T22335	FORMERID	TTDR01213
T22335	UNIPROID	FANCJ_HUMAN
T22335	TARGNAME	BRCA1-associated C-terminal helicase 1 (FANCJ)
T22335	GENENAME	BRIP1
T22335	TARGTYPE	Literature-reported
T22335	SYNONYMS	Protein FACJ; Fanconi anemia group J protein; FANCJ; BRCA1-interacting protein C-terminal helicase 1; BRCA1-interacting protein 1; BACH1; ATP-dependent RNA helicase BRIP1
T22335	FUNCTION	DNA-dependent ATPase and 5' to 3' DNA helicase required for the maintenance of chromosomal stability. Acts late in the Fanconi anemia pathway, after FANCD2 ubiquitination. Involved in the repair of DNA double-strand breaks by homologous recombination in a manner that depends on its association with BRCA1.
T22335	PDBSTRUC	3AL3; 1T29; 1T15
T22335	ECNUMBER	EC 3.6.4.13
T22335	SEQUENCE	MSSMWSEYTIGGVKIYFPYKAYPSQLAMMNSILRGLNSKQHCLLESPTGSGKSLALLCSALAWQQSLSGKPADEGVSEKAEVQLSCCCACHSKDFTNNDMNQGTSRHFNYPSTPPSERNGTSSTCQDSPEKTTLAAKLSAKKQASIYRDENDDFQVEKKRIRPLETTQQIRKRHCFGTEVHNLDAKVDSGKTVKLNSPLEKINSFSPQKPPGHCSRCCCSTKQGNSQESSNTIKKDHTGKSKIPKIYFGTRTHKQIAQITRELRRTAYSGVPMTILSSRDHTCVHPEVVGNFNRNEKCMELLDGKNGKSCYFYHGVHKISDQHTLQTFQGMCKAWDIEELVSLGKKLKACPYYTARELIQDADIIFCPYNYLLDAQIRESMDLNLKEQVVILDEAHNIEDCARESASYSVTEVQLRFARDELDSMVNNNIRKKDHEPLRAVCCSLINWLEANAEYLVERDYESACKIWSGNEMLLTLHKMGITTATFPILQGHFSAVLQKEEKISPIYGKEEAREVPVISASTQIMLKGLFMVLDYLFRQNSRFADDYKIAIQQTYSWTNQIDISDKNGLLVLPKNKKRSRQKTAVHVLNFWCLNPAVAFSDINGKVQTIVLTSGTLSPMKSFSSELGVTFTIQLEANHIIKNSQVWVGTIGSGPKGRNLCATFQNTETFEFQDEVGALLLSVCQTVSQGILCFLPSYKLLEKLKERWLSTGLWHNLELVKTVIVEPQGGEKTNFDELLQVYYDAIKYKGEKDGALLVAVCRGKVSEGLDFSDDNARAVITIGIPFPNVKDLQVELKRQYNDHHSKLRGLLPGRQWYEIQAYRALNQALGRCIRHRNDWGALILVDDRFRNNPSRYISGLSKWVRQQIQHHSTFESALESLAEFSKKHQKVLNVSIKDRTNIQDNESTLEVTSLKYSTSPYLLEAASHLSPENFVEDEAKICVQELQCPKIITKNSPLPSSIISRKEKNDPVFLEEAGKAEKIVISRSTSPTFNKQTKRVSWSSFNSLGQYFTGKIPKATPELGSSENSASSPPRFKTEKMESKTVLPFTDKCESSNLTVNTSFGSCPQSETIISSLKIDATLTRKNHSEHPLCSEEALDPDIELSLVSEEDKQSTSNRDFETEAEDESIYFTPELYDPEDTDEEKNDLAETDRGNRLANNSDCILAKDLFEIRTIKEVDSAREVKAEDCIDTKLNGILHIEESKIDDIDGNVKTTWINELELGKTHEIEIKNFKPSPSKNKGMFPGFK

T61029	TARGETID	T61029
T61029	FORMERID	TTDI03596
T61029	UNIPROID	TRPM6_HUMAN
T61029	TARGNAME	Long transient receptor potential channel 6 (TRPM6)
T61029	GENENAME	TRPM6
T61029	TARGTYPE	Literature-reported
T61029	SYNONYMS	Transient receptor potential cation channel subfamily M member 6; Melastatin-related TRP cation channel 6; Channel kinase 2; CHAK2
T61029	FUNCTION	Essential ion channel and serine/threonine-protein kinase. Crucial for magnesium homeostasis. Has an important role in epithelial magnesium transport and in the active magnesium absorption in the gut and kidney. Isoforms of the type M6-kinase lack the ion channel region.
T61029	BIOCLASS	Transient receptor potential catioin channel
T61029	ECNUMBER	EC 2.7.11.1
T61029	SEQUENCE	MKEQPVLERLQSQKSWIKGVFDKRECSTIIPSSKNPHRCTPVCQVCQNLIRCYCGRLIGDHAGIDYSWTISAAKGKESEQWSVEKHTTKSPTDTFGTINFQDGEHTHHAKYIRTSYDTKLDHLLHLMLKEWKMELPKLVISVHGGIQNFTMPSKFKEIFSQGLVKAAETTGAWIITEGINTGVSKHVGDALKSHSSHSLRKIWTVGIPPWGVIENQRDLIGKDVVCLYQTLDNPLSKLTTLNSMHSHFILSDDGTVGKYGNEMKLRRNLEKYLSLQKIHCRSRQGVPVVGLVVEGGPNVILSVWETVKDKDPVVVCEGTGRAADLLAFTHKHLADEGMLRPQVKEEIICMIQNTFNFSLKQSKHLFQILMECMVHRDCITIFDADSEEQQDLDLAILTALLKGTNLSASEQLNLAMAWDRVDIAKKHILIYEQHWKPDALEQAMSDALVMDRVDFVKLLIEYGVNLHRFLTIPRLEELYNTKQGPTNTLLHHLVQDVKQHTLLSGYRITLIDIGLVVEYLIGRAYRSNYTRKHFRALYNNLYRKYKHQRHSSGNRNESAESTLHSQFIRTAQPYKFKEKSIVLHKSRKKSKEQNVSDDPESTGFLYPYNDLLVWAVLMKRQKMAMFFWQHGEEATVKAVIACILYRAMAHEAKESHMVDDASEELKNYSKQFGQLALDLLEKAFKQNERMAMTLLTYELRNWSNSTCLKLAVSGGLRPFVSHTCTQMLLTDMWMGRLKMRKNSWLKIIISIILPPTILTLEFKSKAEMSHVPQSQDFQFMWYYSDQNASSSKESASVKEYDLERGHDEKLDENQHFGLESGHQHLPWTRKVYEFYSAPIVKFWFYTMAYLAFLMLFTYTVLVEMQPQPSVQEWLVSIYIFTNAIEVVREICISEPGKFTQKVKVWISEYWNLTETVAIGLFSAGFVLRWGDPPFHTAGRLIYCIDIIFWFSRLLDFFAVNQHAGPYVTMIAKMTANMFYIVIIMAIVLLSFGVARKAILSPKEPPSWSLARDIVFEPYWMIYGEVYAGEIDVCSSQPSCPPGSFLTPFLQAVYLFVQYIIMVNLLIAFFNNVYLDMESISNNLWKYNRYRYIMTYHEKPWLPPPLILLSHVGLLLRRLCCHRAPHDQEEGDVGLKLYLSKEDLKKLHDFEEQCVEKYFHEKMEDVNCSCEERIRVTSERVTEMYFQLKEMNEKVSFIKDSLLSLDSQVGHLQDLSALTVDTLKVLSAVDTLQEDEALLAKRKHSTCKKLPHSWSNVICAEVLGSMEIAGEKKYQYYSMPSSLLRSLAGGRHPPRVQRGALLEITNSKREATNVRNDQERQETQSSIVVSGVSPNRQAHSKYGQFLLVPSNLKRVPFSAETVLPLSRPSVPDVLATEQDIQTEVLVHLTGQTPVVSDWASVDEPKEKHEPIAHLLDGQDKAEQVLPTLSCTPEPMTMSSPLSQAKIMQTGGGYVNWAFSEGDETGVFSIKKKWQTCLPSTCDSDSSRSEQHQKQAQDSSLSDNSTRSAQSSECSEVGPWLQPNTSFWINPLRRYRPFARSHSFRFHKEEKLMKICKIKNLSGSSEIGQGAWVKAKMLTKDRRLSKKKKNTQGLQVPIITVNACSQSDQLNPEPGENSISEEEYSKNWFTVSKFSHTGVEPYIHQKMKTKEIGQCAIQISDYLKQSQEDLSKNSLWNSRSTNLNRNSLLKSSIGVDKISASLKSPQEPHHHYSAIERNNLMRLSQTIPFTPVQLFAGEEITVYRLEESSPLNLDKSMSSWSQRGRAAMIQVLSREEMDGGLRKAMRVVSTWSEDDILKPGQVFIVKSFLPEVVRTWHKIFQESTVLHLCLREIQQQRAAQKLIYTFNQVKPQTIPYTPRFLEVFLIYCHSANQWLTIEKYMTGEFRKYNNNNGDEITPTNTLEELMLAFSHWTYEYTRGELLVLDLQGVGENLTDPSVIKPEVKQSRGMVFGPANLGEDAIRNFIAKHHCNSCCRKLKLPDLKRNDYSPERINSTFGLEIKIESAEEPPARETGRNSPEDDMQL
T61029	DRUGINFO	D00HCI	2-APB	Investigative

T42014	TARGETID	T42014
T42014	FORMERID	TTDI02608
T42014	UNIPROID	SGPP1_HUMAN
T42014	TARGNAME	Sphingosine-1-phosphate phosphatase 1 (SGPP1)
T42014	GENENAME	SGPP1
T42014	TARGTYPE	Literature-reported
T42014	SYNONYMS	hSPPase1; hSPP1; Spp1; Sphingosine-1-phosphatase 1; SPPase1; SGPP1
T42014	FUNCTION	Has enzymatic activity against both sphingosine 1- phosphate (S1P) and dihydro-S1P. Regulates intracellular and extracellular S1P levels.
T42014	BIOCLASS	Phosphoric monoester hydrolase
T42014	ECNUMBER	EC 3.1.3.-
T42014	SEQUENCE	MSLRQRLAQLVGRLQDPQKVARFQRLCGVEAPPRRSADRREDEKAEAPLAGDPRLRGRQPGAPGGPQPPGSDRNQCPAKPDGGGAPNGVRNGLAAELGPASPRRAGALRRNSLTGEEGQLARVSNWPLYCLFCFGTELGNELFYILFFPFWIWNLDPLVGRRLVVIWVLVMYLGQCTKDIIRWPRPASPPVVKLEVFYNSEYSMPSTHAMSGTAIPISMVLLTYGRWQYPLIYGLILIPCWCSLVCLSRIYMGMHSILDIIAGFLYTILILAVFYPFVDLIDNFNQTHKYAPFIIIGLHLALGIFSFTLDTWSTSRGDTAEILGSGAGIACGSHVTYNMGLVLDPSLDTLPLAGPPITVTLFGKAILRILIGMVFVLIIRDVMKKITIPLACKIFNIPCDDIRKARQHMEVELPYRYITYGMVGFSITFFVPYIFFFIGIS

T56272	TARGETID	T56272
T56272	FORMERID	TTDI02516
T56272	UNIPROID	HCAR1_HUMAN
T56272	TARGNAME	G protein coupled receptor 81 (HCAR1)
T56272	GENENAME	HCAR1
T56272	TARGTYPE	Literature-reported
T56272	SYNONYMS	Hydroxycarboxylic acid receptor 1; HCAR1; Gprotein coupled receptor 81; Gprotein coupled receptor 104
T56272	FUNCTION	Acts as a receptor for L-lactate and mediates its anti- lipolytic effect through a G(i)-protein-mediated pathway.
T56272	BIOCLASS	GPCR rhodopsin
T56272	SEQUENCE	MYNGSCCRIEGDTISQVMPPLLIVAFVLGALGNGVALCGFCFHMKTWKPSTVYLFNLAVADFLLMICLPFRTDYYLRRRHWAFGDIPCRVGLFTLAMNRAGSIVFLTVVAADRYFKVVHPHHAVNTISTRVAAGIVCTLWALVILGTVYLLLENHLCVQETAVSCESFIMESANGWHDIMFQLEFFMPLGIILFCSFKIVWSLRRRQQLARQARMKKATRFIMVVAIVFITCYLPSVSARLYFLWTVPSSACDPSVHGALHITLSFTYMNSMLDPLVYYFSSPSFPKFYNKLKICSLKPKQPGHSKTQRPEEMPISNLGRRSCISVANSFQSQSDGQWDPHIVEWH
T56272	DRUGINFO	D06FZS	L-lactic acid	Investigative
T56272	DRUGINFO	D0DA9T	D-lactic acid	Investigative
T56272	DRUGINFO	D0W1OR	3,5-dihydroxybenzoic acid	Investigative

T21460	TARGETID	T21460
T21460	FORMERID	TTDI02392
T21460	UNIPROID	BBC3_HUMAN
T21460	TARGNAME	Bcl-2-binding component 3 (BBC3)
T21460	GENENAME	BBC3
T21460	TARGTYPE	Literature-reported
T21460	SYNONYMS	p53 upregulated modulator of apoptosis; p53 up-regulated modulator of apoptosis; PUMA; JFY1; JFY-1; Bcl2binding component 3
T21460	FUNCTION	Functions by promoting partial unfolding of BCL2L1 and dissociation of BCL2L1 from p53/TP53. Regulates ER stress-induced neuronal apoptosis. Essential mediator of p53/TP53-dependent and p53/TP53-independent apoptosis.
T21460	PDBSTRUC	5UUL; 4HNJ; 4BPK; 4BPJ; 4BPI
T21460	BIOCLASS	B-cell lymphoma Bcl-2
T21460	SEQUENCE	MARARQEGSSPEPVEGLARDGPRPFPLGRLVPSAVSCGLCEPGLAAAPAAPTLLPAAYLCAPTAPPAVTAALGGSRWPGGPRSRPRGPRPDGPQPSLSLAEQHLESPVPSAPGALAGGPTQAAPGVRGEEEQWAREIGAQLRRMADDLNAQYERRRQEEQQRHRPSPWRVLYNLIMGLLPLPRGHRAPEMEPN

T26073	TARGETID	T26073
T26073	FORMERID	TTDI02515
T26073	UNIPROID	GPR87_HUMAN
T26073	TARGNAME	G protein coupled receptor 87 (GPR87)
T26073	GENENAME	GPR87
T26073	TARGTYPE	Literature-reported
T26073	SYNONYMS	GPR87; G-protein coupled receptor 95; G-protein coupled receptor 87
T26073	FUNCTION	Receptor for lysophosphatidic acid (LPA). Necessary for p53/TP53-dependent survival in response to DNA damage.
T26073	BIOCLASS	GPCR rhodopsin
T26073	SEQUENCE	MGFNLTLAKLPNNELHGQESHNSGNRSDGPGKNTTLHNEFDTIVLPVLYLIIFVASILLNGLAVWIFFHIRNKTSFIFYLKNIVVADLIMTLTFPFRIVHDAGFGPWYFKFILCRYTSVLFYANMYTSIVFLGLISIDRYLKVVKPFGDSRMYSITFTKVLSVCVWVIMAVLSLPNIILTNGQPTEDNIHDCSKLKSPLGVKWHTAVTYVNSCLFVAVLVILIGCYIAISRYIHKSSRQFISQSSRKRKHNQSIRVVVAVFFTCFLPYHLCRIPFTFSHLDRLLDESAQKILYYCKEITLFLSACNVCLDPIIYFFMCRSFSRRLFKKSNIRTRSESIRSLQSVRRSEVRIYYDYTDV
T26073	DRUGINFO	D02LXI	Ki16425	Investigative
T26073	DRUGINFO	D0G6XT	dioctanoylglycerol pyrophosphate	Investigative
T26073	DRUGINFO	D0X0UR	LPA	Investigative

T98635	TARGETID	T98635
T98635	FORMERID	TTDR00795
T98635	UNIPROID	ANGL4_HUMAN
T98635	TARGNAME	Angiopoietin-related protein 4 (ANGPTL4)
T98635	GENENAME	ANGPTL4
T98635	TARGTYPE	Literature-reported
T98635	SYNONYMS	UNQ171/PRO197; PSEC0166; PP1158; PGAR; Hepatic fibrinogen/angiopoietin-related protein; HFARP; Angiopoietin-like protein PP1158; Angiopoietin-like protein 4; Angiopoietin-like 4; ARP4
T98635	FUNCTION	May also play a role in regulating glucose homeostasis and insulin sensitivity. Inhibits proliferation, migration, and tubule formation of endothelial cells and reduces vascular leakage. Upon heterologous expression, inhibits the adhesion of endothelial cell to the extracellular matrix (ECM), and inhibits the reorganization of the actin cytoskeleton, formation of actin stress fibers and focal adhesions in endothelial cells that have adhered to ANGPTL4-containing ECM (in vitro). Depending on context, may modulate tumor-related angiogenesis. Mediates inactivation of the lipoprotein lipase LPL, and thereby plays a role in the regulation of triglyceride clearance from the blood serum and in lipid metabolism.
T98635	PDBSTRUC	6EUB
T98635	BIOCLASS	Fibrinogen protein
T98635	SEQUENCE	MSGAPTAGAALMLCAATAVLLSAQGGPVQSKSPRFASWDEMNVLAHGLLQLGQGLREHAERTRSQLSALERRLSACGSACQGTEGSTDLPLAPESRVDPEVLHSLQTQLKAQNSRIQQLFHKVAQQQRHLEKQHLRIQHLQSQFGLLDHKHLDHEVAKPARRKRLPEMAQPVDPAHNVSRLHRLPRDCQELFQVGERQSGLFEIQPQGSPPFLVNCKMTSDGGWTVIQRRHDGSVDFNRPWEAYKAGFGDPHGEFWLGLEKVHSITGDRNSRLAVQLRDWDGNAELLQFSVHLGGEDTAYSLQLTAPVAGQLGATTVPPSGLSVPFSTWDQDHDLRRDKNCAKSLSGGWWFGTCSHSNLNGQYFRSIPQQRQKLKKGIFWKTWRGRYYPLQATTMLIQPMAAEAAS

T53468	TARGETID	T53468
T53468	FORMERID	TTDI03619
T53468	UNIPROID	WNK3_HUMAN
T53468	TARGNAME	WNK lysine-deficient protein kinase 3 (WNK3)
T53468	GENENAME	WNK3
T53468	TARGTYPE	Literature-reported
T53468	SYNONYMS	Serine/threonine-protein kinase WNK3; Protein kinase with no lysine 3; Protein kinase lysine-deficient 3; KIAA1566
T53468	FUNCTION	Serine/threonine kinase which plays an important role in the regulation of electrolyte homeostasis, cell signaling, survival and proliferation. Acts as an activator and inhibitor of sodium-coupled chloride cotransporters and potassium-coupled chloride cotransporters respectively. Phosphorylates WNK4. Regulates the phosphorylation of SLC12A1 and SLC12A2. Increases Ca(2+) influx mediated by TRPV5 and TRPV6 by enhancing their membrane expression level via a kinase-dependent pathway. Inhibits the activity of KCNJ1 by decreasing its expression at the cell membrane in a non-catalytic manner.
T53468	PDBSTRUC	5O2C; 5O2B; 5O26; 5O23; 5O21
T53468	ECNUMBER	EC 2.7.11.1
T53468	SEQUENCE	MATDSGDPASTEDSEKPDGISFENRVPQVAATLTVEARLKEKNSTFSASGETVERKRFFRKSVEMTEDDKVAESSPKDERIKAAMNIPRVDKLPSNVLRGGQEVKYEQCSKSTSEISKDCFKEKNEKEMEEEAEMKAVATSPSGRFLKFDIELGRGAFKTVYKGLDTETWVEVAWCELQDRKLTKAEQQRFKEEAEMLKGLQHPNIVRFYDSWESILKGKKCIVLVTELMTSGTLKTYLKRFKVMKPKVLRSWCRQILKGLQFLHTRTPPIIHRDLKCDNIFITGPTGSVKIGDLGLATLMRTSFAKSVIGTPEFMAPEMYEEHYDESVDVYAFGMCMLEMATSEYPYSECQNAAQIYRKVTSGIKPASFNKVTDPEVKEIIEGCIRQNKSERLSIRDLLNHAFFAEDTGLRVELAEEDDCSNSSLALRLWVEDPKKLKGKHKDNEAIEFSFNLETDTPEEVAYEMVKSGFFHESDSKAVAKSIRDRVTPIKKTREKKPAGCLEERRDSQCKSMGNVFPQPQNTTLPLAPAQQTGAECEETEVDQHVRQQLLQRKPQQHCSSVTGDNLSEAGAASVIHSDTSSQPSVAYSSNQTMGSQMVSNIPQAEVNVPGQIYSSQQLVGHYQQVSGLQKHSKLTQPQILPLVQGQSTVLPVHVLGPTVVSQPQVSPLTVQKVPQIKPVSQPVGAEQQAALLKPDLVRSLNQDVATTKENVSSPDNPSGNGKQDRIKQRRASCPRPEKGTKFQLTVLQVSTSGDNMVECQLETHNNKMVTFKFDVDGDAPEDIADYMVEDNFVLESEKEKFVEELRAIVGQAQEILHVHFATERATGVDSITVDSNSSQTGSSEQVQINSTSTQTSNESAPQSSPVGRWRFCINQTIRNRETQSPPSLQHSMSAVPGRHPLPSPKNTSNKEISRDTLLTIENNPCHRALFTSKSEHKDVVDGKISECASVETKQPAILYQVEDNRQIMAPVTNSSSYSTTSVRAVPAECEGLTKQASIFIPVYPCHQTASQADALMSHPGESTQTSGNSLTTLAFDQKPQTLSVQQPAMDAEFISQEGETTVNTEASSPKTVIPTQTPGLEPTTLQPTTVLESDGERPPKLEFADNRIKTLDEKLRNLLYQEHSISSIYPESQKDTQSIDSPFSSSAEDTLSCPVTEVIAISHCGIKDSPVQSPNFQQTGSKLLSNVAASQPANISVFKRDLNVITSVPSELCLHEMSSDASLPGDPEAYPAAVSSGGAIHLQTGGGYFGLSFTCPSLKNPISKKSWTRKLKSWAYRLRQSTSFFKRSKVRQVETEEMRSAIAPDPIPLTRESTADTRALNRCKAMSGSFQRGRFQVITIPQQQSAKMTSFGIEHISVFSETNHSSEEAFIKTAKSQLVEIEPATQNPKTSFSYEKLQALQETCKENKGVPKQGDNFLSFSAACETDVSSVTPEKEFEETSATGSSMQSGSELLLKEREILTAGKQPSSDSEFSASLAGSGKSVAKTGPESNQCLPHHEEQAYAQTQSSLFYSPSSPMSSDDESEIEDEDLKVELQRLREKHIQEVVNLQTQQNKELQELYERLRSIKDSKTQSTEIPLPPASPRRPRSFKSKLRSRPQSLTHVDNGIVATGKSCLINELENPLCVESNAASCQQSPASKKGMFTDDLHKLVDDWTKEAVGNSLIKPSLNQLKQSQHKLETENWNKVSENTPSTMGYTSTWISSLSQIRGAVPTSLPQGLSLPSFPGPLSSYGMPHVCQYNAVAGAGYPVQWVGISGTTQQSVVIPAQSGGPFQPGMNMQAFPTSSVQNPATIPPGPK
T53468	DRUGINFO	D0E7VO	PMID24900538C2c	Investigative

T17552	TARGETID	T17552
T17552	FORMERID	TTDI00194
T17552	UNIPROID	STK33_HUMAN
T17552	TARGNAME	Serine/threonine-protein kinase 33 (STK33)
T17552	GENENAME	STK33
T17552	TARGTYPE	Literature-reported
T17552	SYNONYMS	STK33
T17552	FUNCTION	Serine/threonine protein kinase which phosphorylates VIME. May play a specific role in the dynamic behavior of the intermediate filament cytoskeleton by phosphorylation of VIME. Not essential for the survival of KRAS-dependent AML cell lines.
T17552	BIOCLASS	Kinase
T17552	ECNUMBER	EC 2.7.11.1
T17552	SEQUENCE	MADSGLDKKSTKCPDCSSASQKDVLCVCSSKTRVPPVLVVEMSQTSSIGSAESLISLERKKEKNINRDITSRKDLPSRTSNVERKASQQQWGRGNFTEGKVPHIRIENGAAIEEIYTFGRILGKGSFGIVIEATDKETETKWAIKKVNKEKAGSSAVKLLEREVNILKSVKHEHIIHLEQVFETPKKMYLVMELCEDGELKEILDRKGHFSENETRWIIQSLASAIAYLHNNDIVHRDLKLENIMVKSSLIDDNNEINLNIKVTDFGLAVKKQSRSEAMLQATCGTPIYMAPEVISAHDYSQQCDIWSIGVVMYMLLRGEPPFLASSEEKLFELIRKGELHFENAVWNSISDCAKSVLKQLMKVDPAHRITAKELLDNQWLTGNKLSSVRPTNVLEMMKEWKNNPESVEENTTEEKNKPSTEEKLKSYQPWGNVPDANYTSDEEEEKQSTAYEKQFPATSKDNFDMCSSSFTSSKLLPAEIKGEMEKTPVTPSQGTATKYPAKSGALSRTKKKL
T17552	DRUGINFO	D01TDV	PMID21742770C1	Investigative

T85188	TARGETID	T85188
T85188	FORMERID	TTDR00349
T85188	UNIPROID	RTN4R_HUMAN
T85188	TARGNAME	Reticulon-4 receptor (RTN4R)
T85188	GENENAME	RTN4R
T85188	TARGTYPE	Literature-reported
T85188	SYNONYMS	UNQ330/PRO526; RTN4R; Nogo-66 receptor; Nogo receptor; NgR
T85188	FUNCTION	Receptor for RTN4, OMG and MAG. Mediates axonal growth inhibition and may play a role in regulating axonal regeneration and plasticity in the adult central nervous system. Acts in conjunction with RTN4 and LIGO1 in regulating neuronal precursor cell motility during cortical development.
T85188	PDBSTRUC	1P8T; 1OZN
T85188	SEQUENCE	MKRASAGGSRLLAWVLWLQAWQVAAPCPGACVCYNEPKVTTSCPQQGLQAVPVGIPAASQRIFLHGNRISHVPAASFRACRNLTILWLHSNVLARIDAAAFTGLALLEQLDLSDNAQLRSVDPATFHGLGRLHTLHLDRCGLQELGPGLFRGLAALQYLYLQDNALQALPDDTFRDLGNLTHLFLHGNRISSVPERAFRGLHSLDRLLLHQNRVAHVHPHAFRDLGRLMTLYLFANNLSALPTEALAPLRALQYLRLNDNPWVCDCRARPLWAWLQKFRGSSSEVPCSLPQRLAGRDLKRLAANDLQGCAVATGPYHPIWTGRATDEEPLGLPKCCQPDAADKASVLEPGRPASAGNALKGRVPPGDSPPGNGSGPRHINDSPFGTLPGSAEPPLTAVRPEGSEPPGFPTSGPRRRPGCSRKNRTRSHCRLGQAGSGGGGTGDSEGSGALPSLTCSLTPLGLALVLWTVLGPC
T85188	DRUGINFO	D07LUR	Alpha-D-Mannose	Investigative

T77061	TARGETID	T77061
T77061	FORMERID	TTDI03161
T77061	UNIPROID	DCLK3_HUMAN
T77061	TARGNAME	Doublecortin-like kinase 3 (DCLK3)
T77061	GENENAME	DCLK3
T77061	TARGTYPE	Literature-reported
T77061	SYNONYMS	Serine/threonine-protein kinase DCLK3; KIAA1765; Doublecortin-like and CAM kinase-like 3; Doublecortin domain-containing protein 3C; DCDC3C; DCAMKL3
T77061	FUNCTION	Protein kinase activity, peptidyl-serine phosphorylation.
T77061	BIOCLASS	Kinase
T77061	ECNUMBER	EC 2.7.11.1
T77061	SEQUENCE	MGKEPLTLKSIQVAVEELYPNKARALTLAQHSRAPSPRLRSRLFSKALKGDHRCGETETPKSCSEVAGCKAAMRHQGKIPEELSLDDRARTQKKWGRGKWEPEPSSKPPREATLEERHARGEKHLGVEIEKTSGEIIRCEKCKRERELQQSLERERLSLGTSELDMGKGPMYDVEKLVRTRSCRRSPEANPASGEEGWKGDSHRSSPRNPTQELRRPSKSMDKKEDRGPEDQESHAQGAAKAKKDLVEVLPVTEEGLREVKKDTRPMSRSKHGGWLLREHQAGFEKLRRTRGEEKEAEKEKKPCMSGGRRMTLRDDQPAKLEKEPKTRPEENKPERPSGRKPRPMGIIAANVEKHYETGRVIGDGNFAVVKECRHRETRQAYAMKIIDKSRLKGKEDMVDSEILIIQSLSHPNIVKLHEVYETDMEIYLILEYVQGGDLFDAIIESVKFPEPDAALMIMDLCKALVHMHDKSIVHRDLKPENLLVQRNEDKSTTLKLADFGLAKHVVRPIFTVCGTPTYVAPEILSEKGYGLEVDMWAAGVILYILLCGFPPFRSPERDQDELFNIIQLGHFEFLPPYWDNISDAAKDLVSRLLVVDPKKRYTAHQVLQHPWIETAGKTNTVKRQKQVSPSSEGHFRSQHKRVVEQVS
T77061	DRUGINFO	D08TVU	PMID20483621C5n	Investigative

T63753	TARGETID	T63753
T63753	FORMERID	TTDR00797
T63753	UNIPROID	TRYS_TRYCC
T63753	TARGNAME	Trypanosoma Trypanothione synthetase (Trypano TRS)
T63753	GENENAME	Trypano TRS
T63753	TARGTYPE	Literature-reported
T63753	SYNONYMS	TRS; Cf-TS
T63753	FUNCTION	Bifunctional enzyme which catalyzes the formation oftrypanothione (N(1),N(8)-bis(glutathionyl)spermidine) from glutathione and spermidine. Converts spermidine or glutathionylspermidine into trypanothione. Can also convert aminopropylcadaverine into glutothionylaminopropylcadaverine and homotrypanothione. Also has low amidase activity, hydrolyzing trypanothione, homotrypanothione or glutathionylspermidine to form glutathione and the corresponding polyamine.
T63753	BIOCLASS	Carbon-nitrogen ligase
T63753	ECNUMBER	EC 6.3.1.9
T63753	SEQUENCE	MPTLQSLAVPFGCVQGYAPGGIPAYSNKHESYFSGERSIDGNLFCGFKYQCVEFARRWLFERKSLVLPDVDWAVHIFNLKEVSDARTGKPVRCVAIRNGTAAKPVVDSLLIYPSDDYSPVGHVAAITEVGDKWVRIADQNHRFHKWDANYAAELPLIHEKGVWTILDPLEDEVLKPLGWVTFPDTPDRNPNEPLVLHESLHFKRGELPTLRRLTFTPTSREKDWLDLTNEAEAYFADVCGIDVKNPKLEKASYYQMNRELYLDCAKYGNQLHQMFLEATKFVLGSDELLRLFCIPEEYWPRLRHSWETQPHAITGRFDFAFDEDTQQFKCFEYNADSASTLLECGVIQQKWARSVGLDDGTTYSSGSLVSSRLQLAWEMAEVTGRVHFLIDNDDEEHYTALYVMQHASAAGLETKLCVLFDEFHFDENGVVVDSDGVAVTTVWKTWMWETAIADHQKARVQRGNDWRPTPKDEVRLCDILLGPNWDLRVFEPMWKIIPSNKAILPIIYNKHPDHPALLRASYELTVELQRTGYVRKPIVGRVGRNVTVTEASGDIAAKSDGDFSDRDMVYQELFRLPERDGYYAILGGWVIGDVYCGTGVREDKTIITGLESPFSALRVYQGAQRRPLTHEDLDKAEAAAVGGGLKT

T03404	TARGETID	T03404
T03404	FORMERID	TTDR00533
T03404	UNIPROID	CHST5_HUMAN
T03404	TARGNAME	Intestinal GlcNAc-6-sulfotransferase (CHST5)
T03404	GENENAME	CHST5
T03404	TARGTYPE	Literature-reported
T03404	SYNONYMS	N-acetylglucosamine-6-O-sulfotransferase; N-acetylglucosamine 6-O-sulfotransferase; LSST; L-selectin ligand sulfotransferase GST-3; L-selectin ligand sulfotransferase; Intestinal N-acetylglucosamine-6-O-sulfotransferase; High endothelial cell GlcNAc 6-O-sulfotransferase; HEC-GlcNAc6ST; GlcNAc 6-O-sulfotransferase; Carbohydrate sulfotransferase GST-3; CHST5
T03404	FUNCTION	Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the transfer of sulfate to position 6 of non-reducing N-acetylglucosamine (GlcNAc) residues and O-linked sugars of mucin-type acceptors. Acts on the non-reducing terminal GlcNAc of short carbohydrate substrates. However, it does not transfer sulfate to longer carbohydrate substrates that have poly-N-acetyllactosamine structures. Has no activitytoward keratan. Not involved in generating HEV-expressed ligands for SELL. Its substrate specificity may be influenced by its subcellular location.
T03404	BIOCLASS	Transferases of sulfur-containing groups
T03404	ECNUMBER	EC 2.8.2.-
T03404	SEQUENCE	MGMRARVPKVAHSTRRPPAARMWLPRFSSKTVTVLLLAQTTCLLLFIISRPGPSSPAGGEDRVHVLVLSSWRSGSSFLGQLFSQHPDVFYLMEPAWHVWTTLSQGSAATLHMAVRDLMRSIFLCDMDVFDAYMPQSRNLSAFFNWATSRALCSPPACSAFPRGTISKQDVCKTLCTRQPFSLAREACRSYSHVVLKEVRFFNLQVLYPLLSDPALNLRIVHLVRDPRAVLRSREAAGPILARDNGIVLGTNGKWVEADPHLRLIREVCRSHVRIAEAATLKPPPFLRGRYRLVRFEDLAREPLAEIRALYAFTGLTLTPQLEAWIHNITHGSGIGKPIEAFHTSSRNARNVSQAWRHALPFTKILRVQEVCAGALQLLGYRPVYSADQQRDLTLDLVLPRGPDHFSWASPD

T98352	TARGETID	T98352
T98352	UNIPROID	UBP44_HUMAN
T98352	TARGNAME	Ubiquitin carboxyl-terminal hydrolase 44 (USP44)
T98352	GENENAME	USP44
T98352	TARGTYPE	Literature-reported
T98352	SYNONYMS	Ubiquitin-specific-processing protease 44; Ubiquitin thioesterase 44; Deubiquitinating enzyme 44
T98352	FUNCTION	Deubiquitinase that plays a key regulatory role in the spindle assembly checkpoint or mitotic checkpoint by preventing premature anaphase onset. Acts by specifically mediating deubiquitination of CDC20, a negative regulator of the anaphase promoting complex/cyclosome (APC/C). Deubiquitination of CDC20 leads to stabilize the MAD2L1-CDC20-APC/C ternary complex (also named mitotic checkpoint complex), thereby preventing premature activation of the APC/C. Promotes association of MAD2L1 with CDC20 and reinforces the spindle assembly checkpoint. Acts as a negative regulator of histone H2B (H2BK120ub1) ubiquitination.
T98352	BIOCLASS	Peptidase C19 family. USP44 subfamily
T98352	ECNUMBER	EC 3.4.19.12
T98352	SEQUENCE	MLAMDTCKHVGQLQLAQDHSSLNPQKWHCVDCNTTESIWACLSCSHVACGRYIEEHALKHFQESSHPVALEVNEMYVFCYLCDDYVLNDNTTGDLKLLRRTLSAIKSQNYHCTTRSGRFLRSMGTGDDSYFLHDGAQSLLQSEDQLYTALWHRRRILMGKIFRTWFEQSPIGRKKQEEPFQEKIVVKREVKKRRQELEYQVKAELESMPPRKSLRLQGLAQSTIIEIVSVQVPAQTPASPAKDKVLSTSENEISQKVSDSSVKRRPIVTPGVTGLRNLGNTCYMNSVLQVLSHLLIFRQCFLKLDLNQWLAMTASEKTRSCKHPPVTDTVVYQMNECQEKDTGFVCSRQSSLSSGLSGGASKGRKMELIQPKEPTSQYISLCHELHTLFQVMWSGKWALVSPFAMLHSVWRLIPAFRGYAQQDAQEFLCELLDKIQRELETTGTSLPALIPTSQRKLIKQVLNVVNNIFHGQLLSQVTCLACDNKSNTIEPFWDLSLEFPERYQCSGKDIASQPCLVTEMLAKFTETEALEGKIYVCDQCNSKRRRFSSKPVVLTEAQKQLMICHLPQVLRLHLKRFRWSGRNNREKIGVHVGFEEILNMEPYCCRETLKSLRPECFIYDLSAVVMHHGKGFGSGHYTAYCYNSEGGFWVHCNDSKLSMCTMDEVCKAQAYILFYTQRVTENGHSKLLPPELLLGSQHPNEDADTSSNEILS

T98198	TARGETID	T98198
T98198	FORMERID	TTDI03397
T98198	UNIPROID	MYLK2_HUMAN
T98198	TARGNAME	Myosin light chain kinase 2 (MYLK2)
T98198	GENENAME	MYLK2
T98198	TARGTYPE	Literature-reported
T98198	SYNONYMS	MYLK2
T98198	FUNCTION	Implicated in the level of global muscle contraction and cardiac function. Phosphorylates a specific serine in the N-terminus of a myosin light chain.
T98198	PDBSTRUC	3KF9; 2LV6
T98198	ECNUMBER	EC 2.7.11.18
T98198	SEQUENCE	MATENGAVELGIQNPSTDKAPKGPTGERPLAAGKDPGPPDPKKAPDPPTLKKDAKAPASEKGDGTLAQPSTSSQGPKGEGDRGGGPAEGSAGPPAALPQQTATPETSVKKPKAEQGASGSQDPGKPRVGKKAAEGQAAARRGSPAFLHSPSCPAIISSSEKLLAKKPPSEASELTFEGVPMTHSPTDPRPAKAEEGKNILAESQKEVGEKTPGQAGQAKMQGDTSRGIEFQAVPSEKSEVGQALCLTAREEDCFQILDDCPPPPAPFPHRMVELRTGNVSSEFSMNSKEALGGGKFGAVCTCMEKATGLKLAAKVIKKQTPKDKEMVLLEIEVMNQLNHRNLIQLYAAIETPHEIVLFMEYIEGGELFERIVDEDYHLTEVDTMVFVRQICDGILFMHKMRVLHLDLKPENILCVNTTGHLVKIIDFGLARRYNPNEKLKVNFGTPEFLSPEVVNYDQISDKTDMWSMGVITYMLLSGLSPFLGDDDTETLNNVLSGNWYFDEETFEAVSDEAKDFVSNLIVKDQRARMNAAQCLAHPWLNNLAEKAKRCNRRLKSQILLKKYLMKRRWKKNFIAVSAANRFKKISSSGALMALGV
T98198	DRUGINFO	D0N4LR	GSK2606414	Investigative

T14200	TARGETID	T14200
T14200	FORMERID	TTDI00034
T14200	UNIPROID	ABCG5_HUMAN
T14200	TARGNAME	ATP-binding cassette transporter G5 (ABCG5)
T14200	GENENAME	ABCG5
T14200	TARGTYPE	Literature-reported
T14200	SYNONYMS	Sterolin1; ATPbinding cassette subfamily G member 5; ABCG5
T14200	FUNCTION	Transporter that appears to play an indispensable role in the selective transportof the dietary cholesterol in and out of the enterocytes and in the selective sterol excretion by the liver into bile.
T14200	PDBSTRUC	5DO7
T14200	BIOCLASS	ABC transporter
T14200	SEQUENCE	MGDLSSLTPGGSMGLQVNRGSQSSLEGAPATAPEPHSLGILHASYSVSHRVRPWWDITSCRQQWTRQILKDVSLYVESGQIMCILGSSGSGKTTLLDAMSGRLGRAGTFLGEVYVNGRALRREQFQDCFSYVLQSDTLLSSLTVRETLHYTALLAIRRGNPGSFQKKVEAVMAELSLSHVADRLIGNYSLGGISTGERRRVSIAAQLLQDPKVMLFDEPTTGLDCMTANQIVVLLVELARRNRIVVLTIHQPRSELFQLFDKIAILSFGELIFCGTPAEMLDFFNDCGYPCPEHSNPFDFYMDLTSVDTQSKEREIETSKRVQMIESAYKKSAICHKTLKNIERMKHLKTLPMVPFKTKDSPGVFSKLGVLLRRVTRNLVRNKLAVITRLLQNLIMGLFLLFFVLRVRSNVLKGAIQDRVGLLYQFVGATPYTGMLNAVNLFPVLRAVSDQESQDGLYQKWQMMLAYALHVLPFSVVATMIFSSVCYWTLGLHPEVARFGYFSAALLAPHLIGEFLTLVLLGIVQNPNIVNSVVALLSIAGVLVGSGFLRNIQEMPIPFKIISYFTFQKYCSEILVVNEFYGLNFTCGSSNVSVTTNPMCAFTQGIQFIEKTCPGATSRFTMNFLILYSFIPALVILGIVVFKIRDHLISR

T57307	TARGETID	T57307
T57307	FORMERID	TTDI03000
T57307	UNIPROID	SLK_HUMAN
T57307	TARGNAME	STE20-related serine/threonine-protein kinase (SLK)
T57307	GENENAME	SLK
T57307	TARGTYPE	Literature-reported
T57307	SYNONYMS	hSLK; STE20-related kinase; STE20-like kinase
T57307	FUNCTION	Mediates apoptosis and actin stress fiber dissolution.
T57307	PDBSTRUC	6HVD; 4USF; 2UV2; 2JFM; 2JFL
T57307	ECNUMBER	EC 2.7.11.1
T57307	SEQUENCE	MSFFNFRKIFKLGSEKKKKQYEHVKRDLNPEDFWEIIGELGDGAFGKVYKAQNKETSVLAAAKVIDTKSEEELEDYMVEIDILASCDHPNIVKLLDAFYYENNLWILIEFCAGGAVDAVMLELERPLTESQIQVVCKQTLDALNYLHDNKIIHRDLKAGNILFTLDGDIKLADFGVSAKNTRTIQRRDSFIGTPYWMAPEVVMCETSKDRPYDYKADVWSLGITLIEMAEIEPPHHELNPMRVLLKIAKSEPPTLAQPSRWSSNFKDFLKKCLEKNVDARWTTSQLLQHPFVTVDSNKPIRELIAEAKAEVTEEVEDGKEEDEEEETENSLPIPASKRASSDLSIASSEEDKLSQNACILESVSEKTERSNSEDKLNSKILNEKPTTDEPEKAVEDINEHITDAQLEAMTELHDRTAVIKENEREKRPKLENLPDTEDQETVDINSVSEGKENNIMITLETNIEHNLKSEEEKDQEKQQMFENKLIKSEEIKDTILQTVDLVSQETGEKEANIQAVDSEVGLTKEDTQEKLGEDDKTQKDVISNTSDVIGTCEAADVAQKVDEDSAEDTQSNDGKEVVEVGQKLINKPMVGPEAGGTKEVPIKEIVEMNEIEEGKNKEQAINSSENIMDINEEPGTTEGEEITESSSTEEMEVRSVVADTDQKALGSEVQDASKVTTQIDKEKKEIPVSIKKEPEVTVVSQPTEPQPVLIPSININSDSGENKEEIGSLSKTETILPPESENPKENDNDSGTGSTADTSSIDLNLSISSFLSKTKDSGSISLQETRRQKKTLKKTRKFIVDGVEVSVTTSKIVTDSDSKTEELRFLRRQELRELRFLQKEEQRAQQQLNSKLQQQREQIFRRFEQEMMSKKRQYDQEIENLEKQQKQTIERLEQEHTNRLRDEAKRIKGEQEKELSKFQNMLKNRKKEVINEVEKAPKELRKELMKRRKEELAQSQHAQEQEFVQKQQQELDGSLKKIIQQQKAELANIERECLNNKQQLMRAREAAIWELEERHLQEKHQLLKQQLKDQYFMQRHQLLKRHEKETEQMQRYNQRLIEELKNRQTQERARLPKIQRSEAKTRMAMFKKSLRINSTATPDQDRDKIKQFAAQEEKRQKNERMAQHQKHENQMRDLQLQCEANVRELHQLQNEKCHLLVEHETQKLKELDEEHSQELKEWREKLRPRKKTLEEEFARKLQEQEVFFKMTGESECLNPSTQSRISKFYPIPSLHSTGS
T57307	DRUGINFO	D0N0LN	RN486	Investigative

T63682	TARGETID	T63682
T63682	FORMERID	TTDI03572
T63682	UNIPROID	TAOK3_HUMAN
T63682	TARGNAME	TAO kinase 3 (TAOK3)
T63682	GENENAME	TAOK3
T63682	TARGTYPE	Literature-reported
T63682	SYNONYMS	hKFC-A; Thousand and one amino acid protein 3; Serine/threonine-protein kinase TAO3; MAP3K18; Kinase from chicken homolog A; KDS; Jun kinase-inhibitory kinase; JNK/SAPK-inhibitory kinase; JIK; Dendritic cell-derived protein kinase; DPK; Cutaneous T-cell lymphoma-associated antigen HD-CL-09; CTCL-associated antigen HD-CL-09
T63682	FUNCTION	Serine/threonine-protein kinase that acts as a regulator of the p38/MAPK14 stress-activated MAPK cascade and of the MAPK8/JNK cascade. Acts as an activator of the p38/MAPK14 stress-activated MAPK cascade. In response to DNA damage, involved in the G2/M transition DNA damage checkpoint by activating the p38/MAPK14 stress-activated MAPK cascade, probably by mediating phosphorylation of upstream MAP2K3 and MAP2K6 kinases. Inhibits basal activity of MAPK8/JNK cascade and diminishes its activation in response epidermal growth factor (EGF).
T63682	PDBSTRUC	6BDN
T63682	ECNUMBER	EC 2.7.11.1
T63682	SEQUENCE	MRKGVLKDPEIADLFYKDDPEELFIGLHEIGHGSFGAVYFATNAHTSEVVAIKKMSYSGKQTHEKWQDILKEVKFLRQLKHPNTIEYKGCYLKEHTAWLVMEYCLGSASDLLEVHKKPLQEVEIAAITHGALHGLAYLHSHALIHRDIKAGNILLTEPGQVKLADFGSASMASPANSFVGTPYWMAPEVILAMDEGQYDGKVDIWSLGITCIELAERKPPLFNMNAMSALYHIAQNDSPTLQSNEWTDSFRRFVDYCLQKIPQERPTSAELLRHDFVRRDRPLRVLIDLIQRTKDAVRELDNLQYRKMKKILFQETRNGPLNESQEDEEDSEHGTSLNREMDSLGSNHSIPSMSVSTGSQSSSVNSMQEVMDESSSELVMMHDDESTINSSSSVVHKKDHVFIRDEAGHGDPRPEPRPTQSVQSQALHYRNRERFATIKSASLVTRQIHEHEQENELREQMSGYKRMRRQHQKQLIALENKLKAEMDEHRLKLQKEVETHANNSSIELEKLAKKQVAIIEKEAKVAAADEKKFQQQILAQQKKDLTTFLESQKKQYKICKEKIKEEMNEDHSTPKKEKQERISKHKENLQHTQAEEEAHLLTQQRLYYDKNCRFFKRKIMIKRHEVEQQNIREELNKKRTQKEMEHAMLIRHDESTRELEYRQLHTLQKLRMDLIRLQHQTELENQLEYNKRRERELHRKHVMELRQQPKNLKAMEMQIKKQFQDTCKVQTKQYKALKNHQLEVTPKNEHKTILKTLKDEQTRKLAILAEQYEQSINEMMASQALRLDEAQEAECQALRLQLQQEMELLNAYQSKIKMQTEAQHERELQKLEQRVSLRRAHLEQKIEEELAALQKERSERIKNLLERQEREIETFDMESLRMGFGNLVTLDFPKEDYR
T63682	DRUGINFO	D0T8NU	PMID19115845C89S	Investigative

T53952	TARGETID	T53952
T53952	FORMERID	TTDI03263
T53952	UNIPROID	HIPK2_HUMAN
T53952	TARGNAME	Homeodomain interacting protein kinase 2 (HIPK2)
T53952	GENENAME	HIPK2
T53952	TARGTYPE	Literature-reported
T53952	SYNONYMS	hHIPk2; Homeodomain-interacting protein kinase 2
T53952	FUNCTION	Acts as a corepressor of several transcription factors, including SMAD1 and POU4F1/Brn3a and probably NK homeodomain transcription factors. Phosphorylates PDX1, ATF1, PML, p53/TP53, CREB1, CTBP1, CBX4, RUNX1, EP300, CTNNB1, HMGA1 and ZBTB4. Inhibits cell growth and promotes apoptosis through the activation of p53/TP53 both at the transcription level and at the protein level (by phosphorylation and indirect acetylation). The phosphorylation of p53/TP53 may be mediated by a p53/TP53-HIPK2-AXIN1 complex. Involved in the response to hypoxia by acting as a transcriptional co-suppressor of HIF1A. Mediates transcriptional activation of TP73. In response to TGFB, cooperates with DAXX to activate JNK. Negative regulator through phosphorylation and subsequent proteasomal degradation of CTNNB1 and the antiapoptotic factor CTBP1. In the Wnt/beta-catenin signaling pathway acts as an intermediate kinase between MAP3K7/TAK1 and NLK to promote the proteasomal degradation of MYB. Phosphorylates CBX4 upon DNA damage and promotes its E3 SUMO-protein ligase activity. Activates CREB1 and ATF1 transcription factors by phosphorylation in response to genotoxic stress. In response to DNA damage, stabilizes PML by phosphorylation. PML, HIPK2 and FBXO3 may act synergically to activate p53/TP53-dependent transactivation. Promotes angiogenesis, and is involved in erythroid differentiation, especially during fetal liver erythropoiesis. Phosphorylation of RUNX1 and EP300 stimulates EP300 transcription regulation activity. Triggers ZBTB4 protein degradation in response to DNA damage. Modulates HMGA1 DNA-binding affinity. In response to high glucose, triggers phosphorylation-mediated subnuclear localization shifting of PDX1. Involved in the regulation of eye size, lens formation and retinal lamination during late embryogenesis. Serine/threonine-protein kinase involved in transcription regulation, p53/TP53-mediated cellular apoptosis and regulation of the cell cycle.
T53952	BIOCLASS	Kinase
T53952	ECNUMBER	EC 2.7.11.1
T53952	SEQUENCE	MAPVYEGMASHVQVFSPHTLQSSAFCSVKKLKIEPSSNWDMTGYGSHSKVYSQSKNIPLSQPATTTVSTSLPVPNPSLPYEQTIVFPGSTGHIVVTSASSTSVTGQVLGGPHNLMRRSTVSLLDTYQKCGLKRKSEEIENTSSVQIIEEHPPMIQNNASGATVATATTSTATSKNSGSNSEGDYQLVQHEVLCSMTNTYEVLEFLGRGTFGQVVKCWKRGTNEIVAIKILKNHPSYARQGQIEVSILARLSTESADDYNFVRAYECFQHKNHTCLVFEMLEQNLYDFLKQNKFSPLPLKYIRPVLQQVATALMKLKSLGLIHADLKPENIMLVDPSRQPYRVKVIDFGSASHVSKAVCSTYLQSRYYRAPEIILGLPFCEAIDMWSLGCVIAELFLGWPLYPGASEYDQIRYISQTQGLPAEYLLSAGTKTTRFFNRDTDSPYPLWRLKTPDDHEAETGIKSKEARKYIFNCLDDMAQVNMTTDLEGSDMLVEKADRREFIDLLKKMLTIDADKRITPIETLNHPFVTMTHLLDFPHSTHVKSCFQNMEICKRRVNMYDTVNQSKTPFITHVAPSTSTNLTMTFNNQLTTVHNQAPSSTSATISLANPEVSILNYPSTLYQPSAASMAAVAQRSMPLQTGTAQICARPDPFQQALIVCPPGFQGLQASPSKHAGYSVRMENAVPIVTQAPGAQPLQIQPGLLAQQAWPSGTQQILLPPAWQQLTGVATHTSVQHATVIPETMAGTQQLADWRNTHAHGSHYNPIMQQPALLTGHVTLPAAQPLNVGVAHVMRQQPTSTTSSRKSKQHQSSVRNVSTCEVSSSQAISSPQRSKRVKENTPPRCAMVHSSPACSTSVTCGWGDVASSTTRERQRQTIVIPDTPSPTVSVITISSDTDEEEEQKHAPTSTVSKQRKNVISCVTVHDSPYSDSSSNTSPYSVQQRAGHNNANAFDTKGSLENHCTGNPRTIIVPPLKTQASEVLVECDSLVPVNTSHHSSSYKSKSSSNVTSTSGHSSGSSSGAITYRQQRPGPHFQQQQPLNLSQAQQHITTDRTGSHRRQQAYITPTMAQAPYSFPHNSPSHGTVHPHLAAAAAAAHLPTQPHLYTYTAPAALGSTGTVAHLVASQGSARHTVQHTAYPASIVHQVPVSMGPRVLPSPTIHPSQYPAQFAHQTYISASPASTVYTGYPLSPAKVNQYPYI
T53952	DRUGINFO	D04TPA	PMID24900749C1a	Investigative

T22302	TARGETID	T22302
T22302	FORMERID	TTDI02571
T22302	UNIPROID	S12A5_HUMAN
T22302	TARGNAME	Solute carrier family 12 member 5 (SLC12A5)
T22302	GENENAME	SLC12A5
T22302	TARGTYPE	Literature-reported
T22302	SYNONYMS	hKCC2; SLC12A5; Neuronal K-Cl cotransporter; K-Cl cotransporter 2; Electroneutral potassium-chloride cotransporter 2
T22302	FUNCTION	Mediates electroneutral potassium-chloride cotransportin mature neurons. Transport occurs under isotonic conditions, but is activated 20-fold by cell swelling. Important for Cl(-) homeostasis in neurons.
T22302	BIOCLASS	Cation-chloride cotransporter
T22302	SEQUENCE	MSRRFTVTSLPPAGPARSPDPESRRHSVADPRHLPGEDVKGDGNPKESSPFINSTDTEKGKEYDGKNMALFEEEMDTSPMVSSLLSGLANYTNLPQGSREHEEAENNEGGKKKPVQAPRMGTFMGVYLPCLQNIFGVILFLRLTWVVGIAGIMESFCMVFICCSCTMLTAISMSAIATNGVVPAGGSYYMISRSLGPEFGGAVGLCFYLGTTFAGAMYILGTIEILLAYLFPAMAIFKAEDASGEAAAMLNNMRVYGTCVLTCMATVVFVGVKYVNKFALVFLGCVILSILAIYAGVIKSAFDPPNFPICLLGNRTLSRHGFDVCAKLAWEGNETVTTRLWGLFCSSRFLNATCDEYFTRNNVTEIQGIPGAASGLIKENLWSSYLTKGVIVERSGMTSVGLADGTPIDMDHPYVFSDMTSYFTLLVGIYFPSVTGIMAGSNRSGDLRDAQKSIPTGTILAIATTSAVYISSVVLFGACIEGVVLRDKFGEAVNGNLVVGTLAWPSPWVIVIGSFFSTCGAGLQSLTGAPRLLQAISRDGIVPFLQVFGHGKANGEPTWALLLTACICEIGILIASLDEVAPILSMFFLMCYMFVNLACAVQTLLRTPNWRPRFRYYHWTLSFLGMSLCLALMFICSWYYALVAMLIAGLIYKYIEYRGAEKEWGDGIRGLSLSAARYALLRLEEGPPHTKNWRPQLLVLVRVDQDQNVVHPQLLSLTSQLKAGKGLTIVGSVLEGTFLENHPQAQRAEESIRRLMEAEKVKGFCQVVISSNLRDGVSHLIQSGGLGGLQHNTVLVGWPRNWRQKEDHQTWRNFIELVRETTAGHLALLVTKNVSMFPGNPERFSEGSIDVWWIVHDGGMLMLLPFLLRHHKVWRKCKMRIFTVAQMDDNSIQMKKDLTTFLYHLRITAEVEVVEMHESDISAYTYEKTLVMEQRSQILKQMHLTKNEREREIQSITDESRGSIRRKNPANTRLRLNVPEETAGDSEEKPEEEVQLIHDQSAPSCPSSSPSPGEEPEGEGETDPEKVHLTWTKDKSVAEKNKGPSPVSSEGIKDFFSMKPEWENLNQSNVRRMHTAVRLNEVIVKKSRDAKLVLLNMPGPPRNRNGDENYMEFLEVLTEHLDRVMLVRGGGREVITIYS
T22302	DRUGINFO	D0M2PP	VU0240551	Investigative
T22302	DRUGINFO	D0V6KL	CLP-635	Investigative
T22302	DRUGINFO	D0K9KZ	DIOA	Investigative

T96232	TARGETID	T96232
T96232	UNIPROID	FOXP1_HUMAN
T96232	TARGNAME	Forkhead box protein P1 (FOXP1)
T96232	GENENAME	FOXP1
T96232	TARGTYPE	Literature-reported
T96232	SYNONYMS	Mac-1-regulated forkhead; MFH; FOXP1-ES
T96232	FUNCTION	Transcriptional repressor (PubMed:18347093, PubMed:26647308). Can act with CTBP1 to synergistically repress transcription but CTPBP1 is not essential. Plays an important role in the specification and differentiation of lung epithelium. Acts cooperatively with FOXP4 to regulate lung secretory epithelial cell fate and regeneration by restricting the goblet cell lineage program; the function may involve regulation of AGR2. Essential transcriptional regulator of B-cell development. Involved in regulation of cardiac muscle cell proliferation. Involved in the columnar organization of spinal motor neurons. Promotes the formation of the lateral motor neuron column (LMC) and the preganglionic motor column (PGC) and is required for respective appropriate motor axon projections. The segment-appropriate generation of spinal chord motor columns requires cooperation with other Hox proteins. Can regulate PITX3 promoter activity; may promote midbrain identity in embryonic stem cell-derived dopamine neurons by regulating PITX3. Negatively regulates the differentiation of T follicular helper cells T(FH)s. Involved in maintenance of hair follicle stem cell quiescence; the function probably involves regulation of FGF18. Represses transcription of various pro-apoptotic genes and cooperates with NF-kappa B-signaling in promoting B-cell expansion by inhibition of caspase-dependent apoptosis (PubMed:25267198). Binds to CSF1R promoter elements and is involved in regulation of monocyte differentiation and macrophage functions; repression of CSF1R in monocytes seems to involve NCOR2 as corepressor (PubMed:15286807, PubMed:18799727, PubMed:18347093). Involved in endothelial cell proliferation, tube formation and migration indicative for a role in angiogenesis; the role in neovascularization seems to implicate suppression of SEMA5B (PubMed:24023716). Can negatively regulate androgen receptor signaling (PubMed:18640093).
T96232	PDBSTRUC	2KIU
T96232	SEQUENCE	MMQESGTETKSNGSAIQNGSGGSNHLLECGGLREGRSNGETPAVDIGAADLAHAQQQQQQALQVARQLLLQQQQQQQVSGLKSPKRNDKQPALQVPVSVAMMTPQVITPQQMQQILQQQVLSPQQLQVLLQQQQALMLQQQQLQEFYKKQQEQLQLQLLQQQHAGKQPKEQQQVATQQLAFQQQLLQMQQLQQQHLLSLQRQGLLTIQPGQPALPLQPLAQGMIPTELQQLWKEVTSAHTAEETTGNNHSSLDLTTTCVSSSAPSKTSLIMNPHASTNGQLSVHTPKRESLSHEEHPHSHPLYGHGVCKWPGCEAVCEDFQSFLKHLNSEHALDDRSTAQCRVQMQVVQQLELQLAKDKERLQAMMTHLHVKSTEPKAAPQPLNLVSSVTLSKSASEASPQSLPHTPTTPTAPLTPVTQGPSVITTTSMHTVGPIRRRYSDKYNVPISSADIAQNQEFYKNAEVRPPFTYASLIRQAILESPEKQLTLNEIYNWFTRMFAYFRRNAATWKNAVRHNLSLHKCFVRVENVKGAVWTVDEVEFQKRRPQKISGNPSLIKNMQSSHAYCTPLNAALQASMAENSIPLYTTASMGNPTLGNLASAIREELNGAMEHTNSNESDSSPGRSPMQAVHPVHVKEEPLDPEEAEGPLSLVTTANHSPDFDHDRDYEDEPVNEDME

T77127	TARGETID	T77127
T77127	FORMERID	TTDR00796
T77127	UNIPROID	TXNIP_HUMAN
T77127	TARGNAME	Vitamin D3 up-regulated protein 1 (VDUP1)
T77127	GENENAME	TXNIP
T77127	TARGTYPE	Literature-reported
T77127	SYNONYMS	Vitamin D(3) up-regulating protein-1; Thioredoxin-interacting protein; Thioredoxin-binding protein 2
T77127	FUNCTION	Interacts with COPS5 and restores COPS5-induced suppression of CDKN1B stability, blocking the COPS5-mediated translocation of CDKN1B from the nucleus to the cytoplasm. Functions as a transcriptional repressor, possibly by acting as a bridge molecule between transcription factors and corepressor complexes, and over-expression will induce G0/G1 cell cycle arrest. Required for the maturation of natural killer cells. Acts as a suppressor of tumor cell growth. Inhibits the proteasomal degradation of DDIT4, and thereby contributes to the inhibition of the mammalian target of rapamycin complex 1 (mTORC1). May act as an oxidative stress mediator by inhibiting thioredoxin activity or by limiting its bioavailability.
T77127	PDBSTRUC	5DZD; 5DWS; 5DF6; 5CQ2; 4ROJ
T77127	BIOCLASS	Arrestin protein
T77127	SEQUENCE	MVMFKKIKSFEVVFNDPEKVYGSGEKVAGRVIVEVCEVTRVKAVRILACGVAKVLWMQGSQQCKQTSEYLRYEDTLLLEDQPTGENEMVIMRPGNKYEYKFGFELPQGPLGTSFKGKYGCVDYWVKAFLDRPSQPTQETKKNFEVVDLVDVNTPDLMAPVSAKKEKKVSCMFIPDGRVSVSARIDRKGFCEGDEISIHADFENTCSRIVVPKAAIVARHTYLANGQTKVLTQKLSSVRGNHIISGTCASWRGKSLRVQKIRPSILGCNILRVEYSLLIYVSVPGSKKVILDLPLVIGSRSGLSSRTSSMASRTSSEMSWVDLNIPDTPEAPPCYMDVIPEDHRLESPTTPLLDDMDGSQDSPIFMYAPEFKFMPPPTYTEVDPCILNNNVQ

T92296	TARGETID	T92296
T92296	FORMERID	TTDI02624
T92296	UNIPROID	FN3K_HUMAN
T92296	TARGNAME	Fructosamine-3-kinase (FN3K)
T92296	GENENAME	FN3K
T92296	TARGTYPE	Literature-reported
T92296	SYNONYMS	Fructosamine 3 kinase; FN3K; F3K
T92296	FUNCTION	May initiate a process leading to the deglycation of fructoselysine and of glycated proteins. May play a role in the phosphorylation of 1-deoxy-1-morpholinofructose (DMF), fructoselysine, fructoseglycine, fructose and glycated lysozyme.
T92296	BIOCLASS	Kinase
T92296	ECNUMBER	EC 2.7.1.-
T92296	SEQUENCE	MEQLLRAELRTATLRAFGGPGAGCISEGRAYDTDAGPVFVKVNRRTQARQMFEGEVASLEALRSTGLVRVPRPMKVIDLPGGGAAFVMEHLKMKSLSSQASKLGEQMADLHLYNQKLREKLKEEENTVGRRGEGAEPQYVDKFGFHTVTCCGFIPQVNEWQDDWPTFFARHRLQAQLDLIEKDYADREARELWSRLQVKIPDLFCGLEIVPALLHGDLWSGNVAEDDVGPIIYDPASFYGHSEFELAIALMFGGFPRSFFTAYHRKIPKAPGFDQRLLLYQLFNYLNHWNHFGREYRSPSLGTMRRLLK

T52638	TARGETID	T52638
T52638	FORMERID	TTDI01530
T52638	UNIPROID	WNK1_HUMAN
T52638	TARGNAME	Serine/threonine-protein kinase WNK1 (WNK1)
T52638	GENENAME	WNK1
T52638	TARGTYPE	Literature-reported
T52638	SYNONYMS	p65; hWNK1; Protein kinase with no lysine 1; Protein kinase lysine-deficient 1; Kinase deficient protein; KDP; HSN2; Erythrocyte 65 kDa protein
T52638	FUNCTION	Serine/threonine kinase which plays an important role in the regulation of electrolyte homeostasis, cell signaling, survival, and proliferation. Acts as an activator and inhibitor of sodium-coupled chloride cotransporters and potassium-coupled chloride cotransporters respectively. Activates SCNN1A, SCNN1B, SCNN1D and SGK1. Controls sodium and chloride ion transport by inhibiting the activity of WNK4, by either phosphorylating the kinase or via an interaction between WNK4 and the autoinhibitory domain of WNK1. WNK4 regulates the activity of the thiazide-sensitive Na-Cl cotransporter, SLC12A3, by phosphorylation. WNK1 may also play a role in actin cytoskeletal reorganization. Phosphorylates NEDD4L. Acts as a scaffold to inhibit SLC4A4, SLC26A6 as well as CFTR activities and surface expression, recruits STK39 which mediates the inhibition (By similarity).
T52638	PDBSTRUC	6FBK; 5WE8; 5WDY; 5TF9; 4PWN
T52638	ECNUMBER	EC 2.7.11.1
T52638	SEQUENCE	MSGGAAEKQSSTPGSLFLSPPAPAPKNGSSSDSSVGEKLGAAAADAVTGRTEEYRRRRHTMDKDSRGAAATTTTTEHRFFRRSVICDSNATALELPGLPLSLPQPSIPAAVPQSAPPEPHREETVTATATSQVAQQPPAAAAPGEQAVAGPAPSTVPSSTSKDRPVSQPSLVGSKEEPPPARSGSGGGSAKEPQEERSQQQDDIEELETKAVGMSNDGRFLKFDIEIGRGSFKTVYKGLDTETTVEVAWCELQDRKLTKSERQRFKEEAEMLKGLQHPNIVRFYDSWESTVKGKKCIVLVTELMTSGTLKTYLKRFKVMKIKVLRSWCRQILKGLQFLHTRTPPIIHRDLKCDNIFITGPTGSVKIGDLGLATLKRASFAKSVIGTPEFMAPEMYEEKYDESVDVYAFGMCMLEMATSEYPYSECQNAAQIYRRVTSGVKPASFDKVAIPEVKEIIEGCIRQNKDERYSIKDLLNHAFFQEETGVRVELAEEDDGEKIAIKLWLRIEDIKKLKGKYKDNEAIEFSFDLERDVPEDVAQEMVESGYVCEGDHKTMAKAIKDRVSLIKRKREQRQLVREEQEKKKQEESSLKQQVEQSSASQTGIKQLPSASTGIPTASTTSASVSTQVEPEEPEADQHQQLQYQQPSISVLSDGTVDSGQGSSVFTESRVSSQQTVSYGSQHEQAHSTGTVPGHIPSTVQAQSQPHGVYPPSSVAQGQSQGQPSSSSLTGVSSSQPIQHPQQQQGIQQTAPPQQTVQYSLSQTSTSSEATTAQPVSQPQAPQVLPQVSAGKQLPVSQPVPTIQGEPQIPVATQPSVVPVHSGAHFLPVGQPLPTPLLPQYPVSQIPISTPHVSTAQTGFSSLPITMAAGITQPLLTLASSATTAAIPGVSTVVPSQLPTLLQPVTQLPSQVHPQLLQPAVQSMGIPANLGQAAEVPLSSGDVLYQGFPPRLPPQYPGDSNIAPSSNVASVCIHSTVLSPPMPTEVLATPGYFPTVVQPYVESNLLVPMGGVGGQVQVSQPGGSLAQAPTTSSQQAVLESTQGVSQVAPAEPVAVAQTQATQPTTLASSVDSAHSDVASGMSDGNENVPSSSGRHEGRTTKRHYRKSVRSRSRHEKTSRPKLRILNVSNKGDRVVECQLETHNRKMVTFKFDLDGDNPEEIATIMVNNDFILAIERESFVDQVREIIEKADEMLSEDVSVEPEGDQGLESLQGKDDYGFSGSQKLEGEFKQPIPASSMPQQIGIPTSSLTQVVHSAGRRFIVSPVPESRLRESKVFPSEITDTVAASTAQSPGMNLSHSASSLSLQQAFSELRRAQMTEGPNTAPPNFSHTGPTFPVVPPFLSSIAGVPTTAAATAPVPATSSPPNDISTSVIQSEVTVPTEEGIAGVATSTGVVTSGGLPIPPVSESPVLSSVVSSITIPAVVSISTTSPSLQVPTSTSEIVVSSTALYPSVTVSATSASAGGSTATPGPKPPAVVSQQAAGSTTVGATLTSVSTTTSFPSTASQLCIQLSSSTSTPTLAETVVVSAHSLDKTSHSSTTGLAFSLSAPSSSSSPGAGVSSYISQPGGLHPLVIPSVIASTPILPQAAGPTSTPLLPQVPSIPPLVQPVANVPAVQQTLIHSQPQPALLPNQPHTHCPEVDSDTQPKAPGIDDIKTLEEKLRSLFSEHSSSGAQHASVSLETSLVIESTVTPGIPTTAVAPSKLLTSTTSTCLPPTNLPLGTVALPVTPVVTPGQVSTPVSTTTSGVKPGTAPSKPPLTKAPVLPVGTELPAGTLPSEQLPPFPGPSLTQSQQPLEDLDAQLRRTLSPEMITVTSAVGPVSMAAPTAITEAGTQPQKGVSQVKEGPVLATSSGAGVFKMGRFQVSVAADGAQKEGKNKSEDAKSVHFESSTSESSVLSSSSPESTLVKPEPNGITIPGISSDVPESAHKTTASEAKSDTGQPTKVGRFQVTTTANKVGRFSVSKTEDKITDTKKEGPVASPPFMDLEQAVLPAVIPKKEKPELSEPSHLNGPSSDPEAAFLSRDVDDGSGSPHSPHQLSSKSLPSQNLSQSLSNSFNSSYMSSDNESDIEDEDLKLELRRLRDKHLKEIQDLQSRQKHEIESLYTKLGKVPPAVIIPPAAPLSGRRRRPTKSKGSKSSRSSSLGNKSPQLSGNLSGQSAASVLHPQQTLHPPGNIPESGQNQLLQPLKPSPSSDNLYSAFTSDGAISVPSLSAPGQGTSSTNTVGATVNSQAAQAQPPAMTSSRKGTFTDDLHKLVDNWARDAMNLSGRRGSKGHMNYEGPGMARKFSAPGQLCISMTSNLGGSAPISAASATSLGHFTKSMCPPQQYGFPATPFGAQWSGTGGPAPQPLGQFQPVGTASLQNFNISNLQKSISNPPGSNLRTT

T46216	TARGETID	T46216
T46216	FORMERID	TTDI03065
T46216	UNIPROID	BRD9_HUMAN
T46216	TARGNAME	Bromodomain-containing protein 9 (BRD9)
T46216	GENENAME	BRD9
T46216	TARGTYPE	Literature-reported
T46216	SYNONYMS	Rhabdomyosarcoma antigen MU-RMS-40.8
T46216	FUNCTION	Plays a role in chromatin remodeling and regulation of transcription. Acts as a chromatin reader that recognizes and binds acylated histones: binds histones that are acetylated and/or butyrylated. Component of SWI/SNF chromatin remodeling subcomplex GBAF that carries out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner.
T46216	PDBSTRUC	6HM0; 6BQA; 5TWX; 5MKY; 5JI8
T46216	BIOCLASS	Bromodomain
T46216	SEQUENCE	MGKKHKKHKAEWRSSYEDYADKPLEKPLKLVLKVGGSEVTELSGSGHDSSYYDDRSDHERERHKEKKKKKKKKSEKEKHLDDEERRKRKEEKKRKREREHCDTEGEADDFDPGKKVEVEPPPDRPVRACRTQPAENESTPIQQLLEHFLRQLQRKDPHGFFAFPVTDAIAPGYSMIIKHPMDFGTMKDKIVANEYKSVTEFKADFKLMCDNAMTYNRPDTVYYKLAKKILHAGFKMMSKQAALLGNEDTAVEEPVPEVVPVQVETAKKSKKPSREVISCMFEPEGNACSLTDSTAEEHVLALVEHAADEARDRINRFLPGGKMGYLKRNGDGSLLYSVVNTAEPDADEEETHPVDLSSLSSKLLPGFTTLGFKDERRNKVTFLSSATTALSMQNNSVFGDLKSDEMELLYSAYGDETGVQCALSLQEFVKDAGSYSKKVVDDLLDQITGGDHSRTLFQLKQRRNVPMKPPDEAKVGDTLGDSSSSVLEFMSMKSYPDVSVDISMLSSLGKVKKELDPDDSHLNLDETTKLLQDLHEAQAERGGSRPSSNLSSLSNASERDQHHLGSPSRLSVGEQPDVTHDPYEFLQSPEPAASAKT
T46216	DRUGINFO	D0N5BI	I-BRD9	Investigative
T46216	DRUGINFO	DVZ6M1	BI 7273	Investigative
T46216	DRUGINFO	D08LXU	LP99	Investigative

T39996	TARGETID	T39996
T39996	FORMERID	TTDI03185
T39996	UNIPROID	EHMT1_HUMAN
T39996	TARGNAME	Euchromatic histone-lysine N-methyltransferase 1 (EHMT1)
T39996	GENENAME	EHMT1
T39996	TARGTYPE	Literature-reported
T39996	SYNONYMS	EHMT1
T39996	FUNCTION	Histone methyltransferase that specifically mono- and dimethylates 'Lys-9' of histone H3 (H3K9me1 and H3K9me2, respectively) in euchromatin. H3K9me represents a specific tag for epigenetic transcriptional repression by recruiting HP1 proteins to methylated histones. Also weakly methylates 'Lys-27' of histone H3 (H3K27me). Also required for DNA methylation, the histone methyltransferase activity is not required for DNA methylation, suggesting that these 2 activities function independently. Probably targeted to histone H3 by different DNA-binding proteins like E2F6, MGA, MAX and/or DP1. During G0 phase, it probably contributes to silencing of MYC- and E2F-responsive genes, suggesting a role in G0/G1 transition in cell cycle. In addition to the histone methyltransferase activity, also methylates non-histone proteins: mediates dimethylation of 'Lys-373' of p53/TP53.
T39996	PDBSTRUC	6MBP; 6MBO; 6BY9; 5VSF; 5VSD
T39996	ECNUMBER	EC 2.1.1.-
T39996	SEQUENCE	MAAADAEAVPARGEPQQDCCVKTELLGEETPMAADEGSAEKQAGEAHMAADGETNGSCENSDASSHANAAKHTQDSARVNPQDGTNTLTRIAENGVSERDSEAAKQNHVTADDFVQTSVIGSNGYILNKPALQAQPLRTTSTLASSLPGHAAKTLPGGAGKGRTPSAFPQTPAAPPATLGEGSADTEDRKLPAPGADVKVHRARKTMPKSVVGLHAASKDPREVREARDHKEPKEEINKNISDFGRQQLLPPFPSLHQSLPQNQCYMATTKSQTACLPFVLAAAVSRKKKRRMGTYSLVPKKKTKVLKQRTVIEMFKSITHSTVGSKGEKDLGASSLHVNGESLEMDSDEDDSEELEEDDGHGAEQAAAFPTEDSRTSKESMSEADRAQKMDGESEEEQESVDTGEEEEGGDESDLSSESSIKKKFLKRKGKTDSPWIKPARKRRRRSRKKPSGALGSESYKSSAGSAEQTAPGDSTGYMEVSLDSLDLRVKGILSSQAEGLANGPDVLETDGLQEVPLCSCRMETPKSREITTLANNQCMATESVDHELGRCTNSVVKYELMRPSNKAPLLVLCEDHRGRMVKHQCCPGCGYFCTAGNFMECQPESSISHRFHKDCASRVNNASYCPHCGEESSKAKEVTIAKADTTSTVTPVPGQEKGSALEGRADTTTGSAAGPPLSEDDKLQGAASHVPEGFDPTGPAGLGRPTPGLSQGPGKETLESALIALDSEKPKKLRFHPKQLYFSARQGELQKVLLMLVDGIDPNFKMEHQNKRSPLHAAAEAGHVDICHMLVQAGANIDTCSEDQRTPLMEAAENNHLEAVKYLIKAGALVDPKDAEGSTCLHLAAKKGHYEVVQYLLSNGQMDVNCQDDGGWTPMIWATEYKHVDLVKLLLSKGSDINIRDNEENICLHWAAFSGCVDIAEILLAAKCDLHAVNIHGDSPLHIAARENRYDCVVLFLSRDSDVTLKNKEGETPLQCASLNSQVWSALQMSKALQDSAPDRPSPVERIVSRDIARGYERIPIPCVNAVDSEPCPSNYKYVSQNCVTSPMNIDRNITHLQYCVCIDDCSSSNCMCGQLSMRCWYDKDGRLLPEFNMAEPPLIFECNHACSCWRNCRNRVVQNGLRARLQLYRTRDMGWGVRSLQDIPPGTFVCEYVGELISDSEADVREEDSYLFDLDNKDGEVYCIDARFYGNVSRFINHHCEPNLVPVRVFMAHQDLRFPRIAFFSTRLIEAGEQLGFDYGERFWDIKGKLFSCRCGSPKCRHSSAALAQRQASAAQEAQEDGLPDTSSAAAADPL
T39996	DRUGINFO	D06PPL	BIX-01294	Preclinical
T39996	DRUGINFO	D0C5EG	A-366	Preclinical
T39996	DRUGINFO	D0BI4T	UNC0642	Investigative
T39996	DRUGINFO	D0GK7A	UNC0638	Investigative

T52946	TARGETID	T52946
T52946	FORMERID	TTDS00512
T52946	UNIPROID	S52A2_HUMAN
T52946	TARGNAME	Gamma-hydroxybutyrate receptor (SLC52A2)
T52946	GENENAME	SLC52A2
T52946	TARGTYPE	Literature-reported
T52946	SYNONYMS	SLC52A2; Protein GPR172A; PERV-A receptor 1; GPR172A
T52946	FUNCTION	Riboflavintransporter. Riboflavin transport is Na(+)- independent but moderately pH-sensitive. Activity is strongly inhibited by riboflavin analogs, such as lumiflavin. Weakly inhibited by flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN). In case of infection by retroviruses, acts as a cell receptor to retroviral envelopes similar to the porcine endogenous retrovirus (PERV-A).
T52946	BIOCLASS	Eukaryoticriboflavin transporter
T52946	SEQUENCE	MAAPTPARPVLTHLLVALFGMGSWAAVNGIWVELPVVVKELPEGWSLPSYVSVLVALGNLGLLVVTLWRRLAPGKDEQVPIRVVQVLGMVGTALLASLWHHVAPVAGQLHSVAFLALAFVLALACCASNVTFLPFLSHLPPRFLRSFFLGQGLSALLPCVLALVQGVGRLECPPAPINGTPGPPLDFLERFPASTFFWALTALLVASAAAFQGLLLLLPPPPSVPTGELGSGLQVGAPGAEEEVEESSPLQEPPSQAAGTTPGPDPKAYQLLSARSACLLGLLAATNALTNGVLPAVQSFSCLPYGRLAYHLAVVLGSAANPLACFLAMGVLCRSLAGLGGLSLLGVFCGGYLMALAVLSPCPPLVGTSAGVVLVVLSWVLCLGVFSYVKVAASSLLHGGGRPALLAAGVAIQVGSLLGAVAMFPPTSIYHVFHSRKDCADPCDS
T52946	DRUGINFO	D00ENC	4-Hydroxy-pent-2-enoic acid	Investigative
T52946	DRUGINFO	D00FPB	4-Hydroxy-3-methyl-butyric acid	Investigative
T52946	DRUGINFO	D00XKM	4-Hydroxy-4-phenyl-butyric acid	Investigative
T52946	DRUGINFO	D01TPW	4-hydroxy-but-2-enoate	Investigative
T52946	DRUGINFO	D05SGJ	5-hydroxy-pentanoate	Investigative
T52946	DRUGINFO	D06CQQ	4-Hydroxy-4-phenyl-but-2-enoic acid	Investigative
T52946	DRUGINFO	D06VNT	4-Hydroxy-3-methyl-but-2-enoic acid	Investigative
T52946	DRUGINFO	D07QSV	4-Hydroxy-pentanoic acid	Investigative
T52946	DRUGINFO	D0V0FG	4-Cyclohexyl-4-hydroxy-but-2-enoic acid	Investigative

T39380	TARGETID	T39380
T39380	FORMERID	TTDI03355
T39380	UNIPROID	LPAR2_HUMAN
T39380	TARGNAME	Lysophosphatidic acid receptor 2 (LPAR2)
T39380	GENENAME	LPAR2
T39380	TARGTYPE	Literature-reported
T39380	SYNONYMS	Lysophosphatidic acid receptor Edg-4; LPA2; LPA-2; LPA receptor 2; EDG4
T39380	FUNCTION	Seems to be coupled to the G(i)/G(o), G(12)/G(13), and G(q) families of heteromeric G proteins. Plays a key role in phospholipase C-beta (PLC-beta) signaling pathway. Stimulates phospholipase C (PLC) activity in a manner that is independent of RALA activation. Receptor for lysophosphatidic acid (LPA), a mediator of diverse cellular activities.
T39380	PDBSTRUC	4P0C
T39380	BIOCLASS	GPCR rhodopsin
T39380	SEQUENCE	MVIMGQCYYNETIGFFYNNSGKELSSHWRPKDVVVVALGLTVSVLVLLTNLLVIAAIASNRRFHQPIYYLLGNLAAADLFAGVAYLFLMFHTGPRTARLSLEGWFLRQGLLDTSLTASVATLLAIAVERHRSVMAVQLHSRLPRGRVVMLIVGVWVAALGLGLLPAHSWHCLCALDRCSRMAPLLSRSYLAVWALSSLLVFLLMVAVYTRIFFYVRRRVQRMAEHVSCHPRYRETTLSLVKTVVIILGAFVVCWTPGQVVLLLDGLGCESCNVLAVEKYFLLLAEANSLVNAAVYSCRDAEMRRTFRRLLCCACLRQSTRESVHYTSSAQGGASTRIMLPENGHPLMDSTL
T39380	DRUGINFO	D01PKC	PMID18178086C15	Investigative
T39380	DRUGINFO	D0E0DY	decyl dihydrogen phosphate	Investigative
T39380	DRUGINFO	D0G8FF	GRI977143	Investigative
T39380	DRUGINFO	D06IXI	BrP-LPA	Investigative
T39380	DRUGINFO	D0FZ6A	dodecylphosphate	Investigative
T39380	DRUGINFO	D04KQT	dodecyl-thiophosphate	Investigative
T39380	DRUGINFO	D0K3GQ	oleoyl-thiophosphate	Investigative
T39380	DRUGINFO	D0R8LB	NAEPA	Investigative
T39380	DRUGINFO	D02LXI	Ki16425	Investigative
T39380	DRUGINFO	D0R2VH	2-oleoyl-LPA	Investigative
T39380	DRUGINFO	D0X0UR	LPA	Investigative

T56143	TARGETID	T56143
T56143	FORMERID	TTDI00075
T56143	UNIPROID	GPR35_HUMAN
T56143	TARGNAME	Kynurenic acid receptor (GPR35)
T56143	GENENAME	GPR35
T56143	TARGTYPE	Literature-reported
T56143	SYNONYMS	KYNA receptor; Gprotein coupled receptor 35; GPR35
T56143	FUNCTION	Acts as a receptor for kynurenic acid, an intermediate in the tryptophan metabolic pathway. The activity of this receptor is mediated by G-proteins that elicit calcium mobilization and inositol phosphate production through G(qi/o) proteins.
T56143	BIOCLASS	GPCR rhodopsin
T56143	SEQUENCE	MNGTYNTCGSSDLTWPPAIKLGFYAYLGVLLVLGLLLNSLALWVFCCRMQQWTETRIYMTNLAVADLCLLCTLPFVLHSLRDTSDTPLCQLSQGIYLTNRYMSISLVTAIAVDRYVAVRHPLRARGLRSPRQAAAVCAVLWVLVIGSLVARWLLGIQEGGFCFRSTRHNFNSMAFPLLGFYLPLAVVVFCSLKVVTALAQRPPTDVGQAEATRKAARMVWANLLVFVVCFLPLHVGLTVRLAVGWNACALLETIRRALYITSKLSDANCCLDAICYYYMAKEFQEASALAVAPSAKAHKSQDSLCVTLA
T56143	DRUGINFO	D04BYU	pamoic acid	Investigative
T56143	DRUGINFO	D0R2VH	2-oleoyl-LPA	Investigative

T30829	TARGETID	T30829
T30829	FORMERID	TTDI03402
T30829	UNIPROID	NEK6_HUMAN
T30829	TARGNAME	NIMA-related kinase 6 (NEK6)
T30829	GENENAME	NEK6
T30829	TARGTYPE	Literature-reported
T30829	SYNONYMS	Serine/threonine-protein kinase Nek6; Protein kinase SID6-1512; NimA-related protein kinase 6; Never in mitosis A-related kinase 6
T30829	FUNCTION	Required for chromosome segregation at metaphase-anaphase transition, robust mitotic spindle formation and cytokinesis. Phosphorylates ATF4, CIR1, PTN, RAD26L, RBBP6, RPS7, RPS6KB1, TRIP4, STAT3 and histones H1 and H3. Phosphorylates KIF11 to promote mitotic spindle formation. Involved in G2/M phase cell cycle arrest induced by DNA damage. Inhibition of activity results in apoptosis. May contribute to tumorigenesis by suppressing p53/TP53-induced cancer cell senescence. Protein kinase which plays an important role in mitotic cell cycle progression.
T30829	BIOCLASS	Kinase
T30829	ECNUMBER	EC 2.7.11.1
T30829	SEQUENCE	MAGQPGHMPHGGSSNNLCHTLGPVHPPDPQRHPNTLSFRCSLADFQIEKKIGRGQFSEVYKATCLLDRKTVALKKVQIFEMMDAKARQDCVKEIGLLKQLNHPNIIKYLDSFIEDNELNIVLELADAGDLSQMIKYFKKQKRLIPERTVWKYFVQLCSAVEHMHSRRVMHRDIKPANVFITATGVVKLGDLGLGRFFSSETTAAHSLVGTPYYMSPERIHENGYNFKSDIWSLGCLLYEMAALQSPFYGDKMNLFSLCQKIEQCDYPPLPGEHYSEKLRELVSMCICPDPHQRPDIGYVHQVAKQMHIWMSST
T30829	DRUGINFO	D0V0KA	PMID20462760C22	Investigative

T41702	TARGETID	T41702
T41702	FORMERID	TTDI03082
T41702	UNIPROID	KC1G1_HUMAN
T41702	TARGNAME	Casein kinase I gamma-1 (CSNK1G1)
T41702	GENENAME	CSNK1G1
T41702	TARGTYPE	Literature-reported
T41702	SYNONYMS	Casein kinase I isoform gamma-1; CKI-gamma 1
T41702	FUNCTION	Serine/threonine-protein kinase. Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. It can phosphorylate a large number of proteins. Participates in Wnt signaling. Regulates fast synaptic transmission mediated by glutamate (By similarity). Phosphorylates CLSPN.
T41702	PDBSTRUC	2CMW
T41702	ECNUMBER	EC 2.7.11.1
T41702	SEQUENCE	MDHPSREKDERQRTTKPMAQRSAHCSRPSGSSSSSGVLMVGPNFRVGKKIGCGNFGELRLGKNLYTNEYVAIKLEPIKSRAPQLHLEYRFYKQLGSAGEGLPQVYYFGPCGKYNAMVLELLGPSLEDLFDLCDRTFTLKTVLMIAIQLLSRMEYVHSKNLIYRDVKPENFLIGRQGNKKEHVIHIIDFGLAKEYIDPETKKHIPYREHKSLTGTARYMSINTHLGKEQSRRDDLEALGHMFMYFLRGSLPWQGLKADTLKERYQKIGDTKRNTPIEALCENFPEEMATYLRYVRRLDFFEKPDYEYLRTLFTDLFEKKGYTFDYAYDWVGRPIPTPVGSVHVDSGASAITRESHTHRDRPSQQQPLRNQVVSSTNGELNVDDPTGAHSNAPITAHAEVEVVEEAKCCCFFKRKRKKTAQRHK
T41702	DRUGINFO	D01YWE	PMID19364658C33	Investigative

T99802	TARGETID	T99802
T99802	FORMERID	TTDI03442
T99802	UNIPROID	PDE11_HUMAN
T99802	TARGNAME	Phosphodiesterase 11A (PDE11A)
T99802	GENENAME	PDE11A
T99802	TARGTYPE	Literature-reported
T99802	SYNONYMS	cAMP and cGMP phosphodiesterase 11A; Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A
T99802	FUNCTION	Catalyzes the hydrolysis of both cAMP and cGMP to 5'-AMP and 5'-GMP, respectively. Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides cAMP and cGMP.
T99802	BIOCLASS	Phosphoric diester hydrolase
T99802	ECNUMBER	EC 3.1.4.35
T99802	SEQUENCE	MAASRLDFGEVETFLDRHPELFEDYLMRKGKQEMVEKWLQRHSQGQGALGPRPSLAGTSSLAHSTCRGGSSVGGGTGPNGSAHSQPLPGGGDCGGVPLSPSWAGGSRGDGNLQRRASQKELRKSFARSKAIHVNRTYDEQVTSRAQEPLSSVRRRALLRKASSLPPTTAHILSALLESRVNLPRYPPTAIDYKCHLKKHNERQFFLELVKDISNDLDLTSLSYKILIFVCLMVDADRCSLFLVEGAAAGKKTLVSKFFDVHAGTPLLPCSSTENSNEVQVPWGKGIIGYVGEHGETVNIPDAYQDRRFNDEIDKLTGYKTKSLLCMPIRSSDGEIIGVAQAINKIPEGAPFTEDDEKVMQMYLPFCGIAISNAQLFAASRKEYERSRALLEVVNDLFEEQTDLEKIVKKIMHRAQTLLKCERCSVLLLEDIESPVVKFTKSFELMSPKCSADAENSFKESMEKSSYSDWLINNSIAELVASTGLPVNISDAYQDPRFDAEADQISGFHIRSVLCVPIWNSNHQIIGVAQVLNRLDGKPFDDADQRLFEAFVIFCGLGINNTIMYDQVKKSWAKQSVALDVLSYHATCSKAEVDKFKAANIPLVSELAIDDIHFDDFSLDVDAMITAALRMFMELGMVQKFKIDYETLCRWLLTVRKNYRMVLYHNWRHAFNVCQLMFAMLTTAGFQDILTEVEILAVIVGCLCHDLDHRGTNNAFQAKSGSALAQLYGTSATLEHHHFNHAVMILQSEGHNIFANLSSKEYSDLMQLLKQSILATDLTLYFERRTEFFELVSKGEYDWNIKNHRDIFRSMLMTACDLGAVTKPWEISRQVAELVTSEFFEQGDRERLELKLTPSAIFDRNRKDELPRLQLEWIDSICMPLYQALVKVNVKLKPMLDSVATNRSKWEELHQKRLLASTASSSPASVMVAKEDRN
T99802	DRUGINFO	D03QTH	BC11-38	Investigative

T59082	TARGETID	T59082
T59082	FORMERID	TTDR00854
T59082	UNIPROID	CD209_HUMAN
T59082	TARGNAME	Membrane-associated lectin type-C (CD209)
T59082	GENENAME	CD209
T59082	TARGTYPE	Literature-reported
T59082	SYNONYMS	Surface C-type lectin DC-SIGN; Probable mannose-binding C-type lectin DC-SIGN; MDC-SIGN1A type I isoform; Dendritic cell-specific ICAM-3-grabbing nonintegrin 1; Dendritic cell-specific ICAM-3-grabbing non-integrin 1; DC-specific ICAM-3 grabbing nonintegrin; DC-SIGN1; DC-SIGN; CLEC4L; CD209 antigen; CD 209; C-type lectin domain family 4 member L
T59082	FUNCTION	Pathogen-recognition receptor expressed on the surface of immature dendritic cells (DCs) and involved in initiation of primary immune response. Thought to mediate the endocytosis of pathogens which are subsequently degraded in lysosomal compartments. The receptor returns to the cell membrane surface and the pathogen-derived antigens are presented to resting T-cells via MHC class II proteins to initiate the adaptive immune response.
T59082	PDBSTRUC	2XR6; 2XR5; 2IT6; 2IT5; 2B6B
T59082	SEQUENCE	MSDSKEPRLQQLGLLEEEQLRGLGFRQTRGYKSLAGCLGHGPLVLQLLSFTLLAGLLVQVSKVPSSISQEQSRQDAIYQNLTQLKAAVGELSEKSKLQEIYQELTQLKAAVGELPEKSKLQEIYQELTRLKAAVGELPEKSKLQEIYQELTWLKAAVGELPEKSKMQEIYQELTRLKAAVGELPEKSKQQEIYQELTRLKAAVGELPEKSKQQEIYQELTRLKAAVGELPEKSKQQEIYQELTQLKAAVERLCHPCPWEWTFFQGNCYFMSNSQRNWHDSITACKEVGAQLVVIKSAEEQNFLQLQSSRSNRFTWMGLSDLNQEGTWQWVDGSPLLPSFKQYWNRGEPNNVGEEDCAEFSGNGWNDDKCNLAKFWICKKSAASCSRDEEQFLSPAPATPNPPPA
T59082	DRUGINFO	D0G6XS	Fucose	Investigative
T59082	DRUGINFO	D07LUR	Alpha-D-Mannose	Investigative

T23984	TARGETID	T23984
T23984	FORMERID	TTDI03064
T23984	UNIPROID	BRD7_HUMAN
T23984	TARGNAME	Bromodomain-containing protein 7 (BRD7)
T23984	GENENAME	BRD7
T23984	TARGTYPE	Literature-reported
T23984	SYNONYMS	Protein CELTIX-1; CELTIX1; BP75; 75 kDa bromodomain protein
T23984	FUNCTION	May play a role in chromatin remodeling. Activator of the Wnt signaling pathway in a DVL1-dependent manner by negatively regulating the GSK3B phosphotransferase activity. Induces dephosphorylation of GSK3B at 'Tyr-216'. Down-regulates TRIM24-mediated activation of transcriptional activation by AR. Transcriptional corepressor that down-regulates the expression of target genes. Binds to target promoters, leading to increased histone H3 acetylation at 'Lys-9' (H3K9ac). Binds to the ESR1 promoter. Recruits BRCA1 and POU2F1 to the ESR1 promoter. Coactivator for TP53-mediated activation of transcription of a set of target genes. Required for TP53-mediated cell-cycle arrest in response to oncogene activation. Promotes acetylation of TP53 at 'Lys-382', and thereby promotes efficient recruitment of TP53 to target promoters. Inhibits cell cycle progression from G1 to S phase. Acts both as coactivator and as corepressor.
T23984	PDBSTRUC	5MQ1; 2I7K
T23984	BIOCLASS	Bromodomain
T23984	SEQUENCE	MGKKHKKHKSDKHLYEEYVEKPLKLVLKVGGNEVTELSTGSSGHDSSLFEDKNDHDKHKDRKRKKRKKGEKQIPGEEKGRKRRRVKEDKKKRDRDRVENEAEKDLQCHAPVRLDLPPEKPLTSSLAKQEEVEQTPLQEALNQLMRQLQRKDPSAFFSFPVTDFIAPGYSMIIKHPMDFSTMKEKIKNNDYQSIEELKDNFKLMCTNAMIYNKPETIYYKAAKKLLHSGMKILSQERIQSLKQSIDFMADLQKTRKQKDGTDTSQSGEDGGCWQREREDSGDAEAHAFKSPSKENKKKDKDMLEDKFKSNNLEREQEQLDRIVKESGGKLTRRLVNSQCEFERRKPDGTTTLGLLHPVDPIVGEPGYCPVRLGMTTGRLQSGVNTLQGFKEDKRNKVTPVLYLNYGPYSSYAPHYDSTFANISKDDSDLIYSTYGEDSDLPSDFSIHEFLATCQDYPYVMADSLLDVLTKGGHSRTLQEMEMSLPEDEGHTRTLDTAKEMEITEVEPPGRLDSSTQDRLIALKAVTNFGVPVEVFDSEEAEIFQKKLDETTRLLRELQEAQNERLSTRPPPNMICLLGPSYREMHLAEQVTNNLKELAQQVTPGDIVSTYGVRKAMGISIPSPVMENNFVDLTEDTEEPKKTDVAECGPGGS
T23984	DRUGINFO	D08LXU	LP99	Investigative

T26846	TARGETID	T26846
T26846	FORMERID	TTDR00883
T26846	UNIPROID	PLCB1_HUMAN
T26846	TARGNAME	Phospholipase C-beta-1 (PLCB1)
T26846	GENENAME	PLCB1
T26846	TARGTYPE	Literature-reported
T26846	SYNONYMS	Phospholipase C-beta1; Phospholipase C-I; Phosphoinositide phospholipase C-beta-1; Phosphoinositide phospholipase C; PLC-beta-1; PLC-I; PLC-154; KIAA0581; 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1
T26846	FUNCTION	The production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by activated phosphatidylinositol-specific phospholipase C enzymes.
T26846	BIOCLASS	Phosphoric diester hydrolase
T26846	ECNUMBER	EC 3.1.4.11
T26846	SEQUENCE	MAGAQPGVHALQLKPVCVSDSLKKGTKFVKWDDDSTIVTPIILRTDPQGFFFYWTDQNKETELLDLSLVKDARCGRHAKAPKDPKLRELLDVGNIGRLEQRMITVVYGPDLVNISHLNLVAFQEEVAKEWTNEVFSLATNLLAQNMSRDAFLEKAYTKLKLQVTPEGRIPLKNIYRLFSADRKRVETALEACSLPSSRNDSIPQEDFTPEVYRVFLNNLCPRPEIDNIFSEFGAKSKPYLTVDQMMDFINLKQRDPRLNEILYPPLKQEQVQVLIEKYEPNNSLARKGQISVDGFMRYLSGEENGVVSPEKLDLNEDMSQPLSHYFINSSHNTYLTAGQLAGNSSVEMYRQVLLSGCRCVELDCWKGRTAEEEPVITHGFTMTTEISFKEVIEAIAECAFKTSPFPILLSFENHVDSPKQQAKMAEYCRLIFGDALLMEPLEKYPLESGVPLPSPMDLMYKILVKNKKKSHKSSEGSGKKKLSEQASNTYSDSSSMFEPSSPGAGEADTESDDDDDDDDCKKSSMDEGTAGSEAMATEEMSNLVNYIQPVKFESFEISKKRNKSFEMSSFVETKGLEQLTKSPVEFVEYNKMQLSRIYPKGTRVDSSNYMPQLFWNAGCQMVALNFQTMDLAMQINMGMYEYNGKSGYRLKPEFMRRPDKHFDPFTEGIVDGIVANTLSVKIISGQFLSDKKVGTYVEVDMFGLPVDTRRKAFKTKTSQGNAVNPVWEEEPIVFKKVVLPTLACLRIAVYEEGGKFIGHRILPVQAIRPGYHYICLRNERNQPLTLPAVFVYIEVKDYVPDTYADVIEALSNPIRYVNLMEQRAKQLAALTLEDEEEVKKEADPGETPSEAPSEARTTPAENGVNHTTTLTPKPPSQALHSQPAPGSVKAPAKTEDLIQSVLTEVEAQTIEELKQQKSFVKLQKKHYKEMKDLVKRHHKKTTDLIKEHTTKYNEIQNDYLRRRAALEKSAKKDSKKKSEPSSPDHGSSTIEQDLAALDAEMTQKLIDLKDKQQQQLLNLRQEQYYSEKYQKREHIKLLIQKLTDVAEECQNNQLKKLKEICEKEKKELKKKMDKKRQEKITEAKSKDKSQMEEEKTEMIRSYIQEVVQYIKRLEEAQSKRQEKLVEKHKEIRQQILDEKPKLQVELEQEYQDKFKRLPLEILEFVQEAMKGKISEDSNHGSAPLSLSSDPGKVNHKTPSSEELGGDIPGKEFDTPL

T79726	TARGETID	T79726
T79726	FORMERID	TTDR00918
T79726	UNIPROID	G6PC2_HUMAN
T79726	TARGNAME	Glucose-6-phosphatase 2 (G6PC2)
T79726	GENENAME	G6PC2
T79726	TARGTYPE	Literature-reported
T79726	SYNONYMS	IGRP; G6PC2
T79726	FUNCTION	May hydrolyze glucose-6-phosphate to glucose in the endoplasmic reticulum. May be responsible for glucose production through glycogenolysis and gluconeogenesis.
T79726	BIOCLASS	Phosphoric monoester hydrolase
T79726	ECNUMBER	EC 3.1.3.9
T79726	SEQUENCE	MDFLHRNGVLIIQHLQKDYRAYYTFLNFMSNVGDPRNIFFIYFPLCFQFNQTVGTKMIWVAVIGDWLNLIFKWILFGHRPYWWVQETQIYPNHSSPCLEQFPTTCETGPGSPSGHAMGASCVWYVMVTAALSHTVCGMDKFSITLHRLTWSFLWSVFWLIQISVCISRVFIATHFPHQVILGVIGGMLVAEAFEHTPGIQTASLGTYLKTNLFLFLFAVGFYLLLRVLNIDLLWSVPIAKKWCANPDWIHIDTTPFAGLVRNLGVLFGLGFAINSEMFLLSCRGGNNYTLSFRLLCALTSLTILQLYHFLQIPTHEEHLFYVLSFCKSASIPLTVVAFIPYSVHMLMKQSGKKSQ

T20542	TARGETID	T20542
T20542	FORMERID	TTDI03166
T20542	UNIPROID	DYRK4_HUMAN
T20542	TARGNAME	Dual-specificity tyrosine-phosphorylation regulated kinase 4 (DYRK4)
T20542	GENENAME	DYRK4
T20542	TARGTYPE	Literature-reported
T20542	SYNONYMS	Dual specificity tyrosine-phosphorylation-regulated kinase 4
T20542	FUNCTION	Possible non-essential role in spermiogenesis.
T20542	BIOCLASS	Kinase
T20542	ECNUMBER	EC 2.7.12.1
T20542	SEQUENCE	MPASELKASEIPFHPSIKTQDPKAEEKSPKKQKVTLTAAEALKLFKNQLSPYEQSEILGYAELWFLGLEAKKLDTAPEKFSKTSFDDEHGFYLKVLHDHIAYRYEVLETIGKGSFGQVAKCLDHKNNELVALKIIRNKKRFHQQALMELKILEALRKKDKDNTYNVVHMKDFFYFRNHFCITFELLGINLYELMKNNNFQGFSLSIVRRFTLSVLKCLQMLSVEKIIHCDLKPENIVLYQKGQASVKVIDFGSSCYEHQKVYTYIQSRFYRSPEVILGHPYDVAIDMWSLGCITAELYTGYPLFPGENEVEQLACIMEVLGLPPAGFIQTASRRQTFFDSKGFPKNITNNRGKKRYPDSKDLTMVLKTYDTSFLDFLRRCLVWEPSLRMTPDQALKHAWIHQSRNLKPQPRPQTLRKSNSFFPSETRKDKVQGCHHSSRKADEITKETTEKTKDSPTKHVQHSGDQQDCLQHGADTVQLPQLVDAPKKSEAAVGAEVSMTSPGQSKNFSLKNTNVLPPIV
T20542	DRUGINFO	D04IMY	leucettine L41	Investigative

T55068	TARGETID	T55068
T55068	FORMERID	TTDI03344
T55068	UNIPROID	KCNQ5_HUMAN
T55068	TARGNAME	Voltage-gated potassium channel Kv7.5 (KCNQ5)
T55068	GENENAME	KCNQ5
T55068	TARGTYPE	Literature-reported
T55068	SYNONYMS	Voltage-gated potassium channel subunit Kv7.5; Potassium voltage-gated channel subfamily KQT member 5; Potassium channel subunit alpha KvLQT5; KQT-like 5
T55068	FUNCTION	Therefore, it is important in the regulation of neuronal excitability. May contribute, with other potassium channels, to the molecular diversity of a heterogeneous population of M-channels, varying in kinetic and pharmacological properties, which underlie this physiologically important current. Insensitive to tetraethylammonium, but inhibited by barium, linopirdine and XE991. Activated by niflumic acid and the anticonvulsant retigabine. As the native M-channel, the potassium channel composed of KCNQ3 and KCNQ5 is also suppressed by activation of the muscarinic acetylcholine receptor CHRM1. Associates with KCNQ3 to form a potassium channel which contributes to M-type current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons.
T55068	PDBSTRUC	6B8Q
T55068	BIOCLASS	Voltage-gated ion channel
T55068	SEQUENCE	MPRHHAGGEEGGAAGLWVKSGAAAAAAGGGRLGSGMKDVESGRGRVLLNSAAARGDGLLLLGTRAATLGGGGGGLRESRRGKQGARMSLLGKPLSYTSSQSCRRNVKYRRVQNYLYNVLERPRGWAFIYHAFVFLLVFGCLILSVFSTIPEHTKLASSCLLILEFVMIVVFGLEFIIRIWSAGCCCRYRGWQGRLRFARKPFCVIDTIVLIASIAVVSAKTQGNIFATSALRSLRFLQILRMVRMDRRGGTWKLLGSVVYAHSKELITAWYIGFLVLIFSSFLVYLVEKDANKEFSTYADALWWGTITLTTIGYGDKTPLTWLGRLLSAGFALLGISFFALPAGILGSGFALKVQEQHRQKHFEKRRNPAANLIQCVWRSYAADEKSVSIATWKPHLKALHTCSPTKKEQGEASSSQKLSFKERVRMASPRGQSIKSRQASVGDRRSPSTDITAEGSPTKVQKSWSFNDRTRFRPSLRLKSSQPKPVIDADTALGTDDVYDEKGCQCDVSVEDLTPPLKTVIRAIRIMKFHVAKRKFKETLRPYDVKDVIEQYSAGHLDMLCRIKSLQTRVDQILGKGQITSDKKSREKITAEHETTDDLSMLGRVVKVEKQVQSIESKLDCLLDIYQQVLRKGSASALALASFQIPPFECEQTSDYQSPVDSKDLSGSAQNSGCLSRSTSANISRGLQFILTPNEFSAQTFYALSPTMHSQATQVPISQSDGSAVAATNTIANQINTAPKPAAPTTLQIPPPLPAIKHLPRPETLHPNPAGLQESISDVTTCLVASKENVQVAQSNLTKDRSMRKSFDMGGETLLSVCPMVPKDLGKSLSVQNLIRSTEELNIQLSGSESSGSRGSQDFYPKWRESKLFITDEEVGPEETETDTFDAAPQPAREAAFASDSLRTGRSRSSQSICKAGESTDALSLPHVKLK
T55068	DRUGINFO	D02BGR	(S)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide	Investigative
T55068	DRUGINFO	D07FTI	zinc pyrithione	Investigative
T55068	DRUGINFO	D0P8PH	XE991	Investigative
T55068	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T79824	TARGETID	T79824
T79824	FORMERID	TTDI03538
T79824	UNIPROID	STK36_HUMAN
T79824	TARGNAME	Fused homolog (STK36)
T79824	GENENAME	STK36
T79824	TARGTYPE	Literature-reported
T79824	SYNONYMS	Serine/threonine-protein kinase 36; KIAA1278
T79824	FUNCTION	Controls the activity of the transcriptional regulators GLI1, GLI2 and GLI3 by opposing the effect of SUFU and promoting their nuclear localization. GLI2 requires an additional function of STK36 to become transcriptionally active, but the enzyme does not need to possess an active kinase catalytic site for this to occur. Required for postnatal development, possibly by regulating the homeostasis of cerebral spinal fluid or ciliary function. Essential for construction of the central pair apparatus of motile cilia. Serine/threonine protein kinase which plays an important role in the sonic hedgehog (Shh) pathway by regulating the activity of GLI transcription factors.
T79824	BIOCLASS	Kinase
T79824	ECNUMBER	EC 2.7.11.1
T79824	SEQUENCE	MEKYHVLEMIGEGSFGRVYKGRRKYSAQVVALKFIPKLGRSEKELRNLQREIEIMRGLRHPNIVHMLDSFETDKEVVVVTDYAEGELFQILEDDGKLPEDQVQAIAAQLVSALYYLHSHRILHRDMKPQNILLAKGGGIKLCDFGFARAMSTNTMVLTSIKGTPLYMSPELVEERPYDHTADLWSVGCILYELAVGTPPFYATSIFQLVSLILKDPVRWPSTISPCFKNFLQGLLTKDPRQRLSWPDLLYHPFIAGHVTIITEPAGPDLGTPFTSRLPPELQVLKDEQAHRLAPKGNQSRILTQAYKRMAEEAMQKKHQNTGPALEQEDKTSKVAPGTAPLPRLGATPQESSLLAGILASELKSSWAKSGTGEVPSAPRENRTTPDCERAFPEERPEVLGQRSTDVVDLENEEPDSDNEWQHLLETTEPVPIQLKAPLTLLCNPDFCQRIQSQLHEAGGQILKGILEGASHILPAFRVLSSLLSSCSDSVALYSFCREAGLPGLLLSLLRHSQESNSLQQQSWYGTFLQDLMAVIQAYFACTFNLERSQTSDSLQVFQEAANLFLDLLGKLLAQPDDSEQTLRRDSLMCFTVLCEAMDGNSRAISKAFYSSLLTTQQVVLDGLLHGLTVPQLPVHTPQGAPQVSQPLREQSEDIPGAISSALAAICTAPVGLPDCWDAKEQVCWHLANQLTEDSSQLRPSLISGLQHPILCLHLLKVLYSCCLVSEGLCRLLGQEPLALESLFMLIQGKVKVVDWEESTEVTLYFLSLLVFRLQNLPCGMEKLGSDVATLFTHSHVVSLVSAAACLLGQLGQQGVTFDLQPMEWMAAATHALSAPAEVRLTPPGSCGFYDGLLILLLQLLTEQGKASLIRDMSSSEMWTVLWHRFSMVLRLPEEASAQEGELSLSSPPSPEPDWTLISPQGMAALLSLAMATFTQEPQLCLSCLSQHGSILMSILKHLLCPSFLNQLRQAPHGSEFLPVVVLSVCQLLCFPFALDMDADLLIGVLADLRDSEVAAHLLQVCCYHLPLMQVELPISLLTRLALMDPTSLNQFVNTVSASPRTIVSFLSVALLSDQPLLTSDLLSLLAHTARVLSPSHLSFIQELLAGSDESYRPLRSLLGHPENSVRAHTYRLLGHLLQHSMALRGALQSQSGLLSLLLLGLGDKDPVVRCSASFAVGNAAYQAGPLGPALAAAVPSMTQLLGDPQAGIRRNVASALGNLGPEGLGEELLQCEVPQRLLEMACGDPQPNVKEAALIALRSLQQEPGIHQVLVSLGASEKLSLLSLGNQSLPHSSPRPASAKHCRKLIHLLRPAHSM
T79824	DRUGINFO	D09RYV	Ro-0505124	Investigative

T97821	TARGETID	T97821
T97821	FORMERID	TTDI03623
T97821	UNIPROID	M3K20_HUMAN
T97821	TARGNAME	MLK-related kinase (MLTK)
T97821	GENENAME	MAP3K20
T97821	TARGTYPE	Literature-reported
T97821	SYNONYMS	ZAK; Sterile alpha motif- and leucine zipper-containing kinase AZK; Mixed lineage kinase-related kinase; Mitogen-activated protein kinase kinase kinase MLT; Mitogen-activated protein kinase kinase kinase 20; MRK; MLTK; MLK-like mitogen-activated protein triple kinase; Leucine zipper- and sterile alpha motif-containing kinase; Human cervical cancer suppressor gene 4 protein; HCCS4; HCCS-4
T97821	FUNCTION	Stress-activated component of a protein kinase signal transduction cascade. Regulates the JNK and p38 pathways. Part of a signaling cascade that begins with the activation of the adrenergic receptor ADRA1B and leads to the activation of MAPK14. Pro-apoptotic. Role in regulation of S and G2 cell cycle checkpoint by direct phosphorylation of CHEK2. Involved in limb development.
T97821	PDBSTRUC	5X5O; 5HES
T97821	ECNUMBER	EC 2.7.11.25
T97821	SEQUENCE	MSSLGASFVQIKFDDLQFFENCGGGSFGSVYRAKWISQDKEVAVKKLLKIEKEAEILSVLSHRNIIQFYGVILEPPNYGIVTEYASLGSLYDYINSNRSEEMDMDHIMTWATDVAKGMHYLHMEAPVKVIHRDLKSRNVVIAADGVLKICDFGASRFHNHTTHMSLVGTFPWMAPEVIQSLPVSETCDTYSYGVVLWEMLTREVPFKGLEGLQVAWLVVEKNERLTIPSSCPRSFAELLHQCWEADAKKRPSFKQIISILESMSNDTSLPDKCNSFLHNKAEWRCEIEATLERLKKLERDLSFKEQELKERERRLKMWEQKLTEQSNTPLLPSFEIGAWTEDDVYCWVQQLVRKGDSSAEMSVYASLFKENNITGKRLLLLEEEDLKDMGIVSKGHIIHFKSAIEKLTHDYINLFHFPPLIKDSGGEPEENEEKIVNLELVFGFHLKPGTGPQDCKWKMYMEMDGDEIAITYIKDVTFNTNLPDAEILKMTKPPFVMEKWIVGIAKSQTVECTVTYESDVRTPKSTKHVHSIQWSRTKPQDEVKAVQLAIQTLFTNSDGNPGSRSDSSADCQWLDTLRMRQIASNTSLQRSQSNPILGSPFFSHFDGQDSYAAAVRRPQVPIKYQQITPVNQSRSSSPTQYGLTKNFSSLHLNSRDSGFSSGNTDTSSERGRYSDRSRNKYGRGSISLNSSPRGRYSGKSQHSTPSRGRYPGKFYRVSQSALNPHQSPDFKRSPRDLHQPNTIPGMPLHPETDSRASEEDSKVSEGGWTKVEYRKKPHRPSPAKTNKERARGDHRGWRNF
T97821	DRUGINFO	D06BDC	PMID16539403C15b	Investigative

T75015	TARGETID	T75015
T75015	FORMERID	TTDI01485
T75015	UNIPROID	E2AK3_HUMAN
T75015	TARGNAME	Pancreatic eIF2-alpha kinase (HsPEK)
T75015	GENENAME	EIF2AK3
T75015	TARGTYPE	Literature-reported
T75015	SYNONYMS	PERK; HsPEK; Eukaryotic translation initiation factor 2-alpha kinase 3
T75015	FUNCTION	Metabolic-stress sensing protein kinase that phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (eIF-2-alpha/EIF2S1) on 'Ser-52' during the unfolded protein response (UPR) and in response to low amino acid availability. Converts phosphorylated eIF-2-alpha/EIF2S1 either in a global protein synthesis inhibitor, leading to a reduced overall utilization of amino acids, or to a translation initiation activator of specific mRNAs, such as the transcriptional activator ATF4, and hence allowing ATF4-mediated reprogramming of amino acid biosynthetic gene expression to alleviate nutrient depletion. Serves as a critical effector of unfolded protein response (UPR)-induced G1 growth arrest due to the loss of cyclin-D1 (CCND1). Involved in control of mitochondrial morphology and function.
T75015	PDBSTRUC	5SV7; 4YZS; 4X7O; 4X7N; 4X7L
T75015	ECNUMBER	EC 2.7.11.1
T75015	SEQUENCE	MERAISPGLLVRALLLLLLLLGLAARTVAAGRARGLPAPTAEAAFGLGAAAAPTSATRVPAAGAVAAAEVTVEDAEALPAAAGEQEPRGPEPDDETELRPRGRSLVIISTLDGRIAALDPENHGKKQWDLDVGSGSLVSSSLSKPEVFGNKMIIPSLDGALFQWDQDRESMETVPFTVESLLESSYKFGDDVVLVGGKSLTTYGLSAYSGKVRYICSALGCRQWDSDEMEQEEDILLLQRTQKTVRAVGPRSGNEKWNFSVGHFELRYIPDMETRAGFIESTFKPNENTEESKIISDVEEQEAAIMDIVIKVSVADWKVMAFSKKGGHLEWEYQFCTPIASAWLLKDGKVIPISLFDDTSYTSNDDVLEDEEDIVEAARGATENSVYLGMYRGQLYLQSSVRISEKFPSSPKALESVTNENAIIPLPTIKWKPLIHSPSRTPVLVGSDEFDKCLSNDKFSHEEYSNGALSILQYPYDNGYYLPYYKRERNKRSTQITVRFLDNPHYNKNIRKKDPVLLLHWWKEIVATILFCIIATTFIVRRLFHPHPHRQRKESETQCQTENKYDSVSGEANDSSWNDIKNSGYISRYLTDFEPIQCLGRGGFGVVFEAKNKVDDCNYAIKRIRLPNRELAREKVMREVKALAKLEHPGIVRYFNAWLEAPPEKWQEKMDEIWLKDESTDWPLSSPSPMDAPSVKIRRMDPFATKEHIEIIAPSPQRSRSFSVGISCDQTSSSESQFSPLEFSGMDHEDISESVDAAYNLQDSCLTDCDVEDGTMDGNDEGHSFELCPSEASPYVRSRERTSSSIVFEDSGCDNASSKEEPKTNRLHIGNHCANKLTAFKPTSSKSSSEATLSISPPRPTTLSLDLTKNTTEKLQPSSPKVYLYIQMQLCRKENLKDWMNGRCTIEERERSVCLHIFLQIAEAVEFLHSKGLMHRDLKPSNIFFTMDDVVKVGDFGLVTAMDQDEEEQTVLTPMPAYARHTGQVGTKLYMSPEQIHGNSYSHKVDIFSLGLILFELLYPFSTQMERVRTLTDVRNLKFPPLFTQKYPCEYVMVQDMLSPSPMERPEAINIIENAVFEDLDFPGKTVLRQRSRSLSSSGTKHSRQSNNSHSPLPSN

T02134	TARGETID	T02134
T02134	FORMERID	TTDR00615
T02134	UNIPROID	GSH0_HUMAN
T02134	TARGNAME	Glutamate--cysteine ligase modifier (GCLM)
T02134	GENENAME	GCLM
T02134	TARGTYPE	Literature-reported
T02134	SYNONYMS	Glutamate--cysteine ligase modifier subunit; Gamma-glutamylcysteine synthetase regulatory subunit; Gamma-ECS regulatory subunit; GCS light chain
T02134	FUNCTION	cytosol, glutamate-cysteine ligase complex, enzyme regulator activity, glutamate-cysteine ligase catalytic subunit binding, glutamate metabolic process, glutathione biosynthetic process, positive regulation of glutamate-cysteine ligase activity, regulation of blood vessel size, response to drug, response to oxidative stress.
T02134	BIOCLASS	Aldo/keto reductase family
T02134	SEQUENCE	MGTDSRAAKALLARARTLHLQTGNLLNWGRLRKKCPSTHSEELHDCIQKTLNEWSSQINPDLVREFPDVLECTVSHAVEKINPDEREEMKVSAKLFIVESNSSSSTRSAVDMACSVLGVAQLDSVIIASPPIEDGVNLSLEHLQPYWEELENLVQSKKIVAIGTSDLDKTQLEQLYQWAQVKPNSNQVNLASCCVMPPDLTAFAKQFDIQLLTHNDPKELLSEASFQEALQESIPDIQAHEWVPLWLLRYSVIVKSRGIIKSKGYILQAKRRGS
T02134	DRUGINFO	D0WI3W	Cystamine	Investigative
T02134	DRUGINFO	D0Z6VR	Buthionine sulfoximine	Investigative
T02134	DRUGINFO	D0GV9Q	N-Formylmethionine	Investigative

T37428	TARGETID	T37428
T37428	FORMERID	TTDR00046
T37428	UNIPROID	RBX2_HUMAN
T37428	TARGNAME	RING-box protein 2 (RNF7)
T37428	GENENAME	RNF7
T37428	TARGTYPE	Literature-reported
T37428	SYNONYMS	Sensitive to apoptosis gene protein; SAG; Regulator of cullins 2; Rbx2; ROC2; RING finger protein 7; CKII beta-binding protein 1; CKBBP1
T37428	FUNCTION	CRLs complexes and ARIH1 collaborate in tandem to mediate ubiquitination of target proteins, ARIH1 mediating addition of the first ubiquitin on CRLs targets. Through the RING-type zinc finger, seems to recruit the E2 ubiquitination enzyme to the complex and brings it into close proximity to the substrate. Promotes the neddylation of CUL5 via its interaction with UBE2F. May play a role in protecting cells from apoptosis induced by redox agents. Probable component of the SCF (SKP1-CUL1-F-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins involved in cell cycle progression, signal transduction and transcription.
T37428	PDBSTRUC	2ECL
T37428	BIOCLASS	Zinc-finger
T37428	SEQUENCE	MADVEDGEETCALASHSGSSGSKSGGDKMFSLKKWNAVAMWSWDVECDTCAICRVQVMDACLRCQAENKQEDCVVVWGECNHSFHNCCMSLWVKQNNRCPLCQQDWVVQRIGK

T66206	TARGETID	T66206
T66206	FORMERID	TTDR00506
T66206	UNIPROID	PEMT_HUMAN
T66206	TARGNAME	Phosphatidylethanolamine N-methyltransferase (PEMT)
T66206	GENENAME	PEMT
T66206	TARGTYPE	Literature-reported
T66206	SYNONYMS	PEMT2; PEAMT
T66206	FUNCTION	Catalyzes three sequential methylation of phosphatidylethanolamine (pe) by adomet, thus producing phosphatidylcholine (pc).
T66206	BIOCLASS	Methyltransferase
T66206	ECNUMBER	EC 2.1.1.17
T66206	SEQUENCE	MTRLLGYVDPLDPSFVAAVITITFNPLYWNVVARWEHKTRKLSRAFGSPYLACYSLSVTILLLNFLRSHCFTQAMLSQPRMESLDTPAAYSLGLALLGLGVVLVLSSFFALGFAGTFLGDYFGILKEARVTVFPFNILDNPMYWGSTANYLGWAIMHASPTGLLLTVLVALTYIVALLYEEPFTAEIYRQKASGSHKRS

T91323	TARGETID	T91323
T91323	FORMERID	TTDI00169
T91323	UNIPROID	ST17A_HUMAN
T91323	TARGNAME	Cytoplasmic DRAK1 (STK17A)
T91323	GENENAME	STK17A
T91323	TARGTYPE	Literature-reported
T91323	SYNONYMS	Serine/threonine-protein kinase 17A; STK17A; DAP kinase-related apoptosis-inducing protein kinase 1
T91323	FUNCTION	Acts as a positive regulator of apoptosis. Also acts as a regulator of cellular reactive oxygen species.
T91323	BIOCLASS	Kinase
T91323	ECNUMBER	EC 2.7.11.1
T91323	SEQUENCE	MIPLEKPGSGGSSPGATSGSGRAGRGLSGPCRPPPPPQARGLLTEIRAVVRTEPFQDGYSLCPGRELGRGKFAVVRKCIKKDSGKEFAAKFMRKRRKGQDCRMEIIHEIAVLELAQDNPWVINLHEVYETASEMILVLEYAAGGEIFDQCVADREEAFKEKDVQRLMRQILEGVHFLHTRDVVHLDLKPQNILLTSESPLGDIKIVDFGLSRILKNSEELREIMGTPEYVAPEILSYDPISMATDMWSIGVLTYVMLTGISPFLGNDKQETFLNISQMNLSYSEEEFDVLSESAVDFIRTLLVKKPEDRATAEECLKHPWLTQSSIQEPSFRMEKALEEANALQEGHSVPEINSDTDKSETKESIVTEELIVVTSYTLGQCRQSEKEKMEQKAISKRFKFEEPLLQEIPGEFIY

T08647	TARGETID	T08647
T08647	FORMERID	TTDI03177
T08647	UNIPROID	EPHA6_HUMAN
T08647	TARGNAME	Ephrin type-A receptor 6 (EPHA6)
T08647	GENENAME	EPHA6
T08647	TARGTYPE	Literature-reported
T08647	SYNONYMS	HEK12; EPH-like kinase 12; EPH homology kinase 2; EK12; EHK2; EHK-2
T08647	FUNCTION	The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells.
T08647	BIOCLASS	Kinase
T08647	ECNUMBER	EC 2.7.10.1
T08647	SEQUENCE	MGGCEVREFLLQFGFFLPLLTAWPGDCSHVSNNQVVLLDTTTVLGELGWKTYPLNGWDAITEMDEHNRPIHTYQVCNVMEPNQNNWLRTNWISRDAAQKIYVEMKFTLRDCNSIPWVLGTCKETFNLFYMESDESHGIKFKPNQYTKIDTIAADESFTQMDLGDRILKLNTEIREVGPIERKGFYLAFQDIGACIALVSVRVFYKKCPFTVRNLAMFPDTIPRVDSSSLVEVRGSCVKSAEERDTPKLYCGADGDWLVPLGRCICSTGYEEIEGSCHACRPGFYKAFAGNTKCSKCPPHSLTYMEATSVCQCEKGYFRAEKDPPSMACTRPPSAPRNVVFNINETALILEWSPPSDTGGRKDLTYSVICKKCGLDTSQCEDCGGGLRFIPRHTGLINNSVIVLDFVSHVNYTFEIEAMNGVSELSFSPKPFTAITVTTDQDAPSLIGVVRKDWASQNSIALSWQAPAFSNGAILDYEIKYYEKEHEQLTYSSTRSKAPSVIITGLKPATKYVFHIRVRTATGYSGYSQKFEFETGDETSDMAAEQGQILVIATAAVGGFTLLVILTLFFLITGRCQWYIKAKMKSEEKRRNHLQNGHLRFPGIKTYIDPDTYEDPSLAVHEFAKEIDPSRIRIERVIGAGEFGEVCSGRLKTPGKREIPVAIKTLKGGHMDRQRRDFLREASIMGQFDHPNIIRLEGVVTKRSFPAIGVEAFCPSFLRAGFLNSIQAPHPVPGGGSLPPRIPAGRPVMIVVEYMENGSLDSFLRKHDGHFTVIQLVGMLRGIASGMKYLSDMGYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEAAYTTTGGKIPIRWTAPEAIAYRKFSSASDAWSYGIVMWEVMSYGERPYWEMSNQDVILSIEEGYRLPAPMGCPASLHQLMLHCWQKERNHRPKFTDIVSFLDKLIRNPSALHTLVEDILVMPESPGEVPEYPLFVTVGDWLDSIKMGQYKNNFVAAGFTTFDLISRMSIDDIRRIGVILIGHQRRIVSSIQTLRLHMMHIQEKGFHV
T08647	DRUGINFO	D0X8BU	PMID23489211C20	Investigative

T95947	TARGETID	T95947
T95947	FORMERID	TTDR01257
T95947	UNIPROID	ASIC3_HUMAN
T95947	TARGNAME	Acid-sensing ion channel 3 (ASIC3)
T95947	GENENAME	ASIC3
T95947	TARGTYPE	Literature-reported
T95947	SYNONYMS	hTNaC1; hASIC3; Testis sodium channel 1; TNAC1; SLNAC1; Neuronal amiloride-sensitive cation channel 3; Amiloride-sensitive cation channel 3; ASIC3; ACCN3
T95947	FUNCTION	Cation channel with high affinity for sodium, whichis gated by extracellular protons and inhibited by the diuretic amiloride. Generates a biphasic current with a fast inactivating and a slow sustained phase. In sensory neurons is proposed to mediate the pain induced by acidosis that occurs in ischemic, damaged or inflamed tissue. May be involved in hyperalgesia. May play a role in mechanoreception. Heteromeric channel assembly seems to modulate channel properties.
T95947	BIOCLASS	Amiloride-sensitive sodium channel
T95947	SEQUENCE	MKPTSGPEEARRPASDIRVFASNCSMHGLGHVFGPGSLSLRRGMWAAAVVLSVATFLYQVAERVRYYREFHHQTALDERESHRLIFPAVTLCNINPLRRSRLTPNDLHWAGSALLGLDPAEHAAFLRALGRPPAPPGFMPSPTFDMAQLYARAGHSLDDMLLDCRFRGQPCGPENFTTIFTRMGKCYTFNSGADGAELLTTTRGGMGNGLDIMLDVQQEEYLPVWRDNEETPFEVGIRVQIHSQEEPPIIDQLGLGVSPGYQTFVSCQQQQLSFLPPPWGDCSSASLNPNYEPEPSDPLGSPSPSPSPPYTLMGCRLACETRYVARKCGCRMVYMPGDVPVCSPQQYKNCAHPAIDAMLRKDSCACPNPCASTRYAKELSMVRIPSRAAARFLARKLNRSEAYIAENVLALDIFFEALNYETVEQKKAYEMSELLGDIGGQMGLFIGASLLTILEILDYLCEVFRDKVLGYFWNRQHSQRHSSTNLLQEGLGSHRTQVPHLSLGPRPPTPPCAVTKTLSASHRTCYLVTQL
T95947	DRUGINFO	D0BL6W	THA-902	Investigative
T95947	DRUGINFO	D0K7CV	agmatine	Investigative
T95947	DRUGINFO	D0S6HI	arcaine	Investigative
T95947	DRUGINFO	D0S9UQ	GMQ	Investigative
T95947	DRUGINFO	D0T7GQ	APETX2	Investigative
T95947	DRUGINFO	D06AVE	A-317567	Investigative
T95947	DRUGINFO	D02ACL	benzamil	Investigative

T86877	TARGETID	T86877
T86877	FORMERID	TTDR00878
T86877	UNIPROID	MKRN1_HUMAN
T86877	TARGNAME	E3 ubiquitin-protein ligase makorin-1 (MKRN1)
T86877	GENENAME	MKRN1
T86877	TARGTYPE	Literature-reported
T86877	SYNONYMS	RNF61; RING-type E3 ubiquitin transferase makorin-1; RING finger protein 61
T86877	FUNCTION	E3 ubiquitin ligase catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins. These substrates include FILIP1, p53/TP53, CDKN1A and TERT. Keeps cells alive by suppressing p53/TP53 under normal conditions, but stimulates apoptosis by repressing CDKN1A under stress conditions. Acts as a negative regulator of telomerase. Has negative and positive effects on RNA polymerase II-dependent transcription.
T86877	BIOCLASS	Carbon-nitrogen ligase
T86877	ECNUMBER	EC 2.3.2.27
T86877	SEQUENCE	MAEAATPGTTATTSGAGAAAATAAAASPTPIPTVTAPSLGAGGGGGGSDGSGGGWTKQVTCRYFMHGVCKEGDNCRYSHDLSDSPYSVVCKYFQRGYCIYGDRCRYEHSKPLKQEEATATELTTKSSLAASSSLSSIVGPLVEMNTGEAESRNSNFATVGAGSEDWVNAIEFVPGQPYCGRTAPSCTEAPLQGSVTKEESEKEQTAVETKKQLCPYAAVGECRYGENCVYLHGDSCDMCGLQVLHPMDAAQRSQHIKSCIEAHEKDMELSFAVQRSKDMVCGICMEVVYEKANPSERRFGILSNCNHTYCLKCIRKWRSAKQFESKIIKSCPECRITSNFVIPSEYWVEEKEEKQKLILKYKEAMSNKACRYFDEGRGSCPFGGNCFYKHAYPDGRREEPQRQKVGTSSRYRAQRRNHFWELIEERENSNPFDNDEEEVVTFELGEMLLMLLAAGGDDELTDSEDEWDLFHDELEDFYDLDL

T44584	TARGETID	T44584
T44584	FORMERID	TTDNR00696
T44584	UNIPROID	IL19_HUMAN
T44584	TARGNAME	Interleukin-19 (IL19)
T44584	GENENAME	IL19
T44584	TARGTYPE	Literature-reported
T44584	SYNONYMS	ZMDA1; NG.1; Melanoma differentiation-associated protein-like protein; IL-19
T44584	FUNCTION	Up-regulates IL-6 and TNF-alpha and induces apoptosis. May play some important roles in inflammatory responses.
T44584	PDBSTRUC	1N1F
T44584	BIOCLASS	Cytokine: interleukin
T44584	SEQUENCE	MKLQCVSLWLLGTILILCSVDNHGLRRCLISTDMHHIEESFQEIKRAIQAKDTFPNVTILSTLETLQIIKPLDVCCVTKNLLAFYVDRVFKDHQEPNPKILRKISSIANSFLYMQKTLRQCQEQRQCHCRQEATNATRVIHDNYDQLEVHAAAIKSLGELDVFLAWINKNHEVMFSA

T92768	TARGETID	T92768
T92768	UNIPROID	AMACR_HUMAN
T92768	TARGNAME	Alpha-methylacyl-CoA racemase (AMACR)
T92768	GENENAME	AMACR
T92768	TARGTYPE	Literature-reported
T92768	SYNONYMS	IBLi; 2-methylacyl-CoA racemase
T92768	FUNCTION	Racemization of 2-methyl-branched fatty acid CoA esters. Responsible for the conversion of pristanoyl-CoA and C27-bile acyl-CoAs to their (S)-stereoisomers.
T92768	BIOCLASS	CaiB/BaiF CoA-transferase family
T92768	ECNUMBER	EC 5.1.99.4
T92768	SEQUENCE	MALQGISVVELSGLAPGPFCAMVLADFGARVVRVDRPGSRYDVSRLGRGKRSLVLDLKQPRGAAVLRRLCKRSDVLLEPFRRGVMEKLQLGPEILQRENPRLIYARLSGFGQSGSFCRLAGHDINYLALSGVLSKIGRSGENPYAPLNLLADFAGGGLMCALGIIMALFDRTRTGKGQVIDANMVEGTAYLSSFLWKTQKLSLWEAPRGQNMLDGGAPFYTTYRTADGEFMAVGAIEPQFYELLIKGLGLKSDELPNQMSMDDWPEMKKKFADVFAEKTKAEWCQIFDGTDACVTPVLTFEEVVHHDHNKERGSFITSEEQDVSPRPAPLLLNTPAIPSFKRDPFIGEHTEEILEEFGFSREEIYQLNSDKIIESNKVKASL

T75545	TARGETID	T75545
T75545	FORMERID	TTDR01199
T75545	UNIPROID	S12A6_HUMAN
T75545	TARGNAME	Solute carrier family 12 member 6 (SLC12A6)
T75545	GENENAME	SLC12A6
T75545	TARGTYPE	Literature-reported
T75545	SYNONYMS	SLC12A6; Electroneutral potassium-chloride cotransporter 3
T75545	FUNCTION	Mediates electroneutral potassium-chloride cotransport. May be activated by cell swelling. May contribute to cell volume homeostasis in single cells.
T75545	BIOCLASS	Cation-chloride cotransporter
T75545	SEQUENCE	MHPPETTTKMASVRFMVTPTKIDDIPGLSDTSPDLSSRSSSRVRFSSRESVPETSRSEPMSEMSGATTSLATVALDPPSDRTSHPQDVIEDLSQNSITGEHSQLLDDGHKKARNAYLNNSNYEEGDEYFDKNLALFEEEMDTRPKVSSLLNRMANYTNLTQGAKEHEEAENITEGKKKPTKTPQMGTFMGVYLPCLQNIFGVILFLRLTWVVGTAGVLQAFAIVLICCCCTMLTAISMSAIATNGVVPAGGSYFMISRALGPEFGGAVGLCFYLGTTFAAAMYILGAIEIFLVYIVPRAAIFHSDDALKESAAMLNNMRVYGTAFLVLMVLVVFIGVRYVNKFASLFLACVIVSILAIYAGAIKSSFAPPHFPVCMLGNRTLSSRHIDVCSKTKEINNMTVPSKLWGFFCNSSQFFNATCDEYFVHNNVTSIQGIPGLASGIITENLWSNYLPKGEIIEKPSAKSSDVLGSLNHEYVLVDITTSFTLLVGIFFPSVTGIMAGSNRSGDLKDAQKSIPIGTILAILTTSFVYLSNVVLFGACIEGVVLRDKFGDAVKGNLVVGTLSWPSPWVIVIGSFFSTCGAGLQSLTGAPRLLQAIAKDNIIPFLRVFGHSKANGEPTWALLLTAAIAELGILIASLDLVAPILSMFFLMCYLFVNLACALQTLLRTPNWRPRFRYYHWALSFMGMSICLALMFISSWYYAIVAMVIAGMIYKYIEYQGAEKEWGDGIRGLSLSAARFALLRLEEGPPHTKNWRPQLLVLLKLDEDLHVKHPRLLTFASQLKAGKGLTIVGSVIVGNFLENYGEALAAEQTIKHLMEAEKVKGFCQLVVAAKLREGISHLIQSCGLGGMKHNTVVMGWPNGWRQSEDARAWKTFIGTVRVTTAAHLALLVAKNISFFPSNVEQFSEGNIDVWWIVHDGGMLMLLPFLLKQHKVWRKCSIRIFTVAQLEDNSIQMKKDLATFLYHLRIEAEVEVVEMHDSDISAYTYERTLMMEQRSQMLRHMRLSKTERDREAQLVKDRNSMLRLTSIGSDEDEETETYQEKVHMTWTKDKYMASRGQKAKSMEGFQDLLNMRPDQSNVRRMHTAVKLNEVIVNKSHEAKLVLLNMPGPPRNPEGDENYMEFLEVLTEGLERVLLVRGGGSEVITIYS
T75545	DRUGINFO	D0K9KZ	DIOA	Investigative

T66743	TARGETID	T66743
T66743	FORMERID	TTDI01439
T66743	UNIPROID	MUTYH_HUMAN
T66743	TARGNAME	Adenine DNA glycosylase (MUTYH)
T66743	GENENAME	MUTYH
T66743	TARGTYPE	Literature-reported
T66743	SYNONYMS	hMYH; MutY homolog; MYH
T66743	FUNCTION	Involved in oxidative DNA damage repair. Initiates repair of A*oxoG to C*G by removing the inappropriately paired adenine base from the DNA backbone. Possesses both adenine and 2-OH-A DNA glycosylase activities.
T66743	PDBSTRUC	3N5N; 1X51
T66743	ECNUMBER	EC 3.2.2.31
T66743	SEQUENCE	MTPLVSRLSRLWAIMRKPRAAVGSGHRKQAASQEGRQKHAKNNSQAKPSACDGMIAECPGAPAGLARQPEEVVLQASVSSYHLFRDVAEVTAFRGSLLSWYDQEKRDLPWRRRAEDEMDLDRRAYAVWVSEVMLQQTQVATVINYYTGWMQKWPTLQDLASASLEEVNQLWAGLGYYSRGRRLQEGARKVVEELGGHMPRTAETLQQLLPGVGRYTAGAIASIAFGQATGVVDGNVARVLCRVRAIGADPSSTLVSQQLWGLAQQLVDPARPGDFNQAAMELGATVCTPQRPLCSQCPVESLCRARQRVEQEQLLASGSLSGSPDVEECAPNTGQCHLCLPPSEPWDQTLGVVNFPRKASRKPPREESSATCVLEQPGALGAQILLVQRPNSGLLAGLWEFPSVTWEPSEQLQRKALLQELQRWAGPLPATHLRHLGEVVHTFSHIKLTYQVYGLALEGQTPVTTVPPGARWLTQEEFHTAAVSTAMKKVFRVYQGQQPGTCMGSKRSQVSSPCSRKKPRMGQQVLDNFFRSHISTDAHSLNSAAQ

T25122	TARGETID	T25122
T25122	FORMERID	TTDI00042
T25122	UNIPROID	GGT7_HUMAN
T25122	TARGNAME	Gamma-glutamyl transferase 7 (GGT7)
T25122	GENENAME	GGT7
T25122	TARGTYPE	Literature-reported
T25122	SYNONYMS	Glutathione hydrolase 7; Gamma-glutamyltranspeptidase 7; Gamma-glutamyltransferase-like 5; Gamma-glutamyltransferase-like 3; Gamma-glutamyltransferase 7 light chain; Gamma-glutamyltransferase 7; GGTL5; GGTL3; GGT7; GGT 7
T25122	FUNCTION	Involved in the pathway glutathione metabolism, which is part of Sulfur metabolism. Cleaves glutathione conjugates. Glutathione hydrolase activity. Hypoglycin A gamma-glutamyl transpeptidase activity. Leukotriene C4 gamma-glutamyl transferase activity. Peptidyltransferase activity.
T25122	BIOCLASS	Peptidase
T25122	ECNUMBER	EC 3.4.19.13
T25122	SEQUENCE	MAAENEASQESALGAYSPVDYMSITSFPRLPEDEPAPAAPLRGRKDEDAFLGDPDTDPDSFLKSARLQRLPSSSSEMGSQDGSPLRETRKDPFSAAAAECSCRQDGLTVIVTACLTFATGVTVALVMQIYFGDPQIFQQGAVVTDAARCTSLGIEVLSKQGSSVDAAVAAALCLGIVAPHSSGLGGGGVMLVHDIRRNESHLIDFRESAPGALREETLQRSWETKPGLLVGVPGMVKGLHEAHQLYGRLPWSQVLAFAAAVAQDGFNVTHDLARALAEQLPPNMSERFRETFLPSGRPPLPGSLLHRPDLAEVLDVLGTSGPAAFYAGGNLTLEMVAEAQHAGGVITEEDFSNYSALVEKPVCGVYRGHLVLSPPPPHTGPALISALNILEGFNLTSLVSREQALHWVAETLKIALALASRLGDPVYDSTITESMDDMLSKVEAAYLRGHINDSQAAPAPLLPVYELDGAPTAAQVLIMGPDDFIVAMVSSLNQPFGSGLITPSGILLNSQMLDFSWPNRTANHSAPSLENSVQPGKRPLSFLLPTVVRPAEGLCGTYLALGANGAARGLSGLTQVLLNVLTLNRNLSDSLARGRLHPDLQSNLLQVDSEFTEEEIEFLEARGHHVEKVDVLSWVHGSRRTNNFIIAVKDPRSPDAAGATIL

T72534	TARGETID	T72534
T72534	FORMERID	TTDI03585
T72534	UNIPROID	TNIK_HUMAN
T72534	TARGNAME	TRAF2 and NCK interacting kinase (TNIK)
T72534	GENENAME	TNIK
T72534	TARGTYPE	Literature-reported
T72534	SYNONYMS	TRAF2 and NCK-interacting protein kinase; KIAA0551
T72534	FUNCTION	Serine/threonine kinase that acts as an essential activator of the Wnt signaling pathway. Recruited to promoters of Wnt target genes and required to activate their expression. May act by phosphorylating TCF4/TCF7L2. Appears to act upstream of the JUN N-terminal pathway. May play a role in the response to environmental stress. Part of a signaling complex composed of NEDD4, RAP2A and TNIK which regulates neuronal dendrite extension and arborization during development. More generally, it may play a role in cytoskeletal rearrangements and regulate cell spreading. Phosphorylates SMAD1 on Thr-322.
T72534	PDBSTRUC	5D7A; 5CWZ; 5AX9; 2X7F
T72534	ECNUMBER	EC 2.7.11.1
T72534	SEQUENCE	MASDSPARSLDEIDLSALRDPAGIFELVELVGNGTYGQVYKGRHVKTGQLAAIKVMDVTGDEEEEIKQEINMLKKYSHHRNIATYYGAFIKKNPPGMDDQLWLVMEFCGAGSVTDLIKNTKGNTLKEEWIAYICREILRGLSHLHQHKVIHRDIKGQNVLLTENAEVKLVDFGVSAQLDRTVGRRNTFIGTPYWMAPEVIACDENPDATYDFKSDLWSLGITAIEMAEGAPPLCDMHPMRALFLIPRNPAPRLKSKKWSKKFQSFIESCLVKNHSQRPATEQLMKHPFIRDQPNERQVRIQLKDHIDRTKKKRGEKDETEYEYSGSEEEEEENDSGEPSSILNLPGESTLRRDFLRLQLANKERSEALRRQQLEQQQRENEEHKRQLLAERQKRIEEQKEQRRRLEEQQRREKELRKQQEREQRRHYEEQMRREEERRRAEHEQEYIRRQLEEEQRQLEILQQQLLHEQALLLEYKRKQLEEQRQAERLQRQLKQERDYLVSLQHQRQEQRPVEKKPLYHYKEGMSPSEKPAWAKEVEERSRLNRQSSPAMPHKVANRISDPNLPPRSESFSISGVQPARTPPMLRPVDPQIPHLVAVKSQGPALTASQSVHEQPTKGLSGFQEALNVTSHRVEMPRQNSDPTSENPPLPTRIEKFDRSSWLRQEEDIPPKVPQRTTSISPALARKNSPGNGSALGPRLGSQPIRASNPDLRRTEPILESPLQRTSSGSSSSSSTPSSQPSSQGGSQPGSQAGSSERTRVRANSKSEGSPVLPHEPAKVKPEESRDITRPSRPASYKKAIDEDLTALAKELRELRIEETNRPMKKVTDYSSSSEESESSEEEEEDGESETHDGTVAVSDIPRLIPTGAPGSNEQYNVGMVGTHGLETSHADSFSGSISREGTLMIRETSGEKKRSGHSDSNGFAGHINLPDLVQQSHSPAGTPTEGLGRVSTHSQEMDSGTEYGMGSSTKASFTPFVDPRVYQTSPTDEDEEDEESSAAALFTSELLRQEQAKLNEARKISVVNVNPTNIRPHSDTPEIRKYKKRFNSEILCAALWGVNLLVGTENGLMLLDRSGQGKVYNLINRRRFQQMDVLEGLNVLVTISGKKNKLRVYYLSWLRNRILHNDPEVEKKQGWITVGDLEGCIHYKVVKYERIKFLVIALKNAVEIYAWAPKPYHKFMAFKSFADLQHKPLLVDLTVEEGQRLKVIFGSHTGFHVIDVDSGNSYDIYIPSHIQGNITPHAIVILPKTDGMEMLVCYEDEGVYVNTYGRITKDVVLQWGEMPTSVAYIHSNQIMGWGEKAIEIRSVETGHLDGVFMHKRAQRLKFLCERNDKVFFASVRSGGSSQVFFMTLNRNSMMNW
T72534	DRUGINFO	D0K0UM	PMID23232060C5	Investigative

T87381	TARGETID	T87381
T87381	FORMERID	TTDI02426
T87381	UNIPROID	ADA30_HUMAN
T87381	TARGNAME	ADAM metallopeptidase 30 (ADAM30)
T87381	GENENAME	ADAM30
T87381	TARGTYPE	Literature-reported
T87381	SYNONYMS	Disintegrin and metalloproteinase domaincontaining protein 30; ADAM30
T87381	FUNCTION	May be involved in spermatogenesis and fertilization.
T87381	BIOCLASS	Peptidase
T87381	ECNUMBER	EC 3.4.24.-
T87381	SEQUENCE	MRSVQIFLSQCRLLLLLVPTMLLKSLGEDVIFHPEGEFDSYEVTIPEKLSFRGEVQGVVSPVSYLLQLKGKKHVLHLWPKRLLLPRHLRVFSFTEHGELLEDHPYIPKDCNYMGSVKESLDSKATISTCMGGLRGVFNIDAKHYQIEPLKASPSFEHVVYLLKKEQFGNQVCGLSDDEIEWQMAPYENKARLRDFPGSYKHPKYLELILLFDQSRYRFVNNNLSQVIHDAILLTGIMDTYFQDVRMRIHLKALEVWTDFNKIRVGYPELAEVLGRFVIYKKSVLNARLSSDWAHLYLQRKYNDALAWSFGKVCSLEYAGSVSTLLDTNILAPATWSAHELGHAVGMSHDEQYCQCRGRLNCIMGSGRTGFSNCSYISFFKHISSGATCLNNIPGLGYVLKRCGNKIVEDNEECDCGSTEECQKDRCCQSNCKLQPGANCSIGLCCHDCRFRPSGYVCRQEGNECDLAEYCDGNSSSCPNDVYKQDGTPCKYEGRCFRKGCRSRYMQCQSIFGPDAMEAPSECYDAVNLIGDQFGNCEITGIRNFKKCESANSICGRLQCINVETIPDLPEHTTIISTHLQAENLMCWGTGYHLSMKPMGIPDLGMINDGTSCGEGRVCFKKNCVNSSVLQFDCLPEKCNTRGVCNNRKNCHCMYGWAPPFCEEVGYGGSIDSGPPGLLRGAIPSSIWVVSIIMFRLILLILSVVFVFFRQVIGNHLKPKQEKMPLSKAKTEQEESKTKTVQEESKTKTGQEESEAKTGQEESKAKTGQEESKANIESKRPKAKSVKKQKK

T88104	TARGETID	T88104
T88104	FORMERID	TTDI03136
T88104	UNIPROID	CXD2_HUMAN
T88104	TARGNAME	Gap junction delta-2 protein (Cx36)
T88104	GENENAME	GJD2
T88104	TARGTYPE	Literature-reported
T88104	SYNONYMS	GJA9; Connexin-36
T88104	FUNCTION	One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell.
T88104	PDBSTRUC	2N6A
T88104	BIOCLASS	Gap junction-forming connexin
T88104	SEQUENCE	MGEWTILERLLEAAVQQHSTMIGRILLTVVVIFRILIVAIVGETVYDDEQTMFVCNTLQPGCNQACYDRAFPISHIRYWVFQIIMVCTPSLCFITYSVHQSAKQRERRYSTVFLALDRDPPESIGGPGGTGGGGSGGGKREDKKLQNAIVNGVLQNTENTSKETEPDCLEVKELTPHPSGLRTASKSKLRRQEGISRFYIIQVVFRNALEIGFLVGQYFLYGFSVPGLYECNRYPCIKEVECYVSRPTEKTVFLVFMFAVSGICVVLNLAELNHLGWRKIKLAVRGAQAKRKSIYEIRNKDLPRVSVPNFGRTQSSDSAYV
T88104	DRUGINFO	D00VJY	octanol	Investigative

T65005	TARGETID	T65005
T65005	FORMERID	TTDI03256
T65005	UNIPROID	HCN2_HUMAN
T65005	TARGNAME	Hyperpolarization cyclic nucleotide-gated channel 2 (HCN2)
T65005	GENENAME	HCN2
T65005	TARGTYPE	Literature-reported
T65005	SYNONYMS	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2; Brain cyclic nucleotide-gated channel 2; BCNG2; BCNG-2
T65005	FUNCTION	Contributes to the native pacemaker currents in heart (If) and in neurons (Ih). Can also transport ammonium in the distal nephron. Produces a large instantaneous current. Modulated by intracellular chloride ions and pH; acidic pH shifts the activation to more negative voltages. Hyperpolarization-activated ion channel exhibiting weak selectivity for potassium over sodium ions.
T65005	PDBSTRUC	3U10; 2MPF
T65005	BIOCLASS	Voltage-gated ion channel
T65005	SEQUENCE	MDARGGGGRPGESPGATPAPGPPPPPPPAPPQQQPPPPPPPAPPPGPGPAPPQHPPRAEALPPEAADEGGPRGRLRSRDSSCGRPGTPGAASTAKGSPNGECGRGEPQCSPAGPEGPARGPKVSFSCRGAASGPAPGPGPAEEAGSEEAGPAGEPRGSQASFMQRQFGALLQPGVNKFSLRMFGSQKAVEREQERVKSAGAWIIHPYSDFRFYWDFTMLLFMVGNLIIIPVGITFFKDETTAPWIVFNVVSDTFFLMDLVLNFRTGIVIEDNTEIILDPEKIKKKYLRTWFVVDFVSSIPVDYIFLIVEKGIDSEVYKTARALRIVRFTKILSLLRLLRLSRLIRYIHQWEEIFHMTYDLASAVMRICNLISMMLLLCHWDGCLQFLVPMLQDFPRNCWVSINGMVNHSWSELYSFALFKAMSHMLCIGYGRQAPESMTDIWLTMLSMIVGATCYAMFIGHATALIQSLDSSRRQYQEKYKQVEQYMSFHKLPADFRQKIHDYYEHRYQGKMFDEDSILGELNGPLREEIVNFNCRKLVASMPLFANADPNFVTAMLTKLKFEVFQPGDYIIREGTIGKKMYFIQHGVVSVLTKGNKEMKLSDGSYFGEICLLTRGRRTASVRADTYCRLYSLSVDNFNEVLEEYPMMRRAFETVAIDRLDRIGKKNSILLHKVQHDLNSGVFNNQENAIIQEIVKYDREMVQQAELGQRVGLFPPPPPPPQVTSAIATLQQAAAMSFCPQVARPLVGPLALGSPRLVRRPPPGPAPAAASPGPPPPASPPGAPASPRAPRTSPYGGLPAAPLAGPALPARRLSRASRPLSASQPSLPHGAPGPAASTRPASSSTPRLGPTPAARAAAPSPDRRDSASPGAAGGLDPQDSARSRLSSNL
T65005	DRUGINFO	D0T8LP	cyclic CMP	Investigative
T65005	DRUGINFO	D07ZAJ	PIP2	Investigative

T92966	TARGETID	T92966
T92966	UNIPROID	TPX2_HUMAN
T92966	TARGNAME	Hepatocellular carcinoma-associated antigen 90 (TPX2)
T92966	GENENAME	TPX2
T92966	TARGTYPE	Literature-reported
T92966	SYNONYMS	Restricted expression proliferation-associated protein 100; Protein fls353; Hepatocellular carcinoma-associated antigen 519; HCA519; Differentially expressed in cancerous and non-cancerous lung cells 2; DIL2; DIL-2; C20orf2; C20orf1
T92966	FUNCTION	Spindle assembly factor required for normal assembly of mitotic spindles. Required for normal assembly of microtubules during apoptosis. Required for chromatin and/or kinetochore dependent microtubule nucleation. Mediates AURKA localization to spindle microtubules (PubMed:18663142, PubMed:19208764). Activates AURKA by promoting its autophosphorylation at 'Thr-288' and protects this residue against dephosphorylation (PubMed:18663142, PubMed:19208764). TPX2 is inactivated upon binding to importin-alpha (PubMed:26165940). At the onset of mitosis, GOLGA2 interacts with importin-alpha, liberating TPX2 from importin-alpha, allowing TPX2 to activates AURKA kinase and stimulates local microtubule nucleation (PubMed:26165940).
T92966	PDBSTRUC	6BJC; 5LXM; 4C3P; 3HA6; 3E5A
T92966	BIOCLASS	TPX2 family
T92966	SEQUENCE	MSQVKSSYSYDAPSDFINFSSLDDEGDTQNIDSWFEEKANLENKLLGKNGTGGLFQGKTPLRKANLQQAIVTPLKPVDNTYYKEAEKENLVEQSIPSNACSSLEVEAAISRKTPAQPQRRSLRLSAQKDLEQKEKHHVKMKAKRCATPVIIDEILPSKKMKVSNNKKKPEEEGSAHQDTAEKNASSPEKAKGRHTVPCMPPAKQKFLKSTEEQELEKSMKMQQEVVEMRKKNEEFKKLALAGIGQPVKKSVSQVTKSVDFHFRTDERIKQHPKNQEEYKEVNFTSELRKHPSSPARVTKGCTIVKPFNLSQGKKRTFDETVSTYVPLAQQVEDFHKRTPNRYHLRSKKDDINLLPSKSSVTKICRDPQTPVLQTKHRARAVTCKSTAELEAEELEKLQQYKFKARELDPRILEGGPILPKKPPVKPPTEPIGFDLEIEKRIQERESKKKTEDEHFEFHSRPCPTKILEDVVGVPEKKVLPITVPKSPAFALKNRIRMPTKEDEEEDEPVVIKAQPVPHYGVPFKPQIPEARTVEICPFSFDSRDKERQLQKEKKIKELQKGEVPKFKALPLPHFDTINLPEKKVKNVTQIEPFCLETDRRGALKAQTWKHQLEEELRQQKEAACFKARPNTVISQEPFVPKKEKKSVAEGLSGSLVQEPFQLATEKRAKERQELEKRMAEVEAQKAQQLEEARLQEEEQKKEELARLRRELVHKANPIRKYQGLEIKSSDQPLTVPVSPKFSTRFHC

T36612	TARGETID	T36612
T36612	FORMERID	TTDI03454
T36612	UNIPROID	PADI3_HUMAN
T36612	TARGNAME	Peptidyl arginine deiminase type III (PADI3)
T36612	GENENAME	PADI3
T36612	TARGTYPE	Literature-reported
T36612	SYNONYMS	Protein-arginine deiminase type-3; Protein-arginine deiminase type III; Peptidylarginine deiminase III; PDI3; PAD3
T36612	FUNCTION	Catalyzes the deimination of arginine residues of proteins.
T36612	PDBSTRUC	6CE1
T36612	ECNUMBER	EC 3.5.3.15
T36612	SEQUENCE	MSLQRIVRVSLEHPTSAVCVAGVETLVDIYGSVPEGTEMFEVYGTPGVDIYISPNMERGRERADTRRWRFDATLEIIVVMNSPSNDLNDSHVQISYHSSHEPLPLAYAVLYLTCVDISLDCDLNCEGRQDRNFVDKRQWVWGPSGYGGILLVNCDRDDPSCDVQDNCDQHVHCLQDLEDMSVMVLRTQGPAALFDDHKLVLHTSSYDAKRAQVFHICGPEDVCEAYRHVLGQDKVSYEVPRLHGDEERFFVEGLSFPDAGFTGLISFHVTLLDDSNEDFSASPIFTDTVVFRVAPWIMTPSTLPPLEVYVCRVRNNTCFVDAVAELARKAGCKLTICPQAENRNDRWIQDEMELGYVQAPHKTLPVVFDSPRNGELQDFPYKRILGPDFGYVTREPRDRSVSGLDSFGNLEVSPPVVANGKEYPLGRILIGGNLPGSSGRRVTQVVRDFLHAQKVQPPVELFVDWLAVGHVDEFLSFVPAPDGKGFRMLLASPGACFKLFQEKQKCGHGRALLFQGVVDDEQVKTISINQVLSNKDLINYNKFVQSCIDWNREVLKRELGLAECDIIDIPQLFKTERKKATAFFPDLVNMLVLGKHLGIPKPFGPIINGCCCLEEKVRSLLEPLGLHCTFIDDFTPYHMLHGEVHCGTNVCRKPFSFKWWNMVP
T36612	DRUGINFO	D01FNC	PMID24440480C3	Investigative
T36612	DRUGINFO	D02ZNQ	streptonigrin	Investigative
T36612	DRUGINFO	D0C4DE	PMID25742366C14b	Investigative
T36612	DRUGINFO	D0YP0A	Cl-amidine	Investigative

T55616	TARGETID	T55616
T55616	FORMERID	TTDR00072
T55616	UNIPROID	MMP17_HUMAN
T55616	TARGNAME	Matrix metalloproteinase-17 (MMP17)
T55616	GENENAME	MMP17
T55616	TARGTYPE	Literature-reported
T55616	SYNONYMS	Membrane-type-4 matrix metalloproteinase; Membrane-type matrix metalloproteinase 4; MTMMP4; MT4MMP; MT4-MMP; MT-MMP 4; MMP-17
T55616	FUNCTION	Endopeptidase that degrades various components of the extracellular matrix, such as fibrin. May be involved in the activation of membrane-bound precursors of growth factors or inflammatory mediators, such as tumor necrosis factor-alpha. May also be involved in tumoral process. Cleaves pro-TNF-alpha at the '74-Ala-|-Gln-75' site. Not obvious if able to proteolytically activate progelatinase A. Does not hydrolyze collagen types I, II, III, IV and V, gelatin, fibronectin, laminin, decorin nor alpha1-antitrypsin.
T55616	BIOCLASS	Peptidase
T55616	ECNUMBER	EC 3.4.24.-
T55616	SEQUENCE	MRRRAARGPGPPPPGPGLSRLPLPLLLLLALGTRGGCAAPAPAPRAEDLSLGVEWLSRFGYLPPADPTTGQLQTQEELSKAITAMQQFGGLEATGILDEATLALMKTPRCSLPDLPVLTQARRRRQAPAPTKWNKRNLSWRVRTFPRDSPLGHDTVRALMYYALKVWSDIAPLNFHEVAGSAADIQIDFSKADHNDGYPFDGPGGTVAHAFFPGHHHTAGDTHFDDDEAWTFRSSDAHGMDLFAVAVHEFGHAIGLSHVAAAHSIMRPYYQGPVGDPLRYGLPYEDKVRVWQLYGVRESVSPTAQPEEPPLLPEPPDNRSSAPPRKDVPHRCSTHFDAVAQIRGEAFFFKGKYFWRLTRDRHLVSLQPAQMHRFWRGLPLHLDSVDAVYERTSDHKIVFFKGDRYWVFKDNNVEEGYPRPVSDFSLPPGGIDAAFSWAHNDRTYFFKDQLYWRYDDHTRHMDPGYPAQSPLWRGVPSTLDDAMRWSDGASYFFRGQEYWKVLDGELEVAPGYPQSTARDWLVCGDSQADGSVAAGVDAAEGPRAPPGQHDQSRSEDGYEVCSCTSGASSPPGAPGPLVAATMLLLLPPLSPGALWTAAQALTL

T91113	TARGETID	T91113
T91113	FORMERID	TTDNR00660
T91113	UNIPROID	PA24C_HUMAN
T91113	TARGNAME	Phospholipase A2 group IVC (PLA2G4C)
T91113	GENENAME	PLA2G4C
T91113	TARGTYPE	Literature-reported
T91113	SYNONYMS	cPLA2-gamma; PLA2G4C
T91113	FUNCTION	Has a preference for arachidonic acid at the sn-2 position of phosphatidylcholine as compared with palmitic acid.
T91113	BIOCLASS	Carboxylic ester hydrolase
T91113	ECNUMBER	EC 3.1.1.4
T91113	SEQUENCE	MGSSEVSIIPGLQKEEKAAVERRRLHVLKALKKLRIEADEAPVVAVLGSGGGLRAHIACLGVLSEMKEQGLLDAVTYLAGVSGSTWAISSLYTNDGDMEALEADLKHRFTRQEWDLAKSLQKTIQAARSENYSLTDFWAYMVISKQTRELPESHLSNMKKPVEEGTLPYPIFAAIDNDLQPSWQEARAPETWFEFTPHHAGFSALGAFVSITHFGSKFKKGRLVRTHPERDLTFLRGLWGSALGNTEVIREYIFDQLRNLTLKGLWRRAVANAKSIGHLIFARLLRLQESSQGEHPPPEDEGGEPEHTWLTEMLENWTRTSLEKQEQPHEDPERKGSLSNLMDFVKKTGICASKWEWGTTHNFLYKHGGIRDKIMSSRKHLHLVDAGLAINTPFPLVLPPTREVHLILSFDFSAGDPFETIRATTDYCRRHKIPFPQVEEAELDLWSKAPASCYILKGETGPVVMHFPLFNIDACGGDIEAWSDTYDTFKLADTYTLDVVVLLLALAKKNVRENKKKILRELMNVAGLYYPKDSARSCCLA

T92105	TARGETID	T92105
T92105	UNIPROID	RNF6_HUMAN
T92105	TARGNAME	E3 ubiquitin-protein ligase RNF6 (RNF6)
T92105	GENENAME	RNF6
T92105	TARGTYPE	Literature-reported
T92105	SYNONYMS	SPG2; RING-type E3 ubiquitin transferase RNF6
T92105	FUNCTION	E3 ubiquitin-protein ligase mediating 'Lys-48'-linked polyubiquitination of LIMK1 and its subsequent targeting to the proteasome for degradation. Negatively regulates axonal outgrowth through regulation of the LIMK1 turnover. Mediates 'Lys-6' and 'Lys-27'-linked polyubiquitination of AR/androgen receptor thereby modulating its transcriptional activity. May also bind DNA and function as a transcriptional regulator.
T92105	BIOCLASS	RNF12 family
T92105	ECNUMBER	EC 2.3.2.27
T92105	SEQUENCE	MNQSRSRSDGGSEETLPQDHNHHENERRWQQERLHREEAYYQFINELNDEDYRLMRDHNLLGTPGEITSEELQQRLDGVKEQLASQPDLRDGTNYRDSEVPRESSHEDSLLEWLNTFRRTGNATRSGQNGNQTWRAVSRTNPNNGEFRFSLEIHVNHENRGFEIHGEDYTDIPLSDSNRDHTANRQQRSTSPVARRTRSQTSVNFNGSSSNIPRTRLASRGQNPAEGSFSTLGRLRNGIGGAAGIPRANASRTNFSSHTNQSGGSELRQREGQRFGAAHVWENGARSNVTVRNTNQRLEPIRLRSTSNSRSRSPIQRQSGTVYHNSQRESRPVQQTTRRSVRRRGRTRVFLEQDRERERRGTAYTPFSNSRLVSRITVEEGEESSRSSTAVRRHPTITLDLQVRRIRPGENRDRDSIANRTRSRVGLAENTVTIESNSGGFRRTISRLERSGIRTYVSTITVPLRRISENELVEPSSVALRSILRQIMTGFGELSSLMEADSESELQRNGQHLPDMHSELSNLGTDNNRSQHREGSSQDRQAQGDSTEMHGENETTQPHTRNSDSRGGRQLRNPNNLVETGTLPILRLAHFFLLNESDDDDRIRGLTKEQIDNLSTRHYEHNSIDSELGKICSVCISDYVTGNKLRQLPCMHEFHIHCIDRWLSENCTCPICRQPVLGSNIANNG

T70332	TARGETID	T70332
T70332	FORMERID	TTDR00646
T70332	UNIPROID	RXLT1_HUMAN
T70332	TARGNAME	Beta-1,2-xylosyltransferase (RXYLT1)
T70332	GENENAME	XYLT
T70332	TARGTYPE	Literature-reported
T70332	SYNONYMS	XYLT; Beta-(1,2)-xylosyltransferase
T70332	FUNCTION	Catalyzes beta-1,2 glycosidic linkages.
T70332	BIOCLASS	Pentosyltransferase
T70332	ECNUMBER	EC 2.4.2.-
T70332	SEQUENCE	MRLTRKRLCSFLIALYCLFSLYAAYHVFFGRRRQAPAGSPRGLRKGAAPARERRGREQSTLESEEWNPWEGDEKNEQQHRFKTSLQILDKSTKGKTDLSVQIWGKAAIGLYLWEHIFEGLLDPSDVTAQWREGKSIVGRTQYSFITGPAVIPGYFSVDVNNVVLILNGREKAKIFYATQWLLYAQNLVQIQKLQHLAVVLLGNEHCDNEWINPFLKRNGGFVELLFIIYDSPWINDVDVFQWPLGVATYRNFPVVEASWSMLHDERPYLCNFLGTIYENSSRQALMNILKKDGNDKLCWVSAREHWQPQETNESLKNYQDALLQSDLTLCPVGVNTECYRIYEACSYGSIPVVEDVMTAGNCGNTSVHHGAPLQLLKSMGAPFIFIKNWKELPAVLEKEKTIILQEKIERRKMLLQWYQHFKTELKMKFTNILESSFLMNNKS

T27747	TARGETID	T27747
T27747	FORMERID	TTDR00597
T27747	UNIPROID	PIGL_HUMAN
T27747	TARGNAME	N-acetylglucosaminyl-phosphatidylinositol de-N-acetylase (PIGL)
T27747	GENENAME	PIGL
T27747	TARGTYPE	Literature-reported
T27747	SYNONYMS	Phosphatidylinositol-glycan biosynthesis, class L protein; PIGL; PIG-L; GlcNAc-PI de-N-acetylase
T27747	FUNCTION	Involved in thesecond step of GPI biosynthesis. De-N- acetylation of N-acetylglucosaminyl-phosphatidylinositol.
T27747	BIOCLASS	Carbon-nitrogen hydrolase
T27747	ECNUMBER	EC 3.5.1.89
T27747	SEQUENCE	MEAMWLLCVALAVLAWGFLWVWDSSERMKSREQGGRLGAESRTLLVIAHPDDEAMFFAPTVLGLARLRHWVYLLCFSAGNYYNQGETRKKELLQSCDVLGIPLSSVMIIDNRDFPDDPGMQWDTEHVARVLLQHIEVNGINLVVTFDAGGVSGHSNHIALYAAVRALHSEGKLPKGCSVLTLQSVNVLRKYISLLDLPLSLLHTQDVLFVLNSKEVAQAKKAMSCHRSQLLWFRRLYIIFSRYMRINSLSFL

T71949	TARGETID	T71949
T71949	FORMERID	TTDI03360
T71949	UNIPROID	KDM2A_HUMAN
T71949	TARGNAME	Lysine-specific demethylase 2A (KDM2A)
T71949	GENENAME	KDM2A
T71949	TARGTYPE	Literature-reported
T71949	SYNONYMS	FBXL11; FBL7; F-box/LRR-repeat protein 11; F-box protein Lilina; F-box protein FBL7; F-box and leucine-rich repeat protein 11; CXXC8; CXXC-type zinc finger protein 8; [Histone-H3]-lysine-36 demethylase 1A; KIAA1004; JmjC domain-containing histone demethylation protein 1A; JHDM1A
T71949	FUNCTION	Histone demethylase that specifically demethylates 'Lys-36' of histone H3, thereby playing a central role in histone code. Preferentially demethylates dimethylated H3 'Lys-36' residue while it has weak or no activity for mono- and tri-methylated H3 'Lys-36'. May also recognize and bind to some phosphorylated proteins and promote their ubiquitination and degradation. Required to maintain the heterochromatic state. Associates with centromeres and represses transcription of small non-coding RNAs that are encoded by the clusters of satellite repeats at the centromere. Required to sustain centromeric integrity and genomic stability, particularly during mitosis. Regulates circadian gene expression by repressing the transcriptional activator activity of CLOCK-ARNTL/BMAL1 heterodimer and RORA in a catalytically-independent manner.
T71949	PDBSTRUC	6C16; 6BYH; 4BBQ; 2YU2; 2YU1
T71949	ECNUMBER	EC 1.14.11.27
T71949	SEQUENCE	MEPEEERIRYSQRLRGTMRRRYEDDGISDDEIEGKRTFDLEEKLHTNKYNANFVTFMEGKDFNVEYIQRGGLRDPLIFKNSDGLGIKMPDPDFTVNDVKMCVGSRRMVDVMDVNTQKGIEMTMAQWTRYYETPEEEREKLYNVISLEFSHTRLENMVQRPSTVDFIDWVDNMWPRHLKESQTESTNAILEMQYPKVQKYCLMSVRGCYTDFHVDFGGTSVWYHIHQGGKVFWLIPPTAHNLELYENWLLSGKQGDIFLGDRVSDCQRIELKQGYTFVIPSGWIHAVYTPTDTLVFGGNFLHSFNIPMQLKIYNIEDRTRVPNKFRYPFYYEMCWYVLERYVYCITNRSHLTKEFQKESLSMDLELNGLESGNGDEEAVDREPRRLSSRRSVLTSPVANGVNLDYDGLGKTCRSLPSLKKTLAGDSSSDCSRGSHNGQVWDPQCAPRKDRQVHLTHFELEGLRCLVDKLESLPLHKKCVPTGIEDEDALIADVKILLEELANSDPKLALTGVPIVQWPKRDKLKFPTRPKVRVPTIPITKPHTMKPAPRLTPVRPAAASPIVSGARRRRVRCRKCKACVQGECGVCHYCRDMKKFGGPGRMKQSCVLRQCLAPRLPHSVTCSLCGEVDQNEETQDFEKKLMECCICNEIVHPGCLQMDGEGLLNEELPNCWECPKCYQEDSSEKAQKRKMEESDEEAVQAKVLRPLRSCDEPLTPPPHSPTSMLQLIHDPVSPRGMVTRSSPGAGPSDHHSASRDERFKRRQLLRLQATERTMVREKENNPSGKKELSEVEKAKIRGSYLTVTLQRPTKELHGTSIVPKLQAITASSANLRHSPRVLVQHCPARTPQRGDEEGLGGEEEEEEEEEEEDDSAEEGGAARLNGRGSWAQDGDESWMQREVWMSVFRYLSRRELCECMRVCKTWYKWCCDKRLWTKIDLSRCKAIVPQALSGIIKRQPVSLDLSWTNISKKQLTWLVNRLPGLKDLLLAGCSWSAVSALSTSSCPLLRTLDLRWAVGIKDPQIRDLLTPPADKPGQDNRSKLRNMTDFRLAGLDITDATLRLIIRHMPLLSRLDLSHCSHLTDQSSNLLTAVGSSTRYSLTELNMAGCNKLTDQTLIYLRRIANVTLIDLRGCKQITRKACEHFISDLSINSLYCLSDEKLIQKIS
T71949	DRUGINFO	D0B2WZ	daminozide	Investigative
T71949	DRUGINFO	D0WA3E	IOX2	Investigative

T58937	TARGETID	T58937
T58937	FORMERID	TTDI02367
T58937	UNIPROID	SC6A5_HUMAN
T58937	TARGNAME	Glycine transporter-2 (SLC6A5)
T58937	GENENAME	SLC6A5
T58937	TARGTYPE	Literature-reported
T58937	SYNONYMS	Solute carrier family 6 member 5; Sodium-and chloride-dependent glycine transporter 2; SLC6A5; GlyT2; GlyT-2
T58937	FUNCTION	Terminates the action of glycine by its high affinity sodium-dependent reuptake into presynaptic terminals. May be responsible for the termination of neurotransmission at strychnine-sensitive glycinergic synapses.
T58937	BIOCLASS	Neurotransmitter:sodium symporter
T58937	SEQUENCE	MDCSAPKEMNKLPANSPEAAAAQGHPDGPCAPRTSPEQELPAAAAPPPPRVPRSASTGAQTFQSADARACEAERPGVGSCKLSSPRAQAASAALRDLREAQGAQASPPPGSSGPGNALHCKIPFLRGPEGDANVSVGKGTLERNNTPVVGWVNMSQSTVVLATDGITSVLPGSVATVATQEDEQGDENKARGNWSSKLDFILSMVGYAVGLGNVWRFPYLAFQNGGGAFLIPYLMMLALAGLPIFFLEVSLGQFASQGPVSVWKAIPALQGCGIAMLIISVLIAIYYNVIICYTLFYLFASFVSVLPWGSCNNPWNTPECKDKTKLLLDSCVISDHPKIQIKNSTFCMTAYPNVTMVNFTSQANKTFVSGSEEYFKYFVLKISAGIEYPGEIRWPLALCLFLAWVIVYASLAKGIKTSGKVVYFTATFPYVVLVILLIRGVTLPGAGAGIWYFITPKWEKLTDATVWKDAATQIFFSLSAAWGGLITLSSYNKFHNNCYRDTLIVTCTNSATSIFAGFVIFSVIGFMANERKVNIENVADQGPGIAFVVYPEALTRLPLSPFWAIIFFLMLLTLGLDTMFATIETIVTSISDEFPKYLRTHKPVFTLGCCICFFIMGFPMITQGGIYMFQLVDTYAASYALVIIAIFELVGISYVYGLQRFCEDIEMMIGFQPNIFWKVCWAFVTPTILTFILCFSFYQWEPMTYGSYRYPNWSMVLGWLMLACSVIWIPIMFVIKMHLAPGRFIERLKLVCSPQPDWGPFLAQHRGERYKNMIDPLGTSSLGLKLPVKDLELGTQC
T58937	DRUGINFO	D0E1OC	ALX 1393	Investigative

T93177	TARGETID	T93177
T93177	UNIPROID	STRAP_HUMAN
T93177	TARGNAME	UNR-interacting protein (STRAP)
T93177	GENENAME	STRAP
T93177	TARGTYPE	Literature-reported
T93177	SYNONYMS	WD-40 repeat protein PT-WD; UNRIP; MAWD; MAP activator with WD repeats
T93177	FUNCTION	The SMN complex plays a catalyst role in the assembly of small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome. Thereby, plays an important role in the splicing of cellular pre-mRNAs. Most spliceosomal snRNPs contain a common set of Sm proteins SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG that assemble in a heptameric protein ring on the Sm site of the small nuclear RNA to form the core snRNP. In the cytosol, the Sm proteins SNRPD1, SNRPD2, SNRPE, SNRPF and SNRPG are trapped in an inactive 6S pICln-Sm complex by the chaperone CLNS1A that controls the assembly of the core snRNP. Dissociation by the SMN complex of CLNS1A from the trapped Sm proteins and their transfer to an SMN-Sm complex triggers the assembly of core snRNPs and their transport to the nucleus. STRAP plays a role in the cellular distribution of the SMN complex. Negatively regulates TGF-beta signaling but positively regulates the PDPK1 kinase activity by enhancing its autophosphorylation and by significantly reducing the association of PDPK1 with 14-3-3 protein.
T93177	BIOCLASS	WD repeat STRAP family
T93177	SEQUENCE	MAMRQTPLTCSGHTRPVVDLAFSGITPYGYFLISACKDGKPMLRQGDTGDWIGTFLGHKGAVWGATLNKDATKAATAAADFTAKVWDAVSGDELMTLAHKHIVKTVDFTQDSNYLLTGGQDKLLRIYDLNKPEAEPKEISGHTSGIKKALWCSEDKQILSADDKTVRLWDHATMTEVKSLNFNMSVSSMEYIPEGEILVITYGRSIAFHSAVSLDPIKSFEAPATINSASLHPEKEFLVAGGEDFKLYKYDYNSGEELESYKGHFGPIHCVRFSPDGELYASGSEDGTLRLWQTVVGKTYGLWKCVLPEEDSGELAKPKIGFPETTEEELEEIASENSDCIFPSAPDVKA

T30286	TARGETID	T30286
T30286	FORMERID	TTDI03258
T30286	UNIPROID	HCN4_HUMAN
T30286	TARGNAME	Hyperpolarization cyclic nucleotide-gated channel 4 (HCN4)
T30286	GENENAME	HCN4
T30286	TARGTYPE	Literature-reported
T30286	SYNONYMS	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4
T30286	FUNCTION	Contributes to the native pacemaker currents in heart (If) that regulate the rhythm of heart beat. May contribute to the native pacemaker currents in neurons (Ih). May mediate responses to sour stimuli. Hyperpolarization-activated ion channel with very slow activation and inactivation exhibiting weak selectivity for potassium over sodium ions.
T30286	PDBSTRUC	6GYO; 6GYN; 4NVP; 4KL1; 4HBN
T30286	BIOCLASS	Voltage-gated ion channel
T30286	SEQUENCE	MDKLPPSMRKRLYSLPQQVGAKAWIMDEEEDAEEEGAGGRQDPSRRSIRLRPLPSPSPSAAAGGTESRSSALGAADSEGPARGAGKSSTNGDCRRFRGSLASLGSRGGGSGGTGSGSSHGHLHDSAEERRLIAEGDASPGEDRTPPGLAAEPERPGASAQPAASPPPPQQPPQPASASCEQPSVDTAIKVEGGAAAGDQILPEAEVRLGQAGFMQRQFGAMLQPGVNKFSLRMFGSQKAVEREQERVKSAGFWIIHPYSDFRFYWDLTMLLLMVGNLIIIPVGITFFKDENTTPWIVFNVVSDTFFLIDLVLNFRTGIVVEDNTEIILDPQRIKMKYLKSWFMVDFISSIPVDYIFLIVETRIDSEVYKTARALRIVRFTKILSLLRLLRLSRLIRYIHQWEEIFHMTYDLASAVVRIVNLIGMMLLLCHWDGCLQFLVPMLQDFPDDCWVSINNMVNNSWGKQYSYALFKAMSHMLCIGYGRQAPVGMSDVWLTMLSMIVGATCYAMFIGHATALIQSLDSSRRQYQEKYKQVEQYMSFHKLPPDTRQRIHDYYEHRYQGKMFDEESILGELSEPLREEIINFNCRKLVASMPLFANADPNFVTSMLTKLRFEVFQPGDYIIREGTIGKKMYFIQHGVVSVLTKGNKETKLADGSYFGEICLLTRGRRTASVRADTYCRLYSLSVDNFNEVLEEYPMMRRAFETVALDRLDRIGKKNSILLHKVQHDLNSGVFNYQENEIIQQIVQHDREMAHCAHRVQAAASATPTPTPVIWTPLIQAPLQAAAATTSVAIALTHHPRLPAAIFRPPPGSGLGNLGAGQTPRHLKRLQSLIPSALGSASPASSPSQVDTPSSSSFHIQQLAGFSAPAGLSPLLPSSSSSPPPGACGSPSAPTPSAGVAATTIAGFGHFHKALGGSLSSSDSPLLTPLQPGARSPQAAQPSPAPPGARGGLGLPEHFLPPPPSSRSPSSSPGQLGQPPGELSLGLATGPLSTPETPPRQPEPPSLVAGASGGASPVGFTPRGGLSPPGHSPGPPRTFPSAPPRASGSHGSLLLPPASSPPPPQVPQRRGTPPLTPGRLTQDLKLISASQPALPQDGAQTLRRASPHSSGESMAAFPLFPRAGGGSGGSGSSGGLGPPGRPYGAIPGQHVTLPRKTSSGSLPPPLSLFGARATSSGGPPLTAGPQREPGARPEPVRSKLPSNL
T30286	DRUGINFO	D0W5XD	EC18	Investigative

T25362	TARGETID	T25362
T25362	FORMERID	TTDI03361
T25362	UNIPROID	KDM3A_HUMAN
T25362	TARGNAME	Lysine-specific demethylase 3A (KDM3A)
T25362	GENENAME	KDM3A
T25362	TARGTYPE	Literature-reported
T25362	SYNONYMS	TSGA; KIAA0742; Jumonji domain-containing protein 1A; JmjC domain-containing histone demethylation protein 2A; JMJD1A; JMJD1; JHDM2A
T25362	FUNCTION	Preferentially demethylates mono- and dimethylated H3 'Lys-9' residue, with a preference for dimethylated residue, while it has weak or no activity on trimethylated H3 'Lys-9'. Demethylation of Lys residue generates formaldehyde and succinate. Involved in hormone-dependent transcriptional activation, by participating in recruitment to androgen-receptor target genes, resulting in H3 'Lys-9' demethylation and transcriptional activation. Involved in spermatogenesis by regulating expression of target genes such as PRM1 and TNP1 which are required for packaging and condensation of sperm chromatin. Involved in obesity resistance through regulation of metabolic genes such as PPARA and UCP1. Histone demethylase that specifically demethylates 'Lys-9' of histone H3, thereby playing a central role in histone code.
T25362	BIOCLASS	Paired donor oxygen oxidoreductase
T25362	ECNUMBER	EC 1.14.11.-
T25362	SEQUENCE	MVLTLGESWPVLVGRRFLSLSAADGSDGSHDSWDVERVAEWPWLSGTIRAVSHTDVTKKDLKVCVEFDGESWRKRRWIEVYSLLRRAFLVEHNLVLAERKSPEISERIVQWPAITYKPLLDKAGLGSITSVRFLGDQQRVFLSKDLLKPIQDVNSLRLSLTDNQIVSKEFQALIVKHLDESHLLKGDKNLVGSEVKIYSLDPSTQWFSATVINGNPASKTLQVNCEEIPALKIVDPSLIHVEVVHDNLVTCGNSARIGAVKRKSSENNGTLVSKQAKSCSEASPSMCPVQSVPTTVFKEILLGCTAATPPSKDPRQQSTPQAANSPPNLGAKIPQGCHKQSLPEEISSCLNTKSEALRTKPDVCKAGLLSKSSQIGTGDLKILTEPKGSCTQPKTNTDQENRLESVPQALTGLPKECLPTKASSKAELEIANPPELQKHLEHAPSPSDVSNAPEVKAGVNSDSPNNCSGKKVEPSALACRSQNLKESSVKVDNESCCSRSNNKIQNAPSRKSVLTDPAKLKKLQQSGEAFVQDDSCVNIVAQLPKCRECRLDSLRKDKEQQKDSPVFCRFFHFRRLQFNKHGVLRVEGFLTPNKYDNEAIGLWLPLTKNVVGIDLDTAKYILANIGDHFCQMVISEKEAMSTIEPHRQVAWKRAVKGVREMCDVCDTTIFNLHWVCPRCGFGVCVDCYRMKRKNCQQGAAYKTFSWLKCVKSQIHEPENLMPTQIIPGKALYDVGDIVHSVRAKWGIKANCPCSNRQFKLFSKPASKEDLKQTSLAGEKPTLGAVLQQNPSVLEPAAVGGEAASKPAGSMKPACPASTSPLNWLADLTSGNVNKENKEKQPTMPILKNEIKCLPPLPPLSKSSTVLHTFNSTILTPVSNNNSGFLRNLLNSSTGKTENGLKNTPKILDDIFASLVQNKTTSDLSKRPQGLTIKPSILGFDTPHYWLCDNRLLCLQDPNNKSNWNVFRECWKQGQPVMVSGVHHKLNSELWKPESFRKEFGEQEVDLVNCRTNEIITGATVGDFWDGFEDVPNRLKNEKEPMVLKLKDWPPGEDFRDMMPSRFDDLMANIPLPEYTRRDGKLNLASRLPNYFVRPDLGPKMYNAYGLITPEDRKYGTTNLHLDVSDAANVMVYVGIPKGQCEQEEEVLKTIQDGDSDELTIKRFIEGKEKPGALWHIYAAKDTEKIREFLKKVSEEQGQENPADHDPIHDQSWYLDRSLRKRLHQEYGVQGWAIVQFLGDVVFIPAGAPHQVHNLYSCIKVAEDFVSPEHVKHCFWLTQEFRYLSQTHTNHEDKLQVKNVIYHAVKDAVAMLKASESSFGKP
T25362	DRUGINFO	D0X5US	IOX1	Investigative

T82267	TARGETID	T82267
T82267	FORMERID	TTDI03602
T82267	UNIPROID	TRPV2_HUMAN
T82267	TARGNAME	Transient receptor potential cation channel V2 (TRPV2)
T82267	GENENAME	TRPV2
T82267	TARGTYPE	Literature-reported
T82267	SYNONYMS	Vanilloid receptor-like protein 1; VRL-1; VRL; TrpV2; Transient receptor potential cation channel subfamily V member 2; Osm-9-like TRP channel 2; OTRPC2
T82267	FUNCTION	Calcium-permeable, non-selective cation channel with an outward rectification. Seems to be regulated, at least in part, by IGF-I, PDGF and neuropeptide head activator. May transduce physical stimuli in mast cells. Activated by temperatures higher than 52 degrees Celsius; is not activated by vanilloids and acidic pH.
T82267	PDBSTRUC	2F37
T82267	BIOCLASS	Transient receptor potential catioin channel
T82267	SEQUENCE	MTSPSSSPVFRLETLDGGQEDGSEADRGKLDFGSGLPPMESQFQGEDRKFAPQIRVNLNYRKGTGASQPDPNRFDRDRLFNAVSRGVPEDLAGLPEYLSKTSKYLTDSEYTEGSTGKTCLMKAVLNLKDGVNACILPLLQIDRDSGNPQPLVNAQCTDDYYRGHSALHIAIEKRSLQCVKLLVENGANVHARACGRFFQKGQGTCFYFGELPLSLAACTKQWDVVSYLLENPHQPASLQATDSQGNTVLHALVMISDNSAENIALVTSMYDGLLQAGARLCPTVQLEDIRNLQDLTPLKLAAKEGKIEIFRHILQREFSGLSHLSRKFTEWCYGPVRVSLYDLASVDSCEENSVLEIIAFHCKSPHRHRMVVLEPLNKLLQAKWDLLIPKFFLNFLCNLIYMFIFTAVAYHQPTLKKQAAPHLKAEVGNSMLLTGHILILLGGIYLLVGQLWYFWRRHVFIWISFIDSYFEILFLFQALLTVVSQVLCFLAIEWYLPLLVSALVLGWLNLLYYTRGFQHTGIYSVMIQKVILRDLLRFLLIYLVFLFGFAVALVSLSQEAWRPEAPTGPNATESVQPMEGQEDEGNGAQYRGILEASLELFKFTIGMGELAFQEQLHFRGMVLLLLLAYVLLTYILLLNMLIALMSETVNSVATDSWSIWKLQKAISVLEMENGYWWCRKKQRAGVMLTVGTKPDGSPDERWCFRVEEVNWASWEQTLPTLCEDPSGAGVPRTLENPVLASPPKEDEDGASEENYVPVQLLQSN
T82267	DRUGINFO	D0B3AR	TRIM	Investigative
T82267	DRUGINFO	D00VWN	citral	Investigative
T82267	DRUGINFO	D0U5LL	cannabinol	Investigative
T82267	DRUGINFO	D03TWR	diphenylboronic anhydride	Investigative
T82267	DRUGINFO	D0KT5E	lysophosphatidylcholine	Investigative
T82267	DRUGINFO	D0M1UA	lysophosphatidylinositol	Investigative
T82267	DRUGINFO	D00HCI	2-APB	Investigative
T82267	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T15438	TARGETID	T15438
T15438	FORMERID	TTDI02635
T15438	UNIPROID	JAM1_HUMAN
T15438	TARGNAME	Junctional adhesion molecule A (F11R)
T15438	GENENAME	F11R
T15438	TARGTYPE	Literature-reported
T15438	SYNONYMS	Platelet adhesion molecule 1; Platelet F11 receptor; PAM-1; Junctional adhesion molecule 1; JCAM; JAM1; JAM-A; JAM-1; CD321
T15438	FUNCTION	Seems to play a role in epithelial tight junction formation. Appears early in primordial forms of cell junctions and recruits PARD3. The association of the PARD6-PARD3 complex may prevent the interaction of PARD3 with JAM1, thereby preventing tight junction assembly (By similarity). Plays a role in regulating monocyte transmigration involved in integrity of epithelial barrier (By similarity). Ligand for integrin alpha-L/beta-2 involved in memory T-cell and neutrophil transmigration. Involved in platelet activation.
T15438	PDBSTRUC	4ODB; 3TSZ; 3EOY; 1NBQ
T15438	BIOCLASS	Immunoglobulin
T15438	SEQUENCE	MGTKAQVERKLLCLFILAILLCSLALGSVTVHSSEPEVRIPENNPVKLSCAYSGFSSPRVEWKFDQGDTTRLVCYNNKITASYEDRVTFLPTGITFKSVTREDTGTYTCMVSEEGGNSYGEVKVKLIVLVPPSKPTVNIPSSATIGNRAVLTCSEQDGSPPSEYTWFKDGIVMPTNPKSTRAFSNSSYVLNPTTGELVFDPLSASDTGEYSCEARNGYGTPMTSNAVRMEAVERNVGVIVAAVLVTLILLGILVFGIWFAYSRGHFDRTKKGTSSKKVIYSQPSARSEGEFKQTSSFLV

T29728	TARGETID	T29728
T29728	FORMERID	TTDI03084
T29728	UNIPROID	KC1G3_HUMAN
T29728	TARGNAME	Casein kinase I gamma-3 (CSNK1G3)
T29728	GENENAME	CSNK1G3
T29728	TARGTYPE	Literature-reported
T29728	SYNONYMS	Casein kinase I isoform gamma-3; CKI-gamma 3
T29728	FUNCTION	Serine/threonine-protein kinase. Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. It can phosphorylate a large number of proteins. Participates in Wnt signaling. Regulates fast synaptic transmission mediated by glutamate (By similarity).
T29728	PDBSTRUC	6GRO; 4HGS; 4HGL; 4G17; 4G16
T29728	ECNUMBER	EC 2.7.11.1
T29728	SEQUENCE	MENKKKDKDKSDDRMARPSGRSGHNTRGTGSSSSGVLMVGPNFRVGKKIGCGNFGELRLGKNLYTNEYVAIKLEPMKSRAPQLHLEYRFYKQLGSGDGIPQVYYFGPCGKYNAMVLELLGPSLEDLFDLCDRTFSLKTVLMIAIQLISRMEYVHSKNLIYRDVKPENFLIGRPGNKTQQVIHIIDFGLAKEYIDPETKKHIPYREHKSLTGTARYMSINTHLGKEQSRRDDLEALGHMFMYFLRGSLPWQGLKADTLKERYQKIGDTKRATPIEVLCENFPEMATYLRYVRRLDFFEKPDYDYLRKLFTDLFDRKGYMFDYEYDWIGKQLPTPVGAVQQDPALSSNREAHQHRDKMQQSKNQSADHRAAWDSQQANPHHLRAHLAADRHGGSVQVVSSTNGELNTDDPTAGRSNAPITAPTEVEVMDETKCCCFFKRRKRKTIQRHK
T29728	DRUGINFO	D06UKS	PMID21982499C14k	Investigative

T78492	TARGETID	T78492
T78492	FORMERID	TTDR00146
T78492	UNIPROID	M3K4_HUMAN
T78492	TARGNAME	MAPK/ERK kinase kinase 4 (MAP3K4)
T78492	GENENAME	MAP3K4
T78492	TARGTYPE	Literature-reported
T78492	SYNONYMS	Mitogen-activated protein kinase kinase kinase 4; MTK1; MEKK4; MEKK 4; MEK kinase 4; MAPKKK4; MAP three kinase 1; KIAA0213
T78492	FUNCTION	Activates the CSBP2, P38 and JNK MAPK pathways, but not the ERK pathway. Specifically phosphorylates and activates MAP2K4 and MAP2K6. Component of a protein kinase signal transduction cascade.
T78492	BIOCLASS	Kinase
T78492	ECNUMBER	EC 2.7.11.25
T78492	SEQUENCE	MREAAAALVPPPAFAVTPAAAMEEPPPPPPPPPPPPEPETESEPECCLAARQEGTLGDSACKSPESDLEDFSDETNTENLYGTSPPSTPRQMKRMSTKHQRNNVGRPASRSNLKEKMNAPNQPPHKDTGKTVENVEEYSYKQEKKIRAALRTTERDRKKNVQCSFMLDSVGGSLPKKSIPDVDLNKPYLSLGCSNAKLPVSVPMPIARPARQTSRTDCPADRLKFFETLRLLLKLTSVSKKKDREQRGQENTSGFWLNRSNELIWLELQAWHAGRTINDQDFFLYTARQAIPDIINEILTFKVDYGSFAFVRDRAGFNGTSVEGQCKATPGTKIVGYSTHHEHLQRQRVSFEQVKRIMELLEYIEALYPSLQALQKDYEKYAAKDFQDRVQALCLWLNITKDLNQKLRIMGTVLGIKNLSDIGWPVFEIPSPRPSKGNEPEYEGDDTEGELKELESSTDESEEEQISDPRVPEIRQPIDNSFDIQSRDCISKKLERLESEDDSLGWGAPDWSTEAGFSRHCLTSIYRPFVDKALKQMGLRKLILRLHKLMDGSLQRARIALVKNDRPVEFSEFPDPMWGSDYVQLSRTPPSSEEKCSAVSWEELKAMDLPSFEPAFLVLCRVLLNVIHECLKLRLEQRPAGEPSLLSIKQLVRECKEVLKGGLLMKQYYQFMLQEVLEDLEKPDCNIDAFEEDLHKMLMVYFDYMRSWIQMLQQLPQASHSLKNLLEEEWNFTKEITHYIRGGEAQAGKLFCDIAGMLLKSTGSFLEFGLQESCAEFWTSADDSSASDEIRRSVIEISRALKELFHEARERASKALGFAKMLRKDLEIAAEFRLSAPVRDLLDVLKSKQYVKVQIPGLENLQMFVPDTLAEEKSIILQLLNAAAGKDCSKDSDDVLIDAYLLLTKHGDRARDSEDSWGTWEAQPVKVVPQVETVDTLRSMQVDNLLLVVMQSAHLTIQRKAFQQSIEGLMTLCQEQTSSQPVIAKALQQLKNDALELCNRISNAIDRVDHMFTSEFDAEVDESESVTLQQYYREAMIQGYNFGFEYHKEVVRLMSGEFRQKIGDKYISFARKWMNYVLTKCESGRGTRPRWATQGFDFLQAIEPAFISALPEDDFLSLQALMNECIGHVIGKPHSPVTGLYLAIHRNSPRPMKVPRCHSDPPNPHLIIPTPEGFSTRSMPSDARSHGSPAAAAAAAAAAVAASRPSPSGGDSVLPKSISSAHDTRGSSVPENDRLASIAAELQFRSLSRHSSPTEERDEPAYPRGDSSGSTRRSWELRTLISQSKDTASKLGPIEAIQKSVRLFEEKRYREMRRKNIIGQVCDTPKSYDNVMHVGLRKVTFKWQRGNKIGEGQYGKVYTCISVDTGELMAMKEIRFQPNDHKTIKETADELKIFEGIKHPNLVRYFGVELHREEMYIFMEYCDEGTLEEVSRLGLQEHVIRLYSKQITIAINVLHEHGIVHRDIKGANIFLTSSGLIKLGDFGCSVKLKNNAQTMPGEVNSTLGTAAYMAPEVITRAKGEGHGRAADIWSLGCVVIEMVTGKRPWHEYEHNFQIMYKVGMGHKPPIPERLSPEGKDFLSHCLESDPKMRWTASQLLDHSFVKVCTDEE

T52382	TARGETID	T52382
T52382	FORMERID	TTDR00927
T52382	UNIPROID	LY96_HUMAN
T52382	TARGNAME	Lymphocyte antigen 96 (LY96)
T52382	GENENAME	LY96
T52382	TARGTYPE	Literature-reported
T52382	SYNONYMS	MD-2 protein; MD-2; LY96; ESOP-1
T52382	FUNCTION	Cooperates with TLR4 in the innate immune response to bacterial lipopolysaccharide (LPS), and with TLR2 in the response to cell wall components from Gram-positive and Gram-negative bacteria. Enhances TLR4-dependent activation of NF-kappa-B. Cells expressing both MD2 and TLR4, but not TLR4 alone, respond to LPS.
T52382	PDBSTRUC	4G8A; 3ULA; 3FXI; 2Z65; 2.00E+59
T52382	SEQUENCE	MLPFLFFSTLFSSIFTEAQKQYWVCNSSDASISYTYCDKMQYPISINVNPCIELKRSKGLLHIFYIPRRDLKQLYFNLYITVNTMNLPKRKEVICRGSDDDYSFCRALKGETVNTTISFSFKGIKFSKGKYKCVVEAISGSPEEMLFCLEFVILHQPNSN
T52382	DRUGINFO	D0A0GD	3-Hydroxy-Myristic Acid	Investigative
T52382	DRUGINFO	D0N0UC	Lauric Acid	Investigative
T52382	DRUGINFO	D08OBF	MYRISTIC ACID	Investigative

T69986	TARGETID	T69986
T69986	FORMERID	TTDR00066
T69986	UNIPROID	W8U2K6_STAAU
T69986	TARGNAME	Staphylococcus Replicative DNA helicase (Stap-coc dnaC)
T69986	GENENAME	Stap-coc dnaC
T69986	TARGTYPE	Literature-reported
T69986	SYNONYMS	Replicative DNA helicase
T69986	FUNCTION	Participates in initiation and elongation during chromosome replication; it exhibits DNA-dependent ATPase activity.
T69986	BIOCLASS	Acid anhydride hydrolase
T69986	ECNUMBER	EC 3.6.4.12
T69986	SEQUENCE	MDRMYEQNQMPHNNEAEQSVLGSIIIDPELINTTQEVLLPESFYRGAHQHIFRAMMHLNEDNKEIDVVTLMDQLSTEGTLNEAGGPQYLAELSTNVPTTRNVQYYTDIVSKHALKRRLIQTADSIANDGYNDELELDAILSDAERRILELSSSRESDGFKDIRDVLGQVYETAEELDQNSGQTPGIPTGYRDLDQMTAGFNRNDLIILAARPSVGKTAFALNIAQKVATHEDMYTVGIFSLEMGADQLATRMICSSGNVDSNRLRTGTMTEEDWSRFTIAVGKLSRTKIFIDDTPGIRINDLRSKCRRLKQEHGLDMIVIDYLQLIQGSGSRASDNRQQEVSEISRTLKALARELECPVIALSQLSRGVEQRQDKRPMMSDIRESGSIEQDADIVAFLYRDDYYNRGGDEDDDDDGGFEPQTNDENGEIEIIIAKQRNGPTGTVKLHFMKQYNKFTDIDYAHADMM

T28343	TARGETID	T28343
T28343	FORMERID	TTDR01341
T28343	UNIPROID	E2F3_HUMAN
T28343	TARGNAME	E2F3 messenger RNA (E2F3 mRNA)
T28343	GENENAME	E2F3
T28343	TARGTYPE	Literature-reported
T28343	SYNONYMS	Transcription factor E2F3 (mRNA); KIAA0075 (mRNA); E2F-3 (mRNA)
T28343	FUNCTION	The DRTF1/E2F complex functions in the control of cell-cycle progression from G1 to S phase. E2F3 binds specifically to RB1 in a cell-cycle dependent manner. Inhibits adipogenesis, probably through the repression of CEBPA binding to its target gene promoters. Transcription activator that binds DNA cooperatively with DP proteins through the E2 recognition site, 5'-TTTC[CG]CGC-3' found in the promoter region of a number of genes whose products are involved in cell cycle regulation or in DNA replication.
T28343	BIOCLASS	mRNA target
T28343	SEQUENCE	MRKGIQPALEQYLVTAGGGEGAAVVAAAAAASMDKRALLASPGFAAAAAAAAAPGAYIQILTTNTSTTSCSSSLQSGAVAAGPLLPSAPGAEQTAGSLLYTTPHGPSSRAGLLQQPPALGRGGSGGGGGPPAKRRLELGESGHQYLSDGLKTPKGKGRAALRSPDSPKTPKSPSEKTRYDTSLGLLTKKFIQLLSQSPDGVLDLNKAAEVLKVQKRRIYDITNVLEGIHLIKKKSKNNVQWMGCSLSEDGGMLAQCQGLSKEVTELSQEEKKLDELIQSCTLDLKLLTEDSENQRLAYVTYQDIRKISGLKDQTVIVVKAPPETRLEVPDSIESLQIHLASTQGPIEVYLCPEETETHSPMKTNNQDHNGNIPKPASKDLASTNSGHSDCSVSMGNLSPLASPANLLQQTEDQIPSNLEGPFVNLLPPLLQEDYLLSLGEEEGISDLFDAYDLEKLPLVEDFMCS
T28343	DRUGINFO	D04FHQ	ISIS 114197	Investigative
T28343	DRUGINFO	D05FIN	ISIS 114184	Investigative
T28343	DRUGINFO	D08ZWA	ISIS 114232	Investigative
T28343	DRUGINFO	D0G8CN	ISIS 114170	Investigative

T92714	TARGETID	T92714
T92714	FORMERID	TTDR01347
T92714	UNIPROID	SMAD6_HUMAN
T92714	TARGNAME	MADH6 messenger RNA (MADH6 mRNA)
T92714	GENENAME	SMAD6
T92714	TARGTYPE	Literature-reported
T92714	SYNONYMS	hSMAD6 (mRNA); Smad6 (mRNA); SMAD family member 6 (mRNA); SMAD 6 (mRNA); Mothers against decapentaplegic homolog 6 (mRNA); Mothers against DPP homolog 6 (mRNA); MADH6 (mRNA); MAD homolog 6 (mRNA)
T92714	FUNCTION	Suppresses IL1R-TLR signaling through its direct interaction with PEL1, preventing NF-kappa-B activation, nuclear transport and NF-kappa-B-mediated expression of proinflammatory genes. May block the BMP-SMAD1 signaling pathway by competing with SMAD4 for receptor-activated SMAD1-binding. Binds to regulatory elements in target promoter regions. Acts as a mediator of TGF-beta and BMP antiflammatory activity.
T92714	BIOCLASS	mRNA target
T92714	SEQUENCE	MFRSKRSGLVRRLWRSRVVPDREEGGSGGGGGGDEDGSLGSRAEPAPRAREGGGCGRSEVRPVAPRRPRDAVGQRGAQGAGRRRRAGGPPRPMSEPGAGAGSSLLDVAEPGGPGWLPESDCETVTCCLFSERDAAGAPRDASDPLAGAALEPAGGGRSREARSRLLLLEQELKTVTYSLLKRLKERSLDTLLEAVESRGGVPGGCVLVPRADLRLGGQPAPPQLLLGRLFRWPDLQHAVELKPLCGCHSFAAAADGPTVCCNPYHFSRLCGPESPPPPYSRLSPRDEYKPLDLSDSTLSYTETEATNSLITAPGEFSDASMSPDATKPSHWCSVAYWEHRTRVGRLYAVYDQAVSIFYDLPQGSGFCLGQLNLEQRSESVRRTRSKIGFGILLSKEPDGVWAYNRGEHPIFVNSPTLDAPGGRALVVRKVPPGYSIKVFDFERSGLQHAPEPDAADGPYDPNSVRISFAKGWGPCYSRQFITSCPCWLEILLNNPR
T92714	DRUGINFO	D03HVU	ISIS 101987	Investigative
T92714	DRUGINFO	D06RHG	ISIS 101952	Investigative
T92714	DRUGINFO	D0P2EY	ISIS 101983	Investigative
T92714	DRUGINFO	D0P6AS	ISIS 101985	Investigative
T92714	DRUGINFO	D0U5PS	ISIS 101986	Investigative
T92714	DRUGINFO	D0W0SS	ISIS 101996	Investigative
T92714	DRUGINFO	D0X1NL	ISIS 101998	Investigative
T92714	DRUGINFO	D0X3FC	ISIS 101995	Investigative
T92714	DRUGINFO	D0Y7VA	ISIS 101984	Investigative
T92714	DRUGINFO	D0Z2RM	ISIS 101997	Investigative
T92714	DRUGINFO	D0Z6ZA	ISIS 101960	Investigative

T30397	TARGETID	T30397
T30397	FORMERID	TTDR01350
T30397	UNIPROID	M2_I97A1
T30397	TARGNAME	Influenza M messenger RNA (Influenza M mRNA)
T30397	GENENAME	Influenza M mRNA
T30397	TARGTYPE	Literature-reported
T30397	SYNONYMS	Proton channel protein M2 (mRNA); Matrix protein 2 (mRNA); M (mRNA)
T30397	FUNCTION	After attaching to the cell surface, the virion enters the cell by endocytosis. Acidification of the endosome triggers M2 ion channel activity. The influx of protons into virion interior is believed to disrupt interactions between the viral ribonucleoprotein (RNP), matrix protein 1 (M1), and lipid bilayers, thereby freeing the viral genome from interaction with viral proteins and enabling RNA segments to migrate to the host cell nucleus, where influenza virus RNA transcription and replication occur. Also plays a role in viral proteins secretory pathway. Elevates the intravesicular pH of normally acidic compartments, such as trans-Golgi network, preventing newly formed hemagglutinin from premature switching to the fusion-active conformation. Forms a proton-selective ion channel that is necessary for the efficient release of the viral genome during virus entry.
T30397	PDBSTRUC	6MPN; 6MPM; 6MPL; 4RWC; 4RWB
T30397	BIOCLASS	mRNA target
T30397	SEQUENCE	MSLLTEVETLTRNGWGCRCSDSSDPLVVAASIIGILHLILWILDRLFFKCIYRRFKYGLKRGPSTEGVPESMREEYRQEQQNAVDVDDGHFVNIELE
T30397	DRUGINFO	D0O8FS	ISIS 3309	Investigative

T70278	TARGETID	T70278
T70278	FORMERID	TTDR01351
T70278	UNIPROID	ZN217_HUMAN
T70278	TARGNAME	ZNF217 messenger RNA (ZNF217 mRNA)
T70278	GENENAME	ZNF217
T70278	TARGTYPE	Literature-reported
T70278	SYNONYMS	Zinc finger protein 217 (mRNA); ZABC1 (mRNA)
T70278	FUNCTION	Promotes cell proliferation and antagonizes cell death. Promotes phosphorylation of AKT1 at 'Ser-473'. Binds to the promoters of target genes and functions as repressor.
T70278	PDBSTRUC	4IS1; 4F2J; 3UK3; 2HU2
T70278	BIOCLASS	mRNA target
T70278	SEQUENCE	MQSKVTGNMPTQSLLMYMDGPEVIGSSLGSPMEMEDALSMKGTAVVPFRATQEKNVIQIEGYMPLDCMFCSQTFTHSEDLNKHVLMQHRPTLCEPAVLRVEAEYLSPLDKSQVRTEPPKEKNCKENEFSCEVCGQTFRVAFDVEIHMRTHKDSFTYGCNMCGRRFKEPWFLKNHMRTHNGKSGARSKLQQGLESSPATINEVVQVHAAESISSPYKICMVCGFLFPNKESLIEHRKVHTKKTAFGTSSAQTDSPQGGMPSSREDFLQLFNLRPKSHPETGKKPVRCIPQLDPFTTFQAWQLATKGKVAICQEVKESGQEGSTDNDDSSSEKELGETNKGSCAGLSQEKEKCKHSHGEAPSVDADPKLPSSKEKPTHCSECGKAFRTYHQLVLHSRVHKKDRRAGAESPTMSVDGRQPGTCSPDLAAPLDENGAVDRGEGGSEDGSEDGLPEGIHLDKNDDGGKIKHLTSSRECSYCGKFFRSNYYLNIHLRTHTGEKPYKCEFCEYAAAQKTSLRYHLERHHKEKQTDVAAEVKNDGKNQDTEDALLTADSAQTKNLKRFFDGAKDVTGSPPAKQLKEMPSVFQNVLGSAVLSPAHKDTQDFHKNAADDSADKVNKNPTPAYLDLLKKRSAVETQANNLICRTKADVTPPPDGSTTHNLEVSPKEKQTETAADCRYRPSVDCHEKPLNLSVGALHNCPAISLSKSLIPSITCPFCTFKTFYPEVLMMHQRLEHKYNPDVHKNCRNKSLLRSRRTGCPPALLGKDVPPLSSFCKPKPKSAFPAQSKSLPSAKGKQSPPGPGKAPLTSGIDSSTLAPSNLKSHRPQQNVGVQGAATRQQQSEMFPKTSVSPAPDKTKRPETKLKPLPVAPSQPTLGSSNINGSIDYPAKNDSPWAPPGRDYFCNRSASNTAAEFGEPLPKRLKSSVVALDVDQPGANYRRGYDLPKYHMVRGITSLLPQDCVYPSQALPPKPRFLSSSEVDSPNVLTVQKPYGGSGPLYTCVPAGSPASSSTLEGKRPVSYQHLSNSMAQKRNYENFIGNAHYRPNDKKT
T70278	DRUGINFO	D01KCM	ISIS 114563	Investigative
T70278	DRUGINFO	D03NEA	ISIS 114559	Investigative
T70278	DRUGINFO	D08WJY	ISIS 114531	Investigative
T70278	DRUGINFO	D0AJ0H	ISIS 114527	Investigative
T70278	DRUGINFO	D0E5FG	ISIS 114537	Investigative
T70278	DRUGINFO	D0L3NU	ISIS 14548	Investigative
T70278	DRUGINFO	D0LY0E	ISIS 114532	Investigative
T70278	DRUGINFO	D0N5CF	ISIS 114530	Investigative

T58495	TARGETID	T58495
T58495	FORMERID	TTDR01094
T58495	UNIPROID	FOS_HUMAN
T58495	TARGNAME	c-Fos messenger RNA (c-Fos mRNA)
T58495	GENENAME	FOS
T58495	TARGTYPE	Literature-reported
T58495	SYNONYMS	Proto-oncogene c-Fos (mRNA); G0S7 (mRNA); G0/G1 switch regulatory protein 7 (mRNA); Cellular oncogene fos (mRNA); C-fos (mRNA)
T58495	FUNCTION	In the heterodimer, FOS and JUN/AP-1 basic regions each seems to interact with symmetrical DNA half sites. On TGF-beta activation, forms a multimeric SMAD3/SMAD4/JUN/FOS complex at the AP1/SMAD-binding site to regulate TGF-beta-mediated signaling. Has a critical function in regulating the development of cells destined to form and maintain the skeleton. It is thought to have an important role in signal transduction, cell proliferation and differentiation. In growing cells, activates phospholipid synthesis, possibly by activating CDS1 and PI4K2A. This activity requires Tyr-dephosphorylation and association with the endoplasmic reticulum. Nuclear phosphoprotein which forms a tight but non-covalently linked complex with the JUN/AP-1 transcription factor.
T58495	PDBSTRUC	1S9K; 1FOS; 1A02
T58495	BIOCLASS	mRNA target
T58495	SEQUENCE	MMFSGFNADYEASSSRCSSASPAGDSLSYYHSPADSFSSMGSPVNAQDFCTDLAVSSANFIPTVTAISTSPDLQWLVQPALVSSVAPSQTRAPHPFGVPAPSAGAYSRAGVVKTMTGGRAQSIGRRGKVEQLSPEEEEKRRIRRERNKMAAAKCRNRRRELTDTLQAETDQLEDEKSALQTEIANLLKEKEKLEFILAAHRPACKIPDDLGFPEEMSVASLDLTGGLPEVATPESEEAFTLPLLNDPEPKPSVEPVKSISSMELKTEPFDDFLFPASSRPSGSETARSVPDMDLSGSFYAADWEPLHSGSLGMGPMATELEPLCTPVVTCTPSCTAYTSSFVFTYPEADSFPSCAAAHRKGSSSNEPSSDSLSSPTLLAL
T58495	DRUGINFO	D0Z2OW	ISIS 10639	Investigative

T40516	TARGETID	T40516
T40516	FORMERID	TTDI02388
T40516	UNIPROID	TGFA_HUMAN
T40516	TARGNAME	TGFA messenger RNA (TGFA mRNA)
T40516	GENENAME	TGFA
T40516	TARGTYPE	Literature-reported
T40516	SYNONYMS	TGF-alpha (40-89) (mRNA); TGF type 1 (40-89) (mRNA); Protransforming growth factor alpha (40-89) (mRNA); ETGF (40-89) (mRNA); EGF-like TGF (40-89) (mRNA)
T40516	FUNCTION	TGF alpha is a mitogenic polypeptide that is able to bind to the EGF receptor/EGFR and to act synergistically with TGF beta to promote anchorage-independent cell proliferation in soft agar.
T40516	PDBSTRUC	5KN5; 4TGF; 3TGF; 3.00E+50; 2TGF
T40516	BIOCLASS	mRNA target
T40516	SEQUENCE	MVPSAGQLALFALGIVLAACQALENSTSPLSADPPVAAAVVSHFNDCPDSHTQFCFHGTCRFLVQEDKPACVCHSGYVGARCEHADLLAVVAASQKKQAITALVVVSIVALAVLIITCVLIHCCQVRKHCEWCRALICRHEKPSALLKGRTACCHSETVV

T85810	TARGETID	T85810
T85810	FORMERID	TTDR01359
T85810	UNIPROID	VE2_BPV1
T85810	TARGNAME	Human papillomavirus E2 region messenger RNA (HPV E2 mRNA)
T85810	GENENAME	HPV E2 mRNA
T85810	TARGTYPE	Literature-reported
T85810	SYNONYMS	BPV regulatory protein E2 (mRNA)
T85810	FUNCTION	A dimer of E2 interacts with a dimer of E1 in order to improve specificity of E1 DNA binding activity. Once the complex recognizes and binds DNA at specific sites, the E2 dimer is removed from DNA. E2 also regulates viral transcription through binding to the E2RE response element (5'-ACCNNNNNNGGT-3') present in multiple copies in the regulatory regions of the viral genome. Activates or represses transcription depending on E2RE's position with regards to proximal promoter elements including the TATA-box. Repression occurs by sterically hindering the assembly of the transcription initiation complex. Plays a role in the initiation of viral DNA replication.
T85810	PDBSTRUC	6BUS; 2JEX; 2JEU; 2BOP; 1JJH
T85810	BIOCLASS	mRNA target
T85810	SEQUENCE	METACERLHVAQETQMQLIEKSSDKLQDHILYWTAVRTENTLLYAARKKGVTVLGHCRVPHSVVCQERAKQAIEMQLSLQELSKTEFGDEPWSLLDTSWDRYMSEPKRCFKKGARVVEVEFDGNASNTNWYTVYSNLYMRTEDGWQLAKAGADGTGLYYCTMAGAGRIYYSRFGDEAARFSTTGHYSVRDQDRVYAGVSSTSSDFRDRPDGVWVASEGPEGDPAGKEAEPAQPVSSLLGSPACGPIRAGLGWVRDGPRSHPYNFPAGSGGSILRSSSTPVQGTVPVDLASRQEEEEQSPDSTEEEPVTLPRRTTNDGFHLLKAGGSCFALISGTANQVKCYRFRVKKNHRHRYENCTTTWFTVADNGAERQGQAQILITFGSPSQRQDFLKHVPLPPGMNISGFTASLDF
T85810	DRUGINFO	D02ZPT	ISIS 2324	Investigative
T85810	DRUGINFO	D08LZK	ISIS 1753	Investigative
T85810	DRUGINFO	D0WM8R	ISIS 1751	Investigative

T81018	TARGETID	T81018
T81018	FORMERID	TTDI02658
T81018	UNIPROID	HG2A_HUMAN
T81018	TARGNAME	CD74 messenger RNA (CD74 mRNA)
T81018	GENENAME	CD74
T81018	TARGTYPE	Literature-reported
T81018	SYNONYMS	p33 (mRNA); Ii (mRNA); Ia antigenassociated invariant chain (mRNA); Ia antigen-associated invariant chain (mRNA); HLADR antigensassociated invariant chain (mRNA); HLA-DR antigens-associated invariant chain (mRNA); HLA class II histocompatibility antigen gamma chain (mRNA); DHLAG (mRNA)
T81018	FUNCTION	Serves as cell surface receptor for the cytokine MIF. Plays a critical role in MHC class II antigen processing by stabilizing peptide-free class II alpha/beta heterodimers in a complex soon after their synthesis and directing transport of the complex from the endoplasmic reticulum to the endosomal/lysosomal system where the antigen processing and binding of antigenic peptides to MHC class II takes place.
T81018	PDBSTRUC	5KSV; 5KSU; 4X5W; 4AH2; 4AEN
T81018	BIOCLASS	mRNA target
T81018	SEQUENCE	MHRRRSRSCREDQKPVMDDQRDLISNNEQLPMLGRRPGAPESKCSRGALYTGFSILVTLLLAGQATTAYFLYQQQGRLDKLTVTSQNLQLENLRMKLPKPPKPVSKMRMATPLLMQALPMGALPQGPMQNATKYGNMTEDHVMHLLQNADPLKVYPPLKGSFPENLRHLKNTMETIDWKVFESWMHHWLLFEMSRHSLEQKPTDAPPKVLTKCQEEVSHIPAVHPGSFRPKCDENGNYLPLQCYGSIGYCWCVFPNGTEVPNTRSRGHHNCSESLELEDPSSGLGVTKQDLGPVPM

T46790	TARGETID	T46790
T46790	FORMERID	TTDR01068
T46790	UNIPROID	PAI1_HUMAN
T46790	TARGNAME	PAI-1 messenger RNA (PAI-1 mRNA)
T46790	GENENAME	SERPINE1
T46790	TARGTYPE	Literature-reported
T46790	SYNONYMS	Serpin E1 (mRNA); Plasminogen activator inhibitor type 1 (mRNA); Plasminogen activator inhibitor 1 (mRNA); PLANH1 (mRNA); PAI1 (mRNA); PAI-1 (mRNA); PAI (mRNA); Endothelial plasminogen activator inhibitor (mRNA)
T46790	FUNCTION	Inhibits TMPRSS7. Is a primary inhibitor of tissue-type plasminogen activator (PLAT) and urokinase-type plasminogen activator (PLAU). As PLAT inhibitor, it is required for fibrinolysis down-regulation and is responsible for the controlled degradation of blood clots. As PLAU inhibitor, it is involved in the regulation of cell adhesion and spreading. Acts as a regulator of cell migration, independently of its role as protease inhibitor. It is required for stimulation of keratinocyte migration during cutaneous injury repair. It is involved in cellular and replicative senescence. Plays a role in alveolar type 2 cells senescence in the lung. Is involved in the regulation of cementogenic differentiation of periodontal ligament stem cells, and regulates odontoblast differentiation and dentin formation during odontogenesis. Serine protease inhibitor.
T46790	PDBSTRUC	9PAI; 6I8S; 5ZLZ; 5BRR; 4IC0
T46790	BIOCLASS	mRNA target
T46790	SEQUENCE	MQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPYGVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAIFVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAVDQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPDGHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPKFSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASSSTAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP

T68498	TARGETID	T68498
T68498	FORMERID	TTDI02655
T68498	UNIPROID	ISG15_HUMAN
T68498	TARGNAME	ISG15 messenger RNA (ISG15 mRNA)
T68498	GENENAME	ISG15
T68498	TARGTYPE	Literature-reported
T68498	SYNONYMS	hUCRP (mRNA); Ubiquitin-like protein ISG15 (mRNA); Ubiquitin cross-reactive protein (mRNA); UCRP (mRNA); Interferon-induced 17 kDa protein (mRNA); Interferon-induced 15 kDa protein (mRNA); IP17 (mRNA); G1P2 (mRNA)
T68498	FUNCTION	ISGylation involves a cascade of enzymatic reactions involving E1, E2, and E3 enzymes which catalyze the conjugation of ISG15 to a lysine residue in the target protein. Its target proteins include IFIT1, MX1/MxA, PPM1B, UBE2L6, UBA7, CHMP5, CHMP2A, CHMP4B and CHMP6. Can also isgylate: EIF2AK2/PKR which results in its activation, DDX58/RIG-I which inhibits its function in antiviral signaling response, EIF4E2 which enhances its cap structure-binding activity and translation-inhibition activity, UBE2N and UBE2E1 which negatively regulates their activity, IRF3 which inhibits its ubiquitination and degradation and FLNB which prevents its ability to interact with the upstream activators of the JNK cascade therby inhibiting IFNA-induced JNK signaling. Exhibits antiviral activity towards both DNA and RNA viruses, including influenza A, HIV-1 and Ebola virus. Restricts HIV-1 and ebola virus via disruption of viral budding. Inhibits the ubiquitination of HIV-1 Gag and host TSG101 and disrupts their interaction, thereby preventing assembly and release of virions from infected cells. Inhibits Ebola virus budding mediated by the VP40 protein by disrupting ubiquitin ligase activity of NEDD4 and its ability to ubiquitinate VP40. ISGylates influenza A virus NS1 protein which causes a loss of function of the protein and the inhibition of virus replication. The secreted form of ISG15 can: induce natural killer cell proliferation, act as a chemotactic factor for neutrophils and act as a IFN-gamma-inducing cytokine playing an essential role in antimycobacterial immunity. The secreted form acts through the integrin ITGAL/ITGB2 receptor to initiate activation of SRC family tyrosine kinases including LYN, HCK and FGR which leads to secretion of IFNG and IL10; the interaction is mediated by ITGAL. Ubiquitin-like protein which plays a key role in the innate immune response to viral infection either via its conjugation to a target protein (ISGylation) or via its action as a free or unconjugated protein.
T68498	PDBSTRUC	6FFA; 6BI8; 5W8U; 5W8T; 5TL6
T68498	BIOCLASS	mRNA target
T68498	SEQUENCE	MGWDLTVKMLAGNEFQVSLSSSMSVSELKAQITQKIGVHAFQQRLAVHPSGVALQDRVPLASQGLGPGSTVLLVVDKCDEPLSILVRNNKGRSSTYEVRLTQTVAHLKQQVSGLEGVQDDLFWLTFEGKPLEDQLPLGEYGLKPLSTVFMNLRLRGGGTEPGGRS

T43303	TARGETID	T43303
T43303	FORMERID	TTDR01364
T43303	UNIPROID	VE6_HPV18
T43303	TARGNAME	Human papillomavirus-18 E6 region messenger RNA (HPV-18 E6 mRNA)
T43303	GENENAME	HPV-18 E6 mRNA
T43303	TARGTYPE	Literature-reported
T43303	SYNONYMS	HPV-18 protein E6 (mRNA); HPV-18 E6 (mRNA)
T43303	FUNCTION	Acts mainly as an oncoprotein by stimulating the destruction of many host cell key regulatory proteins. E6 associates with host UBE3A/E6-AP ubiquitin-protein ligase, and inactivates tumor suppressors TP53 and TP73 by targeting them to the 26S proteasome for degradation. In turn, DNA damage and chromosomal instabilities increase and lead to cell proliferation and cancer development. The complex E6/E6AP targets several other substrates to degradation via the proteasome including host DLG1 or NFX1, a repressor of human telomerase reverse transcriptase (hTERT). The resulting increased expression of hTERT prevents the shortening of telomere length leading to cell immortalization. Other cellular targets including BAK1, Fas-associated death domain-containing protein (FADD) and procaspase 8, are degraded by E6/E6AP causing inhibition of apoptosis. E6 also inhibits immune response by interacting with host IRF3 and TYK2. These interactions prevent IRF3 transcriptional activities and inhibit TYK2-mediated JAK-STAT activation by interferon alpha resulting in inhibition of the interferon signaling pathway. Plays a major role in the induction and maintenance of cellular transformation.
T43303	PDBSTRUC	5K4F; 5IC3; 4JOR; 2I0L; 2I0I
T43303	BIOCLASS	mRNA target
T43303	SEQUENCE	MARFEDPTRRPYKLPDLCTELNTSLQDIEITCVYCKTVLELTEVFEFAFKDLFVVYRDSIPHAACHKCIDFYSRIRELRHYSDSVYGDTLEKLTNTGLYNLLIRCLRCQKPLNPAEKLRHLNEKRRFHNIAGHYRGQCHSCCNRARQERLQRRRETQV
T43303	DRUGINFO	D07AMO	ISIS 2490	Investigative

T27984	TARGETID	T27984
T27984	FORMERID	TTDR01097
T27984	UNIPROID	CXB1_HUMAN
T27984	TARGNAME	Connexin 32 messenger RNA (GJB1 mRNA)
T27984	GENENAME	GJB1
T27984	TARGTYPE	Literature-reported
T27984	SYNONYMS	Gap junction beta-1 protein (mRNA); GAP junction 28 kDa liver protein (mRNA); CX32 (mRNA)
T27984	FUNCTION	One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell.
T27984	PDBSTRUC	5KK9; 1TXH
T27984	BIOCLASS	mRNA target
T27984	SEQUENCE	MNWTGLYTLLSGVNRHSTAIGRVWLSVIFIFRIMVLVVAAESVWGDEKSSFICNTLQPGCNSVCYDQFFPISHVRLWSLQLILVSTPALLVAMHVAHQQHIEKKMLRLEGHGDPLHLEEVKRHKVHISGTLWWTYVISVVFRLLFEAVFMYVFYLLYPGYAMVRLVKCDVYPCPNTVDCFVSRPTEKTVFTVFMLAASGICIILNVAEVVYLIIRACARRAQRRSNPPSRKGSGFGHRLSPEYKQNEINKLLSEQDGSLKDILRRSPGTGAGLAEKSDRCSAC
T27984	DRUGINFO	D00LEN	Sc-43077	Investigative
T27984	DRUGINFO	D02VNG	Sc-43076	Investigative

T12354	TARGETID	T12354
T12354	FORMERID	TTDNR00708
T12354	UNIPROID	TAU_HUMAN
T12354	TARGNAME	Tau messenger RNA (TAU mRNA)
T12354	GENENAME	MAPT
T12354	TARGTYPE	Literature-reported
T12354	SYNONYMS	tau phosphorylation (mRNA); TAU (mRNA); Paired helical filamenttau (mRNA); Paired helical filament-tau (mRNA); PHFtau (mRNA); PHF-tau (mRNA); Neurofibrillary tangle protein (mRNA); Microtubule-associated protein tau (mRNA); MTBT1 (mRNA); MAPTL (mRNA)
T12354	FUNCTION	The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization. Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity.
T12354	PDBSTRUC	6QJQ; 6QJP; 6QJM; 6QJH; 6NWQ
T12354	BIOCLASS	mRNA target
T12354	SEQUENCE	MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQEPESGKVVQEGFLREPGPPGLSHQLMSGMPGAPLLPEGPREATRQPSGTGPEDTEGGRHAPELLKHQLLGDLHQEGPPLKGAGGKERPGSKEEVDEDRDVDESSPQDSPPSKASPAQDGRPPQTAAREATSIPGFPAEGAIPLPVDFLSKVSTEIPASEPDGPSVGRAKGQDAPLEFTFHVEITPNVQKEQAHSEEHLGRAAFPGAPGEGPEARGPSLGEDTKEADLPEPSEKQPAAAPRGKPVSRVPQLKARMVSKSKDGTGSDDKKAKTSTRSSAKTLKNRPCLSPKHPTPGSSDPLIQPSSPAVCPEPPSSPKYVSSVTSRTGSSGAKEMKLKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGL

T36651	TARGETID	T36651
T36651	FORMERID	TTDI02378
T36651	UNIPROID	KAP0_HUMAN
T36651	TARGNAME	PRKAR1A messenger RNA (PRKAR1A mRNA)
T36651	GENENAME	PRKAR1A
T36651	TARGTYPE	Literature-reported
T36651	SYNONYMS	cAMP-dependent protein kinase type I-alpha regulatory subunit (mRNA); Tissue-specific extinguisher-1 (mRNA); Tissue-specific extinguisher 1 (mRNA); TSE1 (mRNA); RIalpha subunit of cAMP-dependent protein kinase (mRNA); PRKAR1 (mRNA); PKR1 (mRNA); PKA RIalpha-subunit (mRNA); CAMP-dependent protein kinase (PKA) (mRNA)
T36651	FUNCTION	Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signaling in cells.
T36651	PDBSTRUC	5KJZ; 5KJY; 5KJX
T36651	BIOCLASS	mRNA target
T36651	SEQUENCE	MESGSTAASEEARSLRECELYVQKHNIQALLKDSIVQLCTARPERPMAFLREYFERLEKEEAKQIQNLQKAGTRTDSREDEISPPPPNPVVKGRRRRGAISAEVYTEEDAASYVRKVIPKDYKTMAALAKAIEKNVLFSHLDDNERSDIFDAMFSVSFIAGETVIQQGDEGDNFYVIDQGETDVYVNNEWATSVGEGGSFGELALIYGTPRAATVKAKTNVKLWGIDRDSYRRILMGSTLRKRKMYEEFLSKVSILESLDKWERLTVADALEPVQFEDGQKIVVQGEPGDEFFIILEGSAAVLQRRSENEEFVEVGRLGPSDYFGEIALLMNRPRAATVVARGPLKCVKLDRPRFERVLGPCSDILKRNIQQYNSFVSLSV

T18601	TARGETID	T18601
T18601	FORMERID	TTDC00279
T18601	UNIPROID	NCAP_CVH22
T18601	TARGNAME	Coronavirus Nucleocapsid messenger RNA (HCoV Nucleoprotein mRNA)
T18601	GENENAME	HCoV Nucleoprotein mRNA
T18601	TARGTYPE	Literature-reported
T18601	SYNONYMS	Nc of HCoV (mRNA); N of HCoV (mRNA)
T18601	FUNCTION	Plays an important role in enhancing the efficiency of subgenomic viral RNA transcription as well as viral replication. Packages the positive strand viral genome RNA into a helical ribonucleocapsid (RNP) and plays a fundamental role during virion assembly through its interactions with the viral genome and membrane protein M.
T18601	BIOCLASS	mRNA target
T18601	SEQUENCE	MATVKWADASEPQRGRQGRIPYSLYSPLLVDSEQPWKVIPRNLVPINKKDKNKLIGYWNVQKRFRTRKGKRVDLSPKLHFYYLGTGPHKDAKFRERVEGVVWVAVDGAKTEPTGYGVRRKNSEPEIPHFNQKLPNGVTVVEEPDSRAPSRSQSRSQSRGRGESKPQSRNPSSDRNHNSQDDIMKAVAAALKSLGFDKPQEKDKKSAKTGTPKPSRNQSPASSQTSAKSLARSQSSETKEQKHEMQKPRWKRQPNDDVTSNVTQCFGPRDLDHNFGSAGVVANGVKAKGYPQFAELVPSTAAMLFDSHIVSKESGNTVVLTFTTRVTVPKDHPHLGKFLEELNAFTREMQQHPLLNPSALEFNPSQTSPATAEPVRDEVSIETDIIDEVN

T22298	TARGETID	T22298
T22298	FORMERID	TTDI02683
T22298	UNIPROID	ANPRA_HUMAN
T22298	TARGNAME	NPR1 messenger RNA (NPR1 mRNA)
T22298	GENENAME	NPR1
T22298	TARGTYPE	Literature-reported
T22298	SYNONYMS	NPR-A (mRNA); Guanylate cyclase A (mRNA); GC-A (mRNA); Atrial natriuretic peptide receptor type A (mRNA); Atrial natriuretic peptide receptor 1 (mRNA); ANPRA (mRNA); ANPR-A (mRNA); ANP-A (mRNA)
T22298	FUNCTION	Has guanylate cyclase activity upon binding of the ligand. Receptor for the atrial natriuretic peptide NPPA/ANP and the brain natriuretic peptide NPPB/BNP which are potent vasoactive hormones playing a key role in cardiovascular homeostasis.
T22298	BIOCLASS	mRNA target
T22298	ECNUMBER	EC 4.6.1.2
T22298	SEQUENCE	MPGPRRPAGSRLRLLLLLLLPPLLLLLRGSHAGNLTVAVVLPLANTSYPWSWARVGPAVELALAQVKARPDLLPGWTVRTVLGSSENALGVCSDTAAPLAAVDLKWEHNPAVFLGPGCVYAAAPVGRFTAHWRVPLLTAGAPALGFGVKDEYALTTRAGPSYAKLGDFVAALHRRLGWERQALMLYAYRPGDEEHCFFLVEGLFMRVRDRLNITVDHLEFAEDDLSHYTRLLRTMPRKGRVIYICSSPDAFRTLMLLALEAGLCGEDYVFFHLDIFGQSLQGGQGPAPRRPWERGDGQDVSARQAFQAAKIITYKDPDNPEYLEFLKQLKHLAYEQFNFTMEDGLVNTIPASFHDGLLLYIQAVTETLAHGGTVTDGENITQRMWNRSFQGVTGYLKIDSSGDRETDFSLWDMDPENGAFRVVLNYNGTSQELVAVSGRKLNWPLGYPPPDIPKCGFDNEDPACNQDHLSTLEVLALVGSLSLLGILIVSFFIYRKMQLEKELASELWRVRWEDVEPSSLERHLRSAGSRLTLSGRGSNYGSLLTTEGQFQVFAKTAYYKGNLVAVKRVNRKRIELTRKVLFELKHMRDVQNEHLTRFVGACTDPPNICILTEYCPRGSLQDILENESITLDWMFRYSLTNDIVKGMLFLHNGAICSHGNLKSSNCVVDGRFVLKITDYGLESFRDLDPEQGHTVYAKKLWTAPELLRMASPPVRGSQAGDVYSFGIILQEIALRSGVFHVEGLDLSPKEIIERVTRGEQPPFRPSLALQSHLEELGLLMQRCWAEDPQERPPFQQIRLTLRKFNRENSSNILDNLLSRMEQYANNLEELVEERTQAYLEEKRKAEALLYQILPHSVAEQLKRGETVQAEAFDSVTIYFSDIVGFTALSAESTPMQVVTLLNDLYTCFDAVIDNFDVYKVETIGDAYMVVSGLPVRNGRLHACEVARMALALLDAVRSFRIRHRPQEQLRLRIGIHTGPVCAGVVGLKMPRYCLFGDTVNTASRMESNGEALKIHLSSETKAVLEEFGGFELELRGDVEMKGKGKVRTYWLLGERGSSTRG

T79598	TARGETID	T79598
T79598	FORMERID	TTDI02675
T79598	UNIPROID	IBP2_HUMAN
T79598	TARGNAME	IGFBP2 messenger RNA (IGFBP2 mRNA)
T79598	GENENAME	IGFBP2
T79598	TARGTYPE	Literature-reported
T79598	SYNONYMS	Insulinlike growth factorbinding protein 2 (mRNA); Insulin-like growth factor-binding protein 2 (mRNA); IGFbinding protein 2 (mRNA); IGFBP-2 (mRNA); IGF-binding protein 2 (mRNA); IBP2 (mRNA); IBP-2 (mRNA); BP2 (mRNA)
T79598	FUNCTION	IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. Inhibits IGF-mediated growth and developmental rates.
T79598	PDBSTRUC	2H7T
T79598	BIOCLASS	mRNA target
T79598	SEQUENCE	MLPRVGCPALPLPPPPLLPLLLLLLGASGGGGGARAEVLFRCPPCTPERLAACGPPPVAPPAAVAAVAGGARMPCAELVREPGCGCCSVCARLEGEACGVYTPRCGQGLRCYPHPGSELPLQALVMGEGTCEKRRDAEYGASPEQVADNGDDHSEGGLVENHVDSTMNMLGGGGSAGRKPLKSGMKELAVFREKVTEQHRQMGKGGKHHLGLEEPKKLRPPPARTPCQQELDQVLERISTMRLPDERGPLEHLYSLHIPNCDKHGLYNLKQCKMSLNGQRGECWCVNPNTGKLIQGAPTIRGDPECHLFYNEQQEARGVHTQRMQ

T29095	TARGETID	T29095
T29095	FORMERID	TTDI02653
T29095	UNIPROID	ROA2_HUMAN
T29095	TARGNAME	hnRNP A2/B1 messenger RNA (HNRNPA2B1 mRNA)
T29095	GENENAME	HNRNPA2B1
T29095	TARGTYPE	Literature-reported
T29095	SYNONYMS	hnRNP A2/B1 (mRNA); Heterogeneous nuclear ribonucleoproteins A2/B1 (mRNA); HNRPA2B1 (mRNA)
T29095	FUNCTION	The hnRNP particle arrangement on nascent hnRNA is non-random and sequence-dependent and serves to condense and stabilize the transcripts and minimize tangling and knotting. Packaging plays a role in various processes such as transcription, pre-mRNA processing, RNA nuclear export, subcellular location, mRNA translation and stability of mature mRNAs. Forms hnRNP particles with at least 20 other different hnRNP and heterogeneous nuclear RNA in the nucleus. Involved in transport of specific mRNAs to the cytoplasm in oligodendrocytes and neurons: acts by specifically recognizing and binding the A2RE (21 nucleotide hnRNP A2 response element) or the A2RE11 (derivative 11 nucleotide oligonucleotide) sequence motifs present on some mRNAs, and promotes their transport to the cytoplasm. Specifically binds single-stranded telomeric DNA sequences, protecting telomeric DNA repeat against endonuclease digestion. Also binds other RNA molecules, such as primary miRNA (pri-miRNAs): acts as a nuclear 'reader' of the N6-methyladenosine (m6A) mark by specifically recognizing and binding a subset of nuclear m6A-containing pri-miRNAs. Binding to m6A-containing pri-miRNAs promotes pri-miRNA processing by enhancing binding of DGCR8 to pri-miRNA transcripts. Involved in miRNA sorting into exosomes following sumoylation, possibly by binding (m6A)-containing pre-miRNAs. Acts as a regulator of efficiency of mRNA splicing, possibly by binding to m6A-containing pre-mRNAs. Heterogeneous nuclear ribonucleoprotein (hnRNP) that associates with nascent pre-mRNAs, packaging them into hnRNP particles.
T29095	PDBSTRUC	5WWG; 5WWF; 5WWE; 5HO4; 5EN1
T29095	BIOCLASS	mRNA target
T29095	SEQUENCE	MEKTLETVPLERKKREKEQFRKLFIGGLSFETTEESLRNYYEQWGKLTDCVVMRDPASKRSRGFGFVTFSSMAEVDAAMAARPHSIDGRVVEPKRAVAREESGKPGAHVTVKKLFVGGIKEDTEEHHLRDYFEEYGKIDTIEIITDRQSGKKRGFGFVTFDDHDPVDKIVLQKYHTINGHNAEVRKALSRQEMQEVQSSRSGRGGNFGFGDSRGGGGNFGPGPGSNFRGGSDGYGSGRGFGDGYNGYGGGPGGGNFGGSPGYGGGRGGYGGGGPGYGNQGGGYGGGYDNYGGGNYGSGNYNDFGNYNQQPSNYGPMKSGNFGGSRNMGGPYGGGNYGPGGSGGSGGYGGRSRY

T57428	TARGETID	T57428
T57428	FORMERID	TTDI02686
T57428	UNIPROID	IL4RA_HUMAN
T57428	TARGNAME	IL4R messenger RNA (IL4R mRNA)
T57428	GENENAME	IL4R
T57428	TARGTYPE	Literature-reported
T57428	SYNONYMS	Interleukin-4 receptor subunit alpha (mRNA); IL4RA (mRNA); IL-4RA (mRNA); IL-4R-alpha (mRNA); IL-4R subunit alpha (mRNA); IL-4 receptor subunit alpha (mRNA); CD124 antigen (mRNA); CD124 (mRNA); 582J2.1 (mRNA)
T57428	FUNCTION	Couples to the JAK1/2/3-STAT6 pathway. The IL4 response is involved in promoting Th2 differentiation. The IL4/IL13 responses are involved in regulating IgE production and, chemokine and mucus production at sites of allergic inflammation. In certain cell types, can signal through activation of insulin receptor substrates, IRS1/IRS2. Receptor for both interleukin 4 and interleukin 13.
T57428	PDBSTRUC	5E4E; 3BPO; 3BPN; 3BPL; 1ITE
T57428	BIOCLASS	mRNA target
T57428	SEQUENCE	MGWLCSGLLFPVSCLVLLQVASSGNMKVLQEPTCVSDYMSISTCEWKMNGPTNCSTELRLLYQLVFLLSEAHTCIPENNGGAGCVCHLLMDDVVSADNYTLDLWAGQQLLWKGSFKPSEHVKPRAPGNLTVHTNVSDTLLLTWSNPYPPDNYLYNHLTYAVNIWSENDPADFRIYNVTYLEPSLRIAASTLKSGISYRARVRAWAQCYNTTWSEWSPSTKWHNSYREPFEQHLLLGVSVSCIVILAVCLLCYVSITKIKKEWWDQIPNPARSRLVAIIIQDAQGSQWEKRSRGQEPAKCPHWKNCLTKLLPCFLEHNMKRDEDPHKAAKEMPFQGSGKSAWCPVEISKTVLWPESISVVRCVELFEAPVECEEEEEVEEEKGSFCASPESSRDDFQEGREGIVARLTESLFLDLLGEENGGFCQQDMGESCLLPPSGSTSAHMPWDEFPSAGPKEAPPWGKEQPLHLEPSPPASPTQSPDNLTCTETPLVIAGNPAYRSFSNSLSQSPCPRELGPDPLLARHLEEVEPEMPCVPQLSEPTTVPQPEPETWEQILRRNVLQHGAAAAPVSAPTSGYQEFVHAVEQGGTQASAVVGLGPPGEAGYKAFSSLLASSAVSPEKCGFGASSGEEGYKPFQDLIPGCPGDPAPVPVPLFTFGLDREPPRSPQSSHLPSSSPEHLGLEPGEKVEDMPKPPLPQEQATDPLVDSLGSGIVYSALTCHLCGHLKQCHGQEDGGQTPVMASPCCGCCCGDRSSPPTTPLRAPDPSPGGVPLEASLCPASLAPSGISEKSKSSSSFHPAPGNAQSSSQTPKIVNFVSVGPTYMRVS

T17008	TARGETID	T17008
T17008	FORMERID	TTDI02676
T17008	UNIPROID	IBP5_HUMAN
T17008	TARGNAME	IGFBP5 messenger RNA (IGFBP5 mRNA)
T17008	GENENAME	IGFBP5
T17008	TARGTYPE	Literature-reported
T17008	SYNONYMS	Insulin-like growth factor-binding protein 5 (mRNA); IGFBP-5 (mRNA); IGF-binding protein 5 (mRNA); IBP5 (mRNA); IBP-5 (mRNA)
T17008	FUNCTION	IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors.
T17008	PDBSTRUC	1H59; 1BOE
T17008	BIOCLASS	mRNA target
T17008	SEQUENCE	MVLLTAVLLLLAAYAGPAQSLGSFVHCEPCDEKALSMCPPSPLGCELVKEPGCGCCMTCALAEGQSCGVYTERCAQGLRCLPRQDEEKPLHALLHGRGVCLNEKSYREQVKIERDSREHEEPTTSEMAEETYSPKIFRPKHTRISELKAEAVKKDRRKKLTQSKFVGGAENTAHPRIISAPEMRQESEQGPCRRHMEASLQELKASPRMVPRAVYLPNCDRKGFYKRKQCKPSRGRKRGICWCVDKYGMKLPGMEYVDGDFQCHTFDSSNVE

T21679	TARGETID	T21679
T21679	FORMERID	TTDR01268
T21679	UNIPROID	HD_HUMAN
T21679	TARGNAME	Huntingtin messenger RNA (HTT mRNA)
T21679	GENENAME	HTT
T21679	TARGTYPE	Literature-reported
T21679	SYNONYMS	IT15 (mRNA); Huntington disease protein (mRNA); Huntingtin (mRNA); HD protein (mRNA); HD (mRNA)
T21679	FUNCTION	May play a role in microtubule-mediated transport or vesicle function.
T21679	PDBSTRUC	6N8C; 6EZ8; 4RAV; 4FED; 4FEC
T21679	BIOCLASS	mRNA target
T21679	SEQUENCE	MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQPPPPPPPPPPPQLPQPPPQAQPLLPQPQPPPPPPPPPPGPAVAEEPLHRPKKELSATKKDRVNHCLTICENIVAQSVRNSPEFQKLLGIAMELFLLCSDDAESDVRMVADECLNKVIKALMDSNLPRLQLELYKEIKKNGAPRSLRAALWRFAELAHLVRPQKCRPYLVNLLPCLTRTSKRPEESVQETLAAAVPKIMASFGNFANDNEIKVLLKAFIANLKSSSPTIRRTAAGSAVSICQHSRRTQYFYSWLLNVLLGLLVPVEDEHSTLLILGVLLTLRYLVPLLQQQVKDTSLKGSFGVTRKEMEVSPSAEQLVQVYELTLHHTQHQDHNVVTGALELLQQLFRTPPPELLQTLTAVGGIGQLTAAKEESGGRSRSGSIVELIAGGGSSCSPVLSRKQKGKVLLGEEEALEDDSESRSDVSSSALTASVKDEISGELAASSGVSTPGSAGHDIITEQPRSQHTLQADSVDLASCDLTSSATDGDEEDILSHSSSQVSAVPSDPAMDLNDGTQASSPISDSSQTTTEGPDSAVTPSDSSEIVLDGTDNQYLGLQIGQPQDEDEEATGILPDEASEAFRNSSMALQQAHLLKNMSHCRQPSDSSVDKFVLRDEATEPGDQENKPCRIKGDIGQSTDDDSAPLVHCVRLLSASFLLTGGKNVLVPDRDVRVSVKALALSCVGAAVALHPESFFSKLYKVPLDTTEYPEEQYVSDILNYIDHGDPQVRGATAILCGTLICSILSRSRFHVGDWMGTIRTLTGNTFSLADCIPLLRKTLKDESSVTCKLACTAVRNCVMSLCSSSYSELGLQLIIDVLTLRNSSYWLVRTELLETLAEIDFRLVSFLEAKAENLHRGAHHYTGLLKLQERVLNNVVIHLLGDEDPRVRHVAAASLIRLVPKLFYKCDQGQADPVVAVARDQSSVYLKLLMHETQPPSHFSVSTITRIYRGYNLLPSITDVTMENNLSRVIAAVSHELITSTTRALTFGCCEALCLLSTAFPVCIWSLGWHCGVPPLSASDESRKSCTVGMATMILTLLSSAWFPLDLSAHQDALILAGNLLAASAPKSLRSSWASEEEANPAATKQEEVWPALGDRALVPMVEQLFSHLLKVINICAHVLDDVAPGPAIKAALPSLTNPPSLSPIRRKGKEKEPGEQASVPLSPKKGSEASAASRQSDTSGPVTTSKSSSLGSFYHLPSYLKLHDVLKATHANYKVTLDLQNSTEKFGGFLRSALDVLSQILELATLQDIGKCVEEILGYLKSCFSREPMMATVCVQQLLKTLFGTNLASQFDGLSSNPSKSQGRAQRLGSSSVRPGLYHYCFMAPYTHFTQALADASLRNMVQAEQENDTSGWFDVLQKVSTQLKTNLTSVTKNRADKNAIHNHIRLFEPLVIKALKQYTTTTCVQLQKQVLDLLAQLVQLRVNYCLLDSDQVFIGFVLKQFEYIEVGQFRESEAIIPNIFFFLVLLSYERYHSKQIIGIPKIIQLCDGIMASGRKAVTHAIPALQPIVHDLFVLRGTNKADAGKELETQKEVVVSMLLRLIQYHQVLEMFILVLQQCHKENEDKWKRLSRQIADIILPMLAKQQMHIDSHEALGVLNTLFEILAPSSLRPVDMLLRSMFVTPNTMASVSTVQLWISGILAILRVLISQSTEDIVLSRIQELSFSPYLISCTVINRLRDGDSTSTLEEHSEGKQIKNLPEETFSRFLLQLVGILLEDIVTKQLKVEMSEQQHTFYCQELGTLLMCLIHIFKSGMFRRITAAATRLFRSDGCGGSFYTLDSLNLRARSMITTHPALVLLWCQILLLVNHTDYRWWAEVQQTPKRHSLSSTKLLSPQMSGEEEDSDLAAKLGMCNREIVRRGALILFCDYVCQNLHDSEHLTWLIVNHIQDLISLSHEPPVQDFISAVHRNSAASGLFIQAIQSRCENLSTPTMLKKTLQCLEGIHLSQSGAVLTLYVDRLLCTPFRVLARMVDILACRRVEMLLAANLQSSMAQLPMEELNRIQEYLQSSGLAQRHQRLYSLLDRFRLSTMQDSLSPSPPVSSHPLDGDGHVSLETVSPDKDWYVHLVKSQCWTRSDSALLEGAELVNRIPAEDMNAFMMNSEFNLSLLAPCLSLGMSEISGGQKSALFEAAREVTLARVSGTVQQLPAVHHVFQPELPAEPAAYWSKLNDLFGDAALYQSLPTLARALAQYLVVVSKLPSHLHLPPEKEKDIVKFVVATLEALSWHLIHEQIPLSLDLQAGLDCCCLALQLPGLWSVVSSTEFVTHACSLIYCVHFILEAVAVQPGEQLLSPERRTNTPKAISEEEEEVDPNTQNPKYITAACEMVAEMVESLQSVLALGHKRNSGVPAFLTPLLRNIIISLARLPLVNSYTRVPPLVWKLGWSPKPGGDFGTAFPEIPVEFLQEKEVFKEFIYRINTLGWTSRTQFEETWATLLGVLVTQPLVMEQEESPPEEDTERTQINVLAVQAITSLVLSAMTVPVAGNPAVSCLEQQPRNKPLKALDTRFGRKLSIIRGIVEQEIQAMVSKRENIATHHLYQAWDPVPSLSPATTGALISHEKLLLQINPERELGSMSYKLGQVSIHSVWLGNSITPLREEEWDEEEEEEADAPAPSSPPTSPVNSRKHRAGVDIHSCSQFLLELYSRWILPSSSARRTPAILISEVVRSLLVVSDLFTERNQFELMYVTLTELRRVHPSEDEILAQYLVPATCKAAAVLGMDKAVAEPVSRLLESTLRSSHLPSRVGALHGVLYVLECDLLDDTAKQLIPVISDYLLSNLKGIAHCVNIHSQQHVLVMCATAFYLIENYPLDVGPEFSASIIQMCGVMLSGSEESTPSIIYHCALRGLERLLLSEQLSRLDAESLVKLSVDRVNVHSPHRAMAALGLMLTCMYTGKEKVSPGRTSDPNPAAPDSESVIVAMERVSVLFDRIRKGFPCEARVVARILPQFLDDFFPPQDIMNKVIGEFLSNQQPYPQFMATVVYKVFQTLHSTGQSSMVRDWVMLSLSNFTQRAPVAMATWSLSCFFVSASTSPWVAAILPHVISRMGKLEQVDVNLFCLVATDFYRHQIEEELDRRAFQSVLEVVAAPGSPYHRLLTCLRNVHKVTTC
T21679	DRUGINFO	D00QIJ	Huntingtin gene antisense	Preclinical
T21679	DRUGINFO	D0V7VX	ALN-HTT	Preclinical

T61586	TARGETID	T61586
T61586	FORMERID	TTDI02384
T61586	UNIPROID	KI67_HUMAN
T61586	TARGNAME	Antigen KI-67 messenger RNA (MKI67 mRNA)
T61586	GENENAME	MKI67
T61586	TARGTYPE	Literature-reported
T61586	SYNONYMS	Proliferation marker protein Ki-67 (mRNA); Antigen identified by monoclonal antibody Ki-67 (mRNA); Antigen Ki67 (mRNA); Antigen KI-67 (mRNA)
T61586	FUNCTION	Associates with the surface of the mitotic chromosome, the perichromosomal layer, and covers a substantial fraction of the chromosome surface. Prevents chromosomes from collapsing into a single chromatin mass by forming a steric and electrostatic charge barrier: the protein has a high net electrical charge and acts as a surfactant, dispersing chromosomes and enabling independent chromosome motility. Binds DNA, with a preference for supercoiled DNA and AT-rich DNA. Does not contribute to the internal structure of mitotic chromosomes. May play a role in chromatin organization. It is however unclear whether it plays a direct role in chromatin organization or whether it is an indirect consequence of its function in maintaining mitotic chromosomes dispersed. Required to maintain individual mitotic chromosomes dispersed in the cytoplasm following nuclear envelope disassembly.
T61586	PDBSTRUC	5J28; 2AFF; 1R21
T61586	BIOCLASS	mRNA target
T61586	SEQUENCE	MWPTRRLVTIKRSGVDGPHFPLSLSTCLFGRGIECDIRIQLPVVSKQHCKIEIHEQEAILHNFSSTNPTQVNGSVIDEPVRLKHGDVITIIDRSFRYENESLQNGRKSTEFPRKIREQEPARRVSRSSFSSDPDEKAQDSKAYSKITEGKVSGNPQVHIKNVKEDSTADDSKDSVAQGTTNVHSSEHAGRNGRNAADPISGDFKEISSVKLVSRYGELKSVPTTQCLDNSKKNESPFWKLYESVKKELDVKSQKENVLQYCRKSGLQTDYATEKESADGLQGETQLLVSRKSRPKSGGSGHAVAEPASPEQELDQNKGKGRDVESVQTPSKAVGASFPLYEPAKMKTPVQYSQQQNSPQKHKNKDLYTTGRRESVNLGKSEGFKAGDKTLTPRKLSTRNRTPAKVEDAADSATKPENLSSKTRGSIPTDVEVLPTETEIHNEPFLTLWLTQVERKIQKDSLSKPEKLGTTAGQMCSGLPGLSSVDINNFGDSINESEGIPLKRRRVSFGGHLRPELFDENLPPNTPLKRGEAPTKRKSLVMHTPPVLKKIIKEQPQPSGKQESGSEIHVEVKAQSLVISPPAPSPRKTPVASDQRRRSCKTAPASSSKSQTEVPKRGGRKSGNLPSKRVSISRSQHDILQMICSKRRSGASEANLIVAKSWADVVKLGAKQTQTKVIKHGPQRSMNKRQRRPATPKKPVGEVHSQFSTGHANSPCTIIIGKAHTEKVHVPARPYRVLNNFISNQKMDFKEDLSGIAEMFKTPVKEQPQLTSTCHIAISNSENLLGKQFQGTDSGEEPLLPTSESFGGNVFFSAQNAAKQPSDKCSASPPLRRQCIRENGNVAKTPRNTYKMTSLETKTSDTETEPSKTVSTANRSGRSTEFRNIQKLPVESKSEETNTEIVECILKRGQKATLLQQRREGEMKEIERPFETYKENIELKENDEKMKAMKRSRTWGQKCAPMSDLTDLKSLPDTELMKDTARGQNLLQTQDHAKAPKSEKGKITKMPCQSLQPEPINTPTHTKQQLKASLGKVGVKEELLAVGKFTRTSGETTHTHREPAGDGKSIRTFKESPKQILDPAARVTGMKKWPRTPKEEAQSLEDLAGFKELFQTPGPSEESMTDEKTTKIACKSPPPESVDTPTSTKQWPKRSLRKADVEEEFLALRKLTPSAGKAMLTPKPAGGDEKDIKAFMGTPVQKLDLAGTLPGSKRQLQTPKEKAQALEDLAGFKELFQTPGHTEELVAAGKTTKIPCDSPQSDPVDTPTSTKQRPKRSIRKADVEGELLACRNLMPSAGKAMHTPKPSVGEEKDIIIFVGTPVQKLDLTENLTGSKRRPQTPKEEAQALEDLTGFKELFQTPGHTEEAVAAGKTTKMPCESSPPESADTPTSTRRQPKTPLEKRDVQKELSALKKLTQTSGETTHTDKVPGGEDKSINAFRETAKQKLDPAASVTGSKRHPKTKEKAQPLEDLAGLKELFQTPVCTDKPTTHEKTTKIACRSQPDPVDTPTSSKPQSKRSLRKVDVEEEFFALRKRTPSAGKAMHTPKPAVSGEKNIYAFMGTPVQKLDLTENLTGSKRRLQTPKEKAQALEDLAGFKELFQTRGHTEESMTNDKTAKVACKSSQPDPDKNPASSKRRLKTSLGKVGVKEELLAVGKLTQTSGETTHTHTEPTGDGKSMKAFMESPKQILDSAASLTGSKRQLRTPKGKSEVPEDLAGFIELFQTPSHTKESMTNEKTTKVSYRASQPDLVDTPTSSKPQPKRSLRKADTEEEFLAFRKQTPSAGKAMHTPKPAVGEEKDINTFLGTPVQKLDQPGNLPGSNRRLQTRKEKAQALEELTGFRELFQTPCTDNPTTDEKTTKKILCKSPQSDPADTPTNTKQRPKRSLKKADVEEEFLAFRKLTPSAGKAMHTPKAAVGEEKDINTFVGTPVEKLDLLGNLPGSKRRPQTPKEKAKALEDLAGFKELFQTPGHTEESMTDDKITEVSCKSPQPDPVKTPTSSKQRLKISLGKVGVKEEVLPVGKLTQTSGKTTQTHRETAGDGKSIKAFKESAKQMLDPANYGTGMERWPRTPKEEAQSLEDLAGFKELFQTPDHTEESTTDDKTTKIACKSPPPESMDTPTSTRRRPKTPLGKRDIVEELSALKQLTQTTHTDKVPGDEDKGINVFRETAKQKLDPAASVTGSKRQPRTPKGKAQPLEDLAGLKELFQTPICTDKPTTHEKTTKIACRSPQPDPVGTPTIFKPQSKRSLRKADVEEESLALRKRTPSVGKAMDTPKPAGGDEKDMKAFMGTPVQKLDLPGNLPGSKRWPQTPKEKAQALEDLAGFKELFQTPGTDKPTTDEKTTKIACKSPQPDPVDTPASTKQRPKRNLRKADVEEEFLALRKRTPSAGKAMDTPKPAVSDEKNINTFVETPVQKLDLLGNLPGSKRQPQTPKEKAEALEDLVGFKELFQTPGHTEESMTDDKITEVSCKSPQPESFKTSRSSKQRLKIPLVKVDMKEEPLAVSKLTRTSGETTQTHTEPTGDSKSIKAFKESPKQILDPAASVTGSRRQLRTRKEKARALEDLVDFKELFSAPGHTEESMTIDKNTKIPCKSPPPELTDTATSTKRCPKTRPRKEVKEELSAVERLTQTSGQSTHTHKEPASGDEGIKVLKQRAKKKPNPVEEEPSRRRPRAPKEKAQPLEDLAGFTELSETSGHTQESLTAGKATKIPCESPPLEVVDTTASTKRHLRTRVQKVQVKEEPSAVKFTQTSGETTDADKEPAGEDKGIKALKESAKQTPAPAASVTGSRRRPRAPRESAQAIEDLAGFKDPAAGHTEESMTDDKTTKIPCKSSPELEDTATSSKRRPRTRAQKVEVKEELLAVGKLTQTSGETTHTDKEPVGEGKGTKAFKQPAKRKLDAEDVIGSRRQPRAPKEKAQPLEDLASFQELSQTPGHTEELANGAADSFTSAPKQTPDSGKPLKISRRVLRAPKVEPVGDVVSTRDPVKSQSKSNTSLPPLPFKRGGGKDGSVTGTKRLRCMPAPEEIVEELPASKKQRVAPRARGKSSEPVVIMKRSLRTSAKRIEPAEELNSNDMKTNKEEHKLQDSVPENKGISLRSRRQNKTEAEQQITEVFVLAERIEINRNEKKPMKTSPEMDIQNPDDGARKPIPRDKVTENKRCLRSARQNESSQPKVAEESGGQKSAKVLMQNQKGKGEAGNSDSMCLRSRKTKSQPAASTLESKSVQRVTRSVKRCAENPKKAEDNVCVKKIRTRSHRDSEDI

T42440	TARGETID	T42440
T42440	FORMERID	TTDI02667
T42440	UNIPROID	HEPC_HUMAN
T42440	TARGNAME	Hepcidin messenger RNA (HAMP mRNA)
T42440	GENENAME	HAMP
T42440	TARGTYPE	Literature-reported
T42440	SYNONYMS	UNQ487/PRO1003 (mRNA); Putative liver tumor regressor (mRNA); PLTR (mRNA); Liver-expressed antimicrobial peptide 1 (mRNA); LEAP1 (mRNA); LEAP-1 (mRNA); Hepcidin (mRNA); HEPC (mRNA)
T42440	FUNCTION	Acts by promoting endocytosis and degradation of ferroportin, leading to the retention of iron in iron-exporting cells and decreased flow of iron into plasma. Controls the major flows of iron into plasma: absorption of dietary iron in the intestine, recycling of iron by macrophages, which phagocytose old erythrocytes and other cells, and mobilization of stored iron from hepatocytes. Liver-produced hormone that constitutes the main circulating regulator of iron absorption and distribution across tissues.
T42440	PDBSTRUC	4QAE; 3H0T; 2KEF; 1M4F; 1M4E
T42440	BIOCLASS	mRNA target
T42440	SEQUENCE	MALSSQIWAACLLLLLLLASLTSGSVFPQQTGQLAELQPQDRAGARASWMPMFQRRRRRDTHFPICIFCCGCCHRSKCGMCCKT

T12486	TARGETID	T12486
T12486	FORMERID	TTDI02234
T12486	UNIPROID	HSPB3_HUMAN
T12486	TARGNAME	HSP27 messenger RNA (HSPB3 mRNA)
T12486	GENENAME	HSPB3
T12486	TARGTYPE	Literature-reported
T12486	SYNONYMS	Protein 3 (mRNA); HspB3 (mRNA); Heat shock protein beta-3 (mRNA); Heat shock 17 kDa protein (mRNA); HSPL27 (mRNA); HSP 17 (mRNA)
T12486	FUNCTION	Inhibitor of actin polymerization.
T12486	PDBSTRUC	6F2R
T12486	BIOCLASS	mRNA target
T12486	SEQUENCE	MAKIILRHLIEIPVRYQEEFEARGLEDCRLDHALYALPGPTIVDLRKTRAAQSPPVDSAAETPPREGKSHFQILLDVVQFLPEDIIIQTFEGWLLIKAQHGTRMDEHGFISRSFTRQYKLPDGVEIKDLSAVLCHDGILVVEVKDPVGTK

T77125	TARGETID	T77125
T77125	FORMERID	TTDR01096
T77125	UNIPROID	AGRL3_HUMAN
T77125	TARGNAME	CIRL-3 messenger RNA (CIRL-3 mRNA)
T77125	GENENAME	ADGRL3
T77125	TARGTYPE	Literature-reported
T77125	SYNONYMS	Lectomedin-3 (mRNA); Latrophilin-3 (mRNA); LPHN3 (mRNA); LEC3 (mRNA); KIAA0768 (mRNA); Calcium-independent alpha-latrotoxin receptor 3 (mRNA); CIRL-3 (mRNA); Adhesion G protein-coupled receptor L3 (mRNA)
T77125	FUNCTION	Plays a role in the development of glutamatergic synapses in the cortex. Important in determining the connectivity rates between the principal neurons in the cortex. Plays a role in cell-cell adhesion and neuron guidance via its interactions with FLRT2 and FLRT3 that are expressed at the surface of adjacent cells.
T77125	PDBSTRUC	5CMN
T77125	BIOCLASS	mRNA target
T77125	SEQUENCE	MWPSQLLIFMMLLAPIIHAFSRAPIPMAVVRRELSCESYPIELRCPGTDVIMIESANYGRTDDKICDSDPAQMENIRCYLPDAYKIMSQRCNNRTQCAVVAGPDVFPDPCPGTYKYLEVQYECVPYKVEQKVFLCPGLLKGVYQSEHLFESDHQSGAWCKDPLQASDKIYYMPWTPYRTDTLTEYSSKDDFIAGRPTTTYKLPHRVDGTGFVVYDGALFFNKERTRNIVKFDLRTRIKSGEAIIANANYHDTSPYRWGGKSDIDLAVDENGLWVIYATEQNNGKIVISQLNPYTLRIEGTWDTAYDKRSASNAFMICGILYVVKSVYEDDDNEATGNKIDYIYNTDQSKDSLVDVPFPNSYQYIAAVDYNPRDNLLYVWNNYHVVKYSLDFGPLDSRSGQAHHGQVSYISPPIHLDSELERPSVKDISTTGPLGMGSTTTSTTLRTTTLSPGRSTTPSVSGRRNRSTSTPSPAVEVLDDMTTHLPSASSQIPALEESCEAVEAREIMWFKTRQGQIAKQPCPAGTIGVSTYLCLAPDGIWDPQGPDLSNCSSPWVNHITQKLKSGETAANIARELAEQTRNHLNAGDITYSVRAMDQLVGLLDVQLRNLTPGGKDSAARSLNKAMVETVNNLLQPQALNAWRDLTTSDQLRAATMLLHTVEESAFVLADNLLKTDIVRENTDNIKLEVARLSTEGNLEDLKFPENMGHGSTIQLSANTLKQNGRNGEIRVAFVLYNNLGPYLSTENASMKLGTEALSTNHSVIVNSPVITAAINKEFSNKVYLADPVVFTVKHIKQSEENFNPNCSFWSYSKRTMTGYWSTQGCRLLTTNKTHTTCSCNHLTNFAVLMAHVEVKHSDAVHDLLLDVITWVGILLSLVCLLICIFTFCFFRGLQSDRNTIHKNLCISLFVAELLFLIGINRTDQPIACAVFAALLHFFFLAAFTWMFLEGVQLYIMLVEVFESEHSRRKYFYLVGYGMPALIVAVSAAVDYRSYGTDKVCWLRLDTYFIWSFIGPATLIIMLNVIFLGIALYKMFHHTAILKPESGCLDNIKSWVIGAIALLCLLGLTWAFGLMYINESTVIMAYLFTIFNSLQGMFIFIFHCVLQKKVRKEYGKCLRTHCCSGKSTESSIGSGKTSGSRTPGRYSTGSQSRIRRMWNDTVRKQSESSFITGDINSSASLNREGLLNNARDTSVMDTLPLNGNHGNSYSIASGEYLSNCVQIIDRGYNHNETALEKKILKELTSNYIPSYLNNHERSSEQNRNLMNKLVNNLGSGREDDAIVLDDATSFNHEESLGLELIHEESDAPLLPPRVYSTENHQPHHYTRRRIPQDHSESFFPLLTNEHTEDLQSPHRDSLYTSMPTLAGVAATESVTTSTQTEPPPAKCGDAEDVYYKSMPNLGSRNHVHQLHTYYQLGRGSSDGFIVPPNKDGTPPEGSSKGPAHLVTSL

T85419	TARGETID	T85419
T85419	FORMERID	TTDR01428
T85419	UNIPROID	NRAM_I97A1
T85419	TARGNAME	Influenza NA messenger RNA (Influenza NA mRNA)
T85419	GENENAME	Influenza NA mRNA
T85419	TARGTYPE	Literature-reported
T85419	SYNONYMS	Neuraminidase (mRNA); NA of influenza (mRNA)
T85419	FUNCTION	Cleaves off the terminal sialic acids on the glycosylated HA during virus budding to facilitate virus release. Additionally helps virus spread through the circulation by further removing sialic acids from the cell surface. These cleavages prevent self-aggregation and ensure the efficient spread of the progeny virus from cell to cell. Otherwise, infection would be limited to one round of replication. Described as a receptor-destroying enzyme because it cleaves a terminal sialic acid from the cellular receptors. May facilitate viral invasion of the upper airways by cleaving the sialic acid moities on the mucin of the airway epithelial cells. Likely to plays a role in the budding process through its association with lipid rafts during intracellular transport. May additionally display a raft-association independent effect on budding. Plays a role in the determination of host range restriction on replication and virulence. Sialidase activity in late endosome/lysosome traffic seems to enhance virus replication. Catalyzes the removal of terminal sialic acid residues from viral and cellular glycoconjugates.
T85419	BIOCLASS	mRNA target
T85419	ECNUMBER	EC 3.2.1.18
T85419	SEQUENCE	MNPNQKIITIGSICMVVGIISLMLQIGNIISVWVSHIIQTWHPNQPEPCNQSINFYTEQAAASVTLAGNSSLCPISGWAIYSKDNSIRIGSKGDVFVIREPFISCSHLECRTFFLTQGALLNDKHSNGTVKDRSPYRTLMSCPVGEAPSPYNSRFESVAWSASACHDGISWLTIGISGPDNGAVAVLKYNGIITDTIKSWRNNILRTQESECACVNGSCFTVMTDGPSNEQASYKIFKIEKGRVVKSVELNAPNYHYEECSCYPDAGEITCVCRDNWHGSNRPWVSFNQNLEYQIGYICSGVFGDSPRPNDGTGSCGPVSLNGAYGVKGFSFKYGNGVWIGRTKSTSSRSGFEMIWDPNGWTETDSSFSLKQDIIAITDWSGYSGSFIQHPELTGLNCMRPCFWVELIRGRPKEKTIWTSGSSISFCGVNSDTVGWSWPDGADLPFTIDK
T85419	DRUGINFO	D04DNL	ALN-FLU01	Preclinical
T85419	DRUGINFO	D0N0MY	ISIS 3308	Investigative

T42120	TARGETID	T42120
T42120	FORMERID	TTDR01145
T42120	UNIPROID	A0A072ZJB2_PSEAI
T42120	TARGNAME	Pseudomonas Amidotransferase (Pseudo yafJ)
T42120	GENENAME	Pseudo yafJ
T42120	TARGTYPE	Literature-reported
T42120	SYNONYMS	Putative glutamine amidotransferase yafJ; Putative glutamine amidotransferase; Glutamine amidotransferases class-II; Class II glutamine amidotransferase
T42120	FUNCTION	Catalyses the removal of the ammonia group from a glutamine molecule and its subsequent transfer to a specific substrate, thus creating a new carbon-nitrogen group on the substrate. 
T42120	ECNUMBER	EC 2.4.2.-
T42120	SEQUENCE	MCELLGMSANVPTDIVFSFTGLMQRGGGTGPHRDGWGIAFYEGRGVRLFQDPLASVDSEVARLVQRFPIKSETVIGHIRQANVGKVGLSNTHPFIRELGGRYWTFAHNGQLADFQPKPGFYRPVGETDSEAAFCDLLNRVRRAFPEPVPVEVLLPVLISACDEYRKKGVFNALISDGDWLFTFCSSKLAYITRRAPFGPARLKDADLTVDFHAETTPDDVVTVIATEPLTDNENWTLQQSGEWVLWWGGEVLAKGRV

T46060	TARGETID	T46060
T46060	FORMERID	TTDI01367
T46060	UNIPROID	A0A0F7UUA6_TOXGV
T46060	TARGNAME	Toxoplasma Calcium-dependent protein kinase 1 (Tg CDPK1)
T46060	GENENAME	Tg CDPK1
T46060	TARGTYPE	Literature-reported
T46060	SYNONYMS	CAM kinase, CDPK family TgCDPK1
T46060	FUNCTION	Provides the mechanistic link between calcium signalling and motility, differentiation and invasion. Required for the microneme secretion at the apical complex and parasite proliferation.
T46060	PDBSTRUC	6BFA
T46060	SEQUENCE	MGQQESTLGGAAGEPRSRGHAAGTSGGPGDHLHATPGMFVQHSTAIFSDRYKGQRVLGKGSFGEVILCKDKITGQECAVKVISKRQVKQKTDKESLLREVQLLKQLDHPNIMKLYEFFEDKGYFYLVGEVYTGGELFDEIISRKRFSEVDAARIIRQVLSGITYMHKNKIVHRDLKPENLLLESKSKDANIRIIDFGLSTHFEASKKMKDKIGTAYYIAPEVLHGTYDEKCDVWSTGVILYILLSGCPPFNGANEYDILKKVEKGKYTFELPQWKKVSESAKDLIRKMLTYVPSMRISARDALDHEWIQTYTKEQISVDVPSLDNAILNIRQFQGTQKLAQAALLYMGSKLTSQDETKELTAIFHKMDKNGDGQLDRAELIEGYKELMRMKGQDASMLDASAVEHEVDQVLDAVDFDKNGYIEYSEFVTVAMDRKTLLSRERLERAFRMFDSDNSGKISSTELATIFGVSDVDSETWKSVLSEVDKNNDGEVDFDEFQQMLLKLCGN

T27334	TARGETID	T27334
T27334	FORMERID	TTDS00455
T27334	UNIPROID	A0A0M4UFG9_CAMJU
T27334	TARGNAME	Campylobacter Flavodoxin:quinone reductase (CAMJU FqrB)
T27334	GENENAME	CAMJU FqrB
T27334	TARGTYPE	Literature-reported
T27334	SYNONYMS	NADPH oxidoreductase, putative flavodoxin quinone reductase FqrB
T27334	FUNCTION	Exhibited NADPH quinone reductase activity with menadione or benzoquinone. Reduced flavodoxin (FldA), the electron carrier of PFOR.
T27334	BIOCLASS	Iron-sulfur protein donor oxidoreductase
T27334	SEQUENCE	MKKIDLIVVGAGPTGIGCAVEAKLKNKEVLILEKSNNICQTLMQFYKDGKRVDKAYKGCEGTNHGHVPFEDGTKESTIETFQNALKEHNIEVEFGSEVESVKNENGVFLVSTAKGVYGCKNIIVAIGRMGKPNKPDYKLPMTLTKIINFNANSVLGNEKILVVGGGNSAAEYAVDLANSNQVSLCYRKKEFTRLNDINLKDIHEAGNSGEVELKLGIDINEVEDDNGKAKVNFTDGTSDIYDRIIYAIGGSTPLDFLQKCGINVDDKGVPLMDENKQSNVKGIFVAGDITTKNGASIVTGLNDAVKILSVL

T79181	TARGETID	T79181
T79181	FORMERID	TTDI01334
T79181	UNIPROID	A0A151C7Z8_BIFBI
T79181	TARGNAME	Bifidobacterium Exo-alpha sialidase (BB sialidase)
T79181	GENENAME	BB sialidase
T79181	TARGTYPE	Literature-reported
T79181	SYNONYMS	Exo-alpha-sialidase; BB Sialidase
T79181	FUNCTION	Involved in the degradation of sialyloligosaccharides in human milk and intestinal glycoconjugates.
T79181	ECNUMBER	EC 3.2.1.18
T79181	SEQUENCE	MVRSTKPSLLRRFGALVAAAAMLVVLPAGVSTASAASDDADMLTVTMTRTDALGDEVYVGDTLTYSFTNTNNTSSAFTAFPAESNLSGVLTTGTPNCRYENLAGGASYPCSTASHTITADDLTAGSFTPRTVWKATSDRGGTQVLQDNIVSTGDTVTVKEGKRPDPATIPTDRADGEAVRLATARQNLGTECYRIPALAEAPNGWILAAFDQRPNTAMANGSGVKCWDAPQPNSIVQRISKDGGKSWTPIQYVAQGKNAPERYGYSDPSYVVDKETGEIFLFFVHSYNKGFADSQLGVDESNRNVLHAVVVSSKDNGETWSKPRDITADITKGYENEWKSRFATSGAGIQLKYGKYKGRLIQQYAVGRTTGSNAAVSVYSDDHGKTWQAGNPVTGMLMDENKVVELSDGRVMLNSRPGNGSGYRRVAISEDGGVNYGTVKNETQLPDPNNNAHITRAFPNAPEGSAKAKVLLYSSPRANNEGRANGVVRISLDDGTTWSSGKLYKEGSMAYSVITALSGAAGGGYGLLYEGAWVTGGGIDSHDIMYTHISMDWLGYLSATADDVTASVEEGASTVDVTVPVSNVGSVDYTGVTVTPADLPTGWSASPVNVGALASGTSKDVTVTVNVPATAKKDDVAKIVLRVTGTSAANADATTGFDGSITVNVTEKSEPDPEPEPTITGVSAVTSQAGVKVGDVFDASKVSVTAAMSDGSSKALAAGEYSLSAVDADGKAVDLAEPFAAAGVVTVTVSVPVEGAGPLTASFTIDVAEKSVDPEPKPEPEPKPEPEKPAGPKVDVPTEQPGLSKTGASTAGMSIVFVLLALSGVAALSLRRRSAH

T46395	TARGETID	T46395
T46395	FORMERID	TTDI03126
T46395	UNIPROID	CXE1_HUMAN
T46395	TARGNAME	Connexin-23 (Cx23)
T46395	GENENAME	GJE1
T46395	TARGTYPE	Literature-reported
T46395	SYNONYMS	Putative gap junction epsilon-1 protein
T46395	FUNCTION	Does not form functional gap junctions. Mediates calcium-independent ATP release, suggesting activity as a hemichannel.
T46395	BIOCLASS	Gap junction-forming connexin
T46395	SEQUENCE	MSLNYIKNFYEGCVKPPTVIGQFHTLFFGSIRIFFLGVLGFAVYGNEALHFICDPDKREVNLFCYNQFRPITPQVSFSALQLVIVLVPGALFHLYAACKSINQECILQKPIYTIIYILSVLLRISLAAIAFWLQIYLFGFQVKSLYLCDARSLGENMIIRCMVPEHFEKTIFLIAINTFTTITILLFVAEIFEIIFRRLYFPFRQ
T46395	DRUGINFO	D00VJY	octanol	Investigative

T10490	TARGETID	T10490
T10490	FORMERID	TTDI01348
T10490	UNIPROID	B4EEM8_BURCJ
T10490	TARGNAME	Burkholderia Glutamate racemase (BURCJ murI)
T10490	GENENAME	BURCJ murI
T10490	TARGTYPE	Literature-reported
T10490	SYNONYMS	Glutamate racemase
T10490	FUNCTION	Provides the (R)-glutamate required for cell wall biosynthesis.
T10490	ECNUMBER	EC 5.1.1.3
T10490	SEQUENCE	MTNPSDATALRAAAPVGIFDSGLGGLSVLRAARAHLPDESFVYVADSHHAPYGPRDEAFITERTLAIGEWLAREGAKALVIACNTATARAIAAIRERLSIPLVGVEPGIKPAAALSATGVAGVLATQSTLNSPRFQALLDRYGAGRRFICQPGHGLVEAIERGDTNSPALRALLERYIQPMLDDGADTLVLGCTHYPFFTETIRDLVGERLTIVDTSDAIARQLARVLDERGLRAPAGTHAAPPRFCSTSDGLQLRALASTLLGLDAPVESVTISSPNARACATA

T82584	TARGETID	T82584
T82584	FORMERID	TTDI02466
T82584	UNIPROID	KCJ18_HUMAN
T82584	TARGNAME	Inward rectifier potassium channel Kir2.6 (KCNJ18)
T82584	GENENAME	KCNJ18
T82584	TARGTYPE	Literature-reported
T82584	SYNONYMS	Potassium channel, inwardly rectifying subfamily J member 18; KCNJ18; Inward rectifier potassium channel 18; Inward rectifier K(+) channel Kir2.6
T82584	FUNCTION	Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised,the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium.
T82584	BIOCLASS	Inward rectifier potassium channel
T82584	SEQUENCE	MTAASRANPYSIVSLEEDGLHLVTMSGANGFGNGKVHTRRRCRNRFVKKNGQCNIAFANMDEKSQRYLADMFTTCVDIRWRYMLLIFSLAFLASWLLFGVIFWVIAVAHGDLEPAEGHGRTPCVMQVHGFMAAFLFSIETQTTIGYGLRCVTEECLVAVFMVVAQSIVGCIIDSFMIGAIMAKMARPKKRAQTLLFSHNAVVALRDGKLCLMWRVGNLRKSHIVEAHVRAQLIKPRVTEEGEYIPLDQIDIDVGFDKGLDRIFLVSPITILHEIDEASPLFGISRQDLETDDFEIVVILEGMVEATAMTTQARSSYLANEILWGHRFEPVLFEEKNQYKIDYSHFHKTYEVPSTPRCSAKDLVENKFLLPSANSFCYENELAFLSRDEEDEADGDQDGRSRDGLSPQARHDFDRLQAGGGVLEQRPYRRGSEI

T92184	TARGETID	T92184
T92184	FORMERID	TTDI01696
T92184	UNIPROID	D2Y0P7_EIMTE
T92184	TARGNAME	Eimeria tenella Telomerase reverse transcriptase (EIMTE TERT)
T92184	GENENAME	EIMTE TERT
T92184	TARGTYPE	Literature-reported
T92184	SYNONYMS	EIMTE Telomerase reverse transcriptase; EIMTE Telomerase catalytic subunit
T92184	FUNCTION	Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. It elongates telomeres. It is a reverse transcriptase that adds simple sequence repeats to chromosome ends by copying a template sequence within the RNA component of the enzyme.
T92184	ECNUMBER	EC 2.7.7.49
T92184	SEQUENCE	MVLSKAGLVALKQMELVTGELYLEKQRKRIVKFEELGYNDSSGLERRLEELLITLDPSEPKAILEGFKLGRELLFNTSLDNLSDNGIDRKLRLINGEKLILWSSIELQNGYSSFPNQRSMSSSGRSRKNEYNTELSPTSFITDQIKNIIPDSEKDSLTYQVQDFELLLRKHFPRIRIFHSGSYSGLRTSFDTIKPKKYSFCNSTLYKFQNLHAWNTLLSKIGPIEILFLFVCCIIFRILGDHSEILIQQAGRMLTNDFLEELARLYETGPKTKNKFVSSSSVLTSPLTTIIEKEEVKPELDETERQVNKREPGGIIKSEDRLSKSIYILDIKPYLSTRFLCDHFYSRGGLPCKSLVRLLPPLLLGANRTLRFILQTDHIFIDHNRQSKLGLLGISEMTKYSRVFKKLASACMEEFQMNLLLIRNTNSPVNFLDQICPIEPKLIDDLSLQFNNKLPPCFEITSTRVVNFLSRYLIKVLPKNILLGTFKNFKTFINKKIPIIVNLHIRETFKIQHAMNGIEVSNWVNRLEIESYQFKIKSKNELNESINRSKKQPNNVTRSKSKKSLISLGIKYLATRENIYFLIYLVFPVILRRHYATEIEGFSKVRYFNRPVWIKIVHRQADKWYLESLKGIIQLKDSYMLNLSISQIISKELDKNISFSEENIPKIRWVPKSKGLRPLINSKLVSGQIGLVQNLQEDHTVREEKKCKGFCDICSVWCTNGDCLPTGSCINNNWYYNYYFSYNGNNNGIVNNHYNYGHIYNNGGGIKFTSFSNSQCTQIMTNPPGRGVGLGFGNLNIGIGYISGSSVPTNTPINVMRRPSSNRKIIDIRPSTNNRMLFYPSILRSFKLLRMGKNHTLASLVGQGDIYKFIIKNWIKNWRDKQQFRQMNEFYQNDKQGKMSHVIYIIKADLVNCKFENINKSKIFEFLDVISLPNIESLSLYLSRALKTTSIPPFDNMNRDSYIQDELRSCGITSKGKLNMIVIFEKDHDPEDQKVVKSKIKIIGPRDLDELWNLKLNSCLSKDLSINLGQKAEIFTFKLSRRVINNWLVKEIIKIHKLNTSFRLRTCSFKSLRLISKQLGNSKIKFGRFLSLFKQDFGIKPQGSSSYILCICLYYNFLDLNPEIQNLLGHSFSSSYFISSFLNPIKLQEVQLLDKPTEDLFSQHKDLEGLSRTYPEKENEIFNIYNTSSKTRRLEISEYNINAKSVKLLQPEEFNNNSINQNCQNIRANLSYDQESPKSSNKQQESLLRWVDDLFLLTSDLESFAKKFLKLYIQLLWGSNVKSKDKINSNPWIDHNNEIIFILEDDVLLSSPSSSECSSSCSSSSSSSSSSSSSSSSSSSFPPSTECSSPVTEKRNTNKISEKDCNEKEMINKQAKIASQFHKQVSWTGMKFKSSEYSYNCMVSLPWKNEFICVMLDTVTLTKHQFTTSNYNFHRFKSSTISENLQTKSNYWSVLGMIKLIRYDFRIKFNGLLYCKINSLFTDVSFYNSTNNTEIKN

T32909	TARGETID	T32909
T32909	FORMERID	TTDR00864
T32909	UNIPROID	E9BI04_LEIDB
T32909	TARGNAME	Leishmania Glutathionylspermidine synthase (Leishm GSP)
T32909	GENENAME	Leishm GSP
T32909	TARGTYPE	Literature-reported
T32909	SYNONYMS	GspS; Glutathionylspermidine synthetase; Glutathione:spermidine ligase [ADP-forming]; GSP synthetase; GSP
T32909	FUNCTION	Conjugates glutathione (gamma-Glu-Cys-Gly) and spermidine to form glutathionylspermidine in the biosynthesis trypanothione (N(1),N(8)-bis(glutathionyl)spermidine), which is involved in maintaining intracellular thiol redox and in defense againstoxidants.
T32909	BIOCLASS	Carbon-nitrogen ligase
T32909	SEQUENCE	MLSLPRDHHYHTHHRGTELVPFDQVIGITPDGVPVISNGNEFHFTNLESVTPFYQALCSFDRKAPVTVSYKKLGVKWQCVEFARRYLASRKAVWTASMPIAADMWRAETPFVRVQDGTPVEFTRIANRSHGPAPAMSDIIVWGQSEETPFGHVAVVTEVLPEAVRVAEQNQGFERWPQGMLYSREIPVQRSSAGTVELVDEDPVLGWVTLHCPYYDFRDGDLADKFRIVTGPGCIVRQPFPKHVELPWLQPEERCDFYLKRSLAIGGNVGDDARAKECDVPSAFYFLDYNIWCRLGRAAHSLHRIAMTATAQVLDDADSAYLLEHYFGLPPEIHPLLRRSWEMMPPMSGRFDFGYDGNKVAMLEYNCDSSGALLECCNTQEKMANYYGVSQGMSTGSFLGAKCVSHFARLMSNEKVCPKHKLIHFMIDDDDEERYTAMCMMNFAEKAGFRTKLCVKLIDFRYRDGAPANAAPLSVTCDHPIIVDSDGDEVLLVWKTWSWDTVLREYHRQCSATDSVSSPTLSDILLNNNICVIEPLWKAVTGSKALLPFMHALAPDHEHLLAADFVPTKDIISHHYVSKPINGRAGQNIMMFDPVTDAAELNAAPQEMLSESSSQLFSIKPPAASCSALQSQSIDRTNECSTGTFFDSAVVYQKRFFLKKFEGKYFPIFCGWMIDDEFGGVVVREDTSKITKLDSIVIPARVVRENVSLGGAYTDEGET

T93136	TARGETID	T93136
T93136	UNIPROID	M4Q7H6_PSEAI
T93136	TARGNAME	Pseudomonas Type III secretion system protein PcrV (Pseudo pcrV)
T93136	GENENAME	Pseudo pcrV
T93136	TARGTYPE	Literature-reported
T93136	SYNONYMS	Type III secretion system protein
T93136	FUNCTION	Essential for cytotoxicity. Found both within the bacterial cytoplasm and localized extracellularly.
T93136	PDBSTRUC	6CYF
T93136	SEQUENCE	MEVRNLNAARELFLDELLAASAAPASAEQEELLALLRSERIVLAHAGQPLSEAQVLKALAWLLAANPSAPPGQGLEVLREVLQARRQPGAQWDLREFLVSAYFSLHGRLDEDVIGVYKDVLQTQDGKRKALLDELKALTAELKVYSVIQSQINAALSARQGIRIDAGGIDLVDPTLYGYAVGDPRWKDSPEYALLSNLDTFSGKLSIKDFLSGSPKQSGELKGLSDEYPFEKDNNPVGNFATTVSDRSRPLNDKVNEKTTLLNDTSSRYNSAVEALNRFIQKYDSVLSDILSAI

T64102	TARGETID	T64102
T64102	FORMERID	TTDNR00747
T64102	UNIPROID	SGK1_HUMAN; SGK2_HUMAN; SGK3_HUMAN
T64102	TARGNAME	Serum-and glucocorticoid-inducible kinase SGK (SGK)
T64102	GENENAME	SGK1; SGK2; SGK3
T64102	TARGTYPE	Literature-reported
T64102	SYNONYMS	Serum/glucocorticoid-regulated kinase; Serine/threonine-protein kinase Sgk; SGK
T64102	FUNCTION	Invovled in ion channel and transporter regulation, regulation of cell volume, cell proliferation and apoptosis, memory formation,  transcription and metabolism.
T64102	BIOCLASS	Kinase
T64102	SEQUENCE	MTVKTEAAKGTLTYSRMRGMVAILIAFMKQRRMGLNDFIQKIANNSYACKHPEVQSILKISQPQEPELMNANPSPPPSPSQQINLGPSSNPHAKPSDFHFLKVIGKGSFGKVLLARHKAEEVFYAVKVLQKKAILKKKEEKHIMSERNVLLKNVKHPFLVGLHFSFQTADKLYFVLDYINGGELFYHLQRERCFLEPRARFYAAEIASALGYLHSLNIVYRDLKPENILLDSQGHIVLTDFGLCKENIEHNSTTSTFCGTPEYLAPEVLHKQPYDRTVDWWCLGAVLYEMLYGLPPFYSRNTAEMYDNILNKPLQLKPNITNSARHLLEGLLQKDRTKRLGAKDDFMEIKSHVFFSLINWDDLINKKITPPFNPNVSGPNDLRHFDPEFTEEPVPNSIGKSPDSVLVTASVKEAAEAFLGFSYAPPTDSFL

T24542	TARGETID	T24542
T24542	FORMERID	TTDR00110
T24542	UNIPROID	PAR3_HUMAN
T24542	TARGNAME	Proteinase activated receptor 3 (F2RL2)
T24542	GENENAME	F2RL2
T24542	TARGTYPE	Literature-reported
T24542	SYNONYMS	Thrombin receptor-like 2; Protease activated receptor 3; PAR-3; F2RL2; Coagulation factor II receptor-like 2
T24542	FUNCTION	Receptor for activated thrombin coupled to G proteins that stimulate phosphoinositide hydrolysis.
T24542	BIOCLASS	GPCR rhodopsin
T24542	SEQUENCE	MKALIFAAAGLLLLLPTFCQSGMENDTNNLAKPTLPIKTFRGAPPNSFEEFPFSALEGWTGATITVKIKCPEESASHLHVKNATMGYLTSSLSTKLIPAIYLLVFVVGVPANAVTLWMLFFRTRSICTTVFYTNLAIADFLFCVTLPFKIAYHLNGNNWVFGEVLCRATTVIFYGNMYCSILLLACISINRYLAIVHPFTYRGLPKHTYALVTCGLVWATVFLYMLPFFILKQEYYLVQPDITTCHDVHNTCESSSPFQLYYFISLAFFGFLIPFVLIIYCYAAIIRTLNAYDHRWLWYVKASLLILVIFTICFAPSNIILIIHHANYYYNNTDGLYFIYLIALCLGSLNSCLDPFLYFLMSKTRNHSTAYLTK

T38745	TARGETID	T38745
T38745	FORMERID	TTDR00953
T38745	UNIPROID	DFFA_HUMAN
T38745	TARGNAME	DNA fragmentation factor alpha (DFFA)
T38745	GENENAME	DFFA
T38745	TARGTYPE	Literature-reported
T38745	SYNONYMS	Inhibitor of caspase-3-activated Dnase; Inhibitor of CAD; ICAD; H13; DNA fragmentation factor subunit alpha; DNA fragmentation factor 45 kDa subunit; DFF45; DFF1; DFF-45
T38745	FUNCTION	Inhibitor of the caspase-activated DNase (DFF40).
T38745	PDBSTRUC	1KOY; 1IYR; 1IBX
T38745	SEQUENCE	MEVTGDAGVPESGEIRTLKPCLLRRNYSREQHGVAASCLEDLRSKACDILAIDKSLTPVTLVLAEDGTIVDDDDYFLCLPSNTKFVALASNEKWAYNNSDGGTAWISQESFDVDETDSGAGLKWKNVARQLKEDLSSIILLSEEDLQMLVDAPCSDLAQELRQSCATVQRLQHTLQQVLDQREEVRQSKQLLQLYLQALEKEGSLLSKQEESKAAFGEEVDAVDTGISRETSSDVALASHILTALREKQAPELSLSSQDLELVTKEDPKALAVALNWDIKKTETVQEACERELALRLQQTQSLHSLRSISASKASPPGDLQNPKRARQDPT

T99092	TARGETID	T99092
T99092	UNIPROID	CLIC1_HUMAN
T99092	TARGNAME	Chloride intracellular channel protein 1 (CLIC1)
T99092	GENENAME	CLIC1
T99092	TARGTYPE	Literature-reported
T99092	SYNONYMS	hRNCC; Regulatory nuclear chloride ion channel protein; Nuclear chloride ion channel 27; NCC27; G6; Chloride channel ABP
T99092	FUNCTION	Can insert into membranes and form chloride ion channels. Channel activity depends on the pH. Membrane insertion seems to be redox-regulated and may occur only under oxydizing conditions. Involved in regulation of the cell cycle.
T99092	PDBSTRUC	4K0N; 4K0G; 4JZQ; 4IQA; 3UVH
T99092	SEQUENCE	MAEEQPQVELFVKAGSDGAKIGNCPFSQRLFMVLWLKGVTFNVTTVDTKRRTETVQKLCPGGQLPFLLYGTEVHTDTNKIEEFLEAVLCPPRYPKLAALNPESNTAGLDIFAKFSAYIKNSNPALNDNLEKGLLKALKVLDNYLTSPLPEEVDETSAEDEGVSQRKFLDGNELTLADCNLLPKLHIVQVVCKKYRGFTIPEAFRGVHRYLSNAYAREEFASTCPDDEEIELAYEQVAKALK

T43928	TARGETID	T43928
T43928	FORMERID	TTDR00193
T43928	UNIPROID	TR11B_HUMAN
T43928	TARGNAME	Osteoclastogenesis inhibitory factor (TNFRSF11B)
T43928	GENENAME	TNFRSF11B
T43928	TARGTYPE	Literature-reported
T43928	SYNONYMS	Tumor necrosis factor receptor superfamily member 11B; Osteoprotegerin; Osteoclastogenesis inhibitoryfactor; OPG; OCIF
T43928	FUNCTION	Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis. Acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis.
T43928	PDBSTRUC	3URF
T43928	SEQUENCE	MNNLLCCALVFLDISIKWTTQETFPPKYLHYDEETSHQLLCDKCPPGTYLKQHCTAKWKTVCAPCPDHYYTDSWHTSDECLYCSPVCKELQYVKQECNRTHNRVCECKEGRYLEIEFCLKHRSCPPGFGVVQAGTPERNTVCKRCPDGFFSNETSSKAPCRKHTNCSVFGLLLTQKGNATHDNICSGNSESTQKCGIDVTLCEEAFFRFAVPTKFTPNWLSVLVDNLPGTKVNAESVERIKRQHSSQEQTFQLLKLWKHQNKDQDIVKKIIQDIDLCENSVQRHIGHANLTFEQLRSLMESLPGKKVGAEDIEKTIKACKPSDQILKLLSLWRIKNGDQDTLKGLMHALKHSKTYHFPKTVTQSLKKTIRFLHSFTMYKLYQKLFLEMIGNQVQSVKISCL

T75136	TARGETID	T75136
T75136	FORMERID	TTDR01303
T75136	UNIPROID	NR5A2_HUMAN
T75136	TARGNAME	Alpha-1-fetoprotein transcription factor (NR5A2)
T75136	GENENAME	NR5A2
T75136	TARGTYPE	Literature-reported
T75136	SYNONYMS	hB1F; Nuclear receptor subfamily 5 group A member 2; Liver receptor homolog 1; LRH-1; Hepatocytic transcription factor; FTF; CYP7A promoter-binding factor; CPF; B1F; B1-binding factor
T75136	FUNCTION	Nuclear receptor that acts as a key metabolic sensor by regulating the expression of genes involved in bile acid synthesis, cholesterol homeostasis and triglyceride synthesis. Together with the oxysterol receptors NR1H3/LXR-alpha and NR1H2/LXR-beta, acts as an essential transcriptional regulator of lipid metabolism. Plays an anti-inflammatory role during the hepatic acute phase response by acting as a corepressor: inhibits the hepatic acute phase response by preventing dissociation of the N-Cor corepressor complex. Binds to the sequence element 5'-AACGACCGACCTTGAG-3' of the enhancer II of hepatitis B virus genes, a critical cis-element of their expression and regulation. May be responsible for the liver-specific activity of enhancer II, probably in combination with other hepatocyte transcription factors. Key regulator of cholesterol 7-alpha-hydroxylase gene (CYP7A) expression in liver. May also contribute to the regulation of pancreas-specific genes and play important roles in embryonic development. Activates the transcription of CYP2C38 (By similarity).
T75136	PDBSTRUC	5UNJ; 5SYZ; 5L11; 5L0M; 4RWV
T75136	SEQUENCE	MSSNSDTGDLQESLKHGLTPIGAGLPDRHGSPIPARGRLVMLPKVETEALGLARSHGEQGQMPENMQVSQFKMVNYSYDEDLEELCPVCGDKVSGYHYGLLTCESCKGFFKRTVQNNKRYTCIENQNCQIDKTQRKRCPYCRFQKCLSVGMKLEAVRADRMRGGRNKFGPMYKRDRALKQQKKALIRANGLKLEAMSQVIQAMPSDLTISSAIQNIHSASKGLPLNHAALPPTDYDRSPFVTSPISMTMPPHGSLQGYQTYGHFPSRAIKSEYPDPYTSSPESIMGYSYMDSYQTSSPASIPHLILELLKCEPDEPQVQAKIMAYLQQEQANRSKHEKLSTFGLMCKMADQTLFSIVEWARSSIFFRELKVDDQMKLLQNCWSELLILDHIYRQVVHGKEGSIFLVTGQQVDYSIIASQAGATLNNLMSHAQELVAKLRSLQFDQREFVCLKFLVLFSLDVKNLENFQLVEGVQEQVNAALLDYTMCNYPQQTEKFGQLLLRLPEIRAISMQAEEYLYYKHLNGDVPYNNLLIEMLHAKRA

T72274	TARGETID	T72274
T72274	FORMERID	TTDI01466
T72274	UNIPROID	DLL1_HUMAN
T72274	TARGNAME	Delta-like protein 1 (DLL1)
T72274	GENENAME	DLL1
T72274	TARGTYPE	Literature-reported
T72274	SYNONYMS	H-Delta-1; Drosophila Delta homolog 1; Delta1
T72274	FUNCTION	Transmembrane ligand protein of NOTCH1, NOTCH2 and NOTCH3 receptors that binds the extracellular domain (ECD) of Notch receptor in a cis and trans fashion manner. Following transinteraction, ligand cells produce mechanical force that depends of a clathrin-mediated endocytosis, requiring ligand ubiquitination, EPN1 interaction, and actin polymerisation; these events promote Notch receptor extracellular domain (NECD) transendocytosis and triggers Notch signaling through induction of cleavage, hyperphosphorylation, and nuclear accumulation of the intracellular domain of Notch receptors (NICD) (By similarity). Is required for embryonic development and maintenance of adult stem cells in many different tissues and immune systeme; the DLL1-induced Notch signaling is mediated through an intercellular communication that regulates cell lineage, cell specification, cell patterning and morphogenesis through effects on differentiation and proliferation. Plays a role in brain development at different level, namely by regulating neuronal differentiation of neural precursor cells via cell-cell interaction, most likely through the lateral inhibitory system in an endogenous level dependent-manner. During neocortex development, Dll1-Notch signaling transmission is mediated by dynamic interactions between intermediate neurogenic progenitors and radial glia; the cell-cell interactions are mediated via dynamic and transient elongation processes, likely to reactivate/maintain Notch activity in neighboring progenitors, and coordinate progenitor cell division and differentiation across radial and zonal boundaries. During cerebellar development, regulates Bergmann glial monolayer formation and its morphological maturation through a Notch signaling pathway. At the retina and spinal cord level, regulates neurogenesis by preventing the premature differentiation of neural progenitors and also by maintaining progenitors in spinal cord through Notch signaling pathway. Also controls neurogenesis of the neural tube in a progenitor domain-specific fashion along the dorsoventral axis. Maintains quiescence of neural stem cells and plays a role as a fate determinant that segregates asymmetrically to one daughter cell during neural stem cells mitosis, resulting in neuronal differentiation in Dll1-inheriting cell. Plays a role in immune systeme development, namely the development of all T-cells and marginal zone (MZ) B-cells (By similarity). Blocks the differentiation of progenitor cells into the B-cell lineage while promoting the emergence of a population of cells with the characteristics of a T-cell/NK-cell precursor. Also plays a role during muscle development. During early development, inhibits myoblasts differentiation from the medial dermomyotomal lip and later regulates progenitor cell differentiation. Directly modulates cell adhesion and basal lamina formation in satellite cells through Notch signaling. Maintains myogenic progenitors pool by suppressing differentiation through down-regulation of MYOD1 and is required for satellite cell homing and PAX7 expression. During craniofacial and trunk myogenesis suppresses differentiation of cranial mesoderm-derived and somite-derived muscle via MYOD1 regulation but in cranial mesoderm-derived progenitors, is neither required for satellite cell homing nor for PAX7 expression. Also plays a role during pancreatic cell development. During type B pancreatic cell development, may be involved in the initiation of proximodistal patterning in the early pancreatic epithelium. Stimulates multipotent pancreatic progenitor cells proliferation and pancreatic growth by maintaining HES1 expression and PTF1A protein levels. During fetal stages of development, is required to maintain arterial identity and the responsiveness of arterial endothelial cells for VEGFA through regulation of KDR activation and NRP1 expression. Controls sprouting angiogenesis and subsequent vertical branch formation througth regulation on tip cell differentiation. Negatively regulates goblet cell differentiation in intestine and controls secretory fat commitment through lateral inhibition in small intestine. Plays a role during inner ear development; negatively regulates auditory hair cell differentiation. Plays a role during nephron development through Notch signaling pathway. Regulates growth, blood pressure and energy homeostasis (By similarity).
T72274	PDBSTRUC	4XBM
T72274	SEQUENCE	MGSRCALALAVLSALLCQVWSSGVFELKLQEFVNKKGLLGNRNCCRGGAGPPPCACRTFFRVCLKHYQASVSPEPPCTYGSAVTPVLGVDSFSLPDGGGADSAFSNPIRFPFGFTWPGTFSLIIEALHTDSPDDLATENPERLISRLATQRHLTVGEEWSQDLHSSGRTDLKYSYRFVCDEHYYGEGCSVFCRPRDDAFGHFTCGERGEKVCNPGWKGPYCTEPICLPGCDEQHGFCDKPGECKCRVGWQGRYCDECIRYPGCLHGTCQQPWQCNCQEGWGGLFCNQDLNYCTHHKPCKNGATCTNTGQGSYTCSCRPGYTGATCELGIDECDPSPCKNGGSCTDLENSYSCTCPPGFYGKICELSAMTCADGPCFNGGRCSDSPDGGYSCRCPVGYSGFNCEKKIDYCSSSPCSNGAKCVDLGDAYLCRCQAGFSGRHCDDNVDDCASSPCANGGTCRDGVNDFSCTCPPGYTGRNCSAPVSRCEHAPCHNGATCHERGHRYVCECARGYGGPNCQFLLPELPPGPAVVDLTEKLEGQGGPFPWVAVCAGVILVLMLLLGCAAVVVCVRLRLQKHRPPADPCRGETETMNNLANCQREKDISVSIIGATQIKNTNKKADFHGDHSADKNGFKARYPAVDYNLVQDLKGDDTAVRDAHSKRDTKCQPQGSSGEEKGTPTTLRGGEASERKRPDSGCSTSKDTKYQSVYVISEEKDECVIATEV

T56505	TARGETID	T56505
T56505	FORMERID	TTDR01282
T56505	UNIPROID	CCN1_HUMAN
T56505	TARGNAME	Cellular communication network factor 1 (CCN1)
T56505	GENENAME	CCN1
T56505	TARGTYPE	Literature-reported
T56505	SYNONYMS	Protein GIG1; Protein CYR61; Insulin-like growth factor-binding protein 10; IGFBP10; IGFBP-10; IGF-binding protein 10; IBP-10; GIG1; CYR61; CCN family member 1
T56505	FUNCTION	Promotes cell proliferation, chemotaxis, angiogenesis and cell adhesion. Appears to play a role in wound healing by up-regulating, in skin fibroblasts, the expression of a number of genes involved in angiogenesis, inflammation and matrix remodeling including VEGA-A, VEGA-C, MMP1, MMP3, TIMP1, uPA, PAI-1 and integrins alpha-3 and alpha-5. CCN1-mediated gene regulation is dependent on heparin-binding. Down-regulates the expression of alpha-1 and alpha-2 subunits of collagen type-1. Promotes cell adhesion and adhesive signaling through integrin alpha-6/beta-1, cell migration through integrin alpha-v/beta-5 and cell proliferation through integrin alpha-v/beta-3.
T56505	PDBSTRUC	4D11; 4D0Z
T56505	SEQUENCE	MSSRIARALALVVTLLHLTRLALSTCPAACHCPLEAPKCAPGVGLVRDGCGCCKVCAKQLNEDCSKTQPCDHTKGLECNFGASSTALKGICRAQSEGRPCEYNSRIYQNGESFQPNCKHQCTCIDGAVGCIPLCPQELSLPNLGCPNPRLVKVTGQCCEEWVCDEDSIKDPMEDQDGLLGKELGFDASEVELTRNNELIAVGKGSSLKRLPVFGMEPRILYNPLQGQKCIVQTTSWSQCSKTCGTGISTRVTNDNPECRLVKETRICEVRPCGQPVYSSLKKGKKCSKTKKSPEPVRFTYAGCLSVKKYRPKYCGSCVDGRCCTPQLTRTVKMRFRCEDGETFSKNVMMIQSCKCNYNCPHANEAAFPFYRLFNDIHKFRD

T85289	TARGETID	T85289
T85289	FORMERID	TTDNR00731
T85289	UNIPROID	CYR61_HUMAN
T85289	TARGNAME	Cysteine-rich angiogenic inducer 61 (CYR61)
T85289	GENENAME	CYR61
T85289	TARGTYPE	Literature-reported
T85289	SYNONYMS	CCN1
T85289	FUNCTION	Appears to play a role in wound healing by up-regulating, in skin fibroblasts, the expression of a number of genes involved in angiogenesis, inflammation and matrix remodeling including VEGA-A, VEGA-C, MMP1, MMP3, TIMP1, uPA, PAI-1 and integrins alpha-3 and alpha-5. CYR61-mediated gene regulation is dependent on heparin-binding. Down-regulates the expression of alpha-1 and alpha-2 subunits of collagen type-1. Promotes cell adhesion and adhesive signaling through integrin alpha-6/beta-1, cell migration through integrin alpha-v/beta-5 and cell proliferation through integrin alpha-v/beta-3. Promotes cell proliferation, chemotaxis, angiogenesis and cell adhesion.
T85289	PDBSTRUC	4D11; 4D0Z
T85289	SEQUENCE	MSSRIARALALVVTLLHLTRLALSTCPAACHCPLEAPKCAPGVGLVRDGCGCCKVCAKQLNEDCSKTQPCDHTKGLECNFGASSTALKGICRAQSEGRPCEYNSRIYQNGESFQPNCKHQCTCIDGAVGCIPLCPQELSLPNLGCPNPRLVKVTGQCCEEWVCDEDSIKDPMEDQDGLLGKELGFDASEVELTRNNELIAVGKGSSLKRLPVFGMEPRILYNPLQGQKCIVQTTSWSQCSKTCGTGISTRVTNDNPECRLVKETRICEVRPCGQPVYSSLKKGKKCSKTKKSPEPVRFTYAGCLSVKKYRPKYCGSCVDGRCCTPQLTRTVKMRFRCEDGETFSKNVMMIQSCKCNYNCPHANEAAFPFYRLFNDIHKFRD

T22117	TARGETID	T22117
T22117	FORMERID	TTDR00584
T22117	UNIPROID	CCL22_HUMAN
T22117	TARGNAME	Macrophage-derived chemokine (MDC)
T22117	GENENAME	CCL22
T22117	TARGTYPE	Literature-reported
T22117	SYNONYMS	Stimulated T-cell chemotactic protein 1; Stimulated T cell chemotactic protein1; Small-inducible cytokine A22; SCYA22; MDC(1-69); CC chemokine STCP-1; C-C motif chemokine 22; A-152E5.1
T22117	FUNCTION	Chemotactic for monocytes, dendritic cells and natural killer cells. Mild chemoattractant for primary activated T-lymphocytes and a potent chemoattractant for chronically activated T-lymphocytes but has no chemoattractant activity for neutrophils, eosinophils, and resting T-lymphocytes. Binds to CCR4. Processed forms MDC(3-69), MDC(5-69) and MDC(7-69) seem not be active. May play a role in the trafficking of activated/effector T-lymphocytes to inflammatory sites and other aspects of activated T-lymphocyte physiology.
T22117	BIOCLASS	Cytokine: CC chemokine
T22117	SEQUENCE	MDRLQTALLVVLVLLAVALQATEAGPYGANMEDSVCCRDYVRYRLPLRVVKHFYWTSDSCPRPGVVLLTFRDKEICADPRVPWVKMILNKLSQ

T73908	TARGETID	T73908
T73908	FORMERID	TTDI02557
T73908	UNIPROID	WNT7A_HUMAN
T73908	TARGNAME	Wnt-7a protein (WNT7A)
T73908	GENENAME	WNT7A
T73908	TARGTYPE	Literature-reported
T73908	SYNONYMS	Protein Wnt-7a
T73908	FUNCTION	Plays an important role in embryonic development, including dorsal versus ventral patterning during limb development, skeleton development and urogenital tract development. Required for central nervous system (CNS) angiogenesis and blood-brain barrier regulation. Required for normal, sexually dimorphic development of the Mullerian ducts, and for normal fertility in both sexes. Required for normal neural stem cell proliferation in the hippocampus dentate gyrus. Required for normal progress through the cell cycle in neural progenitor cells, for self-renewal of neural stem cells, and for normal neuronal differentiation and maturation. Promotes formation of synapses via its interaction with FZD5. Ligand for members of the frizzled family of seven transmembrane receptors that functions in the canonical Wnt/beta-catenin signaling pathway.
T73908	PDBSTRUC	4UZQ
T73908	SEQUENCE	MNRKARRCLGHLFLSLGMVYLRIGGFSSVVALGASIICNKIPGLAPRQRAICQSRPDAIIVIGEGSQMGLDECQFQFRNGRWNCSALGERTVFGKELKVGSREAAFTYAIIAAGVAHAITAACTQGNLSDCGCDKEKQGQYHRDEGWKWGGCSADIRYGIGFAKVFVDAREIKQNARTLMNLHNNEAGRKILEENMKLECKCHGVSGSCTTKTCWTTLPQFRELGYVLKDKYNEAVHVEPVRASRNKRPTFLKIKKPLSYRKPMDTDLVYIEKSPNYCEEDPVTGSVGTQGRACNKTAPQASGCDLMCCGRGYNTHQYARVWQCNCKFHWCCYVKCNTCSERTEMYTCK

T91390	TARGETID	T91390
T91390	UNIPROID	CRTN_STAAE
T91390	TARGNAME	Staphylococcus Dehydrosqualene desaturase (Stap-coc crtN)
T91390	GENENAME	Stap-coc crtN
T91390	TARGTYPE	Literature-reported
T91390	SYNONYMS	Dehydrosqualene desaturase; 4,4'-diapophytoene desaturase (4,4'-diaponeurosporene-forming)
T91390	FUNCTION	Involved in the biosynthesis of the yellow-orange carotenoid staphyloxanthin, which plays a role in the virulence via its protective function against oxidative stress. Catalyzes three successive dehydrogenation reactions that lead to the introduction of three double bonds into 4,4'-diapophytoene (dehydrosqualene), with 4,4'-diapophytofluene and 4,4'-diapo-zeta-carotene as intermediates, and 4,4'-diaponeurosporene (the major deep-yellow pigment in staphylococci strains) as the end product.
T91390	ECNUMBER	EC 1.3.8.-
T91390	SEQUENCE	MKIAVIGAGVTGLAAAARIASQGHEVTIFEKNNNVGGRMNQLKKDGFTFDMGPTIVMMPDVYKDVFTACGKNYEDYIELRQLRYIYDVYFDHDDRITVPTDLAELQQMLESIEPGSTHGFMSFLTDVYKKYEIARRYFLERTYRKPSDFYNMTSLVQGAKLKTLNHADQLIEHYIDNEKIQKLLAFQTLYIGIDPKRGPSLYSIIPMIEMMFGVHFIKGGMYGMAQGLAQLNKDLGVNIELNAEIEQIIIDPKFKRADAIKVNGDIRKFDKILCTADFPSVAESLMPDFAPIKKYPPHKIADLDYSCSAFLMYIGIDIDVTDQVRLHNVIFSDDFRGNIEEIFEGRLSYDPSIYVYVPAVADKSLAPEGKTGIYVLMPTPELKTGSGIDWSDEALTQQIKEIIYRKLATIEVFEDIKSHIVSETIFTPNDFEQTYHAKFGSAFGLMPTLAQSNYYRPQNVSRDYKDLYFAGASTHPGAGVPIVLTSAKITVDEMIKDIERGV
T91390	DRUGINFO	D09HYG	NP16	Investigative

T51270	TARGETID	T51270
T51270	FORMERID	TTDI02589
T51270	UNIPROID	CLD4_HUMAN
T51270	TARGNAME	Claudin-4 (CLDN4)
T51270	GENENAME	CLDN4
T51270	TARGTYPE	Literature-reported
T51270	SYNONYMS	WilliamsBeuren syndrome chromosomal region 8 protein; Clostridium perfringens enterotoxin receptor; Claudin4; CPEreceptor; CPER; CLDN4
T51270	FUNCTION	Plays a major role in tight junction-specific obliteration of the intercellularspace.
T51270	PDBSTRUC	5B2G
T51270	SEQUENCE	MASMGLQVMGIALAVLGWLAVMLCCALPMWRVTAFIGSNIVTSQTIWEGLWMNCVVQSTGQMQCKVYDSLLALPQDLQAARALVIISIIVAALGVLLSVVGGKCTNCLEDESAKAKTMIVAGVVFLLAGLMVIVPVSWTAHNIIQDFYNPLVASGQKREMGASLYVGWAASGLLLLGGGLLCCNCPPRTDKPYSAKYSAARSAAASNYV

T41036	TARGETID	T41036
T41036	FORMERID	TTDI03018
T41036	UNIPROID	AGRB1_HUMAN
T41036	TARGNAME	Adhesion G protein-coupled receptor B1 (BAI1)
T41036	GENENAME	BAI1
T41036	TARGTYPE	Literature-reported
T41036	SYNONYMS	Brain-specific angiogenesis inhibitor 1; ADGRB1
T41036	FUNCTION	Mediates the binding and engulfment of Gram-negative bacteria. Stimulates production of reactive oxygen species by macrophages in response to Gram-negative bacteria, resulting in enhanced microbicidal macrophage activity. In the gastric mucosa, required for recognition and engulfment of apoptotic gastric epithelial cells. Promotes myoblast fusion. Activates the Rho pathway in a G-protein-dependent manner. Inhibits MDM2-mediated ubiquitination and degradation of DLG4/PSD95, promoting DLG4 stability and regulating synaptic plasticity. Required for the formation of dendritic spines by ensuring the correct localization of PARD3 and TIAM1. Potent inhibitor of angiogenesis in brain and may play a significant role as a mediator of the p53/TP53 signal in suppression of glioblastoma. Phosphatidylserine receptor which enhances the engulfment of apoptotic cells.
T41036	BIOCLASS	GPCR secretin
T41036	SEQUENCE	MRGQAAAPGPVWILAPLLLLLLLLGRRARAAAGADAGPGPEPCATLVQGKFFGYFSAAAVFPANASRCSWTLRNPDPRRYTLYMKVAKAPVPCSGPGRVRTYQFDSFLESTRTYLGVESFDEVLRLCDPSAPLAFLQASKQFLQMRRQQPPQHDGLRPRAGPPGPTDDFSVEYLVVGNRNPSRAACQMLCRWLDACLAGSRSSHPCGIMQTPCACLGGEAGGPAAGPLAPRGDVCLRDAVAGGPENCLTSLTQDRGGHGATGGWKLWSLWGECTRDCGGGLQTRTRTCLPAPGVEGGGCEGVLEEGRQCNREACGPAGRTSSRSQSLRSTDARRREELGDELQQFGFPAPQTGDPAAEEWSPWSVCSSTCGEGWQTRTRFCVSSSYSTQCSGPLREQRLCNNSAVCPVHGAWDEWSPWSLCSSTCGRGFRDRTRTCRPPQFGGNPCEGPEKQTKFCNIALCPGRAVDGNWNEWSSWSACSASCSQGRQQRTRECNGPSYGGAECQGHWVETRDCFLQQCPVDGKWQAWASWGSCSVTCGAGSQRRERVCSGPFFGGAACQGPQDEYRQCGTQRCPEPHEICDEDNFGAVIWKETPAGEVAAVRCPRNATGLILRRCELDEEGIAYWEPPTYIRCVSIDYRNIQMMTREHLAKAQRGLPGEGVSEVIQTLVEISQDGTSYSGDLLSTIDVLRNMTEIFRRAYYSPTPGDVQNFVQILSNLLAEENRDKWEEAQLAGPNAKELFRLVEDFVDVIGFRMKDLRDAYQVTDNLVLSIHKLPASGATDISFPMKGWRATGDWAKVPEDRVTVSKSVFSTGLTEADEASVFVVGTVLYRNLGSFLALQRNTTVLNSKVISVTVKPPPRSLRTPLEIEFAHMYNGTTNQTCILWDETDVPSSSAPPQLGPWSWRGCRTVPLDALRTRCLCDRLSTFAILAQLSADANMEKATLPSVTLIVGCGVSSLTLLMLVIIYVSVWRYIRSERSVILINFCLSIISSNALILIGQTQTRNKVVCTLVAAFLHFFFLSSFCWVLTEAWQSYMAVTGHLRNRLIRKRFLCLGWGLPALVVAISVGFTKAKGYSTMNYCWLSLEGGLLYAFVGPAAAVVLVNMVIGILVFNKLVSKDGITDKKLKERAGASLWSSCVVLPLLALTWMSAVLAVTDRRSALFQILFAVFDSLEGFVIVMVHCILRREVQDAVKCRVVDRQEEGNGDSGGSFQNGHAQLMTDFEKDVDLACRSVLNKDIAACRTATITGTLKRPSLPEEEKLKLAHAKGPPTNFNSLPANVSKLHLHGSPRYPGGPLPDFPNHSLTLKRDKAPKSSFVGDGDIFKKLDSELSRAQEKALDTSYVILPTATATLRPKPKEEPKYSIHIDQMPQTRLIHLSTAPEASLPARSPPSRQPPSGGPPEAPPAQPPPPPPPPPPPPQQPLPPPPNLEPAPPSLGDPGEPAAHPGPSTGPSTKNENVATLSVSSLERRKSRYAELDFEKIMHTRKRHQDMFQDLNRKLQHAAEKDKEVLGPDSKPEKQQTPNKRPWESLRKAHGTPTWVKKELEPLQPSPLELRSVEWERSGATIPLVGQDIIDLQTEV
T41036	DRUGINFO	D0K4SL	phosphatidylserine	Investigative

T91397	TARGETID	T91397
T91397	UNIPROID	CTRO_HUMAN
T91397	TARGNAME	Citron Rho-interacting kinase (CIT)
T91397	GENENAME	CIT
T91397	TARGTYPE	Literature-reported
T91397	SYNONYMS	Serine/threonine-protein kinase 21; STK21; KIAA0949; CRIK
T91397	FUNCTION	Plays a role in cytokinesis. Required for KIF14 localization to the central spindle and midbody. Putative RHO/RAC effector that binds to the GTP-bound forms of RHO and RAC1. It probably binds p21 with a tighter specificity in vivo. Displays serine/threonine protein kinase activity. Plays an important role in the regulation of cytokinesis and the development of the central nervous system. Phosphorylates MYL9/MLC2.
T91397	ECNUMBER	EC 2.7.11.1
T91397	SEQUENCE	MLKFKYGARNPLDAGAAEPIASRASRLNLFFQGKPPFMTQQQMSPLSREGILDALFVLFEECSQPALMKIKHVSNFVRKYSDTIAELQELQPSAKDFEVRSLVGCGHFAEVQVVREKATGDIYAMKVMKKKALLAQEQVSFFEEERNILSRSTSPWIPQLQYAFQDKNHLYLVMEYQPGGDLLSLLNRYEDQLDENLIQFYLAELILAVHSVHLMGYVHRDIKPENILVDRTGHIKLVDFGSAAKMNSNKMVNAKLPIGTPDYMAPEVLTVMNGDGKGTYGLDCDWWSVGVIAYEMIYGRSPFAEGTSARTFNNIMNFQRFLKFPDDPKVSSDFLDLIQSLLCGQKERLKFEGLCCHPFFSKIDWNNIRNSPPPFVPTLKSDDDTSNFDEPEKNSWVSSSPCQLSPSGFSGEELPFVGFSYSKALGILGRSESVVSGLDSPAKTSSMEKKLLIKSKELQDSQDKCHKMEQEMTRLHRRVSEVEAVLSQKEVELKASETQRSLLEQDLATYITECSSLKRSLEQARMEVSQEDDKALQLLHDIREQSRKLQEIKEQEYQAQVEEMRLMMNQLEEDLVSARRRSDLYESELRESRLAAEEFKRKATECQHKLLKAKDQGKPEVGEYAKLEKINAEQQLKIQELQEKLEKAVKASTEATELLQNIRQAKERAERELEKLQNREDSSEGIRKKLVEAEELEEKHREAQVSAQHLEVHLKQKEQHYEEKIKVLDNQIKKDLADKETLENMMQRHEEEAHEKGKILSEQKAMINAMDSKIRSLEQRIVELSEANKLAANSSLFTQRNMKAQEEMISELRQQKFYLETQAGKLEAQNRKLEEQLEKISHQDHSDKNRLLELETRLREVSLEHEEQKLELKRQLTELQLSLQERESQLTALQAARAALESQLRQAKTELEETTAEAEEEIQALTAHRDEIQRKFDALRNSCTVITDLEEQLNQLTEDNAELNNQNFYLSKQLDEASGANDEIVQLRSEVDHLRREITEREMQLTSQKQTMEALKTTCTMLEEQVMDLEALNDELLEKERQWEAWRSVLGDEKSQFECRVRELQRMLDTEKQSRARADQRITESRQVVELAVKEHKAEILALQQALKEQKLKAESLSDKLNDLEKKHAMLEMNARSLQQKLETERELKQRLLEEQAKLQQQMDLQKNHIFRLTQGLQEALDRADLLKTERSDLEYQLENIQVLYSHEKVKMEGTISQQTKLIDFLQAKMDQPAKKKKGLFSRRKEDPALPTQVPLQYNELKLALEKEKARCAELEEALQKTRIELRSAREEAAHRKATDHPHPSTPATARQQIAMSAIVRSPEHQPSAMSLLAPPSSRRKESSTPEEFSRRLKERMHHNIPHRFNVGLNMRATKCAVCLDTVHFGRQASKCLECQVMCHPKCSTCLPATCGLPAEYATHFTEAFCRDKMNSPGLQTKEPSSSLHLEGWMKVPRNNKRGQQGWDRKYIVLEGSKVLIYDNEAREAGQRPVEEFELCLPDGDVSIHGAVGASELANTAKADVPYILKMESHPHTTCWPGRTLYLLAPSFPDKQRWVTALESVVAGGRVSREKAEADAKLLGNSLLKLEGDDRLDMNCTLPFSDQVVLVGTEEGLYALNVLKNSLTHVPGIGAVFQIYIIKDLEKLLMIAGEERALCLVDVKKVKQSLAQSHLPAQPDISPNIFEAVKGCHLFGAGKIENGLCICAAMPSKVVILRYNENLSKYCIRKEIETSEPCSCIHFTNYSILIGTNKFYEIDMKQYTLEEFLDKNDHSLAPAVFAASSNSFPVSIVQVNSAGQREEYLLCFHEFGVFVDSYGRRSRTDDLKWSRLPLAFAYREPYLFVTHFNSLEVIEIQARSSAGTPARAYLDIPNPRYLGPAISSGAIYLASSYQDKLRVICCKGNLVKESGTEHHRGPSTSRSSPNKRGPPTYNEHITKRVASSPAPPEGPSHPREPSTPHRYREGRTELRRDKSPGRPLEREKSPGRMLSTRRERSPGRLFEDSSRGRLPAGAVRTPLSQVNKVWDQSSV

T80513	TARGETID	T80513
T80513	FORMERID	TTDI03197
T80513	UNIPROID	FFAR3_HUMAN
T80513	TARGNAME	Free fatty acid receptor 3 (FFAR3)
T80513	GENENAME	FFAR3
T80513	TARGTYPE	Literature-reported
T80513	SYNONYMS	GPR41; G-protein coupled receptor 41
T80513	FUNCTION	G protein-coupled receptor that is activated by a major product of dietary fiber digestion, the short chain fatty acids (SCFAs), and that plays a role in the regulation of whole-body energy homeostasis and in intestinal immunity. In omnivorous mammals, the short chain fatty acids acetate, propionate and butyrate are produced primarily by the gut microbiome that metabolizes dietary fibers. SCFAs serve as a source of energy but also act as signaling molecules. That G protein-coupled receptor is probably coupled to the pertussis toxin-sensitive, G(i/o)-alpha family of G proteins. Its activation results in the formation of inositol 1,4,5-trisphosphate, the mobilization of intracellular calcium, the phosphorylation of the MAPK3/ERK1 and MAPK1/ERK2 kinases and the inhibition of intracellular cAMP accumulation. Activated by SCFAs and by beta-hydroxybutyrate, a ketone body produced by the liver upon starvation, it inhibits N-type calcium channels and modulates the activity of sympathetic neurons through a signaling cascade involving the beta and gamma subunits of its coupled G protein, phospholipase C and MAP kinases. Thereby, it may regulate energy expenditure through the control of the sympathetic nervous system that controls for instance heart rate. Upon activation by SCFAs accumulating in the intestine, it may also signal to the brain via neural circuits which in turn would regulate intestinal gluconeogenesis. May also control the production of hormones involved in whole-body energy homeostasis. May for instance, regulate blood pressure through renin secretion. May also regulate secretion of the PYY peptide by enteroendocrine cells and control gut motility, intestinal transit rate, and the harvesting of energy from SCFAs produced by gut microbiota. May also indirectly regulate the production of LEP/Leptin, a hormone acting on the CNS to inhibit food intake, in response to the presence of short-chain fatty acids in the intestine. Finally, may also play a role in glucose homeostasis. Besides its role in energy homeostasis, may play a role in intestinal immunity. May mediate the activation of the inflammatory and immune response by SCFAs in the gut, regulating the rapid production of chemokines and cytokines by intestinal epithelial cells. Among SCFAs, the fatty acids containing less than 6 carbons, the most potent activators are probably propionate, butyrate and pentanoate while acetate is a poor activator.
T80513	BIOCLASS	GPCR rhodopsin
T80513	SEQUENCE	MDTGPDQSYFSGNHWFVFSVYLLTFLVGLPLNLLALVVFVGKLQRRPVAVDVLLLNLTASDLLLLLFLPFRMVEAANGMHWPLPFILCPLSGFIFFTTIYLTALFLAAVSIERFLSVAHPLWYKTRPRLGQAGLVSVACWLLASAHCSVVYVIEFSGDISHSQGTNGTCYLEFRKDQLAILLPVRLEMAVVLFVVPLIITSYCYSRLVWILGRGGSHRRQRRVAGLLAATLLNFLVCFGPYNVSHVVGYICGESPAWRIYVTLLSTLNSCVDPFVYYFSSSGFQADFHELLRRLCGLWGQWQQESSMELKEQKGGEEQRADRPAERKTSEHSQGCGTGGQVACAES
T80513	DRUGINFO	D05UBB	(S)-4-CMTB	Investigative
T80513	DRUGINFO	D06ZVB	isobutyric acid	Investigative
T80513	DRUGINFO	D07FPQ	1-methylcyclopropanecarboxylic acid	Investigative
T80513	DRUGINFO	D0V6IE	pentanoic acid	Investigative

T06146	TARGETID	T06146
T06146	FORMERID	TTDI00028
T06146	UNIPROID	RGS12_HUMAN
T06146	TARGNAME	Regulator of G-protein signaling 12 (RGS12)
T06146	GENENAME	RGS12
T06146	TARGTYPE	Literature-reported
T06146	SYNONYMS	RGS12
T06146	FUNCTION	Regulates G protein-coupled receptor signaling cascades. Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits, thereby driving them into their inactive GDP-bound form.
T06146	PDBSTRUC	2KV8; 2EBZ
T06146	SEQUENCE	MFRAGEASKRPLPGPSPPRVRSVEVARGRAGYGFTLSGQAPCVLSCVMRGSPADFVGLRAGDQILAVNEINVKKASHEDVVKLIGKCSGVLHMVIAEGVGRFESCSSDEEGGLYEGKGWLKPKLDSKALGINRAERVVEEMQSGGIFNMIFENPSLCASNSEPLKLKQRSLSESAATRFDVGHESINNPNPNMLSKEEISKVIHDDSVFSIGLESHDDFALDASILNVAMIVGYLGSIELPSTSSNLESDSLQAIRGCMRRLRAEQKIHSLVTMKIMHDCVQLSTDKAGVVAEYPAEKLAFSAVCPDDRRFFGLVTMQTNDDGSLAQEEEGALRTSCHVFMVDPDLFNHKIHQGIARRFGFECTADPDTNGCLEFPASSLPVLQFISVLYRDMGELIEGMRARAFLDGDADAHQNNSTSSNSDSGIGNFHQEEKSNRVLVVDLGGSSSRHGPGGSAWDGVGGRGAQPWGAPWTGPFCPDPEGSPPFEAAHQTDRFWDLNKHLGPASPVEVPPASLRSSVPPSKRGTVGAGCGFNQRWLPVHVLREWQCGHTSDQDSYTDSTDGWSSINCGTLPPPMSKIPADRYRVEGSFAQPPLNAPKREWSRKAFGMQSIFGPHRNVRKTKEDKKGSKFGRGTGLTQPSQRTSARRSFGRSKRFSITRSLDDLESATVSDGELTGADLKDCVSNNSLSSNASLPSVQSCRRLRERRVASWAVSFERLLQDPVGVRYFSDFLRKEFSEENILFWQACEYFNHVPAHDKKELSYRAREIFSKFLCSKATTPVNIDSQAQLADDVLRAPHPDMFKEQQLQIFNLMKFDSYTRFLKSPLYQECILAEVEGRALPDSQQVPSSPASKHSLGSDHSSVSTPKKLSGKSKSGRSLNEELGDEDSEKKRKGAFFSWSRTRSTGRSQKKREHGDHADDALHANGGLCRRESQGSVSSAGSLDLSEACRTLAPEKDKATKHCCIHLPDGTSCVVAVKAGFSIKDILSGLCERHGINGAAADLFLVGGDKPLVLHQDSSILESRDLRLEKRTLFRLDLVPINRSVGLKAKPTKPVTEVLRPVVARYGLDLSGLLVRLSGEKEPLDLGAPISSLDGQRVVLEEKDPSRGKASADKQKGVPVKQNTAVNSSSRNHSATGEERTLGKSNSIKIKGENGKNARDPRLSKREESIAKIGKKKYQKINLDEAEEFFELISKAQSNRADDQRGLLRKEDLVLPEFLRLPPGSTELTLPTPAAVAKGFSKRSATGNGRESASQPGEQWEPVQESSDSPSTSPGSASSPPGPPGTTPPGQKSPSGPFCTPQSPVSLAQEGTAQIWKRQSQEVEAGGIQTVEDEHVAELTLMGEGDISSPNSTLLPPPSTPQEVPGPSRPGSGTHGSRDLPVNRIIDVDLVTGSAPGRDGGIAGAQAGPGRSQASGGPPTSDLPGLGPVPGEPAKPKTSAHHATFV

T44387	TARGETID	T44387
T44387	FORMERID	TTDI03396
T44387	UNIPROID	MUSK_HUMAN
T44387	TARGNAME	Muscle-specific kinase receptor (MUSK)
T44387	GENENAME	MUSK
T44387	TARGTYPE	Literature-reported
T44387	SYNONYMS	Muscle-specific tyrosine-protein kinase receptor; Muscle, skeletal receptor tyrosine-protein kinase; MuSK
T44387	FUNCTION	Receptor tyrosine kinase which plays a central role in the formation and the maintenance of the neuromuscular junction (NMJ), the synapse between the motor neuron and the skeletal muscle. Recruitment of AGRIN by LRP4 to the MUSK signaling complex induces phosphorylation and activation of MUSK, the kinase of the complex. The activation of MUSK in myotubes regulates the formation of NMJs through the regulation of different processes including the specific expression of genes in subsynaptic nuclei, the reorganization of the actin cytoskeleton and the clustering of the acetylcholine receptors (AChR) in the postsynaptic membrane. May regulate AChR phosphorylation and clustering through activation of ABL1 and Src family kinases which in turn regulate MUSK. DVL1 and PAK1 that form a ternary complex with MUSK are also important for MUSK-dependent regulation of AChR clustering. May positively regulate Rho family GTPases through FNTA. Mediates the phosphorylation of FNTA which promotes prenylation, recruitment to membranes and activation of RAC1 a regulator of the actin cytoskeleton and of gene expression. Other effectors of the MUSK signaling include DNAJA3 which functions downstream of MUSK. May also play a role within the central nervous system by mediating cholinergic responses, synaptic plasticity and memory formation (By similarity).
T44387	ECNUMBER	EC 2.7.10.1
T44387	SEQUENCE	MRELVNIPLVHILTLVAFSGTEKLPKAPVITTPLETVDALVEEVATFMCAVESYPQPEISWTRNKILIKLFDTRYSIRENGQLLTILSVEDSDDGIYCCTANNGVGGAVESCGALQVKMKPKITRPPINVKIIEGLKAVLPCTTMGNPKPSVSWIKGDSPLRENSRIAVLESGSLRIHNVQKEDAGQYRCVAKNSLGTAYSKVVKLEVEVFARILRAPESHNVTFGSFVTLHCTATGIPVPTITWIENGNAVSSGSIQESVKDRVIDSRLQLFITKPGLYTCIATNKHGEKFSTAKAAATISIAEWSKPQKDNKGYCAQYRGEVCNAVLAKDALVFLNTSYADPEEAQELLVHTAWNELKVVSPVCRPAAEALLCNHIFQECSPGVVPTPIPICREYCLAVKELFCAKEWLVMEEKTHRGLYRSEMHLLSVPECSKLPSMHWDPTACARLPHLDYNKENLKTFPPMTSSKPSVDIPNLPSSSSSSFSVSPTYSMTVIISIMSSFAIFVLLTITTLYCCRRRKQWKNKKRESAAVTLTTLPSELLLDRLHPNPMYQRMPLLLNPKLLSLEYPRNNIEYVRDIGEGAFGRVFQARAPGLLPYEPFTMVAVKMLKEEASADMQADFQREAALMAEFDNPNIVKLLGVCAVGKPMCLLFEYMAYGDLNEFLRSMSPHTVCSLSHSDLSMRAQVSSPGPPPLSCAEQLCIARQVAAGMAYLSERKFVHRDLATRNCLVGENMVVKIADFGLSRNIYSADYYKANENDAIPIRWMPPESIFYNRYTTESDVWAYGVVLWEIFSYGLQPYYGMAHEEVIYYVRDGNILSCPENCPVELYNLMRLCWSKLPADRPSFTSIHRILERMCERAEGTVSV
T44387	DRUGINFO	D00ERW	PMID17935989C25	Investigative
T44387	DRUGINFO	D02NNT	PMID21493067C1d	Investigative

T72732	TARGETID	T72732
T72732	FORMERID	TTDI03182
T72732	UNIPROID	EPHB6_HUMAN
T72732	TARGNAME	Ephrin type-B receptor 6 (EPHB6)
T72732	GENENAME	EPHB6
T72732	TARGTYPE	Literature-reported
T72732	SYNONYMS	Tyrosine-protein kinase-defective receptor EPH-6; HEP
T72732	FUNCTION	Binds to ephrin-B1 and ephrin-B2. Modulates cell adhesion and migration by exerting both positive and negative effects upon stimulation with ephrin-B2. Inhibits JNK activation, T-cell receptor-induced IL-2 secretion and CD25 expression upon stimulation with ephrin-B2. Kinase-defective receptor for members of the ephrin-B family.
T72732	BIOCLASS	Kinase
T72732	SEQUENCE	MATEGAAQLGNRVAGMVCSLWVLLLVSSVLALEEVLLDTTGETSEIGWLTYPPGGWDEVSVLDDQRRLTRTFEACHVAGAPPGTGQDNWLQTHFVERRGAQRAHIRLHFSVRACSSLGVSGGTCRETFTLYYRQAEEPDSPDSVSSWHLKRWTKVDTIAADESFPSSSSSSSSSSSAAWAVGPHGAGQRAGLQLNVKERSFGPLTQRGFYVAFQDTGACLALVAVRLFSYTCPAVLRSFASFPETQASGAGGASLVAAVGTCVAHAEPEEDGVGGQAGGSPPRLHCNGEGKWMVAVGGCRCQPGYQPARGDKACQACPRGLYKSSAGNAPCSPCPARSHAPNPAAPVCPCLEGFYRASSDPPEAPCTGPPSAPQELWFEVQGSALMLHWRLPRELGGRGDLLFNVVCKECEGRQEPASGGGGTCHRCRDEVHFDPRQRGLTESRVLVGGLRAHVPYILEVQAVNGVSELSPDPPQAAAINVSTSHEVPSAVPVVHQVSRASNSITVSWPQPDQTNGNILDYQLRYYDQAEDESHSFTLTSETNTATVTQLSPGHIYGFQVRARTAAGHGPYGGKVYFQTLPQGELSSQLPERLSLVIGSILGALAFLLLAAITVLAVVFQRKRRGTGYTEQLQQYSSPGLGVKYYIDPSTYEDPCQAIRELAREVDPAYIKIEEVIGTGSFGEVRQGRLQPRGRREQTVAIQALWAGGAESLQMTFLGRAAVLGQFQHPNILRLEGVVTKSRPLMVLTEFMELGPLDSFLRQREGQFSSLQLVAMQRGVAAAMQYLSSFAFVHRSLSAHSVLVNSHLVCKVARLGHSPQGPSCLLRWAAPEVIAHGKHTTSSDVWSFGILMWEVMSYGERPYWDMSEQEVLNAIEQEFRLPPPPGCPPGLHLLMLDTWQKDRARRPHFDQLVAAFDKMIRKPDTLQAGGDPGERPSQALLTPVALDFPCLDSPQAWLSAIGLECYQDNFSKFGLCTFSDVAQLSLEDLPALGITLAGHQKKLLHHIQLLQQHLRQQGSVEV
T72732	DRUGINFO	D0X8BU	PMID23489211C20	Investigative

T75077	TARGETID	T75077
T75077	FORMERID	TTDR01122
T75077	UNIPROID	SMAD9_HUMAN
T75077	TARGNAME	Mothers against decapentaplegic homolog 9 (SMAD9)
T75077	GENENAME	Smad9
T75077	TARGTYPE	Literature-reported
T75077	SYNONYMS	Smad9; Smad8; SMAD 9; SMAD 8; Mothers against DPP homolog 9
T75077	FUNCTION	Transcriptional modulator activated by BMP (bone morphogenetic proteins) type 1 receptor kinase. SMAD9 is a receptor-regulated SMAD (R-SMAD). Has been shown to be activated by activin type I receptor-like kinases (ALK-2, ALK-3, ALK-6) which stimulate heteromerization between SMAD9 and SMAD4. May play a role in osteoblast differentiation and maturation.
T75077	BIOCLASS	Dwarfin SMAD family
T75077	SEQUENCE	MHSTTPISSLFSFTSPAVKRLLGWKQGDEEEKWAEKAVDSLVKKLKKKKGAMDELERALSCPGQPSKCVTIPRSLDGRLQVSHRKGLPHVIYCRVWRWPDLQSHHELKPLECCEFPFGSKQKEVCINPYHYRRVETPVLPPVLVPRHSEYNPQLSLLAKFRSASLHSEPLMPHNATYPDSFQQPPCSALPPSPSHAFSQSPCTASYPHSPGSPSEPESPYQHSVDTPPLPYHATEASETQSGQPVDATADRHVVLSIPNGDFRPVCYEEPQHWCSVAYYELNNRVGETFQASSRSVLIDGFTDPSNNRNRFCLGLLSNVNRNSTIENTRRHIGKGVHLYYVGGEVYAECVSDSSIFVQSRNCNYQHGFHPATVCKIPSGCSLKVFNNQLFAQLLAQSVHHGFEVVYELTKMCTIRMSFVKGWGAEYHRQDVTSTPCWIEIHLHGPLQWLDKVLTQMGSPHNPISSVS

T96302	TARGETID	T96302
T96302	FORMERID	TTDI02512
T96302	UNIPROID	GP182_HUMAN
T96302	TARGNAME	G protein coupled receptor 182 (GPR182)
T96302	GENENAME	GPR182
T96302	TARGTYPE	Literature-reported
T96302	SYNONYMS	Gprotein coupled receptor 182; GPR182
T96302	FUNCTION	Orphan receptor.
T96302	BIOCLASS	GPCR rhodopsin
T96302	SEQUENCE	MSVKPSWGPGPSEGVTAVPTSDLGEIHNWTELLDLFNHTLSECHVELSQSTKRVVLFALYLAMFVVGLVENLLVICVNWRGSGRAGLMNLYILNMAIADLGIVLSLPVWMLEVTLDYTWLWGSFSCRFTHYFYFVNMYSSIFFLVCLSVDRYVTLTSASPSWQRYQHRVRRAMCAGIWVLSAIIPLPEVVHIQLVEGPEPMCLFMAPFETYSTWALAVALSTTILGFLLPFPLITVFNVLTACRLRQPGQPKSRRHCLLLCAYVAVFVMCWLPYHVTLLLLTLHGTHISLHCHLVHLLYFFYDVIDCFSMLHCVINPILYNFLSPHFRGRLLNAVVHYLPKDQTKAGTCASSSSCSTQHSIIITKGDSQPAAAAPHPEPSLSFQAHHLLPNTSPISPTQPLTPS

T43881	TARGETID	T43881
T43881	FORMERID	TTDI02052
T43881	UNIPROID	DFB4A_HUMAN
T43881	TARGNAME	Beta-defensin 4A (DEFB4A)
T43881	GENENAME	DEFB4A
T43881	TARGTYPE	Literature-reported
T43881	SYNONYMS	hBD2; Skinantimicrobial peptide 1; SAP1; Defensin, beta 2; DEFB4B; DEFB4A; Betadefensin 4A; Betadefensin 2; BD2
T43881	FUNCTION	Has antibacterial activity.
T43881	PDBSTRUC	6CS9; 1FQQ; 1FD4; 1FD3; 1E4Q
T43881	SEQUENCE	MRVLYLLFSFLFIFLMPLPGVFGGIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP
T43881	DRUGINFO	D00XSL	rHuB-D2	Investigative

T30817	TARGETID	T30817
T30817	FORMERID	TTDI02349
T30817	UNIPROID	SPTC1_HUMAN; SPTC2_HUMAN; SPTC3_HUMAN
T30817	TARGNAME	Serine palmitoyltransferase (SPTC)
T30817	GENENAME	SPTLC1; SPTLC2; SPTLC3
T30817	TARGTYPE	Literature-reported
T30817	SYNONYMS	Serine-palmitoyl-CoA transferase; SPT; Long chain base biosynthesis protein; LCB
T30817	FUNCTION	Serine palmitoyltransferase (SPT). The heterodimer formed with SPTLC2 or SPTLC3 constitutes the catalytic core. The composition of the serine palmitoyltransferase (SPT) complex determines the substrate preference. The SPTLC1-SPTLC2-SPTSSA complex shows a strong preference for C16-CoA substrate, while the SPTLC1-SPTLC3-SPTSSA isozyme uses both C14-CoA and C16-CoA as substrates, with a slight preference for C14-CoA. The SPTLC1- SPTLC2-SPTSSB complex shows a strong preference for C18-CoA substrate, while the SPTLC1-SPTLC3-SPTSSB isozyme displays an ability to use a broader range of acyl-CoAs, without apparent preference.
T30817	BIOCLASS	Acyltransferase
T30817	SEQUENCE	MATATEQWVLVEMVQALYEAPAYHLILEGILILWIIRLLFSKTYKLQERSDLTVKEKEELIEEWQPEPLVPPVPKDHPALNYNIVSGPPSHKTVVNGKECINFASFNFLGLLDNPRVKAAALASLKKYGVGTCGPRGFYGTFDVHLDLEDRLAKFMKTEEAIIYSYGFATIASAIPAYSKRGDIVFVDRAACFAIQKGLQASRSDIKLFKHNDMADLERLLKEQEIEDQKNPRKARVTRRFIVVEGLYMNTGTICPLPELVKLKYKYKARIFLEESLSFGVLGEHGRGVTEHYGINIDDIDLISANMENALASIGGFCCGRSFVIDHQRLSGQGYCFSASLPPLLAAAAIEALNIMEENPGIFAVLKEKCGQIHKALQGISGLKVVGESLSPAFHLQLEESTGSREQDVRLLQEIVDQCMNRSIALTQARYLEKEEKCLPPPSIRVVVTVEQTEEELERAASTIKEVAQAVLL
T30817	DRUGINFO	D0Q7JJ	NA-808	Preclinical

T55956	TARGETID	T55956
T55956	FORMERID	TTDI03373
T55956	UNIPROID	GRM6_HUMAN
T55956	TARGNAME	Metabotropic glutamate receptor 6 (mGluR6)
T55956	GENENAME	GRM6
T55956	TARGTYPE	Literature-reported
T55956	SYNONYMS	MGLUR6; GPRC1F
T55956	FUNCTION	G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity (By similarity). Signaling stimulates TRPM1 channel activity and Ca(2+) uptake. Required for normal vision.
T55956	BIOCLASS	GPCR glutamate
T55956	SEQUENCE	MARPRRAREPLLVALLPLAWLAQAGLARAAGSVRLAGGLTLGGLFPVHARGAAGRACGQLKKEQGVHRLEAMLYALDRVNADPELLPGVRLGARLLDTCSRDTYALEQALSFVQALIRGRGDGDEVGVRCPGGVPPLRPAPPERVVAVVGASASSVSIMVANVLRLFAIPQISYASTAPELSDSTRYDFFSRVVPPDSYQAQAMVDIVRALGWNYVSTLASEGNYGESGVEAFVQISREAGGVCIAQSIKIPREPKPGEFSKVIRRLMETPNARGIIIFANEDDIRRVLEAARQANLTGHFLWVGSDSWGAKTSPILSLEDVAVGAITILPKRASIDGFDQYFMTRSLENNRRNIWFAEFWEENFNCKLTSSGTQSDDSTRKCTGEERIGRDSTYEQEGKVQFVIDAVYAIAHALHSMHQALCPGHTGLCPAMEPTDGRMLLQYIRAVRFNGSAGTPVMFNENGDAPGRYDIFQYQATNGSASSGGYQAVGQWAETLRLDVEALQWSGDPHEVPSSLCSLPCGPGERKKMVKGVPCCWHCEACDGYRFQVDEFTCEACPGDMRPTPNHTGCRPTPVVRLSWSSPWAAPPLLLAVLGIVATTTVVATFVRYNNTPIVRASGRELSYVLLTGIFLIYAITFLMVAEPGAAVCAARRLFLGLGTTLSYSALLTKTNRIYRIFEQGKRSVTPPPFISPTSQLVITFSLTSLQVVGMIAWLGARPPHSVIDYEEQRTVDPEQARGVLKCDMSDLSLIGCLGYSLLLMVTCTVYAIKARGVPETFNEAKPIGFTMYTTCIIWLAFVPIFFGTAQSAEKIYIQTTTLTVSLSLSASVSLGMLYVPKTYVILFHPEQNVQKRKRSLKATSTVAAPPKGEDAEAHK
T55956	DRUGINFO	D0L0YF	homo-AMPA	Investigative
T55956	DRUGINFO	D0N0NJ	1-benzyl-APDC	Investigative
T55956	DRUGINFO	D0ZS8N	THPG	Investigative
T55956	DRUGINFO	D0H6BG	PHCCC	Investigative
T55956	DRUGINFO	D0KL4K	LSP4-2022	Investigative
T55956	DRUGINFO	D0LC5O	(S)-3,4-DCPG	Investigative
T55956	DRUGINFO	D0W3PY	ACPT-I	Investigative
T55956	DRUGINFO	D0XG6U	LSP1-2111	Investigative
T55956	DRUGINFO	D09SXN	MAP4	Investigative
T55956	DRUGINFO	D0D2GL	MPPG	Investigative
T55956	DRUGINFO	D0N9UZ	[3H]LY341495	Investigative
T55956	DRUGINFO	D0O8AK	alpha-methylserine-O-phosphate	Investigative
T55956	DRUGINFO	D0PN6Z	L-AP4	Investigative
T55956	DRUGINFO	D04DKM	(1S,3R)-ACPD	Investigative
T55956	DRUGINFO	D0Z7CZ	L-CCG-I	Investigative
T55956	DRUGINFO	D07PZQ	L-serine-O-phosphate	Investigative

T31788	TARGETID	T31788
T31788	FORMERID	TTDI00011
T31788	UNIPROID	MOT4_HUMAN
T31788	TARGNAME	Monocarboxylate transporter 4 (SLC16A3)
T31788	GENENAME	SLC16A3
T31788	TARGTYPE	Literature-reported
T31788	SYNONYMS	Solute carrier family 16 member 3; MCT4; MCT 4
T31788	FUNCTION	Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate. Proton-linked monocarboxylate transporter.
T31788	BIOCLASS	Major facilitator
T31788	SEQUENCE	MGGAVVDEGPTGVKAPDGGWGWAVLFGCFVITGFSYAFPKAVSVFFKELIQEFGIGYSDTAWISSILLAMLYGTGPLCSVCVNRFGCRPVMLVGGLFASLGMVAASFCRSIIQVYLTTGVITGLGLALNFQPSLIMLNRYFSKRRPMANGLAAAGSPVFLCALSPLGQLLQDRYGWRGGFLILGGLLLNCCVCAALMRPLVVTAQPGSGPPRPSRRLLDLSVFRDRGFVLYAVAASVMVLGLFVPPVFVVSYAKDLGVPDTKAAFLLTILGFIDIFARPAAGFVAGLGKVRPYSVYLFSFSMFFNGLADLAGSTAGDYGGLVVFCIFFGISYGMVGALQFEVLMAIVGTHKFSSAIGLVLLMEAVAVLVGPPSGGKLLDATHVYMYVFILAGAEVLTSSLILLLGNFFCIRKKPKEPQPEVAAAEEEKLHKPPADSGVDLREVEHFLKAEPEKNGEVVHTPETSV

T39919	TARGETID	T39919
T39919	FORMERID	TTDI00222
T39919	UNIPROID	MRP4_HUMAN
T39919	TARGNAME	Multidrug resistance protein 4 (ABCC4)
T39919	GENENAME	ABCC4
T39919	TARGTYPE	Literature-reported
T39919	SYNONYMS	Multispecific organic anion transporter B; Multidrug resistanceassociated protein 4; MRP/cMOATrelated ABC transporter; MOATB; ATPbinding cassette subfamily C member 4; ABCC4
T39919	FUNCTION	May be an organic anion pump relevant to cellular detoxification.
T39919	BIOCLASS	ABC transporter
T39919	SEQUENCE	MLPVYQEVKPNPLQDANLCSRVFFWWLNPLFKIGHKRRLEEDDMYSVLPEDRSQHLGEELQGFWDKEVLRAENDAQKPSLTRAIIKCYWKSYLVLGIFTLIEESAKVIQPIFLGKIINYFENYDPMDSVALNTAYAYATVLTFCTLILAILHHLYFYHVQCAGMRLRVAMCHMIYRKALRLSNMAMGKTTTGQIVNLLSNDVNKFDQVTVFLHFLWAGPLQAIAVTALLWMEIGISCLAGMAVLIILLPLQSCFGKLFSSLRSKTATFTDARIRTMNEVITGIRIIKMYAWEKSFSNLITNLRKKEISKILRSSCLRGMNLASFFSASKIIVFVTFTTYVLLGSVITASRVFVAVTLYGAVRLTVTLFFPSAIERVSEAIVSIRRIQTFLLLDEISQRNRQLPSDGKKMVHVQDFTAFWDKASETPTLQGLSFTVRPGELLAVVGPVGAGKSSLLSAVLGELAPSHGLVSVHGRIAYVSQQPWVFSGTLRSNILFGKKYEKERYEKVIKACALKKDLQLLEDGDLTVIGDRGTTLSGGQKARVNLARAVYQDADIYLLDDPLSAVDAEVSRHLFELCICQILHEKITILVTHQLQYLKAASQILILKDGKMVQKGTYTEFLKSGIDFGSLLKKDNEESEQPPVPGTPTLRNRTFSESSVWSQQSSRPSLKDGALESQDTENVPVTLSEENRSEGKVGFQAYKNYFRAGAHWIVFIFLILLNTAAQVAYVLQDWWLSYWANKQSMLNVTVNGGGNVTEKLDLNWYLGIYSGLTVATVLFGIARSLLVFYVLVNSSQTLHNKMFESILKAPVLFFDRNPIGRILNRFSKDIGHLDDLLPLTFLDFIQTLLQVVGVVSVAVAVIPWIAIPLVPLGIIFIFLRRYFLETSRDVKRLESTTRSPVFSHLSSSLQGLWTIRAYKAEERCQELFDAHQDLHSEAWFLFLTTSRWFAVRLDAICAMFVIIVAFGSLILAKTLDAGQVGLALSYALTLMGMFQWCVRQSAEVENMMISVERVIEYTDLEKEAPWEYQKRPPPAWPHEGVIIFDNVNFMYSPGGPLVLKHLTALIKSQEKVGIVGRTGAGKSSLISALFRLSEPEGKIWIDKILTTEIGLHDLRKKMSIIPQEPVLFTGTMRKNLDPFNEHTDEELWNALQEVQLKETIEDLPGKMDTELAESGSNFSVGQRQLVCLARAILRKNQILIIDEATANVDPRTDELIQKKIREKFAHCTVLTIAHRLNTIIDSDKIMVLDSGRLKEYDEPYVLLQNKESLFYKMVQQLGKAEAAALTETAKQVYFKRNYPHIGHTDHMVTNTSNGQPSTLTIFETAL

T95411	TARGETID	T95411
T95411	FORMERID	TTDR00025
T95411	UNIPROID	O15851_LEIME
T95411	TARGNAME	Leishmania Cdc2-related kinase 3 (Leishmania CRK3)
T95411	GENENAME	Leishmania CRK3
T95411	TARGTYPE	Literature-reported
T95411	SYNONYMS	Cdc2-related kinase 3; CRK3 cyclin-dependent kinase; CRK3
T95411	FUNCTION	Form an active protein kinase complex with Leishmania cyclins CYCA and CYC6.
T95411	BIOCLASS	Kinase
T95411	SEQUENCE	MSSFGRVTARSGDAGTRDSLDRYNRLDVLGEGTYGVVYRAVDKITGQYVALKKVRLDRTEEGIPQTALREVSILQEFDHPNIVNLLDVICSDGKLYLVFEYVEADLKKAIEKQEGGYSGMDLKRLIYQLLDGLYFCHRHRIIHRDLKPANILLTSGNVLKLADFGLARAFQVPMHTYTHEVVTLWYRAPEILLGEKHYTPAVDMWSVGCIFAELARRKVLFRGDSEIGQLFEIFQVLGTPTDTEGSWPGVSRLPDYRDVFPKWTAKRLGQVLPELHPDAIDLLSKMLKYDPRERISAKEALQHPWFSDLRW

T21829	TARGETID	T21829
T21829	FORMERID	TTDR00026
T21829	UNIPROID	RIR2_TRYBB
T21829	TARGNAME	Trypanosoma Ribonucleotide reductase R2 (Trypano RNR2)
T21829	GENENAME	Trypano RNR2
T21829	TARGTYPE	Literature-reported
T21829	SYNONYMS	Ribonucleotide reductase R2 subunit; RNR2
T21829	FUNCTION	Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides.
T21829	BIOCLASS	CH/CH(2) oxidoreductase
T21829	SEQUENCE	MPPKSHKCSRKEGEVEEPLLTENPDRYVIFPIKYPDIWQKYKEAESSIWTVEEIDLGNDMTDWEKLDDGERHFIKHVLAFFAASDGIVLENLAERFMCEVQVPEVRCFYGFQIAMENIHSETYSVLIDTYVVDPDEKQRLLHAIRTIPCIEKKAKWAIEWIGSQTSFPTRLVAFAAVEGIFFSGSFCAIFWLKKRGLMPGLTFSNELISRDEGLHTDFACLLYEKYIVNKLPRDRVLEIICNAVSIEREFICDALPVRLIGMNSQLMTQYIEFVADRLLVSLGYDRHYNSKNPFDFMDMISLQGKTNFFEKKVGEYQKAGVMSSERSSKVFSLDADF

T94335	TARGETID	T94335
T94335	FORMERID	TTDI01474
T94335	UNIPROID	MQMTN_HELPY
T94335	TARGNAME	Helicobacter pylori Methylthioadenosine nucleosidase (HELPY mtnN)
T94335	GENENAME	HELPY mtnN
T94335	TARGTYPE	Literature-reported
T94335	SYNONYMS	MTAN; MTA/SAH nucleosidase; Aminofutalosine nucleosidase; Aminodeoxyfutalosine nucleosidase; AFL nucleosidase; 6-amino-6-deoxyfutalosine N-ribosylhydrolase; 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase
T94335	FUNCTION	Catalyzes the direct conversion of aminodeoxyfutalosine (AFL) into dehypoxanthine futalosine (DHFL) and adenine via the hydrolysis of the N-glycosidic bond; this reaction seems to represent an essential step in the menaquinone biosynthesis pathway in Helicobacter species. Can also probably catalyzes the hydrolysis of 5'-methylthioadenosine (MTA) and S-adenosylhomocysteine (SAH) to adenine and the corresponding thioribose, 5'-methylthioribose and S-ribosylhomocysteine, respectively. These other activities highlight the tremendous versatility of the enzyme, which also plays key roles in S-adenosylmethionine recycling and in the biosynthesis of the quorum-sensing molecule autoinducer-2. Does not act on futalosine (FL) as substrate.
T94335	PDBSTRUC	4BN0; 4BMZ; 4BMY; 4BMX
T94335	SEQUENCE	MVQKIGILGAMREEITPILELFGVDFEEIPLGGNVFHKGVYHNKEIIVAYSKIGKVHSTLTTTSMILAFGVQKVLFSGVAGSLVKDLKINDLLVAIQLVQHDVDLSAFDHPLGFIPESAIFIETSESLNALAKEVANEQHIVLKEGVIASGDQFVHSKERKEFLVSEFKASAVEMEGASVAFVCQKFGVPCCVLRSISDNADEEANMSFDAFLEKSAQTSAKFLKSMVDEL

T78670	TARGETID	T78670
T78670	FORMERID	TTDR00800
T78670	UNIPROID	PPK1_MYCLE
T78670	TARGNAME	Mycobacterium Polyphosphate kinase (MycB ppk)
T78670	GENENAME	MycB ppk
T78670	TARGTYPE	Literature-reported
T78670	SYNONYMS	Polyphosphoric acid kinase; PPK; ATP-polyphosphate phosphotransferase
T78670	FUNCTION	Catalyzes the reversible transfer of the terminal phosphate of ATP to form a long-chain polyphosphate (polyP).
T78670	BIOCLASS	Kinase
T78670	SEQUENCE	MMSNDLLVTDIEAEARTEENIWHSDNSALAAPPAATTSASQDQLPDDRYLNRESSWLDFNARVLALAADNSLPLLERAKFLAIFASNLDEFYMVRVAGLKRRDEMDLSVRSADGLTPREQLSRIGEQTQWIASRHARVFLDSVLPALGEEGIYIVTWTDLDQAERDQLSTYFNEQVFPVLTPLAVDPAHPFPFVSGLSLNLAVTVKQPEDGTQHFARVKVPNNVDRFVELANRGAVRDTSAGDEGQLIHRFLPMEELIAAFLPVLFPGTEIVEHHAFRITRNADFEVEEDRDEDLLQALERELARRRFGSPVRLEIADDMTESMLELLLRELDVHPSDVIEVPGLLDLSSLWQIYGLDRPALKDRAFIPDTHPAFAERETPKSIFATLREGDVLVHHPYHSFATSVQRFIEQATADPDVLAIKQTLYRTSGDSPIVLALIEAAEAGKQVVALVEIKARFDEQANIRWARALEHAGVHVVYGIVGLKTHCKTCLVVRREGPTIRRYCHIGTGNYNSKTARLYEDVGLLTAAPDIGADLTDLFNSLTGYSRKLAYRNLLVAPYGIRRGIIERVEREVAAHRESGPQTGKGLIRLKMNALVDEQVIDALYRASQAGVRVEVVVRGICALRPGTEGFSENIFVRSILGRFLEHSRIIHFRAIDEFWIGSADMMHRNLDRRVEVLAQVKDSRLTAQLDELLKSALDPFTRCWELRPDGQWTASPQKGQQVRDHQESLMERHRSR

T94369	TARGETID	T94369
T94369	FORMERID	TTDNR00724
T94369	UNIPROID	O33336_MYCTU
T94369	TARGNAME	Mycobacterium Phosphopantetheinyl transferase (MycB pptT)
T94369	GENENAME	MycB pptT
T94369	TARGTYPE	Literature-reported
T94369	SYNONYMS	Phosphopantetheinyl transferase PptT (CoA:APO-[ACP]pantetheinephosphotransferase) (CoA:APO-[acyl-carrier protein]pantetheinephosphotransferase)
T94369	FUNCTION	Invovled in the assembly-line production of complex molecules such as fatty acids, polyketides and polypeptides, where they activate acyl or peptidyl carrier proteins, transferring a 4'-phosphopantetheinyl moiety from coenzyme A (CoA) to a reactive serine residue on the carrier protein.
T94369	PDBSTRUC	4U89; 4QVH; 4QJK
T94369	SEQUENCE	MTVGTLVASVLPATVFEDLAYAELYSDPPGLTPLPEEAPLIARSVAKRRNEFITVRHCARIALDQLGVPPAPILKGDKGEPCWPDGMVGSLTHCAGYRGAVVGRRDAVRSVGIDAEPHDVLPNGVLDAISLPAERADMPRTMPAALHWDRILFCAKEATYKAWFPLTKRWLGFEDAHITFETDSTGWTGRFVSRILIDGSTLSGPPLTTLRGRWSVERGLVLTAIVL

T79566	TARGETID	T79566
T79566	FORMERID	TTDI03042
T79566	UNIPROID	AQP9_HUMAN
T79566	TARGNAME	Aquaporin-9 (AQP9)
T79566	GENENAME	AQP9
T79566	TARGTYPE	Literature-reported
T79566	SYNONYMS	Small solute channel 1; SSC1; Aquaglyceroporin-9; AQP-9
T79566	FUNCTION	Forms a water channel with a broad specificity. Also permeable glycerol and urea. Mediates passage of a wide variety of small, non-charged solutes including carbamides, polyols, purines, and pyrimidines.
T79566	BIOCLASS	Major intrinsic protein
T79566	SEQUENCE	MQPEGAEKGKSFKQRLVLKSSLAKETLSEFLGTFILIVLGCGCVAQAILSRGRFGGVITINVGFSMAVAMAIYVAGGVSGGHINPAVSLAMCLFGRMKWFKLPFYVGAQFLGAFVGAATVFGIYYDGLMSFAGGKLLIVGENATAHIFATYPAPYLSLANAFADQVVATMILLIIVFAIFDSRNLGAPRGLEPIAIGLLIIVIASSLGLNSGCAMNPARDLSPRLFTALAGWGFEVFRAGNNFWWIPVVGPLVGAVIGGLIYVLVIEIHHPEPDSVFKTEQSEDKPEKYELSVIM
T79566	DRUGINFO	D0HD2G	phloretin	Investigative

T77099	TARGETID	T77099
T77099	FORMERID	TTDNR00721
T77099	UNIPROID	S26A4_HUMAN
T77099	TARGNAME	Solute carrier family 26 member 4 (SLC26A4)
T77099	GENENAME	SLC26A4
T77099	TARGTYPE	Literature-reported
T77099	SYNONYMS	Sodium-independent chloride/iodide transporter; SLC26A4
T77099	FUNCTION	Sodium-independent transporter of chloride and iodide.
T77099	BIOCLASS	Sulfate permease
T77099	SEQUENCE	MAAPGGRSEPPQLPEYSCSYMVSRPVYSELAFQQQHERRLQERKTLRESLAKCCSCSRKRAFGVLKTLVPILEWLPKYRVKEWLLSDVISGVSTGLVATLQGMAYALLAAVPVGYGLYSAFFPILTYFIFGTSRHISVGPFPVVSLMVGSVVLSMAPDEHFLVSSSNGTVLNTTMIDTAARDTARVLIASALTLLVGIIQLIFGGLQIGFIVRYLADPLVGGFTTAAAFQVLVSQLKIVLNVSTKNYNGVLSIIYTLVEIFQNIGDTNLADFTAGLLTIVVCMAVKELNDRFRHKIPVPIPIEVIVTIIATAISYGANLEKNYNAGIVKSIPRGFLPPELPPVSLFSEMLAASFSIAVVAYAIAVSVGKVYATKYDYTIDGNQEFIAFGISNIFSGFFSCFVATTALSRTAVQESTGGKTQVAGIISAAIVMIAILALGKLLEPLQKSVLAAVVIANLKGMFMQLCDIPRLWRQNKIDAVIWVFTCIVSIILGLDLGLLAGLIFGLLTVVLRVQFPSWNGLGSIPSTDIYKSTKNYKNIEEPQGVKILRFSSPIFYGNVDGFKKCIKSTVGFDAIRVYNKRLKALRKIQKLIKSGQLRATKNGIISDAVSTNNAFEPDEDIEDLEELDIPTKEIEIQVDWNSELPVKVNVPKVPIHSLVLDCGAISFLDVVGVRSLRVIVKEFQRIDVNVYFASLQDYVIEKLEQCGFFDDNIRKDTFFLTVHDAILYLQNQVKSQEGQGSILETITLIQDCKDTLELIETELTEEELDVQDEAMRTLAS

T58460	TARGETID	T58460
T58460	FORMERID	TTDR00608
T58460	UNIPROID	ENSA_HUMAN
T58460	TARGNAME	Alpha-endosulfine (ENSA)
T58460	GENENAME	ENSA
T58460	TARGTYPE	Literature-reported
T58460	SYNONYMS	ENSA; ARPP19e
T58460	FUNCTION	Endogenous ligand for sulfonylurea receptor. By inhibitingsulfonylurea from binding to the receptor, it reduces k(atp) channel currents and thereby stimulates insulin secretion.
T58460	BIOCLASS	Endosulfine family
T58460	SEQUENCE	MSQKQEEENPAEETGEEKQDTQEKEGILPERAEEAKLKAKYPSLGQKPGGSDFLMKRLQKGQKYFDSGDYNMAKAKMKNKQLPSAGPDKNLVTGDHIPTPQDLPQRKSSLVTSKLAGGQVE

T68320	TARGETID	T68320
T68320	FORMERID	TTDI03621
T68320	UNIPROID	XPP2_HUMAN
T68320	TARGNAME	X-prolyl aminopeptidase 2 (XPNPEP2)
T68320	GENENAME	XPNPEP2
T68320	TARGTYPE	Literature-reported
T68320	SYNONYMS	mAmP; Xaa-Pro aminopeptidase 2; X-Pro aminopeptidase 2; Membrane-bound aminopeptidase P; Membrane-bound AmP; Membrane-bound APP; Aminoacylproline aminopeptidase
T68320	FUNCTION	Membrane-bound metalloprotease which catalyzes the removal of a penultimate prolyl residue from the N-termini of peptides, such as Arg-Pro-Pro. May play a role in the metabolism of the vasodilator bradykinin.
T68320	ECNUMBER	EC 3.4.11.9
T68320	SEQUENCE	MARAHWGCCPWLVLLCACAWGHTKPVDLGGQDVRNCSTNPPYLPVTVVNTTMSLTALRQQMQTQNLSAYIIPGTDAHMNEYIGQHDERRAWITGFTGSAGTAVVTMKKAAVWTDSRYWTQAERQMDCNWELHKEVGTTPIVTWLLTEIPAGGRVGFDPFLLSIDTWESYDLALQGSNRQLVSITTNLVDLVWGSERPPVPNQPIYALQEAFTGSTWQEKVSGVRSQMQKHQKVPTAVLLSALEETAWLFNLRASDIPYNPFFYSYTLLTDSSIRLFANKSRFSSETLSYLNSSCTGPMCVQIEDYSQVRDSIQAYSLGDVRIWIGTSYTMYGIYEMIPKEKLVTDTYSPVMMTKAVKNSKEQALLKASHVRDAVAVIRYLVWLEKNVPKGTVDEFSGAEIVDKFRGEEQFSSGPSFETISASGLNAALAHYSPTKELNRKLSSDEMYLLDSGGQYWDGTTDITRTVHWGTPSAFQKEAYTRVLIGNIDLSRLIFPAATSGRMVEAFARRALWDAGLNYGHGTGHGIGNFLCVHEWPVGFQSNNIAMAKGMFTSIEPGYYKDGEFGIRLEDVALVVEAKTKYPGSYLTFEVVSFVPYDRNLIDVSLLSPEHLQYLNRYYQTIREKVGPELQRRQLLEEFEWLQQHTEPLAARAPDTASWASVLVVSTLAILGWSV
T68320	DRUGINFO	D0CG7Q	PMID10395480C6	Investigative

T74965	TARGETID	T74965
T74965	FORMERID	TTDR01020
T74965	UNIPROID	CF30_MYCTU
T74965	TARGNAME	Mycobacterium 27kDa antigen Cfp30B (MycB cfp32)
T74965	GENENAME	MycB cfp32
T74965	TARGTYPE	Literature-reported
T74965	SYNONYMS	MycB Putative glyoxylase CF30
T74965	FUNCTION	May function as a glyoxylase involved in the methylglyoxal detoxification pathway. Induces maturation of dendritic cells in a TLR2-dependent manner, causing increased expression of cell-surface molecules (CD80, CD86, MHC class I and II) and proinflammatory cytokines (TNF-alpha, IL-6, IL-1 beta and IL-12p70). Acts via both the NF-kappa-B and MAPK signaling pathways. Induces Th1-polarized immune responses.
T74965	PDBSTRUC	3OXH
T74965	SEQUENCE	MPKRSEYRQGTPNWVDLQTTDQSAAKKFYTSLFGWGYDDNPVPGGGGVYSMATLNGEAVAAIAPMPPGAPEGMPPIWNTYIAVDDVDAVVDKVVPGGGQVMMPAFDIGDAGRMSFITDPTGAAVGLWQANRHIGATLVNETGTLIWNELLTDKPDLALAFYEAVVGLTHSSMEIAAGQNYRVLKAGDAEVGGCMEPPMPGVPNHWHVYFAVDDADATAAKAAAAGGQVIAEPADIPSVGRFAVLSDPQGAIFSVLKPAPQQ

T38453	TARGETID	T38453
T38453	FORMERID	TTDI00033
T38453	UNIPROID	ZEB2_HUMAN
T38453	TARGNAME	Zinc finger E-box-binding homeobox 2 (ZEB2)
T38453	GENENAME	ZEB2
T38453	TARGTYPE	Literature-reported
T38453	SYNONYMS	Zinc finger homeobox protein 1b; ZFX1B; ZFHX1B; Smad-interacting protein 1; SMADIP1; SIP1; KIAA0569; HRIHFB2411
T38453	FUNCTION	Represses transcription of E-cadherin. Transcriptional inhibitor that binds to DNA sequence 5'-CACCT-3' in different promoters.
T38453	PDBSTRUC	2DA7
T38453	SEQUENCE	MKQPIMADGPRCKRRKQANPRRKNVVNYDNVVDTGSETDEEDKLHIAEDDGIANPLDQETSPASVPNHESSPHVSQALLPREEEEDEIREGGVEHPWHNNEILQASVDGPEEMKEDYDTMGPEATIQTAINNGTVKNANCTSDFEEYFAKRKLEERDGHAVSIEEYLQRSDTAIIYPEAPEELSRLGTPEANGQEENDLPPGTPDAFAQLLTCPYCDRGYKRLTSLKEHIKYRHEKNEENFSCPLCSYTFAYRTQLERHMVTHKPGTDQHQMLTQGAGNRKFKCTECGKAFKYKHHLKEHLRIHSGEKPYECPNCKKRFSHSGSYSSHISSKKCIGLISVNGRMRNNIKTGSSPNSVSSSPTNSAITQLRNKLENGKPLSMSEQTGLLKIKTEPLDFNDYKVLMATHGFSGTSPFMNGGLGATSPLGVHPSAQSPMQHLGVGMEAPLLGFPTMNSNLSEVQKVLQIVDNTVSRQKMDCKAEEISKLKGYHMKDPCSQPEEQGVTSPNIPPVGLPVVSHNGATKSIIDYTLEKVNEAKACLQSLTTDSRRQISNIKKEKLRTLIDLVTDDKMIENHNISTPFSCQFCKESFPGPIPLHQHERYLCKMNEEIKAVLQPHENIVPNKAGVFVDNKALLLSSVLSEKGMTSPINPYKDHMSVLKAYYAMNMEPNSDELLKISIAVGLPQEFVKEWFEQRKVYQYSNSRSPSLERSSKPLAPNSNPPTKDSLLPRSPVKPMDSITSPSIAELHNSVTNCDPPLRLTKPSHFTNIKPVEKLDHSRSNTPSPLNLSSTSSKNSHSSSYTPNSFSSEELQAEPLDLSLPKQMKEPKSIIATKNKTKASSISLDHNSVSSSSENSDEPLNLTFIKKEFSNSNNLDNKSTNPVFSMNPFSAKPLYTALPPQSAFPPATFMPPVQTSIPGLRPYPGLDQMSFLPHMAYTYPTGAATFADMQQRRKYQRKQGFQGELLDGAQDYMSGLDDMTDSDSCLSRKKIKKTESGMYACDLCDKTFQKSSSLLRHKYEHTGKRPHQCQICKKAFKHKHHLIEHSRLHSGEKPYQCDKCGKRFSHSGSYSQHMNHRYSYCKREAEEREAAEREAREKGHLEPTELLMNRAYLQSITPQGYSDSEERESMPRDGESEKEHEKEGEDGYGKLGRQDGDEEFEEEEEESENKSMDTDPETIRDEEETGDHSMDDSSEDGKMETKSDHEEDNMEDGM

T71492	TARGETID	T71492
T71492	FORMERID	TTDR01013
T71492	UNIPROID	NHRF3_HUMAN
T71492	TARGNAME	PDZ domain containing-protein (PDZK1)
T71492	GENENAME	PDZK1
T71492	TARGTYPE	Literature-reported
T71492	SYNONYMS	Sodium-hydrogen exchanger regulatory factor 3; PDZD1; PDZ domain-containing protein 1; NaPi-Cap1; Na/Pi cotransporter C-terminal-associated protein 1; Na(+)/H(+) exchanger regulatory factor 3; Na(+)/H(+) exchange regulatory cofactor NHE-RF3; NHERF3; NHERF-3; Multi-PDZ domain containing adaptor protein; CFTR-associated protein of 70 kDa; CAP70
T71492	FUNCTION	May be involved in the coordination of a diverse range of regulatory processes for ion transport and second messenger cascades. In complex with SLC9A3R1, may cluster proteins that are functionally dependent in a mutual fashion and modulate the trafficking and the activity of the associated membrane proteins. May play a role in the cellular mechanisms associated with multidrug resistance through its interaction with ABCC2 and PDZK1IP1. May potentiate the CFTR chloride channel activity. Required for normal cell-surface expression of SCARB1. Plays a role in maintaining normal plasma cholesterol levels via its effects on SCARB1. Plays a role in the normal localization and function of the chloride-anion exchanger SLC26A6 to the plasma membrane in the brush border of the proximal tubule of the kidney. May be involved in the regulation of proximal tubular Na(+)-dependent inorganic phosphate cotransport therefore playing an important role in tubule function. A scaffold protein that connects plasma membrane proteins and regulatory components, regulating their surface expression in epithelial cells apical domains.
T71492	PDBSTRUC	6EZI; 4Q2P; 3TMH; 2VSP; 2EEJ
T71492	SEQUENCE	MTSTFNPRECKLSKQEGQNYGFFLRIEKDTEGHLVRVVEKCSPAEKAGLQDGDRVLRINGVFVDKEEHMQVVDLVRKSGNSVTLLVLDGDSYEKAVKTRVDLKELGQSQKEQGLSDNILSPVMNGGVQTWTQPRLCYLVKEGGSYGFSLKTVQGKKGVYMTDITPQGVAMRAGVLADDHLIEVNGENVEDASHEEVVEKVKKSGSRVMFLLVDKETDKRHVEQKIQFKRETASLKLLPHQPRIVEMKKGSNGYGFYLRAGSEQKGQIIKDIDSGSPAEEAGLKNNDLVVAVNGESVETLDHDSVVEMIRKGGDQTSLLVVDKETDNMYRLAHFSPFLYYQSQELPNGSVKEAPAPTPTSLEVSSPPDTTEEVDHKPKLCRLAKGENGYGFHLNAIRGLPGSFIKEVQKGGPADLAGLEDEDVIIEVNGVNVLDEPYEKVVDRIQSSGKNVTLLVCGKKAYDYFQAKKIPIVSSLADPLDTPPDSKEGIVVESNHDSHMAKERAHSTASHSSSNSEDTEM

T99333	TARGETID	T99333
T99333	FORMERID	TTDI03098
T99333	UNIPROID	CAC1F_HUMAN
T99333	TARGNAME	Voltage-gated calcium channel alpha Cav1.4 (CACNA1F)
T99333	GENENAME	CACNA1F
T99333	TARGTYPE	Literature-reported
T99333	SYNONYMS	Voltage-gated calcium channel subunit alpha Cav1.4; Voltage-dependent L-type calcium channel subunit alpha-1F; CACNAF1
T99333	FUNCTION	Isoform 1: Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1F gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group. They are blocked by dihydropyridines (DHP), phenylalkylamines, and by benzothiazepines. Activates at more negative voltages and does not undergo calcium-dependent inactivation (CDI), due to incoming calcium ions, during depolarization.
T99333	BIOCLASS	Voltage-gated ion channel
T99333	SEQUENCE	MSESEGGKDTTPEPSPANGAGPGPEWGLCPGPPAVEGESSGASGLGTPKRRNQHSKHKTVAVASAQRSPRALFCLTLANPLRRSCISIVEWKPFDILILLTIFANCVALGVYIPFPEDDSNTANHNLEQVEYVFLVIFTVETVLKIVAYGLVLHPSAYIRNGWNLLDFIIVVVGLFSVLLEQGPGRPGDAPHTGGKPGGFDVKALRAFRVLRPLRLVSGVPSLHIVLNSIMKALVPLLHIALLVLFVIIIYAIIGLELFLGRMHKTCYFLGSDMEAEEDPSPCASSGSGRACTLNQTECRGRWPGPNGGITNFDNFFFAMLTVFQCVTMEGWTDVLYWMQDAMGYELPWVYFVSLVIFGSFFVLNLVLGVLSGEFSKEREKAKARGDFQKQREKQQMEEDLRGYLDWITQAEELDMEDPSADDNLGSMAEEGRAGHRPQLAELTNRRRGRLRWFSHSTRSTHSTSSHASLPASDTGSMTETQGDEDEEEGALASCTRCLNKIMKTRVCRRLRRANRVLRARCRRAVKSNACYWAVLLLVFLNTLTIASEHHGQPVWLTQIQEYANKVLLCLFTVEMLLKLYGLGPSAYVSSFFNRFDCFVVCGGILETTLVEVGAMQPLGISVLRCVRLLRIFKVTRHWASLSNLVASLLNSMKSIASLLLLLFLFIIIFSLLGMQLFGGKFNFDQTHTKRSTFDTFPQALLTVFQILTGEDWNVVMYDGIMAYGGPFFPGMLVCIYFIILFICGNYILLNVFLAIAVDNLASGDAGTAKDKGGEKSNEKDLPQENEGLVPGVEKEEEEGARREGADMEEEEEEEEEEEEEEEEEGAGGVELLQEVVPKEKVVPIPEGSAFFCLSQTNPLRKGCHTLIHHHVFTNLILVFIILSSVSLAAEDPIRAHSFRNHILGYFDYAFTSIFTVEILLKMTVFGAFLHRGSFCRSWFNMLDLLVVSVSLISFGIHSSAISVVKILRVLRVLRPLRAINRAKGLKHVVQCVFVAIRTIGNIMIVTTLLQFMFACIGVQLFKGKFYTCTDEAKHTPQECKGSFLVYPDGDVSRPLVRERLWVNSDFNFDNVLSAMMALFTVSTFEGWPALLYKAIDAYAEDHGPIYNYRVEISVFFIVYIIIIAFFMMNIFVGFVIITFRAQGEQEYQNCELDKNQRQCVEYALKAQPLRRYIPKNPHQYRVWATVNSAAFEYLMFLLILLNTVALAMQHYEQTAPFNYAMDILNMVFTGLFTIEMVLKIIAFKPKHYFTDAWNTFDALIVVGSIVDIAVTEVNNGGHLGESSEDSSRISITFFRLFRVMRLVKLLSKGEGIRTLLWTFIKSFQALPYVALLIAMIFFIYAVIGMQMFGKVALQDGTQINRNNNFQTFPQAVLLLFRCATGEAWQEIMLASLPGNRCDPESDFGPGEEFTCGSNFAIAYFISFFMLCAFLIINLFVAVIMDNFDYLTRDWSILGPHHLDEFKRIWSEYDPGAKGRIKHLDVVALLRRIQPPLGFGKLCPHRVACKRLVAMNMPLNSDGTVTFNATLFALVRTSLKIKTEGNLEQANQELRIVIKKIWKRMKQKLLDEVIPPPDEEEVTVGKFYATFLIQDYFRKFRRRKEKGLLGNDAAPSTSSALQAGLRSLQDLGPEMRQALTCDTEEEEEEGQEGVEEEDEKDLETNKATMVSQPSARRGSGISVSLPVGDRLPDSLSFGPSDDDRGTPTSSQPSVPQAGSNTHRRGSGALIFTIPEEGNSQPKGTKGQNKQDEDEEVPDRLSYLDEQAGTPPCSVLLPPHRAQRYMDGHLVPRRRLLPPTPAGRKPSFTIQCLQRQGSCEDLPIPGTYHRGRNSGPNRAQGSWATPPQRGRLLYAPLLLVEEGAAGEGYLGRSSGPLRTFTCLHVPGTHSDPSHGKRGSADSLVEAVLISEGLGLFARDPRFVALAKQEIADACRLTLDEMDNAASDLLAQGTSSLYSDEESILSRFDEEDLGDEMACVHAL
T99333	DRUGINFO	D02RIH	(-)-(S)-BayK8644	Investigative
T99333	DRUGINFO	D00YNI	L-(cis)-diltiazem	Investigative

T78587	TARGETID	T78587
T78587	FORMERID	TTDR00761
T78587	UNIPROID	O61142_PLAFA
T78587	TARGNAME	Plasmodium Subtilisin-like protease (Malaria sub-1)
T78587	GENENAME	Malaria sub-1
T78587	TARGTYPE	Literature-reported
T78587	SYNONYMS	Subtilisin-like protease
T78587	FUNCTION	Plays a dual role at the blood stage by enabling egress of the progeny merozoites from the infected erythrocyte and priming merozoites for subsequent erythrocyte invasion. 
T78587	BIOCLASS	Protease
T78587	SEQUENCE	MMLNKKVVALCTLTLHLFCIFLCLGKEVRSEENGKIQDDAKKIVSELRFLEKVEDVIEKSNIGGNEVDADENSFNPDTEVPIEEIEEIKMRELKDVKEEKNKNDNHNNNNNNNNISSSSSSSSNTFGEEKEEVSKKKKKLRLIVSENHATTPSFFQESLLEPDVLSFLESKGNLSNLKNINSMIIELKEDTTDDELISYIKILEEKGALIESDKLVSADNIDISGIKDAIRRGEENIDVNDYKSMLEVENDAEDYDKMFGMFNESHAATSKRKRHSTNERGYDTFSSPSYKTYSKSDYLYDDDNNNNNYYYSHSSNGHNSSSRNSSSSRSRPGKYHFNDEFRNLQWGLDLSRLDETQELINEHQVMSTRICVIDSGIDYNHPDLKDNIELNLKELHGRKGFDDDNNGIVDDIYGANFVNNSGNPMDDNYHGTHVSGIISAIGNNNIGVVGVDVNSKLIICKALDEHKLGRLGDMFKCLDYCISRNAHMINGSFSFDEYSGIFNSSVEYLQRKGILFFVSASNCSHPKSSTPDIRKCDLSINAKYPPILSTVYDNVISVANLKKNDNNNHYSLSINSFYSNKYCQLAAPGTNIYSTAPHNSYRKLNGTSMAAPHVAAIASLIFSINPDLSYKKVIQILKDSIVYLPSLKNMVAWAGYADINKAVNLAIKSKKTYINSNISNKWKKKSRYLH

T76126	TARGETID	T76126
T76126	FORMERID	TTDR00826
T76126	UNIPROID	O74271_CANAX
T76126	TARGNAME	Candida Histidine kinase (Candi chik1)
T76126	GENENAME	Candi chik1
T76126	TARGTYPE	Literature-reported
T76126	SYNONYMS	Histidine kinase
T76126	FUNCTION	Catalyses the phosphorylation of a histidine residue in response to detection of an extracellular signal such as a chemical ligand or change in environment, to initiate a change in cell state or activity. 
T76126	BIOCLASS	Kinase
T76126	SEQUENCE	MNPTKKPRLSPMQPSVFEILNDPELYSQHCHSLRETLLDHFNHQATLIDTYEHELEKSKNANKAFQQALSEIGTVVISVAMGDLSKKVEIHTVENDPEILKVKITINTMMDQLQTFANEVTKVATEVANGELGGQAKNDGSVGIWRSLTDNVNIMALNLTNQVREIADVTRAVAKGDLSRKINVHAQGEILQLQRTINTMVDQLRTFAFEVSKVARDVGVLGILGGQALIENVEGIWEELTDNVNAMALNLTTQVRNIANVTTAVAKGDLSKKVTADCKGEILDLKLTINQMVDRLQNFALAVTTLSREVGTLGIWGGQANVQDVEGAWKQVTENVNLMATNLTNQVRSIATVTTAVAHGDLSQKIDVHAQGEILQLKNTINKMVDSLQLFASEVSKVAQDVGINGKLGIQAQVSDVDGLWKEITSNVNTMASNLTSQVRAFAQITAAATDGDFTRFITVEASGEMDALKTKINQMVFNLRESLQRNTAAREAAELANSAKSEFLANMSHEIRTPLNGIIGMTQLSLDTELTQYQREMLSIVHNLANSLLTIIDDILDISKIEANRMTVEQIDFSLRGTVFGALKTLAVKAIEKNLDLTYQCDSSFPDNLIGDSFRLRQVILNLAGNAIKFTKEGKVSVSVKKSDKMVLDSKLLLEVCVSDTGIGIEKDKLGLIFDTFCQADGSTTRKFGGTGLGLSISKQLIHLMGGEIWVTSEYGSGSNFYFTVCVSPSNIRYTRQTEQLLPFSSHYVLFVSTEHTQEELDVLRDGIIELGLIPIIVRNIEDATLTEPVKYDIIMIDSIEIAKKLRLLSEVKYIPLVLVHHSIPQLNMRVCIDLGISSYANTPCSITDLASAIIPALESRSISQNSDESVRYKILLAEDNLVNQKLAVRILEKQGHSVEVVENGLEAYEAIKRNKYDVVLMDVQMPVMGGFEATEKIRQWEKKSNPIDSLTFRTPIIALTAHAMLGDREKSLAKGMDDYVSKPLKPKLLMQTINKCIHNINQLKELSRNSRGSDFAKKMTRNTPGSTTRQGSDEGSVEDMIGDTPRQGSVEGGGTSSRPVQRRSATEGSITTISEQIDR

T70797	TARGETID	T70797
T70797	FORMERID	TTDR00792
T70797	UNIPROID	GA45B_HUMAN
T70797	TARGNAME	Negative growth-regulatory protein MyD118 (GADD45B)
T70797	GENENAME	GADD45B
T70797	TARGTYPE	Literature-reported
T70797	SYNONYMS	Myeloid differentiation primary response protein MyD118; GADD45beta; GADD45B; DNA damage-inducible gene 45beta
T70797	FUNCTION	Involved in the regulation of growth and apoptosis. Mediates activation of stress-responsive MTK1/MEKK4 MAPKKK.
T70797	BIOCLASS	Ribosomal protein
T70797	SEQUENCE	MTLEELVACDNAAQKMQTVTAAVEELLVAAQRQDRLTVGVYESAKLMNVDPDSVVLCLLAIDEEEEDDIALQIHFTLIQSFCCDNDINIVRVSGMQRLAQLLGEPAETQGTTEARDLHCLLVTNPHTDAWKSHGLVEVASYCEESRGNNQWVPYISLQER

T17656	TARGETID	T17656
T17656	FORMERID	TTDI01473
T17656	UNIPROID	ERN1_HUMAN
T17656	TARGNAME	Inositol-requiring protein 1 (IRE1a)
T17656	GENENAME	ERN1
T17656	TARGTYPE	Literature-reported
T17656	SYNONYMS	hIRE1p; Serine/threonine-protein kinase/endoribonuclease IRE1; Ire1-alpha; IRE1a; IRE1; Endoplasmic reticulum-to-nucleus signaling 1
T17656	FUNCTION	Serine/threonine-protein kinase and endoribonuclease that acts as a key sensor for the endoplasmic reticulum unfolded protein response (UPR). In unstressed cells, the endoplasmic reticulum luminal domain is maintained in its inactive monomeric state by binding to the endoplasmic reticulum chaperone HSPA5/BiP. Accumulation of misfolded protein in the endoplasmic reticulum causes release of HSPA5/BiP, allowing the luminal domain to homodimerize, promoting autophosphorylation of the kinase domain and subsequent activation of the endoribonuclease activity. The endoribonuclease activity is specific for XBP1 mRNA and excises 26 nucleotides from XBP1 mRNA. The resulting spliced transcript of XBP1 encodes a transcriptional activator protein that up-regulates expression of UPR target genes. Acts as an upstream signal for ER stress-induced GORASP2-mediated unconventional (ER/Golgi-independent) trafficking of CFTR to cell membrane by modulating the expression and localization of SEC16A.
T17656	PDBSTRUC	6HX1; 6HV0; 5HGI; 4Z7H; 4Z7G
T17656	SEQUENCE	MPARRLLLLLTLLLPGLGIFGSTSTVTLPETLLFVSTLDGSLHAVSKRTGSIKWTLKEDPVLQVPTHVEEPAFLPDPNDGSLYTLGSKNNEGLTKLPFTIPELVQASPCRSSDGILYMGKKQDIWYVIDLLTGEKQQTLSSAFADSLCPSTSLLYLGRTEYTITMYDTKTRELRWNATYFDYAASLPEDDVDYKMSHFVSNGDGLVVTVDSESGDVLWIQNYASPVVAFYVWQREGLRKVMHINVAVETLRYLTFMSGEVGRITKWKYPFPKETEAKSKLTPTLYVGKYSTSLYASPSMVHEGVAVVPRGSTLPLLEGPQTDGVTIGDKGECVITPSTDVKFDPGLKSKNKLNYLRNYWLLIGHHETPLSASTKMLERFPNNLPKHRENVIPADSEKKSFEEVINLVDQTSENAPTTVSRDVEEKPAHAPARPEAPVDSMLKDMATIILSTFLLIGWVAFIITYPLSMHQQQQLQHQQFQKELEKIQLLQQQQQQLPFHPPGDTAQDGELLDTSGPYSESSGTSSPSTSPRASNHSLCSGSSASKAGSSPSLEQDDGDEETSVVIVGKISFCPKDVLGHGAEGTIVYRGMFDNRDVAVKRILPECFSFADREVQLLRESDEHPNVIRYFCTEKDRQFQYIAIELCAATLQEYVEQKDFAHLGLEPITLLQQTTSGLAHLHSLNIVHRDLKPHNILISMPNAHGKIKAMISDFGLCKKLAVGRHSFSRRSGVPGTEGWIAPEMLSEDCKENPTYTVDIFSAGCVFYYVISEGSHPFGKSLQRQANILLGACSLDCLHPEKHEDVIARELIEKMIAMDPQKRPSAKHVLKHPFFWSLEKQLQFFQDVSDRIEKESLDGPIVKQLERGGRAVVKMDWRENITVPLQTDLRKFRTYKGGSVRDLLRAMRNKKHHYRELPAEVRETLGSLPDDFVCYFTSRFPHLLAHTYRAMELCSHERLFQPYYFHEPPEPQPPVTPDAL

T94313	TARGETID	T94313
T94313	UNIPROID	CRLF1_HUMAN
T94313	TARGNAME	Cytokine receptor-like factor 1 (CRLF1)
T94313	GENENAME	CRLF1
T94313	TARGTYPE	Literature-reported
T94313	SYNONYMS	ZcytoR5; Cytokine-like factor 1; CLF-1
T94313	FUNCTION	Cytokine receptor subunit, possibly playing a regulatory role in the immune system and during fetal development. May be involved in nervous system development.
T94313	BIOCLASS	Type I cytokine receptor family. Type 3 subfamily
T94313	SEQUENCE	MPAGRRGPAAQSARRPPPLLPLLLLLCVLGAPRAGSGAHTAVISPQDPTLLIGSSLLATCSVHGDPPGATAEGLYWTLNGRRLPPELSRVLNASTLALALANLNGSRQRSGDNLVCHARDGSILAGSCLYVGLPPEKPVNISCWSKNMKDLTCRWTPGAHGETFLHTNYSLKYKLRWYGQDNTCEEYHTVGPHSCHIPKDLALFTPYEIWVEATNRLGSARSDVLTLDILDVVTTDPPPDVHVSRVGGLEDQLSVRWVSPPALKDFLFQAKYQIRYRVEDSVDWKVVDDVSNQTSCRLAGLKPGTVYFVQVRCNPFGIYGSKKAGIWSEWSHPTAASTPRSERPGPGGGACEPRGGEPSSGPVRRELKQFLGWLKKHAYCSNLSFRLYDQWRAWMQKSHKTRNQDEGILPSGRRGTARGPAR

T57387	TARGETID	T57387
T57387	FORMERID	TTDR01117
T57387	UNIPROID	GEMI_HUMAN
T57387	TARGNAME	Geminin (GMNN)
T57387	GENENAME	GMNN
T57387	TARGTYPE	Literature-reported
T57387	SYNONYMS	geminin DNA replication inhibitor; MGORS6
T57387	FUNCTION	It is degraded during the mitotic phase of the cell cycle. Its destruction at the metaphase-anaphase transition permits replication in the succeeding cell cycle. Inhibits DNA replication by preventing the incorporation of MCM complex into pre-replication complex (pre-RC).
T57387	PDBSTRUC	4BRY; 2WVR; 2LP0; 1UII; 1T6F
T57387	SEQUENCE	MNPSMKQKQEEIKENIKNSSVPRRTLKMIQPSASGSLVGRENELSAGLSKRKHRNDHLTSTTSSPGVIVPESSENKNLGGVTQESFDLMIKENPSSQYWKEVAEKRRKALYEALKENEKLHKEIEQKDNEIARLKKENKELAEVAEHVQYMAELIERLNGEPLDNFESLDNQEFDSEEETVEDSLVEDSEIGTCAEGTVSSSTDAKPCI

T64744	TARGETID	T64744
T64744	FORMERID	TTDI01422
T64744	UNIPROID	TNR21_HUMAN
T64744	TARGNAME	Death receptor 6 (CD358)
T64744	GENENAME	TNFRSF21
T64744	TARGTYPE	Literature-reported
T64744	SYNONYMS	UNQ437/PRO868; Tumor necrosis factor receptor superfamily member 21; DR6
T64744	FUNCTION	Can also promote apoptosis mediated by BAX and by the release of cytochrome c from the mitochondria into the cytoplasm. Plays a role in neuronal apoptosis, including apoptosis in response to amyloid peptides derived from APP, and is required for both normal cell body death and axonal pruning. Trophic-factor deprivation triggers the cleavage of surface APP by beta-secretase to release sAPP-beta which is further cleaved to release an N-terminal fragment of APP (N-APP). N-APP binds TNFRSF21; this triggers caspase activation and degeneration of both neuronal cell bodies (via caspase-3) and axons (via caspase-6). Negatively regulates oligodendrocyte survival, maturation and myelination. Plays a role in signaling cascades triggered by stimulation of T-cell receptors, in the adaptive immune response and in the regulation of T-cell differentiation and proliferation. Negatively regulates T-cell responses and the release of cytokines such as IL4, IL5, IL10, IL13 and IFNG by Th2 cells. Negatively regulates the production of IgG, IgM and IgM in response to antigens. May inhibit the activation of JNK in response to T-cell stimulation. Promotes apoptosis, possibly via a pathway that involves the activation of NF-kappa-B.
T64744	PDBSTRUC	3U3V; 3U3T; 3U3S; 3U3Q; 3U3P
T64744	SEQUENCE	MGTSPSSSTALASCSRIARRATATMIAGSLLLLGFLSTTTAQPEQKASNLIGTYRHVDRATGQVLTCDKCPAGTYVSEHCTNTSLRVCSSCPVGTFTRHENGIEKCHDCSQPCPWPMIEKLPCAALTDRECTCPPGMFQSNATCAPHTVCPVGWGVRKKGTETEDVRCKQCARGTFSDVPSSVMKCKAYTDCLSQNLVVIKPGTKETDNVCGTLPSFSSSTSPSPGTAIFPRPEHMETHEVPSSTYVPKGMNSTESNSSASVRPKVLSSIQEGTVPDNTSSARGKEDVNKTLPNLQVVNHQQGPHHRHILKLLPSMEATGGEKSSTPIKGPKRGHPRQNLHKHFDINEHLPWMIVLFLLLVLVVIVVCSIRKSSRTLKKGPRQDPSAIVEKAGLKKSMTPTQNREKWIYYCNGHGIDILKLVAAQVGSQWKDIYQFLCNASEREVAAFSNGYTADHERAYAALQHWTIRGPEASLAQLISALRQHRRNDVVEKIRGLMEDTTQLETDKLALPMSPSPLSPSPIPSPNAKLENSALLTVEPSPQDKNKGFFVDESEPLLRCDSTSSGSSALSRNGSFITKEKKDTVLRQVRLDPCDLQPIFDDMLHFLNPEELRVIEEIPQAEDKLDRLFEIIGVKSQEASQTLLDSVYSHLPDLL

T16326	TARGETID	T16326
T16326	FORMERID	TTDI03132
T16326	UNIPROID	CXB3_HUMAN
T16326	TARGNAME	Gap junction beta-3 protein (Cx31)
T16326	GENENAME	GJB3
T16326	TARGTYPE	Literature-reported
T16326	SYNONYMS	Connexin-31; CX31
T16326	FUNCTION	One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell.
T16326	BIOCLASS	Gap junction-forming connexin
T16326	SEQUENCE	MDWKTLQALLSGVNKYSTAFGRIWLSVVFVFRVLVYVVAAERVWGDEQKDFDCNTKQPGCTNVCYDNYFPISNIRLWALQLIFVTCPSLLVILHVAYREERERRHRQKHGDQCAKLYDNAGKKHGGLWWTYLFSLIFKLIIEFLFLYLLHTLWHGFNMPRLVQCANVAPCPNIVDCYIARPTEKKIFTYFMVGASAVCIVLTICELCYLICHRVLRGLHKDKPRGGCSPSSSASRASTCRCHHKLVEAGEVDPDPGNNKLQASAPNLTPI
T16326	DRUGINFO	D00VJY	octanol	Investigative

T99351	TARGETID	T99351
T99351	FORMERID	TTDI02549
T99351	UNIPROID	SPI2_HUMAN
T99351	TARGNAME	Serpin I2 (SERPINI2)
T99351	GENENAME	SERPINI2
T99351	TARGTYPE	Literature-reported
T99351	SYNONYMS	Peptidase inhibitor 14; Pancreas-specific protein TSA2004; Pancpin; PI14; PI-14; Myoepithelium-derived serine protease inhibitor; MEPI
T99351	FUNCTION	A member of the plasminogen activator inhibitor-1 family, a subset of the serpin superfamily whose members act as tissue-specific tPA inhibitors.Plays central roles in the regulation of a wide variety of physiological processes, including coagulation, fibrinolysis, development, malignancy and inflammation. 
T99351	BIOCLASS	Serpin protein
T99351	SEQUENCE	MDTIFLWSLLLLFFGSQASRCSAQKNTEFAVDLYQEVSLSHKDNIIFSPLGITLVLEMVQLGAKGKAQQQIRQTLKQQETSAGEEFFVLKSFFSAISEKKQEFTFNLANALYLQEGFTVKEQYLHGNKEFFQSAIKLVDFQDAKACAEMISTWVERKTDGKIKDMFSGEEFGPLTRLVLVNAIYFKGDWKQKFRKEDTQLINFTKKNGSTVKIPMMKALLRTKYGYFSESSLNYQVLELSYKGDEFSLIIILPAEGMDIEEVEKLITAQQILKWLSEMQEEEVEISLPRFKVEQKVDFKDVLYSLNITEIFSGGCDLSGITDSSEVYVSQVTQKVFFEINEDGSEAATSTGIHIPVIMSLAQSQFIANHPFLFIMKHNPTESILFMGRVTNPDTQEIKGRDLDSL

T53890	TARGETID	T53890
T53890	FORMERID	TTDR01136
T53890	UNIPROID	PSD10_HUMAN
T53890	TARGNAME	Gankyrin (PSMD10)
T53890	GENENAME	PSMD10
T53890	TARGTYPE	Literature-reported
T53890	SYNONYMS	p28(GANK); 26S proteasome regulatory subunit p28; 26S proteasome non-ATPase regulatory subunit 10
T53890	FUNCTION	In the initial step of the base subcomplex assembly is part of an intermediate PSMD10:PSMC4:PSMC5:PAAF1 module which probably assembles with a PSMD5:PSMC2:PSMC1:PSMD2 module. Independently of the proteasome, regulates EGF-induced AKT activation through inhibition of the RHOA/ROCK/PTEN pathway, leading to prolonged AKT activation. Plays an important role in RAS-induced tumorigenesis. Acts as a chaperone during the assembly of the 26S proteasome, specifically of the PA700/19S regulatory complex (RC).
T53890	PDBSTRUC	5VHR; 5VHQ; 5VHP; 5VHO; 5VHN
T53890	SEQUENCE	MEGCVSNLMVCNLAYSGKLEELKESILADKSLATRTDQDSRTALHWACSAGHTEIVEFLLQLGVPVNDKDDAGWSPLHIAASAGRDEIVKALLGKGAQVNAVNQNGCTPLHYAASKNRHEIAVMLLEGGANPDAKDHYEATAMHRAAAKGNLKMIHILLYYKASTNIQDTEGNTPLHLACDEERVEEAKLLVSQGASIYIENKEEKTPLQVAKGGLGLILKRMVEG

T90360	TARGETID	T90360
T90360	FORMERID	TTDR00912
T90360	UNIPROID	SYUG_HUMAN
T90360	TARGNAME	Gamma-synuclein (SNCG)
T90360	GENENAME	SNCG
T90360	TARGTYPE	Literature-reported
T90360	SYNONYMS	Synoretin; Persyn; PRSN; Breast cancer-specific gene 1 protein; BCSG1
T90360	FUNCTION	May be involved in modulating axonal architecture during development and in the adult. In vitro, increases the susceptibility of neurofilament-H to calcium-dependent proteases. May also function in modulating the keratin network in skin. Activates the MAPK and Elk-1 signal transduction pathway. Plays a role in neurofilament network integrity.
T90360	BIOCLASS	Synuclein
T90360	SEQUENCE	MDVFKKGFSIAKEGVVGAVEKTKQGVTEAAEKTKEGVMYVGAKTKENVVQSVTSVAEKTKEQANAVSEAVVSSVNTVATKTVEEAENIAVTSGVVRKEDLRPSAPQQEGEASKEKEEVAEEAQSGGD

T59486	TARGETID	T59486
T59486	FORMERID	TTDNR00641
T59486	UNIPROID	ZFAN5_HUMAN
T59486	TARGNAME	AN1-type zinc finger protein 5 (ZFAND5)
T59486	GENENAME	ZFAND5
T59486	TARGTYPE	Literature-reported
T59486	SYNONYMS	Zinc finger protein 216; Zinc finger A20 domain-containing protein 2; ZNF216; ZA20D2
T59486	FUNCTION	May act by anchoring ubiquitinated proteins to the proteasome. Plays a role in ubiquitin-mediated protein degradation during muscle atrophy. Plays a role in the regulation of NF-kappa-B activation and apoptosis. Inhibits NF-kappa-B activation triggered by overexpression of RIPK1 and TRAF6 but not of RELA. Inhibits also tumor necrosis factor (TNF), IL-1 and TLR4-induced NF-kappa-B activation in a dose-dependent manner. Overexpression sensitizes cells to TNF-induced apoptosis. Is a potent inhibitory factor for osteoclast differentiation. Involved in protein degradation via the ubiquitin-proteasome system.
T59486	BIOCLASS	Zinc-finger
T59486	SEQUENCE	MAQETNQTPGPMLCSTGCGFYGNPRTNGMCSVCYKEHLQRQQNSGRMSPMGTASGSNSPTSDSASVQRADTSLNNCEGAAGSTSEKSRNVPVAALPVTQQMTEMSISREDKITTPKTEVSEPVVTQPSPSVSQPSTSQSEEKAPELPKPKKNRCFMCRKKVGLTGFDCRCGNLFCGLHRYSDKHNCPYDYKAEAAAKIRKENPVVVAEKIQRI

T53600	TARGETID	T53600
T53600	FORMERID	TTDR00614
T53600	UNIPROID	EF3_CANGA
T53600	TARGNAME	Candida Elongation factor 3 (Candi TEF3)
T53600	GENENAME	Candi TEF3
T53600	TARGTYPE	Literature-reported
T53600	SYNONYMS	TEF3; EF-3
T53600	FUNCTION	The main role of EF-3 may be to transduce nucleoside triphosphate energy into mechanical energy for translocation during translation. EF-3 stimulates EF-1-alpha-dependent binding of aminoacyl-tRNA to the ribosome.
T53600	BIOCLASS	ABC transporter
T53600	SEQUENCE	MTDSDQSLKVLEELFKNLSVATADNRVEAAQEVASFLNGNIIEHDIPEKFFEELAKAVKDKKTSANFLEAVAHIANEANLSPSVEPFVITLVPEICAKAGDKDKDVQAVASKTLVAISKAINPVAIKAYLPHLTKSLETTNKWQEKVSVLAAISALVDAAKEQVALRMPELIPVLSETMWDTKKEVKEAATATMTKATETVDNKDIERFIPQLISCIADPKQVPETVHLLGATTFVAEVTPATLSIMVPLLSRGLAERETSIKRKAAVIIDNMCKLVEDPQVVAPFLDKLLPGLKNNYATIADPEAREVTLRGLKTLRRVGNVTEDDVLPEISHAGDIETTLGVINELLKGENVAPRFKIVVEYIAAMAGDLIDERVIDQQAWFTHITPYMTIFMHERNAKDVLDEFRKRAVDNIPVGPNFDDEEDEGEDLCNCEFSLAYGAKILLNKTQLRLKRGRRYGLCGPNGAGKSTLMRAIANGQVDGFPTPEECMTVYVEHDIDGTHADTSVLDFVVSSEVGTKEAITAKLVEFGFTEEMINMPISSLSGGWKMKLALARAVLKNADILLLDEPTNHLDTVNVAWLVNYLNTCGITSVIVSHDSGFLDNVCQYIIHYEGLKLRKYKGNLSEFVKKCPTAQSYYELGASDLEFKFPEPGYLEGVKTKQKAIVKVSNMTFQYPGTSKPQISDISFQCSLSSRIAVIGPNGAGKSTLINVLTGELLPTSGEVYTHENCRIAYIKQHAFAHIESHLDKTPSEYIQWRFQTGEDRETMDRANRQINENDAEAMNKIFKIEGTPRRIAGIHARRKFKNTYEYECSFLLGENIGMKSERWVPMMSVDNAWIPRGELVESHSKMVAEVDMKEALASGQFRPLTRKEIEEHCAMLGLDAELVSHSRIRGLSGGQKVKLVLAACSWQRPHLIVLDEPTNYLDRDSLGALSKALKAFEGGVIIITHSAEFTKNLTEEVWAVKDGKMTPSGHNWVSGQGAGPRIEKKEDEEDKFDAMGNKIAGGKKKKKLSSAELRKKKKERMKKKKELGDAYVSSDDEDF

T71525	TARGETID	T71525
T71525	FORMERID	TTDR00494
T71525	UNIPROID	HEXI1_HUMAN
T71525	TARGNAME	Hexamethylene bis-acetamide-inducible protein 1 (HEXIM1)
T71525	GENENAME	HEXIM1
T71525	TARGTYPE	Literature-reported
T71525	SYNONYMS	Protein HEXIM1; Menage a quatre protein 1; MAQ1; HIS1; Estrogen down-regulated gene 1 protein; EDG1; Cardiac lineage protein 1; CLP1
T71525	FUNCTION	Transcriptional regulator which functions as a general RNA polymerase II transcription inhibitor. In cooperation with 7SK snRNA sequesters P-TEFb in a large inactive 7SK snRNP complex preventing RNA polymerase II phosphorylation and subsequent transcriptional elongation. May also regulate NF-kappa-B, ESR1, NR3C1 and CIITA-dependent transcriptional activity. Plays a role in the regulation of DNA virus-mediated innate immune response by assembling into the HDP-RNP complex, a complex that serves as a platform for IRF3 phosphorylation and subsequent innate immune response activation through the cGAS-STING pathway.
T71525	PDBSTRUC	3S9G; 2GD7
T71525	SEQUENCE	MAEPFLSEYQHQPQTSNCTGAAAVQEELNPERPPGAEERVPEEDSRWQSRAFPQLGGRPGPEGEGSLESQPPPLQTQACPESSCLREGEKGQNGDDSSAGGDFPPPAEVEPTPEAELLAQPCHDSEASKLGAPAAGGEEEWGQQQRQLGKKKHRRRPSKKKRHWKPYYKLTWEEKKKFDEKQSLRASRIRAEMFAKGQPVAPYNTTQFLMDDHDQEEPDLKTGLYSKRAAAKSDDTSDDDFMEEGGEEDGGSDGMGGDGSEFLQRDFSETYERYHTESLQNMSKQELIKEYLELEKCLSRMEDENNRLRLESKRLGGDDARVRELELELDRLRAENLQLLTENELHRQQERAPLSKFGD

T15914	TARGETID	T15914
T15914	FORMERID	TTDR01121
T15914	UNIPROID	ZN202_HUMAN
T15914	TARGNAME	Zinc finger protein 202 (ZNF202)
T15914	GENENAME	ZNF202
T15914	TARGTYPE	Literature-reported
T15914	SYNONYMS	Zinc finger protein ZNF202; ZNF202
T15914	FUNCTION	Transcriptional repressor that binds to elements found predominantly in genes that participate in lipid metabolism. Among its targets are structural components of lipoprotein particles (apolipoproteins AIV, CIII, and E), enzymes involved in lipidprocessing (lipoprotein lipase, lecithin cholesteryl ester transferase), transporters involved in lipid homeostasis (ABCA1, ABCG1), and several genes involved in processes related to energy metabolism and vascular disease.
T15914	BIOCLASS	Zinc-finger
T15914	SEQUENCE	MATAVEPEDQDLWEEEGILMVKLEDDFTCRPESVLQRDDPVLETSHQNFRRFRYQEAASPREALIRLRELCHQWLRPERRTKEQILELLVLEQFLTVLPGELQSWVRGQRPESGEEAVTLVEGLQKQPRRPRRWVTVHVHGQEVLSEETVHLGVEPESPNELQDPVQSSTPEQSPEETTQSPDLGAPAEQRPHQEEELQTLQESEVPVPEDPDLPAERSSGDSEMVALLTALSQGLVTFKDVAVCFSQDQWSDLDPTQKEFYGEYVLEEDCGIVVSLSFPIPRPDEISQVREEEPWVPDIQEPQETQEPEILSFTYTGDRSKDEEECLEQEDLSLEDIHRPVLGEPEIHQTPDWEIVFEDNPGRLNERRFGTNISQVNSFVNLRETTPVHPLLGRHHDCSVCGKSFTCNSHLVRHLRTHTGEKPYKCMECGKSYTRSSHLARHQKVHKMNAPYKYPLNRKNLEETSPVTQAERTPSVEKPYRCDDCGKHFRWTSDLVRHQRTHTGEKPFFCTICGKSFSQKSVLTTHQRIHLGGKPYLCGECGEDFSEHRRYLAHRKTHAAEELYLCSECGRCFTHSAAFAKHLRGHASVRPCRCNECGKSFSRRDHLVRHQRTHTGEKPFTCPTCGKSFSRGYHLIRHQRTHSEKTS

T49888	TARGETID	T49888
T49888	FORMERID	TTDI02625
T49888	UNIPROID	ELP1_HUMAN
T49888	TARGNAME	IKK complex-associated protein (IKBKAP)
T49888	GENENAME	IKBKAP
T49888	TARGTYPE	Literature-reported
T49888	SYNONYMS	IkappaB kinase complexassociated protein; IkappaB kinase complex-associated protein; IKK complexassociated protein; IKAP; Elongator complex protein 1; ELP1
T49888	FUNCTION	May act as a scaffold protein that may assemble active IKK-MAP3K14 complexes (IKKA, IKKB and MAP3K14/NIK).
T49888	PDBSTRUC	5CQR
T49888	SEQUENCE	MRNLKLFRTLEFRDIQGPGNPQCFSLRTEQGTVLIGSEHGLIEVDPVSREVKNEVSLVAEGFLPEDGSGRIVGVQDLLDQESVCVATASGDVILCSLSTQQLECVGSVASGISVMSWSPDQELVLLATGQQTLIMMTKDFEPILEQQIHQDDFGESKFITVGWGRKETQFHGSEGRQAAFQMQMHESALPWDDHRPQVTWRGDGQFFAVSVVCPETGARKVRVWNREFALQSTSEPVAGLGPALAWKPSGSLIASTQDKPNQQDIVFFEKNGLLHGHFTLPFLKDEVKVNDLLWNADSSVLAVWLEDLQREESSIPKTCVQLWTVGNYHWYLKQSLSFSTCGKSKIVSLMWDPVTPYRLHVLCQGWHYLAYDWHWTTDRSVGDNSSDLSNVAVIDGNRVLVTVFRQTVVPPPMCTYQLLFPHPVNQVTFLAHPQKSNDLAVLDASNQISVYKCGDCPSADPTVKLGAVGGSGFKVCLRTPHLEKRYKIQFENNEDQDVNPLKLGLLTWIEEDVFLAVSHSEFSPRSVIHHLTAASSEMDEEHGQLNVSSSAAVDGVIISLCCNSKTKSVVLQLADGQIFKYLWESPSLAIKPWKNSGGFPVRFPYPCTQTELAMIGEEECVLGLTDRCRFFINDIEVASNITSFAVYDEFLLLTTHSHTCQCFCLRDASFKTLQAGLSSNHVSHGEVLRKVERGSRIVTVVPQDTKLVLQMPRGNLEVVHHRALVLAQIRKWLDKLMFKEAFECMRKLRINLNLIYDHNPKVFLGNVETFIKQIDSVNHINLFFTELKEEDVTKTMYPAPVTSSVYLSRDPDGNKIDLVCDAMRAVMESINPHKYCLSILTSHVKKTTPELEIVLQKVHELQGNAPSDPDAVSAEEALKYLLHLVDVNELYDHSLGTYDFDLVLMVAEKSQKDPKEYLPFLNTLKKMETNYQRFTIDKYLKRYEKAIGHLSKCGPEYFPECLNLIKDKNLYNEALKLYSPSSQQYQDISIAYGEHLMQEHMYEPAGLMFARCGAHEKALSAFLTCGNWKQALCVAAQLNFTKDQLVGLGRTLAGKLVEQRKHIDAAMVLEECAQDYEEAVLLLLEGAAWEEALRLVYKYNRLDIIETNVKPSILEAQKNYMAFLDSQTATFSRHKKRLLVVRELKEQAQQAGLDDEVPHGQESDLFSETSSVVSGSEMSGKYSHSNSRISARSSKNRRKAERKKHSLKEGSPLEDLALLEALSEVVQNTENLKDEVYHILKVLFLFEFDEQGRELQKAFEDTLQLMERSLPEIWTLTYQQNSATPVLGPNSTANSIMASYQQQKTSVPVLDAELFIPPKINRRTQWKLSLLD

T63743	TARGETID	T63743
T63743	FORMERID	TTDNR00756
T63743	UNIPROID	SMC2_HUMAN
T63743	TARGNAME	Structural maintenance of chromosomes protein 2 (SMC2)
T63743	GENENAME	SMC2
T63743	TARGTYPE	Literature-reported
T63743	SYNONYMS	hCAP-E; XCAP-E homolog; SMC2L1; SMC-2; SMC protein 2; PRO0324; Chromosome-associated protein E; CAPE
T63743	FUNCTION	The condensin complex probably introduces positive supercoils into relaxed DNA in the presence of type I topoisomerases and converts nicked DNA into positive knotted forms in the presence of type II topoisomerases. Central component of the condensin complex, a complex required for conversion of interphase chromatin into mitotic-like condense chromosomes.
T63743	PDBSTRUC	4U4P
T63743	SEQUENCE	MHIKSIILEGFKSYAQRTEVNGFDPLFNAITGLNGSGKSNILDSICFLLGISNLSQVRASNLQDLVYKNGQAGITKASVSITFDNSDKKQSPLGFEVHDEITVTRQVVIGGRNKYLINGVNANNTRVQDLFCSVGLNVNNPHFLIMQGRITKVLNMKPPEILSMIEEAAGTRMYEYKKIAAQKTIEKKEAKLKEIKTILEEEITPTIQKLKEERSSYLEYQKVMREIEHLSRLYIAYQFLLAEDTKVRSAEELKEMQDKVIKLQEELSENDKKIKALNHEIEELEKRKDKETGGILRSLEDALAEAQRVNTKSQSAFDLKKKNLACEESKRKELEKNMVEDSKTLAAKEKEVKKITDGLHALQEASNKDAEALAAAQQHFNAVSAGLSSNEDGAEATLAGQMMACKNDISKAQTEAKQAQMKLKHAQQELKNKQAEVKKMDSGYRKDQEALEAVKRLKEKLEAEMKKLNYEENKEESLLEKRRQLSRDIGRLKETYEALLARFPNLRFAYKDPEKNWNRNCVKGLVASLISVKDTSATTALELVAGERLYNVVVDTEVTGKKLLERGELKRRYTIIPLNKISARCIAPETLRVAQNLVGPDNVHVALSLVEYKPELQKAMEFVFGTTFVCDNMDNAKKVAFDKRIMTRTVTLGGDVFDPHGTLSGGARSQAASILTKFQELKDVQDELRIKENELRALEEELAGLKNTAEKYRQLKQQWEMKTEEADLLQTKLQQSSYHKQQEELDALKKTIEESEETLKNTKEIQRKAEEKYEVLENKMKNAEAERERELKDAQKKLDCAKTKADASSKKMKEKQQEVEAITLELEELKREHTSYKQQLEAVNEAIKSYESQIEVMAAEVAKNKESVNKAQEEVTKQKEVITAQDTVIKAKYAEVAKHKEQNNDSQLKIKELDHNISKHKREAEDGAAKVSKMLKDYDWINAERHLFGQPNSAYDFKTNNPKEAGQRLQKLQEMKEKLGRNVNMRAMNVLTEAEERYNDLMKKKRIVENDKSKILTTIEDLDQKKNQALNIAWQKVNKDFGSIFSTLLPGANAMLAPPEGQTVLDGLEFKVALGNTWKENLTELSGGQRSLVALSLILSMLLFKPAPIYILDEVDAALDLSHTQNIGQMLRTHFTHSQFIVVSLKEGMFNNANVLFKTKFVDGVSTVARFTQCQNGKISKEAKSKAKPPKGAHVEV

T20302	TARGETID	T20302
T20302	FORMERID	TTDI00170
T20302	UNIPROID	ATG7_HUMAN
T20302	TARGNAME	Autophagy-related protein 7 (ATG7)
T20302	GENENAME	ATG7
T20302	TARGTYPE	Literature-reported
T20302	SYNONYMS	hAGP7; Ubiquitin-like modifier-activating enzyme ATG7; Ubiquitin-activating enzyme E1-like protein; ATG12-activating enzyme E1 ATG7; APG7L; APG7-like
T20302	FUNCTION	Activates ATG12 for its conjugation with ATG5 as well as the ATG8 family proteins for their conjugation with phosphatidylethanolamine. Both systems are needed for the ATG8 association to Cvt vesicles and autophagosomes membranes. Required for autophagic death induced by caspase-8 inhibition. Required for mitophagy which contributes to regulate mitochondrial quantity and quality by eliminating the mitochondria to a basal level to fulfill cellular energy requirements and preventing excess ROS production. Modulates p53/TP53 activity to regulate cell cycle and survival during metabolic stress. Plays also a key role in the maintenance of axonal homeostasis, the prevention of axonal degeneration, the maintenance of hematopoietic stem cells, the formation of Paneth cell granules, as well as in adipose differentiation. Plays a role in regulating the liver clock and glucose metabolism by mediating the autophagic degradation of CRY1 (clock repressor) in a time-dependent manner. E1-like activating enzyme involved in the 2 ubiquitin-like systems required for cytoplasm to vacuole transport (Cvt) and autophagy.
T20302	BIOCLASS	Autophagy phagophore-formation transporter
T20302	SEQUENCE	MAAATGDPGLSKLQFAPFSSALDVGFWHELTQKKLNEYRLDEAPKDIKGYYYNGDSAGLPARLTLEFSAFDMSAPTPARCCPAIGTLYNTNTLESFKTADKKLLLEQAANEIWESIKSGTALENPVLLNKFLLLTFADLKKYHFYYWFCYPALCLPESLPLIQGPVGLDQRFSLKQIEALECAYDNLCQTEGVTALPYFLIKYDENMVLVSLLKHYSDFFQGQRTKITIGVYDPCNLAQYPGWPLRNFLVLAAHRWSSSFQSVEVVCFRDRTMQGARDVAHSIIFEVKLPEMAFSPDCPKAVGWEKNQKGGMGPRMVNLSECMDPKRLAESSVDLNLKLMCWRLVPTLDLDKVVSVKCLLLGAGTLGCNVARTLMGWGVRHITFVDNAKISYSNPVRQPLYEFEDCLGGGKPKALAAADRLQKIFPGVNARGFNMSIPMPGHPVNFSSVTLEQARRDVEQLEQLIESHDVVFLLMDTRESRWLPAVIAASKRKLVINAALGFDTFVVMRHGLKKPKQQGAGDLCPNHPVASADLLGSSLFANIPGYKLGCYFCNDVVAPGDSTRDRTLDQQCTVSRPGLAVIAGALAVELMVSVLQHPEGGYAIASSSDDRMNEPPTSLGLVPHQIRGFLSRFDNVLPVSLAFDKCTACSSKVLDQYEREGFNFLAKVFNSSHSFLEDLTGLTLLHQETQAAEIWDMSDDETI

T76062	TARGETID	T76062
T76062	FORMERID	TTDI03133
T76062	UNIPROID	CXB5_HUMAN
T76062	TARGNAME	Gap junction beta-5 protein (Cx31.1)
T76062	GENENAME	GJB5
T76062	TARGTYPE	Literature-reported
T76062	SYNONYMS	Connexin-31.1
T76062	FUNCTION	One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell.
T76062	BIOCLASS	Gap junction-forming connexin
T76062	SEQUENCE	MNWSIFEGLLSGVNKYSTAFGRIWLSLVFIFRVLVYLVTAERVWSDDHKDFDCNTRQPGCSNVCFDEFFPVSHVRLWALQLILVTCPSLLVVMHVAYREVQEKRHREAHGENSGRLYLNPGKKRGGLWWTYVCSLVFKASVDIAFLYVFHSFYPKYILPPVVKCHADPCPNIVDCFISKPSEKNIFTLFMVATAAICILLNLVELIYLVSKRCHECLAARKAQAMCTGHHPHGTTSSCKQDDLLSGDLIFLGSDSHPPLLPDRPRDHVKKTIL
T76062	DRUGINFO	D00VJY	octanol	Investigative

T35283	TARGETID	T35283
T35283	FORMERID	TTDI03383
T35283	UNIPROID	M3K6_HUMAN
T35283	TARGNAME	Apoptosis signal-regulating kinase 2 (MAP3K6)
T35283	GENENAME	MAP3K6
T35283	TARGTYPE	Literature-reported
T35283	SYNONYMS	MAP3K6
T35283	FUNCTION	Component of a protein kinase signal transduction cascade. Activates the JNK, but not ERK or p38 kinase pathways.
T35283	ECNUMBER	EC 2.7.11.25
T35283	SEQUENCE	MAGPCPRSGAERAGSCWQDPLAVALSRGRQLAAPPGRGCARSRPLSVVYVLTREPQPGLEPREGTEAEPLPLRCLREACAQVPRPRPPPQLRSLPFGTLELGDTAALDAFYNADVVVLEVSSSLVQPSLFYHLGVRESFSMTNNVLLCSQADLPDLQALREDVFQKNSDCVGSYTLIPYVVTATGRVLCGDAGLLRGLADGLVQAGVGTEALLTPLVGRLARLLEATPTDSCGYFRETIRRDIRQARERFSGPQLRQELARLQRRLDSVELLSPDIIMNLLLSYRDVQDYSAIIELVETLQALPTCDVAEQHNVCFHYTFALNRRNRPGDRAKALSVLLPLVQLEGSVAPDLYCMCGRIYKDMFFSSGFQDAGHREQAYHWYRKAFDVEPSLHSGINAAVLLIAAGQHFEDSKELRLIGMKLGCLLARKGCVEKMQYYWDVGFYLGAQILANDPTQVVLAAEQLYKLNAPIWYLVSVMETFLLYQHFRPTPEPPGGPPRRAHFWLHFLLQSCQPFKTACAQGDQCLVLVLEMNKVLLPAKLEVRGTDPVSTVTLSLLEPETQDIPSSWTFPVASICGVSASKRDERCCFLYALPPAQDVQLCFPSVGHCQWFCGLIQAWVTNPDSTAPAEEAEGAGEMLEFDYEYTETGERLVLGKGTYGVVYAGRDRHTRVRIAIKEIPERDSRFSQPLHEEIALHRRLRHKNIVRYLGSASQGGYLKIFMEEVPGGSLSSLLRSVWGPLKDNESTISFYTRQILQGLGYLHDNHIVHRDIKGDNVLINTFSGLLKISDFGTSKRLAGITPCTETFTGTLQYMAPEIIDQGPRGYGKAADIWSLGCTVIEMATGRPPFHELGSPQAAMFQVGMYKVHPPMPSSLSAEAQAFLLRTFEPDPRLRASAQTLLGDPFLQPGKRSRSPSSPRHAPRPSDAPSASPTPSANSTTQSQTFPCPQAPSQHPPSPPKRCLSYGGTSQLRVPEEPAAEEPASPEESSGLSLLHQESKRRAMLAAVLEQELPALAENLHQEQKQEQGARLGRNHVEELLRCLGAHIHTPNRRQLAQELRALQGRLRAQGLGPALLHRPLFAFPDAVKQILRKRQIRPHWMFVLDSLLSRAVRAALGVLGPEVEKEAVSPRSEELSNEGDSQQSPGQQSPLPVEPEQGPAPLMVQLSLLRAETDRLREILAGKEREYQALVQRALQRLNEEARTYVLAPEPPTALSTDQGLVQWLQELNVDSGTIQMLLNHSFTLHTLLTYATRDDLIYTRIRGGMVCRIWRAILAQRAGSTPVTSGP
T35283	DRUGINFO	D0Q0YV	PMID23147077C10	Investigative

T23655	TARGETID	T23655
T23655	FORMERID	TTDR00820
T23655	UNIPROID	WISP3_HUMAN
T23655	TARGNAME	Cellular communication network factor 6 (CCN6)
T23655	GENENAME	WISP3
T23655	TARGTYPE	Literature-reported
T23655	SYNONYMS	WNT1 inducible signaling pathway protein 3; WISP3; WISP-3; UNQ462/PRO790
T23655	FUNCTION	Appears to be required for normal postnatal skeletal growth and cartilage homeostasis.
T23655	BIOCLASS	Growth factor
T23655	SEQUENCE	MQGLLFSTLLLAGLAQFCCRVQGTGPLDTTPEGRPGEVSDAPQRKQFCHWPCKCPQQKPRCPPGVSLVRDGCGCCKICAKQPGEICNEADLCDPHKGLYCDYSVDRPRYETGVCAYLVAVGCEFNQVHYHNGQVFQPNPLFSCLCVSGAIGCTPLFIPKLAGSHCSGAKGGKKSDQSNCSLEPLLQQLSTSYKTMPAYRNLPLIWKKKCLVQATKWTPCSRTCGMGISNRVTNENSNCEMRKEKRLCYIQPCDSNILKTIKIPKGKTCQPTFQLSKAEKFVFSGCSSTQSYKPTFCGICLDKRCCIPNKSKMITIQFDCPNEGSFKWKMLWITSCVCQRNCREPGDIFSELKIL

T19110	TARGETID	T19110
T19110	FORMERID	TTDI02027
T19110	UNIPROID	BMP10_HUMAN
T19110	TARGNAME	Bone morphogenetic protein 10 (BMP10)
T19110	GENENAME	BMP10
T19110	TARGTYPE	Literature-reported
T19110	SYNONYMS	BMP10
T19110	FUNCTION	Required for maintaining the proliferative activity of embryonic cardiomyocytes by preventing premature activation of the negative cell cycle regulator CDKN1C/p57KIP and maintaining the required expression levels of cardiogenic factors such as MEF2C and NKX2-5. Acts as a ligand for ACVRL1/ALK1, BMPR1A/ALK3 and BMPR1B/ALK6, leading to activation of SMAD1, SMAD5 and SMAD8 transcription factors. Inhibits endothelial cell migration and growth. May reduce cell migration and cell matrix adhesion in breast cancer cell lines.
T19110	BIOCLASS	Growth factor
T19110	SEQUENCE	MGSLVLTLCALFCLAAYLVSGSPIMNLEQSPLEEDMSLFGDVFSEQDGVDFNTLLQSMKDEFLKTLNLSDIPTQDSAKVDPPEYMLELYNKFATDRTSMPSANIIRSFKNEDLFSQPVSFNGLRKYPLLFNVSIPHHEEVIMAELRLYTLVQRDRMIYDGVDRKITIFEVLESKGDNEGERNMLVLVSGEIYGTNSEWETFDVTDAIRRWQKSGSSTHQLEVHIESKHDEAEDASSGRLEIDTSAQNKHNPLLIVFSDDQSSDKERKEELNEMISHEQLPELDNLGLDSFSSGPGEEALLQMRSNIIYDSTARIRRNAKGNYCKRTPLYIDFKEIGWDSWIIAPPGYEAYECRGVCNYPLAEHLTPTKHAIIQALVHLKNSQKASKACCVPTKLEPISILYLDKGVVTYKFKYEGMAVSECGCR

T02346	TARGETID	T02346
T02346	FORMERID	TTDR00574
T02346	UNIPROID	UTS2_HUMAN
T02346	TARGNAME	Urotensin II (UTS2)
T02346	GENENAME	UTS2
T02346	TARGTYPE	Literature-reported
T02346	SYNONYMS	Urotensin-II; UTS2; UII; U-II; HU-II
T02346	FUNCTION	Highly potent vasoconstrictor.
T02346	PDBSTRUC	6HVC; 6HVB
T02346	SEQUENCE	MYKLASCCLLFIGFLNPLLSLPLLDSREISFQLSAPHEDARLTPEELERASLLQILPEMLGAERGDILRKADSSTNIFNPRGNLRKFQDFSGQDPNILLSHLLARIWKPYKKRETPDCFWKYCV

T24820	TARGETID	T24820
T24820	FORMERID	TTDI03129
T24820	UNIPROID	CXB6_HUMAN
T24820	TARGNAME	Connexin-30 (Cx30)
T24820	GENENAME	GJB6
T24820	TARGTYPE	Literature-reported
T24820	SYNONYMS	Gap junction beta-6 protein
T24820	FUNCTION	One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell.
T24820	BIOCLASS	Gap junction-forming connexin
T24820	SEQUENCE	MDWGTLHTFIGGVNKHSTSIGKVWITVIFIFRVMILVVAAQEVWGDEQEDFVCNTLQPGCKNVCYDHFFPVSHIRLWALQLIFVSTPALLVAMHVAYYRHETTRKFRRGEKRNDFKDIEDIKKQKVRIEGSLWWTYTSSIFFRIIFEAAFMYVFYFLYNGYHLPWVLKCGIDPCPNLVDCFISRPTEKTVFTIFMISASVICMLLNVAELCYLLLKVCFRRSKRAQTQKNHPNHALKESKQNEMNELISDSGQNAITGFPS
T24820	DRUGINFO	D00VJY	octanol	Investigative

T89359	TARGETID	T89359
T89359	FORMERID	TTDR00856
T89359	UNIPROID	FSTL3_HUMAN
T89359	TARGNAME	Follistatin-related protein 3 (FSTL3)
T89359	GENENAME	FSTL3
T89359	TARGTYPE	Literature-reported
T89359	SYNONYMS	UNQ674/PRO1308; Follistatin-related gene protein; Follistatin-related gene; Follistatin-like 3; FSTL3; FLRG
T89359	FUNCTION	Isoform 1 or the secreted form is a binding and antagonizing protein for members of the TGF-beta family, such us activin, BMP2 and MSTN. Inhibits activin A-, activin B-, BMP2- and MSDT-induced cellular signaling; more effective on activin Athan on activin B. Involved in bone formation; inhibits osteoclast differentiationc. Involved in hematopoiesis; involved in differentiation of hemopoietic progenitor cells, increases hematopoietic cell adhesion to fibronectin and seems to contribute to the adhesion of hematopoietic precursor cells to the bone marrow stroma. Isoform 2 or the nuclear form is probably involved in transcriptional regulation via interaction with MLLT10.
T89359	PDBSTRUC	3SEK; 3B4V; 2KCX
T89359	SEQUENCE	MRPGAPGPLWPLPWGALAWAVGFVSSMGSGNPAPGGVCWLQQGQEATCSLVLQTDVTRAECCASGNIDTAWSNLTHPGNKINLLGFLGLVHCLPCKDSCDGVECGPGKACRMLGGRPRCECAPDCSGLPARLQVCGSDGATYRDECELRAARCRGHPDLSVMYRGRCRKSCEHVVCPRPQSCVVDQTGSAHCVVCRAAPCPVPSSPGQELCGNNNVTYISSCHMRQATCFLGRSIGVRHAGSCAGTPEEPPGGESAEEEENFV

T72319	TARGETID	T72319
T72319	FORMERID	TTDI00148
T72319	UNIPROID	CBX7_HUMAN
T72319	TARGNAME	Chromobox protein homolog 7 (CBX7)
T72319	GENENAME	CBX7
T72319	TARGTYPE	Literature-reported
T72319	SYNONYMS	Chromobox 7
T72319	FUNCTION	PcG PRC1 complex acts via chromatin remodeling and modification of histones; it mediates monoubiquitination of histone H2A 'Lys-119', rendering chromatin heritably changed in its expressibility. Promotes histone H3 trimethylation at 'Lys-9' (H3K9me3). Binds to trimethylated lysine residues in histones, and possibly also other proteins. Regulator of cellular lifespan by maintaining the repression of CDKN2A, but not by inducing telomerase activity. Component of a Polycomb group (PcG) multiprotein PRC1-like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development.
T72319	PDBSTRUC	5EPJ; 4MN3; 3GS2; 2L1B; 2L12
T72319	SEQUENCE	MELSAIGEQVFAVESIRKKRVRKGKVEYLVKWKGWPPKYSTWEPEEHILDPRLVMAYEEKEERDRASGYRKRGPKPKRLLLQRLYSMDLRSSHKAKGKEKLCFSLTCPLGSGSPEGVVKAGAPELVDKGPLVPTLPFPLRKPRKAHKYLRLSRKKFPPRGPNLESHSHRRELFLQEPPAPDVLQAAGEWEPAAQPPEEEADADLAEGPPPWTPALPSSEVTVTDITANSITVTFREAQAAEGFFRDRSGKF

T46824	TARGETID	T46824
T46824	FORMERID	TTDI02597
T46824	UNIPROID	SG1D2_HUMAN
T46824	TARGNAME	Lipophilin-B (SCGB1D2)
T46824	GENENAME	SCGB1D2
T46824	TARGTYPE	Literature-reported
T46824	SYNONYMS	Secretoglobin family 1D member 2; SCGB1D2
T46824	FUNCTION	May bind androgens and other steroids, may also bind estramustine, a chemotherapeutic agent used for prostate cancer. May be under transcriptional regulation of steroid hormones.
T46824	BIOCLASS	Secretoglobin family
T46824	SEQUENCE	MKLSVCLLLVTLALCCYQANAEFCPALVSELLDFFFISEPLFKLSLAKFDAPPEAVAAKLGVKRCTDQMSLQKRSLIAEVLVKILKKCSV

T34352	TARGETID	T34352
T34352	FORMERID	TTDI02400
T34352	UNIPROID	AGR2_HUMAN
T34352	TARGNAME	Anterior gradient protein 2 (AG-2)
T34352	GENENAME	AGR2
T34352	TARGTYPE	Literature-reported
T34352	SYNONYMS	hAG2; Secreted cement gland protein XAG2 homolog; AGR2; AG2
T34352	FUNCTION	Required for MUC2 post-transcriptional synthesis and secretion. May play a role in the production of mucus by intestinal cells. Proto-oncogene that may play a role in cell migration, cell differentiation and cell growth.
T34352	PDBSTRUC	2LNT; 2LNS
T34352	SEQUENCE	MEKIPVSAFLLLVALSYTLARDTTVKPGAKKDTKDSRPKLPQTLSRGWGDQLIWTQTYEEALYKSKTSNKPLMIIHHLDECPHSQALKKVFAENKEIQKLAEQFVLLNLVYETTDKHLSPDGQYVPRIMFVDPSLTVRADITGRYSNRLYAYEPADTALLLDNMKKALKLLKTEL

T88991	TARGETID	T88991
T88991	FORMERID	TTDR00767
T88991	UNIPROID	O96438_CRIFA
T88991	TARGNAME	Crithidia Tryparedoxin (Crithi TryX)
T88991	GENENAME	Crithi TryX
T88991	TARGTYPE	Literature-reported
T88991	SYNONYMS	Tryparedoxin I
T88991	FUNCTION	Mediates the flux of reduction equivalents from the unique redox metabolite trypanothione
T88991	PDBSTRUC	1QK8; 1OKD; 1O8X; 1O8W; 1O85
T88991	SEQUENCE	MSGLDKYLPGIEKLRRGDGEVEVKSLAGKLVFFYFSASWCPPCRGFTPQLIEFYDKFHESKNFEVVFCTWDEEEDGFAGYFAKMPWLAVPFAQSEAVQKLSKHFNVESIPTLIGVDADSGDVVTTRARATLVKDPEGEQFPWKDAP

T88057	TARGETID	T88057
T88057	FORMERID	TTDR00133
T88057	UNIPROID	LDHA_HUMAN; LDHB_HUMAN; LDHC_HUMAN
T88057	TARGNAME	L-lactate dehydrogenase (LDH)
T88057	GENENAME	LDHA; LDHB; LDHC
T88057	TARGTYPE	Literature-reported
T88057	SYNONYMS	Renal carcinoma antigen NY-REN; LDH
T88057	FUNCTION	Catalyzes the conversion of lactate to pyruvate and back, as it converts NAD+ to NADH and back. Expressed extensively in body tissues, such as blood cells and heart muscle. Functions asa marker of common injuries and disease such as heart failure  because it is released during tissue damage
T88057	BIOCLASS	Short-chain dehydrogenases reductase
T88057	SEQUENCE	MATLKDQLIYNLLKEEQTPQNKITVVGVGAVGMACAISILMKDLADELALVDVIEDKLKGEMMDLQHGSLFLRTPKIVSGKDYNVTANSKLVIITAGARQQEGESRLNLVQRNVNIFKFIIPNVVKYSPNCKLLIVSNPVDILTYVAWKISGFPKNRVIGSGCNLDSARFRYLMGERLGVHPLSCHGWVLGEHGDSSVPVWSGMNVAGVSLKTLHPDLGTDKDKEQWKEVHKQVVESAYEVIKLKGYTSWAIGLSVADLAESIMKNLRRVHPVSTMIKGLYGIKDDVFLSVPCILGQNGISDLVKVTLTSEEEARLKKSADTLWGIQKELQF
T88057	DRUGINFO	D01PLP	3,7-DIHYDROXYNAPHTHALENE-2-CARBOXYLIC ACID	Investigative
T88057	DRUGINFO	D03IMZ	4-Hydroxy-1,2,5-Oxadiazole-3-Carboxylic Acid	Investigative
T88057	DRUGINFO	D09EDP	3-Hydroxyisoxazole-4-Carboxylic Acid	Investigative
T88057	DRUGINFO	D0M6CB	Naphthalene-2,6-disulfonic acid	Investigative
T88057	DRUGINFO	D0T3PV	4-Hydroxy-1,2,5-Thiadiazole-3-Carboxylic Acid	Investigative
T88057	DRUGINFO	D0LP2H	OXAMATE	Investigative
T88057	DRUGINFO	D0R6JE	Nicotinamide-Adenine-Dinucleotide	Investigative

T37384	TARGETID	T37384
T37384	FORMERID	TTDR00028
T37384	UNIPROID	CDK1_YEAST
T37384	TARGNAME	Saccharomyces Cell division control protein 28 (Saccha CDC28)
T37384	GENENAME	Saccha CDC28
T37384	TARGTYPE	Literature-reported
T37384	SYNONYMS	YBR160W; YBR1211; SRM5; HSL5; Cyclindependent kinase 1 of Saccharomyces cerevisiae; Cell division protein kinase 1; Cell division control protein 28; CDK1 of Saccharomyces cerevisiae; CDK1; CDC28
T37384	FUNCTION	More than 200 substrates have been identified. This protein is essential for the completion of the start, the controlling event, in the cell cycle.
T37384	BIOCLASS	Kinase
T37384	SEQUENCE	MSGELANYKRLEKVGEGTYGVVYKALDLRPGQGQRVVALKKIRLESEDEGVPSTAIREISLLKELKDDNIVRLYDIVHSDAHKLYLVFEFLDLDLKRYMEGIPKDQPLGADIVKKFMMQLCKGIAYCHSHRILHRDLKPQNLLINKDGNLKLGDFGLARAFGVPLRAYTHEIVTLWYRAPEVLLGGKQYSTGVDTWSIGCIFAEMCNRKPIFSGDSEIDQIFKIFRVLGTPNEAIWPDIVYLPDFKPSFPQWRRKDLSQVVPSLDPRGIDLLDKLLAYDPINRISARRAAIHPYFQES
T37384	DRUGINFO	D03EIM	Borrelidin	Investigative

T12938	TARGETID	T12938
T12938	FORMERID	TTDI01392
T12938	UNIPROID	LALBA_HUMAN
T12938	TARGNAME	Lactalbumin alpha (LALBA)
T12938	GENENAME	LALBA
T12938	TARGTYPE	Literature-reported
T12938	SYNONYMS	Lysozyme-like protein 7; Lactose synthase B protein; LYZL7; Alpha-lactalbumin
T12938	FUNCTION	Regulatory subunit of lactose synthase, changes the substrate specificity of galactosyltransferase in the mammary gland making glucose a good acceptor substrate for this enzyme. This enables LS to synthesize lactose, the major carbohydrate component of milk. In other tissues, galactosyltransferase transfers galactose onto the N-acetylglucosamine of the oligosaccharide chains in glycoproteins.
T12938	PDBSTRUC	4L41; 3B0O; 3B0I; 1HML; 1CB3
T12938	SEQUENCE	MRFFVPLFLVGILFPAILAKQFTKCELSQLLKDIDGYGGIALPELICTMFHTSGYDTQAIVENNESTEYGLFQISNKLWCKSSQVPQSRNICDISCDKFLDDDITDDIMCAKKILDIKGIDYWLAHKALCTEKLEQWLCEKL

T20975	TARGETID	T20975
T20975	FORMERID	TTDR00262
T20975	UNIPROID	NEU2_HUMAN
T20975	TARGNAME	Arginine vasopressin (AVP)
T20975	GENENAME	AVP
T20975	TARGTYPE	Literature-reported
T20975	SYNONYMS	Vasopressin-neurophysin 2-copeptin; VP; Copeptin; AVP-NPII; ARVP
T20975	FUNCTION	Neurophysin 2 specifically binds vasopressin.
T20975	SEQUENCE	MPDTMLPACFLGLLAFSSACYFQNCPRGGKRAMSDLELRQCLPCGPGGKGRCFGPSICCADELGCFVGTAEALRCQEENYLPSPCQSGQKACGSGGRCAAFGVCCNDESCVTEPECREGFHRRARASDRSNATQLDGPAGALLLRLVQLAGAPEPFEPAQPDAY

T88213	TARGETID	T88213
T88213	FORMERID	TTDI02558
T88213	UNIPROID	VIP_HUMAN
T88213	TARGNAME	Vasoactive intestinal polypeptide (VIP)
T88213	GENENAME	VIP
T88213	TARGTYPE	Literature-reported
T88213	SYNONYMS	Vasoactive intestinal peptide; VIP peptides; Peptide histidine valine 42; Intestinal peptide PHV-42
T88213	FUNCTION	VIP causes vasodilation, lowers arterial blood pressure, stimulates myocardial contractility, increases glycogenolysis and relaxes the smooth muscle of trachea, stomach and gall bladder.
T88213	PDBSTRUC	2RRI; 2RRH
T88213	SEQUENCE	MDTRNKAQLLVLLTLLSVLFSQTSAWPLYRAPSALRLGDRIPFEGANEPDQVSLKEDIDMLQNALAENDTPYYDVSRNARHADGVFTSDFSKLLGQLSAKKYLESLMGKRVSSNISEDPVPVKRHSDAVFTDNYTRLRKQMAVKKYLNSILNGKRSSEGESPDFPEELEK

T29827	TARGETID	T29827
T29827	FORMERID	TTDI01398
T29827	UNIPROID	ETXB_STAAU
T29827	TARGNAME	Staphylococcus Enterotoxin B (Stap-coc entB)
T29827	GENENAME	Stap-coc entB
T29827	TARGTYPE	Literature-reported
T29827	SYNONYMS	SEB; Enterotoxin type B
T29827	FUNCTION	Staphylococcal enterotoxins cause the intoxication staphylococcal food poisoning syndrome. The illness characterized by high fever, hypotension, diarrhea, shock, and in some cases death.
T29827	PDBSTRUC	4RGO; 4RGN; 4RGM; 4C56; 3W2D
T29827	SEQUENCE	MYKRLFISHVILIFALILVISTPNVLAESQPDPKPDELHKSSKFTGLMENMKVLYDDNHVSAINVKSIDQFLYFDLIYSIKDTKLGNYDNVRVEFKNKDLADKYKDKYVDVFGANYYYQCYFSKKTNDINSHQTDKRKTCMYGGVTEHNGNQLDKYRSITVRVFEDGKNLLSFDVQTNKKKVTAQELDYLTRHYLVKNKKLYEFNNSPYETGYIKFIENENSFWYDMMPAPGDKFDQSKYLMMYNDNKMVDSKDVKIEVYLTTKKK

T38610	TARGETID	T38610
T38610	FORMERID	TTDNR00640
T38610	UNIPROID	CRYAA_HUMAN
T38610	TARGNAME	Alpha-crystallin A chain (CRYAA)
T38610	GENENAME	CRYAA
T38610	TARGTYPE	Literature-reported
T38610	SYNONYMS	HspB4; Heat shock protein beta-4; CRYA1
T38610	FUNCTION	Has chaperone-like activity, preventing aggregation of various proteins under a wide range of stress conditions. Contributes to the transparency and refractive index of the lens.
T38610	BIOCLASS	Heat shock protein
T38610	SEQUENCE	MDVTIQHPWFKRTLGPFYPSRLFDQFFGEGLFEYDLLPFLSSTISPYYRQSLFRTVLDSGISEVRSDRDKFVIFLDVKHFSPEDLTVKVQDDFVEIHGKHNERQDDHGYISREFHRRYRLPSNVDQSALSCSLSADGMLTFCGPKIQTGLDATHAERAIPVSREEKPTSAPSS

T43793	TARGETID	T43793
T43793	FORMERID	TTDI02348
T43793	UNIPROID	C1QB_HUMAN
T43793	TARGNAME	Complement C1q component (C1Q)
T43793	GENENAME	C1QB
T43793	TARGTYPE	Literature-reported
T43793	SYNONYMS	C1QB
T43793	FUNCTION	C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takesplace on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.
T43793	PDBSTRUC	6FCZ; 5HZF; 5HKJ; 2WNV; 2WNU
T43793	SEQUENCE	MMMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKGEKGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQKIAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNLCVNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANSIFSGFLLFPDMEA

T45289	TARGETID	T45289
T45289	FORMERID	TTDR00471
T45289	UNIPROID	FETUA_HUMAN
T45289	TARGNAME	Alpha-2-HS-glycoprotein (AHSG)
T45289	GENENAME	AHSG
T45289	TARGTYPE	Literature-reported
T45289	SYNONYMS	PRO2743; Ba-alpha-2-glycoprotein; Alpha2-HS glycoprotein
T45289	FUNCTION	Promotes endocytosis, possesses opsonic properties and influences the mineral phase of bone. Shows affinity for calcium and barium ions.
T45289	BIOCLASS	Fetuin family
T45289	SEQUENCE	MKSLVLLLCLAQLWGCHSAPHGPGLIYRQPNCDDPETEEAALVAIDYINQNLPWGYKHTLNQIDEVKVWPQQPSGELFEIEIDTLETTCHVLDPTPVARCSVRQLKEHAVEGDCDFQLLKLDGKFSVVYAKCDSSPDSAEDVRKVCQDCPLLAPLNDTRVVHAAKAALAAFNAQNNGSNFQLEEISRAQLVPLPPSTYVEFTVSGTDCVAKEATEAAKCNLLAEKQYGFCKATLSEKLGGAEVAVTCMVFQTQPVSSQPQPEGANEAVPTPVVDPDAPPSPPLGAPGLPPAGSPPDSHVLLAAPPGHQLHRAHYDLRHTFMGVVSLGSPSGEVSHPRKTRTVVQPSVGAAAGPVVPPCPGRIRHFKV

T10577	TARGETID	T10577
T10577	FORMERID	TTDI01421
T10577	UNIPROID	DNAA_ECOLI
T10577	TARGNAME	Bacterial Initiator protein DnaA (Bact dnaA)
T10577	GENENAME	Bact dnaA
T10577	TARGTYPE	Literature-reported
T10577	SYNONYMS	Chromosomal replication initiator protein DnaA
T10577	FUNCTION	Plays a key role in the initiation and regulation of chromosomal replication. Binds in an ATP-dependent fashion to the origin of replication (oriC) to initiate formation of the DNA replication initiation complex exactly once per cell cycle. Binds the DnaA box (consensus sequence 5'-TTATC[CA]A[CA]A-3'); subsequent binding of DNA polymerase III subunits leads to replisome formation. The DnaA-ATP form converts to DnaA-ADP; once converted to ADP the protein cannot initiate replication, ensuring only 1 round of replication per cell cycle. DnaA can inhibit its own gene expression as well as that of other genes such as dam, rpoH, ftsA and mioC.
T10577	PDBSTRUC	2E0G; 1J1V
T10577	SEQUENCE	MSLSLWQQCLARLQDELPATEFSMWIRPLQAELSDNTLALYAPNRFVLDWVRDKYLNNINGLLTSFCGADAPQLRFEVGTKPVTQTPQAAVTSNVAAPAQVAQTQPQRAAPSTRSGWDNVPAPAEPTYRSNVNVKHTFDNFVEGKSNQLARAAARQVADNPGGAYNPLFLYGGTGLGKTHLLHAVGNGIMARKPNAKVVYMHSERFVQDMVKALQNNAIEEFKRYYRSVDALLIDDIQFFANKERSQEEFFHTFNALLEGNQQIILTSDRYPKEINGVEDRLKSRFGWGLTVAIEPPELETRVAILMKKADENDIRLPGEVAFFIAKRLRSNVRELEGALNRVIANANFTGRAITIDFVREALRDLLALQEKLVTIDNIQKTVAEYYKIKVADLLSKRRSRSVARPRQMAMALAKELTNHSLPEIGDAFGGRDHTTVLHACRKIEQLREESHDIKEDFSNLIRTLSS

T33869	TARGETID	T33869
T33869	FORMERID	TTDR00316
T33869	UNIPROID	POLG_FMDVO
T33869	TARGNAME	Foot-and-mouth disease virus Capsid VP2 (FMDV VP2)
T33869	GENENAME	FMDV VP2
T33869	TARGTYPE	Literature-reported
T33869	SYNONYMS	Foot-and-mouth disease virus P1B; Foot-and-mouth disease virus Virion protein 2
T33869	FUNCTION	Leader protease: Autocatalytically cleaves itself from the polyprotein at the L/VP0 junction. Cleaves also the host translation initiation factors EIF4G1 and EIF4G3, in order to shutoff the capped cellular mRNA transcription. Plays a role in counteracting host innate antiviral response using diverse mechanisms. Possesses a deubiquitinase activity acting on both 'Lys'-48 and 'Lys'-63-linked polyubiquitin chains. In turn, inhibits the ubiquitination and subsequent activation of key signaling molecules of type I IFN response such as host DDX58, TBK1, TRAF3 and TRAF6. Inhibits host NF-kappa-B activity by inducing a decrease in RELA mRNA levels. Cleaves a peptide bond in the C-terminus of host ISG15, resulting in the damaging of this mofidier that can no longer be attached to target proteins. Cleaves also host G3BP1 and G3BP2 in order to inhibit cytoplasmic stress granules assembly.
T33869	PDBSTRUC	6FFA; 4QBB; 2JQG; 2JQF; 1QQP
T33869	SEQUENCE	DKKTEETTLLEDRILTTRNGHTTSTTQSSVGVTYGYATAEDFVSGPNTSGLETRVVQAERFFKTHLFDWVTSDSFGRCHLLELPTDHKGVYGSLTDSYAYMRNGWDVEVTAVGNQFNGGCLLVAMVPELYSIQKRELYQLTLFPHQFINPRTNMTAHITVPFVGVNRYDQYKVHKPWTLVVMVVAPLTVNTEGAPQIKVYANIAPTNVHVAGEFPSKE

T69204	TARGETID	T69204
T69204	FORMERID	TTDR00317
T69204	UNIPROID	POLG_FMDVO
T69204	TARGNAME	Foot-and-mouth disease virus Capsid VP3 (FMDV VP3)
T69204	GENENAME	FMDV VP3
T69204	TARGTYPE	Literature-reported
T69204	SYNONYMS	Foot-and-mouth disease virus P1C; Foot-and-mouth disease virus Virion protein 3
T69204	FUNCTION	Leader protease: Autocatalytically cleaves itself from the polyprotein at the L/VP0 junction. Cleaves also the host translation initiation factors EIF4G1 and EIF4G3, in order to shutoff the capped cellular mRNA transcription. Plays a role in counteracting host innate antiviral response using diverse mechanisms. Possesses a deubiquitinase activity acting on both 'Lys'-48 and 'Lys'-63-linked polyubiquitin chains. In turn, inhibits the ubiquitination and subsequent activation of key signaling molecules of type I IFN response such as host DDX58, TBK1, TRAF3 and TRAF6. Inhibits host NF-kappa-B activity by inducing a decrease in RELA mRNA levels. Cleaves a peptide bond in the C-terminus of host ISG15, resulting in the damaging of this mofidier that can no longer be attached to target proteins. Cleaves also host G3BP1 and G3BP2 in order to inhibit cytoplasmic stress granules assembly.
T69204	PDBSTRUC	6FFA; 4QBB; 2JQG; 2JQF; 1QQP
T69204	SEQUENCE	GIFPVACSDGYGGLVTTDPKTADPVYGKVFNPPRNQLPGRFTNLLDVAEACPTFLRFEGGVPYVTTKTDSDRVLAQFDMSLAAKQMSNTFLAGLAQYYTQYSGTINLHFMFTGPTDAKARYMVAYAPPGMEPPKTPEAAAHCIHAEWDTGLNSKFTFSIPYLSAADYAYTASGVAETTNVQGWVCLFQITHGKADGDALVVLASAGKDFELRLPVDA

T20556	TARGETID	T20556
T20556	FORMERID	TTDR00315
T20556	UNIPROID	POLG_FMDVO
T20556	TARGNAME	Foot-and-mouth disease virus Capsid VP1 (FMDV VP1)
T20556	GENENAME	FMDV VP1
T20556	TARGTYPE	Literature-reported
T20556	SYNONYMS	Foot-and-mouth disease virus P1D; Foot-and-mouth disease virus Virion protein 1
T20556	FUNCTION	Leader protease: Autocatalytically cleaves itself from the polyprotein at the L/VP0 junction. Cleaves also the host translation initiation factors EIF4G1 and EIF4G3, in order to shutoff the capped cellular mRNA transcription. Plays a role in counteracting host innate antiviral response using diverse mechanisms. Possesses a deubiquitinase activity acting on both 'Lys'-48 and 'Lys'-63-linked polyubiquitin chains. In turn, inhibits the ubiquitination and subsequent activation of key signaling molecules of type I IFN response such as host DDX58, TBK1, TRAF3 and TRAF6. Inhibits host NF-kappa-B activity by inducing a decrease in RELA mRNA levels. Cleaves a peptide bond in the C-terminus of host ISG15, resulting in the damaging of this mofidier that can no longer be attached to target proteins. Cleaves also host G3BP1 and G3BP2 in order to inhibit cytoplasmic stress granules assembly.
T20556	PDBSTRUC	6FFA; 4QBB; 2JQG; 2JQF; 1QQP
T20556	SEQUENCE	TTSAGESADPVTTTVENYGGETQIQRRQHTDVSFIMDRFVKVTPQNQINILDLMQIPSHTLVGALLRASTYYFSDLEIAVKHEGDLTWVPNGAPEKALDNTTNPTAYHKAPLTRLALPYTAPHRVLATVYNGECRYNRNAVPNLRGDLQVLAQKVARTLPTSFNYGAIKATRVTELLYRMKRAETYCPRPLLAIHPTEARHKQKIVAPVKQ

T81210	TARGETID	T81210
T81210	FORMERID	TTDI01481
T81210	UNIPROID	POLG_YEFV1
T81210	TARGNAME	Flavivirus Serine protease NS2B-NS3 (FlaV NS2B-NS3)
T81210	GENENAME	FlaV NS2B-NS3
T81210	TARGTYPE	Literature-reported
T81210	SYNONYMS	FlavivirusNon-structural protein 2B-Non-structural protein 3; Flavivirus Flavivirin protease NS2B regulatory subunit-Flavivirin protease NS3 catalytic subunit Non-structural protein 3
T81210	FUNCTION	Capsid protein C: Plays a role in virus budding by binding to the cell membrane and gathering the viral RNA into a nucleocapsid that forms the core of a mature virus particle. During virus entry, may induce genome penetration into the host cytoplasm after hemifusion induced by the surface proteins. Can migrate to the cell nucleus where it modulates host functions.
T81210	PDBSTRUC	6IW4; 6IW2; 6IW1; 6IW0; 6EPK
T81210	SEQUENCE	SIPVNEALAAAGLVGVLAGLAFQEMENFLGPIAVGGLLMMLVSVAGRVDGLELKKLGEVSWEEEAEISGSSARYDVALSEQGEFKLLSEEKVPWDQVVMTSLALVGAALHPFALLLVLAGWLFHVRGARRSGDVLWDIPTPKIIEECEHLEDGIYGIFQSTFLGASQRGVGVAQGGVFHTMWHVTRGAFLVRNGKKLIPSWASVKEDLVAYGGSWKLEGRWDGEEEVQLIAAVPGKNVVNVQTKPSLFKVRNGGEIGAVALDYPSGTSGSPIVNRNGEVIGLYGNGILVGDNSFVSAISQTEVKEEGKEELQEIPTMLKKGMTTVLDFHPGAGKTRRFLPQILAECARRRLRTLVLAPTRVVLSEMKEAFHGLDVKFHTQAFSAHGSGREVIDAMCHATLTYRMLEPTRVVNWEVIIMDEAHFLDPASIAARGWAAHRARANESATILMTATPPGTSDEFPHSNGEIEDVQTDIPSEPWNTGHDWILADKRPTAWFLPSIRAANVMAASLRKAGKSVVVLNRKTFEREYPTIKQKKPDFILATDIAEMGANLCVERVLDCRTAFKPVLVDEGRKVAIKGPLRISASSAAQRRGRIGRNPNRDGDSYYYSEPTSENNAHHVCWLEASMLLDNMEVRGGMVAPLYGVEGTKTPVSPGEMRLRDDQRKVFRELVRNCDLPVWLSWQVAKAGLKTNDRKWCFEGPEEHEILNDSGETVKCRAPGGAKKPLRPRWCDERVSSDQSALSEFIKFAEGRR

T42838	TARGETID	T42838
T42838	FORMERID	TTDR00456
T42838	UNIPROID	VIF_HV1A2
T42838	TARGNAME	Human immunodeficiency virus Virion infectivity factor (HIV vif)
T42838	GENENAME	HIV vif
T42838	TARGTYPE	Literature-reported
T42838	SYNONYMS	Virion infectivity factor; Vif; SOR protein
T42838	FUNCTION	Counteracts the innate antiviral activity of host APOBEC3F and APOBEC3G. Forms a complex with host APOBEC3F and APOBEC3G thus preventing the entry of these lethally hypermutating enzymes into progeny virions. Recruits an active E3 ubiquitin ligase complex composed of elongin BC, CUL5, and RBX2 to induce polyubiquitination of APOBEC3G and APOBEC3F. In turn, they are directed to the 26S proteasome for degradation. Vif interaction with APOBEC3G also blocks its cytidine deaminase activity in a proteasome-independent manner, suggesting a dual inhibitory mechanism. May interact directly with APOBEC3G mRNA in order to inhibit its translation. Seems to play a role in viral morphology by affecting the stability of the viral nucleoprotein core. Finally, Vif also contributes to the G2 cell cycle arrest observed in HIV infected cells.
T42838	BIOCLASS	Primate lentivirus group Vif protein
T42838	SEQUENCE	MENRWQVMIVWQVDRMRIRTWKSLVKHHMYISKKAKGWFYRHHYESTHPRVSSEVHIPLGDAKLVITTYWGLHTGEREWHLGQGVAIEWRKKKYSTQVDPGLADQLIHLHYFDCFSESAIKNAILGYRVSPRCEYQAGHNKVGSLQYLALAALITPKKTKPPLPSVKKLTEDRWNKPQKTKGHRGSHTMNGH

T55863	TARGETID	T55863
T55863	FORMERID	TTDNR00691
T55863	UNIPROID	NCAP_I34A1
T55863	TARGNAME	Influenza Nucleoprotein (Influ NP)
T55863	GENENAME	Influ NP
T55863	TARGTYPE	Literature-reported
T55863	SYNONYMS	Influ Protein N; Influ Nucleoprotein; Influ Nucleocapsid protein
T55863	FUNCTION	Encapsidates the negative strand viral RNA, protecting it from nucleases. The encapsidated genomic RNA is termed the ribonucleoprotein (RNP) and serves as template for transcription and replication. The RNP needs to be localized in the host nucleus to start an infectious cycle, but is too large to diffuse through the nuclear pore complex. NP comprises at least 2 nuclear localization signals that are responsible for the active RNP import into the nucleus through cellular importin alpha/beta pathway. Later in the infection, nclear export of RNPs are mediated through viral proteins NEP interacting with M1 which binds nucleoproteins. It is possible that nucleoprotein binds directly host exportin-1/XPO1 and plays an active role in RNPs nuclear export. M1 interaction with RNP seems to hide nucleoprotein's nuclear localization signals. Soon after a virion infects a new cell, M1 dissociates from the RNP under acidification of the virion driven by M2 protein. Dissociation of M1 from RNP unmasks nucleoprotein's nuclear localization signals, targeting the RNP to the nucleus.
T55863	PDBSTRUC	5V5O; 5NQ3; 5NPZ; 4ZDU; 4NQV
T55863	SEQUENCE	MASQGTKRSYEQMETDGERQNATEIRASVGKMIGGIGRFYIQMCTELKLSDYEGRLIQNSLTIERMVLSAFDERRNKYLEEHPSAGKDPKKTGGPIYRRVNGKWMRELILYDKEEIRRIWRQANNGDDATAGLTHMMIWHSNLNDATYQRTRALVRTGMDPRMCSLMQGSTLPRRSGAAGAAVKGVGTMVMELVRMIKRGINDRNFWRGENGRKTRIAYERMCNILKGKFQTAAQKAMMDQVRESRNPGNAEFEDLTFLARSALILRGSVAHKSCLPACVYGPAVASGYDFEREGYSLVGIDPFRLLQNSQVYSLIRPNENPAHKSQLVWMACHSAAFEDLRVLSFIKGTKVLPRGKLSTRGVQIASNENMETMESSTLELRSRYWAIRTRSGGNTNQQRASAGQISIQPTFSVQRNLPFDRTTIMAAFNGNTEGRTSDMRTEIIRMMESARPEDVSFQGRGVFELSDEKAASPIVPSFDMSNEGSYFFGDNAEEYDN

T43842	TARGETID	T43842
T43842	FORMERID	TTDNR00730
T43842	UNIPROID	GLYC_PIARV
T43842	TARGNAME	Virus Pre-glycoprotein GP complex (Viru GPC)
T43842	GENENAME	Viru GPC
T43842	TARGTYPE	Literature-reported
T43842	SYNONYMS	Pre-GP-C; GPC
T43842	FUNCTION	Glycoprotein G2 is a viral fusion protein. Membrane fusion is mediated by conformational changes induced upon acidification in the endosome (Potential).
T43842	BIOCLASS	Arenaviridae GPC protein
T43842	SEQUENCE	MGQIVTLIQSIPEVLQEVFNVALIIVSVLCIVKGFVNLMRCGLFQLVTFLILSGRSCDSMMIDRRHNLTHVEFNLTRMFDNLPQSCSKNNTHHYYKGPSNTTWGIELTLTNTSIANETSGNFSNIGSLGYGNISNCDRTREAGHTLKWLLNELHFNVLHVTRHIGARCKTVEGAGVLIQYNLTVGDRGGEVGRHLIASLAQIIGDPKIAWVGKCFNNCSGDTCRLTNCEGGTHYNFLIIQNTTWENHCTYTPMATIRMALQRTAYSSVSRKLLGFFTWDLSDSSGQHVPGGYCLEQWAIIWAGIKCFDNTVMAKCNKDHNEEFCDTMRLFDFNQNAIKTLQLNVENSLNLFKKTINGLISDSLVIRNSLKQLAKIPYCNYTKFWYINDTITGRHSLPQCWLVHNGSYLNETHFKNDWLWESQNLYNEMLMKEYEERQGKTPLALTDICFWSLVFYTITVFLHIVGIPTHRHIIGDGCPKPHRITRNSLCSCGYYKYQRNLTNG

T08722	TARGETID	T08722
T08722	FORMERID	TTDR01237
T08722	UNIPROID	PRIO_HUMAN
T08722	TARGNAME	Major prion protein (PRNP)
T08722	GENENAME	PRNP
T08722	TARGTYPE	Literature-reported
T08722	SYNONYMS	Prion protein PrP(C); Prion protein; PrP33-35C; PrP27-30; PrP; PRNP; CD230 antigen; ASCR
T08722	FUNCTION	The physiological function of prp is not known.
T08722	PDBSTRUC	5YJ5; 5YJ4; 5L6R; 4N9O; 4KML
T08722	SEQUENCE	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQGGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPSKPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYYRENMHRYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERVVEQMCITQYERESQAYYQRGSSMVLFSSPPVILLISFLIFLIVG

T88786	TARGETID	T88786
T88786	FORMERID	TTDR00185
T88786	UNIPROID	MYCN_HUMAN
T88786	TARGNAME	N-myc proto-oncogene protein (MYCN)
T88786	GENENAME	MYCN
T88786	TARGTYPE	Literature-reported
T88786	SYNONYMS	bHLHe37; NMYC; N-myc; Class E basic helix-loop-helix protein 37
T88786	FUNCTION	Positively regulates the transcription of MYCNOS in neuroblastoma cells.
T88786	PDBSTRUC	5G1X
T88786	SEQUENCE	MPSCSTSTMPGMICKNPDLEFDSLQPCFYPDEDDFYFGGPDSTPPGEDIWKKFELLPTPPLSPSRGFAEHSSEPPSWVTEMLLENELWGSPAEEDAFGLGGLGGLTPNPVILQDCMWSGFSAREKLERAVSEKLQHGRGPPTAGSTAQSPGAGAASPAGRGHGGAAGAGRAGAALPAELAHPAAECVDPAVVFPFPVNKREPAPVPAAPASAPAAGPAVASGAGIAAPAGAPGVAPPRPGGRQTSGGDHKALSTSGEDTLSDSDDEDDEEEDEEEEIDVVTVEKRRSSSNTKAVTTFTITVRPKNAALGPGRAQSSELILKRCLPIHQQHNYAAPSPYVESEDAPPQKKIKSEASPRPLKSVIPPKAKSLSPRNSDSEDSERRRNHNILERQRRNDLRSSFLTLRDHVPELVKNEKAAKVVILKKATEYVHSLQAEEHQLLLEKEKLQARQQQLLKKIEHARTC

T45518	TARGETID	T45518
T45518	UNIPROID	DPOL_HHV21-PAP_HHV11
T45518	TARGNAME	Herpes simplex virus DNA polymerase POL (HSV POL)
T45518	GENENAME	HSV POL
T45518	TARGTYPE	Literature-reported
T45518	SYNONYMS	Complex of DNA polymerase processivity factor and DNA polymerase catalytic subunit
T45518	FUNCTION	Synthesize herpes simplex virus DNA from deoxyribonucleotides, the building blocks of DNA.
T45518	BIOCLASS	DNA polymerase type-B family
T45518	SEQUENCE	MTDSPGGVAPASPVEDASDASLGQPEEGAPCQVVLQGAELNGILQAFAPLRTSLLDSLLVMGDRGILIHNTIFGEQVFLPLEHSQFSRYRWRGPTAAFLSLVDQKRSLLSVFRANQYPDLRRVELAITGQAPFRTLVQRIWTTTSDGEAVELASETLMKRELTSFVVLVPQGTPDVQLRLTRPQLTKVLNATGADSATPTTFELGVNGKFSVFTTSTCVTFAAREEGVSSSTSTQVQILSNALTKAGQAAANAKTVYGENTHRTFSVVVDDCSMRAVLRRLQVGGGTLKFFLTTPVPSLCVTATGPNAVSAVFLLKPQKICLDWLGHSQGSPSAGSSASRASGSEPTDSQDSASDAVSHGDPEDLDGAARAGEAGALHACPMPSSTTRVTPTTKRGRSGGEDARADTALKKPKTGSPTAPPPADPVPLDTEDDSDAADGTAARPAAPDARSGSRYACYFRDLPTGEASPGAFSAFRGGPQTPYGFGFPMFCAAGGPASPGGKSAARAASGFFAPHNPRGATQTAPPPCRRQNFYNPHLAQTGTQPKAPGPAQRHTYYSECDEFRFIAPRSLDEDAPAEQRTGVHDGRLRRAPKVYCGGDERDVLRVGPEGFWPRRLRLWGGADHAPEGFDPTVTVFHVYDILEHVEHAYSMRAAQLHERFMDAITPAGTVITLLGLTPEGHRVAVHVYGTRQYFYMNKAEVDRHLQCRAPRDLCERLAAALRESPGASFRGISADHFEAEVVERADVYYYETRPTLYYRVFVRSGRALAYLCDNFCPAIRKYEGGVDATTRFILDNPGFVTFGWYRLKPGRGNAPAQPRPPTAFGTSSDVEFNCTADNLAVEGAMCDLPAYKLMCFDIECKAGGEDELAFPVAERPEDLVIQISCLLYDLSTTALEHILLFSLGSCDLPESHLSDLASRGLPAPVVLEFDSEFEMLLAFMTFVKQYGPEFVTGYNIINFDWPFVLTKLTEIYKVPLDGYGRMNGRGVFRVWDIGQSHFQKRSKIKVNGMVNIDMYGIITDKVKLSSYKLNAVAEAVLKDKKKDLSYRDIPAYYASGPAQRGVIGEYCVQDSLLVGQLFFKFLPHLELSAVARLAGINITRTIYDGQQIRVFTCLLRLAGQKGFILPDTQGRFRGLDKEAPKRPAVPRGEGERPGDGNGDEDKDDDEDGDEDGDEREEVARETGGRHVGYQGARVLDPTSGFHVDPVVVFDFASLYPSIIQAHNLCFSTLSLRPEAVAHLEADRDYLEIEVGGRRLFFVKAHVRESLLSILLRDWLAMRKQIRSRIPQSPPEEAVLLDKQQAAIKVVCNSVYGFTGVQHGLLPCLHVAATVTTIGREMLLATRAYVHARWAEFDQLLADFPEAAGMRAPGPYSMRIIYGDTDSIFVLCRGLTGEALVAMGDKMASHISRALFLPPIKLECEKTFTKLLLIAKKKYIGVICGGKMLIKGVDLVRKNNCAFINRTSRALVDLLFYDDTVSGAAAALAERPAEEWLARPLPEGLQAFGAVLVDAHRRITDPERDIQDFVLTAELSRHPRAYTNKRLAHLTVYYKLMARRAQVPSIKDRIPYVIVAQTREVEETVARLAALRELDAAAPGDEPAPPAALPSPAKRPRETPSHADPPGGASKPRKLLVSELAEDPGYAIARGVPLNTDYYFSHLLGAACVTFKALFGNNAKITESLLKRFIPETWHPPDDVAARLRAAGFGPAGAGATAEETRRMLHRAFDTLA
T45518	DRUGINFO	D08VKN	CP 4010	Investigative

T59432	TARGETID	T59432
T59432	FORMERID	TTDR00182
T59432	UNIPROID	TVB79_HUMAN
T59432	TARGNAME	T-cell receptor beta chain V region CTL-L17 (TCRB)
T59432	GENENAME	TCRB
T59432	TARGTYPE	Literature-reported
T59432	SYNONYMS	V beta 17 T-cell receptor; TRBV7-9; T cell receptor beta variable 7-9
T59432	FUNCTION	Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens. Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation. The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity. V region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition.
T59432	BIOCLASS	Immunoglobulin
T59432	SEQUENCE	MGTSLLCWMALCLLGADHADTGVSQNPRHKITKRGQNVTFRCDPISEHNRLYWYRQTLGQGPEFLTYFQNEAQLEKSRLLSDRFSAERPKGSFSTLEIQRTEQGDSAMYLCASSL

T39701	TARGETID	T39701
T39701	FORMERID	TTDI01262
T39701	UNIPROID	NSP4_ROTS1
T39701	TARGNAME	Rotavirus Toxin (Rota TOX)
T39701	GENENAME	Rota TOX
T39701	TARGTYPE	Literature-reported
T39701	SYNONYMS	Non-structural glycoprotein 4; NSP4; NS28; NCVP5
T39701	FUNCTION	Plays an essential role in the virus replication cycle by acting as a viroporin. Creates a pore in the host reticulum endoplasmic and as a consequence releases Ca(2+) in the cytoplasm of infected cell. In turn, high levels of cytoplasmic calcium trigger membrane trafficking and transport of viral ER-associated proteins to viroplasms, sites of viral genome replication and immature particle assembly.
T39701	PDBSTRUC	2O1K; 1G1J; 1G1I
T39701	SEQUENCE	MEKLTDLNYTLSVITLMNNTLHTILEDPGMAYFPYIASVLTGLFALNKASIPTMKIALKTSKCSYKVVKYCIVTIFNTLLKLAGYKEQITTKDEIEKQMDRVVKEMRRQLEMIDKLTTREIEQVELLKRIYDKLTVQTTGEIDMTKEINQKNVRTLEEWESGKNPYEPREVTAAM

T40728	TARGETID	T40728
T40728	FORMERID	TTDI02574
T40728	UNIPROID	LEG2_HUMAN
T40728	TARGNAME	Galectin-2 (LGALS2)
T40728	GENENAME	LGALS2
T40728	TARGTYPE	Literature-reported
T40728	SYNONYMS	SLac lectin 2; Lactosebinding lectin 2; LGALS2; HL14; Gal2; Betagalactosidebinding lectin L14II
T40728	FUNCTION	This protein binds beta-galactoside. Its physiological function is not yet known.
T40728	PDBSTRUC	5EWS; 5DG2; 5DG1; 1HLC
T40728	SEQUENCE	MTGELEVKNMDMKPGSTLKITGSIADGTDGFVINLGQGTDKLNLHFNPRFSESTIVCNSLDGSNWGQEQREDHLCFSPGSEVKFTVTFESDKFKVKLPDGHELTFPNRLGHSHLSYLSVRGGFNMSSFKLKE

T85715	TARGETID	T85715
T85715	FORMERID	TTDI02582
T85715	UNIPROID	CD5_HUMAN
T85715	TARGNAME	T-cell surface glycoprotein CD5 (CD5)
T85715	GENENAME	CD5
T85715	TARGTYPE	Literature-reported
T85715	SYNONYMS	Lymphocyte antigen T1/Leu-1; LEU1
T85715	FUNCTION	May act as a receptor in regulating T-cell proliferation.
T85715	PDBSTRUC	2OTT; 2JP0; 2JOP; 2JA4
T85715	SEQUENCE	MPMGSLQPLATLYLLGMLVASCLGRLSWYDPDFQARLTRSNSKCQGQLEVYLKDGWHMVCSQSWGRSSKQWEDPSQASKVCQRLNCGVPLSLGPFLVTYTPQSSIICYGQLGSFSNCSHSRNDMCHSLGLTCLEPQKTTPPTTRPPPTTTPEPTAPPRLQLVAQSGGQHCAGVVEFYSGSLGGTISYEAQDKTQDLENFLCNNLQCGSFLKHLPETEAGRAQDPGEPREHQPLPIQWKIQNSSCTSLEHCFRKIKPQKSGRVLALLCSGFQPKVQSRLVGGSSICEGTVEVRQGAQWAALCDSSSARSSLRWEEVCREQQCGSVNSYRVLDAGDPTSRGLFCPHQKLSQCHELWERNSYCKKVFVTCQDPNPAGLAAGTVASIILALVLLVVLLVVCGPLAYKKLVKKFRQKKQRQWIGPTGMNQNMSFHRNHTATVRSHAENPTASHVDNEYSQPPRNSHLSAYPALEGALHRSSMQPDNSSDSDYDLHGAQRL

T24089	TARGETID	T24089
T24089	FORMERID	TTDR00377
T24089	UNIPROID	CCKN_HUMAN
T24089	TARGNAME	Cholecystokinin (CCK)
T24089	GENENAME	CCK
T24089	TARGTYPE	Literature-reported
T24089	SYNONYMS	Procholecystokinin; CCK
T24089	FUNCTION	This peptide hormone induces gall bladder contraction and therelease of pancreatic enzymes in the gut. Its function in the brain is not clear. Binding to CCK-A receptors stimulates amylase release from the pancreas, binding to CCK-B receptors stimulates gastric acid secretion.
T24089	BIOCLASS	Gastrin cholecystokinin
T24089	SEQUENCE	MNSGVCLCVLMAVLAAGALTQPVPPADPAGSGLQRAEEAPRRQLRVSQRTDGESRAHLGALLARYIQQARKAPSGRMSIVKNLQNLDPSHRISDRDYMGWMDFGRRSAEEYEYPS

T31186	TARGETID	T31186
T31186	FORMERID	TTDI00074
T31186	UNIPROID	IF4E_HUMAN
T31186	TARGNAME	Eukaryotic initiation factor 4E (EIF4E)
T31186	GENENAME	EIF4E
T31186	TARGTYPE	Literature-reported
T31186	SYNONYMS	eIF4F 25 kDa subunit; eIF4E; eIF-4F 25 kDa subunit; eIF-4E; Eukaryotic translation initiation factor 4E; EIF4F; EIF4EL1
T31186	FUNCTION	Component of the CYFIP1-EIF4E-FMR1 complex which binds to the mRNA cap and mediates translational repression. In the CYFIP1-EIF4E-FMR1 complex this subunit mediates the binding to the mRNA cap. Recognizes and binds the 7-methylguanosine-containing mRNA cap during an early step in the initiation of protein synthesis and facilitates ribosome binding by inducing the unwinding of the mRNAs secondary structures.
T31186	PDBSTRUC	5ZML; 5ZK9; 5ZK7; 5ZK5; 5ZJZ
T31186	SEQUENCE	MATVEPETTPTPNPPTTEEEKTESNQEVANPEHYIKHPLQNRWALWFFKNDKSKTWQANLRLISKFDTVEDFWALYNHIQLSSNLMPGCDYSLFKDGIEPMWEDEKNKRGGRWLITLNKQQRRSDLDRFWLETLLCLIGESFDDYSDDVCGAVVNVRAKGDKIAIWTTECENREAVTHIGRVYKERLGLPPKIVIGYQSHADTATKSGSTTKNRFVV

T99314	TARGETID	T99314
T99314	FORMERID	TTDI01522
T99314	UNIPROID	TSST_STAAU
T99314	TARGNAME	Staphylococcus Toxic shock syndrome toxin-1 (Stap-coc tst)
T99314	GENENAME	Stap-coc tst
T99314	TARGTYPE	Literature-reported
T99314	SYNONYMS	Toxic shock syndrome toxin-1; TSST-1
T99314	FUNCTION	Responsible for the symptoms of toxic shock syndrome.
T99314	PDBSTRUC	5TSS; 4TSS; 4OHJ; 3TSS; 2TSS
T99314	SEQUENCE	MNKKLLMNFFIVSPLLLATTATDFTPVPLSSNQIIKTAKASTNDNIKDLLDWYSSGSDTFTNSEVLDNSLGSMRIKNTDGSISLIIFPSPYYSPAFTKGEKVDLNTKRTKKSQHTSEGTYIHFQISGVTNTEKLPTPIELPLKVKVHGKDSPLKYGPKFDKKQLAISTLDFEIRHQLTQIHGLYRSSDKTGGYWKITMNDGSTYQSDLSKKFEYNTEKPPINIDEIKTIEAEIN

T80070	TARGETID	T80070
T80070	FORMERID	TTDR00618
T80070	UNIPROID	HGXR_PLAFK
T80070	TARGNAME	Plasmodium Hypoxanthine-guanine-xanthine phosphoribosyltransferase (Malaria LACZ)
T80070	GENENAME	Malaria LACZ
T80070	TARGTYPE	Literature-reported
T80070	SYNONYMS	LACZ of Plasmodium falciparum (isolate K1 / Thailand); HGXPRTase; HGXPRT; HGPRT of Plasmodium falciparum (isolate K1 / Thailand)
T80070	FUNCTION	Converts guanine to guanosine monophosphate, and hypoxanthine to inosine monophosphate. Transfers the 5- phosphoribosyl group from 5-phosphoribosylpyrophosphate onto the purine. Works with guanine, hypoxanthine and xanthine. Plays a central role in the generation of purine nucleotides through the purine salvage pathway.
T80070	BIOCLASS	Pentosyltransferase
T80070	SEQUENCE	MPIPNNPGAGENAFDPVFVKDDDGYDLDSFMIPAHYKKYLTKVLVPNGVIKNRIEKLAYDIKKVYNNEEFHILCLLKGSRGFFTALLKHLSRIHNYSAVEMSKPLFGEHYVRVKSYCNDQSTGTLEIVSEDLSCLKGKHVLIVEDIIDTGKTLVKFCEYLKKFEIKTVAIACLFIKRTPLWNGFKADFVGFSIPDHFVVGYSLDYNEIFRDLDHCCLVNDEGKKKYKATSL
T80070	DRUGINFO	D0A1DU	Pyrophosphate 2-	Investigative

T69541	TARGETID	T69541
T69541	FORMERID	TTDR01189
T69541	UNIPROID	MCR_HUMAN
T69541	TARGNAME	Corticosteroid receptor type I (NR3C2)
T69541	GENENAME	NR3C2
T69541	TARGTYPE	Literature-reported
T69541	SYNONYMS	MCR; MLR; MR; Mineralocorticoid receptor; Nuclear receptor subfamily 3 group C member 2
T69541	FUNCTION	Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates target genes. The effect of MC is to increase ion and water transport and thus raise extracellular fluid volume and blood pressure and lower potassium levels.
T69541	PDBSTRUC	6GGG; 6GG8; 6GEV; 5MWY; 5MWP
T69541	SEQUENCE	METKGYHSLPEGLDMERRWGQVSQAVERSSLGPTERTDENNYMEIVNVSCVSGAIPNNSTQGSSKEKQELLPCLQQDNNRPGILTSDIKTELESKELSATVAESMGLYMDSVRDADYSYEQQNQQGSMSPAKIYQNVEQLVKFYKGNGHRPSTLSCVNTPLRSFMSDSGSSVNGGVMRAVVKSPIMCHEKSPSVCSPLNMTSSVCSPAGINSVSSTTASFGSFPVHSPITQGTPLTCSPNVENRGSRSHSPAHASNVGSPLSSPLSSMKSSISSPPSHCSVKSPVSSPNNVTLRSSVSSPANINNSRCSVSSPSNTNNRSTLSSPAASTVGSICSPVNNAFSYTASGTSAGSSTLRDVVPSPDTQEKGAQEVPFPKTEEVESAISNGVTGQLNIVQYIKPEPDGAFSSSCLGGNSKINSDSSFSVPIKQESTKHSCSGTSFKGNPTVNPFPFMDGSYFSFMDDKDYYSLSGILGPPVPGFDGNCEGSGFPVGIKQEPDDGSYYPEASIPSSAIVGVNSGGQSFHYRIGAQGTISLSRSARDQSFQHLSSFPPVNTLVESWKSHGDLSSRRSDGYPVLEYIPENVSSSTLRSVSTGSSRPSKICLVCGDEASGCHYGVVTCGSCKVFFKRAVEGQHNYLCAGRNDCIIDKIRRKNCPACRLQKCLQAGMNLGARKSKKLGKLKGIHEEQPQQQQPPPPPPPPQSPEEGTTYIAPAKEPSVNTALVPQLSTISRALTPSPVMVLENIEPEIVYAGYDSSKPDTAENLLSTLNRLAGKQMIQVVKWAKVLPGFKNLPLEDQITLIQYSWMCLSSFALSWRSYKHTNSQFLYFAPDLVFNEEKMHQSAMYELCQGMHQISLQFVRLQLTFEEYTIMKVLLLLSTIPKDGLKSQAAFEEMRTNYIKELRKMVTKCPNNSGQSWQRFYQLTKLLDSMHDLVSDLLEFCFYTFRESHALKVEFPAMLVEIISDQLPKVESGNAKPLYFHRK

T66016	TARGETID	T66016
T66016	FORMERID	TTDR00069
T66016	UNIPROID	MMP3_HUMAN; MMP10_HUMAN; MMP11_HUMAN
T66016	TARGNAME	Stromelysin (SL)
T66016	GENENAME	MMP3; MMP10; MMP11
T66016	TARGTYPE	Literature-reported
T66016	SYNONYMS	Transin; STMY; SL; Matrix metalloproteinase SL
T66016	FUNCTION	Plays an important role in tissue remodeling associated with various physiological or pathological processes such as morphogenesis, angiogenesis, tissue repair, cirrhosis, arthritis, and metastasis. Excess MMPs degrade the structural proteins of the aortic wall. Disregulation of the balance between MMPs and TIMPs is also a characteristic of acute and chronic cardiovascular diseases.
T66016	BIOCLASS	Peptidase
T66016	SEQUENCE	MKSLPILLLLCVAVCSAYPLDGAARGEDTSMNLVQKYLENYYDLKKDVKQFVRRKDSGPVVKKIREMQKFLGLEVTGKLDSDTLEVMRKPRCGVPDVGHFRTFPGIPKWRKTHLTYRIVNYTPDLPKDAVDSAVEKALKVWEEVTPLTFSRLYEGEADIMISFAVREHGDFYPFDGPGNVLAHAYAPGPGINGDAHFDDDEQWTKDTTGTNLFLVAAHEIGHSLGLFHSANTEALMYPLYHSLTDLTRFRLSQDDINGIQSLYGPPPDSPETPLVPTEPVPPEPGTPANCDPALSFDAVSTLRGEILIFKDRHFWRKSLRKLEPELHLISSFWPSLPSGVDAAYEVTSKDLVFIFKGNQFWAIRGNEVRAGYPRGIHTLGFPPTVRKIDAAISDKEKNKTYFFVEDKYWRFDEKRNSMEPGFPKQIAEDFPGIDSKIDAVFEEFGFFYFFTGSSQLEFDPNAKKVTHTLKSNSWLNC

T54461	TARGETID	T54461
T54461	FORMERID	TTDI02531
T54461	UNIPROID	K1C19_HUMAN
T54461	TARGNAME	Keratin type I cytoskeletal 19 (KRT19)
T54461	GENENAME	KRT19
T54461	TARGTYPE	Literature-reported
T54461	SYNONYMS	Keratin19; Keratin, type I cytoskeletal 19; KRT19; K19; Cytokeratin19; CK19
T54461	FUNCTION	Involved in the organization of myofibers. Together with KRT8, helps to link the contractile apparatus to dystrophin at the costameres of striated muscle. {ECO:0000269|PubMed:16000376}.
T54461	BIOCLASS	Intermediate filament family
T54461	SEQUENCE	MTSYSYRQSSATSSFGGLGGGSVRFGPGVAFRAPSIHGGSGGRGVSVSSARFVSSSSSGAYGGGYGGVLTASDGLLAGNEKLTMQNLNDRLASYLDKVRALEAANGELEVKIRDWYQKQGPGPSRDYSHYYTTIQDLRDKILGATIENSRIVLQIDNARLAADDFRTKFETEQALRMSVEADINGLRRVLDELTLARTDLEMQIEGLKEELAYLKKNHEEEISTLRGQVGGQVSVEVDSAPGTDLAKILSDMRSQYEVMAEQNRKDAEAWFTSRTEELNREVAGHTEQLQMSRSEVTDLRRTLQGLEIELQSQLSMKAALEDTLAETEARFGAQLAHIQALISGIEAQLGDVRADSERQNQEYQRLMDIKSRLEQEIATYRSLLEGQEDHYNNLSASKVL

T09439	TARGETID	T09439
T09439	FORMERID	TTDR00504
T09439	UNIPROID	SPRC_HUMAN
T09439	TARGNAME	Osteonectin (SPARC)
T09439	GENENAME	SPARC
T09439	TARGTYPE	Literature-reported
T09439	SYNONYMS	Secreted protein acidic and rich in cysteine; ON; Basement-membrane protein 40; Basement membrane protein BM-40; BM-40
T09439	FUNCTION	Binds calcium and copper, several types of collagen, albumin, thrombospondin, PDGF and cell membranes. There are two calcium binding sites; an acidic domain that binds 5 to 8 Ca(2+) with a low affinity and an EF-hand loop that binds a Ca(2+) ion with a high affinity. Appears to regulate cell growth through interactions with the extracellular matrix and cytokines.
T09439	PDBSTRUC	2V53; 1SRA; 1NUB; 1BMO
T09439	SEQUENCE	MRAWIFFLLCLAGRALAAPQQEALPDETEVVEETVAEVTEVSVGANPVQVEVGEFDDGAEETEEEVVAENPCQNHHCKHGKVCELDENNTPMCVCQDPTSCPAPIGEFEKVCSNDNKTFDSSCHFFATKCTLEGTKKGHKLHLDYIGPCKYIPPCLDSELTEFPLRMRDWLKNVLVTLYERDEDNNLLTEKQKLRVKKIHENEKRLEAGDHPVELLARDFEKNYNMYIFPVHWQFGQLDQHPIDGYLSHTELAPLRAPLIPMEHCTTRFFETCDLDNDKYIALDEWAGCFGIKQKDIDKDLVI

T01697	TARGETID	T01697
T01697	FORMERID	TTDR00307
T01697	UNIPROID	FEMB_STAAM
T01697	TARGNAME	Staphylococcus Aminoacyltransferase FemB (Stap-coc femB)
T01697	GENENAME	Stap-coc femB
T01697	TARGTYPE	Literature-reported
T01697	SYNONYMS	Possible protein femB; ORF 419
T01697	FUNCTION	Its function is unknown but its expression is needed for attaining the full level of resistance to the antibiotic methicillin.
T01697	ECNUMBER	EC 2.3.2.18
T01697	SEQUENCE	MKFTELTVTEFDNFVQNPSLESHYFQVKENIVTRENDGFEVVLLGIKDDNNKVIAASLFSKIPTMGSYVYYSNRGPVMDFSDLGLVDYYLKELDKYLQQHQCLYVKLDPYWLYHLYDKDIVPFEGREKNDALVNLFKSHGYEHHGFTTEYDTSSQVRWMGVLNLEGKTPETLKKTFDSQRKRNINKAINYGVKVRFLERDEFNLFLDLYRETEERAGFVSKTDDYFYNFIDTYGDKVLVPLAYIDLDEYVLKLQQELNDKENRRDQMMAKENKSDKQMKKIAELDKQIDHDQHELLNASELSKTDGPILNLASGVYFANAYEVNYFSGGSSEKYNQFMGPYMMHWFMINYCFDNGYDRYNFYGLSGDFTENSEDYGVYRFKRGFNVQIEELIGDFYKPIHKVKYWLFTTLDKLRKKLKK

T24718	TARGETID	T24718
T24718	FORMERID	TTDR00038
T24718	UNIPROID	MTSA1_STRPN
T24718	TARGNAME	Streptococcus Pneumococcal surface adhesin A (Stre-coc psaA)
T24718	GENENAME	Stre-coc psaA
T24718	TARGTYPE	Literature-reported
T24718	SYNONYMS	PsaA
T24718	FUNCTION	Part of an atp-driven transport system for manganese. Also act as an adhesin which is involved on adherence to extracellular matrix. It is an important factor in pathogenesis and infection.
T24718	PDBSTRUC	4UTP; 4UTO; 3ZTT; 3ZKA; 3ZK9
T24718	SEQUENCE	MKKLGTLLVLFLSAIILVACASGKKDTTSGQKLKVVATNSIIADITKNIAGDKIDLHSIVPIGQDPHEYEPLPEDVKKTSEADLIFYNGINLETGGNAWFTKLVENAKKTENKDYFAVSDGVDVIYLEGQNEKGKEDPHAWLNLENGIIFAKNIAKQLSAKDPNNKEFYEKNLKEYTDKLDKLDKESKDKFNKIPAEKKLIVTSEGAFKYFSKAYGVPSAYIWEINTEEEGTPEQIKTLVEKLRQTKVPSLFVESSVDDRPMKTVSQDTNIPIYAQIFTDSIAEQGKEGDSYYSMMKYNLDKIAEGLAK

T88125	TARGETID	T88125
T88125	FORMERID	TTDR00932
T88125	UNIPROID	ENGB_ECOLI
T88125	TARGNAME	Bacterial GTP-binding protein YihA (Bact engB)
T88125	GENENAME	Bact engB
T88125	TARGTYPE	Literature-reported
T88125	SYNONYMS	engB; Probable GTP-binding protein engB
T88125	FUNCTION	Necessary for normal cell division and for the maintenance of normal septation. Depletion of this protein leads to a severe reduction in growth rate and to extensive filamentation, with a block beyond the stage of segregation. Essential for bacteria survivial.
T88125	PDBSTRUC	1PUI
T88125	SEQUENCE	MTNLNYQQTHFVMSAPDIRHLPSDTGIEVAFAGRSNAGKSSALNTLTNQKSLARTSKTPGRTQLINLFEVADGKRLVDLPGYGYAEVPEEMKRKWQRALGEYLEKRQSLQGLVVLMDIRHPLKDLDQQMIEWAVDSNIAVLVLLTKADKLASGARKAQLNMVREAVLAFNGDVQVETFSSLKKQGVDKLRQKLDTWFSEMQPVEETQDGE
T88125	DRUGINFO	D0EQ4T	Guanosine-5'-Triphosphate	Investigative
T88125	DRUGINFO	D0C7LS	Guanosine-5'-Diphosphate	Investigative

T41371	TARGETID	T41371
T41371	FORMERID	TTDI01340
T41371	UNIPROID	MRAY_ECOLI
T41371	TARGNAME	Bacterial Phospho-MurNAc-pentapeptide translocase (Bact MraY)
T41371	GENENAME	Bact MraY
T41371	TARGTYPE	Literature-reported
T41371	SYNONYMS	UDP-MurNAc-pentapeptide phosphotransferase; Phospho-N-acetylmuramoyl-pentapeptide-transferase
T41371	FUNCTION	First step of the lipid cycle reactions in the biosynthesis of the cell wall peptidoglycan.
T41371	ECNUMBER	EC 2.7.8.13
T41371	SEQUENCE	MLVWLAEHLVKYYSGFNVFSYLTFRAIVSLLTALFISLWMGPRMIAHLQKLSFGQVVRNDGPESHFSKRGTPTMGGIMILTAIVISVLLWAYPSNPYVWCVLVVLVGYGVIGFVDDYRKVVRKDTKGLIARWKYFWMSVIALGVAFALYLAGKDTPATQLVVPFFKDVMPQLGLFYILLAYFVIVGTGNAVNLTDGLDGLAIMPTVFVAGGFALVAWATGNMNFASYLHIPYLRHAGELVIVCTAIVGAGLGFLWFNTYPAQVFMGDVGSLALGGALGIIAVLLRQEFLLVIMGGVFVVETLSVILQVGSFKLRGQRIFRMAPIHHHYELKGWPEPRVIVRFWIISLMLVLIGLATLKVR

T53766	TARGETID	T53766
T53766	FORMERID	TTDR01301
T53766	UNIPROID	H2AZ_HUMAN
T53766	TARGNAME	Histone variant H2A.Z (H2AFZ)
T53766	GENENAME	H2AFZ
T53766	TARGTYPE	Literature-reported
T53766	SYNONYMS	Histone H2A.Z; H2AZ; H2A/z
T53766	FUNCTION	Variant histone H2A which replaces conventional H2A in a subset of nucleosomes. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling. May be involved in the formation of constitutive heterochromatin. May be required for chromosome segregation during cell division.
T53766	PDBSTRUC	5Z30; 5FUG; 5CHL; 5B33; 5B32
T53766	SEQUENCE	MAGGKAGKDSGKAKTKAVSRSQRAGLQFPVGRIHRHLKSRTTSHGRVGATAAVYSAAILEYLTAEVLELAGNASKDLKVKRITPRHLQLAIRGDEELDSLIKATIAGGGVIPHIHKSLIGKKGQQKTV

T89752	TARGETID	T89752
T89752	FORMERID	TTDI03563
T89752	UNIPROID	SBK3_HUMAN
T89752	TARGNAME	Sugen kinase 110 (SBK3)
T89752	GENENAME	SBK3
T89752	TARGTYPE	Literature-reported
T89752	SYNONYMS	Uncharacterized serine/threonine-protein kinase SBK3; SH3-binding domain kinase family member 3; SGK110
T89752	FUNCTION	A serine/threonine protein kinase that does not have an activating compound and are either non-specific or their specificity has not been analyzed to date.
T89752	ECNUMBER	EC 2.7.11.1
T89752	SEQUENCE	MERRASETPEDGDPEEDTATALQRLVELTTSRVTPVRSLRDQYHLIRKLGSGSYGRVLLAQPHQGGPAVALKLLRRDLVLRSTFLREFCVGRCVSAHPGLLQTLAGPLQTPRYFAFAQEYAPCGDLSGMLQERGLPELLVKRVVAQLAGALDFLHSRGLVHADVKPDNVLVFDPVCSRVALGDLGLTRPEGSPTPAPPVPLPTAPPELCLLLPPDTLPLRPAVDSWGLGVLLFCAATACFPWDVALAPNPEFEAFAGWVTTKPQPPQPPPPWDQFAPPALALLQGLLDLDPETRSPPLAVLDFLGDDWGLQGNREGPGVLGSAVSYEDREEGGSSLEEWTDEGDDSKSGGRTGTDGGAP
T89752	DRUGINFO	D00EMH	PMID21967808CR-16	Investigative

T12005	TARGETID	T12005
T12005	FORMERID	TTDR00857
T12005	UNIPROID	R1A_CVHSA
T12005	TARGNAME	Coronavirus Main proteinase (CoV 1a)
T12005	GENENAME	CoV 1a
T12005	TARGTYPE	Literature-reported
T12005	SYNONYMS	pp1a; Replicase polyprotein 1a; ORF1a polyprotein
T12005	FUNCTION	The papain-like proteinase (PL-PRO) is responsible for the cleavages located at the N-terminus of replicase polyprotein. In addition, PL-PRO possesses a deubiquitinating/deISGylating activity and processes both 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular substrates. Antagonizes innate immune induction of type I interferon by blocking the phosphorylation, dimerization and subsequent nuclear translocation of host IRF-3.
T12005	PDBSTRUC	5Y3Q; 5Y3E; 5F22; 4OW0; 4OVZ
T12005	SEQUENCE	MESLVLGVNEKTHVQLSLPVLQVRDVLVRGFGDSVEEALSEAREHLKNGTCGLVELEKGVLPQLEQPYVFIKRSDALSTNHGHKVVELVAEMDGIQYGRSGITLGVLVPHVGETPIAYRNVLLRKNGNKGAGGHSYGIDLKSYDLGDELGTDPIEDYEQNWNTKHGSGALRELTRELNGGAVTRYVDNNFCGPDGYPLDCIKDFLARAGKSMCTLSEQLDYIESKRGVYCCRDHEHEIAWFTERSDKSYEHQTPFEIKSAKKFDTFKGECPKFVFPLNSKVKVIQPRVEKKKTEGFMGRIRSVYPVASPQECNNMHLSTLMKCNHCDEVSWQTCDFLKATCEHCGTENLVIEGPTTCGYLPTNAVVKMPCPACQDPEIGPEHSVADYHNHSNIETRLRKGGRTRCFGGCVFAYVGCYNKRAYWVPRASADIGSGHTGITGDNVETLNEDLLEILSRERVNINIVGDFHLNEEVAIILASFSASTSAFIDTIKSLDYKSFKTIVESCGNYKVTKGKPVKGAWNIGQQRSVLTPLCGFPSQAAGVIRSIFARTLDAANHSIPDLQRAAVTILDGISEQSLRLVDAMVYTSDLLTNSVIIMAYVTGGLVQQTSQWLSNLLGTTVEKLRPIFEWIEAKLSAGVEFLKDAWEILKFLITGVFDIVKGQIQVASDNIKDCVKCFIDVVNKALEMCIDQVTIAGAKLRSLNLGEVFIAQSKGLYRQCIRGKEQLQLLMPLKAPKEVTFLEGDSHDTVLTSEEVVLKNGELEALETPVDSFTNGAIVGTPVCVNGLMLLEIKDKEQYCALSPGLLATNNVFRLKGGAPIKGVTFGEDTVWEVQGYKNVRITFELDERVDKVLNEKCSVYTVESGTEVTEFACVVAEAVVKTLQPVSDLLTNMGIDLDEWSVATFYLFDDAGEENFSSRMYCSFYPPDEEEEDDAECEEEEIDETCEHEYGTEDDYQGLPLEFGASAETVRVEEEEEEDWLDDTTEQSEIEPEPEPTPEEPVNQFTGYLKLTDNVAIKCVDIVKEAQSANPMVIVNAANIHLKHGGGVAGALNKATNGAMQKESDDYIKLNGPLTVGGSCLLSGHNLAKKCLHVVGPNLNAGEDIQLLKAAYENFNSQDILLAPLLSAGIFGAKPLQSLQVCVQTVRTQVYIAVNDKALYEQVVMDYLDNLKPRVEAPKQEEPPNTEDSKTEEKSVVQKPVDVKPKIKACIDEVTTTLEETKFLTNKLLLFADINGKLYHDSQNMLRGEDMSFLEKDAPYMVGDVITSGDITCVVIPSKKAGGTTEMLSRALKKVPVDEYITTYPGQGCAGYTLEEAKTALKKCKSAFYVLPSEAPNAKEEILGTVSWNLREMLAHAEETRKLMPICMDVRAIMATIQRKYKGIKIQEGIVDYGVRFFFYTSKEPVASIITKLNSLNEPLVTMPIGYVTHGFNLEEAARCMRSLKAPAVVSVSSPDAVTTYNGYLTSSSKTSEEHFVETVSLAGSYRDWSYSGQRTELGVEFLKRGDKIVYHTLESPVEFHLDGEVLSLDKLKSLLSLREVKTIKVFTTVDNTNLHTQLVDMSMTYGQQFGPTYLDGADVTKIKPHVNHEGKTFFVLPSDDTLRSEAFEYYHTLDESFLGRYMSALNHTKKWKFPQVGGLTSIKWADNNCYLSSVLLALQQLEVKFNAPALQEAYYRARAGDAANFCALILAYSNKTVGELGDVRETMTHLLQHANLESAKRVLNVVCKHCGQKTTTLTGVEAVMYMGTLSYDNLKTGVSIPCVCGRDATQYLVQQESSFVMMSAPPAEYKLQQGTFLCANEYTGNYQCGHYTHITAKETLYRIDGAHLTKMSEYKGPVTDVFYKETSYTTTIKPVSYKLDGVTYTEIEPKLDGYYKKDNAYYTEQPIDLVPTQPLPNASFDNFKLTCSNTKFADDLNQMTGFTKPASRELSVTFFPDLNGDVVAIDYRHYSASFKKGAKLLHKPIVWHINQATTKTTFKPNTWCLRCLWSTKPVDTSNSFEVLAVEDTQGMDNLACESQQPTSEEVVENPTIQKEVIECDVKTTEVVGNVILKPSDEGVKVTQELGHEDLMAAYVENTSITIKKPNELSLALGLKTIATHGIAAINSVPWSKILAYVKPFLGQAAITTSNCAKRLAQRVFNNYMPYVFTLLFQLCTFTKSTNSRIRASLPTTIAKNSVKSVAKLCLDAGINYVKSPKFSKLFTIAMWLLLLSICLGSLICVTAAFGVLLSNFGAPSYCNGVRELYLNSSNVTTMDFCEGSFPCSICLSGLDSLDSYPALETIQVTISSYKLDLTILGLAAEWVLAYMLFTKFFYLLGLSAIMQVFFGYFASHFISNSWLMWFIISIVQMAPVSAMVRMYIFFASFYYIWKSYVHIMDGCTSSTCMMCYKRNRATRVECTTIVNGMKRSFYVYANGGRGFCKTHNWNCLNCDTFCTGSTFISDEVARDLSLQFKRPINPTDQSSYIVDSVAVKNGALHLYFDKAGQKTYERHPLSHFVNLDNLRANNTKGSLPINVIVFDGKSKCDESASKSASVYYSQLMCQPILLLDQALVSDVGDSTEVSVKMFDAYVDTFSATFSVPMEKLKALVATAHSELAKGVALDGVLSTFVSAARQGVVDTDVDTKDVIECLKLSHHSDLEVTGDSCNNFMLTYNKVENMTPRDLGACIDCNARHINAQVAKSHNVSLIWNVKDYMSLSEQLRKQIRSAAKKNNIPFRLTCATTRQVVNVITTKISLKGGKIVSTCFKLMLKATLLCVLAALVCYIVMPVHTLSIHDGYTNEIIGYKAIQDGVTRDIISTDDCFANKHAGFDAWFSQRGGSYKNDKSCPVVAAIITREIGFIVPGLPGTVLRAINGDFLHFLPRVFSAVGNICYTPSKLIEYSDFATSACVLAAECTIFKDAMGKPVPYCYDTNLLEGSISYSELRPDTRYVLMDGSIIQFPNTYLEGSVRVVTTFDAEYCRHGTCERSEVGICLSTSGRWVLNNEHYRALSGVFCGVDAMNLIANIFTPLVQPVGALDVSASVVAGGIIAILVTCAAYYFMKFRRVFGEYNHVVAANALLFLMSFTILCLVPAYSFLPGVYSVFYLYLTFYFTNDVSFLAHLQWFAMFSPIVPFWITAIYVFCISLKHCHWFFNNYLRKRVMFNGVTFSTFEEAALCTFLLNKEMYLKLRSETLLPLTQYNRYLALYNKYKYFSGALDTTSYREAACCHLAKALNDFSNSGADVLYQPPQTSITSAVLQSGFRKMAFPSGKVEGCMVQVTCGTTTLNGLWLDDTVYCPRHVICTAEDMLNPNYEDLLIRKSNHSFLVQAGNVQLRVIGHSMQNCLLRLKVDTSNPKTPKYKFVRIQPGQTFSVLACYNGSPSGVYQCAMRPNHTIKGSFLNGSCGSVGFNIDYDCVSFCYMHHMELPTGVHAGTDLEGKFYGPFVDRQTAQAAGTDTTITLNVLAWLYAAVINGDRWFLNRFTTTLNDFNLVAMKYNYEPLTQDHVDILGPLSAQTGIAVLDMCAALKELLQNGMNGRTILGSTILEDEFTPFDVVRQCSGVTFQGKFKKIVKGTHHWMLLTFLTSLLILVQSTQWSLFFFVYENAFLPFTLGIMAIAACAMLLVKHKHAFLCLFLLPSLATVAYFNMVYMPASWVMRIMTWLELADTSLSGYRLKDCVMYASALVLLILMTARTVYDDAARRVWTLMNVITLVYKVYYGNALDQAISMWALVISVTSNYSGVVTTIMFLARAIVFVCVEYYPLLFITGNTLQCIMLVYCFLGYCCCCYFGLFCLLNRYFRLTLGVYDYLVSTQEFRYMNSQGLLPPKSSIDAFKLNIKLLGIGGKPCIKVATVQSKMSDVKCTSVVLLSVLQQLRVESSSKLWAQCVQLHNDILLAKDTTEAFEKMVSLLSVLLSMQGAVDINRLCEEMLDNRATLQAIASEFSSLPSYAAYATAQEAYEQAVANGDSEVVLKKLKKSLNVAKSEFDRDAAMQRKLEKMADQAMTQMYKQARSEDKRAKVTSAMQTMLFTMLRKLDNDALNNIINNARDGCVPLNIIPLTTAAKLMVVVPDYGTYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEINMDNSPNLAWPLIVTALRANSAVKLQNNELSPVALRQMSCAAGTTQTACTDDNALAYYNNSKGGRFVLALLSDHQDLKWARFPKSDGTGTIYTELEPPCRFVTDTPKGPKVKYLYFIKGLNNLNRGMVLGSLAATVRLQAGNATEVPANSTVLSFCAFAVDPAKAYKDYLASGGQPITNCVKMLCTHTGTGQAITVTPEANMDQESFGGASCCLYCRCHIDHPNPKGFCDLKGKYVQIPTTCANDPVGFTLRNTVCTVCGMWKGYGCSCDQLREPLMQSADASTFLNGFAV
T12005	DRUGINFO	D08ACB	Sabadinine	Investigative

T42335	TARGETID	T42335
T42335	FORMERID	TTDI02112
T42335	UNIPROID	LCRV_YERPE
T42335	TARGNAME	Yersinia pestis Virulence associated V antigen (YP lcrV)
T42335	GENENAME	YP lcrV
T42335	TARGTYPE	Literature-reported
T42335	SYNONYMS	lcrV; YP Virulence-associated V antigen; YP Low calcium response locus protein V
T42335	FUNCTION	Possibly involved in calcium regulation of YOP expression, which includes the export process.
T42335	PDBSTRUC	4JBU; 1R6F
T42335	SEQUENCE	MIRAYEQNPQHFIEDLEKVRVEQLTGHGSSVLEELVQLVKDKNIDISIKYDPRKDSEVFANRVITDDIELLKKILAYFLPEDAILKGGHYDNQLQNGIKRVKEFLESSPNTQWELRAFMAVMHFSLTADRIDDDILKVIVDSMNHHGDARSKLREELAELTAELKIYSVIQAEINKHLSSSGTINIHDKSINLMDKNLYGYTDEEIFKASAEYKILEKMPQTTIQVDGSEKKIVSIKDFLGSENKRTGALGNLKNSYSYNKDNNELSHFATTCSDKSRPLNDLVSQKTTQLSDITSRFNSAIEALNRFIQKYDSVMQRLLDDTSGK

T17863	TARGETID	T17863
T17863	FORMERID	TTDI03449
T17863	UNIPROID	PEPA5_HUMAN
T17863	TARGNAME	Pepsinogen-5 (PGA5)
T17863	GENENAME	PGA5
T17863	TARGTYPE	Literature-reported
T17863	SYNONYMS	Pepsin A-5
T17863	FUNCTION	Shows particularly broad specificity; although bonds involving phenylalanine and leucine are preferred, many others are also cleaved to some extent.
T17863	ECNUMBER	EC 3.4.23.1
T17863	SEQUENCE	MKWLLLLGLVALSECIMYKVPLIRKKSLRRTLSERGLLKDFLKKHNLNPARKYFPQWEAPTLVDEQPLENYLDMEYFGTIGIGTPAQDFTVVFDTGSSNLWVPSVYCSSLACTNHNRFNPEDSSTYQSTSETVSITYGTGSMTGILGYDTVQVGGISDTNQIFGLSETEPGSFLYYAPFDGILGLAYPSISSSGATPVFDNIWNQGLVSQDLFSVYLSADDKSGSVVIFGGIDSSYYTGSLNWVPVTVEGYWQITVDSITMNGETIACAEGCQAIVDTGTSLLTGPTSPIANIQSDIGASENSDGDMVVSCSAISSLPDIVFTINGVQYPVPPSAYILQSEGSCISGFQGMNVPTESGELWILGDVFIRQYFTVFDRANNQVGLAPVA
T17863	DRUGINFO	D0P6RT	PMID8410973C3	Investigative

T55447	TARGETID	T55447
T55447	FORMERID	TTDI01681
T55447	UNIPROID	SAA1_HUMAN
T55447	TARGNAME	Serum amyloid A-1 protein (SAA1)
T55447	GENENAME	SAA1
T55447	TARGTYPE	Literature-reported
T55447	SYNONYMS	SAA
T55447	FUNCTION	Major acute phase protein.
T55447	PDBSTRUC	6MST; 4IP9; 4IP8
T55447	SEQUENCE	MKLLTGLVFCSLVLGVSSRSFFSFLGEAFDGARDMWRAYSDMREANYIGSDKYFHARGNYDAAKRGPGGVWAAEAISDARENIQRFFGHGAEDSLADQAANEWGRSGKDPNHFRPAGLPEKY

T68596	TARGETID	T68596
T68596	FORMERID	TTDR00990
T68596	UNIPROID	TRBR1_HUMAN
T68596	TARGNAME	M1-specific T cell receptor beta chain (TRB)
T68596	GENENAME	TRB
T68596	TARGTYPE	Literature-reported
T68596	SYNONYMS	TR beta chain TRBV19*01J2S7*01C*02
T68596	FUNCTION	The beta chain of TRAV27*01J42*01C*01/TRBV19*01J2S7*01C*02 alpha-beta T cell receptor (TR) clonotype that is specific for HLA-A*02:01-restricted M/matrix protein 1 immunodominant epitope GILGFVFTL of influenza A virus (IAV). Classified as a public TCR clonotype, it is preferentially selected in effector memory CD8-positive T cells among multiple HLA-A*02:01 carriers/individuals and confers long-lived immunity against IAV infection. Can cross-recognize sporadically emerging IAV variants by molecular mimicry, inducing immunity toward different influenza strains. Antigen recognition initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn, ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell differentiation into effector/memory T cells (By similarity).
T68596	PDBSTRUC	5HHO; 5HHM; 2VLR; 2VLK; 2VLJ
T68596	SEQUENCE	MSNQVLCCVVLCLLGANTVDGGITQSPKYLFRKEGQNVTLSCEQNLNHDAMYWYRQDPGQGLRLIYYSQIVNDFQKGDIAEGYSVSREKKESFPLTVTSAQKNPTAFYLCASSIRSSYEQYFGPGTRLTVTEDLKNVFPPKVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSESYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDSRG

T93223	TARGETID	T93223
T93223	UNIPROID	SRGN_HUMAN
T93223	TARGNAME	Serglycin (SRGN)
T93223	GENENAME	SRGN
T93223	TARGTYPE	Literature-reported
T93223	SYNONYMS	Secretory granule proteoglycan core protein; Platelet proteoglycan core protein; PRG1; PRG; P.PG; Hematopoietic proteoglycan core protein
T93223	FUNCTION	Plays a role in formation of mast cell secretory granules and mediates storage of various compounds in secretory vesicles. Required for storage of some proteases in both connective tissue and mucosal mast cells and for storage of granzyme B in T-lymphocytes. Plays a role in localizing neutrophil elastase in azurophil granules of neutrophils. Mediates processing of MMP2. Plays a role in cytotoxic cell granule-mediated apoptosis by forming a complex with granzyme B which is delivered to cells by perforin to induce apoptosis. Regulates the secretion of TNF-alpha and may also regulate protease secretion. Inhibits bone mineralization.
T93223	BIOCLASS	Serglycin family
T93223	SEQUENCE	MMQKLLKCSRLVLALALILVLESSVQGYPTRRARYQWVRCNPDSNSANCLEEKGPMFELLPGESNKIPRLRTDLFPKTRIQDLNRIFPLSEDYSGSGFGSGSGSGSGSGSGFLTEMEQDYQLVDESDAFHDNLRSLDRNLPSDSQDLGQHGLEEDFML

T24595	TARGETID	T24595
T24595	FORMERID	TTDI03009
T24595	UNIPROID	ACRO_HUMAN
T24595	TARGNAME	Acrosin (ACR)
T24595	GENENAME	ACR
T24595	TARGTYPE	Literature-reported
T24595	SYNONYMS	ACRS
T24595	FUNCTION	Acrosin is the major protease of mammalian spermatozoa. It is a serine protease of trypsin-like cleavage specificity, it is synthesized in a zymogen form, proacrosin and stored in the acrosome.
T24595	ECNUMBER	EC 3.4.21.10
T24595	SEQUENCE	MVEMLPTAILLVLAVSVVAKDNATCDGPCGLRFRQNPQGGVRIVGGKAAQHGAWPWMVSLQIFTYNSHRYHTCGGSLLNSRWVLTAAHCFVGKNNVHDWRLVFGAKEITYGNNKPVKAPLQERYVEKIIIHEKYNSATEGNDIALVEITPPISCGRFIGPGCLPHFKAGLPRGSQSCWVAGWGYIEEKAPRPSSILMEARVDLIDLDLCNSTQWYNGRVQPTNVCAGYPVGKIDTCQGDSGGPLMCKDSKESAYVVVGITSWGVGCARAKRPGIYTATWPYLNWIASKIGSNALRMIQSATPPPPTTRPPPIRPPFSHPISAHLPWYFQPPPRPLPPRPPAAQPRPPPSPPPPPPPPASPLPPPPPPPPPTPSSTTKLPQGLSFAKRLQQLIEVLKGKTYSDGKNHYDMETTELPELTSTS
T24595	DRUGINFO	D0F9YV	PMID3514912C9	Investigative

T00032	TARGETID	T00032
T00032	FORMERID	TTDR00484
T00032	UNIPROID	OSTP_HUMAN
T00032	TARGNAME	Osteopontin (SPP1)
T00032	GENENAME	SPP1
T00032	TARGTYPE	Literature-reported
T00032	SYNONYMS	Uropontin; Urinary stone protein; Secreted phosphoprotein 1; SPP-1; PSEC0156; OPN; Nephropontin; Bone sialoprotein 1; BNSP
T00032	FUNCTION	Appears to form an integral part of the mineralized matrix. Probably important to cell-matrix interaction. Binds tightly to hydroxyapatite.
T00032	PDBSTRUC	3DSF; 3CXD
T00032	SEQUENCE	MRIAVICFCLLGITCAIPVKQADSGSSEEKQLYNKYPDAVATWLNPDPSQKQNLLAPQNAVSSEETNDFKQETLPSKSNESHDHMDDMDDEDDDDHVDSQDSIDSNDSDDVDDTDDSHQSDESHHSDESDELVTDFPTDLPATEVFTPVVPTVDTYDGRGDSVVYGLRSKSKKFRRPDIQYPDATDEDITSHMESEELNGAYKAIPVAQDLNAPSDWDSRGKDSYETSQLDDQSAETHSHKQSRLYKRKANDESNEHSDVIDSQELSKVSREFHSHEFHSHEDMLVVDPKSKEEDKHLKFRISHELDSASSEVN

T60443	TARGETID	T60443
T60443	FORMERID	TTDI01493
T60443	UNIPROID	LSTP_STAST
T60443	TARGNAME	Staphylococcus Lysostaphin (Stap-coc lss)
T60443	GENENAME	Stap-coc lss
T60443	TARGTYPE	Literature-reported
T60443	SYNONYMS	Lysostaphin; Glycyl-glycine endopeptidase
T60443	FUNCTION	Lyses staphylococcal cells by hydrolyzing the polyglycine interpeptide bridges of the peptidoglycan.
T60443	ECNUMBER	EC 3.4.24.75
T60443	SEQUENCE	MKKTKNNYYTTPLAIGLSTFALASIVYGGIQNETHASEKSNMDVSKKVAEVETSKPPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKALVQNRTALRAATHEHSAQWLNNYKKGYGYGPYPLGINGGIHYGVDFFMNIGTPVKAISSGKIVEAGWSNYGGGNQIGLIENDGVHRQWYMHLSKYNVKVGDYVKAGQIIGWSGSTGYSTAPHLHFQRMVNSFSNSTAQDPMPFLKSAGYGKAGGTVTPTPNTGWKTNKYGTLYKSESASFTPNTDIITRTTGPFRSMPQSGVLKAGQTIHYDEVMKQDGHVWVGYTGNSGQRIYLPVRTWNKSTNTLGVLWGTIK

T32699	TARGETID	T32699
T32699	FORMERID	TTDI02122
T32699	UNIPROID	MBL2_HUMAN
T32699	TARGNAME	Mannose binding protein (MBL2)
T32699	GENENAME	MBL2
T32699	TARGTYPE	Literature-reported
T32699	SYNONYMS	Mannosebinding protein C; Mannosebinding lectin; Mannanbinding protein; MBPC; MBP1; MBL2; Collectin1
T32699	FUNCTION	Calcium-dependent lectin involved in innate immune defense. Binds mannose, fucose and N-acetylglucosamine on different microorganisms and activates the lectin complement pathway. Binds to late apoptotic cells, as well as to apoptotic blebs and to necrotic cells, but not to early apoptotic cells, facilitating their uptake by macrophages. May bind DNA. {ECO:0000269|PubMed:14515269}.
T32699	PDBSTRUC	1HUP
T32699	SEQUENCE	MSLFPSLPLLLLSMVAASYSETVTCEDAQKTCPAVIACSSPGINGFPGKDGRDGTKGEKGEPGQGLRGLQGPPGKLGPPGNPGPSGSPGPKGQKGDPGKSPDGDSSLAASERKALQTEMARIKKWLTFSLGKQVGNKFFLTNGEIMTFEKVKALCVKFQASVATPRNAAENGAIQNLIKEEAFLGITDEKTEGQFVDLTGNRLTYTNWNEGEPNNAGSDEDCVLLLKNGQWNDVPCSTSHLAVCEFPI

T31145	TARGETID	T31145
T31145	FORMERID	TTDI02604
T31145	UNIPROID	LAMP1_HUMAN
T31145	TARGNAME	Lysosome-associated membrane glycoprotein 1 (CD107a)
T31145	GENENAME	LAMP1
T31145	TARGTYPE	Literature-reported
T31145	SYNONYMS	Lysosomeassociated membrane protein 1; Lysosomeassociated membrane glycoprotein 1; Lysosome-associated membrane protein 1; LAMP-1; CD107 antigenlike family member A; CD107 antigen-like family member A
T31145	FUNCTION	Implicated in tumor cell metastasis. Presents carbohydrate ligands to selectins.
T31145	BIOCLASS	Lysosomal protein import
T31145	SEQUENCE	MAAPGSARRPLLLLLLLLLLGLMHCASAAMFMVKNGNGTACIMANFSAAFSVNYDTKSGPKNMTFDLPSDATVVLNRSSCGKENTSDPSLVIAFGRGHTLTLNFTRNATRYSVQLMSFVYNLSDTHLFPNASSKEIKTVESITDIRADIDKKYRCVSGTQVHMNNVTVTLHDATIQAYLSNSSFSRGETRCEQDRPSPTTAPPAPPSPSPSPVPKSPSVDKYNVSGTNGTCLLASMGLQLNLTYERKDNTTVTRLLNINPNKTSASGSCGAHLVTLELHSEGTTVLLFQFGMNASSSRFFLQGIQLNTILPDARDPAFKAANGSLRALQATVGNSYKCNAEEHVRVTKAFSVNIFKVWVQAFKVEGGQFGSVEECLLDENSMLIPIAVGGALAGLVLIVLIAYLVGRKRSHAGYQTI

T93484	TARGETID	T93484
T93484	FORMERID	TTDI02204
T93484	UNIPROID	UTER_HUMAN
T93484	TARGNAME	Uteroglobin (SCGB1A1)
T93484	GENENAME	SCGB1A1
T93484	TARGTYPE	Literature-reported
T93484	SYNONYMS	Urine protein 1; Urinary protein 1; UP-1; Secretoglobin family 1A member 1; SCGB1A1; Clara cells 10 kDa secretory protein; Clara cell phospholipid-binding protein; CCPBP; CC10
T93484	FUNCTION	Binds phosphatidylcholine, phosphatidylinositol, polychlorinated biphenyls (PCB) and weakly progesterone, potent inhibitor of phospholipase A2.
T93484	BIOCLASS	Secretoglobin family
T93484	SEQUENCE	MKLAVTLTLVTLALCCSSASAEICPSFQRVIETLLMDTPSSYEAAMELFSPDQDMREAGAQLKKLVDTLPQKPRESIIKLMEKIAQSSLCN

T83450	TARGETID	T83450
T83450	FORMERID	TTDI00004
T83450	UNIPROID	CO6A3_HUMAN
T83450	TARGNAME	Collagen VI (COL6A3)
T83450	GENENAME	COL6A3
T83450	TARGTYPE	Literature-reported
T83450	SYNONYMS	COL6A3
T83450	FUNCTION	Collagen VI acts as a cell-binding protein.
T83450	PDBSTRUC	2KNT; 1KUN; 1KTH; 1KNT
T83450	SEQUENCE	MRKHRHLPLVAVFCLFLSGFPTTHAQQQQADVKNGAAADIIFLVDSSWTIGEEHFQLVREFLYDVVKSLAVGENDFHFALVQFNGNPHTEFLLNTYRTKQEVLSHISNMSYIGGTNQTGKGLEYIMQSHLTKAAGSRAGDGVPQVIVVLTDGHSKDGLALPSAELKSADVNVFAIGVEDADEGALKEIASEPLNMHMFNLENFTSLHDIVGNLVSCVHSSVSPERAGDTETLKDITAQDSADIIFLIDGSNNTGSVNFAVILDFLVNLLEKLPIGTQQIRVGVVQFSDEPRTMFSLDTYSTKAQVLGAVKALGFAGGELANIGLALDFVVENHFTRAGGSRVEEGVPQVLVLISAGPSSDEIRYGVVALKQASVFSFGLGAQAASRAELQHIATDDNLVFTVPEFRSFGDLQEKLLPYIVGVAQRHIVLKPPTIVTQVIEVNKRDIVFLVDGSSALGLANFNAIRDFIAKVIQRLEIGQDLIQVAVAQYADTVRPEFYFNTHPTKREVITAVRKMKPLDGSALYTGSALDFVRNNLFTSSAGYRAAEGIPKLLVLITGGKSLDEISQPAQELKRSSIMAFAIGNKGADQAELEEIAFDSSLVFIPAEFRAAPLQGMLPGLLAPLRTLSGTPEVHSNKRDIIFLLDGSANVGKTNFPYVRDFVMNLVNSLDIGNDNIRVGLVQFSDTPVTEFSLNTYQTKSDILGHLRQLQLQGGSGLNTGSALSYVYANHFTEAGGSRIREHVPQLLLLLTAGQSEDSYLQAANALTRAGILTFCVGASQANKAELEQIAFNPSLVYLMDDFSSLPALPQQLIQPLTTYVSGGVEEVPLAQPESKRDILFLFDGSANLVGQFPVVRDFLYKIIDELNVKPEGTRIAVAQYSDDVKVESRFDEHQSKPEILNLVKRMKIKTGKALNLGYALDYAQRYIFVKSAGSRIEDGVLQFLVLLVAGRSSDRVDGPASNLKQSGVVPFIFQAKNADPAELEQIVLSPAFILAAESLPKIGDLHPQIVNLLKSVHNGAPAPVSGEKDVVFLLDGSEGVRSGFPLLKEFVQRVVESLDVGQDRVRVAVVQYSDRTRPEFYLNSYMNKQDVVNAVRQLTLLGGPTPNTGAALEFVLRNILVSSAGSRITEGVPQLLIVLTADRSGDDVRNPSVVVKRGGAVPIGIGIGNADITEMQTISFIPDFAVAIPTFRQLGTVQQVISERVTQLTREELSRLQPVLQPLPSPGVGGKRDVVFLIDGSQSAGPEFQYVRTLIERLVDYLDVGFDTTRVAVIQFSDDPKVEFLLNAHSSKDEVQNAVQRLRPKGGRQINVGNALEYVSRNIFKRPLGSRIEEGVPQFLVLISSGKSDDEVDDPAVELKQFGVAPFTIARNADQEELVKISLSPEYVFSVSTFRELPSLEQKLLTPITTLTSEQIQKLLASTRYPPPAVESDAADIVFLIDSSEGVRPDGFAHIRDFVSRIVRRLNIGPSKVRVGVVQFSNDVFPEFYLKTYRSQAPVLDAIRRLRLRGGSPLNTGKALEFVARNLFVKSAGSRIEDGVPQHLVLVLGGKSQDDVSRFAQVIRSSGIVSLGVGDRNIDRTELQTITNDPRLVFTVREFRELPNIEERIMNSFGPSAATPAPPGVDTPPPSRPEKKKADIVFLLDGSINFRRDSFQEVLRFVSEIVDTVYEDGDSIQVGLVQYNSDPTDEFFLKDFSTKRQIIDAINKVVYKGGRHANTKVGLEHLRVNHFVPEAGSRLDQRVPQIAFVITGGKSVEDAQDVSLALTQRGVKVFAVGVRNIDSEEVGKIASNSATAFRVGNVQELSELSEQVLETLHDAMHETLCPGVTDAAKACNLDVILGFDGSRDQNVFVAQKGFESKVDAILNRISQMHRVSCSGGRSPTVRVSVVANTPSGPVEAFDFDEYQPEMLEKFRNMRSQHPYVLTEDTLKVYLNKFRQSSPDSVKVVIHFTDGADGDLADLHRASENLRQEGVRALILVGLERVVNLERLMHLEFGRGFMYDRPLRLNLLDLDYELAEQLDNIAEKACCGVPCKCSGQRGDRGPIGSIGPKGIPGEDGYRGYPGDEGGPGERGPPGVNGTQGFQGCPGQRGVKGSRGFPGEKGEVGEIGLDGLDGEDGDKGLPGSSGEKGNPGRRGDKGPRGEKGERGDVGIRGDPGNPGQDSQERGPKGETGDLGPMGVPGRDGVPGGPGETGKNGGFGRRGPPGAKGNKGGPGQPGFEGEQGTRGAQGPAGPAGPPGLIGEQGISGPRGSGGAAGAPGERGRTGPLGRKGEPGEPGPKGGIGNRGPRGETGDDGRDGVGSEGRRGKKGERGFPGYPGPKGNPGEPGLNGTTGPKGIRGRRGNSGPPGIVGQKGDPGYPGPAGPKGNRGDSIDQCALIQSIKDKCPCCYGPLECPVFPTELAFALDTSEGVNQDTFGRMRDVVLSIVNDLTIAESNCPRGARVAVVTYNNEVTTEIRFADSKRKSVLLDKIKNLQVALTSKQQSLETAMSFVARNTFKRVRNGFLMRKVAVFFSNTPTRASPQLREAVLKLSDAGITPLFLTRQEDRQLINALQINNTAVGHALVLPAGRDLTDFLENVLTCHVCLDICNIDPSCGFGSWRPSFRDRRAAGSDVDIDMAFILDSAETTTLFQFNEMKKYIAYLVRQLDMSPDPKASQHFARVAVVQHAPSESVDNASMPPVKVEFSLTDYGSKEKLVDFLSRGMTQLQGTRALGSAIEYTIENVFESAPNPRDLKIVVLMLTGEVPEQQLEEAQRVILQAKCKGYFFVVLGIGRKVNIKEVYTFASEPNDVFFKLVDKSTELNEEPLMRFGRLLPSFVSSENAFYLSPDIRKQCDWFQGDQPTKNLVKFGHKQVNVPNNVTSSPTSNPVTTTKPVTTTKPVTTTTKPVTTTTKPVTIINQPSVKPAAAKPAPAKPVAAKPVATKMATVRPPVAVKPATAAKPVAAKPAAVRPPAAAAAKPVATKPEVPRPQAAKPAATKPATTKPMVKMSREVQVFEITENSAKLHWERAEPPGPYFYDLTVTSAHDQSLVLKQNLTVTDRVIGGLLAGQTYHVAVVCYLRSQVRATYHGSFSTKKSQPPPPQPARSASSSTINLMVSTEPLALTETDICKLPKDEGTCRDFILKWYYDPNTKSCARFWYGGCGGNENKFGSQKECEKVCAPVLAKPGVISVMGT

T98090	TARGETID	T98090
T98090	FORMERID	TTDR01036
T98090	UNIPROID	KCRB_HUMAN; KCRS_HUMAN; KCRU_HUMAN; KCRM_HUMAN
T98090	TARGNAME	Creatine kinase (CK)
T98090	GENENAME	CKB; CKMT2; CKMT1A; CKM
T98090	TARGTYPE	Literature-reported
T98090	SYNONYMS	Creatine kinase
T98090	FUNCTION	Reversibly catalyzes the transfer of phosphate between ATP and various phosphogens (e.g. creatine phosphate). Creatine kinase isoenzymes play a central role in energy transduction in tissues with large, fluctuating energy demands, such as skeletal muscle, heart, brain and spermatozoa.
T98090	BIOCLASS	Kinase
T98090	SEQUENCE	MPFSNSHNALKLRFPAEDEFPDLSAHNNHMAKVLTPELYAELRAKSTPSGFTLDDVIQTGVDNPGHPYIMTVGCVAGDEESYEVFKDLFDPIIEDRHGGYKPSDEHKTDLNPDNLQGGDDLDPNYVLSSRVRTGRSIRGFCLPPHCSRGERRAIEKLAVEALSSLDGDLAGRYYALKSMTEAEQQQLIDDHFLFDKPVSPLLLASGMARDWPDARGIWHNDNKTFLVWVNEEDHLRVISMQKGGNMKEVFTRFCTGLTQIETLFKSKDYEFMWNPHLGYILTCPSNLGTGLRAGVHIKLPNLGKHEKFSEVLKRLRLQKRGTGGVDTAAVGGVFDVSNADRLGFSEVELVQMVVDGVKLLIEMEQRLEQGQAIDDLMPAQK
T98090	DRUGINFO	D03GXQ	Iodoacetamide	Investigative
T98090	DRUGINFO	D0B1XN	5-(4'-benzoylbiphenyl-4-yl)-2-furoic acid	Investigative

T52629	TARGETID	T52629
T52629	FORMERID	TTDI01452
T52629	UNIPROID	FCG2A_HUMAN; FCG2B_HUMAN; FCG2C_HUMAN
T52629	TARGNAME	Immunoglobulin gamma Fc receptor II (FCGR2)
T52629	GENENAME	FCGR2A; FCGR2B; FCGR2C
T52629	TARGTYPE	Literature-reported
T52629	SYNONYMS	Low affinity immunoglobulin gamma Fc region receptor II; IgG Fc receptor II; IGFR2; FcRII; Fc-gamma-RII; Fc-gamma RII; FCG2; CDw32; CD32
T52629	FUNCTION	Inhibits the functions of activating FcRs, such as phagocytosis and pro-inflammatory cytokine release, mainly by clustering of FCGR2B with different activating FCGR receptors or with the BCR by immune complexes.
T52629	BIOCLASS	Immunoglobulin
T52629	SEQUENCE	MTMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTLTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVLSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSHLDPTFSIPQANHSHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDDKNIYLTLPPNDHVNSNN

T77410	TARGETID	T77410
T77410	FORMERID	TTDI02477
T77410	UNIPROID	BMP4_HUMAN
T77410	TARGNAME	Bone morphogenetic protein 4 (BMP4)
T77410	GENENAME	BMP4
T77410	TARGTYPE	Literature-reported
T77410	SYNONYMS	DVR4; Bone morphogenetic protein 2B; BMP2B; BMP-4; BMP-2B
T77410	FUNCTION	Acts in mesoderm induction, tooth development, limb formation and fracture repair. Acts in concert with PTHLH/PTHRP to stimulate ductal outgrowth during embryonic mammary development and to inhibit hair follicle induction. Induces cartilage and bone formation.
T77410	BIOCLASS	Growth factor
T77410	SEQUENCE	MIPGNRMLMVVLLCQVLLGGASHASLIPETGKKKVAEIQGHAGGRRSGQSHELLRDFEATLLQMFGLRRRPQPSKSAVIPDYMRDLYRLQSGEEEEEQIHSTGLEYPERPASRANTVRSFHHEEHLENIPGTSENSAFRFLFNLSSIPENEVISSAELRLFREQVDQGPDWERGFHRINIYEVMKPPAEVVPGHLITRLLDTRLVHHNVTRWETFDVSPAVLRWTREKQPNYGLAIEVTHLHQTRTHQGQHVRISRSLPQGSGNWAQLRPLLVTFGHDGRGHALTRRRRAKRSPKHHSQRARKKNKNCRRHSLYVDFSDVGWNDWIVAPPGYQAFYCHGDCPFPLADHLNSTNHAIVQTLVNSVNSSIPKACCVPTELSAISMLYLDEYDKVVLKNYQEMVVEGCGCR

T08919	TARGETID	T08919
T08919	FORMERID	TTDR01008
T08919	UNIPROID	CADH1_HUMAN
T08919	TARGNAME	Epithelial cadherin (CDH1)
T08919	GENENAME	CDH1
T08919	TARGTYPE	Literature-reported
T08919	SYNONYMS	Uvomorulin; UVO; E-cadherin gene; E-cadherin; Cadherin-1; CDHE; CD324; CAM 120/80
T08919	FUNCTION	Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. CDH1 is involved in mechanisms regulating cell-cell adhesions, mobility and proliferation of epithelial cells. Has a potent invasive suppressor role. It is a ligand for integrin alpha-E/beta-7.
T08919	PDBSTRUC	6CXY; 4ZTE; 4ZT1; 3L6Y; 3L6X
T08919	SEQUENCE	MGPWSRSLSALLLLLQVSSWLCQEPEPCHPGFDAESYTFTVPRRHLERGRVLGRVNFEDCTGRQRTAYFSLDTRFKVGTDGVITVKRPLRFHNPQIHFLVYAWDSTYRKFSTKVTLNTVGHHHRPPPHQASVSGIQAELLTFPNSSPGLRRQKRDWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPNTPAWEAVYTILNDDGGQFVVTTNPVNNDGILKTAKGLDFEAKQQYILHVAVTNVVPFEVSLTTSTATVTVDVLDVNEAPIFVPPEKRVEVSEDFGVGQEITSYTAQEPDTFMEQKITYRIWRDTANWLEINPDTGAISTRAELDREDFEHVKNSTYTALIIATDNGSPVATGTGTLLLILSDVNDNAPIPEPRTIFFCERNPKPQVINIIDADLPPNTSPFTAELTHGASANWTIQYNDPTQESIILKPKMALEVGDYKINLKLMDNQNKDQVTTLEVSVCDCEGAAGVCRKAQPVEAGLQIPAILGILGGILALLILILLLLLFLRRRAVVKEPLLPPEDDTRDNVYYYDEEGGGEEDQDFDLSQLHRGLDARPEVTRNDVAPTLMSVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYDSLLVFDYEGSGSEAASLSSLNSSESDKDQDYDYLNEWGNRFKKLADMYGGGEDD

T99686	TARGETID	T99686
T99686	FORMERID	TTDI01745
T99686	UNIPROID	ITA4_HUMAN-ITB4_HUMAN
T99686	TARGNAME	Integrin alpha-4/beta-4 (ITGA4/B4)
T99686	GENENAME	ITGA4-ITGB4
T99686	TARGTYPE	Literature-reported
T99686	SYNONYMS	alpha(4)beta(4) integrin; Alpha 4 beta 4 integrin
T99686	FUNCTION	Heterodimeric integral membrane proteins composed of an alpha chain and a beta chain that function in cell surface adhesion and signaling. The encoded preproprotein is proteolytically processed to generate light and heavy chains that comprise the alpha 4 subunit.
T99686	BIOCLASS	Integrin
T99686	SEQUENCE	MAWEARREPGPRRAAVRETVMLLLCLGVPTGRPYNVDTESALLYQGPHNTLFGYSVVLHSHGANRWLLVGAPTANWLANASVINPGAIYRCRIGKNPGQTCEQLQLGSPNGEPCGKTCLEERDNQWLGVTLSRQPGENGSIVTCGHRWKNIFYIKNENKLPTGGCYGVPPDLRTELSKRIAPCYQDYVKKFGENFASCQAGISSFYTKDLIVMGAPGSSYWTGSLFVYNITTNKYKAFLDKQNQVKFGSYLGYSVGAGHFRSQHTTEVVGGAPQHEQIGKAYIFSIDEKELNILHEMKGKKLGSYFGASVCAVDLNADGFSDLLVGAPMQSTIREEGRVFVYINSGSGAVMNAMETNLVGSDKYAARFGESIVNLGDIDNDGFEDVAIGAPQEDDLQGAIYIYNGRADGISSTFSQRIEGLQISKSLSMFGQSISGQIDADNNGYVDVAVGAFRSDSAVLLRTRPVVIVDASLSHPESVNRTKFDCVENGWPSVCIDLTLCFSYKGKEVPGYIVLFYNMSLDVNRKAESPPRFYFSSNGTSDVITGSIQVSSREANCRTHQAFMRKDVRDILTPIQIEAAYHLGPHVISKRSTEEFPPLQPILQQKKEKDIMKKTINFARFCAHENCSADLQVSAKIGFLKPHENKTYLAVGSMKTLMLNVSLFNAGDDAYETTLHVKLPVGLYFIKILELEEKQINCEVTDNSGVVQLDCSIGYIYVDHLSRIDISFLLDVSSLSRAEEDLSITVHATCENEEEMDNLKHSRVTVAIPLKYEVKLTVHGFVNPTSFVYGSNDENEPETCMVEKMNLTFHVINTGNSMAPNVSVEIMVPNSFSPQTDKLFNILDVQTTTGECHFENYQRVCALEQQKSAMQTLKGIVRFLSKTDKRLLYCIKADPHCLNFLCNFGKMESGKEASVHIQLEGRPSILEMDETSALKFEIRATGFPEPNPRVIELNKDENVAHVLLEGLHHQRPKRYFTIVIISSSLLLGLIVLLLISYVMWKAGFFKRQYKSILQEENRRDSWSYINSKSNDDMAGPRPSPWARLLLAALISVSLSGTLANRCKKAPVKSCTECVRVDKDCAYCTDEMFRDRRCNTQAELLAAGCQRESIVVMESSFQITEETQIDTTLRRSQMSPQGLRVRLRPGEERHFELEVFEPLESPVDLYILMDFSNSMSDDLDNLKKMGQNLARVLSQLTSDYTIGFGKFVDKVSVPQTDMRPEKLKEPWPNSDPPFSFKNVISLTEDVDEFRNKLQGERISGNLDAPEGGFDAILQTAVCTRDIGWRPDSTHLLVFSTESAFHYEADGANVLAGIMSRNDERCHLDTTGTYTQYRTQDYPSVPTLVRLLAKHNIIPIFAVTNYSYSYYEKLHTYFPVSSLGVLQEDSSNIVELLEEAFNRIRSNLDIRALDSPRGLRTEVTSKMFQKTRTGSFHIRRGEVGIYQVQLRALEHVDGTHVCQLPEDQKGNIHLKPSFSDGLKMDAGIICDVCTCELQKEVRSARCSFNGDFVCGQCVCSEGWSGQTCNCSTGSLSDIQPCLREGEDKPCSGRGECQCGHCVCYGEGRYEGQFCEYDNFQCPRTSGFLCNDRGRCSMGQCVCEPGWTGPSCDCPLSNATCIDSNGGICNGRGHCECGRCHCHQQSLYTDTICEINYSAIHPGLCEDLRSCVQCQAWGTGEKKGRTCEECNFKVKMVDELKRAEEVVVRCSFRDEDDDCTYSYTMEGDGAPGPNSTVLVHKKKDCPPGSFWWLIPLLLLLLPLLALLLLLCWKYCACCKACLALLPCCNRGHMVGFKEDHYMLRENLMASDHLDTPMLRSGNLKGRDVVRWKVTNNMQRPGFATHAASINPTELVPYGLSLRLARLCTENLLKPDTRECAQLRQEVEENLNEVYRQISGVHKLQQTKFRQQPNAGKKQDHTIVDTVLMAPRSAKPALLKLTEKQVEQRAFHDLKVAPGYYTLTADQDARGMVEFQEGVELVDVRVPLFIRPEDDDEKQLLVEAIDVPAGTATLGRRLVNITIIKEQARDVVSFEQPEFSVSRGDQVARIPVIRRVLDGGKSQVSYRTQDGTAQGNRDYIPVEGELLFQPGEAWKELQVKLLELQEVDSLLRGRQVRRFHVQLSNPKFGAHLGQPHSTTIIIRDPDELDRSFTSQMLSSQPPPHGDLGAPQNPNAKAAGSRKIHFNWLPPSGKPMGYRVKYWIQGDSESEAHLLDSKVPSVELTNLYPYCDYEMKVCAYGAQGEGPYSSLVSCRTHQEVPSEPGRLAFNVVSSTVTQLSWAEPAETNGEITAYEVCYGLVNDDNRPIGPMKKVLVDNPKNRMLLIENLRESQPYRYTVKARNGAGWGPEREAIINLATQPKRPMSIPIIPDIPIVDAQSGEDYDSFLMYSDDVLRSPSGSQRPSVSDDTGCGWKFEPLLGEELDLRRVTWRLPPELIPRLSASSGRSSDAEAPHGPPDDGGAGGKGGSLPRSATPGPPGEHLVNGRMDFAFPGSTNSLHRMTTTSAAAYGTHLSPHVPHRVLSTSSTLTRDYNSLTRSEHSHSTTLPRDYSTLTSVSSHDSRLTAGVPDTPTRLVFSALGPTSLRVSWQEPRCERPLQGYSVEYQLLNGGELHRLNIPNPAQTSVVVEDLLPNHSYVFRVRAQSQEGWGREREGVITIESQVHPQSPLCPLPGSAFTLSTPSAPGPLVFTALSPDSLQLSWERPRRPNGDIVGYLVTCEMAQGGGPATAFRVDGDSPESRLTVPGLSENVPYKFKVQARTTEGFGPEREGIITIESQDGGPFPQLGSRAGLFQHPLQSEYSSITTTHTSATEPFLVDGLTLGAQHLEAGGSLTRHVTQEFVSRTLTTSGTLSTHMDQQFFQT

T25093	TARGETID	T25093
T25093	FORMERID	TTDR00306
T25093	UNIPROID	FEMA_STAAW
T25093	TARGNAME	Staphylococcus Aminoacyltransferase FemA (Stap-coc femA)
T25093	GENENAME	Stap-coc femA
T25093	TARGTYPE	Literature-reported
T25093	SYNONYMS	Factor essential for expression of methicillin resistance
T25093	FUNCTION	May be involved in cell wall or membrane metabolism, or it might be a control element acting on expression of genes involved in cell wall or membrane biosynthesis. It is involved in resistance to the antibiotic methicillin.
T25093	ECNUMBER	EC 2.3.2.17
T25093	SEQUENCE	MKFTNLTAKEFGAFTDSMPYSHFTQTVGHYELKLAEGYETHLVGIKNNNNEVIAACLLTAVPVMKVFKYFYSNRGPVIDYENQELVHFFFNELSKYVKKHRCLYLHIDPYLPYQYLNHDGEITGNAGNDWFFDKMSNLGFEHTGFHKGFDPVLQIRYHSVLDLKDKTADDIIKNMDGLRKRNTKKVKKNGVKVRFLSEEELPIFRSFMEDTSESKAFADRDDKFYYNRLKYYKDRVLVPLAYINFDEYIKELNEERDILNKDLNKALKDIEKRPENKKAHNKRDNLQQQLDANEQKIEEGKRLQEEHGNELPISAGFFFINPFEVVYYAGGTSNAFRHFAGSYAVQWEMINYALNHGIDRYNFYGVSGKFTEDAEDAGVVKFKKGYNAEIIEYVGDFIKPINKPVYAAYTALKKVKDRIF

T47492	TARGETID	T47492
T47492	FORMERID	TTDR00938
T47492	UNIPROID	NCF1_HUMAN
T47492	TARGNAME	Neutrophil cytosol factor 1 (NCF1)
T47492	GENENAME	NCF1
T47492	TARGTYPE	Literature-reported
T47492	SYNONYMS	SH3PXD1A; SH3 and PX domain-containing protein 1A; P47-phox; P47(phox) NAD(P)H oxidase; Nox-organizing protein 2; Nox organizer 2; Neutrophil NADPH oxidase factor 1; NOXO2; NCF-47K; NCF-1; 47 kDa neutrophil oxidase factor; 47 kDa autosomal chronic granulomatous disease protein
T47492	FUNCTION	NCF2, NCF1, and a membrane bound cytochrome b558 are required for activation of the latent NADPH oxidase (necessary for superoxide production).
T47492	PDBSTRUC	1WLP; 1W70; 1UEC; 1OV3; 1O7K
T47492	SEQUENCE	MGDTFIRHIALLGFEKRFVPSQHYVYMFLVKWQDLSEKVVYRRFTEIYEFHKTLKEMFPIEAGAINPENRIIPHLPAPKWFDGQRAAENRQGTLTEYCSTLMSLPTKISRCPHLLDFFKVRPDDLKLPTDNQTKKPETYLMPKDGKSTATDITGPIILQTYRAIANYEKTSGSEMALSTGDVVEVVEKSESGWWFCQMKAKRGWIPASFLEPLDSPDETEDPEPNYAGEPYVAIKAYTAVEGDEVSLLEGEAVEVIHKLLDGWWVIRKDDVTGYFPSMYLQKSGQDVSQAQRQIKRGAPPRRSSIRNAHSIHQRSRKRLSQDAYRRNSVRFLQQRRRQARPGPQSPGSPLEEERQTQRSKPQPAVPPRPSADLILNRCSESTKRKLASAV

T30215	TARGETID	T30215
T30215	FORMERID	TTDR00328
T30215	UNIPROID	ALGQ_PSEAE
T30215	TARGNAME	Pseudomonas Histidine kinase AlgR2 (Pseudo algQ)
T30215	GENENAME	Pseudo algQ
T30215	TARGTYPE	Literature-reported
T30215	SYNONYMS	algQ; Transcriptional regulatory protein AlgQ (mRNA); Alginate regulatory protein AlgR2 (mRNA)
T30215	FUNCTION	The promoter for a critical alginate biosynthetic gene, AlgD, encoding GDP-mannose dehydrogenase, is activated only under conditions reminiscent of the cystic fibrosis lung (i.e. under high osmolarity), and at least two regulatory genes, AlgP and AlgQ, have been implicated in this activation process.
T30215	BIOCLASS	Kinase
T30215	SEQUENCE	MLESCRNAQERWGGVHQLIDRWLHERQQLVQAFDALSGIQAPAPNAEELQHFCQLLLDYVSAGHFEVYEQLTAEGKAFGDQRGLELAKQIFPRLEAITESALNFNDRCDNGDCREGACLIAELKVLRQQLHERFELEDCLIEVLHNAHSQSGAEGSAVPV
T30215	DRUGINFO	D07UCF	LY266500	Investigative

T89299	TARGETID	T89299
T89299	FORMERID	TTDR00840
T89299	UNIPROID	FOSL1_HUMAN
T89299	TARGNAME	Fos-related antigen 1 (FOSL1)
T89299	GENENAME	FOSL1
T89299	TARGTYPE	Literature-reported
T89299	SYNONYMS	Fra-1; FRA1
T89299	FUNCTION	DNA-binding transcription factor activity, DNA-binding transcription factor activity, RNA polymerase II-specific, RNA polymerase II proximal promoter sequence-specific DNA binding, cellular defense response, chemotaxis, positive regulation of cell population proliferation, positive regulation of DNA-templated transcription, initiation, pri-miRNA transcription by RNA polymerase II.
T89299	BIOCLASS	Basic leucine zipper bZIP
T89299	SEQUENCE	MFRDFGEPGPSSGNGGGYGGPAQPPAAAQAAQQKFHLVPSINTMSGSQELQWMVQPHFLGPSSYPRPLTYPQYSPPQPRPGVIRALGPPPGVRRRPCEQISPEEEERRRVRRERNKLAAAKCRNRRKELTDFLQAETDKLEDEKSGLQREIEELQKQKERLELVLEAHRPICKIPEGAKEGDTGSTSGTSSPPAPCRPVPCISLSPGPVLEPEALHTPTLMTTPSLTPFTPSLVFTYPSTPEPCASAHRKSSSSSGDPSSDPLGSPTLLAL

T32600	TARGETID	T32600
T32600	FORMERID	TTDI00198
T32600	UNIPROID	FOSL2_HUMAN
T32600	TARGNAME	Fos-related antigen 2 (FOSL2)
T32600	GENENAME	FOSL2
T32600	TARGTYPE	Literature-reported
T32600	SYNONYMS	FRA2; FRA-2
T32600	FUNCTION	As a dimer with JUN, activates LIF transcription. Activates CEBPB transcription in PGE2-activated osteoblasts. Controls osteoclast survival and size.
T32600	BIOCLASS	Basic leucine zipper bZIP
T32600	SEQUENCE	MYQDYPGNFDTSSRGSSGSPAHAESYSSGGGGQQKFRVDMPGSGSAFIPTINAITTSQDLQWMVQPTVITSMSNPYPRSHPYSPLPGLASVPGHMALPRPGVIKTIGTTVGRRRRDEQLSPEEEEKRRIRRERNKLAAAKCRNRRRELTEKLQAETEELEEEKSGLQKEIAELQKEKEKLEFMLVAHGPVCKISPEERRSPPAPGLQPMRSGGGSVGAVVVKQEPLEEDSPSSSSAGLDKAQRSVIKPISIAGGFYGEEPLHTPIVVTSTPAVTPGTSNLVFTYPSVLEQESPASPSESCSKAHRRSSSSGDQSSDSLNSPTLLAL

T92834	TARGETID	T92834
T92834	FORMERID	TTDI02393
T92834	UNIPROID	AREG_HUMAN
T92834	TARGNAME	Amphiregulin (AREG)
T92834	GENENAME	AREG
T92834	TARGTYPE	Literature-reported
T92834	SYNONYMS	SDGF; Colorectum cellderived growth factor; Colorectum cell-derived growth factor; CRDGF; AREGB; AR
T92834	FUNCTION	Autocrine growth factor as well as a mitogen for a broad range of target cells including astrocytes, Schwann cells and fibroblasts. Ligand of the EGF receptor/EGFR.
T92834	PDBSTRUC	2RNL
T92834	SEQUENCE	MRAPLLPPAPVVLSLLILGSGHYAAGLDLNDTYSGKREPFSGDHSADGFEVTSRSEMSSGSEISPVSEMPSSSEPSSGADYDYSEEYDNEPQIPGYIVDDSVRVEQVVKPPQNKTESENTSDKPKRKKKGGKNGKNRRNRKKKNPCNAEFQNFCIHGECKYIEHLEAVTCKCQQEYFGERCGEKSMKTHSMIDSSLSKIALAAIAAFMSAVILTAVAVITVQLRRQYVRKYEGEAEERKKLRQENGNVHAIA

T48269	TARGETID	T48269
T48269	FORMERID	TTDR00718
T48269	UNIPROID	HN_PI1HW
T48269	TARGNAME	Parainfluenza Hemagglutinin-neuraminidase glycoprotein (HPIV HN)
T48269	GENENAME	HPIV HN
T48269	TARGTYPE	Literature-reported
T48269	SYNONYMS	Hemagglutinin-neuraminidase
T48269	FUNCTION	Attaches the virus to sialic acid-containing cell receptors and thereby initiating infection. Binding of HN protein to the receptor induces a conformational change that allows the F protein to trigger virion/cell membranes fusion (By similarity).
T48269	ECNUMBER	EC 3.2.1.18
T48269	SEQUENCE	MAEKGKTNSSYWSTTRNDNSTVNTYIDTPAGKTHIWLLIATTMHTILSFIIMILCIDLIIKQDTCMKTNIMTVSSMNESAKTIKETITELIRQEVISRTINIQSSVQSGIPILLNKQSRDLTQLIEKSCNRQELAQICENTIAIHHADGISPLDPHDFWRCPVGEPLLSNNPNISLLPGPSLLSGSTTISGCVRLPSLSIGDAIYAYSSNLITQGCADIGKSYQVLQLGYISLNSDMYPDLKPVISHTYDINDNRKSCSVIAAGTRGYQLCSLPTVNETTDYSSEGIEDLVFDILDLKGKTKSHRYKNEDITFDHPFSAMYPSVGSGIKIENTLIFLGYGGLTTPLQGDTKCVTNRCANVNQSVCNDALKITWLKKRQVVNVLIRINNYLSDRPKIVVETIPITQNYLGAEGRLLKLGKKIYIYTRSSGWHSHLQIGSLDINNPMTIKWAPHEVLSRPGNQDCNWYNRCPRECISGVYTDAYPLSPDAVNVATTTLYANTSRVNPTIMYSNTSEIINMLRLKNVQLEAAYTTTSCITHFGKGYCFHIVEINQTSLNTLQPMLFKTSIPKICKITS

T55244	TARGETID	T55244
T55244	FORMERID	TTDI00168
T55244	UNIPROID	H2AX_HUMAN
T55244	TARGNAME	Gamma-Histone H2AX (H2AFX)
T55244	GENENAME	H2AFX
T55244	TARGTYPE	Literature-reported
T55244	SYNONYMS	Phosphorylation of H2AX; Histone H2AX; Histone H2A.x; H2a/x; H2AX
T55244	FUNCTION	Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling. Required for checkpoint-mediated arrest of cell cycle progression in response to low doses of ionizing radiation and for efficient repair of DNA double strand breaks (DSBs) specifically when modified by C-terminal phosphorylation. Variant histone H2A which replaces conventional H2A in a subset of nucleosomes.
T55244	PDBSTRUC	3U3Z; 3SZM; 3SQD; 3SHV; 2DYP
T55244	SEQUENCE	MSGRGKTGGKARAKAKSRSSRAGLQFPVGRVHRLLRKGHYAERVGAGAPVYLAAVLEYLTAEILELAGNAARDNKKTRIIPRHLQLAIRNDEELNKLLGGVTIAQGGVLPNIQAVLLPKKTSATVGPKAPSGGKKATQASQEY

T88920	TARGETID	T88920
T88920	FORMERID	TTDI01419
T88920	UNIPROID	ANK1_HUMAN
T88920	TARGNAME	Ankyrin (ANK)
T88920	GENENAME	ANK1
T88920	TARGTYPE	Literature-reported
T88920	SYNONYMS	Erythrocyte ankyrin; Ankyrin-R; Ankyrin-1; ANK-1; ANK
T88920	FUNCTION	Attaches integral membrane proteins to cytoskeletal elements; binds to the erythrocyte membrane protein band 4.2, to Na-K ATPase, to the lymphocyte membrane protein GP85, and to the cytoskeletal proteins fodrin, tubulin, vimentin and desmin. Erythrocyte ankyrins also link spectrin (beta chain) to the cytoplasmic domain of the erythrocytes anion exchange protein; they retain most or all of these binding functions.
T88920	PDBSTRUC	3UD2; 3UD1; 3KBU; 3KBT; 3F59
T88920	SEQUENCE	MPYSVGFREADAATSFLRAARSGNLDKALDHLRNGVDINTCNQNGLNGLHLASKEGHVKMVVELLHKEIILETTTKKGNTALHIAALAGQDEVVRELVNYGANVNAQSQKGFTPLYMAAQENHLEVVKFLLENGANQNVATEDGFTPLAVALQQGHENVVAHLINYGTKGKVRLPALHIAARNDDTRTAAVLLQNDPNPDVLSKTGFTPLHIAAHYENLNVAQLLLNRGASVNFTPQNGITPLHIASRRGNVIMVRLLLDRGAQIETKTKDELTPLHCAARNGHVRISEILLDHGAPIQAKTKNGLSPIHMAAQGDHLDCVRLLLQYDAEIDDITLDHLTPLHVAAHCGHHRVAKVLLDKGAKPNSRALNGFTPLHIACKKNHVRVMELLLKTGASIDAVTESGLTPLHVASFMGHLPIVKNLLQRGASPNVSNVKVETPLHMAARAGHTEVAKYLLQNKAKVNAKAKDDQTPLHCAARIGHTNMVKLLLENNANPNLATTAGHTPLHIAAREGHVETVLALLEKEASQACMTKKGFTPLHVAAKYGKVRVAELLLERDAHPNAAGKNGLTPLHVAVHHNNLDIVKLLLPRGGSPHSPAWNGYTPLHIAAKQNQVEVARSLLQYGGSANAESVQGVTPLHLAAQEGHAEMVALLLSKQANGNLGNKSGLTPLHLVAQEGHVPVADVLIKHGVMVDATTRMGYTPLHVASHYGNIKLVKFLLQHQADVNAKTKLGYSPLHQAAQQGHTDIVTLLLKNGASPNEVSSDGTTPLAIAKRLGYISVTDVLKVVTDETSFVLVSDKHRMSFPETVDEILDVSEDEGEELISFKAERRDSRDVDEEKELLDFVPKLDQVVESPAIPRIPCAMPETVVIRSEEQEQASKEYDEDSLIPSSPATETSDNISPVASPVHTGFLVSFMVDARGGSMRGSRHNGLRVVIPPRTCAAPTRITCRLVKPQKLSTPPPLAEEEGLASRIIALGPTGAQFLSPVIVEIPHFASHGRGDRELVVLRSENGSVWKEHRSRYGESYLDQILNGMDEELGSLEELEKKRVCRIITTDFPLYFVIMSRLCQDYDTIGPEGGSLKSKLVPLVQATFPENAVTKRVKLALQAQPVPDELVTKLLGNQATFSPIVTVEPRRRKFHRPIGLRIPLPPSWTDNPRDSGEGDTTSLRLLCSVIGGTDQAQWEDITGTTKLVYANECANFTTNVSARFWLSDCPRTAEAVNFATLLYKELTAVPYMAKFVIFAKMNDPREGRLRCYCMTDDKVDKTLEQHENFVEVARSRDIEVLEGMSLFAELSGNLVPVKKAAQQRSFHFQSFRENRLAMPVKVRDSSREPGGSLSFLRKAMKYEDTQHILCHLNITMPPCAKGSGAEDRRRTPTPLALRYSILSESTPGSLSGTEQAEMKMAVISEHLGLSWAELARELQFSVEDINRIRVENPNSLLEQSVALLNLWVIREGQNANMENLYTALQSIDRGEIVNMLEGSGRQSRNLKPDRRHTDRDYSLSPSQMNGYSSLQDELLSPASLGCALSSPLRADQYWNEVAVLDAIPLAATEHDTMLEMSDMQVWSAGLTPSLVTAEDSSLECSKAEDSDATGHEWKLEGALSEEPRGPELGSLELVEDDTVDSDATNGLIDLLEQEEGQRSEEKLPGSKRQDDATGAGQDSENEVSLVSGHQRGQARITHSPTVSQVTERSQDRLQDWDADGSIVSYLQDAAQGSWQEEVTQGPHSFQGTSTMTEGLEPGGSQEYEKVLVSVSEHTWTEQPEAESSQADRDRRQQGQEEQVQEAKNTFTQVVQGNEFQNIPGEQVTEEQFTDEQGNIVTKKIIRKVVRQIDLSSADAAQEHEEVTVEGPLEDPSELEVDIDYFMKHSKDHTSTPNP

T08985	TARGETID	T08985
T08985	FORMERID	TTDI02499
T08985	UNIPROID	1A33_HUMAN
T08985	TARGNAME	MHC class I antigen A*33 (HLA-A)
T08985	GENENAME	HLA-A
T08985	TARGTYPE	Literature-reported
T08985	SYNONYMS	HLAA; HLA-A; HLA class I histocompatibility antigen, A33 alpha chain; Aw33; Aw19
T08985	FUNCTION	Involved in the presentation of foreign antigens to the immune system.
T08985	BIOCLASS	MHC class I
T08985	SEQUENCE	MAVMAPRTLLLLLSGALALTQTWAGSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDQETRNVKAQSQTDRVDLGTLRGYYNQSEAGSHTIQIMYGCDVGSDGRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITKRKWEAAHEAEQLRAYLDGTCVEWLRRYLENGKETLQRTDPPKTHMTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWELSSQPTIPIVGIIAGLVLLGAVITGAVVAAVMWRRKSSDRKGGSYTQAASSDSAQGSDVSLTACKV

T89056	TARGETID	T89056
T89056	FORMERID	TTDI02394
T89056	UNIPROID	PECA1_HUMAN
T89056	TARGNAME	Platelet endothelial cell adhesion molecule (PECAM1)
T89056	GENENAME	PECAM1
T89056	TARGTYPE	Literature-reported
T89056	SYNONYMS	PECAM-1; PECA1; GPIIA'; EndoCAM; ECAM; CD31 antigen; CD31
T89056	FUNCTION	Tyr-690 plays a critical role in TEM and is required for efficient trafficking of PECAM1 to and from the lateral border recycling compartment (LBRC) and is also essential for the LBRC membrane to be targeted around migrating leukocytes. Trans-homophilic interaction may play a role in endothelial cell-cell adhesion via cell junctions. Heterophilic interaction with CD177 plays a role in transendothelial migration of neutrophils. Homophilic ligation of PECAM1 prevents macrophage-mediated phagocytosis of neighboring viable leukocytes by transmitting a detachment signal. Promotes macrophage-mediated phagocytosis of apoptotic leukocytes by tethering them to the phagocytic cells; PECAM1-mediated detachment signal appears to be disabled in apoptotic leukocytes. Modulates bradykinin receptor BDKRB2 activation. Regulates bradykinin- and hyperosmotic shock-induced ERK1/2 activation in endothelial cells. Induces susceptibility to atherosclerosis. Cell adhesion molecule which is required for leukocyte transendothelial migration (TEM) under most inflammatory conditions.
T89056	PDBSTRUC	5GNI; 5C14; 2KY5
T89056	SEQUENCE	MQPRWAQGATMWLGVLLTLLLCSSLEGQENSFTINSVDMKSLPDWTVQNGKNLTLQCFADVSTTSHVKPQHQMLFYKDDVLFYNISSMKSTESYFIPEVRIYDSGTYKCTVIVNNKEKTTAEYQVLVEGVPSPRVTLDKKEAIQGGIVRVNCSVPEEKAPIHFTIEKLELNEKMVKLKREKNSRDQNFVILEFPVEEQDRVLSFRCQARIISGIHMQTSESTKSELVTVTESFSTPKFHISPTGMIMEGAQLHIKCTIQVTHLAQEFPEIIIQKDKAIVAHNRHGNKAVYSVMAMVEHSGNYTCKVESSRISKVSSIVVNITELFSKPELESSFTHLDQGERLNLSCSIPGAPPANFTIQKEDTIVSQTQDFTKIASKSDSGTYICTAGIDKVVKKSNTVQIVVCEMLSQPRISYDAQFEVIKGQTIEVRCESISGTLPISYQLLKTSKVLENSTKNSNDPAVFKDNPTEDVEYQCVADNCHSHAKMLSEVLRVKVIAPVDEVQISILSSKVVESGEDIVLQCAVNEGSGPITYKFYREKEGKPFYQMTSNATQAFWTKQKASKEQEGEYYCTAFNRANHASSVPRSKILTVRVILAPWKKGLIAVVIIGVIIALLIIAAKCYFLRKAKAKQMPVEMSRPAVPLLNSNNEKMSDPNMEANSHYGHNDDVRNHAMKPINDNKEPLNSDVQYTEVQVSSAESHKDLGKKDTETVYSEVRKAVPDAVESRYSRTEGSLDGT

T19492	TARGETID	T19492
T19492	FORMERID	TTDI03326
T19492	UNIPROID	KCNA2_HUMAN
T19492	TARGNAME	Voltage-gated potassium channel Kv1.2 (KCNA2)
T19492	GENENAME	KCNA2
T19492	TARGTYPE	Literature-reported
T19492	SYNONYMS	Voltage-gated potassium channel subunit Kv1.2; Voltage-gated potassium channel HBK5; Voltage-gated K(+) channel HuKIV; Potassium voltage-gated channel subfamily A member 2; NGK1
T19492	FUNCTION	Prevents aberrant action potential firing and regulates neuronal output. Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage difference across the membrane. Can form functional homotetrameric channels and heterotetrameric channels that contain variable proportions of KCNA1, KCNA2, KCNA4, KCNA5, KCNA6, KCNA7, and possibly other family members as well; channel properties depend on the type of alpha subunits that are part of the channel. Channel properties are modulated by cytoplasmic beta subunits that regulate the subcellular location of the alpha subunits and promote rapid inactivation of delayed rectifier potassium channels. In vivo, membranes probably contain a mixture of heteromeric potassium channel complexes, making it difficult to assign currents observed in intact tissues to any particular potassium channel family member. Homotetrameric KCNA2 forms a delayed-rectifier potassium channel that opens in response to membrane depolarization, followed by slow spontaneous channel closure. In contrast, a heteromultimer formed by KCNA2 and KCNA4 shows rapid inactivation. Regulates neuronal excitability and plays a role as pacemaker in the regulation of neuronal action potentials. KCNA2-containing channels play a presynaptic role and prevent hyperexcitability and aberrant action potential firing. Response to toxins that are selective for KCNA2-containing potassium channels suggests that in Purkinje cells, dendritic subthreshold KCNA2-containing potassium channels prevent random spontaneous calcium spikes, suppressing dendritic hyperexcitability without hindering the generation of somatic action potentials, and thereby play an important role in motor coordination. Plays a role in the induction of long-term potentiation of neuron excitability in the CA3 layer of the hippocampus. May function as down-stream effector for G protein-coupled receptors and inhibit GABAergic inputs to basolateral amygdala neurons. May contribute to the regulation of neurotransmitter release, such as gamma-aminobutyric acid (GABA). Contributes to the regulation of the axonal release of the neurotransmitter dopamine. Reduced KCNA2 expression plays a role in the perception of neuropathic pain after peripheral nerve injury, but not acute pain. Plays a role in the regulation of the time spent in non-rapid eye movement (NREM) sleep. Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and the central nervous system, but also in the cardiovascular system.
T19492	BIOCLASS	Voltage-gated ion channel
T19492	SEQUENCE	MTVATGDPADEAAALPGHPQDTYDPEADHECCERVVINISGLRFETQLKTLAQFPETLLGDPKKRMRYFDPLRNEYFFDRNRPSFDAILYYYQSGGRLRRPVNVPLDIFSEEIRFYELGEEAMEMFREDEGYIKEEERPLPENEFQRQVWLLFEYPESSGPARIIAIVSVMVILISIVSFCLETLPIFRDENEDMHGSGVTFHTYSNSTIGYQQSTSFTDPFFIVETLCIIWFSFEFLVRFFACPSKAGFFTNIMNIIDIVAIIPYFITLGTELAEKPEDAQQGQQAMSLAILRVIRLVRVFRIFKLSRHSKGLQILGQTLKASMRELGLLIFFLFIGVILFSSAVYFAEADERESQFPSIPDAFWWAVVSMTTVGYGDMVPTTIGGKIVGSLCAIAGVLTIALPVPVIVSNFNYFYHRETEGEEQAQYLQVTSCPKIPSSPDLKKSRSASTISKSDYMEIQEGVNNSNEDFREENLKTANCTLANTNYVNITKMLTDV
T19492	DRUGINFO	D02VKU	mast cell degranulating peptide	Investigative
T19492	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T68211	TARGETID	T68211
T68211	FORMERID	TTDNR00688
T68211	UNIPROID	HMGA1_HUMAN
T68211	TARGNAME	High mobility group protein HMG-I/Y (HMGA1)
T68211	GENENAME	HMGA1
T68211	TARGTYPE	Literature-reported
T68211	SYNONYMS	High mobility group protein R; High mobility group protein HMG-I/HMG-Y; High mobility group protein A1; High mobility group AT-hook protein 1; HMGIY; HMG-I(Y)
T68211	FUNCTION	It is suggested that these proteins could function in nucleosome phasing and in the 3'-end processing of mRNA transcripts. They are also involved in the transcription regulation of genes containing, or in close proximity to A+T-rich regions. HMG-I/Y bind preferentially to the minor groove of A+T rich regions in double-stranded DNA.
T68211	PDBSTRUC	2EZG; 2EZF; 2EZE; 2EZD
T68211	SEQUENCE	MSESSSKSSQPLASKQEKDGTEKRGRGRPRKQPPVSPGTALVGSQKEPSEVPTPKRPRGRPKGSKNKGAAKTRKTTTTPGRKPRGRPKKLEKEEEEGISQESSEEEQ

T65561	TARGETID	T65561
T65561	FORMERID	TTDI03328
T65561	UNIPROID	KCNA6_HUMAN
T65561	TARGNAME	Voltage-gated potassium channel Kv1.6 (KCNA6)
T65561	GENENAME	KCNA6
T65561	TARGTYPE	Literature-reported
T65561	SYNONYMS	Voltage-gated potassium channel subunit Kv1.6; Voltage-gated potassium channel HBK2; Potassium voltage-gated channel subfamily A member 6
T65561	FUNCTION	Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes. Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage difference across the membrane. Can form functional homotetrameric channels and heterotetrameric channels that contain variable proportions of KCNA1, KCNA2, KCNA4, KCNA6, and possibly other family members as well; channel properties depend on the type of alpha subunits that are part of the channel (By similarity). Channel properties are modulated by cytoplasmic beta subunits that regulate the subcellular location of the alpha subunits and promote rapid inactivation (By similarity). Homotetrameric channels display rapid activation and slow inactivation.
T65561	BIOCLASS	Voltage-gated ion channel
T65561	SEQUENCE	MRSEKSLTLAAPGEVRGPEGEQQDAGDFPEAGGGGGCCSSERLVINISGLRFETQLRTLSLFPDTLLGDPGRRVRFFDPLRNEYFFDRNRPSFDAILYYYQSGGRLRRPVNVPLDIFLEEIRFYQLGDEALAAFREDEGCLPEGGEDEKPLPSQPFQRQVWLLFEYPESSGPARGIAIVSVLVILISIVIFCLETLPQFRVDGRGGNNGGVSRVSPVSRGSQEEEEDEDDSYTFHHGITPGEMGTGGSSSLSTLGGSFFTDPFFLVETLCIVWFTFELLVRFSACPSKPAFFRNIMNIIDLVAIFPYFITLGTELVQQQEQQPASGGGGQNGQQAMSLAILRVIRLVRVFRIFKLSRHSKGLQILGKTLQASMRELGLLIFFLFIGVILFSSAVYFAEADDDDSLFPSIPDAFWWAVVTMTTVGYGDMYPMTVGGKIVGSLCAIAGVLTIALPVPVIVSNFNYFYHRETEQEEQGQYTHVTCGQPAPDLRATDNGLGKPDFPEANRERRPSYLPTPHRAYAEKRMLTEV
T65561	DRUGINFO	D02VKU	mast cell degranulating peptide	Investigative
T65561	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T93966	TARGETID	T93966
T93966	UNIPROID	NEUM_HUMAN
T93966	TARGNAME	Neuromodulin (GAP43)
T93966	GENENAME	GAP43
T93966	TARGTYPE	Literature-reported
T93966	SYNONYMS	pp46; Neural phosphoprotein B-50; Growth-associated protein 43; Axonal membrane protein GAP-43
T93966	FUNCTION	This protein is associated with nerve growth. It is a major component of the motile "growth cones" that form the tips of elongating axons. Plays a role in axonal and dendritic filopodia induction.
T93966	BIOCLASS	Neuromodulin family
T93966	SEQUENCE	MLCCMRRTKQVEKNDDDQKIEQDGIKPEDKAHKAATKIQASFRGHITRKKLKGEKKDDVQAAEAEANKKDEAPVADGVEKKGEGTTTAEAAPATGSKPDEPGKAGETPSEEKKGEGDAATEQAAPQAPASSEEKAGSAETESATKASTDNSPSSKAEDAPAKEEPKQADVPAAVTAAAATTPAAEDAAAKATAQPPTETGESSQAEENIEAVDETKPKESARQDEGKEEEPEADQEHA

T52110	TARGETID	T52110
T52110	FORMERID	TTDR01109
T52110	UNIPROID	LBP_HUMAN
T52110	TARGNAME	Lipopolysaccharide-binding protein (LBP)
T52110	GENENAME	LBP
T52110	TARGTYPE	Literature-reported
T52110	SYNONYMS	LBP
T52110	FUNCTION	Plays a role in the innate immune response. Binds to the lipid A moiety of bacterial lipopolysaccharides (LPS), a glycolipid present in the outer membrane of all Gram-negative bacteria. Acts as an affinity enhancer for CD14, facilitating its association with LPS. Promotes the release of cytokines in response to bacterial lipopolysaccharide.
T52110	BIOCLASS	Bactericidal permeability increasing protein
T52110	SEQUENCE	MGALARALPSILLALLLTSTPEALGANPGLVARITDKGLQYAAQEGLLALQSELLRITLPDFTGDLRIPHVGRGRYEFHSLNIHSCELLHSALRPVPGQGLSLSISDSSIRVQGRWKVRKSFFKLQGSFDVSVKGISISVNLLLGSESSGRPTVTASSCSSDIADVEVDMSGDLGWLLNLFHNQIESKFQKVLESRICEMIQKSVSSDLQPYLQTLPVTTEIDSFADIDYSLVEAPRATAQMLEVMFKGEIFHRNHRSPVTLLAAVMSLPEEHNKMVYFAISDYVFNTASLVYHEEGYLNFSITDDMIPPDSNIRLTTKSFRPFVPRLARLYPNMNLELQGSVPSAPLLNFSPGNLSVDPYMEIDAFVLLPSSSKEPVFRLSVATNVSATLTFNTSKITGFLKPGKVKVELKESKVGLFNAELLEALLNYYILNTFYPKFNDKLAEGFPLPLLKRVQLYDLGLQIHKDFLFLGANVQYMRV
T52110	DRUGINFO	D0X0EU	E-5531	Discontinued in Phase 2

T11966	TARGETID	T11966
T11966	FORMERID	TTDR00517
T11966	UNIPROID	ATF3_HUMAN
T11966	TARGNAME	Cyclic-AMP-dependent transcription factor ATF-3 (ATF3)
T11966	GENENAME	ATF3
T11966	TARGTYPE	Literature-reported
T11966	SYNONYMS	cAMP-dependent transcription factor ATF-3; Cyclic AMP-dependent transcription factor ATF-3; Activating transcription factor 3
T11966	FUNCTION	Represses transcription from promoters with ATF sites. It may repress transcription by stabilizing the binding of inhibitory cofactors at the promoter. Isoform 2 activates transcription presumably by sequestering inhibitory cofactors away from the promoters. This protein binds the cAMP response element (CRE) (consensus: 5'-GTGACGT[AC][AG]-3'), a sequence present in many viral and cellular promoters.
T11966	BIOCLASS	Basic leucine zipper bZIP
T11966	SEQUENCE	MMLQHPGQVSASEVSASAIVPCLSPPGSLVFEDFANLTPFVKEELRFAIQNKHLCHRMSSALESVTVSDRPLGVSITKAEVAPEEDERKKRRRERNKIAAAKCRNKKKEKTECLQKESEKLESVNAELKAQIEELKNEKQHLIYMLNLHRPTCIVRAQNGRTPEDERNLFIQQIKEGTLQS

T93922	TARGETID	T93922
T93922	FORMERID	TTDR00647
T93922	UNIPROID	PLCG1_HUMAN; PLCG2_HUMAN
T93922	TARGNAME	Phospholipase C-gamma (PPCG)
T93922	GENENAME	PLCG1; PLCG2
T93922	TARGTYPE	Literature-reported
T93922	SYNONYMS	Phospholipase C gamma; Phosphoinositide phospholipase C-gamma; PLC-gamma; PLC; 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma
T93922	FUNCTION	Mediates the production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). Plays an important role in the regulation of intracellular signaling cascades. Becomes activated in response to ligand-mediated activation of receptor-type tyrosine kinases, such as PDGFRA, PDGFRB, FGFR1, FGFR2, FGFR3 and FGFR4. Plays a role in actin reorganization and cell migration.
T93922	BIOCLASS	Phosphoric diester hydrolase
T93922	SEQUENCE	MAGAASPCANGCGPGAPSDAEVLHLCRSLEVGTVMTLFYSKKSQRPERKTFQVKLETRQITWSRGADKIEGAIDIREIKEIRPGKTSRDFDRYQEDPAFRPDQSHCFVILYGMEFRLKTLSLQATSEDEVNMWIKGLTWLMEDTLQAPTPLQIERWLRKQFYSVDRNREDRISAKDLKNMLSQVNYRVPNMRFLRERLTDLEQRSGDITYGQFAQLYRSLMYSAQKTMDLPFLEASTLRAGERPELCRVSLPEFQQFLLDYQGELWAVDRLQVQEFMLSFLRDPLREIEEPYFFLDEFVTFLFSKENSVWNSQLDAVCPDTMNNPLSHYWISSSHNTYLTGDQFSSESSLEAYARCLRMGCRCIELDCWDGPDGMPVIYHGHTLTTKIKFSDVLHTIKEHAFVASEYPVILSIEDHCSIAQQRNMAQYFKKVLGDTLLTKPVEISADGLPSPNQLKRKILIKHKKLAEGSAYEEVPTSMMYSENDISNSIKNGILYLEDPVNHEWYPHYFVLTSSKIYYSEETSSDQGNEDEEEPKEVSSSTELHSNEKWFHGKLGAGRDGRHIAERLLTEYCIETGAPDGSFLVRESETFVGDYTLSFWRNGKVQHCRIHSRQDAGTPKFFLTDNLVFDSLYDLITHYQQVPLRCNEFEMRLSEPVPQTNAHESKEWYHASLTRAQAEHMLMRVPRDGAFLVRKRNEPNSYAISFRAEGKIKHCRVQQEGQTVMLGNSEFDSLVDLISYYEKHPLYRKMKLRYPINEEALEKIGTAEPDYGALYEGRNPGFYVEANPMPTFKCAVKALFDYKAQREDELTFIKSAIIQNVEKQEGGWWRGDYGGKKQLWFPSNYVEEMVNPVALEPEREHLDENSPLGDLLRGVLDVPACQIAIRPEGKNNRLFVFSISMASVAHWSLDVAADSQEELQDWVKKIREVAQTADARLTEGKIMERRKKIALELSELVVYCRPVPFDEEKIGTERACYRDMSSFPETKAEKYVNKAKGKKFLQYNRLQLSRIYPKGQRLDSSNYDPLPMWICGSQLVALNFQTPDKPMQMNQALFMTGRHCGYVLQPSTMRDEAFDPFDKSSLRGLEPCAISIEVLGARHLPKNGRGIVCPFVEIEVAGAEYDSTKQKTEFVVDNGLNPVWPAKPFHFQISNPEFAFLRFVVYEEDMFSDQNFLAQATFPVKGLKTGYRAVPLKNNYSEDLELASLLIKIDIFPAKENGDLSPFSGTSLRERGSDASGQLFHGRAREGSFESRYQQPFEDFRISQEHLADHFDSRERRAPRRTRVNGDNRL

T43901	TARGETID	T43901
T43901	FORMERID	TTDI02429
T43901	UNIPROID	FST_HUMAN
T43901	TARGNAME	Follistatin (FST)
T43901	GENENAME	FST
T43901	TARGTYPE	Literature-reported
T43901	SYNONYMS	FST; FS; Activinbinding protein
T43901	FUNCTION	Binds directly to activin and functions as an activin antagonist. Specific inhibitor of the biosynthesis and secretion of pituitary follicle stimulating hormone (FSH).
T43901	PDBSTRUC	5JHW; 3HH2; 2P6A; 2B0U
T43901	SEQUENCE	MVRARHQPGGLCLLLLLLCQFMEDRSAQAGNCWLRQAKNGRCQVLYKTELSKEECCSTGRLSTSWTEEDVNDNTLFKWMIFNGGAPNCIPCKETCENVDCGPGKKCRMNKKNKPRCVCAPDCSNITWKGPVCGLDGKTYRNECALLKARCKEQPELEVQYQGRCKKTCRDVFCPGSSTCVVDQTNNAYCVTCNRICPEPASSEQYLCGNDGVTYSSACHLRKATCLLGRSIGLAYEGKCIKAKSCEDIQCTGGKKCLWDFKVGRGRCSLCDELCPDSKSDEPVCASDNATYASECAMKEAACSSGVLLEVKHSGSCNSISEDTEEEEEDEDQDYSFPISSILEW

T53033	TARGETID	T53033
T53033	FORMERID	TTDR01238
T53033	UNIPROID	TNR1B_HUMAN
T53033	TARGNAME	Tumor necrosis factor receptor type II (TNF-R2)
T53033	GENENAME	TNFRSF1B
T53033	TARGTYPE	Literature-reported
T53033	SYNONYMS	p80 TNF-alpha receptor; p75; Tumor necrosis factor receptor superfamily member 1B; Tumor necrosis factor receptor 2; TNFR2; TNFR-II; TNFBR; TNF-RII; TNF-R2; Etanercept; CD120b
T53033	FUNCTION	Receptor with high affinity for TNFSF2/TNF-alpha and approximately 5-fold lower affinity for homotrimeric TNFSF1/lymphotoxin-alpha. The TRAF1/TRAF2 complex recruits the apoptotic suppressors BIRC2 and BIRC3 to TNFRSF1B/TNFR2. This receptor mediates most of the metabolic effects of TNF-alpha. Isoform 2 blocks TNF-alpha-induced apoptosis, which suggests that it regulates TNF-alpha function by antagonizing its biological activity.
T53033	PDBSTRUC	3ALQ; 1CA9
T53033	SEQUENCE	MAPVAVWAALAVGLELWAAAHALPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDFALPVGLIVGVTALGLLIIGVVNCVIMTQVKKKPLCLQREAKVPHLPADKARGTQGPEQQHLLITAPSSSSSSLESSASALDRRAPTRNQPQAPGVEASGAGEARASTGSSDSSPGGHGTQVNVTCIVNVCSSSDHSSQCSSQASSTMGDTDSSPSESPKDEQVPFSKEECAFRSQLETPETLLGSTEEKPLPLGVPDAGMKPS

T88356	TARGETID	T88356
T88356	FORMERID	TTDNR00690
T88356	UNIPROID	TRPC_PSEAE
T88356	TARGNAME	Pseudomonas Indole-3-glycerol phosphate synthase (Pseudo trpC)
T88356	GENENAME	Pseudo trpC
T88356	TARGTYPE	Literature-reported
T88356	SYNONYMS	Indole-3-glycerol phosphate synthase; IGPS
T88356	FUNCTION	Catalyzes the fifth reaction in the synthesis of tryptophan from chorismate--a reaction that is absent in mammals.
T88356	BIOCLASS	Carbon-carbon lyase
T88356	SEQUENCE	MSVPTVLQKILARKAEEVAERRARVNLAEVERLARSADAPRGFANALLERAKRKEPAVIAEIKKASPSKGVLREHFVPAEIARSYEAGGAACLSVLTDVDFFQGADAYLKEARAACALPVIRKDFMIDPYQIVEARAIGADCILLIVSALDDVLMAELAATAKSVGLDVLVEVHDGTELERALKTLDTPLVGINNRNLHTFEVSLETTLDLLPEIPRDRLVVTESGILNRADVELMEVSEVYAFLVGEAFMRADDPGLELKRLFFQERGAVVLGADPD

T08379	TARGETID	T08379
T08379	FORMERID	TTDI00116
T08379	UNIPROID	HXA5_HUMAN
T08379	TARGNAME	Homeobox protein Hox-A5 (HOXA5)
T08379	GENENAME	HOXA5
T08379	TARGTYPE	Literature-reported
T08379	SYNONYMS	Homeobox protein HoxA5; Homeobox protein Hox1C; Homeobox protein Hox-1C; HOX1C
T08379	FUNCTION	Binds to its own promoter. Binds specifically to the motif 5'-CYYNATTA[TG]Y-3'. Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis.
T08379	BIOCLASS	Antp homeobox
T08379	SEQUENCE	MSSYFVNSFCGRYPNGPDYQLHNYGDHSSVSEQFRDSASMHSGRYGYGYNGMDLSVGRSGSGHFGSGERARSYAASASAAPAEPRYSQPATSTHSPQPDPLPCSAVAPSPGSDSHHGGKNSLSNSSGASADAGSTHISSREGVGTASGAEEDAPASSEQASAQSEPSPAPPAQPQIYPWMRKLHISHDNIGGPEGKRARTAYTRYQTLELEKEFHFNRYLTRRRRIEIAHALCLSERQIKIWFQNRRMKWKKDNKLKSMSMAAAGGAFRP

T48358	TARGETID	T48358
T48358	FORMERID	TTDR00573
T48358	UNIPROID	EDN2_HUMAN
T48358	TARGNAME	Endothelin (EDN)
T48358	GENENAME	EDN2
T48358	TARGTYPE	Literature-reported
T48358	SYNONYMS	Preproendothelin-2; PPET2; Endothelin-2; ET-2
T48358	FUNCTION	Endothelins are endothelium-derived vasoconstrictor peptides.
T48358	BIOCLASS	Endothelin/sarafotoxin
T48358	SEQUENCE	MVSVPTTWCSVALALLVALHEGKGQAAATLEQPASSSHAQGTHLRLRRCSCSSWLDKECVYFCHLDIIWVNTPEQTAPYGLGNPPRRRRRSLPRRCQCSSARDPACATFCLRRPWTEAGAVPSRKSPADVFQTGKTGATTGELLQRLRDISTVKSLFAKRQQEAMREPRSTHSRWRKR

T21580	TARGETID	T21580
T21580	FORMERID	TTDI02476
T21580	UNIPROID	RASA1_HUMAN
T21580	TARGNAME	GTPase activating protein (RASA1)
T21580	GENENAME	RASA1
T21580	TARGTYPE	Literature-reported
T21580	SYNONYMS	p120GAP; RasGAP; Ras p21 protein activator; Ras GTPase-activating protein 1; RASA; GTPase-activating protein; GAP
T21580	FUNCTION	Stimulates the GTPase of normal but not oncogenic Ras p21; this stimulation may be further increased in the presence of NCK1. Inhibitory regulator of the Ras-cyclic AMP pathway.
T21580	PDBSTRUC	4FSS; 2M51; 2J06; 2J05; 2GSB
T21580	SEQUENCE	MMAAEAGSEEGGPVTAGAGGGGAAAGSSAYPAVCRVKIPAALPVAAAPYPGLVETGVAGTLGGGAALGSEFLGAGSVAGALGGAGLTGGGTAAGVAGAAAGVAGAAVAGPSGDMALTKLPTSLLAETLGPGGGFPPLPPPPYLPPLGAGLGTVDEGDSLDGPEYEEEEVAIPLTAPPTNQWYHGKLDRTIAEERLRQAGKSGSYLIRESDRRPGSFVLSFLSQMNVVNHFRIIAMCGDYYIGGRRFSSLSDLIGYYSHVSCLLKGEKLLYPVAPPEPVEDRRRVRAILPYTKVPDTDEISFLKGDMFIVHNELEDGWMWVTNLRTDEQGLIVEDLVEEVGREEDPHEGKIWFHGKISKQEAYNLLMTVGQVCSFLVRPSDNTPGDYSLYFRTNENIQRFKICPTPNNQFMMGGRYYNSIGDIIDHYRKEQIVEGYYLKEPVPMQDQEQVLNDTVDGKEIYNTIRRKTKDAFYKNIVKKGYLLKKGKGKRWKNLYFILEGSDAQLIYFESEKRATKPKGLIDLSVCSVYVVHDSLFGRPNCFQIVVQHFSEEHYIFYFAGETPEQAEDWMKGLQAFCNLRKSSPGTSNKRLRQVSSLVLHIEEAHKLPVKHFTNPYCNIYLNSVQVAKTHAREGQNPVWSEEFVFDDLPPDINRFEITLSNKTKKSKDPDILFMRCQLSRLQKGHATDEWFLLSSHIPLKGIEPGSLRVRARYSMEKIMPEEEYSEFKELILQKELHVVYALSHVCGQDRTLLASILLRIFLHEKLESLLLCTLNDREISMEDEATTLFRATTLASTLMEQYMKATATQFVHHALKDSILKIMESKQSCELSPSKLEKNEDVNTNLTHLLNILSELVEKIFMASEILPPTLRYIYGCLQKSVQHKWPTNTTMRTRVVSGFVFLRLICPAILNPRMFNIISDSPSPIAARTLILVAKSVQNLANLVEFGAKEPYMEGVNPFIKSNKHRMIMFLDELGNVPELPDTTEHSRTDLSRDLAALHEICVAHSDELRTLSNERGAQQHVLKKLLAITELLQQKQNQYTKTNDVR

T49522	TARGETID	T49522
T49522	FORMERID	TTDR00108
T49522	UNIPROID	PTN_HUMAN
T49522	TARGNAME	Pleiotrophin (PTN)
T49522	GENENAME	PTN
T49522	TARGTYPE	Literature-reported
T49522	SYNONYMS	Osteoblast-specific factor 1; Osteoblast specific factor 1; OSF-1; NEGF1; Heparin-binding neurite outgrowth-promoting factor 1; Heparin-binding neurite outgrowth-promoting factor; Heparin-binding neurite outgrowth promoting factor 1; Heparin-binding growth-associated molecule; Heparin-binding brain mitogen; HBNF1; HBNF-1; HBNF; HBBM; HB-GAM
T49522	FUNCTION	Binds cell-surface proteoglycan receptor via their chondroitin sulfate (CS) groups. Thereby regulates many processes like cell proliferation, cell survival, cell growth, cell differentiation and cell migration in several tissues namely neuron and bone. Also plays a role in synaptic plasticity and learning-related behavior by inhibiting long-term synaptic potentiation. Binds PTPRZ1, leading to neutralization of the negative charges of the CS chains of PTPRZ1, inducing PTPRZ1 clustering, thereby causing the dimerization and inactivation of its phosphatase activity leading to increased tyrosine phosphorylation of each of the PTPRZ1 substrates like ALK, CTNNB1 or AFAP1L2 in order to activate the PI3K-AKT pathway. Through PTPRZ1 binding controls oligodendrocyte precursor cell differentiation by enhancing the phosphorylation of AFAP1L2 in order to activate the PI3K-AKT pathway. Forms a complex with PTPRZ1 and integrin alpha-V/beta-3 (ITGAV:ITGB3) that stimulates endothelial cell migration through SRC dephosphorylation and activation that consequently leads to ITGB3 'Tyr-773' phosphorylation. In adult hippocampus promotes dendritic arborization, spine development, and functional integration and connectivity of newborn granule neurons through ALK by activating AKT signaling pathway. Binds GPC2 and chondroitin sulfate proteoglycans (CSPGs) at the neuron surface, leading to abrogation of binding between PTPRS and CSPGs and neurite outgrowth promotion. Binds SDC3 and mediates bone formation by recruiting and attaching osteoblasts/osteoblast precursors to the sites for new bone deposition. Binds ALK and promotes cell survival and cell proliferation through MAPK pathway activation. Inhibits proliferation and enhances differentiation of neural stem cells by inhibiting FGF2-induced fibroblast growth factor receptor signaling pathway. Mediates regulatory mechanisms in normal hemostasis and in hematopoietic regeneration and in maintaining the balance of myeloid and lymphoid regeneration. In addition may play a role in the female reproductive system, auditory response and the progesterone-induced decidualization pathway. Secreted growth factor that mediates its signal through cell-surface proteoglycan and non-proteoglycan receptors.
T49522	PDBSTRUC	2N6F
T49522	SEQUENCE	MQAQQYQQQRRKFAAAFLAFIFILAAVDTAEAGKKEKPEKKVKKSDCGEWQWSVCVPTSGDCGLGTREGTRTGAECKQTMKTQRCKIPCNWKKQFGAECKYQFQAWGECDLNTALKTRTGSLKRALHNAECQKTVTISKPCGKLTKPKPQAESKKKKKEGKKQEKMLD

T90089	TARGETID	T90089
T90089	FORMERID	TTDI01993
T90089	UNIPROID	SCF_HUMAN
T90089	TARGNAME	Mast cell growth factor (MGF)
T90089	GENENAME	KITLG
T90089	TARGTYPE	Literature-reported
T90089	SYNONYMS	sKITLG; cKit ligand; c-Kit ligand; Stem cell factor; Soluble KIT ligand; SCF; Kit ligand
T90089	FUNCTION	Plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. KITLG/SCF binding can activate several signaling pathways. Promotes phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and subsequent activation of the kinase AKT1. KITLG/SCF and KIT also transmit signals via GRB2 and activation of RAS, RAF1 and the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. KITLG/SCF and KIT promote activation of STAT family members STAT1, STAT3 and STAT5. KITLG/SCF and KIT promote activation of PLCG1, leading to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. KITLG/SCF acts synergistically with other cytokines, probably interleukins. Ligand for the receptor-type protein-tyrosine kinase KIT.
T90089	PDBSTRUC	2E9W; 1SCF; 1EXZ
T90089	SEQUENCE	MKKTQTWILTCIYLQLLLFNPLVKTEGICRNRVTNNVKDVTKLVANLPKDYMITLKYVPGMDVLPSHCWISEMVVQLSDSLTDLLDKFSNISEGLSNYSIIDKLVNIVDDLVECVKENSSKDLKKSFKSPEPRLFTPEEFFRIFNRSIDAFKDFVVASETSDCVVSSTLSPEKDSRVSVTKPFMLPPVAASSLRNDSSSSNRKAKNPPGDSSLHWAAMALPALFSLIIGFAFGALYWKKRQPSLTRAVENIQINEEDNEISMLQEKEREFQEV

T03878	TARGETID	T03878
T03878	FORMERID	TTDR00404
T03878	UNIPROID	MK_HUMAN
T03878	TARGNAME	Midgestation and kidney protein (Midkine)
T03878	GENENAME	MDK
T03878	TARGTYPE	Literature-reported
T03878	SYNONYMS	Neurite outgrowth-promoting protein; Neurite outgrowth-promoting factor 2; NEGF2; MK1; MK; Amphiregulin-associated protein; ARAP
T03878	FUNCTION	Binds cell-surface proteoglycan receptors via their chondroitin sulfate (CS) groups. Thereby regulates many processes like inflammatory response, cell proliferation, cell adhesion, cell growth, cell survival, tissue regeneration, cell differentiation and cell migration. Participates in inflammatory processes by exerting two different activities. Firstly, mediates neutrophils and macrophages recruitment to the sites of inflammation both by direct action by cooperating namely with ITGB2 via LRP1 and by inducing chemokine expression. This inflammation can be accompanied by epithelial cell survival and smooth muscle cell migration after renal and vessel damage, respectively. Secondly, suppresses the development of tolerogenic dendric cells thereby inhibiting the differentiation of regulatory T cells and also promote T cell expansion through NFAT signaling and Th1 cell differentiation. Promotes tissue regeneration after injury or trauma. After heart damage negatively regulates the recruitment of inflammatory cells and mediates cell survival through activation of anti-apoptotic signaling pathways via MAPKs and AKT pathways through the activation of angiogenesis. Also facilites liver regeneration as well as bone repair by recruiting macrophage at trauma site and by promoting cartilage development by facilitating chondrocyte differentiation. Plays a role in brain by promoting neural precursor cells survival and growth through interaction with heparan sulfate proteoglycans. Binds PTPRZ1 and promotes neuronal migration and embryonic neurons survival. Binds SDC3 or GPC2 and mediates neurite outgrowth and cell adhesion. Binds chondroitin sulfate E and heparin leading to inhibition of neuronal cell adhesion induced by binding with GPC2. Binds CSPG5 and promotes elongation of oligodendroglial precursor-like cells. Also binds ITGA6:ITGB1 complex; this interaction mediates MDK-induced neurite outgrowth. Binds LRP1; promotes neuronal survival. Binds ITGA4:ITGB1 complex; this interaction mediates MDK-induced osteoblast cells migration through PXN phosphorylation. Binds anaplastic lymphoma kinase (ALK) which induces ALK activation and subsequent phosphorylation of the insulin receptor substrate (IRS1), followed by the activation of mitogen-activated protein kinase (MAPK) and PI3-kinase, and the induction of cell proliferation. Promotes epithelial to mesenchymal transition through interaction with NOTCH2. During arteriogenesis, plays a role in vascular endothelial cell proliferation by inducing VEGFA expression and release which in turn induces nitric oxide synthase expression. Moreover activates vasodilation through nitric oxide synthase activation. Negatively regulates bone formation in response to mechanical load by inhibiting Wnt/beta-catenin signaling in osteoblasts. In addition plays a role in hippocampal development, working memory, auditory response, early fetal adrenal gland development and the female reproductive system. Secreted protein that functions as cytokine and growth factor and mediates its signal through cell-surface proteoglycan and non-proteoglycan receptors.
T03878	PDBSTRUC	1MKN; 1MKC
T03878	SEQUENCE	MQHRGFLLLTLLALLALTSAVAKKKDKVKKGGPGSECAEWAWGPCTPSSKDCGVGFREGTCGAQTQRIRCRVPCNWKKEFGADCKYKFENWGACDGGTGTKVRQGTLKKARYNAQCQETIRVTKPCTPKTKAKAKAKKGKGKD

T50007	TARGETID	T50007
T50007	FORMERID	TTDR01059
T50007	UNIPROID	MSRE_HUMAN
T50007	TARGNAME	Scavenger receptor A1 (MSR1)
T50007	GENENAME	MSR1
T50007	TARGTYPE	Literature-reported
T50007	SYNONYMS	Macrophage scavenger receptor; Macrophage acetylated LDL receptor I and II; MSR1; CD204 antigen
T50007	FUNCTION	Membrane glycoproteins implicated in the pathologic deposition of cholesterol in arterial walls during atherogenesis. Two types of receptor subunits exist. These receptors mediate the endocytosis of a diverse group of macromolecules, including modified low density lipoproteins (LDL). Isoform III does not internalize acetylated LDL.
T50007	SEQUENCE	MEQWDHFHNQQEDTDSCSESVKFDARSMTALLPPNPKNSPSLQEKLKSFKAALIALYLLVFAVLIPLIGIVAAQLLKWETKNCSVSSTNANDITQSLTGKGNDSEEEMRFQEVFMEHMSNMEKRIQHILDMEANLMDTEHFQNFSMTTDQRFNDILLQLSTLFSSVQGHGNAIDEISKSLISLNTTLLDLQLNIENLNGKIQENTFKQQEEISKLEERVYNVSAEIMAMKEEQVHLEQEIKGEVKVLNNITNDLRLKDWEHSQTLRNITLIQGPPGPPGEKGDRGPTGESGPRGFPGPIGPPGLKGDRGAIGFPGSRGLPGYAGRPGNSGPKGQKGEKGSGNTLTPFTKVRLVGGSGPHEGRVEILHSGQWGTICDDRWEVRVGQVVCRSLGYPGVQAVHKAAHFGQGTGPIWLNEVFCFGRESSIEECKIRQWGTRACSHSEDAGVTCTL
T50007	DRUGINFO	D0ML3S	2,4-bis-docosanoylamino-benzenesulfonate	Investigative

T26304	TARGETID	T26304
T26304	FORMERID	TTDI02504
T26304	UNIPROID	PGS1_HUMAN
T26304	TARGNAME	Bone/cartilage proteoglycan I (BGN)
T26304	GENENAME	BGN
T26304	TARGTYPE	Literature-reported
T26304	SYNONYMS	PGS1; BGN
T26304	FUNCTION	May be involved in collagen fiber assembly.
T26304	BIOCLASS	Small leucine-rich proteoglycan
T26304	SEQUENCE	MWPLWRLVSLLALSQALPFEQRGFWDFTLDDGPFMMNDEEASGADTSGVLDPDSVTPTYSAMCPFGCHCHLRVVQCSDLGLKSVPKEISPDTTLLDLQNNDISELRKDDFKGLQHLYALVLVNNKISKIHEKAFSPLRKLQKLYISKNHLVEIPPNLPSSLVELRIHDNRIRKVPKGVFSGLRNMNCIEMGGNPLENSGFEPGAFDGLKLNYLRISEAKLTGIPKDLPETLNELHLDHNKIQAIELEDLLRYSKLYRLGLGHNQIRMIENGSLSFLPTLRELHLDNNKLARVPSGLPDLKLLQVVYLHSNNITKVGVNDFCPMGFGVKRAYYNGISLFNNPVPYWEVQPATFRCVTDRLAIQFGNYKK

T50574	TARGETID	T50574
T50574	FORMERID	TTDI02572
T50574	UNIPROID	CD9_HUMAN
T50574	TARGNAME	Leukocyte antigen MIC3 (CD9)
T50574	GENENAME	CD9
T50574	TARGTYPE	Literature-reported
T50574	SYNONYMS	p24; Tspan29; Tspan-29; Tetraspanin29; Tetraspanin-29; Motilityrelated protein; Motility-related protein; MRP-1; MIC3; GIG2; Cell growthinhibiting gene 2 protein; Cell growth-inhibiting gene 2 protein; CD9 antigen; 5H9 antigen
T50574	FUNCTION	Present at the cell surface of oocytes and plays a key role in sperm-egg fusion, possibly by organizing multiprotein complexes and the morphology of the membrane required for the fusion. In myoblasts, associates with CD81 and PTGFRN and inhibits myotube fusion during muscle regeneration. In macrophages, associates with CD81 and beta-1 and beta-2 integrins, and prevents macrophage fusion into multinucleated giant cells specialized in ingesting complement-opsonized large particles. Also prevents the fusion between mononuclear cell progenitors into osteoclasts in charge of bone resorption. Acts as a receptor for PSG17. Involved in platelet activation and aggregation. Regulates paranodal junction formation. Involved in cell adhesion, cell motility and tumor metastasis. Integral membrane protein associated with integrins, which regulates different processes, such as sperm-egg fusion, platelet activation and aggregation, and cell adhesion.
T50574	BIOCLASS	Tetraspanin
T50574	SEQUENCE	MPVKGGTKCIKYLLFGFNFIFWLAGIAVLAIGLWLRFDSQTKSIFEQETNNNNSSFYTGVYILIGAGALMMLVGFLGCCGAVQESQCMLGLFFGFLLVIFAIEIAAAIWGYSHKDEVIKEVQEFYKDTYNKLKTKDEPQRETLKAIHYALNCCGLAGGVEQFISDICPKKDVLETFTVKSCPDAIKEVFDNKFHIIGAVGIGIAVVMIFGMIFSMILCCAIRRNREMV

T15665	TARGETID	T15665
T15665	FORMERID	TTDNR00646
T15665	UNIPROID	KCNA4_HUMAN; KCNC4_HUMAN; KCND1_HUMAN; KCND2_HUMAN; KCND3_HUMAN
T15665	TARGNAME	Voltage-gated A-type potassium channel (A-KC)
T15665	GENENAME	KCNA4; KCNC4; KCND1; KCND2; KCND3
T15665	TARGTYPE	Literature-reported
T15665	SYNONYMS	Potassium voltage-gated channel
T15665	FUNCTION	Regulatory subunit of Kv4/D (Shal)-type voltage-gated rapidly inactivating A-type potassium channels. Regulates channel density, inactivation kinetics and rate of recovery from inactivation in a calcium-dependent and isoform-specific manner. In vitro, modulates KCND1/Kv4.1 and KCND2/Kv4.2 currents. Increases the presence of KCND2 at the cell surface.
T15665	BIOCLASS	Voltage-gated ion channel
T15665	SEQUENCE	MEVAMVSAESSGCNSHMPYGYAAQARARERERLAHSRAAAAAAVAAATAAVEGSGGSGGGSHHHHQSRGACTSHDPQSSRGSRRRRRQRSEKKKAHYRQSSFPHCSDLMPSGSEEKILRELSEEEEDEEEEEEEEEEGRFYYSEDDHGDECSYTDLLPQDEGGGGYSSVRYSDCCERVVINVSGLRFETQMKTLAQFPETLLGDPEKRTQYFDPLRNEYFFDRNRPSFDAILYYYQSGGRLKRPVNVPFDIFTEEVKFYQLGEEALLKFREDEGFVREEEDRALPENEFKKQIWLLFEYPESSSPARGIAIVSVLVILISIVIFCLETLPEFRDDRDLVMALSAGGHGGLLNDTSAPHLENSGHTIFNDPFFIVETVCIVWFSFEFVVRCFACPSQALFFKNIMNIIDIVSILPYFITLGTDLAQQQGGGNGQQQQAMSFAILRIIRLVRVFRIFKLSRHSKGLQILGHTLRASMRELGLLIFFLFIGVILFSSAVYFAEADEPTTHFQSIPDAFWWAVVTMTTVGYGDMKPITVGGKIVGSLCAIAGVLTIALPVPVIVSNFNYFYHRETENEEQTQLTQNAVSCPYLPSNLLKKFRSSTSSSLGDKSEYLEMEEGVKESLCAKEEKCQGKGDDSETDKNNCSNAKAVETDV

T67877	TARGETID	T67877
T67877	FORMERID	TTDR00867
T67877	UNIPROID	GALA_HUMAN
T67877	TARGNAME	Galanin (GAL)
T67877	GENENAME	GAL
T67877	TARGTYPE	Literature-reported
T67877	SYNONYMS	Galanin peptides; Galanin messageassociated peptide; GMAP; GAL
T67877	FUNCTION	Contracts smooth muscle of the gastrointestinal and genitourinary tract, regulates growth hormone release, modulates insulin release, and may be involved in the control of adrenal secretion.
T67877	BIOCLASS	Galanin family
T67877	SEQUENCE	MARGSALLLASLLLAAALSASAGLWSPAKEKRGWTLNSAGYLLGPHAVGNHRSFSDKNGLTSKRELRPEDDMKPGSFDRSIPENNIMRTIIEFLSFLHLKEAGALDRLLDLPAAASSEDIERS

T77909	TARGETID	T77909
T77909	FORMERID	TTDR00236
T77909	UNIPROID	POLG_HRV1A
T77909	TARGNAME	Virus Genome polyprotein (Viru POL)
T77909	GENENAME	Viru POL
T77909	TARGTYPE	Literature-reported
T77909	SYNONYMS	Protein VP1; Genome polyprotein of Human rhinovirus 1A
T77909	FUNCTION	RNA-directed RNA polymerase: Replicates the viral genomic RNA on the surface of intracellular membranes. May form linear arrays of subunits that propagate along a strong head-to- tail interaction called interface-I.Covalently attaches UMP to a tyrosine of VPg, which is used to prime RNA synthesis. The positive stranded RNA genome is first replicated at virus induced membranous vesicles, creating a dsRNA genomicreplication form. This dsRNA is then used as template to synthesize positive stranded RNA genomes. ss(+)RNA genomes are either translated, replicated or encapsidated.
T77909	PDBSTRUC	2HWF; 2HWE; 2HWD; 1R1A; 1AYN
T77909	SEQUENCE	MGAQVSRQNVGTHSTQNSVSNGSSLNYFNINYFKDAASSGASRLDFSQDPSKFTDPVKDVLEKGIPTLQSPSVEACGYSDRIMQITRGDSTITSQDVANAVVGYGVWPHYLTPQDATAIDKPTQPDTSSNRFYTLESKHWNGSSKGWWWKLPDALKDMGIFGENMYYHFLGRSGYTVHVQCNASKFHQGTLLVAMIPEHQLASAKHGSVTAGYKLTHPGEAGRDVSQERDASLRQPSDDSWLNFDGTLLGNLLIFPHQFINLRSNNSATLIVPYVNAVPMDSMLRHNNWSLVIIPISPLRSETTSSNIVPITVSISPMCAEFSGARAKNIKQGLPVYITPGSGQFMTTDDMQSPCALPWYHPTKEISIPGEVKNLIEMCQVDTLIPVNNVGNNVGNVSMYTVQLGNQTGMAQKVFSIKVDITSQPLATTLIGEIASYYTHWTGSLRFSFMFCGTANTTLKLLLAYTPPGIDEPTTRKDAMLGTHVVWDVGLQSTISLVVPWVSASHFRLTADNKYSMAGYITCWYQTNLVVPPSTPQTADMLCFVSACKDFCLRMARDTDLHIQSGPIEQNPVENYIDEVLNEVLVVPNIKESHHTTSNSAPLLDAAETGHTSNVQPEDAIETRYVITSQTRDEMSIESFLGRSGCVHISRIKVDYTDYNGQDINFTKWKITLQEMAQIRRKFELFTYVRFDSEITLVPCIAGRGDDIGHIVMQYMYVPPGAPIPSKRNDFSWQSGTNMSIFWQHGQPFPRFSLPFLSIASAYYMFYDGYDGDNTSSKYGSVVTNDMGTICSRIVTEKQKHSVVITTHIYHKAKHTKAWCPRPPRAVPYTHSHVTNYMPETGDVTTAIVRRNTITTAGPSDLYVHVGNLIYRNLHLFNSEMHDSILISYSSDLIIYRTNTIGDDYIPNCNCTEATYYCRHKNRYYPIKVTPHDWYEIQESEYYPKHIQYNLLIGEGPCEPGDCGGKLLCRHGVIGIITAGGEGHVAFIDLRQFHCAEEQGITDYIHMLGEAFGNGFVDSVKEQINAINPINNISKKVIKWLLRIISAMVIIIRNSSDPQTIIATLTLIGCNGSPWRFLKEKFCKWTQLTYIHKESDSWLKKFTEMCNAARGLEWIGNKISKFIDWMKSMLPQAQLKVKYLNEIKKLSLLEKQIENLRAADSATQEKIKCEIDTLHDLSCKFLPLYAHEAKRIKVLYNKCSNIIKQRKRSEPVAVMIHGPPGTGKSITTNFLARMITNESDVYSLPPDPKYFDGYDNQSVVIMDDIMQNPDGEDMTLFCQMVSSVTFIPPMADLPDKGKPFDSRFILCSTNHSLLAPPTISSLPAMNRRFFFDLDIVVHDNYKDTQGKLDVSKAFRPCNVNTKIGNAKCCPFVCGKAVXFKDRSTCSTYTLAQVYNHILEEDKRRRQVVDVMSAIFQGPISLDXPPPPAIXDLLQSVRTPEVIKYCQDNKWVIPAECQVERDLNIANSIIAIIANIISIAGIIFVIYKLFCSLQGPYSGEPKPKTKVPERRVVAQGPEEEFGRSILKNNTCVITTGNGKFTGLGIHDRILIIPTHADPGREVQVNGVHTKVLDSYDLYNRDGVKLEITVIQLDRNEKFRDIRKYIPETEDDYPECNLALSANQDEPTIIKVGDVVSYGNILLSGNQTARMLKYNYPTKSGYCGGVLYKIGQILGIHVGGNGRDGFSAMLLRSYFTDTQGQIKVNKHATECGLPTIHTPSKTKLQPSVFYDVFPGSKEPAVLTDNDPRLEVNFKEALFSKYKGNVECNLNEHMEIAIAHYSAQLMTLDIDSRPIALEDSVFGIEGLEALDLNTSAGFPYVTMGIKKRDLINNKTKDISRLKEALDKYGVDLPMITFLKDELRKKEKISTGKTRVIEASSINDTILFRTTFGNLFSKFHLNPGVVTGSAVGCDPETFWSKIPVMLDGDCIMAFDYTNYDGSIHPVWFQALKKVLENLSFQSNLIDRLCYSKHLFKSTYYEVAGGVPSGCSGTSIFNTMINNIIIRTLVLDAYKNIDLDKLKIIAYGDDVIFSYKYTLDMEAIANEGKKYGLTITPADKSNEFKKLDYSNVTFLKRGFKQDERHTFLIHPTFPVEEIHESIRWTKKPSQMQEHVLSLCHLMWHNGRKVYEDFSSKIRSVSAGRALYIPPYDLLKHEWYEKF
T77909	DRUGINFO	D0N0UC	Lauric Acid	Investigative
T77909	DRUGINFO	D08OBF	MYRISTIC ACID	Investigative

T48040	TARGETID	T48040
T48040	FORMERID	TTDR00873
T48040	UNIPROID	XPA_HUMAN
T48040	TARGNAME	DNA repair protein complementing XP-A cells (XPA)
T48040	GENENAME	XPA
T48040	TARGTYPE	Literature-reported
T48040	SYNONYMS	Xeroderma pigmentosum group A-complementing protein; XPAC; XPA protein
T48040	FUNCTION	Initiates repair by binding to damaged sites with various affinities, depending on the photoproduct and the transcriptional state of the region. Required for UV-induced CHEK1 phosphorylation and the recruitment of CEP164 to cyclobutane pyrimidine dimmers (CPD), sites of DNA damage after UV irradiation. Involved in DNA excision repair.
T48040	PDBSTRUC	2JNW; 1XPA; 1D4U
T48040	SEQUENCE	MAAADGALPEAAALEQPAELPASVRASIERKRQRALMLRQARLAARPYSATAAAATGGMANVKAAPKIIDTGGGFILEEEEEEEQKIGKVVHQPGPVMEFDYVICEECGKEFMDSYLMNHFDLPTCDNCRDADDKHKLITKTEAKQEYLLKDCDLEKREPPLKFIVKKNPHHSQWGDMKLYLKLQIVKRSLEVWGSQEALEEAKEVRQENREKMKQKKFDKKVKELRRAVRSSVWKRETIVHQHEYGPEENLEDDMYRKTCTMCGHELTYEKM

T84553	TARGETID	T84553
T84553	FORMERID	TTDR01022
T84553	UNIPROID	AMPD1_HUMAN; AMPD2_HUMAN; AMPD3_HUMAN
T84553	TARGNAME	Adenosine monophosphate deaminase (AMPD)
T84553	GENENAME	AMPD1; AMPD2; AMPD3
T84553	TARGTYPE	Literature-reported
T84553	SYNONYMS	AMP deaminase
T84553	FUNCTION	AMP deaminase plays a critical role in energy metabolism. Catalyzes the deamination of AMP to IMP and plays an important role in the purine nucleotide cycle.
T84553	BIOCLASS	Carbon-nitrogen hydrolase
T84553	SEQUENCE	MNVRIFYSVSQSPHSLLSLLFYCAILESRISATMPLFKLPAEEKQIDDAMRNFAEKVFASEVKDEGGRQEISPFDVDEICPISHHEMQAHIFHLETLSTSTEARRKKRFQGRKTVNLSIPLSETSSTKLSHIDEYISSSPTYQTVPDFQRVQITGDYASGVTVEDFEIVCKGLYRALCIREKYMQKSFQRFPKTPSKYLRNIDGEAWVANESFYPVFTPPVKKGEDPFRTDNLPENLGYHLKMKDGVVYVYPNEAAVSKDEPKPLPYPNLDTFLDDMNFLLALIAQGPVKTYTHRRLKFLSSKFQVHQMLNEMDELKELKNNPHRDFYNCRKVDTHIHAAACMNQKHLLRFIKKSYQIDADRVVYSTKEKNLTLKELFAKLKMHPYDLTVDSLDVHAGRQTFQRFDKFNDKYNPVGASELRDLYLKTDNYINGEYFATIIKEVGADLVEAKYQHAEPRLSIYGRSPDEWSKLSSWFVCNRIHCPNMTWMIQVPRIYDVFRSKNFLPHFGKMLENIFMPVFEATINPQADPELSVFLKHITGFDSVDDESKHSGHMFSSKSPKPQEWTLEKNPSYTYYAYYMYANIMVLNSLRKERGMNTFLFRPHCGEAGALTHLMTAFMIADDISHGLNLKKSPVLQYLFFLAQIPIAMSPLSNNSLFLEYAKNPFLDFLQKGLMISLSTDDPMQFHFTKEPLMEEYAIAAQVFKLSTCDMCEVARNSVLQCGISHEEKVKFLGDNYLEEGPAGNDIRRTNVAQIRMAYRYETWCYELNLIAEGLKSTE
T84553	DRUGINFO	D0T0OW	Coformycin	Investigative

T69121	TARGETID	T69121
T69121	FORMERID	TTDR00651
T69121	UNIPROID	ITA6_HUMAN
T69121	TARGNAME	Integrin alpha-6 (ITGA6)
T69121	GENENAME	ITGA6
T69121	TARGTYPE	Literature-reported
T69121	SYNONYMS	VLA-6 integrin; VLA-6; CD49f; CD49 antigen-like family member F; Alpha6 beta1 integrin
T69121	FUNCTION	Integrin alpha-6/beta-1 (ITGA6:ITGB1) is present in oocytes and is involved in sperm-egg fusion. Integrin alpha-6/beta-4 (ITGA6:ITGB4) is a receptor for laminin in epithelial cells and it plays a critical structural role in the hemidesmosome. ITGA6:ITGB4 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling. ITGA6:ITGB4 binds to IGF1 and this binding is essential for IGF1 signaling. ITGA6:ITGB4 binds to IGF2 and this binding is essential for IGF2 signaling. Integrin alpha-6/beta-1 (ITGA6:ITGB1) is a receptor for laminin on platelets.
T69121	BIOCLASS	Integrin
T69121	SEQUENCE	MAAAGQLCLLYLSAGLLSRLGAAFNLDTREDNVIRKYGDPGSLFGFSLAMHWQLQPEDKRLLLVGAPRAEALPLQRANRTGGLYSCDITARGPCTRIEFDNDADPTSESKEDQWMGVTVQSQGPGGKVVTCAHRYEKRQHVNTKQESRDIFGRCYVLSQNLRIEDDMDGGDWSFCDGRLRGHEKFGSCQQGVAATFTKDFHYIVFGAPGTYNWKGIVRVEQKNNTFFDMNIFEDGPYEVGGETEHDESLVPVPANSYLGLLFLTSVSYTDPDQFVYKTRPPREQPDTFPDVMMNSYLGFSLDSGKGIVSKDEITFVSGAPRANHSGAVVLLKRDMKSAHLLPEHIFDGEGLASSFGYDVAVVDLNKDGWQDIVIGAPQYFDRDGEVGGAVYVYMNQQGRWNNVKPIRLNGTKDSMFGIAVKNIGDINQDGYPDIAVGAPYDDLGKVFIYHGSANGINTKPTQVLKGISPYFGYSIAGNMDLDRNSYPDVAVGSLSDSVTIFRSRPVINIQKTITVTPNRIDLRQKTACGAPSGICLQVKSCFEYTANPAGYNPSISIVGTLEAEKERRKSGLSSRVQFRNQGSEPKYTQELTLKRQKQKVCMEETLWLQDNIRDKLRPIPITASVEIQEPSSRRRVNSLPEVLPILNSDEPKTAHIDVHFLKEGCGDDNVCNSNLKLEYKFCTREGNQDKFSYLPIQKGVPELVLKDQKDIALEITVTNSPSNPRNPTKDGDDAHEAKLIATFPDTLTYSAYRELRAFPEKQLSCVANQNGSQADCELGNPFKRNSNVTFYLVLSTTEVTFDTPDLDINLKLETTSNQDNLAPITAKAKVVIELLLSVSGVAKPSQVYFGGTVVGEQAMKSEDEVGSLIEYEFRVINLGKPLTNLGTATLNIQWPKEISNGKWLLYLVKVESKGLEKVTCEPQKEINSLNLTESHNSRKKREITEKQIDDNRKFSLFAERKYQTLNCSVNVNCVNIRCPLRGLDSKASLILRSRLWNSTFLEEYSKLNYLDILMRAFIDVTAAAENIRLPNAGTQVRVTVFPSKTVAQYSGVPWWIILVAILAGILMLALLVFILWKCGFFKRSRYDDSVPRYHAVRIRKEEREIKDEKYIDNLEKKQWITKWNENESYS

T48195	TARGETID	T48195
T48195	FORMERID	TTDR00780
T48195	UNIPROID	CXCR1_HUMAN; CXCR2_HUMAN
T48195	TARGNAME	Interleukin 8 receptor (IL8R)
T48195	GENENAME	CXCR1; CXCR2
T48195	TARGTYPE	Literature-reported
T48195	SYNONYMS	IL8R; IL-8R; IL-8 receptor; High affinity interleukin-8 receptor; CXCR; CXC-R; CDw128
T48195	FUNCTION	This receptor binds to IL-8 with a high affinity and to MGSA (GRO) with a low affinity. Receptor to interleukin-8, which is a powerful neutrophils chemotactic factor. Binding of IL-8 to the receptor causes activation of neutrophils. This response is mediated via a G-protein that activate a phosphatidylinositol-calcium second messenger system.
T48195	BIOCLASS	Cytokine receptor
T48195	SEQUENCE	MSNITDPQMWDFDDLNFTGMPPADEDYSPCMLETETLNKYVVIIAYALVFLLSLLGNSLVMLVILYSRVGRSVTDVYLLNLALADLLFALTLPIWAASKVNGWIFGTFLCKVVSLLKEVNFYSGILLLACISVDRYLAIVHATRTLTQKRHLVKFVCLGCWGLSMNLSLPFFLFRQAYHPNNSSPVCYEVLGNDTAKWRMVLRILPHTFGFIVPLFVMLFCYGFTLRTLFKAHMGQKHRAMRVIFAVVLIFLLCWLPYNLVLLADTLMRTQVIQESCERRNNIGRALDATEILGFLHSCLNPIIYAFIGQNFRHGFLKILAMHGLVSKEFLARHRVTSYTSSSVNVSSNL

T05249	TARGETID	T05249
T05249	FORMERID	TTDI01504
T05249	UNIPROID	ZA2G_HUMAN
T05249	TARGNAME	Zinc alpha-2 glycoprotein (AZGP1)
T05249	GENENAME	AZGP1
T05249	TARGTYPE	Literature-reported
T05249	SYNONYMS	Zn-alpha-2-glycoprotein; Zn-alpha-2-GP; Zinc-alpha-2-glycoprotein; ZNGP1; ZAG
T05249	FUNCTION	Stimulates lipid degradation in adipocytes and causes the extensive fat losses associated with some advanced cancers. May bind polyunsaturated fatty acids.
T05249	PDBSTRUC	3ES6; 1ZAG; 1T80; 1T7Z; 1T7Y
T05249	SEQUENCE	MVRMVPVLLSLLLLLGPAVPQENQDGRYSLTYIYTGLSKHVEDVPAFQALGSLNDLQFFRYNSKDRKSQPMGLWRQVEGMEDWKQDSQLQKAREDIFMETLKDIVEYYNDSNGSHVLQGRFGCEIENNRSSGAFWKYYYDGKDYIEFNKEIPAWVPFDPAAQITKQKWEAEPVYVQRAKAYLEEECPATLRKYLKYSKNILDRQDPPSVVVTSHQAPGEKKKLKCLAYDFYPGKIDVHWTRAGEVQEPELRGDVLHNGNGTYQSWVVVAVPPQDTAPYSCHVQHSSLAQPLVVPWEAS

T88321	TARGETID	T88321
T88321	FORMERID	TTDR00335
T88321	UNIPROID	RBTN2_HUMAN
T88321	TARGNAME	Rhombotin-2 (LMO2)
T88321	GENENAME	LMO2
T88321	TARGTYPE	Literature-reported
T88321	SYNONYMS	TTG2; T-cell translocation protein 2; RHOM2; RBTNL1; RBTN2; LMO-2; LIM-only protein 2; LIM-domain protein Lmo2; LIM domain only protein 2; Cysteine-rich protein TTG-2; Cysteine rich protein TTG-2
T88321	FUNCTION	Acts with LDB1 to maintain erythroid precursors in an immature state. Acts with TAL1/SCL to regulate red blood cell development.
T88321	PDBSTRUC	4KFZ; 2YPA; 2XJZ; 2XJY
T88321	SEQUENCE	MSSAIERKSLDPSEEPVDEVLQIPPSLLTCGGCQQNIGDRYFLKAIDQYWHEDCLSCDLCGCRLGEVGRRLYYKLGRKLCRRDYLRLFGQDGLCASCDKRIRAYEMTMRVKDKVYHLECFKCAACQKHFCVGDRYLLINSDIVCEQDIYEWTKINGMI

T62410	TARGETID	T62410
T62410	FORMERID	TTDR00980
T62410	UNIPROID	CYSP_PLAFA
T62410	TARGNAME	Plasmodium Trophozoite cysteine proteinase (Malaria TCP)
T62410	GENENAME	Malaria TCP
T62410	TARGTYPE	Literature-reported
T62410	SYNONYMS	Trophozoite cysteine proteinase; TCP
T62410	FUNCTION	Probably degrades erythrocyte hemoglobin.
T62410	ECNUMBER	EC 3.4.22.-
T62410	SEQUENCE	MVAIKEMKELAFARPSLVETLNKKKKFLKKKEKRTFVLSIYAFITFIIFCIGILYFTNKSSAHNNNNNKNEHSLKKEEIELLRVLLEKYKKQKDGILNESSNEEDEEKYTLNSETYNNKNNVSNIKNDSIKSKKEEYINLERILLEKYKKFINENNEENRKELSNILHKLLEINKLILREEKDDKKVYLINDNYDEKGALEIGMNEEMKYKKEDPINNIKYASKFFKFMKEHNKVYKNIDEQMRKFEIFKINYISIKNHNKLNKNAMYKKKVNQFSDYSEEELKEYFKTLLHVPNHMIEKYSKPFENHLKDNILISEFYTNGKRNEKDIFSKVPEILDYREKGIVHEPKDQGLCGSCWAFASVGNIESVFAKKNKNILSFSEQEVVDCSKDNFGCDGGHPFYSFLYVLQNELCLGDEYKYKAKDDMFCLNYRCKRKVSLSSIGAVKENQLILALNEVGPLSVNVGVNNDFVAYSEGVYNGTCSEELNHSVLLVGYGQVEKTKLNYNNKIQTYNTKENSNQPDDNIIYYWIIKNSWSKKWGENGFMRLSRNKNGDNVFCGIGEEVFYPIL

T24609	TARGETID	T24609
T24609	FORMERID	TTDI00031
T24609	UNIPROID	PTBP1_HUMAN
T24609	TARGNAME	Polypyrimidine tract-binding protein (PTBP1)
T24609	GENENAME	PTBP1
T24609	TARGTYPE	Literature-reported
T24609	SYNONYMS	hnRNP I; Polypyrimidine tractbinding protein 1; Polypyrimidine tract-binding protein 1; PTB; Heterogeneous nuclear ribonucleoprotein I; 57 kDa RNAbinding protein PPTB1; 57 kDa RNA-binding protein PPTB-1
T24609	FUNCTION	Activates exon skipping of its own pre-mRNA during muscle cell differentiation. Binds to the polypyrimidine tract of introns. May promote RNA looping when bound to two separate polypyrimidine tracts in the same pre-mRNA. May promote the binding of U2 snRNP to pre-mRNA. Cooperates with RAVER1 to modulate switching between mutually exclusive exons during maturation of the TPM1 pre-mRNA. Represses the splicing of MAPT/Tau exon 10. In case of infection by picornaviruses, binds to the viral internal ribosome entry site (IRES) and stimulates the IRES-mediated translation. Plays a role in pre-mRNA splicing and in the regulation of alternative splicing events.
T24609	PDBSTRUC	3ZZZ; 3ZZY; 2N3O; 2EVZ; 2ADC
T24609	SEQUENCE	MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRVIHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPVLRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQSPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLSLDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLSVPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGVYGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREGQEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGVVKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTI

T65266	TARGETID	T65266
T65266	FORMERID	TTDNR00687
T65266	UNIPROID	POLG_HCV1
T65266	TARGNAME	Hepatitis C virus Protein p7 (HCV p7)
T65266	GENENAME	HCV p7
T65266	TARGTYPE	Literature-reported
T65266	SYNONYMS	HCV p7
T65266	FUNCTION	Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity).
T65266	PDBSTRUC	3SU4; 3RC5; 3RC4; 3QGI; 3QGH
T65266	SEQUENCE	ALENLVILNAASLAGTHGLVSFLVFFCFAWYLKGKWVPGAVYTFYGMWPLLLLLLALPQRAYA

T94593	TARGETID	T94593
T94593	FORMERID	TTDR00627
T94593	UNIPROID	PPLA_HUMAN
T94593	TARGNAME	Cardiac phospholamban (PLN)
T94593	GENENAME	PLN
T94593	TARGTYPE	Literature-reported
T94593	SYNONYMS	Phospholamban; PLN; PLB
T94593	FUNCTION	Reversibly inhibits the activity of ATP2A2 in cardiac sarcoplasmic reticulum by decreasing the apparent affinity of the ATPase for Ca(2+). Modulates the contractility of the heart muscle in response to physiological stimuli via its effects on ATP2A2. Modulatescalcium re-uptake during muscle relaxation and plays an important role in calcium homeostasis in the heart muscle. The degree of ATP2A2 inhibition depends on the oligomeric state of PLN. ATP2A2 inhibition is alleviated by PLN phosphorylation.
T94593	PDBSTRUC	2HYN; 1ZLL; 1PSL; 1PLP; 1PLN
T94593	SEQUENCE	MEKVQYLTRSAIRRASTIEMPQQARQKLQNLFINFCLILICLLLICIIVMLL

T09341	TARGETID	T09341
T09341	FORMERID	TTDNR00735
T09341	UNIPROID	VP16_BPPRD
T09341	TARGNAME	Virus Protein P16 (Viru GpS)
T09341	GENENAME	Viru GpS
T09341	TARGTYPE	Literature-reported
T09341	SYNONYMS	XVI; Protein S; GpS
T09341	FUNCTION	protein of the infection vertex complex, which increases the vertex stability. Anchors the vertex structure to the viral membrane. Essential for viral infectivity.
T09341	PDBSTRUC	1W8X
T09341	SEQUENCE	MDKKKLLYWVGGGLVLILIWLWFRNRPAAQVASNWEGPPYMTYNQPQAGSVTLPVAGYTSPSPTLPNRNRSCGCNPAVSAAMAQGADLASKLTDSITSQLNDYASSLNDYLASQAGV

T79821	TARGETID	T79821
T79821	FORMERID	TTDNR00664
T79821	UNIPROID	CALR_HUMAN
T79821	TARGNAME	Calreticulin (CALR)
T79821	GENENAME	CALR
T79821	TARGTYPE	Literature-reported
T79821	SYNONYMS	grp60; HACBP; Endoplasmic reticulum resident protein 60; ERp60; ERC; Calregulin; CRTC; CRP55
T79821	FUNCTION	Calcium-binding chaperone that promotes folding, oligomeric assembly and quality control in the endoplasmic reticulum (ER) via the calreticulin/calnexin cycle. This lectin interacts transiently with almost all of the monoglucosylated glycoproteins that are synthesized in the ER. Interacts with the DNA-binding domain of NR3C1 and mediates its nuclear export. Involved in maternal gene expression regulation. May participate in oocyte maturation via the regulation of calcium homeostasis (By similarity).
T79821	PDBSTRUC	6ENY; 5V90; 5LK5; 3POW; 3POS
T79821	SEQUENCE	MLLSVPLLLGLLGLAVAEPAVYFKEQFLDGDGWTSRWIESKHKSDFGKFVLSSGKFYGDEEKDKGLQTSQDARFYALSASFEPFSNKGQTLVVQFTVKHEQNIDCGGGYVKLFPNSLDQTDMHGDSEYNIMFGPDICGPGTKKVHVIFNYKGKNVLINKDIRCKDDEFTHLYTLIVRPDNTYEVKIDNSQVESGSLEDDWDFLPPKKIKDPDASKPEDWDERAKIDDPTDSKPEDWDKPEHIPDPDAKKPEDWDEEMDGEWEPPVIQNPEYKGEWKPRQIDNPDYKGTWIHPEIDNPEYSPDPSIYAYDNFGVLGLDLWQVKSGTIFDNFLITNDEAYAEEFGNETWGVTKAAEKQMKDKQDEEQRLKEEEEDKKRKEEEEAEDKEDDEDKDEDEEDEEDKEEDEEEDVPGQAKDEL

T93830	TARGETID	T93830
T93830	FORMERID	TTDR01125
T93830	UNIPROID	GRN_HUMAN
T93830	TARGNAME	Granulin (GRN)
T93830	GENENAME	GRN
T93830	TARGTYPE	Literature-reported
T93830	SYNONYMS	Progranulin (58-573); Proepithelin (58-573); PGRN (58-573); PEPI (58-573); PCDGF (58-573); PC cell-derived growth factor (58-573); Granulin-epithelin; Granulin precursor (58-573); Glycoprotein of 88 Kda (58-573); Glycoprotein 88 (58-573); GP88 (58-573); Epithelin precursor (58-573); Acrogranin (58-573)
T93830	FUNCTION	Functions as regulator of proteins trafficking to lysosome and activity of lysosomal enzymes. Facilitates also the acidification of lysosomes, causing degradation of mature CTSD by CTSB. In addition, functions as wound-related growth factor that acts directly on dermal fibroblasts and endothelial cells to promote division, migration and the formation of capillary-like tubule structure. Also promotes epithelial cell proliferation by blocking TNF-mediated neutrophil activation preventing release of oxidants and proteases. Moreover, modulates inflammation in neuron by preserving neuron survival, axonal outgrowth and neuronal integrity. Secreted proteins that act as key regulator of lysosomal function and as a growth factor involved in inflammation, wound healing and cell proliferation.
T93830	PDBSTRUC	2JYV; 2JYU; 2JYT; 2JYE; 1G26
T93830	SEQUENCE	GGPCQVDAHCSAGHSCIFTVSGTSSCCPFPEAVACGDGHHCCPRGFHCSADGRSCFQRSGNNSVGAIQCPDSQFECPDFSTCCVMVDGSWGCCPMPQASCCEDRVHCCPHGAFCDLVHTRCITPTGTHPLAKKLPAQRTNRAVALSSSVMCPDARSRCPDGSTCCELPSGKYGCCPMPNATCCSDHLHCCPQDTVCDLIQSKCLSKENATTDLLTKLPAHTVGDVKCDMEVSCPDGYTCCRLQSGAWGCCPFTQAVCCEDHIHCCPAGFTCDTQKGTCEQGPHQVPWMEKAPAHLSLPDPQALKRDVPCDNVSSCPSSDTCCQLTSGEWGCCPIPEAVCCSDHQHCCPQGYTCVAEGQCQRGSEIVAGLEKMPARRASLSHPRDIGCDQHTSCPVGQTCCPSLGGSWACCQLPHAVCCEDRQHCCPAGYTCNVKARSCEKEVVSAQPATFLARSPHVGVKDVECGEGHFCHDNQTCCRDNRQGWACCPYRQGVCCADRRHCCPAGFRCAARGTKCL

T86503	TARGETID	T86503
T86503	FORMERID	TTDI03478
T86503	UNIPROID	PCSK6_HUMAN
T86503	TARGNAME	Proprotein convertase subtilisin/kexin type 6 (PCSK6)
T86503	GENENAME	PCSK6
T86503	TARGTYPE	Literature-reported
T86503	SYNONYMS	Subtilisin/kexin-like protease PACE4; Subtilisin-like proprotein convertase 4; SPC4; Paired basic amino acid cleaving enzyme 4; PACE4
T86503	FUNCTION	Serine endoprotease that processes various proproteins by cleavage at paired basic amino acids, recognizing the RXXX[KR]R consensus motif. Likely functions in the constitutive secretory pathway, with unique restricted distribution in both neuroendocrine and non-neuroendocrine tissues.
T86503	ECNUMBER	EC 3.4.21.-
T86503	SEQUENCE	MPPRAPPAPGPRPPPRAAAATDTAAGAGGAGGAGGAGGPGFRPLAPRPWRWLLLLALPAACSAPPPRPVYTNHWAVQVLGGPAEADRVAAAHGYLNLGQIGNLEDYYHFYHSKTFKRSTLSSRGPHTFLRMDPQVKWLQQQEVKRRVKRQVRSDPQALYFNDPIWSNMWYLHCGDKNSRCRSEMNVQAAWKRGYTGKNVVVTILDDGIERNHPDLAPNYDSYASYDVNGNDYDPSPRYDASNENKHGTRCAGEVAASANNSYCIVGIAYNAKIGGIRMLDGDVTDVVEAKSLGIRPNYIDIYSASWGPDDDGKTVDGPGRLAKQAFEYGIKKGRQGLGSIFVWASGNGGREGDYCSCDGYTNSIYTISVSSATENGYKPWYLEECASTLATTYSSGAFYERKIVTTDLRQRCTDGHTGTSVSAPMVAGIIALALEANSQLTWRDVQHLLVKTSRPAHLKASDWKVNGAGHKVSHFYGFGLVDAEALVVEAKKWTAVPSQHMCVAASDKRPRSIPLVQVLRTTALTSACAEHSDQRVVYLEHVVVRTSISHPRRGDLQIYLVSPSGTKSQLLAKRLLDLSNEGFTNWEFMTVHCWGEKAEGQWTLEIQDLPSQVRNPEKQGKLKEWSLILYGTAEHPYHTFSAHQSRSRMLELSAPELEPPKAALSPSQVEVPEDEEDYTAQSTPGSANILQTSVCHPECGDKGCDGPNADQCLNCVHFSLGSVKTSRKCVSVCPLGYFGDTAARRCRRCHKGCETCSSRAATQCLSCRRGFYHHQEMNTCVTLCPAGFYADESQKNCLKCHPSCKKCVDEPEKCTVCKEGFSLARGSCIPDCEPGTYFDSELIRCGECHHTCGTCVGPGREECIHCAKNFHFHDWKCVPACGEGFYPEEMPGLPHKVCRRCDENCLSCAGSSRNCSRCKTGFTQLGTSCITNHTCSNADETFCEMVKSNRLCERKLFIQFCCRTCLLAG
T86503	DRUGINFO	D0A6FZ	peptide 18	Investigative
T86503	DRUGINFO	D05JJL	furin inhibitor peptide	Investigative

T31641	TARGETID	T31641
T31641	FORMERID	TTDI01412
T31641	UNIPROID	HRR25_YEAST
T31641	TARGNAME	Saccharomyces Casein Kinase I Isoform Hrr25 (Saccha HRR25)
T31641	GENENAME	Saccha HRR25
T31641	TARGTYPE	Literature-reported
T31641	SYNONYMS	Casein kinase I homolog HRR25
T31641	FUNCTION	Associated with repair of damaged DNA and meiosis. Phosphorylates serine and threonine. Can use casein as a substrate.
T31641	PDBSTRUC	5CZO; 5CYZ; 4XHL
T31641	SEQUENCE	MDLRVGRKFRIGRKIGSGSFGDIYHGTNLISGEEVAIKLESIRSRHPQLDYESRVYRYLSGGVGIPFIRWFGREGEYNAMVIDLLGPSLEDLFNYCHRRFSFKTVIMLALQMFCRIQYIHGRSFIHRDIKPDNFLMGVGRRGSTVHVIDFGLSKKYRDFNTHRHIPYRENKSLTGTARYASVNTHLGIEQSRRDDLESLGYVLIYFCKGSLPWQGLKATTKKQKYDRIMEKKLNVSVETLCSGLPLEFQEYMAYCKNLKFDEKPDYLFLARLFKDLSIKLEYHNDHLFDWTMLRYTKAMVEKQRDLLIEKGDLNANSNAASASNSTDNKSETFNKIKLLAMKKFPTHFHYYKNEDKHNPSPEEIKQQTILNNNAASSLPEELLNALDKGMENLRQQQPQQQVQSSQPQPQPQQLQQQPNGQRPNYYPEPLLQQQQRDSQEQQQQVPMATTRATQYPPQINSNNFNTNQASVPPQMRSNPQQPPQDKPAGQSIWL

T06819	TARGETID	T06819
T06819	FORMERID	TTDI01458
T06819	UNIPROID	S100G_HUMAN
T06819	TARGNAME	S100 calcium-binding protein G (S100G)
T06819	GENENAME	S100G
T06819	TARGTYPE	Literature-reported
T06819	SYNONYMS	Vitamin D-dependent calcium-binding protein, intestinal; S100D; Protein S100-G; Calbindin-D9k; CALB3; CABP9K; CABP
T06819	FUNCTION	Vitamin D-dependent. Its expression correlates with calcium transport activity. May increase Ca2+ absorption by buffering Ca2+ in the cytoplasm and increase ATP-dependent Ca2+ transport in duodenal basolateral membrane vesicles.
T06819	BIOCLASS	S100 calcium-binding protein
T06819	SEQUENCE	MSTKKSPEELKRIFEKYAAKEGDPDQLSKDELKLLIQAEFPSLLKGPNTLDDLFQELDKNGDGEVSFEEFQVLVKKISQ

T45034	TARGETID	T45034
T45034	FORMERID	TTDR00729
T45034	UNIPROID	SPB3_HUMAN
T45034	TARGNAME	Squamous cell carcinoma antigen 1 (SCCA-1)
T45034	GENENAME	SERPINB3
T45034	TARGTYPE	Literature-reported
T45034	SYNONYMS	Serpin B3; SCCA1; SCCA-1; SCCA; Protein T4-A
T45034	FUNCTION	May act as a papain-like cysteine protease inhibitor to modulate the host immune response against tumor cells. Also functions as an inhibitor of UV-induced apoptosis via suppression of the activity of c-Jun NH(2)-terminal kinase (JNK1).
T45034	PDBSTRUC	4ZK3; 4ZK0; 2ZV6
T45034	SEQUENCE	MNSLSEANTKFMFDLFQQFRKSKENNIFYSPISITSALGMVLLGAKDNTAQQIKKVLHFDQVTENTTGKAATYHVDRSGNVHHQFQKLLTEFNKSTDAYELKIANKLFGEKTYLFLQEYLDAIKKFYQTSVESVDFANAPEESRKKINSWVESQTNEKIKNLIPEGNIGSNTTLVLVNAIYFKGQWEKKFNKEDTKEEKFWPNKNTYKSIQMMRQYTSFHFASLEDVQAKVLEIPYKGKDLSMIVLLPNEIDGLQKLEEKLTAEKLMEWTSLQNMRETRVDLHLPRFKVEESYDLKDTLRTMGMVDIFNGDADLSGMTGSRGLVLSGVLHKAFVEVTEEGAEAAAATAVVGFGSSPTSTNEEFHCNHPFLFFIRQNKTNSILFYGRFSSP

T01683	TARGETID	T01683
T01683	FORMERID	TTDI01867
T01683	UNIPROID	PML_HUMAN
T01683	TARGNAME	Promyelocytic leukemia protein (PML)
T01683	GENENAME	PML
T01683	TARGTYPE	Literature-reported
T01683	SYNONYMS	Tripartite motif-containing protein 19; TRIM19; RNF71; RING finger protein 71; Protein PML; PP8675; MYL
T01683	FUNCTION	Functions via its association with PML-nuclear bodies (PML-NBs) in a wide range of important cellular processes, including tumor suppression, transcriptional regulation, apoptosis, senescence, DNA damage response, and viral defense mechanisms. Acts as the scaffold of PML-NBs allowing other proteins to shuttle in and out, a process which is regulated by SUMO-mediated modifications and interactions. Isoform PML-4 has a multifaceted role in the regulation of apoptosis and growth suppression: activates RB1 and inhibits AKT1 via interactions with PP1 and PP2A phosphatases respectively, negatively affects the PI3K pathway by inhibiting MTOR and activating PTEN, and positively regulates p53/TP53 by acting at different levels (by promoting its acetylation and phosphorylation and by inhibiting its MDM2-dependent degradation). Isoform PML-4 also: acts as a transcriptional repressor of TBX2 during cellular senescence and the repression is dependent on a functional RBL2/E2F4 repressor complex, regulates double-strand break repair in gamma-irradiation-induced DNA damage responses via its interaction with WRN, acts as a negative regulator of telomerase by interacting with TERT, and regulates PER2 nuclear localization and circadian function. Isoform PML-6 inhibits specifically the activity of the tetrameric form of PKM. The nuclear isoforms (isoform PML-1, isoform PML-2, isoform PML-3, isoform PML-4 and isoform PML-5) in concert with SATB1 are involved in local chromatin-loop remodeling and gene expression regulation at the MHC-I locus. Isoform PML-2 is required for efficient IFN-gamma induced MHC II gene transcription via regulation of CIITA. Cytoplasmic PML is involved in the regulation of the TGF-beta signaling pathway. PML also regulates transcription activity of ELF4 and can act as an important mediator for TNF-alpha- and IFN-alpha-mediated inhibition of endothelial cell network formation and migration.
T01683	PDBSTRUC	5YUF; 4WJO; 4WJN; 2MWX; 2MVW
T01683	SEQUENCE	MEPAPARSPRPQQDPARPQEPTMPPPETPSEGRQPSPSPSPTERAPASEEEFQFLRCQQCQAEAKCPKLLPCLHTLCSGCLEASGMQCPICQAPWPLGADTPALDNVFFESLQRRLSVYRQIVDAQAVCTRCKESADFWCFECEQLLCAKCFEAHQWFLKHEARPLAELRNQSVREFLDGTRKTNNIFCSNPNHRTPTLTSIYCRGCSKPLCCSCALLDSSHSELKCDISAEIQQRQEELDAMTQALQEQDSAFGAVHAQMHAAVGQLGRARAETEELIRERVRQVVAHVRAQERELLEAVDARYQRDYEEMASRLGRLDAVLQRIRTGSALVQRMKCYASDQEVLDMHGFLRQALCRLRQEEPQSLQAAVRTDGFDEFKVRLQDLSSCITQGKDAAVSKKASPEAASTPRDPIDVDLPEEAERVKAQVQALGLAEAQPMAVVQSVPGAHPVPVYAFSIKGPSYGEDVSNTTTAQKRKCSQTQCPRKVIKMESEEGKEARLARSSPEQPRPSTSKAVSPPHLDGPPSPRSPVIGSEVFLPNSNHVASGAGEAEERVVVISSSEDSDAENSSSRELDDSSSESSDLQLEGPSTLRVLDENLADPQAEDRPLVFFDLKIDNETQKISQLAAVNRESKFRVVIQPEAFFSIYSKAVSLEVGLQHFLSFLSSMRRPILACYKLWGPGLPNFFRALEDINRLWEFQEAISGFLAALPLIRERVPGASSFKLKNLAQTYLARNMSERSAMAAVLAMRDLCRLLEVSPGPQLAQHVYPFSSLQCFASLQPLVQAAVLPRAEARLLALHNVSFMELLSAHRRDRQGGLKKYSRYLSLQTTTLPPAQPAFNLQALGTYFEGLLEGPALARAEGVSTPLAGRGLAERASQQS

T34099	TARGETID	T34099
T34099	FORMERID	TTDI01482
T34099	UNIPROID	POLG_DEN26
T34099	TARGNAME	Dengue virus NS2B/NS3 protease (DENV NS2B/NS3)
T34099	GENENAME	DENV NS2B/NS3
T34099	TARGTYPE	Literature-reported
T34099	SYNONYMS	Genome polyprotein
T34099	FUNCTION	Capsid protein C: Plays a role in virus budding by binding to the cell membrane and gathering the viral RNA into a nucleocapsid that forms the core of a mature virus particle. During virus entry, may induce genome penetration into the host cytoplasm after hemifusion induced by the surface proteins. Can migrate to the cell nucleus where it modulates host functions. Overcomes the anti-viral effects of host EXOC1 by sequestering and degrading the latter through the proteasome degradation pathway.
T34099	PDBSTRUC	4O6B; 2R69
T34099	SEQUENCE	MNDQRKKAKNTPFNMLKRERNRVSTVQQLTKRFSLGMLQGRGPLKLYMALVAFLRFLTIPPTAGILKRWGTIKKSKAINVLRGFRKEIGRMLNILNRRRRSAGMIIMLIPTVMAFHLTTRNGEPHMIVSRQEKGKSLLFKTEDGVNMCTLMAMDLGELCEDTITYKCPLLRQNEPEDIDCWCNSTSTWVTYGTCTTMGEHRRQKRSVALVPHVGMGLETRTETWMSSEGAWKHVQRIETWILRHPGFTMMAAILAYTIGTTHFQRALIFILLTAVTPSMTMRCIGMSNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIKTEAKQPATLRKYCIEAKLTNTTTESRCPTQGEPSLNEEQDKRFVCKHSMVDRGWGNGCGLFGKGGIVTCAMFRCKKNMEGKVVQPENLEYTIVITPHSGEEHAVGNDTGKHGKEIKITPQSSTTEAELTGYGTVTMECSPRTGLDFNEMVLLQMENKAWLVHRQWFLDLPLPWLPGADTQGSNWIQKETLVTFKNPHAKKQDVVVLGSQEGAMHTALTGATEIQMSSGNLLFTGHLKCRLRMDKLQLKGMSYSMCTGKFKVVKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGQMFETTMRGAKRMAILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAAFSGVSWTMKILIGVIITWIGMNSRSTSLSVTLVLVGIVTLYLGVMVQADSGCVVSWKNKELKCGSGIFITDNVHTWTEQYKFQPESPSKLASAIQKAHEEGICGIRSVTRLENLMWKQITPELNHILSENEVKLTIMTGDIKGIMQAGKRSLRPQPTELKYSWKTWGKAKMLSTESHNQTFLIDGPETAECPNTNRAWNSLEVEDYGFGVFTTNIWLKLKEKQDVFCDSKLMSAAIKDNRAVHADMGYWIESALNDTWKIEKASFIEVKNCHWPKSHTLWSNGVLESEMIIPKNLAGPVSQHNYRPGYHTQITGPWHLGKLEMDFDFCDGTTVVVTEDCGNRGPSLRTTTASGKLITEWCCRSCTLPPLRYRGEDGCWYGMEIRPLKEKEENLVNSLVTAGHGQVDNFSLGVLGMALFLEEMLRTRVGTKHAILLVAVSFVTLIIGNMSFRDLGRVMVMVGATMTDDIGMGVTYLALLAAFKVRPTFAAGLLLRKLTSKALMMTTIGIVLSSQSTTPETILELTDALALGMMVLKMVRNMEKYQLAVTIMAILCVPNAVILQNAWKVSCTILAVVSVSPLFLTSSQQKTDWIPLALTIKGLNPTAIFLTTLSRTSKKRSWPLNEAIMAVGMVSILASSLLKNDIPMTGPLVAGGPLTVCYVLTGRSADLELERAADVKWEDQAEISGSSPILSITISEDGSMSIKNEEEEQTLTILIRTGLLVISGLFPVSIPITAAAWYLWEVKKQRAGVLWDVPSPPPMGKAELEDGAYRIKQKGILGYSQIGAGVYKEGTFHTMWHVTRGAVLMHKGKRIEPSWADVKKDLISYGGGWKLEGEWKEGEEVQVLALEPGKNPRAVQTKPGLFKTNAGTIGAVSLDFSPGTSGSPIIDKKGKVVGLYGNGVVTRSGAYVSAIAQTEKSIEDNPEIEDDIFRKRRLTIMDLHPGAGKTKRYLPAIVREAIKRGLRTLILAPTRVVAAEMEEALRGLPIRYQTPAIRAEHTGREIVDLMCHATFTMRLLSPVRVPNYNLIIMDEAHFTDPASIAARGYISTRVEMGEAAGIFMTATPPGSRDPFPQSNAPIIDEEREIPERSWNSGHEWVTDFKGKTVWFVPSIKAGNDIAACLSKNGKKVIQLSRKTFDSEYAKTRTNDWDFVVTTDISEMGANFKAERVIDPRRCMKPVILTDGEERVILAGPMPVTHSSAAQRRGRIGRNPKNENDQYIYMGEPLENDEDCAHWKEAKMLLDNINTPEGIIPSMFEPEREKVDAIDGEYRLRGEARTTFVDLMRRGDLPVWLAYRVAAEGINYADRRWCFDGVKNNQILEENVEVEIWTKEGERKKLKPRWLDARIYSDPLALKEFKEFAAGRKSLTLNLITEMGRLPTFMTQKARDALDNLAVLHTAEAGGRAYNHALSELPETLETLLLLTLLATVTGGILLFLMSGRGIGKMTLGMCCIITASILLWYAQIQPHWIAASIILEFFLIVLLIPEPEKQRTPQDNQLTYVVIAILTVVAATMANEMGFLEKTKKDLGLGSIATQQPESNILDIDLRPASAWTLYAVATTFVTPMLRHSIENSSVNVSLTAIANQATVLMGLGKGWPLSKMDIGVPLLAIGCYSQVNPTTLTAALFLLVAHYAIIGPALQAKASREAQKRAAAGIMKNPTVDGITVIDLDPIPYDPKFEKQLGQVMLLVLCVTQVLMMRTTWALCEVLTLATGPISTLWEGNPGRFWNTTIAVSMANIFRGSYLAGAGLLFSIMKNTTNARRGTGNIGETLGEKWKSRLNALGKSEFQIYKKSGIQEVDRTLAKEGIKRGETDHHAVSRGSAKLRWFVERNMVTPEGKVVDLGCGRGGWSYYCGGLKNVREVKGLTKGGPGHEEPIPMSTYGWNLVRLQSGVDVFFIPPEKCDTLLCDIGESSPNPTVEAGRTLRVLNLVENWLNNNTQFCIKVLNPYMPSVIEKMEALQRKYGGALVRNPLSRNSTHEMYWVSNASGNIVSSVNMISRMLINRFTMRYKKATYEPDVDLGSGTRNIGIESEIPNLDIIGKRIEKIKQEHETSWHYDQDHPYKTWAYHGSYETKQTGSASSMVNGVFRLLTKPWDVVPMVTQMAMTDTTPFGQQRVFKEKVDTRTQEPKEGTKKLMKITAEWLWKELGKKKTPRMCTREEFTRKVRSNAALGAIFTDENKWKSAREAVEDSRFWELVDKERNLHLEGKCETCVYNIMGKREKKLGEFGKAKGSRAIWYMWLGARFLEFEALGFLNEDHWFSRENSLSGVEGEGLHKLGYILRDVSKKEGGAMYADDTAGWDTRITLEDLKNEAMVTNHMEGEHKKLAEAIFKLTYQNKVVRVQRPTPRGTVMDIISRRDQRGSGQVGTYGLNTFTNMEAQLIRQMEGEGVFKSIQHLTITEEIAVQNWLARVGRERLSRMAISGDDCVVKPLDDRLPSALTALNDTGKIRKDIQQWEPSRGWNDWTQVPFCSHHFHELIMKDGRVLVVPCRNQDELIGRARISQGAGWSLRETACLGKSYDQMWSLMYFHRRDLRLAANAICSAVPSHWVPTSRTTWSIHAKHEWMTTEDMLTVWNRVWIQENPWMEDKTPVESWEEIPYLGKREDQWCGSLIGLTSRATWAKNIQAAINQVRSLIGNEEYTDYMPSMKRFRREEEEAGVLW

T72507	TARGETID	T72507
T72507	FORMERID	TTDI01801
T72507	UNIPROID	CCND3_HUMAN
T72507	TARGNAME	Cyclin D (CCND3)
T72507	GENENAME	CCND3
T72507	TARGTYPE	Literature-reported
T72507	SYNONYMS	G1/S-specific cyclin-D3
T72507	FUNCTION	Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex, cyclin D3/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex. Regulatory component of the cyclin D3-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition.
T72507	PDBSTRUC	3G33
T72507	SEQUENCE	MELLCCEGTRHAPRAGPDPRLLGDQRVLQSLLRLEERYVPRASYFQCVQREIKPHMRKMLAYWMLEVCEEQRCEEEVFPLAMNYLDRYLSCVPTRKAQLQLLGAVCMLLASKLRETTPLTIEKLCIYTDHAVSPRQLRDWEVLVLGKLKWDLAAVIAHDFLAFILHRLSLPRDRQALVKKHAQTFLALCATDYTFAMYPPSMIATGSIGAAVQGLGACSMSGDELTELLAGITGTEVDCLRACQEQIEAALRESLREASQTSSSPAPKAPRGSSSQGPSQTSTPTDVTAIHL

T43589	TARGETID	T43589
T43589	FORMERID	TTDR00394
T43589	UNIPROID	CTR1_HUMAN
T43589	TARGNAME	High-affinity cationic amino acid transporter-1 (SLC7A1)
T43589	GENENAME	SLC7A1
T43589	TARGTYPE	Literature-reported
T43589	SYNONYMS	System Y+ basic amino acid transporter; Solute carrier family 7 member 1; REC1L; High affinity cationic amino acid transporter 1; Ecotropic retrovirus receptor homolog; Ecotropic retroviral leukemia receptor homolog; CAT-1; ATRC1
T43589	FUNCTION	High-affinity, low capacity permease involved in the transport of the cationic amino acids (arginine, lysine and ornithine) in non-hepatic tissues.
T43589	BIOCLASS	Amino acid-polyamine-organocation
T43589	SEQUENCE	MGCKVLLNIGQQMLRRKVVDCSREETRLSRCLNTFDLVALGVGSTLGAGVYVLAGAVARENAGPAIVISFLIAALASVLAGLCYGEFGARVPKTGSAYLYSYVTVGELWAFITGWNLILSYIIGTSSVARAWSATFDELIGRPIGEFSRTHMTLNAPGVLAENPDIFAVIIILILTGLLTLGVKESAMVNKIFTCINVLVLGFIMVSGFVKGSVKNWQLTEEDFGNTSGRLCLNNDTKEGKPGVGGFMPFGFSGVLSGAATCFYAFVGFDCIATTGEEVKNPQKAIPVGIVASLLICFIAYFGVSAALTLMMPYFCLDNNSPLPDAFKHVGWEGAKYAVAVGSLCALSASLLGSMFPMPRVIYAMAEDGLLFKFLANVNDRTKTPIIATLASGAVAAVMAFLFDLKDLVDLMSIGTLLAYSLVAACVLVLRYQPEQPNLVYQMASTSDELDPADQNELASTNDSQLGFLPEAEMFSLKTILSPKNMEPSKISGLIVNISTSLIAVLIITFCIVTVLGREALTKGALWAVFLLAGSALLCAVVTGVIWRQPESKTKLSFKVPFLPVLPILSIFVNVYLMMQLDQGTWVRFAVWMLIGFIIYFGYGLWHSEEASLDADQARTPDGNLDQCK

T64520	TARGETID	T64520
T64520	FORMERID	TTDR00849
T64520	UNIPROID	GLMM_ECOLI
T64520	TARGNAME	Bacterial Lantibiotic mersacidin (Bact glmM)
T64520	GENENAME	Bact glmM
T64520	TARGTYPE	Literature-reported
T64520	SYNONYMS	glmM of Escherichia coli; Protein mrsA; Mersacidin
T64520	FUNCTION	Catalyzes the conversion of glucosamine-6-phosphate to glucosamine-1-phosphate. Can also catalyze the formation of glucose-6-P from glucose-1-P, although at a 1400-fold lower rate.
T64520	ECNUMBER	EC 5.4.2.10
T64520	SEQUENCE	MSNRKYFGTDGIRGRVGDAPITPDFVLKLGWAAGKVLARHGSRKIIIGKDTRISGYMLESALEAGLAAAGLSALFTGPMPTPAVAYLTRTFRAEAGIVISASHNPFYDNGIKFFSIDGTKLPDAVEEAIEAEMEKEISCVDSAELGKASRIVDAAGRYIEFCKATFPNELSLSELKIVVDCANGATYHIAPNVLRELGANVIAIGCEPNGVNINAEVGATDVRALQARVLAEKADLGIAFDGDGDRVIMVDHEGNKVDGDQIMYIIAREGLRQGQLRGGAVGTLMSNMGLELALKQLGIPFARAKVGDRYVLEKMQEKGWRIGAENSGHVILLDKTTTGDGIVAGLQVLAAMARNHMSLHDLCSGMKMFPQILVNVRYTAGSGDPLEHESVKAVTAEVEAALGNRGRVLLRKSGTEPLIRVMVEGEDEAQVTEFAHRIADAVKAV
T64520	DRUGINFO	D02DXP	Alpha-Aminobutyric Acid	Investigative
T64520	DRUGINFO	D03HHP	2,3-Didehydroalanine	Investigative
T64520	DRUGINFO	D0W8FQ	2-Thioethenamine	Investigative

T26338	TARGETID	T26338
T26338	FORMERID	TTDR01158
T26338	UNIPROID	HXA7_HUMAN
T26338	TARGNAME	Homeobox protein Hox-A7 (HOXA7)
T26338	GENENAME	HOXA7
T26338	TARGTYPE	Literature-reported
T26338	SYNONYMS	HoxA7; Hox-1A; Hox 1.1; Homeobox protein Hox-1A; Homeobox protein Hox 1.1; HOX1A
T26338	FUNCTION	Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis.
T26338	BIOCLASS	Antp homeobox
T26338	SEQUENCE	MSSSYYVNALFSKYTAGASLFQNAEPTSCSFAPNSQRSGYGAGAGAFASTVPGLYNVNSPLYQSPFASGYGLGADAYGNLPCASYDQNIPGLCSDLAKGACDKTDEGALHGAAEANFRIYPWMRSSGPDRKRGRQTYTRYQTLELEKEFHFNRYLTRRRRIEIAHALCLTERQIKIWFQNRRMKWKKEHKDEGPTAAAAPEGAVPSAAATAAADKADEEDDDEEEEDEEE

T25675	TARGETID	T25675
T25675	FORMERID	TTDI00040
T25675	UNIPROID	HXA13_HUMAN
T25675	TARGNAME	Homeobox protein Hox-A13 (HOXA13)
T25675	GENENAME	HOXA13
T25675	TARGTYPE	Literature-reported
T25675	SYNONYMS	Homeobox protein HoxA13; Homeobox protein Hox1J; HOXA13
T25675	FUNCTION	Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis.
T25675	PDBSTRUC	2L7Z
T25675	SEQUENCE	MTASVLLHPRWIEPTVMFLYDNGGGLVADELNKNMEGAAAAAAAAAAAAAAGAGGGGFPHPAAAAAGGNFSVAAAAAAAAAAAANQCRNLMAHPAPLAPGAASAYSSAPGEAPPSAAAAAAAAAAAAAAAAAASSSGGPGPAGPAGAEAAKQCSPCSAAAQSSSGPAALPYGYFGSGYYPCARMGPHPNAIKSCAQPASAAAAAAFADKYMDTAGPAAEEFSSRAKEFAFYHQGYAAGPYHHHQPMPGYLDMPVVPGLGGPGESRHEPLGLPMESYQPWALPNGWNGQMYCPKEQAQPPHLWKSTLPDVVSHPSDASSYRRGRKKRVPYTKVQLKELEREYATNKFITKDKRRRISATTNLSERQVTIWFQNRRVKEKKVINKLKTTS

T90940	TARGETID	T90940
T90940	FORMERID	TTDR00399
T90940	UNIPROID	OTSB_ECOLI
T90940	TARGNAME	Bacterial Trehalose-phosphatase (Bact otsB)
T90940	GENENAME	Bact otsB
T90940	TARGTYPE	Literature-reported
T90940	SYNONYMS	otsB; Trehalose-6-phosphate phosphatase; Trehalose 6-phosphate phosphatase; TPP
T90940	FUNCTION	Removes the phosphate from trehalose 6-phosphate (Tre6P) to produce free trehalose. Also catalyzes the dephosphorylation of glucose-6-phosphate (Glu6P) and 2-deoxyglucose-6-phosphate (2dGlu6P).
T90940	BIOCLASS	Phosphoric monoester hydrolase
T90940	SEQUENCE	MTEPLTETPELSAKYAWFFDLDGTLAEIKPHPDQVVVPDNILQGLQLLATASDGALALISGRSMVELDALAKPYRFPLAGVHGAERRDINGKTHIVHLPDAIARDISVQLHTVIAQYPGAELEAKGMAFALHYRQAPQHEDALMTLAQRITQIWPQMALQQGKCVVEIKPRGTSKGEAIAAFMQEAPFIGRTPVFLGDDLTDESGFAVVNRLGGMSVKIGTGATQASWRLAGVPDVWSWLEMITTALQQKRENNRSDDYESFSRSI

T16243	TARGETID	T16243
T16243	FORMERID	TTDI00204
T16243	UNIPROID	ARRB2_HUMAN
T16243	TARGNAME	Beta-arrestin-2 (ARRB2)
T16243	GENENAME	ARRB2
T16243	TARGTYPE	Literature-reported
T16243	SYNONYMS	Non-visual arrestin-3; Betaarrestin2; Arrestin beta2; Arrestin beta-2; ARR2; ARB2
T16243	FUNCTION	During homologous desensitization, beta-arrestins bind to the GPRK-phosphorylated receptor and sterically preclude its coupling to the cognate G-protein; the binding appears to require additional receptor determinants exposed only in the active receptor conformation. The beta-arrestins target many receptors for internalization by acting as endocytic adapters (CLASPs, clathrin-associated sorting proteins) and recruiting the GPRCs to the adapter protein 2 complex 2 (AP-2) in clathrin-coated pits (CCPs). However, the extent of beta-arrestin involvement appears to vary significantly depending on the receptor, agonist and cell type. Internalized arrestin-receptor complexes traffic to intracellular endosomes, where they remain uncoupled from G-proteins. Two different modes of arrestin-mediated internalization occur. Class A receptors, like ADRB2, OPRM1, ENDRA, D1AR and ADRA1B dissociate from beta-arrestin at or near the plasma membrane and undergo rapid recycling. Class B receptors, like AVPR2, AGTR1, NTSR1, TRHR and TACR1 internalize as a complex with arrestin and traffic with it to endosomal vesicles, presumably as desensitized receptors, for extended periods of time. Receptor resensitization then requires that receptor-bound arrestin is removed so that the receptor can be dephosphorylated and returned to the plasma membrane. Mediates endocytosis of CCR7 following ligation of CCL19 but not CCL21. Involved in internalization of P2RY1, P2RY4, P2RY6 and P2RY11 and ATP-stimulated internalization of P2RY2. Involved in phosphorylation-dependent internalization of OPRD1 and subsequent recycling or degradation. Involved in ubiquitination of IGF1R. Beta-arrestins function as multivalent adapter proteins that can switch the GPCR from a G-protein signaling mode that transmits short-lived signals from the plasma membrane via small molecule second messengers and ion channels to a beta-arrestin signaling mode that transmits a distinct set of signals that are initiated as the receptor internalizes and transits the intracellular compartment. Acts as signaling scaffold for MAPK pathways such as MAPK1/3 (ERK1/2) and MAPK10 (JNK3). ERK1/2 and JNK3 activated by the beta-arrestin scaffold are largely excluded from the nucleus and confined to cytoplasmic locations such as endocytic vesicles, also called beta-arrestin signalosomes. Acts as signaling scaffold for the AKT1 pathway. GPCRs for which the beta-arrestin-mediated signaling relies on both ARRB1 and ARRB2 (codependent regulation) include ADRB2, F2RL1 and PTH1R. For some GPCRs the beta-arrestin-mediated signaling relies on either ARRB1 or ARRB2 and is inhibited by the other respective beta-arrestin form (reciprocal regulation). Increases ERK1/2 signaling in AGTR1- and AVPR2-mediated activation (reciprocal regulation). Involved in CCR7-mediated ERK1/2 signaling involving ligand CCL19. Is involved in type-1A angiotensin II receptor/AGTR1-mediated ERK activity. Is involved in type-1A angiotensin II receptor/AGTR1-mediated MAPK10 activity. Is involved in dopamine-stimulated AKT1 activity in the striatum by disrupting the association of AKT1 with its negative regulator PP2A. Involved in AGTR1-mediated chemotaxis. Appears to function as signaling scaffold involved in regulation of MIP-1-beta-stimulated CCR5-dependent chemotaxis. Involved in attenuation of NF-kappa-B-dependent transcription in response to GPCR or cytokine stimulation by interacting with and stabilizing CHUK. Suppresses UV-induced NF-kappa-B-dependent activation by interacting with CHUK. The function is promoted by stimulation of ADRB2 and dephosphorylation of ARRB2. Involved in p53/TP53-mediated apoptosis by regulating MDM2 and reducing the MDM2-mediated degradation of p53/TP53. May serve as nuclear messenger for GPCRs. Upon stimulation of OR1D2, may be involved in regulation of gene expression during the early processes of fertilization. Also involved in regulation of receptors other than GPCRs. Involved in endocytosis of TGFBR2 and TGFBR3 and down-regulates TGF-beta signaling such as NF-kappa-B activation. Involved in endocytosis of low-density lipoprotein receptor/LDLR. Involved in endocytosis of smoothened homolog/Smo, which also requires GRK2. Involved in endocytosis of SLC9A5. Involved in endocytosis of ENG and subsequent TGF-beta-mediated ERK activation and migration of epithelial cells. Involved in Toll-like receptor and IL-1 receptor signaling through the interaction with TRAF6 which prevents TRAF6 autoubiquitination and oligomerization required for activation of NF-kappa-B and JUN. Involved in insulin resistance by acting as insulin-induced signaling scaffold for SRC, AKT1 and INSR. Involved in regulation of inhibitory signaling of natural killer cells by recruiting PTPN6 and PTPN11 to KIR2DL1. Involved in IL8-mediated granule release in neutrophils. Involved in the internalization of the atypical chemokine receptor ACKR3. Functions in regulating agonist-mediated G-protein coupled receptor (GPCR) signaling by mediating both receptor desensitization and resensitization processes.
T16243	BIOCLASS	Arrestin protein
T16243	SEQUENCE	MGEKPGTRVFKKSSPNCKLTVYLGKRDFVDHLDKVDPVDGVVLVDPDYLKDRKVFVTLTCAFRYGREDLDVLGLSFRKDLFIATYQAFPPVPNPPRPPTRLQDRLLRKLGQHAHPFFFTIPQNLPCSVTLQPGPEDTGKACGVDFEIRAFCAKSLEEKSHKRNSVRLVIRKVQFAPEKPGPQPSAETTRHFLMSDRSLHLEASLDKELYYHGEPLNVNVHVTNNSTKTVKKIKVSVRQYADICLFSTAQYKCPVAQLEQDDQVSPSSTFCKVYTITPLLSDNREKRGLALDGKLKHEDTNLASSTIVKEGANKEVLGILVSYRVKVKLVVSRGGDVSVELPFVLMHPKPHDHIPLPRPQSAAPETDVPVDTNLIEFDTNYATDDDIVFEDFARLRLKGMKDDDYDDQLC

T07775	TARGETID	T07775
T07775	FORMERID	TTDI02421
T07775	UNIPROID	NAC1_HUMAN
T07775	TARGNAME	Sodium calcium exchanger 1 (SLC8A1)
T07775	GENENAME	SLC8A1
T07775	TARGTYPE	Literature-reported
T07775	SYNONYMS	Solute carrier family 8 member 1; Sodium/calcium exchanger 1; Na(+)/Ca(2+)-exchange protein 1; NCX1; CNC
T07775	FUNCTION	Contributes to Ca(2+) transport during excitation-contraction coupling in muscle. In a first phase, voltage-gated channels mediate the rapid increase of cytoplasmic Ca(2+) levels due to release of Ca(2+) stores from the endoplasmic reticulum. SLC8A1 mediates the export of Ca(2+) from the cell during the next phase, so that cytoplasmic Ca(2+) levels rapidly return to baseline. Required for normal embryonic heart development and the onset of heart contractions. Mediates the exchange of one Ca(2+) ion against three to four Na(+) ions across the cell membrane, and thereby contributes to the regulation of cytoplasmic Ca(2+) levels and Ca(2+)-dependent cellular processes.
T07775	BIOCLASS	Calcium:cation antiporter
T07775	SEQUENCE	MYNMRRLSLSPTFSMGFHLLVTVSLLFSHVDHVIAETEMEGEGNETGECTGSYYCKKGVILPIWEPQDPSFGDKIARATVYFVAMVYMFLGVSIIADRFMSSIEVITSQEKEITIKKPNGETTKTTVRIWNETVSNLTLMALGSSAPEILLSVIEVCGHNFTAGDLGPSTIVGSAAFNMFIIIALCVYVVPDGETRKIKHLRVFFVTAAWSIFAYTWLYIILSVISPGVVEVWEGLLTFFFFPICVVFAWVADRRLLFYKYVYKRYRAGKQRGMIIEHEGDRPSSKTEIEMDGKVVNSHVENFLDGALVLEVDERDQDDEEARREMARILKELKQKHPDKEIEQLIELANYQVLSQQQKSRAFYRIQATRLMTGAGNILKRHAADQARKAVSMHEVNTEVTENDPVSKIFFEQGTYQCLENCGTVALTIIRRGGDLTNTVFVDFRTEDGTANAGSDYEFTEGTVVFKPGDTQKEIRVGIIDDDIFEEDENFLVHLSNVKVSSEASEDGILEANHVSTLACLGSPSTATVTIFDDDHAGIFTFEEPVTHVSESIGIMEVKVLRTSGARGNVIVPYKTIEGTARGGGEDFEDTCGELEFQNDEIVKTISVKVIDDEEYEKNKTFFLEIGEPRLVEMSEKKALLLNELGGFTITGKYLFGQPVFRKVHAREHPILSTVITIADEYDDKQPLTSKEEEERRIAEMGRPILGEHTKLEVIIEESYEFKSTVDKLIKKTNLALVVGTNSWREQFIEAITVSAGEDDDDDECGEEKLPSCFDYVMHFLTVFWKVLFAFVPPTEYWNGWACFIVSILMIGLLTAFIGDLASHFGCTIGLKDSVTAVVFVALGTSVPDTFASKVAATQDQYADASIGNVTGSNAVNVFLGIGVAWSIAAIYHAANGEQFKVSPGTLAFSVTLFTIFAFINVGVLLYRRRPEIGGELGGPRTAKLLTSCLFVLLWLLYIFFSSLEAYCHIKGF

T68009	TARGETID	T68009
T68009	FORMERID	TTDR00830
T68009	UNIPROID	CADH5_HUMAN
T68009	TARGNAME	Vascular endothelial cadherin (CDH5)
T68009	GENENAME	CDH5
T68009	TARGTYPE	Literature-reported
T68009	SYNONYMS	VE-cadherin; VE-cad; Cadherin-5; CD144 antigen; CD144; 7B4 antigen
T68009	FUNCTION	Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. This cadherin may play a important role in endothelial cell biology through control of the cohesion and organization of the intercellular junctions. It associates with alpha-catenin forming a link to the cytoskeleton. Acts in concert with KRIT1 to establish and maintain correct endothelial cell polarity and vascular lumen. These effects are mediated by recruitment and activation of the Par polarity complex and RAP1B. Required for activation of PRKCZ and for the localization of phosphorylated PRKCZ, PARD3, TIAM1 and RAP1B to the cell junction.
T68009	BIOCLASS	Cadherin protein
T68009	SEQUENCE	MQRLMMLLATSGACLGLLAVAAVAAAGANPAQRDTHSLLPTHRRQKRDWIWNQMHIDEEKNTSLPHHVGKIKSSVSRKNAKYLLKGEYVGKVFRVDAETGDVFAIERLDRENISEYHLTAVIVDKDTGENLETPSSFTIKVHDVNDNWPVFTHRLFNASVPESSAVGTSVISVTAVDADDPTVGDHASVMYQILKGKEYFAIDNSGRIITITKSLDREKQARYEIVVEARDAQGLRGDSGTATVLVTLQDINDNFPFFTQTKYTFVVPEDTRVGTSVGSLFVEDPDEPQNRMTKYSILRGDYQDAFTIETNPAHNEGIIKPMKPLDYEYIQQYSFIVEATDPTIDLRYMSPPAGNRAQVIINITDVDEPPIFQQPFYHFQLKENQKKPLIGTVLAMDPDAARHSIGYSIRRTSDKGQFFRVTKKGDIYNEKELDREVYPWYNLTVEAKELDSTGTPTGKESIVQVHIEVLDENDNAPEFAKPYQPKVCENAVHGQLVLQISAIDKDITPRNVKFKFILNTENNFTLTDNHDNTANITVKYGQFDREHTKVHFLPVVISDNGMPSRTGTSTLTVAVCKCNEQGEFTFCEDMAAQVGVSIQAVVAILLCILTITVITLLIFLRRRLRKQARAHGKSVPEIHEQLVTYDEEGGGEMDTTSYDVSVLNSVRRGGAKPPRPALDARPSLYAQVQKPPRHAPGAHGGPGEMAAMIEVKKDEADHDGDGPPYDTLHIYGYEGSESIAESLSSLGTDSSDSDVDYDFLNDWGPRFKMLAELYGSDPREELLY

T18796	TARGETID	T18796
T18796	FORMERID	TTDI03137
T18796	UNIPROID	CXA4_HUMAN
T18796	TARGNAME	Gap junction alpha-4 protein (Cx37)
T18796	GENENAME	GJA4
T18796	TARGTYPE	Literature-reported
T18796	SYNONYMS	Connexin-37
T18796	FUNCTION	One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell.
T18796	BIOCLASS	Gap junction-forming connexin
T18796	SEQUENCE	MGDWGFLEKLLDQVQEHSTVVGKIWLTVLFIFRILILGLAGESVWGDEQSDFECNTAQPGCTNVCYDQAFPISHIRYWVLQFLFVSTPTLVYLGHVIYLSRREERLRQKEGELRALPAKDPQVERALAAVERQMAKISVAEDGRLRIRGALMGTYVASVLCKSVLEAGFLYGQWRLYGWTMEPVFVCQRAPCPYLVDCFVSRPTEKTIFIIFMLVVGLISLVLNLLELVHLLCRCLSRGMRARQGQDAPPTQGTSSDPYTDQVFFYLPVGQGPSSPPCPTYNGLSSSEQNWANLTTEERLASSRPPLFLDPPPQNGQKPPSRPSSSASKKQYV
T18796	DRUGINFO	D00VJY	octanol	Investigative

T96396	TARGETID	T96396
T96396	FORMERID	TTDI02601
T96396	UNIPROID	PHB_HUMAN
T96396	TARGNAME	Prohibitin (PHB)
T96396	GENENAME	PHB
T96396	TARGTYPE	Literature-reported
T96396	SYNONYMS	PHB1; HEL-S-54e; HEL-215
T96396	FUNCTION	It has a role in regulating proliferation. As yet it is unclear if the protein or the mRNA exhibits this effect. May play a role in regulating mitochondrial respiration activity and in aging. Prohibitin inhibits DNA synthesis.
T96396	PDBSTRUC	1LU7
T96396	SEQUENCE	MAAKVFESIGKFGLALAVAGGVVNSALYNVDAGHRAVIFDRFRGVQDIVVGEGTHFLIPWVQKPIIFDCRSRPRNVPVITGSKDLQNVNITLRILFRPVASQLPRIFTSIGEDYDERVLPSITTEILKSVVARFDAGELITQRELVSRQVSDDLTERAATFGLILDDVSLTHLTFGKEFTEAVEAKQVAQQEAERARFVVEKAEQQKKAAIISAEGDSKAAELIANSLATAGDGLIELRKLEAAEDIAYQLSRSRNITYLPAGQSVLLQLPQ

T95742	TARGETID	T95742
T95742	FORMERID	TTDR00725
T95742	UNIPROID	MERL_HUMAN
T95742	TARGNAME	Neurofibromin-2 (NF2)
T95742	GENENAME	NF2
T95742	TARGTYPE	Literature-reported
T95742	SYNONYMS	Schwannomin; Schwannomerlin; SCH; Moesin-ezrin-radixin-like protein; Merlin
T95742	FUNCTION	Probable regulator of the Hippo/SWH (Sav/Wts/Hpo) signaling pathway, a signaling pathway that plays a pivotal role in tumor suppression by restricting proliferation and promoting apoptosis. Along with WWC1 can synergistically induce the phosphorylation of LATS1 and LATS2 and can probably function in the regulation of the Hippo/SWH (Sav/Wts/Hpo) signaling pathway. May act as a membrane stabilizing protein. May inhibit PI3 kinase by binding to AGAP2 and impairing its stimulating activity. Suppresses cell proliferation and tumorigenesis by inhibiting the CUL4A-RBX1-DDB1-VprBP/DCAF1 E3 ubiquitin-protein ligase complex.
T95742	PDBSTRUC	6CDS; 4ZRJ; 4ZRI; 3U8Z; 1H4R
T95742	SEQUENCE	MAGAIASRMSFSSLKRKQPKTFTVRIVTMDAEMEFNCEMKWKGKDLFDLVCRTLGLRETWFFGLQYTIKDTVAWLKMDKKVLDHDVSKEEPVTFHFLAKFYPENAEEELVQEITQHLFFLQVKKQILDEKIYCPPEASVLLASYAVQAKYGDYDPSVHKRGFLAQEELLPKRVINLYQMTPEMWEERITAWYAEHRGRARDEAEMEYLKIAQDLEMYGVNYFAIRNKKGTELLLGVDALGLHIYDPENRLTPKISFPWNEIRNISYSDKEFTIKPLDKKIDVFKFNSSKLRVNKLILQLCIGNHDLFMRRRKADSLEVQQMKAQAREEKARKQMERQRLAREKQMREEAERTRDELERRLLQMKEEATMANEALMRSEETADLLAEKAQITEEEAKLLAQKAAEAEQEMQRIKATAIRTEEEKRLMEQKVLEAEVLALKMAEESERRAKEADQLKQDLQEAREAERRAKQKLLEIATKPTYPPMNPIPAPLPPDIPSFNLIGDSLSFDFKDTDMKRLSMEIEKEKVEYMEKSKHLQEQLNELKTEIEALKLKERETALDILHNENSDRGGSSKHNTIKKLTLQSAKSRVAFFEEL

T35862	TARGETID	T35862
T35862	FORMERID	TTDI00104
T35862	UNIPROID	SFTPD_HUMAN
T35862	TARGNAME	Lung surfactant protein D (SFTPD)
T35862	GENENAME	SFTPD
T35862	TARGTYPE	Literature-reported
T35862	SYNONYMS	SP-D; SFTP4; Pulmonary surfactant-associated protein D; PSPD; PSP-D; Collectin-7; COLEC7
T35862	FUNCTION	Contributes to the lung's defense against inhaled microorganisms, organic antigens and toxins. Interacts with compounds such as bacterial lipopolysaccharides, oligosaccharides and fatty acids and modulates leukocyte action in immune response. May participate in the extracellular reorganization or turnover of pulmonary surfactant. Binds strongly maltose residues and to a lesser extent other alpha-glucosyl moieties.
T35862	PDBSTRUC	5OXS; 5OXR; 4M18; 4M17; 4.00E+52
T35862	SEQUENCE	MLLFLLSALVLLTQPLGYLEAEMKTYSHRTMPSACTLVMCSSVESGLPGRDGRDGREGPRGEKGDPGLPGAAGQAGMPGQAGPVGPKGDNGSVGEPGPKGDTGPSGPPGPPGVPGPAGREGPLGKQGNIGPQGKPGPKGEAGPKGEVGAPGMQGSAGARGLAGPKGERGVPGERGVPGNTGAAGSAGAMGPQGSPGARGPPGLKGDKGIPGDKGAKGESGLPDVASLRQQVEALQGQVQHLQAAFSQYKKVELFPNGQSVGEKIFKTAGFVKPFTEAQLLCTQAGGQLASPRSAAENAALQQLVVAKNEAAFLSMTDSKTEGKFTYPTGESLVYSNWAPGEPNDDGGSEDCVEIFTNGKWNDRACGEKRLVVCEF

T57174	TARGETID	T57174
T57174	FORMERID	TTDI03050
T57174	UNIPROID	ARBK2_HUMAN
T57174	TARGNAME	Beta-adrenergic receptor kinase 2 (ADRBK2)
T57174	GENENAME	GRK3
T57174	TARGTYPE	Literature-reported
T57174	SYNONYMS	G-protein-coupled receptor kinase 3; Beta-ARK-2; BARK2; ADRBK2
T57174	FUNCTION	Specifically phosphorylates the agonist-occupied form of the beta-adrenergic and closely related receptors.
T57174	ECNUMBER	EC 2.7.11.15
T57174	SEQUENCE	MADLEAVLADVSYLMAMEKSKATPAARASKRIVLPEPSIRSVMQKYLAERNEITFDKIFNQKIGFLLFKDFCLNEINEAVPQVKFYEEIKEYEKLDNEEDRLCRSRQIYDAYIMKELLSCSHPFSKQAVEHVQSHLSKKQVTSTLFQPYIEEICESLRGDIFQKFMESDKFTRFCQWKNVELNIHLTMNEFSVHRIIGRGGFGEVYGCRKADTGKMYAMKCLDKKRIKMKQGETLALNERIMLSLVSTGDCPFIVCMTYAFHTPDKLCFILDLMNGGDLHYHLSQHGVFSEKEMRFYATEIILGLEHMHNRFVVYRDLKPANILLDEHGHARISDLGLACDFSKKKPHASVGTHGYMAPEVLQKGTAYDSSADWFSLGCMLFKLLRGHSPFRQHKTKDKHEIDRMTLTVNVELPDTFSPELKSLLEGLLQRDVSKRLGCHGGGSQEVKEHSFFKGVDWQHVYLQKYPPPLIPPRGEVNAADAFDIGSFDEEDTKGIKLLDCDQELYKNFPLVISERWQQEVTETVYEAVNADTDKIEARKRAKNKQLGHEEDYALGKDCIMHGYMLKLGNPFLTQWQRRYFYLFPNRLEWRGEGESRQNLLTMEQILSVEETQIKDKKCILFRIKGGKQFVLQCESDPEFVQWKKELNETFKEAQRLLRRAPKFLNKPRSGTVELPKPSLCHRNSNGL
T57174	DRUGINFO	D0U8UK	PMID21596927C101	Investigative

T28758	TARGETID	T28758
T28758	FORMERID	TTDI00165
T28758	UNIPROID	DEK_HUMAN
T28758	TARGNAME	DEK protein (DEK)
T28758	GENENAME	DEK
T28758	TARGTYPE	Literature-reported
T28758	SYNONYMS	Protein DEK
T28758	FUNCTION	Involved in chromatin organization.
T28758	PDBSTRUC	2JX3; 1Q1V
T28758	SEQUENCE	MSASAPAAEGEGTPTQPASEKEPEMPGPREESEEEEDEDDEEEEEEEKEKSLIVEGKREKKKVERLTMQVSSLQREPFTIAQGKGQKLCEIERIHFFLSKKKTDELRNLHKLLYNRPGTVSSLKKNVGQFSGFPFEKGSVQYKKKEEMLKKFRNAMLKSICEVLDLERSGVNSELVKRILNFLMHPKPSGKPLPKSKKTCSKGSKKERNSSGMARKAKRTKCPEILSDESSSDEDEKKNKEESSDDEDKESEEEPPKKTAKREKPKQKATSKSKKSVKSANVKKADSSTTKKNQNSSKKESESEDSSDDEPLIKKLKKPPTDEELKETIKKLLASANLEEVTMKQICKKVYENYPTYDLTERKDFIKTTVKELIS

T72405	TARGETID	T72405
T72405	UNIPROID	GLRX1_HUMAN
T72405	TARGNAME	Glutaredoxin-1 (GLRX)
T72405	GENENAME	GLRX
T72405	TARGTYPE	Literature-reported
T72405	SYNONYMS	Thioltransferase-1; TTase-1; GRX
T72405	FUNCTION	Has a glutathione-disulfide oxidoreductase activity in the presence of NADPH and glutathione reductase. Reduces low molecular weight disulfides and proteins.
T72405	PDBSTRUC	4RQR; 1JHB; 1B4Q
T72405	SEQUENCE	MAQEFVNCKIQPGKVVVFIKPTCPYCRRAQEILSQLPIKQGLLEFVDITATNHTNEIQDYLQQLTGARTVPRVFIGKDCIGGCSDLVSLQQSGELLTRLKQIGALQ

T47988	TARGETID	T47988
T47988	FORMERID	TTDI03138
T47988	UNIPROID	CXA5_HUMAN
T47988	TARGNAME	Gap junction alpha-5 protein (Cx40)
T47988	GENENAME	GJA5
T47988	TARGTYPE	Literature-reported
T47988	SYNONYMS	Connexin-40
T47988	FUNCTION	One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell.
T47988	BIOCLASS	Gap junction-forming connexin
T47988	SEQUENCE	MGDWSFLGNFLEEVHKHSTVVGKVWLTVLFIFRMLVLGTAAESSWGDEQADFRCDTIQPGCQNVCYDQAFPISHIRYWVLQIIFVSTPSLVYMGHAMHTVRMQEKRKLREAERAKEVRGSGSYEYPVAEKAELSCWEEGNGRIALQGTLLNTYVCSILIRTTMEVGFIVGQYFIYGIFLTTLHVCRRSPCPHPVNCYVSRPTEKNVFIVFMLAVAALSLLLSLAELYHLGWKKIRQRFVKPRQHMAKCQLSGPSVGIVQSCTPPPDFNQCLENGPGGKFFNPFSNNMASQQNTDNLVTEQVRGQEQTPGEGFIQVRYGQKPEVPNGVSPGHRLPHGYHSDKRRLSKASSKARSDDLSV
T47988	DRUGINFO	D00VJY	octanol	Investigative

T29652	TARGETID	T29652
T29652	FORMERID	TTDR00555
T29652	UNIPROID	SURE_ECOLI
T29652	TARGNAME	Bacterial Acid phosphatase surE (Bact surE)
T29652	GENENAME	Bact surE
T29652	TARGTYPE	Literature-reported
T29652	SYNONYMS	Stationary-phase survival protein surE; Phosphomonoesterase; Glycerophosphatase; Acid Phosphomonoesterase; Acid Phosphatase
T29652	FUNCTION	This protein is essential for the survival of e.coli in stationary phase and for survival of heat and osmotic stresses.
T29652	BIOCLASS	Phosphoric monoester hydrolase
T29652	SEQUENCE	MRILLSNDDGVHAPGIQTLAKALREFADVQVVAPDRNRSGASNSLTLESSLRTFTFENGDIAVQMGTPTDCVYLGVNALMRPRPDIVVSGINAGPNLGDDVIYSGTVAAAMEGRHLGFPALAVSLDGHKHYDTAAAVTCSILRALCKEPLRTGRILNINVPDLPLDQIKGIRVTRCGTRHPADQVIPQQDPRGNTLYWIGPPGGKCDAGPGTDFAAVDEGYVSITPLHVDLTAHSAQDVVSDWLNSVGVGTQW

T47236	TARGETID	T47236
T47236	FORMERID	TTDR00852
T47236	UNIPROID	SRBP1_HUMAN
T47236	TARGNAME	Sterol regulatory element binding protein-1 (SREBF1)
T47236	GENENAME	SREBF1
T47236	TARGTYPE	Literature-reported
T47236	SYNONYMS	bHLHd1; Sterol regulatory element-binding transcription factor 1; Sterol regulatory element-binding protein 1; SREBP1; SREBP-1; SREBP 1; Class D basic helix-loop-helix protein 1
T47236	FUNCTION	Regulates transcription of the LDL receptor gene as well as the fatty acid and to a lesser degree the cholesterol synthesis pathway. Binds to the sterol regulatory element 1 (SRE-1) (5'-ATCACCCCAC-3'). Has dual sequence specificity binding to both an E-box motif (5'-ATCACGTGA-3') and to SRE-1 (5'-ATCACCCCAC-3'). Transcriptional activator required for lipid homeostasis.
T47236	PDBSTRUC	1AM9
T47236	SEQUENCE	MDEPPFSEAALEQALGEPCDLDAALLTDIEDMLQLINNQDSDFPGLFDPPYAGSGAGGTDPASPDTSSPGSLSPPPATLSSSLEAFLSGPQAAPSPLSPPQPAPTPLKMYPSMPAFSPGPGIKEESVPLSILQTPTPQPLPGALLPQSFPAPAPPQFSSTPVLGYPSPPGGFSTGSPPGNTQQPLPGLPLASPPGVPPVSLHTQVQSVVPQQLLTVTAAPTAAPVTTTVTSQIQQVPVLLQPHFIKADSLLLTAMKTDGATVKAAGLSPLVSGTTVQTGPLPTLVSGGTILATVPLVVDAEKLPINRLAAGSKAPASAQSRGEKRTAHNAIEKRYRSSINDKIIELKDLVVGTEAKLNKSAVLRKAIDYIRFLQHSNQKLKQENLSLRTAVHKSKSLKDLVSACGSGGNTDVLMEGVKTEVEDTLTPPPSDAGSPFQSSPLSLGSRGSGSGGSGSDSEPDSPVFEDSKAKPEQRPSLHSRGMLDRSRLALCTLVFLCLSCNPLASLLGARGLPSPSDTTSVYHSPGRNVLGTESRDGPGWAQWLLPPVVWLLNGLLVLVSLVLLFVYGEPVTRPHSGPAVYFWRHRKQADLDLARGDFAQAAQQLWLALRALGRPLPTSHLDLACSLLWNLIRHLLQRLWVGRWLAGRAGGLQQDCALRVDASASARDAALVYHKLHQLHTMGKHTGGHLTATNLALSALNLAECAGDAVSVATLAEIYVAAALRVKTSLPRALHFLTRFFLSSARQACLAQSGSVPPAMQWLCHPVGHRFFVDGDWSVLSTPWESLYSLAGNPVDPLAQVTQLFREHLLERALNCVTQPNPSPGSADGDKEFSDALGYLQLLNSCSDAAGAPAYSFSISSSMATTTGVDPVAKWWASLTAVVIHWLRRDEEAAERLCPLVEHLPRVLQESERPLPRAALHSFKAARALLGCAKAESGPASLTICEKASGYLQDSLATTPASSSIDKAVQLFLCDLLLVVRTSLWRQQQPPAPAPAAQGTSSRPQASALELRGFQRDLSSLRRLAQSFRPAMRRVFLHEATARLMAGASPTRTHQLLDRSLRRRAGPGGKGGAVAELEPRPTRREHAEALLLASCYLPPGFLSAPGQRVGMLAEAARTLEKLGDRRLLHDCQQMLMRLGGGTTVTSS

T17122	TARGETID	T17122
T17122	FORMERID	TTDI02450
T17122	UNIPROID	ITAE_HUMAN
T17122	TARGNAME	Integrin alpha-E (ITGAE)
T17122	GENENAME	ITGAE
T17122	TARGTYPE	Literature-reported
T17122	SYNONYMS	Mucosal lymphocyte 1 antigen; Integrin alphaIEL; Integrin alphaE heavy chain; Integrin alpha-IEL; HML1 antigen; HML-1 antigen; CD103
T17122	FUNCTION	It mediates adhesion of intra-epithelial T-lymphocytes to epithelial cell monolayers. Integrin alpha-E/beta-7 is a receptor for E-cadherin.
T17122	BIOCLASS	Integrin
T17122	SEQUENCE	MWLFHTLLCIASLALLAAFNVDVARPWLTPKGGAPFVLSSLLHQDPSTNQTWLLVTSPRTKRTPGPLHRCSLVQDEILCHPVEHVPIPKGRHRGVTVVRSHHGVLICIQVLVRRPHSLSSELTGTCSLLGPDLRPQAQANFFDLENLLDPDARVDTGDCYSNKEGGGEDDVNTARQRRALEKEEEEDKEEEEDEEEEEAGTEIAIILDGSGSIDPPDFQRAKDFISNMMRNFYEKCFECNFALVQYGGVIQTEFDLRDSQDVMASLARVQNITQVGSVTKTASAMQHVLDSIFTSSHGSRRKASKVMVVLTDGGIFEDPLNLTTVINSPKMQGVERFAIGVGEEFKSARTARELNLIASDPDETHAFKVTNYMALDGLLSKLRYNIISMEGTVGDALHYQLAQIGFSAQILDERQVLLGAVGAFDWSGGALLYDTRSRRGRFLNQTAAAAADAEAAQYSYLGYAVAVLHKTCSLSYIAGAPRYKHHGAVFELQKEGREASFLPVLEGEQMGSYFGSELCPVDIDMDGSTDFLLVAAPFYHVHGEEGRVYVYRLSEQDGSFSLARILSGHPGFTNARFGFAMAAMGDLSQDKLTDVAIGAPLEGFGADDGASFGSVYIYNGHWDGLSASPSQRIRASTVAPGLQYFGMSMAGGFDISGDGLADITVGTLGQAVVFRSRPVVRLKVSMAFTPSALPIGFNGVVNVRLCFEISSVTTASESGLREALLNFTLDVDVGKQRRRLQCSDVRSCLGCLREWSSGSQLCEDLLLMPTEGELCEEDCFSNASVKVSYQLQTPEGQTDHPQPILDRYTEPFAIFQLPYEKACKNKLFCVAELQLATTVSQQELVVGLTKELTLNINLTNSGEDSYMTSMALNYPRNLQLKRMQKPPSPNIQCDDPQPVASVLIMNCRIGHPVLKRSSAHVSVVWQLEENAFPNRTADITVTVTNSNERRSLANETHTLQFRHGFVAVLSKPSIMYVNTGQGLSHHKEFLFHVHGENLFGAEYQLQICVPTKLRGLQVVAVKKLTRTQASTVCTWSQERACAYSSVQHVEEWHSVSCVIASDKENVTVAAEISWDHSEELLKDVTELQILGEISFNKSLYEGLNAENHRTKITVVFLKDEKYHSLPIIIKGSVGGLLVLIVILVILFKCGFFKRKYQQLNLESIRKAQLKSENLLEEEN

T39855	TARGETID	T39855
T39855	FORMERID	TTDR00667
T39855	UNIPROID	CDN1A_HUMAN
T39855	TARGNAME	Melanoma differentiation-associated protein 6 (CDKN1A)
T39855	GENENAME	CDKN1A
T39855	TARGTYPE	Literature-reported
T39855	SYNONYMS	WAF1; SDI1; PIC1; P21(WAF1); P21; Melanoma differentiation associated protein 6; MDA6; MDA-6; Cyclin-dependent kinase inhibitor 1; CIP1; CDK-interacting protein 1; CAP20
T39855	FUNCTION	Binds to and inhibits cyclin-dependent kinase activity, preventing phosphorylation of critical cyclin-dependent kinase substrates and blocking cell cycle progression. Functions in the nuclear localization and assembly of cyclin D-CDK4 complex and promotes its kinase activity towards RB1. At higher stoichiometric ratios, inhibits the kinase activity of the cyclin D-CDK4 complex. Inhibits DNA synthesis by DNA polymerase delta by competing with POLD3 for PCNA binding. May be involved in p53/TP53 mediated inhibition of cellular proliferation in response to DNA damage.
T39855	PDBSTRUC	6CIX; 6CIV; 6CEJ; 6CBI; 5E0U
T39855	SEQUENCE	MSEPAGDVRQNPCGSKACRRLFGPVDSEQLSRDCDALMAGCIQEARERWNFDFVTETPLEGDFAWERVRGLGLPKLYLPTGPRRGRDELGGGRRPGTSPALLQGTAEEDHVDLSLSCTLVPRSGEQAEGSPGGPGDSQGRKRRQTSMTDFYHSKRRLIFSKRKP

T81179	TARGETID	T81179
T81179	FORMERID	TTDR00870
T81179	UNIPROID	GMT1_YEAST
T81179	TARGNAME	Fungal GDP-mannose transporter (Fung VRG4)
T81179	GENENAME	Fung VRG4
T81179	TARGTYPE	Literature-reported
T81179	SYNONYMS	VRG4 gene; VRG4; Golgi GDP-mannose transporter
T81179	FUNCTION	Involved in the import of GDP-mannose from the cytoplasminto the Golgi lumen. Defective copy causes severe glycosylation defect and abnormal retention of soluble endoplasmic reticulum proteins. Involved in vanadate sensitivity.
T81179	PDBSTRUC	5OGK; 5OGE
T81179	SEQUENCE	MSELKTGHAGHNPWASVANSGPISILSYCGSSILMTVTNKFVVNLKDFNMNFVMLFVQSLVCTITLIILRILGYAKFRSLNKTDAKNWFPISFLLVLMIYTSSKALQYLAVPIYTIFKNLTIILIAYGEVLFFGGSVTSMELSSFLLMVLSSVVATWGDQQAVAAKAASLAEGAAGAVASFNPGYFWMFTNCITSALFVLIMRKRIKLTNFKDFDTMFYNNVLALPILLLFSFCVEDWSSVNLTNNFSNDSLTAMIISGVASVGISYCSGWCVRVTSSTTYSMVGALNKLPIALSGLIFFDAPRNFLSILSIFIGFLSGIIYAVAKQKKQQAQPLRK

T75918	TARGETID	T75918
T75918	FORMERID	TTDR00976
T75918	UNIPROID	KAPB_SCHPO
T75918	TARGNAME	Fungal cAMP-dependent protein kinase (Fung pka1)
T75918	GENENAME	Fung pka1
T75918	TARGTYPE	Literature-reported
T75918	SYNONYMS	cAMP-dependent protein kinase catalytic subunit
T75918	FUNCTION	Has cAMP-dependent protein kinase and protein serine/threonine kinase activity. 
T75918	BIOCLASS	Kinase
T75918	SEQUENCE	MDTTAVASKGSTNVGSSTDTLSTSASLHPSMNAGSVNEYSEQQRHGTNSFNGKPSVHDSVGSDASVSNGHNNHNESSLWTSGIPKALEEATKSKKPDSLVSTSTSGCASAHSVGYQNIDNLIPSPLPESASRSSSQSSHQRHSRDGRGELGSEHGERRSAMDGLRDRHIRKVRVSQLLDLQRRRIRPADHTTKDRYGIQDFNFLQTLGTGSFGRVHLVQSNHNRLYYAIKVLEKKKIVDMKQIEHTCDERYILSRVQHPFITILWGTFQDAKNLFMVMDFAEGGELFSLLRKCHRFPEKVAKFYAAEVILALDYLHHNQIVYRDLKPENLLLDRFGHLKIVDFGFAKRVSTSNCCTLCGTPDYLAPEIISLKPYNKAADWWSLGILIFEMLAGYPPFYSENPMKLYENILEGKVNYPSYFSPASIDLLSHLLQRDITCRYGNLKDGSMDIIMHPWFRDISWDKILTRKIEVPYVPPIQAGMGDSSQFDAYADVATDYGTSEDPEFTSIFKDF

T35799	TARGETID	T35799
T35799	FORMERID	TTDI02598
T35799	UNIPROID	MLH1_HUMAN
T35799	TARGNAME	DNA mismatch repair protein Mlh1 (MLH1)
T35799	GENENAME	MLH1
T35799	TARGTYPE	Literature-reported
T35799	SYNONYMS	MutL protein homolog 1; COCA2
T35799	FUNCTION	DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH3) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. Assembly of the MutL-MutS-heteroduplex ternary complex in presence of RFC and PCNA is sufficient to activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch and thus generates new entry points for the exonuclease EXO1 to degrade the strand containing the mismatch. DNA methylation would prevent cleavage and therefore assure that only the newly mutated DNA strand is going to be corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp loader subunits of DNA polymerase III, suggesting that it may play a role to recruit the DNA polymerase III to the site of the MMR. Also implicated in DNA damage signaling, a process which induces cell cycle arrest and can lead to apoptosis in case of major DNA damages. Heterodimerizes with MLH3 to form MutL gamma which plays a role in meiosis. Heterodimerizes with PMS2 to form MutL alpha, a component of the post-replicative DNA mismatch repair system (MMR).
T35799	PDBSTRUC	5U5P; 4P7A; 3RBN
T35799	SEQUENCE	MSFVAGVIRRLDETVVNRIAAGEVIQRPANAIKEMIENCLDAKSTSIQVIVKEGGLKLIQIQDNGTGIRKEDLDIVCERFTTSKLQSFEDLASISTYGFRGEALASISHVAHVTITTKTADGKCAYRASYSDGKLKAPPKPCAGNQGTQITVEDLFYNIATRRKALKNPSEEYGKILEVVGRYSVHNAGISFSVKKQGETVADVRTLPNASTVDNIRSIFGNAVSRELIEIGCEDKTLAFKMNGYISNANYSVKKCIFLLFINHRLVESTSLRKAIETVYAAYLPKNTHPFLYLSLEISPQNVDVNVHPTKHEVHFLHEESILERVQQHIESKLLGSNSSRMYFTQTLLPGLAGPSGEMVKSTTSLTSSSTSGSSDKVYAHQMVRTDSREQKLDAFLQPLSKPLSSQPQAIVTEDKTDISSGRARQQDEEMLELPAPAEVAAKNQSLEGDTTKGTSEMSEKRGPTSSNPRKRHREDSDVEMVEDDSRKEMTAACTPRRRIINLTSVLSLQEEINEQGHEVLREMLHNHSFVGCVNPQWALAQHQTKLYLLNTTKLSEELFYQILIYDFANFGVLRLSEPAPLFDLAMLALDSPESGWTEEDGPKEGLAEYIVEFLKKKAEMLADYFSLEIDEEGNLIGLPLLIDNYVPPLEGLPIFILRLATEVNWDEEKECFESLSKECAMFYSIRKQYISEESTLSGQQSEVPGSIPNSWKWTVEHIVYKALRSHILPPKHFTEDGNILQLANLPDLYKVFERC

T46208	TARGETID	T46208
T46208	UNIPROID	PMEL_HUMAN
T46208	TARGNAME	Gp100[209-217] peptide (PMEL)
T46208	GENENAME	PMEL
T46208	TARGTYPE	Literature-reported
T46208	SYNONYMS	Silver locus protein homolog (209-217); SILV (209-217); Premelanosome protein (209-217); PMEL17 (209-217); P100 (209-217); P1 (209-217); Melanomaassociated ME20 antigen (209-217); Melanoma-associated ME20 antigen (209-217); Melanocyte protein Pmel 17 (209-217); Melanocyte protein PMEL (209-217); Mbeta (209-217); ME20S (209-217); ME20M (209-217); ME20-M (209-217); D12S53E (209-217)
T46208	FUNCTION	Involved in the maturation of melanosomes from stage I to II. The transition from stage I melanosomes to stage II melanosomes involves an elongation of the vesicle, and the appearance within of distinct fibrillar structures. Release of the soluble form, ME20-S, could protect tumor cells from antibody mediated immunity. Plays a central role in the biogenesis of melanosomes.
T46208	PDBSTRUC	5EU6; 5EU5; 5EU4; 5EU3; 4IS6
T46208	SEQUENCE	MDLVLKRCLLHLAVIGALLAVGATKVPRNQDWLGVSRQLRTKAWNRQLYPEWTEAQRLDCWRGGQVSLKVSNDGPTLIGANASFSIALNFPGSQKVLPDGQVIWVNNTIINGSQVWGGQPVYPQETDDACIFPDGGPCPSGSWSQKRSFVYVWKTWGQYWQVLGGPVSGLSIGTGRAMLGTHTMEVTVYHRRGSRSYVPLAHSSSAFTITDQVPFSVSVSQLRALDGGNKHFLRNQPLTFALQLHDPSGYLAEADLSYTWDFGDSSGTLISRALVVTHTYLEPGPVTAQVVLQAAIPLTSCGSSPVPGTTDGHRPTAEAPNTTAGQVPTTEVVGTTPGQAPTAEPSGTTSVQVPTTEVISTAPVQMPTAESTGMTPEKVPVSEVMGTTLAEMSTPEATGMTPAEVSIVVLSGTTAAQVTTTEWVETTARELPIPEPEGPDASSIMSTESITGSLGPLLDGTATLRLVKRQVPLDCVLYRYGSFSVTLDIVQGIESAEILQAVPSGEGDAFELTVSCQGGLPKEACMEISSPGCQPPAQRLCQPVLPSPACQLVLHQILKGGSGTYCLNVSLADTNSLAVVSTQLIMPGQEAGLGQVPLIVGILLVLMAVVLASLIYRRRLMKQDFSVPQLPHSSSHWLRLPRIFCSCPIGENSPLLSGQQV
T46208	DRUGINFO	D0YU0L	GPA-TriMAR-T cells	Phase 1

T79485	TARGETID	T79485
T79485	FORMERID	TTDR00468
T79485	UNIPROID	LEP_HUMAN
T79485	TARGNAME	Leptin (LEP)
T79485	GENENAME	LEP
T79485	TARGTYPE	Literature-reported
T79485	SYNONYMS	Obesity factor; Obese protein; LEP
T79485	FUNCTION	May function as part of a signaling pathway that acts to regulate the size of the body fat depot. An increase in the level of LEP may act directly or indirectly on the CNS to inhibit food intake and/or regulate energy expenditure as part of a homeostatic mechanism to maintain constancy of the adipose mass.
T79485	PDBSTRUC	1AX8
T79485	SEQUENCE	MHWGTLCGFLWLWPYLFYVQAVPIQKVQDDTKTLIKTIVTRINDISHTQSVSSKQKVTGLDFIPGLHPILTLSKMDQTLAVYQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSCHLPWASGLETLDSLGGVLEASGYSTEVVALSRLQGSLQDMLWQLDLSPGC

T43548	TARGETID	T43548
T43548	FORMERID	TTDI01407
T43548	UNIPROID	BCL6_HUMAN
T43548	TARGNAME	B-cell lymphoma 6 protein (BCL-6)
T43548	GENENAME	BCL6
T43548	TARGTYPE	Literature-reported
T43548	SYNONYMS	Zinc finger protein 51; Zinc finger and BTB domain-containing protein 27; ZNF51; ZBTB27; Protein LAZ-3; LAZ3; BCL5; BCL-6; BCL-5; B-cell lymphoma 5 protein
T43548	FUNCTION	Transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. An important function is to allow GC B-cells to proliferate very rapidly in response to T-cell dependent antigens and tolerate the physiological DNA breaks required for immunglobulin class switch recombination and somatic hypermutation without inducing a p53/TP53-dependent apoptotic response. In follicular helper CD4(+) T-cells (T(FH) cells), promotes the expression of T(FH)-related genes but inhibits the differentiation of T(H)1, T(H)2 and T(H)17 cells. Also required for the establishment and maintenance of immunological memory for both T- and B-cells. Suppresses macrophage proliferation through competition with STAT5 for STAT-binding motifs binding on certain target genes, such as CCL2 and CCND2. In response to genotoxic stress, controls cell cycle arrest in GC B-cells in both p53/TP53-dependedent and -independent manners. Besides, also controls neurogenesis through the alteration of the composition of NOTCH-dependent transcriptional complexes at selective NOTCH targets, such as HES5, including the recruitment of the deacetylase SIRT1 and resulting in an epigenetic silencing leading to neuronal differentiation.
T43548	PDBSTRUC	6EW8; 6EW7; 6EW6; 6CQ1; 6C3N
T43548	SEQUENCE	MASPADSCIQFTRHASDVLLNLNRLRSRDILTDVVIVVSREQFRAHKTVLMACSGLFYSIFTDQLKCNLSVINLDPEINPEGFCILLDFMYTSRLNLREGNIMAVMATAMYLQMEHVVDTCRKFIKASEAEMVSAIKPPREEFLNSRMLMPQDIMAYRGREVVENNLPLRSAPGCESRAFAPSLYSGLSTPPASYSMYSHLPVSSLLFSDEEFRDVRMPVANPFPKERALPCDSARPVPGEYSRPTLEVSPNVCHSNIYSPKETIPEEARSDMHYSVAEGLKPAAPSARNAPYFPCDKASKEEERPSSEDEIALHFEPPNAPLNRKGLVSPQSPQKSDCQPNSPTESCSSKNACILQASGSPPAKSPTDPKACNWKKYKFIVLNSLNQNAKPEGPEQAELGRLSPRAYTAPPACQPPMEPENLDLQSPTKLSASGEDSTIPQASRLNNIVNRSMTGSPRSSSESHSPLYMHPPKCTSCGSQSPQHAEMCLHTAGPTFPEEMGETQSEYSDSSCENGAFFCNECDCRFSEEASLKRHTLQTHSDKPYKCDRCQASFRYKGNLASHKTVHTGEKPYRCNICGAQFNRPANLKTHTRIHSGEKPYKCETCGARFVQVAHLRAHVLIHTGEKPYPCEICGTRFRHLQTLKSHLRIHTGEKPYHCEKCNLHFRHKSQLRLHLRQKHGAITNTKVQYRVSATDLPPELPKAC

T38325	TARGETID	T38325
T38325	FORMERID	TTDNR00742
T38325	UNIPROID	RGS2_HUMAN
T38325	TARGNAME	G0/G1 switch regulatory protein 8 (RGS2)
T38325	GENENAME	RGS2
T38325	TARGTYPE	Literature-reported
T38325	SYNONYMS	Regulator of G-protein signaling 2; GIG31; G0S8; Cell growth-inhibiting gene 31 protein
T38325	FUNCTION	Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits, thereby driving them into their inactive GDP-bound form. It is involved in the negative regulation of the angiotensin-activated signaling pathway. Plays a role in the regulation of blood pressure in response to signaling via G protein-coupled receptors and GNAQ. Plays a role in regulating the constriction and relaxation of vascular smooth muscle. Binds EIF2B5 and blocks its activity, thereby inhibiting the translation of mRNA into protein. Regulates G protein-coupled receptor signaling cascades.
T38325	PDBSTRUC	4EKD; 4EKC; 2V4Z; 2AF0
T38325	SEQUENCE	MQSAMFLAVQHDCRPMDKSAGSGHKSEEKREKMKRTLLKDWKTRLSYFLQNSSTPGKPKTGKKSKQQAFIKPSPEEAQLWSEAFDELLASKYGLAAFRAFLKSEFCEENIEFWLACEDFKKTKSPQKLSSKARKIYTDFIEKEAPKEINIDFQTKTLIAQNIQEATSGCFTTAQKRVYSLMENNSYPRFLESEFYQDLCKKPQITTEPHAT

T78332	TARGETID	T78332
T78332	FORMERID	TTDI02073
T78332	UNIPROID	FOLR3_HUMAN
T78332	TARGNAME	Folate receptor gamma (FOLR3)
T78332	GENENAME	FOLR3
T78332	TARGTYPE	Literature-reported
T78332	SYNONYMS	Folate receptor 3; FRgamma; FOLR3
T78332	FUNCTION	Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate to the interior of cells. Isoform Short does not bind folate.
T78332	BIOCLASS	Folate receptor
T78332	SEQUENCE	MDMAWQMMQLLLLALVTAAGSAQPRSARARTDLLNVCMNAKHHKTQPSPEDELYGQCSPWKKNACCTASTSQELHKDTSRLYNFNWDHCGKMEPTCKRHFIQDSCLYECSPNLGPWIRQVNQSWRKERILNVPLCKEDCERWWEDCRTSYTCKSNWHKGWNWTSGINECPAGALCSTFESYFPTPAALCEGLWSHSFKVSNYSRGSGRCIQMWFDSAQGNPNEEVAKFYAAAMNAGAPSRGIIDS

T65161	TARGETID	T65161
T65161	FORMERID	TTDR00996
T65161	UNIPROID	TSN7_HUMAN
T65161	TARGNAME	Tetraspanin-7 (TSPAN7)
T65161	GENENAME	TSPAN7
T65161	TARGTYPE	Literature-reported
T65161	SYNONYMS	TSPAN7; TALLA-1; T-cell acute lymphoblastic leukemia-associated antigen 1; T-cell acute lymphoblastic leukemia associated antigen 1; Membrane component, X chromosome, surface marker 1; Cell surface glycoprotein A15; CD231 antigen
T65161	FUNCTION	May be involved in cell proliferation and cell motility.
T65161	BIOCLASS	Tetraspanin family
T65161	SEQUENCE	MASRRMETKPVITCLKTLLIIYSFVFWITGVILLAVGVWGKLTLGTYISLIAENSTNAPYVLIGTGTTIVVFGLFGCFATCRGSPWMLKLYAMFLSLVFLAELVAGISGFVFRHEIKDTFLRTYTDAMQTYNGNDERSRAVDHVQRSLSCCGVQNYTNWSTSPYFLEHGIPPSCCMNETDCNPQDLHNLTVAATKVNQKGCYDLVTSFMETNMGIIAGVAFGIAFSQLIGMLLACCLSRFITANQYEMV

T91906	TARGETID	T91906
T91906	FORMERID	TTDR00842
T91906	UNIPROID	ELK3_HUMAN
T91906	TARGNAME	ETS domain-containing protein Elk-3 (ELK3)
T91906	GENENAME	ELK3
T91906	TARGTYPE	Literature-reported
T91906	SYNONYMS	Serum response factor accessory protein 2; SRF accessory protein 2; SAP2; SAP-2; ETS-related protein NET; ETS-related protein ERP
T91906	FUNCTION	Forms a ternary complex with the serum response factor and the ETS and SRF motifs of the Fos serum response element. May be a negative regulator of transcription, but can activate transcription when coexpressed with Ras, Src or Mos.
T91906	BIOCLASS	E26 transformation-specific ETS
T91906	SEQUENCE	MESAITLWQFLLQLLLDQKHEHLICWTSNDGEFKLLKAEEVAKLWGLRKNKTNMNYDKLSRALRYYYDKNIIKKVIGQKFVYKFVSFPEILKMDPHAVEISRESLLLQDSDCKASPEGREAHKHGLAALRSTSRNEYIHSGLYSSFTINSLQNPPDAFKAIKTEKLEEPPEDSPPVEEVRTVIRFVTNKTDKHVTRPVVSLPSTSEAAAASAFLASSVSAKISSLMLPNAASISSASPFSSRSPSLSPNSPLPSEHRSLFLEAACHDSDSLEPLNLSSGSKTKSPSLPPKAKKPKGLEISAPPLVLSGTDIGSIALNSPALPSGSLTPAFFTAQTPNGLLLTPSPLLSSIHFWSSLSPVAPLSPARLQGPSTLFQFPTLLNGHMPVPIPSLDRAASPVLLSSNSQKS

T90897	TARGETID	T90897
T90897	UNIPROID	GRIA2_HUMAN
T90897	TARGNAME	Phosphorylated GluA2 (pGluA2)
T90897	GENENAME	GRIA2
T90897	TARGTYPE	Literature-reported
T90897	SYNONYMS	Glutamate receptor ionotropic, AMPA 2 (phosphorylated); Glutamate receptor 2 (phosphorylated); GluR-K2 (phosphorylated); GluR-B (phosphorylated); GluR-2 (phosphorylated); GluA2 (phosphorylated); GLUR2 (phosphorylated); AMPA-selective glutamate receptor 2  (phosphorylated)
T90897	FUNCTION	Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist. In the presence of CACNG4 or CACNG7 or CACNG8, shows resensitization which is characterized by a delayed accumulation of current flux upon continued application of glutamate. Through complex formation with NSG1, GRIP1 and STX12 controls the intracellular fate of AMPAR and the endosomal sorting of the GRIA2 subunit toward recycling and membrane targeting (By similarity).
T90897	PDBSTRUC	5ZG3; 5ZG2; 5ZG1; 5ZG0; 5YBG
T90897	SEQUENCE	MQKIMHISVLLSPVLWGLIFGVSSNSIQIGGLFPRGADQEYSAFRVGMVQFSTSEFRLTPHIDNLEVANSFAVTNAFCSQFSRGVYAIFGFYDKKSVNTITSFCGTLHVSFITPSFPTDGTHPFVIQMRPDLKGALLSLIEYYQWDKFAYLYDSDRGLSTLQAVLDSAAEKKWQVTAINVGNINNDKKDEMYRSLFQDLELKKERRVILDCERDKVNDIVDQVITIGKHVKGYHYIIANLGFTDGDLLKIQFGGANVSGFQIVDYDDSLVSKFIERWSTLEEKEYPGAHTTTIKYTSALTYDAVQVMTEAFRNLRKQRIEISRRGNAGDCLANPAVPWGQGVEIERALKQVQVEGLSGNIKFDQNGKRINYTINIMELKTNGPRKIGYWSEVDKMVVTLTELPSGNDTSGLENKTVVVTTILESPYVMMKKNHEMLEGNERYEGYCVDLAAEIAKHCGFKYKLTIVGDGKYGARDADTKIWNGMVGELVYGKADIAIAPLTITLVREEVIDFSKPFMSLGISIMIKKPQKSKPGVFSFLDPLAYEIWMCIVFAYIGVSVVLFLVSRFSPYEWHTEEFEDGRETQSSESTNEFGIFNSLWFSLGAFMQQGCDISPRSLSGRIVGGVWWFFTLIIISSYTANLAAFLTVERMVSPIESAEDLSKQTEIAYGTLDSGSTKEFFRRSKIAVFDKMWTYMRSAEPSVFVRTTAEGVARVRKSKGKYAYLLESTMNEYIEQRKPCDTMKVGGNLDSKGYGIATPKGSSLRNAVNLAVLKLNEQGLLDKLKNKWWYDKGECGSGGGDSKEKTSALSLSNVAGVFYILVGGLGLAMLVALIEFCYKSRAEAKRMKVAKNAQNINPSSSQNSQNFATYKEGYNVYGIESVKI

T26765	TARGETID	T26765
T26765	FORMERID	TTDR00703
T26765	UNIPROID	BCRA_BACLI
T26765	TARGNAME	Bacterial Bacitracin transport ATP-binding bcrA (Bact bcrA)
T26765	GENENAME	Bact bcrA
T26765	TARGTYPE	Literature-reported
T26765	SYNONYMS	BCRA
T26765	FUNCTION	Part of the binding-protein-dependent transport system for bacitracin that confer resistance to this antibiotic. Probably responsible for energy coupling to the transport system.
T26765	BIOCLASS	ABC transporter
T26765	SEQUENCE	MSTIIKTTDLTKMYGSQKSVDHLNINVKQGDIYGFLGRNGAGKTTTIRMLLGLIKPTSGQIEIFGENFFKNKKEILRRIGSIVEVPGFYANLTARENLLINAKIIGIHKKNAIDEVLEIVGLQHETKKLVGKFSLGMKQRLGIARALLHYPELLILDEPTNGLDPIGIKEMRRLIHSLAKERNITIFISSHILSEIEQLVDHVGIIHEGKLLEEIPFDHLKKRNRKYLEFQLSDQNKAVVLMEQHFDIHDYEVHQDGIIRVYSHLGQQGKLNKLFVENGIDVLKITMSEDSLEDYFVKLIGGGTIG

T16452	TARGETID	T16452
T16452	FORMERID	TTDR00604
T16452	UNIPROID	CDN2A_HUMAN
T16452	TARGNAME	Multiple tumor suppressor 1 (CDKN2A)
T16452	GENENAME	CDKN2A
T16452	TARGTYPE	Literature-reported
T16452	SYNONYMS	p16INK4A; Tumour suppressor gene p16; P16-INK4a; P16-INK4; P16 gene; MTS-1; Cyclin-dependent kinase inhibitor 2A; Cyclin-dependent kinase 4 inhibitor A; CDK4I
T16452	FUNCTION	Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein.
T16452	PDBSTRUC	2A5E; 1DC2; 1BI7; 1A5E
T16452	SEQUENCE	MEPAAGSSMEPSADWLATAAARGRVEEVRALLEAGALPNAPNSYGRRPIQVMMMGSARVAELLLLHGAEPNCADPATLTRPVHDAAREGFLDTLVVLHRAGARLDVRDAWGRLPVDLAEELGHRDVARYLRAAAGGTRGSNHARIDAAEGPSDIPD

T45755	TARGETID	T45755
T45755	FORMERID	TTDR00822
T45755	UNIPROID	CDN2C_HUMAN
T45755	TARGNAME	CDK inhibitor 4C p18-INK4c (CDKN2C)
T45755	GENENAME	CDKN2C
T45755	TARGTYPE	Literature-reported
T45755	SYNONYMS	P18-INK6; P18-INK4c; P18(INK4c) protein; P18(INK4c); P18 INK4c protein; Cyclin-dependent kinase 6 inhibitor; Cyclin-dependent kinase 4 inhibitor C
T45755	FUNCTION	Inhibits cell growth and proliferation with a correlated dependence on endogenous retinoblastoma protein RB. Interacts strongly with CDK6, weakly with CDK4.
T45755	PDBSTRUC	1MX6; 1MX4; 1MX2; 1IHB; 1G3N
T45755	SEQUENCE	MAEPWGNELASAAARGDLEQLTSLLQNNVNVNAQNGFGRTALQVMKLGNPEIARRLLLRGANPDLKDRTGFAVIHDAARAGFLDTLQTLLEFQADVNIEDNEGNLPLHLAAKEGHLRVVEFLVKHTASNVGHRNHKGDTACDLARLYGRNEVVSLMQANGAGGATNLQ

T86582	TARGETID	T86582
T86582	FORMERID	TTDI03190
T86582	UNIPROID	EAA1_HUMAN
T86582	TARGNAME	Excitatory amino acid transporter 1 (SLC1A3)
T86582	GENENAME	SLC1A3
T86582	TARGTYPE	Literature-reported
T86582	SYNONYMS	Solute carrier family 1 member 3; Sodium-dependent glutamate/aspartate transporter 1; GLAST-1; EAAT1
T86582	FUNCTION	Sodium-dependent, high-affinity amino acid transporter that mediates the uptake of L-glutamate and also L-aspartate and D-aspartate. Functions as a symporter that transports one amino acid molecule together with two or three Na(+) ions and one proton, in parallel with the counter-transport of one K(+) ion. Mediates Cl(-) flux that is not coupled to amino acid transport; this avoids the accumulation of negative charges due to aspartate and Na(+) symport. Plays a redundant role in the rapid removal of released glutamate from the synaptic cleft, which is essential for terminating the postsynaptic action of glutamate (By similarity).
T86582	PDBSTRUC	5MJU; 5LM4; 5LLU; 5LLM
T86582	SEQUENCE	MTKSNGEEPKMGGRMERFQQGVRKRTLLAKKKVQNITKEDVKSYLFRNAFVLLTVTAVIVGTILGFTLRPYRMSYREVKYFSFPGELLMRMLQMLVLPLIISSLVTGMAALDSKASGKMGMRAVVYYMTTTIIAVVIGIIIVIIIHPGKGTKENMHREGKIVRVTAADAFLDLIRNMFPPNLVEACFKQFKTNYEKRSFKVPIQANETLVGAVINNVSEAMETLTRITEELVPVPGSVNGVNALGLVVFSMCFGFVIGNMKEQGQALREFFDSLNEAIMRLVAVIMWYAPVGILFLIAGKIVEMEDMGVIGGQLAMYTVTVIVGLLIHAVIVLPLLYFLVTRKNPWVFIGGLLQALITALGTSSSSATLPITFKCLEENNGVDKRVTRFVLPVGATINMDGTALYEALAAIFIAQVNNFELNFGQIITISITATAASIGAAGIPQAGLVTMVIVLTSVGLPTDDITLIIAVDWFLDRLRTTTNVLGDSLGAGIVEHLSRHELKNRDVEMGNSVIEENEMKKPYQLIAQDNETEKPIDSETKM
T86582	DRUGINFO	D0I3EE	UCPH-101	Investigative
T86582	DRUGINFO	D07CIW	[3H]ETB-TBOA	Investigative
T86582	DRUGINFO	D07GUB	DL-TBOA	Investigative
T86582	DRUGINFO	D0S8AN	SYM2081	Investigative
T86582	DRUGINFO	D08CAB	D-aspartic acid	Investigative

T31721	TARGETID	T31721
T31721	FORMERID	TTDI03191
T31721	UNIPROID	EAA3_HUMAN
T31721	TARGNAME	Excitatory amino acid transporter 3 (SLC1A1)
T31721	GENENAME	SLC1A1
T31721	TARGTYPE	Literature-reported
T31721	SYNONYMS	Solute carrier family 1 member 1; Sodium-dependent glutamate/aspartate transporter 3; Neuronal and epithelial glutamate transporter; Excitatory amino-acid carrier 1; EAAT3; EAAC1
T31721	FUNCTION	Can also transport L-cysteine. Functions as a symporter that transports one amino acid molecule together with two or three Na(+) ions and one proton, in parallel with the counter-transport of one K(+) ion. Mediates Cl(-) flux that is not coupled to amino acid transport; this avoids the accumulation of negative charges due to aspartate and Na(+) symport. Plays an important role in L-glutamate and L-aspartate reabsorption in renal tubuli. Plays a redundant role in the rapid removal of released glutamate from the synaptic cleft, which is essential for terminating the postsynaptic action of glutamate. Negatively regulated by ARL6IP5. Sodium-dependent, high-affinity amino acid transporter that mediates the uptake of L-glutamate and also L-aspartate and D-aspartate.
T31721	BIOCLASS	Dicarboxylate/amino acid:cation symporter
T31721	SEQUENCE	MGKPARKGCEWKRFLKNNWVLLSTVAAVVLGITTGVLVREHSNLSTLEKFYFAFPGEILMRMLKLIILPLIISSMITGVAALDSNVSGKIGLRAVVYYFCTTLIAVILGIVLVVSIKPGVTQKVGEIARTGSTPEVSTVDAMLDLIRNMFPENLVQACFQQYKTKREEVKPPSDPEMNMTEESFTAVMTTAISKNKTKEYKIVGMYSDGINVLGLIVFCLVFGLVIGKMGEKGQILVDFFNALSDATMKIVQIIMCYMPLGILFLIAGKIIEVEDWEIFRKLGLYMATVLTGLAIHSIVILPLIYFIVVRKNPFRFAMGMAQALLTALMISSSSATLPVTFRCAEENNQVDKRITRFVLPVGATINMDGTALYEAVAAVFIAQLNDLDLGIGQIITISITATSASIGAAGVPQAGLVTMVIVLSAVGLPAEDVTLIIAVDWLLDRFRTMVNVLGDAFGTGIVEKLSKKELEQMDVSSEVNIVNPFALESTILDNEDSDTKKSYVNGGFAVDKSDTISFTQTSQF
T31721	DRUGINFO	D09HET	L-beta-BA	Investigative
T31721	DRUGINFO	D0F5SO	NBI-59159	Investigative
T31721	DRUGINFO	D07CIW	[3H]ETB-TBOA	Investigative
T31721	DRUGINFO	D07GUB	DL-TBOA	Investigative
T31721	DRUGINFO	D08CAB	D-aspartic acid	Investigative

T46849	TARGETID	T46849
T46849	FORMERID	TTDR00809
T46849	UNIPROID	MSH2_HUMAN
T46849	TARGNAME	DNA mismatch repair protein MSH2 (MSH2)
T46849	GENENAME	MSH2
T46849	TARGTYPE	Literature-reported
T46849	SYNONYMS	hMSH2; MutS protein homolog 2; Mismatch repair gene Msh2
T46849	FUNCTION	Forms two different heterodimers: MutS alpha (MSH2-MSH6 heterodimer) and MutS beta (MSH2-MSH3 heterodimer) which binds to DNA mismatches thereby initiating DNA repair. When bound, heterodimers bend the DNA helix and shields approximately 20 base pairs. MutS alpha recognizes single base mismatches and dinucleotide insertion-deletion loops (IDL) in the DNA. MutS beta recognizes larger insertion-deletion loops up to 13 nucleotides long. After mismatch binding, MutS alpha or beta forms a ternary complex with the MutL alpha heterodimer, which is thought to be responsible for directing the downstream MMR events, including strand discrimination, excision, and resynthesis. Recruits DNA helicase MCM9 to chromatin which unwinds the mismatch containg DNA strand. ATP binding and hydrolysis play a pivotal role in mismatch repair functions. The ATPase activity associated with MutS alpha regulates binding similar to a molecular switch: mismatched DNA provokes ADP-->ATP exchange, resulting in a discernible conformational transition that converts MutS alpha into a sliding clamp capable of hydrolysis-independent diffusion along the DNA backbone. This transition is crucial for mismatch repair. MutS alpha may also play a role in DNA homologous recombination repair. In melanocytes may modulate both UV-B-induced cell cycle regulation and apoptosis. Component of the post-replicative DNA mismatch repair system (MMR).
T46849	PDBSTRUC	3THZ; 3THY; 3THX; 3THW; 2O8F
T46849	SEQUENCE	MAVQPKETLQLESAAEVGFVRFFQGMPEKPTTTVRLFDRGDFYTAHGEDALLAAREVFKTQGVIKYMGPAGAKNLQSVVLSKMNFESFVKDLLLVRQYRVEVYKNRAGNKASKENDWYLAYKASPGNLSQFEDILFGNNDMSASIGVVGVKMSAVDGQRQVGVGYVDSIQRKLGLCEFPDNDQFSNLEALLIQIGPKECVLPGGETAGDMGKLRQIIQRGGILITERKKADFSTKDIYQDLNRLLKGKKGEQMNSAVLPEMENQVAVSSLSAVIKFLELLSDDSNFGQFELTTFDFSQYMKLDIAAVRALNLFQGSVEDTTGSQSLAALLNKCKTPQGQRLVNQWIKQPLMDKNRIEERLNLVEAFVEDAELRQTLQEDLLRRFPDLNRLAKKFQRQAANLQDCYRLYQGINQLPNVIQALEKHEGKHQKLLLAVFVTPLTDLRSDFSKFQEMIETTLDMDQVENHEFLVKPSFDPNLSELREIMNDLEKKMQSTLISAARDLGLDPGKQIKLDSSAQFGYYFRVTCKEEKVLRNNKNFSTVDIQKNGVKFTNSKLTSLNEEYTKNKTEYEEAQDAIVKEIVNISSGYVEPMQTLNDVLAQLDAVVSFAHVSNGAPVPYVRPAILEKGQGRIILKASRHACVEVQDEIAFIPNDVYFEKDKQMFHIITGPNMGGKSTYIRQTGVIVLMAQIGCFVPCESAEVSIVDCILARVGAGDSQLKGVSTFMAEMLETASILRSATKDSLIIIDELGRGTSTYDGFGLAWAISEYIATKIGAFCMFATHFHELTALANQIPTVNNLHVTALTTEETLTMLYQVKKGVCDQSFGIHVAELANFPKHVIECAKQKALELEEFQYIGESQGYDIMEPAAKKCYLEREQGEKIIQEFLSKVKQMPFTEMSEENITIKLKQLKAEVIAKNNSFVNEIISRIKVTT

T47098	TARGETID	T47098
T47098	FORMERID	TTDI00233
T47098	UNIPROID	ABCG1_HUMAN
T47098	TARGNAME	ATP-binding cassette transporter G1 (ABCG1)
T47098	GENENAME	ABCG1
T47098	TARGTYPE	Literature-reported
T47098	SYNONYMS	White protein homolog; WHT1; ATP-binding cassette transporter 8; ATP-binding cassette sub-family G member 1; ABC8
T47098	FUNCTION	Catalyzes the efflux of phospholipids such as sphingomyelin, cholesterol and its oxygenated derivatives like 7beta-hydroxycholesterol and this transport is coupled to hydrlysis of ATP. The lipid efflux is ALB-dependent. Is an active component of the macrophage lipid export complex. Could also be involved in intracellular lipid transport processes. The role in cellular lipid homeostasis may not be limited to macrophages. Prevents cell death by transporting cytotoxic 7beta-hydroxycholesterol.
T47098	BIOCLASS	ABC transporter
T47098	SEQUENCE	MACLMAAFSVGTAMNASSYSAEMTEPKSVCVSVDEVVSSNMEATETDLLNGHLKKVDNNLTEAQRFSSLPRRAAVNIEFRDLSYSVPEGPWWRKKGYKTLLKGISGKFNSGELVAIMGPSGAGKSTLMNILAGYRETGMKGAVLINGLPRDLRCFRKVSCYIMQDDMLLPHLTVQEAMMVSAHLKLQEKDEGRREMVKEILTALGLLSCANTRTGSLSGGQRKRLAIALELVNNPPVMFFDEPTSGLDSASCFQVVSLMKGLAQGGRSIICTIHQPSAKLFELFDQLYVLSQGQCVYRGKVCNLVPYLRDLGLNCPTYHNPADFVMEVASGEYGDQNSRLVRAVREGMCDSDHKRDLGGDAEVNPFLWHRPSEEVKQTKRLKGLRKDSSSMEGCHSFSASCLTQFCILFKRTFLSIMRDSVLTHLRITSHIGIGLLIGLLYLGIGNEAKKVLSNSGFLFFSMLFLMFAALMPTVLTFPLEMGVFLREHLNYWYSLKAYYLAKTMADVPFQIMFPVAYCSIVYWMTSQPSDAVRFVLFAALGTMTSLVAQSLGLLIGAASTSLQVATFVGPVTAIPVLLFSGFFVSFDTIPTYLQWMSYISYVRYGFEGVILSIYGLDREDLHCDIDETCHFQKSEAILRELDVENAKLYLDFIVLGIFFISLRLIAYFVLRYKIRAER

T73414	TARGETID	T73414
T73414	FORMERID	TTDI02108
T73414	UNIPROID	KI67_HUMAN
T73414	TARGNAME	Proliferation marker protein Ki-67 (MKI67)
T73414	GENENAME	MKI67
T73414	TARGTYPE	Literature-reported
T73414	SYNONYMS	Antigen identified by monoclonal antibody Ki-67; Antigen Ki67; Antigen KI-67
T73414	FUNCTION	Associates with the surface of the mitotic chromosome, the perichromosomal layer, and covers a substantial fraction of the chromosome surface. Prevents chromosomes from collapsing into a single chromatin mass by forming a steric and electrostatic charge barrier: the protein has a high net electrical charge and acts as a surfactant, dispersing chromosomes and enabling independent chromosome motility. Binds DNA, with a preference for supercoiled DNA and AT-rich DNA. Does not contribute to the internal structure of mitotic chromosomes. May play a role in chromatin organization. It is however unclear whether it plays a direct role in chromatin organization or whether it is an indirect consequence of its function in maintaining mitotic chromosomes dispersed. Required to maintain individual mitotic chromosomes dispersed in the cytoplasm following nuclear envelope disassembly.
T73414	PDBSTRUC	5J28; 2AFF; 1R21
T73414	SEQUENCE	MWPTRRLVTIKRSGVDGPHFPLSLSTCLFGRGIECDIRIQLPVVSKQHCKIEIHEQEAILHNFSSTNPTQVNGSVIDEPVRLKHGDVITIIDRSFRYENESLQNGRKSTEFPRKIREQEPARRVSRSSFSSDPDEKAQDSKAYSKITEGKVSGNPQVHIKNVKEDSTADDSKDSVAQGTTNVHSSEHAGRNGRNAADPISGDFKEISSVKLVSRYGELKSVPTTQCLDNSKKNESPFWKLYESVKKELDVKSQKENVLQYCRKSGLQTDYATEKESADGLQGETQLLVSRKSRPKSGGSGHAVAEPASPEQELDQNKGKGRDVESVQTPSKAVGASFPLYEPAKMKTPVQYSQQQNSPQKHKNKDLYTTGRRESVNLGKSEGFKAGDKTLTPRKLSTRNRTPAKVEDAADSATKPENLSSKTRGSIPTDVEVLPTETEIHNEPFLTLWLTQVERKIQKDSLSKPEKLGTTAGQMCSGLPGLSSVDINNFGDSINESEGIPLKRRRVSFGGHLRPELFDENLPPNTPLKRGEAPTKRKSLVMHTPPVLKKIIKEQPQPSGKQESGSEIHVEVKAQSLVISPPAPSPRKTPVASDQRRRSCKTAPASSSKSQTEVPKRGGRKSGNLPSKRVSISRSQHDILQMICSKRRSGASEANLIVAKSWADVVKLGAKQTQTKVIKHGPQRSMNKRQRRPATPKKPVGEVHSQFSTGHANSPCTIIIGKAHTEKVHVPARPYRVLNNFISNQKMDFKEDLSGIAEMFKTPVKEQPQLTSTCHIAISNSENLLGKQFQGTDSGEEPLLPTSESFGGNVFFSAQNAAKQPSDKCSASPPLRRQCIRENGNVAKTPRNTYKMTSLETKTSDTETEPSKTVSTANRSGRSTEFRNIQKLPVESKSEETNTEIVECILKRGQKATLLQQRREGEMKEIERPFETYKENIELKENDEKMKAMKRSRTWGQKCAPMSDLTDLKSLPDTELMKDTARGQNLLQTQDHAKAPKSEKGKITKMPCQSLQPEPINTPTHTKQQLKASLGKVGVKEELLAVGKFTRTSGETTHTHREPAGDGKSIRTFKESPKQILDPAARVTGMKKWPRTPKEEAQSLEDLAGFKELFQTPGPSEESMTDEKTTKIACKSPPPESVDTPTSTKQWPKRSLRKADVEEEFLALRKLTPSAGKAMLTPKPAGGDEKDIKAFMGTPVQKLDLAGTLPGSKRQLQTPKEKAQALEDLAGFKELFQTPGHTEELVAAGKTTKIPCDSPQSDPVDTPTSTKQRPKRSIRKADVEGELLACRNLMPSAGKAMHTPKPSVGEEKDIIIFVGTPVQKLDLTENLTGSKRRPQTPKEEAQALEDLTGFKELFQTPGHTEEAVAAGKTTKMPCESSPPESADTPTSTRRQPKTPLEKRDVQKELSALKKLTQTSGETTHTDKVPGGEDKSINAFRETAKQKLDPAASVTGSKRHPKTKEKAQPLEDLAGLKELFQTPVCTDKPTTHEKTTKIACRSQPDPVDTPTSSKPQSKRSLRKVDVEEEFFALRKRTPSAGKAMHTPKPAVSGEKNIYAFMGTPVQKLDLTENLTGSKRRLQTPKEKAQALEDLAGFKELFQTRGHTEESMTNDKTAKVACKSSQPDPDKNPASSKRRLKTSLGKVGVKEELLAVGKLTQTSGETTHTHTEPTGDGKSMKAFMESPKQILDSAASLTGSKRQLRTPKGKSEVPEDLAGFIELFQTPSHTKESMTNEKTTKVSYRASQPDLVDTPTSSKPQPKRSLRKADTEEEFLAFRKQTPSAGKAMHTPKPAVGEEKDINTFLGTPVQKLDQPGNLPGSNRRLQTRKEKAQALEELTGFRELFQTPCTDNPTTDEKTTKKILCKSPQSDPADTPTNTKQRPKRSLKKADVEEEFLAFRKLTPSAGKAMHTPKAAVGEEKDINTFVGTPVEKLDLLGNLPGSKRRPQTPKEKAKALEDLAGFKELFQTPGHTEESMTDDKITEVSCKSPQPDPVKTPTSSKQRLKISLGKVGVKEEVLPVGKLTQTSGKTTQTHRETAGDGKSIKAFKESAKQMLDPANYGTGMERWPRTPKEEAQSLEDLAGFKELFQTPDHTEESTTDDKTTKIACKSPPPESMDTPTSTRRRPKTPLGKRDIVEELSALKQLTQTTHTDKVPGDEDKGINVFRETAKQKLDPAASVTGSKRQPRTPKGKAQPLEDLAGLKELFQTPICTDKPTTHEKTTKIACRSPQPDPVGTPTIFKPQSKRSLRKADVEEESLALRKRTPSVGKAMDTPKPAGGDEKDMKAFMGTPVQKLDLPGNLPGSKRWPQTPKEKAQALEDLAGFKELFQTPGTDKPTTDEKTTKIACKSPQPDPVDTPASTKQRPKRNLRKADVEEEFLALRKRTPSAGKAMDTPKPAVSDEKNINTFVETPVQKLDLLGNLPGSKRQPQTPKEKAEALEDLVGFKELFQTPGHTEESMTDDKITEVSCKSPQPESFKTSRSSKQRLKIPLVKVDMKEEPLAVSKLTRTSGETTQTHTEPTGDSKSIKAFKESPKQILDPAASVTGSRRQLRTRKEKARALEDLVDFKELFSAPGHTEESMTIDKNTKIPCKSPPPELTDTATSTKRCPKTRPRKEVKEELSAVERLTQTSGQSTHTHKEPASGDEGIKVLKQRAKKKPNPVEEEPSRRRPRAPKEKAQPLEDLAGFTELSETSGHTQESLTAGKATKIPCESPPLEVVDTTASTKRHLRTRVQKVQVKEEPSAVKFTQTSGETTDADKEPAGEDKGIKALKESAKQTPAPAASVTGSRRRPRAPRESAQAIEDLAGFKDPAAGHTEESMTDDKTTKIPCKSSPELEDTATSSKRRPRTRAQKVEVKEELLAVGKLTQTSGETTHTDKEPVGEGKGTKAFKQPAKRKLDAEDVIGSRRQPRAPKEKAQPLEDLASFQELSQTPGHTEELANGAADSFTSAPKQTPDSGKPLKISRRVLRAPKVEPVGDVVSTRDPVKSQSKSNTSLPPLPFKRGGGKDGSVTGTKRLRCMPAPEEIVEELPASKKQRVAPRARGKSSEPVVIMKRSLRTSAKRIEPAEELNSNDMKTNKEEHKLQDSVPENKGISLRSRRQNKTEAEQQITEVFVLAERIEINRNEKKPMKTSPEMDIQNPDDGARKPIPRDKVTENKRCLRSARQNESSQPKVAEESGGQKSAKVLMQNQKGKGEAGNSDSMCLRSRKTKSQPAASTLESKSVQRVTRSVKRCAENPKKAEDNVCVKKIRTRSHRDSEDI

T91180	TARGETID	T91180
T91180	FORMERID	TTDI03450
T91180	UNIPROID	S15A1_HUMAN
T91180	TARGNAME	Solute carrier family 15 member 1 (SLC15A1)
T91180	GENENAME	SLC15A1
T91180	TARGTYPE	Literature-reported
T91180	SYNONYMS	PEPT1; Oligopeptide transporter, small intestine isoform; Intestinal H(+)/peptide cotransporter
T91180	FUNCTION	May constitute a major route for the absorption of protein digestion end-products. Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
T91180	BIOCLASS	Proton-dependent oligopeptide transporter
T91180	SEQUENCE	MGMSKSHSFFGYPLSIFFIVVNEFCERFSYYGMRAILILYFTNFISWDDNLSTAIYHTFVALCYLTPILGALIADSWLGKFKTIVSLSIVYTIGQAVTSVSSINDLTDHNHDGTPDSLPVHVVLSLIGLALIALGTGGIKPCVSAFGGDQFEEGQEKQRNRFFSIFYLAINAGSLLSTIITPMLRVQQCGIHSKQACYPLAFGVPAALMAVALIVFVLGSGMYKKFKPQGNIMGKVAKCIGFAIKNRFRHRSKAFPKREHWLDWAKEKYDERLISQIKMVTRVMFLYIPLPMFWALFDQQGSRWTLQATTMSGKIGALEIQPDQMQTVNAILIVIMVPIFDAVLYPLIAKCGFNFTSLKKMAVGMVLASMAFVVAAIVQVEIDKTLPVFPKGNEVQIKVLNIGNNTMNISLPGEMVTLGPMSQTNAFMTFDVNKLTRINISSPGSPVTAVTDDFKQGQRHTLLVWAPNHYQVVKDGLNQKPEKGENGIRFVNTFNELITITMSGKVYANISSYNASTYQFFPSGIKGFTISSTEIPPQCQPNFNTFYLEFGSAYTYIVQRKNDSCPEVKVFEDISANTVNMALQIPQYFLLTCGEVVFSVTGLEFSYSQAPSNMKSVLQAGWLLTVAVGNIIVLIVAGAGQFSKQWAEYILFAALLLVVCVIFAIMARFYTYINPAEIEAQFDEDEKKNRLEKSNPYFMSGANSQKQM
T91180	DRUGINFO	D0S3VV	4-AMBA	Investigative
T91180	DRUGINFO	D02FZM	Lys[Z(NO2)]-Pro	Investigative
T91180	DRUGINFO	D06PWQ	[14C]GlySar	Investigative
T91180	DRUGINFO	D08QDL	[11C]GlySar	Investigative
T91180	DRUGINFO	D0Q3VU	[3H]GlySar	Investigative

T14006	TARGETID	T14006
T14006	FORMERID	TTDI02616
T14006	UNIPROID	CDN1B_HUMAN
T14006	TARGNAME	CDK inhibitor 1B p27Kip1 (CDKN1B)
T14006	GENENAME	CDKN1B
T14006	TARGTYPE	Literature-reported
T14006	SYNONYMS	p27Kip1; KIP1; Cyclindependent kinase inhibitor p27; Cyclin-dependent kinase inhibitor p27; Cyclin-dependent kinase inhibitor 1B
T14006	FUNCTION	Inhibits the kinase activity of CDK2 bound to cyclin A, but has little inhibitory activity on CDK2 bound to SPDYA. Involved in G1 arrest. Potent inhibitor of cyclin E- and cyclin A-CDK2 complexes. Forms a complex with cyclin type D-CDK4 complexes and is involved in the assembly, stability, and modulation of CCND1-CDK4 complex activation. Acts either as an inhibitor or an activator of cyclin type D-CDK4 complexes depending on its phosphorylation state and/or stoichometry. Important regulator of cell cycle progression.
T14006	PDBSTRUC	6ATH; 5UQ3; 2AST; 1JSU; 1H27
T14006	SEQUENCE	MSNVRVSNGSPSLERMDARQAEHPKPSACRNLFGPVDHEELTRDLEKHCRDMEEASQRKWNFDFQNHKPLEGKYEWQEVEKGSLPEFYYRPPRPPKGACKVPAQESQDVSGSRPAAPLIGAPANSEDTHLVDPKTDPSDSQTGLAEQCAGIRKRPATDDSSTQNKRANRTEENVSDGSPNAGSVEQTPKKPGLRRRQT

T94048	TARGETID	T94048
T94048	FORMERID	TTDI00223
T94048	UNIPROID	YAP1_HUMAN
T94048	TARGNAME	Yes-associated protein 1 (YAP1)
T94048	GENENAME	YAP1
T94048	TARGTYPE	Literature-reported
T94048	SYNONYMS	Yorkie homolog; Yes-associated protein YAP65 homolog; YAP65; Transcriptional coactivator YAP1; Protein yorkie homolog; 65 kDa Yes-associated protein
T94048	FUNCTION	The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Plays a key role in tissue tension and 3D tissue shape by regulating cortical actomyosin network formation. Acts via ARHGAP18, a Rho GTPase activating protein that suppresses F-actin polymerization. Plays a key role to control cell proliferation in response to cell contact. Phosphorylation of YAP1 by LATS1/2 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. The presence of TEAD transcription factors are required for it to stimulate gene expression, cell growth, anchorage-independent growth, and epithelial mesenchymal transition (EMT) induction. Transcriptional regulator which can act both as a coactivator and a corepressor and is the critical downstream regulatory target in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis.
T94048	PDBSTRUC	6HIL; 6HIK; 6GEK; 6GEI; 6GEG
T94048	SEQUENCE	MDPGQQPPPQPAPQGQGQPPSQPPQGQGPPSGPGQPAPAATQAAPQAPPAGHQIVHVRGDSETDLEALFNAVMNPKTANVPQTVPMRLRKLPDSFFKPPEPKSHSRQASTDAGTAGALTPQHVRAHSSPASLQLGAVSPGTLTPTGVVSGPAATPTAQHLRQSSFEIPDDVPLPAGWEMAKTSSGQRYFLNHIDQTTTWQDPRKAMLSQMNVTAPTSPPVQQNMMNSASGPLPDGWEQAMTQDGEIYYINHKNKTTSWLDPRLDPRFAMNQRISQSAPVKQPPPLAPQSPQGGVMGGSNSNQQQQMRLQQLQMEKERLRLKQQELLRQAMRNINPSTANSPKCQELALRSQLPTLEQDGGTQNPVSSPGMSQELRTMTTNSSDPFLNSGTYHSRDESTDSGLSMSSYSVPRTPDDFLNSVDEMDTGDTINQSTLPSQQNRFPDYLEAIPGTNVDLGTLEGDGMNIEGEELMPSLQEALSSDILNDMESVLAATKLDKESFLTWL

T17721	TARGETID	T17721
T17721	FORMERID	TTDI03319
T17721	UNIPROID	KCNJ6_HUMAN
T17721	TARGNAME	Inward rectifier potassium channel Kir3.2 (KCNJ6)
T17721	GENENAME	KCNJ6
T17721	TARGTYPE	Literature-reported
T17721	SYNONYMS	Potassium channel, inwardly rectifying subfamily J member 6; KCNJ7; KATP2; KATP-2; Inward rectifier K(+) channel Kir3.2; GIRK2; GIRK-2; G protein-activated inward rectifier potassium channel 2; BIR1
T17721	FUNCTION	This potassium channel may be involved in the regulation of insulin secretion by glucose and/or neurotransmitters acting through G-protein-coupled receptors. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium.
T17721	BIOCLASS	Inward rectifier potassium channel
T17721	SEQUENCE	MAKLTESMTNVLEGDSMDQDVESPVAIHQPKLPKQARDDLPRHISRDRTKRKIQRYVRKDGKCNVHHGNVRETYRYLTDIFTTLVDLKWRFNLLIFVMVYTVTWLFFGMIWWLIAYIRGDMDHIEDPSWTPCVTNLNGFVSAFLFSIETETTIGYGYRVITDKCPEGIILLLIQSVLGSIVNAFMVGCMFVKISQPKKRAETLVFSTHAVISMRDGKLCLMFRVGDLRNSHIVEASIRAKLIKSKQTSEGEFIPLNQTDINVGYYTGDDRLFLVSPLIISHEINQQSPFWEISKAQLPKEELEIVVILEGMVEATGMTCQARSSYITSEILWGYRFTPVLTLEDGFYEVDYNSFHETYETSTPSLSAKELAELASRAELPLSWSVSSKLNQHAELETEEEEKNLEEQTERNGDVANLENESKV
T17721	DRUGINFO	D0P0ZB	F3	Investigative
T17721	DRUGINFO	D07ZAJ	PIP2	Investigative

T14252	TARGETID	T14252
T14252	FORMERID	TTDR00201
T14252	UNIPROID	S6A11_HUMAN
T14252	TARGNAME	Gamma-aminobutyric acid transporter 4 (SLC6A11)
T14252	GENENAME	Slc6a11
T14252	TARGTYPE	Literature-reported
T14252	SYNONYMS	Sodium- and chloride-dependent GABA transporter 4; Slc6a11; GAT4; GABA transporter 4
T14252	FUNCTION	Terminates the action of GABA by its high affinity sodium-dependent reuptake into presynaptic terminals. Can also transport beta-alanine and taurine.
T14252	BIOCLASS	Neurotransmitter:sodium symporter
T14252	SEQUENCE	MTAEKALPLGNGKAAEEARESEAPGGGCSSGGAAPARHPRVKRDKAVHERGHWNNKVEFVLSVAGEIIGLGNVWRFPYLCYKNGGGAFLIPYVVFFICCGIPVFFLETALGQFTSEGGITCWRKVCPLFEGIGYATQVIEAHLNVYYIIILAWAIFYLSNCFTTELPWATCGHEWNTENCVEFQKLNVSNYSHVSLQNATSPVMEFWEHRVLAISDGIEHIGNLRWELALCLLAAWTICYFCIWKGTKSTGKVVYVTATFPYIMLLILLIRGVTLPGASEGIKFYLYPDLSRLSDPQVWVDAGTQIFFSYAICLGCLTALGSYNNYNNNCYRDCIMLCCLNSGTSFVAGFAIFSVLGFMAYEQGVPIAEVAESGPGLAFIAYPKAVTMMPLSPLWATLFFMMLIFLGLDSQFVCVESLVTAVVDMYPKVFRRGYRRELLILALSVISYFLGLVMLTEGGMYIFQLFDSYAASGMCLLFVAIFECICIGWVYGSNRFYDNIEDMIGYRPPSLIKWCWMIMTPGICAGIFIFFLIKYKPLKYNNIYTYPAWGYGIGWLMALSSMLCIPLWICITVWKTEGTLPEKLQKLTTPSTDLKMRGKLGVSPRMVTVNDCDAKLKSDGTIAAITEKETHF
T14252	DRUGINFO	D0H7WK	SNAP-5114	Investigative

T16353	TARGETID	T16353
T16353	FORMERID	TTDI02404
T16353	UNIPROID	CXA8_HUMAN
T16353	TARGNAME	Gap junction alpha-8 protein (Cx50)
T16353	GENENAME	GJA8
T16353	TARGTYPE	Literature-reported
T16353	SYNONYMS	Lens fiber protein MP70; GJA8; Cx50; Connexin50
T16353	FUNCTION	One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell.
T16353	BIOCLASS	Gap junction-forming connexin
T16353	SEQUENCE	MGDWSFLGNILEEVNEHSTVIGRVWLTVLFIFRILILGTAAEFVWGDEQSDFVCNTQQPGCENVCYDEAFPISHIRLWVLQIIFVSTPSLMYVGHAVHYVRMEEKRKSREAEELGQQAGTNGGPDQGSVKKSSGSKGTKKFRLEGTLLRTYICHIIFKTLFEVGFIVGHYFLYGFRILPLYRCSRWPCPNVVDCFVSRPTEKTIFILFMLSVASVSLFLNVMELGHLGLKGIRSALKRPVEQPLGEIPEKSLHSIAVSSIQKAKGYQLLEEEKIVSHYFPLTEVGMVETSPLPAKPFNQFEEKISTGPLGDLSRGYQETLPSYAQVGAQEVEGEGPPAEEGAEPEVGEKKEEAERLTTEEQEKVAVPEGEKVETPGVDKEGEKEEPQSEKVSKQGLPAEKTPSLCPELTTDDARPLSRLSKASSRARSDDLTV
T16353	DRUGINFO	D05QML	PQ-1	Investigative
T16353	DRUGINFO	D00VJY	octanol	Investigative

T00724	TARGETID	T00724
T00724	FORMERID	TTDNR00762
T00724	UNIPROID	SOX2_HUMAN
T00724	TARGNAME	Transcription factor SOX-2 (SOX2)
T00724	GENENAME	SOX2
T00724	TARGTYPE	Literature-reported
T00724	SYNONYMS	SRY-box 2; MCOPS3; ANOP3
T00724	FUNCTION	Critical for early embryogenesis and for embryonic stem cell pluripotency. May function as a switch in neuronal development. Downstream SRRT target that mediates the promotion of neural stem cell self-renewal. Keeps neural cells undifferentiated by counteracting the activity of proneural proteins and suppresses neuronal differentiation. Transcription factor that forms a trimeric complex with OCT4 on DNA and controls the expression of a number of genes involved in embryonic development such as YES1, FGF4, UTF1 and ZFP206.
T00724	PDBSTRUC	2LE4; 1O4X
T00724	SEQUENCE	MYNMMETELKPPGPQQTSGGGGGNSTAAAAGGNQKNSPDRVKRPMNAFMVWSRGQRRKMAQENPKMHNSEISKRLGAEWKLLSETEKRPFIDEAKRLRALHMKEHPDYKYRPRRKTKTLMKKDKYTLPGGLLAPGGNSMASGVGVGAGLGAGVNQRMDSYAHMNGWSNGSYSMMQDQLGYPQHPGLNAHGAAQMQPMHRYDVSALQYNSMTSSQTYMNGSPTYSMSYSQQGTPGMALGSMGSVVKSEASSSPPVVTSSSHSRAPCQAGDLRDMISMYLPGAEVPEPAAPSRLHMSQHYQSGPVPGTAINGTLPLSHM

T49080	TARGETID	T49080
T49080	FORMERID	TTDI03338
T49080	UNIPROID	KCNC1_HUMAN
T49080	TARGNAME	Voltage-gated potassium channel Kv3.1 (KCNC1)
T49080	GENENAME	KCNC1
T49080	TARGTYPE	Literature-reported
T49080	SYNONYMS	Voltage-gated potassium channel subunit Kv4; Voltage-gated potassium channel subunit Kv3.1; Potassium voltage-gated channel subfamily C member 1; NGK2
T49080	FUNCTION	The channel opens in response to the voltage difference across the membrane, forming a potassium-selective channel through which potassium ions pass in accordance with their electrochemical gradient. Can form functional homotetrameric channels and heterotetrameric channels that contain variable proportions of KCNC2, and possibly other family members as well. Contributes to fire sustained trains of very brief action potentials at high frequency in pallidal neurons. Voltage-gated potassium channel that plays an important role in the rapid repolarization of fast-firing brain neurons.
T49080	BIOCLASS	Voltage-gated ion channel
T49080	SEQUENCE	MGQGDESERIVINVGGTRHQTYRSTLRTLPGTRLAWLAEPDAHSHFDYDPRADEFFFDRHPGVFAHILNYYRTGKLHCPADVCGPLYEEELAFWGIDETDVEPCCWMTYRQHRDAEEALDSFGGAPLDNSADDADADGPGDSGDGEDELEMTKRLALSDSPDGRPGGFWRRWQPRIWALFEDPYSSRYARYVAFASLFFILVSITTFCLETHERFNPIVNKTEIENVRNGTQVRYYREAETEAFLTYIEGVCVVWFTFEFLMRVIFCPNKVEFIKNSLNIIDFVAILPFYLEVGLSGLSSKAAKDVLGFLRVVRFVRILRIFKLTRHFVGLRVLGHTLRASTNEFLLLIIFLALGVLIFATMIYYAERIGAQPNDPSASEHTHFKNIPIGFWWAVVTMTTLGYGDMYPQTWSGMLVGALCALAGVLTIAMPVPVIVNNFGMYYSLAMAKQKLPKKKKKHIPRPPQLGSPNYCKSVVNSPHHSTQSDTCPLAQEEILEINRAGRKPLRGMSI
T49080	DRUGINFO	D0C2NK	norfluoxetine	Investigative
T49080	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T15033	TARGETID	T15033
T15033	FORMERID	TTDR00629
T15033	UNIPROID	CX3C1_HUMAN
T15033	TARGNAME	C-X3-C chemokine receptor 1 (CX3CR1)
T15033	GENENAME	CX3CR1
T15033	TARGTYPE	Literature-reported
T15033	SYNONYMS	V28; GPR13; G-protein coupled receptor 13; Fractalkine receptor CX3CR1; Fractalkine receptor; CX3C chemokine receptor 1; CMKBRL1; CMKBLR1; CMK-BRL1; CMK-BRL-1; C-X3-C CKR-1; Beta chemokine receptor-like1; Beta chemokine receptor-like 1
T15033	FUNCTION	Acts as coreceptor with CD4 for HIV-1 virus envelope protein (in vitro). Isoform 2 and isoform 3 seem to be more potent HIV-1 coreceptors than isoform 1. Receptor for the CX3C chemokine fractalkine (CX3CL1); binds to CX3CL1 and mediates both its adhesive and migratory functions.
T15033	BIOCLASS	GPCR rhodopsin
T15033	SEQUENCE	MDQFPESVTENFEYDDLAEACYIGDIVVFGTVFLSIFYSVIFAIGLVGNLLVVFALTNSKKPKSVTDIYLLNLALSDLLFVATLPFWTHYLINEKGLHNAMCKFTTAFFFIGFFGSIFFITVISIDRYLAIVLAANSMNNRTVQHGVTISLGVWAAAILVAAPQFMFTKQKENECLGDYPEVLQEIWPVLRNVETNFLGFLLPLLIMSYCYFRIIQTLFSCKNHKKAKAIKLILLVVIVFFLFWTPYNVMIFLETLKLYDFFPSCDMRKDLRLALSVTETVAFSHCCLNPLIYAFAGEKFRRYLYHLYGKCLAVLCGRSVHVDFSSSESQRSRHGSVLSSNFTYHTSDGDALLLL

T33063	TARGETID	T33063
T33063	FORMERID	TTDI01535
T33063	UNIPROID	STAR_HUMAN
T33063	TARGNAME	Steroidogenic acute regulatory protein (STAR)
T33063	GENENAME	STAR
T33063	TARGTYPE	Literature-reported
T33063	SYNONYMS	Steroidogenic acute regulatory protein, mitochondrial; StARD1; START domain-containing protein 1
T33063	FUNCTION	Plays a key role in steroid hormone synthesis by enhancing the metabolism of cholesterol into pregnenolone. Mediates the transfer of cholesterol from the outer mitochondrial membrane to the inner mitochondrial membrane where it is cleaved to pregnenolone.
T33063	PDBSTRUC	5OMA; 3P0L; 2I93; 1IMG
T33063	SEQUENCE	MLLATFKLCAGSSYRHMRNMKGLRQQAVMAISQELNRRALGGPTPSTWINQVRRRSSLLGSRLEETLYSDQELAYLQQGEEAMQKALGILSNQEGWKKESQQDNGDKVMSKVVPDVGKVFRLEVVVDQPMERLYEELVERMEAMGEWNPNVKEIKVLQKIGKDTFITHELAAEAAGNLVGPRDFVSVRCAKRRGSTCVLAGMATDFGNMPEQKGVIRAEHGPTCMVLHPLAGSPSKTKLTWLLSIDLKGWLPKSIINQVLSQTQVDFANHLRKRLESHPASEARC

T33909	TARGETID	T33909
T33909	FORMERID	TTDNR00743
T33909	UNIPROID	RGS6_HUMAN
T33909	TARGNAME	Regulator of G-protein signaling 6 (RGS6)
T33909	GENENAME	RGS6
T33909	TARGTYPE	Literature-reported
T33909	SYNONYMS	S914
T33909	FUNCTION	Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits, thereby driving them into their inactive GDP-bound form. The RGS6/GNB5 dimer enhances GNAO1 GTPase activity. Regulates G protein-coupled receptor signaling cascades.
T33909	PDBSTRUC	2ES0
T33909	SEQUENCE	MAQGSGDQRAVGVADPEESSPNMIVYCKIEDIITKMQDDKTGGVPIRTVKSFLSKIPSVVTGTDIVQWLMKNLSIEDPVEAIHLGSLIAAQGYIFPISDHVLTMKDDGTFYRFQAPYFWPSNCWEPENTDYAIYLCKRTMQNKARLELADYEAENLARLQRAFARKWEFIFMQAEAQVKIDRKKDKTERKILDSQERAFWDVHRPVPGCVNTTEMDIRKCRRLKNPQKVKKSVYGVTEESQAQSPVHVLSQPIRKTTKEDIRKQITFLNAQIDRHCLKMSKVAESLIAYTEQYVEYDPLITPAEPSNPWISDDVALWDIEMSKEPSQQRVKRWGFSFDEILKDQVGRDQFLRFLESEFSSENLRFWLAVQDLKKQPLQDVAKRVEEIWQEFLAPGAPSAINLDSHSYEITSQNVKDGGRYTFEDAQEHIYKLMKSDSYARFLRSNAYQDLLLAKKKGKSLAGKRLTGLMQSS

T11561	TARGETID	T11561
T11561	FORMERID	TTDR00497
T11561	UNIPROID	ERF_HUMAN
T11561	TARGNAME	ETS-domain transcription factor ERF (ERF)
T11561	GENENAME	ERF
T11561	TARGTYPE	Literature-reported
T11561	SYNONYMS	Transcription factor Ets2; PE-2; Ets2 repressor factor; ETS domain-containing transcription factor ERF
T11561	FUNCTION	May regulate other genes involved in cellular proliferation. Required for extraembryonic ectoderm differentiation, ectoplacental cone cavity closure, and chorioallantoic attachment. May be important for regulating trophoblast stem cell differentiation. Potent transcriptional repressor that binds to the H1 element of the Ets2 promoter.
T11561	BIOCLASS	E26 transformation-specific ETS
T11561	SEQUENCE	MKTPADTGFAFPDWAYKPESSPGSRQIQLWHFILELLRKEEYQGVIAWQGDYGEFVIKDPDEVARLWGVRKCKPQMNYDKLSRALRYYYNKRILHKTKGKRFTYKFNFNKLVLVNYPFIDVGLAGGAVPQSAPPVPSGGSHFRFPPSTPSEVLSPTEDPRSPPACSSSSSSLFSAVVARRLGRGSVSDCSDGTSELEEPLGEDPRARPPGPPDLGAFRGPPLARLPHDPGVFRVYPRPRGGPEPLSPFPVSPLAGPGSLLPPQLSPALPMTPTHLAYTPSPTLSPMYPSGGGGPSGSGGGSHFSFSPEDMKRYLQAHTQSVYNYHLSPRAFLHYPGLVVPQPQRPDKCPLPPMAPETPPVPSSASSSSSSSSSPFKFKLQPPPLGRRQRAAGEKAVAGADKSGGSAGGLAEGAGALAPPPPPPQIKVEPISEGESEEVEVTDISDEDEEDGEVFKTPRAPPAPPKPEPGEAPGASQCMPLKLRFKRRWSEDCRLEGGGGPAGGFEDEGEDKKVRGEGPGEAGGPLTPRRVSSDLQHATAQLSLEHRDS

T60671	TARGETID	T60671
T60671	FORMERID	TTDI03114
T60671	UNIPROID	CLCN3_HUMAN
T60671	TARGNAME	Chloride channel protein 3 (CLC-3)
T60671	GENENAME	CLCN3
T60671	TARGTYPE	Literature-reported
T60671	SYNONYMS	H(+)/Cl(-) exchange transporter 3; ClC-3
T60671	FUNCTION	Functions as antiporter and contributes to the acidification of the endosome and synaptic vesicle lumen, and may thereby affect vesicle trafficking and exocytosis. May play an important role in neuronal cell function through regulation of membrane excitability by protein kinase C. It could help neuronal cells to establish short-term memory. Mediates the exchange of chloride ions against protons.
T60671	BIOCLASS	Chloride channel
T60671	SEQUENCE	MESEQLFHRGYYRNSYNSITSASSDEELLDGAGVIMDFQTSEDDNLLDGDTAVGTHYTMTNGGSINSSTHLLDLLDEPIPGVGTYDDFHTIDWVREKCKDRERHRRINSKKKESAWEMTKSLYDAWSGWLVVTLTGLASGALAGLIDIAADWMTDLKEGICLSALWYNHEQCCWGSNETTFEERDKCPQWKTWAELIIGQAEGPGSYIMNYIMYIFWALSFAFLAVSLVKVFAPYACGSGIPEIKTILSGFIIRGYLGKWTLMIKTITLVLAVASGLSLGKEGPLVHVACCCGNIFSYLFPKYSTNEAKKREVLSAASAAGVSVAFGAPIGGVLFSLEEVSYYFPLKTLWRSFFAALVAAFVLRSINPFGNSRLVLFYVEYHTPWYLFELFPFILLGVFGGLWGAFFIRANIAWCRRRKSTKFGKYPVLEVIIVAAITAVIAFPNPYTRLNTSELIKELFTDCGPLESSSLCDYRNDMNASKIVDDIPDRPAGIGVYSAIWQLCLALIFKIIMTVFTFGIKVPSGLFIPSMAIGAIAGRIVGIAVEQLAYYHHDWFIFKEWCEVGADCITPGLYAMVGAAACLGGVTRMTVSLVVIVFELTGGLEYIVPLMAAVMTSKWVGDAFGREGIYEAHIRLNGYPFLDAKEEFTHTTLAADVMRPRRNDPPLAVLTQDNMTVDDIENMINETSYNGFPVIMSKESQRLVGFALRRDLTIAIESARKKQEGIVGSSRVCFAQHTPSLPAESPRPLKLRSILDMSPFTVTDHTPMEIVVDIFRKLGLRQCLVTHNGRLLGIITKKDILRHMAQTANQDPASIMFN
T60671	DRUGINFO	D0HD2G	phloretin	Investigative

T20455	TARGETID	T20455
T20455	FORMERID	TTDI03116
T20455	UNIPROID	CLCN6_HUMAN
T20455	TARGNAME	Chloride channel protein 6 (ClC-6)
T20455	GENENAME	CLCN6
T20455	TARGTYPE	Literature-reported
T20455	SYNONYMS	KIAA0046; ClC-6; Chloride transport protein 6
T20455	FUNCTION	Chloride transport protein, initially identified as voltage-gated chloride channel. The presence of the conserved gating glutamate residues suggests that is functions as antiporter.
T20455	BIOCLASS	Chloride channel
T20455	SEQUENCE	MAGCRGSLCCCCRWCCCCGERETRTPEELTILGETQEEEDEILPRKDYESLDYDRCINDPYLEVLETMDNKKGRRYEAVKWMVVFAIGVCTGLVGLFVDFFVRLFTQLKFGVVQTSVEECSQKGCLALSLLELLGFNLTFVFLASLLVLIEPVAAGSGIPEVKCYLNGVKVPGIVRLRTLLCKVLGVLFSVAGGLFVEKEGPMIHSGSVVGAGLPQFQSISLRKIQFNFPYFRSDRDKRDFVSAGAAAGVAAAFGAPIGGTLFSLEEGSSFWNQGLTWKVLFCSMSATFTLNFFRSGIQFGSWGSFQLPGLLNFGEFKCSDSDKKCHLWTAMDLGFFVVMGVIGGLLGATFNCLNKRLAKYRMRNVHPKPKLVRVLESLLVSLVTTVVVFVASMVLGECRQMSSSSQIGNDSFQLQVTEDVNSSIKTFFCPNDTYNDMATLFFNPQESAILQLFHQDGTFSPVTLALFFVLYFLLACWTYGISVPSGLFVPSLLCGAAFGRLVANVLKSYIGLGHIYSGTFALIGAAAFLGGVVRMTISLTVILIESTNEITYGLPIMVTLMVAKWTGDFFNKGIYDIHVGLRGVPLLEWETEVEMDKLRASDIMEPNLTYVYPHTRIQSLVSILRTTVHHAFPVVTENRGNEKEFMKGNQLISNNIKFKKSSILTRAGEQRKRSQSMKSYPSSELRNMCDEHIASEEPAEKEDLLQQMLERRYTPYPNLYPDQSPSEDWTMEERFRPLTFHGLILRSQLVTLLVRGVCYSESQSSASQPRLSYAEMAEDYPRYPDIHDLDLTLLNPRMIVDVTPYMNPSPFTVSPNTHVSQVFNLFRTMGLRHLPVVNAVGEIVGIITRHNLTYEFLQARLRQHYQTI
T20455	DRUGINFO	D0PW7B	DIDS	Investigative

T43531	TARGETID	T43531
T43531	FORMERID	TTDI03370
T43531	UNIPROID	CLCN7_HUMAN
T43531	TARGNAME	Chloride channel protein 7 (ClC-7)
T43531	GENENAME	CLCN7
T43531	TARGTYPE	Literature-reported
T43531	SYNONYMS	H(+)/Cl(-) exchange transporter 7; ClC-7; Chloride channel 7 alpha subunit
T43531	FUNCTION	Slowly voltage-gated channel mediating the exchange of chloride ions against protons. Functions as antiporter and contributes to the acidification of the lysosome lumen.
T43531	BIOCLASS	Chloride channel
T43531	SEQUENCE	MANVSKKVSWSGRDRDDEEAAPLLRRTARPGGGTPLLNGAGPGAARQSPRSALFRVGHMSSVELDDELLDPDMDPPHPFPKEIPHNEKLLSLKYESLDYDNSENQLFLEEERRINHTAFRTVEIKRWVICALIGILTGLVACFIDIVVENLAGLKYRVIKGNIDKFTEKGGLSFSLLLWATLNAAFVLVGSVIVAFIEPVAAGSGIPQIKCFLNGVKIPHVVRLKTLVIKVSGVILSVVGGLAVGKEGPMIHSGSVIAAGISQGRSTSLKRDFKIFEYFRRDTEKRDFVSAGAAAGVSAAFGAPVGGVLFSLEEGASFWNQFLTWRIFFASMISTFTLNFVLSIYHGNMWDLSSPGLINFGRFDSEKMAYTIHEIPVFIAMGVVGGVLGAVFNALNYWLTMFRIRYIHRPCLQVIEAVLVAAVTATVAFVLIYSSRDCQPLQGGSMSYPLQLFCADGEYNSMAAAFFNTPEKSVVSLFHDPPGSYNPLTLGLFTLVYFFLACWTYGLTVSAGVFIPSLLIGAAWGRLFGISLSYLTGAAIWADPGKYALMGAAAQLGGIVRMTLSLTVIMMEATSNVTYGFPIMLVLMTAKIVGDVFIEGLYDMHIQLQSVPFLHWEAPVTSHSLTAREVMSTPVTCLRRREKVGVIVDVLSDTASNHNGFPVVEHADDTQPARLQGLILRSQLIVLLKHKVFVERSNLGLVQRRLRLKDFRDAYPRFPPIQSIHVSQDERECTMDLSEFMNPSPYTVPQEASLPRVFKLFRALGLRHLVVVDNRNQVVGLVTRKDLARYRLGKRGLEELSLAQT
T43531	DRUGINFO	D00UTF	NS5818	Investigative
T43531	DRUGINFO	D03APP	diphenylamine-2-carboxylic acid	Investigative
T43531	DRUGINFO	D0A2UX	SITS	Investigative
T43531	DRUGINFO	D0Z4AU	GTPgammaS	Investigative
T43531	DRUGINFO	D08DQL	NPPB	Investigative
T43531	DRUGINFO	D0PW7B	DIDS	Investigative

T78758	TARGETID	T78758
T78758	FORMERID	TTDI03119
T78758	UNIPROID	CLCKB_HUMAN
T78758	TARGNAME	Chloride channel protein ClC-Kb (ClC-K2)
T78758	GENENAME	CLCNKB
T78758	TARGTYPE	Literature-reported
T78758	SYNONYMS	ClC-K2; Chloride channel Kb
T78758	FUNCTION	Voltage-gated chloride channel. Chloride channels have several functions including the regulation of cell volume; membrane potential stabilization, signal transduction and transepithelial transport. May be important in urinary concentrating mechanisms.
T78758	BIOCLASS	Chloride channel
T78758	SEQUENCE	MEEFVGLREGSSGNPVTLQELWGPCPRIRRGIRGGLEWLKQKLFRLGEDWYFLMTLGVLMALVSCAMDLAVESVVRAHQWLYREIGDSHLLRYLSWTVYPVALVSFSSGFSQSITPSSGGSGIPEVKTMLAGVVLEDYLDIKNFGAKVVGLSCTLACGSTLFLGKVGPFVHLSVMMAAYLGRVRTTTIGEPENKSKQNEMLVAAAAVGVATVFAAPFSGVLFSIEVMSSHFSVWDYWRGFFAATCGAFMFRLLAVFNSEQETITSLYKTSFRVDVPFDLPEIFFFVALGGLCGILGSAYLFCQRIFFGFIRNNRFSSKLLATSKPVYSALATLVLASITYPPSAGRFLASRLSMKQHLDSLFDNHSWALMTQNSSPPWPEELDPQHLWWEWYHPRFTIFGTLAFFLVMKFWMLILATTIPMPAGYFMPIFVYGAAIGRLFGETLSFIFPEGIVAGGITNPIMPGGYALAGAAAFSGAVTHTISTALLAFEVTGQIVHALPVLMAVLAANAIAQSCQPSFYDGTVIVKKLPYLPRILGRNIGSHRVRVEHFMNHSITTLAKDMPLEEVVKVVTSTDVAKYPLVESTESQILVGIVRRAQLVQALKAEPPSWAPGHQQCLQDILAAGCPTEPVTLKLSPETSLHEAHNLFELLNLHSLFVTSRGRAVGCVSWVEMKKAISNLTNPPAPK
T78758	DRUGINFO	D0S2HQ	3-phenyl-CPP	Investigative
T78758	DRUGINFO	D0PW7B	DIDS	Investigative

T84341	TARGETID	T84341
T84341	FORMERID	TTDR00875
T84341	UNIPROID	HDGF_HUMAN
T84341	TARGNAME	Hepatoma-derived growth factor (HDGF)
T84341	GENENAME	HDGF
T84341	TARGTYPE	Literature-reported
T84341	SYNONYMS	High-mobility group protein 1-like 2; High mobility group protein 1-like 2; HMG1L2; HMG-1L2
T84341	FUNCTION	Acts as a transcriptional repressor. Heparin-binding protein, with mitogenic activity for fibroblasts.
T84341	PDBSTRUC	2NLU; 1RI0
T84341	SEQUENCE	MSRSNRQKEYKCGDLVFAKMKGYPHWPARIDEMPEAAVKSTANKYQVFFFGTHETAFLGPKDLFPYEESKEKFGKPNKRKGFSEGLWEIENNPTVKASGYQSSQKKSCVEEPEPEPEAAEGDGDKKGNAEGSSDEEGKLVIDEPAKEKNEKGALKRRAGDLLEDSPKRPKEAENPEGEEKEAATLEVERPLPMEVEKNSTPSEPGSGRGPPQEEEEEEDEEEEATKEDAEAPGIRDHESL

T30035	TARGETID	T30035
T30035	FORMERID	TTDR01114
T30035	UNIPROID	STC1_HUMAN
T30035	TARGNAME	Stanniocalcin 1 (STC1)
T30035	GENENAME	STC1
T30035	TARGTYPE	Literature-reported
T30035	SYNONYMS	Stanniocalcin-1; STC1
T30035	FUNCTION	Stimulates renal phosphate reabsorption, and could therefore prevent hypercalcemia.
T30035	BIOCLASS	Stanniocalcin family
T30035	SEQUENCE	MLQNSAVLLVLVISASATHEAEQNDSVSPRKSRVAAQNSAEVVRCLNSALQVGCGAFACLENSTCDTDGMYDICKSFLYSAAKFDTQGKAFVKESLKCIANGVTSKVFLAIRRCSTFQRMIAEVQEECYSKLNVCSIAKRNPEAITEVVQLPNHFSNRYYNRLVRSLLECDEDTVSTIRDSLMEKIGPNMASLFHILQTDHCAQTHPRADFNRRRTNEPQKLKVLLRNLRGEEDSPSHIKRTSHESA

T35983	TARGETID	T35983
T35983	FORMERID	TTDI01489
T35983	UNIPROID	PDX1_HUMAN
T35983	TARGNAME	Pancreas duodenum homeobox 1 (PDX1)
T35983	GENENAME	PDX1
T35983	TARGTYPE	Literature-reported
T35983	SYNONYMS	Somatostatin-transactivating factor 1; STF1; STF-1; Pancreas/duodenum homeobox protein 1; PDX-1; Islet/duodenum homeobox-1; Insulin upstream factor 1; Insulin promoter factor 1; IUF-1; IPF1; IPF-1; IDX-1; Glucose-sensitive factor; GSF
T35983	FUNCTION	Activates insulin, somatostatin, glucokinase, islet amyloid polypeptide and glucose transporter type 2 gene transcription. Particularly involved in glucose-dependent regulation of insulin gene transcription. As part of a PDX1:PBX1b:MEIS2b complex in pancreatic acinar cells is involved in the transcriptional activation of the ELA1 enhancer; the complex binds to the enhancer B element and cooperates with the transcription factor 1 complex (PTF1) bound to the enhancer A element. Binds preferentially the DNA motif 5'-[CT]TAAT[TG]-3'. During development, specifies the early pancreatic epithelium, permitting its proliferation, branching and subsequent differentiation. At adult stage, required for maintaining the hormone-producing phenotype of the beta-cell.
T35983	PDBSTRUC	6F8F
T35983	SEQUENCE	MNGEEQYYAATQLYKDPCAFQRGPAPEFSASPPACLYMGRQPPPPPPHPFPGALGALEQGSPPDISPYEVPPLADDPAVAHLHHHLPAQLALPHPPAGPFPEGAEPGVLEEPNRVQLPFPWMKSTKAHAWKGQWAGGAYAAEPEENKRTRTAYTRAQLLELEKEFLFNKYISRPRRVELAVMLNLTERHIKIWFQNRRMKWKKEEDKKRGGGTAVGGGGVAEPEQDCAVTSGEELLALPPPPPPGGAVPPAAPVAAREGRLPPGLSASPQPSSVAPRRPQEPR

T10704	TARGETID	T10704
T10704	FORMERID	TTDR00442
T10704	UNIPROID	MKC7_YEAST
T10704	TARGNAME	Fungal Glycosylphosphatidylinositol-aspartyl-protease (Fung MKC7)
T10704	GENENAME	Fung MKC7
T10704	TARGTYPE	Literature-reported
T10704	SYNONYMS	Yapsin 2; MKC7; Glycosylphosphatidylinositol-anchored protein; GPI-anchored aspartyl protease
T10704	FUNCTION	Cleaves proteins C-terminally to the most C-terminal basic residue. Can process the alpha-mating factor precursor. Required for cell wall integrity.
T10704	BIOCLASS	Peptidase
T10704	SEQUENCE	MKLSVLTFVVDALLVCSSIVDAGVTDFPSLPSNEVYVKMNFQKKYGSSFENALDDTKGRTRLMTRDDDYELVELTNQNSFYSVELDIGTPPQKVTVLVDTGSSDLWVTGSDNPYCSTKKKDTTGSSFKQVNKDALASVVESVFTEISYDTTIVTSEATATFDSTASTSQLIDCATYGTFNTSKSSTFNSNNTEFSIAYGDTTFASGTWGHDQLSLNDLNITGLSFAVANETNSTVGVLGIGLPGLESTYSGVSLSSVQKSYTYNNFPMVLKNSGVIKSTAYSLFANDSDSKHGTILFGAVDHGKYAGDLYTIPIINTLQHRGYKDPIQFQVTLQGLGTSKGDKEDNLTTLTTTKIPVLLDSGTTISYMPTELVKMLADQVGATYSSAYGYYIMDCIKEMEEESSIIFDFGGFYLSNWLSDFQLVTDSRSNICILGIAPQSDPTIILGDNFLANTYVVYDLDNMEISMAQANFSDDGEYIEIIESAVPSALKAPGYSSTWSTYESIVSGGNMFSTAANSSISYFASTSHSATSSSSSKGQKTQTSTTALSISKSTSSTSSTGMLSPTSSSSTRKENGGHNLNPPFFARFITAIFHHI

T38622	TARGETID	T38622
T38622	FORMERID	TTDR00674
T38622	UNIPROID	CRBB1_HUMAN
T38622	TARGNAME	Beta-crystallin B1 (CRYBB1)
T38622	GENENAME	CRYBB1
T38622	TARGTYPE	Literature-reported
T38622	SYNONYMS	CRYBB1; Beta B1-crystallin
T38622	FUNCTION	Crystallins are the dominant structural components of the vertebrate eye lens.
T38622	PDBSTRUC	1OKI
T38622	SEQUENCE	MSQAAKASASATVAVNPGPDTKGKGAPPAGTSPSPGTTLAPTTVPITSAKAAELPPGNYRLVVFELENFQGRRAEFSGECSNLADRGFDRVRSIIVSAGPWVAFEQSNFRGEMFILEKGEYPRWNTWSSSYRSDRLMSFRPIKMDAQEHKISLFEGANFKGNTIEIQGDDAPSLWVYGFSDRVGSVKVSSGTWVGYQYPGYRGYQYLLEPGDFRHWNEWGAFQPQMQSLRRLRDKQWHLEGSFPVLATEPPK
T38622	DRUGINFO	D0H1GU	Double Oxidized Cysteine	Investigative

T93033	TARGETID	T93033
T93033	FORMERID	TTDNR00692
T93033	UNIPROID	ITA8_HUMAN
T93033	TARGNAME	Integrin alpha-8 (ITGA8)
T93033	GENENAME	ITGA8
T93033	TARGTYPE	Literature-reported
T93033	SYNONYMS	Integrin alpha-8 light chain; Integrin alpha-8 heavy chain
T93033	FUNCTION	It recognizes the sequence R-G-D in a wide array of ligands including TNC, FN1, SPP1 TGFB1, TGFB3 and VTN. NPNT is probably its functional ligand in kidney genesis. Neuronal receptor for TNC it mediates cell-cell interactions and regulates neurite outgrowth of sensory and motor neurons. Integrin alpha-8/beta-1 functions in the genesis of kidney and probably of other organs by regulating the recruitment of mesenchymal cells into epithelial structures.
T93033	BIOCLASS	Integrin
T93033	SEQUENCE	MSPGASRGPRGSQAPLIAPLCCAAAALGMLLWSPACQAFNLDVEKLTVYSGPKGSYFGYAVDFHIPDARTASVLVGAPKANTSQPDIVEGGAVYYCPWPAEGSAQCRQIPFDTTNNRKIRVNGTKEPIEFKSNQWFGATVKAHKGKVVACAPLYHWRTLKPTPEKDPVGTCYVAIQNFSAYAEFSPCRNSNADPEGQGYCQAGFSLDFYKNGDLIVGGPGSFYWQGQVITASVADIIANYSFKDILRKLAGEKQTEVAPASYDDSYLGYSVAAGEFTGDSQQELVAGIPRGAQNFGYVSIINSTDMTFIQNFTGEQMASYFGYTVVVSDVNSDGLDDVLVGAPLFMEREFESNPREVGQIYLYLQVSSLLFRDPQILTGTETFGRFGSAMAHLGDLNQDGYNDIAIGVPFAGKDQRGKVLIYNGNKDGLNTKPSQVLQGVWASHAVPSGFGFTLRGDSDIDKNDYPDLIVGAFGTGKVAVYRARPVVTVDAQLLLHPMIINLENKTCQVPDSMTSAACFSLRVCASVTGQSIANTIVLMAEVQLDSLKQKGAIKRTLFLDNHQAHRVFPLVIKRQKSHQCQDFIVYLRDETEFRDKLSPINISLNYSLDESTFKEGLEVKPILNYYRENIVSEQAHILVDCGEDNLCVPDLKLSARPDKHQVIIGDENHLMLIINARNEGEGAYEAELFVMIPEEADYVGIERNNKGFRPLSCEYKMENVTRMVVCDLGNPMVSGTNYSLGLRFAVPRLEKTNMSINFDLQIRSSNKDNPDSNFVSLQINITAVAQVEIRGVSHPPQIVLPIHNWEPEEEPHKEEEVGPLVEHIYELHNIGPSTISDTILEVGWPFSARDEFLLYIFHIQTLGPLQCQPNPNINPQDIKPAASPEDTPELSAFLRNSTIPHLVRKRDVHVVEFHRQSPAKILNCTNIECLQISCAVGRLEGGESAVLKVRSRLWAHTFLQRKNDPYALASLVSFEVKKMPYTDQPAKLPEGSIVIKTSVIWATPNVSFSIPLWVIILAILLGLLVLAILTLALWKCGFFDRARPPQEDMTDREQLTNDKTPEA

T95842	TARGETID	T95842
T95842	FORMERID	TTDR00653
T95842	UNIPROID	MOT1_HUMAN
T95842	TARGNAME	Monocarboxylate transporter 1 (SLC16A1)
T95842	GENENAME	SLC16A1
T95842	TARGTYPE	Literature-reported
T95842	SYNONYMS	Solute carrier family 16 member 1; MCT1; MCT 1
T95842	FUNCTION	Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate. Depending on the tissue and on cicumstances, mediates the import or export of lactic acid and ketone bodies. Required for normal nutrient assimilation, increase of white adipose tissue and body weight gain when on a high-fat diet. Plays a role in cellular responses to a high-fat diet by modulating the cellular levels of lactate and pyruvate, small molecules that contribute to the regulation of central metabolic pathways and insulin secretion, with concomitant effects on plasma insulin levels and blood glucose homeostasis. Proton-coupled monocarboxylate transporter.
T95842	BIOCLASS	Major facilitator
T95842	SEQUENCE	MPPAVGGPVGYTPPDGGWGWAVVIGAFISIGFSYAFPKSITVFFKEIEGIFHATTSEVSWISSIMLAVMYGGGPISSILVNKYGSRIVMIVGGCLSGCGLIAASFCNTVQQLYVCIGVIGGLGLAFNLNPALTMIGKYFYKRRPLANGLAMAGSPVFLCTLAPLNQVFFGIFGWRGSFLILGGLLLNCCVAGALMRPIGPKPTKAGKDKSKASLEKAGKSGVKKDLHDANTDLIGRHPKQEKRSVFQTINQFLDLTLFTHRGFLLYLSGNVIMFFGLFAPLVFLSSYGKSQHYSSEKSAFLLSILAFVDMVARPSMGLVANTKPIRPRIQYFFAASVVANGVCHMLAPLSTTYVGFCVYAGFFGFAFGWLSSVLFETLMDLVGPQRFSSAVGLVTIVECCPVLLGPPLLGRLNDMYGDYKYTYWACGVVLIISGIYLFIGMGINYRLLAKEQKANEQKKESKEEETSIDVAGKPNEVTKAAESPDQKDTDGGPKEEESPV

T80042	TARGETID	T80042
T80042	FORMERID	TTDI00102
T80042	UNIPROID	TERF1_HUMAN
T80042	TARGNAME	Telomeric repeat-binding factor 1 (TERF1)
T80042	GENENAME	TERF1
T80042	TARGTYPE	Literature-reported
T80042	SYNONYMS	Telomeric protein Pin2/TRF1; TTAGGG repeat-binding factor 1; TRF1; TRF; TRBF1; PIN2; NIMA-interacting protein 2
T80042	FUNCTION	Involved in the regulation of the mitotic spindle. Component of the shelterin complex (telosome) that is involved in the regulation of telomere length and protection. Shelterin associates with arrays of double-stranded 5'-TTAGGG-3' repeats added by telomerase and protects chromosome ends; without its protective activity, telomeres are no longer hidden from the DNA damage surveillance and chromosome ends are inappropriately processed by DNA repair pathways. Binds the telomeric double-stranded 5'-TTAGGG-3' repeat and negatively regulates telomere length.
T80042	PDBSTRUC	5XUP; 5WIR; 5HKP; 3L82; 3BQO
T80042	SEQUENCE	MAEDVSSAAPSPRGCADGRDADPTEEQMAETERNDEEQFECQELLECQVQVGAPEEEEEEEEDAGLVAEAEAVAAGWMLDFLCLSLCRAFRDGRSEDFRRTRNSAEAIIHGLSSLTACQLRTIYICQFLTRIAAGKTLDAQFENDERITPLESALMIWGSIEKEHDKLHEEIQNLIKIQAIAVCMENGNFKEAEEVFERIFGDPNSHMPFKSKLLMIISQKDTFHSFFQHFSYNHMMEKIKSYVNYVLSEKSSTFLMKAAAKVVESKRTRTITSQDKPSGNDVEMETEANLDTRKSVSDKQSAVTESSEGTVSLLRSHKNLFLSKLQHGTQQQDLNKKERRVGTPQSTKKKKESRRATESRIPVSKSQPVTPEKHRARKRQAWLWEEDKNLRSGVRKYGEGNWSKILLHYKFNNRTSVMLKDRWRTMKKLKLISSDSED

T45779	TARGETID	T45779
T45779	FORMERID	TTDI02467
T45779	UNIPROID	PMS1_HUMAN
T45779	TARGNAME	DNA mismatch repair protein PMS1 (PMS1)
T45779	GENENAME	PMS1
T45779	TARGTYPE	Literature-reported
T45779	SYNONYMS	PMSL1; PMS1 protein homolog 1
T45779	FUNCTION	Probably involved in the repair of mismatches in DNA.
T45779	PDBSTRUC	2CS1
T45779	SEQUENCE	MKQLPAATVRLLSSSQIITSVVSVVKELIENSLDAGATSVDVKLENYGFDKIEVRDNGEGIKAVDAPVMAMKYYTSKINSHEDLENLTTYGFRGEALGSICCIAEVLITTRTAADNFSTQYVLDGSGHILSQKPSHLGQGTTVTALRLFKNLPVRKQFYSTAKKCKDEIKKIQDLLMSFGILKPDLRIVFVHNKAVIWQKSRVSDHKMALMSVLGTAVMNNMESFQYHSEESQIYLSGFLPKCDADHSFTSLSTPERSFIFINSRPVHQKDILKLIRHHYNLKCLKESTRLYPVFFLKIDVPTADVDVNLTPDKSQVLLQNKESVLIALENLMTTCYGPLPSTNSYENNKTDVSAADIVLSKTAETDVLFNKVESSGKNYSNVDTSVIPFQNDMHNDESGKNTDDCLNHQISIGDFGYGHCSSEISNIDKNTKNAFQDISMSNVSWENSQTEYSKTCFISSVKHTQSENGNKDHIDESGENEEEAGLENSSEISADEWSRGNILKNSVGENIEPVKILVPEKSLPCKVSNNNYPIPEQMNLNEDSCNKKSNVIDNKSGKVTAYDLLSNRVIKKPMSASALFVQDHRPQFLIENPKTSLEDATLQIEELWKTLSEEEKLKYEEKATKDLERYNSQMKRAIEQESQMSLKDGRKKIKPTSAWNLAQKHKLKTSLSNQPKLDELLQSQIEKRRSQNIKMVQIPFSMKNLKINFKKQNKVDLEEKDEPCLIHNLRFPDAWLMTSKTEVMLLNPYRVEEALLFKRLLENHKLPAEPLEKPIMLTESLFNGSHYLDVLYKMTADDQRYSGSTYLSDPRLTANGFKIKLIPGVSITENYLEIEGMANCLPFYGVADLKEILNAILNRNAKEVYECRPRKVISYLEGEAVRLSRQLPMYLSKEDIQDIIYRMKHQFGNEIKECVHGRPFFHHLTYLPETT

T30777	TARGETID	T30777
T30777	FORMERID	TTDI00157
T30777	UNIPROID	AIF1_HUMAN
T30777	TARGNAME	Allograft inflammatory factor-1 (AIF1)
T30777	GENENAME	AIF1
T30777	TARGTYPE	Literature-reported
T30777	SYNONYMS	Protein G1; Ionized calciumbinding adapter molecule 1; Allograft inflammatory factor 1; AIF1
T30777	FUNCTION	Actin-binding protein that enhances membrane ruffling and RAC activation. Enhances the actin-bundling activity of LCP1. Binds calcium. Plays a role in RAC signaling and in phagocytosis. May play a role in macrophage activation and function. Promotes the proliferation of vascular smooth muscle cells and of T- lymphocytes. Enhances lymphocyte migration. Plays a role in vascular inflammation.
T30777	PDBSTRUC	2G2B; 2D58
T30777	SEQUENCE	MSQTRDLQGGKAFGLLKAQQEERLDEINKQFLDDPKYSSDEDLPSKLEGFKEKYMEFDLNGNGDIDIMSLKRMLEKLGVPKTHLELKKLIGEVSSGSGETFSYPDFLRMMLGKRSAILKMILMYEEKAREKEKPTGPPAKKAISELP

T78650	TARGETID	T78650
T78650	FORMERID	TTDR00336
T78650	UNIPROID	PLTP_HUMAN
T78650	TARGNAME	Phospholipid transfer protein (PLTP)
T78650	GENENAME	PLTP
T78650	TARGTYPE	Literature-reported
T78650	SYNONYMS	Plasma phospholipid transfer protein; Lipid transfer protein II; Lipid II precursor
T78650	FUNCTION	Essential for the transfer of excess surface lipids from triglyceride-rich lipoproteins to HDL, thereby facilitating the formation of smaller lipoprotein remnants, contributing to the formation of LDL, and assisting in the maturation of HDL particles. PLTP also plays a key role in the uptake of cholesterol from peripheral cells and tissues that is subsequently transported to the liver for degradation and excretion. Two distinct forms of PLTP exist in plasma: an active form that can transfer PC from phospholipid vesicles to high-density lipoproteins (HDL), and an inactive form that lacks this capability. Facilitates the transfer of a spectrum of different lipid molecules, including diacylglycerol, phosphatidic acid, sphingomyelin, phosphatidylcholine, phosphatidylglycerol, cerebroside and phosphatidyl ethanolamine.
T78650	BIOCLASS	Bactericidal permeability increasing protein
T78650	SEQUENCE	MALFGALFLALLAGAHAEFPGCKIRVTSKALELVKQEGLRFLEQELETITIPDLRGKEGHFYYNISEVKVTELQLTSSELDFQPQQELMLQITNASLGLRFRRQLLYWFFYDGGYINASAEGVSIRTGLELSRDPAGRMKVSNVSCQASVSRMHAAFGGTFKKVYDFLSTFITSGMRFLLNQQICPVLYHAGTVLLNSLLDTVPVRSSVDELVGIDYSLMKDPVASTSNLDMDFRGAFFPLTERNWSLPNRAVEPQLQEEERMVYVAFSEFFFDSAMESYFRAGALQLLLVGDKVPHDLDMLLRATYFGSIVLLSPAVIDSPLKLELRVLAPPRCTIKPSGTTISVTASVTIALVPPDQPEVQLSSMTMDARLSAKMALRGKALRTQLDLRRFRIYSNHSALESLALIPLQAPLKTMLQIGVMPMLNERTWRGVQIPLPEGINFVHEVVTNHAGFLTIGADLHFAKGLREVIEKNRPADVRASTAPTPSTAAV

T62415	TARGETID	T62415
T62415	FORMERID	TTDI02643
T62415	UNIPROID	MANF_HUMAN
T62415	TARGNAME	Mesencephalic astrocyte-derived neurotrophic factor (ARMET)
T62415	GENENAME	MANF
T62415	TARGTYPE	Literature-reported
T62415	SYNONYMS	Mesencephalic astrocytederived neurotrophic factor; MANF; Argininerich protein
T62415	FUNCTION	Selectively promotes the survival of dopaminergic neurons of the ventral mid-brain. Modulates GABAergic transmission to the dopaminergic neurons of the substantia nigra. Enhances spontaneous, as well as evoked, GABAergic inhibitory postsynaptic currents in dopaminergic neurons. Inhibits cell proliferation and endoplasmic reticulum (ER) stress-induced cell death.
T62415	PDBSTRUC	2W51; 2KVE; 2KVD
T62415	SEQUENCE	MRRMWATQGLAVALALSVLPGSRALRPGDCEVCISYLGRFYQDLKDRDVTFSPATIENELIKFCREARGKENRLCYYIGATDDAATKIINEVSKPLAHHIPVEKICEKLKKKDSQICELKYDKQIDLSTVDLKKLRVKELKKILDDWGETCKGCAEKSDYIRKINELMPKYAPKAASARTDL

T41145	TARGETID	T41145
T41145	FORMERID	TTDI03061
T41145	UNIPROID	BRPF1_HUMAN
T41145	TARGNAME	Bromodomain and PHD finger containing 1 (BRPF1)
T41145	GENENAME	BRPF1
T41145	TARGTYPE	Literature-reported
T41145	SYNONYMS	Protein Br140; Peregrin; Bromodomain and PHD finger-containing protein 1; BR140
T41145	FUNCTION	Component of the MOZ/MORF complex which has a histone H3 acetyltransferase activity. Preferentially mediates histone H3-K23 acetylation. Positively regulates the transcription of RUNX1 and RUNX2.
T41145	PDBSTRUC	6EKQ; 5T4V; 5T4U; 5OWE; 5OWB
T41145	SEQUENCE	MGVDFDVKTFCHNLRATKPPYECPVETCRKVYKSYSGIEYHLYHYDHDNPPPPQQTPLRKHKKKGRQSRPANKQSPSPSEVSQSPGREVMSYAQAQRMVEVDLHGRVHRISIFDNLDVVSEDEEAPEEAPENGSNKENTETPAATPKSGKHKNKEKRKDSNHHHHHNVSASTTPKLPEVVYRELEQDTPDAPPRPTSYYRYIEKSAEELDEEVEYDMDEEDYIWLDIMNERRKTEGVSPIPQEIFEYLMDRLEKESYFESHNKGDPNALVDEDAVCCICNDGECQNSNVILFCDMCNLAVHQECYGVPYIPEGQWLCRRCLQSPSRAVDCALCPNKGGAFKQTDDGRWAHVVCALWIPEVCFANTVFLEPIDSIEHIPPARWKLTCYICKQRGSGACIQCHKANCYTAFHVTCAQQAGLYMKMEPVRETGANGTSFSVRKTAYCDIHTPPGSARRLPALSHSEGEEDEDEEEDEGKGWSSEKVKKAKAKSRIKMKKARKILAEKRAAAPVVSVPCIPPHRLSKITNRLTIQRKSQFMQRLHSYWTLKRQSRNGVPLLRRLQTHLQSQRNCDQVGRDSEDKNWALKEQLKSWQRLRHDLERARLLVELIRKREKLKRETIKVQQIAMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMGIDFETGMHIPHSLAGDEATHHTEDAAEEERLVLLENQKHLPVEEQLKLLLERLDEVNASKQSVGRSRRAKMIKKEMTALRRKLAHQRETGRDGPERHGPSSRGSLTPHPAACDKDGQTDSAAEESSSQETSKGLGPNMSSTPAHEVGRRTSVLFSKKNPKTAGPPKRPGRPPKNRESQMTPSHGGSPVGPPQLPIMSSLRQRKRGRSPRPSSSSDSDSDKSTEDPPMDLPANGFSGGNQPVKKSFLVYRNDCSLPRSSSDSESSSSSSSSAASDRTSTTPSKQGRGKPSFSRGTFPEDSSEDTSGTENEAYSVGTGRGVGHSMVRKSLGRGAGWLSEDEDSPLDALDLVWAKCRGYPSYPALIIDPKMPREGMFHHGVPIPVPPLEVLKLGEQMTQEAREHLYLVLFFDNKRTWQWLPRTKLVPLGVNQDLDKEKMLEGRKSNIRKSVQIAYHRALQHRSKVQGEQSSETSDSD
T41145	DRUGINFO	D0Q7IU	PFI-4	Investigative
T41145	DRUGINFO	D03BTJ	PMID25408830C3	Investigative
T41145	DRUGINFO	D08RDI	OF-1	Investigative
T41145	DRUGINFO	D09ZPM	PMID25408830C1	Investigative
T41145	DRUGINFO	D0C2PD	PMID25974391C34	Investigative
T41145	DRUGINFO	D0J6XI	PMID25408830C2	Investigative
T41145	DRUGINFO	D0O6XT	NI-57	Investigative

T91529	TARGETID	T91529
T91529	FORMERID	TTDR00900
T91529	UNIPROID	PRP1_ECOLI
T91529	TARGNAME	Bacterial Serine/threonine protein phosphatase 1 (Bact pphA)
T91529	GENENAME	Bact pphA
T91529	TARGTYPE	Literature-reported
T91529	SYNONYMS	pphA; Nuclear PP1
T91529	FUNCTION	Plays a key role in signaling protein misfolding via the CpxR/CPXA transducing system. It also modulates the phosphorylated status of many phosphoproteins in E.coli, some of which acting as major chaperones. Has been shown, in vitro, to act on Ser, Thr and Tyr-phosphorylated substrates.
T91529	BIOCLASS	Phosphoric monoester hydrolase
T91529	SEQUENCE	MKQPAPVYQRIAGHQWRHIWLSGDIHGCLEQLRRKLWHCRFDPWRDLLISVGDVIDRGPQSLRCLQLLEQHWVCAVRGNHEQMAMDALASQQMSLWLMNGGDWFIALADNQQKQAKTALEKCQHLPFILEVHSRTGKHVIAHADYPDDVYEWQKDVDLHQVLWSRSRLGERQKGQGITGADHFWFGHTPLRHRVDIGNLHYIDTGAVFGGELTLVQLQ

T02937	TARGETID	T02937
T02937	FORMERID	TTDR01086
T02937	UNIPROID	PPSA_HELPY
T02937	TARGNAME	Bacterial Phosphoenolpyruvate synthase (Bact ppsA)
T02937	GENENAME	Bact ppsA
T02937	TARGTYPE	Literature-reported
T02937	SYNONYMS	ppsA; Pyruvate,water dikinase; Pyruvate, water dikinase; PEP synthase
T02937	FUNCTION	Catalyzes the phosphorylation of pyruvate to phosphoenolpyruvate.
T02937	BIOCLASS	Kinase
T02937	SEQUENCE	MRYIKFFKELNNKNVNLVGGKNASIGEMFQELVPIGIKVPDGFAITSEAYWYLLEQGGAKQKIIELLENVDATEIDVLKIRSKQIRELIFGTPFPSDLRDEIFQAYEILSQQYHMKEADVAVRSSATAEDLPDASFAGQQDTYLNIKGKTELIHYIKSCLASLFTDRAISYRASRGFDHLKVALSVGVQKMVRADKGSAGVMFSIDTETGFKDAVFITSAWGLGENVVGGTINPDEFYVFKPTLEQNKRPIIKRQLGNKTQKMVYAPRGSEHPTRNIKTTKKEWQSFSLSDEDVLILAKYAIEIEKHYSKEAKQYRPMDIEWAKDGESGEIFIVQARPETVQSQKSKEESQVFEKFKFKNPNEKKEIILQGRAIGSKIGSGKVRIINDLEHMNSFKEGEILVTDNTDPDWEPCMKKASAVITNRGGRTCHAAIVAREIGVPAIVGVSGATDSLYTGMEITVSCAEGEEGYVYAGIYEHEIERVELSNMQETQTKIYINIGNPEKAFGFSQLPNHGVGLARMEMIILNQIKAHPLALVDLHHKKSVKEKNEIENLMAGYANPKDFFVKKIAEGIGMISAAFYPKPVIVRTSDFKSNEYMRMLGGSSYEPNEENPMLGYRGASRYYSESYNEAFSWECEALALVREEMGLTNMKVMIPFLRTIEEGKKVLEILRKNNLESGKNGLEIYIMCELPVNVILADDFLSLFDGFSIGSNDLTQLTLGVDRDSELVSHVFDERNEAMLKMFKKAIEACKRHNKYCGICGQAPSDYPEVTEFLVKEGITSISLNPDSVIPTWNAVAKLEKELKEHGLTEH

T74109	TARGETID	T74109
T74109	FORMERID	TTDI01809
T74109	UNIPROID	ITA1_HUMAN-ITB3_HUMAN
T74109	TARGNAME	Integrin alpha-1/beta-3 (ITGA1/B3)
T74109	GENENAME	ITGA1-ITGB3
T74109	TARGTYPE	Literature-reported
T74109	SYNONYMS	alpha(1)beta(3) integrin; Alpha 1 beta 3 integrin
T74109	FUNCTION	The heterodimeric receptor is involved in cell-cell adhesion and may play a role in inflammation and fibrosis. The alpha 1 subunit contains an inserted (I) von Willebrand factor type I domain which is thought to be involved in collagen binding.
T74109	BIOCLASS	Integrin
T74109	SEQUENCE	MRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLGSPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRPDDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFGAFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSRNRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCHVGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLSMDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDTVSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGTFECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFGKITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLLCSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRYCRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDILVVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTFTNITYRGTMAPRPRARPGVAVACCWLLTVVLRCCVSFNVDVKNSMTFSGPVEDMFGYTVQQYENEEGKWVLIGSPLVGQPKNRTGDVYKCPVGRGESLPCVKLDLPVNTSIPNVTEVKENMTFGSTLVTNPNGGFLACGPLYAYRCGHLHYTTGICSDVSPTFQVVNSIAPVQECSTQLDIVIVLDGSNSIYPWDSVTAFLNDLLERMDIGPKQTQVGIVQYGENVTHEFNLNKYSSTEEVLVAAKKIVQRGGRQTMTALGIDTARKEAFTEARGARRGVKKVMVIVTDGESHDNHRLKKVIQDCEDENIQRFSIAILGSYNRGNLSTEKFVEEIKSIASEPTEKHFFNVSDELALVTIVKTLGERIFALEATADQSAASFEMEMSQTGFSAHYSQDWVMLGAVGAYDWNGTVVMQKASQIIIPRNTTFNVESTKKNEPLASYLGYTVNSATASSGDVLYIAGQPRYNHTGQVIIYRMEDGNIKILQTLSGEQIGSYFGSILTTTDIDKDSNTDILLVGAPMYMGTEKEEQGKVYVYALNQTRFEYQMSLEPIKQTCCSSRQHNSCTTENKNEPCGARFGTAIAAVKDLNLDGFNDIVIGAPLEDDHGGAVYIYHGSGKTIRKEYAQRIPSGGDGKTLKFFGQSIHGEMDLNGDGLTDVTIGGLGGAALFWSRDVAVVKVTMNFEPNKVNIQKKNCHMEGKETVCINATVCFDVKLKSKEDTIYEADLQYRVTLDSLRQISRSFFSGTQERKVQRNITVRKSECTKHSFYMLDKHDFQDSVRITLDFNLTDPENGPVLDDSLPNSVHEYIPFAKDCGNKEKCISDLSLHVATTEKDLLIVRSQNDKFNVSLTVKNTKDSAYNTRTIVHYSPNLVFSGIEAIQKDSCESNHNITCKVGYPFLRRGEMVTFKILFQFNTSYLMENVTIYLSATSDSEEPPETLSDNVVNISIPVKYEVGLQFYSSASEYHISIAANETVPEVINSTEDIGNEINIFYLIRKSGSFPMPELKLSISFPNMTSNGYPVLYPTGLSSSENANCRPHIFEDPFSINSGKKMTTSTDHLKRGTILDCNTCKFATITCNLTSSDISQVNVSLILWKPTFIKSYFSSLNLTIRGELRSENASLVLSSSNQKRELAIQISKDGLPGRVPLWVILLSAFAGLLLLMLLILALWKIGFFKRPLKKKMEK

T06717	TARGETID	T06717
T06717	FORMERID	TTDI01805
T06717	UNIPROID	ITA1_HUMAN-ITB1_HUMAN
T06717	TARGNAME	Integrin alpha-1/beta-1 (ITGA1/B1)
T06717	GENENAME	ITGA1-ITGB1
T06717	TARGTYPE	Literature-reported
T06717	SYNONYMS	alpha(1)beta(1) integrin; Alpha 1 beta 1 integrin
T06717	FUNCTION	Integrin alpha-1/beta-1 is a receptor for laminin and collagen. It recognizes the proline-hydroxylated sequence G-F-P-G- E-R in collagen. Involved in anchorage-dependent, negative regulation of EGF-stimulated cell growth.
T06717	BIOCLASS	Integrin
T06717	SEQUENCE	MNLQPIFWIGLISSVCCVFAQTDENRCLKANAKSCGECIQAGPNCGWCTNSTFLQEGMPTSARCDDLEALKKKGCPPDDIENPRGSKDIKKNKNVTNRSKGTAEKLKPEDITQIQPQQLVLRLRSGEPQTFTLKFKRAEDYPIDLYYLMDLSYSMKDDLENVKSLGTDLMNEMRRITSDFRIGFGSFVEKTVMPYISTTPAKLRNPCTSEQNCTSPFSYKNVLSLTNKGEVFNELVGKQRISGNLDSPEGGFDAIMQVAVCGSLIGWRNVTRLLVFSTDAGFHFAGDGKLGGIVLPNDGQCHLENNMYTMSHYYDYPSIAHLVQKLSENNIQTIFAVTEEFQPVYKELKNLIPKSAVGTLSANSSNVIQLIIDAYNSLSSEVILENGKLSEGVTISYKSYCKNGVNGTGENGRKCSNISIGDEVQFEISITSNKCPKKDSDSFKIRPLGFTEEVEVILQYICECECQSEGIPESPKCHEGNGTFECGACRCNEGRVGRHCECSTDEVNSEDMDAYCRKENSSEICSNNGECVCGQCVCRKRDNTNEIYSGKFCECDNFNCDRSNGLICGGNGVCKCRVCECNPNYTGSACDCSLDTSTCEASNGQICNGRGICECGVCKCTDPKFQGQTCEMCQTCLGVCAEHKECVQCRAFNKGEKKDTCTQECSYFNITKVESRDKLPQPVQPDPVSHCKEKDVDDCWFYFTYSVNGNNEVMVHVVENPECPTGPDIIPIVAGVVAGIVLIGLALLLIWKLLMIIHDRREFAKFEKEKMNAKWDTGENPIYKSAVTTVVNPKYEGKMAPRPRARPGVAVACCWLLTVVLRCCVSFNVDVKNSMTFSGPVEDMFGYTVQQYENEEGKWVLIGSPLVGQPKNRTGDVYKCPVGRGESLPCVKLDLPVNTSIPNVTEVKENMTFGSTLVTNPNGGFLACGPLYAYRCGHLHYTTGICSDVSPTFQVVNSIAPVQECSTQLDIVIVLDGSNSIYPWDSVTAFLNDLLERMDIGPKQTQVGIVQYGENVTHEFNLNKYSSTEEVLVAAKKIVQRGGRQTMTALGIDTARKEAFTEARGARRGVKKVMVIVTDGESHDNHRLKKVIQDCEDENIQRFSIAILGSYNRGNLSTEKFVEEIKSIASEPTEKHFFNVSDELALVTIVKTLGERIFALEATADQSAASFEMEMSQTGFSAHYSQDWVMLGAVGAYDWNGTVVMQKASQIIIPRNTTFNVESTKKNEPLASYLGYTVNSATASSGDVLYIAGQPRYNHTGQVIIYRMEDGNIKILQTLSGEQIGSYFGSILTTTDIDKDSNTDILLVGAPMYMGTEKEEQGKVYVYALNQTRFEYQMSLEPIKQTCCSSRQHNSCTTENKNEPCGARFGTAIAAVKDLNLDGFNDIVIGAPLEDDHGGAVYIYHGSGKTIRKEYAQRIPSGGDGKTLKFFGQSIHGEMDLNGDGLTDVTIGGLGGAALFWSRDVAVVKVTMNFEPNKVNIQKKNCHMEGKETVCINATVCFDVKLKSKEDTIYEADLQYRVTLDSLRQISRSFFSGTQERKVQRNITVRKSECTKHSFYMLDKHDFQDSVRITLDFNLTDPENGPVLDDSLPNSVHEYIPFAKDCGNKEKCISDLSLHVATTEKDLLIVRSQNDKFNVSLTVKNTKDSAYNTRTIVHYSPNLVFSGIEAIQKDSCESNHNITCKVGYPFLRRGEMVTFKILFQFNTSYLMENVTIYLSATSDSEEPPETLSDNVVNISIPVKYEVGLQFYSSASEYHISIAANETVPEVINSTEDIGNEINIFYLIRKSGSFPMPELKLSISFPNMTSNGYPVLYPTGLSSSENANCRPHIFEDPFSINSGKKMTTSTDHLKRGTILDCNTCKFATITCNLTSSDISQVNVSLILWKPTFIKSYFSSLNLTIRGELRSENASLVLSSSNQKRELAIQISKDGLPGRVPLWVILLSAFAGLLLLMLLILALWKIGFFKRPLKKKMEK

T84671	TARGETID	T84671
T84671	FORMERID	TTDR00999
T84671	UNIPROID	TCL1A_HUMAN
T84671	TARGNAME	T-cell leukemia/lymphoma protein 1A (TCL1A)
T84671	GENENAME	TCL1A
T84671	TARGTYPE	Literature-reported
T84671	SYNONYMS	TCL1 oncogene; TCL1; TCL-1 protein; T-cell leukemia/lymphoma 1 oncogene; Protein p14 TCL1; P14 TCL1 protein; Oncogene TCL1; Oncogene TCL-1
T84671	FUNCTION	Promotes nuclear translocation of AKT1. Enhances cell proliferation, stabilizes mitochondrial membrane potential and promotes cell survival. Enhances the phosphorylation and activation of AKT1, AKT2 and AKT3.
T84671	PDBSTRUC	1JSG
T84671	SEQUENCE	MAECPTLGEAVTDHPDRLWAWEKFVYLDEKQHAWLPLTIEIKDRLQLRVLLRREDVVLGRPMTPTQIGPSLLPIMWQLYPDGRYRSSDSSFWRLVYHIKIDGVEDMLLELLPDD

T01529	TARGETID	T01529
T01529	FORMERID	TTDI03143
T01529	UNIPROID	CXA9_HUMAN
T01529	TARGNAME	Connexin-59 (Cx59)
T01529	GENENAME	GJA9
T01529	TARGTYPE	Literature-reported
T01529	SYNONYMS	Gap junction alpha-9 protein; GJA10; Cx58; Connexin-58
T01529	FUNCTION	One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell.
T01529	BIOCLASS	Gap junction-forming connexin
T01529	SEQUENCE	MGDWNLLGDTLEEVHIHSTMIGKIWLTILFIFRMLVLGVAAEDVWNDEQSGFICNTEQPGCRNVCYDQAFPISLIRYWVLQVIFVSSPSLVYMGHALYRLRVLEEERQRMKAQLRVELEEVEFEMPRDRRRLEQELCQLEKRKLNKAPLRGTLLCTYVIHIFTRSVVEVGFMIGQYLLYGFHLEPLFKCHGHPCPNIIDCFVSRPTEKTIFLLFMQSIATISLFLNILEIFHLGFKKIKRGLWGKYKLKKEHNEFHANKAKQNVAKYQSTSANSLKRLPSAPDYNLLVEKQTHTAVYPSLNSSSVFQPNPDNHSVNDEKCILDEQETVLSNEISTLSTSCSHFQHISSNNNKDTHKIFGKELNGNQLMEKRETEGKDSKRNYYSRGHRSIPGVAIDGENNMRQSPQTVFSLPANCDWKPRWLRATWGSSTEHENRGSPPKGNLKGQFRKGTVRTLPPSQGDSQSLDIPNTADSLGGLSFEPGLVRTCNNPVCPPNHVVSLTNNLIGRRVPTDLQI
T01529	DRUGINFO	D00VJY	octanol	Investigative

T06525	TARGETID	T06525
T06525	FORMERID	TTDI01491
T06525	UNIPROID	RAC3_HUMAN
T06525	TARGNAME	Rac family small GTPase 3 (RAC3)
T06525	GENENAME	RAC3
T06525	TARGTYPE	Literature-reported
T06525	SYNONYMS	p21-Rac3; Ras-related C3 botulinum toxin substrate 3
T06525	FUNCTION	Plasma membrane-associated small GTPase which cycles between an active GTP-bound and inactive GDP-bound state. In active state binds to a variety of effector proteins to regulate cellular responses, such as cell spreading and the formation of actin-based protusions including lamellipodia and membrane ruffles. Promotes cell adhesion and spreading on fibrinogen in a CIB1 and alpha-IIb/beta3 integrin-mediated manner.
T06525	PDBSTRUC	2QME; 2OV2; 2IC5; 2G0N; 2C2H
T06525	SEQUENCE	MQAIKCVVVGDGAVGKTCLLISYTTNAFPGEYIPTVFDNYSANVMVDGKPVNLGLWDTAGQEDYDRLRPLSYPQTDVFLICFSLVSPASFENVRAKWYPEVRHHCPHTPILLVGTKLDLRDDKDTIERLRDKKLAPITYPQGLAMAREIGSVKYLECSALTQRGLKTVFDEAIRAVLCPPPVKKPGKKCTVF

T10864	TARGETID	T10864
T10864	FORMERID	TTDI02514
T10864	UNIPROID	GPR85_HUMAN
T10864	TARGNAME	Super conserved receptor brain 2 (GPR85)
T10864	GENENAME	GPR85
T10864	TARGTYPE	Literature-reported
T10864	SYNONYMS	Super conserved receptor expressed in brain 2; SREB2; Probable Gprotein coupled receptor 85; Probable G-protein coupled receptor 85
T10864	FUNCTION	Orphan receptor.
T10864	BIOCLASS	GPCR rhodopsin
T10864	SEQUENCE	MANYSHAADNILQNLSPLTAFLKLTSLGFIIGVSVVGNLLISILLVKDKTLHRAPYYFLLDLCCSDILRSAICFPFVFNSVKNGSTWTYGTLTCKVIAFLGVLSCFHTAFMLFCISVTRYLAIAHHRFYTKRLTFWTCLAVICMVWTLSVAMAFPPVLDVGTYSFIREEDQCTFQHRSFRANDSLGFMLLLALILLATQLVYLKLIFFVHDRRKMKPVQFVAAVSQNWTFHGPGASGQAAANWLAGFGRGPTPPTLLGIRQNANTTGRRRLLVLDEFKMEKRISRMFYIMTFLFLTLWGPYLVACYWRVFARGPVVPGGFLTAAVWMSFAQAGINPFVCIFSNRELRRCFSTTLLYCRKSRLPREPYCVI

T73230	TARGETID	T73230
T73230	FORMERID	TTDI01512
T73230	UNIPROID	RL15_HUMAN
T73230	TARGNAME	Large ribosomal subunit protein eL15 (RPL15)
T73230	GENENAME	RPL15
T73230	TARGTYPE	Literature-reported
T73230	SYNONYMS	TCBAP0781; EC45; 60S ribosomal protein L15
T73230	FUNCTION	Up-regulated in gastric cancer tissues. Also highly expressed in gastric cancer cell lines AGS, MKN45, MKN28, SGC7901 and KATOIII. 
T73230	PDBSTRUC	6QZP; 6EK0; 5T2C; 5LKS; 5AJ0
T73230	SEQUENCE	MGAYKYIQELWRKKQSDVMRFLLRVRCWQYRQLSALHRAPRPTRPDKARRLGYKAKQGYVIYRIRVRRGGRKRPVPKGATYGKPVHHGVNQLKFARSLQSVAEERAGRHCGALRVLNSYWVGEDSTYKFFEVILIDPFHKAIRRNPDTQWITKPVHKHREMRGLTSAGRKSRGLGKGHKFHHTIGGSRRAAWRRRNTLQLHRYR

T58080	TARGETID	T58080
T58080	FORMERID	TTDR01280
T58080	UNIPROID	B2MG_HUMAN
T58080	TARGNAME	Beta-2-microglobulin (B2M)
T58080	GENENAME	B2M
T58080	TARGTYPE	Literature-reported
T58080	SYNONYMS	Beta-2-microglobulin
T58080	FUNCTION	Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system. Exogenously applied M.tuberculosis EsxA or EsxA-EsxB (or EsxA expressed in host) binds B2M and decreases its export to the cell surface (total protein levels do not change), probably leading to defects in class I antigen presentation.
T58080	PDBSTRUC	6MTM; 6MTL; 6MT6; 6MT5; 6MT4
T58080	SEQUENCE	MSRSVALAVLALLSLSGLEAIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM

T77393	TARGETID	T77393
T77393	FORMERID	TTDI03618
T77393	UNIPROID	WDR5_HUMAN
T77393	TARGNAME	WD repeat-containing protein 5 (WDR5)
T77393	GENENAME	WDR5
T77393	TARGTYPE	Literature-reported
T77393	SYNONYMS	BMP2-induced 3-kb gene protein; BIG3
T77393	FUNCTION	May position the N-terminus of histone H3 for efficient trimethylation at 'Lys-4'. As part of the MLL1/MLL complex it is involved in methylation and dimethylation at 'Lys-4' of histone H3. H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation. As part of the NSL complex it may be involved in acetylation of nucleosomal histone H4 on several lysine residues. May regulate osteoblasts differentiation. Contributes to histone modification.
T77393	PDBSTRUC	6IAM; 6E1Z; 6E1Y; 6DYA; 6DY7
T77393	SEQUENCE	MATEEKKPETEAARAQPTPSSSATQSKPTPVKPNYALKFTLAGHTKAVSSVKFSPNGEWLASSSADKLIKIWGAYDGKFEKTISGHKLGISDVAWSSDSNLLVSASDDKTLKIWDVSSGKCLKTLKGHSNYVFCCNFNPQSNLIVSGSFDESVRIWDVKTGKCLKTLPAHSDPVSAVHFNRDGSLIVSSSYDGLCRIWDTASGQCLKTLIDDDNPPVSFVKFSPNGKYILAATLDNTLKLWDYSKGKCLKTYTGHKNEKYCIFANFSVTGGKWIVSGSEDNLVYIWNLQTKEIVQKLQGHTDVVISTACHPTENIIASAALENDKTIKLWKSDC
T77393	DRUGINFO	D0XI3W	OICR-9429	Investigative

T58361	TARGETID	T58361
T58361	FORMERID	TTDR00964
T58361	UNIPROID	RHOB_HUMAN
T58361	TARGNAME	Transforming protein RhoB (RHOB)
T58361	GENENAME	RHOB
T58361	TARGTYPE	Literature-reported
T58361	SYNONYMS	RhoB
T58361	FUNCTION	Regulates a signal transduction pathway linking plasma membrane receptors to the assembly of focal adhesions and actin stress fibers.
T58361	PDBSTRUC	2FV8
T58361	SEQUENCE	MAAIRKKLVVVGDGACGKTCLLIVFSKDEFPEVYVPTVFENYVADIEVDGKQVELALWDTAGQEDYDRLRPLSYPDTDVILMCFSVDSPDSLENIPEKWVPEVKHFCPNVPIILVANKKDLRSDEHVRTELARMKQEPVRTDDGRAMAVRIQAYDYLECSAKTKEGVREVFETATRAALQKRYGSQNGCINCCKVL

T46929	TARGETID	T46929
T46929	FORMERID	TTDR01292
T46929	UNIPROID	IF5A1_HUMAN
T46929	TARGNAME	Eukaryotic translation initiation factor 5A-1 (EIF5A)
T46929	GENENAME	EIF5A
T46929	TARGTYPE	Literature-reported
T46929	SYNONYMS	eIF-5A1; eIF-5A-1; eIF-5A; eIF-4D; Rev-binding factor; Eukaryotic initiation factor 5A isoform 1
T46929	FUNCTION	A GTPase-activating protein, which helps the large ribosomal subunit associate with the small subunit. Involved in the initiation phase of eukaryotic translation. Stabilize the formation of ribosomal preinitiation complexes around the start codon and are an important input for post-transcription gene regulation. Helps with elongation and also plays a role in termination.
T46929	PDBSTRUC	5DLQ; 3CPF; 1FH4
T46929	SEQUENCE	MADDLDFETGDAGASATFPMQCSALRKNGFVVLKGRPCKIVEMSTSKTGKHGHAKVHLVGIDIFTGKKYEDICPSTHNMDVPNIKRNDFQLIGIQDGYLSLLQDSGEVREDLRLPEGDLGKEIEQKYDCGEEILITVLSAMTEEAAVAIKAMAK

T74570	TARGETID	T74570
T74570	FORMERID	TTDI03315
T74570	UNIPROID	KCNJ2_HUMAN
T74570	TARGNAME	Inward rectifier potassium channel Kir2.1 (KCNJ2)
T74570	GENENAME	KCNJ2
T74570	TARGTYPE	Literature-reported
T74570	SYNONYMS	hIRK1; Potassium channel, inwardly rectifying subfamily J member 2; Inward rectifier K(+) channel Kir2.1; IRK1; IRK-1; Cardiac inward rectifier potassium channel
T74570	FUNCTION	Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. Can be blocked by extracellular barium or cesium. Probably participates in establishing action potential waveform and excitability of neuronal and muscle tissues.
T74570	BIOCLASS	Inward rectifier potassium channel
T74570	SEQUENCE	MGSVRTNRYSIVSSEEDGMKLATMAVANGFGNGKSKVHTRQQCRSRFVKKDGHCNVQFINVGEKGQRYLADIFTTCVDIRWRWMLVIFCLAFVLSWLFFGCVFWLIALLHGDLDASKEGKACVSEVNSFTAAFLFSIETQTTIGYGFRCVTDECPIAVFMVVFQSIVGCIIDAFIIGAVMAKMAKPKKRNETLVFSHNAVIAMRDGKLCLMWRVGNLRKSHLVEAHVRAQLLKSRITSEGEYIPLDQIDINVGFDSGIDRIFLVSPITIVHEIDEDSPLYDLSKQDIDNADFEIVVILEGMVEATAMTTQCRSSYLANEILWGHRYEPVLFEEKHYYKVDYSRFHKTYEVPNTPLCSARDLAEKKYILSNANSFCYENEVALTSKEEDDSENGVPESTSTDTPPDIDLHNQASVPLEPRPLRRESEI
T74570	DRUGINFO	D05HXE	oleoyl-CoA	Investigative
T74570	DRUGINFO	D07ZAJ	PIP2	Investigative

T27457	TARGETID	T27457
T27457	FORMERID	TTDI01880
T27457	UNIPROID	ACTG_HUMAN
T27457	TARGNAME	Gamma-actin (ACTG)
T27457	GENENAME	ACTG1
T27457	TARGTYPE	Literature-reported
T27457	SYNONYMS	Actin, cytoplasmic 2; ACTG
T27457	FUNCTION	Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells.
T27457	PDBSTRUC	6G2T; 6CXJ; 6CXI; 5JLH
T27457	SEQUENCE	MEEEIAALVIDNGSGMCKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEAQSKRGILTLKYPIEHGIVTNWDDMEKIWHHTFYNELRVAPEEHPVLLTEAPLNPKANREKMTQIMFETFNTPAMYVAIQAVLSLYASGRTTGIVMDSGDGVTHTVPIYEGYALPHAILRLDLAGRDLTDYLMKILTERGYSFTTTAEREIVRDIKEKLCYVALDFEQEMATAASSSSLEKSYELPDGQVITIGNERFRCPEALFQPSFLGMESCGIHETTFNSIMKCDVDIRKDLYANTVLSGGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWISKQEYDESGPSIVHRKCF

T31442	TARGETID	T31442
T31442	FORMERID	TTDR01209
T31442	UNIPROID	EMBA_MYCAV
T31442	TARGNAME	Mycobacterium Arabinosyltransferase A (MycB embA)
T31442	GENENAME	MycB embA
T31442	TARGTYPE	Literature-reported
T31442	SYNONYMS	Probable arabinosyltransferase A
T31442	FUNCTION	Arabinosyl transferase responsible for the polymerization of arabinose into the arabinan of arabinogalactan.
T31442	ECNUMBER	EC 2.4.2.-
T31442	SEQUENCE	MPHDGKQRSQRIPRSVAAVAGIAGLLLCLAVPLLPVRQTTATVLWPQGTVDGHVSQITAPLVSGAPRALDISIPCPAVATLPADGGLVVSTLPPGGMDAGKNGLFVRANKDVVVVAFRDTVAAVAQRPAVAAGACSVLHAWADAGAAGAEFVGIPGAAGTLPAEKKPQVGGIFTDLKVPAGPGLSARVDIDTRFITAPTVLKQIVMVLGTLAVLTAIVALAVLDRRSRGGGTLINWRSPIAWLSRYRPGTHLANWRRVGLATWIADAAVLATLLLWHVVGATSSDDGYNLTIARVAPKAGYLVDYYRYFGTTDAPFDWYLGLLSRLASVSTAGVWMRLPATLAGIGCWLIISHWVLRRLGPGRGGLAANRVAVFTAGAVFVAAWLPFNNGLRPEPLIALGVLVTWMLVERAIALQRLAPAAVAVVVALLTATLAPQGLIAVAALLTGARAVAQAIRRRRASDGLLAPLAVLAAALSLILVVVFRSQTVATVLESARIKYKVGPTIAWYQDWLRYYFLTVESNPDGSMARRFAVLVMLLCLFGMLVILLRRGHVPGVASGPRWRLIGTTAVGLLLLTFTPTKWAVQFGAFAGLAGALGALTAFACSRIGLHNRRNLTLYVTALLFVLAWATSGINGWFYVGNYGVPWYDIQPVIASHPVTSMFLTLSIITGLLAAWQHFRMDYAGHTEVKDSRRNRVLASTPLLVVATIMVVGEVASLTKGAVFRYPLYTTGKANLAAIASGLSPTSCAMADDVLAEPDANAGMLQPLPGQTFGPDGPLGGVNPVGFKPDGVGDDLQSDPVVTKPGLVNSDASPNKPNVAYSDSAGTAGGKGPVGVNGSHAALPFGLDPARTPVMGSYGENSLAATATSAWYQLPPRTPDRPLVVVSAAGAIWSYKEDGTFTYGQSLKLQWGVARPDGSTVPLAEVQPIDIGPQPAWRNLRFPLAWAPPEANVARIVAYDPNLSSEQWFAFTPPRVPVTETLQQLIGSQTPVMMDIATAANFPCQRPFSEHLGVAELPAYRILPDRKQTAASSNLWQSSEAGGPFLFLQALLRTSTIPTYLRGDWYRDWGSVEQYFRLVPADQAPDAAIEQGVMTVHGWSRQGPIRALP

T68114	TARGETID	T68114
T68114	FORMERID	TTDR01210
T68114	UNIPROID	EMBB_MYCAV
T68114	TARGNAME	Mycobacterium Arabinosyltransferase B (MycB embB)
T68114	GENENAME	MycB embB
T68114	TARGTYPE	Literature-reported
T68114	SYNONYMS	Probable arabinosyltransferase B
T68114	FUNCTION	Arabinosyl transferase responsible for the polymerization of arabinose into the arabinan of arabinogalactan.
T68114	ECNUMBER	EC 2.4.2.-
T68114	SEQUENCE	MSVSTVGGDVRVTRWVATIAGLIGFVLSVATPLLPVVQTTATLNWPQGGQLNSVTAPLISLTPVDLTATVPCSLVRDLPPGGGVILSTGPKKGKDAALNALFVVAHGKRVDVTDRNVVIASASRDQVAGAGCSRIEIASTRAGTFATFVGLTDPAGKPLGGGFPDPNLRPQIVGVFTDLTGPAPAGLKLSATIDTRFSTTPTTLKLAAMVTAILATIVALVALWRLDQLDGHRMRRLIPANWRTFTLADVAVIFGFVLWHVIGANSSDDGYILGMARVADRAGYMSNYFRWFGSPEDPFGWYYNLLALMTHVSDASLWMRLPDLFAGIVCWLLLSREVLPRLGPAVAASRPANWAAGMVLLTAWMPFDNGLRPEPIIALGSLVTYVLIERSMRYSRLTPAALAVITAAFTLGVQPTGLIAVAALVAGGRPILRILVRRHRVVGTWPLVAPMLAAGTVILTVVFADQTLATVLEATRIRTAIGPSQAWYTENLRYYYLILPTVDGSLSRRFGFLITALCLFTAVFIMLRRKRIPGVARGPAWRLMGVIFGTMFFLMFTPTKWVHHFGLFAAVGAAMAALTTVLVSPAVLGWSRNRMAFLAALLFMMALCFATTNGWWYVSSYGVPFNSTMPKIGGITVSTVFFSMFVAAALYAIWLHFASREHGEGRLARALTAAPVPLAAGFMALVFIASMVAGIVRQYPTYSNAWDNLREFSGGCGLADDVLVEPDSNVGYMTPLGGDYGPLGPLGGQHPVGFSPNGVPEHTVAEAIRITPNQPGTDYDWDAPTKLSAPGINGSTVPLPYGLDAARVPLAGSYTTGAQQQSRLTSAWYRLPAPDDGHPLVVVTAAGKIAGNSVLHHHTDGQTVVLEYGRPGPGGDIVPAGRLVPYDLYGEQPKAWRNLRFARSDMPADTVAVRVVAEDLSLTPEDWIAVTPPRVPEMRSLQEYVGSTQPVLMDWAVGLAFPCQQPMLHVNGVTEIPKFRITPDYTAKKMDTDTWEDGTNGGLLGITDLLLRAHVMSTYLSHDWGRDWGSLRRFETIADAHPAQLDLGTATRTGWWSPGPIRIKP

T82604	TARGETID	T82604
T82604	FORMERID	TTDNR00659
T82604	UNIPROID	CP4F2_HUMAN; CP4F3_HUMAN
T82604	TARGNAME	Cytochrome P450 4f (P450-4F)
T82604	GENENAME	CYP4F2; CYP4F3
T82604	TARGTYPE	Literature-reported
T82604	SYNONYMS	Leukotriene-B(4) omega-hydroxylase; Leukotriene-B(4) 20-monooxygenase; Cytochrome P450-LTB-omega; CYPIVF; 20-hydroxyeicosatetraenoic acid synthase; 20-HETE synthase
T82604	FUNCTION	Hydroxylates arachidonic acid (20:4n-6) to (18R)- hydroxyarachidonate. Shows little activity against prostaglandin (PG) D2, PGE1, PGE2, PGF2alpha, and leukotriene B4. Catalyzes omega-2 and omega-3-hydroxylation of PGH1 and PGH2. Catalyzes epoxidation of 4,7,10,13,16,19-(Z)-docosahexaenoic acid (22:6n-3) and 7,10,13,16,19-(Z)-docosapentaenoic acid (22:5n-3) and omega-3- hydroxylation of 4,7,10,13,16-(Z)-docosapentaenoic acid (22:5n-6). Catalyzes hydroxylation of PGI2 and carbaprostacyclin.
T82604	BIOCLASS	Paired donor oxygen oxidoreductase
T82604	SEQUENCE	MSQLSLSWLGLWPVAASPWLLLLLVGASWLLAHVLAWTYAFYDNCRRLRCFPQPPRRNWFWGHQGMVNPTEEGMRVLTQLVATYPQGFKVWMGPISPLLSLCHPDIIRSVINASAAIAPKDKFFYSFLEPWLGDGLLLSAGDKWSRHRRMLTPAFHFNILKPYMKIFNESVNIMHAKWQLLASEGSACLDMFEHISLMTLDSLQKCVFSFDSHCQEKPSEYIAAILELSALVSKRHHEILLHIDFLYYLTPDGQRFRRACRLVHDFTDAVIQERRRTLPSQGVDDFLQAKAKSKTLDFIDVLLLSKDEDGKKLSDEDIRAEADTFMFEGHDTTASGLSWVLYHLAKHPEYQERCRQEVQELLKDREPKEIEWDDLAHLPFLTMCMKESLRLHPPVPVISRHVTQDIVLPDGRVIPKGIICLISVFGTHHNPAVWPDPEVYDPFRFDPENIKERSPLAFIPFSAGPRNCIGQTFAMAEMKVVLALTLLRFRVLPDHTEPRRKPELVLRAEGGLWLRVEPLS

T34405	TARGETID	T34405
T34405	FORMERID	TTDR00524
T34405	UNIPROID	X3CL1_HUMAN
T34405	TARGNAME	Fractalkine (CX3CL1)
T34405	GENENAME	CX3CL1
T34405	TARGTYPE	Literature-reported
T34405	SYNONYMS	Small-inducible cytokine D1; Small inducible cytokine D1; SCYD1; Neurotactin; NTT; FKN; CX3C membrane-anchored chemokine; C-X3-C motif chemokine 1; A-152E5.2
T34405	FUNCTION	Binds to CX3CR1. Binds to integrins ITGAV:ITGB3 and ITGA4:ITGB1. Can activate integrins in both a CX3CR1-dependent and CX3CR1-independent manner. In the presence of CX3CR1, activates integrins by binding to the classical ligand-binding site (site 1) in integrins. In the absence of CX3CR1, binds to a second site (site 2) in integrins which is distinct from site 1 and enhances the binding of other integrin ligands to site 1. The soluble form is chemotactic for T-cells and monocytes and not for neutrophils. The membrane-bound form promotes adhesion of those leukocytes to endothelial cells. May play a role in regulating leukocyte adhesion and migration processes at the endothelium. Acts as a ligand for both CX3CR1 and integrins.
T34405	PDBSTRUC	5WB2; 4XT3; 4XT1; 3ONA; 1F2L
T34405	SEQUENCE	MAPISLSWLLRLATFCHLTVLLAGQHHGVTKCNITCSKMTSKIPVALLIHYQQNQASCGKRAIILETRQHRLFCADPKEQWVKDAMQHLDRQAAALTRNGGTFEKQIGEVKPRTTPAAGGMDESVVLEPEATGESSSLEPTPSSQEAQRALGTSPELPTGVTGSSGTRLPPTPKAQDGGPVGTELFRVPPVSTAATWQSSAPHQPGPSLWAEAKTSEAPSTQDPSTQASTASSPAPEENAPSEGQRVWGQGQSPRPENSLEREEMGPVPAHTDAFQDWGPGSMAHVSVVPVSSEGTPSREPVASGSWTPKAEEPIHATMDPQRLGVLITPVPDAQAATRRQAVGLLAFLGLLFCLGVAMFTYQSLQGCPRKMAGEMAEGLRYIPRSCGSNSYVLVPV

T90766	TARGETID	T90766
T90766	UNIPROID	H33_HUMAN
T90766	TARGNAME	Mutated Histone H3.3 (H3F3A)
T90766	GENENAME	H3F3A
T90766	TARGTYPE	Literature-reported
T90766	SYNONYMS	PP781; Histone H3.3; H3F3; H3.3B; H3.3A
T90766	FUNCTION	Variant histone H3 which replaces conventional H3 in a wide range of nucleosomes in active genes. Constitutes the predominant form of histone H3 in non-dividing cells and is incorporated into chromatin independently of DNA synthesis. Deposited at sites of nucleosomal displacement throughout transcribed genes, suggesting that it represents an epigenetic imprint of transcriptionally active chromatin. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling.
T90766	PDBSTRUC	6J51; 6J50; 6J4Z; 6J4Y; 6J4X
T90766	SEQUENCE	MARTKQTARKSTGGKAPRKQLATKAARKSAPSTGGVKKPHRYRPGTVALREIRRYQKSTELLIRKLPFQRLVREIAQDFKTDLRFQSAAIGALQEASEAYLVGLFEDTNLCAIHAKRVTIMPKDIQLARRIRGERA

T73675	TARGETID	T73675
T73675	FORMERID	TTDR00595
T73675	UNIPROID	P96966_PORGN
T73675	TARGNAME	Bacterial Kgp protease (Bact kgp-381)
T73675	GENENAME	Bact kgp-381
T73675	TARGTYPE	Literature-reported
T73675	SYNONYMS	Cysteine protease
T73675	FUNCTION	Important for both nutrition and virulence of P. gingivalis
T73675	BIOCLASS	Protease
T73675	SEQUENCE	MRKLLLLIAASLLGVGLYAQSAKIKLDAPTTRTTCTNNSFKQFDASFSFNEVELTKVETKGGTFASVSIPGAFPTGEVGSPEVPAVRKLIAVPVGATPVVRVKSFTEQVYSLNQYGSEKLMPHQPSMSKSDDPEKVPFVYNAAAYARKGFVGQELTQVEMLGTMRGVRIAALTINPVQYDVVANQLKVRNNIEIEVSFQGADEVATQRLYDASFSPYFETAYKQLFNRDVYTDHGDLYNTPVRMLVVAGAKFKEALKPWLTWKAQKGFYLDVHYTDEAEVGTTNASIKAFIHKKYNDGLAASAAPVFLALVGDTDVISGEKGKKTKKVTDLYYSAVDGDYFPEMYTFRMSASSPEELTNIIDKY

T33755	TARGETID	T33755
T33755	FORMERID	TTDR00594
T33755	UNIPROID	MP63_MYCTU
T33755	TARGNAME	Mycobacterium Immunogenic protein MPT63/MPB63 (MycB mpt63)
T33755	GENENAME	MycB mpt63
T33755	TARGTYPE	Literature-reported
T33755	SYNONYMS	Immunogenic protein MPT63; Antigen MPT63; 16 kDa immunoprotective extracellular protein
T33755	FUNCTION	A secreted protein of unknown function that is specific to mycobacteria.
T33755	PDBSTRUC	1LMI
T33755	SEQUENCE	MKLTTMIKTAVAVVAMAAIATFAAPVALAAYPITGKLGSELTMTDTVGQVVLGWKVSDLKSSTAVIPGYPVAGQVWEATATVNAIRGSVTPAVSQFNARTADGINYRVLWQAAGPDTISGATIPQGEQSTGKIYFDVTGPSPTIVAMNNGMEDLLIWEP

T16285	TARGETID	T16285
T16285	FORMERID	TTDI02428
T16285	UNIPROID	MUC5A_HUMAN
T16285	TARGNAME	Tracheobronchial mucin 5A (MUC5AC)
T16285	GENENAME	MUC5AC
T16285	TARGTYPE	Literature-reported
T16285	SYNONYMS	Tracheobronchial mucin; TBM; Mucin5AC; Mucin5 subtype AC, tracheobronchial; Mucin-5AC; Mucin-5 subtype AC, tracheobronchial; Major airway glycoprotein; MUC5; MUC-5AC; Lewis B blood group antigen; LeB; Gastric mucin
T16285	FUNCTION	Gel-forming glycoprotein of gastric and respiratoy tract epithelia that protects the mucosa from infection and chemical damage by binding to inhaled microrganisms and particles that are subsequently removed by the mucocilary system.
T16285	PDBSTRUC	5AJP; 5AJO; 5AJN
T16285	SEQUENCE	MSVGRRKLALLWALALALACTRHTGHAQDGSSESSYKHHPALSPIARGPSGVPLRGATVFPSLRTIPVVRASNPAHNGRVCSTWGSFHYKTFDGDVFRFPGLCNYVFSEHCGAAYEDFNIQLRRSQESAAPTLSRVLMKVDGVVIQLTKGSVLVNGHPVLLPFSQSGVLIQQSSSYTKVEARLGLVLMWNHDDSLLLELDTKYANKTCGLCGDFNGMPVVSELLSHNTKLTPMEFGNLQKMDDPTDQCQDPVPEPPRNCSTGFGICEELLHGQLFSGCVALVDVGSYLEACRQDLCFCEDTDLLSCVCHTLAEYSRQCTHAGGLPQDWRGPDFCPQKCPNNMQYHECRSPCADTCSNQEHSRACEDHCVAGCFCPEGTVLDDIGQTGCVPVSKCACVYNGAAYAPGATYSTDCTNCTCSGGRWSCQEVPCPGTCSVLGGAHFSTFDGKQYTVHGDCSYVLTKPCDSSAFTVLAELRRCGLTDSETCLKSVTLSLDGAQTVVVIKASGEVFLNQIYTQLPISAANVTIFRPSTFFIIAQTSLGLQLNLQLVPTMQLFMQLAPKLRGQTCGLCGNFNSIQADDFRTLSGVVEATAAAFFNTFKTQAACPNIRNSFEDPCSLSVENEKYAQHWCSQLTDADGPFGRCHAAVKPGTYYSNCMFDTCNCERSEDCLCAALSSYVHACAAKGVQLGGWRDGVCTKPMTTCPKSMTYHYHVSTCQPTCRSLSEGDITCSVGFIPVDGCICPKGTFLDDTGKCVQASNCPCYHRGSMIPNGESVHDSGAICTCTHGKLSCIGGQAPAPVCAAPMVFFDCRNATPGDTGAGCQKSCHTLDMTCYSPQCVPGCVCPDGLVADGEGGCITAEDCPCVHNEASYRAGQTIRVGCNTCTCDSRMWRCTDDPCLATCAVYGDGHYLTFDGQSYSFNGDCEYTLVQNHCGGKDSTQDSFRVVTENVPCGTTGTTCSKAIKIFLGGFELKLSHGKVEVIGTDESQEVPYTIRQMGIYLVVDTDIGLVLLWDKKTSIFINLSPEFKGRVCGLCGNFDDIAVNDFATRSRSVVGDVLEFGNSWKLSPSCPDALAPKDPCTANPFRKSWAQKQCSILHGPTFAACHAHVEPARYYEACVNDACACDSGGDCECFCTAVAAYAQACHEVGLCVSWRTPSICPLFCDYYNPEGQCEWHYQPCGVPCLRTCRNPRGDCLRDVRGLEGCYPKCPPEAPIFDEDKMQCVATCPTPPLPPRCHVHGKSYRPGAVVPSDKNCQSCLCTERGVECTYKAEACVCTYNGQRFHPGDVIYHTTDGTGGCISARCGANGTIERRVYPCSPTTPVPPTTFSFSTPPLVVSSTHTPSNGPSSAHTGPPSSAWPTTAGTSPRTRLPTASASLPPVCGEKCLWSPWMDVSRPGRGTDSGDFDTLENLRAHGYRVCESPRSVECRAEDAPGVPLRALGQRVQCSPDVGLTCRNREQASGLCYNYQIRVQCCTPLPCSTSSSPAQTTPPTTSKTTETRASGSSAPSSTPGTVSLSTARTTPAPGTATSVKKTFSTPSPPPVPATSTSSMSTTAPGTSVVSSKPTPTEPSTSSCLQELCTWTEWIDGSYPAPGINGGDFDTFQNLRDEGYTFCESPRSVQCRAESFPNTPLADLGQDVICSHTEGLICLNKNQLPPICYNYEIRIQCCETVNVCRDITRLPKTVATTRPTPHPTGAQTQTTFTTHMPSASTEQPTATSRGGPTATSVTQGTHTTLVTRNCHPRCTWTKWFDVDFPSPGPHGGDKETYNNIIRSGEKICRRPEEITRLQCRAKSHPEVSIEHLGQVVQCSREEGLVCRNQDQQGPFKMCLNYEVRVLCCETPRGCHMTSTPGSTSSSPAQTTPSTTSKTTETQASGSSAPSSTPGTVSLSTARTTPAPGTATSVKKTFSTPSPPPVPATSTSSMSTTAPGTSVVSSKPTPTEPSTSSCLQELCTWTEWIDGSYPAPGINGGDFDTFQNLRDEGYTFCESPRSVQCRAESFPNTPLADLGQDVICSHTEGLICLNKNQLPPICYNYEIRIQCCETVNVCRDITRPPKTVATTRPTPHPTGAQTQTTFTTHMPSASTEQPTATSRGGPTATSVTQGTHTTPVTRNCHPRCTWTTWFDVDFPSPGPHGGDKETYNNIIRSGEKICRRPEEITRLQCRAKSHPEVSIEHLGQVVQCSREEGLVCRNQDQQGPFKMCLNYEVRVLCCETPKGCPVTSTPVTAPSTPSGRATSPTQSTSSWQKSRTTTLVTTSTTSTPQTSTTYAHTTSTTSAPTARTTSAPTTRTTSASPASTTSGPGNTPSPVPTTSTISAPTTSITSAPTTSTTSAPTSSTTSGPGTTPSPVPTTSITSAPTTSTTSAPTTSTTSARTSSTTSATTTSRISGPETTPSPVPTTSTTSATTTSTTSAPTTSTTSAPTSSTTSSPQTSTTSAPTTSTTSGPGTTPSPVPTTSTTSAPTTRTTSAPKSSTTSAATTSTTSGPETTPRPVPTTSTTSSPTTSTTSAPTTSTTSASTTSTTSGAGTTPSPVPTTSTTSAPTTSTTSAPISSTTSATTTSTTSGPGTTPSPVPTTSTTSAPTTSTTSGPGTTPSAVPTTSITSAPTTSTNSAPISSTTSATTTSRISGPETTPSPVPTASTTSASTTSTTSGPGTTPSPVPTTSTISVPTTSTTSASTTSTTSASTTSTTSGPGTTPSPVPTTSTTSAPTTSTTSAPTTSTISAPTTSTTSATTTSTTSAPTPRRTSAPTTSTISASTTSTTSATTTSTTSATTTSTISAPTTSTTLSPTTSTTSTTITSTTSAPISSTTSTPQTSTTSAPTTSTTSGPGTTSSPVPTTSTTSAPTTSTTSAPTTRTTSVPTSSTTSTATTSTTSGPGTTPSPVPTTSTTSAPTTRTTSAPTTSTTSAPTTSTTSAPTSSTTSATTTSTISVPTTSTTSVPGTTPSPVPTTSTISVPTTSTTSASTTSTTSGPGTTPSPVPTTSTTSAPTTSTTSAPTTSTISAPTTSTPSAPTTSTTLAPTTSTTSAPTTSTTSTPTSSTTSSPQTSTTSASTTSITSGPGTTPSPVPTTSTTSAPTTSTTSAATTSTISAPTTSTTSAPTTSTTSASTASKTSGLGTTPSPIPTTSTTSPPTTSTTSASTASKTSGPGTTPSPVPTTSTIFAPRTSTTSASTTSTTPGPGTTPSPVPTTSTASVSKTSTSHVSISKTTHSQPVTRDCHLRCTWTKWFDIDFPSPGPHGGDKETYNNIIRSGEKICRRPEEITRLQCRAESHPEVSIEHLGQVVQCSREEGLVCRNQDQQGPFKMCLNYEVRVLCCETPKGCPVTSTPVTAPSTPSGRATSPTQSTSSWQKSRTTTLVTTSTTSTPQTSTTSAPTTSTTSAPTTSTTSAPTTSTTSTPQTSISSAPTSSTTSAPTSSTISARTTSIISAPTTSTTSSPTTSTTSATTTSTTSAPTSSTTSTPQTSKTSAATSSTTSGSGTTPSPVTTTSTASVSKTSTSHVSVSKTTHSQPVTRDCHPRCTWTKWFDVDFPSPGPHGGDKETYNNIIRSGEKICRRPEEITRLQCRAKSHPEVSIEHLGQVVQCSREEGLVCRNQDQQGPFKMCLNYEVRVLCCETPKGCPVTSTSVTAPSTPSGRATSPTQSTSSWQKSRTTTLVTSSITSTTQTSTTSAPTTSTTPASIPSTTSAPTTSTTSAPTTSTTSAPTTSTTSTPQTTTSSAPTSSTTSAPTTSTISAPTTSTISAPTTSTTSAPTASTTSAPTSTSSAPTTNTTSAPTTSTTSAPITSTISAPTTSTTSTPQTSTISSPTTSTTSTPQTSTTSSPTTSTTSAPTTSTTSAPTTSTTSTPQTSISSAPTSSTTSAPTASTISAPTTSTTSFHTTSTTSPPTSSTSSTPQTSKTSAATSSTTSGSGTTPSPVPTTSTASVSKTSTSHVSVSKTTHSQPVTRDCHPRCTWTKWFDVDFPSPGPHGGDKETYNNIIRSGEKICRRPEEITRLQCRAESHPEVSIEHLGQVVQCSREEGLVCRNQDQQGPFKMCLNYEVRVLCCETPKGCPVTSTPVTAPSTPSGRATSPTQSTSSWQKSRTTTLVTTSTTSTPQTSTTSAPTTSTIPASTPSTTSAPTTSTTSAPTTSTTSAPTHRTTSGPTTSTTLAPTTSTTSAPTTSTNSAPTTSTISASTTSTISAPTTSTISSPTSSTTSTPQTSKTSAATSSTTSGSGTTPSPVPTTSTTSASTTSTTSAPTTSTTSGPGTTPSPVPSTSTTSAATTSTTSAPTTRTTSAPTSSMTSGPGTTPSPVPTTSTTSAPTTSTTSGPGTTPSPVPTTSTTSAPITSTTSGPGSTPSPVPTTSTTSAPTTSTTSASTASTTSGPGTTPSPVPTTSTTSAPTTRTTSASTASTTSGPGSTPSPVPTTSTTSAPTTRTTPASTASTTSGPGTTPSPVPTTSTTSASTTSTISLPTTSTTSAPITSMTSGPGTTPSPVPTTSTTSAPTTSTTSASTASTTSGPGTTPSPVPTTSTTSAPTTSTTSASTASTTSGPGTSLSPVPTTSTTSAPTTSTTSGPGTTPSPVPTTSTTSAPTTSTTSGPGTTPSPVPTTSTTPVSKTSTSHLSVSKTTHSQPVTSDCHPLCAWTKWFDVDFPSPGPHGGDKETYNNIIRSGEKICRRPEEITRLQCRAESHPEVNIEHLGQVVQCSREEGLVCRNQDQQGPFKMCLNYEVRVLCCETPRGCPVTSVTPYGTSPTNALYPSLSTSMVSASVASTSVASSSVASSSVAYSTQTCFCNVADRLYPAGSTIYRHRDLAGHCYYALCSQDCQVVRGVDSDCPSTTLPPAPATSPSISTSEPVTELGCPNAVPPRKKGETWATPNCSEATCEGNNVISLRPRTCPRVEKPTCANGYPAVKVADQDGCCHHYQCQCVCSGWGDPHYITFDGTYYTFLDNCTYVLVQQIVPVYGHFRVLVDNYFCGAEDGLSCPRSIILEYHQDRVVLTRKPVHGVMTNEIIFNNKVVSPGFRKNGIVVSRIGVKMYATIPELGVQVMFSGLIFSVEVPFSKFANNTEGQCGTCTNDRKDECRTPRGTVVASCSEMSGLWNVSIPDQPACHRPHPTPTTVGPTTVGSTTVGPTTVGSTTVGPTTPPAPCLPSPICQLILSKVFEPCHTVIPPLLFYEGCVFDRCHMTDLDVVCSSLELYAALCASHDICIDWRGRTGHMCPFTCPADKVYQPCGPSNPSYCYGNDSASLGALPEAGPITEGCFCPEGMTLFSTSAQVCVPTGCPRCLGPHGEPVKVGHTVGMDCQECTCEAATWTLTCRPKLCPLPPACPLPGFVPVPAAPQAGQCCPQYSCACNTSRCPAPVGCPEGARAIPTYQEGACCPVQNCSWTVCSINGTLYQPGAVVSSSLCETCRCELPGGPPSDAFVVSCETQICNTHCPVGFEYQEQSGQCCGTCVQVACVTNTSKSPAHLFYPGETWSDAGNHCVTHQCEKHQDGLVVVTTKKACPPLSCSLDEARMSKDGCCRFCPPPPPPYQNQSTCAVYHRSLIIQQQGCSSSEPVRLAYCRGNCGDSSSMYSLEGNTVEHRCQCCQELRTSLRNVTLHCTDGSSRAFSYTEVEECGCMGRRCPAPGDTQHSEEAEPEPSQEAESGSWERGVPVSPMH

T28516	TARGETID	T28516
T28516	FORMERID	TTDNC00588
T28516	UNIPROID	FABG_MYCTU
T28516	TARGNAME	Mycobacterium Beta-ketoacyl-ACP reductase (MycB fabG1)
T28516	GENENAME	MycB fabG1
T28516	TARGTYPE	Literature-reported
T28516	SYNONYMS	Beta-ketoacyl-acyl carrier protein reductase; Beta-ketoacyl-ACP reductase; 3-oxoacyl-[acyl-carrier-protein] reductase FabG1; 3-ketoacyl-acyl carrier protein reductase
T28516	FUNCTION	Catalyzes the NADPH-dependent reduction of beta-ketoacyl-ACP substrates to beta-hydroxyacyl-ACP products, the first reductive step in the elongation cycle of fatty acid biosynthesis. MabA preferentially metabolizes long-chain substrates (C8-C20) and has a poor affinity for the C4 substrate.
T28516	PDBSTRUC	2NTN; 1UZN; 1UZM; 1UZL
T28516	SEQUENCE	MTATATEGAKPPFVSRSVLVTGGNRGIGLAIAQRLAADGHKVAVTHRGSGAPKGLFGVECDVTDSDAVDRAFTAVEEHQGPVEVLVSNAGLSADAFLMRMTEEKFEKVINANLTGAFRVAQRASRSMQRNKFGRMIFIGSVSGSWGIGNQANYAASKAGVIGMARSIARELSKANVTANVVAPGYIDTDMTRALDERIQQGALQFIPAKRVGTPAEVAGVVSFLASEDASYISGAVIPVDGGMGMGH

T55435	TARGETID	T55435
T55435	FORMERID	TTDI02545
T55435	UNIPROID	PKNB_MYCTU
T55435	TARGNAME	Mycobacterium Serine/threonine-protein kinase PknB (MycB pknB)
T55435	GENENAME	MycB pknB
T55435	TARGTYPE	Literature-reported
T55435	SYNONYMS	pknB; Serine/threonineprotein kinase PknB
T55435	FUNCTION	Key component of a signal transduction pathway that regulates cell growth and cell division via phosphorylation of target proteins such as GarA, GlmU, PapA5, PbpA, FhaB (Rv0019c), FhaA(Rv0020c), MviN, PstP, EmbR, Rv1422, Rv1747 and RseA. Shows a strong preference for Thr versus Ser as the phosphoacceptor.
T55435	PDBSTRUC	6I2P; 6B2P; 5U94; 5E0Z; 5E0Y
T55435	SEQUENCE	MTTPSHLSDRYELGEILGFGGMSEVHLARDLRLHRDVAVKVLRADLARDPSFYLRFRREAQNAAALNHPAIVAVYDTGEAETPAGPLPYIVMEYVDGVTLRDIVHTEGPMTPKRAIEVIADACQALNFSHQNGIIHRDVKPANIMISATNAVKVMDFGIARAIADSGNSVTQTAAVIGTAQYLSPEQARGDSVDARSDVYSLGCVLYEVLTGEPPFTGDSPVSVAYQHVREDPIPPSARHEGLSADLDAVVLKALAKNPENRYQTAAEMRADLVRVHNGEPPEAPKVLTDAERTSLLSSAAGNLSGPRTDPLPRQDLDDTDRDRSIGSVGRWVAVVAVLAVLTVVVTIAINTFGGITRDVQVPDVRGQSSADAIATLQNRGFKIRTLQKPDSTIPPDHVIGTDPAANTSVSAGDEITVNVSTGPEQREIPDVSTLTYAEAVKKLTAAGFGRFKQANSPSTPELVGKVIGTNPPANQTSAITNVVIIIVGSGPATKDIPDVAGQTVDVAQKNLNVYGFTKFSQASVDSPRPAGEVTGTNPPAGTTVPVDSVIELQVSKGNQFVMPDLSGMFWVDAEPRLRALGWTGMLDKGADVDAGGSQHNRVVYQNPPAGTGVNRDGIITLRFGQ

T04369	TARGETID	T04369
T04369	FORMERID	TTDR01000
T04369	UNIPROID	CFP32_MYCTU
T04369	TARGNAME	Mycobacterium Glyoxylase CFP32 (MycB cfp32)
T04369	GENENAME	MycB cfp32
T04369	TARGTYPE	Literature-reported
T04369	SYNONYMS	MycB Putative glyoxylase CFP32; 27 kDa antigen Cfp30B
T04369	FUNCTION	May function as a glyoxylase involved in the methylglyoxal detoxification pathway. Induces maturation of dendritic cells in a TLR2-dependent manner, causing increased expression of cell-surface molecules (CD80, CD86, MHC class I and II) and proinflammatory cytokines (TNF-alpha, IL-6, IL-1 beta and IL-12p70). Acts via both the NF-kappa-B and MAPK signaling pathways. Induces Th1-polarized immune responses.
T04369	PDBSTRUC	3OXH
T04369	SEQUENCE	MPKRSEYRQGTPNWVDLQTTDQSAAKKFYTSLFGWGYDDNPVPGGGGVYSMATLNGEAVAAIAPMPPGAPEGMPPIWNTYIAVDDVDAVVDKVVPGGGQVMMPAFDIGDAGRMSFITDPTGAAVGLWQANRHIGATLVNETGTLIWNELLTDKPDLALAFYEAVVGLTHSSMEIAAGQNYRVLKAGDAEVGGCMEPPMPGVPNHWHVYFAVDDADATAAKAAAAGGQVIAEPADIPSVGRFAVLSDPQGAIFSVLKPAPQQ

T89162	TARGETID	T89162
T89162	FORMERID	TTDI01467
T89162	UNIPROID	GLMU_MYCTU
T89162	TARGNAME	Mycobacterium Bifunctional protein GlmU (MycB glmU)
T89162	GENENAME	MycB glmU
T89162	TARGTYPE	Literature-reported
T89162	SYNONYMS	Bifunctional protein GlmU
T89162	FUNCTION	Catalyzes the last two sequential reactions in the de novo biosynthetic pathway for UDP-N-acetylglucosamine (UDP-GlcNAc). The C-terminal domain catalyzes the transfer of acetyl group from acetyl coenzyme A to glucosamine-1-phosphate (GlcN-1-P) to produce N-acetylglucosamine-1-phosphate (GlcNAc-1-P), which is converted into UDP-GlcNAc by the transfer of uridine 5-monophosphate (from uridine 5-triphosphate), a reaction catalyzed by the N-terminal domain.
T89162	PDBSTRUC	4HCQ; 4G87; 4G3S; 4G3Q; 4G3P
T89162	SEQUENCE	MTFPGDTAVLVLAAGPGTRMRSDTPKVLHTLAGRSMLSHVLHAIAKLAPQRLIVVLGHDHQRIAPLVGELADTLGRTIDVALQDRPLGTGHAVLCGLSALPDDYAGNVVVTSGDTPLLDADTLADLIATHRAVSAAVTVLTTTLDDPFGYGRILRTQDHEVMAIVEQTDATPSQREIREVNAGVYAFDIAALRSALSRLSSNNAQQELYLTDVIAILRSDGQTVHASHVDDSALVAGVNNRVQLAELASELNRRVVAAHQLAGVTVVDPATTWIDVDVTIGRDTVIHPGTQLLGRTQIGGRCVVGPDTTLTDVAVGDGASVVRTHGSSSSIGDGAAVGPFTYLRPGTALGADGKLGAFVEVKNSTIGTGTKVPHLTYVGDADIGEYSNIGASSVFVNYDGTSKRRTTVGSHVRTGSDTMFVAPVTIGDGAYTGAGTVVREDVPPGALAVSAGPQRNIENWVQRKRPGSPAAQASKRASEMACQQPTQPPDADQTP

T50583	TARGETID	T50583
T50583	FORMERID	TTDI01525
T50583	UNIPROID	ESXA_MYCTU
T50583	TARGNAME	Mycobacterium 6kDa early secretory antigenic target (MycB esxA)
T50583	GENENAME	MycB esxA
T50583	TARGTYPE	Literature-reported
T50583	SYNONYMS	ESAT-6; 6 kDa early secretory antigenic target
T50583	FUNCTION	A secreted protein that plays a number of roles in modulating the host's immune response to infection as well as being responsible for bacterial escape into the host cytoplasm. Acts as a strong host (human) T-cell antigen. Inhibits IL-12 p40 (IL12B) and TNF-alpha expression by infected host (mouse) macrophages, reduces the nitric oxide response by about 75%. In mice previously exposed to the bacterium, elicits high level of IFN-gamma production by T-cells upon subsequent challenge by M.tuberculosis, in the first phase of a protective immune response. Higher levels (1.6-3.3 uM) of recombinant protein inhibit IFN-gamma production by host (human) T-cells and also IL-17 and TNF-alpha production but not IL-2; decreases expression of host ATF-2 and JUN transcription factors by affecting T-cell receptors signaling downstream of ZAP70, without cytotoxicity or apoptosis. EsxA inhibits IFN-gamma production in human T-cells by activating p38 MAPK (MAPK14), p38 MAPK is not responsible for IL-17 decrease. Binds host (mouse) Toll-like receptor 2 (TLR2) and decreases host MYD88-dependent signaling; binding to TLR2 activates host kinase AKT and subsequently inhibits downstream activation of NF-kappa-B; the C-terminal 20 residues (76-95) are necessary and sufficient for the TLR2 inhibitory effect. Required for induction of host (human) IL-1B maturation and release by activating the host NLRP3/ASC inflammasome; may also promote access of other tuberculosis proteins to the host cells cytoplasm. Induces IL-8 (CXCL8) expression in host (human) lung epithelial cells. Exogenously applied protein, or protein expressed in host (human and mouse), binds beta-2-microglobulin (B2M) and decreases its export to the cell surface, probably leading to defects in class I antigen presentation by the host cell. Responsible for mitochondrial fragmention, redistribution around the cell nucleus and decreased mitochondrial mass; this effect is not seen until 48 hours post-infection. Able to disrupt artificial planar bilayers in the absence of EsxB (CFP-10). Native protein binds artificial liposomes in the absence but not presence of EsxB and is able to rigidify and lyse them; the EsxA-EsxB complex dissociates at acidic pH, EsxB might serve as a chaperone to prevent membrane lysis. Recombinant protein induces leakage of phosphocholine liposomes at acidic pH in the absence of ExsB, undergoes conformational change, becoming more alpha-helical at acidic pH. The study using recombinant protein did not find dissociation of EsxA-EsxB complex at acidic pH. Involved in translocation of bacteria from the host (human) phagolysosome to the host cytoplasm. Translocation into host cytoplasm is visible 3 days post-infection using cultured human cells and precedes host cell death. Recombinant protein induces apoptosis in host (human) differentiated cell lines, which is cell-line dependent; bacteria missing the ESX-1 locus do not induce apoptosis. Host (human) cells treated with EsxA become permeable to extracellular dye. EsxA and EsxA-EsxB are cytotoxic to pneumocytes. ESX-1 secretion system-induced host (mouse) cell apoptosis, which is probably responsible for infection of new host cells, might be due to EsxA. EsxA induces necrosis in aged neutrophils. May help regulate assembly and function of the type VII secretion system (T7SS) (By similarity). EsxA disassembles pre-formed EccC-EsxB multimers, possibly by making EccC-EsxA-EsxB trimers instead of EccC-EsxB-EsxB-EccC tetramers (By similarity).
T50583	PDBSTRUC	3FAV; 1WA8
T50583	SEQUENCE	MTEQQWNFAGIEAAASAIQGNVTSIHSLLDEGKQSLTKLAAAWGGSGSEAYQGVQQKWDATATELNNALQNLARTISEAGQAMASTEGNVTGMFA

T26109	TARGETID	T26109
T26109	FORMERID	TTDR00004
T26109	UNIPROID	LIGD_MYCTU
T26109	TARGNAME	Mycobacterium Primase (MycB ligD)
T26109	GENENAME	MycB ligD
T26109	TARGTYPE	Literature-reported
T26109	SYNONYMS	NHEJ DNA repair protein D; NHEJ DNA polymerase; Multifunctional non-homologous end joining DNA repair protein LigD; Mt-Lig
T26109	FUNCTION	With Ku forms a non-homologous end joining (NHEJ) repair enzyme which repairs DNA double-strand breaks (DSB) with reduced fidelity. Recognizes, processes and reseals DSBs, including repairs on incompatible DSB which require 3'-resection, gap filling and ligation. Anneals the 3' overhanging strands from opposing breaks to form a gapped intermediate, which then can be extended in trans by using the termini as primers for extension of the annealed break. Binds to the recessed 5'-phosphate moiety of the downstream DNA strand forming a stable synaptic complex even when the 3'-protruding ends of the template DNA strands are not complementary. Has numerous activites; gap filling copies the template strand, and prefers a 5'-phosphate in the gap and rNTPS, DNA-directed DNA or RNA polymerase on 5'-overhangs, terminal transferase (extending ssDNA or blunt dsDNA in a non-templated fashion, preferentially with rNTPs), DNA-dependent RNA primase (synthesizes short RNAs on unprimed closed ssDNA) and 3'- to 5'-exonuclease on ssDNA. Isolated Pol domain (and presumably the holoenzyme) is able to form complexes between 2 noncompatible protruding 3'-ends DNA ends via microhomologous DNA strands, in a end-bridging function to which it adds a templated nucleotide. Minimal primer length is 2 nucleotides.
T26109	PDBSTRUC	4MKY; 3PKY; 2R9L; 2IRY; 2IRX
T26109	SEQUENCE	MGSASEQRVTLTNADKVLYPATGTTKSDIFDYYAGVAEVMLGHIAGRPATRKRWPNGVDQPAFFEKQLALSAPPWLSRATVAHRSGTTTYPIIDSATGLAWIAQQAALEVHVPQWRFVAEPGSGELNPGPATRLVFDLDPGEGVMMAQLAEVARAVRDLLADIGLVTFPVTSGSKGLHLYTPLDEPVSSRGATVLAKRVAQRLEQAMPALVTSTMTKSLRAGKVFVDWSQNSGSKTTIAPYSLRGRTHPTVAAPRTWAELDDPALRQLSYDEVLTRIARDGDLLERLDADAPVADRLTRYRRMRDASKTPEPIPTAKPVTGDGNTFVIQEHHARRPHYDFRLECDGVLVSWAVPKNLPDNTSVNHLAIHTEDHPLEYATFEGAIPSGEYGAGKVIIWDSGTYDTEKFHDDPHTGEVIVNLHGGRISGRYALIRTNGDRWLAHRLKNQKDQKVFEFDNLAPMLATHGTVAGLKASQWAFEGKWDGYRLLVEADHGAVRLRSRSGRDVTAEYPQLRALAEDLADHHVVLDGEAVVLDSSGVPSFSQMQNRGRDTRVEFWAFDLLYLDGRALLGTRYQDRRKLLETLANATSLTVPELLPGDGAQAFACSRKHGWEGVIAKRRDSRYQPGRRCASWVKDKHWNTQEVVIGGWRAGEGGRSSGVGSLLMGIPGPGGLQFAGRVGTGLSERELANLKEMLAPLHTDESPFDVPLPARDAKGITYVKPALVAEVRYSEWTPEGRLRQSSWRGLRPDKKPSEVVRE

T61765	TARGETID	T61765
T61765	FORMERID	TTDR01297
T61765	UNIPROID	GLGE_MYCTU
T61765	TARGNAME	Mycobacterium Alpha-glucan:maltose-phosphate maltosyltransferase (MycB glgE)
T61765	GENENAME	MycB glgE
T61765	TARGTYPE	Literature-reported
T61765	SYNONYMS	GMPMT; Alpha-1,4-glucan:maltose-1-phosphate maltosyltransferase; (1->4)-alpha-D-glucan:phosphate alpha-D-maltosyltransferase; (1->4)-alpha-D-glucan:maltose-1-phosphate alpha-D-maltosyltransferase
T61765	FUNCTION	Essential maltosyltransferase that uses maltose 1-phosphate (M1P) as the sugar donor to elongate linear or branched alpha-(1->4)-glucans. Maltooligosaccharides with a degree of polymerization (DP) superior or equal to 4 are efficient acceptors, with DP5 being optimal in the GlgE-catalyzed polymerization with M1P. Is specific for the alpha-anomer of M1P as substrate, since the beta-anomer of M1P gives no activity. Exhibits an alpha-retaining catalytic mechanism. Is also able to catalyze the reverse reaction in vitro, releasing M1P from glycogen in the presence of inorganic phosphate. Also catalyzes disproportionation reactions through maltosyl transfer between maltooligosaccharides. Is involved in a branched alpha-glucan biosynthetic pathway from trehalose, together with TreS, Mak and GlgB.
T61765	BIOCLASS	Glycosyl transferase
T61765	SEQUENCE	MSGRAIGTETEWWVPGRVEIDDVAPVVSCGVYPAKAVVGEVVPVSAAVWREGHEAVAATLVVRYLGVRYPHLTDRPRARVLPTPSEPQQRVKPLLIPMTSGQEPFVFHGQFTPDRVGLWTFRVDGWGDPIHTWRHGLIAKLDAGQGETELSNDLLVGAVLLERAATGVPRGLRDPLLAAAAALRTPGDPVTRTALALTPEIEELLADYPLRDLVTRGEQFGVWVDRPLARFGAWYEMFPRSTGGWDDDGNPVHGTFATAAAELPRIAGMGFDVVYLPPIHPIGKVHRKGRNNSPTAAPTDVGSPWAIGSDEGGHDTVHPSLGTIDDFDDFVSAARDLGMEVALDLALQCAPDHPWAREHRQWFTELPDGTIAYAENPPKKYQDIYPLNFDNDPEGLYDEVLRVVQHWVNHGVKFFRVDNPHTKPPNFWAWLIAQVKTVDPDVLFLSEAFTPPARQYGLAKLGFTQSYSYFTWRTTKWELTEFGNQIAELADYRRPNLFVNTPDILHAVLQHNGPGMFAIRAVLAATMSPAWGMYCGYELFEHRAVREGSEEYLDSEKYELRPRDFASALDQGRSLQPFITRLNIIRRLHPAFQQLRTIHFHHVDNDALLAYSKFDPATGDCVLVVVTLNAFGPEEATLWLDMAALGMEDYDRFWVRDEITGEEYQWGQANYIRIDPARAVAHIINMPAVPYESRNTLLRRR

T51032	TARGETID	T51032
T51032	FORMERID	TTDR01012
T51032	UNIPROID	PHAS_MYCTU
T51032	TARGNAME	Mycobacterium Polyketide synthase (MycB pks2)
T51032	GENENAME	MycB pks2
T51032	TARGTYPE	Literature-reported
T51032	SYNONYMS	Polyketide synthase pks2; Phthioceranic/hydroxyphthioceranic acid synthase
T51032	FUNCTION	Catalyzes the synthesis of the hepta- and octamethyl phthioceranic acids and/or hydroxyphthioceranic acids that are the major acyl constituents of sulfolipids.
T51032	ECNUMBER	EC 2.3.1.-
T51032	SEQUENCE	MGLGSAASGTGADRGAWTLAEPRVTPVAVIGMACRLPGGIDSPELLWKALLRGDDLITEVPPDRWDCDEFYDPQPGVPGRTVCKWGGFLDNPADFDCEFFGIGEREAIAIDPQQRLLLETSWEAMEHAGLTQQTLAGSATGVFAGVTHGDYTMVAADAKQLEEPYGYLGNSFSMASGRVAYAMRLHGPAITVDTACSSGLTAVHMACRSLHEGESDVALAGGVALMLEPRKAAAGSALGMLSPTGRCRAFDVAADGFVSGEGCAVVVLKRLPDALADGDRILAVIRGTSANQDGHTVNIATPSQPAQVAAYRAALAAGGVDAATVGMVEAHGPGTPIGDPIEYASVSEVYGVDGPCALASVKTNFGHTQSTAGVLGLIKVVLALKHGVVPRNLHFTRLPDEIAGITTNLFVPEVTTPWPTNGRQVPRRAAVSSYGFSGTNVHAVVEQAPQTEAQPHAASTPPTGTPALFTLSASSADALRQTAQRLTDWIQQHADSLVLSDLAYTLARRRTHRSVRTAVIASSVDELIAGLGEVADGDTVYQPAVGQDDRGPVWLFSGQGSQWAAMGADLLTNESVFAATVAELEPLIAAESGFSVTEAMTAPETVTGIDRVQPTIFAMQVALAATMAAYGVRPGAVIGHSMGESAAAVVAGVLSAEDGVRVICRRSKLMATIAGSAAMASVELPALAVQSELTALGIDDVVVAVVTAPQSTVIAGGTESVRKLVDIWERRDVLARAVAVDVASHSPQVDPILDELIAALADLNPKAPEIPYYSATLFDPREAPACDARYWADNLRHTVRFSAAVRSALDDGYRVFAELSPHPLLTHAVDQIAGSVGMPVAALAGMRREQPLPLGLRRLLTDLHNAGAAVDFSVLCPQGRLVDAPLPAWSHRFLFYDREGVDNRSPGGSTVAVHPLLGAHVRLPEEPERHAWQADVGTATLPWLGDHRIHNVAALPGAAYCEMALSAARAVLGEQSEVRDMRFEAMLLLDDQTPVSTVATVTSPGVVDFAVEALQEGVGHHLRRASAVLQQVSGECEPPAYDMASLLEAHPCRVDGEDLRRQFDKHGVQYGPAFTGLAVAYVAEDATATMLAEVALPGSIRSQQGLYAIHPALLDACFQSVGAHPDSQSVGSGLLVPLGVRRVRAYAPVRTARYCYTRVTKVELVGVEADIDVLDAHGTVLLAVCGLRIGTGVSERDKHNRVLNERLLTIEWHQRELPEMDPSGAGKWLLISDCAASDVTATRLADAFREHSAACTTMRWPLHDDQLAAADQLRDQVGSDEFSGVVVLTGSNTGTPHQGSADRGAEYVRRLVGIARELSDLPGAVPRMYVVTRGAQRVLADDCVNLEQGGLRGLLRTIGAEHPHLRATQIDVDEQTGVEQLARQLLATSEEDETAWRDNEWYVARLCPTPLRPQERRTIVADHQQSGMRLQIRTPGDMQTIELAAFHRVPPGPGQIEVAVRASSVNFADVLIAFGRYPSFEGHLPQLGTDFAGVVTAVGPGVTDHKVGDHVGGMSPNGCWGTFVTCDARLAATLPPGLGDAQAAAVTTAHATAWYGLHELARIRAGDTVLIHSGTGGVGQAAIAIARAAGAEIFATAGTPQRRELLRNMGIEHVYDSRSIEFAEQIRRDTNGRGVDVVLNSVTGAAQLAGLKLLAFRGRFVEIGKRDIYGDTKLGLFPFRRNLSFYAVDLGLLSATHPEELRDLLGTVYRLTAAGELPMPQSTHYPLVEAATAIRVMGNAEHTGKLVLHIPQTGKSLVTLPPEQAQVFRPDGSYIITGGLGGLGLFLAEKMAAAGCGRIVLNSRTQPTQKMRETIEAIAAMGSEVVVECGDIAQPGTAERLVATAVATGLPVRGVLHAAAVVEDATLANITDELLARDWAPKVHGAWELHEATSGQPLDWFCLFSSAAALTGSPGQSAYSAANSWLDAFAHWRQAQGLPATAIAWGAWSDIGQLGWWSASPARASALEESNYTAITPDEGAYAFEALLRHNRVYTGYAPVIGAPWLVAFAERSRFFEVFSSSNGSGTSKFRVELNELPRDEWPARLRQLVAEQVSLILRRTVDPDRPLPEYGLDSLGALELRTRIETETGIRLAPKNVSATVRGLADHLYEQLAPDDAPAAALSSQ

T43711	TARGETID	T43711
T43711	FORMERID	TTDI01725
T43711	UNIPROID	RUNX1_HUMAN
T43711	TARGNAME	Runt-related transcription factor 1 (RUNX1)
T43711	GENENAME	RUNX1
T43711	TARGTYPE	Literature-reported
T43711	SYNONYMS	SL3/AKV core-binding factor alpha B subunit; SL3-3 enhancer factor 1 alpha B subunit; Polyomavirus enhancer-binding protein 2 alpha B subunit; PEBP2-alpha B; PEA2-alpha B; Oncogene AML-1; Core-binding factor subunit alpha-2; CBFA2; CBF-alpha-2; Acute myeloid leukemia 1 protein; AML1
T43711	FUNCTION	Forms the heterodimeric complex core-binding factor (CBF) with CBFB. RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. The heterodimers bind to the core site of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL3 and GM-CSF promoters (Probable). Essential for the development of normal hematopoiesis. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the BLK promoter. Inhibits KAT6B-dependent transcriptional activation (By similarity). Involved in lineage commitment of immature T cell precursors. CBF complexes repress ZBTB7B transcription factor during cytotoxic (CD8+) T cell development. They bind to RUNX-binding sequence within the ZBTB7B locus acting as transcriptional silencer and allowing for cytotoxic T cell differentiation. CBF complexes binding to the transcriptional silencer is essential for recruitment of nuclear protein complexes that catalyze epigenetic modifications to establish epigenetic ZBTB7B silencing (By similarity). Controls the anergy and suppressive function of regulatory T-cells (Treg) by associating with FOXP3. Activates the expression of IL2 and IFNG and down-regulates the expression of TNFRSF18, IL2RA and CTLA4, in conventional T-cells. Positively regulates the expression of RORC in T-helper 17 cells (By similarity).
T43711	PDBSTRUC	1LJM; 1H9D; 1CO1; 1CMO; 1.00E+50
T43711	SEQUENCE	MRIPVDASTSRRFTPPSTALSPGKMSEALPLGAPDAGAALAGKLRSGDRSMVEVLADHPGELVRTDSPNFLCSVLPTHWRCNKTLPIAFKVVALGDVPDGTLVTVMAGNDENYSAELRNATAAMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPPQVATYHRAIKITVDGPREPRRHRQKLDDQTKPGSLSFSERLSELEQLRRTAMRVSPHHPAPTPNPRASLNHSTAFNPQPQSQMQDTRQIQPSPPWSYDQSYQYLGSIASPSVHPATPISPGRASGMTTLSAELSSRLSTAPDLTAFSDPRQFPALPSISDPRMHYPGAFTYSPTPVTSGIGIGMSAMGSATRYHTYLPPPYPGSSQAQGGPFQASSPSYHLYYGASAGSYQFSMVGGERSPPRILPPCTNASTGSALLNPSLPNQSDVVEAEGSHSNSPTNMAPSARLEEAVWRPY

T93292	TARGETID	T93292
T93292	FORMERID	TTDI00217
T93292	UNIPROID	TAGL_HUMAN
T93292	TARGNAME	Transgelin (TAGLN)
T93292	GENENAME	TAGLN
T93292	TARGTYPE	Literature-reported
T93292	SYNONYMS	TAGLN; Smooth muscle protein 22-alpha; SM22-alpha; Protein WS3-10; 22 kDa actin-binding protein
T93292	FUNCTION	Actin cross-linking/gelling protein. Involved in calcium interactions and contractile properties of the cell that may contribute to replicative senescence.
T93292	BIOCLASS	Calponin family
T93292	SEQUENCE	MANKGPSYGMSREVQSKIEKKYDEELEERLVEWIIVQCGPDVGRPDRGRLGFQVWLKNGVILSKLVNSLYPDGSKPVKVPENPPSMVFKQMEQVAQFLKAAEDYGVIKTDMFQTVDLFEGKDMAAVQRTLMALGSLAVTKNDGHYRGDPNWFMKKAQEHKREFTESQLQEGKHVIGLQMGSNRGASQAGMTGYGRPRQIIS

T68877	TARGETID	T68877
T68877	FORMERID	TTDR00810
T68877	UNIPROID	ID2_HUMAN
T68877	TARGNAME	DNA-binding protein inhibitor ID-2 (ID2)
T68877	GENENAME	ID2
T68877	TARGTYPE	Literature-reported
T68877	SYNONYMS	bHLHb26; Inhibitor of differentiation 2; Inhibitor of DNA binding 2; Id2; Class B basic helix-loop-helix protein 26
T68877	FUNCTION	Implicated in regulating a variety of cellular processes, including cellular growth, senescence, differentiation, apoptosis, angiogenesis, and neoplastic transformation. Inhibits skeletal muscle and cardiac myocyte differentiation. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer. Restricts the CLOCK and ARNTL/BMAL1 localization to the cytoplasm. Plays a role in both the input and output pathways of the circadian clock: in the input component, is involved in modulating the magnitude of photic entrainment and in the output component, contributes to the regulation of a variety of liver clock-controlled genes involved in lipid metabolism. Transcriptional regulator (lacking a basic DNA binding domain) which negatively regulates the basic helix-loop-helix (bHLH) transcription factors by forming heterodimers and inhibiting their DNA binding and transcriptional activity.
T68877	PDBSTRUC	4AYA
T68877	SEQUENCE	MKAFSPVRSVRKNSLSDHSLGISRSKTPVDDPMSLLYNMNDCYSKLKELVPSIPQNKKVSKMEILQHVIDYILDLQIALDSHPTIVSLHHQRPGQNQASRTPLTTLNTDISILSLQASEFPSELMSNDSKALCG

T29818	TARGETID	T29818
T29818	FORMERID	TTDR00464
T29818	UNIPROID	PAX5_HUMAN
T29818	TARGNAME	Paired box protein Pax-5 (PAX5)
T29818	GENENAME	PAX5
T29818	TARGTYPE	Literature-reported
T29818	SYNONYMS	PAX5; BSAP; B-cell specific transcription factor
T29818	FUNCTION	May play an important role in b-cell differentiation as well as neural development and spermatogenesis. Involved in the regulation of the cd19 gene, a b-lymphoid-specific target gene.
T29818	PDBSTRUC	1MDM; 1K78
T29818	SEQUENCE	MDLEKNYPTPRTSRTGHGGVNQLGGVFVNGRPLPDVVRQRIVELAHQGVRPCDISRQLRVSHGCVSKILGRYYETGSIKPGVIGGSKPKVATPKVVEKIAEYKRQNPTMFAWEIRDRLLAERVCDNDTVPSVSSINRIIRTKVQQPPNQPVPASSHSIVSTGSVTQVSSVSTDSAGSSYSISGILGITSPSADTNKRKRDEGIQESPVPNGHSLPGRDFLRKQMRGDLFTQQQLEVLDRVFERQHYSDIFTTTEPIKPEQTTEYSAMASLAGGLDDMKANLASPTPADIGSSVPGPQSYPIVTGRDLASTTLPGYPPHVPPAGQGSYSAPTLTGMVPGSEFSGSPYSHPQYSSYNDSWRFPNPGLLGSPYYYSAAARGAAPPAAATAYDRH

T93945	TARGETID	T93945
T93945	FORMERID	TTDI02602
T93945	UNIPROID	CAV1_HUMAN
T93945	TARGNAME	Caveolin 1 (CAV1)
T93945	GENENAME	CAV1
T93945	TARGTYPE	Literature-reported
T93945	SYNONYMS	Caveolin1; Caveolin-1; Cav-1
T93945	FUNCTION	Forms a stable heterooligomeric complex with CAV2 that targets to lipid rafts and drives caveolae formation. Mediates the recruitment of CAVIN proteins (CAVIN1/2/3/4) to the caveolae. Interacts directly with G-protein alpha subunits and can functionally regulate their activity. Involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Its binding to DPP4 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Recruits CTNNB1 to caveolar membranes and may regulate CTNNB1-mediated signaling through the Wnt pathway. Negatively regulates TGFB1-mediated activation of SMAD2/3 by mediating the internalization of TGFBR1 from membrane rafts leading to its subsequent degradation. May act as a scaffolding protein within caveolar membranes.
T93945	BIOCLASS	Caveolin protein
T93945	SEQUENCE	MSGGKYVDSEGHLYTVPIREQGNIYKPNNKAMADELSEKQVYDAHTKEIDLVNRDPKHLNDDVVKIDFEDVIAEPEGTHSFDGIWKASFTTFTVTKYWFYRLLSALFGIPMALIWGIYFAILSFLHIWAVVPCIKSFLIEIQCISRVYSIYVHTVCDPLFEAVGKIFSNVRINLQKEI

T36147	TARGETID	T36147
T36147	FORMERID	TTDI01383
T36147	UNIPROID	UPAR_HUMAN
T36147	TARGNAME	Urokinase plasminogen receptor (PLAUR)
T36147	GENENAME	PLAUR
T36147	TARGTYPE	Literature-reported
T36147	SYNONYMS	UPAR; U-PAR; Monocyte activation antigen Mo3; MO3
T36147	FUNCTION	Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form.
T36147	PDBSTRUC	4QTI; 4K24; 3U74; 3U73; 3BT2
T36147	SEQUENCE	MGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEELELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISCGSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNGFHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGPMNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDVQYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT

T22945	TARGETID	T22945
T22945	FORMERID	TTDI01517
T22945	UNIPROID	TAP1_HUMAN
T22945	TARGNAME	Antigen peptide transporter 1 (TAP1)
T22945	GENENAME	TAP1
T22945	TARGTYPE	Literature-reported
T22945	SYNONYMS	Y3; Really interesting new gene 4 protein; RING4; Peptide transporter involved in antigen processing 1; Peptide transporter TAP1; Peptide transporter PSF1; Peptide supply factor 1; PSF1; PSF-1; ATP-binding cassette sub-family B member 2; ABCB2
T22945	FUNCTION	Involved in the transport of antigens from the cytoplasm to the endoplasmic reticulum for association with MHC class I molecules. Also acts as a molecular scaffold for the final stage of MHC class I folding, namely the binding of peptide. Nascent MHC class I molecules associate with TAP via tapasin. Inhibited by the covalent attachment of herpes simplex virus ICP47 protein, which blocks the peptide-binding site of TAP. Inhibited by human cytomegalovirus US6 glycoprotein, which binds to the lumenal side of the TAP complex and inhibits peptide translocation by specifically blocking ATP-binding to TAP1 and prevents the conformational rearrangement of TAP induced by peptide binding. Inhibited by human adenovirus E3-19K glycoprotein, which binds the TAP complex and acts as a tapasin inhibitor, preventing MHC class I/TAP association. Expression of TAP1 is down-regulated by human Epstein-Barr virus vIL-10 protein, thereby affecting the transport of peptides into the endoplasmic reticulum and subsequent peptide loading by MHC class I molecules.
T22945	PDBSTRUC	5U1D; 1JJ7
T22945	SEQUENCE	MAELLASAGSACSWDFPRAPPSFPPPAASRGGLGGTRSFRPHRGAESPRPGRDRDGVRVPMASSRCPAPRGCRCLPGASLAWLGTVLLLLADWVLLRTALPRIFSLLVPTALPLLRVWAVGLSRWAVLWLGACGVLRATVGSKSENAGAQGWLAALKPLAAALGLALPGLALFRELISWGAPGSADSTRLLHWGSHPTAFVVSYAAALPAAALWHKLGSLWVPGGQGGSGNPVRRLLGCLGSETRRLSLFLVLVVLSSLGEMAIPFFTGRLTDWILQDGSADTFTRNLTLMSILTIASAVLEFVGDGIYNNTMGHVHSHLQGEVFGAVLRQETEFFQQNQTGNIMSRVTEDTSTLSDSLSENLSLFLWYLVRGLCLLGIMLWGSVSLTMVTLITLPLLFLLPKKVGKWYQLLEVQVRESLAKSSQVAIEALSAMPTVRSFANEEGEAQKFREKLQEIKTLNQKEAVAYAVNSWTTSISGMLLKVGILYIGGQLVTSGAVSSGNLVTFVLYQMQFTQAVEVLLSIYPRVQKAVGSSEKIFEYLDRTPRCPPSGLLTPLHLEGLVQFQDVSFAYPNRPDVLVLQGLTFTLRPGEVTALVGPNGSGKSTVAALLQNLYQPTGGQLLLDGKPLPQYEHRYLHRQVAAVGQEPQVFGRSLQENIAYGLTQKPTMEEITAAAVKSGAHSFISGLPQGYDTEVDEAGSQLSGGQRQAVALARALIRKPCVLILDDATSALDANSQLQVEQLLYESPERYSRSVLLITQHLSLVEQADHILFLEGGAIREGGTHQQLMEKKGCYWAMVQAPADAPE

T07591	TARGETID	T07591
T07591	FORMERID	TTDNR00699
T07591	UNIPROID	K1C17_HUMAN
T07591	TARGNAME	Keratin type I cytoskeletal 17 (KRT17)
T07591	GENENAME	KRT17
T07591	TARGTYPE	Literature-reported
T07591	SYNONYMS	Keratin-17; KRT17; K17; Cytokeratin-17; CK-17
T07591	FUNCTION	May play a role in the formation and maintenance of various skin appendages, specifically in determining shape and orientation of hair. May be a marker of basal cell differentiation in complex epithelia and therefore indicative of a certain type of epithelial stem cells". May act as an autoantigen in the immunopathogenesis of psoriasis with certain peptide regions being a major target for autoreactive T-cells and hence causing their proliferation. Required for the correct growth of hair follicles in particular for the persistence of the anagen (growth) state. Modulates the function of TNF-alpha in the specific context of hair cycling. Regulates protein synthesis and epithelial cell growth through binding to the adapter protein SFN and by stimulating Akt/mTOR pathway. Involved in tissue repair.
T07591	BIOCLASS	Intermediate filament family
T07591	SEQUENCE	MTTSIRQFTSSSSIKGSSGLGGGSSRTSCRLSGGLGAGSCRLGSAGGLGSTLGGSSYSSCYSFGSGGGYGSSFGGVDGLLAGGEKATMQNLNDRLASYLDKVRALEEANTELEVKIRDWYQRQAPGPARDYSQYYRTIEELQNKILTATVDNANILLQIDNARLAADDFRTKFETEQALRLSVEADINGLRRVLDELTLARADLEMQIENLKEELAYLKKNHEEEMNALRGQVGGEINVEMDAAPGVDLSRILNEMRDQYEKMAEKNRKDAEDWFFSKTEELNREVATNSELVQSGKSEISELRRTMQALEIELQSQLSMKASLEGNLAETENRYCVQLSQIQGLIGSVEEQLAQLRCEMEQQNQEYKILLDVKTRLEQEIATYRRLLEGEDAHLTQYKKEPVTTRQVRTIVEEVQDGKVISSREQVHQTTR

T52886	TARGETID	T52886
T52886	FORMERID	TTDI02566
T52886	UNIPROID	1433F_HUMAN
T52886	TARGNAME	AS1 14-3-3 protein eta (YWHAH)
T52886	GENENAME	YWHAH
T52886	TARGTYPE	Literature-reported
T52886	SYNONYMS	YWHA1; Protein AS1; 14-3-3 protein eta
T52886	FUNCTION	Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. Negatively regulates the kinase activity of PDPK1. Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways.
T52886	PDBSTRUC	2C74; 2C63
T52886	SEQUENCE	MGDREQLLQRARLAEQAERYDDMASAMKAVTELNEPLSNEDRNLLSVAYKNVVGARRSSWRVISSIEQKTMADGNEKKLEKVKAYREKIEKELETVCNDVLSLLDKFLIKNCNDFQYESKVFYLKMKGDYYRYLAEVASGEKKNSVVEASEAAYKEAFEISKEQMQPTHPIRLGLALNFSVFYYEIQNAPEQACLLAKQAFDDAIAELDTLNEDSYKDSTLIMQLLRDNLTLWTSDQQDEEAGEGN

T50072	TARGETID	T50072
T50072	FORMERID	TTDI00100
T50072	UNIPROID	PLP2_HUMAN
T50072	TARGNAME	Proteolipid protein 2 (PLP2)
T50072	GENENAME	PLP2
T50072	TARGTYPE	Literature-reported
T50072	SYNONYMS	PLP2; Intestinal membrane A4 protein; Differentiation-dependent protein A4
T50072	FUNCTION	May play a role in cell differentiation in the intestinal epithelium.
T50072	BIOCLASS	Plasmolipin family
T50072	SEQUENCE	MADSERLSAPGCWAACTNFSRTRKGILLFAEIILCLVILICFSASTPGYSSLSVIEMILAAIFFVVYMCDLHTKIPFINWPWSDFFRTLIAAILYLITSIVVLVERGNHSKIVAGVLGLIATCLFGYDAYVTFPVRQPRHTAAPTDPADGPV

T04827	TARGETID	T04827
T04827	FORMERID	TTDNR00741
T04827	UNIPROID	SUH_HUMAN
T04827	TARGNAME	Recombining binding protein suppressor of hairless (RBPJ)
T04827	GENENAME	RBPJ
T04827	TARGTYPE	Literature-reported
T04827	SYNONYMS	Renal carcinoma antigen NY-REN-30; RBPSUH; RBPJK; RBP-JK; RBP-J kappa; RBP-J; J kappa-recombination signal-binding protein; IGKJRB1; IGKJRB; CBF-1
T04827	FUNCTION	Acts as a transcriptional repressor when it is not associated with Notch proteins. When associated with some NICD product of Notch proteins (Notch intracellular domain), it acts as a transcriptional activator that activates transcription of Notch target genes. Probably represses or activates transcription via the recruitment of chromatin remodeling complexes containing histone deacetylase or histone acetylase proteins, respectively. Specifically binds to the immunoglobulin kappa-type J segment recombination signal sequence. Binds specifically to methylated DNA. Binds to the oxygen responsive element of COX4I2 and activates its transcription under hypoxia conditions (4% oxygen). Negatively regulates the phagocyte oxidative burst in response to bacterial infection by repressing transcription of NADPH oxidase subunits. Transcriptional regulator that plays a central role in Notch signaling, a signaling pathway involved in cell-cell communication that regulates a broad spectrum of cell-fate determinations.
T04827	PDBSTRUC	3V79; 3NBN; 2F8X
T04827	SEQUENCE	MDHTEGSPAEEPPAHAPSPGKFGERPPPKRLTREAMRNYLKERGDQTVLILHAKVAQKSYGNEKRFFCPPPCVYLMGSGWKKKKEQMERDGCSEQESQPCAFIGIGNSDQEMQQLNLEGKNYCTAKTLYISDSDKRKHFMLSVKMFYGNSDDIGVFLSKRIKVISKPSKKKQSLKNADLCIASGTKVALFNRLRSQTVSTRYLHVEGGNFHASSQQWGAFFIHLLDDDESEGEEFTVRDGYIHYGQTVKLVCSVTGMALPRLIIRKVDKQTALLDADDPVSQLHKCAFYLKDTERMYLCLSQERIIQFQATPCPKEPNKEMINDGASWTIISTDKAEYTFYEGMGPVLAPVTPVPVVESLQLNGGGDVAMLELTGQNFTPNLRVWFGDVEAETMYRCGESMLCVVPDISAFREGWRWVRQPVQVPVTLVRNDGIIYSTSLTFTYTPEPGPRPHCSAAGAILRANSSQVPPNESNTNSEGSYTNASTNSTSVTSSTATVVS

T69192	TARGETID	T69192
T69192	FORMERID	TTDR01306
T69192	UNIPROID	C1QBP_HUMAN
T69192	TARGNAME	ASF/SF2-associated protein p32 (C1QBP)
T69192	GENENAME	C1QBP
T69192	TARGTYPE	Literature-reported
T69192	SYNONYMS	p33; gC1q-R protein; SF2P32; SF2AP32; Mitochondrial matrix protein p32; Hyaluronan-binding protein 1; HABP1; Glycoprotein gC1qBP; GC1QBP; Complement component 1 Q subcomponent-binding protein, mitochondrial; C1qBP
T69192	FUNCTION	Is believed to be a multifunctional and multicompartmental protein involved in inflammation and infection processes, ribosome biogenesis, protein synthesis in mitochondria, regulation of apoptosis, transcriptional regulation and pre-mRNA splicing. At the cell surface is thought to act as an endothelial receptor for plasma proteins of the complement and kallikrein-kinin cascades. Putative receptor for C1q; specifically binds to the globular "heads" of C1q thus inhibiting C1; may perform the receptor function through a complex with C1qR/CD93. In complex with cytokeratin-1/KRT1 is a high affinity receptor for kininogen-1/HMWK. Can also bind other plasma proteins, such as coagulation factor XII leading to its autoactivation. May function to bind initially fluid kininogen-1 to the cell membrane. The secreted form may enhance both extrinsic and intrinsic coagulation pathways. It is postulated that the cell surface form requires docking with transmembrane proteins for downstream signaling which might be specific for a cell-type or response. By acting as C1q receptor is involved in chemotaxis of immature dendritic cells and neutrophils and is proposed to signal through CD209/DC-SIGN on immature dendritic cells, through integrin alpha-4/beta-1 during trophoblast invasion of the decidua, and through integrin beta-1 during endothelial cell adhesion and spreading. Signaling involved in inhibition of innate immune response is implicating the PI3K-AKT/PKB pathway. Required for protein synthesis in mitochondria. In mitochondrial translation may be involved in formation of functional 55S mitoribosomes; the function seems to involve its RNA-binding activity. May be involved in the nucleolar ribosome maturation process; the function may involve the exchange of FBL for RRP1 in the association with pre-ribosome particles. Involved in regulation of RNA splicing by inhibiting the RNA-binding capacity of SRSF1 and its phosphorylation. Is required for the nuclear translocation of splicing factor U2AF1L4. Involved in regulation of CDKN2A- and HRK-mediated apoptosis. Stabilizes mitochondrial CDKN2A isoform smARF. May be involved in regulation of FOXC1 transcriptional activity and NFY/CCAAT-binding factor complex-mediated transcription. May play a role in antibacterial defense as it can bind to cell surface hyaluronan and inhibit Streptococcus pneumoniae hyaluronate lyase. May be involved in modulation of the immune response; ligation by HCV core protein is resulting in suppression of interleukin-12 production in monocyte-derived dendritic cells. Involved in regulation of antiviral response by inhibiting DDX58- and IFIH1-mediated signaling pathways probably involving its association with MAVS after viral infection.
T69192	PDBSTRUC	3RPX; 1P32
T69192	SEQUENCE	MLPLLRCVPRVLGSSVAGLRAAAPASPFRQLLQPAPRLCTRPFGLLSVRAGSERRPGLLRPRGPCACGCGCGSLHTDGDKAFVDFLSDEIKEERKIQKHKTLPKMSGGWELELNGTEAKLVRKVAGEKITVTFNINNSIPPTFDGEEEPSQGQKVEEQEPELTSTPNFVVEVIKNDDGKKALVLDCHYPEDEVGQEDEAESDIFSIREVSFQSTGESEWKDTNYTLNTDSLDWALYDHLMDFLADRGVDNTFADELVELSTALEHQEYITFLEDLKSFVKSQ

T48780	TARGETID	T48780
T48780	FORMERID	TTDI02536
T48780	UNIPROID	CD69_HUMAN
T48780	TARGNAME	Early activation antigen CD69 (CD69)
T48780	GENENAME	CD69
T48780	TARGTYPE	Literature-reported
T48780	SYNONYMS	MLR3; Leukocyte surface antigen Leu23; GP32/28; Early Tcell activation antigen p60; EA1; Ctype lectin domain family 2 member C; CD69; BLAC/P26; Activation inducer molecule
T48780	FUNCTION	Involved in lymphocyte proliferation and functions as a signal transmitting receptor in lymphocytes, natural killer (NK) cells, and platelets.
T48780	PDBSTRUC	3HUP; 3CCK; 1FM5; 1E8I; 1.00E+87
T48780	SEQUENCE	MSSENCFVAENSSLHPESGQENDATSPHFSTRHEGSFQVPVLCAVMNVVFITILIIALIALSVGQYNCPGQYTFSMPSDSHVSSCSEDWVGYQRKCYFISTVKRSWTSAQNACSEHGATLAVIDSEKDMNFLKRYAGREEHWVGLKKEPGHPWKWSNGKEFNNWFNVTGSDKCVFLKNTEVSSMECEKNLYWICNKPYK

T44658	TARGETID	T44658
T44658	FORMERID	TTDR01281
T44658	UNIPROID	TISB_HUMAN
T44658	TARGNAME	CCCH tandem zinc finger protein ZFP36L1 (ERF-1)
T44658	GENENAME	ZFP36L1
T44658	TARGTYPE	Literature-reported
T44658	SYNONYMS	mRNA decay activator protein ZFP36L1; Zinc finger protein 36, C3H1 type-like 1; ZFP36-like 1; TPA-induced sequence 11b; ERF-1; EGF-response factor 1; Butyrate response factor 1; BERG36
T44658	FUNCTION	Zinc-finger RNA-binding protein that destabilizes several cytoplasmic AU-rich element (ARE)-containing mRNA transcripts by promoting their poly(A) tail removal or deadenylation, and hence provide a mechanism for attenuating protein synthesis. Acts as a 3'-untranslated region (UTR) ARE mRNA-binding adapter protein to communicate signaling events to the mRNA decay machinery. Functions by recruiting the CCR4-NOT deadenylase complex and components of the cytoplasmic RNA decay machinery to the bound ARE-containing mRNAs, and hence promotes ARE-mediated mRNA deadenylation and decay processes. Induces also the degradation of ARE-containing mRNAs even in absence of poly(A) tail (By similarity). Binds to 3'-UTR ARE of numerous mRNAs. Positively regulates early adipogenesis by promoting ARE-mediated mRNA decay of immediate early genes (IEGs) (By similarity). Promotes ARE-mediated mRNA decay of mineralocorticoid receptor NR3C2 mRNA in response to hypertonic stress. Negatively regulates hematopoietic/erythroid cell differentiation by promoting ARE-mediated mRNA decay of the transcription factor STAT5B mRNA. Positively regulates monocyte/macrophage cell differentiation by promoting ARE-mediated mRNA decay of the cyclin-dependent kinase CDK6 mRNA. Promotes degradation of ARE-containing pluripotency-associated mRNAs in embryonic stem cells (ESCs), such as NANOG, through a fibroblast growth factor (FGF)-induced MAPK-dependent signaling pathway, and hence attenuates ESC self-renewal and positively regulates mesendoderm differentiation (By similarity). May play a role in mediating pro-apoptotic effects in malignant B-cells by promoting ARE-mediated mRNA decay of BCL2 mRNA. In association with ZFP36L2 maintains quiescence on developing B lymphocytes by promoting ARE-mediated decay of several mRNAs encoding cell cycle regulators that help B cells progress through the cell cycle, and hence ensuring accurate variable-diversity-joining (VDJ) recombination and functional immune cell formation (By similarity). Together with ZFP36L2 is also necessary for thymocyte development and prevention of T-cell acute lymphoblastic leukemia (T-ALL) transformation by promoting ARE-mediated mRNA decay of the oncogenic transcription factor NOTCH1 mRNA (By similarity). Participates in the delivery of target ARE-mRNAs to processing bodies (PBs). In addition to its cytosolic mRNA-decay function, plays a role in the regulation of nuclear mRNA 3'-end processing; modulates mRNA 3'-end maturation efficiency of the DLL4 mRNA through binding with an ARE embedded in a weak noncanonical polyadenylation (poly(A)) signal in endothelial cells. Also involved in the regulation of stress granule (SG) and P-body (PB) formation and fusion. Plays a role in vasculogenesis and endocardial development (By similarity). Plays a role in the regulation of keratinocyte proliferation, differentiation and apoptosis. Plays a role in myoblast cell differentiation (By similarity).
T44658	PDBSTRUC	1W0W; 1W0V
T44658	SEQUENCE	MTTTLVSATIFDLSEVLCKGNKMLNYSAPSAGGCLLDRKAVGTPAGGGFPRRHSVTLPSSKFHQNQLLSSLKGEPAPALSSRDSRFRDRSFSEGGERLLPTQKQPGGGQVNSSRYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEERRALAGARDLSADRPRLQHSFSFAGFPSAAATAAATGLLDSPTSITPPPILSADDLLGSPTLPDGTNNPFAFSSQELASLFAPSMGLPGGGSPTTFLFRPMSESPHMFDSPPSPQDSLSDQEGYLSSSSSSHSGSDSPTLDNSRRLPIFSRLSISDD

T80395	TARGETID	T80395
T80395	FORMERID	TTDI00045
T80395	UNIPROID	KHDR1_HUMAN
T80395	TARGNAME	GAP-associated tyrosine phosphoprotein p62 (KHDRBS1)
T80395	GENENAME	KHDRBS1
T80395	TARGTYPE	Literature-reported
T80395	SYNONYMS	p68; p21 Ras GTPaseactivating proteinassociated p62; p21 Ras GTPase-activating protein-associated p62; Srcassociated in mitosis 68 kDa protein; Src-associated in mitosis 68 kDa protein; Sam68; KH domaincontaining, RNAbinding, signal transductionassociated protein 1; KH domain-containing, RNA-binding, signal transduction-associated protein 1; GAPassociated tyrosine phosphoprotein p62
T80395	FUNCTION	Once phosphorylated, functions as an adapter protein in signal transduction cascades by binding to SH2 and SH3 domain-containing proteins. Role in G2-M progression in the cell cycle. Represses CBP-dependent transcriptional activation apparently by competing with other nuclear factors for binding to CBP. Also acts as a putative regulator of mRNA stability and/or translation rates and mediates mRNA nuclear export. Positively regulates the association of constitutive transport element (CTE)-containing mRNA with large polyribosomes and translation initiation. According to some authors, is not involved in the nucleocytoplasmic export of unspliced (CTE)-containing RNA species according to. RNA-binding protein that plays a role in the regulation of alternative splicing and influences mRNA splice site selection and exon inclusion. Binds to RNA containing 5'-[AU]UAA-3' as a bipartite motif spaced by more than 15 nucleotides. Binds poly(A). Can regulate CD44 alternative splicing in a Ras pathway-dependent manner. In cooperation with HNRNPA1 modulates alternative splicing of BCL2L1 by promoting splicing toward isoform Bcl-X(S), and of SMN1. Can regulate alternative splicing of NRXN1 and NRXN3 in the laminin G-like domain 6 containing the evolutionary conserved neurexin alternative spliced segment 4 (AS4) involved in neurexin selective targeting to postsynaptic partners. In a neuronal activity-dependent manner cooperates synergistically with KHDRBS2/SLIM-1 in regulation of NRXN1 exon skipping at AS4. The cooperation with KHDRBS2/SLIM-1 is antagonistic for regulation of NXRN3 alternative splicing at AS4. Recruited and tyrosine phosphorylated by several receptor systems, for example the T-cell, leptin and insulin receptors.
T80395	PDBSTRUC	3QHE; 2XA6
T80395	SEQUENCE	MQRRDDPAARMSRSSGRSGSMDPSGAHPSVRQTPSRQPPLPHRSRGGGGGSRGGARASPATQPPPLLPPSATGPDATVGGPAPTPLLPPSATASVKMEPENKYLPELMAEKDSLDPSFTHAMQLLTAEIEKIQKGDSKKDDEENYLDLFSHKNMKLKERVLIPVKQYPKFNFVGKILGPQGNTIKRLQEETGAKISVLGKGSMRDKAKEEELRKGGDPKYAHLNMDLHVFIEVFGPPCEAYALMAHAMEEVKKFLVPDMMDDICQEQFLELSYLNGVPEPSRGRGVPVRGRGAAPPPPPVPRGRGVGPPRGALVRGTPVRGAITRGATVTRGVPPPPTVRGAPAPRARTAGIQRIPLPPPPAPETYEEYGYDDTYAEQSYEGYEGYYSQSQGDSEYYDYGHGEVQDSYEAYGQDDWNGTRPSLKAPPARPVKGAYREHPYGRY

T13510	TARGETID	T13510
T13510	FORMERID	TTDR00383
T13510	UNIPROID	LRP1_HUMAN
T13510	TARGNAME	Apolipoprotein E receptor (LRP1)
T13510	GENENAME	LRP1
T13510	TARGTYPE	Literature-reported
T13510	SYNONYMS	Prolow-density lipoprotein receptor-related protein 1; LRP-1; CD91; APR; APOER
T13510	FUNCTION	Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells. Required for early embryonic development. Involved in cellular lipid homeostasis. Involved in the plasma clearance of chylomicron remnants and activated LRPAP1 (alpha 2-macroglobulin), as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. May modulate cellular events, such as APP metabolism, kinase-dependent intracellular signaling, neuronal calcium signaling as well as neurotransmission. Acts as an alpha-2-macroglobulin receptor.
T13510	PDBSTRUC	2KNY; 2KNX; 2FYL; 2FYJ; 1J8E
T13510	SEQUENCE	MLTPPLLLLLPLLSALVAAAIDAPKTCSPKQFACRDQITCISKGWRCDGERDCPDGSDEAPEICPQSKAQRCQPNEHNCLGTELCVPMSRLCNGVQDCMDGSDEGPHCRELQGNCSRLGCQHHCVPTLDGPTCYCNSSFQLQADGKTCKDFDECSVYGTCSQLCTNTDGSFICGCVEGYLLQPDNRSCKAKNEPVDRPPVLLIANSQNILATYLSGAQVSTITPTSTRQTTAMDFSYANETVCWVHVGDSAAQTQLKCARMPGLKGFVDEHTINISLSLHHVEQMAIDWLTGNFYFVDDIDDRIFVCNRNGDTCVTLLDLELYNPKGIALDPAMGKVFFTDYGQIPKVERCDMDGQNRTKLVDSKIVFPHGITLDLVSRLVYWADAYLDYIEVVDYEGKGRQTIIQGILIEHLYGLTVFENYLYATNSDNANAQQKTSVIRVNRFNSTEYQVVTRVDKGGALHIYHQRRQPRVRSHACENDQYGKPGGCSDICLLANSHKARTCRCRSGFSLGSDGKSCKKPEHELFLVYGKGRPGIIRGMDMGAKVPDEHMIPIENLMNPRALDFHAETGFIYFADTTSYLIGRQKIDGTERETILKDGIHNVEGVAVDWMGDNLYWTDDGPKKTISVARLEKAAQTRKTLIEGKMTHPRAIVVDPLNGWMYWTDWEEDPKDSRRGRLERAWMDGSHRDIFVTSKTVLWPNGLSLDIPAGRLYWVDAFYDRIETILLNGTDRKIVYEGPELNHAFGLCHHGNYLFWTEYRSGSVYRLERGVGGAPPTVTLLRSERPPIFEIRMYDAQQQQVGTNKCRVNNGGCSSLCLATPGSRQCACAEDQVLDADGVTCLANPSYVPPPQCQPGEFACANSRCIQERWKCDGDNDCLDNSDEAPALCHQHTCPSDRFKCENNRCIPNRWLCDGDNDCGNSEDESNATCSARTCPPNQFSCASGRCIPISWTCDLDDDCGDRSDESASCAYPTCFPLTQFTCNNGRCININWRCDNDNDCGDNSDEAGCSHSCSSTQFKCNSGRCIPEHWTCDGDNDCGDYSDETHANCTNQATRPPGGCHTDEFQCRLDGLCIPLRWRCDGDTDCMDSSDEKSCEGVTHVCDPSVKFGCKDSARCISKAWVCDGDNDCEDNSDEENCESLACRPPSHPCANNTSVCLPPDKLCDGNDDCGDGSDEGELCDQCSLNNGGCSHNCSVAPGEGIVCSCPLGMELGPDNHTCQIQSYCAKHLKCSQKCDQNKFSVKCSCYEGWVLEPDGESCRSLDPFKPFIIFSNRHEIRRIDLHKGDYSVLVPGLRNTIALDFHLSQSALYWTDVVEDKIYRGKLLDNGALTSFEVVIQYGLATPEGLAVDWIAGNIYWVESNLDQIEVAKLDGTLRTTLLAGDIEHPRAIALDPRDGILFWTDWDASLPRIEAASMSGAGRRTVHRETGSGGWPNGLTVDYLEKRILWIDARSDAIYSARYDGSGHMEVLRGHEFLSHPFAVTLYGGEVYWTDWRTNTLAKANKWTGHNVTVVQRTNTQPFDLQVYHPSRQPMAPNPCEANGGQGPCSHLCLINYNRTVSCACPHLMKLHKDNTTCYEFKKFLLYARQMEIRGVDLDAPYYNYIISFTVPDIDNVTVLDYDAREQRVYWSDVRTQAIKRAFINGTGVETVVSADLPNAHGLAVDWVSRNLFWTSYDTNKKQINVARLDGSFKNAVVQGLEQPHGLVVHPLRGKLYWTDGDNISMANMDGSNRTLLFSGQKGPVGLAIDFPESKLYWISSGNHTINRCNLDGSGLEVIDAMRSQLGKATALAIMGDKLWWADQVSEKMGTCSKADGSGSVVLRNSTTLVMHMKVYDESIQLDHKGTNPCSVNNGDCSQLCLPTSETTRSCMCTAGYSLRSGQQACEGVGSFLLYSVHEGIRGIPLDPNDKSDALVPVSGTSLAVGIDFHAENDTIYWVDMGLSTISRAKRDQTWREDVVTNGIGRVEGIAVDWIAGNIYWTDQGFDVIEVARLNGSFRYVVISQGLDKPRAITVHPEKGYLFWTEWGQYPRIERSRLDGTERVVLVNVSISWPNGISVDYQDGKLYWCDARTDKIERIDLETGENREVVLSSNNMDMFSVSVFEDFIYWSDRTHANGSIKRGSKDNATDSVPLRTGIGVQLKDIKVFNRDRQKGTNVCAVANGGCQQLCLYRGRGQRACACAHGMLAEDGASCREYAGYLLYSERTILKSIHLSDERNLNAPVQPFEDPEHMKNVIALAFDYRAGTSPGTPNRIFFSDIHFGNIQQINDDGSRRITIVENVGSVEGLAYHRGWDTLYWTSYTTSTITRHTVDQTRPGAFERETVITMSGDDHPRAFVLDECQNLMFWTNWNEQHPSIMRAALSGANVLTLIEKDIRTPNGLAIDHRAEKLYFSDATLDKIERCEYDGSHRYVILKSEPVHPFGLAVYGEHIFWTDWVRRAVQRANKHVGSNMKLLRVDIPQQPMGIIAVANDTNSCELSPCRINNGGCQDLCLLTHQGHVNCSCRGGRILQDDLTCRAVNSSCRAQDEFECANGECINFSLTCDGVPHCKDKSDEKPSYCNSRRCKKTFRQCSNGRCVSNMLWCNGADDCGDGSDEIPCNKTACGVGEFRCRDGTCIGNSSRCNQFVDCEDASDEMNCSATDCSSYFRLGVKGVLFQPCERTSLCYAPSWVCDGANDCGDYSDERDCPGVKRPRCPLNYFACPSGRCIPMSWTCDKEDDCEHGEDETHCNKFCSEAQFECQNHRCISKQWLCDGSDDCGDGSDEAAHCEGKTCGPSSFSCPGTHVCVPERWLCDGDKDCADGADESIAAGCLYNSTCDDREFMCQNRQCIPKHFVCDHDRDCADGSDESPECEYPTCGPSEFRCANGRCLSSRQWECDGENDCHDQSDEAPKNPHCTSQEHKCNASSQFLCSSGRCVAEALLCNGQDDCGDSSDERGCHINECLSRKLSGCSQDCEDLKIGFKCRCRPGFRLKDDGRTCADVDECSTTFPCSQRCINTHGSYKCLCVEGYAPRGGDPHSCKAVTDEEPFLIFANRYYLRKLNLDGSNYTLLKQGLNNAVALDFDYREQMIYWTDVTTQGSMIRRMHLNGSNVQVLHRTGLSNPDGLAVDWVGGNLYWCDKGRDTIEVSKLNGAYRTVLVSSGLREPRALVVDVQNGYLYWTDWGDHSLIGRIGMDGSSRSVIVDTKITWPNGLTLDYVTERIYWADAREDYIEFASLDGSNRHVVLSQDIPHIFALTLFEDYVYWTDWETKSINRAHKTTGTNKTLLISTLHRPMDLHVFHALRQPDVPNHPCKVNNGGCSNLCLLSPGGGHKCACPTNFYLGSDGRTCVSNCTASQFVCKNDKCIPFWWKCDTEDDCGDHSDEPPDCPEFKCRPGQFQCSTGICTNPAFICDGDNDCQDNSDEANCDIHVCLPSQFKCTNTNRCIPGIFRCNGQDNCGDGEDERDCPEVTCAPNQFQCSITKRCIPRVWVCDRDNDCVDGSDEPANCTQMTCGVDEFRCKDSGRCIPARWKCDGEDDCGDGSDEPKEECDERTCEPYQFRCKNNRCVPGRWQCDYDNDCGDNSDEESCTPRPCSESEFSCANGRCIAGRWKCDGDHDCADGSDEKDCTPRCDMDQFQCKSGHCIPLRWRCDADADCMDGSDEEACGTGVRTCPLDEFQCNNTLCKPLAWKCDGEDDCGDNSDENPEECARFVCPPNRPFRCKNDRVCLWIGRQCDGTDNCGDGTDEEDCEPPTAHTTHCKDKKEFLCRNQRCLSSSLRCNMFDDCGDGSDEEDCSIDPKLTSCATNASICGDEARCVRTEKAAYCACRSGFHTVPGQPGCQDINECLRFGTCSQLCNNTKGGHLCSCARNFMKTHNTCKAEGSEYQVLYIADDNEIRSLFPGHPHSAYEQAFQGDESVRIDAMDVHVKAGRVYWTNWHTGTISYRSLPPAAPPTTSNRHRRQIDRGVTHLNISGLKMPRGIAIDWVAGNVYWTDSGRDVIEVAQMKGENRKTLISGMIDEPHAIVVDPLRGTMYWSDWGNHPKIETAAMDGTLRETLVQDNIQWPTGLAVDYHNERLYWADAKLSVIGSIRLNGTDPIVAADSKRGLSHPFSIDVFEDYIYGVTYINNRVFKIHKFGHSPLVNLTGGLSHASDVVLYHQHKQPEVTNPCDRKKCEWLCLLSPSGPVCTCPNGKRLDNGTCVPVPSPTPPPDAPRPGTCNLQCFNGGSCFLNARRQPKCRCQPRYTGDKCELDQCWEHCRNGGTCAASPSGMPTCRCPTGFTGPKCTQQVCAGYCANNSTCTVNQGNQPQCRCLPGFLGDRCQYRQCSGYCENFGTCQMAADGSRQCRCTAYFEGSRCEVNKCSRCLEGACVVNKQSGDVTCNCTDGRVAPSCLTCVGHCSNGGSCTMNSKMMPECQCPPHMTGPRCEEHVFSQQQPGHIASILIPLLLLLLLVLVAGVVFWYKRRVQGAKGFQHQRMTNGAMNVEIGNPTYKMYEGGEPDDVGGLLDADFALDPDKPTNFTNPVYATLYMGGHGSRHSLASTDEKRELLGRGPEDEIGDPLA

T22538	TARGETID	T22538
T22538	FORMERID	TTDR00682
T22538	UNIPROID	MFGM_HUMAN
T22538	TARGNAME	Lactadherin (MFGE8)
T22538	GENENAME	MFGE8
T22538	TARGTYPE	Literature-reported
T22538	SYNONYMS	Milk fat globule-EGF factor 8; MFGM; MFGE8; MFG-E8; Human milk fat globule membrane protein BA46; HMFG; Breast epithelial antigen BA46
T22538	FUNCTION	Medin is the main constituent of aortic medial amyloid.
T22538	BIOCLASS	Growth factor
T22538	SEQUENCE	MPRPRLLAALCGALLCAPSLLVALDICSKNPCHNGGLCEEISQEVRGDVFPSYTCTCLKGYAGNHCETKCVEPLGLENGNIANSQIAASSVRVTFLGLQHWVPELARLNRAGMVNAWTPSSNDDNPWIQVNLLRRMWVTGVVTQGASRLASHEYLKAFKVAYSLNGHEFDFIHDVNKKHKEFVGNWNKNAVHVNLFETPVEAQYVRLYPTSCHTACTLRFELLGCELNGCANPLGLKNNSIPDKQITASSSYKTWGLHLFSWNPSYARLDKQGNFNAWVAGSYGNDQWLQVDLGSSKEVTGIITQGARNFGSVQFVASYKVAYSNDSANWTEYQDPRTGSSKIFPGNWDNHSHKKNLFETPILARYVRILPVAWHNRIALRLELLGC

T73616	TARGETID	T73616
T73616	FORMERID	TTDR00039
T73616	UNIPROID	SENX3_MYCTU
T73616	TARGNAME	Mycobacterium Sensor-like histidine kinase senX3 (MycB senX3)
T73616	GENENAME	MycB senX3
T73616	TARGTYPE	Literature-reported
T73616	SYNONYMS	SenX3; Rv0490; MTCY20G9.16
T73616	FUNCTION	Probably forms part of a two-component regulatory system senx3/regx3. Phosphorylates regx3.
T73616	ECNUMBER	EC 2.7.13.3
T73616	SEQUENCE	MTVFSALLLAGVLSALALAVGGAVGMRLTSRVVEQRQRVATEWSGITVSQMLQCIVTLMPLGAAVVDTHRDVVYLNERAKELGLVRDRQLDDQAWRAARQALGGEDVEFDLSPRKRSATGRSGLSVHGHARLLSEEDRRFAVVFVHDQSDYARMEAARRDFVANVSHELKTPVGAMALLAEALLASADDSETVRRFAEKVLIEANRLGDMVAELIELSRLQGAERLPNMTDVDVDTIVSEAISRHKVAADNADIEVRTDAPSNLRVLGDQTLLVTALANLVSNAIAYSPRGSLVSISRRRRGANIEIAVTDRGIGIAPEDQERVFERFFRGDKARSRATGGSGLGLAIVKHVAANHDGTIRVWSKPGTGSTFTLALPALIEAYHDDERPEQAREPELRSNRSQREEELSR

T03385	TARGETID	T03385
T03385	FORMERID	TTDI01456
T03385	UNIPROID	SRBP2_HUMAN
T03385	TARGNAME	SREBP transcription factor 2 (SREBF2)
T03385	GENENAME	SREBF2
T03385	TARGTYPE	Literature-reported
T03385	SYNONYMS	Sterol regulatory element-binding transcription factor 2; Sterol regulatory element-binding protein 2; SREBP2; SREBP-2; Class D basic helix-loop-helix protein 2; BHLHD2
T03385	FUNCTION	Transcriptional activator required for lipid homeostasis. Regulates transcription of the LDL receptor gene as well as the cholesterol and to a lesser degree the fatty acid synthesis pathway (By similarity). Binds the sterol regulatory element 1 (SRE-1) (5'-ATCACCCCAC-3') found in the flanking region of the LDRL and HMG-CoA synthase genes.
T03385	PDBSTRUC	1UKL
T03385	SEQUENCE	MDDSGELGGLETMETLTELGDELTLGDIDEMLQFVSNQVGEFPDLFSEQLCSSFPGSGGSGSSSGSSGSSSSSSNGRGSSSGAVDPSVQRSFTQVTLPSFSPSAASPQAPTLQVKVSPTSVPTTPRATPILQPRPQPQPQPQTQLQQQTVMITPTFSTTPQTRIIQQPLIYQNAATSFQVLQPQVQSLVTSSQVQPVTIQQQVQTVQAQRVLTQTANGTLQTLAPATVQTVAAPQVQQVPVLVQPQIIKTDSLVLTTLKTDGSPVMAAVQNPALTALTTPIQTAALQVPTLVGSSGTILTTMPVMMGQEKVPIKQVPGGVKQLEPPKEGERRTTHNIIEKRYRSSINDKIIELKDLVMGTDAKMHKSGVLRKAIDYIKYLQQVNHKLRQENMVLKLANQKNKLLKGIDLGSLVDNEVDLKIEDFNQNVLLMSPPASDSGSQAGFSPYSIDSEPGSPLLDDAKVKDEPDSPPVALGMVDRSRILLCVLTFLCLSFNPLTSLLQWGGAHDSDQHPHSGSGRSVLSFESGSGGWFDWMMPTLLLWLVNGVIVLSVFVKLLVHGEPVIRPHSRSSVTFWRHRKQADLDLARGDFAAAAGNLQTCLAVLGRALPTSRLDLACSLSWNVIRYSLQKLRLVRWLLKKVFQCRRATPATEAGFEDEAKTSARDAALAYHRLHQLHITGKLPAGSACSDVHMALCAVNLAECAEEKIPPSTLVEIHLTAAMGLKTRCGGKLGFLASYFLSRAQSLCGPEHSAVPDSLRWLCHPLGQKFFMERSWSVKSAAKESLYCAQRNPADPIAQVHQAFCKNLLERAIESLVKPQAKKKAGDQEEESCEFSSALEYLKLLHSFVDSVGVMSPPLSRSSVLKSALGPDIICRWWTSAITVAISWLQGDDAAVRSHFTKVERIPKALEVTESPLVKAIFHACRAMHASLPGKADGQQSSFCHCERASGHLWSSLNVSGATSDPALNHVVQLLTCDLLLSLRTALWQKQASASQAVGETYHASGAELAGFQRDLGSLRRLAHSFRPAYRKVFLHEATVRLMAGASPTRTHQLLEHSLRRRTTQSTKHGEVDAWPGQRERATAILLACRHLPLSFLSSPGQRAVLLAEAARTLEKVGDRRSCNDCQQMIVKLGGGTAIAAS

T26983	TARGETID	T26983
T26983	FORMERID	TTDNR00763
T26983	UNIPROID	TP53B_HUMAN
T26983	TARGNAME	Tumor suppressor p53-binding protein 1 (TP53BP1)
T26983	GENENAME	TP53BP1
T26983	TARGTYPE	Literature-reported
T26983	SYNONYMS	p53BP1; p53-binding protein 1; TP53-binding protein 1; 53BP1
T26983	FUNCTION	Plays a key role in the repair of double-strand DNA breaks (DSBs) in response to DNA damage by promoting non-homologous end joining (NHEJ)-mediated repair of DSBs and specifically counteracting the function of the homologous recombination (HR) repair protein BRCA1. In response to DSBs, phosphorylation by ATM promotes interaction with RIF1 and dissociation from NUDT16L1/TIRR, leading to recruitment to DSBs sites. Recruited to DSBs sites by recognizing and binding histone H2A monoubiquitinated at 'Lys-15' (H2AK15Ub) and histone H4 dimethylated at 'Lys-20' (H4K20me2), two histone marks that are present at DSBs sites. Required for immunoglobulin class-switch recombination (CSR) during antibody genesis, a process that involves the generation of DNA DSBs. Participates to the repair and the orientation of the broken DNA ends during CSR. In contrast, it is not required for classic NHEJ and V(D)J recombination. Promotes NHEJ of dysfunctional telomeres via interaction with PAXIP1. Double-strand break (DSB) repair protein involved in response to DNA damage, telomere dynamics and class-switch recombination (CSR) during antibody genesis.
T26983	PDBSTRUC	6IUA; 6IU7; 6CO2; 6CO1; 5ZCJ
T26983	SEQUENCE	MDPTGSQLDSDFSQQDTPCLIIEDSQPESQVLEDDSGSHFSMLSRHLPNLQTHKENPVLDVVSNPEQTAGEERGDGNSGFNEHLKENKVADPVDSSNLDTCGSISQVIEQLPQPNRTSSVLGMSVESAPAVEEEKGEELEQKEKEKEEDTSGNTTHSLGAEDTASSQLGFGVLELSQSQDVEENTVPYEVDKEQLQSVTTNSGYTRLSDVDANTAIKHEEQSNEDIPIAEQSSKDIPVTAQPSKDVHVVKEQNPPPARSEDMPFSPKASVAAMEAKEQLSAQELMESGLQIQKSPEPEVLSTQEDLFDQSNKTVSSDGCSTPSREEGGCSLASTPATTLHLLQLSGQRSLVQDSLSTNSSDLVAPSPDAFRSTPFIVPSSPTEQEGRQDKPMDTSVLSEEGGEPFQKKLQSGEPVELENPPLLPESTVSPQASTPISQSTPVFPPGSLPIPSQPQFSHDIFIPSPSLEEQSNDGKKDGDMHSSSLTVECSKTSEIEPKNSPEDLGLSLTGDSCKLMLSTSEYSQSPKMESLSSHRIDEDGENTQIEDTEPMSPVLNSKFVPAENDSILMNPAQDGEVQLSQNDDKTKGDDTDTRDDISILATGCKGREETVAEDVCIDLTCDSGSQAVPSPATRSEALSSVLDQEEAMEIKEHHPEEGSSGSEVEEIPETPCESQGEELKEENMESVPLHLSLTETQSQGLCLQKEMPKKECSEAMEVETSVISIDSPQKLAILDQELEHKEQEAWEEATSEDSSVVIVDVKEPSPRVDVSCEPLEGVEKCSDSQSWEDIAPEIEPCAENRLDTKEEKSVEYEGDLKSGTAETEPVEQDSSQPSLPLVRADDPLRLDQELQQPQTQEKTSNSLTEDSKMANAKQLSSDAEAQKLGKPSAHASQSFCESSSETPFHFTLPKEGDIIPPLTGATPPLIGHLKLEPKRHSTPIGISNYPESTIATSDVMSESMVETHDPILGSGKGDSGAAPDVDDKLCLRMKLVSPETEASEESLQFNLEKPATGERKNGSTAVAESVASPQKTMSVLSCICEARQENEARSEDPPTTPIRGNLLHFPSSQGEEEKEKLEGDHTIRQSQQPMKPISPVKDPVSPASQKMVIQGPSSPQGEAMVTDVLEDQKEGRSTNKENPSKALIERPSQNNIGIQTMECSLRVPETVSAATQTIKNVCEQGTSTVDQNFGKQDATVQTERGSGEKPVSAPGDDTESLHSQGEEEFDMPQPPHGHVLHRHMRTIREVRTLVTRVITDVYYVDGTEVERKVTEETEEPIVECQECETEVSPSQTGGSSGDLGDISSFSSKASSLHRTSSGTSLSAMHSSGSSGKGAGPLRGKTSGTEPADFALPSSRGGPGKLSPRKGVSQTGTPVCEEDGDAGLGIRQGGKAPVTPRGRGRRGRPPSRTTGTRETAVPGPLGIEDISPNLSPDDKSFSRVVPRVPDSTRRTDVGAGALRRSDSPEIPFQAAAGPSDGLDASSPGNSFVGLRVVAKWSSNGYFYSGKITRDVGAGKYKLLFDDGYECDVLGKDILLCDPIPLDTEVTALSEDEYFSAGVVKGHRKESGELYYSIEKEGQRKWYKRMAVILSLEQGNRLREQYGLGPYEAVTPLTKAADISLDNLVEGKRKRRSNVSSPATPTASSSSSTTPTRKITESPRASMGVLSGKRKLITSEEERSPAKRGRKSATVKPGAVGAGEFVSPCESGDNTGEPSALEEQRGPLPLNKTLFLGYAFLLTMATTSDKLASRSKLPDGPTGSSEEEEEFLEIPPFNKQYTESQLRAGAGYILEDFNEAQCNTAYQCLLIADQHCRTRKYFLCLASGIPCVSHVWVHDSCHANQLQNYRNYLLPAGYSLEEQRILDWQPRENPFQNLKVLLVSDQQQNFLELWSEILMTGGAASVKQHHSSAHNKDIALGVFDVVVTDPSCPASVLKCAEALQLPVVSQEWVIQCLIVGERIGFKQHPKYKHDYVSH

T80454	TARGETID	T80454
T80454	FORMERID	TTDI00126
T80454	UNIPROID	TIAM1_HUMAN
T80454	TARGNAME	T-lymphoma invasion and metastasis 1 (TIAM1)
T80454	GENENAME	TIAM1
T80454	TARGTYPE	Literature-reported
T80454	SYNONYMS	TIAM-1; T-lymphoma invasion and metastasis-inducing protein 1
T80454	FUNCTION	Acts as a GDP-dissociation stimulator protein that stimulates the GDP-GTP exchange activity of RHO-like GTPases and activates them. Activates RAC1, CDC42, and to a lesser extent RHOA. Required for normal cell adhesion and cell migration. Modulates the activity of RHO-like proteins and connects extracellular signals to cytoskeletal activities.
T80454	PDBSTRUC	4NXR; 4NXQ; 4NXP; 4K2P; 4K2O
T80454	SEQUENCE	MGNAESQHVEHEFYGEKHASLGRKHTSRSLRLSHKTRRTRHASSGKVIHRNSEVSTRSSSTPSIPQSLAENGLEPFSQDGTLEDFGSPIWVDRVDMGLRPVSYTDSSVTPSVDSSIVLTAASVQSMPDTEESRLYGDDATYLAEGGRRQHSYTSNGPTFMETASFKKKRSKSADIWREDSLEFSLSDLSQEHLTSNEEILGSAEEKDCEEARGMETRASPRQLSTCQRANSLGDLYAQKNSGVTANGGPGSKFAGYCRNLVSDIPNLANHKMPPAAAEETPPYSNYNTLPCRKSHCLSEGATNPQISHSNSMQGRRAKTTQDVNAGEGSEFADSGIEGATTDTDLLSRRSNATNSSYSPTTGRAFVGSDSGSSSTGDAARQGVYENFRRELEMSTTNSESLEEAGSAHSDEQSSGTLSSPGQSDILLTAAQGTVRKAGALAVKNFLVHKKNKKVESATRRKWKHYWVSLKGCTLFFYESDGRSGIDHNSIPKHAVWVENSIVQAVPEHPKKDFVFCLSNSLGDAFLFQTTSQTELENWITAIHSACATAVARHHHKEDTLRLLKSEIKKLEQKIDMDEKMKKMGEMQLSSVTDSKKKKTILDQIFVWEQNLEQFQMDLFRFRCYLASLQGGELPNPKRLLAFASRPTKVAMGRLGIFSVSSFHALVAARTGETGVRRRTQAMSRSASKRRSRFSSLWGLDTTSKKKQGRPSINQVFGEGTEAVKKSLEGIFDDIVPDGKREKEVVLPNVHQHNPDCDIWVHEYFTPSWFCLPNNQPALTVVRPGDTARDTLELICKTHQLDHSAHYLRLKFLIENKMQLYVPQPEEDIYELLYKEIEICPKVTQSIHIEKSDTAADTYGFSLSSVEEDGIRRLYVNSVKETGLASKKGLKAGDEILEINNRAADALNSSMLKDFLSQPSLGLLVRTYPELEEGVELLESPPHRVDGPADLGESPLAFLTSNPGHSLCSEQGSSAETAPEETEGPDLESSDETDHSSKSTEQVAAFCRSLHEMNPSDQSPSPQDSTGPQLATMRQLSDADKLRKVICELLETERTYVKDLNCLMERYLKPLQKETFLTQDELDVLFGNLTEMVEFQVEFLKTLEDGVRLVPDLEKLEKVDQFKKVLFSLGGSFLYYADRFKLYSAFCASHTKVPKVLVKAKTDTAFKAFLDAQNPKQQHSSTLESYLIKPIQRILKYPLLLRELFALTDAESEEHYHLDVAIKTMNKVASHINEMQKIHEEFGAVFDQLIAEQTGEKKEVADLSMGDLLLHTTVIWLNPPASLGKWKKEPELAAFVFKTAVVLVYKDGSKQKKKLVGSHRLSIYEDWDPFRFRHMIPTEALQVRALASADAEANAVCEIVHVKSESEGRPERVFHLCCSSPESRKDFLKAVHSILRDKHRRQLLKTESLPSSQQYVPFGGKRLCALKGARPAMSRAVSAPSKSLGRRRRRLARNRFTIDSDAVSASSPEKESQQPPGGGDTDRWVEEQFDLAQYEEQDDIKETDILSDDDEFCESVKGASVDRDLQERLQATSISQRERGRKTLDSHASRMAQLKKQAALSGINGGLESASEEVIWVRREDFAPSRKLNTEI

T98569	TARGETID	T98569
T98569	FORMERID	TTDI01389
T98569	UNIPROID	AIMP2_HUMAN
T98569	TARGNAME	AIMP multisynthetase complex protein 2 (AIMP2)
T98569	GENENAME	AIMP2
T98569	TARGTYPE	Literature-reported
T98569	SYNONYMS	Protein JTV-1; PRO0992; Multisynthase complex auxiliary component p38; JTV1; Aminoacyl tRNA synthase complex-interacting multifunctional protein 2
T98569	FUNCTION	Required for assembly and stability of the aminoacyl-tRNA synthase complex. Mediates ubiquitination and degradation of FUBP1, a transcriptional activator of MYC, leading to MYC down-regulation which is required for aveolar type II cell differentiation. Blocks MDM2-mediated ubiquitination and degradation of p53/TP53. Functions as a proapoptotic factor.
T98569	PDBSTRUC	6ILD; 5Y6L; 5A5H; 5A34; 5A1N
T98569	SEQUENCE	MPMYQVKPYHGGGAPLRVELPTCMYRLPNVHGRSYGPAPGAGHVQEESNLSLQALESRQDDILKRLYELKAAVDGLSKMIQTPDADLDVTNIIQADEPTTLTTNALDLNSVLGKDYGALKDIVINANPASPPLSLLVLHRLLCEHFRVLSTVHTHSSVKSVPENLLKCFGEQNKKQPRQDYQLGFTLIWKNVPKTQMKFSIQTMCPIEGEGNIARFLFSLFGQKHNAVNATLIDSWVDIAIFQLKEGSSKEKAAVFRSMNSALGKSPWLAGNELTVADVVLWSVLQQIGGCSVTVPANVQRWMRSCENLAPFNTALKLLK

T31577	TARGETID	T31577
T31577	FORMERID	TTDR00860
T31577	UNIPROID	SG2A2_HUMAN
T31577	TARGNAME	Mammaglobin A (SCGB2A2)
T31577	GENENAME	SCGB2A2
T31577	TARGTYPE	Literature-reported
T31577	SYNONYMS	UGB2; Secretoglobin family 2A member 2; Mammaglobin-A; Mammaglobin-1; MGB1
T31577	FUNCTION	Expressed mainly in mucosa. Involved in cell signalling, immune response, and chemotaxis, and may also serve as transporters for steroid hormones in humans.
T31577	BIOCLASS	Secretoglobin family
T31577	SEQUENCE	MKLLMVLMLAALSQHCYAGSGCPLLENVISKTINPQVSKTEYKELLQEFIDDNATTNAIDELKECFLNQTDETLSNVEVFMQLIYDSSLCDLF

T80306	TARGETID	T80306
T80306	FORMERID	TTDR00814
T80306	UNIPROID	SKP2_HUMAN
T80306	TARGNAME	S-phase kinase-associated protein 2 (SKP2)
T80306	GENENAME	SKP2
T80306	TARGTYPE	Literature-reported
T80306	SYNONYMS	Skp2; P45skp2; FBXL1; F-box/LRR-repeat protein 1; F-box protein Skp2; Cyclin-A/CDK2-associated protein p45; Cyclin A/CDK2-associated protein p45; Cyclin A/CDK2-associated p45
T80306	FUNCTION	Specifically recognizes phosphorylated CDKN1B/p27kip and is involved in regulation of G1/S transition. Degradation of CDKN1B/p27kip also requires CKS1. Recognizes target proteins ORC1, CDT1, RBL2, KMT2A/MLL1, CDK9, RAG2, FOXO1, UBP43, and probably MYC, TOB1 and TAL1. Degradation of TAL1 also requires STUB1. Recognizes CDKN1A in association with CCNE1 or CCNE2 and CDK2. Promotes ubiquitination and destruction of CDH1 in a CK1-Dependent Manner, thereby regulating cell migration. Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins involved in cell cycle progression, signal transduction and transcription.
T80306	PDBSTRUC	2AST; 2ASS; 1LDK; 1FS2; 1FS1
T80306	SEQUENCE	MHRKHLQEIPDLSSNVATSFTWGWDSSKTSELLSGMGVSALEKEEPDSENIPQELLSNLGHPESPPRKRLKSKGSDKDFVIVRRPKLNRENFPGVSWDSLPDELLLGIFSCLCLPELLKVSGVCKRWYRLASDESLWQTLDLTGKNLHPDVTGRLLSQGVIAFRCPRSFMDQPLAEHFSPFRVQHMDLSNSVIEVSTLHGILSQCSKLQNLSLEGLRLSDPIVNTLAKNSNLVRLNLSGCSGFSEFALQTLLSSCSRLDELNLSWCFDFTEKHVQVAVAHVSETITQLNLSGYRKNLQKSDLSTLVRRCPNLVHLDLSDSVMLKNDCFQEFFQLNYLQHLSLSRCYDIIPETLLELGEIPTLKTLQVFGIVPDGTLQLLKEALPHLQINCSHFTTIARPTIGNKKNQEIWGIKCRLTLQKPSCL

T16401	TARGETID	T16401
T16401	FORMERID	TTDI02172
T16401	UNIPROID	SGCG_HUMAN
T16401	TARGNAME	Sarcoglycan gamma (SGCG)
T16401	GENENAME	SGCG
T16401	TARGTYPE	Literature-reported
T16401	SYNONYMS	SGCG; Gammasarcoglycan; GammaSG; 35DAG; 35 kDa dystrophinassociated glycoprotein
T16401	FUNCTION	Component of the sarcoglycan complex, a subcomplexof the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix.
T16401	BIOCLASS	Sarcoglycan
T16401	SEQUENCE	MVREQYTTATEGICIERPENQYVYKIGIYGWRKRCLYLFVLLLLIILVVNLALTIWILKVMWFSPAGMGHLCVTKDGLRLEGESEFLFPLYAKEIHSRVDSSLLLQSTQNVTVNARNSEGEVTGRLKVGPKMVEVQNQQFQINSNDGKPLFTVDEKEVVVGTDKLRVTGPEGALFEHSVETPLVRADPFQDLRLESPTRSLSMDAPRGVHIQAHAGKIEALSQMDILFHSSDGMLVLDAETVCLPKLVQGTWGPSGSSQSLYEICVCPDGKLYLSVAGVSTTCQEHNHICL

T91598	TARGETID	T91598
T91598	FORMERID	TTDI03608
T91598	UNIPROID	TNK1_HUMAN
T91598	TARGNAME	Non-receptor tyrosine-protein kinase TNK1 (TNK1)
T91598	GENENAME	TNK1
T91598	TARGTYPE	Literature-reported
T91598	SYNONYMS	CD38 negative kinase 1
T91598	FUNCTION	Involved in negative regulation of cell growth. Has tumor suppressor properties. Plays a negative regulatory role in the Ras-MAPK pathway. May function in signaling pathways utilized broadly during fetal development and more selectively in adult tissues and in cells of the lymphohematopoietic system. Could specifically be involved in phospholipid signal transduction.
T91598	ECNUMBER	EC 2.7.10.2
T91598	SEQUENCE	MLPEAGSLWLLKLLRDIQLAQFYWPILEELNVTRPEHFDFVKPEDLDGIGMGRPAQRRLSEALKRLRSGPKSKNWVYKILGGFAPEHKEPTLPSDSPRHLPEPEGGLKCLIPEGAVCRGELLGSGCFGVVHRGLWTLPSGKSVPVAVKSLRVGPEGPMGTELGDFLREVSVMMNLEHPHVLRLHGLVLGQPLQMVMELAPLGSLHARLTAPAPTPPLLVALLCLFLRQLAGAMAYLGARGLVHRDLATRNLLLASPRTIKVADFGLVRPLGGARGRYVMGGPRPIPYAWCAPESLRHGAFSSASDVWMFGVTLWEMFSGGEEPWAGVPPYLILQRLEDRARLPRPPLCSRALYSLALRCWAPHPADRPSFSHLEGLLQEAGPSEACCVRDVTEPGALRMETGDPITVIEGSSSFHSPDSTIWKGQNGRTFKVGSFPASAVTLADAGGLPATRPVHRGTPARGDQHPGSIDGDRKKANLWDAPPARGQRRNMPLERMKGISRSLESVLSLGPRPTGGGSSPPEIRQARAVPQGPPGLPPRPPLSSSSPQPSQPSRERLPWPKRKPPHNHPMGMPGARKAAALSGGLLSDPELQRKIMEVELSVHGVTHQECQTALGATGGDVVSAIRNLKVDQLFHLSSRSRADCWRILEHYQWDLSAASRYVLARP
T91598	DRUGINFO	D0M0QQ	XMD8-92	Investigative

T84941	TARGETID	T84941
T84941	FORMERID	TTDNR00669
T84941	UNIPROID	4EBP1_HUMAN
T84941	TARGNAME	Eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1)
T84941	GENENAME	EIF4EBP1
T84941	TARGTYPE	Literature-reported
T84941	SYNONYMS	eIF4E-binding protein 1; Phosphorylated heat- andacid-stable protein regulated by insulin 1; Phosphorylated heat- and acid-stable protein regulated by insulin 1; PHAS-I; 4E-BP1
T84941	FUNCTION	In contrast, hyperphosphorylated form dissociates from EIF4E, allowing interaction between EIF4G1/EIF4G3 and EIF4E, leading to initiation of translation. Mediates the regulation of protein translation by hormones, growth factors and other stimuli that signal through the MAP kinase and mTORC1 pathways. Repressor of translation initiation that regulates EIF4E activity by preventing its assembly into the eIF4F complex: hypophosphorylated form competes with EIF4G1/EIF4G3 and strongly binds to EIF4E, leading to repress translation.
T84941	PDBSTRUC	6BCX; 6BCU; 5WBJ; 5NVN; 5EKV
T84941	SEQUENCE	MSGGSSCSQTPSRAIPATRRVVLGDGVQLPPGDYSTTPGGTLFSTTPGGTRIIYDRKFLMECRNSPVTKTPPRDLPTIPGVTSPSSDEPPMEASQSHLRNSPEDKRAGGEESQFEMDI

T04364	TARGETID	T04364
T04364	FORMERID	TTDI00246
T04364	UNIPROID	CUL3_HUMAN
T04364	TARGNAME	Cullin-3 (CUL-3)
T04364	GENENAME	CUL3
T04364	TARGTYPE	Literature-reported
T04364	SYNONYMS	KIAA0617; Cullin3
T04364	FUNCTION	BCR complexes and ARIH1 collaborate in tandem to mediate ubiquitination of target proteins. As a scaffold protein may contribute to catalysis through positioning of the substrate and the ubiquitin-conjugating enzyme. The E3 ubiquitin-protein ligase activity of the complex is dependent on the neddylation of the cullin subunit and is inhibited by the association of the deneddylated cullin subunit with TIP120A/CAND1. The functional specificity of the BCR complex depends on the BTB domain-containing protein as the substrate recognition component. BCR(KLHL42) is involved in ubiquitination of KATNA1. BCR(SPOP) is involved in ubiquitination of BMI1/PCGF4, BRMS1, H2AFY and DAXX, GLI2 and GLI3. Can also form a cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex containing homodimeric SPOPL or the heterodimer formed by SPOP and SPOPL; these complexes have lower ubiquitin ligase activity. BCR(KLHL9-KLHL13) controls the dynamic behavior of AURKB on mitotic chromosomes and thereby coordinates faithful mitotic progression and completion of cytokinesis. BCR(KLHL12) is involved in ER-Golgi transport by regulating the size of COPII coats, thereby playing a key role in collagen export, which is required for embryonic stem (ES) cells division: BCR(KLHL12) acts by mediating monoubiquitination of SEC31 (SEC31A or SEC31B). BCR(KLHL3) acts as a regulator of ion transport in the distal nephron; by mediating ubiquitination of WNK4. The BCR(KLHL20) E3 ubiquitin ligase complex is involved in interferon response and anterograde Golgi to endosome transport: it mediates both ubiquitination leading to degradation and 'Lys-33'-linked ubiquitination. The BCR(KLHL21) E3 ubiquitin ligase complex regulates localization of the chromosomal passenger complex (CPC) from chromosomes to the spindle midzone in anaphase and mediates the ubiquitination of AURKB. The BCR(KLHL22) ubiquitin ligase complex mediates monoubiquitination of PLK1, leading to PLK1 dissociation from phosphoreceptor proteins and subsequent removal from kinetochores, allowing silencing of the spindle assembly checkpoint (SAC) and chromosome segregation. The BCR(KLHL22) ubiquitin ligase complex is also responsible for the amino acid-stimulated 'Lys-48' polyubiquitination and proteasomal degradation of DEPDC5. Through the degradation of DEPDC5, releases the GATOR1 complex-mediated inhibition of the TORC1 pathway. The BCR(KLHL25) ubiquitin ligase complex is involved in translational homeostasis by mediating ubiquitination and subsequent degradation of hypophosphorylated EIF4EBP1 (4E-BP1). The BCR(KBTBD8) complex acts by mediating monoubiquitination of NOLC1 and TCOF1, leading to remodel the translational program of differentiating cells in favor of neural crest specification. Involved in ubiquitination of cyclin E and of cyclin D1 (in vitro) thus involved in regulation of G1/S transition. Involved in the ubiquitination of KEAP1, ENC1 and KLHL41. In concert with ATF2 and RBX1, promotes degradation of KAT5 thereby attenuating its ability to acetylate and activate ATM. The BCR(KCTD17) E3 ubiquitin ligase complex mediates ubiquitination and degradation of TCHP, a down-regulator of cilium assembly, thereby inducing ciliogenesis. The BCR(KLHL24) E3 ubiquitin ligase complex mediates ubiquitination of KRT14, controls KRT14 levels during keratinocytes differentiation, and is essential for skin integrity. Core component of multiple cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complexes which mediate the ubiquitination and subsequent proteasomal degradation of target proteins.
T04364	PDBSTRUC	6I2M; 5NLB; 4HXI; 4EOZ; 4APF
T04364	SEQUENCE	MSNLSKGTGSRKDTKMRIRAFPMTMDEKYVNSIWDLLKNAIQEIQRKNNSGLSFEELYRNAYTMVLHKHGEKLYTGLREVVTEHLINKVREDVLNSLNNNFLQTLNQAWNDHQTAMVMIRDILMYMDRVYVQQNNVENVYNLGLIIFRDQVVRYGCIRDHLRQTLLDMIARERKGEVVDRGAIRNACQMLMILGLEGRSVYEEDFEAPFLEMSAEFFQMESQKFLAENSASVYIKKVEARINEEIERVMHCLDKSTEEPIVKVVERELISKHMKTIVEMENSGLVHMLKNGKTEDLGCMYKLFSRVPNGLKTMCECMSSYLREQGKALVSEEGEGKNPVDYIQGLLDLKSRFDRFLLESFNNDRLFKQTIAGDFEYFLNLNSRSPEYLSLFIDDKLKKGVKGLTEQEVETILDKAMVLFRFMQEKDVFERYYKQHLARRLLTNKSVSDDSEKNMISKLKTECGCQFTSKLEGMFRDMSISNTTMDEFRQHLQATGVSLGGVDLTVRVLTTGYWPTQSATPKCNIPPAPRHAFEIFRRFYLAKHSGRQLTLQHHMGSADLNATFYGPVKKEDGSEVGVGGAQVTGSNTRKHILQVSTFQMTILMLFNNREKYTFEEIQQETDIPERELVRALQSLACGKPTQRVLTKEPKSKEIENGHIFTVNDQFTSKLHRVKIQTVAAKQGESDPERKETRQKVDDDRKHEIEAAIVRIMKSRKKMQHNVLVAEVTQQLKARFLPSPVVIKKRIEGLIEREYLARTPEDRKVYTYVA

T81135	TARGETID	T81135
T81135	FORMERID	TTDI00008
T81135	UNIPROID	FHL1_HUMAN
T81135	TARGNAME	Skeletal muscle LIM-protein 1 (FHL1)
T81135	GENENAME	FHL1
T81135	TARGTYPE	Literature-reported
T81135	SYNONYMS	Skeletal muscle LIMprotein 1; SLIM1; SLIM; Four and a half LIM domains protein 1; FHL1
T81135	FUNCTION	May have an involvement in muscle development or hypertrophy.
T81135	PDBSTRUC	2EGQ; 2CUR; 2CUP; 1X63
T81135	SEQUENCE	MAEKFDCHYCRDPLQGKKYVQKDGHHCCLKCFDKFCANTCVECRKPIGADSKEVHYKNRFWHDTCFRCAKCLHPLANETFVAKDNKILCNKCTTREDSPKCKGCFKAIVAGDQNVEYKGTVWHKDCFTCSNCKQVIGTGSFFPKGEDFYCVTCHETKFAKHCVKCNKAITSGGITYQDQPWHADCFVCVTCSKKLAGQRFTAVEDQYYCVDCYKNFVAKKCAGCKNPITGKRTVSRVSHPVSKARKPPVCHGKRLPLTLFPSANLRGRHPGGERTCPSWVVVLYRKNRSLAAPRGPGLVKAPVWWPMKDNPGTTTASTAKNAP

T75613	TARGETID	T75613
T75613	FORMERID	TTDI02360
T75613	UNIPROID	LAMC2_HUMAN
T75613	TARGNAME	Laminin gamma-2 subunit (LAMC2)
T75613	GENENAME	LAMC2
T75613	TARGTYPE	Literature-reported
T75613	SYNONYMS	Nicein subunit gamma; Large adhesive scatter factor 140 kDa subunit; Laminin5 subunit gamma; Laminin-5 subunit gamma; Laminin subunit gamma2; Laminin subunit gamma-2; Laminin B2t chain; Ladsin 140 kDa subunit; LAMNB2; LAMB2T; Kalinin/nicein/epiligrin 100 kDa subunit; Kalinin subunit gamma; Epiligrin subunit gamma; Cellscattering factor 140 kDa subunit; Cell-scattering factor 140 kDa subunit; CSF 140 kDa subunit
T75613	FUNCTION	Ladsin exerts cell-scattering activity toward a wide variety of cells, including epithelial, endothelial, and fibroblastic cells. Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components.
T75613	SEQUENCE	MPALWLGCCLCFSLLLPAARATSRREVCDCNGKSRQCIFDRELHRQTGNGFRCLNCNDNTDGIHCEKCKNGFYRHRERDRCLPCNCNSKGSLSARCDNSGRCSCKPGVTGARCDRCLPGFHMLTDAGCTQDQRLLDSKCDCDPAGIAGPCDAGRCVCKPAVTGERCDRCRSGYYNLDGGNPEGCTQCFCYGHSASCRSSAEYSVHKITSTFHQDVDGWKAVQRNGSPAKLQWSQRHQDVFSSAQRLDPVYFVAPAKFLGNQQVSYGQSLSFDYRVDRGGRHPSAHDVILEGAGLRITAPLMPLGKTLPCGLTKTYTFRLNEHPSNNWSPQLSYFEYRRLLRNLTALRIRATYGEYSTGYIDNVTLISARPVSGAPAPWVEQCICPVGYKGQFCQDCASGYKRDSARLGPFGTCIPCNCQGGGACDPDTGDCYSGDENPDIECADCPIGFYNDPHDPRSCKPCPCHNGFSCSVMPETEEVVCNNCPPGVTGARCELCADGYFGDPFGEHGPVRPCQPCQCNNNVDPSASGNCDRLTGRCLKCIHNTAGIYCDQCKAGYFGDPLAPNPADKCRACNCNPMGSEPVGCRSDGTCVCKPGFGGPNCEHGAFSCPACYNQVKIQMDQFMQQLQRMEALISKAQGGDGVVPDTELEGRMQQAEQALQDILRDAQISEGASRSLGLQLAKVRSQENSYQSRLDDLKMTVERVRALGSQYQNRVRDTHRLITQMQLSLAESEASLGNTNIPASDHYVGPNGFKSLAQEATRLAESHVESASNMEQLTRETEDYSKQALSLVRKALHEGVGSGSGSPDGAVVQGLVEKLEKTKSLAQQLTREATQAEIEADRSYQHSLRLLDSVSRLQGVSDQSFQVEEAKRIKQKADSLSSLVTRHMDEFKRTQKNLGNWKEEAQQLLQNGKSGREKSDQLLSRANLAKSRAQEALSMGNATFYEVESILKNLREFDLQVDNRKAEAEEAMKRLSYISQKVSDASDKTQQAERALGSAAADAQRAKNGAGEALEISSEIEQEIGSLNLEANVTADGALAMEKGLASLKSEMREVEGELERKELEFDTNMDAVQMVITEAQKVDTRAKNAGVTIQDTLNTLDGLLHLMDQPLSVDEEGLVLLEQKLSRAKTQINSQLRPMMSELEERARQQRGHLHLLETSIDGILADVKNLENIRDNLPPGCYNTQALEQQ
T75613	DRUGINFO	D08DSC	BST-1005	Preclinical

T29630	TARGETID	T29630
T29630	FORMERID	TTDI02414
T29630	UNIPROID	RUNX3_HUMAN
T29630	TARGNAME	Runt-related transcription factor 3 (RUNX3)
T29630	GENENAME	RUNX3
T29630	TARGTYPE	Literature-reported
T29630	SYNONYMS	SL3/AKV core-binding factor alpha C subunit; SL3-3 enhancer factor 1 alpha C subunit; Polyomavirus enhancer-binding protein 2 alpha C subunit; PEBP2A3; PEBP2-alpha C; PEA2-alpha C; Oncogene AML-2; Core-binding factor subunit alpha-3; CBFA3; CBF-alpha-3; Acute myeloid leukemia 2 protein; AML2
T29630	FUNCTION	RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. The heterodimers bind to the core site of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL3 and GM-CSF promoters. May be involved in the control of cellular proliferation and/or differentiation. In association with ZFHX3, upregulates CDKN1A promoter activity following TGF-beta stimulation. CBF complexes repress ZBTB7B transcription factor during cytotoxic (CD8+) T cell development. They bind to RUNX-binding sequence within the ZBTB7B locus acting as transcriptional silencer and allowing for cytotoxic T cell differentiation. CBF complexes binding to the transcriptional silencer is essential for recruitment of nuclear protein complexes that catalyze epigenetic modifications to establish epigenetic ZBTB7B silencing. Forms the heterodimeric complex core-binding factor (CBF) with CBFB.
T29630	PDBSTRUC	5W69
T29630	SEQUENCE	MRIPVDPSTSRRFTPPSPAFPCGGGGGKMGENSGALSAQAAVGPGGRARPEVRSMVDVLADHAGELVRTDSPNFLCSVLPSHWRCNKTLPVAFKVVALGDVPDGTVVTVMAGNDENYSAELRNASAVMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPTQVATYHRAIKVTVDGPREPRRHRQKLEDQTKPFPDRFGDLERLRMRVTPSTPSPRGSLSTTSHFSSQPQTPIQGTSELNPFSDPRQFDRSFPTLPTLTESRFPDPRMHYPGAMSAAFPYSATPSGTSISSLSVAGMPATSRFHHTYLPPPYPGAPQNQSGPFQANPSPYHLYYGTSSGSYQFSMVAGSSSGGDRSPTRMLASCTSSAASVAAGNLMNPSLGGQSDGVEADGSHSNSPTALSTPGRMDEAVWRPY

T45794	TARGETID	T45794
T45794	FORMERID	TTDR00388
T45794	UNIPROID	NCOA4_HUMAN
T45794	TARGNAME	Nuclear receptor coactivator 4 (NCOA4)
T45794	GENENAME	NCOA4
T45794	TARGTYPE	Literature-reported
T45794	SYNONYMS	Ret-activating protein ELE1; RFG; NCoA-4; ELE1; Androgen receptor-associated protein of 70 kDa; Androgen receptor coactivator 70 kDa protein; ARA70 (dARA70N); ARA70; 70 kDa androgen receptor coactivator; 70 kDa AR-activator
T45794	FUNCTION	Ligand-independent coactivator of the peroxisome proliferator-activated receptor (PPAR) gamma. Enhances the androgen receptor transcriptional activity in prostate cancer cells.
T45794	PDBSTRUC	1T5Z
T45794	SEQUENCE	MNTFQDQSGSSSNREPLLRCSDARRDLELAIGGVLRAEQQIKDNLREVKAQIHSCISRHLECLRSREVWLYEQVDLIYQLKEETLQQQAQQLYSLLGQFNCLTHQLECTQNKDLANQVSVCLERLGSLTLKPEDSTVLLFEADTITLRQTITTFGSLKTIQIPEHLMAHASSANIGPFLEKRGCISMPEQKSASGIVAVPFSEWLLGSKPASGYQAPYIPSTDPQDWLTQKQTLENSQTSSRACNFFNNVGGNLKGLENWLLKSEKSSYQKCNSHSTTSSFSIEMEKVGDQELPDQDEMDLSDWLVTPQESHKLRKPENGSRETSEKFKLLFQSYNVNDWLVKTDSCTNCQGNQPKGVEIENLGNLKCLNDHLEAKKPLSTPSMVTEDWLVQNHQDPCKVEEVCRANEPCTSFAECVCDENCEKEALYKWLLKKEGKDKNGMPVEPKPEPEKHKDSLNMWLCPRKEVIEQTKAPKAMTPSRIADSFQVIKNSPLSEWLIRPPYKEGSPKEVPGTEDRAGKQKFKSPMNTSWCSFNTADWVLPGKKMGNLSQLSSGEDKWLLRKKAQEVLLNSPLQEEHNFPPDHYGLPAVCDLFACMQLKVDKEKWLYRTPLQM

T28858	TARGETID	T28858
T28858	FORMERID	TTDI03340
T28858	UNIPROID	KCNC3_HUMAN
T28858	TARGNAME	Voltage-gated potassium channel Kv3.3 (KCNC3)
T28858	GENENAME	KCNC3
T28858	TARGTYPE	Literature-reported
T28858	SYNONYMS	Voltage-gated potassium channel subunit Kv3.3; Potassium voltage-gated channel subfamily C member 3; KSHIIID
T28858	FUNCTION	Voltage-gated potassium channel that plays an important role in the rapid repolarization of fast-firing brain neurons. The channel opens in response to the voltage difference across the membrane, forming a potassium-selective channel through which potassium ions pass in accordance with their electrochemical gradient. The channel displays rapid activation and inactivation kinetics. It plays a role in the regulation of the frequency, shape and duration of action potentials in Purkinje cells. Required for normal survival of cerebellar neurons, probably via its role in regulating the duration and frequency of action potentials that in turn regulate the activity of voltage-gated Ca(2+) channels and cellular Ca(2+) homeostasis (By similarity). Required for normal motor function. Plays a role in the reorganization of the cortical actin cytoskeleton and the formation of actin veil structures in neuronal growth cones via its interaction with HAX1 and the Arp2/3 complex.
T28858	BIOCLASS	Voltage-gated ion channel
T28858	SEQUENCE	MLSSVCVSSFRGRQGASKQQPAPPPQPPESPPPPPLPPQQQQPAQPGPAASPAGPPAPRGPGDRRAEPCPGLPAAAMGRHGGGGGDSGKIVINVGGVRHETYRSTLRTLPGTRLAGLTEPEAAARFDYDPGADEFFFDRHPGVFAYVLNYYRTGKLHCPADVCGPLFEEELGFWGIDETDVEACCWMTYRQHRDAEEALDSFEAPDPAGAANAANAAGAHDGGLDDEAGAGGGGLDGAGGELKRLCFQDAGGGAGGPPGGAGGAGGTWWRRWQPRVWALFEDPYSSRAARYVAFASLFFILISITTFCLETHEGFIHISNKTVTQASPIPGAPPENITNVEVETEPFLTYVEGVCVVWFTFEFLMRITFCPDKVEFLKSSLNIIDCVAILPFYLEVGLSGLSSKAAKDVLGFLRVVRFVRILRIFKLTRHFVGLRVLGHTLRASTNEFLLLIIFLALGVLIFATMIYYAERIGADPDDILGSNHTYFKNIPIGFWWAVVTMTTLGYGDMYPKTWSGMLVGALCALAGVLTIAMPVPVIVNNFGMYYSLAMAKQKLPKKKNKHIPRPPQPGSPNYCKPDPPPPPPPHPHHGSGGISPPPPITPPSMGVTVAGAYPAGPHTHPGLLRGGAGGLGIMGLPPLPAPGEPCPLAQEEVIEINRADPRPNGDPAAAALAHEDCPAIDQPAMSPEDKSPITPGSRGRYSRDRACFLLTDYAPSPDGSIRKATGAPPLPPQDWRKPGPPSFLPDLNANAAAWISP
T28858	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T03409	TARGETID	T03409
T03409	FORMERID	TTDR00962
T03409	UNIPROID	COX17_HUMAN
T03409	TARGNAME	Cytochrome c oxidase copper chaperone (COX17)
T03409	GENENAME	COX17
T03409	TARGTYPE	Literature-reported
T03409	SYNONYMS	Cytochrome c oxidase assembly protein COX17; COX17; CCO assembly protein COX17
T03409	FUNCTION	Copper chaperone for cytochromec oxidase (COX). Binds two copper ions and deliver them to the Cu(A) site of COX.
T03409	PDBSTRUC	2RNB; 2RN9; 2LGQ; 2L0Y
T03409	SEQUENCE	MPGLVDSNPAPPESQEKKPLKPCCACPETKKARDACIIEKGEEHCGHLIEAHKECMRALGFKI

T81409	TARGETID	T81409
T81409	FORMERID	TTDI00173
T81409	UNIPROID	SEPT6_HUMAN
T81409	TARGNAME	Septin-6 (SEPT6)
T81409	GENENAME	SEPTIN6
T81409	TARGTYPE	Literature-reported
T81409	SYNONYMS	KIAA0128
T81409	FUNCTION	Filament-forming cytoskeletal GTPase. Required for normal organization of the actin cytoskeleton. Involved in cytokinesis. May play a role in HCV RNA replication.
T81409	PDBSTRUC	2QAG
T81409	SEQUENCE	MAATDIARQVGEGCRTVPLAGHVGFDSLPDQLVNKSVSQGFCFNILCVGETGLGKSTLMDTLFNTKFEGEPATHTQPGVQLQSNTYDLQESNVRLKLTIVSTVGFGDQINKEDSYKPIVEFIDAQFEAYLQEELKIRRVLHTYHDSRIHVCLYFIAPTGHSLKSLDLVTMKKLDSKVNIIPIIAKADAISKSELTKFKIKITSELVSNGVQIYQFPTDDESVAEINGTMNAHLPFAVIGSTEELKIGNKMMRARQYPWGTVQVENEAHCDFVKLREMLIRVNMEDLREQTHTRHYELYRRCKLEEMGFKDTDPDSKPFSLQETYEAKRNEFLGELQKKEEEMRQMFVQRVKEKEAELKEAEKELHEKFDRLKKLHQDEKKKLEDKKKSLDDEVNAFKQRKTAAELLQSQGSQAGGSQTLKRDKEKKNNPWLCTE

T16180	TARGETID	T16180
T16180	FORMERID	TTDR00885
T16180	UNIPROID	E2F2_HUMAN
T16180	TARGNAME	Transcription factor E2F2 (E2F2)
T16180	GENENAME	E2F2
T16180	TARGTYPE	Literature-reported
T16180	SYNONYMS	E2F-2
T16180	FUNCTION	The DRTF1/E2F complex functions in the control of cell-cycle progression from g1 to s phase. E2F2 binds specifically to RB1 in a cell-cycle dependent manner. Transcription activator that binds DNA cooperatively with DP proteins through the E2 recognition site, 5'-TTTC[CG]CGC-3' found in the promoter region of a number of genes whose products are involved in cell cycle regulation or in DNA replication.
T16180	PDBSTRUC	1N4M
T16180	SEQUENCE	MLQGPRALASAAGQTPKVVPAMSPTELWPSGLSSPQLCPATATYYTPLYPQTAPPAAAPGTCLDATPHGPEGQVVRCLPAGRLPAKRKLDLEGIGRPVVPEFPTPKGKCIRVDGLPSPKTPKSPGEKTRYDTSLGLLTKKFIYLLSESEDGVLDLNWAAEVLDVQKRRIYDITNVLEGIQLIRKKAKNNIQWVGRGMFEDPTRPGKQQQLGQELKELMNTEQALDQLIQSCSLSFKHLTEDKANKRLAYVTYQDIRAVGNFKEQTVIAVKAPPQTRLEVPDRTEDNLQIYLKSTQGPIEVYLCPEEVQEPDSPSEEPLPSTSTLCPSPDSAQPSSSTDPSIMEPTASSVPAPAPTPQQAPPPPSLVPLEATDSLLELPHPLLQQTEDQFLSPTLACSSPLISFSPSLDQDDYLWGLEAGEGISDLFDSYDLGDLLIN

T02231	TARGETID	T02231
T02231	FORMERID	TTDI00176
T02231	UNIPROID	IL27B_HUMAN
T02231	TARGNAME	Interleukin-35 (IL35)
T02231	GENENAME	EBI3
T02231	TARGTYPE	Literature-reported
T02231	SYNONYMS	Interleukin-27 subunit beta; IL27B; IL-27B; IL-27 subunit beta; Epstein-Barr virus-induced gene 3 protein; EBV-induced gene 3 protein
T02231	FUNCTION	IL-27 has pro- and anti-inflammatory properties, that can regulate T-helper cell development, suppress T-cell proliferation, stimulate cytotoxic T-cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells. Among its target cells are CD4 T-helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. It also strongly synergizes with IL-12 to trigger interferon-gamma/IFN-gamma production of naive CD4 T-cells, binds to the cytokine receptor WSX-1/TCCR. Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines. Associates with IL27 to form the IL-27 interleukin, a heterodimeric cytokine which functions in innate immunity.
T02231	BIOCLASS	Cytokine: interleukin
T02231	SEQUENCE	MTPQLLLALVLWASCPPCSGRKGPPAALTLPRVQCRASRYPIAVDCSWTLPPAPNSTSPVSFIATYRLGMAARGHSWPCLQQTPTSTSCTITDVQLFSMAPYVLNVTAVHPWGSSSSFVPFITEHIIKPDPPEGVRLSPLAERQLQVQWEPPGSWPFPEIFSLKYWIRYKRQGAARFHRVGPIEATSFILRAVRPRARYYVQVAAQDLTDYGELSDWSLPATATMSLGK

T85835	TARGETID	T85835
T85835	FORMERID	TTDR01131
T85835	UNIPROID	FGL2_HUMAN
T85835	TARGNAME	Fibroleukin (FGL2)
T85835	GENENAME	FGL2
T85835	TARGTYPE	Literature-reported
T85835	SYNONYMS	PT49; Hfgl2; Fibrinogen-like protein 2; FGL2
T85835	FUNCTION	May play a role in physiologic lymphocyte functions at mucosal sites.
T85835	BIOCLASS	Fibrinogen
T85835	SEQUENCE	MKLANWYWLSSAVLATYGFLVVANNETEEIKDERAKDVCPVRLESRGKCEEAGECPYQVSLPPLTIQLPKQFSRIEEVFKEVQNLKEIVNSLKKSCQDCKLQADDNGDPGRNGLLLPSTGAPGEVGDNRVRELESEVNKLSSELKNAKEEINVLHGRLEKLNLVNMNNIENYVDSKVANLTFVVNSLDGKCSKCPSQEQIQSRPVQHLIYKDCSDYYAIGKRSSETYRVTPDPKNSSFEVYCDMETMGGGWTVLQARLDGSTNFTRTWQDYKAGFGNLRREFWLGNDKIHLLTKSKEMILRIDLEDFNGVELYALYDQFYVANEFLKYRLHVGNYNGTAGDALRFNKHYNHDLKFFTTPDKDNDRYPSGNCGLYYSSGWWFDACLSANLNGKYYHQKYRGVRNGIFWGTWPGVSEAHPGGYKSSFKEAKMMIRPKHFKP

T84616	TARGETID	T84616
T84616	FORMERID	TTDI00108
T84616	UNIPROID	BECN1_HUMAN
T84616	TARGNAME	Beclin-1 (BECN1)
T84616	GENENAME	BECN1
T84616	TARGTYPE	Literature-reported
T84616	SYNONYMS	Protein GT197; GT197; Coiledcoil myosinlike BCL2interacting protein; Coiled-coil myosin-like BCL2-interacting protein
T84616	FUNCTION	Acts as core subunit of the PI3K complex that mediates formation of phosphatidylinositol 3-phosphate; different complex forms are believed to play a role in multiple membrane trafficking pathways: PI3KC3-C1 is involved in initiation of autophagosomes and PI3KC3-C2 in maturation of autophagosomes and endocytosis. Involved in regulation of degradative endocytic trafficking and required for the abcission step in cytokinesis, probably in the context of PI3KC3-C2. Essential for the formation of PI3KC3-C2 but not PI3KC3-C1 PI3K complex forms. Involved in endocytosis. Protects against infection by a neurovirulent strain of Sindbis virus. May play a role in antiviral host defense. Plays a central role in autophagy.
T84616	PDBSTRUC	6HOK; 6HOJ; 6HOI; 6DCO; 6DCN
T84616	SEQUENCE	MEGSKTSNNSTMQVSFVCQRCSQPLKLDTSFKILDRVTIQELTAPLLTTAQAKPGETQEEETNSGEEPFIETPRQDGVSRRFIPPARMMSTESANSFTLIGEASDGGTMENLSRRLKVTGDLFDIMSGQTDVDHPLCEECTDTLLDQLDTQLNVTENECQNYKRCLEILEQMNEDDSEQLQMELKELALEEERLIQELEDVEKNRKIVAENLEKVQAEAERLDQEEAQYQREYSEFKRQQLELDDELKSVENQMRYAQTQLDKLKKTNVFNATFHIWHSGQFGTINNFRLGRLPSVPVEWNEINAAWGQTVLLLHALANKMGLKFQRYRLVPYGNHSYLESLTDKSKELPLYCSGGLRFFWDNKFDHAMVAFLDCVQQFKEEVEKGETRFCLPYRMDVEKGKIEDTGGSGGSYSIKTQFNSEEQWTKALKFMLTNLKWGLAWVSSQFYNK

T42890	TARGETID	T42890
T42890	FORMERID	TTDNR00666
T42890	UNIPROID	CASL_HUMAN
T42890	TARGNAME	Enhancer of filamentation 1 (NEDD9)
T42890	GENENAME	NEDD9
T42890	TARGTYPE	Literature-reported
T42890	SYNONYMS	p105; hEF1; Renal carcinoma antigen NY-REN-12; Neural precursor cell expressed developmentally down-regulated protein 9; NEDD-9; CasL; Cas scaffolding protein family member 2; CRK-associated substrate-related protein; CASS2; CAS-L
T42890	FUNCTION	May function in transmitting growth control signals between focal adhesions at the cell periphery and the mitotic spindle in response to adhesion or growth factor signals initiating cell proliferation. May play an important role in integrin beta-1 or B cell antigen receptor (BCR) mediated signaling in B- and T-cells. Integrin beta-1 stimulation leads to recruitment of various proteins including CRK, NCK and SHPTP2 to the tyrosine phosphorylated form. Docking protein which plays a central coordinating role for tyrosine-kinase-based signaling related to cell adhesion.
T42890	PDBSTRUC	5X3S; 2L81
T42890	SEQUENCE	MKYKNLMARALYDNVPECAEELAFRKGDILTVIEQNTGGLEGWWLCSLHGRQGIVPGNRVKLLIGPMQETASSHEQPASGLMQQTFGQQKLYQVPNPQAAPRDTIYQVPPSYQNQGIYQVPTGHGTQEQEVYQVPPSVQRSIGGTSGPHVGKKVITPVRTGHGYVYEYPSRYQKDVYDIPPSHTTQGVYDIPPSSAKGPVFSVPVGEIKPQGVYDIPPTKGVYAIPPSACRDEAGLREKDYDFPPPMRQAGRPDLRPEGVYDIPPTCTKPAGKDLHVKYNCDIPGAAEPVARRHQSLSPNHPPPQLGQSVGSQNDAYDVPRGVQFLEPPAETSEKANPQERDGVYDVPLHNPPDAKGSRDLVDGINRLSFSSTGSTRSNMSTSSTSSKESSLSASPAQDKRLFLDPDTAIERLQRLQQALEMGVSSLMALVTTDWRCYGYMERHINEIRTAVDKVELFLKEYLHFVKGAVANAACLPELILHNKMKRELQRVEDSHQILSQTSHDLNECSWSLNILAINKPQNKCDDLDRFVMVAKTVPDDAKQLTTTINTNAEALFRPGPGSLHLKNGPESIMNSTEYPHGGSQGQLLHPGDHKAQAHNKALPPGLSKEQAPDCSSSDGSERSWMDDYDYVHLQGKEEFERQQKELLEKENIMKQNKMQLEHHQLSQFQLLEQEITKPVENDISKWKPSQSLPTTNSGVSAQDRQLLCFYYDQCETHFISLLNAIDALFSCVSSAQPPRIFVAHSKFVILSAHKLVFIGDTLTRQVTAQDIRNKVMNSSNQLCEQLKTIVMATKMAALHYPSTTALQEMVHQVTDLSRNAQLFKRSLLEMATF

T43605	TARGETID	T43605
T43605	FORMERID	TTDR00313
T43605	UNIPROID	FGFP1_HUMAN
T43605	TARGNAME	Heparin binding protein (FGFBP1)
T43605	GENENAME	FGFBP1
T43605	TARGTYPE	Literature-reported
T43605	SYNONYMS	HBp17; HBP17 heparin-binding and FGF-binding protein; Fibroblast growth factor binding protein 1; FGFBP1; FGF-binding protein HBp17; FGF-BP
T43605	FUNCTION	Acts as a carrier protein that release fibroblast- binding factors (FGFs) from the extracellular matrix (EM) storage and thus enhance the mitogenic activity of FGFs. Enhances FGF2 signaling during tissue repair, angiogenesis and in tumor growth.
T43605	BIOCLASS	Fibroblast growth factor-binding
T43605	SEQUENCE	MKICSLTLLSFLLLAAQVLLVEGKKKVKNGLHSKVVSEQKDTLGNTQIKQKSRPGNKGKFVTKDQANCRWAATEQEEGISLKVECTQLDHEFSCVFAGNPTSCLKLKDERVYWKQVARNLRSQKDICRYSKTAVKTRVCRKDFPESSLKLVSSTLFGNTKPRKEKTEMSPREHIKGKETTPSSLAVTQTMATKAPECVEDPDMANQRKTALEFCGETWSSLCTFFLSIVQDTSC

T61227	TARGETID	T61227
T61227	FORMERID	TTDI03294
T61227	UNIPROID	ITPR1_HUMAN
T61227	TARGNAME	IP3 receptor isoform 1 (ITPR1)
T61227	GENENAME	ITPR1
T61227	TARGTYPE	Literature-reported
T61227	SYNONYMS	Type 1 inositol 1,4,5-trisphosphate receptor; Type 1 InsP3 receptor; InsP3R1; Inositol 1,4,5-trisphosphate receptor type 1; IP3R 1
T61227	FUNCTION	Involved in the regulation of epithelial secretion of electrolytes and fluid through the interaction with AHCYL1. Plays a role in ER stress-induced apoptosis. Cytoplasmic calcium released from the ER triggers apoptosis by the activation of CaM kinase II, eventually leading to the activation of downstream apoptosis pathways. Intracellular channel that mediates calcium release from the endoplasmic reticulum following stimulation by inositol 1,4,5-trisphosphate.
T61227	BIOCLASS	Ryanodine-inositol triphosphate calcium channel
T61227	SEQUENCE	MSDKMSSFLHIGDICSLYAEGSTNGFISTLGLVDDRCVVQPETGDLNNPPKKFRDCLFKLCPMNRYSAQKQFWKAAKPGANSTTDAVLLNKLHHAADLEKKQNETENRKLLGTVIQYGNVIQLLHLKSNKYLTVNKRLPALLEKNAMRVTLDEAGNEGSWFYIQPFYKLRSIGDSVVIGDKVVLNPVNAGQPLHASSHQLVDNPGCNEVNSVNCNTSWKIVLFMKWSDNKDDILKGGDVVRLFHAEQEKFLTCDEHRKKQHVFLRTTGRQSATSATSSKALWEVEVVQHDPCRGGAGYWNSLFRFKHLATGHYLAAEVDPDFEEECLEFQPSVDPDQDASRSRLRNAQEKMVYSLVSVPEGNDISSIFELDPTTLRGGDSLVPRNSYVRLRHLCTNTWVHSTNIPIDKEEEKPVMLKIGTSPVKEDKEAFAIVPVSPAEVRDLDFANDASKVLGSIAGKLEKGTITQNERRSVTKLLEDLVYFVTGGTNSGQDVLEVVFSKPNRERQKLMREQNILKQIFKLLQAPFTDCGDGPMLRLEELGDQRHAPFRHICRLCYRVLRHSQQDYRKNQEYIAKQFGFMQKQIGYDVLAEDTITALLHNNRKLLEKHITAAEIDTFVSLVRKNREPRFLDYLSDLCVSMNKSIPVTQELICKAVLNPTNADILIETKLVLSRFEFEGVSSTGENALEAGEDEEEVWLFWRDSNKEIRSKSVRELAQDAKEGQKEDRDVLSYYRYQLNLFARMCLDRQYLAINEISGQLDVDLILRCMSDENLPYDLRASFCRLMLHMHVDRDPQEQVTPVKYARLWSEIPSEIAIDDYDSSGASKDEIKERFAQTMEFVEEYLRDVVCQRFPFSDKEKNKLTFEVVNLARNLIYFGFYNFSDLLRLTKILLAILDCVHVTTIFPISKMAKGEENKGNNDVEKLKSSNVMRSIHGVGELMTQVVLRGGGFLPMTPMAAAPEGNVKQAEPEKEDIMVMDTKLKIIEILQFILNVRLDYRISCLLCIFKREFDESNSQTSETSSGNSSQEGPSNVPGALDFEHIEEQAEGIFGGSEENTPLDLDDHGGRTFLRVLLHLTMHDYPPLVSGALQLLFRHFSQRQEVLQAFKQVQLLVTSQDVDNYKQIKQDLDQLRSIVEKSELWVYKGQGPDETMDGASGENEHKKTEEGNNKPQKHESTSSYNYRVVKEILIRLSKLCVQESASVRKSRKQQQRLLRNMGAHAVVLELLQIPYEKAEDTKMQEIMRLAHEFLQNFCAGNQQNQALLHKHINLFLNPGILEAVTMQHIFMNNFQLCSEINERVVQHFVHCIETHGRNVQYIKFLQTIVKAEGKFIKKCQDMVMAELVNSGEDVLVFYNDRASFQTLIQMMRSERDRMDENSPLMYHIHLVELLAVCTEGKNVYTEIKCNSLLPLDDIVRVVTHEDCIPEVKIAYINFLNHCYVDTEVEMKEIYTSNHMWKLFENFLVDICRACNNTSDRKHADSILEKYVTEIVMSIVTTFFSSPFSDQSTTLQTRQPVFVQLLQGVFRVYHCNWLMPSQKASVESCIRVLSDVAKSRAIAIPVDLDSQVNNLFLKSHSIVQKTAMNWRLSARNAARRDSVLAASRDYRNIIERLQDIVSALEDRLRPLVQAELSVLVDVLHRPELLFPENTDARRKCESGGFICKLIKHTKQLLEENEEKLCIKVLQTLREMMTKDRGYGEKLISIDELDNAELPPAPDSENATEELEPSPPLRQLEDHKRGEALRQVLVNRYYGNVRPSGRRESLTSFGNGPLSAGGPGKPGGGGGGSGSSSMSRGEMSLAEVQCHLDKEGASNLVIDLIMNASSDRVFHESILLAIALLEGGNTTIQHSFFCRLTEDKKSEKFFKVFYDRMKVAQQEIKATVTVNTSDLGNKKKDDEVDRDAPSRKKAKEPTTQITEEVRDQLLEASAATRKAFTTFRREADPDDHYQPGEGTQATADKAKDDLEMSAVITIMQPILRFLQLLCENHNRDLQNFLRCQNNKTNYNLVCETLQFLDCICGSTTGGLGLLGLYINEKNVALINQTLESLTEYCQGPCHENQNCIATHESNGIDIITALILNDINPLGKKRMDLVLELKNNASKLLLAIMESRHDSENAERILYNMRPKELVEVIKKAYMQGEVEFEDGENGEDGAASPRNVGHNIYILAHQLARHNKELQSMLKPGGQVDGDEALEFYAKHTAQIEIVRLDRTMEQIVFPVPSICEFLTKESKLRIYYTTERDEQGSKINDFFLRSEDLFNEMNWQKKLRAQPVLYWCARNMSFWSSISFNLAVLMNLLVAFFYPFKGVRGGTLEPHWSGLLWTAMLISLAIVIALPKPHGIRALIASTILRLIFSVGLQPTLFLLGAFNVCNKIIFLMSFVGNCGTFTRGYRAMVLDVEFLYHLLYLVICAMGLFVHEFFYSLLLFDLVYREETLLNVIKSVTRNGRSIILTAVLALILVYLFSIVGYLFFKDDFILEVDRLPNETAVPETGESLASEFLFSDVCRVESGENCSSPAPREELVPAEETEQDKEHTCETLLMCIVTVLSHGLRSGGGVGDVLRKPSKEEPLFAARVIYDLLFFFMVIIIVLNLIFGVIIDTFADLRSEKQKKEEILKTTCFICGLERDKFDNKTVTFEEHIKEEHNMWHYLCFIVLVKVKDSTEYTGPESYVAEMIKERNLDWFPRMRAMSLVSSDSEGEQNELRNLQEKLESTMKLVTNLSGQLSELKDQMTEQRKQKQRIGLLGHPPHMNVNPQQPA
T61227	DRUGINFO	D0MY2Y	xestospongin C	Investigative
T61227	DRUGINFO	D06YZB	inositol 2,4,5-trisphosphate	Investigative
T61227	DRUGINFO	D06KHR	decavanadate	Investigative
T61227	DRUGINFO	D07ZAJ	PIP2	Investigative

T95992	TARGETID	T95992
T95992	UNIPROID	LASP1_HUMAN
T95992	TARGNAME	LIM and SH3 domain protein 1 (LASP1)
T95992	GENENAME	LASP1
T95992	TARGTYPE	Literature-reported
T95992	SYNONYMS	Metastatic lymph node gene 50 protein; MLN50; MLN 50; LASP-1
T95992	FUNCTION	Plays an important role in the regulation of dynamic actin-based, cytoskeletal activities. Agonist-dependent changes in LASP1 phosphorylation may also serve to regulate actin-associated ion transport activities, not only in the parietal cell but also in certain other F-actin-rich secretory epithelial cell types.
T95992	PDBSTRUC	3I35
T95992	SEQUENCE	MNPNCARCGKIVYPTEKVNCLDKFWHKACFHCETCKMTLNMKNYKGYEKKPYCNAHYPKQSFTMVADTPENLRLKQQSELQSQVRYKEEFEKNKGKGFSVVADTPELQRIKKTQDQISNIKYHEEFEKSRMGPSGGEGMEPERRDSQDGSSYRRPLEQQQPHHIPTSAPVYQQPQQQPVAQSYGGYKEPAAPVSIQRSAPGGGGKRYRAVYDYSAADEDEVSFQDGDTIVNVQQIDDGWMYGTVERTGDTGMLPANYVEAI

T52595	TARGETID	T52595
T52595	FORMERID	TTDNC00408
T52595	UNIPROID	MTF1_HUMAN
T52595	TARGNAME	Metal regulatory transcription factor 1 (MTF1)
T52595	GENENAME	MTF1
T52595	TARGTYPE	Literature-reported
T52595	SYNONYMS	Transcription factor MTF1; MTF1; MREbinding transcription factor
T52595	FUNCTION	Activates the metallothionein I promoter. Binds to the metal responsive element (MRE).
T52595	BIOCLASS	Zinc-finger
T52595	SEQUENCE	MGEHSPDNNIIYFEAEEDELTPDDKMLRFVDKNGLVPSSSGTVYDRTTVLIEQDPGTLEDEDDDGQCGEHLPFLVGGEEGFHLIDHEAMSQGYVQHIISPDQIHLTINPGSTPMPRNIEGATLTLQSECPETKRKEVKRYQCTFEGCPRTYSTAGNLRTHQKTHRGEYTFVCNQEGCGKAFLTSYSLRIHVRVHTKEKPFECDVQGCEKAFNTLYRLKAHQRLHTGKTFNCESEGCSKYFTTLSDLRKHIRTHTGEKPFRCDHDGCGKAFAASHHLKTHVRTHTGERPFFCPSNGCEKTFSTQYSLKSHMKGHDNKGHSYNALPQHNGSEDTNHSLCLSDLSLLSTDSELRENSSTTQGQDLSTISPAIIFESMFQNSDDTAIQEDPQQTASLTESFNGDAESVSDVPPSTGNSASLSLPLVLQPGLSEPPQPLLPASAPSAPPPAPSLGPGSQQAAFGNPPALLQPPEVPVPHSTQFAANHQEFLPHPQAPQPIVPGLSVVAGASASAAAVASAVAAPAPPQSTTEPLPAMVQTLPLGANSVLTNNPTITITPTPNTAILQSSLVMGEQNLQWILNGATSSPQNQEQIQQASKVEKVFFTTAVPVASSPGSSVQQIGLSVPVIIIKQEEACQCQCACRDSAKERASSRRKGCSSPPPPEPSPQAPDGPSLQLPAQTFSSAPVPGSSSSTLPSSCEQSRQAETPSDPQTETLSAMDVSEFLSLQSLDTPSNLIPIEALLQGEEEMGLTSSFSK

T39738	TARGETID	T39738
T39738	FORMERID	TTDI00109
T39738	UNIPROID	CUL7_HUMAN
T39738	TARGNAME	Cullin-7 (CUL-7)
T39738	GENENAME	CUL7
T39738	TARGTYPE	Literature-reported
T39738	SYNONYMS	KIAA0076
T39738	FUNCTION	Core component of the 3M complex, a complex required to regulate microtubule dynamics and genome integrity. It is unclear how the 3M complex regulates microtubules, it could act by controlling the level of a microtubule stabilizer. Interaction with CUL9 is required to inhibit CUL9 activity and ubiquitination of BIRC5. Core component of a Cul7-RING ubiquitin-protein ligase with FBXW8, which mediates ubiquitination and consequent degradation of target proteins such as GORASP1, IRS1 and MAP4K1/HPK1. Ubiquitination of GORASP1 regulates Golgi morphogenesis and dendrite patterning in brain. Mediates ubiquitination and degradation of IRS1 in a mTOR-dependent manner: the Cul7-RING(FBXW8) complex recognizes and binds IRS1 previously phosphorylated by S6 kinase (RPS6KB1 or RPS6KB2). The Cul7-RING(FBXW8) complex also mediates ubiquitination of MAP4K1/HPK1: recognizes and binds autophosphorylated MAP4K1/HPK1, leading to its degradation, thereby affecting cell proliferation and differentiation. Acts as a regulator in trophoblast cell epithelial-mesenchymal transition and placental development. Does not promote polyubiquitination and proteasomal degradation of p53/TP53. While the Cul7-RING(FBXW8) and the 3M complexes are associated and involved in common processes, CUL7 and the Cul7-RING(FBXW8) complex may be have additional functions. Core component of the 3M and Cul7-RING(FBXW8) complexes, which mediates the ubiquitination of target proteins.
T39738	PDBSTRUC	2JNG
T39738	SEQUENCE	MVGELRYREFRVPLGPGLHAYPDELIRQRVGHDGHPEYQIRWLILRRGDEGDGGSGQVDCKAEHILLWMSKDEIYANCHKMLGEDGQVIGPSQESAGEVGALDKSVLEEMETDVKSLIQRALRQLEECVGTIPPAPLLHTVHVLSAYASIEPLTGVFKDPRVLDLLMHMLSSPDYQIRWSAGRMIQALSSHDAGTRTQILLSLSQQEAIEKHLDFDSRCALLALFAQATLSEHPMSFEGIQLPQVPGRVLFSLVKRYLHVTSLLDQLNDSAAEPGAQNTSAPEELSGERGQLELEFSMAMGTLISELVQAMRWDQASDRPRSSARSPGSIFQPQLADVSPGLPAAQAQPSFRRSRRFRPRSEFASGNTYALYVRDTLQPGMRVRMLDDYEEISAGDEGEFRQSNNGVPPVQVFWESTGRTYWVHWHMLEILGFEEDIEDMVEADEYQGAVASRVLGRALPAWRWRPMTELYAVPYVLPEDEDTEECEHLTLAEWWELLFFIKKLDGPDHQEVLQILQENLDGEILDDEILAELAVPIELAQDLLLTLPQRLNDSALRDLINCHVYKKYGPEALAGNQAYPSLLEAQEDVLLLDAQAQAKDSEDAAKVEAKEPPSQSPNTPLQRLVEGYGPAGKILLDLEQALSSEGTQENKVKPLLLQLQRQPQPFLALMQSLDTPETNRTLHLTVLRILKQLVDFPEALLLPWHEAVDACMACLRSPNTDREVLQELIFFLHRLTSVSRDYAVVLNQLGARDAISKALEKHLGKLELAQELRDMVFKCEKHAHLYRKLITNILGGCIQMVLGQIEDHRRTHQPINIPFFDVFLRYLCQGSSVEVKEDKCWEKVEVSSNPHRASKLTDHNPKTYWESNGSAGSHYITLHMRRGILIRQLTLLVASEDSSYMPARVVVCGGDSTSSLHTELNSVNVMPSASRVILLENLTRFWPIIQIRIKRCQQGGIDTRIRGLEILGPKPTFWPVFREQLCRHTRLFYMVRAQAWSQDMAEDRRSLLHLSSRLNGALRQEQNFADRFLPDDEAAQALGKTCWEALVSPVVQNITSPDEDGISPLGWLLDQYLECQEAVFNPQSRGPAFFSRVRRLTHLLVHVEPCEAPPPVVATPRPKGRNRSHDWSSLATRGLPSSIMRNLTRCWRAVVEKQVNNFLTSSWRDDDFVPRYCEHFNILQNSSSELFGPRAAFLLALQNGCAGALLKLPFLKAAHVSEQFARHIDQQIQGSRIGGAQEMERLAQLQQCLQAVLIFSGLEIATTFEHYYQHYMADRLLGVVSSWLEGAVLEQIGPCFPNRLPQQMLQSLSTSKELQRQFHVYQLQQLDQELLKLEDTEKKIQVGLGASGKEHKSEKEEEAGAAAVVDVAEGEEEEEENEDLYYEGAMPEVSVLVLSRHSWPVASICHTLNPRTCLPSYLRGTLNRYSNFYNKSQSHPALERGSQRRLQWTWLGWAELQFGNQTLHVSTVQMWLLLYLNDLKAVSVESLLAFSGLSADMLNQAIGPLTSSRGPLDLHEQKDIPGGVLKIRDGSKEPRSRWDIVRLIPPQTYLQAEGEDGQNLEKRRNLLNCLIVRILKAHGDEGLHIDQLVCLVLEAWQKGPCPPRGLVSSLGKGSACSSTDVLSCILHLLGKGTLRRHDDRPQVLSYAVPVTVMEPHTESLNPGSSGPNPPLTFHTLQIRSRGVPYASCTATQSFSTFR

T29187	TARGETID	T29187
T29187	FORMERID	TTDI02618
T29187	UNIPROID	POSTN_HUMAN
T29187	TARGNAME	Periostin (POSTN)
T29187	GENENAME	POSTN
T29187	TARGTYPE	Literature-reported
T29187	SYNONYMS	POSTN; PN; Osteoblastspecific factor 2
T29187	FUNCTION	Enhances incorporation of BMP1 in the fibronectin matrix ofconnective tissues, and subsequent proteolytic activation of lysyl oxidase LOX. Induces cell attachment and spreading and plays a role in cell adhesion. May play a role in extracellular matrix mineralization. {ECO:0000250, ECO:0000269|PubMed:12235007, ECO:0000269|PubMed:18450759}.
T29187	PDBSTRUC	5YJH; 5YJG; 5WT7
T29187	SEQUENCE	MIPFLPMFSLLLLLIVNPINANNHYDKILAHSRIRGRDQGPNVCALQQILGTKKKYFSTCKNWYKKSICGQKTTVLYECCPGYMRMEGMKGCPAVLPIDHVYGTLGIVGATTTQRYSDASKLREEIEGKGSFTYFAPSNEAWDNLDSDIRRGLESNVNVELLNALHSHMINKRMLTKDLKNGMIIPSMYNNLGLFINHYPNGVVTVNCARIIHGNQIATNGVVHVIDRVLTQIGTSIQDFIEAEDDLSSFRAAAITSDILEALGRDGHFTLFAPTNEAFEKLPRGVLERIMGDKVASEALMKYHILNTLQCSESIMGGAVFETLEGNTIEIGCDGDSITVNGIKMVNKKDIVTNNGVIHLIDQVLIPDSAKQVIELAGKQQTTFTDLVAQLGLASALRPDGEYTLLAPVNNAFSDDTLSMDQRLLKLILQNHILKVKVGLNELYNGQILETIGGKQLRVFVYRTAVCIENSCMEKGSKQGRNGAIHIFREIIKPAEKSLHEKLKQDKRFSTFLSLLEAADLKELLTQPGDWTLFVPTNDAFKGMTSEEKEILIRDKNALQNIILYHLTPGVFIGKGFEPGVTNILKTTQGSKIFLKEVNDTLLVNELKSKESDIMTTNGVIHVVDKLLYPADTPVGNDQLLEILNKLIKYIQIKFVRGSTFKEIPVTVYTTKIITKVVEPKIKVIEGSLQPIIKTEGPTLTKVKIEGEPEFRLIKEGETITEVIHGEPIIKKYTKIIDGVPVEITEKETREERIITGPEIKYTRISTGGGETEETLKKLLQEEVTKVTKFIEGGDGHLFEDEEIKRLLQGDTPVRKLQANKKVQGSRRRLREGRSQ

T86587	TARGETID	T86587
T86587	FORMERID	TTDR00793
T86587	UNIPROID	OZF_HUMAN
T86587	TARGNAME	Zinc finger protein OZF (ZNF146)
T86587	GENENAME	ZNF146
T86587	TARGTYPE	Literature-reported
T86587	SYNONYMS	Zinc finger protein 146; Only zinc finger protein; OZF
T86587	FUNCTION	A nuclear zinc finger protein consisting of a single domain of 10 zinc finger motifs of the Kruppel type, preceded by 10 amino acids. Involved in gene regulation and  tumorigenesis.
T86587	BIOCLASS	Zinc-finger
T86587	SEQUENCE	MSHLSQQRIYSGENPFACKVCGKVFSHKSNLTEHEHFHTREKPFECNECGKAFSQKQYVIKHQNTHTGEKLFECNECGKSFSQKENLLTHQKIHTGEKPFECKDCGKAFIQKSNLIRHQRTHTGEKPFVCKECGKTFSGKSNLTEHEKIHIGEKPFKCSECGTAFGQKKYLIKHQNIHTGEKPYECNECGKAFSQRTSLIVHVRIHSGDKPYECNVCGKAFSQSSSLTVHVRSHTGEKPYGCNECGKAFSQFSTLALHLRIHTGKKPYQCSECGKAFSQKSHHIRHQKIHTH

T09513	TARGETID	T09513
T09513	FORMERID	TTDI02622
T09513	UNIPROID	CD5R1_HUMAN
T09513	TARGNAME	CDK5 activator 1 (CDK5R1)
T09513	GENENAME	CDK5R1
T09513	TARGTYPE	Literature-reported
T09513	SYNONYMS	TPKII regulatory subunit; NCK5A; Cyclindependent kinase 5 regulatory subunit 1; Cyclindependent kinase 5 activator 1, p25; Cyclindependent kinase 5 activator 1; Cyclin-dependent kinase 5 regulatory subunit 1; Cyclin-dependent kinase 5 activator 1; CDK5R
T09513	FUNCTION	The complex p35/CDK5 is required for neurite outgrowth and cortical lamination. Involved in dendritic spine morphogenesis by mediating the EFNA1-EPHA4 signaling. Activator of TPKII. The complex p35/CDK5 participates in the regulation of the circadian clock by modulating the function of CLOCK protein: phosphorylates CLOCK at 'Thr-451' and 'Thr-461' and regulates the transcriptional activity of the CLOCK-ARNTL/BMAL1 heterodimer in association with altered stability and subcellular distribution. p35 is a neuron specific activator of CDK5.
T09513	PDBSTRUC	3O0G; 1UNL; 1UNH; 1UNG; 1H4L
T09513	SEQUENCE	MGTVLSLSPSYRKATLFEDGAATVGHYTAVQNSKNAKDKNLKRHSIISVLPWKRIVAVSAKKKNSKKVQPNSSYQNNITHLNNENLKKSLSCANLSTFAQPPPAQPPAPPASQLSGSQTGGSSSVKKAPHPAVTSAGTPKRVIVQASTSELLRCLGEFLCRRCYRLKHLSPTDPVLWLRSVDRSLLLQGWQDQGFITPANVVFLYMLCRDVISSEVGSDHELQAVLLTCLYLSYSYMGNEISYPLKPFLVESCKEAFWDRCLSVINLMSSKMLQINADPHYFTQVFSDLKNESGQEDKKRLLLGLDR

T57291	TARGETID	T57291
T57291	FORMERID	TTDR00363
T57291	UNIPROID	2A5A_HUMAN
T57291	TARGNAME	PP2A B subunit isoform R5-alpha (PPP2R5A)
T57291	GENENAME	PPP2R5A
T57291	TARGTYPE	Literature-reported
T57291	SYNONYMS	Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit alpha isoform; Protein phosphatase-2A; PR61alpha; PP2A, B subunit, R5 alpha isoform; PP2A, B subunit, PR61 alpha isoform; PP2A, B subunit, B56 alpha isoform; PP2A, B subunit, B' alpha isoform; PP2A B subunit isoform PR61-alpha; PP2A B subunit isoform B56-alpha; PP2A B subunit isoform B'-alpha
T57291	FUNCTION	The B regulatory subunit might modulate substrate selectivity and catalytic activity, and also might direct the localization of the catalytic enzyme to a particular subcellular compartment.
T57291	SEQUENCE	MSSSSPPAGAASAAISASEKVDGFTRKSVRKAQRQKRSQGSSQFRSQGSQAELHPLPQLKDATSNEQQELFCQKLQQCCILFDFMDSVSDLKSKEIKRATLNELVEYVSTNRGVIVESAYSDIVKMISANIFRTLPPSDNPDFDPEEDEPTLEASWPHIQLVYEFFLRFLESPDFQPSIAKRYIDQKFVQQLLELFDSEDPRERDFLKTVLHRIYGKFLGLRAFIRKQINNIFLRFIYETEHFNGVAELLEILGSIINGFALPLKAEHKQFLMKVLIPMHTAKGLALFHAQLAYCVVQFLEKDTTLTEPVIRGLLKFWPKTCSQKEVMFLGEIEEILDVIEPTQFKKIEEPLFKQISKCVSSSHFQVAERALYFWNNEYILSLIEENIDKILPIMFASLYKISKEHWNPTIVALVYNVLKTLMEMNGKLFDDLTSSYKAERQREKKKELEREELWKKLEELKLKKALEKQNSAYNMHSILSNTSAE
T57291	DRUGINFO	D0W4IL	NORCANTHARIDIN	Investigative

T16555	TARGETID	T16555
T16555	FORMERID	TTDI03438
T16555	UNIPROID	P2Y14_HUMAN
T16555	TARGNAME	P2Y purinoceptor 14 (P2RY14)
T16555	GENENAME	P2RY14
T16555	TARGTYPE	Literature-reported
T16555	SYNONYMS	UDP-glucose receptor; P2Y14; KIAA0001; GPR105; G-protein coupled receptor 105
T16555	FUNCTION	Receptor for UDP-glucose and other UDP-sugar coupled to G-proteins. Not activated by ATP, ADP, UTP or ATP.
T16555	PDBSTRUC	2B6V
T16555	SEQUENCE	MINSTSTQPPDESCSQNLLITQQIIPVLYCMVFIAGILLNGVSGWIFFYVPSSKSFIIYLKNIVIADFVMSLTFPFKILGDSGLGPWQLNVFVCRVSAVLFYVNMYVSIVFFGLISFDRYYKIVKPLWTSFIQSVSYSKLLSVIVWMLMLLLAVPNIILTNQSVREVTQIKCIELKSELGRKWHKASNYIFVAIFWIVFLLLIVFYTAITKKIFKSHLKSSRNSTSVKKKSSRNIFSIVFVFFVCFVPYHIARIPYTKSQTEAHYSCQSKEILRYMKEFTLLLSAANVCLDPIIYFFLCQPFREILCKKLHIPLKAQNDLDISRIKRGNTTLESTDTL
T16555	DRUGINFO	D05MXI	PPTN	Investigative
T16555	DRUGINFO	D07TSE	2-thio-UDP	Investigative
T16555	DRUGINFO	D09EGQ	MRS2905	Investigative
T16555	DRUGINFO	D0E8TW	MRS2690	Investigative
T16555	DRUGINFO	D0O8AN	UDP-glucuronic acid	Investigative
T16555	DRUGINFO	D0Q5SV	alpha.beta-methylene-2-thio-UDP	Investigative
T16555	DRUGINFO	D0V9TZ	MRS2802	Investigative
T16555	DRUGINFO	D07MIE	UDP-glucose	Investigative

T14181	TARGETID	T14181
T14181	FORMERID	TTDI00103
T14181	UNIPROID	TERF2_HUMAN
T14181	TARGNAME	Telomeric repeat-binding factor 2 (TERF2)
T14181	GENENAME	TERF2
T14181	TARGTYPE	Literature-reported
T14181	SYNONYMS	Telomeric DNA-binding protein; TTAGGG repeat-binding factor 2; TRF2; TRBF2
T14181	FUNCTION	Binds the telomeric double-stranded 5'-TTAGGG-3' repeat and plays a central role in telomere maintenance and protection against end-to-end fusion of chromosomes. In addition to its telomeric DNA-binding role, required to recruit a number of factors and enzymes required for telomere protection, including the shelterin complex, TERF2IP/RAP1 and DCLRE1B/Apollo. Component of the shelterin complex (telosome) that is involved in the regulation of telomere length and protection. Shelterin associates with arrays of double-stranded 5'-TTAGGG-3' repeats added by telomerase and protects chromosome ends; without its protective activity, telomeres are no longer hidden from the DNA damage surveillance and chromosome ends are inappropriately processed by DNA repair pathways. Together with DCLRE1B/Apollo, plays a key role in telomeric loop (T loop) formation by generating 3' single-stranded overhang at the leading end telomeres: T loops have been proposed to protect chromosome ends from degradation and repair. Required both to recruit DCLRE1B/Apollo to telomeres and activate the exonuclease activity of DCLRE1B/Apollo. Preferentially binds to positive supercoiled DNA. Together with DCLRE1B/Apollo, required to control the amount of DNA topoisomerase (TOP1, TOP2A and TOP2B) needed for telomere replication during fork passage and prevent aberrant telomere topology. Recruits TERF2IP/RAP1 to telomeres, thereby participating in to repressing homology-directed repair (HDR), which can affect telomere length.
T14181	PDBSTRUC	6J67; 5XYF; 5WQD; 4RQI; 4M7C
T14181	SEQUENCE	MAAGAGTAGPASGPGVVRDPAASQPRKRPGREGGEGARRSDTMAGGGGSSDGSGRAAGRRASRSSGRARRGRHEPGLGGPAERGAGEARLEEAVNRWVLKFYFHEALRAFRGSRYGDFRQIRDIMQALLVRPLGKEHTVSRLLRVMQCLSRIEEGENLDCSFDMEAELTPLESAINVLEMIKTEFTLTEAVVESSRKLVKEAAVIICIKNKEFEKASKILKKHMSKDPTTQKLRNDLLNIIREKNLAHPVIQNFSYETFQQKMLRFLESHLDDAEPYLLTMAKKALKSESAASSTGKEDKQPAPGPVEKPPREPARQLRNPPTTIGMMTLKAAFKTLSGAQDSEAAFAKLDQKDLVLPTQALPASPALKNKRPRKDENESSAPADGEGGSELQPKNKRMTISRLVLEEDSQSTEPSAGLNSSQEAASAPPSKPTVLNQPLPGEKNPKVPKGKWNSSNGVEEKETWVEEDELFQVQAAPDEDSTTNITKKQKWTVEESEWVKAGVQKYGEGNWAAISKNYPFVNRTAVMIKDRWRTMKRLGMN

T49542	TARGETID	T49542
T49542	FORMERID	TTDI03575
T49542	UNIPROID	TESK1_HUMAN
T49542	TARGNAME	Testis-specific kinase 1 (TESK1)
T49542	GENENAME	TESK1
T49542	TARGTYPE	Literature-reported
T49542	SYNONYMS	Testicular protein kinase 1; Dual specificity testis-specific protein kinase 1
T49542	FUNCTION	Dual specificity protein kinase activity catalyzing autophosphorylation and phosphorylation of exogenous substrates on both serine/threonine and tyrosine residues. Probably plays a central role at and after the meiotic phase of spermatogenesis (By similarity).
T49542	ECNUMBER	EC 2.7.12.1
T49542	SEQUENCE	MAGERPPLRGPGPGPGEVPGEGPPGPGGTGGGPGRGRPSSYRALRSAVSSLARVDDFHCAEKIGAGFFSEVYKVRHRQSGQVMVLKMNKLPSNRGNTLREVQLMNRLRHPNILRFMGVCVHQGQLHALTEYMNGGTLEQLLSSPEPLSWPVRLHLALDIARGLRYLHSKGVFHRDLTSKNCLVRREDRGFTAVVGDFGLAEKIPVYREGARKEPLAVVGSPYWMAPEVLRGELYDEKADVFAFGIVLCELIARVPADPDYLPRTEDFGLDVPAFRTLVGDDCPLPFLLLAIHCCNLEPSTRAPFTEITQHLEWILEQLPEPAPLTRTALTHNQGSVARGGPSATLPRPDPRLSRSRSDLFLPPSPESPPNWGDNLTRVNPFSLREDLRGGKIKLLDTPSKPVLPLVPPSPFPSTQLPLVTTPETLVQPGTPARRCRSLPSSPELPRRMETALPGPGPPAVGPSAEEKMECEGSSPEPEPPGPAPQLPLAVATDNFISTCSSASQPWSPRSGPVLNNNPPAVVVNSPQGWAGEPWNRAQHSLPRAAALERTEPSPPPSAPREPDEGLPCPGCCLGPFSFGFLSMCPRPTPAVARYRNLNCEAGSLLCHRGHHAKPPTPSLQLPGARS
T49542	DRUGINFO	D0F6NZ	PMID22902653C30	Investigative
T49542	DRUGINFO	D0FC4Y	PMID22902653C31	Investigative
T49542	DRUGINFO	D0S0XD	PMID22902653C35	Investigative

T78349	TARGETID	T78349
T78349	FORMERID	TTDR00841
T78349	UNIPROID	ELAV1_HUMAN
T78349	TARGNAME	ELAV-like protein 1 (ELAVL1)
T78349	GENENAME	ELAVL1
T78349	TARGTYPE	Literature-reported
T78349	SYNONYMS	HuR; Hu-antigen R
T78349	FUNCTION	Involved in embryonic stem cells (ESCs) differentiation: preferentially binds mRNAs that are not methylated by N6-methyladenosine (m6A), stabilizing them, promoting ESCs differentiation. Binds to poly-U elements and AU-rich elements (AREs) in the 3'-UTR of target mRNAs. Binds avidly to the AU-rich element in FOS and IL3/interleukin-3 mRNAs. In the case of the FOS AU-rich element, binds to a core element of 27 nucleotides that contain AUUUA, AUUUUA, and AUUUUUA motifs. Binds preferentially to the 5'-UUUU[AG]UUU-3' motif in vitro. With ZNF385A, binds the 3'-UTR of p53/TP53 mRNA to control their nuclear export induced by CDKN2A. Hence, may regulate p53/TP53 expression and mediate in part the CDKN2A anti-proliferative activity. May also bind with ZNF385A the CCNB1 mRNA. Increases the stability of the leptin mRNA harboring an AU-rich element (ARE) in its 3' UTR. RNA-binding protein that binds to the 3'-UTR region of mRNAs and increases their stability.
T78349	PDBSTRUC	6GD3; 6GD2; 6GD1; 6GC5; 6G2K
T78349	SEQUENCE	MSNGYEDHMAEDCRGDIGRTNLIVNYLPQNMTQDELRSLFSSIGEVESAKLIRDKVAGHSLGYGFVNYVTAKDAERAINTLNGLRLQSKTIKVSYARPSSEVIKDANLYISGLPRTMTQKDVEDMFSRFGRIINSRVLVDQTTGLSRGVAFIRFDKRSEAEEAITSFNGHKPPGSSEPITVKFAANPNQNKNVALLSQLYHSPARRFGGPVHHQAQRFRFSPMGVDHMSGLSGVNVPGNASSGWCIFIYNLGQDADEGILWQMFGPFGAVTNVKVIRDFNTNKCKGFGFVTMTNYEEAAMAIASLNGYRLGDKILQVSFKTNKSHK

T59493	TARGETID	T59493
T59493	FORMERID	TTDI03023
T59493	UNIPROID	AAAT_HUMAN
T59493	TARGNAME	Alanine/serine/cysteine transporter 2 (SLC1A5)
T59493	GENENAME	SLC1A5
T59493	TARGTYPE	Literature-reported
T59493	SYNONYMS	Solute carrier family 1 member 5; Sodium-dependent neutral amino acid transporter type 2; RDRC; RDR; RD114/simian type D retrovirus receptor; Neutral amino acid transporter B(0); M7V1; Baboon M7 virus receptor; ATB(0); ASCT2
T59493	FUNCTION	Sodium-dependent amino acids transporter that has a broad substrate specificity, with a preference for zwitterionic amino acids. It accepts as substrates all neutral amino acids, including glutamine, asparagine, and branched-chain and aromatic amino acids, and excludes methylated, anionic, and cationic amino acids. Through binding of the fusogenic protein syncytin-1/ERVW-1 may mediate trophoblasts syncytialization, the spontaneous fusion of their plasma membranes, an essential process in placental development.
T59493	PDBSTRUC	6GCT; 5MJU; 5LM4; 5LLU; 5LLM
T59493	SEQUENCE	MVADPPRDSKGLAAAEPTANGGLALASIEDQGAAAGGYCGSRDQVRRCLRANLLVLLTVVAVVAGVALGLGVSGAGGALALGPERLSAFVFPGELLLRLLRMIILPLVVCSLIGGAASLDPGALGRLGAWALLFFLVTTLLASALGVGLALALQPGAASAAINASVGAAGSAENAPSKEVLDSFLDLARNIFPSNLVSAAFRSYSTTYEERNITGTRVKVPVGQEVEGMNILGLVVFAIVFGVALRKLGPEGELLIRFFNSFNEATMVLVSWIMWYAPVGIMFLVAGKIVEMEDVGLLFARLGKYILCCLLGHAIHGLLVLPLIYFLFTRKNPYRFLWGIVTPLATAFGTSSSSATLPLMMKCVEENNGVAKHISRFILPIGATVNMDGAALFQCVAAVFIAQLSQQSLDFVKIITILVTATASSVGAAGIPAGGVLTLAIILEAVNLPVDHISLILAVDWLVDRSCTVLNVEGDALGAGLLQNYVDRTESRSTEPELIQVKSELPLDPLPVPTEEGNPLLKHYRGPAGDATVASEKESVM
T59493	DRUGINFO	D00IWH	p-nitrophenyl glutamyl anilide	Investigative
T59493	DRUGINFO	D0VX9R	benzylserine	Investigative

T69271	TARGETID	T69271
T69271	FORMERID	TTDI00066
T69271	UNIPROID	IBP7_HUMAN
T69271	TARGNAME	Insulin-like growth factor-binding protein 7 (IGFBP7)
T69271	GENENAME	IGFBP7
T69271	TARGTYPE	Literature-reported
T69271	SYNONYMS	Tumorderived adhesion factor; Tumor-derived adhesion factor; TAF; Prostacyclinstimulating factor; Prostacyclin-stimulating factor; PSF; PGI2stimulating factor; PGI2-stimulating factor; MAC25 protein; MAC25; Insulinlike growth factorbinding protein 7; IGFbinding protein 7; IGFBPrP1; IGFBP-rP1; IGFBP-7; IGF-binding protein 7; IBP7; IBP-7
T69271	FUNCTION	Stimulates prostacyclin (PGI2) production. Stimulates cell adhesion. Binds IGF-I and IGF-II with a relatively low affinity.
T69271	BIOCLASS	Immunoglobulin
T69271	SEQUENCE	MERPSLRALLLGAAGLLLLLLPLSSSSSSDTCGPCEPASCPPLPPLGCLLGETRDACGCCPMCARGEGEPCGGGGAGRGYCAPGMECVKSRKRRKGKAGAAAGGPGVSGVCVCKSRYPVCGSDGTTYPSGCQLRAASQRAESRGEKAITQVSKGTCEQGPSIVTPPKDIWNVTGAQVYLSCEVIGIPTPVLIWNKVKRGHYGVQRTELLPGDRDNLAIQTRGGPEKHEVTGWVLVSPLSKEDAGEYECHASNSQGQASASAKITVVDALHEIPVKKGEGAEL

T31882	TARGETID	T31882
T31882	FORMERID	TTDI03330
T31882	UNIPROID	KCA10_HUMAN
T31882	TARGNAME	Voltage-gated potassium channel Kv1.8 (KCNA10)
T31882	GENENAME	KCNA10
T31882	TARGTYPE	Literature-reported
T31882	SYNONYMS	Voltage-gated potassium channel subunit Kv1.8; Potassium voltage-gated channel subfamily A member 10
T31882	FUNCTION	Mediates voltage-dependent potassium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a potassium-selective channel through which potassium ions may pass in accordance with their electrochemical gradient. The channel activity is up-regulated by cAMP.
T31882	BIOCLASS	Voltage-gated ion channel
T31882	SEQUENCE	MDVCGWKEMEVALVNFDNSDEIQEEPGYATDFDSTSPKGRPGGSSFSNGKILISESTNHETAFSKLPGDYADPPGPEPVVLNEGNQRVIINIAGLRFETQLRTLSQFPETLLGDREKRMQFFDSMRNEYFFDRNRPSFDGILYYYQSGGKIRRPANVPIDIFADEISFYELGSEAMDQFREDEGFIKDPETLLPTNDIHRQFWLLFEYPESSSAARAVAVVSVLVVVISITIFCLETLPEFREDRELKVVRDPNLNMSKTVLSQTMFTDPFFMVESTCIVWFTFELVLRFVVCPSKTDFFRNIMNIIDIISIIPYFATLITELVQETEPSAQQNMSLAILRIIRLVRVFRIFKLSRHSKGLQILGQTLKASMRELGLLIFFLFIGVILFSSAVYFAEVDEPESHFSSIPDGFWWAVVTMTTVGYGDMCPTTPGGKIVGTLCAIAGVLTIALPVPVIVSNFNYFYHRETENEEKQNIPGEIERILNSVGSRMGSTDSLNKTNGGCSTEKSRK
T31882	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T52067	TARGETID	T52067
T52067	FORMERID	TTDI03451
T52067	UNIPROID	S15A2_HUMAN
T52067	TARGNAME	Solute carrier family 15 member 2 (SLC15A2)
T52067	GENENAME	SLC15A2
T52067	TARGTYPE	Literature-reported
T52067	SYNONYMS	Peptide transporter 2; PEPT2; Oligopeptide transporter, kidney isoform; Kidney H(+)/peptide cotransporter
T52067	FUNCTION	Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. Transports the dipeptide-like aminopeptidase inhibitor bestatin (By similarity). Can also transport the aminocephalosporin antibiotic cefadroxil (By similarity).
T52067	PDBSTRUC	6EZI
T52067	SEQUENCE	MNPFQKNESKETLFSPVSIEEVPPRPPSPPKKPSPTICGSNYPLSIAFIVVNEFCERFSYYGMKAVLILYFLYFLHWNEDTSTSIYHAFSSLCYFTPILGAAIADSWLGKFKTIIYLSLVYVLGHVIKSLGALPILGGQVVHTVLSLIGLSLIALGTGGIKPCVAAFGGDQFEEKHAEERTRYFSVFYLSINAGSLISTFITPMLRGDVQCFGEDCYALAFGVPGLLMVIALVVFAMGSKIYNKPPPEGNIVAQVFKCIWFAISNRFKNRSGDIPKRQHWLDWAAEKYPKQLIMDVKALTRVLFLYIPLPMFWALLDQQGSRWTLQAIRMNRNLGFFVLQPDQMQVLNPLLVLIFIPLFDFVIYRLVSKCGINFSSLRKMAVGMILACLAFAVAAAVEIKINEMAPAQPGPQEVFLQVLNLADDEVKVTVVGNENNSLLIESIKSFQKTPHYSKLHLKTKSQDFHFHLKYHNLSLYTEHSVQEKNWYSLVIREDGNSISSMMVKDTESRTTNGMTTVRFVNTLHKDVNISLSTDTSLNVGEDYGVSAYRTVQRGEYPAVHCRTEDKNFSLNLGLLDFGAAYLFVITNNTNQGLQAWKIEDIPANKMSIAWQLPQYALVTAGEVMFSVTGLEFSYSQAPSSMKSVLQAAWLLTIAVGNIIVLVVAQFSGLVQWAEFILFSCLLLVICLIFSIMGYYYVPVKTEDMRGPADKHIPHIQGNMIKLETKKTKL
T52067	DRUGINFO	D0E1YE	Lys[Z(NO2)]-Lys[Z(NO2)]	Investigative
T52067	DRUGINFO	D02FZM	Lys[Z(NO2)]-Pro	Investigative
T52067	DRUGINFO	D06PWQ	[14C]GlySar	Investigative
T52067	DRUGINFO	D08QDL	[11C]GlySar	Investigative
T52067	DRUGINFO	D0Q3VU	[3H]GlySar	Investigative

T87930	TARGETID	T87930
T87930	FORMERID	TTDI03223
T87930	UNIPROID	GRIK5_HUMAN
T87930	TARGNAME	Glutamate receptor ionotropic kainate 5 (GRIK5)
T87930	GENENAME	GRIK5
T87930	TARGTYPE	Literature-reported
T87930	SYNONYMS	KA2; Glutamate receptor ionotropic, kainate 5; Glutamate receptor KA-2; GluK5; GRIK2; Excitatory amino acid receptor 2; EAA2
T87930	FUNCTION	L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists. This receptor binds kainate > quisqualate > domoate > L-glutamate >> AMPA >> NMDA = 1S,3R-ACPD. Receptor for glutamate.
T87930	BIOCLASS	Glutamate-gated ion channel
T87930	SEQUENCE	MPAELLLLLIVAFASPSCQVLSSLRMAAILDDQTVCGRGERLALALAREQINGIIEVPAKARVEVDIFELQRDSQYETTDTMCQILPKGVVSVLGPSSSPASASTVSHICGEKEIPHIKVGPEETPRLQYLRFASVSLYPSNEDVSLAVSRILKSFNYPSASLICAKAECLLRLEELVRGFLISKETLSVRMLDDSRDPTPLLKEIRDDKVSTIIIDANASISHLILRKASELGMTSAFYKYILTTMDFPILHLDGIVEDSSNILGFSMFNTSHPFYPEFVRSLNMSWRENCEASTYLGPALSAALMFDAVHVVVSAVRELNRSQEIGVKPLACTSANIWPHGTSLMNYLRMVEYDGLTGRVEFNSKGQRTNYTLRILEKSRQGHREIGVWYSNRTLAMNATTLDINLSQTLANKTLVVTTILENPYVMRRPNFQALSGNERFEGFCVDMLRELAELLRFRYRLRLVEDGLYGAPEPNGSWTGMVGELINRKADLAVAAFTITAEREKVIDFSKPFMTLGISILYRVHMGRKPGYFSFLDPFSPAVWLFMLLAYLAVSCVLFLAARLSPYEWYNPHPCLRARPHILENQYTLGNSLWFPVGGFMQQGSEIMPRALSTRCVSGVWWAFTLIIISSYTANLAAFLTVQRMEVPVESADDLADQTNIEYGTIHAGSTMTFFQNSRYQTYQRMWNYMQSKQPSVFVKSTEEGIARVLNSRYAFLLESTMNEYHRRLNCNLTQIGGLLDTKGYGIGMPLGSPFRDEITLAILQLQENNRLEILKRKWWEGGRCPKEEDHRAKGLGMENIGGIFIVLICGLIIAVFVAVMEFIWSTRRSAESEEVSVCQEMLQELRHAVSCRKTSRSRRRRRPGGPSRALLSLRAVREMRLSNGKLYSAGAGGDAGSAHGGPQRLLDDPGPPSGARPAAPTPCTHVRVCQECRRIQALRASGAGAPPRGLGVPAEATSPPRPRPGPAGPRELAEHE
T87930	DRUGINFO	D09KRH	domoic acid	Investigative
T87930	DRUGINFO	D0K6AF	dysiherbaine	Investigative
T87930	DRUGINFO	D0S8AN	SYM2081	Investigative
T87930	DRUGINFO	D04PFN	[3H]kainate	Investigative

T33211	TARGETID	T33211
T33211	FORMERID	TTDI03479
T33211	UNIPROID	PCSK7_HUMAN
T33211	TARGNAME	Proprotein convertase subtilisin/kexin type 7 (PCSK7)
T33211	GENENAME	PCSK7
T33211	TARGTYPE	Literature-reported
T33211	SYNONYMS	Subtilisin/kexin-like protease PC7; SPC7; Proprotein convertase 8; Proprotein convertase 7; Prohormone convertase 7; PC8; PC7; Lymphoma proprotein convertase; LPC
T33211	FUNCTION	Serine endoprotease that processes various proproteins by cleavage at paired basic amino acids, recognizing the RXXX[KR]R consensus motif. Likely functions in the constitutive secretory pathway.
T33211	ECNUMBER	EC 3.4.21.-
T33211	SEQUENCE	MPKGRQKVPHLDAPLGLPTCLWLELAGLFLLVPWVMGLAGTGGPDGQGTGGPSWAVHLESLEGDGEEETLEQQADALAQAAGLVNAGRIGELQGHYLFVQPAGHRPALEVEAIRQQVEAVLAGHEAVRWHSEQRLLRRAKRSVHFNDPKYPQQWHLNNRRSPGRDINVTGVWERNVTGRGVTVVVVDDGVEHTIQDIAPNYSPEGSYDLNSNDPDPMPHPDVENGNHHGTRCAGEIAAVPNNSFCAVGVAYGSRIAGIRVLDGPLTDSMEAVAFNKHYQINDIYSCSWGPDDDGKTVDGPHQLGKAALQHGVIAGRQGFGSIFVVASGNGGQHNDNCNYDGYANSIYTVTIGAVDEEGRMPFYAEECASMLAVTFSGGDKMLRSIVTTDWDLQKGTGCTEGHTGTSAAAPLAAGMIALMLQVRPCLTWRDVQHIIVFTATRYEDRRAEWVTNEAGFSHSHQHGFGLLNAWRLVNAAKIWTSVPYLASYVSPVLKENKAIPQSPRSLEVLWNVSRMDLEMSGLKTLEHVAVTVSITHPRRGSLELKLFCPSGMMSLIGAPRSMDSDPNGFNDWTFSTVRCWGERARGTYRLVIRDVGDESFQVGILRQWQLTLYGSVWSAVDIRDRQRLLESAMSGKYLHDDFALPCPPGLKIPEEDGYTITPNTLKTLVLVGCFTVFWTVYYMLEVYLSQRNVASNQVCRSGPCHWPHRSRKAKEEGTELESVPLCSSKDPDEVETESRGPPTTSDLLAPDLLEQGDWSLSQNKSALDCPHQHLDVPHGKEEQIC
T33211	DRUGINFO	D0A6FZ	peptide 18	Investigative
T33211	DRUGINFO	D05JJL	furin inhibitor peptide	Investigative

T36440	TARGETID	T36440
T36440	FORMERID	TTDI01382
T36440	UNIPROID	AMHR2_HUMAN
T36440	TARGNAME	Anti-mullerian hormone II receptor (AMHR2)
T36440	GENENAME	AMHR2
T36440	TARGTYPE	Literature-reported
T36440	SYNONYMS	MRII; MISRII; MISR2; MIS type II receptor; Anti-Muellerian hormone type-2 receptor; Anti-Muellerian hormone type II receptor; AMHR; AMH type II receptor
T36440	FUNCTION	On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for anti-Muellerian hormone.
T36440	ECNUMBER	EC 2.7.11.30
T36440	SEQUENCE	MLGSLGLWALLPTAVEAPPNRRTCVFFEAPGVRGSTKTLGELLDTGTELPRAIRCLYSRCCFGIWNLTQDRAQVEMQGCRDSDEPGCESLHCDPSPRAHPSPGSTLFTCSCGTDFCNANYSHLPPPGSPGTPGSQGPQAAPGESIWMALVLLGLFLLLLLLLGSIILALLQRKNYRVRGEPVPEPRPDSGRDWSVELQELPELCFSQVIREGGHAVVWAGQLQGKLVAIKAFPPRSVAQFQAERALYELPGLQHDHIVRFITASRGGPGRLLSGPLLVLELHPKGSLCHYLTQYTSDWGSSLRMALSLAQGLAFLHEERWQNGQYKPGIAHRDLSSQNVLIREDGSCAIGDLGLALVLPGLTQPPAWTPTQPQGPAAIMEAGTQRYMAPELLDKTLDLQDWGMALRRADIYSLALLLWEILSRCPDLRPDSSPPPFQLAYEAELGNTPTSDELWALAVQERRRPYIPSTWRCFATDPDGLRELLEDCWDADPEARLTAECVQQRLAALAHPQESHPFPESCPRGCPPLCPEDCTSIPAPTILPCRPQRSACHFSVQQGPCSRNPQPACTLSPV

T78350	TARGETID	T78350
T78350	FORMERID	TTDI01503
T78350	UNIPROID	MIA_HUMAN
T78350	TARGNAME	Melanoma derived growth regulator (MIA)
T78350	GENENAME	MIA
T78350	TARGTYPE	Literature-reported
T78350	SYNONYMS	Melanoma-derived growth regulatory protein; Melanoma inhibitory activity protein
T78350	FUNCTION	Elicits growth inhibition on melanoma cells in vitro as well as some other neuroectodermal tumors, including gliomas.
T78350	PDBSTRUC	5IXB; 1K0X; 1I1J; 1HJD
T78350	SEQUENCE	MARSLVCLGVIILLSAFSGPGVRGGPMPKLADRKLCADQECSHPISMAVALQDYMAPDCRFLTIHRGQVVYVFSKLKGRGRLFWGGSVQGDYYGDLAARLGYFPSSIVREDQTLKPGKVDVKTDKWDFYCQ

T97388	TARGETID	T97388
T97388	FORMERID	TTDI02007
T97388	UNIPROID	UPP1_HUMAN; UPP2_HUMAN
T97388	TARGNAME	Uridine phosphorylase (UPP)
T97388	GENENAME	UPP1; UPP2
T97388	TARGTYPE	Literature-reported
T97388	SYNONYMS	UrdPase; UPase
T97388	FUNCTION	Catalyzes the reversible phosphorylytic cleavage ofuridine and deoxyuridine to uracil and ribose- or deoxyribose-1- phosphate. The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis.
T97388	BIOCLASS	Pentosyltransferase
T97388	SEQUENCE	MAATGANAEKAESHNDCPVRLLNPNIAKMKEDILYHFNLTTSRHNFPALFGDVKFVCVGGSPSRMKAFIRCVGAELGLDCPGRDYPNICAGTDRYAMYKVGPVLSVSHGMGIPSISIMLHELIKLLYYARCSNVTIIRIGTSGGIGLEPGTVVITEQAVDTCFKAEFEQIVLGKRVIRKTDLNKKLVQELLLCSAELSEFTTVVGNTMCTLDFYEGQGRLDGALCSYTEKDKQAYLEAAYAAGVRNIEMESSVFAAMCSACGLQAAVVCVTLLNRLEGDQISSPRNVLSEYQQRPQRLVSYFIKKKLSKA
T97388	DRUGINFO	D03LNM	TK-112690	Investigative

T74891	TARGETID	T74891
T74891	FORMERID	TTDR01291
T74891	UNIPROID	Q27641_ENTDI
T74891	TARGNAME	Entamoeba Cysteine proteinase CP4  (Eh CP4)
T74891	GENENAME	Eh CP4
T74891	TARGTYPE	Literature-reported
T74891	SYNONYMS	Entamoeba Cysteine proteinase CP4; Cysteine proteinase
T74891	FUNCTION	Plays a key role in disrupting the colonic epithelial barrier and the innate host immune response during invasion of E. histolytica, the protozoan cause of human amebiasis.
T74891	ECNUMBER	EC 3.4.22.35
T74891	SEQUENCE	FVAAATAIDFKSWAAKNNKHFTAVEALRRRAIFNMNAKFVAKFNKANSFELSVDGPFAAMTNEEYNHLLRVHETEAAADSVYDNTIITASSKDWRAEGKVTPVRDQGNCGSCYSFSSLAVLESRLLIAGSKYNQNNQDLSEQQIVDCSTANNGCNGGSLSATYLYVKNNGVTDEASYPYTATKGTCKAFTPKVQTTGLTHVTPNEDALTSALEQGPVAVCIDAGKASFQLYKSGVYDEPKCSKTVNHGVAAVGYGTQDGKDYYIVKNSWGTSWGDKGYILMSRNKNNQCAIASVAYFPNGAHDAN
T74891	DRUGINFO	D0J6WV	WRR605	Investigative

T74371	TARGETID	T74371
T74371	FORMERID	TTDI00128
T74371	UNIPROID	KI26B_HUMAN
T74371	TARGNAME	Kinesin-like protein KIF26B (KIF26B)
T74371	GENENAME	KIF26B
T74371	TARGTYPE	Literature-reported
T74371	SYNONYMS	Kinesinlike protein KIF26B
T74371	FUNCTION	Plays an important role in the compact adhesion between mesenchymal cells adjacent to the ureteric buds, possibly by interacting with MYH10. This could lead to the establishment of the basolateral integrity of the mesenchyme and the polarized expression of ITGA8, which maintains the GDNF expression required for further ureteric bud attraction. Although it seems to lack ATPase activity it is constitutively associated with microtubules. Essential for embryonic kidney development.
T74371	BIOCLASS	Myosin-kinesin ATPase
T74371	SEQUENCE	MNSVAGNKERLAVSTRGKKYGVNEVCSPTKPAAPFSPESWYRKAYEESRAGSRPTPEGAGSALGSSGTPSPGSGTSSPSSFTGSPGPASPGIGTSSPGSLGGSPGFGTGSPGSGSGGGSSPGSDRGVWCENCNARLVELKRQALRLLLPGPFPGKDPAFSAVIHDKLQVPNTIRKAWNDRDNRCDICATHLNQLKQEAIQMVLTLEQAAGSEHYDASPCSPPPLSNIPTLVGSRHVGGLQQPRDWAFVPAPCATSNYTGFANKHGSKPSSLGVSNGAEKKSGSPTHQAKVSLQMATSPSNGNILNSVAIQAHQYLDGTWSLSRTNGVTLYPYQISQLMTESSREGLTEAVLNRYNADKPSACSVPASQGSCVASETSTGTSVAASFFARAAQKLNLSSKKKKHRPSTSSAAEPPLFATSFSGILQTSPPPAPPCLLRAVNKVKDTPGLGKVKVMLRICSTLARDTSESSSFLKVDPRKKQITLYDPLTCGGQNAFQKRGNQVPPKMFAFDAVFPQDASQAEVCAGTVAEVIQSVVNGADGCVFCFGHAKLGKSYTMIGKDDSMQNLGIIPCAISWLFKLINERKEKTGARFSVRVSAVEVWGKEENLRDLLSEVATGSLQDGQSPGVYLCEDPICGTQLQNQSELRAPTAEKAAFFLDAAIASRRSHQQDCDEDDHRNSHVFFTLHIYQYRMEKSGKGGMSGGRSRLHLIDLGSCVKALSKNREGGSGLCLSLSALGNVILALVNGSKHIPYKESKLAMLLRESLGNMNCRTTMIAHISAAVGSYAETLSTIQIASRVLRMKKKKTKYTSSSSGGESSCEEGRMRRPTQLRPFHTRATVDPDFPIAHLSSDPDYSSSSEQSCDTVIYIGPNGTALSDKELTDNEGPPDFVPIVPALQKTRGDSRPAEAGEAAAGKSERDCLKCNTFAELQERLDCIDGSEEPSSFPFEELPAQFGPEQASRGPRLSQAAGASPLSESDKEDNGSEGQLTNREGPELPASKMQRSHSPVPAAAPAHSPSPASPRSVPGSSSQHSASPLVQSPSLQSSRESLNSCGFVEGKPRPMGSPRLGIASLSKTSEYKPPSSPSQRCKVYTQKGVLPSPAPLPPSSKDSGVASRESLLQPEVRTPPVGMSPQVLKKSMSAGSEGFPETPVDDEQQAATPSESKKEILSTTMVTVQQPLELNGEDELVFTLVEELTISGVLDSGRPTSIISFNSDCSARALASGSRPVSIISSISEDLECYSSTAPVSEVSITQFLPLPKMSLDEKAQDAGSRRSSISSWLSEMSAGSEGEQSCHSFIAQTCFGHGEAMAEPVASEFVSSLQNTAVVCREKPKASPDNLLILSEMGDDSFNKAAPIKGCKISTVSKAMVTISNTANLSSCEGYIPMKTNITVYPCIAMSPRNIQEPEAPTATPKAGPTLAQSRESKENSAKKEMKFEDPWLKREEEVKKETAHPNEEGMMRCETATGPSNAETRAEQEQDGKPSPGDRLSSSSGEVSASPVTDNFRRVVDGCEMALPGLATQSPVHPNKSVKSSSLPRAFQKASRQEEPDSLSYYCAAETNGVGAASGTPPSKATLEGKVASPKHCVLARPKGTPPLPPVRKSSLDQKNRASPQHSASGSGTSSPLNQPAAFPAGLPDEPSGKTKDASSSSKLFSAKLEQLASRSNSLGRATVSHYECLSLERAESLSSVSSRLHAGKDGTMPRAGRSLGRSAGTSPPSSGASPKAGQSKISAVSRLLLASPRARGPSASTTKTLSFSTKSLPQAVGQGSSSPPGGKHTPWSTQSLSRNRSSGLASKLPLRAVSGRISELLQGGAGARGLQLRAGPEAEARGGALAEDEPAAAHLLPSPYSKITPPRRPHRCSSGHGSDNSSVLSGELPPAMGKTALFYHSGGSSGYESVMRDSEATGSASSAQDSTSENSSSVGGRCRSLKTPKKRSNPGSQRRRLIPALSLDTSSPVRKPPNSTGVRWVDGPLRSSPRGLGEPFEIKVYEIDDVERLQRRRGGASKEAMCFNAKLKILEHRQQRIAEVRAKYEWLMKELEATKQYLMLDPNKWLSEFDLEQVWELDSLEYLEALECVTERLESRVNFCKAHLMMITCFDITSRRR

T16240	TARGETID	T16240
T16240	FORMERID	TTDI03590
T16240	UNIPROID	Q3C1U7_HUMAN
T16240	TARGNAME	Short transient receptor potential channel 2 (TRPC2)
T16240	GENENAME	TRPC2
T16240	TARGTYPE	Literature-reported
T16240	SYNONYMS	Uncharacterized protein
T16240	FUNCTION	Has calcium channel activity.
T16240	BIOCLASS	Transient receptor potential catioin channel
T16240	SEQUENCE	SCACLECSNARRYDLLKLSLSRINTYLGIASRAHLSLASEDAMLAAFQLSRELRRLARKEPEFKPEYIALESLSQDYGFQLLGMCWNQSEVTAVLNDLAEDSETEPEAEGLGLAFEEGIPSLVRPRLAVNYNQKRFVAHLICQQVLSSI
T16240	DRUGINFO	D0Y6ST	SAG	Investigative
T16240	DRUGINFO	D0T6DU	OAG	Investigative
T16240	DRUGINFO	D00HCI	2-APB	Investigative

T78575	TARGETID	T78575
T78575	FORMERID	TTDI03475
T78575	UNIPROID	PPCEL_HUMAN
T78575	TARGNAME	Prolyl endopeptidase-like (PREPL)
T78575	GENENAME	PREPL
T78575	TARGTYPE	Literature-reported
T78575	SYNONYMS	Prolylendopeptidase-like; KIAA0436
T78575	FUNCTION	Probable serine peptidase whose precise substrate specificity remains unclear. Does not cleave peptides after a arginine or lysine residue. May play a role in the regulation of synaptic vesiscle exocytosis.
T78575	ECNUMBER	EC 3.4.21.-
T78575	SEQUENCE	MQQKTKLFLQALKYSIPHLGKCMQKQHLNHYNFADHCYNRIKLKKYHLTKCLQNKPKISELARNIPSRSFSCKDLQPVKQENEKPLPENMDAFEKVRTKLETQPQEEYEIINVEVKHGGFVYYQEGCCLVRSKDEEADNDNYEVLFNLEELKLDQPFIDCIRVAPDEKYVAAKIRTEDSEASTCVIIKLSDQPVMEASFPNVSSFEWVKDEEDEDVLFYTFQRNLRCHDVYRATFGDNKRNERFYTEKDPSYFVFLYLTKDSRFLTINIMNKTTSEVWLIDGLSPWDPPVLIQKRIHGVLYYVEHRDDELYILTNVGEPTEFKLMRTAADTPAIMNWDLFFTMKRNTKVIDLDMFKDHCVLFLKHSNLLYVNVIGLADDSVRSLKLPPWACGFIMDTNSDPKNCPFQLCSPIRPPKYYTYKFAEGKLFEETGHEDPITKTSRVLRLEAKSKDGKLVPMTVFHKTDSEDLQKKPLLVHVYGAYGMDLKMNFRPERRVLVDDGWILAYCHVRGGGELGLQWHADGRLTKKLNGLADLEACIKTLHGQGFSQPSLTTLTAFSAGGVLAGALCNSNPELVRAVTLEAPFLDVLNTMMDTTLPLTLEELEEWGNPSSDEKHKNYIKRYCPYQNIKPQHYPSIHITAYENDERVPLKGIVSYTEKLKEAIAEHAKDTGEGYQTPNIILDIQPGGNHVIEDSHKKITAQIKFLYEELGLDSTSVFEDLKKYLKF
T78575	DRUGINFO	D05OLW	PMID21692504C8	Investigative

T46541	TARGETID	T46541
T46541	FORMERID	TTDI00230
T46541	UNIPROID	BOREA_HUMAN
T46541	TARGNAME	Borealin (CDCA8)
T46541	GENENAME	CDCA8
T46541	TARGTYPE	Literature-reported
T46541	SYNONYMS	hDasraB; hDasra-B; Pluripotent embryonic stem cellrelated gene 3 protein; Pluripotent embryonic stem cell-related gene 3 protein; PESCRG3; DasraB; Dasra-B; Dasra B; Cell division cycleassociated protein 8; Cell division cycle-associated protein 8
T46541	FUNCTION	The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Major effector of the TTK kinase in the control of attachment-error-correction and chromosome alignment. Component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis.
T46541	PDBSTRUC	2RAX; 2RAW; 2QFA; 2KDD
T46541	SEQUENCE	MAPRKGSSRVAKTNSLRRRKLASFLKDFDREVEIRIKQIESDRQNLLKEVDNLYNIEILRLPKALREMNWLDYFALGGNKQALEEAATADLDITEINKLTAEAIQTPLKSAKTRKVIQVDEMIVEEEEEEENERKNLQTARVKRCPPSKKRTQSIQGKGKGKRSSRANTVTPAVGRLEVSMVKPTPGLTPRFDSRVFKTPGLRTPAAGERIYNISGNGSPLADSKEIFLTVPVGGGESLRLLASDLQRHSIAQLDPEALGNIKKLSNRLAQICSSIRTHK

T74685	TARGETID	T74685
T74685	FORMERID	TTDR00702
T74685	UNIPROID	AHPD_MYCTU
T74685	TARGNAME	Mycobacterium Alkylhydroperoxidase AhpD (MycB ahpD)
T74685	GENENAME	MycB ahpD
T74685	TARGTYPE	Literature-reported
T74685	SYNONYMS	Alkylhydroperoxidase AhpD; Alkyl hydroperoxide reductase AhpD
T74685	FUNCTION	Antioxidant protein with alkyl hydroperoxidase activity. Required for the reduction of the AhpC active site cysteine residues and for the regeneration of the AhpC enzyme activity.
T74685	PDBSTRUC	1ME5; 1LW1; 1KNC; 1GU9
T74685	SEQUENCE	MSIEKLKAALPEYAKDIKLNLSSITRSSVLDQEQLWGTLLASAAATRNPQVLADIGAEATDHLSAAARHAALGAAAIMGMNNVFYRGRGFLEGRYDDLRPGLRMNIIANPGIPKANFELWSFAVSAINGCSHCLVAHEHTLRTVGVDREAIFEALKAAAIVSGVAQALATIEALSPS

T20033	TARGETID	T20033
T20033	FORMERID	TTDR00843
T20033	UNIPROID	EF2_CANAL
T20033	TARGNAME	Candida Elongation factor 2 (Candi EFT2)
T20033	GENENAME	Candi EFT2
T20033	TARGTYPE	Literature-reported
T20033	SYNONYMS	EFT2; EF2
T20033	FUNCTION	Catalyzes the GTP-dependent ribosomal translocation step during translation elongation. During this step, the ribosome changes from the pre-translocational (PRE) to the post- translocational (POST) state as the newly formed A-site-bound peptidyl-tRNA and P-site-bound deacylated tRNA move to the P and E sites, respectively. Catalyzes the coordinated movement of the two tRNA molecules, the mRNA and conformational changes in the ribosome.
T20033	BIOCLASS	Acid anhydrides hydrolase
T20033	SEQUENCE	MVAFTIEQIRGLMDKVTNVRNMSVIAHVDHGKSTLSDSLVQKAGIISAAKAGDARFMDTRKDEQERGITIKSTAISLYASMTDEDVKDIKQKTDGNSFLVNLIDSPGHVDFSSEVTAALRVTDGALVVVDTVEGVCVQTETVLRQALGERIKPVVVINKVDRALLELQTTKEDLYQTFARTVESVNVIISTYCDPVLGDVQVYPQKGTVAFASGLHGWAFTVRQFANKYSKKFGVDKEKMMERLWGDSYFNPKTKKWTNKDKDADGKPLERAFNMFILDPIFRLFAAIMNFKKDEIPVLLEKLEIQLKGDEKDLEGKALLKVVMRKFLPAADALLEMIVLHLPSPVTAQAYRAETLYEGPSDDPFCTAIRNCDPNADLMLYVSKMVPTSDKGRFYAFGRVFAGTVKSGQKVRIQGPNYQVGKKEDLFLKSIQRTVLMMGRSVEQIDDCPAGNIIGLVGIDQFLLKSGTITTNEAAHNMKVMKFSVSPVVQVAVEVKNANDLPKLVEGLKRLSKSDPCVLTYMSESGEHIVAGTGELHLEICLQDLENDHAGVPLRISPPVVSYRETVEGESSMVALSKSPNKHNRIYVKAQPIDEEVSLDIENGVINPRDDFKARARILADKHGWDVVDARKIWCFGPDGNGPNLVVDQTKAVQYLNEIKDSVVAAFQWATKEGPIFGENCRSVRVNILDVTLHADAIHRGGGQIIPTMRRVTYASMLLAEPAIQEPVFLVEIQCPENAIGGIYSVLNKKRGQVISEEQRPGTPLFTVKAYLPVNESFGFTGELRQATGGQAFPQLIFDHWQVMSGDVTDENSKPGAIVKEKRVRAGLKPEVPEYTEYYDKL
T20033	DRUGINFO	D09IVQ	Adenosine-5-Diphosphoribose	Investigative
T20033	DRUGINFO	D0OY0X	Diphthamide	Investigative
T20033	DRUGINFO	D0C7LS	Guanosine-5'-Diphosphate	Investigative

T86265	TARGETID	T86265
T86265	FORMERID	TTDI00132
T86265	UNIPROID	SGO1_HUMAN
T86265	TARGNAME	Shugoshin-like protein 1 (SGO1)
T86265	GENENAME	SGO1
T86265	TARGTYPE	Literature-reported
T86265	SYNONYMS	hSgo1; Serologically defined breast cancer antigen NY-BR-85; SGOL1; SGO1
T86265	FUNCTION	Plays a central role in chromosome cohesion during mitosis by preventing premature dissociation of cohesin complex from centromeres after prophase, when most of cohesin complex dissociates from chromosomes arms. May act by preventing phosphorylation of the STAG2 subunit of cohesin complex at the centromere, ensuring cohesin persistence at centromere until cohesin cleavage by ESPL1/separase at anaphase. Essential for proper chromosome segregation during mitosis and this function requires interaction with PPP2R1A. Its phosphorylated form is necessary for chromosome congression and for the proper attachment of spindle microtubule to the kinetochore. Necessary for kinetochore localization of PLK1 and CENPF. May play a role in the tension sensing mechanism of the spindle-assembly checkpoint by regulating PLK1 kinetochore affinity. Isoform 3 plays a role in maintaining centriole cohesion involved in controlling spindle pole integrity. Involved in centromeric enrichment of AUKRB in prometaphase.
T86265	PDBSTRUC	4A0I; 3Q6S; 3FGA
T86265	SEQUENCE	MAKERCLKKSFQDSLEDIKKRMKEKRNKNLAEIGKRRSFIAAPCQIITNTSTLLKNYQDNNKMLVLALENEKSKVKEAQDIILQLRKECYYLTCQLYALKGKLTSQQTVEPAQNQEICSSGMDPNSDDSSRNLFVKDLPQIPLEETELPGQGESFQIEDQIPTIPQDTLGVDFDSGEAKSTDNVLPRTVSVRSSLKKHCNSICQFDSLDDFETSHLAGKSFEFERVGFLDPLVNMHIPENVQHNACQWSKDQVNLSPKLIQPGTFTKTKEDILESKSEQTKSKQRDTQERKREEKRKANRRKSKRMSKYKENKSENKKTVPQKKMHKSVSSNDAYNFNLEEGVHLTPFRQKVSNDSNREENNESEVSLCESSGSGDDSDDLYLPTCKYIQNPTSNSDRPVTRPLAKRALKYTDEKETEGSKPTKTPTTTPPETQQSPHLSLKDITNVSLYPVVKIRRLSLSPKKNKASPAVALPKRRCTASVNYKEPTLASKLRRGDPFTDLCFLNSPIFKQKKDLRRSKKRALEVSPAKEAIFILYYVREFVSRFPDCRKCKLETHICLR

T14928	TARGETID	T14928
T14928	FORMERID	TTDNR00733
T14928	UNIPROID	FA83B_HUMAN
T14928	TARGNAME	Protein FAM83B (FA83B)
T14928	GENENAME	FAM83B
T14928	TARGTYPE	Literature-reported
T14928	SYNONYMS	C6orf143
T14928	FUNCTION	Probable proto-oncogene that functions in the epidermal growth factor receptor/EGFR signaling pathway. May activate both the EGFR itself and downstream RAS/MAPK and PI3K/AKT/TOR signaling cascades.
T14928	PDBSTRUC	5QHS; 5QHR; 5QHQ; 5QHP; 5QHO
T14928	SEQUENCE	METSSMLSSLNDECKSDNYIEPHYKEWYRVAIDILIEHGLEAYQEFLVQERVSDFLAEEEINYILKNVQKVAQSTAHGTDDSCDDTLSSGTYWPVESDVEAPNLDLGWPYVMPGLLGGTHIDLLFHPPRAHLLTIKETIRKMIKEARKVIALVMDIFTDVDIFKEIVEASTRGVSVYILLDESNFNHFLNMTEKQGCSVQRLRNIRVRTVKGQDYLSKTGAKFHGKMEQKFLLVDCQKVMYGSYSYMWSFEKAHLSMVQIITGQLVESFDEEFRTLYARSCVPSSFAQEESARVKHGKALWENGTYQHSVSSLASVSSQRNLFGRQDKIHKLDSSYFKNRGIYTLNEHDKYNIRSHGYKPHFVPNFNGPNAIRQFQPNQINENWKRHSYAGEQPETVPYLLLNRALNRTNNPPGNWKKPSDSLSVASSSREGYVSHHNTPAQSFANRLAQRKTTNLADRNSNVRRSFNGTDNHIRFLQQRMPTLEHTTKSFLRNWRIESYLNDHSEATPDSNGSALGDRFEGYDNPENLKANALYTHSRLRSSLVFKPTLPEQKEVNSCTTGSSNSTIIGSQGSETPKEVPDTPTNVQHLTDKPLPESIPKLPLQSEAPKMHTLQVPENHSVALNQTTNGHTESNNYIYKTLGVNKQTENLKNQQTENLLKRRSFPLFDNSKANLDPGNSKHYVYSTLTRNRVRQPEKPKEDLLKSSKSMHNVTHNLEEDEEEVTKRNSPSGTTTKSVSIAALLDVNKEESNKELASKKEVKGSPSFLKKGSQKLRSLLSLTPDKKENLSKNKAPAFYRLCSSSDTLVSEGEENQKPKKSDTKVDSSPRRKHSSSSNSQGSIHKSKEDVTVSPSQEINAPPDENKRTPSPGPVESKFLERAGDASAPRFNTEQIQYRDSREINAVVTPERRPTSSPRPTSSELLRSHSTDRRVYSRFEPFCKIESSIQPTSNMPNTSINRPEIKSATMGNSYGRSSPLLNYNTGVYRSYQPNENKFRGFMQKFGNFIHKNK

T65626	TARGETID	T65626
T65626	FORMERID	TTDI03142
T65626	UNIPROID	CXG2_HUMAN
T65626	TARGNAME	Gap junction gamma-2 protein (Cx47)
T65626	GENENAME	GJC2
T65626	TARGTYPE	Literature-reported
T65626	SYNONYMS	Gap junction alpha-12 protein; GJA12; Cx46.6; Connexin-47; Connexin-46.6
T65626	FUNCTION	May play a role in myelination in central and peripheral nervous systems. One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell.
T65626	BIOCLASS	Gap junction-forming connexin
T65626	SEQUENCE	MTNMSWSFLTRLLEEIHNHSTFVGKVWLTVLVVFRIVLTAVGGEAIYSDEQAKFTCNTRQPGCDNVCYDAFAPLSHVRFWVFQIVVISTPSVMYLGYAVHRLARASEQERRRALRRRPGPRRAPRAHLPPPHAGWPEPADLGEEEPMLGLGEEEEEEETGAAEGAGEEAEEAGAEEACTKAVGADGKAAGTPGPTGQHDGRRRIQREGLMRVYVAQLVARAAFEVAFLVGQYLLYGFEVRPFFPCSRQPCPHVVDCFVSRPTEKTVFLLVMYVVSCLCLLLNLCEMAHLGLGSAQDAVRGRRGPPASAPAPAPRPPPCAFPAAAAGLACPPDYSLVVRAAERARAHDQNLANLALQALRDGAAAGDRDRDSSPCVGLPAASRGPPRAGAPASRTGSATSAGTVGEQGRPGTHERPGAKPRAGSEKGSASSRDGKTTVWI
T65626	DRUGINFO	D00VJY	octanol	Investigative

T96365	TARGETID	T96365
T96365	UNIPROID	DEP1A_HUMAN
T96365	TARGNAME	DEP domain-containing protein 1A (DEPDC1)
T96365	GENENAME	DEPDC1
T96365	TARGTYPE	Literature-reported
T96365	SYNONYMS	DEPDC1A
T96365	FUNCTION	May be involved in transcriptional regulation as a transcriptional corepressor. The DEPDC1A-ZNF224 complex may play a critical role in bladder carcinogenesis by repressing the transcription of the A20 gene, leading to transport of NF-KB protein into the nucleus, resulting in suppression of apoptosis of bladder cancer cells.
T96365	PDBSTRUC	2YSR
T96365	SEQUENCE	MESQGVPPGPYRATKLWNEVTTSFRAGMPLRKHRQHFKKYGNCFTAGEAVDWLYDLLRNNSNFGPEVTRQQTIQLLRKFLKNHVIEDIKGRWGSENVDDNNQLFRFPATSPLKTLPRRYPELRKNNIENFSKDKDSIFKLRNLSRRTPKRHGLHLSQENGEKIKHEIINEDQENAIDNRELSQEDVEEVWRYVILIYLQTILGVPSLEEVINPKQVIPQYIMYNMANTSKRGVVILQNKSDDLPHWVLSAMKCLANWPRSNDMNNPTYVGFERDVFRTIADYFLDLPEPLLTFEYYELFVNILVVCGYITVSDRSSGIHKIQDDPQSSKFLHLNNLNSFKSTECLLLSLLHREKNKEESDSTERLQISNPGFQERCAKKMQLVNLRNRRVSANDIMGGSCHNLIGLSNMHDLSSNSKPRCCSLEGIVDVPGNSSKEASSVFHQSFPNIEGQNNKLFLESKPKQEFLLNLHSEENIQKPFSAGFKRTSTLTVQDQEELCNGKCKSKQLCRSQSLLLRSSTRRNSYINTPVAEIIMKPNVGQGSTSVQTAMESELGESSATINKRLCKSTIELSENSLLPASSMLTGTQSLLQPHLERVAIDALQLCCLLLPPPNRRKLQLLMRMISRMSQNVDMPKLHDAMGTRSLMIHTFSRCVLCCAEEVDLDELLAGRLVSFLMDHHQEILQVPSYLQTAVEKHLDYLKKGHIENPGDGLFAPLPTYSYCKQISAQEFDEQKVSTSQAAIAELLENIIKNRSLPLKEKRKKLKQFQKEYPLIYQKRFPTTESEAALFGDKPTIKQPMLILRKPKFRSLR

T34708	TARGETID	T34708
T34708	FORMERID	TTDI02584
T34708	UNIPROID	MBNL2_HUMAN
T34708	TARGNAME	Muscleblind-like protein 1 (MBNL2)
T34708	GENENAME	MBNL2
T34708	TARGTYPE	Literature-reported
T34708	SYNONYMS	Muscleblindlike proteinlike 39; Muscleblindlike proteinlike; Muscleblindlike protein 2; Muscleblindlike protein 1; Muscleblind-like protein-like 39; Muscleblind-like protein-like; Muscleblind-like protein 2; MLP1; MBLL39; MBLL
T34708	FUNCTION	Acts either as activator or repressor of splicing on specific pre-mRNA targets. Inhibits cardiac troponin-T (TNNT2) pre-mRNA exon inclusion but induces insulin receptor (IR) pre-mRNA exon inclusion in muscle. Antagonizes the alternative splicing activity pattern of CELF proteins. RNA-binding protein that binds to 5'ACACCC-3' core sequence, termed zipcode, within the 3'UTR of ITGA3. Binds to CUG triplet repeat expansion in myotonic dystrophy muscle cells by sequestering the target RNAs. Seems to regulate expression and localization of ITGA3 by transporting it from the nucleus to cytoplasm at adhesion plaques. May play a role in myotonic dystrophy pathophysiology (DM). Mediates pre-mRNA alternative splicing regulation.
T34708	PDBSTRUC	2RPP; 2E5S
T34708	SEQUENCE	MALNVAPVRDTKWLTLEVCRQFQRGTCSRSDEECKFAHPPKSCQVENGRVIACFDSLKGRCSRENCKYLHPPTHLKTQLEINGRNNLIQQKTAAAMLAQQMQFMFPGTPLHPVPTFPVGPAIGTNTAISFAPYLAPVTPGVGLVPTEILPTTPVIVPGSPPVTVPGSTATQKLLRTDKLEVCREFQRGNCARGETDCRFAHPADSTMIDTSDNTVTVCMDYIKGRCMREKCKYFHPPAHLQAKIKAAQHQANQAAVAAQAAAAAATVMAFPPGALHPLPKRQALEKSNGTSAVFNPSVLHYQQALTSAQLQQHAAFIPTGSVLCMTPATSIDNSEIISRNGMECQESALRITKHCYCTYYPVSSSIELPQTAC

T87719	TARGETID	T87719
T87719	FORMERID	TTDI01500
T87719	UNIPROID	CLC6A_HUMAN
T87719	TARGNAME	Dendritic cell-associated C-type lectin 2 (CLEC6A)
T87719	GENENAME	CLEC6A
T87719	TARGTYPE	Literature-reported
T87719	SYNONYMS	Dectin-2; DECTIN2; DC-associated C-type lectin 2; CLECSF10; C-type lectin superfamily member 10; C-type lectin domain family 6 member A
T87719	FUNCTION	Binds high-mannose carbohydrates in a Ca(2+)-dependent manner. Functional receptor for alpha-mannans on C.albicans hypheas. Plays an important role in the host defense against C.albicans infection by inducing TH17 cell differentiation. Recognizes also, in a mannose-dependent manner, allergens from house dust mite and fungi, by promoting cysteinyl leukotriene production. Recognizes soluble elements from the eggs of Shistosoma mansoni altering adaptive immune responses. Transduces signals through an Fc receptor gamma chain /FCER1G and Syk-CARD9-NF-kappa-B-dependent pathway (By similarity).
T87719	PDBSTRUC	5VYB
T87719	SEQUENCE	MMQEQQPQSTEKRGWLSLRLWSVAGISIALLSACFIVSCVVTYHFTYGETGKRLSELHSYHSSLTCFSEGTKVPAWGCCPASWKSFGSSCYFISSEEKVWSKSEQNCVEMGAHLVVFNTEAEQNFIVQQLNESFSYFLGLSDPQGNNNWQWIDKTPYEKNVRFWHLGEPNHSAEQCASIVFWKPTGWGWNDVICETRRNSICEMNKIYL

T51996	TARGETID	T51996
T51996	FORMERID	TTDR00308
T51996	UNIPROID	FEMX_STAAR
T51996	TARGNAME	Staphylococcus Lipid II:glycine glycyltransferase (Stap-coc femX)
T51996	GENENAME	Stap-coc femX
T51996	TARGTYPE	Literature-reported
T51996	SYNONYMS	femX; Lipid II:glycine glycyltransferase; Factor essential for expression of methicillin resistance X
T51996	FUNCTION	Catalyzes the incorporation of the first glycine of the pentaglycine interpeptide bridge, which is characteristic of the S.aureus peptidoglycan. This glycine is added to the epsilon-amino group of the L-lysine of the membrane-bound lipid II intermediate (GlcNAc-(beta-1,4)-N-acetylmuramic acid(-L-Ala-D-iGln-L-Lys-D-Ala- D-Ala)-pyrophosphoryl-undecaprenol), using glycyl-tRNA(Gly) as donor, in a ribosome-independent mechanism. Involved in methicillin resistance.
T51996	ECNUMBER	EC 2.3.2.16
T51996	SEQUENCE	MEKMHITNQEHDAFVKSNPNGDLLQLTKWAETKKLTGWYARRIAVGRDGEIQGVAQLLFKKVPKLPYTLCYISRGFVVDYSNKEALNALLDSAKEIAKAEKAYAIKIDPDVEVDKGTDALQNLKALGFKHKGFKEGLSKDYIQPRMTMITPIDKNDDELLNSFERRNRSKVRLALKRGTTVERSDREGLKTFAELMKITGERDGFLTRDISYFENIYDALHEDGDAELFLVKLDPKENIAKVNQELNELHAEIAKWQQKMETSEKQAKKAQNMINDAQNKIAKNEDLKRDLEALEKEHPEGIYLSGALLMFAGSKSYYLYGASSNEFRDFLPNHHMQYTMMKYAREHGATTYDFGGTDNDPDKDSEHYGLWAFKKVWGTYLSEKIGEFDYVLNQPLYQLIEQVKPRLTKAKIKISRKLKRK

T25924	TARGETID	T25924
T25924	FORMERID	TTDI00089
T25924	UNIPROID	GRHL2_HUMAN
T25924	TARGNAME	Grainyhead-like 2 (GRHL2)
T25924	GENENAME	GRHL2
T25924	TARGTYPE	Literature-reported
T25924	SYNONYMS	Transcription factor CP2like 3; Grainyheadlike protein 2 homolog; GRHL2; Brother of mammalian grainyhead
T25924	FUNCTION	Transcription factor playing an important role in primary neurulationand in epithelial development (PubMed:25152456). Binds directly to the consensus DNA sequence 5'-AACCGGTT-3' acting as an activator and repressor on distinct target genes. During embryogenesis, plays unique and cooperative roles with GRHL3 in establishing distinct zones of primary neurulation. Essential for closure 3 (rostral end of the forebrain), functions cooperatively with GRHL3 in closure 2 (forebrain/midbrain boundary) and posterior neuropore closure. Regulates epithelial morphogenesis acting as a target gene-associated transcriptional activator of apicaljunctional complex components. Up-regulates of CLDN3 and CLDN4, as well as of RAB25, which increases the CLDN4 protein and its localization at tight junctions. Comprises an essential component of the transcriptional machinery that establishes appropriate expression levels of CLDN4 and CDH1 in different types of epithelia. Exhibits functional redundancy with GRHL3 in epidermal morphogenetic events and epidermal wound repair. In lung, forms a regulatory loop with NKX2-1 that coordinates lung epithelial cell morphogenesis and differentiation. In keratinocytes, plays a role in telomerase activation during cellular proliferation, regulates TERT expression by binding to TERT promoter region and inhibiting DNA methylation at the 5'-CpG island, possibly by interfering with DNMT1 enzyme activity (PubMed:19015635, PubMed:20938050). In addition, impairs keratinocyte differentiation and epidermal function by inhibiting the expression of genes clustered at the epidermal differentiation complex (EDC) as well as GRHL1 and GRHL3 through epigenetic mechanisms (PubMed:23254293).
T25924	PDBSTRUC	5MR7
T25924	SEQUENCE	MSQESDNNKRLVALVPMPSDPPFNTRRAYTSEDEAWKSYLENPLTAATKAMMSINGDEDSAAALGLLYDYYKVPRDKRLLSVSKASDSQEDQEKRNCLGTSEAQSNLSGGENRVQVLKTVPVNLSLNQDHLENSKREQYSISFPESSAIIPVSGITVVKAEDFTPVFMAPPVHYPRGDGEEQRVVIFEQTQYDVPSLATHSAYLKDDQRSTPDSTYSESFKDAATEKFRSASVGAEEYMYDQTSSGTFQYTLEATKSLRQKQGEGPMTYLNKGQFYAITLSETGDNKCFRHPISKVRSVVMVVFSEDKNRDEQLKYWKYWHSRQHTAKQRVLDIADYKESFNTIGNIEEIAYNAVSFTWDVNEEAKIFITVNCLSTDFSSQKGVKGLPLMIQIDTYSYNNRSNKPIHRAYCQIKVFCDKGAERKIRDEERKQNRKKGKGQASQTQCNSSSDGKLAAIPLQKKSDITYFKTMPDLHSQPVLFIPDVHFANLQRTGQVYYNTDDEREGGSVLVKRMFRPMEEEFGPVPSKQMKEEGTKRVLLYVRKETDDVFDALMLKSPTVKGLMEAISEKYGLPVEKIAKLYKKSKKGILVNMDDNIIEHYSNEDTFILNMESMVEGFKVTLMEI

T35828	TARGETID	T35828
T35828	FORMERID	TTDR00075
T35828	UNIPROID	RK18_PLAF7
T35828	TARGNAME	Plasmodium Apicoplast ribosome (Malaria RPL18)
T35828	GENENAME	Malaria RPL18
T35828	TARGTYPE	Literature-reported
T35828	SYNONYMS	Putative 50S ribosomal protein L18, apicoplastic
T35828	FUNCTION	Has a unique composition, resulting from the loss of several large and small subunit proteins accompanied by significant sequence and size divergences in parasite orthologues of ribosomal proteins. Many more ribosomal proteins with apicoplast and mitochondrial targeting sequences that are post-translationally processed for targeting to organelles.
T35828	BIOCLASS	Ribosomal protein
T35828	SEQUENCE	MYISFILFSIIFIFLGVIENFIINKRVLYKPNFLLYSEKKNKKKSTPEQVTTRVNKDLKEKKRKRPRSKILECLLKEKVEKVEKVEKNSDENQCSNVDKEIREGKRVPRLRVRNTNNHIYASIIDDYKKYVLCSTCSRDATLSKILGTYRRKATNRVINNGRTIKSAWEIGKIIGKKALSKGIFKVRFDRARHPYAGKVEALAEGARAVGLLL

T95865	TARGETID	T95865
T95865	FORMERID	TTDNC00437
T95865	UNIPROID	TAF2_HUMAN
T95865	TARGNAME	Cofactor of initiator function (CIF)
T95865	GENENAME	TAF2
T95865	TARGTYPE	Literature-reported
T95865	SYNONYMS	Transcription initiation factor TFIID subunit 2; Transcription initiation factor TFIID 150 kDa subunit; TBP-associated factor 150 kDa; TAFII150; TAFII-150; TAF2; TAF(II)150; RNA polymerase II TBP-associated factor subunit B; 150 kDa cofactor of initiator function
T95865	FUNCTION	Transcription factor TFIID is one of the general factors required for accurate and regulated initiation by RNA polymerase II. TFIID is a multimeric protein complex that plays a central role in mediating promoter responses to various activators and repressors. It requires core promoter-specific cofactors for productive transcription stimulation. TAF2 stabilizes TFIID binding to core promoter.
T95865	PDBSTRUC	6MZM; 6MZL; 6MZC; 5FUR
T95865	SEQUENCE	MPLTGVEPARMNRKKGDKGFESPRPYKLTHQVVCINNINFQRKSVVGFVELTIFPTVANLNRIKLNSKQCRIYRVRINDLEAAFIYNDPTLEVCHSESKQRNLNYFSNAYAAAVSAVDPDAGNGELCIKVPSELWKHVDELKVLKIHINFSLDQPKGGLHFVVPSVEGSMAERGAHVFSCGYQNSTRFWFPCVDSYSELCTWKLEFTVDAAMVAVSNGDLVETVYTHDMRKKTFHYMLTIPTAASNISLAIGPFEILVDPYMHEVTHFCLPQLLPLLKHTTSYLHEVFEFYEEILTCRYPYSCFKTVFIDEAYVEVAAYASMSIFSTNLLHSAMIIDETPLTRRCLAQSLAQQFFGCFISRMSWSDEWVLKGISGYIYGLWMKKTFGVNEYRHWIKEELDKIVAYELKTGGVLLHPIFGGGKEKDNPASHLHFSIKHPHTLSWEYYSMFQCKAHLVMRLIENRISMEFMLQVFNKLLSLASTASSQKFQSHMWSQMLVSTSGFLKSISNVSGKDIQPLIKQWVDQSGVVKFYGSFAFNRKRNVLELEIKQDYTSPGTQKYVGPLKVTVQELDGSFNHTLQIEENSLKHDIPCHSKSRRNKKKKIPLMNGEEVDMDLSAMDADSPLLWIRIDPDMSVLRKVEFEQADFMWQYQLRYERDVVAQQESILALEKFPTPASRLALTDILEQEQCFYRVRMSACFCLAKIANSMVSTWTGPPAMKSLFTRMFCCKSCPNIVKTNNFMSFQSYFLQKTMPVAMALLRDVHNLCPKEVLTFILDLIKYNDNRKNKFSDNYYRAEMIDALANSVTPAVSVNNEVRTLDNLNPDVRLILEEITRFLNMEKLLPSYRHTITVSCLRAIRVLQKNGHVPSDPALFKSYAEYGHFVDIRIAALEAVVDYTKVDRSYEELQWLLNMIQNDPVPYVRHKILNMLTKNPPFTKNMESPLCNEALVDQLWKLMNSGTSHDWRLRCGAVDLYFTLFGLSRPSCLPLPELGLVLNLKEKKAVLNPTIIPESVAGNQEAANNPSSHPQLVGFQNPFSSSQDEEEIDMDTVHDSQAFISHHLNMLERPSTPGLSKYRPASSRSALIPQHSAGCDSTPTTKPQWSLELARKGTGKEQAPLEMSMHPAASAPLSVFTKESTASKHSDHHHHHHHEHKKKKKKHKHKHKHKHKHDSKEKDKEPFTFSSPASGRSIRSPSLSD

T38772	TARGETID	T38772
T38772	FORMERID	TTDI03127
T38772	UNIPROID	CXB7_HUMAN
T38772	TARGNAME	Connexin-25 (Cx25)
T38772	GENENAME	GJB7
T38772	TARGTYPE	Literature-reported
T38772	SYNONYMS	Gap junction beta-7 protein; CX25
T38772	FUNCTION	One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell.
T38772	BIOCLASS	Gap junction-forming connexin
T38772	SEQUENCE	MSWMFLRDLLSGVNKYSTGTGWIWLAVVFVFRLLVYMVAAEHVWKDEQKEFECNSRQPGCKNVCFDDFFPISQVRLWALQLIMVSTPSLLVVLHVAYHEGREKRHRKKLYVSPGTMDGGLWYAYLISLIVKTGFEIGFLVLFYKLYDGFSVPYLIKCDLKPCPNTVDCFISKPTEKTIFILFLVITSCLCIVLNFIELSFLVLKCFIKCCLQKYLKKPQVLSV
T38772	DRUGINFO	D00VJY	octanol	Investigative

T93711	TARGETID	T93711
T93711	UNIPROID	RHDF2_HUMAN
T93711	TARGNAME	Inactive rhomboid protein 2 (RHBDF2)
T93711	GENENAME	RHBDF2
T93711	TARGTYPE	Literature-reported
T93711	SYNONYMS	iRhom2; Rhomboid veinlet-like protein 6; Rhomboid veinlet-like protein 5; Rhomboid family member 2; Rhomboid 5 homolog 2; RHBDL6; RHBDL5
T93711	FUNCTION	Rhomboid protease-like protein which has no protease activity but regulates the secretion of several ligands of the epidermal growth factor receptor. Indirectly activates the epidermal growth factor receptor signaling pathway and may thereby regulate sleep, cell survival, proliferation and migration.
T93711	BIOCLASS	Peptidase S54 family
T93711	SEQUENCE	MASADKNGGSVSSVSSSRLQSRKPPNLSITIPPPEKETQAPGEQDSMLPEGFQNRRLKKSQPRTWAAHTTACPPSFLPKRKNPAYLKSVSLQEPRSRWQESSEKRPGFRRQASLSQSIRKGAAQWFGVSGDWEGQRQQWQRRSLHHCSMRYGRLKASCQRDLELPSQEAPSFQGTESPKPCKMPKIVDPLARGRAFRHPEEMDRPHAPHPPLTPGVLSLTSFTSVRSGYSHLPRRKRMSVAHMSLQAAAALLKGRSVLDATGQRCRVVKRSFAFPSFLEEDVVDGADTFDSSFFSKEEMSSMPDDVFESPPLSASYFRGIPHSASPVSPDGVQIPLKEYGRAPVPGPRRGKRIASKVKHFAFDRKKRHYGLGVVGNWLNRSYRRSISSTVQRQLESFDSHRPYFTYWLTFVHVIITLLVICTYGIAPVGFAQHVTTQLVLRNKGVYESVKYIQQENFWVGPSSIDLIHLGAKFSPCIRKDGQIEQLVLRERDLERDSGCCVQNDHSGCIQTQRKDCSETLATFVKWQDDTGPPMDKSDLGQKRTSGAVCHQDPRTCEEPASSGAHIWPDDITKWPICTEQARSNHTGFLHMDCEIKGRPCCIGTKGSCEITTREYCEFMHGYFHEEATLCSQVHCLDKVCGLLPFLNPEVPDQFYRLWLSLFLHAGVVHCLVSVVFQMTILRDLEKLAGWHRIAIIFILSGITGNLASAIFLPYRAEVGPAGSQFGLLACLFVELFQSWPLLERPWKAFLNLSAIVLFLFICGLLPWIDNIAHIFGFLSGLLLAFAFLPYITFGTSDKYRKRALILVSLLAFAGLFAALVLWLYIYPINWPWIEHLTCFPFTSRFCEKYELDQVLH
T93711	DRUGINFO	D0X4IO	Sulforaphane	Investigative

T78181	TARGETID	T78181
T78181	FORMERID	TTDI00094
T78181	UNIPROID	RICTR_HUMAN
T78181	TARGNAME	MTOR complex 2 (RICTOR)
T78181	GENENAME	RICTOR
T78181	TARGTYPE	Literature-reported
T78181	SYNONYMS	hAVO3; Rapamycin-insensitive companion of mTOR; KIAA1999; AVO3 homolog
T78181	FUNCTION	mTORC2 is activated by growth factors, but, in contrast to mTORC1, seems to be nutrient-insensitive. mTORC2 seems to function upstream of Rho GTPases to regulate the actin cytoskeleton, probably by activating one or more Rho-type guanine nucleotide exchange factors. mTORC2 promotes the serum-induced formation of stress-fibers or F-actin. mTORC2 plays a critical role in AKT1 'Ser-473' phosphorylation, which may facilitate the phosphorylation of the activation loop of AKT1 on 'Thr-308' by PDK1 which is a prerequisite for full activation. mTORC2 regulates the phosphorylation of SGK1 at 'Ser-422'. mTORC2 also modulates the phosphorylation of PRKCA on 'Ser-657'. Plays an essential role in embryonic growth and development. Subunit of mTORC2, which regulates cell growth and survival in response to hormonal signals.
T78181	PDBSTRUC	5ZCS
T78181	SEQUENCE	MAAIGRGRSLKNLRVRGRNDSGEENVPLDLTREPSDNLREILQNVARLQGVSNMRKLGHLNNFTKLLCDIGHSEEKLGFHYEDIIICLRLALLNEAKEVRAAGLRALRYLIQDSSILQKVLKLKVDYLIARCIDIQQSNEVERTQALRLVRKMITVNASLFPSSVTNSLIAVGNDGLQERDRMVRACIAIICELALQNPEVVALRGGLNTILKNVIDCQLSRINEALITTILHLLNHPKTRQYVRADVELERILAPYTDFHYRHSPDTAEGQLKEDREARFLASKMGIIATFRSWAGIINLCKPGNSGIQSLIGVLCIPNMEIRRGLLEVLYDIFRLPLPVVTEEFIEALLSVDPGRFQDSWRLSDGFVAAEAKTILPHRARSRPDLMDNYLALILSAFIRNGLLEGLVEVITNSDDHISVRATILLGELLHMANTILPHSHSHHLHCLPTLMNMAASFDIPKEKRLRASAALNCLKRFHEMKKRGPKPYSLHLDHIIQKAIATHQKRDQYLRVQKDIFILKDTEEALLINLRDSQVLQHKENLEWNWNLIGTILKWPNVNLRNYKDEQLHRFVRRLLYFYKPSSKLYANLDLDFAKAKQLTVVGCQFTEFLLESEEDGQGYLEDLVKDIVQWLNASSGMKPERSLQNNGLLTTLSQHYFLFIGTLSCHPHGVKMLEKCSVFQCLLNLCSLKNQDHLLKLTVSSLDYSRDGLARVILSKILTAATDACRLYATKHLRVLLRANVEFFNNWGIELLVTQLHDKNKTISSEALDILDEACEDKANLHALIQMKPALSHLGDKGLLLLLRFLSIPKGFSYLNERGYVAKQLEKWHREYNSKYVDLIEEQLNEALTTYRKPVDGDNYVRRSNQRLQRPHVYLPIHLYGQLVHHKTGCHLLEVQNIITELCRNVRTPDLDKWEEIKKLKASLWALGNIGSSNWGLNLLQEENVIPDILKLAKQCEVLSIRGTCVYVLGLIAKTKQGCDILKCHNWDAVRHSRKHLWPVVPDDVEQLCNELSSIPSTLSLNSESTSSRHNSESESVPSSMFILEDDRFGSSSTSTFFLDINEDTEPTFYDRSGPIKDKNSFPFFASSKLVKNRILNSLTLPNKKHRSSSDPKGGKLSSESKTSNRRIRTLTEPSVDFNHSDDFTPISTVQKTLQLETSFMGNKHIEDTGSTPSIGENDLKFTKNFGTENHRENTSRERLVVESSTSSHMKIRSQSFNTDTTTSGISSMSSSPSRETVGVDATTMDTDCGSMSTVVSTKTIKTSHYLTPQSNHLSLSKSNSVSLVPPGSSHTLPRRAQSLKAPSIATIKSLADCNFSYTSSRDAFGYATLKRLQQQRMHPSLSHSEALASPAKDVLFTDTITMKANSFESRLTPSRFMKALSYASLDKEDLLSPINQNTLQRSSSVRSMVSSATYGGSDDYIGLALPVDINDIFQVKDIPYFQTKNIPPHDDRGARAFAHDAGGLPSGTGGLVKNSFHLLRQQMSLTEIMNSIHSDASLFLESTEDTGLQEHTDDNCLYCVCIEILGFQPSNQLSAICSHSDFQDIPYSDWCEQTIHNPLEVVPSKFSGISGCSDGVSQEGSASSTKSTELLLGVKTIPDDTPMCRILLRKEVLRLVINLSSSVSTKCHETGLLTIKEKYPQTFDDICLYSEVSHLLSHCTFRLPCRRFIQELFQDVQFLQMHEEAEAVLATPPKQPIVDTSAES

T77063	TARGETID	T77063
T77063	FORMERID	TTDI03477
T77063	UNIPROID	PCSK4_HUMAN
T77063	TARGNAME	Proprotein convertase subtilisin/kexin type 4 (PCSK4)
T77063	GENENAME	PCSK4
T77063	TARGTYPE	Literature-reported
T77063	SYNONYMS	UNQ2757/PRO6496; Proprotein convertase 4; PC4
T77063	FUNCTION	Proprotein convertase involved in the processing of hormone and other protein precursors at sites comprised of pairs of basic amino acid residues (By similarity). In males, important for ADAM2 processing as well as other acrosomal proteins with roles in fertilization and critical for normal fertilization events such as sperm capacitation, acrosome reaction and binding of sperm to zona pellucida (By similarity). Plays also a role in female fertility, involved in the regulation of trophoblast migration and placental development, may be through the proteolytical processing and activation of proteins such as IGF2. May also participate in folliculogenesis in the ovaries (By similarity).
T77063	ECNUMBER	EC 3.4.21.-
T77063	SEQUENCE	MRPAPIALWLRLVLALALVRPRAVGWAPVRAPIYVSSWAVQVSQGNREVERLARKFGFVNLGPIFPDGQYFHLRHRGVVQQSLTPHWGHRLHLKKNPKVQWFQQQTLQRRVKRSVVVPTDPWFSKQWYMNSEAQPDLSILQAWSQGLSGQGIVVSVLDDGIEKDHPDLWANYDPLASYDFNDYDPDPQPRYTPSKENRHGTRCAGEVAAMANNGFCGVGVAFNARIGGVRMLDGTITDVIEAQSLSLQPQHIHIYSASWGPEDDGRTVDGPGILTREAFRRGVTKGRGGLGTLFIWASGNGGLHYDNCNCDGYTNSIHTLSVGSTTQQGRVPWYSEACASTLTTTYSSGVATDPQIVTTDLHHGCTDQHTGTSASAPLAAGMIALALEANPFLTWRDMQHLVVRASKPAHLQAEDWRTNGVGRQVSHHYGYGLLDAGLLVDTARTWLPTQPQRKCAVRVQSRPTPILPLIYIRENVSACAGLHNSIRSLEHVQAQLTLSYSRRGDLEISLTSPMGTRSTLVAIRPLDVSTEGYNNWVFMSTHFWDENPQGVWTLGLENKGYYFNTGTLYRYTLLLYGTAEDMTARPTGPQVTSSACVQRDTEGLCQACDGPAYILGQLCLAYCPPRFFNHTRLVTAGPGHTAAPALRVCSSCHASCYTCRGGSPRDCTSCPPSSTLDQQQGSCMGPTTPDSRPRLRAAACPHHRCPASAMVLSLLAVTLGGPVLCGMSMDLPLYAWLSRARATPTKPQVWLPAGT
T77063	DRUGINFO	D05JJL	furin inhibitor peptide	Investigative

T68206	TARGETID	T68206
T68206	FORMERID	TTDI02470
T68206	UNIPROID	BTNL3_HUMAN
T68206	TARGNAME	Butyrophilin-like protein 3 (BTNL3)
T68206	GENENAME	BTNL3
T68206	TARGTYPE	Literature-reported
T68206	SYNONYMS	UNQ744/PRO1472; COLF4100; Butyrophilin-like receptor; BTNLR
T68206	FUNCTION	Regulate the homing and maturation of V7+ and V4+ T cells to the gut epithelium.
T68206	BIOCLASS	Immunoglobulin
T68206	SEQUENCE	MAFVLILVLSFYELVSGQWQVTGPGKFVQALVGEDAVFSCSLFPETSAEAMEVRFFRNQFHAVVHLYRDGEDWESKQMPQYRGRTEFVKDSIAGGRVSLRLKNITPSDIGLYGCWFSSQIYDEEATWELRVAALGSLPLISIVGYVDGGIQLLCLSSGWFPQPTAKWKGPQGQDLSSDSRANADGYSLYDVEISIIVQENAGSILCSIHLAEQSHEVESKVLIGETFFQPSPWRLASILLGLLCGALCGVVMGMIIVFFKSKGKIQAELDWRRKHGQAELRDARKHAVEVTLDPETAHPKLCVSDLKTVTHRKAPQEVPHSEKRFTRKSVVASQGFQAGKHYWEVDVGQNVGWYVGVCRDDVDRGKNNVTLSPNNGYWVLRLTTEHLYFTFNPHFISLPPSTPPTRVGVFLDYEGGTISFFNTNDQSLIYTLLTCQFEGLLRPYIQHAMYDEEKGTPIFICPVSWG

T70513	TARGETID	T70513
T70513	FORMERID	TTDI02537
T70513	UNIPROID	CLC9A_HUMAN
T70513	TARGNAME	C-type lectin domain containing 9A (CLEC9A)
T70513	GENENAME	CLEC9A
T70513	TARGTYPE	Literature-reported
T70513	SYNONYMS	CLEC9A
T70513	FUNCTION	Functions as an endocytic receptor on a small subset of myeloid cells specialized for the uptake and processing of material from dead cells. Recognizes filamentous form of actin in association with particular actin-binding domains of cytoskeletal proteins, including spectrin, exposed when cell membranes are damaged, and mediate the cross-presentation of dead-cell associated antigens in a Syk-dependent manner.
T70513	PDBSTRUC	3VPP
T70513	SEQUENCE	MHEEEIYTSLQWDSPAPDTYQKCLSSNKCSGACCLVMVISCVFCMGLLTASIFLGVKLLQVSTIAMQQQEKLIQQERALLNFTEWKRSCALQMKYCQAFMQNSLSSAHNSSPCPNNWIQNRESCYYVSEIWSIWHTSQENCLKEGSTLLQIESKEEMDFITGSLRKIKGSYDYWVGLSQDGHSGRWLWQDGSSPSPGLLPAERSQSANQVCGYVKSNSLLSSNCSTWKYFICEKYALRSSV

T97016	TARGETID	T97016
T97016	FORMERID	TTDI03571
T97016	UNIPROID	TAOK1_HUMAN
T97016	TARGNAME	TAO kinase 1 (TAOK1)
T97016	GENENAME	TAOK1
T97016	TARGTYPE	Literature-reported
T97016	SYNONYMS	hTAOK1; hKFC-B; Thousand and one amino acid protein kinase 1; TAOK1; Serine/threonine-protein kinase TAO1; Prostate-derived sterile 20-like kinase 2; Prostate-derived STE20-like kinase 2; PSK2; PSK-2; MARKK; MARK Kinase; MAP3K16; Kinase from chicken homolog B; KIAA1361
T97016	FUNCTION	Serine/threonine-protein kinase involved in various processes such as p38/MAPK14 stress-activated MAPK cascade, DNA damage response and regulation of cytoskeleton stability. Phosphorylates MAP2K3, MAP2K6 and MARK2. Acts as an activator of the p38/MAPK14 stress-activated MAPK cascade by mediating phosphorylation and subsequent activation of the upstream MAP2K3 and MAP2K6 kinases. Involved in G-protein coupled receptor signaling to p38/MAPK14. In response to DNA damage, involved in the G2/M transition DNA damage checkpoint by activating the p38/MAPK14 stress-activated MAPK cascade, probably by mediating phosphorylation of MAP2K3 and MAP2K6. Acts as a regulator of cytoskeleton stability by phosphorylating 'Thr-208' of MARK2, leading to activate MARK2 kinase activity and subsequent phosphorylation and detachment of MAPT/TAU from microtubules. Also acts as a regulator of apoptosis: regulates apoptotic morphological changes, including cell contraction, membrane blebbing and apoptotic bodies formation via activation of the MAPK8/JNK cascade.
T97016	ECNUMBER	EC 2.7.11.1
T97016	SEQUENCE	MPSTNRAGSLKDPEIAELFFKEDPEKLFTDLREIGHGSFGAVYFARDVRTNEVVAIKKMSYSGKQSTEKWQDIIKEVKFLQRIKHPNSIEYKGCYLREHTAWLVMEYCLGSASDLLEVHKKPLQEVEIAAITHGALQGLAYLHSHTMIHRDIKAGNILLTEPGQVKLADFGSASMASPANSFVGTPYWMAPEVILAMDEGQYDGKVDVWSLGITCIELAERKPPLFNMNAMSALYHIAQNESPTLQSNEWSDYFRNFVDSCLQKIPQDRPTSEELLKHIFVLRERPETVLIDLIQRTKDAVRELDNLQYRKMKKLLFQEAHNGPAVEAQEEEEEQDHGVGRTGTVNSVGSNQSIPSMSISASSQSSSVNSLPDVSDDKSELDMMEGDHTVMSNSSVIHLKPEEENYREEGDPRTRASDPQSPPQVSRHKSHYRNREHFATIRTASLVTRQMQEHEQDSELREQMSGYKRMRRQHQKQLMTLENKLKAEMDEHRLRLDKDLETQRNNFAAEMEKLIKKHQAAMEKEAKVMSNEEKKFQQHIQAQQKKELNSFLESQKREYKLRKEQLKEELNENQSTPKKEKQEWLSKQKENIQHFQAEEEANLLRRQRQYLELECRRFKRRMLLGRHNLEQDLVREELNKRQTQKDLEHAMLLRQHESMQELEFRHLNTIQKMRCELIRLQHQTELTNQLEYNKRRERELRRKHVMEVRQQPKSLKSKELQIKKQFQDTCKIQTRQYKALRNHLLETTPKSEHKAVLKRLKEEQTRKLAILAEQYDHSINEMLSTQALRLDEAQEAECQVLKMQLQQELELLNAYQSKIKMQAEAQHDRELRELEQRVSLRRALLEQKIEEEMLALQNERTERIRSLLERQAREIEAFDSESMRLGFSNMVLSNLSPEAFSHSYPGASGWSHNPTGGPGPHWGHPMGGPPQAWGHPMQGGPQPWGHPSGPMQGVPRGSSMGVRNSPQALRRTASGGRTEQGMSRSTSVTSQISNGSHMSYT
T97016	DRUGINFO	D08HFG	PMID20873740C18	Investigative

T52116	TARGETID	T52116
T52116	FORMERID	TTDI00087
T52116	UNIPROID	S26A9_HUMAN
T52116	TARGNAME	Solute carrier family 26 member 9 (SLC26A9)
T52116	GENENAME	SLC26A9
T52116	TARGTYPE	Literature-reported
T52116	SYNONYMS	SLC26A9; Anion transporter/exchanger protein 9
T52116	FUNCTION	DIDS- and thiosulfate- sensitive anion exchanger mediating chloride, sulfate and oxalate transport. Mediates chloride/bicarbonate exchange or chloride-independent bicarbonate extrusion thus assuring bicarbonate secretion. Inhibited by ammonium and thiosulfate.
T52116	BIOCLASS	Sulfate permease
T52116	SEQUENCE	MSQPRPRYVVDRAAYSLTLFDDEFEKKDRTYPVGEKLRNAFRCSSAKIKAVVFGLLPVLSWLPKYKIKDYIIPDLLGGLSGGSIQVPQGMAFALLANLPAVNGLYSSFFPLLTYFFLGGVHQMVPGTFAVISILVGNICLQLAPESKFQVFNNATNESYVDTAAMEAERLHVSATLACLTAIIQMGLGFMQFGFVAIYLSESFIRGFMTAAGLQILISVLKYIFGLTIPSYTGPGSIVFTFIDICKNLPHTNIASLIFALISGAFLVLVKELNARYMHKIRFPIPTEMIVVVVATAISGGCKMPKKYHMQIVGEIQRGFPTPVSPVVSQWKDMIGTAFSLAIVSYVINLAMGRTLANKHGYDVDSNQEMIALGCSNFFGSFFKIHVICCALSVTLAVDGAGGKSQVASLCVSLVVMITMLVLGIYLYPLPKSVLGALIAVNLKNSLKQLTDPYYLWRKSKLDCCIWVVSFLSSFFLSLPYGVAVGVAFSVLVVVFQTQFRNGYALAQVMDTDIYVNPKTYNRAQDIQGIKIITYCSPLYFANSEIFRQKVIAKTGMDPQKVLLAKQKYLKKQEKRRMRPTQQRRSLFMKTKTVSLQELQQDFENAPPTDPNNNQTPANGTSVSYITFSPDSSSPAQSEPPASAEAPGEPSDMLASVPPFVTFHTLILDMSGVSFVDLMGIKALAKLSSTYGKIGVKVFLVNIHAQVYNDISHGGVFEDGSLECKHVFPSIHDAVLFAQANARDVTPGHNFQGAPGDAELSLYDSEEDIRSYWDLEQEMFGSMFHAETLTAL

T91259	TARGETID	T91259
T91259	FORMERID	TTDI00146
T91259	UNIPROID	CXXC5_HUMAN
T91259	TARGNAME	Retinoid-inducible nuclear factor (CXXC5)
T91259	GENENAME	CXXC5
T91259	TARGTYPE	Literature-reported
T91259	SYNONYMS	TCCCIA00297; Retinoidinducible nuclear factor; RINF; Putative NFkappaBactivating protein 102; Putative NF-kappa-B-activating protein 102; Putative MAPKactivating protein PM08; Putative MAPK-activating protein PM08; HSPC195; CXXCtype zinc finger protein 5; CXXC-type zinc finger protein 5; CF5
T91259	FUNCTION	Acts as a mediator of BMP4-mediated modulation of canonical Wnt signaling activity in neural stem cells. Required for DNA damage-induced ATM phosphorylation, p53 activation and cell cycle arrest. Involved in myelopoiesis. Transcription factor. Binds to the oxygen responsive element of COX4I2 and represses its transcription under hypoxia conditions (4% oxygen), as well as normoxia conditions (20% oxygen). May repress COX4I2 transactivation induced by CHCHD2 and RBPJ. May indirectly participate in activation of the NF-kappa-B and MAPK pathways.
T91259	PDBSTRUC	5W9S
T91259	SEQUENCE	MSSLGGGSQDAGGSSSSSTNGSGGSGSSGPKAGAADKSAVVAAAAPASVADDTPPPERRNKSGIISEPLNKSLRRSRPLSHYSSFGSSGGSGGGSMMGGESADKATAAAAAASLLANGHDLAAAMAVDKSNPTSKHKSGAVASLLSKAERATELAAEGQLTLQQFAQSTEMLKRVVQEHLPLMSEAGAGLPDMEAVAGAEALNGQSDFPYLGAFPINPGLFIMTPAGVFLAESALHMAGLAEYPMQGELASAISSGKKKRKRCGMCAPCRRRINCEQCSSCRNRKTGHQICKFRKCEELKKKPSAALEKVMLPTGAAFRWFQ

T07944	TARGETID	T07944
T07944	FORMERID	TTDI01516
T07944	UNIPROID	CHSTF_HUMAN
T07944	TARGNAME	Carbohydrate sulfotransferase 15 (CHST15)
T07944	GENENAME	CHST15
T07944	TARGTYPE	Literature-reported
T07944	SYNONYMS	hBRAG; N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase; KIAA0598; GalNAc4S-6ST; GALNAC4S6ST; BRAG; B-cell RAG-associated gene protein
T07944	FUNCTION	Sulfotransferase that transfers sulfate from 3'-phosphoadenosine 5'-phosphosulfate (PAPS) to the C-6 hydroxyl group of the GalNAc 4-sulfate residue of chondroitin sulfate A and forms chondroitin sulfate E containing GlcA-GalNAc(4,6-SO(4)) repeating units. It also transfers sulfate to a unique non-reducing terminal sequence, GalNAc(4SO4)-GlcA(2SO4)-GalNAc(6SO4), to yield a highly sulfated structure similar to the structure found in thrombomodulin chondroitin sulfate. May also act as a B-cell receptor involved in BCR ligation-mediated early activation that mediate regulatory signals key to B-cell development and/or regulation of B-cell-specific RAG expression; however such results are unclear in vivo.
T07944	ECNUMBER	EC 2.8.2.33
T07944	SEQUENCE	MRHCINCCIQLLPDGAHKQQVNCQGGPHHGHQACPTCKGENKILFRVDSKQMNLLAVLEVRTEGNENWGGFLRFKKGKRCSLVFGLIIMTLVMASYILSGAHQELLISSPFHYGGFPSNPSLMDSENPSDTKEHHHQSSVNNISYMKDYPSIKLIINSITTRIEFTTRQLPDLEDLKKQELHMFSVIPNKFLPNSKSPCWYEEFSGQNTTDPYLTNSYVLYSKRFRSTFDALRKAFWGHLAHAHGKHFRLRCLPHFYIIGQPKCGTTDLYDRLRLHPEVKFSAIKEPHWWTRKRFGIVRLRDGLRDRYPVEDYLDLFDLAAHQIHQGLQASSAKEQSKMNTIIIGEASASTMWDNNAWTFFYDNSTDGEPPFLTQDFIHAFQPNARLIVMLRDPVERLYSDYLYFASSNKSADDFHEKVTEALQLFENCMLDYSLRACVYNNTLNNAMPVRLQVGLYAVYLLDWLSVFDKQQFLILRLEDHASNVKYTMHKVFQFLNLGPLSEKQEALMTKSPASNARRPEDRNLGPMWPITQKILRDFYRPFNARLAQVLADEAFAWKTT

T16614	TARGETID	T16614
T16614	FORMERID	TTDI03593
T16614	UNIPROID	TRPM1_HUMAN
T16614	TARGNAME	Long transient receptor potential channel 1 (TRPM1)
T16614	GENENAME	TRPM1
T16614	TARGTYPE	Literature-reported
T16614	SYNONYMS	Transient receptor potential cation channel subfamily M member 1; Melastatin-1; MLSN; LTRPC1
T16614	FUNCTION	Cation channel essential for the depolarizing photoresponse of retinal ON bipolar cells. It is part of the GRM6 signaling cascade. May play a role in metastasis suppression (By similarity). May act as a spontaneously active, calcium-permeable plasma membrane channel.
T16614	BIOCLASS	Transient receptor potential catioin channel
T16614	SEQUENCE	MKDSNRCCCGQFTNQHIPPLPSATPSKNEEESKQVETQPEKWSVAKHTQSYPTDSYGVLEFQGGGYSNKAMYIRVSYDTKPDSLLHLMVKDWQLELPKLLISVHGGLQNFEMQPKLKQVFGKGLIKAAMTTGAWIFTGGVSTGVISHVGDALKDHSSKSRGRVCAIGIAPWGIVENKEDLVGKDVTRVYQTMSNPLSKLSVLNNSHTHFILADNGTLGKYGAEVKLRRLLEKHISLQKINTRLGQGVPLVGLVVEGGPNVVSIVLEYLQEEPPIPVVICDGSGRASDILSFAHKYCEEGGIINESLREQLLVTIQKTFNYNKAQSHQLFAIIMECMKKKELVTVFRMGSEGQQDIEMAILTALLKGTNVSAPDQLSLALAWNRVDIARSQIFVFGPHWPPLGSLAPPTDSKATEKEKKPPMATTKGGRGKGKGKKKGKVKEEVEEETDPRKIELLNWVNALEQAMLDALVLDRVDFVKLLIENGVNMQHFLTIPRLEELYNTRLGPPNTLHLLVRDVKKSNLPPDYHISLIDIGLVLEYLMGGAYRCNYTRKNFRTLYNNLFGPKRPKALKLLGMEDDEPPAKGKKKKKKKKEEEIDIDVDDPAVSRFQYPFHELMVWAVLMKRQKMAVFLWQRGEESMAKALVACKLYKAMAHESSESDLVDDISQDLDNNSKDFGQLALELLDQSYKHDEQIAMKLLTYELKNWSNSTCLKLAVAAKHRDFIAHTCSQMLLTDMWMGRLRMRKNPGLKVIMGILLPPTILFLEFRTYDDFSYQTSKENEDGKEKEEENTDANADAGSRKGDEENEHKKQRSIPIGTKICEFYNAPIVKFWFYTISYLGYLLLFNYVILVRMDGWPSLQEWIVISYIVSLALEKIREILMSEPGKLSQKIKVWLQEYWNITDLVAISTFMIGAILRLQNQPYMGYGRVIYCVDIIFWYIRVLDIFGVNKYLGPYVMMIGKMMIDMLYFVVIMLVVLMSFGVARQAILHPEEKPSWKLARNIFYMPYWMIYGEVFADQIDLYAMEINPPCGENLYDEEGKRLPPCIPGAWLTPALMACYLLVANILLVNLLIAVFNNTFFEVKSISNQVWKFQRYQLIMTFHDRPVLPPPMIILSHIYIIIMRLSGRCRKKREGDQEERDRGLKLFLSDEELKRLHEFEEQCVQEHFREKEDEQQSSSDERIRVTSERVENMSMRLEEINERETFMKTSLQTVDLRLAQLEELSNRMVNALENLAGIDRSDLIQARSRASSECEATYLLRQSSINSADGYSLYRYHFNGEELLFEDTSLSTSPGTGVRKKTCSFRIKEEKDVKTHLVPECQNSLHLSLGTSTSATPDGSHLAVDDLKNAEESKLGPDIGISKEDDERQTDSKKEETISPSLNKTDVIHGQDKSDVQNTQLTVETTNIEGTISYPLEETKITRYFPDETINACKTMKSRSFVYSRGRKLVGGVNQDVEYSSITDQQLTTEWQCQVQKITRSHSTDIPYIVSEAAVQAEHKEQFADMQDEHHVAEAIPRIPRLSLTITDRNGMENLLSVKPDQTLGFPSLRSKSLHGHPRNVKSIQGKLDRSGHASSVSSLVIVSGMTAEEKKVKKEKASTETEC

T51314	TARGETID	T51314
T51314	FORMERID	TTDR00738
T51314	UNIPROID	Q82443_9DELA
T51314	TARGNAME	T-cell leukemia virus Type-1 proteinase (TLV pro)
T51314	GENENAME	TLV pro
T51314	TARGTYPE	Literature-reported
T51314	SYNONYMS	Protease
T51314	FUNCTION	Critical for virion replication.
T51314	BIOCLASS	Protease
T51314	SEQUENCE	KEFNMGGGLTSPPTLQQVLLNQDPASILPVIPLDPARRPVIKAQVDTQTSHPKTIEALLDTGADMTVLPIALFSSNTPLKNTSVLGAGGQTQDHFKLTSLPVLIRLPFRTTPIVLTSCLVDTKNNWAIIGRDALQQCQGVLYLPEAKGPPVILPIQAPAVLGLEHLPRPPEISQFPLNQNASRPCNTWSERPWRQAISNPTPDQEITQYSQLKRPMEPGDSSTTCGPLTL

T00973	TARGETID	T00973
T00973	FORMERID	TTDI03473
T00973	UNIPROID	PB1_HUMAN
T00973	TARGNAME	Polybromo-1 (PBRM1)
T00973	GENENAME	PBRM1
T00973	TARGTYPE	Literature-reported
T00973	SYNONYMS	hPB1; Protein polybromo-1; Polybromo-1D; PB1; BRG1-associated factor 180; BAF180
T00973	FUNCTION	Required for the stability of the SWI/SNF chromatin remodeling complex SWI/SNF-B (PBAF). Acts as a negative regulator of cell proliferation. Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology).
T00973	PDBSTRUC	5IID; 5II2; 5II1; 5HRX; 5HRW
T00973	SEQUENCE	MGSKRRRATSPSSSVSGDFDDGHHSVSTPGPSRKRRRLSNLPTVDPIAVCHELYNTIRDYKDEQGRLLCELFIRAPKRRNQPDYYEVVSQPIDLMKIQQKLKMEEYDDVNLLTADFQLLFNNAKSYYKPDSPEYKAACKLWDLYLRTRNEFVQKGEADDEDDDEDGQDNQGTVTEGSSPAYLKEILEQLLEAIVVATNPSGRLISELFQKLPSKVQYPDYYAIIKEPIDLKTIAQRIQNGSYKSIHAMAKDIDLLAKNAKTYNEPGSQVFKDANSIKKIFYMKKAEIEHHEMAKSSLRMRTPSNLAAARLTGPSHSKGSLGEERNPTSKYYRNKRAVQGGRLSAITMALQYGSESEEDAALAAARYEEGESEAESITSFMDVSNPFYQLYDTVRSCRNNQGQLIAEPFYHLPSKKKYPDYYQQIKMPISLQQIRTKLKNQEYETLDHLECDLNLMFENAKRYNVPNSAIYKRVLKLQQVMQAKKKELARRDDIEDGDSMISSATSDTGSAKRKSKKNIRKQRMKILFNVVLEAREPGSGRRLCDLFMVKPSKKDYPDYYKIILEPMDLKIIEHNIRNDKYAGEEGMIEDMKLMFRNARHYNEEGSQVYNDAHILEKLLKEKRKELGPLPDDDDMASPKLKLSRKSGISPKKSKYMTPMQQKLNEVYEAVKNYTDKRGRRLSAIFLRLPSRSELPDYYLTIKKPMDMEKIRSHMMANKYQDIDSMVEDFVMMFNNACTYNEPESLIYKDALVLHKVLLETRRDLEGDEDSHVPNVTLLIQELIHNLFVSVMSHQDDEGRCYSDSLAEIPAVDPNFPNKPPLTFDIIRKNVENNRYRRLDLFQEHMFEVLERARRMNRTDSEIYEDAVELQQFFIKIRDELCKNGEILLSPALSYTTKHLHNDVEKERKEKLPKEIEEDKLKREEEKREAEKSEDSSGAAGLSGLHRTYSQDCSFKNSMYHVGDYVYVEPAEANLQPHIVCIERLWEDSAGEKWLYGCWFYRPNETFHLATRKFLEKEVFKSDYYNKVPVSKILGKCVVMFVKEYFKLCPENFRDEDVFVCESRYSAKTKSFKKIKLWTMPISSVRFVPRDVPLPVVRVASVFANADKGDDEKNTDNSEDSRAEDNFNLEKEKEDVPVEMSNGEPGCHYFEQLHYNDMWLKVGDCVFIKSHGLVRPRVGRIEKVWVRDGAAYFYGPIFIHPEETEHEPTKMFYKKEVFLSNLEETCPMTCILGKCAVLSFKDFLSCRPTEIPENDILLCESRYNESDKQMKKFKGLKRFSLSAKVVDDEIYYFRKPIVPQKEPSPLLEKKIQLLEAKFAELEGGDDDIEEMGEEDSEVIEPPSLPQLQTPLASELDLMPYTPPQSTPKSAKGSAKKEGSKRKINMSGYILFSSEMRAVIKAQHPDYSFGELSRLVGTEWRNLETAKKAEYEERAAKVAEQQERERAAQQQQPSASPRAGTPVGALMGVVPPPTPMGMLNQQLTPVAGMMGGYPPGLPPLQGPVDGLVSMGSMQPLHPGGPPPHHLPPGVPGLPGIPPPGVMNQGVAPMVGTPAPGGSPYGQQVGVLGPPGQQAPPPYPGPHPAGPPVIQQPTTPMFVAPPPKTQRLLHSEAYLKYIEGLSAESNSISKWDQTLAARRRDVHLSKEQESRLPSHWLKSKGAHTTMADALWRLRDLMLRDTLNIRQAYNLENV
T00973	DRUGINFO	D09GNM	PFI-3	Investigative

T52547	TARGETID	T52547
T52547	FORMERID	TTDNR00734
T52547	UNIPROID	LYRIC_HUMAN
T52547	TARGNAME	Metastasis adhesion protein (MTDH)
T52547	GENENAME	MTDH
T52547	TARGTYPE	Literature-reported
T52547	SYNONYMS	Protein LYRIC; Metadherin; Lysine-rich CEACAM1 co-isolated protein; LYRIC; Astrocyte elevated gene-1 protein; AEG1; AEG-1; 3D3/LYRIC
T52547	FUNCTION	Activates the nuclear factor kappa-B (NF-kappa-B) transcription factor. Promotes anchorage-independent growth of immortalized melanocytes and astrocytes which is a key component in tumor cell expansion. Promotes lung metastasis and also has an effect on bone and brain metastasis, possibly by enhancing the seeding of tumor cells to the target organ endothelium. Induces chemoresistance. Downregulates SLC1A2/EAAT2 promoter activity when expressed ectopically.
T52547	PDBSTRUC	4QMG
T52547	SEQUENCE	MAARSWQDELAQQAEEGSARLREMLSVGLGFLRTELGLDLGLEPKRYPGWVILVGTGALGLLLLFLLGYGWAAACAGARKKRRSPPRKREEAAAVPAAAPDDLALLKNLRSEEQKKKNRKKLSEKPKPNGRTVEVAEGEAVRTPQSVTAKQPPEIDKKNEKSKKNKKKSKSDAKAVQNSSRHDGKEVDEGAWETKISHREKRQQRKRDKVLTDSGSLDSTIPGIENTITVTTEQLTTASFPVGSKKNKGDSHLNVQVSNFKSGKGDSTLQVSSGLNENLTVNGGGWNEKSVKLSSQISAGEEKWNSVSPASAGKRKTEPSAWSQDTGDANTNGKDWGRSWSDRSIFSGIGSTAEPVSQSTTSDYQWDVSRNQPYIDDEWSGLNGLSSADPNSDWNAPAEEWGNWVDEERASLLKSQEPIPDDQKVSDDDKEKGEGALPTGKSKKKKKKKKKQGEDNSTAQDTEELEKEIREDLPVNTSKTRPKQEKAFSLKTISTSDPAEVLVKNSQPIKTLPPATSTEPSVILSKSDSDKSSSQVPPILQETDKSKSNTKQNSVPPSQTKSETSWESPKQIKKKKKARRET

T91643	TARGETID	T91643
T91643	FORMERID	TTDI02519
T91643	UNIPROID	P2RY8_HUMAN
T91643	TARGNAME	P2Y purinoceptor 8 (P2RY8)
T91643	GENENAME	P2RY8
T91643	TARGTYPE	Literature-reported
T91643	SYNONYMS	P2Y8; P2RY8
T91643	FUNCTION	Probable receptor for purines coupled to G-proteins.
T91643	BIOCLASS	GPCR rhodopsin
T91643	SEQUENCE	MQVPNSTGPDNATLQMLRNPAIAVALPVVYSLVAAVSIPGNLFSLWVLCRRMGPRSPSVIFMINLSVTDLMLASVLPFQIYYHCNRHHWVFGVLLCNVVTVAFYANMYSSILTMTCISVERFLGVLYPLSSKRWRRRRYAVAACAGTWLLLLTALSPLARTDLTYPVHALGIITCFDVLKWTMLPSVAMWAVFLFTIFILLFLIPFVITVACYTATILKLLRTEEAHGREQRRRAVGLAAVVLLAFVTCFAPNNFVLLAHIVSRLFYGKSYYHVYKLTLCLSCLNNCLDPFVYYFASREFQLRLREYLGCRRVPRDTLDTRRESLFSARTTSVRSEAGAHPEGMEGATRPGLQRQESVF

T93951	TARGETID	T93951
T93951	UNIPROID	NLRC5_HUMAN
T93951	TARGNAME	Caterpiller protein 16.1 (NLRC5)
T93951	GENENAME	NLRC5
T93951	TARGTYPE	Literature-reported
T93951	SYNONYMS	Nucleotide-binding oligomerization domain protein 4; Nucleotide-binding oligomerization domain protein 27; NOD4; NOD27; CLR16.1
T93951	FUNCTION	Probable regulator of the NF-kappa-B and type I interferon signaling pathways. May also regulate the type II interferon signaling pathway. Plays a role in homeostatic control of innate immunity and in antiviral defense mechanisms.
T93951	BIOCLASS	NLRP family
T93951	SEQUENCE	MDPVGLQLGNKNLWSCLVRLLTKDPEWLNAKMKFFLPNTDLDSRNETLDPEQRVILQLNKLHVQGSDTWQSFIHCVCMQLEVPLDLEVLLLSTFGYDDGFTSQLGAEGKSQPESQLHHGLKRPHQSCGSSPRRKQCKKQQLELAKKYLQLLRTSAQQRYRSQIPGSGQPHAFHQVYVPPILRRATASLDTPEGAIMGDVKVEDGADVSISDLFNTRVNKGPRVTVLLGKAGMGKTTLAHRLCQKWAEGHLNCFQALFLFEFRQLNLITRFLTPSELLFDLYLSPESDHDTVFQYLEKNADQVLLIFDGLDEALQPMGPDGPGPVLTLFSHLCNGTLLPGCRVMATSRPGKLPACLPAEAAMVHMLGFDGPRVEEYVNHFFSAQPSREGALVELQTNGRLRSLCAVPALCQVACLCLHHLLPDHAPGQSVALLPNMTQLYMQMVLALSPPGHLPTSSLLDLGEVALRGLETGKVIFYAKDIAPPLIAFGATHSLLTSFCVCTGPGHQQTGYAFTHLSLQEFLAALHLMASPKVNKDTLTQYVTLHSRWVQRTKARLGLSDHLPTFLAGLASCTCRPFLSHLAQGNEDCVGAKQAAVVQVLKKLATRKLTGPKVVELCHCVDETQEPELASLTAQSLPYQLPFHNFPLTCTDLATLTNILEHREAPIHLDFDGCPLEPHCPEALVGCGQIENLSFKSRKCGDAFAEALSRSLPTMGRLQMLGLAGSKITARGISHLVKALPLCPQLKEVSFRDNQLSDQVVLNIVEVLPHLPRLRKLDLSSNSICVSTLLCLARVAVTCPTVRMLQAREADLIFLLSPPTETTAELQRAPDLQESDGQRKGAQSRSLTLRLQKCQLQVHDAEALIALLQEGPHLEEVDLSGNQLEDEGCRLMAEAASQLHIARKLDLSNNGLSVAGVHCVLRAVSACWTLAELHISLQHKTVIFMFAQEPEEQKGPQERAAFLDSLMLQMPSELPLSSRRMRLTHCGLQEKHLEQLCKALGGSCHLGHLHLDFSGNALGDEGAARLAQLLPGLGALQSLNLSENGLSLDAVLGLVRCFSTLQWLFRLDISFESQHILLRGDKTSRDMWATGSLPDFPAAAKFLGFRQRCIPRSLCLSECPLEPPSLTRLCATLKDCPGPLELQLSCEFLSDQSLETLLDCLPQLPQLSLLQLSQTGLSPKSPFLLANTLSLCPRVKKVDLRSLHHATLHFRSNEEEEGVCCGRFTGCSLSQEHVESLCWLLSKCKDLSQVDLSANLLGDSGLRCLLECLPQVPISGLLDLSHNSISQESALYLLETLPSCPRVREASVNLGSEQSFRIHFSREDQAGKTLRLSECSFRPEHVSRLATGLSKSLQLTELTLTQCCLGQKQLAILLSLVGRPAGLFSLRVQEPWADRARVLSLLEVCAQASGSVTEISISETQQQLCVQLEFPRQEENPEAVALRLAHCDLGAHHSLLVGQLMETCARLQQLSLSQVNLCEDDDASSLLLQSLLLSLSELKTFRLTSSCVSTEGLAHLASGLGHCHHLEELDLSNNQFDEEGTKALMRALEGKWMLKRLDLSHLLLNSSTLALLTHRLSQMTCLQSLRLNRNSIGDVGCCHLSEALRAATSLEELDLSHNQIGDAGVQHLATILPGLPELRKIDLSGNSISSAGGVQLAESLVLCRRLEELMLGCNALGDPTALGLAQELPQHLRVLHLPFSHLGPGGALSLAQALDGSPHLEEISLAENNLAGGVLRFCMELPLLRQIDLVSCKIDNQTAKLLTSSFTSCPALEVILLSWNLLGDEAAAELAQVLPQMGRLKRVDLEKNQITALGAWLLAEGLAQGSSIQVIRLWNNPIPCDMAQHLKSQEPRLDFAFFDNQPQAPWGT

T11203	TARGETID	T11203
T11203	FORMERID	TTDI00052
T11203	UNIPROID	FBX11_HUMAN
T11203	TARGNAME	Vitiligo-associated protein 1 (FBXO11)
T11203	GENENAME	FBXO11
T11203	TARGTYPE	Literature-reported
T11203	SYNONYMS	Vitiligoassociated protein 1; VIT1; VIT-1; UG063H01; Protein arginine N-methyltransferase 9; PRMT9; Fbox only protein 11; FBX11; F-box only protein 11
T11203	FUNCTION	The SCF(FBXO11) complex mediates ubiquitination and degradation of BCL6, thereby playing a role in the germinal center B-cells terminal differentiation toward memory B-cells and plasma cells. The SCF(FBXO11) complex also mediates ubiquitination and degradation of DTL, an important step for the regulation of TGF-beta signaling, cell migration and the timing of the cell-cycle progression and exit. Binds to and neddylates phosphorylated p53/TP53, inhibiting its transcriptional activity. SCF(FBXO11) does not seem to direct ubiquitination of p53/TP53. Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as DTL/CDT2, BCL6 and PRDM1/BLIMP1.
T11203	PDBSTRUC	5VMD
T11203	SEQUENCE	MNSVRAANRRPRRVSRPRPVQQQQQQPPQQPPPQPPQQQPPQQQPPPPPQQQQQQQPPPPPPPPPPLPQERNNVGERDDDVPADMVAEESGPGAQNSPYQLRRKTLLPKRTACPTKNSMEGASTSTTENFGHRAKRARVSGKSQDLSAAPAEQYLQEKLPDEVVLKIFSYLLEQDLCRAACVCKRFSELANDPILWKRLYMEVFEYTRPMMHPEPGKFYQINPEEYEHPNPWKESFQQLYKGAHVKPGFAEHFYSNPARYKGRENMLYYDTIEDALGGVQEAHFDGLIFVHSGIYTDEWIYIESPITMIGAAPGKVADKVIIENTRDSTFVFMEGSEDAYVGYMTIRFNPDDKSAQHHNAHHCLEITVNCSPIIDHCIIRSTCTVGSAVCVSGQGACPTIKHCNISDCENVGLYITDHAQGIYEDNEISNNALAGIWVKNHGNPIIRRNHIHHGRDVGVFTFDHGMGYFESCNIHRNRIAGFEVKAYANPTVVRCEIHHGQTGGIYVHEKGRGQFIENKIYANNFAGVWITSNSDPTIRGNSIFNGNQGGVYIFGDGRGLIEGNDIYGNALAGIQIRTNSCPIVRHNKIHDGQHGGIYVHEKGQGVIEENEVYSNTLAGVWVTTGSTPVLRRNRIHSGKQVGVYFYDNGHGVLEDNDIYNHMYSGVQIRTGSNPKIRRNKIWGGQNGGILVYNSGLGCIEDNEIFDNAMAGVWIKTDSNPTLRRNKIHDGRDGGICIFNGGRGLLEENDIFRNAQAGVLISTNSHPILRKNRIFDGFAAGIEITNHATATLEGNQIFNNRFGGLFLASGVNVTMKDNKIMNNQDAIEKAVSRGQCLYKISSYTSYPMHDFYRCHTCNTTDRNAICVNCIKKCHQGHDVEFIRHDRFFCDCGAGTLSNPCTLAGEPTHDTDTLYDSAPPIESNTLQHN

T83794	TARGETID	T83794
T83794	FORMERID	TTDR00074
T83794	UNIPROID	Q8I5S7_PLAF7
T83794	TARGNAME	Plasmodium Choline transporter (Malaria CT)
T83794	GENENAME	Malaria CT
T83794	TARGTYPE	Literature-reported
T83794	SYNONYMS	Glycerol-3-phosphate 1-O-acyltransferase
T83794	FUNCTION	Mediates the delivery of these compounds to the intracellular parasite
T83794	ECNUMBER	EC 2.3.1.15
T83794	SEQUENCE	MPDFYFLIRWLCKVIVKSVFRDVNVINPENVPLYGSVIFVGNHNNQFIDACVLIANIPRQVKFIVAEKSMRRAVIGKLASVIGCISVKRPQDLKFKGIGHICWNEGDVKITGINTRFRLDVQIGDKLLIQNKMFPVVKIESETELLIQEVINIECEDKMNGVPFKIIPKINQTEVYNLVTNSLKNGDTIGIFPEGGSHDRTNLLPLKPGVAIMTLCALADGIEDVSIIPVGLSYSKLYQLQGCATLFYGNAIIISQDLCKEYNNNNREAISKLLSKIEEGMRSCMLTSKDHETSRCIELCVSLYTPERMTISKNKIYNNLQLFCKMFWKFGNSKVIENLSYELKCYEKLLQANKIKDDEVWMLKQSTSAATLKFIEHICTFIFCVIFGMTFSLLWLPLVLISIYLAERHRKAALRNSTIKIQGGDVVSSYKVLVLIVLLPTFNIVYGLLFSIYLYHSWLKRILFVFLSMCILPICYYINLNYAVQIPSLLRQMKILLKVICGKINVWRDNERELISTRHELQLKVRDLVSTLGPDVSDDFLEQLYRNIPKFVVDVDTKRLIRGKDEFLPILQRSQLEYKEEIL
T83794	DRUGINFO	D0Z8GS	G-25	Investigative

T14380	TARGETID	T14380
T14380	FORMERID	TTDI01494
T14380	UNIPROID	Q8I6Z5_PLAF7
T14380	TARGNAME	Plasmodium Plasmepsin 5 (Malaria PLA5)
T14380	GENENAME	Malaria PLA5
T14380	TARGTYPE	Literature-reported
T14380	SYNONYMS	Plasmepsin V
T14380	FUNCTION	endoplasmic reticulum, integral component of membrane, aspartic-type endopeptidase activity, protein catabolic process, proteolysis
T14380	ECNUMBER	EC 3.4.23.-
T14380	SEQUENCE	MNNYFLRKENFFILFCFVFVSIFFVSNVTIIKCNNVENKIDNVGKKIENVGKKIGDMENKNDNVENKNDNVGNKNDNVKNASSDLYKYKLYGDIDEYAYYFLDIDIGKPSQRISLILDTGSSSLSFPCNGCKDCGIHMEKPYNLNYSKTSSILYCNKSNCPYGLKCVGNKCEYLQSYCEGSQIYGFYFSDIVTLPSYNNKNKISFEKLMGCHMHEESLFLHQQATGVLGFSLTKPNGVPTFVDLLFKHTPSLKPIYSICVSEHGGELIIGGYEPDYFLSNQKEKQKMDKSDNNSSNKGNVSIKLKNNDKNDDEENNSKDVIVSNNVEDIVWQAITRKYYYYIKIYGLDLYGTNIMDKKELDMLVDSGSTFTHIPENIYNQINYYLDILCIHDMTNIYEINKRLKLTNESLNKPLVYFEDFKTALKNIIQNENLCIKIVDGVQCWKSLENLPNLYITLSNNYKMIWKPSSYLYKKESFWCKGLEKQVNNKPILGLTFFKNKQVIFDLQQNQIAFIESKCPSNLTSSRPRTFNEYREKENIFLKVSYINLYCLWLLLALTILLSLILYVRKMFYMDYFPLSDQNKSPIQEST

T73077	TARGETID	T73077
T73077	FORMERID	TTDR00708
T73077	UNIPROID	Q8ITL2_9TRYP
T73077	TARGNAME	Leishmania 65kD membrane-associated NADH-fumarate reductase (Leishm nfr65)
T73077	GENENAME	Leishm nfr65
T73077	TARGTYPE	Literature-reported
T73077	SYNONYMS	NADH-dependent fumarate reductase
T73077	FUNCTION	An obligatory component of the respiratory chain of the parasite. Important in the intermediate metabolism in the Leishmania parasite and is absent in mammalian cells.
T73077	BIOCLASS	CH-CH donor oxidoreductase
T73077	SEQUENCE	MVDGRSSASIVAVDPERAARERDAAARALLQDSPLHTTMQYATSGLELTVPYALKVVASADTFDRAKEVADEVLRCAWQLADTVLNSFNPNSEVSLVGRLPVGQKHQMSAPLKRVMACCQRVYNSSAGCFDPSTAPVAKALREIALGKERNNACLEALTQACTLPNSFVIDFEAGTISRKHEHASLDLGGVSKGYIVDYVIDNINAAGFQNVFFDWGGDCRASGMNARNTPWVVGITRPPSLDMLPNPPKEASYISVISLDNEALATSGDYENLIYTADDKPLTCTYDWKGKELMKPSQSNIAQVSVKCYSAMYADALATACFIKRDPAKVRQLLDGWRYVRDTVRDYRVYVRENERVAKMFEIATEDAEMRKRRISNTLPARVIVVGGGLAGLSAAIEAAGCGAQVVLMEKEAKLGGNSAKATSGINGWGTRAQAKASIVDGGKYFERDTYKSGIGGNTDPALVKTLSMKSADAIGWLTSLGVPLTVLSQLGGHSRKRTHRAPDKKDGTPLPIGFTIMKTLEDHVRGNLSGRITIMENCSVTSLLSETKERPDGTKQIRVTGVEFTQAGSGKTTILADAVILATGGFSNDKTADSLLREHAPHLVNFPTTNGPWATGDGVKLAQRLGAQLVDMDKVQLHPTGLINPKDPANPTKFLGPEALRGSGGVLLNKQGKRFVNELDLRSVVSKAIMEQGAEYPGSGGSMFAYCVLNAAAQKLFGVSSHEFYWKKMGLFVKADTMRDLAALIGCPVESVQQTLEEYERLSISQRSCPITRKSVYPCVLGTKGPYYVAFVTPSIHYTMGGCLISPSAEIQMKNTSSRAPLSHSNPILGLFGAGEVTGGVHGGNRLGGNSLLECVVFGRIAGDRASTILQRKSSALSFKVWTTVVLREVREGGVYGAGSRVLRFNLPGALQRSGLSLGQFIAIRGDWDGQQLIGYYSPITLPDDLGMIDILARSDKGTLREWISALEPGDAVEMKACGGLVIERRLSDKHFVFMGHIINKLCLIAGGTGVAPMLQIIKAAFMKPFIDTLESVHLIYAAEDVTELTYREVLEERRRESRGKFKKTFVLNRPPPLWTDGVGFIDRGILTNHVQPPSDNLLVAICGPPVMQRIVKATLKTLGYNMNLVRTVDETEPSGSSKI

T13863	TARGETID	T13863
T13863	FORMERID	TTDI03587
T13863	UNIPROID	TMPS6_HUMAN
T13863	TARGNAME	Transmembrane protease serine 6 (TMPRSS6)
T13863	GENENAME	TMPRSS6
T13863	TARGTYPE	Literature-reported
T13863	SYNONYMS	Matriptase-2
T13863	FUNCTION	Serine protease which hydrolyzes a range of proteins including type I collagen, fibronectin and fibrinogen. Can also activate urokinase-type plasminogen activator with low efficiency. May play a specialized role in matrix remodeling processes in liver. Through the cleavage of HJV, a regulator of the expression of the iron absorption-regulating hormone hepicidin/HAMP, plays a role in iron homeostasis.
T13863	ECNUMBER	EC 3.4.21.-
T13863	SEQUENCE	MLLLFHSKRMPVAEAPQVAGGQGDGGDGEEAEPEGMFKACEDSKRKARGYLRLVPLFVLLALLVLASAGVLLWYFLGYKAEVMVSQVYSGSLRVLNRHFSQDLTRRESSAFRSETAKAQKMLKELITSTRLGTYYNSSSVYSFGEGPLTCFFWFILQIPEHRRLMLSPEVVQALLVEELLSTVNSSAAVPYRAEYEVDPEGLVILEASVKDIAALNSTLGCYRYSYVGQGQVLRLKGPDHLASSCLWHLQGPKDLMLKLRLEWTLAECRDRLAMYDVAGPLEKRLITSVYGCSRQEPVVEVLASGAIMAVVWKKGLHSYYDPFVLSVQPVVFQACEVNLTLDNRLDSQGVLSTPYFPSYYSPQTHCSWHLTVPSLDYGLALWFDAYALRRQKYDLPCTQGQWTIQNRRLCGLRILQPYAERIPVVATAGITINFTSQISLTGPGVRVHYGLYNQSDPCPGEFLCSVNGLCVPACDGVKDCPNGLDERNCVCRATFQCKEDSTCISLPKVCDGQPDCLNGSDEEQCQEGVPCGTFTFQCEDRSCVKKPNPQCDGRPDCRDGSDEEHCDCGLQGPSSRIVGGAVSSEGEWPWQASLQVRGRHICGGALIADRWVITAAHCFQEDSMASTVLWTVFLGKVWQNSRWPGEVSFKVSRLLLHPYHEEDSHDYDVALLQLDHPVVRSAAVRPVCLPARSHFFEPGLHCWITGWGALREGGPISNALQKVDVQLIPQDLCSEVYRYQVTPRMLCAGYRKGKKDACQGDSGGPLVCKALSGRWFLAGLVSWGLGCGRPNYFGVYTRITGVISWIQQVVT
T13863	DRUGINFO	D0W2SV	Inhibitor 1 [Colombo et al., 2012]	Investigative

T63580	TARGETID	T63580
T63580	FORMERID	TTDNR00727
T63580	UNIPROID	PLDX1_HUMAN
T63580	TARGNAME	Plexin domain-containing protein 1 (PLXDC1)
T63580	GENENAME	PLXDC1
T63580	TARGTYPE	Literature-reported
T63580	SYNONYMS	Tumor endothelial marker 7; Tumor endothelial marker 3; PLXDC1
T63580	FUNCTION	Plays a critical role in endothelial cell capillarymorphogenesis.
T63580	BIOCLASS	Plexin family
T63580	SEQUENCE	MRGELWLLVLVLREAARALSPQPGAGHDEGPGSGWAAKGTVRGWNRRARESPGHVSEPDRTQLSQDLGGGTLAMDTLPDNRTRVVEDNHSYYVSRLYGPSEPHSRELWVDVAEANRSQVKIHTILSNTHRQASRVVLSFDFPFYGHPLRQITIATGGFIFMGDVIHRMLTATQYVAPLMANFNPGYSDNSTVVYFDNGTVFVVQWDHVYLQGWEDKGSFTFQAALHHDGRIVFAYKEIPMSVPEISSSQHPVKTGLSDAFMILNPSPDVPESRRRSIFEYHRIELDPSKVTSMSAVEFTPLPTCLQHRSCDACMSSDLTFNCSWCHVLQRCSSGFDRYRQEWMDYGCAQEAEGRMCEDFQDEDHDSASPDTSFSPYDGDLTTTSSSLFIDSLTTEDDTKLNPYAGGDGLQNNLSPKTKGTPVHLGTIVGIVLAVLLVAAIILAGIYINGHPTSNAALFFIERRPHHWPAMKFRSHPDHSTYAEVEPSGHEKEGFMEAEQC

T28620	TARGETID	T28620
T28620	FORMERID	TTDNR00668
T28620	UNIPROID	EGFL6_HUMAN
T28620	TARGNAME	Epidermal growth factor-like protein 6 (EGFL6)
T28620	GENENAME	EGFL6
T28620	TARGTYPE	Literature-reported
T28620	SYNONYMS	MAM and EGF domains-containing gene protein; EGFL6; EGF-like protein 6
T28620	FUNCTION	May bind integrin alpha-8/beta-1 and play a role in hair follicle morphogenesis. Promotes matrix assembly.
T28620	BIOCLASS	Growth factor
T28620	SEQUENCE	MPLPWSLALPLLLSWVAGGFGNAASARHHGLLASARQPGVCHYGTKLACCYGWRRNSKGVCEATCEPGCKFGECVGPNKCRCFPGYTGKTCSQDVNECGMKPRPCQHRCVNTHGSYKCFCLSGHMLMPDATCVNSRTCAMINCQYSCEDTEEGPQCLCPSSGLRLAPNGRDCLDIDECASGKVICPYNRRCVNTFGSYYCKCHIGFELQYISGRYDCIDINECTMDSHTCSHHANCFNTQGSFKCKCKQGYKGNGLRCSAIPENSVKEVLRAPGTIKDRIKKLLAHKNSMKKKAKIKNVTPEPTRTPTPKVNLQPFNYEEIVSRGGNSHGGKKGNEEKMKEGLEDEKREEKALKNDIEERSLRGDVFFPKVNEAGEFGLILVQRKALTSKLEHKDLNISVDCSFNHGICDWKQDREDDFDWNPADRDNAIGFYMAVPALAGHKKDIGRLKLLLPDLQPQSNFCLLFDYRLAGDKVGKLRVFVKNSNNALAWEKTTSEDEKWKTGKIQLYQGTDATKSIIFEAERGKGKTGEIAVDGVLLVSGLCPDSLLSVDD

T10375	TARGETID	T10375
T10375	FORMERID	TTDI03058
T10375	UNIPROID	BRSK2_HUMAN
T10375	TARGNAME	BR serine/threonine kinase 2 (BRSK2)
T10375	GENENAME	BRSK2
T10375	TARGTYPE	Literature-reported
T10375	SYNONYMS	Serine/threonine-protein kinase SAD-A; Serine/threonine-protein kinase BRSK2; Serine/threonine-protein kinase 29; STK29; SADA; PEN11B; HUSSY-12; C11orf7; Brain-specific serine/threonine-protein kinase 2; Brain-selective kinase 2; BR serine/threonine-protein kinase 2
T10375	FUNCTION	Serine/threonine-protein kinase that plays a key role in polarization of neurons and axonogenesis, cell cycle progress and insulin secretion. Phosphorylates CDK16, CDC25C, MAPT/TAU, PAK1 and WEE1. Following phosphorylation and activation by STK11/LKB1, acts as a key regulator of polarization of cortical neurons, probably by mediating phosphorylation of microtubule-associated proteins such as MAPT/TAU at 'Thr-529' and 'Ser-579'. Also regulates neuron polarization by mediating phosphorylation of WEE1 at 'Ser-642' in postmitotic neurons, leading to down-regulate WEE1 activity in polarized neurons. Plays a role in the regulation of the mitotic cell cycle progress and the onset of mitosis. Plays a role in the regulation of insulin secretion in response to elevated glucose levels, probably via phosphorylation of CDK16 and PAK1. While BRSK2 phosphorylated at Thr-174 can inhibit insulin secretion, BRSK2 phosphorylated at Thr-260 can promote insulin secretion. Regulates reorganization of the actin cytoskeleton. May play a role in the apoptotic response triggered by endoplasmic reticulum (ER) stress.
T10375	ECNUMBER	EC 2.7.11.1
T10375	SEQUENCE	MTSTGKDGGAQHAQYVGPYRLEKTLGKGQTGLVKLGVHCVTCQKVAIKIVNREKLSESVLMKVEREIAILKLIEHPHVLKLHDVYENKKYLYLVLEHVSGGELFDYLVKKGRLTPKEARKFFRQIISALDFCHSHSICHRDLKPENLLLDEKNNIRIADFGMASLQVGDSLLETSCGSPHYACPEVIRGEKYDGRKADVWSCGVILFALLVGALPFDDDNLRQLLEKVKRGVFHMPHFIPPDCQSLLRGMIEVDAARRLTLEHIQKHIWYIGGKNEPEPEQPIPRKVQIRSLPSLEDIDPDVLDSMHSLGCFRDRNKLLQDLLSEEENQEKMIYFLLLDRKERYPSQEDEDLPPRNEIDPPRKRVDSPMLNRHGKRRPERKSMEVLSVTDGGSPVPARRAIEMAQHGQRSRSISGASSGLSTSPLSSPRVTPHPSPRGSPLPTPKGTPVHTPKESPAGTPNPTPPSSPSVGGVPWRARLNSIKNSFLGSPRFHRRKLQVPTPEEMSNLTPESSPELAKKSWFGNFISLEKEEQIFVVIKDKPLSSIKADIVHAFLSIPSLSHSVISQTSFRAEYKATGGPAVFQKPVKFQVDITYTEGGEAQKENGIYSVTFTLLSGPSRRFKRVVETIQAQLLSTHDPPAAQHLSDTTNCMEMMTGRLSKCGSPLSNFFDVIKQLFSDEKNGQAAQAPSTPAKRSAHGPLGDSAAAGPGPGGDAEYPTGKDTAKMGPPTARREQP
T10375	DRUGINFO	D0Z8PT	CCT244747	Investigative

T92902	TARGETID	T92902
T92902	UNIPROID	TRI59_HUMAN
T92902	TARGNAME	Tripartite motif-containing 59 (TRIM59)
T92902	GENENAME	TRIM59
T92902	TARGTYPE	Literature-reported
T92902	SYNONYMS	Tumor suppressor TSBF-1; TSBF1; TRIM57; RNF104; RING finger protein 104
T92902	FUNCTION	May serve as a multifunctional regulator for innate immune signaling pathways.
T92902	BIOCLASS	TRIM/RBCC family
T92902	SEQUENCE	MHNFEEELTCPICYSIFEDPRVLPCSHTFCRNCLENILQASGNFYIWRPLRIPLKCPNCRSITEIAPTGIESLPVNFALRAIIEKYQQEDHPDIVTCPEHYRQPLNVYCLLDKKLVCGHCLTIGQHHGHPIDDLQSAYLKEKDTPQKLLEQLTDTHWTDLTHLIEKLKEQKSHSEKMIQGDKEAVLQYFKELNDTLEQKKKSFLTALCDVGNLINQEYTPQIERMKEIREQQLELMALTISLQEESPLKFLEKVDDVRQHVQILKQRPLPEVQPVEIYPRVSKILKEEWSRTEIGQIKNVLIPKMKISPKRMSCSWPGKDEKEVEFLKILNIVVVTLISVILMSILFFNQHIITFLSEITLIWFSEASLSVYQSLSNSLHKVKNILCHIFYLLKEFVWKIVSH

T12714	TARGETID	T12714
T12714	FORMERID	TTDI02606
T12714	UNIPROID	ZNT8_HUMAN
T12714	TARGNAME	Zinc transporter 8 (SLC30A8)
T12714	GENENAME	SLC30A8
T12714	TARGTYPE	Literature-reported
T12714	SYNONYMS	ZnT-8; Solute carrier family 30 member 8; SLC30A8
T12714	FUNCTION	Facilitates the accumulation of zinc from the cytoplasm into intracellular vesicles, being a zinc-efflux transporter. May be a major component for providing zinc to insulin maturation and/or storage processes in insulin-secreting pancreatic beta-cells.
T12714	BIOCLASS	Cation diffusion facilitator
T12714	SEQUENCE	MEFLERTYLVNDKAAKMYAFTLESVELQQKPVNKDQCPRERPEELESGGMYHCHSGSKPTEKGANEYAYAKWKLCSASAICFIFMIAEVVGGHIAGSLAVVTDAAHLLIDLTSFLLSLFSLWLSSKPPSKRLTFGWHRAEILGALLSILCIWVVTGVLVYLACERLLYPDYQIQATVMIIVSSCAVAANIVLTVVLHQRCLGHNHKEVQANASVRAAFVHALGDLFQSISVLISALIIYFKPEYKIADPICTFIFSILVLASTITILKDFSILLMEGVPKSLNYSGVKELILAVDGVLSVHSLHIWSLTMNQVILSAHVATAASRDSQVVRREIAKALSKSFTMHSLTIQMESPVDQDPDCLFCEDPCD

T69651	TARGETID	T69651
T69651	FORMERID	TTDR01161
T69651	UNIPROID	Q8MTU2_TOXGO
T69651	TARGNAME	Toxoplasma Toxopain-1 (Tg cp1)
T69651	GENENAME	Tg cp1
T69651	TARGTYPE	Literature-reported
T69651	SYNONYMS	Toxoplasma Cysteine proteinase
T69651	FUNCTION	A cathepsin B, play a critical role in the pathogenesis of toxoplasmosis. Secreted in the parasitophorous vacuole, where it may be involved in the degradation of host cell peptides, a process extensively studied in the related apicomplexan Plasmodium falciparum
T69651	BIOCLASS	Protease
T69651	SEQUENCE	MEGRKSFRVLGTPLPFAALAAILLLGCMYTRAAGTPDDSLFPLSEDTSVDPRESFSAEDVLNAFVSPESVESLFDSIVAEQVVATSGNLTESAPRDRDSAPERRSDGGTLRGHPEDAGELLRLLLADSEDMELWKANFFRHLTHSMRHIVRDSVLVSEKAFPSEQAGEAGRDPGDLKKALEETGEDVFWESRPASSNAAVALIKKKMEKQAGKTGEGAGHTWEPEVSLRFRYLSLKDAKKLMGTFLVNTKVEGFPTPKGMPLPAKEFENATEPVPAHFDARTAFPACKDVVGHVRDQGDCGSCWAFASTEAFNDRLCIRSQGKRLMPLSAQHTTSCCNAIHCASFGCNGGQPGMAWRWFERKGVVTGGDFDALGKGTTCWPYEVPFCAHHAKAPFPDCDATLVPRKTPKCRKDCEEQAYADNVHPFDQDTHKATSAYSLRSRDDVKRDMMTHGPVSGAFMVYEDFLSYKSGVYKHVSGLPVGGHAIKIIGWGTENGEEYWHAVNSWNTYWGDGGQFKIAMGQCGIDGEMVAGEAAWQETEGVVNGEEELPGQRAAGARAGAHAEEEREM

T10336	TARGETID	T10336
T10336	FORMERID	TTDI03134
T10336	UNIPROID	CXD3_HUMAN
T10336	TARGNAME	Gap junction delta-3 protein (Cx31.9)
T10336	GENENAME	GJD3
T10336	TARGTYPE	Literature-reported
T10336	SYNONYMS	Gap junction chi-1 protein; Gap junction alpha-11 protein; GJC1; GJA11; Connexin-31.9
T10336	FUNCTION	One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell.
T10336	BIOCLASS	Gap junction-forming connexin
T10336	SEQUENCE	MGEWAFLGSLLDAVQLQSPLVGRLWLVVMLIFRILVLATVGGAVFEDEQEEFVCNTLQPGCRQTCYDRAFPVSHYRFWLFHILLLSAPPVLFVVYSMHRAGKEAGGAEAAAQCAPGLPEAQCAPCALRARRARRCYLLSVALRLLAELTFLGGQALLYGFRVAPHFACAGPPCPHTVDCFVSRPTEKTVFVLFYFAVGLLSALLSVAELGHLLWKGRPRAGERDNRCNRAHEEAQKLLPPPPPPPPPPALPSRRPGPEPCAPPAYAHPAPASLRECGSGRGKASPATGRRDLAI
T10336	DRUGINFO	D00VJY	octanol	Investigative

T58216	TARGETID	T58216
T58216	FORMERID	TTDI02130
T58216	UNIPROID	MUC15_HUMAN
T58216	TARGNAME	Mucin-15 (MUC15)
T58216	GENENAME	MUC15
T58216	TARGTYPE	Literature-reported
T58216	SYNONYMS	Mucin15; MUC15
T58216	FUNCTION	May play a role in the cell adhesion to the extracellular matrix.
T58216	BIOCLASS	Mucin
T58216	SEQUENCE	MLALAKILLISTLFYSLLSGSHGKENQDINTTQNIAEVFKTMENKPISLESEANLNSDKENITTSNLKASHSPPLNLPNNSHGITDFSSNSSAEHSLGSLKPTSTISTSPPLIHSFVSKVPWNAPIADEDLLPISAHPNATPALSSENFTWSLVNDTVKTPDNSSITVSILSSEPTSPSVTPLIVEPSGWLTTNSDSFTGFTPYQEKTTLQPTLKFTNNSKLFPNTSDPQKENRNTGIVFGAILGAILGVSLLTLVGYLLCGKRKTDSFSHRRLYDDRNEPVLRLDNAPEPYDVSFGNSSYYNPTLNDSAMPESEENARDGIPMDDIPPLRTSV

T15509	TARGETID	T15509
T15509	FORMERID	TTDI03154
T15509	UNIPROID	DGLB_HUMAN
T15509	TARGNAME	Diacylglycerol lipase beta (DAGLB)
T15509	GENENAME	DAGLB
T15509	TARGTYPE	Literature-reported
T15509	SYNONYMS	Sn1-specific diacylglycerol lipase beta; KCCR13L; DGL-beta
T15509	FUNCTION	Catalyzes the hydrolysis of diacylglycerol (DAG) to 2-arachidonoyl-glycerol (2-AG), the most abundant endocannabinoid in tissues. Required for axonal growth during development and for retrograde synaptic signaling at mature synapses.
T15509	ECNUMBER	EC 3.1.1.-
T15509	SEQUENCE	MPGMVLFGRRWAIASDDLVFPGFFELVVRVLWWIGILTLYLMHRGKLDCAGGALLSSYLIVLMILLAVVICTVSAIMCVSMRGTICNPGPRKSMSKLLYIRLALFFPEMVWASLGAAWVADGVQCDRTVVNGIIATVVVSWIIIAATVVSIIIVFDPLGGKMAPYSSAGPSHLDSHDSSQLLNGLKTAATSVWETRIKLLCCCIGKDDHTRVAFSSTAELFSTYFSDTDLVPSDIAAGLALLHQQQDNIRNNQEPAQVVCHAPGSSQEADLDAELENCHHYMQFAAAAYGWPLYIYRNPLTGLCRIGGDCCRSRTTDYDLVGGDQLNCHFGSILHTTGLQYRDFIHVSFHDKVYELPFLVALDHRKESVVVAVRGTMSLQDVLTDLSAESEVLDVECEVQDRLAHKGISQAARYVYQRLINDGILSQAFSIAPEYRLVIVGHSLGGGAAALLATMLRAAYPQVRCYAFSPPRGLWSKALQEYSQSFIVSLVLGKDVIPRLSVTNLEDLKRRILRVVAHCNKPKYKILLHGLWYELFGGNPNNLPTELDGGDQEVLTQPLLGEQSLLTRWSPAYSFSSDSPLDSSPKYPPLYPPGRIIHLQEEGASGRFGCCSAAHYSAKWSHEAEFSKILIGPKMLTDHMPDILMRALDSVVSDRAACVSCPAQGVSSVDVA
T15509	DRUGINFO	D05LXG	RHC80267	Investigative

T89345	TARGETID	T89345
T89345	FORMERID	TTDI03332
T89345	UNIPROID	KCNH5_HUMAN
T89345	TARGNAME	Voltage-gated potassium channel Kv10.2 (KCNH5)
T89345	GENENAME	KCNH5
T89345	TARGTYPE	Literature-reported
T89345	SYNONYMS	hEAG2; Voltage-gated potassium channel subunit Kv10.2; Potassium voltage-gated channel subfamily H member 5; Ether-a-go-go potassium channel 2; EAG2
T89345	FUNCTION	Pore-forming (alpha) subunit of voltage-gated potassium channel. Elicits a non-inactivating outward rectifying current. Channel properties may be modulated by cAMP and subunit assembly.
T89345	BIOCLASS	Voltage-gated ion channel
T89345	SEQUENCE	MPGGKRGLVAPQNTFLENIVRRSSESSFLLGNAQIVDWPVVYSNDGFCKLSGYHRADVMQKSSTCSFMYGELTDKKTIEKVRQTFDNYESNCFEVLLYKKNRTPVWFYMQIAPIRNEHEKVVLFLCTFKDITLFKQPIEDDSTKGWTKFARLTRALTNSRSVLQQLTPMNKTEVVHKHSRLAEVLQLGSDILPQYKQEAPKTPPHIILHYCAFKTTWDWVILILTFYTAIMVPYNVSFKTKQNNIAWLVLDSVVDVIFLVDIVLNFHTTFVGPGGEVISDPKLIRMNYLKTWFVIDLLSCLPYDIINAFENVDEGISSLFSSLKVVRLLRLGRVARKLDHYLEYGAAVLVLLVCVFGLVAHWLACIWYSIGDYEVIDEVTNTIQIDSWLYQLALSIGTPYRYNTSAGIWEGGPSKDSLYVSSLYFTMTSLTTIGFGNIAPTTDVEKMFSVAMMMVGSLLYATIFGNVTTIFQQMYANTNRYHEMLNNVRDFLKLYQVPKGLSERVMDYIVSTWSMSKGIDTEKVLSICPKDMRADICVHLNRKVFNEHPAFRLASDGCLRALAVEFQTIHCAPGDLIYHAGESVDALCFVVSGSLEVIQDDEVVAILGKGDVFGDIFWKETTLAHACANVRALTYCDLHIIKREALLKVLDFYTAFANSFSRNLTLTCNLRKRIIFRKISDVKKEEEERLRQKNEVTLSIPVDHPVRKLFQKFKQQKELRNQGSTQGDPERNQLQVESRSLQNGASITGTSVVTVSQITPIQTSLAYVKTSESLKQNNRDAMELKPNGGADQKCLKVNSPIRMKNGNGKGWLRLKNNMGAHEEKKEDWNNVTKAESMGLLSEDPKSSDSENSVTKNPLRKTDSCDSGITKSDLRLDKAGEARSPLEHSPIQADAKHPFYPIPEQALQTTLQEVKHELKEDIQLLSCRMTALEKQVAEILKILSEKSVPQASSPKSQMPLQVPPQIPCQDIFSVSRPESPESDKDEIHF
T89345	DRUGINFO	D02WWM	LY97241	Investigative

T98633	TARGETID	T98633
T98633	FORMERID	TTDI03130
T98633	UNIPROID	CXG3_HUMAN
T98633	TARGNAME	Gap junction gamma-3 protein (Cx30.2)
T98633	GENENAME	GJC3
T98633	TARGTYPE	Literature-reported
T98633	SYNONYMS	Gap junction epsilon-1 protein; GJE1; Cx31.3; Connexin-31.3; Connexin-30.2
T98633	FUNCTION	One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell.
T98633	BIOCLASS	Gap junction-forming connexin
T98633	SEQUENCE	MCGRFLRRLLAEESRRSTPVGRLLLPVLLGFRLVLLAASGPGVYGDEQSEFVCHTQQPGCKAACFDAFHPLSPLRFWVFQVILVAVPSALYMGFTLYHVIWHWELSGKGKEEETLIQGREGNTDVPGAGSLRLLWAYVAQLGARLVLEGAALGLQYHLYGFQMPSSFACRREPCLGSITCNLSRPSEKTIFLKTMFGVSGFCLLFTFLELVLLGLGRWWRTWKHKSSSSKYFLTSESTRRHKKATDSLPVVETKEQFQEAVPGRSLAQEKQRPVGPRDA
T98633	DRUGINFO	D00VJY	octanol	Investigative

T97754	TARGETID	T97754
T97754	FORMERID	TTDI03584
T97754	UNIPROID	TPC2_HUMAN
T97754	TARGNAME	Two pore calcium channel protein 2 (TPC2)
T97754	GENENAME	TPCN2
T97754	TARGTYPE	Literature-reported
T97754	SYNONYMS	Voltage-dependent calcium channel protein TPC2; TPC2
T97754	FUNCTION	Nicotinic acid adenine dinucleotide phosphate (NAADP) receptor that may function as one of the major voltage-gated Ca(2+) channels (VDCC) across the lysosomal membrane. May be involved in smooth muscle contraction.
T97754	PDBSTRUC	6NQ2; 6NQ1; 6NQ0
T97754	SEQUENCE	MAEPQAESEPLLGGARGGGGDWPAGLTTYRSIQVGPGAAARWDLCIDQAVVFIEDAIQYRSINHRVDASSMWLYRRYYSNVCQRTLSFTIFLILFLAFIETPSSLTSTADVRYRAAPWEPPCGLTESVEVLCLLVFAADLSVKGYLFGWAHFQKNLWLLGYLVVLVVSLVDWTVSLSLVCHEPLRIRRLLRPFFLLQNSSMMKKTLKCIRWSLPEMASVGLLLAIHLCLFTMFGMLLFAGGKQDDGQDRERLTYFQNLPESLTSLLVLLTTANNPDVMIPAYSKNRAYAIFFIVFTVIGSLFLMNLLTAIIYSQFRGYLMKSLQTSLFRRRLGTRAAFEVLSSMVGEGGAFPQAVGVKPQNLLQVLQKVQLDSSHKQAMMEKVRSYGSVLLSAEEFQKLFNELDRSVVKEHPPRPEYQSPFLQSAQFLFGHYYFDYLGNLIALANLVSICVFLVLDADVLPAERDDFILGILNCVFIVYYLLEMLLKVFALGLRGYLSYPSNVFDGLLTVVLLVLEISTLAVYRLPHPGWRPEMVGLLSLWDMTRMLNMLIVFRFLRIIPSMKLMAVVASTVLGLVQNMRAFGGILVVVYYVFAIIGINLFRGVIVALPGNSSLAPANGSAPCGSFEQLEYWANNFDDFAAALVTLWNLMVVNNWQVFLDAYRRYSGPWSKIYFVLWWLVSSVIWVNLFLALILENFLHKWDPRSHLQPLAGTPEATYQMTVELLFRDILEEPGEDELTERLSQHPHLWLCR
T97754	DRUGINFO	D01ZCI	phosphatidyl (3,5) inositol biphosphate	Investigative

T63747	TARGETID	T63747
T63747	FORMERID	TTDI01465
T63747	UNIPROID	PAFA_CORGL
T63747	TARGNAME	Corynebacterium Pup-protein ligase (Cory pafA)
T63747	GENENAME	Cory pafA
T63747	TARGTYPE	Literature-reported
T63747	SYNONYMS	Pup-conjugating enzyme; Pup--protein ligase; Proteasome accessory factor A
T63747	FUNCTION	Catalyzes the covalent attachment of the prokaryotic ubiquitin-like protein modifier Pup to the proteasomal substrate proteins, thereby targeting them for proteasomal degradation. This tagging system is termed pupylation. The ligation reaction involves the side-chain carboxylate of the C-terminal glutamate of Pup and the side-chain amino group of a substrate lysine.
T63747	PDBSTRUC	4BJR; 4B0T
T63747	SEQUENCE	MSTVESALTRRIMGIETEYGLTFVDGDSKKLRPDEIARRMFRPIVEKYSSSNIFIPNGSRLYLDVGSHPEYATAECDNLTQLINFEKAGDVIADRMAVDAEESLAKEDIAGQVYLFKNNVDSVGNSYGCHENYLVGRSMPLKALGKRLMPFLITRQLICGAGRIHHPNPLDKGESFPLGYCISQRSDHVWEGVSSATTRSRPIINTRDEPHADSHSYRRLHVIVGDANMAEPSIALKVGSTLLVLEMIEADFGLPSLELANDIASIREISRDATGSTLLSLKDGTTMTALQIQQVVFEHASKWLEQRPEPEFSGTSNTEMARVLDLWGRMLKAIESGDFSEVDTEIDWVIKKKLIDRFIQRGNLGLDDPKLAQVDLTYHDIRPGRGLFSVLQSRGMIKRWTTDEAILAAVDTAPDTTRAHLRGRILKAADTLGVPVTVDWMRHKVNRPEPQSVELGDPFSAVNSEVDQLIEYMTVHAESYRS

T96301	TARGETID	T96301
T96301	UNIPROID	DPTOR_HUMAN
T96301	TARGNAME	DEP domain-containing protein 6 (DEPTOR)
T96301	GENENAME	DEPTOR
T96301	TARGTYPE	Literature-reported
T96301	SYNONYMS	DEPDC6
T96301	FUNCTION	Negative regulator of the mTORC1 and mTORC2 signaling pathways. Inhibits the kinase activity of both complexes.
T96301	SEQUENCE	MEEGGSTGSAGSDSSTSGSGGAQQRELERMAEVLVTGEQLRLRLHEEKVIKDRRHHLKTYPNCFVAKELIDWLIEHKEASDRETAIKLMQKLADRGIIHHVCDEHKEFKDVKLFYRFRKDDGTFPLDNEVKAFMRGQRLYEKLMSPENTLLQPREEEGVKYERTFMASEFLDWLVQEGEATTRKEAEQLCHRLMEHGIIQHVSNKHPFVDSNLLYQFRMNFRRRRRLMELLNEKSPSSQETHDSPFCLRKQSHDNRKSTSFMSVSPSKEIKIVSAVRRSSMSSCGSSGYFSSSPTLSSSPPVLCNPKSVLKRPVTSEELLTPGAPYARKTFTIVGDAVGWGFVVRGSKPCHIQAVDPSGPAAAAGMKVCQFVVSVNGLNVLHVDYRTVSNLILTGPRTIVMEVMEELEC

T40243	TARGETID	T40243
T40243	FORMERID	TTDI03106
T40243	UNIPROID	CERK1_HUMAN
T40243	TARGNAME	Ceramide kinase (CERK)
T40243	GENENAME	CERK
T40243	TARGTYPE	Literature-reported
T40243	SYNONYMS	hCERK; Lipid kinase 4; LK4; KIAA1646; Acylsphingosine kinase
T40243	FUNCTION	Catalyzes specifically the phosphorylation of ceramide to form ceramide 1-phosphate. Acts efficiently on natural and analog ceramides (C6, C8, C16 ceramides, and C8-dihydroceramide), to a lesser extent on C2-ceramide and C6-dihydroceramide, but not on other lipids, such as various sphingosines. Shows a greater preference for D-erythro isomer of ceramides. Binds phosphoinositides.
T40243	ECNUMBER	EC 2.7.1.138
T40243	SEQUENCE	MGATGAAEPLQSVLWVKQQRCAVSLEPARALLRWWRSPGPGAGAPGADACSVPVSEIIAVEETDVHGKHQGSGKWQKMEKPYAFTVHCVKRARRHRWKWAQVTFWCPEEQLCHLWLQTLREMLEKLTSRPKHLLVFINPFGGKGQGKRIYERKVAPLFTLASITTDIIVTEHANQAKETLYEINIDKYDGIVCVGGDGMFSEVLHGLIGRTQRSAGVDQNHPRAVLVPSSLRIGIIPAGSTDCVCYSTVGTSDAETSALHIVVGDSLAMDVSSVHHNSTLLRYSVSLLGYGFYGDIIKDSEKKRWLGLARYDFSGLKTFLSHHCYEGTVSFLPAQHTVGSPRDRKPCRAGCFVCRQSKQQLEEEQKKALYGLEAAEDVEEWQVVCGKFLAINATNMSCACRRSPRGLSPAAHLGDGSSDLILIRKCSRFNFLRFLIRHTNQQDQFDFTFVEVYRVKKFQFTSKHMEDEDSDLKEGGKKRFGHICSSHPSCCCTVSNSSWNCDGEVLHSPAIEVRVHCQLVRLFARGIEENPKPDSHS
T40243	DRUGINFO	D0S9JG	NVP 231	Investigative

T60156	TARGETID	T60156
T60156	FORMERID	TTDI00158
T60156	UNIPROID	GTR12_HUMAN
T60156	TARGNAME	Glucose transporter type 12 (GLUT12)
T60156	GENENAME	SLC2A12
T60156	TARGTYPE	Literature-reported
T60156	SYNONYMS	Solute carrier family 2, facilitated glucose transporter member 12; SLC2A12
T60156	FUNCTION	Facilitative glucose transporter.
T60156	BIOCLASS	Major facilitator superfamily
T60156	SEQUENCE	MVPVENTEGPSLLNQKGTAVETEGSGSRHPPWARGCGMFTFLSSVTAAVSGLLVGYELGIISGALLQIKTLLALSCHEQEMVVSSLVIGALLASLTGGVLIDRYGRRTAIILSSCLLGLGSLVLILSLSYTVLIVGRIAIGVSISLSSIATCVYIAEIAPQHRRGLLVSLNELMIVIGILSAYISNYAFANVFHGWKYMFGLVIPLGVLQAIAMYFLPPSPRFLVMKGQEGAASKVLGRLRALSDTTEELTVIKSSLKDEYQYSFWDLFRSKDNMRTRIMIGLTLVFFVQITGQPNILFYASTVLKSVGFQSNEAASLASTGVGVVKVISTIPATLLVDHVGSKTFLCIGSSVMAASLVTMGIVNLNIHMNFTHICRSHNSINQSLDESVIYGPGNLSTNNNTLRDHFKGISSHSRSSLMPLRNDVDKRGETTSASLLNAGLSHTEYQIVTDPGDVPAFLKWLSLASLLVYVAAFSIGLGPMPWLVLSEIFPGGIRGRAMALTSSMNWGINLLISLTFLTVTDLIGLPWVCFIYTIMSLASLLFVVMFIPETKGCSLEQISMELAKVNYVKNNICFMSHHQEELVPKQPQKRKPQEQLLECNKLCGRGQSRQLSPET

T20053	TARGETID	T20053
T20053	FORMERID	TTDI03057
T20053	UNIPROID	BRSK1_HUMAN
T20053	TARGNAME	BR serine/threonine kinase 1 (BRSK1)
T20053	GENENAME	BRSK1
T20053	TARGTYPE	Literature-reported
T20053	SYNONYMS	hSAD1; Synapses of Amphids Defective homolog 1; Serine/threonine-protein kinase SAD-B; Serine/threonine-protein kinase BRSK1; SADB; SAD1 homolog; SAD1; KIAA1811; Brain-specific serine/threonine-protein kinase 1; Brain-selective kinase 1; BR serine/threonine-protein kinase 1
T20053	FUNCTION	Serine/threonine-protein kinase that plays a key role in polarization of neurons and centrosome duplication. Phosphorylates CDC25B, CDC25C, MAPT/TAU, RIMS1, TUBG1, TUBG2 and WEE1. Following phosphorylation and activation by STK11/LKB1, acts as a key regulator of polarization of cortical neurons, probably by mediating phosphorylation of microtubule-associated proteins such as MAPT/TAU at 'Thr-529' and 'Ser-579'. Also regulates neuron polarization by mediating phosphorylation of WEE1 at 'Ser-642' in post-mitotic neurons, leading to down-regulate WEE1 activity in polarized neurons. In neurons, localizes to synaptic vesicles and plays a role in neurotransmitter release, possibly by phosphorylating RIMS1. Also acts as a positive regulator of centrosome duplication by mediating phosphorylation of gamma-tubulin (TUBG1 and TUBG2) at 'Ser-131', leading to translocation of gamma-tubulin and its associated proteins to the centrosome. Involved in the UV-induced DNA damage checkpoint response, probably by inhibiting CDK1 activity through phosphorylation and activation of WEE1, and inhibition of CDC25B and CDC25C.
T20053	ECNUMBER	EC 2.7.11.1
T20053	SEQUENCE	MSSGAKEGGGGSPAYHLPHPHPHPPQHAQYVGPYRLEKTLGKGQTGLVKLGVHCITGQKVAIKIVNREKLSESVLMKVEREIAILKLIEHPHVLKLHDVYENKKYLYLVLEHVSGGELFDYLVKKGRLTPKEARKFFRQIVSALDFCHSYSICHRDLKPENLLLDEKNNIRIADFGMASLQVGDSLLETSCGSPHYACPEVIKGEKYDGRRADMWSCGVILFALLVGALPFDDDNLRQLLEKVKRGVFHMPHFIPPDCQSLLRGMIEVEPEKRLSLEQIQKHPWYLGGKHEPDPCLEPAPGRRVAMRSLPSNGELDPDVLESMASLGCFRDRERLHRELRSEEENQEKMIYYLLLDRKERYPSCEDQDLPPRNDVDPPRKRVDSPMLSRHGKRRPERKSMEVLSITDAGGGGSPVPTRRALEMAQHSQRSRSVSGASTGLSSSPLSSPRSPVFSFSPEPGAGDEARGGGSPTSKTQTLPSRGPRGGGAGEQPPPPSARSTPLPGPPGSPRSSGGTPLHSPLHTPRASPTGTPGTTPPPSPGGGVGGAAWRSRLNSIRNSFLGSPRFHRRKMQVPTAEEMSSLTPESSPELAKRSWFGNFISLDKEEQIFLVLKDKPLSSIKADIVHAFLSIPSLSHSVLSQTSFRAEYKASGGPSVFQKPVRFQVDISSSEGPEPSPRRDGSGGGGIYSVTFTLISGPSRRFKRVVETIQAQLLSTHDQPSVQALADEKNGAQTRPAGAPPRSLQPPPGRPDPELSSSPRRGPPKDKKLLATNGTPLP
T20053	DRUGINFO	D0Z8PT	CCT244747	Investigative

T14241	TARGETID	T14241
T14241	FORMERID	TTDI03599
T14241	UNIPROID	MCLN3_HUMAN
T14241	TARGNAME	Mucolipin-3 (TRPML3)
T14241	GENENAME	MCOLN3
T14241	TARGTYPE	Literature-reported
T14241	SYNONYMS	Transient receptor potential channel mucolipin 3; TRPML3
T14241	FUNCTION	Nonselective ligand-gated cation channel probably playing a role in the regulation of membrane trafficking events. Acts as Ca(2+)-permeable cation channel with inwardly rectifying activity. Mediates release of Ca(2+) from endosomes to the cytoplasm, contributes to endosomal acidification and is involved in the regulation of membrane trafficking and fusion in the endosomal pathway. Does not seem to act as mechanosensory transduction channel in inner ear sensory hair cells. Proposed to play a critical role at the cochlear stereocilia ankle-link region during hair-bundle growth (By similarity). Involved in the regulation of autophagy. Through association with GABARAPL2 may be involved in autophagosome formation possibly providing Ca(2+) for the fusion process (By similarity). Through a possible and probably tissue-specific heteromerization with MCOLN1 may be at least in part involved in many lysosome-dependent cellular events. Possible heteromeric ion channel assemblies with TRPV5 show pharmacological similarity with TRPML3.
T14241	PDBSTRUC	6AYG; 6AYF; 6AYE
T14241	SEQUENCE	MADPEVVVSSCSSHEEENRCNFNQQTSPSEELLLEDQMRRKLKFFFMNPCEKFWARGRKPWKLAIQILKIAMVTIQLVLFGLSNQMVVAFKEENTIAFKHLFLKGYMDRMDDTYAVYTQSDVYDQLIFAVNQYLQLYNVSVGNHAYENKGTKQSAMAICQHFYKRGNIYPGNDTFDIDPEIETECFFVEPDEPFHIGTPAENKLNLTLDFHRLLTVELQFKLKAINLQTVRHQELPDCYDFTLTITFDNKAHSGRIKISLDNDISIRECKDWHVSGSIQKNTHYMMIFDAFVILTCLVSLILCIRSVIRGLQLQQEFVNFFLLHYKKEVSVSDQMEFVNGWYIMIIISDILTIIGSILKMEIQAKSLTSYDVCSILLGTSTMLVWLGVIRYLGFFAKYNLLILTLQAALPNVIRFCCCAAMIYLGYCFCGWIVLGPYHDKFRSLNMVSECLFSLINGDDMFATFAKMQQKSYLVWLFSRIYLYSFISLFIYMILSLFIALITDTYETIKQYQQDGFPETELRTFISECKDLPNSGKYRLEDDPPVSLFCCCKK
T14241	DRUGINFO	D04OPE	SF-11	Investigative
T14241	DRUGINFO	D0BK2Y	SF-21	Investigative
T14241	DRUGINFO	D0E9FD	SN-1	Investigative
T14241	DRUGINFO	D0G1LN	SN-2	Investigative

T56207	TARGETID	T56207
T56207	FORMERID	TTDR01017
T56207	UNIPROID	ASAP3_HUMAN
T56207	TARGNAME	Development and differentiation-enhancing factor-like 1 (DDEFL1)
T56207	GENENAME	ASAP3
T56207	TARGTYPE	Literature-reported
T56207	SYNONYMS	UPLC1; Protein up-regulated in liver cancer 1; DDEFL1; Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 3
T56207	FUNCTION	Promotes cell proliferation.
T56207	PDBSTRUC	3LVR; 3LVQ; 2B0O
T56207	SEQUENCE	MPEQFSVAEFLAVTAEDLSSPAGAAAFAAKMPRYRGAALAREEILEGDQAILQRIKKAVRAIHSSGLGHVENEEQYREAVESLGNSHLSQNSHELSTGFLNLAVFTREVAALFKNLIQNLNNIVSFPLDSLMKGQLRDGRQDSKKQLEKAWKDYEAKMAKLEKERDRARVTGGIPGEVAQDMQRERRIFQLHMCEYLLKAGESQMKQGPDFLQSLIKFFHAQHNFFQDGWKAAQSLFPFIEKLAASVHALHQAQEDELQKLTQLRDSLRGTLQLESREEHLSRKNSGCGYSIHQHQGNKQFGTEKVGFLYKKSDGIRRVWQKRKCGVKYGCLTISHSTINRPPVKLTLLTCQVRPNPEEKKCFDLVTHNRTYHFQAEDEHECEAWVSVLQNSKDEALSSAFLGEPSAGPGSWGSAGHDGEPHDLTKLLIAEVKSRPGNSQCCDCGAADPTWLSTNLGVLTCIQCSGVHRELGVRFSRMQSLTLDLLGPSELLLALNMGNTSFNEVMEAQLPSHGGPKPSAESDMGTRRDYIMAKYVEHRFARRCTPEPQRLWTAICNRDLLSVLEAFANGQDFGQPLPGPDAQAPEELVLHLAVKVANQASLPLVDFIIQNGGHLDAKAADGNTALHYAALYNQPDCLKLLLKGRALVGTVNEAGETALDIARKKHHKECEELLEQAQAGTFAFPLHVDYSWVISTEPGSDSEEDEEEKRCLLKLPAQAHWASGRLDISNKTYETVASLGAATPQGESEDCPPPLPVKNSSRTLVQGCARHASGDRSEVSSLSSEAPETPESLGSPASSSSLMSPLEPGDPSQAPPNSEEGLREPPGTSRPSLTSGTTPSEMYLPVRFSSESTRSYRRGARSPEDGPSARQPLPRRNVPVGITEGDGSRTGSLPASSVQLLQD

T62998	TARGETID	T62998
T62998	FORMERID	TTDR00384
T62998	UNIPROID	SCRB1_HUMAN
T62998	TARGNAME	Scavenger receptor class B member 1 (SCARB1)
T62998	GENENAME	SCARB1
T62998	TARGTYPE	Literature-reported
T62998	SYNONYMS	SRB1; SR-BI; Collagen type I receptor, thrombospondin receptor-like 1; CLA1; CLA-1; CD36L1; CD36 antigen-like 1; CD36 and LIMPII analogous 1; CD36
T62998	FUNCTION	Receptor for different ligands such as phospholipids, cholesterol ester, lipoproteins, phosphatidylserine and apoptotic cells. Receptor for HDL, mediating selective uptake of cholesteryl ether and HDL-dependent cholesterol efflux. Also facilitates the flux of free and esterified cholesterol between the cell surface and apoB-containing lipoproteins and modified lipoproteins, although less efficiently than HDL. May be involved in the phagocytosis of apoptotic cells, via its phosphatidylserine binding activity.
T62998	BIOCLASS	Long chain fatty acid translocase
T62998	SEQUENCE	MGCSAKARWAAGALGVAGLLCAVLGAVMIVMVPSLIKQQVLKNVRIDPSSLSFNMWKEIPIPFYLSVYFFDVMNPSEILKGEKPQVRERGPYVYREFRHKSNITFNNNDTVSFLEYRTFQFQPSKSHGSESDYIVMPNILVLGAAVMMENKPMTLKLIMTLAFTTLGERAFMNRTVGEIMWGYKDPLVNLINKYFPGMFPFKDKFGLFAELNNSDSGLFTVFTGVQNISRIHLVDKWNGLSKVDFWHSDQCNMINGTSGQMWPPFMTPESSLEFYSPEACRSMKLMYKESGVFEGIPTYRFVAPKTLFANGSIYPPNEGFCPCLESGIQNVSTCRFSAPLFLSHPHFLNADPVLAEAVTGLHPNQEAHSLFLDIHPVTGIPMNCSVKLQLSLYMKSVAGIGQTGKIEPVVLPLLWFAESGAMEGETLHTFYTQLVLMPKVMHYAQYVLLALGCVLLLVPVICQIRSQVGAGQRAARADSHSLACWGKGASDRTLWPTAAWSPPPAAVLRLCRSGSGHCWGLRSTLASFACRVATTLPVLEGLGPSLGGGTGS

T89560	TARGETID	T89560
T89560	FORMERID	TTDNR00753
T89560	UNIPROID	STAB2_HUMAN
T89560	TARGNAME	Stabilin-2 (STAB2)
T89560	GENENAME	STAB2
T89560	TARGTYPE	Literature-reported
T89560	SYNONYMS	STAB2; Hyaluronan receptor for endocytosis; Fasciclin, EGF-like, laminin-type EGF-like and link domain-containing scavenger receptor 2; FEEL-2; FAS1 EGF-like and X-link domain-containing adhesion molecule 2
T89560	FUNCTION	Phosphatidylserine receptor that enhances the engulfment of apoptotic cells. Hyaluronan receptor that binds to and mediates endocytosis of hyaluronic acid (HA). Acts also, in different species, as a primary systemic scavenger receptor for heparin (Hep), chondroitin sulfate (CS), dermatan sulfate (DS), nonglycosaminoglycan (GAG), acetylated low-density lipoprotein (AcLDL), pro-collagen propeptides and advanced glycation end products (AGE). May serve to maintain tissue integrity by supporting extracellular matrix turnover or it may contribute to maintaining fluidity of bodily liquids by resorption of hyaluronan. Counter receptor which plays an important role in lymphocyte recruitment in the hepatic vasculature. Binds to both Gram-positive and Gram-negative bacteria and may play a role in defense against bacterial infection. The proteolytically processed 190 kDa form also functions as an endocytosis receptor for heparin internalisation as well as HA and CS.
T89560	PDBSTRUC	5N86
T89560	SEQUENCE	MMLQHLVIFCLGLVVQNFCSPAETTGQARRCDRKSLLTIRTECRSCALNLGVKCPDGYTMITSGSVGVRDCRYTFEVRTYSLSLPGCRHICRKDYLQPRCCPGRWGPDCIECPGGAGSPCNGRGSCAEGMEGNGTCSCQEGFGGTACETCADDNLFGPSCSSVCNCVHGVCNSGLDGDGTCECYSAYTGPKCDKPIPECAALLCPENSRCSPSTEDENKLECKCLPNYRGDGKYCDPINPCLRKICHPHAHCTYLGPNRHSCTCQEGYRGDGQVCLPVDPCQINFGNCPTKSTVCKYDGPGQSHCECKEHYQNFVPGVGCSMTDICKSDNPCHRNANCTTVAPGRTECICQKGYVGDGLTCYGNIMERLRELNTEPRGKWQGRLTSFISLLDKAYAWPLSKLGPFTVLLPTDKGLKGFNVNELLVDNKAAQYFVKLHIIAGQMNIEYMNNTDMFYTLTGKSGEIFNSDKDNQIKLKLHGGKKKVKIIQGDIIASNGLLHILDRAMDKLEPTFESNNEQTIMTMLQPRYSKFRSLLEETNLGHALDEDGVGGPYTIFVPNNEALNNMKDGTLDYLLSPEGSRKLLELVRYHIVPFTQLEVATLISTPHIRSMANQLIQFNTTDNGQILANDVAMEEIEITAKNGRIYTLTGVLIPPSIVPILPHRCDETKREMKLGTCVSCSLVYWSRCPANSEPTALFTHRCVYSGRFGSLKSGCARYCNATVKIPKCCKGFYGPDCNQCPGGFSNPCSGNGQCADSLGGNGTCICEEGFQGSQCQFCSDPNKYGPRCNKKCLCVHGTCNNRIDSDGACLTGTCRDGSAGRLCDKQTSACGPYVQFCHIHATCEYSNGTASCICKAGYEGDGTLCSEMDPCTGLTPGGCSRNAECIKTGTGTHTCVCQQGWTGNGRDCSEINNCLLPSAGGCHDNASCLYVGPGQNECECKKGFRGNGIDCEPITSCLEQTGKCHPLASCQSTSSGVWSCVCQEGYEGDGFLCYGNAAVELSFLSEAAIFNRWINNASLQPTLSATSNLTVLVPSQQATEDMDQDEKSFWLSQSNIPALIKYHMLLGTYRVADLQTLSSSDMLATSLQGNFLHLAKVDGNITIEGASIVDGDNAATNGVIHIINKVLVPQRRLTGSLPNLLMRLEQMPDYSIFRGYIIQYNLANAIEAADAYTVFAPNNNAIENYIREKKVLSLEEDVLRYHVVLEEKLLKNDLHNGMHRETMLGFSYFLSFFLHNDQLYVNEAPINYTNVATDKGVIHGLGKVLEIQKNRCDNNDTTIIRGRCRTCSSELTCPFGTKSLGNEKRRCIYTSYFMGRRTLFIGCQPKCVRTVITRECCAGFFGPQCQPCPGNAQNVCFGNGICLDGVNGTGVCECGEGFSGTACETCTEGKYGIHCDQACSCVHGRCNQGPLGDGSCDCDVGWRGVHCDNATTEDNCNGTCHTSANCLTNSDGTASCKCAAGFQGNGTICTAINACEISNGGCSAKADCKRTTPGRRVCTCKAGYTGDGIVCLEINPCLENHGGCDKNAECTQTGPNQAACNCLPAYTGDGKVCTLINVCLTKNGGCSEFAICNHTGQVERTCTCKPNYIGDGFTCRGSIYQELPKNPKTSQYFFQLQEHFVKDLVGPGPFTVFAPLSAAFDEEARVKDWDKYGLMPQVLRYHVVACHQLLLENLKLISNATSLQGEPIVISVSQSTVYINNKAKIISSDIISTNGIVHIIDKLLSPKNLLITPKDNSGRILQNLTTLATNNGYIKFSNLIQDSGLLSVITDPIHTPVTLFWPTDQALHALPAEQQDFLFNQDNKDKLKEYLKFHVIRDAKVLAVDLPTSTAWKTLQGSELSVKCGAGRDIGDLFLNGQTCRIVQRELLFDLGVAYGIDCLLIDPTLGGRCDTFTTFDASGECGSCVNTPSCPRWSKPKGVKQKCLYNLPFKRNLEGCRERCSLVIQIPRCCKGYFGRDCQACPGGPDAPCNNRGVCLDQYSATGECKCNTGFNGTACEMCWPGRFGPDCLPCGCSDHGQCDDGITGSGQCLCETGWTGPSCDTQAVLPAVCTPPCSAHATCKENNTCECNLDYEGDGITCTVVDFCKQDNGGCAKVARCSQKGTKVSCSCQKGYKGDGHSCTEIDPCADGLNGGCHEHATCKMTGPGKHKCECKSHYVGDGLNCEPEQLPIDRCLQDNGQCHADAKCVDLHFQDTTVGVFHLRSPLGQYKLTFDKAREACANEAATMATYNQLSYAQKAKYHLCSAGWLETGRVAYPTAFASQNCGSGVVGIVDYGPRPNKSEMWDVFCYRMKDVNCTCKVGYVGDGFSCSGNLLQVLMSFPSLTNFLTEVLAYSNSSARGRAFLEHLTDLSIRGTLFVPQNSGLGENETLSGRDIEHHLANVSMFFYNDLVNGTTLQTRLGSKLLITASQDPLQPTETRFVDGRAILQWDIFASNGIIHVISRPLKAPPAPVTLTHTGLGAGIFFAIILVTGAVALAAYSYFRINRRTIGFQHFESEEDINVAALGKQQPENISNPLYESTTSAPPEPSYDPFTDSEERQLEGNDPLRTL

T11578	TARGETID	T11578
T11578	FORMERID	TTDI00149
T11578	UNIPROID	SRS12_HUMAN
T11578	TARGNAME	Serine/arginine-rich splicing factor 12 (Srrp35)
T11578	GENENAME	SRSF12
T11578	TARGTYPE	Literature-reported
T11578	SYNONYMS	Splicing factor, arginine/serine-rich 19; Splicing factor, arginine/serine-rich 13B; SRSF12; 35 kDa SR repressor protein
T11578	FUNCTION	Splicing factor that seems to antagonize SR proteins in pre-mRNA splicing regulation.
T11578	BIOCLASS	Splicing factor SR family
T11578	SEQUENCE	MSRYTRPPNTSLFIRNVADATRPEDLRREFGRYGPIVDVYIPLDFYTRRPRGFAYVQFEDVRDAEDALYNLNRKWVCGRQIEIQFAQGDRKTPGQMKSKERHPCSPSDHRRSRSPSQRRTRSRSSSWGRNRRRSDSLKESRHRRFSYSQSKSRSKSLPRRSTSARQSRTPRRNFGSRGRSRSKSLQKRSKSIGKSQSSSPQKQTSSGTKSRSHGRHSDSIARSPCKSPKGYTNSETKVQTAKHSHFRSHSRSRSYRHKNSW

T23763	TARGETID	T23763
T23763	FORMERID	TTDI02480
T23763	UNIPROID	ROBO4_HUMAN
T23763	TARGNAME	Roundabout homolog 4 (ROBO4)
T23763	GENENAME	ROBO4
T23763	TARGTYPE	Literature-reported
T23763	SYNONYMS	ROBO4; Magic roundabout
T23763	FUNCTION	Receptor for Slit proteins, at least for SLIT2, and seemsto be involved in angiogenesis and vascular patterning. May mediate the inhibition of primary endothelial cell migration by Slit proteins.
T23763	BIOCLASS	Immunoglobulin
T23763	SEQUENCE	MGSGGDSLLGGRGSLPLLLLLIMGGMAQDSPPQILVHPQDQLFQGPGPARMSCQASGQPPPTIRWLLNGQPLSMVPPDPHHLLPDGTLLLLQPPARGHAHDGQALSTDLGVYTCEASNRLGTAVSRGARLSVAVLREDFQIQPRDMVAVVGEQFTLECGPPWGHPEPTVSWWKDGKPLALQPGRHTVSGGSLLMARAEKSDEGTYMCVATNSAGHRESRAARVSIQEPQDYTEPVELLAVRIQLENVTLLNPDPAEGPKPRPAVWLSWKVSGPAAPAQSYTALFRTQTAPGGQGAPWAEELLAGWQSAELGGLHWGQDYEFKVRPSSGRARGPDSNVLLLRLPEKVPSAPPQEVTLKPGNGTVFVSWVPPPAENHNGIIRGYQVWSLGNTSLPPANWTVVGEQTQLEIATHMPGSYCVQVAAVTGAGAGEPSRPVCLLLEQAMERATQEPSEHGPWTLEQLRATLKRPEVIATCGVALWLLLLGTAVCIHRRRRARVHLGPGLYRYTSEDAILKHRMDHSDSQWLADTWRSTSGSRDLSSSSSLSSRLGADARDPLDCRRSLLSWDSRSPGVPLLPDTSTFYGSLIAELPSSTPARPSPQVPAVRRLPPQLAQLSSPCSSSDSLCSRRGLSSPRLSLAPAEAWKAKKKQELQHANSSPLLRGSHSLELRACELGNRGSKNLSQSPGAVPQALVAWRALGPKLLSSSNELVTRHLPPAPLFPHETPPTQSQQTQPPVAPQAPSSILLPAAPIPILSPCSPPSPQASSLSGPSPASSRLSSSSLSSLGEDQDSVLTPEEVALCLELSEGEETPRNSVSPMPRAPSPPTTYGYISVPTASEFTDMGRTGGGVGPKGGVLLCPPRPCLTPTPSEGSLANGWGSASEDNAASARASLVSSSDGSFLADAHFARALAVAVDSFGFGLEPREADCVFIDASSPPSPRDEIFLTPNLSLPLWEWRPDWLEDMEVSHTQRLGRGMPPWPPDSQISSQRSQLHCRMPKAGASPVDYS

T69984	TARGETID	T69984
T69984	FORMERID	TTDR00695
T69984	UNIPROID	PGTA_HUMAN; PGTB2_HUMAN
T69984	TARGNAME	Geranylgeranyl transferase II (GGTase-II)
T69984	GENENAME	RABGGTA; RABGGTB
T69984	TARGTYPE	Literature-reported
T69984	SYNONYMS	Rab geranylgeranyltransferase; Rab geranyl-geranyltransferase; Rab GGTase; Rab GG transferase; Geranylgeranyl transferase type-2; Geranylgeranyl transferase type II
T69984	FUNCTION	Catalyzes the transfer of a geranylgeranyl moiety from geranylgeranyl diphosphate to both cysteines of Rab proteins with the C-terminal sequence -XXCC, -XCXC and -CCXX, such as RAB1A, RAB3A, RAB5A and RAB7A.
T69984	BIOCLASS	Alkyl aryl transferase
T69984	SEQUENCE	MHGRLKVKTSEEQAEAKRLEREQKLKLYQSATQAVFQKRQAGELDESVLELTSQILGANPDFATLWNCRREVLQQLETQKSPEELAALVKAELGFLESCLRVNPKSYGTWHHRCWLLGRLPEPNWTRELELCARFLEVDERNFHCWDYRRFVATQAAVPPAEELAFTDSLITRNFSNYSSWHYRSCLLPQLHPQPDSGPQGRLPEDVLLKELELVQNAFFTDPNDQSAWFYHRWLLGRADPQDALRCLHVSRDEACLTVSFSRPLLVGSRMEILLLMVDDSPLIVEWRTPDGRNRPSHVWLCDLPAASLNDQLPQHTFRVIWTAGDVQKECVLLKGRQEGWCRDSTTDEQLFRCELSVEKSTVLQSELESCKELQELEPENKWCLLTIILLMRALDPLLYEKETLQYFQTLKAVDPMRATYLDDLRSKFLLENSVLKMEYAEVRVLHLAHKDLTVLCHLEQLLLVTHLDLSHNRLRTLPPALAALRCLEVLQASDNAIESLDGVTNLPRLQELLLCNNRLQQPAVLQPLASCPRLVLLNLQGNPLCQAVGILEQLAELLPSVSSVLT

T53186	TARGETID	T53186
T53186	FORMERID	TTDI03320
T53186	UNIPROID	KCNJ9_HUMAN
T53186	TARGNAME	Inward rectifier potassium channel Kir3.3 (KCNJ9)
T53186	GENENAME	KCNJ9
T53186	TARGTYPE	Literature-reported
T53186	SYNONYMS	Potassium channel, inwardly rectifying subfamily J member 9; Inward rectifier K(+) channel Kir3.3; GIRK3; GIRK-3; G protein-activated inward rectifier potassium channel 3
T53186	FUNCTION	This receptor is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium (By similarity).
T53186	BIOCLASS	Inward rectifier potassium channel
T53186	SEQUENCE	MAQENAAFSPGQEEPPRRRGRQRYVEKDGRCNVQQGNVRETYRYLTDLFTTLVDLQWRLSLLFFVLAYALTWLFFGAIWWLIAYGRGDLEHLEDTAWTPCVNNLNGFVAAFLFSIETETTIGYGHRVITDQCPEGIVLLLLQAILGSMVNAFMVGCMFVKISQPNKRAATLVFSSHAVVSLRDGRLCLMFRVGDLRSSHIVEASIRAKLIRSRQTLEGEFIPLHQTDLSVGFDTGDDRLFLVSPLVISHEIDAASPFWEASRRALERDDFEIVVILEGMVEATGMTCQARSSYLVDEVLWGHRFTSVLTLEDGFYEVDYASFHETFEVPTPSCSARELAEAAARLDAHLYWSIPSRLDEKVEEEGAGEGAGGEAGADKEQNGCLPPPESESKV
T53186	DRUGINFO	D07ZAJ	PIP2	Investigative

T84032	TARGETID	T84032
T84032	FORMERID	TTDR00756
T84032	UNIPROID	HXB13_HUMAN
T84032	TARGNAME	Homeobox protein Hox-B13 (HOXB13)
T84032	GENENAME	HOXB13
T84032	TARGTYPE	Literature-reported
T84032	SYNONYMS	Hoxb-13; HOXB13
T84032	FUNCTION	Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis.
T84032	PDBSTRUC	5NO6; 5EGO; 5EG0; 5EF6; 5EEA
T84032	SEQUENCE	MEPGNYATLDGAKDIEGLLGAGGGRNLVAHSPLTSHPAAPTLMPAVNYAPLDLPGSAEPPKQCHPCPGVPQGTSPAPVPYGYFGGGYYSCRVSRSSLKPCAQAATLAAYPAETPTAGEEYPSRPTEFAFYPGYPGTYQPMASYLDVSVVQTLGAPGEPRHDSLLPVDSYQSWALAGGWNSQMCCQGEQNPPGPFWKAAFADSSGQHPPDACAFRRGRKKRIPYSKGQLRELEREYAANKFITKDKRRKISAATSLSERQITIWFQNRRVKEKKVLAKVKNSATP

T29481	TARGETID	T29481
T29481	FORMERID	TTDI02395
T29481	UNIPROID	FGF14_HUMAN
T29481	TARGNAME	Fibroblast growth factor-14 (FGF14)
T29481	GENENAME	FGF14
T29481	TARGTYPE	Literature-reported
T29481	SYNONYMS	Fibroblast growth factor homologous factor 4; Fibroblast growth factor 14; FHF4; FGF14
T29481	FUNCTION	Probably involved in nervous system development and function.
T29481	BIOCLASS	Growth factor
T29481	SEQUENCE	MAAAIASGLIRQKRQAREQHWDRPSASRRRSSPSKNRGLCNGNLVDIFSKVRIFGLKKRRLRRQDPQLKGIVTRLYCRQGYYLQMHPDGALDGTKDDSTNSTLFNLIPVGLRVVAIQGVKTGLYIAMNGEGYLYPSELFTPECKFKESVFENYYVIYSSMLYRQQESGRAWFLGLNKEGQAMKGNRVKKTKPAAHFLPKPLEVAMYREPSLHDVGETVPKPGVTPSKSTSASAIMNGGKPVNKSKTT

T65932	TARGETID	T65932
T65932	FORMERID	TTDI03337
T65932	UNIPROID	KCNB2_HUMAN
T65932	TARGNAME	Voltage-gated potassium channel Kv2.2 (KCNB2)
T65932	GENENAME	KCNB2
T65932	TARGTYPE	Literature-reported
T65932	SYNONYMS	Voltage-gated potassium channel subunit Kv2.2; Potassium voltage-gated channel subfamily B member 2
T65932	FUNCTION	Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and smooth muscle cells. Channels open or close in response to the voltage difference across the membrane, letting potassium ions pass in accordance with their electrochemical gradient. Homotetrameric channels mediate a delayed-rectifier voltage-dependent outward potassium current that display rapid activation and slow inactivation in response to membrane depolarization. Can form functional homotetrameric and heterotetrameric channels that contain variable proportions of KCNB1; channel properties depend on the type of alpha subunits that are part of the channel. Can also form functional heterotetrameric channels with other alpha subunits that are non-conducting when expressed alone, such as KCNS1 and KCNS2, creating a functionally diverse range of channel complexes. In vivo, membranes probably contain a mixture of heteromeric potassium channel complexes, making it difficult to assign currents observed in intact tissues to any particular potassium channel family member. Contributes to the delayed-rectifier voltage-gated potassium current in cortical pyramidal neurons and smooth muscle cells.
T65932	BIOCLASS	Voltage-gated ion channel
T65932	SEQUENCE	MAEKAPPGLNRKTSRSTLSLPPEPVDIIRSKTCSRRVKINVGGLNHEVLWRTLDRLPRTRLGKLRDCNTHESLLEVCDDYNLNENEYFFDRHPGAFTSILNFYRTGKLHMMEEMCALSFGQELDYWGIDEIYLESCCQARYHQKKEQMNEELRREAETMREREGEEFDNTCCPDKRKKLWDLLEKPNSSVAAKILAIVSILFIVLSTIALSLNTLPELQETDEFGQLNDNRQLAHVEAVCIAWFTMEYLLRFLSSPNKWKFFKGPLNVIDLLAILPYYVTIFLTESNKSVLQFQNVRRVVQIFRIMRILRILKLARHSTGLQSLGFTLRRSYNELGLLILFLAMGIMIFSSLVFFAEKDEDATKFTSIPASFWWATITMTTVGYGDIYPKTLLGKIVGGLCCIAGVLVIALPIPIIVNNFSEFYKEQKRQEKAIKRREALERAKRNGSIVSMNLKDAFARSMELIDVAVEKAGESANTKDSADDNHLSPSRWKWARKALSETSSNKSFENKYQEVSQKDSHEQLNNTSSSSPQHLSAQKLEMLYNEITKTQPHSHPNPDCQEKPERPSAYEEEIEMEEVVCPQEQLAVAQTEVIVDMKSTSSIDSFTSCATDFTETERSPLPPPSASHLQMKFPTDLPGTEEHQRARGPPFLTLSREKGPAARDGTLEYAPVDITVNLDASGSQCGLHSPLQSDNATDSPKSSLKGSNPLKSRSLKVNFKENRGSAPQTPPSTARPLPVTTADFSLTTPQHISTILLEETPSQGDRPLLGTEVSAPCQGPSKGLSPRFPKQKLFPFSSRERRSFTEIDTGDDEDFLELPGAREEKQVDSSPNCFADKPSDGRDPLREEGSVGSSSPQDTGHNCRQDIYHAVSEVKKDSSQEGCKMENHLFAPEIHSNPGDTGYCPTRETSM
T65932	DRUGINFO	D0I7VY	RY796	Investigative
T65932	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T43817	TARGETID	T43817
T43817	FORMERID	TTDNR00673
T43817	UNIPROID	GLMN_HUMAN
T43817	TARGNAME	FKBP-associated protein (FAP48)
T43817	GENENAME	GLMN
T43817	TARGTYPE	Literature-reported
T43817	SYNONYMS	Glomulin; FK506-binding protein-associated protein; FAP48
T43817	FUNCTION	Isoform 1: Regulatory component of cullin-RING-based SCF (SKP1-Cullin-F-box protein) E3 ubiquitin-protein ligase complexes. Inhibits E3 ubiquitin ligase activity by binding to RBX1 (via RING domain) and inhibiting its interaction with the E2 ubiquitin-conjugating enzyme CDC34. Inhibits RBX1-mediated neddylation of CUL1. Required for normal stability and normal cellular levels of key components of SCF ubiquitin ligase complexes, including FBXW7, RBX1, CUL1, CUL2, CUL3, CUL4A, and thereby contributes to the regulation of CCNE1 and MYC levels (By similarity). Essential for normal development of the vasculature. Contributes to the regulation of RPS6KB1 phosphorylation.
T43817	PDBSTRUC	4F52
T43817	SEQUENCE	MAVEELQSIIKRCQILEEQDFKEEDFGLFQLAGQRCIEEGHTDQLLEIIQNEKNKVIIKNMGWNLVGPVVRCLLCKDKEDSKRKVYFLIFDLLVKLCNPKELLLGLLELIEEPSGKQISQSILLLLQPLQTVIQKLHNKAYSIGLALSTLWNQLSLLPVPYSKEQIQMDDYGLCQCCKALIEFTKPFVEEVIDNKENSLENEKLKDELLKFCFKSLKCPLLTAQFFEQSEEGGNDPFRYFASEIIGFLSAIGHPFPKMIFNHGRKKRTWNYLEFEEEENKQLADSMASLAYLVFVQGIHIDQLPMVLSPLYLLQFNMGHIEVFLQRTEESVISKGLELLENSLLRIEDNSLLYQYLEIKSFLTVPQGLVKVMTLCPIETLRKKSLAMLQLYINKLDSQGKYTLFRCLLNTSNHSGVEAFIIQNIKNQIDMSLKRTRNNKWFTGPQLISLLDLVLFLPEGAETDLLQNSDRIMASLNLLRYLVIKDNENDNQTGLWTELGNIENNFLKPLHIGLNMSKAHYEAEIKNSQEAQKSKDLCSITVSGEEIPNMPPEMQLKVLHSALFTFDLIESVLARVEELIEIKTKSTSEENIGIK

T21705	TARGETID	T21705
T21705	FORMERID	TTDR00937
T21705	UNIPROID	FBXW7_HUMAN
T21705	TARGNAME	F-box and WD-40 domain protein 7 (Fbxw7)
T21705	GENENAME	FBXW7
T21705	TARGTYPE	Literature-reported
T21705	SYNONYMS	hCdc4; hAgo; SEL10; SEL-10; FBX30; FBW7; F-box/WD repeat-containing protein 7; F-box-WD40 repeat protein 6; F-box protein Fbxw6; F-box protein FBX30; F-box protein FBW7; F-box and WD-40 domain-containing protein 7; Archipelago homolog
T21705	FUNCTION	Recognizes and binds phosphorylated sites/phosphodegrons within target proteins and thereafter bring them to the SCF complex for ubiquitination. Identified substrates include cyclin-E (CCNE1 or CCNE2), DISC1, JUN, MYC, NOTCH1 released notch intracellular domain (NICD), NOTCH2, MCL1, and probably PSEN1. Acts as a negative regulator of JNK signaling by binding to phosphorylated JUN and promoting its ubiquitination and subsequent degradation. SCF(FBXW7) complex mediates the ubiquitination and subsequent degradation of NFE2L1. Involved in bone homeostasis and negative regulation of osteoclast differentiation. Regulates the amplitude of the cyclic expression of hepatic core clock genes and genes involved in lipid and glucose metabolism via ubiquitination and proteasomal degradation of their transcriptional repressor NR1D1; CDK1-dependent phosphorylation of NR1D1 is necessary for SCF(FBXW7)-mediated ubiquitination. Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins.
T21705	PDBSTRUC	5V4B; 5IBK; 2OVR; 2OVQ; 2OVP
T21705	SEQUENCE	MNQELLSVGSKRRRTGGSLRGNPSSSQVDEEQMNRVVEEEQQQQLRQQEEEHTARNGEVVGVEPRPGGQNDSQQGQLEENNNRFISVDEDSSGNQEEQEEDEEHAGEQDEEDEEEEEMDQESDDFDQSDDSSREDEHTHTNSVTNSSSIVDLPVHQLSSPFYTKTTKMKRKLDHGSEVRSFSLGKKPCKVSEYTSTTGLVPCSATPTTFGDLRAANGQGQQRRRITSVQPPTGLQEWLKMFQSWSGPEKLLALDELIDSCEPTQVKHMMQVIEPQFQRDFISLLPKELALYVLSFLEPKDLLQAAQTCRYWRILAEDNLLWREKCKEEGIDEPLHIKRRKVIKPGFIHSPWKSAYIRQHRIDTNWRRGELKSPKVLKGHDDHVITCLQFCGNRIVSGSDDNTLKVWSAVTGKCLRTLVGHTGGVWSSQMRDNIIISGSTDRTLKVWNAETGECIHTLYGHTSTVRCMHLHEKRVVSGSRDATLRVWDIETGQCLHVLMGHVAAVRCVQYDGRRVVSGAYDFMVKVWDPETETCLHTLQGHTNRVYSLQFDGIHVVSGSLDTSIRVWDVETGNCIHTLTGHQSLTSGMELKDNILVSGNADSTVKIWDIKTGQCLQTLQGPNKHQSAVTCLQFNKNFVITSSDDGTVKLWDLKTGEFIRNLVTLESGGSGGVVWRIRASNTKLVCAVGSRNGTEETKLLVLDFDVDMK

T70012	TARGETID	T70012
T70012	FORMERID	TTDI03144
T70012	UNIPROID	CXA10_HUMAN
T70012	TARGNAME	Connexin-62 (Cx62)
T70012	GENENAME	GJA10
T70012	TARGTYPE	Literature-reported
T70012	SYNONYMS	Gap junction alpha-10 protein; CX62
T70012	FUNCTION	Involved in tracer coupling between horizontal cells of the retina. May play a role in the regulation of horizontal cell patterning. One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell.
T70012	BIOCLASS	Gap junction-forming connexin
T70012	SEQUENCE	MGDWNLLGGILEEVHSHSTIVGKIWLTILFIFRMLVLRVAAEDVWDDEQSAFACNTRQPGCNNICYDDAFPISLIRFWVLQIIFVSSPSLVYMGHALYRLRAFEKDRQRKKSHLRAQMENPDLDLEEQQRIDRELRRLEEQKRIHKVPLKGCLLRTYVLHILTRSVLEVGFMIGQYILYGFQMHPLYKCTQPPCPNAVDCFVSRPTEKTIFMLFMHSIAAISLLLNILEIFHLGIRKIMRTLYKKSSSEGIEDETGPPFHLKKYSVAQQCMICSSLPERISPLQANNQQQVIRVNVPKSKTMWQIPQPRQLEVDPSNGKKDWSEKDQHSGQLHVHSPCPWAGSAGNQHLGQQSDHSSFGLQNTMSQSWLGTTTAPRNCPSFAVGTWEQSQDPEPSGEPLTDLHSHCRDSEGSMRESGVWIDRSRPGSRKASFLSRLLSEKRHLHSDSGSSGSRNSSCLDFPHWENSPSPLPSVTGHRTSMVRQAALPIMELSQELFHSGCFLFPFFLPGVCMYVCVDREADGGGDYLWRDKIIHSIHSVKFNS
T70012	DRUGINFO	D00VJY	octanol	Investigative

T40299	TARGETID	T40299
T40299	FORMERID	TTDI00212
T40299	UNIPROID	ATG2B_HUMAN
T40299	TARGNAME	Autophagy-related 2B (ATG2B)
T40299	GENENAME	ATG2B
T40299	TARGTYPE	Literature-reported
T40299	SYNONYMS	C14orf103; Autophagyrelated protein 2 homolog B; Autophagy-related protein 2 homolog B
T40299	FUNCTION	Required for both autophagosome formation and regulation of lipid droplet morphology and dispersion.
T40299	BIOCLASS	Autophagy phagophore-formation transporter
T40299	SEQUENCE	MPWPFSESIKKRACRYLLQRYLGHFLQEKLSLEQLSLDLYQGTGSLAQVPLDKWCLNEILESADAPLEVTEGFIQSISLSVPWGSLLQDNCALEVRGLEMVFRPRPRPATGSEPMYWSSFMTSSMQLAKECLSQKLTDEQGEGSQPFEGLEKFAETIETVLRRVKVTFIDTVLRIEHVPENSKTGTALEIRIERTVYCDETADESSGINVHQPTAFAHKLLQLSGVSLFWDEFSASAKSSPVCSTAPVETEPKLSPSWNPKIIYEPHPQLTRNLPEIAPSDPVQIGRLIGRLELSLTLKQNEVLPGAKLDVDGQIDSIHLLLSPRQVHLLLDMLAAIAGPENSSKIGLANKDRKNRPMQQEDEYRIQMELNRYYLRKDSLSVGVSSEQSFYETETARTPSSREEEVFFSMADMDMSHSLSSLPPLGDPPNMDLELSLTSTYTNTPAGSPLSATVLQPTWGEFLDHHKEQPVRGSTFPSNLVHPTPLQKTSLPSRSVSVDESRPELIFRLAVGTFSISVLHIDPLSPPETSQNLNPLTPMAVAFFTCIEKIDPARFSTEDFKSFRAVFAEACSHDHLRFIGTGIKVSYEQRQRSASRYFSTDMSIGQMEFLECLFPTDFHSVPPHYTELLTFHSKEETGSHSPVCLQLHYKHSENRGPQGNQARLSSVPHKAELQIKLNPVCCELDISIVDRLNSLLQPQKLATVEMMASHMYTSYNKHISLHKAFTEVFLDDSHSPANCRISVQVATPALNLSVRFPIPDLRSDQERGPWFKKSLQKEILYLAFTDLEFKTEFIGGSTPEQIKLELTFRELIGSFQEEKGDPSIKFFHVSSGVDGDTTSSDDFDWPRIVLKINPPAMHSILERIAAEEEEENDGHYQEEEEGGAHSLKDVCDLRRPAPSPFSSRRVMFENEQMVMPGDPVEMTEFQDKAISNSHYVLELTLPNIYVTLPNKSFYEKLYNRIFNDLLLWEPTAPSPVETFENISYGIGLSVASQLINTFNKDSFSAFKSAVHYDEESGSEEETLQYFSTVDPNYRSRRKKKLDSQNKNSQSFLSVLLNINHGLIAVFTDVKQDNGDLLENKHGEFWLEFNSGSLFCVTKYEGFDDKHYICLHSSSFSLYHKGIVNGVILPTETRLPSSTRPHWLEPTIYSSEEDGLSKTSSDGVGGDSLNMLSVAVKILSDKSESNTKEFLIAVGLKGATLQHRMLPSGLSWHEQILYFLNIADEPVLGYNPPTSFTTFHVHLWSCALDYRPLYLPIRSLLTVETFSVSSSVALDKSSSTLRIILDEAALHLSDKCNTVTINLSRDYVRVMDMGLLELTITAVKSDSDGEQTEPRFELHCSSDVVHIRTCSDSCAALMNLIQYIASYGDLQTPNKADMKPGAFQRRSKVDSSGRSSSRGPVLPEADQQMLRDLMSDAMEEIDMQQGTSSVKPQANGVLDEKSQIQEPCCSDLFLFPDESGNVSQESGPTYASFSHHFISDAMTGVPTENDDFCILFAPKAAMQEKEEEPVIKIMVDDAIVIRDNYFSLPVNKTDTSKAPLHFPIPVIRYVVKEVSLVWHLYGGKDFGIVPPTSPAKSYISPHSSPSHTPTRHGRNTVCGGKGRNHDFLMEIQLSKVKFQHEVYPPCKPDCDSSLSEHPVSRQVFIVQDLEIRDRLATSQMNKFLYLYCSKEMPRKAHSNMLTVKALHVCPESGRSPQECCLRVSLMPLRLNIDQDALFFLKDFFTSLSAEVELQMTPDPEVKKSPGADVTCSLPRHLSTSKEPNLVISFSGPKQPSQNDSANSVEVVNGMEEKNFSAEEASFRDQPVFFREFRFTSEVPIRLDYHGKHVSMDQGTLAGILIGLAQLNCSELKLKRLSYRHGLLGVDKLFSYAITEWLNDIKKNQLPGILGGVGPMHSLVQLVQGLKDLVWLPIEQYRKDGRIVRGFQRGAASFGTSTAMAALELTNRMVQTIQAAAETAYDMVSPGTLSIEPKKTKRFPHHRLAHQPVDLREGVAKAYSVVKEGITDTAQTIYETAAREHESRGVTGAVGEVLRQIPPAVVKPLIVATEATSNVLGGMRNQIRPDVRQDESQKWRHGDD

T33931	TARGETID	T33931
T33931	FORMERID	TTDI03345
T33931	UNIPROID	LMBL3_HUMAN
T33931	TARGNAME	Lethal(3)malignant brain tumor-like 3 (L3MBTL3)
T33931	GENENAME	L3MBTL3
T33931	TARGTYPE	Literature-reported
T33931	SYNONYMS	MBT1; MBT-1; Lethal(3)malignant brain tumor-like protein 3; L(3)mbt-like protein 3; KIAA1798; H-l(3)mbt-like protein 3
T33931	FUNCTION	Putative Polycomb group (PcG) protein. PcG proteins maintain the transcriptionally repressive state of genes, probably via a modification of chromatin, rendering it heritably changed in its expressibility. Required for normal maturation of myeloid progenitor cells (By similarity).
T33931	PDBSTRUC	4L59; 4FL6; 3UT1; 1WJS; 1WJQ
T33931	SEQUENCE	MTESASSTSGQEFDVFSVMDWKDGVGTLPGSDLKFRVNEFGALEVITDENEMENVKKATATTTWMVPTAQEAPTSPPSSRPVFPPAYWTSPPGCPTVFSEKTGMPFRLKDPVKVEGLQFCENCCQYGNVDECLSGGNYCSQNCARHIKDKDQKEERDVEEDNEEEDPKCSRKKKPKLSLKADTKEDGEERDDEMENKQDVRILRGSQRARRKRRGDSAVLKQGLPPKGKKAWCWASYLEEEKAVAVPAKLFKEHQSFPYNKNGFKVGMKLEGVDPEHQSVYCVLTVAEVCGYRIKLHFDGYSDCYDFWVNADALDIHPVGWCEKTGHKLHPPKGYKEEEFNWQTYLKTCKAQAAPKSLFENQNITVIPSGFRVGMKLEAVDKKNPSFICVATVTDMVDNRFLVHFDNWDESYDYWCEASSPHIHPVGWCKEHRRTLITPPGYPNVKHFSWDKYLEETNSLPAPARAFKVKPPHGFQKKMKLEVVDKRNPMFIRVATVADTDDHRVKVHFDGWNNCYDYWIDADSPDIHPVGWCSKTGHPLQPPLSPLELMEASEHGGCSTPGCKGIGHFKRARHLGPHSAANCPYSEINLNKDRIFPDRLSGEMPPASPSFPRNKRTDANESSSSPEIRDQHADDVKEDFEERTESEMRTSHEARGAREEPTVQQAQRRSAVFLSFKSPIPCLPLRWEQQSKLLPTVAGIPASKVSKWSTDEVSEFIQSLPGCEEHGKVFKDEQIDGEAFLLMTQTDIVKIMSIKLGPALKIFNSILMFKAAEKNSHNEL
T33931	DRUGINFO	D0W9RR	UNC1215	Investigative

T78355	TARGETID	T78355
T78355	FORMERID	TTDI03139
T78355	UNIPROID	CXD4_HUMAN
T78355	TARGNAME	Gap junction delta-4 protein (Cx40.1)
T78355	GENENAME	GJD4
T78355	TARGTYPE	Literature-reported
T78355	SYNONYMS	Connexin-40.1; CX40.1
T78355	FUNCTION	One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell.
T78355	BIOCLASS	Gap junction-forming connexin
T78355	SEQUENCE	MEGVDLLGFLIITLNCNVTMVGKLWFVLTMLLRMLVIVLAGRPVYQDEQERFVCNTLQPGCANVCYDVFSPVSHLRFWLIQGVCVLLPSAVFSVYVLHRGATLAALGPRRCPDPREPASGQRRCPRPFGERGGLQVPDFSAGYIIHLLLRTLLEAAFGALHYFLFGFLAPKKFPCTRPPCTGVVDCYVSRPTEKSLLMLFLWAVSALSFLLGLADLVCSLRRRMRRRPGPPTSPSIRKQSGASGHAEGRRTDEEGGREEEGAPAPPGARAGGEGAGSPRRTSRVSGHTKIPDEDESEVTSSASEKLGRQPRGRPHREAAQDPRGSGSEEQPSAAPSRLAAPPSCSSLQPPDPPASSSGAPHLRARKSEWV
T78355	DRUGINFO	D00VJY	octanol	Investigative

T14071	TARGETID	T14071
T14071	FORMERID	TTDI00029
T14071	UNIPROID	HS12B_HUMAN
T14071	TARGNAME	Heat shock protein A 12B (HSPA12B)
T14071	GENENAME	HSPA12B
T14071	TARGTYPE	Literature-reported
T14071	SYNONYMS	Heat shock 70 kDa protein 12B; C20orf60
T14071	FUNCTION	Interacts with extended peptide segments of proteins as well as partially folded proteins to prevent aggregation, remodel folding pathways, and regulate activity. When not interacting with a substrate peptide, usually in an ATP bound state. Hsp70 by itself is characterized by a very weak ATPase activity. As newly synthesized proteins emerge from the ribosomes, the substrate binding domain of Hsp70 recognizes sequences of hydrophobic amino acid residues, and interacts with them. This spontaneous interaction is reversible, and in the ATP bound state Hsp70 may relatively freely bind and release peptides.
T14071	BIOCLASS	Heat shock protein
T14071	SEQUENCE	MLAVPEMGLQGLYIGSSPERSPVPSPPGSPRTQESCGIAPLTPSQSPKPEVRAPQQASFSVVVAIDFGTTSSGYAFSFASDPEAIHMMRKWEGGDPGVAHQKTPTCLLLTPEGAFHSFGYTARDYYHDLDPEEARDWLYFEKFKMKIHSATDLTLKTQLEAVNGKTMPALEVFAHALRFFREHALQELREQSPSLPEKDTVRWVLTVPAIWKQPAKQFMREAAYLAGLVSRENAEQLLIALEPEAASVYCRKLRLHQLLDLSGRAPGGGRLGERRSIDSSFRQAREQLRRSRHSRTFLVESGVGELWAEMQAGDRYVVADCGGGTVDLTVHQLEQPHGTLKELYKASGGPYGAVGVDLAFEQLLCRIFGEDFIATFKRQRPAAWVDLTIAFEARKRTAGPHRAGALNISLPFSFIDFYRKQRGHNVETALRRSSVNFVKWSSQGMLRMSCEAMNELFQPTVSGIIQHIEALLARPEVQGVKLLFLVGGFAESAVLQHAVQAALGARGLRVVVPHDVGLTILKGAVLFGQAPGVVRVRRSPLTYGVGVLNRFVPGRHPPEKLLVRDGRRWCTDVFERFVAAEQSVALGEEVRRSYCPARPGQRRVLINLYCCAAEDARFITDPGVRKCGALSLELEPADCGQDTAGAPPGRREIRAAMQFGDTEIKVTAVDVSTNRSVRASIDFLSN

T86026	TARGETID	T86026
T86026	FORMERID	TTDI01532
T86026	UNIPROID	H6ST2_HUMAN
T86026	TARGNAME	Heparan sulfate 6-O-sulfotransferase-2 (HS6ST2)
T86026	GENENAME	HS6ST2
T86026	TARGTYPE	Literature-reported
T86026	SYNONYMS	Heparan-sulfate 6-O-sulfotransferase 2; HS6ST-2
T86026	FUNCTION	6-O-sulfation enzyme which catalyzes the transfer of sulfate from 3'-phosphoadenosine 5'-phosphosulfate (PAPS) to position 6 of the N-sulfoglucosamine residue (GlcNS) of heparan sulfate.
T86026	ECNUMBER	EC 2.8.2.-
T86026	SEQUENCE	MALPACAVREFEPPRQPERGAPVRTTCPRRHSRVEAELAASRPGSVAASVRAGPPRGVSHGFHTRPLLDKPRKASSSLAGAACAPLFALLSRGRRRRMHVLRRRWDLGSLCRALLTRGLAALGHSLKHVLGAIFSKIFGPMASVGNMDEKSNKLLLALVMLFLFAVIVLQYVCPGTECQLLRLQAFSSPVPDPYRSEDESSARFVPRYNFTRGDLLRKVDFDIKGDDLIVFLHIQKTGGTTFGRHLVRNIQLEQPCECRVGQKKCTCHRPGKRETWLFSRFSTGWSCGLHADWTELTSCVPSVVDGKRDARLRPSRNFHYITILRDPVSRYLSEWRHVQRGATWKASLHVCDGRPPTSEELPSCYTGDDWSGCPLKEFMDCPYNLANNRQVRMLSDLTLVGCYNLSVMPEKQRNKVLLESAKSNLKHMAFFGLTEFQRKTQYLFEKTFNMNFISPFTQYNTTRASSVEINEEIQKRIEGLNFLDMELYSYAKDLFLQRYQFMRQKEHQEARRKRQEQRKFLKGRLLQTHFQSQGQGQSQNPNQNQSQNPNPNANQNLTQNLMQNLTQSLSQKENRESPKQNSGKEQNDNTSNGTNDYIGSVEKWR

T42884	TARGETID	T42884
T42884	FORMERID	TTDI02511
T42884	UNIPROID	GP101_HUMAN
T42884	TARGNAME	G protein coupled receptor 101 (GPR101)
T42884	GENENAME	GPR101
T42884	TARGTYPE	Literature-reported
T42884	SYNONYMS	Probable Gprotein coupled receptor 101; GPR101
T42884	FUNCTION	Orphan receptor.
T42884	BIOCLASS	GPCR rhodopsin
T42884	SEQUENCE	MTSTCTNSTRESNSSHTCMPLSKMPISLAHGIIRSTVLVIFLAASFVGNIVLALVLQRKPQLLQVTNRFIFNLLVTDLLQISLVAPWVVATSVPLFWPLNSHFCTALVSLTHLFAFASVNTIVVVSVDRYLSIIHPLSYPSKMTQRRGYLLLYGTWIVAILQSTPPLYGWGQAAFDERNALCSMIWGASPSYTILSVVSFIVIPLIVMIACYSVVFCAARRQHALLYNVKRHSLEVRVKDCVENEDEEGAEKKEEFQDESEFRRQHEGEVKAKEGRMEAKDGSLKAKEGSTGTSESSVEARGSEEVRESSTVASDGSMEGKEGSTKVEENSMKADKGRTEVNQCSIDLGEDDMEFGEDDINFSEDDVEAVNIPESLPPSRRNSNSNPPLPRCYQCKAAKVIFIIIFSYVLSLGPYCFLAVLAVWVDVETQVPQWVITIIIWLFFLQCCIHPYVYGYMHKTIKKEIQDMLKKFFCKEKPPKEDSHPDLPGTEGGTEGKIVPSYDSATFP

T04413	TARGETID	T04413
T04413	FORMERID	TTDI03578
T04413	UNIPROID	TSSK2_HUMAN
T04413	TARGNAME	Testis-specific serine kinase 2 (TSSK2)
T04413	GENENAME	TSSK2
T04413	TARGTYPE	Literature-reported
T04413	SYNONYMS	Testis-specific serine/threonine-protein kinase 2; TSSK-2; TSK2; TSK-2; Serine/threonine-protein kinase 22B; STK22B; SPOGA2; DiGeorge syndrome protein G; DGSG; DGS-G
T04413	FUNCTION	Testis-specific serine/threonine-protein kinase required during spermatid development. Phosphorylates TSKS at 'Ser-288' and SPAG16. Involved in the late stages of spermatogenesis, during the reconstruction of the cytoplasm. During spermatogenesis, required for the transformation of a ring-shaped structure around the base of the flagellum originating from the chromatoid body.
T04413	ECNUMBER	EC 2.7.11.1
T04413	SEQUENCE	MDDATVLRKKGYIVGINLGKGSYAKVKSAYSERLKFNVAVKIIDRKKTPTDFVERFLPREMDILATVNHGSIIKTYEIFETSDGRIYIIMELGVQGDLLEFIKCQGALHEDVARKMFRQLSSAVKYCHDLDIVHRDLKCENLLLDKDFNIKLSDFGFSKRCLRDSNGRIILSKTFCGSAAYAAPEVLQSIPYQPKVYDIWSLGVILYIMVCGSMPYDDSDIRKMLRIQKEHRVDFPRSKNLTCECKDLIYRMLQPDVSQRLHIDEILSHSWLQPPKPKATSSASFKREGEGKYRAECKLDTKTGLRPDHRPDHKLGAKTQHRLLVVPENENRMEDRLAETSRAKDHHISGAEVGKAST
T04413	DRUGINFO	D0E7VO	PMID24900538C2c	Investigative

T13394	TARGETID	T13394
T13394	FORMERID	TTDI03339
T13394	UNIPROID	KCNC2_HUMAN
T13394	TARGNAME	Voltage-gated potassium channel Kv3.2 (KCNC2)
T13394	GENENAME	KCNC2
T13394	TARGTYPE	Literature-reported
T13394	SYNONYMS	Shaw-like potassium channel; Potassium voltage-gated channel subfamily C member 2
T13394	FUNCTION	Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain. Contributes to the regulation of the fast action potential repolarization and in sustained high-frequency firing in neurons of the central nervous system. Homotetramer channels mediate delayed-rectifier voltage-dependent potassium currents that activate rapidly at high-threshold voltages and inactivate slowly. Forms tetrameric channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage difference across the membrane. Can form functional homotetrameric and heterotetrameric channels that contain variable proportions of KCNC1, and possibly other family members as well; channel properties depend on the type of alpha subunits that are part of the channel. Channel properties may be modulated either by the association with ancillary subunits, such as KCNE1, KCNE2 or KCNE3 or indirectly by nitric oxide (NO) through a cGMP- and PKG-mediated signaling cascade, slowing channel activation and deactivation of delayed rectifier potassium channels (By similarity). Contributes to fire sustained trains of very brief action potentials at high frequency in retinal ganglion cells, thalamocortical and suprachiasmatic nucleus (SCN) neurons and in hippocampal and neocortical interneurons. Sustained maximal action potential firing frequency in inhibitory hippocampal interneurons is negatively modulated by histamine H2 receptor activation in a cAMP- and protein kinase (PKA) phosphorylation-dependent manner. Plays a role in maintaining the fidelity of synaptic transmission in neocortical GABAergic interneurons by generating action potential (AP) repolarization at nerve terminals, thus reducing spike-evoked calcium influx and GABA neurotransmitter release. Required for long-range synchronization of gamma oscillations over distance in the neocortex. Contributes to the modulation of the circadian rhythm of spontaneous action potential firing in suprachiasmatic nucleus (SCN) neurons in a light-dependent manner (By similarity).
T13394	BIOCLASS	Voltage-gated ion channel
T13394	SEQUENCE	MGKIENNERVILNVGGTRHETYRSTLKTLPGTRLALLASSEPPGDCLTTAGDKLQPSPPPLSPPPRAPPLSPGPGGCFEGGAGNCSSRGGRASDHPGGGREFFFDRHPGVFAYVLNYYRTGKLHCPADVCGPLFEEELAFWGIDETDVEPCCWMTYRQHRDAEEALDIFETPDLIGGDPGDDEDLAAKRLGIEDAAGLGGPDGKSGRWRRLQPRMWALFEDPYSSRAARFIAFASLFFILVSITTFCLETHEAFNIVKNKTEPVINGTSVVLQYEIETDPALTYVEGVCVVWFTFEFLVRIVFSPNKLEFIKNLLNIIDFVAILPFYLEVGLSGLSSKAAKDVLGFLRVVRFVRILRIFKLTRHFVGLRVLGHTLRASTNEFLLLIIFLALGVLIFATMIYYAERVGAQPNDPSASEHTQFKNIPIGFWWAVVTMTTLGYGDMYPQTWSGMLVGALCALAGVLTIAMPVPVIVNNFGMYYSLAMAKQKLPRKRKKHIPPAPQASSPTFCKTELNMACNSTQSDTCLGKDNRLLEHNRSVLSGDDSTGSEPPLSPPERLPIRRSSTRDKNRRGETCFLLTTGDYTCASDGGIRKGYEKSRSLNNIAGLAGNALRLSPVTSPYNSPCPLRRSRSPIPSIL
T13394	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T92865	TARGETID	T92865
T92865	FORMERID	TTDI00228
T92865	UNIPROID	KI20B_HUMAN
T92865	TARGNAME	Kinesin-like protein KIF20B (MPHOSPH1)
T92865	GENENAME	KIF20B
T92865	TARGTYPE	Literature-reported
T92865	SYNONYMS	Mphase phosphoprotein 1; MPP1; M-phase phosphoprotein 1; Kinesinrelated motor interacting with PIN1; Kinesinlike protein KIF20B; Kinesin-related motor interacting with PIN1; Kinesin family member 20B; KRMP1; Cancer/testis antigen 90; CT90
T92865	FUNCTION	Required for proper midbody organization and abscission in polarized cortical stem cells. Plays a role in the regulation of neuronal polarization by mediating the transport of specific cargos. Participates in the mobilization of SHTN1 and in the accumulation of PIP3 in the growth cone of primary hippocampal neurons in a tubulin and actin-dependent manner. In the developing telencephalon, cooperates with SHTN1 to promote both the transition from the multipolar to the bipolar stage and the radial migration of cortical neurons from the ventricular zone toward the superficial layer of the neocortex. Involved in cerebral cortex growth. Acts as an oncogene for promoting bladder cancer cells proliferation, apoptosis inhibition and carcinogenic progression. Plus-end-directed motor enzyme that is required for completion of cytokinesis.
T92865	BIOCLASS	Myosin-kinesin ATPase
T92865	SEQUENCE	MESNFNQEGVPRPSYVFSADPIARPSEINFDGIKLDLSHEFSLVAPNTEANSFESKDYLQVCLRIRPFTQSEKELESEGCVHILDSQTVVLKEPQCILGRLSEKSSGQMAQKFSFSKVFGPATTQKEFFQGCIMQPVKDLLKGQSRLIFTYGLTNSGKTYTFQGTEENIGILPRTLNVLFDSLQERLYTKMNLKPHRSREYLRLSSEQEKEEIASKSALLRQIKEVTVHNDSDDTLYGSLTNSLNISEFEESIKDYEQANLNMANSIKFSVWVSFFEIYNEYIYDLFVPVSSKFQKRKMLRLSQDVKGYSFIKDLQWIQVSDSKEAYRLLKLGIKHQSVAFTKLNNASSRSHSIFTVKILQIEDSEMSRVIRVSELSLCDLAGSERTMKTQNEGERLRETGNINTSLLTLGKCINVLKNSEKSKFQQHVPFRESKLTHYFQSFFNGKGKICMIVNISQCYLAYDETLNVLKFSAIAQKVCVPDTLNSSQEKLFGPVKSSQDVSLDSNSNSKILNVKRATISWENSLEDLMEDEDLVEELENAEETQNVETKLLDEDLDKTLEENKAFISHEEKRKLLDLIEDLKKKLINEKKEKLTLEFKIREEVTQEFTQYWAQREADFKETLLQEREILEENAERRLAIFKDLVGKCDTREEAAKDICATKVETEETHNYVGFEDIIDSLQDNVADIKKQAEIAHLYIASLPDPQEATACLELKFNQIKAELAKTKGELIKTKEELKKRENESDSLIQELETSNKKIITQNQRIKELINIIDQKEDTINEFQNLKSHMENTFKCNDKADTSSLIINNKLICNETVEVPKDSKSKICSERKRVNENELQQDEPPAKKGSIHVSSAITEDQKKSEEVRPNIAEIEDIRVLQENNEGLRAFLLTIENELKNEKEEKAELNKQIVHFQQELSLSEKKNLTLSKEVQQIQSNYDIAIAELHVQKSKNQEQEEKIMKLSNEIETATRSITNNVSQIKLMHTKIDELRTLDSVSQISNIDLLNLRDLSNGSEEDNLPNTQLDLLGNDYLVSKQVKEYRIQEPNRENSFHSSIEAIWEECKEIVKASSKKSHQIEELEQQIEKLQAEVKGYKDENNRLKEKEHKNQDDLLKEKETLIQQLKEELQEKNVTLDVQIQHVVEGKRALSELTQGVTCYKAKIKELETILETQKVECSHSAKLEQDILEKESIILKLERNLKEFQEHLQDSVKNTKDLNVKELKLKEEITQLTNNLQDMKHLLQLKEEEEETNRQETEKLKEELSASSARTQNLKADLQRKEEDYADLKEKLTDAKKQIKQVQKEVSVMRDEDKLLRIKINELEKKKNQCSQELDMKQRTIQQLKEQLNNQKVEEAIQQYERACKDLNVKEKIIEDMRMTLEEQEQTQVEQDQVLEAKLEEVERLATELEKWKEKCNDLETKNNQRSNKEHENNTDVLGKLTNLQDELQESEQKYNADRKKWLEEKMMLITQAKEAENIRNKEMKKYAEDRERFFKQQNEMEILTAQLTEKDSDLQKWREERDQLVAALEIQLKALISSNVQKDNEIEQLKRIISETSKIETQIMDIKPKRISSADPDKLQTEPLSTSFEISRNKIEDGSVVLDSCEVSTENDQSTRFPKPELEIQFTPLQPNKMAVKHPGCTTPVTVKIPKARKRKSNEMEEDLVKCENKKNATPRTNLKFPISDDRNSSVKKEQKVAIRPSSKKTYSLRSQASIIGVNLATKKKEGTLQKFGDFLQHSPSILQSKAKKIIETMSSSKLSNVEASKENVSQPKRAKRKLYTSEISSPIDISGQVILMDQKMKESDHQIIKRRLRTKTAK

T78311	TARGETID	T78311
T78311	FORMERID	TTDNR00716
T78311	UNIPROID	NACC1_HUMAN
T78311	TARGNAME	Nucleus accumbens-associated protein 1 (NACC1)
T78311	GENENAME	NACC1
T78311	TARGTYPE	Literature-reported
T78311	SYNONYMS	NAC1; NAC-1; BTBD14B; BTB/POZ domain-containing protein 14B
T78311	FUNCTION	Seems to function as a transcriptional corepressor in neuronal cells through recruitment of HDAC3 and HDAC4. Contributes to tumor progression, and tumor cell proliferation and survival. This may be mediated at least in part through repressing transcriptional activity of GADD45GIP1. Required for recruiting the proteasome from the nucleus to the cytoplasm and dendritic spines. Functions as a transcriptional repressor.
T78311	PDBSTRUC	4U2N; 3GA1
T78311	SEQUENCE	MAQTLQMEIPNFGNSILECLNEQRLQGLYCDVSVVVKGHAFKAHRAVLAASSSYFRDLFNNSRSAVVELPAAVQPQSFQQILSFCYTGRLSMNVGDQFLLMYTAGFLQIQEIMEKGTEFFLKVSSPSCDSQGLHAEEAPSSEPQSPVAQTSGWPACSTPLPLVSRVKTEQQESDSVQCMPVAKRLWDSGQKEAGGGGNGSRKMAKFSTPDLAANRPHQPPPPQQAPVVAAAQPAVAAGAGQPAGGVAAAGGVVSGPSTSERTSPGTSSAYTSDSPGSYHNEEDEEEDGGEEGMDEQYRQICNMYTMYSMMNVGQTAEKVEALPEQVAPESRNRIRVRQDLASLPAELINQIGNRCHPKLYDEGDPSEKLELVTGTNVYITRAQLMNCHVSAGTRHKVLLRRLLASFFDRNTLANSCGTGIRSSTNDPRRKPLDSRVLHAVKYYCQNFAPNFKESEMNAIAADMCTNARRVVRKSWMPKVKVLKAEDDAYTTFISETGKIEPDMMGVEHGFETASHEGEAGPSAEALQ

T84737	TARGETID	T84737
T84737	FORMERID	TTDI03329
T84737	UNIPROID	KCNA7_HUMAN
T84737	TARGNAME	Voltage-gated potassium channel Kv1.7 (KCNA7)
T84737	GENENAME	KCNA7
T84737	TARGTYPE	Literature-reported
T84737	SYNONYMS	Voltage-gated potassium channel subunit Kv1.7; Potassium voltage-gated channel subfamily A member 7
T84737	FUNCTION	Mediates the voltage-dependent potassium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a potassium-selective channel through which potassium ions may pass in accordance with their electrochemical gradient (By similarity).
T84737	BIOCLASS	Voltage-gated ion channel
T84737	SEQUENCE	MEPRCPPPCGCCERLVLNVAGLRFETRARTLGRFPDTLLGDPARRGRFYDDARREYFFDRHRPSFDAVLYYYQSGGRLRRPAHVPLDVFLEEVAFYGLGAAALARLREDEGCPVPPERPLPRRAFARQLWLLFEFPESSQAARVLAVVSVLVILVSIVVFCLETLPDFRDDRDGTGLAAAAAAGPFPAPLNGSSQMPGNPPRLPFNDPFFVVETLCICWFSFELLVRLLVCPSKAIFFKNVMNLIDFVAILPYFVALGTELARQRGVGQQAMSLAILRVIRLVRVFRIFKLSRHSKGLQILGQTLRASMRELGLLIFFLFIGVVLFSSAVYFAEVDRVDSHFTSIPESFWWAVVTMTTVGYGDMAPVTVGGKIVGSLCAIAGVLTISLPVPVIVSNFSYFYHRETEGEEAGMFSHVDMQPCGPLEGKANGGLVDGEVPELPPPLWAPPGKHLVTEV
T84737	DRUGINFO	D0G4SU	tedisamil	Investigative
T84737	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T23785	TARGETID	T23785
T23785	FORMERID	TTDI03576
T23785	UNIPROID	TESK2_HUMAN
T23785	TARGNAME	Testis-specific kinase 2 (TESK2)
T23785	GENENAME	TESK2
T23785	TARGTYPE	Literature-reported
T23785	SYNONYMS	Testicular protein kinase 2; Dual specificity testis-specific protein kinase 2
T23785	FUNCTION	Dual specificity protein kinase activity catalyzing autophosphorylation and phosphorylation of exogenous substrates on both serine/threonine and tyrosine residues. Phosphorylates cofilin at 'Ser-3'. May play an important role in spermatogenesis.
T23785	ECNUMBER	EC 2.7.12.1
T23785	SEQUENCE	MDRSKRNSIAGFPPRVERLEEFEGGGGGEGNVSQVGRVWPSSYRALISAFSRLTRLDDFTCEKIGSGFFSEVFKVRHRASGQVMALKMNTLSSNRANMLKEVQLMNRLSHPNILRFMGVCVHQGQLHALTEYINSGNLEQLLDSNLHLPWTVRVKLAYDIAVGLSYLHFKGIFHRDLTSKNCLIKRDENGYSAVVADFGLAEKIPDVSMGSEKLAVVGSPFWMAPEVLRDEPYNEKADVFSYGIILCEIIARIQADPDYLPRTENFGLDYDAFQHMVGDCPPDFLQLTFNCCNMDPKLRPSFVEIGKTLEEILSRLQEEEQERDRKLQPTARGLLEKAPGVKRLSSLDDKIPHKSPCPRRTIWLSRSQSDIFSRKPPRTVSVLDPYYRPRDGAARTPKVNPFSARQDLMGGKIKFFDLPSKSVISLVFDLDAPGPGTMPLADWQEPLAPPIRRWRSLPGSPEFLHQEACPFVGREESLSDGPPPRLSSLKYRVKEIPPFRASALPAAQAHEAMDCSILQEENGFGSRPQGTSPCPAGASEEMEVEERPAGSTPATFSTSGIGLQTQGKQDG
T23785	DRUGINFO	D0F6NZ	PMID22902653C30	Investigative
T23785	DRUGINFO	D0FC4Y	PMID22902653C31	Investigative
T23785	DRUGINFO	D0S0XD	PMID22902653C35	Investigative

T13319	TARGETID	T13319
T13319	FORMERID	TTDI01496
T13319	UNIPROID	PNKP_HUMAN
T13319	TARGNAME	Polynucleotide kinase-3'-phosphatase (PNKP)
T13319	GENENAME	PNKP
T13319	TARGTYPE	Literature-reported
T13319	SYNONYMS	DNA 5'-kinase/3'-phosphatase; Bifunctional polynucleotide phosphatase/kinase
T13319	FUNCTION	Plays a key role in the repair of DNA damage, functioning as part of both the non-homologous end-joining (NHEJ) and base excision repair (BER) pathways. Through its two catalytic activities, PNK ensures that DNA termini are compatible with extension and ligation by either removing 3'-phosphates from, or by phosphorylating 5'-hydroxyl groups on, the ribose sugar of the DNA backbone.
T13319	PDBSTRUC	2W3O; 2BRF
T13319	SEQUENCE	MGEVEAPGRLWLESPPGGAPPIFLPSDGQALVLGRGPLTQVTDRKCSRTQVELVADPETRTVAVKQLGVNPSTTGTQELKPGLEGSLGVGDTLYLVNGLHPLTLRWEETRTPESQPDTPPGTPLVSQDEKRDAELPKKRMRKSNPGWENLEKLLVFTAAGVKPQGKVAGFDLDGTLITTRSGKVFPTGPSDWRILYPEIPRKLRELEAEGYKLVIFTNQMSIGRGKLPAEEFKAKVEAVVEKLGVPFQVLVATHAGLYRKPVTGMWDHLQEQANDGTPISIGDSIFVGDAAGRPANWAPGRKKKDFSCADRLFALNLGLPFATPEEFFLKWPAAGFELPAFDPRTVSRSGPLCLPESRALLSASPEVVVAVGFPGAGKSTFLKKHLVSAGYVHVNRDTLGSWQRCVTTCETALKQGKRVAIDNTNPDAASRARYVQCARAAGVPCRCFLFTATLEQARHNNRFREMTDSSHIPVSDMVMYGYRKQFEAPTLAEGFSAILEIPFRLWVEPRLGRLYCQFSEG

T95817	TARGETID	T95817
T95817	FORMERID	TTDR00720
T95817	UNIPROID	RIMP_STRPN
T95817	TARGNAME	Streptococcus UPF0090 protein SP0552 (Stre-coc rimP)
T95817	GENENAME	Stre-coc rimP
T95817	TARGTYPE	Literature-reported
T95817	SYNONYMS	rimP; SP14.3; Hypothetical protein SP14.3
T95817	FUNCTION	Required for maturation of 30S ribosomal subunits.
T95817	PDBSTRUC	1IB8
T95817	SEQUENCE	MDAIATIVELVREVVEPVIEAPFELVDIEYGKIGSDMILSIFVDKPEGITLNDTADLTEIISPVLDTIKPDPFPEQYFLEITSPGLERPLKTKDAVAGAVGKYIHVGLYQAIDKQKVFEGTLLAFEEDELTMEYMDKTRKKTVQIPYSLVSKARLAVKL

T78567	TARGETID	T78567
T78567	FORMERID	TTDNR00717
T78567	UNIPROID	OSMR_HUMAN
T78567	TARGNAME	Oncostatin-M-specific receptor beta (OSMR)
T78567	GENENAME	OSMR
T78567	TARGTYPE	Literature-reported
T78567	SYNONYMS	Oncostatin-M-specific receptor subunit beta; OSMRB; Interleukin-31 receptor subunit beta; IL-31RB; IL-31R-beta; IL-31R subunit beta; IL-31 receptor subunit beta
T78567	FUNCTION	Binds IL31 to activate STAT3 and possibly STAT1 and STAT5. Capable of transducing OSM-specific signaling events. Associates with IL31RA to form the IL31 receptor.
T78567	BIOCLASS	Cytokine receptor
T78567	SEQUENCE	MALFAVFQTTFFLTLLSLRTYQSEVLAERLPLTPVSLKVSTNSTRQSLHLQWTVHNLPYHQELKMVFQIQISRIETSNVIWVGNYSTTVKWNQVLHWSWESELPLECATHFVRIKSLVDDAKFPEPNFWSNWSSWEEVSVQDSTGQDILFVFPKDKLVEEGTNVTICYVSRNIQNNVSCYLEGKQIHGEQLDPHVTAFNLNSVPFIRNKGTNIYCEASQGNVSEGMKGIVLFVSKVLEEPKDFSCETEDFKTLHCTWDPGTDTALGWSKQPSQSYTLFESFSGEKKLCTHKNWCNWQITQDSQETYNFTLIAENYLRKRSVNILFNLTHRVYLMNPFSVNFENVNATNAIMTWKVHSIRNNFTYLCQIELHGEGKMMQYNVSIKVNGEYFLSELEPATEYMARVRCADASHFWKWSEWSGQNFTTLEAAPSEAPDVWRIVSLEPGNHTVTLFWKPLSKLHANGKILFYNVVVENLDKPSSSELHSIPAPANSTKLILDRCSYQICVIANNSVGASPASVIVISADPENKEVEEERIAGTEGGFSLSWKPQPGDVIGYVVDWCDHTQDVLGDFQWKNVGPNTTSTVISTDAFRPGVRYDFRIYGLSTKRIACLLEKKTGYSQELAPSDNPHVLVDTLTSHSFTLSWKDYSTESQPGFIQGYHVYLKSKARQCHPRFEKAVLSDGSECCKYKIDNPEEKALIVDNLKPESFYEFFITPFTSAGEGPSATFTKVTTPDEHSSMLIHILLPMVFCVLLIMVMCYLKSQWIKETCYPDIPDPYKSSILSLIKFKENPHLIIMNVSDCIPDAIEVVSKPEGTKIQFLGTRKSLTETELTKPNYLYLLPTEKNHSGPGPCICFENLTYNQAASDSGSCGHVPVSPKAPSMLGLMTSPENVLKALEKNYMNSLGEIPAGETSLNYVSQLASPMFGDKDSLPTNPVEAPHCSEYKMQMAVSLRLALPPPTENSSLSSITLLDPGEHYC
T78567	DRUGINFO	D4XL6Z	Vixarelimab	Phase 1

T43524	TARGETID	T43524
T43524	FORMERID	TTDR01104
T43524	UNIPROID	I12R2_HUMAN
T43524	TARGNAME	Interleukin 12 receptor beta-2 (IL12RB2)
T43524	GENENAME	IL12RB2
T43524	TARGTYPE	Literature-reported
T43524	SYNONYMS	Interleukin-12 receptor subunit beta-2; IL-12RB2; IL-12R-beta2; IL-12R-beta-2; IL-12R subunit beta-2; IL-12R beta 2; IL-12 receptor subunit beta-2; IL-12 receptor beta-2
T43524	FUNCTION	Receptor for interleukin-12. This subunit is the signaling component coupling to the JAK2/STAT4 pathway. Promotes the proliferation of T-cells as well as NK cells. Induces the promotion of T-cells towards the Th1 phenotype by strongly enhancing IFN-gamma production.
T43524	BIOCLASS	Cytokine receptor
T43524	SEQUENCE	MAHTFRGCSLAFMFIITWLLIKAKIDACKRGDVTVKPSHVILLGSTVNITCSLKPRQGCFHYSRRNKLILYKFDRRINFHHGHSLNSQVTGLPLGTTLFVCKLACINSDEIQICGAEIFVGVAPEQPQNLSCIQKGEQGTVACTWERGRDTHLYTEYTLQLSGPKNLTWQKQCKDIYCDYLDFGINLTPESPESNFTAKVTAVNSLGSSSSLPSTFTFLDIVRPLPPWDIRIKFQKASVSRCTLYWRDEGLVLLNRLRYRPSNSRLWNMVNVTKAKGRHDLLDLKPFTEYEFQISSKLHLYKGSWSDWSESLRAQTPEEEPTGMLDVWYMKRHIDYSRQQISLFWKNLSVSEARGKILHYQVTLQELTGGKAMTQNITGHTSWTTVIPRTGNWAVAVSAANSKGSSLPTRINIMNLCEAGLLAPRQVSANSEGMDNILVTWQPPRKDPSAVQEYVVEWRELHPGGDTQVPLNWLRSRPYNVSALISENIKSYICYEIRVYALSGDQGGCSSILGNSKHKAPLSGPHINAITEEKGSILISWNSIPVQEQMGCLLHYRIYWKERDSNSQPQLCEIPYRVSQNSHPINSLQPRVTYVLWMTALTAAGESSHGNEREFCLQGKANWMAFVAPSICIAIIMVGIFSTHYFQQKVFVLLAALRPQWCSREIPDPANSTCAKKYPIAEEKTQLPLDRLLIDWPTPEDPEPLVISEVLHQVTPVFRHPPCSNWPQREKGIQGHQASEKDMMHSASSPPPPRALQAESRQLVDLYKVLESRGSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDLPSHEAPLADSLEELEPQHISLSVFPSSSLHPLTFSCGDKLTLDQLKMRCDSLML

T14630	TARGETID	T14630
T14630	FORMERID	TTDI03462
T14630	UNIPROID	PI51A_HUMAN
T14630	TARGNAME	PtdIns(4)P-5-kinase 1 alpha (PIP5K1A)
T14630	GENENAME	PIP5K1A
T14630	TARGTYPE	Literature-reported
T14630	SYNONYMS	Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha; Phosphatidylinositol 4-phosphate 5-kinase type I alpha; PIP5KIalpha; PIP5K1-alpha; 68 kDa type I phosphatidylinositol 4-phosphate 5-kinase alpha
T14630	FUNCTION	Catalyzes the phosphorylation of phosphatidylinositol 4-phosphate (PtdIns4P) to form phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2). PtdIns(4,5)P2 is involved in a variety of cellular processes and is the substrate to form phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3), another second messenger. The majority of PtdIns(4,5)P2 is thought to occur via type I phosphatidylinositol 4-phosphate 5-kinases given the abundance of PtdIns4P. Participates in a variety of cellular processes such as actin cytoskeleton organization, cell adhesion, migration and phagocytosis. Required for membrane ruffling formation, actin organization and focal adhesion formation during directional cell migration by controlling integrin-induced translocation of RAC1 to the plasma membrane. Together with PIP5K1C is required for phagocytosis, but they regulate different types of actin remodeling at sequential steps. Promotes particle ingestion by activating WAS that induces Arp2/3 dependent actin polymerization at the nascent phagocytic cup. Together with PIP5K1B is required after stimulation of G-protein coupled receptors for stable platelet adhesion. Plays a role during calcium-induced keratinocyte differentiation. Recruited to the plasma membrane by the E-cadherin/beta-catenin complex where it provides the substrate PtdIns(4,5)P2 for the production of PtdIns(3,4,5)P3, diacylglycerol and inositol 1,4,5-trisphosphate that mobilize internal calcium and drive keratinocyte differentiation. Together with PIP5K1C have a role during embryogenesis. Functions also in the nucleus where acts as an activator of TUT1 adenylyltransferase activity in nuclear speckles, thereby regulating mRNA polyadenylation of a select set of mRNAs. Positively regulates insulin-induced translocation of SLC2A4 to the cell membrane in adipocytes (By similarity).
T14630	ECNUMBER	EC 2.7.1.68
T14630	SEQUENCE	MASASSGPSSSVGFSSFDPAVPSCTLSSAASGIKRPMASEVLEARQDSYISLVPYASGMPIKKIGHRSVDSSGETTYKKTTSSALKGAIQLGITHTVGSLSTKPERDVLMQDFYVVESIFFPSEGSNLTPAHHYNDFRFKTYAPVAFRYFRELFGIRPDDYLYSLCSEPLIELCSSGASGSLFYVSSDDEFIIKTVQHKEAEFLQKLLPGYYMNLNQNPRTLLPKFYGLYCVQAGGKNIRIVVMNNLLPRSVKMHIKYDLKGSTYKRRASQKEREKPLPTFKDLDFLQDIPDGLFLDADMYNALCKTLQRDCLVLQSFKIMDYSLLMSIHNIDHAQREPLSSETQYSVDTRRPAPQKALYSTAMESIQGEARRGGTMETDDHMGGIPARNSKGERLLLYIGIIDILQSYRFVKKLEHSWKALVHDGDTVSVHRPGFYAERFQRFMCNTVFKKIPLKPSPSKKFRSGSSFSRRAGSSGNSCITYQPSVSGEHKAQVTTKAEVEPGVHLGRPDVLPQTPPLEEISEGSPIPDPSFSPLVGETLQMLTTSTTLEKLEVAESEFTH
T14630	DRUGINFO	D0GG9W	ISA-2011B	Investigative

T41988	TARGETID	T41988
T41988	FORMERID	TTDI02533
T41988	UNIPROID	NKX31_HUMAN
T41988	TARGNAME	Homeobox protein Nkx-3.1 (NKX3-1)
T41988	GENENAME	NKX3-1
T41988	TARGTYPE	Literature-reported
T41988	SYNONYMS	NKX3A; NKX31; NKX3.1; Homeobox protein Nkx3.1; Homeobox protein NK3 homolog A; Homeobox protein NK-3 homolog A
T41988	FUNCTION	Plays an important role in normal prostate development, regulating proliferation of glandular epithelium and in the formation of ducts in prostate. Acts as a tumor suppressor controlling prostate carcinogenesis, as shown by the ability to inhibit proliferation and invasion activities of PC-3 prostate cancer cells. Transcription factor, which binds preferentially the consensus sequence 5'-TAAGT[AG]-3' and can behave as a transcriptional repressor.
T41988	PDBSTRUC	2L9R
T41988	SEQUENCE	MLRVPEPRPGEAKAEGAAPPTPSKPLTSFLIQDILRDGAQRQGGRTSSQRQRDPEPEPEPEPEGGRSRAGAQNDQLSTGPRAAPEEAETLAETEPERHLGSYLLDSENTSGALPRLPQTPKQPQKRSRAAFSHTQVIELERKFSHQKYLSAPERAHLAKNLKLTETQVKIWFQNRRYKTKRKQLSSELGDLEKHSSLPALKEEAFSRASLVSVYNSYPYYPYLYCVGSWSPAFW

T46092	TARGETID	T46092
T46092	FORMERID	TTDI00196
T46092	UNIPROID	FOXC2_HUMAN
T46092	TARGNAME	Forkhead box protein C2 (FOXC2)
T46092	GENENAME	FOXC2
T46092	TARGTYPE	Literature-reported
T46092	SYNONYMS	Transcription factor FKH14; Mesenchyme fork head protein 1; MFH1 protein; Forkheadrelated protein FKHL14; FOXC2
T46092	FUNCTION	Transcriptional activator. Might be involved in the formation of special mesenchymal tissues.
T46092	PDBSTRUC	6AKP; 6AKO; 1D5V
T46092	SEQUENCE	MQARYSVSDPNALGVVPYLSEQNYYRAAGSYGGMASPMGVYSGHPEQYSAGMGRSYAPYHHHQPAAPKDLVKPPYSYIALITMAIQNAPEKKITLNGIYQFIMDRFPFYRENKQGWQNSIRHNLSLNECFVKVPRDDKKPGKGSYWTLDPDSYNMFENGSFLRRRRRFKKKDVSKEKEERAHLKEPPPAASKGAPATPHLADAPKEAEKKVVIKSEAASPALPVITKVETLSPESALQGSPRSAASTPAGSPDGSLPEHHAAAPNGLPGFSVENIMTLRTSPPGGELSPGAGRAGLVVPPLALPYAAAPPAAYGQPCAQGLEAGAAGGYQCSMRAMSLYTGAERPAHMCVPPALDEALSDHPSGPTSPLSALNLAAGQEGALAATGHHHQHHGHHHPQAPPPPPAPQPQPTPQPGAAAAQAASWYLNHSGDLNHLPGHTFAAQQQTFPNVREMFNSHRLGIENSTLGESQVSGNASCQLPYRSTPPLYRHAAPYSYDCTKY

T31808	TARGETID	T31808
T31808	FORMERID	TTDI01387
T31808	UNIPROID	ADAM2_HUMAN; ADAM7_HUMAN
T31808	TARGNAME	A disintegrin and metalloproteinase (ADAM)
T31808	GENENAME	ADAM2; ADAM7
T31808	TARGTYPE	Literature-reported
T31808	SYNONYMS	Disintegrin and metalloproteinase domain-containing protein; ADAM
T31808	FUNCTION	Sperm surface membrane protein that may be involved in sperm-egg plasma membrane adhesion and fusion during fertilization. Could have a direct role in sperm-zona binding or migration of sperm from the uterus into the oviduct. Interactions with egg membrane could be mediated via binding between its disintegrin-like domain to one or more integrins receptors on the egg. This is a non catalytic metalloprotease-like protein. 
T31808	BIOCLASS	Peptidase
T31808	SEQUENCE	MWRVLFLLSGLGGLRMDSNFDSLPVQITVPEKIRSIIKEGIESQASYKIVIEGKPYTVNLMQKNFLPHNFRVYSYSGTGIMKPLDQDFQNFCHYQGYIEGYPKSVVMVSTCTGLRGVLQFENVSYGIEPLESSVGFEHVIYQVKHKKADVSLYNEKDIESRDLSFKLQSVEPQQDFAKYIEMHVIVEKQLYNHMGSDTTVVAQKVFQLIGLTNAIFVSFNITIILSSLELWIDENKIATTGEANELLHTFLRWKTSYLVLRPHDVAFLLVYREKSNYVGATFQGKMCDANYAGGVVLHPRTISLESLAVILAQLLSLSMGITYDDINKCQCSGAVCIMNPEAIHFSGVKIFSNCSFEDFAHFISKQKSQCLHNQPRLDPFFKQQAVCGNAKLEAGEECDCGTEQDCALIGETCCDIATCRFKAGSNCAEGPCCENCLFMSKERMCRPSFEECDLPEYCNGSSASCPENHYVQTGHPCGLNQWICIDGVCMSGDKQCTDTFGKEVEFGPSECYSHLNSKTDVSGNCGISDSGYTQCEADNLQCGKLICKYVGKFLLQIPRATIIYANISGHLCIAVEFASDHADSQKMWIKDGTSCGSNKVCRNQRCVSSSYLGYDCTTDKCNDRGVCNNKKHCHCSASYLPPDCSVQSDLWPGGSIDSGNFPPVAIPARLPERRYIENIYHSKPMRWPFFLFIPFFIIFCVLIAIMVKVNFQRKKWRTEDYSSDEQPESESEPKG

T98158	TARGETID	T98158
T98158	FORMERID	TTDR00021
T98158	UNIPROID	GLPO_STRP1
T98158	TARGNAME	Streptococcus Glycerol-3-phosphate oxidase (Stre-coc glpO)
T98158	GENENAME	Stre-coc glpO
T98158	TARGTYPE	Literature-reported
T98158	SYNONYMS	Glycerol-3-phosphate oxidase; Alpha-glycerophosphate oxidase
T98158	FUNCTION	A FAD-dependent -glycerophosphate oxidase and catalyzes the formation of dihydroxyacetonephosphate. Used in the kinetic assay to study gluconeogenesis in liver and in immobilization studies on pencil graphite (PG) electrode.
T98158	BIOCLASS	Short-chain dehydrogenases reductase
T98158	SEQUENCE	MEFSRETRRLALQKMQERDLDLLIIGGGITGAGVALQAAASGLDTGLIEMQDFAQGTSSRSTKLVHGGLRYLKQFDVEVVSDTVSERAVVQQIAPHIPKPDPMLLPVYDEPGSTFSMFRLKVAMDLYDLLAGVSNTPAANKVLTKEEVLKREPDLKQEGLLGGGVYLDFRNNDARLVIENIKRANRDGALIASHVKAEDFLLDDNGKIIGVKARDLLSDQEIIIKAKLVINTTGPWSDEIRQFSHKGQPIHQMRPTKGVHLVVDRQKLPVSQPVYVDTGLNDGRMVFVLPREEKTYFGTTDTDYTGDLEHPQVTQEDVDYLLGVVNNRFPNANVTIDDIESSWAGLRPLLSGNSASDYNGGNSGKVSDDSFDHLVDTVKAYINHEDSREAVEKAIKQVETSTSEKELDPSAVSRGSSFERDENGLFTLAGGKITDYRKMAEGALTGIIQILKEEFGKSFKLINSKTYPVSGGEINPANVDSEIEAYAQLGTLSGLSMDDARYLANLYGSNAPKVFALTRQLTAAEGLSLAETLSLHYAMDYEMALKPTDYFLRRTNHLLFMRDSLDALIDPVINEMAKHFEWSDQERVAQEDDLRRVIADNDLSALKGHQEG

T35664	TARGETID	T35664
T35664	FORMERID	TTDI03437
T35664	UNIPROID	P2Y13_HUMAN
T35664	TARGNAME	P2Y purinoceptor 13 (P2RY13)
T35664	GENENAME	P2RY13
T35664	TARGTYPE	Literature-reported
T35664	SYNONYMS	P2Y13; GPR94; GPR86; G-protein coupled receptor 94; G-protein coupled receptor 86; FKSG77
T35664	FUNCTION	Receptor for ADP. Coupled to G(i)-proteins. May play a role in hematopoiesis and the immune system.
T35664	PDBSTRUC	2B6U
T35664	SEQUENCE	MTAAIRRQRELSILPKVTLEAMNTTVMQGFNRSERCPRDTRIVQLVFPALYTVVFLTGILLNTLALWVFVHIPSSSTFIIYLKNTLVADLIMTLMLPFKILSDSHLAPWQLRAFVCRFSSVIFYETMYVGIVLLGLIAFDRFLKIIRPLRNIFLKKPVFAKTVSIFIWFFLFFISLPNTILSNKEATPSSVKKCASLKGPLGLKWHQMVNNICQFIFWTVFILMLVFYVVIAKKVYDSYRKSKSKDRKNNKKLEGKVFVVVAVFFVCFAPFHFARVPYTHSQTNNKTDCRLQNQLFIAKETTLFLAATNICMDPLIYIFLCKKFTEKLPCMQGRKTTASSQENHSSQTDNITLG
T35664	DRUGINFO	D08MPL	MRS2211	Investigative
T35664	DRUGINFO	D08WNN	[33P]2MeSADP	Investigative
T35664	DRUGINFO	D0V7WT	MRS2603	Investigative
T35664	DRUGINFO	D01GRB	2MeSAMP	Investigative
T35664	DRUGINFO	D07QYU	PPADS	Investigative
T35664	DRUGINFO	D0BB0O	2MeSADP	Investigative
T35664	DRUGINFO	D0S3WN	ATPgammaS	Investigative
T35664	DRUGINFO	D0U1OJ	2MeSATP	Investigative
T35664	DRUGINFO	D05NWF	adenosine diphosphate	Investigative

T02439	TARGETID	T02439
T02439	FORMERID	TTDI03188
T02439	UNIPROID	E2AK1_HUMAN
T02439	TARGNAME	Eukaryotic translation initiation factor 2-alpha kinase 1 (EIF2AK1)
T02439	GENENAME	EIF2AK1
T02439	TARGTYPE	Literature-reported
T02439	SYNONYMS	PRO1362; KIAA1369; Hemin-sensitive initiation factor 2-alpha kinase; Heme-regulated inhibitor; Heme-regulated eukaryotic initiation factor eIF-2-alpha kinase; HRI
T02439	FUNCTION	Inhibits protein synthesis at the translation initiation level, in response to various stress conditions, including oxidative stress, heme deficiency, osmotic shock and heat shock. Exerts its function through the phosphorylation of EIF2S1 at 'Ser-48' and 'Ser-51', thus preventing its recycling. Binds hemin forming a 1:1 complex through a cysteine thiolate and histidine nitrogenous coordination. This binding occurs with moderate affinity, allowing it to sense the heme concentration within the cell. Thanks to this unique heme-sensing capacity, plays a crucial role to shut off protein synthesis during acute heme-deficient conditions. In red blood cells (RBCs), controls hemoglobin synthesis ensuring a coordinated regulation of the synthesis of its heme and globin moieties. Thus plays an essential protective role for RBC survival in anemias of iron deficiency. Similarly, in hepatocytes, involved in heme-mediated translational control of CYP2B and CYP3A and possibly other hepatic P450 cytochromes. May also contain ER stress during acute heme-deficient conditions (By similarity).
T02439	ECNUMBER	EC 2.7.11.1
T02439	SEQUENCE	MQGGNSGVRKREEEGDGAGAVAAPPAIDFPAEGPDPEYDESDVPAEIQVLKEPLQQPTFPFAVANQLLLVSLLEHLSHVHEPNPLRSRQVFKLLCQTFIKMGLLSSFTCSDEFSSLRLHHNRAITHLMRSAKERVRQDPCEDISRIQKIRSREVALEAQTSRYLNEFEELAILGKGGYGRVYKVRNKLDGQYYAIKKILIKGATKTVCMKVLREVKVLAGLQHPNIVGYHTAWIEHVHVIQPRADRAAIELPSLEVLSDQEEDREQCGVKNDESSSSSIIFAEPTPEKEKRFGESDTENQNNKSVKYTTNLVIRESGELESTLELQENGLAGLSASSIVEQQLPLRRNSHLEESFTSTEESSEENVNFLGQTEAQYHLMLHIQMQLCELSLWDWIVERNKRGREYVDESACPYVMANVATKIFQELVEGVFYIHNMGIVHRDLKPRNIFLHGPDQQVKIGDFGLACTDILQKNTDWTNRNGKRTPTHTSRVGTCLYASPEQLEGSEYDAKSDMYSLGVVLLELFQPFGTEMERAEVLTGLRTGQLPESLRKRCPVQAKYIQHLTRRNSSQRPSAIQLLQSELFQNSGNVNLTLQMKIIEQEKEIAELKKQLNLLSQDKGVRDDGKDGGVG
T02439	DRUGINFO	D02LIR	PMID19854648C27	Investigative

T81482	TARGETID	T81482
T81482	FORMERID	TTDI01353
T81482	UNIPROID	E2AK1_HUMAN
T81482	TARGNAME	Heme-controlled repressor (HCR)
T81482	GENENAME	EIF2AK1
T81482	TARGTYPE	Literature-reported
T81482	SYNONYMS	HCR
T81482	FUNCTION	Inhibits protein synthesis at the translation initiation level, in response to various stress conditions, including oxidative stress, heme deficiency, osmotic shock and heat shock. Exerts its function through the phosphorylation of EIF2S1 at 'Ser-48' and 'Ser-51', thus preventing its recycling. Binds hemin forming a 1:1 complex through a cysteine thiolate and histidine nitrogenous coordination. This binding occurs with moderate affinity, allowing it to sense the heme concentration within the cell. Thanks to this unique heme-sensing capacity, plays a crucial role to shut off protein synthesis during acute heme-deficient conditions. In red blood cells (RBCs), controls hemoglobin synthesis ensuring a coordinated regulation of the synthesis of its heme and globin moieties. Thus plays an essential protective role for RBC survival in anemias of iron deficiency. Similarly, in hepatocytes, involved in heme-mediated translational control of CYP2B and CYP3A and possibly other hepatic P450 cytochromes. May also contain ER stress during acute heme-deficient conditions (By similarity).
T81482	ECNUMBER	EC 2.7.11.1
T81482	SEQUENCE	MQGGNSGVRKREEEGDGAGAVAAPPAIDFPAEGPDPEYDESDVPAEIQVLKEPLQQPTFPFAVANQLLLVSLLEHLSHVHEPNPLRSRQVFKLLCQTFIKMGLLSSFTCSDEFSSLRLHHNRAITHLMRSAKERVRQDPCEDISRIQKIRSREVALEAQTSRYLNEFEELAILGKGGYGRVYKVRNKLDGQYYAIKKILIKGATKTVCMKVLREVKVLAGLQHPNIVGYHTAWIEHVHVIQPRADRAAIELPSLEVLSDQEEDREQCGVKNDESSSSSIIFAEPTPEKEKRFGESDTENQNNKSVKYTTNLVIRESGELESTLELQENGLAGLSASSIVEQQLPLRRNSHLEESFTSTEESSEENVNFLGQTEAQYHLMLHIQMQLCELSLWDWIVERNKRGREYVDESACPYVMANVATKIFQELVEGVFYIHNMGIVHRDLKPRNIFLHGPDQQVKIGDFGLACTDILQKNTDWTNRNGKRTPTHTSRVGTCLYASPEQLEGSEYDAKSDMYSLGVVLLELFQPFGTEMERAEVLTGLRTGQLPESLRKRCPVQAKYIQHLTRRNSSQRPSAIQLLQSELFQNSGNVNLTLQMKIIEQEKEIAELKKQLNLLSQDKGVRDDGKDGGVG

T94532	TARGETID	T94532
T94532	FORMERID	TTDR01150
T94532	UNIPROID	REG4_HUMAN
T94532	TARGNAME	Regenerating islet-derived protein IV (REG4)
T94532	GENENAME	REG4
T94532	TARGTYPE	Literature-reported
T94532	SYNONYMS	Regenerating islet-derived protein 4; Regenerating islet-derived family, member 4; Reg IV; RELP; REGIV; REG-like protein; REG-4; Gastrointestinal secretory protein GISP; Gastrointestinal secretory protein; GISP
T94532	FUNCTION	May be involved in inflammatory and metaplastic responses of the gastrointestinal epithelium. Calcium-independent lectin displaying mannose-binding specificity and able to maintain carbohydrate recognition activity in an acidic environment.
T94532	PDBSTRUC	2KV3
T94532	SEQUENCE	MASRSMRLLLLLSCLAKTGVLGDIIMRPSCAPGWFYHKSNCYGYFRKLRNWSDAELECQSYGNGAHLASILSLKEASTIAEYISGYQRSQPIWIGLHDPQKRQQWQWIDGAMYLYRSWSGKSMGGNKHCAEMSSNNNFLTWSSNECNKRQHFLCKYRP

T15126	TARGETID	T15126
T15126	FORMERID	TTDI02223
T15126	UNIPROID	NUF2_HUMAN
T15126	TARGNAME	Kinetochore protein Nuf2 (NUF2)
T15126	GENENAME	NUF2
T15126	TARGTYPE	Literature-reported
T15126	SYNONYMS	hsNuf2; hNuf2R; hNuf2; NUF2R; Cell division cycleassociated protein 1; Cell division cycle-associated protein 1; CDCA1
T15126	FUNCTION	Required for kinetochore integrity and the organization of stable microtubule binding sites in the outer plate of the kinetochore. The NDC80 complex synergistically enhances the affinity of the SKA1 complex for microtubules and may allow the NDC80 complex to track depolymerizing microtubules. Acts as a component of the essential kinetochore-associated NDC80 complex, which is required for chromosome segregation and spindle checkpoint activity.
T15126	PDBSTRUC	3IZ0; 2VE7
T15126	SEQUENCE	METLSFPRYNVAEIVIHIRNKILTGADGKNLTKNDLYPNPKPEVLHMIYMRALQIVYGIRLEHFYMMPVNSEVMYPHLMEGFLPFSNLVTHLDSFLPICRVNDFETADILCPKAKRTSRFLSGIINFIHFREACRETYMEFLWQYKSSADKMQQLNAAHQEALMKLERLDSVPVEEQEEFKQLSDGIQELQQSLNQDFHQKTIVLQEGNSQKKSNISEKTKRLNELKLSVVSLKEIQESLKTKIVDSPEKLKNYKEKMKDTVQKLKNARQEVVEKYEIYGDSVDCLPSCQLEVQLYQKKIQDLSDNREKLASILKESLNLEDQIESDESELKKLKTEENSFKRLMIVKKEKLATAQFKINKKHEDVKQYKRTVIEDCNKVQEKRGAVYERVTTINQEIQKIKLGIQQLKDAAEREKLKSQEIFLNLKTALEKYHDGIEKAAEDSYAKIDEKTAELKRKMFKMST

T89793	TARGETID	T89793
T89793	FORMERID	TTDI00208
T89793	UNIPROID	TBL1R_HUMAN
T89793	TARGNAME	Transducin beta-like 1X-related protein 1 (TBL1XR1)
T89793	GENENAME	TBL1XR1
T89793	TARGTYPE	Literature-reported
T89793	SYNONYMS	Transducin betalike 1Xrelated protein 1; TBLR1; TBL1related protein 1; TBL1-related protein 1; Nuclear receptor corepressor/HDAC3 complexsubunit TBLR1; Nuclear receptor corepressor/HDAC3 complex subunit TBLR1; IRA1; Fboxlike/WD repeatcontaining protein TBL1XR1; F-box-like/WD repeat-containing protein TBL1XR1
T89793	FUNCTION	Plays an essential role in transcription activation mediated by nuclear receptors. Probably acts as integral component of the N-Cor corepressor complex that mediates the recruitment of the 19S proteasome complex, leading to the subsequent proteasomal degradation of N-Cor complex, thereby allowing cofactor exchange, and transcription activation. F-box-like protein involved in the recruitment of the ubiquitin/19S proteasome complex to nuclear receptor-regulated transcription units.
T89793	PDBSTRUC	4LG9
T89793	SEQUENCE	MSISSDEVNFLVYRYLQESGFSHSAFTFGIESHISQSNINGALVPPAALISIIQKGLQYVEAEVSINEDGTLFDGRPIESLSLIDAVMPDVVQTRQQAYRDKLAQQQAAAAAAAAAAASQQGSAKNGENTANGEENGAHTIANNHTDMMEVDGDVEIPPNKAVVLRGHESEVFICAWNPVSDLLASGSGDSTARIWNLSENSTSGSTQLVLRHCIREGGQDVPSNKDVTSLDWNSEGTLLATGSYDGFARIWTKDGNLASTLGQHKGPIFALKWNKKGNFILSAGVDKTTIIWDAHTGEAKQQFPFHSAPALDVDWQSNNTFASCSTDMCIHVCKLGQDRPIKTFQGHTNEVNAIKWDPTGNLLASCSDDMTLKIWSMKQDNCVHDLQAHNKEIYTIKWSPTGPGTNNPNANLMLASASFDSTVRLWDVDRGICIHTLTKHQEPVYSVAFSPDGRYLASGSFDKCVHIWNTQTGALVHSYRGTGGIFEVCWNAAGDKVGASASDGSVCVLDLRK

T95661	TARGETID	T95661
T95661	UNIPROID	TM6S2_HUMAN
T95661	TARGNAME	Transmembrane 6 superfamily member 2 (TM6SF2)
T95661	GENENAME	TM6SF2
T95661	TARGTYPE	Literature-reported
T95661	SYNONYMS	KIAA1926
T95661	FUNCTION	Regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content (PubMed:24531328, PubMed:24927523). May function as sterol isomerase (PubMed:25566323).
T95661	BIOCLASS	TM6SF family
T95661	SEQUENCE	MDIPPLAGKIAALSLSALPVSYALNHVSALSHPLWVALMSALILGLLFVAVYSLSHGEVSYDPLYAVFAVFAFTSVVDLIIALQEDSYVVGFMEFYTKEGEPYLRTAHGVFICYWDGTVHYLLYLAMAGAICRRKRYRNFGLYWLGSFAMSILVFLTGNILGKYSSEIRPAFFLTIPYLLVPCWAGMKVFSQPRALTRCTANMVQEEQRKGLLQRPADLALVIYLILAGFFTLFRGLVVLDCPTDACFVYIYQYEPYLRDPVAYPKVQMLMYMFYVLPFCGLAAYALTFPGCSWLPDWALVFAGGIGQAQFSHMGASMHLRTPFTYRVPEDTWGCFFVCNLLYALGPHLLAYRCLQWPAFFHQPPPSDPLALHKKQH

T86910	TARGETID	T86910
T86910	FORMERID	TTDI03404
T86910	UNIPROID	NLRP1_HUMAN
T86910	TARGNAME	NLR pyrin domain containing 1 (NLRP1)
T86910	GENENAME	NLRP1
T86910	TARGTYPE	Literature-reported
T86910	SYNONYMS	Nucleotide-binding domain and caspase recruitment domain; NACHT, LRR and PYD domains-containing protein 1; NAC; KIAA0926; Death effector filament-forming ced-4-like apoptosis protein; DEFCAP; Caspase recruitment domain-containing protein 7; CARD7
T86910	FUNCTION	As the sensor component of the NLRP1 inflammasome, plays a crucial role in innate immunity and inflammation. In response to pathogens and other damage-associated signals, initiates the formation of the inflammasome polymeric complex, made of NLRP1, CASP1, and possibly PYCARD. Recruitment of proCASP1 to the inflammasome promotes its activation and CASP1-catalyzed IL1B and IL18 maturation and secretion in the extracellular milieu. Activation of NLRP1 inflammasome is also required for HMGB1 secretion. The active cytokines and HMGB1 stimulate inflammatory responses. Inflammasomes can also induce pyroptosis, an inflammatory form of programmed cell death. May be activated by muramyl dipeptide (MDP), a fragment of bacterial peptidoglycan, in a NOD2-dependent manner. Contrary to its mouse ortholog, not activated by Bacillus anthracis lethal toxin. It is unclear whether isoform 2 is involved in inflammasome formation. It is not cleaved within the FIIND domain, does not assemble into specks, nor promote IL1B release. However, in an vitro cell-free system, it has been shown to be activated by MDP. Binds ATP.
T86910	PDBSTRUC	5Y3S; 4IM6; 4IFP; 3KAT; 1PN5
T86910	SEQUENCE	MAGGAWGRLACYLEFLKKEELKEFQLLLANKAHSRSSSGETPAQPEKTSGMEVASYLVAQYGEQRAWDLALHTWEQMGLRSLCAQAQEGAGHSPSFPYSPSEPHLGSPSQPTSTAVLMPWIHELPAGCTQGSERRVLRQLPDTSGRRWREISASLLYQALPSSPDHESPSQESPNAPTSTAVLGSWGSPPQPSLAPREQEAPGTQWPLDETSGIYYTEIREREREKSEKGRPPWAAVVGTPPQAHTSLQPHHHPWEPSVRESLCSTWPWKNEDFNQKFTQLLLLQRPHPRSQDPLVKRSWPDYVEENRGHLIEIRDLFGPGLDTQEPRIVILQGAAGIGKSTLARQVKEAWGRGQLYGDRFQHVFYFSCRELAQSKVVSLAELIGKDGTATPAPIRQILSRPERLLFILDGVDEPGWVLQEPSSELCLHWSQPQPADALLGSLLGKTILPEASFLITARTTALQNLIPSLEQARWVEVLGFSESSRKEYFYRYFTDERQAIRAFRLVKSNKELWALCLVPWVSWLACTCLMQQMKRKEKLTLTSKTTTTLCLHYLAQALQAQPLGPQLRDLCSLAAEGIWQKKTLFSPDDLRKHGLDGAIISTFLKMGILQEHPIPLSYSFIHLCFQEFFAAMSYVLEDEKGRGKHSNCIIDLEKTLEAYGIHGLFGASTTRFLLGLLSDEGEREMENIFHCRLSQGRNLMQWVPSLQLLLQPHSLESLHCLYETRNKTFLTQVMAHFEEMGMCVETDMELLVCTFCIKFSRHVKKLQLIEGRQHRSTWSPTMVVLFRWVPVTDAYWQILFSVLKVTRNLKELDLSGNSLSHSAVKSLCKTLRRPRCLLETLRLAGCGLTAEDCKDLAFGLRANQTLTELDLSFNVLTDAGAKHLCQRLRQPSCKLQRLQLVSCGLTSDCCQDLASVLSASPSLKELDLQQNNLDDVGVRLLCEGLRHPACKLIRLGLDQTTLSDEMRQELRALEQEKPQLLIFSRRKPSVMTPTEGLDTGEMSNSTSSLKRQRLGSERAASHVAQANLKLLDVSKIFPIAEIAEESSPEVVPVELLCVPSPASQGDLHTKPLGTDDDFWGPTGPVATEVVDKEKNLYRVHFPVAGSYRWPNTGLCFVMREAVTVEIEFCVWDQFLGEINPQHSWMVAGPLLDIKAEPGAVEAVHLPHFVALQGGHVDTSLFQMAHFKEEGMLLEKPARVELHHIVLENPSFSPLGVLLKMIHNALRFIPVTSVVLLYHRVHPEEVTFHLYLIPSDCSIRKAIDDLEMKFQFVRIHKPPPLTPLYMGCRYTVSGSGSGMLEILPKELELCYRSPGEDQLFSEFYVGHLGSGIRLQVKDKKDETLVWEALVKPGDLMPATTLIPPARIAVPSPLDAPQLLHFVDQYREQLIARVTSVEVVLDKLHGQVLSQEQYERVLAENTRPSQMRKLFSLSQSWDRKCKDGLYQALKETHPHLIMELWEKGSKKGLLPLSS
T86910	DRUGINFO	D05UGC	muramyl dipeptide	Investigative

T90464	TARGETID	T90464
T90464	FORMERID	TTDI02149
T90464	UNIPROID	PDGFD_HUMAN
T90464	TARGNAME	Platelet-derived growth factor D (PDGFD)
T90464	GENENAME	PDGFD
T90464	TARGTYPE	Literature-reported
T90464	SYNONYMS	Spinal cordderived growth factor B; SCDGFB; Plateletderived growth factor D, receptorbinding form; PDGFD receptorbinding form; PDGFD latent form; PDGFD; Irisexpressed growth factor
T90464	FUNCTION	Growth factor that plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis. Potent mitogen for cells of mesenchymal origin. Plays an important role in wound healing. Induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis. Can initiate events that lead to a mesangial proliferative glomerulonephritis, including influx of monocytes and macrophages and production of extracellular matrix.
T90464	BIOCLASS	Growth factor
T90464	SEQUENCE	MHRLIFVYTLICANFCSCRDTSATPQSASIKALRNANLRRDESNHLTDLYRRDETIQVKGNGYVQSPRFPNSYPRNLLLTWRLHSQENTRIQLVFDNQFGLEEAENDICRYDFVEVEDISETSTIIRGRWCGHKEVPPRIKSRTNQIKITFKSDDYFVAKPGFKIYYSLLEDFQPAAASETNWESVTSSISGVSYNSPSVTDPTLIADALDKKIAEFDTVEDLLKYFNPESWQEDLENMYLDTPRYRGRSYHDRKSKVDLDRLNDDAKRYSCTPRNYSVNIREELKLANVVFFPRCLLVQRCGGNCGCGTVNWRSCTCNSGKTVKKYHEVLQFEPGHIKRRGRAKTMALVDIQLDHHERCDCICSSRPPR

T13039	TARGETID	T13039
T13039	FORMERID	TTDI00082
T13039	UNIPROID	IF5A2_HUMAN
T13039	TARGNAME	Eukaryotic initiation factor 5A2 (EIF5A2)
T13039	GENENAME	EIF5A2
T13039	TARGTYPE	Literature-reported
T13039	SYNONYMS	eIF5A2; eIF-5A2; eIF-5A-2; Eukaryotic translation initiation factor 5A-2; Eukaryotic initiation factor 5A isoform 2
T13039	FUNCTION	Has an important function at the level of mRNA turnover, probably acting downstream of decapping. Involved in actin dynamics and cell cycle progression, mRNA decay and probably in a pathway involved in stress response and maintenance of cell wall integrity. Functions as a regulator of apoptosis. Mediates effects of polyamines on neuronal process extension and survival. May play an important role in brain development and function, and in skeletal muscle stem cell differentiation. mRNA-binding protein involved in translation elongation.
T13039	BIOCLASS	Eukaryotic nuclear pore complex
T13039	SEQUENCE	MADEIDFTTGDAGASSTYPMQCSALRKNGFVVLKGRPCKIVEMSTSKTGKHGHAKVHLVGIDIFTGKKYEDICPSTHNMDVPNIKRNDYQLICIQDGYLSLLTETGEVREDLKLPEGELGKEIEGKYNAGEDVQVSVMCAMSEEYAVAIKPCK

T55005	TARGETID	T55005
T55005	FORMERID	TTDI03414
T55005	UNIPROID	NUAK2_HUMAN
T55005	TARGNAME	NUAK family SNF1-like kinase 2 (NUAK2)
T55005	GENENAME	NUAK2
T55005	TARGTYPE	Literature-reported
T55005	SYNONYMS	SNF1/AMP kinase-related kinase; SNARK; Omphalocele kinase 2; OMPHK2
T55005	FUNCTION	Stress-activated kinase involved in tolerance to glucose starvation. Induces cell-cell detachment by increasing F-actin conversion to G-actin. Expression is induced by CD95 or TNF-alpha, via NF-kappa-B. Protects cells from CD95-mediated apoptosis and is required for the increased motility and invasiveness of CD95-activated tumor cells. Able to phosphorylate 'Ser-464' of LATS1.
T55005	ECNUMBER	EC 2.7.11.1
T55005	SEQUENCE	MESLVFARRSGPTPSAAELARPLAEGLIKSPKPLMKKQAVKRHHHKHNLRHRYEFLETLGKGTYGKVKKARESSGRLVAIKSIRKDKIKDEQDLMHIRREIEIMSSLNHPHIIAIHEVFENSSKIVIVMEYASRGDLYDYISERQQLSEREARHFFRQIVSAVHYCHQNRVVHRDLKLENILLDANGNIKIADFGLSNLYHQGKFLQTFCGSPLYASPEIVNGKPYTGPEVDSWSLGVLLYILVHGTMPFDGHDHKILVKQISNGAYREPPKPSDACGLIRWLLMVNPTRRATLEDVASHWWVNWGYATRVGEQEAPHEGGHPGSDSARASMADWLRRSSRPLLENGAKVCSFFKQHAPGGGSTTPGLERQHSLKKSRKENDMAQSLHSDTADDTAHRPGKSNLKLPKGILKKKVSASAEGVQEDPPELSPIPASPGQAAPLLPKKGILKKPRQRESGYYSSPEPSESGELLDAGDVFVSGDPKEQKPPQASGLLLHRKGILKLNGKFSQTALELAAPTTFGSLDELAPPRPLARASRPSGAVSEDSILSSESFDQLDLPERLPEPPLRGCVSVDNLTGLEEPPSEGPGSCLRRWRQDPLGDSCFSLTDCQEVTATYRQALRVCSKLT
T55005	DRUGINFO	D00HLW	WZ4003	Investigative

T85823	TARGETID	T85823
T85823	FORMERID	TTDR00390
T85823	UNIPROID	SVIL_HUMAN
T85823	TARGNAME	Supervillin (SVIL)
T85823	GENENAME	SVIL
T85823	TARGTYPE	Literature-reported
T85823	SYNONYMS	p205/p250; Archvillin
T85823	FUNCTION	Isoform 1: Forms a high-affinity link between the actin cytoskeleton and the membrane. Is among the first costameric proteins to assemble during myogenesis and it contributes to myogenic membrane structure and differentiation. Appears to be involved in myosin II assembly. May modulate myosin II regulation through MLCK during cell spreading, an initial step in cell migration. May play a role in invadopodial function.
T85823	PDBSTRUC	2K6N; 2K6M
T85823	SEQUENCE	MKRKERIARRLEGIENDTQPILLQSCTGLVTHRLLEEDTPRYMRASDPASPHIGRSNEEEETSDSSLEKQTRSKYCTETSGVHGDSPYGSGTMDTHSLESKAERIARYKAERRRQLAEKYGLTLDPEADSEYLSRYTKSRKEPDAVEKRGGKSDKQEESSRDASSLYPGTETMGLRTCAGESKDYALHVGDGSSDPEVLLNIENQRRGQELSATRQAHDLSPAAESSSTFSFSGRDSSFTEVPRSPKHAHSSSLQQAASRSPSFGDPQLSPEARPSTGKPKHEWFLQKDSEGDTPSLINWPSRVKVREKLVKEESARNSPELASESVTQRRHQPAPVHYVSFQSEHSAFDRVPSKAAGSTRQPIRGYVQPADTGHTAKLVTPETPENASECSWVASATQNVPKPPSLTVLEGDGRDSPVLHVCESKAEEEEGEGEGEEKEEDVCFTEALEQSKKTLLALEGDGLVRSPEDPSRNEDFGKPAVSTVTLEHQKELENVAQPPQAPHQPTERTGRSEMVLYIQSEPVSQDAKPTGHNREASKKRKVRTRSLSDFTGPPQLQALKYKDPASRRELELPSSKTEGPYGEISMLDTKVSVAQLRSAFLASANACRRPELKSRVERSAEGPGLPTGVERERGSRKPRRYFSPGESRKTSERFRTQPITSAERKESDRCTSHSETPTVDDEEKVDERAKLSVAAKRLLFREMEKSFDEQNVPKRRSRNTAVEQRLRRLQDRSLTQPITTEEVVIAATEPIPASCSGGTHPVMARLPSPTVARSAVQPARLQASAHQKALAKDQTNEGKELAEQGEPDSSTLSLAEKLALFNKLSQPVSKAISTRNRIDTRQRRMNARYQTQPVTLGEVEQVQSGKLIPFSPAVNTSVSTVASTVAPMYAGDLRTKPPLDHNASATDYKFSSSIENSDSPVRSILKSQAWQPLVEGSENKGMLREYGETESKRALTGRDSGMEKYGSFEEAEASYPILNRAREGDSHKESKYAVPRRGSLERANPPITHLGDEPKEFSMAKMNAQGNLDLRDRLPFEEKVEVENVMKRKFSLRAAEFGEPTSEQTGTAAGKTIAQTTAPVSWKPQDSSEQPQEKLCKNPCAMFAAGEIKTPTGEGLLDSPSKTMSIKERLALLKKSGEEDWRNRLSRRQEGGKAPASSLHTQEAGRSLIKKRVTESRESQMTIEERKQLITVREEAWKTRGRGAANDSTQFTVAGRMVKKGLASPTAITPVASPICGKTRGTTPVSKPLEDIEARPDMQLESDLKLDRLETFLRRLNNKVGGMHETVLTVTGKSVKEVMKPDDDETFAKFYRSVDYNMPRSPVEMDEDFDVIFDPYAPKLTSSVAEHKRAVRPKRRVQASKNPLKMLAAREDLLQEYTEQRLNVAFMESKRMKVEKMSSNSNFSEVTLAGLASKENFSNVSLRSVNLTEQNSNNSAVPYKRLMLLQIKGRRHVQTRLVEPRASALNSGDCFLLLSPHCCFLWVGEFANVIEKAKASELATLIQTKRELGCRATYIQTIEEGINTHTHAAKDFWKLLGGQTSYQSAGDPKEDELYEAAIIETNCIYRLMDDKLVPDDDYWGKIPKCSLLQPKEVLVFDFGSEVYVWHGKEVTLAQRKIAFQLAKHLWNGTFDYENCDINPLDPGECNPLIPRKGQGRPDWAIFGRLTEHNETILFKEKFLDWTELKRSNEKNPGELAQHKEDPRTDVKAYDVTRMVSMPQTTAGTILDGVNVGRGYGLVEGHDRRQFEITSVSVDVWHILEFDYSRLPKQSIGQFHEGDAYVVKWKFMVSTAVGSRQKGEHSVRAAGKEKCVYFFWQGRHSTVSEKGTSALMTVELDEERGAQVQVLQGKEPPCFLQCFQGGMVVHSGRREEEEENVQSEWRLYCVRGEVPVEGNLLEVACHCSSLRSRTSMVVLNVNKALIYLWHGCKAQAHTKEVGRTAANKIKEQCPLEAGLHSSSKVTIHECDEGSEPLGFWDALGRRDRKAYDCMLQDPGSFNFAPRLFILSSSSGDFAATEFVYPARAPSVVSSMPFLQEDLYSAPQPALFLVDNHHEVYLWQGWWPIENKITGSARIRWASDRKSAMETVLQYCKGKNLKKPAPKSYLIHAGLEPLTFTNMFPSWEHREDIAEITEMDTEVSNQITLVEDVLAKLCKTIYPLADLLARPLPEGVDPLKLEIYLTDEDFEFALDMTRDEYNALPAWKQVNLKKAKGLF

T31060	TARGETID	T31060
T31060	FORMERID	TTDR00832
T31060	UNIPROID	O51E2_HUMAN
T31060	TARGNAME	Olfactory receptor 51E2 (OR51E2)
T31060	GENENAME	OR51E2
T31060	TARGTYPE	Literature-reported
T31060	SYNONYMS	Prostate specific G-protein coupled receptor; PSGR; OR51E2; HPRAJ
T31060	FUNCTION	Probable G protein-coupled receptor that is activated bythe short chain fatty acids (SCFA) acetate and propionate. In response to SCFA, may positively regulate renin secretion and increase blood pressure (PubMed:23401498). May also be activated by steroidhormones and regulate cell proliferation (PubMed:19389702). May also function as an olfactory receptor being activated by beta-ionone (PubMed:19389702).
T31060	BIOCLASS	GPCR rhodopsin
T31060	SEQUENCE	MSSCNFTHATFVLIGIPGLEKAHFWVGFPLLSMYVVAMFGNCIVVFIVRTERSLHAPMYLFLCMLAAIDLALSTSTMPKILALFWFDSREISFEACLTQMFFIHALSAIESTILLAMAFDRYVAICHPLRHAAVLNNTVTAQIGIVAVVRGSLFFFPLPLLIKRLAFCHSNVLSHSYCVHQDVMKLAYADTLPNVVYGLTAILLVMGVDVMFISLSYFLIIRTVLQLPSKSERAKAFGTCVSHIGVVLAFYVPLIGLSVVHRFGNSLHPIVRVVMGDIYLLLPPVINPIIYGAKTKQIRTRVLAMFKISCDKDLQAVGGK

T03023	TARGETID	T03023
T03023	FORMERID	TTDI03559
T03023	UNIPROID	SRMS_HUMAN
T03023	TARGNAME	Tyrosine-protein kinase Srms (SRMS)
T03023	GENENAME	SRMS
T03023	TARGTYPE	Literature-reported
T03023	SYNONYMS	C20orf148
T03023	FUNCTION	Non-receptor tyrosine-protein kinase which phosphorylates DOK1 on tyrosine residues. Also phosphorylates KHDRBS1/SAM68 and VIM on tyrosine residues. Phosphorylation of KHDRBS1 is EGF-dependent.
T03023	ECNUMBER	EC 2.7.10.2
T03023	SEQUENCE	MEPFLRRRLAFLSFFWDKIWPAGGEPDHGTPGSLDPNTDPVPTLPAEPCSPFPQLFLALYDFTARCGGELSVRRGDRLCALEEGGGYIFARRLSGQPSAGLVPITHVAKASPETLSDQPWYFSGVSRTQAQQLLLSPPNEPGAFLIRPSESSLGGYSLSVRAQAKVCHYRVSMAADGSLYLQKGRLFPGLEELLTYYKANWKLIQNPLLQPCMPQKAPRQDVWERPHSEFALGRKLGEGYFGEVWEGLWLGSLPVAIKVIKSANMKLTDLAKEIQTLKGLRHERLIRLHAVCSGGEPVYIVTELMRKGNLQAFLGTPEGRALRLPPLLGFACQVAEGMSYLEEQRVVHRDLAARNVLVDDGLACKVADFGLARLLKDDIYSPSSSSKIPVKWTAPEAANYRVFSQKSDVWSFGVLLHEVFTYGQCPYEGMTNHETLQQIMRGYRLPRPAACPAEVYVLMLECWRSSPEERPSFATLREKLHAIHRCHP
T03023	DRUGINFO	D09ADW	PMID21802293C66	Investigative

T47731	TARGETID	T47731
T47731	FORMERID	TTDI00046
T47731	UNIPROID	CHM4B_HUMAN
T47731	TARGNAME	Charged multivesicular body protein 4B (CHMP4B)
T47731	GENENAME	CHMP4B
T47731	TARGTYPE	Literature-reported
T47731	SYNONYMS	hVps322; hVps32-2; hSnf72; hSnf7-2; Vps322; Vps32-2; Vacuolar protein sortingassociated protein 322; Vacuolar protein sorting-associated protein 32-2; SNF72; SNF7-2; SNF7 homolog associated with Alix 1; SHAX1; Chromatinmodifying protein 4b; Chromatin-modifying protein 4b; CHMP4b; C20orf178
T47731	FUNCTION	MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis. Together with SPAST, the ESCRT-III complex promotes nuclear envelope sealing and mitotic spindle disassembly during late anaphase. Plays a role in the endosomal sorting pathway. ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4. When overexpressed, membrane-assembled circular arrays of CHMP4B filaments can promote or stabilize negative curvature and outward budding. CHMP4A/B/C are required for the exosomal release of SDCBP, CD63 and syndecan. Probable core component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs.
T47731	PDBSTRUC	5MK2; 4ABM; 3UM3; 3C3Q
T47731	SEQUENCE	MSVFGKLFGAGGGKAGKGGPTPQEAIQRLRDTEEMLSKKQEFLEKKIEQELTAAKKHGTKNKRAALQALKRKKRYEKQLAQIDGTLSTIEFQREALENANTNTEVLKNMGYAAKAMKAAHDNMDIDKVDELMQDIADQQELAEEISTAISKPVGFGEEFDEDELMAELEELEQEELDKNLLEISGPETVPLPNVPSIALPSKPAKKKEEEDDDMKELENWAGSM

T57818	TARGETID	T57818
T57818	FORMERID	TTDI03043
T57818	UNIPROID	AMPB_HUMAN
T57818	TARGNAME	Arginyl aminopeptidase (RNPEP)
T57818	GENENAME	RNPEP
T57818	TARGTYPE	Literature-reported
T57818	SYNONYMS	Arginine aminopeptidase; Aminopeptidase B; APB; AP-B
T57818	FUNCTION	Exopeptidase which selectively removes arginine and/or lysine residues from the N-terminus of several peptide substrates including Arg(0)-Leu-enkephalin, Arg(0)-Met-enkephalin and Arg(-1)-Lys(0)-somatostatin-14. Can hydrolyze leukotriene A4 (LTA-4) into leukotriene B4 (LTB-4) (By similarity).
T57818	ECNUMBER	EC 3.4.11.6
T57818	SEQUENCE	MASGEHSPGSGAARRPLHSAQAVDVASASNFRAFELLHLHLDLRAEFGPPGPGAGSRGLSGTAVLDLRCLEPEGAAELRLDSHPCLEVTAAALRRERPGSEEPPAEPVSFYTQPFSHYGQALCVSFPQPCRAAERLQVLLTYRVGEGPGVCWLAPEQTAGKKKPFVYTQGQAVLNRAFFPCFDTPAVKYKYSALIEVPDGFTAVMSASTWEKRGPNKFFFQMCQPIPSYLIALAIGDLVSAEVGPRSRVWAEPCLIDAAKEEYNGVIEEFLATGEKLFGPYVWGRYDLLFMPPSFPFGGMENPCLTFVTPCLLAGDRSLADVIIHEISHSWFGNLVTNANWGEFWLNEGFTMYAQRRISTILFGAAYTCLEAATGRALLRQHMDITGEENPLNKLRVKIEPGVDPDDTYNETPYEKGFCFVSYLAHLVGDQDQFDSFLKAYVHEFKFRSILADDFLDFYLEYFPELKKKRVDIIPGFEFDRWLNTPGWPPYLPDLSPGDSLMKPAEELAQLWAAEELDMKAIEAVAISPWKTYQLVYFLDKILQKSPLPPGNVKKLGDTYPSISNARNAELRLRWGQIVLKNDHQEDFWKVKEFLHNQGKQKYTLPLYHAMMGGSEVAQTLAKETFASTASQLHSNVVNYVQQIVAPKGS
T57818	DRUGINFO	D02BLC	Lys-thiol	Investigative

T40698	TARGETID	T40698
T40698	FORMERID	TTDI00130
T40698	UNIPROID	FA83D_HUMAN
T40698	TARGNAME	Spindle protein CHICA (FAM83D)
T40698	GENENAME	FAM83D
T40698	TARGTYPE	Literature-reported
T40698	SYNONYMS	Protein FAM83D; FAM83D
T40698	FUNCTION	Probable proto-oncogene that regulates cell proliferation, growth, migration and epithelial to mesenchymal transition. Through the degradation of FBXW7, may act indirectly on the expression and downstream signaling of MTOR, JUN and MYC. May play also a role in cell proliferation through activation of the ERK1/ERK2 signaling cascade. May also be important for proper chromosome congression and alignment during mitosis through its interaction with KIF22.
T40698	PDBSTRUC	5E0M; 5E0L
T40698	SEQUENCE	MALLSEGLDEVPAACLSPCGPPNPTELFSESRRLALEELVAGGPEAFAAFLRRERLARFLNPDEVHAILRAAERPGEEGAAAAAAAEDSFGSSHDCSSGTYFPEQSDLEPPLLELGWPAFYQGAYRGATRVETHFQPRGAGEGGPYGCKDALRQQLRSAREVIAVVMDVFTDIDIFRDLQEICRKQGVAVYILLDQALLSQFLDMCMDLKVHPEQEKLMTVRTITGNIYYARSGTKIIGKVHEKFTLIDGIRVATGSYSFTWTDGKLNSSNLVILSGQVVEHFDLEFRILYAQSKPISPKLLSHFQSSNKFDHLTNRKPQSKELTLGNLLRMRLARLSSTPRKADLDPEMPAEGKAERKPHDCESSTVSEEDYFSSHRDELQSRKAIDAATQTEPGEEMPGLSVSEVGTQTSITTACAGTQTAVITRIASSQTTIWSRSTTTQTDMDENILFPRGTQSTEGSPVSKMSVSRSSSLKSSSSVSSQGSVASSTGSPASIRTTDFHNPGYPKYLGTPHLELYLSDSLRNLNKERQFHFAGIRSRLNHMLAMLSRRTLFTENHLGLHSGNFSRVNLLAVRDVALYPSYQ

T49593	TARGETID	T49593
T49593	FORMERID	TTDI01397
T49593	UNIPROID	LN28A_HUMAN
T49593	TARGNAME	Zinc finger CCHC domain-containing 1 (Lin-28A)
T49593	GENENAME	LIN28A
T49593	TARGTYPE	Literature-reported
T49593	SYNONYMS	Zinc finger CCHC domain-containing protein 1; ZCCHC1; Protein lin-28 homolog A; Lin-28A; LIN28; CSDD1
T49593	FUNCTION	RNA-binding protein that inhibits processing of pre-let-7 miRNAs and regulates translation of mRNAs that control developmental timing, pluripotency and metabolism. Seems to recognize a common structural G-quartet (G4) feature in its miRNA and mRNA targets (Probable). 'Translational enhancer' that drives specific mRNAs to polysomes and increases the efficiency of protein synthesis. Its association with the translational machinery and target mRNAs results in an increased number of initiation events per molecule of mRNA and, indirectly, in mRNA stabilization. Binds IGF2 mRNA, MYOD1 mRNA, ARBP/36B4 ribosomal protein mRNA and its own mRNA. Essential for skeletal muscle differentiation program through the translational up-regulation of IGF2 expression. Suppressor of microRNA (miRNA) biogenesis, including that of let-7, miR107, miR-143 and miR-200c. Specifically binds the miRNA precursors (pre-miRNAs), recognizing an 5'-GGAG-3' motif found in pre-miRNA terminal loop, and recruits TUT4 AND tut7 uridylyltransferaseS. This results in the terminal uridylation of target pre-miRNAs. Uridylated pre-miRNAs fail to be processed by Dicer and undergo degradation. The repression of let-7 expression is required for normal development and contributes to maintain the pluripotent state by preventing let-7-mediated differentiation of embryonic stem cells. Localized to the periendoplasmic reticulum area, binds to a large number of spliced mRNAs and inhibits the translation of mRNAs destined for the ER, reducing the synthesis of transmembrane proteins, ER or Golgi lumen proteins, and secretory proteins. Binds to and enhances the translation of mRNAs for several metabolic enzymes, such as PFKP, PDHA1 or SDHA, increasing glycolysis and oxidative phosphorylation. Which, with the let-7 repression may enhance tissue repair in adult tissue (By similarity).
T49593	PDBSTRUC	5UDZ; 2LI8; 2CQF
T49593	SEQUENCE	MGSVSNQQFAGGCAKAAEEAPEEAPEDAARAADEPQLLHGAGICKWFNVRMGFGFLSMTARAGVALDPPVDVFVHQSKLHMEGFRSLKEGEAVEFTFKKSAKGLESIRVTGPGGVFCIGSERRPKGKSMQKRRSKGDRCYNCGGLDHHAKECKLPPQPKKCHFCQSISHMVASCPLKAQQGPSAQGKPTYFREEEEEIHSPTLLPEAQN

T55667	TARGETID	T55667
T55667	FORMERID	TTDI00084
T55667	UNIPROID	PKHA5_HUMAN
T55667	TARGNAME	Pleckstrin homology domain-containing A5 (PLEKHA5)
T55667	GENENAME	PLEKHA5
T55667	TARGTYPE	Literature-reported
T55667	SYNONYMS	Pleckstrin homology domain-containing family A member 5; Phosphoinositol 3-phosphate-binding protein 2; PH domain-containing family A member 5; PEPP2; PEPP-2; KIAA1686
T55667	FUNCTION	Involved in the mechanism of CNS homing of metastatic disease. Functions as a regulator of brain metastasis in melanoma. 
T55667	PDBSTRUC	2DKP
T55667	SEQUENCE	MAADLNLEWISLPRSWTYGITRGGRVFFINEEAKSTTWLHPVTGEAVVTGHRRQSTDLPTGWEEAYTFEGARYYINHNERKVTCKHPVTGQPSQDNCIFVVNEQTVATMTSEEKKERPISMINEASNYNVTSDYAVHPMSPVGRTSRASKKVHNFGKRSNSIKRNPNAPVVRRGWLYKQDSTGMKLWKKRWFVLSDLCLFYYRDEKEEGILGSILLPSFQIALLTSEDHINRKYAFKAAHPNMRTYYFCTDTGKEMELWMKAMLDAALVQTEPVKRVDKITSENAPTKETNNIPNHRVLIKPEIQNNQKNKEMSKIEEKKALEAEKYGFQKDGQDRPLTKINSVKLNSLPSEYESGSACPAQTVHYRPINLSSSENKIVNVSLADLRGGNRPNTGPLYTEADRVIQRTNSMQQLEQWIKIQKGRGHEEETRGVISYQTLPRNMPSHRAQIMARYPEGYRTLPRNSKTRPESICSVTPSTHDKTLGPGAEEKRRSMRDDTMWQLYEWQQRQFYNKQSTLPRHSTLSSPKTMVNISDQTMHSIPTSPSHGSIAAYQGYSPQRTYRSEVSSPIQRGDVTIDRRHRAHHPKHVYVPDRRSVPAGLTLQSVSPQSLQGKTLSQDEGRGTLYKYRPEEVDIDAKLSRLCEQDKVVHALEEKLQQLHKEKYTLEQALLSASQEIEMHADNPAAIQTVVLQRDDLQNGLLSTCRELSRATAELERAWREYDKLEYDVTVTRNQMQEQLDHLGEVQTESAGIQRAQIQKELWRIQDVMEGLSKHKQQRGTTEIGMIGSKPFSTVKYKNEGPDYRLYKSEPELTTVAEVDESNGEEKSEPVSEIETSVVKGSHFPVGVVPPRAKSPTPESSTIASYVTLRKTKKMMDLRTERPRSAVEQLCLAESTRPRMTVEEQMERIRRHQQACLREKKKGLNVIGASDQSPLQSPSNLRDNPFRTTQTRRRDDKELDTAIRENDVKPDHETPATEIVQLKETEPQNVDFSKELKKTENISYEMLFEPEPNGVNSVEMMDKERNKDKMPEDVTFSPQDETQTANHKPEEHPEENTKNSVDEQEETVISYESTPEVSRGNQTMAVKSLSPSPESSASPVPSTQPQLTEGSHFMCV

T20296	TARGETID	T20296
T20296	FORMERID	TTDR01289
T20296	UNIPROID	EMAL4_HUMAN
T20296	TARGNAME	Echinoderm microtubule-associated protein-like 4 (EMAP-4)
T20296	GENENAME	EML4
T20296	TARGTYPE	Literature-reported
T20296	SYNONYMS	Ropp 120; Restrictedly overexpressed proliferation-associated protein; EMAPL4; EMAP-4; C2orf2
T20296	FUNCTION	May modify the assembly dynamics of microtubules, such that microtubules are slightly longer, but more dynamic.
T20296	PDBSTRUC	4CGC
T20296	SEQUENCE	MDGFAGSLDDSISAASTSDVQDRLSALESRVQQQEDEITVLKAALADVLRRLAISEDHVASVKKSVSSKGQPSPRAVIPMSCITNGSGANRKPSHTSAVSIAGKETLSSAAKSGTEKKKEKPQGQREKKEESHSNDQSPQIRASPSPQPSSQPLQIHRQTPESKNATPTKSIKRPSPAEKSHNSWENSDDSRNKLSKIPSTPKLIPKVTKTADKHKDVIINQEGEYIKMFMRGRPITMFIPSDVDNYDDIRTELPPEKLKLEWAYGYRGKDCRANVYLLPTGKIVYFIASVVVLFNYEERTQRHYLGHTDCVKCLAIHPDKIRIATGQIAGVDKDGRPLQPHVRVWDSVTLSTLQIIGLGTFERGVGCLDFSKADSGVHLCIIDDSNEHMLTVWDWQKKAKGAEIKTTNEVVLAVEFHPTDANTIITCGKSHIFFWTWSGNSLTRKQGIFGKYEKPKFVQCLAFLGNGDVLTGDSGGVMLIWSKTTVEPTPGKGPKGVYQISKQIKAHDGSVFTLCQMRNGMLLTGGGKDRKIILWDHDLNPEREIEVPDQYGTIRAVAEGKADQFLVGTSRNFILRGTFNDGFQIEVQGHTDELWGLATHPFKDLLLTCAQDRQVCLWNSMEHRLEWTRLVDEPGHCADFHPSGTVVAIGTHSGRWFVLDAETRDLVSIHTDGNEQLSVMRYSIDGTFLAVGSHDNFIYLYVVSENGRKYSRYGRCTGHSSYITHLDWSPDNKYIMSNSGDYEILYWDIPNGCKLIRNRSDCKDIDWTTYTCVLGFQVFGVWPEGSDGTDINALVRSHNRKVIAVADDFCKVHLFQYPCSKAKAPSHKYSAHSSHVTNVSFTHNDSHLISTGGKDMSIIQWKLVEKLSLPQNETVADTTLTKAPVSSTESVIQSNTPTPPPSQPLNETAEEESRISSSPTLLENSLEQTVEPSEDHSEEESEEGSGDLGEPLYEEPCNEISKEQAKATLLEDQQDPSPSS

T78992	TARGETID	T78992
T78992	FORMERID	TTDR01325
T78992	UNIPROID	NEK6_HUMAN
T78992	TARGNAME	Serine/threonine-protein kinase Nek6 (NEK6)
T78992	GENENAME	NEK6
T78992	TARGTYPE	Literature-reported
T78992	SYNONYMS	Protein kinase SID6-1512; NimA-related protein kinase 6; Never in mitosis A-related kinase 6
T78992	FUNCTION	Protein kinase which plays an important role in mitotic cell cycle progression. Required for chromosome segregation at metaphase-anaphase transition, robust mitotic spindle formation and cytokinesis. Phosphorylates ATF4, CIR1, PTN, RAD26L, RBBP6, RPS7, RPS6KB1, TRIP4, STAT3 and histones H1 and H3. Phosphorylates KIF11 to promote mitotic spindle formation. Involved in G2/M phase cell cycle arrest induced by DNA damage. Inhibition of activity results in apoptosis. May contribute to tumorigenesis by suppressing p53/TP53-induced cancer cell senescence.
T78992	ECNUMBER	EC 2.7.11.1
T78992	SEQUENCE	MAGQPGHMPHGGSSNNLCHTLGPVHPPDPQRHPNTLSFRCSLADFQIEKKIGRGQFSEVYKATCLLDRKTVALKKVQIFEMMDAKARQDCVKEIGLLKQLNHPNIIKYLDSFIEDNELNIVLELADAGDLSQMIKYFKKQKRLIPERTVWKYFVQLCSAVEHMHSRRVMHRDIKPANVFITATGVVKLGDLGLGRFFSSETTAAHSLVGTPYYMSPERIHENGYNFKSDIWSLGCLLYEMAALQSPFYGDKMNLFSLCQKIEQCDYPPLPGEHYSEKLRELVSMCICPDPHQRPDIGYVHQVAKQMHIWMSST

T69184	TARGETID	T69184
T69184	FORMERID	TTDI03594
T69184	UNIPROID	TRPM3_HUMAN
T69184	TARGNAME	Long transient receptor potential channel 3 (TRPM3)
T69184	GENENAME	TRPM3
T69184	TARGTYPE	Literature-reported
T69184	SYNONYMS	Transient receptor potential cation channel subfamily M member 3; Melastatin-2; MLSN2; LTrpC3; LTrpC-3; KIAA1616
T69184	FUNCTION	Its activity is increased by reduction in extracellular osmolarity, by store depletion and muscarinic receptor activation. Calcium channel mediating constitutive calcium ion entry.
T69184	BIOCLASS	Transient receptor potential catioin channel
T69184	SEQUENCE	MPEPWGTVYFLGIAQVFSFLFSWWNLEGVMNQADAPRPLNWTIRKLCHAAFLPSVRLLKAQKSWIERAFYKRECVHIIPSTKDPHRCCCGRLIGQHVGLTPSISVLQNEKNESRLSRNDIQSEKWSISKHTQLSPTDAFGTIEFQGGGHSNKAMYVRVSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAWIFTGGVNTGVIRHVGDALKDHASKSRGKICTIGIAPWGIVENQEDLIGRDVVRPYQTMSNPMSKLTVLNSMHSHFILADNGTTGKYGAEVKLRRQLEKHISLQKINTRCLPFFSLDSRLFYSFWGSCQLDSVGIGQGVPVVALIVEGGPNVISIVLEYLRDTPPVPVVVCDGSGRASDILAFGHKYSEEGGLINESLRDQLLVTIQKTFTYTRTQAQHLFIILMECMKKKELITVFRMGSEGHQDIDLAILTALLKGANASAPDQLSLALAWNRVDIARSQIFIYGQQWPVGSLEQAMLDALVLDRVDFVKLLIENGVSMHRFLTISRLEELYNTRHGPSNTLYHLVRDVKKGNLPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRFRTLYHNLFGPKRPKALKLLGMEDDIPLRRGRKTTKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMALFFWQHGEEAMAKALVACKLCKAMAHEASENDMVDDISQELNHNSRDFGQLAVELLDQSYKQDEQLAMKLLTYELKNWSNATCLQLAVAAKHRDFIAHTCSQMLLTDMWMGRLRMRKNSGLKVILGILLPPSILSLEFKNKDDMPYMSQAQEIHLQEKEAEEPEKPTKEKEEEDMELTAMLGRNNGESSRKKDEEEVQSKHRLIPLGRKIYEFYNAPIVKFWFYTLAYIGYLMLFNYIVLVKMERWPSTQEWIVISYIFTLGIEKMREILMSEPGKLLQKVKVWLQEYWNVTDLIAILLFSVGMILRLQDQPFRSDGRVIYCVNIIYWYIRLLDIFGVNKYLGPYVMMIGKMMIDMMYFVIIMLVVLMSFGVARQAILFPNEEPSWKLAKNIFYMPYWMIYGEVFADQIDPPCGQNETREDGKIIQLPPCKTGAWIVPAIMACYLLVANILLVNLLIAVFNNTFFEVKSISNQVWKFQRYQLIMTFHERPVLPPPLIIFSHMTMIFQHLCCRWRKHESDPDERDYGLKLFITDDELKKVHDFEEQCIEEYFREKDDRFNSSNDERIRVTSERVENMSMRLEEVNEREHSMKASLQTVDIRLAQLEDLIGRMATALERLTGLERAESNKIRSRTSSDCTDAAYIVRQSSFNSQEGNTFKLQESIDPAGEETMSPTSPTLMPRMRSHSFYSVNMKDKGGIEKLESIFKERSLSLHRATSSHSVAKEPKAPAAPANTLAIVPDSRRPSSCIDIYVSAMDELHCDIDPLDNSVNILGLGEPSFSTPVPSTAPSSSAYATLAPTDRPPSRSIDFEDITSMDTRSFSSDYTHLPECQNPWDSEPPMYHTIERSKSSRYLATTPFLLEEAPIVKSHSFMFSPSRSYYANFGVPVKTAEYTSITDCIDTRCVNAPQAIADRAAFPGGLGDKVEDLTCCHPEREAELSHPSSDSEENEAKGRRATIAISSQEGDNSERTLSNNITVPKIERANSYSAEEPSAPYAHTRKSFSISDKLDRQRNTASLRNPFQRSKSSKPEGRGDSLSMRRLSRTSAFQSFESKHN
T69184	DRUGINFO	D06ATM	sphinganine	Investigative
T69184	DRUGINFO	D0A5RA	epipregnanolone sulphate	Investigative
T69184	DRUGINFO	D0OS7U	NN-dimethyl-D-erythrosphingosine	Investigative
T69184	DRUGINFO	D00HCI	2-APB	Investigative

T10918	TARGETID	T10918
T10918	FORMERID	TTDI03592
T10918	UNIPROID	TRPC7_HUMAN
T10918	TARGNAME	Short transient receptor potential channel 7 (TRPC7)
T10918	GENENAME	TRPC7
T10918	TARGTYPE	Literature-reported
T10918	SYNONYMS	hTRP7; Transient receptor protein 7; TRP7; TRP-7
T10918	FUNCTION	Thought to form a receptor-activated non-selective calcium permeant cation channel. Probably is operated by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases or G-protein coupled receptors. Activated by diacylglycerol (DAG) (By similarity). May also be activated by intracellular calcium store depletion.
T10918	BIOCLASS	Transient receptor potential catioin channel
T10918	SEQUENCE	MLRNSTFKNMQRRHTTLREKGRRQAIRGPAYMFNEKGTSLTPEEERFLDSAEYGNIPVVRKMLEESKTLNFNCVDYMGQNALQLAVGNEHLEVTELLLKKENLARVGDALLLAISKGYVRIVEAILNHPAFAQGQRLTLSPLEQELRDDDFYAYDEDGTRFSHDITPIILAAHCQEYEIVHILLLKGARIERPHDYFCKCNECTEKQRKDSFSHSRSRMNAYKGLASAAYLSLSSEDPVLTALELSNELARLANIETEFKNDYRKLSMQCKDFVVGVLDLCRDTEEVEAILNGDVNFQVWSDHHRPSLSRIKLAIKYEVKKFVAHPNCQQQLLTMWYENLSGLRQQSIAVKFLAVFGVSIGLPFLAIAYWIAPCSKLGRTLRSPFMKFVAHAVSFTIFLGLLVVNASDRFEGVKTLPNETFTDYPKQIFRVKTTQFSWTEMLIMKWVLGMIWSECKEIWEEGPREYVLHLWNLLDFGMLSIFVASFTARFMAFLKATEAQLYVDQHVQDDTLHNVSLPPEVAYFTYARDKWWPSDPQIISEGLYAIAVVLSFSRIAYILPANESFGPLQISLGRTVKDIFKFMVIFIMVFVAFMIGMFNLYSYYRGAKYNPAFTTVEESFKTLFWSIFGLSEVISVVLKYDHKFIENIGYVLYGVYNVTMVVVLLNMLIAMINNSYQEIEEDADVEWKFARAKLWLSYFDEGRTLPAPFNLVPSPKSFYYLIMRIKMCLIKLCKSKAKSCENDLEMGMLNSKFKKTRYQAGMRNSENLTANNTLSKPTRYQKIMKRLIKRYVLKAQVDRENDEVNEGELKEIKQDISSLRYELLEEKSQATGELADLIQQLSEKFGKNLNKDHLRVNKGKDI
T10918	DRUGINFO	D0T6DU	OAG	Investigative
T10918	DRUGINFO	D00HCI	2-APB	Investigative

T98320	TARGETID	T98320
T98320	UNIPROID	Q9I1N2_PSEAE
T98320	TARGNAME	Pseudomonas Aeruginosa Psl (Pseudo pslG)
T98320	GENENAME	Pseudo pslG
T98320	TARGTYPE	Literature-reported
T98320	SYNONYMS	Pseudo PslG
T98320	FUNCTION	Involved in the synthesis of a key biofilm matrix exopolysaccharide Psl in Pseudomonas aeruginosa. Prevents biofilm formation and disassembles existing biofilms within minutes at nanomolar concentrations when supplied exogenously.
T98320	PDBSTRUC	5BXA; 5BX9; 4ZN2
T98320	SEQUENCE	MARKGLYLGGSALLLAVVLLLVFWGRPADAEIQVLKAPRAVVWKDFLGVNAQFLWFSPERYNKQIDRLQDLGLEWVRLDLHWDRLETAEDQYQLASLDQLVKDLEARQLKSVFYLVGSARFITTAPFYSPFQDQYPPRDPEVFARRMAMLSQRYPSVAAWQVWNEPNLIGFWRPKADPEGYAKLLQASTIALRMVDPEKPVVSAGMAFFSEMPDGRTMFDALGHLGVESLGTIATYHPYTQLPEGNYPWNLDFVSHANQINRALRNAGVPAIWSTEWGWSAYKGPKELQDIIGVEGQADYVLRRLALMSALDYDRIFLFTLSDLDQRASVRDRDYGLLDLDANPKPVYLALQRFLKVTGPKLRPADPPVTEDLPDGSFSIGWTREDGRNVWLFWSARGGNVRLPKLKEATLHDPLSGKVTPLSGSDGLEVPVKSSLQMLVWE

T32306	TARGETID	T32306
T32306	FORMERID	TTDR01016
T32306	UNIPROID	Q9NG20_PLABE
T32306	TARGNAME	Plasmodium Subtilisin-like protease 2 (Malaria sub2)
T32306	GENENAME	Malaria sub2
T32306	TARGTYPE	Literature-reported
T32306	SYNONYMS	Subtilisin-like protease 2
T32306	FUNCTION	Essential for red cell invasion.
T32306	BIOCLASS	Protease
T32306	SEQUENCE	MLRTFYVLSLMLIEFILHNGQYNKHICSKNSKKYNFVGKKHRILVSDIEDRENHIEGIADIYKPIFNIYEISAEFHKKKNIADKKKKRKYGINQSIEKRRIAEENERRQLNKTEGTQFLELSNRYPNIGKQNSQQNKVNEINNQNAASNSNDNIGNDNIGNDNIGNDEDDDEDDDEDLIEGRKDNLEEDDLIEKNDSNLPRGKMHEKEEKNKNINTTPGNESSNKNVNDKKKNGISLKDKIDNKQNNGGLKEKGNNLDDNIKTYTFDHYKIITNSDNILNDIKVDASDISKLSINSINIEYNEKNKAEYTHQRHIVLSNNGNRRYKIFLMTKNPKFTKTEDIEEPGMSFIQTETGENEDEKEDEENYLNENLYSGFGTIDYENDYSKKKKKIESEHASGLNDKISNSQNIEKSGSHENEKYNHGYIEKIRSFFSFLSMPSSKKDDSIGSEKKTEERSNTDSKAKLNKKTNDMAKKNNSNAFLSVDKIIDQYLLNLKNKNMKEQELIFIFHGNLDLHSKEMKTVINEANAKFTKYINMHFKDVKNIRYDISSPINFVCFFIPIIFDMSNLKILKEALIILNNELKDYIDNWNFSNTYVAFDNNYENEDIDNVMNKLNENMEKYIKKPKKLYNIKYSFLRKIWGLKSIISLSKNQDKKDAEIEEKILSALPKELKEYSTWNLSFIRVFNAWLLSGYGNKNVKICVIDSGIDKNHIDLANNIYTPKYSDRYEMTDELFDFMVKNPIDTSGHGTHVSGIAAASANSLGMVGVAPNINLISLRFIDGDNYGGSFHVIKAINICILNKSPIINASWGSRNYDTNMFLAIERLKYTFKGKGTVFIAAAGNENKNNDLYPIYPASYKLQNVYSVGSINKFLQISPFSNYGANSVHILAPGHHIYSTTPMNTYKMNTGTSMAAPHVSGVAGLIYSVCYKQGFIPDADEVLEIITRTSIKIVSKDKKTIHNSLINAEAAVLTTLLGGLWIQMDCHFAKFYLNENKQKSVPIVFSAYKDGVYESDIIIGIQPEDANSKEYGEIVIPIKILTNPKLKDFSLSPRVGKKIRIDENESNDDILSYICENALYNLYEHDNSFLISSLILFFIGIILIVLASIVFFLKHHQSKQRDGEKYMHQKMVDRTYNVKYNFKDSGTDGIKRINTLDDNINNHRNTQRFTIVQNEDNMYVLKKKSSIQAKYEPRNELVKRSLVKRPIVKHADINVNFSNVDVLYEPKNNSSE

T93909	TARGETID	T93909
T93909	UNIPROID	PALMD_HUMAN
T93909	TARGNAME	Palmdelphin (PALMD)
T93909	GENENAME	PALMD
T93909	TARGTYPE	Literature-reported
T93909	SYNONYMS	Paralemmin-like protein; PALML; C1orf11
T93909	FUNCTION	cytoplasm.
T93909	BIOCLASS	Paralemmin family
T93909	SEQUENCE	MEEAELVKGRLQAITDKRKIQEEISQKRLKIEEDKLKHQHLKKKALREKWLLDGISSGKEQEEMKKQNQQDQHQIQVLEQSILRLEKEIQDLEKAELQISTKEEAILKKLKSIERTTEDIIRSVKVEREERAEESIEDIYANIPDLPKSYIPSRLRKEINEEKEDDEQNRKALYAMEIKVEKDLKTGESTVLSSIPLPSDDFKGTGIKVYDDGQKSVYAVSSNHSAAYNGTDGLAPVEVEELLRQASERNSKSPTEYHEPVYANPFYRPTTPQRETVTPGPNFQERIKIKTNGLGIGVNESIHNMGNGLSEERGNNFNHISPIPPVPHPRSVIQQAEEKLHTPQKRLMTPWEESNVMQDKDAPSPKPRLSPRETIFGKSEHQNSSPTCQEDEEDVRYNIVHSLPPDINDTEPVTMIFMGYQQAEDSEEDKKFLTGYDGIIHAELVVIDDEEEEDEGEAEKPSYHPIAPHSQVYQPAKPTPLPRKRSEASPHENTNHKSPHKNSISLKEQEESLGSPVHHSPFDAQTTGDGTEDPSLTALRMRMAKLGKKVI

T89780	TARGETID	T89780
T89780	FORMERID	TTDR00452
T89780	UNIPROID	TREM1_HUMAN
T89780	TARGNAME	Triggering receptor expressed on monocytes 1 (TREM1)
T89780	GENENAME	Trem1
T89780	TARGTYPE	Literature-reported
T89780	SYNONYMS	Trem1; TREM-1
T89780	FUNCTION	Stimulates neutrophil and monocyte-mediated inflammatory responses. Triggers release of pro-inflammatory chemokines and cytokines, as well as increased surface expression of cell activation markers. Amplifier of inflammatory responses that are triggered by bacterial and fungal infections and is a crucial mediator of septic shock.
T89780	PDBSTRUC	1SMO; 1Q8M
T89780	SEQUENCE	MRKTRLWGLLWMLFVSELRAATKLTEEKYELKEGQTLDVKCDYTLEKFASSQKAWQIIRDGEMPKTLACTERPSKNSHPVQVGRIILEDYHDHGLLRVRMVNLQVEDSGLYQCVIYQPPKEPHMLFDRIRLVVTKGFSGTPGSNENSTQNVYKIPPTTTKALCPLYTSPRTVTQAPPKSTADVSTPDSEINLTNVTDIIRVPVFNIVILLAGGFLSKSLVFSVLFAVTLRSFVP
T89780	DRUGINFO	D0K2BZ	D-tartaric acid	Investigative

T57613	TARGETID	T57613
T57613	FORMERID	TTDR01198
T57613	UNIPROID	KCNK9_HUMAN
T57613	TARGNAME	TWIK-related acid-sensitive potassium channel 3 (TASK3)
T57613	GENENAME	KCNK9
T57613	TARGTYPE	Literature-reported
T57613	SYNONYMS	Two pore potassium channel KT3.2; TWIK-related acid-sensitive K+ channel 3; KCNK9; Acid-sensitive potassium channel protein TASK-3
T57613	FUNCTION	pH-dependent, voltage-insensitive, background potassium channel protein.
T57613	PDBSTRUC	6GHP; 4FR3; 3UX0; 3SPR; 3SP5
T57613	SEQUENCE	MKRQNVRTLSLIVCTFTYLLVGAAVFDALESDHEMREEEKLKAEEIRIKGKYNISSEDYRQLELVILQSEPHRAGVQWKFAGSFYFAITVITTIGYGHAAPGTDAGKAFCMFYAVLGIPLTLVMFQSLGERMNTFVRYLLKRIKKCCGMRNTDVSMENMVTVGFFSCMGTLCIGAAAFSQCEEWSFFHAYYYCFITLTTIGFGDYVALQTKGALQKKPLYVAFSFMYILVGLTVIGAFLNLVVLRFLTMNSEDERRDAEERASLAGNRNSMVIHIPEEPRPSRPRYKADVPDLQSVCSCTCYRSQDYGGRSVAPQNSFSAKLAPHYFHSISYKIEEISPSTLKNSLFPSPISSISPGLHSFTDHQRLMKRRKSV

T84706	TARGETID	T84706
T84706	FORMERID	TTDI02534
T84706	UNIPROID	CD320_HUMAN
T84706	TARGNAME	Transcobalamin receptor (CD320)
T84706	GENENAME	CD320
T84706	TARGTYPE	Literature-reported
T84706	SYNONYMS	UNQ198/PRO224; TCblR; FDCsignaling molecule 8D6; FDCSM8D6; FDC-signaling molecule 8D6; FDC-SM-8D6; CD320 antigen; 8D6A; 8D6 antigen
T84706	FUNCTION	Plays an important role in cobalamin uptake. Plasma membrane protein that is expressed on follicular dendritic cells (FDC) and mediates interaction with germinal center B cells. Functions as costimulator to promote B cell responses to antigenic stimuli; promotes B cell differentiation and proliferation. Germinal center-B (GC-B) cells differentiate into memory B-cells and plasma cells (PC) through interaction with T-cells and follicular dendritic cells (FDC). CD320 augments the proliferation of PC precursors generated by IL-10. Receptor for transcobalamin saturated with cobalamin (TCbl).
T84706	PDBSTRUC	4ZRQ; 4ZRP
T84706	SEQUENCE	MSGGWMAQVGAWRTGALGLALLLLLGLGLGLEAAASPLSTPTSAQAAGPSSGSCPPTKFQCRTSGLCVPLTWRCDRDLDCSDGSDEEECRIEPCTQKGQCPPPPGLPCPCTGVSDCSGGTDKKLRNCSRLACLAGELRCTLSDDCIPLTWRCDGHPDCPDSSDELGCGTNEILPEGDATTMGPPVTLESVTSLRNATTMGPPVTLESVPSVGNATSSSAGDQSGSPTAYGVIAAAAVLSASLVTATLLLLSWLRAQERLRPLGLLVAMKESLLLSEQKTSLP

T75419	TARGETID	T75419
T75419	FORMERID	TTDR01107
T75419	UNIPROID	FANCF_HUMAN
T75419	TARGNAME	Fanconi anemia group F protein (FANCF)
T75419	GENENAME	FANCF
T75419	TARGTYPE	Literature-reported
T75419	SYNONYMS	Protein FACF
T75419	FUNCTION	May be implicated in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability. DNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function.
T75419	PDBSTRUC	2IQC
T75419	SEQUENCE	MESLLQHLDRFSELLAVSSTTYVSTWDPATVRRALQWARYLRHIHRRFGRHGPIRTALERRLHNQWRQEGGFGRGPVPGLANFQALGHCDVLLSLRLLENRALGDAARYHLVQQLFPGPGVRDADEETLQESLARLARRRSAVHMLRFNGYRENPNLQEDSLMKTQAELLLERLQEVGKAEAERPARFLSSLWERLPQNNFLKVIAVALLQPPLSRRPQEELEPGIHKSPGEGSQVLVHWLLGNSEVFAAFCRALPAGLLTLVTSRHPALSPVYLGLLTDWGQRLHYDLQKGIWVGTESQDVPWEELHNRFQSLCQAPPPLKDKVLTALETCKAQDGDFEVPGLSIWTDLLLALRSGAFRKRQVLGLSAGLSSV

T14196	TARGETID	T14196
T14196	FORMERID	TTDI00214
T14196	UNIPROID	RIC8A_HUMAN
T14196	TARGNAME	Synembryn-A (RIC8A)
T14196	GENENAME	RIC8A
T14196	TARGTYPE	Literature-reported
T14196	SYNONYMS	Protein Ric-8A
T14196	FUNCTION	Able to activate GNAI1, GNAO1 and GNAQ, but not GNAS by exchanging bound GDP for free GTP. Involved in regulation of microtubule pulling forces during mitotic movement of chromosomes by stimulating G(i)-alpha protein, possibly leading to release G(i)-alpha-GTP and NuMA proteins from the NuMA-GPSM2-G(i)-alpha-GDP complex. Also acts as an activator for G(q)-alpha (GNAQ) protein by enhancing the G(q)-coupled receptor-mediated ERK activation. Guanine nucleotide exchange factor (GEF), which can activate some, but not all, G-alpha proteins.
T14196	BIOCLASS	Synembryn
T14196	SEQUENCE	MEPRAVAEAVETGEEDVIMEALRSYNQEHSQSFTFDDAQQEDRKRLAELLVSVLEQGLPPSHRVIWLQSVRILSRDRNCLDPFTSRQSLQALACYADISVSEGSVPESADMDVVLESLKCLCNLVLSSPVAQMLAAEARLVVKLTERVGLYRERSFPHDVQFFDLRLLFLLTALRTDVRQQLFQELKGVRLLTDTLELTLGVTPEGNPPPTLLPSQETERAMEILKVLFNITLDSIKGEVDEEDAALYRHLGTLLRHCVMIATAGDRTEEFHGHAVNLLGNLPLKCLDVLLTLEPHGDSTEFMGVNMDVIRALLIFLEKRLHKTHRLKESVAPVLSVLTECARMHRPARKFLKAQVLPPLRDVRTRPEVGEMLRNKLVRLMTHLDTDVKRVAAEFLFVLCSESVPRFIKYTGYGNAAGLLAARGLMAGGRPEGQYSEDEDTDTDEYKEAKASINPVTGRVEEKPPNPMEGMTEEQKEHEAMKLVTMFDKLSRNRVIQPMGMSPRGHLTSLQDAMCETMEQQLSSDPDSDPD

T54646	TARGETID	T54646
T54646	FORMERID	TTDR01118
T54646	UNIPROID	TF7L2_HUMAN
T54646	TARGNAME	Transcription factor 7-like 2 (TCF7L2)
T54646	GENENAME	TCF7L2
T54646	TARGTYPE	Literature-reported
T54646	SYNONYMS	TCF4; TCF-4; T-cell-specific transcription factor 4; T-cell transcription factor-4; T-cell factor 4; HTCF-4; HMG box transcription factor 4
T54646	FUNCTION	Acts as repressor in the absence of CTNNB1, and as activator in its presence. Activates transcription from promoters with several copies of the Tcf motif 5'-CCTTTGATC-3' in the presence of CTNNB1. TLE1, TLE2, TLE3 and TLE4 repress transactivation mediated by TCF7L2/TCF4 and CTNNB1. Expression of dominant-negative mutants results in cell-cycle arrest in G1. Necessary for the maintenance of the epithelial stem-cell compartment of the small intestine. Participates in the Wnt signaling pathway and modulates MYC expression by binding to its promoter in a sequence-specific manner.
T54646	PDBSTRUC	2GL7; 1JPW; 1JDH
T54646	SEQUENCE	MPQLNGGGGDDLGANDELISFKDEGEQEEKSSENSSAERDLADVKSSLVNESETNQNSSSDSEAERRPPPRSESFRDKSRESLEEAAKRQDGGLFKGPPYPGYPFIMIPDLTSPYLPNGSLSPTARTLHFQSGSTHYSAYKTIEHQIAVQYLQMKWPLLDVQAGSLQSRQALKDARSPSPAHIVSNKVPVVQHPHHVHPLTPLITYSNEHFTPGNPPPHLPADVDPKTGIPRPPHPPDISPYYPLSPGTVGQIPHPLGWLVPQQGQPVYPITTGGFRHPYPTALTVNASMSRFPPHMVPPHHTLHTTGIPHPAIVTPTVKQESSQSDVGSLHSSKHQDSKKEEEKKKPHIKKPLNAFMLYMKEMRAKVVAECTLKESAAINQILGRRWHALSREEQAKYYELARKERQLHMQLYPGWSARDNYGKKKKRKRDKQPGETNEHSECFLNPCLSLPPITDLSAPKKCRARFGLDQQNNWCGPCRRKKKCVRYIQGEGSCLSPPSSDGSLLDSPPPSPNLLGSPPRDAKSQTEQTQPLSLSLKPDPLAHLSMMPPPPALLLAEATHKASALCPNGALDLPPAALQPAAPSSSIAQPSTSSLHSHSSLAGTQPQPLSLVTKSLE

T72236	TARGETID	T72236
T72236	FORMERID	TTDNC00605
T72236	UNIPROID	RTN4_HUMAN
T72236	TARGNAME	Neurite outgrowth inhibitor NOGO-A (RTN4)
T72236	GENENAME	RTN4
T72236	TARGTYPE	Literature-reported
T72236	SYNONYMS	Reticulon-5; RTN-x; Nogo protein; Neuroendocrine-specific protein C homolog; Neuroendocrine-specific protein; Neurite outgrowth inhibitor; NSP; NOGO; KIAA0886; Foocen
T72236	FUNCTION	Required to induce the formation and stabilization of endoplasmic reticulum (ER) tubules. They regulate membrane morphogenesis in the ER by promoting tubular ER production. They influence nuclear envelope expansion, nuclear pore complex formation and proper localization of inner nuclear membrane proteins. However each isoform have specific functions mainly depending on their tissue expression specificities (Probable).
T72236	PDBSTRUC	2JV5; 2G31
T72236	SEQUENCE	MEDLDQSPLVSSSDSPPRPQPAFKYQFVREPEDEEEEEEEEEEDEDEDLEELEVLERKPAAGLSAAPVPTAPAAGAPLMDFGNDFVPPAPRGPLPAAPPVAPERQPSWDPSPVSSTVPAPSPLSAAAVSPSKLPEDDEPPARPPPPPPASVSPQAEPVWTPPAPAPAAPPSTPAAPKRRGSSGSVDETLFALPAASEPVIRSSAENMDLKEQPGNTISAGQEDFPSVLLETAASLPSLSPLSAASFKEHEYLGNLSTVLPTEGTLQENVSEASKEVSEKAKTLLIDRDLTEFSELEYSEMGSSFSVSPKAESAVIVANPREEIIVKNKDEEEKLVSNNILHNQQELPTALTKLVKEDEVVSSEKAKDSFNEKRVAVEAPMREEYADFKPFERVWEVKDSKEDSDMLAAGGKIESNLESKVDKKCFADSLEQTNHEKDSESSNDDTSFPSTPEGIKDRSGAYITCAPFNPAATESIATNIFPLLGDPTSENKTDEKKIEEKKAQIVTEKNTSTKTSNPFLVAAQDSETDYVTTDNLTKVTEEVVANMPEGLTPDLVQEACESELNEVTGTKIAYETKMDLVQTSEVMQESLYPAAQLCPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASVIQPSSSPLEASSVNYESIKHEPENPPPYEEAMSVSLKKVSGIKEEIKEPENINAALQETEAPYISIACDLIKETKLSAEPAPDFSDYSEMAKVEQPVPDHSELVEDSSPDSEPVDLFSDDSIPDVPQKQDETVMLVKESLTETSFESMIEYENKEKLSALPPEGGKPYLESFKLSLDNTKDTLLPDEVSTLSKKEKIPLQMEELSTAVYSNDDLFISKEAQIRETETFSDSSPIEIIDEFPTLISSKTDSFSKLAREYTDLEVSHKSEIANAPDGAGSLPCTELPHDLSLKNIQPKVEEKISFSDDFSKNGSATSKVLLLPPDVSALATQAEIESIVKPKVLVKEAEKKLPSDTEKEDRSPSAIFSAELSKTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLKRKAE

T78150	TARGETID	T78150
T78150	FORMERID	TTDR01113
T78150	UNIPROID	DBLOH_HUMAN
T78150	TARGNAME	Direct IAP-binding protein with low pI (DIABLO)
T78150	GENENAME	DIABLO
T78150	TARGTYPE	Literature-reported
T78150	SYNONYMS	Smac protein; Smac; Second mitochondria-derived activator of caspase; Direct IAP binding protein with low pI; Diablo homolog, mitochondrial
T78150	FUNCTION	Acts by opposing the inhibitory activity of inhibitor of apoptosis proteins (IAP). Inhibits the activity of BIRC6/bruce by inhibiting its binding to caspases. Isoform 3 attenuates the stability and apoptosis-inhibiting activity of XIAP/BIRC4 by promoting XIAP/BIRC4 ubiquitination and degradation through the ubiquitin-proteasome pathway. Isoform 3 also disrupts XIAP/BIRC4 interacting with processed caspase-9 and promotes caspase-3 activation. Isoform 1 is defective in the capacity to down-regulate the XIAP/BIRC4 abundance. Promotes apoptosis by activating caspases in the cytochrome c/Apaf-1/caspase-9 pathway.
T78150	PDBSTRUC	4TX5; 3UIJ; 3UIH; 3D9U; 1XB1
T78150	SEQUENCE	MAALKSWLSRSVTSFFRYRQCLCVPVVANFKKRCFSELIRPWHKTVTIGFGVTLCAVPIAQKSEPHSLSSEALMRRAVSLVTDSTSTFLSQTTYALIEAITEYTKAVYTLTSLYRQYTSLLGKMNSEEEDEVWQVIIGARAEMTSKHQEYLKLETTWMTAVGLSEMAAEAAYQTGADQASITARNHIQLVKLQVEEVHQLSRKAETKLAEAQIEELRQKTQEEGEERAESEQEAYLRED

T59510	TARGETID	T59510
T59510	UNIPROID	PDGFC_HUMAN
T59510	TARGNAME	Platelet-derived growth factor C (PDGFC)
T59510	GENENAME	PDGFC
T59510	TARGTYPE	Literature-reported
T59510	SYNONYMS	VEGF-E; UNQ174/PRO200; Spinal cord-derived growth factor; SCDGF; PDGF-C; Fallotein
T59510	FUNCTION	Growth factor that plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis. Potent mitogen and chemoattractant for cells of mesenchymal origin. Required for normal skeleton formation during embryonic development, especially for normal development of the craniofacial skeleton and for normal development of the palate. Required for normal skin morphogenesis during embryonic development. Plays an important role in wound healing, where it appears to be involved in three stages: inflammation, proliferation and remodeling. Plays an important role in angiogenesis and blood vessel development. Involved in fibrotic processes, in which transformation of interstitial fibroblasts into myofibroblasts plus collagen deposition occurs. The CUB domain has mitogenic activity in coronary artery smooth muscle cells, suggesting a role beyond the maintenance of the latency of the PDGF domain. In the nucleus, PDGFC seems to have additional function.
T59510	BIOCLASS	Growth factor
T59510	SEQUENCE	MSLFGLLLLTSALAGQRQGTQAESNLSSKFQFSSNKEQNGVQDPQHERIITVSTNGSIHSPRFPHTYPRNTVLVWRLVAVEENVWIQLTFDERFGLEDPEDDICKYDFVEVEEPSDGTILGRWCGSGTVPGKQISKGNQIRIRFVSDEYFPSEPGFCIHYNIVMPQFTEAVSPSVLPPSALPLDLLNNAITAFSTLEDLIRYLEPERWQLDLEDLYRPTWQLLGKAFVFGRKSRVVDLNLLTEEVRLYSCTPRNFSVSIREELKRTDTIFWPGCLLVKRCGGNCACCLHNCNECQCVPSKVTKKYHEVLQLRPKTGVRGLHKSLTDVALEHHEECDCVCRGSTGG

T44305	TARGETID	T44305
T44305	FORMERID	TTDR00605
T44305	UNIPROID	S17A5_HUMAN
T44305	TARGNAME	Vesicular H(+)/Aspartate-glutamate cotransporter (HP59)
T44305	GENENAME	SLC17A5
T44305	TARGTYPE	Literature-reported
T44305	SYNONYMS	Solute carrier family 17 member 5; Sodium/sialic acid cotransporter; SLC17A5; Membrane glycoprotein HP59; AST
T44305	FUNCTION	Transports glucuronic acid and free sialic acid out of the lysosome after it is cleaved from sialoglycoconjugates undergoing degradation, this is required for normal CNS myelination. Mediates aspartate and glutamate membrane potential- dependent uptake into synaptic vesicles and synaptic-like microvesicles. Also functions as an electrogenic 2NO(3)(-)/H(+) cotransporter in the plasma membrane of salivary gland acinar cells, mediating the physiological nitrate efflux, 25% of the circulating nitrate ions is typically removed and secreted in saliva.
T44305	BIOCLASS	Major facilitator superfamily
T44305	SEQUENCE	MRSPVRDLARNDGEESTDRTPLLPGAPRAEAAPVCCSARYNLAILAFFGFFIVYALRVNLSVALVDMVDSNTTLEDNRTSKACPEHSAPIKVHHNQTGKKYQWDAETQGWILGSFFYGYIITQIPGGYVASKIGGKMLLGFGILGTAVLTLFTPIAADLGVGPLIVLRALEGLGEGVTFPAMHAMWSSWAPPLERSKLLSISYAGAQLGTVISLPLSGIICYYMNWTYVFYFFGTIGIFWFLLWIWLVSDTPQKHKRISHYEKEYILSSLRNQLSSQKSVPWVPILKSLPLWAIVVAHFSYNWTFYTLLTLLPTYMKEILRFNVQENGFLSSLPYLGSWLCMILSGQAADNLRAKWNFSTLCVRRIFSLIGMIGPAVFLVAAGFIGCDYSLAVAFLTISTTLGGFCSSGFSINHLDIAPSYAGILLGITNTFATIPGMVGPVIAKSLTPDNTVGEWQTVFYIAAAINVFGAIFFTLFAKGEVQNWALNDHHGHRH

T74425	TARGETID	T74425
T74425	UNIPROID	GLRX2_HUMAN
T74425	TARGNAME	Glutaredoxin-2 (GLRX2)
T74425	GENENAME	GLRX2
T74425	TARGTYPE	Literature-reported
T74425	SYNONYMS	Glutaredoxin-2, mitochondrial; GRX2; CGI-133
T74425	FUNCTION	Glutathione-dependent oxidoreductase that facilitates the maintenance of mitochondrial redox homeostasis upon induction of apoptosis by oxidative stress. Involved in response to hydrogen peroxide and regulation of apoptosis caused by oxidative stress. Acts as a very efficient catalyst of monothiol reactions because of its high affinity for protein glutathione-mixed disulfides. Can receive electrons not only from glutathione (GSH), but also from thioredoxin reductase supporting both monothiol and dithiol reactions. Efficiently catalyzes both glutathionylation and deglutathionylation of mitochondrial complex I, which in turn regulates the superoxide production by the complex. Overexpression decreases the susceptibility to apoptosis and prevents loss of cardiolipin and cytochrome c release.
T74425	PDBSTRUC	2HT9; 2FLS; 2CQ9
T74425	SEQUENCE	MIWRRAALAGTRLVWSRSGSAGWLDRAAGAAGAAAAAASGMESNTSSSLENLATAPVNQIQETISDNCVVIFSKTSCSYCTMAKKLFHDMNVNYKVVELDLLEYGNQFQDALYKMTGERTVPRIFVNGTFIGGATDTHRLHKEGKLLPLVHQCYLKKSKRKEFQ

T90905	TARGETID	T90905
T90905	FORMERID	TTDI03342
T90905	UNIPROID	KCND1_HUMAN
T90905	TARGNAME	Voltage-gated potassium channel Kv4.1 (KCND1)
T90905	GENENAME	KCND1
T90905	TARGTYPE	Literature-reported
T90905	SYNONYMS	Voltage-gated potassium channel subunit Kv4.1; Potassium voltage-gated channel subfamily D member 1
T90905	FUNCTION	Pore-forming (alpha) subunit of voltage-gated rapidly inactivating A-type potassium channels. May contribute to I(To) current in heart and I(Sa) current in neurons. Channel properties are modulated by interactions with other alpha subunits and with regulatory subunits.
T90905	BIOCLASS	Voltage-gated ion channel
T90905	SEQUENCE	MAAGLATWLPFARAAAVGWLPLAQQPLPPAPGVKASRGDEVLVVNVSGRRFETWKNTLDRYPDTLLGSSEKEFFYDADSGEYFFDRDPDMFRHVLNFYRTGRLHCPRQECIQAFDEELAFYGLVPELVGDCCLEEYRDRKKENAERLAEDEEAEQAGDGPALPAGSSLRQRLWRAFENPHTSTAALVFYYVTGFFIAVSVIANVVETIPCRGSARRSSREQPCGERFPQAFFCMDTACVLIFTGEYLLRLFAAPSRCRFLRSVMSLIDVVAILPYYIGLLVPKNDDVSGAFVTLRVFRVFRIFKFSRHSQGLRILGYTLKSCASELGFLLFSLTMAIIIFATVMFYAEKGTNKTNFTSIPAAFWYTIVTMTTLGYGDMVPSTIAGKIFGSICSLSGVLVIALPVPVIVSNFSRIYHQNQRADKRRAQQKVRLARIRLAKSGTTNAFLQYKQNGGLEDSGSGEEQALCVRNRSAFEQQHHHLLHCLEKTTCHEFTDELTFSEALGAVSPGGRTSRSTSVSSQPVGPGSLLSSCCPRRAKRRAIRLANSTASVSRGSMQELDMLAGLRRSHAPQSRSSLNAKPHDSLDLNCDSRDFVAAIISIPTPPANTPDESQPSSPGGGGRAGSTLRNSSLGTPCLFPETVKISSL
T90905	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T61316	TARGETID	T61316
T61316	FORMERID	TTDI03131
T61316	UNIPROID	CXB4_HUMAN
T61316	TARGNAME	Gap junction beta-4 protein (Cx30.3)
T61316	GENENAME	GJB4
T61316	TARGTYPE	Literature-reported
T61316	SYNONYMS	Connexin-30.3
T61316	FUNCTION	Gap junctions are dodecameric channels that connect the cytoplasm of adjoining cells. They are formed by the docking of two hexameric hemichannels, one from each cell membrane. Small molecules and ions diffuse from one cell to a neighboring cell via the central pore. Structural component of gap junctions.
T61316	BIOCLASS	Gap junction-forming connexin
T61316	SEQUENCE	MNWAFLQGLLSGVNKYSTVLSRIWLSVVFIFRVLVYVVAAEEVWDDEQKDFVCNTKQPGCPNVCYDEFFPVSHVRLWALQLILVTCPSLLVVMHVAYREERERKHHLKHGPNAPSLYDNLSKKRGGLWWTYLLSLIFKAAVDAGFLYIFHRLYKDYDMPRVVACSVEPCPHTVDCYISRPTEKKVFTYFMVTTAAICILLNLSEVFYLVGKRCMEIFGPRHRRPRCRECLPDTCPPYVLSQGGHPEDGNSVLMKAGSAPVDAGGYP
T61316	DRUGINFO	D00VJY	octanol	Investigative

T64642	TARGETID	T64642
T64642	FORMERID	TTDR00483
T64642	UNIPROID	IMP3_HUMAN
T64642	TARGNAME	U3 snoRNP protein IMP3 (IMP3)
T64642	GENENAME	IMP3
T64642	TARGTYPE	Literature-reported
T64642	SYNONYMS	U3 small nucleolar ribonucleoprotein protein IMP3; MRPS4; C15orf12; BRMS2
T64642	FUNCTION	Component of the 60-80S U3 small nucleolar ribonucleoprotein (U3 snoRNP). Required for the early cleavages during pre-18S ribosomal RNA processing.
T64642	PDBSTRUC	2CQJ
T64642	SEQUENCE	MVRKLKFHEQKLLKQVDFLNWEVTDHNLHELRVLRRYRLQRREDYTRYNQLSRAVRELARRLRDLPERDQFRVRASAALLDKLYALGLVPTRGSLELCDFVTASSFCRRRLPTVLLKLRMAQHLQAAVAFVEQGHVRVGPDVVTDPAFLVTRSMEDFVTWVDSSKIKRHVLEYNEERDDFDLEA

T93337	TARGETID	T93337
T93337	UNIPROID	S38A7_HUMAN
T93337	TARGNAME	Solute carrier family 38 member 7 (SLC38A7)
T93337	GENENAME	SLC38A7
T93337	TARGTYPE	Literature-reported
T93337	SYNONYMS	SNAT7
T93337	FUNCTION	Mediates sodium-dependent transport of amino acids, preferentially L-glutamine.
T93337	BIOCLASS	Amino acid/polyamine transporter 2 family
T93337	SEQUENCE	MAQVSINNDYSEWDLSTDAGERARLLQSPCVDTAPKSEWEASPGGLDRGTTSTLGAIFIVVNACLGAGLLNFPAAFSTAGGVAAGIALQMGMLVFIISGLVILAYCSQASNERTYQEVVWAVCGKLTGVLCEVAIAVYTFGTCIAFLIIIGDQQDKIIAVMAKEPEGASGPWYTDRKFTISLTAFLFILPLSIPREIGFQKYASFLSVVGTWYVTAIVIIKYIWPDKEMTPGNILTRPASWMAVFNAMPTICFGFQCHVSSVPVFNSMQQPEVKTWGGVVTAAMVIALAVYMGTGICGFLTFGAAVDPDVLLSYPSEDMAVAVARAFIILSVLTSYPILHFCGRAVVEGLWLRYQGVPVEEDVGRERRRRVLQTLVWFLLTLLLALFIPDIGKVISVIGGLAACFIFVFPGLCLIQAKLSEMEEVKPASWWVLVSYGVLLVTLGAFIFGQTTANAIFVDLLA

T79501	TARGETID	T79501
T79501	FORMERID	TTDI03488
T79501	UNIPROID	ANM7_HUMAN
T79501	TARGNAME	Protein arginine methyltransferase 7 (PRMT7)
T79501	GENENAME	PRMT7
T79501	TARGTYPE	Literature-reported
T79501	SYNONYMS	Protein arginine N-methyltransferase 7; KIAA1933; Histone-arginine N-methyltransferase PRMT7; [Myelin basic protein]-arginine N-methyltransferase PRMT7
T79501	FUNCTION	Arginine methyltransferase that can both catalyze the formation of omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA), with a preference for the formation of MMA. Specifically mediates the symmetrical dimethylation of arginine residues in the small nuclear ribonucleoproteins Sm D1 (SNRPD1) and Sm D3 (SNRPD3); such methylation being required for the assembly and biogenesis of snRNP core particles. Specifically mediates the symmetric dimethylation of histone H4 'Arg-3' to form H4R3me2s. Plays a role in gene imprinting by being recruited by CTCFL at the H19 imprinted control region (ICR) and methylating histone H4 to form H4R3me2s, possibly leading to recruit DNA methyltransferases at these sites. May also play a role in embryonic stem cell (ESC) pluripotency. Also able to mediate the arginine methylation of histone H2A and myelin basic protein (MBP) in vitro; the relevance of such results is however unclear in vivo.
T79501	ECNUMBER	EC 2.1.1.321
T79501	SEQUENCE	MKIFCSRANPTTGSVEWLEEDEHYDYHQEIARSSYADMLHDKDRNVKYYQGIRAAVSRVKDRGQKALVLDIGTGTGLLSMMAVTAGADFCYAIEVFKPMADAAVKIVEKNGFSDKIKVINKHSTEVTVGPEGDMPCRANILVTELFDTELIGEGALPSYEHAHRHLVEENCEAVPHRATVYAQLVESGRMWSWNKLFPIHVQTSLGEQVIVPPVDVESCPGAPSVCDIQLNQVSPADFTVLSDVLPMFSIDFSKQVSSSAACHSRRFEPLTSGRAQVVLSWWDIEMDPEGKIKCTMAPFWAHSDPEEMQWRDHWMQCVYFLPQEEPVVQGSALYLVAHHDDYCVWYSLQRTSPEKNERVRQMRPVCDCQAHLLWNRPRFGEINDQDRTDRYVQALRTVLKPDSVCLCVSDGSLLSVLAHHLGVEQVFTVESSAASHKLLRKIFKANHLEDKINIIEKRPELLTNEDLQGRKVSLLLGEPFFTTSLLPWHNLYFWYVRTAVDQHLGPGAMVMPQAASLHAVVVEFRDLWRIRSPCGDCEGFDVHIMDDMIKRALDFRESREAEPHPLWEYPCRSLSEPWQILTFDFQQPVPLQPLCAEGTVELRRPGQSHAAVLWMEYHLTPECTLSTGLLEPADPEGGCCWNPHCKQAVYFFSPAPDPRALLGGPRTVSYAVEFHPDTGDIIMEFRHADTPD
T79501	DRUGINFO	D00QZA	DS-437	Investigative

T44961	TARGETID	T44961
T44961	FORMERID	TTDI00215
T44961	UNIPROID	RIC8B_HUMAN
T44961	TARGNAME	Synembryn-B (RIC8B)
T44961	GENENAME	RIC8B
T44961	TARGTYPE	Literature-reported
T44961	SYNONYMS	hSyn; Protein Ric-8B; Brain synembryn
T44961	FUNCTION	Able to potentiate G(olf)-alpha-dependent cAMP accumulation suggesting that it may be an important component for odorant signal transduction. Guanine nucleotide exchange factor (GEF), which can activate some, but not all, G-alpha proteins by exchanging bound GDP for free GTP.
T44961	BIOCLASS	Synembryn
T44961	SEQUENCE	MDEERALYIVRAGEAGAIERVLRDYSDKHRATFKFESTDEDKRKKLCEGIFKVLIKDIPTTCQVSCLEVLRILSRDKKVLVPVTTKENMQILLRLAKLNELDDSLEKVSEFPVIVESLKCLCNIVFNSQMAQQLSLELNLAAKLCNLLRKCKDRKFINDIKCFDLRLLFLLSLLHTDIRSQLRYELQGLPLLTQILESAFSIKWTDEYESAIDHNGPPLSPQETDCAIEALKALFNVTVDSWKVHKESDSHQFRVMAAVLRHCLLIVGPTEDKTEELHSNAVNLLSNVPVSCLDVLICPLTHEETAQEATTLDELPSNKTAEKETVLKNNTMVYNGMNMEAIHVLLNFMEKRIDKGSSYREGLTPVLSLLTECSRAHRNIRKFLKDQVLPPLRDVTNRPEVGSTVRNKLVRLMTHVDLGVKQIAAEFLFVLCKERVDSLLKYTGYGNAAGLLAARGLLAGGRGDNWYSEDEDTDTEEYKNAKPKEELLKPMGLKPDGTITPLEEALNQYSVIEETSSDTD

T01255	TARGETID	T01255
T01255	FORMERID	TTDI03537
T01255	UNIPROID	ST32B_HUMAN
T01255	TARGNAME	Yet another novel kinase 2 (STK32B)
T01255	GENENAME	STK32B
T01255	TARGTYPE	Literature-reported
T01255	SYNONYMS	YANK2; Serine/threonine-protein kinase 32B
T01255	FUNCTION	Catalyzes the conversion of L-seryl-protein into O-phospho-L-seryl-protein.
T01255	ECNUMBER	EC 2.7.11.1
T01255	SEQUENCE	MGGNHSHKPPVFDENEEVNFDHFQILRAIGKGSFGKVCIVQKRDTKKMYAMKYMNKQKCIERDEVRNVFRELQIMQGLEHPFLVNLWYSFQDEEDMFMVVDLLLGGDLRYHLQQNVHFTEGTVKLYICELALALEYLQRYHIIHRDIKPDNILLDEHGHVHITDFNIATVVKGAERASSMAGTKPYMAPEVFQVYMDRGPGYSYPVDWWSLGITAYELLRGWRPYEIHSVTPIDEILNMFKVERVHYSSTWCKGMVALLRKLLTKDPESRVSSLHDIQSVPYLADMNWDAVFKKALMPGFVPNKGRLNCDPTFELEEMILESKPLHKKKKRLAKNRSRDGTKDSCPLNGHLQHCLETVREEFIIFNREKLRRQQGQGSQLLDTDSRGGGQAQSKLQDGCNNNLLTHTCTRGCSS
T01255	DRUGINFO	D0RJ8J	PMID24793884C74	Investigative

T89521	TARGETID	T89521
T89521	UNIPROID	DTL_HUMAN
T89521	TARGNAME	DDB1- and CUL4-associated factor 2 (DTL)
T89521	GENENAME	DTL
T89521	TARGTYPE	Literature-reported
T89521	SYNONYMS	Retinoic acid-regulated nuclear matrix-associated protein; RAMP; Lethal(2) denticleless protein homolog; L2DTL; Denticleless protein homolog; DCAF2; CDW1; CDT2
T89521	FUNCTION	Substrate-specific adapter of a DCX (DDB1-CUL4-X-box) E3 ubiquitin-protein ligase complex required for cell cycle control, DNA damage response and translesion DNA synthesis. The DCX(DTL) complex, also named CRL4(CDT2) complex, mediates the polyubiquitination and subsequent degradation of CDT1, CDKN1A/p21(CIP1), FBH1, KMT5A and SDE2. CDT1 degradation in response to DNA damage is necessary to ensure proper cell cycle regulation of DNA replication. CDKN1A/p21(CIP1) degradation during S phase or following UV irradiation is essential to control replication licensing. KMT5A degradation is also important for a proper regulation of mechanisms such as TGF-beta signaling, cell cycle progression, DNA repair and cell migration. Most substrates require their interaction with PCNA for their polyubiquitination: substrates interact with PCNA via their PIP-box, and those containing the 'K+4' motif in the PIP box, recruit the DCX(DTL) complex, leading to their degradation. In undamaged proliferating cells, the DCX(DTL) complex also promotes the 'Lys-164' monoubiquitination of PCNA, thereby being involved in PCNA-dependent translesion DNA synthesis. The DDB1-CUL4A-DTL E3 ligase complex regulates the circadian clock function by mediating the ubiquitination and degradation of CRY1.
T89521	PDBSTRUC	6QC0
T89521	SEQUENCE	MLFNSVLRQPQLGVLRNGWSSQYPLQSLLTGYQCSGNDEHTSYGETGVPVPPFGCTFSSAPNMEHVLAVANEEGFVRLYNTESQSFRKKCFKEWMAHWNAVFDLAWVPGELKLVTAAGDQTAKFWDVKAGELIGTCKGHQCSLKSVAFSKFEKAVFCTGGRDGNIMVWDTRCNKKDGFYRQVNQISGAHNTSDKQTPSKPKKKQNSKGLAPSVDFQQSVTVVLFQDENTLVSAGAVDGIIKVWDLRKNYTAYRQEPIASKSFLYPGSSTRKLGYSSLILDSTGSTLFANCTDDNIYMFNMTGLKTSPVAIFNGHQNSTFYVKSSLSPDDQFLVSGSSDEAAYIWKVSTPWQPPTVLLGHSQEVTSVCWCPSDFTKIATCSDDNTLKIWRLNRGLEEKPGGDKLSTVGWASQKKKESRPGLVTVTSSQSTPAKAPRAKCNPSNSSPSSAACAPSCAGDLPLPSNTPTFSIKTSPAKARSPINRRGSVSSVSPKPPSSFKMSIRNWVTRTPSSSPPITPPASETKIMSPRKALIPVSQKSSQAEACSESRNRVKRRLDSSCLESVKQKCVKSCNCVTELDGQVENLHLDLCCLAGNQEDLSKDSLGPTKSSKIEGAGTSISEPPSPISPYASESCGTLPLPLRPCGEGSEMVGKENSSPENKNWLLAMAAKRKAENPSPRSPSSQTPNSRRQSGKKLPSPVTITPSSMRKICTYFHRKSQEDFCGPEHSTEL

T85545	TARGETID	T85545
T85545	FORMERID	TTDI02402
T85545	UNIPROID	TRPM5_HUMAN
T85545	TARGNAME	Long transient receptor potential channel 5 (TRPM5)
T85545	GENENAME	TRPM5
T85545	TARGTYPE	Literature-reported
T85545	SYNONYMS	Transient receptor potential cation channelsubfamily M member 5; TRPM5; MLSN1- and TRP-related gene 1 protein; LTrpC5; LTrpC-5
T85545	FUNCTION	Voltage-modulated Ca(2+)-activated, monovalent cation channel (VCAM) that mediates a transient membrane depolarization and plays a central role in taste transduction. Monovalent- specific, non-selective cation channel that mediates the transport of Na(+), K(+) and Cs(+) ions equally well. Activated directly by increases in intracellular Ca(2+), but is impermeable to it. Gating is voltage-dependent and displays rapid activation and deactivation kinetics upon channel stimulation even during sustained elevations in Ca(2+). Also activated by a fast intracellular Ca(2+) increase in response to inositol 1,4,5- triphosphate-producing receptoragonists. The channel is blocked by extracellular acidification. External acidification has 2 effects, a fast reversible block of the current and a slower irreversible enhancement of current inactivation. Is a highly temperature-sensitive, heat activated channel showing a steep increase of inward currents at temperatures between 15 and 35 degrees Celsius. Heat activation is due to a shift of the voltage- dependent activation curve to negative potentials. Activated by arachidonic acid in vitro. May be involved in perception of bitter, sweet and umami tastes. May also be involved in sensing semiochemicals.
T85545	BIOCLASS	Transient receptor potential catioin channel
T85545	SEQUENCE	MQDVQGPRPGSPGDAEDRRELGLHRGEVNFGGSGKKRGKFVRVPSGVAPSVLFDLLLAEWHLPAPNLVVSLVGEEQPFAMKSWLRDVLRKGLVKAAQSTGAWILTSALRVGLARHVGQAVRDHSLASTSTKVRVVAVGMASLGRVLHRRILEEAQEDFPVHYPEDDGGSQGPLCSLDSNLSHFILVEPGPPGKGDGLTELRLRLEKHISEQRAGYGGTGSIEIPVLCLLVNGDPNTLERISRAVEQAAPWLILVGSGGIADVLAALVNQPHLLVPKVAEKQFKEKFPSKHFSWEDIVRWTKLLQNITSHQHLLTVYDFEQEGSEELDTVILKALVKACKSHSQEPQDYLDELKLAVAWDRVDIAKSEIFNGDVEWKSCDLEEVMVDALVSNKPEFVRLFVDNGADVADFLTYGRLQELYRSVSRKSLLFDLLQRKQEEARLTLAGLGTQQAREPPAGPPAFSLHEVSRVLKDFLQDACRGFYQDGRPGDRRRAEKGPAKRPTGQKWLLDLNQKSENPWRDLFLWAVLQNRHEMATYFWAMGQEGVAAALAACKILKEMSHLETEAEAARATREAKYERLALDLFSECYSNSEARAFALLVRRNRCWSKTTCLHLATEADAKAFFAHDGVQAFLTRIWWGDMAAGTPILRLLGAFLCPALVYTNLITFSEEAPLRTGLEDLQDLDSLDTEKSPLYGLQSRVEELVEAPRAQGDRGPRAVFLLTRWRKFWGAPVTVFLGNVVMYFAFLFLFTYVLLVDFRPPPQGPSGPEVTLYFWVFTLVLEEIRQGFFTDEDTHLVKKFTLYVGDNWNKCDMVAIFLFIVGVTCRMLPSAFEAGRTVLAMDFMVFTLRLIHIFAIHKQLGPKIIVVERMMKDVFFFLFFLSVWLVAYGVTTQALLHPHDGRLEWIFRRVLYRPYLQIFGQIPLDEIDEARVNCSTHPLLLEDSPSCPSLYANWLVILLLVTFLLVTNVLLMNLLIAMFSYTFQVVQGNADMFWKFQRYNLIVEYHERPALAPPFILLSHLSLTLRRVFKKEAEHKREHLERDLPDPLDQKVVTWETVQKENFLSKMEKRRRDSEGEVLRKTAHRVDFIAKYLGGLREQEKRIKCLESQINYCSVLVSSVADVLAQGGGPRSSQHCGEGSQLVAADHRGGLDGWEQPGAGQPPSDT

T18978	TARGETID	T18978
T18978	FORMERID	TTDI03601
T18978	UNIPROID	PK2L1_HUMAN
T18978	TARGNAME	Polycystic kidney disease 2-like 1 (TRPP2)
T18978	GENENAME	PKD2L1
T18978	TARGTYPE	Literature-reported
T18978	SYNONYMS	Polycystin-L1; Polycystin-L; Polycystin-2L1; Polycystin-2 homolog; Polycystic kidney disease 2-like 1 protein; PKDL; PKD2L
T18978	FUNCTION	Pore-forming subunit of a heterotetrameric, non-selective cation channel that is permeable to Ca(2+). Pore-forming subunit of a calcium-permeant ion channel formed by PKD1L2 and PKD1L1 in primary cilia, where it controls cilium calcium concentration, but does not affect cytoplasmic calcium concentration. The channel formed by PKD1L2 and PKD1L1 in primary cilia regulates sonic hedgehog/SHH signaling and GLI2 transcription. Pore-forming subunit of a channel formed by PKD1L2 and PKD1L3 that contributes to sour taste perception in gustatory cells. The heteromeric channel formed by PKD1L2 and PKD1L3 is activated by low pH, but opens only when the extracellular pH rises again. May play a role in the perception of carbonation taste (By similarity). May play a role in the sensory perception of water, via a mechanism that activates the channel in response to dilution of salivary bicarbonate and changes in salivary pH (By similarity).
T18978	PDBSTRUC	6DU8; 4GIF; 3TE3
T18978	SEQUENCE	MNAVGSPEGQELQKLGSGAWDNPAYSGPPSPHGTLRVCTISSTGPLQPQPKKPEDEPQETAYRTQVSSCCLHICQGIRGLWGTTLTENTAENRELYIKTTLRELLVYIVFLVDICLLTYGMTSSSAYYYTKVMSELFLHTPSDTGVSFQAISSMADFWDFAQGPLLDSLYWTKWYNNQSLGHGSHSFIYYENMLLGVPRLRQLKVRNDSCVVHEDFREDILSCYDVYSPDKEEQLPFGPFNGTAWTYHSQDELGGFSHWGRLTSYSGGGYYLDLPGSRQGSAEALRALQEGLWLDRGTRVVFIDFSVYNANINLFCVLRLVVEFPATGGAIPSWQIRTVKLIRYVSNWDFFIVGCEVIFCVFIFYYVVEEILELHIHRLRYLSSIWNILDLVVILLSIVAVGFHIFRTLEVNRLMGKLLQQPNTYADFEFLAFWQTQYNNMNAVNLFFAWIKIFKYISFNKTMTQLSSTLARCAKDILGFAVMFFIVFFAYAQLGYLLFGTQVENFSTFIKCIFTQFRIILGDFDYNAIDNANRILGPAYFVTYVFFVFFVLLNMFLAIINDTYSEVKEELAGQKDELQLSDLLKQGYNKTLLRLRLRKERVSDVQKVLQGGEQEIQFEDFTNTLRELGHAEHEITELTATFTKFDRDGNRILDEKEQEKMRQDLEEERVALNTEIEKLGRSIVSSPQGKSGPEAARAGGWVSGEEFYMLTRRVLQLETVLEGVVSQIDAVGSKLKMLERKGWLAPSPGVKEQAIWKHPQPAPAVTPDPWGVQGGQESEVPYKREEEALEERRLSRGEIPTLQRS
T18978	DRUGINFO	D03WNI	malic acid	Investigative
T18978	DRUGINFO	D05OEV	phenamil	Investigative
T18978	DRUGINFO	D0TV1R	flufenamate	Investigative
T18978	DRUGINFO	D02ACL	benzamil	Investigative
T18978	DRUGINFO	D02RTS	citric acid	Investigative

T02891	TARGETID	T02891
T02891	FORMERID	TTDI03004
T02891	UNIPROID	HTR5B_HUMAN
T02891	TARGNAME	5-HT 5B receptor (HTR5B)
T02891	GENENAME	HTR5B
T02891	TARGTYPE	Literature-reported
T02891	SYNONYMS	KIAA1414; HEATR5B; HEAT repeat-containing protein 5B
T02891	FUNCTION	endocytic vesicle, membrane, endocytosis, protein localization, retrograde transport, endosome to Golgi.
T02891	BIOCLASS	GPCR rhodopsin
T02891	SEQUENCE	MELAHSLLLNEEALAQITEAKRPVFIFEWLRFLDKVLVAANKTDVKEKQKKLVEQLTGLISSSPGPPTRKLLAKNLAALYSIGDTFTVFQTLDKCNDIIRNKDDTAAYLPTKLAAVACVGAFYEKMGRMLGSAFPETVNNLLKSLKSAESQGRSEILMSLQKVLSGLGGAAASSHRDIYKNARSLLTDRSMAVRCAVAKCLLELQNEAVFMWTAELENIATLCFKALENSNYGVRVAVSKLLGTVMATALMPKQATVMRQNVKRATFDEVLELMATGFLRGGSGFLKSGGEMLKVGGSVNREVRVGVTQAYVVFVTTLGGQWLERSFATFLSHVLDLVSHPRATQTHVEAVYSRRCVSFILRATVGSLLGEKAQIAAAKEICQAIGKQMKAVEAVVNDTSGENKSGAADIAASQHVMVCALQELGSLVQSLNATASPLIQEASIGLLEIVTSVLLHPSMAARLAAAWCLRCVAVALPFQLTPFLDRCAERLNNLKTSPEAVSGYSFAMAALLGGVHQCPLGIPHAKGKMVVSIAEDLLRTAAQNSRLSLQRTQAGWLLLGALMTLGPSVVRYHLPKMLLLWRNVFPRSLKELEAEKARGDSFTWQVTLEGRAGALCAMRSFVAHCPELLTEDVIRKLMTPIECAMTMMSHIPSVMKAHGAHLKASAAMVRLRLYDILALLPPKTYEGSFNALLRELVAEFTLTDNSANTTTSLLRSLCHYDDSVLLGSWLQETDHKSIEDQLQPNSASGSGALEHDPSSIYLRIPAGEAVPGPLPLGVSVIDASVALFGVVFPHVSYKHRLQMLDHFAECVKQAKGVRQQAVQLNIFTAVLSALKGLAENKSTLGPEEVRKSALTLVMGPLDNPNPILRCAAGEALGRMAQVVGEATFIARMAQYSFDKLKSARDVVSRTGHSLALGCLHRYVGGIGSGQHLKTSVSILLALAQDGTSPEVQTWSLHSLALIVDSSGPMYRGYVEPTLSLVLTLLLTVPPSHTEVHQCLGRCLGAIITTVGPELQGNGATTSTIRSSCLVGCAITQDHSDSLVQAAAISCLQQLHMFAPRHVNLSSLVPSLCVHLCSSHLLLRRAAVACLRQLAQREAAEVCEYAMSLAKNTGDKESSSANVSPFAPGVSSRTDIHCRHQGVNITETGLEGLLFGMLDRETDRKLCSDIHDTLGHMLSSLAVEKLSHWLMLCKDVLAASSDMSTATLLSSGKDEEAEKKDEMDDDTMFTTLGEEDKSKPFVAPRWATRVFAADCLCRIINLCENADQAHFDLALARSAKLRNPTNDLLVLHLSDLIRMAFMAATDHSNQLRMAGLQALEDIIKKFASVPEPEFPGHVILEQYQANVGAALRPAFSQDTPSDIIAKACQVCSTWIGSGVVSDLNDLRRVHNLLVSSLDKVQAGKGSSSQLYRESATTMEKLAVLKAWAEVYVVAMNIKKEAESKPKRAIKNTDDDDDDCGTIDELPPDSLITLVQPELPTLSRLWLAALKDYALLTLPAEFSSQLPPDGGAFYTPETIDTARLHYRNSWAPILHAVALWLNSTGFTCSESTEAAAISGLQKRSTSVNLNQASGAVGSAKSLPEINKDRMHLILGVSIQFLCSPRPEEPIEHVTACLQALHTLLDSPYARVHIAEDQLIGVELLSVLHRLLLTWNPSSVQLLVTGVVQQIVRAAQDYLQEKRNTLNEDDMEKEACTVLGEGGDSGGLIPGKSLVFATMELLMFILVRHMPHLSTKVSDSPSHIATKTRLSEESARLVAATVTILSDLPSLCSPAGCMTILPTILFLIARILKDTAIKSADNQVPPPVSAALQGIKSIVTLSMAKTEAGVQKQWTALIRSTLACILEYSQPEDSVPTPDEVSMLTAIALFLWSASNEIIGVQSLQNGCMNRFKNALNSCDPWVQAKCYQLLLSVFQHSNRALSTPYIHSLAPIVVEKLKAVERNRPASNIELLAVQEGIKVLETLVALGEEQNRVQLLALLVPTLISYLLDENSFASASSASKDLHEFALQNLMHIGPLYPHAFKTVMGAAPELKVRLETAVRASQASKAKAAARQPAPAIHSAPTIKLKTSFF
T02891	DRUGINFO	D0BW9V	[125I]LSD	Investigative
T02891	DRUGINFO	D08PJK	[3H]5-CT	Investigative

T66396	TARGETID	T66396
T66396	FORMERID	TTDI03187
T66396	UNIPROID	E2AK4_HUMAN
T66396	TARGNAME	Eukaryotic translation initiation factor 2-alpha kinase 4 (EIF2AK4)
T66396	GENENAME	EIF2AK4
T66396	TARGTYPE	Literature-reported
T66396	SYNONYMS	eIF-2-alpha kinase GCN2; KIAA1338; GCN2-like protein; GCN2
T66396	FUNCTION	Metabolic-stress sensing protein kinase that phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (eIF-2-alpha/EIF2S1) on 'Ser-52' in response to low amino acid availability. Plays a role as an activator of the integrated stress response (ISR) required for adapatation to amino acid starvation. Converts phosphorylated eIF-2-alpha/EIF2S1 either to a competitive inhibitor of the translation initiation factor eIF-2B, leading to a global protein synthesis repression, and thus to a reduced overall utilization of amino acids, or to a translational initiation activation of specific mRNAs, such as the transcriptional activator ATF4, and hence allowing ATF4-mediated reprogramming of amino acid biosynthetic gene expression to alleviate nutrient depletion. Binds uncharged tRNAs (By similarity). Involved in cell cycle arrest by promoting cyclin D1 mRNA translation repression after the unfolded protein response pathway (UPR) activation or cell cycle inhibitor CDKN1A/p21 mRNA translation activation in response to amino acid deprivation. Plays a role in the consolidation of synaptic plasticity, learning as well as formation of long-term memory. Plays a role in neurite outgrowth inhibition. Plays a proapoptotic role in response to glucose deprivation. Promotes global cellular protein synthesis repression in response to UV irradiation independently of the stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) and p38 MAPK signaling pathways (By similarity). Plays a role in the antiviral response against alphavirus infection; impairs early viral mRNA translation of the incoming genomic virus RNA, thus preventing alphavirus replication (By similarity).
T66396	ECNUMBER	EC 2.7.11.1
T66396	SEQUENCE	MAGGRGAPGRGRDEPPESYPQRQDHELQALEAIYGADFQDLRPDACGPVKEPPEINLVLYPQGLTGEEVYVKVDLRVKCPPTYPDVVPEIELKNAKGLSNESVNLLKSRLEELAKKHCGEVMIFELAYHVQSFLSEHNKPPPKSFHEEMLERRAQEEQQRLLEAKRKEEQEQREILHEIQRRKEEIKEEKKRKEMAKQERLEIASLSNQDHTSKKDPGGHRTAAILHGGSPDFVGNGKHRANSSGRSRRERQYSVCNSEDSPGSCEILYFNMGSPDQLMVHKGKCIGSDEQLGKLVYNALETATGGFVLLYEWVLQWQKKMGPFLTSQEKEKIDKCKKQIQGTETEFNSLVKLSHPNVVRYLAMNLKEQDDSIVVDILVEHISGVSLAAHLSHSGPIPVHQLRRYTAQLLSGLDYLHSNSVVHKVLSASNVLVDAEGTVKITDYSISKRLADICKEDVFEQTRVRFSDNALPYKTGKKGDVWRLGLLLLSLSQGQECGEYPVTIPSDLPADFQDFLKKCVCLDDKERWSPQQLLKHSFINPQPKMPLVEQSPEDSEGQDYVETVIPSNRLPSAAFFSETQRQFSRYFIEFEELQLLGKGAFGAVIKVQNKLDGCCYAVKRIPINPASRQFRRIKGEVTLLSRLHHENIVRYYNAWIERHERPAGPGTPPPDSGPLAKDDRAARGQPASDTDGLDSVEAAAPPPILSSSVEWSTSGERSASARFPATGPGSSDDEDDDEDEHGGVFSQSFLPASDSESDIIFDNEDENSKSQNQDEDCNEKNGCHESEPSVTTEAVHYLYIQMEYCEKSTLRDTIDQGLYRDTVRLWRLFREILDGLAYIHEKGMIHRDLKPVNIFLDSDDHVKIGDFGLATDHLAFSADSKQDDQTGDLIKSDPSGHLTGMVGTALYVSPEVQGSTKSAYNQKVDLFSLGIIFFEMSYHPMVTASERIFVLNQLRDPTSPKFPEDFDDGEHAKQKSVISWLLNHDPAKRPTATELLKSELLPPPQMEESELHEVLHHTLTNVDGKAYRTMMAQIFSQRISPAIDYTYDSDILKGNFSIRTAKMQQHVCETIIRIFKRHGAVQLCTPLLLPRNRQIYEHNEAALFMDHSGMLVMLPFDLRIPFARYVARNNILNLKRYCIERVFRPRKLDRFHPKELLECAFDIVTSTTNSFLPTAEIIYTIYEIIQEFPALQERNYSIYLNHTMLLKAILLHCGIPEDKLSQVYIILYDAVTEKLTRREVEAKFCNLSLSSNSLCRLYKFIEQKGDLQDLMPTINSLIKQKTGIAQLVKYGLKDLEEVVGLLKKLGIKLQVLINLGLVYKVQQHNGIIFQFVAFIKRRQRAVPEILAAGGRYDLLIPQFRGPQALGPVPTAIGVSIAIDKISAAVLNMEESVTISSCDLLVVSVGQMSMSRAINLTQKLWTAGITAEIMYDWSQSQEELQEYCRHHEITYVALVSDKEGSHVKVKSFEKERQTEKRVLETELVDHVLQKLRTKVTDERNGREASDNLAVQNLKGSFSNASGLFEIHGATVVPIVSVLAPEKLSASTRRRYETQVQTRLQTSLANLHQKSSEIEILAVDLPKETILQFLSLEWDADEQAFNTTVKQLLSRLPKQRYLKLVCDEIYNIKVEKKVSVLFLYSYRDDYYRILF
T66396	DRUGINFO	D0T5VB	WO2013110309CA127	Investigative

T93511	TARGETID	T93511
T93511	FORMERID	TTDR00984
T93511	UNIPROID	PHLN_BURPS
T93511	TARGNAME	Bacterial Phosphatidylcholine-specificphospholipase C (Bact plcN)
T93511	GENENAME	Bact plcN
T93511	TARGTYPE	Literature-reported
T93511	SYNONYMS	plcN; Phosphatidylcholine-hydrolyzing phospholipase C; Phosphatidylcholine cholinephosphohydrolase; PLC-N; PC-PLC; Non-hemolytic phospholipase C; Lecithinase
T93511	FUNCTION	Hydrolyzes phosphatidylserine as well as phosphatidylcholine.
T93511	BIOCLASS	Phosphoric diester hydrolase
T93511	SEQUENCE	MTNQNRRDFLRLAAGTAGAAALQLFPPVIREALAIPANRRTGTIRDVEHIVILMQENRSFDHYFGKLRGVRGFGDPRPLALQNGKSVFHQPVLLGPAELLPFHPDASNLGMQFLQDLPHGWQDMHGAWNKGRYDRWIANKGTTTMAYLERDDIPFHYQLADAFTICDAYHCSIPSSTDPNRYYMWTGYVGNDGAGGGPVLGNEEAGYGWSTYPETLEQAGVSWKIYQDIGTGLDAAGSWGWTQNPYIGNYGDNSLLYFNQYRNAQPGSPLYDKARTGTNVSAGGTLFDVLQQDVKNGTLPQVSWICAPEAYSEHPNWPANYGAWYVEQVLKALTSNPDVWSKTALFITYDENDGFFDHVAPPFAPQSRENGLSTVSTAGEIFAGDATHMAGPYGLGPRVPMLVVSPWTKGGWVCSQTFDHTSLLQFIEARFNDRYSVRAPNVTPWRRAVCGDLTSAFNFSSPDGSWPQLPDTSGYAPPDRNRHPSYVPVPPAAQSMPKQEAGLRAARALPYELFVLGRIDQSTGKFKLTFANTGRAGAAFQVTAGNRLDGPWAYTVEARKRLSDEWSTALTLSIYDLTVYGPNGFLCQFRGSTAAALGLSANPEVIYGYDVANGNITLRLSNRGRAAVRLTVTNAYGNAAPRVYELKPGQRINDYWDLRDSHSWYDLSVSDGAPNGFLRRFAGHVETGRPSTSDPLIATA
T93511	DRUGINFO	D0W1AW	D609	Investigative

T25740	TARGETID	T25740
T25740	FORMERID	TTDR00539
T25740	UNIPROID	Q9U738_PLAFA
T25740	TARGNAME	Plasmodium Folylpolyglutamate synthase (Malaria dhfs-fpgs)
T25740	GENENAME	Malaria dhfs-fpgs
T25740	TARGTYPE	Literature-reported
T25740	SYNONYMS	dhfs-fpgs; Folylpolyglutamate synthetase; Folylpoly-gamma-glutamate synthetase; FPGS
T25740	FUNCTION	Catalyzes conversion of folates to polyglutamate derivatives allowing concentration of folate compounds in the cell and the intracellular retention of these cofactors, which are important substrates for most of the folate-dependent enzymes that are involved in one-carbon transfer reactions involved in purine, pyrimidine and amino acid synthesis. Unsubstitued reduced folates are the preferred substrates. Metabolizes methotrexate (MTX) to polyglutamates.
T25740	BIOCLASS	Carbon-nitrogen ligase
T25740	SEQUENCE	MEKNQNDKSNKNDIIHMNDKSGNYDKNNINNFIDKNDEHDMSDILHKINNEEKKYEEIKSYSECLELLYKTHALKLGLDNPKKLNESFGHPCDKYKTIHIAGTNGKGSVCYKIYTCLKIKKFKVGLFSSPHIFSLRERIIVNDEPISEKELIHLVNEVLNKAKKLYINPSFFEIITLVAFLHFLNKKVDYAIIETGIGGRLDATNILTKPEVIVITSIGYDHLNILGDNLPIICNEKIGIFKKDANVVIGPSVAIYKNVFDKAKELNCTIHTVVPEPRGERYNEENSRIALRTLEILNISIDYFLKSIIPIKPPLRIQYLATEQIQHIKKKFSPDNLEHNVQYPLAVILDVGHNETAIDRLCTDINYFHKGQNIRICISITKPRNLSVFHPFIAQFGDTLKDIFYLPSLNERTYDFEEIVEMLNNEEEIKNEIKELILSSSKKVGKWLAHEKQGNINEEDALKLYKRGCIPLIIKNAFLECCKDNSILLVCGTFFVFDEVLNVFDIHSDMQDTIFMNEPSLV

T17291	TARGETID	T17291
T17291	FORMERID	TTDI03028
T17291	UNIPROID	RHCG_HUMAN
T17291	TARGNAME	Ammonium transporter Rh type C (RHCG)
T17291	GENENAME	RHCG
T17291	TARGTYPE	Literature-reported
T17291	SYNONYMS	Tumor-related protein DRC2; Rhesus blood group family type C glycoprotein; Rh type C glycoprotein; Rh glycoprotein kidney; Rh family type C glycoprotein; RHGK; PDRC2; CDRC2; C15orf6
T17291	FUNCTION	Functions as an electroneutral and bidirectional ammonium transporter. May regulate transepithelial ammonia secretion.
T17291	PDBSTRUC	3HD6
T17291	SEQUENCE	MAWNTNLRWRLPLTCLLLQVIMVILFGVFVRYDFEADAHWWSERTHKNLSDMENEFYYRYPSFQDVHVMVFVGFGFLMTFLQRYGFSAVGFNFLLAAFGIQWALLMQGWFHFLQDRYIVVGVENLINADFCVASVCVAFGAVLGKVSPIQLLIMTFFQVTLFAVNEFILLNLLKVKDAGGSMTIHTFGAYFGLTVTRILYRRNLEQSKERQNSVYQSDLFAMIGTLFLWMYWPSFNSAISYHGDSQHRAAINTYCSLAACVLTSVAISSALHKKGKLDMVHIQNATLAGGVAVGTAAEMMLMPYGALIIGFVCGIISTLGFVYLTPFLESRLHIQDTCGINNLHGIPGIIGGIVGAVTAASASLEVYGKEGLVHSFDFQGFNGDWTARTQGKFQIYGLLVTLAMALMGGIIVGLILRLPFWGQPSDENCFEDAVYWEMPEGNSTVYIPEDPTFKPSGPSVPSVPMVSPLPMASSVPLVP
T17291	DRUGINFO	D0JS4B	[14C]methylamine	Investigative

T10125	TARGETID	T10125
T10125	FORMERID	TTDNC00497
T10125	UNIPROID	DKK2_HUMAN
T10125	TARGNAME	Dickkopf-related protein 2 (DKK2)
T10125	GENENAME	DKK2
T10125	TARGTYPE	Literature-reported
T10125	SYNONYMS	hDkk2; hDkk-2; UNQ682/PRO1316; Dkk2; Dkk-2; Dickkopfrelated protein 2; Dickkopf2; Dickkopf-2
T10125	FUNCTION	DKKs play an important role in vertebrate development, where they locally inhibit Wnt regulated processes such as antero-posterior axial patterning, limb development, somitogenesis and eye formation. In the adult, Dkks are implicated in bone formation and bone disease, cancer and Alzheimer disease. Antagonizes canonical Wnt signaling by inhibiting LRP5/6 interaction with Wnt and by forming a ternary complex with the transmembrane protein KREMEN that promotes internalization of LRP5/6.
T10125	BIOCLASS	Dickkopf protein
T10125	SEQUENCE	MAALMRSKDSSCCLLLLAAVLMVESSQIGSSRAKLNSIKSSLGGETPGQAANRSAGMYQGLAFGGSKKGKNLGQAYPCSSDKECEVGRYCHSPHQGSSACMVCRRKKKRCHRDGMCCPSTRCNNGICIPVTESILTPHIPALDGTRHRDRNHGHYSNHDLGWQNLGRPHTKMSHIKGHEGDPCLRSSDCIEGFCCARHFWTKICKPVLHQGEVCTKQRKKGSHGLEIFQRCDCAKGLSCKVWKDATYSSKARLHVCQKI

T67837	TARGETID	T67837
T67837	FORMERID	TTDR01328
T67837	UNIPROID	STK39_HUMAN
T67837	TARGNAME	Ste-20-related kinase (STK39)
T67837	GENENAME	STK39
T67837	TARGTYPE	Literature-reported
T67837	SYNONYMS	Serine/threonine-protein kinase 39; STE20/SPS1-related proline-alanine-rich protein kinase; SPAK; DCHT
T67837	FUNCTION	May act as a mediator of stress-activated signals. Mediates the inhibition of SLC4A4, SLC26A6 as well as CFTR activities by the WNK scaffolds, probably through phosphorylation. Phosphorylates RELT.
T67837	ECNUMBER	EC 2.7.11.1
T67837	SEQUENCE	MAEPSGSPVHVQLPQQAAPVTAAAAAAPAAATAAPAPAAPAAPAPAPAPAAQAVGWPICRDAYELQEVIGSGATAVVQAALCKPRQERVAIKRINLEKCQTSMDELLKEIQAMSQCSHPNVVTYYTSFVVKDELWLVMKLLSGGSMLDIIKYIVNRGEHKNGVLEEAIIATILKEVLEGLDYLHRNGQIHRDLKAGNILLGEDGSVQIADFGVSAFLATGGDVTRNKVRKTFVGTPCWMAPEVMEQVRGYDFKADMWSFGITAIELATGAAPYHKYPPMKVLMLTLQNDPPTLETGVEDKEMMKKYGKSFRKLLSLCLQKDPSKRPTAAELLKCKFFQKAKNREYLIEKLLTRTPDIAQRAKKVRRVPGSSGHLHKTEDGDWEWSDDEMDEKSEEGKAAFSQEKSRRVKEENPEIAVSASTIPEQIQSLSVHDSQGPPNANEDYREASSCAVNLVLRLRNSRKELNDIRFEFTPGRDTADGVSQELFSAGLVDGHDVVIVAANLQKIVDDPKALKTLTFKLASGCDGSEIPDEVKLIGFAQLSVS

T88567	TARGETID	T88567
T88567	FORMERID	TTDNR00657
T88567	UNIPROID	CLM8_HUMAN
T88567	TARGNAME	CMRF35-like molecule 8 (CD300A)
T88567	GENENAME	CD300A
T88567	TARGTYPE	Literature-reported
T88567	SYNONYMS	NK inhibitory receptor; Inhibitory receptor protein 60; Immunoglobulin superfamily member 12; IgSF12; IRp60; IRC1/IRC2; HSPC083; CMRF35H; CMRF35-H9; CMRF35-H; CMRF-35-H9; CLM-8; CD300a; CD300 antigen-like family member A
T88567	FUNCTION	Negatively regulates the Toll-like receptor (TLR) signaling mediated by MYD88 but not TRIF through activation of PTPN6. Inhibitory receptor which may contribute to the down-regulation of cytolytic activity in natural killer (NK) cells, and to the down-regulation of mast cell degranulation.
T88567	PDBSTRUC	2Q87
T88567	SEQUENCE	MWLPWALLLLWVPGCFALSKCRTVAGPVGGSLSVQCPYEKEHRTLNKYWCRPPQIFLCDKIVETKGSAGKRNGRVSIRDSPANLSFTVTLENLTEEDAGTYWCGVDTPWLRDFHDPVVEVEVSVFPASTSMTPASITAAKTSTITTAFPPVSSTTLFAVGATHSASIQEETEEVVNSQLPLLLSLLALLLLLLVGASLLAWRMFQKWIKAGDHSELSQNPKQAATQSELHYANLELLMWPLQEKPAPPREVEVEYSTVASPREELHYASVVFDSNTNRIAAQRPREEEPDSDYSVIRKT

T15745	TARGETID	T15745
T15745	FORMERID	TTDI03060
T15745	UNIPROID	BAZ2B_HUMAN
T15745	TARGNAME	Bromodomain adjacent to zinc finger 2B (BAZ2B)
T15745	GENENAME	BAZ2B
T15745	TARGTYPE	Literature-reported
T15745	SYNONYMS	hWALp4; KIAA1476; Bromodomain adjacent to zinc finger domain protein 2B
T15745	FUNCTION	May play a role in transcriptional regulation interacting with ISWI.
T15745	PDBSTRUC	6FI1; 6FHQ; 6FH7; 6FH6; 6FGU
T15745	SEQUENCE	MESGERLPSSAASSTTPTSSSTPSVASVVSKGGLSTGVASLSSTINPCGHLFRTAGDQPFNLSTVSSAFPMVSHPVFGLHSASSGHSEFGGLGTLGTPTALAAHPQLASFPGAEWWRTTDAHTRTGATFFPPLLGIPPLFAPPAQNHDSSSFHSRTSGKSNRNGPEKGVNGSINGSNTSSVIGINTSVLSTTASSSMGQTKSTSSGGGNRKCNQEQSKNQPLDARVDKIKDKKPRKKAMESSSNSDSDSGTSSDTSSEGISSSDSDDLEEDEEEEDQSIEESEDDDSDSESEAQHKSNNQVLLHGISDPKADGQKATEKAQEKRIHQPLPLASESQTHSFQSQQKQPQVLSQQLPFIFQSSQAKEESVNKHTSVIQSTGLVSNVKPLSLVNQAKKETYMKLIVPSPDVLKAGNKNTSEESSLLTSELRSKREQYKQAFPSQLKKQESSKSLKKVIAALSNPKATSSSPAHPKQTLENNHPNPFLTNALLGNHQPNGVIQSVIQEAPLALTTKTKMQSKINENIAAASSTPFSSPVNLSTSGRRTPGNQTPVMPSASPILHSQGKEKAVSNNVNPVKTQHHSHPAKSLVEQFRGTDSDIPSSKDSEDSNEDEEEDDEEEDEEDDEDDESDDSQSESDSNSESDTEGSEEEDDDDKDQDESDSDTEGEKTSMKLNKTTSSVKSPSMSLTGHSTPRNLHIAKAPGSAPAALCSESQSPAFLGTSSSTLTSSPHSGTSKRRRVTDERELRIPLEYGWQRETRIRNFGGRLQGEVAYYAPCGKKLRQYPEVIKYLSRNGIMDISRDNFSFSAKIRVGDFYEARDGPQGMQWCLLKEEDVIPRIRAMEGRRGRPPNPDRQRAREESRMRRRKGRPPNVGNAEFLDNADAKLLRKLQAQEIARQAAQIKLLRKLQKQEQARVAKEAKKQQAIMAAEEKRKQKEQIKIMKQQEKIKRIQQIRMEKELRAQQILEAKKKKKEEAANAKLLEAEKRIKEKEMRRQQAVLLKHQERERRRQHMMLMKAMEARKKAEEKERLKQEKRDEKRLNKERKLEQRRLELEMAKELKKPNEDMCLADQKPLPELPRIPGLVLSGSTFSDCLMVVQFLRNFGKVLGFDVNIDVPNLSVLQEGLLNIGDSMGEVQDLLVRLLSAAVCDPGLITGYKAKTALGEHLLNVGVNRDNVSEILQIFMEAHCGQTELTESLKTKAFQAHTPAQKASVLAFLINELACSKSVVSEIDKNIDYMSNLRRDKWVVEGKLRKLRIIHAKKTGKRDTSGGIDLGEEQHPLGTPTPGRKRRRKGGDSDYDDDDDDDSDDQGDEDDEDEEDKEDKKGKKTDICEDEDEGDQAASVEELEKQIEKLSKQQSQYRRKLFDASHSLRSVMFGQDRYRRRYWILPQCGGIFVEGMESGEGLEEIAKEREKLKKAESVQIKEEMFETSGDSLNCSNTDHCEQKEDLKEKDNTNLFLQKPGSFSKLSKLLEVAKMPPESEVMTPKPNAGANGCTLSYQNSGKHSLGSVQSTATQSNVEKADSNNLFNTGSSGPGKFYSPLPNDQLLKTLTEKNRQWFSLLPRTPCDDTSLTHADMSTASLVTPQSQPPSKSPSPTPAPLGSSAQNPVGLNPFALSPLQVKGGVSMMGLQFCGWPTGVVTSNIPFTSSVPSLGSGLGLSEGNGNSFLTSNVASSKSESPVPQNEKATSAQPAAVEVAKPVDFPSPKPIPEEMQFGWWRIIDPEDLKALLKVLHLRGIREKALQKQIQKHLDYITQACLKNKDVAIIELNENEENQVTRDIVENWSVEEQAMEMDLSVLQQVEDLERRVASASLQVKGWMCPEPASEREDLVYFEHKSFTKLCKEHDGEFTGEDESSAHALERKSDNPLDIAVTRLADLERNIERRIEEDIAPGLRVWRRALSEARSAAQVALCIQQLQKSIAWEKSIMKVYCQICRKGDNEELLLLCDGCDKGCHTYCHRPKITTIPDGDWFCPACIAKASGQTLKIKKLHVKGKKTNESKKGKKVTLTGDTEDEDSASTSSSLKRGNKDLKKRKMEENTSINLSKQESFTSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS
T15745	DRUGINFO	D02KSN	PMID25719566C7	Investigative
T15745	DRUGINFO	D07HET	PMID25719566C1	Investigative
T15745	DRUGINFO	D0I4FP	BAZ2-ICR	Investigative
T15745	DRUGINFO	D0T3WL	GSK2801	Investigative

T95682	TARGETID	T95682
T95682	FORMERID	TTDI03059
T95682	UNIPROID	BAZ2A_HUMAN
T95682	TARGNAME	Bromodomain adjacent to zinc finger 2A (BAZ2A)
T95682	GENENAME	BAZ2A
T95682	TARGTYPE	Literature-reported
T95682	SYNONYMS	hWALp3; Transcription termination factor I-interacting protein 5; Tip5; TTF-I-interacting protein 5; KIAA0314; Bromodomain adjacent to zinc finger domain protein 2A
T95682	FUNCTION	In the complex, it plays a central role by being recruited to rDNA and by targeting chromatin modifying enzymes such as HDAC1, leading to repress RNA polymerase I transcription. Recruited to rDNA via its interaction with TTF1 and its ability to recognize and bind histone H4 acetylated on 'Lys-16' (H4K16ac), leading to deacetylation of H4K5ac, H4K8ac, H4K12ac but not H4K16ac. Specifically binds pRNAs, 150-250 nucleotide RNAs that are complementary in sequence to the rDNA promoter; pRNA-binding is required for heterochromatin formation and rDNA silencing. Essential component of the NoRC (nucleolar remodeling complex) complex, a complex that mediates silencing of a fraction of rDNA by recruiting histone-modifying enzymes and DNA methyltransferases, leading to heterochromatin formation and transcriptional silencing.
T95682	PDBSTRUC	6FKP; 6FI0; 6FHU; 6FGW; 6FGV
T95682	SEQUENCE	MEMEANDHFNFTGLPPAPAASGLKPSPSSGEGLYTNGSPMNFPQQGKSLNGDVNVNGLSTVSHTTTSGILNSAPHSSSTSHLHHPSVAYDCLWNYSQYPSANPGSNLKDPPLLSQFSGGQYPLNGILGGSRQPSSPSHNTNLRAGSQEFWANGTQSPMGLNFDSQELYDSFPDQNFEVMPNGPPSFFTSPQTSPMLGSSIQTFAPSQEVGSGIHPDEAAEKEMTSVVAENGTGLVGSLELEEEQPELKMCGYNGSVPSVESLHQEVSVLVPDPTVSCLDDPSHLPDQLEDTPILSEDSLEPFNSLAPEPVSGGLYGIDDTELMGAEDKLPLEDSPVISALDCPSLNNATAFSLLADDSQTSTSIFASPTSPPVLGESVLQDNSFDLNNGSDAEQEEMETQSSDFPPSLTQPAPDQSSTIQLHPATSPAVSPTTSPAVSLVVSPAASPEISPEVCPAASTVVSPAVFSVVSPASSAVLPAVSLEVPLTASVTSPKASPVTSPAAAFPTASPANKDVSSFLETTADVEEITGEGLTASGSGDVMRRRIATPEEVRLPLQHGWRREVRIKKGSHRWQGETWYYGPCGKRMKQFPEVIKYLSRNVVHSVRREHFSFSPRMPVGDFFEERDTPEGLQWVQLSAEEIPSRIQAITGKRGRPRNTEKAKTKEVPKVKRGRGRPPKVKITELLNKTDNRPLKKLEAQETLNEEDKAKIAKSKKKMRQKVQRGECQTTIQGQARNKRKQETKSLKQKEAKKKSKAEKEKGKTKQEKLKEKVKREKKEKVKMKEKEEVTKAKPACKADKTLATQRRLEERQRQQMILEEMKKPTEDMCLTDHQPLPDFSRVPGLTLPSGAFSDCLTIVEFLHSFGKVLGFDPAKDVPSLGVLQEGLLCQGDSLGEVQDLLVRLLKAALHDPGFPSYCQSLKILGEKVSEIPLTRDNVSEILRCFLMAYGVEPALCDRLRTQPFQAQPPQQKAAVLAFLVHELNGSTLIINEIDKTLESMSSYRKNKWIVEGRLRRLKTVLAKRTGRSEVEMEGPEECLGRRRSSRIMEETSGMEEEEEEESIAAVPGRRGRRDGEVDATASSIPELERQIEKLSKRQLFFRKKLLHSSQMLRAVSLGQDRYRRRYWVLPYLAGIFVEGTEGNLVPEEVIKKETDSLKVAAHASLNPALFSMKMELAGSNTTASSPARARGRPRKTKPGSMQPRHLKSPVRGQDSEQPQAQLQPEAQLHAPAQPQPQLQLQLQSHKGFLEQEGSPLSLGQSQHDLSQSAFLSWLSQTQSHSSLLSSSVLTPDSSPGKLDPAPSQPPEEPEPDEAESSPDPQALWFNISAQMPCNAAPTPPPAVSEDQPTPSPQQLASSKPMNRPSAANPCSPVQFSSTPLAGLAPKRRAGDPGEMPQSPTGLGQPKRRGRPPSKFFKQMEQRYLTQLTAQPVPPEMCSGWWWIRDPEMLDAMLKALHPRGIREKALHKHLNKHRDFLQEVCLRPSADPIFEPRQLPAFQEGIMSWSPKEKTYETDLAVLQWVEELEQRVIMSDLQIRGWTCPSPDSTREDLAYCEHLSDSQEDITWRGRGREGLAPQRKTTNPLDLAVMRLAALEQNVERRYLREPLWPTHEVVLEKALLSTPNGAPEGTTTEISYEITPRIRVWRQTLERCRSAAQVCLCLGQLERSIAWEKSVNKVTCLVCRKGDNDEFLLLCDGCDRGCHIYCHRPKMEAVPEGDWFCTVCLAQQVEGEFTQKPGFPKRGQKRKSGYSLNFSEGDGRRRRVLLRGRESPAAGPRYSEEGLSPSKRRRLSMRNHHSDLTFCEIILMEMESHDAAWPFLEPVNPRLVSGYRRIIKNPMDFSTMRERLLRGGYTSSEEFAADALLVFDNCQTFNEDDSEVGKAGHIMRRFFESRWEEFYQGKQANL
T95682	DRUGINFO	D0I4FP	BAZ2-ICR	Investigative
T95682	DRUGINFO	D0T3WL	GSK2801	Investigative

T86025	TARGETID	T86025
T86025	FORMERID	TTDR00693
T86025	UNIPROID	ANX10_HUMAN
T86025	TARGNAME	Annexin A10 (ANXA10)
T86025	GENENAME	ANXA10
T86025	TARGTYPE	Literature-reported
T86025	SYNONYMS	Annexin-14; Annexin-10; ANX14
T86025	FUNCTION	The expression of the tissue- and tumor-restricted ANXA10 is a marker of liver cell differentiation and growth arrest, and its down-regulation associated with malignant phenotype of hepatocytes, vascular invasion, and progression of HCC, leading to poor prognosis.
T86025	BIOCLASS	Annexin protein
T86025	SEQUENCE	MFCGDYVQGTIFPAPNFNPIMDAQMLGGALQGFDCDKDMLINILTQRCNAQRMMIAEAYQSMYGRDLIGDMREQLSDHFKDVMAGLMYPPPLYDAHELWHAMKGVGTDENCLIEILASRTNGEIFQMREAYCLQYSNNLQEDIYSETSGHFRDTLMNLVQGTREEGYTDPAMAAQDAMVLWEACQQKTGEHKTMLQMILCNKSYQQLRLVFQEFQNISGQDMVDAINECYDGYFQELLVAIVLCVRDKPAYFAYRLYSAIHDFGFHNKTVIRILIARSEIDLLTIRKRYKERYGKSLFHDIRNFASGHYKKALLAICAGDAEDY

T35161	TARGETID	T35161
T35161	FORMERID	TTDI02525
T35161	UNIPROID	HSPB8_HUMAN
T35161	TARGNAME	Heat shock protein beta-8 (HSPB8)
T35161	GENENAME	HSPB8
T35161	TARGTYPE	Literature-reported
T35161	SYNONYMS	Small stress proteinlike protein HSP22; Small stress protein-like protein HSP22; Protein kinase H11; PP1629; HspB8; Heat shock protein beta8; HSP22; E2induced gene 1 protein; E2IG1; E2-induced gene 1 protein; CRYAC; Alphacrystallin C chain; Alpha-crystallin C chain
T35161	FUNCTION	Displays temperature-dependent chaperone activity.
T35161	BIOCLASS	Heat shock protein
T35161	SEQUENCE	MADGQMPFSCHYPSRLRRDPFRDSPLSSRLLDDGFGMDPFPDDLTASWPDWALPRLSSAWPGTLRSGMVPRGPTATARFGVPAEGRTPPPFPGEPWKVCVNVHSFKPEELMVKTKDGYVEVSGKHEEKQQEGGIVSKNFTKKIQLPAEVDPVTVFASLSPEGLLIIEAPQVPPYSTFGESSFNNELPQDSQEVTCT

T90071	TARGETID	T90071
T90071	FORMERID	TTDI02405
T90071	UNIPROID	MYH2_HUMAN
T90071	TARGNAME	Myosin-2 (MYH2)
T90071	GENENAME	MYH2
T90071	TARGTYPE	Literature-reported
T90071	SYNONYMS	Myosin heavy chain, skeletal muscle, adult 2; Myosin heavy chain IIa; Myosin heavy chain 2a; Myosin heavy chain 2; MyHCIIa; MyHC2a; MyHC-IIa; MyHC-2a; MYHSA2
T90071	FUNCTION	Required for cytoskeleton organization. Muscle contraction.
T90071	BIOCLASS	Myosin-kinesin ATPase
T90071	SEQUENCE	MSSDSELAVFGEAAPFLRKSERERIEAQNRPFDAKTSVFVAEPKESFVKGTIQSREGGKVTVKTEGGATLTVKDDQVFPMNPPKYDKIEDMAMMTHLHEPAVLYNLKERYAAWMIYTYSGLFCVTVNPYKWLPVYKPEVVTAYRGKKRQEAPPHIFSISDNAYQFMLTDRENQSILITGESGAGKTVNTKRVIQYFATIAVTGEKKKEEITSGKIQGTLEDQIISANPLLEAFGNAKTVRNDNSSRFGKFIRIHFGTTGKLASADIETYLLEKSRVVFQLKAERSYHIFYQITSNKKPELIEMLLITTNPYDYPFVSQGEISVASIDDQEELMATDSAIDILGFTNEEKVSIYKLTGAVMHYGNLKFKQKQREEQAEPDGTEVADKAAYLQSLNSADLLKALCYPRVKVGNEYVTKGQTVEQVSNAVGALAKAVYEKMFLWMVARINQQLDTKQPRQYFIGVLDIAGFEIFDFNSLEQLCINFTNEKLQQFFNHHMFVLEQEEYKKEGIEWTFIDFGMDLAACIELIEKPMGIFSILEEECMFPKATDTSFKNKLYDQHLGKSANFQKPKVVKGKAEAHFALIHYAGVVDYNITGWLEKNKDPLNETVVGLYQKSAMKTLAQLFSGAQTAEGEGAGGGAKKGGKKKGSSFQTVSALFRENLNKLMTNLRSTHPHFVRCIIPNETKTPGAMEHELVLHQLRCNGVLEGIRICRKGFPSRILYADFKQRYKVLNASAIPEGQFIDSKKASEKLLASIDIDHTQYKFGHTKVFFKAGLLGLLEEMRDDKLAQLITRTQARCRGFLARVEYQRMVERREAIFCIQYNIRSFMNVKHWPWMKLFFKIKPLLKSAETEKEMATMKEEFQKIKDELAKSEAKRKELEEKMVTLLKEKNDLQLQVQAEAEGLADAEERCDQLIKTKIQLEAKIKEVTERAEDEEEINAELTAKKRKLEDECSELKKDIDDLELTLAKVEKEKHATENKVKNLTEEMAGLDETIAKLTKEKKALQEAHQQTLDDLQAEEDKVNTLTKAKIKLEQQVDDLEGSLEQEKKLRMDLERAKRKLEGDLKLAQESIMDIENEKQQLDEKLKKKEFEISNLQSKIEDEQALGIQLQKKIKELQARIEELEEEIEAERASRAKAEKQRSDLSRELEEISERLEEAGGATSAQIEMNKKREAEFQKMRRDLEEATLQHEATAATLRKKHADSVAELGEQIDNLQRVKQKLEKEKSEMKMEIDDLASNVETVSKAKGNLEKMCRTLEDQLSELKSKEEEQQRLINDLTAQRGRLQTESGEFSRQLDEKEALVSQLSRGKQAFTQQIEELKRQLEEEIKAKNALAHALQSSRHDCDLLREQYEEEQESKAELQRALSKANTEVAQWRTKYETDAIQRTEELEEAKKKLAQRLQAAEEHVEAVNAKCASLEKTKQRLQNEVEDLMLDVERTNAACAALDKKQRNFDKILAEWKQKCEETHAELEASQKEARSLGTELFKIKNAYEESLDQLETLKRENKNLQQEISDLTEQIAEGGKRIHELEKIKKQVEQEKCELQAALEEAEASLEHEEGKILRIQLELNQVKSEVDRKIAEKDEEIDQLKRNHIRIVESMQSTLDAEIRSRNDAIRLKKKMEGDLNEMEIQLNHANRMAAEALRNYRNTQGILKDTQIHLDDALRSQEDLKEQLAMVERRANLLQAEIEELRATLEQTERSRKIAEQELLDASERVQLLHTQNTSLINTKKKLETDISQMQGEMEDILQEARNAEEKAKKAITDAAMMAEELKKEQDTSAHLERMKKNMEQTVKDLQLRLDEAEQLALKGGKKQIQKLEARVRELEGEVESEQKRNAEAVKGLRKHERRVKELTYQTEEDRKNILRLQDLVDKLQAKVKSYKRQAEEAEEQSNTNLAKFRKLQHELEEAEERADIAESQVNKLRVKSREVHTKVISEE

T98577	TARGETID	T98577
T98577	FORMERID	TTDI02498
T98577	UNIPROID	ITA11_HUMAN
T98577	TARGNAME	Integrin alpha-11 (ITGA11)
T98577	GENENAME	ITGA11
T98577	TARGTYPE	Literature-reported
T98577	SYNONYMS	MSTP018
T98577	FUNCTION	Integrin alpha-11/beta-1 is a receptor for collagen.
T98577	BIOCLASS	Integrin
T98577	SEQUENCE	MDLPRGLVVAWALSLWPGFTDTFNMDTRKPRVIPGSRTAFFGYTVQQHDISGNKWLVVGAPLETNGYQKTGDVYKCPVIHGNCTKLNLGRVTLSNVSERKDNMRLGLSLATNPKDNSFLACSPLWSHECGSSYYTTGMCSRVNSNFRFSKTVAPALQRCQTYMDIVIVLDGSNSIYPWVEVQHFLINILKKFYIGPGQIQVGVVQYGEDVVHEFHLNDYRSVKDVVEAASHIEQRGGTETRTAFGIEFARSEAFQKGGRKGAKKVMIVITDGESHDSPDLEKVIQQSERDNVTRYAVAVLGYYNRRGINPETFLNEIKYIASDPDDKHFFNVTDEAALKDIVDALGDRIFSLEGTNKNETSFGLEMSQTGFSSHVVEDGVLLGAVGAYDWNGAVLKETSAGKVIPLRESYLKEFPEELKNHGAYLGYTVTSVVSSRQGRVYVAGAPRFNHTGKVILFTMHNNRSLTIHQAMRGQQIGSYFGSEITSVDIDGDGVTDVLLVGAPMYFNEGRERGKVYVYELRQNLFVYNGTLKDSHSYQNARFGSSIASVRDLNQDSYNDVVVGAPLEDNHAGAIYIFHGFRGSILKTPKQRITASELATGLQYFGCSIHGQLDLNEDGLIDLAVGALGNAVILWSRPVVQINASLHFEPSKINIFHRDCKRSGRDATCLAAFLCFTPIFLAPHFQTTTVGIRYNATMDERRYTPRAHLDEGGDRFTNRAVLLSSGQELCERINFHVLDTADYVKPVTFSVEYSLEDPDHGPMLDDGWPTTLRVSVPFWNGCNEDEHCVPDLVLDARSDLPTAMEYCQRVLRKPAQDCSAYTLSFDTTVFIIESTRQRVAVEATLENRGENAYSTVLNISQSANLQFASLIQKEDSDGSIECVNEERRLQKQVCNVSYPFFRAKAKVAFRLDFEFSKSIFLHHLEIELAAGSDSNERDSTKEDNVAPLRFHLKYEADVLFTRSSSLSHYEVKPNSSLERYDGIGPPFSCIFRIQNLGLFPIHGMMMKITIPIATRSGNRLLKLRDFLTDEANTSCNIWGNSTEYRPTPVEEDLRRAPQLNHSNSDVVSINCNIRLVPNQEINFHLLGNLWLRSLKALKYKSMKIMVNAALQRQFHSPFIFREEDPSRQIVFEISKQEDWQVPIWIIVGSTLGGLLLLALLVLALWKLGFFRSARRRREPGLDPTPKVLE

T82955	TARGETID	T82955
T82955	FORMERID	TTDI00181
T82955	UNIPROID	RB22A_HUMAN
T82955	TARGNAME	Ras-related protein Rab-22A (Rab22a)
T82955	GENENAME	RAB22A
T82955	TARGTYPE	Literature-reported
T82955	SYNONYMS	Rab-22; RAB22
T82955	FUNCTION	Mediates trafficking of TF from early endosomes to recycling endosomes. Required for NGF-mediated endocytosis of NTRK1, and subsequent neurite outgrowth. Binds GTP and GDP and has low GTPase activity. Alternates between a GTP-bound active form and a GDP-bound inactive form. Plays a role in endocytosis and intracellular protein transport.
T82955	BIOCLASS	Small GTPase
T82955	SEQUENCE	MALRELKVCLLGDTGVGKSSIVWRFVEDSFDPNINPTIGASFMTKTVQYQNELHKFLIWDTAGQERFRALAPMYYRGSAAAIIVYDITKEETFSTLKNWVKELRQHGPPNIVVAIAGNKCDLIDVREVMERDAKDYADSIHAIFVETSAKNAININELFIEISRRIPSTDANLPSGGKGFKLRRQPSEPKRSCC

T27466	TARGETID	T27466
T27466	FORMERID	TTDI03062
T27466	UNIPROID	BRPF3_HUMAN
T27466	TARGNAME	Bromodomain and PHD finger containing 3 (BRPF3)
T27466	GENENAME	BRPF3
T27466	TARGTYPE	Literature-reported
T27466	SYNONYMS	KIAA1286; Bromodomain and PHD finger-containing protein 3
T27466	FUNCTION	Component of the MOZ/MORF complex which has a histone H3 acetyltransferase activity.
T27466	PDBSTRUC	3PFS
T27466	SEQUENCE	MRKPRRKSRQNAEGRRSPSPYSLKCSPTRETLTYAQAQRIVEVDIDGRLHRISIYDPLKIITEDELTAQDITECNSNKENSEQPQFPGKSKKPSSKGKKKESCSKHASGTSFHLPQPSFRMVDSGIQPEAPPLPAAYYRYIEKPPEDLDAEVEYDMDEEDLAWLDMVNEKRRVDGHSLVSADTFELLVDRLEKESYLESRSSGAQQSLIDEDAFCCVCLDDECHNSNVILFCDICNLAVHQECYGVPYIPEGQWLCRCCLQSPSRPVDCILCPNKGGAFKQTSDGHWAHVVCAIWIPEVCFANTVFLEPIEGIDNIPPARWKLTCYICKQKGLGAAIQCHKVNCYTAFHVTCAQRAGLFMKIEPMRETSLNGTIFTVRKTAYCEAHSPPGAATARRKGDSPRSISETGDEEGLKEGDGEEEEEEEVEEEEQEAQGGVSGSLKGVPKKSKMSLKQKIKKEPEEAGQDTPSTLPMLAVPQIPSYRLNKICSGLSFQRKNQFMQRLHNYWLLKRQARNGVPLIRRLHSHLQSQRNAEQREQDEKTSAVKEELKYWQKLRHDLERARLLIELIRKREKLKREQVKVQQAAMELELMPFNVLLRTTLDLLQEKDPAHIFAEPVNLSEVPDYLEFISKPMDFSTMRRKLESHLYRTLEEFEEDFNLIVTNCMKYNAKDTIFHRAAVRLRDLGGAILRHARRQAENIGYDPERGTHLPESPKLEDFYRFSWEDVDNILIPENRAHLSPEVQLKELLEKLDLVSAMRSSGARTRRVRLLRREINALRQKLAQPPPPQPPSLNKTVSNGELPAGPQGDAAVLEQALQEEPEDDGDRDDSKLPPPPTLEPTGPAPSLSEQESPPEPPTLKPINDSKPPSRFLKPRKVEEDELLEKSPLQLGNEPLQRLLSDNGINRLSLMAPDTPAGTPLSGVGRRTSVLFKKAKNGVKLQRSPDRVLENGEDHGVAGSPASPASIEEERHSRKRPRSRSCSESEGERSPQQEEETGMTNGFGKHTESGSDSECSLGLSGGLAFEACSGLTPPKRSRGKPALSRVPFLEGVNGDSDYNGSGRSLLLPFEDRGDLEPLELVWAKCRGYPSYPALIIDPKMPREGLLHNGVPIPVPPLDVLKLGEQKQAEAGEKLFLVLFFDNKRTWQWLPRDKVLPLGVEDTVDKLKMLEGRKTSIRKSVQVAYDRAMIHLSRVRGPHSFVTSSYL
T27466	DRUGINFO	D0O6XT	NI-57	Investigative

T62643	TARGETID	T62643
T62643	FORMERID	TTDI03336
T62643	UNIPROID	KCNH3_HUMAN
T62643	TARGNAME	Voltage-gated potassium channel Kv12.2 (KCNH3)
T62643	GENENAME	KCNH3
T62643	TARGTYPE	Literature-reported
T62643	SYNONYMS	Voltage-gated potassium channel subunit Kv12.2; Potassium voltage-gated channel subfamily H member 3; KIAA1282; Ether-a-go-go-like potassium channel 2; ELK2; ELK channel 2; Brain-specific eag-like channel 1; BEC1
T62643	FUNCTION	Pore-forming (alpha) subunit of voltage-gated potassium channel. Elicits an outward current with fast inactivation. Channel properties may be modulated by cAMP and subunit assembly.
T62643	BIOCLASS	Voltage-gated ion channel
T62643	SEQUENCE	MPAMRGLLAPQNTFLDTIATRFDGTHSNFVLGNAQVAGLFPVVYCSDGFCDLTGFSRAEVMQRGCACSFLYGPDTSELVRQQIRKALDEHKEFKAELILYRKSGLPFWCLLDVIPIKNEKGEVALFLVSHKDISETKNRGGPDRWKETGGGRRRYGRARSKGFNANRRRSRAVLYHLSGHLQKQPKGKHKLNKGVFGEKPNLPEYKVAAIRKSPFILLHCGALRATWDGFILLATLYVAVTVPYSVCVSTAREPSAARGPPSVCDLAVEVLFILDIVLNFRTTFVSKSGQVVFAPKSICLHYVTTWFLLDVIAALPFDLLHAFKVNVYFGAHLLKTVRLLRLLRLLPRLDRYSQYSAVVLTLLMAVFALLAHWVACVWFYIGQREIESSESELPEIGWLQELARRLETPYYLVGRRPAGGNSSGQSDNCSSSSEANGTGLELLGGPSLRSAYITSLYFALSSLTSVGFGNVSANTDTEKIFSICTMLIGALMHAVVFGNVTAIIQRMYARRFLYHSRTRDLRDYIRIHRIPKPLKQRMLEYFQATWAVNNGIDTTELLQSLPDELRADIAMHLHKEVLQLPLFEAASRGCLRALSLALRPAFCTPGEYLIHQGDALQALYFVCSGSMEVLKGGTVLAILGKGDLIGCELPRREQVVKANADVKGLTYCVLQCLQLAGLHDSLALYPEFAPRFSRGLRGELSYNLGAGGGSAEVDTSSLSGDNTLMSTLEEKETDGEQGPTVSPAPADEPSSPLLSPGCTSSSSAAKLLSPRRTAPRPRLGGRGRPGRAGALKAEAGPSAPPRALEGLRLPPMPWNVPPDLSPRVVDGIEDGCGSDQPKFSFRVGQSGPECSSSPSPGPESGLLTVPHGPSEARNTDTLDKLRQAVTELSEQVLQMREGLQSLRQAVQLVLAPHREGPCPRASGEGPCPASTSGLLQPLCVDTGASSYCLQPPAGSVLSGTWPHPRPGPPPLMAPWPWGPPASQSSPWPRATAFWTSTSDSEPPASGDLCSEPSTPASPPPSEEGARTGPAEPVSQAEATSTGEPPPGSGGLALPWDPHSLEMVLIGCHGSGTVQWTQEEGTGV
T62643	DRUGINFO	D0F5KY	CX4	Investigative

T27819	TARGETID	T27819
T27819	FORMERID	TTDR00754
T27819	UNIPROID	MD1L1_HUMAN
T27819	TARGNAME	Mitotic checkpoint protein (MAD1L1)
T27819	GENENAME	MAD1L1
T27819	TARGTYPE	Literature-reported
T27819	SYNONYMS	hMAD1; Tax-binding protein 181; TXBP181; Mitotic spindle assembly checkpoint protein MAD1; Mitotic checkpoint gene hMAD1; Mitotic checkpoint MAD1 protein homolog; Mitotic arrest deficient 1-like protein 1; MAD1-like protein 1; MAD1 (Mitotic arrest deficient, yeast, homolog)-like 1; MAD1; HsMAD1
T27819	FUNCTION	May recruit MAD2L1 to unattached kinetochores. Has a role in the correct positioning of the septum. Required for anchoring MAD2L1 to the nuclear periphery. Binds to the TERT promoter and represses telomerase expression, possibly by interfering with MYC binding. Component of the spindle-assembly checkpoint that prevents the onset of anaphase until all chromosomes are properly aligned at the metaphase plate.
T27819	PDBSTRUC	4DZO; 1GO4
T27819	SEQUENCE	MEDLGENTMVLSTLRSLNNFISQRVEGGSGLDISTSAPGSLQMQYQQSMQLEERAEQIRSKSHLIQVEREKMQMELSHKRARVELERAASTSARNYEREVDRNQELLTRIRQLQEREAGAEEKMQEQLERNRQCQQNLDAASKRLREKEDSLAQAGETINALKGRISELQWSVMDQEMRVKRLESEKQELQEQLDLQHKKCQEANQKIQELQASQEARADHEQQIKDLEQKLSLQEQDAAIVKNMKSELVRLPRLERELKQLREESAHLREMRETNGLLQEELEGLQRKLGRQEKMQETLVGLELENERLLAKLQSWERLDQTMGLSIRTPEDLSRFVVELQQRELALKDKNSAVTSSARGLEKARQQLQEELRQVSGQLLEERKKRETHEALARRLQKRVLLLTKERDGMRAILGSYDSELTPAEYSPQLTRRMREAEDMVQKVHSHSAEMEAQLSQALEELGGQKQRADMLEMELKMLKSQSSSAEQSFLFSREEADTLRLKVEELEGERSRLEEEKRMLEAQLERRALQGDYDQSRTKVLHMSLNPTSVARQRLREDHSQLQAECERLRGLLRAMERGGTVPADLEAAAASLPSSKEVAELKKQVESAELKNQRLKEVFQTKIQEFRKACYTLTGYQIDITTENQYRLTSLYAEHPGDCLIFKATSPSGSKMQLLETEFSHTVGELIEVHLRRQDSIPAFLSSLTLELFSRQTVA

T44585	TARGETID	T44585
T44585	FORMERID	TTDI00122
T44585	UNIPROID	SH2B3_HUMAN
T44585	TARGNAME	Signal transduction protein Lnk (SH2B3)
T44585	GENENAME	SH2B3
T44585	TARGTYPE	Literature-reported
T44585	SYNONYMS	SH2B3; SH2B adapter protein 3; Lymphocyte-specific adapter protein Lnk; Lymphocyte adapter protein
T44585	FUNCTION	Links T-cell receptor activation signal to phospholipaseC-gamma-1, GRB2 and phosphatidylinositol 3-kinase.
T44585	BIOCLASS	SH2B adapter family
T44585	SEQUENCE	MNGPALQPSSPSSAPSASPAAAPRGWSEFCELHAVAAARELARQYWLFAREHPQHAPLRAELVSLQFTDLFQRYFCREVRDGRAPGRDYRDTGRGPPAKAEASPEPGPGPAAPGLPKARSSEELAPPRPPGPCSFQHFRRSLRHIFRRRSAGELPAAHTAAAPGTPGEAAETPARPGLAKKFLPWSLAREPPPEALKEAVLRYSLADEASMDSGARWQRGRLALRRAPGPDGPDRVLELFDPPKSSRPKLQAACSSIQEVRWCTRLEMPDNLYTFVLKVKDRTDIIFEVGDEQQLNSWMAELSECTGRGLESTEAEMHIPSALEPSTSSSPRGSTDSLNQGASPGGLLDPACQKTDHFLSCYPWFHGPISRVKAAQLVQLQGPDAHGVFLVRQSETRRGEYVLTFNFQGIAKHLRLSLTERGQCRVQHLHFPSVVDMLHHFQRSPIPLECGAACDVRLSSYVVVVSQPPGSCNTVLFPFSLPHWDSESLPHWGSELGLPHLSSSGCPRGLSPEGLPGRSSPPEQIFHLVPSPEELANSLQHLEHEPVNRARDSDYEMDSSSRSHLRAIDNQYTPL

T34408	TARGETID	T34408
T34408	FORMERID	TTDR00839
T34408	UNIPROID	Q9UVD0_PNECA
T34408	TARGNAME	Fungal Kexin-like serine endoprotease (Fung klse)
T34408	GENENAME	Fung klse
T34408	TARGTYPE	Literature-reported
T34408	SYNONYMS	Kexin-like serine endoprotease
T34408	FUNCTION	Cleave secretory proproteins to their active forms.  Required for N-Glycan processing, morphogenesis and virulence
T34408	BIOCLASS	Peptidase
T34408	SEQUENCE	EPPAPPSQPEPPAPQPQPEPPAPPPQPEPPAPPPQPEPPAPPPQPEPPAPPSQPEPPAPPPQPEPPAPPPQPEPPAPPPKPQPEQKPTSITSSTFTTSSSKTKISTIRKASSTKTSSTTKTSTRPSPTEGTFTGSSASYLSFFEKRHLLLQMILLLFFFLFLSYSF

T83701	TARGETID	T83701
T83701	FORMERID	TTDR01083
T83701	UNIPROID	PDX1_EMENI
T83701	TARGNAME	Fungal Pyridoxin biosynthesis pyroA (Fung pyroA)
T83701	GENENAME	Fung pyroA
T83701	TARGTYPE	Literature-reported
T83701	SYNONYMS	pyroA; Pdx1 homolog
T83701	FUNCTION	Catalyzes the formation of pyridoxal 5'-phosphate from ribose 5-phosphate (RBP), glyceraldehyde 3-phosphate (G3P) and ammonia. The ammonia is provided by PDX2. Can also use ribulose 5- phosphate and dihydroxyacetone phosphate as substrates, resulting from enzyme-catalyzed isomerization of RBP and G3P, respectively. Also plays an indirect role in resistance to singlet oxygen- generating photosensitizers.
T83701	ECNUMBER	EC 4.3.3.6
T83701	SEQUENCE	MAATNGASNDFTVKAGLAQMLKGGVIMDVVNAEQARIAEEAGAAAVMALERVPADIRAQGGVARMSDPSMIKEIMEAVTIPVMAKARIGHFVECQILEAIGVDYIDESEVLTPADNLYHVTKHNFKAPFVCGCRNLGEALRRISEGAAMIRTKGEAGTGDVVEAVKHMRTVNAEIARARAILQSSPDPEPELRAYARELEAPYELLREAAEKGRLPVVNFAAGGVATPADAALMMQLGCDGVFVGSGIFKSGDAKKRAKAIVQAVTHYKDPKVLAEVSQGLGEAMVGINVSHMKDEDKLAKRGW

T52513	TARGETID	T52513
T52513	FORMERID	TTDR00047
T52513	UNIPROID	RPOA_PRRSR
T52513	TARGNAME	Virus Papain-like cysteine protease (Viru pcp)
T52513	GENENAME	Viru pcp
T52513	TARGTYPE	Literature-reported
T52513	SYNONYMS	rep of Porcine reproductive and respiratory syndrome virus; Pol; ORF1ab polyprotein of Porcine reproductive and respiratory syndrome virus; Nsp8; Nsp5-6-7; Nsp3; Nsp12; Nsp11; Non-structural protein 12; Hel; CP of Porcine reproductive and respiratory syndrome virus; 3CLSP
T52513	FUNCTION	The helicase chain, which contains a zinc finger structure,displays RNA and DNA duplex-unwinding activities with 5' to 3' polarity.
T52513	BIOCLASS	Arteriviridae polyprotein family
T52513	SEQUENCE	MSGILDRCTCTPNARVFMAEGQVYCTRCLSARSLLPLNLQVSELGVLGLFYRPEEPLRWTLPRAFPTVECSPAGACWLSAIFPIARMTSGNLNFQQRMVRVAAELYRAGQLTPAVLKALQVYERGCRWYPIVGPVPGVAVFANSLHVSDKPFPGATHVLTNLPLPQRPKPEDFCPFECAMATVYDIGHDAVMYVAERKVSWAPRGGDEVKFEAVPGELKLIANRLRTSFPPHHTVDMSKFAFTAPGCGVSMRVERQHGCLPADTVPEGNCWWSLFDLLPLEVQNKEIRHANQFGYQTKHGVSGKYLQRRLQVNGLRAVTDLNGPIVVQYFSVKESWIRHLKLAGEPSYSGFEDLLRIRVEPNTSPLADKEEKIFRFGSHKWYGAGKRARKARSCATATVAGRALSVRETRQAKEHEVAGANKAEHLKHYSPPAEGNCGWHCISAIANRMVNSKFETTLPERVRPPDDWATDEDLVNAIQILRLPAALDRNGACTSAKYVLKLEGEHWTVTVTPGMSPSLLPLECVQGCCGHKGGLGSPDAVEVSGFDPACLDRLAEVMHLPSSAIPAALAEMSGDSDRSASPVTTVWTVSQFFARHSGGNHPDQVRLGKIISLCQVIEDCCCSQNKTNRVTPEEVAAKIDLYLRGATNLEECLARLEKARPPRVIDTSFDWDVVLPGVEAATQTIKLPQVNQCRALVPVVTQKSLDNNSVPLTAFSLANYYYRAQGDEVRHRERLTAVLSKLEKVVREEYGLMPTEPGPRPTLPRGLDELKDQMEEDLLKLANAQTTSDMMAWAVEQVDLKTWVKNYPRWTPPPPPPKVQPRKTKPVKSLPERKPVPAPRRKVGSDCGSPVSLGGDVPNSWEDLAVSSPFDLPTPPEPATPSSELVIVSSPQCIFRPATPLSEPAPIPAPRGTVSRPVTPLSEPIPVPAPRRKFQQVKRLSSAAAIPPYQDEPLDLSASSQTEYEASPPAPPQSGGVLGVEGHEAEETLSEISDMSGNIKPASVSSSSSLSSVRITRPKYSAQAIIDSGGPCSGHLQEVKETCLSVMREACDATKLDDPATQEWLSRMWDRVDMLTWRNTSVYQAICTLDGRLKFLPKMILETPPPYPCEFVMMPHTPAPSVGAESDLTIGSVATEDVPRILEKIENVGEMANQGPLAFSEDKPVDDQLVNDPRISSRRPDESTSAPSAGTGGAGSFTDLPPSDGADADGGGPFRTVKRKAERLFDQLSRQVFDLVSHLPVFFSRLFYPGGGYSPGDWGFAAFTLLCLFLCYSYPAFGIAPLLGVFSGSSRRVRMGVFGCWLAFAVGLFKPVSDPVGAACEFDSPECRNILHSFELLKPWDPVRSLVVGPVGLGLAILGRLLGGARCIWHFLLRLGIVADCILAGAYVLSQGRCKKCWGSCIRTAPNEVAFNVFPFTRATRSSLIDLCDRFCAPKGMDPIFLATGWRGCWAGRSPIEQPSEKPIAFAQLDEKKITARTVVAQPYDPNQAVKCLRVLQSGGAMVAKAVPKVVKVSAVPFRAPFFPTGVKVDPDCRVVVDPDTFTAALRSGYSTTNLVLGVGDFAQLNGLKIRQISKPSGGGPHLMAALHVACSMALHMLAGIYVTAVGSCGTGTNDPWCANPFAVPGYGPGSLCTSRLCISQHGLTLPLTALVAGFGIQEIALVVLIFVSIGGMAHRLSCKADMLCVLLAIASYVWVPLTWLLCVFPCWLRCFSLHPLTILWLVFFLISVNMPSGILAMVLLVSLWLLGRYTNVAGLVTPYDIHHYTSGPRGVAALATAPDGTYLAAVRRAALTGRTMLFTPSQLGSLLEGAFRTRKPSLNTVNVIGSSMGSGGVFTIDGKVKCVTAAHVLTGNSARVSGVGFNQMLDFDVKGDFAIADCPNWQGAAPKTQFCTDGWTGRAYWLTSSGVEPGVIGKGFAFCFTACGDSGSPVITEAGELVGVHTGSNKQGGGIVTRPSGQFCNVAPIKLSELSEFFAGPKVPLGDVKVGSHIIKDISEVPSDLCALLAAKPELEGGLSTVQLLCVFFLLWRMMGHAWTPLVAVSFFILNEVLPAVLVRSVFSFGMFVLSWLTPWSAQVLMIRLLTAALNRNRWSLAFFSLGAVTGFVADLAATQGHPLQAVMNLSTYAFLPRMMVVTSPVPVITCGVVHLLAIILYLFKYRGPHHILVGDGVFSAAFFLRYFAEGKLREGVSQSCGMNHESLTGALAMRLNDEDLDFLMKWTDFKCFVSASNMRNAAGQFIEAAYAKALRVELAQLVQVDKVRGTLAKLEAFADTVAPQLSPGDIVVALGHTPVGSIFDLKVGSTKHTLQAIETRVLAGSKMTVARVVDPTPTPPPAPVPIPLPPKVLENGPNAWGDEDRLNKKKRRRMEALGIYVMGGKKYQKFWDKNSGDVFYEEVHNNTDEWECLRVGDPADFDPEKGTLCGHVTIENKAYHVYTSPSGKKFLVPVNPENGRVQWEAAKLSVEQALGMMNVDGELTAKELEKLKRIIDKLQGLTKEQCLNCLAASDLTRCGRGGLVVTETAVKIVKFHNRTFTLGPVNLKVASEVELKDAVEHNQHPVARPIDGGVVLLRSAVPSLIDVLISGADASPKLLAHHGPGNTGIDGTLWDFESEATKEEVALSAQIIQACDIRRGDAPEIGLPYKLYPVRGNPERVKGVLQNTRFGDIPYKTPSDTGSPVHAAACLTPNATPVTDGRSVLATTMPPGFELYVPTIPASVLDYLDSRPDCPKQLTEHGCEDAALKDLSKYDLSTQGFVLPGVLRLVRKYLFAHVGKCPPVHRPSTYPAKNSMAGINGNRFPTKDIQSVPEIDVLCAQAVRENWQTVTPCTLKKQYCGKKKTRTILGTNNFIALAHRAVLSGVTQGFMKKAFNSPIALGKNKFKELQTPVLGRCLEADLASCDRSTPAIVRWFAANLLYELACAEEHLPSYVLNCCHDLLVTQSGAVTKRGGLSSGDPITSVSNTIYSLVIYAQHMVLSYFKSGHPHGLLFLQDQLKFEDMLKVQPLIVYSDDLVLYAESPTMPNYHWWVEHLNLMLGFQTDPKKTAITDSPSFLGCRIINGRQLVPNRDRILAALAYHMKASNVSEYYASAAAILMDSCACLEYDPEWFEELVVGIAQCARKDGYSFPGTPFFMSMWEKLRSNYEGKKSRVCGYCGAPAPYATACGLDVCIYHTHFHQHCPVTIWCGHPAGSGSCSECKSPVGKGTSPLDEVLEQVPYKPPRTVIMHVEQGLTPLDPGRYQTRRGLVSVRRGIRGNEVGLPDGDYASTALLPTCKEINMVAVASNVLRSRFIIGPPGAGKTYWLLQQVQDGDVIYTPTHQTMLDMIRALGTCRFNVPAGTTLQFPVPSRTGPWVRILAGGWCPGKNSFLDEAAYCNHLDVLRLLSKTTLTCLGDFKQLHPVGFDSHCYVFDIMPQTQLKTIWRFGQNICDAIQPDYRDKLMSMVNTTRVTYVEKPVRYGQVLTPYHRDREDDAITIDSSQGATFDVVTLHLPTKDSLNRQRALVAITRARHAIFVYDPHRQLQGLFDLPAKGTPVNLAVHCDGQLIVLDRNNKECTVAQALGNGDKFRATDKRVVDSLRAICADLEGSSSPLPKVAHNLGFYFSPDLTQFAKLPVELAPHWPVVSTQNNEKWPDRLVASLRPIHKYSRACIGAGYMVGPSVFLGTPGVVSYYLTKFVKGGAQVLPETVFSTGRIEVDCREYLDDREREVAASLPHGFIGDVKGTTVGGCHHVTSRYLPRVLPKESVAVVGVSSPGKAAKALCTLTDVYLPDLEAYLHPETQSKCWKMMLDFKEVRLMVWKDKTAYFQLEGRYFTWYQLASYASYIRVPVNSTVYLDPCMGPALCNRRVVGSTHWGADLAVTPYDYGAKIILSSAYHGEMPPGYKILACAEFSLDDPVKYKHTWGFESDTAYLYEFTGNGEDWEDYNDAFRARQEGKIYKATATSLKFYFPPGPVIEPTLGLN

T68237	TARGETID	T68237
T68237	FORMERID	TTDR00327
T68237	UNIPROID	Q9WWI2_PSESY
T68237	TARGNAME	Pseudomonas Histidine kinase AlgR1 (Pseudo algR1)
T68237	GENENAME	Pseudo algR1
T68237	TARGTYPE	Literature-reported
T68237	SYNONYMS	Response regulator transcription factor; Alginate biosynthesis regulatory protein
T68237	FUNCTION	Plays an important role in essential signal transduction for adapting to bacterial stress.
T68237	BIOCLASS	Kinase
T68237	SEQUENCE	MNVLIVDDEPLARERLSRMVNEIEGYRVLEPSASNGEEALALIETHKPDVVLLDIRMPGLDGLQVAARLCEREAPPAVVFCTAHDEFALEAFQVSAVGYLVKPVRPEHLVEALRKAERPNRVQLAALTRPAAESGSGPRSHISARTRKGIELIPLDQVIYFIADHKYVTLRHEGGEVLLDEPLKALEDEFGDRFVRIHRNALVARERIERLQRTPLGHFQLFLRGLNGDALIVSRRHVAGVRKMMQQL

T90439	TARGETID	T90439
T90439	FORMERID	TTDI00151
T90439	UNIPROID	JAG2_HUMAN
T90439	TARGNAME	Jagged-2 protein (JAG2)
T90439	GENENAME	JAG2
T90439	TARGTYPE	Literature-reported
T90439	SYNONYMS	hJ2; Protein jagged-2; Jagged2
T90439	FUNCTION	Involved in limb development. Putative Notch ligand involved in the mediation of Notch signaling.
T90439	PDBSTRUC	5MWF; 5MW7; 5MW5
T90439	SEQUENCE	MRAQGRGRLPRRLLLLLALWVQAARPMGYFELQLSALRNVNGELLSGACCDGDGRTTRAGGCGHDECDTYVRVCLKEYQAKVTPTGPCSYGHGATPVLGGNSFYLPPAGAAGDRARARARAGGDQDPGLVVIPFQFAWPRSFTLIVEAWDWDNDTTPNEELLIERVSHAGMINPEDRWKSLHFSGHVAHLELQIRVRCDENYYSATCNKFCRPRNDFFGHYTCDQYGNKACMDGWMGKECKEAVCKQGCNLLHGGCTVPGECRCSYGWQGRFCDECVPYPGCVHGSCVEPWQCNCETNWGGLLCDKDLNYCGSHHPCTNGGTCINAEPDQYRCTCPDGYSGRNCEKAEHACTSNPCANGGSCHEVPSGFECHCPSGWSGPTCALDIDECASNPCAAGGTCVDQVDGFECICPEQWVGATCQLDANECEGKPCLNAFSCKNLIGGYYCDCIPGWKGINCHINVNDCRGQCQHGGTCKDLVNGYQCVCPRGFGGRHCELERDECASSPCHSGGLCEDLADGFHCHCPQGFSGPLCEVDVDLCEPSPCRNGARCYNLEGDYYCACPDDFGGKNCSVPREPCPGGACRVIDGCGSDAGPGMPGTAASGVCGPHGRCVSQPGGNFSCICDSGFTGTYCHENIDDCLGQPCRNGGTCIDEVDAFRCFCPSGWEGELCDTNPNDCLPDPCHSRGRCYDLVNDFYCACDDGWKGKTCHSREFQCDAYTCSNGGTCYDSGDTFRCACPPGWKGSTCAVAKNSSCLPNPCVNGGTCVGSGASFSCICRDGWEGRTCTHNTNDCNPLPCYNGGICVDGVNWFRCECAPGFAGPDCRINIDECQSSPCAYGATCVDEINGYRCSCPPGRAGPRCQEVIGFGRSCWSRGTPFPHGSSWVEDCNSCRCLDGRRDCSKVWCGWKPCLLAGQPEALSAQCPLGQRCLEKAPGQCLRPPCEAWGECGAEEPPSTPCLPRSGHLDNNCARLTLHFNRDHVPQGTTVGAICSGIRSLPATRAVARDRLLVLLCDRASSGASAVEVAVSFSPARDLPDSSLIQGAAHAIVAAITQRGNSSLLLAVTEVKVETVVTGGSSTGLLVPVLCGAFSVLWLACVVLCVWWTRKRRKERERSRLPREESANNQWAPLNPIRNPIERPGGHKDVLYQCKNFTPPPRRADEALPGPAGHAAVREDEEDEDLGRGEEDSLEAEKFLSHKFTKDPGRSPGRPAHWASGPKVDNRAVRSINEARYAGKE

T21038	TARGETID	T21038
T21038	FORMERID	TTDI03416
T21038	UNIPROID	NOD1_HUMAN
T21038	TARGNAME	Pattern recognition receptor NOD1 (NOD1)
T21038	GENENAME	NOD1
T21038	TARGTYPE	Literature-reported
T21038	SYNONYMS	Nucleotide-binding oligomerization domain-containing protein 1; Caspase recruitment domain-containing protein 4; CARD4
T21038	FUNCTION	Induces NF-kappa-B activity via RIPK2 and IKK-gamma. Confers responsiveness to intracellular bacterial lipopolysaccharides (LPS). Forms an intracellular sensing system along with ARHGEF2 for the detection of microbial effectors during cell invasion by pathogens. Required for RHOA and RIPK2 dependent NF-kappa-B signaling pathway activation upon S. flexneri cell invasion. Involved not only in sensing peptidoglycan (PGN)-derived muropeptides but also in the activation of NF-kappa-B by Shigella effector proteins IpgB2 and OspB. Recruits NLRP10 to the cell membrane following bacterial infection. Enhances caspase-9-mediated apoptosis.
T21038	PDBSTRUC	4JQW; 4E9M; 2NZ7; 2NSN; 2DBD
T21038	SEQUENCE	MEEQGHSEMEIIPSESHPHIQLLKSNRELLVTHIRNTQCLVDNLLKNDYFSAEDAEIVCACPTQPDKVRKILDLVQSKGEEVSEFFLYLLQQLADAYVDLRPWLLEIGFSPSLLTQSKVVVNTDPVSRYTQQLRHHLGRDSKFVLCYAQKEELLLEEIYMDTIMELVGFSNESLGSLNSLACLLDHTTGILNEQGETIFILGDAGVGKSMLLQRLQSLWATGRLDAGVKFFFHFRCRMFSCFKESDRLCLQDLLFKHYCYPERDPEEVFAFLLRFPHVALFTFDGLDELHSDLDLSRVPDSSCPWEPAHPLVLLANLLSGKLLKGASKLLTARTGIEVPRQFLRKKVLLRGFSPSHLRAYARRMFPERALQDRLLSQLEANPNLCSLCSVPLFCWIIFRCFQHFRAAFEGSPQLPDCTMTLTDVFLLVTEVHLNRMQPSSLVQRNTRSPVETLHAGRDTLCSLGQVAHRGMEKSLFVFTQEEVQASGLQERDMQLGFLRALPELGPGGDQQSYEFFHLTLQAFFTAFFLVLDDRVGTQELLRFFQEWMPPAGAATTSCYPPFLPFQCLQGSGPAREDLFKNKDHFQFTNLFLCGLLSKAKQKLLRHLVPAAALRRKRKALWAHLFSSLRGYLKSLPRVQVESFNQVQAMPTFIWMLRCIYETQSQKVGQLAARGICANYLKLTYCNACSADCSALSFVLHHFPKRLALDLDNNNLNDYGVRELQPCFSRLTVLRLSVNQITDGGVKVLSEELTKYKIVTYLGLYNNQITDVGARYVTKILDECKGLTHLKLGKNKITSEGGKYLALAVKNSKSISEVGMWGNQVGDEGAKAFAEALRNHPSLTTLSLASNGISTEGGKSLARALQQNTSLEILWLTQNELNDEVAESLAEMLKVNQTLKHLWLIQNQITAKGTAQLADALQSNTGITEICLNGNLIKPEEAKVYEDEKRIICF
T21038	DRUGINFO	D0A1GQ	meso-DAP	Investigative

T10756	TARGETID	T10756
T10756	FORMERID	TTDI03509
T10756	UNIPROID	FACE2_HUMAN
T10756	TARGNAME	Ras converting CAAX endopeptidase 1 (RCE1)
T10756	GENENAME	RCE1
T10756	TARGTYPE	Literature-reported
T10756	SYNONYMS	hRCE1; RCE1B; RCE1A; RCE1 homolog; Prenyl protein-specific endoprotease 2; Farnesylated proteins-converting enzyme 2; FACE2; FACE-2; CAAX prenyl protease 2
T10756	FUNCTION	Proteolytically removes the C-terminal three residues of farnesylated and geranylated proteins. Seems to be able to process K-Ras, N-Ras, H-Ras, RAP1B and G-gamma-1.
T10756	ECNUMBER	EC 3.4.22.-
T10756	SEQUENCE	MAALGGDGLRLLSVSRPERPPESAALGGLGPGLCCWVSVFSCLSLACSYVGSLYVWKSELPRDHPAVIKRRFTSVLVVSSLSPLCVLLWRELTGIQPGTSLLTLMGFRLEGIFPAALLPLLLTMILFLGPLMQLSMDCPCDLADGLKVVLAPRSWARCLTDMRWLRNQVIAPLTEELVFRACMLPMLAPCMGLGPAVFTCPLFFGVAHFHHIIEQLRFRQSSVGNIFLSAAFQFSYTAVFGAYTAFLFIRTGHLIGPVLCHSFCNYMGFPAVCAALEHPQRRPLLAGYALGVGLFLLLLQPLTDPKLYGSLPLCVLLERAGDSEAPLCS
T10756	DRUGINFO	D0E2SI	CID16197121	Investigative
T10756	DRUGINFO	D0F3TM	PMID17942791C3	Investigative

T78943	TARGETID	T78943
T78943	FORMERID	TTDR00479
T78943	UNIPROID	NISCH_HUMAN
T78943	TARGNAME	Imidazoline receptor 1 (IR1)
T78943	GENENAME	NISCH
T78943	TARGTYPE	Literature-reported
T78943	SYNONYMS	hIRAS; KIAA0975; Imidazoline-1 receptor candidate protein; Imidazoline-1 receptor; Imidazoline receptor antisera-selected protein; IRAS; IR1; I1R candidate protein; I-1 receptor candidate protein; I-1
T78943	FUNCTION	Acts either as the functional imidazoline-1 receptor (I1R) candidate or as a membrane-associated mediator of the I1R signaling. Binds numerous imidazoline ligands that induces initiation of cell-signaling cascades triggering to cell survival, growth and migration. Its activation by the agonist rilmenidine induces an increase in phosphorylation of mitogen-activated protein kinases MAPK1 and MAPK3 in rostral ventrolateral medulla (RVLM) neurons that exhibited rilmenidine-evoked hypotension (By similarity). Blocking its activation with efaroxan abolished rilmenidine-induced mitogen-activated protein kinase phosphorylation in RVLM neurons (By similarity). Acts as a modulator of Rac-regulated signal transduction pathways (By similarity). Suppresses Rac1-stimulated cell migration by interacting with PAK1 and inhibiting its kinase activity (By similarity). Also blocks Pak-independent Rac signaling by interacting with RAC1 and inhibiting Rac1-stimulated NF-kB response element and cyclin D1 promoter activation (By similarity). Inhibits also LIMK1 kinase activity by reducing LIMK1 'Tyr-508' phosphorylation (By similarity). Inhibits Rac-induced cell migration and invasion in breast and colon epithelial cells (By similarity). Inhibits lamellipodia formation, when overexpressed (By similarity). Plays a role in protection against apoptosis. Involved in association with IRS4 in the enhancement of insulin activation of MAPK1 and MAPK3. When overexpressed, induces a redistribution of cell surface ITGA5 integrin to intracellular endosomal structures.
T78943	PDBSTRUC	3P0C
T78943	SEQUENCE	MATARTFGPEREAEPAKEARVVGSELVDTYTVYIIQVTDGSHEWTVKHRYSDFHDLHEKLVAERKIDKNLLPPKKIIGKNSRSLVEKREKDLEVYLQKLLAAFPGVTPRVLAHFLHFHFYEINGITAALAEELFEKGEQLLGAGEVFAIGPLQLYAVTEQLQQGKPTCASGDAKTDLGHILDFTCRLKYLKVSGTEGPFGTSNIQEQLLPFDLSIFKSLHQVEISHCDAKHIRGLVASKPTLATLSVRFSATSMKEVLVPEASEFDEWEPEGTTLEGPVTAVIPTWQALTTLDLSHNSVSEIDESVKLIPKIEFLDLSHNGLLVVDNLQHLYNLVHLDLSYNKLSSLEGLHTKLGNIKTLNLAGNLLESLSGLHKLYSLVNLDLRDNRIEQMEEVRSIGSLPCLEHVSLLNNPLSIIPDYRTKVLAQFGERASEVCLDDTVTTEKELDTVEVLKAIQKAKEVKSKLSNPEKKGGEDSRLSAAPCIRPSSSPPTVAPASASLPQPILSNQGIMFVQEEALASSLSSTDSLTPEHQPIAQGCSDSLESIPAGQAASDDLRDVPGAVGGASPEHAEPEVQVVPGSGQIIFLPFTCIGYTATNQDFIQRLSTLIRQAIERQLPAWIEAANQREEGQGEQGEEEDEEEEEEEDVAENRYFEMGPPDVEEEEGGGQGEEEEEEEEDEEAEEERLALEWALGADEDFLLEHIRILKVLWCFLIHVQGSIRQFAACLVLTDFGIAVFEIPHQESRGSSQHILSSLRFVFCFPHGDLTEFGFLMPELCLVLKVRHSENTLFIISDAANLHEFHADLRSCFAPQHMAMLCSPILYGSHTSLQEFLRQLLTFYKVAGGCQERSQGCFPVYLVYSDKRMVQTAAGDYSGNIEWASCTLCSAVRRSCCAPSEAVKSAAIPYWLLLTPQHLNVIKADFNPMPNRGTHNCRNRNSFKLSRVPLSTVLLDPTRSCTQPRGAFADGHVLELLVGYRFVTAIFVLPHEKFHFLRVYNQLRASLQDLKTVVIAKTPGTGGSPQGSFADGQPAERRASNDQRPQEVPAEALAPAPAEVPAPAPAAASASGPAKTPAPAEASTSALVPEETPVEAPAPPPAEAPAQYPSEHLIQATSEENQIPSHLPACPSLRHVASLRGSAIIELFHSSIAEVENEELRHLMWSSVVFYQTPGLEVTACVLLSTKAVYFVLHDGLRRYFSEPLQDFWHQKNTDYNNSPFHISQCFVLKLSDLQSVNVGLFDQHFRLTGSTPMQVVTCLTRDSYLTHCFLQHLMVVLSSLERTPSPEPVDKDFYSEFGNKTTGKMENYELIHSSRVKFTYPSEEEIGDLTFTVAQKMAEPEKAPALSILLYVQAFQVGMPPPGCCRGPLRPKTLLLTSSEIFLLDEDCVHYPLPEFAKEPPQRDRYRLDDGRRVRDLDRVLMGYQTYPQALTLVFDDVQGHDLMGSVTLDHFGEVPGGPARASQGREVQWQVFVPSAESREKLISLLARQWEALCGRELPVELTG

T65689	TARGETID	T65689
T65689	FORMERID	TTDNR00712
T65689	UNIPROID	NISCH_HUMAN
T65689	TARGNAME	Nischarin (NISCH)
T65689	GENENAME	NISCH
T65689	TARGTYPE	Literature-reported
T65689	SYNONYMS	NISCH; I1R
T65689	FUNCTION	Acts either as the functional imidazoline-1 receptor (I1R) candidate or as amembrane-associated mediator of the I1R signaling. Binds numerous imidazoline ligands that induces initiation of cell-signaling cascades triggering to cell survival, growth and migration. Its activation by the agonist rilmenidine induces an increase in phosphorylation of mitogen-activated protein kinases MAPK1 and MAPK3 in rostral ventrolateral medulla (RVLM) neurons that exhibited rilmenidine-evoked hypotension. Blocking its activation with efaroxan abolished rilmenidine-induced mitogen-activated protein kinase phosphorylation in RVLM neurons. Acts as a modulator of Rac-regulated signal transduction pathways. Suppresses Rac1-stimulated cell migration by interacting with PAK1 and inhibiting its kinase activity. Also blocks Pak-independent Rac signaling by interacting with RAC1 and inhibiting Rac1-stimulated NF-kB response element and cyclin D1 promoter activation. Inhibits also LIMK1 kinase activity by reducing LIMK1 'Tyr-508' phosphorylation. Inhibits Rac-induced cell migration and invasion in breast and colon epithelial cells. Inhibits lamellipodia formation, when overexpressed. Plays a role in protection against apoptosis. Involved in association with IRS4 in the enhancement of insulin activation of MAPK1 and MAPK3. When overexpressed, induces a redistribution of cell surface ITGA5 integrin to intracellular endosomal structures. .
T65689	PDBSTRUC	3P0C
T65689	SEQUENCE	MATARTFGPEREAEPAKEARVVGSELVDTYTVYIIQVTDGSHEWTVKHRYSDFHDLHEKLVAERKIDKNLLPPKKIIGKNSRSLVEKREKDLEVYLQKLLAAFPGVTPRVLAHFLHFHFYEINGITAALAEELFEKGEQLLGAGEVFAIGPLQLYAVTEQLQQGKPTCASGDAKTDLGHILDFTCRLKYLKVSGTEGPFGTSNIQEQLLPFDLSIFKSLHQVEISHCDAKHIRGLVASKPTLATLSVRFSATSMKEVLVPEASEFDEWEPEGTTLEGPVTAVIPTWQALTTLDLSHNSVSEIDESVKLIPKIEFLDLSHNGLLVVDNLQHLYNLVHLDLSYNKLSSLEGLHTKLGNIKTLNLAGNLLESLSGLHKLYSLVNLDLRDNRIEQMEEVRSIGSLPCLEHVSLLNNPLSIIPDYRTKVLAQFGERASEVCLDDTVTTEKELDTVEVLKAIQKAKEVKSKLSNPEKKGGEDSRLSAAPCIRPSSSPPTVAPASASLPQPILSNQGIMFVQEEALASSLSSTDSLTPEHQPIAQGCSDSLESIPAGQAASDDLRDVPGAVGGASPEHAEPEVQVVPGSGQIIFLPFTCIGYTATNQDFIQRLSTLIRQAIERQLPAWIEAANQREEGQGEQGEEEDEEEEEEEDVAENRYFEMGPPDVEEEEGGGQGEEEEEEEEDEEAEEERLALEWALGADEDFLLEHIRILKVLWCFLIHVQGSIRQFAACLVLTDFGIAVFEIPHQESRGSSQHILSSLRFVFCFPHGDLTEFGFLMPELCLVLKVRHSENTLFIISDAANLHEFHADLRSCFAPQHMAMLCSPILYGSHTSLQEFLRQLLTFYKVAGGCQERSQGCFPVYLVYSDKRMVQTAAGDYSGNIEWASCTLCSAVRRSCCAPSEAVKSAAIPYWLLLTPQHLNVIKADFNPMPNRGTHNCRNRNSFKLSRVPLSTVLLDPTRSCTQPRGAFADGHVLELLVGYRFVTAIFVLPHEKFHFLRVYNQLRASLQDLKTVVIAKTPGTGGSPQGSFADGQPAERRASNDQRPQEVPAEALAPAPAEVPAPAPAAASASGPAKTPAPAEASTSALVPEETPVEAPAPPPAEAPAQYPSEHLIQATSEENQIPSHLPACPSLRHVASLRGSAIIELFHSSIAEVENEELRHLMWSSVVFYQTPGLEVTACVLLSTKAVYFVLHDGLRRYFSEPLQDFWHQKNTDYNNSPFHISQCFVLKLSDLQSVNVGLFDQHFRLTGSTPMQVVTCLTRDSYLTHCFLQHLMVVLSSLERTPSPEPVDKDFYSEFGNKTTGKMENYELIHSSRVKFTYPSEEEIGDLTFTVAQKMAEPEKAPALSILLYVQAFQVGMPPPGCCRGPLRPKTLLLTSSEIFLLDEDCVHYPLPEFAKEPPQRDRYRLDDGRRVRDLDRVLMGYQTYPQALTLVFDDVQGHDLMGSVTLDHFGEVPGGPARASQGREVQWQVFVPSAESREKLISLLARQWEALCGRELPVELTG

T75644	TARGETID	T75644
T75644	FORMERID	TTDI00005
T75644	UNIPROID	SGT1_HUMAN
T75644	TARGNAME	Suppressor of G2 allele of SKP1 homolog (Sgt1)
T75644	GENENAME	SUGT1
T75644	TARGTYPE	Literature-reported
T75644	SYNONYMS	Protein SGT1 homolog; Protein 40-6-3
T75644	FUNCTION	May play a role in ubiquitination and subsequent proteasomal degradation of target proteins.
T75644	PDBSTRUC	1RL1
T75644	SEQUENCE	MAAAAAGTATSQRFFQSFSDALIDEDPQAALEELTKALEQKPDDAQYYCQRAYCHILLGNYCVAVADAKKSLELNPNNSTAMLRKGICEYHEKNYAAALETFTEGQKLDIETGFHRVGQAGLQLLTSSDPPALDSQSAGITGADANFSVWIKRCQEAQNGSESEVWTHQSKIKYDWYQTESQVVITLMIKNVQKNDVNVEFSEKELSALVKLPSGEDYNLKLELLHPIIPEQSTFKVLSTKIEIKLKKPEAVRWEKLEGQGDVPTPKQFVADVKNLYPSSSPYTRNWDKLVGEIKEEEKNEKLEGDAALNRLFQQIYSDGSDEVKRAMNKSFMESGGTVLSTNWSDVGKRKVEINPPDDMEWKKY

T32386	TARGETID	T32386
T32386	FORMERID	TTDR00582
T32386	UNIPROID	MRC2_HUMAN
T32386	TARGNAME	Endocytic receptor Endo180 (MRC2)
T32386	GENENAME	MRC2
T32386	TARGTYPE	Literature-reported
T32386	SYNONYMS	Urokinase-type plasminogen activator receptor-associated protein; Urokinase receptor-associated protein; UPARAP; UPAR-associated protein; Macrophage mannose receptor 2; KIAA0709; Endocytic receptor 180; ENDO180; CLEC13E; CD280; C-type mannose receptor 2; C-type lectin domain family 13 member E
T32386	FUNCTION	May play a role as endocytotic lectin receptor displaying calcium-dependent lectin activity. Internalizes glycosylated ligands from the extracellular space for release in an endosomal compartment via clathrin-mediated endocytosis. May be involved in plasminogen activation system controlling the extracellular level of PLAUR/PLAU, and thus may regulate protease activity at the cell surface. May contribute to cellular uptake, remodeling and degradation of extracellular collagen matrices. May play a role during cancer progression as well as in other chronic tissue destructive diseases acting on collagen turnover. May participate in remodeling of extracellular matrix cooperating with the matrix metalloproteinases (MMPs).
T32386	PDBSTRUC	5EW6; 5E4L; 5E4K; 5AO6; 5AO5
T32386	SEQUENCE	MGPGRPAPAPWPRHLLRCVLLLGCLHLGRPGAPGDAALPEPNVFLIFSHGLQGCLEAQGGQVRVTPACNTSLPAQRWKWVSRNRLFNLGTMQCLGTGWPGTNTTASLGMYECDREALNLRWHCRTLGDQLSLLLGARTSNISKPGTLERGDQTRSGQWRIYGSEEDLCALPYHEVYTIQGNSHGKPCTIPFKYDNQWFHGCTSTGREDGHLWCATTQDYGKDERWGFCPIKSNDCETFWDKDQLTDSCYQFNFQSTLSWREAWASCEQQGADLLSITEIHEQTYINGLLTGYSSTLWIGLNDLDTSGGWQWSDNSPLKYLNWESDQPDNPSEENCGVIRTESSGGWQNRDCSIALPYVCKKKPNATAEPTPPDRWANVKVECEPSWQPFQGHCYRLQAEKRSWQESKKACLRGGGDLVSIHSMAELEFITKQIKQEVEELWIGLNDLKLQMNFEWSDGSLVSFTHWHPFEPNNFRDSLEDCVTIWGPEGRWNDSPCNQSLPSICKKAGQLSQGAAEEDHGCRKGWTWHSPSCYWLGEDQVTYSEARRLCTDHGSQLVTITNRFEQAFVSSLIYNWEGEYFWTALQDLNSTGSFFWLSGDEVMYTHWNRDQPGYSRGGCVALATGSAMGLWEVKNCTSFRARYICRQSLGTPVTPELPGPDPTPSLTGSCPQGWASDTKLRYCYKVFSSERLQDKKSWVQAQGACQELGAQLLSLASYEEEHFVANMLNKIFGESEPEIHEQHWFWIGLNRRDPRGGQSWRWSDGVGFSYHNFDRSRHDDDDIRGCAVLDLASLQWVAMQCDTQLDWICKIPRGTDVREPDDSPQGRREWLRFQEAEYKFFEHHSTWAQAQRICTWFQAELTSVHSQAELDFLSHNLQKFSRAQEQHWWIGLHTSESDGRFRWTDGSIINFISWAPGKPRPVGKDKKCVYMTASREDWGDQRCLTALPYICKRSNVTKETQPPDLPTTALGGCPSDWIQFLNKCFQVQGQEPQSRVKWSEAQFSCEQQEAQLVTITNPLEQAFITASLPNVTFDLWIGLHASQRDFQWVEQEPLMYANWAPGEPSGPSPAPSGNKPTSCAVVLHSPSAHFTGRWDDRSCTEETHGFICQKGTDPSLSPSPAALPPAPGTELSYLNGTFRLLQKPLRWHDALLLCESRNASLAYVPDPYTQAFLTQAARGLRTPLWIGLAGEEGSRRYSWVSEEPLNYVGWQDGEPQQPGGCTYVDVDGAWRTTSCDTKLQGAVCGVSSGPPPPRRISYHGSCPQGLADSAWIPFREHCYSFHMELLLGHKEARQRCQRAGGAVLSILDEMENVFVWEHLQSYEGQSRGAWLGMNFNPKGGTLVWQDNTAVNYSNWGPPGLGPSMLSHNSCYWIQSNSGLWRPGACTNITMGVVCKLPRAEQSSFSPSALPENPAALVVVLMAVLLLLALLTAALILYRRRQSIERGAFEGARYSRSSSSPTEATEKNILVSDMEMNEQQE

T27600	TARGETID	T27600
T27600	FORMERID	TTDI00091
T27600	UNIPROID	TACC3_HUMAN
T27600	TARGNAME	Transforming acidic coiled-coil protein 3 (TACC3)
T27600	GENENAME	TACC3
T27600	TARGTYPE	Literature-reported
T27600	SYNONYMS	Transforming acidic coiled-coil-containing protein 3; ERIC1; ERIC-1
T27600	FUNCTION	Involved in the processes that regulate centrosome-mediated interkinetic nuclear migration (INM) of neural progenitors. Acts as component of the TACC3/ch-TOG/clathrin complex proposed to contribute to stabilization of kinetochore fibers of the mitotic spindle by acting as inter-microtubule bridge. The TACC3/ch-TOG/clathrin complex is required for the maintenance of kinetochore fiber tension. May be involved in the control of cell growth and differentiation. May contribute to cancer. Plays a role in the microtubule-dependent coupling of the nucleus and the centrosome.
T27600	PDBSTRUC	5ODT; 5ODS; 5LXO; 5LXN
T27600	SEQUENCE	MSLQVLNDKNVSNEKNTENCDFLFSPPEVTGRSSVLRVSQKENVPPKNLAKAMKVTFQTPLRDPQTHRILSPSMASKLEAPFTQDDTLGLENSHPVWTQKENQQLIKEVDAKTTHGILQKPVEADTDLLGDASPAFGSGSSSESGPGALADLDCSSSSQSPGSSENQMVSPGKVSGSPEQAVEENLSSYSLDRRVTPASETLEDPCRTESQHKAETPHGAEEECKAETPHGAEEECRHGGVCAPAAVATSPPGAIPKEACGGAPLQGLPGEALGCPAGVGTPVPADGTQTLTCAHTSAPESTAPTNHLVAGRAMTLSPQEEVAAGQMASSSRSGPVKLEFDVSDGATSKRAPPPRRLGERSGLKPPLRKAAVRQQKAPQEVEEDDGRSGAGEDPPMPASRGSYHLDWDKMDDPNFIPFGGDTKSGCSEAQPPESPETRLGQPAAEQLHAGPATEEPGPCLSQQLHSASAEDTPVVQLAAETPTAESKERALNSASTSLPTSCPGSEPVPTHQQGQPALELKEESFRDPAEVLGTGAEVDYLEQFGTSSFKESALRKQSLYLKFDPLLRDSPGRPVPVATETSSMHGANETPSGRPREAKLVEFDFLGALDIPVPGPPPGVPAPGGPPLSTGPIVDLLQYSQKDLDAVVKATQEENRELRSRCEELHGKNLELGKIMDRFEEVVYQAMEEVQKQKELSKAEIQKVLKEKDQLTTDLNSMEKSFSDLFKRFEKQKEVIEGYRKNEESLKKCVEDYLARITQEGQRYQALKAHAEEKLQLANEEIAQVRSKAQAEALALQASLRKEQMRIQSLEKTVEQKTKENEELTRICDDLISKMEKI

T30614	TARGETID	T30614
T30614	FORMERID	TTDI03141
T30614	UNIPROID	CXA3_HUMAN
T30614	TARGNAME	Gap junction alpha-3 protein (Cx46)
T30614	GENENAME	GJA3
T30614	TARGTYPE	Literature-reported
T30614	SYNONYMS	Connexin-46
T30614	FUNCTION	Gap junctions are dodecameric channels that connect the cytoplasm of adjoining cells. They are formed by the docking of two hexameric hemichannels, one from each cell membrane. Small molecules and ions diffuse from one cell to a neighboring cell via the central pore. Structural component of lens fiber gap junctions.
T30614	BIOCLASS	Gap junction-forming connexin
T30614	SEQUENCE	MGDWSFLGRLLENAQEHSTVIGKVWLTVLFIFRILVLGAAAEDVWGDEQSDFTCNTQQPGCENVCYDRAFPISHIRFWALQIIFVSTPTLIYLGHVLHIVRMEEKKKEREEEEQLKRESPSPKEPPQDNPSSRDDRGRVRMAGALLRTYVFNIIFKTLFEVGFIAGQYFLYGFELKPLYRCDRWPCPNTVDCFISRPTEKTIFIIFMLAVACASLLLNMLEIYHLGWKKLKQGVTSRLGPDASEAPLGTADPPPLPPSSRPPAVAIGFPPYYAHTAAPLGQARAVGYPGAPPPAADFKLLALTEARGKGQSAKLYNGHHHLLMTEQNWANQAAERQPPALKAYPAASTPAAPSPVGSSSPPLAHEAEAGAAPLLLDGSGSSLEGSALAGTPEEEEQAVTTAAQMHQPPLPLGDPGRASKASRASSGRARPEDLAI
T30614	DRUGINFO	D00VJY	octanol	Investigative

T46814	TARGETID	T46814
T46814	FORMERID	TTDI03418
T46814	UNIPROID	SO1B1_HUMAN
T46814	TARGNAME	Liver organic anion transporter 1 (SLCO1B1)
T46814	GENENAME	SLCO1B1
T46814	TARGTYPE	Literature-reported
T46814	SYNONYMS	Solute carrier organic anion transporter family member 1B1; Solute carrier family 21 member 6; Sodium-independent organic anion-transporting polypeptide 2; SLC21A6; OATPC; OATP2; OATP-C; OATP-2; Liver-specific organic anion transporter 1; LST1; LST-1
T46814	FUNCTION	Involved in the clearance of bile acids and organic anions from the liver. Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine.
T46814	BIOCLASS	Organo anion transporter
T46814	SEQUENCE	MDQNQHLNKTAEAQPSENKKTRYCNGLKMFLAALSLSFIAKTLGAIIMKSSIIHIERRFEISSSLVGFIDGSFEIGNLLVIVFVSYFGSKLHRPKLIGIGCFIMGIGGVLTALPHFFMGYYRYSKETNINSSENSTSTLSTCLINQILSLNRASPEIVGKGCLKESGSYMWIYVFMGNMLRGIGETPIVPLGLSYIDDFAKEGHSSLYLGILNAIAMIGPIIGFTLGSLFSKMYVDIGYVDLSTIRITPTDSRWVGAWWLNFLVSGLFSIISSIPFFFLPQTPNKPQKERKASLSLHVLETNDEKDQTANLTNQGKNITKNVTGFFQSFKSILTNPLYVMFVLLTLLQVSSYIGAFTYVFKYVEQQYGQPSSKANILLGVITIPIFASGMFLGGYIIKKFKLNTVGIAKFSCFTAVMSLSFYLLYFFILCENKSVAGLTMTYDGNNPVTSHRDVPLSYCNSDCNCDESQWEPVCGNNGITYISPCLAGCKSSSGNKKPIVFYNCSCLEVTGLQNRNYSAHLGECPRDDACTRKFYFFVAIQVLNLFFSALGGTSHVMLIVKIVQPELKSLALGFHSMVIRALGGILAPIYFGALIDTTCIKWSTNNCGTRGSCRTYNSTSFSRVYLGLSSMLRVSSLVLYIILIYAMKKKYQEKDINASENGSVMDEANLESLNKNKHFVPSAGADSETHC
T46814	DRUGINFO	D0I3LQ	[3H]estradiol-17beta-glucuronide	Investigative
T46814	DRUGINFO	D04AXP	[3H]estrone-3-sulphate	Investigative

T72944	TARGETID	T72944
T72944	FORMERID	TTDR01321
T72944	UNIPROID	ROBO1_HUMAN
T72944	TARGNAME	Roundabout homolog 1 (ROBO1)
T72944	GENENAME	ROBO1
T72944	TARGTYPE	Literature-reported
T72944	SYNONYMS	H-Robo-1; Deleted in U twenty twenty; DUTT1
T72944	FUNCTION	Receptor for SLIT1 and SLIT2 that mediates cellular responses to molecular guidance cues in cellular migration, including axonal navigation at the ventral midline of the neural tube and projection of axons to different regions during neuronal development. Interaction with the intracellular domain of FLRT3 mediates axon attraction towards cells expressing NTN1. In axon growth cones, the silencing of the attractive effect of NTN1 by SLIT2 may require the formation of a ROBO1-DCC complex (By similarity). Plays a role in the regulation of cell migration via its interaction with MYO9B; inhibits MYO9B-mediated stimulation of RHOA GTPase activity, and thereby leads to increased levels of active, GTP-bound RHOA. May be required for lung development (By similarity).
T72944	PDBSTRUC	6A79; 6A78; 6A77; 5OPE; 5O5I
T72944	SEQUENCE	MKWKHVPFLVMISLLSLSPNHLFLAQLIPDPEDVERGNDHGTPIPTSDNDDNSLGYTGSRLRQEDFPPRIVEHPSDLIVSKGEPATLNCKAEGRPTPTIEWYKGGERVETDKDDPRSHRMLLPSGSLFFLRIVHGRKSRPDEGVYVCVARNYLGEAVSHNASLEVAILRDDFRQNPSDVMVAVGEPAVMECQPPRGHPEPTISWKKDGSPLDDKDERITIRGGKLMITYTRKSDAGKYVCVGTNMVGERESEVAELTVLERPSFVKRPSNLAVTVDDSAEFKCEARGDPVPTVRWRKDDGELPKSRYEIRDDHTLKIRKVTAGDMGSYTCVAENMVGKAEASATLTVQEPPHFVVKPRDQVVALGRTVTFQCEATGNPQPAIFWRREGSQNLLFSYQPPQSSSRFSVSQTGDLTITNVQRSDVGYYICQTLNVAGSIITKAYLEVTDVIADRPPPVIRQGPVNQTVAVDGTFVLSCVATGSPVPTILWRKDGVLVSTQDSRIKQLENGVLQIRYAKLGDTGRYTCIASTPSGEATWSAYIEVQEFGVPVQPPRPTDPNLIPSAPSKPEVTDVSRNTVTLSWQPNLNSGATPTSYIIEAFSHASGSSWQTVAENVKTETSAIKGLKPNAIYLFLVRAANAYGISDPSQISDPVKTQDVLPTSQGVDHKQVQRELGNAVLHLHNPTVLSSSSIEVHWTVDQQSQYIQGYKILYRPSGANHGESDWLVFEVRTPAKNSVVIPDLRKGVNYEIKARPFFNEFQGADSEIKFAKTLEEAPSAPPQGVTVSKNDGNGTAILVSWQPPPEDTQNGMVQEYKVWCLGNETRYHINKTVDGSTFSVVIPFLVPGIRYSVEVAASTGAGSGVKSEPQFIQLDAHGNPVSPEDQVSLAQQISDVVKQPAFIAGIGAACWIILMVFSIWLYRHRKKRNGLTSTYAGIRKVPSFTFTPTVTYQRGGEAVSSGGRPGLLNISEPAAQPWLADTWPNTGNNHNDCSISCCTAGNGNSDSNLTTYSRPADCIANYNNQLDNKQTNLMLPESTVYGDVDLSNKINEMKTFNSPNLKDGRFVNPSGQPTPYATTQLIQSNLSNNMNNGSGDSGEKHWKPLGQQKQEVAPVQYNIVEQNKLNKDYRANDTVPPTIPYNQSYDQNTGGSYNSSDRGSSTSGSQGHKKGARTPKVPKQGGMNWADLLPPPPAHPPPHSNSEEYNISVDESYDQEMPCPVPPARMYLQQDELEEEEDERGPTPPVRGAASSPAAVSYSHQSTATLTPSPQEELQPMLQDCPEETGHMQHQPDRRRQPVSPPPPPRPISPPHTYGYISGPLVSDMDTDAPEEEEDEADMEVAKMQTRRLLLRGLEQTPASSVGDLESSVTGSMINGWGSASEEDNISSGRSSVSSSDGSFFTDADFAQAVAAAAEYAGLKVARRQMQDAAGRRHFHASQCPRPTSPVSTDSNMSAAVMQKTRPAKKLKHQPGHLRRETYTDDLPPPPVPPPAIKSPTAQSKTQLEVRPVVVPKLPSMDARTDRSSDRKGSSYKGREVLDGRQVVDMRTNPGDPREAQEQQNDGKGRGNKAAKRDLPPAKTHLIQEDILPYCRPTFPTSNNPRDPSSSSSMSSRGSGSRQREQANVGRRNIAEMQVLGGYERGEDNNEELEETES

T85746	TARGETID	T85746
T85746	FORMERID	TTDI02528
T85746	UNIPROID	TNR11_HUMAN
T85746	TARGNAME	Osteoclast differentiation factor receptor (ODFR)
T85746	GENENAME	TNFRSF11A
T85746	TARGTYPE	Literature-reported
T85746	SYNONYMS	Tumor necrosis factor receptor superfamily member 11A; Receptor activator of NF-KB; RANK; ODFR; CD265
T85746	FUNCTION	Involved in the regulation of interactions between T-cells and dendritic cells. Receptor for TNFSF11/RANKL/TRANCE/OPGL; essential for RANKL-mediated osteoclastogenesis.
T85746	PDBSTRUC	1LB5
T85746	SEQUENCE	MAPRARRRRPLFALLLLCALLARLQVALQIAPPCTSEKHYEHLGRCCNKCEPGKYMSSKCTTTSDSVCLPCGPDEYLDSWNEEDKCLLHKVCDTGKALVAVVAGNSTTPRRCACTAGYHWSQDCECCRRNTECAPGLGAQHPLQLNKDTVCKPCLAGYFSDAFSSTDKCRPWTNCTFLGKRVEHHGTEKSDAVCSSSLPARKPPNEPHVYLPGLIILLLFASVALVAAIIFGVCYRKKGKALTANLWHWINEACGRLSGDKESSGDSCVSTHTANFGQQGACEGVLLLTLEEKTFPEDMCYPDQGGVCQGTCVGGGPYAQGEDARMLSLVSKTEIEEDSFRQMPTEDEYMDRPSQPTDQLLFLTEPGSKSTPPFSEPLEVGENDSLSQCFTGTQSTVGSESCNCTEPLCRTDWTPMSSENYLQKEVDSGHCPHWAASPSPNWADVCTGCRNPPGEDCEPLVGSPKRGPLPQCAYGMGLPPEEEASRTEARDQPEDGADGRLPSSARAGAGSGSSPGGQSPASGNVTGNSNSTFISSGQVMNFKGDIIVVYVSQTSQEGAAAAAEPMGRPVQEETLARRDSFAGNGPRFPDPCGGPEGLREPEKASRPVQEQGGAKA

T74777	TARGETID	T74777
T74777	FORMERID	TTDR01348
T74777	UNIPROID	HEMA_I97A1
T74777	TARGNAME	Influenza HA messenger RNA (Influ HA mRNA)
T74777	GENENAME	Influ HA mRNA
T74777	TARGTYPE	Literature-reported
T74777	SYNONYMS	Hemagglutinin (mRNA); HA of influenza (mRNA)
T74777	FUNCTION	Binds to sialic acid-containing receptors on the cell surface, bringing about the attachment of the virus particle to the cell. This attachment induces virion internalization of about two third of the virus particles through clathrin-dependent endocytosis and about one third through a clathrin- and caveolin-independent pathway. Plays a major role in the determination of host range restriction and virulence. Class I viral fusion protein. Responsible for penetration of the virus into the cell cytoplasm by mediating the fusion of the membrane of the endocytosed virus particle with the endosomal membrane. Low pH in endosomes induces an irreversible conformational change in HA2, releasing the fusion hydrophobic speptide. Several trimers are required to form a competent fusion pore.
T74777	BIOCLASS	mRNA target
T74777	SEQUENCE	MEKTVLLLATVSLVKSDQICIGYHANNSTEQVDTIMEKNVTVTHAQDILERTHNGKLCDLNGVKPLILRDCSVAGWLLGNPMCDEFINVPEWSYIVEKASPANDLCYPGNFNDYEELKHLLSRINHFEKIQIIPKSSWSNHDASSGVSSACPYLGRSSFFRNVVWLIKKNSAYPTIKRSYNNTNQEDLLVLWGIHHPNDAAEQTKLYQNPTTYISVGTSTLNQRLVPEIATRPKVNGQSGRMEFFWTILKPNDAINFESNGNFIAPEYAYKIVKKGDSTIMKSELEYGNCNTKCQTPMGAINSSMPFHNIHPLTIGECPKYVKSNRLVLATGLRNTPQRERRRKKRGLFGAIAGFIEGGWQGMVDGWYGYHHSNEQGSGYAADKESTQKAIDGVTNKVNSIINKMNTQFEAVGREFNNLERRIENLNKKMEDGFLDVWTYNAELLVLMENERTLDFHDSNVKNLYDKVRLQLRDNAKELGNGCFEFYHKCDNECMESVKNGTYDYPQYSEEARLNREEISGVKLESMGTYQILSIYSTVASSLALAIMVAGLSLWMCSNGSLQCRICI
T74777	DRUGINFO	D0Y4II	ISIS 3306	Investigative

T15381	TARGETID	T15381
T15381	FORMERID	TTDR01349
T15381	UNIPROID	PB2_I97A1
T15381	TARGNAME	Influenza PB2 messenger RNA (Influ PB2 mRNA)
T15381	GENENAME	Influ PB2 mRNA
T15381	TARGTYPE	Literature-reported
T15381	SYNONYMS	RNA-directed RNA polymerase subunit P3 (mRNA); Polymerase basic protein 2 (mRNA); PB2 (mRNA)
T15381	FUNCTION	Recognizes and binds the 7-methylguanosine-containing cap of the target pre-RNA which is subsequently cleaved after 10-13 nucleotides by the viral protein PA. Plays a role in the initiation of the viral genome replication and modulates the activity of the ribonucleoprotein (RNP) complex. Plays an essential role in transcription initiation and cap-stealing mechanism, in which cellular capped pre-mRNAs are used to generate primers for viral transcription.
T15381	BIOCLASS	mRNA target
T15381	SEQUENCE	MERIKELRDLMSQSRTREILTKTTVDHMAIIKKYTSGRQEKNPALRMKWMMAMKYPITADKRIMEMIPERNEQGQTLWSKTNDAGSDRVMVSPLAVTWWNRNGPTTSTVHYPKVYKTYFEKVERLKHGTFGPVHFRNQVKIRRRVDMNPGHADLSAKEAQDVIMEVVFPNEVGARILTSESQLTITKEKREELKNCNISPLMVAYMLERELVRKTRFLPVAGGTSSVYIEVLHLTQGTCWEQMYTPGGEVRNDDVDQSLIIAARNIVRRATVSADPLASLLEMCHSTQIGGVRMVDILKQNPTEEQAVDICKAAMGLRISSSFSFGGFTFKRTKGFSVKREEEVLTGNLQTLKIKVHEGYEEFTMVGRRATAILRKATRRMIQLIVSGRDEQSIAEAIIVAMVFSQEDCMIKAVRGDLNFVNRANQRLNPMHQLLRHFQKDAKVLFQNWGIEPIDNVMGMIGILPDMTPSTEMSLRGVRVSKMGVDEYSSTERVVVSIDRFLRVRDQQGNVLLSPEEVSETQGMEKLTITYSSSMMWEINGPESVLVNTYQWIIRNWETVKIQWSQEPTMLYNKMEFEPFQSLVPKAARSQYSGFVRTLFQQMRDVLGTFDTVQIIKLLPFAAAPPEQSRMQFSSLTVNVRGSGMRILVRGNSPAFNYNKTTKRLTILGKDAGALTEDPDEGTAGVESAVLRGFLILGKEDKRYGPALSINELSNLTKGEKANVLIRQGDVVLVMKRKRDSSILTDSQTATKRIRMAIN
T15381	DRUGINFO	D0ZF2W	ISIS 3303	Investigative

T19527	TARGETID	T19527
T19527	FORMERID	TTDI02233
T19527	UNIPROID	ENV_HV190
T19527	TARGNAME	Influenza Env messenger RNA (Influ Env mRNA)
T19527	GENENAME	Influ Env mRNA
T19527	TARGTYPE	Literature-reported
T19527	SYNONYMS	HIV-1 90CF056 envelope glycoprotein gp160 (mRNA); HIV-1 90CF056 env polyprotein (mRNA)
T19527	FUNCTION	Envelope glycoprotein gp160: Oligomerizes in the host endoplasmic reticulum into predominantly trimers. In a second time, gp160 transits in the host Golgi, where glycosylation is completed. The precursor is then proteolytically cleaved in the trans-Golgi and thereby activated by cellular furin or furin-like proteases to produce gp120 and gp41.
T19527	BIOCLASS	mRNA target
T19527	SEQUENCE	METQRNYPSLWRWGTLILGMLLICSAAQNLWVTVYYGVPVWKEAKTTLFCASDAKAYETEKHNVWATHACVPTDPNPQEMVMENVTESFNMWENNMVEQMHTDIISLWDQSLKPCVKLTPLCVTLNCTNVRNNTSNSTSSMEAGGELTNCSFNVTTVLRDKQQKVHALFYRLDVVPIDNNSTQYRLINCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCNNKTFNGTGLCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEQIIIRTKNISDNTKNIIVQLKTPVNITCTRPNNNTRTSIHLGPGRAFYATGDIIGDIRQAHCNISRTDWNKTLHQVVTQLGIHLNNRTISFKPNSGGDMEVRTHSFNCRGEFFYCNTSGLFNSSWEMHTNYTSNDTKGNENITLPCRIKQIVNMWQRVGRAMYAPPIQGNIMCVSNITGLILTIDEGNASAENYTFRPGGGDMRDNWRSELYKYKVVKIEPLGIAPTKTRRRVVEREKRAVGMGASFLGFLGAAGSTMGAASITLTVQARQLLSGIVQQQSNLLRAIQARQHMLQLTVWGIKQLQARVLAVERYLRDQQLLGIWGCSGKLICTTNVPWNSSWSNKSQSEIWDNMTWMEWDKQISNYTEEIYRLLEVSQTQQEKNEQDLLALDKWASLWTWFDISHWLWYIKIFIMIVGGLIGLRIIFAVLSIVNRVRQGYSPLSFQTLVPNPRGPDRPEGTEEGGGEQDRDRSVRLVNGFLPVVWDDLRSLSLFSYRLLRDLLLIVVRTVELLGRRGREALKYLWNLLQYWGQELKNSAIDLLNTTAIAVAEGTDGIIVIVQRAWRAILHIPRRIRQGFERSLL

T24979	TARGETID	T24979
T24979	FORMERID	TTDR01354
T24979	UNIPROID	NCAP_I97A1
T24979	TARGNAME	Influenza NP messenger RNA (Influ NP mRNA)
T24979	GENENAME	Influ NP mRNA
T24979	TARGTYPE	Literature-reported
T24979	SYNONYMS	Influenza nucleoprotein (mRNA); Influenza nucleocapsid protein (mRNA)
T24979	FUNCTION	The encapsidated genomic RNA is termed the ribonucleoprotein (RNP) and serves as template for transcription and replication. The RNP needs to be localized in the host nucleus to start an infectious cycle, but is too large to diffuse through the nuclear pore complex. NP comprises at least 2 nuclear localization signals that are responsible for the active RNP import into the nucleus through cellular importin alpha/beta pathway. Later in the infection, nclear export of RNPs are mediated through viral proteins NEP interacting with M1 which binds nucleoproteins. It is possible that nucleoprotein binds directly host exportin-1/XPO1 and plays an active role in RNPs nuclear export. M1 interaction with RNP seems to hide nucleoprotein's nuclear localization signals. Soon after a virion infects a new cell, M1 dissociates from the RNP under acidification of the virion driven by M2 protein. Dissociation of M1 from RNP unmasks nucleoprotein's nuclear localization signals, targeting the RNP to the nucleus. Encapsidates the negative strand viral RNA, protecting it from nucleases.
T24979	BIOCLASS	mRNA target
T24979	SEQUENCE	MASQGTKRSYEQMETGGERQNATEIRASVGRMVGGIGRFYIQMCTELKLSDQEGRLIQNSITIERMVLSAFDERRNRYLEEHPSAGKDPKKTGGPIYRRRDGKWVRELILYDKEEIRRIWRQANNGEDATAGLTHMMIWHSNLNDATYQRTRALVRTGMDPRMCSLMQGSTLPRRSGAAGAAIKGVGTMVMELIRMIKRGINDRNFWRGENGRRTRIAYERMCNILKGKFQTAAQKAMMDQVRESRNPGNAEIEDLIFLARSALILRGSVAHKSCLPACVYGPAVASGYDFEREGYSLVGIDPFRLLQNSQVFSLIRPKENPAHKSQLVWMACHSAAFEDLRVSSFIRGTRVIPRGQLSTRGVQIASNENVEAMDSTTLELRSRYWAIRTRSGGNTNQQRASAGQISVQPTFSVQRNLPFERVTIMAAFKGNTEGRTSDMRTEIIRMMESARPEDVSFQGRGVFELSDEKATNPIVPSFDMSNEGSYFFGDNAEEYDN
T24979	DRUGINFO	D0Y0EJ	ISIS 3307	Investigative

T72614	TARGETID	T72614
T72614	FORMERID	TTDR01095
T72614	UNIPROID	AGRL1_HUMAN
T72614	TARGNAME	CIRL-1 messenger RNA (CIRL-1 mRNA)
T72614	GENENAME	ADGRL1
T72614	TARGTYPE	Literature-reported
T72614	SYNONYMS	Lectomedin-2 (mRNA); Latrophilin-1 (mRNA); LPHN1 (mRNA); LEC2 (mRNA); KIAA0821 (mRNA); Calcium-independent alpha-latrotoxin receptor 1 (mRNA); CIRL-1 (mRNA); Adhesion G protein-coupled receptor L1 (mRNA)
T72614	FUNCTION	Receptor for TENM2 that mediates heterophilic synaptic cell-cell contact and postsynaptic specialization. Receptor probably implicated in the regulation of exocytosis. Calcium-independent receptor of high affinity for alpha-latrotoxin, an excitatory neurotoxin present in black widow spider venom which triggers massive exocytosis from neurons and neuroendocrine cells.
T72614	BIOCLASS	mRNA target
T72614	SEQUENCE	MARLAAVLWNLCVTAVLVTSATQGLSRAGLPFGLMRRELACEGYPIELRCPGSDVIMVENANYGRTDDKICDADPFQMENVQCYLPDAFKIMSQRCNNRTQCVVVAGSDAFPDPCPGTYKYLEVQYDCVPYKVEQKVFVCPGTLQKVLEPTSTHESEHQSGAWCKDPLQAGDRIYVMPWIPYRTDTLTEYASWEDYVAARHTTTYRLPNRVDGTGFVVYDGAVFYNKERTRNIVKYDLRTRIKSGETVINTANYHDTSPYRWGGKTDIDLAVDENGLWVIYATEGNNGRLVVSQLNPYTLRFEGTWETGYDKRSASNAFMVCGVLYVLRSVYVDDDSEAAGNRVDYAFNTNANREEPVSLTFPNPYQFISSVDYNPRDNQLYVWNNYFVVRYSLEFGPPDPSAGPATSPPLSTTTTARPTPLTSTASPAATTPLRRAPLTTHPVGAINQLGPDLPPATAPVPSTRRPPAPNLHVSPELFCEPREVRRVQWPATQQGMLVERPCPKGTRGIASFQCLPALGLWNPRGPDLSNCTSPWVNQVAQKIKSGENAANIASELARHTRGSIYAGDVSSSVKLMEQLLDILDAQLQALRPIERESAGKNYNKMHKRERTCKDYIKAVVETVDNLLRPEALESWKDMNATEQVHTATMLLDVLEEGAFLLADNVREPARFLAAKENVVLEVTVLNTEGQVQELVFPQEEYPRKNSIQLSAKTIKQNSRNGVVKVVFILYNNLGLFLSTENATVKLAGEAGPGGPGGASLVVNSQVIAASINKESSRVFLMDPVIFTVAHLEDKNHFNANCSFWNYSERSMLGYWSTQGCRLVESNKTHTTCACSHLTNFAVLMAHREIYQGRINELLLSVITWVGIVISLVCLAICISTFCFLRGLQTDRNTIHKNLCINLFLAELLFLVGIDKTQYEIACPIFAGLLHYFFLAAFSWLCLEGVHLYLLLVEVFESEYSRTKYYYLGGYCFPALVVGIAAAIDYRSYGTEKACWLRVDNYFIWSFIGPVSFVIVVNLVFLMVTLHKMIRSSSVLKPDSSRLDNIKSWALGAIALLFLLGLTWAFGLLFINKESVVMAYLFTTFNAFQGVFIFVFHCALQKKVHKEYSKCLRHSYCCIRSPPGGTHGSLKTSAMRSNTRYYTGTQSRIRRMWNDTVRKQTESSFMAGDINSTPTLNRGTMGNHLLTNPVLQPRGGTSPYNTLIAESVGFNPSSPPVFNSPGSYREPKHPLGGREACGMDTLPLNGNFNNSYSLRSGDFPPGDGGPEPPRGRNLADAAAFEKMIISELVHNNLRGSSSAAKGPPPPEPPVPPVPGGGGEEEAGGPGGADRAEIELLYKALEEPLLLPRAQSVLYQSDLDESESCTAEDGATSRPLSSPPGRDSLYASGANLRDSPSYPDSSPEGPSEALPPPPPAPPGPPEIYYTSRPPALVARNPLQGYYQVRRPSHEGYLAAPGLEGPGPDGDGQMQLVTSL

T25220	TARGETID	T25220
T25220	FORMERID	TTDR00092
T25220	UNIPROID	VIE1_HCMVT; VIE2_HCMVT; VIE3_HCMVT
T25220	TARGNAME	Cytomegalovirus Immediate-early protein messenger RNA (CMV IE mRNA)
T25220	GENENAME	CMV IE mRNA
T25220	TARGTYPE	Literature-reported
T25220	SYNONYMS	Human cytomegalovirus immediate-early protein (mRNA)
T25220	FUNCTION	Alters host cell cycle progression, probably through its interaction with host E2F1 or RB1 that overcomes the RB1-mediated repression of E2F-responsive promoters. Plays an important role in transactivating viral early genes as well as activating its own promoter. Targets and disrupts host PML/nuclear domain 10 (ND10). Promotes efficient viral growth by interacting with and directing host SP100 to degradation, leading to enhanced acetylation level of histones. In addition, functions in counteracting the host innate antiviral response. Inhibits the type I interferon pathway by directly interacting with and sequestrating host STAT2.
T25220	BIOCLASS	mRNA target
T25220	SEQUENCE	MESSAKRKMDPDNPDEGPSSKVPRPETPVTKATTFLQTMLRKEVNSQLSLGDPLFPELAEESLKTFERVTEDCNENPEKDVLAELVKQIKVRVDMVRHRIKEHMLKKYTQTEEKFTGAFNMMGGCLQNALDILDKVHEPFEEMKCIGLTMQSMYENYIVPEDKREMWMACIKELHDVSKGAANKLGGALQAKARAKKDELRRKMMYMCYRNIEFFTKNSAFPKTTNGCSQAMAALQNLPQCSPDEIMAYAQKIFKILDEERDKVLTHIDHIFMDILTTCVETMCNEYKVTSDACMMTMYGGISLLSEFCRVLSCYVLEETSVMLAKRPLITKPEVISVMKRRIEEICMKVFAQYILGADPLRVCSPSVDDLRAIAEESDEEEAIVAYTLATRGASSSDSLVSPPESPVPATIPLSSVIVAENSDQEESEQSDEEEEEGAQEEREDTVSVKSEPVSEIEEVAPEEEEDGAEEPTASGGKSTHPMVTRSKADQ

T71342	TARGETID	T71342
T71342	FORMERID	TTDR01365
T71342	UNIPROID	VE7_HPV18
T71342	TARGNAME	Human papillomavirus-18 E7 region messenger RNA (HPV-18 E7 mRNA)
T71342	GENENAME	HPV-18 E7 mRNA
T71342	TARGTYPE	Literature-reported
T71342	SYNONYMS	HPV-18 protein E7 (mRNA); HPV-18 E7 (mRNA)
T71342	FUNCTION	Stimulation of progression from G1 to S phase allows the virus to efficiently use the cellular DNA replicating machinery to achieve viral genome replication. E7 protein has both transforming and trans-activating activities. Induces the disassembly of the E2F1 transcription factor from RB1, with subsequent transcriptional activation of E2F1-regulated S-phase genes. Interferes with host histone deacetylation mediated by HDAC1 and HDAC2, leading to transcription activation. Plays also a role in the inhibition of both antiviral and antiproliferative functions of host interferon alpha. Interaction with host TMEM173/STING impairs the ability of TMEM173/STING to sense cytosolic DNA and promote the production of type I interferon (IFN-alpha and IFN-beta). Plays a role in viral genome replication by driving entry of quiescent cells into the cell cycle.
T71342	BIOCLASS	mRNA target
T71342	SEQUENCE	MHGPKATLQDIVLHLEPQNEIPVDLLCHEQLSDSEEENDEIDGVNHQHLPARRAEPQRHTMLCMCCKCEARIKLVVESSADDLRAFQQLFLNTLSFVCPWCASQQ
T71342	DRUGINFO	D0X9EH	ISIS 2491	Investigative

T29672	TARGETID	T29672
T29672	FORMERID	TTDI02652
T29672	UNIPROID	GLI2_HUMAN
T29672	TARGNAME	GLI2 messenger RNA (GLI2 mRNA)
T29672	GENENAME	GLI2
T29672	TARGTYPE	Literature-reported
T29672	SYNONYMS	Zinc finger protein GLI2 (mRNA); Tax helper protein (mRNA); THP (mRNA); GLI family zinc finger protein 2 (mRNA)
T29672	FUNCTION	Functions as transcriptional activator. May also function as transcriptional repressor. Requires STK36 for full transcriptional activator activity. Required for normal embryonic development. Functions as transcription regulator in the hedgehog (Hh) pathway.
T29672	BIOCLASS	mRNA target
T29672	SEQUENCE	METSASATASEKQEAKSGILEAAGFPDPGKKASPLVVAAAAAAAVAAQGVPQHLLPPFHAPLPIDMRHQEGRYHYEPHSVHGVHGPPALSGSPVISDISLIRLSPHPAGPGESPFNAPHPYVNPHMEHYLRSVHSSPTLSMISAARGLSPADVAQEHLKERGLFGLPAPGTTPSDYYHQMTLVAGHPAPYGDLLMQSGGAASAPHLHDYLNPVDVSRFSSPRVTPRLSRKRALSISPLSDASLDLQRMIRTSPNSLVAYINNSRSSSAASGSYGHLSAGALSPAFTFPHPINPVAYQQILSQQRGLGSAFGHTPPLIQPSPTFLAQQPMALTSINATPTQLSSSSNCLSDTNQNKQSSESAVSSTVNPVAIHKRSKVKTEPEGLRPASPLALTQGQVSGHGSCGCALPLSQEQLADLKEDLDRDDCKQEAEVVIYETNCHWEDCTKEYDTQEQLVHHINNEHIHGEKKEFVCRWQACTREQKPFKAQYMLVVHMRRHTGEKPHKCTFEGCSKAYSRLENLKTHLRSHTGEKPYVCEHEGCNKAFSNASDRAKHQNRTHSNEKPYICKIPGCTKRYTDPSSLRKHVKTVHGPDAHVTKKQRNDVHLRTPLLKENGDSEAGTEPGGPESTEASSTSQAVEDCLHVRAIKTESSGLCQSSPGAQSSCSSEPSPLGSAPNNDSGVEMPGTGPGSLGDLTALDDTPPGADTSALAAPSAGGLQLRKHMTTMHRFEQLKKEKLKSLKDSCSWAGPTPHTRNTKLPPLPGSGSILENFSGSGGGGPAGLLPNPRLSELSASEVTMLSQLQERRDSSTSTVSSAYTVSRRSSGISPYFSSRRSSEASPLGAGRPHNASSADSYDPISTDASRRSSEASQCSGGSGLLNLTPAQQYSLRAKYAAATGGPPPTPLPGLERMSLRTRLALLDAPERTLPAGCPRPLGPRRGSDGPTYGHGHAGAAPAFPHEAPGGGARRASDPVRRPDALSLPRVQRFHSTHNVNPGPLPPCADRRGLRLQSHPSTDGGLARGAYSPRPPSISENVAMEAVAAGVDGAGPEADLGLPEDDLVLPDDVVQYIKAHASGALDEGTGQVYPTESTGFSDNPRLPSPGLHGQRRMVAADSNVGPSAPMLGGCQLGFGAPSSLNKNNMPVQWNEVSSGTVDALASQVKPPPFPQGNLAVVQQKPAFGQYPGYSPQGLQASPGGLDSTQPHLQPRSGAPSQGIPRVNYMQQLRQPVAGSQCPGMTTTMSPHACYGQVHPQLSPSTISGALNQFPQSCSNMPAKPGHLGHPQQTEVAPDPTTMGNRHRELGVPDSALAGVPPPHPVQSYPQQSHHLAASMSQEGYHQVPSLLPARQPGFMEPQTGPMGVATAGFGLVQPRPPLEPSPTGRHRGVRAVQQQLAYARATGHAMAAMPSSQETAEAVPKGAMGNMGSVPPQPPPQDAGGAPDHSMLYYYGQIHMYEQDGGLENLGSCQVMRSQPPQPQACQDSIQPQPLPSPGVNQVSSTVDSQLLEAPQIDFDAIMDDGDHSSLFSGALSPSLLHSLSQNSSRLTTPRNSLTLPSIPAGISNMAVGDMSSMLTSLAEESKFLNMMT

T31665	TARGETID	T31665
T31665	FORMERID	TTDR01419
T31665	UNIPROID	TFE2_HUMAN-PBX1_HUMAN
T31665	TARGNAME	E2A-Pbx1 messenger RNA (E2A-Pbx1 mRNA)
T31665	GENENAME	TCF3-PBX1
T31665	TARGTYPE	Literature-reported
T31665	SYNONYMS	Transcription factor 3-Homeobox protein PRL (mRNA)
T31665	FUNCTION	E2A-PBX1 perturbs signaling pathways upstream of PLC2 and renders leukemias amenable to targeted therapeutic inhibition.
T31665	BIOCLASS	mRNA target
T31665	SEQUENCE	MNQPQRMAPVGTDKELSDLLDFSMMFPLPVTNGKGRPASLAGAQFGGSGLEDRPSSGSWGSGDQSSSSFDPSRTFSEGTHFTESHSSLSSSTFLGPGLGGKSGERGAYASFGRDAGVGGLTQAGFLSGELALNSPGPLSPSGMKGTSQYYPSYSGSSRRRAADGSLDTQPKKVRKVPPGLPSSVYPPSSGEDYGRDATAYPSAKTPSSTYPAPFYVADGSLHPSAELWSPPGQAGFGPMLGGGSSPLPLPPGSGPVGSSGSSSTFGGLHQHERMGYQLHGAEVNGGLPSASSFSSAPGATYGGVSSHTPPVSGADSLLGSRGTTAGSSGDALGKALASIYSPDHSSNNFSSSPSTPVGSPQGLAGTSQWPRAGAPGALSPSYDGGLHGLQSKIEDHLDEAIHVLRSHAVGTAGDMHTLLPGHGALASGFTGPMSLGGRHAGLVGGSHPEDGLAGSTSLMHNHAALPSQPGTLPDLSRPPDSYSGLGRAGATAAASEIKREEKEDEENTSAADHSEEEKKELKAPRARTSPDEDEDDLLPPEQKAEREKERRVANNARERLRVRDINEAFKELGRMCQLHLNSEKPQTKLLILHQAVSVILNLEQQVRERNLNPKAACLKRREEEKVSGVVGDPQMVLSAPHPGLSEAHNPAGHMMDEQPRLMHSHAGVGMAGHPGLSQHLQDGAGGTEGEGGRKQDIGDILQQIMTITDQSLDEAQARKHALNCHRMKPALFNVLCEIKEKTVLSIRGAQEEEPTDPQLMRLDNMLLAEGVAGPEKGGGSAAAAAAAAASGGAGSDNSVEHSDYRAKLSQIRQIYHTELEKYEQACNEFTTHVMNLLREQSRTRPISPKEIERMVSIIHRKFSSIQMQLKQSTCEAVMILRSRFLDARRKRRNFNKQATEILNEYFYSHLSNPYPSEEAKEELAKKCGITVSQVSNWFGNKRIRYKKNIGKFQEEANIYAAKTAVTATNVSAHGSQANSPSTPNSAGSSSSFNMSNSGDLFMSVQSLNGDSYQGAQVGANVQSQVDTLRHVISQTGGYSDGLAASQMYSPQGISANGGWQDATTPSSVTSPTEGPGSVHSDTSN
T31665	DRUGINFO	D02PGM	ISIS 16124	Investigative
T31665	DRUGINFO	D06LWP	ISIS 16112	Investigative
T31665	DRUGINFO	D09EQS	ISIS 16123	Investigative
T31665	DRUGINFO	D0KF3D	ISIS 16108	Investigative
T31665	DRUGINFO	D0Z6AS	ISIS 16121	Investigative

T13059	TARGETID	T13059
T13059	FORMERID	TTDR00056
T13059	UNIPROID	PRP8_YEAST
T13059	TARGNAME	Fungal Pre-mRNA splicing factor PRP8 (Fung PRP8)
T13059	GENENAME	Fung PRP8
T13059	TARGTYPE	Literature-reported
T13059	SYNONYMS	Prp8 intein; PRP8; Intein (PRP8)
T13059	FUNCTION	Functions as a scaffold that mediates the ordered assembly of spliceosomal proteins and snRNAs. Required for association of BRR2 with the spliceosomal U5 snRNP, and the subsequent assembly of the U4/U6-U5 tri-snRNP complex. Functions as scaffold thatpositions spliceosomal U2, U5 and U6 snRNAs at splice sites on pre-mRNA substrates, so that splicing can occur. Interacts with both the 5' and the 3' splice site, as well as the branch region. Has a role in branch site-3' splice site selection. Associates with the branch site-3' splice 3'-exon region. Also has a role in cell cycle.
T13059	PDBSTRUC	6J6Q; 6J6N; 6J6H; 6J6G; 6EXN
T13059	SEQUENCE	MSGLPPPPPGFEEDSDLALPPPPPPPPGYEIEELDNPMVPSSVNEDTFLPPPPPPPSNFEINAEEIVDFTLPPPPPPPGLDELETKAEKKVELHGKRKLDIGKDTFVTRKSRKRAKKMTKKAKRSNLYTPKAEMPPEHLRKIINTHSDMASKMYNTDKKAFLGALKYLPHAILKLLENMPHPWEQAKEVKVLYHTSGAITFVNETPRVIEPVYTAQWSATWIAMRREKRDRTHFKRMRFPPFDDDEPPLSYEQHIENIEPLDPINLPLDSQDDEYVKDWLYDSRPLEEDSKKVNGTSYKKWSFDLPEMSNLYRLSTPLRDEVTDKNYYYLFDKKSFFNGKALNNAIPGGPKFEPLYPREEEEDYNEFNSIDRVIFRVPIRSEYKVAFPHLYNSRPRSVRIPWYNNPVSCIIQNDEEYDTPALFFDPSLNPIPHFIDNNSSLNVSNTKENGDFTLPEDFAPLLAEEEELILPNTKDAMSLYHSPFPFNRTKGKMVRAQDVALAKKWFLQHPDEEYPVKVKVSYQKLLKNYVLNELHPTLPTNHNKTKLLKSLKNTKYFQQTTIDWVEAGLQLCRQGHNMLNLLIHRKGLTYLHLDYNFNLKPTKTLTTKERKKSRLGNSFHLMRELLKMMKLIVDTHVQFRLGNVDAFQLADGIHYILNHIGQLTGIYRYKYKVMHQIRACKDLKHIIYYKFNKNLGKGPGCGFWQPAWRVWLNFLRGTIPLLERYIGNLITRQFEGRSNEIVKTTTKQRLDAYYDLELRNSVMDDILEMMPESIRQKKARTILQHLSEAWRCWKANIPWDVPGMPAPIKKIIERYIKSKADAWVSAAHYNRERIKRGAHVEKTMVKKNLGRLTRLWIKNEQERQRQIQKNGPEITPEEATTIFSVMVEWLESRSFSPIPFPPLTYKNDTKILVLALEDLKDVYASKVRLNASEREELALIEEAYDNPHDTLNRIKKYLLTQRVFKPVDITMMENYQNISPVYSVDPLEKITDAYLDQYLWYEADQRKLFPNWIKPSDSEIPPLLVYKWTQGINNLSEIWDVSRGQSAVLLETTLGEMAEKIDFTLLNRLLRLIVDPNIADYITAKNNVVINFKDMSHVNKYGLIRGLKFASFIFQYYGLVIDLLLLGQERATDLAGPANNPNEFMQFKSKEVEKAHPIRLYTRYLDRIYMLFHFEEDEGEELTDEYLAENPDPNFENSIGYNNRKCWPKDSRMRLIRQDVNLGRAVFWEIQSRVPTSLTSIKWENAFVSVYSKNNPNLLFSMCGFEVRILPRQRMEEVVSNDEGVWDLVDERTKQRTAKAYLKVSEEEIKKFDSRIRGILMASGSTTFTKVAAKWNTSLISLFTYFREAIVATEPLLDILVKGETRIQNRVKLGLNSKMPTRFPPAVFYTPKELGGLGMISASHILIPASDLSWSKQTDTGITHFRAGMTHEDEKLIPTIFRYITTWENEFLDSQRVWAEYATKRQEAIQQNRRLAFEELEGSWDRGIPRISTLFQRDRHTLAYDRGHRIRREFKQYSLERNSPFWWTNSHHDGKLWNLNAYRTDVIQALGGIETILEHTLFKGTGFNSWEGLFWEKASGFEDSMQFKKLTHAQRTGLSQIPNRRFTLWWSPTINRANVYVGFLVQLDLTGIFLHGKIPTLKISLIQIFRAHLWQKIHESIVFDICQILDGELDVLQIESVTKETVHPRKSYKMNSSAADITMESVHEWEVSKPSLLHETNDSFKGLITNKMWFDVQLRYGDYDSHDISRYVRAKFLDYTTDNVSMYPSPTGVMIGIDLAYNMYDAYGNWFNGLKPLIQNSMRTIMKANPALYVLRERIRKGLQIYQSSVQEPFLNSSNYAELFNNDIKLFVDDTNVYRVTVHKTFEGNVATKAINGCIFTLNPKTGHLFLKIIHTSVWAGQKRLSQLAKWKTAEEVSALVRSLPKEEQPKQIIVTRKAMLDPLEVHMLDFPNIAIRPTELRLPFSAAMSIDKLSDVVMKATEPQMVLFNIYDDWLDRISSYTAFSRLTLLLRALKTNEESAKMILLSDPTITIKSYHLWPSFTDEQWITIESQMRDLILTEYGRKYNVNISALTQTEIKDIILGQNIKAPSVKRQKMAELEAARSEKQNDEEAAGASTVMKTKTINAQGEEIVVVASADYESQTFSSKNEWRKSAIANTLLYLRLKNIYVSADDFVEEQNVYVLPKNLLKKFIEISDVKIQVAAFIYGMSAKDHPKVKEIKTVVLVPQLGHVGSVQISNIPDIGDLPDTEGLELLGWIHTQTEELKFMAASEVATHSKLFADKKRDCIDISIFSTPGSVSLSAYNLTDEGYQWGEENKDIMNVLSEGFEPTFSTHAQLLLSDRITGNFIIPSGNVWNYTFMGTAFNQEGDYNFKYGIPLEFYNEMHRPVHFLQFSELAGDEELEAEQIDVFS

T92128	TARGETID	T92128
T92128	FORMERID	TTDI02654
T92128	UNIPROID	ID1_HUMAN
T92128	TARGNAME	ID1 messenger RNA (ID1 mRNA)
T92128	GENENAME	ID1
T92128	TARGTYPE	Literature-reported
T92128	SYNONYMS	bHLHb24 (mRNA); Inhibitor of differentiation 1 (mRNA); Inhibitor of DNA binding 1 (mRNA); ID (mRNA); DNA-binding protein inhibitor ID-1 (mRNA); Class B basic helix-loop-helix protein 24 (mRNA)
T92128	FUNCTION	Implicated in regulating a variety of cellular processes, including cellular growth, senescence, differentiation, apoptosis, angiogenesis, and neoplastic transformation. Inhibits skeletal muscle and cardiac myocyte differentiation. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer. Transcriptional regulator (lacking a basic DNA binding domain) which negatively regulates the basic helix-loop-helix (bHLH) transcription factors by forming heterodimers and inhibiting their DNA binding and transcriptional activity.
T92128	BIOCLASS	mRNA target
T92128	SEQUENCE	MKVASGSTATAAAGPSCALKAGKTASGAGEVVRCLSEQSVAISRCAGGAGARLPALLDEQQVNVLLYDMNGCYSRLKELVPTLPQNRKVSKVEILQHVIDYIRDLQLELNSESEVGTPGGRGLPVRAPLSTLNGEISALTAEAACVPADDRILCR

T48548	TARGETID	T48548
T48548	FORMERID	TTDR01093
T48548	UNIPROID	ARRB1_HUMAN; ARRB2_HUMAN
T48548	TARGNAME	Beta-arrestin messenger RNA (ARRB mRNA)
T48548	GENENAME	ARRB1; ARRB2
T48548	TARGTYPE	Literature-reported
T48548	SYNONYMS	Non-visual arrestin; Beta-arrestin; Arrestin beta; ARR
T48548	FUNCTION	The extent of beta-arrestin involvement appears to vary significantly depending on the receptor, agonist and cell type. Internalized arrestin-receptor complexes traffic to intracellular endosomes, where they remain uncoupled from G-proteins. Functions in regulating agonist-mediated G-protein coupled receptor (GPCR) signaling by mediating both receptor desensitization and resensitization processes. During homologous desensitization, beta-arrestins bind to the GPRK-phosphorylated receptor and sterically preclude its coupling to the cognate G-protein; the binding appears to require additional receptor determinants exposed only in the active receptor conformation. The beta-arrestins target many receptors for internalization by acting as endocytic adapters (CLASPs, clathrin-associated sorting proteins) and recruiting the GPRCs to the adapter protein 2 complex 2 (AP-2) in clathrin-coated pits (CCPs).
T48548	BIOCLASS	mRNA target
T48548	SEQUENCE	MGDKGTRVFKKASPNGKLTVYLGKRDFVDHIDLVDPVDGVVLVDPEYLKERRVYVTLTCAFRYGREDLDVLGLTFRKDLFVANVQSFPPAPEDKKPLTRLQERLIKKLGEHAYPFTFEIPPNLPCSVTLQPGPEDTGKACGVDYEVKAFCAENLEEKIHKRNSVRLVIRKVQYAPERPGPQPTAETTRQFLMSDKPLHLEASLDKEIYYHGEPISVNVHVTNNTNKTVKKIKISVRQYADICLFNTAQYKCPVAMEEADDTVAPSSTFCKVYTLTPFLANNREKRGLALDGKLKHEDTNLASSTLLREGANREILGIIVSYKVKVKLVVSRGGLLGDLASSDVAVELPFTLMHPKPKEEPPHREVPENETPVDTNLIELDTNDDDIVFEDFARQRLKGMKDDKEEEEDGTGSPQLNNR

T03571	TARGETID	T03571
T03571	FORMERID	TTDI02387
T03571	UNIPROID	CTCFL_HUMAN
T03571	TARGNAME	BORIS messenger RNA (CTCFL mRNA)
T03571	GENENAME	CTCFL
T03571	TARGTYPE	Literature-reported
T03571	SYNONYMS	Zinc finger protein CTCF-T (mRNA); Transcriptional repressor CTCFL (mRNA); Cancer/testis antigen 27 (mRNA); CTCF-like protein (mRNA); CTCF paralog (mRNA); CT27 (mRNA); CCCTC-binding factor (mRNA); Brother of the regulator of imprinted sites (mRNA); BORIS (mRNA)
T03571	FUNCTION	Plays a key role in gene imprinting in male germline, by participating in the establishment of differential methylation at the IGF2/H19 imprinted control region (ICR). Directly binds the unmethylated H19 ICR and recruits the PRMT7 methyltransferase, leading to methylate histone H4 'Arg-3' to form H4R3sme2. This probably leads to recruit de novo DNA methyltransferases at these sites. Seems to act as tumor suppressor. In association with DNMT1 and DNMT3B, involved in activation of BAG1 gene expression by binding to its promoter. Required for dimethylation of H3 lysine 4 (H3K4me2) of MYC and BRCA1 promoters. Testis-specific DNA binding protein responsible for insulator function, nuclear architecture and transcriptional control, which probably acts by recruiting epigenetic chromatin modifiers.
T03571	BIOCLASS	mRNA target
T03571	SEQUENCE	MAATEISVLSEQFTKIKELELMPEKGLKEEEKDGVCREKDHRSPSELEAERTSGAFQDSVLEEEVELVLAPSEESEKYILTLQTVHFTSEAVELQDMSLLSIQQQEGVQVVVQQPGPGLLWLEEGPRQSLQQCVAISIQQELYSPQEMEVLQFHALEENVMVASEDSKLAVSLAETTGLIKLEEEQEKNQLLAERTKEQLFFVETMSGDERSDEIVLTVSNSNVEEQEDQPTAGQADAEKAKSTKNQRKTKGAKGTFHCDVCMFTSSRMSSFNRHMKTHTSEKPHLCHLCLKTFRTVTLLRNHVNTHTGTRPYKCNDCNMAFVTSGELVRHRRYKHTHEKPFKCSMCKYASVEASKLKRHVRSHTGERPFQCCQCSYASRDTYKLKRHMRTHSGEKPYECHICHTRFTQSGTMKIHILQKHGENVPKYQCPHCATIIARKSDLRVHMRNLHAYSAAELKCRYCSAVFHERYALIQHQKTHKNEKRFKCKHCSYACKQERHMTAHIRTHTGEKPFTCLSCNKCFRQKQLLNAHFRKYHDANFIPTVYKCSKCGKGFSRWINLHRHSEKCGSGEAKSAASGKGRRTRKRKQTILKEATKGQKEAAKGWKEAANGDEAAAEEASTTKGEQFPGEMFPVACRETTARVKEEVDEGVTCEMLLNTMDK

T20722	TARGETID	T20722
T20722	FORMERID	TTDI01539
T20722	UNIPROID	E2AK1_HUMAN; E2AK2_HUMAN; E2AK3_HUMAN; E2AK4_HUMAN
T20722	TARGNAME	EIF protein kinase messenger RNA (EIFK mRNA)
T20722	GENENAME	EIF2AK1; EIF2AK2; EIF2AK3; EIF2AK4
T20722	TARGTYPE	Literature-reported
T20722	SYNONYMS	eIF-2A kinase; Eukaryotic translation initiation factor 2-alpha kinase
T20722	FUNCTION	A kinase enzyme that phosphorylates eIF-2. These are all responsible for the phosphorylation of the alpha subunit of eIF-2 at serine 51, one of the best-characterized mechanisms for down-regulating protein synthesis in eukaryotes in response to various cellular stress response's.
T20722	BIOCLASS	mRNA target
T20722	SEQUENCE	MQGGNSGVRKREEEGDGAGAVAAPPAIDFPAEGPDPEYDESDVPAEIQVLKEPLQQPTFPFAVANQLLLVSLLEHLSHVHEPNPLRSRQVFKLLCQTFIKMGLLSSFTCSDEFSSLRLHHNRAITHLMRSAKERVRQDPCEDISRIQKIRSREVALEAQTSRYLNEFEELAILGKGGYGRVYKVRNKLDGQYYAIKKILIKGATKTVCMKVLREVKVLAGLQHPNIVGYHTAWIEHVHVIQPRADRAAIELPSLEVLSDQEEDREQCGVKNDESSSSSIIFAEPTPEKEKRFGESDTENQNNKSVKYTTNLVIRESGELESTLELQENGLAGLSASSIVEQQLPLRRNSHLEESFTSTEESSEENVNFLGQTEAQYHLMLHIQMQLCELSLWDWIVERNKRGREYVDESACPYVMANVATKIFQELVEGVFYIHNMGIVHRDLKPRNIFLHGPDQQVKIGDFGLACTDILQKNTDWTNRNGKRTPTHTSRVGTCLYASPEQLEGSEYDAKSDMYSLGVVLLELFQPFGTEMERAEVLTGLRTGQLPESLRKRCPVQAKYIQHLTRRNSSQRPSAIQLLQSELFQNSGNVNLTLQMKIIEQEKEIAELKKQLNLLSQDKGVRDDGKDGGVG

T81227	TARGETID	T81227
T81227	FORMERID	TTDI01702
T81227	UNIPROID	HV551_HUMAN; HV5X1_HUMAN
T81227	TARGNAME	Immunoglobulin heavy variable 5 (IGHV5)
T81227	GENENAME	IGHV5-10-1; IGHV5-51
T81227	TARGTYPE	Literature-reported
T81227	SYNONYMS	Immunoglobulin heavy variable 5
T81227	FUNCTION	V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens. The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen.
T81227	SEQUENCE	MGSTAILALLLAVLQGVCAEVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCAR

T42413	TARGETID	T42413
T42413	FORMERID	TTDI01400
T42413	UNIPROID	A0A0G4DCU0_HYPRU
T42413	TARGNAME	Trichoderma L-Lysine alpha-oxidase (HYPRU LysOX)
T42413	GENENAME	HYPRU LysOX
T42413	TARGTYPE	Literature-reported
T42413	SYNONYMS	L-Lysine alpha-oxidase
T42413	FUNCTION	An antitumor enzyme of Trichoderma harzianum. Inhibit highly infectious viruses INSV and TRSV, Mycoplasma hominis, and tick-borne encephalitis virus.
T42413	SEQUENCE	MDNVDFAESVRTRWARRLIREKVAKELNILTERLGEVPGIPPPREGRFLGGGYSHDNLPSDPLYSSIKPALLKEAPRAEEELPPRKVCIVGAGVSGLYIAMILDDLKIPNLTYDIFESSSRTGGRLYTHHFTDAKHDYYDIGAMRYPDIPSMKRTFNLFKRTGMPLIKYYLDGENTPQLYNNHFFAKGVVDPYMVSVANGGTVPDDVVDSVGEKLQQAFGYYKEKLAEDFDKGFDELMLVDDMTTREYLKRGGPKGEAPKYDFFAIQWMETQNTGTNLFDQAFSESVIDSFDFDNPTKPEWYCIEGGTSLLVDAMKETLVHKVQNNKRVEAISIDLDAPDDGNMSVKIGGKDYSGYSTVFNTTALGCLDRMDLRGLNLHPTQADAIRCLHYDNSTKVALKFSYPWWIKDCGITCGGAASTDLPLRTCVYPSYNLGDTGEAVLLASYTWSQDATRIGSLVKDAPPQPPKEDELVELILQNLARLHAEHMTYEKIKEAYTGVYHAYCWANDPNVGGAFALFGPGQFSNLYPYLMRPAAGGKFHIVGEASSVHHAWIIGSLESAYTAVYQFLYKYKMWDYLRLLLERWQYGLQELETGKHGTAHLQFILGSLPKEYQVKI

T95640	TARGETID	T95640
T95640	FORMERID	TTDR01318
T95640	UNIPROID	A0A1C7BG45_PSEAI
T95640	TARGNAME	Pseudomonas Protein KerV (Pseudo KerV)
T95640	GENENAME	Pseudo KerV
T95640	TARGTYPE	Literature-reported
T95640	SYNONYMS	KerV protein
T95640	FUNCTION	A  methyltransferase, well-conserved across numerous Proteobacteria, including both well-known and emerging pathogens.
T95640	SEQUENCE	MNEPQAFAQTDAEWLASINRARDWFQGPLGSLMLAEERRLLCDELTRYFGGYLVHYGPHAELPPSTGQIQRGVRLGPPLPGVDIACEEGAWPLSEHAADVVLLQHGLDFCLSPHRLLREAARTVRPGGHLLLIGINPWSLWGIRHYFAGDALRQARCIPPSRACDWLNLLGFALEKRRFGCYRPPLASAAWQSRLARLERWGDAWQSSGAGFYLLVARKLVVGLRPLRQSKREPRGQLVPMPVAKVSRRDSEI

T55817	TARGETID	T55817
T55817	FORMERID	TTDNR00689
T55817	UNIPROID	A0A1D8PIG5_CANAL
T55817	TARGNAME	Candida Co-chaperone SGT1 (Candi SGT1)
T55817	GENENAME	Candi SGT1
T55817	TARGTYPE	Literature-reported
T55817	SYNONYMS	orf19.4089; CAALFM_C209270CA
T55817	FUNCTION	Involved in ubiquitination and subsequent proteasomal degradation of target proteins. Required for both entry into S phase and kinetochore function. Also involved in cyclic AMP (cAMP) pathway, possibly by participating in the assembly or the conformational activation of specific multiprotein complexes.
T55817	SEQUENCE	MAIEQFITKGDDALKSKDYLGAISYYSQAIKENPQAFSPYLKRSTAYQKLKNNDKAKADISSAFSIATEKGKRVDIGLCYFKLGLVYYQEKKVKLSLTQFEKAVEYDCKEPTLSMWKAKAEYDLKNHPEWNVEGDKEEDDDIDLVLGVENEYTQSMANTEKDKSHEPKIVELDANEESSEKKSNQESTSSAPAAQATTQAPKSTNVDVINKIAPLNVKFRDDWYQSNEEVIITIYAKKVNEEKLKVEFDTNSVCISFPSAAASEYKYYLDPLFAEIVPSESKYKVYSTKLEITLKKKDANKWPELEKQAVEGVTDNQDKDKKVDPSELVYPTSSKKKINWNNFKIDDDDKEEGNENDFFRKIFKDVDEDSRRAMMKSYVQSNGTVLTTSWDEAKDKEFEVLPPDGMEVKKWDT

T22135	TARGETID	T22135
T22135	FORMERID	TTDNR00755
T22135	UNIPROID	A0A2X2N8M2_STAAU
T22135	TARGNAME	Staphylococcus Pmt ABC transporter (Stap-coc Pmt)
T22135	GENENAME	Stap-coc Pmt
T22135	TARGTYPE	Literature-reported
T22135	SYNONYMS	Predicted membrane-bound dolichyl-phosphate-mannose-protein mannosyltransferase
T22135	FUNCTION	A general export system for membrane-damaging peptides, secreting host-derived AMPs in addition to the bacterial PSM cytotoxins. Defends the bacteria from killing by important human AMPs and elimination by human neutrophils.
T22135	SEQUENCE	MTAPVPLLPAPEERSTRYGQLRDRLLRDPDWGRAIRWLAPLVITAIAALLRLINVAHPHQLAFDETYYVKDAWSLWTLGYEGTWGENANDAFITLQQLPLSEQGAFIVHPPLGKWLIALGMAIGGPDNSAGWRLATALLGTASVLLVYLIARRLSGSVVVASVAGTLLAIDGLSIVMSRIALLDGILTFFVLLGVLFVIIDRQRTIPVLERRDPDKPDPFWGPVLWRRPWLIAAGTALGAASAVKWSGLYVLAGFGLYVVVTDALARRRAGVVLWPTGAAFRQGPVSFVLLVFPALAVYLISWTGWLVTAGGYDRQSDPNPLIALWKYHESMLGFHVGLTRGHPYASPAWEWPLLLRPTAVWVDSDPTGCGTDHCIGVISAIPNPLIWYAGVAAAIYLLYRLVRGWITRRPVGPELSIPLVGLAVTYVPWLMFPDRTIFQFYTVVMMPFLVIALAMTLRIIAGTREDPLHRRQSGERTVMIFLAFVVLVSAFFLPLWTGMSVPYEFWLLHNWLPGWV

T89185	TARGETID	T89185
T89185	FORMERID	TTDI01440
T89185	UNIPROID	PM2P1_HUMAN; PM2P2_HUMAN; PM2P3_HUMAN
T89185	TARGNAME	Postmeiotic segregation increased 2-like protein (PMS2L)
T89185	GENENAME	PMS2P1; PMS2P2; PMS2P3
T89185	TARGTYPE	Literature-reported
T89185	SYNONYMS	Putative postmeiotic segregation increased 2-like protein; Putative postmeiotic segregation increased 2 pseudogene; Postmeiotic segregation increased protein; PMS2L; PMS2-related protein; PMS
T89185	FUNCTION	Expressed ubiquitously except in the heart. Analysis of the proteins interacting with PMS2Ls may lead to the elucidation of the function of PMS2Ls or of the downstream pathway in the MMR system.
T89185	SEQUENCE	MVTMCGGHRPENFLHQVLTEFGEELAGEGKSEVGGGAPRSYLQVASAECWAAAPAVHVGEPVHAGGLHTERGADPVIGLYLVHRGGACQTPTVGNRQTPTLGIHARPRRRATTSLLTLLLAFGKNAVRCALIGPGSLTSRTRPLTEPLGEKERREVFFPPRPERVEHNVESSRWEPRRRGACGSRGGNFPSPRGGSGVASLERAESSSTEPAKAIKPIDRKSVHQICSGPVVPSLSTAVKELVENSLDAGATNIDLKLKDYGVDLIEVSGNGCGVEEENFEGLTLKHHTSKIQEFADLPQVETFGFRGEALSSLCALSDVTISTCHVSAKVGTRLVFDHYGKIIQKTPYPHPRGMTVSVKQLFSTLPVHHKEFQRNIKKKRACFPFAFCRDCQFPEASPAMLPVQPAELTPRSTPPHPCSLEDNVITVFSSVKNGPGSSR

T58028	TARGETID	T58028
T58028	FORMERID	TTDI01521
T58028	UNIPROID	LIRA5_HUMAN; LIRB5_HUMAN
T58028	TARGNAME	Leukocyte Ig-like receptor-5 (LILR5)
T58028	GENENAME	LILRA5; LILRB5
T58028	TARGTYPE	Literature-reported
T58028	SYNONYMS	ILT-11
T58028	FUNCTION	May play a role in triggering innate immune responses. Does not seem to play a role for any class I MHC antigen recognition.
T58028	SEQUENCE	MAPWSHPSAQLQPVGGDAVSPALMVLLCLGLSLGPRTHVQAGNLSKATLWAEPGSVISRGNSVTIRCQGTLEAQEYRLVKEGSPEPWDTQNPLEPKNKARFSIPSMTEHHAGRYRCYYYSPAGWSEPSDPLELVVTGFYNKPTLSALPSPVVTSGENVTLQCGSRLRFDRFILTEEGDHKLSWTLDSQLTPSGQFQALFPVGPVTPSHRWMLRCYGSRRHILQVWSEPSDLLEIPVSGAADNLSPSQNKSDSGTASHLQDYAVENLIRMGMAGLILVVLGILIFQDWHSQRSPQAAAGR

T11858	TARGETID	T11858
T11858	FORMERID	TTDI03212
T11858	UNIPROID	GBRR3_HUMAN
T11858	TARGNAME	GABA(A) receptor rho3 (GABRR3)
T11858	GENENAME	GABRR3
T11858	TARGTYPE	Literature-reported
T11858	SYNONYMS	Gamma-aminobutyric acid receptor subunit rho-3; GABA(C) receptor3; GABA(A) receptor subunit rho-3
T11858	FUNCTION	GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
T11858	SEQUENCE	MVLAFQLVSFTYIWIILKPNVCAASNIKMTHQRCSSSMKQTCKQETRMKKDDSTKARPQKYEQLLHIEDNDFAMRPGFGGSPVPVGIDVHVESIDSISETNMDFTMTFYLRHYWKDERLSFPSTANKSMTFDHRLTRKIWVPDIFFVHSKRSFIHDTTMENIMLRVHPDGNVLLSLRITVSAMCFMDFSRFPLDTQNCSLELESYAYNEDDLMLYWKHGNKSLNTEEHMSLSQFFIEDFSASSGLAFYSSTGWYNRLFINFVLRRHVFFFVLQTYFPAILMVMLSWVSFWIDRRAVPARVSLGITTVLTMSTIITAVSASMPQVSYLKAVDVYLWVSSLFVFLSVIEYAAVNYLTTVEERKQFKKTGKISRMYNIDAVQAMAFDGCYHDSEIDMDQTSLSLNSEDFMRRKSICSPSTDSSRIKRRKSLGGHVGRIILENNHVIDTYSRILFPIVYILFNLFYWGVYV
T11858	DRUGINFO	D0A6RM	trans-3-ACPBPA	Investigative
T11858	DRUGINFO	D0B0WU	cis-3-ACPBPA	Investigative
T11858	DRUGINFO	D0C7PZ	5-Me-IAA	Investigative
T11858	DRUGINFO	D0OY1R	aza-THIP	Investigative
T11858	DRUGINFO	D0U4HM	TPMPA	Investigative
T11858	DRUGINFO	D0WV8K	(+/-)-cis-2-CAMP	Investigative
T11858	DRUGINFO	D0VW5M	piperidine-4-sulphonic acid	Investigative
T11858	DRUGINFO	D0AC2H	isonipecotic acid	Investigative
T11858	DRUGINFO	D0P0TI	TBPS	Investigative

T86074	TARGETID	T86074
T86074	FORMERID	TTDR00059
T86074	UNIPROID	C4QPC8_SCHMA
T86074	TARGNAME	Schistosoma P2X receptor (sch P2X)
T86074	GENENAME	sch P2X
T86074	TARGTYPE	Literature-reported
T86074	SYNONYMS	p2X receptor subunit (AJ703803)
T86074	FUNCTION	A non-vertebrate ATP-gated ion channel. 
T86074	SEQUENCE	MYFKGDSEFLGLKQCAREQMVKGIAVLFEYETPKLVQISNIKIGVTQRLLQLVILIYVVCWVMIYEKGYQENDIAKSAVTTKVKGVGFTNFSHIPGIGMRSWDVADYIVPPLENNALFVITNLVKTERQSLSKCQESSWVPEAACYKDSDCKPYFISHLGNGAHTGKCIIKPGNDIGSCEIYSWCPLENDTLPLGRKSFLFPMVYNYTLLIKNDINFEKFGIHRRNIQNWASKKFLRTCLYNKTDPENRFCPIFQFGTIFEEANVDQSIFISGGVIGIDIDWKCDLDWDVQYCNPTYSFRRLDDAHAKIASGFNFR

T88838	TARGETID	T88838
T88838	UNIPROID	TEG7_HCMVM
T88838	TARGNAME	Cytomegalovirus Phosphorylated tegument protein UL51 homolog (CMV pUL71)
T88838	GENENAME	CMV pUL71
T88838	TARGTYPE	Literature-reported
T88838	SYNONYMS	Tegument protein UL51 homolog
T88838	FUNCTION	Plays several roles during the time course of infection, including egress of virus particles from the perinuclear space and secondary envelopment of cytoplasmic capsids that bud into specific trans-Golgi network (TGN)-derived membranes.
T88838	SEQUENCE	MQLAQRLCELLMCRRKAAPVADYVLLQPSEDVELRELQAFLDENFKQLEITPADLRTFSRDTDVVNHLLKLLPLYRQCQSKCAFLKGYLSEGCLPHTRPAAEVECKKSQRILEALDILILKLVVGEFAMSEADSLEMLLDKFSTDQASLVEVQRVMGLVDMDCEKSAYMLEAGAAATVAPPTPPAVVQGESGVREDGETVAAVSAFACSSVSDSLIPEETGVTRPMMSLAHINTVSCPTVMRFDQRLLEEGDEEDEVTVMSPSPEPVQQQPPVEPVQQQPQGRGSHRRRYKESAPQETLPTNHEREILDLMRHSPDVPREAVMSPTMVTIPPPQIPFVGSARELRGVKKKKPTAAALLSSA

T33712	TARGETID	T33712
T33712	FORMERID	TTDI01372
T33712	UNIPROID	G0TQ18_MYCCP
T33712	TARGNAME	Mycobacterium Shikimate kinase (MycB aroK)
T33712	GENENAME	MycB aroK
T33712	TARGTYPE	Literature-reported
T33712	SYNONYMS	Shikimate kinase; MycB SK
T33712	FUNCTION	Catalyzes the specific phosphorylation of the 3-hydroxyl group of shikimic acid using ATP as a cosubstrate.
T33712	SEQUENCE	MAPKAVLVGLPGSGKSTIGRRLAKALGVSLLDTDVAIEQRTGRSIADIFATDGEQEFRRIEEDVVRAALADHDGVLSLGGGAVTSPGVRAALAGHTVVYLEISAAEGVRRTGGNTVRPLLAGPDRAEKYRALMAKRAPLYRRVATMRVDTNRRNPGAVVRYILSRLQVPSPSEAAT

T20256	TARGETID	T20256
T20256	FORMERID	TTDNR00684
T20256	UNIPROID	HAX1_HUMAN
T20256	TARGNAME	HCLS1-associated protein X-1 (HAX1)
T20256	GENENAME	HAX1
T20256	TARGTYPE	Literature-reported
T20256	SYNONYMS	HSP1BP-1; HS1BP1; HS1-binding protein 1; HS1-associating protein X-1; HAX-1
T20256	FUNCTION	Slows down the rate of inactivation of KCNC3 channels. Promotes GNA13-mediated cell migration. Involved in the clathrin-mediated endocytosis pathway. May be involved in internalization of ABC transporters such as ABCB11. May inhibit CASP9 and CASP3. Promotes cell survival. May regulate intracellular calcium pools. Recruits the Arp2/3 complex to the cell cortex and regulates reorganization of the cortical actin cytoskeleton via its interaction with KCNC3 and the Arp2/3 complex.
T20256	SEQUENCE	MSLFDLFRGFFGFPGPRSHRDPFFGGMTRDEDDDEEEEEEGGSWGRGNPRFHSPQHPPEEFGFGFSFSPGGGIRFHDNFGFDDLVRDFNSIFSDMGAWTLPSHPPELPGPESETPGERLREGQTLRDSMLKYPDSHQPRIFGGVLESDARSESPQPAPDWGSQRPFHRFDDVWPMDPHPRTREDNDLDSQVSQEGLGPVLQPQPKSYFKSISVTKITKPDGIVEERRTVVDSEGRTETTVTRHEADSSPRGDPESPRPPALDDAFSILDLFLGRWFRSR

T80858	TARGETID	T80858
T80858	FORMERID	TTDI03239
T80858	UNIPROID	GPR31_HUMAN
T80858	TARGNAME	G-protein coupled receptor 31 (GPR31)
T80858	GENENAME	GPR31
T80858	TARGTYPE	Literature-reported
T80858	SYNONYMS	12-HETER; 12-(S)-hydroxy-5,8,10,14-eicosatetraenoic acid receptor; 12-(S)-HETE receptor
T80858	FUNCTION	High-affinity receptor for 12-(S)-hydroxy-5,8,10,14-eicosatetraenoic acid (12-S-HETE). 12-(S)-HETE is an arachidonic acid metabolite secreted by platelets and tumor cells, and known to induce endothelial cells retraction allowing invasive cell access to the subendothelial matrix, which is a critical step for extravasation or metastasis. Ligand-binding lead to activation of ERK1/2 (MAPK3/MAPK1), MEK, and NF-kappa-B.
T80858	SEQUENCE	MPFPNCSAPSTVVATAVGVLLGLECGLGLLGNAVALWTFLFRVRVWKPYAVYLLNLALADLLLAACLPFLAAFYLSLQAWHLGRVGCWALHFLLDLSRSVGMAFLAAVALDRYLRVVHPRLKVNLLSPQAALGVSGLVWLLMVALTCPGLLISEAAQNSTRCHSFYSRADGSFSIIWQEALSCLQFVLPFGLIVFCNAGIIRALQKRLREPEKQPKLQRAQALVTLVVVLFALCFLPCFLARVLMHIFQNLGSCRALCAVAHTSDVTGSLTYLHSVLNPVVYCFSSPTFRSSYRRVFHTLRGKGQAAEPPDFNPRDSYS
T80858	DRUGINFO	D0Z5QA	12S-HETE	Investigative

T47498	TARGETID	T47498
T47498	FORMERID	TTDI03193
T47498	UNIPROID	EAA5_HUMAN
T47498	TARGNAME	Excitatory amino acid transporter 5 (SLC1A7)
T47498	GENENAME	SLC1A7
T47498	TARGTYPE	Literature-reported
T47498	SYNONYMS	Solute carrier family 1 member 7; Retinal glutamate transporter; EAAT5
T47498	FUNCTION	Transports L-glutamate; the L-glutamate uptake is sodium- and voltage-dependent and chloride-independent. Its associated chloride conductance may participate in visual processing.
T47498	SEQUENCE	MVPHAILARGRDVCRRNGLLILSVLSVIVGCLLGFFLRTRRLSPQEISYFQFPGELLMRMLKMMILPLVVSSLMSGLASLDAKTSSRLGVLTVAYYLWTTFMAVIVGIFMVSIIHPGSAAQKETTEQSGKPIMSSADALLDLIRNMFPANLVEATFKQYRTKTTPVVKSPKVAPEEAPPRRILIYGVQEENGSHVQNFALDLTPPPEVVYKSEPGTSDGMNVLGIVFFSATMGIMLGRMGDSGAPLVSFCQCLNESVMKIVAVAVWYFPFGIVFLIAGKILEMDDPRAVGKKLGFYSVTVVCGLVLHGLFILPLLYFFITKKNPIVFIRGILQALLIALATSSSSATLPITFKCLLENNHIDRRIARFVLPVGATINMDGTALYEAVAAIFIAQVNNYELDFGQIITISITATAASIGAAGIPQAGLVTMVIVLTSVGLPTDDITLIIAVDWALDRFRTMINVLGDALAAGIMAHICRKDFARDTGTEKLLPCETKPVSLQEIVAAQQNGCVKSVAEASELTLGPTCPHHVPVQVEQDEELPAASLNHCTIQISELETNV
T47498	DRUGINFO	D07CIW	[3H]ETB-TBOA	Investigative
T47498	DRUGINFO	D07GUB	DL-TBOA	Investigative
T47498	DRUGINFO	D08CAB	D-aspartic acid	Investigative

T00488	TARGETID	T00488
T00488	FORMERID	TTDI03434
T00488	UNIPROID	P2Y10_HUMAN
T00488	TARGNAME	P2Y purinoceptor 10 (P2RY10)
T00488	GENENAME	P2RY10
T00488	TARGTYPE	Literature-reported
T00488	SYNONYMS	Putative P2Y purinoceptor 10; P2Y10; P2Y-like receptor
T00488	FUNCTION	Putative receptor for purines coupled to G-proteins.
T00488	SEQUENCE	MANLDKYTETFKMGSNSTSTAEIYCNVTNVKFQYSLYATTYILIFIPGLLANSAALWVLCRFISKKNKAIIFMINLSVADLAHVLSLPLRIYYYISHHWPFQRALCLLCFYLKYLNMYASICFLTCISLQRCFFLLKPFRARDWKRRYDVGISAAIWIVVGTACLPFPILRSTDLNNNKSCFADLGYKQMNAVALVGMITVAELAGFVIPVIIIAWCTWKTTISLRQPPMAFQGISERQKALRMVFMCAAVFFICFTPYHINFIFYTMVKETIISSCPVVRIALYFHPFCLCLASLCCLLDPILYYFMASEFRDQLSRHGSSVTRSRLMSKESGSSMIG
T00488	DRUGINFO	D0G6XT	dioctanoylglycerol pyrophosphate	Investigative
T00488	DRUGINFO	D0X0UR	LPA	Investigative

T49208	TARGETID	T49208
T49208	FORMERID	TTDI03209
T49208	UNIPROID	GBRP_HUMAN
T49208	TARGNAME	GABA(A) receptor pi (GABRP)
T49208	GENENAME	GABRP
T49208	TARGTYPE	Literature-reported
T49208	SYNONYMS	Gamma-aminobutyric acid receptor subunit pi; GABA(A) receptor subunit pi
T49208	FUNCTION	GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the uterus, the function of the receptor appears to be related to tissue contractility. The binding of this pI subunit with other GABA(A) receptor subunits alters the sensitivity of recombinant receptors to modulatory agents such as pregnanolone.
T49208	SEQUENCE	MNYSLHLAFVCLSLFTERMCIQGSQFNVEVGRSDKLSLPGFENLTAGYNKFLRPNFGGEPVQIALTLDIASISSISESNMDYTATIYLRQRWMDQRLVFEGNKSFTLDARLVEFLWVPDTYIVESKKSFLHEVTVGNRLIRLFSNGTVLYALRITTTVACNMDLSKYPMDTQTCKLQLESWGYDGNDVEFTWLRGNDSVRGLEHLRLAQYTIERYFTLVTRSQQETGNYTRLVLQFELRRNVLYFILETYVPSTFLVVLSWVSFWISLDSVPARTCIGVTTVLSMTTLMIGSRTSLPNTNCFIKAIDVYLGICFSFVFGALLEYAVAHYSSLQQMAAKDRGTTKEVEEVSITNIINSSISSFKRKISFASIEISSDNVDYSDLTMKTSDKFKFVFREKMGRIVDYFTIQNPSNVDHYSKLLFPLIFMLANVFYWAYYMYF
T49208	DRUGINFO	D0P0TI	TBPS	Investigative

T39811	TARGETID	T39811
T39811	FORMERID	TTDI01376
T39811	UNIPROID	DHSD_HUMAN
T39811	TARGNAME	Succinate dehydrogenase (SDHD)
T39811	GENENAME	SDHD
T39811	TARGTYPE	Literature-reported
T39811	SYNONYMS	Succinate-ubiquinone reductase membrane anchor subunit; Succinate-ubiquinone oxidoreductase cytochrome b small subunit; Succinate dehydrogenase complex subunit D; Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial; SDH4; QPs3; CybS; CII-4
T39811	FUNCTION	Membrane-anchoring subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to ubiquinone (coenzyme Q).
T39811	SEQUENCE	MAVLWRLSAVCGALGGRALLLRTPVVRPAHISAFLQDRPIPEWCGVQHIHLSPSHHSGSKAASLHWTSERVVSVLLLGLLPAAYLNPCSAMDYSLAAALTLHGHWGLGQVVTDYVHGDALQKAAKAGLLALSALTFAGLCYFNYHDVGICKAVAMLWKL

T92477	TARGETID	T92477
T92477	FORMERID	TTDR00893
T92477	UNIPROID	SOCS3_HUMAN
T92477	TARGNAME	Suppressor of cytokine signaling 3 (SOCS3)
T92477	GENENAME	SOCS3
T92477	TARGTYPE	Literature-reported
T92477	SYNONYMS	STAT-induced STAT inhibitor 3; STAT induced STAT inhibitor 3; SSI3; SSI-3; SOCS-3; Cytokine-inducible SH2 protein 3; CIS3; CIS-3
T92477	FUNCTION	SOCS3 is involved in negative regulation of cytokines that signal through the JAK/STAT pathway. Inhibits cytokine signal transduction by binding to tyrosine kinase receptors including gp130, LIF, erythropoietin, insulin, IL12, GCSF and leptin receptors. Binding to JAK2 inhibits its kinase activity. Suppresses fetal liver erythropoiesis. Regulates onset and maintenance of allergic responses mediated by T-helper type 2 cells. Regulates IL-6 signaling in vivo. Probable substrate recognition component of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Seems to recognize IL6ST. SOCS family proteins form part of a classical negative feedback system that regulates cytokine signal transduction.
T92477	SEQUENCE	MVTHSKFPAAGMSRPLDTSLRLKTFSSKSEYQLVVNAVRKLQESGFYWSAVTGGEANLLLSAEPAGTFLIRDSSDQRHFFTLSVKTQSGTKNLRIQCEGGSFSLQSDPRSTQPVPRFDCVLKLVHHYMPPPGAPSFPSPPTEPSSEVPEQPSAQPLPGSPPRRAYYIYSGGEKIPLVLSRPLSSNVATLQHLCRKTVNGHLDSYEKVTQLPGPIREFLDQYDAPL

T53070	TARGETID	T53070
T53070	FORMERID	TTDR00906
T53070	UNIPROID	UN13B_HUMAN
T53070	TARGNAME	Protein unc-13 homolog B (UNC13B)
T53070	GENENAME	UNC13B
T53070	TARGTYPE	Literature-reported
T53070	SYNONYMS	UNC13B; Munc13-2; Munc13-1
T53070	FUNCTION	Plays a role in vesicle maturation during exocytosis as a target of thediacylglycerol second messenger pathway. Is involved in neurotransmitter release by acting in synaptic vesicle priming prior to vesicle fusion and participates in the activity- depending refilling ofreadily releasable vesicle pool (RRP). Essential for synaptic vesicle maturation in a subset of excitatory/glutamatergic but not inhibitory/GABA-mediated synapses.
T53070	SEQUENCE	MSLLCVRVKRAKFQGSPDKFNTYVTLKVQNVKSTTVAVRGDQPSWEQDFMFEISRLDLGLSVEVWNKGLIWDTMVGTVWIALKTIRQSDEEGPGEWSTLEAETLMKDDEICGTRNPTPHKILLDTRFELPFDIPEEEARYWTYKWEQINALGADNEYSSQEESQRKPLPTAAAQCSFEDPDSAVDDRDSDYRSETSNSFPPPYHTASQPNASVHQFPVPVRSPQQLLLQGSSRDSCNDSMQSYDLDYPERRAISPTSSSRYGSSCNVSQGSSQLSELDQYHEQDDDHRETDSIHSCHSSHSLSRDGQAGFGEQEKPLEVTGQAEKEAACEPKEMKEDATTHPPPDLVLQKDHFLGPQESFPEENASSPFTQARAHWIRAVTKVRLQLQEIPDDGDPSLPQWLPEGPAGGLYGIDSMPDLRRKKPLPLVSDLSLVQSRKAGITSAMATRTSLKDEELKSHVYKKTLQALIYPISCTTPHNFEVWTATTPTYCYECEGLLWGIARQGMRCSECGVKCHEKCQDLLNADCLQRAAEKSCKHGAEDRTQNIIMAMKDRMKIRERNKPEIFEVIRDVFTVNKAAHVQQMKTVKQSVLDGTSKWSAKITITVVCAQGLQAKDKTGSSDPYVTVQVSKTKKRTKTIFGNLNPVWEEKFHFECHNSSDRIKVRVWDEDDDIKSRVKQRLKRESDDFLGQTIIEVRTLSGEMDVWYNLEKRTDKSAVSGAIRLQISVEIKGEEKVAPYHVQYTCLHENLFHYLTDIQGSGGVRIPEARGDDAWKVYFDETAQEIVDEFAMRYGIESIYQAMTHFACLSSKYMCPGVPAVMSTLLANINAYYAHTTASTNVSASDRFAASNFGKERFVKLLDQLHNSLRIDLSTYRNNFPAGSPERLQDLKSTVDLLTSITFFRMKVQELQSPPRASQVVKDCVKACLNSTYEYIFNNCHDLYSRQYQLKQELPPEEQGPSIRNLDFWPKLITLIVSIIEEDKNSYTPVLNQFPQELNVGKVSAEVMWHLFAQDMKYALEEHEKDHLCKSADYMNLHFKVKWLHNEYVRDLPVLQGQVPEYPAWFEQFVLQWLDENEDVSLEFLRGALERDKKDGFQQTSEHALFSCSVVDVFTQLNQSFEIIRKLECPDPSILAHYMRRFAKTIGKVLMQYADILSKDFPAYCTKEKLPCILMNNVQQLRVQLEKMFEAMGGKELDLEAADSLKELQVKLNTVLDELSMVFGNSFQVRIDECVRQMADILGQVRGTGNASPDARASAAQDADSVLRPLMDFLDGNLTLFATVCEKTVLKRVLKELWRVVMNTMERMIVLPPLTDQTGTQLIFTAAKELSHLSKLKDHMVREETRNLTPKQCAVLDLALDTIKQYFHAGGNGLKKTFLEKSPDLQSLRYALSLYTQTTDTLIKTFVRSQTTQGSGVDDPVGEVSIQVDLFTHPGTGEHKVTVKVVAANDLKWQTAGMFRPFVEVTMVGPHQSDKKRKFTTKSKSNNWAPKYNETFHFLLGNEEGPESYELQICVKDYCFAREDRVLGLAVMPLRDVTAKGSCACWCPLGRKIHMDETGLTILRILSQRSNDEVAREFVKLKSESRSTEEGS

T60362	TARGETID	T60362
T60362	FORMERID	TTDI03569
T60362	UNIPROID	TAAR5_HUMAN
T60362	TARGNAME	Trace amine receptor 5 (TAAR5)
T60362	GENENAME	TAAR5
T60362	TARGTYPE	Literature-reported
T60362	SYNONYMS	hTaar5; Trace amine-associated receptor 5; TaR-5; Putative neurotransmitter receptor; PNR
T60362	FUNCTION	Olfactory receptor specific for trimethylamine, a trace amine. Also activated at lower level by dimethylethylamine. Trimethylamine is a bacterial metabolite found in some animal odors, and to humans it is a repulsive odor associated with bad breath and spoiled food. This receptor is probably mediated by the G(s)-class of G-proteins which activate adenylate cyclase.
T60362	SEQUENCE	MRAVFIQGAEEHPAAFCYQVNGSCPRTVHTLGIQLVIYLACAAGMLIIVLGNVFVAFAVSYFKALHTPTNFLLLSLALADMFLGLLVLPLSTIRSVESCWFFGDFLCRLHTYLDTLFCLTSIFHLCFISIDRHCAICDPLLYPSKFTVRVALRYILAGWGVPAAYTSLFLYTDVVETRLSQWLEEMPCVGSCQLLLNKFWGWLNFPLFFVPCLIMISLYVKIFVVATRQAQQITTLSKSLAGAAKHERKAAKTLGIAVGIYLLCWLPFTIDTMVDSLLHFITPPLVFDIFIWFAYFNSACNPIIYVFSYQWFRKALKLTLSQKVFSPQTRTVDLYQE
T60362	DRUGINFO	D04DOV	trimethylamine	Investigative
T60362	DRUGINFO	D0S5DR	dimethylethylamine	Investigative

T77344	TARGETID	T77344
T77344	FORMERID	TTDR00833
T77344	UNIPROID	LSM1_HUMAN
T77344	TARGNAME	Small nuclear ribonuclear CaSm (LSM1)
T77344	GENENAME	LSM1
T77344	TARGTYPE	Literature-reported
T77344	SYNONYMS	LSM1; Cancer-associated Sm-like (CaSm) oncogene; Cancer-associated Sm-like; CaSm
T77344	FUNCTION	Plays a role in replication-dependenthistone mRNA degradation. Binds specifically to the 3'-terminal U-tract of U6 snRNA.
T77344	SEQUENCE	MNYMPGTASLIEDIDKKHLVLLRDGRTLIGFLRSIDQFANLVLHQTVERIHVGKKYGDIPRGIFVVRGENVVLLGEIDLEKESDTPLQQVSIEEILEEQRVEQQTKLEAEKLKVQALKDRGLSIPRADTLDEY

T56588	TARGETID	T56588
T56588	FORMERID	TTDI03225
T56588	UNIPROID	NMDE4_HUMAN
T56588	TARGNAME	Glutamate receptor ionotropic NMDA 2D (GluN2D)
T56588	GENENAME	GRIN2D
T56588	TARGTYPE	Literature-reported
T56588	SYNONYMS	NR2D; NMDAR2D; N-methyl D-aspartate receptor subtype 2D; Glutamate receptor ionotropic, NMDA 2D; Glutamate [NMDA] receptor subunit epsilon-4; GluN2D; EB11
T56588	FUNCTION	Component of NMDA receptor complexes that function as heterotetrameric, ligand-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Channel activation requires binding of the neurotransmitter glutamate to the epsilon subunit, glycine binding to the zeta subunit, plus membrane depolarization to eliminate channel inhibition by Mg(2+). Sensitivity to glutamate and channel kinetics depend on the subunit composition.
T56588	SEQUENCE	MRGAGGPRGPRGPAKMLLLLALACASPFPEEAPGPGGAGGPGGGLGGARPLNVALVFSGPAYAAEAARLGPAVAAAVRSPGLDVRPVALVLNGSDPRSLVLQLCDLLSGLRVHGVVFEDDSRAPAVAPILDFLSAQTSLPIVAVHGGAALVLTPKEKGSTFLQLGSSTEQQLQVIFEVLEEYDWTSFVAVTTRAPGHRAFLSYIEVLTDGSLVGWEHRGALTLDPGAGEAVLSAQLRSVSAQIRLLFCAREEAEPVFRAAEEAGLTGSGYVWFMVGPQLAGGGGSGAPGEPPLLPGGAPLPAGLFAVRSAGWRDDLARRVAAGVAVVARGAQALLRDYGFLPELGHDCRAQNRTHRGESLHRYFMNITWDNRDYSFNEDGFLVNPSLVVISLTRDRTWEVVGSWEQQTLRLKYPLWSRYGRFLQPVDDTQHLTVATLEERPFVIVEPADPISGTCIRDSVPCRSQLNRTHSPPPDAPRPEKRCCKGFCIDILKRLAHTIGFSYDLYLVTNGKHGKKIDGVWNGMIGEVFYQRADMAIGSLTINEERSEIVDFSVPFVETGISVMVARSNGTVSPSAFLEPYSPAVWVMMFVMCLTVVAVTVFIFEYLSPVGYNRSLATGKRPGGSTFTIGKSIWLLWALVFNNSVPVENPRGTTSKIMVLVWAFFAVIFLASYTANLAAFMIQEEYVDTVSGLSDRKFQRPQEQYPPLKFGTVPNGSTEKNIRSNYPDMHSYMVRYNQPRVEEALTQLKAGKLDAFIYDAAVLNYMARKDEGCKLVTIGSGKVFATTGYGIALHKGSRWKRPIDLALLQFLGDDEIEMLERLWLSGICHNDKIEVMSSKLDIDNMAGVFYMLLVAMGLSLLVFAWEHLVYWRLRHCLGPTHRMDFLLAFSRGMYSCCSAEAAPPPAKPPPPPQPLPSPAYPAPRPAPGPAPFVPRERASVDRWRRTKGAGPPGGAGLADGFHRYYGPIEPQGLGLGLGEARAAPRGAAGRPLSPPAAQPPQKPPPSYFAIVRDKEPAEPPAGAFPGFPSPPAPPAAAATAVGPPLCRLAFEDESPPAPARWPRSDPESQPLLGPGAGGAGGTGGAGGGAPAAPPPCRAAPPPCPYLDLEPSPSDSEDSESLGGASLGGLEPWWFADFPYPYAERLGPPPGRYWSVDKLGGWRAGSWDYLPPRSGPAAWHCRHCASLELLPPPRHLSCSHDGLDGGWWAPPPPPWAAGPLPRRRARCGCPRSHPHRPRASHRTPAAAAPHHHRHRRAAGGWDLPPPAPTSRSLEDLSSCPRAAPARRLTGPSRHARRCPHAAHWGPPLPTASHRRHRGGDLGTRRGSAHFSSLESEV
T56588	DRUGINFO	D03UNN	L-689560	Terminated
T56588	DRUGINFO	D0Z8YM	QNZ 46	Investigative
T56588	DRUGINFO	D0HF0A	DQP-1105	Investigative
T56588	DRUGINFO	D02PXN	N1-dansyl-spermine	Investigative
T56588	DRUGINFO	D03XLS	d-CCPene	Investigative
T56588	DRUGINFO	D04NPE	UBP141	Investigative
T56588	DRUGINFO	D08RVB	LY233053	Investigative
T56588	DRUGINFO	D0FT0J	d-AP5	Investigative
T56588	DRUGINFO	D00ZKW	[3H]CPP	Investigative
T56588	DRUGINFO	D06GKL	2-Methylamino-succinic acid(NMDA)	Investigative
T56588	DRUGINFO	D07COG	[3H]MDL105519	Investigative
T56588	DRUGINFO	D08UDC	[3H]CGP39653	Investigative
T56588	DRUGINFO	D0B5ZA	homoquinolinic acid	Investigative
T56588	DRUGINFO	D0D2ZH	[3H]dizocilpine	Investigative
T56588	DRUGINFO	D0F5ZW	CGP61594	Investigative
T56588	DRUGINFO	D0FW8K	(RS)-(tetrazol-5-yl)glycine	Investigative
T56588	DRUGINFO	D0KO6Y	[3H]CGS19755	Investigative
T56588	DRUGINFO	D0OT9B	L-aspartic acid	Investigative
T56588	DRUGINFO	D08CAB	D-aspartic acid	Investigative

T06800	TARGETID	T06800
T06800	FORMERID	TTDR00493
T06800	UNIPROID	SOCS1_HUMAN
T06800	TARGNAME	Suppressor of cytokine signaling 1 (SOCS1)
T06800	GENENAME	SOCS1
T06800	TARGTYPE	Literature-reported
T06800	SYNONYMS	Tec-interacting protein 3; TIP3; TIP-3; STAT-induced STAT inhibitor 1; STAT induced STAT inhibitor 1; SSI1; SSI-1; SOCS-1; JAK-binding protein; JAB
T06800	FUNCTION	SOCS1 is involved in negative regulation of cytokines that signal through the JAK/STAT3 pathway. Through binding to JAKs, inhibits their kinase activity. In vitro, also suppresses Tec protein-tyrosine activity. Appears to be a major regulator of signaling by interleukin 6 (IL6) and leukemia inhibitory factor (LIF). Regulates interferon-gamma mediated sensory neuron survival. Probable substrate recognition component of an ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Seems to recognize JAK2. SOCS1 appears to be a negative regulator in IGF1R signaling pathway. SOCS family proteins form part of a classical negative feedback system that regulates cytokine signal transduction.
T06800	SEQUENCE	MVAHNQVAADNAVSTAAEPRRRPEPSSSSSSSPAAPARPRPCPAVPAPAPGDTHFRTFRSHADYRRITRASALLDACGFYWGPLSVHGAHERLRAEPVGTFLVRDSRQRNCFFALSVKMASGPTSIRVHFQAGRFHLDGSRESFDCLFELLEHYVAAPRRMLGAPLRQRRVRPLQELCRQRIVATVGRENLARIPLNPVLRDYLSSFPFQI

T21715	TARGETID	T21715
T21715	FORMERID	TTDI00202
T21715	UNIPROID	MSI1H_HUMAN
T21715	TARGNAME	RNA-binding protein Musashi-1 (MSI1)
T21715	GENENAME	MSI1
T21715	TARGTYPE	Literature-reported
T21715	SYNONYMS	RNA-binding protein Musashi homolog 1; Musashi-1
T21715	FUNCTION	Regulates expression of the NOTCH1 antagonist NUMB. Binds RNA containing the sequence 5'-GUUAGUUAGUUAGUU-3' and other sequences containing the pattern 5'-[GA]U(1-3)AGU-3'. May play a role in the proliferation and maintenance of stem cells in the central nervous system. RNA binding protein that regulates the expression of target mRNAs at the translation level.
T21715	SEQUENCE	METDAPQPGLASPDSPHDPCKMFIGGLSWQTTQEGLREYFGQFGEVKECLVMRDPLTKRSRGFGFVTFMDQAGVDKVLAQSRHELDSKTIDPKVAFPRRAQPKMVTRTKKIFVGGLSVNTTVEDVKQYFEQFGKVDDAMLMFDKTTNRHRGFGFVTFESEDIVEKVCEIHFHEINNKMVECKKAQPKEVMSPTGSARGRSRVMPYGMDAFMLGIGMLGYPGFQATTYASRSYTGLAPGYTYQFPEFRVERTPLPSAPVLPELTAIPLTAYGPMAAAAAAAAVVRGTGSHPWTMAPPPGSTPSRTGGFLGTTSPGPMAELYGAANQDSGVSSYISAASPAPSTGFGHSLGGPLIATAFTNGYH

T76540	TARGETID	T76540
T76540	FORMERID	TTDR01327
T76540	UNIPROID	SPY1_HUMAN
T76540	TARGNAME	Sprouty homolog 1 (SPRY-1)
T76540	GENENAME	SPRY1
T76540	TARGTYPE	Literature-reported
T76540	SYNONYMS	Spry-1; Protein sprouty homolog 1
T76540	FUNCTION	May function as an antagonist of fibroblast growth factor (FGF) pathways and may negatively modulate respiratory organogenesis.
T76540	SEQUENCE	MDPQNQHGSGSSLVVIQQPSLDSRQRLDYEREIQPTAILSLDQIKAIRGSNEYTEGPSVVKRPAPRTAPRQEKHERTHEIIPINVNNNYEHRHTSHLGHAVLPSNARGPILSRSTSTGSAASSGSNSSASSEQGLLGRSPPTRPVPGHRSERAIRTQPKQLIVDDLKGSLKEDLTQHKFICEQCGKCKCGECTAPRTLPSCLACNRQCLCSAESMVEYGTCMCLVKGIFYHCSNDDEGDSYSDNPCSCSQSHCCSRYLCMGAMSLFLPCLLCYPPAKGCLKLCRRCYDWIHRPGCRCKNSNTVYCKLESCPSRGQGKPS

T94627	TARGETID	T94627
T94627	FORMERID	TTDI03552
T94627	UNIPROID	S28A2_HUMAN
T94627	TARGNAME	Solute carrier family 28 member 2 (SLC28A2)
T94627	GENENAME	SLC28A2
T94627	TARGTYPE	Literature-reported
T94627	SYNONYMS	hCNT2; Sodium/purine nucleoside co-transporter; Sodium/nucleoside cotransporter 2; Sodium-coupled nucleoside transporter 2; SPNT; Na(+)/nucleoside cotransporter 2; Concentrative nucleoside transporter 2; CNT2; CNT 2
T94627	FUNCTION	Sodium-dependent and purine-selective transporter. Exhibits the transport characteristics of the nucleoside transport system cif or N1 subtype (N1/cif) (selective for purine nucleosides and uridine). Plays a critical role in specific uptake and salvage of purine nucleosides in kidney and other tissues.
T94627	SEQUENCE	MEKASGRQSIALSTVETGTVNPGLELMEKEVEPEGSKRTDAQGHSLGDGLGPSTYQRRSRWPFSKARSFCKTHASLFKKILLGLLCLAYAAYLLAACILNFQRALALFVITCLVIFVLVHSFLKKLLGKKLTRCLKPFENSRLRLWTKWVFAGVSLVGLILWLALDTAQRPEQLIPFAGICMFILILFACSKHHSAVSWRTVFSGLGLQFVFGILVIRTDLGYTVFQWLGEQVQIFLNYTVAGSSFVFGDTLVKDVFAFQALPIIIFFGCVVSILYYLGLVQWVVQKVAWFLQITMGTTATETLAVAGNIFVGMTEAPLLIRPYLGDMTLSEIHAVMTGGFATISGTVLGAFIAFGVDASSLISASVMAAPCALASSKLAYPEVEESKFKSEEGVKLPRGKERNVLEAASNGAVDAIGLATNVAANLIAFLAVLAFINAALSWLGELVDIQGLTFQVICSYLLRPMVFMMGVEWTDCPMVAEMVGIKFFINEFVAYQQLSQYKNKRLSGMEEWIEGEKQWISVRAEIITTFSLCGFANLSSIGITLGGLTSIVPHRKSDLSKVVVRALFTGACVSLISACMAGILYVPRGAEADCVSFPNTSFTNRTYETYMCCRGLFQSTSLNGTNPPSFSGPWEDKEFSAMALTNCCGFYNNTVCA
T94627	DRUGINFO	D05TGQ	PMID25815140C48	Investigative

T97897	TARGETID	T97897
T97897	FORMERID	TTDR00727
T97897	UNIPROID	PLIN1_HUMAN
T97897	TARGNAME	Lipid droplet-associated protein (PLIN1)
T97897	GENENAME	PLIN1
T97897	TARGTYPE	Literature-reported
T97897	SYNONYMS	PLIN1; PERI
T97897	FUNCTION	Modulator of adipocyte lipid metabolism. Coats lipid storage droplets to protect them from breakdown by hormone- sensitive lipase (HSL). Its absence may result in leanness. Plays a role in unilocular lipid droplet formation by activating CIDEC. Their interaction promotes lipid droplet enlargement and directional net neutral lipid transfer. May modulate lipolysis and triglyceride levels.
T97897	SEQUENCE	MAVNKGLTLLDGDLPEQENVLQRVLQLPVVSGTCECFQKTYTSTKEAHPLVASVCNAYEKGVQSASSLAAWSMEPVVRRLSTQFTAANELACRGLDHLEEKIPALQYPPEKIASELKDTISTRLRSARNSISVPIASTSDKVLGAALAGCELAWGVARDTAEFAANTRAGRLASGGADLALGSIEKVVEYLLPPDKEESAPAPGHQQAQKSPKAKPSLLSRVGALTNTLSRYTVQTMARALEQGHTVAMWIPGVVPLSSLAQWGASVAMQAVSRRRSEVRVPWLHSLAAAQEEDHEDQTDTEGEDTEEEEELETEENKFSEVAALPGPRGLLGGVAHTLQKTLQTTISAVTWAPAAVLGMAGRVLHLTPAPAVSSTKGRAMSLSDALKGVTDNVVDTVVHYVPLPRLSLMEPESEFRDIDNPPAEVERREAERRASGAPSAGPEPAPRLAQPRRSLRSAQSPGAPPGPGLEDEVATPAAPRPGFPAVPREKPKRRVSDSFFRPSVMEPILGRTHYSQLRKKS

T47966	TARGETID	T47966
T47966	FORMERID	TTDR00465
T47966	UNIPROID	GBG7_HUMAN
T47966	TARGNAME	GN-binding protein G(I)/G(S)/G(O) gamma-7 (GNG7)
T47966	GENENAME	GNG7
T47966	TARGTYPE	Literature-reported
T47966	SYNONYMS	Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-7; GNGT7; G protein gamma 7
T47966	FUNCTION	The beta and gamma chains are required for the GTPase activity, for replacement of GDP by GTP, and for G protein-effector interaction. Plays a role in the regulation of adenylyl cyclase signaling in certain regions of the brain. Plays a role in the formation or stabilzation of a G protein heterotrimer (G(olf) subunit alpha-beta-gamma-7) that is required for adenylyl cyclase activity in the striatum. Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems.
T47966	SEQUENCE	MSATNNIAQARKLVEQLRIEAGIERIKVSKAASDLMSYCEQHARNDPLLVGVPASENPFKDKKPCIIL

T91373	TARGETID	T91373
T91373	UNIPROID	DPM1_HUMAN; DPM2_HUMAN; DPM3_HUMAN
T91373	TARGNAME	Dolichol phosphate mannose synthase (DPMS)
T91373	GENENAME	DPM1; DPM2; DPM3
T91373	TARGTYPE	Literature-reported
T91373	SYNONYMS	Mannose-P-dolichol synthase; MPD synthase; Dolichyl-phosphate beta-D-mannosyltransferase; Dolichol-phosphate mannosyltransferase; Dolichol-phosphate mannose synthase; DPM synthase
T91373	FUNCTION	Synthesize dolichol-phosphate mannose (Dol-P-Man) from GDP-mannose and dolichol-phosphate on the cytosolic side of the ER. Dolichol-phosphate mannose serves as a donor of mannosyl residues on the lumenal side of the endoplasmic reticulum (ER). Lack of Dol-P-Man results in defective surface expression of GPI-anchored proteins. 
T91373	SEQUENCE	MASLEVSRSPRRSRRELEVRSPRQNKYSVLLPTYNERENLPLIVWLLVKSFSESGINYEIIIIDDGSPDGTRDVAEQLEKIYGSDRILLRPREKKLGLGTAYIHGMKHATGNYIIIMDADLSHHPKFIPEFIRKQKEGNFDIVSGTRYKGNGGVYGWDLKRKIISRGANFLTQILLRPGASDLTGSFRLYRKEVLEKLIEKCVSKGYVFQMEMIVRARQLNYTIGEVPISFVDRVYGESKLGGNEIVSFLKGLLTLFATT

T95997	TARGETID	T95997
T95997	FORMERID	TTDI03579
T95997	UNIPROID	S19A2_HUMAN
T95997	TARGNAME	Solute carrier family 19 member 2 (SLC19A2)
T95997	GENENAME	SLC19A2
T95997	TARGTYPE	Literature-reported
T95997	SYNONYMS	Thiamine transporter 1; Thiamine carrier 1; ThTr1; ThTr-1; TRMA; THT1; TC1
T95997	FUNCTION	High-affinity transporter for the intake of thiamine.
T95997	SEQUENCE	MDVPGPVSRRAAAAAATVLLRTARVRRECWFLPTALLCAYGFFASLRPSEPFLTPYLLGPDKNLTEREVFNEIYPVWTYSYLVLLFPVFLATDYLRYKPVVLLQGLSLIVTWFMLLYAQGLLAIQFLEFFYGIATATEIAYYSYIYSVVDLGMYQKVTSYCRSATLVGFTVGSVLGQILVSVAGWSLFSLNVISLTCVSVAFAVAWFLPMPQKSLFFHHIPSTCQRVNGIKVQNGGIVTDTPASNHLPGWEDIESKIPLNMEEPPVEEPEPKPDRLLVLKVLWNDFLMCYSSRPLLCWSVWWALSTCGYFQVVNYTQGLWEKVMPSRYAAIYNGGVEAVSTLLGAVAVFAVGYIKISWSTWGEMTLSLFSLLIAAAVYIMDTVGNIWVCYASYVVFRIIYMLLITIATFQIAANLSMERYALVFGVNTFIALALQTLLTLIVVDASGLGLEITTQFLIYASYFALIAVVFLASGAVSVMKKCRKLEDPQSSSQVTTS
T95997	DRUGINFO	D07TYL	[3H]thiamine	Investigative

T14144	TARGETID	T14144
T14144	FORMERID	TTDR00460
T14144	UNIPROID	OPHN1_HUMAN
T14144	TARGNAME	Oligophrenin-1 (OPHN1)
T14144	GENENAME	OPHN1
T14144	TARGTYPE	Literature-reported
T14144	SYNONYMS	Oligophrenin1; OPHN1
T14144	FUNCTION	Stimulates GTP hydrolysis of members of the Rho family. Its action on RHOA activity and signaling is implicated in growth and stabilization of dendritic spines, and therefore in synaptic function. Critical for the stabilization of AMPA receptors at postsynaptic sites. Critical for the regulation of synaptic vesicle endocytosis at presynaptic terminals. Required for the localization of NR1D1 to dendrites, can suppress its repressor activity and protect it fromproteasomal degradation.
T14144	SEQUENCE	MGHPPLEFSDCYLDSPDFRERLKCYEQELERTNKFIKDVIKDGNALISAMRNYSSAVQKFSQTLQSFQFDFIGDTLTDDEINIAESFKEFAELLNEVENERMMMVHNASDLLIKPLENFRKEQIGFTKERKKKFEKDGERFYSLLDRHLHLSSKKKESQLQEADLQVDKERHNFFESSLDYVYQIQEVQESKKFNIVEPVLAFLHSLFISNSLTVELTQDFLPYKQQLQLSLQNTRNHFSSTREEMEELKKRMKEAPQTCKLPGQPTIEGYLYTQEKWALGISWVKYYCQYEKETKTLTMTPMEQKPGAKQGPLDLTLKYCVRRKTESIDKRFCFDIETNERPGTITLQALSEANRRLWMEAMDGKEPIYHSPITKQQEMELNEVGFKFVRKCINIIETKGIKTEGLYRTVGSNIQVQKLLNAFFDPKCPGDVDFHNSDWDIKTITSSLKFYLRNLSEPVMTYRLHKELVSAAKSDNLDYRLGAIHSLVYKLPEKNREMLELLIRHLVNVCEHSKENLMTPSNMGVIFGPTLMRAQEDTVAAMMNIKFQNIVVEILIEHFGKIYLGPPEESAAPPVPPPRVTARRHKPITISKRLLRERTVFYTSSLDESEDEIQHQTPNGTITSSIEPPKPPQHPKLPIQRSGETDPGRKSPSRPILDGKLEPCPEVDVGKLVSRLQDGGTKITPKATNGPMPGSGPTKTPSFHIKRPAPRPLAHHKEGDADSFSKVRPPGEKPTIIRPPVRPPDPPCRAATPQKPEPKPDIVAGNAGEITSSVVASRTRFFETASRKTGSSQGRLPGDES

T16336	TARGETID	T16336
T16336	FORMERID	TTDI03240
T16336	UNIPROID	GPR32_HUMAN
T16336	TARGNAME	G-protein coupled receptor 32 (GPR32)
T16336	GENENAME	GPR32
T16336	TARGTYPE	Literature-reported
T16336	SYNONYMS	Probable G-protein coupled receptor 32
T16336	FUNCTION	Orphan receptor.
T16336	SEQUENCE	MNGVSEGTRGCSDRQPGVLTRDRSCSRKMNSSGCLSEEVGSLRPLTVVILSASIVVGVLGNGLVLWMTVFRMARTVSTVCFFHLALADFMLSLSLPIAMYYIVSRQWLLGEWACKLYITFVFLSYFASNCLLVFISVDRCISVLYPVWALNHRTVQRASWLAFGVWLLAAALCSAHLKFRTTRKWNGCTHCYLAFNSDNETAQIWIEGVVEGHIIGTIGHFLLGFLGPLAIIGTCAHLIRAKLLREGWVHANRPKRLLLVLVSAFFIFWSPFNVVLLVHLWRRVMLKEIYHPRMLLILQASFALGCVNSSLNPFLYVFVGRDFQEKFFQSLTSALARAFGEEEFLSSCPRGNAPRE
T16336	DRUGINFO	D0V8YH	RvD1-ME	Investigative
T16336	DRUGINFO	D0P0KG	[3H]resolvin D1	Investigative
T16336	DRUGINFO	D0R1FZ	LXA4	Investigative

T01151	TARGETID	T01151
T01151	FORMERID	TTDI00193
T01151	UNIPROID	SPAG6_HUMAN
T01151	TARGNAME	Sperm-associated antigen 6 (SPAG6)
T01151	GENENAME	SPAG6
T01151	TARGTYPE	Literature-reported
T01151	SYNONYMS	Sperm flagellar protein; SPAG6; Repro-SA-1; Protein PF16 homolog
T01151	FUNCTION	Important for structural integrity of the central apparatus in the sperm tail andfor flagellar motility.
T01151	SEQUENCE	MSQRQVLQVFEQYQKARTQFVQMVAELATRPQNIETLQNAGVMSLLRTLLLDVVPTIQQTAALALGRLANYNDDLAEAVVKCDILPQLVYSLAEQNRFYKKAAAFVLRAVGKHSPQLAQAIVDCGALDTLVICLEDFDPGVKEAAAWALRYIARHNAELSQAVVDAGAVPLLVLCIQEPEIALKRIAASALSDIAKHSPELAQTVVDAGAVAHLAQMILNPDAKLKHQILSALSQVSKHSVDLAEMVVEAEIFPVVLTCLKDKDEYVKKNASTLIREIAKHTPELSQLVVNAGGVAAVIDCIGSCKGNTRLPGIMMLGYVAAHSENLAMAVIISKGVPQLSVCLSEEPEDHIKAAAAWALGQIGRHTPEHARAVAVTNTLPVLLSLYMSTESSEDLQVKSKKAIKNILQKCTYLPALEPFLYDAPPNILKHVVGQFSKVLPHDSKARRLFVTSGGLKKVQEIKAEPGSLLQEYINSINSCYPEEIVRYYSPGYSDTLLQRVDSYQPLNN

T55948	TARGETID	T55948
T55948	FORMERID	TTDI01533
T55948	UNIPROID	S22A3_HUMAN
T55948	TARGNAME	Organic cation transporter 3 (OCT3)
T55948	GENENAME	SLC22A3
T55948	TARGTYPE	Literature-reported
T55948	SYNONYMS	Solute carrier family 22 member 3; Extraneuronal monoamine transporter; EMTH
T55948	FUNCTION	Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
T55948	SEQUENCE	MPSFDEALQRVGEFGRFQRRVFLLLCLTGVTFAFLFVGVVFLGTQPDHYWCRGPSAAALAERCGWSPEEEWNRTAPASRGPEPPERRGRCQRYLLEAANDSASATSALSCADPLAAFPNRSAPLVPCRGGWRYAQAHSTIVSEFDLVCVNAWMLDLTQAILNLGFLTGAFTLGYAADRYGRIVIYLLSCLGVGVTGVVVAFAPNFPVFVIFRFLQGVFGKGTWMTCYVIVTEIVGSKQRRIVGIVIQMFFTLGIIILPGIAYFIPNWQGIQLAITLPSFLFLLYYWVVPESPRWLITRKKGDKALQILRRIAKCNGKYLSSNYSEITVTDEEVSNPSFLDLVRTPQMRKCTLILMFAWFTSAVVYQGLVMRLGIIGGNLYIDFFISGVVELPGALLILLTIERLGRRLPFAASNIVAGVACLVTAFLPEGIAWLRTTVATLGRLGITMAFEIVYLVNSELYPTTLRNFGVSLCSGLCDFGGIIAPFLLFRLAAVWLELPLIIFGILASICGGLVMLLPETKGIALPETVDDVEKLGSPHSCKCGRNKKTPVSRSHL

T08350	TARGETID	T08350
T08350	FORMERID	TTDI01508
T08350	UNIPROID	RNH2A_HUMAN; RNH2B_HUMAN; RNH2C_HUMAN
T08350	TARGNAME	Ribonuclease H2 (RNase H2)
T08350	GENENAME	RNASEH2A; RNASEH2B; RNASEH2C
T08350	TARGTYPE	Literature-reported
T08350	SYNONYMS	Ribonuclease H; RNase H; Aicardi-Goutieres syndrome  protein; AGS
T08350	FUNCTION	Subunit of RNase HII, an endonuclease that specifically degrades the RNA of RNA:DNA hybrids. Participates in DNA replication, possibly by mediating the removal of lagging-strand Okazaki fragment RNA primers during DNA replication. Mediates the excision of single ribonucleotides from DNA:RNA duplexes.
T08350	SEQUENCE	MDLSELERDNTGRCRLSSPVPAVCRKEPCVLGVDEAGRGPVLGPMVYAICYCPLPRLADLEALKVADSKTLLESERERLFAKMEDTDFVGWALDVLSPNLISTSMLGRVKYNLNSLSHDTATGLIQYALDQGVNVTQVFVDTVGMPETYQARLQQSFPGIEVTVKAKADALYPVVSAASICAKVARDQAVKKWQFVEKLQDLDTDYGSGYPNDPKTKAWLKEHVEPVFGFPQFVRFSWRTAQTILEKEAEDVIWEDSASENQEGLRKITSYFLNEGSQARPRSSHRYFLERGLESATSL

T58548	TARGETID	T58548
T58548	FORMERID	TTDNR00754
T58548	UNIPROID	STC2_HUMAN
T58548	TARGNAME	Stanniocalcin-2 (STC2)
T58548	GENENAME	STC2
T58548	TARGTYPE	Literature-reported
T58548	SYNONYMS	Stanniocalcin-related protein; STCRP; STC-related protein; STC-2
T58548	FUNCTION	Has an anti-hypocalcemic action on calcium and phosphate homeostasis.
T58548	SEQUENCE	MCAERLGQFMTLALVLATFDPARGTDATNPPEGPQDRSSQQKGRLSLQNTAEIQHCLVNAGDVGCGVFECFENNSCEIRGLHGICMTFLHNAGKFDAQGKSFIKDALKCKAHALRHRFGCISRKCPAIREMVSQLQRECYLKHDLCAAAQENTRVIVEMIHFKDLLLHEPYVDLVNLLLTCGEEVKEAITHSVQVQCEQNWGSLCSILSFCTSAIQKPPTAPPERQPQVDRTKLSRAHHGEAGHHLPEPSSRETGRGAKGERGSKSHPNAHARGRVGGLGAQGPSGSSEWEDEQSEYSDIRR

T20594	TARGETID	T20594
T20594	FORMERID	TTDI01507
T20594	UNIPROID	RRF_STRCO
T20594	TARGNAME	Streptomyces Ribosome recycling factor (Stre frr)
T20594	GENENAME	Stre frr
T20594	TARGTYPE	Literature-reported
T20594	SYNONYMS	Ribosome-releasing factor; Ribosome-recycling factor; RRF
T20594	FUNCTION	Responsible for the release of ribosomes from messenger RNA at the termination of protein biosynthesis. May increase the efficiency of translation by recycling ribosomes from one round of translation to another.
T20594	SEQUENCE	MIEETLLEAEEKMEKAVVVAKEDFAAIRTGRAHPAMFNKIVAEYYGAPTPINQLASFSVPEPRMAVVTPFDKTALRNIEQAIRDSDLGVNPSNDGNIIRVTFPELTEERRREYIKVAKAKGEDAKVSIRSVRRKAKDSIDKMVKDGEVGEDEGRRAEKELDDTTAKYVAQVDELLKHKEAELLEV

T34064	TARGETID	T34064
T34064	FORMERID	TTDI03422
T34064	UNIPROID	SO2B1_HUMAN
T34064	TARGNAME	Organic anion transporter B (SLCO2B1)
T34064	GENENAME	SLCO2B1
T34064	TARGTYPE	Literature-reported
T34064	SYNONYMS	Solute carrier organic anion transporter family member 2B1; Solute carrier family 21 member 9; SLC21A9; Organic anion transporter polypeptide-related protein 2; OATPRP2; OATPB; OATP2B1; OATP-RP2; OATP-B; KIAA0880
T34064	FUNCTION	Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
T34064	SEQUENCE	MGPRIGPAGEVPQVPDKETKATMGTENTPGGKASPDPQDVRPSVFHNIKLFVLCHSLLQLAQLMISGYLKSSISTVEKRFGLSSQTSGLLASFNEVGNTALIVFVSYFGSRVHRPRMIGYGAILVALAGLLMTLPHFISEPYRYDNTSPEDMPQDFKASLCLPTTSAPASAPSNGNCSSYTETQHLSVVGIMFVAQTLLGVGGVPIQPFGISYIDDFAHNSNSPLYLGILFAVTMMGPGLAFGLGSLMLRLYVDINQMPEGGISLTIKDPRWVGAWWLGFLIAAGAVALAAIPYFFFPKEMPKEKRELQFRRKVLAVTDSPARKGKDSPSKQSPGESTKKQDGLVQIAPNLTVIQFIKVFPRVLLQTLRHPIFLLVVLSQVCLSSMAAGMAIFLPKFLERQFSITASYANLLIGCLSFPSVIVGIVVGGVLVKRLHLGPVGCGALCLLGMLLCLFFSLPLFFIGCSSHQIAGITHQTSAHPGLELSPSCMEACSCPLDGFNPVCDPSTRVEYITPCHAGCSSWVVQDALDNSQVFYTNCSCVVEGNPVLAGSCDSTCSHLVVPFLLLVSLGSALACLTHTPSFMLILRGVKKEDKTLAVGIQFMFLRILAWMPSPVIHGSAIDTTCVHWALSCGRRAVCRYYNNDLLRNRFIGLQFFFKTGSVICFALVLAVLRQQDKEARTKESRSSPAVEQQLLVSGPGKKPEDSRV
T34064	DRUGINFO	D04AXP	[3H]estrone-3-sulphate	Investigative

T95621	TARGETID	T95621
T95621	UNIPROID	ZWINT_HUMAN
T95621	TARGNAME	ZW10 interactor (ZWINT)
T95621	GENENAME	ZWINT
T95621	TARGTYPE	Literature-reported
T95621	SYNONYMS	Zwint-1; ZW10-interacting protein 1
T95621	FUNCTION	Part of the MIS12 complex, which is required for kinetochore formation and spindle checkpoint activity. Required to target ZW10 to the kinetochore at prometaphase.
T95621	SEQUENCE	MEAAETEAEAAALEVLAEVAGILEPVGLQEEAELPAKILVEFVVDSQKKDKLLCSQLQVADFLQNILAQEDTAKGLDPLASEDTSRQKAIAAKEQWKELKATYREHVEAIKIGLTKALTQMEEAQRKRTQLREAFEQLQAKKQMAMEKRRAVQNQWQLQQEKHLQHLAEVSAEVRERKTGTQQELDRVFQKLGNLKQQAEQERDKLQRYQTFLQLLYTLQGKLLFPEAEAEAENLPDDKPQQPTRPQEQSTGDTMGRDPGVSFKAVGLQPAGDVNLP

T71859	TARGETID	T71859
T71859	FORMERID	TTDI02486
T71859	UNIPROID	WISP1_HUMAN
T71859	TARGNAME	WNT1-inducible-signaling pathway protein 1 (WISP1)
T71859	GENENAME	WISP1
T71859	TARGTYPE	Literature-reported
T71859	SYNONYMS	Wnt-1-induced secreted protein; WISP1; WISP-1; CCN family member 4
T71859	FUNCTION	Downstream regulator in the Wnt/Frizzled-signalingpathway. Associated with cell survival. Attenuates p53-mediated apoptosis in response to DNA damage through activation of AKT kinase. Up-regulates the anti-apoptotic Bcl-X(L) protein. Adheres to skinand melanoma fibroblasts. In vitro binding to skin fibroblasts occurs through the proteoglycans, decorin and biglycan.
T71859	SEQUENCE	MRWFLPWTLAAVTAAAASTVLATALSPAPTTMDFTPAPLEDTSSRPQFCKWPCECPPSPPRCPLGVSLITDGCECCKMCAQQLGDNCTEAAICDPHRGLYCDYSGDRPRYAIGVCAQVVGVGCVLDGVRYNNGQSFQPNCKYNCTCIDGAVGCTPLCLRVRPPRLWCPHPRRVSIPGHCCEQWVCEDDAKRPRKTAPRDTGAFDAVGEVEAWHRNCIAYTSPWSPCSTSCGLGVSTRISNVNAQCWPEQESRLCNLRPCDVDIHTLIKAGKKCLAVYQPEASMNFTLAGCISTRSYQPKYCGVCMDNRCCIPYKSKTIDVSFQCPDGLGFSRQVLWINACFCNLSCRNPNDIFADLESYPDFSEIAN

T89530	TARGETID	T89530
T89530	FORMERID	TTDI01343
T89530	UNIPROID	RPA1_HUMAN; RPA2_HUMAN
T89530	TARGNAME	DNA-directed RNA polymerase I (RNAP I)
T89530	GENENAME	POLR1A; POLR1B
T89530	TARGTYPE	Literature-reported
T89530	SYNONYMS	RPA; RNA polymerase I
T89530	FUNCTION	DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. Largest and catalytic core component of RNA polymerase I which synthesizes ribosomal RNA precursors. Forms the polymerase active center together with the second largest subunit. A single stranded DNA template strand of the promoter is positioned within the central active site cleft of Pol I. Pol I is composed of mobile elements and RPA1/RPA2 is part of the core element with the central large cleft and probably a clamp element that moves to open and close the cleft
T89530	SEQUENCE	MLISKNMPWRRLQGISFGMYSAEELKKLSVKSITNPRYLDSLGNPSANGLYDLALGPADSKEVCSTCVQDFSNCSGHLGHIELPLTVYNPLLFDKLYLLLRGSCLNCHMLTCPRAVIHLLLCQLRVLEVGALQAVYELERILNRFLEENPDPSASEIREELEQYTTEIVQNNLLGSQGAHVKNVCESKSKLIALFWKAHMNAKRCPHCKTGRSVVRKEHNSKLTITFPAMVHRTAGQKDSEPLGIEEAQIGKRGYLTPTSAREHLSALWKNEGFFLNYLFSGMDDDGMESRFNPSVFFLDFLVVPPSRYRPVSRLGDQMFTNGQTVNLQAVMKDVVLIRKLLALMAQEQKLPEEVATPTTDEEKDSLIAIDRSFLSTLPGQSLIDKLYNIWIRLQSHVNIVFDSEMDKLMMDKYPGIRQILEKKEGLFRKHMMGKRVDYAARSVICPDMYINTNEIGIPMVFATKLTYPQPVTPWNVQELRQAVINGPNVHPGASMVINEDGSRTALSAVDMTQREAVAKQLLTPATGAPKPQGTKIVCRHVKNGDILLLNRQPTLHRPSIQAHRARILPEEKVLRLHYANCKAYNADFDGDEMNAHFPQSELGRAEAYVLACTDQQYLVPKDGQPLAGLIQDHMVSGASMTTRGCFFTREHYMELVYRGLTDKVGRVKLLSPSILKPFPLWTGKQVVSTLLINIIPEDHIPLNLSGKAKITGKAWVKETPRSVPGFNPDSMCESQVIIREGELLCGVLDKAHYGSSAYGLVHCCYEIYGGETSGKVLTCLARLFTAYLQLYRGFTLGVEDILVKPKADVKRQRIIEESTHCGPQAVRAALNLPEAASYDEVRGKWQDAHLGKDQRDFNMIDLKFKEEVNHYSNEINKACMPFGLHRQFPENSLQMMVQSGAKGSTVNTMQISCLLGQIELEGRRPPLMASGKSLPCFEPYEFTPRAGGFVTGRFLTGIKPPEFFFHCMAGREGLVDTAVKTSRSGYLQRCIIKHLEGLVVQYDLTVRDSDGSVVQFLYGEDGLDIPKTQFLQPKQFPFLASNYEVIMKSQHLHEVLSRADPKKALHHFRAIKKWQSKHPNTLLRRGAFLSYSQKIQEAVKALKLESENRNGRSPGTQEMLRMWYELDEESRRKYQKKAAACPDPSLSVWRPDIYFASVSETFETKVDDYSQEWAAQTEKSYEKSELSLDRLRTLLQLKWQRSLCEPGEAVGLLAAQSIGEPSTQMTLNTFHFAGRGEMNVTLGIPRLREILMVASANIKTPMMSVPVLNTKKALKRVKSLKKQLTRVCLGEVLQKIDVQESFCMEEKQNKFQVYQLRFQFLPHAYYQQEKCLRPEDILRFMETRFFKLLMESIKKKNNKASAFRNVNTRRATQRDLDNAGELGRSRGEQEGDEEEEGHIVDAEAEEGDADASDAKRKEKQEEEVDYESEEEEEREGEENDDEDMQEERNPHREGARKTQEQDEEVGLGTEEDPSLPALLTQPRKPTHSQEPQGPEAMERRVQAVREIHPFIDDYQYDTEESLWCQVTVKLPLMKINFDMSSLVVSLAHGAVIYATKGITRCLLNETTNNKNEKELVLNTEGINLPELFKYAEVLDLRRLYSNDIHAIANTYGIEAALRVIEKEIKDVFAVYGIAVDPRHLSLVADYMCFEGVYKPLNRFGIRSNSSPLQQMTFETSFQFLKQATMLGSHDELRSPSACLVVGKVVRGGTGLFELKQPLR

T95605	TARGETID	T95605
T95605	FORMERID	TTDI03412
T95605	UNIPROID	NTR2_HUMAN
T95605	TARGNAME	Neurotensin receptor type 2 (NTSR2)
T95605	GENENAME	NTSR2
T95605	TARGTYPE	Literature-reported
T95605	SYNONYMS	NTR2; NT-R-2; Levocabastine-sensitive neurotensin receptor
T95605	FUNCTION	Receptor for the tridecapeptide neurotensin. It is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system.
T95605	SEQUENCE	METSSPRPPRPSSNPGLSLDARLGVDTRLWAKVLFTALYALIWALGAAGNALSAHVVLKARAGRAGRLRHHVLSLALAGLLLLLVGVPVELYSFVWFHYPWVFGDLGCRGYYFVHELCAYATVLSVAGLSAERCLAVCQPLRARSLLTPRRTRWLVALSWAASLGLALPMAVIMGQKHELETADGEPEPASRVCTVLVSRTALQVFIQVNVLVSFVLPLALTAFLNGVTVSHLLALCSQVPSTSTPGSSTPSRLELLSEEGLLSFIVWKKTFIQGGQVSLVRHKDVRRIRSLQRSVQVLRAIVVMYVICWLPYHARRLMYCYVPDDAWTDPLYNFYHYFYMVTNTLFYVSSAVTPLLYNAVSSSFRKLFLEAVSSLCGEHHPMKRLPPKPQSPTLMDTASGFGDPPETRT
T95605	DRUGINFO	D0OF3B	xenin	Investigative
T95605	DRUGINFO	D09RSL	JMV458	Investigative

T57907	TARGETID	T57907
T57907	FORMERID	TTDI02396
T57907	UNIPROID	BY55_HUMAN
T57907	TARGNAME	Natural killer cell receptor BY55 (CD160)
T57907	GENENAME	CD160
T57907	TARGTYPE	Literature-reported
T57907	SYNONYMS	CD160 antigen; BY55
T57907	FUNCTION	Exists as a GPI-anchored and as a transmembrane form, each likely initiating distinct signaling pathways via phosphoinositol 3-kinase in activated NK cells and via LCK and CD247/CD3 zeta chain in activated T cells. Receptor for both classical and non-classical MHC class I molecules. In the context of acute viral infection, recognizes HLA-C and triggers NK cell cytotoxic activity, likely playing a role in anti-viral innate immune response. On CD8+ T cells, binds HLA-A2-B2M in complex with a viral peptide and provides a costimulatory signal to activated/memory T cells. Upon persistent antigen stimulation, such as occurs during chronic viral infection, may progressively inhibit TCR signaling in memory CD8+ T cells, contributing to T cell exhaustion. On endothelial cells, recognizes HLA-G and controls angiogenesis in immune privileged sites. Receptor or ligand for TNF superfamily member TNFRSF14, participating in bidirectional cell-cell contact signaling between antigen presenting cells and lymphocytes. Upon ligation of TNFRSF14, provides stimulatory signal to NK cells enhancing IFNG production and anti-tumor immune response. On activated CD4+ T cells, interacts with TNFRSF14 and downregulates CD28 costimulatory signaling, restricting memory and alloantigen-specific immune response. In the context of bacterial infection, acts as a ligand for TNFRSF14 on epithelial cells, triggering the production of antimicrobial proteins and proinflammatory cytokines. CD160 antigen: Receptor on immune cells capable to deliver stimulatory or inhibitory signals that regulate cell activation and differentiation.
T57907	SEQUENCE	MLLEPGRGCCALAILLAIVDIQSGGCINITSSASQEGTRLNLICTVWHKKEEAEGFVVFLCKDRSGDCSPETSLKQLRLKRDPGIDGVGEISSQLMFTISQVTPLHSGTYQCCARSQKSGIRLQGHFFSILFTETGNYTVTGLKQRQHLEFSHNEGTLSSGFLQEKVWVMLVTSLVALQAL

T28012	TARGETID	T28012
T28012	FORMERID	TTDI00178
T28012	UNIPROID	RECK_HUMAN
T28012	TARGNAME	Suppressor of tumorigenicity 15 protein (ST15)
T28012	GENENAME	RECK
T28012	TARGTYPE	Literature-reported
T28012	SYNONYMS	hRECK; Reversion-inducing cysteine-rich protein with Kazal motifs
T28012	FUNCTION	Plays a key role in Wnt7-specific responses: required for central nervous system (CNS) angiogenesis and blood-brain barrier regulation. Acts as a Wnt7-specific coactivator of canonical Wnt signaling by decoding Wnt ligands: acts by interacting specifically with the disordered linker region of Wnt7, thereby conferring ligand selectivity for Wnt7. ADGRA2 is then required to deliver RECK-bound Wnt7 to frizzled by assembling a higher-order RECK-ADGRA2-Fzd-LRP5-LRP6 complex. Also acts as a serine protease inhibitor: negatively regulates matrix metalloproteinase-9 (MMP9) by suppressing MMP9 secretion and by direct inhibition of its enzymatic activity. Also inhibits metalloproteinase activity of MMP2 and MMP14 (MT1-MMP). Functions together with ADGRA2 to enable brain endothelial cells to selectively respond to Wnt7 signals (WNT7A or WNT7B).
T28012	SEQUENCE	MATVRASLRGALLLLLAVAGVAEVAGGLAPGSAGALCCNHSKDNQMCRDVCEQIFSSKSESRLKHLLQRAPDYCPETMVEIWNCMNSSLPGVFKKSDGWVGLGCCELAIALECRQACKQASSKNDISKVCRKEYENALFSCISRNEMGSVCCSYAGHHTNCREYCQAIFRTDSSPGPSQIKAVENYCASISPQLIHCVNNYTQSYPMRNPTDSLYCCDRAEDHACQNACKRILMSKKTEMEIVDGLIEGCKTQPLPQDPLWQCFLESSQSVHPGVTVHPPPSTGLDGAKLHCCSKANTSTCRELCTKLYSMSWGNTQSWQEFDRFCEYNPVEVSMLTCLADVREPCQLGCRNLTYCTNFNNRPTELFRSCNAQSDQGAMNDMKLWEKGSIKMPFINIPVLDIKKCQPEMWKAIACSLQIKPCHSKSRGSIICKSDCVEILKKCGDQNKFPEDHTAESICELLSPTDDLKNCIPLDTYLRPSTLGNIVEEVTHPCNPNPCPANELCEVNRKGCPSGDPCLPYFCVQGCKLGEASDFIVRQGTLIQVPSSAGEVGCYKICSCGQSGLLENCMEMHCIDLQKSCIVGGKRKSHGTSFSIDCNVCSCFAGNLVCSTRLCLSEHSSEDDRRTFTGLPCNCADQFVPVCGQNGRTYPSACIARCVGLQDHQFEFGSCMSKDPCNPNPCQKNQRCIPKPQVCLTTFDKFGCSQYECVPRQLACDQVQDPVCDTDHMEHNNLCTLYQRGKSLSYKGPCQPFCRATEPVCGHNGETYSSVCAAYSDRVAVDYYGDCQAVGVLSEHSSVAECASVKCPSLLAAGCKPIIPPGACCPLCAGMLRVLFDKEKLDTIAKVTNKKPITVLEILQKIRMHVSVPQCDVFGYFSIESEIVILIIPVDHYPKALQIEACNKEAEKIESLINSDSPTLASHVPLSALIISQVQVSSSVPSAGVRARPSCHSLLLPLSLGLALHLLWTYN

T27418	TARGETID	T27418
T27418	FORMERID	TTDI00019
T27418	UNIPROID	APCL_HUMAN
T27418	TARGNAME	Adenomatous polyposis coli 2 (APC2)
T27418	GENENAME	APC2
T27418	TARGTYPE	Literature-reported
T27418	SYNONYMS	Adenomatous polyposis coli proteinlike; Adenomatous polyposis coli protein-like; Adenomatous polyposis coli protein 2; APClike; APCL; APC-like
T27418	FUNCTION	May also function in Wnt signaling by promoting the rapid degradation of CTNNB1. Stabilizes microtubules and may regulate actin fiber dynamics through the activation of Rho family GTPases.
T27418	SEQUENCE	MASSVAPYEQLVRQVEALKAENSHLRQELRDNSSHLSKLETETSGMKEVLKHLQGKLEQEARVLVSSGQTEVLEQLKALQMDITSLYNLKFQPPTLGPEPAARTPEGSPVHGSGPSKDSFGELSRATIRLLEELDRERCFLLNEIEKEEKEKLWYYSQLQGLSKRLDELPHVETQFSMQMDLIRQQLEFEAQHIRSLMEERFGTSDEMVQRAQIRASRLEQIDKELLEAQDRVQQTEPQALLAVKSVPVDEDPETEVPTHPEDGTPQPGNSKVEVVFWLLSMLATRDQEDTARTLLAMSSSPESCVAMRRSGCLPLLLQILHGTEAAAGGRAGAPGAPGAKDARMRANAALHNIVFSQPDQGLARKEMRVLHVLEQIRAYCETCWDWLQARDGGPEGGGAGSAPIPIEPQICQATCAVMKLSFDEEYRRAMNELGGLQAVAELLQVDYEMHKMTRDPLNLALRRYAGMTLTNLTFGDVANKATLCARRGCMEAIVAQLASDSEELHQVVSSILRNLSWRADINSKKVLREAGSVTALVQCVLRATKESTLKSVLSALWNLSAHSTENKAAICQVDGALGFLVSTLTYKCQSNSLAIIESGGGILRNVSSLVATREDYRQVLRDHNCLQTLLQHLTSHSLTIVSNACGTLWNLSARSARDQELLWDLGAVGMLRNLVHSKHKMIAMGSAAALRNLLAHRPAKHQAAATAVSPGSCVPSLYVRKQRALEAELDARHLAQALEHLEKQGPPAAEAATKKPLPPLRHLDGLAQDYASDSGCFDDDDAPSSLAAAAATGEPASPAALSLFLGSPFLQGQALARTPPTRRGGKEAEKDTSGEAAVAAKAKAKLALAVARIDQLVEDISALHTSSDDSFSLSSGDPGQEAPREGRAQSCSPCRGPEGGRREAGSRAHPLLRLKAAHASLSNDSLNSGSASDGYCPREHMLPCPLAALASRREDPRCGQPRPSRLDLDLPGCQAEPPAREATSADARVRTIKLSPTYQHVPLLEGASRAGAEPLAGPGISPGARKQAWLPADHLSKVPEKLAAAPLSVASKALQKLAAQEGPLSLSRCSSLSSLSSAGRPGPSEGGDLDDSDSSLEGLEEAGPSEAELDSTWRAPGATSLPVAIPAPRRNRGRGLGVEDATPSSSSENYVQETPLVLSRCSSVSSLGSFESPSIASSIPSEPCSGQGSGTISPSELPDSPGQTMPPSRSKTPPLAPAPQGPPEATQFSLQWESYVKRFLDIADCRERCRLPSELDAGSVRFTVEKPDENFSCASSLSALALHEHYVQQDVELRLLPSACPERGGGAGGAGLHFAGHRRREEGPAPTGSRPRGAADQELELLRECLGAAVPARLRKVASALVPGRRALPVPVYMLVPAPAPAQEDDSCTDSAEGTPVNFSSAASLSDETLQGPPRDQPGGPAGRQRPTGRPTSARQAMGHRHKAGGAGRSAEQSRGAGKNRAGLELPLGRPPSAPADKDGSKPGRTRGDGALQSLCLTTPTEEAVYCFYGNDSDEEPPAAAPTPTHRRTSAIPRAFTRERPQGRKEAPAPSKAAPAAPPPARTQPSLIADETPPCYSLSSSASSLSEPEPSEPPAVHPRGREPAVTKDPGPGGGRDSSPSPRAAEELLQRCISSALPRRRPPVSGLRRRKPRATRLDERPAEGSRERGEEAAGSDRASDLDSVEWRAIQEGANSIVTWLHQAAAATREASSESDSILSFVSGLSVGSTLQPPKHRKGRQAEGEMGSARRPEKRGAASVKTSGSPRSPAGPEKPRGTQKTTPGVPAVLRGRTVIYVPSPAPRAQPKGTPGPRATPRKVAPPCLAQPAAPAKVPSPGQQRSRSLHRPAKTSELATLSQPPRSATPPARLAKTPSSSSSQTSPASQPLPRKRPPVTQAAGALPGPGASPVPKTPARTLLAKQHKTQRSPVRIPFMQRPARRGPPPLARAVPEPGPRGRAGTEAGPGARGGRLGLVRVASALSSGSESSDRSGFRRQLTFIKESPGLRRRRSELSSAESAASAPQGASPRRGRPALPAVFLCSSRCEELRAAPRQGPAPARQRPPAARPSPGERPARRTTSESPSRLPVRAPAARPETVKRYASLPHISVARRPDGAVPAAPASADAARRSSDGEPRPLPRVAAPGTTWRRIRDEDVPHILRSTLPATALPLRGSTPEDAPAGPPPRKTSDAVVQTEEVAAPKTNSSTSPSLETREPPGAPAGGQLSLLGSDVDGPSLAKAPISAPFVHEGLGVAVGGFPASRHGSPSRSARVPPFNYVPSPMVVAATTDSAAEKAPATASATLLE

T19027	TARGETID	T19027
T19027	FORMERID	TTDI00057
T19027	UNIPROID	CCNE2_HUMAN
T19027	TARGNAME	G1/S-specific cyclin-E2 (CCNE2)
T19027	GENENAME	CCNE2
T19027	TARGTYPE	Literature-reported
T19027	SYNONYMS	G1/Sspecific cyclinE2
T19027	FUNCTION	Essential for the control of the cell cycle at the late G1 and early S phase.
T19027	SEQUENCE	MSRRSSRLQAKQQPQPSQTESPQEAQIIQAKKRKTTQDVKKRREEVTKKHQYEIRNCWPPVLSGGISPCIIIETPHKEIGTSDFSRFTNYRFKNLFINPSPLPDLSWGCSKEVWLNMLKKESRYVHDKHFEVLHSDLEPQMRSILLDWLLEVCEVYTLHRETFYLAQDFFDRFMLTQKDINKNMLQLIGITSLFIASKLEEIYAPKLQEFAYVTDGACSEEDILRMELIILKALKWELCPVTIISWLNLFLQVDALKDAPKVLLPQYSQETFIQIAQLLDLCILAIDSLEFQYRILTAAALCHFTSIEVVKKASGLEWDSISECVDWMVPFVNVVKSTSPVKLKTFKKIPMEDRHNIQTHTNYLAMLEEVNYINTFRKGGQLSPVCNGGIMTPPKSTEKPPGKH

T01865	TARGETID	T01865
T01865	FORMERID	TTDR00598
T01865	UNIPROID	O97467_PLAFA
T01865	TARGNAME	Plasmodium Hexose transporter 1 (Malaria ht1)
T01865	GENENAME	Malaria ht1
T01865	TARGTYPE	Literature-reported
T01865	SYNONYMS	ht1; Putative sugar transporter; Hexose transporter
T01865	FUNCTION	High-affinity glucose transporter.
T01865	SEQUENCE	MTKSSKDICSENEGKKNGKSGFFSTSFKYVLSACIASFIFGYQVSVLNTIKNFIVVEFEWCKGEKDRLNCSNNTIQSSFLLASVFIGAVLGCGFSGYLVQFGRRLSLLIIYNFFFLVSILTSITHHFHTILFARLLSGFGIGLVTVSVPMYISEMTHKDKKGAYGVMHQLFITFGIFVAVMLGLAMGEGPKADSTEPLTSFAKLWWRLMFLFPSVISLIGILALVVFFKEETPYFLFEKGRIEESKNILKKIYETDNVDEPLNAIKEAVEQNESAKKNSLSLLSALKIPSYRYVIILGCLLSGLQQFTGINVLVSNSNELYKEFLDSHLITILSVVMTAVNFLMTFPAIYIVEKLGRKTLLLWGCVGVLVAYLPTAIANEINRNSNFVKILSIVATFVMIISFAVSYGPVLWIYLHEMFPSEIKDSAASLASLVNWVCAIIVVFPSDIIIKKSPSILFIVFSVMSILTFFFIFFFIKETKGGEIGTSPYITMEERQKHMTKSVV
T01865	DRUGINFO	D08MTN	Glucose analogue	Investigative

T33318	TARGETID	T33318
T33318	FORMERID	TTDR01026
T33318	UNIPROID	MAS_HUMAN
T33318	TARGNAME	Angiotensin-(1-7) receptor (MAS1)
T33318	GENENAME	MAS1
T33318	TARGTYPE	Literature-reported
T33318	SYNONYMS	MAS
T33318	FUNCTION	Receptor for angiotensin 1-7 (By similarity). Acts specifically as a functional antagonist of AGTR1 (angiotensin-2 type 1 receptor), although it up-regulates AGTR1 receptor levels. Positive regulation of AGTR1 levels occurs through activation of the G-proteins GNA11 and GNAQ, and stimulation of the protein kinase C signaling cascade. The antagonist effect on AGTR1 function is probably due to AGTR1 being physically altered by MAS1.
T33318	SEQUENCE	MDGSNVTSFVVEEPTNISTGRNASVGNAHRQIPIVHWVIMSISPVGFVENGILLWFLCFRMRRNPFTVYITHLSIADISLLFCIFILSIDYALDYELSSGHYYTIVTLSVTFLFGYNTGLYLLTAISVERCLSVLYPIWYRCHRPKYQSALVCALLWALSCLVTTMEYVMCIDREEESHSRNDCRAVIIFIAILSFLVFTPLMLVSSTILVVKIRKNTWASHSSKLYIVIMVTIIIFLIFAMPMRLLYLLYYEYWSTFGNLHHISLLFSTINSSANPFIYFFVGSSKKKRFKESLKVVLTRAFKDEMQPRRQKDNCNTVTVETVV

T43850	TARGETID	T43850
T43850	FORMERID	TTDI01642
T43850	UNIPROID	ENV_HV1H2-HEMA_I34A1
T43850	TARGNAME	Virus fusion protein HIV gp41-influenza HA (HIV gp41-Influ HA)
T43850	GENENAME	HIV gp41-Influ HA
T43850	TARGTYPE	Literature-reported
T43850	SYNONYMS	Virus fusion protein Env polyprotein-influenza Hemagglutinin
T43850	FUNCTION	Functions as a passive -helical anchor of the protein to the virus envelope during its merger with the cell membrane
T43850	SEQUENCE	KLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVVLVNVTENFNMWKNDMVEQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTNTNSSSGRMIMEKGEIKNCSFNISTSIRGKVQKEYAFFYKLDIIPIDNDTTSYKLTSCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSVNFTDNAKTIIVQLNTSVEINCTRPNNNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKLREQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNSTWSTEGSNNTEGSDTITLPCRIKQIINMWQKVGKAMYAPPISGQIRCSSNITGLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTKAKMKANLLVLLCALAAADADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHNGKLCRLKGIAPLQLGKCNIAGWLLGNPECDPLLPVRSWSYIVETPNSENGICYPGDFIDYEELREQLSSVSSFERFEIFPKESSWPNHNTNGVTAACSHEGKSSFYRNLLWLTEKEGSYPKLKNSYVNKKGKEVLVLWGIHHPPNSKEQQNLYQNENAYVSVVTSNYNRRFTPEIAERPKVRDQAGRMNYYWTLLKPGDTIIFEANGNLIAPMYAFALSRGFGSGIITSNASMHECNTKCQTPLGAINSSLPYQNIHPVTIGECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNTVIEKMNIQFTAVGKEFNKLEKRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCDNECMESVRNGTYDYPKYSEESKLNREKVDGVKLESMGIYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI

T56636	TARGETID	T56636
T56636	FORMERID	TTDR00055
T56636	UNIPROID	TAT_HV1H2-TAR RNA
T56636	TARGNAME	Human immunodeficiency virus Tat-TAR RNA interaction (HIV Tat-TAR PPI)
T56636	GENENAME	HIV Tat-TAR PPI
T56636	TARGTYPE	Literature-reported
T56636	SYNONYMS	HIV Protein Tat-TAR RNA interaction
T56636	FUNCTION	Inhibit Tat-dependent transcription of  HIV DNA.
T56636	SEQUENCE	MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKALGISYGRKKRRQRRRAHQNSQTHQASLSKQPTSQPRGDPTGPKE
T56636	DRUGINFO	D0K5EP	2'-O-Methyl G-Clamp Containing Oligonucleotides	Investigative

T71317	TARGETID	T71317
T71317	FORMERID	TTDI00120
T71317	UNIPROID	AP2A_HUMAN
T71317	TARGNAME	AP-2 transcription factor (TFAP2A)
T71317	GENENAME	TFAP2A
T71317	TARGTYPE	Literature-reported
T71317	SYNONYMS	Transcription factor AP-2-alpha; TFAP2; Activator protein 2; Activating enhancer-binding protein 2-alpha; AP2TF; AP2-alpha; AP-2
T71317	FUNCTION	AP-2 factors bind to the consensus sequence 5'-GCCNNNGGC-3' and activate genes involved in a large spectrum of important biological functions including proper eye, face, body wall, limb and neural tube development. They also suppress a number of genes including MCAM/MUC18, C/EBP alpha and MYC. AP-2-alpha is the only AP-2 protein required for early morphogenesis of the lens vesicle. Together with the CITED2 coactivator, stimulates the PITX2 P1 promoter transcription activation. Associates with chromatin to the PITX2 P1 promoter region. Sequence-specific DNA-binding protein that interacts with inducible viral and cellular enhancer elements to regulate transcription of selected genes.
T71317	SEQUENCE	MLWKLTDNIKYEDCEDRHDGTSNGTARLPQLGTVGQSPYTSAPPLSHTPNADFQPPYFPPPYQPIYPQSQDPYSHVNDPYSLNPLHAQPQPQHPGWPGQRQSQESGLLHTHRGLPHQLSGLDPRRDYRRHEDLLHGPHALSSGLGDLSIHSLPHAIEEVPHVEDPGINIPDQTVIKKGPVSLSKSNSNAVSAIPINKDNLFGGVVNPNEVFCSVPGRLSLLSSTSKYKVTVAEVQRRLSPPECLNASLLGGVLRRAKSKNGGRSLREKLDKIGLNLPAGRRKAANVTLLTSLVEGEAVHLARDFGYVCETEFPAKAVAEFLNRQHSDPNEQVTRKNMLLATKQICKEFTDLLAQDRSPLGNSRPNPILEPGIQSCLTHFNLISHGFGSPAVCAAVTALQNYLTEALKAMDKMYLSNNPNSHTDNNAKSSDKEEKHRK

T67883	TARGETID	T67883
T67883	FORMERID	TTDI02505
T67883	UNIPROID	PGS2_HUMAN
T67883	TARGNAME	Decorin (DCN)
T67883	GENENAME	DCN
T67883	TARGTYPE	Literature-reported
T67883	SYNONYMS	SLRR1B; PGS2; PG40; PG-S2; Bone proteoglycan II
T67883	FUNCTION	May affect the rate of fibrils formation.
T67883	SEQUENCE	MKATIILLLLAQVSWAGPFQQRGLFDFMLEDEASGIGPEVPDDRDFEPSLGPVCPFRCQCHLRVVQCSDLGLDKVPKDLPPDTTLLDLQNNKITEIKDGDFKNLKNLHALILVNNKISKVSPGAFTPLVKLERLYLSKNQLKELPEKMPKTLQELRAHENEITKVRKVTFNGLNQMIVIELGTNPLKSSGIENGAFQGMKKLSYIRIADTNITSIPQGLPPSLTELHLDGNKISRVDAASLKGLNNLAKLGLSFNSISAVDNGSLANTPHLRELHLDNNKLTRVPGGLAEHKYIQVVYLHNNNISVVGSSDFCPPGHNTKKASYSGVSLFSNPVQYWEIQPSTFRCVYVRSAIQLGNYK

T36508	TARGETID	T36508
T36508	FORMERID	TTDR01300
T36508	UNIPROID	CH10_HELPY
T36508	TARGNAME	Helicobacter pylori Heat shock protein A (HELPY HspA)
T36508	GENENAME	HELPY HspA
T36508	TARGTYPE	Literature-reported
T36508	SYNONYMS	Protein Cpn10; Heat shock protein 10; HELPY 10 kDa chaperonin; GroES protein
T36508	FUNCTION	Binds to Cpn60 in the presence of Mg-ATP and suppresses the ATPase activity of the latter.
T36508	SEQUENCE	MKFQPLGERVLVERLEEENKTSSGIIIPDNAKEKPLMGVVKAVSHKISEGCKCVKEGDVIAFGKYKGAEIVLDGTEYMVLELEDILGIVGSGSCCHTGNHDHKHAKEHEACCHDHKKH

T40683	TARGETID	T40683
T40683	FORMERID	TTDI02418
T40683	UNIPROID	BXA1_CLOBH; BXB_CLOBO; BXE_CLOBO
T40683	TARGNAME	Clostridium botulinum Botulinum neurotoxin (CB bot)
T40683	GENENAME	CB botA; CB botB; CB botE
T40683	TARGTYPE	Literature-reported
T40683	SYNONYMS	Botulinum neurotoxin; Bontoxilysin; BoNT
T40683	FUNCTION	Inhibits acetylcholine release. The botulinum toxin binds with high affinity to peripheral neuronal presynaptic membrane to the secretory vesicle protein SV2. It binds directly to the largest luminal loop of SV2A, SV2B and SV2C. It is then internalized by receptor-mediated endocytosis. The C-terminus of the heavy chain (H) is responsible for the adherence of the toxin to the cell surface while the N-terminus mediates transport of the light chain from the endocytic vesicle to the cytosol. After translocation, the light chain (L) hydrolyzes the 197-Gln-|-Arg- 198 bond in SNAP-25, thereby blocking neurotransmitter release. Inhibition of acetylcholine release results in flaccid paralysis, with frequent heart or respiratory failure.
T40683	SEQUENCE	MPFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVRGIITSKTKSLDKGYNKALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLSTFTEYIKNIINTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNNEYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTITNNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELNEKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPRGSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQAGVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAKLVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL

T09067	TARGETID	T09067
T09067	FORMERID	TTDR00286
T09067	UNIPROID	CALCB_HUMAN
T09067	TARGNAME	Calcitonin gene-related peptide 2 (CALCB)
T09067	GENENAME	CALCB
T09067	TARGTYPE	Literature-reported
T09067	SYNONYMS	Calcitonin gene-related peptide II; CGRP-II; CALC2; Beta-type CGRP; Beta-CGRP
T09067	FUNCTION	CGRP induces vasodilation. It dilates a variety of vessels including the coronary, cerebral and systemic vasculature. Its abundance in the CNS also points toward a neurotransmitter or neuromodulator role.
T09067	SEQUENCE	MGFRKFSPFLALSILVLYQAGSLQAAPFRSALESSPDPATLSKEDARLLLAALVQDYVQMKASELKQEQETQGSSSAAQKRACNTATCVTHRLAGLLSRSGGMVKSNFVPTNVGSKAFGRRRRDLQA

T96669	TARGETID	T96669
T96669	FORMERID	TTDI02596
T96669	UNIPROID	CLUS_HUMAN
T96669	TARGNAME	Clusterin (CLU)
T96669	GENENAME	CLU
T96669	TARGTYPE	Literature-reported
T96669	SYNONYMS	Testosteronerepressed prostate message 2; Testosterone-repressed prostate message 2; TRPM-2; NA1/NA2; Ku70binding protein 1; Ku70-binding protein 1; KUB1; Complementassociated protein SP40,40; Complement-associated protein SP-40,40; Complement cytolysis inhibitor; Clusterin alpha chain; CLI; Apolipoprotein J; ApoJ; Apo-J; Agingassociated gene 4 protein; Aging-associated gene 4 protein; AAG4
T96669	FUNCTION	Prevents stress-induced aggregation of blood plasma proteins. Inhibits formation of amyloid fibrils by APP, APOC2, B2M, CALCA, CSN3, SNCA and aggregation-prone LYZ variants (in vitro). Does not require ATP. Maintains partially unfolded proteins in a state appropriate for subsequent refolding by other chaperones, such as HSPA8/HSC70. Does not refold proteins by itself. Binding to cell surface receptors triggers internalization of the chaperone-client complex and subsequent lysosomal or proteasomal degradation. Secreted isoform 1 protects cells against apoptosis and against cytolysis by complement. Intracellular isoforms interact with ubiquitin and SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complexes and promote the ubiquitination and subsequent proteasomal degradation of target proteins. Promotes proteasomal degradation of COMMD1 and IKBKB. Modulates NF-kappa-B transcriptional activity. Nuclear isoforms promote apoptosis. Mitochondrial isoforms suppress BAX-dependent release of cytochrome c into the cytoplasm and inhibit apoptosis. Plays a role in the regulation of cell proliferation. Isoform 1 functions as extracellular chaperone that prevents aggregation of nonnative proteins.
T96669	SEQUENCE	MMKTLLLFVGLLLTWESGQVLGDQTVSDNELQEMSNQGSKYVNKEIQNAVNGVKQIKTLIEKTNEERKTLLSNLEEAKKKKEDALNETRESETKLKELPGVCNETMMALWEECKPCLKQTCMKFYARVCRSGSGLVGRQLEEFLNQSSPFYFWMNGDRIDSLLENDRQQTHMLDVMQDHFSRASSIIDELFQDRFFTREPQDTYHYLPFSLPHRRPHFFFPKSRIVRSLMPFSPYEPLNFHAMFQPFLEMIHEAQQAMDIHFHSPAFQHPPTEFIREGDDDRTVCREIRHNSTGCLRMKDQCDKCREILSVDCSTNNPSQAKLRRELDESLQVAERLTRKYNELLKSYQWKMLNTSSLLEQLNEQFNWVSRLANLTQGEDQYYLRVTTVASHTSDSDVPSGVTEVVVKLFDSDPITVTVPVEVSRKNPKFMETVAEKALQEYRKKHREE

T02723	TARGETID	T02723
T02723	FORMERID	TTDR00427
T02723	UNIPROID	IRF1_HUMAN
T02723	TARGNAME	Interferon regulatory factor 1 (IRF1)
T02723	GENENAME	IRF1
T02723	TARGTYPE	Literature-reported
T02723	SYNONYMS	IRF-1
T02723	FUNCTION	These include the regulation of IFN and IFN-inducible genes, host response to viral and bacterial infections, regulation of many genes expressed during hematopoiesis, inflammation, immune responses and cell proliferation and differentiation, regulation of the cell cycle and induction of growth arrest and programmed cell death following DNA damage. Stimulates both innate and acquired immune responses through the activation of specific target genes and can act as a transcriptional activator and repressor regulating target genes by binding to an interferon-stimulated response element (ISRE) in their promoters. Its target genes for transcriptional activation activity include: genes involved in anti-viral response, such as IFN-alpha/beta, DDX58/RIG-I, TNFSF10/TRAIL, OAS1/2, PIAS1/GBP, EIF2AK2/PKR and RSAD2/viperin; antibacterial response, such as NOS2/INOS; anti-proliferative response, such as p53/TP53, LOX and CDKN1A; apoptosis, such as BBC3/PUMA, CASP1, CASP7 and CASP8; immune response, such as IL7, IL12A/B and IL15, PTGS2/COX2 and CYBB; DNA damage responses and DNA repair, such as POLQ/POLH; MHC class I expression, such as TAP1, PSMB9/LMP2, PSME1/PA28A, PSME2/PA28B and B2M and MHC class II expression, such as CIITA. Represses genes involved in anti-proliferative response, such as BIRC5/survivin, CCNB1, CCNE1, CDK1, CDK2 and CDK4 and in immune response, such as FOXP3, IL4, ANXA2 and TLR4. Stimulates p53/TP53-dependent transcription through enhanced recruitment of EP300 leading to increased acetylation of p53/TP53. Plays an important role in immune response directly affecting NK maturation and activity, macrophage production of IL12, Th1 development and maturation of CD8+ T-cells. Also implicated in the differentiation and maturation of dendritic cells and in the suppression of regulatory T (Treg) cells development. Acts as a tumor suppressor and plays a role not only in antagonism of tumor cell growth but also in stimulating an immune response against tumor cells. Transcriptional regulator which displays a remarkable functional diversity in the regulation of cellular responses.
T02723	SEQUENCE	MPITRMRMRPWLEMQINSNQIPGLIWINKEEMIFQIPWKHAAKHGWDINKDACLFRSWAIHTGRYKAGEKEPDPKTWKANFRCAMNSLPDIEEVKDQSRNKGSSAVRVYRMLPPLTKNQRKERKSKSSRDAKSKAKRKSCGDSSPDTFSDGLSSSTLPDDHSSYTVPGYMQDLEVEQALTPALSPCAVSSTLPDWHIPVEVVPDSTSDLYNFQVSPMPSTSEATTDEDEEGKLPEDIMKLLEQSEWQPTNVDGKGYLLNEPGVQPTSVYGDFSCKEEPEIDSPGGDIGLSLQRVFTDLKNMDATWLDSLLTPVRLPSIQAIPCAP

T33895	TARGETID	T33895
T33895	FORMERID	TTDI01654
T33895	UNIPROID	MTDC_HUMAN; MTD2L_HUMAN
T33895	TARGNAME	NAD-dependent methylenetetrahydrofolate dehydrogenase (NMD)
T33895	GENENAME	MTHFD2; MTHFD2L
T33895	TARGTYPE	Literature-reported
T33895	SYNONYMS	Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase
T33895	FUNCTION	Although its dehydrogenase activity is NAD-specific, it can also utilize NADP at a reduced efficiency.
T33895	SEQUENCE	MAATSLMSALAARLLQPAHSCSLRLRPFHLAAVRNEAVVISGRKLAQQIKQEVRQEVEEWVASGNKRPHLSVILVGENPASHSYVLNKTRAAAVVGINSETIMKPASISEEELLNLINKLNNDDNVDGLLVQLPLPEHIDERRICNAVSPDKDVDGFHVINVGRMCLDQYSMLPATPWGVWEIIKRTGIPTLGKNVVVAGRSKNVGMPIAMLLHTDGAHERPGGDATVTISHRYTPKEQLKKHTILADIVISAAGIPNLITADMIKEGAAVIDVGINRVHDPVTAKPKLVGDVDFEGVRQKAGYITPVPGGVGPMTVAMLMKNTIIAAKKVLRLEEREVLKSKELGVATN

T97201	TARGETID	T97201
T97201	FORMERID	TTDR00844
T97201	UNIPROID	LEUK_HUMAN
T97201	TARGNAME	Leukosialin (SPN)
T97201	GENENAME	SPN
T97201	TARGTYPE	Literature-reported
T97201	SYNONYMS	Sialophorin; Leukocyte sialoglycoprotein; Leucocyte sialoglycoprotein; Galactoglycoprotein; GPL115; GALGP; CD43 antigen; CD43
T97201	FUNCTION	Positively regulates T-cell trafficking to lymph-nodes via its association with ERM proteins (EZR, RDX and MSN). Negatively regulates Th2 cell differentiation and predisposes the differentiation of T-cells towards a Th1 lineage commitment. Promotes the expression of IFN-gamma by T-cells during T-cell receptor (TCR) activation of naive cells and induces the expression of IFN-gamma by CD4(+) T-cells and to a lesser extent by CD8(+) T-cells. Plays a role in preparing T-cells for cytokine sensing and differentiation into effector cells by inducing the expression of cytokine receptors IFNGR and IL4R, promoting IFNGR and IL4R signaling and by mediating the clustering of IFNGR with TCR. Acts as a major E-selectin ligand responsible for Th17 cell rolling on activated vasculature and recruitment during inflammation. Mediates Th17 cells, but not Th1 cells, adhesion to E-selectin. Acts as a T-cell counter-receptor for SIGLEC1. Predominant cell surface sialoprotein of leukocytes which regulates multiple T-cell functions, including T-cell activation, proliferation, differentiation, trafficking and migration.
T97201	SEQUENCE	MATLLLLLGVLVVSPDALGSTTAVQTPTSGEPLVSTSEPLSSKMYTTSITSDPKADSTGDQTSALPPSTSINEGSPLWTSIGASTGSPLPEPTTYQEVSIKMSSVPQETPHATSHPAVPITANSLGSHTVTGGTITTNSPETSSRTSGAPVTTAASSLETSRGTSGPPLTMATVSLETSKGTSGPPVTMATDSLETSTGTTGPPVTMTTGSLEPSSGASGPQVSSVKLSTMMSPTTSTNASTVPFRNPDENSRGMLPVAVLVALLAVIVLVALLLLWRRRQKRRTGALVLSRGGKRNGVVDAWAGPAQVPEEGAVTVTVGGSGGDKGSGFPDGEGSSRRPTLTTFFGRRKSRQGSLAMEELKSGSGPSLKGEEEPLVASEDGAVDAPAPDEPEGGDGAAP

T36325	TARGETID	T36325
T36325	FORMERID	TTDI02089
T36325	UNIPROID	H13_HUMAN
T36325	TARGNAME	Histone H1s-2 (H1.3)
T36325	GENENAME	HIST1H1D
T36325	TARGTYPE	Literature-reported
T36325	SYNONYMS	Histone H1s2; Histone H1c; HIST1H1D
T36325	FUNCTION	Histone H1 protein binds to linker DNA between nucleosomes forming the macromolecular structure known as the chromatin fiber. Histones H1 are necessary for the condensation of nucleosome chains into higher-order structured fibers. Acts also as a regulator of individual gene transcription through chromatin remodeling, nucleosome spacing and DNA methylation.
T36325	SEQUENCE	MSETAPLAPTIPAPAEKTPVKKKAKKAGATAGKRKASGPPVSELITKAVAASKERSGVSLAALKKALAAAGYDVEKNNSRIKLGLKSLVSKGTLVQTKGTGASGSFKLNKKAASGEGKPKAKKAGAAKPRKPAGAAKKPKKVAGAATPKKSIKKTPKKVKKPATAAGTKKVAKSAKKVKTPQPKKAAKSPAKAKAPKPKAAKPKSGKPKVTKAKKAAPKKK

T71190	TARGETID	T71190
T71190	FORMERID	TTDNC00407
T71190	UNIPROID	STMN1_HUMAN
T71190	TARGNAME	Stathmin-1 (STMN1)
T71190	GENENAME	STMN1
T71190	TARGTYPE	Literature-reported
T71190	SYNONYMS	pp19; pp17; Stathmin; Protein Pr22; Prosolin; Phosphoprotein p19; Oncoprotein 18; OP18; Metablastin; Leukemia-associated phosphoprotein p18; LAP18; C1orf215
T71190	FUNCTION	Involved in the regulation of the microtubule (MT) filament system by destabilizing microtubules. Prevents assembly and promotes disassembly of microtubules. Phosphorylation at Ser-16 may be required for axon formation during neurogenesis. Involved in the control of the learned and innate fear (By similarity).
T71190	SEQUENCE	MASSDIQVKELEKRASGQAFELILSPRSKESVPEFPLSPPKKKDLSLEEIQKKLEAAEERRKSHEAEVLKQLAEKREHEKEVLQKAIEENNNFSKMAEEKLTHKMEANKENREAQMAAKLERLREKDKHIEEVRKNKESKDPADETEAD

T94115	TARGETID	T94115
T94115	FORMERID	TTDR00621
T94115	UNIPROID	SYN1_HUMAN; SYN2_HUMAN; SYN3_HUMAN
T94115	TARGNAME	Synapsin (SYN)
T94115	GENENAME	SYN1; SYN2; SYN3
T94115	TARGTYPE	Literature-reported
T94115	SYNONYMS	Synapsin
T94115	FUNCTION	Neuronal phosphoprotein that coats synaptic vesicles, binds to the cytoskeleton, and is believed to function in the regulation of neurotransmitter release. The complex formed with NOS1 and CAPON proteins is necessary for specific nitric-oxid functions at a presynaptic level. May be involved in the regulation of noradrenaline secretion, neurotransmitter release and synaptogenesis.
T94115	SEQUENCE	MNYLRRRLSDSNFMANLPNGYMTDLQRPQPPPPPPGAHSPGATPGPGTATAERSSGVAPAASPAAPSPGSSGGGGFFSSLSNAVKQTTAAAAATFSEQVGGGSGGAGRGGAASRVLLVIDEPHTDWAKYFKGKKIHGEIDIKVEQAEFSDLNLVAHANGGFSVDMEVLRNGVKVVRSLKPDFVLIRQHAFSMARNGDYRSLVIGLQYAGIPSVNSLHSVYNFCDKPWVFAQMVRLHKKLGTEEFPLIDQTFYPNHKEMLSSTTYPVVVKMGHAHSGMGKVKVDNQHDFQDIASVVALTKTYATAEPFIDAKYDVRVQKIGQNYKAYMRTSVSGNWKTNTGSAMLEQIAMSDRYKLWVDTCSEIFGGLDICAVEALHGKDGRDHIIEVVGSSMPLIGDHQDEDKQLIVELVVNKMAQALPRQRQRDASPGRGSHGQTPSPGALPLGRQTSQQPAGPPAQQRPPPQGGPPQPGPGPQRQGPPLQQRPPPQGQQHLSGLGPPAGSPLPQRLPSPTSAPQQPASQAAPPTQGQGRQSRPVAGGPGAPPAARPPASPSPQRQAGPPQATRQTSVSGPAPPKASGAPPGGQQRQGPPQKPPGPAGPTRQASQAGPVPRTGPPTTQQPRPSGPGPAGRPKPQLAQKPSQDVPPPATAAAGGPPHPQLNKSQSLTNAFNLPEPAPPRPSLSQDEVKAETIRSLRKSFASLFSD

T25670	TARGETID	T25670
T25670	FORMERID	TTDI01828
T25670	UNIPROID	TNNI1_HUMAN; TNNI2_HUMAN; TNNI3_HUMAN
T25670	TARGNAME	Troponin I (TNNI)
T25670	GENENAME	TNNI1; TNNI2; TNNI3
T25670	TARGTYPE	Literature-reported
T25670	SYNONYMS	Troponin I
T25670	FUNCTION	Troponin I is the inhibitory subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity.
T25670	SEQUENCE	MPEVERKPKITASRKLLLKSLMLAKAKECWEQEHEEREAEKVRYLAERIPTLQTRGLSLSALQDLCRELHAKVEVVDEERYDIEAKCLHNTREIKDLKLKVMDLRGKFKRPPLRRVRVSADAMLRALLGSKHKVSMDLRANLKSVKKEDTEKERPVEVGDWRKNVEAMSGMEGRKKMFDAAKSPTSQ

T09742	TARGETID	T09742
T09742	FORMERID	TTDI01431
T09742	UNIPROID	GGT1_HUMAN; GGT2_HUMAN
T09742	TARGNAME	Gamma glutamyltranspeptidase (GGT)
T09742	GENENAME	GGT1; GGT2
T09742	TARGTYPE	Literature-reported
T09742	SYNONYMS	Gamma-glutamyltranspeptidase; Gamma-glutamyltransferase; GGT
T09742	FUNCTION	GGT1 cleaves the gamma-glutamyl bond of extracellular glutathione (gamma-Glu-Cys-Gly), glutathione conjugates, and other gamma-glutamyl compounds. The metabolism of glutathione releases free glutamate and the dipeptide cysteinyl-glycine, which is hydrolyzed to cysteine and glycine by dipeptidases. In the presence of high concentrations of dipeptides and some amino acids, it can also catalyze a transpeptidation reaction, transferring the gamma-glutamyl moiety to an acceptor amino acid to form a new gamma-glutamyl compound. However GGT2  lack catalytic activity due to its inability to undergo the autocatalytic cleavage needed to produce a mature, enzymatically active heterodimer.
T09742	SEQUENCE	MKKKLVVLGLLAVVLVLVIVGLCLWLPSASKEPDNHVYTRAAVAADAKQCSKIGRDALRDGGSAVDAAIAALLCVGLMNAHSMGIGGGLFLTIYNSTTRKAEVINAREVAPRLAFATMFNSSEQSQKGGLSVAVPGEIRGYELAHQRHGRLPWARLFQPSIQLARQGFPVGKGLAAALENKRTVIEQQPVLCEVFCRDRKVLREGERLTLPQLADTYETLAIEGAQAFYNGSLTAQIVKDIQAAGGIVTAEDLNNYRAELIEHPLNISLGDVVLYMPSAPLSGPVLALILNILKGYNFSRESVESPEQKGLTYHRIVEAFRFAYAKRTLLGDPKFVDVTEVVRNMTSEFFAAQLRAQISDDTTHPISYYKPEFYTPDDGGTAHLSVVAEDGSAVSATSTINLYFGSKVRSPVSGILFNNEMDDFSSPSITNEFGVPPSPANFIQPGKQPLSSMCPTIMVGQDGQVRMVVGAAGGTQITTATALAIIYNLWFGYDVKRAVEEPRLHNQLLPNVTTVERNIDQAVTAALETRHHHTQIASTFIAVVQAIVRTAGGWAAASDSRKGGEPAGY

T15811	TARGETID	T15811
T15811	FORMERID	TTDI00090
T15811	UNIPROID	SRCH_HUMAN
T15811	TARGNAME	Histidine-rich calcium binding protein (HRC)
T15811	GENENAME	HRC
T15811	TARGTYPE	Literature-reported
T15811	SYNONYMS	Sarcoplasmic reticulum histidine-rich calcium-binding protein; HRC
T15811	FUNCTION	May play a role in the regulation of calcium sequestration or release in the SR of skeletal and cardiac muscle.
T15811	SEQUENCE	MGHHRPWLHASVLWAGVASLLLPPAMTQQLRGDGLGFRNRNNSTGVAGLSEEASAELRHHLHSPRDHPDENKDVSTENGHHFWSHPDREKEDEDVSKEYGHLLPGHRSQDHKVGDEGVSGEEVFAEHGGQARGHRGHGSEDTEDSAEHRHHLPSHRSHSHQDEDEDEVVSSEHHHHILRHGHRGHDGEDDEGEEEEEEEEEEEEASTEYGHQAHRHRGHGSEEDEDVSDGHHHHGPSHRHQGHEEDDDDDDDDDDDDDDDDVSIEYRHQAHRHQGHGIEEDEDVSDGHHHRDPSHRHRSHEEDDNDDDDVSTEYGHQAHRHQDHRKEEVEAVSGEHHHHVPDHRHQGHRDEEEDEDVSTERWHQGPQHVHHGLVDEEEEEEEITVQFGHYVASHQPRGHKSDEEDFQDEYKTEVPHHHHHRVPREEDEEVSAELGHQAPSHRQSHQDEETGHGQRGSIKEMSHHPPGHTVVKDRSHLRKDDSEEEKEKEEDPGSHEEDDESSEQGEKGTHHGSRDQEDEEDEEEGHGLSLNQEEEEEEDKEEEEEEEDEERREERAEVGAPLSPDHSEEEEEEEEGLEEDEPRFTIIPNPLDRREEAGGASSEEESGEDTGPQDAQEYGNYQPGSLCGYCSFCNRCTECESCHCDEENMGEHCDQCQHCQFCYLCPLVCETVCAPGSYVDYFSSSLYQALADMLETPEP

T99665	TARGETID	T99665
T99665	FORMERID	TTDI03210
T99665	UNIPROID	GBRR1_HUMAN
T99665	TARGNAME	GABA(A) receptor rho1 (GABRR1)
T99665	GENENAME	GABRR1
T99665	TARGTYPE	Literature-reported
T99665	SYNONYMS	Gamma-aminobutyric acid receptor subunit rho-1; GABA(C) receptor1; GABA(A) receptor subunit rho-1
T99665	FUNCTION	GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA receptor could play a role in retinal neurotransmission.
T99665	SEQUENCE	MLAVPNMRFGIFLLWWGWVLATESRMHWPGREVHEMSKKGRPQRQRREVHEDAHKQVSPILRRSPDITKSPLTKSEQLLRIDDHDFSMRPGFGGPAIPVGVDVQVESLDSISEVDMDFTMTLYLRHYWKDERLSFPSTNNLSMTFDGRLVKKIWVPDMFFVHSKRSFIHDTTTDNVMLRVQPDGKVLYSLRVTVTAMCNMDFSRFPLDTQTCSLEIESYAYTEDDLMLYWKKGNDSLKTDERISLSQFLIQEFHTTTKLAFYSSTGWYNRLYINFTLRRHIFFFLLQTYFPATLMVMLSWVSFWIDRRAVPARVPLGITTVLTMSTIITGVNASMPRVSYIKAVDIYLWVSFVFVFLSVLEYAAVNYLTTVQERKEQKLREKLPCTSGLPPPRTAMLDGNYSDGEVNDLDNYMPENGEKPDRMMVQLTLASERSSPQRKSQRSSYVSMRIDTHAIDKYSRIIFPAAYILFNLIYWSIFS
T99665	DRUGINFO	D0O9UH	CACA	Investigative
T99665	DRUGINFO	D0A6RM	trans-3-ACPBPA	Investigative
T99665	DRUGINFO	D0B0WU	cis-3-ACPBPA	Investigative
T99665	DRUGINFO	D0C7PZ	5-Me-IAA	Investigative
T99665	DRUGINFO	D0OY1R	aza-THIP	Investigative
T99665	DRUGINFO	D0U4HM	TPMPA	Investigative
T99665	DRUGINFO	D0WV8K	(+/-)-cis-2-CAMP	Investigative
T99665	DRUGINFO	D0VW5M	piperidine-4-sulphonic acid	Investigative
T99665	DRUGINFO	D0AC2H	isonipecotic acid	Investigative
T99665	DRUGINFO	D0P0TI	TBPS	Investigative

T36423	TARGETID	T36423
T36423	FORMERID	TTDR00386
T36423	UNIPROID	CRHBP_HUMAN
T36423	TARGNAME	Corticotropin-releasing factor binding protein (CRHBP)
T36423	GENENAME	CRHBP
T36423	TARGTYPE	Literature-reported
T36423	SYNONYMS	Corticotropin-releasing hormone-binding protein; Corticotropin-releasing factor-binding protein; CRH-BP; CRFBP; CRF-binding protein; CRF-BP
T36423	FUNCTION	May prevent inappropriate pituitary-adrenal stimulation in pregnancy. Binds CRF and inactivates it.
T36423	SEQUENCE	MSPNFKLQCHFILIFLTALRGESRYLELREAADYDPFLLFSANLKRELAGEQPYRRALRCLDMLSLQGQFTFTADRPQLHCAAFFISEPEEFITIHYDQVSIDCQGGDFLKVFDGWILKGEKFPSSQDHPLPSAERYIDFCESGLSRRSIRSSQNVAMIFFRVHEPGNGFTLTIKTDPNLFPCNVISQTPNGKFTLVVPHQHRNCSFSIIYPVVIKISDLTLGHVNGLQLKKSSAGCEGIGDFVELLGGTGLDPSKMTPLADLCYPFHGPAQMKVGCDNTVVRMVSSGKHVNRVTFEYRQLEPYELENPNGNSIGEFCLSGL

T23409	TARGETID	T23409
T23409	FORMERID	TTDR00052
T23409	UNIPROID	GA45A_HUMAN; GA45B_HUMAN; GA45G_HUMAN
T23409	TARGNAME	Growth arrest and DNA-damage-inducible protein (GADD45)
T23409	GENENAME	GADD45A; GADD45B; GADD45G
T23409	TARGTYPE	Literature-reported
T23409	SYNONYMS	Growth arrest and DNA damage-inducible protein GADD45; DNA damage-inducible transcript protein; DDIT
T23409	FUNCTION	Involved in the regulation of growth and apoptosis. Mediates activation of stress-responsive MTK1/MEKK4 MAPKKK.
T23409	SEQUENCE	MTLEEFSAGEQKTERMDKVGDALEEVLSKALSQRTITVGVYEAAKLLNVDPDNVVLCLLAADEDDDRDVALQIHFTLIQAFCCENDINILRVSNPGRLAELLLLETDAGPAASEGAEQPPDLHCVLVTNPHSSQWKDPALSQLICFCRESRYMDQWVPVINLPER

T65906	TARGETID	T65906
T65906	FORMERID	TTDI02648
T65906	UNIPROID	CD24_HUMAN
T65906	TARGNAME	Small cell lung carcinoma cluster 4 antigen (CD24)
T65906	GENENAME	CD24
T65906	TARGTYPE	Literature-reported
T65906	SYNONYMS	Signal transducer CD24; CD24A
T65906	FUNCTION	Signaling could be triggered by the binding of a lectin-like ligand to the CD24 carbohydrates, and transduced by the release of second messengers derived from the GPI-anchor. Modulates B-cell activation responses. Promotes AG-dependent proliferation of B-cells, and prevents their terminal differentiation into antibody-forming cells. In association with SIGLEC10 may be involved in the selective suppression of the immune response to danger-associated molecular patterns (DAMPs) such as HMGB1, HSP70 and HSP90. Plays a role in the control of autoimmunity. May have a pivotal role in cell differentiation of different cell types.
T65906	SEQUENCE	MGRAMVARLGLGLLLLALLLPTQIYSSETTTGTSSNSSQSTSNSGLAPNPTNATTKAAGGALQSTASLFVVSLSLLHLYS
T65906	DRUGINFO	D0FZ7D	BsAb cG7-MICA	Investigative

T25705	TARGETID	T25705
T25705	FORMERID	TTDI03200
T25705	UNIPROID	FPR3_HUMAN
T25705	TARGNAME	N-formyl peptide receptor 3 (FPR3)
T25705	GENENAME	FPR3
T25705	TARGTYPE	Literature-reported
T25705	SYNONYMS	Formyl peptide receptor-like 2; FPRL2; FPRH1; FMLP-related receptor II; FMLP-R-II
T25705	FUNCTION	Low affinity receptor for N-formyl-methionyl peptides, which are powerful neutrophils chemotactic factors. Binding of FMLP to the receptor causes activation of neutrophils. This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system.
T25705	SEQUENCE	METNFSIPLNETEEVLPEPAGHTVLWIFSLLVHGVTFVFGVLGNGLVIWVAGFRMTRTVNTICYLNLALADFSFSAILPFRMVSVAMREKWPFGSFLCKLVHVMIDINLFVSVYLITIIALDRCICVLHPAWAQNHRTMSLAKRVMTGLWIFTIVLTLPNFIFWTTISTTNGDTYCIFNFAFWGDTAVERLNVFITMAKVFLILHFIIGFSVPMSIITVCYGIIAAKIHRNHMIKSSRPLRVFAAVVASFFICWFPYELIGILMAVWLKEMLLNGKYKIILVLINPTSSLAFFNSCLNPILYVFMGRNFQERLIRSLPTSLERALTEVPDSAQTSNTDTTSASPPEETELQAM
T25705	DRUGINFO	D09TXO	humanin	Preclinical
T25705	DRUGINFO	D0R1FZ	LXA4	Investigative

T12974	TARGETID	T12974
T12974	FORMERID	TTDI00127
T12974	UNIPROID	HMGB2_HUMAN
T12974	TARGNAME	High-mobility group protein B2 (HMGB2)
T12974	GENENAME	HMGB2
T12974	TARGTYPE	Literature-reported
T12974	SYNONYMS	High mobility group protein B2; High mobility group protein 2; HMG2; HMG-2
T12974	FUNCTION	May act in a redox sensitive manner. In the nucleus is an abundant chromatin-associated non-histone protein involved in transcription, chromatin remodeling and V(D)J recombination and probably other processes. Binds DNA with a preference to non-canonical DNA structures such as single-stranded DNA. Can bent DNA and enhance DNA flexibility by looping thus providing a mechanism to promote activities on various gene promoters by enhancing transcription factor binding and/or bringing distant regulatory sequences into close proximity. Involved in V(D)J recombination by acting as a cofactor of the RAG complex: acts by stimulating cleavage and RAG protein binding at the 23 bp spacer of conserved recombination signal sequences (RSS). Proposed to be involved in the innate immune response to nucleic acids by acting as a promiscuous immunogenic DNA/RNA sensor which cooperates with subsequent discriminative sensing by specific pattern recognition receptors. In the extracellular compartment acts as a chemokine. Promotes proliferation and migration of endothelial cells implicating AGER/RAGE. Has antimicrobial activity in gastrointestinal epithelial tissues. Involved in inflammatory response to antigenic stimulus coupled with proinflammatory activity. Involved in modulation of neurogenesis probably by regulation of neural stem proliferation. Involved in articular cartilage surface maintenance implicating LEF1 and the Wnt/beta-catenin pathway. Multifunctional protein with various roles in different cellular compartments.
T12974	SEQUENCE	MGKGDPNKPRGKMSSYAFFVQTCREEHKKKHPDSSVNFAEFSKKCSERWKTMSAKEKSKFEDMAKSDKARYDREMKNYVPPKGDKKGKKKDPNAPKRPPSAFFLFCSEHRPKIKSEHPGLSIGDTAKKLGEMWSEQSAKDKQPYEQKAAKLKEKYEKDIAAYRAKGKSEAGKKGPGRPTGSKKKNEPEDEEEEEEEEDEDEEEEDEDEE

T97960	TARGETID	T97960
T97960	UNIPROID	NKG2D_HUMAN-ULBP1_HUMAN/ULBP2_HUMAN/ULBP3_HUMAN
T97960	TARGNAME	NKG2D-NKG2D ligand interaction (NKG2D-NKG2DL PPI)
T97960	GENENAME	KLRK1-ULBP1/ULBP2/ULBP3
T97960	TARGTYPE	Literature-reported
T97960	SYNONYMS	NK cell receptor D-NKG2D ligand interaction
T97960	FUNCTION	Inhibits the outgrowth of naturally arising low-grade B cell lymphoma In vivo.
T97960	SEQUENCE	MGWIRGRRSRHSWEMSEFHNYNLDLKKSDFSTRWQKQRCPVVKSKCRENASPFFFCCFIAVAMGIRFIIMVAIWSAVFLNSLFNQEVQIPLTESYCGPCPKNWICYKNNCYQFFDESKNWYESQASCMSQNASLLKVYSKEDQDLLKLVKSYHWMGLVHIPTNGSWQWEDGSILSPNLLTIIEMQKGDCALYASSFKGYIENCSTPNTYICMQRTVMAAAASPAFLLCLPLLHLLSGWSRAGWVDTHCLCYDFIITPKSRPEPQWCEVQGLVDERPFLHYDCVNHKAKAFASLGKKVNVTKTWEEQTETLRDVVDFLKGQLLDIQVENLIPIEPLTLQARMSCEHEAHGHGRGSWQFLFNGQKFLLFDSNNRKWTALHPGAKKMTEKWEKNRDVTMFFQKISLGDCKMWLEEFLMYWEQMLDPTKPPSLAPGTTQPKAMATTLSPWSLLIIFLCFILAGR

T52651	TARGETID	T52651
T52651	FORMERID	TTDI02576
T52651	UNIPROID	MAP4_HUMAN
T52651	TARGNAME	Microtubule-associated protein 4 (MAP4)
T52651	GENENAME	MAP4
T52651	TARGTYPE	Literature-reported
T52651	SYNONYMS	Microtubuleassociated protein 4; MAP4
T52651	FUNCTION	Non-neuronal microtubule-associated protein. Promotes microtubule assembly.
T52651	SEQUENCE	MADLSLADALTEPSPDIEGEIKRDFIATLEAEAFDDVVGETVGKTDYIPLLDVDEKTGNSESKKKPCSETSQIEDTPSSKPTLLANGGHGVEGSDTTGSPTEFLEEKMAYQEYPNSQNWPEDTNFCFQPEQVVDPIQTDPFKMYHDDDLADLVFPSSATADTSIFAGQNDPLKDSYGMSPCNTAVVPQGWSVEALNSPHSESFVSPEAVAEPPQPTAVPLELAKEIEMASEERPPAQALEIMMGLKTTDMAPSKETEMALAKDMALATKTEVALAKDMESPTKLDVTLAKDMQPSMESDMALVKDMELPTEKEVALVKDVRWPTETDVSSAKNVVLPTETEVAPAKDVTLLKETERASPIKMDLAPSKDMGPPKENKKETERASPIKMDLAPSKDMGPPKENKIVPAKDLVLLSEIEVAQANDIISSTEISSAEKVALSSETEVALARDMTLPPETNVILTKDKALPLEAEVAPVKDMAQLPETEIAPAKDVAPSTVKEVGLLKDMSPLSETEMALGKDVTPPPETEVVLIKNVCLPPEMEVALTEDQVPALKTEAPLAKDGVLTLANNVTPAKDVPPLSETEATPVPIKDMEIAQTQKGISEDSHLESLQDVGQSAAPTFMISPETVTGTGKKCSLPAEEDSVLEKLGERKPCNSQPSELSSETSGIARPEEGRPVVSGTGNDITTPPNKELPPSPEKKTKPLATTQPAKTSTSKAKTQPTSLPKQPAPTTIGGLNKKPMSLASGLVPAAPPKRPAVASARPSILPSKDVKPKPIADAKAPEKRASPSKPASAPASRSGSKSTQTVAKTTTAAAVASTGPSSRSPSTLLPKKPTAIKTEGKPAEVKKMTAKSVPADLSRPKSTSTSSMKKTTTLSGTAPAAGVVPSRVKATPMPSRPSTTPFIDKKPTSAKPSSTTPRLSRLATNTSAPDLKNVRSKVGSTENIKHQPGGGRAKVEKKTEAAATTRKPESNAVTKTAGPIASAQKQPAGKVQIVSKKVSYSHIQSKCGSKDNIKHVPGGGNVQIQNKKVDISKVSSKCGSKANIKHKPGGGDVKIESQKLNFKEKAQAKVGSLDNVGHLPAGGAVKTEGGGSEAPLCPGPPAGEEPAISEAAPEAGAPTSASGLNGHPTLSGGGDQREAQTLDSQIQETSI

T90682	TARGETID	T90682
T90682	FORMERID	TTDI03211
T90682	UNIPROID	GBRR2_HUMAN
T90682	TARGNAME	GABA(A) receptor rho2 (GABRR2)
T90682	GENENAME	GABRR2
T90682	TARGTYPE	Literature-reported
T90682	SYNONYMS	Gamma-aminobutyric acid receptor subunit rho-2; GABA(C) receptor2; GABA(A) receptor subunit rho-2
T90682	FUNCTION	GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA receptor could play a role in retinal neurotransmission.
T90682	SEQUENCE	MPYFTRLILFLFCLMVLVESRKPKRKRWTGQVEMPKPSHLYKKNLDVTKIRKGKPQQLLRVDEHDFSMRPAFGGPAIPVGVDVQVESLDSISEVDMDFTMTLYLRHYWKDERLAFSSASNKSMTFDGRLVKKIWVPDVFFVHSKRSFTHDTTTDNIMLRVFPDGHVLYSMRITVTAMCNMDFSHFPLDSQTCSLELESYAYTDEDLMLYWKNGDESLKTDEKISLSQFLIQKFHTTSRLAFYSSTGWYNRLYINFTLRRHIFFFLLQTYFPATLMVMLSWVSFWIDRRAVPARVSLGITTVLTMTTIITGVNASMPRVSYVKAVDIYLWVSFVFVFLSVLEYAAVNYLTTVQERKERKLREKFPCMCGMLHSKTMMLDGSYSESEANSLAGYPRSHILTEEERQDKIVVHLGLSGEANAARKKGLLKGQTGFRIFQNTHAIDKYSRLIFPASYIFFNLIYWSVFS
T90682	DRUGINFO	D0A6RM	trans-3-ACPBPA	Investigative
T90682	DRUGINFO	D0B0WU	cis-3-ACPBPA	Investigative
T90682	DRUGINFO	D0C7PZ	5-Me-IAA	Investigative
T90682	DRUGINFO	D0OY1R	aza-THIP	Investigative
T90682	DRUGINFO	D0U4HM	TPMPA	Investigative
T90682	DRUGINFO	D0WV8K	(+/-)-cis-2-CAMP	Investigative
T90682	DRUGINFO	D0VW5M	piperidine-4-sulphonic acid	Investigative
T90682	DRUGINFO	D0AC2H	isonipecotic acid	Investigative
T90682	DRUGINFO	D0P0TI	TBPS	Investigative

T40569	TARGETID	T40569
T40569	FORMERID	TTDI01344
T40569	UNIPROID	MPIP1_HUMAN; MPIP2_HUMAN; MPIP3_HUMAN
T40569	TARGNAME	Dual specificity phosphatase Cdc25 (CDC25)
T40569	GENENAME	CDC25A; CDC25B; CDC25C
T40569	TARGTYPE	Literature-reported
T40569	SYNONYMS	M-phase inducer phosphatase
T40569	FUNCTION	A dual-specificity phosphatase first isolated from the yeast Schizosaccharomyces pombe as a cell cycle defective mutant. As with other cell cycle proteins or genes such as Cdc2 and Cdc4, the "cdc" in its name refers to "cell division cycle". Dual-specificity phosphatases are considered a sub-class of protein tyrosine phosphatases. By removing inhibitory phosphate residues from target cyclin-dependent kinases (Cdks), Cdc25 proteins control entry into and progression through various phases of the cell cycle, including mitosis and S ("Synthesis") phase.
T40569	SEQUENCE	MELGPEPPHRRRLLFACSPPPASQPVVKALFGASAAGGLSPVTNLTVTMDQLQGLGSDYEQPLEVKNNSNLQRMGSSESTDSGFCLDSPGPLDSKENLENPMRRIHSLPQKLLGCSPALKRSHSDSLDHDIFQLIDPDENKENEAFEFKKPVRPVSRGCLHSHGLQEGKDLFTQRQNSAPARMLSSNERDSSEPGNFIPLFTPQSPVTATLSDEDDGFVDLLDGENLKNEEETPSCMASLWTAPLVMRTTNLDNRCKLFDSPSLCSSSTRSVLKRPERSQEESPPGSTKRRKSMSGASPKESTNPEKAHETLHQSLSLASSPKGTIENILDNDPRDLIGDFSKGYLFHTVAGKHQDLKYISPEIMASVLNGKFANLIKEFVIIDCRYPYEYEGGHIKGAVNLHMEEEVEDFLLKKPIVPTDGKRVIVVFHCEFSSERGPRMCRYVRERDRLGNEYPKLHYPELYVLKGGYKEFFMKCQSYCEPPSYRPMHHEDFKEDLKKFRTKSRTWAGEKSKREMYSRLKKL

T56290	TARGETID	T56290
T56290	FORMERID	TTDI00134
T56290	UNIPROID	HXA11_HUMAN
T56290	TARGNAME	Homeobox protein Hox-A11 (HOXA11)
T56290	GENENAME	HOXA11
T56290	TARGTYPE	Literature-reported
T56290	SYNONYMS	Homeobox protein HoxA11; Homeobox protein Hox1I; Homeobox protein Hox-1I; HOX1I
T56290	FUNCTION	Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis.
T56290	SEQUENCE	MDFDERGPCSSNMYLPSCTYYVSGPDFSSLPSFLPQTPSSRPMTYSYSSNLPQVQPVREVTFREYAIEPATKWHPRGNLAHCYSAEELVHRDCLQAPSAAGVPGDVLAKSSANVYHHPTPAVSSNFYSTVGRNGVLPQAFDQFFETAYGTPENLASSDYPGDKSAEKGPPAATATSAAAAAAATGAPATSSSDSGGGGGCRETAAAAEEKERRRRPESSSSPESSSGHTEDKAGGSSGQRTRKKRCPYTKYQIRELEREFFFSVYINKEKRLQLSRMLNLTDRQVKIWFQNRRMKEKKINRDRLQYYSANPLL

T97413	TARGETID	T97413
T97413	FORMERID	TTDI01337
T97413	UNIPROID	BRS3_HUMAN
T97413	TARGNAME	Bombesin-like receptor 3 (BRS3)
T97413	GENENAME	BRS3
T97413	TARGTYPE	Literature-reported
T97413	SYNONYMS	Bombesin receptor subtype-3; BRS-3
T97413	FUNCTION	Role in sperm cell division, maturation, or function. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
T97413	SEQUENCE	MAQRQPHSPNQTLISITNDTESSSSVVSNDNTNKGWSGDNSPGIEALCAIYITYAVIISVGILGNAILIKVFFKTKSMQTVPNIFITSLAFGDLLLLLTCVPVDATHYLAEGWLFGRIGCKVLSFIRLTSVGVSVFTLTILSADRYKAVVKPLERQPSNAILKTCVKAGCVWIVSMIFALPEAIFSNVYTFRDPNKNMTFESCTSYPVSKKLLQEIHSLLCFLVFYIIPLSIISVYYSLIARTLYKSTLNIPTEEQSHARKQIESRKRIARTVLVLVALFALCWLPNHLLYLYHSFTSQTYVDPSAMHFIFTIFSRVLAFSNSCVNPFALYWLSKSFQKHFKAQLFCCKAERPEPPVADTSLTTLAVMGTVPGTGSIQMSEISVTSFTGCSVKQAEDRF
T97413	DRUGINFO	D04JSE	MK-7725	Investigative

T59577	TARGETID	T59577
T59577	FORMERID	TTDI03237
T59577	UNIPROID	GP183_HUMAN
T59577	TARGNAME	EBV-induced G-protein coupled receptor 2 (GPR183)
T59577	GENENAME	GPR183
T59577	TARGTYPE	Literature-reported
T59577	SYNONYMS	hEBI2; G-protein coupled receptor 183; Epstein-Barr virus-induced G-protein coupled receptor 2; EBI2
T59577	FUNCTION	G-protein coupled receptor expressed in lymphocytes that acts as a chemotactic receptor for B-cells, T-cells, splenic dendritic cells, monocytes/macrophages and astrocytes (By similarity). Receptor for oxysterol 7-alpha,25-dihydroxycholesterol (7-alpha,25-OHC) and other related oxysterols. Mediates cell positioning and movement of a number of cells by binding the 7-alpha,25-OHC ligand that forms a chemotactic gradient (By similarity). Binding of 7-alpha,25-OHC mediates the correct localization of B-cells during humoral immune responses (By similarity). Guides B-cell movement along the B-cell zone-T-cell zone boundary and later to interfollicular and outer follicular regions (By similarity). Its specific expression during B-cell maturation helps position B-cells appropriately for mounting T-dependent antibody responses (By similarity). Collaborates with CXCR5 to mediate B-cell migration; probably by forming a heterodimer with CXCR5 that affects the interaction between of CXCL13 and CXCR5. Also acts as a chemotactic receptor for some T-cells upon binding to 7-alpha,25-OHC ligand (By similarity). Promotes follicular helper T (Tfh) cells differentiation by positioning activated T-cells at the follicle-T-zone interface, promoting contact of newly activated CD4 T-cells with activated dendritic cells and exposing them to Tfh-cell-promoting inducible costimulator (ICOS) ligand (By similarity). Expression in splenic dendritic cells is required for their homeostasis, localization and ability to induce B- and T-cell responses: GPR183 acts as a chemotactic receptor in dendritic cells that mediates the accumulation of CD4(+) dendritic cells in bridging channels (By similarity). Regulates migration of astrocytes and is involved in communication between astrocytes and macrophages. Promotes osteoclast precursor migration to bone surfaces (By similarity). Signals constitutively through G(i)-alpha, but not G(s)-alpha or G(q)-alpha. Signals constitutively also via MAPK1/3 (ERK1/2) (By similarity).
T59577	SEQUENCE	MDIQMANNFTPPSATPQGNDCDLYAHHSTARIVMPLHYSLVFIIGLVGNLLALVVIVQNRKKINSTTLYSTNLVISDILFTTALPTRIAYYAMGFDWRIGDALCRITALVFYINTYAGVNFMTCLSIDRFIAVVHPLRYNKIKRIEHAKGVCIFVWILVFAQTLPLLINPMSKQEAERITCMEYPNFEETKSLPWILLGACFIGYVLPLIIILICYSQICCKLFRTAKQNPLTEKSGVNKKALNTIILIIVVFVLCFTPYHVAIIQHMIKKLRFSNFLECSQRHSFQISLHFTVCLMNFNCCMDPFIYFFACKGYKRKVMRMLKRQVSVSISSAVKSAPEENSREMTETQMMIHSKSSNGK
T59577	DRUGINFO	D02JXQ	7alpha,25-dihydroxycholesterol	Investigative
T59577	DRUGINFO	D04BOQ	7alpha,27-dihydroxycholesterol	Investigative
T59577	DRUGINFO	D0FB7S	7beta-hydroxycholesterol	Investigative
T59577	DRUGINFO	D0H7NV	7beta, 27-dihydroxycholesterol	Investigative
T59577	DRUGINFO	D0K5QH	7alpha-hydroxycholesterol	Investigative
T59577	DRUGINFO	D0L7PI	7beta, 25-dihydroxycholesterol	Investigative
T59577	DRUGINFO	D06OVX	25-hydroxycholesterol	Investigative
T59577	DRUGINFO	D0H2YM	27-hydroxycholesterol	Investigative

T49085	TARGETID	T49085
T49085	FORMERID	TTDI00156
T49085	UNIPROID	SOX5_HUMAN
T49085	TARGNAME	Transcription factor SOX-5 (SOX5)
T49085	GENENAME	SOX5
T49085	TARGTYPE	Literature-reported
T49085	SYNONYMS	SRY-box 5; LAMSHF; L-SOX5F; L-SOX5B; L-SOX5
T49085	FUNCTION	Activates transcription of COL2A1 and AGC1 in vitro. Binds specifically to the DNA sequence 5'-AACAAT-3'.
T49085	SEQUENCE	MLTDPDLPQEFERMSSKRPASPYGEADGEVAMVTSRQKVEEEESDGLPAFHLPLHVSFPNKPHSEEFQPVSLLTQETCGHRTPTSQHNTMEVDGNKVMSSFAPHNSSTSPQKAEEGGRQSGESLSSTALGTPERRKGSLADVVDTLKQRKMEELIKNEPEETPSIEKLLSKDWKDKLLAMGSGNFGEIKGTPESLAEKERQLMGMINQLTSLREQLLAAHDEQKKLAASQIEKQRQQMELAKQQQEQIARQQQQLLQQQHKINLLQQQIQVQGQLPPLMIPVFPPDQRTLAAAAQQGFLLPPGFSYKAGCSDPYPVQLIPTTMAAAAAATPGLGPLQLQQLYAAQLAAMQVSPGGKLPGIPQGNLGAAVSPTSIHTDKSTNSPPPKSKDEVAQPLNLSAKPKTSDGKSPTSPTSPHMPALRINSGAGPLKASVPAALASPSARVSTIGYLNDHDAVTKAIQEARQMKEQLRREQQVLDGKVAVVNSLGLNNCRTEKEKTTLESLTQQLAVKQNEEGKFSHAMMDFNLSGDSDGSAGVSESRIYRESRGRGSNEPHIKRPMNAFMVWAKDERRKILQAFPDMHNSNISKILGSRWKAMTNLEKQPYYEEQARLSKQHLEKYPDYKYKPRPKRTCLVDGKKLRIGEYKAIMRNRRQEMRQYFNVGQQAQIPIATAGVVYPGAIAMAGMPSPHLPSEHSSVSSSPEPGMPVIQSTYGVKGEEPHIKEEIQAEDINGEIYDEYDEEEDDPDVDYGSDSENHIAGQAN

T62977	TARGETID	T62977
T62977	FORMERID	TTDR00067
T62977	UNIPROID	RBBA_ECOLI
T62977	TARGNAME	Bacterial Ribosomal ATPase RbbA (Bact rbbA)
T62977	GENENAME	Bact rbbA
T62977	TARGTYPE	Literature-reported
T62977	SYNONYMS	Ribosome-associated ATPase; Ribosomal bound ATPase
T62977	FUNCTION	Exhibits an intrinsic ATPase activity that is stimulated by both 70S ribosomes and 30S ribosomal subunits. Could be involved in protein-chain elongation and in release of deacyl-tRNA from ribosomes after peptide bond synthesis. Stimulates the synthesis of polyphenylalanine in vitro.
T62977	SEQUENCE	MTHLELVPVPPVAQLAGVSQHYGKTVALNNITLDIPARCMVGLIGPDGVGKSSLLSLISGARVIEQGNVMVLGGDMRDPKHRRDVCPRIAWMPQGLGKNLYHTLSVYENVDFFARLFGHDKAEREVRINELLTSTGLAPFRDRPAGKLSGGMKQKLGLCCALIHDPELLILDEPTTGVDPLSRSQFWDLIDSIRQRQSNMSVLVATAYMEEAERFDWLVAMNAGEVLATGSAEELRQQTQSATLEEAFINLLPQAQRQAHQAVVIPPYQPENAEIAIEARDLTMRFGSFVAVDHVNFRIPRGEIFGFLGSNGCGKSTTMKMLTGLLPASEGEAWLFGQPVDPKDIDTRRRVGYMSQAFSLYNELTVRQNLELHARLFHIPEAEIPARVAEMSERFKLNDVEDILPESLPLGIRQRLSLAVAVIHRPEMLILDEPTSGVDPVARDMFWQLMVDLSRQDKVTIFISTHFMNEAERCDRISLMHAGKVLASGTPQELVEKRGAASLEEAFIAYLQEAAGQSNEAEAPPVVHDTTHAPRQGFSLRRLFSYSRREALELRRDPVRSTLALMGTVILMLIMGYGISMDVENLRFAVLDRDQTVSSQAWTLNLSGSRYFIEQPPLTSYDELDRRMRAGDITVAIEIPPNFGRDIARGTPVELGVWIDGAMPSRAETVKGYVQAMHQSWLQDVASRQSTPASQSGLMNIETRYRYNPDVKSLPAIVPAVIPLLLMMIPSMLSALSVVREKELGSIINLYVTPTTRSEFLLGKQLPYIALGMLNFFLLCGLSVFVFGVPHKGSFLTLTLAALLYIIIATGMGLLISTFMKSQIAAIFGTAIITLIPATQFSGMIDPVASLEGPGRWIGEVYPTSHFLTIARGTFSKALDLTDLWQLFIPLLIAIPLVMGLSILLLKKQEG
T62977	DRUGINFO	D0S6RD	Hygromycin B	Investigative

T13175	TARGETID	T13175
T13175	FORMERID	TTDI02556
T13175	UNIPROID	WNT5A_HUMAN
T13175	TARGNAME	Wnt-5a protein (WNT5A)
T13175	GENENAME	WNT5A
T13175	TARGTYPE	Literature-reported
T13175	SYNONYMS	Protein Wnt-5a
T13175	FUNCTION	Can activate or inhibit canonical Wnt signaling, depending on receptor context. In the presence of FZD4, activates beta-catenin signaling. In the presence of ROR2, inhibits the canonical Wnt pathway by promoting beta-catenin degradation through a GSK3-independent pathway which involves down-regulation of beta-catenin-induced reporter gene expression. Suppression of the canonical pathway allows chondrogenesis to occur and inhibits tumor formation. Stimulates cell migration. Decreases proliferation, migration, invasiveness and clonogenicity of carcinoma cells and may act as a tumor suppressor. Mediates motility of melanoma cells. Required during embryogenesis for extension of the primary anterior-posterior axis and for outgrowth of limbs and the genital tubercle. Inhibits type II collagen expression in chondrocytes. Ligand for members of the frizzled family of seven transmembrane receptors.
T13175	SEQUENCE	MKKSIGILSPGVALGMAGSAMSSKFFLVALAIFFSFAQVVIEANSWWSLGMNNPVQMSEVYIIGAQPLCSQLAGLSQGQKKLCHLYQDHMQYIGEGAKTGIKECQYQFRHRRWNCSTVDNTSVFGRVMQIGSRETAFTYAVSAAGVVNAMSRACREGELSTCGCSRAARPKDLPRDWLWGGCGDNIDYGYRFAKEFVDARERERIHAKGSYESARILMNLHNNEAGRRTVYNLADVACKCHGVSGSCSLKTCWLQLADFRKVGDALKEKYDSAAAMRLNSRGKLVQVNSRFNSPTTQDLVYIDPSPDYCVRNESTGSLGTQGRLCNKTSEGMDGCELMCCGRGYDQFKTVQTERCHCKFHWCCYVKCKKCTEIVDQFVCK

T82979	TARGETID	T82979
T82979	FORMERID	TTDR00631
T82979	UNIPROID	MTSA_STREE
T82979	TARGNAME	Streptococcus Metal-transporter protein PsaA (Stre-coc psaA)
T82979	GENENAME	Stre-coc psaA
T82979	TARGTYPE	Literature-reported
T82979	SYNONYMS	Pneumococcal surface adhesin A
T82979	FUNCTION	Part of an ATP-driven transport system for manganese. Also act as an adhesin which is involved on adherence to extracellular matrix. It is an important factor in pathogenesis and infection.
T82979	SEQUENCE	MKKIASVLALFVALLFGLLACSKGTSSKSSSDKLKVVTTNSILADITKNIAGDKIELHSIVPVGQDPHEYEPLPEDVKKTSQADLIFYNGINLETGGNAWFTKLVKNANKVENKDYFAASDGVEVIYLEGQNQAGKEDPHAWLNLENGIIYAKNIAKQLIAKDPKNKDFYEKNLAAYTEKLSKLDQEAKQAFNNIPAEKKMIVTSEGCFKYFSKAYGVPSAYIWEINTEVEGTPEQIKTLLEKLRQTKVPSLFVESSVDERPMKTVSKDSNIPIFAKIFTDSIAKEGEEGDSYYSMMKWNLEKIAEGLNK

T51569	TARGETID	T51569
T51569	FORMERID	TTDR00807
T51569	UNIPROID	MUC18_HUMAN
T51569	TARGNAME	Cell surface glycoprotein MUC18 (MCAM)
T51569	GENENAME	MCAM
T51569	TARGTYPE	Literature-reported
T51569	SYNONYMS	S-endo 1 endothelial-associated antigen; Melanoma-associated antigen MUC18; Melanoma-associated antigen A32; Melanoma cell adhesion molecule; Melanoma adhesion molecule; MUC18; Cell surface glycoprotein P1H12; CD146 antigen; CD146
T51569	FUNCTION	Its expression may allow melanoma cells to interact with cellular elements of the vascular system, thereby enhancing hematogeneous tumor spread. Could be an adhesion molecule active in neural crest cells during embryonic development. Acts as surface receptor that triggers tyrosine phosphorylation of FYN and PTK2/FAK1, and a transient increase in the intracellular calcium concentration. Plays a role in cell adhesion, and in cohesion of the endothelial monolayer at intercellular junctions in vascular tissue.
T51569	SEQUENCE	MGLPRLVCAFLLAACCCCPRVAGVPGEAEQPAPELVEVEVGSTALLKCGLSQSQGNLSHVDWFSVHKEKRTLIFRVRQGQGQSEPGEYEQRLSLQDRGATLALTQVTPQDERIFLCQGKRPRSQEYRIQLRVYKAPEEPNIQVNPLGIPVNSKEPEEVATCVGRNGYPIPQVIWYKNGRPLKEEKNRVHIQSSQTVESSGLYTLQSILKAQLVKEDKDAQFYCELNYRLPSGNHMKESREVTVPVFYPTEKVWLEVEPVGMLKEGDRVEIRCLADGNPPPHFSISKQNPSTREAEEETTNDNGVLVLEPARKEHSGRYECQGLDLDTMISLLSEPQELLVNYVSDVRVSPAAPERQEGSSLTLTCEAESSQDLEFQWLREETGQVLERGPVLQLHDLKREAGGGYRCVASVPSIPGLNRTQLVNVAIFGPPWMAFKERKVWVKENMVLNLSCEASGHPRPTISWNVNGTASEQDQDPQRVLSTLNVLVTPELLETGVECTASNDLGKNTSILFLELVNLTTLTPDSNTTTGLSTSTASPHTRANSTSTERKLPEPESRGVVIVAVIVCILVLAVLGAVLYFLYKKGKLPCRRSGKQEITLPPSRKSELVVEVKSDKLPEEMGLLQGSSGDKRAPGDQGEKYIDLRH

T93848	TARGETID	T93848
T93848	UNIPROID	MAGA2_HUMAN
T93848	TARGNAME	Melanoma-associated antigen 2 (MAGEA2)
T93848	GENENAME	MAGEA2
T93848	TARGTYPE	Literature-reported
T93848	SYNONYMS	MAGEA2B; MAGEA2A; MAGE2; MAGE-2 antigen; Cancer/testis antigen 1.2; CT1.2
T93848	FUNCTION	Represses p73/TP73 activity. Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. In vitro enhances ubiquitin ligase activity of TRIM28 and stimulates p53/TP53 ubiquitination by TRIM28 potentially in presence of Ubl-conjugating enzyme UBE2H. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex. May play a role in embryonal development and tumor transformation or aspects of tumor progression. In vitro promotes cell viability in melanoma cell lines. Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes. Negatively regulates acetylation and sumoylation of PML and represses PML-induced p53/TP53 acetylation and activation. Reduces p53/TP53 transactivation function through recruitment of HDAC3 to p53/TP53 transcription sites.
T93848	SEQUENCE	MPLEQRSQHCKPEEGLEARGEALGLVGAQAPATEEQQTASSSSTLVEVTLGEVPAADSPSPPHSPQGASSFSTTINYTLWRQSDEGSSNQEEEGPRMFPDLESEFQAAISRKMVELVHFLLLKYRAREPVTKAEMLESVLRNCQDFFPVIFSKASEYLQLVFGIEVVEVVPISHLYILVTCLGLSYDGLLGDNQVMPKTGLLIIVLAIIAIEGDCAPEEKIWEELSMLEVFEGREDSVFAHPRKLLMQDLVQENYLEYRQVPGSDPACYEFLWGPRALIETSYVKVLHHTLKIGGEPHISYPPLHERALREGEE

T13484	TARGETID	T13484
T13484	FORMERID	TTDI03358
T13484	UNIPROID	LPAR6_HUMAN
T13484	TARGNAME	Lysophosphatidic acid receptor 6 (LPAR6)
T13484	GENENAME	LPAR6
T13484	TARGTYPE	Literature-reported
T13484	SYNONYMS	RB intron encoded G-protein coupled receptor; Purinergic receptor 5; P2Y5; P2Y purinoceptor 5; P2RY5; Oleoyl-L-alpha-lysophosphatidic acid receptor; LPA-6; LPA receptor 6
T13484	FUNCTION	Binds to oleoyl-L-alpha-lysophosphatidic acid (LPA). Intracellular cAMP is involved in the receptor activation. Important for the maintenance of hair growth and texture.
T13484	SEQUENCE	MVSVNSSHCFYNDSFKYTLYGCMFSMVFVLGLISNCVAIYIFICVLKVRNETTTYMINLAMSDLLFVFTLPFRIFYFTTRNWPFGDLLCKISVMLFYTNMYGSILFLTCISVDRFLAIVYPFKSKTLRTKRNAKIVCTGVWLTVIGGSAPAVFVQSTHSQGNNASEACFENFPEATWKTYLSRIVIFIEIVGFFIPLILNVTCSSMVLKTLTKPVTLSRSKINKTKVLKMIFVHLIIFCFCFVPYNINLILYSLVRTQTFVNCSVVAAVRTMYPITLCIAVSNCCFDPIVYYFTSDTIQNSIKMKNWSVRRSDFRFSEVHGAENFIQHNLQTLKSKIFDNESAA
T13484	DRUGINFO	D0X0UR	LPA	Investigative

T31227	TARGETID	T31227
T31227	FORMERID	TTDI03238
T31227	UNIPROID	GPR3_HUMAN
T31227	TARGNAME	G protein-coupled receptor 3 (GPR3)
T31227	GENENAME	GPR3
T31227	TARGTYPE	Literature-reported
T31227	SYNONYMS	G-protein coupled receptor 3; ACCA orphan receptor; ACCA
T31227	FUNCTION	Orphan receptor with constitutive G(s) signaling activity that activate cyclic AMP. Has a potential role in modulating a number of brain functions, including behavioral responses to stress (By similarity), amyloid-beta peptide generation in neurons and neurite outgrowth (By similarity). Maintains also meiotic arrest in oocytes (By similarity).
T31227	SEQUENCE	MMWGAGSPLAWLSAGSGNVNVSSVGPAEGPTGPAAPLPSPKAWDVVLCISGTLVSCENALVVAIIVGTPAFRAPMFLLVGSLAVADLLAGLGLVLHFAAVFCIGSAEMSLVLVGVLAMAFTASIGSLLAITVDRYLSLYNALTYYSETTVTRTYVMLALVWGGALGLGLLPVLAWNCLDGLTTCGVVYPLSKNHLVVLAIAFFMVFGIMLQLYAQICRIVCRHAQQIALQRHLLPASHYVATRKGIATLAVVLGAFAACWLPFTVYCLLGDAHSPPLYTYLTLLPATYNSMINPIIYAFRNQDVQKVLWAVCCCCSSSKIPFRSRSPSDV
T31227	DRUGINFO	D0N0GJ	diphenyleneiodonium chloride	Investigative

T00569	TARGETID	T00569
T00569	FORMERID	TTDI03417
T00569	UNIPROID	SO1A2_HUMAN
T00569	TARGNAME	Sodium-independent organic anion transporter (SLCO1A2)
T00569	GENENAME	SLCO1A2
T00569	TARGTYPE	Literature-reported
T00569	SYNONYMS	Solute carrier organic anion transporter family member 1A2; Solute carrier family 21 member 3; SLC21A3; Organic anion-transporting polypeptide 1; OATP1A2; OATP-A; OATP-1; OATP
T00569	FUNCTION	Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
T00569	SEQUENCE	MGETEKRIETHRIRCLSKLKMFLLAITCAFVSKTLSGSYMNSMLTQIERQFNIPTSLVGFINGSFEIGNLLLIIFVSYFGTKLHRPIMIGIGCVVMGLGCFLKSLPHFLMNQYEYESTVSVSGNLSSNSFLCMENGTQILRPTQDPSECTKEVKSLMWVYVLVGNIVRGMGETPILPLGISYIEDFAKFENSPLYIGLVETGAIIGPLIGLLLASFCANVYVDTGFVNTDDLIITPTDTRWVGAWWFGFLICAGVNVLTAIPFFFLPNTLPKEGLETNADIIKNENEDKQKEEVKKEKYGITKDFLPFMKSLSCNPIYMLFILVSVIQFNAFVNMISFMPKYLEQQYGISSSDAIFLMGIYNLPPICIGYIIGGLIMKKFKITVKQAAHIGCWLSLLEYLLYFLSFLMTCENSSVVGINTSYEGIPQDLYVENDIFADCNVDCNCPSKIWDPVCGNNGLSYLSACLAGCETSIGTGINMVFQNCSCIQTSGNSSAVLGLCDKGPDCSLMLQYFLILSAMSSFIYSLAAIPGYMVLLRCMKSEEKSLGVGLHTFCTRVFAGIPAPIYFGALMDSTCLHWGTLKCGESGACRIYDSTTFRYIYLGLPAALRGSSFVPALIILILLRKCHLPGENASSGTELIETKVKGKENECKDIYQKSTVLKDDELKTKL
T00569	DRUGINFO	D09VQM	naringin	Investigative
T00569	DRUGINFO	D04AXP	[3H]estrone-3-sulphate	Investigative

T37360	TARGETID	T37360
T37360	FORMERID	TTDI03230
T37360	UNIPROID	GPR12_HUMAN
T37360	TARGNAME	G-protein coupled receptor 12 (GPR12)
T37360	GENENAME	GPR12
T37360	TARGTYPE	Literature-reported
T37360	SYNONYMS	G-protein coupled receptor 12
T37360	FUNCTION	Promotes neurite outgrowth and blocks myelin inhibition in neurons (By similarity). Receptor with constitutive G(s) signaling activity that stimulates cyclic AMP production.
T37360	SEQUENCE	MNEDLKVNLSGLPRDYLDAAAAENISAAVSSRVPAVEPEPELVVNPWDIVLCTSGTLISCENAIVVLIIFHNPSLRAPMFLLIGSLALADLLAGIGLITNFVFAYLLQSEATKLVTIGLIVASFSASVCSLLAITVDRYLSLYYALTYHSERTVTFTYVMLVMLWGTSICLGLLPVMGWNCLRDESTCSVVRPLTKNNAAILSVSFLFMFALMLQLYIQICKIVMRHAHQIALQHHFLATSHYVTTRKGVSTLAIILGTFAACWMPFTLYSLIADYTYPSIYTYATLLPATYNSIINPVIYAFRNQEIQKALCLICCGCIPSSLAQRARSPSDV
T37360	DRUGINFO	D0J4NQ	sphingosylphosphorylcholine	Investigative

T08446	TARGETID	T08446
T08446	FORMERID	TTDI03052
T08446	UNIPROID	S6A12_HUMAN
T08446	TARGNAME	Na(+)/Cl(-) betaine/GABA transporter (SLC6A12)
T08446	GENENAME	SLC6A12
T08446	TARGTYPE	Literature-reported
T08446	SYNONYMS	Solute carrier family 6 member 12; Sodium- and chloride-dependent betaine transporter; BGT-1
T08446	FUNCTION	Transports betaine and GABA. May have a role in regulation of GABAergic transmission in the brain through the reuptake of GABA into presynaptic terminals, as well as in osmotic regulation.
T08446	SEQUENCE	MDGKVAVQECGPPAVSWVPEEGEKLDQEDEDQVKDRGQWTNKMEFVLSVAGEIIGLGNVWRFPYLCYKNGGGAFFIPYFIFFFVCGIPVFFLEVALGQYTSQGSVTAWRKICPLFQGIGLASVVIESYLNVYYIIILAWALFYLFSSFTSELPWTTCNNFWNTEHCTDFLNHSGAGTVTPFENFTSPVMEFWERRVLGITSGIHDLGSLRWELALCLLLAWVICYFCIWKGVKSTGKVVYFTATFPYLMLVILLIRGVTLPGAYQGIIYYLKPDLFRLKDPQVWMDAGTQIFFSFAICQGCLTALGSYNKYHNNCYKDCIALCFLNSATSFVAGFVVFSILGFMSQEQGVPISEVAESGPGLAFIAFPKAVTMMPLSQLWSCLFFIMLIFLGLDSQFVCVECLVTASIDMFPRQLRKSGRRELLILTIAVMCYLIGLFLVTEGGMYIFQLFDYYASSGICLLFLSLFEVVCISWVYGADRFYDNIEDMIGYRPWPLVKISWLFLTPGLCLATFLFSLSKYTPLKYNNVYVYPPWGYSIGWFLALSSMVCVPLFVVITLLKTRGPFRKRLRQLITPDSSLPQPKQHPCLDGSAGRNFGPSPTREGLIAGEKETHL
T08446	DRUGINFO	D0P3KI	NNC052090	Investigative
T08446	DRUGINFO	D02SDM	LU32-176B	Investigative
T08446	DRUGINFO	D0H2HC	(R/S) EF-1500	Investigative
T08446	DRUGINFO	D0I7AL	(R)-EF-1520	Investigative
T08446	DRUGINFO	D0WT5D	(S)-EF-1520	Investigative

T30163	TARGETID	T30163
T30163	FORMERID	TTDI03192
T30163	UNIPROID	EAA4_HUMAN
T30163	TARGNAME	Excitatory amino acid transporter 4 (SLC1A6)
T30163	GENENAME	SLC1A6
T30163	TARGTYPE	Literature-reported
T30163	SYNONYMS	Solute carrier family 1 member 6; Sodium-dependent glutamate/aspartate transporter; EAAT4
T30163	FUNCTION	Sodium-dependent, high-affinity amino acid transporter that mediates the uptake of L-glutamate and also L-aspartate and D-aspartate. Functions as a symporter that transports one amino acid molecule together with two or three Na(+) ions and one proton, in parallel with the counter-transport of one K(+) ion. Mediates Cl(-) flux that is not coupled to amino acid transport; this avoids the accumulation of negative charges due to aspartate and Na(+) symport (By similarity). Plays a redundant role in the rapid removal of released glutamate from the synaptic cleft, which is essential for terminating the postsynaptic action of glutamate (Probable).
T30163	SEQUENCE	MSSHGNSLFLRESGQRLGRVGWLQRLQESLQQRALRTRLRLQTMTLEHVLRFLRRNAFILLTVSAVVIGVSLAFALRPYQLTYRQIKYFSFPGELLMRMLQMLVLPLIVSSLVTGMASLDNKATGRMGMRAAVYYMVTTIIAVFIGILMVTIIHPGKGSKEGLHREGRIETIPTADAFMDLIRNMFPPNLVEACFKQFKTQYSTRVVTRTMVRTENGSEPGASMPPPFSVENGTSFLENVTRALGTLQEMLSFEETVPVPGSANGINALGLVVFSVAFGLVIGGMKHKGRVLRDFFDSLNEAIMRLVGIIIWYAPVGILFLIAGKILEMEDMAVLGGQLGMYTLTVIVGLFLHAGIVLPLIYFLVTHRNPFPFIGGMLQALITAMGTSSSSATLPITFRCLEEGLGVDRRITRFVLPVGATVNMDGTALYEALAAIFIAQVNNYELNLGQITTISITATAASVGAAGIPQAGLVTMVIVLTSVGLPTEDITLIIAVDWFLDRLRTMTNVLGDSIGAAVIEHLSQRELELQEAELTLPSLGKPYKSLMAQEKGASRGRGGNESAM
T30163	DRUGINFO	D04MSI	threo-3-methylglutamate	Investigative
T30163	DRUGINFO	D07CIW	[3H]ETB-TBOA	Investigative
T30163	DRUGINFO	D07GUB	DL-TBOA	Investigative
T30163	DRUGINFO	D08CAB	D-aspartic acid	Investigative

T97135	TARGETID	T97135
T97135	FORMERID	TTDI02532
T97135	UNIPROID	NEST_HUMAN
T97135	TARGNAME	Nestin (NES)
T97135	GENENAME	NES
T97135	TARGTYPE	Literature-reported
T97135	SYNONYMS	Nbla00170
T97135	FUNCTION	Promotes the disassembly of phosphorylated vimentin intermediate filaments (IF) during mitosis and may play a role in the trafficking and distribution of IF proteins and other cellular factors to daughter cells during progenitor cell division. Required for survival, renewal and mitogen-stimulated proliferation of neural progenitor cells. Required for brain and eye development.
T97135	SEQUENCE	MEGCMGEESFQMWELNRRLEAYLARVKALEEQNELLSAELGGLRAQSADTSWRAHADDELAALRALVDQRWREKHAAEVARDNLAEELEGVAGRCQQLRLARERTTEEVARNRRAVEAEKCARAWLSSQVAELERELEALRVAHEEERVGLNAQAACAPRCPAPPRGPPAPAPEVEELARRLGEAWRGAVRGYQERVAHMETSLGQARERLGRAVQGAREGRLELQQLQAERGGLLERRAALEQRLEGRWQERLRATEKFQLAVEALEQEKQGLQSQIAQVLEGRQQLAHLKMSLSLEVATYRTLLEAENSRLQTPGGGSKTSLSFQDPKLELQFPRTPEGRRLGSLLPVLSPTSLPSPLPATLETPVPAFLKNQEFLQARTPTLASTPIPPTPQAPSPAVDAEIRAQDAPLSLLQTQGGRKQAPEPLRAEARVAIPASVLPGPEEPGGQRQEASTGQSPEDHASLAPPLSPDHSSLEAKDGESGGSRVFSICRGEGEGQIWGLVEKETAIEGKVVSSLQQEIWEEEDLNRKEIQDSQVPLEKETLKSLGEEIQESLKTLENQSHETLERENQECPRSLEEDLETLKSLEKENKELLKDVEVVRPLEKEAVGQLKPTGKEDTQTLQSLQKENQELMKSLEGNLETFLFPGTENQELVSSLQENLESLTALEKENQEPLRSPEVGDEEALRPLTKENQEPLRSLEDENKEAFRSLEKENQEPLKTLEEEDQSIVRPLETENHKSLRSLEEQDQETLRTLEKETQQRRRSLGEQDQMTLRPPEKVDLEPLKSLDQEIARPLENENQEFLKSLKEESVEAVKSLETEILESLKSAGQENLETLKSPETQAPLWTPEEINQGAMNPLEKEIQEPLESVEVNQETFRLLEEENQESLRSLGAWNLENLRSPEEVDKESQRNLEEEENLGKGEYQESLRSLEEEGQELPQSADVQRWEDTVEKDQELAQESPPGMAGVENEDEAELNLREQDGFTGKEEVVEQGELNATEEVWIPGEGHPESPEPKEQRGLVEGASVKGGAEGLQDPEGQSQQVGAPGLQAPQGLPEAIEPLVEDDVAPGGDQASPEVMLGSEPAMGESAAGAEPGPGQGVGGLGDPGHLTREEVMEPPLEEESLEAKRVQGLEGPRKDLEEAGGLGTEFSELPGKSRDPWEPPREGREESEAEAPRGAEEAFPAETLGHTGSDAPSPWPLGSEEAEEDVPPVLVSPSPTYTPILEDAPGPQPQAEGSQEASWGVQGRAEALGKVESEQEELGSGEIPEGPQEEGEESREESEEDELGETLPDSTPLGFYLRSPTSPRWDPTGEQRPPPQGETGKEGWDPAVLASEGLEAPPSEKEEGEEGEEECGRDSDLSEEFEDLGTEAPFLPGVPGEVAEPLGQVPQLLLDPAAWDRDGESDGFADEEESGEEGEEDQEEGREPGAGRWGPGSSVGSLQALSSSQRGEFLESDSVSVSVPWDDSLRGAVAGAPKTALETESQDSAEPSGSEEESDPVSLEREDKVPGPLEIPSGMEDAGPGADIIGVNGQGPNLEGKSQHVNGGVMNGLEQSEEVGQGMPLVSEGDRGSPFQEEEGSALKTSWAGAPVHLGQGQFLKFTQREGDRESWSSGED

T93580	TARGETID	T93580
T93580	FORMERID	TTDI03512
T93580	UNIPROID	RGS4_HUMAN
T93580	TARGNAME	Regulator of G-protein signaling 4 (RGS4)
T93580	GENENAME	RGS4
T93580	TARGTYPE	Literature-reported
T93580	SYNONYMS	RGP4
T93580	FUNCTION	Activity on G(z)-alpha is inhibited by phosphorylation of the G-protein. Activity on G(z)-alpha and G(i)-alpha-1 is inhibited by palmitoylation of the G-protein. Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits thereby driving them into their inactive GDP-bound form.
T93580	SEQUENCE	MCKGLAGLPASCLRSAKDMKHRLGFLLQKSDSCEHNSSHNKKDKVVICQRVSQEEVKKWAESLENLISHECGLAAFKAFLKSEYSEENIDFWISCEEYKKIKSPSKLSPKAKKIYNEFISVQATKEVNLDSCTREETSRNMLEPTITCFDEAQKKIFNLMEKDSYRRFLKSRFYLDLVNPSSCGAEKQKGAKSSADCASLVPQCA
T93580	DRUGINFO	D05AMQ	thiadiazolidinone (TDZD) deriv. 6	Investigative
T93580	DRUGINFO	D0C2GR	CCG-50014	Investigative
T93580	DRUGINFO	D0M5DR	RGS4 inhibitor 13	Investigative

T16459	TARGETID	T16459
T16459	FORMERID	TTDR00475
T16459	UNIPROID	CDN1C_HUMAN
T16459	TARGNAME	CDK inhibitor 1C p57Kip2 (CDKN1C)
T16459	GENENAME	CDKN1C
T16459	TARGTYPE	Literature-reported
T16459	SYNONYMS	P57KIP2; P57(KIP2); KIP2; Cyclin-dependent kinase inhibitor p57; Cyclin-dependent kinase inhibitor 1C
T16459	FUNCTION	Negative regulator of cell proliferation. May play a role in maintenance of the non-proliferative state throughout life. Potent tight-binding inhibitor of several G1 cyclin/CDK complexes (cyclin E-CDK2, cyclin D2-CDK4, and cyclin A-CDK2) and, to lesser extent, of the mitotic cyclin B-CDC2.
T16459	SEQUENCE	MSDASLRSTSTMERLVARGTFPVLVRTSACRSLFGPVDHEELSRELQARLAELNAEDQNRWDYDFQQDMPLRGPGRLQWTEVDSDSVPAFYRETVQVGRCRLLLAPRPVAVAVAVSPPLEPAAESLDGLEEAPEQLPSVPVPAPASTPPPVPVLAPAPAPAPAPVAAPVAAPVAVAVLAPAPAPAPAPAPAPAPVAAPAPAPAPAPAPAPAPAPAPDAAPQESAEQGANQGQRGQEPLADQLHSGISGRPAAGTAAASANGAAIKKLSGPLISDFFAKRKRSAPEKSSGDVPAPCPSPSAAPGVGSVEQTPRKRLR

T12290	TARGETID	T12290
T12290	FORMERID	TTDR00985
T12290	UNIPROID	GNAQ_HUMAN
T12290	TARGNAME	Guanine nucleotide-binding alpha-q (GNAQ)
T12290	GENENAME	GNAQ
T12290	TARGTYPE	Literature-reported
T12290	SYNONYMS	GNAQ; G alphaq; G alpha(q)
T12290	FUNCTION	Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signaling systems. Regulates B-cell selection and survival and is required to prevent B-cell-dependent autoimmunity. Regulates chemotaxis of BM-derived neutrophils and dendritic cells (in vitro).
T12290	SEQUENCE	MTLESIMACCLSEEAKEARRINDEIERQLRRDKRDARRELKLLLLGTGESGKSTFIKQMRIIHGSGYSDEDKRGFTKLVYQNIFTAMQAMIRAMDTLKIPYKYEHNKAHAQLVREVDVEKVSAFENPYVDAIKSLWNDPGIQECYDRRREYQLSDSTKYYLNDLDRVADPAYLPTQQDVLRVRVPTTGIIEYPFDLQSVIFRMVDVGGQRSERRKWIHCFENVTSIMFLVALSEYDQVLVESDNENRMEESKALFRTIITYPWFQNSSVILFLNKKDLLEEKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDSDKIIYSHFTCATDTENIRFVFAAVKDTILQLNLKEYNLV

T56104	TARGETID	T56104
T56104	FORMERID	TTDR01299
T56104	UNIPROID	SERPH_HUMAN
T56104	TARGNAME	Rheumatoid arthritis-related antigen RA-A47 (SERPINH1)
T56104	GENENAME	SERPINH1
T56104	TARGTYPE	Literature-reported
T56104	SYNONYMS	Serpin H1; SERPINH2; PIG14; HSP47; Colligin; Collagen-binding protein; Cell proliferation-inducing gene 14 protein; CBP2; CBP1; AsTP3; Arsenic-transactivated protein 3; 47 kDa heat shock protein
T56104	FUNCTION	Binds specifically to collagen. Could be involved as a chaperone in the biosynthetic pathway of collagen.
T56104	SEQUENCE	MRSLLLLSAFCLLEAALAAEVKKPAAAAAPGTAEKLSPKAATLAERSAGLAFSLYQAMAKDQAVENILVSPVVVASSLGLVSLGGKATTASQAKAVLSAEQLRDEEVHAGLGELLRSLSNSTARNVTWKLGSRLYGPSSVSFADDFVRSSKQHYNCEHSKINFRDKRSALQSINEWAAQTTDGKLPEVTKDVERTDGALLVNAMFFKPHWDEKFHHKMVDNRGFMVTRSYTVGVMMMHRTGLYNYYDDEKEKLQIVEMPLAHKLSSLIILMPHHVEPLERLEKLLTKEQLKIWMGKMQKKAVAISLPKGVVEVTHDLQKHLAGLGLTEAIDKNKADLSRMSGKKDLYLASVFHATAFELDTDGNPFDQDIYGREELRSPKLFYADHPFIFLVRDTQSGSLLFIGRLVRPKGDKMRDEL

T69091	TARGETID	T69091
T69091	FORMERID	TTDI03435
T69091	UNIPROID	P2RX1_HUMAN
T69091	TARGNAME	P2X purinoceptor 1 (P2RX1)
T69091	GENENAME	P2RX1
T69091	TARGTYPE	Literature-reported
T69091	SYNONYMS	Purinergic receptor 1; P2X1
T69091	FUNCTION	Ligand-gated ion channel with relatively high calcium permeability. Binding to ATP mediates synaptic transmission between neurons and from neurons to smooth muscle. Seems to be linked to apoptosis, by increasing the intracellular concentration of calcium in the presence of ATP, leading to programmed cell death (By similarity).
T69091	SEQUENCE	MARRFQEELAAFLFEYDTPRMVLVRNKKVGVIFRLIQLVVLVYVIGWVFLYEKGYQTSSGLISSVSVKLKGLAVTQLPGLGPQVWDVADYVFPAQGDNSFVVMTNFIVTPKQTQGYCAEHPEGGICKEDSGCTPGKAKRKAQGIRTGKCVAFNDTVKTCEIFGWCPVEVDDDIPRPALLREAENFTLFIKNSISFPRFKVNRRNLVEEVNAAHMKTCLFHKTLHPLCPVFQLGYVVQESGQNFSTLAEKGGVVGITIDWHCDLDWHVRHCRPIYEFHGLYEEKNLSPGFNFRFARHFVENGTNYRHLFKVFGIRFDILVDGKAGKFDIIPTMTTIGSGIGIFGVATVLCDLLLLHILPKRHYYKQKKFKYAEDMGPGAAERDLAATSSTLGLQENMRTS
T69091	DRUGINFO	D03EEO	MRS 2219	Investigative
T69091	DRUGINFO	D0B7MW	NF023	Investigative
T69091	DRUGINFO	D0D9AA	NF449	Investigative
T69091	DRUGINFO	D0Q1BD	Ip5I	Investigative
T69091	DRUGINFO	D01VVM	TNP-ATP	Investigative
T69091	DRUGINFO	D06HDW	BzATP	Investigative
T69091	DRUGINFO	D0UG4S	L-betagamma-meATP	Investigative

T48166	TARGETID	T48166
T48166	FORMERID	TTDI00152
T48166	UNIPROID	HMGA2_HUMAN
T48166	TARGNAME	High mobility group protein HMGI-C (HMGA2)
T48166	GENENAME	HMGA2
T48166	TARGTYPE	Literature-reported
T48166	SYNONYMS	High mobility group AThook protein 2; High mobility group AT-hook protein 2; HMGIC
T48166	FUNCTION	Functions in cell cycle regulation through CCNA2. Plays an important role in chromosome condensation during the meiotic G2/M transition of spermatocytes. Plays a role in postnatal myogenesis, is involved in satellite cell activation. Functions as a transcriptional regulator.
T48166	SEQUENCE	MSARGEGAGQPSTSAQGQPAAPAPQKRGRGRPRKQQQEPTGEPSPKRPRGRPKGSKNKSPSKAAQKKAEATGEKRPRGRPRKWPQQVVQKKPAQEETEETSSQESAEED

T06064	TARGETID	T06064
T06064	FORMERID	TTDI03375
T06064	UNIPROID	TXTP_HUMAN
T06064	TARGNAME	Mitochondrial citrate transporter (SLC25A1)
T06064	GENENAME	SLC25A1
T06064	TARGTYPE	Literature-reported
T06064	SYNONYMS	Tricarboxylate transport protein, mitochondrial; Tricarboxylate carrier protein; Solute carrier family 25 member 1; SLC20A3; Citrate transport protein; CTP
T06064	FUNCTION	Citrate transporter that mediates the exchange of mitochondrial citrate for cytosolic malate. Also able to mediate the exchange of citrate for isocitrate, phosphoenolpyruvate, cis- but not trans-aconitate and to a lesser extend maleate and succinate. Important for the bioenergetics of hepatic cells as it provides a carbon source for fatty acid and sterol biosyntheses, and NAD(+) for the glycolytic pathway. Required for proper neuromuscular junction formation (Probable).
T06064	SEQUENCE	MPAPRAPRALAAAAPASGKAKLTHPGKAILAGGLAGGIEICITFPTEYVKTQLQLDERSHPPRYRGIGDCVRQTVRSHGVLGLYRGLSSLLYGSIPKAAVRFGMFEFLSNHMRDAQGRLDSTRGLLCGLGAGVAEAVVVVCPMETIKVKFIHDQTSPNPKYRGFFHGVREIVREQGLKGTYQGLTATVLKQGSNQAIRFFVMTSLRNWYRGDNPNKPMNPLITGVFGAIAGAASVFGNTPLDVIKTRMQGLEAHKYRNTWDCGLQILKKEGLKAFYKGTVPRLGRVCLDVAIVFVIYDEVVKLLNKVWKTD
T06064	DRUGINFO	D05UYC	1,2,3-benzenetricarboxylic acid	Investigative

T59690	TARGETID	T59690
T59690	FORMERID	TTDR00628
T59690	UNIPROID	MNN9_CANAL
T59690	TARGNAME	Candida Mannan polymerase complex MNN9 (Candi MNN9)
T59690	GENENAME	Candi MNN9
T59690	TARGTYPE	Literature-reported
T59690	SYNONYMS	MNN9; C. albicans MNN9
T59690	FUNCTION	Required for the addition of the long alpha 1,6-mannose backbone ofN-linked glycans on cell wall and periplasmic proteins.
T59690	SEQUENCE	MVHYRNRYLNYIRRKPLALLAPITLLVVIYFYFFSAHGFSSNKQKYNYNKKSRGWFYKNRDTVILKDLPKNHISHYDLNKLTASKDALNKREEVLILTPMSKFLPEYWENINKLTYDHSLISLGFIFPRTTQGDDALKELENALKKTKREKRLNFKKITILRQDSNSLQSQLEKDRHAFKVQKERRSMMALARNSLVFSTILPSTSWVLWLDADIVETPVTLIQDLTGHNKPVVSANVHQRFINQDTKQPDIRPYDFNNWVESEEGLKLAASLPDDEIIVEGYSEMVTHRALMAHFYDPKGDPSTEMTLDGVGGGAVMVKADVHRDGAMFPSFPFYHLIETEGFAKMAKRLGYEVYGLPNYLVFHYNE

T90652	TARGETID	T90652
T90652	UNIPROID	SYRC_HUMAN-MD1L1_HUMAN
T90652	TARGNAME	Fusion protein RARS-MAD1L1 (RARS-MAD1L1)
T90652	GENENAME	RARS-MAD1L1
T90652	TARGTYPE	Literature-reported
T90652	SYNONYMS	Fusion protein CArginyl-tRNA synthetase and MAD1-like protein 1
T90652	FUNCTION	RARS-MAD1L1 overexpression increased cell proliferation, colony formation, and tumorigenicity in vitro, and the silencing of endogenous RARS-MAD1L1 reduced cancer cell growth and colony formation in vitro. In addition, RARS-MAD1L1 increased the side population (SP) ratio and induced chemo- and radioresistance. Furthermore RARS-MAD1L1 interacted with AIMP2, which resulted in activation of FUBP1/c-Myc pathway.
T90652	SEQUENCE	MEDLGENTMVLSTLRSLNNFISQRVEGGSGLDISTSAPGSLQMQYQQSMQLEERAEQIRSKSHLIQVEREKMQMELSHKRARVELERAASTSARNYEREVDRNQELLTRIRQLQEREAGAEEKMQEQLERNRQCQQNLDAASKRLREKEDSLAQAGETINALKGRISELQWSVMDQEMRVKRLESEKQELQEQLDLQHKKCQEANQKIQELQASQEARADHEQQIKDLEQKLSLQEQDAAIVKNMKSELVRLPRLERELKQLREESAHLREMRETNGLLQEELEGLQRKLGRQEKMQETLVGLELENERLLAKLQSWERLDQTMGLSIRTPEDLSRFVVELQQRELALKDKNSAVTSSARGLEKARQQLQEELRQVSGQLLEERKKRETHEALARRLQKRVLLLTKERDGMRAILGSYDSELTPAEYSPQLTRRMREAEDMVQKVHSHSAEMEAQLSQALEELGGQKQRADMLEMELKMLKSQSSSAEQSFLFSREEADTLRLKVEELEGERSRLEEEKRMLEAQLERRALQGDYDQSRTKVLHMSLNPTSVARQRLREDHSQLQAECERLRGLLRAMERGGTVPADLEAAAASLPSSKEVAELKKQVESAELKNQRLKEVFQTKIQEFRKACYTLTGYQIDITTENQYRLTSLYAEHPGDCLIFKATSPSGSKMQLLETEFSHTVGELIEVHLRRQDSIPAFLSSLTLELFSRQTVAMDVLVSECSARLLQQEEEIKSLTAEIDRLKNCGCLGASPNLEQLQEENLKLKYRLNILRKSLQAERNKPTKNMINIISRLQEVFGHAIKAAYPDLENPPLLVTPSQQAKFGDYQCNSAMGISQMLKTKEQKVNPREIAENITKHLPDNECIEKVEIAGPGFINVHLRKDFVSEQLTSLLVNGVQLPALGENKKVIVDFSSPNIAKEMHVGHLRSTIIGESISRLFEFAGYDVLRLNHVGDWGTQFGMLIAHLQDKFPDYLTVSPPIGDLQVFYKESKKRFDTEEEFKKRAYQCVVLLQGKNPDITKAWKLICDVSRQELNKIYDALDVSLIERGESFYQDRMNDIVKEFEDRGFVQVDDGRKIVFVPGCSIPLTIVKSDGGYTYDTSDLAAIKQRLFEEKADMIIYVVDNGQSVHFQTIFAAAQMIGWYDPKVTRVFHAGFGVVLGEDKKKFKTRSGETVRLMDLLGEGLKRSMDKLKEKERDKVLTAEELNAAQTSVAYGCIKYADLSHNRLNDYIFSFDKMLDDRGNTAAYLLYAFTRIRSIARLANIDEEMLQKAARETKILLDHEKEWKLGRCILRFPEILQKILDDLFLHTLCDYIYELATAFTEFYDSCYCVEKDRQTGKILKVNMWRMLLCEAVAAVMAKGFDILGIKPVQRM

T05324	TARGETID	T05324
T05324	FORMERID	TTDNR00672
T05324	UNIPROID	XPO2_HUMAN
T05324	TARGNAME	Exportin-2 (CSE1L)
T05324	GENENAME	CSE1L
T05324	TARGTYPE	Literature-reported
T05324	SYNONYMS	Importin-alpha re-exporter; Exp2; Chromosome segregation 1-like protein; Cellular apoptosis susceptibility protein; CSE1L
T05324	FUNCTION	Export receptor for importin-alpha. Mediates importin- alpha re-export fromthe nucleus to the cytoplasm after import substrates (cargos) have been released into the nucleoplasm. In the nucleus binds cooperatively to importin-alpha and to the GTPase Ran in its active GTP-bound form. Docking of this trimeric complex to the nuclear pore complex (NPC) is mediated through binding to nucleoporins. Upon transit of a nuclear export complex into the cytoplasm, disassembling of the complex and hydrolysis of Ran-GTP to Ran-GDP (induced by RANBP1 and RANGAP1, respectively) cause release of the importin-alpha from the export receptor. CSE1L/XPO2 then return to the nuclear compartment and mediate another round of transport. The directionality of nuclear export is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasmand nucleus. .
T05324	SEQUENCE	MELSDANLQTLTEYLKKTLDPDPAIRRPAEKFLESVEGNQNYPLLLLTLLEKSQDNVIKVCASVTFKNYIKRNWRIVEDEPNKICEADRVAIKANIVHLMLSSPEQIQKQLSDAISIIGREDFPQKWPDLLTEMVNRFQSGDFHVINGVLRTAHSLFKRYRHEFKSNELWTEIKLVLDAFALPLTNLFKATIELCSTHANDASALRILFSSLILISKLFYSLNFQDLPEFFEDNMETWMNNFHTLLTLDNKLLQTDDEEEAGLLELLKSQICDNAALYAQKYDEEFQRYLPRFVTAIWNLLVTTGQEVKYDLLVSNAIQFLASVCERPHYKNLFEDQNTLTSICEKVIVPNMEFRAADEEAFEDNSEEYIRRDLEGSDIDTRRRAACDLVRGLCKFFEGPVTGIFSGYVNSMLQEYAKNPSVNWKHKDAAIYLVTSLASKAQTQKHGITQANELVNLTEFFVNHILPDLKSANVNEFPVLKADGIKYIMIFRNQVPKEHLLVSIPLLINHLQAESIVVHTYAAHALERLFTMRGPNNATLFTAAEIAPFVEILLTNLFKALTLPGSSENEYIMKAIMRSFSLLQEAIIPYIPTLITQLTQKLLAVSKNPSKPHFNHYMFEAICLSIRITCKANPAAVVNFEEALFLVFTEILQNDVQEFIPYVFQVMSLLLETHKNDIPSSYMALFPHLLQPVLWERTGNIPALVRLLQAFLERGSNTIASAAADKIPGLLGVFQKLIASKANDHQGFYLLNSIIEHMPPESVDQYRKQIFILLFQRLQNSKTTKFIKSFLVFINLYCIKYGALALQEIFDGIQPKMFGMVLEKIIIPEIQKVSGNVEKKICAVGITKLLTECPPMMDTEYTKLWTPLLQSLIGLFELPEDDTIPDEEHFIDIEDTPGYQTAFSQLAFAGKKEHDPVGQMVNNPKIHLAQSLHKLSTACPGRVPSMVSTSLNAEALQYLQGYLQAASVTLL

T29594	TARGETID	T29594
T29594	FORMERID	TTDR00915
T29594	UNIPROID	BI1_HUMAN
T29594	TARGNAME	Testis-enhanced gene transcript protein (TMBIM6)
T29594	GENENAME	TMBIM6
T29594	TARGTYPE	Literature-reported
T29594	SYNONYMS	Testis enhanced gene transcript; TMBIM6; BI-1
T29594	FUNCTION	Suppressor of apoptosis. Modulates unfolded protein response signaling. Modulate ER calcium homeostasis by acting as a calcium-leak channel.
T29594	SEQUENCE	MNIFDRKINFDALLKFSHITPSTQQHLKKVYASFALCMFVAAAGAYVHMVTHFIQAGLLSALGSLILMIWLMATPHSHETEQKRLGLLAGFAFLTGVGLGPALEFCIAVNPSILPTAFMGTAMIFTCFTLSALYARRRSYLFLGGILMSALSLLLLSSLGNVFFGSIWLFQANLYVGLVVMCGFVLFDTQLIIEKAEHGDQDYIWHCIDLFLDFITVFRKLMMILAMNEKDKKKEKK

T60042	TARGETID	T60042
T60042	FORMERID	TTDR00438
T60042	UNIPROID	MAZ_HUMAN
T60042	TARGNAME	Serum amyloid A-activating factor-1 (MAZ)
T60042	GENENAME	MAZ
T60042	TARGTYPE	Literature-reported
T60042	SYNONYMS	Zinc finger protein 801; ZNF801; ZF87; Transcription factor Zif87; SAF-1; Purine-binding transcription factor; Pur-1; Myc-associated zinc finger protein; MAZI
T60042	FUNCTION	May function as a transcription factor with dual roles in transcription initiation and termination. Binds to two sites, ME1a1 and ME1a2, within the MYC promoter having greater affinity for the former. Also binds to multiple G/C-rich sites within the promoter of the Sp1 family of transcription factors. Regulates inflammation-induced expression of serum amyloid A proteins.
T60042	SEQUENCE	MFPVFPCTLLAPPFPVLGLDSRGVGGLMNSFPPPQGHAQNPLQVGAELQSRFFASQGCAQSPFQAAPAPPPTPQAPAAEPLQVDLLPVLAAAQESAAAAAAAAAAAAAVAAAPPAPAAASTVDTAALKQPPAPPPPPPPVSAPAAEAAPPASAATIAAAAATAVVAPTSTVAVAPVASALEKKTKSKGPYICALCAKEFKNGYNLRRHEAIHTGAKAGRVPSGAMKMPTMVPLSLLSVPQLSGAGGGGGEAGAGGGAAAVAAGGVVTTTASGKRIRKNHACEMCGKAFRDVYHLNRHKLSHSDEKPYQCPVCQQRFKRKDRMSYHVRSHDGAVHKPYNCSHCGKSFSRPDHLNSHVRQVHSTERPFKCEKCEAAFATKDRLRAHTVRHEEKVPCHVCGKMLSSAYISDHMKVHSQGPHHVCELCNKGTGEVCPMAAAAAAAAAAAAAAVAAPPTAVGSLSGAEGVPVSSQPLPSQPW

T45357	TARGETID	T45357
T45357	FORMERID	TTDI02641
T45357	UNIPROID	BTG1_HUMAN
T45357	TARGNAME	B-cell translocation gene 1 protein (BTG1)
T45357	GENENAME	BTG1
T45357	TARGTYPE	Literature-reported
T45357	SYNONYMS	Protein BTG1
T45357	FUNCTION	Anti-proliferative protein.
T45357	SEQUENCE	MHPFYTRAATMIGEIAAAVSFISKFLRTKGLTSERQLQTFSQSLQELLAEHYKHHWFPEKPCKGSGYRCIRINHKMDPLIGQAAQRIGLSSQELFRLLPSELTLWVDPYEVSYRIGEDGSICVLYEASPAGGSTQNSTNVQMVDSRISCKEELLLGRTSPSKNYNMMTVSG

T72269	TARGETID	T72269
T72269	FORMERID	TTDR01290
T72269	UNIPROID	EF1A1_HUMAN; EF1A2_HUMAN
T72269	TARGNAME	Elongation factor 1A (EF1A)
T72269	GENENAME	EEF1A1; EEF1A2
T72269	TARGTYPE	Literature-reported
T72269	SYNONYMS	eEF1A; Eukaryotic elongation factor 1 A; Elongation factor 1-alpha; Elongation factor; EF-1-alpha
T72269	FUNCTION	This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis.
T72269	SEQUENCE	MGKEKTHINIVVIGHVDSGKSTTTGHLIYKCGGIDKRTIEKFEKEAAEMGKGSFKYAWVLDKLKAERERGITIDISLWKFETSKYYVTIIDAPGHRDFIKNMITGTSQADCAVLIVAAGVGEFEAGISKNGQTREHALLAYTLGVKQLIVGVNKMDSTEPPYSQKRYEEIVKEVSTYIKKIGYNPDTVAFVPISGWNGDNMLEPSANMPWFKGWKVTRKDGNASGTTLLEALDCILPPTRPTDKPLRLPLQDVYKIGGIGTVPVGRVETGVLKPGMVVTFAPVNVTTEVKSVEMHHEALSEALPGDNVGFNVKNVSVKDVRRGNVAGDSKNDPPMEAAGFTAQVIILNHPGQISAGYAPVLDCHTAHIACKFAELKEKIDRRSGKKLEDGPKFLKSGDAAIVDMVPGKPMCVESFSDYPPLGRFAVRDMRQTVAVGVIKAVDKKAAGAGKVTKSAQKAQKAK
T72269	DRUGINFO	D0OQ1I	Narciclasine	Investigative

T23311	TARGETID	T23311
T23311	FORMERID	TTDI03208
T23311	UNIPROID	GBRE_HUMAN
T23311	TARGNAME	GABA(A) receptor epsilon (GABRE)
T23311	GENENAME	GABRE
T23311	TARGTYPE	Literature-reported
T23311	SYNONYMS	Gamma-aminobutyric acid receptor subunit epsilon; GABA(A) receptor subunit epsilon
T23311	FUNCTION	GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
T23311	SEQUENCE	MLSKVLPVLLGILLILQSRVEGPQTESKNEASSRDVVYGPQPQPLENQLLSEETKSTETETGSRVGKLPEASRILNTILSNYDHKLRPGIGEKPTVVTVEISVNSLGPLSILDMEYTIDIIFSQTWYDERLCYNDTFESLVLNGNVVSQLWIPDTFFRNSKRTHEHEITMPNQMVRIYKDGKVLYTIRMTIDAGCSLHMLRFPMDSHSCPLSFSSFSYPENEMIYKWENFKLEINEKNSWKLFQFDFTGVSNKTEIITTPVGDFMVMTIFFNVSRRFGYVAFQNYVPSSVTTMLSWVSFWIKTESAPARTSLGITSVLTMTTLGTFSRKNFPRVSYITALDFYIAICFVFCFCALLEFAVLNFLIYNQTKAHASPKLRHPRINSRAHARTRARSRACARQHQEAFVCQIVTTEGSDGEERPSCSAQQPPSPGSPEGPRSLCSKLACCEWCKRFKKYFCMVPDCEGSTWQQGRLCIHVYRLDNYSRVVFPVTFFFFNVLYWLVCLNL
T23311	DRUGINFO	D0P0TI	TBPS	Investigative

T90665	TARGETID	T90665
T90665	UNIPROID	DLG4_HUMAN-NOS1_HUMAN
T90665	TARGNAME	PSD95-nNOS interaction (PSD95-nNOS PPI)
T90665	GENENAME	DLG4-NOS1
T90665	TARGTYPE	Literature-reported
T90665	SYNONYMS	Disks large homolog 4-Constitutive NOS interaction
T90665	FUNCTION	Functions as a novel molecular target to modulate conditioned fear: relevance to PTSD.
T90665	SEQUENCE	MEDHMFGVQQIQPNVISVRLFKRKVGGLGFLVKERVSKPPVIISDLIRGGAAEQSGLIQAGDIILAVNGRPLVDLSYDSALEVLRGIASETHVVLILRGPEGFTTHLETTFTGDGTPKTIRVTQPLGPPTKAVDLSHQPPAGKEQPLAVDGASGPGNGPQHAYDDGQEAGSLPHANGLAPRPPGQDPAKKATRVSLQGRGENNELLKEIEPVLSLLTSGSRGVKGGAPAKAEMKDMGIQVDRDLDGKSHKPLPLGVENDRVFNDLWGKGNVPVVLNNPYSEKEQPPTSGKQSPTKNGSPSKCPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVRTKGQLFPLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRCVGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVWNSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQIPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGVRDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAVLYSFQSDKVTIVDHHSATESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPSFEYQPDPWNTHVWKGTNGTPTKRRAIGFKKLAEAVKFSAKLMGQAMAKRVKATILYATETGKSQAYAKTLCEIFKHAFDAKVMSMEEYDIVHLEHETLVLVVTSTFGNGDPPENGEKFGCALMEMRHPNSVQEERKSYKVRFNSVSSYSDSQKSSGDGPDLRDNFESAGPLANVRFSVFGLGSRAYPHFCAFGHAVDTLLEELGGERILKMREGDELCGQEEAFRTWAKKVFKAACDVFCVGDDVNIEKANNSLISNDRSWKRNKFRLTFVAEAPELTQGLSNVHKKRVSAARLLSRQNLQSPKSSRSTIFVRLHTNGSQELQYQPGDHLGVFPGNHEDLVNALIERLEDAPPVNQMVKVELLEERNTALGVISNWTDELRLPPCTIFQAFKYYLDITTPPTPLQLQQFASLATSEKEKQRLLVLSKGLQEYEEWKWGKNPTIVEVLEEFPSIQMPATLLLTQLSLLQPRYYSISSSPDMYPDEVHLTVAIVSYRTRDGEGPIHHGVCSSWLNRIQADELVPCFVRGAPSFHLPRNPQVPCILVGPGTGIAPFRSFWQQRQFDIQHKGMNPCPMVLVFGCRQSKIDHIYREETLQAKNKGVFRELYTAYSREPDKPKKYVQDILQEQLAESVYRALKEQGGHIYVCGDVTMAADVLKAIQRIMTQQGKLSAEDAGVFISRMRDDNRYHEDIFGVTLRTYEVTNRLRSESIAFIEESKKDTDEVFSSMDCLCIVTTKKYRYQDEDTPPLEHSPAHLPNQANSPPVIVNTDTLEAPGYELQVNGTEGEMEYEEITLERGNSGLGFSIAGGTDNPHIGDDPSIFITKIIPGGAAAQDGRLRVNDSILFVNEVDVREVTHSAAVEALKEAGSIVRLYVMRRKPPAEKVMEIKLIKGPKGLGFSIAGGVGNQHIPGDNSIYVTKIIEGGAAHKDGRLQIGDKILAVNSVGLEDVMHEDAVAALKNTYDVVYLKVAKPSNAYLSDSYAPPDITTSYSQHLDNEISHSSYLGTDYPTAMTPTSPRRYSPVAKDLLGEEDIPREPRRIVIHRGSTGLGFNIVGGEDGEGIFISFILAGGPADLSGELRKGDQILSVNGVDLRNASHEQAAIALKNAGQTVTIIAQYKPEEYSRFEAKIHDLREQLMNSSLGSGTASLRSNPKRGFYIRALFDYDKTKDCGFLSQALSFRFGDVLHVIDASDEEWWQARRVHSDSETDDIGFIPSKRRVERREWSRLKAKDWGSSSGSQGREDSVLSYETVTQMEVHYARPIIILGPTKDRANDDLLSEFPDKFGSCVPHTTRPKREYEIDGRDYHFVSSREKMEKDIQAHKFIEAGQYNSHLYGTSVQSVREVAEQGKHCILDVSANAVRRLQAAHLHPIAIFIRPRSLENVLEINKRITEEQARKAFDRATKLEQEFTECFSAIVEGDSFEEIYHKVKRVIEDLSGPYIWVPARERL
T90665	DRUGINFO	D00SBX	ZL006	Investigative

T37328	TARGETID	T37328
T37328	FORMERID	TTDR00599
T37328	UNIPROID	P90582_PLAFA
T37328	TARGNAME	Plasmodium Histidine-rich protein II (Malaria HRP II)
T37328	GENENAME	Malaria HRP II
T37328	TARGTYPE	Literature-reported
T37328	SYNONYMS	Histidine-rich protein II
T37328	FUNCTION	Functions as a diagnostic and prognostic marker for falciparum malaria.
T37328	SEQUENCE	MVSFSKNKVLSAAVFASVLLLDNNNSAFNNNLCSKNAKGLNLNKRLLHETQAHVDDAHHAHHVADAHHAHHAADAHHAHHAADAHHAHHAADAHHAHHAADAHHAHHAAYAHHAHHAADAHHAHHASDAHHAADAHHAAYAHHAHHAADAHHAHHASDAHHAADAHHAAYAHHAHHAADAHHAADAHHATDAHHAHHAADARHATDAHHAADAHHATDAHHAADAHHAADAHHATDAHHAADAHHATDAHHAADAHHAADAHHATDAHHAHHAADAHHAAAHHATDAHHATDAHHAAAHHEAATHCLRH

T26381	TARGETID	T26381
T26381	FORMERID	TTDI00239
T26381	UNIPROID	PIMA_MYCTU
T26381	TARGNAME	Mycobacterium Phosphatidyl-myo-inositol mannosyltransferase (MycB pimA)
T26381	GENENAME	MycB pimA
T26381	TARGTYPE	Literature-reported
T26381	SYNONYMS	Phosphatidylinositol alpha-mannosyltransferase; Phosphatidyl-myo-inositol mannosyltransferase; PI alpha-mannosyltransferase; Guanosine diphosphomannose-phosphatidyl-inositol alpha-mannosyltransferase; GDP-mannose-dependent alpha-(1-2)-phosphatidylinositol mannosyltransferase; Alpha-mannosyltransferase
T26381	FUNCTION	Involved in the biosynthesis of phosphatidyl-myo-inositol mannosides (PIM) which are early precursors in the biosynthesis of lipomannans (LM) and lipoarabinomannans (LAM). Catalyzes the addition of a mannosyl residue from GDP-D-mannose (GDP-Man) to the position 2 of the carrier lipid phosphatidyl-myo-inositol (PI) to generate a phosphatidyl-myo-inositol bearing an alpha-1,2-linked mannose residue (PIM1). PimA plays an essential role for growth in macrophages and during both the acute and chronic phases of infection.
T26381	SEQUENCE	MRIGMICPYSFDVPGGVQSHVLQLAEVMRTRGHLVSVLAPASPHAALPDYFVSGGRAVPIPYNGSVARLRFGPATHRKVKKWLAHGDFDVLHLHEPNAPSLSMLALNIAEGPIVATFHTSTTKSLTLTVFQGILRPMHEKIVGRIAVSDLARRWQMEALGSDAVEIPNGVDVDSFASAARLDGYPRQGKTVLFLGRYDEPRKGMAVLLDALPKVVQRFPDVQLLIVGHGDADQLRGQAGRLAAHLRFLGQVDDAGKASAMRSADVYCAPNTGGESFGIVLVEAMAAGTAVVASDLDAFRRVLRDGEVGHLVPVDPPDLQAAALADGLIAVLENDVLRERYVAAGNAAVRRYDWSVVASQIMRVYETVAGSGAKVQVAS

T17362	TARGETID	T17362
T17362	FORMERID	TTDR01181
T17362	UNIPROID	Q01680_PNECA
T17362	TARGNAME	Fungal Plasma membrane H(+)-ATPase (Fung pma)
T17362	GENENAME	Fung pma
T17362	TARGTYPE	Literature-reported
T17362	SYNONYMS	Plasma membrane H(+)-ATPase
T17362	FUNCTION	Essential to fungal cell physiology, being required for the formation of a large electrochemical proton gradient and the maintenance of intracellular pH.
T17362	SEQUENCE	DDIDALIDDLESQDGDQEDNIEDTEFQSQRQVPEELLATDTRIGLTSQEVINRRKKYGLNKMKEEKENMIIKFLMYFVGPIQFVMEAAAILAAGLQDWVEFGVICALLLLNAFVGFIQEFQAGSIVDELKKTLALKATVLRDGRLIDIEAEEVVPGDILQLEEGSIVPADGRIVTEEAYLQVDQSAITGESLAVDIHKGDSIYSSSVAKPGETFMVVTATGDRT

T65239	TARGETID	T65239
T65239	FORMERID	TTDI03027
T65239	UNIPROID	RHAG_HUMAN
T65239	TARGNAME	Ammonium transporter Rh type A (RHAG)
T65239	GENENAME	RHAG
T65239	TARGTYPE	Literature-reported
T65239	SYNONYMS	Rhesus blood group-associated glycoprotein; Rhesus blood group-associated ammonia channel; Rhesus blood group family type A glycoprotein; Rh50A; Rh type A glycoprotein; Rh family type A glycoprotein; RH50; Erythrocyte plasma membrane 50 kDa glycoprotein; Erythrocyte membrane glycoprotein Rh50; CD241
T65239	FUNCTION	Associated with rhesus blood group antigen expression. May be part of an oligomeric complex which is likely to have a transport or channel function in the erythrocyte membrane. Involved in ammonia transport across the erythrocyte membrane. Seems to act in monovalent cation transport.
T65239	SEQUENCE	MRFTFPLMAIVLEIAMIVLFGLFVEYETDQTVLEQLNITKPTDMGIFFELYPLFQDVHVMIFVGFGFLMTFLKKYGFSSVGINLLVAALGLQWGTIVQGILQSQGQKFNIGIKNMINADFSAATVLISFGAVLGKTSPTQMLIMTILEIVFFAHNEYLVSEIFKASDIGASMTIHAFGAYFGLAVAGILYRSGLRKGHENEESAYYSDLFAMIGTLFLWMFWPSFNSAIAEPGDKQCRAIVNTYFSLAACVLTAFAFSSLVEHRGKLNMVHIQNATLAGGVAVGTCADMAIHPFGSMIIGSIAGMVSVLGYKFLTPLFTTKLRIHDTCGVHNLHGLPGVVGGLAGIVAVAMGASNTSMAMQAAALGSSIGTAVVGGLMTGLILKLPLWGQPSDQNCYDDSVYWKVPKTR
T65239	DRUGINFO	D0JS4B	[14C]methylamine	Investigative

T04599	TARGETID	T04599
T04599	FORMERID	TTDR00991
T04599	UNIPROID	IRF8_HUMAN
T04599	TARGNAME	Interferon consensus sequence binding protein (IRF8)
T04599	GENENAME	IRF8
T04599	TARGTYPE	Literature-reported
T04599	SYNONYMS	Interferon regulatory factor 8; Interferon consensus sequence-binding protein; IRF-8; ICSBP1; ICSBP; H-ICSBP
T04599	FUNCTION	Specifically binds to the upstream regulatory region of type I IFN and IFN-inducible MHC class I genes (the interferon consensus sequence (ICS)). Plays a negative regulatory role in cells of the immune system. Involved in CD8(+) dendritic cell differentiation by forming a complex with the BATF-JUNB heterodimer in immune cells, leading to recognition of AICE sequence (5'-TGAnTCA/GAAA-3'), an immune-specific regulatory element, followed by cooperative binding of BATF and IRF8 and activation of genes. Positively regulates macroautophagy in dendritic cells. Plays a role as a transcriptional activator or repressor.
T04599	SEQUENCE	MCDRNGGRRLRQWLIEQIDSSMYPGLIWENEEKSMFRIPWKHAGKQDYNQEVDASIFKAWAVFKGKFKEGDKAEPATWKTRLRCALNKSPDFEEVTDRSQLDISEPYKVYRIVPEEEQKCKLGVATAGCVNEVTEMECGRSEIDELIKEPSVDDYMGMIKRSPSPPEACRSQLLPDWWAQQPSTGVPLVTGYTTYDAHHSAFSQMVISFYYGGKLVGQATTTCPEGCRLSLSQPGLPGTKLYGPEGLELVRFPPADAIPSERQRQVTRKLFGHLERGVLLHSSRQGVFVKRLCQGRVFCSGNAVVCKGRPNKLERDEVVQVFDTSQFFRELQQFYNSQGRLPDGRVVLCFGEEFPDMAPLRSKLILVQIEQLYVRQLAEEAGKSCGAGSVMQAPEEPPPDQVFRMFPDICASHQRSFFRENQQITV

T22547	TARGETID	T22547
T22547	FORMERID	TTDR01126
T22547	UNIPROID	REL_HUMAN
T22547	TARGNAME	Proto-oncogene c-Rel (REL)
T22547	GENENAME	REL
T22547	TARGTYPE	Literature-reported
T22547	SYNONYMS	C-Rel
T22547	FUNCTION	NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. The NF-kappa-B heterodimer RELA/p65-c-Rel is a transcriptional activator. Proto-oncogene that may play a role in differentiation and lymphopoiesis.
T22547	SEQUENCE	MASGAYNPYIEIIEQPRQRGMRFRYKCEGRSAGSIPGEHSTDNNRTYPSIQIMNYYGKGKVRITLVTKNDPYKPHPHDLVGKDCRDGYYEAEFGQERRPLFFQNLGIRCVKKKEVKEAIITRIKAGINPFNVPEKQLNDIEDCDLNVVRLCFQVFLPDEHGNLTTALPPVVSNPIYDNRAPNTAELRICRVNKNCGSVRGGDEIFLLCDKVQKDDIEVRFVLNDWEAKGIFSQADVHRQVAIVFKTPPYCKAITEPVTVKMQLRRPSDQEVSESMDFRYLPDEKDTYGNKAKKQKTTLLFQKLCQDHVETGFRHVDQDGLELLTSGDPPTLASQSAGITVNFPERPRPGLLGSIGEGRYFKKEPNLFSHDAVVREMPTGVSSQAESYYPSPGPISSGLSHHASMAPLPSSSWSSVAHPTPRSGNTNPLSSFSTRTLPSNSQGIPPFLRIPVGNDLNASNACIYNNADDIVGMEASSMPSADLYGISDPNMLSNCSVNMMTTSSDSMGETDNPRLLSMNLENPSCNSVLDPRDLRQLHQMSSSSMSAGANSNTTVFVSQSDAFEGSDFSCADNSMINESGPSNSTNPNSHGFVQDSQYSGIGSMQNEQLSDSFPYEFFQV

T22284	TARGETID	T22284
T22284	FORMERID	TTDR00779
T22284	UNIPROID	ICA69_HUMAN
T22284	TARGNAME	Islet cell autoantigen p69 (ICA1)
T22284	GENENAME	ICA1
T22284	TARGTYPE	Literature-reported
T22284	SYNONYMS	P69; Islet cell autoantigen 1; ICAp69; ICA69; ICA1
T22284	FUNCTION	May play a role in neurotransmitter secretion.
T22284	SEQUENCE	MSGHKCSYPWDLQDRYAQDKSVVNKMQQKYWETKQAFIKATGKKEDEHVVASDADLDAKLELFHSIQRTCLDLSKAIVLYQKRICFLSQEENELGKFLRSQGFQDKTRAGKMMQATGKALCFSSQQRLALRNPLCRFHQEVETFRHRAISDTWLTVNRMEQCRTEYRGALLWMKDVSQELDPDLYKQMEKFRKVQTQVRLAKKNFDKLKMDVCQKVDLLGASRCNLLSHMLATYQTTLLHFWEKTSHTMAAIHESFKGYQPYEFTTLKSLQDPMKKLVEKEEKKKINQQESTDAAVQEPSQLISLEEENQRKESSSFKTEDGKSILSALDKGSTHTACSGPIDELLDMKSEEGACLGPVAGTPEPEGADKDDLLLLSEIFNASSLEEGEFSKEWAAVFGDGQVKEPVPTMALGEPDPKAQTGSGFLPSQLLDQNMKDLQASLQEPAKAASDLTAWFSLFADLDPLSNPDAVGKTDKEHELLNA

T90408	TARGETID	T90408
T90408	UNIPROID	VP30_EBOZM-NCAP_EBOZM
T90408	TARGNAME	Ebola virus VP30-NP interaction (EV VP30-NP PPI)
T90408	GENENAME	EV VP30-NP PPI
T90408	TARGTYPE	Literature-reported
T90408	SYNONYMS	Ebola VP30-Nucleocapsid protein interaction
T90408	FUNCTION	Plays both essential and inhibitory roles in Ebola virus RNA synthesis.
T90408	SEQUENCE	MEASYERGRPRAARQHSRDGHDHHVRARSSSRENYRGEYRQSRSASQVRVPTVFHKKRVEPLTVPPAPKDICPTLKKGFLCDSSFCKKDHQLESLTDRELLLLIARKTCGSVEQQLNITAPKDSRLANPTADDFQQEEGPKITLLTLIKTAEHWARQDIRTIEDSKLRALLTLCAVMTRKFSKSQLSLLCETHLRREGLGQDQAEPVLEVYQRLHSDKGGSFEAALWQQWDRQSLIMFITAFLNIALQLPCESSAVVVSGLRTLVPQSDNEEASTNPGTCSWSDEGTPMDSRPQKIWMAPSLTESDMDYHKILTAGLSVQQGIVRQRVIPVYQVNNLEEICQLIIQAFEAGVDFQESADSFLLMLCLHHAYQGDYKLFLESGAVKYLEGHGFRFEVKKRDGVKRLEELLPAVSSGKNIKRTLAAMPEEETTEANAGQFLSFASLFLPKLVVGEKACLEKVQRQIQVHAEQGLIQYPTAWQSVGHMMVIFRLMRTNFLIKFLLIHQGMHMVAGHDANDAVISNSVAQARFSGLLIVKTVLDHILQKTERGVRLHPLARTAKVKNEVNSFKAALSSLAKHGEYAPFARLLNLSGVNNLEHGLFPQLSAIALGVATAHGSTLAGVNVGEQYQQLREAATEAEKQLQQYAESRELDHLGLDDQEKKILMNFHQKKNEISFQQTNAMVTLRKERLAKLTEAITAASLPKTSGHYDDDDDIPFPGPINDDDNPGHQDDDPTDSQDTTIPDVVVDPDDGSYGEYQSYSENGMNAPDDLVLFDLDEDDEDTKPVPNRSTKGGQQKNSQKGQHIEGRQTQSRPIQNVPGPHRTIHHASAPLTDNDRRNEPSGSTSPRMLTPINEEADPLDDADDETSSLPPLESDDEEQDRDGTSNRTPTVAPPAPVYRDHSEKKELPQDEQQDQDHTQEARNQDSDNTQSEHSFEEMYRHILRSQGPFDAVLYYHMMKDEPVVFSTSDGKEYTYPDSLEEEYPPWLTEKEAMNEENRFVTLDGQQFYWPVMNHKNKFMAILQHHQ

T69413	TARGETID	T69413
T69413	FORMERID	TTDI01336
T69413	UNIPROID	SOS1_HUMAN; SOS2_HUMAN
T69413	TARGNAME	Son of sevenless (SOS)
T69413	GENENAME	SOS1; SOS2
T69413	TARGTYPE	Literature-reported
T69413	SYNONYMS	Son of sevenless homolog; SOS
T69413	FUNCTION	Promotes the exchange of Ras-bound GDP by GTP. Probably by promoting Ras activation, regulates phosphorylation of MAP kinase MAPK3 in response to EGF. Catalytic component of a trimeric complex that participates in transduction of signals from Ras to Rac by promoting the Rac-specific guanine nucleotide exchange factor (GEF) activity.
T69413	SEQUENCE	MQAQQLPYEFFSEENAPKWRGLLVPALKKVQGQVHPTLESNDDALQYVEELILQLLNMLCQAQPRSASDVEERVQKSFPHPIDKWAIADAQSAIEKRKRRNPLSLPVEKIHPLLKEVLGYKIDHQVSVYIVAVLEYISADILKLVGNYVRNIRHYEITKQDIKVAMCADKVLMDMFHQDVEDINILSLTDEEPSTSGEQTYYDLVKAFMAEIRQYIRELNLIIKVFREPFVSNSKLFSANDVENIFSRIVDIHELSVKLLGHIEDTVEMTDEGSPHPLVGSCFEDLAEELAFDPYESYARDILRPGFHDRFLSQLSKPGAALYLQSIGEGFKEAVQYVLPRLLLAPVYHCLHYFELLKQLEEKSEDQEDKECLKQAITALLNVQSGMEKICSKSLAKRRLSESACRFYSQQMKGKQLAIKKMNEIQKNIDGWEGKDIGQCCNEFIMEGTLTRVGAKHERHIFLFDGLMICCKSNHGQPRLPGASNAEYRLKEKFFMRKVQINDKDDTNEYKHAFEIILKDENSVIFSAKSAEEKNNWMAALISLQYRSTLERMLDVTMLQEEKEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGTMRHPTPLQQEPRKISYSRIPESETESTASAPNSPRTPLTPPPASGASSTTDVCSVFDSDHSSPFHSSNDTVFIQVTLPHGPRSASVSSISLTKGTDEVPVPPPVPPRRRPESAPAESSPSKIMSKHLDSPPAIPPRQPTSKAYSPRYSISDRTSISDPPESPPLLPPREPVRTPDVFSSSPLHLQPPPLGKKSDHGNAFFPNSPSPFTPPPPQTPSPHGTRRHLPSPPLTQEVDLHSIAGPPVPPRQSTSQHIPKLPPKTYKREHTHPSMHRDGPPLLENAHSS

T96859	TARGETID	T96859
T96859	FORMERID	TTDNR00758
T96859	UNIPROID	TICN1_HUMAN
T96859	TARGNAME	Testican-1 (SPOCK1)
T96859	GENENAME	SPOCK1
T96859	TARGTYPE	Literature-reported
T96859	SYNONYMS	SPOCK1; Protein SPOCK
T96859	FUNCTION	May play a role in cell-cell and cell-matrix interactions. May contribute to various neuronal mechanisms in the central nervous system.
T96859	SEQUENCE	MPAIAVLAAAAAAWCFLQVESRHLDALAGGAGPNHGNFLDNDQWLSTVSQYDRDKYWNRFRDDDYFRNWNPNKPFDQALDPSKDPCLKVKCSPHKVCVTQDYQTALCVSRKHLLPRQKKGNVAQKHWVGPSNLVKCKPCPVAQSAMVCGSDGHSYTSKCKLEFHACSTGKSLATLCDGPCPCLPEPEPPKHKAERSACTDKELRNLASRLKDWFGALHEDANRVIKPTSSNTAQGRFDTSILPICKDSLGWMFNKLDMNYDLLLDPSEINAIYLDKYEPCIKPLFNSCDSFKDGKLSNNEWCYCFQKPGGLPCQNEMNRIQKLSKGKSLLGAFIPRCNEEGYYKATQCHGSTGQCWCVDKYGNELAGSRKQGAVSCEEEQETSGDFGSGGSVVLLDDLEYERELGPKDKEGKLRVHTRAVTEDDEDEDDDKEDEVGYIW

T10798	TARGETID	T10798
T10798	FORMERID	TTDNR00738
T10798	UNIPROID	Q0PCM2_PLAVI
T10798	TARGNAME	Plasmodium Serine repeat antigen 4 (Malaria PvSERA4)
T10798	GENENAME	Malaria PvSERA4
T10798	TARGTYPE	Literature-reported
T10798	SYNONYMS	Serine repeat antigen 4
T10798	FUNCTION	Constitutes major substrates of SUB1, may lead to the identification of parasite and/or host cell substrates and the underlying molecular mechanisms of proteolysis.
T10798	SEQUENCE	FNLDMPLATHSINKDPEISDYYLKNSSDYYENLYYKKFQGSGATGGAGKQWVQGASTVYGQEGDPKVADEAGGEAAQSITTHSRAEPAGDAPPSGPLHAGTDSEQGEGTGPTDGEGPTRVVDEKAQAGGPLTSPGTLQDAVAPGGPQGPPEQGSPGPQLPPVQPTAPVPPVLPVPPAAPLPDAPTNSTVPTTESDVKEVLH

T86062	TARGETID	T86062
T86062	FORMERID	TTDR01072
T86062	UNIPROID	SCAP_HUMAN
T86062	TARGNAME	SREBP cleavage-activating protein (SCAP)
T86062	GENENAME	SCAP
T86062	TARGTYPE	Literature-reported
T86062	SYNONYMS	SREBPcleavage-activating protein; SREBP-cleavage activating protein; SCAP
T86062	FUNCTION	Escort protein required for cholesterol as well as lipid homeostasis. Regulates export of the SCAP/SREBF complex from the ER upon low cholesterol. Formation of a ternary complex with INSIG at high sterol concentrations leads to masking of an ER-export signal in SCAP and retention of the complex in the ER. Low sterol concentrations trigger release of INSIG, a conformational change in the SSC domain of SCAP, unmasking of the ER export signal, recruitment into COPII-coated vesicles, transport to the Golgi complex, proteolytic cleavage of SREBF in the Golgi, release of the transcription factor fragmentof SREBF from the membrane, its import into the nucleus and up-regulation of LDLR, INSIG1 and the mevalonate pathway.
T86062	SEQUENCE	MTLTERLREKISRAFYNHGLLCASYPIPIILFTGFCILACCYPLLKLPLPGTGPVEFTTPVKDYSPPPVDSDRKQGEPTEQPEWYVGAPVAYVQQIFVKSSVFPWHKNLLAVDVFRSPLSRAFQLVEEIRNHVLRDSSGIRSLEELCLQVTDLLPGLRKLRNLLPEHGCLLLSPGNFWQNDWERFHADPDIIGTIHQHEPKTLQTSATLKDLLFGVPGKYSGVSLYTRKRMVSYTITLVFQHYHAKFLGSLRARLMLLHPSPNCSLRAESLVHVHFKEEIGVAELIPLVTTYIILFAYIYFSTRKIDMVKSKWGLALAAVVTVLSSLLMSVGLCTLFGLTPTLNGGEIFPYLVVVIGLENVLVLTKSVVSTPVDLEVKLRIAQGLSSESWSIMKNMATELGIILIGYFTLVPAIQEFCLFAVVGLVSDFFLQMLFFTTVLSIDIRRMELADLNKRLPPEACLPSAKPVGQPTRYERQLAVRPSTPHTITLQPSSFRNLRLPKRLRVVYFLARTRLAQRLIMAGTVVWIGILVYTDPAGLRNYLAAQVTEQSPLGEGALAPMPVPSGMLPPSHPDPAFSIFPPDAPKLPENQTSPGESPERGGPAEVVHDSPVPEVTWGPEDEELWRKLSFRHWPTLFSYYNITLAKRYISLLPVIPVTLRLNPREALEGRHPQDGRSAWPPPGPIPAGHWEAGPKGPGGVQAHGDVTLYKVAALGLATGIVLVLLLLCLYRVLCPRNYGQLGGGPGRRRRGELPCDDYGYAPPETEIVPLVLRGHLMDIECLASDGMLLVSCCLAGHVCVWDAQTGDCLTRIPRPGRQRRDSGVGSGLEAQESWERLSDGGKAGPEEPGDSPPLRHRPRGPPPPSLFGDQPDLTCLIDTNFSAQPRSSQPTQPEPRHRAVCGRSRDSPGYDFSCLVQRVYQEEGLAAVCTPALRPPSPGPVLSQAPEDEGGSPEKGSPSLAWAPSAEGSIWSLELQGNLIVVGRSSGRLEVWDAIEGVLCCSSEEVSSGITALVFLDKRIVAARLNGSLDFFSLETHTALSPLQFRGTPGRGSSPASPVYSSSDTVACHLTHTVPCAHQKPITALKAAAGRLVTGSQDHTLRVFRLEDSCCLFTLQGHSGAITTVYIDQTMVLASGGQDGAICLWDVLTGSRVSHVFAHRGDVTSLTCTTSCVISSGLDDLISIWDRSTGIKFYSIQQDLGCGASLGVISDNLLVTGGQGCVSFWDLNYGDLLQTVYLGKNSEAQPARQILVLDNAAIVCNFGSELSLVYVPSVLEKLD

T99829	TARGETID	T99829
T99829	FORMERID	TTDNR00677
T99829	UNIPROID	FOXC1_HUMAN
T99829	TARGNAME	Forkhead box protein C1 (FOXC1)
T99829	GENENAME	FOXC1
T99829	TARGTYPE	Literature-reported
T99829	SYNONYMS	Forkhead-related transcription factor 3; Forkhead-related protein FKHL7; FREAC3; FREAC-3; FKHL7
T99829	FUNCTION	Acts either as a transcriptional activator or repressor. Binds to the consensus binding site 5'-[G/C][A/T]AAA[T/C]AA[A/C]-3' in promoter of target genes. Upon DNA-binding, promotes DNA bending. Acts as a transcriptional coactivator. Stimulates Indian hedgehog (Ihh)-induced target gene expression mediated by the transcription factor GLI2, and hence regulates endochondral ossification. Acts also as a transcriptional coregulator by increasing DNA-binding capacity of GLI2 in breast cancer cells. Regulates FOXO1 through binding to a conserved element, 5'-GTAAACAAA-3' in its promoter region, implicating FOXC1 as an important regulator of cell viability and resistance to oxidative stress in the eye. Cooperates with transcription factor FOXC2 in regulating expression of genes that maintain podocyte integrity. Promotes cell growth inhibition by stopping the cell cycle in the G1 phase through TGFB1-mediated signals. Involved in epithelial-mesenchymal transition (EMT) induction by increasing cell proliferation, migration and invasion. Involved in chemokine CXCL12-induced endothelial cell migration through the control of CXCR4 expression. Plays a role in the gene regulatory network essential for epidermal keratinocyte terminal differentiation. Essential developmental transcriptional factor required for mesoderm-derived tissues, such as the somites, skin, bone and cartilage. Positively regulates CXCL12 and stem cell factor expression in bone marrow mesenchymal progenitor cells, and hence plays a role in the development and maintenance of mesenchymal niches for haematopoietic stem and progenitor cells (HSPC). Plays a role in corneal transparency by preventing both blood vessel and lymphatic vessel growth during embryonic development in a VEGF-dependent manner. Involved in chemokine CXCL12-induced endothelial cell migration through the control of CXCR4 expression. May function as a tumor suppressor. DNA-binding transcriptional factor that plays a role in a broad range of cellular and developmental processes such as eye, bones, cardiovascular, kidney and skin development.
T99829	SEQUENCE	MQARYSVSSPNSLGVVPYLGGEQSYYRAAAAAAGGGYTAMPAPMSVYSHPAHAEQYPGGMARAYGPYTPQPQPKDMVKPPYSYIALITMAIQNAPDKKITLNGIYQFIMDRFPFYRDNKQGWQNSIRHNLSLNECFVKVPRDDKKPGKGSYWTLDPDSYNMFENGSFLRRRRRFKKKDAVKDKEEKDRLHLKEPPPPGRQPPPAPPEQADGNAPGPQPPPVRIQDIKTENGTCPSPPQPLSPAAALGSGSAAAVPKIESPDSSSSSLSSGSSPPGSLPSARPLSLDGADSAPPPPAPSAPPPHHSQGFSVDNIMTSLRGSPQSAAAELSSGLLASAAASSRAGIAPPLALGAYSPGQSSLYSSPCSQTSSAGSSGGGGGGAGAAGGAGGAGTYHCNLQAMSLYAAGERGGHLQGAPGGAGGSAVDDPLPDYSLPPVTSSSSSSLSHGGGGGGGGGGQEAGHHPAAHQGRLTSWYLNQAGGDLGHLASAAAAAAAAGYPGQQQNFHSVREMFESQRIGLNNSPVNGNSSCQMAFPSSQSLYRTSGAFVYDCSKF

T68876	TARGETID	T68876
T68876	FORMERID	TTDI03221
T68876	UNIPROID	GRIK3_HUMAN
T68876	TARGNAME	Glutamate receptor ionotropic kainate 3 (GluK3)
T68876	GENENAME	GRIK3
T68876	TARGTYPE	Literature-reported
T68876	SYNONYMS	Glutamate receptor ionotropic, kainate 3; Glutamate receptor 7; GluR7; GluR-7; GluK3; Excitatory amino acid receptor 5; EAA5
T68876	FUNCTION	Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists. This receptor binds domoate > kainate >> L-glutamate = quisqualate >> AMPA = NMDA.
T68876	SEQUENCE	MTAPWRRLRSLVWEYWAGLLVCAFWIPDSRGMPHVIRIGGIFEYADGPNAQVMNAEEHAFRFSANIINRNRTLLPNTTLTYDIQRIHFHDSFEATKKACDQLALGVVAIFGPSQGSCTNAVQSICNALEVPHIQLRWKHHPLDNKDTFYVNLYPDYASLSHAILDLVQYLKWRSATVVYDDSTGLIRLQELIMAPSRYNIRLKIRQLPIDSDDSRPLLKEMKRGREFRIIFDCSHTMAAQILKQAMAMGMMTEYYHFIFTTLDLYALDLEPYRYSGVNLTGFRILNVDNPHVSAIVEKWSMERLQAAPRSESGLLDGVMMTDAALLYDAVHIVSVCYQRAPQMTVNSLQCHRHKAWRFGGRFMNFIKEAQWEGLTGRIVFNKTSGLRTDFDLDIISLKEDGLEKVGVWSPADGLNITEVAKGRGPNVTDSLTNRSLIVTTVLEEPFVMFRKSDRTLYGNDRFEGYCIDLLKELAHILGFSYEIRLVEDGKYGAQDDKGQWNGMVKELIDHKADLAVAPLTITHVREKAIDFSKPFMTLGVSILYRKPNGTNPSVFSFLNPLSPDIWMYVLLAYLGVSCVLFVIARFSPYEWYDAHPCNPGSEVVENNFTLLNSFWFGMGSLMQQGSELMPKALSTRIIGGIWWFFTLIIISSYTANLAAFLTVERMESPIDSADDLAKQTKIEYGAVKDGATMTFFKKSKISTFEKMWAFMSSKPSALVKNNEEGIQRALTADYALLMESTTIEYVTQRNCNLTQIGGLIDSKGYGIGTPMGSPYRDKITIAILQLQEEDKLHIMKEKWWRGSGCPEEENKEASALGIQKIGGIFIVLAAGLVLSVLVAVGEFVYKLRKTAEREQRSFCSTVADEIRFSLTCQRRVKHKPQPPMMVKTDAVINMHTFNDRRLPGKDSMACSTSLAPVFP
T68876	DRUGINFO	D0K5UI	UBP310	Investigative
T68876	DRUGINFO	D0K6AF	dysiherbaine	Investigative
T68876	DRUGINFO	D0S8AN	SYM2081	Investigative
T68876	DRUGINFO	D04PFN	[3H]kainate	Investigative

T18571	TARGETID	T18571
T18571	FORMERID	TTDI02642
T18571	UNIPROID	BAGE1_HUMAN
T18571	TARGNAME	B melanoma antigen 1 (BAGE)
T18571	GENENAME	BAGE
T18571	TARGTYPE	Literature-reported
T18571	SYNONYMS	Cancer/testis antigen 2.1; CT2.1; BAGE1; B melanoma antigen; Antigen MZ2BA; Antigen MZ2-BA
T18571	FUNCTION	Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes.
T18571	SEQUENCE	MAARAVFLALSAQLLQARLMKEESPVVSWRLEPEDGTALCFIF

T33902	TARGETID	T33902
T33902	FORMERID	TTDI03234
T33902	UNIPROID	GPR17_HUMAN
T33902	TARGNAME	Uracil nucleotide/cysteinyl leukotriene receptor (GPR17)
T33902	GENENAME	GPR17
T33902	TARGTYPE	Literature-reported
T33902	SYNONYMS	UDP/CysLT receptor; R12; G-protein coupled receptor 17
T33902	FUNCTION	Dual specificity receptor for uracil nucleotides and cysteinyl leukotrienes (CysLTs). Signals through G(i) and inhibition of adenylyl cyclase. May mediate brain damage by nucleotides and CysLTs following ischemia.
T33902	SEQUENCE	MSKRSWWAGSRKPPREMLKLSGSDSSQSMNGLEVAPPGLITNFSLATAEQCGQETPLENMLFASFYLLDFILALVGNTLALWLFIRDHKSGTPANVFLMHLAVADLSCVLVLPTRLVYHFSGNHWPFGEIACRLTGFLFYLNMYASIYFLTCISADRFLAIVHPVKSLKLRRPLYAHLACAFLWVVVAVAMAPLLVSPQTVQTNHTVVCLQLYREKASHHALVSLAVAFTFPFITTVTCYLLIIRSLRQGLRVEKRLKTKAVRMIAIVLAIFLVCFVPYHVNRSVYVLHYRSHGASCATQRILALANRITSCLTSLNGALDPIMYFFVAEKFRHALCNLLCGKRLKGPPPSFEGKTNESSLSAKSEL
T33902	DRUGINFO	D00DPX	ASN04421891	Investigative
T33902	DRUGINFO	D07ZGV	ASN04450772	Investigative
T33902	DRUGINFO	D0J4RI	ASN06917370	Investigative
T33902	DRUGINFO	D0KI5P	ASN02563583	Investigative
T33902	DRUGINFO	D0Z2TV	ASN04885796	Investigative
T33902	DRUGINFO	D03YBH	LTD4	Investigative
T33902	DRUGINFO	D07MIE	UDP-glucose	Investigative
T33902	DRUGINFO	D0EW6H	LTC4	Investigative
T33902	DRUGINFO	D0C0KJ	LTE4	Investigative

T70685	TARGETID	T70685
T70685	FORMERID	TTDR00752
T70685	UNIPROID	MOBP_HUMAN
T70685	TARGNAME	Myelin-associated/oligodendrocyte basic protein (MOBP)
T70685	GENENAME	MOBP
T70685	TARGTYPE	Literature-reported
T70685	SYNONYMS	Myelin-associated oligodendrocyte basic protein
T70685	FUNCTION	May play a role in compacting or stabilizing the myelin sheath, possibly by binding the negatively charged acidic phospholipids of the cytoplasmic membrane.
T70685	SEQUENCE	MSQKPAKEGPRLSKNQKYSEHFSIHCCPPFTFLNSKKEIVDRKYSICKSGCFYQKKEEDWICCACQKTRTSRRAKSPQRPKQQPAAPPAVVRAPAKPRSPPRSERQPRSPPRSERQPRSPPRSERQPRSPPRSERQPRPRPEVRPPPAKQRPPQKSKQQPRSSPLRGPGASRGGSPVKASRFW

T02259	TARGETID	T02259
T02259	FORMERID	TTDI02413
T02259	UNIPROID	RUNX2_HUMAN
T02259	TARGNAME	Runt-related transcription factor 2 (RUNX2)
T02259	GENENAME	RUNX2
T02259	TARGTYPE	Literature-reported
T02259	SYNONYMS	SL3/AKV core-binding factor alpha A subunit; SL3-3 enhancer factor 1 alpha A subunit; Polyomavirus enhancer-binding protein 2 alpha Asubunit; Polyomavirus enhancer-binding protein 2 alpha A subunit; PEBP2A; PEBP2-alpha A; PEA2-alpha A; Osteoblast-specific transcription factor 2; Oncogene AML-3; OSF2; OSF-2; Core-binding factor subunit alpha-1; CBFA1; CBF-alpha-1; Acute myeloid leukemia 3 protein; AML3
T02259	FUNCTION	Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters. In osteoblasts, supports transcription activation: synergizes with SPEN/MINT to enhance FGFR2-mediated activation of the osteocalcin FGF-responsive element (OCFRE). Inhibits KAT6B-dependent transcriptional activation. Transcription factor involved in osteoblastic differentiation and skeletal morphogenesis.
T02259	SEQUENCE	MASNSLFSTVTPCQQNFFWDPSTSRRFSPPSSSLQPGKMSDVSPVVAAQQQQQQQQQQQQQQQQQQQQQQQEAAAAAAAAAAAAAAAAAVPRLRPPHDNRTMVEIIADHPAELVRTDSPNFLCSVLPSHWRCNKTLPVAFKVVALGEVPDGTVVTVMAGNDENYSAELRNASAVMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPPQVATYHRAIKVTVDGPREPRRHRQKLDDSKPSLFSDRLSDLGRIPHPSMRVGVPPQNPRPSLNSAPSPFNPQGQSQITDPRQAQSSPPWSYDQSYPSYLSQMTSPSIHSTTPLSSTRGTGLPAITDVPRRISDDDTATSDFCLWPSTLSKKSQAGASELGPFSDPRQFPSISSLTESRFSNPRMHYPATFTYTPPVTSGMSLGMSATTHYHTYLPPPYPGSSQSQSGPFQTSSTPYLYYGTSSGSYQFPMVPGGDRSPSRMLPPCTTTSNGSTLLNPNLPNQNDGVDADGSHSSSPTVLNSSGRMDESVWRPY

T03317	TARGETID	T03317
T03317	FORMERID	TTDR00981
T03317	UNIPROID	LY6D_HUMAN
T03317	TARGNAME	Lymphocyte antigen 6D (LY6D)
T03317	GENENAME	LY6D
T03317	TARGTYPE	Literature-reported
T03317	SYNONYMS	LY6D; E48 antigen; Desmoglein III (dg4)
T03317	FUNCTION	May act as a specification marker at earliest stage specification of lymphocytes between B- and T-cell development. Marks the earliest stage of B-cell specification.
T03317	SEQUENCE	MRTALLLLAALAVATGPALTLRCHVCTSSSNCKHSVVCPASSRFCKTTNTVEPLRGNLVKKDCAESCTPSYTLQGQVSSGTSSTQCCQEDLCNEKLHNAAPTRTALAHSALSLGLALSLLAVILAPSL

T72267	TARGETID	T72267
T72267	FORMERID	TTDI03236
T72267	UNIPROID	GPR18_HUMAN
T72267	TARGNAME	N-arachidonyl glycine receptor (GPR18)
T72267	GENENAME	GPR18
T72267	TARGTYPE	Literature-reported
T72267	SYNONYMS	NAGly receptor; GPCRW; G-protein coupled receptor 18
T72267	FUNCTION	Receptor for endocannabinoid N-arachidonyl glycine (NAGly). However, conflicting results about the role of NAGly as an agonist are reported. Can also be activated by plant-derived and synthetic cannabinoid agonists. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. May contribute to regulation of the immune system. Is required for normal homeostasis of CD8+ subsets of intraepithelial lymphocytes (IELs) (CD8alphaalpha and CD8alphabeta IELs)in small intstine by supporting preferential migration of CD8alphaalpha T-cells to intraepithelial compartment over lamina propria compartment, and by mediating their reconstitution into small intestine after bone marrow transplant (By similarity). Plays a role in hypotensive responses, mediating reduction in intraocular and blood pressure (By similarity). Mediates NAGly-induced process of reorganization of actin filaments and induction of acrosomal exocytosis.
T72267	SEQUENCE	MITLNNQDQPVPFNSSHPDEYKIAALVFYSCIFIIGLFVNITALWVFSCTTKKRTTVTIYMMNVALVDLIFIMTLPFRMFYYAKDEWPFGEYFCQILGALTVFYPSIALWLLAFISADRYMAIVQPKYAKELKNTCKAVLACVGVWIMTLTTTTPLLLLYKDPDKDSTPATCLKISDIIYLKAVNVLNLTRLTFFFLIPLFIMIGCYLVIIHNLLHGRTSKLKPKVKEKSIRIIITLLVQVLVCFMPFHICFAFLMLGTGENSYNPWGAFTTFLMNLSTCLDVILYYIVSKQFQARVISVMLYRNYLRSMRRKSFRSGSLRSLSNINSEML
T72267	DRUGINFO	D01ZHW	N-arachidonoylglycine	Investigative
T72267	DRUGINFO	D02HDI	arachidonylcyclopropylamide	Investigative
T72267	DRUGINFO	D06NAM	O-1602	Investigative
T72267	DRUGINFO	D0S3UM	abnormal cannabidiol	Investigative

T96242	TARGETID	T96242
T96242	UNIPROID	FAT1_HUMAN
T96242	TARGNAME	Protocadherin Fat 1 (FAT1)
T96242	GENENAME	FAT1
T96242	TARGTYPE	Literature-reported
T96242	SYNONYMS	Protocadherin Fat 1, nuclear form; Protein fat homolog; Cadherin-related tumor suppressor homolog; Cadherin family member 7; CDHF7
T96242	FUNCTION	Plays an essential role for cellular polarization, directed cell migration and modulating cell-cell contact.
T96242	SEQUENCE	MGRHLALLLLLLLLFQHFGDSDGSQRLEQTPLQFTHLEYNVTVQENSAAKTYVGHPVKMGVYITHPAWEVRYKIVSGDSENLFKAEEYILGDFCFLRIRTKGGNTAILNREVKDHYTLIVKALEKNTNVEARTKVRVQVLDTNDLRPLFSPTSYSVSLPENTAIRTSIARVSATDADIGTNGEFYYSFKDRTDMFAIHPTSGVIVLTGRLDYLETKLYEMEILAADRGMKLYGSSGISSMAKLTVHIEQANECAPVITAVTLSPSELDRDPAYAIVTVDDCDQGANGDIASLSIVAGDLLQQFRTVRSFPGSKEYKVKAIGGIDWDSHPFGYNLTLQAKDKGTPPQFSSVKVIHVTSPQFKAGPVKFEKDVYRAEISEFAPPNTPVVMVKAIPAYSHLRYVFKSTPGKAKFSLNYNTGLISILEPVKRQQAAHFELEVTTSDRKASTKVLVKVLGANSNPPEFTQTAYKAAFDENVPIGTTVMSLSAVDPDEGENGYVTYSIANLNHVPFAIDHFTGAVSTSENLDYELMPRVYTLRIRASDWGLPYRREVEVLATITLNNLNDNTPLFEKINCEGTIPRDLGVGEQITTVSAIDADELQLVQYQIEAGNELDFFSLNPNSGVLSLKRSLMDGLGAKVSFHSLRITATDGENFATPLYINITVAASHKLVNLQCEETGVAKMLAEKLLQANKLHNQGEVEDIFFDSHSVNAHIPQFRSTLPTGIQVKENQPVGSSVIFMNSTDLDTGFNGKLVYAVSGGNEDSCFMIDMETGMLKILSPLDRETTDKYTLNITVYDLGIPQKAAWRLLHVVVVDANDNPPEFLQESYFVEVSEDKEVHSEIIQVEATDKDLGPNGHVTYSIVTDTDTFSIDSVTGVVNIARPLDRELQHEHSLKIEARDQAREEPQLFSTVVVKVSLEDVNDNPPTFIPPNYRVKVREDLPEGTVIMWLEAHDPDLGQSGQVRYSLLDHGEGNFDVDKLSGAVRIVQQLDFEKKQVYNLTVRAKDKGKPVSLSSTCYVEVEVVDVNENLHPPVFSSFVEKGTVKEDAPVGSLVMTVSAHDEDARRDGEIRYSIRDGSGVGVFKIGEETGVIETSDRLDRESTSHYWLTVFATDQGVVPLSSFIEIYIEVEDVNDNAPQTSEPVYYPEIMENSPKDVSVVQIEAFDPDSSSNDKLMYKITSGNPQGFFSIHPKTGLITTTSRKLDREQQDEHILEVTVTDNGSPPKSTIARVIVKILDENDNKPQFLQKFYKIRLPEREKPDRERNARREPLYHVIATDKDEGPNAEISYSIEDGNEHGKFFIEPKTGVVSSKRFSAAGEYDILSIKAVDNGRPQKSSTTRLHIEWISKPKPSLEPISFEESFFTFTVMESDPVAHMIGVISVEPPGIPLWFDITGGNYDSHFDVDKGTGTIIVAKPLDAEQKSNYNLTVEATDGTTTILTQVFIKVIDTNDHRPQFSTSKYEVVIPEDTAPETEILQISAVDQDEKNKLIYTLQSSRDPLSLKKFRLDPATGSLYTSEKLDHEAVHQHTLTVMVRDQDVPVKRNFARIVVNVSDTNDHAPWFTASSYKGRVYESAAVGSVVLQVTALDKDKGKNAEVLYSIESGNIGNSFMIDPVLGSIKTAKELDRSNQAEYDLMVKATDKGSPPMSEITSVRIFVTIADNASPKFTSKEYSVELSETVSIGSFVGMVTAHSQSSVVYEIKDGNTGDAFDINPHSGTIITQKALDFETLPIYTLIIQGTNMAGLSTNTTVLVHLQDENDNAPVFMQAEYTGLISESASINSVVLTDRNVPLVIRAADADKDSNALLVYHIVEPSVHTYFAIDSSTGAIHTVLSLDYEETSIFHFTVQVHDMGTPRLFAEYAANVTVHVIDINDCPPVFAKPLYEASLLLPTYKGVKVITVNATDADSSAFSQLIYSITEGNIGEKFSMDYKTGALTVQNTTQLRSRYELTVRASDGRFAGLTSVKINVKESKESHLKFTQDVYSAVVKENSTEAETLAVITAIGNPINEPLFYHILNPDRRFKISRTSGVLSTTGTPFDREQQEAFDVVVEVTEEHKPSAVAHVVVKVIVEDQNDNAPVFVNLPYYAVVKVDTEVGHVIRYVTAVDRDSGRNGEVHYYLKEHHEHFQIGPLGEISLKKQFELDTLNKEYLVTVVAKDGGNPAFSAEVIVPITVMNKAMPVFEKPFYSAEIAESIQVHSPVVHVQANSPEGLKVFYSITDGDPFSQFTINFNTGVINVIAPLDFEAHPAYKLSIRATDSLTGAHAEVFVDIIVDDINDNPPVFAQQSYAVTLSEASVIGTSVVQVRATDSDSEPNRGISYQMFGNHSKSHDHFHVDSSTGLISLLRTLDYEQSRQHTIFVRAVDGGMPTLSSDVIVTVDVTDLNDNPPLFEQQIYEARISEHAPHGHFVTCVKAYDADSSDIDKLQYSILSGNDHKHFVIDSATGIITLSNLHRHALKPFYSLNLSVSDGVFRSSTQVHVTVIGGNLHSPAFLQNEYEVELAENAPLHTLVMEVKTTDGDSGIYGHVTYHIVNDFAKDRFYINERGQIFTLEKLDRETPAEKVISVRLMAKDAGGKVAFCTVNVILTDDNDNAPQFRATKYEVNIGSSAAKGTSVVKVLASDADEGSNADITYAIEADSESVKENLEINKLSGVITTKESLIGLENEFFTFFVRAVDNGSPSKESVVLVYVKILPPEMQLPKFSEPFYTFTVSEDVPIGTEIDLIRAEHSGTVLYSLVKGNTPESNRDESFVIDRQSGRLKLEKSLDHETTKWYQFSILARCTQDDHEMVASVDVSIQVKDANDNSPVFESSPYEAFIVENLPGGSRVIQIRASDADSGTNGQVMYSLDQSQSVEVIESFAINMETGWITTLKELDHEKRDNYQIKVVASDHGEKIQLSSTAIVDVTVTDVNDSPPRFTAEIYKGTVSEDDPQGGVIAILSTTDADSEEINRQVTYFITGGDPLGQFAVETIQNEWKVYVKKPLDREKRDNYLLTITATDGTFSSKAIVEVKVLDANDNSPVCEKTLYSDTIPEDVLPGKLIMQISATDADIRSNAEITYTLLGSGAEKFKLNPDTGELKTSTPLDREEQAVYHLLVRATDGGGRFCQASIVLTLEDVNDNAPEFSADPYAITVFENTEPGTLLTRVQATDADAGLNRKILYSLIDSADGQFSINELSGIIQLEKPLDRELQAVYTLSLKAVDQGLPRRLTATGTVIVSVLDINDNPPVFEYREYGATVSEDILVGTEVLQVYAASRDIEANAEITYSIISGNEHGKFSIDSKTGAVFIIENLDYESSHEYYLTVEATDGGTPSLSDVATVNVNVTDINDNTPVFSQDTYTTVISEDAVLEQSVITVMADDADGPSNSHIHYSIIDGNQGSSFTIDPVRGEVKVTKLLDRETISGYTLTVQASDNGSPPRVNTTTVNIDVSDVNDNAPVFSRGNYSVIIQENKPVGFSVLQLVVTDEDSSHNGPPFFFTIVTGNDEKAFEVNPQGVLLTSSAIKRKEKDHYLLQVKVADNGKPQLSSLTYIDIRVIEESIYPPAILPLEIFITSSGEEYSGGVIGKIHATDQDVYDTLTYSLDPQMDNLFSVSSTGGKLIAHKKLDIGQYLLNVSVTDGKFTTVADITVHIRQVTQEMLNHTIAIRFANLTPEEFVGDYWRNFQRALRNILGVRRNDIQIVSLQSSEPHPHLDVLLFVEKPGSAQISTKQLLHKINSSVTDIEEIIGVRILNVFQKLCAGLDCPWKFCDEKVSVDESVMSTHSTARLSFVTPRHHRAAVCLCKEGRCPPVHHGCEDDPCPEGSECVSDPWEEKHTCVCPSGRFGQCPGSSSMTLTGNSYVKYRLTENENKLEMKLTMRLRTYSTHAVVMYARGTDYSILEIHHGRLQYKFDCGSGPGIVSVQSIQVNDGQWHAVALEVNGNYARLVLDQVHTASGTAPGTLKTLNLDNYVFFGGHIRQQGTRHGRSPQVGNGFRGCMDSIYLNGQELPLNSKPRSYAHIEESVDVSPGCFLTATEDCASNPCQNGGVCNPSPAGGYYCKCSALYIGTHCEISVNPCSSKPCLYGGTCVVDNGGFVCQCRGLYTGQRCQLSPYCKDEPCKNGGTCFDSLDGAVCQCDSGFRGERCQSDIDECSGNPCLHGALCENTHGSYHCNCSHEYRGRHCEDAAPNQYVSTPWNIGLAEGIGIVVFVAGIFLLVVVFVLCRKMISRKKKHQAEPKDKHLGPATAFLQRPYFDSKLNKNIYSDIPPQVPVRPISYTPSIPSDSRNNLDRNSFEGSAIPEHPEFSTFNPESVHGHRKAVAVCSVAPNLPPPPPSNSPSDSDSIQKPSWDFDYDTKVVDLDPCLSKKPLEEKPSQPYSARESLSEVQSLSSFQSESCDDNGYHWDTSDWMPSVPLPDIQEFPNYEVIDEQTPLYSADPNAIDTDYYPGGYDIESDFPPPPEDFPAADELPPLPPEFSNQFESIHPPRDMPAAGSLGSSSRNRQRFNLNQYLPNFYPLDMSEPQTKGTGENSTCREPHAPYPPGYQRHFEAPAVESMPMSVYASTASCSDVSACCEVESEVMMSDYESGDDGHFEEVTIPPLDSQQHTEV

T76678	TARGETID	T76678
T76678	FORMERID	TTDI03295
T76678	UNIPROID	ITPR2_HUMAN
T76678	TARGNAME	IP3 receptor isoform 2 (IP3R2)
T76678	GENENAME	ITPR2
T76678	TARGTYPE	Literature-reported
T76678	SYNONYMS	Type 2 inositol 1,4,5-trisphosphate receptor; Type 2 InsP3 receptor; InsP3R2; Inositol 1,4,5-trisphosphate receptor type 2; IP3R 2
T76678	FUNCTION	Receptor for inositol 1,4,5-trisphosphate, a second messenger that mediates the release of intracellular calcium. This release is regulated by cAMP both dependently and independently of PKA (By similarity).
T76678	SEQUENCE	MTEKMSSFLYIGDIVSLYAEGSVNGFISTLGLVDDRCVVHPEAGDLANPPKKFRDCLFKVCPMNRYSAQKQYWKAKQAKQGNHTEAALLKKLQHAAELEQKQNESENKKLLGEIVKYSNVIQLLHIKSNKYLTVNKRLPALLEKNAMRVSLDAAGNEGSWFYIHPFWKLRSEGDNIVVGDKVVLMPVNAGQPLHASNIELLDNPGCKEVNAVNCNTSWKITLFMKYSSYREDVLKGGDVVRLFHAEQEKFLTCDEYEKKQHIFLRTTLRQSATSATSSKALWEIEVVHHDPCRGGAGQWNSLFRFKHLATGNYLAAELNPDYRDAQNEGKNVRDGVPPTSKKKRQAGEKIMYTLVSVPHGNDIASLFELDATTLQRADCLVPRNSYVRLRHLCTNTWVTSTSIPIDTDEERPVMLKIGTCQTKEDKEAFAIVSVPLSEVRDLDFANDANKVLATTVKKLENGTITQNERRFVTKLLEDLIFFVADVPNNGQEVLDVVITKPNRERQKLMREQNILAQVFGILKAPFKEKAGEGSMLRLEDLGDQRYAPYKYMLRLCYRVLRHSQQDYRKNQEYIAKNFCVMQSQIGYDILAEDTITALLHNNRKLLEKHITAKEIETFVSLLRRNREPRFLDYLSDLCVSNTTAIPVTQELICKFMLSPGNADILIQTKVVSMQADNPMESSILSDDIDDEEVWLYWIDSNKEPHGKAIRHLAQEAKEGTKADLEVLTYYRYQLNLFARMCLDRQYLAINQISTQLSVDLILRCVSDESLPFDLRASFCRLMLHMHVDRDPQESVVPVRYARLWTEIPTKITIHEYDSITDSSRNDMKRKFALTMEFVEEYLKEVVNQPFPFGDKEKNKLTFEVVHLARNLIYFGFYSFSELLRLTRTLLAILDIVQAPMSSYFERLSKFQDGGNNVMRTIHGVGEMMTQMVLSRGSIFPMSVPDVPPSIHPSKQGSPTEHEDVTVMDTKLKIIEILQFILSVRLDYRISYMLSIYKKEFGEDNDNAETSASGSPDTLLPSAIVPDIDEIAAQAETMFAGRKEKNPVQLDDEGGRTFLRVLIHLIMHDYPPLLSGALQLLFKHFSQRAEVLQAFKQVQLLVSNQDVDNYKQIKADLDQLRLTVEKSELWVEKSSNYENGEIGESQVKGGEEPIEESNILSPVQDGTKKPQIDSNKSNNYRIVKEILIRLSKLCVQNKKCRNQHQRLLKNMGAHSVVLDLLQIPYEKNDEKMNEVMNLAHTFLQNFCRGNPQNQVLLHKHLNLFLTPGLLEAETMRHIFMNNYHLCNEISERVVQHFVHCIETHGRHVEYLRFLQTIVKADGKYVKKCQDMVMTELINGGEDVLIFYNDRASFPILLHMMCSERDRGDESGPLAYHITLVELLAACTEGKNVYTEIKCNSLLPLDDIVRVVTHDDCIPEVKIAYVNFVNHCYVDTEVEMKEIYTSNHIWKLFENFLVDMARVCNTTTDRKHADIFLEKCVTESIMNIVSGFFNSPFSDNSTSLQTHQPVFIQLLQSAFRIYNCTWPNPAQKASVESCIRTLAEVAKNRGIAIPVDLDSQVNTLFMKSHSNMVQRAAMGWRLSARSGPRFKEALGGPAWDYRNIIEKLQDVVASLEHQFSPMMQAEFSVLVDVLYSPELLFPEGSDARIRCGAFMSKLINHTKKLMEKEEKLCIKILQTLREMLEKKDSFVEEGNTLRKILLNRYFKGDYSIGVNGHLSGAYSKTAQVGGSFSGQDSDKMGISMSDIQCLLDKEGASELVIDVIVNTKNDRIFSEGIFLGIALLEGGNTQTQYSFYQQLHEQKKSEKFFKVLYDRMKAAQKEIRSTVTVNTIDLGNKKRDDDNELMTSGPRMRVRDSTLHLKEGMKGQLTEASSATSKAYCVYRREMDPEIDIMCTGPEAGNTEEKSAEEVTMSPAIAIMQPILRFLQLLCENHNRELQNFLRNQNNKTNYNLVCETLQFLDCICGSTTGGLGLLGLYINEKNVALVNQNLESLTEYCQGPCHENQTCIATHESNGIDIIIALILNDINPLGKYRMDLVLQLKNNASKLLLAIMESRHDSENAERILFNMRPRELVDVMKNAYNQGLECDHGDDEGGDDGVSPKDVGHNIYILAHQLARHNKLLQQMLKPGSDPDEGDEALKYYANHTAQIEIVRHDRTMEQIVFPVPNICEYLTRESKCRVFNTTERDEQGSKVNDFFQQTEDLYNEMKWQKKIRNNPALFWFSRHISLWGSISFNLAVFINLAVALFYPFGDDGDEGTLSPLFSVLLWIAVAICTSMLFFFSKPVGIRPFLVSIMLRSIYTIGLGPTLILLGAANLCNKIVFLVSFVGNRGTFTRGYRAVILDMAFLYHVAYVLVCMLGLFVHEFFYSFLLFDLVYREETLLNVIKSVTRNGRSIILTAVLALILVYLFSIIGFLFLKDDFTMEVDRLKNRTPVTGSHQVPTMTLTTMMEACAKENCSPTIPASNTADEEYEDGIERTCDTLLMCIVTVLNQGLRNGGGVGDVLRRPSKDEPLFAARVVYDLLFYFIVIIIVLNLIFGVIIDTFADLRSEKQKKEEILKTTCFICGLERDKFDNKTVSFEEHIKSEHNMWHYLYFIVLVKVKDPTEYTGPESYVAQMIVEKNLDWFPRMRAMSLVSNEGDSEQNEIRSLQEKLESTMSLVKQLSGQLAELKEQMTEQRKNKQRLGFLGSNTPHVNHHMPPH
T76678	DRUGINFO	D06YZB	inositol 2,4,5-trisphosphate	Investigative
T76678	DRUGINFO	D06KHR	decavanadate	Investigative

T59856	TARGETID	T59856
T59856	FORMERID	TTDNC00593
T59856	UNIPROID	GPNMB_HUMAN
T59856	TARGNAME	Transmembrane glycoprotein NMB (GPNMB)
T59856	GENENAME	GPNMB
T59856	TARGTYPE	Literature-reported
T59856	SYNONYMS	NMB; Hematopoietic growth factor inducible neurokinin-1 type; HGFIN
T59856	FUNCTION	Could be a melanogenic enzyme.
T59856	SEQUENCE	MECLYYFLGFLLLAARLPLDAAKRFHDVLGNERPSAYMREHNQLNGWSSDENDWNEKLYPVWKRGDMRWKNSWKGGRVQAVLTSDSPALVGSNITFAVNLIFPRCQKEDANGNIVYEKNCRNEAGLSADPYVYNWTAWSEDSDGENGTGQSHHNVFPDGKPFPHHPGWRRWNFIYVFHTLGQYFQKLGRCSVRVSVNTANVTLGPQLMEVTVYRRHGRAYVPIAQVKDVYVVTDQIPVFVTMFQKNDRNSSDETFLKDLPIMFDVLIHDPSHFLNYSTINYKWSFGDNTGLFVSTNHTVNHTYVLNGTFSLNLTVKAAAPGPCPPPPPPPRPSKPTPSLATTLKSYDSNTPGPAGDNPLELSRIPDENCQINRYGHFQATITIVEGILEVNIIQMTDVLMPVPWPESSLIDFVVTCQGSIPTEVCTIISDPTCEITQNTVCSPVDVDEMCLLTVRRTFNGSGTYCVNLTLGDDTSLALTSTLISVPDRDPASPLRMANSALISVGCLAIFVTVISLLVYKKHKEYNPIENSPGNVVRSKGLSVFLNRAKAVFFPGNQEKDPLLKNQEFKGVS

T72595	TARGETID	T72595
T72595	FORMERID	TTDI03224
T72595	UNIPROID	NMDE3_HUMAN
T72595	TARGNAME	Glutamate receptor ionotropic NMDA 2C (GluN2C)
T72595	GENENAME	GRIN2C
T72595	TARGTYPE	Literature-reported
T72595	SYNONYMS	NR2C; NMDAR2C; N-methyl D-aspartate receptor subtype 2C; Glutamate receptor ionotropic, NMDA 2C; Glutamate [NMDA] receptor subunit epsilon-3; GluN2C
T72595	FUNCTION	Component of NMDA receptor complexes that function as heterotetrameric, ligand-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Channel activation requires binding of the neurotransmitter glutamate to the epsilon subunit, glycine binding to the zeta subunit, plus membrane depolarization to eliminate channel inhibition by Mg(2+). Sensitivity to glutamate and channel kinetics depend on the subunit composition (Probable). Plays a role in regulating the balance between excitatory and inhibitory activity of pyramidal neurons in the prefrontal cortex. Contributes to the slow phase of excitatory postsynaptic current, long-term synaptic potentiation, and learning (By similarity).
T72595	SEQUENCE	MGGALGPALLLTSLFGAWAGLGPGQGEQGMTVAVVFSSSGPPQAQFRARLTPQSFLDLPLEIQPLTVGVNTTNPSSLLTQICGLLGAAHVHGIVFEDNVDTEAVAQILDFISSQTHVPILSISGGSAVVLTPKEPGSAFLQLGVSLEQQLQVLFKVLEEYDWSAFAVITSLHPGHALFLEGVRAVADASHVSWRLLDVVTLELGPGGPRARTQRLLRQLDAPVFVAYCSREEAEVLFAEAAQAGLVGPGHVWLVPNLALGSTDAPPATFPVGLISVVTESWRLSLRQKVRDGVAILALGAHSYWRQHGTLPAPAGDCRVHPGPVSPAREAFYRHLLNVTWEGRDFSFSPGGYLVQPTMVVIALNRHRLWEMVGRWEHGVLYMKYPVWPRYSASLQPVVDSRHLTVATLEERPFVIVESPDPGTGGCVPNTVPCRRQSNHTFSSGDVAPYTKLCCKGFCIDILKKLARVVKFSYDLYLVTNGKHGKRVRGVWNGMIGEVYYKRADMAIGSLTINEERSEIVDFSVPFVETGISVMVARSNGTVSPSAFLEPYSPAVWVMMFVMCLTVVAITVFMFEYFSPVSYNQNLTRGKKSGGPAFTIGKSVWLLWALVFNNSVPIENPRGTTSKIMVLVWAFFAVIFLASYTANLAAFMIQEQYIDTVSGLSDKKFQRPQDQYPPFRFGTVPNGSTERNIRSNYRDMHTHMVKFNQRSVEDALTSLKMGKLDAFIYDAAVLNYMAGKDEGCKLVTIGSGKVFATTGYGIAMQKDSHWKRAIDLALLQFLGDGETQKLETVWLSGICQNEKNEVMSSKLDIDNMAGVFYMLLVAMGLALLVFAWEHLVYWKLRHSVPNSSQLDFLLAFSRGIYSCFSGVQSLASPPRQASPDLTASSAQASVLKMLQAARDMVTTAGVSSSLDRATRTIENWGGGRRAPPPSPCPTPRSGPSPCLPTPDPPPEPSPTGWGPPDGGRAALVRRAPQPPGRPPTPGPPLSDVSRVSRRPAWEARWPVRTGHCGRHLSASERPLSPARCHYSSFPRADRSGRPFLPLFPELEDLPLLGPEQLARREALLHAAWARGSRPRHASLPSSVAEAFARPSSLPAGCTGPACARPDGHSACRRLAQAQSMCLPIYREACQEGEQAGAPAWQHRQHVCLHAHAHLPFCWGAVCPHLPPCASHGSWLSGAWGPLGHRGRTLGLGTGYRDSGGLDEISRVARGTQGFPGPCTWRRISSLESEV
T72595	DRUGINFO	D03UNN	L-689560	Terminated
T72595	DRUGINFO	D0HF0A	DQP-1105	Investigative
T72595	DRUGINFO	D02PXN	N1-dansyl-spermine	Investigative
T72595	DRUGINFO	D03XLS	d-CCPene	Investigative
T72595	DRUGINFO	D04NPE	UBP141	Investigative
T72595	DRUGINFO	D08RVB	LY233053	Investigative
T72595	DRUGINFO	D0FT0J	d-AP5	Investigative
T72595	DRUGINFO	D00ZKW	[3H]CPP	Investigative
T72595	DRUGINFO	D06GKL	2-Methylamino-succinic acid(NMDA)	Investigative
T72595	DRUGINFO	D07COG	[3H]MDL105519	Investigative
T72595	DRUGINFO	D08UDC	[3H]CGP39653	Investigative
T72595	DRUGINFO	D0B5ZA	homoquinolinic acid	Investigative
T72595	DRUGINFO	D0D2ZH	[3H]dizocilpine	Investigative
T72595	DRUGINFO	D0F5ZW	CGP61594	Investigative
T72595	DRUGINFO	D0FW8K	(RS)-(tetrazol-5-yl)glycine	Investigative
T72595	DRUGINFO	D0KO6Y	[3H]CGS19755	Investigative
T72595	DRUGINFO	D0OT9B	L-aspartic acid	Investigative
T72595	DRUGINFO	D08CAB	D-aspartic acid	Investigative

T87588	TARGETID	T87588
T87588	FORMERID	TTDI03222
T87588	UNIPROID	GRIK4_HUMAN
T87588	TARGNAME	Glutamate receptor ionotropic kainate 4 (GluK4)
T87588	GENENAME	GRIK4
T87588	TARGTYPE	Literature-reported
T87588	SYNONYMS	KA1; Glutamate receptor ionotropic, kainate 4; Glutamate receptor KA-1; GluK4; GRIK; Excitatory amino acid receptor 1; EAA1
T87588	FUNCTION	Receptor for glutamate. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists.
T87588	SEQUENCE	MPRVSAPLVLLPAWLVMVACSPHSLRIAAILDDPMECSRGERLSITLAKNRINRAPERLGKAKVEVDIFELLRDSEYETAETMCQILPKGVVAVLGPSSSPASSSIISNICGEKEVPHFKVAPEEFVKFQFQRFTTLNLHPSNTDISVAVAGILNFFNCTTACLICAKAECLLNLEKLLRQFLISKDTLSVRMLDDTRDPTPLLKEIRDDKTATIIIHANASMSHTILLKAAELGMVSAYYTYIFTNLEFSLQRMDSLVDDRVNILGFSIFNQSHAFFQEFAQSLNQSWQENCDHVPFTGPALSSALLFDAVYAVVTAVQELNRSQEIGVKPLSCGSAQIWQHGTSLMNYLRMVELEGLTGHIEFNSKGQRSNYALKILQFTRNGFRQIGQWHVAEGLSMDSHLYASNISDTLFNTTLVVTTILENPYLMLKGNHQEMEGNDRYEGFCVDMLKELAEILRFNYKIRLVGDGVYGVPEANGTWTGMVGELIARKADLAVAGLTITAEREKVIDFSKPFMTLGISILYRVHMGRKPGYFSFLDPFSPGVWLFMLLAYLAVSCVLFLVARLTPYEWYSPHPCAQGRCNLLVNQYSLGNSLWFPVGGFMQQGSTIAPRALSTRCVSGVWWAFTLIIISSYTANLAAFLTVQRMDVPIESVDDLADQTAIEYGTIHGGSSMTFFQNSRYQTYQRMWNYMYSKQPSVFVKSTEEGIARVLNSNYAFLLESTMNEYYRQRNCNLTQIGGLLDTKGYGIGMPVGSVFRDEFDLAILQLQENNRLEILKRKWWEGGKCPKEEDHRAKGLGMENIGGIFVVLICGLIVAIFMAMLEFLWTLRHSEATEVSVCQEMVTELRSIILCQDSIHPRRRRAAVPPPRPPIPEERRPRGTATLSNGKLCGAGEPDQLAQRLAQEAALVARGCTHIRVCPECRRFQGLRARPSPARSEESLEWEKTTNSSEPE
T87588	DRUGINFO	D09KRH	domoic acid	Investigative
T87588	DRUGINFO	D0K6AF	dysiherbaine	Investigative
T87588	DRUGINFO	D0S8AN	SYM2081	Investigative
T87588	DRUGINFO	D04PFN	[3H]kainate	Investigative

T90843	TARGETID	T90843
T90843	FORMERID	TTDI02060
T90843	UNIPROID	ENOX2_HUMAN
T90843	TARGNAME	Tumor-associated hydroquinone oxidase (tNOX)
T90843	GENENAME	ENOX2
T90843	TARGTYPE	Literature-reported
T90843	SYNONYMS	Tumorassociated hydroquinone oxidase; Protein disulfidethiol oxidoreductase; EctoNOX disulfidethiol exchanger 2; Ecto-NOX disulfide-thiol exchanger 2; Cytosolic ovarian carcinoma antigen 1; COVA1; APK1 antigen
T90843	FUNCTION	Probably acts as a terminal oxidase of plasma electron transport from cytosolic NAD(P)H via hydroquinones to acceptors at the cell surface. Hydroquinone oxidase activity alternates with a protein disulfide-thiol interchange/oxidoreductase activity which may control physical membrane displacements associated with vesicle budding or cell enlargement. The activities oscillate with a period length of 22 minutes and play a role in control of the ultradian cellular biological clock. May be involved in cell growth.
T90843	SEQUENCE	MQRDFRWLWVYEIGYAADNSRTLNVDSTAMTLPMSDPTAWATAMNNLGMAPLGIAGQPILPDFDPALGMMTGIPPITPMMPGLGIVPPPIPPDMPVVKEIIHCKSCTLFPPNPNLPPPATRERPPGCKTVFVGGLPENGTEQIIVEVFEQCGEIIAIRKSKKNFCHIRFAEEYMVDKALYLSGYRIRLGSSTDKKDTGRLHVDFAQARDDLYEWECKQRMLAREERHRRRMEEERLRPPSPPPVVHYSDHECSIVAEKLKDDSKFSEAVQTLLTWIERGEVNRRSANNFYSMIQSANSHVRRLVNEKAAHEKDMEEAKEKFKQALSGILIQFEQIVAVYHSASKQKAWDHFTKAQRKNISVWCKQAEEIRNIHNDELMGIRREEEMEMSDDEIEEMTETKETEESALVSQAEALKEENDSLRWQLDAYRNEVELLKQEQGKVHREDDPNKEQQLKLLQQALQGMQQHLLKVQEEYKKKEAELEKLKDDKLQVEKMLENLKEKESCASRLCASNQDSEYPLEKTMNSSPIKSEREALLVGIISTFLHVHPFGASIEYICSYLHRLDNKICTSDVECLMGRLQHTFKQEMTGVGASLEKRWKFCGFEGLKLT

T30219	TARGETID	T30219
T30219	FORMERID	TTDI03067
T30219	UNIPROID	C3AR_HUMAN
T30219	TARGNAME	C3a anaphylatoxin chemotactic receptor (C3AR1)
T30219	GENENAME	C3AR1
T30219	TARGTYPE	Literature-reported
T30219	SYNONYMS	HNFAG09; C3a-R; C3R1; C3AR; AZ3B
T30219	FUNCTION	Receptor for the chemotactic and inflammatory peptide anaphylatoxin C3a. This receptor stimulates chemotaxis, granule enzyme release and superoxide anion production.
T30219	SEQUENCE	MASFSAETNSTDLLSQPWNEPPVILSMVILSLTFLLGLPGNGLVLWVAGLKMQRTVNTIWFLHLTLADLLCCLSLPFSLAHLALQGQWPYGRFLCKLIPSIIVLNMFASVFLLTAISLDRCLVVFKPIWCQNHRNVGMACSICGCIWVVAFVMCIPVFVYREIFTTDNHNRCGYKFGLSSSLDYPDFYGDPLENRSLENIVQPPGEMNDRLDPSSFQTNDHPWTVPTVFQPQTFQRPSADSLPRGSARLTSQNLYSNVFKPADVVSPKIPSGFPIEDHETSPLDNSDAFLSTHLKLFPSASSNSFYESELPQGFQDYYNLGQFTDDDQVPTPLVAITITRLVVGFLLPSVIMIACYSFIVFRMQRGRFAKSQSKTFRVAVVVVAVFLVCWTPYHIFGVLSLLTDPETPLGKTLMSWDHVCIALASANSCFNPFLYALLGKDFRKKARQSIQGILEAAFSEELTRSTHCPSNNVISERNSTTV
T30219	DRUGINFO	D01OIJ	PMID25259874C21	Investigative
T30219	DRUGINFO	D01QQD	PMID25259874C4	Investigative
T30219	DRUGINFO	D0S8NM	SB290157	Investigative

T90334	TARGETID	T90334
T90334	UNIPROID	Q16ME2_AEDAE
T90334	TARGNAME	Yellow fever mosquito Eggshell organizing factor 1 (YFM EOF1)
T90334	GENENAME	YFM EOF1
T90334	TARGTYPE	Literature-reported
T90334	SYNONYMS	AAEL012336-PA
T90334	FUNCTION	Plays an essential role in the formation and melanization of the eggshell.
T90334	SEQUENCE	MEESQQLQFPIRGNNNNKPLNVSGGNDGSGQFTDSGYTSYHSISASGSVARSVLATIEEDNEADSSFEEARSSEDIFQMGGGSNVLTPTTAASIERISNFHLTTPNSTGKPVGQHRGLVRKPTFDNLFEQYTPKKADYGPPCRTTQTPVRSDRKVELGSQTPRKNKASAKRKLGEFREKLYSDGDALELAPSRDLNDSLEGDCKKLDQEDISPIYHTKRRRSSVIDLIRSSTPKTASLRSNFHVEVRENIDWDAVQQGKASGRGGKSRALRKFQSFSPSKMHSYKKRDVLQEKSVIANRRAPFQRQDALRQVSLEQDLSKQSTPQKAQESSLDKSFELPLEGLITPSKQSNLGVLLDAPILVQPSSEADFKESDLEQQISQIPSFEECAYPQTPSKQTLSLDDSGVIRHAPVCTEVNKSIPSILGTESPSFVSLSIPKTPTSTNKSRNRLKRLSSTKKDKPRSKPPSPIHRAQPFIPGTYRRPSYVNVERLNILKWLNEHDKDALGIVLDYLNDSDLVRVVRVSTGWRDIIEHHRPSYRRLRAHFAREKEVKENLSFPSFVSREGSLLGKTGGSLLSSFGDSSKEIAVSLPRQPFSLCNSIDSNQSVGGELRRSGSVQRSPPVSPSKRKFRENQKIASHLKKSERLKPCPRCEKPSRVVLTKSSIKLAMATGSLDSSTTRTVASGKLDRSYTLPDSLMGSSATSMIAAAALDCTSTTIGSPQSPTNPDRIRRNLFSTSLLPRSQSVDARTPVTRSPRRRRSTDVQGSSASLLERKNGKTKSAEAIQCDYAVCSGKNCGFMFCIKCLCEYHPSSVCKDLAPNSPSKEDEPAHNVACSKQSRRSLLRLRK

T57843	TARGETID	T57843
T57843	FORMERID	TTDR00660
T57843	UNIPROID	LY6K_HUMAN
T57843	TARGNAME	Lymphocyte antigen 6K (LY6K)
T57843	GENENAME	LY6K
T57843	TARGTYPE	Literature-reported
T57843	SYNONYMS	Ly-6K; CO16
T57843	FUNCTION	Required for sperm migration into the oviduct and male fertility by controlling binding of sperm to zona pellucida (By similarity). May play a role in cell growth.
T57843	SEQUENCE	MALLALLLVVALPRVWTDANLTARQRDPEDSQRTDEGDNRVWCHVCERENTFECQNPRRCKWTEPYCVIAAVKIFPRFFMVAKQCSAGCAAMERPKPEEKRFLLEEPMPFFYLKCCKIRYCNLEGPPINSSVFKEYAGSMGESCGGLWLAILLLLASIAAGLSLS

T83064	TARGETID	T83064
T83064	FORMERID	TTDR00997
T83064	UNIPROID	GBLP_LEIMA
T83064	TARGNAME	Leishmania Guanine nucleotide-binding protein (Leishm LACK)
T83064	GENENAME	Leishm LACK
T83064	TARGTYPE	Literature-reported
T83064	SYNONYMS	Guanine nucleotide-binding protein subunit beta-like protein; Antigen LACK
T83064	FUNCTION	Involved as modulators or transducers in various transmembrane signaling systems.
T83064	SEQUENCE	MNYEGHLKGHRGWVTSLACPQQAGSYIKVVSTSRDGTVISWKANPDRHSVDSDYGLPNHRLEGHTGFVSCVSLAHATDYALTASWDRSIRMWDLRNGQCQRKFLKHTKDVLAVAFSPDDRLIVSAGRDNVIRVWNVAGECMHEFLRDGHEDWVSSICFSPSLEHPIVVSGSWDNTIKVWNVNGGKCERTLKGHSNYVSTVTVSPDGSLCASGGKDGAALLWDLSTGEQLFKINVESPINQIGFSPNRFWMCVATERSLSVYDLESKAVIAELTPDGAKPSECISIAWSADGNTLYSGHKDNLIRVWSISDAE

T39684	TARGETID	T39684
T39684	FORMERID	TTDR00914
T39684	UNIPROID	DQB2_HUMAN
T39684	TARGNAME	Leukocyte antigen class II (HLA-DQB2)
T39684	GENENAME	HLA-DQB2
T39684	TARGTYPE	Literature-reported
T39684	SYNONYMS	MHC class II antigen DQB2; HLA-DXB; HLA class II histocompatibility antigen, DX beta chain; HLA class II histocompatibility antigen, DQ beta 2 chain
T39684	FUNCTION	Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.
T39684	SEQUENCE	MSWKMALQIPGGFWAAAVTVMLVMLSTPVAEARDFPKDFLVQFKGMCYFTNGTERVRGVARYIYNREEYGRFDSDVGEFQAVTELGRSIEDWNNYKDFLEQERAAVDKVCRHNYEAELRTTLQRQVEPTVTISPSRTEALNHHNLLVCSVTDFYPAQIKVRWFRNDQEETAGVVSTSLIRNGDWTFQILVMLEITPQRGDIYTCQVEHPSLQSPITVEWRAQSESAQSKMLSGIGGFVLGLIFLGLGLIIRHRGQKGPRGPPPAGLLH

T26923	TARGETID	T26923
T26923	FORMERID	TTDR01111
T26923	UNIPROID	Q2L8D9_HUMAN
T26923	TARGNAME	Abeta-binding alcohol dehydrogenase (ABAD)
T26923	GENENAME	ABAD
T26923	TARGTYPE	Literature-reported
T26923	SYNONYMS	Amyloid beta-binding alcohol dehydrogenase
T26923	FUNCTION	A direct molecular link from Abeta to mitochondrial toxicity. An ABAD peptide specifically inhibits ABAD-Abeta interaction and suppresses Abeta-induced apoptosis and free-radical generation in neurons. 
T26923	SEQUENCE	MAAACRSVK

T97858	TARGETID	T97858
T97858	FORMERID	TTDI01463
T97858	UNIPROID	GAPN_STREI
T97858	TARGNAME	Streptococcus Triosephosphate dehydrogenase (Stre gapN)
T97858	GENENAME	Stre gapN
T97858	TARGTYPE	Literature-reported
T97858	SYNONYMS	Triosephosphate dehydrogenase; Non-phosphorylating glyceraldehyde 3-phosphate dehydrogenase; NADP-dependent glyceraldehyde-3-phosphate dehydrogenase; Glyceraldehyde-3-phosphate dehydrogenase [NADP(+)]; GAPN
T97858	FUNCTION	Catalyzes the irreversible NADP-dependent oxidation of glyceraldehyde-3-phosphate to 3-phosphoglycerate. Is not able to use NAD instead of NADP. May play an important role in NADPH production in S.equinus.
T97858	SEQUENCE	MTKQYKNYVNGEWKLSKEEIKIYAPATGEELGSVPAMSQEEVDYVYASAKAAQKAWRALSYVERAEYLHKAADILMRDAEKIGAVLSKEIAKGYKSAVGEVIRTAEIINYAAEEGVRLEGEVLEGGSFDPASKKKIAIVRREPVGLVLAISPFNYPINLAGSKIAPALISGNVVALKPPTQGSISGLLLAEAFAEAGLPAGVFNTITGRGSVIGDYIVEHEAVNYINFTGSTPVGEHIGHLAGMRPIMLELGGKDSAIILEDADLDLAAKNIVAGAYGYSGQRCTAVKRVLVMDSIADKLVEKVSALVNNLTVGMPEDNADITPLIDTKAADYVEGLIKDAQEKGAKEVISFKREGNLISPVLFDNVTTDMRLAWEEPFGPVLPFIRVNSVEEAIEISNKSEYGLQASVFTNNFPLAFKIAEQLEVGTVHINNKTQRGTDNFPFLGAKKSGAGVQGVKYSIEAMTTVKSTVFDIAK

T80966	TARGETID	T80966
T80966	FORMERID	TTDI00133
T80966	UNIPROID	AX2R_HUMAN
T80966	TARGNAME	Annexin II receptor (ANXA2R)
T80966	GENENAME	ANXA2R
T80966	TARGTYPE	Literature-reported
T80966	SYNONYMS	Annexin2 receptor; AXIIR; ANXA2R
T80966	FUNCTION	May act as a receptor for annexin II on marrow stromal cells to induce osteoclast formation.
T80966	SEQUENCE	MEQHFLGCVKRAWDSAEVAPEPQPPPIVSSEDRGPWPLPLYPVLGEYSLDSCDLGLLSSPCWRLPGVYWQNGLSPGVQSTLEPSTAKPTEFSWPGTQKQQEAPVEEVGQAEEPDRLRLQQLPWSSPLHPWDRQQDTEVCDSGCLLERRHPPALQPWRHLPGFSDCLEWILRVGFAAFSVLWACCSRICGAKQP

T32938	TARGETID	T32938
T32938	FORMERID	TTDI03500
T32938	UNIPROID	S36A2_HUMAN
T32938	TARGNAME	Solute carrier family 36 member 2 (SLC36A2)
T32938	GENENAME	SLC36A2
T32938	TARGTYPE	Literature-reported
T32938	SYNONYMS	Tramdorin-1; TRAMD1; Proton/amino acid transporter 2; Proton-coupled amino acid transporter 2; PAT2
T32938	FUNCTION	Involved in a pH-dependent electrogenic neuronal transport and sequestration of small amino acids. Transports glycine and proline. Inhibited by sarcosine (By similarity).
T32938	SEQUENCE	MSVTKSTEGPQGAVAIKLDLMSPPESAKKLENKDSTFLDESPSESAGLKKTKGITVFQALIHLVKGNMGTGILGLPLAVKNAGILMGPLSLLVMGFIACHCMHILVKCAQRFCKRLNKPFMDYGDTVMHGLEANPNAWLQNHAHWGRHIVSFFLIITQLGFCCVYIVFLADNLKQVVEAVNSTTNNCYSNETVILTPTMDSRLYMLSFLPFLVLLVLIRNLRILTIFSMLANISMLVSLVIIIQYITQEIPDPSRLPLVASWKTYPLFFGTAIFSFESIGVVLPLENKMKNARHFPAILSLGMSIVTSLYIGMAALGYLRFGDDIKASISLNLPNCWLYQSVKLLYIAGILCTYALQFYVPAEIIIPFAISRVSTRWALPLDLSIRLVMVCLTCLLAILIPRLDLVISLVGSVSGTALALIIPPLLEVTTFYSEGMSPLTIFKDALISILGFVGFVVGTYQALDELLKSEDSHPFSNSTTFVR
T32938	DRUGINFO	D0OX9Q	NOX-200	Terminated
T32938	DRUGINFO	D09BNS	5-hydroxy-L-tryptophan	Investigative

T47510	TARGETID	T47510
T47510	FORMERID	TTDI02644
T47510	UNIPROID	AMOT_HUMAN
T47510	TARGNAME	Angiomotin (AMOT)
T47510	GENENAME	AMOT
T47510	TARGTYPE	Literature-reported
T47510	SYNONYMS	KIAA1071
T47510	FUNCTION	Appears to regulate endothelial cell migration and tube formation. May also play a role in the assembly of endothelial cell-cell junctions. Plays a central role in tight junction maintenance via the complex formed with ARHGAP17, which acts by regulating the uptake of polarity proteins at tight junctions.
T47510	SEQUENCE	MRNSEEQPSGGTTVLQRLLQEQLRYGNPSENRSLLAIHQQATGNGPPFPSGSGNPGPQSDVLSPQDHHQQLVAHAARQEPQGQEIQSENLIMEKQLSPRMQNNEELPTYEEAKVQSQYFRGQQHASVGAAFYVTGVTNQKMRTEGRPSVQRLNPGKMHQDEGLRDLKQGHVRSLSERLMQMSLATSGVKAHPPVTSAPLSPPQPNDLYKNPTSSSEFYKAQGPLPNQHSLKGMEHRGPPPEYPFKGMPPQSVVCKPQEPGHFYSEHRLNQPGRTEGQLMRYQHPPEYGAARPAQDISLPLSARNSQPHSPTSSLTSGGSLPLLQSPPSTRLSPARHPLVPNQGDHSAHLPRPQQHFLPNQAHQGDHYRLSQPGLSQQQQQQQQQHHHHHHHQQQQQQQPQQQPGEAYSAMPRAQPSSASYQPVPADPFAIVSRAQQMVEILSDENRNLRQELEGCYEKVARLQKVETEIQRVSEAYENLVKSSSKREALEKAMRNKLEGEIRRMHDFNRDLRERLETANKQLAEKEYEGSEDTRKTISQLFAKNKESQREKEKLEAELATARSTNEDQRRHIEIRDQALSNAQAKVVKLEEELKKKQVYVDKVEKMQQALVQLQAACEKREQLEHRLRTRLERELESLRIQQRQGNCQPTNVSEYNAAALMELLREKEERILALEADMTKWEQKYLEENVMRHFALDAAATVAAQRDTTVISHSPNTSYDTALEARIQKEEEEILMANKRCLDMEGRIKTLHAQIIEKDAMIKVLQQRSRKEPSKTEQLSCMRPAKSLMSISNAGSGLLSHSSTLTGSPIMEEKRDDKSWKGSLGILLGGDYRAEYVPSTPSPVPPSTPLLSAHSKTGSRDCSTQTERGTESNKTAAVAPISVPAPVAAAATAAAITATAATITTTMVAAAPVAVAAAAAPAAAAAPSPATAAATAAAVSPAAAGQIPAAASVASAAAVAPSAAAAAAVQVAPAAPAPVPAPALVPVPAPAAAQASAPAQTQAPTSAPAVAPTPAPTPTPAVAQAEVPASPATGPGPHRLSIPSLTCNPDKTDGPVFHSNTLERKTPIQILGQEPDAEMVEYLI

T93722	TARGETID	T93722
T93722	FORMERID	TTDI01252
T93722	UNIPROID	FNDC1_HUMAN
T93722	TARGNAME	Activation-associated cDNA protein (FNDC1)
T93722	GENENAME	FNDC1
T93722	TARGTYPE	Literature-reported
T93722	SYNONYMS	MEL4B3; KIAA1866; Fibronectin type III domain-containing protein 1; FNDC2; Expressed in synovial lining protein
T93722	FUNCTION	May be an activator of G protein signaling.
T93722	SEQUENCE	MAPEAGATLRAPRRLSWAALLLLAALLPVASSAAASVDHPLKPRHVKLLSTKMGLKVTWDPPKDATSRPVEHYNIAYGKSLKSLKYIKVNAETYSFLIEDVEPGVVYFVLLTAENHSGVSRPVYRAESPPGGEWIEIDGFPIKGPGPFNETVTEKEVPNKPLRVRVRSSDDRLSVAWKAPRLSGAKSPRRSRGFLLGYGESGRKMNYVPLTRDERTHEIKKLASESVYVVSLQSMNSQGRSQPVYRAALTKRKISEEDELDVPDDISVRVMSSQSVLVSWVDPVLEKQKKVVASRQYTVRYREKGELARWDYKQIANRRVLIENLIPDTVYEFAVRISQGERDGKWSTSVFQRTPESAPTTAPENLNVWPVNGKPTVVAASWDALPETEGKVKEYILSYAPALKPFGAKSLTYPGDTTSALVDGLQPGERYLFKIRATNRRGLGPHSKAFIVAMPTTSKADVEQNTEDNGKPEKPEPSSPSPRAPASSQHPSVPASPQGRNAKDLLLDLKNKILANGGAPRKPQLRAKKAEELDLQSTEITGEEELGSREDSPMSPSDTQDQKRTLRPPSRHGHSVVAPGRTAVRARMPALPRREGVDKPGFSLATQPRPGAPPSASASPAHHASTQGTSHRPSLPASLNDNDLVDSDEDERAVGSLHPKGAFAQPRPALSPSRQSPSSVLRDRSSVHPGAKPASPARRTPHSGAAEEDSSASAPPSRLSPPHGGSSRLLPTQPHLSSPLSKGGKDGEDAPATNSNAPSRSTMSSSVSSHLSSRTQVSEGAEASDGESHGDGDREDGGRQAEATAQTLRARPASGHFHLLRHKPFAANGRSPSRFSIGRGPRLQPSSSPQSTVPSRAHPRVPSHSDSHPKLSSGIHGDEEDEKPLPATVVNDHVPSSSRQPISRGWEDLRRSPQRGASLHRKEPIPENPKSTGADTHPQGKYSSLASKAQDVQQSTDADTEGHSPKAQPGSTDRHASPARPPAARSQQHPSVPRRMTPGRAPQQQPPPPVATSQHHPGPQSRDAGRSPSQPRLSLTQAGRPRPTSQGRSHSSSDPYTASSRGMLPTALQNQDEDAQGSYDDDSTEVEAQDVRAPAHAARAKEAAASLPKHQQVESPTGAGAGGDHRSQRGHAASPARPSRPGGPQSRARVPSRAAPGKSEPPSKRPLSSKSQQSVSAEDDEEEDAGFFKGGKEDLLSSSVPKWPSSSTPRGGKDADGSLAKEEREPAIALAPRGGSLAPVKRPLPPPPGSSPRASHVPSRLPPRSAATVSPVAGTHPWPQYTTRAPPGHFSTTPMLSLRQRMMHARFRNPLSRQPARPSYRQGYNGRPNVEGKVLPGSNGKPNGQRIINGPQGTKWVVDLDRGLVLNAEGRYLQDSHGNPLRIKLGGDGRTIVDLEGTPVVSPDGLPLFGQGRHGTPLANAQDKPILSLGGKPLVGLEVIKKTTHPPTTTMQPTTTTTPLPTTTTPRPTTATTRRTTTTRRTTTRRPTTTVRTTTRTTTTTTPTPTTPIPTCPPGTLERHDDDGNLIMSSNGIPECYAEEDEFSGLETDTAVPTEEAYVIYDEDYEFETSRPPTTTEPSTTATTPRVIPEEGAISSFPEEEFDLAGRKRFVAPYVTYLNKDPSAPCSLTDALDHFQVDSLDEIIPNDLKKSDLPPQHAPRNITVVAVEGCHSFVIVDWDKATPGDVVTGYLVYSASYEDFIRNKWSTQASSVTHLPIENLKPNTRYYFKVQAQNPHGYGPISPSVSFVTESDNPLLVVRPPGGEPIWIPFAFKHDPSYTDCHGRQYVKRTWYRKFVGVVLCNSLRYKIYLSDNLKDTFYSIGDSWGRGEDHCQFVDSHLDGRTGPQSYVEALPTIQGYYRQYRQEPVRFGNIGFGTPYYYVGWYECGVSIPGKW

T41075	TARGETID	T41075
T41075	FORMERID	TTDR01319
T41075	UNIPROID	RABL3_HUMAN
T41075	TARGNAME	Rab-like protein 3 (RABL3)
T41075	GENENAME	RABL3
T41075	TARGTYPE	Literature-reported
T41075	SYNONYMS	Rab-like protein 3
T41075	FUNCTION	GTPase activity, intracellular protein transport, Rab protein signal transduction
T41075	SEQUENCE	MASLDRVKVLVLGDSGVGKSSLVHLLCQNQVLGNPSWTVGCSVDVRVHDYKEGTPEEKTYYIELWDVGGSVGSASSVKSTRAVFYNSVNGIIFVHDLTNKKSSQNLRRWSLEALNRDLVPTGVLVTNGDYDQEQFADNQIPLLVIGTKLDQIHETKRHEVLTRTAFLAEDFNPEEINLDCTNPRYLAAGSSNAVKLSRFFDKVIEKRYFLREGNQIPGFPDRKRFGAGTLKSLHYD

T72032	TARGETID	T72032
T72032	FORMERID	TTDI03250
T72032	UNIPROID	GPC6A_HUMAN
T72032	TARGNAME	G-protein coupled receptor GPCR33 (GPRC6A)
T72032	GENENAME	GPRC6A
T72032	TARGTYPE	Literature-reported
T72032	SYNONYMS	hGPRC6A; hGPCR33; G-protein coupled receptor family C group 6 member A
T72032	FUNCTION	Receptor activated by amino acids with a preference for basic amino acids such as L-Lys, L-Arg and L-ornithine but also by small and polar amino acids. The L-alpha amino acids respond is augmented by divalent cations Ca(2+) and Mg(2+). Activated by extracellular calcium and osteocalcin. Seems to act through a G(q)/G(11) and G(i)-coupled pathway. Mediates the non-genomic effects of androgens in multiple tissue. May coordinate nutritional and hormonal anabolic signals through the sensing of extracellular amino acids, osteocalcin, divalent ions and its responsiveness to anabolic steroids.
T72032	SEQUENCE	MAFLIILITCFVIILATSQPCQTPDDFVAATSPGHIIIGGLFAIHEKMLSSEDSPRRPQIQECVGFEISVFLQTLAMIHSIEMINNSTLLPGVKLGYEIYDTCTEVTVAMAATLRFLSKFNCSRETVEFKCDYSSYMPRVKAVIGSGYSEITMAVSRMLNLQLMPQVGYESTAEILSDKIRFPSFLRTVPSDFHQIKAMAHLIQKSGWNWIGIITTDDDYGRLALNTFIIQAEANNVCIAFKEVLPAFLSDNTIEVRINRTLKKIILEAQVNVIVVFLRQFHVFDLFNKAIEMNINKMWIASDNWSTATKITTIPNVKKIGKVVGFAFRRGNISSFHSFLQNLHLLPSDSHKLLHEYAMHLSACAYVKDTDLSQCIFNHSQRTLAYKANKAIERNFVMRNDFLWDYAEPGLIHSIQLAVFALGYAIRDLCQARDCQNPNAFQPWELLGVLKNVTFTDGWNSFHFDAHGDLNTGYDVVLWKEINGHMTVTKMAEYDLQNDVFIIPDQETKNEFRNLKQIQSKCSKECSPGQMKKTTRSQHICCYECQNCPENHYTNQTDMPHCLLCNNKTHWAPVRSTMCFEKEVEYLNWNDSLAILLLILSLLGIIFVLVVGIIFTRNLNTPVVKSSGGLRVCYVILLCHFLNFASTSFFIGEPQDFTCKTRQTMFGVSFTLCISCILTKSLKILLAFSFDPKLQKFLKCLYRPILIIFTCTGIQVVICTLWLIFAAPTVEVNVSLPRVIILECEEGSILAFGTMLGYIAILAFICFIFAFKGKYENYNEAKFITFGMLIYFIAWITFIPIYATTFGKYVPAVEIIVILISNYGILYCTFIPKCYVIICKQEINTKSAFLKMIYSYSSHSVSSIALSPASLDSMSGNVTMTNPSSSGKSATWQKSKDLQAQAFAHICRENATSVSKTLPRKRMSSI
T72032	DRUGINFO	D01XPY	L-citrulline	Phase 3
T72032	DRUGINFO	D03ZNB	L-ornithine	Investigative
T72032	DRUGINFO	D07TMZ	L-lysine	Investigative
T72032	DRUGINFO	D0T6GM	L-serine	Investigative
T72032	DRUGINFO	D0HS5P	calindol	Investigative

T75307	TARGETID	T75307
T75307	FORMERID	TTDR01152
T75307	UNIPROID	Q69128_EBVG
T75307	TARGNAME	Epstein-Barr virus Nuclear antigen gene (EBV NA)
T75307	GENENAME	EBV NA
T75307	TARGTYPE	Literature-reported
T75307	SYNONYMS	EBV Uncharacterized protein
T75307	FUNCTION	A multifunctional, dimeric viral protein associated with EpsteinBarr virus (EBV). The only EBV protein found in all EBV-related malignancies.
T75307	SEQUENCE	MSDEGPGTGPGNGLGEKGDTSGPEGSGGSGPQRRGGDNHGRGRGRGRGRGGGRPGAPG

T36721	TARGETID	T36721
T36721	FORMERID	TTDR00515
T36721	UNIPROID	Q69133_EBVG
T36721	TARGNAME	Epstein-Barr virus Latent membrane protein 2A (EBV LMP2A)
T36721	GENENAME	EBV LMP2A
T36721	TARGTYPE	Literature-reported
T36721	SYNONYMS	Latent membrane protein 2A
T36721	FUNCTION	A virally encoded membrane protein that is expressed in EBV latent infection and in most of the tumors associated with EBV infection.
T36721	SEQUENCE	PMGAGPPSPGGDPDGDDGGNNSQYPSASGSSGNTPTPPNDEERESNEEPPPPYEDLDWGNGDRHSDYQPLGNQDPSLYLGLQHDGNDGLPPPPYSPRDDSSQHIYEEAGRGSMNPVC

T93727	TARGETID	T93727
T93727	FORMERID	TTDI02416
T93727	UNIPROID	SFRP4_HUMAN
T93727	TARGNAME	Secreted frizzled related protein-4 (SFRP4)
T93727	GENENAME	SFRP4
T93727	TARGTYPE	Literature-reported
T93727	SYNONYMS	sFRP-4; Secreted frizzled-related protein 4; FrpHE; Frizzled protein, human endometrium
T93727	FUNCTION	Soluble frizzled-related proteins (sFRPS) function as modulators of Wnt signaling through direct interaction with Wnts. They have a role in regulating cell growth and differentiation in specific cell types. SFRP4 plays a role in bone morphogenesis. May also act as a regulator of adult uterine morphology and function. May also increase apoptosis during ovulation possibly through modulation of FZ1/FZ4/WNT4 signaling. Has phosphaturic effects by specifically inhibiting sodium-dependent phosphate uptake.
T93727	SEQUENCE	MFLSILVALCLWLHLALGVRGAPCEAVRIPMCRHMPWNITRMPNHLHHSTQENAILAIEQYEELVDVNCSAVLRFFLCAMYAPICTLEFLHDPIKPCKSVCQRARDDCEPLMKMYNHSWPESLACDELPVYDRGVCISPEAIVTDLPEDVKWIDITPDMMVQERPLDVDCKRLSPDRCKCKKVKPTLATYLSKNYSYVIHAKIKAVQRSGCNEVTTVVDVKEIFKSSSPIPRTQVPLITNSSCQCPHILPHQDVLIMCYEWRSRMMLLENCLVEKWRDQLSKRSIQWEERLQEQRRTVQDKKKTAGRTSRSNPPKPKGKPPAPKPASPKKNIKTRSAQKRTNPKRV

T94485	TARGETID	T94485
T94485	FORMERID	TTDR01135
T94485	UNIPROID	ANO7_HUMAN
T94485	TARGNAME	Prostate cancer-associated protein 5 (NGEP)
T94485	GENENAME	ANO7
T94485	TARGTYPE	Literature-reported
T94485	SYNONYMS	Transmembrane protein 16G; TMEM16G; PCANAP5; New gene expressed in prostate; NGEP; IPCA-5; Dresden transmembrane protein of the prostate; D-TMPP; Anoctamin-7
T94485	FUNCTION	Has calcium-dependent phospholipid scramblase activity; scrambles phosphatidylserine, phosphatidylcholine and galactosylceramide (By similarity). Does not exhibit calcium-activated chloride channel (CaCC) activity. May play a role in cell-cell interactions.
T94485	SEQUENCE	MRMAATAWAGLQGPPLPTLCPAVRTGLYCRDQAHAERWAMTSETSSGSHCARSRMLRRRAQEEDSTVLIDVSPPEAEKRGSYGSTAHASEPGGQQAAACRAGSPAKPRIADFVLVWEEDLKLDRQQDSAARDRTDMHRTWRETFLDNLRAAGLCVDQQDVQDGNTTVHYALLSASWAVLCYYAEDLRLKLPLQELPNQASNWSAGLLAWLGIPNVLLEVVPDVPPEYYSCRFRVNKLPRFLGSDNQDTFFTSTKRHQILFEILAKTPYGHEKKNLLGIHQLLAEGVLSAAFPLHDGPFKTPPEGPQAPRLNQRQVLFQHWARWGKWNKYQPLDHVRRYFGEKVALYFAWLGFYTGWLLPAAVVGTLVFLVGCFLVFSDIPTQELCGSKDSFEMCPLCLDCPFWLLSSACALAQAGRLFDHGGTVFFSLFMALWAVLLLEYWKRKSATLAYRWDCSDYEDTEERPRPQFAASAPMTAPNPITGEDEPYFPERSRARRMLAGSVVIVVMVAVVVMCLVSIILYRAIMAIVVSRSGNTLLAAWASRIASLTGSVVNLVFILILSKIYVSLAHVLTRWEMHRTQTKFEDAFTLKVFIFQFVNFYSSPVYIAFFKGRFVGYPGNYHTLFGVRNEECAAGGCLIELAQELLVIMVGKQVINNMQEVLIPKLKGWWQKFRLRSKKRKAGASAGASQGPWEDDYELVPCEGLFDEYLEMVLQFGFVTIFVAACPLAPLFALLNNWVEIRLDARKFVCEYRRPVAERAQDIGIWFHILAGLTHLAVISNAFLLAFSSDFLPRAYYRWTRAHDLRGFLNFTLARAPSSFAAAHNRTCRYRAFRDDDGHYSQTYWNLLAIRLAFVIVFEHVVFSVGRLLDLLVPDIPESVEIKVKREYYLAKQALAENEVLFGTNGTKDEQPEGSELSSHWTPFTVPKASQLQQ

T32232	TARGETID	T32232
T32232	FORMERID	TTDR01305
T32232	UNIPROID	NCLX_HUMAN
T32232	TARGNAME	Sodium/potassium/calcium exchanger 6 (SLC8B1)
T32232	GENENAME	SLC8B1
T32232	TARGTYPE	Literature-reported
T32232	SYNONYMS	Solute carrier family 8 member B1; Solute carrier family 24 member 6; Sodium/calcium exchanger protein, mitochondrial; Na(+)/K(+)/Ca(2+)-exchange protein 6; NCKX6; Mitochondrial sodium/calcium exchanger protein
T32232	FUNCTION	Mitochondrial sodium/calcium antiporter that mediates sodium-dependent calcium efflux from mitochondrion, by mediating the exchange of 3 sodium ions per 1 calcium ion. Plays a central role in mitochondrial calcium homeostasis by mediating mitochondrial calcium extrusion: calcium efflux is essential for mitochondrial function and cell survival, notably in cardiomyocytes (By similarity). Regulates rates of glucose-dependent insulin secretion in pancreatic beta-cells during the first phase of insulin secretion: acts by mediating efflux of calcium from mitochondrion, thereby affecting cytoplasmic calcium responses. Required for store-operated Ca(2+) entry (SOCE) and Ca(2+) release-activated Ca(2+) (CRAC) channel regulation: sodium transport by SLC8B1 leads to promote calcium-shuttling that modulates mitochondrial redox status, thereby regulating SOCE activity. Involved in B-lymphocyte chemotaxis (By similarity). Able to transport Ca(2+) in exchange of either Li(+) or Na(+), explaining how Li(+) catalyzes Ca(2+) exchange. In contrast to other members of the family its function is independent of K(+).
T32232	SEQUENCE	MAGRRLNLRWALSVLCVLLMAETVSGTRGSSTGAHISPQFPASGVNQTPVVDCRKVCGLNVSDRCDFIRTNPDCHSDGGYLDYLEGIFCHFPPSLLPLAVTLYVSWLLYLFLILGVTAAKFFCPNLSAISTTLKLSHNVAGVTFLAFGNGAPDIFSALVAFSDPHTAGLALGALFGAGVLVTTVVAGGITILHPFMAASRPFFRDIVFYMVAVFLTFLMLFRGRVTLAWALGYLGLYVFYVVTVILCTWIYQRQRRGSLFCPMPVTPEILSDSEEDRVSSNTNSYDYGDEYRPLFFYQETTAQILVRALNPLDYMKWRRKSAYWKALKVFKLPVEFLLLLTVPVVDPDKDDQNWKRPLNCLHLVISPLVVVLTLQSGTYGVYEIGGLVPVWVVVVIAGTALASVTFFATSDSQPPRLHWLFAFLGFLTSALWINAAATEVVNILRSLGVVFRLSNTVLGLTLLAWGNSIGDAFSDFTLARQGYPRMAFSACFGGIIFNILVGVGLGCLLQISRSHTEVKLEPDGLLVWVLAGALGLSLVFSLVSVPLQCFQLSRVYGFCLLLFYLNFLVVALLTEFGVIHLKSM

T43778	TARGETID	T43778
T43778	FORMERID	TTDI01346
T43778	UNIPROID	PHLB3_HUMAN
T43778	TARGNAME	Pleckstrin homology-like domain B 3 (PHLDB3)
T43778	GENENAME	PHLDB3
T43778	TARGTYPE	Literature-reported
T43778	SYNONYMS	Pleckstrin homology-like domain family B member 3
T43778	FUNCTION	Binds to MDM2 and facilitates MDM2-mediated ubiquitination and degradation of p53. Promotes cell growth and inhibits apoptosis. Plays an oncogenic role by in part inhibiting p53 activity in a feedback fashion.
T43778	SEQUENCE	MGTRSSPEEGTPPPLVPECDVEVQPQGHPEESREQEASEVLAEPSSRGGAEQQAEEEEVGEGSSTESSRDAPEATPPIAMAATPPASTSSREGVRGAARRLQGQQLEALTRVALMEQRVKELQRQRKELRIEMEVEVALLRGELAGERVAARREEEQLRELLEQQAASEQRGRQQREQEQRRLSQERDRLEGLRQRLRKAQGQLDSQPEDQRERLLQGVQEMREQLDVAQRAYEDLEFQQLERESRQEEEDRDSPGPQVPDPKVQELQASMAQHRRGALQHRIRVLEEQLKSLGEQMAAESRGLSRKKEEALQALSQERSRLLELNCLQGTPGGDFSEPNPALTKLLFTQKTDRQLLVLQDAVAHSAATPTSSCLFSVHSSLQGSIGLQRTGSLPRKRGERGSQRGSPRPLSFHCTESLEASALPPAVGDSGRYPLYQLLNCGRGNSCGAIHPDIAHMERLLQQAMAERERLLKAREGTRRGTEGSSGPAVPAITAPPTPPHPPGPRILDLRQHLEGWGHNPENCPHVQVSGCCCRGPLVKMGGRIKTWRKRWFCFDRQARRLAYYADKEETKLKGVIYFQAIEEVYYDHLRCAFKSPNPRLTFCVKTYERLFYMVAPSPEAMRIWMDVIVTAADENHAP

T57923	TARGETID	T57923
T57923	FORMERID	TTDR01219
T57923	UNIPROID	FIP1_HUMAN-PGFRA_HUMAN
T57923	TARGNAME	Fusion protein FIP1L1-PDGFR alpha (FIP1L1-PDGFRA)
T57923	GENENAME	RHE-CD140a
T57923	TARGTYPE	Literature-reported
T57923	SYNONYMS	Fusion protein RHE-CD140a
T57923	FUNCTION	Provides a molecular explanation for the pathogenesis of approximately half of the patients with the hypereosinophilic syndrome (HES).
T57923	SEQUENCE	MSAGEVERLVSELSGGTGGDEEEEWLYGGPWDVHVHSDLAKDLDENEVERPEEENASANPPSGIEDETAENGVPKPKVTETEDDSDSDSDDDEDDVHVTIGDIKTGAPQYGSYGTAPVNLNIKTGGRVYGTTGTKVKGVDLDAPGSINGVPLLEVDLDSFEDKPWRKPGADLSDYFNYGFNEDTWKAYCEKQKRIRMGLEVIPVTSTTNKITAEDCTMEVTPGAEIQDGRFNLFKVQQGRTGNSEKETALPSTKAEFTSPPSLFKTGLPPSRNSTSSQSQTSTASRKANSSVGKWQDRYGRAESPDLRRLPGAIDVIGQTITISRVEGRRRANENSNIQVLSERSATEVDNNFSKPPPFFPPGAPPTHLPPPPFLPPPPTVSTAPPLIPPPGFPPPPGAPPPSLIPTIESGHSSGYDSRSARAFPYGNVAFPHLPGSAPSWPSLVDTSKQWDYYARREKDRDRERDRDRERDRDRDRERERTRERERERDHSPTPSVFNSDEERYRYREYAERGYERHRASREKEERHRERRHREKEETRHKSSRSNSRRRHESEEGDSHRRHKHKKSKRSKEGKEAGSEPAPEQESTEATPAEMGTSHPAFLVLGCLLTGLSLILCQLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPCRTTDPETPVTLHNSEGVVPASYDSRQGFNGTFTVGPYICEATVKGKKFQTIPFNVYALKATSELDLEMEALKTVYKSGETIVVTCAVFNNEVVDLQWTYPGEVKGKGITMLEEIKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVKEMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENLTEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDLVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRDRSTVEGRVTFAKVEETIAVRCLAKNLLGAENRELKLVAPTLRSELTVAAAVLVLLVIVIISLIVLVVIWKQKPRYEIRWRVIESISPDGHEYIYVDPMQLPYDSRWEFPRDGLVLGRVLGSGAFGKVVEGTAYGLSRSQPVMKVAVKMLKPTARSSEKQALMSELKIMTHLGPHLNIVNLLGACTKSGPIYIITEYCFYGDLVNYLHKNRDSFLSHHPEKPKKELDIFGLNPADESTRSYVILSFENNGDYMDMKQADTTQYVPMLERKEVSKYSDIQRSLYDRPASYKKKSMLDSEVKNLLSDDNSEGLTLLDLLSFTYQVARGMEFLASKNCVHRDLAARNVLLAQGKIVKICDFGLARDIMHDSNYVSKGSTFLPVKWMAPESIFDNLYTTLSDVWSYGILLWEIFSLGGTPYPGMMVDSTFYNKIKSGYRMAKPDHATSEVYEIMVKCWNSEPEKRPSFYHLSEIVENLLPGQYKKSYEKIHLDFLKSDHPAVARMRVDSDNAYIGVTYKNEEDKLKDWEGGLDEQRLSADSGYIIPLPDIDPVPEEEDLGKRNRHSSQTSEESAIETGSSSSTFIKREDETIEDIDMMDDIGIDSSDLVEDSFL

T38041	TARGETID	T38041
T38041	FORMERID	TTDR01286
T38041	UNIPROID	CSPG4_HUMAN
T38041	TARGNAME	Chondroitin sulfate proteoglycan 4 (CSPG4)
T38041	GENENAME	CSPG4
T38041	TARGTYPE	Literature-reported
T38041	SYNONYMS	Melanoma-associated chondroitin sulfate proteoglycan; Melanoma chondroitin sulfate proteoglycan; MCSP; Chondroitin sulfate proteoglycan NG2
T38041	FUNCTION	Proteoglycan playing a role in cell proliferation and migration which stimulates endothelial cells motility during microvascular morphogenesis. May also inhibit neurite outgrowth and growth cone collapse during axon regeneration. Cell surface receptor for collagen alpha 2(VI) which may confer cells ability to migrate on that substrate. Binds through its extracellular N-terminus growth factors, extracellular matrix proteases modulating their activity. May regulate MPP16-dependent degradation and invasion of type I collagen participating in melanoma cells invasion properties. May modulate the plasminogen system by enhancing plasminogen activation and inhibiting angiostatin. Functions also as a signal transducing protein by binding through its cytoplasmic C-terminus scaffolding and signaling proteins. May promote retraction fiber formation and cell polarization through Rho GTPase activation. May stimulate alpha-4, beta-1 integrin-mediated adhesion and spreading by recruiting and activating a signaling cascade through CDC42, ACK1 and BCAR1. May activate FAK and ERK1/ERK2 signaling cascades.
T38041	SEQUENCE	MQSGPRPPLPAPGLALALTLTMLARLASAASFFGENHLEVPVATALTDIDLQLQFSTSQPEALLLLAAGPADHLLLQLYSGRLQVRLVLGQEELRLQTPAETLLSDSIPHTVVLTVVEGWATLSVDGFLNASSAVPGAPLEVPYGLFVGGTGTLGLPYLRGTSRPLRGCLHAATLNGRSLLRPLTPDVHEGCAEEFSASDDVALGFSGPHSLAAFPAWGTQDEGTLEFTLTTQSRQAPLAFQAGGRRGDFIYVDIFEGHLRAVVEKGQGTVLLHNSVPVADGQPHEVSVHINAHRLEISVDQYPTHTSNRGVLSYLEPRGSLLLGGLDAEASRHLQEHRLGLTPEATNASLLGCMEDLSVNGQRRGLREALLTRNMAAGCRLEEEEYEDDAYGHYEAFSTLAPEAWPAMELPEPCVPEPGLPPVFANFTQLLTISPLVVAEGGTAWLEWRHVQPTLDLMEAELRKSQVLFSVTRGARHGELELDIPGAQARKMFTLLDVVNRKARFIHDGSEDTSDQLVLEVSVTARVPMPSCLRRGQTYLLPIQVNPVNDPPHIIFPHGSLMVILEHTQKPLGPEVFQAYDPDSACEGLTFQVLGTSSGLPVERRDQPGEPATEFSCRELEAGSLVYVHRGGPAQDLTFRVSDGLQASPPATLKVVAIRPAIQIHRSTGLRLAQGSAMPILPANLSVETNAVGQDVSVLFRVTGALQFGELQKQGAGGVEGAEWWATQAFHQRDVEQGRVRYLSTDPQHHAYDTVENLALEVQVGQEILSNLSFPVTIQRATVWMLRLEPLHTQNTQQETLTTAHLEATLEEAGPSPPTFHYEVVQAPRKGNLQLQGTRLSDGQGFTQDDIQAGRVTYGATARASEAVEDTFRFRVTAPPYFSPLYTFPIHIGGDPDAPVLTNVLLVVPEGGEGVLSADHLFVKSLNSASYLYEVMERPRHGRLAWRGTQDKTTMVTSFTNEDLLRGRLVYQHDDSETTEDDIPFVATRQGESSGDMAWEEVRGVFRVAIQPVNDHAPVQTISRIFHVARGGRRLLTTDDVAFSDADSGFADAQLVLTRKDLLFGSIVAVDEPTRPIYRFTQEDLRKRRVLFVHSGADRGWIQLQVSDGQHQATALLEVQASEPYLRVANGSSLVVPQGGQGTIDTAVLHLDTNLDIRSGDEVHYHVTAGPRWGQLVRAGQPATAFSQQDLLDGAVLYSHNGSLSPRDTMAFSVEAGPVHTDATLQVTIALEGPLAPLKLVRHKKIYVFQGEAAEIRRDQLEAAQEAVPPADIVFSVKSPPSAGYLVMVSRGALADEPPSLDPVQSFSQEAVDTGRVLYLHSRPEAWSDAFSLDVASGLGAPLEGVLVELEVLPAAIPLEAQNFSVPEGGSLTLAPPLLRVSGPYFPTLLGLSLQVLEPPQHGALQKEDGPQARTLSAFSWRMVEEQLIRYVHDGSETLTDSFVLMANASEMDRQSHPVAFTVTVLPVNDQPPILTTNTGLQMWEGATAPIPAEALRSTDGDSGSEDLVYTIEQPSNGRVVLRGAPGTEVRSFTQAQLDGGLVLFSHRGTLDGGFRFRLSDGEHTSPGHFFRVTAQKQVLLSLKGSQTLTVCPGSVQPLSSQTLRASSSAGTDPQLLLYRVVRGPQLGRLFHAQQDSTGEALVNFTQAEVYAGNILYEHEMPPEPFWEAHDTLELQLSSPPARDVAATLAVAVSFEAACPQRPSHLWKNKGLWVPEGQRARITVAALDASNLLASVPSPQRSEHDVLFQVTQFPSRGQLLVSEEPLHAGQPHFLQSQLAAGQLVYAHGGGGTQQDGFHFRAHLQGPAGASVAGPQTSEAFAITVRDVNERPPQPQASVPLRLTRGSRAPISRAQLSVVDPDSAPGEIEYEVQRAPHNGFLSLVGGGLGPVTRFTQADVDSGRLAFVANGSSVAGIFQLSMSDGASPPLPMSLAVDILPSAIEVQLRAPLEVPQALGRSSLSQQQLRVVSDREEPEAAYRLIQGPQYGHLLVGGRPTSAFSQFQIDQGEVVFAFTNFSSSHDHFRVLALARGVNASAVVNVTVRALLHVWAGGPWPQGATLRLDPTVLDAGELANRTGSVPRFRLLEGPRHGRVVRVPRARTEPGGSQLVEQFTQQDLEDGRLGLEVGRPEGRAPGPAGDSLTLELWAQGVPPAVASLDFATEPYNAARPYSVALLSVPEAARTEAGKPESSTPTGEPGPMASSPEPAVAKGGFLSFLEANMFSVIIPMCLVLLLLALILPLLFYLRKRNKTGKHDVQVLTAKPRNGLAGDTETFRKVEPGQAIPLTAVPGQGPPPGGQPDPELLQFCRTPNPALKNGQYWV

T96398	TARGETID	T96398
T96398	UNIPROID	ARAID_HUMAN
T96398	TARGNAME	Apoptosis-related protein 3 (ATRAID)
T96398	GENENAME	ATRAID
T96398	TARGTYPE	Literature-reported
T96398	SYNONYMS	p18; C2orf28
T96398	FUNCTION	Promotes osteoblast cell differentiation and terminal mineralization. Plays a role in inducing the cell cycle arrest via inhibiting CCND1 expression in all-trans-retinoic acid (ATRA) signal pathway.
T96398	SEQUENCE	MAPHDPGSLTTLVPWAAALLLALGVERALALPEICTQCPGSVQNLSKVAFYCKTTRELMLHARCCLNQKGTILGLDLQNCSLEDPGPNFHQAHTTVIIDLQANPLKGDLANTFRGFTQLQTLILPQHVNCPGGINAWNTITSYIDNQICQGQKNLCNNTGDPEMCPENGSCVPDGPGLLQCVCADGFHGYKCMRQGSFSLLMFFGILGATTLSVSILLWATQRRKAKTS

T58513	TARGETID	T58513
T58513	FORMERID	TTDR01307
T58513	UNIPROID	OLFM4_HUMAN
T58513	TARGNAME	Olfactomedin 4 (OLFM4)
T58513	GENENAME	OLFM4
T58513	TARGTYPE	Literature-reported
T58513	SYNONYMS	hOLfD; hGC-1; UNQ362/PRO698; Olfactomedin-4; OLM4; GW112; G-CSF-stimulated clone 1 protein; Antiapoptotic protein GW112
T58513	FUNCTION	May promote proliferation of pancreatic cancer cells by favoring the transition from the S to G2/M phase. In myeloid leukemic cell lines, inhibits cell growth and induces cell differentiation and apoptosis. May play a role in the inhibition of EIF4EBP1 phosphorylation/deactivation. Facilitates cell adhesion, most probably through interaction with cell surface lectins and cadherin.
T58513	SEQUENCE	MRPGLSFLLALLFFLGQAAGDLGDVGPPIPSPGFSSFPGVDSSSSFSSSSRSGSSSSRSLGSGGSVSQLFSNFTGSVDDRGTCQCSVSLPDTTFPVDRVERLEFTAHVLSQKFEKELSKVREYVQLISVYEKKLLNLTVRIDIMEKDTISYTELDFELIKVEVKEMEKLVIQLKESFGGSSEIVDQLEVEIRNMTLLVEKLETLDKNNVLAIRREIVALKTKLKECEASKDQNTPVVHPPPTPGSCGHGGVVNISKPSVVQLNWRGFSYLYGAWGRDYSPQHPNKGLYWVAPLNTDGRLLEYYRLYNTLDDLLLYINARELRITYGQGSGTAVYNNNMYVNMYNTGNIARVNLTTNTIAVTQTLPNAAYNNRFSYANVAWQDIDFAVDENGLWVIYSTEASTGNMVISKLNDTTLQVLNTWYTKQYKPSASNAFMVCGVLYATRTMNTRTEEIFYYYDTNTGKEGKLDIVMHKMQEKVQSINYNPFDQKLYVYNDGYLLNYDLSVLQKPQ

T70119	TARGETID	T70119
T70119	FORMERID	TTDI01744
T70119	UNIPROID	TBA1A_HUMAN; TBA1B_HUMAN
T70119	TARGNAME	Tubulin alpha (TUBA)
T70119	GENENAME	TUBA1A; TUBA1B
T70119	TARGTYPE	Literature-reported
T70119	SYNONYMS	Tubulin alpha-1 chain; Alpha-tubulin
T70119	FUNCTION	Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
T70119	SEQUENCE	MRECISIHVGQAGVQIGNACWELYCLEHGIQPDGQMPSDKTIGGGDDSFNTFFSETGAGKHVPRAVFVDLEPTVIDEVRTGTYRQLFHPEQLITGKEDAANNYARGHYTIGKEIIDLVLDRIRKLADQCTGLQGFLVFHSFGGGTGSGFTSLLMERLSVDYGKKSKLEFSIYPAPQVSTAVVEPYNSILTTHTTLEHSDCAFMVDNEAIYDICRRNLDIERPTYTNLNRLIGQIVSSITASLRFDGALNVDLTEFQTNLVPYPRIHFPLATYAPVISAEKAYHEQLSVAEITNACFEPANQMVKCDPRHGKYMACCLLYRGDVVPKDVNAAIATIKTKRTIQFVDWCPTGFKVGINYQPPTVVPGGDLAKVQRAVCMLSNTTAIAEAWARLDHKFDLMYAKRAFVHWYVGEGMEEGEFSEAREDMAALEKDYEEVGVDSVEGEGEEEGEEY

T24938	TARGETID	T24938
T24938	FORMERID	TTDR01335
T24938	UNIPROID	Q76SY1_WEEV
T24938	TARGNAME	Western equine encephalitis virus Envelope glycoprotein E1 (WEEV E1)
T24938	GENENAME	WEEV E1
T24938	TARGTYPE	Literature-reported
T24938	SYNONYMS	Envelope glycoprotein E1
T24938	FUNCTION	A class II membrane fusion protein, containing a hydrophobic fusion peptide conserved among the alphaviruses. Induced a strong WEEV-specific T cell response. 
T24938	SEQUENCE	RASNCAYGHIPISIDIPDAAFVRSSESPTILEVSCTVADCIYSADFGGSLTLQYKADREGHCPVHSHSTTAVLKEATTHVTATGSITLHFSTSSPQANFIVSLCGKKTTCNAECKPPADHIIGEPHKVDQEFQAAVSKTSWNWLLALFGGASSLIVVGLIVLVCSSMLINTRR

T25728	TARGETID	T25728
T25728	FORMERID	TTDI03467
T25728	UNIPROID	S29A4_HUMAN
T25728	TARGNAME	Solute carrier family 29 member 4 (SLC29A4)
T25728	GENENAME	SLC29A4
T25728	TARGTYPE	Literature-reported
T25728	SYNONYMS	hENT4; Plasma membrane monoamine transporter; PSEC0113; PMAT; Equilibrative nucleoside transporter 4; ENT4
T25728	FUNCTION	Functions as a polyspecific organic cation transporter, efficiently transporting many organic cations such as monoamine neurotransmitters 1-methyl-4-phenylpyridinium and biogenic amines including serotonin, dopamine, norepinephrine and epinephrine. May play a role in regulating central nervous system homeostasis of monoamine neurotransmitters. May be involved in luminal transport of organic cations in the kidney and seems to use luminal proton gradient to drive organic cation reabsorption. Does not seem to transport nucleoside and nucleoside analogs such as uridine, cytidine, thymidine, adenosine, inosine, guanosine, and azidothymidine. In adenosine is efficiently transported but in a fashion highly sensitive to extracellular pH, with maximal activity in the pH range 5.5 to 6.5. Glu-206 is essential for the cation selectivity and may function as the charge sensor for cationic substrates. Transport is chloride and sodium-independent but appears to be sensitive to changes in membrane potential. Weakly inhibited by the classical inhibitors of equilibrative nucleoside transport, dipyridamole, dilazep, and nitrobenzylthioinosine. May play a role in the regulation of extracellular adenosine concentrations in cardiac tissues, in particular during ischemia.
T25728	SEQUENCE	MGSVGSQRLEEPSVAGTPDPGVVMSFTFDSHQLEEAAEAAQGQGLRARGVPAFTDTTLDEPVPDDRYHAIYFAMLLAGVGFLLPYNSFITDVDYLHHKYPGTSIVFDMSLTYILVALAAVLLNNVLVERLTLHTRITAGYLLALGPLLFISICDVWLQLFSRDQAYAINLAAVGTVAFGCTVQQSSFYGYTGMLPKRYTQGVMTGESTAGVMISLSRILTKLLLPDERASTLIFFLVSVALELLCFLLHLLVRRSRFVLFYTTRPRDSHRGRPGLGRGYGYRVHHDVVAGDVHFEHPAPALAPNESPKDSPAHEVTGSGGAYMRFDVPRPRVQRSWPTFRALLLHRYVVARVIWADMLSIAVTYFITLCLFPGLESEIRHCILGEWLPILIMAVFNLSDFVGKILAALPVDWRGTHLLACSCLRVVFIPLFILCVYPSGMPALRHPAWPCIFSLLMGISNGYFGSVPMILAAGKVSPKQRELAGNTMTVSYMSGLTLGSAVAYCTYSLTRDAHGSCLHASTANGSILAGL
T25728	DRUGINFO	D0I5YK	decynium 22	Investigative

T13937	TARGETID	T13937
T13937	FORMERID	TTDS00222
T13937	UNIPROID	Q7X2I2_MYCTX
T13937	TARGNAME	Mycobacterium DNA-dependent RNA polymerase beta (MycB rpoB)
T13937	GENENAME	MycB rpoB
T13937	TARGTYPE	Literature-reported
T13937	SYNONYMS	DNA-dependent RNA polymerase beta subunit
T13937	FUNCTION	Transcribes the message carried by DNA. Has important implications in transcriptional regulation.
T13937	SEQUENCE	TVPGGVEVPVETDDIDHFGNRRLRTVGELIQNQIRVGMSRMERVVRERMTTQDVEAITPQTLINIRPVVAAIKEFFGTSQLSQFMDQNNPLSGLTHKRRLWALGPGGLSRERAGLEVRDVHPS

T31935	TARGETID	T31935
T31935	FORMERID	TTDI03499
T31935	UNIPROID	S36A1_HUMAN
T31935	TARGNAME	Solute carrier family 36 member 1 (SLC36A1)
T31935	GENENAME	SLC36A1
T31935	TARGTYPE	Literature-reported
T31935	SYNONYMS	hPAT1; Proton/amino acid transporter 1; Proton-coupled amino acid transporter 1; PAT1
T31935	FUNCTION	Neutral amino acid/proton symporter. Has a pH-dependent electrogenic transport activity for small amino acids such as glycine, alanine and proline. Besides small apolar L-amino acids, it also recognizes their D-enantiomers and selected amino acid derivatives such as gamma-aminobutyric acid (By similarity).
T31935	SEQUENCE	MSTQRLRNEDYHDYSSTDVSPEESPSEGLNNLSSPGSYQRFGQSNSTTWFQTLIHLLKGNIGTGLLGLPLAVKNAGIVMGPISLLIIGIVAVHCMGILVKCAHHFCRRLNKSFVDYGDTVMYGLESSPCSWLRNHAHWGRRVVDFFLIVTQLGFCCVYFVFLADNFKQVIEAANGTTNNCHNNETVILTPTMDSRLYMLSFLPFLVLLVFIRNLRALSIFSLLANITMLVSLVMIYQFIVQRIPDPSHLPLVAPWKTYPLFFGTAIFSFEGIGMVLPLENKMKDPRKFPLILYLGMVIVTILYISLGCLGYLQFGANIQGSITLNLPNCWLYQSVKLLYSIGIFFTYALQFYVPAEIIIPFFVSRAPEHCELVVDLFVRTVLVCLTCILAILIPRLDLVISLVGSVSSSALALIIPPLLEVTTFYSEGMSPLTIFKDALISILGFVGFVVGTYEALYELIQPSNAPIFINSTCAFI
T31935	DRUGINFO	D00ZYK	indole-3-propionic acid	Investigative
T31935	DRUGINFO	D09BNS	5-hydroxy-L-tryptophan	Investigative

T82309	TARGETID	T82309
T82309	FORMERID	TTDR01330
T82309	UNIPROID	KCNKI_HUMAN
T82309	TARGNAME	TWIK-related spinal cord potassium channel (TRESK)
T82309	GENENAME	KCNK18
T82309	TARGTYPE	Literature-reported
T82309	SYNONYMS	TWIK-related individual potassium channel; TRIK; TRESK; Potassium channel subfamily K member 18
T82309	FUNCTION	Outward rectifying potassium channel. Produces rapidly activating outward rectifier K(+) currents. May function as background potassium channel that sets the resting membrane potential. Channel activity is directly activated by calcium signal. Activated by the G(q)-protein coupled receptor pathway. The calcium signal robustly activates the channel via calcineurin, whereas the anchoring of 14-3-3/YWHAH interferes with the return of the current to the resting state after activation. Inhibited also by arachidonic acid and other naturally occurring unsaturated free fatty acids. Channel activity is also enhanced by volatile anesthetics, such as isoflurane. Appears to be the primary target of hydroxy-alpha-sanshool, an ingredient of Schezuan pepper. May be involved in the somatosensory function with special respect to pain sensation (By similarity).
T82309	SEQUENCE	MEVSGHPQARRCCPEALGKLFPGLCFLCFLVTYALVGAVVFSAIEDGQVLVAADDGEFEKFLEELCRILNCSETVVEDRKQDLQGHLQKVKPQWFNRTTHWSFLSSLFFCCTVFSTVGYGYIYPVTRLGKYLCMLYALFGIPLMFLVLTDTGDILATILSTSYNRFRKFPFFTRPLLSKWCPKSLFKKKPDPKPADEAVPQIIISAEELPGPKLGTCPSRPSCSMELFERSHALEKQNTLQLPPQAMERSNSCPELVLGRLSYSIISNLDEVGQQVERLDIPLPIIALIVFAYISCAAAILPFWETQLDFENAFYFCFVTLTTIGFGDTVLEHPNFFLFFSIYIIVGMEIVFIAFKLVQNRLIDIYKNVMLFFAKGKFYHLVKK
T82309	DRUGINFO	D01ZMR	Calcineurin	Investigative

T61909	TARGETID	T61909
T61909	FORMERID	TTDI00092
T61909	UNIPROID	DAAM2_HUMAN
T61909	TARGNAME	Disheveled-associated activator of morphogenesis 2 (DAAM2)
T61909	GENENAME	DAAM2
T61909	TARGTYPE	Literature-reported
T61909	SYNONYMS	KIAA0381; Disheveledassociated activator of morphogenesis 2
T61909	FUNCTION	Acts downstream of Wnt ligands and upstream of beta-catenin (CTNNB1). Required for canonical Wnt signaling pathway during patterning in the dorsal spinal cord by promoting the aggregation of Disheveled (Dvl) complexes, thereby clustering and formation of Wnt receptor signalosomes and potentiating Wnt activity. During dorsal patterning of the spinal cord, inhibits oligodendrocytes differentiation via interaction with PIP5K1A. Also regulates non-canonical Wnt signaling pathway. Acts downstream of PITX2 in the developing gut and is required for left/right asymmetry within dorsal mesentery: affects mesenchymal condensation by lengthening cadherin-based junctions through WNT5A and non-canonical Wnt signaling, inducing polarized condensation in the left dorsal mesentery necessary to initiate gut rotation. Together with DAAM1, required for myocardial maturation and sarcomere assembly. Key regulator of the Wnt signaling pathway, which is required for various processes during development, such as dorsal patterning, determination of left/right symmetry or myelination in the central nervous system.
T61909	SEQUENCE	MAPRKRSHHGLGFLCCFGGSDIPEINLRDNHPLQFMEFSSPIPNAEELNIRFAELVDELDLTDKNREAMFALPPEKKWQIYCSKKKEQEDPNKLATSWPDYYIDRINSMAAMQSLYAFDEEETEMRNQVVEDLKTALRTQPMRFVTRFIELEGLTCLLNFLRSMDHATCESRIHTSLIGCIKALMNNSQGRAHVLAQPEAISTIAQSLRTENSKTKVAVLEILGAVCLVPGGHKKVLQAMLHYQVYAAERTRFQTLLNELDRSLGRYRDEVNLKTAIMSFINAVLNAGAGEDNLEFRLHLRYEFLMLGIQPVIDKLRQHENAILDKHLDFFEMVRNEDDLELARRFDMVHIDTKSASQMFELIHKKLKYTEAYPCLLSVLHHCLQMPYKRNGGYFQQWQLLDRILQQIVLQDERGVDPDLAPLENFNVKNIVNMLINENEVKQWRDQAEKFRKEHMELVSRLERKERECETKTLEKEEMMRTLNKMKDKLARESQELRQARGQVAELVAQLSELSTGPVSSPPPPGGPLTLSSSMTTNDLPPPPPPLPFACCPPPPPPPLPPGGPPTPPGAPPCLGMGLPLPQDPYPSSDVPLRKKRVPQPSHPLKSFNWVKLNEERVPGTVWNEIDDMQVFRILDLEDFEKMFSAYQRHQKELGSTEDIYLASRKVKELSVIDGRRAQNCIILLSKLKLSNEEIRQAILKMDEQEDLAKDMLEQLLKFIPEKSDIDLLEEHKHEIERMARADRFLYEMSRIDHYQQRLQALFFKKKFQERLAEAKPKVEAILLASRELVRSKRLRQMLEVILAIGNFMNKGQRGGAYGFRVASLNKIADTKSSIDRNISLLHYLIMILEKHFPDILNMPSELQHLPEAAKVNLAELEKEVGNLRRGLRAVEVELEYQRRQVREPSDKFVPVMSDFITVSSFSFSELEDQLNEARDKFAKALMHFGEHDSKMQPDEFFGIFDTFLQAFSEARQDLEAMRRRKEEEERRARMEAMLKEQRERERWQRQRKVLAAGSSLEEGGEFDDLVSALRSGEVFDKDLCKLKRSRKRSGSQALEVTRERAINRLNY

T36576	TARGETID	T36576
T36576	FORMERID	TTDI02581
T36576	UNIPROID	C163A_HUMAN
T36576	TARGNAME	Hemoglobin scavenger receptor (CD163)
T36576	GENENAME	CD163
T36576	TARGTYPE	Literature-reported
T36576	SYNONYMS	sCD163; Soluble CD163; Scavenger receptor cysteine-rich type 1 protein M130; M130
T36576	FUNCTION	May play a role in the uptake and recycling of iron, via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization, inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells. Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage.
T36576	SEQUENCE	MSKLRMVLLEDSGSADFRRHFVNLSPFTITVVLLLSACFVTSSLGGTDKELRLVDGENKCSGRVEVKVQEEWGTVCNNGWSMEAVSVICNQLGCPTAIKAPGWANSSAGSGRIWMDHVSCRGNESALWDCKHDGWGKHSNCTHQQDAGVTCSDGSNLEMRLTRGGNMCSGRIEIKFQGRWGTVCDDNFNIDHASVICRQLECGSAVSFSGSSNFGEGSGPIWFDDLICNGNESALWNCKHQGWGKHNCDHAEDAGVICSKGADLSLRLVDGVTECSGRLEVRFQGEWGTICDDGWDSYDAAVACKQLGCPTAVTAIGRVNASKGFGHIWLDSVSCQGHEPAIWQCKHHEWGKHYCNHNEDAGVTCSDGSDLELRLRGGGSRCAGTVEVEIQRLLGKVCDRGWGLKEADVVCRQLGCGSALKTSYQVYSKIQATNTWLFLSSCNGNETSLWDCKNWQWGGLTCDHYEEAKITCSAHREPRLVGGDIPCSGRVEVKHGDTWGSICDSDFSLEAASVLCRELQCGTVVSILGGAHFGEGNGQIWAEEFQCEGHESHLSLCPVAPRPEGTCSHSRDVGVVCSRYTEIRLVNGKTPCEGRVELKTLGAWGSLCNSHWDIEDAHVLCQQLKCGVALSTPGGARFGKGNGQIWRHMFHCTGTEQHMGDCPVTALGASLCPSEQVASVICSGNQSQTLSSCNSSSLGPTRPTIPEESAVACIESGQLRLVNGGGRCAGRVEIYHEGSWGTICDDSWDLSDAHVVCRQLGCGEAINATGSAHFGEGTGPIWLDEMKCNGKESRIWQCHSHGWGQQNCRHKEDAGVICSEFMSLRLTSEASREACAGRLEVFYNGAWGTVGKSSMSETTVGVVCRQLGCADKGKINPASLDKAMSIPMWVDNVQCPKGPDTLWQCPSSPWEKRLASPSEETWITCDNKIRLQEGPTSCSGRVEIWHGGSWGTVCDDSWDLDDAQVVCQQLGCGPALKAFKEAEFGQGTGPIWLNEVKCKGNESSLWDCPARRWGHSECGHKEDAAVNCTDISVQKTPQKATTGRSSRQSSFIAVGILGVVLLAIFVALFFLTKKRRQRQRLAVSSRGENLVHQIQYREMNSCLNADDLDLMNSSENSHESADFSAAELISVSKFLPISGMEKEAILSHTEKENGNL

T31603	TARGETID	T31603
T31603	FORMERID	TTDI00190
T31603	UNIPROID	LAP4B_HUMAN
T31603	TARGNAME	Lysosome-associated transmembrane 4b-35 protein (LAPTM4B)
T31603	GENENAME	LAPTM4B
T31603	TARGTYPE	Literature-reported
T31603	SYNONYMS	Lysosome-associated transmembrane protein 4-beta; Lysosomal-associated transmembrane protein 4B
T31603	FUNCTION	Required for optimal lysosomal function. Blocks EGF-stimulated EGFR intraluminal sorting and degradation. Conversely by binding with the phosphatidylinositol 4,5-bisphosphate, regulates its PIP5K1C interaction, inhibits HGS ubiquitination and relieves LAPTM4B inhibition of EGFR degradation. Recruits SLC3A2 and SLC7A5 (the Leu transporter) to the lysosome, promoting entry of leucine and other essential amino acid (EAA) into the lysosome, stimulating activation of proton-transporting vacuolar (V)-ATPase protein pump (V-ATPase) and hence mTORC1 activation. Plays a role as negative regulator of TGFB1 production in regulatory T cells. Binds ceramide and facilitates its exit from late endosome in order to control cell death pathways.
T31603	SEQUENCE	MTSRTRVTWPSPPRPLPVPAAAAVAFGAKGTDPAEARSSRGIEEAGPRAHGRAGREPERRRSRQQRRGGLQARRSTLLKTCARARATAPGAMKMVAPWTRFYSNSCCLCCHVRTGTILLGVWYLIINAVVLLILLSALADPDQYNFSSSELGGDFEFMDDANMCIAIAISLLMILICAMATYGAYKQRAAWIIPFFCYQIFDFALNMLVAITVLIYPNSIQEYIRQLPPNFPYRDDVMSVNPTCLVLIILLFISIILTFKGYLISCVWNCYRYINGRNSSDVLVYVTSNDTTVLLPPYDDATVNGAAKEPPPPYVSA

T78127	TARGETID	T78127
T78127	FORMERID	TTDI03369
T78127	UNIPROID	S47A2_HUMAN
T78127	TARGNAME	Multidrug and toxin extrusion protein 2 (MATE2)
T78127	GENENAME	SLC47A2
T78127	TARGTYPE	Literature-reported
T78127	SYNONYMS	hMATE-2; Solute carrier family 47 member 2; MATE2; MATE-2; Kidney-specific H(+)/organic cation antiporter
T78127	FUNCTION	Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide, metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfate, acyclovir, and ganciclovir. Responsible for the secretion of cationic drugs across the brush border membranes.
T78127	SEQUENCE	MDSLQDTVALDHGGCCPALSRLVPRGFGTEMWTLFALSGPLFLFQVLTFMIYIVSTVFCGHLGKVELASVTLAVAFVNVCGVSVGVGLSSACDTLMSQSFGSPNKKHVGVILQRGALVLLLCCLPCWALFLNTQHILLLFRQDPDVSRLTQDYVMIFIPGLPVIFLYNLLAKYLQNQGWLKGQEEESPFQTPGLSILHPSHSHLSRASFHLFQKITWPQVLSGVVGNCVNGVANYALVSVLNLGVRGSAYANIISQFAQTVFLLLYIVLKKLHLETWAGWSSQCLQDWGPFFSLAVPSMLMICVEWWAYEIGSFLMGLLSVVDLSAQAVIYEVATVTYMIPLGLSIGVCVRVGMALGAADTVQAKRSAVSGVLSIVGISLVLGTLISILKNQLGHIFTNDEDVIALVSQVLPVYSVFHVFEAICCVYGGVLRGTGKQAFGAAVNAITYYIIGLPLGILLTFVVRMRIMGLWLGMLACVFLATAAFVAYTARLDWKLAAEEAKKHSGRQQQQRAESTATRPGPEKAVLSSVATGSSPGITLTTYSRSECHVDFFRTPEEAHALSAPTSRLSVKQLVIRRGAALGAASATLMVGLTVRILATRH
T78127	DRUGINFO	D06PZZ	[14C]TEA	Investigative

T69336	TARGETID	T69336
T69336	FORMERID	TTDR00863
T69336	UNIPROID	S22AG_HUMAN
T69336	TARGNAME	Solute carrier family 22 member 16 (SLC22A16)
T69336	GENENAME	SLC22A16
T69336	TARGTYPE	Literature-reported
T69336	SYNONYMS	Organic cation/carnitine transporter 6; Organic cation transporter OKB1; Fly-like putative transporter 2; Flipt 2; FLIPT2; Carnitine transporter 2; CT2
T69336	FUNCTION	High affinity carnitine transporter; the uptake is partially sodium-ion dependent. Thought to mediate the L-carnitine secretion mechanism from testis epididymal epithelium into the lumen which is involved in the maturation of spermatozoa. Also transports organic cations such as tetraethylammonium (TEA) and doxorubicin. The uptake of TEA is inhibited by various organic cations. The uptake of doxorubicin is sodium-independent.
T69336	SEQUENCE	MGSRHFEGIYDHVGHFGRFQRVLYFICAFQNISCGIHYLASVFMGVTPHHVCRPPGNVSQVVFHNHSNWSLEDTGALLSSGQKDYVTVQLQNGEIWELSRCSRNKRENTSSLGYEYTGSKKEFPCVDGYIYDQNTWKSTAVTQWNLVCDRKWLAMLIQPLFMFGVLLGSVTFGYFSDRLGRRVVLWATSSSMFLFGIAAAFAVDYYTFMAARFFLAMVASGYLVVGFVYVMEFIGMKSRTWASVHLHSFFAVGTLLVALTGYLVRTWWLYQMILSTVTVPFILCCWVLPETPFWLLSEGRYEEAQKIVDIMAKWNRASSCKLSELLSLDLQGPVSNSPTEVQKHNLSYLFYNWSITKRTLTVWLIWFTGSLGFYSFSLNSVNLGGNEYLNLFLLGVVEIPAYTFVCIAMDKVGRRTVLAYSLFCSALACGVVMVIPQKHYILGVVTAMVGKFAIGAAFGLIYLYTAELYPTIVRSLAVGSGSMVCRLASILAPFSVDLSSIWIFIPQLFVGTMALLSGVLTLKLPETLGKRLATTWEEAAKLESENESKSSKLLLTTNNSGLEKTEAITPRDSGLGE

T15552	TARGETID	T15552
T15552	FORMERID	TTDI03096
T15552	UNIPROID	CTSR3_HUMAN
T15552	TARGNAME	Cation channel sperm-associated protein 3 (CatSper3)
T15552	GENENAME	CATSPER3
T15552	TARGTYPE	Literature-reported
T15552	SYNONYMS	One-repeat calcium channel-like protein; CatSper3; Ca(v)-like protein
T15552	FUNCTION	Voltage-gated calcium channel that plays a central role in calcium-dependent physiological responses essential for successful fertilization, such as sperm hyperactivation, acrosome reaction and chemotaxis towards the oocyte.
T15552	SEQUENCE	MSQHRHQRHSRVISSSPVDTTSVGFCPTFKKFKRNDDECRAFVKRVIMSRFFKIIMISTVTSNAFFMALWTSYDIRYRLFRLLEFSEIFFVSICTSELSMKVYVDPINYWKNGYNLLDVIIIIVMFLPYALRQLMGKQFTYLYIADGMQSLRILKLIGYSQGIRTLITAVGQTVYTVASVLLLLFLLMYIFAILGFCLFGSPDNGDHDNWGNLAAAFFTLFSLATVDGWTDLQKQLDNREFALSRAFTIIFILLASFIFLNMFVGVMIMHTEDSIRKFERELMLEQQEMLMGEKQVILQRQQEEISRLMHIQKNADCTSFSELVENFKKTLSHTDPMVLDDFGTSLPFIDIYFSTLDYQDTTVHKLQELYYEIVHVLSLMLEDLPQEKPQSLEKVDEK
T15552	DRUGINFO	D03BSR	NNC55-0396	Investigative
T15552	DRUGINFO	D0JF0W	PGF1alpha	Investigative

T02328	TARGETID	T02328
T02328	UNIPROID	TM219_HUMAN
T02328	TARGNAME	IGF-binding protein 3 receptor (TMEM219)
T02328	GENENAME	TMEM219
T02328	TARGTYPE	Literature-reported
T02328	SYNONYMS	Transmembrane protein 219; Insulin-like growth factor-binding protein 3 receptor; IGFBP-3R
T02328	FUNCTION	Cell death receptor specific for IGFBP3, may mediate caspase-8-dependent apoptosis upon ligand binding.
T02328	SEQUENCE	MGNCQAGHNLHLCLAHHPPLVCATLILLLLGLSGLGLGSFLLTHRTGLRSPDIPQDWVSFLRSFGQLTLCPRNGTVTGKWRGSHVVGLLTTLNFGDGPDRNKTRTFQATVLGSQMGLKGSSAGQLVLITARVTTERTAGTCLYFSAVPGILPSSQPPISCSEEGAGNATLSPRMGEECVSVWSHEGLVLTKLLTSEELALCGSRLLVLGSFLLLFCGLLCCVTAMCFHPRRESHWSRTRL

T29363	TARGETID	T29363
T29363	FORMERID	TTDI00161
T29363	UNIPROID	TXND6_HUMAN
T29363	TARGNAME	Thioredoxin-like protein 2b (NME9)
T29363	GENENAME	NME9
T29363	TARGTYPE	Literature-reported
T29363	SYNONYMS	Txl-2; Thioredoxin-like protein 2; Thioredoxin domain-containing protein 6; NME9
T29363	FUNCTION	May be a regulator of microtubule physiology.
T29363	SEQUENCE	MGSRKKEIALQVNISTQELWEEMLSSKGLTVVDVYQGWCGPCKPVVSLFQKMRIEVGLDLLHFALAEADRLDVLEKYRGKCEPTFLFYAGGELVAVVRGANAPLLQKTILDQLEAEKKVLAEGRERKVIKDEALSDEDECVSHGKNNGEDEDMVSSERTCTLAIIKPDAVAHGKTDEIIMKIQEAGFEILTNEERTMTEAEVRLFYQHKAGEEAFEKLVHHMCSGPSHLLILTRTEGFEDVVTTWRTVMGPRDPNVARREQPESLRAQYGTEMPFNAVHGSRDREDADRELALLFPSLKFSDKDTEAPQGGEAEATAGPTEALCFPEDVD

T81547	TARGETID	T81547
T81547	FORMERID	TTDR00899
T81547	UNIPROID	S13A5_HUMAN
T81547	TARGNAME	Solute carrier family 13 member 5 (SLC13A5)
T81547	GENENAME	SLC13A5
T81547	TARGTYPE	Literature-reported
T81547	SYNONYMS	Sodium-coupled citrate transporter; SLC13A5; NaCT; Na(+)-coupled citrate transporter; Human sodium-coupled citrate transporter
T81547	FUNCTION	High-affinity sodium/citrate cotransporter that mediates citrate entry into cells. The transport process is electrogenic; it is the trivalent form of citrate rather than the divalent form that is recognized as a substrate. May facilitate the utilization of circulating citrate for the generation of metabolic energy and for the synthesis of fatty acids and cholesterol.
T81547	SEQUENCE	MASALSYVSKFKSFVILFVTPLLLLPLVILMPAKFVRCAYVIILMAIYWCTEVIPLAVTSLMPVLLFPLFQILDSRQVCVQYMKDTNMLFLGGLIVAVAVERWNLHKRIALRTLLWVGAKPARLMLGFMGVTALLSMWISNTATTAMMVPIVEAILQQMEATSAATEAGLELVDKGKAKELPGSQVIFEGPTLGQQEDQERKRLCKAMTLCICYAASIGGTATLTGTGPNVVLLGQMNELFPDSKDLVNFASWFAFAFPNMLVMLLFAWLWLQFVYMRFNFKKSWGCGLESKKNEKAALKVLQEEYRKLGPLSFAEINVLICFFLLVILWFSRDPGFMPGWLTVAWVEGETKYVSDATVAIFVATLLFIVPSQKPKFNFRSQTEEERKTPFYPPPLLDWKVTQEKVPWGIVLLLGGGFALAKGSEASGLSVWMGKQMEPLHAVPPAAITLILSLLVAVFTECTSNVATTTLFLPIFASMSRSIGLNPLYIMLPCTLSASFAFMLPVATPPNAIVFTYGHLKVADMVKTGVIMNIIGVFCVFLAVNTWGRAIFDLDHFPDWANVTHIET

T22641	TARGETID	T22641
T22641	FORMERID	TTDR01002
T22641	UNIPROID	Q89857_BDV1
T22641	TARGNAME	Borna disease virus Glycoprotein p56 (BoDV p56)
T22641	GENENAME	BoDV p56
T22641	TARGTYPE	Literature-reported
T22641	SYNONYMS	Glycoprotein
T22641	FUNCTION	Required for neuronal dissemination of Borna disease virus
T22641	SEQUENCE	MQPSMSFLIGFGTLVLVLSARTFDLQGLSCNTDSTPGLIDLEIRRLCHTPTENVISCEVSYLNHTTISLPAVHTSCLKYHCKTYWGFFGSYSADRIINRYTGTVKGCLNNSAPEDPFECNWFYCCSAITTEICRCSITNVTVAVQTFPPFMYCSFADCSTVSQQELESGKAMLSDGSTLTYTPYILQSEVVNKTLNGTILCNSSSKIVSFDEFRRSYSLTNGSYQSSSINVTCANYTSSCRPRLKRRRRDTQQIEYLVHKLRPTLKDAWEDCEILQSLLLGVFGTGIASASQFLRSWLNHPDIIGYIVNGVGVVWQCHRVNVTFMTWNESTYYPPVDYNGRKYFLNDEGRLQTNTPEARPGLKRVMWFGRYFLGTVGSGVKPRRIRYNKTSHDYHLEEFEASLNMTPQTSIASGHETDPINHAYGTQADLLPYTRSSNITSTDTGSGWVHIGLPSFAFLNPLGWLRDLLAWAAWLGGVLYLISLCVSLPASFARRRRLGRWQE

T14224	TARGETID	T14224
T14224	FORMERID	TTDR00402
T14224	UNIPROID	Q8B6C3_9REOV
T14224	TARGNAME	Virus Capsid glycoprotein VP7 (Viru VP7)
T14224	GENENAME	Viru VP7
T14224	TARGTYPE	Literature-reported
T14224	SYNONYMS	Outer capsid glycoprotein VP7
T14224	FUNCTION	Rotavirus attachment and entry into the host cell probably involves multiple sequential contacts between the outer capsid proteins VP4 and VP7, and the cell receptors.
T14224	SEQUENCE	MVCTTLYTVCAILFILFIYILFFRKMFHLITDTLIVMLILSNCVEWSQCQMFIDDIYYNGNVETIINSTDPFNVESLCIYFPNAVVGSQGPGKSDGHLNDGNYAQTIATLFETKGFPKGSIILKTYTQTSDFINSVEMTCSYNIVIIPDSPNDSESIEQIAEWILNVWKCDDMNLEIYTYEQIGINNLWAAFGSDCDISVCPLDTTSNGIGCSPASTETYEVVSNDTQLALINVVDNVRHRIQMNTAQCKLKNCIKGEARLNTALIRISTSSSFDNSLSPLNNGQTTRSFKINAKKWWTIFYTIIDYINTIVQAMTPRHRAIYPEGWMLRYA

T62936	TARGETID	T62936
T62936	FORMERID	TTDR00685
T62936	UNIPROID	YYAP1_HUMAN
T62936	TARGNAME	Hepatocellular carcinoma-associated protein (HCAP)
T62936	GENENAME	YY1AP1
T62936	TARGTYPE	Literature-reported
T62936	SYNONYMS	YY1AP; YY1-associated protein 1; Hepatocellular carcinoma-associated protein 2; Hepatocellular carcinoma susceptibility protein; HCCA2; HCCA1
T62936	FUNCTION	Enhances transcription activation by YY1. Plays a role in cell cycle regulation. Associates with the INO80 chromatin remodeling complex, which is responsible for transcriptional regulation, DNA repair, and replication.
T62936	SEQUENCE	MEEEASRSAAATNPGSRLTRWPPPDKREGSAVDPGKRRSLAATPSSSLPCTLIALGLRHEKEANELMEDLFETFQDEMGFSNMEDDGPEEEERVAEPQANFNTPQALRFEELLANLLNEQHQIAKELFEQLKMKKPSAKQQKEVEKVKPQCKEVHQTLILDPAQRKRLQQQMQQHVQLLTQIHLLATCNPNLNPEASSTRICLKELGTFAQSSIALHHQYNPKFQTLFQPCNLMGAMQLIEDFSTHVSIDCSPHKTVKKTANEFPCLPKQVAWILATSKVFMYPELLPVCSLKAKNPQDKILFTKAEDNKYLLTCKTARQLTVRIKNLNMNRAPDNIIKFYKKTKQLPVLGKCCEEIQPHQWKPPIEREEHRLPFWLKASLPSIQEELRHMADGAREVGNMTGTTEINSDQGLEKDNSELGSETRYPLLLPKGVVLKLKPVADRFPKKAWRQKRSSVLKPLLIQPSPSLQPSFNPGKTPAQSTHSEAPPSKMVLRIPHPIQPATVLQTVPGVPPLGVSGGESFESPAALPAMPPEARTSFPLSESQTLLSSAPVPKVMMPSPASSMFRKPYVRRRPSKRRGARAFRCIKPAPVIHPASVIFTVPATTVKIVSLGGGCNMIQPVNAAVAQSPQTIPIATLLVNPTSFPCPLNQPLVASSVSPLIVSGNSVNLPIPSTPEDKAHMNVDIACAVADGENAFQGLEPKLEPQELSPLSATVFPKVEHSPGPPPVDKQCQEGLSENSAYRWTVVKTEEGRQALEPLPQGIQESLNNSSPGDLEEVVKMEPEDATEEISGFL

T54473	TARGETID	T54473
T54473	FORMERID	TTDI03452
T54473	UNIPROID	S15A3_HUMAN
T54473	TARGNAME	Solute carrier family 15 member 3 (SLC15A3)
T54473	GENENAME	SLC15A3
T54473	TARGTYPE	Literature-reported
T54473	SYNONYMS	Peptide/histidine transporter 2; Peptide transporter 3; PTR3; PHT2; Osteoclast transporter; OCTP
T54473	FUNCTION	Proton oligopeptide cotransporter. Transports free histidine and certain di- and tripeptides (By similarity).
T54473	SEQUENCE	MPAPRAREQPRVPGERQPLLPRGARGPRRWRRAAGAAVLLVEMLERAAFFGVTANLVLYLNSTNFNWTGEQATRAALVFLGASYLLAPVGGWLADVYLGRYRAVALSLLLYLAASGLLPATAFPDGRSSFCGEMPASPLGPACPSAGCPRSSPSPYCAPVLYAGLLLLGLAASSVRSNLTSFGADQVMDLGRDATRRFFNWFYWSINLGAVLSLLVVAFIQQNISFLLGYSIPVGCVGLAFFIFLFATPVFITKPPMGSQVSSMLKLALQNCCPQLWQRHSARDRQCARVLADERSPQPGASPQEDIANFQVLVKILPVMVTLVPYWMVYFQMQSTYVLQGLHLHIPNIFPANPANISVALRAQGSSYTIPEAWLLLANVVVVLILVPLKDRLIDPLLLRCKLLPSALQKMALGMFFGFTSVIVAGVLEMERLHYIHHNETVSQQIGEVLYNAAPLSIWWQIPQYLLIGISEIFASIPGLEFAYSEAPRSMQGAIMGIFFCLSGVGSLLGSSLVALLSLPGGWLHCPKDFGNINNCRMDLYFFLLAGIQAVTALLFVWIAGRYERASQGPASHSRFSRDRG
T54473	DRUGINFO	D07UTZ	[3H]histidine	Investigative
T54473	DRUGINFO	D0XT2X	[14C]histidine	Investigative

T09132	TARGETID	T09132
T09132	FORMERID	TTDI00184
T09132	UNIPROID	TENS4_HUMAN
T09132	TARGNAME	C-terminal tensin-like protein (Cten)
T09132	GENENAME	TNS4
T09132	TARGTYPE	Literature-reported
T09132	SYNONYMS	Tensin-4; TNS4
T09132	FUNCTION	May be involved in cell migration, cartilage development and in linking signal transduction pathways to the cytoskeleton. May promote apoptosis, via its cleavage by caspase-3.
T09132	SEQUENCE	MSQVMSSPLLAGGHAVSLAPCDEPRRTLHPAPSPSLPPQCSYYTTEGWGAQALMAPVPCMGPPGRLQQAPQVEAKATCFLPSPGEKALGTPEDLDSYIDFSLESLNQMILELDPTFQLLPPGTGGSQAELAQSTMSMRKKEESEALDIKYIEVTSARSRCHDGPQHCSSPSVTPPFGSLRSGGLLLSRDVPRETRSSSESLIFSGNQGRGHQRPLPPSEGLSPRPPNSPSISIPCMGSKASSPHGLGSPLVASPRLEKRLGGLAPQRGSRISVLSASPVSDVSYMFGSSQSLLHSSNSSHQSSSRSLESPANSSSSLHSLGSVSLCTRPSDFQAPRNPTLTMGQPRTPHSPPLAKEHASSCPPSITNSMVDIPIVLINGCPEPGSSPPQRTPGHQNSVQPGAASPSNPCPATRSNSQTLSDAPFTTCPEGPARDMQPTMKFVMDTSKYWFKPNITREQAIELLRKEEPGAFVIRDSSSYRGSFGLALKVQEVPASAQSRPGEDSNDLIRHFLIESSAKGVHLKGADEEPYFGSLSAFVCQHSIMALALPCKLTIPQRELGGADGASDSTDSPASCQKKSAGCHTLYLSSVSVETLTGALAVQKAISTTFERDILPTPTVVHFKVTEQGITLTDVQRKVFFRRHYPLTTLRFCGMDPEQRKWQKYCKPSWIFGFVAKSQTEPQENVCHLFAEYDMVQPASQVIGLVTALLQDAERM

T12623	TARGETID	T12623
T12623	FORMERID	TTDR01288
T12623	UNIPROID	DYNAP_HUMAN
T12623	TARGNAME	Dynactin-associated protein (DYNAP)
T12623	GENENAME	DYNAP
T12623	TARGTYPE	Literature-reported
T12623	SYNONYMS	Full; C18orf26
T12623	FUNCTION	Plays a role in the regulation of cell proliferation. Promotes activation of the AKT1 signaling pathway. Promotes phosphorylation of AKT1 at 'Ser-473'.
T12623	SEQUENCE	MVADIKGNEQIEKYSWREACDTGSSRMDRKHGKYILNVEHSENQPPITHPNDQEAHSSICWCLPSNDITSDVSPNLTGVCVNPGILAHSRCLQSESCNTQVKEYCRNDWSMWKVFLACLLACVIMTAIGVLIICLVNNKGSANSSIVIQLSTNDGECVTVKPGTPSPACPPTMTTTSTVPASTATESTTSTATAATTSTEPITVAPTDHL

T09063	TARGETID	T09063
T09063	FORMERID	TTDI03453
T09063	UNIPROID	S15A4_HUMAN
T09063	TARGNAME	Solute carrier family 15 member 4 (SLC15A4)
T09063	GENENAME	SLC15A4
T09063	TARGTYPE	Literature-reported
T09063	SYNONYMS	SLC15A4
T09063	FUNCTION	Proton oligopeptide cotransporter. Transports free histidine and certain di- and tripeptides.
T09063	SEQUENCE	MEGSGGGAGERAPLLGARRAAAAAAAAGAFAGRRAACGAVLLTELLERAAFYGITSNLVLFLNGAPFCWEGAQASEALLLFMGLTYLGSPFGGWLADARLGRARAILLSLALYLLGMLAFPLLAAPATRAALCGSARLLNCTAPGPDAAARCCSPATFAGLVLVGLGVATVKANITPFGADQVKDRGPEATRRFFNWFYWSINLGAILSLGGIAYIQQNVSFVTGYAIPTVCVGLAFVVFLCGQSVFITKPPDGSAFTDMFKILTYSCCSQKRSGERQSNGEGIGVFQQSSKQSLFDSCKMSHGGPFTEEKVEDVKALVKIVPVFLALIPYWTVYFQMQTTYVLQSLHLRIPEISNITTTPHTLPAAWLTMFDAVLILLLIPLKDKLVDPILRRHGLLPSSLKRIAVGMFFVMCSAFAAGILESKRLNLVKEKTINQTIGNVVYHAADLSLWWQVPQYLLIGISEIFASIAGLEFAYSAAPKSMQSAIMGLFFFFSGVGSFVGSGLLALVSIKAIGWMSSHTDFGNINGCYLNYYFFLLAAIQGATLLLFLIISVKYDHHRDHQRSRANGVPTSRRA
T09063	DRUGINFO	D07UTZ	[3H]histidine	Investigative
T09063	DRUGINFO	D0XT2X	[14C]histidine	Investigative

T66479	TARGETID	T66479
T66479	FORMERID	TTDI01520
T66479	UNIPROID	LIRA3_HUMAN; LIRB3_HUMAN
T66479	TARGNAME	Leukocyte Ig-like receptor-3 (LILR3)
T66479	GENENAME	LILRA3; LILRB3
T66479	TARGTYPE	Literature-reported
T66479	SYNONYMS	Monocyte inhibitory receptor; Leukocyte immunoglobulin-like receptor; LIR; Immunoglobulin-like transcript; ILT; CD85 antigen-like family member; CD85
T66479	FUNCTION	Binds with high affinity to the surface of monocytes, leading to abolish LPS-induced TNF-alpha production by monocytes. Acts as soluble receptor for class I MHC antigens. Binds both classical and non-classical HLA class I molecules but with reduced affinities compared to LILRB1 or LILRB2.
T66479	SEQUENCE	MTPILTVLICLGLSLDPRTHVQAGPLPKPTLWAEPGSVITQGSPVTLRCQGSLETQEYHLYREKKTALWITRIPQELVKKGQFPILSITWEHAGRYCCIYGSHTAGLSESSDPLELVVTGAYSKPTLSALPSPVVTSGGNVTIQCDSQVAFDGFILCKEGEDEHPQCLNSHSHARGSSRAIFSVGPVSPSRRWSYRCYGYDSRAPYVWSLPSDLLGLLVPGVSKKPSLSVQPGPVVAPGEKLTFQCGSDAGYDRFVLYKEWGRDFLQRPGRQPQAGLSQANFTLGPVSRSYGGQYTCSGAYNLSSEWSAPSDPLDILITGQIRARPFLSVRPGPTVASGENVTLLCQSQGGMHTFLLTKEGAADSPLRLKSKRQSHKYQAEFPMSPVTSAHAGTYRCYGSLSSNPYLLTHPSDPLELVVSGAAETLSPPQNKSDSKAGE

T32434	TARGETID	T32434
T32434	FORMERID	TTDI03094
T32434	UNIPROID	CTSR1_HUMAN
T32434	TARGNAME	Cation channel sperm-associated protein 1 (CatSper1)
T32434	GENENAME	CATSPER1
T32434	TARGTYPE	Literature-reported
T32434	SYNONYMS	hCatSper; CatSper1
T32434	FUNCTION	Voltage-gated calcium channel that plays a central role in calcium-dependent physiological responses essential for successful fertilization, such as sperm hyperactivation, acrosome reaction and chemotaxis towards the oocyte.
T32434	SEQUENCE	MDQNSVPEKAQNEADTNNADRFFRSHSSPPHHRPGHSRALHHYELHHHGVPHQRGESHHPPEFQDFHDQALSSHVHQSHHHSEARNHGRAHGPTGFGLAPSQGAVPSHRSYGEDYHDELQRDGRRHHDGSQYGGFHQQSDSHYHRGSHHGRPQYLGENLSHYSSGVPHHGEASHHGGSYLPHGPNPYSESFHHSEASHLSGLQHDESQHHQVPHRGWPHHHQVHHHGRSRHHEAHQHGKSPHHGETISPHSSVGSYQRGISDYHSEYHQGDHHPSEYHHGDHPHHTQHHYHQTHRHRDYHQHQDHHGAYHSSYLHGDYVQSTSQLSIPHTSRSLIHDAPGPAASRTGVFPYHVAHPRGSAHSMTRSSSTIRSRVTQMSKKVHTQDISTKHSEDWGKEEGQFQKRKTGRLQRTRKKGHSTNLFQWLWEKLTFLIQGFREMIRNLTQSLAFETFIFFVVCLNTVMLVAQTFAEVEIRGEWYFMALDSIFFCIYVVEALLKIIALGLSYFFDFWNNLDFFIMAMAVLDFLLMQTHSFAIYHQSLFRILKVFKSLRALRAIRVLRRLSFLTSVQEVTGTLGQSLPSIAAILILMFTCLFLFSAVLRALFRKSDPKRFQNIFTTIFTLFTLLTLDDWSLIYMDSRAQGAWYIIPILVIYIIIQYFIFLNLVITVLVDSFQTALFKGLEKAKQERAARIQEKLLEDSLTELRAAEPKEVASEGTMLKRLIEKKFGTMTEKQQELLFHYLQLVASVEQEQQKFRSQAAVIDEIVDTTFEAGEEDFRN
T32434	DRUGINFO	D05SRQ	HC-056456	Investigative
T32434	DRUGINFO	D03BSR	NNC55-0396	Investigative
T32434	DRUGINFO	D0JF0W	PGF1alpha	Investigative

T96542	TARGETID	T96542
T96542	UNIPROID	SHCBP_HUMAN
T96542	TARGNAME	SHC SH2 domain-binding protein 1 (SHCBP1)
T96542	GENENAME	SHCBP1
T96542	TARGTYPE	Literature-reported
T96542	SYNONYMS	PAL
T96542	FUNCTION	May play a role in signaling pathways governing cellular proliferation, cell growth and differentiation. May be a component of a novel signaling pathway downstream of Shc. Acts as a positive regulator of FGF signaling in neural progenitor cells.
T96542	SEQUENCE	MADGSLTGGGLEAAAMAPERMGWAVEQELASLEKGLFQDEDSCSDCSYRDKPGSSLQSFMPEGKTFFPEIFQTNQLLFYERFRAYQDYILADCKASEVQEFTAEFLEKVLEPSGWRAVWHTNVFKVLVEITDVDFAALKAVVRLAEPYLCDSQVSTFTMECMKELLDLKEHRLPLQELWVVFDDSGVFDQTALAIEHVRFFYQNIWRSWDEEEEDEYDYFVRCVEPRLRLHYDILEDRVPSGLIVDYHNLLSQCEESYRKFLNLRSSLSNCNSDSEQENISMVEGLKLYSEMEQLKQKLKLIENPLLRYVFGYQKNSNIQAKGVRSSGQKITHVVSSTMMAGLLRSLLTDRLCQEPGEEEREIQFHSDPLSAINACFEGDTVIVCPGHYVVHGTFSIADSIELEGYGLPDDIVIEKRGKGDTFVDCTGADIKISGIKFVQHDAVEGILIVHRGKTTLENCVLQCETTGVTVRTSAEFLMKNSDLYGAKGAGIEIYPGSQCTLSDNGIHHCKEGILIKDFLDEHYDIPKISMVNNIIHNNEGYGVVLVKPTIFSDLQENAEDGTEENKALKIQTSGEPDVAERVDLEELIECATGKMELCARTDPSEQVEGNCEIVNELIAASTQKGQIKKKRLSELGITQADDNLMSQEMFVGIVGNQFKWNGKGSFGTFLF

T04497	TARGETID	T04497
T04497	FORMERID	TTDI03466
T04497	UNIPROID	PKR2_HUMAN
T04497	TARGNAME	Prokineticin receptor 2 (PKR2)
T04497	GENENAME	PROKR2
T04497	TARGTYPE	Literature-reported
T04497	SYNONYMS	PKR2; PK-R2; GPRg2; GPR73b; GPR73L1; G-protein coupled receptor I5E; G-protein coupled receptor 73-like 1
T04497	FUNCTION	Receptor for prokineticin 2. Exclusively coupled to the G(q) subclass of heteromeric G proteins. Activation leads to mobilization of calcium, stimulation of phosphoinositide turnover and activation of p44/p42 mitogen-activated protein kinase.
T04497	SEQUENCE	MAAQNGNTSFTPNFNPPQDHASSLSFNFSYGDYDLPMDEDEDMTKTRTFFAAKIVIGIALAGIMLVCGIGNFVFIAALTRYKKLRNLTNLLIANLAISDFLVAIICCPFEMDYYVVRQLSWEHGHVLCASVNYLRTVSLYVSTNALLAIAIDRYLAIVHPLKPRMNYQTASFLIALVWMVSILIAIPSAYFATETVLFIVKSQEKIFCGQIWPVDQQLYYKSYFLFIFGVEFVGPVVTMTLCYARISRELWFKAVPGFQTEQIRKRLRCRRKTVLVLMCILTAYVLCWAPFYGFTIVRDFFPTVFVKEKHYLTAFYVVECIAMSNSMINTVCFVTVKNNTMKYFKKMMLLHWRPSQRGSKSSADLDLRTNGVPTTEEVDCIRLK
T04497	DRUGINFO	D03TIA	PKR-A	Investigative
T04497	DRUGINFO	D02VQO	triazine compound PC10	Investigative

T32912	TARGETID	T32912
T32912	FORMERID	TTDI02357
T32912	UNIPROID	CTCFL_HUMAN
T32912	TARGNAME	Transcriptional repressor CTCFL (CTCFL)
T32912	GENENAME	CTCFL
T32912	TARGTYPE	Literature-reported
T32912	SYNONYMS	Zinc finger protein CTCF-T; Cancer/testis antigen 27; CTCF-like protein; CTCF paralog; CT27; CCCTC-binding factor; Brother of the regulator of imprinted sites; BORIS
T32912	FUNCTION	Plays a key role in gene imprinting in male germline, by participating in the establishment of differential methylation at the IGF2/H19 imprinted control region (ICR). Directly binds the unmethylated H19 ICR and recruits the PRMT7 methyltransferase, leading to methylate histone H4 'Arg-3' to form H4R3sme2. This probably leads to recruit de novo DNA methyltransferases at these sites. Seems to act as tumor suppressor. In association with DNMT1 and DNMT3B, involved in activation of BAG1 gene expression by binding to its promoter. Required for dimethylation of H3 lysine 4 (H3K4me2) of MYC and BRCA1 promoters. Testis-specific DNA binding protein responsible for insulator function, nuclear architecture and transcriptional control, which probably acts by recruiting epigenetic chromatin modifiers.
T32912	SEQUENCE	MAATEISVLSEQFTKIKELELMPEKGLKEEEKDGVCREKDHRSPSELEAERTSGAFQDSVLEEEVELVLAPSEESEKYILTLQTVHFTSEAVELQDMSLLSIQQQEGVQVVVQQPGPGLLWLEEGPRQSLQQCVAISIQQELYSPQEMEVLQFHALEENVMVASEDSKLAVSLAETTGLIKLEEEQEKNQLLAERTKEQLFFVETMSGDERSDEIVLTVSNSNVEEQEDQPTAGQADAEKAKSTKNQRKTKGAKGTFHCDVCMFTSSRMSSFNRHMKTHTSEKPHLCHLCLKTFRTVTLLRNHVNTHTGTRPYKCNDCNMAFVTSGELVRHRRYKHTHEKPFKCSMCKYASVEASKLKRHVRSHTGERPFQCCQCSYASRDTYKLKRHMRTHSGEKPYECHICHTRFTQSGTMKIHILQKHGENVPKYQCPHCATIIARKSDLRVHMRNLHAYSAAELKCRYCSAVFHERYALIQHQKTHKNEKRFKCKHCSYACKQERHMTAHIRTHTGEKPFTCLSCNKCFRQKQLLNAHFRKYHDANFIPTVYKCSKCGKGFSRWINLHRHSEKCGSGEAKSAASGKGRRTRKRKQTILKEATKGQKEAAKGWKEAANGDEAAAEEASTTKGEQFPGEMFPVACRETTARVKEEVDEGVTCEMLLNTMDK

T38183	TARGETID	T38183
T38183	FORMERID	TTDR00577
T38183	UNIPROID	VANG1_HUMAN
T38183	TARGNAME	Vang-like protein 1 (VANGL1)
T38183	GENENAME	VANGL1
T38183	TARGTYPE	Literature-reported
T38183	SYNONYMS	Van Gogh-like protein 1; Strabismus 2; STB2; Loop-tail protein 2 homolog; LPP2
T38183	FUNCTION	Invovled in multicellular organism development, Wnt signaling pathway and planar cell polarity pathway.
T38183	SEQUENCE	MDTESTYSGYSYYSSHSKKSHRQGERTRERHKSPRNKDGRGSEKSVTIQPPTGEPLLGNDSTRTEEVQDDNWGETTTAITGTSEHSISQEDIARISKDMEDSVGLDCKRYLGLTVASFLGLLVFLTPIAFILLPPILWRDELEPCGTICEGLFISMAFKLLILLIGTWALFFRKRRADMPRVFVFRALLLVLIFLFVVSYWLFYGVRILDSRDRNYQGIVQYAVSLVDALLFIHYLAIVLLELRQLQPMFTLQVVRSTDGESRFYSLGHLSIQRAALVVLENYYKDFTIYNPNLLTASKFRAAKHMAGLKVYNVDGPSNNATGQSRAMIAAAARRRDSSHNELYYEEAEHERRVKKRKARLVVAVEEAFIHIQRLQAEEQQKAPGEVMDPREAAQAIFPSMARALQKYLRITRQQNYHSMESILQHLAFCITNGMTPKAFLERYLSAGPTLQYDKDRWLSTQWRLVSDEAVTNGLRDGIVFVLKCLDFSLVVNVKKIPFIILSEEFIDPKSHKFVLRLQSETSV

T68834	TARGETID	T68834
T68834	FORMERID	TTDI03427
T68834	UNIPROID	OXER1_HUMAN
T68834	TARGNAME	Oxoeicosanoid receptor 1 (OXER1)
T68834	GENENAME	OXER1
T68834	TARGTYPE	Literature-reported
T68834	SYNONYMS	TG1019; GPR170; G-protein coupled receptor TG1019; G-protein coupled receptor R527; G-protein coupled receptor 170; 5-oxo-ETE G-protein coupled receptor
T68834	FUNCTION	Receptor for eicosanoids and polyunsaturated fatty acids such as 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid (5-OXO-ETE), 5(S)-hydroperoxy-6E,8Z,11Z,14Z-eicosatetraenoic acid (5(S)-HPETE) and arachidonic acid. Seems to be coupled to the G(i)/G(o), families of heteromeric G proteins.
T68834	SEQUENCE	MLCHRGGQLIVPIIPLCPEHSCRGRRLQNLLSGPWPKQPMELHNLSSPSPSLSSSVLPPSFSPSPSSAPSAFTTVGGSSGGPCHPTSSSLVSAFLAPILALEFVLGLVGNSLALFIFCIHTRPWTSNTVFLVSLVAADFLLISNLPLRVDYYLLHETWRFGAAACKVNLFMLSTNRTASVVFLTAIALNRYLKVVQPHHVLSRASVGAAARVAGGLWVGILLLNGHLLLSTFSGPSCLSYRVGTKPSASLRWHQALYLLEFFLPLALILFAIVSIGLTIRNRGLGGQAGPQRAMRVLAMVVAVYTICFLPSIIFGMASMVAFWLSACRSLDLCTQLFHGSLAFTYLNSVLDPVLYCFSSPNFLHQSRALLGLTRGRQGPVSDESSYQPSRQWRYREASRKAEAIGKLKVQGEVSLEKEGSSQG
T68834	DRUGINFO	D05LJD	5-oxo-C20:3	Investigative
T68834	DRUGINFO	D07TXF	5-(6-chloro-2-hexyl-1H-indol-1-yl)-5-oxo-valeric acid	Investigative
T68834	DRUGINFO	D0D2MN	5-oxo-12-HETE	Investigative
T68834	DRUGINFO	D0JH4U	5-oxo-15-HETE	Investigative
T68834	DRUGINFO	D0T0HS	Gue1654	Investigative
T68834	DRUGINFO	D0US4S	[3H]5-oxo-ETE	Investigative
T68834	DRUGINFO	D0XL8C	5-oxo-ODE	Investigative
T68834	DRUGINFO	D0Z6SY	5-oxo-20-HETE	Investigative
T68834	DRUGINFO	D0Q2LG	5S-HPETE	Investigative
T68834	DRUGINFO	D07CJR	5S-HETE	Investigative

T86817	TARGETID	T86817
T86817	FORMERID	TTDI03557
T86817	UNIPROID	S38A5_HUMAN
T86817	TARGNAME	Solute carrier family 38 member 5 (SLC38A5)
T86817	GENENAME	SLC38A5
T86817	TARGTYPE	Literature-reported
T86817	SYNONYMS	System N transporter 2; Sodium-coupled neutral amino acid transporter 5; SNAT5; SN2; PP7194; JM24
T86817	FUNCTION	Functions as a sodium-dependent amino acid transporter which countertransport protons. Mediates the saturable, pH-sensitive, and electrogenic cotransport of several neutral amino acids including glycine, asparagine, alanine, serine, glutamine and histidine with sodium.
T86817	SEQUENCE	MELQDPKMNGALPSDAVGYRQEREGFLPSRGPAPGSKPVQFMDFEGKTSFGMSVFNLSNAIMGSGILGLAYAMAHTGVIFFLALLLCIALLSSYSIHLLLTCAGIAGIRAYEQLGQRAFGPAGKVVVATVICLHNVGAMSSYLFIIKSELPLVIGTFLYMDPEGDWFLKGNLLIIIVSVLIILPLALMKHLGYLGYTSGLSLTCMLFFLVSVIYKKFQLGCAIGHNETAMESEALVGLPSQGLNSSCEAQMFTVDSQMSYTVPIMAFAFVCHPEVLPIYTELCRPSKRRMQAVANVSIGAMFCMYGLTATFGYLTFYSSVKAEMLHMYSQKDPLILCVRLAVLLAVTLTVPVVLFPIRRALQQLLFPGKAFSWPRHVAIALILLVLVNVLVICVPTIRDIFGVIGSTSAPSLIFILPSIFYLRIVPSEVEPFLSWPKIQALCFGVLGVLFMAVSLGFMFANWATGQSRMSGH
T86817	DRUGINFO	D07UTZ	[3H]histidine	Investigative
T86817	DRUGINFO	D0XT2X	[14C]histidine	Investigative

T97314	TARGETID	T97314
T97314	FORMERID	TTDI01480
T97314	UNIPROID	NRG4_HUMAN
T97314	TARGNAME	Neuregulin 4 (NRG4)
T97314	GENENAME	NRG4
T97314	TARGTYPE	Literature-reported
T97314	SYNONYMS	Pro-neuregulin-4, membrane-bound isoform; Pro-NRG4
T97314	FUNCTION	Low affinity ligand for the ERBB4 tyrosine kinase receptor. Concomitantly recruits ERBB1 and ERBB2 coreceptors, resulting in ligand-stimulated tyrosine phosphorylation and activation of the ERBB receptors. Does not bind to the ERBB1, ERBB2 and ERBB3 receptors (By similarity).
T97314	SEQUENCE	MPTDHEEPCGPSHKSFCLNGGLCYVIPTIPSPFCRCVENYTGARCEEVFLPGSSIQTKSNLFEAFVALAVLVTLIIGAFYFLCRKGHFQRASSVQYDINLVETSSTSAHHSHEQH

T95730	TARGETID	T95730
T95730	UNIPROID	SCG3_HUMAN
T95730	TARGNAME	Secretogranin-3 (SCG3)
T95730	GENENAME	SCG3
T95730	TARGTYPE	Literature-reported
T95730	SYNONYMS	SgIII; Secretogranin III
T95730	FUNCTION	endoplasmic reticulum lumen, extracellular region, secretory granule lumen, RNA binding, cellular protein metabolic process, platelet degranulation, post-translational protein modification.
T95730	SEQUENCE	MGFLGTGTWILVLVLPIQAFPKPGGSQDKSLHNRELSAERPLNEQIAEAEEDKIKKTYPPENKPGQSNYSFVDNLNLLKAITEKEKIEKERQSIRSSPLDNKLNVEDVDSTKNRKLIDDYDSTKSGLDHKFQDDPDGLHQLDGTPLTAEDIVHKIAARIYEENDRAVFDKIVSKLLNLGLITESQAHTLEDEVAEVLQKLISKEANNYEEDPNKPTSWTENQAGKIPEKVTPMAAIQDGLAKGENDETVSNTLTLTNGLERRTKTYSEDNFEELQYFPNFYALLKSIDSEKEAKEKETLITIMKTLIDFVKMMVKYGTISPEEGVSYLENLDEMIALQTKNKLEKNATDNISKLFPAPSEKSHEETDSTKEEAAKMEKEYGSLKDSTKDDNSNPGGKTDEPKGKTEAYLEAIRKNIEWLKKHDKKGNKEDYDLSKMRDFINKQADAYVEKGILDKEEAEAIKRIYSSL

T74607	TARGETID	T74607
T74607	FORMERID	TTDI03174
T74607	UNIPROID	RPGF4_HUMAN
T74607	TARGNAME	Rap guanine nucleotide exchange factor 4 (EPAC2)
T74607	GENENAME	RAPGEF4
T74607	TARGTYPE	Literature-reported
T74607	SYNONYMS	cAMP-regulated guanine nucleotide exchange factor II; cAMP-GEFII; Exchange protein directly activated by cAMP 2; Exchange factor directly activated by cAMP 2; EPAC2; EPAC 2; CGEF2
T74607	FUNCTION	Guanine nucleotide exchange factor (GEF) for RAP1A, RAP1B and RAP2A small GTPases that is activated by binding cAMP. Seems not to activate RAB3A. Involved in cAMP-dependent, PKA-independent exocytosis through interaction with RIMS2 (By similarity).
T74607	SEQUENCE	MVAAHAAHSSSSAEWIACLDKRPLERSSEDVDIIFTRLKEVKAFEKFHPNLLHQICLCGYYENLEKGITLFRQGDIGTNWYAVLAGSLDVKVSETSSHQDAVTICTLGIGTAFGESILDNTPRHATIVTRESSELLRIEQKDFKALWEKYRQYMAGLLAPPYGVMETGSNNDRIPDKENTPLIEPHVPLRPANTITKVPSEKILRAGKILRNAILSRAPHMIRDRKYHLKTYRQCCVGTELVDWMMQQTPCVHSRTQAVGMWQVLLEDGVLNHVDQEHHFQDKYLFYRFLDDEHEDAPLPTEEEKKECDEELQDTMLLLSQMGPDAHMRMILRKPPGQRTVDDLEIIYEELLHIKALSHLSTTVKRELAGVLIFESHAKGGTVLFNQGEEGTSWYIILKGSVNVVIYGKGVVCTLHEGDDFGKLALVNDAPRAASIVLREDNCHFLRVDKEDFNRILRDVEANTVRLKEHDQDVLVLEKVPAGNRASNQGNSQPQQKYTVMSGTPEKILEHFLETIRLEATLNEATDSVLNDFIMMHCVFMPNTQLCPALVAHYHAQPSQGTEQEKMDYALNNKRRVIRLVLQWAAMYGDLLQEDDVSMAFLEEFYVSVSDDARMIAALKEQLPELEKIVKQISEDAKAPQKKHKVLLQQFNTGDERAQKRQPIRGSDEVLFKVYCMDHTYTTIRVPVATSVKEVISAVADKLGSGEGLIIVKMSSGGEKVVLKPNDVSVFTTLTINGRLFACPREQFDSLTPLPEQEGPTVGTVGTFELMSSKDLAYQMTIYDWELFNCVHELELIYHTFGRHNFKKTTANLDLFLRRFNEIQFWVVTEICLCSQLSKRVQLLKKFIKIAAHCKEYKNLNSFFAIVMGLSNVAVSRLALTWEKLPSKFKKFYAEFESLMDPSRNHRAYRLTVAKLEPPLIPFMPLLIKDMTFTHEGNKTFIDNLVNFEKMRMIANTARTVRYYRSQPFNPDAAQANKNHQDVRSYVRQLNVIDNQRTLSQMSHRLEPRRP
T74607	DRUGINFO	D00EHP	HJC 0350	Investigative
T74607	DRUGINFO	D0WW2X	ESI-09	Investigative

T95359	TARGETID	T95359
T95359	FORMERID	TTDR01322
T95359	UNIPROID	Q8Z939_SALTI
T95359	TARGNAME	Salmonella typhi 27-kDa outer membrane protein T2544 (SALTI STY0351)
T95359	GENENAME	SALTI STY0351
T95359	TARGTYPE	Literature-reported
T95359	SYNONYMS	Possible outer membrane adhesin
T95359	FUNCTION	Plays a major role in bacterial adhesion to the host through high-affinity binding to laminin. 
T95359	SEQUENCE	MKNFFAVCIIPLVVTWSATASAKEGIYITGKAGTSVVNVYGINSTFSQEEIVNGHATLPDRTKGVFGGGVAIGYDFYDPFQLPVRLELDTTFRGETDAKGGQDIIAFGQPVHINVKNQVRMTTYIVNGYYDFHNSTAFTPYISAGVGLAHVKLSNNTIPVGFGINETLSASKNNFAWGAGIGAKYAVTDNIMIDASYKYINAGKVSISKNHYAGDEHTAYDADTKAASNDFMLGITYAF

T86226	TARGETID	T86226
T86226	FORMERID	TTDR01278
T86226	UNIPROID	AQP3_HUMAN
T86226	TARGNAME	Aquaporin 3 (AQP3)
T86226	GENENAME	AQP3
T86226	TARGTYPE	Literature-reported
T86226	SYNONYMS	Aquaporin-3; Aquaglyceroporin-3; AQP-3
T86226	FUNCTION	Water channel required to promote glycerol permeability and water transport across cell membranes. Acts as a glycerol transporter in skin and plays an important role in regulating SC (stratum corneum) and epidermal glycerol content. Involved in skin hydration, wound healing, and tumorigenesis. Provides kidney medullary collecting duct with high permeability to water, thereby permitting water to move in the direction of an osmotic gradient. Slightly permeable to urea and may function as a water and urea exit mechanism in antidiuresis in collecting duct cells. It may play an important role in gastrointestinal tract water transport and in glycerol metabolism (By similarity).
T86226	SEQUENCE	MGRQKELVSRCGEMLHIRYRLLRQALAECLGTLILVMFGCGSVAQVVLSRGTHGGFLTINLAFGFAVTLGILIAGQVSGAHLNPAVTFAMCFLAREPWIKLPIYTLAQTLGAFLGAGIVFGLYYDAIWHFADNQLFVSGPNGTAGIFATYPSGHLDMINGFFDQFIGTASLIVCVLAIVDPYNNPVPRGLEAFTVGLVVLVIGTSMGFNSGYAVNPARDFGPRLFTALAGWGSAVFTTGQHWWWVPIVSPLLGSIAGVFVYQLMIGCHLEQPPPSNEEENVKLAHVKHKEQI

T22368	TARGETID	T22368
T22368	FORMERID	TTDI02451
T22368	UNIPROID	NELL1_HUMAN
T22368	TARGNAME	Nel-related protein 1 (NELL1)
T22368	GENENAME	NELL1
T22368	TARGTYPE	Literature-reported
T22368	SYNONYMS	NELL1; NEL-like protein 1
T22368	FUNCTION	Plays a role in the control of cell growth and differentiation. Promotes osteoblast cell differentiation and terminal mineralization.
T22368	SEQUENCE	MPMDLILVVWFCVCTARTVVGFGMDPDLQMDIVTELDLVNTTLGVAQVSGMHNASKAFLFQDIEREIHAAPHVSEKLIQLFRNKSEFTILATVQQKPSTSGVILSIRELEHSYFELESSGLRDEIRYHYIHNGKPRTEALPYRMADGQWHKVALSVSASHLLLHVDCNRIYERVIDPPDTNLPPGINLWLGQRNQKHGLFKGIIQDGKIIFMPNGYITQCPNLNHTCPTCSDFLSLVQGIMDLQELLAKMTAKLNYAETRLSQLENCHCEKTCQVSGLLYRDQDSWVDGDHCRNCTCKSGAVECRRMSCPPLNCSPDSLPVHIAGQCCKVCRPKCIYGGKVLAEGQRILTKSCRECRGGVLVKITEMCPPLNCSEKDHILPENQCCRVCRGHNFCAEGPKCGENSECKNWNTKATCECKSGYISVQGDSAYCEDIDECAAKMHYCHANTVCVNLPGLYRCDCVPGYIRVDDFSCTEHDECGSGQHNCDENAICTNTVQGHSCTCKPGYVGNGTICRAFCEEGCRYGGTCVAPNKCVCPSGFTGSHCEKDIDECSEGIIECHNHSRCVNLPGWYHCECRSGFHDDGTYSLSGESCIDIDECALRTHTCWNDSACINLAGGFDCLCPSGPSCSGDCPHEGGLKHNGQVWTLKEDRCSVCSCKDGKIFCRRTACDCQNPSADLFCCPECDTRVTSQCLDQNGHKLYRSGDNWTHSCQQCRCLEGEVDCWPLTCPNLSCEYTAILEGECCPRCVSDPCLADNITYDIRKTCLDSYGVSRLSGSVWTMAGSPCTTCKCKNGRVCCSVDFECLQNN

T94942	TARGETID	T94942
T94942	FORMERID	TTDI02442
T94942	UNIPROID	PRG4_HUMAN
T94942	TARGNAME	Proteoglycan 4 (PRG4)
T94942	GENENAME	PRG4
T94942	TARGTYPE	Literature-reported
T94942	SYNONYMS	Superficial zone proteoglycan; Proteoglycan 4 C-terminal part; PRG4; Megakaryocyte-stimulating factor; Lubricin
T94942	FUNCTION	Isoform F plays a role as a growth factor acting on the primitive cells of both hematopoietic and endothelial cell lineages.
T94942	SEQUENCE	MAWKTLPIYLLLLLSVFVIQQVSSQDLSSCAGRCGEGYSRDATCNCDYNCQHYMECCPDFKRVCTAELSCKGRCFESFERGRECDCDAQCKKYDKCCPDYESFCAEVHNPTSPPSSKKAPPPSGASQTIKSTTKRSPKPPNKKKTKKVIESEEITEEHSVSENQESSSSSSSSSSSSTIRKIKSSKNSAANRELQKKLKVKDNKKNRTKKKPTPKPPVVDEAGSGLDNGDFKVTTPDTSTTQHNKVSTSPKITTAKPINPRPSLPPNSDTSKETSLTVNKETTVETKETTTTNKQTSTDGKEKTTSAKETQSIEKTSAKDLAPTSKVLAKPTPKAETTTKGPALTTPKEPTPTTPKEPASTTPKEPTPTTIKSAPTTPKEPAPTTTKSAPTTPKEPAPTTTKEPAPTTPKEPAPTTTKEPAPTTTKSAPTTPKEPAPTTPKKPAPTTPKEPAPTTPKEPTPTTPKEPAPTTKEPAPTTPKEPAPTAPKKPAPTTPKEPAPTTPKEPAPTTTKEPSPTTPKEPAPTTTKSAPTTTKEPAPTTTKSAPTTPKEPSPTTTKEPAPTTPKEPAPTTPKKPAPTTPKEPAPTTPKEPAPTTTKKPAPTTPKEPAPTTPKETAPTTPKKLTPTTPEKLAPTTPEKPAPTTPEELAPTTPEEPTPTTPEEPAPTTPKAAAPNTPKEPAPTTPKEPAPTTPKEPAPTTPKETAPTTPKGTAPTTLKEPAPTTPKKPAPKELAPTTTKEPTSTTSDKPAPTTPKGTAPTTPKEPAPTTPKEPAPTTPKGTAPTTLKEPAPTTPKKPAPKELAPTTTKGPTSTTSDKPAPTTPKETAPTTPKEPAPTTPKKPAPTTPETPPPTTSEVSTPTTTKEPTTIHKSPDESTPELSAEPTPKALENSPKEPGVPTTKTPAATKPEMTTTAKDKTTERDLRTTPETTTAAPKMTKETATTTEKTTESKITATTTQVTSTTTQDTTPFKITTLKTTTLAPKVTTTKKTITTTEIMNKPEETAKPKDRATNSKATTPKPQKPTKAPKKPTSTKKPKTMPRVRKPKTTPTPRKMTSTMPELNPTSRIAEAMLQTTTRPNQTPNSKLVEVNPKSEDAGGAEGETPHMLLRPHVFMPEVTPDMDYLPRVPNQGIIINPMLSDETNICNGKPVDGLTTLRNGTLVAFRGHYFWMLSPFSPPSPARRITEVWGIPSPIDTVFTRCNCEGKTFFFKDSQYWRFTNDIKDAGYPKPIFKGFGGLTGQIVAALSTAKYKNWPESVYFFKRGGSIQQYIYKQEPVQKCPGRRPALNYPVYGETTQVRRRRFERAIGPSQTHTIRIQYSPARLAYQDKGVLHNEVKVSILWRGLPNVVTSAISLPNIRKPDGYDYYAFSKDQYYNIDVPSRTARAITTRSGQTLSKVWYNCP

T22603	TARGETID	T22603
T22603	FORMERID	TTDI01426
T22603	UNIPROID	Q95VF2_LEIDO
T22603	TARGNAME	Leishmania Elongation factor 1-alpha (Leishm EF1A)
T22603	GENENAME	Leishm EF1A
T22603	TARGTYPE	Literature-reported
T22603	SYNONYMS	Leishmania Elongation factor 1A
T22603	FUNCTION	This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis.
T22603	SEQUENCE	MGKDKVHMNLVVVGHVDAGKSTATGHLIYKCGGIDKRTIEKFEKEAAEIGKASFKYAWVLDKLKAERERGITIDIALWKFESPKSVFTIIDAPGHRDFIKNMITGTSQADAAILMIDSTHGGFEAGISKDGQTREHALLAFTLGVKQMVVCCNKMDDKTVTYAQSRYDEISKEVGAYLKRVGYNPEKVRFIPISGWQGDNMIERSDNMPWYKGPTLLDALDMLEPPVRPVDKPLRLPLQDVYKIGGIGTVPVGRVETGIMKPGDVVTFAPANVTTEVKSIEMHHEQLAEAQPGDNVGFNVKNVSVKDIRRGNVCGNSKNDPPKEAADFTAQVIVLNHPGQISNGYAPVLDCHTSHIACRFAEIESKIDRRSGKELEKNPKAIKSGDAAIVKMVPQKPMCVEVFNDYAPLGRFAVRDMRQTVAVGIIKGVNKKEGSGGKVTKAAAKAAKK

T13252	TARGETID	T13252
T13252	FORMERID	TTDI03556
T13252	UNIPROID	S38A4_HUMAN
T13252	TARGNAME	Solute carrier family 38 member 4 (SLC38A4)
T13252	GENENAME	SLC38A4
T13252	TARGTYPE	Literature-reported
T13252	SYNONYMS	System N amino acid transporter 3; System A amino acid transporter 3; Sodium-coupled neutral amino acid transporter 4; SNAT4; Na(+)-coupled neutral amino acid transporter 4; NAT3; Amino acid transporter A3; ATA3
T13252	FUNCTION	Sodium-dependent amino acid transporter. Mediates electrogenic symport of neutral amino acids and sodium ions. Has a broad specificity, with a preference for Ala, followed by His, Cys, Asn, Ser, Gly, Val, Thr, Gln and Met. May mediate sodium-independent transport of cationic amino acids, such as Arg and Lys. Amino acid uptake is pH-dependent, with low transport activities at pH 6.5, intermediate at pH 7.0 and highest between pH 7.5 and 8.5.
T13252	SEQUENCE	MDPMELRNVNIEPDDESSSGESAPDSYIGIGNSEKAAMSSQFANEDTESQKFLTNGFLGKKKLADYADEHHPGTTSFGMSSFNLSNAIMGSGILGLSYAMANTGIILFIIMLLAVAILSLYSVHLLLKTAKEGGSLIYEKLGEKAFGWPGKIGAFVSITMQNIGAMSSYLFIIKYELPEVIRAFMGLEENTGEWYLNGNYLIIFVSVGIILPLSLLKNLGYLGYTSGFSLTCMVFFVSVVIYKKFQIPCPLPVLDHSVGNLSFNNTLPMHVVMLPNNSESSDVNFMMDYTHRNPAGLDENQAKGSLHDSGVEYEAHSDDKCEPKYFVFNSRTAYAIPILVFAFVCHPEVLPIYSELKDRSRRKMQTVSNISITGMLVMYLLAALFGYLTFYGEVEDELLHAYSKVYTLDIPLLMVRLAVLVAVTLTVPIVLFPIRTSVITLLFPKRPFSWIRHFLIAAVLIALNNVLVILVPTIKYIFGFIGASSATMLIFILPAVFYLKLVKKETFRSPQKVGALIFLVVGIFFMIGSMALIIIDWIYDPPNSKHH

T09266	TARGETID	T09266
T09266	FORMERID	TTDI02439
T09266	UNIPROID	PAQR1_HUMAN; PAQR2_HUMAN
T09266	TARGNAME	Adiponectin receptor (ADIPOR)
T09266	GENENAME	ADIPOR1; ADIPOR2
T09266	TARGTYPE	Literature-reported
T09266	SYNONYMS	Progestin and adipoQ receptor family member; PAQR; Adiponectin receptor protein
T09266	FUNCTION	Receptor for globular and full-length adiponectin (APM1), an essential hormone secreted by adipocytes that acts as an antidiabetic. Probably involved in metabolic pathways that regulate lipid metabolism such as fatty acid oxidation. Mediates increased AMPK, PPARA ligand activity, fatty acid oxidation and glucose uptake by adiponectin. Has some high-affinity receptor for globular adiponectin but low-affinity receptor for full-length adiponectin.
T09266	SEQUENCE	MSSHKGSVVAQGNGAPASNREADTVELAELGPLLEEKGKRVIANPPKAEEEQTCPVPQEEEEEVRVLTLPLQAHHAMEKMEEFVYKVWEGRWRVIPYDVLPDWLKDNDYLLHGHRPPMPSFRACFKSIFRIHTETGNIWTHLLGFVLFLFLGILTMLRPNMYFMAPLQEKVVFGMFFLGAVLCLSFSWLFHTVYCHSEKVSRTFSKLDYSGIALLIMGSFVPWLYYSFYCSPQPRLIYLSIVCVLGISAIIVAQWDRFATPKHRQTRAGVFLGLGLSGVVPTMHFTIAEGFVKATTVGQMGWFFLMAVMYITGAGLYAARIPERFFPGKFDIWFQSHQIFHVLVVAAAFVHFYGVSNLQEFRYGLEGGCTDDTLL

T97322	TARGETID	T97322
T97322	FORMERID	TTDI03424
T97322	UNIPROID	SO4A1_HUMAN
T97322	TARGNAME	Organic anion transporter E (SLCO4A1)
T97322	GENENAME	SLCO4A1
T97322	TARGTYPE	Literature-reported
T97322	SYNONYMS	Solute carrier organic anion transporter family member 4A1; Solute carrier family 21 member 12; Sodium-independent organic anion transporter E; SLC21A12; POAT; Organic anion-transporting polypeptide E; Organic anion transporter polypeptide-related protein 1; OATPRP1; OATPE; OATP4A1; OATP1; OATP-RP1; OATP-E; Colon organic anion transporter
T97322	FUNCTION	Mediates the Na(+)-independent transport of organic anions such as the thyroid hormones T3 (triiodo-L-thyronine), T4 (thyroxine) and rT3, and of estrone-3-sulfate and taurocholate.
T97322	SEQUENCE	MPLHQLGDKPLTFPSPNSAMENGLDHTPPSRRASPGTPLSPGSLRSAAHSPLDTSKQPLCQLWAEKHGARGTHEVRYVSAGQSVACGWWAFAPPCLQVLNTPKGILFFLCAAAFLQGMTVNGFINTVITSLERRYDLHSYQSGLIASSYDIAACLCLTFVSYFGGSGHKPRWLGWGVLLMGTGSLVFALPHFTAGRYEVELDAGVRTCPANPGAVCADSTSGLSRYQLVFMLGQFLHGVGATPLYTLGVTYLDENVKSSCSPVYIAIFYTAAILGPAAGYLIGGALLNIYTEMGRRTELTTESPLWVGAWWVGFLGSGAAAFFTAVPILGYPRQLPGSQRYAVMRAAEMHQLKDSSRGEASNPDFGKTIRDLPLSIWLLLKNPTFILLCLAGATEATLITGMSTFSPKFLESQFSLSASEAATLFGYLVVPAGGGGTFLGGFFVNKLRLRGSAVIKFCLFCTVVSLLGILVFSLHCPSVPMAGVTASYGGSLLPEGHLNLTAPCNAACSCQPEHYSPVCGSDGLMYFSLCHAGCPAATETNVDGQKVYRDCSCIPQNLSSGFGHATAGKCTSTCQRKPLLLVFIFVVIFFTFLSSIPALTATLRCVRDPQRSFALGIQWIVVRILGGIPGPIAFGWVIDKACLLWQDQCGQQGSCLVYQNSAMSRYILIMGLLYKVLGVLFFAIACFLYKPLSESSDGLETCLPSQSSAPDSATDSQLQSSV
T97322	DRUGINFO	D04AXP	[3H]estrone-3-sulphate	Investigative

T59136	TARGETID	T59136
T59136	FORMERID	TTDNR00725
T59136	UNIPROID	PINX1_HUMAN
T59136	TARGNAME	PIN2/TERF1-interacting telomerase inhibitor 1 (PINX1)
T59136	GENENAME	PINX1
T59136	TARGTYPE	Literature-reported
T59136	SYNONYMS	TRF1-interacting protein 1; Protein 67-11-3; Pin2-interacting protein X1; Liver-related putative tumor suppressor; LPTS; LPTL
T59136	FUNCTION	Mediates TRF1 and TERT accumulation in nucleolus and enhances TRF1 binding to telomeres. Inhibits telomerase activity. May inhibit cell proliferation and act as tumor suppressor. Microtubule-binding protein essential for faithful chromosome segregation.
T59136	SEQUENCE	MSMLAERRRKQKWAVDPQNTAWSNDDSKFGQRMLEKMGWSKGKGLGAQEQGATDHIKVQVKNNHLGLGATINNEDNWIAHQDDFNQLLAELNTCHGQETTDSSDKKEKKSFSLEEKSKISKNRVHYMKFTKGKDLSSRSKTDLDCIFGKRQSKKTPEGDASPSTPEENETTTTSAFTIQEYFAKRMAALKNKPQVPVPGSDISETQVERKRGKKRNKEATGKDVESYLQPKAKRHTEGKPERAEAQERVAKKKSAPAEEQLRGPCWDQSSKASAQDAGDHVQPPEGRDFTLKPKKRRGKKKLQKPVEIAEDATLEETLVKKKKKKDSK

T52719	TARGETID	T52719
T52719	FORMERID	TTDI01710
T52719	UNIPROID	PAGE5_HUMAN
T52719	TARGNAME	Prostate-associated gene 5 protein (PAGE5)
T52719	GENENAME	PAGE5
T52719	TARGTYPE	Literature-reported
T52719	SYNONYMS	PAGE-5; P antigen family member 5; GAGEE1; G antigen family E member 1; Cancer/testis antigen 16.1; CT16.1
T52719	FUNCTION	A member of family of proteins that are expressed in a variety of tumors and in some fetal and reproductive tissues. The encoded protein may protect cells from programmed cell death. Multiple alternatively spliced transcript variants encoding distinct isoforms have been found.
T52719	SEQUENCE	MQAPWAGNRGWAGTREEVRDMSEHVTRSQSSERGNDQESSQPVGPVIVQQPTEEKRQEEEPPTDNQGIAPSGEIKNEGAPAVQGTDVEAFQQELALLKIEDAPGDGPDVREGTLPTFDPTKVLEAGEGQL

T57253	TARGETID	T57253
T57253	FORMERID	TTDI01728
T57253	UNIPROID	MRGX1_HUMAN
T57253	TARGNAME	Mas-related G protein-coupled receptor X1 (MRGX1)
T57253	GENENAME	MRGPRX1
T57253	TARGTYPE	Literature-reported
T57253	SYNONYMS	Sensory neuron-specific G-protein coupled receptor 3/4; SNSR4; SNSR3; Mas-related G-protein coupled receptor member X1; MRGX1
T57253	FUNCTION	Orphan receptor. Probably involved in the function of nociceptive neurons. May regulate nociceptor function and/or development, including the sensation or modulation of pain. Potently activated by enkephalins including BAM22 (bovine adrenal medulla peptide 22) and BAM (8-22). BAM22 is the most potent compound and evoked a large and dose-dependent release of intracellular calcium in stably transfected cells. G(alpha)q proteins are involved in the calcium-signaling pathway. Activated by the antimalarial drug, chloroquine. May mediate chloroquine-induced itch, in a histamine-independent manner.
T57253	SEQUENCE	MDPTISTLDTELTPINGTEETLCYKQTLSLTVLTCIVSLVGLTGNAVVLWLLGCRMRRNAFSIYILNLAAADFLFLSGRLIYSLLSFISIPHTISKILYPVMMFSYFAGLSFLSAVSTERCLSVLWPIWYRCHRPTHLSAVVCVLLWALSLLRSILEWMLCGFLFSGADSAWCQTSDFITVAWLIFLCVVLCGSSLVLLIRILCGSRKIPLTRLYVTILLTVLVFLLCGLPFGIQFFLFLWIHVDREVLFCHVHLVSIFLSALNSSANPIIYFFVGSFRQRQNRQNLKLVLQRALQDASEVDEGGGQLPEEILELSGSRLEQ

T96179	TARGETID	T96179
T96179	UNIPROID	G137A_HUMAN
T96179	TARGNAME	Integral membrane protein GPR137 (GPR137)
T96179	GENENAME	GPR137
T96179	TARGTYPE	Literature-reported
T96179	SYNONYMS	Transmembrane 7 superfamily member 1-like 1 protein; TM7SF1L1; GPR137A; C11orf4
T96179	FUNCTION	It is a peptide which displays four putative transmembrane domains and is predicted to have a cytoplasmic localization. The receptor is available in the following formats: stable over-expression cell line, membrane preparation, or purified receptor in HEK293 or CHO.
T96179	SEQUENCE	MESNLSGLVPAAGLVPALPPAVTLGLTAAYTTLYALLFFSVYAQLWLVLLYGHKRLSYQTVFLALCLLWAALRTTLFSFYFRDTPRANRLGPLPFWLLYCCPVCLQFFTLTLMNLYFAQVVFKAKVKRRPEMSRGLLAVRGAFVGASLLFLLVNVLCAVLSHRRRAQPWALLLVRVLVSDSLFVICALSLAACLCLVARRAPSTSIYLEAKGTSVCQAAAMGGAMVLLYASRACYNLTALALAPQSRLDTFDYDWYNVSDQADLVNDLGNKGYLVFGLILFVWELLPTTLLVGFFRVHRPPQDLSTSHILNGQVFASRSYFFDRAGHCEDEGCSWEHSRGESTRCQDQAATTTVSTPPHRRDPPPSPTEYPGPSPPHPRPLCQVCLPLLAQDPGGRGYPLLWPAPCCSCHSELVPSP

T69476	TARGETID	T69476
T69476	FORMERID	TTDI03095
T69476	UNIPROID	CTSR2_HUMAN
T69476	TARGNAME	Cation channel sperm-associated protein 2 (CatSper2)
T69476	GENENAME	CATSPER2
T69476	TARGTYPE	Literature-reported
T69476	SYNONYMS	CatSper2
T69476	FUNCTION	Voltage-gated calcium channel that plays a central role in calcium-dependent physiological responses essential for successful fertilization, such as sperm hyperactivation, acrosome reaction and chemotaxis towards the oocyte.
T69476	SEQUENCE	MAAYQQEEQMQLPRADAIRSRLIDTFSLIEHLQGLSQAVPRHTIRELLDPSRQKKLVLGDQHQLVRFSIKPQRIEQISHAQRLLSRLHVRCSQRPPLSLWAGWVLECPLFKNFIIFLVFLNTIILMVEIELLESTNTKLWPLKLTLEVAAWFILLIFILEILLKWLSNFSVFWKSAWNVFDFVVTMLSLLPEVVVLVGVTGQSVWLQLLRICRVLRSLKLLAQFRQIQIIILVLVRALKSMTFLLMLLLIFFYIFAVTGVYVFSEYTRSPRQDLEYHVFFSDLPNSLVTVFILFTLDHWYALLQDVWKVPEVSRIFSSIYFILWLLLGSIIFRSIIVAMMVTNFQNIRKELNEEMARREVQLKADMFKRQIIQRRKNMSHEALTSSHSKIEDSSRGASQQRESLDLSEVSEVESNYGATEEDLITSASKTEETLSKKREYQSSSCVSSTSSSYSSSSESRFSESIGRLDWETLVHENLPGLMEMDQDDRVWPRDSLFRYFELLEKLQYNLEERKKLQEFAVQALMNLEDK
T69476	DRUGINFO	D03BSR	NNC55-0396	Investigative
T69476	DRUGINFO	D0JF0W	PGF1alpha	Investigative

T63393	TARGETID	T63393
T63393	FORMERID	TTDI03429
T63393	UNIPROID	OXGR1_HUMAN
T63393	TARGNAME	Oxoglutarate receptor (OXGR1)
T63393	GENENAME	OXGR1
T63393	TARGTYPE	Literature-reported
T63393	SYNONYMS	P2Y15; P2Y-like nucleotide receptor; P2Y-like GPCR; P2Y purinoceptor 15; P2RY15; GPR99; GPR80; G-protein coupled receptor 99; G-protein coupled receptor 80; Alpha-ketoglutarate receptor 1; 2-oxoglutarate receptor 1
T63393	FUNCTION	Receptor for alpha-ketoglutarate. Seems to act exclusively through a G(q)-mediated pathway (By similarity).
T63393	SEQUENCE	MNEPLDYLANASDFPDYAAAFGNCTDENIPLKMHYLPVIYGIIFLVGFPGNAVVISTYIFKMRPWKSSTIIMLNLACTDLLYLTSLPFLIHYYASGENWIFGDFMCKFIRFSFHFNLYSSILFLTCFSIFRYCVIIHPMSCFSIHKTRCAVVACAVVWIISLVAVIPMTFLITSTNRTNRSACLDLTSSDELNTIKWYNLILTATTFCLPLVIVTLCYTTIIHTLTHGLQTDSCLKQKARRLTILLLLAFYVCFLPFHILRVIRIESRLLSISCSIENQIHEAYIVSRPLAALNTFGNLLLYVVVSDNFQQAVCSTVRCKVSGNLEQAKKISYSNNP
T63393	DRUGINFO	D09KQZ	alpha-ketoglutaric acid	Investigative
T63393	DRUGINFO	D0C0KJ	LTE4	Investigative

T96273	TARGETID	T96273
T96273	FORMERID	TTDI03554
T96273	UNIPROID	S38A2_HUMAN
T96273	TARGNAME	Solute carrier family 38 member 2 (SLC38A2)
T96273	GENENAME	SLC38A2
T96273	TARGTYPE	Literature-reported
T96273	SYNONYMS	System N amino acid transporter 2; System A transporter 1; System A amino acid transporter 2; Sodium-coupled neutral amino acid transporter 2; SNAT2; SAT2; Protein 40-9-1; KIAA1382; Amino acid transporter A2; ATA2
T96273	FUNCTION	Functions as a sodium-dependent amino acid transporter. Mediates the saturable, pH-sensitive and electrogenic cotransport of neutral amino acids and sodium ions with a stoichiometry of 1:1. May function in the transport of amino acids at the blood-brain barrier and in the supply of maternal nutrients to the fetus through the placenta.
T96273	SEQUENCE	MKKAEMGRFSISPDEDSSSYSSNSDFNYSYPTKQAALKSHYADVDPENQNFLLESNLGKKKYETEFHPGTTSFGMSVFNLSNAIVGSGILGLSYAMANTGIALFIILLTFVSIFSLYSVHLLLKTANEGGSLLYEQLGYKAFGLVGKLAASGSITMQNIGAMSSYLFIVKYELPLVIQALTNIEDKTGLWYLNGNYLVLLVSLVVILPLSLFRNLGYLGYTSGLSLLCMVFFLIVVICKKFQVPCPVEAALIINETINTTLTQPTALVPALSHNVTENDSCRPHYFIFNSQTVYAVPILIFSFVCHPAVLPIYEELKDRSRRRMMNVSKISFFAMFLMYLLAALFGYLTFYEHVESELLHTYSSILGTDILLLIVRLAVLMAVTLTVPVVIFPIRSSVTHLLCASKDFSWWRHSLITVSILAFTNLLVIFVPTIRDIFGFIGASAASMLIFILPSAFYIKLVKKEPMKSVQKIGALFFLLSGVLVMTGSMALIVLDWVHNAPGGGH

T95783	TARGETID	T95783
T95783	UNIPROID	RSF1_HUMAN
T95783	TARGNAME	Remodeling and spacing factor 1 (RSF1)
T95783	GENENAME	RSF1
T95783	TARGTYPE	Literature-reported
T95783	SYNONYMS	p325 subunit of RSF chromatin-remodeling complex; XAP8; Rsf-1; Hepatitis B virus X-associated protein; HBXAP; HBV pX-associated protein 8
T95783	FUNCTION	Required for assembly of regular nucleosome arrays by the RSF chromatin-remodeling complex (PubMed:12972596). Facilitates transcription of hepatitis B virus (HBV) genes by the pX transcription activator. In case of infection by HBV, together with pX, it represses TNF-alpha induced NF-kappa-B transcription activation. Represses transcription when artificially recruited to chromatin by fusion to a heterogeneous DNA binding domain (PubMed:11944984, PubMed:11788598).
T95783	SEQUENCE	MATAAAAAAVMAPPGCPGSCPNFAVVCSFLERYGPLLDLPELPFPELERVLQAPPPDVGNGEVPKELVELHLKLMRKIGKSVTADRWEKYLIKICQEFNSTWAWEMEKKGYLEMSVECKLALLKYLCECQFDDNLKFKNIINEEDADTMRLQPIGRDKDGLMYWYQLDQDHNVRMYIEEQDDQDGSSWKCIVRNRNELAETLALLKAQIDPVLLKNSSQQDNSSRESPSLEDEETKKEEETPKQEEQKESEKMKSEEQPMDLENRSTANVLEETTVKKEKEDEKELVKLPVIVKLEKPLPENEEKKIIKEESDSFKENVKPIKVEVKECRADPKDTKSSMEKPVAQEPERIEFGGNIKSSHEITEKSTEETEKLKNDQQAKIPLKKREIKLSDDFDSPVKGPLCKSVTPTKEFLKDEIKQEEETCKRISTITALGHEGKQLVNGEVSDERVAPNFKTEPIETKFYETKEESYSPSKDRNIITEGNGTESLNSVITSMKTGELEKETAPLRKDADSSISVLEIHSQKAQIEEPDPPEMETSLDSSEMAKDLSSKTALSSTESCTMKGEEKSPKTKKDKRPPILECLEKLEKSKKTFLDKDAQRLSPIPEEVPKSTLESEKPGSPEAAETSPPSNIIDHCEKLASEKEVVECQSTSTVGGQSVKKVDLETLKEDSEFTKVEMDNLDNAQTSGIEEPSETKGSMQKSKFKYKLVPEEETTASENTEITSERQKEGIKLTIRISSRKKKPDSPPKVLEPENKQEKTEKEEEKTNVGRTLRRSPRISRPTAKVAEIRDQKADKKRGEGEDEVEEESTALQKTDKKEILKKSEKDTNSKVSKVKPKGKVRWTGSRTRGRWKYSSNDESEGSGSEKSSAASEEEEEKESEEAILADDDEPCKKCGLPNHPELILLCDSCDSGYHTACLRPPLMIIPDGEWFCPPCQHKLLCEKLEEQLQDLDVALKKKERAERRKERLVYVGISIENIIPPQEPDFSEDQEEKKKDSKKSKANLLERRSTRTRKCISYRFDEFDEAIDEAIEDDIKEADGGGVGRGKDISTITGHRGKDISTILDEERKENKRPQRAAAARRKKRRRLNDLDSDSNLDEEESEDEFKISDGSQDEFVVSDENPDESEEDPPSNDDSDTDFCSRRLRRHPSRPMRQSRRLRRKTPKKKYSDDDEEEESEENSRDSESDFSDDFSDDFVETRRRRSRRNQKRQINYKEDSESDGSQKSLRRGKEIRRVHKRRLSSSESEESYLSKNSEDDELAKESKRSVRKRGRSTDEYSEADEEEEEEEGKPSRKRLHRIETDEEESCDNAHGDANQPARDSQPRVLPSEQESTKKPYRIESDEEEDFENVGKVGSPLDYSLVDLPSTNGQSPGKAIENLIGKPTEKSQTPKDNSTASASLASNGTSGGQEAGAPEEEEDELLRVTDLVDYVCNSEQL

T55201	TARGETID	T55201
T55201	FORMERID	TTDR01127
T55201	UNIPROID	VGPCR_HHV8P
T55201	TARGNAME	Herpesvirus G-protein coupled receptor (KSHV vGPCR)
T55201	GENENAME	KSHV vGPCR
T55201	TARGTYPE	Literature-reported
T55201	SYNONYMS	viral G-protein coupled receptor; vGPCR; Protein ORF74
T55201	FUNCTION	Receptor that signals constitutively via several signaling pathways including PI3K/AKT as well as mitogen- and stress-activated/MAP kinases. Promotes host cell proliferation and survival, modulates cell migration, stimulates angiogenesis, and recruits inflammatory cells, both in expressing cells and in neighboring cells. Maintains chronic activation of NF-kappa-B via interaction with host CADM1.
T55201	SEQUENCE	MAAEDFLTIFLDDDESWNETLNMSGYDYSGNFSLEVSVCEMTTVVPYTWNVGILSLIFLINVLGNGLVTYIFCKHRSRAGAIDILLLGICLNSLCLSISLLAEVLMFLFPNIISTGLCRLEIFFYYLYVYLDIFSVVCVSLVRYLLVAYSTRSWPKKQSLGWVLTSAALLIALVLSGDACRHRSRVVDPVSKQAMCYENAGNMTADWRLHVRTVSVTAGFLLPLALLILFYALTWCVVRRTKLQARRKVRGVIVAVVLLFFVFCFPYHVLNLLDTLLRRRWIRDSCYTRGLINVGLAVTSLLQALYSAVVPLIYSCLGSLFRQRMYGLFQSLRQSFMSGATT

T75351	TARGETID	T75351
T75351	FORMERID	TTDI03555
T75351	UNIPROID	S38A3_HUMAN
T75351	TARGNAME	Solute carrier family 38 member 3 (SLC38A3)
T75351	GENENAME	SLC38A3
T75351	TARGTYPE	Literature-reported
T75351	SYNONYMS	Sodium-coupled neutral amino acid transporter 3; SNAT3; SN1; Na(+)-coupled neutral amino acid transporter 3; N-system amino acid transporter 1; G17
T75351	FUNCTION	Sodium-dependent amino acid/proton antiporter. Mediates electrogenic cotransport of glutamine and sodium ions in exchange for protons. Also recognizes histidine, asparagine and alanine. May mediate amino acid transport in either direction under physiological conditions. May play a role in nitrogen metabolism and synaptic transmission.
T75351	SEQUENCE	MEAPLQTEMVELVPNGKHSEGLLPVITPMAGNQRVEDPARSCMEGKSFLQKSPSKEPHFTDFEGKTSFGMSVFNLSNAIMGSGILGLAYAMANTGIILFLFLLTAVALLSSYSIHLLLKSSGVVGIRAYEQLGYRAFGTPGKLAAALAITLQNIGAMSSYLYIIKSELPLVIQTFLNLEEKTSDWYMNGNYLVILVSVTIILPLALMRQLGYLGYSSGFSLSCMVFFLIAVIYKKFHVPCPLPPNFNNTTGNFSHVEIVKEKVQLQVEPEASAFCTPSYFTLNSQTAYTIPIMAFAFVCHPEVLPIYTELKDPSKKKMQHISNLSIAVMYIMYFLAALFGYLTFYNGVESELLHTYSKVDPFDVLILCVRVAVLTAVTLTVPIVLFPVRRAIQQMLFPNQEFSWLRHVLIAVGLLTCINLLVIFAPNILGIFGVIGATSAPFLIFIFPAIFYFRIMPTEKEPARSTPKILALCFAMLGFLLMTMSLSFIIIDWASGTSRHGGNH

T58130	TARGETID	T58130
T58130	FORMERID	TTDI03356
T58130	UNIPROID	LPAR4_HUMAN
T58130	TARGNAME	Lysophosphatidic acid receptor 4 (LPAR4)
T58130	GENENAME	LPAR4
T58130	TARGTYPE	Literature-reported
T58130	SYNONYMS	Purinergic receptor 9; P2Y9; P2Y5-like receptor; P2Y purinoceptor 9; P2RY9; LPA4; LPA-4; LPA receptor 4; GPR23; G-protein coupled receptor 23
T58130	FUNCTION	Receptor for lysophosphatidic acid (LPA), a mediator of diverse cellular activities. Transduces a signal by increasing the intracellular calcium ions and by stimulating adenylyl cyclase activity. The rank order of potency for agonists of this receptor is 1-oleoyl- > 1-stearoyl- > 1-palmitoyl- > 1-myristoyl- > 1-alkyl- > 1-alkenyl-LPA.
T58130	SEQUENCE	MGDRRFIDFQFQDSNSSLRPRLGNATANNTCIVDDSFKYNLNGAVYSVVFILGLITNSVSLFVFCFRMKMRSETAIFITNLAVSDLLFVCTLPFKIFYNFNRHWPFGDTLCKISGTAFLTNIYGSMLFLTCISVDRFLAIVYPFRSRTIRTRRNSAIVCAGVWILVLSGGISASLFSTTNVNNATTTCFEGFSKRVWKTYLSKITIFIEVVGFIIPLILNVSCSSVVLRTLRKPATLSQIGTNKKKVLKMITVHMAVFVVCFVPYNSVLFLYALVRSQAITNCFLERFAKIMYPITLCLATLNCCFDPFIYYFTLESFQKSFYINAHIRMESLFKTETPLTTKPSLPAIQEEVSDQTTNNGGELMLESTF
T58130	DRUGINFO	D05TVG	[1-bromo-(3S)-hydrox-4-(palmitoyloxy)butyl]phosphate	Investigative
T58130	DRUGINFO	D0X0UR	LPA	Investigative

T15888	TARGETID	T15888
T15888	FORMERID	TTDI03108
T15888	UNIPROID	CML1_HUMAN
T15888	TARGNAME	Chemerin receptor (CMKLR1)
T15888	GENENAME	CMKLR1
T15888	TARGTYPE	Literature-reported
T15888	SYNONYMS	G-protein coupled receptor DEZ; G-protein coupled receptor ChemR23; DEZ; Chemokine-like receptor 1; CHEMR23
T15888	FUNCTION	Receptor for the chemoattractant adipokine chemerin/RARRES2 and for the omega-3 fatty acid derived molecule resolvin E1. Interaction with RARRES2 induces activation of intracellular signaling molecules, such as SKY, MAPK1/3 (ERK1/2), MAPK14/P38MAPK and PI3K leading to multifunctional effects, like, reduction of immune responses, enhancing of adipogenesis and angionesis. Resolvin E1 down-regulates cytokine production in macrophages by reducing the activation of MAPK1/3 (ERK1/2) and NF-kappa-B. Positively regulates adipogenesis and adipocyte metabolism. Acts as a coreceptor for several SIV strains (SIVMAC316, SIVMAC239, SIVMACL7E-FR and SIVSM62A), as well as a primary HIV-1 strain (92UG024-2).
T15888	SEQUENCE	MRMEDEDYNTSISYGDEYPDYLDSIVVLEDLSPLEARVTRIFLVVVYSIVCFLGILGNGLVIIIATFKMKKTVNMVWFLNLAVADFLFNVFLPIHITYAAMDYHWVFGTAMCKISNFLLIHNMFTSVFLLTIISSDRCISVLLPVWSQNHRSVRLAYMACMVIWVLAFFLSSPSLVFRDTANLHGKISCFNNFSLSTPGSSSWPTHSQMDPVGYSRHMVVTVTRFLCGFLVPVLIITACYLTIVCKLQRNRLAKTKKPFKIIVTIIITFFLCWCPYHTLNLLELHHTAMPGSVFSLGLPLATALAIANSCMNPILYVFMGQDFKKFKVALFSRLVNALSEDTGHSSYPSHRSFTKMSSMNERTSMNERETGML
T15888	DRUGINFO	D01IUB	[3H]resolvin E1	Investigative

T54982	TARGETID	T54982
T54982	FORMERID	TTDI03480
T54982	UNIPROID	SC6A7_HUMAN
T54982	TARGNAME	Sodium-dependent proline transporter (SLC6A7)
T54982	GENENAME	SLC6A7
T54982	TARGTYPE	Literature-reported
T54982	SYNONYMS	Solute carrier family 6 member 7; PROT
T54982	FUNCTION	Terminates the action of proline by its high affinity sodium-dependent reuptake into presynaptic terminals.
T54982	SEQUENCE	MKKLQGAHLRKPVTPDLLMTPSDQGDVDLDVDFAAHRGNWTGKLDFLLSCIGYCVGLGNVWRFPYRAYTNGGGAFLVPYFLMLAICGIPLFFLELSLGQFSSLGPLAVWKISPLFKGAGAAMLLIVGLVAIYYNMIIAYVLFYLFASLTSDLPWEHCGNWWNTELCLEHRVSKDGNGALPLNLTCTVSPSEEYWSRYVLHIQGSQGIGSPGEIRWNLCLCLLLAWVIVFLCILKGVKSSGKVVYFTATFPYLILLMLLVRGVTLPGAWKGIQFYLTPQFHHLLSSKVWIEAALQIFYSLGVGFGGLLTFASYNTFHQNIYRDTFIVTLGNAITSILAGFAIFSVLGYMSQELGVPVDQVAKAGPGLAFVVYPQAMTMLPLSPFWSFLFFFMLLTLGLDSQFAFLETIVTAVTDEFPYYLRPKKAVFSGLICVAMYLMGLILTTDGGMYWLVLLDDYSASFGLMVVVITTCLAVTRVYGIQRFCRDIHMMLGFKPGLYFRACWLFLSPATLLALMVYSIVKYQPSEYGSYRFPPWAELLGILMGLLSCLMIPAGMLVAVLREEGSLWERLQQASRPAMDWGPSLEENRTGMYVATLAGSQSPKPLMVHMRKYGGITSFENTAIEVDREIAEEEESMM
T54982	DRUGINFO	D02KNP	LP-403812	Investigative
T54982	DRUGINFO	D0M6UK	PMID25037917C58	Investigative

T70633	TARGETID	T70633
T70633	FORMERID	TTDI03562
T70633	UNIPROID	SUCR1_HUMAN
T70633	TARGNAME	Succinate receptor (SUCNR1)
T70633	GENENAME	SUCNR1
T70633	TARGTYPE	Literature-reported
T70633	SYNONYMS	Succinate receptor 1; P2Y purinoceptor 1-like; GPR91; G-protein coupled receptor 91
T70633	FUNCTION	Receptor for succinate.
T70633	SEQUENCE	MLGIMAWNATCKNWLAAEAALEKYYLSIFYGIEFVVGVLGNTIVVYGYIFSLKNWNSSNIYLFNLSVSDLAFLCTLPMLIRSYANGNWIYGDVLCISNRYVLHANLYTSILFLTFISIDRYLIIKYPFREHLLQKKEFAILISLAIWVLVTLELLPILPLINPVITDNGTTCNDFASSGDPNYNLIYSMCLTLLGFLIPLFVMCFFYYKIALFLKQRNRQVATALPLEKPLNLVIMAVVIFSVLFTPYHVMRNVRIASRLGSWKQYQCTQVVINSFYIVTRPLAFLNSVINPVFYFLLGDHFRDMLMNQLRHNFKSLTSFSRWAHELLLSFREK
T70633	DRUGINFO	D02FGK	PMID21571530C5g	Investigative
T70633	DRUGINFO	D0GC5Y	PMID21571530C7e	Investigative

T87661	TARGETID	T87661
T87661	FORMERID	TTDI03235
T87661	UNIPROID	GP174_HUMAN
T87661	TARGNAME	G-protein coupled receptor 174 (GPR174)
T87661	GENENAME	GPR174
T87661	TARGTYPE	Literature-reported
T87661	SYNONYMS	Probable G-protein coupled receptor 174
T87661	FUNCTION	Putative receptor for purines coupled to G-proteins.
T87661	SEQUENCE	MPANYTCTRPDGDNTDFRYFIYAVTYTVILVPGLIGNILALWVFYGYMKETKRAVIFMINLAIADLLQVLSLPLRIFYYLNHDWPFGPGLCMFCFYLKYVNMYASIYFLVCISVRRFWFLMYPFRFHDCKQKYDLYISIAGWLIICLACVLFPLLRTSDDTSGNRTKCFVDLPTRNVNLAQSVVMMTIGELIGFVTPLLIVLYCTWKTVLSLQDKYPMAQDLGEKQKALKMILTCAGVFLICFAPYHFSFPLDFLVKSNEIKSCLARRVILIFHSVALCLASLNSCLDPVIYYFSTNEFRRRLSRQDLHDSIQLHAKSFVSNHTASTMTPELC
T87661	DRUGINFO	D0M8IT	lysophosphatidylserine	Investigative

T69393	TARGETID	T69393
T69393	FORMERID	TTDI03245
T69393	UNIPROID	GPR63_HUMAN
T69393	TARGNAME	G-protein coupled receptor 63 (GPR63)
T69393	GENENAME	GPR63
T69393	TARGTYPE	Literature-reported
T69393	SYNONYMS	Probable G-protein coupled receptor 63; PSP24B; PSP24-beta; PSP24-2
T69393	FUNCTION	Orphan receptor. May play a role in brain function.
T69393	SEQUENCE	MVFSAVLTAFHTGTSNTTFVVYENTYMNITLPPPFQHPDLSPLLRYSFETMAPTGLSSLTVNSTAVPTTPAAFKSLNLPLQITLSAIMIFILFVSFLGNLVVCLMVYQKAAMRSAINILLASLAFADMLLAVLNMPFALVTILTTRWIFGKFFCRVSAMFFWLFVIEGVAILLIISIDRFLIIVQRQDKLNPYRAKVLIAVSWATSFCVAFPLAVGNPDLQIPSRAPQCVFGYTTNPGYQAYVILISLISFFIPFLVILYSFMGILNTLRHNALRIHSYPEGICLSQASKLGLMSLQRPFQMSIDMGFKTRAFTTILILFAVFIVCWAPFTTYSLVATFSKHFYYQHNFFEISTWLLWLCYLKSALNPLIYYWRIKKFHDACLDMMPKSFKFLPQLPGHTKRRIRPSAVYVCGEHRTVV
T69393	DRUGINFO	D07KBZ	dioleoylphosphatidic acid	Investigative
T69393	DRUGINFO	D02UUO	dihydrosphingosine-1-phosphate	Investigative

T55932	TARGETID	T55932
T55932	FORMERID	TTDI03580
T55932	UNIPROID	S19A3_HUMAN
T55932	TARGNAME	Solute carrier family 19 member 3 (SLC19A3)
T55932	GENENAME	SLC19A3
T55932	TARGTYPE	Literature-reported
T55932	SYNONYMS	Thiamine transporter 2; ThTr2; ThTr-2
T55932	FUNCTION	Mediates high affinity thiamine uptake, probably via a proton anti-port mechanism. Has no folate transport activity.
T55932	SEQUENCE	MDCYRTSLSSSWIYPTVILCLFGFFSMMRPSEPFLIPYLSGPDKNLTSAEITNEIFPVWTYSYLVLLLPVFVLTDYVRYKPVIILQGISFIITWLLLLFGQGVKTMQVVEFFYGMVTAAEVAYYAYIYSVVSPEHYQRVSGYCRSVTLAAYTAGSVLAQLLVSLANMSYFYLNVISLASVSVAFLFSLFLPMPKKSMFFHAKPSREIKKSSSVNPVLEETHEGEAPGCEEQKPTSEILSTSGKLNKGQLNSLKPSNVTVDVFVQWFQDLKECYSSKRLFYWSLWWAFATAGFNQVLNYVQILWDYKAPSQDSSIYNGAVEAIATFGGAVAAFAVGYVKVNWDLLGELALVVFSVVNAGSLFLMHYTANIWACYAGYLIFKSSYMLLITIAVFQIAVNLNVERYALVFGINTFIALVIQTIMTVIVVDQRGLNLPVSIQFLVYGSYFAVIAGIFLMRSMYITYSTKSQKDVQSPAPSENPDVSHPEEESNIIMSTKL
T55932	DRUGINFO	D07TYL	[3H]thiamine	Investigative

T38428	TARGETID	T38428
T38428	FORMERID	TTDI00021
T38428	UNIPROID	FOXQ1_HUMAN
T38428	TARGNAME	Forkhead box protein Q1 (FOXQ1)
T38428	GENENAME	FOXQ1
T38428	TARGTYPE	Literature-reported
T38428	SYNONYMS	Hepatocyte nuclear factor 3 forkhead homolog 1; HNF3/forkheadlike protein 1; HNF-3/forkhead-like protein 1; HFH1; HFH-1
T38428	FUNCTION	Plays a role in hair follicle differentiation.
T38428	SEQUENCE	MKLEVFVPRAAHGDKQGSDLEGAGGSDAPSPLSAAGDDSLGSDGDCAANSPAAGGGARDTQGDGEQSAGGGPGAEEAIPAAAAAAVVAEGAEAGAAGPGAGGAGSGEGARSKPYTRRPKPPYSYIALIAMAIRDSAGGRLTLAEINEYLMGKFPFFRGSYTGWRNSVRHNLSLNDCFVKVLRDPSRPWGKDNYWMLNPNSEYTFADGVFRRRRKRLSHRAPVPAPGLRPEEAPGLPAAPPPAPAAPASPRMRSPARQEERASPAGKFSSSFAIDSILRKPFRSRRLRDTAPGTTLQWGAAPCPPLPAFPALLPAAPCRALLPLCAYGAGEPARLGAREAEVPPTAPPLLLAPLPAAAPAKPLRGPAAGGAHLYCPLRLPAALQAASVRRPGPHLPYPVETLLA

T02343	TARGETID	T02343
T02343	FORMERID	TTDS00511
T02343	UNIPROID	Q9F0I5_PAEMA
T02343	TARGNAME	Bacterial Cycloinulo-oligosaccharide fructanotransferase (Bact cft)
T02343	GENENAME	Bact cft
T02343	TARGTYPE	Literature-reported
T02343	SYNONYMS	Cycloinulo-oligosaccharide fructanotransferase
T02343	FUNCTION	Converts inulin into cyclooligosaccharides (cyclofructans) consisting of 6 to 8 molecules of (21)linked cyclic Dfructofuranose through intramolecular transfructosylation.
T02343	SEQUENCE	MRKVKRGKCWISGMVIWAMVLQLVVPGISVASENRTVAGETLIPKNDVKSSVTDAIYQIKNIPQNDMGLSVTDSVYQIRNPGFETGDLTGWTVIKGDAFGPNSVTDETTWWAEKIPYNQEGAYHLNGWKYDESATGVLRSSTFELGGSGGISFKLGGAKNPDKVFINIVEVDTGQVIARYGNSAFADVGFPDPAQGMRLANMVQYKADLSTQLGKKLYVEVVDNATSDWGVIFADAFSMYHESEPAEGIVATDIKPDFKRYEIDNPSFETGNLDGWTVEEDAFEVTDEAHASKEGNFYAKSSLQGKGSITSNTFTLQGTGTINFTVLDILKPENAYVALFDANSNTLLMKTGNVSANEKISWKVQEHYNKKLYVKVVDHSNEASIAVDSFQASDRGTIFYLNLDEGAGKKALEKVHNLRHDVNYVFNNARYMASKDPRWTPRGIKGGALLFDGSSNYIEVNANVTVPVSDALTIEAWVAPRSYEWGDGNKLSAIVNQSDQDKAEGFSLGMYRHGTWSMQVGIGGQWIQVWVKDHPLEKYKWNYVAATFSKEDGKIKLYLNGEEVASQATPVNVPITPSTESLIIGKNNKPVELAGVFSFNMFSGLLDEVKLHNKALTNQEILAGYESVKALHGGSIPKIPNADIDEDPSVFDGDQHRPQYHAMPPQNWMNEAHAPIYYNGKYHLFYQHNPQGPFWHQIHWGHWVSDDMVNWENVRPALAPEAGTLDPDGTWSGSAAYDRNGNPVLFYTAGNDSLSPNQRTGLATPADLSDPYLEKWEKYPKPVTEQNGKGIHNEFRDPFVWYDKEVDKWYQLVTSGLPDFSSGTALVYVSDDMYNWKYKGPLYVSDRIRYPELGTVWELPVLLPLGTDSTGKQKYIFMINPHEKPEHVPPANDVQRDVEVFYWIGTWDRDNFKFIPDQEAPSKMDVGDGYLTAESGLVTPDGRTVVFSMVQNVRTPQAEYQSGWAHNLSLPVSLSLDKYDKLHIEPIKELQSLRGEKWVDFSDKNLESANQLIKNVKGDMLEIVMEIDPREAQKFGLKVRRSEKGQEETLIYYDKKNGTFNVDRTKSSIDPDVRVDGIQGGYVDLEGENLKLHIFLDRSVIEAFANYKKKLTTRVYVGRYDSLGLQIWADGDINIKSMQVWDMNALTGKPAAPVYVPDKWDNSVYKDITELPNHDFATGDLTGWMTEGDAFQNVHVTNTQFFWDNIFFNPSHKIPGSYHLWGFNEQAGGDSLTGALRSQNFVLGGNGKINFLISGGRDIDRLYVALVRASDDKELFKETATNYEEYQRKIWDATDYIGEELYIKVVDHSKGGFGHINVDDFNVPVQVKKKTNN

T37505	TARGETID	T37505
T37505	FORMERID	TTDI03249
T37505	UNIPROID	GPR88_HUMAN
T37505	TARGNAME	Striatum-specific G-protein coupled receptor (GPR88)
T37505	GENENAME	GPR88
T37505	TARGTYPE	Literature-reported
T37505	SYNONYMS	STRG; Probable G-protein coupled receptor 88
T37505	FUNCTION	Probable G-protein coupled receptor implicated in a large repertoire of behavioral responses that engage motor activities, spatial learning, and emotional processing. May play a role in the regulation of cognitive and motor function.
T37505	SEQUENCE	MTNSSSTSTSSTTGGSLLLLCEEEESWAGRRIPVSLLYSGLAIGGTLANGMVIYLVSSFRKLQTTSNAFIVNGCAADLSVCALWMPQEAVLGLLPTGSAEPPADWDGAGGSYRLLRGGLLGLGLTVSLLSHCLVALNRYLLITRAPATYQALYQRRHTAGMLALSWALALGLVLLLPPWAPRPGAAPPRVHYPALLAAAALLAQTALLLHCYLGIVRRVRVSVKRVSVLNFHLLHQLPGCAAAAAAFPGAQHAPGPGGAAHPAQAQPLPPALHPRRAQRRLSGLSVLLLCCVFLLATQPLVWVSLASGFSLPVPWGVQAASWLLCCALSALNPLLYTWRNEEFRRSVRSVLPGVGDAAAAAVAATAVPAVSQAQLGTRAAGQHW
T37505	DRUGINFO	D0O6ZN	PMID24793972C2	Investigative

T04210	TARGETID	T04210
T04210	FORMERID	TTDI03407
T04210	UNIPROID	NMUR2_HUMAN
T04210	TARGNAME	Neuromedin-U receptor 2 (NMUR2)
T04210	GENENAME	NMUR2
T04210	TARGTYPE	Literature-reported
T04210	SYNONYMS	TGR1; NMU2R; NMU-R2; G-protein coupled receptor TGR-1; G-protein coupled receptor FM-4
T04210	FUNCTION	Receptor for the neuromedin-U and neuromedin-S neuropeptides.
T04210	SEQUENCE	MSGMEKLQNASWIYQQKLEDPFQKHLNSTEEYLAFLCGPRRSHFFLPVSVVYVPIFVVGVIGNVLVCLVILQHQAMKTPTNYYLFSLAVSDLLVLLLGMPLEVYEMWRNYPFLFGPVGCYFKTALFETVCFASILSITTVSVERYVAILHPFRAKLQSTRRRALRILGIVWGFSVLFSLPNTSIHGIKFHYFPNGSLVPGSATCTVIKPMWIYNFIIQVTSFLFYLLPMTVISVLYYLMALRLKKDKSLEADEGNANIQRPCRKSVNKMLFVLVLVFAICWAPFHIDRLFFSFVEEWSESLAAVFNLVHVVSGVFFYLSSAVNPIIYNLLSRRFQAAFQNVISSFHKQWHSQHDPQLPPAQRNIFLTECHFVELTEDIGPQFPCQSSMHNSHLPAALSSEQMSRTNYQSFHFNKT
T04210	DRUGINFO	D00EFA	R-PSOP	Investigative
T04210	DRUGINFO	D0I0LW	PMID24999562C6b	Investigative

T79780	TARGETID	T79780
T79780	FORMERID	TTDI03410
T79780	UNIPROID	NPFF1_HUMAN
T79780	TARGNAME	Neuropeptide FF receptor 1 (NPFFR1)
T79780	GENENAME	NPFFR1
T79780	TARGTYPE	Literature-reported
T79780	SYNONYMS	RFamide-related peptide receptor OT7T022; NPFF1; GPR147; G-protein coupled receptor 147
T79780	FUNCTION	Receptor for NPAF (A-18-F-amide) and NPFF (F-8-F-amide) neuropeptides, also known as morphine-modulating peptides. Can also be activated by a variety of naturally occurring or synthetic FMRF-amide like ligands. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
T79780	SEQUENCE	MEGEPSQPPNSSWPLSQNGTNTEATPATNLTFSSYYQHTSPVAAMFIVAYALIFLLCMVGNTLVCFIVLKNRHMHTVTNMFILNLAVSDLLVGIFCMPTTLVDNLITGWPFDNATCKMSGLVQGMSVSASVFTLVAIAVERFRCIVHPFREKLTLRKALVTIAVIWALALLIMCPSAVTLTVTREEHHFMVDARNRSYPLYSCWEAWPEKGMRRVYTTVLFSHIYLAPLALIVVMYARIARKLCQAPGPAPGGEEAADPRASRRRARVVHMLVMVALFFTLSWLPLWALLLLIDYGQLSAPQLHLVTVYAFPFAHWLAFFNSSANPIIYGYFNENFRRGFQAAFRARLCPRPSGSHKEAYSERPGGLLHRRVFVVVRPSDSGLPSESGPSSGAPRPGRLPLRNGRVAHHGLPREGPGCSHLPLTIPAWDI
T79780	DRUGINFO	D05NKX	1DMe	Investigative
T79780	DRUGINFO	D08UWO	RF9	Investigative

T83143	TARGETID	T83143
T83143	FORMERID	TTDI03110
T83143	UNIPROID	SC5A7_HUMAN
T83143	TARGNAME	High affinity choline transporter 1 (CHT)
T83143	GENENAME	SLC5A7
T83143	TARGTYPE	Literature-reported
T83143	SYNONYMS	Solute carrier family 5 member 7; Hemicholinium-3-sensitive choline transporter; CHT1; CHT
T83143	FUNCTION	Transmembrane transporter that imports choline from the extracellular space into the neuron with high affinity. Choline uptake is the rate-limiting step in acetylcholine synthesis. Sodium ion- and chloride ion-dependent.
T83143	SEQUENCE	MAFHVEGLIAIIVFYLLILLVGIWAAWRTKNSGSAEERSEAIIVGGRDIGLLVGGFTMTATWVGGGYINGTAEAVYVPGYGLAWAQAPIGYSLSLILGGLFFAKPMRSKGYVTMLDPFQQIYGKRMGGLLFIPALMGEMFWAAAIFSALGATISVIIDVDMHISVIISALIATLYTLVGGLYSVAYTDVVQLFCIFVGLWISVPFALSHPAVADIGFTAVHAKYQKPWLGTVDSSEVYSWLDSFLLLMLGGIPWQAYFQRVLSSSSATYAQVLSFLAAFGCLVMAIPAILIGAIGASTDWNQTAYGLPDPKTTEEADMILPIVLQYLCPVYISFFGLGAVSAAVMSSADSSILSASSMFARNIYQLSFRQNASDKEIVWVMRITVFVFGASATAMALLTKTVYGLWYLSSDLVYIVIFPQLLCVLFVKGTNTYGAVAGYVSGLFLRITGGEPYLYLQPLIFYPGYYPDDNGIYNQKFPFKTLAMVTSFLTNICISYLAKYLFESGTLPPKLDVFDAVVARHSEENMDKTILVKNENIKLDELALVKPRQSMTLSSTFTNKEAFLDVDSSPEGSGTEDNLQ
T83143	DRUGINFO	D05AFI	[3H]hemicholinium-3	Investigative

T18616	TARGETID	T18616
T18616	FORMERID	TTDI03357
T18616	UNIPROID	LPAR5_HUMAN
T18616	TARGNAME	Lysophosphatidic acid receptor 5 (LPAR5)
T18616	GENENAME	LPAR5
T18616	TARGTYPE	Literature-reported
T18616	SYNONYMS	LPA-5; LPA receptor 5; GPR93; GPR92; G-protein coupled receptor 93; G-protein coupled receptor 92
T18616	FUNCTION	Receptor for lysophosphatidic acid (LPA), a mediator of diverse cellular activities.
T18616	SEQUENCE	MLANSSSTNSSVLPCPDYRPTHRLHLVVYSLVLAAGLPLNALALWVFLRALRVHSVVSVYMCNLAASDLLFTLSLPVRLSYYALHHWPFPDLLCQTTGAIFQMNMYGSCIFLMLINVDRYAAIVHPLRLRHLRRPRVARLLCLGVWALILVFAVPAARVHRPSRCRYRDLEVRLCFESFSDELWKGRLLPLVLLAEALGFLLPLAAVVYSSGRVFWTLARPDATQSQRRRKTVRLLLANLVIFLLCFVPYNSTLAVYGLLRSKLVAASVPARDRVRGVLMVMVLLAGANCVLDPLVYYFSAEGFRNTLRGLGTPHRARTSATNGTRAALAQSERSAVTTDATRPDAASQGLLRPSDSHSLSSFTQCPQDSAL
T18616	DRUGINFO	D01STE	alkyl glycerol phosphate 18:1	Investigative
T18616	DRUGINFO	D0GH9J	octyl thiophosphatidic acid	Investigative
T18616	DRUGINFO	D01ZHW	N-arachidonoylglycine	Investigative
T18616	DRUGINFO	D0X0UR	LPA	Investigative

T15822	TARGETID	T15822
T15822	FORMERID	TTDI01446
T15822	UNIPROID	S6A17_HUMAN
T15822	TARGNAME	Neurotransmitter transporter NTT4 (SLC6A17)
T15822	GENENAME	SLC6A17
T15822	TARGTYPE	Literature-reported
T15822	SYNONYMS	Solute carrier family 6 member 17; Sodium-dependent neutral amino acid transporter SLC6A17; Sodium-dependent neurotransmitter transporter NTT4; NTT4
T15822	FUNCTION	Functions as a sodium-dependent vesicular transporter selective for proline, glycine, leucine and alanine. In contrast to other members of this neurotransmitter transporter family, does not appear to be chloride-dependent (By similarity).
T15822	SEQUENCE	MPKNSKVTQREHSSEHVTESVADLLALEEPVDYKQSVLNVAGEAGGKQKAVEEELDAEDRPAWNSKLQYILAQIGFSVGLGNIWRFPYLCQKNGGGAYLVPYLVLLIIIGIPLFFLELAVGQRIRRGSIGVWHYICPRLGGIGFSSCIVCLFVGLYYNVIIGWSIFYFFKSFQYPLPWSECPVVRNGSVAVVEAECEKSSATTYFWYREALDISDSISESGGLNWKMTLCLLVAWSIVGMAVVKGIQSSGKVMYFSSLFPYVVLACFLVRGLLLRGAVDGILHMFTPKLDKMLDPQVWREAATQVFFALGLGFGGVIAFSSYNKQDNNCHFDAALVSFINFFTSVLATLVVFAVLGFKANIMNEKCVVENAEKILGYLNTNVLSRDLIPPHVNFSHLTTKDYMEMYNVIMTVKEDQFSALGLDPCLLEDELDKSVQGTGLAFIAFTEAMTHFPASPFWSVMFFLMLINLGLGSMIGTMAGITTPIIDTFKVPKEMFTVGCCVFAFLVGLLFVQRSGNYFVTMFDDYSATLPLTLIVILENIAVAWIYGTKKFMQELTEMLGFRPYRFYFYMWKFVSPLCMAVLTTASIIQLGVTPPGYSAWIKEEAAERYLYFPNWAMALLITLIVVATLPIPVVFVLRHFHLLSDGSNTLSVSYKKGRMMKDISNLEENDETRFILSKVPSEAPSPMPTHRSYLGPGSTSPLETSGNPNGRYGSGYLLASTPESEL

T30844	TARGETID	T30844
T30844	FORMERID	TTDI03553
T30844	UNIPROID	S38A1_HUMAN
T30844	TARGNAME	Solute carrier family 38 member 1 (SLC38A1)
T30844	GENENAME	SLC38A1
T30844	TARGTYPE	Literature-reported
T30844	SYNONYMS	System N amino acid transporter 1; System A amino acid transporter 1; Sodium-coupled neutral amino acid transporter 1; SNAT1; SAT1; NAT2; N-system amino acid transporter 2; Amino acid transporter A1; ATA1
T30844	FUNCTION	Functions as a sodium-dependent amino acid transporter. Mediates the saturable, pH-sensitive and electrogenic cotransport of glutamine and sodium ions with a stoichiometry of 1:1. May also transport small zwitterionic and aliphatic amino acids with a lower affinity. May supply glutamatergic and GABAergic neurons with glutamine which is required for the synthesis of the neurotransmitters glutamate and GABA.
T30844	SEQUENCE	MMHFKSGLELTELQNMTVPEDDNISNDSNDFTEVENGQINSKFISDRESRRSLTNSHLEKKKCDEYIPGTTSLGMSVFNLSNAIMGSGILGLAFALANTGILLFLVLLTSVTLLSIYSINLLLICSKETGCMVYEKLGEQVFGTTGKFVIFGATSLQNTGAMLSYLFIVKNELPSAIKFLMGKEETFSAWYVDGRVLVVIVTFGIILPLCLLKNLGYLGYTSGFSLSCMVFFLIVVIYKKFQIPCIVPELNSTISANSTNADTCTPKYVTFNSKTVYALPTIAFAFVCHPSVLPIYSELKDRSQKKMQMVSNISFFAMFVMYFLTAIFGYLTFYDNVQSDLLHKYQSKDDILILTVRLAVIVAVILTVPVLFFTVRSSLFELAKKTKFNLCRHTVVTCILLVVINLLVIFIPSMKDIFGVVGVTSANMLIFILPSSLYLKITDQDGDKGTQRIWAALFLGLGVLFSLVSIPLVIYDWACSSSSDEGH

T00088	TARGETID	T00088
T00088	FORMERID	TTDR01119
T00088	UNIPROID	PIGU_HUMAN
T00088	TARGNAME	GPI transamidase component PIG-U (PIGU)
T00088	GENENAME	PIGU
T00088	TARGTYPE	Literature-reported
T00088	SYNONYMS	UNQ3055/PRO9875; Phosphatidylinositol-glycan biosynthesis, class U protein; PIGU; PIG-U; Cell division cycle protein 91-like 1; CDC91L1; CDC91-like 1 protein
T00088	FUNCTION	Component of the GPI transamidase complex. May be involved in the recognition of either the GPI attachment signal or the lipid portion of GPI.
T00088	SEQUENCE	MAAPLVLVLVVAVTVRAALFRSSLAEFISERVEVVSPLSSWKRVVEGLSLLDLGVSPYSGAVFHETPLIIYLFHFLIDYAELVFMITDALTAIALYFAIQDFNKVVFKKQKLLLELDQYAPDVAELIRTPMEMRYIPLKVALFYLLNPYTILSCVAKSTCAINNTLIAFFILTTIKGSAFLSAIFLALATYQSLYPLTLFVPGLLYLLQRQYIPVKMKSKAFWIFSWEYAMMYVGSLVVIICLSFFLLSSWDFIPAVYGFILSVPDLTPNIGLFWYFFAEMFEHFSLFFVCVFQINVFFYTIPLAIKLKEHPIFFMFIQIAVIAIFKSYPTVGDVALYMAFFPVWNHLYRFLRNIFVLTCIIIVCSLLFPVLWHLWIYAGSANSNFFYAITLTFNVGQILLISDYFYAFLRREYYLTHGLYLTAKDGTEAMLVLK

T83382	TARGETID	T83382
T83382	FORMERID	TTDI03406
T83382	UNIPROID	NMUR1_HUMAN
T83382	TARGNAME	Neuromedin-U receptor 1 (NMUR1)
T83382	GENENAME	NMUR1
T83382	TARGTYPE	Literature-reported
T83382	SYNONYMS	NMU-R1; GPR66; G-protein coupled receptor FM-3; G-protein coupled receptor 66
T83382	FUNCTION	Receptor for the neuromedin-U and neuromedin-S neuropeptides.
T83382	SEQUENCE	MTPLCLNCSVLPGDLYPGGARNPMACNGSAARGHFDPEDLNLTDEALRLKYLGPQQTELFMPICATYLLIFVVGAVGNGLTCLVILRHKAMRTPTNYYLFSLAVSDLLVLLVGLPLELYEMWHNYPFLLGVGGCYFRTLLFEMVCLASVLNVTALSVERYVAVVHPLQARSMVTRAHVRRVLGAVWGLAMLCSLPNTSLHGIRQLHVPCRGPVPDSAVCMLVRPRALYNMVVQTTALLFFCLPMAIMSVLYLLIGLRLRRERLLLMQEAKGRGSAAARSRYTCRLQQHDRGRRQVTKMLFVLVVVFGICWAPFHADRVMWSVVSQWTDGLHLAFQHVHVISGIFFYLGSAANPVLYSLMSSRFRETFQEALCLGACCHRLRPRHSSHSLSRMTTGSTLCDVGSLGSWVHPLAGNDGPEAQQETDPS
T83382	DRUGINFO	D0M9DD	PMID24999562C8d	Investigative

T38464	TARGETID	T38464
T38464	FORMERID	TTDNR00761
T38464	UNIPROID	LY9_HUMAN
T38464	TARGNAME	T-lymphocyte surface antigen Ly-9 (LY9)
T38464	GENENAME	LY9
T38464	TARGTYPE	Literature-reported
T38464	SYNONYMS	Signaling lymphocytic activation molecule 3; SLAMF3; SLAM family member 3; Lymphocyte antigen 9; LY9; Cell surface molecule Ly-9
T38464	FUNCTION	May participate in adhesion reactions between T lymphocytes and accessory cells by homophilic interaction.
T38464	SEQUENCE	MVAPKSHTDDWAPGPFSSKPQRSQLQIFSSVLQTSLLFLLMGLRASGKDSAPTVVSGILGGSVTLPLNISVDTEIENVIWIGPKNALAFARPKENVTIMVKSYLGRLDITKWSYSLCISNLTLNDAGSYKAQINQRNFEVTTEEEFTLFVYEQLQEPQVTMKSVKVSENFSCNITLMCSVKGAEKSVLYSWTPREPHASESNGGSILTVSRTPCDPDLPYICTAQNPVSQRSSLPVHVGQFCTDPGASRGGTTGETVVGVLGEPVTLPLALPACRDTEKVVWLFNTSIISKEREEAATADPLIKSRDPYKNRVWVSSQDCSLKISQLKIEDAGPYHAYVCSEASSVTSMTHVTLLIYRRLRKPKITWSLRHSEDGICRISLTCSVEDGGNTVMYTWTPLQKEAVVSQGESHLNVSWRSSENHPNLTCTASNPVSRSSHQFLSENICSGPERNTKLWIGLFLMVCLLCVGIFSWCIWKRKGRCSVPAFCSSQAEAPADTPEPTAGHTLYSVLSQGYEKLDTPLRPARQQPTPTSDSSSDSNLTTEEDEDRPEVHKPISGRYEVFDQVTQEGAGHDPAPEGQADYDPVTPYVTEVESVVGENTMYAQVFNLQGKTPVSQKEESSATIYCSIRKPQVVPPPQQNDLEIPESPTYENFT

T29712	TARGETID	T29712
T29712	FORMERID	TTDI02554
T29712	UNIPROID	PLAC1_HUMAN
T29712	TARGNAME	Placenta specific protein 1 (PLAC1)
T29712	GENENAME	PLAC1
T29712	TARGTYPE	Literature-reported
T29712	SYNONYMS	Placentaspecific protein 1; PLAC1
T29712	FUNCTION	May play a role in placental development.
T29712	SEQUENCE	MKVFKFIGLMILLTSAFSAGSGQSPMTVLCSIDWFMVTVHPFMLNNDVCVHFHELHLGLGCPPNHVQPHAYQFTYRVTECGIRAKAVSQDMVIYSTEIHYSSKGTPSKFVIPVSCAAPQKSPWLTKPCSMRVASKSRATAQKDEKCYEVFSLSQSSQRPNCDCPPCVFSEEEHTQVPCHQAGAQEAQPLQPSHFLDISEDWSLHTDDMIGSM

T17555	TARGETID	T17555
T17555	FORMERID	TTDNR00745
T17555	UNIPROID	ENK5_HUMAN; ENK6_HUMAN
T17555	TARGNAME	Endogenous retrovirus group K Env polyprotein (ENK)
T17555	GENENAME	ERVK-5; ERVK-6
T17555	TARGTYPE	Literature-reported
T17555	SYNONYMS	HERV-envelope protein; HERV-K provirus ancestral Env polyprotein; HERV-K envelope protein; Envelope polyprotein; Endogenous retrovirus group K member  Env polyprotein; ERVK
T17555	FUNCTION	Retroviral envelope proteins mediate receptor recognition and membrane fusion during early infection. Endogenous envelope proteins may have kept, lost or modified their original function during evolution. This endogenous envelope protein has lost its original fusogenic properties.
T17555	SEQUENCE	MVTPVTWMDNPIEVYVNDSVWVPGPTDDRCPAKPEEEGMMINISIVYRYPPICLGRAPGCLMPAVQNWLVEVPTVSPNSRFTYHMVSGMSLRPRVNYLQDFSYQRSLKFRPKGKPCPKEIPKESKNTEVLVWEECVANSAVILQNNEFGTIIDWAPRGQFYHNCSGQTQSCPSAQVSPAVDSDLTESLDKHKHKKLQSFYPWEWGEKGISTPRPEIISPVSGPEHPELWRLWPDTTLEFGLEIKL

T02565	TARGETID	T02565
T02565	FORMERID	TTDI03419
T02565	UNIPROID	SO1B3_HUMAN
T02565	TARGNAME	Liver organic anion transporter 2 (SLCO1B3)
T02565	GENENAME	SLCO1B3
T02565	TARGTYPE	Literature-reported
T02565	SYNONYMS	Solute carrier organic anion transporter family member 1B3; Solute carrier family 21 member 8; SLC21A8; Organic anion-transporting polypeptide 8; Organic anion transporter 8; OATP8; OATP1B3; OATP-8; Liver-specific organic anion transporter 2; LST2; LST-2
T02565	FUNCTION	Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
T02565	SEQUENCE	MDQHQHLNKTAESASSEKKKTRRCNGFKMFLAALSFSYIAKALGGIIMKISITQIERRFDISSSLAGLIDGSFEIGNLLVIVFVSYFGSKLHRPKLIGIGCLLMGTGSILTSLPHFFMGYYRYSKETHINPSENSTSSLSTCLINQTLSFNGTSPEIVEKDCVKESGSHMWIYVFMGNMLRGIGETPIVPLGISYIDDFAKEGHSSLYLGSLNAIGMIGPVIGFALGSLFAKMYVDIGYVDLSTIRITPKDSRWVGAWWLGFLVSGLFSIISSIPFFFLPKNPNKPQKERKISLSLHVLKTNDDRNQTANLTNQGKNVTKNVTGFFQSLKSILTNPLYVIFLLLTLLQVSSFIGSFTYVFKYMEQQYGQSASHANFLLGIITIPTVATGMFLGGFIIKKFKLSLVGIAKFSFLTSMISFLFQLLYFPLICESKSVAGLTLTYDGNNSVASHVDVPLSYCNSECNCDESQWEPVCGNNGITYLSPCLAGCKSSSGIKKHTVFYNCSCVEVTGLQNRNYSAHLGECPRDNTCTRKFFIYVAIQVINSLFSATGGTTFILLTVKIVQPELKALAMGFQSMVIRTLGGILAPIYFGALIDKTCMKWSTNSCGAQGACRIYNSVFFGRVYLGLSIALRFPALVLYIVFIFAMKKKFQGKDTKASDNERKVMDEANLEFLNNGEHFVPSAGTDSKTCNLDMQDNAAAN
T02565	DRUGINFO	D0I3LQ	[3H]estradiol-17beta-glucuronide	Investigative

T55465	TARGETID	T55465
T55465	FORMERID	TTDNR00710
T55465	UNIPROID	NRN1_HUMAN
T55465	TARGNAME	Neuritin (NRN1)
T55465	GENENAME	NRN1
T55465	TARGTYPE	Literature-reported
T55465	SYNONYMS	NRN
T55465	FUNCTION	Promotes neurite outgrowth and especially branching of neuritic processes in primary hippocampal and cortical cells.
T55465	SEQUENCE	MGLKLNGRYISLILAVQIAYLVQAVRAAGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGAKDMWDKLRKESKNLNIQGSLFELCGSGNGAAGSLLPAFPVLLVSLSAALATWLSF

T27170	TARGETID	T27170
T27170	FORMERID	TTDI00119
T27170	UNIPROID	SCUB2_HUMAN
T27170	TARGNAME	Signal peptide CUB-EGF-like-domain containing 2 (SCUBE2)
T27170	GENENAME	SCUBE2
T27170	TARGTYPE	Literature-reported
T27170	SYNONYMS	Signal peptide, CUB and EGF-like domain-containing protein 2; Scube/You; Protein CEGP1; CEGP1
T27170	FUNCTION	Lipid-binding protein required for SHH long-range signaling by binding to the dually lipid-modified SHH (ShhNp) and by promoting ShhNp mobilization, solubilization and release from the cell membrane. Acts by enhancing the proteolytic processing (shedding) of the lipid-modified N- and C- terminal of ShhNp at the cell surface. Synergizes with DISP1 to increase SHH secretion. Probable cell surface coreceptor for VEGFR2 involved in VEGFR2-mediated angiogenesis.
T27170	SEQUENCE	MGVAGRNRPGAAWAVLLLLLLLPPLLLLAGAVPPGRGRAAGPQEDVDECAQGLDDCHADALCQNTPTSYKCSCKPGYQGEGRQCEDIDECGNELNGGCVHDCLNIPGNYRCTCFDGFMLAHDGHNCLDVDECLENNGGCQHTCVNVMGSYECCCKEGFFLSDNQHTCIHRSEEGLSCMNKDHGCSHICKEAPRGSVACECRPGFELAKNQRDCILTCNHGNGGCQHSCDDTADGPECSCHPQYKMHTDGRSCLEREDTVLEVTESNTTSVVDGDKRVKRRLLMETCAVNNGGCDRTCKDTSTGVHCSCPVGFTLQLDGKTCKDIDECQTRNGGCDHFCKNIVGSFDCGCKKGFKLLTDEKSCQDVDECSLDRTCDHSCINHPGTFACACNRGYTLYGFTHCGDTNECSINNGGCQQVCVNTVGSYECQCHPGYKLHWNKKDCVEVKGLLPTSVSPRVSLHCGKSGGGDGCFLRCHSGIHLSSDVTTIRTSVTFKLNEGKCSLKNAELFPEGLRPALPEKHSSVKESFRYVNLTCSSGKQVPGAPGRPSTPKEMFITVEFELETNQKEVTASCDLSCIVKRTEKRLRKAIRTLRKAVHREQFHLQLSGMNLDVAKKPPRTSERQAESCGVGQGHAENQCVSCRAGTYYDGARERCILCPNGTFQNEEGQMTCEPCPRPGNSGALKTPEAWNMSECGGLCQPGEYSADGFAPCQLCALGTFQPEAGRTSCFPCGGGLATKHQGATSFQDCETRVQCSPGHFYNTTTHRCIRCPVGTYQPEFGKNNCVSCPGNTTTDFDGSTNITQCKNRRCGGELGDFTGYIESPNYPGNYPANTECTWTINPPPKRRILIVVPEIFLPIEDDCGDYLVMRKTSSSNSVTTYETCQTYERPIAFTSRSKKLWIQFKSNEGNSARGFQVPYVTYDEDYQELIEDIVRDGRLYASENHQEILKDKKLIKALFDVLAHPQNYFKYTAQESREMFPRSFIRLLRSKVSRFLRPYK

T96393	TARGETID	T96393
T96393	UNIPROID	ARHG3_HUMAN
T96393	TARGNAME	Rho guanine nucleotide exchange factor 3 (ARHGEF3)
T96393	GENENAME	ARHGEF3
T96393	TARGTYPE	Literature-reported
T96393	SYNONYMS	XPLN; Exchange factor found in platelets and leukemic and neuronal tissues
T96393	FUNCTION	Acts as guanine nucleotide exchange factor (GEF) for RhoA and RhoB GTPases.
T96393	SEQUENCE	MVAKDYPFYLTVKRANCSLELPPASGPAKDAEEPSNKRVKPLSRVTSLANLIPPVKATPLKRFSQTLQRSISFRSESRPDILAPRPWSRNAAPSSTKRRDSKLWSETFDVCVNQMLTSKEIKRQEAIFELSQGEEDLIEDLKLAKKAYHDPMLKLSIMTEQELNQIFGTLDSLIPLHEELLSQLRDVRKPDGSTEHVGPILVGWLPCLSSYDSYCSNQVAAKALLDHKKQDHRVQDFLQRCLESPFSRKLDLWNFLDIPRSRLVKYPLLLREILRHTPNDNPDQQHLEEAINIIQGIVAEINTKTGESECRYYKERLLYLEEGQKDSLIDSSRVLCCHGELKNNRGVKLHVFLFQEVLVITRAVTHNEQLCYQLYRQPIPVKDLLLEDLQDGEVRLGGSLRGAFSNNERIKNFFRVSFKNGSQSQTHSLQANDTFNKQQWLNCIRQAKETVLCAAGQAGVLDSEGSFLNPTTGSRELQGETKLEQMDQSDSESDCSMDTSEVSLDCERMEQTDSSCGNSRHGESNV

T88944	TARGETID	T88944
T88944	FORMERID	TTDI03524
T88944	UNIPROID	RL3R1_HUMAN
T88944	TARGNAME	Relaxin-3 receptor 1 (RXFP3)
T88944	GENENAME	RXFP3
T88944	TARGTYPE	Literature-reported
T88944	SYNONYMS	Somatostatin- and angiotensin-like peptide receptor; SALPR; Relaxin family peptide receptor 3; RLN3R1; RLN3 receptor 1; G-protein coupled receptor GPCR135; G protein-coupled receptor SALPR
T88944	FUNCTION	Receptor for RNL3/relaxin-3. Binding of the ligand inhibit cAMP accumulation.
T88944	SEQUENCE	MQMADAATIATMNKAAGGDKLAELFSLVPDLLEAANTSGNASLQLPDLWWELGLELPDGAPPGHPPGSGGAESADTEARVRILISVVYWVVCALGLAGNLLVLYLMKSMQGWRKSSINLFVTNLALTDFQFVLTLPFWAVENALDFKWPFGKAMCKIVSMVTSMNMYASVFFLTAMSVTRYHSVASALKSHRTRGHGRGDCCGRSLGDSCCFSAKALCVWIWALAALASLPSAIFSTTVKVMGEELCLVRFPDKLLGRDRQFWLGLYHSQKVLLGFVLPLGIIILCYLLLVRFIADRRAAGTKGGAAVAGGRPTGASARRLSKVTKSVTIVVLSFFLCWLPNQALTTWSILIKFNAVPFSQEYFLCQVYAFPVSVCLAHSNSCLNPVLYCLVRREFRKALKSLLWRIASPSITSMRPFTATTKPEHEDQGLQAPAPPHAAAEPDLLYYPPGVVVYSGGRYDLLPSSSAY
T88944	DRUGINFO	D0CE5B	135PAM1	Investigative

T16923	TARGETID	T16923
T16923	FORMERID	TTDI02399
T16923	UNIPROID	CNTLN_HUMAN
T16923	TARGNAME	Centrosomal protein (CNTLN)
T16923	GENENAME	CNTLN
T16923	TARGTYPE	Literature-reported
T16923	SYNONYMS	Centlein; C9orf39; C9orf101
T16923	FUNCTION	Required for centrosome cohesion and recruitment of CEP68 to centrosomes.
T16923	SEQUENCE	MAARSPPSPHPSPPARQLGPRSPRVGRGAEVHAMRSEASGFAGAAREVVADESDKIWVGEEGSGGRRGPGGAAPAHAPLLSAPMGSRRLEGISVEEAMVTRTQLLEEELSSLKEELALCQADKEFVWSLWKRLQVTNPDLTQVVSLVVEREKQKSEAKDRKVLEILQVKDAKIQEFEQRESVLKQEINDLVKRKIAVDEENAFLRKEFSDLEKKFKDKSQEIKDTKECVQNKEEQNRLVIKNLEEENKKLSTRCTDLLNDLEKLRKQEAHLRKEKYSTDAKIKTFEDNLIEARKEVEVSQSKYNALSLQLSNKQTELIQKDMDITLVRKELQELQNLYKQNSTHTAQQAELIQQLQVLNMDTQKVLRNQEDVHTAESISYQKLYNELHICFETTKSNEAMLRQSVTNLQDQLLQKEQENAKLKEKLQESQGAPLPLPQESDPDYSAQVPHRPSLSSLETLMVSQKSEIEYLQEKLKIANEKLSENISANKGFSRKSIMTSAEGKHKEPPVKRSRSLSPKSSFTDSEELQKLRKAERKIENLEKALQLKSQENDELRDAHEKRKERLQMLQTNYRAVKEQLKQWEEGSGMTEIRKIKRADPQQLRQEDSDAVWNELAYFKRENQELMIQKMNLEEELDELKVHISIDKAAIQELNRCVAERREEQLFRSGEDDEVKRSTPEKNGKEMLEQTLQKVTELENRLKSFEKRSRKLKEGNKKLMKENDFLKSLLKQQQEDTETREKELEQIIKGSKDVEKENTELQVKISELETEVTSLRRQVAEANALRNENEELINPMEKSHQSADRAKSEMATMKVRSGRYDCKTTMTKVKFKAAKKNCSVGRHHTVLNHSIKVMSNVFENLSKDGWEDVSESSSDSEAQTSQTLGTIIVETSQKISPTEDGKDQKESDPTEDSQTQGKEIVQTYLNIDGKTPKDYFHDKNAKKPTFQKKNCKMQKSSHTAVPTRVNREKYKNITAQKSSSNIILLRERIISLQQQNSVLQNAKKTAELSVKEYKEVNEKLLHQQQVSDQRFQTSRQTIKKLNLDLAGLRKEKEDLLKKLESSSEITSLAEENSQVTFPRIQVTSLSPSRSMDLEMKQLQYKLKNATNELTKQSSNVKTLKFELLAKEEHIKEMHEKISRMERDITMKRHLIEDLKFRQKVNLESNKSFSEMLQNLDKKVKTLTEECSNKKVSIDSLKQRLNVAVKEKSQYEQMYQKSKEELEKKDLKLTLLVSRISETESAMAEIETAASKQLQELALQSEQVLEGAQKTLLLANEKVEEFTTFVKALAKELQNDVHVVRRQIRELKKMKKNRDACKTSTHKAQTLAASILNISRSDLEEILDTEDQVEIEKTKIDAENDKEWMLYIQKLLEGQSLTLSPRLKCNGAIVAHQNLRLPDSSSSASAS

T67246	TARGETID	T67246
T67246	FORMERID	TTDI02488
T67246	UNIPROID	STAB1_HUMAN
T67246	TARGNAME	Stabilin-1 (STAB1)
T67246	GENENAME	STAB1
T67246	TARGTYPE	Literature-reported
T67246	SYNONYMS	STAB1; MS-1 antigen; Fasciclin, EGF-like, laminin-type EGF-like and link domain-containing scavenger receptor 1; FEEL-1
T67246	FUNCTION	Acts as a scavenger receptor for acetylated low density lipoprotein. Binds to both Gram-positive and Gram-negative bacteria and may play a role in defense against bacterial infection. When inhibited in endothelial tube formation assays, there is a marked decreasein cell-cell interactions, suggesting a role in angiogenesis. Involved in the delivery of newly synthesized CHID1/SI-CLP from the biosynthetic compartment to the endosomal/lysosomal system.
T67246	SEQUENCE	MAGPRGLLPLCLLAFCLAGFSFVRGQVLFKGCDVKTTFVTHVPCTSCAAIKKQTCPSGWLRELPDQITQDCRYEVQLGGSMVSMSGCRRKCRKQVVQKACCPGYWGSRCHECPGGAETPCNGHGTCLDGMDRNGTCVCQENFRGSACQECQDPNRFGPDCQSVCSCVHGVCNHGPRGDGSCLCFAGYTGPHCDQELPVCQELRCPQNTQCSAEAPSCRCLPGYTQQGSECRAPNPCWPSPCSLLAQCSVSPKGQAQCHCPENYHGDGMVCLPKDPCTDNLGGCPSNSTLCVYQKPGQAFCTCRPGLVSINSNASAGCFAFCSPFSCDRSATCQVTADGKTSCVCRESEVGDGRACYGHLLHEVQKATQTGRVFLQLRVAVAMMDQGCREILTTAGPFTVLVPSVSSFSSRTMNASLAQQLCRQHIIAGQHILEDTRTQQTRRWWTLAGQEITVTFNQFTKYSYKYKDQPQQTFNIYKANNIAANGVFHVVTGLRWQAPSGTPGDPKRTIGQILASTEAFSRFETILENCGLPSILDGPGPFTVFAPSNEAVDSLRDGRLIYLFTAGLSKLQELVRYHIYNHGQLTVEKLISKGRILTMANQVLAVNISEEGRILLGPEGVPLQRVDVMAANGVIHMLDGILLPPTILPILPKHCSEEQHKIVAGSCVDCQALNTSTCPPNSVKLDIFPKECVYIHDPTGLNVLKKGCASYCNQTIMEQGCCKGFFGPDCTQCPGGFSNPCYGKGNCSDGIQGNGACLCFPDYKGIACHICSNPNKHGEQCQEDCGCVHGLCDNRPGSGGVCQQGTCAPGFSGRFCNESMGDCGPTGLAQHCHLHARCVSQEGVARCRCLDGFEGDGFSCTPSNPCSHPDRGGCSENAECVPGSLGTHHCTCHKGWSGDGRVCVAIDECELDMRGGCHTDALCSYVGPGQSRCTCKLGFAGDGYQCSPIDPCRAGNGGCHGLATCRAVGGGQRVCTCPPGFGGDGFSCYGDIFRELEANAHFSIFYQWLKSAGITLPADRRVTALVPSEAAVRQLSPEDRAFWLQPRTLPNLVRAHFLQGALFEEELARLGGQEVATLNPTTRWEIRNISGRVWVQNASVDVADLLATNGVLHILSQVLLPPRGDVPGGQGLLQQLDLVPAFSLFRELLQHHGLVPQIEAATAYTIFVPTNRSLEAQGNSSHLDADTVRHHVVLGEALSMETLRKGGHRNSLLGPAHWIVFYNHSGQPEVNHVPLEGPMLEAPGRSLIGLSGVLTVGSSRCLHSHAEALREKCVNCTRRFRCTQGFQLQDTPRKSCVYRSGFSFSRGCSYTCAKKIQVPDCCPGFFGTLCEPCPGGLGGVCSGHGQCQDRFLGSGECHCHEGFHGTACEVCELGRYGPNCTGVCDCAHGLCQEGLQGDGSCVCNVGWQGLRCDQKITSPQCPRKCDPNANCVQDSAGASTCACAAGYSGNGIFCSEVDPCAHGHGGCSPHANCTKVAPGQRTCTCQDGYMGDGELCQEINSCLIHHGGCHIHAECIPTGPQQVSCSCREGYSGDGIRTCELLDPCSKNNGGCSPYATCKSTGDGQRTCTCDTAHTVGDGLTCRARVGLELLRDKHASFFSLRLLEYKELKGDGPFTIFVPHADLMSNLSQDELARIRAHRQLVFRYHVVGCRRLRSEDLLEQGYATALSGHPLRFSEREGSIYLNDFARVVSSDHEAVNGILHFIDRVLLPPEALHWEPDDAPIPRRNVTAAAQGFGYKIFSGLLKVAGLLPLLREASHRPFTMLWPTDAAFRALPPDRQAWLYHEDHRDKLAAILRGHMIRNVEALASDLPNLGPLRTMHGTPISFSCSRTRAGELMVGEDDARIVQRHLPFEGGLAYGIDQLLEPPGLGARCDHFETRPLRLNTCSICGLEPPCPEGSQEQGSPEACWRFYPKFWTSPPLHSLGLRSVWVHPSLWGRPQGLGRGCHRNCVTTTWKPSCCPGHYGSECQACPGGPSSPCSDRGVCMDGMSGSGQCLCRSGFAGTACELCAPGAFGPHCQACRCTVHGRCDEGLGGSGSCFCDEGWTGPRCEVQLELQPVCTPPCAPEAVCRAGNSCECSLGYEGDGRVCTVADLCQDGHGGCSEHANCSQVGTMVTCTCLPDYEGDGWSCRARNPCTDGHRGGCSEHANCLSTGLNTRRCECHAGYVGDGLQCLEESEPPVDRCLGQPPPCHSDAMCTDLHFQEKRAGVFHLQATSGPYGLNFSEAEAACEAQGAVLASFPQLSAAQQLGFHLCLMGWLANGSTAHPVVFPVADCGNGRVGIVSLGARKNLSERWDAYCFRVQDVACRCRNGFVGDGISTCNGKLLDVLAATANFSTFYGMLLGYANATQRGLDFLDFLDDELTYKTLFVPVNEGFVDNMTLSGPDLELHASNATLLSANASQGKLLPAHSGLSLIISDAGPDNSSWAPVAPGTVVVSRIIVWDIMAFNGIIHALASPLLAPPQPQAVLAPEAPPVAAGVGAVLAAGALLGLVAGALYLRARGKPMGFGFSAFQAEDDADDDFSPWQEGTNPTLVSVPNPVFGSDTFCEPFDDSLLEEDFPDTQRILTVK

T38157	TARGETID	T38157
T38157	FORMERID	TTDI03420
T38157	UNIPROID	SO1C1_HUMAN
T38157	TARGNAME	Organic anion transporter F (SLCO1C1)
T38157	GENENAME	SLCO1C1
T38157	TARGTYPE	Literature-reported
T38157	SYNONYMS	Thyroxine transporter; Solute carrier organic anion transporter family member 1C1; Solute carrier family 21 member 14; SLC21A14; Organic anion-transporting polypeptide 14; Organic anion transporter polypeptide-related protein 5; OATPRP5; OATPF; OATP1C1; OATP14; OATP-F; OATP-14; OAT-RP-5
T38157	FUNCTION	Mediates the Na(+)-independent high affinity transport of organic anions such as the thyroid hormones thyroxine (T4) and rT3. Other potential substrates, such as triiodothyronine (T3), 17-beta-glucuronosyl estradiol, estrone-3-sulfate and sulfobromophthalein (BSP) are transported with much lower efficiency. May play a significant role in regulating T4 flux into and out of the brain (By similarity).
T38157	SEQUENCE	MDTSSKENIQLFCKTSVQPVGRPSFKTEYPSSEEKQPCCGELKVFLCALSFVYFAKALAEGYLKSTITQIERRFDIPSSLVGVIDGSFEIGNLLVITFVSYFGAKLHRPKIIGAGCVIMGVGTLLIAMPQFFMEQYKYERYSPSSNSTLSISPCLLESSSQLPVSVMEKSKSKISNECEVDTSSSMWIYVFLGNLLRGIGETPIQPLGIAYLDDFASEDNAAFYIGCVQTVAIIGPIFGFLLGSLCAKLYVDIGFVNLDHITITPKDPQWVGAWWLGYLIAGIISLLAAVPFWYLPKSLPRSQSREDSNSSSEKSKFIIDDHTDYQTPQGENAKIMEMARDFLPSLKNLFGNPVYFLYLCTSTVQFNSLFGMVTYKPKYIEQQYGQSSSRANFVIGLINIPAVALGIFSGGIVMKKFRISVCGAAKLYLGSSVFGYLLFLSLFALGCENSDVAGLTVSYQGTKPVSYHERALFSDCNSRCKCSETKWEPMCGENGITYVSACLAGCQTSNRSGKNIIFYNCTCVGIAASKSGNSSGIVGRCQKDNGCPQMFLYFLVISVITSYTLSLGGIPGYILLLRCIKPQLKSFALGIYTLAIRVLAGIPAPVYFGVLIDTSCLKWGFKRCGSRGSCRLYDSNVFRHIYLGLTVILGTVSILLSIAVLFILKKNYVSKHRSFITKRERTMVSTRFQKENYTTSDHLLQPNYWPGKETQL
T38157	DRUGINFO	D04AXP	[3H]estrone-3-sulphate	Investigative

T96236	TARGETID	T96236
T96236	UNIPROID	FOXJ2_HUMAN
T96236	TARGNAME	Forkhead box protein J2 (FOXJ2)
T96236	GENENAME	FOXJ2
T96236	TARGTYPE	Literature-reported
T96236	SYNONYMS	Fork head homologous X; FHX
T96236	FUNCTION	Transcriptional activator. Able to bind to two different type of DNA binding sites. Isoform FOXJ2.L behaves as a more potent transactivator than FOXJ2.S.
T96236	SEQUENCE	MASDLESSLTSIDWLPQLTLRATIEKLGSASQAGPPGSSRKCSPGSPTDPNATLSKDEAAVHQDGKPRYSYATLITYAINSSPAKKMTLSEIYRWICDNFPYYKNAGIGWKNSIRHNLSLNKCFRKVPRPRDDPGKGSYWTIDTCPDISRKRRHPPDDDLSQDSPEQEASKSPRGGVAGSGEASLPPEGNPQMSLQSPTSIASYSQGTGSVDGGAVAAGASGRESAEGPPPLYNTNHDFKFSYSEINFQDLSWSFRNLYKSMLEKSSSSSQHGFSSLLGDIPPSNNYYMYQQQQPPPPQQQQQQQQPPQPPPQQSQPQQQQAPAQGPSAVGGAPPLHTPSTDGCTPPGGKQAGAEGYGPPPVMAMHPPPLQHGGYHPHQHHPHSHPAQQPPPPQPQAQGQAPINNTGFAFPSDWCSNIDSLKESFKMVNRLNWSSIEQSQFSELMESLRQAEQKNWTLDQHHIANLCDSLNHFLTQTGHVPPQGGTHRPPAPARIADSCALTSGKQESAMSQVNSYGHPQAPHLYPGPSPMYPIPTQDSAGYNRPAHHMVPRPSVPPPGANEEIPDDFDWDLIT

T82922	TARGETID	T82922
T82922	FORMERID	TTDI03567
T82922	UNIPROID	TAAR3_HUMAN
T82922	TARGNAME	Trace amine receptor 3 (TAAR3)
T82922	GENENAME	TAAR3P
T82922	TARGTYPE	Literature-reported
T82922	SYNONYMS	hTaar3; TaR-3; TAAR3; Putative trace amine-associated receptor 3; GPR57; G-protein coupled receptor 57
T82922	FUNCTION	G protein-coupled receptor activity, trace-amine receptor activity, sensory perception of chemical stimulus
T82922	SEQUENCE	MDLTYIPEDLSSCPKFVNKILSSHQPLFSCPGDNVFGYDWSHDYPLFGNLVIMVSISHFKQLHSPTNFLILSMATTDFLLGFVIMPYSIMRSVESCWYFGDGFCKFHTSFDMMLRLTSIFHLCSIAIDRFYAVCYPLHYTTKMTNSTIKQLLAFCWSVPALFSFGLVLSEADVSGMQSYKILVACFNFCALTFNKFWGTILFTTCFFTPGSIMVGIYGKIFIVSKQHARVISHVPENTKGAVKKHLSKKKDRKAAKTLGIVMGVFLACWLPCFLAVLIDPYLDYSTPILILDLLVWLRYFNSTCNPLIHGFFNPWFQKAFKYIVSGKIFSSHSETANLFPEAH
T82922	DRUGINFO	D0XO7J	isoamylamine	Investigative

T84019	TARGETID	T84019
T84019	FORMERID	TTDI02632
T84019	UNIPROID	CLCF1_HUMAN
T84019	TARGNAME	Cardiotrophin-like cytokine factor 1 (CLCF1)
T84019	GENENAME	CLCF1
T84019	TARGTYPE	Literature-reported
T84019	SYNONYMS	Novel neurotrophin1; NNT1; CLCF1; Bcellstimulating factor 3; BSF3
T84019	FUNCTION	Cytokine with B-cell stimulating capability. Binds to and activates the ILST/gp130 receptor.
T84019	SEQUENCE	MDLRAGDSWGMLACLCTVLWHLPAVPALNRTGDPGPGPSIQKTYDLTRYLEHQLRSLAGTYLNYLGPPFNEPDFNPPRLGAETLPRATVDLEVWRSLNDKLRLTQNYEAYSHLLCYLRGLNRQAATAELRRSLAHFCTSLQGLLGSIAGVMAALGYPLPQPLPGTEPTWTPGPAHSDFLQKMDDFWLLKELQTWLWRSAKDFNRLKKKMQPPAAAVTLHLGAHGF

T73533	TARGETID	T73533
T73533	FORMERID	TTDI02650
T73533	UNIPROID	KAAG1_HUMAN
T73533	TARGNAME	Kidney associated antigen 1 (KAAG1)
T73533	GENENAME	KAAG1
T73533	TARGTYPE	Literature-reported
T73533	SYNONYMS	RU2AS; RU2 antisense gene protein; Kidney-associated antigen 1
T73533	FUNCTION	Invovled in immune response.
T73533	SEQUENCE	MDDDAAPRVEGVPVAVHKHALHDGLRQVAGPGAAAAHLPRWPPPQLAASRREAPPLSQRPHRTQGAGSPPETNEKLTNPQVKEK

T99255	TARGETID	T99255
T99255	FORMERID	TTDI03423
T99255	UNIPROID	SO3A1_HUMAN
T99255	TARGNAME	Organic anion transporter D (SLCO3A1)
T99255	GENENAME	SLCO3A1
T99255	TARGTYPE	Literature-reported
T99255	SYNONYMS	Solute carrier organic anion transporter family member 3A1; Solute carrier family 21 member 11; Sodium-independent organic anion transporter D; SLC21A11; PGE1 transporter; Organic anion-transporting polypeptide D; Organic anion transporter polypeptide-related protein 3; OATPRP3; OATPD; OATP3A1; OATP-RP3; OATP-D
T99255	FUNCTION	Mediates the Na(+)-independent transport of organic anions such as estrone-3-sulfate. Mediates transport of prostaglandins (PG) E1 and E2, thyroxine (T4), deltorphin II, BQ-123 and vasopressin, but not DPDPE (a derivative of enkephalin lacking an N-terminal tyrosine residue), estrone-3-sulfate, taurocholate, digoxin nor DHEAS.
T99255	SEQUENCE	MQGKKPGGSSGGGRSGELQGDEAQRNKKKKKKVSCFSNIKIFLVSECALMLAQGTVGAYLVSVLTTLERRFNLQSADVGVIASSFEIGNLALILFVSYFGARGHRPRLIGCGGIVMALGALLSALPEFLTHQYKYEAGEIRWGAEGRDVCAANGSGGDEGPDPDLICRNRTATNMMYLLLIGAQVLLGIGATPVQPLGVSYIDDHVRRKDSSLYIGILFTMLVFGPACGFILGSFCTKIYVDAVFIDTSNLDITPDDPRWIGAWWGGFLLCGALLFFSSLLMFGFPQSLPPHSEPAMESEQAMLSEREYERPKPSNGVLRHPLEPDSSASCFQQLRVIPKVTKHLLSNPVFTCIILAACMEIAVVAGFAAFLGKYLEQQFNLTTSSANQLLGMTAIPCACLGIFLGGLLVKKLSLSALGAIRMAMLVNLVSTACYVSFLFLGCDTGPVAGVTVPYGNSTAPGSALDPYSPCNNNCECQTDSFTPVCGADGITYLSACFAGCNSTNLTGCACLTTVPAENATVVPGKCPSPGCQEAFLTFLCVMCICSLIGAMAQTPSVIILIRTVSPELKSYALGVLFLLLRLLGFIPPPLIFGAGIDSTCLFWSTFCGEQGACVLYDNVVYRYLYVSIAIALKSFAFILYTTTWQCLRKNYKRYIKNHEGGLSTSEFFASTLTLDNLGRDPVPANQTHRTKFIYNLEDHEWCENMESVL
T99255	DRUGINFO	D04AXP	[3H]estrone-3-sulphate	Investigative

T75962	TARGETID	T75962
T75962	FORMERID	TTDI00114
T75962	UNIPROID	STML2_HUMAN
T75962	TARGNAME	Stomatin-like protein 2 (STOML2)
T75962	GENENAME	STOML2
T75962	TARGTYPE	Literature-reported
T75962	SYNONYMS	Stomatin-like protein 2, mitochondrial; SLP2; SLP-2; Paratarg-7; Paraprotein target 7; HSPC108; EPB72-like protein 2
T75962	FUNCTION	Stimulates cardiolipin biosynthesis, binds cardiolipin-enriched membranes where it recruits and stabilizes some proteins including prohibitin and may therefore act in the organization of functional microdomains in mitochondrial membranes. Through regulation of the mitochondrial function may play a role into several biological processes including cell migration, cell proliferation, T-cell activation, calcium homeostasis and cellular response to stress. May play a role in calcium homeostasis through negative regulation of calcium efflux from mitochondria. Required for mitochondrial hyperfusion a pro-survival cellular response to stress which results in increased ATP production by mitochondria. May also regulate the organization of functional domains at the plasma membrane and play a role in T-cell activation through association with the T-cell receptor signaling complex and its regulation. Mitochondrial protein that probably regulates the biogenesis and the activity of mitochondria.
T75962	SEQUENCE	MLARAARGTGALLLRGSLLASGRAPRRASSGLPRNTVVLFVPQQEAWVVERMGRFHRILEPGLNILIPVLDRIRYVQSLKEIVINVPEQSAVTLDNVTLQIDGVLYLRIMDPYKASYGVEDPEYAVTQLAQTTMRSELGKLSLDKVFRERESLNASIVDAINQAADCWGIRCLRYEIKDIHVPPRVKESMQMQVEAERRKRATVLESEGTRESAINVAEGKKQAQILASEAEKAEQINQAAGEASAVLAKAKAKAEAIRILAAALTQHNGDAAASLTVAEQYVSAFSKLAKDSNTILLPSNPGDVTSMVAQAMGVYGALTKAPVPGTPDSLSSGSSRDVQGTDASLDEELDRVKMS

T52112	TARGETID	T52112
T52112	FORMERID	TTDR00994
T52112	UNIPROID	Q9UK79_HUMAN
T52112	TARGNAME	Neuro/glioblastoma derived oncogene (Herstatin)
T52112	GENENAME	HER-2
T52112	TARGTYPE	Literature-reported
T52112	SYNONYMS	V-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (Avian), isoform CRA_a; Herstatin; ERBB2
T52112	FUNCTION	An autoinhibitor of the ErbB family consisting of subdomains I and II of the human epidermal growth factor receptor 2 (ErbB-2) extracellular domain and a novel C-terminal domain encoded by an intron. Binds to human epidermal growth factor receptor 2 and to the epidermal growth factor receptor (EGFR), blocking receptor oligomerization and tyrosine phosphorylation.
T52112	SEQUENCE	MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNLELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNGDPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLALTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQCAAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACPYNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARGTHSLPPRPAAVPVPLRMQPGPAHPVLSFLRPSWDLVSAFYSLPLAPLSPTSVPISPVSVGRGPDPDAHVAVDLSRYEG

T26741	TARGETID	T26741
T26741	FORMERID	TTDR00480
T26741	UNIPROID	TBX21_HUMAN
T26741	TARGNAME	T-box transcription factor TBX21 (TBX21)
T26741	GENENAME	TBX21
T26741	TARGTYPE	Literature-reported
T26741	SYNONYMS	Transcription factor TBLYM; TBX21; T-cell-specific T-box transcription factor T-bet; T-box protein 21; T-bet
T26741	FUNCTION	Transcription factor that controls the expression of the TH1 cytokine, interferon-gamma. Initiates TH1 lineage development from naive TH precursor cells both by activating TH1 genetic programs and by repressing the opposing TH2 programs.
T26741	SEQUENCE	MGIVEPGCGDMLTGTEPMPGSDEGRAPGADPQHRYFYPEPGAQDADERRGGGSLGSPYPGGALVPAPPSRFLGAYAYPPRPQAAGFPGAGESFPPPADAEGYQPGEGYAAPDPRAGLYPGPREDYALPAGLEVSGKLRVALNNHLLWSKFNQHQTEMIITKQGRRMFPFLSFTVAGLEPTSHYRMFVDVVLVDQHHWRYQSGKWVQCGKAEGSMPGNRLYVHPDSPNTGAHWMRQEVSFGKLKLTNNKGASNNVTQMIVLQSLHKYQPRLHIVEVNDGEPEAACNASNTHIFTFQETQFIAVTAYQNAEITQLKIDNNPFAKGFRENFESMYTSVDTSIPSPPGPNCQFLGGDHYSPLLPNQYPVPSRFYPDLPGQAKDVVPQAYWLGAPRDHSYEAEFRAVSMKPAFLPSAPGPTMSYYRGQEVLAPGAGWPVAPQYPPKMGPASWFRPMRTLPMEPGPGGSEGRGPEDQGPPLVWTEIAPIRPESSDSGLGEGDSKRRRVSPYPSSGDSSSPAGAPSPFDKEAEGQFYNYFPN

T58264	TARGETID	T58264
T58264	FORMERID	TTDI03583
T58264	UNIPROID	TPC1_HUMAN
T58264	TARGNAME	Two pore calcium channel protein 1 (TPC1)
T58264	GENENAME	TPCN1
T58264	TARGTYPE	Literature-reported
T58264	SYNONYMS	Voltage-dependent calcium channel protein TPC1; TPC1; KIAA1169
T58264	FUNCTION	Nicotinic acid adenine dinucleotide phosphate (NAADP) receptor that may function as one of the major voltage-gated Ca(2+) channels (VDCC) across the lysosomal and endosomal membrane.
T58264	SEQUENCE	MAVSLDDDVPLILTLDEGGSAPLAPSNGLGQEELPSKNGGSYAIHDSQAPSLSSGGESSPSSPAHNWEMNYQEAAIYLQEGENNDKFFTHPKDAKALAAYLFAHNHLFYLMELATALLLLLLSLCEAPAVPALRLGIYVHATLELFALMVVVFELCMKLRWLGLHTFIRHKRTMVKTSVLVVQFVEAIVVLVRQMSHVRVTRALRCIFLVDCRYCGGVRRNLRQIFQSLPPFMDILLLLLFFMIIFAILGFYLFSPNPSDPYFSTLENSIVSLFVLLTTANFPDVMMPSYSRNPWSCVFFIVYLSIELYFIMNLLLAVVFDTFNDIEKRKFKSLLLHKRTAIQHAYRLLISQRRPAGISYRQFEGLMRFYKPRMSARERYLTFKALNQNNTPLLSLKDFYDIYEVAALKWKAKKNREHWFDELPRTALLIFKGINILVKSKAFQYFMYLVVAVNGVWILVETFMLKGGNFFSKHVPWSYLVFLTIYGVELFLKVAGLGPVEYLSSGWNLFDFSVTVFAFLGLLALALNMEPFYFIVVLRPLQLLRLFKLKERYRNVLDTMFELLPRMASLGLTLLIFYYSFAIVGMEFFCGIVFPNCCNTSTVADAYRWRNHTVGNRTVVEEGYYYLNNFDNILNSFVTLFELTVVNNWYIIMEGVTSQTSHWSRLYFMTFYIVTMVVMTIIVAFILEAFVFRMNYSRKNQDSEVDGGITLEKEISKEELVAVLELYREARGASSDVTRLLETLSQMERYQQHSMVFLGRRSRTKSDLSLKMYQEEIQEWYEEHAREQEQQRQLSSSAAPAAQQPPGSRQRSQTVT
T58264	DRUGINFO	D01ZCI	phosphatidyl (3,5) inositol biphosphate	Investigative

T58674	TARGETID	T58674
T58674	FORMERID	TTDI00115
T58674	UNIPROID	APEL_HUMAN
T58674	TARGNAME	APJ endogenous ligand (Apelin)
T58674	GENENAME	APLN
T58674	TARGTYPE	Literature-reported
T58674	SYNONYMS	Apelin13; APEL
T58674	FUNCTION	Drives internalization of the apelin receptor. Apelin-36 dissociates more hardly than (pyroglu)apelin-13 from APLNR. Hormone involved in the regulation of cardiac precursor cell movements during gastrulation and heart morphogenesis. Has an inhibitory effect on cytokine production in response to T-cell receptor/CD3 cross-linking; the oral intake of apelin in the colostrum and the milk might therefore modulate immune responses in neonates. Plays a role in early coronary blood vessels formation. Mediates myocardial contractility in an ERK1/2-dependent manner. May also have a role in the central control of body fluid homeostasis by influencing vasopressin release and drinking behavior. Endogenous ligand for the apelin receptor (APLNR).
T58674	SEQUENCE	MNLRLCVQALLLLWLSLTAVCGGSLMPLPDGNGLEDGNVRHLVQPRGSRNGPGPWQGGRRKFRRQRPRLSHKGPMPF

T47818	TARGETID	T47818
T47818	FORMERID	TTDI03044
T47818	UNIPROID	S6A14_HUMAN
T47818	TARGNAME	Amino acid transporter ATB0+ (SLC6A14)
T47818	GENENAME	SLC6A14
T47818	TARGTYPE	Literature-reported
T47818	SYNONYMS	Solute carrier family 6 member 14; Sodium- and chloride-dependent neutral and basic amino acid transporter B(0+)
T47818	FUNCTION	Mediates the uptake of a broad range of neutral and cationic amino acids (with the exception of proline) in a Na(+)/Cl(-)-dependent manner.
T47818	SEQUENCE	MDKLKCPSFFKCREKEKVSASSENFHVGENDENQDRGNWSKKSDYLLSMIGYAVGLGNVWRFPYLTYSNGGGAFLIPYAIMLALAGLPLFFLECSLGQFASLGPVSVWRILPLFQGVGITMVLISIFVTIYYNVIIAYSLYYMFASFQSELPWKNCSSWSDKNCSRSPIVTHCNVSTVNKGIQEIIQMNKSWVDINNFTCINGSEIYQPGQLPSEQYWNKVALQRSSGMNETGVIVWYLALCLLLAWLIVGAALFKGIKSSGKVVYFTALFPYVVLLILLVRGATLEGASKGISYYIGAQSNFTKLKEAEVWKDAATQIFYSLSVAWGGLVALSSYNKFKNNCFSDAIVVCLTNCLTSVFAGFAIFSILGHMAHISGKEVSQVVKSGFDLAFIAYPEALAQLPGGPFWSILFFFMLLTLGLDSQFASIETITTTIQDLFPKVMKKMRVPITLGCCLVLFLLGLVCVTQAGIYWVHLIDHFCAGWGILIAAILELVGIIWIYGGNRFIEDTEMMIGAKRWIFWLWWRACWFVITPILLIAIFIWSLVQFHRPNYGAIPYPDWGVALGWCMIVFCIIWIPIMAIIKIIQAKGNIFQRLISCCRPASNWGPYLEQHRGERYKDMVDPKKEADHEIPTVSGSRKPE
T47818	DRUGINFO	D0OX9Q	NOX-200	Terminated

T15161	TARGETID	T15161
T15161	FORMERID	TTDI03213
T15161	UNIPROID	GBRT_HUMAN
T15161	TARGNAME	GABA(A) receptor theta (GABRQ)
T15161	GENENAME	GABRQ
T15161	TARGTYPE	Literature-reported
T15161	SYNONYMS	Gamma-aminobutyric acid receptor subunit theta; GABA(A) receptor subunit theta
T15161	FUNCTION	GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
T15161	SEQUENCE	MGIRGMLRAAVILLLIRTWLAEGNYPSPIPKFHFEFSSAVPEVVLNLFNCKNCANEAVVQKILDRVLSRYDVRLRPNFGGAPVPVRISIYVTSIEQISEMNMDYTITMFFHQTWKDSRLAYYETTLNLTLDYRMHEKLWVPDCYFLNSKDAFVHDVTVENRVFQLHPDGTVRYGIRLTTTAACSLDLHKFPMDKQACNLVVESYGYTVEDIILFWDDNGNAIHMTEELHIPQFTFLGRTITSKEVYFYTGSYIRLILKFQVQREVNSYLVQVYWPTVLTTITSWISFWMNYDSSAARVTIGLTSMLILTTIDSHLRDKLPNISCIKAIDIYILVCLFFVFLSLLEYVYINYLFYSRGPRRQPRRHRRPRRVIARYRYQQVVVGNVQDGLINVEDGVSSLPITPAQAPLASPESLGSLTSTSEQAQLATSESLSPLTSLSGQAPLATGESLSDLPSTSEQARHSYGVRFNGFQADDSIFPTEIRNRVEAHGHGVTHDHEDSNESLSSDERHGHGPSGKPMLHHGEKGVQEAGWDLDDNNDKSDCLAIKEQFKCDTNSTWGLNDDELMAHGQEKDSSSESEDSCPPSPGCSFTEGFSFDLFNPDYVPKVDKWSRFLFPLAFGLFNIVYWVYHMY
T15161	DRUGINFO	D0P0TI	TBPS	Investigative

T63465	TARGETID	T63465
T63465	FORMERID	TTDI03231
T63465	UNIPROID	GP132_HUMAN
T63465	TARGNAME	G2 accumulation protein (GPR132)
T63465	GENENAME	GPR132
T63465	TARGTYPE	Literature-reported
T63465	SYNONYMS	Probable G-protein coupled receptor 132; G2A
T63465	FUNCTION	May be a receptor for oxidized free fatty acids derived from linoleic and arachidonic acids such as 9-hydroxyoctadecadienoic acid (9-HODE). Activates a G alpha protein, most likely G alpha(q). May be involved in apoptosis. Functions at the G2/M checkpoint to delay mitosis. May function as a sensor that monitors the oxidative states and mediates appropriate cellular responses such as secretion of paracrine signals and attenuation of proliferation. May mediate ths accumulation of intracellular inositol phosphates at acidic pH through proton-sensing activity.
T63465	SEQUENCE	MCPMLLKNGYNGNATPVTTTAPWASLGLSAKTCNNVSFEESRIVLVVVYSAVCTLGVPANCLTAWLALLQVLQGNVLAVYLLCLALCELLYTGTLPLWVIYIRNQHRWTLGLLACKVTAYIFFCNIYVSILFLCCISCDRFVAVVYALESRGRRRRRTAILISACIFILVGIVHYPVFQTEDKETCFDMLQMDSRIAGYYYARFTVGFAIPLSIIAFTNHRIFRSIKQSMGLSAAQKAKVKHSAIAVVVIFLVCFAPYHLVLLVKAAAFSYYRGDRNAMCGLEERLYTASVVFLCLSTVNGVADPIIYVLATDHSRQEVSRIHKGWKEWSMKTDVTRLTHSRDTEELQSPVALADHYTFSRPVHPPGSPCPAKRLIEESC
T63465	DRUGINFO	D0SZ4T	9-hydroxyoctadecadienoic acid	Investigative

T58890	TARGETID	T58890
T58890	FORMERID	TTDI03312
T58890	UNIPROID	S12A4_HUMAN
T58890	TARGNAME	Solute carrier family 12 member 4 (SLC12A4)
T58890	GENENAME	SLC12A4
T58890	TARGTYPE	Literature-reported
T58890	SYNONYMS	hKCC1; KCC1; Erythroid K-Cl cotransporter 1; Electroneutral potassium-chloride cotransporter 1
T58890	FUNCTION	Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May contribute to cell volume homeostasis in single cells. May be involved in the regulation of basolateral Cl(-) exit in NaCl absorbing epithelia (By similarity). Isoform 4 has no transport activity.
T58890	SEQUENCE	MPHFTVVPVDGPRRGDYDNLEGLSWVDYGERAELDDSDGHGNHRESSPFLSPLEASRGIDYYDRNLALFEEELDIRPKVSSLLGKLVSYTNLTQGAKEHEEAESGEGTRRRAAEAPSMGTLMGVYLPCLQNIFGVILFLRLTWMVGTAGVLQALLIVLICCCCTLLTAISMSAIATNGVVPAGGSYFMISRSLGPEFGGAVGLCFYLGTTFAAAMYILGAIEILLTYIAPPAAIFYPSGAHDTSNATLNNMRVYGTIFLTFMTLVVFVGVKYVNKFASLFLACVIISILSIYAGGIKSIFDPPVFPVCMLGNRTLSRDQFDICAKTAVVDNETVATQLWSFFCHSPNLTTDSCDPYFMLNNVTEIPGIPGAAAGVLQENLWSAYLEKGDIVEKHGLPSADAPSLKESLPLYVVADIATSFTVLVGIFFPSVTGIMAGSNRSGDLRDAQKSIPVGTILAIITTSLVYFSSVVLFGACIEGVVLRDKYGDGVSRNLVVGTLAWPSPWVIVIGSFFSTCGAGLQSLTGAPRLLQAIAKDNIIPFLRVFGHGKVNGEPTWALLLTALIAELGILIASLDMVAPILSMFFLMCYLFVNLACAVQTLLRTPNWRPRFKYYHWALSFLGMSLCLALMFVSSWYYALVAMLIAGMIYKYIEYQGAEKEWGDGIRGLSLSAARYALLRLEEGPPHTKNWRPQLLVLLKLDEDLHVKYPRLLTFASQLKAGKGLTIVGSVIQGSFLESYGEAQAAEQTIKNMMEIEKVKGFCQVVVASKVREGLAHLIQSCGLGGMRHNSVVLGWPYGWRQSEDPRAWKTFIDTVRCTTAAHLALLVPKNIAFYPSNHERYLEGHIDVWWIVHDGGMLMLLPFLLRQHKVWRKCRMRIFTVAQMDDNSIQMKKDLAVFLYHLRLEAEVEVVEMHNSDISAYTYERTLMMEQRSQMLRQMRLTKTEREREAQLVKDRHSALRLESLYSDEEDESAVGADKIQMTWTRDKYMTETWDPSHAPDNFRELVHIKPDQSNVRRMHTAVKLNEVIVTRSHDARLVLLNMPGPPRNSEGDENYMEFLEVLTEGLERVLLVRGGGREVITIYS
T58890	DRUGINFO	D0K9KZ	DIOA	Investigative

T73859	TARGETID	T73859
T73859	FORMERID	TTDI03241
T73859	UNIPROID	GPR34_HUMAN
T73859	TARGNAME	G-protein coupled receptor 34 (GPR34)
T73859	GENENAME	GPR34
T73859	TARGTYPE	Literature-reported
T73859	SYNONYMS	Probable G-protein coupled receptor 34
T73859	FUNCTION	Orphan receptor.
T73859	SEQUENCE	MRSHTITMTTTSVSSWPYSSHRMRFITNHSDQPPQNFSATPNVTTCPMDEKLLSTVLTTSYSVIFIVGLVGNIIALYVFLGIHRKRNSIQIYLLNVAIADLLLIFCLPFRIMYHINQNKWTLGVILCKVVGTLFYMNMYISIILLGFISLDRYIKINRSIQQRKAITTKQSIYVCCIVWMLALGGFLTMIILTLKKGGHNSTMCFHYRDKHNAKGEAIFNFILVVMFWLIFLLIILSYIKIGKNLLRISKRRSKFPNSGKYATTARNSFIVLIIFTICFVPYHAFRFIYISSQLNVSSCYWKEIVHKTNEIMLVLSSFNSCLDPVMYFLMSSNIRKIMCQLLFRRFQGEPSRSESTSEFKPGYSLHDTSVAVKIQSSSKST
T73859	DRUGINFO	D0M8IT	lysophosphatidylserine	Investigative

T55968	TARGETID	T55968
T55968	FORMERID	TTDI01476
T55968	UNIPROID	SPEG_STRP1
T55968	TARGNAME	Streptococcus Exotoxin type G (Stre-coc speG)
T55968	GENENAME	Stre-coc speG
T55968	TARGTYPE	Literature-reported
T55968	SYNONYMS	SPE G; Pyrogenic exotoxin G; Exotoxin type G
T55968	FUNCTION	Mitogenic for human peripheral blood lymphocytes.
T55968	SEQUENCE	MKTNILTIIILSCVFSYGSQLAYADENLKDLKRSLRFAYNITPCDYENVEIAFVTTNSIHINTKQKRSECILYVDSIVSLGITDQFIKGDKVDVFGLPYNFSPPYVDNIYGGIVKHSNQGNKSLQFVGILNQDGKETYLPSEAVRIKKKQFTLQEFDFKIRKFLMEKYNIYDSESRYTSGSLFLATKDSKHYEVDLFNKDDKLLSRDSFFKRYKDNKIFNSEEISHFDIYLKTH

T75947	TARGETID	T75947
T75947	FORMERID	TTDNR00637
T75947	UNIPROID	ADIP_HUMAN
T75947	TARGNAME	SSX2-interacting protein (SSX2IP)
T75947	GENENAME	SSX2IP
T75947	TARGTYPE	Literature-reported
T75947	SYNONYMS	KIAA0923; Afadin- and alpha-actinin-binding protein; Afadin DIL domain-interacting protein; ADIP
T75947	FUNCTION	May connect the nectin-afadin and E-cadherin-catenin system through alpha-actinin and may be involved in organization of the actin cytoskeleton at AJs through afadin and alpha-actinin. Involved in cell movement: localizes at the leading edge of moving cells in response to PDGF and is required for the formation of the leading edge and the promotion of cell movement, possibly via activation of Rac signaling. Acts as a centrosome maturation factor, probably by maintaining the integrity of the pericentriolar material and proper microtubule nucleation at mitotic spindle poles. The function seems to implicate at least in part WRAP73; the SSX2IP:WRAP73 complex is proposed to act as regulator of spindle anchoring at the mitotic centrosome. Involved in ciliogenesis. It is required for targeted recruitment of the BBSome, CEP290, RAB8, and SSTR3 to the cilia. Belongs to an adhesion system, which plays a role in the organization of homotypic, interneuronal and heterotypic cell-cell adherens junctions (AJs).
T75947	SEQUENCE	MGDWMTVTDPGLSSESKTISQYTSETKMSPSSLYSQQVLCSSIPLSKNVHSFFSAFCTEDNIEQSISYLDQELTTFGFPSLYEESKGKETKRELNIVAVLNCMNELLVLQRKNLLAQENVETQNLKLGSDMDHLQSCYSKLKEQLETSRREMIGLQERDRQLQCKNRNLHQLLKNEKDEVQKLQNIIASRATQYNHDMKRKEREYNKLKERLHQLVMNKKDKKIAMDILNYVGRADGKRGSWRTGKTEARNEDEMYKILLNDYEYRQKQILMENAELKKVLQQMKKEMISLLSPQKKKPRERVDDSTGTVISDVEEDAGELSRESMWDLSCETVREQLTNSIRKQWRILKSHVEKLDNQVSKVHLEGFNDEDVISRQDHEQETEKLELEIQQCKEMIKTQQQLLQQQLATAYDDDTTSLLRDCYLLEEKERLKEEWSLFKEQKKNFERERRSFTEAAIRLGLERKAFEEERASWLKQQFLNMTTFDHQNSENVKLFSAFSGSSDWDNLIVHSRQPQKKPHSVSNGSPVCMSKLTKSLPASPSTSDFCQTRSCISEHSSINVLNITAEEIKPNQVGGECTNQKWSVASRPGSQEGCYSGCSLSYTNSHVEKDDLP

T95922	TARGETID	T95922
T95922	UNIPROID	RP3A_HUMAN
T95922	TARGNAME	Rabphilin-3A (RPH3A)
T95922	GENENAME	RPH3A
T95922	TARGTYPE	Literature-reported
T95922	SYNONYMS	KIAA0985; Exophilin-1
T95922	FUNCTION	Protein transport. Probably involved with Ras-related protein Rab-3A in synaptic vesicle traffic and/or synaptic vesicle fusion. Could play a role in neurotransmitter release by regulating membrane flow in the nerve terminal.
T95922	SEQUENCE	MTDTVFSNSSNRWMYPSDRPLQSNDKEQLQAGWSVHPGGQPDRQRKQEELTDEEKEIINRVIARAEKMEEMEQERIGRLVDRLENMRKNVAGDGVNRCILCGEQLGMLGSACVVCEDCKKNVCTKCGVETNNRLHSVWLCKICIEQREVWKRSGAWFFKGFPKQVLPQPMPIKKTKPQQPVSEPAAPEQPAPEPKHPARAPARGDSEDRRGPGQKTGPDPASAPGRGNYGPPVRRASEARMSSSSRDSESWDHSGGAGDSSRSPAGLRRANSVQASRPAPGSVQSPAPPQPGQPGTPGGSRPGPGPAGRFPDQKPEVAPSDPGTTAPPREERTGGVGGYPAVGAREDRMSHPSGPYSQASAAAPQPAAARQPPPPEEEEEEANSYDSDEATTLGALEFSLLYDQDNSSLQCTIIKAKGLKPMDSNGLADPYVKLHLLPGASKSNKLRTKTLRNTRNPIWNETLVYHGITDEDMQRKTLRISVCDEDKFGHNEFIGETRFSLKKLKPNQRKNFNICLERVIPMKRAGTTGSARGMALYEEEQVERVGDIEERGKILVSLMYSTQQGGLIVGIIRCVHLAAMDANGYSDPFVKLWLKPDMGKKAKHKTQIKKKTLNPEFNEEFFYDIKHSDLAKKSLDISVWDYDIGKSNDYIGGCQLGISAKGERLKHWYECLKNKDKKIERWHQLQNENHVSSD

T90818	TARGETID	T90818
T90818	FORMERID	TTDI03411
T90818	UNIPROID	NPFF2_HUMAN
T90818	TARGNAME	Neuropeptide FF receptor 2 (NPFFR2)
T90818	GENENAME	NPFFR2
T90818	TARGTYPE	Literature-reported
T90818	SYNONYMS	Neuropeptide G-protein coupled receptor; NPGPR; NPFF2; GPR74; G-protein coupled receptor HLWAR77; G-protein coupled receptor 74
T90818	FUNCTION	Receptor for NPAF (A-18-F-amide) and NPFF (F-8-F-amide) neuropeptides, also known as morphine-modulating peptides. Can also be activated by a variety of naturally occurring or synthetic FMRF-amide like ligands. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
T90818	SEQUENCE	MNSFFGTPAASWCLLESDVSSAPDKEAGRERRALSVQQRGGPAWSGSLEWSRQSAGDRRRLGLSRQTAKSSWSRSRDRTCCCRRAWWILVPAADRARRERFIMNEKWDTNSSENWHPIWNVNDTKHHLYSDINITYVNYYLHQPQVAAIFIISYFLIFFLCMMGNTVVCFIVMRNKHMHTVTNLFILNLAISDLLVGIFCMPITLLDNIIAGWPFGNTMCKISGLVQGISVAASVFTLVAIAVDRFQCVVYPFKPKLTIKTAFVIIMIIWVLAITIMSPSAVMLHVQEEKYYRVRLNSQNKTSPVYWCREDWPNQEMRKIYTTVLFANIYLAPLSLIVIMYGRIGISLFRAAVPHTGRKNQEQWHVVSRKKQKIIKMLLIVALLFILSWLPLWTLMMLSDYADLSPNELQIINIYIYPFAHWLAFGNSSVNPIIYGFFNENFRRGFQEAFQLQLCQKRAKPMEAYALKAKSHVLINTSNQLVQESTFQNPHGETLLYRKSAEKPQQELVMEELKETTNSSEI
T90818	DRUGINFO	D05NKX	1DMe	Investigative
T90818	DRUGINFO	D08UWO	RF9	Investigative

T47438	TARGETID	T47438
T47438	FORMERID	TTDNC00378
T47438	UNIPROID	BACE2_HUMAN; PEN2_HUMAN; APH1A_HUMAN; APH1B_HUMAN
T47438	TARGNAME	Amyloid precursor protein secretase (Secretase)
T47438	GENENAME	BACE2; PSENEN; APH1A; APH1B
T47438	TARGTYPE	Literature-reported
T47438	SYNONYMS	Secretase
T47438	FUNCTION	Enzymes that "snip" pieces off a longer protein that is embedded in the cell membrane. Among other roles in the cell, secretases act on the amyloid precursor protein (APP) to cleave the protein into three fragments. Sequential cleavage by -secretase (BACE) and -secretase produces the amyloid- peptide fragment that aggregates into clumps called "plaques" in the brains of Alzheimer's disease patients.
T47438	SEQUENCE	MGALARALLLPLLAQWLLRAAPELAPAPFTLPLRVAAATNRVVAPTPGPGTPAERHADGLALALEPALASPAGAANFLAMVDNLQGDSGRGYYLEMLIGTPPQKLQILVDTGSSNFAVAGTPHSYIDTYFDTERSSTYRSKGFDVTVKYTQGSWTGFVGEDLVTIPKGFNTSFLVNIATIFESENFFLPGIKWNGILGLAYATLAKPSSSLETFFDSLVTQANIPNVFSMQMCGAGLPVAGSGTNGGSLVLGGIEPSLYKGDIWYTPIKEEWYYQIEILKLEIGGQSLNLDCREYNADKAIVDSGTTLLRLPQKVFDAVVEAVARASLIPEFSDGFWTGSQLACWTNSETPWSYFPKISIYLRDENSSRSFRITILPQLYIQPMMGAGLNYECYRFGISPSTNALVIGATVMEGFYVIFDRAQKRVGFAASPCAEIAGAAVSEISGPFSTEDVASNCVPAQSLSEPILWIVSYALMSVCGAILLVLIVLLLLPFRCQRRPRDPEVVNDESSLVRHRWK

T83320	TARGETID	T83320
T83320	FORMERID	TTDI03313
T83320	UNIPROID	S12A7_HUMAN
T83320	TARGNAME	Solute carrier family 12 member 7 (SLC12A7)
T83320	GENENAME	SLC12A7
T83320	TARGTYPE	Literature-reported
T83320	SYNONYMS	KCC4; K-Cl cotransporter 4; Electroneutral potassium-chloride cotransporter 4
T83320	FUNCTION	Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May mediate K(+) uptake into Deiters' cells in the cochlea and contribute to K(+) recycling in the inner ear. Important for the survival of cochlear outer and inner hair cells and the maintenance of the organ of Corti. May be required for basolateral Cl(-) extrusion in the kidney and contribute to renal acidification (By similarity).
T83320	SEQUENCE	MPTNFTVVPVEAHADGGGDETAERTEAPGTPEGPEPERPSPGDGNPRENSPFLNNVEVEQESFFEGKNMALFEEEMDSNPMVSSLLNKLANYTNLSQGVVEHEEDEESRRREAKAPRMGTFIGVYLPCLQNILGVILFLRLTWIVGVAGVLESFLIVAMCCTCTMLTAISMSAIATNGVVPAGGSYYMISRSLGPEFGGAVGLCFYLGTTFAGAMYILGTIEIFLTYISPGAAIFQAEAAGGEAAAMLHNMRVYGTCTLVLMALVVFVGVKYVNKLALVFLACVVLSILAIYAGVIKSAFDPPDIPVCLLGNRTLSRRSFDACVKAYGIHNNSATSALWGLFCNGSQPSAACDEYFIQNNVTEIQGIPGAASGVFLENLWSTYAHAGAFVEKKGVPSVPVAEESRASALPYVLTDIAASFTLLVGIYFPSVTGIMAGSNRSGDLKDAQKSIPTGTILAIVTTSFIYLSCIVLFGACIEGVVLRDKFGEALQGNLVIGMLAWPSPWVIVIGSFFSTCGAGLQSLTGAPRLLQAIARDGIVPFLQVFGHGKANGEPTWALLLTVLICETGILIASLDSVAPILSMFFLMCYLFVNLACAVQTLLRTPNWRPRFKFYHWTLSFLGMSLCLALMFICSWYYALSAMLIAGCIYKYIEYRGAEKEWGDGIRGLSLNAARYALLRVEHGPPHTKNWRPQVLVMLNLDAEQAVKHPRLLSFTSQLKAGKGLTIVGSVLEGTYLDKHMEAQRAEENIRSLMSTEKTKGFCQLVVSSSLRDGMSHLIQSAGLGGLKHNTVLMAWPASWKQEDNPFSWKNFVDTVRDTTAAHQALLVAKNVDSFPQNQERFGGGHIDVWWIVHDGGMLMLLPFLLRQHKVWRKCRMRIFTVAQVDDNSIQMKKDLQMFLYHLRISAEVEVVEMVENDISAFTYERTLMMEQRSQMLKQMQLSKNEQEREAQLIHDRNTASHTAAAARTQAPPTPDKVQMTWTREKLIAEKYRSRDTSLSGFKDLFSMKPDQSNVRRMHTAVKLNGVVLNKSQDAQLVLLNMPGPPKNRQGDENYMEFLEVLTEGLNRVLLVRGGGREVITIYS
T83320	DRUGINFO	D0K9KZ	DIOA	Investigative

T39753	TARGETID	T39753
T39753	FORMERID	TTDR00541
T39753	TARGNAME	Hepatitis C virus Nucleoside triphosphatase (HCV NTP)
T39753	TARGTYPE	Literature-reported
T39753	SYNONYMS	Nucleoside-triphosphatase; Nucleoside triphosphate phosphohydrolase; NTPase; MJ0226
T39753	FUNCTION	Pyrophosphatase that hydrolyzes non-canonical purine nucleotides such as XTP and ITP to their respective monophosphate derivatives. Probably excludes non-canonical purines from DNA precursor pool, thus preventing their incorporation into DNA and avoiding chromosomal lesions.

T21196	TARGETID	T21196
T21196	FORMERID	TTDR00775
T21196	TARGNAME	Monosialic ganglioside 2 (GM2)
T21196	TARGTYPE	Literature-reported
T21196	SYNONYMS	Gamma-M2; GM2
T21196	FUNCTION	Crystallins are the dominant structural components of the vertebrate eye lens.

T91031	TARGETID	T91031
T91031	TARGNAME	Epstein-Barr virus microRNA miR-BART1 (EBV MIRBART1)
T91031	TARGTYPE	Literature-reported
T91031	BIOCLASS	Non-coding RNA target

T82849	TARGETID	T82849
T82849	FORMERID	TTDI01406
T82849	TARGNAME	H19 imprinted maternally expressed transcript (H19)
T82849	TARGTYPE	Literature-reported
T82849	BIOCLASS	Non-coding RNA target

T61881	TARGETID	T61881
T61881	FORMERID	TTDI00039
T61881	TARGNAME	HOXA distal transcript antisense RNA (HOTTIP)
T61881	TARGTYPE	Literature-reported
T61881	BIOCLASS	Non-coding RNA target

T37498	TARGETID	T37498
T37498	FORMERID	TTDI00177
T37498	TARGNAME	Long intergenic noncoding RNA AATBC (lincRNA AATBC)
T37498	TARGTYPE	Literature-reported
T37498	BIOCLASS	Non-coding RNA target

T90764	TARGETID	T90764
T90764	TARGNAME	Long intergenic noncoding RNA p21 (lincRNA p21)
T90764	TARGTYPE	Literature-reported
T90764	BIOCLASS	Non-coding RNA target

T04431	TARGETID	T04431
T04431	FORMERID	TTDI00175
T04431	TARGNAME	microRNA hsa-miR-100 (MIR100)
T04431	TARGTYPE	Literature-reported
T04431	BIOCLASS	Non-coding RNA target

T64947	TARGETID	T64947
T64947	FORMERID	TTDI00143
T64947	TARGNAME	microRNA hsa-miR-101 (MIR101)
T64947	TARGTYPE	Literature-reported
T64947	BIOCLASS	Non-coding RNA target

T45122	TARGETID	T45122
T45122	FORMERID	TTDI00225
T45122	TARGNAME	microRNA hsa-miR-105 (MIR105)
T45122	TARGTYPE	Literature-reported
T45122	BIOCLASS	Non-coding RNA target

T53611	TARGETID	T53611
T53611	FORMERID	TTDI00201
T53611	TARGNAME	microRNA hsa-miR-107 (MIR107)
T53611	TARGTYPE	Literature-reported
T53611	BIOCLASS	Non-coding RNA target

T51677	TARGETID	T51677
T51677	FORMERID	TTDI02668
T51677	TARGNAME	microRNA hsa-miR-10b (MIR10b)
T51677	TARGTYPE	Literature-reported
T51677	BIOCLASS	Non-coding RNA target

T62451	TARGETID	T62451
T62451	FORMERID	TTDI00113
T62451	TARGNAME	microRNA hsa-miR-1207-5p (MIR1207-5p)
T62451	TARGTYPE	Literature-reported
T62451	BIOCLASS	Non-coding RNA target

T63799	TARGETID	T63799
T63799	FORMERID	TTDI01304
T63799	TARGNAME	microRNA hsa-miR-122 (MIR122)
T63799	TARGTYPE	Literature-reported
T63799	BIOCLASS	Non-coding RNA target

T04345	TARGETID	T04345
T04345	FORMERID	TTDI00048
T04345	TARGNAME	microRNA hsa-miR-1269a (MIR1269a)
T04345	TARGTYPE	Literature-reported
T04345	BIOCLASS	Non-coding RNA target

T95748	TARGETID	T95748
T95748	FORMERID	TTDI00117
T95748	TARGNAME	microRNA hsa-miR-1271 (MIR1271)
T95748	TARGTYPE	Literature-reported
T95748	BIOCLASS	Non-coding RNA target

T17838	TARGETID	T17838
T17838	FORMERID	TTDI00150
T17838	TARGNAME	microRNA hsa-miR-1280 (MIR1280)
T17838	TARGTYPE	Literature-reported
T17838	BIOCLASS	Non-coding RNA target

T31926	TARGETID	T31926
T31926	FORMERID	TTDI00206
T31926	TARGNAME	microRNA hsa-miR-129-5p (MIR129-5p)
T31926	TARGTYPE	Literature-reported
T31926	BIOCLASS	Non-coding RNA target

T06870	TARGETID	T06870
T06870	FORMERID	TTDI00163
T06870	TARGNAME	microRNA hsa-miR-130b (MIR130b)
T06870	TARGTYPE	Literature-reported
T06870	BIOCLASS	Non-coding RNA target

T00704	TARGETID	T00704
T00704	FORMERID	TTDI00243
T00704	TARGNAME	microRNA hsa-miR-132 (MIR132)
T00704	TARGTYPE	Literature-reported
T00704	BIOCLASS	Non-coding RNA target

T38740	TARGETID	T38740
T38740	FORMERID	TTDI00073
T38740	TARGNAME	microRNA hsa-miR-133a (MIR133a)
T38740	TARGTYPE	Literature-reported
T38740	BIOCLASS	Non-coding RNA target

T40971	TARGETID	T40971
T40971	FORMERID	TTDI00220
T40971	TARGNAME	microRNA hsa-miR-134 (MIR134)
T40971	TARGTYPE	Literature-reported
T40971	BIOCLASS	Non-coding RNA target

T70791	TARGETID	T70791
T70791	FORMERID	TTDI00211
T70791	TARGNAME	microRNA hsa-miR-143 (MIR143)
T70791	TARGTYPE	Literature-reported
T70791	BIOCLASS	Non-coding RNA target

T62818	TARGETID	T62818
T62818	FORMERID	TTDI00015
T62818	TARGNAME	microRNA hsa-miR-144 (MIR144)
T62818	TARGTYPE	Literature-reported
T62818	BIOCLASS	Non-coding RNA target

T65256	TARGETID	T65256
T65256	FORMERID	TTDI02670
T65256	TARGNAME	microRNA hsa-miR-146a (MIR146a)
T65256	TARGTYPE	Literature-reported
T65256	BIOCLASS	Non-coding RNA target

T68299	TARGETID	T68299
T68299	FORMERID	TTDI00110
T68299	TARGNAME	microRNA hsa-miR-148a (MIR148a)
T68299	TARGTYPE	Literature-reported
T68299	BIOCLASS	Non-coding RNA target

T15386	TARGETID	T15386
T15386	FORMERID	TTDI00241
T15386	TARGNAME	microRNA hsa-miR-152 (MIR152)
T15386	TARGTYPE	Literature-reported
T15386	BIOCLASS	Non-coding RNA target

T09162	TARGETID	T09162
T09162	FORMERID	TTDI00097
T09162	TARGNAME	microRNA hsa-miR-181a (MIR181a)
T09162	TARGTYPE	Literature-reported
T09162	BIOCLASS	Non-coding RNA target

T63102	TARGETID	T63102
T63102	FORMERID	TTDI00014
T63102	TARGNAME	microRNA hsa-miR-181c (MIR181c)
T63102	TARGTYPE	Literature-reported
T63102	BIOCLASS	Non-coding RNA target

T27276	TARGETID	T27276
T27276	FORMERID	TTDI02671
T27276	TARGNAME	microRNA hsa-miR-182 (MIR182)
T27276	TARGTYPE	Literature-reported
T27276	BIOCLASS	Non-coding RNA target

T17579	TARGETID	T17579
T17579	FORMERID	TTDI00085
T17579	TARGNAME	microRNA hsa-miR-183 (MIR183)
T17579	TARGTYPE	Literature-reported
T17579	BIOCLASS	Non-coding RNA target

T34022	TARGETID	T34022
T34022	FORMERID	TTDI00216
T34022	TARGNAME	microRNA hsa-miR-185 (MIR185)
T34022	TARGTYPE	Literature-reported
T34022	BIOCLASS	Non-coding RNA target

T93941	TARGETID	T93941
T93941	FORMERID	TTDI00093
T93941	TARGNAME	microRNA hsa-miR-188 (MIR188)
T93941	TARGTYPE	Literature-reported
T93941	BIOCLASS	Non-coding RNA target

T52864	TARGETID	T52864
T52864	FORMERID	TTDI00136
T52864	TARGNAME	microRNA hsa-miR-18a (MIR18a)
T52864	TARGTYPE	Literature-reported
T52864	BIOCLASS	Non-coding RNA target

T01141	TARGETID	T01141
T01141	FORMERID	TTDR01304
T01141	TARGNAME	microRNA hsa-miR-191 (MIR191)
T01141	TARGTYPE	Literature-reported
T01141	BIOCLASS	Non-coding RNA target
T01141	DRUGINFO	D0IC2O	Anti-miR-191 modified oligonucleotide	Investigative

T35385	TARGETID	T35385
T35385	FORMERID	TTDI00016
T35385	TARGNAME	microRNA hsa-miR-194 (MIR194)
T35385	TARGTYPE	Literature-reported
T35385	BIOCLASS	Non-coding RNA target

T90109	TARGETID	T90109
T90109	TARGNAME	microRNA hsa-miR-197-3p (MIR197-3p)
T90109	TARGTYPE	Literature-reported
T90109	BIOCLASS	Non-coding RNA target

T00064	TARGETID	T00064
T00064	FORMERID	TTDI00234
T00064	TARGNAME	microRNA hsa-miR-199a (MIR199a)
T00064	TARGTYPE	Literature-reported
T00064	BIOCLASS	Non-coding RNA target

T96068	TARGETID	T96068
T96068	FORMERID	TTDI00032
T96068	TARGNAME	microRNA hsa-miR-200c (MIR200c)
T96068	TARGTYPE	Literature-reported
T96068	BIOCLASS	Non-coding RNA target

T97940	TARGETID	T97940
T97940	FORMERID	TTDI00221
T97940	TARGNAME	microRNA hsa-miR-205 (MIR205)
T97940	TARGTYPE	Literature-reported
T97940	BIOCLASS	Non-coding RNA target

T78052	TARGETID	T78052
T78052	FORMERID	TTDI00070
T78052	TARGNAME	microRNA hsa-miR-206 (MIR206)
T78052	TARGTYPE	Literature-reported
T78052	BIOCLASS	Non-coding RNA target

T85293	TARGETID	T85293
T85293	FORMERID	TTDI02672
T85293	TARGNAME	microRNA hsa-miR-21 (MIR21)
T85293	TARGTYPE	Literature-reported
T85293	BIOCLASS	Non-coding RNA target

T54024	TARGETID	T54024
T54024	FORMERID	TTDI00162
T54024	TARGNAME	microRNA hsa-miR-210 (MIR210)
T54024	TARGTYPE	Literature-reported
T54024	BIOCLASS	Non-coding RNA target

T25381	TARGETID	T25381
T25381	FORMERID	TTDI00187
T25381	TARGNAME	microRNA hsa-miR-212 (MIR212)
T25381	TARGTYPE	Literature-reported
T25381	BIOCLASS	Non-coding RNA target

T81158	TARGETID	T81158
T81158	FORMERID	TTDI00060
T81158	TARGNAME	microRNA hsa-miR-214 (MIR214)
T81158	TARGTYPE	Literature-reported
T81158	BIOCLASS	Non-coding RNA target

T78745	TARGETID	T78745
T78745	FORMERID	TTDI00055
T78745	TARGNAME	microRNA hsa-miR-218 (MIR218)
T78745	TARGTYPE	Literature-reported
T78745	BIOCLASS	Non-coding RNA target

T43071	TARGETID	T43071
T43071	FORMERID	TTDI00209
T43071	TARGNAME	microRNA hsa-miR-22 (MIR22)
T43071	TARGTYPE	Literature-reported
T43071	BIOCLASS	Non-coding RNA target

T86185	TARGETID	T86185
T86185	FORMERID	TTDI00172
T86185	TARGNAME	microRNA hsa-miR-223-3p (MIR223-3p)
T86185	TARGTYPE	Literature-reported
T86185	BIOCLASS	Non-coding RNA target

T90106	TARGETID	T90106
T90106	TARGNAME	microRNA hsa-miR-23a (MIR23a)
T90106	TARGTYPE	Literature-reported
T90106	BIOCLASS	Non-coding RNA target

T29413	TARGETID	T29413
T29413	FORMERID	TTDI00167
T29413	TARGNAME	microRNA hsa-miR-26a (MIR26a)
T29413	TARGTYPE	Literature-reported
T29413	BIOCLASS	Non-coding RNA target

T84409	TARGETID	T84409
T84409	FORMERID	TTDI02673
T84409	TARGNAME	microRNA hsa-miR-296 (MIR296)
T84409	TARGTYPE	Literature-reported
T84409	BIOCLASS	Non-coding RNA target

T77895	TARGETID	T77895
T77895	FORMERID	TTDI00020
T77895	TARGNAME	microRNA hsa-miR-29c (MIR29c)
T77895	TARGTYPE	Literature-reported
T77895	BIOCLASS	Non-coding RNA target

T60392	TARGETID	T60392
T60392	FORMERID	TTDI00171
T60392	TARGNAME	microRNA hsa-miR-302a (MIR302a)
T60392	TARGTYPE	Literature-reported
T60392	BIOCLASS	Non-coding RNA target

T43065	TARGETID	T43065
T43065	FORMERID	TTDI00107
T43065	TARGNAME	microRNA hsa-miR-30a (MIR30a)
T43065	TARGTYPE	Literature-reported
T43065	BIOCLASS	Non-coding RNA target

T20736	TARGETID	T20736
T20736	FORMERID	TTDI00135
T20736	TARGNAME	microRNA hsa-miR-30d (MIR30d)
T20736	TARGTYPE	Literature-reported
T20736	BIOCLASS	Non-coding RNA target

T61334	TARGETID	T61334
T61334	FORMERID	TTDI00056
T61334	TARGNAME	microRNA hsa-miR-30d-5p (MIR30d-5p)
T61334	TARGTYPE	Literature-reported
T61334	BIOCLASS	Non-coding RNA target

T35475	TARGETID	T35475
T35475	FORMERID	TTDI00125
T35475	TARGNAME	microRNA hsa-miR-329 (MIR329)
T35475	TARGTYPE	Literature-reported
T35475	BIOCLASS	Non-coding RNA target

T64374	TARGETID	T64374
T64374	FORMERID	TTDI02674
T64374	TARGNAME	microRNA hsa-miR-33 (MIR33)
T64374	TARGTYPE	Literature-reported
T64374	BIOCLASS	Non-coding RNA target

T21479	TARGETID	T21479
T21479	FORMERID	TTDI00049
T21479	TARGNAME	microRNA hsa-miR-371-5p (MIR371-5p)
T21479	TARGTYPE	Literature-reported
T21479	BIOCLASS	Non-coding RNA target

T65323	TARGETID	T65323
T65323	FORMERID	TTDI00180
T65323	TARGNAME	microRNA hsa-miR-373 (MIR373)
T65323	TARGTYPE	Literature-reported
T65323	BIOCLASS	Non-coding RNA target

T36512	TARGETID	T36512
T36512	FORMERID	TTDI00025
T36512	TARGNAME	microRNA hsa-miR-375 (MIR375)
T36512	TARGTYPE	Literature-reported
T36512	BIOCLASS	Non-coding RNA target

T51878	TARGETID	T51878
T51878	FORMERID	TTDI00131
T51878	TARGNAME	microRNA hsa-miR-429 (MIR429)
T51878	TARGTYPE	Literature-reported
T51878	BIOCLASS	Non-coding RNA target

T89002	TARGETID	T89002
T89002	TARGNAME	microRNA hsa-miR-451 (MIR451)
T89002	TARGTYPE	Literature-reported
T89002	BIOCLASS	Non-coding RNA target

T09050	TARGETID	T09050
T09050	FORMERID	TTDI00203
T09050	TARGNAME	microRNA hsa-miR-455 (MIR455)
T09050	TARGTYPE	Literature-reported
T09050	BIOCLASS	Non-coding RNA target

T62602	TARGETID	T62602
T62602	FORMERID	TTDNR00704
T62602	TARGNAME	microRNA hsa-miR-486 (MIR486)
T62602	TARGTYPE	Literature-reported
T62602	BIOCLASS	Non-coding RNA target

T90444	TARGETID	T90444
T90444	FORMERID	TTDI00231
T90444	TARGNAME	microRNA hsa-miR-492 (MIR492)
T90444	TARGTYPE	Literature-reported
T90444	BIOCLASS	Non-coding RNA target

T44467	TARGETID	T44467
T44467	FORMERID	TTDI00124
T44467	TARGNAME	microRNA hsa-miR-509 (MIR509)
T44467	TARGTYPE	Literature-reported
T44467	BIOCLASS	Non-coding RNA target

T61101	TARGETID	T61101
T61101	FORMERID	TTDI00036
T61101	TARGNAME	microRNA hsa-miR-572 (MIR572)
T61101	TARGTYPE	Literature-reported
T61101	BIOCLASS	Non-coding RNA target

T20572	TARGETID	T20572
T20572	FORMERID	TTDI00051
T20572	TARGNAME	microRNA hsa-miR-621 (MIR621)
T20572	TARGTYPE	Literature-reported
T20572	BIOCLASS	Non-coding RNA target

T84602	TARGETID	T84602
T84602	FORMERID	TTDI00099
T84602	TARGNAME	microRNA hsa-miR-664 (MIR664)
T84602	TARGTYPE	Literature-reported
T84602	BIOCLASS	Non-coding RNA target

T88995	TARGETID	T88995
T88995	TARGNAME	microRNA hsa-miR-7 (MIR7)
T88995	TARGTYPE	Literature-reported
T88995	BIOCLASS	Non-coding RNA target

T88910	TARGETID	T88910
T88910	TARGNAME	microRNA hsa-miR-709 (MIR709)
T88910	TARGTYPE	Literature-reported
T88910	BIOCLASS	Non-coding RNA target

T13247	TARGETID	T13247
T13247	FORMERID	TTDI00147
T13247	TARGNAME	microRNA hsa-miR-9 (MIR9)
T13247	TARGTYPE	Literature-reported
T13247	BIOCLASS	Non-coding RNA target

T82013	TARGETID	T82013
T82013	FORMERID	TTDI00018
T82013	TARGNAME	microRNA hsa-miR-939 (MIR939)
T82013	TARGTYPE	Literature-reported
T82013	BIOCLASS	Non-coding RNA target

T32618	TARGETID	T32618
T32618	FORMERID	TTDI00179
T32618	TARGNAME	microRNA hsa-miR-96 (MIR96)
T32618	TARGTYPE	Literature-reported
T32618	BIOCLASS	Non-coding RNA target

T22072	TARGETID	T22072
T22072	FORMERID	TTDI00044
T22072	TARGNAME	Small nucleolar RNA 40 (snoRNA40)
T22072	TARGTYPE	Literature-reported
T22072	BIOCLASS	Non-coding RNA target

T56412	TARGETID	T56412
T56412	FORMERID	TTDI00009
T56412	TARGNAME	Small nucleolar RNA 78 (snoRNA78)
T56412	TARGTYPE	Literature-reported
T56412	BIOCLASS	Non-coding RNA target

T46863	TARGETID	T46863
T46863	FORMERID	TTDI01537
T46863	TARGNAME	Cyclic nucleotide (CN)
T46863	TARGTYPE	Literature-reported
T46863	SYNONYMS	cNMP

T76634	TARGETID	T76634
T76634	FORMERID	TTDR00439
T76634	TARGNAME	Endotoxin (LPS)
T76634	TARGTYPE	Literature-reported
T76634	SYNONYMS	Endotoxin (lipopolysaccharide)

T35667	TARGETID	T35667
T35667	FORMERID	TTDR00944
T35667	TARGNAME	High density lipoprotein (HDL)
T35667	TARGTYPE	Literature-reported
T35667	SYNONYMS	HDL

T67046	TARGETID	T67046
T67046	FORMERID	TTDR00161
T67046	TARGNAME	Platelet activating factor (PAF)
T67046	TARGTYPE	Literature-reported
T67046	SYNONYMS	PAF
T67046	DRUGINFO	D0J6VN	Indol-3-carbinol	Preclinical
T67046	DRUGINFO	D01WJV	F-0401	Terminated
T67046	DRUGINFO	D0Q8YA	UR-12670	Terminated
T67046	DRUGINFO	D0R7MN	SRI 63-441	Terminated
T67046	DRUGINFO	D0X9MW	SCH 44643	Investigative

T10277	TARGETID	T10277
T10277	FORMERID	TTDI00063
T10277	TARGNAME	HOX transcript antisense RNA (HOTAIR)
T10277	TARGTYPE	Literature-reported

T03276	TARGETID	T03276
T03276	FORMERID	TTDR01140
T03276	TARGNAME	Human immunodeficiency virus RNA (HIV RNA)
T03276	TARGTYPE	Literature-reported

T76563	TARGETID	T76563
T76563	FORMERID	TTDR00204
T76563	TARGNAME	Human immunodeficiency virus TAR RNA (HIV TAR-RNA)
T76563	TARGTYPE	Literature-reported
T76563	DRUGINFO	D0I6YL	Chimeric small nucleolar RNA-TAR decoy	Investigative
T76563	DRUGINFO	D0K9CL	2,4-diaminoquinozalines and quinoxaline-2,3-diones	Investigative
T76563	DRUGINFO	D08ZHT	Diazaborines	Investigative

T98648	TARGETID	T98648
T98648	FORMERID	TTDNC00659
T98648	TARGNAME	Lactobacillus 16S rRNA (Lacto 16RNA)
T98648	TARGTYPE	Literature-reported

T42789	TARGETID	T42789
T42789	FORMERID	TTDR00749
T42789	TARGNAME	G-quadruplex DNA (GQDNA)
T42789	TARGTYPE	Literature-reported

T99170	TARGETID	T99170
T99170	FORMERID	TTDR00382
T99170	TARGNAME	Intermediate-density lipoprotein (IDL)
T99170	TARGTYPE	Literature-reported

T98886	TARGETID	T98886
T98886	FORMERID	TTDNC00679
T98886	TARGNAME	Potassium-competitive acid (PCA)
T98886	TARGTYPE	Literature-reported

T65505	TARGETID	T65505
T65505	FORMERID	TTDI01210
T65505	TARGNAME	Src tyrosine kinase signaling pathway (Src pathway)
T65505	TARGTYPE	Literature-reported

T00576	TARGETID	T00576
T00576	TARGNAME	Amine oxidase (AO)
T00576	TARGTYPE	Literature-reported
T00576	SYNONYMS	Amine oxidase (copper-containing); AOC

T25889	TARGETID	T25889
T25889	FORMERID	TTDR00979
T25889	TARGNAME	Adenylate cyclase (ADCY)
T25889	TARGTYPE	Literature-reported
T25889	SYNONYMS	Adenylyl cyclase; ATP pyrophosphate-lyase
T25889	FUNCTION	Catalyzes the formation of the second messenger cAMP from ATP. Its transcript is probably degraded by endoribonuclease LS (rnlA), decreasing cAMP levels and the negative regulator Crp- cAMP, which then induces its own transcription again.
T25889	BIOCLASS	Phosphorus-oxygen lyase
T25889	DRUGINFO	D0D8KI	Ad5-AC6	Terminated
T25889	DRUGINFO	D00PZE	2-hydroxy-17beta-estradiol	Investigative
T25889	DRUGINFO	D00QYO	2,5-didesoxy-3-ATP	Investigative
T25889	DRUGINFO	D0C6LS	Adenosine-5'-Rp-Alpha-Thio-Triphosphate	Investigative
T25889	DRUGINFO	D0E0OJ	DEOXYADENOSINE	Investigative
T25889	DRUGINFO	D0Z3KV	NSC-270718	Investigative
T25889	DRUGINFO	D00QLM	[3H]alphabeta-meATP	Investigative
T25889	DRUGINFO	D09KUE	NSC-88915	Investigative
T25889	DRUGINFO	D0UB2J	[3H]cAMP	Investigative
T25889	DRUGINFO	D03RFA	N6-CYCLOPENTYLADENOSINE	Investigative

T05127	TARGETID	T05127
T05127	FORMERID	TTDR01442
T05127	TARGNAME	Cytochrome P450 2B2 (CYP2B2)
T05127	TARGTYPE	Literature-reported
T05127	SYNONYMS	Cytochrome P450E; Cytochrome P450 PB4; Cyp2b2; Cyp2b-2; CYPIIB2
T05127	FUNCTION	Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
T05127	BIOCLASS	Paired donor oxygen oxidoreductase

T55114	TARGETID	T55114
T55114	FORMERID	TTDR01011
T55114	TARGNAME	Cation channel sperm-associated protein (CatSper)
T55114	TARGTYPE	Literature-reported
T55114	SYNONYMS	Chemokine (C-C motif) receptor
T55114	FUNCTION	Voltage-gated calcium channel that plays a central role in calcium-dependent physiological responses essential for successful fertilization, such as sperm hyperactivation, acrosome reaction and chemotaxis towards the oocyte. Activated by extracellular progesterone and prostaglandins following the sequence: progesterone > PGF1-alpha = PGE1 > PGA1 > PGE2 >> PGD2. The primary effect of progesterone activation is to shift voltage dependence towards more physiological, negative membrane potentials; it is not mediated by metabotropic receptors and second messengers. Sperm capacitation enhances the effect of progesterone by providing additional negative shift. Also activated by the elevation of intracellular pH.
T55114	DRUGINFO	D03BSR	NNC55-0396	Investigative
T55114	DRUGINFO	D0JF0W	PGF1alpha	Investigative

T71054	TARGETID	T71054
T71054	FORMERID	TTDI01772
T71054	TARGNAME	C-C chemokine receptor (CCR)
T71054	TARGTYPE	Literature-reported
T71054	SYNONYMS	Chemokine (C-C motif) receptor
T71054	FUNCTION	Receptor for a C-C type chemokine. Binds to MIP-1-alpha, MIP-1-delta, RANTES, and MCP-3 and, less efficiently, to MIP-1- beta or MCP-1 and subsequently transduces a signal by increasing the intracellular calcium ions level. Responsible for affecting stem cell proliferation.
T71054	DRUGINFO	D06QRP	CP-481,715	Investigative
T71054	DRUGINFO	D0B3PC	UCB35625	Investigative
T71054	DRUGINFO	D0S8QZ	PMID12614873C2b-1	Investigative
T71054	DRUGINFO	D0Y5NT	VT-224	Investigative
T71054	DRUGINFO	D09PZD	viral macrophage inflammatory protein-II	Investigative

T14263	TARGETID	T14263
T14263	FORMERID	TTDR00358
T14263	TARGNAME	Phospholipase D (PLD)
T14263	TARGTYPE	Literature-reported
T14263	SYNONYMS	PLD-A; PLD; Choline phosphatase
T14263	BIOCLASS	Phosphoric diester hydrolase
T14263	DRUGINFO	D07RPV	HALOPEMIDE	Investigative

T44150	TARGETID	T44150
T44150	FORMERID	TTDS00179
T44150	TARGNAME	Prolyl hydroxylase (PH)
T44150	TARGTYPE	Literature-reported
T44150	SYNONYMS	Procollagen-proline,2-oxoglutarate-4-dioxygenase alpha; 4-PH alpha
T44150	BIOCLASS	Paired donor oxygen oxidoreductase

T97769	TARGETID	T97769
T97769	FORMERID	TTDC00278
T97769	TARGNAME	Inflammatory cytokine messenger RNA (Cytokine mRNA)
T97769	TARGTYPE	Literature-reported
T97769	SYNONYMS	mRNA of Inflammatory cytokine
T97769	BIOCLASS	mRNA target

T59099	TARGETID	T59099
T59099	FORMERID	TTDR01024
T59099	TARGNAME	Anandamide amidase (ANA)
T59099	TARGTYPE	Literature-reported
T59099	SYNONYMS	Arachidonylethanolamide synthase; Anandamide synthase
T59099	BIOCLASS	Carbon-nitrogen hydrolase

T42951	TARGETID	T42951
T42951	FORMERID	TTDR00798
T42951	TARGNAME	Calprotectin (CP)
T42951	TARGTYPE	Literature-reported
T42951	SYNONYMS	S100A9/S100A8; MRP8/MRP14 complex; MRP-8/MRP-14; Leucocyte protein L1; L1 protein; L1 antigen; Cytosolic protein complex L1
T42951	FUNCTION	Expressed by macrophages in chronic inflammations. Also expressed in epithelial cells constitutively or induced during dermatoses. May interact with components of the intermediate filaments in monocytes and epithelial cells.

T97288	TARGETID	T97288
T97288	FORMERID	TTDR01052
T97288	TARGNAME	Homocitrate synthase (HCS)
T97288	TARGTYPE	Literature-reported
T97288	SYNONYMS	Homocitrate synthetase; Acetyl-coenzyme A:2-ketoglutarate C-acetyl transferase; 2-hydroxybutane-1,2,4-tricarboxylate 2-oxoglutarate-lyase (CoA-acetylating)
T97288	BIOCLASS	Acyltransferase

T82514	TARGETID	T82514
T82514	FORMERID	TTDI01759
T82514	TARGNAME	Neurokinin receptor (NKR)
T82514	TARGTYPE	Literature-reported
T82514	FUNCTION	This is a receptor for the tachykinin neuropeptide substance P. It is probably associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of affinity of this receptor to tachykinins is: substance P > substance K > neuromedin-K.
T82514	DRUGINFO	D0V3QE	NSL-036	Terminated

T35264	TARGETID	T35264
T35264	FORMERID	TTDR01196
T35264	TARGNAME	P2Y purinoceptor (P2RY)
T35264	TARGTYPE	Literature-reported
T35264	SYNONYMS	Platelet adenosine diphosphatereceptor; P2Y receptor; Adenosine diphosphate (ADP) receptor; Adenosine 5'-Diphosphate Receptor; ADP receptor
T35264	BIOCLASS	GPCR rhodopsin
T35264	DRUGINFO	D0V4GQ	Adenosine-5'-O-(2-thiodiphosphate)	Investigative

T59174	TARGETID	T59174
T59174	FORMERID	TTDI01757
T59174	TARGNAME	Sodium/hydrogen exchanger (SLC)
T59174	TARGTYPE	Literature-reported
T59174	FUNCTION	Involved in pH regulation to eliminate acids generated by active metabolism or to counter adverse environmental conditions. Major proton extruding system driven by the inward sodium ion chemical gradient. Plays an important role in signal transduction.
T59174	DRUGINFO	D05DNA	FR-183998	Terminated
T59174	DRUGINFO	D0F1PH	Rimeporide	Investigative

T46508	TARGETID	T46508
T46508	FORMERID	TTDR00516
T46508	TARGNAME	Voltage-gated potassium channel (VGKC)
T46508	TARGTYPE	Literature-reported
T46508	BIOCLASS	Voltage-gated ion channel
T46508	DRUGINFO	D08KCZ	(2S)-2-(BUTYRYLOXY)-3-HYDROXYPROPYL NONANOATE	Investigative
T46508	DRUGINFO	D0K7LF	Tetrabutylammonium Ion	Investigative

T29460	TARGETID	T29460
T29460	FORMERID	TTDR00648
T29460	TARGNAME	CoA-independent transacylase (CIT)
T29460	TARGTYPE	Literature-reported
T29460	SYNONYMS	Glycerophospholipid arachidonoyl-transferase(CoA-independent); Coenzyme A-independent transacylase; CoA-IT; 1-alkylglycerophosphocholine Acyltransferase
T29460	BIOCLASS	Acyltransferase

T08149	TARGETID	T08149
T08149	FORMERID	TTDI01270
T08149	TARGNAME	Lentivirus messenger RNA (Lentivirus mRNA)
T08149	TARGTYPE	Literature-reported
T08149	SYNONYMS	mRNA of Lentivirus
T08149	BIOCLASS	mRNA target

T20537	TARGETID	T20537
T20537	FORMERID	TTDR00552
T20537	TARGNAME	Protein kinase A alpha messenger RNA (PKA-alpha mRNA)
T20537	TARGTYPE	Literature-reported
T20537	SYNONYMS	mRNA of PKA alpha
T20537	BIOCLASS	mRNA target
T20537	DRUGINFO	D0G1ML	(35)S-labeled oligonucleotide	Investigative

T91382	TARGETID	T91382
T91382	FORMERID	TTDR00344
T91382	TARGNAME	Protein kinase A Ri alpha messenger RNA (PKA-Ri-alpha mRNA)
T91382	TARGTYPE	Literature-reported
T91382	SYNONYMS	mRNA of PKA Ri alpha
T91382	BIOCLASS	mRNA target
T91382	DRUGINFO	D0G1ML	(35)S-labeled oligonucleotide	Investigative

T18170	TARGETID	T18170
T18170	FORMERID	TTDR00378
T18170	TARGNAME	Protein kinase A1 messenger RNA (PKA mRNA)
T18170	TARGTYPE	Literature-reported
T18170	SYNONYMS	mRNA of PKA
T18170	BIOCLASS	mRNA target

T04144	TARGETID	T04144
T04144	FORMERID	TTDR00128
T04144	TARGNAME	Protein kinase C messenger RNA (PKC mRNA)
T04144	TARGTYPE	Literature-reported
T04144	SYNONYMS	mRNA of PKC
T04144	BIOCLASS	mRNA target

T44620	TARGETID	T44620
T44620	FORMERID	TTDR01274
T44620	TARGNAME	Acid-sensing ion channel (ASIC)
T44620	TARGTYPE	Literature-reported
T44620	BIOCLASS	Amiloride-sensitive sodium channel

T38528	TARGETID	T38528
T38528	FORMERID	TTDI01601
T38528	TARGNAME	AdoHcy hydrolase (SAHase)
T38528	TARGTYPE	Literature-reported
T38528	SYNONYMS	AdoHcyase
T38528	DRUGINFO	D0I7TN	3-DEAZAADENOSINE	Terminated

T67286	TARGETID	T67286
T67286	FORMERID	TTDR01267
T67286	TARGNAME	Beta-lactoglobulin 1 (BetaL1)
T67286	TARGTYPE	Literature-reported
T67286	FUNCTION	Primary component of whey, it binds retinol and is probably involved in the transport of that molecule.

T68544	TARGETID	T68544
T68544	FORMERID	TTDI01802
T68544	TARGNAME	Estrogen-related receptor (ESRR)
T68544	TARGTYPE	Literature-reported
T68544	FUNCTION	Binds to an ERR-alpha response element (ERRE) containinga single consensus half-site, 5'-TNAAGGTCA-3'. Can bind to the medium-chain acyl coenzyme A dehydrogenase (MCAD) response element NRRE-1 and may act as an important regulator of MCAD promoter. Binds to the C1 region of the lactoferrin gene promoter. Requires dimerization and the coactivator, PGC-1A, for full activity. The ERRalpha/PGC1alpha complex is a regulator of energy metabolism. Induces theexpression of PERM1 in the skeletal muscle.

T23342	TARGETID	T23342
T23342	FORMERID	TTDI02001
T23342	TARGNAME	GDNF receptor complexes (GDNFR)
T23342	TARGTYPE	Literature-reported
T23342	FUNCTION	Receptor for GDNF. Mediates the GDNF-induced autophosphorylation and activation of the RET receptor.

T42436	TARGETID	T42436
T42436	FORMERID	TTDI01724
T42436	TARGNAME	Interleukin receptor (ILR)
T42436	TARGTYPE	Literature-reported
T42436	SYNONYMS	Interleukin receptor

T44788	TARGETID	T44788
T44788	FORMERID	TTDR00285
T44788	TARGNAME	Large subunit Cp complex Cdc68p (CDC68)
T44788	TARGTYPE	Literature-reported
T44788	SYNONYMS	Cdc68p; CDC68

T26428	TARGETID	T26428
T26428	FORMERID	TTDR00131
T26428	TARGNAME	Melanin-concentrating hormone receptor (MCHR)
T26428	TARGTYPE	Literature-reported
T26428	SYNONYMS	MCH receptor
T26428	DRUGINFO	D00AQY	IDDB-41331	Preclinical

T01853	TARGETID	T01853
T01853	FORMERID	TTDR00150
T01853	TARGNAME	Mitogen-activated protein kinase kinase (MAPKK)
T01853	TARGTYPE	Literature-reported
T01853	BIOCLASS	Kinase
T01853	DRUGINFO	D0GD8Y	U0126	Investigative

T61862	TARGETID	T61862
T61862	FORMERID	TTDI01818
T61862	TARGNAME	Relaxin receptor (RXFP)
T61862	TARGTYPE	Literature-reported
T61862	FUNCTION	Receptor for relaxins. The activity of this receptor is mediated by G proteins leading to stimulation of adenylate cyclase and an increase of cAMP. Binding of the ligand may also activate a tyrosine kinase pathway that inhibits the activity of a phosphodiesterase that degrades cAMP.

T39845	TARGETID	T39845
T39845	FORMERID	TTDR00933
T39845	TARGNAME	TNF receptor-associated factor (TRAF)
T39845	TARGTYPE	Literature-reported
T39845	SYNONYMS	TRAF; TNF-receptor-associated factor

T86882	TARGETID	T86882
T86882	FORMERID	TTDI01810
T86882	TARGNAME	Tumor suppressor candidate (TUSC)
T86882	TARGTYPE	Literature-reported
T86882	SYNONYMS	Candidate tumor suppressor protein

T44833	TARGETID	T44833
T44833	FORMERID	TTDI01688
T44833	TARGNAME	Tumor-associated peptide (TAP)
T44833	TARGTYPE	Literature-reported
T44833	SYNONYMS	Tumor associated peptide

T14191	TARGETID	T14191
T14191	FORMERID	TTDR00496
T14191	TARGNAME	Voltage-gated potassium channel Kv1 (KCNA)
T14191	TARGTYPE	Literature-reported
T14191	BIOCLASS	Voltage-gated ion channel

T67172	TARGETID	T67172
T67172	FORMERID	TTDI03617
T67172	TARGNAME	Volume regulated chloride channel (VRAC)
T67172	TARGTYPE	Literature-reported
T67172	BIOCLASS	Chloride channel
T67172	DRUGINFO	D00BEA	1,9-dideoxyforskolin	Investigative
T67172	DRUGINFO	D02EPD	diBA-(5)-C4	Investigative
T67172	DRUGINFO	D02MYV	IAA-94	Investigative
T67172	DRUGINFO	D0J3QC	DCPIB	Investigative
T67172	DRUGINFO	D0Z4AU	GTPgammaS	Investigative
T67172	DRUGINFO	D0O6KR	9-anthroic acid	Investigative
T67172	DRUGINFO	D08DQL	NPPB	Investigative
T67172	DRUGINFO	D0PW7B	DIDS	Investigative

T22912	TARGETID	T22912
T22912	FORMERID	TTDR00787
T22912	TARGNAME	Endothelium-derived hyperpolarizing factor (EDHF)
T22912	TARGTYPE	Literature-reported
T22912	SYNONYMS	EDHF

T38988	TARGETID	T38988
T38988	FORMERID	TTDR00946
T38988	TARGNAME	Glycoprotein Ib-IX-V receptor (GPIbIXV)
T38988	TARGTYPE	Literature-reported
T38988	SYNONYMS	Glycoprotein Ib-IX-V; Glycoprotein (GP) Ib-IX-V; GP Ib-IX-V

T26862	TARGETID	T26862
T26862	FORMERID	TTDR01205
T26862	TARGNAME	Leukotriene E4 receptor (LTE4R)
T26862	TARGTYPE	Literature-reported
T26862	SYNONYMS	LTE4 receptor

T96547	TARGETID	T96547
T96547	TARGNAME	Nerve/glial antigen-2 (NG2)
T96547	TARGTYPE	Literature-reported
T96547	SYNONYMS	Tubulin protein

T18401	TARGETID	T18401
T18401	FORMERID	TTDR00694
T18401	TARGNAME	Tumor-associated carbohydrate antigen KH-1 (KH-1)
T18401	TARGTYPE	Literature-reported
T18401	SYNONYMS	Antigen KH-1

T80180	TARGETID	T80180
T80180	FORMERID	TTDI01199
T80180	TARGNAME	Carcinogenesis (Tumorigenesis)
T80180	TARGTYPE	Literature-reported
T80180	SYNONYMS	Biogenesis of tumor

T89440	TARGETID	T89440
T89440	TARGNAME	CXCL5/CXCR2 axis (CXCL5/CXCR2 axis)
T89440	TARGTYPE	Literature-reported
T89440	SYNONYMS	C-X-C motif chemokine 5/C-X-C motif chemokine receptor 2 axis

T55234	TARGETID	T55234
T55234	FORMERID	TTDR01115
T55234	TARGNAME	Cyclin E/cdk2 pathway (CCNE2/CDK2 pathway)
T55234	TARGTYPE	Literature-reported
T55234	SYNONYMS	Cyclin E/CDK2 pathway signalling

T06446	TARGETID	T06446
T06446	FORMERID	TTDI01171
T06446	TARGNAME	Leukotriene biosynthesis (LT synth)
T06446	TARGTYPE	Literature-reported
T06446	SYNONYMS	Leukotriene synthesis
T06446	DRUGINFO	D04LBJ	ASOBAMAST	Investigative

T69141	TARGETID	T69141
T69141	FORMERID	TTDR00098
T69141	TARGNAME	Monoamine uptake (MA uptake)
T69141	TARGTYPE	Literature-reported
T69141	SYNONYMS	Monoamine(MA) uptake
T69141	DRUGINFO	D0A0KE	Norzimelidine	Investigative
T69141	DRUGINFO	D0L4CI	Desmethylclomipramine	Investigative

T98600	TARGETID	T98600
T98600	FORMERID	TTDR00079
T98600	TARGNAME	Permeability pathway (NP pathway)
T98600	TARGTYPE	Literature-reported
T98600	SYNONYMS	NPPs
T98600	DRUGINFO	D0K3SI	Decyltrimethylammonium	Investigative
T98600	DRUGINFO	D02COM	7-tert-butyl-2, 3-dihydro-3, 3-dimethyl substituted dihydrofuran 30 (DHDMBF30)	Investigative
T98600	DRUGINFO	D08DQL	NPPB	Investigative

T16132	TARGETID	T16132
T16132	FORMERID	TTDI01281
T16132	TARGNAME	TNF alpha synthesis (TNFA synthesis)
T16132	TARGTYPE	Literature-reported
T16132	SYNONYMS	Tumor necrosis factor alpha synthesis

T62648	TARGETID	T62648
T62648	FORMERID	TTDI01193
T62648	TARGNAME	Tumour metastasis (Tmet)
T62648	TARGTYPE	Literature-reported
T62648	SYNONYMS	Metastasis; Cancer metastasis

T53255	TARGETID	T53255
T53255	FORMERID	TTDI01384
T53255	TARGNAME	Adrenomedullin receptor (AMR)
T53255	TARGTYPE	Literature-reported

T55352	TARGETID	T55352
T55352	FORMERID	TTDI00191
T55352	TARGNAME	Amyloid precursor protein (APP)
T55352	TARGTYPE	Literature-reported
T55352	DRUGINFO	DPYA76	SHR‐1707	Phase 1

T98519	TARGETID	T98519
T98519	FORMERID	TTDNC00480
T98519	TARGNAME	Anaphase-promoting complex (APC/C)
T98519	TARGTYPE	Literature-reported

T61732	TARGETID	T61732
T61732	FORMERID	TTDI01729
T61732	TARGNAME	Aspartic protease (ASPP)
T61732	TARGTYPE	Literature-reported

T75907	TARGETID	T75907
T75907	FORMERID	TTDI01822
T75907	TARGNAME	ATP synthase (ATPS)
T75907	TARGTYPE	Literature-reported
T75907	DRUGINFO	DW4O2J	J147	Phase 1

T57781	TARGETID	T57781
T57781	FORMERID	TTDR00003
T57781	TARGNAME	ATP-sensitive potassium channel (KATP channel)
T57781	TARGTYPE	Literature-reported

T74864	TARGETID	T74864
T74864	FORMERID	TTDI01823
T74864	TARGNAME	Bacterial ATP synthase (Bact atps)
T74864	TARGTYPE	Literature-reported

T09495	TARGETID	T09495
T09495	FORMERID	TTDI01896
T09495	TARGNAME	Bacterial Transpeptidase (Bact TPP)
T09495	TARGTYPE	Literature-reported

T90244	TARGETID	T90244
T90244	TARGNAME	Bilophila glycyl radical enzyme (GRE)
T90244	TARGTYPE	Literature-reported

T03888	TARGETID	T03888
T03888	FORMERID	TTDNC00386
T03888	TARGNAME	Catenin (CTNN)
T03888	TARGTYPE	Literature-reported

T47215	TARGETID	T47215
T47215	FORMERID	TTDR00566
T47215	TARGNAME	Cholecystokinin receptor (CCKR)
T47215	TARGTYPE	Literature-reported
T47215	DRUGINFO	D06JVU	A-68552	Terminated
T47215	DRUGINFO	D0O7PT	Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)]	Investigative

T70410	TARGETID	T70410
T70410	FORMERID	TTDR01188
T70410	TARGNAME	Corticosteroid receptor (CCR)
T70410	TARGTYPE	Literature-reported

T47409	TARGETID	T47409
T47409	FORMERID	TTDI01624
T47409	TARGNAME	C-X-C chemokine receptor (CXCR)
T47409	TARGTYPE	Literature-reported

T40098	TARGETID	T40098
T40098	FORMERID	TTDI01641
T40098	TARGNAME	Cytochrome P450 3 (CYP3)
T40098	TARGTYPE	Literature-reported

T94620	TARGETID	T94620
T94620	FORMERID	TTDI01418
T94620	TARGNAME	Death associated protein kinase (DAPK)
T94620	TARGTYPE	Literature-reported

T39549	TARGETID	T39549
T39549	FORMERID	TTDI01692
T39549	TARGNAME	Deoxyribonuclease (DNASE)
T39549	TARGTYPE	Literature-reported

T68302	TARGETID	T68302
T68302	FORMERID	TTDNC00544
T68302	TARGNAME	DNA methyltransferase (DNMT)
T68302	TARGTYPE	Literature-reported

T12811	TARGETID	T12811
T12811	FORMERID	TTDI01513
T12811	TARGNAME	DNA-binding protein inhibitor (ID)
T12811	TARGTYPE	Literature-reported

T39664	TARGETID	T39664
T39664	FORMERID	TTDI01673
T39664	TARGNAME	Estradiol 17 beta-dehydrogenase (17-beta-HSD)
T39664	TARGTYPE	Literature-reported
T39664	DRUGINFO	D0T5ZC	BAY-50-9062	Terminated

T29653	TARGETID	T29653
T29653	FORMERID	TTDI01302
T29653	TARGNAME	Gluten (GLEN)
T29653	TARGTYPE	Literature-reported

T86609	TARGETID	T86609
T86609	FORMERID	TTDI01675
T86609	TARGNAME	Glycoside hydrolase (GlyH)
T86609	TARGTYPE	Literature-reported
T86609	DRUGINFO	D03MFV	MNLP-18	Preclinical

T00803	TARGETID	T00803
T00803	FORMERID	TTDI01470
T00803	TARGNAME	GPCR frizzled protein unspecific (GPCRF)
T00803	TARGTYPE	Literature-reported

T05241	TARGETID	T05241
T05241	FORMERID	TTDI01436
T05241	TARGNAME	GPCR rhodopsin protein unspecific (GPCRA)
T05241	TARGTYPE	Literature-reported

T36309	TARGETID	T36309
T36309	FORMERID	TTDR00781
T36309	TARGNAME	Guanosine phosphotransferase (GPTase)
T36309	TARGTYPE	Literature-reported

T17666	TARGETID	T17666
T17666	FORMERID	TTDI01640
T17666	TARGNAME	Hematopoietic protein-tyrosine phosphatase (PTPN)
T17666	TARGTYPE	Literature-reported

T96281	TARGETID	T96281
T96281	FORMERID	TTDI01676
T96281	TARGNAME	Hepatitis C virus Envelope glycoprotein (HCV Env)
T96281	TARGTYPE	Literature-reported
T96281	DRUGINFO	D0VV3O	GNI-104	Terminated

T79716	TARGETID	T79716
T79716	FORMERID	TTDI01639
T79716	TARGNAME	Hydroxylase (HYL)
T79716	TARGTYPE	Literature-reported

T23286	TARGETID	T23286
T23286	FORMERID	TTDI01733
T23286	TARGNAME	Immunoglobulin gamma Fc receptor (FCGR)
T23286	TARGTYPE	Literature-reported

T40183	TARGETID	T40183
T40183	FORMERID	TTDI01840
T40183	TARGNAME	Inflammatory cytokine (IC)
T40183	TARGTYPE	Literature-reported

T92195	TARGETID	T92195
T92195	FORMERID	TTDI01483
T92195	TARGNAME	Ligand-gated ion channel (LGIC)
T92195	TARGTYPE	Literature-reported

T02709	TARGETID	T02709
T02709	FORMERID	TTDI01368
T02709	TARGNAME	Lysine-specific histone demethylase (LSD)
T02709	TARGTYPE	Literature-reported

T30519	TARGETID	T30519
T30519	FORMERID	TTDR00431
T30519	TARGNAME	Monocyte derived cytokine (MDC)
T30519	TARGTYPE	Literature-reported

T66451	TARGETID	T66451
T66451	FORMERID	TTDI01455
T66451	TARGNAME	Mothers against decapentaplegic homolog (SMAD)
T66451	TARGTYPE	Literature-reported

T65594	TARGETID	T65594
T65594	FORMERID	TTDI01687
T65594	TARGNAME	Motoneuronotrophic factor (MNTF)
T65594	TARGTYPE	Literature-reported

T51975	TARGETID	T51975
T51975	FORMERID	TTDI01462
T51975	TARGNAME	NEDD4-like E3 ubiquitin-protein ligase WWP (WWP)
T51975	TARGTYPE	Literature-reported

T21903	TARGETID	T21903
T21903	FORMERID	TTDI01385
T21903	TARGNAME	Opsin (OP)
T21903	TARGTYPE	Literature-reported

T54940	TARGETID	T54940
T54940	FORMERID	TTDI01428
T54940	TARGNAME	Plasmodium Cysteine protease falcipain (Malaria CPF)
T54940	TARGTYPE	Literature-reported
T54940	DRUGINFO	D04ZIJ	Pepstatin	Terminated
T54940	DRUGINFO	D08KCA	Leupeptin	Investigative

T97822	TARGETID	T97822
T97822	FORMERID	TTDI01611
T97822	TARGNAME	Prostaglandin synthetase (PGS)
T97822	TARGTYPE	Literature-reported
T97822	DRUGINFO	D0E9NJ	PARCETASAL	Investigative

T59909	TARGETID	T59909
T59909	FORMERID	TTDI01564
T59909	TARGNAME	Protein prenyl transferase (PPTF)
T59909	TARGTYPE	Literature-reported
T59909	DRUGINFO	D03GQH	B-581	Terminated

T59234	TARGETID	T59234
T59234	FORMERID	TTDI01437
T59234	TARGNAME	Stretch-gated ion channel (MSC)
T59234	TARGTYPE	Literature-reported

T39135	TARGETID	T39135
T39135	FORMERID	TTDR00366
T39135	TARGNAME	Sulfur mustard-stimulated protease (SMSP)
T39135	TARGTYPE	Literature-reported
T39135	DRUGINFO	D0G6OU	Ca(2+) chelator	Investigative
T39135	DRUGINFO	D0O5VI	EGTA	Investigative

T71446	TARGETID	T71446
T71446	FORMERID	TTDI01727
T71446	TARGNAME	Transporter unspecfic (TP)
T71446	TARGTYPE	Literature-reported
T71446	DRUGINFO	D0A7NI	LIM-5310	Investigative

T04524	TARGETID	T04524
T04524	FORMERID	TTDI01659
T04524	TARGNAME	Type II transmembrane serine proteases (TTSP)
T04524	TARGTYPE	Literature-reported

T06124	TARGETID	T06124
T06124	FORMERID	TTDI01622
T06124	TARGNAME	Acetaminophen binding protein 58kDa (ABP58)
T06124	TARGTYPE	Literature-reported

T01246	TARGETID	T01246
T01246	FORMERID	TTDNR00705
T01246	TARGNAME	Ascaris NADH-fumarate reductase (Asc OSM)
T01246	TARGTYPE	Literature-reported

T20210	TARGETID	T20210
T20210	FORMERID	TTDI02376
T20210	TARGNAME	Feto-acinar pancreatic protein (FAPP)
T20210	TARGTYPE	Literature-reported
T20210	DRUGINFO	D0F6HW	IPH-4201	Terminated

T66315	TARGETID	T66315
T66315	FORMERID	TTDI01342
T66315	TARGNAME	Imidazoline I2 receptor (I2R)
T66315	TARGTYPE	Literature-reported

T90207	TARGETID	T90207
T90207	TARGNAME	Mechanistic target of rapamycin complex 3 (mTORC3)
T90207	TARGTYPE	Literature-reported

T07209	TARGETID	T07209
T07209	FORMERID	TTDI01881
T07209	TARGNAME	Streptococcus Capsular antigen (Stre CA)
T07209	TARGTYPE	Literature-reported

T12598	TARGETID	T12598
T12598	FORMERID	TTDI01202
T12598	TARGNAME	Mitochondrial membrane (MIM)
T12598	TARGTYPE	Literature-reported

T83040	TARGETID	T83040
T83040	FORMERID	TTDI01540
T83040	TARGNAME	Advanced glycation end-product pathway (AGE pathway)
T83040	TARGTYPE	Literature-reported

T49958	TARGETID	T49958
T49958	FORMERID	TTDI01399
T49958	TARGNAME	Autophagy (AUT)
T49958	TARGTYPE	Literature-reported

T03938	TARGETID	T03938
T03938	FORMERID	TTDR00063
T03938	TARGNAME	Axon loss (AXL)
T03938	TARGTYPE	Literature-reported

T46371	TARGETID	T46371
T46371	FORMERID	TTDI01408
T46371	TARGNAME	Bacterial Quorum sensing (Bact BQS)
T46371	TARGTYPE	Literature-reported

T47782	TARGETID	T47782
T47782	FORMERID	TTDR01235
T47782	TARGNAME	Catecholamine uptake (CA uptake)
T47782	TARGTYPE	Literature-reported
T47782	DRUGINFO	D03HKV	Metanephrine	Investigative

T06707	TARGETID	T06707
T06707	FORMERID	TTDI01544
T06707	TARGNAME	Energy metabolism (Energy metab)
T06707	TARGTYPE	Literature-reported

T98559	TARGETID	T98559
T98559	FORMERID	TTDI01203
T98559	TARGNAME	Ergosterol synthesis (EG synth)
T98559	TARGTYPE	Literature-reported

T93405	TARGETID	T93405
T93405	FORMERID	TTDI01842
T93405	TARGNAME	Glutamate release (GLU rele)
T93405	TARGTYPE	Literature-reported

T58371	TARGETID	T58371
T58371	FORMERID	TTDI01266
T58371	TARGNAME	Glycolysis (GLYS)
T58371	TARGTYPE	Literature-reported

T53443	TARGETID	T53443
T53443	FORMERID	TTDI01231
T53443	TARGNAME	Hepatic oligosaccharide/glycolipid storage (HOGS)
T53443	TARGTYPE	Literature-reported

T70193	TARGETID	T70193
T70193	FORMERID	TTDI01335
T70193	TARGNAME	Heterotrimeric G-protein signaling pathway (HGP pathway)
T70193	TARGTYPE	Literature-reported

T99976	TARGETID	T99976
T99976	FORMERID	TTDI01273
T99976	TARGNAME	Human immunodeficiency virus Cell fusion (HIV CF)
T99976	TARGTYPE	Literature-reported

T42261	TARGETID	T42261
T42261	FORMERID	TTDI01286
T42261	TARGNAME	IKB-beta-NFKB signaling pathway (IKBB-NFKB pathway)
T42261	TARGTYPE	Literature-reported

T83371	TARGETID	T83371
T83371	FORMERID	TTDI01831
T83371	TARGNAME	Inflammatory mediator release (IM rele)
T83371	TARGTYPE	Literature-reported

T87128	TARGETID	T87128
T87128	FORMERID	TTDI01212
T87128	TARGNAME	Interleukin-12 signaling pathway (IL12 pathway)
T87128	TARGTYPE	Literature-reported

T63205	TARGETID	T63205
T63205	FORMERID	TTDI01679
T63205	TARGNAME	Ligand-nuclear hormone receptor interaction (LNHRI)
T63205	TARGTYPE	Literature-reported

T88072	TARGETID	T88072
T88072	FORMERID	TTDI00068
T88072	TARGNAME	LPS-miR-34a-CCL22 axis (LmCa)
T88072	TARGTYPE	Literature-reported

T23461	TARGETID	T23461
T23461	FORMERID	TTDI01223
T23461	TARGNAME	Mast cell degranulation pathway (MCD pathway)
T23461	TARGTYPE	Literature-reported

T88582	TARGETID	T88582
T88582	FORMERID	TTDNC00678
T88582	TARGNAME	Non-steroidal androgen synthesis (NSAD synth)
T88582	TARGTYPE	Literature-reported

T21987	TARGETID	T21987
T21987	FORMERID	TTDI01194
T21987	TARGNAME	Plasmodium Gametocytogenesis (Plasm Gamet)
T21987	TARGTYPE	Literature-reported

T15197	TARGETID	T15197
T15197	FORMERID	TTDI01172
T15197	TARGNAME	Potential penetration (PP)
T15197	TARGTYPE	Literature-reported
T15197	DRUGINFO	D06UOL	PIROTIODECANE	Investigative

T46188	TARGETID	T46188
T46188	FORMERID	TTDI01216
T46188	TARGNAME	Pro-inflammatory autologous messenger (PAM)
T46188	TARGTYPE	Literature-reported

T82070	TARGETID	T82070
T82070	FORMERID	TTDI01184
T82070	TARGNAME	Prostaglandin metabolism (PG metab)
T82070	TARGTYPE	Literature-reported

T79533	TARGETID	T79533
T79533	FORMERID	TTDI01307
T79533	TARGNAME	Protein phosphorylation (PP)
T79533	TARGTYPE	Literature-reported

T52144	TARGETID	T52144
T52144	FORMERID	TTDI01887
T52144	TARGNAME	Protein translation (hPT)
T52144	TARGTYPE	Literature-reported

T90645	TARGETID	T90645
T90645	TARGNAME	S100A6/p38/MAPK signaling pathway (SpM pathway)
T90645	TARGTYPE	Literature-reported

T48872	TARGETID	T48872
T48872	FORMERID	TTDNC00405
T48872	TARGNAME	Sonic hedgehog pathway (Shh pathway)
T48872	TARGTYPE	Literature-reported

T21262	TARGETID	T21262
T21262	FORMERID	TTDI01854
T21262	TARGNAME	Thyroid hormone synthesis (TH synth)
T21262	TARGTYPE	Literature-reported

T68371	TARGETID	T68371
T68371	FORMERID	TTDI01365
T68371	TARGNAME	TLR signaling pathway (TLR pathway)
T68371	TARGTYPE	Literature-reported

T98056	TARGETID	T98056
T98056	FORMERID	TTDI01214
T98056	TARGNAME	Tumor necrosis factor synthesis (TNF synth)
T98056	TARGTYPE	Literature-reported

T48436	TARGETID	T48436
T48436	FORMERID	TTDNC00488
T48436	TARGNAME	Ubiquitin-proteasome pathway (UP pathway)
T48436	TARGTYPE	Literature-reported

T17893	TARGETID	T17893
T17893	FORMERID	TTDI01305
T17893	TARGNAME	mRNA-decapping enzyme (DCP)
T17893	TARGTYPE	Literature-reported

T47583	TARGETID	T47583
T47583	UNIPROID	WRN_HUMAN
T47583	TARGNAME	Werner syndrome ATP-dependent helicase (WRN)
T47583	GENENAME	WRN
T47583	TARGTYPE	Literature-reported
T47583	SYNONYMS	DNA helicase, RecQ-like type 3; RecQ3; Exonuclease WRN; RecQ protein-like 2
T47583	FUNCTION	Multifunctional enzyme that has both magnesium and ATP-dependent DNA-helicase activity and 3'->5' exonuclease activity towards double-stranded DNA with a 5'-overhang. Has no nuclease activity towards single-stranded DNA or blunt-ended double-stranded DNA. Binds preferentially to DNA substrates containing alternate secondary structures, such as replication forks and Holliday junctions. May play an important role in the dissociation of joint DNA molecules that can arise as products of homologous recombination, at stalled replication forks or during DNA repair. Alleviates stalling of DNA polymerases at the site of DNA lesions. Important for genomic integrity. Plays a role in the formation of DNA replication focal centers; stably associates with foci elements generating binding sites for RP-A (By similarity). Plays a role in double-strand break repair after gamma-irradiation.
T47583	ECNUMBER	EC 3.1.-.-
T47583	SEQUENCE	MSEKKLETTAQQRKCPEWMNVQNKRCAVEERKACVRKSVFEDDLPFLEFTGSIVYSYDASDCSFLSEDISMSLSDGDVVGFDMEWPPLYNRGKLGKVALIQLCVSESKCYLFHVSSMSVFPQGLKMLLENKAVKKAGVGIEGDQWKLLRDFDIKLKNFVELTDVANKKLKCTETWSLNSLVKHLLGKQLLKDKSIRCSNWSKFPLTEDQKLYAATDAYAGFIIYRNLEILDDTVQRFAINKEEEILLSDMNKQLTSISEEVMDLAKHLPHAFSKLENPRRVSILLKDISENLYSLRRMIIGSTNIETELRPSNNLNLLSFEDSTTGGVQQKQIREHEVLIHVEDETWDPTLDHLAKHDGEDVLGNKVERKEDGFEDGVEDNKLKENMERACLMSLDITEHELQILEQQSQEEYLSDIAYKSTEHLSPNDNENDTSYVIESDEDLEMEMLKHLSPNDNENDTSYVIESDEDLEMEMLKSLENLNSGTVEPTHSKCLKMERNLGLPTKEEEEDDENEANEGEEDDDKDFLWPAPNEEQVTCLKMYFGHSSFKPVQWKVIHSVLEERRDNVAVMATGYGKSLCFQYPPVYVGKIGLVISPLISLMEDQVLQLKMSNIPACFLGSAQSENVLTDIKLGKYRIVYVTPEYCSGNMGLLQQLEADIGITLIAVDEAHCISEWGHDFRDSFRKLGSLKTALPMVPIVALTATASSSIREDIVRCLNLRNPQITCTGFDRPNLYLEVRRKTGNILQDLQPFLVKTSSHWEFEGPTIIYCPSRKMTQQVTGELRKLNLSCGTYHAGMSFSTRKDIHHRFVRDEIQCVIATIAFGMGINKADIRQVIHYGAPKDMESYYQEIGRAGRDGLQSSCHVLWAPADINLNRHLLTEIRNEKFRLYKLKMMAKMEKYLHSSRCRRQIILSHFEDKQVQKASLGIMGTEKCCDNCRSRLDHCYSMDDSEDTSWDFGPQAFKLLSAVDILGEKFGIGLPILFLRGSNSQRLADQYRRHSLFGTGKDQTESWWKAFSRQLITEGFLVEVSRYNKFMKICALTKKGRNWLHKANTESQSLILQANEELCPKKLLLPSSKTVSSGTKEHCYNQVPVELSTEKKSNLEKLYSYKPCDKISSGSNISKKSIMVQSPEKAYSSSQPVISAQEQETQIVLYGKLVEARQKHANKMDVPPAILATNKILVDMAKMRPTTVENVKRIDGVSEGKAAMLAPLLEVIKHFCQTNSVQTDLFSSTKPQEEQKTSLVAKNKICTLSQSMAITYSLFQEKKMPLKSIAESRILPLMTIGMHLSQAVKAGCPLDLERAGLTPEVQKIIADVIRNPPVNSDMSKISLIRMLVPENIDTYLIHMAIEILKHGPDSGLQPSCDVNKRRCFPGSEEICSSSKRSKEEVGINTETSSAERKRRLPVWFAKGSDTSKKLMDKTKRGGLFS
T47583	DRUGINFO	DF5LB8	NSC 19630	Investigative

T50261	TARGETID	T50261
T50261	UNIPROID	Family
T50261	TARGNAME	PI3-kinase (PIK3C)
T50261	TARGTYPE	Literature-reported
T50261	DRUGINFO	DHG36S	ETP-45658	Investigative

T74839	TARGETID	T74839
T74839	UNIPROID	CDK13_HUMAN
T74839	TARGNAME	Cyclin-dependent kinase 13 (CDK13)
T74839	GENENAME	CDK13
T74839	TARGTYPE	Literature-reported
T74839	SYNONYMS	CDC2-related protein kinase 5; Cell division cycle 2-like protein kinase 5; Cell division protein kinase 13; hCDK13; Cholinesterase-related cell division controller
T74839	FUNCTION	Cyclin-dependent kinase which displays CTD kinase activity and is required for RNA splicing. Has CTD kinase activity by hyperphosphorylating the C-terminal heptapeptide repeat domain (CTD) of the largest RNA polymerase II subunit RPB1, thereby acting as a key regulator of transcription elongation. Required for RNA splicing, probably by phosphorylating SRSF1/SF2. Required during hematopoiesis. In case of infection by HIV-1 virus, interacts with HIV-1 Tat protein acetylated at 'Lys-50' and 'Lys-51', thereby increasing HIV-1 mRNA splicing and promoting the production of the doubly spliced HIV-1 protein Nef.
T74839	BIOCLASS	Kinase
T74839	ECNUMBER	EC 2.7.11.22
T74839	SEQUENCE	MPSSSDTALGGGGGLSWAEKKLEERRKRRRFLSPQQPPLLLPLLQPQLLQPPPPPPPLLFLAAPGTAAAAAAAAAASSSCFSPGPPLEVKRLARGKRRAGGRQKRRRGPRAGQEAEKRRVFSLPQPQQDGGGGASSGGGVTPLVEYEDVSSQSEQGLLLGGASAATAATAAGGTGGSGGSPASSSGTQRRGEGSERRPRRDRRSSSGRSKERHREHRRRDGQRGGSEASKSRSRHSHSGEERAEVAKSGSSSSSGGRRKSASATSSSSSSRKDRDSKAHRSRTKSSKEPPSAYKEPPKAYREDKTEPKAYRRRRSLSPLGGRDDSPVSHRASQSLRSRKSPSPAGGGSSPYSRRLPRSPSPYSRRRSPSYSRHSSYERGGDVSPSPYSSSSWRRSRSPYSPVLRRSGKSRSRSPYSSRHSRSRSRHRLSRSRSRHSSISPSTLTLKSSLAAELNKNKKARAAEAARAAEAAKAAEATKAAEAAAKAAKASNTSTPTKGNTETSASASQTNHVKDVKKIKIEHAPSPSSGGTLKNDKAKTKPPLQVTKVENNLIVDKATKKAVIVGKESKSAATKEESVSLKEKTKPLTPSIGAKEKEQHVALVTSTLPPLPLPPMLPEDKEADSLRGNISVKAVKKEVEKKLRCLLADLPLPPELPGGDDLSKSPEEKKTATQLHSKRRPKICGPRYGETKEKDIDWGKRCVDKFDIIGIIGEGTYGQVYKARDKDTGEMVALKKVRLDNEKEGFPITAIREIKILRQLTHQSIINMKEIVTDKEDALDFKKDKGAFYLVFEYMDHDLMGLLESGLVHFNENHIKSFMRQLMEGLDYCHKKNFLHRDIKCSNILLNNRGQIKLADFGLARLYSSEESRPYTNKVITLWYRPPELLLGEERYTPAIDVWSCGCILGELFTKKPIFQANQELAQLELISRICGSPCPAVWPDVIKLPYFNTMKPKKQYRRKLREEFVFIPAAALDLFDYMLALDPSKRCTAEQALQCEFLRDVEPSKMPPPDLPLWQDCHELWSKKRRRQKQMGMTDDVSTIKAPRKDLSLGLDDSRTNTPQGVLPSSQLKSQGSSNVAPVKTGPGQHLNHSELAILLNLLQSKTSVNMADFVQVLNIKVNSETQQQLNKINLPAGILATGEKQTDPSTPQQESSKPLGGIQPSSQTIQPKVETDAAQAAVQSAFAVLLTQLIKAQQSKQKDVLLEERENGSGHEASLQLRPPPEPSTPVSGQDDLIQHQDMRILELTPEPDRPRILPPDQRPPEPPEPPPVTEEDLDYRTENQHVPTTSSSLTDPHAGVKAALLQLLAQHQPQDDPKREGGIDYQAGDTYVSTSDYKDNFGSSSFSSAPYVSNDGLGSSSAPPLERRSFIGNSDIQSLDNYSTASSHSGGPPQPSAFSESFPSSVAGYGDIYLNAGPMLFSGDKDHRFEYSHGPIAVLANSSDPSTGPESTHPLPAKMHNYNYGGNLQENPSGPSLMHGQTWTSPAQGPGYSQGYRGHISTSTGRGRGRGLPY
T74839	DRUGINFO	D7RK2M	THZ531	Investigative